<SEC-DOCUMENT>0001956827-26-000012.txt : 20260323
<SEC-HEADER>0001956827-26-000012.hdr.sgml : 20260323
<ACCEPTANCE-DATETIME>20260323165447
ACCESSION NUMBER:		0001956827-26-000012
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		165
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260323
DATE AS OF CHANGE:		20260323

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Abivax S.A.
		CENTRAL INDEX KEY:			0001956827
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41842
		FILM NUMBER:		26783055

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		7 BD HAUSSMANN
		CITY:			PARIS
		PROVINCE COUNTRY:   	I0
		BUSINESS PHONE:		01 53 83 09 63

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		7 BD HAUSSMANN
		CITY:			PARIS
		PROVINCE COUNTRY:   	I0
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>abvx-20251231.htm
<DESCRIPTION>20-F
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:3ade1e9c-8754-4bce-84b9-83231d17b989,g:c324a16d-aca9-45c2-8b50-8666bee7377b,d:7a006daedb3d4216a4128b76247285d7-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full" xmlns:srt="http://fasb.org/srt/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:abvx="http://www.abivax.com/20251231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/><title>abvx-20251231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-39">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-40">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-41">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-42">0001956827</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="dei:NoTradingSymbolFlag" format="ixt:fixed-true" id="f-43">TRUE</ix:nonNumeric><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="abvx:NumberOfOperatingSegment" scale="0" id="f-707">1</ix:nonFraction><ix:nonNumeric contextRef="c-503" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-1718">one year</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-504" decimals="6" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentagePerMonth" scale="0" id="f-1719">0.020833</ix:nonFraction><ix:nonNumeric contextRef="c-685" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-1720">one year</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-686" decimals="6" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentagePerMonth" scale="0" id="f-1721">0.020833</ix:nonFraction><ix:nonNumeric contextRef="c-650" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-1722">one year</ix:nonNumeric><ix:nonNumeric contextRef="c-651" name="abvx:VestingRequirementsForShareBasedPaymentArrangementServicePeriod" format="ixt-sec:durwordsen" id="f-1723">one year</ix:nonNumeric><ix:nonNumeric contextRef="c-687" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-1724">one year</ix:nonNumeric><ix:nonNumeric contextRef="c-688" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-1725">one year</ix:nonNumeric><ix:nonNumeric contextRef="c-689" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-1726">one year</ix:nonNumeric><ix:nonNumeric contextRef="c-655" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-1727">one year</ix:nonNumeric><ix:nonNumeric contextRef="c-657" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-1728">one year</ix:nonNumeric><ix:nonNumeric contextRef="c-690" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-1729">one year</ix:nonNumeric><ix:nonNumeric contextRef="c-982" name="abvx:ConvertibleLoansNotesPeriod" format="ixt-sec:durwordsen" id="f-2144">one year</ix:nonNumeric><ix:nonNumeric contextRef="c-79" name="abvx:ConvertibleLoansNotesConversionOptionMaximumPeriodPriorToMaturityDate" format="ixt-sec:durday" id="f-2145">5</ix:nonNumeric><ix:nonNumeric contextRef="c-1047" name="abvx:LeaseExtensionPeriod" id="f-2257">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="c-1297" name="abvx:OtherFinancialLiabilitiesAnnualRevenueFromSaleOfProductsDevelopedPeriod" id="f-3336">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="c-1302" name="abvx:OtherFinancialLiabilitiesAnnualRevenueFromSaleOfProductsDevelopedPeriod" id="f-3344">P5Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="abvx-20251231.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="eurPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="plan"><xbrli:measure>abvx:plan</xbrli:measure></xbrli:unit><xbrli:unit id="transaction"><xbrli:measure>abvx:transaction</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="note"><xbrli:measure>abvx:note</xbrli:measure></xbrli:unit><xbrli:unit id="criteria"><xbrli:measure>abvx:criteria</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>abvx:segment</xbrli:measure></xbrli:unit><xbrli:unit id="tranche"><xbrli:measure>abvx:tranche</xbrli:measure></xbrli:unit><xbrli:unit id="scenario"><xbrli:measure>abvx:scenario</xbrli:measure></xbrli:unit><xbrli:unit id="closing"><xbrli:measure>abvx:closing</xbrli:measure></xbrli:unit><xbrli:unit id="installment"><xbrli:measure>abvx:installment</xbrli:measure></xbrli:unit><xbrli:unit id="employee"><xbrli:measure>abvx:employee</xbrli:measure></xbrli:unit><xbrli:unit id="license"><xbrli:measure>abvx:license</xbrli:measure></xbrli:unit><xbrli:unit id="academic_institution"><xbrli:measure>abvx:academic_institution</xbrli:measure></xbrli:unit><xbrli:unit id="project"><xbrli:measure>abvx:project</xbrli:measure></xbrli:unit><xbrli:unit id="financial_institution"><xbrli:measure>abvx:financial_institution</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">abvx:AmericanDepositorySharesNASDAQGlobalMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">abvx:OrdinarySharesNASDAQGlobalMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:Kreos1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:Kreos1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:Kreos1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:OtherEquityAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:OtherEquityAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:KreosClaretFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:KreosClaretFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:OtherEquityAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:OtherEquityAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:OtherEquityAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">abvx:KreosOCABSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">abvx:KreosOCABSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">abvx:KreosOCABSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">abvx:KreosOCABSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2013-12-04</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:SaleOfStockAxis">abvx:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:SaleOfStockAxis">abvx:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:SaleOfStockAxis">abvx:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abvx:BanquePubliqueDInvestissementBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-12-04</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:A130.0MillionCrossOverFinancingFebruary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:A130.0MillionCrossOverFinancingFebruary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-22</xbrli:startDate><xbrli:endDate>2023-02-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:A49.2MillionCrossOverFinancingSeptember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:A130.0MillionCrossOverFinancingFebruary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-22</xbrli:startDate><xbrli:endDate>2023-02-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:Kreos1ConvertibleBondLoansTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-24</xbrli:startDate><xbrli:endDate>2023-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:Kreos1ConvertibleBondLoansTrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-24</xbrli:startDate><xbrli:endDate>2023-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FreeSharesAGAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:A150.0MillionFinancingAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:A150.0MillionFinancingAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-20</xbrli:startDate><xbrli:endDate>2023-08-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-22</xbrli:startDate><xbrli:endDate>2023-08-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-24</xbrli:startDate><xbrli:endDate>2023-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-24</xbrli:startDate><xbrli:endDate>2023-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:Kreos1ConvertibleBondLoansTrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-24</xbrli:startDate><xbrli:endDate>2023-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:OCEANEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-24</xbrli:startDate><xbrli:endDate>2023-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingAndHeightsConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-24</xbrli:startDate><xbrli:endDate>2023-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosCBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-02</xbrli:startDate><xbrli:endDate>2023-11-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-24</xbrli:startDate><xbrli:endDate>2023-10-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">abvx:AmericanDepositorySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-24</xbrli:startDate><xbrli:endDate>2023-10-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-24</xbrli:startDate><xbrli:endDate>2023-10-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">abvx:AmericanDepositorySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20246Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-11</xbrli:startDate><xbrli:endDate>2024-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20241Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingTrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-28</xbrli:startDate><xbrli:endDate>2024-03-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingTrancheCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-21</xbrli:startDate><xbrli:endDate>2024-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingTrancheBAndCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-12-01</xbrli:startDate><xbrli:endDate>2016-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIAndCARENAConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:SaleOfStockAxis">abvx:AtTheMarketATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-19</xbrli:startDate><xbrli:endDate>2024-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:ShareSubscriptionWarrantsBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:ShareSubscriptionWarrantsBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:BoardMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20252Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20255Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20251Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:ShareSubscriptionWarrantsBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:ShareSubscriptionWarrantsBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:BoardMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">abvx:AmericanDepositorySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-28</xbrli:startDate><xbrli:endDate>2025-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">abvx:AmericanDepositorySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-28</xbrli:startDate><xbrli:endDate>2025-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-23</xbrli:startDate><xbrli:endDate>2025-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-08</xbrli:startDate><xbrli:endDate>2025-08-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosABCBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-30</xbrli:startDate><xbrli:endDate>2025-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosABCBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-28</xbrli:startDate><xbrli:endDate>2025-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-25</xbrli:startDate><xbrli:endDate>2025-11-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingBAndCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-12-23</xbrli:startDate><xbrli:endDate>2025-12-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">abvx:MajorShareBasedTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FreeSharesAGAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-01</xbrli:startDate><xbrli:endDate>2026-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">abvx:MajorShareBasedTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FreeSharesAGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-01</xbrli:startDate><xbrli:endDate>2026-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">abvx:MajorShareBasedTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FreeSharesAGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-01</xbrli:startDate><xbrli:endDate>2026-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">abvx:MajorShareBasedTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FreeSharesAGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-01</xbrli:startDate><xbrli:endDate>2026-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">abvx:MajorShareBasedTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:ShareSubscriptionWarrantsBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-01</xbrli:startDate><xbrli:endDate>2026-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">abvx:MajorShareBasedTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:ShareSubscriptionWarrantsBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:BoardMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-01</xbrli:startDate><xbrli:endDate>2026-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">abvx:CSOSettlementAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-03-01</xbrli:startDate><xbrli:endDate>2026-03-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">abvx:CSOSettlementAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FreeSharesAGAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:IndustrialMaterialsAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:IndustrialMaterialsAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:TechnicalFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:TechnicalFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">abvx:WittycelSASABX196Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">abvx:SplicosSASABX464Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">abvx:SplicosSASABX464Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">abvx:SplicosSASABX464Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:PrincipalAgreementsAxis">abvx:ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">abvx:WittycelSASABX196Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:PrincipalAgreementsAxis">abvx:ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:AssetsAcquisitionsAxis">abvx:ProsynergiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">abvx:WittycelSASABX196Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">abvx:WittycelSASABX196Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">abvx:WittycelSASABX196Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">abvx:LeaseFacilitiesParisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">abvx:DeferredFinancingCostsNettingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingTrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherReceivablesAndAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherReceivablesAndAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherReceivablesAndAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherReceivablesAndAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:CashAndCashEquivalentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:CashAndCashEquivalentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:CashAndCashEquivalentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:CashAndCashEquivalentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:TradePayablesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:TradePayablesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:TradePayablesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:TradePayablesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherReceivablesAndAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherReceivablesAndAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherReceivablesAndAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherReceivablesAndAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:CashAndCashEquivalentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:CashAndCashEquivalentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:CashAndCashEquivalentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:CashAndCashEquivalentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:TradePayablesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:TradePayablesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:TradePayablesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:TradePayablesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherReceivablesAndAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherReceivablesAndAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherReceivablesAndAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherReceivablesAndAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:CashAndCashEquivalentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:CashAndCashEquivalentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:CashAndCashEquivalentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:CashAndCashEquivalentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:TradePayablesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:TradePayablesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:TradePayablesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:TradePayablesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:NonCurrentAdvancesToCROContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:NonCurrentAdvancesToCROContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:NonCurrentAdvancesToCROContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:NonCurrentAdvancesToCROContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:NonCurrentAdvancesToCROContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:NonCurrentAdvancesToCROContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:NonCurrentAdvancesToCROContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:NonCurrentAdvancesToCROContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:NonCurrentAdvancesToCROContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretFinancingTrancheABAndCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretFinancingTrancheABAndCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretFinancingTrancheABAndCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretFinancingTrancheABAndCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-31</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-22</xbrli:startDate><xbrli:endDate>2023-08-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-31</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-443"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretFinancingTrancheABAndCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-31</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:ConditionalAdvancesAndPGELoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:ConditionalAdvancesAndPGELoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-31</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-31</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-448"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-31</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-449"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-31</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-450"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:EbolaConditionalAdvanceBPIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-31</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-22</xbrli:startDate><xbrli:endDate>2023-02-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:KreosABSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:Kreos1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-24</xbrli:startDate><xbrli:endDate>2023-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-454"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:KreosBBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:Kreos1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-24</xbrli:startDate><xbrli:endDate>2023-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:Kreos1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-24</xbrli:startDate><xbrli:endDate>2023-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-456"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-457"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:Kreos1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-10-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:OtherEquityAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20241AndBSA20242Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-461"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20241AndBSA20242Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:OtherEquityAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-463"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:OtherEquityAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-464"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-08-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-465"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-11-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-466"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:OtherEquityAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-467"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20161Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-07</xbrli:startDate><xbrli:endDate>2016-11-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20161Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-469"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20161Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-470"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20161Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-471"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20171Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-23</xbrli:startDate><xbrli:endDate>2017-01-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-472"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20171Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-473"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20171Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-474"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20171Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-475"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20172Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-20</xbrli:startDate><xbrli:endDate>2017-11-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-476"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20172Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-477"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20172Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-478"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20172Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-479"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20174Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-20</xbrli:startDate><xbrli:endDate>2017-11-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-480"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20174Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-481"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20174Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-482"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20174Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-483"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20175Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-20</xbrli:startDate><xbrli:endDate>2017-11-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-484"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20175Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-485"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20175Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-486"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20175Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-487"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-15</xbrli:startDate><xbrli:endDate>2018-03-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-488"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-489"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-490"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-491"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20184Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-14</xbrli:startDate><xbrli:endDate>2018-05-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-492"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20184Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-493"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20184Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-494"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20184Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-495"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20185Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-14</xbrli:startDate><xbrli:endDate>2018-05-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-496"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20185Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-497"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20185Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-498"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20185Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-499"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FoundersShareSubscriptionWarrantsBCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-07</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-500"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FoundersShareSubscriptionWarrantsBCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FoundersShareSubscriptionWarrantsBCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FoundersShareSubscriptionWarrantsBCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FoundersShareSubscriptionWarrantsBCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FoundersShareSubscriptionWarrantsBCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCEExceptBCE20142Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA201511Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-12-04</xbrli:startDate><xbrli:endDate>2015-12-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA201511Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA201511Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA201511Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA201512Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-12-04</xbrli:startDate><xbrli:endDate>2015-12-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA201512Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA201512Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA201512Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20171Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-18</xbrli:startDate><xbrli:endDate>2017-09-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20171Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20171Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20171Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-22</xbrli:startDate><xbrli:endDate>2018-01-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-520"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20241Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-04</xbrli:startDate><xbrli:endDate>2024-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20241Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20241Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20241Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20242Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-04</xbrli:startDate><xbrli:endDate>2024-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20242Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20242Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20242Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20251Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-13</xbrli:startDate><xbrli:endDate>2025-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20251Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-532"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20251Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-533"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20251Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-534"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20252Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-13</xbrli:startDate><xbrli:endDate>2025-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-535"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20252Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-536"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20252Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-537"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20252Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-538"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20253Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-22</xbrli:startDate><xbrli:endDate>2025-04-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-539"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20253Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-540"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20253Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-541"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20253Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-542"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:ShareSubscriptionWarrantsBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-07</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-543"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:ShareSubscriptionWarrantsBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-544"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:ShareSubscriptionWarrantsBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-545"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:ShareSubscriptionWarrantsBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-546"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:ShareSubscriptionWarrantsBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-547"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:ShareSubscriptionWarrantsBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-548"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:ShareSubscriptionWarrantsBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-549"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20251AndBSA20252Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-550"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20253Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-551"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20241Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-04</xbrli:startDate><xbrli:endDate>2024-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-552"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20241Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-04</xbrli:startDate><xbrli:endDate>2024-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-553"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20242Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-04</xbrli:startDate><xbrli:endDate>2024-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-554"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20242Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-04</xbrli:startDate><xbrli:endDate>2024-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-555"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20251Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-13</xbrli:startDate><xbrli:endDate>2025-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-556"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20251Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-13</xbrli:startDate><xbrli:endDate>2025-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-557"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20252Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-13</xbrli:startDate><xbrli:endDate>2025-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-558"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20252Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-13</xbrli:startDate><xbrli:endDate>2025-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-559"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20253Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-22</xbrli:startDate><xbrli:endDate>2025-04-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-560"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20253Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-22</xbrli:startDate><xbrli:endDate>2025-04-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-561"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-11</xbrli:startDate><xbrli:endDate>2023-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-562"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-563"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-564"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-565"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20232Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-11</xbrli:startDate><xbrli:endDate>2023-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-566"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20232Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-567"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20232Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-568"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20232Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-569"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20233Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-28</xbrli:startDate><xbrli:endDate>2023-09-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-570"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20233Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-571"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20233Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-572"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20233Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-573"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20234Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-28</xbrli:startDate><xbrli:endDate>2023-09-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-574"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20234Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-575"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20234Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-576"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20234Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-577"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20235Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-578"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20235Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-579"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20235Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-580"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20235Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-581"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20241Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-02</xbrli:startDate><xbrli:endDate>2024-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-582"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20241Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-583"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20241Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-584"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20241Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-585"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20242Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-28</xbrli:startDate><xbrli:endDate>2024-03-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-586"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20242Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-587"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20242Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-588"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20242Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-589"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20243Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-23</xbrli:startDate><xbrli:endDate>2024-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-590"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20243Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-591"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20243Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-592"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20243Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-593"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20244Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-11</xbrli:startDate><xbrli:endDate>2024-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-594"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20244Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-595"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20244Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-596"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20244Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-597"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20245Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-11</xbrli:startDate><xbrli:endDate>2024-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-598"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20245Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-599"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20245Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-600"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20245Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20246Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20246Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20246Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20247Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-05</xbrli:startDate><xbrli:endDate>2024-09-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-605"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20247Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20247Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20247Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20251Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-06</xbrli:startDate><xbrli:endDate>2025-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20251Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20251Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20251Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-612"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20252Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-06</xbrli:startDate><xbrli:endDate>2025-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-613"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20252Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20252Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20252Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20253Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-06</xbrli:startDate><xbrli:endDate>2025-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20253Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20253Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20253Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-620"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20254Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-06</xbrli:startDate><xbrli:endDate>2025-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20254Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20254Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-623"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20254Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-624"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20255Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-20</xbrli:startDate><xbrli:endDate>2025-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20255Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20255Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-627"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20255Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20256Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-30</xbrli:startDate><xbrli:endDate>2025-05-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20256Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20256Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-631"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20256Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-632"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20257Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-01</xbrli:startDate><xbrli:endDate>2025-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-633"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20257Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-634"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20257Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-635"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20257Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-636"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20258Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-13</xbrli:startDate><xbrli:endDate>2025-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-637"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20258Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-638"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20258Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-639"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20258Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-640"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FreeSharesAGAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-11</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-641"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FreeSharesAGAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-642"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FreeSharesAGAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-643"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FreeSharesAGAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-644"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TranchesOneToFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-11</xbrli:startDate><xbrli:endDate>2023-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-645"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-11</xbrli:startDate><xbrli:endDate>2023-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-646"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-11</xbrli:startDate><xbrli:endDate>2023-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-647"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20232Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-11</xbrli:startDate><xbrli:endDate>2023-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-648"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20232Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-11</xbrli:startDate><xbrli:endDate>2023-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-649"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-11</xbrli:startDate><xbrli:endDate>2023-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-650"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-11</xbrli:startDate><xbrli:endDate>2023-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-651"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-11</xbrli:startDate><xbrli:endDate>2023-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-652"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-11</xbrli:startDate><xbrli:endDate>2023-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-653"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-11</xbrli:startDate><xbrli:endDate>2023-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-654"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-11</xbrli:startDate><xbrli:endDate>2023-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-655"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-11</xbrli:startDate><xbrli:endDate>2023-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-656"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20232Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-11</xbrli:startDate><xbrli:endDate>2023-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-657"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20232Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-11</xbrli:startDate><xbrli:endDate>2023-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-658"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20232Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-11</xbrli:startDate><xbrli:endDate>2023-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-659"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20233AndAGA20234Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-28</xbrli:startDate><xbrli:endDate>2023-09-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-660"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20233AGA20234AndAGA20235Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-28</xbrli:startDate><xbrli:endDate>2023-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-661"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20233AGA20234AndAGA20235Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-28</xbrli:startDate><xbrli:endDate>2023-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-662"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20233AGA20234AndAGA20235Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-28</xbrli:startDate><xbrli:endDate>2023-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-663"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20233AGA20234AndAGA20235Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-28</xbrli:startDate><xbrli:endDate>2023-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-664"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20244AGA20245AndAGA20246Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-11</xbrli:startDate><xbrli:endDate>2024-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-665"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20241AGE20242AGA20243AGA20244AGA20245AndAGA20247Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-09-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-666"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20241AGE20242AGA20243AGA20244AGA20245AndAGA20247Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-09-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-667"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20241AGE20242AGA20243AGA20244AGA20245AndAGA20247Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-09-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-668"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20246Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-02</xbrli:startDate><xbrli:endDate>2024-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-669"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20246Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-02</xbrli:startDate><xbrli:endDate>2024-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-670"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20246Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-02</xbrli:startDate><xbrli:endDate>2024-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-671"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20253Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-672"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20254Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-673"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20256Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-674"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20257Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-675"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20258Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-676"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20251AGA20253AGA20254AGA20256AGA20257AndAGA20258Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-677"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20251AGA20253AGA20254AGA20256AGA20257AndAGA20258Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-678"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20251AGA20253AGA20254AGA20256AGA20257AndAGA20258Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-679"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20255Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-680"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FoundersShareSubscriptionWarrantsBCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-681"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FoundersShareSubscriptionWarrantsBCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-682"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:ShareSubscriptionWarrantsBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-683"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FreeSharesAGAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-684"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FreeSharesAGAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-685"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:ShareSubscriptionWarrantsBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-686"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:ShareSubscriptionWarrantsBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-687"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-11</xbrli:startDate><xbrli:endDate>2023-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-688"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-11</xbrli:startDate><xbrli:endDate>2023-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-689"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-11</xbrli:startDate><xbrli:endDate>2023-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-690"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20232Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-11</xbrli:startDate><xbrli:endDate>2023-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-691"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:Kreos1ClaretBondLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-692"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:Kreos1ClaretBondLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-693"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:Kreos1ClaretBondLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-694"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-695"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-696"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-697"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-698"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-699"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-700"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:Borrowings1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:Borrowings1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:Borrowings1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-705"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:ConvertibleLoansNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-707"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:ConvertibleLoansNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-708"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:ConvertibleLoansNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-709"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-711"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-714"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:ConditionalAdvancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-716"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:ConditionalAdvancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-717"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:ConditionalAdvancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-718"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-721"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OtherFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-722"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OtherFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OtherFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-724"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-725"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-728"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:Kreos1BondLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-22</xbrli:startDate><xbrli:endDate>2023-08-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-732"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-733"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingTrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-734"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingTrancheCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-735"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">abvx:EuropeanCentralBankBaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-736"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">abvx:EuropeanCentralBankBaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-737"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">abvx:EuropeanCentralBankBaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-738"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-739"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosABBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-740"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosABBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-20</xbrli:startDate><xbrli:endDate>2023-08-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-741"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosCBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-742"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-20</xbrli:startDate><xbrli:endDate>2023-08-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-743"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosABCBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:KreosClaretFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-30</xbrli:startDate><xbrli:endDate>2025-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-744"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosABCBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:KreosClaretFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-30</xbrli:startDate><xbrli:endDate>2025-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-745"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosABCBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:KreosClaretFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-28</xbrli:startDate><xbrli:endDate>2025-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-746"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:KreosClaretFinancingTrancheABAndCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-747"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingBAndCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-748"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-12-23</xbrli:startDate><xbrli:endDate>2025-12-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-749"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-30</xbrli:startDate><xbrli:endDate>2025-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-750"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-28</xbrli:startDate><xbrli:endDate>2025-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-751"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-752"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:MarketRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-753"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:MarketRateMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-754"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:MarketRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-20</xbrli:startDate><xbrli:endDate>2023-08-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-755"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-756"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-757"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:MinimalReturnMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-758"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:MinimalReturnMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-759"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-760"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-761"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-762"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-763"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-764"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-765"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-766"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-767"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-768"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-769"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionFairValueOfMRIMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-770"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:TenderOfferFairValueOfMRIMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-771"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionFairValueOfMRIMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-772"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:TenderOfferFairValueOfMRIMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-773"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-774"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-775"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-776"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-777"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:MinimalReturnMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-778"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:MinimalReturnMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-779"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-780"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-781"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-782"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-783"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-784"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-785"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-786"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-787"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-788"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-789"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionFairValueOfMRIMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-790"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:TenderOfferFairValueOfMRIMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-791"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionFairValueOfMRIMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-792"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:TenderOfferFairValueOfMRIMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-793"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-794"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-795"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-796"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:BlackScholesModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-797"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-798"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:BlackScholesModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-799"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-800"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:BlackScholesModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-802"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:BlackScholesModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-809"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-810"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-28</xbrli:startDate><xbrli:endDate>2024-03-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-811"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-28</xbrli:startDate><xbrli:endDate>2024-03-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-812"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-28</xbrli:startDate><xbrli:endDate>2024-03-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-813"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-28</xbrli:startDate><xbrli:endDate>2024-03-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-28</xbrli:startDate><xbrli:endDate>2024-03-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-817"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-818"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-819"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-820"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-21</xbrli:startDate><xbrli:endDate>2024-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-21</xbrli:startDate><xbrli:endDate>2024-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-822"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-21</xbrli:startDate><xbrli:endDate>2024-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-21</xbrli:startDate><xbrli:endDate>2024-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-824"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-21</xbrli:startDate><xbrli:endDate>2024-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-826"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-827"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-829"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-832"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-833"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-834"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-835"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosABBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-836"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosABBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-837"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosABBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-838"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosABBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-839"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExercisePricePerShareMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-840"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExercisePricePerShareMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-841"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExercisePricePerShareMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-842"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-843"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-844"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-845"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpiryScenarioProbablityMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-846"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpiryScenarioProbablityMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-847"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpiryScenarioProbablityMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-848"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VolatilityForSharesMeasurementInputExpiryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-849"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VolatilityForSharesMeasurementInputTenderOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-850"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VolatilityForSharesMeasurementInputExpiryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-851"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VolatilityForSharesMeasurementInputTenderOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-852"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VolatilityForSharesMeasurementInputExpiryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-853"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VolatilityForSharesMeasurementInputTenderOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-854"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpectedDividendMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-855"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpectedDividendMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-856"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpectedDividendMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-857"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-858"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-859"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputExpiryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-860"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputTenderOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-861"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosCBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-862"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosCBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-863"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosCBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-864"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExercisePricePerShareMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-865"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExercisePricePerShareMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-866"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExercisePricePerShareMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-867"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-868"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-869"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-870"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpiryScenarioProbablityMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-871"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpiryScenarioProbablityMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-872"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpiryScenarioProbablityMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-873"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:DrawdownProbablityMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-874"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:DrawdownProbablityMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-875"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VolatilityForSharesMeasurementInputExpiryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-876"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VolatilityForSharesMeasurementInputTenderOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-877"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VolatilityForSharesMeasurementInputExpiryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-878"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VolatilityForSharesMeasurementInputTenderOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-879"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VolatilityForSharesMeasurementInputExpiryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-880"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VolatilityForSharesMeasurementInputTenderOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-881"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpectedDividendMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-882"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpectedDividendMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-883"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpectedDividendMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-884"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-885"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-886"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputExpiryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-887"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputTenderOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-888"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-889"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-890"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-891"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpiryScenarioProbablityMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-892"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosABBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-20</xbrli:startDate><xbrli:endDate>2023-08-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-893"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-20</xbrli:startDate><xbrli:endDate>2023-08-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-894"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-20</xbrli:startDate><xbrli:endDate>2023-08-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-895"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-20</xbrli:startDate><xbrli:endDate>2023-08-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-896"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpiryScenarioProbablityMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-20</xbrli:startDate><xbrli:endDate>2023-08-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-897"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-898"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-899"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-900"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpiryScenarioProbablityMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosCBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-02</xbrli:startDate><xbrli:endDate>2023-11-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-902"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-02</xbrli:startDate><xbrli:endDate>2023-11-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-903"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-02</xbrli:startDate><xbrli:endDate>2023-11-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-904"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-02</xbrli:startDate><xbrli:endDate>2023-11-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-905"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpiryScenarioProbablityMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-02</xbrli:startDate><xbrli:endDate>2023-11-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-906"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-907"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-908"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-909"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpiryScenarioProbablityMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosABCBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-31</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-911"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABCBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-31</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-912"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABCBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-31</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-913"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABCBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-31</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-914"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpiryScenarioProbablityMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABCBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-31</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpiryScenarioProbablityMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-916"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosABCBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-31</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-917"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABCBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-31</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-918"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABCBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-31</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-919"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABCBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-31</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-920"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpiryScenarioProbablityMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABCBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-31</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-921"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-24</xbrli:startDate><xbrli:endDate>2023-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-922"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-923"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesTrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-924"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesTrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-20</xbrli:startDate><xbrli:endDate>2023-08-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-925"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-20</xbrli:startDate><xbrli:endDate>2023-08-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-926"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-20</xbrli:startDate><xbrli:endDate>2023-08-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-928"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-929"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-931"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-932"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-933"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-934"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-935"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-936"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-937"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ConversionPricePerShareMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-938"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ConversionPricePerShareMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-939"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ConversionPricePerShareMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-940"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-941"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-942"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-943"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VoluntaryConversionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-944"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VoluntaryConversionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-945"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VoluntaryConversionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-946"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:InitialPriceLimitMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-947"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:InitialPriceLimitMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-948"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:InitialPriceLimitMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-949"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:EarlyRedemptionAmountMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-950"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:EarlyRedemptionAmountMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-951"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:EarlyRedemptionAmountMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-952"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-953"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-954"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-955"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-956"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-957"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-958"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-959"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-960"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-961"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-962"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-963"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-964"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VoluntaryConversionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-965"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-24</xbrli:startDate><xbrli:endDate>2023-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-966"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-24</xbrli:startDate><xbrli:endDate>2023-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-967"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-24</xbrli:startDate><xbrli:endDate>2023-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-968"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VoluntaryConversionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-24</xbrli:startDate><xbrli:endDate>2023-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-969"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-970"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-971"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-972"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VoluntaryConversionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-973"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-31</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-974"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-31</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-975"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-31</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-976"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VoluntaryConversionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-31</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-977"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VoluntaryConversionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-978"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-31</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-979"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-31</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-980"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-31</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-981"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VoluntaryConversionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-31</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-982"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesTrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-20</xbrli:startDate><xbrli:endDate>2023-08-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-983"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:Kreos1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-984"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:Kreos1NonConvertibleBondLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-985"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:Kreos1ConvertibleBondLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-986"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-987"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:Kreos1ConvertibleBondLoansTrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-21</xbrli:startDate><xbrli:endDate>2023-08-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-988"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:Kreos12BondLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-21</xbrli:startDate><xbrli:endDate>2023-08-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-989"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosABSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-990"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosBBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-991"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosABBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-992"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-993"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:Kreos2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-994"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:Kreos2TrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-995"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:Kreos2TrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-996"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:OCEANEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-997"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:OCEANEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-998"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:OCEANEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:RemeasurementPeriodAxis">abvx:After18MonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-999"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:OCEANEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:RemeasurementPeriodAxis">abvx:After24MonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1000"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:OCEANEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abvx:RemeasurementPeriodAxis">abvx:After36MonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1004"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1005"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1006"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1008"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1009"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-24</xbrli:startDate><xbrli:endDate>2023-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1010"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-24</xbrli:startDate><xbrli:endDate>2023-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1011"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-24</xbrli:startDate><xbrli:endDate>2023-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1012"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:OCEANEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1013"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1015"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1016"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1017"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1018"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1020"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1024"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1025"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:EbolaConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:EbolaConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1027"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:EbolaConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1028"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-16</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1030"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1032"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1033"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1034"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-12-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1035"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-12-16</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1036"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-12-01</xbrli:startDate><xbrli:endDate>2013-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1037"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-09-01</xbrli:startDate><xbrli:endDate>2014-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1038"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-01</xbrli:startDate><xbrli:endDate>2016-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1039"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1040"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:EbolaConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1041"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:EbolaConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1042"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:EbolaConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1043"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">abvx:LeaseFacilitiesParisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1044"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">abvx:LeaseFacilitiesParisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1045"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">abvx:LeaseFacilitiesParisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-02</xbrli:startDate><xbrli:endDate>2024-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1046"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">abvx:LeaseFacilitiesBostonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1047"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">abvx:LeaseFacilitiesBostonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1048"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">abvx:LeaseFacilitiesBostonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1049"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">abvx:LeaseFacilitiesMontpellierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1050"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">abvx:LeaseFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1051"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">abvx:LeaseFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1052"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">abvx:LeaseFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1053"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1054"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-02</xbrli:startDate><xbrli:endDate>2022-09-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1055"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-02</xbrli:startDate><xbrli:endDate>2022-09-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1056"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1057"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1058"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1059"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1060"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1061"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1062"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ProbabilityOfSuccessMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1063"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:PeakPenetrationMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1064"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ProbabilityOfSuccessMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1065"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:PeakPenetrationMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1066"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ProbabilityOfSuccessMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1067"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:PeakPenetrationMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1068"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:WeightedAverageCostOfCapitalMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1069"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1070"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ProbabilityOfSuccessMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-31</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1071"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:PeakPenetrationMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-31</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1072"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:WeightedAverageCostOfCapitalMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-31</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1073"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-31</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1074"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ProbabilityOfSuccessMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1075"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:PeakPenetrationMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1076"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:WeightedAverageCostOfCapitalMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1077"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1078"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ProbabilityOfSuccessMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-31</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1079"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:PeakPenetrationMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-31</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1080"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:WeightedAverageCostOfCapitalMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-31</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1081"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-31</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1082"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:WeightedAverageCostOfCapitalMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1083"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:WeightedAverageCostOfCapitalMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1084"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:Kreos12BondLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1085"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1086"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1087"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:Kreos1ClaretBondLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1088"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1089"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1090"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:ConditionalAdvancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1091"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1092"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1093"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:Kreos12BondLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1094"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1095"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1096"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:Kreos1ClaretBondLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1097"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1098"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1099"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:ConditionalAdvancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:Kreos12BondLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:Kreos1ClaretBondLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:ConditionalAdvancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:Kreos12BondLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:Kreos1ClaretBondLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:ConditionalAdvancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:Kreos12BondLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:Kreos1ClaretBondLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:ConditionalAdvancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:Kreos12BondLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:Kreos1ClaretBondLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:ConditionalAdvancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:Kreos12BondLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:Kreos1ClaretBondLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:ConditionalAdvancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OceaneConversionOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:OCEANEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingTrancheCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingTrancheABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosBBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OceaneConversionOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosBBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosBBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OceaneConversionOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosBBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OceaneConversionOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosBBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OceaneConversionOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosBBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OceaneConversionOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosBBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OceaneConversionOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretBondLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretBondLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretBondLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretBondLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretBondLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:OtherEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:OtherEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:OtherEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:OtherEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:OtherEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:CIRTaxYearAxis">abvx:A2022TaxYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:CIRTaxYearAxis">abvx:A2023TaxYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:CIRTaxYearAxis">abvx:A2024TaxYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:CIRTaxYearAxis">abvx:A2021TaxYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">abvx:SalesAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">abvx:SalesAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">abvx:SalesAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">abvx:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">abvx:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">abvx:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">abvx:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">abvx:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">abvx:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">abvx:KreosClaretFinancingBSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:RetirementBenefitObligationsRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:RetirementBenefitObligationsRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:RetirementBenefitObligationsRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:LeasesRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:LeasesRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:LeasesRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:OtherFinancialLiabilitiesRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:OtherFinancialLiabilitiesRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:OtherFinancialLiabilitiesRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:ProvisionsForAGATaxesRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:ProvisionsForAGATaxesRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:ProvisionsForAGATaxesRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:SubsidiesRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:SubsidiesRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:SubsidiesRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:RoyaltyCertificatesRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:RoyaltyCertificatesRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:RoyaltyCertificatesRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:RoyaltyCertificatesRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">abvx:AbivaxLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">abvx:AbivaxLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">abvx:AbivaxLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:BoardOfDirectorsAndChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:BoardOfDirectorsAndChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:BoardOfDirectorsAndChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:AdvisorToTheChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-18</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:PrincipalAgreementsAxis">abvx:ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2008-12-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abvx:PrincipalAgreementsAxis">abvx:ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2006-11-11</xbrli:startDate><xbrli:endDate>2006-11-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">abvx:TheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-12-16</xbrli:startDate><xbrli:endDate>2013-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-12-16</xbrli:startDate><xbrli:endDate>2013-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-12-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-12-16</xbrli:startDate><xbrli:endDate>2013-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-16</xbrli:startDate><xbrli:endDate>2016-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-16</xbrli:startDate><xbrli:endDate>2016-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-16</xbrli:startDate><xbrli:endDate>2016-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:EbolaConditionalAdvanceBPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:EbolaConditionalAdvanceBPILanguedocRoussillonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:EbolaConditionalAdvanceBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">abvx:LeaseFacilitiesMontpellierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesTrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">abvx:EuropeanCentralBankBaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">abvx:EuropeanCentralBankBaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">abvx:EuropeanCentralBankBaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001956827</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:303.5pt;position:var(--position);text-decoration:none;white-space:pre">1</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_1"></div><div style="line-height:12pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:bold;left:258.18pt;position:var(--position);text-decoration:none;white-space:pre">UNITED STATES<span id="i98aa23105ba341f8bf1d1846356a7638"></span></span></div><div style="line-height:12pt;position:var(--position);top:86.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:bold;left:176.9pt;position:var(--position);text-decoration:none;white-space:pre">SECURITIES AND EXCHANGE COMMISSION<span id="i706f9aa12e884a719ceca320f63647a1"></span></span></div><div style="line-height:12pt;position:var(--position);top:100.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:bold;left:232.19pt;position:var(--position);text-decoration:none;white-space:pre">WASHINGTON, D.C. 20549<span id="i607ae415c226481da02f90e21af444f0"></span></span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:129.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:bold;left:274.52pt;position:var(--position);text-decoration:none;white-space:pre">FORM <span id="ie775176e779f4ddab451b044bce324f5"></span></span><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:bold;left:314.15999999999997pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">20-F</ix:nonNumeric></span></div><div style="line-height:10pt;position:var(--position);top:158.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);white-space:pre">(Mark One)</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:169.6pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1" name="dei:DocumentRegistrationStatement" format="ixt:fixed-false" id="f-2">&#9744;</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:81.37pt;position:var(--position);white-space:pre">&#160; &#160; &#160;  REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES </span></div><div style="line-height:10pt;position:var(--position);top:183.04pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);white-space:pre">EXCHANGE ACT OF 1934</span></div><div style="line-height:10pt;position:var(--position);top:194.24pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:298.5pt;position:var(--position);white-space:pre">OR</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:205.44pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="f-3">&#9746;</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:81.37pt;position:var(--position);white-space:pre">&#160; &#160; &#160; ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE </span></div><div style="line-height:10pt;position:var(--position);top:218.88pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);white-space:pre">ACT OF 1934</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:230.08pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:211.65pt;position:var(--position);white-space:pre">For the fiscal year ended </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:319.59000000000003pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-5">December 31</ix:nonNumeric>, 2025</ix:nonNumeric></span></div><div style="line-height:10pt;position:var(--position);top:252.48pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:298.5pt;position:var(--position);white-space:pre">OR</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:263.68pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="f-6">&#9744;</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:81.37pt;position:var(--position);white-space:pre">&#160; &#160; &#160;  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:424.81pt;position:var(--position);text-decoration:none;white-space:pre">SECURITIES</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:485.35pt;position:var(--position);white-space:pre"> </span></div><div style="line-height:10pt;position:var(--position);top:277.12pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);white-space:pre">EXCHANGE ACT OF 1934</span></div><div style="line-height:10pt;position:var(--position);top:288.32pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:298.5pt;position:var(--position);white-space:pre">OR</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:310.72pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1" name="dei:DocumentShellCompanyReport" format="ixt-sec:boolballotbox" id="f-7">&#9744;</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:81.37pt;position:var(--position);white-space:pre">&#160; &#160; &#160;  SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES </span></div><div style="line-height:10pt;position:var(--position);top:324.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);white-space:pre">EXCHANGE ACT OF 1934</span></div><div style="line-height:10pt;position:var(--position);top:346.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:200.95pt;position:var(--position);white-space:pre">Date of event requiring this shell company report</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:368.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:228.95pt;position:var(--position);white-space:pre">Commission file number: </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:339.71pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-8">001-41842</ix:nonNumeric></span></div><div style="font-size:12pt;line-height:18pt;position:var(--position);top:393.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:18pt;font-style:normal;font-weight:bold;left:264.75pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-9">Abivax SA</ix:nonNumeric></span></div><div style="line-height:10pt;position:var(--position);top:414.12pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:101.96pt;position:var(--position);white-space:pre">(Exact name of Registrant as specified in its charter and translation of Registrant&#8217;s name into English)</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:436.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:291.02pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="f-10">France</ix:nonNumeric></span></div><div style="line-height:10pt;position:var(--position);top:448.02pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:214.15pt;position:var(--position);white-space:pre">(Jurisdiction of incorporation or organization)</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:470.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:247.4pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-11">7-11 boulevard Haussmann</ix:nonNumeric></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:481.62pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:263.68pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">75009</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:288.68pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:291.18pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-13">Paris</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:313.37pt;position:var(--position);white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:318.37pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="f-14">France</ix:nonNumeric></span></div><div style="line-height:10pt;position:var(--position);top:492.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:226.65pt;position:var(--position);white-space:pre">(Address of principal executive offices)</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:515.22pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:270.49pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-2" name="dei:ContactPersonnelName" id="f-15">Marc de Garidel</ix:nonNumeric></span></div><div style="line-height:10pt;position:var(--position);top:526.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:255.79pt;position:var(--position);white-space:pre">Chief Executive Officer</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:537.62pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:247.4pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-2" name="dei:EntityAddressAddressLine1" id="f-16">7-11 boulevard Haussmann</ix:nonNumeric></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:548.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:263.68pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-2" name="dei:EntityAddressPostalZipCode" id="f-17">75009</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:288.68pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:291.18pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-2" name="dei:EntityAddressCityOrTown" id="f-18">Paris</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:313.37pt;position:var(--position);white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:318.37pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-2" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="f-19">France</ix:nonNumeric></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:560.02pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:252.48pt;position:var(--position);white-space:pre">Tel: </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:272.17pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-2" name="dei:CityAreaCode" id="f-20">+33</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:287.86pt;position:var(--position);white-space:pre"> (0) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:304.52pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-2" name="dei:LocalPhoneNumber" id="f-21">1 53 83 09 63</ix:nonNumeric></span></div><div style="line-height:10pt;position:var(--position);top:571.22pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:268.72pt;position:var(--position);white-space:pre">info@abivax.com</span></div><div style="line-height:10pt;position:var(--position);top:582.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:117.73pt;position:var(--position);white-space:pre">(Name, Telephone, Email and/or Facsimile number and Address of Company Contact Person)</span></div><div style="line-height:10pt;position:var(--position);top:604.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);white-space:pre">Securities registered or to be registered pursuant to Section 12(b) of the Act.</span></div><div style="position:var(--position);top:616.02pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:465.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:191.25pt"/><td style="padding:0;width:95.25pt"/><td style="padding:0;width:179.25pt"/></tr><tr style="height:12.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:191.25pt"><div><div style="line-height:9pt;position:var(--position);top:3.22pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:bold;left:61.78pt;position:var(--position);text-decoration:none;white-space:pre">Title of each class</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);width:95.25pt"><div><div style="line-height:9pt;position:var(--position);top:3.22pt;width:95.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:bold;left:11.52pt;position:var(--position);text-decoration:none;white-space:pre">Trading Symbol(s)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:286.5pt;position:var(--position);width:179.25pt"><div><div style="line-height:9pt;position:var(--position);top:3.22pt;width:179.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:bold;left:5.96pt;position:var(--position);text-decoration:none;white-space:pre">Name of each exchange on which registered</span></div></div></div></td></tr><tr style="height:23.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12.75pt;width:191.25pt"><div><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-22"><div style="line-height:9pt;position:var(--position);top:2.63pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:10.1pt;position:var(--position);text-decoration:none;white-space:pre">American Depositary Shares, each representing </span></div><div style="line-height:9pt;position:var(--position);top:12.71pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:5.57pt;position:var(--position);text-decoration:none;white-space:pre">one ordinary share, nominal value &#8364;0.01 per share</span></div></ix:nonNumeric></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:12.75pt;width:95.25pt"><div><div style="line-height:9pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:34.89pt;position:var(--position);white-space:pre"><ix:nonNumeric contextRef="c-3" name="dei:TradingSymbol" id="f-23">ABVX</ix:nonNumeric></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:286.5pt;position:var(--position);top:12.75pt;width:179.25pt"><div><div style="line-height:9pt;position:var(--position);top:2.63pt;width:179.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:40.55pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-24">The Nasdaq Global Market</ix:nonNumeric></span></div></div></div></td></tr><tr style="height:12.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:36pt;width:191.25pt"><div><div style="font-size:12pt;line-height:9pt;position:var(--position);top:2.63pt;width:191.25pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:8.2pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-4" name="dei:Security12bTitle" id="f-25">Ordinary shares, nominal value &#8364;0.01 per share</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:178.54999999999998pt;position:var(--position);white-space:pre">*</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:36pt;width:95.25pt"><div><div style="line-height:9pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:45.37pt;position:var(--position);text-decoration:none;white-space:pre">*</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:286.5pt;position:var(--position);top:36pt;width:179.25pt"><div><div style="font-size:12pt;line-height:9pt;position:var(--position);top:2.63pt;width:179.25pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:38.3pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-4" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-26">The Nasdaq Global Market</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:136.45pt;position:var(--position);white-space:pre">*</span></div></div></div></td></tr></tbody></table></div></div></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:669.77pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:389.09pt">*Not for trading, but only in connection with the registration of the American Depositary Shares.</span></div><div style="line-height:10pt;position:var(--position);top:692.17pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:141.18pt;position:var(--position);white-space:pre">Securities registered or to be registered pursuant to Section 12(g) of the Act. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:448.61pt;position:var(--position);white-space:pre">None</span></div><div style="line-height:10pt;position:var(--position);top:703.37pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:118.69pt;position:var(--position);white-space:pre">Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:471.1pt;position:var(--position);white-space:pre">None</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:303.5pt;position:var(--position);text-decoration:none;white-space:pre">2</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:83.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">Indicate the number of outstanding shares of each of the issuer&#8217;s classes of capital or common stock as of the close </span></div><div style="line-height:10pt;position:var(--position);top:94.7pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">of the period covered by the annual report.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:117.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Ordinary shares: </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:148.05pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-27">78,536,412</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:193.05pt;position:var(--position);text-decoration:none;white-space:pre"> shares outstanding as of December 31, 2025</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:139.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Indicate</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:104.16pt;position:var(--position);white-space:pre"> by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:150.7pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">Act. </span><span style="font-family:'Arial', sans-serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.42pt;position:var(--position);white-space:pre">&#9746;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:99.23pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:101.73pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-28">Yes</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:117.27000000000001pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Arial', sans-serif;font-size:10pt;font-style:normal;font-weight:normal;left:119.77000000000001pt;position:var(--position);white-space:pre">&#9744;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.58pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:130.07999999999998pt;position:var(--position);text-decoration:none;white-space:pre">No</span></div><div style="line-height:10pt;position:var(--position);top:173.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:184.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. </span><span style="font-family:'Arial', sans-serif;font-size:10pt;font-style:normal;font-weight:normal;left:361.19pt;position:var(--position);white-space:pre">&#9744;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:369pt;position:var(--position);white-space:pre"> Yes </span><span style="font-family:'Arial', sans-serif;font-size:10pt;font-style:normal;font-weight:normal;left:389.54pt;position:var(--position);white-space:pre">&#9746;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:397.35pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:399.85pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-29">No</ix:nonNumeric></span></div><div style="line-height:10pt;position:var(--position);top:206.7pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of </span></div><div style="line-height:10pt;position:var(--position);top:217.9pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:229.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="font-family:'Arial', sans-serif;font-size:10pt;font-style:normal;font-weight:normal;left:501.01pt;position:var(--position);white-space:pre">&#9746;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:508.82pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:511.32pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-30">Yes</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:526.86pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Arial', sans-serif;font-size:10pt;font-style:normal;font-weight:normal;left:529.36pt;position:var(--position);white-space:pre">&#9744;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:537.1700000000001pt;position:var(--position);white-space:pre"> </span></div><div style="line-height:10pt;position:var(--position);top:240.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">No</span></div><div style="line-height:10pt;position:var(--position);top:262.7pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be </span></div><div style="line-height:10pt;position:var(--position);top:273.9pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:285.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">such shorter period that the registrant was required to submit such files). </span><span style="font-family:'Arial', sans-serif;font-size:10pt;font-style:normal;font-weight:normal;left:363.63pt;position:var(--position);white-space:pre">&#9746;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:371.44pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:373.94pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-31">Yes</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:389.48pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Arial', sans-serif;font-size:10pt;font-style:normal;font-weight:normal;left:391.98pt;position:var(--position);white-space:pre">&#9744;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:399.79pt;position:var(--position);white-space:pre"> No</span></div><div style="line-height:10pt;position:var(--position);top:307.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, </span></div><div style="line-height:10pt;position:var(--position);top:318.7pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">or an emerging growth company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging </span></div><div style="line-height:10pt;position:var(--position);top:329.9pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="position:var(--position);top:352.3pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:469.5pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:117pt"/><td style="padding:0;width:105pt"/><td style="padding:0;width:117pt"/><td style="padding:0;width:130.5pt"/></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:117pt"><div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:2.63pt;width:117pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre;width:92.3pt">Large accelerated filer </span><span style="font-family:'Arial', sans-serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.92999999999999pt;position:var(--position);white-space:pre;width:7.81pt">&#9744;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:117pt;position:var(--position);width:105pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:2.63pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre;width:66.8pt"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-32">Accelerated filer</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:69.42999999999999pt;position:var(--position);white-space:pre;width:2.5pt"> </span><span style="font-family:'Arial', sans-serif;font-size:10pt;font-style:normal;font-weight:normal;left:71.92999999999999pt;position:var(--position);white-space:pre;width:7.81pt">&#9746;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:222pt;position:var(--position);width:117pt"><div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:2.63pt;width:117pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre;width:87.06pt">Non-accelerated filer </span><span style="font-family:'Arial', sans-serif;font-size:10pt;font-style:normal;font-weight:normal;left:89.69pt;position:var(--position);white-space:pre;width:7.81pt">&#9744;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:339pt;position:var(--position);width:130.5pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:2.63pt;width:130.5pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre;width:111.85pt">Emerging growth company </span><span style="font-family:'Arial', sans-serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre;width:7.81pt"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-33">&#9746;</ix:nonNumeric></span></div></div></div></td></tr></tbody></table></div></div></div><div style="line-height:10pt;position:var(--position);top:371.55pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by </span></div><div style="line-height:10pt;position:var(--position);top:382.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">check mark if the registrant has elected not to use the extended transition period for complying with any new or </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:393.95pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">revised financial accounting standards&#8224; provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-family:'Arial', sans-serif;font-size:10pt;font-style:normal;font-weight:normal;left:460.46pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-34">&#9744;</ix:nonNumeric></span></div><div style="line-height:10pt;position:var(--position);top:416.35pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">&#8224; The term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting </span></div><div style="line-height:10pt;position:var(--position);top:427.55pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">Standards Board to its Accounting Standards Codification after April 5, 2012.</span></div><div style="line-height:10pt;position:var(--position);top:449.95pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of </span></div><div style="line-height:10pt;position:var(--position);top:461.15pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:472.35pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-family:'Arial', sans-serif;font-size:10pt;font-style:normal;font-weight:normal;left:458pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="f-35">&#9744;</ix:nonNumeric></span></div><div style="line-height:10pt;position:var(--position);top:494.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial </span></div><div style="line-height:10pt;position:var(--position);top:505.95pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">statements of the registrant included in the filing reflect the correction of an error to previously issued financial </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:517.15pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">statements. </span><span style="font-family:'Arial', sans-serif;font-size:10pt;font-style:normal;font-weight:normal;left:119.15pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-36">&#9744;</ix:nonNumeric></span></div><div style="line-height:10pt;position:var(--position);top:539.55pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of </span></div><div style="line-height:10pt;position:var(--position);top:550.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery </span></div><div style="line-height:10pt;position:var(--position);top:561.95pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">period pursuant to &#167;240.10D-1(b). </span><span style="font-family:'Arial', sans-serif;font-size:10pt;font-style:normal;font-weight:normal;left:211.93pt;position:var(--position);white-space:pre">&#9744;</span></div><div style="line-height:10pt;position:var(--position);top:584.35pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements </span></div><div style="line-height:10pt;position:var(--position);top:595.55pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">included in this filing:</span></div><div style="line-height:10pt;position:var(--position);top:606.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">U.S. GAAP </span><span style="font-family:'Arial', sans-serif;font-size:10pt;font-style:normal;font-weight:normal;left:122pt;position:var(--position);white-space:pre">&#9744;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:617.95pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAccountingStandard" id="f-37">International Financial Reporting Standards</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:247.06pt;position:var(--position);white-space:pre"> as issued by the International Accounting Standards Board </span><span style="font-family:'Arial', sans-serif;font-size:10pt;font-style:normal;font-weight:normal;left:486.54pt;position:var(--position);white-space:pre">&#9746;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:494.35pt;position:var(--position);white-space:pre"> Other </span><span style="font-family:'Arial', sans-serif;font-size:10pt;font-style:normal;font-weight:normal;left:522.1pt;position:var(--position);white-space:pre">&#9744;</span></div><div style="line-height:10pt;position:var(--position);top:640.35pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">If &#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement </span></div><div style="line-height:10pt;position:var(--position);top:651.55pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">item the registrant has elected to follow. </span><span style="font-family:'Arial', sans-serif;font-size:10pt;font-style:normal;font-weight:normal;left:235.1pt;position:var(--position);white-space:pre">&#9744;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:242.91pt;position:var(--position);white-space:pre"> Item 17 </span><span style="font-family:'Arial', sans-serif;font-size:10pt;font-style:normal;font-weight:normal;left:278.71000000000004pt;position:var(--position);white-space:pre">&#9744;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:286.52pt;position:var(--position);white-space:pre"> Item 18</span></div><div style="line-height:10pt;position:var(--position);top:673.95pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:685.15pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">12b-2 of the Exchange Act). </span><span style="font-family:'Arial', sans-serif;font-size:10pt;font-style:normal;font-weight:normal;left:188pt;position:var(--position);white-space:pre">&#9744;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:195.81pt;position:var(--position);white-space:pre"> Yes </span><span style="font-family:'Arial', sans-serif;font-size:10pt;font-style:normal;font-weight:normal;left:216.35pt;position:var(--position);white-space:pre">&#9746;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:224.16pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:226.66pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-38">No</ix:nonNumeric></span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:303.5pt;position:var(--position);text-decoration:none;white-space:pre">3</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_7"></div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:252.15pt;position:var(--position);text-decoration:none;white-space:pre">TABLE OF CONTENTS<span id="i302b23de585247f68bf8d6b2cf92580a"></span></span></div><div style="position:var(--position);top:96pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:468pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:421.2pt"/><td style="padding:0;width:46.8pt"/></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:14.87pt;position:var(--position);text-decoration:none;white-space:pre">Page</span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:13.21pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i4e22b06be0c44d2cabc326de2e1882d8">INTRODUCTION</a></span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:78.13pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:78.42pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:78.5pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:78.53999999999999pt;position:var(--position);text-decoration:none;white-space:pre">........................................................................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:13.21pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i4e22b06be0c44d2cabc326de2e1882d8">4</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:26.42pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i65510cfcb2864326a61f3f2e13481e7c">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:302.43pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:303.01pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:303.3pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:303.45pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:303.46999999999997pt;position:var(--position);text-decoration:none;white-space:pre">..............................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:26.42pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i65510cfcb2864326a61f3f2e13481e7c">4</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:39.63pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i13e1e72cc7ae45e8830bd4d542384c62">PART I</a></span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:34pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:35.160000000000004pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:35.74pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:35.82pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:35.86pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:35.88pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:35.89pt;position:var(--position);text-decoration:none;white-space:pre">.........................................................................................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:39.63pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i13e1e72cc7ae45e8830bd4d542384c62">6</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:52.84pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#ie196e9032fe441a8afa3177be9646649">Item 1.</a></span><span style="left:38.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#ie196e9032fe441a8afa3177be9646649"></a></span><span style="left:74.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#ie196e9032fe441a8afa3177be9646649">Identity of Directors, Senior Management and Advisers</a></span></span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:296.9pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:298.06pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:298.35pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:298.39pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:298.40999999999997pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.42pt;position:var(--position);text-decoration:none;white-space:pre">................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:52.84pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#ie196e9032fe441a8afa3177be9646649">6</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.05pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i7697a21334f3485182ed483576a7dadc">Item 2.</a></span><span style="left:38.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i7697a21334f3485182ed483576a7dadc"></a></span><span style="left:74.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i7697a21334f3485182ed483576a7dadc">Offer Statistics and Expected Timetable</a></span></span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:234.38pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:235.54pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:235.82999999999998pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:235.91pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:235.92pt;position:var(--position);text-decoration:none;white-space:pre">.........................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:66.05pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i7697a21334f3485182ed483576a7dadc">7</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:79.26pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#ib43ff824c8cb4cdc8f73a1cd6ab95c7f">Item 3.</a></span><span style="left:38.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#ib43ff824c8cb4cdc8f73a1cd6ab95c7f"></a></span><span style="left:74.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#ib43ff824c8cb4cdc8f73a1cd6ab95c7f">Key Information</a></span></span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:141.51pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:142.67pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:143.25pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:143.32999999999998pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:143.37pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:143.39pt;position:var(--position);text-decoration:none;white-space:pre">..............................................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:79.26pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#ib43ff824c8cb4cdc8f73a1cd6ab95c7f">8</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:92.47pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i3d6258ec83f54eaa8b87bfa0ba58ad89">Item 4.</a></span><span style="left:38.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i3d6258ec83f54eaa8b87bfa0ba58ad89"></a></span><span style="left:74.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i3d6258ec83f54eaa8b87bfa0ba58ad89">Information on the Company.</a></span></span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:193.42pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:193.5pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:193.54pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:193.56pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:193.57pt;position:var(--position);text-decoration:none;white-space:pre">..........................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:92.47pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:34.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i3d6258ec83f54eaa8b87bfa0ba58ad89">54</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:105.68pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#ie82dae1123824ba79a19f35aa9a77092">Item 4A. </a></span><span style="left:74.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#ie82dae1123824ba79a19f35aa9a77092">Unresolved Staff Comments.</a></span></span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:190.91pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:191.06pt;position:var(--position);text-decoration:none;white-space:pre">...........................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:105.68pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:34.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#ie82dae1123824ba79a19f35aa9a77092">84</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:118.89pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i154ad1556b5a479b8ca342cd539f13f3">Item 5.</a></span><span style="left:38.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i154ad1556b5a479b8ca342cd539f13f3"></a></span><span style="left:74.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i154ad1556b5a479b8ca342cd539f13f3">Operating and Financial Review and Prospects</a></span></span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:261.90999999999997pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:263.07pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:263.36pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:263.4pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:263.42pt;position:var(--position);text-decoration:none;white-space:pre">..............................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:118.89pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:34.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i154ad1556b5a479b8ca342cd539f13f3">85</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:132.1pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i96a97c7e6faa4dd0bc0a9cfd7a05f587">Item 6.</a></span><span style="left:38.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i96a97c7e6faa4dd0bc0a9cfd7a05f587"></a></span><span style="left:74.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i96a97c7e6faa4dd0bc0a9cfd7a05f587">Directors, Senior Management and Employees</a></span></span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:261.36pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:262.52pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:263.1pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:263.25pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:263.33pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:263.37pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:263.38pt;position:var(--position);text-decoration:none;white-space:pre">..............................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:132.1pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:29.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i96a97c7e6faa4dd0bc0a9cfd7a05f587">101</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:145.31pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i221c3f04e7be4082a734a3bd88d62251">Item 7.</a></span><span style="left:38.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i221c3f04e7be4082a734a3bd88d62251"></a></span><span style="left:74.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i221c3f04e7be4082a734a3bd88d62251">Major Shareholders and Related Party Transactions</a></span></span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:280.77pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:280.92pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:281pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:281.04pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:281.06pt;position:var(--position);text-decoration:none;white-space:pre">.......................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:145.31pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:29.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i221c3f04e7be4082a734a3bd88d62251">132</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:158.52pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i6c7811576aae4cba9fc453dd4dfa1201">Item 8.</a></span><span style="left:38.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i6c7811576aae4cba9fc453dd4dfa1201"></a></span><span style="left:74.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i6c7811576aae4cba9fc453dd4dfa1201">Financial Information</a></span></span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:162.01999999999998pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:163.18pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:163.32999999999998pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:163.41pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:163.43pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:163.44pt;position:var(--position);text-decoration:none;white-space:pre">......................................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:158.52pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:29.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i6c7811576aae4cba9fc453dd4dfa1201">135</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:171.73pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i4293f704253543c3bf3137249451c700">Item 9.</a></span><span style="left:38.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i4293f704253543c3bf3137249451c700"></a></span><span style="left:74.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i4293f704253543c3bf3137249451c700">The Offer and Listing</a></span></span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:162.03pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:163.19pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:163.34pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:163.42pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:163.44pt;position:var(--position);text-decoration:none;white-space:pre">......................................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:171.73pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:29.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i4293f704253543c3bf3137249451c700">136</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:184.94pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i14117f6a019d493ea833e57b36a6fc1f">Item 10.</a></span><span style="left:38.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i14117f6a019d493ea833e57b36a6fc1f"></a></span><span style="left:74.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i14117f6a019d493ea833e57b36a6fc1f">Additional Information.</a></span></span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:170.09pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:170.67pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:170.96pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:170.98pt;position:var(--position);text-decoration:none;white-space:pre">...................................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:184.94pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:29.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i14117f6a019d493ea833e57b36a6fc1f">137</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:198.15pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#if89bd01dc74b40a1a7e3a5e16ee9e3c4">Item 11.</a></span><span style="left:38.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#if89bd01dc74b40a1a7e3a5e16ee9e3c4"></a></span><span style="left:74.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#if89bd01dc74b40a1a7e3a5e16ee9e3c4">Quantitative and Qualitative Disclosures About Market Risk</a></span></span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:316.56pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:317.71999999999997pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:318.3pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:318.38pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:318.39pt;position:var(--position);text-decoration:none;white-space:pre">........................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:198.15pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:29.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#if89bd01dc74b40a1a7e3a5e16ee9e3c4">147</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:211.36pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#iaf9377f05838460298f4958d0f3b253c">Item 12.</a></span><span style="left:38.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#iaf9377f05838460298f4958d0f3b253c"></a></span><span style="left:74.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#iaf9377f05838460298f4958d0f3b253c">Description of Securities Other than Equity Securities</a></span></span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:289.92pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:290.5pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:290.79pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:290.94pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:290.96pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:290.96999999999997pt;position:var(--position);text-decoration:none;white-space:pre">...................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:211.36pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:29.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#iaf9377f05838460298f4958d0f3b253c">149</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:224.57pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#ia9786d3f07b147668722cff2baa4d714">PART II</a></span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:37.330000000000005pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:37.910000000000004pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:38.2pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:38.35pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:38.43pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:38.470000000000006pt;position:var(--position);text-decoration:none;white-space:pre">........................................................................................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:224.57pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:29.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#ia9786d3f07b147668722cff2baa4d714">151</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:237.78pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i916ad87a5ab840128257c67e003d2686">Item 13.</a></span><span style="left:38.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i916ad87a5ab840128257c67e003d2686"></a></span><span style="left:74.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i916ad87a5ab840128257c67e003d2686">Defaults, Dividend Arrearages and Delinquencies</a></span></span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:273.55pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:273.57pt;position:var(--position);text-decoration:none;white-space:pre">..........................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:237.78pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:29.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i916ad87a5ab840128257c67e003d2686">151</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:250.99pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i4ea7fbbf56ad4bf094735d9b45bf2ac6">Item 14.</a></span><span style="left:38.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i4ea7fbbf56ad4bf094735d9b45bf2ac6"></a></span><span style="left:74.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i4ea7fbbf56ad4bf094735d9b45bf2ac6">Material Modifications to the Rights of Security Holders and Use of Proceeds</a></span></span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:385.69pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:385.98pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:386.02pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:386.04pt;position:var(--position);text-decoration:none;white-space:pre">.............</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:250.99pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:29.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i4ea7fbbf56ad4bf094735d9b45bf2ac6">152</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:264.2pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i7b73f7b395614f9e98f390ec15bcb896">Item 15.</a></span><span style="left:38.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i7b73f7b395614f9e98f390ec15bcb896"></a></span><span style="left:74.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i7b73f7b395614f9e98f390ec15bcb896">Controls and Procedures</a></span></span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:172.88pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:173.46pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:173.5pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:173.51pt;position:var(--position);text-decoration:none;white-space:pre">..................................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:264.2pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:29.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i7b73f7b395614f9e98f390ec15bcb896">153</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:277.41pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i93a99af6c6324362a28db117160ebf43">Item 16.</a></span><span style="left:38.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i93a99af6c6324362a28db117160ebf43"></a></span><span style="left:74.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i93a99af6c6324362a28db117160ebf43">[Reserved]</a></span></span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:118.46pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:118.53999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:118.56pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:118.57pt;position:var(--position);text-decoration:none;white-space:pre">........................................................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:277.41pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:29.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i93a99af6c6324362a28db117160ebf43">155</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:290.62pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i4f04e7552da04af7ba749682bdcc2685">Item 16A.</a></span><span style="left:74.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i4f04e7552da04af7ba749682bdcc2685">Audit Committee Financial Expert</a></span></span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:213.04999999999998pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:213.34pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:213.49pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:213.53pt;position:var(--position);text-decoration:none;white-space:pre">..................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:290.62pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:29.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i4f04e7552da04af7ba749682bdcc2685">155</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:303.83pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i8d421226ce09418182ea3e608ed6d1e6">Item 16B.</a></span><span style="left:74.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i8d421226ce09418182ea3e608ed6d1e6">Code of Ethics</a></span></span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:134.01pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:135.17pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:135.75pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:135.82999999999998pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:135.87pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:135.89pt;position:var(--position);text-decoration:none;white-space:pre">.................................................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:303.83pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:29.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i8d421226ce09418182ea3e608ed6d1e6">155</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:317.04pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i07d5b04f6c1d4fde95fa37694d9e3c37">Item 16C.</a></span><span style="left:74.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i07d5b04f6c1d4fde95fa37694d9e3c37">Principal Accountant Fees and Services</a></span></span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:233.32pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:233.47pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:233.54999999999998pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:233.56pt;position:var(--position);text-decoration:none;white-space:pre">..........................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:317.04pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:29.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i07d5b04f6c1d4fde95fa37694d9e3c37">155</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:330.25pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i0ee554ab85064c87a702440c74e03176">Item 16D.</a></span><span style="left:74.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i0ee554ab85064c87a702440c74e03176">Exemptions from the Listing Standards for Audit Committees</a></span></span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:321.88pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:323.04pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:323.33pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:323.40999999999997pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:323.42pt;position:var(--position);text-decoration:none;white-space:pre">......................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:330.25pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:29.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i0ee554ab85064c87a702440c74e03176">156</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:343.46pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#ia8b8ac26e96945569ca28bd17a24670a">Item 16E.</a></span><span style="left:74.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#ia8b8ac26e96945569ca28bd17a24670a">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</a></span></span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:354.05pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:355.21pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:355.79pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:355.87pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:355.89pt;position:var(--position);text-decoration:none;white-space:pre">.........................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:343.46pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:29.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#ia8b8ac26e96945569ca28bd17a24670a">156</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:356.67pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i10ce1263950b4e8aa37013ff8539a1c3">Item 16F.</a></span><span style="left:74.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i10ce1263950b4e8aa37013ff8539a1c3">Change in Registrant&#8217;s Certifying Accountant</a></span></span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:258.3pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:258.45pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:258.53000000000003pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:258.55pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:258.56pt;position:var(--position);text-decoration:none;white-space:pre">................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:356.67pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:29.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i10ce1263950b4e8aa37013ff8539a1c3">156</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:369.88pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i64ffcd16ece64067895873399d959ae2">Item 16G.</a></span><span style="left:74.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i64ffcd16ece64067895873399d959ae2">Corporate Governance</a></span></span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:165.35pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:165.93pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:166.01pt;position:var(--position);text-decoration:none;white-space:pre">.....................................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:369.88pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:29.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i64ffcd16ece64067895873399d959ae2">156</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:383.09pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i18640a52a27d412d91865c66bc841e5b">Item 16H.</a></span><span style="left:74.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i18640a52a27d412d91865c66bc841e5b">Mine Safety Disclosure</a></span></span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:168.97pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:170.13pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:170.71pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:170.85999999999999pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:170.88pt;position:var(--position);text-decoration:none;white-space:pre">...................................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:383.09pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:29.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i18640a52a27d412d91865c66bc841e5b">157</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:396.3pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i1d00a4ce11604ea38478030d23e246c5">Item 16I.</a></span><span style="left:74.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i1d00a4ce11604ea38478030d23e246c5">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:346.58pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:347.74pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:348.32pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:348.36pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:348.38pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:348.39pt;position:var(--position);text-decoration:none;white-space:pre">............................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:396.3pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:29.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i1d00a4ce11604ea38478030d23e246c5">157</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:409.51pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i3477383588404220960707720441ccc9">Item 16J.</a></span><span style="left:74.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i3477383588404220960707720441ccc9">Insider Trading Policies</a></span></span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:170.63pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:170.92pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:171pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:171.04pt;position:var(--position);text-decoration:none;white-space:pre">...................................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:409.51pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:29.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i3477383588404220960707720441ccc9">157</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:422.72pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#id5656c62ef694bc8855e8fa9b7fd2901">Item 16K.</a></span><span style="left:74.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#id5656c62ef694bc8855e8fa9b7fd2901">Cybersecurity</a></span></span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:130.67pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:130.96pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:131.04pt;position:var(--position);text-decoration:none;white-space:pre">...................................................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:422.72pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:29.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#id5656c62ef694bc8855e8fa9b7fd2901">157</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:435.93pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i8af2598290454e508a5b4a9567a69f9b">PART III</a></span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:40.660000000000004pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:40.95pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:41.03pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:41.04pt;position:var(--position);text-decoration:none;white-space:pre">.......................................................................................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:435.93pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:29.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i8af2598290454e508a5b4a9567a69f9b">159</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:449.14pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i08a771d6c5d34609b9358f3317868108">Item 17.</a></span><span style="left:38.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i08a771d6c5d34609b9358f3317868108"></a></span><span style="left:74.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i08a771d6c5d34609b9358f3317868108">Financial Statements</a></span></span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:158.10999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:158.4pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:158.48pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:158.51999999999998pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.54pt;position:var(--position);text-decoration:none;white-space:pre">........................................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:449.14pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:29.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i08a771d6c5d34609b9358f3317868108">159</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:462.35pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i5612c3da844146c6969843b8cdd93991">Item 18.</a></span><span style="left:38.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i5612c3da844146c6969843b8cdd93991"></a></span><span style="left:74.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i5612c3da844146c6969843b8cdd93991">Financial Statements</a></span></span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:158.10999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:158.4pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:158.48pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:158.51999999999998pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.54pt;position:var(--position);text-decoration:none;white-space:pre">........................................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:462.35pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:29.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i5612c3da844146c6969843b8cdd93991">160</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:475.56pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i358eba766ca24ae98940620872dbb5ed">Item 19.</a></span><span style="left:38.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i358eba766ca24ae98940620872dbb5ed"></a></span><span style="left:74.63pt;position:var(--position)"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i358eba766ca24ae98940620872dbb5ed">Exhibits</a></span></span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:107.92999999999999pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108.50999999999999pt;position:var(--position);text-decoration:none;white-space:pre">............................................................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:475.56pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:29.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i358eba766ca24ae98940620872dbb5ed">161</a></span></div></div></div></td></tr><tr style="height:13.21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:488.77pt;width:421.2pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:421.2pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#ibef2644fce1c434982fa363e312aa70a">SIGNATURES</a></span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:64.82pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:65.4pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:65.69pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:65.84pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:65.92pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:65.96pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:65.97pt;position:var(--position);text-decoration:none;white-space:pre">.............................................................................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:421.2pt;position:var(--position);top:488.77pt;width:46.8pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:46.8pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:29.17pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#ibef2644fce1c434982fa363e312aa70a">163</a></span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:602.98pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:468pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:422.25pt"/><td style="padding:0;width:45.75pt"/></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:422.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:422.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i7a006daedb3d4216a4128b76247285d7_259">INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS</a></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:274.94pt;position:var(--position);text-decoration:none;white-space:pre">.........................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:45.75pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:29.23pt;position:var(--position);text-decoration:none;white-space:pre">F-</span><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:38.120000000000005pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i7a006daedb3d4216a4128b76247285d7_259">1</a></span></div></div></div></td></tr></tbody></table></div></div></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:303.5pt;position:var(--position);text-decoration:none;white-space:pre">4</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_10"></div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:266.02pt;position:var(--position);text-decoration:none;white-space:pre">INTRODUCTION<span id="i4e22b06be0c44d2cabc326de2e1882d8"></span></span></div><div style="line-height:10pt;position:var(--position);top:90pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">Unless otherwise indicated or the context otherwise requires, &#8220;Abivax,&#8221; &#8220;the company,&#8221; &#8220;our company,&#8221; </span></div><div style="line-height:10pt;position:var(--position);top:100pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">&#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Abivax </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:222.92pt;position:var(--position);text-decoration:none;white-space:pre">SA</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:235.7pt;position:var(--position);white-space:pre"> and its consolidated subsidiary, taken as a whole. </span></div><div style="line-height:10pt;position:var(--position);top:116pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">&#8220;Abivax&#8221; and the Abivax logo and other trademarks or service marks of Abivax SA appearing in this Annual </span></div><div style="line-height:10pt;position:var(--position);top:126pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">Report on Form 20-F are the property of Abivax SA. Solely for convenience, the trademarks, service marks and </span></div><div style="line-height:10pt;position:var(--position);top:136pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">trade names referred to in this annual report are listed without the </span><span style="font-family:'Times New Roman', serif;font-size:4.875pt;font-style:normal;font-weight:normal;left:336.1pt;position:var(--position);top:-2.4254999999999995pt;vertical-align:super;white-space:pre">&#174;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:339.8pt;position:var(--position);white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:4.875pt;font-style:normal;font-weight:normal;left:359.23pt;position:var(--position);top:-2.4254999999999995pt;vertical-align:super;white-space:pre">&#8482;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:364pt;position:var(--position);white-space:pre"> symbols, but such references should not be </span></div><div style="line-height:10pt;position:var(--position);top:146pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their </span></div><div style="line-height:10pt;position:var(--position);top:156pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">right thereto. All other </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:164.39pt;position:var(--position);text-decoration:none;white-space:pre">trademarks</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:208.77pt;position:var(--position);white-space:pre">, trade names and service marks appearing in this annual report are the property of </span></div><div style="line-height:10pt;position:var(--position);top:166pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">their respective owners. We do not intend to use or display other companies&#8217; trademarks and trade names to imply </span></div><div style="line-height:10pt;position:var(--position);top:176pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">any relationship with, or endorsement or sponsorship of us by, any other companies. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:192pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">This Annual Report on Form </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:215.03pt;position:var(--position);text-decoration:none;white-space:pre">20-F</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:233.92pt;position:var(--position);white-space:pre"> includes our audited financial statements as of and for the years ended</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:516.9pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:202pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">December 31, 2025, 2024 and 2023</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:214.97pt;position:var(--position);white-space:pre"> prepared in accordance with International Financial Reporting Standards </span></div><div style="line-height:10pt;position:var(--position);top:212pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">(&#8220;IFRS&#8221;), as issued by the International Accounting Standards Board (&#8220;IASB&#8221;). None of our financial statements </span></div><div style="line-height:10pt;position:var(--position);top:222pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">were prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). Our financial </span></div><div style="line-height:10pt;position:var(--position);top:232pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">statements are presented in euros and, unless otherwise stated, all monetary amounts are in euros. All references in </span></div><div style="line-height:10pt;position:var(--position);top:242pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">this annual report to &#8220;$&#8221;, &#8220;U.S. dollars&#8221; and &#8220;dollars&#8221; mean U.S. dollars, and all references to &#8220;&#8364;&#8221;, &#8220;EUR&#8221; and </span></div><div style="line-height:10pt;position:var(--position);top:252pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">&#8220;euros&#8221; mean European Monetary Union euros, unless otherwise noted. Throughout this annual report, references to </span></div><div style="line-height:10pt;position:var(--position);top:262pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">&#8220;ADSs&#8221; mean American Depositary Shares representing an ownership interest in our ordinary shares or ordinary </span></div><div style="line-height:10pt;position:var(--position);top:272pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">shares represented by such American Depositary Shares, as the case may be.</span></div><div style="position:absolute;top:293.2pt" id="i7a006daedb3d4216a4128b76247285d7_13"></div><div style="line-height:10pt;position:var(--position);top:293.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:147.48pt;position:var(--position);text-decoration:none;white-space:pre">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS<span id="i65510cfcb2864326a61f3f2e13481e7c"></span></span></div><div style="line-height:10pt;position:var(--position);top:311.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">This Annual </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:148.68pt;position:var(--position);text-decoration:none;white-space:pre">Report</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:175.87pt;position:var(--position);white-space:pre"> on Form 20-F, or annual report, contains forward-looking statements within the meaning </span></div><div style="line-height:10pt;position:var(--position);top:321.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, </span></div><div style="line-height:10pt;position:var(--position);top:331.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">as amended ("Exchange Act"), that are based on our management&#8217;s beliefs and assumptions and on information </span></div><div style="line-height:10pt;position:var(--position);top:341.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">currently available to our management. All statements other than present and historical facts and conditions </span></div><div style="line-height:10pt;position:var(--position);top:351.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">contained in this </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.53pt;position:var(--position);white-space:pre">annual</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:167.16pt;position:var(--position);white-space:pre"> report, including statements regarding our future results of operations and financial </span></div><div style="line-height:10pt;position:var(--position);top:361.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">positions, business strategy, plans and our objectives for future operations, are forward-looking statements. When </span></div><div style="line-height:10pt;position:var(--position);top:371.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">used in this annual report, the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;is </span></div><div style="line-height:10pt;position:var(--position);top:381.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">designed to,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;objective,&#8221; &#8220;should,&#8221; or the negative </span></div><div style="line-height:10pt;position:var(--position);top:391.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">of these and similar expressions identify forward-looking statements. Forward-looking statements include, but are </span></div><div style="line-height:10pt;position:var(--position);top:401.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">not limited to, statements about:</span></div><div style="line-height:10pt;position:var(--position);top:423.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.5pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:103.5pt;position:var(--position);white-space:pre">the prospects of attaining, maintaining and expanding marketing authorization for our lead drug candidate, </span></div><div style="line-height:10pt;position:var(--position);top:434.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:103.5pt;position:var(--position);white-space:pre">obefazimod; </span></div><div style="line-height:10pt;position:var(--position);top:445.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.5pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:103.5pt;position:var(--position);white-space:pre">the potential attributes and clinical advantages of obefazimod and our future drug candidates; </span></div><div style="line-height:10pt;position:var(--position);top:456.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.5pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:103.5pt;position:var(--position);white-space:pre">the initiation, timing, progress and results of our preclinical and clinical trials (and those conducted by third </span></div><div style="line-height:10pt;position:var(--position);top:468pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:103.5pt;position:var(--position);white-space:pre">parties) and other research and development programs; </span></div><div style="line-height:10pt;position:var(--position);top:479.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.5pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:103.5pt;position:var(--position);white-space:pre">the timing of the availability of data from our clinical trials, including our Phase 3 maintenance trial of </span></div><div style="line-height:10pt;position:var(--position);top:490.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:103.5pt;position:var(--position);white-space:pre">obefazimod in moderately to severely active ulcerative colitis and Phase 2b trial of obefazimod in Crohn's </span></div><div style="line-height:10pt;position:var(--position);top:501.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:103.5pt;position:var(--position);white-space:pre">disease; </span></div><div style="line-height:10pt;position:var(--position);top:512.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.5pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:103.5pt;position:var(--position);white-space:pre">the timing of and our ability to advance drug candidates through clinical development; </span></div><div style="line-height:10pt;position:var(--position);top:524pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.5pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:103.5pt;position:var(--position);white-space:pre">the timing or likelihood of regulatory meetings and filings; </span></div><div style="line-height:10pt;position:var(--position);top:535.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.5pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:103.5pt;position:var(--position);white-space:pre">the timing of and our ability to obtain and maintain regulatory approvals for obefazimod and any of our </span></div><div style="line-height:10pt;position:var(--position);top:546.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:103.5pt;position:var(--position);white-space:pre">future drug candidates; </span></div><div style="line-height:10pt;position:var(--position);top:557.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.5pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:103.5pt;position:var(--position);white-space:pre">our ability to identify and develop new drug candidates from our preclinical studies; </span></div><div style="line-height:10pt;position:var(--position);top:568.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.5pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:103.5pt;position:var(--position);white-space:pre">our ability to develop sales and marketing capabilities and transition into a commercial-stage company; </span></div><div style="line-height:10pt;position:var(--position);top:580pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.5pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:103.5pt;position:var(--position);white-space:pre">the effects of increased competition as well as innovations by new and existing competitors in our industry; </span></div><div style="line-height:10pt;position:var(--position);top:591.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.5pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:103.5pt;position:var(--position);white-space:pre">our ability to enter into strategic relationships or partnerships; </span></div><div style="line-height:10pt;position:var(--position);top:602.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.5pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:103.5pt;position:var(--position);white-space:pre">our ability to obtain, maintain, protect and enforce our intellectual property rights and propriety technologies </span></div><div style="line-height:10pt;position:var(--position);top:613.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:103.5pt;position:var(--position);white-space:pre">and to operate our business without infringing the intellectual property rights and proprietary technology of </span></div><div style="line-height:10pt;position:var(--position);top:624.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:103.5pt;position:var(--position);white-space:pre">third parties;&#160; </span></div><div style="line-height:10pt;position:var(--position);top:636pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.5pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:103.5pt;position:var(--position);white-space:pre">our estimates regarding expenses, future revenues, capital requirements and the need for additional </span></div><div style="line-height:10pt;position:var(--position);top:647.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:103.5pt;position:var(--position);white-space:pre">financing; </span></div><div style="line-height:10pt;position:var(--position);top:658.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.5pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:103.5pt;position:var(--position);white-space:pre">the impact of government laws and regulations;</span></div><div style="line-height:10pt;position:var(--position);top:669.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.5pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:103.5pt;position:var(--position);white-space:pre">our competitive position;</span></div><div style="line-height:10pt;position:var(--position);top:680.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.5pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:103.5pt;position:var(--position);white-space:pre">unfavorable conditions in our industry, the global economy or global supply chain, including financial and </span></div><div style="line-height:10pt;position:var(--position);top:692pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:103.5pt;position:var(--position);white-space:pre">credit market fluctuations, international trade relations, political turmoil, natural catastrophes, warfare (such </span></div><div style="line-height:10pt;position:var(--position);top:703.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:103.5pt;position:var(--position);white-space:pre">as the Russia-Ukraine war or the conflict in the Middle East), and terrorist attacks; and </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:303.5pt;position:var(--position);text-decoration:none;white-space:pre">5</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.5pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:103.5pt;position:var(--position);white-space:pre">other risks and uncertainties, including those listed in this annual report under the caption &#8220;Risk Factors.&#8221; </span></div><div style="line-height:10pt;position:var(--position);top:89.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">You should refer to the section of this annual report titled &#8220;Item 3.D-Risk Factors&#8221; for a discussion of </span></div><div style="line-height:10pt;position:var(--position);top:99.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">important factors that may cause our actual results to differ materially from those expressed or implied by our </span></div><div style="line-height:10pt;position:var(--position);top:109.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in </span></div><div style="line-height:10pt;position:var(--position);top:119.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">this annual report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, </span></div><div style="line-height:10pt;position:var(--position);top:129.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">the inaccuracy may be </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:164.07999999999998pt;position:var(--position);text-decoration:none;white-space:pre">material</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:196.78pt;position:var(--position);white-space:pre">. In light of the significant uncertainties in these forward-looking statements, you </span></div><div style="line-height:10pt;position:var(--position);top:139.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">should not regard these statements as a representation or warranty by us or any other person that we will achieve our </span></div><div style="line-height:10pt;position:var(--position);top:149.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">objectives and plans in any specified time frame or at all. We undertake no obligation to publicly update any </span></div><div style="line-height:10pt;position:var(--position);top:159.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">forward-looking statements, whether as a result of new information, future events or otherwise, except as required </span></div><div style="line-height:10pt;position:var(--position);top:169.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">by law.</span></div><div style="line-height:10pt;position:var(--position);top:185.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">You should read this annual report and the documents that we reference in this annual report and have filed as </span></div><div style="line-height:10pt;position:var(--position);top:195.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">exhibits to this annual </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:162.45999999999998pt;position:var(--position);text-decoration:none;white-space:pre">report</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:186.32pt;position:var(--position);white-space:pre"> completely and with the understanding that our actual future results may be materially </span></div><div style="line-height:10pt;position:var(--position);top:205.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.</span></div><div style="line-height:10pt;position:var(--position);top:221.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">This annual report </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:172.25pt;position:var(--position);text-decoration:none;white-space:pre">contains</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:205.54000000000002pt;position:var(--position);white-space:pre"> market data and industry forecasts that were obtained from industry publications. </span></div><div style="line-height:10pt;position:var(--position);top:231.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such </span></div><div style="line-height:10pt;position:var(--position);top:241.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">estimates. We have not independently verified any third-party information. While we believe the market position, </span></div><div style="line-height:10pt;position:var(--position);top:251.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">market opportunity and market size information included in this annual report is generally reliable, such information </span></div><div style="line-height:10pt;position:var(--position);top:261.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">is inherently imprecise.</span></div><div style="line-height:10pt;position:var(--position);top:282.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);white-space:pre">Summary Risk Factors</span></div><div style="line-height:10pt;position:var(--position);top:304.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">We are a clinical-stage company with a limited operating history and no approved products and no </span></div><div style="line-height:10pt;position:var(--position);top:316pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">historical product revenues, which makes it difficult to assess our future prospects and financial results. </span></div><div style="line-height:10pt;position:var(--position);top:327.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">We have incurred considerable losses historically, which we anticipate will continue and may increase in </span></div><div style="line-height:10pt;position:var(--position);top:338.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">the future. </span></div><div style="line-height:10pt;position:var(--position);top:349.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">Drug candidates under development must undergo costly, rigorous and highly regulated preclinical studies </span></div><div style="line-height:10pt;position:var(--position);top:360.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">and clinical trials, whose time of completion, number and outcomes are uncertain. </span></div><div style="line-height:10pt;position:var(--position);top:372pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">We are heavily dependent on the success of our drug candidates, in particular obefazimod, and we cannot </span></div><div style="line-height:10pt;position:var(--position);top:383.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">be certain that obefazimod or any of our other current or future drug candidates will receive regulatory </span></div><div style="line-height:10pt;position:var(--position);top:394.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">approval, and, without regulatory approval, we will not be able to market our drug candidates.</span></div><div style="line-height:10pt;position:var(--position);top:405.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">Clinical failure can occur at any stage of clinical development. The results of earlier clinical trials as well as </span></div><div style="line-height:10pt;position:var(--position);top:416.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">data from any interim analysis of ongoing trials are not necessarily predictive of future results and any drug </span></div><div style="line-height:10pt;position:var(--position);top:428pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">candidate we advance through clinical trials may not have favorable results in later clinical trials. </span></div><div style="line-height:10pt;position:var(--position);top:439.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">Our future may depend on our most advanced clinical development program, obefazimod, since our other </span></div><div style="line-height:10pt;position:var(--position);top:450.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">drug candidates are in a less advanced stage of development. </span></div><div style="line-height:10pt;position:var(--position);top:461.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">We expect to expand our organization, and as a result, we may encounter difficulties in managing our </span></div><div style="line-height:10pt;position:var(--position);top:472.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">growth, which could disrupt our operations. </span></div><div style="line-height:10pt;position:var(--position);top:484pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">We rely on a small number of third-party suppliers and manufacturers, and in certain cases a single-source </span></div><div style="line-height:10pt;position:var(--position);top:495.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">supplier, and we may be in a position of dependence with respect to these third parties. </span></div><div style="line-height:10pt;position:var(--position);top:506.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">Our future success depends on our ability to retain our key executives and to attract, retain and motivate </span></div><div style="line-height:10pt;position:var(--position);top:517.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">qualified personnel. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:528.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);text-decoration:none;white-space:pre">There are material weaknesses in our internal controls over financial reporting and if we are unable to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:540pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);text-decoration:none;white-space:pre">maintain effective internal controls over financial reporting, the accuracy and timeliness of our financial </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:551.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);text-decoration:none;white-space:pre">reporting may be adversely affected, which could adversely affect our business, investor confidence and the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:562.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);text-decoration:none;white-space:pre">market price of our securities.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:227.56pt;position:var(--position);white-space:pre"> </span></div><div style="line-height:10pt;position:var(--position);top:573.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">Our ability to exclusively commercialize our drug candidates may decrease if we are unable to protect our </span></div><div style="line-height:10pt;position:var(--position);top:584.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">intellectual property rights or if these rights are insufficient for our purposes.</span></div><div style="line-height:10pt;position:var(--position);top:596pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">Failure or perceived failure to comply with existing or future laws, regulations, contracts, self-regulatory </span></div><div style="line-height:10pt;position:var(--position);top:607.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">schemes, standards, and other obligations related to data privacy or security (including security incidents) </span></div><div style="line-height:10pt;position:var(--position);top:618.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">could harm our business.&#160; Compliance or the actual or perceived failure to comply with such obligations </span></div><div style="line-height:10pt;position:var(--position);top:629.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">could increase our costs, limit our ability to engage in our business, and otherwise negatively affect our </span></div><div style="line-height:10pt;position:var(--position);top:640.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">operating results and business. </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:303.5pt;position:var(--position);text-decoration:none;white-space:pre">6</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_16"></div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:289.2pt;position:var(--position);text-decoration:none;white-space:pre">PART I<span id="i13e1e72cc7ae45e8830bd4d542384c62"></span></span></div><div style="position:absolute;top:108pt" id="i7a006daedb3d4216a4128b76247285d7_19"></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">Item 1.<span style="display:inline-block;height:6.77pt;width:6.02pt"></span></span><span style="left:108pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:36pt"></span></span><span style="left:144pt;position:var(--position)">Identity of Directors, Senior Management and Advisers</span><span id="ie196e9032fe441a8afa3177be9646649"></span></span></div><div style="line-height:10pt;position:var(--position);top:132pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">Not applicable.</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:303.5pt;position:var(--position);text-decoration:none;white-space:pre">7</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_22"></div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">Item 2.<span style="display:inline-block;height:6.77pt;width:6.02pt"></span></span><span style="left:108pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:36pt"></span></span><span style="left:144pt;position:var(--position)">Offer Statistics and Expected Timetable</span><span id="i7697a21334f3485182ed483576a7dadc"></span></span></div><div style="line-height:10pt;position:var(--position);top:96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">Not applicable.</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:303.5pt;position:var(--position);text-decoration:none;white-space:pre">8</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_25"></div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">Item 3.<span style="display:inline-block;height:6.77pt;width:6.02pt"></span></span><span style="left:108pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:36pt"></span></span><span style="left:144pt;position:var(--position)">Key Information</span><span id="ib43ff824c8cb4cdc8f73a1cd6ab95c7f"></span></span></div><div style="position:absolute;top:96pt" id="i7a006daedb3d4216a4128b76247285d7_28"></div><div style="line-height:10pt;position:var(--position);top:96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">A.<span id="i4c98aeb850294828a296e325b0eb8ba4"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">[Reserved]</span></div><div style="line-height:10pt;position:var(--position);top:120pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.5pt;position:var(--position);white-space:pre">Not applicable.</span></div><div style="position:absolute;top:144pt" id="i7a006daedb3d4216a4128b76247285d7_31"></div><div style="line-height:10pt;position:var(--position);top:144pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">B.<span id="ib340fc81ccc94e7f84b20a903958943c"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Capitalization and Indebtedness</span></div><div style="line-height:10pt;position:var(--position);top:168pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.5pt;position:var(--position);white-space:pre">Not applicable.</span></div><div style="position:absolute;top:192pt" id="i7a006daedb3d4216a4128b76247285d7_34"></div><div style="line-height:10pt;position:var(--position);top:192pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">C.<span id="i7772549aecf346039eaec3bada9a7d1c"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Reasons for the Offer and Use of Proceeds</span></div><div style="line-height:10pt;position:var(--position);top:216pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.5pt;position:var(--position);white-space:pre">Not applicable.</span></div><div style="position:absolute;top:240pt" id="i7a006daedb3d4216a4128b76247285d7_37"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:240pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">D.<span id="i35a9d4522dfb4268892f5a62870b17e7"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Risk Factors</span></div><div style="line-height:10pt;position:var(--position);top:264pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our business faces significant risks. You should carefully consider all of the information set forth in this </span></div><div style="line-height:10pt;position:var(--position);top:274pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">annual report and in our other filings with the United States Securities and Exchange Commission (the "SEC"), </span></div><div style="line-height:10pt;position:var(--position);top:284pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">including the following risk factors which we face and which are faced by our industry. Our business, financial </span></div><div style="line-height:10pt;position:var(--position);top:294pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">condition or results of operations could be materially adversely affected by any of these risks. This report also </span></div><div style="line-height:10pt;position:var(--position);top:304pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">contains forward-looking statements that involve risks and uncertainties. Our results could materially differ from </span></div><div style="line-height:10pt;position:var(--position);top:314pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">those anticipated in these forward-looking statements, as a result of certain factors including the risks described </span></div><div style="line-height:10pt;position:var(--position);top:324pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">below and elsewhere in this annual report and our other SEC filings. See &#8220;Special Note Regarding Forward-</span></div><div style="line-height:10pt;position:var(--position);top:334pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Looking Statements&#8221; above.</span></div><div style="line-height:10pt;position:var(--position);top:362pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Risks Related to our Financial Position and Need for Additional Capital </span></div><div style="line-height:10pt;position:var(--position);top:378pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">We are a clinical-stage company with a limited operating history and no approved products and no historical </span></div><div style="line-height:10pt;position:var(--position);top:388pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">product revenues, which makes it difficult to assess our future prospects and financial results. </span></div><div style="line-height:10pt;position:var(--position);top:404pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We are a clinical-stage biopharmaceutical company with a limited operating history upon which you can </span></div><div style="line-height:10pt;position:var(--position);top:414pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">evaluate our business and prospects. We were incorporated as a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:328.64pt;position:var(--position);text-decoration:none;white-space:pre">soci&#233;t&#233; anonyme</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:394.94pt;position:var(--position);text-decoration:none;white-space:pre"> (limited liability company) on </span></div><div style="line-height:10pt;position:var(--position);top:424pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">December&#160;4, 2013 and, to date, we have focused primarily on organizing and staffing our company, business </span></div><div style="line-height:10pt;position:var(--position);top:434pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">planning, raising capital, identifying, acquiring and&#160;in-licensing&#160;our drug candidates, establishing our intellectual </span></div><div style="line-height:10pt;position:var(--position);top:444pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">property portfolio, conducting research, preclinical studies and clinical trials, establishing arrangements with third </span></div><div style="line-height:10pt;position:var(--position);top:454pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">parties for the manufacture of our drug candidates and related raw materials and providing general and </span></div><div style="line-height:10pt;position:var(--position);top:464pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">administrative support for these operations.&#160;Investment in product development in the healthcare industry, including </span></div><div style="line-height:10pt;position:var(--position);top:474pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of biopharmaceutical products, is highly speculative because it entails substantial upfront capital expenditures and </span></div><div style="line-height:10pt;position:var(--position);top:484pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">significant risk that any potential drug candidate will fail to demonstrate adequate effect or an acceptable safety </span></div><div style="line-height:10pt;position:var(--position);top:494pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">profile, gain regulatory approval or become commercially viable. As a result, our ability to reduce our losses and </span></div><div style="line-height:10pt;position:var(--position);top:504pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reach consistent profitability from product sales is unproven, and we may never sustain profitability. We have no </span></div><div style="line-height:10pt;position:var(--position);top:514pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">products approved for commercial sale and have not generated any revenue from product sales to date. </span></div><div style="line-height:10pt;position:var(--position);top:530pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our ability to generate revenue from product sales and achieve and maintain profitability depends on our </span></div><div style="line-height:10pt;position:var(--position);top:540pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ability, alone or with any future collaborators, to successfully complete the development of, and obtain the </span></div><div style="line-height:10pt;position:var(--position);top:550pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regulatory approvals necessary to commercialize, our lead drug candidate, obefazimod. Our prospects, including our </span></div><div style="line-height:10pt;position:var(--position);top:560pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ability to finance our operations and generate revenue from product sales, therefore will depend substantially on the </span></div><div style="line-height:10pt;position:var(--position);top:570pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">development and commercialization of obefazimod, as other programs in our preclinical portfolio are still in earlier </span></div><div style="line-height:10pt;position:var(--position);top:580pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">stages of development. Since our inception in 2013, the majority of our operating income has been derived from our </span></div><div style="line-height:10pt;position:var(--position);top:590pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reliance on research collaborations unrelated to obefazimod, and we do not anticipate generating revenue from </span></div><div style="line-height:10pt;position:var(--position);top:600pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">product sales for the next several years, if ever. Our ability to generate revenue from product sales depends heavily </span></div><div style="line-height:10pt;position:var(--position);top:610pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">on our or any future collaborators&#8217; success in: </span></div><div style="line-height:10pt;position:var(--position);top:626pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">timely and successful completion of clinical development of obefazimod, our lead drug candidate; </span></span></div><div style="line-height:10pt;position:var(--position);top:642pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">obtaining and maintaining regulatory and marketing approval for obefazimod and any future drug </span></span></div><div style="line-height:10pt;position:var(--position);top:652pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">candidates for which we successfully complete clinical trials; </span></div><div style="line-height:10pt;position:var(--position);top:668pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">launching and commercializing any drug candidates for which we obtain regulatory and marketing </span></span></div><div style="line-height:10pt;position:var(--position);top:678pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">approval by establishing a sales force, marketing and distribution infrastructure or, alternatively, </span></div><div style="line-height:10pt;position:var(--position);top:688pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">collaborating with a commercialization partner; </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:303.5pt;position:var(--position);text-decoration:none;white-space:pre">9</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">obtaining coverage and adequate reimbursement from government and third-party payors for our </span></span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">current or any future drug candidates, if approved, both in the United States and internationally, and </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">reaching acceptable agreements with foreign government and third-party payors on pricing terms; </span></div><div style="line-height:1pt;position:var(--position);top:106.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="line-height:10pt;position:var(--position);top:107.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">developing, validating and maintaining a commercially viable, sustainable, scalable, reproducible and </span></span></div><div style="line-height:10pt;position:var(--position);top:117.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">transferable manufacturing process for obefazimod or any future drug candidates that are compliant </span></div><div style="line-height:10pt;position:var(--position);top:127.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">with current good manufacturing practices; </span></div><div style="line-height:10pt;position:var(--position);top:143.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">establishing and maintaining supply and manufacturing relationships with third parties that can provide </span></span></div><div style="line-height:10pt;position:var(--position);top:153.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">an adequate amount and quality of drugs and services to support our planned clinical development, as </span></div><div style="line-height:10pt;position:var(--position);top:163.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">well as the market demand for obefazimod and any future drug candidates, if approved; </span></div><div style="line-height:10pt;position:var(--position);top:179.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">obtaining market acceptance, if and when approved, of obefazimod or any future drug candidates as a </span></span></div><div style="line-height:10pt;position:var(--position);top:189.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">viable treatment option by physicians, patients, third-party payors and others in the medical </span></div><div style="line-height:10pt;position:var(--position);top:199.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">community; </span></div><div style="line-height:10pt;position:var(--position);top:215.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">effectively addressing any competing technological and market developments; </span></span></div><div style="line-height:10pt;position:var(--position);top:231.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">implementing additional internal systems and infrastructure, as needed; </span></span></div><div style="line-height:10pt;position:var(--position);top:247.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may </span></span></div><div style="line-height:10pt;position:var(--position);top:257.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">enter, and performing our obligations pursuant to such arrangements; </span></div><div style="line-height:10pt;position:var(--position);top:273.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, </span></span></div><div style="line-height:10pt;position:var(--position);top:283.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">trade secrets and know-how; </span></div><div style="line-height:10pt;position:var(--position);top:299.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">avoiding and defending against third-party interference or infringement claims; and </span></span></div><div style="line-height:10pt;position:var(--position);top:315.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">attracting, hiring and retaining qualified personnel. </span></span></div><div style="line-height:10pt;position:var(--position);top:331.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">We have incurred considerable losses historically, which we anticipate will continue and may increase in the </span></div><div style="line-height:10pt;position:var(--position);top:341.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">future. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:357.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Since our inception, we have incurred net losses. For the years ended </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:375.09pt;position:var(--position);text-decoration:none;white-space:pre">December&#160;31, 2025, 2024 and 2023, we </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:367.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reported net losses of &#8364;336.1 million, &#8364;176.2&#160;million, and &#8364;147.7 million, respectively.</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:418.92pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> As of December 31, 2025, </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:377.5pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">we carried forward accumulated tax losse</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:238.15pt;position:var(--position);text-decoration:none;white-space:pre">s of &#8364;912.9&#160;million. </span></div><div style="line-height:10pt;position:var(--position);top:393.5pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">We have devoted most of our financial resources to research and development, including our clinical and </span></span></div><div style="line-height:10pt;position:var(--position);top:403.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">preclinical development activities. Even if we obtain regulatory approval to market a drug candidate, our future </span></div><div style="line-height:10pt;position:var(--position);top:413.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">revenues will depend upon the size of any markets in which our drug candidates have received approval and our </span></div><div style="line-height:10pt;position:var(--position);top:423.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ability to achieve sufficient market acceptance, reimbursement from third-party payors and adequate market share </span></div><div style="line-height:10pt;position:var(--position);top:433.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for our drug candidates in those markets. There can be no assurance that we will ever earn any revenues or revenues </span></div><div style="line-height:10pt;position:var(--position);top:443.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">sufficient to offset past, current and future losses or achieve profitability, which would impair our ability to sustain </span></div><div style="line-height:10pt;position:var(--position);top:453.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">our operations. Moreover, even if we achieve profitability, such profitability may not be sustainable. Any inability to </span></div><div style="line-height:10pt;position:var(--position);top:463.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">generate sustained profits could have a material adverse effect on our business, prospects, financial condition, cash </span></div><div style="line-height:10pt;position:var(--position);top:473.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">flows and results of operations. </span></div><div style="line-height:10pt;position:var(--position);top:489.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We expect to continue to incur significant expenses and operating losses for the foreseeable future. We do not </span></div><div style="line-height:10pt;position:var(--position);top:499.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">anticipate achieving profitability in the future unless we obtain the regulatory approvals necessary to commercialize </span></div><div style="line-height:10pt;position:var(--position);top:509.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">obefazimod and any additional drug candidates that we may pursue in the future. We anticipate that our expenses </span></div><div style="line-height:10pt;position:var(--position);top:519.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">will increase substantially if, and as, we: </span></div><div style="line-height:10pt;position:var(--position);top:535.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">timely and successfully complete clinical development of obefazimod, our clinical-stage drug </span></span></div><div style="line-height:10pt;position:var(--position);top:545.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">candidate; </span></div><div style="line-height:10pt;position:var(--position);top:561.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">seek and maintain regulatory and marketing approvals for obefazimod and any future drug candidates </span></span></div><div style="line-height:10pt;position:var(--position);top:571.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">for which we successfully complete clinical trials; </span></div><div style="line-height:10pt;position:var(--position);top:587.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">continue the preclinical and clinical development of our drug candidates; </span></span></div><div style="line-height:10pt;position:var(--position);top:603.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">expand the scope of our current clinical trials for our drug candidates; </span></span></div><div style="line-height:1pt;position:var(--position);top:618pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="line-height:10pt;position:var(--position);top:619pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">begin new clinical trials for our drug candidates; </span></span></div><div style="line-height:10pt;position:var(--position);top:635pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">develop, scale and validate our commercial manufacturing capabilities for our drug candidates; </span></span></div><div style="line-height:10pt;position:var(--position);top:651pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">establish a sales, marketing and distribution infrastructure to commercialize any drugs for which we </span></span></div><div style="line-height:10pt;position:var(--position);top:661pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">may obtain marketing approval for which we have not entered into a collaboration with a third-party; </span></div><div style="line-height:10pt;position:var(--position);top:677pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">seek to discover, identify and validate additional drug candidates; </span></span></div><div style="line-height:10pt;position:var(--position);top:693pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">acquire or in-license other drug candidates and technologies; </span></span></div><div style="line-height:10pt;position:var(--position);top:709pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">make milestone, royalty or other payments under in-license or collaboration agreements; </span></span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">10</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">obtain, maintain, protect, enforce and expand our intellectual property portfolio; </span></span></div><div style="line-height:10pt;position:var(--position);top:88pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">attract new and retain existing skilled personnel; and </span></span></div><div style="line-height:10pt;position:var(--position);top:104pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">continue our operations as a U.S. public company. </span></span></div><div style="line-height:10pt;position:var(--position);top:120pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In addition, following the issuance of royalty certificates in September 2022 and other royalties that may </span></div><div style="line-height:10pt;position:var(--position);top:130pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">become payable under our royalty agreements, the payment of royalties in the event of commercialization of </span></div><div style="line-height:10pt;position:var(--position);top:140pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">obefazimod will result in a decrease in cash flows generated by sales of the product, which could have an </span></div><div style="line-height:10pt;position:var(--position);top:150pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">unfavorable impact on our financial position, particularly at the beginning of the commercialization phase. </span></div><div style="line-height:10pt;position:var(--position);top:166pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The net losses we incur may fluctuate significantly from quarter-to-quarter and year-to-year, such that a </span></div><div style="line-height:10pt;position:var(--position);top:176pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">period-to-period comparison of our results of operations may not be a good indication of our future performance. In </span></div><div style="line-height:10pt;position:var(--position);top:186pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">any particular period or periods, our operating results could be below the expectations of securities analysts or </span></div><div style="line-height:10pt;position:var(--position);top:196pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">investors, which could cause the price of the ordinary shares (which may be in the form of ADSs) to decline. An </span></div><div style="line-height:10pt;position:var(--position);top:206pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">increase in operational losses would have a material adverse effect on our business, financial position, income, </span></div><div style="line-height:10pt;position:var(--position);top:216pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">growth and outlook. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:232pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">There are </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:114.72999999999999pt;position:var(--position);text-decoration:none;white-space:pre">material</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:149.13pt;position:var(--position);text-decoration:none;white-space:pre"> weaknesses in our internal controls over financial reporting and</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:416.46pt;position:var(--position);text-decoration:none;white-space:pre"> if we are unable to maintain </span></div><div style="line-height:10pt;position:var(--position);top:242pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">effective internal controls over financial reporting, the accuracy and timeliness of our financial reporting may be </span></div><div style="line-height:10pt;position:var(--position);top:252pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">adversely affected, which could adversely affect our business, investor confidence and the market price of our </span></div><div style="line-height:10pt;position:var(--position);top:262pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">securities. </span></div><div style="line-height:10pt;position:var(--position);top:278pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Internal control over financial reporting is a process designed by, or under the supervision of, the company's </span></div><div style="line-height:10pt;position:var(--position);top:288pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">principal executive and principal financial officers, or persons performing similar functions, and effected by the </span></div><div style="line-height:10pt;position:var(--position);top:298pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">company's board of directors, management and other personnel, to provide reasonable assurance regarding the </span></div><div style="line-height:10pt;position:var(--position);top:308pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reliability of financial reporting and the preparation of financial statements for external purposes in accordance with </span></div><div style="line-height:10pt;position:var(--position);top:318pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">generally accepted accounting principles. Internal control over financial reporting includes those policies and </span></div><div style="line-height:10pt;position:var(--position);top:328pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">procedures that pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the </span></div><div style="line-height:10pt;position:var(--position);top:338pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">company's transactions and dispositions of the company's assets; provide reasonable assurance that transactions are </span></div><div style="line-height:10pt;position:var(--position);top:348pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">recorded as necessary to permit preparation of financial statements in accordance with generally accepted </span></div><div style="line-height:10pt;position:var(--position);top:358pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">accounting principles, and that receipts and expenditures of the company are being made only in accordance with </span></div><div style="line-height:10pt;position:var(--position);top:368pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">authorizations of management and directors of the company; and provide reasonable assurance regarding prevention </span></div><div style="line-height:10pt;position:var(--position);top:378pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">or timely detection of unauthorized acquisition, use or disposition of the company's assets that could have a material </span></div><div style="line-height:10pt;position:var(--position);top:388pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">effect on the financial statements. Because of its inherent limitations, internal control over financial reporting is not </span></div><div style="line-height:10pt;position:var(--position);top:398pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">intended to provide absolute assurance that a misstatement of our financial statements would be prevented or </span></div><div style="line-height:10pt;position:var(--position);top:408pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">detected. </span></div><div style="line-height:10pt;position:var(--position);top:424pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We must maintain effective internal controls over financial reporting in order to accurately and timely report </span></div><div style="line-height:10pt;position:var(--position);top:434pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">our results of operations and financial condition. In addition, as a public company listed in the United States, the </span></div><div style="line-height:10pt;position:var(--position);top:444pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Sarbanes-Oxley Act requires, among other things, that we assess the effectiveness of our internal controls over </span></div><div style="line-height:10pt;position:var(--position);top:454pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">financial reporting at the end of each fiscal year. However, our independent registered public accounting firm will </span></div><div style="line-height:10pt;position:var(--position);top:464pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">not be required to attest to the effectiveness of our internal controls over financial reporting for so long as we are an </span></div><div style="line-height:10pt;position:var(--position);top:474pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8220;emerging growth company,&#8221; which may be up to five fiscal years following our initial public offering of our ADSs </span></div><div style="line-height:10pt;position:var(--position);top:484pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">in the United States. An independent assessment of the effectiveness of our internal controls could detect problems </span></div><div style="line-height:10pt;position:var(--position);top:494pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">that our management&#8217;s assessment might not. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:510pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our independent registered public accounting firm has not conducted an audit of our internal controls over </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:520pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">financial reporting. As previously disclosed in our Form 20-F for the period ended December 31, 2023 and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:530pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">originally in our Form F-1, management identified material weaknesses in our internal controls over financial </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:540pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reporting. These material weaknesses continue to exist as of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:314.47pt;position:var(--position);text-decoration:none;white-space:pre">December 31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:393.01pt;position:var(--position);text-decoration:none;white-space:pre">. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:398.01pt;position:var(--position);text-decoration:none;white-space:pre">The material weaknesses identified </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:550pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">in December 31, 2025 are related to a lack of (i) design and implementation of effective risk assessment process </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:560pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(Risk Assessment), (ii) formal, documented and implemented processes, controls and review procedures (Control </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:570pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Activities), (iii) sufficient processes to identify, capture and communicate information necessary to support the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:580pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">functioning of internal controls over financial reporting (Information and Communication) and (iv) process to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:590pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">identify, maintain, and develop all control activities (Monitoring Activities). These material weaknesses are </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:600pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">specifically due to a lack of sufficient number of professionals with an appropriate level of internal control </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:610pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">knowledge, training and experience and the need to continue to reinforce our internal control governance (Control </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:620pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Environment). </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:132.5pt;position:var(--position);text-decoration:none;white-space:pre">These material weaknesses did not result in a material misstatement to our financial statements </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:630pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">included herein, however these material weaknesses could result in material inaccuracies in our financial statements </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:640pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and impair our ability to comply with applicable financial reporting requirements and related regulatory filings on a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:650pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">timely basis. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:666pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We have developed a remediation plan to address these material weaknesses and strengthen our controls in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:676pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">these areas. In this regard, we have reorganized our finance and accounting function by hiring additional </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:686pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">experienced employees to provide more review and oversight over our financial processes. While we are working to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:696pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">remediate the material weaknesses as quickly and efficiently as possible, we cannot at this time provide the expected </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:706pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">timeline in connection with implementing our remediation. As of December 31, 2025, we had not fully completed </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">11</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the remediation of these material weaknesses. These remediation measures may be time-consuming and costly and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">might place significant demands on our financial and operational resources. There is no assurance that the actions </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">we may take in the future will be sufficient to remediate the control deficiencies that led to these material </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">weaknesses in our internal control over financial reporting or that they will prevent or avoid potential future material </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:112pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">weaknesses. </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The rules governing the standards that will have to be met for our management to assess our internal controls </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">over financial reporting pursuant to Section&#160;404 of the Sarbanes-Oxley Act are complex and require significant </span></div><div style="line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">documentation, testing and possible remediation. These stringent standards require that our audit committee be </span></div><div style="line-height:10pt;position:var(--position);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">advised and regularly updated on management&#8217;s review of internal controls over financial reporting. Designing, </span></div><div style="line-height:10pt;position:var(--position);top:168pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">implementing, and testing internal controls over financial reporting required to comply with this obligation is time-</span></div><div style="line-height:10pt;position:var(--position);top:178pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">consuming, costly, and complicated. Our management may not be able to effectively and timely implement controls </span></div><div style="line-height:10pt;position:var(--position);top:188pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and procedures that adequately respond to the increased regulatory compliance and reporting requirements that are </span></div><div style="line-height:10pt;position:var(--position);top:198pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">applicable to us as a public company listed in the United States. If we fail to staff our accounting and finance </span></div><div style="line-height:10pt;position:var(--position);top:208pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">function adequately or maintain internal controls over financial reporting adequate to meet the demands that are </span></div><div style="line-height:10pt;position:var(--position);top:218pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">placed upon us as a public company listed in the United States, our business and reputation may be harmed and the </span></div><div style="line-height:10pt;position:var(--position);top:228pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">price of our ordinary shares and ADSs may decline. In addition, undetected material weaknesses in our internal </span></div><div style="line-height:10pt;position:var(--position);top:238pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">controls over financial reporting could lead to restatements of financial statements and require us to incur the </span></div><div style="line-height:10pt;position:var(--position);top:248pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">expense of remediation. Any of these developments could result in investor perceptions of us being adversely </span></div><div style="line-height:10pt;position:var(--position);top:258pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">affected, which could cause a decline in the market price of our securities. </span></div><div style="line-height:10pt;position:var(--position);top:274pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our management is responsible for establishing and maintaining adequate internal control over financial </span></div><div style="line-height:10pt;position:var(--position);top:284pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reporting. Our growth will place significant additional pressure on our system of internal control over financial </span></div><div style="line-height:10pt;position:var(--position);top:294pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reporting. Any failure to maintain an effective system of internal control over financial reporting could limit our </span></div><div style="line-height:10pt;position:var(--position);top:304pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ability to report our financial results accurately and timely or to detect and prevent fraud. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:320pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72.25pt;position:var(--position);text-decoration:none;white-space:pre">Significant impairment of our goodwill could materially impact our financial position and results of our </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:330pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">operations. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:346pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We carry a goodwill amount of &#8364;18.4 million on our balance sheet as a result of past business acquisitions </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:356pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">with respect to obefazimod. We are required to review our goodwill for impairment on an annual basis or more </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:366pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">frequently if events or changes in circumstances indicate evidence of impairment. We did not record any goodwill </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:376pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">impairment loss for the years ended December 31, 2025, 2024 or 2023, as we have not identified reasons to impair </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:386pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the goodwill related to obefazimod. However, there can be no assurance that, based on the results of our annual </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:396pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">goodwill impairment tests, we will not be required to identify further goodwill impairment losses, which could have </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:406pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">a material adverse effect on our results of operations. </span></div><div style="line-height:10pt;position:var(--position);top:422pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Current equity agreements and convertible debt instruments may dilute our equity resulting in dilution to our </span></div><div style="line-height:10pt;position:var(--position);top:432pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">shareholders. </span></div><div style="line-height:10pt;position:var(--position);top:448pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Since our incorporation, we have issued and granted founder&#8217;s share warrants (BCE) and share warrants </span></div><div style="line-height:10pt;position:var(--position);top:458pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(BSA) and granted free shares (AGA) to persons linked to us and financing entities. We have also issued convertible </span></div><div style="line-height:10pt;position:var(--position);top:468pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">bonds. See "Item 5.B&#8212;Liquidity and Capital Resources." </span></div><div style="line-height:10pt;position:var(--position);top:484pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The theoretical exercise or vesting of all the founder&#8217;s share warrants (BCE), share warrants (BSA) and free </span></div><div style="line-height:10pt;position:var(--position);top:494pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">shares (AGA) issued and outstanding as of December&#160;31, 2025, excluding securities held by financing entities, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:504pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">would result in the issuance of</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:193.82pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:196.32pt;position:var(--position);text-decoration:none;white-space:pre">8,857,084</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:236.32pt;position:var(--position);text-decoration:none;white-space:pre"> po</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:248.82pt;position:var(--position);text-decoration:none;white-space:pre">tential new ordinary shares, resulting in a hypothetical dilution equal to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:514pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">11.3 </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:92pt;position:var(--position);text-decoration:none;white-space:pre">% based on our outstanding share capital as of December&#160;31, 2025. </span></div><div style="line-height:10pt;position:var(--position);top:530pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our general meeting of June 6, 2025 delegated authority to the board of directors (the &#8220;Board&#8221;) to carry out </span></div><div style="line-height:10pt;position:var(--position);top:540pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">one or more capital increases and/or issues of securities giving access to our capital subject to the following </span></div><div style="line-height:10pt;position:var(--position);top:550pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">limitations: </span></div><div style="line-height:10pt;position:var(--position);top:566pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">a total maximum nominal amount of the capital increases set at &#8364;250,000 (or the equivalent value of </span></span></div><div style="line-height:10pt;position:var(--position);top:576pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">that amount in the event of an issue in another currency) with a total maximum nominal amount of the </span></div><div style="line-height:10pt;position:var(--position);top:586pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">debt securities that may be issued set at &#8364;150,000,000 (or the equivalent value of that amount in the </span></div><div style="line-height:10pt;position:var(--position);top:596pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">event of an issue in another currency); and </span></div><div style="line-height:10pt;position:var(--position);top:612pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the shares that may be issued or allotted in the context of equity incentive plans (share warrants (BSA), </span></span></div><div style="line-height:10pt;position:var(--position);top:622pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">share options and/or free shares (AGA)) may not exceed 10% of the share capital on a fully diluted </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:632pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">basis recorded as of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:208.63pt;position:var(--position);text-decoration:none;white-space:pre">June 6, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:259.45pt;position:var(--position);text-decoration:none;white-space:pre">. As of December 31, 2025, our equity incentive plans were 9.2% of </span></div><div style="line-height:10pt;position:var(--position);top:642pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">our share capital on a fully diluted basis. </span></div><div style="line-height:10pt;position:var(--position);top:658pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Our failure to maintain certain tax benefits applicable to French biopharmaceutical companies may adversely </span></div><div style="line-height:10pt;position:var(--position);top:668pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">affect our operations and finances. </span></div><div style="line-height:10pt;position:var(--position);top:684pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">As a French biopharmaceutical company, we have benefited from certain tax advantages, including, for </span></div><div style="line-height:10pt;position:var(--position);top:694pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">example, the Research and Development Tax Credit (</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:286.7pt;position:var(--position);text-decoration:none;white-space:pre">cr&#233;dit imp&#244;t recherche</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:377.68pt;position:var(--position);text-decoration:none;white-space:pre">) (&#8220;CIR&#8221;), which is a French tax credit </span></div><div style="line-height:10pt;position:var(--position);top:704pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">aimed at stimulating research and development. CIR can be offset against French corporate income tax due and the </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">12</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">portion in excess, if any, may be refunded. CIR is calculated based on our claimed amount of eligible research and </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">development expenditures in France and represents &#8364;3.1 million for 2025. The French tax authorities, with the </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">assistance of the Higher Education and Research Ministry, may audit each research and development program in </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">respect of which a CIR benefit has been claimed and assess whether such program qualifies in its view for the CIR </span></div><div style="line-height:10pt;position:var(--position);top:112pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">benefit. The French tax authorities may challenge our eligibility for, or our calculation of, certain tax reductions or </span></div><div style="line-height:10pt;position:var(--position);top:122pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">deductions in respect of our research and development activities and, should the French tax authorities be successful, </span></div><div style="line-height:10pt;position:var(--position);top:132pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">our credits may be reduced, which would have a negative impact on our results of operations and future cash flows. </span></div><div style="line-height:10pt;position:var(--position);top:142pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Furthermore, the French Parliament may decide to eliminate, or to reduce the scope or the rate of, the CIR benefit, </span></div><div style="line-height:10pt;position:var(--position);top:152pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">either of which it could decide to do at any time. If we fail to receive future CIR amounts, our business, prospects, </span></div><div style="line-height:10pt;position:var(--position);top:162pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">financial condition, cash flows or results of operations could be adversely affected. </span></div><div style="line-height:10pt;position:var(--position);top:178pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">We may be unable to carry forward existing tax losses. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:194pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2025, we carried forward accumulated tax losses of &#8364;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:392.85pt;position:var(--position);text-decoration:none;white-space:pre">912.9</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:415.35pt;position:var(--position);text-decoration:none;white-space:pre"> million. In 2014, we acquired </span></div><div style="line-height:10pt;position:var(--position);top:204pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the companies Splicos, Wittycell and Zophis by means of a universal transfer of assets and liabilities. The tax losses </span></div><div style="line-height:10pt;position:var(--position);top:214pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">carried forward of the three companies combined (Splicos, Wittycell and Zophis) amounted to &#8364;26.0&#160;million on the </span></div><div style="line-height:10pt;position:var(--position);top:224pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">date of the mergers and transfer of remaining assets. The transfer to us of these losses was subject to a post-merger </span></div><div style="line-height:10pt;position:var(--position);top:234pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">approval by the French tax authorities, which approved the transfer of a total amount of &#8364;22.5 million of tax losses. </span></div><div style="line-height:10pt;position:var(--position);top:244pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">To the extent we have continued conducting the business that led to these losses for a minimum period of three </span></div><div style="line-height:10pt;position:var(--position);top:254pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">years, without making significant changes during this period, the transfer of such tax losses should be definitive. In </span></div><div style="line-height:10pt;position:var(--position);top:264pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">France, the maximum amount of carried forward tax losses that can be written off against the tax profits of a given </span></div><div style="line-height:10pt;position:var(--position);top:274pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">financial year is limited to &#8364;1&#160;million plus 50% of the amount of taxable profits for the financial year exceeding </span></div><div style="line-height:10pt;position:var(--position);top:284pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1&#160;million. The outstanding tax losses remain valid and can be carried forward to be written off against tax profits of </span></div><div style="line-height:10pt;position:var(--position);top:294pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">subsequent financial years subject to the same limit, for an unlimited period of time (subject to any &#8220;significant </span></div><div style="line-height:10pt;position:var(--position);top:304pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">change of activity&#8221; at our level). It cannot be ruled out that regulatory or legislative changes in corporate taxation </span></div><div style="line-height:10pt;position:var(--position);top:314pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">may suppress or limit all or part of the ability to use carried forward tax losses, or limit how long they can be used, </span></div><div style="line-height:10pt;position:var(--position);top:324pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to offset future profits. Changes in corporate taxation regarding the use of carried forward tax losses to offset future </span></div><div style="line-height:10pt;position:var(--position);top:334pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">tax profits could have a material adverse effect on our financial position and results of operations. </span></div><div style="line-height:10pt;position:var(--position);top:362pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Risks Related to Product Development, Regulatory Approval and Commercialization </span></div><div style="line-height:10pt;position:var(--position);top:378pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Drug candidates under development must undergo costly, rigorous and highly regulated preclinical studies and </span></div><div style="line-height:10pt;position:var(--position);top:388pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">clinical trials, whose time of completion, number and outcomes are uncertain. </span></div><div style="line-height:10pt;position:var(--position);top:404pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The development of a drug candidate is a long and expensive process with an uncertain outcome, progressing </span></div><div style="line-height:10pt;position:var(--position);top:414pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">in several phases, where the objective is to demonstrate the therapeutic benefit provided by the drug candidate for </span></div><div style="line-height:10pt;position:var(--position);top:424pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">one or more indications. Any failure during the various preclinical and clinical phases for a given indication could </span></div><div style="line-height:10pt;position:var(--position);top:434pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">delay development, production and commercialization of the therapeutic product concerned or even lead to </span></div><div style="line-height:10pt;position:var(--position);top:444pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">discontinuing its development. Identifying and developing potential drug candidates is a time-consuming, expensive </span></div><div style="line-height:10pt;position:var(--position);top:454pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and uncertain process that takes years to complete, and we may never generate the data or results required to obtain </span></div><div style="line-height:10pt;position:var(--position);top:464pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regulatory approval and achieve commercialization. </span></div><div style="line-height:10pt;position:var(--position);top:480pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">During clinical trials, we may encounter difficulties determining and recruiting patients with the appropriate </span></div><div style="line-height:10pt;position:var(--position);top:490pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">profile as well as other enrollment issues, which could delay our clinical trials. This profile could also vary </span></div><div style="line-height:10pt;position:var(--position);top:500pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">depending on the different phases of these clinical trials. Patients might then not be recruited according to a </span></div><div style="line-height:10pt;position:var(--position);top:510pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">timetable compatible with our financial resources which may result in a harm to our operating results. </span></div><div style="line-height:10pt;position:var(--position);top:526pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">At each phase of clinical development, we must ask for authorization </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:375.59pt;position:var(--position);white-space:pre">or absence of opposition </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:476.06pt;position:var(--position);text-decoration:none;white-space:pre">from the </span></div><div style="line-height:10pt;position:var(--position);top:536pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">relevant authorities of various countries, according to our development plan, to conduct clinical trials and then </span></div><div style="line-height:10pt;position:var(--position);top:546pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">present the results of the clinical trials to these authorities. The authorities may </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:389.33pt;position:var(--position);white-space:pre">issue negative opinion, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:483.68pt;position:var(--position);text-decoration:none;white-space:pre">refuse to </span></div><div style="line-height:10pt;position:var(--position);top:556pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">provide the authorizations necessary for clinical trials or have additional requirements (for example, relating to study </span></div><div style="line-height:10pt;position:var(--position);top:566pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">protocols, patient characteristics, treatment durations, post-treatment follow-up, or certain differences in interpreting </span></div><div style="line-height:10pt;position:var(--position);top:576pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">results between local regulatory agencies), and in some cases may require additional studies. Any </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:464.29pt;position:var(--position);white-space:pre">negative opinion, </span></div><div style="line-height:10pt;position:var(--position);top:586pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">refusal or decision by health authorities to require additional trials or examinations would be likely to result in the </span></div><div style="line-height:10pt;position:var(--position);top:596pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">discontinuation or delay of the development of the product candidates concerned. An absence of or delay in </span></div><div style="line-height:10pt;position:var(--position);top:606pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">therapeutic response could also result in the delay or even discontinuation of the development of our drug </span></div><div style="line-height:10pt;position:var(--position);top:616pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">candidates. </span></div><div style="line-height:10pt;position:var(--position);top:632pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We cannot guarantee that the development of our drug candidates will ultimately be successful, especially </span></div><div style="line-height:10pt;position:var(--position);top:642pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">within time frames compatible with our financial resources or market needs. Any failure or delay in the development </span></div><div style="line-height:10pt;position:var(--position);top:652pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of these product candidates would have a material adverse effect on our business, income, financial position and </span></div><div style="line-height:10pt;position:var(--position);top:662pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">outlook. </span></div><div style="line-height:10pt;position:var(--position);top:678pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We are developing drug candidates for inflammatory diseases. To our knowledge, currently there are no </span></div><div style="line-height:10pt;position:var(--position);top:688pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">similar immunological treatments with a mechanism of action based on enhanced expression of a single microRNA </span></div><div style="line-height:10pt;position:var(--position);top:698pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">miR-124 with marketing authorization granted by competent regulatory authorities. As a result, the outlook is </span></div><div style="line-height:10pt;position:var(--position);top:708pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">uncertain for the development and profitability of obefazimod in the area of inflammatory diseases, its efficacy and </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">13</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">acceptance by patients, doctors and paying agencies. Animal testing does not necessarily predict the results that will </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">be obtained in humans. Positive results for obefazimod during Phase 1, Phase 2b or Phase&#160;3 clinical trials or those </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for all the products in the portfolio during their research or preclinical phases might not be confirmed by subsequent </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">phases. Such outcomes could have a material adverse impact on our business, income, financial position and growth. </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">We are heavily dependent on the success of our drug candidates, in particular obefazimod, and we cannot be </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">certain that obefazimod or any of our other current or future drug candidates will receive regulatory approval, </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and, without regulatory approval, we will not be able to market our drug candidates. </span></div><div style="line-height:10pt;position:var(--position);top:154pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We currently have no drug candidates approved for marketing, and we cannot guarantee that we will ever have </span></div><div style="line-height:10pt;position:var(--position);top:164pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">marketable drug candidates. Our ability to generate revenue related to sales, if any, will in the near future depend </span></div><div style="line-height:10pt;position:var(--position);top:174pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">entirely on the successful development and regulatory approval of obefazimod. In Europe and the United States, as </span></div><div style="line-height:10pt;position:var(--position);top:184pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">well as in many other countries, access to the drug market is strictly controlled and marketing must be authorized by </span></div><div style="line-height:10pt;position:var(--position);top:194pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">a regulatory authority. Most of the time, this registration application is filed with a national or federal health </span></div><div style="line-height:10pt;position:var(--position);top:204pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">authority. However, in the European Union, the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:265.15pt;position:var(--position);white-space:pre">application for a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:333.11pt;position:var(--position);text-decoration:none;white-space:pre">marketing authorization (&#8220;MA&#8221;) must be submitted </span></div><div style="line-height:10pt;position:var(--position);top:214pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">at the EU-level to the European Medicines Agency (&#8220;EMA&#8221;) for categories of the most innovative medicinal </span></div><div style="line-height:10pt;position:var(--position);top:224pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">products, in order to obtain a centralized marketing authorization valid for all the European Union territory. </span></div><div style="line-height:10pt;position:var(--position);top:240pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The research, testing, manufacturing, safety, efficacy, labeling, approval, sale, marketing and distribution of </span></div><div style="line-height:10pt;position:var(--position);top:250pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">our drug candidates are, and will remain, subject to comprehensive and extensive regulation controlled by the EMA </span></div><div style="line-height:10pt;position:var(--position);top:260pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and European Union Member States national authorities in the European Union, the Food and Drug Administration </span></div><div style="line-height:10pt;position:var(--position);top:270pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(&#8220;FDA&#8221;) in the United States, the Pharmaceuticals and Medical Devices Agency (&#8220;PMDA&#8221;) in Japan and other </span></div><div style="line-height:10pt;position:var(--position);top:280pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regulatory authorities in other countries, with regulations differing from country to country. Subject to limited </span></div><div style="line-height:10pt;position:var(--position);top:290pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">exceptions, we are not permitted to market our drug candidates in the European Union, the United States or Japan </span></div><div style="line-height:10pt;position:var(--position);top:300pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">until we receive a MA from the European Commission following EMA&#8217;s opinion or (a) European Union Member </span></div><div style="line-height:10pt;position:var(--position);top:310pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">State(s) authority(ies) or a new drug application (&#8220;NDA&#8221;) from the FDA or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:375.58pt;position:var(--position);white-space:pre">an approval from </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:446.9pt;position:var(--position);text-decoration:none;white-space:pre">the PMDA, </span></div><div style="line-height:10pt;position:var(--position);top:320pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">respectively. Regulators of each jurisdiction have their own procedures for approval of drug candidates. We have not </span></div><div style="line-height:10pt;position:var(--position);top:330pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">applied for any MA for any of our drug candidates yet. Failure to obtain regulatory approval for our drug candidates </span></div><div style="line-height:10pt;position:var(--position);top:340pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">in any jurisdiction will prevent us from commercializing and marketing our drug candidates in such jurisdictions, </span></div><div style="line-height:10pt;position:var(--position);top:350pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and marketing authorizations may be granted for narrow indications which may significantly reduce the scope of </span></div><div style="line-height:10pt;position:var(--position);top:360pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">market of our drug candidates. </span></div><div style="line-height:10pt;position:var(--position);top:376pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Obtaining and maintaining MA, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:227.21pt;position:var(--position);white-space:pre">as the case may be </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:304.03999999999996pt;position:var(--position);text-decoration:none;white-space:pre">by country or by geographical area in the case of the </span></div><div style="line-height:10pt;position:var(--position);top:386pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">European Union, presupposes compliance with the mandatory standards imposed by the concerned regulatory </span></div><div style="line-height:10pt;position:var(--position);top:396pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">authorities and submission to the authorities of a great deal of information about the drug candidate regarding its </span></div><div style="line-height:10pt;position:var(--position);top:406pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">toxicity, dosage, quality, efficacy and safety all over its life cycle. The authorization process is long and expensive, </span></div><div style="line-height:10pt;position:var(--position);top:416pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and the result of this process remains highly uncertain. We are therefore careful to continuously comply with good </span></div><div style="line-height:10pt;position:var(--position);top:426pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">practices in order not to jeopardize our chances of ultimately obtaining, directly or via our business partners, </span></div><div style="line-height:10pt;position:var(--position);top:436pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">marketing authorization for the products we are developing. Furthermore, obtaining marketing authorization for a </span></div><div style="line-height:10pt;position:var(--position);top:446pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">product in a given country or geographical area does not automatically ensure or immediately lead to obtaining </span></div><div style="line-height:10pt;position:var(--position);top:456pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">marketing authorization in other countries for the same product. </span></div><div style="line-height:10pt;position:var(--position);top:472pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In order to obtain MA for one of our drug candidates, we have to perform preclinical animal studies and </span></div><div style="line-height:10pt;position:var(--position);top:482pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">complete human clinical trials in order to demonstrate the safety and efficacy of the drug candidates. MAs, NDAs </span></div><div style="line-height:10pt;position:var(--position);top:492pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and similar authorizations must include extensive preclinical and clinical data and supporting information to </span></div><div style="line-height:10pt;position:var(--position);top:502pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">establish the drug candidate&#8217;s safety and efficacy for each desired indication. In the event patients are exposed to </span></div><div style="line-height:10pt;position:var(--position);top:512pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">unforeseen and serious risks, we or the regulatory authorities may choose to suspend or early terminate these clinical </span></div><div style="line-height:10pt;position:var(--position);top:522pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">trials. </span></div><div style="line-height:10pt;position:var(--position);top:538pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">NDAs, MAs and similar authorizations must also include significant information regarding the chemistry, </span></div><div style="line-height:10pt;position:var(--position);top:548pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">manufacturing and controls for the drug. Obtaining approval of a MA or a NDA and similar authorizations, and </span></div><div style="line-height:10pt;position:var(--position);top:558pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">collecting all required information, proof and data for this process, is a lengthy, expensive and uncertain process, </span></div><div style="line-height:10pt;position:var(--position);top:568pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and we may not be successful in obtaining approval. This is further enhanced by the fact that each regulator has its </span></div><div style="line-height:10pt;position:var(--position);top:578pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">own requirements and procedures for the scientific evaluation or approval of drug candidates. The EMA, European </span></div><div style="line-height:10pt;position:var(--position);top:588pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Union Member States national authorities, FDA and PMDA review processes can therefore take years to complete </span></div><div style="line-height:10pt;position:var(--position);top:598pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and approval is never guaranteed.</span></div><div style="line-height:10pt;position:var(--position);top:614pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In addition, delays in approvals or rejections of marketing applications in the European Union, the United </span></div><div style="line-height:10pt;position:var(--position);top:624pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">States or other countries may be based upon many factors, including regulatory requests for additional analyses, </span></div><div style="line-height:10pt;position:var(--position);top:634pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reports, data, preclinical studies and clinical trials, regulatory questions regarding different interpretations of data </span></div><div style="line-height:10pt;position:var(--position);top:644pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and results, changes in regulatory policy during the period of drug development and the emergence of new </span></div><div style="line-height:10pt;position:var(--position);top:654pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">information regarding our drug candidates or other drug candidates. Even if a drug is approved, the FDA, the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:664pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">European Commission</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:163.31pt;position:var(--position);text-decoration:none;white-space:pre"> or the PMDA, as the case may be, may limit the indications for which the drug may be </span></div><div style="line-height:10pt;position:var(--position);top:674pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">marketed, require extensive warnings on the drug labeling or require expensive and time-consuming post-marketing </span></div><div style="line-height:10pt;position:var(--position);top:684pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">clinical trials or reporting as conditions of approval. </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">14</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Even if we receive regulatory approval for any drug candidate, we will be subject to ongoing regulatory </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">obligations and continued regulatory review, which may result in significant additional expense </span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Even if we receive approval of any of our drug candidates, such regulatory approval may be withdrawn, or </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">such approvals may be contingent on ongoing obligations and continued regulatory review, which may result in </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">significant additional expense. As a general matter, any regulatory approvals that we may receive for our drug </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">advertising, promotion, import, export and recordkeeping for our drug candidates will be subject to extensive and </span></div><div style="line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ongoing regulatory requirements. These requirements include submissions of safety, efficacy and other post-</span></div><div style="line-height:10pt;position:var(--position);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">marketing information and reports, registration, as well as ongoing compliance with current Good Manufacturing </span></div><div style="line-height:10pt;position:var(--position);top:168pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Practice (&#8220;GMP&#8221;) and Good Clinical Practice requirements (&#8220;GCPs&#8221;) for any clinical trials that we may be required </span></div><div style="line-height:10pt;position:var(--position);top:178pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to conduct post-marketing. In addition, manufacturers of drug products and their facilities are subject to continual </span></div><div style="line-height:10pt;position:var(--position);top:188pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with </span></div><div style="line-height:10pt;position:var(--position);top:198pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">GMP regulations and standards.&#160; </span></div><div style="line-height:10pt;position:var(--position);top:214pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Additionally, our drug candidates, even if approved, may be subject to restrictions or prohibition on </span></div><div style="line-height:10pt;position:var(--position);top:224pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">advertising, include limitations related to prescriptions by specialists, use restrictions for specified age groups, </span></div><div style="line-height:10pt;position:var(--position);top:234pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">warnings, precautions or contraindications, and may include burdensome post-approval study or risk management </span></div><div style="line-height:10pt;position:var(--position);top:244pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">requirements. For example, the FDA may require a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) as a condition </span></div><div style="line-height:10pt;position:var(--position);top:254pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of approval of our drugs candidates, which could include requirements for a medication guide, physician training </span></div><div style="line-height:10pt;position:var(--position);top:264pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient </span></div><div style="line-height:10pt;position:var(--position);top:274pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">registries and other risk minimization tools. </span></div><div style="line-height:10pt;position:var(--position);top:290pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Obtaining and maintaining a Good Manufacturing Practice (&#8220;GMP&#8221;) certificate will be required in order to </span></div><div style="line-height:10pt;position:var(--position);top:300pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">produce the immunotherapies that we are developing (for clinical trial purposes and during the commercialization </span></div><div style="line-height:10pt;position:var(--position);top:310pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">phase). We cannot guarantee that we will obtain or be able to maintain this certificate, nor that certain additional </span></div><div style="line-height:10pt;position:var(--position);top:320pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">constraints related to this certificate will not be imposed on us in the future. Any failure to follow and document </span></div><div style="line-height:10pt;position:var(--position);top:330pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">adherence to such GMP regulations or other regulatory requirements may lead to significant delays in the </span></div><div style="line-height:10pt;position:var(--position);top:340pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">availability of products for commercial sale or clinical trials, may result in the termination of or a hold on a clinical </span></div><div style="line-height:10pt;position:var(--position);top:350pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">trial, or may delay or prevent filing or approval of marketing applications for our products. Failure to comply with </span></div><div style="line-height:10pt;position:var(--position);top:360pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">applicable regulations could also result in the FDA or other applicable regulatory authorities taking various actions, </span></div><div style="line-height:10pt;position:var(--position);top:370pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">including: </span></div><div style="line-height:10pt;position:var(--position);top:386pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">levying fines and other civil penalties; </span></span></div><div style="line-height:10pt;position:var(--position);top:402pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">imposing consent decrees or injunctions; </span></span></div><div style="line-height:10pt;position:var(--position);top:418pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">requiring us to suspend or put on hold one or more of our clinical trials; </span></span></div><div style="line-height:10pt;position:var(--position);top:434pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">suspending, varying or withdrawing regulatory approvals; </span></span></div><div style="line-height:10pt;position:var(--position);top:450pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">delaying or refusing to approve pending applications or supplements to approved applications; </span></span></div><div style="line-height:10pt;position:var(--position);top:466pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">requiring us or our third-party manufacturers to suspend manufacturing activities or product sales, </span></span></div><div style="line-height:10pt;position:var(--position);top:476pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">imports or exports; </span></div><div style="line-height:10pt;position:var(--position);top:492pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">requiring us to communicate with physicians and other customers about concerns related to actual or </span></span></div><div style="line-height:10pt;position:var(--position);top:502pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">potential safety, efficacy and other issues involving our products; </span></div><div style="line-height:10pt;position:var(--position);top:518pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">mandating product recalls or withdrawals or seizing products; </span></span></div><div style="line-height:10pt;position:var(--position);top:534pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">imposing operating restrictions; and </span></span></div><div style="line-height:10pt;position:var(--position);top:550pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">seeking criminal prosecutions. </span></span></div><div style="line-height:10pt;position:var(--position);top:566pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Failure to obtain or maintain authorization for our drug candidates in one or more jurisdictions, particularly in </span></div><div style="line-height:10pt;position:var(--position);top:576pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">respect of our lead drug candidate, obefazimod, would have a material adverse effect on our business, outlook, </span></div><div style="line-height:10pt;position:var(--position);top:586pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">financial position, results and development. </span></div><div style="line-height:10pt;position:var(--position);top:602pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Our drug candidates may cause undesirable side effects or have other properties that could delay or prevent their </span></div><div style="line-height:10pt;position:var(--position);top:612pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regulatory approval, or, if approval is received, require our drug candidates to be withdrawn from the market, </span></div><div style="line-height:10pt;position:var(--position);top:622pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">require them to include safety warnings or otherwise limit their sales. </span></div><div style="line-height:10pt;position:var(--position);top:638pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Undesirable side effects caused by our drug candidates could cause us or regulatory authorities to interrupt, </span></div><div style="line-height:10pt;position:var(--position);top:648pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">delay or halt clinical trials, or even discontinuation and could result in a more restrictive label or the delay or denial </span></div><div style="line-height:10pt;position:var(--position);top:658pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of regulatory approval by the European Commission, FDA, PDMA or other comparable authorities in other </span></div><div style="line-height:10pt;position:var(--position);top:668pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">jurisdictions. If severe side effects were to occur, or if one of our drug candidates is shown to have other unexpected </span></div><div style="line-height:10pt;position:var(--position);top:678pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">characteristics, we may need to either restrict the use of such product to a smaller population or abandon </span></div><div style="line-height:10pt;position:var(--position);top:688pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">development of such drug candidates. </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">15</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">If one or more of our drug candidates received marketing approval, and we or others later identify undesirable </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">side effects caused by such drugs or negative interactions with other products or treatments (including, for example, </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">as a result of interactions with other products once on the market), a number of potentially significant negative </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">consequences could result, including: </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">regulatory authorities may withdraw or reduce the scope of approvals of such product; </span></span></div><div style="line-height:10pt;position:var(--position);top:134pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">regulatory authorities may require additional warnings on the product&#8217;s label; </span></span></div><div style="line-height:10pt;position:var(--position);top:150pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">we may be required to create a medication guide outlining the risks of such side effects for distribution </span></span></div><div style="line-height:10pt;position:var(--position);top:160pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">to patients; </span></div><div style="line-height:1pt;position:var(--position);top:174.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="line-height:10pt;position:var(--position);top:175.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">we could be sued and held liable for harm caused to patients; </span></span></div><div style="line-height:10pt;position:var(--position);top:191.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">physicians, healthcare payors, patients or the medical community in general may not recommend/use </span></span></div><div style="line-height:10pt;position:var(--position);top:201.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">our products; </span></div><div style="line-height:10pt;position:var(--position);top:217.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">sales of the product may decrease significantly; and </span></span></div><div style="line-height:10pt;position:var(--position);top:233.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">our reputation may suffer. </span></span></div><div style="line-height:10pt;position:var(--position);top:249.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Any of these events could prevent us from achieving or maintaining market acceptance of the particular drug </span></div><div style="line-height:10pt;position:var(--position);top:259.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">candidate, if approved, and could have a material adverse effect on our business, prospects, financial condition, cash </span></div><div style="line-height:10pt;position:var(--position);top:269.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">flows or results of operations. </span></div><div style="line-height:10pt;position:var(--position);top:285.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Clinical failure can occur at any stage of clinical development. The results of earlier clinical trials as well as data </span></div><div style="line-height:10pt;position:var(--position);top:295.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">from any interim analysis of ongoing trials are not necessarily predictive of future results and any drug candidate </span></div><div style="line-height:10pt;position:var(--position);top:305.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">we advance through clinical trials may not have favorable results in later clinical trials. </span></div><div style="line-height:10pt;position:var(--position);top:321.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. </span></div><div style="line-height:10pt;position:var(--position);top:331.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Clinical failure can occur at any stage of our clinical development. Success in preclinical studies and early clinical </span></div><div style="line-height:10pt;position:var(--position);top:341.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">trials, as well as data from any interim analysis of ongoing trials do not ensure that subsequent clinical trials will </span></div><div style="line-height:10pt;position:var(--position);top:351.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">generate the same or similar results. A number of companies in the pharmaceuticals industry, including those with </span></div><div style="line-height:10pt;position:var(--position);top:361.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">greater resources and experience than us, have suffered significant setbacks in the last development phase (Phase 3) </span></div><div style="line-height:10pt;position:var(--position);top:371.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">clinical trials, even after seeing promising results in earlier clinical trials, and we could face similar setbacks. In </span></div><div style="line-height:10pt;position:var(--position);top:381.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">some instances, there can be significant variation in safety or efficacy results between different clinical trials of the </span></div><div style="line-height:10pt;position:var(--position);top:391.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">same drug candidate due to numerous factors, including changes in trial procedures set forth in protocols, </span></div><div style="line-height:10pt;position:var(--position);top:401.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other </span></div><div style="line-height:10pt;position:var(--position);top:411.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">clinical trial protocols and the rate of dropout among clinical trial participants. Any such delays or failures could </span></div><div style="line-height:10pt;position:var(--position);top:421.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">negatively impact our business, financial condition, results of operation and prospects. The positive results generated </span></div><div style="line-height:10pt;position:var(--position);top:431.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">in preclinical and clinical trials for obefazimod does not ensure that current or future trials will continue to </span></div><div style="line-height:10pt;position:var(--position);top:441.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">demonstrate similar safety and/or efficacy results. </span></div><div style="line-height:10pt;position:var(--position);top:457.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Drug candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite </span></div><div style="line-height:10pt;position:var(--position);top:467.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">having progressed through preclinical studies and earlier clinical trials. In addition to the safety and efficacy traits of </span></div><div style="line-height:10pt;position:var(--position);top:477.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">any drug candidate, clinical trial failures may result from a multitude of factors including flaws in trial design, dose </span></div><div style="line-height:10pt;position:var(--position);top:487.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">selection, placebo effect and patient enrollment criteria. Based upon negative or inconclusive results, we or our </span></div><div style="line-height:10pt;position:var(--position);top:497.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">collaborators may decide, or regulators may require us, to conduct additional clinical trials or preclinical studies. </span></div><div style="line-height:10pt;position:var(--position);top:507.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Further, data obtained from trials and studies are susceptible to varying interpretation, and regulators may not </span></div><div style="line-height:10pt;position:var(--position);top:517.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">interpret our data as favorably as we do, which may delay, limit or prevent regulatory approval. </span></div><div style="line-height:10pt;position:var(--position);top:533.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">We cannot guarantee the commercial success or the pricing and reimbursement of the drug candidates that we </span></div><div style="line-height:10pt;position:var(--position);top:543.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">develop. </span></div><div style="line-height:10pt;position:var(--position);top:559.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">If we or one or more of our commercial partners succeeds in obtaining marketing authorization, allowing us or </span></div><div style="line-height:10pt;position:var(--position);top:569.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">them to market the therapeutic products developed by us, it may nevertheless take time to gain the support of the </span></div><div style="line-height:10pt;position:var(--position);top:579.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">medical community, health care providers and third-party payors. </span></div><div style="line-height:10pt;position:var(--position);top:595.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The level of market acceptance for each of our products will depend on several factors, notably on the </span></div><div style="line-height:10pt;position:var(--position);top:605.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">following: </span></div><div style="line-height:10pt;position:var(--position);top:621.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">prescribers&#8217; perception of the product&#8217;s therapeutic benefit; </span></span></div><div style="line-height:10pt;position:var(--position);top:637.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">healthcare policies established in each of the countries in which we are considering marketing our </span></span></div><div style="line-height:10pt;position:var(--position);top:647.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">products; </span></div><div style="line-height:1pt;position:var(--position);top:662pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="line-height:10pt;position:var(--position);top:663pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">possible occurrence of adverse reactions once marketing authorization has been obtained; </span></span></div><div style="line-height:10pt;position:var(--position);top:679pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">ease of use of the product, especially relating to its mode of administration; </span></span></div><div style="line-height:10pt;position:var(--position);top:695pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">cost of treatment; </span></span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">16</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">reimbursement policies of governments and other third parties; </span></span></div><div style="line-height:10pt;position:var(--position);top:88pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">effectiveness of sales and marketing efforts; </span></span></div><div style="line-height:10pt;position:var(--position);top:104pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">effective implementation of a scientific publication strategy; </span></span></div><div style="line-height:10pt;position:var(--position);top:120pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">willingness of the target patient population to try new therapies and of physicians to prescribe these </span></span></div><div style="line-height:10pt;position:var(--position);top:130pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">therapies; </span></div><div style="line-height:10pt;position:var(--position);top:146pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">prevalence and severity of any side effects; </span></span></div><div style="line-height:10pt;position:var(--position);top:162pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">development of one or more competing products for the same indication; and </span></span></div><div style="line-height:10pt;position:var(--position);top:178pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">restrictions on the use of the product together with medications. </span></span></div><div style="line-height:10pt;position:var(--position);top:194pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Although the products we are developing are intended to provide a therapeutic response to a need that is </span></div><div style="line-height:10pt;position:var(--position);top:204pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">presently </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:111.12pt;position:var(--position);white-space:pre">not entirely or adequately</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:213.48pt;position:var(--position);text-decoration:none;white-space:pre"> met, poor market penetration resulting from one or more of the factors described </span></div><div style="line-height:10pt;position:var(--position);top:214pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">above would have a negative impact on their commercialization and on our ability to generate profits, which could </span></div><div style="line-height:10pt;position:var(--position);top:224pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">have a material adverse effect on our business, outlook, financial position, income and growth. </span></div><div style="line-height:10pt;position:var(--position);top:240pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The level of market acceptance and sale of our drug candidates, if approved, will heavily depend on the </span></div><div style="line-height:10pt;position:var(--position);top:250pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">availability of coverage and adequate reimbursement from third-party payors. The conditions for setting the sales </span></div><div style="line-height:10pt;position:var(--position);top:260pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">price and reimbursement rate for drugs are beyond the control of pharmaceutical companies. They are decided by </span></div><div style="line-height:10pt;position:var(--position);top:270pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">competent public committees and bodies and by social security or private insurance companies and are dependent on </span></div><div style="line-height:10pt;position:var(--position);top:280pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">a number of factors. Pricing and reimbursement schemes vary widely from country to country. In the European </span></div><div style="line-height:10pt;position:var(--position);top:290pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Union, pricing and reimbursement are determined individually by European Union Member States. For example, </span></div><div style="line-height:10pt;position:var(--position);top:300pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">some countries may approve a specific price for a product while others may instead allow companies to fix their </span></div><div style="line-height:10pt;position:var(--position);top:310pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">own prices for products but monitor and control company profits. Within the US, as a principle, drug companies set </span></div><div style="line-height:10pt;position:var(--position);top:320pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">their own list prices, which may then be discounted through negotiations with payors. However, the U.S. </span></div><div style="line-height:10pt;position:var(--position);top:330pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Department of Health and Human Services ("HHS") has been empowered to negotiate the price of certain single-</span></div><div style="line-height:10pt;position:var(--position);top:340pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">source drugs that have been on the market for at least seven (7) years under Medicare as part of the Medicare Drug </span></div><div style="line-height:10pt;position:var(--position);top:350pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Price Negotiation Program. Each year up to twenty (20) products will be selected by HHS for the Medicare Drug </span></div><div style="line-height:10pt;position:var(--position);top:360pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Price Negotiation Program. Products subject to the Medicare Drug Price Negotiation Program are expected to </span></div><div style="line-height:10pt;position:var(--position);top:370pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">experience a significant reduction in reimbursement from the Medicare program on a per unit basis. Additionally, </span></div><div style="line-height:10pt;position:var(--position);top:380pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">HHS imposes rebates on Medicare Part B and Medicare Part D products to penalize price increases that outpace </span></div><div style="line-height:10pt;position:var(--position);top:390pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">inflation on an annual basis.&#160; </span></div><div style="line-height:10pt;position:var(--position);top:406pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Generally, the downward pressure on health care costs has become intense. As a result, increasingly high </span></div><div style="line-height:10pt;position:var(--position);top:416pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">barriers are being erected to the entry of new products. Delays in the price negotiation procedure may result in a </span></div><div style="line-height:10pt;position:var(--position);top:426pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">significant delay in marketing, our product may not obtain an appropriate level of reimbursement, or the accepted </span></div><div style="line-height:10pt;position:var(--position);top:436pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">price level and reimbursement rate of the treatments we market may be changed. We are also unable to guarantee </span></div><div style="line-height:10pt;position:var(--position);top:446pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">that we will succeed in maintaining, over time, the price level of our products or the accepted reimbursement rate. </span></div><div style="line-height:10pt;position:var(--position);top:462pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Our future may depend on our most advanced clinical development program, obefazimod, since our other drug </span></div><div style="line-height:10pt;position:var(--position);top:472pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">candidates are in a less advanced stage of development. </span></div><div style="line-height:10pt;position:var(--position);top:488pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Obefazimod is our most advanced drug candidate. Obefazimod has required, and may continue to require, </span></div><div style="line-height:10pt;position:var(--position);top:498pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">significant investments of our time and financial resources, as well as the special attention of highly qualified staff. </span></div><div style="line-height:10pt;position:var(--position);top:508pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Consequently, if we were unable to obtain conclusive results in ongoing maintenance trials, Phase 3 of obefazimod </span></div><div style="line-height:10pt;position:var(--position);top:518pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">in UC or Phase 2 of obefazimod in CD, it could have a material adverse effect on our business, outlook, financial </span></div><div style="line-height:10pt;position:var(--position);top:528pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">position, results and development. </span></div><div style="line-height:10pt;position:var(--position);top:544pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We may experience setbacks that could delay or prevent regulatory approval of our drug candidates or our </span></div><div style="line-height:10pt;position:var(--position);top:554pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ability to commercialize any products, including: </span></div><div style="line-height:10pt;position:var(--position);top:570pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">negative or inconclusive results from our preclinical studies or clinical trials or the clinical trials of </span></span></div><div style="line-height:10pt;position:var(--position);top:580pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">others for drug candidates similar to ours, leading to a decision or requirement to conduct additional </span></div><div style="line-height:10pt;position:var(--position);top:590pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">preclinical testing or clinical trials or abandon a program; </span></div><div style="line-height:10pt;position:var(--position);top:606pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">product-related side effects experienced by subjects in our clinical trials or by individuals using drugs </span></span></div><div style="line-height:10pt;position:var(--position);top:616pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">or therapeutics comparable to our drug candidates; </span></div><div style="line-height:10pt;position:var(--position);top:632pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">delays in submitting investigational new drug applications in the United States or comparable foreign </span></span></div><div style="line-height:10pt;position:var(--position);top:642pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">applications or delays or failure in obtaining the necessary approvals from regulators or institutional </span></div><div style="line-height:10pt;position:var(--position);top:652pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">review boards (&#8220;IRBs&#8221;) or positive opinions from ethics committees to commence a clinical trial, or a </span></div><div style="line-height:10pt;position:var(--position);top:662pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">suspension or termination of a clinical trial once commenced; </span></div><div style="line-height:10pt;position:var(--position);top:678pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">if the FDA or comparable foreign authorities do not accept the earlier preclinical and clinical trial </span></span></div><div style="line-height:10pt;position:var(--position);top:688pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">work, then we may need to conduct additional preclinical studies or clinical trials beyond that which </span></div><div style="line-height:10pt;position:var(--position);top:698pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">we currently have planned and significant preclinical study or clinical trial delays also could shorten </span></div><div style="line-height:10pt;position:var(--position);top:708pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">any periods during which we may have the exclusive right to commercialize our drug candidates or </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">17</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">allow our competitors to bring products to market before we do and impair our ability to successfully </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">commercialize our drug candidates and may harm our business; </span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">conditions imposed by the FDA or comparable foreign authorities regarding the scope or design of our </span></span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">clinical trials; </span></div><div style="line-height:1pt;position:var(--position);top:122.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="line-height:10pt;position:var(--position);top:123.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">delays in contracting with clinical sites or enrolling subjects in clinical trials, including due to any </span></span></div><div style="line-height:10pt;position:var(--position);top:133.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">health pandemic and/or other macroeconomic factors; </span></div><div style="line-height:10pt;position:var(--position);top:149.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">delays or interruptions in the supply of materials necessary for the conduct of our clinical trials; </span></span></div><div style="line-height:10pt;position:var(--position);top:165.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">regulators or IRBs may not authorize us or our investigators to commence a clinical trial or conduct a </span></span></div><div style="line-height:10pt;position:var(--position);top:175.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">clinical trial at a prospective trial site or ethics committees may not issue required positive opinions; </span></div><div style="line-height:10pt;position:var(--position);top:191.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the FDA or other comparable regulatory authorities may disagree with our clinical trial design, </span></span></div><div style="line-height:10pt;position:var(--position);top:201.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">including with respect to dosing levels administered in our planned clinical trials, which may delay or </span></div><div style="line-height:10pt;position:var(--position);top:211.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">prevent us from initiating our clinical trials with our originally intended trial design; </span></div><div style="line-height:10pt;position:var(--position);top:227.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">delays in reaching, or failure to reach, agreement on acceptable terms with prospective trial sites, </span></span></div><div style="line-height:10pt;position:var(--position);top:237.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">investigators and prospective contract research organizations (&#8220;CROs&#8221;) which can be subject to </span></div><div style="line-height:10pt;position:var(--position);top:247.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">extensive negotiation and may vary significantly among different CROs and trial sites; </span></div><div style="line-height:10pt;position:var(--position);top:263.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the number of subjects required for clinical trials of any drug candidates may be larger than we </span></span></div><div style="line-height:10pt;position:var(--position);top:273.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">anticipate or subjects may drop out of these clinical trials or fail to return for post-treatment follow-up </span></div><div style="line-height:10pt;position:var(--position);top:283.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">at a higher rate than we anticipate; </span></div><div style="line-height:10pt;position:var(--position);top:299.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">our CROs for preclinical studies or clinical trials may fail to comply with regulatory requirements or </span></span></div><div style="line-height:10pt;position:var(--position);top:309.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical </span></div><div style="line-height:10pt;position:var(--position);top:319.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">trial protocol or take actions that could cause clinical sites or clinical investigators to drop out of the </span></div><div style="line-height:10pt;position:var(--position);top:329.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">trial, which may require that we add new clinical trial sites or investigators; </span></div><div style="line-height:10pt;position:var(--position);top:345.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">greater than anticipated clinical trial costs, including as a result of delays or interruptions that could </span></span></div><div style="line-height:10pt;position:var(--position);top:355.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">increase the overall costs to finish our clinical trials as our fixed costs are not substantially reduced </span></div><div style="line-height:10pt;position:var(--position);top:365.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">during delays; </span></div><div style="line-height:10pt;position:var(--position);top:381.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">we may elect to, or regulators, IRBs, ethics committees or Data Safety Monitoring Boards (&#8220;DSMBs&#8221;) </span></span></div><div style="line-height:10pt;position:var(--position);top:391.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">may require that we or our investigators, suspend or terminate clinical research or trials for various </span></div><div style="line-height:10pt;position:var(--position);top:401.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">reasons, including noncompliance with regulatory requirements or a finding that the participants are </span></div><div style="line-height:10pt;position:var(--position);top:411.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">being exposed to unacceptable health risks; </span></div><div style="line-height:10pt;position:var(--position);top:427.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">we may not have the financial resources available to begin and complete the planned trials, or the cost </span></span></div><div style="line-height:10pt;position:var(--position);top:437.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">of clinical trials of any drug candidates may be greater than we anticipate; </span></div><div style="line-height:10pt;position:var(--position);top:453.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the supply or quality of our drug candidates or other materials necessary to conduct clinical trials of </span></span></div><div style="line-height:10pt;position:var(--position);top:463.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">our drug candidates may be insufficient or inadequate to initiate or complete a given clinical trial; </span></div><div style="line-height:10pt;position:var(--position);top:479.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the FDA or other comparable foreign regulatory authorities may require us to submit additional data </span></span></div><div style="line-height:10pt;position:var(--position);top:489.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">such as long term toxicology studies, or impose other requirements before permitting us to initiate a </span></div><div style="line-height:10pt;position:var(--position);top:499.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">clinical trial, including because the FDA has not reviewed our preclinical or clinical data, to date, </span></div><div style="line-height:10pt;position:var(--position);top:509.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">having been developed outside the United States; </span></div><div style="line-height:10pt;position:var(--position);top:525.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">inability to compete with other therapies; </span></span></div><div style="line-height:10pt;position:var(--position);top:541.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">poor efficacy of our drug candidates during clinical trials; </span></span></div><div style="line-height:10pt;position:var(--position);top:557.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">unfavorable FDA or other regulatory agency inspection and review of clinical trial sites or </span></span></div><div style="line-height:10pt;position:var(--position);top:567.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">manufacturing facilities; </span></div><div style="line-height:10pt;position:var(--position);top:583.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">unfavorable product labeling associated with any product approvals and any requirements for a Risk </span></span></div><div style="line-height:10pt;position:var(--position);top:593.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) that may be required by the FDA or comparable </span></div><div style="line-height:10pt;position:var(--position);top:603.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">requirements in other jurisdictions to ensure the benefits of an individual product outweigh its risks; </span></div><div style="line-height:10pt;position:var(--position);top:619.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">unfavorable acceptance of our clinical trial data by the patient or medical communities or third-party </span></span></div><div style="line-height:10pt;position:var(--position);top:629.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">payors; </span></div><div style="line-height:1pt;position:var(--position);top:644pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="line-height:10pt;position:var(--position);top:651pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">delays and changes in regulatory requirements, policy and guidelines, including the imposition of </span></span></div><div style="line-height:10pt;position:var(--position);top:661pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">additional regulatory oversight around clinical testing generally or with respect to our technology in </span></div><div style="line-height:10pt;position:var(--position);top:671pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">particular; or </span></div><div style="line-height:10pt;position:var(--position);top:687pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">varying interpretations of data by the FDA and similar foreign regulatory agencies. </span></span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">18</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We do not have complete control over many of these factors, including certain aspects of clinical development </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and the regulatory submission process, potential threats to our intellectual property rights and our manufacturing, </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">marketing, distribution and sales efforts or that of any future collaborator. </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">We may find it difficult to enroll patients in our clinical trials. If we encounter difficulties enrolling patients in </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">our clinical trials, our clinical development activities could be delayed or otherwise adversely affected. </span></div><div style="line-height:10pt;position:var(--position);top:134pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Patient enrollment is a significant factor in the timing of clinical trials, including with respect to data read and </span></div><div style="line-height:10pt;position:var(--position);top:144pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the timing of our clinical trials will depend, in part, on the speed at which we can recruit patients to participate in our </span></div><div style="line-height:10pt;position:var(--position);top:154pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">trials, as well as completion of required follow-up periods. We may not be able to initiate or continue clinical trials </span></div><div style="line-height:10pt;position:var(--position);top:164pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for our drug candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in </span></div><div style="line-height:10pt;position:var(--position);top:174pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">these trials to such trial&#8217;s conclusion as required by applicable regulatory authorities. The eligibility criteria of our </span></div><div style="line-height:10pt;position:var(--position);top:184pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">clinical trials, once established, may further limit the pool of available trial participants. </span></div><div style="line-height:10pt;position:var(--position);top:200pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Patient enrollment in clinical trials may be affected by other factors, including: </span></div><div style="line-height:10pt;position:var(--position);top:216pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">size and nature of the targeted patient population; </span></span></div><div style="line-height:10pt;position:var(--position);top:232pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">severity of the disease or condition under investigation; </span></span></div><div style="line-height:10pt;position:var(--position);top:248pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">availability and efficacy of approved therapies for the disease or condition under investigation; </span></span></div><div style="line-height:10pt;position:var(--position);top:264pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">patient eligibility criteria for the trial in question as defined in the protocol; </span></span></div><div style="line-height:10pt;position:var(--position);top:280pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">perceived risks and benefits of the drug candidate under study; </span></span></div><div style="line-height:10pt;position:var(--position);top:296pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug candidate being studied </span></span></div><div style="line-height:10pt;position:var(--position);top:306pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">in relation to other available therapies, including any products that may be approved for, or any drug </span></div><div style="line-height:10pt;position:var(--position);top:316pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">candidates under investigation for, the indications we are investigating; </span></div><div style="line-height:10pt;position:var(--position);top:332pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">efforts to facilitate timely enrollment in clinical trials; </span></span></div><div style="line-height:10pt;position:var(--position);top:348pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">patient referral practices of physicians; </span></span></div><div style="line-height:10pt;position:var(--position);top:364pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the ability to monitor patients adequately during and after treatment; </span></span></div><div style="line-height:10pt;position:var(--position);top:380pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">proximity and availability of clinical trial sites for prospective patients;</span></span></div><div style="line-height:10pt;position:var(--position);top:402pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:126pt;position:var(--position);text-decoration:none;white-space:pre">any instability in the geographic regions in which our clinical trial sites are located;</span></div><div style="line-height:10pt;position:var(--position);top:420pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">continued enrollment of prospective patients by clinical trial sites; and </span></span></div><div style="line-height:10pt;position:var(--position);top:436pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the risk that patients enrolled in clinical trials will drop out of such trials before completion. </span></span></div><div style="line-height:10pt;position:var(--position);top:452pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Additionally, other pharmaceutical companies targeting these same diseases are recruiting clinical trial </span></div><div style="line-height:10pt;position:var(--position);top:462pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">patients from these patient populations, which may make it more difficult to fully enroll any clinical trials. We also </span></div><div style="line-height:10pt;position:var(--position);top:472pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">rely on, and will continue to rely on, CROs and clinical trial sites to ensure proper and timely conduct of our clinical </span></div><div style="line-height:10pt;position:var(--position);top:482pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">trials and preclinical studies. Though we have entered into agreements governing their services, we will have limited </span></div><div style="line-height:10pt;position:var(--position);top:492pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">influence over their actual performance. Our inability to enroll a sufficient number of patients for our clinical trials </span></div><div style="line-height:10pt;position:var(--position);top:502pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment </span></div><div style="line-height:10pt;position:var(--position);top:512pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">delays in our clinical trials may result in increased development costs for our drug candidates and jeopardize our </span></div><div style="line-height:10pt;position:var(--position);top:522pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ability to obtain regulatory approval for the sale of our drug candidates. Furthermore, even if we are able to enroll a </span></div><div style="line-height:10pt;position:var(--position);top:532pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">sufficient number of patients for our clinical trials, we may have difficulty maintaining enrollment of such patients </span></div><div style="line-height:10pt;position:var(--position);top:542pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">in our clinical trials. </span></div><div style="line-height:10pt;position:var(--position);top:558pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">We are developing certain of our drug candidates in combination with other therapies, and safety or supply issues </span></div><div style="line-height:10pt;position:var(--position);top:568pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">with combination use products may delay or prevent development and approval of our therapeutic candidates. </span></div><div style="line-height:10pt;position:var(--position);top:584pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We are developing certain of our drug candidates in combination with one or more approved or investigational </span></div><div style="line-height:10pt;position:var(--position);top:594pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">therapies. Even if any drug candidate we develop were to receive marketing approval or be commercialized for use </span></div><div style="line-height:10pt;position:var(--position);top:604pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">in combination with other existing therapies, we would continue to be subject to the risks that the FDA, European </span></div><div style="line-height:10pt;position:var(--position);top:614pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Commission, PDMA or similar foreign regulatory authorities could revoke approval of the therapy used in </span></div><div style="line-height:10pt;position:var(--position);top:624pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">combination with our product or that safety, efficacy, manufacturing or supply issues could arise with any of those </span></div><div style="line-height:10pt;position:var(--position);top:634pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">existing therapies. If the therapies we use in combination with our drug candidates are replaced as the standard of </span></div><div style="line-height:10pt;position:var(--position);top:644pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">care for the indications we choose for any of our drug candidates, the EMA, FDA, PDMA or similar foreign </span></div><div style="line-height:10pt;position:var(--position);top:654pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regulatory authorities outside may require us to conduct additional clinical trials. The occurrence of any of these </span></div><div style="line-height:10pt;position:var(--position);top:664pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">risks could result in our own products, if approved, being removed from the market or being less successful </span></div><div style="line-height:10pt;position:var(--position);top:674pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">commercially. </span></div><div style="line-height:10pt;position:var(--position);top:690pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We also may evaluate our drug candidates in combination with one or more therapies that have not yet been </span></div><div style="line-height:10pt;position:var(--position);top:700pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">approved for marketing by the FDA, European Commission, PDMA or similar foreign regulatory authorities. We </span></div><div style="line-height:10pt;position:var(--position);top:710pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">will not be able to market and sell any drug candidate we develop in combination with an unapproved therapy if that </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">19</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">unapproved therapy does not ultimately obtain marketing approval. In addition, unapproved therapies face the same </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">risks described with respect to our drug candidates currently in development, including the potential for serious </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">adverse effects, delay in their clinical trials and lack of FDA, European Commission, PDMA, or similar foreign </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regulatory authorities approval. </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">If the FDA, European Commission or similar foreign regulatory authorities do not approve these other </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">therapies or revoke their approval of, or if safety, efficacy, manufacturing or supply issues arise with, the therapies </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">we choose to evaluate in combination with our drug candidates, we may be unable to obtain approval of or market </span></div><div style="line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">any such drug candidate. </span></div><div style="line-height:10pt;position:var(--position);top:164pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">We may conduct clinical trials for our drug candidates outside of the U.S., and the FDA may not accept data </span></div><div style="line-height:10pt;position:var(--position);top:174pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">from such trials, in which case our development plans may be delayed, which could materially harm our </span></div><div style="line-height:10pt;position:var(--position);top:184pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">business. </span></div><div style="line-height:10pt;position:var(--position);top:200pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We have in the past conducted clinical trials or a portion of our clinical trials for our drug candidates outside </span></div><div style="line-height:10pt;position:var(--position);top:210pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the U.S. The acceptance of study data from clinical trials conducted outside the U.S. or another jurisdiction by the </span></div><div style="line-height:10pt;position:var(--position);top:220pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">FDA or comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. </span></div><div style="line-height:10pt;position:var(--position);top:230pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the </span></div><div style="line-height:10pt;position:var(--position);top:240pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">U.S., for example, the FDA will generally not approve the application on the basis of foreign data alone unless (i) </span></div><div style="line-height:10pt;position:var(--position);top:250pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical </span></div><div style="line-height:10pt;position:var(--position);top:260pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid </span></div><div style="line-height:10pt;position:var(--position);top:270pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the </span></div><div style="line-height:10pt;position:var(--position);top:280pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">FDA is able to validate the data through an on-site inspection or other appropriate means. In addition, even where </span></div><div style="line-height:10pt;position:var(--position);top:290pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as </span></div><div style="line-height:10pt;position:var(--position);top:300pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">support for an application for marketing approval unless the study is well-designed and well-conducted in </span></div><div style="line-height:10pt;position:var(--position);top:310pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite </span></div><div style="line-height:10pt;position:var(--position);top:320pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">inspection if deemed necessary. Many foreign regulatory authorities have similar requirements for clinical data </span></div><div style="line-height:10pt;position:var(--position);top:330pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">gathered outside of their respective jurisdictions. In addition, such foreign trials would be subject to the applicable </span></div><div style="line-height:10pt;position:var(--position);top:340pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any </span></div><div style="line-height:10pt;position:var(--position);top:350pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">comparable foreign regulatory authority will accept data from trials conducted outside of the U.S. or the relevant </span></div><div style="line-height:10pt;position:var(--position);top:360pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it may result in </span></div><div style="line-height:10pt;position:var(--position);top:370pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the need for additional trials, which could be costly and time-consuming, and which may result in current or future </span></div><div style="line-height:10pt;position:var(--position);top:380pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">drug candidates that we may develop not receiving approval for commercialization in the applicable jurisdiction. </span></div><div style="line-height:10pt;position:var(--position);top:396pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72.25pt;position:var(--position);text-decoration:none;white-space:pre">Interim, &#8220;top-line&#8221; and preliminary data from our clinical trials and preclinical studies that we announce or </span></div><div style="line-height:10pt;position:var(--position);top:406pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">publish from time to time may change as more patient data become available and are subject to audit and </span></div><div style="line-height:10pt;position:var(--position);top:416pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">verification procedures that could result in material changes in the final data. </span></div><div style="line-height:10pt;position:var(--position);top:432pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">From time to time, we may publicly disclose interim, top-line or preliminary data from our clinical trials and </span></div><div style="line-height:10pt;position:var(--position);top:442pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">preclinical studies, which is based on a preliminary analysis of then-available data, and the results and related </span></div><div style="line-height:10pt;position:var(--position);top:452pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">findings and conclusions are subject to change following a more comprehensive review of the data related to the </span></div><div style="line-height:10pt;position:var(--position);top:462pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses </span></div><div style="line-height:10pt;position:var(--position);top:472pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the </span></div><div style="line-height:10pt;position:var(--position);top:482pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">interim, top-line or preliminary results that we report may differ from future results of the same studies or trials, or </span></div><div style="line-height:10pt;position:var(--position);top:492pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">different conclusions or considerations may qualify such results, once additional data have been received and fully </span></div><div style="line-height:10pt;position:var(--position);top:502pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">evaluated. Top-line and preliminary data also remain subject to audit and verification procedures that may result in </span></div><div style="line-height:10pt;position:var(--position);top:512pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the final data being materially different from the top-line or preliminary data we previously published. As a result, </span></div><div style="line-height:10pt;position:var(--position);top:522pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">top-line and preliminary data should be viewed with caution until the final data are available. Moreover, caution </span></div><div style="line-height:10pt;position:var(--position);top:532pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">should be exercised in drawing any conclusions from a comparison of data that does not come from head-to-head </span></div><div style="line-height:10pt;position:var(--position);top:542pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">analysis.</span></div><div style="line-height:10pt;position:var(--position);top:558pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Interim data from clinical trials that we may complete are further subject to the risk that one or more of the </span></div><div style="line-height:10pt;position:var(--position);top:568pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">clinical outcomes may materially change as patient enrollment continues and more patient data become available. </span></div><div style="line-height:10pt;position:var(--position);top:578pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Adverse differences between interim, top-line or preliminary data and final data could significantly harm our </span></div><div style="line-height:10pt;position:var(--position);top:588pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">business prospects. Further, disclosure of such data by us or by our competitors could result in volatility in the price </span></div><div style="line-height:10pt;position:var(--position);top:598pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of our securities. </span></div><div style="line-height:10pt;position:var(--position);top:614pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, </span></div><div style="line-height:10pt;position:var(--position);top:624pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could </span></div><div style="line-height:10pt;position:var(--position);top:634pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">impact the value of the particular development program, the approvability or commercialization of the particular </span></div><div style="line-height:10pt;position:var(--position);top:644pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">drug candidate or product and our company in general. In addition, the information we choose to publicly disclose </span></div><div style="line-height:10pt;position:var(--position);top:654pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regarding a particular study or clinical trial is based on what is typically extensive information, and you or others </span></div><div style="line-height:10pt;position:var(--position);top:664pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">may not agree with what we determine is material or otherwise appropriate information to include in our disclosure, </span></div><div style="line-height:10pt;position:var(--position);top:674pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and any information we determine not to disclose may ultimately be deemed significant with respect to future </span></div><div style="line-height:10pt;position:var(--position);top:684pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">decisions, conclusions, views, activities or otherwise regarding a particular drug candidate or our business. If the </span></div><div style="line-height:10pt;position:var(--position);top:694pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">interim, top-line or preliminary data that we report differ from actual results, or if others, including regulatory </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">20</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our drug </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">candidates may be harmed, which could harm our business, operating results, prospects or financial condition. </span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">could hinder their ability to hire, retain or deploy key leadership and other personnel, prevent new or modified </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">products from being developed, reviewed, approved or commercialized in a timely manner or at all, which could </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">negatively impact our business. </span></div><div style="line-height:10pt;position:var(--position);top:144pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The ability of the FDA and foreign regulatory authorities to review and approve new products can be affected </span></div><div style="line-height:10pt;position:var(--position);top:154pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">by a variety of factors, including government budget and funding levels, statutory, regulatory and policy changes, </span></div><div style="line-height:10pt;position:var(--position);top:164pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the FDA&#8217;s or foreign regulatory authorities&#8217; ability to hire and retain key personnel and accept the payment of user </span></div><div style="line-height:10pt;position:var(--position);top:174pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">fees, and other events that may otherwise affect the FDA&#8217;s or foreign regulatory authorities&#8217; ability to perform </span></div><div style="line-height:10pt;position:var(--position);top:184pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">routine functions. Average review times at the FDA and foreign regulatory authorities have fluctuated in recent </span></div><div style="line-height:10pt;position:var(--position);top:194pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">years as a result. In addition, government funding of other government agencies that fund research and development </span></div><div style="line-height:10pt;position:var(--position);top:204pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and </span></div><div style="line-height:10pt;position:var(--position);top:214pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">other agencies may also slow the time necessary for new drugs or modifications to approved drugs and to be </span></div><div style="line-height:10pt;position:var(--position);top:224pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reviewed and/or approved by necessary government agencies, which would adversely affect our business. For </span></div><div style="line-height:10pt;position:var(--position);top:234pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">example, over the last several years, the U.S. government has shut down several times and certain regulatory </span></div><div style="line-height:10pt;position:var(--position);top:244pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged </span></div><div style="line-height:10pt;position:var(--position);top:254pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">government shutdown occurs, or if a public health crisis prevents the FDA or other regulatory authorities from </span></div><div style="line-height:10pt;position:var(--position);top:264pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability </span></div><div style="line-height:10pt;position:var(--position);top:274pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could </span></div><div style="line-height:10pt;position:var(--position);top:284pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">have a material adverse effect on our business. </span></div><div style="line-height:10pt;position:var(--position);top:300pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of </span></div><div style="line-height:10pt;position:var(--position);top:310pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">off-label uses. </span></div><div style="line-height:10pt;position:var(--position);top:326pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The FDA strictly regulates marketing, labeling, advertising and promotion of prescription drugs. These </span></div><div style="line-height:10pt;position:var(--position);top:336pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regulations include standards and restrictions for direct-to-consumer advertising, industry-sponsored scientific and </span></div><div style="line-height:10pt;position:var(--position);top:346pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">educational activities, promotional activities involving the internet and off-label promotion. Any regulatory approval </span></div><div style="line-height:10pt;position:var(--position);top:356pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">that the FDA grants is limited to those specific diseases and indications for which a product is deemed to be safe and </span></div><div style="line-height:10pt;position:var(--position);top:366pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">effective by FDA. While physicians in the United States may choose, and are generally permitted, to prescribe drugs </span></div><div style="line-height:10pt;position:var(--position);top:376pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for uses that are not described in the product&#8217;s labeling and for uses that differ from those tested in clinical trials and </span></div><div style="line-height:10pt;position:var(--position);top:386pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">approved by the regulatory authorities, our ability to promote any products will be narrowly limited to those </span></div><div style="line-height:10pt;position:var(--position);top:396pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">indications that are specifically approved by the FDA. </span></div><div style="line-height:10pt;position:var(--position);top:412pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">If we are found to have promoted such off-label uses, we may become subject to significant liability. The U.S. </span></div><div style="line-height:10pt;position:var(--position);top:422pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">federal government has levied large civil and criminal fines against companies for alleged improper promotion of </span></div><div style="line-height:10pt;position:var(--position);top:432pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested </span></div><div style="line-height:10pt;position:var(--position);top:442pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is </span></div><div style="line-height:10pt;position:var(--position);top:452pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">changed or curtailed. Similar requirements and related risks apply outside the U.S. If we cannot successfully manage </span></div><div style="line-height:10pt;position:var(--position);top:462pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the promotion of any drug candidates, if approved, we could become subject to significant liability, which would </span></div><div style="line-height:10pt;position:var(--position);top:472pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">materially adversely affect our business and financial condition. </span></div><div style="line-height:10pt;position:var(--position);top:488pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">We may not be able to find industrial partners to pursue the clinical and commercial development of obefazimod. </span></div><div style="line-height:10pt;position:var(--position);top:504pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We may enter into licensing and distribution partnerships with pharmaceutical companies in order to fund the </span></div><div style="line-height:10pt;position:var(--position);top:514pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">completion of the clinical development and marketing preparation of our lead drug candidate, obefazimod. </span></div><div style="line-height:10pt;position:var(--position);top:524pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Consequently, we should find partners with sufficient capacity to perform Phase 1, 2 and/or 3 clinical trials on a </span></div><div style="line-height:10pt;position:var(--position);top:534pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">national or international scale and mass-produce, distribute and market immunotherapies and anti-inflammatory </span></div><div style="line-height:10pt;position:var(--position);top:544pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">treatments such as obefazimod. If we were to enter into such partnerships, the commercialization of our products </span></div><div style="line-height:10pt;position:var(--position);top:554pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">would depend, in part, on the clinical, industrial, marketing and commercial development efforts of our business </span></div><div style="line-height:10pt;position:var(--position);top:564pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">partners and the ability of these partners to produce and sell obefazimod. Any failure on the part of our partners </span></div><div style="line-height:10pt;position:var(--position);top:574pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">could have a material adverse effect on our growth and outlook. </span></div><div style="line-height:10pt;position:var(--position);top:590pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">It is also possible that we may not be able to enter into partnerships under economically reasonable conditions </span></div><div style="line-height:10pt;position:var(--position);top:600pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">or at all. This could have a material adverse effect on our business, outlook, financial position, results and </span></div><div style="line-height:10pt;position:var(--position);top:610pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">development. </span></div><div style="line-height:10pt;position:var(--position);top:626pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">We may not be able to conduct, or contract others to conduct, animal testing in the future, which could harm our </span></div><div style="line-height:10pt;position:var(--position);top:636pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">research and development activities. </span></div><div style="line-height:10pt;position:var(--position);top:652pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Certain laws and regulations relating to drug development require us to test our drug candidates on animals </span></div><div style="line-height:10pt;position:var(--position);top:662pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">before initiating clinical trials involving humans. Animal testing activities have been the subject of controversy and </span></div><div style="line-height:10pt;position:var(--position);top:672pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal </span></div><div style="line-height:10pt;position:var(--position);top:682pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">testing activities by pressing for legislation and regulation in these areas and by disrupting these activities through </span></div><div style="line-height:10pt;position:var(--position);top:692pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">protests and other means. To the extent the activities of these groups are successful, our research and development </span></div><div style="line-height:10pt;position:var(--position);top:702pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">activities may be interrupted or delayed. </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">21</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Risks Related to our Operations and Strategic Development </span></div><div style="line-height:10pt;position:var(--position);top:88pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">We expect to expand our organization, and as a result, we may encounter difficulties in managing our growth, </span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">which could disrupt our operations. </span></div><div style="line-height:10pt;position:var(--position);top:114pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In order to manage our anticipated development and expansion, including the potential commercialization of </span></div><div style="line-height:10pt;position:var(--position);top:124pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">our drug candidates in Europe and the United States, we must continue to implement and improve our managerial, </span></div><div style="line-height:10pt;position:var(--position);top:134pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">operational and financial systems, expand our facilities and continue to recruit and train additional qualified </span></div><div style="line-height:10pt;position:var(--position);top:144pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">personnel. Due to our limited financial resources and the limited experience of our management team in managing a </span></div><div style="line-height:10pt;position:var(--position);top:154pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">company with such expected growth, we may not be able to effectively manage the expansion of our operations or </span></div><div style="line-height:10pt;position:var(--position);top:164pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and </span></div><div style="line-height:10pt;position:var(--position);top:174pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">may divert the attention of our management and business development resources away from day-to-day activities </span></div><div style="line-height:10pt;position:var(--position);top:184pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and devote a substantial amount of time to managing internal or external growth. Our inability to manage growth or </span></div><div style="line-height:10pt;position:var(--position);top:194pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">unexpected difficulties encountered during expansion could have a material adverse effect on our business, income, </span></div><div style="line-height:10pt;position:var(--position);top:204pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">financial position, growth and outlook. </span></div><div style="line-height:10pt;position:var(--position);top:220pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Our international operations subject us to various risks, and our failure to manage these risks could adversely </span></div><div style="line-height:10pt;position:var(--position);top:230pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">affect our results of operations. </span></div><div style="line-height:10pt;position:var(--position);top:246pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We face significant operational risks as a result of doing business internationally, such as: </span></div><div style="line-height:10pt;position:var(--position);top:262pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">fluctuations in foreign currency exchange rates; </span></span></div><div style="line-height:10pt;position:var(--position);top:278pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">differing payor reimbursement regimes, governmental payors or patient&#160;self-pay&#160;systems and price </span></span></div><div style="line-height:10pt;position:var(--position);top:288pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">controls; </span></div><div style="line-height:10pt;position:var(--position);top:304pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">potential changes to the accounting standards, which may influence our financial situation and results; </span></span></div><div style="line-height:10pt;position:var(--position);top:320pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">becoming subject to the different, complex and changing laws, regulations and court systems of </span></span></div><div style="line-height:10pt;position:var(--position);top:330pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">multiple jurisdictions and compliance with a wide variety of foreign laws, treaties and regulations; </span></div><div style="line-height:10pt;position:var(--position);top:346pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">reduced protection of, or significant difficulties in enforcing, intellectual property rights in certain </span></span></div><div style="line-height:10pt;position:var(--position);top:356pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">countries; </span></div><div style="line-height:10pt;position:var(--position);top:372pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">difficulties in attracting and retaining qualified personnel; </span></span></div><div style="line-height:10pt;position:var(--position);top:388pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">restrictions imposed by local labor practices and laws on our business and operations, including </span></span></div><div style="line-height:10pt;position:var(--position);top:398pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">unilateral cancellation or modification of contracts; </span></div><div style="line-height:10pt;position:var(--position);top:414pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">rapid changes in global government, economic and political policies and conditions, political or civil </span></span></div><div style="line-height:10pt;position:var(--position);top:424pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">unrest or instability, terrorism or epidemics and other similar outbreaks or events, and potential failure </span></div><div style="line-height:10pt;position:var(--position);top:434pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">in confidence of our suppliers or customers due to such changes or events; and </span></div><div style="line-height:10pt;position:var(--position);top:450pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">tariffs, trade protection measures, import or export licensing requirements, trade embargoes and other </span></span></div><div style="line-height:10pt;position:var(--position);top:460pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">trade barriers, including any governmental responses thereto. </span></div><div style="line-height:10pt;position:var(--position);top:476pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The market opportunities for our drug candidates may be limited to patients who are ineligible for or have failed </span></div><div style="line-height:10pt;position:var(--position);top:486pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">prior treatments and may be small or different from our estimates. </span></div><div style="line-height:10pt;position:var(--position);top:502pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The current IBD treatment approach is influenced by multiple factors, including disease severity, previous </span></div><div style="line-height:10pt;position:var(--position);top:512pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">response to treatment, side effects and co-morbidities. The current standard of care for treatment of patients with </span></div><div style="line-height:10pt;position:var(--position);top:522pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">mild IBD involves the use of conventional anti-inflammatory therapies. Conventional anti-inflammatory therapies </span></div><div style="line-height:10pt;position:var(--position);top:532pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">include: aminosalicylates (e.g., 5-ASA), immunosuppressants or immunomodulators (e.g., 6-mercaptopurine (&#8220;6-</span></div><div style="line-height:10pt;position:var(--position);top:542pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">MP&#8221;), methotrexate (&#8220;MTX&#8221;)) and corticosteroids that are usually prescribed for short-term treatment to manage </span></div><div style="line-height:10pt;position:var(--position);top:552pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">flare-ups. Despite these conventional therapies, patients suffering from mild IBD may evolve towards moderate and </span></div><div style="line-height:10pt;position:var(--position);top:562pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">severe forms of IBD requiring the use of advanced therapies. However, available therapies often only have moderate </span></div><div style="line-height:10pt;position:var(--position);top:572pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">efficacy that changes or may wane over time, as patients have the potential to stop responding or do not respond at </span></div><div style="line-height:10pt;position:var(--position);top:582pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">all to these treatments and thus require new therapeutic management options. </span></div><div style="line-height:10pt;position:var(--position);top:598pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">While we hope to position obefazimod as a potential first-line advanced therapy, there is no guarantee that </span></div><div style="line-height:10pt;position:var(--position);top:608pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">even if approved, it would be approved for first-line advanced therapy. This could limit our potential market </span></div><div style="line-height:10pt;position:var(--position);top:618pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">opportunity. In addition, we may have to conduct additional clinical trials prior to gaining approval for first-line </span></div><div style="line-height:10pt;position:var(--position);top:628pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">advanced therapy. </span></div><div style="line-height:10pt;position:var(--position);top:644pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The estimates of market opportunity and forecasts of market growth included in this Annual Report on Form 20-</span></div><div style="line-height:10pt;position:var(--position);top:654pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">F may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our </span></div><div style="line-height:10pt;position:var(--position);top:664pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">business may not grow at similar rates, or at all. </span></div><div style="line-height:10pt;position:var(--position);top:680pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Market opportunity estimates and growth forecasts included in this Annual Report on Form 20-F are subject to </span></div><div style="line-height:10pt;position:var(--position);top:690pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">significant uncertainty and are based on assumptions and estimates which may not prove to be accurate. The </span></div><div style="line-height:10pt;position:var(--position);top:700pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">estimates and forecasts included in this Annual Report on Form 20-F relating to size and expected growth of our </span></div><div style="line-height:10pt;position:var(--position);top:710pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">target market may prove to be inaccurate. Even if the markets in which we compete meet the size estimates and </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">22</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">growth forecasts included in this Annual Report on Form 20-F, our business may not grow at similar rates, or at all. </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Our growth is subject to many factors, including our success in implementing our business strategy, which is subject </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to many risks and uncertainties. </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Sales of our drug candidates, if approved, could be adversely impacted by the reluctance of physicians, healthcare </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">payors, patients or the medical community in general to adopt them and by the availability of competing drugs. </span></div><div style="line-height:10pt;position:var(--position);top:134pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Even if we obtain regulatory approval for one or more of our drug candidates, physicians, healthcare payors, </span></div><div style="line-height:10pt;position:var(--position);top:144pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">patients or the medical community in general may be reluctant to try a new drug due to the high degree of risk </span></div><div style="line-height:10pt;position:var(--position);top:154pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">associated with the application of new drugs in the field of human medicine, especially if the new drug differs from </span></div><div style="line-height:10pt;position:var(--position);top:164pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the currently prevailing medication for a given complaint. We will need to expend significant sums of money to </span></div><div style="line-height:10pt;position:var(--position);top:174pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">market our products to increase the public&#8217;s awareness within numerous limits set by the regulations concerning the </span></div><div style="line-height:10pt;position:var(--position);top:184pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">promotion of drugs. If our products do not achieve an adequate level of acceptance, we may not generate enough </span></div><div style="line-height:10pt;position:var(--position);top:194pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">revenues to become profitable or the profitability may occur much later. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:210pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Competing drug candidates in the chronic inflammatory disease field are being manufactured and marketed by </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:220pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">other companies, including, but not limited to, AbbVie, Eli Lilly, Johnson&#160;&amp; Johnson, Pfizer and Takeda. Merck, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:230pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Roche, and Teva/Sanofi are all potential future competitors based on recent acquisitions of TL1A molecules.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:506.99pt;position:var(--position);text-decoration:none;white-space:pre"> To </span></div><div style="line-height:10pt;position:var(--position);top:240pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">compete with other drugs, particularly any that sell at lower prices, our drug candidates will have to provide </span></div><div style="line-height:10pt;position:var(--position);top:250pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">medically significant advantages or be more cost-effective. Even if we can overcome physician reluctance and </span></div><div style="line-height:10pt;position:var(--position);top:260pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">compete with products that are currently on the market, our competitors may succeed in developing new, safer, more </span></div><div style="line-height:10pt;position:var(--position);top:270pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">accurate or more cost-effective treatments or therapeutic indications that could render our drug candidates obsolete </span></div><div style="line-height:10pt;position:var(--position);top:280pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">or non-competitive. </span></div><div style="line-height:10pt;position:var(--position);top:296pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Global economic conditions could materially adversely impact demand for our drug candidates. </span></div><div style="line-height:10pt;position:var(--position);top:312pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our operations and performance depend significantly on economic conditions. Global financial conditions </span></div><div style="line-height:10pt;position:var(--position);top:322pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">continue to be subject to volatility arising from international geopolitical developments, such as the wars in Ukraine </span></div><div style="line-height:10pt;position:var(--position);top:332pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and Iran, tariffs and global economic phenomena, as well as general financial market turbulence, natural phenomena </span></div><div style="line-height:10pt;position:var(--position);top:342pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and any public health crisis. Uncertainty about global economic conditions could result in: </span></div><div style="line-height:10pt;position:var(--position);top:358pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">third-party suppliers being unable to produce components for our drug candidates in the same quantity </span></span></div><div style="line-height:10pt;position:var(--position);top:368pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">or on the same timeline or being unable to deliver such parts and components as quickly as before or </span></div><div style="line-height:10pt;position:var(--position);top:378pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">subject to price fluctuations, which could have a material adverse effect on our production or the cost </span></div><div style="line-height:10pt;position:var(--position);top:388pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">of such production; and </span></div><div style="line-height:1pt;position:var(--position);top:402.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="line-height:10pt;position:var(--position);top:403.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">once our drug candidates are available for sale, customers postponing purchases of our drug candidates </span></span></div><div style="line-height:10pt;position:var(--position);top:413.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">in response to tighter credit, unemployment, negative financial news and/or declines in income or asset </span></div><div style="line-height:10pt;position:var(--position);top:423.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">values and other macroeconomic factors, which could have a material adverse effect on demand for </span></div><div style="line-height:10pt;position:var(--position);top:433.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">our drug candidates, </span></div><div style="line-height:10pt;position:var(--position);top:449.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">either of which could, accordingly, have a material adverse effect on our business, results of operations or </span></div><div style="line-height:10pt;position:var(--position);top:459.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">financial condition. </span></div><div style="line-height:10pt;position:var(--position);top:475.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Access to public financing and credit can be negatively affected by the effect of these events on European, </span></div><div style="line-height:10pt;position:var(--position);top:485.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">U.S. and global credit markets. The health of the global financing and credit markets may affect our ability to obtain </span></div><div style="line-height:10pt;position:var(--position);top:495.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">equity or debt financing in the future and the terms at which financing or credit is available to us. These instances of </span></div><div style="line-height:10pt;position:var(--position);top:505.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">volatility and market turmoil could adversely affect our operations and the trading price of our ordinary shares. </span></div><div style="line-height:10pt;position:var(--position);top:521.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Changes to trade policy, tariffs, and import/export regulations may have a material adverse effect on our </span></div><div style="line-height:10pt;position:var(--position);top:531.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">business, financial condition, and results of operations. </span></div><div style="line-height:10pt;position:var(--position);top:547.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Changes in laws and policies governing foreign trade could adversely affect our business. As a result of recent </span></div><div style="line-height:10pt;position:var(--position);top:557.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and future policy changes, there may be greater restrictions and economic disincentives on international trade. Such </span></div><div style="line-height:10pt;position:var(--position);top:567.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">changes have the potential to adversely impact the global and local economies, our industry and global demand for </span></div><div style="line-height:10pt;position:var(--position);top:577.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">our drug candidates and, as a result, could have a material adverse effect on our business, financial condition and </span></div><div style="line-height:10pt;position:var(--position);top:587.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">results of operations. </span></div><div style="line-height:10pt;position:var(--position);top:603.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Fluctuations in currency exchange rates may significantly impact our results of operations. </span></div><div style="line-height:10pt;position:var(--position);top:619.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our business is located, and our operations are conducted, in Europe. As a result, we are exposed to an </span></div><div style="line-height:10pt;position:var(--position);top:629.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">exchange rate risk between the U.S. dollar and the Euro. The exchange rates between these currencies in recent years </span></div><div style="line-height:10pt;position:var(--position);top:639.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">have fluctuated significantly and may continue to do so in the future. An appreciation of the Euro against the </span></div><div style="line-height:10pt;position:var(--position);top:649.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">U.S.&#160;dollar could increase the relative cost of our drug candidates outside of Europe, which could have a negative </span></div><div style="line-height:10pt;position:var(--position);top:659.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">effect on sales. Conversely, to the extent that we are required to pay for goods or services in U.S.&#160;dollars, the </span></div><div style="line-height:10pt;position:var(--position);top:669.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">depreciation of the Euro against the U.S.&#160;dollar would increase the cost of such goods and services. </span></div><div style="line-height:10pt;position:var(--position);top:685.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We do not hedge our currency exposure and, therefore, we incur currency transaction risk whenever we enter </span></div><div style="line-height:10pt;position:var(--position);top:695.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">into either a purchase or sale transaction using a currency other than the Euro. Given the volatility of exchange rates, </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">23</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">we might not be able to effectively manage our currency transaction risks, and volatility in currency exchange rates </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">might have a material adverse effect on our business, financial condition or results of operations. </span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">We rely on a small number of third-party suppliers and manufacturers, and in certain cases a single-source </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">supplier, and we may be in a position of dependence with respect to these third parties. </span></div><div style="line-height:10pt;position:var(--position);top:124pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We do not own or operate manufacturing facilities and have no current plans to develop our own clinical or </span></div><div style="line-height:10pt;position:var(--position);top:134pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">commercial-scale manufacturing capabilities. We currently rely, and expect to continue to rely, on a small number of </span></div><div style="line-height:10pt;position:var(--position);top:144pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">third-party suppliers, and in certain cases a single-source supplier, for the supply of various raw materials and </span></div><div style="line-height:10pt;position:var(--position);top:154pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">chemical products and clinical batches needed for our preclinical studies and clinical trials. In the case of certain </span></div><div style="line-height:10pt;position:var(--position);top:164pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">manufactured and clinical supplies, we rely on single-source suppliers. The supply of specific raw materials and </span></div><div style="line-height:10pt;position:var(--position);top:174pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">products required for conducting clinical trials and manufacturing our products cannot be guaranteed. </span></div><div style="line-height:10pt;position:var(--position);top:190pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We are dependent on third parties for the supply of various materials, including chemical or biological </span></div><div style="line-height:10pt;position:var(--position);top:200pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">products that </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:126.39pt;position:var(--position);white-space:pre">can barely be substituted and</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:242.36pt;position:var(--position);text-decoration:none;white-space:pre"> are necessary to produce drug candidates for our clinical trials and, </span></div><div style="line-height:10pt;position:var(--position);top:210pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ultimately, commercial supply for any of our drug candidates that may receive approval. </span></div><div style="line-height:10pt;position:var(--position);top:226pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The facilities used by our third-party manufacturers must be approved for the manufacture of our drug </span></div><div style="line-height:10pt;position:var(--position);top:236pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">candidates by the FDA, the national competent authorities of EU Member States and any comparable foreign </span></div><div style="line-height:10pt;position:var(--position);top:246pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regulatory authorities in other jurisdictions, pursuant to inspections that may be conducted after we submit an NDA </span></div><div style="line-height:10pt;position:var(--position);top:256pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to the FDA, a marketing authorization application ("MAA") to the EMA, or submit a comparable marketing </span></div><div style="line-height:10pt;position:var(--position);top:266pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">application to a comparable regulatory authority. We do not control the manufacturing process of, and are </span></div><div style="line-height:10pt;position:var(--position);top:276pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">completely dependent on, third-party manufacturers for compliance with GMP requirements for manufacture of our </span></div><div style="line-height:10pt;position:var(--position);top:286pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">drug candidates. If these third-party manufacturers cannot successfully manufacture material that conforms to our </span></div><div style="line-height:10pt;position:var(--position);top:296pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">specifications and the strict regulatory requirements of any applicable regulatory authority, they will not be able to </span></div><div style="line-height:10pt;position:var(--position);top:306pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">secure and/or maintain regulatory approval for the use of their manufacturing facilities. </span></div><div style="line-height:10pt;position:var(--position);top:322pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In addition, we have no control over the ability of third-party manufacturers to maintain adequate quality </span></div><div style="line-height:10pt;position:var(--position);top:332pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">control, quality assurance and qualified personnel. If any regulatory authority does not approve these facilities for </span></div><div style="line-height:10pt;position:var(--position);top:342pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the manufacture of our drug candidates, or if such authorities withdraw any such approval in the future, we may be </span></div><div style="line-height:10pt;position:var(--position);top:352pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">required to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain </span></div><div style="line-height:10pt;position:var(--position);top:362pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regulatory approval for or market our drug candidates, if approved. Our failure, or the failure of our third-party </span></div><div style="line-height:10pt;position:var(--position);top:372pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including </span></div><div style="line-height:10pt;position:var(--position);top:382pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls, </span></div><div style="line-height:10pt;position:var(--position);top:392pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">operating restrictions and criminal prosecutions, any of which could significantly and adversely affect our financial </span></div><div style="line-height:10pt;position:var(--position);top:402pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">position. </span></div><div style="line-height:10pt;position:var(--position);top:418pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our or a third party&#8217;s failure to execute on our manufacturing requirements on commercially reasonable terms </span></div><div style="line-height:10pt;position:var(--position);top:428pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and in compliance with GMP or other regulatory requirements could adversely affect our business in a number of </span></div><div style="line-height:10pt;position:var(--position);top:438pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ways, including: </span></div><div style="line-height:10pt;position:var(--position);top:454pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">an inability to initiate or complete clinical trials of our drug candidates in a timely manner; </span></span></div><div style="line-height:10pt;position:var(--position);top:470pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">delay in submitting regulatory applications, or receiving regulatory approvals, for our drug candidates; </span></span></div><div style="line-height:10pt;position:var(--position);top:486pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">subjecting third-party manufacturing facilities to additional inspections by regulatory authorities; </span></span></div><div style="line-height:10pt;position:var(--position);top:502pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">requirements to cease development or to recall batches of our drug candidates; and </span></span></div><div style="line-height:10pt;position:var(--position);top:518pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">in the event of approval to market and commercialize any drug candidate, an inability to meet </span></span></div><div style="line-height:10pt;position:var(--position);top:528pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">commercial demands. </span></div><div style="line-height:10pt;position:var(--position);top:544pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In addition, we do not have any long-term commitments or supply agreements with any third-party </span></div><div style="line-height:10pt;position:var(--position);top:554pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">manufacturers. We may be unable to establish any long-term supply agreements with third-party manufacturers or to </span></div><div style="line-height:10pt;position:var(--position);top:564pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">do so on acceptable terms, which increases the risk of failing to timely obtain sufficient quantities of our drug </span></div><div style="line-height:10pt;position:var(--position);top:574pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">candidates or such quantities at an acceptable cost. Any performance failure on the part of our existing or future </span></div><div style="line-height:10pt;position:var(--position);top:584pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">manufacturers or suppliers could delay clinical development or marketing approval, and any related remedial </span></div><div style="line-height:10pt;position:var(--position);top:594pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">measures may be costly or time consuming to implement. We do not currently have second source for all required </span></div><div style="line-height:10pt;position:var(--position);top:604pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">raw materials used in the manufacture of our drug candidates. If our existing or future third-party manufacturers </span></div><div style="line-height:10pt;position:var(--position);top:614pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">cannot perform as agreed, we may be required to replace such manufacturers and we may be unable to replace them </span></div><div style="line-height:10pt;position:var(--position);top:624pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">on a timely basis or at all, which would have a material adverse impact on our financial position. </span></div><div style="line-height:10pt;position:var(--position);top:640pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">We rely on third parties to conduct our preclinical studies and clinical trials. If these third parties do not </span></div><div style="line-height:10pt;position:var(--position);top:650pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory </span></div><div style="line-height:10pt;position:var(--position);top:660pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">approval for or commercialize our drug candidates and our business could be substantially harmed. </span></div><div style="line-height:10pt;position:var(--position);top:676pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We are dependent on third parties to conduct our clinical trials and preclinical studies. Specifically, we rely </span></div><div style="line-height:10pt;position:var(--position);top:686pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">on, and will continue to rely on, medical institutions, clinical investigators, CROs and consultants to conduct </span></div><div style="line-height:10pt;position:var(--position);top:696pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">preclinical studies and clinical trials, in each case in accordance with trial protocols and regulatory requirements. </span></div><div style="line-height:10pt;position:var(--position);top:706pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">These CROs, investigators and other third parties play a significant role in the conduct and timing of these trials and </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">24</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">subsequent collection and analysis of data. Though we expect to carefully manage our relationships with such </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">CROs, investigators and other third parties, there can be no assurance that we will not encounter challenges or </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">delays in the future, or that these delays or challenges will not have a material adverse impact on our business, </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">financial condition and prospects. Further, while we have and will have agreements governing the activities of our </span></div><div style="line-height:10pt;position:var(--position);top:112pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">third-party contractors, we have limited influence over their actual performance. Nevertheless, we are responsible </span></div><div style="line-height:10pt;position:var(--position);top:122pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol and legal, </span></div><div style="line-height:10pt;position:var(--position);top:132pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regulatory and scientific standards and requirements, and our reliance on our CROs and other third parties does not </span></div><div style="line-height:10pt;position:var(--position);top:142pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">relieve us of our regulatory responsibilities. </span></div><div style="line-height:10pt;position:var(--position);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In addition, we and our CROs are required to comply with stringent standards governing the conduct of </span></div><div style="line-height:10pt;position:var(--position);top:168pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">preclinical studies and clinical trials, including Good Laboratory Practice (&#8220;GLP&#8221;) and GCP requirements, which are </span></div><div style="line-height:10pt;position:var(--position);top:178pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities, for our drug </span></div><div style="line-height:10pt;position:var(--position);top:188pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">candidates in clinical development. Regulatory authorities enforce GCPs through periodic inspections of trial </span></div><div style="line-height:10pt;position:var(--position);top:198pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">sponsors, principal investigators and trial sites. If we or any of our CROs or trial sites fail to comply with applicable </span></div><div style="line-height:10pt;position:var(--position);top:208pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">GLP, GCP or other requirements, the data generated in our clinical trials may be deemed unreliable, and the FDA or </span></div><div style="line-height:10pt;position:var(--position);top:218pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our </span></div><div style="line-height:10pt;position:var(--position);top:228pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">marketing applications, if ever. Furthermore, our clinical trials must be conducted with materials manufactured in </span></div><div style="line-height:10pt;position:var(--position);top:238pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">accordance with GMP regulations. Failure to comply with these regulations may require us to repeat clinical trials, </span></div><div style="line-height:10pt;position:var(--position);top:248pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">which would delay the regulatory approval process. </span></div><div style="line-height:10pt;position:var(--position);top:264pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">There is no guarantee that any of our CROs, investigators or other third parties will devote adequate time and </span></div><div style="line-height:10pt;position:var(--position);top:274pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">resources to such trials or studies or perform as contractually required. If any of these third parties fails to meet </span></div><div style="line-height:10pt;position:var(--position);top:284pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">expected deadlines, adhere to our clinical protocols or meet regulatory requirements, or otherwise perform in a </span></div><div style="line-height:10pt;position:var(--position);top:294pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">substandard manner, our clinical trials may be extended, delayed or terminated. In addition, many of the third parties </span></div><div style="line-height:10pt;position:var(--position);top:304pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">with whom we contract may also have relationships with other commercial entities, including our competitors, for </span></div><div style="line-height:10pt;position:var(--position);top:314pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">whom they may also be conducting clinical trials or other activities that could harm our competitive position. In </span></div><div style="line-height:10pt;position:var(--position);top:324pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">addition, principal investigators for our clinical trials may be asked to serve as scientific advisors or consultants to us </span></div><div style="line-height:10pt;position:var(--position);top:334pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">from time to time and may receive cash or equity compensation in connection with such services. If these </span></div><div style="line-height:10pt;position:var(--position);top:344pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes </span></div><div style="line-height:10pt;position:var(--position);top:354pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">that the financial relationship may have affected the interpretation of the study, the integrity of the data generated at </span></div><div style="line-height:10pt;position:var(--position);top:364pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which </span></div><div style="line-height:10pt;position:var(--position);top:374pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">could result in the delay or rejection by the FDA of any NDA we submit. Any such delay or rejection could prevent </span></div><div style="line-height:10pt;position:var(--position);top:384pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">us from commercializing our drug candidates. </span></div><div style="line-height:10pt;position:var(--position);top:400pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In addition, our CROs have the right to terminate their agreements with us in the event of an uncured material </span></div><div style="line-height:10pt;position:var(--position);top:410pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">breach and under other specified circumstances. If any of our relationships with these third parties terminate, we </span></div><div style="line-height:10pt;position:var(--position);top:420pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">may not be able to enter into arrangements with alternative third parties on commercially reasonable terms or at all. </span></div><div style="line-height:10pt;position:var(--position);top:430pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Switching or adding additional CROs, investigators and other third parties involves additional cost and requires our </span></div><div style="line-height:10pt;position:var(--position);top:440pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">management&#8217;s time and focus. In addition, there is a natural transition period when a new CRO commences work. </span></div><div style="line-height:10pt;position:var(--position);top:450pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. </span></div><div style="line-height:10pt;position:var(--position);top:460pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Though we work to carefully manage our relationships with our CROs, investigators and other third parties, there </span></div><div style="line-height:10pt;position:var(--position);top:470pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges </span></div><div style="line-height:10pt;position:var(--position);top:480pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">will not have a material adverse impact on our business, financial condition and prospects. </span></div><div style="line-height:10pt;position:var(--position);top:496pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">If any of our relationships with these third parties terminate, we may not be able to enter into arrangements </span></div><div style="line-height:10pt;position:var(--position);top:506pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">with alternative third parties on commercially reasonable terms or at all. Switching or adding additional CROs, </span></div><div style="line-height:10pt;position:var(--position);top:516pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">investigators and other third parties involves additional cost and requires our management&#8217;s time and focus. In </span></div><div style="line-height:10pt;position:var(--position);top:526pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can </span></div><div style="line-height:10pt;position:var(--position);top:536pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">materially impact our ability to meet our desired clinical development timelines. Though we work to carefully </span></div><div style="line-height:10pt;position:var(--position);top:546pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">manage our relationships with our CROs, investigators and other third parties, there can be no assurance that we will </span></div><div style="line-height:10pt;position:var(--position);top:556pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse </span></div><div style="line-height:10pt;position:var(--position);top:566pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">impact on our business, financial condition and prospects. </span></div><div style="line-height:10pt;position:var(--position);top:582pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Our future success depends on our ability to retain our key executives and to attract, retain and motivate </span></div><div style="line-height:10pt;position:var(--position);top:592pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">qualified personnel. </span></div><div style="line-height:10pt;position:var(--position);top:608pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We are highly dependent on our management, scientific and medical personnel whose services are critical to </span></div><div style="line-height:10pt;position:var(--position);top:618pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">our success. Our success depends greatly on the involvement and expertise of our senior executives and qualified </span></div><div style="line-height:10pt;position:var(--position);top:628pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">scientific staff. We do not maintain key person insurance. The temporary or permanent unavailability of our </span></div><div style="line-height:10pt;position:var(--position);top:638pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">management and scientific staff could lead to: </span></div><div style="line-height:10pt;position:var(--position);top:654pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">loss of know-how and weakening of certain activities, especially in the case of transfer to the </span></span></div><div style="line-height:10pt;position:var(--position);top:664pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">competition; and </span></div><div style="line-height:10pt;position:var(--position);top:680pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">deficiencies in terms of technical skills that could slow down activity and ultimately impair our ability </span></span></div><div style="line-height:10pt;position:var(--position);top:690pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">to reach our objectives. </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">25</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Recruiting and retaining additional qualified management and scientific, clinical, manufacturing and sales and </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">marketing personnel will also be critical to our success, particularly as we expand in order to acquire additional </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">skills, such as manufacturing, quality assurance and regulatory and medical affairs. The loss of the services of our </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">senior management team or other key employees could impede the achievement of our research, development and </span></div><div style="line-height:10pt;position:var(--position);top:112pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">commercialization objectives and seriously harm our ability to successfully implement our business strategy. </span></div><div style="line-height:10pt;position:var(--position);top:122pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of </span></div><div style="line-height:10pt;position:var(--position);top:132pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">time because of the limited number of individuals in our industry with the breadth of skills and experience required </span></div><div style="line-height:10pt;position:var(--position);top:142pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to successfully develop, gain regulatory approval of and commercialize drug candidates. Competition to hire from </span></div><div style="line-height:10pt;position:var(--position);top:152pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable </span></div><div style="line-height:10pt;position:var(--position);top:162pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. </span></div><div style="line-height:10pt;position:var(--position);top:178pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We also experience intense competition for the hiring of scientific and clinical personnel from other </span></div><div style="line-height:10pt;position:var(--position);top:188pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">companies, universities and research institutions. We may not be able to attract or retain qualified management and </span></div><div style="line-height:10pt;position:var(--position);top:198pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">scientific personnel in the future due to intense competition for a limited number of qualified personnel. Many of </span></div><div style="line-height:10pt;position:var(--position);top:208pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">those that compete with us for qualified personnel have greater financial and other resources, different risk profiles </span></div><div style="line-height:10pt;position:var(--position);top:218pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and a longer history in the industry than we do. Our competitors may also provide more diverse opportunities and </span></div><div style="line-height:10pt;position:var(--position);top:228pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">better chances for career advancement. An inability to attract and retain high quality personnel will have a material </span></div><div style="line-height:10pt;position:var(--position);top:238pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">adverse effect on our business, prospects, financial condition, cash flow or results of operations. </span></div><div style="line-height:10pt;position:var(--position);top:254pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in </span></div><div style="line-height:10pt;position:var(--position);top:264pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">formulating our research and development and commercialization strategy. Our consultants and advisors may be </span></div><div style="line-height:10pt;position:var(--position);top:274pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">employed by employers other than us and may have commitments under consulting or advisory contracts with other </span></div><div style="line-height:10pt;position:var(--position);top:284pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">entities that may limit their availability to us. If we are unable to continue to attract and retain high quality </span></div><div style="line-height:10pt;position:var(--position);top:294pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">personnel, the marketing and production of our drugs could be delayed or prevented, which could, in turn, have a </span></div><div style="line-height:10pt;position:var(--position);top:304pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">material adverse effect on our business, prospects, financial condition, cash flows or results of operations. </span></div><div style="line-height:10pt;position:var(--position);top:320pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other </span></div><div style="line-height:10pt;position:var(--position);top:330pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">improper activities, including noncompliance with regulatory standards and requirements and insider trading. </span></div><div style="line-height:10pt;position:var(--position);top:346pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants </span></div><div style="line-height:10pt;position:var(--position);top:356pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and commercial partners. Misconduct by these parties could include intentional failures, reckless and/or negligent </span></div><div style="line-height:10pt;position:var(--position);top:366pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">conduct or unauthorized activity that violates (i)&#160;the laws and regulations of the European Economic Area (&#8220;EEA&#8221;) </span></div><div style="line-height:10pt;position:var(--position);top:376pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">countries, the European Union, FDA and other regulatory authorities, including those laws requiring the reporting of </span></div><div style="line-height:10pt;position:var(--position);top:386pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">true, complete and accurate information to such authorities, (ii)&#160;manufacturing standards, (iii)&#160;federal and state data </span></div><div style="line-height:10pt;position:var(--position);top:396pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">privacy, security, fraud and abuse and other healthcare laws and regulations in Europe, the United States and </span></div><div style="line-height:10pt;position:var(--position);top:406pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">elsewhere, (iv)&#160;laws that require the true, complete and accurate reporting of financial information or data and (v) </span></div><div style="line-height:10pt;position:var(--position);top:416pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">insider trading laws of the European Union, the United States or other jurisdictions. In particular, sales, marketing </span></div><div style="line-height:10pt;position:var(--position);top:426pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to </span></div><div style="line-height:10pt;position:var(--position);top:436pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or </span></div><div style="line-height:10pt;position:var(--position);top:446pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive </span></div><div style="line-height:10pt;position:var(--position);top:456pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">programs and other business arrangements. Such misconduct also could involve the improper use of individually </span></div><div style="line-height:10pt;position:var(--position);top:466pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">identifiable information, including, without limitation, information obtained in the course of clinical trials, creating </span></div><div style="line-height:10pt;position:var(--position);top:476pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of drug product, which could </span></div><div style="line-height:10pt;position:var(--position);top:486pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter </span></div><div style="line-height:10pt;position:var(--position);top:496pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may </span></div><div style="line-height:10pt;position:var(--position);top:506pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government </span></div><div style="line-height:10pt;position:var(--position);top:516pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. </span></div><div style="line-height:10pt;position:var(--position);top:526pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, </span></div><div style="line-height:10pt;position:var(--position);top:536pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">even if none occurred. If any such actions are instituted against us and we are not successful in defending ourselves </span></div><div style="line-height:10pt;position:var(--position);top:546pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">or asserting our rights, those actions could result in significant civil, criminal and administrative penalties, damages, </span></div><div style="line-height:10pt;position:var(--position);top:556pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">fines, disgorgement, imprisonment, exclusion from participating in government-funded healthcare programs, such as </span></div><div style="line-height:10pt;position:var(--position);top:566pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate </span></div><div style="line-height:10pt;position:var(--position);top:576pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, contractual </span></div><div style="line-height:10pt;position:var(--position);top:586pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">damages, reputational harm and the curtailment or restructuring of our operations, any of which could have a </span></div><div style="line-height:10pt;position:var(--position);top:596pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">negative impact on our business, financial condition, results of operations and prospects. </span></div><div style="line-height:10pt;position:var(--position);top:612pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Moreover, governmental investigations by health regulatory agencies such as the FDA or EMA or securities </span></div><div style="line-height:10pt;position:var(--position);top:622pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regulatory agencies, such as the AMF or SEC, litigation or other legal proceedings may cause us to incur significant </span></div><div style="line-height:10pt;position:var(--position);top:632pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">expenses and could distract our technical and management personnel from their normal responsibilities. In addition, </span></div><div style="line-height:10pt;position:var(--position);top:642pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">there could be public announcements of the results of hearings, motions or other interim proceedings or </span></div><div style="line-height:10pt;position:var(--position);top:652pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">developments. If securities analysts or investors perceive these results to be negative, it could have a substantial </span></div><div style="line-height:10pt;position:var(--position);top:662pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">adverse effect on the price of our ordinary shares. Such investigations, litigation or proceedings could substantially </span></div><div style="line-height:10pt;position:var(--position);top:672pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">increase our operating losses and reduce the resources available for development, manufacturing, sales, marketing or </span></div><div style="line-height:10pt;position:var(--position);top:682pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">distribution activities. Uncertainties resulting from the initiation and continuation of litigation or other proceedings </span></div><div style="line-height:10pt;position:var(--position);top:692pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">relating to applicable laws and regulations could have an adverse effect on our ability to compete in the marketplace.</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">26</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">We have limited infrastructure in market access, sales, marketing and distribution. </span></div><div style="line-height:10pt;position:var(--position);top:88pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We lack infrastructure and resources in the fields of sales, marketing and distribution. We need to develop our </span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">own marketing and sales capacity, either alone or with partners once marketing authorizations have been obtained. </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">As part of setting up our sales and marketing infrastructure, we will need to incur additional expenses, mobilize </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">management resources, implement new skills and take the time necessary to set up the appropriate organization and </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">structure to support the products in accordance with current legislation and, more generally, optimize </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">commercialization efforts. We compete with many companies that currently have extensive, experienced and well-</span></div><div style="line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">funded market access, marketing and sales operations to recruit, hire, train and retain marketing and sales personnel, </span></div><div style="line-height:10pt;position:var(--position);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and will have to compete with those companies to recruit, hire, train and retain any of our own market access, </span></div><div style="line-height:10pt;position:var(--position);top:168pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">marketing and sales personnel. If we are unable to expand our sales and marketing team, we may be unable to </span></div><div style="line-height:10pt;position:var(--position);top:178pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">compete successfully against these more established companies. Alternatively, if we choose to collaborate, either </span></div><div style="line-height:10pt;position:var(--position);top:188pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">globally or on a territory-by-territory basis, with third parties that have direct sales forces and established </span></div><div style="line-height:10pt;position:var(--position);top:198pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force </span></div><div style="line-height:10pt;position:var(--position);top:208pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and distribution systems, we will be required to negotiate and enter into arrangements with such third parties relating </span></div><div style="line-height:10pt;position:var(--position);top:218pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to the proposed collaboration. If we are unable to enter into such arrangements when needed, on acceptable terms, or </span></div><div style="line-height:10pt;position:var(--position);top:228pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">at all, we may not be able to successfully commercialize any of our drug candidates that receive regulatory approval </span></div><div style="line-height:10pt;position:var(--position);top:238pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">or any such commercialization may experience delays or limitations. Factors that may inhibit our efforts to build a </span></div><div style="line-height:10pt;position:var(--position);top:248pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">sales, marketing and distribution organization include: </span></div><div style="line-height:10pt;position:var(--position);top:264pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel; </span></span></div><div style="line-height:10pt;position:var(--position);top:280pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the inability of sales personnel to obtain access to physicians, educate physicians about patients for </span></span></div><div style="line-height:10pt;position:var(--position);top:290pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">whom our drug candidates may be appropriate treatment options and attain adequate numbers of </span></div><div style="line-height:10pt;position:var(--position);top:300pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">physicians to prescribe any drugs; </span></div><div style="line-height:10pt;position:var(--position);top:316pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the inability of reimbursement professionals to negotiate arrangements for formulary access, </span></span></div><div style="line-height:10pt;position:var(--position);top:326pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">reimbursement and other acceptance by payors; </span></div><div style="line-height:1pt;position:var(--position);top:340.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="line-height:10pt;position:var(--position);top:341.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">restricted or closed distribution channels that make it difficult to distribute our products to segments of </span></span></div><div style="line-height:10pt;position:var(--position);top:351.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">the patient population; </span></div><div style="line-height:10pt;position:var(--position);top:367.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the lack of complementary medicines to be offered by sales personnel, which may put us at a </span></span></div><div style="line-height:10pt;position:var(--position);top:377.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">competitive disadvantage relative to companies with more extensive product lines; and </span></div><div style="line-height:10pt;position:var(--position);top:393.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">unforeseen costs and expenses associated with creating an independent sales and marketing </span></span></div><div style="line-height:10pt;position:var(--position);top:403.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">organization. </span></div><div style="line-height:10pt;position:var(--position);top:419.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">There are numerous competitors in the market for therapeutic treatments of inflammatory diseases. </span></div><div style="line-height:10pt;position:var(--position);top:435.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.53pt;position:var(--position);white-space:pre">biotechnology</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:171.7pt;position:var(--position);text-decoration:none;white-space:pre"> and pharmaceutical industries are highly competitive and subject to significant and rapid </span></div><div style="line-height:10pt;position:var(--position);top:445.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">technological change as researchers learn more about diseases and develop new technologies and treatments. Many </span></div><div style="line-height:10pt;position:var(--position);top:455.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">pharmaceutical companies, biotech companies, institutions, universities and other research organizations are actively </span></div><div style="line-height:10pt;position:var(--position);top:465.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">engaged in the research, discovery, development and commercialization of therapeutic responses for the treatment of </span></div><div style="line-height:10pt;position:var(--position);top:475.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the diseases targeted by us. Significant competitive factors in our industry include: (i)&#160;product efficacy and safety; </span></div><div style="line-height:10pt;position:var(--position);top:485.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(ii)&#160;quality and breadth of an organization&#8217;s technology; (iii)&#160;skill of an organization&#8217;s employees and its ability to </span></div><div style="line-height:10pt;position:var(--position);top:495.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">recruit and retain key employees; (iv)&#160;timing and scope of regulatory approvals; (v)&#160;government reimbursement rates </span></div><div style="line-height:10pt;position:var(--position);top:505.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for, and the average selling price of, pharmaceutical products; (vi)&#160;the availability of raw materials and qualified </span></div><div style="line-height:10pt;position:var(--position);top:515.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">manufacturing capacity; (vii)&#160;manufacturing costs; (viii)&#160;intellectual property and patent rights and their protection; </span></div><div style="line-height:10pt;position:var(--position);top:525.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and (ix)&#160;sales and marketing capabilities. Given the intense competition in our industry, we cannot assure you that </span></div><div style="line-height:10pt;position:var(--position);top:535.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">any of the products that we successfully develop will be clinically superior or scientifically preferable to products </span></div><div style="line-height:10pt;position:var(--position);top:545.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">developed or introduced by our competitors. In addition, significant delays in the development of our drug </span></div><div style="line-height:10pt;position:var(--position);top:555.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">candidates could allow our competitors to succeed in obtaining European Commission, FDA, PMDA or other </span></div><div style="line-height:10pt;position:var(--position);top:565.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regulatory approvals for their drug candidates more rapidly than us, which could place us at a significant competitive </span></div><div style="line-height:10pt;position:var(--position);top:575.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">disadvantage or deny us marketing exclusivity rights. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:591.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our competitors in the chronic inflammatory disease field are primarily large pharmaceuticals companies </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:601.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">including, but not limited to AbbVie, Eli Lilly, Johnson&#160;&amp; Johnson, Pfizer and Takeda. Several lines of research are </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:611.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">being developed to improve the treatment of IBD. Many companies are working to develop new, more effective and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:621.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">better tolerated treatments with more practical formulations, especially small molecules administered orally, better </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:631.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">accepted than monoclonal antibodies that require administration by injection. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:383.25pt;position:var(--position);text-decoration:none;white-space:pre">See &#8220;Item 4.C. Business Overview&#8212;</span></div><div style="line-height:10pt;position:var(--position);top:641.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Competition.&#8221; </span></div><div style="line-height:10pt;position:var(--position);top:657.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Further, our competitors may be more effective at using their technologies to develop commercial products. </span></div><div style="line-height:10pt;position:var(--position);top:667.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Many of the organizations competing with us have significantly greater financial resources and expertise in research </span></div><div style="line-height:10pt;position:var(--position);top:677.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and development, manufacturing, preclinical studies, conducting clinical trials, obtaining regulatory approvals and </span></div><div style="line-height:10pt;position:var(--position);top:687.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more </span></div><div style="line-height:10pt;position:var(--position);top:697.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may </span></div><div style="line-height:10pt;position:var(--position);top:707.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">also prove to be significant competitors, particularly through partnership arrangements with large and established </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">27</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">companies. These companies also compete with us in recruiting and retaining qualified scientific and management </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">technologies complementary to, or necessary for, our programs. </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The development potential in the markets in which we operate is such that the arrival of new competition is </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">probable. New market entrants, increased competition in specific areas, or in general, would have a material adverse </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">effect on our business, income, financial position and outlook for growth. </span></div><div style="line-height:10pt;position:var(--position);top:144pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">We depend on, and will continue to depend on, collaboration and strategic alliances with third partners. To the </span></div><div style="line-height:10pt;position:var(--position);top:154pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">extent we are able to enter into collaborative arrangements or strategic alliances, we will be exposed to risks </span></div><div style="line-height:10pt;position:var(--position);top:164pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">related to those collaborations and alliances. </span></div><div style="line-height:10pt;position:var(--position);top:180pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">An important element of our strategy for developing, manufacturing and commercializing our drug candidates </span></div><div style="line-height:10pt;position:var(--position);top:190pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">is entering into partnerships and strategic alliances with other pharmaceutical companies or other industry </span></div><div style="line-height:10pt;position:var(--position);top:200pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">participants. The collaboration agreements that we have established, and any collaboration arrangements that we </span></div><div style="line-height:10pt;position:var(--position);top:210pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">may enter into in the future, may not be successful, which would have a negative impact on our business, results of </span></div><div style="line-height:10pt;position:var(--position);top:220pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">operations, financial condition and growth prospects. </span></div><div style="line-height:10pt;position:var(--position);top:236pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Any partnerships or alliance we have or may have in the future may be terminated for reasons beyond our </span></div><div style="line-height:10pt;position:var(--position);top:246pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">control or we may not be able to negotiate future alliances on acceptable terms, if at all. These arrangements may </span></div><div style="line-height:10pt;position:var(--position);top:256pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">result in us receiving less revenue than if we sold our products directly, may place the development, sales and </span></div><div style="line-height:10pt;position:var(--position);top:266pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">marketing of our products outside of our control, may require us to relinquish important rights or may otherwise be </span></div><div style="line-height:10pt;position:var(--position);top:276pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">on unfavorable terms. Collaborative arrangements or strategic alliances will also subject us to a number of risks, </span></div><div style="line-height:10pt;position:var(--position);top:286pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">including the risk that: </span></div><div style="line-height:10pt;position:var(--position);top:302pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">we may not be able to control the amount and timing of resources that our strategic partner/</span></span></div><div style="line-height:10pt;position:var(--position);top:312pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">collaborators may devote to the drug candidates; </span></div><div style="line-height:10pt;position:var(--position);top:328pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">strategic partner/collaborators may experience financial difficulties; </span></span></div><div style="line-height:10pt;position:var(--position);top:344pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the failure to successfully collaborate with third parties may delay, prevent or otherwise impair the </span></span></div><div style="line-height:10pt;position:var(--position);top:354pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">development or commercialization of our drug candidates or revenue expectations; </span></div><div style="line-height:10pt;position:var(--position);top:370pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">products being developed by partners/collaborators may never reach commercial stage resulting in </span></span></div><div style="line-height:10pt;position:var(--position);top:380pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">reduced or even no milestone or royalty payments; </span></div><div style="line-height:10pt;position:var(--position);top:396pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">business combinations or significant changes in a collaborator&#8217;s business strategy may also adversely </span></span></div><div style="line-height:10pt;position:var(--position);top:406pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">affect a collaborator&#8217;s willingness or ability to complete their obligations under any arrangement; </span></div><div style="line-height:10pt;position:var(--position);top:422pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">a collaborator could independently move forward with a competing product developed either </span></span></div><div style="line-height:10pt;position:var(--position);top:432pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">independently or in collaboration with others, including our competitors; and </span></div><div style="line-height:10pt;position:var(--position);top:448pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">collaborative arrangements are often terminated or allowed to expire, which would delay the </span></span></div><div style="line-height:10pt;position:var(--position);top:458pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">development and may increase the cost of developing drug candidates. </span></div><div style="line-height:10pt;position:var(--position);top:474pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Our partnerships and licensing agreements relating to the technologies belonging to us may not be successful. </span></div><div style="line-height:10pt;position:var(--position);top:490pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The various drug candidates developed by us arise from proprietary or licensed technologies with leading </span></div><div style="line-height:10pt;position:var(--position);top:500pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">academic partners, including Scripps Research Institute, University of Chicago, Brigham Young University, the </span></div><div style="line-height:10pt;position:var(--position);top:510pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Montpellier Institute of Molecular Genetics at the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:273.11pt;position:var(--position);text-decoration:none;white-space:pre">Centre National de la Recherche Scientifique</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:454.24pt;position:var(--position);text-decoration:none;white-space:pre"> (&#8220;CNRS&#8221;) and the </span></div><div style="line-height:10pt;position:var(--position);top:520pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Institut Curie</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:125.55pt;position:var(--position);text-decoration:none;white-space:pre">. If the clinical trials conducted by us were to reveal safety and/or therapeutic efficacy problems or if </span></div><div style="line-height:10pt;position:var(--position);top:530pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the use of one of the platforms were to violate an intellectual property right held by a third party, this could threaten </span></div><div style="line-height:10pt;position:var(--position);top:540pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the use and operation of some of our technology platforms and require additional research and development efforts </span></div><div style="line-height:10pt;position:var(--position);top:550pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and additional time and expense to address these difficulties, with success not being guaranteed. The development of </span></div><div style="line-height:10pt;position:var(--position);top:560pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">a portion of our product portfolio would be affected, which would have a material adverse effect on our business, </span></div><div style="line-height:10pt;position:var(--position);top:570pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">outlook, growth, financial position and income. </span></div><div style="line-height:10pt;position:var(--position);top:586pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The reimbursement of drugs and treatments is beyond our control. </span></div><div style="line-height:10pt;position:var(--position);top:602pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">After achieving regulatory authorization and once marketing authorization is granted, the process of setting </span></div><div style="line-height:10pt;position:var(--position);top:612pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the sales price of drugs and their reimbursement rates begins. The conditions for setting the sales price and </span></div><div style="line-height:10pt;position:var(--position);top:622pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reimbursement rate for drugs are beyond the control of pharmaceutical companies. They are decided by competent </span></div><div style="line-height:10pt;position:var(--position);top:632pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">public committees and bodies and by social security or private insurance companies. In this context, we or our </span></div><div style="line-height:10pt;position:var(--position);top:642pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">partners could be asked to perform additional studies on our products. These studies could generate additional costs </span></div><div style="line-height:10pt;position:var(--position);top:652pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for us or our partners and lead to delays in marketing the drug, which could have an impact on our financial position. </span></div><div style="line-height:10pt;position:var(--position);top:668pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">There is significant uncertainty related to the reimbursement of newly-approved drugs. The level of </span></div><div style="line-height:10pt;position:var(--position);top:678pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reimbursement will impact market acceptance and sale of our drug candidates. Reimbursement by a third-party is </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">28</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">dependent on a number of factors, including, without limitation, the third-party payor&#8217;s determination that use of a </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">product is: </span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">a covered benefit under its health plan; </span></span></div><div style="line-height:10pt;position:var(--position);top:114pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">safe, effective and medically necessary; </span></span></div><div style="line-height:10pt;position:var(--position);top:130pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">appropriate for the specific patient; </span></span></div><div style="line-height:10pt;position:var(--position);top:146pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">cost-effective; and </span></span></div><div style="line-height:10pt;position:var(--position);top:162pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">neither experimental nor investigational. </span></span></div><div style="line-height:10pt;position:var(--position);top:178pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The possibility that we could receive royalties from our industrial partner or partners on the sale of some of </span></div><div style="line-height:10pt;position:var(--position);top:188pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">our products and our ability to make sufficient profits on the marketing of our treatments or those for which we have </span></div><div style="line-height:10pt;position:var(--position);top:198pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">entered into distribution contracts will depend on these reimbursement conditions. If delays in the price negotiation </span></div><div style="line-height:10pt;position:var(--position);top:208pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">procedure result in a significant delay in marketing, if our product does not obtain an appropriate level of </span></div><div style="line-height:10pt;position:var(--position);top:218pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reimbursement, or if the accepted price level and reimbursement rate of the treatments we market are changed, our </span></div><div style="line-height:10pt;position:var(--position);top:228pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">profitability will be reduced. </span></div><div style="line-height:10pt;position:var(--position);top:244pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We are also unable to guarantee that we will succeed in maintaining, over time, the price level of our products </span></div><div style="line-height:10pt;position:var(--position);top:254pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">or those for which licenses have been granted, or the accepted reimbursement rate. Under these conditions, there </span></div><div style="line-height:10pt;position:var(--position);top:264pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">could be a material adverse effect on our business, financial position and results of operations. </span></div><div style="line-height:10pt;position:var(--position);top:280pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The pricing, insurance coverage and reimbursement status of newly-approved products is uncertain. Failure to </span></div><div style="line-height:10pt;position:var(--position);top:290pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">obtain or maintain adequate coverage and reimbursement for our drug candidates, if approved, could limit our </span></div><div style="line-height:10pt;position:var(--position);top:300pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ability to market those products and decrease our ability to generate product revenue. </span></div><div style="line-height:10pt;position:var(--position);top:316pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Successful sales of our drug candidates, if approved, depend on the availability of coverage and adequate </span></div><div style="line-height:10pt;position:var(--position);top:326pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reimbursement from third-party payors including governmental healthcare programs, such as Medicare and </span></div><div style="line-height:10pt;position:var(--position);top:336pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Medicaid in the United States, managed care organizations and commercial payors, among others. Significant </span></div><div style="line-height:10pt;position:var(--position);top:346pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">uncertainty exists as to the coverage and reimbursement status of any drug candidates for which we obtain </span></div><div style="line-height:10pt;position:var(--position);top:356pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regulatory approval. </span></div><div style="line-height:10pt;position:var(--position);top:372pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In the United States, no uniform policy for coverage and reimbursement exists, and coverage and </span></div><div style="line-height:10pt;position:var(--position);top:382pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reimbursement for drug products can differ significantly from payor to payor. Therefore, one payor&#8217;s determination </span></div><div style="line-height:10pt;position:var(--position);top:392pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug </span></div><div style="line-height:10pt;position:var(--position);top:402pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">product. Third-party payors often follow Medicare coverage policy and payment limitations in setting their own </span></div><div style="line-height:10pt;position:var(--position);top:412pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As </span></div><div style="line-height:10pt;position:var(--position);top:422pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">a result, the coverage determination process is often a time-consuming and costly process that will require us to </span></div><div style="line-height:10pt;position:var(--position);top:432pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">provide scientific and clinical support for the use of our products to each payor separately, with no assurance that </span></div><div style="line-height:10pt;position:var(--position);top:442pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Moreover, </span></div><div style="line-height:10pt;position:var(--position);top:452pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and </span></div><div style="line-height:10pt;position:var(--position);top:462pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable </span></div><div style="line-height:10pt;position:var(--position);top:472pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">coverage policies and reimbursement rates may be implemented in the future. </span></div><div style="line-height:10pt;position:var(--position);top:488pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Reimbursement may impact the demand for, and/or the price of, any product for which we obtain marketing </span></div><div style="line-height:10pt;position:var(--position);top:498pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">approval. Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement </span></div><div style="line-height:10pt;position:var(--position);top:508pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients who </span></div><div style="line-height:10pt;position:var(--position);top:518pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on </span></div><div style="line-height:10pt;position:var(--position);top:528pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">third-party payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely </span></div><div style="line-height:10pt;position:var(--position);top:538pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to use our products unless coverage is provided, and reimbursement is adequate to cover all or a significant portion </span></div><div style="line-height:10pt;position:var(--position);top:548pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of the cost of our products. Therefore, coverage and adequate reimbursement is critical to new product acceptance. </span></div><div style="line-height:10pt;position:var(--position);top:564pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Additionally, we or our collaborators may develop companion diagnostic tests for use with our drug </span></div><div style="line-height:10pt;position:var(--position);top:574pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">candidates. We or our collaborators will be required to obtain coverage and reimbursement for these tests separate </span></div><div style="line-height:10pt;position:var(--position);top:584pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and apart from the coverage and reimbursement we seek for our drug candidates, once approved. Similar challenges </span></div><div style="line-height:10pt;position:var(--position);top:594pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to </span></div><div style="line-height:10pt;position:var(--position);top:604pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">companion diagnostics. Our inability to promptly obtain coverage and adequate reimbursement from both third-</span></div><div style="line-height:10pt;position:var(--position);top:614pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">party payors for the drug candidates and companion diagnostic tests that we or our collaborators develop and for </span></div><div style="line-height:10pt;position:var(--position);top:624pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">which we obtain regulatory approval could have a material and adverse effect on our business, financial condition, </span></div><div style="line-height:10pt;position:var(--position);top:634pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">results of operations and prospects. </span></div><div style="line-height:10pt;position:var(--position);top:650pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide </span></div><div style="line-height:10pt;position:var(--position);top:660pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">that products may be marketed only after a reimbursement price has been agreed. Some countries may require the </span></div><div style="line-height:10pt;position:var(--position);top:670pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">completion of additional studies that compare the cost-effectiveness of a particular drug candidate to currently </span></div><div style="line-height:10pt;position:var(--position);top:680pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">available therapies. EU member states may approve a specific price for a product or may instead adopt a system of </span></div><div style="line-height:10pt;position:var(--position);top:690pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">direct or indirect controls on the profitability of the company placing the product on the market. Other member </span></div><div style="line-height:10pt;position:var(--position);top:700pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">states allow companies to fix their own prices for products, but monitor and control company profits. The downward </span></div><div style="line-height:10pt;position:var(--position);top:710pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">pressure on health care costs has become intense. In addition, EU Member States may require the completion of </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">29</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">additional health technology assessments that compare the cost- effectiveness of a particular product candidate to </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">currently available therapies. This Health Technology Assessment (HTA) process is the procedure according to </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">which the assessment of the public health impact, therapeutic impact and the economic and societal impact of use of </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">a given medicinal product in the national healthcare systems of the individual country is conducted. The outcome of </span></div><div style="line-height:10pt;position:var(--position);top:112pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">HTA regarding specific medicinal products will often influence the pricing and reimbursement status granted to </span></div><div style="line-height:10pt;position:var(--position);top:122pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">these medicinal products by the competent authorities of individual EU Member States. At the EU level, Regulation </span></div><div style="line-height:10pt;position:var(--position);top:132pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">No 2021/2282 on Health Technology Assessment (&#8220;HTA Regulation&#8221;) amending Directive 2011/24/EU, was </span></div><div style="line-height:10pt;position:var(--position);top:142pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">adopted on December 13, 2021 and entered into application on January 12, 2025 through a phased implementation. </span></div><div style="line-height:10pt;position:var(--position);top:152pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The HTA Regulation initially applies to new active substances for oncology and ATMPs. It will be expanded to </span></div><div style="line-height:10pt;position:var(--position);top:162pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">orphan medicinal products in January 2028, and to all centrally authorized medicinal products as of 2030. Select </span></div><div style="line-height:10pt;position:var(--position);top:172pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">high-risk medical devices also came into scope in 2026. The HTA Regulation is intended to boost cooperation </span></div><div style="line-height:10pt;position:var(--position);top:182pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">among Member States in assessing health technologies, including new medicinal products. The HTA Regulation </span></div><div style="line-height:10pt;position:var(--position);top:192pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">establishes a framework for EU level joint clinical assessments, joint scientific consultations, and the early </span></div><div style="line-height:10pt;position:var(--position);top:202pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">identification of emerging health technologies, in order to speed up the availability of innovative products on the EU </span></div><div style="line-height:10pt;position:var(--position);top:212pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">market. The HTA Regulation permits EU Member States to use common tools, methodologies, and procedures and </span></div><div style="line-height:10pt;position:var(--position);top:222pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">requires them to rely on and take into consideration EU level joint clinical assessment reports for the clinical </span></div><div style="line-height:10pt;position:var(--position);top:232pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">components of their national HTA evaluations. Individual EU Member States will continue to be responsible for </span></div><div style="line-height:10pt;position:var(--position);top:242pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">assessing non-clinical (e.g., economic, social, ethical) aspects of health technologies, and making decisions on </span></div><div style="line-height:10pt;position:var(--position);top:252pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">pricing and reimbursement.</span></div><div style="line-height:10pt;position:var(--position);top:268pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some </span></div><div style="line-height:10pt;position:var(--position);top:278pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">countries, cross-border imports from low-priced markets exert competitive pressure that may reduce pricing within a </span></div><div style="line-height:10pt;position:var(--position);top:288pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">country. Any country that has price controls or reimbursement limitations may not allow favorable reimbursement </span></div><div style="line-height:10pt;position:var(--position);top:298pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and pricing arrangements, and prices are usually revised periodically, such that any given price may decrease upon </span></div><div style="line-height:10pt;position:var(--position);top:308pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">various occurrences. </span></div><div style="line-height:10pt;position:var(--position);top:324pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Additionally, the containment of healthcare costs has become a priority of federal and state governments, and </span></div><div style="line-height:10pt;position:var(--position);top:334pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the prices of drugs have been a focus of this effort. The U.S. government, state legislatures and foreign governments </span></div><div style="line-height:10pt;position:var(--position);top:344pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">have shown significant interest in implementing cost-containment programs, including price controls, restrictions on </span></div><div style="line-height:10pt;position:var(--position);top:354pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-</span></div><div style="line-height:10pt;position:var(--position);top:364pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, </span></div><div style="line-height:10pt;position:var(--position);top:374pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">could further limit our net revenue and results. </span></div><div style="line-height:10pt;position:var(--position);top:390pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Price controls may be imposed in markets in which we operate, which may negatively affect our future </span></div><div style="line-height:10pt;position:var(--position);top:400pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">profitability. </span></div><div style="line-height:10pt;position:var(--position);top:416pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In some countries, particularly EU member states, Japan, Australia and Canada, the pricing of prescription </span></div><div style="line-height:10pt;position:var(--position);top:426pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can </span></div><div style="line-height:10pt;position:var(--position);top:436pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">take considerable time after receipt of marketing approval for a product. In addition, there can be considerable </span></div><div style="line-height:10pt;position:var(--position);top:446pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost </span></div><div style="line-height:10pt;position:var(--position);top:456pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">containment measures. Political, economic and regulatory developments may further complicate pricing </span></div><div style="line-height:10pt;position:var(--position);top:466pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used </span></div><div style="line-height:10pt;position:var(--position);top:476pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">by various EU member states and parallel distribution, or arbitrage between low-priced and high-priced member </span></div><div style="line-height:10pt;position:var(--position);top:486pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">states, can further reduce prices. In some countries, we or our collaborators may be required to conduct a clinical </span></div><div style="line-height:10pt;position:var(--position);top:496pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">trial or other studies that compare the cost-effectiveness of our drug candidates to other available therapies in order </span></div><div style="line-height:10pt;position:var(--position);top:506pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or </span></div><div style="line-height:10pt;position:var(--position);top:516pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and </span></div><div style="line-height:10pt;position:var(--position);top:526pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">other countries. If reimbursement of our drug candidates is unavailable or limited in scope or amount, or if pricing is </span></div><div style="line-height:10pt;position:var(--position);top:536pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">set at unsatisfactory levels, there could be a material adverse effect on our business, financial condition or results of </span></div><div style="line-height:10pt;position:var(--position);top:546pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">operations.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:562pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">If our information technology systems or those of the third parties with whom we work, or our data are or were </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:572pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">compromised, we could experience adverse consequences resulting from such compromise, including but not </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:582pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">limited to: regulatory investigations or actions; litigation; fines and penalties; disruptions of our business </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:592pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">operations; reputational harm; loss of revenue and profits; and other adverse consequences.</span></div><div style="line-height:10pt;position:var(--position);top:608pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In the ordinary course of our business, we and the third parties with whom we work process personal data </span></div><div style="line-height:10pt;position:var(--position);top:618pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(including data we collect about trial participants in connection with clinical trials) and other sensitive information, </span></div><div style="line-height:10pt;position:var(--position);top:628pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">including proprietary and confidential business data, trade secrets, intellectual property, sensitive third-party data, </span></div><div style="line-height:10pt;position:var(--position);top:638pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">business plans, transactions, and financial information (collectively, sensitive data). We and the third parties with </span></div><div style="line-height:10pt;position:var(--position);top:648pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">whom we work face a variety of evolving threats to information technology systems and data. </span></div><div style="line-height:10pt;position:var(--position);top:664pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Cyber-attacks, malicious internet-based activity, online and offline fraud and other similar activities threaten </span></div><div style="line-height:10pt;position:var(--position);top:674pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the confidentiality, integrity and availability of our sensitive data and information technology systems, and those of </span></div><div style="line-height:10pt;position:var(--position);top:684pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the third parties with whom we work. Such threats are prevalent and continue to rise, are increasingly difficult to </span></div><div style="line-height:10pt;position:var(--position);top:694pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; </span></div><div style="line-height:10pt;position:var(--position);top:704pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">organized criminal threat actors, personnel (such as through error, theft or misuse), sophisticated nation states and </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">30</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">nation-state-supported actors. For geopolitical reasons and in conjunction with military conflicts and defense </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">activities, some actors have in the past and are expected to in the future engage in nefarious cybersecurity attacks. </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">During times of war and other major conflicts, we and the third parties with whom we work are vulnerable to a </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and </span></div><div style="line-height:10pt;position:var(--position);top:112pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">operations, supply chain and ability to produce, sell and distribute our services. </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We and the third parties with whom we work are subject to and have experienced a variety of evolving threats, </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">including but not limited to social-engineering attacks (including through deep fakes, which may be increasingly </span></div><div style="line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">more difficult to identify as a fake, and phishing attacks), malicious code (such as viruses and worms), malware </span></div><div style="line-height:10pt;position:var(--position);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(including as a result of advanced persistent threat intrusions), denial-of-service attacks, credential stuffing attacks, </span></div><div style="line-height:10pt;position:var(--position);top:168pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, </span></div><div style="line-height:10pt;position:var(--position);top:178pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, </span></div><div style="line-height:10pt;position:var(--position);top:188pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">telecommunications failures, earthquakes, fires, floods, other natural disasters, attacks enhanced or facilitated by AI, </span></div><div style="line-height:10pt;position:var(--position);top:198pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and other similar threats. In particular, severe ransomware attacks are becoming increasingly prevalent and can lead </span></div><div style="line-height:10pt;position:var(--position);top:208pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to significant interruptions in our operations, ability to provide our services, loss of sensitive data and income, </span></div><div style="line-height:10pt;position:var(--position);top:218pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware </span></div><div style="line-height:10pt;position:var(--position);top:228pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or </span></div><div style="line-height:10pt;position:var(--position);top:238pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regulations prohibiting such payments.</span></div><div style="line-height:10pt;position:var(--position);top:254pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In addition, some of our customers may be subject to the EU&#8217;s Digital Operational Resilience Act (DORA) </span></div><div style="line-height:10pt;position:var(--position);top:264pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and similar UK regulatory requirements on operational resilience. These laws may obligate our customers to impose </span></div><div style="line-height:10pt;position:var(--position);top:274pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">contractual provisions on us, including certain mandatory third-party risk management provisions. If we fail to </span></div><div style="line-height:10pt;position:var(--position);top:284pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">materially comply with these contractual requirements, we may be subject to investigations, audits or other adverse </span></div><div style="line-height:10pt;position:var(--position);top:294pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">consequences.</span></div><div style="line-height:10pt;position:var(--position);top:310pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Remote work has increased risks to our information technology systems and data, as our personnel utilize </span></div><div style="line-height:10pt;position:var(--position);top:320pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">network connections, computers, and devices outside our premises or network, including working at home, while in </span></div><div style="line-height:10pt;position:var(--position);top:330pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">transit and in public locations. Additionally, future or past business transactions (such as acquisitions or integrations) </span></div><div style="line-height:10pt;position:var(--position);top:340pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by </span></div><div style="line-height:10pt;position:var(--position);top:350pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. Furthermore, we may discover </span></div><div style="line-height:10pt;position:var(--position);top:360pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">security issues that were not found during due diligence of such acquired or integrated entities, and it may be </span></div><div style="line-height:10pt;position:var(--position);top:370pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">difficult to integrate companies into our information technology environment and security program. </span></div><div style="line-height:10pt;position:var(--position);top:386pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In addition, our reliance on third-party service providers could introduce new cybersecurity risks and </span></div><div style="line-height:10pt;position:var(--position);top:396pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">vulnerabilities, including supply-chain attacks, and other threats to our business operations. We rely on third-party </span></div><div style="line-height:10pt;position:var(--position);top:406pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">service providers and technologies to operate critical business systems to process sensitive data in a variety of </span></div><div style="line-height:10pt;position:var(--position);top:416pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">contexts, including, without limitation, cloud-based infrastructure, cybersecurity monitoring, data hosting, personnel </span></div><div style="line-height:10pt;position:var(--position);top:426pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">email, and other functions. We also rely on third-party service providers to provide other products, services, parts, or </span></div><div style="line-height:10pt;position:var(--position);top:436pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">otherwise to operate our business. Our ability to monitor these third parties&#8217; information security practices is limited, </span></div><div style="line-height:10pt;position:var(--position);top:446pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and these third parties may not have adequate information security measures in place. Our third-party service </span></div><div style="line-height:10pt;position:var(--position);top:456pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">providers have in the past and may in the future experience a security incident or other interruption. While we may </span></div><div style="line-height:10pt;position:var(--position);top:466pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations </span></div><div style="line-height:10pt;position:var(--position);top:476pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. In addition, </span></div><div style="line-height:10pt;position:var(--position);top:486pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; </span></div><div style="line-height:10pt;position:var(--position);top:496pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised. </span></div><div style="line-height:10pt;position:var(--position);top:512pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">While we have implemented security measures designed to protect against security incidents, there can be no </span></div><div style="line-height:10pt;position:var(--position);top:522pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">assurance that these measures have been or will be effective. We take steps designed to detect, mitigate, and </span></div><div style="line-height:10pt;position:var(--position);top:532pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">remediate vulnerabilities in our information systems (such as our hardware and/or software, including that of third </span></div><div style="line-height:10pt;position:var(--position);top:542pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">parties with whom we work). We have not and may not in the future, however, detect and remediate all such </span></div><div style="line-height:10pt;position:var(--position);top:552pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">vulnerabilities including on a timely and effective basis. Further, we have and may in the future experience delays in </span></div><div style="line-height:10pt;position:var(--position);top:562pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">developing and deploying remedial measures and patches designed to address identified vulnerabilities. These </span></div><div style="line-height:10pt;position:var(--position);top:572pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">vulnerabilities could be exploited and result in a security incident. </span></div><div style="line-height:10pt;position:var(--position);top:588pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">It may be difficult and/or costly to detect, investigate, mitigate, contain, and remediate a security incident. Our </span></div><div style="line-height:10pt;position:var(--position);top:598pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">efforts to do so may not be successful. Actions taken by us or the third parties with whom we work to detect, </span></div><div style="line-height:10pt;position:var(--position);top:608pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">investigate, mitigate, contain, and remediate a security incident could result in outages, data losses, and disruptions </span></div><div style="line-height:10pt;position:var(--position);top:618pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of our business. Threat actors may also gain access to other networks and systems after a compromise of our </span></div><div style="line-height:10pt;position:var(--position);top:628pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">networks and systems. For example, threat actors may use an initial compromise of one part of our environment to </span></div><div style="line-height:10pt;position:var(--position);top:638pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">gain access to other parts of our environment, or leverage a compromise of our networks or systems to gain access to </span></div><div style="line-height:10pt;position:var(--position);top:648pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the networks or systems of third parties with whom we work, such as through phishing or supply chain attacks.</span></div><div style="line-height:10pt;position:var(--position);top:664pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Any of the previously identified or similar threats have in the past&#160; caused and could in the future cause a </span></div><div style="line-height:10pt;position:var(--position);top:674pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">security incident or other interruption that has caused in the past or could in the future result in unauthorized, </span></div><div style="line-height:10pt;position:var(--position);top:684pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to </span></div><div style="line-height:10pt;position:var(--position);top:694pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">or other compromise of our sensitive data or our information technology systems, or those of the third parties upon </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">31</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">whom we rely. A security incident or other interruption could disrupt our ability (and that of third parties with whom </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">we work) to provide our services. </span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We may expend significant resources or modify our business activities (including our clinical trial activities) </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to try to protect against security incidents. Additionally, certain data privacy and security obligations require us to </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">implement and maintain specific security measures or industry-standard or reasonable security measures to protect </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">our information technology systems and sensitive data. </span></div><div style="line-height:10pt;position:var(--position);top:144pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Applicable data privacy and security obligations may require us, or we may voluntarily choose, to notify </span></div><div style="line-height:10pt;position:var(--position);top:154pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">relevant stakeholders, including affected individuals, regulators, investors and others, of security incidents, or to take </span></div><div style="line-height:10pt;position:var(--position);top:164pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">other actions, such as providing credit monitoring and identity theft protection services. We have in the past notified </span></div><div style="line-height:10pt;position:var(--position);top:174pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">relevant stakeholders of such security incidents. Such disclosures and related actions can be costly, and the </span></div><div style="line-height:10pt;position:var(--position);top:184pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">disclosure or the failure to comply with such applicable requirements could lead to adverse consequences.</span></div><div style="line-height:10pt;position:var(--position);top:200pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">If we (or a third party with whom we work) experience a security incident or are perceived to have </span></div><div style="line-height:10pt;position:var(--position);top:210pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">experienced a security incident, we may experience adverse consequences. These consequences may include: </span></div><div style="line-height:10pt;position:var(--position);top:220pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional </span></div><div style="line-height:10pt;position:var(--position);top:230pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reporting requirements and/or oversight; restrictions on processing sensitive data (including personal data); litigation </span></div><div style="line-height:10pt;position:var(--position);top:240pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund </span></div><div style="line-height:10pt;position:var(--position);top:250pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms. </span></div><div style="line-height:10pt;position:var(--position);top:260pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Security incidents and attendant consequences may cause relevant stakeholders to stop using our services, deter new </span></div><div style="line-height:10pt;position:var(--position);top:270pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">stakeholders from using our services, and negatively impact our ability to grow and operate our business.</span></div><div style="line-height:10pt;position:var(--position);top:286pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that </span></div><div style="line-height:10pt;position:var(--position);top:296pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our </span></div><div style="line-height:10pt;position:var(--position);top:306pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient </span></div><div style="line-height:10pt;position:var(--position);top:316pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will </span></div><div style="line-height:10pt;position:var(--position);top:326pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></div><div style="line-height:10pt;position:var(--position);top:342pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Additionally, sensitive information of the Company could be leaked, disclosed, or revealed as a result of or in </span></div><div style="line-height:10pt;position:var(--position);top:352pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">connection with our personnel&#8217;s or vendors&#8217; use of generative AI technologies.</span></div><div style="line-height:10pt;position:var(--position);top:368pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">An outbreak of communicable diseases around the world may cause disruption to our business. </span></div><div style="line-height:10pt;position:var(--position);top:384pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Any public health crisis due to the outbreak of communicable diseases may cause any of the following: </span></div><div style="line-height:10pt;position:var(--position);top:400pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">delays or difficulties in recruiting patients for our clinical trials; </span></span></div><div style="line-height:10pt;position:var(--position);top:416pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">delays or difficulties in launching clinical trial sites, including difficulties in recruiting investigators </span></span></div><div style="line-height:10pt;position:var(--position);top:426pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">and clinical site staff; and </span></div><div style="line-height:1pt;position:var(--position);top:440.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="line-height:10pt;position:var(--position);top:441.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">diversion of health care resources from the conduct of clinical trials, of hospital staff supporting the </span></span></div><div style="line-height:10pt;position:var(--position);top:451.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">conduct of clinical trials. </span></div><div style="line-height:10pt;position:var(--position);top:467.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In addition to the risks listed above, and as part of our clinical trials in countries in pandemic zones, we may </span></div><div style="line-height:10pt;position:var(--position);top:477.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">also experience the following adverse effects: </span></div><div style="line-height:10pt;position:var(--position);top:493.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">potential delays in the conduct of our research and preclinical studies, preventing research and </span></span></div><div style="line-height:10pt;position:var(--position);top:503.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">preclinical studies from being conducted as planned; </span></div><div style="line-height:10pt;position:var(--position);top:519.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">delays in obtaining authorizations from the administrative and regulatory authorities required to launch </span></span></div><div style="line-height:10pt;position:var(--position);top:529.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">the planned preclinical studies and clinical trials; </span></div><div style="line-height:10pt;position:var(--position);top:545.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">delays in the receipt of supplies and equipment necessary for the completion of our research activities </span></span></div><div style="line-height:10pt;position:var(--position);top:555.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">and our preclinical studies and clinical trials; </span></div><div style="line-height:10pt;position:var(--position);top:571.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">interruption or delays affecting the activity of contractors who provide research services to us; </span></span></div><div style="line-height:10pt;position:var(--position);top:587.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">refusal of the competent regulatory authorities to accept data from clinical trials conducted in the </span></span></div><div style="line-height:10pt;position:var(--position);top:597.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">geographical areas affected by the pandemic; </span></div><div style="line-height:10pt;position:var(--position);top:613.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the interruption of global maritime trade could affect the transportation of research materials for </span></span></div><div style="line-height:10pt;position:var(--position);top:623.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">preclinical studies and clinical trials, such as experimental drugs and comparator drugs used in our </span></div><div style="line-height:10pt;position:var(--position);top:633.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">clinical trials; and </span></div><div style="line-height:10pt;position:var(--position);top:649.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">delays in the necessary interactions with local authorities, ethics committees or other important and </span></span></div><div style="line-height:10pt;position:var(--position);top:659.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">third-party co-contracting bodies due to limitations in human resources or forced leave of state </span></div><div style="line-height:10pt;position:var(--position);top:669.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">employees. </span></div><div style="line-height:10pt;position:var(--position);top:685.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">If one or more of the above risks were to materialize, the planned and ongoing clinical trials and, therefore, the </span></div><div style="line-height:10pt;position:var(--position);top:695.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">publication of the data and results of these studies and all subsequent steps leading to the commercialization of drug </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">32</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">candidates being studied, could be significantly delayed. Such a situation could have a material adverse effect on our </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">business, income, financial position and growth. </span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The extent to which the outbreak of communicable diseases around the world may impact our activity and </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">clinical trials will depend on future developments, which cannot be predicted with certainty, such as the emergence </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of diseases that may be resistant to the vaccines or treatments currently available, access to vaccines and treatments </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for the various populations worldwide, the final geographical spread of the disease, its duration, travel restrictions </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and social distancing measures in the European Union, the United States and other countries, business closures or </span></div><div style="line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">disruptions, and the effectiveness of measures taken in those countries to contain and treat the disease. There can be </span></div><div style="line-height:10pt;position:var(--position);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">no assurance that the outbreak of communicable diseases around the world will not result in an adverse effect on </span></div><div style="line-height:10pt;position:var(--position);top:168pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">financial markets, our share price and our ability to obtain finance. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:184pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The war between Ukraine and Russia may affect our business, industry and the markets in which we operate. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:200pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The Russia-Ukraine war continues. The conflict has already had major implications for the global economy </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:210pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and the rate of inflation, particularly in relation to the supply of energy, raw materials and food products. It has also </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:220pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">caused intense volatility on the financial markets, something that is still ongoing at the reporting date and has pushed </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:230pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">down stock market prices around the world. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:246pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Given these developments, we have decided not to include Russia and Belarus in our global Phase&#160;3 program </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:256pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for obefazimod in UC. However, the global scale of this conflict remains uncertain. We, therefore, cannot rule out </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:266pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">an adverse impact of this conflict on our business, including in terms of access to raw materials, logistics, the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:276pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">performance of clinical trials and in relation to any future financing we may seek. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:292pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our global Phase 3 clinical trials currently have clinical sites in Ukraine. None of these sites are located in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:302pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Crimea Region of Ukraine, the so-called Donetsk People&#8217;s Republic, or the so-called Luhansk People&#8217;s Republic. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:312pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">We continue to monitor developments in the region, but any instability as a result of the war may have material </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:322pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">adverse impacts on these clinical sites, which could negatively impact our Phase 3 clinical trials. </span></div><div style="line-height:10pt;position:var(--position);top:350pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Risks Related to Intellectual Property </span></div><div style="line-height:10pt;position:var(--position);top:366pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Our ability to exclusively commercialize our drug candidates may decrease if we are unable to protect our </span></div><div style="line-height:10pt;position:var(--position);top:376pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">intellectual property rights or if these rights are insufficient for our purposes. </span></div><div style="line-height:10pt;position:var(--position);top:392pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our commercial success depends in part on our ability and the ability of our partners to obtain, maintain and </span></div><div style="line-height:10pt;position:var(--position);top:402pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ensure, against third parties, the protection of our patents, trademarks and related applications and other intellectual </span></div><div style="line-height:10pt;position:var(--position);top:412pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">property rights or similar rights (such as trade secrets, business secrets and know-how) or those we are authorized to </span></div><div style="line-height:10pt;position:var(--position);top:422pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">use in the course of our business in Europe, the United States, Asia and other key countries. We dedicate substantial </span></div><div style="line-height:10pt;position:var(--position);top:432pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">financial and human resources to this and intend to continue our policy of protection through new patent </span></div><div style="line-height:10pt;position:var(--position);top:442pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">applications as soon as we deem it appropriate. </span></div><div style="line-height:10pt;position:var(--position);top:458pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our technology is currently protected by patents and patent applications that we have filed or for which we </span></div><div style="line-height:10pt;position:var(--position);top:468pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">have an exclusive license. However, we or our partners might not be able to maintain the protection of our </span></div><div style="line-height:10pt;position:var(--position);top:478pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">intellectual property rights and we could, thereby, lose our technological and competitive advantage in whole or in </span></div><div style="line-height:10pt;position:var(--position);top:488pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">part. </span></div><div style="line-height:10pt;position:var(--position);top:504pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Firstly, our intellectual property rights and those of our partners offer protection for a period that may vary </span></div><div style="line-height:10pt;position:var(--position);top:514pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">from one territory to another. The term of individual patents depends upon the legal term of the patents in the </span></div><div style="line-height:10pt;position:var(--position);top:524pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">countries in which they are obtained. In most countries in which we have obtained or are seeking patent protection </span></div><div style="line-height:10pt;position:var(--position);top:534pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for our drug candidates, the patent term is 20 years from the earliest filing date of a non-provisional patent </span></div><div style="line-height:10pt;position:var(--position);top:544pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">application. In the United States, the term of a patent may be lengthened by a patent term adjustment, which </span></div><div style="line-height:10pt;position:var(--position);top:554pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">provides for term extension in the case of administrative delays at the United States Patent and Trademark Office </span></div><div style="line-height:10pt;position:var(--position);top:564pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(&#8220;USPTO&#8221;) in granting a patent, or may be shortened if a patent is terminally disclaimed over another patent with an </span></div><div style="line-height:10pt;position:var(--position);top:574pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">earlier expiration date. Furthermore, in the United States, the term of a patent covering an FDA approved drug may </span></div><div style="line-height:10pt;position:var(--position);top:584pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">be eligible for a patent term extension under the Hatch-Waxman Amendments as compensation for the loss of patent </span></div><div style="line-height:10pt;position:var(--position);top:594pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">term during the FDA regulatory review process. The period of extension may be up to five years beyond the </span></div><div style="line-height:10pt;position:var(--position);top:604pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">expiration of the patent but cannot extend the term of a patent beyond a total of 14 years from the date of product </span></div><div style="line-height:10pt;position:var(--position);top:614pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">approval. Only one patent covering a single FDA-approved product among those eligible for an extension may be </span></div><div style="line-height:10pt;position:var(--position);top:624pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">extended. In the future, if any of our drug candidates receives FDA approval, we expect to apply for a patent term </span></div><div style="line-height:10pt;position:var(--position);top:634pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">extension, if available, to extend the term of the patent covering such approved drug product. In France and the rest </span></div><div style="line-height:10pt;position:var(--position);top:644pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of Europe generally, the term of a patent is 20 years from the date the patent application is filed, with the </span></div><div style="line-height:10pt;position:var(--position);top:654pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">understanding that this period may be extended up to another five years if a supplementary protection certificate is </span></div><div style="line-height:10pt;position:var(--position);top:664pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">filed and an additional six months if a pediatric investigation plan is applied. We expect to seek patent term </span></div><div style="line-height:10pt;position:var(--position);top:674pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">extensions in any jurisdictions where they are available, however, there is no guarantee that the applicable </span></div><div style="line-height:10pt;position:var(--position);top:684pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">authorities, including the FDA, will agree with our assessment of whether such an extension should be granted, and </span></div><div style="line-height:10pt;position:var(--position);top:694pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">even if granted, the length of such an extension. </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">33</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Secondly, we and our partners could encounter difficulties in the filing or examination of some of our patent, </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">trademark or other intellectual property rights applications currently being examined/registered. During the patent </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">application process, we may receive Office Actions from the USPTO or from comparable agencies in foreign </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">jurisdictions rejecting the claims of the patent application. Although we would be given an opportunity to respond to </span></div><div style="line-height:10pt;position:var(--position);top:112pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">those objections, we may be unable to overcome such rejections. At the time a patent application is filed, there may </span></div><div style="line-height:10pt;position:var(--position);top:122pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">be other patents that could constitute opposable prior art that may have not yet been published. Despite prior art </span></div><div style="line-height:10pt;position:var(--position);top:132pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">searches and monitoring, we cannot be certain that we are the first to conceive of an invention and file a patent </span></div><div style="line-height:10pt;position:var(--position);top:142pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">application relating thereto; in particular, it should be noted that in most countries, the publication of patent </span></div><div style="line-height:10pt;position:var(--position);top:152pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">applications takes place 18 months after the earliest priority date of patent filing, or in some cases not at all, and that </span></div><div style="line-height:10pt;position:var(--position);top:162pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">discoveries are sometimes only the subject of publication or patent application months or even years later. Likewise, </span></div><div style="line-height:10pt;position:var(--position);top:172pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">when filing one of our trademarks in a country where it is not covered, we could find that the trademark in question </span></div><div style="line-height:10pt;position:var(--position);top:182pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">is not available in that country. A new trademark would then need to be sought for the country in question or an </span></div><div style="line-height:10pt;position:var(--position);top:192pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">agreement negotiated with the prior holder of the trademark. We may not be able to prevent a disclosure of </span></div><div style="line-height:10pt;position:var(--position);top:202pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">information to third parties that could have an impact on our future intellectual property rights. Therefore, it is in no </span></div><div style="line-height:10pt;position:var(--position);top:212pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">way certain that our current and future applications for patents, trademarks and other intellectual property rights will </span></div><div style="line-height:10pt;position:var(--position);top:222pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">result in registrations. </span></div><div style="line-height:10pt;position:var(--position);top:238pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Thirdly, the simple granting or registration of a patent, trademark or other intellectual property right does not </span></div><div style="line-height:10pt;position:var(--position);top:248pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">guarantee validity or enforceability. Our competitors may at any time contest the validity or enforceability of our or </span></div><div style="line-height:10pt;position:var(--position);top:258pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">our partners&#8217; patents, trademarks or applications relating thereto before a court or in the context of other specific </span></div><div style="line-height:10pt;position:var(--position);top:268pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">procedures which, depending on the outcome of such disputes, could reduce their scope, result in their invalidation </span></div><div style="line-height:10pt;position:var(--position);top:278pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">or allow them to be circumvented by competitors. In addition, developments, changes or divergences in the </span></div><div style="line-height:10pt;position:var(--position);top:288pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">interpretation of the legal framework governing intellectual property in Europe, the United States or other countries </span></div><div style="line-height:10pt;position:var(--position);top:298pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">could allow competitors to use our or our partners&#8217; inventions or intellectual property rights to develop or market our </span></div><div style="line-height:10pt;position:var(--position);top:308pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">products or technologies without financial compensation. Moreover, there are still certain countries that do not </span></div><div style="line-height:10pt;position:var(--position);top:318pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">protect intellectual property rights in the same way as in Europe and the United States, and the effective procedures </span></div><div style="line-height:10pt;position:var(--position);top:328pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and rules necessary to ensure the defense of our rights may not exist in these countries. There is therefore no </span></div><div style="line-height:10pt;position:var(--position);top:338pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">certainty that our existing and future patents, trademarks and other intellectual property rights will not be disputed, </span></div><div style="line-height:10pt;position:var(--position);top:348pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">invalidated or circumvented, or that they will provide effective protection against competition. </span></div><div style="line-height:10pt;position:var(--position);top:364pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Consequently, our rights to our owned or licensed patents, trademarks and related applications and other </span></div><div style="line-height:10pt;position:var(--position);top:374pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">intellectual property rights may not confer the protection expected against competition. We therefore cannot </span></div><div style="line-height:10pt;position:var(--position);top:384pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">guarantee with certainty that: </span></div><div style="line-height:10pt;position:var(--position);top:400pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">we will be able to develop novel inventions for which a patent could be filed or issued; </span></span></div><div style="line-height:10pt;position:var(--position);top:416pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">applications for patents and other property rights currently under review will actually result in the </span></span></div><div style="line-height:10pt;position:var(--position);top:426pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">granting of patents, trademarks or other registered intellectual property rights; </span></div><div style="line-height:10pt;position:var(--position);top:442pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">patents or other intellectual property rights granted to us or our partners will not be contested, </span></span></div><div style="line-height:10pt;position:var(--position);top:452pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">invalidated or circumvented; or </span></div><div style="line-height:10pt;position:var(--position);top:468pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the scope of protection conferred by our or our partners&#8217; patents, trademarks and other intellectual </span></span></div><div style="line-height:10pt;position:var(--position);top:478pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">property rights is and will remain sufficient to protect us against competition. </span></div><div style="line-height:10pt;position:var(--position);top:494pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Were these eventualities to occur, they could have a material adverse effect on our business and growth. </span></div><div style="line-height:10pt;position:var(--position);top:510pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In addition, third parties (or even our employees) could use or attempt to use elements of our technologies </span></div><div style="line-height:10pt;position:var(--position);top:520pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">protected by an intellectual property right, which would create a detrimental situation for us. We may therefore be </span></div><div style="line-height:10pt;position:var(--position);top:530pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">compelled to bring legal or administrative proceedings against these third parties in order to enforce our intellectual </span></div><div style="line-height:10pt;position:var(--position);top:540pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">property rights (patents, trademarks, designs and models or domain names) in court. </span></div><div style="line-height:10pt;position:var(--position);top:556pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Enforcing a claim that a party illegally infringed or misappropriated our intellectual property is difficult, </span></div><div style="line-height:10pt;position:var(--position);top:566pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">expensive and time-consuming, and the outcome is unpredictable. Any litigation or dispute, regardless of the </span></div><div style="line-height:10pt;position:var(--position);top:576pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">outcome, could lead to substantial costs, affect our reputation, negatively influence our income and financial </span></div><div style="line-height:10pt;position:var(--position);top:586pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">position and possibly not lead to the desired protection or sanction. Some competitors with more substantial </span></div><div style="line-height:10pt;position:var(--position);top:596pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">resources than us may be able to bear the costs of litigation more easily. </span></div><div style="line-height:10pt;position:var(--position);top:612pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72.25pt;position:var(--position);text-decoration:none;white-space:pre">If we fail to comply with our obligations in any agreements under which we may license intellectual property </span></div><div style="line-height:10pt;position:var(--position);top:622pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we </span></div><div style="line-height:10pt;position:var(--position);top:632pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">could lose rights that are important to our business. </span></div><div style="line-height:10pt;position:var(--position);top:648pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our ability to pursue the development of some of our drug-based candidates partially depends on the </span></div><div style="line-height:10pt;position:var(--position);top:658pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">maintenance in force of the licensing agreements entered into with various institutes. We have licenses granted by </span></div><div style="line-height:10pt;position:var(--position);top:668pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the CNRS, the University of Montpellier and/or the Institut Curie for certain patent and patent applications co-</span></div><div style="line-height:10pt;position:var(--position);top:678pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ownership rights resulting from cooperation with the CNRS, the University of Montpellier and the Institut Curie, </span></div><div style="line-height:10pt;position:var(--position);top:688pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">which allowed obefazimod to be developed. </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">34</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">These license contracts provide the possibility for the licensor to end an agreed exclusivity or terminate the </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">contracts in certain events, including the event of non-payment of fees, a dispute over the validity of the patents </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">licensed or a violation by us of our obligations. </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We may from time to time be party to license or collaboration agreements with third parties to advance our </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">research or allow commercialization of current or future drug candidates. Such agreements may impose numerous </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">obligations, such as development, diligence, payment, commercialization, funding, milestone, royalty, sublicensing, </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">insurance, patent prosecution, enforcement and other obligations on us and may require us to meet development </span></div><div style="line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products, in order to </span></div><div style="line-height:10pt;position:var(--position);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">maintain the licenses. In spite of our best efforts, our licensors might conclude that we have materially breached our </span></div><div style="line-height:10pt;position:var(--position);top:168pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to </span></div><div style="line-height:10pt;position:var(--position);top:178pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">develop and commercialize products and technologies covered by these license agreements. </span></div><div style="line-height:10pt;position:var(--position);top:194pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Any termination of these licenses, or if the underlying licensed rights fail to provide the intended exclusivity, </span></div><div style="line-height:10pt;position:var(--position);top:204pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">could result in the loss of significant rights and could harm our ability to commercialize our current or future drug </span></div><div style="line-height:10pt;position:var(--position);top:214pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">candidates, and competitors or other third parties would have the freedom to seek regulatory approval of, and to </span></div><div style="line-height:10pt;position:var(--position);top:224pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">market, products identical to ours and we may be required to cease our development and commercialization of </span></div><div style="line-height:10pt;position:var(--position);top:234pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">certain of our current or future drug candidates. Any of the foregoing could have a material adverse effect on our </span></div><div style="line-height:10pt;position:var(--position);top:244pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">competitive position, business, financial conditions, results of operations, and prospects. </span></div><div style="line-height:10pt;position:var(--position);top:260pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Disputes may also arise between us and our licensors regarding intellectual property subject to a license </span></div><div style="line-height:10pt;position:var(--position);top:270pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">agreement, including: </span></div><div style="line-height:10pt;position:var(--position);top:286pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the scope of rights granted under the license agreement and other interpretation-related issues; </span></span></div><div style="line-height:10pt;position:var(--position);top:302pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">whether and the extent to which our technology and processes infringe, misappropriate or otherwise </span></span></div><div style="line-height:10pt;position:var(--position);top:312pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">violate intellectual property rights of the licensor that is not subject to the licensing agreement; </span></div><div style="line-height:10pt;position:var(--position);top:328pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">our right to sublicense patent and other rights to third parties under collaborative development </span></span></div><div style="line-height:10pt;position:var(--position);top:338pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">relationships; </span></div><div style="line-height:10pt;position:var(--position);top:354pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">our diligence obligations with respect to the use of the licensed technology in relation to our </span></span></div><div style="line-height:10pt;position:var(--position);top:364pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">development and commercialization of our current or future drug candidates, and what activities </span></div><div style="line-height:10pt;position:var(--position);top:374pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">satisfy those diligence obligations; </span></div><div style="line-height:10pt;position:var(--position);top:390pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the priority of invention of any patented technology; and </span></span></div><div style="line-height:10pt;position:var(--position);top:406pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the ownership of inventions and&#160;know-how&#160;resulting from the joint creation or use of intellectual </span></span></div><div style="line-height:10pt;position:var(--position);top:416pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">property by our future licensors and us and our partners. </span></div><div style="line-height:10pt;position:var(--position);top:432pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In addition, the agreements under which we may license intellectual property or technology from third parties </span></div><div style="line-height:10pt;position:var(--position);top:442pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">are likely to be complex, and certain provisions in such agreements may be susceptible to multiple interpretations. </span></div><div style="line-height:10pt;position:var(--position);top:452pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The adverse resolution of any contract interpretation disagreement that may arise could narrow what we believe to </span></div><div style="line-height:10pt;position:var(--position);top:462pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our </span></div><div style="line-height:10pt;position:var(--position);top:472pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">financial or other obligations under the relevant agreement, either of which could have a material adverse effect on </span></div><div style="line-height:10pt;position:var(--position);top:482pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property </span></div><div style="line-height:10pt;position:var(--position);top:492pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">that we have licensed or may license prevent or impair our ability to maintain future licensing arrangements on </span></div><div style="line-height:10pt;position:var(--position);top:502pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">acceptable terms, we may be unable to successfully develop and commercialize the affected current or future drug </span></div><div style="line-height:10pt;position:var(--position);top:512pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">candidates, which could have a material adverse effect on our business, financial conditions, results of operations </span></div><div style="line-height:10pt;position:var(--position);top:522pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and prospects. </span></div><div style="line-height:10pt;position:var(--position);top:538pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">We may be sued for infringing or misappropriating the intellectual property rights of third parties, and if we are, </span></div><div style="line-height:10pt;position:var(--position);top:548pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">such litigation could be costly and time consuming and could prevent or delay us from developing or </span></div><div style="line-height:10pt;position:var(--position);top:558pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">commercializing our drug candidates. </span></div><div style="line-height:10pt;position:var(--position);top:574pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our commercial success will also depend on our ability to develop products and technologies that do not </span></div><div style="line-height:10pt;position:var(--position);top:584pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">infringe the patents or other rights of third parties. It is important for the success of our business that we are able to </span></div><div style="line-height:10pt;position:var(--position);top:594pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">use our products and conduct research and development efforts leading to commercialization of our products </span></div><div style="line-height:10pt;position:var(--position);top:604pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">without infringing patents or other third-party rights. </span></div><div style="line-height:10pt;position:var(--position);top:620pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We continue to carry out, as we have done to date, the preliminary studies that we consider necessary in view </span></div><div style="line-height:10pt;position:var(--position);top:630pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of the above risks, before investing in the development of our various products and technologies. With the help of </span></div><div style="line-height:10pt;position:var(--position);top:640pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">intellectual property consulting and law firms, we monitor our competitors&#8217; activity (particularly with respect to </span></div><div style="line-height:10pt;position:var(--position);top:650pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">patent filings). </span></div><div style="line-height:10pt;position:var(--position);top:666pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We therefore cannot guarantee with certainty that: </span></div><div style="line-height:10pt;position:var(--position);top:682pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">there are no prior patents or other intellectual property rights of third parties covering certain of our </span></span></div><div style="line-height:10pt;position:var(--position);top:692pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">products, methods, technologies, results or activities and that, consequently, third parties might bring </span></div><div style="line-height:10pt;position:var(--position);top:702pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">an action for infringement or violation of their rights against us with a view to obtaining damages and </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">35</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">interest and/or the cessation of our activities in the manufacture and/or commercialization of products, </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">methods and the like thus disputed; </span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">there are no trademark rights or other prior rights of third parties that could be the basis of an </span></span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">infringement or liability action against us; and </span></div><div style="line-height:10pt;position:var(--position);top:124pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">our domain names are not subject, on the part of third parties who have prior rights (for example </span></span></div><div style="line-height:10pt;position:var(--position);top:134pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">trademark rights), to a Uniform Domain-Name Dispute-Resolution Policy (&#8220;UDRP&#8221;) or similar policy, </span></div><div style="line-height:10pt;position:var(--position);top:144pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">or an infringement action. </span></div><div style="line-height:10pt;position:var(--position);top:160pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In the event of intellectual property litigation, we may have to: </span></div><div style="line-height:10pt;position:var(--position);top:176pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">stop developing, making, selling, offering for sale or using the product or products that depended on </span></span></div><div style="line-height:10pt;position:var(--position);top:186pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">the disputed intellectual property; </span></div><div style="line-height:10pt;position:var(--position);top:202pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">obtain a license from the holder of the intellectual property rights, however, such a license may be </span></span></div><div style="line-height:10pt;position:var(--position);top:212pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">unobtainable or only be obtainable under unfavorable economic conditions for us; or </span></div><div style="line-height:10pt;position:var(--position);top:228pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">revise the design of some of our products/technologies or, in the case of trademark applications, </span></span></div><div style="line-height:10pt;position:var(--position);top:238pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">rename our products to avoid infringing the intellectual property rights of third parties, which may </span></div><div style="line-height:10pt;position:var(--position);top:248pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">prove impossible or time-consuming and expensive, and could impact our marketing efforts. </span></div><div style="line-height:10pt;position:var(--position);top:264pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Litigation can also result in an order to pay damages (including treble damages) and being subject to </span></div><div style="line-height:10pt;position:var(--position);top:274pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">injunctions. </span></div><div style="line-height:10pt;position:var(--position);top:290pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Patent terms may be inadequate to protect our competitive position on our drugs for an adequate amount of time, </span></div><div style="line-height:10pt;position:var(--position);top:300pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and we may seek to rely, but may not be able to rely, on other forms of protection, such as regulatory exclusivity. </span></div><div style="line-height:10pt;position:var(--position);top:316pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Given the amount of time required for the development, testing and regulatory review of new drug candidates, </span></div><div style="line-height:10pt;position:var(--position);top:326pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">patents protecting such candidates might expire before or shortly after such candidates are commercialized. For </span></div><div style="line-height:10pt;position:var(--position);top:336pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">example, the certain patents protecting obefazimod&#8217;s composition of matter expire in 2030 and the certain patents </span></div><div style="line-height:10pt;position:var(--position);top:346pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">protecting obefazimod methods of use expire in 2035 which pose a risk to its successful commercialization. We </span></div><div style="line-height:10pt;position:var(--position);top:356pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">expect to seek extensions of patent terms in the United States and, if available, in other countries where we are </span></div><div style="line-height:10pt;position:var(--position);top:366pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">prosecuting patents. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 </span></div><div style="line-height:10pt;position:var(--position);top:376pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">permits a patent term extension of up to five years beyond the normal expiration of the patent, which is limited to the </span></div><div style="line-height:10pt;position:var(--position);top:386pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">approved indication (or any additional indications approved during the period of extension). However, the applicable </span></div><div style="line-height:10pt;position:var(--position);top:396pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other </span></div><div style="line-height:10pt;position:var(--position);top:406pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant </span></div><div style="line-height:10pt;position:var(--position);top:416pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">extensions to our patents, or may grant more limited extensions than we request. We may also seek to rely on other </span></div><div style="line-height:10pt;position:var(--position);top:426pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">forms of protection, such as regulatory exclusivity, but there can be no assurance that such other forms of protection </span></div><div style="line-height:10pt;position:var(--position);top:436pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">will be available or sufficient. </span></div><div style="line-height:10pt;position:var(--position);top:452pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">We will not seek to protect our intellectual property rights in all jurisdictions throughout the world and we may </span></div><div style="line-height:10pt;position:var(--position);top:462pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek </span></div><div style="line-height:10pt;position:var(--position);top:472pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">protection. </span></div><div style="line-height:10pt;position:var(--position);top:488pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Filing, prosecuting and defending patents on our drug candidates in all countries and jurisdictions throughout </span></div><div style="line-height:10pt;position:var(--position);top:498pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United </span></div><div style="line-height:10pt;position:var(--position);top:508pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">States could be less extensive than those in the United States, assuming that rights are obtained in the United States. </span></div><div style="line-height:10pt;position:var(--position);top:518pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Competitors may use our technologies in jurisdictions where we do not pursue and obtain patent protection to </span></div><div style="line-height:10pt;position:var(--position);top:528pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">develop their own products and further, may export otherwise infringing products to territories where we have patent </span></div><div style="line-height:10pt;position:var(--position);top:538pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">protection, but enforcement is not as strong as that in the United States. These products may compete with our drugs </span></div><div style="line-height:10pt;position:var(--position);top:548pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and our patents or other intellectual property rights may not be effective or sufficient to prevent them from </span></div><div style="line-height:10pt;position:var(--position);top:558pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">competing. Even if we pursue and obtain issued patents in particular jurisdictions, our patent claims or other </span></div><div style="line-height:10pt;position:var(--position);top:568pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">intellectual property rights may not be effective or sufficient to prevent third parties from so competing. </span></div><div style="line-height:10pt;position:var(--position);top:584pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as </span></div><div style="line-height:10pt;position:var(--position);top:594pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the federal and state laws in the United States. Many companies have encountered significant problems in protecting </span></div><div style="line-height:10pt;position:var(--position);top:604pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, </span></div><div style="line-height:10pt;position:var(--position);top:614pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, </span></div><div style="line-height:10pt;position:var(--position);top:624pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">especially those relating to biopharmaceuticals or biotechnologies. This could make it difficult for us to stop the </span></div><div style="line-height:10pt;position:var(--position);top:634pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">infringement of our patents, if obtained, or the misappropriation of our other intellectual property rights. For </span></div><div style="line-height:10pt;position:var(--position);top:644pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to </span></div><div style="line-height:10pt;position:var(--position);top:654pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">third parties. In addition, many countries limit the enforceability of patents against third parties, including </span></div><div style="line-height:10pt;position:var(--position);top:664pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">government agencies or government contractors. In these countries, patents may provide limited or no benefit. </span></div><div style="line-height:10pt;position:var(--position);top:674pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Patent protection must ultimately be sought on a country-by-country basis, which is an expensive and time-</span></div><div style="line-height:10pt;position:var(--position);top:684pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain </span></div><div style="line-height:10pt;position:var(--position);top:694pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">countries, and we will not have the benefit of patent protection in such countries. </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">36</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">interpreted narrowly, could put our patent applications at risk of not being issued and could provoke third parties to </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies </span></div><div style="line-height:10pt;position:var(--position);top:112pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">awarded, if any, may not be commercially meaningful. In addition, changes in the law and legal decisions by courts </span></div><div style="line-height:10pt;position:var(--position);top:122pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">in the United States and foreign countries may affect our ability to obtain adequate protection for our technology and </span></div><div style="line-height:10pt;position:var(--position);top:132pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the enforcement of our intellectual property. In addition, monitoring the unauthorized use of our products and </span></div><div style="line-height:10pt;position:var(--position);top:142pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">technology and the infringement of our intellectual property rights is challenging. We cannot guarantee with </span></div><div style="line-height:10pt;position:var(--position);top:152pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">certainty that we will be able to prevent, take legal action against and obtain compensation for infringement, </span></div><div style="line-height:10pt;position:var(--position);top:162pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">misappropriation or unauthorized use of our products and technologies, particularly in foreign countries where our </span></div><div style="line-height:10pt;position:var(--position);top:172pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">rights are less well protected because of the territorial scope of intellectual property rights. Accordingly, our efforts </span></div><div style="line-height:10pt;position:var(--position);top:182pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial </span></div><div style="line-height:10pt;position:var(--position);top:192pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">advantage from the intellectual property that we develop or license. </span></div><div style="line-height:10pt;position:var(--position);top:208pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Further, in Europe, a new unitary patent system took effect June 1, 2023, which significantly impacts </span></div><div style="line-height:10pt;position:var(--position);top:218pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">European patents, including those granted before the introduction of such a system. Under the unitary patent system, </span></div><div style="line-height:10pt;position:var(--position);top:228pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">European applications have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to </span></div><div style="line-height:10pt;position:var(--position);top:238pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the jurisdiction of the Unitary Patent Court (the "UPC"). As the UPC is a new court system, there is currently little </span></div><div style="line-height:10pt;position:var(--position);top:248pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the </span></div><div style="line-height:10pt;position:var(--position);top:258pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">UPC will have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC </span></div><div style="line-height:10pt;position:var(--position);top:268pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based </span></div><div style="line-height:10pt;position:var(--position);top:278pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. </span></div><div style="line-height:10pt;position:var(--position);top:288pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">We cannot predict with certainty the long-term effects of these changes. </span></div><div style="line-height:10pt;position:var(--position);top:304pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In addition, geo-political actions in the United States and in foreign countries could increase the uncertainties </span></div><div style="line-height:10pt;position:var(--position);top:314pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and costs surrounding the prosecution or maintenance of our patent applications and the maintenance, enforcement </span></div><div style="line-height:10pt;position:var(--position);top:324pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">or defense of our issued patents. For example, the United States and foreign government actions related to Russia&#8217;s </span></div><div style="line-height:10pt;position:var(--position);top:334pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">invasion of Ukraine may limit or prevent filing, prosecution, and maintenance of patent applications in Russia. </span></div><div style="line-height:10pt;position:var(--position);top:344pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Government actions may also prevent maintenance of issued patents in Russia. These actions could result in </span></div><div style="line-height:10pt;position:var(--position);top:354pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">abandonment or lapse of our patents or patent applications, resulting in partial or complete loss of patent rights in </span></div><div style="line-height:10pt;position:var(--position);top:364pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Russia. If such an event were to occur, it could have a material adverse effect on our business. In addition, a decree </span></div><div style="line-height:10pt;position:var(--position);top:374pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit </span></div><div style="line-height:10pt;position:var(--position);top:384pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">inventions owned by patentees from the United States without consent or compensation. Consequently, we would </span></div><div style="line-height:10pt;position:var(--position);top:394pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">not be able to prevent third parties from practicing our inventions in Russia or from selling or importing products </span></div><div style="line-height:10pt;position:var(--position);top:404pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our </span></div><div style="line-height:10pt;position:var(--position);top:414pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">business, financial condition, results of operations and prospects may be adversely affected. </span></div><div style="line-height:10pt;position:var(--position);top:430pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">If our trademarks and trade names are not adequately protected by us or our partners that develop trademarks </span></div><div style="line-height:10pt;position:var(--position);top:440pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for our future products, then we may not be able to build name or brand recognition in our markets of interest, </span></div><div style="line-height:10pt;position:var(--position);top:450pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and our business may be adversely affected. </span></div><div style="line-height:10pt;position:var(--position);top:466pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our registered or unregistered trademarks and trade names and the registered or unregistered trademarks and </span></div><div style="line-height:10pt;position:var(--position);top:476pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">trade names that our partners will develop may be challenged, infringed, diluted, circumvented or declared generic </span></div><div style="line-height:10pt;position:var(--position);top:486pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">or determined to be infringing on other marks. We and our partners may not be able to protect our rights to these </span></div><div style="line-height:10pt;position:var(--position);top:496pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">trademarks and trade names, which we need to build name and brand recognition among potential partners or </span></div><div style="line-height:10pt;position:var(--position);top:506pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">customers in our markets of interest. We expect to rely on our partners to protect the trade names and trademarks </span></div><div style="line-height:10pt;position:var(--position);top:516pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">that they will develop, and they may not adequately protect such tradenames and trademarks, and we may have little </span></div><div style="line-height:10pt;position:var(--position);top:526pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">or no recourse in respect thereof. At times, competitors may adopt trademarks and trade names similar to ours, </span></div><div style="line-height:10pt;position:var(--position);top:536pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">thereby impeding our ability to build brand identity and possibly leading to market confusion. During the trademark </span></div><div style="line-height:10pt;position:var(--position);top:546pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">registration process, we may receive Office Actions from the USPTO or from comparable agencies in foreign </span></div><div style="line-height:10pt;position:var(--position);top:556pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">jurisdictions objecting to the registration of our trademark. Although we would be given an opportunity to respond </span></div><div style="line-height:10pt;position:var(--position);top:566pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to those objections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable </span></div><div style="line-height:10pt;position:var(--position);top:576pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark </span></div><div style="line-height:10pt;position:var(--position);top:586pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">applications and/or to seek the cancellation of registered trademarks. Opposition or cancellation proceedings may be </span></div><div style="line-height:10pt;position:var(--position);top:596pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">filed against our trademark applications or registrations, and our trademark applications or registrations may not </span></div><div style="line-height:10pt;position:var(--position);top:606pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">survive such proceedings. In addition, there could be potential trademark infringement claims brought by owners of </span></div><div style="line-height:10pt;position:var(--position);top:616pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks. </span></div><div style="line-height:10pt;position:var(--position);top:626pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Over the long term, if we are unable to establish name and brand recognition based on our trademarks, then we may </span></div><div style="line-height:10pt;position:var(--position);top:636pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">not be able to compete effectively and our business may be adversely affected. </span></div><div style="line-height:10pt;position:var(--position);top:652pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Obtaining and maintaining patent protection depends on compliance with various procedural, document </span></div><div style="line-height:10pt;position:var(--position);top:662pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">submission, fee payment and other requirements imposed by governmental patent agencies, and our patent </span></div><div style="line-height:10pt;position:var(--position);top:672pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="line-height:10pt;position:var(--position);top:688pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and </span></div><div style="line-height:10pt;position:var(--position);top:698pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">applications are required to be paid to the USPTO and various governmental patent agencies outside of the United </span></div><div style="line-height:10pt;position:var(--position);top:708pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">States in several stages over the lifetime of the patents and applications. The USPTO and various non-U.S. </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">37</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">similar provisions during the patent application process and after a patent has issued. There are situations in which </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">complete loss of patent rights in the relevant jurisdiction. </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">If we are unable to protect the confidentiality of our trade secrets and know-how, our business and competitive </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">position could be harmed. </span></div><div style="line-height:10pt;position:var(--position);top:144pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In addition to seeking patent protection for our drug candidates, we also rely on trade secrets, including </span></div><div style="line-height:10pt;position:var(--position);top:154pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">unpatented know-how, technology and other proprietary information, to establish and maintain our competitive </span></div><div style="line-height:10pt;position:var(--position);top:164pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">position. </span></div><div style="line-height:10pt;position:var(--position);top:180pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">It is also important for us to protect against the unauthorized use and disclosure of our confidential </span></div><div style="line-height:10pt;position:var(--position);top:190pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">information, know-how and trade secrets. Unpatented and/or unpatentable technologies, processes, methods, know-</span></div><div style="line-height:10pt;position:var(--position);top:200pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">how and data are considered trade secrets that we seek to protect, in part, by entering into non-disclosure and </span></div><div style="line-height:10pt;position:var(--position);top:210pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">confidentiality agreements with parties who have access to them, such as our employees, collaborators, consultants, </span></div><div style="line-height:10pt;position:var(--position);top:220pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">advisors, university and/or institutional researchers and other third parties. We also have entered or seek to enter into </span></div><div style="line-height:10pt;position:var(--position);top:230pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">confidentiality and invention or patent assignment agreements with our employees, advisors and consultants. </span></div><div style="line-height:10pt;position:var(--position);top:246pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In the context of collaboration, partnership or research contracts, or other types of cooperation between us and </span></div><div style="line-height:10pt;position:var(--position);top:256pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">researchers from academic institutions, and with other public or private entities, subcontractors, or any co-</span></div><div style="line-height:10pt;position:var(--position);top:266pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">contracting third parties, various information and/or products may be entrusted to them in order to conduct certain </span></div><div style="line-height:10pt;position:var(--position);top:276pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">tests and clinical trials. In such cases, we require that confidentiality agreements be signed. Furthermore, as a general </span></div><div style="line-height:10pt;position:var(--position);top:286pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">rule, we take care that the collaboration or research contracts that we are party to give us access to full ownership or </span></div><div style="line-height:10pt;position:var(--position);top:296pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">co-ownership of results and/or inventions resulting from the collaboration, or to an exclusive license based on these </span></div><div style="line-height:10pt;position:var(--position);top:306pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">results and/or inventions resulting from the collaboration. </span></div><div style="line-height:10pt;position:var(--position);top:322pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Despite these efforts, counterparties may breach our agreements and disclose our proprietary information, </span></div><div style="line-height:10pt;position:var(--position);top:332pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Our trade secrets </span></div><div style="line-height:10pt;position:var(--position);top:342pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">may also be obtained by third parties by other means, such as breaches of our physical or computer security systems. </span></div><div style="line-height:10pt;position:var(--position);top:352pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-</span></div><div style="line-height:10pt;position:var(--position);top:362pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less </span></div><div style="line-height:10pt;position:var(--position);top:372pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">willing or unwilling to protect trade secrets. Moreover, if any of our trade secrets were to be lawfully obtained or </span></div><div style="line-height:10pt;position:var(--position);top:382pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">independently developed by a competitor, we would have no right to prevent them, or those to whom they </span></div><div style="line-height:10pt;position:var(--position);top:392pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be </span></div><div style="line-height:10pt;position:var(--position);top:402pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">disclosed to, or independently developed by, a competitor, our competitive position would be harmed and our </span></div><div style="line-height:10pt;position:var(--position);top:412pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">business may be adversely affected. </span></div><div style="line-height:10pt;position:var(--position);top:428pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">There can be no assurance that the agreements put in place to protect our technology and trade secrets and/or </span></div><div style="line-height:10pt;position:var(--position);top:438pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the know-how being used will provide the protection sought or will not be violated, that we will have appropriate </span></div><div style="line-height:10pt;position:var(--position);top:448pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">solutions for such violations, or that our trade secrets will not be disclosed to or independently developed by our </span></div><div style="line-height:10pt;position:var(--position);top:458pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">competitors. In the context of contracts that we enter into with third parties, we sometimes take the precaution of </span></div><div style="line-height:10pt;position:var(--position);top:468pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">providing that they are not authorized to use third-party services or that they may only do so with our prior approval. </span></div><div style="line-height:10pt;position:var(--position);top:478pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">However, it cannot be ruled out that some of these co-contractors may nevertheless use third parties. In this event, </span></div><div style="line-height:10pt;position:var(--position);top:488pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">we have no control over the conditions under which third parties with which we do not contract protect their </span></div><div style="line-height:10pt;position:var(--position);top:498pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">confidential information, irrespective of whether we provide in our agreements with our co-contractors that they </span></div><div style="line-height:10pt;position:var(--position);top:508pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">undertake to pass on confidentiality obligations to their own co-contractors. </span></div><div style="line-height:10pt;position:var(--position);top:524pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Such contracts therefore expose us to the risk of having the third parties concerned (i)&#160;claim the benefit of </span></div><div style="line-height:10pt;position:var(--position);top:534pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">intellectual property rights on our inventions or other intellectual property rights, (ii)&#160;fail to ensure the </span></div><div style="line-height:10pt;position:var(--position);top:544pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">confidentiality of unpatented innovations or improvements of our confidential information and know-how, </span></div><div style="line-height:10pt;position:var(--position);top:554pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(iii)&#160;disclose our trade secrets to our competitors or independently develop these trade secrets and/or (iv)&#160;violate </span></div><div style="line-height:10pt;position:var(--position);top:564pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">such agreements, without our having an appropriate solution for such violations. </span></div><div style="line-height:10pt;position:var(--position);top:580pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Consequently, our rights to our confidential information, trade secrets and know-how may not confer the </span></div><div style="line-height:10pt;position:var(--position);top:590pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">expected protection against competition and we cannot guarantee with certainty that: </span></div><div style="line-height:10pt;position:var(--position);top:606pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">our knowledge and trade secrets will not be obtained, stolen, circumvented, transmitted or used </span></span></div><div style="line-height:10pt;position:var(--position);top:616pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">without our authorization; </span></div><div style="line-height:10pt;position:var(--position);top:632pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">our competitors have not already developed similar technologies or products, or ones similar in nature </span></span></div><div style="line-height:10pt;position:var(--position);top:642pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">or purpose to ours; </span></div><div style="line-height:10pt;position:var(--position);top:658pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">no co-contracting party will claim the benefit of all or part of the intellectual property rights relating to </span></span></div><div style="line-height:10pt;position:var(--position);top:668pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">inventions, knowledge or results that we hold in our own right or in co-ownership, or for which we </span></div><div style="line-height:10pt;position:var(--position);top:678pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">would be entitled to a license; or </span></div><div style="line-height:10pt;position:var(--position);top:694pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">our employees will not claim rights or payment of additional compensation or fair price for inventions </span></span></div><div style="line-height:10pt;position:var(--position);top:704pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">in the creation of which they participated. </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">38</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The occurrence of one or more of these risks could have a material adverse effect on our business, outlook, </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">financial position, income and growth. </span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Intellectual property rights do not address all potential threats to our competitive advantage. </span></div><div style="line-height:10pt;position:var(--position);top:114pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual </span></div><div style="line-height:10pt;position:var(--position);top:124pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">property rights have limitations, and may not adequately protect our business, or permit us to maintain our </span></div><div style="line-height:10pt;position:var(--position);top:134pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">competitive advantage. The following examples are illustrative. </span></div><div style="line-height:10pt;position:var(--position);top:150pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">Competitors may be able to formulate compositions that are similar to ours but that are not covered by </span></span></div><div style="line-height:10pt;position:var(--position);top:160pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">our intellectual property rights. </span></div><div style="line-height:10pt;position:var(--position);top:176pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">Competitors may independently develop similar or alternative compositions or otherwise circumvent </span></span></div><div style="line-height:10pt;position:var(--position);top:186pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">any of our applications or registrations without infringing our intellectual property rights. </span></div><div style="line-height:1pt;position:var(--position);top:200.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="line-height:10pt;position:var(--position);top:201.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">We or any of our collaboration partners might not have been the first to conceive and reduce to </span></span></div><div style="line-height:10pt;position:var(--position);top:211.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">practice the inventions covered by the patents or patent applications that we own, license or will own </span></div><div style="line-height:10pt;position:var(--position);top:221.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">or license. </span></div><div style="line-height:10pt;position:var(--position);top:237.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">We or any of our collaboration partners might not have been the first to file patent applications </span></span></div><div style="line-height:10pt;position:var(--position);top:247.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">covering certain of the patents or patent applications that we or they own or have licensed, or will own </span></div><div style="line-height:10pt;position:var(--position);top:257.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">or will have licensed. </span></div><div style="line-height:10pt;position:var(--position);top:273.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">It is possible that any pending patent applications that we have filed, or will file, will not lead to issued </span></span></div><div style="line-height:10pt;position:var(--position);top:283.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">patents. </span></div><div style="line-height:10pt;position:var(--position);top:299.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">Issued patents that we own may not provide us with any competitive advantage, or may be held invalid </span></span></div><div style="line-height:10pt;position:var(--position);top:309.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">or unenforceable, as a result of legal challenges by our competitors. </span></div><div style="line-height:10pt;position:var(--position);top:325.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">Our competitors might conduct research and development activities in countries where we do not have </span></span></div><div style="line-height:10pt;position:var(--position);top:335.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">patent rights, or in countries where research and development safe harbor laws exist, and then use the </span></div><div style="line-height:10pt;position:var(--position);top:345.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">information learned from such activities to develop competitive products for sale in our major </span></div><div style="line-height:10pt;position:var(--position);top:355.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">commercial markets. </span></div><div style="line-height:10pt;position:var(--position);top:371.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">Ownership of our patents or patent applications may be challenged by third parties. </span></span></div><div style="line-height:10pt;position:var(--position);top:387.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">We may infringe on the patents of third parties or pending or future applications of third parties, if </span></span></div><div style="line-height:10pt;position:var(--position);top:397.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">issued, and the patents of third parties or pending or future applications of third parties, if issued, may </span></div><div style="line-height:10pt;position:var(--position);top:407.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">have an adverse effect on our business. </span></div><div style="line-height:10pt;position:var(--position);top:435.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Risks Related to Legal and Compliance </span></div><div style="line-height:10pt;position:var(--position);top:451.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Our business is subject to a restrictive and changing regulatory framework. </span></div><div style="line-height:10pt;position:var(--position);top:467.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">One of the major issues for a growing company like ours is to successfully develop, alone or with the help of </span></div><div style="line-height:10pt;position:var(--position);top:477.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">partners, products incorporating our technologies in an increasingly restrictive regulatory environment. The </span></div><div style="line-height:10pt;position:var(--position);top:487.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">pharmaceutical industry faces constant changes in its legal and regulatory environment and increased oversight by </span></div><div style="line-height:10pt;position:var(--position);top:497.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the competent authorities, such as the National Agency for Medicines and Health Products Safety (&#8220;ANSM&#8221;) in </span></div><div style="line-height:10pt;position:var(--position);top:507.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">France and other national competent authorities of EU Member States and the EMA in the European Union, the </span></div><div style="line-height:10pt;position:var(--position);top:517.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">FDA in the United States or the PMDA in Japan, and other regulatory authorities in the rest of the world. At the </span></div><div style="line-height:10pt;position:var(--position);top:527.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">same time, the public is demanding more guarantees and transparency regarding drug safety and efficacy. This may </span></div><div style="line-height:10pt;position:var(--position);top:537.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">at any time lead to a more restrictive regulatory environment for our drug candidates which may have a material </span></div><div style="line-height:10pt;position:var(--position);top:547.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">adverse effect on business, financial position, income, growth and outlook. </span></div><div style="line-height:10pt;position:var(--position);top:563.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Health authorities oversee preclinical studies, clinical trials, pharmaceutical operations of companies, and drug </span></div><div style="line-height:10pt;position:var(--position);top:573.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">manufacturing, commercialization and distribution. This increasing stringency of the legislative and regulatory </span></div><div style="line-height:10pt;position:var(--position);top:583.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">framework is common worldwide; however, requirements may vary from country to country. In particular, health </span></div><div style="line-height:10pt;position:var(--position);top:593.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">authorities, especially the ANSM, EMA, FDA and PMDA, have imposed increasingly burdensome requirements in </span></div><div style="line-height:10pt;position:var(--position);top:603.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">terms of the volume and quality of data required to demonstrate the efficacy and safety of a product. These increased </span></div><div style="line-height:10pt;position:var(--position);top:613.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">requirements may have thus reduced the number of products authorized in comparison to the number of applications </span></div><div style="line-height:10pt;position:var(--position);top:623.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">filed. The risk/benefit ratio of products on the market is also subject to continuous monitoring and periodic review </span></div><div style="line-height:10pt;position:var(--position);top:633.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">after their authorization. The delayed discovery of problems not identified at the research and development or initial </span></div><div style="line-height:10pt;position:var(--position);top:643.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">assessment stage can lead at any time to marketing restrictions, suspension of the marketing or withdrawal of the </span></div><div style="line-height:10pt;position:var(--position);top:653.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">products from the market, and to an increased risk of litigation. </span></div><div style="line-height:10pt;position:var(--position);top:669.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Therefore, the authorization process is long and expensive; it can take many years and the result is not </span></div><div style="line-height:10pt;position:var(--position);top:679.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">predictable and likely to continuously evolve. Insofar as new legal or regulatory provisions would result in an </span></div><div style="line-height:10pt;position:var(--position);top:689.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">increase in the requirements and associated costs for obtaining and maintaining product marketing authorizations or </span></div><div style="line-height:10pt;position:var(--position);top:699.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">would limit the targeted indications for a product that a product targets or the economic value of a new product to its </span></div><div style="line-height:10pt;position:var(--position);top:709.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">inventor, the growth prospects for the pharmaceutical industry, and us, could be reduced. If we experience delays </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">39</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">completing, or if we terminate early, any of our clinical trials, or if we are required to conduct additional clinical </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">trials, the commercial prospects for our drug candidates may be harmed and our ability to generate product revenue </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">will be delayed. The occurrence of one or more of these risks could have a material adverse effect on our business, </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">outlook, financial position, income and growth. </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">We are subject to healthcare laws and regulations which may require substantial compliance efforts and could </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">expose us to criminal sanctions, civil and administrative penalties, contractual damages, reputational harm and </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">diminished profits and future earnings, among other penalties. </span></div><div style="line-height:10pt;position:var(--position);top:154pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Healthcare providers, including physicians, and others will play a primary role in the recommendation and </span></div><div style="line-height:10pt;position:var(--position);top:164pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">prescription of our products, if approved. Our arrangements with such persons and third-party payors and our </span></div><div style="line-height:10pt;position:var(--position);top:174pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">general business operations will expose us to broadly applicable fraud and abuse and other healthcare laws and </span></div><div style="line-height:10pt;position:var(--position);top:184pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regulations that may constrain the business or financial arrangements and relationships through which we research, </span></div><div style="line-height:10pt;position:var(--position);top:194pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">market, sell and distribute our drugs, if we obtain marketing approval. Restrictions under applicable U.S. federal, </span></div><div style="line-height:10pt;position:var(--position);top:204pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">state and foreign healthcare laws and regulations include, but are not limited to, the following: </span></div><div style="line-height:10pt;position:var(--position);top:220pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from </span></span></div><div style="line-height:10pt;position:var(--position);top:230pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">knowingly and willfully soliciting, offering, receiving or providing remuneration, including any </span></div><div style="line-height:10pt;position:var(--position);top:240pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">kickback, bribe or rebate, directly or indirectly, in cash or in kind, to induce or reward, or in return for, </span></div><div style="line-height:10pt;position:var(--position);top:250pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">either the referral of an individual for, or the purchase or lease, order or recommendation of, any item, </span></div><div style="line-height:10pt;position:var(--position);top:260pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">good, facility or service, for which payment may be made under federal healthcare programs such as </span></div><div style="line-height:10pt;position:var(--position);top:270pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or </span></div><div style="line-height:10pt;position:var(--position);top:280pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">specific intent to violate it in order to have committed a violation; </span></div><div style="line-height:10pt;position:var(--position);top:296pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">U.S. federal civil and criminal false claims laws and civil monetary penalties laws, including the civil </span></span></div><div style="line-height:10pt;position:var(--position);top:306pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">False Claims Act (&#8220;FCA&#8221;), which impose criminal and civil penalties, including those from civil </span></div><div style="line-height:10pt;position:var(--position);top:316pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly </span></div><div style="line-height:10pt;position:var(--position);top:326pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">presenting, or causing to be presented, claims for payment that are false or fraudulent or making a false </span></div><div style="line-height:10pt;position:var(--position);top:336pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">statement to avoid, decrease, or conceal an obligation to pay money to the federal government. For </span></div><div style="line-height:10pt;position:var(--position);top:346pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">example, pharmaceutical companies have been prosecuted under the FCA in connection with their </span></div><div style="line-height:10pt;position:var(--position);top:356pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">alleged off-label promotion of drugs, purportedly concealing price concessions in the pricing </span></div><div style="line-height:10pt;position:var(--position);top:366pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">information submitted to the government for government price reporting purposes, and allegedly </span></div><div style="line-height:10pt;position:var(--position);top:376pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">providing free product to customers with the expectation that the customers would bill federal health </span></div><div style="line-height:10pt;position:var(--position);top:386pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">care programs for the product. In addition, the government may assert that a claim including items and </span></div><div style="line-height:10pt;position:var(--position);top:396pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent </span></div><div style="line-height:10pt;position:var(--position);top:406pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">claim for purposes of the FCA; </span></div><div style="line-height:10pt;position:var(--position);top:422pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the U.S. federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which </span></span></div><div style="line-height:10pt;position:var(--position);top:432pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">created additional federal criminal statutes that impose criminal and civil liability for, among other </span></div><div style="line-height:10pt;position:var(--position);top:442pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">things, executing or attempting to execute a scheme to defraud any healthcare benefit program or </span></div><div style="line-height:10pt;position:var(--position);top:452pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">knowingly and willingly falsifying, concealing or covering up a material fact or making false </span></div><div style="line-height:10pt;position:var(--position);top:462pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or </span></div><div style="line-height:10pt;position:var(--position);top:472pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">entity does not need to have actual knowledge of the healthcare fraud statute implemented under </span></div><div style="line-height:10pt;position:var(--position);top:482pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">HIPAA or specific intent to violate it in order to have committed a violation; </span></div><div style="line-height:10pt;position:var(--position);top:498pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act </span></span></div><div style="line-height:10pt;position:var(--position);top:508pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">(&#8220;HITECH&#8221;) and its implementing regulations, which impose certain requirements on covered entities </span></div><div style="line-height:10pt;position:var(--position);top:518pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">and their business associates, as well as their covered subcontractors, including mandatory contractual </span></div><div style="line-height:10pt;position:var(--position);top:528pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">terms, with respect to safeguarding the privacy, security and transmission of individually identifiable </span></div><div style="line-height:10pt;position:var(--position);top:538pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">health information; </span></div><div style="line-height:10pt;position:var(--position);top:554pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">federal and state consumer protection and unfair competition laws, which broadly regulate marketplace </span></span></div><div style="line-height:10pt;position:var(--position);top:564pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">activities and activities that potentially harm consumers; </span></div><div style="line-height:10pt;position:var(--position);top:580pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">U.S. federal transparency requirements under the Physician Payments Sunshine Act, enacted as part of </span></span></div><div style="line-height:10pt;position:var(--position);top:590pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">the Patient Protection and Affordable Care Act, as amended by the Health Care and Education </span></div><div style="line-height:10pt;position:var(--position);top:600pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">Reconciliation Act, or collectively the (&#8220;ACA&#8221;), that require applicable manufacturers of covered </span></div><div style="line-height:10pt;position:var(--position);top:610pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">drugs, devices, biologics and medical supplies for which payment is available under Medicare, </span></div><div style="line-height:10pt;position:var(--position);top:620pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to track and annually </span></div><div style="line-height:10pt;position:var(--position);top:630pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">report to Concerned Member States (&#8220;CMS&#8221;) payments and other transfers of value provided to </span></div><div style="line-height:10pt;position:var(--position);top:640pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">physicians, certain other healthcare providers (such as physicians assistants and nurse practitioners), </span></div><div style="line-height:10pt;position:var(--position);top:650pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">and teaching hospitals, and require certain manufacturers and group purchasing organizations to report </span></div><div style="line-height:10pt;position:var(--position);top:660pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">annually certain ownership and investment interests held by physicians or their immediate family </span></div><div style="line-height:10pt;position:var(--position);top:670pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">members; and </span></div><div style="line-height:1pt;position:var(--position);top:684.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="line-height:10pt;position:var(--position);top:685.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">analogous state or foreign laws and regulations, such as state and foreign anti-kickback and false </span></span></div><div style="line-height:10pt;position:var(--position);top:695.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">claims laws, which may apply to items or services reimbursed by any third-party payor, including </span></div><div style="line-height:10pt;position:var(--position);top:705.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">commercial insurers, state and foreign marketing and/or transparency laws applicable to manufacturers </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">40</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">that may be broader in scope than the U.S. federal requirements, state and foreign laws that require </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">regulatory licenses to manufacture or distribute our products commercially and/or the registration of </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">pharmaceutical sales representatives in the jurisdiction, state and foreign laws that require </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">biopharmaceutical companies to comply with the biopharmaceutical industry&#8217;s voluntary compliance </span></div><div style="line-height:10pt;position:var(--position);top:112pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">guidelines and the relevant compliance guidance promulgated by the government and state and foreign </span></div><div style="line-height:10pt;position:var(--position);top:122pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">laws governing the privacy and security of health information in certain circumstances, many of which </span></div><div style="line-height:10pt;position:var(--position);top:132pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">differ from each other in significant ways and may not have the same effect as HIPAA, thus </span></div><div style="line-height:10pt;position:var(--position);top:142pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">complicating compliance efforts. </span></div><div style="line-height:10pt;position:var(--position);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Ensuring that our business arrangements with third parties comply with applicable healthcare laws and </span></div><div style="line-height:10pt;position:var(--position);top:168pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regulations will likely be costly. It cannot be excluded that governmental authorities will conclude that our business </span></div><div style="line-height:10pt;position:var(--position);top:178pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse </span></div><div style="line-height:10pt;position:var(--position);top:188pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">or other healthcare laws and regulations. If our operations were found to be in violation of any of these laws or any </span></div><div style="line-height:10pt;position:var(--position);top:198pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">other governmental regulations that may apply to us, we may be subject to significant civil, criminal and </span></div><div style="line-height:10pt;position:var(--position);top:208pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">administrative penalties, damages, fines, disgorgement, imprisonment, possible exclusion from government funded </span></div><div style="line-height:10pt;position:var(--position);top:218pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits </span></div><div style="line-height:10pt;position:var(--position);top:228pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and future earnings and curtailment of our operations, any of which could substantially disrupt our operations. If the </span></div><div style="line-height:10pt;position:var(--position);top:238pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">physicians or other providers or entities with whom we expect to do business are found not to be in compliance with </span></div><div style="line-height:10pt;position:var(--position);top:248pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from </span></div><div style="line-height:10pt;position:var(--position);top:258pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">government funded healthcare programs. We may incur significant costs achieving and maintaining compliance with </span></div><div style="line-height:10pt;position:var(--position);top:268pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">applicable federal and state privacy, security, and fraud laws. Any action against us for violation of these laws, even </span></div><div style="line-height:10pt;position:var(--position);top:278pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s </span></div><div style="line-height:10pt;position:var(--position);top:288pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">attention from the operation of our business. </span></div><div style="line-height:10pt;position:var(--position);top:304pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Current and future health reform measures could adversely affect our business operations. </span></div><div style="line-height:10pt;position:var(--position);top:320pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In the United States and some foreign jurisdictions there have been, and we expect there will continue to be, </span></div><div style="line-height:10pt;position:var(--position);top:330pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">several legislative and regulatory changes and proposed reforms of the healthcare system to contain costs, improve </span></div><div style="line-height:10pt;position:var(--position);top:340pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">quality, and expand access to care. For example, in March 2010, President Obama signed the ACA into law, which </span></div><div style="line-height:10pt;position:var(--position);top:350pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">substantially changed the way healthcare is financed by both governmental and private insurers and continues to </span></div><div style="line-height:10pt;position:var(--position);top:360pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">significantly impact the United States pharmaceutical industry. </span></div><div style="line-height:10pt;position:var(--position);top:376pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">There have been judicial, congressional and executive branch challenges to certain aspects of the ACA. For </span></div><div style="line-height:10pt;position:var(--position);top:386pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">example, on July 4, 2025, the One Big Beautiful Bill Act, or OBBBA, was signed into law, which narrowed access </span></div><div style="line-height:10pt;position:var(--position);top:396pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to ACA marketplace exchange enrollment and declined to extend the ACA enhanced advanced premium tax credits </span></div><div style="line-height:10pt;position:var(--position);top:406pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">that expired at the end of 2025, which, among other provisions in the law, are anticipated to reduce the number of </span></div><div style="line-height:10pt;position:var(--position);top:416pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Americans with health insurance.&#160; The OBBBA also is expected to reduce Medicaid spending and enrollment by </span></div><div style="line-height:10pt;position:var(--position);top:426pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">implementing work requirements for some beneficiaries, capping state-directed payments, reducing federal funding, </span></div><div style="line-height:10pt;position:var(--position);top:436pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and limiting provider taxes used to fund the program. Congress is considering proposed legislation intended to </span></div><div style="line-height:10pt;position:var(--position);top:446pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">further reduce healthcare costs with alternatives to replace the expired ACA subsidies.&#160; We expect that additional </span></div><div style="line-height:10pt;position:var(--position);top:456pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">U.S. federal healthcare reform measures will be adopted in the future. </span></div><div style="line-height:10pt;position:var(--position);top:472pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. </span></div><div style="line-height:10pt;position:var(--position);top:482pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">For example, on August&#160;2, 2011, the Budget Control Act of 2011 was signed into law which among other things, led </span></div><div style="line-height:10pt;position:var(--position);top:492pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to aggregate reductions in Medicare payments to providers. These reductions went into effect on April&#160;1, 2013 and&#160; </span></div><div style="line-height:10pt;position:var(--position);top:502pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">will remain in effect until 2032, unless additional Congressional action is taken. </span></div><div style="line-height:10pt;position:var(--position);top:518pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The current U.S. presidential administration is pursuing policies to reduce regulations and expenditures across </span></div><div style="line-height:10pt;position:var(--position);top:528pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">government. These actions, presently directed by executive orders or memoranda from the Office of Management </span></div><div style="line-height:10pt;position:var(--position);top:538pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and Budget, may propose policy changes that create additional uncertainty for our business. For example, the current </span></div><div style="line-height:10pt;position:var(--position);top:548pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">administration has announced agreements with pharmaceutical companies that require the drug manufacturers to </span></div><div style="line-height:10pt;position:var(--position);top:558pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">offer, through a direct-to-consumer platform (TrumpRx), U.S. patients and Medicaid programs prescription drug </span></div><div style="line-height:10pt;position:var(--position);top:568pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Most-Favored Nation pricing equal to or lower than those paid in other developed nations, with additional mandates </span></div><div style="line-height:10pt;position:var(--position);top:578pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for direct-to-patient discounts and repatriation of foreign revenues. Other recent actions and proposals include, for </span></div><div style="line-height:10pt;position:var(--position);top:588pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">example (1) reducing agency workforce and cut programs; (2) directing HHS and other agencies to lower </span></div><div style="line-height:10pt;position:var(--position);top:598pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">prescription drug costs through a variety of initiatives; (3) imposing tariffs on imported pharmaceutical products; </span></div><div style="line-height:10pt;position:var(--position);top:608pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and (4) as part of the Make America Healthy Again Commission&#8217;s Strategy Report released in September 2025, </span></div><div style="line-height:10pt;position:var(--position);top:618pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">working across government agencies to increase enforcement on direct-to-consumer pharmaceutical advertising. </span></div><div style="line-height:10pt;position:var(--position);top:628pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Additionally, the current administration recently called on Congress to enact &#8220;The Great Healthcare Plan,&#8221; to codify </span></div><div style="line-height:10pt;position:var(--position);top:638pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and expand Most-Favored Nation pricing, lower government subsidies to private insurance companies, increase </span></div><div style="line-height:10pt;position:var(--position);top:648pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">healthcare price transparency, expand pharmaceutical drugs available for over-the-counter purchase, and enact </span></div><div style="line-height:10pt;position:var(--position);top:658pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">restrictions on pharmacy benefit manager payment methodologies, among other things. These actions and policies </span></div><div style="line-height:10pt;position:var(--position);top:668pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">may significantly reduce U.S. drug prices, potentially impacting manufacturers&#8217; global pricing strategies and </span></div><div style="line-height:10pt;position:var(--position);top:678pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">profitability, while increasing their operational costs and compliance risks.&#160; In June 2024, in Loper Bright </span></div><div style="line-height:10pt;position:var(--position);top:688pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Enterprises v. Raimondo, the U.S. Supreme Court greatly reduced judicial deference to regulatory agencies, which </span></div><div style="line-height:10pt;position:var(--position);top:698pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">could increase successful legal challenges to federal regulations affecting our operations.&#160; </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">41</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">some cases, designed to encourage importation from other countries and bulk purchasing.&#160; </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We expect that other healthcare reform measures may be adopted in the future, which may result in more </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">product. Any reduction in reimbursement from Medicare or other government programs may result in a similar </span></div><div style="line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reduction in payments from private payors. The implementation of cost containment measures or other healthcare </span></div><div style="line-height:10pt;position:var(--position);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drug </span></div><div style="line-height:10pt;position:var(--position);top:168pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">candidates. </span></div><div style="line-height:10pt;position:var(--position);top:184pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In addition, on December 11, 2025, the European Commission, the Parliament and the European Council </span></div><div style="line-height:10pt;position:var(--position);top:194pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reached a political agreement on a comprehensive overhaul of EU pharmaceutical legislation (the &#8220;Pharma </span></div><div style="line-height:10pt;position:var(--position);top:204pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Package&#8221;). The reform has been under negotiation since the European Commission submitted its proposal in April </span></div><div style="line-height:10pt;position:var(--position);top:214pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">2023. This package - comprised of a new directive and regulation to replace existing legislation &#8211; aims to modernize </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:224pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the EU framework. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:151.36pt;position:var(--position);text-decoration:none;white-space:pre">The political agreement is still subject to formal approval by the European Parliament and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:234pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Council.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:106.13pt;position:var(--position);text-decoration:none;white-space:pre"> If approved in the form proposed, the Pharma Package will, among other changes, reduce the baseline </span></div><div style="line-height:10pt;position:var(--position);top:244pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">market protection period by one year, with limited opportunities for extensions; reshape the incentives regime for </span></div><div style="line-height:10pt;position:var(--position);top:254pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">orphan medicinal products; and expand the Bolar exemption. A decrease in market exclusivity opportunities for our </span></div><div style="line-height:10pt;position:var(--position);top:264pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">product candidates in the EU, combined with the expanded Bolar exemption, could open them to generic or </span></div><div style="line-height:10pt;position:var(--position);top:274pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">biosimilar competition earlier than under the current regime, potentially impacting reimbursement status and the </span></div><div style="line-height:10pt;position:var(--position);top:284pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">commercial prospects of our product candidates.</span></div><div style="line-height:10pt;position:var(--position);top:300pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">We are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other </span></div><div style="line-height:10pt;position:var(--position);top:310pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal </span></div><div style="line-height:10pt;position:var(--position);top:320pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">penalties, other remedial measures and legal expenses, which could adversely affect our business, results of </span></div><div style="line-height:10pt;position:var(--position);top:330pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">operations and financial condition. </span></div><div style="line-height:10pt;position:var(--position);top:346pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We are subject to other laws and regulations governing our international operations, including regulations </span></div><div style="line-height:10pt;position:var(--position);top:356pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">administered by the governments of the United States, and authorities in the European Union and in Japan, including </span></div><div style="line-height:10pt;position:var(--position);top:366pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">applicable export control regulations, economic sanctions on countries and persons, customs requirements and </span></div><div style="line-height:10pt;position:var(--position);top:376pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">currency exchange regulations, collectively referred to as the trade control laws. </span></div><div style="line-height:10pt;position:var(--position);top:392pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We are also subject to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act of 1977, as </span></div><div style="line-height:10pt;position:var(--position);top:402pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">amended (&#8220;FCPA&#8221;), which prohibits any U.S. individual or business from paying, offering, or authorizing payment </span></div><div style="line-height:10pt;position:var(--position);top:412pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">or offering of anything of value, directly or indirectly, to any foreign official, political party, or candidate for the </span></div><div style="line-height:10pt;position:var(--position);top:422pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in </span></div><div style="line-height:10pt;position:var(--position);top:432pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">obtaining or retaining business, and other state and national anti-bribery and anti-money laundering laws in the </span></div><div style="line-height:10pt;position:var(--position);top:442pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">countries in which we conduct activities, including the French anti-corruption laws: </span></div><div style="line-height:10pt;position:var(--position);top:458pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">Article 433-1 of the French Criminal Code (bribery of domestic public officials); </span></span></div><div style="line-height:1pt;position:var(--position);top:472.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="line-height:10pt;position:var(--position);top:473.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">Article 433-2 of the French Criminal Code (influence peddling involving domestic public officials); </span></span></div><div style="line-height:10pt;position:var(--position);top:489.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">Article 434-9 of the French Criminal Code (bribery of domestic judicial staff); </span></span></div><div style="line-height:10pt;position:var(--position);top:505.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">Article 434-9-1 of the French Criminal Code (influence peddling involving domestic judicial staff); </span></span></div><div style="line-height:10pt;position:var(--position);top:521.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">Articles 435-1 and 435-3 of the French Criminal Code (bribery of foreign or international public </span></span></div><div style="line-height:10pt;position:var(--position);top:531.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">officials); </span></div><div style="line-height:10pt;position:var(--position);top:547.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">Articles 435-7 and 435-9 of the French Criminal Code (bribery of foreign or international judicial </span></span></div><div style="line-height:10pt;position:var(--position);top:557.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">staff); </span></div><div style="line-height:10pt;position:var(--position);top:573.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">Articles 435-2, 435-4, 435-8 and 435-10 of the French Criminal Code (active and passive influence </span></span></div><div style="line-height:10pt;position:var(--position);top:583.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">peddling involving foreign or international public officials and foreign or international judicial staff); </span></div><div style="line-height:10pt;position:var(--position);top:599.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">Articles 445-1 and 445-2 of the French Criminal Code (bribery of private individuals); and </span></span></div><div style="line-height:10pt;position:var(--position);top:615.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">French Law No.&#160;2016-1691 of December&#160;9, 2016 on Transparency, the Fight Against Corruption and </span></span></div><div style="line-height:10pt;position:var(--position);top:625.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">the Modernization of the Economy (Sapin 2 Law), which provides for numerous new obligations for </span></div><div style="line-height:10pt;position:var(--position);top:635.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">large companies such as the obligation to draw up and adopt a code of conduct defining and </span></div><div style="line-height:10pt;position:var(--position);top:645.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">illustrating the different types of behavior to be proscribed as being likely to characterize acts of </span></div><div style="line-height:10pt;position:var(--position);top:655.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">corruption or influence peddling, to set up an internal warning system designed to enable the </span></div><div style="line-height:10pt;position:var(--position);top:665.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">collections of reports from employees relating to the existence of conduct or situations contrary to the </span></div><div style="line-height:10pt;position:var(--position);top:675.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">company&#8217;s code of conduct, to set up accounting control procedures, whether internal or external, </span></div><div style="line-height:10pt;position:var(--position);top:685.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">designed to ensure that the books, registers and accounts are not used to conceal acts of corruption or </span></div><div style="line-height:10pt;position:var(--position);top:695.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">influence peddling, to set up a disciplinary system for sanctioning company employees in the event of </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">42</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">a breach of the company&#8217;s code of conduct or a system for monitoring and evaluating the measures </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">implemented. </span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The FCPA also obligates companies whose securities are listed in the United States to comply with accounting </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">accounting controls for international operations. Activities that violate the FCPA, even if they occur wholly outside </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the United States, can result in criminal and civil fines, imprisonment, disgorgement, oversight, and debarment from </span></div><div style="line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">government contracts. The scope and enforcement of these laws is uncertain and subject to rapid change. </span></div><div style="line-height:10pt;position:var(--position);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Responding to investigations can be both resource and time consuming and can divert management&#8217;s attention from </span></div><div style="line-height:10pt;position:var(--position);top:168pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the business. Any such investigation or settlement could increase our costs or otherwise have a material adverse </span></div><div style="line-height:10pt;position:var(--position);top:178pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">effect on our business, outlook, financial position, income and growth. </span></div><div style="line-height:10pt;position:var(--position);top:194pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The FCPA and other anti-corruption laws are interpreted broadly and prohibit companies and their employees, </span></div><div style="line-height:10pt;position:var(--position);top:204pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or </span></div><div style="line-height:10pt;position:var(--position);top:214pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage </span></div><div style="line-height:10pt;position:var(--position);top:224pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">third parties to sell our products outside the United States, to conduct clinical trials and/or to obtain necessary </span></div><div style="line-height:10pt;position:var(--position);top:234pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">permits, licenses, patent registrations, and other regulatory approvals. We have direct or indirect interactions with </span></div><div style="line-height:10pt;position:var(--position);top:244pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">officials and employees of government agencies or government-affiliated hospitals, universities, and other </span></div><div style="line-height:10pt;position:var(--position);top:254pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, </span></div><div style="line-height:10pt;position:var(--position);top:264pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. </span></div><div style="line-height:10pt;position:var(--position);top:280pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">There is no complete assurance that we will be effective in ensuring our compliance with all applicable anti-</span></div><div style="line-height:10pt;position:var(--position);top:290pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">corruption laws, including the FCPA, the French anti-corruption laws or other legal requirements, including trade </span></div><div style="line-height:10pt;position:var(--position);top:300pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">control laws. If we are not in compliance with the FCPA, the French anti-corruption laws and other anti-corruption </span></div><div style="line-height:10pt;position:var(--position);top:310pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">laws or trade control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and </span></div><div style="line-height:10pt;position:var(--position);top:320pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">remedial measures and legal expenses, which could have an adverse impact on our business, financial condition, </span></div><div style="line-height:10pt;position:var(--position);top:330pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">results of operations and liquidity. Likewise, any investigation of any potential violations of the FCPA, the French </span></div><div style="line-height:10pt;position:var(--position);top:340pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">anti-corruption laws, other anti-corruption laws or trade control laws by U.S. or other authorities could also have an </span></div><div style="line-height:10pt;position:var(--position);top:350pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">adverse impact on our reputation, our business, results of operations and financial condition. </span></div><div style="line-height:10pt;position:var(--position);top:366pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In addition, changes in our products and drug candidates or changes in applicable export or import laws and </span></div><div style="line-height:10pt;position:var(--position);top:376pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regulations may create delays in the introduction or provision of our products and drug candidates in other </span></div><div style="line-height:10pt;position:var(--position);top:386pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">jurisdictions, prevent others from using our products and drug candidates or, in some cases, prevent the export or </span></div><div style="line-height:10pt;position:var(--position);top:396pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">import of our products and drug candidates to certain countries, governments or persons altogether. Any limitation </span></div><div style="line-height:10pt;position:var(--position);top:406pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">on our ability to export or provide our products and drug candidates could adversely affect our business, financial </span></div><div style="line-height:10pt;position:var(--position);top:416pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">condition and results of operations. </span></div><div style="line-height:10pt;position:var(--position);top:432pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Product liability and other lawsuits could divert our resources, result in substantial liabilities and reduce the </span></div><div style="line-height:10pt;position:var(--position);top:442pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">commercial potential of our drug candidates. </span></div><div style="line-height:10pt;position:var(--position);top:458pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The risk that we may be sued on product liability claims is inherent in the development and commercialization </span></div><div style="line-height:10pt;position:var(--position);top:468pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of our drug candidates. Side effects of, or manufacturing defects in, drugs that we develop could result in the </span></div><div style="line-height:10pt;position:var(--position);top:478pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">deterioration of a patient&#8217;s condition, injury or even death. For example, our liability could be sought after by </span></div><div style="line-height:10pt;position:var(--position);top:488pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">patients participating in the clinical trials of the drug candidates tested, who suffer from unexpected side effects </span></div><div style="line-height:10pt;position:var(--position);top:498pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">resulting from the administration of these drugs. In addition, we could face liability due to undetected side-effects </span></div><div style="line-height:10pt;position:var(--position);top:508pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">caused by the interaction of our drugs with other drugs following release of the drug candidate to the market. Once a </span></div><div style="line-height:10pt;position:var(--position);top:518pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">product is approved for sale and commercialized, the likelihood of product liability lawsuits increases. Criminal or </span></div><div style="line-height:10pt;position:var(--position);top:528pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">civil proceedings might also be filed against us by patients, regulatory authorities, biopharmaceutical companies and </span></div><div style="line-height:10pt;position:var(--position);top:538pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">any other third party using or marketing our drugs. Physicians and patients may not comply with any warnings that </span></div><div style="line-height:10pt;position:var(--position);top:548pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">identify known potential adverse effects and patients who should not use our drug candidates. These actions could </span></div><div style="line-height:10pt;position:var(--position);top:558pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">include claims resulting from actions by our partners, licensees and subcontractors, over which we have little or no </span></div><div style="line-height:10pt;position:var(--position);top:568pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">control. These lawsuits may divert our management from pursuing our business strategy and may be costly to </span></div><div style="line-height:10pt;position:var(--position);top:578pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">defend. In addition, if we are held liable in any of these lawsuits, we may incur substantial liabilities, may be forced </span></div><div style="line-height:10pt;position:var(--position);top:588pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to limit or forgo further commercialization of the affected products and may suffer damage to our reputation. </span></div><div style="line-height:10pt;position:var(--position);top:604pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We maintain product liability insurance coverage for our clinical trials at levels which we believe are </span></div><div style="line-height:10pt;position:var(--position);top:614pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">appropriate for our clinical trials. Nevertheless, we cannot guarantee that the insurance policy taken out or the </span></div><div style="line-height:10pt;position:var(--position);top:624pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">indemnification (that may be contractually limited) granted by our subcontractors will be sufficient to cover the </span></div><div style="line-height:10pt;position:var(--position);top:634pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">claims that could be brought against us or losses we may suffer. </span></div><div style="line-height:10pt;position:var(--position);top:650pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">If our liability, or that of our partners, licensees and subcontractors, was thereby activated, if we or our </span></div><div style="line-height:10pt;position:var(--position);top:660pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">partners, licensees and subcontractors were unable to obtain and maintain appropriate insurance coverage at an </span></div><div style="line-height:10pt;position:var(--position);top:670pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">acceptable cost or protect ourselves in any way against liability claims, this would seriously affect the </span></div><div style="line-height:10pt;position:var(--position);top:680pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">commercialization of our products and, more generally, have a material adverse effect on our business, income, </span></div><div style="line-height:10pt;position:var(--position);top:690pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">financial position and outlook for growth. </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">43</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">We and the third parties with whom we work are subject to stringent and evolving U.S. and foreign laws, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regulations, rules, contractual obligations, industry standards, policies and other obligations related to data </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">privacy and security. Our (or the third parties with whom we work) actual or perceived failure to comply with </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">such obligations could lead to regulatory investigations or actions; litigation (including class claims) and mass </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:112pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">arbitration demands; fines and penalties; disruptions of our business operations; reputational harm; loss of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:122pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">revenue or profits; and other adverse business consequences. </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In the ordinary course of business, we (and others on our behalf) collect, receive, store, process, generate, use, </span></div><div style="line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">transfer, archive, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) </span></div><div style="line-height:10pt;position:var(--position);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">personal data and other sensitive information, including proprietary and confidential business data, trade secrets, </span></div><div style="line-height:10pt;position:var(--position);top:168pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">intellectual property, sensitive third-party data, personal data/personal information (including data we collected </span></div><div style="line-height:10pt;position:var(--position);top:178pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">about trial participants in connection with clinical trials), business plans, transactions, and financial information </span></div><div style="line-height:10pt;position:var(--position);top:188pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(collectively, sensitive data). </span></div><div style="line-height:10pt;position:var(--position);top:204pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our data processing activities subjects us to numerous data privacy and security obligations, such as various </span></div><div style="line-height:10pt;position:var(--position);top:214pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual </span></div><div style="line-height:10pt;position:var(--position);top:224pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">requirements, and other obligations relating to data privacy and security. New data privacy and security laws may be </span></div><div style="line-height:10pt;position:var(--position);top:234pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">proposed or enacted.</span></div><div style="line-height:10pt;position:var(--position);top:250pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In the United States, federal, state, and local governments have enacted numerous data privacy and security </span></div><div style="line-height:10pt;position:var(--position);top:260pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section&#160;5 </span></div><div style="line-height:10pt;position:var(--position);top:270pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). For example, the California </span></div><div style="line-height:10pt;position:var(--position);top:280pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;) requires businesses to provide specific disclosures in privacy notices and </span></div><div style="line-height:10pt;position:var(--position);top:290pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">honor requests of California residents to exercise certain privacy rights. The CCPA provides for fines and allows </span></div><div style="line-height:10pt;position:var(--position);top:300pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">private litigants affected by certain data breaches to recover significant statutory damages.&#160; </span></div><div style="line-height:10pt;position:var(--position);top:316pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Numerous other states have also passed comprehensive privacy laws, and similar laws are being considered in </span></div><div style="line-height:10pt;position:var(--position);top:326pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">several other states, as well as at the federal and local levels. While the CCPA and other comprehensive U.S. state </span></div><div style="line-height:10pt;position:var(--position);top:336pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">privacy laws exempt some data processed in the context of clinical trials, these developments may further </span></div><div style="line-height:10pt;position:var(--position);top:346pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">complicate compliance efforts and may increase legal risk and compliance costs for us and the third parties upon </span></div><div style="line-height:10pt;position:var(--position);top:356pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">whom we rely. </span></div><div style="line-height:10pt;position:var(--position);top:372pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Outside the United States, an increasing number of laws, regulations, and industry standards may govern data </span></div><div style="line-height:10pt;position:var(--position);top:382pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">privacy and security. For example, among other laws, the European Union&#8217;s Regulation (EU) 2016/679 of 27 April </span></div><div style="line-height:10pt;position:var(--position);top:392pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of </span></div><div style="line-height:10pt;position:var(--position);top:402pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">such data, as amended (&#8220;EU GDPR&#8221;), the United Kingdom&#8217;s GDPR (&#8220;UK GDPR&#8221;) (collectively, the EU GDPR and </span></div><div style="line-height:10pt;position:var(--position);top:412pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the UK GDPR are the &#8220;GDPR&#8221;), Brazil&#8217;s General Data Protection Law (Lei Geral de Prote&#231;&#227;o de Dados Pessoais, or </span></div><div style="line-height:10pt;position:var(--position);top:422pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8220;LGPD&#8221;) (Law No.&#160;13,709/2018), Canada&#8217;s Personal Information Protection and Electronic Documents Act </span></div><div style="line-height:10pt;position:var(--position);top:432pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(&#8220;PIPEDA&#8221;), and China&#8217;s Personal Information Protection Law (&#8220;PIPL&#8221;) impose strict requirements for processing </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:442pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">personal data. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.98pt;position:var(--position);text-decoration:none;white-space:pre">In Europe, the Network and Information Security Directive (&#8220;NIS2&#8221;) regulates resilience and incident </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:452pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">response capabilities of entities operating in a number of sectors, including the health sector. Non-compliance with </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:462pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">NIS2 may lead up to administrative fines of a maximum of 10 million Euros or up to 2% of the total worldwide </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:472pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">revenue of the preceding fiscal year.</span></div><div style="line-height:10pt;position:var(--position);top:488pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The collection and use of personal health data in the European Union and the United Kingdom is governed by </span></div><div style="line-height:10pt;position:var(--position);top:498pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the provisions of the GDPR. Under the GDPR, companies may face temporary or definitive bans on data processing </span></div><div style="line-height:10pt;position:var(--position);top:508pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and other corrective actions; fines of up to &#8364;20&#160;million under the EU GDPR, 17.5 million pounds sterling under the </span></div><div style="line-height:10pt;position:var(--position);top:518pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">UK GDPR or, in each case, 4% of annual global revenue, whichever is greater; or private litigation related to </span></div><div style="line-height:10pt;position:var(--position);top:528pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">processing of personal data brought by classes of data subjects or consumer protection organizations authorized at </span></div><div style="line-height:10pt;position:var(--position);top:538pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">law to represent their interests. We also engage in clinical trial activities in other foreign jurisdictions.&#160; </span></div><div style="line-height:10pt;position:var(--position);top:554pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In addition, we may be unable to transfer personal data from Europe and other jurisdictions to the United </span></div><div style="line-height:10pt;position:var(--position);top:564pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">States or other third party countries in which local data privacy laws are less stringent due to limitations on cross-</span></div><div style="line-height:10pt;position:var(--position);top:574pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">border data flows. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the </span></div><div style="line-height:10pt;position:var(--position);top:584pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">transfer of personal data to other countries. In particular, the European Economic Area ("EEA") and the United </span></div><div style="line-height:10pt;position:var(--position);top:594pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Kingdom (&#8220;UK&#8221;) have significantly restricted the transfer of personal data to countries whose privacy laws it </span></div><div style="line-height:10pt;position:var(--position);top:604pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">believes are inadequate. Other jurisdictions may adopt or have adopted similarly stringent data localization and </span></div><div style="line-height:10pt;position:var(--position);top:614pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer </span></div><div style="line-height:10pt;position:var(--position);top:624pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">personal data from the EEA and UK to the United States in compliance with law, such as the EU-U.S. Trans-</span></div><div style="line-height:10pt;position:var(--position);top:634pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Atlantic Data Privacy Framework, the UK&#8217;s International Data Transfer Agreement, or the EEA and UK&#8217;s standard </span></div><div style="line-height:10pt;position:var(--position);top:644pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">contractual clauses, these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or </span></div><div style="line-height:10pt;position:var(--position);top:654pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">rely on these measures to lawfully transfer personal data to the United States or other third party countries. If there is </span></div><div style="line-height:10pt;position:var(--position);top:664pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the United States, </span></div><div style="line-height:10pt;position:var(--position);top:674pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse </span></div><div style="line-height:10pt;position:var(--position);top:684pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our </span></div><div style="line-height:10pt;position:var(--position);top:694pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">business or data processing activities to other jurisdictions at significant expense, increased exposure to regulatory </span></div><div style="line-height:10pt;position:var(--position);top:704pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">44</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">parties, and injunctions against our processing or transferring of personal data necessary to operate our business. </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Some European regulators have prevented companies from transferring personal data out of Europe for allegedly </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">violating the EU GDPR&#8217;s cross-border data transfer limitations. </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Additionally, the U.S. Department of Justice issued a rule entitled the Preventing Access to U.S. Sensitive </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Personal Data and Government-Related Data by Countries of Concern or Covered Persons, which places additional </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">restriction on certain data transactions involving countries of concern (e.g., China, Russia, Iran) and covered persons </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">that may impact certain business activities such as vendor engagements, sale or sharing of data, employment of </span></div><div style="line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">certain individuals, and investor agreements. Violations of the rule could lead to significant civil and criminal fines </span></div><div style="line-height:10pt;position:var(--position);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and penalties. The rule applies regardless of whether data is anonymized, key-coded, pseudonymized, de-identified </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:168pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">or encrypted, which presents particular challenges for companies like ours and may </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:407.99pt;position:var(--position);text-decoration:none;white-space:pre">impact o</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:442.66pt;position:var(--position);text-decoration:none;white-space:pre">ur ability to transfer </span></div><div style="line-height:10pt;position:var(--position);top:178pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">data in connection with certain transactions or agreements.</span></div><div style="line-height:10pt;position:var(--position);top:194pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In addition to data privacy and security laws, we are contractually subject to industry standards adopted by </span></div><div style="line-height:10pt;position:var(--position);top:204pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">industry groups and may become subject to such obligations in the future. Depending upon the context, we may also </span></div><div style="line-height:10pt;position:var(--position);top:214pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">be bound by other contractual obligations related to data privacy and security, and our efforts to comply with such </span></div><div style="line-height:10pt;position:var(--position);top:224pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">obligations may not be successful. </span></div><div style="line-height:10pt;position:var(--position);top:240pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We publish and may publish privacy policies, marketing materials, whitepapers, and other statements, such as </span></div><div style="line-height:10pt;position:var(--position);top:250pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">compliance with certain certifications or self-regulatory principles, concerning data privacy and security. Regulators </span></div><div style="line-height:10pt;position:var(--position);top:260pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">in the United States are increasingly scrutinizing these statements, and if these policies, materials or statements are </span></div><div style="line-height:10pt;position:var(--position);top:270pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">found to be deficient, lacking in transparency, deceptive, unfair, misleading, or misrepresentative of our practices, </span></div><div style="line-height:10pt;position:var(--position);top:280pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">we may be subject to investigation, enforcement actions by regulators, or other adverse consequences. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:296pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our employees and personnel use artificial intelligence (including generative AI, agentic AI, or machine </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:306pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">learning &#8211; collectively &#8220;AI&#8221;) and/or automated decision-making technologies to perform their work, and the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:316pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">disclosure and use of personal data in AI technologies is subject to various privacy laws and other privacy </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:326pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">obligations.&#160; Governments have passed and are likely to pass additional laws and regulations regulating AI and/or </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:336pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">automated decision-making technologies.&#160; Our use of this technology could result in additional compliance costs, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:346pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regulatory investigations and actions, and lawsuits.</span></div><div style="line-height:10pt;position:var(--position);top:362pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Obligations related to data privacy and security are quickly changing, becoming increasingly stringent, and </span></div><div style="line-height:10pt;position:var(--position);top:372pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">creating regulatory uncertainty. Additionally, these obligations may be subject to differing applications and </span></div><div style="line-height:10pt;position:var(--position);top:382pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these </span></div><div style="line-height:10pt;position:var(--position);top:392pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">obligations requires us to devote significant resources and may necessitate changes to our services, information </span></div><div style="line-height:10pt;position:var(--position);top:402pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">technologies, systems, and practices and to those of any third parties that process personal data on our behalf. </span></div><div style="line-height:10pt;position:var(--position);top:418pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and </span></div><div style="line-height:10pt;position:var(--position);top:428pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">security obligations. Moreover, despite our efforts, our personnel or third parties with whom we work may fail to </span></div><div style="line-height:10pt;position:var(--position);top:438pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">comply with such obligations, which could negatively impact our business operations. If we or the third parties with </span></div><div style="line-height:10pt;position:var(--position);top:448pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">whom we work fail, or are perceived to have failed, to address or comply with applicable data privacy or security </span></div><div style="line-height:10pt;position:var(--position);top:458pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">obligations, we could face significant consequences, including but not limited to: government enforcement actions </span></div><div style="line-height:10pt;position:var(--position);top:468pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims); and </span></div><div style="line-height:10pt;position:var(--position);top:478pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">mass arbitration demands; additional reporting requirements and/or oversight; bans on processing personal data; and </span></div><div style="line-height:10pt;position:var(--position);top:488pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">orders to destroy or not use personal data. Any of these events could have a material adverse effect on our </span></div><div style="line-height:10pt;position:var(--position);top:498pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reputation, business, or financial condition, including but not limited to: loss of customers; inability to process </span></div><div style="line-height:10pt;position:var(--position);top:508pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; </span></div><div style="line-height:10pt;position:var(--position);top:518pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our </span></div><div style="line-height:10pt;position:var(--position);top:528pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">business model or operations. </span></div><div style="line-height:10pt;position:var(--position);top:556pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Risks Related to Ownership of Our ADSs and Our Status as a Non-U.S. Company with Foreign Private </span></div><div style="line-height:10pt;position:var(--position);top:566pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Issuer Status </span></div><div style="line-height:10pt;position:var(--position);top:582pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">If we do not achieve our projected development and commercialization goals in the timeframes we announce and </span></div><div style="line-height:10pt;position:var(--position);top:592pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">expect, our business will be harmed, and the price of our securities could decline as a result. </span></div><div style="line-height:10pt;position:var(--position);top:608pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We sometimes estimate for planning purposes the timing of the accomplishment of various scientific, clinical, </span></div><div style="line-height:10pt;position:var(--position);top:618pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regulatory and other product development objectives. These milestones may include our expectations regarding the </span></div><div style="line-height:10pt;position:var(--position);top:628pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">commencement or completion of scientific studies, clinical trials, the submission of regulatory filings, or </span></div><div style="line-height:10pt;position:var(--position);top:638pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">commercialization objectives. From time to time, we may publicly announce the expected timing of some of these </span></div><div style="line-height:10pt;position:var(--position);top:648pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">milestones, such as the completion of an ongoing clinical trial, the initiation of other clinical programs, receipt of </span></div><div style="line-height:10pt;position:var(--position);top:658pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">marketing approval, or a commercial launch of a product. The achievement of many of these milestones may be </span></div><div style="line-height:10pt;position:var(--position);top:668pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">outside of our control. All of these milestones are based on a variety of assumptions which may cause the timing of </span></div><div style="line-height:10pt;position:var(--position);top:678pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">achievement of the milestones to vary considerably from our estimates, including: </span></div><div style="line-height:10pt;position:var(--position);top:694pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">our available capital resources or capital constraints we experience; </span></span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">45</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the rate of progress, costs and results of our clinical trials and research and development activities, </span></span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">including the extent of scheduling conflicts with participating clinicians and collaborators, and our </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">ability to identify and enroll patients who meet clinical trial eligibility criteria; </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">our receipt of approvals by the European Commission, FDA and other regulatory agencies and the </span></span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">timing thereof; </span></div><div style="line-height:10pt;position:var(--position);top:134pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">other actions, decisions or rules issued by regulators; </span></span></div><div style="line-height:10pt;position:var(--position);top:150pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">our ability to access sufficient, reliable and affordable supplies of compounds and raw materials used </span></span></div><div style="line-height:10pt;position:var(--position);top:160pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">in the manufacture of our drug candidates; </span></div><div style="line-height:10pt;position:var(--position);top:176pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the efforts of our collaborators with respect to the commercialization of our products; and </span></span></div><div style="line-height:10pt;position:var(--position);top:192pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the securing of, costs related to, and timing issues associated with, product manufacturing as well as </span></span></div><div style="line-height:10pt;position:var(--position);top:202pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">sales and marketing activities. </span></div><div style="line-height:10pt;position:var(--position);top:224pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">If we fail to achieve announced milestones in the timeframes we expect, the commercialization of our drug </span></div><div style="line-height:10pt;position:var(--position);top:234pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">candidates may be delayed, our business and results of operations may be harmed, and the trading price of the ADSs </span></div><div style="line-height:10pt;position:var(--position);top:244pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">may decline as a result. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:260pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">We may be a &#8220;passive foreign investment company&#8221; for U.S. federal income tax purposes, which could result in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:270pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">adverse U.S. federal income tax consequences to U.S. investors. </span></div><div style="line-height:10pt;position:var(--position);top:286pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Generally, if, for any taxable year, at least 75% of our gross income is passive income (&#8220;income test&#8221;), or at </span></div><div style="line-height:10pt;position:var(--position);top:296pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">least 50% of the value of our assets (based on an average of the quarterly values of the assets during a taxable year) </span></div><div style="line-height:10pt;position:var(--position);top:306pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">is attributable to assets that produce passive income or are held for the production of passive income, including cash, </span></div><div style="line-height:10pt;position:var(--position);top:316pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">we would be characterized as a passive foreign investment company (&#8220;PFIC&#8221;) for U.S. federal income tax purposes. </span></div><div style="line-height:10pt;position:var(--position);top:326pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">For purposes of these tests, passive income includes, among other things, dividends, interest, and gains from the sale </span></div><div style="line-height:10pt;position:var(--position);top:336pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">or exchange of investment property and rents or royalties other than rents or royalties which are received from </span></div><div style="line-height:10pt;position:var(--position);top:346pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">unrelated parties in connection with the active conduct of a trade or business. Cash and cash equivalents are </span></div><div style="line-height:10pt;position:var(--position);top:356pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">generally treated as passive assets. Goodwill is treated as an active asset to the extent associated with business </span></div><div style="line-height:10pt;position:var(--position);top:366pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">activities that produce active income. For purposes of the PFIC rules, a non-U.S. corporation that owns, directly or </span></div><div style="line-height:10pt;position:var(--position);top:376pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">indirectly, at least 25% by value of the equity interests of another corporation or partnership is treated as if it held its </span></div><div style="line-height:10pt;position:var(--position);top:386pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">proportionate share of the assets of the other corporation or partnership, and received directly its proportionate share </span></div><div style="line-height:10pt;position:var(--position);top:396pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of the income of the other corporation or partnership. Equity interests of less than 25% by value in any other </span></div><div style="line-height:10pt;position:var(--position);top:406pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">corporation or partnership are treated as passive assets, regardless of the nature of the other corporation or </span></div><div style="line-height:10pt;position:var(--position);top:416pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">partnership&#8217;s business. </span></div><div style="line-height:10pt;position:var(--position);top:432pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">If we are a PFIC for any taxable year in which a U.S. Holder (as defined in Item 10.E. Taxation&#8212;Material </span></div><div style="line-height:10pt;position:var(--position);top:442pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">U.S. Federal Income Tax Considerations for U.S. Holders) holds an ADS, certain adverse U.S. federal income tax </span></div><div style="line-height:10pt;position:var(--position);top:452pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">consequences could apply to such U.S. Holder including increased tax liability on disposition gains and certain </span></div><div style="line-height:10pt;position:var(--position);top:462pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8220;excess distributions&#8221; and additional reporting requirements. See Item 10.E. Taxation&#8212;Material U.S. Federal </span></div><div style="line-height:10pt;position:var(--position);top:472pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Income Tax Considerations for U.S. Holders&#8212;Passive Foreign Investment Company Rules. </span></div><div style="line-height:10pt;position:var(--position);top:488pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Based on our analysis of our financial statements, activities and relevant market and shareholder data, we do </span></div><div style="line-height:10pt;position:var(--position);top:498pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">not believe that we were a PFIC for the taxable year ended December 31, 2025. The determination of whether we </span></div><div style="line-height:10pt;position:var(--position);top:508pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">are a PFIC is a fact-intensive determination made on an annual basis and the applicable law is subject to varying </span></div><div style="line-height:10pt;position:var(--position);top:518pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">interpretation. Whether we are a PFIC for any taxable year will depend on the composition of our income and the </span></div><div style="line-height:10pt;position:var(--position);top:528pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">composition, nature and value of our assets from time to time (including the value of our goodwill, which may be </span></div><div style="line-height:10pt;position:var(--position);top:538pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">determined by reference to the value of our ADSs, which could fluctuate considerably). We currently do not </span></div><div style="line-height:10pt;position:var(--position);top:548pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">generate product revenues and therefore we may be a PFIC for any taxable year in which we do not generate </span></div><div style="line-height:10pt;position:var(--position);top:558pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">sufficient amounts of non-passive income to offset our passive income. As a result, there can be no assurance that </span></div><div style="line-height:10pt;position:var(--position);top:568pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">we will not be treated as a PFIC for the current or any future taxable year and our U.S. counsel expresses no opinion </span></div><div style="line-height:10pt;position:var(--position);top:578pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">with respect to our PFIC status for any prior, current or future taxable year. Even if we determine that we are not a </span></div><div style="line-height:10pt;position:var(--position);top:588pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">PFIC for a taxable year, there can be no assurance that the Internal Revenue Service (the "IRS") will agree with our </span></div><div style="line-height:10pt;position:var(--position);top:598pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">conclusion and that the IRS would not successfully challenge our position. Each U.S. holder is strongly urged to </span></div><div style="line-height:10pt;position:var(--position);top:608pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">consult its tax advisor regarding these issues and any available elections to mitigate such tax consequences.</span></div><div style="line-height:10pt;position:var(--position);top:624pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The rights of shareholders in companies subject to French corporate law differ in material respects from the </span></div><div style="line-height:10pt;position:var(--position);top:634pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">rights of shareholders of corporations incorporated in the United States. </span></div><div style="line-height:10pt;position:var(--position);top:650pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We are a French company with limited liability. Our corporate affairs are governed by our by-laws and by the </span></div><div style="line-height:10pt;position:var(--position);top:660pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">laws governing companies incorporated in France. The rights of shareholders and the responsibilities of members of </span></div><div style="line-height:10pt;position:var(--position);top:670pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">our Board are in many ways different from the rights and obligations of shareholders in companies governed by the </span></div><div style="line-height:10pt;position:var(--position);top:680pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">laws of U.S. jurisdictions. For example, in the performance of its duties, our Board is required by French law to </span></div><div style="line-height:10pt;position:var(--position);top:690pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">consider the interests of our company, its shareholders, its employees and other stakeholders, rather than solely our </span></div><div style="line-height:10pt;position:var(--position);top:700pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">shareholders and/or creditors. It is possible that some of these parties will have interests that are different from, or in </span></div><div style="line-height:10pt;position:var(--position);top:710pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">addition to, your interests as a shareholder or holder of ADSs.&#160; </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">46</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">You may face difficulties protecting your interests, and your ability to protect your rights through the U.S.&#160;federal </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">courts may be limited because we are incorporated under the laws of France, all of our assets are in the </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">European Union and a majority of our directors and executive officers reside outside the United&#160;States. </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We are constituted under the laws of France. A majority of our officers and directors reside outside the </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">United&#160;States. In addition, a substantial portion of their assets and our assets are located outside of the United&#160;States. </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">As a result, you may have difficulty serving legal process within the United&#160;States upon us or any of these persons. </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">You may also have difficulty enforcing, both in and outside of the United&#160;States, judgments you may obtain in </span></div><div style="line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">U.S.&#160;courts against us or these persons in any action, including actions based upon the civil liability provisions of </span></div><div style="line-height:10pt;position:var(--position);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">U.S.&#160;Federal or state securities laws. Furthermore, there is substantial doubt as to the enforceability in France against </span></div><div style="line-height:10pt;position:var(--position);top:168pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">us or against any of our directors and officers who are not residents of the United&#160;States, in original actions or in </span></div><div style="line-height:10pt;position:var(--position);top:178pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">actions for enforcement of judgments of U.S.&#160;courts, of liabilities based solely upon the civil liability provisions of </span></div><div style="line-height:10pt;position:var(--position);top:188pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the U.S.&#160;federal securities laws. In addition, shareholders in French corporations may not have standing to initiate a </span></div><div style="line-height:10pt;position:var(--position);top:198pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">shareholder derivative action in U.S.&#160;federal courts. </span></div><div style="line-height:10pt;position:var(--position);top:214pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">As a result, our public shareholders may have more difficulty in protecting their interests through actions </span></div><div style="line-height:10pt;position:var(--position);top:224pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">against us, our management, our directors or our major shareholders than would shareholders of a corporation </span></div><div style="line-height:10pt;position:var(--position);top:234pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">incorporated in a jurisdiction in the United&#160;States. </span></div><div style="line-height:10pt;position:var(--position);top:250pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The dual listing of our ordinary shares and the ADSs may adversely affect the liquidity and value of the ADSs. </span></div><div style="line-height:10pt;position:var(--position);top:266pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our ordinary shares are listed on Euronext Paris and our ADSs are listed on the Nasdaq Stock Market. Trading </span></div><div style="line-height:10pt;position:var(--position);top:276pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of the ADSs or ordinary shares in these markets will take place in different currencies (U.S. dollars on Nasdaq and </span></div><div style="line-height:10pt;position:var(--position);top:286pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">euros on Euronext Paris), and at different times (resulting from different time zones, different trading days and </span></div><div style="line-height:10pt;position:var(--position);top:296pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">different public holidays in the United States and France). The trading prices of our ordinary shares on these two </span></div><div style="line-height:10pt;position:var(--position);top:306pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">markets may differ due to these and other factors. Any decrease in the price of our ordinary shares on Euronext Paris </span></div><div style="line-height:10pt;position:var(--position);top:316pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">could cause a decrease in the trading price of the ADSs on Nasdaq. Investors could seek to sell or buy our ordinary </span></div><div style="line-height:10pt;position:var(--position);top:326pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">shares to take advantage of any price differences between the markets through a practice referred to as arbitrage. </span></div><div style="line-height:10pt;position:var(--position);top:336pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Any arbitrage activity could create unexpected volatility in both our share prices on one exchange, and the ordinary </span></div><div style="line-height:10pt;position:var(--position);top:346pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">shares available for trading on the other exchange. In addition, holders of ADSs will not be immediately able to </span></div><div style="line-height:10pt;position:var(--position);top:356pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">surrender their ADSs and withdraw the underlying ordinary shares for trading on the other market without effecting </span></div><div style="line-height:10pt;position:var(--position);top:366pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">necessary procedures with the depositary. This could result in time delays and additional cost for holders of ADSs. </span></div><div style="line-height:10pt;position:var(--position);top:376pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">We cannot predict the effect of this dual listing on the value of our ordinary shares and the ADSs. However, the dual </span></div><div style="line-height:10pt;position:var(--position);top:386pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">listing of our ordinary shares and the ADSs may reduce the liquidity of these securities in one or both markets and </span></div><div style="line-height:10pt;position:var(--position);top:396pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">may adversely affect the development of an active trading market for the ADSs in the United States. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:412pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Our by-laws and French corporate law contain provisions that may delay or discourage a takeover attempt. </span></div><div style="line-height:10pt;position:var(--position);top:428pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Provisions contained in our by-laws and French corporate law could make it more difficult for a third party to </span></div><div style="line-height:10pt;position:var(--position);top:438pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">acquire us, even if doing so might be beneficial to our shareholders. In addition, provisions of our by-laws impose </span></div><div style="line-height:10pt;position:var(--position);top:448pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">various procedural and other requirements, which could make it more difficult for shareholders to effect certain </span></div><div style="line-height:10pt;position:var(--position);top:458pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">corporate actions. These provisions include the following: </span></div><div style="line-height:10pt;position:var(--position);top:474pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">under French law, the owner of 90% of the share capital or voting rights of a public company listed on </span></span></div><div style="line-height:10pt;position:var(--position);top:484pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">a regulated market in a Member State of the European Union or in a state party to the EEA Agreement, </span></div><div style="line-height:10pt;position:var(--position);top:494pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">including from the main French stock exchange, has the right to force out minority shareholders </span></div><div style="line-height:10pt;position:var(--position);top:504pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">following a tender offer made to all shareholders; </span></div><div style="line-height:10pt;position:var(--position);top:520pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">under French law, a non-resident of France as well as any French entity controlled by non-residents of </span></span></div><div style="line-height:10pt;position:var(--position);top:530pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">France may have to file a declaration for statistical purposes with the Bank of France (</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:472.43pt;position:var(--position);text-decoration:none;white-space:pre">Banque de </span></div><div style="line-height:10pt;position:var(--position);top:540pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">France</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.9pt;position:var(--position);text-decoration:none;white-space:pre">) within 20 working days following the date of certain direct foreign investments in us, </span></div><div style="line-height:10pt;position:var(--position);top:550pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">including any purchase of our ADSs. In particular, such filings are required in connection with </span></div><div style="line-height:10pt;position:var(--position);top:560pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">investments exceeding &#8364;15&#160;million that lead to the acquisition of at least 10% of our share capital or </span></div><div style="line-height:10pt;position:var(--position);top:570pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">voting rights or cross such 10% threshold. See &#8220;Limitations Affecting Shareholders of a French </span></div><div style="line-height:10pt;position:var(--position);top:580pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">Company&#8221;; </span></div><div style="line-height:10pt;position:var(--position);top:596pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">under French law, certain foreign investments in companies incorporated under French laws are </span></span></div><div style="line-height:10pt;position:var(--position);top:606pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">subject to the prior authorization from the French Minister of Economy, where all or part of the </span></div><div style="line-height:10pt;position:var(--position);top:616pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">target&#8217;s business and activity relate to a strategic sector, such as energy, transportation, the protection </span></div><div style="line-height:10pt;position:var(--position);top:626pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">of public health, telecommunications, research and development in biotechnologies, etc.; </span></div><div style="line-height:10pt;position:var(--position);top:642pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">a merger (i.e.,&#160;in a French law context, a share for share exchange following which our company </span></span></div><div style="line-height:10pt;position:var(--position);top:652pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">would be dissolved into the acquiring entity and our shareholders would become shareholders of the </span></div><div style="line-height:10pt;position:var(--position);top:662pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">acquiring entity) of our company into a company incorporated in the European Union would require </span></div><div style="line-height:10pt;position:var(--position);top:672pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">the approval of our Board as well as a two-thirds majority of the votes held by the shareholders </span></div><div style="line-height:10pt;position:var(--position);top:682pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">present, represented by proxy or voting by mail at the relevant meeting; </span></div><div style="line-height:10pt;position:var(--position);top:698pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">a merger of our company into a company incorporated outside of the European Union would require </span></span></div><div style="line-height:10pt;position:var(--position);top:708pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">100% of our shareholders to approve it; </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">47</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">under French law, a cash merger is treated as a share purchase and would require the consent of each </span></span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">participating shareholder; </span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">our shareholders have granted and may grant in the future our Board broad authorizations to increase </span></span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">our share capital or to issue additional ordinary shares or other securities, such as warrants, to our </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">shareholders, the public or qualified investors, including as a possible defense following the launching </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">of a tender offer for our shares; </span></div><div style="line-height:10pt;position:var(--position);top:144pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.94pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">our shareholders have preferential subscription rights on a </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:361.8pt;position:var(--position);text-decoration:none;white-space:pre">pro rata</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:394.84999999999997pt;position:var(--position);text-decoration:none;white-space:pre"> basis on the issuance by us of any </span></div><div style="line-height:10pt;position:var(--position);top:154pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">additional securities for cash or a set-off of cash debts, which rights may only be waived by the </span></div><div style="line-height:10pt;position:var(--position);top:164pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">extraordinary general meeting by a two-thirds majority vote of our shareholders or on an individual </span></div><div style="line-height:10pt;position:var(--position);top:174pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">basis by each shareholder; </span></div><div style="line-height:10pt;position:var(--position);top:190pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">our Board has the right to appoint directors to fill a vacancy created by the resignation or death of a </span></span></div><div style="line-height:10pt;position:var(--position);top:200pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">director, subject to the approval by the shareholders of such appointment at the next shareholders&#8217; </span></div><div style="line-height:10pt;position:var(--position);top:210pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">meeting, which prevents shareholders from having the sole right to fill vacancies on our Board; </span></div><div style="line-height:10pt;position:var(--position);top:226pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">our Board can be convened by our chairman, including upon request from our Chief Executive Officer </span></span></div><div style="line-height:10pt;position:var(--position);top:236pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">(</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:130.38pt;position:var(--position);text-decoration:none;white-space:pre">directeur g&#233;n&#233;ral</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:200.01pt;position:var(--position);text-decoration:none;white-space:pre">), if the positions of Chief Executive Officer and Chairman of the Board are not held </span></div><div style="line-height:10pt;position:var(--position);top:246pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">by the same person, or, when no board meeting has been held for more than two consecutive months, </span></div><div style="line-height:10pt;position:var(--position);top:256pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">from directors representing at least one-third of the total number of directors; </span></div><div style="line-height:10pt;position:var(--position);top:272pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">our Board meetings can only be regularly held if at least half of the directors attend either physically or </span></span></div><div style="line-height:10pt;position:var(--position);top:282pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">by way of videoconference or teleconference enabling the directors&#8217; identification and ensuring their </span></div><div style="line-height:10pt;position:var(--position);top:292pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">effective participation in the Board&#8217;s decisions; </span></div><div style="line-height:10pt;position:var(--position);top:308pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">our shares are registered or bearer, if the legislation so permits, according to the shareholder&#8217;s choice; </span></span></div><div style="line-height:1pt;position:var(--position);top:322.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="line-height:10pt;position:var(--position);top:323.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">approval of at least a majority of the votes held by shareholders present, represented by a proxy, or </span></span></div><div style="line-height:10pt;position:var(--position);top:333.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">voting by mail at the relevant ordinary shareholders&#8217; general meeting is required to remove directors </span></div><div style="line-height:10pt;position:var(--position);top:343.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">with or without cause; </span></div><div style="line-height:10pt;position:var(--position);top:359.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">advance notice is required for nominations to the Board or for proposing matters to be acted upon at a </span></span></div><div style="line-height:10pt;position:var(--position);top:369.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">shareholders&#8217; meeting, except that a vote to remove and replace a director can be proposed at any </span></div><div style="line-height:10pt;position:var(--position);top:379.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">shareholders&#8217; meeting without notice; </span></div><div style="line-height:10pt;position:var(--position);top:395.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">our by-laws can be changed in accordance with applicable French laws and regulations; </span></span></div><div style="line-height:10pt;position:var(--position);top:411.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the crossing of certain thresholds must be disclosed and can impose certain obligations (including </span></span></div><div style="line-height:10pt;position:var(--position);top:421.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">filing a mandatory public tender offer); </span></div><div style="line-height:10pt;position:var(--position);top:437.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">transfers of shares shall comply with applicable insider trading rules and regulations and, in particular, </span></span></div><div style="line-height:10pt;position:var(--position);top:447.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">with the EU Market Abuse Directive and Regulation dated April&#160;16, 2014; and </span></div><div style="line-height:10pt;position:var(--position);top:463.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">pursuant to French law, the sections of our by-laws relating to the number of directors and election and </span></span></div><div style="line-height:10pt;position:var(--position);top:473.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">removal of a director from office, may only be modified by a resolution adopted by two-thirds of the </span></div><div style="line-height:10pt;position:var(--position);top:483.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">votes of our shareholders present, represented by a proxy or voting by mail at the meeting. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:499.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Existing and potential investors in our ordinary shares or ADSs may have to request the prior authorization from </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:509.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the French Ministry of Economy prior to acquiring an interest in our ordinary shares or ADSs. </span></div><div style="line-height:10pt;position:var(--position);top:525.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Under French law, direct and indirect acquisition of control of all or part of a branch of activity, or, acting </span></div><div style="line-height:10pt;position:var(--position);top:535.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">alone or in concert, of more than 25% (10% for investments made by non-EU/EEA investors in companies like ours </span></div><div style="line-height:10pt;position:var(--position);top:545.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">whose shares are admitted to trading on a French or EU regulated market) of voting rights of a French company </span></div><div style="line-height:10pt;position:var(--position);top:555.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">deemed to be active in a strategic industry, by foreign investors is subject to prior authorization of the French </span></div><div style="line-height:10pt;position:var(--position);top:565.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Ministry of Economy pursuant to Articles L. 151-1 et seq. and R. 151-1 et seq. of the French Monetary and </span></div><div style="line-height:10pt;position:var(--position);top:575.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Financial Code. Industries essential to the protection of public health and research and development activities in </span></div><div style="line-height:10pt;position:var(--position);top:585.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">biotechnologies are among the categories which fall within the scope of this regulation. </span></div><div style="line-height:10pt;position:var(--position);top:601.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">If necessary to protect strategic assets, the ministry may oppose to the transaction or condition its </span></div><div style="line-height:10pt;position:var(--position);top:611.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">authorization upon the commitment of the investor to certain structural and behavioral remedies that aim at </span></div><div style="line-height:10pt;position:var(--position);top:621.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">maintaining strategic activities, knowledge, MAs and intellectual property in France. </span></div><div style="line-height:10pt;position:var(--position);top:637.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">If an investment requiring the prior authorization of the French Minister of Economy is completed without </span></div><div style="line-height:10pt;position:var(--position);top:647.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">such authorization having been granted, the French Minister of Economy might order the relevant investor to </span></div><div style="line-height:10pt;position:var(--position);top:657.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(i)&#160;submit a request for authorization, (ii)&#160;have the situation prior to the completion of the investment restored at its </span></div><div style="line-height:10pt;position:var(--position);top:667.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">own expense or (iii)&#160;amend the investment. Non-compliance with the authorization requirement or breach to the </span></div><div style="line-height:10pt;position:var(--position);top:677.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">conditions imposed may expose the relevant investor to a criminal fine which cannot exceed the greater of: (i)&#160;twice </span></div><div style="line-height:10pt;position:var(--position);top:687.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the amount of the relevant investment, (ii) 10% of the annual turnover before tax of the target company and (iii) </span></div><div style="line-height:10pt;position:var(--position);top:697.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5&#160;million (for an entity) or &#8364;1&#160;million (for an individual). The French Minister of Economy may also adopt </span></div><div style="line-height:10pt;position:var(--position);top:707.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">precautionary measures it deems necessary to protect strategic sovereign assets, including the suspension of voting </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">48</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">rights or the prohibition or limitation of the distribution of dividends and remuneration attached to shares whose </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ownership by the investor should have been subject to prior authorization. </span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The non-EU/EEA investors in French companies whose shares are admitted to trading on a French or EU </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regulated market reaching the 10% voting rights threshold benefit from a &#8220;fast-track procedure&#8221; pursuant to which </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the investor is exempt from the authorization request sets forth in Article R. 151-5 of the Monetary and Financial </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Code, provided that the investment project has been the subject of a prior simplified notification to the French </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Minister of Economy, and the French Minister of Economy did not oppose to the transaction or request to follow the </span></div><div style="line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">standard authorization process, the transaction can proceed as from ten working days following notification. </span></div><div style="line-height:10pt;position:var(--position);top:164pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Failure to comply with such measures could result in significant consequences in the concerned investment. </span></div><div style="line-height:10pt;position:var(--position);top:174pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Such measures could also delay or discourage a takeover or more broadly a foreign investment attempt, and we </span></div><div style="line-height:10pt;position:var(--position);top:184pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">cannot predict whether these measures will result in a lower or more volatile market price of our ADSs. </span></div><div style="line-height:10pt;position:var(--position);top:200pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72.25pt;position:var(--position);text-decoration:none;white-space:pre">You may not be able to exercise your right to vote the ordinary shares underlying your ADSs. </span></div><div style="line-height:10pt;position:var(--position);top:216pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Holders of ADSs may exercise voting rights with respect to the ordinary shares represented by the ADSs only </span></div><div style="line-height:10pt;position:var(--position);top:226pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">in accordance with the provisions of the deposit agreement. The deposit agreement provides that, upon receipt of </span></div><div style="line-height:10pt;position:var(--position);top:236pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">notice of any meeting of holders of our ordinary shares, the depositary will fix a record date for the determination of </span></div><div style="line-height:10pt;position:var(--position);top:246pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ADS holders who shall be entitled to give instructions for the exercise of voting rights. Upon timely receipt of notice </span></div><div style="line-height:10pt;position:var(--position);top:256pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">from us, if we so request, the depositary shall distribute to the holders as of the record date (i)&#160;the notice of the </span></div><div style="line-height:10pt;position:var(--position);top:266pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">meeting or solicitation of consent or proxy sent by us and (ii)&#160;a statement as to the manner in which instructions may </span></div><div style="line-height:10pt;position:var(--position);top:276pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">be given by the holders. </span></div><div style="line-height:10pt;position:var(--position);top:292pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Purchasers of ADSs may instruct the depositary of their ADSs to vote the ordinary shares underlying their </span></div><div style="line-height:10pt;position:var(--position);top:302pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ADSs. Otherwise, purchasers of ADSs will not be able to exercise voting rights unless they withdraw the ordinary </span></div><div style="line-height:10pt;position:var(--position);top:312pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">shares underlying the ADSs they hold. However, a holder of ADSs may not know about the meeting far enough in </span></div><div style="line-height:10pt;position:var(--position);top:322pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">advance to withdraw those ordinary shares. If we ask for a holder of ADSs&#8217; instructions, the depositary, upon timely </span></div><div style="line-height:10pt;position:var(--position);top:332pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">notice from us, will notify him or her of the upcoming vote and arrange to deliver our voting materials to him or her. </span></div><div style="line-height:10pt;position:var(--position);top:342pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">We cannot guarantee to any holder of ADSs that he or she will receive the voting materials in time to ensure that he </span></div><div style="line-height:10pt;position:var(--position);top:352pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">or she can instruct the depositary to vote his or her ordinary shares or to withdraw his or her ordinary shares so that </span></div><div style="line-height:10pt;position:var(--position);top:362pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">he or she can vote them. If the depositary does not receive timely voting instructions from a holder of ADSs, it may </span></div><div style="line-height:10pt;position:var(--position);top:372pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">give a proxy to a person designated by us to vote the ordinary shares underlying his or her ADSs. In addition, the </span></div><div style="line-height:10pt;position:var(--position);top:382pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying </span></div><div style="line-height:10pt;position:var(--position);top:392pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">out voting instructions. This means that a holder of ADSs may not be able to exercise his or her right to vote, and </span></div><div style="line-height:10pt;position:var(--position);top:402pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">there may be nothing he or she can do if the ordinary shares underlying his or her ADSs are not voted as he or she </span></div><div style="line-height:10pt;position:var(--position);top:412pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">requested. </span></div><div style="line-height:10pt;position:var(--position);top:428pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Purchasers of ADSs are not holders of our ordinary shares. </span></div><div style="line-height:10pt;position:var(--position);top:444pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">A holder of ADSs will not be treated as one of our shareholders and will not have direct shareholder rights. </span></div><div style="line-height:10pt;position:var(--position);top:454pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">French law governs our shareholder rights. The depositary will be the holder of the ordinary shares underlying ADSs </span></div><div style="line-height:10pt;position:var(--position);top:464pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">held by purchasers of ADSs. Purchasers of ADSs will have ADS holder rights. The deposit agreement among us, the </span></div><div style="line-height:10pt;position:var(--position);top:474pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">depositary and purchasers of ADSs, as ADS holders, and all other persons directly and indirectly holding ADSs, sets </span></div><div style="line-height:10pt;position:var(--position);top:484pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">out ADS holder rights, as well as the rights and obligations of the depositary. </span></div><div style="line-height:10pt;position:var(--position);top:500pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">A double voting right is attached to each registered ordinary share (except treasury shares) that is held in the </span></div><div style="line-height:10pt;position:var(--position);top:510pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">name of the same shareholder for at least two years. However, the ordinary shares underlying our ADSs will not be </span></div><div style="line-height:10pt;position:var(--position);top:520pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">entitled to double voting rights as the depositary will hold the ordinary shares underlying our ADSs in bearer form. </span></div><div style="line-height:10pt;position:var(--position);top:536pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The right as a holder of ADSs to participate in any future preferential subscription rights or to elect to receive </span></div><div style="line-height:10pt;position:var(--position);top:546pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">dividends in shares may be limited, which may cause dilution to the holdings of purchasers of ADSs. </span></div><div style="line-height:10pt;position:var(--position);top:562pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">According to French law, if we issue additional securities for cash, current shareholders will have preferential </span></div><div style="line-height:10pt;position:var(--position);top:572pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">subscription rights for these securities on a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:245.43pt;position:var(--position);text-decoration:none;white-space:pre">pro rata</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:278.48pt;position:var(--position);text-decoration:none;white-space:pre"> basis unless they waive those rights at an extraordinary meeting </span></div><div style="line-height:10pt;position:var(--position);top:582pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of our shareholders by a two-thirds majority vote or individually by each shareholder. However, ADS holders will </span></div><div style="line-height:10pt;position:var(--position);top:592pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">not be entitled to exercise or sell such rights unless we register the rights and the securities to which the rights relate </span></div><div style="line-height:10pt;position:var(--position);top:602pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">under the Securities Act or an exemption from the registration requirements is available. In addition, the deposit </span></div><div style="line-height:10pt;position:var(--position);top:612pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">agreement provides that the depositary will not make rights available to purchasers of ADSs unless the distribution </span></div><div style="line-height:10pt;position:var(--position);top:622pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to ADS holders of both the rights and any related securities are either registered under the Securities Act or </span></div><div style="line-height:10pt;position:var(--position);top:632pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">exempted from registration under the Securities Act. Further, if we offer holders of our ordinary shares the option to </span></div><div style="line-height:10pt;position:var(--position);top:642pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">receive dividends in either cash or shares, under the deposit agreement the depositary may require satisfactory </span></div><div style="line-height:10pt;position:var(--position);top:652pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">assurances from us that extending the offer to holders of ADSs does not require registration of any securities under </span></div><div style="line-height:10pt;position:var(--position);top:662pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the Securities Act before making the option available to holders of ADSs. We are under no obligation to file&#160;a </span></div><div style="line-height:10pt;position:var(--position);top:672pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">registration statement with respect to any such rights or securities or to endeavor to cause such a registration </span></div><div style="line-height:10pt;position:var(--position);top:682pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">statement to be declared effective. Moreover, we may not be able to establish an exemption from registration under </span></div><div style="line-height:10pt;position:var(--position);top:692pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the Securities Act. Accordingly, ADS holders may be unable to participate in our rights offerings or to elect to </span></div><div style="line-height:10pt;position:var(--position);top:702pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">receive dividends in shares and may experience dilution in their holdings. In addition, if the depositary is unable to </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">49</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">sell rights that are not exercised or not distributed or if the sale is not lawful or reasonably practicable, it will allow </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the rights to lapse, in which case you will receive no value for these rights. </span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Purchasers of ADSs may be subject to limitations on the withdrawal of the underlying ordinary shares. </span></div><div style="line-height:10pt;position:var(--position);top:114pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Temporary delays in the cancellation of ADSs and withdrawal of the underlying ordinary shares may arise </span></div><div style="line-height:10pt;position:var(--position);top:124pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">because the depositary has closed its transfer books or we have closed our transfer books, the transfer of ordinary </span></div><div style="line-height:10pt;position:var(--position);top:134pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">shares is blocked to permit voting at a shareholders&#8217; meeting or we are paying a dividend on our ordinary shares. In </span></div><div style="line-height:10pt;position:var(--position);top:144pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">addition, a holder of ADSs may not be able to cancel his or her ADSs and withdraw the underlying ordinary shares </span></div><div style="line-height:10pt;position:var(--position);top:154pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">when he or she owes money for fees, taxes and similar charges and when it is necessary to prohibit withdrawals in </span></div><div style="line-height:10pt;position:var(--position);top:164pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary </span></div><div style="line-height:10pt;position:var(--position);top:174pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">shares or other deposited securities.</span></div><div style="line-height:10pt;position:var(--position);top:190pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ADS holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which </span></div><div style="line-height:10pt;position:var(--position);top:200pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">could result in less favorable outcomes to the plaintiffs in any such action. </span></div><div style="line-height:10pt;position:var(--position);top:216pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The deposit agreement governing the ADSs representing our ordinary shares provides that, to the fullest extent </span></div><div style="line-height:10pt;position:var(--position);top:226pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">permitted by law, ADS holders waive the right to a jury trial of any claim they may have against us or the depositary </span></div><div style="line-height:10pt;position:var(--position);top:236pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">arising out of or relating to our shares, the ADSs or the deposit agreement, including any claim under the U.S. </span></div><div style="line-height:10pt;position:var(--position);top:246pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">federal securities laws. </span></div><div style="line-height:10pt;position:var(--position);top:262pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether </span></div><div style="line-height:10pt;position:var(--position);top:272pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the waiver was enforceable based on the facts and circumstances of that case in accordance with the applicable state </span></div><div style="line-height:10pt;position:var(--position);top:282pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and federal law. To our knowledge, the enforceability of a contractual pre-dispute jury trial waiver in connection </span></div><div style="line-height:10pt;position:var(--position);top:292pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">with claims arising under the federal securities laws has not been finally adjudicated by the United States Supreme </span></div><div style="line-height:10pt;position:var(--position);top:302pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Court. However, we believe that a contractual pre-dispute jury trial waiver provision is generally enforceable, </span></div><div style="line-height:10pt;position:var(--position);top:312pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">including under the laws of the State of New York, which govern the deposit agreement, by a federal or state court </span></div><div style="line-height:10pt;position:var(--position);top:322pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">in the City of New York, which has non-exclusive jurisdiction over matters arising under the deposit agreement. In </span></div><div style="line-height:10pt;position:var(--position);top:332pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">determining whether to enforce a contractual pre-dispute jury trial waiver provision, courts will generally consider </span></div><div style="line-height:10pt;position:var(--position);top:342pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">whether a party knowingly, intelligently and voluntarily waived the right to a jury trial. We believe that this is the </span></div><div style="line-height:10pt;position:var(--position);top:352pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">case with respect to the deposit agreement and the ADSs. It is advisable that you consult legal counsel regarding the </span></div><div style="line-height:10pt;position:var(--position);top:362pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">jury waiver provision before entering into the deposit agreement. </span></div><div style="line-height:10pt;position:var(--position);top:378pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">If you or any other holders or beneficial owners of ADSs bring a claim against us or the depositary in </span></div><div style="line-height:10pt;position:var(--position);top:388pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">connection with matters arising under the deposit agreement or the ADSs, including claims under federal securities </span></div><div style="line-height:10pt;position:var(--position);top:398pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">laws, you or such other holder or beneficial owner may not be entitled to a jury trial with respect to such claims, </span></div><div style="line-height:10pt;position:var(--position);top:408pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">which may have the effect of limiting and discouraging lawsuits against us and the depositary. If a lawsuit is brought </span></div><div style="line-height:10pt;position:var(--position);top:418pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">against either or both of us and the depositary under the deposit agreement, it may be heard only by a judge or </span></div><div style="line-height:10pt;position:var(--position);top:428pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">justice of the applicable trial court, which would be conducted according to different civil procedures and may result </span></div><div style="line-height:10pt;position:var(--position);top:438pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">in different outcomes than a trial by jury would have, including results that could be less favorable to the plaintiffs in </span></div><div style="line-height:10pt;position:var(--position);top:448pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">any such action. </span></div><div style="line-height:10pt;position:var(--position);top:464pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Nevertheless, if this jury trial waiver provision is not permitted by applicable law, an action could proceed </span></div><div style="line-height:10pt;position:var(--position);top:474pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">under the terms of the deposit agreement with a jury trial. No condition, stipulation or provision of the deposit </span></div><div style="line-height:10pt;position:var(--position);top:484pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary of </span></div><div style="line-height:10pt;position:var(--position);top:494pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">compliance with U.S. federal securities laws and the rules and regulations promulgated thereunder. </span></div><div style="line-height:10pt;position:var(--position);top:510pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">As a foreign private issuer, we are exempt from a number of rules under the U.S. securities laws and are </span></div><div style="line-height:10pt;position:var(--position);top:520pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">permitted to file less information with the SEC than a U.S. public company. This may limit the information </span></div><div style="line-height:10pt;position:var(--position);top:530pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">available to holders of ADSs. </span></div><div style="line-height:10pt;position:var(--position);top:546pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We are a foreign private issuer, as defined in the SEC&#8217;s rules and regulations and, consequently, we are not </span></div><div style="line-height:10pt;position:var(--position);top:556pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">subject to all of the disclosure requirements applicable to public companies organized within the United States. For </span></div><div style="line-height:10pt;position:var(--position);top:566pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">example, we are exempt from certain rules under the Exchange Act that regulate disclosure obligations and </span></div><div style="line-height:10pt;position:var(--position);top:576pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">procedural requirements related to the solicitation of proxies, consents or authorizations applicable to a security </span></div><div style="line-height:10pt;position:var(--position);top:586pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">registered under the Exchange Act, including the U.S. proxy rules under Section&#160;14 of the Exchange Act. In </span></div><div style="line-height:10pt;position:var(--position);top:596pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">addition, our officers and directors are exempt from the &#8220;short-swing&#8221; profit recovery provisions of Section&#160;16 of the </span></div><div style="line-height:10pt;position:var(--position);top:606pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Exchange Act and related rules with respect to their purchases and sales of our securities. Moreover, while we make </span></div><div style="line-height:10pt;position:var(--position);top:616pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">annual and semi-annual filings with respect to our listing on Euronext Paris, we are not required to file periodic </span></div><div style="line-height:10pt;position:var(--position);top:626pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reports and financial statements with the SEC as frequently or as promptly as U.S. public companies and are not </span></div><div style="line-height:10pt;position:var(--position);top:636pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">required to file quarterly reports on Form&#160;10-Q or current reports on Form&#160;8-K under the Exchange Act. </span></div><div style="line-height:10pt;position:var(--position);top:646pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Accordingly, there will be less publicly available information concerning our company than there would be if we </span></div><div style="line-height:10pt;position:var(--position);top:656pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">were not a foreign private issuer. </span></div><div style="line-height:10pt;position:var(--position);top:672pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">As a foreign private issuer, we are permitted, and we expect, to follow certain home country practices in relation </span></div><div style="line-height:10pt;position:var(--position);top:682pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to corporate governance matters that differ significantly from Nasdaq&#8217;s corporate governance standards. These </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">50</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">practices may afford less protection to shareholders than they would enjoy if we complied fully with the corporate </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">governance standards of the Nasdaq Global Market. </span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">As a foreign private issuer listed on the Nasdaq Global Market, we are subject to Nasdaq&#8217;s corporate </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">governance standards. However, Nasdaq rules provide that foreign private issuers are permitted to follow home </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">country corporate governance practices in lieu of Nasdaq&#8217;s corporate governance standards, with certain exceptions, </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">as long as notification is provided to Nasdaq of the intention to take advantage of such exemptions. We intend to </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">rely on exemptions for foreign private issuers and follow French corporate governance practices in lieu of Nasdaq&#8217;s </span></div><div style="line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">corporate governance standards, to the extent possible. Certain corporate governance practices in France, which is </span></div><div style="line-height:10pt;position:var(--position);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">our home country, may differ significantly from Nasdaq corporate governance standards. For example, as a French </span></div><div style="line-height:10pt;position:var(--position);top:168pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">company, neither the corporate laws of France nor our by-laws require a majority of our directors to be independent </span></div><div style="line-height:10pt;position:var(--position);top:178pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and we can include non-independent directors as members of our remuneration committee, and our independent </span></div><div style="line-height:10pt;position:var(--position);top:188pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">directors are not required to hold regularly scheduled meetings at which only independent directors are present. </span></div><div style="line-height:10pt;position:var(--position);top:204pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We are also exempt from provisions set forth in Nasdaq rules which require an issuer to provide in its by-laws </span></div><div style="line-height:10pt;position:var(--position);top:214pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for a generally applicable quorum, and that such quorum may not be less than one-third of the outstanding voting </span></div><div style="line-height:10pt;position:var(--position);top:224pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">stock. Consistent with French law, our by-laws provide that a quorum requires the presence of shareholders having </span></div><div style="line-height:10pt;position:var(--position);top:234pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">at least (i)&#160;20% of the shares entitled to vote in the case of an ordinary shareholders&#8217; general meeting or at an </span></div><div style="line-height:10pt;position:var(--position);top:244pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">extraordinary shareholders&#8217; general meeting where shareholders are voting on a capital increase by capitalization of </span></div><div style="line-height:10pt;position:var(--position);top:254pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reserves, profits or share premium, or (ii)&#160;25% of the shares entitled to vote in the case of any other extraordinary </span></div><div style="line-height:10pt;position:var(--position);top:264pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">shareholders&#8217; general meeting. If a quorum is not present, the meeting is adjourned. There is no quorum requirement </span></div><div style="line-height:10pt;position:var(--position);top:274pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">when an ordinary general meeting is reconvened, but the reconvened meeting may consider only questions which </span></div><div style="line-height:10pt;position:var(--position);top:284pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">were on the agenda of the adjourned meeting. When an extraordinary general meeting is reconvened, the quorum </span></div><div style="line-height:10pt;position:var(--position);top:294pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">required is 20% of the shares entitled to vote, except where the reconvened meeting is considering capital increases </span></div><div style="line-height:10pt;position:var(--position);top:304pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">through capitalization of reserves, profits or share premium. For these matters, no quorum is required at the </span></div><div style="line-height:10pt;position:var(--position);top:314pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reconvened meeting. If a quorum is not present at a reconvened meeting requiring a quorum, then the meeting may </span></div><div style="line-height:10pt;position:var(--position);top:324pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">be adjourned for a maximum of two months. </span></div><div style="line-height:10pt;position:var(--position);top:340pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">As a foreign private issuer, we are required to comply with Rule&#160;10A-3 of the Exchange Act, relating to audit </span></div><div style="line-height:10pt;position:var(--position);top:350pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">committee composition and responsibilities. Under French law, the audit committee may only have an advisory role </span></div><div style="line-height:10pt;position:var(--position);top:360pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and appointment of our statutory auditors, in particular, must be decided by the shareholders at our annual meeting. </span></div><div style="line-height:10pt;position:var(--position);top:370pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Therefore, our shareholders may be afforded less protection than they otherwise would have under Nasdaq&#8217;s </span></div><div style="line-height:10pt;position:var(--position);top:380pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">corporate governance standards applicable to U.S. domestic issuers. For an overview of our corporate governance </span></div><div style="line-height:10pt;position:var(--position);top:390pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">practices, see &#8220;Part II&#8212;Item 16G&#8212;Corporate Governance.&#8221; </span></div><div style="line-height:10pt;position:var(--position);top:406pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">We are an &#8220;emerging growth company&#8221; under the JOBS Act and will be able to avail ourselves of reduced </span></div><div style="line-height:10pt;position:var(--position);top:416pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">disclosure requirements applicable to emerging growth companies, which could make our ADSs less attractive to </span></div><div style="line-height:10pt;position:var(--position);top:426pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">investors. </span></div><div style="line-height:10pt;position:var(--position);top:442pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act, and we intend to take advantage of </span></div><div style="line-height:10pt;position:var(--position);top:452pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">certain exemptions from various reporting requirements that are applicable to other public companies that are not </span></div><div style="line-height:10pt;position:var(--position);top:462pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8220;emerging growth companies&#8221;, including not being required to comply with the auditor attestation requirements of </span></div><div style="line-height:10pt;position:var(--position);top:472pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Section&#160;404(b) of the Sarbanes-Oxley Act of 2002 (&#8220;Sarbanes-Oxley Act&#8221;), and exemptions from the requirements </span></div><div style="line-height:10pt;position:var(--position);top:482pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute </span></div><div style="line-height:10pt;position:var(--position);top:492pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">payments not previously approved. In addition, Section&#160;107 of the JOBS Act also provides that an emerging growth </span></div><div style="line-height:10pt;position:var(--position);top:502pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">company can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B) of the Securities Act, </span></div><div style="line-height:10pt;position:var(--position);top:512pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for complying with new or revised accounting standards. We will not take advantage of the extended transition </span></div><div style="line-height:10pt;position:var(--position);top:522pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">period provided under Section&#160;7(a)(2)(B) of the Securities Act for complying with new or revised accounting </span></div><div style="line-height:10pt;position:var(--position);top:532pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">standards. Since IFRS makes no distinction between public and private companies for purposes of compliance with </span></div><div style="line-height:10pt;position:var(--position);top:542pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">new or revised accounting standards, the requirements for our compliance as a private company and as a public </span></div><div style="line-height:10pt;position:var(--position);top:552pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">company are the same. </span></div><div style="line-height:10pt;position:var(--position);top:568pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We cannot predict if investors will find our ADSs less attractive because we may rely on these exemptions. If </span></div><div style="line-height:10pt;position:var(--position);top:578pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">some investors find our ADSs less attractive as a result, there may be a less active trading market for our ADSs and </span></div><div style="line-height:10pt;position:var(--position);top:588pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the price of our ADSs may be more volatile. We may take advantage of these reporting exemptions until we are no </span></div><div style="line-height:10pt;position:var(--position);top:598pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">longer an emerging growth company. We will remain an emerging growth company until the earliest of (1)&#160;the last </span></div><div style="line-height:10pt;position:var(--position);top:608pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">day of the fiscal year in which we have total annual gross revenue of $1.235&#160;billion or more; (2)&#160;the last day of our </span></div><div style="line-height:10pt;position:var(--position);top:618pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">fiscal year following the fifth anniversary of the date of the completion of our U.S. initial public offering and listing </span></div><div style="line-height:10pt;position:var(--position);top:628pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">on Nasdaq; (3)&#160;the date on which we have issued more than $1.0&#160;billion in nonconvertible debt during the previous </span></div><div style="line-height:10pt;position:var(--position);top:638pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">three years; and (4)&#160;the date on which we are deemed to be a large accelerated filer under the rules of the SEC. </span></div><div style="line-height:10pt;position:var(--position);top:654pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">We may lose our foreign private issuer status in the future, which could result in significant additional cost and </span></div><div style="line-height:10pt;position:var(--position);top:664pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">expense. </span></div><div style="line-height:10pt;position:var(--position);top:680pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">While we currently qualify as a foreign private issuer, the determination of foreign private issuer status is </span></div><div style="line-height:10pt;position:var(--position);top:690pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">made annually on the last business day of an issuer&#8217;s most recently completed second fiscal quarter and, </span></div><div style="line-height:10pt;position:var(--position);top:700pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">accordingly, the next determination will be made with respect to us on June&#160;30, 2026. In the future, we could lose </span></div><div style="line-height:10pt;position:var(--position);top:710pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">our foreign private issuer status if we fail to meet the requirements necessary to maintain our foreign private issuer </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">51</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">status as of the relevant determination date. We will remain a foreign private issuer until such time that more than </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">50% of our outstanding voting securities are held by U.S. residents and any of the following three circumstances </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">applies: (i)&#160;the majority of our executive officers or directors are U.S. citizens or residents; (ii)&#160;more than 50% of our </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">assets are located in the United States; or (iii)&#160;our business is administered principally in the United States. For </span></div><div style="line-height:10pt;position:var(--position);top:112pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">additional information relating to our principal shareholders, see "Item 7.A Major Shareholders". </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The regulatory and compliance costs to us under U.S. securities laws as a U.S. domestic issuer may be </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">significantly more than costs we incur as a foreign private issuer. If we are not a foreign private issuer, we will be </span></div><div style="line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">required to file periodic reports and registration statements on U.S. domestic issuer forms with the SEC, which are </span></div><div style="line-height:10pt;position:var(--position);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">more detailed and extensive in certain respects than the forms available to a foreign private issuer. We would be </span></div><div style="line-height:10pt;position:var(--position);top:168pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">required under current SEC rules to prepare our financial statements in accordance with U.S.&#160;GAAP, rather than </span></div><div style="line-height:10pt;position:var(--position);top:178pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">IFRS, and modify certain of our policies to comply with corporate governance practices associated with U.S. </span></div><div style="line-height:10pt;position:var(--position);top:188pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">domestic issuers. Such conversion of our financial statements to U.S.&#160;GAAP would involve significant time and </span></div><div style="line-height:10pt;position:var(--position);top:198pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">cost. In addition, we may lose our ability to rely upon exemptions from certain corporate governance requirements </span></div><div style="line-height:10pt;position:var(--position);top:208pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">on U.S. stock exchanges that are available to foreign private issuers such as the ones described herein and </span></div><div style="line-height:10pt;position:var(--position);top:218pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">exemptions from procedural requirements related to the solicitation of proxies. </span></div><div style="line-height:10pt;position:var(--position);top:246pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">General Risk Factors </span></div><div style="line-height:10pt;position:var(--position);top:262pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">We may not be successful in obtaining or maintaining necessary rights to product components and processes for </span></div><div style="line-height:10pt;position:var(--position);top:272pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">our development pipeline through acquisitions and&#160;in-licenses. </span></div><div style="line-height:10pt;position:var(--position);top:288pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The growth of our business may depend in part on our ability to acquire,&#160;in-license&#160;or use third-party </span></div><div style="line-height:10pt;position:var(--position);top:298pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">proprietary rights. For example, our drug candidates may require specific formulations to work effectively and </span></div><div style="line-height:10pt;position:var(--position);top:308pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">efficiently, we may develop drug candidates containing our compounds and&#160;pre-existing&#160;pharmaceutical compounds, </span></div><div style="line-height:10pt;position:var(--position);top:318pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">or we may be required by the FDA or comparable foreign regulatory authorities to provide a companion diagnostic </span></div><div style="line-height:10pt;position:var(--position);top:328pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">test or tests with our drug candidates, any of which could require us to obtain rights to use intellectual property held </span></div><div style="line-height:10pt;position:var(--position);top:338pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">by third parties. In addition, with respect to any patents we may&#160;co-own&#160;with third parties, we may require licenses </span></div><div style="line-height:10pt;position:var(--position);top:348pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to such&#160;co-owner&#8217;s&#160;interest to such patents. We may be unable to acquire or&#160;in-license&#160;any compositions, methods of </span></div><div style="line-height:10pt;position:var(--position);top:358pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">use, processes or other third-party intellectual property rights from third parties that we identify as necessary or </span></div><div style="line-height:10pt;position:var(--position);top:368pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">important to our business operations. In addition, we may fail to obtain any of these licenses at a reasonable cost or </span></div><div style="line-height:10pt;position:var(--position);top:378pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">on reasonable terms, if at all. Were that to happen, we may need to cease use of the compositions or methods </span></div><div style="line-height:10pt;position:var(--position);top:388pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">covered by those third-party intellectual property rights, and may need to seek to develop alternative approaches that </span></div><div style="line-height:10pt;position:var(--position);top:398pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">do not infringe on those intellectual property rights, which may entail additional costs and development delays, even </span></div><div style="line-height:10pt;position:var(--position);top:408pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it </span></div><div style="line-height:10pt;position:var(--position);top:418pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">may be&#160;non-exclusive,&#160;which means that our competitors may also receive access to the same technologies licensed </span></div><div style="line-height:10pt;position:var(--position);top:428pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to us. In that event, we may be required to expend significant time and resources to develop or license replacement </span></div><div style="line-height:10pt;position:var(--position);top:438pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">technology. </span></div><div style="line-height:10pt;position:var(--position);top:454pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Additionally, we sometimes collaborate with academic institutions to accelerate our preclinical research or </span></div><div style="line-height:10pt;position:var(--position);top:464pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">development under written agreements with these institutions. In certain cases, these institutions provide us with an </span></div><div style="line-height:10pt;position:var(--position);top:474pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Even if </span></div><div style="line-height:10pt;position:var(--position);top:484pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">we hold such an option, we may be unable to negotiate a license from the institution within the specified timeframe </span></div><div style="line-height:10pt;position:var(--position);top:494pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property </span></div><div style="line-height:10pt;position:var(--position);top:504pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">rights to others, potentially blocking our ability to pursue our program. </span></div><div style="line-height:10pt;position:var(--position);top:520pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies </span></div><div style="line-height:10pt;position:var(--position);top:530pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">that may be more established or have greater resources than we do may also be pursuing strategies to license or </span></div><div style="line-height:10pt;position:var(--position);top:540pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize </span></div><div style="line-height:10pt;position:var(--position);top:550pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">our drug candidates. More established companies may have a competitive advantage over us due to their size, cash </span></div><div style="line-height:10pt;position:var(--position);top:560pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">resources and greater clinical development and commercialization capabilities. In addition, companies that perceive </span></div><div style="line-height:10pt;position:var(--position);top:570pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">us to be a competitor may be unwilling to assign or license rights to us. There can be no assurance that we will be </span></div><div style="line-height:10pt;position:var(--position);top:580pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">able to successfully complete these types of negotiations and ultimately acquire the rights to the intellectual property </span></div><div style="line-height:10pt;position:var(--position);top:590pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">surrounding the additional drug candidates that we may seek to develop or market. If we are unable to successfully </span></div><div style="line-height:10pt;position:var(--position);top:600pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we </span></div><div style="line-height:10pt;position:var(--position);top:610pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">have, we may have to abandon development of certain programs and our business financial condition, results of </span></div><div style="line-height:10pt;position:var(--position);top:620pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">operations and prospects could suffer. </span></div><div style="line-height:10pt;position:var(--position);top:636pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The market price of our equity securities may be volatile, and purchasers of our ADSs could incur substantial </span></div><div style="line-height:10pt;position:var(--position);top:646pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">losses. </span></div><div style="line-height:10pt;position:var(--position);top:662pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The market price for our ADSs may be volatile. The stock market in general and the market for </span></div><div style="line-height:10pt;position:var(--position);top:672pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the </span></div><div style="line-height:10pt;position:var(--position);top:682pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">operating performance of particular companies. As a result of this volatility, investors may not be able to sell their </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">52</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ADSs at or above the price originally paid for the security. The market price for our ADSs and ordinary shares may </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">be influenced by many factors, including: </span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">actual or anticipated fluctuations in our financial condition and operating results; </span></span></div><div style="line-height:10pt;position:var(--position);top:114pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">actual or anticipated changes in our growth rate relative to our competitors; </span></span></div><div style="line-height:10pt;position:var(--position);top:130pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">competition from existing products or new products that may emerge; </span></span></div><div style="line-height:10pt;position:var(--position);top:146pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint </span></span></div><div style="line-height:10pt;position:var(--position);top:156pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">ventures, collaborations, or capital commitments; </span></div><div style="line-height:10pt;position:var(--position);top:172pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">failure to meet or exceed financial estimates and projections of the investment community or that we </span></span></div><div style="line-height:10pt;position:var(--position);top:182pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">provide to the public; </span></div><div style="line-height:10pt;position:var(--position);top:198pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">issuance of new or updated research or reports by securities analysts; </span></span></div><div style="line-height:10pt;position:var(--position);top:214pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">fluctuations in the valuation of companies perceived by investors to be comparable to us; </span></span></div><div style="line-height:10pt;position:var(--position);top:230pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares; </span></span></div><div style="line-height:10pt;position:var(--position);top:246pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">additions or departures of key management or scientific personnel; </span></span></div><div style="line-height:10pt;position:var(--position);top:262pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">lawsuits threatened or filed against us, disputes or other developments related to proprietary rights, </span></span></div><div style="line-height:10pt;position:var(--position);top:272pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">including patents, litigation matters, and our ability to obtain patent protection for our technologies; </span></div><div style="line-height:10pt;position:var(--position);top:288pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">changes to coverage policies or reimbursement levels by commercial third-party payors and </span></span></div><div style="line-height:10pt;position:var(--position);top:298pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">government payors and any announcements relating to coverage policies or reimbursement levels; </span></div><div style="line-height:10pt;position:var(--position);top:314pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">announcement or expectation of additional debt or equity financing efforts; </span></span></div><div style="line-height:10pt;position:var(--position);top:330pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">sales of our ordinary shares or ADSs by us, our insiders or our other shareholders; and </span></span></div><div style="line-height:10pt;position:var(--position);top:346pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">general economic and market conditions. </span></span></div><div style="line-height:10pt;position:var(--position);top:362pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">These and other market and industry factors may cause the market price and demand for our ADSs to fluctuate </span></div><div style="line-height:10pt;position:var(--position);top:372pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">substantially, regardless of our actual operating performance, which may limit or prevent investors from readily </span></div><div style="line-height:10pt;position:var(--position);top:382pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">selling their ADSs and may otherwise negatively affect the liquidity of the trading market for our ADSs. </span></div><div style="line-height:10pt;position:var(--position);top:398pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our </span></div><div style="line-height:10pt;position:var(--position);top:408pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">business, the price of our ADSs and their trading volume could decline. </span></div><div style="line-height:10pt;position:var(--position);top:424pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The trading market for our ADSs depends in part on the research and reports that securities or industry </span></div><div style="line-height:10pt;position:var(--position);top:434pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">analysts publish about us or our business. If no or few securities or industry analysts cover our company, the trading </span></div><div style="line-height:10pt;position:var(--position);top:444pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">price for our ADSs would be negatively impacted. If one or more of the analysts who covers us downgrades our </span></div><div style="line-height:10pt;position:var(--position);top:454pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">equity securities or publishes incorrect or unfavorable research about our business, the price of our ADSs would </span></div><div style="line-height:10pt;position:var(--position);top:464pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">likely decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us </span></div><div style="line-height:10pt;position:var(--position);top:474pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regularly, or downgrades our securities, demand for our ADSs could decrease, which could cause the price of our </span></div><div style="line-height:10pt;position:var(--position);top:484pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ADSs or their trading volume to decline. </span></div><div style="line-height:10pt;position:var(--position);top:500pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The requirements of being a U.S. public company may strain our resources and divert management&#8217;s attention. </span></div><div style="line-height:10pt;position:var(--position);top:516pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We are required to comply with various corporate governance and financial reporting requirements under the </span></div><div style="line-height:10pt;position:var(--position);top:526pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Sarbanes-Oxley Act, the Exchange Act, Nasdaq listing rules, and the rules and regulations adopted by the SEC and </span></div><div style="line-height:10pt;position:var(--position);top:536pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the Public Company Accounting Oversight Board, in addition to operating as a dual-listed company in France. </span></div><div style="line-height:10pt;position:var(--position);top:546pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Further, compliance with various regulatory reporting requires significant commitments of time from our </span></div><div style="line-height:10pt;position:var(--position);top:556pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">management and our directors, which reduces the time available for the performance of their other responsibilities. </span></div><div style="line-height:10pt;position:var(--position);top:566pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Our failure to track and comply with the various rules may materially adversely affect our reputation, ability to </span></div><div style="line-height:10pt;position:var(--position);top:576pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">obtain the necessary certifications to financial statements, lead to additional regulatory enforcement actions, and </span></div><div style="line-height:10pt;position:var(--position);top:586pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">could adversely affect the value of our ordinary shares or ADSs. </span></div><div style="line-height:10pt;position:var(--position);top:602pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">We may be at an increased risk of securities class action litigation. </span></div><div style="line-height:10pt;position:var(--position);top:618pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Historically, securities class action litigation has often been brought against a company following a decline in </span></div><div style="line-height:10pt;position:var(--position);top:628pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the market price of its securities. This risk is especially relevant for us because biotechnology and biopharmaceutical </span></div><div style="line-height:10pt;position:var(--position);top:638pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">companies have experienced significant share price volatility in recent years. If we were to be sued, it could result in </span></div><div style="line-height:10pt;position:var(--position);top:648pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">substantial costs, which could be insufficiently covered by insurance, and a diversion of management&#8217;s attention and </span></div><div style="line-height:10pt;position:var(--position);top:658pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">resources, which could harm our business. </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">53</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">We do not currently intend to pay dividends on our securities and, consequently, your ability to achieve a return </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">on your investment will depend on appreciation in the price of the ordinary shares and our ADSs. In addition, </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">French law may limit the amount of dividends we are able to distribute. </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We have never declared or paid any cash dividends on our ordinary shares and do not currently intend to do so </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. Therefore, </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">you are not likely to receive any dividends on your ADSs for the foreseeable future and the success of an investment </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">in ADSs will depend upon any future appreciation in its value. Consequently, investors may need to sell all or part </span></div><div style="line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of their holdings of ADSs after price appreciation, which may never occur, as the only way to realize any future </span></div><div style="line-height:10pt;position:var(--position);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">gains on their investment. There is no guarantee that the ADSs will appreciate in value or even maintain the price at </span></div><div style="line-height:10pt;position:var(--position);top:168pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">which our shareholders have purchased them. Investors seeking cash dividends should not purchase our ADSs. </span></div><div style="line-height:10pt;position:var(--position);top:178pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Furthermore, certain of our debt instruments restrict the payment of dividends or require consent to pay dividends. </span></div><div style="line-height:10pt;position:var(--position);top:188pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">See &#8220;Item 8.A Consolidated Statements and Other Financial Information&#8212;Dividend Policy.&#8221; </span></div><div style="line-height:10pt;position:var(--position);top:204pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Further, under French law, the determination of whether we have been sufficiently profitable to pay dividends </span></div><div style="line-height:10pt;position:var(--position);top:214pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">is made on the basis of our statutory financial statements prepared and presented in accordance with accounting </span></div><div style="line-height:10pt;position:var(--position);top:224pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">standards applicable in France. In addition, payment of dividends may subject us to additional taxes under French </span></div><div style="line-height:10pt;position:var(--position);top:234pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">law. Therefore, we may be more restricted in our ability to declare dividends than companies not based in France. </span></div><div style="line-height:10pt;position:var(--position);top:250pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In addition, exchange rate fluctuations may affect the amount of euros that we are able to distribute, and the </span></div><div style="line-height:10pt;position:var(--position);top:260pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">amount in U.S. dollars that our shareholders receive upon the payment of cash dividends or other distributions we </span></div><div style="line-height:10pt;position:var(--position);top:270pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">declare and pay in euros, if any. These factors could harm the value of our ADSs, and, in turn, the U.S. dollar </span></div><div style="line-height:10pt;position:var(--position);top:280pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">proceeds that holders receive from the sale of our ADSs. </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">54</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_40"></div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">Item 4.<span style="display:inline-block;height:6.77pt;width:6.02pt"></span></span><span style="left:108pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:36pt"></span></span><span style="left:144pt;position:var(--position)">Information on the Company.</span><span id="i3d6258ec83f54eaa8b87bfa0ba58ad89"></span></span></div><div style="position:absolute;top:96pt" id="i7a006daedb3d4216a4128b76247285d7_43"></div><div style="line-height:10pt;position:var(--position);top:96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">A.<span id="i80dbab105ce3449686ffe8cea731dfd3"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">History and Development of the Company</span></div><div style="line-height:10pt;position:var(--position);top:114pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our legal and commercial name is Abivax SA. We were incorporated as a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:395.01pt;position:var(--position);text-decoration:none;white-space:pre">soci&#233;t&#233; anonyme</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:461.31pt;position:var(--position);text-decoration:none;white-space:pre"> (limited liability </span></div><div style="line-height:10pt;position:var(--position);top:124pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">company) under the laws of France on December&#160;4, 2013 for a period of 99 years until December 22, 2112, subject </span></div><div style="line-height:10pt;position:var(--position);top:134pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to extension or early dissolution and registered at the Paris Trade and Company Register on December&#160;27, 2013 </span></div><div style="line-height:10pt;position:var(--position);top:144pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">under the number 799&#160;363&#160;718. Our principal executive offices are located at 7-11 boulevard Haussmann 75009 </span></div><div style="line-height:10pt;position:var(--position);top:154pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Paris, France, and our telephone number is +33&#160;(0)&#160;1&#160;53&#160;83&#160;09&#160;63. We have one wholly owned subsidiary, Abivax </span></div><div style="line-height:10pt;position:var(--position);top:164pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">LLC, a Delaware limited liability company, formed on March 20, 2023. Our agent for service of process in the </span></div><div style="line-height:10pt;position:var(--position);top:174pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">United States is CT Corporation System, 1015 15th Street N.W., Suite 1000, Washington, D.C. 20005. </span></div><div style="line-height:10pt;position:var(--position);top:190pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">We have </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:134.22pt;position:var(--position);text-decoration:none;white-space:pre">been</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:153.07999999999998pt;position:var(--position);white-space:pre"> listed on Euronext Paris since June 2015. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:322.65999999999997pt;position:var(--position);text-decoration:none;white-space:pre">In October 2023, we completed the initial public </span></div><div style="line-height:10pt;position:var(--position);top:200pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">offering of our ordinary shares in the form of ADSs on the Nasdaq Global Market, raising approximately $235.8 </span></div><div style="line-height:10pt;position:var(--position);top:210pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">million in gross proceeds (equivalent to approximately &#8364;223.3 million based on the exchange rate then in effect), </span></div><div style="line-height:10pt;position:var(--position);top:220pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">inclusive of proceeds from our concurrent private placement of ordinary shares in certain jurisdictions outside of the </span></div><div style="line-height:10pt;position:var(--position);top:230pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">United States.</span></div><div style="line-height:10pt;position:var(--position);top:246pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We did not incur any material capital expenditures for the years ended December 31, 2025, 2024 and 2023 </span></div><div style="line-height:10pt;position:var(--position);top:256pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">other than in the ordinary course of business, as described below in Item 5&#8212;Operating and Financial Review and </span></div><div style="line-height:10pt;position:var(--position);top:266pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Prospects.</span></div><div style="line-height:10pt;position:var(--position);top:282pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The SEC maintains an Internet site that contains reports, proxy information statements and other information </span></div><div style="line-height:10pt;position:var(--position);top:292pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regarding issuers that file electronically with the SEC. The address of that site is http://www.sec.gov. Our website </span></div><div style="line-height:10pt;position:var(--position);top:302pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">address is www.abivax.com. The reference to our website is an inactive textual reference only and information </span></div><div style="line-height:10pt;position:var(--position);top:312pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">contained in, or that can be accessed through, our website or any other website cited in this annual report is not part </span></div><div style="line-height:10pt;position:var(--position);top:322pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of this annual report.</span></div><div style="position:absolute;top:344pt" id="i7a006daedb3d4216a4128b76247285d7_46"></div><div style="line-height:10pt;position:var(--position);top:344pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">B.<span id="i2797c40cb302419f91a01779a685d618"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Business Overview</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:368pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Overview</span></div><div style="line-height:10pt;position:var(--position);top:384pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We are a clinical-stage biotechnology company focused on developing therapeutics that harness the body&#8217;s </span></div><div style="line-height:10pt;position:var(--position);top:394pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. We </span></div><div style="line-height:10pt;position:var(--position);top:404pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">focus on indications where existing treatments have left patients with significant unmet needs, and where we believe </span></div><div style="line-height:10pt;position:var(--position);top:414pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">our investigational agents have the potential to be meaningfully differentiated from currently available therapies. </span></div><div style="line-height:10pt;position:var(--position);top:424pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Our initial focus is on inflammatory bowel diseases ("IBD"), chronic conditions involving inflammation of the </span></div><div style="line-height:10pt;position:var(--position);top:434pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">gastrointestinal tract, of which the two most common forms are ulcerative colitis ("UC") and Crohn&#8217;s disease </span></div><div style="line-height:10pt;position:var(--position);top:444pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">("CD"). </span></div><div style="line-height:10pt;position:var(--position);top:460pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We believe our lead drug candidate, obefazimod, is differentiated from competing approaches for the </span></div><div style="line-height:10pt;position:var(--position);top:470pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">treatment of IBD via its novel mechanism of action ("MOA"). Obefazimod was demonstrated to specifically </span></div><div style="line-height:10pt;position:var(--position);top:480pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">enhance the expression of a single micro-RNA, miR-124, which plays a critical role in the regulation of the </span></div><div style="line-height:10pt;position:var(--position);top:490pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">inflammatory response. In the context of inflammation, miR-124 is a natural regulator of the inflammatory response, </span></div><div style="line-height:10pt;position:var(--position);top:500pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">controlling progression of inflammation and restoring homeostasis of the immune system, without causing broader </span></div><div style="line-height:10pt;position:var(--position);top:510pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">immunosuppression. In contrast to currently available advanced therapies, prescribed post-conventional therapies, </span></div><div style="line-height:10pt;position:var(--position);top:520pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">some of which target only a single cytokine or pathway, miR-124 modulates the expression of several key cytokines </span></div><div style="line-height:10pt;position:var(--position);top:530pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and pathways. Modulating multiple inflammatory pathways simultaneously may lead to more durability of efficacy </span></div><div style="line-height:10pt;position:var(--position);top:540pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">results over the long-term, which is critical in lifelong conditions such as IBD, potentially differentiating </span></div><div style="line-height:10pt;position:var(--position);top:550pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">obefazimod from currently available IBD treatments.</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">55</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Our Pipeline </span></div><div style="line-height:10pt;position:var(--position);top:90pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our lead drug candidate, obefazimod, is currently in Phase 3 clinical development for the treatment of </span></div><div style="line-height:10pt;position:var(--position);top:100pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">moderately to severely active UC. We are continuing to develop obefazimod for the treatment of CD and are </span></div><div style="line-height:10pt;position:var(--position);top:110pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">evaluating potential combination therapy opportunities in IBD to pursue. In parallel, we are in the process of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:120pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">strengthening our development portfolio by generating follow-on co</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:344.8pt;position:var(--position);text-decoration:none;white-space:pre">mpounds based on our miR-124 platform and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:130pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">assessing external early drug candidates in IBD. The chart below sets forth details of our pipeline:</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:463.75pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="position:var(--position);top:152pt;width:612pt"><div style="left:72pt;position:var(--position)"><div style="position:var(--position)"><img src="abvx-20251231_g1.gif" alt="Pipeline Chart March 2026.gif" style="height:171.37pt;width:468pt" id="i-1"/></div></div></div><div style="line-height:8pt;position:var(--position);top:328.37pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:5.2pt;font-style:normal;font-weight:normal;left:78.1pt;position:var(--position);text-decoration:none;top:-1.9389999999999998pt;vertical-align:super;white-space:pre">1 </span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:82pt;position:var(--position);text-decoration:none;white-space:pre">Under evaluation based on induction and maintenance Phase 3 clinical trials. </span></div><div style="line-height:10pt;position:var(--position);top:348.37pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Our Strategy </span></div><div style="line-height:10pt;position:var(--position);top:366.37pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">Our primary goal is to develop and commercialize obefazimod for the treatment of IBD, starting with </span></div><div style="line-height:10pt;position:var(--position);top:376.37pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">moderately to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.7pt;position:var(--position);text-decoration:none;white-space:pre">severely</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:162.98000000000002pt;position:var(--position);white-space:pre"> active UC and CD. We focus on indications with high unmet needs with substantial </span></div><div style="line-height:10pt;position:var(--position);top:386.37pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">commercial potential. To achieve our goal, we are pursuing the following key elements of our strategy:</span></div><div style="line-height:10pt;position:var(--position);top:402.37pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);white-space:pre">Advance obefazimod through pivotal clinical trials and establish obefazimod as a potential preferred </span></div><div style="line-height:10pt;position:var(--position);top:413.57pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);white-space:pre">advanced therapy for IBD. </span></div><div style="line-height:10pt;position:var(--position);top:430.77pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">We believe that the strength of the induction data we have generated in July 2025 in our Phase 3 clinical </span></div><div style="line-height:10pt;position:var(--position);top:440.77pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">trials, with a pooled 16.4% placebo-adjusted clinical remission rate after 8 weeks of treatment, and a highly </span></div><div style="line-height:10pt;position:var(--position);top:450.77pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">differentiated placebo adjusted clinical response rate across all lines of bio-na&#239;ve and bio-refractory </span></div><div style="line-height:10pt;position:var(--position);top:460.77pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">patients, including JAK resistant patients, with no major safety concerns, uniquely positions obefazimod as </span></div><div style="line-height:10pt;position:var(--position);top:470.77pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">a potential&#160; highly competitive advanced therapy choice for moderately to severely active UC, if approved.</span></div><div style="line-height:10pt;position:var(--position);top:486.77pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">We also believe that the strength of the maintenance data demonstrated in our Phase 2b trial (as evidenced </span></div><div style="line-height:10pt;position:var(--position);top:496.77pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">by a clinical remission rate of 53%, clinical response rate of 73% and no new adverse safety signals </span></div><div style="line-height:10pt;position:var(--position);top:506.77pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">observed from our two-year Phase 2b open label maintenance trial), should they be confirmed in our </span></div><div style="line-height:10pt;position:var(--position);top:516.77pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">ongoing Phase 3 maintenance trial, could further position obefazimod as a potential treatment of choice for </span></div><div style="line-height:10pt;position:var(--position);top:526.77pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">all UC patient treatment lines.</span></div><div style="line-height:10pt;position:var(--position);top:542.77pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">Based on the positive clinical data generated in our UC trials, preclinical studies in dextran sulfate sodium </span></div><div style="line-height:10pt;position:var(--position);top:552.77pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">("DSS") mouse model which provide support for pursuing further development in CD, and underlying </span></div><div style="line-height:10pt;position:var(--position);top:562.77pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">biological and mechanistic rationale, we also initiated a Phase 2b clinical trial in patients with CD in the </span></div><div style="line-height:10pt;position:var(--position);top:572.77pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">fourth quarter of 2024, with a planned top-line induction data read-out in the fourth quarter of 2026. CD </span></div><div style="line-height:10pt;position:var(--position);top:582.77pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">causes long-lasting inflammation and ulcers in the digestive tract, with fibrosis and structuring, playing a </span></div><div style="line-height:10pt;position:var(--position);top:592.77pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">key role in disease progression. It differs from UC in that it affects the entire thickness of the bowel wall </span></div><div style="line-height:10pt;position:var(--position);top:602.77pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">and all parts of the digestive tract from mouth to anus. However, CD shares many of the underlying </span></div><div style="line-height:10pt;position:var(--position);top:612.77pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">pathophysiological processes and clinical manifestations of UC, and, as a result, the current treatment </span></div><div style="line-height:10pt;position:var(--position);top:622.77pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">paradigm of CD is similar to UC, as described further below.</span></div><div style="line-height:10pt;position:var(--position);top:638.77pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">In addition, we believe that obefazimod&#8217;s clinical profile observed to date lends itself to potential </span></div><div style="line-height:10pt;position:var(--position);top:648.77pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">combinations with existing or new therapies, which we are exploring. </span></div><div style="line-height:10pt;position:var(--position);top:664.77pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90.7pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);white-space:pre">Potential combination therapy in IBD with obefazimod. </span></div><div style="line-height:10pt;position:var(--position);top:681.97pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">Currently available therapies have limited efficacy and durability that wane over time, have extensive pre-</span></div><div style="line-height:10pt;position:var(--position);top:691.97pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">initiation requirements, carry significant safety and tolerability challenges (such as black box safety </span></div><div style="line-height:10pt;position:var(--position);top:701.97pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">warnings), and many of them are injectable biologics. We believe several of obefazimod&#8217;s attributes make </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">56</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">it a potentially attractive candidate to pair with other advanced treatments. First, the oral route of </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">administration is preferred by a majority of patients, potentially resulting in higher levels of medication </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">adherence. Further, obefazimod&#8217;s proposed MOA harnesses the body&#8217;s natural regulatory mechanisms to </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">stabilize the immune response in patients with chronic inflammatory diseases. The novel MOA of </span></div><div style="line-height:10pt;position:var(--position);top:112pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">obefazimod potentially lends itself as complementary to other oral or injectable agents with the potential of </span></div><div style="line-height:10pt;position:var(--position);top:122pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">improving the induction and remission efficacy over monotherapy. We have initiated a formal process </span></div><div style="line-height:10pt;position:var(--position);top:132pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">evaluating oral and injectable combination therapy candidate with obefazimod in UC. In September 2024, </span></div><div style="line-height:10pt;position:var(--position);top:142pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">we announced initial preclinical combination data of obefazimod combined with etrasimod in a mouse </span></div><div style="line-height:10pt;position:var(--position);top:152pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">model of IBD. The results showed that treatment with the combination improved the response on body </span></div><div style="line-height:10pt;position:var(--position);top:162pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">weight protection and Disease Activity Index, and a synergistic and statistically significant reduction of </span></div><div style="line-height:10pt;position:var(--position);top:172pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">several cytokines (TNFa, IL-17, IL-6, IFNg) in the blood compared to each drug alone. Beyond this current </span></div><div style="line-height:10pt;position:var(--position);top:182pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">S1P opportunity, we are also investigating potential synergies with agents resulting from several other </span></div><div style="line-height:10pt;position:var(--position);top:192pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">MOAs (a4b7, IL-23, PDE-4 and ahR).</span></div><div style="line-height:10pt;position:var(--position);top:208pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">Additional preclinical data to support our decision-making on a combination agent, which would also be </span></div><div style="line-height:10pt;position:var(--position);top:218pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">based on an evaluation of our induction and maintenance data from our Phase 3 clinical trials, is expected </span></div><div style="line-height:10pt;position:var(--position);top:228pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">in 2026.</span></div><div style="line-height:10pt;position:var(--position);top:244pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90.7pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);white-space:pre">Leverage library of miR-124 enhancers to expand our pipeline in chronic inflammatory diseases. </span></div><div style="line-height:10pt;position:var(--position);top:261.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">Based on the mechanistic concept of obefazimod, we have launched a research and development program </span></div><div style="line-height:10pt;position:var(--position);top:271.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">to generate new potential drug candidates to strengthen our intellectual property portfolio on the miR-124 </span></div><div style="line-height:10pt;position:var(--position);top:281.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">platform and to identify additional drug candidates from our proprietary small molecule library that </span></div><div style="line-height:10pt;position:var(--position);top:291.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">includes additional miR-124 enhancers. We expect to announce an obefazimod follow-on candidate </span></div><div style="line-height:10pt;position:var(--position);top:301.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">selection in 2026.</span></div><div style="line-height:10pt;position:var(--position);top:317.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">We may also consider R&amp;D portfolio additions anytime, with compounds resulting from external scientific </span></div><div style="line-height:10pt;position:var(--position);top:328.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">and medical partnerships in chronic inflammatory diseases.at preclinical or clinical stage.</span></div><div style="line-height:10pt;position:var(--position);top:345.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);white-space:pre">Opportunistically evaluate strategic partnerships to maximize the value of obefazimod and our </span></div><div style="line-height:10pt;position:var(--position);top:356.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);white-space:pre">therapeutic pipeline. </span></div><div style="line-height:10pt;position:var(--position);top:374pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">We have discovered and are developing obefazimod as an innovative medicinal product and we currently </span></div><div style="line-height:10pt;position:var(--position);top:384pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">hold its worldwide rights. We intend to retain worldwide development and commercialization rights for </span></div><div style="line-height:10pt;position:var(--position);top:394pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">obefazimod. For certain </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:206.20999999999998pt;position:var(--position);text-decoration:none;white-space:pre">geographies</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:254.49pt;position:var(--position);white-space:pre">, we may opportunistically enter into strategic partnerships to </span></div><div style="line-height:10pt;position:var(--position);top:404pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">accelerate development activities in order to realize the commercial potential of obefazimod as well as </span></div><div style="line-height:10pt;position:var(--position);top:414pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">other assets in our pipeline. In connection with any potential strategic partnership, we plan to pursue and </span></div><div style="line-height:10pt;position:var(--position);top:424pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">receive upfront funding, milestone payments and future royalties for these agreements. </span></div><div style="line-height:10pt;position:var(--position);top:446pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Our Lead Drug Candidate for the Treatment of Inflammatory Diseases: Obefazimod</span></div><div style="line-height:10pt;position:var(--position);top:464pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Obefazimod is an oral small molecule drug candidate in clinical development for the treatment of moderately </span></div><div style="line-height:10pt;position:var(--position);top:474pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to severely active UC and CD. We believe that obefazimod is the only small molecule drug candidate in clinical </span></div><div style="line-height:10pt;position:var(--position);top:484pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">development with a mechanism of action that was demonstrated to specifically enhance the expression of a single </span></div><div style="line-height:10pt;position:var(--position);top:494pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">micro-RNA, miR-124, which plays a critical role in the regulation of the inflammatory response. </span></div><div style="line-height:10pt;position:var(--position);top:516pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Our Market Opportunity: UC and CD</span></div><div style="line-height:10pt;position:var(--position);top:534pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The estimated market opportunity for UC was approximately $9.2&#160;billion in worldwide sales in 2025 and is </span></div><div style="line-height:10pt;position:var(--position);top:544pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">expected to reach $21.8 billion in worldwide sales in 2032. In the United States, UC sales were approximately $6.0 </span></div><div style="line-height:10pt;position:var(--position);top:554pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">billion in 2025 and are expected to reach $14.9 billion by 2032. The UC market has seen tremendous growth which </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:564pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">is expected to continue. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:168.82pt;position:var(--position);text-decoration:none;white-space:pre">From 2020 to 2025, U.S. advanced therapy usage has increased by approximately 96% from </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:574pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">approximately 138,000 advanced therapy patients in 2020 to approximately 271,000 advanced therapy patients in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:584pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">2025. Recent and future anticipated growth stems from recent launches in UC, increased advanced therapy use, and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:594pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">differentiated MOA currently in the pipeline.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.32pt;position:var(--position);text-decoration:none;white-space:pre"> We currently estimate that approximately 300,000 moderate-to-severe </span></div><div style="line-height:10pt;position:var(--position);top:604pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">UC patients in the United States, out of an estimated 500,000 patients, are on conventional therapy or steroids only, </span></div><div style="line-height:10pt;position:var(--position);top:614pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and a safe, efficacious, oral therapy will have the unique ability to further penetrate this patient segment. We believe </span></div><div style="line-height:10pt;position:var(--position);top:624pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the potential for oral agents to gain significant market share is supported by physician and patient preference for the </span></div><div style="line-height:10pt;position:var(--position);top:634pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">convenience of oral administration over injectable agents, increasing demand for therapies with long-term efficacy </span></div><div style="line-height:10pt;position:var(--position);top:644pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">profiles and the opportunity for potent and well-tolerated oral agents to expand the overall segment of the </span></div><div style="line-height:10pt;position:var(--position);top:654pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">moderately to severely active UC population undergoing treatment.</span></div><div style="line-height:10pt;position:var(--position);top:670pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The estimated market opportunity for CD was approximately $15.2&#160;billion in worldwide sales in 2025 and is </span></div><div style="line-height:10pt;position:var(--position);top:680pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">expected to reach $19.4&#160;billion in worldwide sales in 2032. In 2025, approximately $10.5&#160;billion of sales were </span></div><div style="line-height:10pt;position:var(--position);top:690pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">generated from the United States. Similar to the UC market, we believe oral agents represent a significant </span></div><div style="line-height:10pt;position:var(--position);top:700pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">commercial opportunity, particularly if such therapeutics can provide long-term safety and efficacy profiles </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">57</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">comparable to injectable agents. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:203.18pt;position:var(--position);text-decoration:none;white-space:pre">We currently estimate that there are approximately 480,000 moderate-to-severe CD </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">patients in the United States, out of an estimated 800,000 patients.</span></div><div style="line-height:10pt;position:var(--position);top:110pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Summary of Obefazimod&#8217;s Mechanism of Action</span></div><div style="line-height:10pt;position:var(--position);top:126pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We believe our lead drug candidate, obefazimod, is differentiated from competing approaches for the </span></div><div style="line-height:10pt;position:var(--position);top:136pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">treatment of IBD via its novel MOA. It has been demonstrated that obefazimod enhances the expression of a single </span></div><div style="line-height:10pt;position:var(--position);top:146pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">micro-RNA, miR-124, which plays a critical role in the regulation of the inflammatory response. In the context of </span></div><div style="line-height:10pt;position:var(--position);top:156pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">inflammation, miR-124 is a natural regulator of the inflammatory response, controlling progression of inflammation </span></div><div style="line-height:10pt;position:var(--position);top:166pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and restoring homeostasis of the immune system, without causing broader immunosuppression. Once expressed, </span></div><div style="line-height:10pt;position:var(--position);top:176pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">micro-RNA interact with specific mRNA targets and decrease their translation into proteins to regulate specific </span></div><div style="line-height:10pt;position:var(--position);top:186pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">pathways. miR-124 is known to have an effect on two key immune cells, Th17 cells and macrophages, which causes </span></div><div style="line-height:10pt;position:var(--position);top:196pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reductions in both cell populations in the gut, as well as decreases in key related cytokines such as IL-17 and IL-6. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:206pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">IL-23, and TNF&#945;. In addition, we now have pre-clinical evidence that obefazimod has an effect on fibrobl</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:495.35pt;position:var(--position);text-decoration:none;white-space:pre">asts and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:216pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">other fibrosis-related cell types. We know that miR-124 can target both TGF-&#946; pathways and matrix </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:226pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">metalloproteinases ("MMPs"), and this can potentially have an anti-fibrotic effect, as illustrated in the images below.</span></div><div style="position:var(--position);top:248pt;width:612pt"><div style="left:72pt;position:var(--position)"><div style="position:var(--position)"><img src="abvx-20251231_g2.gif" alt="MoA - CBC Graphic.gif" style="height:207.48pt;width:468pt" id="i-2"/></div></div></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">58</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:var(--position);top:72pt;width:612pt"><div style="left:72pt;position:var(--position)"><div style="position:var(--position)"><img src="abvx-20251231_g3.gif" alt="MoA - Restore Immune Balance.gif" style="height:197.01pt;width:468pt" id="i-3"/></div></div></div><div style="line-height:1pt;position:var(--position);top:274.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:281.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">As</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:107.61pt;position:var(--position);text-decoration:none;white-space:pre"> further support of our understanding of obefazimod's MOA, in both ABTECT Phase 3 induction trials, we </span></div><div style="line-height:10pt;position:var(--position);top:291.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">observed that obefazimod significantly reduced IL-17A and IL-6 levels in serum in patients at week 8 compared </span></div><div style="line-height:10pt;position:var(--position);top:301.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">with placebo as seen in the image below. IL-17A and IL-6 reflect effects on the Th17 and inflammatory macrophage </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:311.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">populations, which are all drivers of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:218.79pt;position:var(--position);text-decoration:none;white-space:pre">mucosal inflammation in both UC and CD.</span></div><div style="position:var(--position);top:321.01pt;width:612pt"><div style="left:68.4pt;position:var(--position)"><div style="position:var(--position)"><img src="abvx-20251231_g4.gif" alt="Biomarker Data.gif" style="height:164.12pt;width:475.2pt" id="i-4"/></div></div></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">59</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Overview of Our Completed Phase 3 ABTECT Induction Trials and Ongoing Phase 3 ABTECT Maintenance </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Trial</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We initiated our pivotal Phase 3 clinical trials of obefazimod for the treatment of moderately to severely active&#160; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">UC in October 2022, which consists of two induction trials (ABTECT-1 and ABTECT-2) and one ABTECT </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">maintenance trial. In July 2025, we announced the top-line data from the two ABTECT induction trials. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:489.02pt;position:var(--position);text-decoration:none;white-space:pre">Overall, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">1,275 patients were randomized and 1,272 patients were treated in ABTECT-1 (N=636) and ABTECT-2 (N=636). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Below are the trial designs of our ABTECT induction and maintenance trials</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:379.11pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="position:var(--position);top:160pt;width:612pt"><div style="left:72pt;position:var(--position)"><div style="position:var(--position)"><img src="abvx-20251231_g5.gif" alt="UC Phase 3 Timeline.gif" style="height:150.13pt;width:468pt" id="i-5"/></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:333.13pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In both trials, baseline demographics and disease characteristics were similar between group</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:465.45pt;position:var(--position);text-decoration:none;white-space:pre">s; 45% and 49% </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:343.13pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of patients had inadequ</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:164.95pt;position:var(--position);text-decoration:none;white-space:pre">ate response to one or more advanced therapies. A slightly more severe and refractory </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:353.13pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">population were randomized to the 25 mg group in ABTECT-2 compared to ABTECT-1. Overall this was a highly </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:363.13pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">refractory patient population with approximately 21% of advanced therapy inadequate responders having previously </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:373.13pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">failed a JAK inhibitor.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:389.13pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In the pooled analysis of ABTECT trials, a significantly higher proportion of patients receiving obefazimod 50 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:399.13pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">mg (20.8%) or obefazimod 25 mg (17.6%) versus placebo (4.4%) achieved clinical remission (obefazimod 50 mg-</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:409.13pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">placebo difference: 16.4%, p&lt;0.0001; obefazimod 25 mg-placebo difference: 13.2%, p&lt;0.0001) and met all key </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:419.13pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">secondary endpoints </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:156.37pt;position:var(--position);text-decoration:none;white-space:pre">in</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:164.14pt;position:var(--position);text-decoration:none;white-space:pre"> both trials. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:211.87pt;position:var(--position);text-decoration:none;white-space:pre">A significantly higher proportion of patients receiving obefazimod 50 mg </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:429.13pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(ABTECT-1: 21.7%, ABTECT-2: 19.8%) versus placebo (2.5% and 6.3%) achieved clinical remission (obefazimod </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:439.13pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">50 mg-placebo difference: ABTECT-1: 19.3%, p&lt;0.0001; ABTECT-2: 13.4%, p=0.0001) and met all key secondary </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:449.13pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">endpoints in both trials. In ABTECT-1, a significantly higher proportion of patients receiving obefazimod 25 mg </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:459.13pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">versus placebo achieved clinical remission (obefazimod 25 mg -placebo difference: 21.4%, p&lt;0.0001) and met all </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:469.13pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">key secondary endpoi</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:159.14pt;position:var(--position);text-decoration:none;white-space:pre">nts. These results are shown in the charts below. </span></div><div style="position:var(--position);top:491.13pt;width:612pt"><div style="left:72pt;position:var(--position)"><div style="position:var(--position)"><img src="abvx-20251231_g6.gif" alt="ABTECT-1 (105) Induction Results.gif" style="height:182.74pt;width:468pt" id="i-6"/></div></div></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">60</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:var(--position);top:72pt;width:612pt"><div style="left:72pt;position:var(--position)"><div style="position:var(--position)"><img src="abvx-20251231_g7.gif" alt="Abtect-2 (106) Induction Results.gif" style="height:182.09pt;width:468pt" id="i-7"/></div></div></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:271.09pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Notes:</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:280.69pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(a)&#160;% Difference is for ABX464 minus placebo and is based on estimated common risk difference using the Mantel-Haenszel weights adjusting </span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:290.29pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for the randomization stratification f</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:188.34pt;position:var(--position);text-decoration:none;white-space:pre">actors: inadequate response to advanced therapies (yes/no), Baseline oral corticosteroids usage (yes/no). P-</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:299.89pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">values are two sided. NRI is used for subjects with missing outcome at Week 8 and subjects reporting any IE prior to Week 8.</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:309.49pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(b)&#160;Clinical remission is defined as SFS = 0 or 1, and RBS = 0 and MES = 0 or 1 (MES of 1 modified to exclude friability).</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:319.09pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Endoscopic improvement is defined as MES = 0 or 1 (MES of 1 modified to exclude friability).</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:328.69pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Clinical response is defined as a reduction from Baseline in MMS &gt;= 2 points and a relative reduction from Baseline in MMS &gt;= 30%, and a </span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:338.29pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reduction from Baseline in RBS &gt;= 1 point and/or RBS = 0 or 1. HEMI is defined as MES = 0 or 1 and Geboes Index score &lt;3.1 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:353.89pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The overall rates of serious adverse events and treatment emergent adverse events ("TEAEs") leading to study </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:363.89pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">drug discontinuation for patients treated with obefazimod were similar to placebo. Proportions of patients who </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:373.89pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reported at least one TEAE in ABTECT-1 were 59.4%, 46.9%, and 53.2% for obefazimod 50 mg, obefazimod 25 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:383.89pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">mg, and placebo, respectively. For ABTECT-2, TEAEs occurred in 61.0%, 50.9%, and 48.4% for obefazimod 50 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:393.89pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">mg, obefazimod 25 mg, and placebo, respectively. The most frequent TEAE was headache (obefazimod 50 mg: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:403.89pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">20.8-25.8%; obefazimod 25 mg: 14.5-15.6%; placebo: 5.7%). The headaches were mild, transient, short in duration </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:413.89pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and not a barrier to treatment, as evidenced by a low discontinuation rate of 1.6%. No signal was observed for </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:423.89pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">serious, severe, or opportunistic infections or malignancies. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:312.28999999999996pt;position:var(--position);text-decoration:none;white-space:pre">No clustering of serious TEAEs was observed; only </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:433.89pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">worsening of UC and pneumonia were reported more than once in any individual treatment arm.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:449.89pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Obefazimod&#8217;s tolerability profile indicates potentially important clinical differentiation. As of the data cutoff </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:459.89pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">date (September 30, 2025), 1,372 patients have received obefazimod in all completed and ongoing clinical trials </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:469.89pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">across all indications, including 324 patients for longer than one year. Additionally, 1,163 patients have received </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:479.89pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">only blinded obefazimod or placebo in the ABTECT program or Phase 2b clinical trial in CD. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:495.89pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We also conducted sub-group analyses for efficacy endpoints at week 8 for patients with and without prior </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:505.89pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">inadequate response to advanced therapies (AT-IR-Yes, AT-IR-No). In a pooled analysis of ABTECT-1 and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:515.89pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ABTECT-2, a higher proportion of the AT-IR-Yes subgroup receiving obefazimod 50 mg achieved all efficacy </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:525.89pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">measures relative to placebo including clinical remission (obefazimod 50 mg &#8211; placebo difference: 10.1%). In the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:535.89pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">AT-IR-Yes subgroup, the difference from placebo across all efficacy measures was lower for patients receiving </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:545.89pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">obefazimod 25 mg relative to obefazimod 50 mg. In the AT-IR-No subgroup, larger proportions achieved all </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:555.89pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">efficacy measures relative to placebo including clinical remission (obefazimod 50 mg &#8211; placebo difference: 22.4%). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:565.89pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">In the AT-IR-No subgroup, obefazimod 50 mg and obefazimod 25 mg performed similarly in the pooled analysis </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:575.89pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">across efficacy measures. In the subset of patients who failed JAKi, higher proportions of patients receiving </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:585.89pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">obefazimod 50 mg or obefazimod 25 mg achieved clinical response vs. placebo. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:394.97pt;position:var(--position);text-decoration:none;white-space:pre">The difference from placebo in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:595.89pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">clinical response for obefazimod 50 mg was </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:250.97pt;position:var(--position);text-decoration:underline;white-space:pre">&gt;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:256.6pt;position:var(--position);text-decoration:none;white-space:pre">25% across lines of treatment, from AT-IR-No through 4+ AT-IRs as </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:605.89pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">seen below.</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">61</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:var(--position);top:72pt;width:612pt"><div style="left:72pt;position:var(--position)"><div style="position:var(--position)"><img src="abvx-20251231_g8.gif" alt="Pooled Clinical Response by Number of prior AT Fail.gif" style="height:162.34pt;width:468pt" id="i-8"/></div></div></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:239.34pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Notes:</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:248.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(a)&#160;% Difference is for ABX464 minus placebo and is based on estimated common risk difference using the Mantel-Haenszel weights adjusting </span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:258.54pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for the randomization stratification factors: inadequate response to advanced therapies (yes/no), Baseline oral corticosteroids usage (yes/no). P-</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:268.14pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">values are two sided. NRI is used for subjects with missing outcome at Week 8 and subjects repo</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:382.46pt;position:var(--position);text-decoration:none;white-space:pre">rting any IE prior to Week 8.</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:277.74pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(b)&#160;Clinical response is defined as a reduction from Baseline in MMS &gt;= 2 points and a relative reduction from Baseline in MMS &gt;= 30%, and a </span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:287.34pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reduction from Baseline in RBS &gt;= 1 point and/or RBS = 0 or 1</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:302.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We expect to report top-line data from our Phase 3 ABTECT maintenance trial in late second quarter of 2026. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:312.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Subject to positive data, we currently expect to submit our NDA with the FDA in the fourth quarter of 2026.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:334.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Overview of Our Completed Maintenance Phase 2b Clinical Trial of Obefazimod for the Treatment of UC </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:350.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Of the 222 patients who completed our 16-week Phase 2b induction trial, 217 patients (98%) enrolled in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:360.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">subsequent open-label maintenance trial to evaluate the long-term safety and efficacy profile of obefazimod for up to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:370.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">two years, irrespective of treatments or treatment outcome during the induction phase. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:386.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">At week 48, of those 217 patients who received a 50 mg once-daily oral dosing with obefazimod, 178 patients </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:396.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(82%) had clinical response, 119 patients (55%) were in clinical remission, 133 patients (61%) had endoscopic </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:406.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">improvement and 72 patients (33%) had endoscopic remission. Among the 98 bio-refractory patients, 66 patients </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:416.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(67%) had a clinical response, 38 patients (39%) were in clinical remission, 46 patients (47%) had endoscopic </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:426.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">improvement and 20 patients (20%) had endoscopic remission at week 96. These results demonstrate potential for&#160; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:436.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">long-term clinical remission and clinical response of obefazimod in patients who were refractory to conventional </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:446.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">treatments, as well as patients who had previously failed treatment with biologics and/or JAK inhibitors. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:462.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Of the patients included in the maintenance trial, 164 patients (76%) completed two years of once-daily oral </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:472.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">dosing with 50 mg obefazimod. Thirty patients dropped out during the first year of treatment. Six&#160;patients did not </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:482.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">qualify for the second year due to non-response after the first year of treatment, and 17&#160;patients dropped out during </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:492.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the second year. These patients were all considered as treatment failures in the intent-to-treat analysis. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:508.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Of all 217 patients who entered the Phase 2b open-label maintenance trial, regardless of their status at the end </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:518.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of the 8-week induction period, 119 patients (55%) achieved clinical remission at week 48 and 114 patients (53%) </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:528.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">achieved clinical remission at week 96. Among the 124 patients who achieved clinical response at the end of the 8-</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:538.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">week induction period of the double-blind trial, 82 patients (66%) achieved clinical remission at week 48, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:548.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">mimicking the re-randomization of responders approach typically utilized in Phase 3 maintenance trials, and 74 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:558.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">patients (60%) achieved clinical remission at week 96. This comparison is shown below: </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:568.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">62</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:var(--position);top:72pt;width:612pt"><div style="left:72pt;position:var(--position)"><div style="position:var(--position)"><img src="abvx-20251231_g9.gif" alt="Clinical Remission Among All Patients and Week 8 Responders (ITT Analysis).gif" style="height:186.38pt;width:468pt" id="i-9"/></div></div></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:275.38pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Notes:</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:284.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">1. 217/222 eligible patients enrolled into open-label maintenance trial. </span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:294.58pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">2. Irrespective of the outcome at the end of the 8-week induction phase. </span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:304.18pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">3. n = Number of patients that met the respective e</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:233.95pt;position:var(--position);text-decoration:none;white-space:pre">ndpoint. </span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:313.78pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">4. N = Number of patients in the relevant analysis set. </span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:323.38pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">5. 124 patients achieved clinical response at end of the 8-week induction phase. </span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:332.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">6. 93 patients did not achieve clinical response at end of the 8-week induction phase.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:354.58pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Overview of Our Completed Phase 2 Open-Label Trial to Evaluate Long-Term Safety and Efficacy of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:364.58pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Obefazimod at 25 mg in UC</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:380.58pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In this open-label maintenance trial, patients who had completed the four-year Phase 2a or 2-year Phase 2b </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:390.58pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">open label maintenance trials, where they had received 50 mg of once-daily obefazimod, were given the opportunity </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:400.58pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to continue receiving obefazimod at a reduced dose of 25 mg daily for up to five additional years (provided they met </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:410.58pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the eligibility criteria of Mayo Endoscopic Subscore = 0 or 1). A total of 130 patients entered the trial, as of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:420.58pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">September 11, 2024, the data cut-off date, 113 patients have been evaluated out to 48 weeks and 74 patients have </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:430.58pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">undergone the full 96-week evaluation.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:446.58pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">At study baseline, 89% (116/130) of patients were in clinical remission. At weeks 48 and 96 of treatment, 84% </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:456.58pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(95/113) and 87% (64/74) of patients evaluated were in clinical remission, respectively. Similarly, 92% (119/130) of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:466.58pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">patients were in symptomatic remission at study baseline. At weeks 48 and 96, 91% (103/113) and 92% (68/74) of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:476.58pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">patients evaluated were in symptomatic remission, respectively. Similar trends were observed with other efficacy </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:486.58pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">analyses.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:502.58pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The safety results were consistent with previous trials, with no new safety signals detected. Patient retention </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:512.58pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">rates were high, with only 12% (16/130) of patients discontinuing in the first year and 5% (6/114) discontinuing </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:522.58pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">during the second year of treatment. Thirty-three patients had not reached week 96 as of September 11, 2024, the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:532.58pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">data cutoff date.</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">63</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Overview of Our Ongoing Phase 2b Crohn's Disease Trial (ENHANCE-CD)</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:88pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We have also initiated a Phase 2b clinical trial of obefazimod in patients with CD. Our Investigational New </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Drug ("IND") application for a Phase 2b clinical trial in patients with CD (trial design shown below) was cleared by </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the FDA in the fourth quarter of 2023, and we initiated enrollment in Octob</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:374.47pt;position:var(--position);text-decoration:none;white-space:pre">er 2024. We intend to announce Phase </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">2b induction trial top-line results in the fourth quarter of 2026 with the objective to demonstrate clinical response </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and a tolerability profile consistent with that already observed in our clinical trials for moderately to severely active </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">UC. Based on the results from this Phase 2b clinical trial, if positive, we intend to proceed to a Phase 3 clinical trial. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Below is the design of our Phase 2b trial</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:234.07pt;position:var(--position);text-decoration:none;white-space:pre">:</span></div><div style="position:var(--position);top:169.2pt;width:612pt"><div style="left:72pt;position:var(--position)"><div style="position:var(--position)"><img src="abvx-20251231_g10.gif" alt="CD Study Timeline.gif" style="height:181.56pt;width:468pt" id="i-10"/></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:355.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:379.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Existing UC Therapies and Their Limitations </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:397.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The c</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:118.96000000000001pt;position:var(--position);text-decoration:none;white-space:pre">urrent UC treatment approach is influenced by multiple factors, including disease severity, previous </span></div><div style="line-height:10pt;position:var(--position);top:407.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">response to treatment, side effects and co-morbidities. Both existing conventional therapies as well as advanced </span></div><div style="line-height:10pt;position:var(--position);top:417.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">therapies, including approved products and drug candidates in development, face significant room for improvement </span></div><div style="line-height:10pt;position:var(--position);top:427.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">in efficacy, safety and tolerability, and convenience from dosing and route of administration standpoints as </span></div><div style="line-height:10pt;position:var(--position);top:437.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">discussed below. </span></div><div style="line-height:1pt;position:var(--position);top:461.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="line-height:10pt;position:var(--position);top:462.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Conventional Therapies for UC </span></div><div style="line-height:10pt;position:var(--position);top:478.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Aminosalicylates (5-ASAs) are used as a first-line therapy in mildly to moderately active UC. Corticosteroids </span></div><div style="line-height:10pt;position:var(--position);top:488.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">are used primarily during induction therapy and are effective for reducing symptoms, but do not address mucosal </span></div><div style="line-height:10pt;position:var(--position);top:498.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">healing which limit their ability to modify and improve the underlying cause of disease. In addition, there are safety </span></div><div style="line-height:10pt;position:var(--position);top:508.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">considerations with extended corticosteroid use, including lowered quality of life, bone loss, weight gain and </span></div><div style="line-height:10pt;position:var(--position);top:518.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">cardiovascular complications. As a result, corticosteroids are used primarily as a bridge to manage symptoms until </span></div><div style="line-height:10pt;position:var(--position);top:528.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">immunomodulators or biologic agents become effective and enable mucosal healing. Oral immunosuppressants (e.g. </span></div><div style="line-height:10pt;position:var(--position);top:538.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">azathioprine, 6-mercatopurine and methotrexate) have not been effective as induction agents and are generally used </span></div><div style="line-height:10pt;position:var(--position);top:548.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for steroid-sparing or as an adjunctive therapy for reducing immunogenicity against biologic agents. Oral </span></div><div style="line-height:10pt;position:var(--position);top:558.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">immunosuppressants are also associated with known toxicities such as drops in white blood cell counts and </span></div><div style="line-height:10pt;position:var(--position);top:568.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">increased risk for infection. </span></div><div style="line-height:10pt;position:var(--position);top:584.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Given the above insufficiencies of these conventional therapies, patients suffering from mild UC may evolve </span></div><div style="line-height:10pt;position:var(--position);top:594.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">towards moderate and severe forms requiring the use of advanced therapies. </span></div><div style="line-height:10pt;position:var(--position);top:622.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Advanced Therapies for UC </span></div><div style="line-height:10pt;position:var(--position);top:638.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Advanced therapies for UC include biological agents as well as emerging oral molecules. Biological agents </span></div><div style="line-height:10pt;position:var(--position);top:648.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">such as TNF-alpha inhibitors (including infliximab, adalimumab and golimumab), IL-12/23 inhibitors (such as </span></div><div style="line-height:10pt;position:var(--position);top:658.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ustekinumab) or IL-23 inhibitors (mirikizumab, guselkumab, risankizumab), specifically block certain inflammatory </span></div><div style="line-height:10pt;position:var(--position);top:668.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">factors involved in UC. Biological agents also include gut-specific anti-integrin antibodies (such as vedolizumab and </span></div><div style="line-height:10pt;position:var(--position);top:678.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">natalizumab). Current oral therapies that target inflammatory pathways include JAK inhibitors (such as tofacitinib </span></div><div style="line-height:10pt;position:var(--position);top:688.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and upadacitinib), as well as agents that reduce the trafficking of inflammatory cells, such as S1P receptor agonists </span></div><div style="line-height:10pt;position:var(--position);top:698.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(e.g., ozanimod and etrasimod).</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">64</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">However, these therapies often only have moderate efficacy that may wane over time, as patients stop </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">responding or do not respond at all to these treatments and thus require new therapeutic management options. For </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">patients who do not or no longer respond to treatment, or experience complications, surgical treatment may be </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">necessary. Approximately 10% to 30% of UC patients require surgery over their lifetime. </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In addition, while TNF-alpha inhibitors and JAK inhibitors and newer biological agents, including anti-</span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">integrin antibodies, IL-12/23 inhibitors and IL-23 inhibitors, have generally improved the care of moderate to </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">severely active IBD, these are all anti-inflammatory agents with safety and tolerability concerns. These include </span></div><div style="line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">increased risks for cancers, infections and blood clots due to their systemic impact and resulting effects on the </span></div><div style="line-height:10pt;position:var(--position);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">immune system outside of the GI tract. In addition, prolonged treatment with biological therapies can lead to anti-</span></div><div style="line-height:10pt;position:var(--position);top:168pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">drug antibody development by patients&#8217; immune systems which may lead to gradual waning of therapeutic efficacy </span></div><div style="line-height:10pt;position:var(--position);top:178pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and patients needing to switch to other biological agents. Furthermore, biological agents require injections or </span></div><div style="line-height:10pt;position:var(--position);top:188pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">intravenous infusions, resulting in patient inconvenience and burden, which often negatively impacts patient </span></div><div style="line-height:10pt;position:var(--position);top:198pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">compliance. Injections can also lead to injection-related events such as sciatica, neuralgia, neuropathic pain and </span></div><div style="line-height:10pt;position:var(--position);top:208pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">peripheral neuropathy. </span></div><div style="line-height:10pt;position:var(--position);top:224pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In September 2021, the FDA published strict warnings about increased risk of serious heart-related events, </span></div><div style="line-height:10pt;position:var(--position);top:234pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">cancer, blood clots and death for JAK inhibitors that treat certain chronic inflammatory conditions (including UC). </span></div><div style="line-height:10pt;position:var(--position);top:244pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">In January 2023, the EMA stated recommendations to minimize the risk of serious side effects with JAK inhibitors </span></div><div style="line-height:10pt;position:var(--position);top:254pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">used to treat several chronic inflammatory disorders, noting that these side effects include cardiovascular conditions, </span></div><div style="line-height:10pt;position:var(--position);top:264pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">blood clots, cancer and serious infections which were adopted by the European Commission in March 2023. </span></div><div style="line-height:10pt;position:var(--position);top:280pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Recently, there have been efforts to develop drug candidates targeting novel mechanisms, such as S1P </span></div><div style="line-height:10pt;position:var(--position);top:290pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">receptor agonists and TL1A inhibitors. S1P agonists, while offering convenient oral dosing, have not achieved </span></div><div style="line-height:10pt;position:var(--position);top:300pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">meaningful commercial adoption. Ozanimod and etrasimod work by blocking the capacity of lymphocytes to egress </span></div><div style="line-height:10pt;position:var(--position);top:310pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">from lymph nodes, thereby reducing the number of lymphocytes in peripheral blood, which can lead to increased </span></div><div style="line-height:10pt;position:var(--position);top:320pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">susceptibility to infections. Furthermore, ozanimod, in its UC Study 1 which assessed efficacy during the induction </span></div><div style="line-height:10pt;position:var(--position);top:330pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">period, achieved 18% clinical remission in all patients compared to 6% for placebo at week 10.&#160; For patients with </span></div><div style="line-height:10pt;position:var(--position);top:340pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">prior exposure to TNF inhibitors, only 10% of patients achieved clinical remission compared to 5% for placebo. </span></div><div style="line-height:10pt;position:var(--position);top:350pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">TL1A inhibitors have garnered interest from those seeking newer targets and agents with differentiated clinical </span></div><div style="line-height:10pt;position:var(--position);top:360pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">profiles. Merck-Prometheus and Pfizer-Roivant have generated promising early Phase 2 data in both biologic-</span></div><div style="line-height:10pt;position:var(--position);top:370pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">experienced and biologic-na&#239;ve patients, and have recently initiated Phase 3 clinical trials. </span></div><div style="line-height:10pt;position:var(--position);top:386pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In summary, we believe that there is significant unmet medical need in the UC treatment paradigm due to </span></div><div style="line-height:10pt;position:var(--position);top:396pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">imperfect existing therapies with unfavorable clinical characteristics and limited efficacy that frequently wanes over </span></div><div style="line-height:10pt;position:var(--position);top:406pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">time. </span></div><div style="line-height:10pt;position:var(--position);top:422pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Obefazimod is being developed as a once-daily, oral medication which, combined with its observed </span></div><div style="line-height:10pt;position:var(--position);top:432pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">tolerability to date, would represent a meaningfully differentiated clinical profile from existing therapies. We believe </span></div><div style="line-height:10pt;position:var(--position);top:442pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">this may position obefazimod as a potential first-line advanced therapy choice for both prescribers and patients, if </span></div><div style="line-height:10pt;position:var(--position);top:452pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">approved. </span></div><div style="line-height:10pt;position:var(--position);top:480pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Phase 3 Clinical Trials and Regulatory Pathway in UC </span></div><div style="line-height:10pt;position:var(--position);top:496pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We are working with IQVIA, a global premier contract research organization, to conduct the Phase 3 clinical </span></div><div style="line-height:10pt;position:var(--position);top:506pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">trials with obefazimod in moderately to severely active UC, following consultations with regulatory agencies, </span></div><div style="line-height:10pt;position:var(--position);top:516pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">including FDA, EMA, CDE and PMDA. </span></div><div style="line-height:10pt;position:var(--position);top:532pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">These pivotal Phase 3 clinical trials consist of two induction trials (ABTECT-1 and ABTECT-2) and the </span></div><div style="line-height:10pt;position:var(--position);top:542pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">subsequent ABTECT maintenance trial investigating obefazimod at doses of 25 mg and 50 mg across 36&#160;countries </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:552pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">in North America, Latin America, Europe and Asia Pacific, involvin</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:345.55pt;position:var(--position);text-decoration:none;white-space:pre">g 1,275 </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:378.05pt;position:var(--position);text-decoration:none;white-space:pre">moderately to severely active UC </span></div><div style="line-height:10pt;position:var(--position);top:562pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">patients in over 600 sites. Each of the trials were randomized, double-blind and placebo-controlled, using </span></div><div style="line-height:10pt;position:var(--position);top:572pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">independent and central review of the video-taped endoscopies with the primary endpoint of clinical remission </span></div><div style="line-height:10pt;position:var(--position);top:582pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">according to the Modified Mayo Score assessed at week 8 (induction) and at the end of the 44-week maintenance </span></div><div style="line-height:10pt;position:var(--position);top:592pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">trial (total 52 weeks), as recommended by the FDA. </span></div><div style="line-height:10pt;position:var(--position);top:608pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The Modified Mayo Score evaluates UC disease activity, based on three parameters: stool frequency, rectal </span></div><div style="line-height:10pt;position:var(--position);top:618pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">bleeding and endoscopic evaluation. Each parameter of the score ranges from zero (normal or inactive disease) to </span></div><div style="line-height:10pt;position:var(--position);top:628pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">three (severe activity). The patient rates stool frequency score (&#8220;SFS&#8221;) and rectal bleeding score (&#8220;RBS&#8221;) daily. The </span></div><div style="line-height:10pt;position:var(--position);top:638pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">endoscopy subscore is evaluated by a central reader (who is blinded to any clinical information about the patient) </span></div><div style="line-height:10pt;position:var(--position);top:648pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">from an endoscopy that is performed at the trial site. The inclusion criteria based on FDA guidance for moderately to </span></div><div style="line-height:10pt;position:var(--position);top:658pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">severely active UC is active disease defined by a Modified Mayo Score &#8805; 5 with (RBS) &#8805; 1 and endoscopy subscore </span></div><div style="line-height:10pt;position:var(--position);top:668pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of 2 or 3 (confirmed by central reader). The primary endpoint for induction and maintenance is clinical remission </span></div><div style="line-height:10pt;position:var(--position);top:678pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">defined as SFS of 0 or 1 and not greater than baseline and RBS = 0 and endoscopy subscore of 0 or 1. At week 8, </span></div><div style="line-height:10pt;position:var(--position);top:688pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">secondary endpoints include endoscopic improvement, clinical response, symptomatic remission and histologic-</span></div><div style="line-height:10pt;position:var(--position);top:698pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">endoscopic mucosal improvement (&#8220;HEMI&#8221;). At week 44 of the maintenance trial, secondary endpoints include </span></div><div style="line-height:10pt;position:var(--position);top:708pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">endoscopic improvement, symptomatic remission, corticosteroid-free clinical remission, sustained clinical </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">65</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">remission, HEMI and endoscopic remission. After week 44, a long-term extension trial will follow for eligible and </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">willing subjects for an additional for up to 4&#160; years, or until the commercialization of obefazimod, whichever occurs </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">first.</span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Enrollment of the first patient under this program in the United States occurred on October&#160;11, 2022. Top-line </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">data from the ABTECT-1 and ABTECT-2 induction trials </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:306.73pt;position:var(--position);text-decoration:none;white-space:pre">were announced in July 2</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:408.86pt;position:var(--position);text-decoration:none;white-space:pre">025, and top-line data from the </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ABTECT maintenance trial is expected to be announced in late second quarter of 2026. </span></div><div style="line-height:1pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="line-height:10pt;position:var(--position);top:157pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Additional Clinical Trials Completed with Obefazimod </span></div><div style="line-height:10pt;position:var(--position);top:173pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In addition, three Phase 1 clinical trials have been completed in 2025 to assess the tolerability and safety </span></div><div style="line-height:10pt;position:var(--position);top:183pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">profile of obefazimod: (i) two drug-drug interaction trials, for the purposes of providing further information on any </span></div><div style="line-height:10pt;position:var(--position);top:193pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">possible interactions of obefazimod with other drugs, for which we enrolled 24 and 36 healthy volunteers </span></div><div style="line-height:10pt;position:var(--position);top:203pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">respectively; and (ii) a trial in participants with mild and moderate hepatic impairment compared to matched control </span></div><div style="line-height:10pt;position:var(--position);top:213pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">normal liver function participants, for the purposes of assessing pharmacokinetics, safety and tolerability in this </span></div><div style="line-height:10pt;position:var(--position);top:223pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">population, for which we enrolled 30 participants. The results of these Phase 1 clinical trials provide supportive data </span></div><div style="line-height:10pt;position:var(--position);top:233pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for our further clinical development and New Drug Application (&#8220;NDA&#8221;) submission. Furthermore, additional Phase </span></div><div style="line-height:10pt;position:var(--position);top:243pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">1 clinical trials to support NDA submission are ongoing. While we have decided not to pursue additional clinical </span></div><div style="line-height:10pt;position:var(--position);top:253pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">work in rheumatoid arthritis ("RA") at this point, we have completed a Phase 2a clinical trial in patients with RA, </span></div><div style="line-height:10pt;position:var(--position);top:263pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">where we saw encouraging proof-of-concept data supporting obefazimod&#8217;s potential role in addressing inflammatory </span></div><div style="line-height:10pt;position:var(--position);top:273pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">conditions beyond IBD. </span></div><div style="line-height:10pt;position:var(--position);top:301pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Potential Combination Therapy for the Treatment of IBD with Obefazimod as the Cornerstone </span></div><div style="line-height:10pt;position:var(--position);top:317pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Despite the development of various advanced targeted therapies for IBD over the past 20 years, a single agent </span></div><div style="line-height:10pt;position:var(--position);top:327pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">with transformational efficacy remains elusive. Although cross-trial efficacy comparisons must be interpreted with </span></div><div style="line-height:10pt;position:var(--position);top:337pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">caution, induction of clinical remission rates have currently reached a placebo-adjusted therapeutic ceiling up to </span></div><div style="line-height:10pt;position:var(--position);top:347pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">30%. Improved efficacy of combination therapy with thiopurines and TNF-alpha inhibitors has been well described </span></div><div style="line-height:10pt;position:var(--position);top:357pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(SONIC and UC-SUCCESS) but did not breach the aforementioned efficacy ceiling. Emerging data utilizing dual </span></div><div style="line-height:10pt;position:var(--position);top:367pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">advanced targeted therapy affecting complementary mechanisms of action indicate a potential path to higher </span></div><div style="line-height:10pt;position:var(--position);top:377pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">efficacy rates. The first trial utilizing this strategy (VEGA) randomized patients to three parallel treatment groups: </span></div><div style="line-height:10pt;position:var(--position);top:387pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(1) dual combination therapy with guselkumab (IL-23 inhibitor) plus golimumab (TNF-alpha inhibitor); (2) </span></div><div style="line-height:10pt;position:var(--position);top:397pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">guselkumab alone; or (3)&#160;golimumab alone. At the end of the 12-week induction period, a greater proportion of </span></div><div style="line-height:10pt;position:var(--position);top:407pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">patients randomized to dual combination therapy achieved clinical remission (approximately 47%) compared to </span></div><div style="line-height:10pt;position:var(--position);top:417pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">either monotherapy treatment arms (guselkumab at approximately 25%; golimumab at approximately 24%). </span></div><div style="line-height:10pt;position:var(--position);top:427pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Importantly, adverse events, serious adverse events and infection rates were comparable among treatment groups. </span></div><div style="line-height:10pt;position:var(--position);top:437pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">J&amp;J has progressed these findings and initiated a fixed-dose combination phase 2 clinical trial of guselkumab plus </span></div><div style="line-height:10pt;position:var(--position);top:447pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">golimumab (JNJ-4804) in UC/CD.</span></div><div style="line-height:10pt;position:var(--position);top:463pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We believe synergistic improvements that may be achieved with advanced combination therapy should be </span></div><div style="line-height:10pt;position:var(--position);top:473pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">balanced with patient adherence to multiple biologic injections and safety considerations associated with immune </span></div><div style="line-height:10pt;position:var(--position);top:483pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">suppression. Several of obefazimod&#8217;s attributes make it a potentially attractive candidate to pair with other advanced </span></div><div style="line-height:10pt;position:var(--position);top:493pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">treatments. First, the oral route of administration is preferred by a majority of patients, potentially resulting in higher </span></div><div style="line-height:10pt;position:var(--position);top:503pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">levels of medication adherence. Further, obefazimod&#8217;s proposed mechanism of action harnesses the body&#8217;s natural </span></div><div style="line-height:10pt;position:var(--position);top:513pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The novel </span></div><div style="line-height:10pt;position:var(--position);top:523pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">mechanism of action of obefazimod potentially lends itself as complementary to other oral or injectable agents with </span></div><div style="line-height:10pt;position:var(--position);top:533pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the potential of improving the induction and remission efficacy over monotherapy. We believe the current clinical </span></div><div style="line-height:10pt;position:var(--position);top:543pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">results we have observed with obefazimod including a lack of safety signals up to 96 weeks of treatment support </span></div><div style="line-height:10pt;position:var(--position);top:553pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">development as an agent to be used in potential combination therapy. </span></div><div style="line-height:10pt;position:var(--position);top:569pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We have initiated a formal process evaluating oral and injectable combination therapy candidate with </span></div><div style="line-height:10pt;position:var(--position);top:579pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">obefazimod in UC. In September 2024, we announced results of initial preclinical combination data of obefazimod </span></div><div style="line-height:10pt;position:var(--position);top:589pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">combined with etrasimod in a mouse model of IBD. The results showed that treatment with the combination </span></div><div style="line-height:10pt;position:var(--position);top:599pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">improved the response on body weight protection and Disease Activity Index with a synergistic and statistically </span></div><div style="line-height:10pt;position:var(--position);top:609pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">significant reduction of several cytokines (TNFa, IL-17, IL-6, IFNg) in the blood compared to each drug alone. </span></div><div style="line-height:10pt;position:var(--position);top:619pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Additional preclinical data to support our decision-making on a combination agent is expected by the end of 2026.</span></div><div style="line-height:10pt;position:var(--position);top:647pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Follow-On Compounds Program </span></div><div style="line-height:10pt;position:var(--position);top:663pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Based on the mechanistic concept of obefazimod, a research and development program is currently ongoing to </span></div><div style="line-height:10pt;position:var(--position);top:673pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">generate new potential drug candidates to strengthen our intellectual property portfolio on the miR-124 platform. </span></div><div style="line-height:10pt;position:var(--position);top:683pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The first follow-on drug candidate is expected to be selected in 2026. </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">66</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Additional Ongoing Pre-Clinical Research</span></div><div style="line-height:10pt;position:var(--position);top:88pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">A major complication of chronic inflammation in IBD is fibrosis, particularly in CD. To date, no efficacious </span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">anti-fibrotic treatment for IBD patients is available. As miR-124 is reduced in fibrotic tissue and can suppress TGF-</span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#946;, a central driver of fibrogenesis, we assessed whether obefazimod-mediated miR-124 induction affects collagen </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">deposition and fibrotic markers in preclinical models.</span></div><div style="line-height:10pt;position:var(--position);top:134pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Two sets of experiments were performed to assess the anti-fibrotic effects of obefazimod: (1) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:471.6pt;position:var(--position);text-decoration:none;white-space:pre">in vitro</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:500.73pt;position:var(--position);text-decoration:none;white-space:pre"> fibrosis </span></div><div style="line-height:10pt;position:var(--position);top:144pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">was evaluated in the Scar-in-a-Jar ("SiaJ") model using human small-intestinal fibroblasts, stimulated with an IBD-</span></div><div style="line-height:10pt;position:var(--position);top:154pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">fibrotic cytokine cocktail ("IBD-FC"). Nintedanib, omipalisib and upadacitinib were used as comparators. Readouts </span></div><div style="line-height:10pt;position:var(--position);top:164pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">included cytotoxicity, PRO-C3, and &#945;-SMA; and (2) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:284.56pt;position:var(--position);text-decoration:none;white-space:pre">in vivo</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:311.46000000000004pt;position:var(--position);text-decoration:none;white-space:pre"> effects were assessed in the chronic TNBS-colitis </span></div><div style="line-height:10pt;position:var(--position);top:174pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">mouse model, where obefazimod (100 mg/kg) or control (vehicle or thalidomide) were administered orally either </span></div><div style="line-height:10pt;position:var(--position);top:184pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">from day 5 (anti-inflammatory + fibrosis-preventive effect) or from day 20 (early-onset anti-fibrotic effect). Disease </span></div><div style="line-height:10pt;position:var(--position);top:194pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">activity, body weight, colon parameters, histology and collagen deposition were analyzed.</span></div><div style="line-height:10pt;position:var(--position);top:210pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our results were as follows:</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:208.61pt;position:var(--position);text-decoration:none;white-space:pre"> in vitro</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:240.24pt;position:var(--position);text-decoration:none;white-space:pre">, obefazimod induced a statistically significant 50% reduction in PRO-C3 </span></div><div style="line-height:10pt;position:var(--position);top:220pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">at day 12, compared with the IBD-FC condition and upadacitinib (live-cell&#8211;adjusted, p&lt;0.0001 vs. IBD-FC). </span></div><div style="line-height:10pt;position:var(--position);top:230pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Notably, the IBD-FC SiaJ assay showed pathway specificity: nintedanib showed no activity, while omipalisib did </span></div><div style="line-height:10pt;position:var(--position);top:240pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(as shown below). Additionally, cell-number&#8211;adjusted analysis showed significant &#945;-SMA reduction by obefazimod </span></div><div style="line-height:10pt;position:var(--position);top:250pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">indicating a strong inhibition of fibroblast activation (p&lt; 0.0001 vs. IBD-FC, as shown below).</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:451.49pt;position:var(--position);text-decoration:none;white-space:pre"> In vivo</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:481.45pt;position:var(--position);text-decoration:none;white-space:pre">, the known </span></div><div style="line-height:10pt;position:var(--position);top:260pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">anti-inflammatory effects of obefazimod were confirmed in the chronic colitis model under both dosing schedules. </span></div><div style="line-height:10pt;position:var(--position);top:270pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Moreover, results from this initial experiment showed a reduction in the fibrosis score and collagen deposition was </span></div><div style="line-height:10pt;position:var(--position);top:280pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reduced by approximately 52% with day 5 dosing and approximately 42% with day 20 dosing in the Sirius Red </span></div><div style="line-height:10pt;position:var(--position);top:290pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">assay, whereas thalidomide as a positive control achieved approximately 24%. These data support an anti-fibrotic </span></div><div style="line-height:10pt;position:var(--position);top:300pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">effect of obefazimod in two well-established models, inhibiting collagen deposition and fibroblast activation. Initial </span></div><div style="line-height:10pt;position:var(--position);top:310pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">in vivo</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:98.9pt;position:var(--position);text-decoration:none;white-space:pre"> mouse data, aligned with the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:218.48pt;position:var(--position);text-decoration:none;white-space:pre">in vitro</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:247.61pt;position:var(--position);text-decoration:none;white-space:pre"> findings, indicate that obefazimod may act in a unique way on both </span></div><div style="line-height:10pt;position:var(--position);top:320pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">intestinal inflammation and fibrosis. We believe these promising results provide a strong rationale to further </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:330pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">investigate obefazimod&#8217;s anti-fibrotic potential in our ongoing Phase 2b CD trial. These results below </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:481.26pt;position:var(--position);text-decoration:none;white-space:pre">were </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:340pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">presented</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:110.28pt;position:var(--position);text-decoration:none;white-space:pre"> at ECCO 2</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:156.62pt;position:var(--position);text-decoration:none;white-space:pre">026. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:176.62pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="position:var(--position);top:362pt;width:612pt"><div style="left:72pt;position:var(--position)"><div style="position:var(--position)"><img src="abvx-20251231_g11.gif" alt="Anti-Fibrosis Studies.gif" style="height:182.06pt;width:468pt" id="i-11"/></div></div></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">67</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:var(--position);top:72pt;width:612pt"><div style="left:72pt;position:var(--position)"><div style="position:var(--position)"><img src="abvx-20251231_g12.gif" alt="Anti-Fibrosis Studies pt 2.gif" style="height:197.16pt;width:468pt" id="i-12"/></div></div></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:292.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Notes: Obefazimod treatment i</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:170.8pt;position:var(--position);text-decoration:none;white-space:pre">nitiated on either day 5 (anti-inflammatory + fibrosis-preventive effect) or from day 20 (early-onset anti-fibrotic </span></div><div style="line-height:8pt;position:var(--position);top:300.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">effect); ***p&lt;0.001,&#160;****p&lt;0.0001&#160;one-way ANOVA with Tukey&#8217;s multiple comparisons test</span></div><div style="line-height:10pt;position:var(--position);top:320.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Manufacturing and Supply </span></div><div style="line-height:10pt;position:var(--position);top:338.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Obefazimod </span></div><div style="line-height:10pt;position:var(--position);top:354.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our lead compound, obefazimod, is manufactured using commercially available, widely used raw materials </span></div><div style="line-height:10pt;position:var(--position);top:364.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and common chemical engineering and synthetic processes. The historical volatility in the prices of these raw </span></div><div style="line-height:10pt;position:var(--position);top:374.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">materials has not had a material impact on our operating results. Obefazimod is formulated as an oral solid capsule. </span></div><div style="line-height:10pt;position:var(--position);top:384.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">We have successfully scaled-up active pharmaceutical ingredients and drug product processes, and we have a large </span></div><div style="line-height:10pt;position:var(--position);top:394.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">supply of active pharmaceutical ingredients and capsules available for clinical trials. </span></div><div style="line-height:10pt;position:var(--position);top:410.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We outsource all manufacturing operations and rely on European and North American third-party CMOs to </span></div><div style="line-height:10pt;position:var(--position);top:420.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">supply clinical trials and finalize the development of obefazimod. These operations are designed to be in compliance </span></div><div style="line-height:10pt;position:var(--position);top:430.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">with the standards imposed by Good Manufacturing Practice (&#8220;GMP&#8221;). We believe our outsourcing strategy and </span></div><div style="line-height:10pt;position:var(--position);top:440.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">internal organization allow us to focus our resources on the development of different drug candidates and the </span></div><div style="line-height:10pt;position:var(--position);top:450.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">management of third parties, without investing in expensive manufacturing facilities and equipment. All third parties </span></div><div style="line-height:10pt;position:var(--position);top:460.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">are assessed under our quality system and agreements are in place to compel compliance and we maintain </span></div><div style="line-height:10pt;position:var(--position);top:470.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">agreements with manufacturers which include confidentiality and intellectual property provisions to protect </span></div><div style="line-height:10pt;position:var(--position);top:480.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">proprietary rights. </span></div><div style="line-height:10pt;position:var(--position);top:496.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We are in the process of further optimizing and scaling up our supply chain for obefazimod to ensure capacity </span></div><div style="line-height:10pt;position:var(--position);top:506.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for our expected commercial supply, if the FDA or foreign regulatory authority approved.&#160; In addition, w</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:491.87pt;position:var(--position);white-space:pre">e are in </span></div><div style="line-height:10pt;position:var(--position);top:516.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">process of establishing a second source manufacturer for obefazimod to ensure continuity of product supply.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:544.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Competition</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:125.3pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="line-height:10pt;position:var(--position);top:560.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We compete with companies that have drugs on the market or are developing drug candidates for chronic IBD. </span></div><div style="line-height:10pt;position:var(--position);top:570.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The biotechnology and pharmaceutical industries are highly competitive and subject to significant and rapid </span></div><div style="line-height:10pt;position:var(--position);top:580.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">technological change, as researchers learn more about chronic IBD and develop new technologies and treatments. </span></div><div style="line-height:10pt;position:var(--position);top:596.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Significant competitive factors in our industry include: (i)&#160;product efficacy and safety; (ii)&#160;quality and breadth </span></div><div style="line-height:10pt;position:var(--position);top:606.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of an organization&#8217;s technology; (iii)&#160;skill of an organization&#8217;s employees and its ability to recruit and retain key </span></div><div style="line-height:10pt;position:var(--position);top:616.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">employees; (iv)&#160;timing and scope of regulatory approvals; (v)&#160;government reimbursement rates for, and the average </span></div><div style="line-height:10pt;position:var(--position);top:626.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">selling price of, pharmaceutical products; (vi)&#160;the availability of raw materials and qualified manufacturing capacity; </span></div><div style="line-height:10pt;position:var(--position);top:636.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(vii)&#160;manufacturing costs; intellectual property and patent rights and their protection; and (viii)&#160;sales and marketing </span></div><div style="line-height:10pt;position:var(--position);top:646.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">capabilities. Our competitors in the chronic inflammatory disease field are primarily large pharmaceuticals </span></div><div style="line-height:10pt;position:var(--position);top:656.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">companies including, but not limited to, AbbVie, Johnson&#160;&amp; Johnson, Takeda, Pfizer and Eli Lilly. Merck, Roche, </span></div><div style="line-height:10pt;position:var(--position);top:666.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and Teva/Sanofi are all potential future competitors based on recent acquisitions of TL1A molecules. Several lines </span></div><div style="line-height:10pt;position:var(--position);top:676.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of research are being developed to improve the treatment of IBD. Many companies are working to develop new, </span></div><div style="line-height:10pt;position:var(--position);top:686.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">more effective and better tolerated treatments with more practical formulations, especially small molecules </span></div><div style="line-height:10pt;position:var(--position);top:696.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">administered orally, better accepted than monoclonal antibodies that require administration by injection or </span></div><div style="line-height:10pt;position:var(--position);top:706.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">intravenous infusions. </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">68</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The molecules on the market and in development have various mechanisms of action and are primarily: </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(i)&#160;TNF-alpha inhibitors; (ii)&#160;IL-12/23 inhibitors; (iii)&#160;anti-integrin antibodies; (iv)&#160;IL-23 inhibitors; (v)&#160;JAK </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">inhibitors; (vi)&#160;S1P receptor agonists; or (vii)&#160;TL1A inhibitors. </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In the TNF-alpha treatment class, Remicade</span><span style="font-family:'Times New Roman', serif;font-size:4.875pt;font-style:normal;font-weight:normal;left:272.9pt;position:var(--position);text-decoration:none;top:-2.4254999999999995pt;vertical-align:super;white-space:pre">&#174;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:276.6pt;position:var(--position);text-decoration:none;white-space:pre"> (Janssen) was first approved by the FDA in 1998. In 2012, the </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">European Commission approved AbbVie&#8217;s Humira</span><span style="font-family:'Times New Roman', serif;font-size:4.875pt;font-style:normal;font-weight:normal;left:277.38pt;position:var(--position);text-decoration:none;top:-2.4254999999999995pt;vertical-align:super;white-space:pre">&#174;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:281.08000000000004pt;position:var(--position);text-decoration:none;white-space:pre"> for the treatment of pediatric patients aged six to 17 years with </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">severe active CD who have an inadequate response, are intolerant or have contraindications to conventional therapy. </span></div><div style="line-height:1pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="line-height:10pt;position:var(--position);top:145.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">IL-12/23 inhibitors entered the UC market in 2019 as ustekinumab (Johnson&#160;&amp; Johnson&#8217;s Stelara</span><span style="font-family:'Times New Roman', serif;font-size:4.875pt;font-style:normal;font-weight:normal;left:484.78pt;position:var(--position);text-decoration:none;top:-2.4254999999999995pt;vertical-align:super;white-space:pre">&#174;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:488.48pt;position:var(--position);text-decoration:none;white-space:pre">). In 2021, </span></div><div style="line-height:10pt;position:var(--position);top:155.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">AbbVie filed an authorization application with FDA and EMA for risankizumab (Anti-IL-23&#8212;Skyrizi</span><span style="font-family:'Times New Roman', serif;font-size:4.875pt;font-style:normal;font-weight:normal;left:481.86pt;position:var(--position);text-decoration:none;top:-2.4254999999999995pt;vertical-align:super;white-space:pre">&#174;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.56pt;position:var(--position);text-decoration:none;white-space:pre">) for the </span></div><div style="line-height:10pt;position:var(--position);top:165.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">treatment of moderately to severely active CD and in 2024 it was approved for UC. </span></div><div style="line-height:10pt;position:var(--position);top:181.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The anti-integrin class is currently represented by vedolizumab/Entyvio</span><span style="font-family:'Times New Roman', serif;font-size:4.875pt;font-style:normal;font-weight:normal;left:383.08pt;position:var(--position);text-decoration:none;top:-2.4254999999999995pt;vertical-align:super;white-space:pre">&#174;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:386.78pt;position:var(--position);text-decoration:none;white-space:pre"> and natalizumab/Tysabri</span><span style="font-family:'Times New Roman', serif;font-size:4.875pt;font-style:normal;font-weight:normal;left:488.3pt;position:var(--position);text-decoration:none;top:-2.4254999999999995pt;vertical-align:super;white-space:pre">&#174;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:492pt;position:var(--position);text-decoration:none;white-space:pre">. We are </span></div><div style="line-height:10pt;position:var(--position);top:191.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">also aware of Morphic Therapeutic&#8217;s MORF-057 and Protagonist Therapeutics/Johnson&#160;&amp; Johnson&#8217;s PN-943 </span></div><div style="line-height:10pt;position:var(--position);top:201.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">currently in development. The anti-integrin drugs work by preventing the leukocytes to move from the blood vessels </span></div><div style="line-height:10pt;position:var(--position);top:211.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to sites of inflammation. They block the action of integrin on the surface of circulating immune cells and endothelial </span></div><div style="line-height:10pt;position:var(--position);top:221.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">cell adhesion molecules, thereby inhibiting the interactions between leukocytes and intestinal blood vessels. </span></div><div style="line-height:10pt;position:var(--position);top:231.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Natalizumab and vedolizumab block alpha4-integrin and alpha4beta7-integrin respectively. These drugs are </span></div><div style="line-height:10pt;position:var(--position);top:241.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">injectable (Humanized mAb). </span></div><div style="line-height:10pt;position:var(--position);top:257.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In 2021, Eli Lilly reported that mirikizumab (Anti-IL-23) generated data in a Phase 3 maintenance trial in </span></div><div style="line-height:10pt;position:var(--position);top:267.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">patients with UC that led to European Commission and FDA approvals for UC. Regulatory filings have also been </span></div><div style="line-height:10pt;position:var(--position);top:277.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">submitted for CD. All these drugs are injectable (Humanized mAb). Abbvie received FDA approval in moderately to </span></div><div style="line-height:10pt;position:var(--position);top:287.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">severely active UC for Skyrizi in June 2024 and J&amp;J received FDA approval for Tremfya in September 2024. IL-23 </span></div><div style="line-height:10pt;position:var(--position);top:297.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">is a regulator of T-helper (Th)-17 cell. IL-23 prevents regulatory T-cell response in the intestine, and therefore </span></div><div style="line-height:10pt;position:var(--position);top:307.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">increases inflammation in the gut. Anti-interleukins targeting the IL-23 have been shown to be effective for </span></div><div style="line-height:10pt;position:var(--position);top:317.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">induction and maintenance of remission in patients with moderate-severe UC. </span></div><div style="line-height:10pt;position:var(--position);top:333.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The JAK correspond to four intracellular tyrosine kinases: JAK1, JAK2, JAK3 and tyrosine kinase 2. </span></div><div style="line-height:10pt;position:var(--position);top:343.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Inhibition of the JAK-STAT signal channel makes it possible to block the production of pro-inflammatory </span></div><div style="line-height:10pt;position:var(--position);top:353.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">cytokines, including TNF-alpha, to block other pathways of inflammation and to regulate innate and adaptive </span></div><div style="line-height:10pt;position:var(--position);top:363.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">immunity. Thus, several cytokines and several inflammation pathways are blocked simultaneously, unlike TNF-</span></div><div style="line-height:10pt;position:var(--position);top:373.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">alpha inhibitors, which only have a single target. In September 2021, FDA published a black box warning, requiring </span></div><div style="line-height:10pt;position:var(--position);top:383.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">pharmaceutical companies to provide a warning for increased risk of serious cardiac events, cancer, blood clots and </span></div><div style="line-height:10pt;position:var(--position);top:393.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">death linked to JAK inhibitor treatments used for the treatment of certain IBD, including UC. Consequently, these </span></div><div style="line-height:10pt;position:var(--position);top:403.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">treatments are only accessible to patients who do not respond to any other available treatment and who have certain </span></div><div style="line-height:10pt;position:var(--position);top:413.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">well-defined conditions. In the JAK inhibitor class, to our knowledge the following products are authorized or in </span></div><div style="line-height:10pt;position:var(--position);top:423.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">advanced development: </span></div><div style="line-height:10pt;position:var(--position);top:439.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">Pfizer&#8217;s tofacitinib (Xeljanz</span></span><span style="font-family:'Times New Roman', serif;font-size:4.875pt;font-style:normal;font-weight:normal;left:238.54000000000002pt;position:var(--position);text-decoration:none;top:-2.4254999999999995pt;vertical-align:super;white-space:pre">&#174;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:242.24pt;position:var(--position);text-decoration:none;white-space:pre">) is a non-selective JAK inhibitor. It obtained marketing approval in UC </span></div><div style="line-height:10pt;position:var(--position);top:449.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">in June 2018. In September 2021, the FDA concluded that there was a high risk of serious side effects </span></div><div style="line-height:10pt;position:var(--position);top:459.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">following a randomized clinical trial conducted to assess the safety of tofacitinib. Consequently, the </span></div><div style="line-height:10pt;position:var(--position);top:469.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">molecule will be used as a third line treatment in patients who meet specific criteria. </span></div><div style="line-height:10pt;position:var(--position);top:485.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">Gilead and Galapagos&#8217; filgotinib (Jyseleca</span></span><span style="font-family:'Times New Roman', serif;font-size:4.875pt;font-style:normal;font-weight:normal;left:297.38pt;position:var(--position);text-decoration:none;top:-2.4254999999999995pt;vertical-align:super;white-space:pre">&#174;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301.08pt;position:var(--position);text-decoration:none;white-space:pre">) is a selective JAK1 inhibitor. Since November 2021, </span></div><div style="line-height:10pt;position:var(--position);top:495.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">filgotinib has been approved for the treatment of UC in the European Union (the &#8220;EU&#8221;). Authorization </span></div><div style="line-height:10pt;position:var(--position);top:505.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">requests have also been submitted to the UK Medicines and Healthcare products Regulatory Agency </span></div><div style="line-height:10pt;position:var(--position);top:515.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">(&#8220;MHRA&#8221;) and the Japanese PMDA for the treatment of moderately to severely active UC. In January </span></div><div style="line-height:10pt;position:var(--position);top:525.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">2024, Alfasigma acquired the rights to filgotinib from Galapagos.</span></div><div style="line-height:10pt;position:var(--position);top:541.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">AbbVie&#8217;s upadacitinib (Rinvoq</span></span><span style="font-family:'Times New Roman', serif;font-size:4.875pt;font-style:normal;font-weight:normal;left:253.04000000000002pt;position:var(--position);text-decoration:none;top:-2.4254999999999995pt;vertical-align:super;white-space:pre">&#174;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:256.74pt;position:var(--position);text-decoration:none;white-space:pre">), which is also a selective JAK1 inhibitor, was approved by the FDA </span></div><div style="line-height:10pt;position:var(--position);top:551.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">in March 2022 for the treatment of moderately to severely active UC. European Commission </span></div><div style="line-height:10pt;position:var(--position);top:561.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">authorization for the treatment of moderately to severely active UC was granted in July 2022. Rinvoq </span></div><div style="line-height:10pt;position:var(--position);top:571.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">was then approved in moderately to severely active CD in 2023.</span></div><div style="line-height:10pt;position:var(--position);top:587.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">S1P receptor agonists allow sequestration of activated lymphocytes in lymph nodes and thus reduce their </span></div><div style="line-height:10pt;position:var(--position);top:597.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">circulation in the GI tract. Ozanimod (Zeposia</span><span style="font-family:'Times New Roman', serif;font-size:4.875pt;font-style:normal;font-weight:normal;left:257.02pt;position:var(--position);text-decoration:none;top:-2.4254999999999995pt;vertical-align:super;white-space:pre">&#174;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:260.72pt;position:var(--position);text-decoration:none;white-space:pre">) is a S1P receptor modulator that is selective for the S1P1 and S1P5 </span></div><div style="line-height:10pt;position:var(--position);top:607.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">receptors. It was approved by the FDA and European Commission for the treatment of moderately to severely active </span></div><div style="line-height:10pt;position:var(--position);top:617.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">UC in 2021. In March 2024, BMS announced that ozanimod failed their first Phase 3 induction clinical trial for CD. </span></div><div style="line-height:10pt;position:var(--position);top:627.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">In October 2023, Pfizer announced approval of Velsipity for moderately to severely active UC. Phase 2/3 CD </span></div><div style="line-height:10pt;position:var(--position);top:637.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Velsipity clinical trials are underway. In addition, in October 2023, Ventyx Biosciences announced results from its </span></div><div style="line-height:10pt;position:var(--position);top:647.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Phase 2 clinical trial of VTX002 in UC. However, further development is contingent on finding a strategic partner to </span></div><div style="line-height:10pt;position:var(--position);top:657.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">advance VTX002 to Phase 3 clinical trials.</span></div><div style="line-height:10pt;position:var(--position);top:673.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We are also aware of other types of treatments currently under various stages of development, such as </span></div><div style="line-height:10pt;position:var(--position);top:683.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">NImmune Biopharma&#8217;s omilancor (a Lanthionine Synthetase C-Like 2 activator) as well as tyrosine kinase 2 </span></div><div style="line-height:10pt;position:var(--position);top:693.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">inhibitors from Bristol Myers Squibb&#8217;s Sotyktu (deucravacitinib &#8211; approved in the EU) and Ventyx Biosciences&#8217; </span></div><div style="line-height:10pt;position:var(--position);top:703.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">VTX 958. </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">69</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Furthermore, TL1A inhibitors have garnered interest from those seeking newer targets and agents with </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">differentiated clinical profile. Merck-Prometheus and Pfizer-Roivant have generated promising early Phase 2 data in </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">both biologics-experienced and biologics-na&#239;ve patients, and have recently initiated Phase 3 clinical trials. </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Market acceptance of our drug candidates will depend on a number of factors, including: (i)&#160;potential </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">advantages over existing or alternative therapies or tests; (ii)&#160;the actual or perceived safety of similar classes of </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">products; (iii)&#160;the effectiveness of our sales, marketing, and distribution capabilities; and (iv)&#160;the scope of any </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">approval provided by the FDA or foreign regulatory authorities. </span></div><div style="line-height:10pt;position:var(--position);top:154pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We anticipate that we will face intense and increasing competition as new drugs and therapies enter the market </span></div><div style="line-height:10pt;position:var(--position);top:164pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and advanced technologies become available. </span></div><div style="line-height:10pt;position:var(--position);top:192pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Government Regulation </span></div><div style="line-height:10pt;position:var(--position);top:208pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Companies operating in the pharmaceutical industry are subject to increased scrutiny by the competent </span></div><div style="line-height:10pt;position:var(--position);top:218pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">authorities and must deal with an ever-changing and increasingly restrictive legal and regulatory environment. </span></div><div style="line-height:10pt;position:var(--position);top:234pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The development of drugs involves several stages: research and development, preclinical tests, clinical trials, </span></div><div style="line-height:10pt;position:var(--position);top:244pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">authorization, manufacturing, commercialization and post-marketing surveillance. </span></div><div style="line-height:10pt;position:var(--position);top:260pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">All of these stages are subject to specific requirements that impose substantial and onerous constraints, </span></div><div style="line-height:10pt;position:var(--position);top:270pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">compliance with which is ensured by various national (in France, the ANSM), regional (in the EU, the EMA and the </span></div><div style="line-height:10pt;position:var(--position);top:280pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">national competent authorities of EU Member States) or federal (in the United States, the FDA) authorities. </span></div><div style="line-height:10pt;position:var(--position);top:296pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Failure to comply with these regulations may be subject to fines, to the suspension, variation or withdrawal of </span></div><div style="line-height:10pt;position:var(--position);top:306pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the authorizations and certifications required to perform pharmaceutical activities, to the seizure or withdrawal of </span></div><div style="line-height:10pt;position:var(--position);top:316pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">products from the market, or to partial or total suspension of their manufacturing. Regulatory authorities may also </span></div><div style="line-height:10pt;position:var(--position);top:326pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">withdraw marketing authorizations (&#8220;MAs&#8221;) previously granted, reject MA applications (&#8220;MAAs&#8221;) and initiate legal </span></div><div style="line-height:10pt;position:var(--position);top:336pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">proceedings whose outcome remains uncertain. </span></div><div style="line-height:10pt;position:var(--position);top:352pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Although the regulatory constraints may differ from a country to another, development of therapeutic products </span></div><div style="line-height:10pt;position:var(--position);top:362pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for human use must comply with requirements shared by all developed countries. The steps to be completed before </span></div><div style="line-height:10pt;position:var(--position);top:372pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">obtaining an MA in the EU and in the United States are generally as follows: </span></div><div style="line-height:10pt;position:var(--position);top:388pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">conduct of preclinical laboratory tests and studies in animals, in accordance with Good Laboratory </span></span></div><div style="line-height:10pt;position:var(--position);top:398pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">Practice (&#8220;GLP&#8221;); </span></div><div style="line-height:10pt;position:var(--position);top:414pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">conduct of clinical trials in humans to demonstrate the safety and efficacy of the product for each </span></span></div><div style="line-height:10pt;position:var(--position);top:424pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">considered indication, in accordance with Good Clinical Practice (&#8220;GCP&#8221;), after authorization by a </span></div><div style="line-height:10pt;position:var(--position);top:434pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">competent authority and a positive ethics committee opinion; </span></div><div style="line-height:10pt;position:var(--position);top:450pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">if trial results are positive, preparation and submission of an MAA to the competent authority, in order </span></span></div><div style="line-height:10pt;position:var(--position);top:460pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">to market the product; </span></div><div style="line-height:1pt;position:var(--position);top:474.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="line-height:10pt;position:var(--position);top:475.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">inspection by the competent authority of the manufacturing facilities in which the product and/or its </span></span></div><div style="line-height:10pt;position:var(--position);top:485.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">ingredients are manufactured to assess compliance with Good Manufacturing Practices (&#8220;GMP&#8221;); </span></div><div style="line-height:10pt;position:var(--position);top:501.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">inspection by the competent authority of establishments distributing medicinal products in order to </span></span></div><div style="line-height:10pt;position:var(--position);top:511.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">assess their compliance with Good Distribution Practice (&#8220;GDP&#8221;); and </span></div><div style="line-height:10pt;position:var(--position);top:527.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">if needed, commitment by the applicant to comply with post-MA requirements. </span></span></div><div style="line-height:10pt;position:var(--position);top:543.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Due to these regulatory constraints, the development and approval process of a drug candidate for </span></div><div style="line-height:10pt;position:var(--position);top:553.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">commercialization, which varies according to its nature, complexity and novelty, usually extends over several years. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:581.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">EU Regulation </span></div><div style="line-height:10pt;position:var(--position);top:597.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Preclinical Studies </span></div><div style="line-height:10pt;position:var(--position);top:613.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Within all EU Member States, preclinical studies include laboratory evaluation of the composition, purity and </span></div><div style="line-height:10pt;position:var(--position);top:623.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">stability of the active pharmaceutical ingredient and the formulated product, as well as studies to evaluate the </span></div><div style="line-height:10pt;position:var(--position);top:633.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">tolerance (toxicological studies), activity and behavior of the product candidate in vitro and in animals (in vivo). </span></div><div style="line-height:10pt;position:var(--position);top:649.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The conduct of preclinical studies is subject to legal and regulatory provisions. Non-clinical studies are </span></div><div style="line-height:10pt;position:var(--position);top:659.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">performed to demonstrate the health or environmental safety of new chemical or biological substances. Non-clinical </span></div><div style="line-height:10pt;position:var(--position);top:669.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(pharmaco-toxicological) studies must be conducted in compliance with GLP, as set forth in EU Directive 2004/10/</span></div><div style="line-height:10pt;position:var(--position);top:679.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">EC (unless otherwise justified for certain particular medicinal products &#8211; e.g., radio-pharmaceutical precursors for </span></div><div style="line-height:10pt;position:var(--position);top:689.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">radio-labelling purposes). In particular, non-clinical studies, both in vitro and in vivo, must be planned, performed, </span></div><div style="line-height:10pt;position:var(--position);top:699.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">monitored, recorded, reported and archived in accordance with the GLP principles, which define a set of rules and </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">70</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">criteria for a quality system for the organizational process and the conditions for non-clinical studies. These GLP </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">standards reflect the Organization for Economic Co-operation and Development requirements. </span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Preclinical studies are a prerequisite for the initiation of clinical trials in humans: all the results of these trials </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">are submitted to the regulatory authorities at the same time as the application to initiate clinical trials. However, </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">while preclinical tests must be performed prior to conducting clinical trials in humans, certain long-term preclinical </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">tests, such as tests on reproductive toxicity and carcinogenicity, may continue after the submission of an application </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to initiate clinical trials. </span></div><div style="line-height:10pt;position:var(--position);top:166pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Clinical Trials in Humans </span></div><div style="line-height:10pt;position:var(--position);top:182pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The various phases of clinical trials in the EU are subject to significant regulatory controls. They must be </span></div><div style="line-height:10pt;position:var(--position);top:192pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">conducted in accordance with EU and national regulations, the standards adopted by the International Conference on </span></div><div style="line-height:10pt;position:var(--position);top:202pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Harmonization (&#8220;ICH&#8221;) and GCP. </span></div><div style="line-height:10pt;position:var(--position);top:218pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Directive no. 2001/20/EC on the conduct of clinical trials sought to harmonize the regulatory framework for </span></div><div style="line-height:10pt;position:var(--position);top:228pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">clinical trials in the EU, setting out common rules for the monitoring and authorization of clinical trials in the EU. </span></div><div style="line-height:10pt;position:var(--position);top:238pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">To reduce disparities between the transpositions by the Member States, Regulation 536/2014 on clinical trials on </span></div><div style="line-height:10pt;position:var(--position);top:248pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">medicinal products for human use and repealing Directive 2001/20/EC, was adopted on April 16, 2014. This </span></div><div style="line-height:10pt;position:var(--position);top:258pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regulation aims to further harmonize and streamline the clinical trial authorization process, improve their </span></div><div style="line-height:10pt;position:var(--position);top:268pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">supervision, simplify adverse event reporting procedures and increase the transparency of clinical trials. This </span></div><div style="line-height:10pt;position:var(--position);top:278pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regulation became applicable on January 31, 2022. Following a three-year transition period, all clinical trials </span></div><div style="line-height:10pt;position:var(--position);top:288pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(including those ongoing and whose conduct was authorized in accordance with Directive no. 2001/20/EC), are fully </span></div><div style="line-height:10pt;position:var(--position);top:298pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">subject to the provisions of the Regulation 536/2014 since January 31, 2025 and must have been brought into </span></div><div style="line-height:10pt;position:var(--position);top:308pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">compliance with the legal framework it provides. Failing this, the trial loses its authorization and must be stopped. </span></div><div style="line-height:10pt;position:var(--position);top:324pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.75pt;position:var(--position);text-decoration:none;white-space:pre">Under the clinical trials regulation, the sponsor may submit its application for a clinical trial authorization to </span></div><div style="line-height:10pt;position:var(--position);top:334pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">one or several Member States, in which case the evaluation of Part I of the dossier (scientific part) is carried out </span></div><div style="line-height:10pt;position:var(--position);top:344pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">according to a coordinated procedure. In this framework, the sponsor must submit a single application for </span></div><div style="line-height:10pt;position:var(--position);top:354pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">authorization via the portal associated with the EU database (&#8220;CTIS&#8221;), comprising a common scientific part </span></div><div style="line-height:10pt;position:var(--position);top:364pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">evaluated jointly by all the EU Member States in which the trial will be carried out (with one of the Member States </span></div><div style="line-height:10pt;position:var(--position);top:374pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">concerned acting as rapporteur Member State) and a national part covering the ethical aspects of the trial, evaluated </span></div><div style="line-height:10pt;position:var(--position);top:384pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">independently by each Member State. </span></div><div style="line-height:10pt;position:var(--position);top:400pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The conclusion of the rapporteur Member State with regard to Part I of the assessment report is deemed to be </span></div><div style="line-height:10pt;position:var(--position);top:410pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the conclusion of all Member States concerned. However, the Member States concerned may disagree with this </span></div><div style="line-height:10pt;position:var(--position);top:420pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">conclusion for a number of limited reasons, for example when they consider that participation in the clinical trial </span></div><div style="line-height:10pt;position:var(--position);top:430pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">would lead to a subject receiving a treatment inferior to that of normal clinical practice on their territory. The </span></div><div style="line-height:10pt;position:var(--position);top:440pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Member State concerned may then refuse the conduct of the clinical trial on its territory. </span></div><div style="line-height:10pt;position:var(--position);top:456pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">A &#8220;single&#8221; decision covering the conclusions of the Part I and Part II evaluations is issued by each of the </span></div><div style="line-height:10pt;position:var(--position);top:466pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Member States concerned and is notified to the sponsor on the dedicated European portal. </span></div><div style="line-height:10pt;position:var(--position);top:482pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The sponsor of a clinical trial conducted in the EU notifies through the EudraVigilance database without delay </span></div><div style="line-height:10pt;position:var(--position);top:492pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and at the latest within the deadlines set by the clinical trials regulation, of all relevant information on suspected </span></div><div style="line-height:10pt;position:var(--position);top:502pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">serious and unexpected adverse reactions to the investigational medicinal product. If the competent bodies </span></div><div style="line-height:10pt;position:var(--position);top:512pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">concerned consider that the adverse effects outweigh the benefits for the participants, they may require the </span></div><div style="line-height:10pt;position:var(--position);top:522pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">immediate suspension or early termination of the trial at any time. </span></div><div style="line-height:10pt;position:var(--position);top:538pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In addition, the sponsor must submit through CTIS once a year, for the duration of the clinical trial, an Annual </span></div><div style="line-height:10pt;position:var(--position);top:548pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Safety Report (ASR) for each investigational drug used in the clinical trial. </span></div><div style="line-height:10pt;position:var(--position);top:564pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Finally, the EU framework applicable to clinical trials has also been significantly strengthened with </span></div><div style="line-height:10pt;position:var(--position);top:574pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Regulation (EU) 2016/679 of the European Parliament and of the Council of April&#160;27, 2016, on the protection of </span></div><div style="line-height:10pt;position:var(--position);top:584pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">natural persons with regard to the processing of personal data and on the free movement of such data, and repealing </span></div><div style="line-height:10pt;position:var(--position);top:594pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Directive 95/46/EC (General Data Protection Regulation, &#8220;GDPR&#8221;), which entered into force on May&#160;25, 2018. This </span></div><div style="line-height:10pt;position:var(--position);top:604pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regulation has significantly increased EU citizens&#8217; rights by giving them more control over their personal data. Thus, </span></div><div style="line-height:10pt;position:var(--position);top:614pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">depending on the type of personal data processing carried out during clinical trials and the nature of such trials, it </span></div><div style="line-height:10pt;position:var(--position);top:624pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">might be necessary to carry out formalities by the local Data Protection Authority, in addition to seeking formal </span></div><div style="line-height:10pt;position:var(--position);top:634pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">informed consent which must be obtained from each clinical trial subject. </span></div><div style="line-height:10pt;position:var(--position);top:662pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Responsibility of the Sponsor and Insurance Obligation of the Sponsor </span></div><div style="line-height:10pt;position:var(--position);top:678pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In the EU, the sponsor shall indemnify the subjects of the trial in case of damage arising as a consequence of </span></div><div style="line-height:10pt;position:var(--position);top:688pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">their participation in the research, unless he proves that the damage does not result from his fault or the fault of any </span></div><div style="line-height:10pt;position:var(--position);top:698pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">other person intervening in the trial. In the EU, Member States generally require a sponsor to have an insurance </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">71</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">covering its civil liability and the liability of any person intervening in the research. In addition, any breach to the </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">provisions concerning clinical trials may lead to significant administrative, criminal and/or reputational penalties. </span></div><div style="line-height:10pt;position:var(--position);top:110pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Marketing Approval </span></div><div style="line-height:10pt;position:var(--position);top:126pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Within the EU, marketing of medicinal products is governed by EU regulations (including but not limited to </span></div><div style="line-height:10pt;position:var(--position);top:136pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Directive 2001/83/EC and Regulation 726/2004/EU). </span></div><div style="line-height:10pt;position:var(--position);top:152pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">On April 26, 2023, the European Commission issued proposals for a revision of the current legal framework </span></div><div style="line-height:10pt;position:var(--position);top:162pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">aiming at granting timely access to patients for safe, effective and affordable medicines and at enhancing supply of </span></div><div style="line-height:10pt;position:var(--position);top:172pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">medicines (namely, the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:167.42000000000002pt;position:var(--position);text-decoration:none;white-space:pre">pharma</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:197.38pt;position:var(--position);white-space:pre"> package). On December 11, 2025, the European Parliament and the EU Council </span></div><div style="line-height:10pt;position:var(--position);top:182pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">reached political </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.76pt;position:var(--position);text-decoration:none;white-space:pre">agreement</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:182.35pt;position:var(--position);white-space:pre"> on the reform. The new legal framework, which will significantly amend some of the </span></div><div style="line-height:10pt;position:var(--position);top:192pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">general principles described above, notably timelines and market exclusivity periods, will enter into force in 2026 </span></div><div style="line-height:10pt;position:var(--position);top:202pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">and will become fully applicable in 2028 after a transition phase. </span></div><div style="line-height:1pt;position:var(--position);top:221pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="line-height:10pt;position:var(--position);top:228pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In the EU, medicinal product candidates can only be commercialized after obtaining an MA. To obtain </span></div><div style="line-height:10pt;position:var(--position);top:238pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regulatory approval of a product candidate under EU regulatory systems, we must submit an MAA. The process for </span></div><div style="line-height:10pt;position:var(--position);top:248pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">doing this depends, among other things, on the nature of the medicinal product. There are two types of MAs: </span></div><div style="line-height:10pt;position:var(--position);top:264pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">&#8220;Centralized MAs&#8221; are granted by the European Commission through the centralized procedure based </span></span></div><div style="line-height:10pt;position:var(--position);top:274pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">on the opinion of the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) of the EMA. The </span></div><div style="line-height:10pt;position:var(--position);top:284pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">MA issued under this procedure is valid in all EU Member States. </span></div><div style="line-height:10pt;position:var(--position);top:300pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">The centralized procedure is compulsory for some types of medicinal products such as biotechnology </span></span></div><div style="line-height:10pt;position:var(--position);top:310pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">products, designated orphan medicinal products, products containing a new active substance indicated </span></div><div style="line-height:10pt;position:var(--position);top:320pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes or autoimmune and viral </span></div><div style="line-height:10pt;position:var(--position);top:330pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">diseases, advanced therapy medicinal products (such as gene therapy, somatic cell therapy and tissue </span></div><div style="line-height:10pt;position:var(--position);top:340pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">engineered products). The centralized procedure is optional for products containing a new active </span></div><div style="line-height:10pt;position:var(--position);top:350pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">substance that has not yet been authorized in the EU or for products which present a significant </span></div><div style="line-height:10pt;position:var(--position);top:360pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">therapeutic, scientific or technical innovation or are of interest for the public health in the EU. </span></div><div style="line-height:10pt;position:var(--position);top:376pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">&#8220;National MAs&#8221; are issued at a national level by the competent authorities of the concerned Member </span></span></div><div style="line-height:10pt;position:var(--position);top:386pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">States. They are valid only on their territory. National MAs can be issued for products that do not fall </span></div><div style="line-height:10pt;position:var(--position);top:396pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">within the mandatory scope of the centralized procedure. Medicinal products which have not received </span></div><div style="line-height:10pt;position:var(--position);top:406pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">a national MA in any of the Member States, may be authorized through the decentralized procedure. </span></div><div style="line-height:10pt;position:var(--position);top:416pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">This procedure enables the simultaneous issuance of national MAs in several EU countries. Under the </span></div><div style="line-height:10pt;position:var(--position);top:426pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">decentralized procedure, an identical dossier is submitted to the competent authorities of each of the </span></div><div style="line-height:10pt;position:var(--position);top:436pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">Member States in which an MA is sought. One of these Member States is designated by the applicant </span></div><div style="line-height:10pt;position:var(--position);top:446pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">to act as the Reference Member State (&#8220;RMS&#8221;). The competent authority of the RMS drafts an </span></div><div style="line-height:10pt;position:var(--position);top:456pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">assessment report and prepares an SmPC, a package leaflet and a draft labelling, which are sent to the </span></div><div style="line-height:10pt;position:var(--position);top:466pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">other Member States involved in the procedure, known as the Concerned Member States (&#8220;CMS&#8221;), for </span></div><div style="line-height:10pt;position:var(--position);top:476pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">approval. If no CMS raises any objections based on a potential serious risk to public health, a national </span></div><div style="line-height:10pt;position:var(--position);top:486pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">MA is granted for the product in all Member States involved in the procedure (i.e., in the RMS and the </span></div><div style="line-height:10pt;position:var(--position);top:496pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">CMS). </span></div><div style="line-height:10pt;position:var(--position);top:512pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:18.35pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">Where a product has already been authorized for marketing in an EU Member State, this national MA </span></span></div><div style="line-height:10pt;position:var(--position);top:522pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">can be recognized in another Member State through the mutual recognition procedure. In this </span></div><div style="line-height:10pt;position:var(--position);top:532pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">procedure, the Member State which issued the initial MA, known as the RMS, must prepare an </span></div><div style="line-height:10pt;position:var(--position);top:542pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">assessment report on the medicinal product or update any existing report. This report is sent to the </span></div><div style="line-height:10pt;position:var(--position);top:552pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">CMS, together with the approved SmPC and the labelling and package leaflet. Unless an objection </span></div><div style="line-height:10pt;position:var(--position);top:562pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">based on a potential serious risk to public health is raised, the CMS issue(s) a national MA for the </span></div><div style="line-height:10pt;position:var(--position);top:572pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">product, the terms of which are identical to the MA granted by the RMS. </span></div><div style="line-height:10pt;position:var(--position);top:588pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Depending on the procedure used, the EMA or the national competent authority(ies) must, before granting a </span></div><div style="line-height:10pt;position:var(--position);top:598pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">MA, make an assessment of the benefit/risk ratio of the product based on scientific criteria of quality, safety of use </span></div><div style="line-height:10pt;position:var(--position);top:608pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and efficacy. Under the centralized procedure the maximum timeframe for the evaluation of an MAA by the EMA is </span></div><div style="line-height:10pt;position:var(--position);top:618pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">210 days, excluding clock stops. In exceptional cases, the CHMP might perform an accelerated review of an MAA </span></div><div style="line-height:10pt;position:var(--position);top:628pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">in no more than 150 days (not including clock stops). Innovative products that target an unmet medical need and are </span></div><div style="line-height:10pt;position:var(--position);top:638pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">likely to be of major public health interest may be eligible for a number of expedited development and review </span></div><div style="line-height:10pt;position:var(--position);top:648pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">programs, such as the Priority Medicines (&#8220;PRIME&#8221;) scheme, which provides incentives similar to the breakthrough </span></div><div style="line-height:10pt;position:var(--position);top:658pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">therapy designation in the U.S. This program was launched by the EMA in March 2016, and aims at enhancing the </span></div><div style="line-height:10pt;position:var(--position);top:668pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">EMA&#8217;s support for the development of medicines that target unmet medical needs. It is based on increased </span></div><div style="line-height:10pt;position:var(--position);top:678pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">interaction through early dialogue with companies developing promising medicines, to optimize their development </span></div><div style="line-height:10pt;position:var(--position);top:688pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">plans and speed up their evaluation to help them reach patients earlier. More specifically, product developers that </span></div><div style="line-height:10pt;position:var(--position);top:698pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">benefit from PRIME access can benefit from early and proactive regulatory dialogue with the EMA and frequent </span></div><div style="line-height:10pt;position:var(--position);top:708pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">discussions on clinical trial designs and other development program elements. Importantly, a dedicated contact and </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">72</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">rapporteur from the CHMP is appointed early in the PRIME scheme facilitating increased understanding of the </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">product at EMA&#8217;s committee level. A team of multidisciplinary experts at the EMA is also composed to provide </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">guidance on the overall </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:167.99pt;position:var(--position);white-space:pre">development</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:219.59pt;position:var(--position);text-decoration:none;white-space:pre"> and regulatory strategies. Thus, PRIME access is intended at speeding up the </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">assessment process of MAAs, without guarantee as to the outcome of the process. </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Moreover, in the EU, a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:191.13pt;position:var(--position);white-space:pre">conditional</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:236.07pt;position:var(--position);text-decoration:none;white-space:pre"> MA may be granted by the European Commission for a period of one year </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and is renewable annually. </span></div><div style="line-height:10pt;position:var(--position);top:144pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">A conditional MA is granted in the absence of sufficient clinical data to obtain an ordinary MA if the </span></div><div style="line-height:10pt;position:var(--position);top:154pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">following requirements are met: (i)&#160;the medicinal product is intended to treat, prevent or diagnose a fatal or seriously </span></div><div style="line-height:10pt;position:var(--position);top:164pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">debilitating disease, (ii)&#160;it fulfils to an unmet medical need, (iii)&#160;its benefit/risk ratio is, on the basis of the available </span></div><div style="line-height:10pt;position:var(--position);top:174pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">data, positive, (iv)&#160;it is likely that the applicant will be able to provide the required comprehensive post-MA clinical </span></div><div style="line-height:10pt;position:var(--position);top:184pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">data and (v)&#160;in terms of public health, the benefits of the product&#8217;s immediate availability to patients outweigh the </span></div><div style="line-height:10pt;position:var(--position);top:194pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">risks inherent to the lack of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:183.54000000000002pt;position:var(--position);white-space:pre">sufficient</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:221.26pt;position:var(--position);text-decoration:none;white-space:pre"> clinical data. </span></div><div style="line-height:10pt;position:var(--position);top:210pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The granting of a conditional MA is accompanied by specific obligations, in particular relating to the </span></div><div style="line-height:10pt;position:var(--position);top:220pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">completion of clinical trials, the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:201.8pt;position:var(--position);white-space:pre">performance</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.28pt;position:var(--position);text-decoration:none;white-space:pre"> of new studies and the collection of pharmacovigilance data in order to </span></div><div style="line-height:10pt;position:var(--position);top:230pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">confirm the benefit/risk ratio of the product. Once the pending studies are provided, it can become an unconditional </span></div><div style="line-height:10pt;position:var(--position);top:240pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">MA. </span></div><div style="line-height:10pt;position:var(--position);top:256pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">MAs may also be granted under exceptional circumstances to medicinal products for which a complete </span></div><div style="line-height:10pt;position:var(--position);top:266pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">evaluation file cannot be provided </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:210.99pt;position:var(--position);white-space:pre">when</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:232.64pt;position:var(--position);text-decoration:none;white-space:pre"> the product&#8217;s indication is too rarely encountered and prevents the provision </span></div><div style="line-height:10pt;position:var(--position);top:276pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of comprehensive evidence, when the current state of scientific knowledge prevents the provision of such data or </span></div><div style="line-height:10pt;position:var(--position);top:286pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">when the collection of the necessary data would be unethical. This MA is close to the conditional MA as it is </span></div><div style="line-height:10pt;position:var(--position);top:296pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reserved to medicinal products to be approved for severe diseases or unmet medical needs and the applicant does not </span></div><div style="line-height:10pt;position:var(--position);top:306pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">hold the complete data set legally required for the grant of an ordinary MA. However, unlike the conditional MA, </span></div><div style="line-height:10pt;position:var(--position);top:316pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the applicant will not have to provide the missing data later. However, although the MA &#8220;under exceptional </span></div><div style="line-height:10pt;position:var(--position);top:326pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">circumstances&#8221; is granted </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:177.12pt;position:var(--position);white-space:pre">for the standard validity period of 5-year</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:339.72pt;position:var(--position);text-decoration:none;white-space:pre">, the risk-benefit balance of the medicinal product </span></div><div style="line-height:10pt;position:var(--position);top:336pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">is reviewed annually and the MA is withdrawn in case the risk-benefit ratio is no longer favorable. </span></div><div style="line-height:10pt;position:var(--position);top:352pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Despite the granting </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:180.01pt;position:var(--position);white-space:pre">of</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:188.34pt;position:var(--position);text-decoration:none;white-space:pre"> a MA, both the MA holder and the competent authorities may decide at any time to </span></div><div style="line-height:10pt;position:var(--position);top:362pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">withdraw (voluntarily or compulsorily) a product from the market or a MA, when it appears that the product </span></div><div style="line-height:10pt;position:var(--position);top:372pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">presents more risks than benefits for the patients. </span></div><div style="line-height:10pt;position:var(--position);top:400pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Data and Marketing Exclusivity </span></div><div style="line-height:10pt;position:var(--position);top:416pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In the EU, new products authorized for marketing on the basis of a complete file (</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:423.91pt;position:var(--position);text-decoration:none;white-space:pre">i.e.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:436.11pt;position:var(--position);text-decoration:none;white-space:pre">, reference products) </span></div><div style="line-height:10pt;position:var(--position);top:426pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">generally receive eight years of data exclusivity and an additional two years of market exclusivity upon granting of </span></div><div style="line-height:10pt;position:var(--position);top:436pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the MA. The data exclusivity period prevents generic and biosimilar applicants from relying on the preclinical and </span></div><div style="line-height:10pt;position:var(--position);top:446pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar MA in </span></div><div style="line-height:10pt;position:var(--position);top:456pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the EU during a period of eight years from the date on which the reference product was first authorized in the EU. </span></div><div style="line-height:10pt;position:var(--position);top:466pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The market exclusivity period prevents generic or biosimilar from being commercialized in the EU until ten years </span></div><div style="line-height:10pt;position:var(--position);top:476pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">have elapsed from the first MA of the reference product in the EU. The&#160; ten-year market exclusivity period can be </span></div><div style="line-height:10pt;position:var(--position);top:486pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">extended to a maximum of eleven years if, during the first eight years of those ten years, the MA holder obtains an </span></div><div style="line-height:10pt;position:var(--position);top:496pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">authorization for one or more new therapeutic indications, which, during the scientific evaluation prior to their </span></div><div style="line-height:10pt;position:var(--position);top:506pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">authorization, are held to bring a significant clinical benefit in comparison with existing therapies. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:466.48pt;position:var(--position);white-space:pre">The pharma </span></div><div style="line-height:10pt;position:var(--position);top:516pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">package will amend these principles: data exclusivity period will be granted for eight years, and may be extended for </span></div><div style="line-height:10pt;position:var(--position);top:526pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">one additional year </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:151.06pt;position:var(--position);text-decoration:none;white-space:pre">when</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:172.70999999999998pt;position:var(--position);white-space:pre"> the product addressed an unmet medical need at the time of the MA or, under specific </span></div><div style="line-height:10pt;position:var(--position);top:536pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">circumstances, for medicinal products containing new actives substances, and for another additional one year when </span></div><div style="line-height:10pt;position:var(--position);top:546pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">the MAH obtains a MA for one or more new therapeutic indications, during the regulatory data protection, which, </span></div><div style="line-height:10pt;position:var(--position);top:556pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in </span></div><div style="line-height:10pt;position:var(--position);top:566pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">comparison with existing therapies. In addition, the market exclusivity duration will be reduced as a principle to one </span></div><div style="line-height:10pt;position:var(--position);top:576pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">year after the expiry of the data exclusivity period, and it can also be reduced if the company does not launch the </span></div><div style="line-height:10pt;position:var(--position);top:586pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">product in all countries which so request. </span></div><div style="line-height:10pt;position:var(--position);top:614pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Pediatric Development </span></div><div style="line-height:10pt;position:var(--position);top:630pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In the EU, MAAs for new medicinal products must include the results of studies conducted in the pediatric </span></div><div style="line-height:10pt;position:var(--position);top:640pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">population, in compliance with a Pediatric Investigation Plan (&#8220;PIP&#8221;) agreed with the EMA&#8217;s Pediatric Committee </span></div><div style="line-height:10pt;position:var(--position);top:650pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(&#8220;PDCO&#8221;). The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of </span></div><div style="line-height:10pt;position:var(--position);top:660pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the medicinal product for which MA is being sought. The PDCO can grant a deferral of the obligation to implement </span></div><div style="line-height:10pt;position:var(--position);top:670pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the </span></div><div style="line-height:10pt;position:var(--position);top:680pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when </span></div><div style="line-height:10pt;position:var(--position);top:690pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">these data is not needed or appropriate because the product is likely to be ineffective or unsafe in children, the </span></div><div style="line-height:10pt;position:var(--position);top:700pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">disease or condition for which the product is intended occurs only in adult populations, or when the product does not </span></div><div style="line-height:10pt;position:var(--position);top:710pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the MA is obtained in </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">73</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">all the EU member states and study results are included in the product information, even when negative, the product </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">is eligible for six months&#8217; supplementary protection certificate extension (if any is in effect at the time of approval) </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">or, in the case of orphan pharmaceutical products, a two-year extension of the orphan market exclusivity is granted. </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">The pharma package removes the possibility to obtain a two-year extension of orphan market exclusivity for </span></div><div style="line-height:10pt;position:var(--position);top:112pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">conducting research in compliance with a PIP. </span></div><div style="line-height:10pt;position:var(--position);top:140pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Manufacturing and Distribution-related Requirements </span></div><div style="line-height:10pt;position:var(--position);top:156pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">To ensure patients&#8217; safety, the manufacturing, distribution and import of active pharmaceutical ingredients and </span></div><div style="line-height:10pt;position:var(--position);top:166pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">finished products into the EU are also subject to extensive requirements and both MA holders, manufacturers and </span></div><div style="line-height:10pt;position:var(--position);top:176pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">distributors of medicinal products are subject to comprehensive regulatory oversight by the EMA, the European </span></div><div style="line-height:10pt;position:var(--position);top:186pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Commission and/or the competent regulatory authorities of the Member States. </span></div><div style="line-height:10pt;position:var(--position);top:202pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Medicines (including their active substances) must be manufactured in accordance with GMP requirements. </span></div><div style="line-height:10pt;position:var(--position);top:212pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">These regulations govern manufacturing processes and procedures, and notably provide for requirements relating to </span></div><div style="line-height:10pt;position:var(--position);top:222pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the implementation of quality systems to control and ensure the quality of materials and products. Manufacturing </span></div><div style="line-height:10pt;position:var(--position);top:232pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">activities must be performed only within companies holding valid licenses from the competent regulatory authorities </span></div><div style="line-height:10pt;position:var(--position);top:242pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of the Member States which is issued following an inspection of the concerned facilities. In addition, routine </span></div><div style="line-height:10pt;position:var(--position);top:252pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">inspections are conducted on a regularly basis to ensure that compliance is maintained. </span></div><div style="line-height:10pt;position:var(--position);top:268pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Distributors must also comply with very strict requirements, including good distribution practices (&#8220;GDP&#8221;). </span></div><div style="line-height:10pt;position:var(--position);top:278pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">These regulations provide for strict requirements including the implementation of an effective quality system and </span></div><div style="line-height:10pt;position:var(--position);top:288pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">adequate procedures to ensure the quality of the products all over the distribution chain and efficiently respond to </span></div><div style="line-height:10pt;position:var(--position);top:298pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">claims, recalls, and risks of falsification, or the use of appropriate facilities, equipment and personnel. Similarly to </span></div><div style="line-height:10pt;position:var(--position);top:308pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">manufacturing, distribution activities are subject to a prior approval from the competent regulatory authorities of the </span></div><div style="line-height:10pt;position:var(--position);top:318pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Member States which is issued following an inspection of the concerned facilities which aims at ensuring that the </span></div><div style="line-height:10pt;position:var(--position);top:328pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">establishment complies with the applicable regulations. Routine inspections are also conducted on a regularly basis. </span></div><div style="line-height:10pt;position:var(--position);top:344pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Finally, the import of active pharmaceutical ingredients and medicines into the EU must also be authorized in </span></div><div style="line-height:10pt;position:var(--position);top:354pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">advance, in order to ensure that the products are manufactured and distributed in accordance with standards at least </span></div><div style="line-height:10pt;position:var(--position);top:364pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">equivalent to those existing for the EU market. </span></div><div style="line-height:10pt;position:var(--position);top:380pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Failure to comply with the above requirements may be sanctioned by the suspension or withdrawal of the </span></div><div style="line-height:10pt;position:var(--position);top:390pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">manufacturing/distribution/import authorization, civil, criminal or administrative penalties, or the withdrawal of the </span></div><div style="line-height:10pt;position:var(--position);top:400pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">concerned active ingredients and finished products from the market. </span></div><div style="line-height:10pt;position:var(--position);top:428pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Post-Approval Requirements </span></div><div style="line-height:10pt;position:var(--position);top:444pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:underline;white-space:pre">Pharmacovigilance Requirements</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:207.67pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="line-height:10pt;position:var(--position);top:460pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The MA holder must establish and maintain a pharmacovigilance system and designate a Qualified Person </span></div><div style="line-height:10pt;position:var(--position);top:470pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Responsible for Pharmacovigilance (&#8220;QPPV&#8221;) who is responsible for the establishment and maintenance of that </span></div><div style="line-height:10pt;position:var(--position);top:480pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">system, and oversees the safety profiles of medicinal products and any emerging safety concerns. The main </span></div><div style="line-height:10pt;position:var(--position);top:490pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">obligations of the QPPV include prompt reporting of suspected serious adverse reactions to competent authorities </span></div><div style="line-height:10pt;position:var(--position);top:500pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and submission of periodic pharmacovigilance update reports (&#8220;PSURs&#8221;). </span></div><div style="line-height:10pt;position:var(--position);top:516pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.75pt;position:var(--position);text-decoration:none;white-space:pre">All new MAA must include a risk management plan (&#8220;RMP&#8221;) describing the risk management system that the </span></div><div style="line-height:10pt;position:var(--position);top:526pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">company will put in place and setting out measures to prevent or minimize the risks associated with the medicinal </span></div><div style="line-height:10pt;position:var(--position);top:536pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">product. The regulatory authorities may also issue an MA subject to the fulfillment of specific obligations. These </span></div><div style="line-height:10pt;position:var(--position);top:546pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">risk reduction measures or post-authorization obligations may consist, in particular, of reinforced safety monitoring, </span></div><div style="line-height:10pt;position:var(--position);top:556pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">more frequent submission of PSURs, the conduct of additional clinical trials or the performance of post- </span></div><div style="line-height:10pt;position:var(--position);top:566pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">authorization safety studies. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:186.3pt;position:var(--position);white-space:pre">The pharma package will limit the RMP requirement for generic and biosimilar </span></div><div style="line-height:10pt;position:var(--position);top:576pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">products, as well as for hybrid and bio-hybrid medicinal products. </span></div><div style="line-height:10pt;position:var(--position);top:604pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:underline;white-space:pre">Advertising Requirements</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:175.48000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="line-height:10pt;position:var(--position);top:620pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In the EU, the advertising and promotion of medicinal products is also subject to laws concerning promotion </span></div><div style="line-height:10pt;position:var(--position);top:630pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of medicinal products, interactions with healthcare professionals, misleading and comparative advertising and unfair </span></div><div style="line-height:10pt;position:var(--position);top:640pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">commercial practices. The general principles applicable to the advertising of medicines, which is broadly defined as </span></div><div style="line-height:10pt;position:var(--position);top:650pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">any form of door-to-door information, canvassing activity or inducement designed to promote the prescription, </span></div><div style="line-height:10pt;position:var(--position);top:660pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">supply, sale or consumption of medicinal products, are established by EU directive. </span></div><div style="line-height:10pt;position:var(--position);top:676pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Any advertising or promotion of a medicinal product must comply with its approved SmPC. Consequently, </span></div><div style="line-height:10pt;position:var(--position);top:686pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">any promotion of off-label promotion is prohibited. Indeed, the advertising must encourage the proper use of </span></div><div style="line-height:10pt;position:var(--position);top:696pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">medicines by presenting them objectively without exaggeration and thus, must not be misleading. Direct-to-</span></div><div style="line-height:10pt;position:var(--position);top:706pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">consumer advertising of prescription medicines is also prohibited in the EU. Although general requirements for </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">74</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">advertising and promotion of medicinal products are established under EU directives, the details are governed by </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regulations in each Member State and can differ from one country to another. </span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Depending on the Member States, advertising-related regulatory requirements may be sanctioned notably by </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the suspension or withdrawal of regulatory authorizations, medicinal products recalls, medicinal products seizures, </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">operating restrictions and even criminal and/or civil prosecution and significant financial sanctions. </span></div><div style="line-height:10pt;position:var(--position);top:134pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The aforementioned EU rules are generally applicable in the European Economic Area (&#8220;EEA&#8221;) which </span></div><div style="line-height:10pt;position:var(--position);top:144pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">consists of the 27 EU member states plus Norway, Liechtenstein and Iceland. </span></div><div style="line-height:10pt;position:var(--position);top:172pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Coverage and Reimbursement </span></div><div style="line-height:10pt;position:var(--position);top:188pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In the EU, pricing and reimbursement systems widely vary from one country to another and remain </span></div><div style="line-height:10pt;position:var(--position);top:198pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">exclusively the responsibility of the Member States. </span></div><div style="line-height:10pt;position:var(--position);top:214pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Thus, Member States may restrict the range of medicines for which their national health insurance system </span></div><div style="line-height:10pt;position:var(--position);top:224pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">provides reimbursement and control their price, provided that time limits for review of a reimbursement application </span></div><div style="line-height:10pt;position:var(--position);top:234pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">provided in Directive 89/105/EEC of 21&#160;December 1988 must be complied with. </span></div><div style="line-height:10pt;position:var(--position);top:250pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Some Member States use a system of positive and negative lists, whereby medicines can only be marketed </span></div><div style="line-height:10pt;position:var(--position);top:260pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">after a reimbursement price has been agreed. Others may require additional studies comparing the cost-effectiveness </span></div><div style="line-height:10pt;position:var(--position);top:270pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of a medicinal product to existing therapies in order to obtain approval for reimbursement or pricing. Finally, </span></div><div style="line-height:10pt;position:var(--position);top:280pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Member States can agree to a set price or, instead, allow companies to set their own prices while having their profits </span></div><div style="line-height:10pt;position:var(--position);top:290pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">monitored and controlled (e.g., control of the quantity of prescriptions). </span></div><div style="line-height:10pt;position:var(--position);top:306pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Over the last few years, many EU Member States have increased the amount of rebates applied to medicinal </span></div><div style="line-height:10pt;position:var(--position);top:316pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">products, and these efforts may continue as Member States exercise greater control over their healthcare spending </span></div><div style="line-height:10pt;position:var(--position);top:326pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">due to often large debts. The downward pressure on healthcare costs in general, including medicinal products subject </span></div><div style="line-height:10pt;position:var(--position);top:336pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to mandatory prescription, has become considerable. Changing political, economic and regulatory conditions can </span></div><div style="line-height:10pt;position:var(--position);top:346pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">complicate price negotiations. This price negotiation can continue after reimbursement has been achieved and is </span></div><div style="line-height:10pt;position:var(--position);top:356pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">generally subject to periodic reviews. Finally, reference prices used by various EU Member States and parallel trade </span></div><div style="line-height:10pt;position:var(--position);top:366pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(i.e., arbitrage by distributors between low and high price Member States) may also lead to further price reductions. </span></div><div style="line-height:10pt;position:var(--position);top:382pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">On December 13, 2021, Regulation No 2021/2282 on Health Technology Assessment (&#8220;HTA Regulation&#8221;) </span></div><div style="line-height:10pt;position:var(--position);top:392pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">amending Directive 2011/24/EU, was adopted. While the HTA Regulation entered into force in January 2022 it has </span></div><div style="line-height:10pt;position:var(--position);top:402pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">only started to apply from January 12, 2025. Implementation is progressive. To date, it only applies to drugs </span></div><div style="line-height:10pt;position:var(--position);top:412pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">containing new active substances for the treatment of cancer and advanced therapy drugs. This regulation intends to </span></div><div style="line-height:10pt;position:var(--position);top:422pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">boost cooperation among EU Member States in assessing health technologies, in order to speed up the availability of </span></div><div style="line-height:10pt;position:var(--position);top:432pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">innovative products on the EU market. The HTA Regulation permits EU Member States to use common HTA tools, </span></div><div style="line-height:10pt;position:var(--position);top:442pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">methodologies, and procedures across the EU. It also provides for joint clinical assessment of the innovative health </span></div><div style="line-height:10pt;position:var(--position);top:452pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">technologies at the EU level, joint scientific consultations whereby developers can seek advice from HTA </span></div><div style="line-height:10pt;position:var(--position);top:462pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">authorities, and identification of emerging health technologies to identify promising technologies early. Nonetheless, </span></div><div style="line-height:10pt;position:var(--position);top:472pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">individual EU Member States continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) </span></div><div style="line-height:10pt;position:var(--position);top:482pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">aspects of health technology, and making decisions on pricing and reimbursement, provided they take into </span></div><div style="line-height:10pt;position:var(--position);top:492pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">consideration the joint clinical assessment conducted at the EU level. </span></div><div style="line-height:10pt;position:var(--position);top:520pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Other Healthcare Laws </span></div><div style="line-height:10pt;position:var(--position);top:536pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Relationships between the pharmaceutical industry and healthcare professionals are subject to national </span></div><div style="line-height:10pt;position:var(--position);top:546pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">restrictions and regulations in order to avoid any incentive to use or prescribe health products that is not exclusively </span></div><div style="line-height:10pt;position:var(--position);top:556pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">justified by the patient&#8217;s state of health and profile. </span></div><div style="line-height:10pt;position:var(--position);top:572pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For example, in France, relations between the industry and healthcare professionals practicing in France are </span></div><div style="line-height:10pt;position:var(--position);top:582pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">governed by the &#8220;anti-gift&#8221; and &#8220;transparency&#8221; laws. </span></div><div style="line-height:10pt;position:var(--position);top:598pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">By way of principle, under the French anti-gift law, persons providing health services, manufacturing or </span></div><div style="line-height:10pt;position:var(--position);top:608pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">marketing healthcare products, regardless of their nationality and of the effective marketing of their health products </span></div><div style="line-height:10pt;position:var(--position);top:618pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">on the French market, are prohibited from promising or offering advantages of any kind whatsoever, in cash or in </span></div><div style="line-height:10pt;position:var(--position);top:628pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">kind, either directly or indirectly, to healthcare professionals practicing in France, students intending to enter such </span></div><div style="line-height:10pt;position:var(--position);top:638pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">professions or associations of these individuals, including learned societies and national professional councils. </span></div><div style="line-height:10pt;position:var(--position);top:654pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The list of benefits that do that do not qualify as &#8220;advantages&#8221; under the anti-kickback regulation is very </span></div><div style="line-height:10pt;position:var(--position);top:664pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">limited and includes, for example, benefits that relate to the exercise of the beneficiary&#8217;s profession and of negligible </span></div><div style="line-height:10pt;position:var(--position);top:674pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">value, which may not exceed the amounts provided for by a Ministerial Order. </span></div><div style="line-height:10pt;position:var(--position);top:690pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">By way of exception, above-mentioned health stakeholders may provide advantages to the healthcare </span></div><div style="line-height:10pt;position:var(--position);top:700pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">professionals/associations mentioned above, subject to the conclusion of a written agreement and to a prior </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">75</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">declaration to or approval from the authority or board to which the concerned beneficiary belongs, depending on the </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">amount of advantages granted. </span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">This exception is however limited to specific situations mainly including: </span></div><div style="line-height:10pt;position:var(--position);top:114pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">The remuneration, compensation and expenses for research activities, research promotion, scientific </span></span></div><div style="line-height:10pt;position:var(--position);top:124pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">evaluation, consultancy, provision of services or commercial promotion, provided that the </span></div><div style="line-height:10pt;position:var(--position);top:134pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">remuneration is proportionate to the service provided and that the compensation or expenses do not </span></div><div style="line-height:10pt;position:var(--position);top:144pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">exceed the costs actually incurred by the persons concerned; </span></div><div style="line-height:10pt;position:var(--position);top:160pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">Donations and gifts, in cash or in kind, exclusively intended to finance research activities, the </span></span></div><div style="line-height:10pt;position:var(--position);top:170pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">promotion of research or scientific evaluation; or </span></div><div style="line-height:10pt;position:var(--position);top:186pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">Hospitality offered during events of an exclusively professional or scientific nature, or during events </span></span></div><div style="line-height:10pt;position:var(--position);top:196pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">promoting healthcare products or services, provided that this hospitality is of a reasonable level, </span></div><div style="line-height:10pt;position:var(--position);top:206pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">strictly limited to the main purpose of the event and to healthcare professionals (excluding students); </span></div><div style="line-height:1pt;position:var(--position);top:225pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="line-height:10pt;position:var(--position);top:232pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">When failing to comply with this regulation, in addition to a significant risk to their reputation, the companies </span></div><div style="line-height:10pt;position:var(--position);top:242pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and professionals concerned may be subject to significant criminal penalties and, in the case of the latter, </span></div><div style="line-height:10pt;position:var(--position);top:252pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">disciplinary penalties. </span></div><div style="line-height:10pt;position:var(--position);top:268pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The French transparency provision, for its part, provides citizens with access to certain information on a </span></div><div style="line-height:10pt;position:var(--position);top:278pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">website so that they can more objectively assess the direct and indirect relationships between health actors (i.e., a </span></div><div style="line-height:10pt;position:var(--position);top:288pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">broad list including healthcare professionals, associations of healthcare professionals, students, associations of users </span></div><div style="line-height:10pt;position:var(--position);top:298pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of the health system, health establishments, academic institutions, foundations, learned societies and societies or </span></div><div style="line-height:10pt;position:var(--position);top:308pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">advisory bodies involved in the health product or health services sector, etc.) and companies producing or marketing </span></div><div style="line-height:10pt;position:var(--position);top:318pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">health products or providing services associated with these products. Under the terms of this regulation, the </span></div><div style="line-height:10pt;position:var(--position);top:328pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">companies concerned must disclose the main information relating to their relationships with healthcare </span></div><div style="line-height:10pt;position:var(--position);top:338pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">professionals, such as compensation or benefits paid, and agreements entered into. Companies that knowingly fails </span></div><div style="line-height:10pt;position:var(--position);top:348pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to disclose such information may be subject to criminal penalties. </span></div><div style="line-height:10pt;position:var(--position);top:376pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">UK Regulation </span></div><div style="line-height:10pt;position:var(--position);top:392pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Since the end of the Brexit transition period on January&#160;1, 2021, Great Britain (&#8220;GB&#8221;) (England, Scotland and </span></div><div style="line-height:10pt;position:var(--position);top:402pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Wales) has not been directly subject to EU laws. However, under the terms of the Ireland/Northern Ireland Protocol, </span></div><div style="line-height:10pt;position:var(--position);top:412pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">EU laws have generally applied to Northern Ireland. On February&#160;27, 2023, the UK government and the European </span></div><div style="line-height:10pt;position:var(--position);top:422pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Commission reached a political agreement on the so-called &#8220;Windsor Framework&#8221; which is intended to revise the </span></div><div style="line-height:10pt;position:var(--position);top:432pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Ireland/Northern Ireland Protocol in order to address some of the perceived shortcomings in its operation. The </span></div><div style="line-height:10pt;position:var(--position);top:442pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">agreement was adopted at the Withdrawal Agreement Joint Committee on March&#160;24, 2023. If the changes are </span></div><div style="line-height:10pt;position:var(--position);top:452pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">adopted in the form proposed, medicinal products to be placed on the market in the UK will be authorized solely in </span></div><div style="line-height:10pt;position:var(--position);top:462pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">accordance with UK laws. Northern Ireland would be reintegrated back into a UK-only regulatory environment </span></div><div style="line-height:10pt;position:var(--position);top:472pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">under the authority of the MHRA with respect to all medicinal products. The implementation of the Windsor </span></div><div style="line-height:10pt;position:var(--position);top:482pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Framework would occur in various stages, with new arrangements relating to the supply of medicines into Northern </span></div><div style="line-height:10pt;position:var(--position);top:492pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Ireland anticipated to take effect in 2025. </span></div><div style="line-height:10pt;position:var(--position);top:508pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The EU laws that have been transposed into United Kingdom (&#8220;UK&#8221;) law through secondary legislation </span></div><div style="line-height:10pt;position:var(--position);top:518pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">remain applicable in Great Britain. However, new EU legislation that was either adopted or entered into application </span></div><div style="line-height:10pt;position:var(--position);top:528pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">after Brexit such as the EU CTR is not applicable in Great Britain. The UK regulatory framework in relation to </span></div><div style="line-height:10pt;position:var(--position);top:538pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">clinical trials is derived from previously existing EU legislation (as implemented into UK law, through secondary </span></div><div style="line-height:10pt;position:var(--position);top:548pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">legislation). On January&#160;17, 2022, the UK MHRA launched an 8-week consultation on reframing the UK legislation </span></div><div style="line-height:10pt;position:var(--position);top:558pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for clinical trials. The consultation closed on March&#160;14, 2022, and aims to streamline clinical trial approvals, enable </span></div><div style="line-height:10pt;position:var(--position);top:568pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">innovation, enhance clinical trials transparency, enable greater risk proportionality and promote patient and public </span></div><div style="line-height:10pt;position:var(--position);top:578pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">involvement in clinical trials. The outcome of the consultation is being closely watched and will determine whether </span></div><div style="line-height:10pt;position:var(--position);top:588pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the UK chooses to align with the (EU) CTR or diverge from it. Under the terms of the Ireland/Northern Ireland </span></div><div style="line-height:10pt;position:var(--position);top:598pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Protocol, provisions of the EU CTR which relate to the manufacture and import of investigational medicinal </span></div><div style="line-height:10pt;position:var(--position);top:608pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">products and auxiliary medicinal products currently apply in Northern Ireland. </span></div><div style="line-height:10pt;position:var(--position);top:624pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Since January&#160;1, 2021, the MHRA has been the sole regulatory of medicines and medical devices in GB and </span></div><div style="line-height:10pt;position:var(--position);top:634pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for medicinal products that are not authorized through the centralized procedure in Northern Ireland. The MHRA </span></div><div style="line-height:10pt;position:var(--position);top:644pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">has introduced changes to national licensing procedures, including procedures to prioritize access to new medicines </span></div><div style="line-height:10pt;position:var(--position);top:654pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">that will benefit patients, including a 150-day assessment and a rolling review procedure. All existing EU MAs for </span></div><div style="line-height:10pt;position:var(--position);top:664pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">centrally authorized products were automatically converted or grandfathered into UK MAs, effective in GB (only), </span></div><div style="line-height:10pt;position:var(--position);top:674pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">free of charge on January&#160;1, 2021, unless the MA holder opted-out. In order to use the centralized procedure to </span></div><div style="line-height:10pt;position:var(--position);top:684pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">obtain an MA that will be valid throughout the EEA, companies must be established in the EEA. Therefore, since </span></div><div style="line-height:10pt;position:var(--position);top:694pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Brexit, companies established in the UK can no longer use the EU centralized procedure for authorization of </span></div><div style="line-height:10pt;position:var(--position);top:704pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">medicinal products intended to be marketed in the UK. In order to obtain a UK MA to commercialize products in the </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">76</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">UK, an applicant must be established in the UK and must follow one of the UK national authorization procedures or </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">one of the remaining post-Brexit international cooperation procedures to obtain an MA to commercialize products in </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the UK. Until December&#160;31, 2023, the MHRA may rely on a decision taken by the European Commission on the </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">approval of a new (centralized procedure) MA when reviewing an application for authorization of a medicinal </span></div><div style="line-height:10pt;position:var(--position);top:112pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">product to be supplied in GB. Depending on the nature and intended therapeutic purpose of the medicinal product, </span></div><div style="line-height:10pt;position:var(--position);top:122pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the MHRA may, alternatively, use its own decentralized or mutual recognition procedures which enable the MHRA </span></div><div style="line-height:10pt;position:var(--position);top:132pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to have regard to MAs approved in EU Member States, Iceland, Liechtenstein, and Norway when granting an MA in </span></div><div style="line-height:10pt;position:var(--position);top:142pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the UK or GB. From the first quarter of 2024, a new international recognition framework should be in place with an </span></div><div style="line-height:10pt;position:var(--position);top:152pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">aim to extend the countries whose assessments the MHRA will take into account. The UK government will need to </span></div><div style="line-height:10pt;position:var(--position);top:162pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">adopt new legislation to introduce this route. </span></div><div style="line-height:10pt;position:var(--position);top:178pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">There is no pre-MA orphan designation procedure. Applications for orphan designation are made at the same </span></div><div style="line-height:10pt;position:var(--position);top:188pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">time as an application for MA and the MHRA will review applications for orphan designation in parallel to the </span></div><div style="line-height:10pt;position:var(--position);top:198pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">corresponding MA application. The criteria are essentially the same, but have been tailored for the market (i.e., the </span></div><div style="line-height:10pt;position:var(--position);top:208pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">prevalence of the condition in GB, rather than the EU, must not be more than five in 10,000). Should an orphan </span></div><div style="line-height:10pt;position:var(--position);top:218pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">designation be granted, the period or market exclusivity will be set from the date of first approval of the product in </span></div><div style="line-height:10pt;position:var(--position);top:228pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">GB. </span></div><div style="line-height:10pt;position:var(--position);top:256pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">U.S. Government Regulation </span></div><div style="line-height:10pt;position:var(--position);top:272pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, (&#8220;FDCA&#8221;) </span></div><div style="line-height:10pt;position:var(--position);top:282pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with </span></div><div style="line-height:10pt;position:var(--position);top:292pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">applicable federal, state, and local statutes and regulations requires the expenditure of substantial time and financial </span></div><div style="line-height:10pt;position:var(--position);top:302pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">resources. Failure to comply with the applicable U.S. requirements at any time during the product development </span></div><div style="line-height:10pt;position:var(--position);top:312pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">process, approval process, or after approval, may subject an applicant to a variety of administrative or judicial </span></div><div style="line-height:10pt;position:var(--position);top:322pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">sanctions, such as the FDA&#8217;s refusal to approve pending NDAs, withdrawal of an approval, imposition of a clinical </span></div><div style="line-height:10pt;position:var(--position);top:332pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">hold on a clinical trial, issuance of warning letters, product recalls, product seizures, total or partial suspension of </span></div><div style="line-height:10pt;position:var(--position);top:342pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or </span></div><div style="line-height:10pt;position:var(--position);top:352pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">criminal penalties. </span></div><div style="line-height:10pt;position:var(--position);top:368pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The process required by the FDA before a drug may be marketed in the United States generally involves the </span></div><div style="line-height:10pt;position:var(--position);top:378pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">following: </span></div><div style="line-height:10pt;position:var(--position);top:394pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">Completion of preclinical laboratory studies, animal studies and formulation studies in compliance </span></span></div><div style="line-height:10pt;position:var(--position);top:404pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">with the FDA&#8217;s GLP regulations, and other applicable regulations; </span></div><div style="line-height:10pt;position:var(--position);top:420pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">Submission to the FDA of an IND which must become effective before human clinical trials may </span></span></div><div style="line-height:10pt;position:var(--position);top:430pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">begin; </span></div><div style="line-height:10pt;position:var(--position);top:446pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">Approval by the Institutional Review Board (&#8220;IRB&#8221;) or ethics committee, at each clinical site before </span></span></div><div style="line-height:10pt;position:var(--position);top:456pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">each trial may be initiated; </span></div><div style="line-height:10pt;position:var(--position);top:472pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">Performance of adequate and well-controlled human clinical trials, in accordance with GCP </span></span></div><div style="line-height:10pt;position:var(--position);top:482pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">requirements to establish the safety and effectiveness of the proposed drug product for each indication; </span></div><div style="line-height:10pt;position:var(--position);top:498pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">Submission to the FDA of an NDA; </span></span></div><div style="line-height:10pt;position:var(--position);top:514pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">Satisfactory completion of an FDA advisory committee review, if applicable; </span></span></div><div style="line-height:10pt;position:var(--position);top:530pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the </span></span></div><div style="line-height:10pt;position:var(--position);top:540pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">product is produced to assess compliance with current good manufacturing practice (&#8220;cGMP&#8221;) </span></div><div style="line-height:10pt;position:var(--position);top:550pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">requirements and to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s </span></div><div style="line-height:10pt;position:var(--position);top:560pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">identity, strength, quality and purity, and of potential inspection of selected clinical investigation sites </span></div><div style="line-height:10pt;position:var(--position);top:570pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">to assess compliance with GCPs; and </span></div><div style="line-height:10pt;position:var(--position);top:586pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">FDA review and approval of the NDA. </span></span></div><div style="line-height:1pt;position:var(--position);top:609.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="line-height:10pt;position:var(--position);top:610.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Preclinical Studies and INDs </span></div><div style="line-height:10pt;position:var(--position);top:626.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as </span></div><div style="line-height:10pt;position:var(--position);top:636.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">animal studies to assess potential safety and efficacy. An IND sponsor must submit the results of the preclinical </span></div><div style="line-height:10pt;position:var(--position);top:646.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">studies, together with manufacturing information, analytical data and any available clinical data or literature, among </span></div><div style="line-height:10pt;position:var(--position);top:656.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">other things, to the FDA as part of an IND. Some preclinical studies may continue even after the IND is submitted. </span></div><div style="line-height:10pt;position:var(--position);top:666.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises </span></div><div style="line-height:10pt;position:var(--position);top:676.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In </span></div><div style="line-height:10pt;position:var(--position);top:686.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. </span></div><div style="line-height:10pt;position:var(--position);top:696.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">77</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Clinical Trials </span></div><div style="line-height:10pt;position:var(--position);top:88pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Clinical trials involve the administration of the investigational drug to human patients under the supervision of </span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">qualified investigators in accordance with GCP requirements, which include, among other things, the requirement </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, the IRB(s) </span></div><div style="line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">competent for the institution(s) participating in the clinical trial must review and approve the plan for any clinical </span></div><div style="line-height:10pt;position:var(--position);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">trial before it commences. Information about certain clinical trials must be submitted within specific timeframes to </span></div><div style="line-height:10pt;position:var(--position);top:168pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the National Institutes of Health for public dissemination on their www.clinicaltrials.gov website. </span></div><div style="line-height:10pt;position:var(--position);top:184pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">While the IND is active, progress reports detailing the results of the clinical trials and nonclinical studies </span></div><div style="line-height:10pt;position:var(--position);top:194pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">performed since the last progress report, among other information, must be submitted at least annually to the FDA </span></div><div style="line-height:10pt;position:var(--position);top:204pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected </span></div><div style="line-height:10pt;position:var(--position);top:214pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar </span></div><div style="line-height:10pt;position:var(--position);top:224pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">drugs, findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important </span></div><div style="line-height:10pt;position:var(--position);top:234pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator </span></div><div style="line-height:10pt;position:var(--position);top:244pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">brochure. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various </span></div><div style="line-height:10pt;position:var(--position);top:254pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">grounds, including a finding that the research patients are being exposed to an unacceptable health risk. Similarly, an </span></div><div style="line-height:10pt;position:var(--position);top:264pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">IRB can suspend or terminate approval of a clinical trial if the clinical trial is not being conducted in accordance </span></div><div style="line-height:10pt;position:var(--position);top:274pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. In addition, </span></div><div style="line-height:10pt;position:var(--position);top:284pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a </span></div><div style="line-height:10pt;position:var(--position);top:294pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial may </span></div><div style="line-height:10pt;position:var(--position);top:304pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">move forward at designated check points based on access to certain data from the trial. </span></div><div style="line-height:10pt;position:var(--position);top:320pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For purposes of FDA approval, human clinical trials are generally conducted in three sequential phases that </span></div><div style="line-height:10pt;position:var(--position);top:330pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">may overlap or be combined: </span></div><div style="line-height:10pt;position:var(--position);top:346pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.94pt;width:14.85pt"></span></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:127.05000000000001pt;position:var(--position);text-decoration:none;white-space:pre">Phase 1:</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:162.3pt;position:var(--position);text-decoration:none;white-space:pre"> The drug candidate is initially introduced into healthy human subjects and tested for safety, </span></div><div style="line-height:10pt;position:var(--position);top:356pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">dosage tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain an early </span></div><div style="line-height:10pt;position:var(--position);top:366pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">indication of its effectiveness. </span></div><div style="line-height:10pt;position:var(--position);top:382pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.94pt;width:14.85pt"></span></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:127.05000000000001pt;position:var(--position);text-decoration:none;white-space:pre">Phase 2:</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:162.3pt;position:var(--position);text-decoration:none;white-space:pre"> The drug candidate is administered to a limited patient population with a specified disease or </span></div><div style="line-height:10pt;position:var(--position);top:392pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">condition to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of </span></div><div style="line-height:10pt;position:var(--position);top:402pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">the drug candidate for specific targeted diseases and to determine dosage tolerance and appropriate </span></div><div style="line-height:10pt;position:var(--position);top:412pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">dosage. </span></div><div style="line-height:10pt;position:var(--position);top:428pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.94pt;width:14.85pt"></span></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:127.05000000000001pt;position:var(--position);text-decoration:none;white-space:pre">Phase 3:</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:162.3pt;position:var(--position);text-decoration:none;white-space:pre"> The drug candidate is administered to an expanded patient population to further evaluate </span></div><div style="line-height:10pt;position:var(--position);top:438pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">dosage, to provide substantial evidence of efficacy and to further test for safety, generally at multiple </span></div><div style="line-height:10pt;position:var(--position);top:448pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall </span></div><div style="line-height:10pt;position:var(--position);top:458pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">risk-benefit ratio of the drug candidate and provide an adequate basis for product labeling. </span></div><div style="line-height:10pt;position:var(--position);top:474pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Post-approval trials, sometimes referred to as Phase 4 studies, may be conducted after initial marketing </span></div><div style="line-height:10pt;position:var(--position);top:484pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">approval. These trials are used to, among other things, gain additional experience from the treatment of patients in </span></div><div style="line-height:10pt;position:var(--position);top:494pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical </span></div><div style="line-height:10pt;position:var(--position);top:504pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">trials as a condition of approval of an NDA. </span></div><div style="line-height:10pt;position:var(--position);top:520pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop </span></div><div style="line-height:10pt;position:var(--position);top:530pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">additional information about the chemistry and physical characteristics of the drug and finalize a process for </span></div><div style="line-height:10pt;position:var(--position);top:540pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">manufacturing the product in commercial quantities in accordance with GMPs. The manufacturing process must be </span></div><div style="line-height:10pt;position:var(--position);top:550pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">capable of consistently producing quality batches of the drug candidate and, among other things, the manufacturer </span></div><div style="line-height:10pt;position:var(--position);top:560pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate </span></div><div style="line-height:10pt;position:var(--position);top:570pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">packaging must be selected and tested, and stability studies must be conducted to demonstrate that the drug </span></div><div style="line-height:10pt;position:var(--position);top:580pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">candidate does not undergo unacceptable deterioration over its shelf life. </span></div><div style="line-height:10pt;position:var(--position);top:608pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Marketing Approval </span></div><div style="line-height:10pt;position:var(--position);top:624pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Assuming successful completion of the required clinical testing, the results of the preclinical studies and </span></div><div style="line-height:10pt;position:var(--position);top:634pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">clinical trials, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and </span></div><div style="line-height:10pt;position:var(--position);top:644pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market </span></div><div style="line-height:10pt;position:var(--position);top:654pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the product for one or more indications. In most cases, the submission of an NDA is subject to a substantial </span></div><div style="line-height:10pt;position:var(--position);top:664pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">application user fee. Under the Prescription Drug User Fee Act guidelines that are currently in effect, the FDA has a </span></div><div style="line-height:10pt;position:var(--position);top:674pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">goal of ten months from the date of &#8220;filing&#8221; of a standard NDA for a new molecular entity to review and act on the </span></div><div style="line-height:10pt;position:var(--position);top:684pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">submission. This review typically takes twelve months from the date the NDA is submitted to FDA because the </span></div><div style="line-height:10pt;position:var(--position);top:694pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">FDA has approximately two months to make a &#8220;filing&#8221; decision. </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">78</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In addition, under the Pediatric Research Equity Act of 2003, as amended and reauthorized, certain NDAs or </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">supplements to an NDA must contain data that are adequate to assess the safety and effectiveness of the drug for the </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the </span></div><div style="line-height:10pt;position:var(--position);top:112pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the </span></div><div style="line-height:10pt;position:var(--position);top:122pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">product for use in adults, or full or partial waivers from the pediatric data requirements. </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The FDA also may require submission of a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) plan to ensure </span></div><div style="line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">that the benefits of the drug outweigh its risks. The REMS plan could include Medication Guides (FDA approved </span></div><div style="line-height:10pt;position:var(--position);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">patient labeling to be provided to patients when the drug is dispensed), physician communication plans, assessment </span></div><div style="line-height:10pt;position:var(--position);top:168pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">plans, or Elements to Assure Safe Use, such as restricted distribution methods, patient registries, or other risk </span></div><div style="line-height:10pt;position:var(--position);top:178pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">minimization tools. </span></div><div style="line-height:10pt;position:var(--position);top:194pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before </span></div><div style="line-height:10pt;position:var(--position);top:204pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The </span></div><div style="line-height:10pt;position:var(--position);top:214pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">FDA may request additional information rather than accept an NDA for filing. In this event, the application must be </span></div><div style="line-height:10pt;position:var(--position);top:224pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">resubmitted with the additional information. The resubmitted application is also subject to review before the FDA </span></div><div style="line-height:10pt;position:var(--position);top:234pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The </span></div><div style="line-height:10pt;position:var(--position);top:244pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the </span></div><div style="line-height:10pt;position:var(--position);top:254pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s </span></div><div style="line-height:10pt;position:var(--position);top:264pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">continued safety, quality and purity. </span></div><div style="line-height:10pt;position:var(--position);top:280pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The FDA may refer an application for a novel drug to an Advisory Committee. An Advisory Committee is a </span></div><div style="line-height:10pt;position:var(--position);top:290pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a </span></div><div style="line-height:10pt;position:var(--position);top:300pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">recommendation as to whether the application should be approved and under what conditions. The FDA is not </span></div><div style="line-height:10pt;position:var(--position);top:310pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">bound by the recommendations of an Advisory Committee, but it considers such recommendations carefully when </span></div><div style="line-height:10pt;position:var(--position);top:320pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">making decisions. </span></div><div style="line-height:10pt;position:var(--position);top:336pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Before approving an NDA, the FDA typically will inspect the facility or facilities where the commercial </span></div><div style="line-height:10pt;position:var(--position);top:346pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">product would be manufactured. The FDA will not approve an application unless it determines that the </span></div><div style="line-height:10pt;position:var(--position);top:356pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent </span></div><div style="line-height:10pt;position:var(--position);top:366pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">production of the product within required specifications. Additionally, before approving an NDA, the FDA may </span></div><div style="line-height:10pt;position:var(--position);top:376pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">inspect one or more clinical trial sites to verify the clinical data submitted in the NDA, and to assure compliance </span></div><div style="line-height:10pt;position:var(--position);top:386pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">with GCP requirements. </span></div><div style="line-height:10pt;position:var(--position);top:402pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">After evaluating the NDA and all related information, including the Advisory Committee recommendation, if </span></div><div style="line-height:10pt;position:var(--position);top:412pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an </span></div><div style="line-height:10pt;position:var(--position);top:422pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">approval letter, or, in some cases, a Complete Response Letter. An approval letter authorizes commercial marketing </span></div><div style="line-height:10pt;position:var(--position);top:432pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of the drug with specific prescribing information for specific indications. A Complete Response Letter indicates that </span></div><div style="line-height:10pt;position:var(--position);top:442pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the review cycle of the application is complete, and the application will not be approved in its present form, and </span></div><div style="line-height:10pt;position:var(--position);top:452pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such </span></div><div style="line-height:10pt;position:var(--position);top:462pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">as an additional clinical trial or other significant and time-consuming requirements related to clinical trials, </span></div><div style="line-height:10pt;position:var(--position);top:472pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">nonclinical studies or manufacturing. If a CRL is issued, the sponsor must resubmit the NDA, addressing all of the </span></div><div style="line-height:10pt;position:var(--position);top:482pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the </span></div><div style="line-height:10pt;position:var(--position);top:492pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">FDA may decide that the NDA does not satisfy the criteria for approval. </span></div><div style="line-height:10pt;position:var(--position);top:508pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that </span></div><div style="line-height:10pt;position:var(--position);top:518pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, </span></div><div style="line-height:10pt;position:var(--position);top:528pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">including Phase 4 clinical trials, be conducted to further assess a drug&#8217;s safety after approval, require testing and </span></div><div style="line-height:10pt;position:var(--position);top:538pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">surveillance programs to monitor the product after commercialization, or impose other conditions, including </span></div><div style="line-height:10pt;position:var(--position);top:548pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect </span></div><div style="line-height:10pt;position:var(--position);top:558pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the potential market and profitability of the product. The FDA may at any time prevent or limit further marketing of </span></div><div style="line-height:10pt;position:var(--position);top:568pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">a product based on the results of post-marketing studies or surveillance programs. After initial approval, some types </span></div><div style="line-height:10pt;position:var(--position);top:578pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling </span></div><div style="line-height:10pt;position:var(--position);top:588pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">claims, are subject to further testing requirements and FDA review and approval. </span></div><div style="line-height:10pt;position:var(--position);top:616pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Post-Approval Requirements </span></div><div style="line-height:10pt;position:var(--position);top:632pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing </span></div><div style="line-height:10pt;position:var(--position);top:642pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, </span></div><div style="line-height:10pt;position:var(--position);top:652pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">product sampling and distribution, the submission of advertising and promotion, and reporting of adverse </span></div><div style="line-height:10pt;position:var(--position);top:662pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">experiences with the product. After approval, most changes to the approved product, such as adding new indications </span></div><div style="line-height:10pt;position:var(--position);top:672pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">or other labeling claims are subject to prior FDA review and approval. There also are continuing, annual program </span></div><div style="line-height:10pt;position:var(--position);top:682pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">user fee requirements for any marketed products, as well as new application fees for certain supplemental </span></div><div style="line-height:10pt;position:var(--position);top:692pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">applications. </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">79</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">assess and monitor the product&#8217;s safety and effectiveness after commercialization. </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. </span></div><div style="line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">FDA regulations also require manufacturers to investigate and correct of any deviations from cGMP requirements </span></div><div style="line-height:10pt;position:var(--position);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the </span></div><div style="line-height:10pt;position:var(--position);top:168pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area </span></div><div style="line-height:10pt;position:var(--position);top:178pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of production and quality control to maintain cGMP compliance. </span></div><div style="line-height:10pt;position:var(--position);top:194pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements </span></div><div style="line-height:10pt;position:var(--position);top:204pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and standards is not maintained or if problems occur after the product reaches the market. Later discovery of </span></div><div style="line-height:10pt;position:var(--position);top:214pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or </span></div><div style="line-height:10pt;position:var(--position);top:224pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions </span></div><div style="line-height:10pt;position:var(--position);top:234pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess </span></div><div style="line-height:10pt;position:var(--position);top:244pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">new safety risks; or imposition of distribution or other restrictions under a REMS program. </span></div><div style="line-height:10pt;position:var(--position);top:260pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Other potential consequences include, among other things: </span></div><div style="line-height:10pt;position:var(--position);top:276pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product </span></span></div><div style="line-height:10pt;position:var(--position);top:286pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">from the market or product recalls; </span></div><div style="line-height:10pt;position:var(--position);top:302pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">Fines, warning letters or holds on post-approval clinical trials; </span></span></div><div style="line-height:10pt;position:var(--position);top:318pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">Refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or </span></span></div><div style="line-height:10pt;position:var(--position);top:328pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">revocation of product approvals; </span></div><div style="line-height:10pt;position:var(--position);top:344pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">Product seizure or detention, or refusal to permit the import or export of products; or </span></span></div><div style="line-height:10pt;position:var(--position);top:360pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">Injunctions or the imposition of civil or criminal penalties. </span></span></div><div style="line-height:10pt;position:var(--position);top:376pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the </span></div><div style="line-height:10pt;position:var(--position);top:386pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the </span></div><div style="line-height:10pt;position:var(--position);top:396pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion </span></div><div style="line-height:10pt;position:var(--position);top:406pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of unapproved uses (&#8220;off-label&#8221; uses), and a company that is found to have improperly promoted off-label uses may </span></div><div style="line-height:10pt;position:var(--position);top:416pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">be subject to significant liability. Physicians may prescribe legally available products for uses that are not described </span></div><div style="line-height:10pt;position:var(--position);top:426pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. The FDA does not </span></div><div style="line-height:10pt;position:var(--position);top:436pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s </span></div><div style="line-height:10pt;position:var(--position);top:446pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">communications on the subject of off-label use of their products. </span></div><div style="line-height:10pt;position:var(--position);top:474pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Marketing Exclusivity </span></div><div style="line-height:10pt;position:var(--position);top:490pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Market exclusivity provisions under the FDCA can delay the submission or the approval of certain marketing </span></div><div style="line-height:10pt;position:var(--position);top:500pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">applications. The FDCA provides a five-year period of non-patent data exclusivity within the United States to the </span></div><div style="line-height:10pt;position:var(--position);top:510pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA </span></div><div style="line-height:10pt;position:var(--position);top:520pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">has not previously approved any other new drug containing the same active moiety, which is the molecule or ion </span></div><div style="line-height:10pt;position:var(--position);top:530pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review </span></div><div style="line-height:10pt;position:var(--position);top:540pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">an abbreviated new drug application (&#8220;ANDA&#8221;), or an NDA submitted under Section&#160;505(b)(2) (&#8220;505(b)(2) NDA&#8221;) </span></div><div style="line-height:10pt;position:var(--position);top:550pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">submitted by another company for another drug based on the same active moiety, regardless of whether the drug is </span></div><div style="line-height:10pt;position:var(--position);top:560pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">intended for the same indication as the original innovative drug or for another indication, where the applicant does </span></div><div style="line-height:10pt;position:var(--position);top:570pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">not own or have a legal right of reference to all the data required for approval. However, an application may be </span></div><div style="line-height:10pt;position:var(--position);top:580pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents </span></div><div style="line-height:10pt;position:var(--position);top:590pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">listed with the FDA by the innovator NDA holder. </span></div><div style="line-height:10pt;position:var(--position);top:606pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an </span></div><div style="line-height:10pt;position:var(--position);top:616pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by </span></div><div style="line-height:10pt;position:var(--position);top:626pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, </span></div><div style="line-height:10pt;position:var(--position);top:636pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug </span></div><div style="line-height:10pt;position:var(--position);top:646pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving </span></div><div style="line-height:10pt;position:var(--position);top:656pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. </span></div><div style="line-height:10pt;position:var(--position);top:666pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">80</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">submitting a full NDA would be required to conduct, or obtain a right of reference to, all of the preclinical studies </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. </span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">exclusivity provides for an additional six months of marketing exclusivity attached to another period of exclusivity if </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">request does not require the sponsor to undertake the described clinical trials. </span></div><div style="line-height:10pt;position:var(--position);top:156pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Coverage and Reimbursement </span></div><div style="line-height:10pt;position:var(--position);top:172pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Sales of our drug candidates, if approved, will depend, in part, on the extent to which such products will be </span></div><div style="line-height:10pt;position:var(--position);top:182pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">covered by third-party payors, such as government health care programs, commercial insurance and managed </span></div><div style="line-height:10pt;position:var(--position);top:192pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">healthcare organizations. These third-party payors determine which medications they will cover and establish </span></div><div style="line-height:10pt;position:var(--position);top:202pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reimbursement levels. In addition, these third-party payors are increasingly limiting coverage or reducing </span></div><div style="line-height:10pt;position:var(--position);top:212pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reimbursements for medical products and services. In the United States, no uniform policy of coverage and </span></div><div style="line-height:10pt;position:var(--position);top:222pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for products </span></div><div style="line-height:10pt;position:var(--position);top:232pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">can differ significantly from payor to payor. In addition, the U.S. government and state legislatures have continued </span></div><div style="line-height:10pt;position:var(--position);top:242pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements </span></div><div style="line-height:10pt;position:var(--position);top:252pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for substitution of generic products. For example, the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) </span></div><div style="line-height:10pt;position:var(--position);top:262pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">imposes rebates on Medicare Part B and Medicare Part D products to penalize price increases that outpace inflation </span></div><div style="line-height:10pt;position:var(--position);top:272pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">on an annual basis. HHS has also been empowered to negotiate the price of certain single-source drugs that have </span></div><div style="line-height:10pt;position:var(--position);top:282pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">been on the market for at least seven (7) years under Medicare as part of the Medicare Drug Price Negotiation </span></div><div style="line-height:10pt;position:var(--position);top:292pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Program. Each year up to twenty (20) products will be selected by HHS for the Medicare Drug Price Negotiation </span></div><div style="line-height:10pt;position:var(--position);top:302pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Program. Products subject to the Medicare Drug Price Negotiation Program are expected to experience a significant </span></div><div style="line-height:10pt;position:var(--position);top:312pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reduction in reimbursement from the Medicare program on a per unit basis. Patients who are prescribed medications </span></div><div style="line-height:10pt;position:var(--position);top:322pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to </span></div><div style="line-height:10pt;position:var(--position);top:332pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely to use our products </span></div><div style="line-height:10pt;position:var(--position);top:342pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of our </span></div><div style="line-height:10pt;position:var(--position);top:352pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">products. As a result, adoption of price controls and cost-containment measures, and adoption of more restrictive </span></div><div style="line-height:10pt;position:var(--position);top:362pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. </span></div><div style="line-height:10pt;position:var(--position);top:372pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Decreases in third-party reimbursement for our drug candidates or a decision by a third-party payor to not cover our </span></div><div style="line-height:10pt;position:var(--position);top:382pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">drug candidates could reduce physician usage of our drug candidates, once approved, and have a material adverse </span></div><div style="line-height:10pt;position:var(--position);top:392pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">effect on our sales, results of operations and financial condition. Additionally, we or our collaborators may develop </span></div><div style="line-height:10pt;position:var(--position);top:402pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">companion diagnostic tests for use with our drug candidates. We or our collaborators will be required to obtain </span></div><div style="line-height:10pt;position:var(--position);top:412pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we seek for our </span></div><div style="line-height:10pt;position:var(--position);top:422pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">drug candidates, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:139.98000000000002pt;position:var(--position);white-space:pre">once</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.84pt;position:var(--position);text-decoration:none;white-space:pre"> approved. Similar challenges to obtaining coverage and reimbursement, applicable to </span></div><div style="line-height:10pt;position:var(--position);top:432pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">pharmaceutical or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:146.32pt;position:var(--position);white-space:pre">biological</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:186.26pt;position:var(--position);text-decoration:none;white-space:pre"> products, will apply to companion diagnostics. </span></div><div style="line-height:10pt;position:var(--position);top:460pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Other Healthcare Laws </span></div><div style="line-height:10pt;position:var(--position);top:476pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We will also be subject to other healthcare regulation and enforcement by the U.S. federal government and the </span></div><div style="line-height:10pt;position:var(--position);top:486pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">states in which we will conduct our business once our drug candidates are approved. Failure to comply with these </span></div><div style="line-height:10pt;position:var(--position);top:496pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">laws, where applicable, can result in the imposition of significant administrative, civil, and criminal penalties. The </span></div><div style="line-height:10pt;position:var(--position);top:506pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">laws that may affect our ability to operate in the United States include: </span></div><div style="line-height:10pt;position:var(--position);top:522pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">The </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:145.08pt;position:var(--position);white-space:pre">federal</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:172.8pt;position:var(--position);text-decoration:none;white-space:pre"> healthcare programs&#8217; Anti-Kickback Statute, which prohibits, among other things, persons </span></div><div style="line-height:10pt;position:var(--position);top:532pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or </span></div><div style="line-height:10pt;position:var(--position);top:542pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or </span></div><div style="line-height:10pt;position:var(--position);top:552pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">recommendation of, any good or service for which payment may be made under federal healthcare </span></div><div style="line-height:10pt;position:var(--position);top:562pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">programs such as the Medicare and Medicaid programs; </span></div><div style="line-height:10pt;position:var(--position);top:578pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">Federal false claims act laws, including the civil False Claims Act, which prohibit, among other things, </span></span></div><div style="line-height:10pt;position:var(--position);top:588pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">individuals or entities from knowingly presenting, or causing to be presented, claims for payment from </span></div><div style="line-height:10pt;position:var(--position);top:598pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">Medicare, Medicaid, or other third-party payors that are false or fraudulent; </span></div><div style="line-height:10pt;position:var(--position);top:614pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">The federal health care fraud statutes, which created additional federal criminal statutes that impose </span></span></div><div style="line-height:10pt;position:var(--position);top:624pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">criminal and civil liability for, among other things, executing or attempting to execute a scheme to </span></div><div style="line-height:10pt;position:var(--position);top:634pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">defraud any healthcare benefit program or knowingly and willingly falsifying, concealing or covering </span></div><div style="line-height:10pt;position:var(--position);top:644pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">up a material fact or making false statements relating to healthcare matters; </span></div><div style="line-height:1pt;position:var(--position);top:658.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="line-height:10pt;position:var(--position);top:659.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">The Physician Payments Sunshine Act, which requires manufacturers of drugs, devices, biologics, and </span></span></div><div style="line-height:10pt;position:var(--position);top:669.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">medical supplies to report annually to the Centers for Medicare&#160;&amp; Medicaid Services, information </span></div><div style="line-height:10pt;position:var(--position);top:679.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">related to payments and other transfers of value to physicians (defined to include doctors, dentists, </span></div><div style="line-height:10pt;position:var(--position);top:689.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">optometrists, podiatrists and chiropractors), other health care professionals (such as physicians </span></div><div style="line-height:10pt;position:var(--position);top:699.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">assistants and nurse practitioners), and teaching hospitals, as well as and ownership and investment </span></div><div style="line-height:10pt;position:var(--position);top:709.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">interests held by physicians and their immediate family members; </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">81</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">The U.S. federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which </span></span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">created additional federal criminal statutes that impose criminal and civil liability for, among other </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">things, executing or attempting to execute a scheme to defraud any healthcare benefit program or </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">knowingly and willingly falsifying, concealing or covering up a material fact or making false </span></div><div style="line-height:10pt;position:var(--position);top:112pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">statements relating to healthcare matters; and </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act </span></span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">(&#8220;HITECH&#8221;), which governs the conduct of covered entities, business associates, and their covered </span></div><div style="line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">subcontractors regarding certain electronic healthcare transactions and protects the security and </span></div><div style="line-height:10pt;position:var(--position);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">privacy of protected health information. </span></div><div style="line-height:10pt;position:var(--position);top:174pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In addition, many states have similar laws and regulations, such as anti-kickback and false claims laws that </span></div><div style="line-height:10pt;position:var(--position);top:184pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under </span></div><div style="line-height:10pt;position:var(--position);top:194pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Medicaid and other state programs. Further, certain states require certain regulatory licenses to manufacture or </span></div><div style="line-height:10pt;position:var(--position);top:204pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">distribute products commercially and/or the registration of pharmaceutical sales representatives in the jurisdiction, </span></div><div style="line-height:10pt;position:var(--position);top:214pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary </span></div><div style="line-height:10pt;position:var(--position);top:224pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">compliance guidelines and the relevant compliance guidance promulgated by the federal government; drug </span></div><div style="line-height:10pt;position:var(--position);top:234pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">manufacturers to report information related to payments and other transfers of value to physicians and other </span></div><div style="line-height:10pt;position:var(--position);top:244pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">healthcare providers or marketing expenditures; and the reporting of information related to drug pricing. Certain </span></div><div style="line-height:10pt;position:var(--position);top:254pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">states have also enacted legislation to govern the privacy and security of health information, many of which differ </span></div><div style="line-height:10pt;position:var(--position);top:264pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </span></div><div style="line-height:10pt;position:var(--position);top:274pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Additionally, to the extent that our product is sold in a foreign country, we may be subject to similar foreign laws. </span></div><div style="line-height:10pt;position:var(--position);top:284pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Violation of any of these laws or any other governmental regulations, may result in significant civil, criminal and </span></div><div style="line-height:10pt;position:var(--position);top:294pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">administrative penalties, damages, fines, disgorgement, imprisonment, possible exclusion from government funded </span></div><div style="line-height:10pt;position:var(--position);top:304pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, and diminished </span></div><div style="line-height:10pt;position:var(--position);top:314pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">profits and future earnings.</span></div><div style="line-height:10pt;position:var(--position);top:342pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:underline;white-space:pre">Healthcare Reform </span></div><div style="line-height:10pt;position:var(--position);top:358pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The enactment of the Patient Protection and Affordable Care Act, as amended by the Health Care and </span></div><div style="line-height:10pt;position:var(--position);top:368pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Education Reconciliation Act, or collectively the (&#8220;ACA&#8221;) has substantially changed healthcare financing and </span></div><div style="line-height:10pt;position:var(--position);top:378pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">delivery by both governmental and private insurers, and significantly impacted the pharmaceutical industry.&#160; </span></div><div style="line-height:10pt;position:var(--position);top:394pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Since its enactment, there have been judicial and congressional challenges to certain aspects of the ACA. For </span></div><div style="line-height:10pt;position:var(--position);top:404pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">example, on July 4, 2025, the One Big Beautiful Bill Act, or OBBBA, was signed into law, which narrowed access </span></div><div style="line-height:10pt;position:var(--position);top:414pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to ACA marketplace exchange enrollment and declined to extend the ACA enhanced advanced premium tax credits </span></div><div style="line-height:10pt;position:var(--position);top:424pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">that expired at the end of 2025, which, among other provisions in the law, are anticipated to reduce the number of </span></div><div style="line-height:10pt;position:var(--position);top:434pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Americans with health insurance.&#160; The OBBBA also is expected to reduce Medicaid spending and enrollment by </span></div><div style="line-height:10pt;position:var(--position);top:444pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">implementing work requirements for some beneficiaries, capping state-directed payments, reducing federal funding, </span></div><div style="line-height:10pt;position:var(--position);top:454pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and limiting provider taxes used to fund the program. Congress is considering proposed legislation intended to </span></div><div style="line-height:10pt;position:var(--position);top:464pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">further reduce healthcare costs with alternatives to replace the expired ACA subsidies. </span></div><div style="line-height:10pt;position:var(--position);top:480pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Other legislative changes have been proposed and adopted since the ACA was enacted. For example, on </span></div><div style="line-height:10pt;position:var(--position);top:490pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">August&#160;2, 2011, the Budget Control Act of 2011 was signed into law which among other things, led to aggregate </span></div><div style="line-height:10pt;position:var(--position);top:500pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reductions in Medicare payments to providers. These reductions went into effect on April&#160;1, 2013, and, due to </span></div><div style="line-height:10pt;position:var(--position);top:510pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">subsequent legislative amendments, will remain in effect until 2032 unless additional Congressional action is taken.</span></div><div style="line-height:10pt;position:var(--position);top:526pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In addition, there has been heightened governmental scrutiny over the manner in which manufacturers set </span></div><div style="line-height:10pt;position:var(--position);top:536pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">prices for their marketed products. For example, there have been several U.S. presidential executive orders, </span></div><div style="line-height:10pt;position:var(--position);top:546pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">congressional inquiries and proposed and enacted legislation at the federal and state designed to, among other things, </span></div><div style="line-height:10pt;position:var(--position);top:556pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, </span></div><div style="line-height:10pt;position:var(--position);top:566pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and reform government program reimbursement methodologies for drug products. The current U.S. presidential </span></div><div style="line-height:10pt;position:var(--position);top:576pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">administration is pursuing policies to reduce regulations and expenditures across government. These actions, </span></div><div style="line-height:10pt;position:var(--position);top:586pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">presently directed by executive orders or memoranda from the Office of Management and Budget, may propose </span></div><div style="line-height:10pt;position:var(--position);top:596pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">policy changes that create additional uncertainty for our business. For example, the current administration has </span></div><div style="line-height:10pt;position:var(--position);top:606pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">announced agreements with pharmaceutical companies that require the drug manufacturers to offer, through a direct-</span></div><div style="line-height:10pt;position:var(--position);top:616pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to-consumer platform (TrumpRx), U.S. patients and Medicaid programs prescription drug Most-Favored Nation </span></div><div style="line-height:10pt;position:var(--position);top:626pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">pricing equal to or lower than those paid in other developed nations, with additional mandates for direct-to-patient </span></div><div style="line-height:10pt;position:var(--position);top:636pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">discounts and repatriation of foreign revenues. Other recent actions and proposals include, for example (1) reducing </span></div><div style="line-height:10pt;position:var(--position);top:646pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">agency workforce and cut programs; (2) directing HHS and other agencies to lower prescription drug costs through a </span></div><div style="line-height:10pt;position:var(--position);top:656pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">variety of initiatives; (3) imposing tariffs on imported pharmaceutical products; and (4) as part of the Make America </span></div><div style="line-height:10pt;position:var(--position);top:666pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Healthy Again Commission&#8217;s Strategy Report released in September 2025, working across government agencies to </span></div><div style="line-height:10pt;position:var(--position);top:676pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">increase enforcement on direct-to-consumer pharmaceutical advertising. Additionally, the current administration </span></div><div style="line-height:10pt;position:var(--position);top:686pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">recently called on Congress to enact &#8220;The Great Healthcare Plan,&#8221; to codify and expand Most-Favored Nation </span></div><div style="line-height:10pt;position:var(--position);top:696pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">pricing, lower government subsidies to private insurance companies, increase healthcare price transparency, expand </span></div><div style="line-height:10pt;position:var(--position);top:706pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">pharmaceutical drugs available for over-the-counter purchase, and enact restrictions on pharmacy benefit manager </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">82</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">payment methodologies, among other things. These actions and policies may significantly reduce U.S. drug prices, </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">potentially impacting manufacturers&#8217; global pricing strategies and profitability, while increasing their operational </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">costs and compliance risks.&#160; In June 2024, in Loper Bright Enterprises v. Raimondo, the U.S. Supreme Court greatly </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reduced judicial deference to regulatory agencies, which could increase successful legal challenges to federal </span></div><div style="line-height:10pt;position:var(--position);top:112pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regulations affecting our operations.</span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">At the state level, legislatures are increasingly passing legislation and implementing regulations designed to </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, </span></div><div style="line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in </span></div><div style="line-height:10pt;position:var(--position);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div style="line-height:10pt;position:var(--position);top:174pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We expect that additional U.S. healthcare reform measures will be adopted in the future, any of which could </span></div><div style="line-height:10pt;position:var(--position);top:184pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result </span></div><div style="line-height:10pt;position:var(--position);top:194pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">in reduced demand for our drug candidates or additional pricing pressures. </span></div><div style="line-height:10pt;position:var(--position);top:222pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Intellectual Property </span></div><div style="line-height:10pt;position:var(--position);top:238pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our success will depend upon our ability to obtain and maintain patents and other intellectual property for our </span></div><div style="line-height:10pt;position:var(--position);top:248pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">drug candidates in the United States and internationally, including composition-of-matter, pharmaceutical </span></div><div style="line-height:10pt;position:var(--position);top:258pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">composition, synthesis process, method of manufacture and method of treatment for an obefazimod's intellectual </span></div><div style="line-height:10pt;position:var(--position);top:268pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">property protection in the United States to 2039, as well as patent and other intellectual property and proprietary </span></div><div style="line-height:10pt;position:var(--position);top:278pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">protection for our novel discoveries and other important technology inventions and know-how. </span></div><div style="line-height:10pt;position:var(--position);top:294pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">One of our strategies is also to generate new intellectual property through the protection of potential follow-on </span></div><div style="line-height:10pt;position:var(--position);top:304pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">compounds. </span></div><div style="line-height:10pt;position:var(--position);top:320pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In addition to patents, we rely upon unpatented trade secrets, know-how, and continuing technological </span></div><div style="line-height:10pt;position:var(--position);top:330pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">innovation to develop and maintain our competitive position. We protect our proprietary information, in part, using </span></div><div style="line-height:10pt;position:var(--position);top:340pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">confidentiality agreements with our commercial partners, collaborators, employees and consultants and invention </span></div><div style="line-height:10pt;position:var(--position);top:350pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">assignment agreements with our employees. We also have confidentiality agreements or invention assignment </span></div><div style="line-height:10pt;position:var(--position);top:360pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">agreements with our commercial partners and selected consultants. Despite these measures, any of our intellectual </span></div><div style="line-height:10pt;position:var(--position);top:370pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">property and proprietary rights could be challenged, invalidated, circumvented, infringed or misappropriated, or </span></div><div style="line-height:10pt;position:var(--position);top:380pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">such intellectual property and proprietary rights may not be sufficient to permit us to take advantage of current </span></div><div style="line-height:10pt;position:var(--position);top:390pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">market trends or otherwise to provide competitive advantages. In addition, such confidentiality agreements and </span></div><div style="line-height:10pt;position:var(--position);top:400pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">invention assignment agreements can be breached and we may not have adequate remedies for any such breach. For </span></div><div style="line-height:10pt;position:var(--position);top:410pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">more information, please see &#8220;Risk Factors&#8212;Risks Related to Intellectual Property.&#8221; </span></div><div style="line-height:10pt;position:var(--position);top:426pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The term of individual patents depends upon the legal term of the patents in the countries in which they are </span></div><div style="line-height:10pt;position:var(--position);top:436pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">obtained. In most countries in which we are seeking patent protection for our drug candidates, the patent term is 20 </span></div><div style="line-height:10pt;position:var(--position);top:446pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">years from the earliest date of filing a non-provisional patent application. In the United States, the term of a patent </span></div><div style="line-height:10pt;position:var(--position);top:456pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">may be lengthened by a patent term adjustment, which provides for term extension in the case of administrative </span></div><div style="line-height:10pt;position:var(--position);top:466pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">delays at the United States Patent and Trademark Office in granting a patent, or may be shortened if a patent is </span></div><div style="line-height:10pt;position:var(--position);top:476pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">terminally disclaimed over another patent with an earlier expiration date. Furthermore, in the United States, the term </span></div><div style="line-height:10pt;position:var(--position);top:486pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of a patent covering an FDA approved drug may be eligible for patent term extension (&#8220;PTE&#8221;) under the Hatch-</span></div><div style="line-height:10pt;position:var(--position);top:496pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Waxman Amendments as compensation for the loss of patent term during the FDA regulatory review process. The </span></div><div style="line-height:10pt;position:var(--position);top:506pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">period of extension may be up to five years beyond the expiration of the patent but cannot extend the term of a </span></div><div style="line-height:10pt;position:var(--position);top:516pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">patent beyond a total of 14 years from the date of product approval. Only one patent covering a single FDA-</span></div><div style="line-height:10pt;position:var(--position);top:526pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">approved product among those eligible for an extension may be extended. In the future, if any of our drug candidates </span></div><div style="line-height:10pt;position:var(--position);top:536pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">receives FDA approval, we expect to apply for a PTE, if available, to extend the term of a patent covering such </span></div><div style="line-height:10pt;position:var(--position);top:546pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">approved drug product. We also expect to seek PTEs in any jurisdictions where they are available, however, there is </span></div><div style="line-height:10pt;position:var(--position);top:556pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such an </span></div><div style="line-height:10pt;position:var(--position);top:566pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">extension should be granted, and even if granted, the length of such an extension. See &#8220;Item 3.D. Risk Factors&#8212;</span></div><div style="line-height:10pt;position:var(--position);top:576pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Risks Related to Intellectual Property &#8212; Our ability to commercialize our drug candidates may decrease if we are </span></div><div style="line-height:10pt;position:var(--position);top:586pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">unable to protect our intellectual property rights or if these rights are insufficient for our purposes." </span></div><div style="line-height:10pt;position:var(--position);top:614pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Patents </span></div><div style="line-height:10pt;position:var(--position);top:630pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">All the patents and patent applications covering obefazimod are co-owned with the French National Centre for </span></div><div style="line-height:10pt;position:var(--position);top:640pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Scientific Research (the &#8220;CNRS&#8221;), the University of Montpellier, and the Institut Curie, except U.S. patent </span></div><div style="line-height:10pt;position:var(--position);top:650pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">10,464,903, U.S. patent 10,745,357,&#160; U.S. patent applications 18/729,018, U.S. patent application 18/893,339, U.S. </span></div><div style="line-height:10pt;position:var(--position);top:660pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">patent application 18/832,670 and U.S. patent application 19/149,308, as described below. </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">83</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Obefazimod </span></div><div style="line-height:10pt;position:var(--position);top:88pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2025, the principal patent rights related to obefazimod, include: </span></div><div style="line-height:10pt;position:var(--position);top:104pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">U.S. patent 10,017,498, which is directed to the composition of matter of obefazimod generically and </span></span></div><div style="line-height:10pt;position:var(--position);top:114pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">specifically and to a pharmaceutical composition comprising it. This patent is also granted in Europe </span></div><div style="line-height:10pt;position:var(--position);top:124pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">and several other countries (Australia, Brazil, Canada, China, Hong Kong,&#160; India, Japan, South Korea, </span></div><div style="line-height:10pt;position:var(--position);top:134pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">Mexico, Russia, South Africa) and has an expiry date of 2030, not including patent term adjustment or </span></div><div style="line-height:10pt;position:var(--position);top:144pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">any potential PTE. </span></div><div style="line-height:10pt;position:var(--position);top:160pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">U.S. patent 10,975,063, which is directed specifically to obefazimod (composition of matter), free base </span></span></div><div style="line-height:10pt;position:var(--position);top:170pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">and salts of obefazimod, a pharmaceutical composition comprising it, a process for preparing it and a </span></div><div style="line-height:10pt;position:var(--position);top:180pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">method for treating HIV infection. This patent has an expiry date of 2030, not including patent term </span></div><div style="line-height:10pt;position:var(--position);top:190pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">adjustment or any potential PTE. </span></div><div style="line-height:10pt;position:var(--position);top:206pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">U.S. patent 10,435,370, which is directed to methods of treating inflammatory diseases including UC </span></span></div><div style="line-height:10pt;position:var(--position);top:216pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">and CD by obefazimod generically and specifically. This patent is also granted in Europe and several </span></div><div style="line-height:10pt;position:var(--position);top:226pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">other countries (Australia, Brazil, Canada, China, Hong Kong,&#160; India, Japan, South Korea, Mexico, </span></div><div style="line-height:10pt;position:var(--position);top:236pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">Russia, South Africa). </span></div><div style="line-height:10pt;position:var(--position);top:252pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">U.S. continuation patent 11,649,211 is directed to the method of treating inflammatory diseases </span></span></div><div style="line-height:10pt;position:var(--position);top:262pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">including UC and CD by obefazimod specifically. Divisional U.S. patents protect methods of treating </span></div><div style="line-height:10pt;position:var(--position);top:272pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">additional inflammatory diseases (U.S. patent 10,981,874 and U.S. patent 11,649,210). These patents </span></div><div style="line-height:10pt;position:var(--position);top:282pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">have an expiry date of 2035, not including patent term adjustment or any potential PTE. </span></div><div style="line-height:10pt;position:var(--position);top:298pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">U.S. patent 10,464,903 and U.S. patent 10,745,357, which are directed to a synthesis process for </span></span></div><div style="line-height:10pt;position:var(--position);top:308pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">manufacturing obefazimod and derivatives thereof, a polymorphic form of the free base of obefazimod </span></div><div style="line-height:10pt;position:var(--position);top:318pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">and crystalline forms of various salts of obefazimod. These patents have an expiry date of 2037, not </span></div><div style="line-height:10pt;position:var(--position);top:328pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">including patent term adjustment or any potential PTE. A corresponding European patent has also been </span></div><div style="line-height:10pt;position:var(--position);top:338pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">granted. These patents are solely owned by us. </span></div><div style="line-height:1pt;position:var(--position);top:352.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="line-height:10pt;position:var(--position);top:353.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">Further indications are also protected by other patents: U.S. patent 9,145,367, which is directed to the </span></span></div><div style="line-height:10pt;position:var(--position);top:363.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">method of treating AIDS by obefazimod generically and specifically. This patent is also granted in </span></div><div style="line-height:10pt;position:var(--position);top:373.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">Europe and several other countries and has an expiry date of 2030. U.S. patent 9,108,919, which is </span></div><div style="line-height:10pt;position:var(--position);top:383.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">directed to the method of treating cancer by obefazimod generically and specifically. This patent is </span></div><div style="line-height:10pt;position:var(--position);top:393.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">also granted in Europe and several other countries and has an expiry date of 2030. Another patent </span></div><div style="line-height:10pt;position:var(--position);top:403.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">application published under US2019/17416679, directed to a method of treating cancer, has been filed </span></div><div style="line-height:10pt;position:var(--position);top:413.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">worldwide in 2019, with patents granted or patent applications pending in other countries. U.S. patent </span></div><div style="line-height:10pt;position:var(--position);top:423.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">10,806,729, which is directed to the method of treating HIV resistant patients by obefazimod </span></div><div style="line-height:10pt;position:var(--position);top:433.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">generically and specifically. This patent is also granted in some countries in Europe and has an expiry </span></div><div style="line-height:10pt;position:var(--position);top:443.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">date of 2036. </span></div><div style="line-height:10pt;position:var(--position);top:453.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">U.S. patent applications 17/416,856, now granted under U.S. 11,992,499, continuation application </span></span></div><div style="line-height:10pt;position:var(--position);top:464.7pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);white-space:pre">18/635,542 and divisional application 18/635,693</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:325.79pt;position:var(--position);text-decoration:none;white-space:pre">, which are respectively directed to the method of </span></div><div style="line-height:10pt;position:var(--position);top:475.9pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">treating other inflammatory diseases by obefazimod specifically and generically or its N-glucuronide </span></div><div style="line-height:10pt;position:var(--position);top:487.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">metabolite have been filed in 2019, as well as counterpart applications and granted patents in other </span></div><div style="line-height:10pt;position:var(--position);top:498.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">countries. </span></div><div style="line-height:10pt;position:var(--position);top:515.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">U.S. patent application 17/796,834, which is directed to the amorphous solid dispersion (ASD) of </span></span></div><div style="line-height:10pt;position:var(--position);top:525.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">obefazimod, its method of preparation, pharmaceutical composition and method of treating </span></div><div style="line-height:10pt;position:var(--position);top:535.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">inflammatory disease, cancer and viral diseases therewith has been filed in 2021, as well as counterpart </span></div><div style="line-height:10pt;position:var(--position);top:545.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">applications in other countries. </span></div><div style="line-height:10pt;position:var(--position);top:561.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">U.S. patent application 17/793,133, which is directed to co-crystals and salts of obefazimod, </span></span></div><div style="line-height:10pt;position:var(--position);top:571.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">pharmaceutical composition and method of treating inflammatory disease, cancer and viral diseases </span></div><div style="line-height:10pt;position:var(--position);top:581.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">therewith has been filed in 2021, as well as counterpart applications in other countries. </span></div><div style="line-height:10pt;position:var(--position);top:597.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">U.S. patent application 18/284,253, which is directed to a synthesis process for manufacturing </span></span></div><div style="line-height:10pt;position:var(--position);top:607.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">obefazimod and derivatives thereof and was filed in 2022, as well as counterpart applications in other </span></div><div style="line-height:10pt;position:var(--position);top:617.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">countries. </span></div><div style="line-height:10pt;position:var(--position);top:633.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">U.S. patent applications 18/729,018 and continuation in part application 18/893,339, which are </span></span></div><div style="line-height:10pt;position:var(--position);top:643.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">directed to combinations products with obefazimod and etrasimod or ozanimod were respectively filed </span></div><div style="line-height:10pt;position:var(--position);top:653.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">in 2023 and 2024, as well as counterpart applications in other countries.</span></div><div style="line-height:11pt;position:var(--position);top:669.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:11pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:126pt;position:var(--position);text-decoration:none;white-space:pre">U.S. patent application 18/832,670, which is directed to combinations products with obefazimod and </span></div><div style="line-height:10pt;position:var(--position);top:680.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:126pt;position:var(--position);text-decoration:none;white-space:pre">Rinvoq, filed in 2023, as well as counterpart applications in other countries.</span></div><div style="line-height:11pt;position:var(--position);top:697.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:11pt;font-style:normal;font-weight:normal;left:108.69999999999999pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">U.S. patent application 19/149,308, which is directed to obefazimod for treatment of ulcerative colitis, </span></div><div style="line-height:10pt;position:var(--position);top:708.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">was filed in 2024, as well as counterpart applications in other countries.</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">84</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Trademarks and Domain Names </span></div><div style="line-height:10pt;position:var(--position);top:88pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We own a number of registered and pending trademarks and registered domain names. The URL for our </span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">website, as well as a number of domain names including the wording &#8220;abivax&#8221; or &#8220;obefazimod.&#8221; &#8220;Abivax&#8221; is a </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">registered trademark of our company in Australia, Brazil, Canada, Cuba, the EU, France, India, South Africa, the </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">United Kingdom and the United States. The &#8220;Abivax&#8221; trademark is pending in Canada, China, India, Japan, Mexico, </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">South Africa, South Korea and the United States. </span></div><div style="position:absolute;top:166pt" id="i7a006daedb3d4216a4128b76247285d7_49"></div><div style="line-height:10pt;position:var(--position);top:166pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">C.<span id="ie78b6cdebd624d27bae02ea0ce991767"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Organizational Structure</span></div><div style="line-height:10pt;position:var(--position);top:196pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">Abivax SA </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:143.7pt;position:var(--position);text-decoration:none;white-space:pre">is</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:150.36pt;position:var(--position);white-space:pre"> the parent company of Abivax, LLC, a wholly-owned subsidiary organized in Delaware, United </span></div><div style="line-height:10pt;position:var(--position);top:206pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">States. </span></div><div style="position:var(--position);top:216pt;width:612pt"><div style="left:79.92pt;position:var(--position)"><div style="position:var(--position)"><img src="abvx-20251231_g13.jpg" alt="Organization Structure.jpg" style="height:225.83pt;width:452.16pt" id="i-13"/></div></div></div><div style="position:absolute;top:458.83pt" id="i7a006daedb3d4216a4128b76247285d7_52"></div><div style="line-height:10pt;position:var(--position);top:458.83pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">D.<span id="i38d845d104784587821625b299708d5b"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Property, Plants and Equipment.</span></div><div style="line-height:10pt;position:var(--position);top:476.83pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our corporate head<span id="i371cc70ebd344063a6b126fde7bb4cd3"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:173.63pt;position:var(--position);text-decoration:none;white-space:pre">quarters is located in Paris, France, where we occupy approximately 850</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:463.85pt;position:var(--position);white-space:pre"> square meters</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:521.55pt;position:var(--position);text-decoration:none;white-space:pre"> of </span></div><div style="line-height:10pt;position:var(--position);top:486.83pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">office space that we sublease and we lease 150 square meters of office space in Jacou, Region of Occitanie in the </span></div><div style="line-height:10pt;position:var(--position);top:496.83pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">south of France. We lease an additional 279 square meters of office space in Boston, Massachusetts. We believe our </span></div><div style="line-height:10pt;position:var(--position);top:506.83pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">existing facilities meet our current needs.</span></div><div style="position:absolute;top:528.83pt" id="i7a006daedb3d4216a4128b76247285d7_55"></div><div style="line-height:10pt;position:var(--position);top:540.83pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">Item 4A. <span style="display:inline-block;height:6.77pt;width:32.3pt"></span></span><span style="left:144pt;position:var(--position)">Unresolved Staff Comments.</span><span id="ie82dae1123824ba79a19f35aa9a77092"></span></span></div><div style="line-height:10pt;position:var(--position);top:564.83pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.5pt;position:var(--position);white-space:pre">Not applicable.</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">85</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_58"></div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">Item 5.<span style="display:inline-block;height:6.77pt;width:6.02pt"></span></span><span style="left:108pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:36pt"></span></span><span style="left:144pt;position:var(--position)">Operating and Financial Review and Prospects</span><span id="i154ad1556b5a479b8ca342cd539f13f3"></span></span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre;width:443.48pt">You should read the following discussion of our financial condition and results of operations in conjunction</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:539.98pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:106pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre;width:467.97pt">with our financial statements and the related notes thereto included elsewhere in this Annual Report on Form 20-F.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:539.97pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:116pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre;width:467.99pt">In addition to historical information, the following discussion and analysis contains forward-looking statements that</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:539.99pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:126pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre;width:467.83pt">reflect our plans, estimates and beliefs. Our actual results and the timing of events could differ materially from those</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:539.8299999999999pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:136pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre;width:467.95pt">anticipated in the forward-looking statements. Factors that could cause or contribute to these differences include</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:539.95pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:146pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre;width:467.92pt">those discussed below and elsewhere in this annual report, particularly in the sections titled &#8220;Item 3.D&#8212;Risk</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:539.9200000000001pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:156pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre;width:285.62pt">Factors&#8221; and &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:357.62pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);top:184pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Overview </span></div><div style="line-height:10pt;position:var(--position);top:200pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We are a clinical-stage biotechnology company focused on developing therapeutics that harness the body&#8217;s </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:210pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.</span></div><div style="line-height:10pt;position:var(--position);top:226pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We focus on indications where existing treatments have left patients with significant unmet needs, and where </span></div><div style="line-height:10pt;position:var(--position);top:236pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">we believe our investigational agents have the potential to be meaningfully differentiated from currently available </span></div><div style="line-height:10pt;position:var(--position);top:246pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">therapies.&#160; Our initial focus is on inflammatory bowel diseases (&#8220;IBD&#8221;), chronic conditions involving inflammation </span></div><div style="line-height:10pt;position:var(--position);top:256pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of the gastrointestinal tract, of which the two most common forms are ulcerative colitis ("UC") and Crohn's disease </span></div><div style="line-height:10pt;position:var(--position);top:266pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">("CD"). </span></div><div style="line-height:10pt;position:var(--position);top:282pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We believe our lead drug candidate, obefazimod, is differentiated from competing approaches for the </span></div><div style="line-height:10pt;position:var(--position);top:292pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">treatment of IBD via its novel mechanism of action. Obefazimod was demonstrated to specifically enhance the </span></div><div style="line-height:10pt;position:var(--position);top:302pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">expression of a single micro-RNA, miR-124, which plays a critical role in the regulation of the inflammatory </span></div><div style="line-height:10pt;position:var(--position);top:312pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">response. In the context of inflammation, miR-124 is a natural regulator of the inflammatory response, controlling </span></div><div style="line-height:10pt;position:var(--position);top:322pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">progression of inflammation and restoring homeostasis of the immune system, without causing broader </span></div><div style="line-height:10pt;position:var(--position);top:332pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">immunosuppression. In contrast to currently available advanced therapies, prescribed post-conventional therapies, </span></div><div style="line-height:10pt;position:var(--position);top:342pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">some of which target only a single cytokine or pathway, miR-124 modulates the expression of several key cytokines </span></div><div style="line-height:10pt;position:var(--position);top:352pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and pathways. Modulating multiple inflammatory pathways simultaneously may lead to more durability of efficacy </span></div><div style="line-height:10pt;position:var(--position);top:362pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">results over the long-term, which is critical in lifelong conditions such as IBD, potentially differentiating </span></div><div style="line-height:10pt;position:var(--position);top:372pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">obefazimod from currently available IBD treatments. </span></div><div style="line-height:10pt;position:var(--position);top:388pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Obefazimod is currently in Phase 3 clinical development for the treatment of moderately to severely active </span></div><div style="line-height:10pt;position:var(--position);top:398pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">UC. We are continuing to develop obefazimod for the treatment of CD and are evaluating additional potential </span></div><div style="line-height:10pt;position:var(--position);top:408pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">inflammatory indications to pursue, subject to the availability of necessary resources and funding. In parallel, we are </span></div><div style="line-height:10pt;position:var(--position);top:418pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">in the process of generating follow-on compounds based on our miR-124 platform.</span></div><div style="line-height:10pt;position:var(--position);top:434pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We were incorporated as a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:205.51pt;position:var(--position);text-decoration:none;white-space:pre">soci&#233;t&#233; anonyme </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:274.31pt;position:var(--position);text-decoration:none;white-space:pre">on December 4, 2013 and, in 2014, we acquired Splicos, </span></div><div style="line-height:10pt;position:var(--position);top:444pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Wittycell and Zophis by means of a universal transfer of assets and liabilities (</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:385.77pt;position:var(--position);text-decoration:none;white-space:pre">Transmission Universelle du </span></div><div style="line-height:10pt;position:var(--position);top:454pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Patrimoine </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:119.45pt;position:var(--position);text-decoration:none;white-space:pre">(&#8220;TUP&#8221;)). We have been listed on Euronext Paris since June&#160;26, 2015, and on the Nasdaq Global Market </span></div><div style="line-height:10pt;position:var(--position);top:464pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">since October 24, 2023.</span></div><div style="line-height:10pt;position:var(--position);top:480pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.75pt;position:var(--position);text-decoration:none;white-space:pre">On March 20, 2023, our United States-based subsidiary Abivax LLC (the &#8220;Subsidiary&#8221;) was formed as a </span></div><div style="line-height:10pt;position:var(--position);top:490pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">limited liability company under the laws of the State of Delaware. The Subsidiary hosts our operations in the United </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:500pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">States.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:98.35pt;position:var(--position);text-decoration:none;white-space:pre"> We have prepared audited consolidated statements of financial position of the Company and the Subsidiary </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:510pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">as of December 31, 2025, 2024 and 2023, and the related consolidated </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:355.9pt;position:var(--position);text-decoration:none;white-space:pre">statements of income (loss),</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:467.99pt;position:var(--position);text-decoration:none;white-space:pre"> comprehensive </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:520pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">income (loss), changes in shareholders&#8217; equity and cash flows for each of the three years in the period ended </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:530pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">December 31, 2025, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). </span></div><div style="line-height:10pt;position:var(--position);top:540pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2025, the Subsidiary&#8217;s contribution to our consolidated results of operations was a net operating </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:550pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">loss of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:100.88pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(246.1) million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:166.39pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><div style="line-height:10pt;position:var(--position);top:566pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Since our inception</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:174.19pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:176.69pt;position:var(--position);text-decoration:none;white-space:pre">in 2013, we have devoted substantially all of our efforts to organizing and staffing our </span></div><div style="line-height:10pt;position:var(--position);top:576pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">company, business planning, raising capital, establishing our intellectual property portfolio, acquiring or discovering </span></div><div style="line-height:10pt;position:var(--position);top:586pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">drug candidates, research and development activities for obefazimod and other compounds, establishing </span></div><div style="line-height:10pt;position:var(--position);top:596pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">arrangements with third parties for the manufacture of our drug candidates and component materials, and providing </span></div><div style="line-height:10pt;position:var(--position);top:606pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">general and administrative support for these operations. We do not have any products approved for sale and have not </span></div><div style="line-height:10pt;position:var(--position);top:616pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">generated any revenue from product sales or otherwise. We do not expect to generate significant revenue from </span></div><div style="line-height:10pt;position:var(--position);top:626pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">product sales or royalties unless and until our drug candidates are approved for marketing and successfully </span></div><div style="line-height:10pt;position:var(--position);top:636pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">commercialized. </span></div><div style="line-height:10pt;position:var(--position);top:652pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We have incurred significant operating losses since inception, and we expect to continue to incur significant </span></div><div style="line-height:10pt;position:var(--position);top:662pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">expenses and operating losses for the foreseeable future. Our ability to generate product revenue sufficient to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:672pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">achieve profitability will depend heavily o</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:241.49pt;position:var(--position);text-decoration:none;white-space:pre">n the successful development and eventual commercialization of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:682pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">obefazimod and any future drug candidates. For the years ended </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:330.89pt;position:var(--position);text-decoration:none;white-space:pre">December&#160;31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:409.43pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:414.43pt;position:var(--position);text-decoration:none;white-space:pre">2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:434.43pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:453.86pt;position:var(--position);text-decoration:none;white-space:pre">2023</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:473.86pt;position:var(--position);text-decoration:none;white-space:pre"> we reported net </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:692pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">losses of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:109.2pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;336.1</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:136.7pt;position:var(--position);text-decoration:none;white-space:pre"> million, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:173.05pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;176.2&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:231.9pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:251.33pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;147.7 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:310.18pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:315.18pt;position:var(--position);text-decoration:none;white-space:pre">respectively. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:368.43pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:471.41pt;position:var(--position);text-decoration:none;white-space:pre">, we carried </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:702pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">forward accumulated tax losses of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:211pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;912.9 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:269.85pt;position:var(--position);text-decoration:none;white-space:pre">. We expect to continue to incur net operating losses for at least the </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">86</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">next several years, and we do not anticipate achieving profitability in the future unless we obtain regulatory </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">approvals necessary to commercialize obefazimod and any additional drug candidates that we may pursue in the </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">future. We expect that our research and development expenses, general and administrative expenses, and capital </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">expenditures will increase substantially in connection with our ongoing activities, particularly if and as we: </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position);width:3.5pt">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position);width:317.67pt">continue to advance our existing drug candidates through clinical development;</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:444.71999999999997pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:134pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position);width:3.5pt">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position);width:412.91pt">timely and successfully complete clinical development of obefazimod, our clinical-stage drug</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.96pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:144pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre;width:41.03pt">candidate;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:168.07999999999998pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:160pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position);width:3.5pt">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position);width:412.85pt">seek and maintain regulatory and marketing approvals for obefazimod and any future drug candidates</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.9pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:170pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre;width:200.26pt">for which we successfully complete clinical trials;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:327.31pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:186pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position);width:3.5pt">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position);width:291.54pt">continue the preclinical and clinical development of our drug candidates;</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:418.59pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:202pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position);width:3.5pt">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position);width:278.83pt">expand the scope of our current clinical trials for our drug candidates;</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:405.88pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:218pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position);width:3.5pt">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position);width:193.92pt">begin new clinical trials for our drug candidates;</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:320.97pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:234pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position);width:3.5pt">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position);width:380.03pt">develop, scale and validate our commercial manufacturing capabilities for our drug candidates;</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:507.08pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:250pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position);width:3.5pt">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position);width:412.9pt">establish a sales, marketing and distribution infrastructure to commercialize any drugs for which we</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.95pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:260pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre;width:412.95pt">may obtain regulatory and marketing approval for which we have not entered into a collaboration with</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:540pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:270pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre;width:52.43pt">a third-party;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:179.48pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:286pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position);width:3.5pt">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position);width:262.16pt">seek to discover, identify and validate additional drug candidates;</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:389.21pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:302pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position);width:3.5pt">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position);width:242.74pt">acquire or in-license other drug candidates and technologies;</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:369.78999999999996pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:318pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position);width:3.5pt">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position);width:354.27pt">make milestone, royalty or other payments under in-license or collaboration agreements;</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:481.32pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="line-height:1pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:332.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre;width:0.25pt">&#160;</span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:333.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position);width:3.5pt">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position);width:320.15pt">obtain, maintain, protect, enforce and expand our intellectual property portfolio;</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:447.2pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:349.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position);width:3.5pt">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position);width:412.95pt">manufacture, or have manufactured, non-clinical, clinical and potentially commercial supplies of</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:540pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:359.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre;width:175.63pt">obefazimod and any future drug candidates;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:302.68pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:375.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position);width:3.5pt">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position);width:412.9pt">attract new and retain existing clinical, scientific, operational, financial and management personnel;</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.95pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:385.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre;width:14.43pt">and</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:141.48pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:401.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position);width:3.5pt">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position);width:412.82pt">incur additional legal, accounting, and other costs associated with operating as a dual-listed French and</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.87pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:411.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre;width:86.88pt">U.S. public company.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:213.93pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);top:427.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our net losses may fluctuate significantly from period to period, depending on the timing of expenditures </span></div><div style="line-height:10pt;position:var(--position);top:437.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">related to our research and development activities. </span></div><div style="line-height:10pt;position:var(--position);top:453.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We will not generate revenue from product sales unless and until we successfully complete clinical </span></div><div style="line-height:10pt;position:var(--position);top:463.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">development and obtain regulatory approval for a drug candidate. In particular, following the issuance of royalty </span></div><div style="line-height:10pt;position:var(--position);top:473.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">certificates in September 2022 and other royalties that may become payable under our royalty agreements, the </span></div><div style="line-height:10pt;position:var(--position);top:483.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">payment of royalties in the event of commercialization of obefazimod would result in a decrease in cash flows </span></div><div style="line-height:10pt;position:var(--position);top:493.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">generated by sales of the product, which could have an unfavorable impact on our financial position, particularly at </span></div><div style="line-height:10pt;position:var(--position);top:503.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the beginning of the commercialization phase. In addition, if we obtain regulatory approval for a drug candidate and </span></div><div style="line-height:10pt;position:var(--position);top:513.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">do not enter into a third-party commercialization partnership, we expect to incur significant expenses related to </span></div><div style="line-height:10pt;position:var(--position);top:523.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">developing our commercialization capability to support product sales, marketing, manufacturing and distribution </span></div><div style="line-height:10pt;position:var(--position);top:533.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">activities. </span></div><div style="line-height:10pt;position:var(--position);top:549.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">As a result, we will need substantial additional funding to support our continuing operations and pursue our </span></div><div style="line-height:10pt;position:var(--position);top:559.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to </span></div><div style="line-height:10pt;position:var(--position);top:569.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">finance our operations through equity offerings, debt financings or other capital sources, which could include </span></div><div style="line-height:10pt;position:var(--position);top:579.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">collaborations, strategic alliances or additional licensing arrangements. We may be unable to raise additional funds </span></div><div style="line-height:10pt;position:var(--position);top:589.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">or enter into such arrangements when needed, on favorable terms, or at all. Our failure to raise capital or enter into </span></div><div style="line-height:10pt;position:var(--position);top:599.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">such agreements as, and when, needed, could have a material adverse effect on our business, results of operations </span></div><div style="line-height:10pt;position:var(--position);top:609.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and financial condition, including requiring us to have to delay, reduce or eliminate product development or future </span></div><div style="line-height:10pt;position:var(--position);top:619.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">commercialization efforts. The amount and timing of our future funding requirements will depend on many factors, </span></div><div style="line-height:10pt;position:var(--position);top:629.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">including the successful advancement of obefazimod or any future drug candidates. Our ability to raise additional </span></div><div style="line-height:10pt;position:var(--position);top:639.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">funds may also be adversely impacted by potential worsening global economic conditions and disruptions to and </span></div><div style="line-height:10pt;position:var(--position);top:649.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">volatility in the credit and financial markets in the United States and worldwide, such as those resulting from the </span></div><div style="line-height:10pt;position:var(--position);top:659.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ongoing war in Ukraine. </span></div><div style="line-height:10pt;position:var(--position);top:675.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Due to the numerous risks and uncertainties associated with development of treatment of chronic </span></div><div style="line-height:10pt;position:var(--position);top:685.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">inflammatory diseases, we are unable to predict the timing or amount of increased expenses or when or if we will be </span></div><div style="line-height:10pt;position:var(--position);top:695.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">87</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">unable to continue our operations at planned levels and be forced to reduce or terminate our operations. </span></div><div style="line-height:10pt;position:var(--position);top:110pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Principal Factors Affecting Our Results of Operations </span></div><div style="line-height:10pt;position:var(--position);top:126pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The following factors have affected, and we expect will continue to affect, our results of operations. </span></div><div style="line-height:10pt;position:var(--position);top:154pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Research and Development Activities </span></div><div style="line-height:10pt;position:var(--position);top:170pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Research and development activities are central to our business. Since our inception, most of our resources </span></div><div style="line-height:10pt;position:var(--position);top:180pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">have been allocated to research and development and it accounts for the majority of our operating expenses. For the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:190pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:196.59pt;position:var(--position);text-decoration:none;white-space:pre">, research and development expenses accounted for </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:404.11pt;position:var(--position);text-decoration:none;white-space:pre">71%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:422.44pt;position:var(--position);text-decoration:none;white-space:pre"> of our total operating </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:200pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">expenses, as compared to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:176.05pt;position:var(--position);text-decoration:none;white-space:pre">79%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:194.38pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:213.81pt;position:var(--position);text-decoration:none;white-space:pre">78%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:232.14pt;position:var(--position);text-decoration:none;white-space:pre"> for the years ended </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:313.44pt;position:var(--position);text-decoration:none;white-space:pre">December 31, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:371.98pt;position:var(--position);text-decoration:none;white-space:pre">2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:391.98pt;position:var(--position);text-decoration:none;white-space:pre"> and</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:408.91pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:411.41pt;position:var(--position);text-decoration:none;white-space:pre">2023</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:431.41pt;position:var(--position);text-decoration:none;white-space:pre"> respectively. Drug </span></div><div style="line-height:10pt;position:var(--position);top:210pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">candidates in later stages of clinical development generally have higher development costs than those in earlier </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:220pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:499.98pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:230pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Accordingly, we expect that our research and development expenses to remain in line with current spending in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:240pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">foreseeable future as we seek to advance the development of our drug candidates. The successful development of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:250pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">our drug candidates remains highly uncertain. </span></div><div style="line-height:10pt;position:var(--position);top:266pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">At this time, we cannot accurately determine or estimate the nature, timing and costs of the research and </span></div><div style="line-height:10pt;position:var(--position);top:276pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">development activities that will be necessary to complete the remainder of the development of obefazimod, and we </span></div><div style="line-height:10pt;position:var(--position);top:286pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">may never succeed in obtaining regulatory approval for obefazimod or any future drug candidates we may develop. </span></div><div style="line-height:10pt;position:var(--position);top:296pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The duration, costs and timing of clinical trials and the development of our drug candidates will depend on </span></div><div style="line-height:10pt;position:var(--position);top:306pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">numerous risks and uncertainties associated with clinical development, including risks and uncertainties related to: </span></div><div style="line-height:10pt;position:var(--position);top:322pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the scope, progress, outcome and expenses of our clinical trials and other research and development </span></span></div><div style="line-height:10pt;position:var(--position);top:332pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">activities; </span></div><div style="line-height:10pt;position:var(--position);top:348pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the length of time required to enroll suitable patients and successful patient enrollment in, and the </span></span></div><div style="line-height:10pt;position:var(--position);top:358pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">initiation and completion of, clinical trials; </span></div><div style="line-height:10pt;position:var(--position);top:374pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the results of our clinical trials; </span></span></div><div style="line-height:10pt;position:var(--position);top:390pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the timing, receipt and terms of any marketing approvals from applicable regulatory authorities; </span></span></div><div style="line-height:10pt;position:var(--position);top:406pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the establishment of commercial manufacturing capabilities or making arrangements with third-party </span></span></div><div style="line-height:10pt;position:var(--position);top:416pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">manufacturers; </span></div><div style="line-height:10pt;position:var(--position);top:432pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the expense of filing, prosecuting, maintaining, defending and enforcing patent claims and other </span></span></div><div style="line-height:10pt;position:var(--position);top:442pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">intellectual property rights; </span></div><div style="line-height:10pt;position:var(--position);top:458pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">changing government regulation; </span></span></div><div style="line-height:10pt;position:var(--position);top:474pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">launching commercial sales of our drug candidates, if and when approved, whether alone or in </span></span></div><div style="line-height:10pt;position:var(--position);top:484pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">collaboration with others; </span></div><div style="line-height:10pt;position:var(--position);top:500pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">maintaining a continued acceptable safety profile of the drug candidates following regulatory approval; </span></span></div><div style="line-height:10pt;position:var(--position);top:516pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the ability to market, commercialize and achieve market acceptance for obefazimod or any other drug </span></span></div><div style="line-height:10pt;position:var(--position);top:526pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">candidate that we may develop in the future; and </span></div><div style="line-height:10pt;position:var(--position);top:542pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">significant competition and rapidly changing technologies within the biopharmaceutical industry. </span></span></div><div style="line-height:10pt;position:var(--position);top:558pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">A change in the outcome of any of these variables with respect to the development of any of our drug </span></div><div style="line-height:10pt;position:var(--position);top:568pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">candidates could significantly change the costs and timing associated with the development of that drug candidate. </span></div><div style="line-height:10pt;position:var(--position);top:578pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The actual probability of success for our drug candidates will be affected by a variety of factors, including the safety </span></div><div style="line-height:10pt;position:var(--position);top:588pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and efficacy of our drug candidates, investment in our clinical programs, manufacturing capability and competition </span></div><div style="line-height:10pt;position:var(--position);top:598pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">with other products and drug candidates. As a result of these variables, we are unable to determine the duration and </span></div><div style="line-height:10pt;position:var(--position);top:608pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">completion costs of our research and development projects or when and to what extent we may generate revenue </span></div><div style="line-height:10pt;position:var(--position);top:618pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">from the commercialization and sale of our drug candidates. </span></div><div style="line-height:10pt;position:var(--position);top:646pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Marketing Approval and Market Acceptance of our Drug Candidates </span></div><div style="line-height:10pt;position:var(--position);top:662pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We may never succeed in achieving marketing approval for any of our drug candidates. We may obtain </span></div><div style="line-height:10pt;position:var(--position);top:672pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">unexpected and/or negative results from our clinical trials. We may elect to discontinue, delay or modify the </span></div><div style="line-height:10pt;position:var(--position);top:682pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">development plan and clinical trials of some drug candidates or focus on others. A change in the outcome of any of </span></div><div style="line-height:10pt;position:var(--position);top:692pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">these factors with respect to the development of drug candidates that we are developing could result in a significant </span></div><div style="line-height:10pt;position:var(--position);top:702pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">change in the costs and timing associated with the development of such drug candidates. For example, if the EMA or </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">88</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the FDA or other regulatory authority were to require us to conduct non-clinical studies and clinical trials beyond </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">those that we currently anticipate will be required for the completion of clinical development, or if we experience </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">significant delays in enrollment in any clinical trials, we could be required to spend significant additional financial </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">resources and time on the completion of clinical development of our drug candidates. </span></div><div style="line-height:10pt;position:var(--position);top:130pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Equity and Debt Financing </span></div><div style="line-height:10pt;position:var(--position);top:146pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">At this stage, we have not generated any revenue from sales of products or otherwise, and we do not expect to </span></div><div style="line-height:10pt;position:var(--position);top:156pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">do so unless and until we successfully complete development of, obtain marketing approval for, and successfully </span></div><div style="line-height:10pt;position:var(--position);top:166pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">commercialize, one or more of our drug candidates. Until such time that we can generate substantial revenue from </span></div><div style="line-height:10pt;position:var(--position);top:176pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">sales of products, if ever, we expect to finance our operating activities through a combination of equity offerings, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:186pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">debt financings and</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:150.25pt;position:var(--position);text-decoration:none;white-space:pre"> government or other third-party fundin</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:308.16999999999996pt;position:var(--position);text-decoration:none;white-space:pre">g. However, we may be unable to raise additional funds </span></div><div style="line-height:10pt;position:var(--position);top:196pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">or enter into such arrangements when needed on favorable terms, or at all, which would have a negative impact on </span></div><div style="line-height:10pt;position:var(--position);top:206pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">our financial condition and could force us to delay, limit, reduce or terminate our development programs or </span></div><div style="line-height:10pt;position:var(--position);top:216pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">commercialization efforts or grant to others the rights to develop or market drug candidates that we would otherwise </span></div><div style="line-height:10pt;position:var(--position);top:226pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">prefer to develop and market ourselves. Failure to receive additional funding could cause us to cease operations, in </span></div><div style="line-height:10pt;position:var(--position);top:236pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">part or in full. </span></div><div style="line-height:10pt;position:var(--position);top:264pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Acquisition of Prosynergia</span></div><div style="line-height:10pt;position:var(--position);top:280pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">On April 1, 2022, we acquired 100% of the share capital of Prosynergia with the aim of strengthening our </span></div><div style="line-height:10pt;position:var(--position);top:290pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">research and development portfolio, for an amount of &#8364;3.25&#160;million. On December 12, 2022, we completed the </span></div><div style="line-height:10pt;position:var(--position);top:300pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">merger with Prosynergia through a TUP and all of Prosynergia&#8217;s assets and liabilities were transferred to us. </span></div><div style="line-height:10pt;position:var(--position);top:310pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Following the merger, Prosynergia was dissolved. Accordingly, as Prosynergia was dissolved in December 2022, we </span></div><div style="line-height:10pt;position:var(--position);top:320pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">did not prepare consolidated financial statements as of December&#160;31, 2022. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:341.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Impact of the Russia-Ukraine </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:192.44pt;position:var(--position);text-decoration:none;white-space:pre">War </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:212.16pt;position:var(--position);text-decoration:none;white-space:pre">on our Business </span></div><div style="line-height:10pt;position:var(--position);top:359.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The Russia-Ukraine war continues. The conflict has already had major implications for the global economy </span></div><div style="line-height:10pt;position:var(--position);top:369.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and the rate of inflation, particularly in relation to the supply of energy, raw materials and food products. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:493.46pt;position:var(--position);white-space:pre">It has also </span></div><div style="line-height:10pt;position:var(--position);top:379.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">caused intense </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:132.47pt;position:var(--position);text-decoration:none;white-space:pre">volatility</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:168.51999999999998pt;position:var(--position);white-space:pre"> on the financial markets. </span></div><div style="line-height:10pt;position:var(--position);top:395.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">Given these developments, we have decided not to include Russia and Belarus in our global Phase 3 clinical </span></div><div style="line-height:10pt;position:var(--position);top:405.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">trials for obefazimod in UC. However, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:229.06pt;position:var(--position);text-decoration:none;white-space:pre">the global scale of this conflict cannot be predicted at this stage. We, </span></div><div style="line-height:10pt;position:var(--position);top:415.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">therefore, cannot rule out an adverse impact of this conflict on our business, including in terms of access to raw </span></div><div style="line-height:10pt;position:var(--position);top:425.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">materials, logistics, the performance of clinical trials and in relation to any future financing we may seek. </span></div><div style="line-height:11pt;position:var(--position);top:441.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.53pt;position:var(--position);white-space:pre">long-term safety and efficacy extension of the</span><span style="color:#ff0000;font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:298.18pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:300.65999999999997pt;position:var(--position);text-decoration:none;white-space:pre">Phase 2b maintenance trial of obefazimod in moderately to </span></div><div style="line-height:10pt;position:var(--position);top:452.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">severely active UC is our only clinical trial </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:246.19pt;position:var(--position);white-space:pre">with patients currently enrolled </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:373.8pt;position:var(--position);text-decoration:none;white-space:pre">in Ukraine. The Phase 2b 12-month </span></div><div style="line-height:10pt;position:var(--position);top:462.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">assessment was carried out in all the Ukrainian patients before the war broke out and these patients are therefore </span></div><div style="line-height:10pt;position:var(--position);top:472.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">included in the one-year maintenance results that were reported on April&#160;6, 2022. Ukrainian patients who completed </span></div><div style="line-height:10pt;position:var(--position);top:482.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the two-year Phase 2b maintenance trial have been transitioned to the long-term safety and efficacy trial that is still </span></div><div style="line-height:10pt;position:var(--position);top:492.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">on-going. None of these sites are located i</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:240.14pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">n the Crimea Region of Ukraine, the so-called Donetsk People&#8217;s Republic, </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:502.2pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">or the so-called Luhansk People&#8217;s Republic. </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:250.97pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">We have a few sites active in the western part of Ukraine in the </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:512.2pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">ABTECT Phase 3 clinical trials. </span></span></div><div style="line-height:10pt;position:var(--position);top:528.2pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">Together with our CRO, we are making considerable efforts to ensure the follow-up of patients who are </span></span></div><div style="line-height:10pt;position:var(--position);top:538.2pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">unable to come to </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:145.8pt;position:var(--position);text-decoration:none;white-space:pre">the</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> study centers. Monitoring takes place through a remote monitoring system that was </span></span></div><div style="line-height:10pt;position:var(--position);top:548.2pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">established and used successfully during the COVID-19 pandemic. </span></span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">89</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_61"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">A.<span id="id3f9083e20444d49871219acf93a6b16"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Operating Results</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:90pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Comparison of Years Ended December 31, 2023, 2024 an</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:314.65pt;position:var(--position);text-decoration:none;white-space:pre">d 2025 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:106pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">The following </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.89pt;position:var(--position);text-decoration:none;white-space:pre">table</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:175.29000000000002pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> sets forth our results of operations for the years ended </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:395.36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">December&#160;31, 2023</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:473.9pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">, </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:478.9pt;position:var(--position);text-decoration:none;white-space:pre">2024</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:498.9pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:501.4pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">and</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:515.8299999999999pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:116pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">2025</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:92pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">. </span></span></div><div style="position:var(--position);top:138pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:466.5pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:125.25pt"/><td style="padding:0;width:68.25pt"/><td style="padding:0;width:68.25pt"/><td style="padding:0;width:68.25pt"/><td style="padding:0;width:68.25pt"/><td style="padding:0;width:68.25pt"/></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:13.12pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(In thousands of euros)</span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:81.44999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:82.03pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:82.32pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:82.47pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:82.50999999999999pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:82.52pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:125.25pt;position:var(--position);width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.12pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Year ended </span></div><div style="line-height:8pt;position:var(--position);top:13.12pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">December 31, </span></div><div style="line-height:8pt;position:var(--position);top:23.12pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:193.5pt;position:var(--position);width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.12pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Year ended </span></div><div style="line-height:8pt;position:var(--position);top:13.12pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">December 31, </span></div><div style="line-height:8pt;position:var(--position);top:23.12pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:261.75pt;position:var(--position);width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.12pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Year ended </span></div><div style="line-height:8pt;position:var(--position);top:13.12pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">December 31, </span></div><div style="line-height:8pt;position:var(--position);top:23.12pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:330pt;position:var(--position);width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:8.12pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:bold;left:12.79pt;position:var(--position);text-decoration:none;white-space:pre">2024 vs 2023 </span></div><div style="line-height:8pt;position:var(--position);top:18.12pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:bold;left:21.24pt;position:var(--position);text-decoration:none;white-space:pre">Change</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:398.25pt;position:var(--position);width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:8.12pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:bold;left:12.79pt;position:var(--position);text-decoration:none;white-space:pre">2025 vs 2024 </span></div><div style="line-height:8pt;position:var(--position);top:18.12pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:bold;left:21.24pt;position:var(--position);text-decoration:none;white-space:pre">Change</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:32.25pt;width:125.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other operating income</span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:98.64999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:100.96pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:102.11999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:102.19999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:102.24pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:102.25pt;position:var(--position);text-decoration:none;white-space:pre"> . . . .</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:125.25pt;position:var(--position);top:32.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:39.04pt"></span></span><span style="left:41.67pt;position:var(--position)">4,621<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:193.5pt;position:var(--position);top:32.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:34.04pt"></span></span><span style="left:36.67pt;position:var(--position)">12,449<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:261.75pt;position:var(--position);top:32.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:39.04pt"></span></span><span style="left:41.67pt;position:var(--position)">4,570<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330pt;position:var(--position);top:32.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:40.84pt;position:var(--position)"></span><span style="left:40.84pt;position:var(--position)">169<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span><span style="left:59.17pt;position:var(--position)">%</span></span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:398.25pt;position:var(--position);top:32.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:42.51pt;position:var(--position)"></span><span style="left:42.51pt;position:var(--position)">(63)</span><span style="left:59.17pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:46.5pt;width:125.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total operating income</span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:101.99pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:102.28pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:102.42999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:102.50999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:102.55pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:102.57pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:102.58pt;position:var(--position);text-decoration:none;white-space:pre"> . . . .</span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:125.25pt;position:var(--position);top:46.5pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:39.04pt"></span></span><span style="left:41.67pt;position:var(--position)">4,621<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span></span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:193.5pt;position:var(--position);top:46.5pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:34.04pt"></span></span><span style="left:36.67pt;position:var(--position)">12,449<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span></span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:261.75pt;position:var(--position);top:46.5pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:39.04pt"></span></span><span style="left:41.67pt;position:var(--position)">4,570<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span></span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330pt;position:var(--position);top:46.5pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:40.84pt;position:var(--position)"></span><span style="left:40.84pt;position:var(--position)">169<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span><span style="left:59.17pt;position:var(--position)">%</span></span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:398.25pt;position:var(--position);top:46.5pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:42.51pt;position:var(--position)"></span><span style="left:42.51pt;position:var(--position)">(63)</span><span style="left:59.17pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:60.75pt;width:125.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Sales and marketing expenses</span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:122.22999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:122.52pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:122.56pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:122.58pt;position:var(--position);white-space:pre"> </span></div></div></div></td><td style="border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:125.25pt;position:var(--position);top:60.75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">(6,431)</span></span></div></div></div></td><td style="border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:193.5pt;position:var(--position);top:60.75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">(5,954)</span></span></div></div></div></td><td style="border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:261.75pt;position:var(--position);top:60.75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">(5,194)</span></span></div></div></div></td><td style="border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330pt;position:var(--position);top:60.75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:47.51pt;position:var(--position)"></span><span style="left:47.51pt;position:var(--position)">(7)</span><span style="left:59.17pt;position:var(--position)">%</span></span></div></div></div></td><td style="border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:398.25pt;position:var(--position);top:60.75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:42.51pt;position:var(--position)"></span><span style="left:42.51pt;position:var(--position)">(13)</span><span style="left:59.17pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:26.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:75pt;width:125.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.89pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Research and development </span></div><div style="line-height:10pt;position:var(--position);top:15.39pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">expenses</span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:38.13pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:40.440000000000005pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:41.6pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:42.18pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:42.190000000000005pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . . . . . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:125.25pt;position:var(--position);top:75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:25.71pt"></span></span><span style="left:28.34pt;position:var(--position)">(103,176)</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:193.5pt;position:var(--position);top:75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:25.71pt"></span></span><span style="left:28.34pt;position:var(--position)">(146,532)</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:261.75pt;position:var(--position);top:75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:25.71pt"></span></span><span style="left:28.34pt;position:var(--position)">(177,761)</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:330pt;position:var(--position);top:75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.14pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:45.84pt;position:var(--position)"></span><span style="left:45.84pt;position:var(--position)">42<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span><span style="left:59.17pt;position:var(--position)">%</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:398.25pt;position:var(--position);top:75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.14pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:45.84pt;position:var(--position)"></span><span style="left:45.84pt;position:var(--position)">21<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span><span style="left:59.17pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:26.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:101.25pt;width:125.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.89pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">General and administrative </span></div><div style="line-height:10pt;position:var(--position);top:15.39pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">expenses</span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:38.13pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:40.440000000000005pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:41.6pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:42.18pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:42.190000000000005pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . . . . . . . . .</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:125.25pt;position:var(--position);top:101.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:30.71pt"></span></span><span style="left:33.34pt;position:var(--position)">(22,390)</span></span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:193.5pt;position:var(--position);top:101.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:30.71pt"></span></span><span style="left:33.34pt;position:var(--position)">(32,946)</span></span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:261.75pt;position:var(--position);top:101.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:30.71pt"></span></span><span style="left:33.34pt;position:var(--position)">(67,670)</span></span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330pt;position:var(--position);top:101.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.14pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:45.84pt;position:var(--position)"></span><span style="left:45.84pt;position:var(--position)">47<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span><span style="left:59.17pt;position:var(--position)">%</span></span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:398.25pt;position:var(--position);top:101.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.14pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:40.84pt;position:var(--position)"></span><span style="left:40.84pt;position:var(--position)">105<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span><span style="left:59.17pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:127.5pt;width:125.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total Operating expenses</span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:111.42999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:112.00999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:112.3pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:112.44999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:112.49pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:112.50999999999999pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:112.52pt;position:var(--position);text-decoration:none;white-space:pre"> . .</span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:125.25pt;position:var(--position);top:127.5pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:25.71pt"></span></span><span style="left:28.34pt;position:var(--position)">(131,997)</span></span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:193.5pt;position:var(--position);top:127.5pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:25.71pt"></span></span><span style="left:28.34pt;position:var(--position)">(185,433)</span></span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:261.75pt;position:var(--position);top:127.5pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:25.71pt"></span></span><span style="left:28.34pt;position:var(--position)">(250,626)</span></span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330pt;position:var(--position);top:127.5pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:45.84pt;position:var(--position)"></span><span style="left:45.84pt;position:var(--position)">40<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span><span style="left:59.17pt;position:var(--position)">%</span></span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:398.25pt;position:var(--position);top:127.5pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:45.84pt;position:var(--position)"></span><span style="left:45.84pt;position:var(--position)">35<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span><span style="left:59.17pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:141.75pt;width:125.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Operating loss</span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:64.53pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:66.83999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:67.13pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:67.28pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:67.32pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:67.33pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . . . .</span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:125.25pt;position:var(--position);top:141.75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:25.71pt"></span></span><span style="left:28.34pt;position:var(--position)">(127,376)</span></span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:193.5pt;position:var(--position);top:141.75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:25.71pt"></span></span><span style="left:28.34pt;position:var(--position)">(172,984)</span></span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:261.75pt;position:var(--position);top:141.75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:25.71pt"></span></span><span style="left:28.34pt;position:var(--position)">(246,056)</span></span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330pt;position:var(--position);top:141.75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:45.84pt;position:var(--position)"></span><span style="left:45.84pt;position:var(--position)">36<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span><span style="left:59.17pt;position:var(--position)">%</span></span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:398.25pt;position:var(--position);top:141.75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:45.84pt;position:var(--position)"></span><span style="left:45.84pt;position:var(--position)">42<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span><span style="left:59.17pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:156pt;width:125.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial expenses</span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:79.47pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:81.78pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:82.07pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:82.22pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:82.3pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:82.32pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:82.33pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . .</span></div></div></div></td><td style="border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:125.25pt;position:var(--position);top:156pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:30.71pt"></span></span><span style="left:33.34pt;position:var(--position)">(27,875)</span></span></div></div></div></td><td style="border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:193.5pt;position:var(--position);top:156pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:30.71pt"></span></span><span style="left:33.34pt;position:var(--position)">(16,991)</span></span></div></div></div></td><td style="border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:261.75pt;position:var(--position);top:156pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:25.71pt"></span></span><span style="left:28.34pt;position:var(--position)">(112,307)</span></span></div></div></div></td><td style="border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330pt;position:var(--position);top:156pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:42.51pt;position:var(--position)"></span><span style="left:42.51pt;position:var(--position)">(39)</span><span style="left:59.17pt;position:var(--position)">%</span></span></div></div></div></td><td style="border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:398.25pt;position:var(--position);top:156pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:40.84pt;position:var(--position)"></span><span style="left:40.84pt;position:var(--position)">561<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span><span style="left:59.17pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:170.25pt;width:125.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial income</span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:72.82pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:75.13pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:76.28999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:76.86999999999999pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:77.16pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . .</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:125.25pt;position:var(--position);top:170.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:39.04pt"></span></span><span style="left:41.67pt;position:var(--position)">7,511<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:193.5pt;position:var(--position);top:170.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:34.04pt"></span></span><span style="left:36.67pt;position:var(--position)">13,732<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:261.75pt;position:var(--position);top:170.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:34.04pt"></span></span><span style="left:36.67pt;position:var(--position)">28,110<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330pt;position:var(--position);top:170.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:45.84pt;position:var(--position)"></span><span style="left:45.84pt;position:var(--position)">83<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span><span style="left:59.17pt;position:var(--position)">%</span></span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:398.25pt;position:var(--position);top:170.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:40.84pt;position:var(--position)"></span><span style="left:40.84pt;position:var(--position)">105<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span><span style="left:59.17pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:184.5pt;width:125.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial loss</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:60.64pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:61.800000000000004pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:62.38pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:62.42pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:62.440000000000005pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . . . . .</span></div></div></div></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:125.25pt;position:var(--position);top:184.5pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:30.71pt"></span></span><span style="left:33.34pt;position:var(--position)">(20,364)</span></span></div></div></div></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:193.5pt;position:var(--position);top:184.5pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">(3,258)</span></span></div></div></div></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:261.75pt;position:var(--position);top:184.5pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:30.71pt"></span></span><span style="left:33.34pt;position:var(--position)">(84,198)</span></span></div></div></div></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330pt;position:var(--position);top:184.5pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:42.51pt;position:var(--position)"></span><span style="left:42.51pt;position:var(--position)">(84)</span><span style="left:59.17pt;position:var(--position)">%</span></span></div></div></div></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:398.25pt;position:var(--position);top:184.5pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:35.84pt;position:var(--position)"></span><span style="left:35.84pt;position:var(--position)">2484<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span><span style="left:59.17pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:198.75pt;width:125.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Net loss before tax</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:81.17pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:82.33pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:82.47999999999999pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:82.49pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . .</span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:125.25pt;position:var(--position);top:198.75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:25.71pt"></span></span><span style="left:28.34pt;position:var(--position)">(147,740)</span></span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:193.5pt;position:var(--position);top:198.75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:25.71pt"></span></span><span style="left:28.34pt;position:var(--position)">(176,242)</span></span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:261.75pt;position:var(--position);top:198.75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:25.71pt"></span></span><span style="left:28.34pt;position:var(--position)">(330,254)</span></span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330pt;position:var(--position);top:198.75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:45.84pt;position:var(--position)"></span><span style="left:45.84pt;position:var(--position)">19<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span><span style="left:59.17pt;position:var(--position)">%</span></span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:398.25pt;position:var(--position);top:198.75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:45.84pt;position:var(--position)"></span><span style="left:45.84pt;position:var(--position)">87<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span><span style="left:59.17pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:213pt;width:125.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Income Tax</span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:49.53pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:51.84pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:52.13pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:52.28pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:52.32pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:52.330000000000005pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . . . . . . .</span></div></div></div></td><td style="border-bottom:1pt solid #000;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:125.25pt;position:var(--position);top:213pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:51.54pt"></span></span><span style="left:54.17pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="border-bottom:1pt solid #000;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:193.5pt;position:var(--position);top:213pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:51.54pt"></span></span><span style="left:54.17pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="border-bottom:1pt solid #000;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:261.75pt;position:var(--position);top:213pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">(5,848)</span></span></div></div></div></td><td style="border-bottom:1pt solid #000;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330pt;position:var(--position);top:213pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:46.95pt;position:var(--position)"></span><span style="left:46.95pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span><span style="left:59.17pt;position:var(--position)">%</span></span></div></div></div></td><td style="border-bottom:1pt solid #000;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:398.25pt;position:var(--position);top:213pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:46.95pt;position:var(--position)"></span><span style="left:46.95pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span><span style="left:59.17pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:227.25pt;width:125.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Net loss for the period</span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:96.99pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:97.28pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:97.42999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:97.50999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:97.55pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:97.57pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:97.58pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . .</span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:125.25pt;position:var(--position);top:227.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:25.71pt"></span></span><span style="left:28.34pt;position:var(--position)">(147,740)</span></span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:193.5pt;position:var(--position);top:227.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:25.71pt"></span></span><span style="left:28.34pt;position:var(--position)">(176,242)</span></span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:261.75pt;position:var(--position);top:227.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:25.71pt"></span></span><span style="left:28.34pt;position:var(--position)">(336,102)</span></span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330pt;position:var(--position);top:227.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:45.84pt;position:var(--position)"></span><span style="left:45.84pt;position:var(--position)">19<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span><span style="left:59.17pt;position:var(--position)">%</span></span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:398.25pt;position:var(--position);top:227.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:45.84pt;position:var(--position)"></span><span style="left:45.84pt;position:var(--position)">91<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span><span style="left:59.17pt;position:var(--position)">%</span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="line-height:10pt;position:var(--position);top:402.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Total Operating Income </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:431.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">For </span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.89pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">the</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:125.09pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);white-space:pre">, our total operating income was </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:383.42pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;4.6 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:432.27pt;position:var(--position);white-space:pre">, as compared to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:500.25pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.4 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:441.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:100.85pt;position:var(--position);white-space:pre"> for the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:132.21pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:256.8pt;position:var(--position);white-space:pre">, a decrease of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:316.43pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(7.9) million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:371.94pt;position:var(--position);white-space:pre">, or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:387.77pt;position:var(--position);text-decoration:none;white-space:pre">(63)%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:412.76pt;position:var(--position);white-space:pre">, as detailed below. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:457.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);text-decoration:none;white-space:pre">, our total operating income was </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:383.42pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.4 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:437.27pt;position:var(--position);text-decoration:none;white-space:pre">, as compared to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:505.25pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;4.6 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:467.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:100.85pt;position:var(--position);text-decoration:none;white-space:pre"> for </span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:117.50999999999999pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">the</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.71pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:132.21pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2023</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:256.8pt;position:var(--position);text-decoration:none;white-space:pre">, an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:319.77pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;7.8&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:368.62pt;position:var(--position);text-decoration:none;white-space:pre">, or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:384.45pt;position:var(--position);text-decoration:none;white-space:pre">169%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:407.78pt;position:var(--position);text-decoration:none;white-space:pre">, as detailed below. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:495.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre;width:69.39pt">Other Operating </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:141.39pt;position:var(--position);text-decoration:none;white-space:pre;width:29.41pt">Income</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:170.8pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:511.94pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">The following table sets forth our other operating income for the years ended </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:406.99pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">December&#160;31, 2023</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.53pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">, </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:490.53pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">2024</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:510.53pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> and </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:521.94pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">2025</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:92pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">.</span></span></div><div style="position:var(--position);top:537.94pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:468pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:133.5pt"/><td style="padding:0;width:75pt"/><td style="padding:0;width:75pt"/><td style="padding:0;width:75pt"/><td style="padding:0;width:54.75pt"/><td style="padding:0;width:54.75pt"/></tr><tr style="height:38.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:133.5pt"><div><div style="line-height:10pt;position:var(--position);top:15.23pt;width:133.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(In thousands of euros)</span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:101.22999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:103.53999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:104.69999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:105.28pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:105.42999999999999pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:133.5pt;position:var(--position);width:75pt"><div><div style="line-height:10pt;position:var(--position);top:2.73pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:12.94pt;position:var(--position);text-decoration:none;white-space:pre">Year ended </span></div><div style="line-height:10pt;position:var(--position);top:15.23pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:8.37pt;position:var(--position);text-decoration:none;white-space:pre">December 31, </span></div><div style="line-height:10pt;position:var(--position);top:27.73pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:27.5pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:208.5pt;position:var(--position);width:75pt"><div><div style="line-height:10pt;position:var(--position);top:2.73pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:12.94pt;position:var(--position);text-decoration:none;white-space:pre">Year ended </span></div><div style="line-height:10pt;position:var(--position);top:15.23pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:8.37pt;position:var(--position);text-decoration:none;white-space:pre">December 31, </span></div><div style="line-height:10pt;position:var(--position);top:27.73pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:27.5pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);width:75pt"><div><div style="line-height:10pt;position:var(--position);top:2.73pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:12.94pt;position:var(--position);text-decoration:none;white-space:pre">Year ended </span></div><div style="line-height:10pt;position:var(--position);top:15.23pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:8.37pt;position:var(--position);text-decoration:none;white-space:pre">December 31, </span></div><div style="line-height:10pt;position:var(--position);top:27.73pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:27.5pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:358.5pt;position:var(--position);width:54.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.73pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:11.68pt;position:var(--position);text-decoration:none;white-space:pre">2024 vs </span></div><div style="line-height:10pt;position:var(--position);top:15.23pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:17.37pt;position:var(--position);text-decoration:none;white-space:pre">2023 </span></div><div style="line-height:10pt;position:var(--position);top:27.73pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:10.99pt;position:var(--position);text-decoration:none;white-space:pre">Change</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:413.25pt;position:var(--position);width:54.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.73pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:11.68pt;position:var(--position);text-decoration:none;white-space:pre">2025 vs </span></div><div style="line-height:10pt;position:var(--position);top:15.23pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:17.37pt;position:var(--position);text-decoration:none;white-space:pre">2024 </span></div><div style="line-height:10pt;position:var(--position);top:27.73pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:10.99pt;position:var(--position);text-decoration:none;white-space:pre">Change</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:38.25pt;width:133.5pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:133.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">CIR (Research Tax Credits)</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:114.42pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:115.58pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:115.72999999999999pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:115.74pt;position:var(--position);text-decoration:none;white-space:pre"> . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:133.5pt;position:var(--position);top:38.25pt;width:75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:45.79pt"></span></span><span style="left:48.42pt;position:var(--position)">4,493<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:208.5pt;position:var(--position);top:38.25pt;width:75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:45.79pt"></span></span><span style="left:48.42pt;position:var(--position)">6,651<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:38.25pt;width:75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:45.79pt"></span></span><span style="left:48.42pt;position:var(--position)">3,061<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:358.5pt;position:var(--position);top:38.25pt;width:54.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:32.34pt;position:var(--position)"></span><span style="left:32.34pt;position:var(--position)">48<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span><span style="left:45.67pt;position:var(--position)">%</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:413.25pt;position:var(--position);top:38.25pt;width:54.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:29.01pt;position:var(--position)"></span><span style="left:29.01pt;position:var(--position)">(54)</span><span style="left:45.67pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:52.5pt;width:133.5pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:133.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Subsidies</span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:40.940000000000005pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:43.25pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:44.410000000000004pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:44.99pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:45.28pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:45.36pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:45.400000000000006pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:45.410000000000004pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . . . . . . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:133.5pt;position:var(--position);top:52.5pt;width:75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:58.29pt"></span></span><span style="left:60.92pt;position:var(--position)">81<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:208.5pt;position:var(--position);top:52.5pt;width:75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:45.79pt"></span></span><span style="left:48.42pt;position:var(--position)">4,140<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:52.5pt;width:75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:58.29pt"></span></span><span style="left:60.92pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:358.5pt;position:var(--position);top:52.5pt;width:54.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:22.34pt;position:var(--position)"></span><span style="left:22.34pt;position:var(--position)">5017<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span><span style="left:45.67pt;position:var(--position)">%</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:413.25pt;position:var(--position);top:52.5pt;width:54.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:24.01pt;position:var(--position)"></span><span style="left:24.01pt;position:var(--position)">(100)</span><span style="left:45.67pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:133.5pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:133.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Depositary service fees</span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:95.83pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:95.86999999999999pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:133.5pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:58.29pt"></span></span><span style="left:60.92pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:208.5pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:45.79pt"></span></span><span style="left:48.42pt;position:var(--position)">1,634<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:45.79pt"></span></span><span style="left:48.42pt;position:var(--position)">1,509<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:358.5pt;position:var(--position);top:66.75pt;width:54.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:33.45pt;position:var(--position)"></span><span style="left:33.45pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span><span style="left:45.67pt;position:var(--position)">%</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:413.25pt;position:var(--position);top:66.75pt;width:54.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:34.01pt;position:var(--position)"></span><span style="left:34.01pt;position:var(--position)">(8)</span><span style="left:45.67pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:81pt;width:133.5pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:133.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other</span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:25.38pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:25.669999999999998pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:25.82pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:25.83pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . . . . . . . . . . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:133.5pt;position:var(--position);top:81pt;width:75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:58.29pt"></span></span><span style="left:60.92pt;position:var(--position)">47<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:208.5pt;position:var(--position);top:81pt;width:75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:58.29pt"></span></span><span style="left:60.92pt;position:var(--position)">23<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:81pt;width:75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:58.29pt"></span></span><span style="left:60.92pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:358.5pt;position:var(--position);top:81pt;width:54.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:29.01pt;position:var(--position)"></span><span style="left:29.01pt;position:var(--position)">(52)</span><span style="left:45.67pt;position:var(--position)">%</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:413.25pt;position:var(--position);top:81pt;width:54.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:24.01pt;position:var(--position)"></span><span style="left:24.01pt;position:var(--position)">(100)</span><span style="left:45.67pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:95.25pt;width:133.5pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:133.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total other operating income</span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:127.24pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:129.55pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:130.13pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:130.42000000000002pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:130.5pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:130.52pt;position:var(--position);white-space:pre"> </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:133.5pt;position:var(--position);top:95.25pt;width:75pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:45.79pt"></span></span><span style="left:48.42pt;position:var(--position)">4,621<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:208.5pt;position:var(--position);top:95.25pt;width:75pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:40.79pt"></span></span><span style="left:43.42pt;position:var(--position)">12,449<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:95.25pt;width:75pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:45.79pt"></span></span><span style="left:48.42pt;position:var(--position)">4,570<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:358.5pt;position:var(--position);top:95.25pt;width:54.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:27.34pt;position:var(--position)"></span><span style="left:27.34pt;position:var(--position)">169<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span><span style="left:45.67pt;position:var(--position)">%</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:413.25pt;position:var(--position);top:95.25pt;width:54.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:29.01pt;position:var(--position)"></span><span style="left:29.01pt;position:var(--position)">(63)</span><span style="left:45.67pt;position:var(--position)">%</span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:658.44pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">For</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:110.39pt;position:var(--position);white-space:pre"> the </span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">year ended December 31, 2025</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);white-space:pre">, our other operating income was </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:386.21pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;4.6 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:435.06pt;position:var(--position);white-space:pre">, as compared to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:503.04pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.4 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:668.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:100.85pt;position:var(--position);white-space:pre"> for the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:132.21pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:256.8pt;position:var(--position);white-space:pre">, a decrease of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:316.43pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(7.9) million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:371.94pt;position:var(--position);white-space:pre">, or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:387.77pt;position:var(--position);text-decoration:none;white-space:pre">(63)%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:412.76pt;position:var(--position);white-space:pre">.&#160; This variation is primarily </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:678.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">due to a decrease in subsidies by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:204.91pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(4.1) million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:260.41999999999996pt;position:var(--position);white-space:pre"> and a decrease in research tax credits by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:426.01pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(3.6) million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:481.52pt;position:var(--position);white-space:pre"> or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:494.85pt;position:var(--position);text-decoration:none;white-space:pre">(54)%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:519.8399999999999pt;position:var(--position);white-space:pre">.</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">90</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">For</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:110.39pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.89pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">the</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:125.09pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);text-decoration:none;white-space:pre">, our other operating income was </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:386.21pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.4 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:440.06pt;position:var(--position);text-decoration:none;white-space:pre">, as compared to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:508.04pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;4.6 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:100.85pt;position:var(--position);text-decoration:none;white-space:pre"> for the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:132.21pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2023</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:256.8pt;position:var(--position);text-decoration:none;white-space:pre">, an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:319.77pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;7.8&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:368.62pt;position:var(--position);text-decoration:none;white-space:pre">, or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:384.45pt;position:var(--position);text-decoration:none;white-space:pre">169%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:407.78pt;position:var(--position);text-decoration:none;white-space:pre">. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:412.78pt;position:var(--position);white-space:pre">This increase was primarily </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">due to an increase in subsidies of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:206.58pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;4.1 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:255.43pt;position:var(--position);white-space:pre"> or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:268.76pt;position:var(--position);text-decoration:none;white-space:pre">5,017%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:299.59000000000003pt;position:var(--position);white-space:pre">, an increase in research tax credits of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:452.42pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;2.2 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:501.27pt;position:var(--position);white-space:pre"> or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:514.6pt;position:var(--position);text-decoration:none;white-space:pre">48%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:532.9300000000001pt;position:var(--position);white-space:pre">, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">and an increase in depositary service fees of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:250.65pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1.63 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:304.5pt;position:var(--position);white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:130pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">R</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:78.66pt;position:var(--position);text-decoration:none;white-space:pre">esearch Tax Credits ("CIR")</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:146pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">For</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:110.39pt;position:var(--position);white-space:pre"> </span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.89pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">the</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:125.09pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);white-space:pre">, we recognized research tax credits for our research and development </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:156pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">projects of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:116.95pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3.1 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:165.8pt;position:var(--position);white-space:pre">, as compared to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:233.78pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.7 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:282.63pt;position:var(--position);white-space:pre"> for the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:313.99pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:438.58pt;position:var(--position);white-space:pre">, a decrease of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:498.21pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(3.6) </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:166pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:100.85pt;position:var(--position);white-space:pre">, or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:116.68pt;position:var(--position);text-decoration:none;white-space:pre">(54)%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:141.67000000000002pt;position:var(--position);white-space:pre">. Although research and development expenses for the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:361.16pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.75pt;position:var(--position);white-space:pre"> increased by </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:176pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">21%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90.33pt;position:var(--position);white-space:pre"> as compared to the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:170.51pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:295.1pt;position:var(--position);white-space:pre">, the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:314.8pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(3.6) million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:370.31pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:372.81pt;position:var(--position);white-space:pre">decrease in research tax credits was </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:186pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">mainly driven by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:142.76999999999998pt;position:var(--position);text-decoration:none;white-space:pre">(i) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:154.7pt;position:var(--position);white-space:pre">the maximum amount of eligible outsourced research and development expenses being capped, </span></div><div style="line-height:10pt;position:var(--position);top:196pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">(ii) a decrease in internal research and development costs (for &#8364;2.6 million), (iii) the reimbursement of the CARENA </span></div><div style="line-height:10pt;position:var(--position);top:206pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">and RNP-VIR conditional advances, deducted from the 2024 CIR calculation (for &#8364;0.6 million) and (iv) a change in </span></div><div style="line-height:10pt;position:var(--position);top:216pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">the CIR regulation related to eligible expenses (for &#8364;0.4 million).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:232pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For </span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.89pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">the</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:125.09pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);text-decoration:none;white-space:pre">, we recognized research tax credits for our research and development </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:242pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">projects of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:116.95pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.7 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:165.8pt;position:var(--position);text-decoration:none;white-space:pre">, as compared to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:233.78pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;4.5 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:282.63pt;position:var(--position);text-decoration:none;white-space:pre"> for the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:313.99pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2023</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:438.58pt;position:var(--position);text-decoration:none;white-space:pre">, an increase of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:252pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;2.2&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.85pt;position:var(--position);text-decoration:none;white-space:pre">, or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:136.68pt;position:var(--position);text-decoration:none;white-space:pre">48%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.01pt;position:var(--position);text-decoration:none;white-space:pre">. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:160.01pt;position:var(--position);white-space:pre">The increase corresponds to a</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:278.75pt;position:var(--position);white-space:pre">n additional CIR payment received in 2024 related to the 2021 </span></div><div style="line-height:10pt;position:var(--position);top:262pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">tax year, for an amount of &#8364;1.0 million, and an increase in the CIR for the tax year 2024 as compared to the tax year </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:272pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">2023 of &#8364;1.1 million,</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:156.68pt;position:var(--position);text-decoration:none;white-space:pre"> or 26%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:188.34pt;position:var(--position);white-space:pre">. This increase is mainly due to the reimbursements of conditional advances and </span></div><div style="line-height:10pt;position:var(--position);top:282pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">overpayment of conditional advances made to Bpifrance in relation to the RNP-VIR and CARENA projects, </span></div><div style="line-height:10pt;position:var(--position);top:292pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">following the termination of both projects (see </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:260.4pt;position:var(--position);white-space:pre">Bpifrance - Conditional Advances and Subsidies</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:454.39pt;position:var(--position);white-space:pre"> within the </span></div><div style="line-height:10pt;position:var(--position);top:302pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">"Liquidity and Capital Resources" section).</span></div><div style="line-height:10pt;position:var(--position);top:324pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Subsidies </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:340pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);text-decoration:none;white-space:pre">, our subsidy income was nil, as compared to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:434.52pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;4.1 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:483.37pt;position:var(--position);text-decoration:none;white-space:pre"> for the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:514.73pt;position:var(--position);text-decoration:none;white-space:pre">year </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:350pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ended December 31, 2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:176.9pt;position:var(--position);text-decoration:none;white-space:pre">. The subsidy income recognized in 2024 was </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:362.01pt;position:var(--position);text-decoration:none;white-space:pre">related to the RNP-VIR and CARENA </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:360pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">conditional advances granted by Bpifrance </span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:245.39pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">between</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:278.66999999999996pt;position:var(--position);text-decoration:none;white-space:pre"> 2013 and 2019. Following the termination of both projects, in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:370pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">June 2024, Bpifrance </span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:159.7pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">agreed</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:186.32pt;position:var(--position);text-decoration:none;white-space:pre"> to waive 60% of the remaining conditional advances and accrued interests, resulting in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:380pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">a non-cash subsidy income of &#8364;4.1 million (see </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:263.22pt;position:var(--position);text-decoration:none;white-space:pre">Bpifrance - Conditional Advances and Subsidies</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:457.21pt;position:var(--position);text-decoration:none;white-space:pre"> within the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:390pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">"Liquidity and Capital Resources" section</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:239.95pt;position:var(--position);white-space:pre">)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:243.28pt;position:var(--position);white-space:pre">. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:406pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">For</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:110.39pt;position:var(--position);white-space:pre"> </span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.89pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">the</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:125.09pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);white-space:pre">, our subsidy income was </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:356pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;4.1 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:404.85pt;position:var(--position);white-space:pre"> as compared to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:470.33pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.1 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:519.1800000000001pt;position:var(--position);white-space:pre"> for </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:416pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:86.7pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2023</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:211.29pt;position:var(--position);white-space:pre">. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:216.29pt;position:var(--position);white-space:pre">The </span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:234.32pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">increase</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:267.03pt;position:var(--position);white-space:pre"> is related to the RNP-VIR and CARENA conditional advances </span></div><div style="line-height:10pt;position:var(--position);top:426pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">granted by Bpifrance between 2013 and 2019, as explained above.</span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:454pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre;width:98.75pt">Depositary Service Fees</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:170.75pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);top:470pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">As part of our depositary agreement with Citibank (which is acting as our exclusive depositary for our </span></div><div style="line-height:10pt;position:var(--position);top:480pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">publicly listed ADSs), </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:163.59pt;position:var(--position);white-space:pre">we</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:175.24pt;position:var(--position);text-decoration:none;white-space:pre"> are </span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:192.43pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">entitled</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:222.37pt;position:var(--position);text-decoration:none;white-space:pre"> to receive a portion of the fees collected by Citibank on ADS transactions </span></div><div style="line-height:10pt;position:var(--position);top:490pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(e.g., issuance, cancellation and depositary service fees).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:506pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">For the year ended December 31, 2025, our income related to depositary service fees was </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:456.36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1.5 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:505.21pt;position:var(--position);white-space:pre">, as </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:516pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">compared to &#8364;1.6 million </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:175.51pt;position:var(--position);white-space:pre">for</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:187.17000000000002pt;position:var(--position);white-space:pre"> the year ended December 31,</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:306.46000000000004pt;position:var(--position);text-decoration:none;white-space:pre"> 2024, a decrease of &#8364;(0.1) million, or (8)%.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:482.42pt;position:var(--position);white-space:pre"> The 2025 </span></div><div style="line-height:10pt;position:var(--position);top:526pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">fees mainly reflect</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:146.31pt;position:var(--position);text-decoration:none;white-space:pre"> the large number of transactions that occurred over the second half of 2025, following the </span></div><div style="line-height:10pt;position:var(--position);top:536pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">announcement of the results from our Phase 3 ABTECT trials and the completion of our follow-on offering of </span></div><div style="line-height:10pt;position:var(--position);top:546pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ordinary shares in the form of </span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:193.56pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">ADSs</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:217.45pt;position:var(--position);text-decoration:none;white-space:pre"> on the Nasdaq Global Market in July 2025 (the &#8220;July 2025 Nasdaq Offering&#8221;). </span></div><div style="line-height:10pt;position:var(--position);top:556pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The 2024 fees were related to the higher number of transactions following our U.S. initial public offering on the </span></div><div style="line-height:10pt;position:var(--position);top:566pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Nasdaq Global Market completed in October 2023. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:582pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We did not </span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:143.4pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">recognize</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:182.22pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:184.72pt;position:var(--position);text-decoration:none;white-space:pre">any</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:199.15pt;position:var(--position);text-decoration:none;white-space:pre"> income related to depositary service fees f</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:370.29pt;position:var(--position);text-decoration:none;white-space:pre">or the year ended December 31, 2023.</span></div><div style="line-height:10pt;position:var(--position);top:603.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Total Operating Expenses </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:621.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">For the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);white-space:pre">, our total operating expenses were </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:393.96pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;250.6&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:452.81pt;position:var(--position);white-space:pre">, as compared to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:631.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;185.4 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:130.85pt;position:var(--position);white-space:pre"> for the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:162.20999999999998pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:286.8pt;position:var(--position);white-space:pre">, an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:349.77pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;65.2 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:403.62pt;position:var(--position);white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:408.62pt;position:var(--position);text-decoration:none;white-space:pre">o</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:413.62pt;position:var(--position);white-space:pre">r </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:419.45pt;position:var(--position);text-decoration:none;white-space:pre">35%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:437.78pt;position:var(--position);white-space:pre">. This increase was </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:641.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">primarily due to an increase in research and development expenses of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:352.48pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;31.2 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:406.33pt;position:var(--position);white-space:pre">, or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:422.16pt;position:var(--position);text-decoration:none;white-space:pre">21.3%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:447.99pt;position:var(--position);white-space:pre"> and an increase in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:651.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">general and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.82pt;position:var(--position);white-space:pre">administrative</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:177.95pt;position:var(--position);white-space:pre"> expenses of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:229.85pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;34.7 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:283.7pt;position:var(--position);white-space:pre">, or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:299.53pt;position:var(--position);text-decoration:none;white-space:pre">105.4%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:330.36pt;position:var(--position);white-space:pre">, each as described </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:407.75pt;position:var(--position);text-decoration:none;white-space:pre">below</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:432.17pt;position:var(--position);white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:667.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.89pt;position:var(--position);white-space:pre">the</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:125.09pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);text-decoration:none;white-space:pre">, our total operating expenses were </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:393.96pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;185.4 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:452.81pt;position:var(--position);text-decoration:none;white-space:pre">, as compared to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:677.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;132.0 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:130.85pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:133.35pt;position:var(--position);white-space:pre">for</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:145.01pt;position:var(--position);text-decoration:none;white-space:pre"> the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:162.20999999999998pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2023</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:286.8pt;position:var(--position);text-decoration:none;white-space:pre">, an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:349.77pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;53.4&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:403.62pt;position:var(--position);text-decoration:none;white-space:pre">, or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:419.45pt;position:var(--position);text-decoration:none;white-space:pre">40%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:437.78pt;position:var(--position);text-decoration:none;white-space:pre">. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:442.78pt;position:var(--position);white-space:pre">This increase was </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:687.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">primarily due to an increase in research and development expenses of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:352.48pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;43.4 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:406.33pt;position:var(--position);white-space:pre">,</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:408.83pt;position:var(--position);text-decoration:none;white-space:pre"> or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:422.16pt;position:var(--position);text-decoration:none;white-space:pre">42%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:440.49pt;position:var(--position);white-space:pre"> and an increase in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:697.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">general and administrative expenses of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:229.85pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;11 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:276.2pt;position:var(--position);white-space:pre">, or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:292.03pt;position:var(--position);text-decoration:none;white-space:pre">47%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:310.36pt;position:var(--position);white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:315.36pt;position:var(--position);white-space:pre">each as described </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:387.75pt;position:var(--position);text-decoration:none;white-space:pre">below.</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">91</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Sales and Marketing Expenses </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:90pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Sales </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.08pt;position:var(--position);text-decoration:none;white-space:pre">and</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:134.51pt;position:var(--position);text-decoration:none;white-space:pre"> marketing expenses consist primarily of personnel expenses, including share-based compensation </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:100pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">expenses, for employees </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:172.45pt;position:var(--position);text-decoration:none;white-space:pre">engaged</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:205.74pt;position:var(--position);text-decoration:none;white-space:pre"> in sales and marketing activities, as well as consulting costs associated with </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:110pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">market research in preparation for our potential future sales and commercialization efforts in the U.S</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:474.52pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.89pt;position:var(--position);white-space:pre">the</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:125.09pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);text-decoration:none;white-space:pre">, our total sales and marketing expenses were </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:435.57pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.2&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:484.42pt;position:var(--position);text-decoration:none;white-space:pre">, as compared </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:136pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:82.27pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.0 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:131.12pt;position:var(--position);text-decoration:none;white-space:pre"> for the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:162.48000000000002pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:287.07pt;position:var(--position);white-space:pre">,</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:289.57pt;position:var(--position);text-decoration:none;white-space:pre"> a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:299pt;position:var(--position);text-decoration:none;white-space:pre">decrease </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:335.87pt;position:var(--position);text-decoration:none;white-space:pre">of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:346.7pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(0.8) million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:402.21pt;position:var(--position);text-decoration:none;white-space:pre">, or</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:415.54pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:418.04pt;position:var(--position);text-decoration:none;white-space:pre">(13)%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:443.03pt;position:var(--position);text-decoration:none;white-space:pre">. The decrease is driven </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:146pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">by one-time </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:122.5pt;position:var(--position);text-decoration:none;white-space:pre">costs</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:142.48000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> of &#8364;1.8 million that were incurred in 2024 for our corporate re-branding, including its new </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:156pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">website, largely offset by an increase in personnel costs of &#8364;1.0 million, of which &#8364;0.3 million relate to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.44pt;position:var(--position);text-decoration:none;white-space:pre">employer </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:166pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">taxes and social contributions related to our AGAs, resulting predominantly from the increase in our share price </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:176pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">during the second half of 2025.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:192pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);white-space:pre">, our </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:273.01pt;position:var(--position);white-space:pre">total</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:290.75pt;position:var(--position);text-decoration:none;white-space:pre"> sales and marketing expenses were </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:435.57pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.0 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:484.42pt;position:var(--position);white-space:pre"> as compared </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:202pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:82.27pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.4 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:131.12pt;position:var(--position);white-space:pre"> for the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:162.48000000000002pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2023</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:287.07pt;position:var(--position);text-decoration:none;white-space:pre">, a decrease of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:346.7pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:349.2pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(0.5) million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:404.71pt;position:var(--position);white-space:pre">, or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:420.54pt;position:var(--position);text-decoration:none;white-space:pre">(7)%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:440.53pt;position:var(--position);white-space:pre">. The decrease was </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:212pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">primarily </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:111.67pt;position:var(--position);white-space:pre">driven</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:137.2pt;position:var(--position);white-space:pre"> by the reduction in the headcount of our Sales and Marketing department part-way through 2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:525.99pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:240pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Research and Development </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:184.37pt;position:var(--position);text-decoration:none;white-space:pre">Expenses</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:221.54pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:256pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.53pt;position:var(--position);text-decoration:none;white-space:pre">following</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:153.39pt;position:var(--position);text-decoration:none;white-space:pre"> table sets </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:195.26999999999998pt;position:var(--position);text-decoration:none;white-space:pre">forth</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:214.7pt;position:var(--position);text-decoration:none;white-space:pre"> our research and develop</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:317.36pt;position:var(--position);text-decoration:none;white-space:pre">ment expenses by drug candidate and therapeutic </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:266pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">indication for the years ended December 31, 2025, 2024 and 2023. </span></div><div style="line-height:12pt;position:var(--position);top:276pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="position:var(--position);text-align:justify;text-align-last:var(--justify);top:288pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:456pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:122.25pt"/><td style="padding:0;width:66.75pt"/><td style="padding:0;width:66.75pt"/><td style="padding:0;width:66.75pt"/><td style="padding:0;width:66.75pt"/><td style="padding:0;width:66.75pt"/></tr><tr style="height:35.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:122.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:122.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(In thousands of euros)</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:81.44999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:82.61pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:83.19pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:83.33999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:83.42pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:83.42999999999999pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:122.25pt;position:var(--position);width:66.75pt"><div><div style="line-height:8pt;position:var(--position);top:4.62pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.73pt;position:var(--position);text-decoration:none;white-space:pre">Year ended </span></div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.06pt;position:var(--position);text-decoration:none;white-space:pre">December 31, </span></div><div style="line-height:8pt;position:var(--position);top:24.62pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.37pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:189pt;position:var(--position);width:66.75pt"><div><div style="line-height:8pt;position:var(--position);top:4.62pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.73pt;position:var(--position);text-decoration:none;white-space:pre">Year ended </span></div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.06pt;position:var(--position);text-decoration:none;white-space:pre">December 31, </span></div><div style="line-height:8pt;position:var(--position);top:24.62pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.37pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:255.75pt;position:var(--position);width:66.75pt"><div><div style="line-height:8pt;position:var(--position);top:4.62pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.73pt;position:var(--position);text-decoration:none;white-space:pre">Year ended </span></div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.06pt;position:var(--position);text-decoration:none;white-space:pre">December 31, </span></div><div style="line-height:8pt;position:var(--position);top:24.62pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.37pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:322.5pt;position:var(--position);width:66.75pt"><div><div style="line-height:8pt;position:var(--position);top:9.62pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:bold;left:12.04pt;position:var(--position);text-decoration:none;white-space:pre">2024 vs 2023 </span></div><div style="line-height:8pt;position:var(--position);top:19.62pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:bold;left:20.49pt;position:var(--position);text-decoration:none;white-space:pre">Change</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:389.25pt;position:var(--position);width:66.75pt"><div><div style="line-height:8pt;position:var(--position);top:9.62pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:bold;left:12.04pt;position:var(--position);text-decoration:none;white-space:pre">2025 vs 2024 </span></div><div style="line-height:8pt;position:var(--position);top:19.62pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:bold;left:20.49pt;position:var(--position);text-decoration:none;white-space:pre">Change</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:35.25pt;width:122.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:122.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">OBEFAZIMOD </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:74.50999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:74.58999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:74.61pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:74.61999999999999pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:122.25pt;position:var(--position);top:35.25pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">97,490</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:189pt;position:var(--position);top:35.25pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:31.62pt;position:var(--position);text-decoration:none;white-space:pre">142,678</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:255.75pt;position:var(--position);top:35.25pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:31.62pt;position:var(--position);text-decoration:none;white-space:pre">171,574</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:322.5pt;position:var(--position);top:35.25pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:44.34pt;position:var(--position)"></span><span style="left:44.34pt;position:var(--position)">46<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span><span style="left:57.67pt;position:var(--position)">%</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:389.25pt;position:var(--position);top:35.25pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:44.34pt;position:var(--position)"></span><span style="left:44.34pt;position:var(--position)">20<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span><span style="left:57.67pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:49.5pt;width:122.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:122.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:20.63pt;position:var(--position);text-decoration:none;white-space:pre">Ulcerative Colitis</span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:91.89999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:94.21pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.36pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:122.25pt;position:var(--position);top:49.5pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">83,788</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:189pt;position:var(--position);top:49.5pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:31.62pt;position:var(--position);text-decoration:none;white-space:pre">115,818</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:255.75pt;position:var(--position);top:49.5pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:31.62pt;position:var(--position);text-decoration:none;white-space:pre">117,405</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:322.5pt;position:var(--position);top:49.5pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:44.34pt;position:var(--position)"></span><span style="left:44.34pt;position:var(--position)">38<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span><span style="left:57.67pt;position:var(--position)">%</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:389.25pt;position:var(--position);top:49.5pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:49.34pt;position:var(--position)"></span><span style="left:49.34pt;position:var(--position)">1<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span><span style="left:57.67pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:63.75pt;width:122.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:122.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:20.63pt;position:var(--position);text-decoration:none;white-space:pre">Crohn's Disease</span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:86.33pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:88.64pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:89.22pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:89.3pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:89.31pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:122.25pt;position:var(--position);top:63.75pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:41.62pt;position:var(--position);text-decoration:none;white-space:pre">2,735</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:189pt;position:var(--position);top:63.75pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:41.62pt;position:var(--position);text-decoration:none;white-space:pre">7,354</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:255.75pt;position:var(--position);top:63.75pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">17,554</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:322.5pt;position:var(--position);top:63.75pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:39.34pt;position:var(--position)"></span><span style="left:39.34pt;position:var(--position)">169<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span><span style="left:57.67pt;position:var(--position)">%</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:389.25pt;position:var(--position);top:63.75pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:39.34pt;position:var(--position)"></span><span style="left:39.34pt;position:var(--position)">139<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span><span style="left:57.67pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:26.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78pt;width:122.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.89pt;width:122.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:20.63pt;position:var(--position);text-decoration:none;white-space:pre">Obefazimod Other </span></div><div style="line-height:10pt;position:var(--position);top:15.39pt;width:122.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:20.63pt;position:var(--position);text-decoration:none;white-space:pre">Indications</span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:65.59pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:67.9pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:69.06pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:69.21pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:69.23pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:69.24pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:122.25pt;position:var(--position);top:78pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:9.15pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:49.12pt;position:var(--position);text-decoration:none;white-space:pre">169</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:189pt;position:var(--position);top:78pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:9.15pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:49.12pt;position:var(--position);text-decoration:none;white-space:pre">474</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:255.75pt;position:var(--position);top:78pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:9.15pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:41.62pt;position:var(--position);text-decoration:none;white-space:pre">4,596</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:322.5pt;position:var(--position);top:78pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:9.14pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:39.34pt;position:var(--position)"></span><span style="left:39.34pt;position:var(--position)">181<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span><span style="left:57.67pt;position:var(--position)">%</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:389.25pt;position:var(--position);top:78pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:9.14pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:39.34pt;position:var(--position)"></span><span style="left:39.34pt;position:var(--position)">870<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span><span style="left:57.67pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:104.25pt;width:122.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:122.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:20.63pt;position:var(--position);text-decoration:none;white-space:pre">Transversal Activities</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:108.00999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:109.17pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:109.46pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:109.47pt;position:var(--position);text-decoration:none;white-space:pre"> . .</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:122.25pt;position:var(--position);top:104.25pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">10,798</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189pt;position:var(--position);top:104.25pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">19,032</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:255.75pt;position:var(--position);top:104.25pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">32,018</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:322.5pt;position:var(--position);top:104.25pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:44.34pt;position:var(--position)"></span><span style="left:44.34pt;position:var(--position)">76<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span><span style="left:57.67pt;position:var(--position)">%</span></span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:389.25pt;position:var(--position);top:104.25pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:44.34pt;position:var(--position)"></span><span style="left:44.34pt;position:var(--position)">68<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span><span style="left:57.67pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:118.5pt;width:122.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:122.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Others </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:34.54pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:34.62pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . . . . . . . . . .</span></div></div></div></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:122.25pt;position:var(--position);top:118.5pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:41.62pt;position:var(--position);text-decoration:none;white-space:pre">5,686</span></div></div></div></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189pt;position:var(--position);top:118.5pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:41.62pt;position:var(--position);text-decoration:none;white-space:pre">3,854</span></div></div></div></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:255.75pt;position:var(--position);top:118.5pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:41.62pt;position:var(--position);text-decoration:none;white-space:pre">6,187</span></div></div></div></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:322.5pt;position:var(--position);top:118.5pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:41.01pt;position:var(--position)"></span><span style="left:41.01pt;position:var(--position)">(32)</span><span style="left:57.67pt;position:var(--position)">%</span></span></div></div></div></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:389.25pt;position:var(--position);top:118.5pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:44.34pt;position:var(--position)"></span><span style="left:44.34pt;position:var(--position)">61<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span><span style="left:57.67pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:26.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:132.75pt;width:122.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.98pt;width:122.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Research and Development </span></div><div style="line-height:10pt;position:var(--position);top:15.48pt;width:122.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">expenses.</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:42.32pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:43.480000000000004pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:44.06pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:44.35pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:44.39pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:44.410000000000004pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . . . . . . . .</span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:122.25pt;position:var(--position);top:132.75pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:9.23pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:31.62pt;position:var(--position);text-decoration:none;white-space:pre">103,176</span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189pt;position:var(--position);top:132.75pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:9.23pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:31.62pt;position:var(--position);text-decoration:none;white-space:pre">146,532</span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:255.75pt;position:var(--position);top:132.75pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:9.23pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:31.62pt;position:var(--position);text-decoration:none;white-space:pre">177,761</span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:322.5pt;position:var(--position);top:132.75pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:9.23pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:44.34pt;position:var(--position)"></span><span style="left:44.34pt;position:var(--position)">42<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span><span style="left:57.67pt;position:var(--position)">%</span></span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:389.25pt;position:var(--position);top:132.75pt;width:66.75pt"><div><div style="line-height:10pt;position:var(--position);top:9.23pt;width:66.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:44.34pt;position:var(--position)"></span><span style="left:44.34pt;position:var(--position)">21<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span><span style="left:57.67pt;position:var(--position)">%</span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:458pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">For the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);white-space:pre">, our research and development expenses were </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:440.29pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;177.8 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:499.14pt;position:var(--position);white-space:pre">, as </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:468pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">compared to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:124.16pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;146.5 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:183.01pt;position:var(--position);white-space:pre"> for the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:214.37pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:338.96pt;position:var(--position);white-space:pre">, an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:401.93pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;31.2&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:455.78pt;position:var(--position);white-space:pre">, or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:471.61pt;position:var(--position);text-decoration:none;white-space:pre">21%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:489.94pt;position:var(--position);white-space:pre">. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:494.94pt;position:var(--position);text-decoration:none;white-space:pre">This </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:478pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">increase was primarily due to a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:199.05pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;13.0</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:221.55pt;position:var(--position);text-decoration:none;white-space:pre"> million, or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:268.73pt;position:var(--position);text-decoration:none;white-space:pre">68%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:287.06pt;position:var(--position);text-decoration:none;white-space:pre">, increase in transversal activities related to increased </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:488pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">chemistry, manufacturing and controls ("CMC") and supply chain costs related to the progression of clinical trials </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:498pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and anticipation of future commercial launch, a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:263.95pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;10.2</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:286.45pt;position:var(--position);text-decoration:none;white-space:pre"> million, or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:333.63pt;position:var(--position);text-decoration:none;white-space:pre">139%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:356.96pt;position:var(--position);text-decoration:none;white-space:pre">, increase in </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:407.44pt;position:var(--position);white-space:pre">expenses related to our CD </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:508pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">clinical program, resulting from the progression of our Phase 2b CD trial, a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:375.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1.6</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:392.81pt;position:var(--position);white-space:pre"> million, or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:439.99pt;position:var(--position);text-decoration:none;white-space:pre">1%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:453.32pt;position:var(--position);white-space:pre">, increase in expenses </span></div><div style="line-height:10pt;position:var(--position);top:518pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">related to our UC clinical program </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:212.37pt;position:var(--position);white-space:pre">resulting from our continued progression of our UC clinical program and the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:528pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">Phase 3 induction trials data read-out during the second half of 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:345.34pt;position:var(--position);text-decoration:none;white-space:pre">, and a &#8364;4.1 million, or 870%, increase in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:538pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">expenses related to new indications (including the combination therapy) for obefazimod.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:426.3pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:428.8pt;position:var(--position);text-decoration:none;white-space:pre">In addition,</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:474.87pt;position:var(--position);white-space:pre"> a sharp rise in </span></div><div style="line-height:10pt;position:var(--position);top:548pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">employer tax and social contributions related to our stock-based compensation ("AGAs"), in turn predominantly </span></div><div style="line-height:10pt;position:var(--position);top:558pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">attributable to the increase in our share price during the second half of 2025, contributed to the overall increase in </span></div><div style="line-height:10pt;position:var(--position);top:568pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">research and development expenses across all destinations for the year ended December 31, 2025 as compared to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:578pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">year ended December 31, 2024, in an amount of &#8364;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:272.09000000000003pt;position:var(--position);text-decoration:none;white-space:pre">20.1 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:320.94pt;position:var(--position);white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:594pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">For the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);white-space:pre">, our research and development expenses were</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:437.79pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:440.29pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;146.5 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:499.14pt;position:var(--position);white-space:pre">, as </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:604pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">compared to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:124.16pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;103.2 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:183.01pt;position:var(--position);white-space:pre"> for the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:214.37pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2023</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:338.96pt;position:var(--position);white-space:pre">, an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:401.93pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;43.4&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:455.78pt;position:var(--position);white-space:pre">, or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:471.61pt;position:var(--position);text-decoration:none;white-space:pre">42%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:489.94pt;position:var(--position);white-space:pre">. This </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:614pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">increase was primarily due to a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:199.05pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;32.0 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.9pt;position:var(--position);white-space:pre">, or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:268.73pt;position:var(--position);text-decoration:none;white-space:pre">38%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:287.06pt;position:var(--position);white-space:pre">, increase in expenses related to our UC clinical program, </span></div><div style="line-height:10pt;position:var(--position);top:624pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">driven by the progression of Phase 3 clinical trials for obefazimod in UC </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:365.31pt;position:var(--position);white-space:pre">(where Phase 3 clinical trial costs were </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:634pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">significantly higher than in Phase 2)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:216.57pt;position:var(--position);white-space:pre">,</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:219.07pt;position:var(--position);white-space:pre"> a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:228.5pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;8.2 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:277.35pt;position:var(--position);white-space:pre">, or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:293.18pt;position:var(--position);text-decoration:none;white-space:pre">76%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:311.51pt;position:var(--position);white-space:pre">, increase in transversal activities related to the overall </span></div><div style="line-height:10pt;position:var(--position);top:644pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">expansion of the research and development headcount to support our organizational growth and the issuance of new </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:654pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">equity awards to officers and employees in research and development and a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:376.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;4.6 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:425.48pt;position:var(--position);white-space:pre"> increase in expenses related </span></div><div style="line-height:10pt;position:var(--position);top:664pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">to our CD clinical program, driven by planning costs incurred for the Phase 2b CD trial.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:423.6pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="line-height:1pt;position:var(--position);top:687.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">92</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">General and Administrative Expenses </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:88pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">The </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.53pt;position:var(--position);white-space:pre">following</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:153.39pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> table </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:177.79000000000002pt;position:var(--position);white-space:pre">sets</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:192.76999999999998pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> forth our operating expenses for the years ended </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:390.63pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">December&#160;31, 2023</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:469.17pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">, </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:474.17pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">2024</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:494.17pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> and </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:513.6pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">2025</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:533.6pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">.</span></span></div><div style="position:var(--position);top:104pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:468pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:128.25pt"/><td style="padding:0;width:69.75pt"/><td style="padding:0;width:69.75pt"/><td style="padding:0;width:69.75pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:65.25pt"/></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:13.12pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(In thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:128.25pt;position:var(--position);width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.12pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.23pt;position:var(--position);text-decoration:none;white-space:pre">Year ended </span></div><div style="line-height:8pt;position:var(--position);top:13.12pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.56pt;position:var(--position);text-decoration:none;white-space:pre">December 31, </span></div><div style="line-height:8pt;position:var(--position);top:23.12pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.87pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:198pt;position:var(--position);width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.12pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.23pt;position:var(--position);text-decoration:none;white-space:pre">Year ended </span></div><div style="line-height:8pt;position:var(--position);top:13.12pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.56pt;position:var(--position);text-decoration:none;white-space:pre">December 31, </span></div><div style="line-height:8pt;position:var(--position);top:23.12pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.87pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.12pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.23pt;position:var(--position);text-decoration:none;white-space:pre">Year ended </span></div><div style="line-height:8pt;position:var(--position);top:13.12pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.56pt;position:var(--position);text-decoration:none;white-space:pre">December 31, </span></div><div style="line-height:8pt;position:var(--position);top:23.12pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.87pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:337.5pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:8.12pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:bold;left:12.23pt;position:var(--position);text-decoration:none;white-space:pre">2024 vs 2023 </span></div><div style="line-height:8pt;position:var(--position);top:18.12pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:bold;left:20.68pt;position:var(--position);text-decoration:none;white-space:pre">Change</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:8.12pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:bold;left:12.23pt;position:var(--position);text-decoration:none;white-space:pre">2025 vs 2024 </span></div><div style="line-height:8pt;position:var(--position);top:18.12pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:bold;left:20.68pt;position:var(--position);text-decoration:none;white-space:pre">Change</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:32.25pt;width:128.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:8.63pt;position:var(--position);text-decoration:none;white-space:pre">Personnel costs</span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:70.52pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:70.6pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:70.62pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:128.25pt;position:var(--position);top:32.25pt;width:69.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.62pt;position:var(--position);text-decoration:none;white-space:pre">13,104</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:198pt;position:var(--position);top:32.25pt;width:69.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.62pt;position:var(--position);text-decoration:none;white-space:pre">19,434</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:32.25pt;width:69.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.62pt;position:var(--position);text-decoration:none;white-space:pre">52,817</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:337.5pt;position:var(--position);top:32.25pt;width:65.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:42.84pt;position:var(--position)"></span><span style="left:42.84pt;position:var(--position)">48<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span><span style="left:56.17pt;position:var(--position)">%</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:32.25pt;width:65.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.14pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:37.84pt;position:var(--position)"></span><span style="left:37.84pt;position:var(--position)">172<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span><span style="left:56.17pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:26.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:46.5pt;width:128.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.9pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:8.63pt;position:var(--position);text-decoration:none;white-space:pre">Consulting and professional </span></div><div style="line-height:10pt;position:var(--position);top:15.4pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:8.63pt;position:var(--position);text-decoration:none;white-space:pre">fees</span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:24.71pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:25.29pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:25.439999999999998pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:25.520000000000003pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:25.54pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:25.550000000000004pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . . . . . . . . . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:128.25pt;position:var(--position);top:46.5pt;width:69.75pt"><div><div style="line-height:10pt;position:var(--position);top:9.15pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre">6,393</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:198pt;position:var(--position);top:46.5pt;width:69.75pt"><div><div style="line-height:10pt;position:var(--position);top:9.15pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre">7,990</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:46.5pt;width:69.75pt"><div><div style="line-height:10pt;position:var(--position);top:9.15pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre">9,984</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:337.5pt;position:var(--position);top:46.5pt;width:65.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.14pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:42.84pt;position:var(--position)"></span><span style="left:42.84pt;position:var(--position)">25<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span><span style="left:56.17pt;position:var(--position)">%</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:46.5pt;width:65.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.14pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:42.84pt;position:var(--position)"></span><span style="left:42.84pt;position:var(--position)">25<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span><span style="left:56.17pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:26.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:72.75pt;width:128.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.9pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:8.63pt;position:var(--position);text-decoration:none;white-space:pre">Other general and </span></div><div style="line-height:10pt;position:var(--position);top:15.4pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:8.63pt;position:var(--position);text-decoration:none;white-space:pre">administrative expenses</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:104.33pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:105.49pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:105.5pt;position:var(--position);text-decoration:none;white-space:pre"> . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:128.25pt;position:var(--position);top:72.75pt;width:69.75pt"><div><div style="line-height:10pt;position:var(--position);top:9.15pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre">2,893</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:198pt;position:var(--position);top:72.75pt;width:69.75pt"><div><div style="line-height:10pt;position:var(--position);top:9.15pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre">5,522</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:72.75pt;width:69.75pt"><div><div style="line-height:10pt;position:var(--position);top:9.15pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre">4,870</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:337.5pt;position:var(--position);top:72.75pt;width:65.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.14pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:42.84pt;position:var(--position)"></span><span style="left:42.84pt;position:var(--position)">91<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span><span style="left:56.17pt;position:var(--position)">%</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:72.75pt;width:65.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.14pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:39.51pt;position:var(--position)"></span><span style="left:39.51pt;position:var(--position)">(12)</span><span style="left:56.17pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:26.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:99pt;width:128.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.98pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:8.63pt;position:var(--position);text-decoration:none;white-space:pre">General and </span></div><div style="line-height:10pt;position:var(--position);top:15.48pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:8.63pt;position:var(--position);text-decoration:none;white-space:pre">administrative expenses</span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:110.49pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:110.57pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:110.61pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:110.61999999999999pt;position:var(--position);text-decoration:none;white-space:pre"> . . .</span></div></div></div></td><td style="border-bottom:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:128.25pt;position:var(--position);top:99pt;width:69.75pt"><div><div style="line-height:10pt;position:var(--position);top:9.23pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:39.62pt;position:var(--position);text-decoration:none;white-space:pre">22,390</span></div></div></div></td><td style="border-bottom:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:198pt;position:var(--position);top:99pt;width:69.75pt"><div><div style="line-height:10pt;position:var(--position);top:9.23pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:39.62pt;position:var(--position);text-decoration:none;white-space:pre">32,946</span></div></div></div></td><td style="border-bottom:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:99pt;width:69.75pt"><div><div style="line-height:10pt;position:var(--position);top:9.23pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:39.62pt;position:var(--position);text-decoration:none;white-space:pre">67,670</span></div></div></div></td><td style="border-bottom:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:337.5pt;position:var(--position);top:99pt;width:65.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.23pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:42.84pt;position:var(--position)"></span><span style="left:42.84pt;position:var(--position)">47<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span><span style="left:56.17pt;position:var(--position)">%</span></span></div></div></div></td><td style="border-bottom:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:99pt;width:65.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.23pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:37.84pt;position:var(--position)"></span><span style="left:37.84pt;position:var(--position)">105<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span><span style="left:56.17pt;position:var(--position)">%</span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:240.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">For the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);white-space:pre">, our general and administrative expenses were </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:441.94pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;67.7 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:495.79pt;position:var(--position);white-space:pre">, as </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:250.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">compared to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:124.16pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;32.9 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:178.01pt;position:var(--position);white-space:pre"> for the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:209.37pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:333.96pt;position:var(--position);white-space:pre">, an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:396.93pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;34.7 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:450.78pt;position:var(--position);white-space:pre">, or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:466.61pt;position:var(--position);text-decoration:none;white-space:pre">105%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:489.94pt;position:var(--position);white-space:pre">. This </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:260.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">increase </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:107.21000000000001pt;position:var(--position);white-space:pre">was</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:122.75pt;position:var(--position);white-space:pre"> primarily due to an increase in personnel costs of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:324.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;33.4</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:346.69pt;position:var(--position);white-space:pre"> million, or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:393.87pt;position:var(--position);text-decoration:none;white-space:pre">172%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:417.2pt;position:var(--position);white-space:pre">,</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:419.7pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:422.2pt;position:var(--position);white-space:pre">mainly explained by the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:270.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">increase in employer taxes and social contributions related to our AGAs by</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:372.49pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:374.99pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;27.3 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:428.84pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:431.34pt;position:var(--position);white-space:pre">resulting predominantly </span></div><div style="line-height:10pt;position:var(--position);top:280.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">from the increase in our share price during the second half of 2025 and to a lesser degree by an increase in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:290.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">consulting and professional fees of</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:211.31pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:213.81pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;2.0 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:262.65999999999997pt;position:var(--position);white-space:pre">, or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:278.49pt;position:var(--position);text-decoration:none;white-space:pre">25%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:296.82pt;position:var(--position);white-space:pre">, driven by an increase in legal and professional fees and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:300.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">costs </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.48pt;position:var(--position);text-decoration:none;white-space:pre">associated with building our infrastructure to support future growth in our operations.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:316.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);text-decoration:none;white-space:pre">, our general and administrative expenses were </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:441.94pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;32.9 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:495.79pt;position:var(--position);text-decoration:none;white-space:pre">, as </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:326.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">compared</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:111.39pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.89pt;position:var(--position);white-space:pre">to</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:121.66pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:124.16pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;22.4 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:178.01pt;position:var(--position);text-decoration:none;white-space:pre"> for the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:209.37pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2023</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:333.96pt;position:var(--position);text-decoration:none;white-space:pre">, an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:396.93pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;10.6&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:450.78pt;position:var(--position);text-decoration:none;white-space:pre">, or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:466.61pt;position:var(--position);text-decoration:none;white-space:pre">47%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:484.94pt;position:var(--position);text-decoration:none;white-space:pre">. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:489.94pt;position:var(--position);white-space:pre">This </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:336.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">increase was primarily due to an increase in personnel costs of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:324.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.3</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:341.69pt;position:var(--position);white-space:pre"> million, or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:388.87pt;position:var(--position);text-decoration:none;white-space:pre">48%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:407.2pt;position:var(--position);white-space:pre">. This increase in personnel costs </span></div><div style="line-height:10pt;position:var(--position);top:346.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">represents the full year impact of the build out of our G&amp;A organization (increased headcount and equity-based </span></div><div style="line-height:10pt;position:var(--position);top:356.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">compensation costs) which started in late 2023 to support the expansion of the company, as well as increased legal </span></div><div style="line-height:10pt;position:var(--position);top:366.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">and professional fees and other costs associated with operating as a dual-listed public company.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:394.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Operating Income (Loss) </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:410.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">For the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);white-space:pre">, our operating loss was </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:349.33000000000004pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;246.1&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:408.18pt;position:var(--position);white-space:pre">, as compared to an operating </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:420.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">loss of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:100.88pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;173.0&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:159.73000000000002pt;position:var(--position);white-space:pre"> for the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:191.09pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:315.68pt;position:var(--position);white-space:pre">, an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:378.65pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;73.1&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:432.5pt;position:var(--position);white-space:pre">, or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:448.33pt;position:var(--position);text-decoration:none;white-space:pre">42%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:466.66pt;position:var(--position);white-space:pre">. This increase </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:430.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">was primarily due to an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:214.88pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;31.2&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:268.73pt;position:var(--position);white-space:pre"> in research and development expenses and an increase of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:440.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;34.7&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:125.85pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:128.35pt;position:var(--position);white-space:pre">in</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:136.12pt;position:var(--position);white-space:pre"> general and administrative expenses. There expenses were offset, to a lesser degree, by a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:495.65pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(0.8) </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:450.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:100.85pt;position:var(--position);white-space:pre"> decrease in sales and marketing expenses.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:466.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.89pt;position:var(--position);white-space:pre">the</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:125.09pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);text-decoration:none;white-space:pre">, our operating loss was </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:349.33000000000004pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;173.0&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:408.18pt;position:var(--position);text-decoration:none;white-space:pre">, as compared to an operating </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:476.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">loss of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:100.88pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;127.4&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:159.73000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> for the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:191.09pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2023</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:315.68pt;position:var(--position);text-decoration:none;white-space:pre">, an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:378.65pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;45.6&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:432.5pt;position:var(--position);text-decoration:none;white-space:pre">, or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:448.33pt;position:var(--position);text-decoration:none;white-space:pre">36%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:466.66pt;position:var(--position);text-decoration:none;white-space:pre">. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:471.66pt;position:var(--position);white-space:pre">This increase </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:486.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">was primarily due to an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:214.88pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;43.4 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:268.73pt;position:var(--position);white-space:pre"> in research and development expenses and an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:501.77pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;10.6 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:496.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:100.85pt;position:var(--position);white-space:pre"> in </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.62pt;position:var(--position);white-space:pre">general</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:143.01pt;position:var(--position);white-space:pre"> and administrative expenses. These expenses were offset, to a lesser degree, by a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:471.21pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(0.5) million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:526.72pt;position:var(--position);white-space:pre"> </span></div><div style="line-height:10pt;position:var(--position);top:506.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">decrease in sales and marketing expenses. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:534.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">F</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:78.66pt;position:var(--position);text-decoration:none;white-space:pre">inancial Income (Loss) </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:550.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);text-decoration:none;white-space:pre">, our financial loss was </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:346.53pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;84.2</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:369.03pt;position:var(--position);text-decoration:none;white-space:pre"> million, as compared to a financial loss of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:560.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3.3&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.85pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:123.35pt;position:var(--position);text-decoration:none;white-space:pre">and</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:137.78pt;position:var(--position);text-decoration:none;white-space:pre"> a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:147.20999999999998pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;20.4&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:201.06pt;position:var(--position);text-decoration:none;white-space:pre"> for the years ended December 31, 2024 and 2023, respectively. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:576.25pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">For </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.89pt;position:var(--position);white-space:pre">the</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:125.09pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">year ended December 31, 2025</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">, </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:257.18pt;position:var(--position);white-space:pre">our financial loss was mainly driven by (i) increases in the fair values </span></div><div style="line-height:10pt;position:var(--position);top:586.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">of the senior convertible notes (</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:198.8pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">the "Heights Convertible Notes") issued pursuant to the subscription agreement </span></span></div><div style="line-height:10pt;position:var(--position);top:596.25pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">entered into in </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:132.2pt;position:var(--position);white-space:pre">August</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:161.07999999999998pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> 2023 with entities affiliated with Heights Capital Management (the "Heights Financing") and </span></span></div><div style="line-height:10pt;position:var(--position);top:606.25pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">the&#160; warrants issued in August 2023 to Kreos Capital and Claret European Growth Capital (the &#8220;Kreos / Claret </span></span></div><div style="line-height:10pt;position:var(--position);top:616.25pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">BSA") of &#8364;36.0 million and &#8364;29.9 million, respectively (predominantly driven by the increase in our share price and </span></span></div><div style="line-height:10pt;position:var(--position);top:626.25pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">the remeasurement of these instr</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:201.82pt;position:var(--position);white-space:pre">uments prior to their conversion into ordinary shares), (ii) foreign exchange losses </span></div><div style="line-height:10pt;position:var(--position);top:636.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">of &#8364;13.4 million (including the &#8364;9.6 million non-c</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:271.56pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">ash impact of the revaluation of U.S. dollar-denominated cash and </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:646.25pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">cash equivalents as of December 31, 2025),</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:246.26pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:248.76pt;position:var(--position);text-decoration:none;white-space:pre">(iii) interests of </span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:312.84000000000003pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;17.2 million </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:369.19pt;position:var(--position);text-decoration:none;white-space:pre">in relati</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:399.96pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">on to our royalty certificates,</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:515.64pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> (iv) </span></span></div><div style="line-height:10pt;position:var(--position);top:656.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">interest expenses o</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:147.45999999999998pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">f &#8364;11.1 million </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:209.64pt;position:var(--position);white-space:pre">in relation to the first tranche of senior secured convertible bonds with warrants </span></div><div style="line-height:10pt;position:var(--position);top:666.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">attached in the Kreos / Claret Financing (the &#8220;Kreos / Claret OCABSA&#8221;), the second and third tranches of senior </span></div><div style="line-height:10pt;position:var(--position);top:676.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">secured bonds in the Kreos / Claret Financing and the senior convertible notes in the Heights Financing (the </span></div><div style="line-height:10pt;position:var(--position);top:686.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">"Heights Convertible Notes") and (v) a &#8364;3.8 million loss on derecognition on the Kreos / Claret Tranches B and C. </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">93</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre;width:23.85pt">These</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.35pt;position:var(--position);text-decoration:none;white-space:pre;width:3.37pt"><span style="background-color:inherit"> </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:123.72pt;position:var(--position);white-space:pre;width:19.98pt">costs</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:143.7pt;position:var(--position);text-decoration:none;white-space:pre;width:146.19pt"><span style="background-color:inherit"> were partially offset mainly by (i) </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:289.89pt;position:var(--position);white-space:pre;width:106.11pt">foreign exchange gains of</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:396pt;position:var(--position);text-decoration:none;white-space:pre;width:64.79pt"><span style="background-color:inherit"> &#8364;11.9 million (</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:460.79pt;position:var(--position);white-space:pre;width:79.18pt">including the &#8364;10.7</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.97pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:28.85pt">million</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:100.85pt;position:var(--position);text-decoration:none;white-space:pre;width:187.78pt"><span style="background-color:inherit"> gain related to our July 2025 Nasdaq Offering</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:288.63pt;position:var(--position);white-space:pre;width:23.35pt">), (ii) </span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:311.98pt;position:var(--position);text-decoration:none;white-space:pre;width:227.84pt"><span style="background-color:inherit">interest income of &#8364;5.6 million and fair value changes of</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.8199999999999pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"><span style="background-color:inherit"> </span></span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:92pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre;width:54.16pt"><span style="background-color:inherit">&#8364;4.7 million i</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:126.16pt;position:var(--position);white-space:pre;width:7.52pt">n </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:133.68pt;position:var(--position);white-space:pre;width:30.5pt">relation</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:164.18pt;position:var(--position);white-space:pre;width:139.17pt"> to the invested proceeds from our </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:303.35pt;position:var(--position);white-space:pre;width:7.22pt">U</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:310.57pt;position:var(--position);white-space:pre;width:229.4pt">.S. initial public offering and listing on Nasdaq and (iii) a</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.97pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:146.45pt">decrease in derivatives fair value by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:218.45pt;position:var(--position);text-decoration:none;white-space:pre;width:17.5pt">&#8364;3.6</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:235.95pt;position:var(--position);white-space:pre;width:33.85pt"> million.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre;width:16.77pt">For </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.27pt;position:var(--position);text-decoration:none;white-space:pre;width:12.2pt">the</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:125.47pt;position:var(--position);text-decoration:none;white-space:pre;width:2.88pt"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:128.35pt;position:var(--position);text-decoration:none;white-space:pre;width:126.11pt">year ended December 31, 2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:254.46pt;position:var(--position);text-decoration:none;white-space:pre;width:5.38pt">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:259.84000000000003pt;position:var(--position);text-decoration:none;white-space:pre;width:149.9pt">our financial loss was mainly driven </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:409.74pt;position:var(--position);text-decoration:none;white-space:pre;width:54.58pt">by (i) interest</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:464.32pt;position:var(--position);text-decoration:none;white-space:pre;width:75.54pt"> expenses of &#8364;11.5</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.86pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre;width:467.96pt">million in relation to the first tranche of senior secured convertible bonds with warrants attached in the Kreos /</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.96pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre;width:28.4pt">Claret </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:100.4pt;position:var(--position);text-decoration:none;white-space:pre;width:39.96pt">Financing</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.36pt;position:var(--position);text-decoration:none;white-space:pre;width:399.6pt"> (the &#8220;Kreos / Claret OCABSA&#8221;), the second and third tranches of senior secured bonds in the</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.96pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre;width:467.96pt">Kreos / Claret Financing (drawn on March 28, 2024 and June 21, 2024, respectively) and the senior convertible</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.96pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre;width:467.86pt">notes in the Heights Financing (the "Heights Convertible Notes"), (ii) a &#8364;1.5 million increase in the fair value of the</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.86pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:168pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre;width:410.94pt">Kreos / Claret Minimum Return Indemnifications and (iii) transaction costs amounting to &#8364;1.6 million.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:184pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre;width:50.79pt">These costs </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:147.29pt;position:var(--position);text-decoration:none;white-space:pre;width:392.71pt">were partially offset mainly by (i) an interest income of &#8364;8.2 million in relation to the invested</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:540pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:194pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre;width:467.92pt">proceeds from our U.S. initial public offering and listing on Nasdaq, and (ii) foreign exchange gains of &#8364;2.7 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.9200000000001pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:204pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre;width:467.99pt">(including the &#8364;1.7 million non-cash impact of the revaluation of U.S. dollar-denominated cash and cash equivalents</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.99pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:214pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre;width:106.02pt">as of December 31, 2024).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:230pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre;width:33.01pt">For the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.51pt;position:var(--position);text-decoration:none;white-space:pre;width:128.43pt">year ended December 31, 2023</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:257.94pt;position:var(--position);text-decoration:none;white-space:pre;width:5.96pt">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:263.9pt;position:var(--position);white-space:pre;width:169.04pt">our net financial loss was mainly driven </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:432.94pt;position:var(--position);text-decoration:none;white-space:pre;width:55.74pt">by (i) interest</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:488.68pt;position:var(--position);white-space:pre;width:51.32pt"> expenses of</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:540pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:240pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:467.94pt">&#8364;3.9 million in relation to the Kreos / Claret OCABSA and the Heights Convertible Notes, (ii) a &#8364;8.9 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.94pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:250pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:467.84pt">expense in relation to our royalty certificates, a (iii) &#8364;3.0 million increase in the fair value of derivatives, transaction</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.8399999999999pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:260pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:144.67pt">costs amounting to &#8364;1.9 million, (</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:216.67pt;position:var(--position);white-space:pre;width:7.77pt">iv</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:224.44pt;position:var(--position);white-space:pre;width:315.56pt">) a net &#8364;3.2 million loss on derecognition of the OCEANE bonds and the</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:540pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:270pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:467.95pt">recognition of the Heights convertible notes, and (v) and foreign exchange losses of &#8364;5.6 million (including the &#8364;3.2</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.95pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:280pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:430.6pt">million non-cash impact of the year-end revaluation of U.S. dollar-denominated cash and cash equivalents).</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:502.6pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:296pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre;width:49.91pt">These costs </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:146.41pt;position:var(--position);white-space:pre;width:22.45pt">were </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:168.86pt;position:var(--position);white-space:pre;width:33.27pt">partially</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:202.13pt;position:var(--position);white-space:pre;width:337.72pt"> offset by (i) an interest income of &#8364;2.4 million in relation to the invested proceeds</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.85pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:306pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:467.82pt">from our U.S. initial public offering and listing on Nasdaq, (ii) a decrease in the fair value of the Heights</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.8199999999999pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:316pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:378.45pt">Convertible Notes by &#8364;3.2 million and a (iii) decrease in derivatives fair value by &#8364;1.0 million.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:344pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Income Taxes </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:372pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">For the year ended </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:173.64pt;position:var(--position);white-space:pre">December</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:214.68pt;position:var(--position);white-space:pre"> 31, 2025, our deferred income tax charge was </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:402.55pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(5.8) million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:458.06pt;position:var(--position);white-space:pre">, as compared to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:382pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;&#8212;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:87pt;position:var(--position);white-space:pre"> for the years ended December 31, 2024 and 2023.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:398pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre;width:69.58pt">This increase is </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:166.07999999999998pt;position:var(--position);white-space:pre;width:38.83pt">explained</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:204.91pt;position:var(--position);white-space:pre;width:267pt"> by the net deferred tax liability of &#8364;5.8 million recognized in </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:471.91pt;position:var(--position);text-decoration:none;white-space:pre;width:67.97pt">our consolidated</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.88pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:408pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre;width:42.15pt">statements</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.15pt;position:var(--position);white-space:pre;width:185.65pt"> of financial position as of December 31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:299.8pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:424pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The deferred </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:150.31pt;position:var(--position);white-space:pre">tax </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:165.01pt;position:var(--position);white-space:pre">liability</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:196.06pt;position:var(--position);white-space:pre"> resulted from the significant taxable temporary difference arising from our royalty </span></div><div style="line-height:10pt;position:var(--position);top:434pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">certificates as of December 31, 2025, which in turn resulted from the difference between (i) the amount already </span></div><div style="line-height:10pt;position:var(--position);top:444pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">deducted from our taxable income as of December 31, 2025 (based on the certificates' fair value minus their </span></div><div style="line-height:10pt;position:var(--position);top:454pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">subscription price) and (</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:169.4pt;position:var(--position);white-space:pre">ii</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:174.94pt;position:var(--position);white-space:pre">) the amount of the related financial liability recognized in our Statements of Financial </span></div><div style="line-height:10pt;position:var(--position);top:464pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">Position at that date (measured at amortized cost using the original effective interest rate). </span></div><div style="line-height:10pt;position:var(--position);top:480pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">Further explanation </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:177.51999999999998pt;position:var(--position);white-space:pre">on</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:187.51999999999998pt;position:var(--position);white-space:pre"> the calculation of the deferred tax liability is disclosed in Note 22 to our financial </span></div><div style="line-height:10pt;position:var(--position);top:490pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">statements as of and for the year ended December 31, 2025, appearing elsewhere in this Annual Report on Form 20-</span></div><div style="line-height:10pt;position:var(--position);top:500pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">F. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:516pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The d</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:119.53pt;position:var(--position);white-space:pre">eferred tax expense is non-cash for the year ended December 31, 2025. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:544pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Net Loss </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:576pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">For</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:110.39pt;position:var(--position);white-space:pre"> the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);white-space:pre">, our net loss for the period was </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:380.69pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;336.1&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:439.54pt;position:var(--position);white-space:pre">, as compared to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:586pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;176.2&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:130.85pt;position:var(--position);white-space:pre"> for</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:145.01pt;position:var(--position);white-space:pre"> the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:162.20999999999998pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:286.8pt;position:var(--position);white-space:pre">, an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:349.77pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;159.9&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:408.62pt;position:var(--position);white-space:pre">, or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:424.45pt;position:var(--position);text-decoration:none;white-space:pre">91%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:442.78pt;position:var(--position);white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:602pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);text-decoration:none;white-space:pre">, our net loss for the period was </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:380.69pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;176.2&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:439.54pt;position:var(--position);text-decoration:none;white-space:pre">, as compared to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:612pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;147.7&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:130.85pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:133.35pt;position:var(--position);white-space:pre">for</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:145.01pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:147.51pt;position:var(--position);white-space:pre">the</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:159.70999999999998pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:162.20999999999998pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2023</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:286.8pt;position:var(--position);text-decoration:none;white-space:pre">, an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:349.77pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;28.5&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:403.62pt;position:var(--position);text-decoration:none;white-space:pre">, or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:419.45pt;position:var(--position);text-decoration:none;white-space:pre">19%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:437.78pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><div style="line-height:1pt;position:var(--position);top:647.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="position:absolute;top:648.5pt" id="i7a006daedb3d4216a4128b76247285d7_67"></div><div style="line-height:10pt;position:var(--position);top:648.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">B.<span id="i75b373dca5bc417593eac73bd4a8a984"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Liquidity and Capital Resources</span></div><div style="line-height:10pt;position:var(--position);top:678.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Sources of Liquidity </span></div><div style="line-height:10pt;position:var(--position);top:694.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We have incurred substantial operating losses since inception and expect to continue to incur significant </span></div><div style="line-height:10pt;position:var(--position);top:704.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">operating losses for the foreseeable future and may never become profitable. For the years ended December 31, </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">94</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">2025, 2024 and 2023, we </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:175.57999999999998pt;position:var(--position);white-space:pre">reported</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:208.87pt;position:var(--position);text-decoration:none;white-space:pre"> net losses of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:263.27pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;336.1&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:322.12pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:327.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;176.2&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:385.97pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:405.4pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;147.7&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:464.25pt;position:var(--position);text-decoration:none;white-space:pre">, respectively. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:522.5pt;position:var(--position);text-decoration:none;white-space:pre">As </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of December 31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:161.37pt;position:var(--position);text-decoration:none;white-space:pre">, we carried forward accumulated tax losses of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:349.74pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;912.9 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:408.59pt;position:var(--position);white-space:pre">.</span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Since inception, we have financed our operations primarily through the issuance of ordinary shares, as well as </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">bank borrowings </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:141.97pt;position:var(--position);white-space:pre">and</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:156.4pt;position:var(--position);text-decoration:none;white-space:pre"> loans, receipt of research tax credits and subsidiaries, and sales of royalty certificates, for gross </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">aggregate proceeds of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:162.16pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,194.7 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:228.51pt;position:var(--position);text-decoration:none;white-space:pre">, of which </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:271.26pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;130.0&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:330.11pt;position:var(--position);text-decoration:none;white-space:pre"> of gross proceeds were from our offerings of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ordinary shares on Euronext Paris in February 2023, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:283.78999999999996pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;223.3&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:342.64pt;position:var(--position);text-decoration:none;white-space:pre"> of gross proceeds were from our offering of </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ordinary shares in the form of ADSs on the Nasdaq Global Market in our U.S. initial public offering as well as </span></div><div style="line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ordinary shares in Europe (including France) and countries outside of the United States in a concurrent private </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">placement in October 2023, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:185.48000000000002pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;637.5 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:244.33pt;position:var(--position);text-decoration:none;white-space:pre"> of gross proceeds were from our offering of ordinary shares in the form </span></div><div style="line-height:10pt;position:var(--position);top:168pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of ADSs on the Nasdaq Global Market in the July 2025 </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:296.56pt;position:var(--position);white-space:pre">Nasdaq Offering</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:363.44pt;position:var(--position);text-decoration:none;white-space:pre">, bank borrowings and structured loans of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:178pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;175.0 million, reimbursements of CIR in an amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:297.64pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;41.2 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:351.49pt;position:var(--position);text-decoration:none;white-space:pre">, subsidies received from Bpifrance (including </span></div><div style="line-height:10pt;position:var(--position);top:188pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;21.3&#160;million of subsidies and &#8364;1.8 million of conditional advances) and royalty certificates in an amount of </span></div><div style="line-height:10pt;position:var(--position);top:198pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;2.9&#160;million.</span></div><div style="line-height:10pt;position:var(--position);top:214pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In addition, on November 19, 2024, we entered into an equity distribution agreement with Piper Sandler &amp; Co. </span></div><div style="line-height:10pt;position:var(--position);top:224pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(&#8220;Piper Sandler&#8221;) allowing us to issue and sell from time to time, in one or more "at the market" offerings through </span></div><div style="line-height:10pt;position:var(--position);top:234pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Piper Sandler acting as sales agent, ordinary shares in the form of ADSs, with aggregate gross sales proceeds of up </span></div><div style="line-height:10pt;position:var(--position);top:244pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to $150.0 million (the "ATM Program"). To date, we have not sold any ADSs pursuant to the ATM Program.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:260pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Based on our existing cash and cash equivalents </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:291.28999999999996pt;position:var(--position);text-decoration:none;white-space:pre">and other short-term investments </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:425.59pt;position:var(--position);text-decoration:none;white-space:pre">of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:436.42pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;530.4 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:495.27pt;position:var(--position);text-decoration:none;white-space:pre"> as of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:270pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">December 31, 2025, we expect, as of the date of issuance o</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:308.4pt;position:var(--position);text-decoration:none;white-space:pre">f the consolidated financial statements </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:464pt;position:var(--position);text-decoration:none;white-space:pre">included in th</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:518.94pt;position:var(--position);text-decoration:none;white-space:pre">is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:280pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Annual R</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:110.58pt;position:var(--position);text-decoration:none;white-space:pre">eport on Form 20-F, to be able to fund our forecasted cash flow requirements into the fourth quarter of </span></div><div style="line-height:10pt;position:var(--position);top:290pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">2027, allowing us to reach 12 months of expected cash runway following the planned new drug application ("NDA") </span></div><div style="line-height:10pt;position:var(--position);top:300pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">submission of obefazimod for UC, assuming positive results from its Phase 3 maintenance trial. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:457.17pt;position:var(--position);white-space:pre">Our forecasted cash </span></div><div style="line-height:10pt;position:var(--position);top:310pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">flow requirements</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:144.97pt;position:var(--position);text-decoration:none;white-space:pre"> take into account our assumption of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:292.88pt;position:var(--position);white-space:pre">continued</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:332.28pt;position:var(--position);text-decoration:none;white-space:pre"> R&amp;D expenditure related to the continuation of the </span></div><div style="line-height:10pt;position:var(--position);top:320pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Phase 3 clinical trials of obefazimod in UC, progression of the Phase 2b clinical trials for CD and the initial stages of </span></div><div style="line-height:10pt;position:var(--position);top:330pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the scale up of the commercial organization as we prepare for a potential launch of obefazimod in UC.</span></div><div style="line-height:10pt;position:var(--position);top:346pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Based on the above, management has concluded that its existing cash, cash equivalents and other short-term </span></div><div style="line-height:10pt;position:var(--position);top:356pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">investments are sufficient to fund its operating and capital expenditure requirements for a period greater than 12 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:366pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">months from the date of issuance of the financial statements accompanying thi</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:385.77pt;position:var(--position);text-decoration:none;white-space:pre">s annual rep</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:434.05pt;position:var(--position);text-decoration:none;white-space:pre">ort, and the </span></div><div style="line-height:10pt;position:var(--position);top:376pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">accompanying financial statements have been prepared on a going concern basis.</span></div><div style="line-height:10pt;position:var(--position);top:404pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Capital Increases </span></div><div style="line-height:10pt;position:var(--position);top:420pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our operations have been financed primarily by capital increases from our founders and investors, net </span></div><div style="line-height:10pt;position:var(--position);top:430pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">proceeds from the initial public offering of our ordinary shares on Euronext Paris in France in 2015, and additional </span></div><div style="line-height:10pt;position:var(--position);top:440pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">follow-on capital increases, including the initial public offering of our ordinary shares in the form of ADSs on the </span></div><div style="line-height:10pt;position:var(--position);top:450pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Nasdaq Global Market in 2023 and our July 2025 Nasdaq Offering. We have not yet commercialized any of our </span></div><div style="line-height:10pt;position:var(--position);top:460pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">drug candidates, which are in various phases of clinical development, and we do not expect to generate revenue from </span></div><div style="line-height:10pt;position:var(--position);top:470pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">sales of any products in 2026, if at all. Until such time as we can generate significant revenue from product sales, if </span></div><div style="line-height:10pt;position:var(--position);top:480pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, </span></div><div style="line-height:10pt;position:var(--position);top:490pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">including potential collaborations with other companies or other strategic transactions.</span></div><div style="line-height:10pt;position:var(--position);top:506pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The following table sets forth our main capital increases carried out during the years ended December 31, </span></div><div style="line-height:10pt;position:var(--position);top:516pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">2023, 2024 and 2025: </span></div><div style="line-height:12pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:526pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre;width:3pt">&#160;</span></div><div style="position:var(--position);text-align:justify;text-align-last:var(--justify);top:538pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:468pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:387.75pt"/><td style="padding:0;width:80.25pt"/></tr><tr style="height:23.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:387.75pt"><div><div style="line-height:9.24pt;position:var(--position);top:13.36pt;width:387.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(In thousands of euros)</span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:81.44999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:83.75999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:84.33999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:84.63pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:84.71pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:84.75pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:84.77pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:84.78pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:387.75pt;position:var(--position);width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.62pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.44pt;position:var(--position);text-decoration:none;white-space:pre">Gross proceeds </span></div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:51.42pt;position:var(--position);text-decoration:none;white-space:pre">amount</span></div></div></div></td></tr><tr style="height:23.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:23.25pt;width:387.75pt"><div><div style="line-height:10pt;position:var(--position);top:7.65pt;width:387.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Capital increase from issuance of ordinary shares - February 23, 2023 </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:284.01pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:284.59pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:284.88pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:284.96pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:285pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:285.02pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:285.03pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . . . . . . . . . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:387.75pt;position:var(--position);top:23.25pt;width:80.25pt"><div><div style="line-height:10pt;position:var(--position);top:7.65pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:45.12pt;position:var(--position);text-decoration:none;white-space:pre">130,000</span></div></div></div></td></tr><tr style="height:23.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:46.5pt;width:387.75pt"><div><div style="line-height:10pt;position:var(--position);top:7.65pt;width:387.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Initial Public Offering (Nasdaq) - October 24, 2023</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:208.54999999999998pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:209.71pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:209.85999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:209.94pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:209.98pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:209.99pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387.75pt;position:var(--position);top:46.5pt;width:80.25pt"><div><div style="line-height:10pt;position:var(--position);top:7.65pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:45.12pt;position:var(--position);text-decoration:none;white-space:pre">223,300</span></div></div></div></td></tr><tr style="height:23.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:69.75pt;width:387.75pt"><div><div style="line-height:10pt;position:var(--position);top:7.65pt;width:387.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Capital increase from issuance of ordinary shares - July 24, 2025</span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:262.09pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:264.4pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:264.69pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:264.77pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:264.81pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:264.83pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:264.84pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . . . . . . . . . . . . . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:387.75pt;position:var(--position);top:69.75pt;width:80.25pt"><div><div style="line-height:10pt;position:var(--position);top:7.65pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:45.12pt;position:var(--position);text-decoration:none;white-space:pre">637,500</span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:642pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">On March&#160;1, 2023, we received gross proceeds of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:297.72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;130.0 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:356.57pt;position:var(--position);text-decoration:none;white-space:pre"> from the issuance of 20,000,000 ordinary </span></div><div style="line-height:10pt;position:var(--position);top:652pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">shares at a subscription price of &#8364;6.50 per share. The proceeds were primarily used to finance the progress of </span></div><div style="line-height:10pt;position:var(--position);top:662pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">obefazimod clinical trials in chronic inflammatory diseases and for general corporate purposes (research and </span></div><div style="line-height:10pt;position:var(--position);top:672pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">development expenses and loans maturities payments).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:688pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">On October&#160;24, 2023, we received gross proceeds of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:308.82pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;223.3&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:367.67pt;position:var(--position);text-decoration:none;white-space:pre"> from the issuance of 20,325,500 ordinary </span></div><div style="line-height:10pt;position:var(--position);top:698pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">shares (including ordinary shares in the form of ADSs) at a price of &#8364;10.99 per share in connection with our U.S. </span></div><div style="line-height:10pt;position:var(--position);top:708pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">initial public offering. The proceeds were primarily used to finance the progress of obefazimod clinical trials in </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">95</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">chronic inflammatory diseases and for general corporate purposes (research and development expenses and loans </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">maturities payments).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">On July&#160;28, 2025, we received gross proceeds of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:293.3pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;637.5&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:352.15pt;position:var(--position);text-decoration:none;white-space:pre"> from the issuance of 11,679,400 ADSs at a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">price of $64.00 per ADS (corresponding to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:246.33pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;54.58</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:273.83000000000004pt;position:var(--position);text-decoration:none;white-space:pre"> per ordinary share, based on the exchange rate of &#8364;1.00 = </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">$</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:77pt;position:var(--position);text-decoration:none;white-space:pre">1.1726</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:104.5pt;position:var(--position);text-decoration:none;white-space:pre"> as published by the European Central Bank on July 23, 2025) in connection with our July 2025 Nasdaq </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Offering. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:111.41pt;position:var(--position);text-decoration:none;white-space:pre">The proceeds were primarily used to finance the progress of obefazimod clinical trials in chronic </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">inflammatory diseases and for general corporate purposes (research and development expenses and loans maturities </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">payments).</span></div><div style="line-height:10pt;position:var(--position);top:176pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Research Tax Credits </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:192pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">From our inception to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:186.43pt;position:var(--position);text-decoration:none;white-space:pre">December&#160;31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:264.97pt;position:var(--position);text-decoration:none;white-space:pre">, we have benefited from refunds of CIRs in a total amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:514.1600000000001pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;41.2 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:202pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:100.85pt;position:var(--position);text-decoration:none;white-space:pre">. In November 2024, we received CIRs of &#8364;4.5 million with respect to the year ended December 31, 2023. In </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:212pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">June 2025, we received CIRs of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:202.16pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.7 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:251.01pt;position:var(--position);text-decoration:none;white-space:pre"> with respect to the year ended December 31, 2024. </span></div><div style="line-height:1pt;position:var(--position);top:235.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="line-height:10pt;position:var(--position);top:236.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Bpifrance&#8212;Conditional Advances and Subsidies </span></div><div style="line-height:10pt;position:var(--position);top:252.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We have received several conditional advances and subsidies from Bpifrance since our inception. Funds </span></div><div style="line-height:10pt;position:var(--position);top:262.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">received from Bpifrance in the form of conditional advances are recognized as financial liabilities, as we have a </span></div><div style="line-height:10pt;position:var(--position);top:272.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">contractual obligation to reimburse Bpifrance for such conditional advances in cash based on a repayment schedule. </span></div><div style="line-height:10pt;position:var(--position);top:282.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Each award of an advance is made to help fund a specific development milestone. Subsidies are non-repayable </span></div><div style="line-height:10pt;position:var(--position);top:292.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">grants, which are recognized in the financial statements when there exists reasonable assurance that we will comply </span></div><div style="line-height:10pt;position:var(--position);top:302.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">with the conditions attached to the subsidies and the subsidies will be received. </span></div><div style="line-height:10pt;position:var(--position);top:318.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The following table sets forth the funds received from Bpifrance as of December 31, 2025, in relation to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:328.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">contracts that were ongoing or terminated during the years ended</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:331.97pt;position:var(--position);text-decoration:none;white-space:pre"> December 31, 2023 and 2024:</span></div><div style="line-height:12pt;position:var(--position);top:338.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="position:var(--position);top:350.5pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:468pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:156pt"/><td style="padding:0;width:156pt"/><td style="padding:0;width:156pt"/></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);width:156pt"><div><div style="line-height:10pt;position:var(--position);top:3.83pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:48.17pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2025</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:14.25pt;width:156pt"><div><div style="line-height:10pt;position:var(--position);top:3.83pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:28.7pt;position:var(--position);text-decoration:none;white-space:pre">(In thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:14.25pt;width:156pt"><div><div style="line-height:10pt;position:var(--position);top:3.83pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:45.1pt;position:var(--position);text-decoration:none;white-space:pre">Contract status </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:14.25pt;width:156pt"><div><div style="line-height:10pt;position:var(--position);top:3.83pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:78.72pt;position:var(--position);text-decoration:none;white-space:pre">Amount collected</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:28.5pt;width:156pt"><div><div style="line-height:10pt;position:var(--position);top:3.83pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Conditional advances</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:94.53999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:95.69999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:95.74pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:95.75pt;position:var(--position);text-decoration:none;white-space:pre">.......................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:28.5pt;width:156pt"><div><div style="line-height:10pt;position:var(--position);top:3.83pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)">&#8364;<span style="display:inline-block;height:6.77pt;width:121.79pt"></span></span><span style="left:129.42000000000002pt;position:var(--position)">1,802<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:156pt"><div><div style="line-height:10pt;position:var(--position);top:3.66pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Carena (1)</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:46.77pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:47.93pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:48.220000000000006pt;position:var(--position);text-decoration:none;white-space:pre">..........................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:42.75pt;width:156pt"><div><div style="line-height:10pt;position:var(--position);top:3.66pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:61.9pt;position:var(--position);text-decoration:none;white-space:pre">Stopped</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:42.75pt;width:156pt"><div><div style="line-height:10pt;position:var(--position);top:3.66pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)">&#8364;<span style="display:inline-block;height:6.94pt;width:129.29pt"></span></span><span style="left:136.92pt;position:var(--position)">234<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:57pt;width:156pt"><div><div style="line-height:10pt;position:var(--position);top:3.66pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">RNP-VIR (2)</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:54.510000000000005pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:55.67pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:55.75pt;position:var(--position);text-decoration:none;white-space:pre">.......................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:57pt;width:156pt"><div><div style="line-height:10pt;position:var(--position);top:3.66pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:61.9pt;position:var(--position);text-decoration:none;white-space:pre">Stopped</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:57pt;width:156pt"><div><div style="line-height:10pt;position:var(--position);top:3.66pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)">&#8364;<span style="display:inline-block;height:6.94pt;width:121.79pt"></span></span><span style="left:129.42000000000002pt;position:var(--position)">1,178<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:71.25pt;width:156pt"><div><div style="line-height:10pt;position:var(--position);top:3.66pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Ebola </span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:29pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:30.16pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:30.45pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:30.599999999999998pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:30.68pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:30.709999999999997pt;position:var(--position);text-decoration:none;white-space:pre">.................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:71.25pt;width:156pt"><div><div style="line-height:10pt;position:var(--position);top:3.66pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:61.9pt;position:var(--position);text-decoration:none;white-space:pre">Stopped</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:71.25pt;width:156pt"><div><div style="line-height:10pt;position:var(--position);top:3.66pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)">&#8364;<span style="display:inline-block;height:6.94pt;width:129.29pt"></span></span><span style="left:136.92pt;position:var(--position)">390<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:85.5pt;width:156pt"><div><div style="line-height:10pt;position:var(--position);top:3.83pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Subsidies</span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:42.620000000000005pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:43.2pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:43.28pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:43.300000000000004pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:43.31pt;position:var(--position);text-decoration:none;white-space:pre">............................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:85.5pt;width:156pt"><div><div style="line-height:10pt;position:var(--position);top:3.83pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)">&#8364;<span style="display:inline-block;height:6.77pt;width:121.79pt"></span></span><span style="left:129.42000000000002pt;position:var(--position)">5,875<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:99.75pt;width:156pt"><div><div style="line-height:10pt;position:var(--position);top:3.66pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Carena (1)</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:46.77pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:47.93pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:48.220000000000006pt;position:var(--position);text-decoration:none;white-space:pre">..........................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:99.75pt;width:156pt"><div><div style="line-height:10pt;position:var(--position);top:3.66pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:61.9pt;position:var(--position);text-decoration:none;white-space:pre">Stopped</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:99.75pt;width:156pt"><div><div style="line-height:10pt;position:var(--position);top:3.66pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)">&#8364;<span style="display:inline-block;height:6.94pt;width:121.79pt"></span></span><span style="left:129.42000000000002pt;position:var(--position)">3,140<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:114pt;width:156pt"><div><div style="line-height:10pt;position:var(--position);top:3.66pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">RNP-VIR (2)</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:54.510000000000005pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:55.67pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:55.75pt;position:var(--position);text-decoration:none;white-space:pre">.......................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:114pt;width:156pt"><div><div style="line-height:10pt;position:var(--position);top:3.66pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:61.9pt;position:var(--position);text-decoration:none;white-space:pre">Stopped</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:114pt;width:156pt"><div><div style="line-height:10pt;position:var(--position);top:3.66pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)">&#8364;<span style="display:inline-block;height:6.94pt;width:121.79pt"></span></span><span style="left:129.42000000000002pt;position:var(--position)">2,735<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:128.25pt;width:156pt"><div><div style="line-height:10pt;position:var(--position);top:3.66pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Ebola</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:26.5pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:27.66pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:27.95pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:28.099999999999998pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:28.18pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:28.2pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:28.209999999999997pt;position:var(--position);text-decoration:none;white-space:pre">..................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:128.25pt;width:156pt"><div><div style="line-height:10pt;position:var(--position);top:3.66pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:61.9pt;position:var(--position);text-decoration:none;white-space:pre">Stopped</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:128.25pt;width:156pt"><div><div style="line-height:10pt;position:var(--position);top:3.66pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)">&#8364;<span style="display:inline-block;height:6.94pt;width:135.4pt"></span></span><span style="left:143.03pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span></span></div></div></div></td></tr><tr style="height:3pt"><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:145.5pt;width:156pt"><div><div style="line-height:10pt;position:var(--position);top:3.83pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total</span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:25.39pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:25.68pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:25.83pt;position:var(--position);text-decoration:none;white-space:pre">...................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:145.5pt;width:156pt"><div><div style="line-height:10pt;position:var(--position);top:3.83pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)">&#8364;<span style="display:inline-block;height:6.77pt;width:121.79pt"></span></span><span style="left:129.42000000000002pt;position:var(--position)">7,677<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span></span></div></div></div></td></tr><tr style="height:3pt"><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"/></tr></tbody></table></div></div></div><div style="position:var(--position);top:518.25pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:551.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:551.25pt"/></tr><tr style="height:12.75pt"><td style="border-bottom:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:551.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:551.25pt"><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:5.38pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr></tbody></table></div></div></div><div style="line-height:8pt;position:var(--position);top:542pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">(1)<span style="display:inline-block;height:5.54pt;width:26.68pt"></span></span><span style="left:108pt;position:var(--position)">Following termination of the project due to technical failure in June 2024, the repayment of an amount of conditional advance of &#8364;2.0 </span></span></div><div style="line-height:8pt;position:var(--position);top:550pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">million (excluding accrued interests) was waived by Bpifrance and therefore reclassified as a subsidy.</span></div><div style="line-height:8pt;position:var(--position);top:564pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">(2)<span style="display:inline-block;height:5.54pt;width:26.68pt"></span></span><span style="left:108pt;position:var(--position)">Following the termination of the project due to technical failure in June 2024, the repayment of an amount of conditional advance of </span></span></div><div style="line-height:8pt;position:var(--position);top:572pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1.8 million (excluding accrued interests) was waived by Bpifrance and therefore reclassified as a subsidy.</span></div><div style="line-height:10pt;position:var(--position);top:598pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Bpifrance&#8212;CARENA Contract </span></div><div style="line-height:10pt;position:var(--position);top:614pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">As part of the development of therapeutic and diagnostic solutions targeting alternative splicing and RNA </span></div><div style="line-height:10pt;position:var(--position);top:624pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">interference in the fields of virology (HIV-AIDS, HTLV-1) and metabolism (obesity), SPLICOS, which we acquired </span></div><div style="line-height:10pt;position:var(--position);top:634pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">in October 2014, entered into a Master Support Agreement and a conditional advance contract on December 2013 </span></div><div style="line-height:10pt;position:var(--position);top:644pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for the &#8220;CARENA&#8221; Strategic Industrial Innovation Project (&#8220;CARENA project&#8221;), with Bpifrance. Under this </span></div><div style="line-height:10pt;position:var(--position);top:654pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">contract, we were eligible to receive up to &#8364;3.8&#160;million in conditional advances to develop a therapeutic HIV </span></div><div style="line-height:10pt;position:var(--position);top:664pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">treatment program with obefazimod. As of December 31, 2024, we had received &#8364;3.4 million of conditional </span></div><div style="line-height:10pt;position:var(--position);top:674pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">advances and subsidies.</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">96</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In June 2024, the Company and Bpifrance agreed to terminate the project due to technical failure. Bpifrance </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">granted an additional amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:202.13pt;position:var(--position);white-space:pre">&#8364;1.1 million payable to the Company to reimburse additional expenses incurred as </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">part of the project, and agreed to waive 60% of the remaining </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:320.32pt;position:var(--position);text-decoration:none;white-space:pre">conditional</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:365.26pt;position:var(--position);white-space:pre"> advance of &#8364;3.3 million and accrued </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">interests, for which we recognized a subsidy income of &#8364;2.3 million in the aggregate. We repaid the outstanding </span></div><div style="line-height:10pt;position:var(--position);top:112pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">amounts</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:105.86pt;position:var(--position);text-decoration:none;white-space:pre"> during the second half of 2024.</span></div><div style="line-height:10pt;position:var(--position);top:140pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Bpifrance&#8212;RNP-VIR Contract </span></div><div style="line-height:10pt;position:var(--position);top:156pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">As part of the CARENA project, focused on the clinical development of a drug molecule and demonstrating </span></div><div style="line-height:10pt;position:var(--position);top:166pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the validity of an innovative therapeutic approach targeting viral RNPs, we entered into a Master Support </span></div><div style="line-height:10pt;position:var(--position);top:176pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Agreement with Bpifrance, as well as a beneficiary agreement dated March 21, 2017, with conditional advances for </span></div><div style="line-height:10pt;position:var(--position);top:186pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the &#8220;RNP-VIR&#8221; structuring research and development project for competitiveness. Under the RNP-VIR contract, we </span></div><div style="line-height:10pt;position:var(--position);top:196pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">were eligible to receive up to &#8364;6.3&#160;million in conditional advances to develop methods for the discovery of new </span></div><div style="line-height:10pt;position:var(--position);top:206pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">molecules for the treatment of viral infectious diseases through the development of the &#8220;Modulation of RNA </span></div><div style="line-height:10pt;position:var(--position);top:216pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">biogenesis&#8221; platform. As of December 31, 2024, we had received &#8364;3.9 million of conditional advances and </span></div><div style="line-height:10pt;position:var(--position);top:226pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">subsidies.</span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:242pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre;width:254.91pt">In June 2024, the Company and Bpifrance agreed to terminate</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:351.40999999999997pt;position:var(--position);white-space:pre;width:188.5pt"> the project due to technical failure. Bpifrance</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.9100000000001pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:252pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:467.93pt">claimed the reimbursement of &#8364;1.2 million corresponding to overpayments of conditional advances and subsidies</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.9300000000001pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:262pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:467.96pt">(for which we had not incurred the corresponding R&amp;D expenses) and agreed to waive 60% of the remaining</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.96pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:272pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:280.14pt">advances of &#8364;3.0 million and accrued interests, for which the we reco</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:352.14pt;position:var(--position);white-space:pre;width:187.82pt">gnized a subsidy income of &#8364;1.9 million in the</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.96pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:282pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:43.82pt">aggregate. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:115.82pt;position:var(--position);white-space:pre;width:141.51pt">We repaid the outstanding amounts</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:257.33000000000004pt;position:var(--position);text-decoration:none;white-space:pre;width:127.41pt"> during the second half of 2024.</span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:310pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre;width:75.5pt">Bpifrance&#8212;Ebola</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:147.5pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);top:326pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:114.53pt;position:var(--position);text-decoration:none;white-space:pre">Bpifrance </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:156.42000000000002pt;position:var(--position);text-decoration:none;white-space:pre">and Occitanie Region joint support agreement was entered into on June&#160;2, 2017 and provides </span></div><div style="line-height:10pt;position:var(--position);top:336pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for conditional advances for a total amount of &#8364;0.4&#160;million (&#8364;0.1&#160;million from the Languedoc Roussillon Midi </span></div><div style="line-height:10pt;position:var(--position);top:346pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Pyr&#233;n&#233;es Region and &#8364;0.3&#160;million from </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:232.14pt;position:var(--position);text-decoration:none;white-space:pre">Bpifrance</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:271.53pt;position:var(--position);text-decoration:none;white-space:pre">) for the Ebola program. All funds under this contract were </span></div><div style="line-height:10pt;position:var(--position);top:356pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">received. In September 2019, we terminated this program due to the imminent licensing of a competing vaccine for </span></div><div style="line-height:10pt;position:var(--position);top:366pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">this indication, as well as changes in the macroeconomic climate for public funding. The reimbursement of the </span></div><div style="line-height:10pt;position:var(--position);top:376pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">conditional advance was spread over the period from September 2019 to June 2024.</span></div><div style="line-height:10pt;position:var(--position);top:404pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Indebtedness </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:426pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.5pt;position:var(--position);text-decoration:none;white-space:pre;width:352.42pt">For a description of material financing agreements, see "Item 10.C. Material Contracts."</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">97</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Historical Changes in Cash Flows </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:88pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The following table sets forth our cash inflows and outflows for the years ended December 31, 2023, 2024 </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:525.01pt;position:var(--position);text-decoration:none;white-space:pre">and</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.44pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">2025. </span></div><div style="line-height:12pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="position:var(--position);top:120pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:468pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:173.25pt"/><td style="padding:0;width:68.25pt"/><td style="padding:0;width:68.25pt"/><td style="padding:0;width:68.25pt"/><td style="padding:0;width:45pt"/><td style="padding:0;width:45pt"/></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:173.25pt"><div><div style="line-height:8pt;position:var(--position);top:13.12pt;width:173.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(In thousands of euros)</span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:81.44999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:82.03pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:82.32pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:82.47pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:82.50999999999999pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:82.52pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . . . . . . . . . . . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:173.25pt;position:var(--position);width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.12pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.48pt;position:var(--position);text-decoration:none;white-space:pre">Year ended </span></div><div style="line-height:8pt;position:var(--position);top:13.12pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.81pt;position:var(--position);text-decoration:none;white-space:pre">December 31, </span></div><div style="line-height:8pt;position:var(--position);top:23.12pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.12pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.12pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.48pt;position:var(--position);text-decoration:none;white-space:pre">Year ended </span></div><div style="line-height:8pt;position:var(--position);top:13.12pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.81pt;position:var(--position);text-decoration:none;white-space:pre">December 31, </span></div><div style="line-height:8pt;position:var(--position);top:23.12pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.12pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:309.75pt;position:var(--position);width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.12pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.48pt;position:var(--position);text-decoration:none;white-space:pre">Year ended </span></div><div style="line-height:8pt;position:var(--position);top:13.12pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.81pt;position:var(--position);text-decoration:none;white-space:pre">December 31, </span></div><div style="line-height:8pt;position:var(--position);top:23.12pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.12pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);width:45pt"><div><div style="line-height:8pt;position:var(--position);top:3.12pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:bold;left:11.11pt;position:var(--position);text-decoration:none;white-space:pre">2024 vs </span></div><div style="line-height:8pt;position:var(--position);top:13.12pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:bold;left:15.44pt;position:var(--position);text-decoration:none;white-space:pre">2023 </span></div><div style="line-height:8pt;position:var(--position);top:23.12pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:bold;left:10.56pt;position:var(--position);text-decoration:none;white-space:pre">Change</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);width:45pt"><div><div style="line-height:8pt;position:var(--position);top:3.12pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:bold;left:11.11pt;position:var(--position);text-decoration:none;white-space:pre">2025 vs </span></div><div style="line-height:8pt;position:var(--position);top:13.12pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:bold;left:15.44pt;position:var(--position);text-decoration:none;white-space:pre">2024 </span></div><div style="line-height:8pt;position:var(--position);top:23.12pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:bold;left:10.56pt;position:var(--position);text-decoration:none;white-space:pre">Change</span></div></div></div></td></tr><tr style="height:26.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:32.25pt;width:173.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.9pt;width:173.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Net cash flows used in operating </span></div><div style="line-height:10pt;position:var(--position);top:15.4pt;width:173.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">activities </span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:41.160000000000004pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:43.470000000000006pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:44.63pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:44.92pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:45.07pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:45.150000000000006pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:45.190000000000005pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:45.21pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . . . . . . . . . . . . . . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:173.25pt;position:var(--position);top:32.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:30.71pt"></span></span><span style="left:33.34pt;position:var(--position)">(97,130)</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:32.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:25.71pt"></span></span><span style="left:28.34pt;position:var(--position)">(154,072)</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:309.75pt;position:var(--position);top:32.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:25.71pt"></span></span><span style="left:28.34pt;position:var(--position)">(161,129)</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:32.25pt;width:45pt"><div><div style="line-height:10pt;position:var(--position);top:9.14pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:22.59pt;position:var(--position)"></span><span style="left:22.59pt;position:var(--position)">59<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span><span style="left:35.92pt;position:var(--position)">%</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:32.25pt;width:45pt"><div><div style="line-height:10pt;position:var(--position);top:9.14pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:27.59pt;position:var(--position)"></span><span style="left:27.59pt;position:var(--position)">5<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span><span style="left:35.92pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:26.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:58.5pt;width:173.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.9pt;width:173.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Net cash flows (used in) provided by </span></div><div style="line-height:10pt;position:var(--position);top:15.4pt;width:173.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">investing activities </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:80.28999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:80.58pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:80.58999999999999pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . . . . . . . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:173.25pt;position:var(--position);top:58.5pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">(8,095)</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:58.5pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:34.04pt"></span></span><span style="left:36.67pt;position:var(--position)">15,762<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:309.75pt;position:var(--position);top:58.5pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">(8,193)</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:58.5pt;width:45pt"><div><div style="line-height:10pt;position:var(--position);top:9.14pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:14.26pt;position:var(--position)"></span><span style="left:14.26pt;position:var(--position)">(295)</span><span style="left:35.92pt;position:var(--position)">%</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:58.5pt;width:45pt"><div><div style="line-height:10pt;position:var(--position);top:9.14pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:14.26pt;position:var(--position)"></span><span style="left:14.26pt;position:var(--position)">(152)</span><span style="left:35.92pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:26.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:84.75pt;width:173.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.9pt;width:173.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Net cash flows provided by financing </span></div><div style="line-height:10pt;position:var(--position);top:15.4pt;width:173.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">activities</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:38.660000000000004pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:39.82pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:40.400000000000006pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:40.440000000000005pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . . . . . . . . . . . . . . . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:173.25pt;position:var(--position);top:84.75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:29.04pt"></span></span><span style="left:31.669999999999998pt;position:var(--position)">335,290<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:84.75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:34.04pt"></span></span><span style="left:36.67pt;position:var(--position)">28,207<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:309.75pt;position:var(--position);top:84.75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:29.04pt"></span></span><span style="left:31.669999999999998pt;position:var(--position)">547,307<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:84.75pt;width:45pt"><div><div style="line-height:10pt;position:var(--position);top:9.14pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:19.26pt;position:var(--position)"></span><span style="left:19.26pt;position:var(--position)">(92)</span><span style="left:35.92pt;position:var(--position)">%</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:84.75pt;width:45pt"><div><div style="line-height:10pt;position:var(--position);top:9.14pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:12.59pt;position:var(--position)"></span><span style="left:12.59pt;position:var(--position)">1840<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span><span style="left:35.92pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:26.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:111pt;width:173.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.9pt;width:173.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Effect of movements in exchange rates </span></div><div style="line-height:10pt;position:var(--position);top:15.4pt;width:173.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">on cash held</span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:52.580000000000005pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:54.89pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:55.18pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:55.330000000000005pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . . . . . . . . . . . . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:173.25pt;position:var(--position);top:111pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">(5,072)</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:111pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:39.04pt"></span></span><span style="left:41.67pt;position:var(--position)">2,382<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:309.75pt;position:var(--position);top:111pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:30.71pt"></span></span><span style="left:33.34pt;position:var(--position)">(10,251)</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:111pt;width:45pt"><div><div style="line-height:10pt;position:var(--position);top:9.14pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:14.26pt;position:var(--position)"></span><span style="left:14.26pt;position:var(--position)">(147)</span><span style="left:35.92pt;position:var(--position)">%</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:111pt;width:45pt"><div><div style="line-height:10pt;position:var(--position);top:9.14pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:14.26pt;position:var(--position)"></span><span style="left:14.26pt;position:var(--position)">(530)</span><span style="left:35.92pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:26.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:137.25pt;width:173.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.9pt;width:173.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Revaluation of cash equivalents </span></div><div style="line-height:10pt;position:var(--position);top:15.4pt;width:173.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">measured at fair value</span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:91.1pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:93.41pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:94.57pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:95.14999999999999pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:95.19pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . . . . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:173.25pt;position:var(--position);top:137.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:51.54pt"></span></span><span style="left:54.17pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:137.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:51.54pt"></span></span><span style="left:54.17pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:309.75pt;position:var(--position);top:137.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.15pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:39.04pt"></span></span><span style="left:41.67pt;position:var(--position)">4,730<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:137.25pt;width:45pt"><div><div style="line-height:10pt;position:var(--position);top:9.14pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:23.7pt;position:var(--position)"></span><span style="left:23.7pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span><span style="left:35.92pt;position:var(--position)">%</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:137.25pt;width:45pt"><div><div style="line-height:10pt;position:var(--position);top:9.14pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:23.7pt;position:var(--position)"></span><span style="left:23.7pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.94pt;width:3.33pt"></span></span><span style="left:35.92pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:26.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:163.5pt;width:173.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.98pt;width:173.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Net increase (decrease) in cash and </span></div><div style="line-height:10pt;position:var(--position);top:15.48pt;width:173.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">cash equivalents&#160; </span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:77.31pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:79.61999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:80.19999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:80.28pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:80.3pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:80.31pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . . . . . . . . . . .</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:173.25pt;position:var(--position);top:163.5pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:29.04pt"></span></span><span style="left:31.669999999999998pt;position:var(--position)">224,992<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span></span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:163.5pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:25.71pt"></span></span><span style="left:28.34pt;position:var(--position)">(107,720)</span></span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:309.75pt;position:var(--position);top:163.5pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:29.04pt"></span></span><span style="left:31.669999999999998pt;position:var(--position)">372,464<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span></span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:163.5pt;width:45pt"><div><div style="line-height:10pt;position:var(--position);top:9.23pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:14.26pt;position:var(--position)"></span><span style="left:14.26pt;position:var(--position)">(148)</span><span style="left:35.92pt;position:var(--position)">%</span></span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:163.5pt;width:45pt"><div><div style="line-height:10pt;position:var(--position);top:9.23pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:14.26pt;position:var(--position)"></span><span style="left:14.26pt;position:var(--position)">(446)</span><span style="left:35.92pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:26.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:189.75pt;width:173.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.98pt;width:173.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cash and cash equivalents at the </span></div><div style="line-height:10pt;position:var(--position);top:15.48pt;width:173.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">beginning of the period&#160; </span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:106.74pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:109.05pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:110.21pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:110.25pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . . . . .</span></div></div></div></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:173.25pt;position:var(--position);top:189.75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:34.04pt"></span></span><span style="left:36.67pt;position:var(--position)">26,950<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span></span></div></div></div></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:189.75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:29.04pt"></span></span><span style="left:31.669999999999998pt;position:var(--position)">251,942<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span></span></div></div></div></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:309.75pt;position:var(--position);top:189.75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:29.04pt"></span></span><span style="left:31.669999999999998pt;position:var(--position)">144,221<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span></span></div></div></div></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:189.75pt;width:45pt"><div><div style="line-height:10pt;position:var(--position);top:9.23pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:17.59pt;position:var(--position)"></span><span style="left:17.59pt;position:var(--position)">835<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span><span style="left:35.92pt;position:var(--position)">%</span></span></div></div></div></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:189.75pt;width:45pt"><div><div style="line-height:10pt;position:var(--position);top:9.23pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:19.26pt;position:var(--position)"></span><span style="left:19.26pt;position:var(--position)">(43)</span><span style="left:35.92pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:26.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:216pt;width:173.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.98pt;width:173.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cash and cash equivalents at the end </span></div><div style="line-height:10pt;position:var(--position);top:15.48pt;width:173.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">of the period&#160; </span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:62.03pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:64.34pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:64.92pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:65.21pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:65.25pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:65.27pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:65.28pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . . . . . . . . . . . . . .</span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:173.25pt;position:var(--position);top:216pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:29.04pt"></span></span><span style="left:31.669999999999998pt;position:var(--position)">251,942<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span></span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:216pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:29.04pt"></span></span><span style="left:31.669999999999998pt;position:var(--position)">144,221<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span></span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:309.75pt;position:var(--position);top:216pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:9.23pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:29.04pt"></span></span><span style="left:31.669999999999998pt;position:var(--position)">516,685<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span></span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:216pt;width:45pt"><div><div style="line-height:10pt;position:var(--position);top:9.23pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:19.26pt;position:var(--position)"></span><span style="left:19.26pt;position:var(--position)">(43)</span><span style="left:35.92pt;position:var(--position)">%</span></span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:216pt;width:45pt"><div><div style="line-height:10pt;position:var(--position);top:9.23pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:17.59pt;position:var(--position)"></span><span style="left:17.59pt;position:var(--position)">258<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span><span style="left:35.92pt;position:var(--position)">%</span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="line-height:10pt;position:var(--position);top:385.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Operating Activities </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:401.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);text-decoration:none;white-space:pre">, cash used in operating activities was </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:405.32pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(161.1) million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:470.83pt;position:var(--position);text-decoration:none;white-space:pre">, as compared to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:411.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(154.1) million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:137.51pt;position:var(--position);text-decoration:none;white-space:pre"> for the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:168.87pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:293.46000000000004pt;position:var(--position);text-decoration:none;white-space:pre">, a decrease of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:353.09pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;7.1 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:401.94pt;position:var(--position);text-decoration:none;white-space:pre">, or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:417.77pt;position:var(--position);text-decoration:none;white-space:pre">5%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:431.1pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:427.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);text-decoration:none;white-space:pre">, cash used in operating activities was </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:405.32pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(154.1) million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:470.83pt;position:var(--position);text-decoration:none;white-space:pre">, as compared to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:437.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(97.1) million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:132.51pt;position:var(--position);text-decoration:none;white-space:pre"> for the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:163.87pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2023</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:288.46000000000004pt;position:var(--position);text-decoration:none;white-space:pre">, an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:351.43pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(56.9) million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:411.94pt;position:var(--position);text-decoration:none;white-space:pre">, or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:427.77pt;position:var(--position);text-decoration:none;white-space:pre">59%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:446.1pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:453.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:257.18pt;position:var(--position);text-decoration:none;white-space:pre">cash u</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:282.43pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">sed in operating activities was predominantly related to </span></span></div><div style="line-height:10pt;position:var(--position);top:463.25pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">payments </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.78999999999999pt;position:var(--position);text-decoration:none;white-space:pre">for</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:124.45pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> the progression of our UC and CD trials and personnel, legal, professional and infrastructure costs </span></span></div><div style="line-height:10pt;position:var(--position);top:473.25pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">associated with operating as a du</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:203.78pt;position:var(--position);text-decoration:none;white-space:pre">al-listed public company. The increase was mostly driven by the increase in our </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:483.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">operating loss (as explained above), p</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:222.95pt;position:var(--position);text-decoration:none;white-space:pre">artly offset by changes in our working capital requirements, from &#8364;0.5 million </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:493.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for the year ended December 31, 2024 to &#8364;4.1 million for the year ended December 31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:443.02pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:509.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);text-decoration:none;white-space:pre">, cash used in operating activities is attributable to increased R&amp;D </span></div><div style="line-height:10pt;position:var(--position);top:519.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">spend driven by the progression of the UC Phase 3 clinical trial and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:344.78pt;position:var(--position);white-space:pre">the initiation of the Phase 2b CD trial, the full </span></div><div style="line-height:10pt;position:var(--position);top:529.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">year impact of increased legal and professional fees and other </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:321.11pt;position:var(--position);text-decoration:none;white-space:pre">infrastructure</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:374.92pt;position:var(--position);white-space:pre"> costs associated with operating as a </span></div><div style="line-height:10pt;position:var(--position);top:539.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">dual-listed public company</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:180.76pt;position:var(--position);text-decoration:none;white-space:pre"> and changes in working capital.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:555.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2023</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);text-decoration:none;white-space:pre">, cash used in operating activities is attributable to increased R&amp;D </span></div><div style="line-height:10pt;position:var(--position);top:565.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">spend driven by the progression of the UC Phase 3 clinical trial,</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:327.85pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:330.35pt;position:var(--position);text-decoration:none;white-space:pre">increased</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:368.06pt;position:var(--position);white-space:pre"> headcount to support the expansion of the </span></div><div style="line-height:10pt;position:var(--position);top:575.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">overall</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:99.73pt;position:var(--position);white-space:pre"> organization, including a newly created sales and marketing department, increased legal and professional </span></div><div style="line-height:10pt;position:var(--position);top:585.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">fees and other infrastructure costs associated with operating as a dual-listed public company</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:439.87pt;position:var(--position);text-decoration:none;white-space:pre"> and changes in working </span></div><div style="line-height:10pt;position:var(--position);top:595.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">capital. </span></div><div style="line-height:10pt;position:var(--position);top:623.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Investing Activities </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:645.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);text-decoration:none;white-space:pre">, cash used in investing activities was </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:404.22pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;8.2 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:453.07pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:455.57pt;position:var(--position);text-decoration:none;white-space:pre">and was mainly due </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:657.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">to an</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.7pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.2pt;position:var(--position);white-space:pre">investment in 9- and 12-month term deposits, partially offset by the interests received from our cash and cash </span></div><div style="line-height:10pt;position:var(--position);top:669.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">equivalents and short-term investments of &#8364;5.5 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:290.94pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">98</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.89pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:237.48pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:242.48pt;position:var(--position);text-decoration:none;white-space:pre">cash</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:260.23pt;position:var(--position);text-decoration:none;white-space:pre"> from investing activities was </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:380.36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;15.8&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:434.21pt;position:var(--position);text-decoration:none;white-space:pre"> and was mainly due </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:518.85pt;position:var(--position);white-space:pre">to </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">the payment of the our 6-month term </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:222.13pt;position:var(--position);text-decoration:none;white-space:pre">deposit</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:250.99pt;position:var(--position);white-space:pre"> of &#8364;9.0 million and from interests received from cash, cash equivalents </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">and short-term investments of &#8364;8.2 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:242.95pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2023</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);text-decoration:none;white-space:pre">, cash used in investing activities was </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:404.22pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;8.1 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:453.07pt;position:var(--position);text-decoration:none;white-space:pre"> and was mainly due </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to a</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:86.7pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:89.2pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;9.0 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:138.05pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.55pt;position:var(--position);text-decoration:none;white-space:pre">investment in a 6-month term deposit and the payment of additional long-term CRO advances </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">amounting to &#8364;1.6 million, partially offset by interests received amounting to &#8364;2.4 million.</span></div><div style="line-height:10pt;position:var(--position);top:150pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Financing Activities </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:166pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);text-decoration:none;white-space:pre">, cash from financing activities was </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:396.16pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;547.3 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:455.01pt;position:var(--position);text-decoration:none;white-space:pre">, which mainly </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:176pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">consisted of net proceeds from our July 2025 Nasdaq Offering of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:334.85pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;607.2</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:362.35pt;position:var(--position);text-decoration:none;white-space:pre"> million as well as cash received from </span></div><div style="line-height:10pt;position:var(--position);top:186pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">exercises of share warrants of &#8364;5.8 million, partially offset by debt repayments of &#8364;59.6 million (of which &#8364;2.1 </span></div><div style="line-height:10pt;position:var(--position);top:196pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">million related to tranche A of the Kreos / Claret Financing and &#8364;53.9 million related to tranches B and C (of which </span></div><div style="line-height:10pt;position:var(--position);top:206pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;33.8 million correspond to the full prepayment of the outstanding balance and related fees as of December 23, </span></div><div style="line-height:10pt;position:var(--position);top:216pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">2025), &#8364;2.2 million related to the Heights convertible notes and &#8364;2.5 million related to the State-guaranteed loan </span></div><div style="line-height:10pt;position:var(--position);top:226pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(Pr&#234;t garanti par l'Etat, or "PGE")), and interest payments of &#8364;6.5 million.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:242pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);text-decoration:none;white-space:pre">, cash from financing activities was </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:396.16pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;28.2 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:450.01pt;position:var(--position);text-decoration:none;white-space:pre">, which mainly </span></div><div style="line-height:10pt;position:var(--position);top:252pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">consisted of drawdowns on tranche B (in an amount of &#8364;25 million) and tranche C (in an amount of &#8364;25 million) of </span></div><div style="line-height:10pt;position:var(--position);top:262pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the senior secured non-convertible bonds from the Kreos / Claret Financing, net of disbursed transaction costs and </span></div><div style="line-height:10pt;position:var(--position);top:272pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">deposits (in an amount of &#8364;2.6 million in the aggregate), partially offset by repayments of &#8364;13.2 million (of which </span></div><div style="line-height:10pt;position:var(--position);top:282pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;8.8 million related to the Heights convertible notes and &#8364;2.7 million related to conditional advances) and interest </span></div><div style="line-height:10pt;position:var(--position);top:292pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">payments of &#8364;7.7 million.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:308pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2023</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);text-decoration:none;white-space:pre">, cash from financing activities was </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:396.16pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;335.3 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:455.01pt;position:var(--position);text-decoration:none;white-space:pre">, which consisted of </span></div><div style="line-height:10pt;position:var(--position);top:318pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">net proceeds from our offering of ordinary shares on Euronext Paris of &#8364;123.3 million (after deducting transaction </span></div><div style="line-height:10pt;position:var(--position);top:328pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">costs of &#8364;6.7&#160;million), net proceeds from our offering of ordinary shares and ADSs of &#8364;202.0 million (after </span></div><div style="line-height:10pt;position:var(--position);top:338pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">deducting transaction costs of &#8364;21.3 million) from our U.S. initial public offering and listing on Nasdaq and </span></div><div style="line-height:10pt;position:var(--position);top:348pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">concurrent private placement (after deducting transaction costs and underwriting commissions of &#8364;28.1 million), net </span></div><div style="line-height:10pt;position:var(--position);top:358pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">proceeds from the August 2023 drawdown of the first tranches of the Kreos / Claret Financing and the Heights </span></div><div style="line-height:10pt;position:var(--position);top:368pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Financing, collectively amounting to &#8364;27.2 million (net of repayments of all outstanding amounts that remained due </span></div><div style="line-height:10pt;position:var(--position);top:378pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">under the 2018 venture loan agreement with Kreos Capital ("First KC Agreement"), the 2020 bonds issue agreement </span></div><div style="line-height:10pt;position:var(--position);top:388pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">with Kreos Capital ("Second KC Agreement") and the OCEANE bonds), partially offset by repayments under the </span></div><div style="line-height:10pt;position:var(--position);top:398pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">notes issued under the First KC Agreement and Second KC Agreement (in an amount of &#8364;5.0&#160;million), PGE (in an </span></div><div style="line-height:10pt;position:var(--position);top:408pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">amount of &#8364;1.3 million) and interest paid (in an amount of &#8364;5.3 million). </span></div><div style="line-height:10pt;position:var(--position);top:430pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Material Cash Requirements </span></div><div style="line-height:10pt;position:var(--position);top:448pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Contractual Obligations and Loans </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:464pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The following table sets forth aggregate information about material contractual obligations as of</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:481pt;position:var(--position);text-decoration:none;white-space:pre"> December&#160;31, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:474pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">2025.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.5pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="line-height:10pt;position:var(--position);top:490pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The commitment amounts in the table below are associated with contracts that are enforceable and legally </span></div><div style="line-height:10pt;position:var(--position);top:500pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">binding and that specify all significant terms, including fixed or minimum services to be used, fixed, minimum or </span></div><div style="line-height:10pt;position:var(--position);top:510pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">variable price provisions, and the approximate timing of the actions under the contracts. Future events could cause </span></div><div style="line-height:10pt;position:var(--position);top:520pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">actual payments to differ from these estimates. All amounts except the retirement benefits in the table below are </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:530pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">presented gross and are </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:168.01pt;position:var(--position);text-decoration:none;white-space:pre">undiscounted</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:221.3pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><div style="line-height:12pt;position:var(--position);top:540pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="position:var(--position);top:552pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:468pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:168.75pt"/><td style="padding:0;width:99.75pt"/><td style="padding:0;width:99.75pt"/><td style="padding:0;width:99.75pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.79pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.63pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:368.25pt;position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.63pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:12pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:66.36pt;position:var(--position);text-decoration:none;white-space:pre">Less than</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:12pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:62.81pt;position:var(--position);text-decoration:none;white-space:pre">More than</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24pt;width:168.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:168.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(In thousands of euros)</span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:81.44999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:82.03pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:82.05pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:82.06pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . . . . . . . . . . . . . .</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:24pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:77.9pt;position:var(--position);text-decoration:none;white-space:pre">1 year</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:24pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:77.9pt;position:var(--position);text-decoration:none;white-space:pre">1 year</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:368.25pt;position:var(--position);top:24pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:80.79pt;position:var(--position);text-decoration:none;white-space:pre">Total</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:36pt;width:168.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:168.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Lease obligations</span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:72.81pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:75.11999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:75.69999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:75.78pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:75.8pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:75.81pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . . . . . . . . . . .</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:36pt;width:99.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:70.54pt"></span></span><span style="left:73.17pt;position:var(--position)">1,340<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:36pt;width:99.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:78.04pt"></span></span><span style="left:80.67pt;position:var(--position)">566<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:368.25pt;position:var(--position);top:36pt;width:99.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:70.54pt"></span></span><span style="left:73.17pt;position:var(--position)">1,906<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:50.25pt;width:168.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:168.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Retirement benefits</span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:81.11pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:81.11999999999999pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . . . . . . . . . .</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:50.25pt;width:99.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:83.04pt"></span></span><span style="left:85.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:50.25pt;width:99.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:78.04pt"></span></span><span style="left:80.67pt;position:var(--position)">627<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:368.25pt;position:var(--position);top:50.25pt;width:99.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:78.04pt"></span></span><span style="left:80.67pt;position:var(--position)">627<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:64.5pt;width:168.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:168.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Off-balance sheet obligations</span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:120.25pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:120.83pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:120.97999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:121.02pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:121.03999999999999pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:121.05pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . .</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:64.5pt;width:99.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:60.54pt"></span></span><span style="left:63.17pt;position:var(--position)">205,131<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:64.5pt;width:99.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:83.04pt"></span></span><span style="left:85.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:368.25pt;position:var(--position);top:64.5pt;width:99.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:60.54pt"></span></span><span style="left:63.17pt;position:var(--position)">205,131<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:168.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:168.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total</span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:25.39pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:25.97pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:26.05pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:26.06pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . . . . . . . . . . . . . . . . . . . . .</span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:78.75pt;width:99.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:60.54pt"></span></span><span style="left:63.17pt;position:var(--position)">206,471<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span></span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:78.75pt;width:99.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:70.54pt"></span></span><span style="left:73.17pt;position:var(--position)">1,193<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span></span></div></div></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:368.25pt;position:var(--position);top:78.75pt;width:99.75pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:60.54pt"></span></span><span style="left:63.17pt;position:var(--position)">207,664<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="line-height:10pt;position:var(--position);top:668pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In the ordinary course of our business, we regularly use the services of subcontractors and enter into research </span></div><div style="line-height:10pt;position:var(--position);top:678pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and partnership arrangements with various CROs and with public-sector partners or subcontractors, who conduct </span></div><div style="line-height:10pt;position:var(--position);top:688pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">clinical trials and studies in relation to the drug candidates. Off-balance sheet obligations in the table above are </span></div><div style="line-height:10pt;position:var(--position);top:698pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">commitments related to these research and partnership agreements. They are classified at less than one year maturity </span></div><div style="line-height:10pt;position:var(--position);top:708pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">in the absence of a fixed schedule in contracts, in case of multiple-year contracts, such as CRO contracts. CRO </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301pt;position:var(--position);text-decoration:none;white-space:pre">99</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">contracts include payments that are conditional to the completion of future development milestones. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:474.26pt;position:var(--position);white-space:pre">The majority of </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">the commitments with our CROs are cancellable under certain circumstances such as insolvency, study put on hold </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">by competent authorities, breach in regulations or negligence in the provision of the services.</span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our material cash requirements in the above table do not include potential future royalty payments related to </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the royalty certificates, amounting to 2% of the future net sales of obefazimod (worldwide and for all indications). </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The amount of royalties that may be paid under the royalty certificates is capped at &#8364;172.0 million in the aggregate. </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Royalty payments are expected to take place before the expiry date of the certificates, which is 15 years after their </span></div><div style="line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">issuance date (September 2, 2037). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:164pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:199.48000000000002pt;position:var(--position);text-decoration:none;white-space:pre">, our contractual obligations</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:311.57pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:314.07pt;position:var(--position);text-decoration:none;white-space:pre">were </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:335.98pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;207.7 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:394.83pt;position:var(--position);text-decoration:none;white-space:pre"> comprising off-balance sheet </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:174pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">obligations of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.73pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;205.1 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:188.57999999999998pt;position:var(--position);text-decoration:none;white-space:pre"> with respect to purchase obligations, lease obligations of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:419.98pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1.9 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:468.83pt;position:var(--position);white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:488.26pt;position:var(--position);text-decoration:none;white-space:pre">retirement </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:184pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">benefits obligations of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:163.85pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.6 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:212.7pt;position:var(--position);white-space:pre">.</span></div><div style="line-height:10pt;position:var(--position);top:212pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Operating Capital and Capital Expenditures Requirements </span></div><div style="line-height:10pt;position:var(--position);top:228pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We have incurred substantial operating losses since inception and expect to continue to incur significant </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:238pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">operating losses for the foreseeable future and may never become profitable. For the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:411.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:536.1800000000001pt;position:var(--position);text-decoration:none;white-space:pre">, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:248pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">we recorded a net loss of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:174.11pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;336.1 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:232.96pt;position:var(--position);white-space:pre">. Until such time as we can generate significant revenue from product sales, </span></div><div style="line-height:10pt;position:var(--position);top:258pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">if ever, we expect to continue to finance our operations from the sale of additional equity or debt financings, or other </span></div><div style="line-height:10pt;position:var(--position);top:268pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">capital which comes in the form of strategic collaborations, licensing, or other arrangements.</span></div><div style="line-height:10pt;position:var(--position);top:290pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our present and future funding requirements will depend on many factors, including, among other things: </span></div><div style="line-height:10pt;position:var(--position);top:306pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the size, progress, timing, and completion of our preclinical studies and clinical trials; </span></span></div><div style="line-height:10pt;position:var(--position);top:322pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the number of potential new drug candidates we identify and decide to develop; </span></span></div><div style="line-height:10pt;position:var(--position);top:338pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the costs involved in filing patent applications and maintaining and enforcing patents or defending </span></span></div><div style="line-height:10pt;position:var(--position);top:348pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">against claims or infringements raised by third parties; </span></div><div style="line-height:10pt;position:var(--position);top:364pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the time and costs involved in obtaining regulatory approval for our drug candidates and any delays we </span></span></div><div style="line-height:10pt;position:var(--position);top:374pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">may encounter as a result of evolving regulatory requirements or adverse results with respect to any of </span></div><div style="line-height:10pt;position:var(--position);top:384pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">these drug candidates; </span></div><div style="line-height:1pt;position:var(--position);top:398.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="line-height:10pt;position:var(--position);top:399.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">selling and marketing activities undertaken in connection with the anticipated commercialization of </span></span></div><div style="line-height:10pt;position:var(--position);top:409.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">obefazimod and any other current or future drug candidates and costs involved in the creation of an </span></div><div style="line-height:10pt;position:var(--position);top:419.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">effective sales and marketing organization; </span></div><div style="line-height:10pt;position:var(--position);top:435.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the amount of revenue, if any, we may derive either directly or in the form of milestones or royalty </span></span></div><div style="line-height:10pt;position:var(--position);top:445.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">payments from our existing or future partnership or collaboration agreements; and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:461.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the severity, duration and impact of the Russia/Ukraine war, which may continue to adversely impact </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:471.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">our business and clinical trials. </span></div><div style="line-height:10pt;position:var(--position);top:487.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">See </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.42pt;position:var(--position);white-space:pre">&#8220;Risk Factors&#8212;Risks Related to our Financial Position and Need for Additional Capital&#8221; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:472.46pt;position:var(--position);text-decoration:none;white-space:pre">for additional </span></div><div style="line-height:10pt;position:var(--position);top:499.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">risks associated with our substantial capital requirements.</span></div><div style="position:absolute;top:535.5pt" id="i7a006daedb3d4216a4128b76247285d7_70"></div><div style="line-height:10pt;position:var(--position);top:535.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">C.<span id="i9d1dddbd5b10423f946f510d0d639e80"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Research and Development, Patents and Licenses, Etc.</span></div><div style="line-height:10pt;position:var(--position);top:565.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:110.39pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.89pt;position:var(--position);text-decoration:none;white-space:pre">a</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:117.32pt;position:var(--position);white-space:pre"> discussion of our research and development activities, see &#8220;Item 4.B&#8212;Business Overview&#8221; and &#8220;Item </span></div><div style="line-height:10pt;position:var(--position);top:575.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">5.A&#8212;Operating Results.&#8221;</span></div><div style="position:absolute;top:609.5pt" id="i7a006daedb3d4216a4128b76247285d7_73"></div><div style="line-height:10pt;position:var(--position);top:609.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">D.<span id="i8af0d4819c7548b9b8199cd314b3c4ad"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Trend Information</span></div><div style="line-height:10pt;position:var(--position);top:639.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:110.39pt;position:var(--position);white-space:pre"> a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:119.82pt;position:var(--position);text-decoration:none;white-space:pre">discussion</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:161.45999999999998pt;position:var(--position);white-space:pre"> of trends, see &#8220;Item 4.B&#8212;Business Overview,&#8221; &#8220;Item 5.A&#8212;Operating Results&#8221; and &#8220;Item </span></div><div style="line-height:10pt;position:var(--position);top:649.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">5.B&#8212;Liquidity and Capital Resources.&#8221;</span></div><div style="position:absolute;top:683.5pt" id="i7a006daedb3d4216a4128b76247285d7_76"></div><div style="line-height:10pt;position:var(--position);top:683.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">E.<span id="i0a15636973f9497dae804e84cd8afa72"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Critical Accounting Estimates</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">100</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our audited financial statements as of, and for the years ended, D</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:358.13pt;position:var(--position);text-decoration:none;white-space:pre">ecember 31, 2025, 2024 and 2023 were </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">prepared in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;), as issued by the International </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Accounting Standards Board (&#8220;IASB&#8221;), and IFRS as adopted by the European Union ("EU") regulation n&#176;1606/2022 </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of July 19, 2022.</span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">A description of accounting policies and estimates along with a description of the recently-issued accounting </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">pronouncements that may potentially impact our financial position and results of operations is disclosed in Notes 4 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and 2 respectively to our financial statements as of and for the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:322.8pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:447.39pt;position:var(--position);text-decoration:none;white-space:pre">, appearing elsewhere </span></div><div style="line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">in this Annual Report on Form 20-F. We</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:235.22pt;position:var(--position);white-space:pre"> applied the amendment to IAS 21 The Effects of Changes in Foreign </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">Exchange Rates &#8211; Lack of Exchangeability that is effective as of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:332.46pt;position:var(--position);text-decoration:none;white-space:pre">December&#160;31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:411pt;position:var(--position);white-space:pre">.</span></div><div style="line-height:10pt;position:var(--position);top:174pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We did not have to change our accounting policies or make retrospective adjustments as a result of adopting </span></div><div style="line-height:10pt;position:var(--position);top:184pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">this standard.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:125.28pt;position:var(--position);white-space:pre"> The impacts resulting from the application of this amendment are described in N</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:450.15pt;position:var(--position);text-decoration:none;white-space:pre">ote 2 to our financial </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:194pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">statements as of and for the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:184.09pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:308.68pt;position:var(--position);text-decoration:none;white-space:pre">, appearing elsewhere in this Annual Report on Form 20-</span></div><div style="line-height:10pt;position:var(--position);top:204pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">F.</span></div><div style="line-height:10pt;position:var(--position);top:220pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);text-decoration:none;white-space:pre">We did not elect for early application of the new standards, amendments and interpretations, which were </span></div><div style="line-height:10pt;position:var(--position);top:230pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">issued but not mandatory as of December 31, 2025. Our assessment of the impacts resulting from the application of </span></div><div style="line-height:10pt;position:var(--position);top:240pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">these recently issued accounting pronouncements is described in Note 2 to our financial statements as of and for the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:250pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:196.59pt;position:var(--position);text-decoration:none;white-space:pre">, appearing elsewhere in this Annual Report on Form 20-F.</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">101</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_82"></div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">Item 6.<span style="display:inline-block;height:6.77pt;width:6.02pt"></span></span><span style="left:108pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:36pt"></span></span><span style="left:144pt;position:var(--position)">Directors, Senior Management and Employees</span><span id="i96a97c7e6faa4dd0bc0a9cfd7a05f587"></span></span></div><div style="position:absolute;top:96pt" id="i7a006daedb3d4216a4128b76247285d7_85"></div><div style="line-height:10pt;position:var(--position);top:96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">A.<span id="ic117f197052c4425a5860d254f5becc6"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Directors and Senior Management</span></div><div style="line-height:10pt;position:var(--position);top:114pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The following table sets forth the name, age and position of each of our executive officers and directors as of </span></div><div style="line-height:10pt;position:var(--position);top:124pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the date of this Annual Report on Form 20-F. The business address of our executive officers and directors is our </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:134pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">principal executive offices located at 7-11 boulevard Haussmann, 75009 Paris, France</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:416.05pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><div style="line-height:12pt;position:var(--position);top:144pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="position:var(--position);top:156pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:465pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:137.25pt"/><td style="padding:0;width:43.5pt"/><td style="padding:0;width:284.25pt"/></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:137.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.83pt;width:137.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:underline;white-space:pre">Name</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:137.25pt;position:var(--position);width:43.5pt"><div><div style="line-height:10pt;position:var(--position);top:3.83pt;width:43.5pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:13.42pt;position:var(--position);text-decoration:underline;white-space:pre">Age</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:180.75pt;position:var(--position);width:284.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.83pt;width:284.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:119.64pt;position:var(--position);text-decoration:underline;white-space:pre">Position(s)</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:14.25pt;width:137.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:137.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Executive Officers</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:137.25pt;position:var(--position);top:14.25pt;width:43.5pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:180.75pt;position:var(--position);top:14.25pt;width:284.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:284.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:6pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:28.5pt;width:137.25pt"><div><div style="line-height:1pt;position:var(--position);top:3.11pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:137.25pt;position:var(--position);top:28.5pt;width:43.5pt"><div><div style="line-height:1pt;position:var(--position);top:3.11pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:180.75pt;position:var(--position);top:28.5pt;width:284.25pt"><div><div style="line-height:1pt;position:var(--position);top:3.11pt;width:284.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:34.5pt;width:137.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:137.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Marc de Garidel</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:68.08999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:69.25pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:69.39999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:69.47999999999999pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:69.49pt;position:var(--position);text-decoration:none;white-space:pre">..........................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:137.25pt;position:var(--position);top:34.5pt;width:43.5pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:16.75pt;position:var(--position);text-decoration:none;white-space:pre">68</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:180.75pt;position:var(--position);top:34.5pt;width:284.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:284.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);white-space:pre">Chief Executive Officer and Director</span></div></div></div></td></tr><tr style="height:26.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:48.75pt;width:137.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:137.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Didier Blondel</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:62.28pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:63.440000000000005pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:64.02pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:64.31pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:64.39pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:64.41pt;position:var(--position);text-decoration:none;white-space:pre">............................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:137.25pt;position:var(--position);top:48.75pt;width:43.5pt"><div><div style="line-height:10pt;position:var(--position);top:15.67pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:16.75pt;position:var(--position);text-decoration:none;white-space:pre">63</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:180.75pt;position:var(--position);top:48.75pt;width:284.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:284.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);white-space:pre">Executive Vice President, Chief Financial Officer and Board </span></div><div style="line-height:10pt;position:var(--position);top:15.13pt;width:284.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);white-space:pre">Secretary</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:75pt;width:137.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:137.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Fabio Cataldi</span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:56.720000000000006pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:57.010000000000005pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:57.09pt;position:var(--position);text-decoration:none;white-space:pre">...............................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:137.25pt;position:var(--position);top:75pt;width:43.5pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:16.75pt;position:var(--position);text-decoration:none;white-space:pre">59</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:180.75pt;position:var(--position);top:75pt;width:284.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:284.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Chief Medical Officer</span></div></div></div></td></tr><tr style="height:6pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:89.25pt;width:137.25pt"><div><div style="line-height:1pt;position:var(--position);top:3.11pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:137.25pt;position:var(--position);top:89.25pt;width:43.5pt"><div><div style="line-height:1pt;position:var(--position);top:3.11pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:21.62pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:180.75pt;position:var(--position);top:89.25pt;width:284.25pt"><div><div style="line-height:1pt;position:var(--position);top:3.11pt;width:284.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:95.25pt;width:137.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:137.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Directors*</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:137.25pt;position:var(--position);top:95.25pt;width:43.5pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:20.5pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:180.75pt;position:var(--position);top:95.25pt;width:284.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:284.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:6pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:109.5pt;width:137.25pt"><div><div style="line-height:1pt;position:var(--position);top:3.11pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:137.25pt;position:var(--position);top:109.5pt;width:43.5pt"><div><div style="line-height:1pt;position:var(--position);top:3.11pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:21.62pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:180.75pt;position:var(--position);top:109.5pt;width:284.25pt"><div><div style="line-height:1pt;position:var(--position);top:3.11pt;width:284.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:26.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:115.5pt;width:137.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:137.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Sylvie Gr&#233;goire</span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:66.17pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:66.75pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:66.89999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:66.97999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:67.02pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:67.03999999999999pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:67.05pt;position:var(--position);text-decoration:none;white-space:pre">...........................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:137.25pt;position:var(--position);top:115.5pt;width:43.5pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:16.75pt;position:var(--position);text-decoration:none;white-space:pre">64</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:180.75pt;position:var(--position);top:115.5pt;width:284.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:284.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Board Chair, Independent Director, Chair of the Nomination and </span></div><div style="line-height:10pt;position:var(--position);top:15.13pt;width:284.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Governance Committee, Member of the Audit Committee</span></div></div></div></td></tr><tr style="height:26.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:141.75pt;width:137.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:137.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">June Lee</span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:38.410000000000004pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:38.99pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:39.28pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:39.43pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:39.510000000000005pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.52pt;position:var(--position);text-decoration:none;white-space:pre">......................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:137.25pt;position:var(--position);top:141.75pt;width:43.5pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:16.75pt;position:var(--position);text-decoration:none;white-space:pre">60</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:180.75pt;position:var(--position);top:141.75pt;width:284.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:284.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Independent Director, Chair of the Remuneration Committee, Chair </span></div><div style="line-height:10pt;position:var(--position);top:15.13pt;width:284.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">of the Science and Clinical Committee</span></div></div></div></td></tr><tr style="height:26.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:168pt;width:137.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:137.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Troy Ignelzi</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:52.29pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:53.45pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:54.03pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:54.32pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:54.400000000000006pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.410000000000004pt;position:var(--position);text-decoration:none;white-space:pre">................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:137.25pt;position:var(--position);top:168pt;width:43.5pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:16.75pt;position:var(--position);text-decoration:none;white-space:pre">58</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:180.75pt;position:var(--position);top:168pt;width:284.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:284.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Independent Director, Chair of the Audit Committee, Member of the </span></div><div style="line-height:10pt;position:var(--position);top:15.13pt;width:284.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Remuneration Committee</span></div></div></div></td></tr><tr style="height:26.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:194.25pt;width:137.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:137.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Corinna zur Bonsen-Thomas</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:118.08pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:119.24pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:119.39pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:119.47pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:119.49pt;position:var(--position);text-decoration:none;white-space:pre">......</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:137.25pt;position:var(--position);top:194.25pt;width:43.5pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:16.75pt;position:var(--position);text-decoration:none;white-space:pre">66</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:180.75pt;position:var(--position);top:194.25pt;width:284.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:284.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Independent Director, Member of the Audit Committee, Member of </span></div><div style="line-height:10pt;position:var(--position);top:15.13pt;width:284.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Nomination and Governance Committee</span></div></div></div></td></tr><tr style="height:38.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:220.5pt;width:137.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:137.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Camilla Soenderby</span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:79.47999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:79.56pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:79.6pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:79.61999999999999pt;position:var(--position);text-decoration:none;white-space:pre">......................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:137.25pt;position:var(--position);top:220.5pt;width:43.5pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:16.75pt;position:var(--position);text-decoration:none;white-space:pre">54</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:180.75pt;position:var(--position);top:220.5pt;width:284.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.67pt;width:284.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Independent Director, Chair of the Commercial Committee, Member </span></div><div style="line-height:10pt;position:var(--position);top:15.17pt;width:284.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">of the Remuneration Committee, Member of the Science and Clinical </span></div><div style="line-height:10pt;position:var(--position);top:27.67pt;width:284.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Committee, Member of the Nomination and Governance Committee</span></div></div></div></td></tr><tr style="height:26.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:258.75pt;width:137.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Dominik H&#246;chli</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:67.85pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:69.00999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:69.3pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:69.44999999999999pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:69.46pt;position:var(--position);text-decoration:none;white-space:pre">..........................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:137.25pt;position:var(--position);top:258.75pt;width:43.5pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:16.75pt;position:var(--position);text-decoration:none;white-space:pre">58</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:180.75pt;position:var(--position);top:258.75pt;width:284.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.17pt;width:284.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Independent Director, Member of the Science and Clinical </span></div><div style="line-height:10pt;position:var(--position);top:15.67pt;width:284.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Committee, Member of the Commercial Committee</span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:446pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:468pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:468pt"/></tr><tr style="height:12.75pt"><td style="border-bottom:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:468pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:468pt"><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:5.38pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr></tbody></table></div></div></div><div style="line-height:10pt;position:var(--position);top:463.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:71.95pt;position:var(--position)">*<span style="display:inline-block;height:6.94pt;width:7.25pt"></span></span><span style="left:84.2pt;position:var(--position)">Independence criteria assessed in accordance with the definition provided in the Middlenext Code of Corporate </span></span></div><div style="line-height:10pt;position:var(--position);top:475.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:84.2pt;position:var(--position);text-decoration:none;white-space:pre">Governance</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:133.03pt;position:var(--position);white-space:pre">. Marc de Garidel is also a director but is listed with the Executive Officers.</span></div><div style="line-height:10pt;position:var(--position);top:504.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Executive Officers </span></div><div style="line-height:10pt;position:var(--position);top:520.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Marc de Garidel</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:167.51pt;position:var(--position);text-decoration:none;white-space:pre"> has served as our Chief Executive Officer since May 5, 2023 and Interim Chairman of the </span></div><div style="line-height:10pt;position:var(--position);top:530.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Board from May 5, 2023 to July 2024. He is currently the Chief Executive Officer and member of our Board and has </span></div><div style="line-height:10pt;position:var(--position);top:540.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">more than 40 years of experience in the pharmaceutical and biotechnology sector, including 12 years of experience </span></div><div style="line-height:10pt;position:var(--position);top:550.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">as Chief Executive Officer of pharmaceutical and biotechnology companies. Between July 2021 and April 2023, he </span></div><div style="line-height:10pt;position:var(--position);top:560.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">served as Chief Executive Officer of CinCor Pharma and led its successful sale for up to $1.8&#160;billion, subject to the </span></div><div style="line-height:10pt;position:var(--position);top:570.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">achievement of certain milestones, to AstraZeneca in February 2023. Between September 2020 and May 2021, </span></div><div style="line-height:10pt;position:var(--position);top:580.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Mr.&#160;de Garidel served as Chief Executive Officer of AZTherapies. From April&#160;2018 until August 2020, he was Chief </span></div><div style="line-height:10pt;position:var(--position);top:590.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Executive Officer of Corvidia Therapeutics and led its sale to Novo Nordisk for $2.1 billion in total consideration. </span></div><div style="line-height:10pt;position:var(--position);top:600.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Mr. de Garidel was the Chief Executive Officer of Ipsen between November 2010 and July 2016, overseeing the </span></div><div style="line-height:10pt;position:var(--position);top:610.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">development of its U.S. presence. Prior to that, he worked for Amgen and Eli Lilly in jobs of increasing </span></div><div style="line-height:10pt;position:var(--position);top:620.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">responsibilities and in various markets, including the United States and Europe. Mr. de Garidel has served as </span></div><div style="line-height:10pt;position:var(--position);top:630.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">chairman of the board of directors of Ipsen since 2010 and has been a member of the board of directors of Claris Bio </span></div><div style="line-height:10pt;position:var(--position);top:640.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">since 2020. He holds a degree in Civil Engineering from the Ecole des Travaux Publics in Paris, a Master&#8217;s degree </span></div><div style="line-height:10pt;position:var(--position);top:650.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">in International Management from Thunderbird Global School Management and an executive MBA from Harvard </span></div><div style="line-height:10pt;position:var(--position);top:660.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Business School. We believe that Mr. de Garidel is qualified to serve on our Board because of his experience as an </span></div><div style="line-height:10pt;position:var(--position);top:670.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">executive and member of the boards of companies in the life sciences industry. </span></div><div style="line-height:10pt;position:var(--position);top:686.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Didier Blondel</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.93pt;position:var(--position);text-decoration:none;white-space:pre"> has served as our Executive Vice President, Chief Financial Officer and Board Secretary since </span></div><div style="line-height:10pt;position:var(--position);top:696.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">January 2017. From January 2012 to December 2016, he was Chief Financial Officer at Sanofi Pasteur MSD, a </span></div><div style="line-height:10pt;position:var(--position);top:706.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Lyon-based joint-venture between Sanofi and Merck and a European leader in human vaccines. Prior to that, over a </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">102</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">20-year period, Mr.&#160;Blondel held a wide range of senior finance positions at Sanofi, in Commercial Operations and </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">then research and development, where he became global research and development Chief Financial Officer. He </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">started his career as an auditor at PricewaterhouseCoopers, after graduating with a Master&#8217;s degree in Business and </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Administration from the Commercial Institute of Nancy, a leading French business school. Mr.&#160;Blondel also holds a </span></div><div style="line-height:10pt;position:var(--position);top:112pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Master&#8217;s degree in Finance and Accounting from Nancy II University, as well as a Graduate Diploma in Finance and </span></div><div style="line-height:10pt;position:var(--position);top:122pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Accounting. </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Fabio Cataldi</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.07999999999998pt;position:var(--position);text-decoration:none;white-space:pre"> has served as our Chief Medical Officer since July 2024. Dr. Cataldi has over 20 years of </span></div><div style="line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">experience in the development and commercialization of innovative therapies. He brings deep clinical, medical and </span></div><div style="line-height:10pt;position:var(--position);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">scientific knowledge and expertise in immunology and gastroenterology, having served in senior research and </span></div><div style="line-height:10pt;position:var(--position);top:168pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">development roles at Arena Pharmaceuticals, AbbVie, Shire, Pfizer, Biogen and Novartis. Most recently, he held the </span></div><div style="line-height:10pt;position:var(--position);top:178pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">role of CMO at Landos Biopharma until the successful sale to AbbVie. Dr. Cataldi currently manages our clinical </span></div><div style="line-height:10pt;position:var(--position);top:188pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">operations, clinical development, pharmacovigilance and medical affairs. Dr. Cataldi holds an M.D. in Medicine and </span></div><div style="line-height:10pt;position:var(--position);top:198pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Surgery from the Seconda Universit&#224; degli Studi di Napoli.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:220pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Directors</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:111.93pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="line-height:10pt;position:var(--position);top:236pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Sylvie Gr&#233;goire</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:162.79000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> has served as Chair of our Board and independent director since July 2024.&#160; Dr. Gr&#233;goire is a </span></div><div style="line-height:10pt;position:var(--position);top:246pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">distinguished pharmaceutical and biotech executive with over 30 years in international leadership roles. Her </span></div><div style="line-height:10pt;position:var(--position);top:256pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">expertise encompasses late-stage development, financial raises and commercial expansion. Dr. Gr&#233;goire is the Co-</span></div><div style="line-height:10pt;position:var(--position);top:266pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Founder and was Executive Chair of the Board at EIP Pharma Inc., based in Boston, MA. Under her leadership, EIP </span></div><div style="line-height:10pt;position:var(--position);top:276pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Pharma transitioned into CervoMed, a publicly listed company on NASDAQ (CRVO), developing the first disease-</span></div><div style="line-height:10pt;position:var(--position);top:286pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">modifying treatment for Dementia with Lewy Bodies. Dr. Gr&#233;goire has previously served on the board of Cubist, </span></div><div style="line-height:10pt;position:var(--position);top:296pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Glycofi, Vifor Pharma, Revvity, Novo Nordisk and chaired the board of IDM Pharma, Corvidia and CervoMed. Dr. </span></div><div style="line-height:10pt;position:var(--position);top:306pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Gr&#233;goire is currently a member of the board of CervoMed and F2G Ltd. Dr. Gr&#233;goire holds a Science College </span></div><div style="line-height:10pt;position:var(--position);top:316pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">degree from S&#233;minaire de Sherbrooke in Canada, a BA in Pharmacy from Laval University in Canada, and a </span></div><div style="line-height:10pt;position:var(--position);top:326pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Pharmacy Doctorate degree from the State University of New York at Buffalo. We believe that Dr. Gr&#233;goire is </span></div><div style="line-height:10pt;position:var(--position);top:336pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">qualified to serve on our Board because of her experience as an executive and member of the boards of companies in </span></div><div style="line-height:10pt;position:var(--position);top:346pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the life sciences industry. </span></div><div style="line-height:10pt;position:var(--position);top:362pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">June Lee</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:135.07pt;position:var(--position);text-decoration:none;white-space:pre"> has served as one of our independent directors since July 2023. Dr. Lee has served as a venture </span></div><div style="line-height:10pt;position:var(--position);top:372pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">partner at 5AM Venture Management, LLC since July 2022. Dr. Lee was most recently Founder and Chief </span></div><div style="line-height:10pt;position:var(--position);top:382pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Executive Officer of Esker Therapeutics until September 2021. Dr. Lee previously served as the Executive Vice </span></div><div style="line-height:10pt;position:var(--position);top:392pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">President and Chief Development Officer of MyoKardia, Inc. from January 2019 to June 2020, and was the Chief </span></div><div style="line-height:10pt;position:var(--position);top:402pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Operating Officer from February 2017 until January 2019, and the Chief Development Officer from October 2017 to </span></div><div style="line-height:10pt;position:var(--position);top:412pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">January 2019. From April 2011 until February 2017, Dr. Lee served on the faculty of the University of California, </span></div><div style="line-height:10pt;position:var(--position);top:422pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">San Francisco, or UCSF, where she was director of the Catalyst program at the Clinical and Translational Science </span></div><div style="line-height:10pt;position:var(--position);top:432pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Institute and a professor in the School of Medicine, and was responsible for overall strategy and operations for </span></div><div style="line-height:10pt;position:var(--position);top:442pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">enabling and supporting translational research at the university. Catalyst is an internal UCSF accelerator for </span></div><div style="line-height:10pt;position:var(--position);top:452pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">therapeutics, devices, diagnostics, and digital health technologies. Prior to UCSF, Dr. Lee was a disease area lead, </span></div><div style="line-height:10pt;position:var(--position);top:462pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">early clinical development, at Genentech, Inc. from 2006 to 2011, where she was responsible for all strategy and </span></div><div style="line-height:10pt;position:var(--position);top:472pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">activities as well as management of staff, budget, and resource allocation in the early clinical development group in </span></div><div style="line-height:10pt;position:var(--position);top:482pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">multiple therapeutic areas. Dr. Lee served as a Medical Director in the clinical development group at Genentech, Inc. </span></div><div style="line-height:10pt;position:var(--position);top:492pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">from 2004 to 2006, where she was responsible for clinical activities for licensed product of the company. She </span></div><div style="line-height:10pt;position:var(--position);top:502pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">currently serves on Johns Hopkins University Center for Therapeutic Translation&#8217;s Advisory Board, serves on the </span></div><div style="line-height:10pt;position:var(--position);top:512pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">board of directors of Tenaya Therapeutics Inc, Eledon Pharmaceuticals Inc. and GenEdit, is a member of the </span></div><div style="line-height:10pt;position:var(--position);top:522pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Scientific Advisory Board for Foresite Labs, and previously served as a member of the board of directors of CinCor </span></div><div style="line-height:10pt;position:var(--position);top:532pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Pharma, Inc. and Renasant Bio. Dr. Lee holds a B.A. in chemistry from Johns Hopkins University and an M.D. from </span></div><div style="line-height:10pt;position:var(--position);top:542pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the University of California, Davis. We believe that Dr.&#160;Lee is qualified to serve on our Board because of her </span></div><div style="line-height:10pt;position:var(--position);top:552pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">experience as an investor and member of the boards of companies in the life sciences industry. </span></div><div style="line-height:10pt;position:var(--position);top:568pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Troy Ignelzi</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:148.94pt;position:var(--position);text-decoration:none;white-space:pre"> has served as one of our independent directors since July 2023. Mr. Ignelzi has served as the </span></div><div style="line-height:10pt;position:var(--position);top:578pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Chief Financial Officer of Rapport Therapeutics, Inc. since October 2023. Prior to that, Mr. Ignelzi served as the </span></div><div style="line-height:10pt;position:var(--position);top:588pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Chief Financial Officer of Karuna Therapeutics, Inc. from March 2019 to October 2023 until its sale to Bristol </span></div><div style="line-height:10pt;position:var(--position);top:598pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Myers Squibb. Prior to his position at Karuna Therapeutics, Mr. Ignelzi was the Chief Financial Officer of </span></div><div style="line-height:10pt;position:var(--position);top:608pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">scPharmaceuticals Inc. from March 2016 to February 2019, and provided consulting services to scPharmaceuticals </span></div><div style="line-height:10pt;position:var(--position);top:618pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Inc. in February and March 2016. Mr. Ignelzi previously served as Chief Financial Officer and as a member of the </span></div><div style="line-height:10pt;position:var(--position);top:628pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">executive leadership teams at Juventas Therapeutics Inc., a privately held biotechnology company, from October </span></div><div style="line-height:10pt;position:var(--position);top:638pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">2014 to February 2016. From October 2013 to October 2014, Mr. Ignelzi served as Senior Vice President&#8212;</span></div><div style="line-height:10pt;position:var(--position);top:648pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Operations and Business Development of Pharmalex GmbH. Prior to Pharmalex, Mr. Ignelzi was Vice President&#8212;</span></div><div style="line-height:10pt;position:var(--position);top:658pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Business Development at Esperion Therapeutics, Inc., a public pharmaceutical company, from January 2009 to </span></div><div style="line-height:10pt;position:var(--position);top:668pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">September 2013. Mr. Ignelzi served as Vice President, Business Development &amp; Strategic Planning at Insys </span></div><div style="line-height:10pt;position:var(--position);top:678pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Therapeutics, Inc., a specialty pharmaceutical company, from February 2007 to February 2009. Previously, Mr. </span></div><div style="line-height:10pt;position:var(--position);top:688pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Ignelzi had served as a specialty senior sales representative at Eli Lilly from February 2002 to August 2005. Mr. </span></div><div style="line-height:10pt;position:var(--position);top:698pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Ignelzi currently serves as a member of the board of directors of Contineum Therapeutics, Inc. and previously </span></div><div style="line-height:10pt;position:var(--position);top:708pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">served as a member of the board of directors of CinCor Pharma, Inc. and Vedanta Biosciences, Inc. Mr. Ignelzi has a </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">103</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">B.S. in accounting from Ferris State University. We believe that Mr. Ignelzi is qualified to serve on our Board </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">because of his experience as an executive and member of the boards of companies in the life sciences industry. </span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Corinna zur Bonsen-Thomas </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:222.82999999999998pt;position:var(--position);text-decoration:none;white-space:pre">served as our Chair between August 2022 and May 2023 and has served as one </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of our independent directors since June 2017. Since April 2020, Ms. zur Bonsen-Thomas has held the position of </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Managing Director and Chief Executive Officer of RetInSight GmbH, a company which she co-founded in </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">April&#160;2020 and specializes in ophthalmic imaging. Ms. zur Bonsen-Thomas was General Counsel for Smart </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Reporting GmbH from February 2017 to December 2022. From 1999 to 2015, she served as a member of the </span></div><div style="line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Supervisory Board of Baxter AG, an Austrian company. She has more than thirty years of international professional </span></div><div style="line-height:10pt;position:var(--position);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">experience in the pharmaceutical, biopharmaceutical, medical and biotechnology industries. Ms. zur Bonsen-</span></div><div style="line-height:10pt;position:var(--position);top:168pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Thomas received her First Law State Examination from Ludwig Maximilian Universitaet and her Second Law State </span></div><div style="line-height:10pt;position:var(--position);top:178pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Examination from the Bavarian Ministry of Justice. We believe that Ms. zur Bonsen-Thomas is qualified to serve on </span></div><div style="line-height:10pt;position:var(--position);top:188pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">our Board because of her extensive professional experience in the life sciences industry. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:204pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Camilla S</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:138.42000000000002pt;position:var(--position);text-decoration:none;white-space:pre">oenderby</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:178.39pt;position:var(--position);text-decoration:none;white-space:pre"> has served as one of our independent directors since March 2024. She brings 25 years of </span></div><div style="line-height:10pt;position:var(--position);top:214pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">international leadership experience from leading biopharma companies in Europe, the US, and Asia. Currently, Ms. </span></div><div style="line-height:10pt;position:var(--position);top:224pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Soenderby is a member of the Board of Directors for the investment company BB Biotech and the biotech company, </span></div><div style="line-height:10pt;position:var(--position);top:234pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">F2G, and previously served on the Board of Directors of the biotechnology company Affibody. In addition, she is a </span></div><div style="line-height:10pt;position:var(--position);top:244pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">member of Novo Holdings Advisory Group and industrial advisor for the private equity group EQT. Formally, Ms. </span></div><div style="line-height:10pt;position:var(--position);top:254pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Soenderby was a corporate officer at Takeda leading global portfolio commercialization in her role as Chief Patient </span></div><div style="line-height:10pt;position:var(--position);top:264pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Value and Product Strategy Officer for Takeda Pharmaceutical Co Ltd. Ms. Soenderby led and oversaw Global </span></div><div style="line-height:10pt;position:var(--position);top:274pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Product Strategy at Shire until its acquisition by Takeda. Prior to joining Shire, Ms. Soenderby was Region Head for </span></div><div style="line-height:10pt;position:var(--position);top:284pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Roche Pharma with profit and loss responsibility for 11 countries in Europe. Prior to that, she worked as General </span></div><div style="line-height:10pt;position:var(--position);top:294pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Manager for Abbott (now AbbVie), first for Sweden and later for the United Kingdom. She also held several </span></div><div style="line-height:10pt;position:var(--position);top:304pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">operational and strategic roles of increasing responsibility at Schering Plough in Asia Pacific, including General </span></div><div style="line-height:10pt;position:var(--position);top:314pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Manager for Taiwan. Ms. Soenderby began her career as a management consultant at McKinsey &amp; Company </span></div><div style="line-height:10pt;position:var(--position);top:324pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">focusing on the healthcare industries. Ms. Soenderby holds a Master's degree from the University of Copenhagen. </span></div><div style="line-height:10pt;position:var(--position);top:334pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">We believe that Ms. Soenderby is qualified to serve on our Board because of her extensive experience as an </span></div><div style="line-height:10pt;position:var(--position);top:344pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">executive and as a member of the boards of companies in the life sciences industry. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:360pt;width:612pt"><span style="background-color:#ffff00;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">D</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:103.72pt;position:var(--position);text-decoration:none;white-space:pre">ominik H&#246;chli</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:164.51pt;position:var(--position);text-decoration:none;white-space:pre"> has served as one of our independent directors since April</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:398.71pt;position:var(--position);text-decoration:none;white-space:pre"> 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:421.21pt;position:var(--position);text-decoration:none;white-space:pre">. He is a member of both the </span></div><div style="line-height:10pt;position:var(--position);top:370pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Clinical and Science Committee as well as the Commercial Committee. Dr. H&#246;chli brings over two decades of </span></div><div style="line-height:10pt;position:var(--position);top:380pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">leadership experience in global biopharma, most notably a 20-year tenure at AbbVie/Abbott, where he served as </span></div><div style="line-height:10pt;position:var(--position);top:390pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Vice President of Global Marketing for Immunology and later as Head of Global Medical Affairs. In addition to his </span></div><div style="line-height:10pt;position:var(--position);top:400pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">experience at AbbVie, Dr. H&#246;chli served as Interim CEO of Catapult Therapeutics, a hematology-oncology </span></div><div style="line-height:10pt;position:var(--position);top:410pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">company, from 2021 to 2024. He is also the founder of Abinode, a pharmaceutical strategy consulting firm, and </span></div><div style="line-height:10pt;position:var(--position);top:420pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">currently serves on the Board of Directors at Molecular Partners AG, where he is a member of both the Audit </span></div><div style="line-height:10pt;position:var(--position);top:430pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Committee and the Research &amp; Development Committee. Dr. H&#246;chli received his medical degree (M.D.) from the </span></div><div style="line-height:10pt;position:var(--position);top:440pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">University of Bern in Switzerland. We believe Dr. H&#246;chli is qualified to serve on our Board because of his extensive </span></div><div style="line-height:10pt;position:var(--position);top:450pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">experience as an executive and as a member of the boards of companies in the life sciences industry. </span></div><div style="line-height:10pt;position:var(--position);top:472pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Family Relationships </span></div><div style="line-height:10pt;position:var(--position);top:490pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">There are no family relationships among any of our executive officers or directors.</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">104</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_88"></div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">B.<span id="i699eb219cc2449e4872f3e7f7fee4efa"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Compensation</span></div><div style="line-height:10pt;position:var(--position);top:90pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Compensation of Chief Executive Officer </span></div><div style="line-height:10pt;position:var(--position);top:106pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The following table sets out the compensation awarded to our Chief Executive Officer in the applicable </span></div><div style="line-height:10pt;position:var(--position);top:116pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">period: </span></div><div style="line-height:12pt;position:var(--position);top:126pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="position:var(--position);top:138pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:468pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:295.5pt"/><td style="padding:0;width:86.25pt"/><td style="padding:0;width:86.25pt"/></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:295.5pt"><div><div style="line-height:8pt;position:var(--position);top:5.49pt;width:295.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td colspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:295.5pt;position:var(--position);width:172.5pt"><div><div style="line-height:10pt;position:var(--position);top:3.83pt;width:172.5pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:31.31pt;position:var(--position);text-decoration:none;white-space:pre">Year ended December&#160;31,</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:14.25pt;width:295.5pt"><div><div style="line-height:8pt;position:var(--position);top:5.49pt;width:295.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:295.5pt;position:var(--position);top:14.25pt;width:86.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:86.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:33.12pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:381.75pt;position:var(--position);top:14.25pt;width:86.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:86.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:33.12pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:28.5pt;width:295.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:295.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:295.5pt;position:var(--position);top:28.5pt;width:86.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:86.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:38.46pt;position:var(--position);text-decoration:none;white-space:pre">(&#8364;)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:381.75pt;position:var(--position);top:28.5pt;width:86.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:86.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:38.46pt;position:var(--position);text-decoration:none;white-space:pre">(&#8364;)</span></div></div></div></td></tr><tr style="height:23.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:40.5pt;width:295.5pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:295.5pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Marc de Garidel&#8212;Chief Executive Officer from May 5, 2023 and </span></div><div style="line-height:10pt;position:var(--position);top:12.63pt;width:295.5pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:14.63pt;position:var(--position);text-decoration:none;white-space:pre">Chairman from May 5, 2023 until July 11, 2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:381.75pt;position:var(--position);top:40.5pt;width:86.25pt"><div><div style="line-height:10pt;position:var(--position);top:12.67pt;width:86.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:76.55pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:63.75pt;width:295.5pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:295.5pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Fixed compensation</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:83.36999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:84.53pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:85.11pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.19pt;position:var(--position);text-decoration:none;white-space:pre">...................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:295.5pt;position:var(--position);top:63.75pt;width:86.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:86.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:46.55pt;position:var(--position);text-decoration:none;white-space:pre">577,500</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:381.75pt;position:var(--position);top:63.75pt;width:86.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:86.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:46.55pt;position:var(--position);text-decoration:none;white-space:pre">600,600</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78pt;width:295.5pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:295.5pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Variable annual compensation</span><span style="font-family:'Times New Roman', serif;font-size:4.875pt;font-style:italic;font-weight:normal;left:125.86999999999999pt;position:var(--position);text-decoration:none;top:-2.429pt;vertical-align:super;white-space:pre">(1) (2)</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:138.42pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:139.57999999999998pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:140.16pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:140.18pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.19pt;position:var(--position);text-decoration:none;white-space:pre">.............................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:295.5pt;position:var(--position);top:78pt;width:86.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:86.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:69.05pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:381.75pt;position:var(--position);top:78pt;width:86.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:86.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:46.55pt;position:var(--position);text-decoration:none;white-space:pre">300,300</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:92.25pt;width:295.5pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:295.5pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Variable multi-year compensation</span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:139.71pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:140.29pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.31pt;position:var(--position);text-decoration:none;white-space:pre">.............................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:295.5pt;position:var(--position);top:92.25pt;width:86.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:86.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:69.05pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:381.75pt;position:var(--position);top:92.25pt;width:86.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:86.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:69.05pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:106.5pt;width:295.5pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:295.5pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Exceptional variable compensation</span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:144.13pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:144.71pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:145pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:145.15pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:145.23pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:145.26999999999998pt;position:var(--position);text-decoration:none;white-space:pre">...........................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:295.5pt;position:var(--position);top:106.5pt;width:86.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:86.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:69.05pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:381.75pt;position:var(--position);top:106.5pt;width:86.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:86.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:46.55pt;position:var(--position);text-decoration:none;white-space:pre">150,150</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:120.75pt;width:295.5pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:295.5pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Remuneration allocated due to mandate as director</span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:209.1pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:209.68pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:209.97pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:210.12pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:210.2pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:210.24pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:210.26pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:210.26999999999998pt;position:var(--position);text-decoration:none;white-space:pre">.................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:295.5pt;position:var(--position);top:120.75pt;width:86.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:86.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:69.05pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:381.75pt;position:var(--position);top:120.75pt;width:86.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:86.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:69.05pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:135pt;width:295.5pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:295.5pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Benefits in kind</span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:64.76pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:65.05pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:65.2pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:65.28pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:65.32pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:65.33pt;position:var(--position);text-decoration:none;white-space:pre">...........................................................................................</span></div></div></div></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:295.5pt;position:var(--position);top:135pt;width:86.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:86.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:51.55pt;position:var(--position);text-decoration:none;white-space:pre">53,442</span></div></div></div></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:381.75pt;position:var(--position);top:135pt;width:86.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:86.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:51.55pt;position:var(--position);text-decoration:none;white-space:pre">97,264</span></div></div></div></td></tr><tr style="height:5.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:149.25pt;width:295.5pt"><div><div style="line-height:1pt;position:var(--position);top:2.85pt;width:295.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td style="border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"/><td style="border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:381.75pt;position:var(--position);top:149.25pt;width:86.25pt"><div><div style="line-height:1pt;position:var(--position);top:2.85pt;width:86.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:83.37pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:154.5pt;width:295.5pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:295.5pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:25.39pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:26.55pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:27.13pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:27.419999999999998pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:27.57pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:27.65pt;position:var(--position);text-decoration:none;white-space:pre">..........................................................................................................</span></div></div></div></td><td style="border-bottom:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:295.5pt;position:var(--position);top:154.5pt;width:86.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.83pt;width:86.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:46.55pt;position:var(--position);text-decoration:none;white-space:pre">630,942</span></div></div></div></td><td style="border-bottom:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:381.75pt;position:var(--position);top:154.5pt;width:86.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.83pt;width:86.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:39.05pt;position:var(--position);text-decoration:none;white-space:pre">1,148,314</span></div></div></div></td></tr><tr style="height:5.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:168.75pt;width:295.5pt"><div><div style="line-height:1pt;position:var(--position);top:2.85pt;width:295.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td style="border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"/><td style="border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:381.75pt;position:var(--position);top:168.75pt;width:86.25pt"><div><div style="line-height:1pt;position:var(--position);top:2.85pt;width:86.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:83.37pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr></tbody></table></div></div></div><div style="line-height:10pt;position:var(--position);top:329pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">(1)<span style="display:inline-block;height:6.93pt;width:10.84pt"></span></span><span style="left:94.5pt;position:var(--position)">Variable compensation paid for the financial year corresponds to the amount due for the previous year. </span></span></div><div style="line-height:10pt;position:var(--position);top:339pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(2)&#160; &#160; Variable annual compensation for 2024 has be granted under an equity plan in 2025.</span></div><div style="line-height:10pt;position:var(--position);top:357pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The aggregate compensation paid and benefits in-kind granted by us to our current executive officers and </span></div><div style="line-height:10pt;position:var(--position);top:367pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">directors, including share-based compensatio</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.34pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">n and vestings, for the years ended December 31, 2025 and 2024 were </span></span></div><div style="line-height:10pt;position:var(--position);top:377pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;24.8 million </span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:128.35pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">and &#8364;19.1 million, respectively</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.38pt;position:var(--position);text-decoration:none;white-space:pre">. For both years, we did not allocate any amounts to be set aside or </span></div><div style="line-height:10pt;position:var(--position);top:387pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">accrued to provide pension, retirement or similar benefits to our directors or executive officers. </span></div><div style="line-height:10pt;position:var(--position);top:415pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Compensation of Directors </span></div><div style="line-height:10pt;position:var(--position);top:431pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The following table sets out the compensation awarded to our directors other than our Chief Executive Officer </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:441pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">during the year ended </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:161.35pt;position:var(--position);text-decoration:none;white-space:pre">December</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:202.39pt;position:var(--position);text-decoration:none;white-space:pre"> 31, 2025: </span></div><div style="line-height:12pt;position:var(--position);top:451pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="position:var(--position);top:463pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:466.5pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:326.25pt"/><td style="padding:0;width:140.25pt"/></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:326.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.83pt;width:326.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">Name</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);width:140.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.83pt;width:140.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:22.81pt;position:var(--position);text-decoration:underline;white-space:pre">Gross Fees Earned (&#8364;)</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:14.25pt;width:326.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:326.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Sylvie Gr&#233;goire</span><span style="font-family:'Times New Roman', serif;font-size:6.5pt;font-style:normal;font-weight:normal;left:66.17pt;position:var(--position);text-decoration:none;top:-2.4254999999999995pt;vertical-align:super;white-space:pre">(1)</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:73.74pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:74.89999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:75.47999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:75.77pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:75.85pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:75.89pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:75.91pt;position:var(--position);text-decoration:none;white-space:pre">...................................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:14.25pt;width:140.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:140.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:99.8pt"></span></span><span style="left:102.42999999999999pt;position:var(--position)">143,750</span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:28.5pt;width:326.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:326.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">June Lee</span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:38.410000000000004pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:38.56pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:38.6pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:38.61pt;position:var(--position);text-decoration:none;white-space:pre">..................................................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:28.5pt;width:140.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:140.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:99.8pt"></span></span><span style="left:102.42999999999999pt;position:var(--position)">127,500</span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:326.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:326.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Troy Ignelzi</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:52.29pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:53.45pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:53.49pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:53.5pt;position:var(--position);text-decoration:none;white-space:pre">............................................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:42.75pt;width:140.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:140.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:99.8pt"></span></span><span style="left:102.42999999999999pt;position:var(--position)">128,750</span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:57pt;width:326.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:326.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Corinna zur Bonsen-Thomas</span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:118.08pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:118.36999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:118.52pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:118.56pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:118.58pt;position:var(--position);text-decoration:none;white-space:pre">..................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:57pt;width:140.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:140.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:99.8pt"></span></span><span style="left:102.42999999999999pt;position:var(--position)">115,000</span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:71.25pt;width:326.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:326.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Sofinnova Partners (permanent representative to the Board: Kinam Hong)</span><span style="font-family:'Times New Roman', serif;font-size:6.5pt;font-style:normal;font-weight:normal;left:297.86pt;position:var(--position);text-decoration:none;top:-2.4254999999999995pt;vertical-align:super;white-space:pre">(2)</span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:305.43pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:306.01pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:306.05pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:306.06pt;position:var(--position);text-decoration:none;white-space:pre">.......</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:71.25pt;width:140.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:140.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:122.3pt"></span></span><span style="left:124.92999999999999pt;position:var(--position)">&#8212;</span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:85.5pt;width:326.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:326.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:1.13pt;position:var(--position);text-decoration:none;white-space:pre">Camilla Soenderby</span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:77.97999999999999pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:78.56pt;position:var(--position);text-decoration:none;white-space:pre">..................................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:85.5pt;width:140.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:140.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:99.8pt"></span></span><span style="left:102.42999999999999pt;position:var(--position)">118,750</span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:99.75pt;width:326.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:326.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Dominik H&#246;chli</span><span style="font-family:'Times New Roman', serif;font-size:6.5pt;font-style:normal;font-weight:normal;left:67.85pt;position:var(--position);text-decoration:none;top:-2.4254999999999995pt;vertical-align:super;white-space:pre">(3)</span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:75.42pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:76pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:76.03999999999999pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:76.06pt;position:var(--position);text-decoration:none;white-space:pre">...................................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:99.75pt;width:140.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:140.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:104.8pt"></span></span><span style="left:107.42999999999999pt;position:var(--position)">86,250</span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:114pt;width:326.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:326.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total</span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:25.39pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:25.97pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:26.05pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:26.06pt;position:var(--position);text-decoration:none;white-space:pre">.......................................................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:114pt;width:140.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.83pt;width:140.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:99.8pt"></span></span><span style="left:102.42999999999999pt;position:var(--position)">720,000</span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="line-height:1pt;position:var(--position);top:605.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="line-height:10pt;position:var(--position);top:606.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:6.5pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;top:-2.4254999999999995pt;vertical-align:super;white-space:pre">(1)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:79.57pt;position:var(--position);text-decoration:none;white-space:pre"> Sylvie Gregoire was appointed chair of the Board in June 2025.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:616.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:6.5pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;top:-2.4254999999999995pt;vertical-align:super;white-space:pre">(2)</span><span style="font-family:'Times New Roman', serif;font-size:6.5pt;font-style:normal;font-weight:normal;left:79.57pt;position:var(--position);text-decoration:none;top:2.4254999999999995pt;vertical-align:sub;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:81.19pt;position:var(--position);text-decoration:none;white-space:pre">Sofinnova Partners resigned from the Board effective March 19, 2026.</span></div><div style="line-height:10pt;position:var(--position);top:628.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:6.5pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;top:-2.4254999999999995pt;vertical-align:super;white-space:pre">(3)</span><span style="font-family:'Times New Roman', serif;font-size:6.5pt;font-style:normal;font-weight:normal;left:79.57pt;position:var(--position);text-decoration:none;top:2.4254999999999995pt;vertical-align:sub;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:81.19pt;position:var(--position);text-decoration:none;white-space:pre">Dominik H</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:126.44pt;position:var(--position);white-space:pre">&#246;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:131.44pt;position:var(--position);text-decoration:none;white-space:pre">chli was appointed to the Board in June 2025.</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">105</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">At the general meeting of shareholders held on June 6, 2025, our shareholders approved a package of </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">attendance fees and the compensation policy applicable to the chairperson of the Board and the Chief Executive </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Officer.&#160; </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The following table sets forth the AGAs allocated to the chairperson and chief executive officer as of </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">December 31, 2025: </span></div><div style="line-height:12pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="position:var(--position);top:140pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:468pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:78pt"/><td style="padding:0;width:78pt"/><td style="padding:0;width:78pt"/><td style="padding:0;width:78pt"/><td style="padding:0;width:68.25pt"/><td style="padding:0;width:87.75pt"/></tr><tr style="height:27.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:78pt"><div><div style="line-height:8pt;position:var(--position);top:19.12pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;position:var(--position);text-decoration:none;white-space:pre">Chairperson&#160;&amp; CEO</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);width:78pt"><div><div style="line-height:8pt;position:var(--position);top:19.12pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.13pt;position:var(--position);text-decoration:none;white-space:pre">Allocation date</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);width:78pt"><div><div style="line-height:8pt;position:var(--position);top:19.12pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.57pt;position:var(--position);text-decoration:none;white-space:pre">Type&#160;of&#160;AGAs</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);width:78pt"><div><div style="line-height:8pt;position:var(--position);top:11.12pt;width:78pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.03pt;position:var(--position);text-decoration:none;white-space:pre">Number&#160;of&#160;AGAs</span></div><div style="line-height:8pt;position:var(--position);top:19.12pt;width:78pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.68pt;position:var(--position);text-decoration:none;white-space:pre">allocated</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:19.12pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.71pt;position:var(--position);text-decoration:none;white-space:pre">Subscription&#160;price</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);width:87.75pt"><div><div style="line-height:8pt;position:var(--position);top:19.12pt;width:87.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.24pt;position:var(--position);text-decoration:none;white-space:pre">Acquisition period</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:27.75pt;width:78pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:78pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Marc de Garidel</span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:55.02pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:55.31pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:55.330000000000005pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:55.34pt;position:var(--position);text-decoration:none;white-space:pre">..........</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:27.75pt;width:78pt"><div><div style="line-height:8pt;position:var(--position);top:5.49pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.67pt;position:var(--position);text-decoration:none;white-space:pre">July-11-2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:27.75pt;width:78pt"><div><div style="line-height:8pt;position:var(--position);top:5.49pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:7.91pt;position:var(--position);text-decoration:none;white-space:pre">Free&#160;Shares&#160;2023-1</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:27.75pt;width:78pt"><div><div style="line-height:8pt;position:var(--position);top:5.49pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:23pt;position:var(--position);text-decoration:none;white-space:pre">1,382,796</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:27.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.49pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:27.24pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:27.75pt;width:87.75pt"><div><div style="line-height:8pt;position:var(--position);top:5.49pt;width:87.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:8.64pt;position:var(--position);text-decoration:none;white-space:pre">Minimum&#160;of&#160;1&#160;year </span><span style="font-family:'Times New Roman', serif;font-size:5.2pt;font-style:normal;font-weight:normal;left:73.05pt;position:var(--position);text-decoration:none;top:-1.9389999999999998pt;vertical-align:super;white-space:pre">(1)</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:42pt;width:78pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:9.91pt;position:var(--position);text-decoration:none;white-space:pre">February-01-2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:42pt;width:78pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:7.91pt;position:var(--position);text-decoration:none;white-space:pre">Free Shares 2024-1</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:42pt;width:78pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:26pt;position:var(--position);text-decoration:none;white-space:pre">400,000</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:42pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:27.24pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:42pt;width:87.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:87.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:7.08pt;position:var(--position);text-decoration:none;white-space:pre">Minimum of 2 years </span><span style="font-family:'Times New Roman', serif;font-size:5.2pt;font-style:normal;font-weight:normal;left:74.6pt;position:var(--position);text-decoration:none;top:-1.9389999999999998pt;vertical-align:super;white-space:pre">(2)</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:54pt;width:78pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:9.91pt;position:var(--position);text-decoration:none;white-space:pre">February-06-2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:54pt;width:78pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:7.91pt;position:var(--position);text-decoration:none;white-space:pre">Free Shares 2025-1</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:54pt;width:78pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:26pt;position:var(--position);text-decoration:none;white-space:pre">936,000</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:54pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:27.24pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:54pt;width:87.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:87.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:7.08pt;position:var(--position);text-decoration:none;white-space:pre">Minimum of 2 years </span><span style="font-family:'Times New Roman', serif;font-size:5.2pt;font-style:normal;font-weight:normal;left:74.6pt;position:var(--position);text-decoration:none;top:-1.9389999999999998pt;vertical-align:super;white-space:pre">(3)</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:66pt;width:78pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:9.91pt;position:var(--position);text-decoration:none;white-space:pre">February-06-2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:66pt;width:78pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:7.91pt;position:var(--position);text-decoration:none;white-space:pre">Free Shares 2025-2</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:66pt;width:78pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:28pt;position:var(--position);text-decoration:none;white-space:pre">47,052</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:66pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:27.24pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:66pt;width:87.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:87.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:32.44pt;position:var(--position);text-decoration:none;white-space:pre">2 years</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:78pt;width:78pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:12.79pt;position:var(--position);text-decoration:none;white-space:pre">August-01-2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:78pt;width:78pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:7.91pt;position:var(--position);text-decoration:none;white-space:pre">Free Shares 2025-7</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:78pt;width:78pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:26pt;position:var(--position);text-decoration:none;white-space:pre">100,000</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:78pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:27.24pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:78pt;width:87.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:87.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:7.08pt;position:var(--position);text-decoration:none;white-space:pre">Minimum of 2 years </span><span style="font-family:'Times New Roman', serif;font-size:5.2pt;font-style:normal;font-weight:normal;left:74.6pt;position:var(--position);text-decoration:none;top:-1.9389999999999998pt;vertical-align:super;white-space:pre">(2)</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90pt;width:78pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:78pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:1.13pt;position:var(--position);text-decoration:none;white-space:pre">Sylvie Gr&#233;goire</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:51.970000000000006pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:53.13pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:53.21pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:53.25pt;position:var(--position);text-decoration:none;white-space:pre">...........</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:90pt;width:78pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.67pt;position:var(--position);text-decoration:none;white-space:pre">July-11-2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:90pt;width:78pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:7.91pt;position:var(--position);text-decoration:none;white-space:pre">Free Shares 2024-5</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:90pt;width:78pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:28pt;position:var(--position);text-decoration:none;white-space:pre">25,000</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:90pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:27.24pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:90pt;width:87.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:87.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:7.08pt;position:var(--position);text-decoration:none;white-space:pre">Minimum of 2 years </span><span style="font-family:'Times New Roman', serif;font-size:5.2pt;font-style:normal;font-weight:normal;left:74.6pt;position:var(--position);text-decoration:none;top:-1.9389999999999998pt;vertical-align:super;white-space:pre">(2)</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:102pt;width:78pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:9.91pt;position:var(--position);text-decoration:none;white-space:pre">February-06-2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:102pt;width:78pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:7.91pt;position:var(--position);text-decoration:none;white-space:pre">Free Shares 2025-4</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:102pt;width:78pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:28pt;position:var(--position);text-decoration:none;white-space:pre">30,500</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:102pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:27.24pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:102pt;width:87.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:87.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:7.08pt;position:var(--position);text-decoration:none;white-space:pre">Minimum of 2 years </span><span style="font-family:'Times New Roman', serif;font-size:5.2pt;font-style:normal;font-weight:normal;left:74.6pt;position:var(--position);text-decoration:none;top:-1.9389999999999998pt;vertical-align:super;white-space:pre">(2)</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:114pt;width:78pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:78pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:19.5pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:20.66pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:20.95pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:21.099999999999998pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:21.18pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:21.2pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.209999999999997pt;position:var(--position);text-decoration:none;white-space:pre">...........................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:114pt;width:78pt"><div><div style="line-height:8pt;position:var(--position);top:5.49pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:114pt;width:78pt"><div><div style="line-height:8pt;position:var(--position);top:5.49pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:114pt;width:78pt"><div><div style="line-height:8pt;position:var(--position);top:5.49pt;width:78pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:23pt;position:var(--position);text-decoration:none;white-space:pre">1,807,796</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:114pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.49pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:33.12pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:114pt;width:87.75pt"><div><div style="line-height:8pt;position:var(--position);top:5.49pt;width:87.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:42.87pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr></tbody></table></div></div></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">106</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:71.95pt;position:var(--position)">(1)<span style="display:inline-block;height:6.93pt;width:12.84pt"></span></span><span style="left:96.45pt;position:var(--position)">Ac</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108.1pt;position:var(--position);text-decoration:none;white-space:pre">quisition Periods shall be as follows: </span></div><div style="line-height:10pt;position:var(--position);top:88pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">For 212,738 Free Shares 2023-1: the Acquisition Period shall end on the first (1st) anniversary of the </span></span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">allocation date; </span></div><div style="line-height:10pt;position:var(--position);top:114pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">For 638,214 Free Shares 2023-1: the Free Shares 2023-1 shall progressively be definitively acquired </span></span></div><div style="line-height:10pt;position:var(--position);top:124pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">on a monthly basis over a period of three (3) years starting after the first (1st) anniversary of the </span></div><div style="line-height:10pt;position:var(--position);top:134pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">allocation date (i.e. 17,728 Free Shares 2023-1 per month except for the last month of the three-year </span></div><div style="line-height:10pt;position:var(--position);top:144pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">period where 17,734 Free Shares 2023-1 shall be acquired). The duration of the Acquisition Period of </span></div><div style="line-height:10pt;position:var(--position);top:154pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">these Free Shares 2023-1 shall be calculated accordingly; </span></div><div style="line-height:10pt;position:var(--position);top:170pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">For 212,738 Free Shares 2023-1: the Acquisition Period shall end on the latest date between (i)&#160;the </span></span></div><div style="line-height:10pt;position:var(--position);top:180pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">first (1st) anniversary of the allocation date, and (ii)&#160;the date on which a specific performance </span></div><div style="line-height:10pt;position:var(--position);top:190pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">condition is fulfilled (condition&#160;1); </span></div><div style="line-height:10pt;position:var(--position);top:206pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">For 106,369 Free Shares 2023-1: the Acquisition Period shall end on the latest date between (i)&#160;the </span></span></div><div style="line-height:10pt;position:var(--position);top:216pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">first (1st) anniversary of the allocation date, and (ii)&#160;the date on which a specific performance </span></div><div style="line-height:10pt;position:var(--position);top:226pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">condition is fulfilled (condition&#160;2); </span></div><div style="line-height:10pt;position:var(--position);top:242pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">For 106,369 Free Shares 2023-1: the Acquisition Period shall end on the latest date between (i)&#160;the </span></span></div><div style="line-height:10pt;position:var(--position);top:252pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">first (1st) anniversary of the allocation date, and (ii)&#160;the date on which a specific performance </span></div><div style="line-height:10pt;position:var(--position);top:262pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">condition is fulfilled (condition&#160;3); </span></div><div style="line-height:10pt;position:var(--position);top:278pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">For 106,368 Free Shares 2023-1: the Acquisition Period shall end on the first (1st)&#160;anniversary of the </span></span></div><div style="line-height:10pt;position:var(--position);top:288pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">allocation date subject to the completion, prior to such date, of a specific performance condition </span></div><div style="line-height:10pt;position:var(--position);top:298pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">(condition&#160;4). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:308pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(2)&#160; &#160; &#160; Acquisition Periods shall be as follows: </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:318pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:111.5pt;position:var(--position);text-decoration:none;white-space:pre">&#160; &#160; &#160; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.5pt;position:var(--position);text-decoration:none;white-space:pre">For 50% of the Free Shares (rounded down to the closest unit): the Acquisition Period shall end on the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:330pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:126pt;position:var(--position);text-decoration:none;white-space:pre">second (2nd) anniversary of the allocation date;</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:340pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:111.5pt;position:var(--position);text-decoration:none;white-space:pre">&#160; &#160; &#160; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.5pt;position:var(--position);text-decoration:none;white-space:pre">For 25% of the Free Shares (rounded down to the closest unit): the Acquisition Period shall end on the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:352pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:126pt;position:var(--position);text-decoration:none;white-space:pre">third (3rd) anniversary of the allocation date;</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:362pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:111.5pt;position:var(--position);text-decoration:none;white-space:pre">&#160; &#160; &#160; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.5pt;position:var(--position);text-decoration:none;white-space:pre">For the remainder of the Free Shares: the Acquisition Period shall end on the fourth (4th) anniversary </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:374pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:126pt;position:var(--position);text-decoration:none;white-space:pre">of the allocation date.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:384pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(3)&#160; &#160; &#160; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:98.66pt;position:var(--position);text-decoration:none;white-space:pre">Acquisitio</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.28pt;position:var(--position);text-decoration:none;white-space:pre">n Periods shall be as follows: </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:394pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:111.5pt;position:var(--position);text-decoration:none;white-space:pre">&#160; &#160; &#160; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.5pt;position:var(--position);text-decoration:none;white-space:pre">For 230,500 of the Free Shares 2025-1 (rounded down to the closest unit): the Acquisition Period </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:406pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:126pt;position:var(--position);text-decoration:none;white-space:pre">shall end on the second (2nd) anniversary of the allocation date;</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:416pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:111.5pt;position:var(--position);text-decoration:none;white-space:pre">&#160; &#160; &#160; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.5pt;position:var(--position);text-decoration:none;white-space:pre">For 115,250 of the Free Shares 2025-1 (rounded down to the closest unit): the Acquisition Period </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:428pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:126pt;position:var(--position);text-decoration:none;white-space:pre">shall end on the third (3rd) anniversary of the allocation date;</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:438pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:111.5pt;position:var(--position);text-decoration:none;white-space:pre">&#160; &#160; &#160; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.5pt;position:var(--position);text-decoration:none;white-space:pre">For 115,250 of the Free Shares 2025-1: the Acquisition Period shall end on the fourth (4th) </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:450pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:126pt;position:var(--position);text-decoration:none;white-space:pre">anniversary of the allocation date.</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:460pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:111.5pt;position:var(--position);text-decoration:none;white-space:pre">&#160; &#160; &#160; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.5pt;position:var(--position);text-decoration:none;white-space:pre">For 475,000 of the Free Shares 2025-1: the shares will be definitively acquired on the latest date </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:472pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:126pt;position:var(--position);text-decoration:none;white-space:pre">between (i) February 6, 2027 and (ii) the date on which </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:349.66999999999996pt;position:var(--position);text-decoration:none;white-space:pre">a specific performance condition</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:480.87pt;position:var(--position);text-decoration:none;white-space:pre"> is fulfilled. </span></div><div style="line-height:10pt;position:var(--position);top:500pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Provisions or Allocations to Pay Pensions, Retirement or Other Benefits for Directors and Management </span></div><div style="line-height:10pt;position:var(--position);top:516pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For the fiscal year ended December&#160;31, 2025, none of the amounts set aside or accrued to provide pension, </span></div><div style="line-height:10pt;position:var(--position);top:526pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">retirement or similar benefits to our employees was attributable to our administrative, supervisory or management </span></div><div style="line-height:10pt;position:var(--position);top:536pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">bodies. We have not set aside any provisions to pay pensions, retirement and other benefits for corporate directors. </span></div><div style="line-height:10pt;position:var(--position);top:546pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The directors&#8217; compensation does not include any profit-sharing plans. </span></div><div style="line-height:10pt;position:var(--position);top:568pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Employment Agreements</span></div><div style="line-height:10pt;position:var(--position);top:586pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We have entered into employment agreements with each of our executive officers, except for our Chief </span></div><div style="line-height:10pt;position:var(--position);top:596pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Executive Officer, who is a corporate officer (</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:256.75pt;position:var(--position);text-decoration:none;white-space:pre">mandataire social</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:329.19pt;position:var(--position);text-decoration:none;white-space:pre">) with whom we have entered into a management </span></div><div style="line-height:10pt;position:var(--position);top:606pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">contract. We have also entered into a management contract with Ms. Sylvie Gr&#233;goire. </span></div><div style="line-height:10pt;position:var(--position);top:622pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our Chief Executive Officer has been appointed for a term lasting until the end of the Board meeting </span></div><div style="line-height:10pt;position:var(--position);top:632pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">following the general meeting of shareholders held to approve the financial statements for the year ending December </span></div><div style="line-height:10pt;position:var(--position);top:642pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">31, 2026. He was also appointed as Chairman of the Board for a term lasting until the end of the Board meeting </span></div><div style="line-height:10pt;position:var(--position);top:652pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">following the general meeting of shareholders held to approve the financial statements for the year ending December </span></div><div style="line-height:10pt;position:var(--position);top:662pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">31, 2024; however, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:151.68pt;position:var(--position);white-space:pre">Mr. de Garidel resigned from his office as Chairman of the Board on July 11, 2024.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.83pt;position:var(--position);text-decoration:none;white-space:pre"> In case of </span></div><div style="line-height:10pt;position:var(--position);top:672pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">termination of the Chief Executive Officer as a result of (i)&#160;non-renewal, (ii) revocation except for gross negligence </span></div><div style="line-height:10pt;position:var(--position);top:682pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">or willful misconduct and/or (iii) resignation justified by invalidity or health issues or Mr. de Garidel&#8217;s definitive </span></div><div style="line-height:10pt;position:var(--position);top:692pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">retirement (a &#8220;Qualifying Departure&#8221;), Mr. de Garidel shall be entitled to a severance payment equal to 12 months of </span></div><div style="line-height:10pt;position:var(--position);top:702pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the higher of either (i) the monthly average fixed remuneration and variable remuneration received by Mr. de </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">107</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Garidel during the 12-month period preceding the effective date of the Qualifying Departure, or (ii) the monthly </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">average fixed remuneration received by Mr. de Garidel during the 12-month period preceding the effective date of </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the Qualifying Departure plus 1/12th of the variable remuneration for the financial year immediately preceding the </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">date of the Qualifying Departure, irrespective of the date of payment of that variable remuneration. </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Dr. Gr&#233;goire was appointed, effective on July 11, 2024, as Chairperson of the Board. We entered into a </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">management contract with Ms. Sylvie Gr&#233;goire to set forth the terms and conditions of her office. For the duration </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of the contract and a period of twelve (12) months maximum from the effective date of the termination of her </span></div><div style="line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">functions as Chairperson, Dr. Gr&#233;goire is bound by non-compete and non-solicitation undertakings. It is specified </span></div><div style="line-height:10pt;position:var(--position);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">that the compensation for the undertakings set forth above is included in the compensation paid to Dr. Gr&#233;goire </span></div><div style="line-height:10pt;position:var(--position);top:168pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">during the term of her office as Chairperson and that no additional compensation shall be paid to Dr. Gr&#233;goire in </span></div><div style="line-height:10pt;position:var(--position);top:178pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">connection therewith (including after the term of her office as Chairperson). The corporate office of Dr. Gr&#233;goire </span></div><div style="line-height:10pt;position:var(--position);top:188pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">terminates in accordance with the applicable law and the provisions of the by-laws of the Company.</span></div><div style="line-height:10pt;position:var(--position);top:204pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Each of our executive officers has agreed to maintain the confidentiality of any confidential information, both </span></div><div style="line-height:10pt;position:var(--position);top:214pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">during and after the employment/management agreement expires or is earlier terminated. In addition, they are </span></div><div style="line-height:10pt;position:var(--position);top:224pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">subject to loyalty and confidentiality obligations and certain of them are bound by a non-solicitation covenant that </span></div><div style="line-height:10pt;position:var(--position);top:234pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">prohibits such executive officer from soliciting our customers, or soliciting or hiring our executive employees and </span></div><div style="line-height:10pt;position:var(--position);top:244pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">those of our employees working in the same team as our executive officer, during his or her employment/office and </span></div><div style="line-height:10pt;position:var(--position);top:254pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for one year after the termination of his or her employment/office.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:282pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Free Shares (AGA)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:154.13pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:298pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">On February 6, 2025, Mr. de Garidel, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:248.9pt;position:var(--position);text-decoration:none;white-space:pre">Mr. Didier Blondel, and Mr. Fabio Cataldi</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:419.01pt;position:var(--position);white-space:pre"> were allocated</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:479.45pt;position:var(--position);text-decoration:none;white-space:pre"> 1,846,000 free </span></div><div style="line-height:10pt;position:var(--position);top:308pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">shares (AGA) in the aggregate, the vesting of which is subject to a presence condition. Subject to remaining </span></div><div style="line-height:10pt;position:var(--position);top:318pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">employed with us, each such officer or employee&#8217;s free shares (AGA) will be vested as follows: (i) 50% at the end </span></div><div style="line-height:10pt;position:var(--position);top:328pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">of a two-year period from the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:192.43pt;position:var(--position);text-decoration:none;white-space:pre">allocation</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:231.8pt;position:var(--position);white-space:pre"> date, (ii) 25% at the end of a three-year period from the allocation date and </span></div><div style="line-height:10pt;position:var(--position);top:338pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">(iii) 25% at the end of a four-year period from the allocation date. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:354pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">On February 6, 2025, Mr. de Garidel, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:248.9pt;position:var(--position);text-decoration:none;white-space:pre">Mr. Didier Blondel, and Mr. Fabio Cataldi</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:419.01pt;position:var(--position);white-space:pre"> were further allocated</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:509.14pt;position:var(--position);text-decoration:none;white-space:pre"> 70,139</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.14pt;position:var(--position);white-space:pre"> </span></div><div style="line-height:10pt;position:var(--position);top:364pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">free shares (AGA) in </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.57999999999998pt;position:var(--position);text-decoration:none;white-space:pre">the</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:170.78pt;position:var(--position);white-space:pre"> aggregate, the vesting of which is subject to a presence condition. Subject to remaining </span></div><div style="line-height:10pt;position:var(--position);top:374pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">employed with us, each such officer or employee&#8217;s free shares (AGA) will be fully vested at the end of a two-year </span></div><div style="line-height:10pt;position:var(--position);top:384pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">period from the allocation date. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:400pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">On February 6, 2025, Dr. Gr&#233;goire was allocated</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:292.43pt;position:var(--position);text-decoration:none;white-space:pre"> 30,500</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:322.43pt;position:var(--position);white-space:pre"> free shares (AGA), the vesting of which is subject to </span></div><div style="line-height:10pt;position:var(--position);top:410pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">a presence </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:116.37pt;position:var(--position);text-decoration:none;white-space:pre">condition</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:154.11pt;position:var(--position);white-space:pre">. Subject to remaining Chairman of the Board, free shares (AGA) will be vested as follows: (i) </span></div><div style="line-height:10pt;position:var(--position);top:420pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">50% at the end of a two-year period from the allocation date, (ii) 25% at the end of a three-year period from the </span></div><div style="line-height:10pt;position:var(--position);top:430pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">allocation date and (iii) 25% at the end of a four-year period from the allocation date. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:446pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">On </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:111.22pt;position:var(--position);text-decoration:none;white-space:pre">August</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.1pt;position:var(--position);white-space:pre"> 1, 2025, Mr. de Garidel, Mr. Didier Blondel, and Mr. Fabio Cataldi were allocated </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:474.75pt;position:var(--position);text-decoration:none;white-space:pre">280,000</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:507.25pt;position:var(--position);white-space:pre"> free </span></div><div style="line-height:10pt;position:var(--position);top:456pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">shares (AGA) in the aggregate, the vesting of which is subject to a presence condition. Subject to remaining </span></div><div style="line-height:10pt;position:var(--position);top:466pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">employed with us, each such officer or employee&#8217;s free shares (AGA) will be vested as follows: (i) 50% at the end </span></div><div style="line-height:10pt;position:var(--position);top:476pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">of a two-year period from the allocation date, (ii) 25% at the end of a three-year period from the allocation date and </span></div><div style="line-height:10pt;position:var(--position);top:486pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">(iii) 25% at the end of a four-year period from the allocation date.</span></div><div style="line-height:1pt;position:var(--position);top:502pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:503pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:77pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="line-height:10pt;position:var(--position);top:513pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Equity Incentives</span></div><div style="line-height:10pt;position:var(--position);top:531pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We believe our ability to grant equity incentives is a valuable and necessary compensation tool that allows us </span></div><div style="line-height:10pt;position:var(--position);top:541pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to attract and retain the best personnel for positions of substantial responsibility, provides additional incentives to </span></div><div style="line-height:10pt;position:var(--position);top:551pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">employees and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:134.15pt;position:var(--position);white-space:pre">promotes</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:171.34pt;position:var(--position);text-decoration:none;white-space:pre"> the success of our business. Due to French corporate law and tax considerations, we have </span></div><div style="line-height:10pt;position:var(--position);top:561pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">historically granted several different equity incentive instruments to our executive officers, Board members and </span></div><div style="line-height:10pt;position:var(--position);top:571pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">employees, including founder's share warrants (BCE), share warrants (BSA) and free shares (AGA).</span></div><div style="line-height:10pt;position:var(--position);top:587pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our Board's </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:147.16pt;position:var(--position);white-space:pre">authority</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:183.23000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> to grant these equity incentive instruments and the aggregate amount authorized to be </span></div><div style="line-height:10pt;position:var(--position);top:597pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">granted under these instruments must be approved by a two-thirds majority of the votes held by our shareholders </span></div><div style="line-height:10pt;position:var(--position);top:607pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">present, represented or voting by authorized means, at the relevant extraordinary shareholders&#8217; meeting. Once </span></div><div style="line-height:10pt;position:var(--position);top:617pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">approved by our shareholders, our Board can grant share warrants (BSA) for up to 18 months, and stock options </span></div><div style="line-height:10pt;position:var(--position);top:627pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and/or free shares (AGA) for up to 38 months from the date of the applicable shareholders&#8217; approval. The authority </span></div><div style="line-height:10pt;position:var(--position);top:637pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of our Board to grant equity incentives may be extended or increased only by extraordinary shareholders&#8217; meetings. </span></div><div style="line-height:10pt;position:var(--position);top:647pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">As a result, we typically request that our shareholders authorize new pools of equity incentive instruments at every </span></div><div style="line-height:10pt;position:var(--position);top:657pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">annual shareholders&#8217; meeting.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:679pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Founder's Share Warrants (BCE)</span></div><div style="line-height:10pt;position:var(--position);top:697pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Founder&#8217;s share warrants (BCE) have traditionally been granted to certain of our employees who were French </span></div><div style="line-height:10pt;position:var(--position);top:707pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">tax residents because the warrants carry favorable tax and social security treatment for French tax residents. Similar </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">108</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to options, founder&#8217;s share warrants (BCE) entitle a holder to exercise the warrant for the underlying vested shares at </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">an exercise price per share determined by our Board and at least equal to the fair market value of an ordinary share </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">on the date of grant. However, unlike options, the exercise price per share is fixed as of the date of implementation </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of the plans pursuant to which the warrants may be granted, rather than as of the date of grant of the individual </span></div><div style="line-height:10pt;position:var(--position);top:112pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">warrants.</span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our shareholders, or pursuant to delegations granted by our shareholders, our Board, determines the recipients </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of the warrants, the dates of grant, the number and exercise price of the founder&#8217;s share warrants (BCE) to be </span></div><div style="line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">granted, the number of shares issuable upon exercise and certain other terms and conditions of the founder&#8217;s share </span></div><div style="line-height:10pt;position:var(--position);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">warrants (BCE), including the period of their exercisability and their vesting schedule.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:174pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">As of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.94pt;position:var(--position);text-decoration:none;white-space:pre">F</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:126.5pt;position:var(--position);text-decoration:none;white-space:pre">ebruary 28</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:169.51999999999998pt;position:var(--position);white-space:pre">, 2026, we had several types of founder&#8217;s share warrants (BCE) oustanding as follows: </span></div><div style="position:var(--position);top:195.2pt;width:612pt"><div style="font-size:0pt;left:68.63pt;position:var(--position);width:474.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:99.75pt"/><td style="padding:0;width:75pt"/><td style="padding:0;width:75pt"/><td style="padding:0;width:75pt"/><td style="padding:0;width:75pt"/><td style="padding:0;width:75pt"/></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Category</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:27.95pt;position:var(--position);text-decoration:none;white-space:pre">BCE-</span></div><div style="line-height:8pt;position:var(--position);top:11.67pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.17pt;position:var(--position);text-decoration:none;white-space:pre">2017-1</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:174.75pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:27.95pt;position:var(--position);text-decoration:none;white-space:pre">BCE-</span></div><div style="line-height:8pt;position:var(--position);top:11.67pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.17pt;position:var(--position);text-decoration:none;white-space:pre">2017-2</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:249.75pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:27.95pt;position:var(--position);text-decoration:none;white-space:pre">BCE-</span></div><div style="line-height:8pt;position:var(--position);top:11.67pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.17pt;position:var(--position);text-decoration:none;white-space:pre">2017-4</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:27.95pt;position:var(--position);text-decoration:none;white-space:pre">BCE-</span></div><div style="line-height:8pt;position:var(--position);top:11.67pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.17pt;position:var(--position);text-decoration:none;white-space:pre">2017-5</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.62pt;position:var(--position);text-decoration:none;white-space:pre">BCE-2018-4</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:36.75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Expiration date</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:36.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:35.93pt;position:var(--position);text-decoration:none;white-space:pre">23/01/2027</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:174.75pt;position:var(--position);top:36.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:35.93pt;position:var(--position);text-decoration:none;white-space:pre">20/11/2027</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:249.75pt;position:var(--position);top:36.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:35.93pt;position:var(--position);text-decoration:none;white-space:pre">20/11/2027</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);top:36.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:35.93pt;position:var(--position);text-decoration:none;white-space:pre">20/11/2027</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:36.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:35.93pt;position:var(--position);text-decoration:none;white-space:pre">14/05/2028</span></div></div></div></td></tr><tr style="height:20.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:48.75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Subscription or purchase </span></div><div style="line-height:8pt;position:var(--position);top:11.59pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">price (&#8364;)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:48.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:68.37pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:174.75pt;position:var(--position);top:48.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:68.37pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:249.75pt;position:var(--position);top:48.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:68.37pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);top:48.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:68.37pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:48.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:68.37pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:69pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Exercise price per share (&#8364;)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:69pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.37pt;position:var(--position);text-decoration:none;white-space:pre">6.39</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:174.75pt;position:var(--position);top:69pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.37pt;position:var(--position);text-decoration:none;white-space:pre">11.14</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:249.75pt;position:var(--position);top:69pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.37pt;position:var(--position);text-decoration:none;white-space:pre">11.14</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);top:69pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.37pt;position:var(--position);text-decoration:none;white-space:pre">11.14</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:69pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.37pt;position:var(--position);text-decoration:none;white-space:pre">7.33</span></div></div></div></td></tr><tr style="height:30pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:81pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Exercise conditions</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:81pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.08pt;position:var(--position);text-decoration:none;white-space:pre">Achievement of </span></div><div style="line-height:8pt;position:var(--position);top:11.59pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:39.95pt;position:var(--position);text-decoration:none;white-space:pre">objectives</span></div><div style="line-height:8pt;position:var(--position);top:20.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:45.51pt;position:var(--position);text-decoration:none;white-space:pre">Note (1)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:174.75pt;position:var(--position);top:81pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.08pt;position:var(--position);text-decoration:none;white-space:pre">Achievement of </span></div><div style="line-height:8pt;position:var(--position);top:11.59pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:11.09pt;position:var(--position);text-decoration:none;white-space:pre">objectives Note (2)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:249.75pt;position:var(--position);top:81pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.08pt;position:var(--position);text-decoration:none;white-space:pre">Achievement of </span></div><div style="line-height:8pt;position:var(--position);top:11.59pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:11.09pt;position:var(--position);text-decoration:none;white-space:pre">objectives Note (3)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);top:81pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.08pt;position:var(--position);text-decoration:none;white-space:pre">Achievement of </span></div><div style="line-height:8pt;position:var(--position);top:11.59pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:11.09pt;position:var(--position);text-decoration:none;white-space:pre">objectives Note (4)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:81pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.08pt;position:var(--position);text-decoration:none;white-space:pre">Achievement of </span></div><div style="line-height:8pt;position:var(--position);top:11.59pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:11.09pt;position:var(--position);text-decoration:none;white-space:pre">objectives Note (5)</span></div></div></div></td></tr><tr style="height:20.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:111pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Number of shares </span></div><div style="line-height:8pt;position:var(--position);top:11.59pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">subscribed</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:111pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:50.37pt;position:var(--position);text-decoration:none;white-space:pre">33,687</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:174.75pt;position:var(--position);top:111pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:68.37pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:249.75pt;position:var(--position);top:111pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:50.37pt;position:var(--position);text-decoration:none;white-space:pre">33,687</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);top:111pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">23,843<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:111pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.37pt;position:var(--position);text-decoration:none;white-space:pre">8,422</span></div></div></div></td></tr><tr style="height:30pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:131.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);white-space:pre">Beneficiaries </span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:48.580000000000005pt;position:var(--position);white-space:pre">(remaining </span></div><div style="line-height:8pt;position:var(--position);top:11.59pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">number of shares that can be </span></div><div style="line-height:8pt;position:var(--position);top:20.55pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">subscribed)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:161.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Marc de Garidel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:173.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:173.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:50.37pt;position:var(--position);text-decoration:none;white-space:pre">33,687</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:174.75pt;position:var(--position);top:173.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.96pt"></span></span><span style="left:45.59pt;position:var(--position)">112,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:249.75pt;position:var(--position);top:173.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:50.37pt;position:var(--position);text-decoration:none;white-space:pre">33,687</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);top:173.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">16,844<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:173.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.37pt;position:var(--position);text-decoration:none;white-space:pre">8,421</span></div></div></div></td></tr><tr style="height:20.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:185.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cumulative number of </span></div><div style="line-height:8pt;position:var(--position);top:11.59pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">cancelled or lapsed BCEs</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:185.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:68.37pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:174.75pt;position:var(--position);top:185.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">37,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:249.75pt;position:var(--position);top:185.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:68.37pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);top:185.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">26,687<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:185.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:68.37pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:20.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:205.5pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BCEs outstanding as of </span></div><div style="line-height:8pt;position:var(--position);top:11.59pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">28/02/2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:205.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:50.37pt;position:var(--position);text-decoration:none;white-space:pre">33,687</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:174.75pt;position:var(--position);top:205.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.96pt"></span></span><span style="left:45.59pt;position:var(--position)">112,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:249.75pt;position:var(--position);top:205.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:50.37pt;position:var(--position);text-decoration:none;white-space:pre">33,687</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);top:205.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">16,844<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:205.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.37pt;position:var(--position);text-decoration:none;white-space:pre">8,421</span></div></div></div></td></tr><tr style="height:20.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:225.75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BCEs exercisable at </span></div><div style="line-height:8pt;position:var(--position);top:11.59pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">28/02/2026*</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:225.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:50.37pt;position:var(--position);text-decoration:none;white-space:pre">33,687</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:174.75pt;position:var(--position);top:225.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.96pt"></span></span><span style="left:45.59pt;position:var(--position)">112,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:249.75pt;position:var(--position);top:225.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:50.37pt;position:var(--position);text-decoration:none;white-space:pre">33,687</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);top:225.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">16,844<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:225.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.37pt;position:var(--position);text-decoration:none;white-space:pre">8,421</span></div></div></div></td></tr></tbody></table></div></div></div><div style="line-height:8pt;position:var(--position);top:446.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);white-space:pre">*&#160; &#160; The number of shares to which the exercise of the BSAs and BCEs entitles the holder has been multiplied by 100 for all BSAs and BCEs </span></div><div style="line-height:8pt;position:var(--position);top:455.39pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);white-space:pre">issued prior to the division by 100 of the nominal value of the shares, decided by our general meeting on February 20, 2015. According the&#160; </span></div><div style="line-height:8pt;position:var(--position);top:464.58pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);white-space:pre">exercise conditions provided in the notes below and assuming that performance objectives have been achieved. </span></div><div style="line-height:12pt;position:var(--position);top:484.97pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:78.1pt;position:var(--position);white-space:pre">(1)</span><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:87.41999999999999pt;position:var(--position);white-space:pre">&#160; </span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:93.41999999999999pt;position:var(--position);white-space:pre">33,687 BCE-2017-1 are exercisable subject to a service condition, which is fully fulfilled on the date hereof, 16,844 BCE-2017-1 are </span></div><div style="line-height:8pt;position:var(--position);top:498.41pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">exercisable exclusively in the event of achievement of the qualitative objectives (non-market conditions) set by the Board, and 16,843 </span></div><div style="line-height:8pt;position:var(--position);top:507.37pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">BCE-2017-1 are exercisable exclusively in the event of achievement of the quantitative targets (market conditions) set by the Board. </span></div><div style="line-height:12pt;position:var(--position);top:516.33pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:78.1pt;position:var(--position);white-space:pre">(2)</span><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:87.41999999999999pt;position:var(--position);white-space:pre">&#160; </span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:93.41999999999999pt;position:var(--position);white-space:pre">75,000 BCE-2017-2 are exercisable subject to a service condition, which is fully fulfilled on the date hereof: and 75,000 BCE-2017-2 are </span></div><div style="line-height:8pt;position:var(--position);top:529.77pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">exercisable exclusively in the event of the achievement of qualitative objectives (non-market conditions) set by the Board. </span></div><div style="line-height:12pt;position:var(--position);top:538.73pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:78.1pt;position:var(--position);white-space:pre">(3)</span><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:87.41999999999999pt;position:var(--position);white-space:pre">&#160; </span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:93.41999999999999pt;position:var(--position);white-space:pre">33,687 BCE-2017-4 are exercisable subject to a service condition, which is fully fulfilled on the date hereof, and 33,687 BCE-2017-4 are </span></div><div style="line-height:8pt;position:var(--position);top:552.17pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">exercisable exclusively in the event of the achievement of qualitative objectives (non-market conditions) set by the Board. </span></div><div style="line-height:12pt;position:var(--position);top:561.13pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:78.1pt;position:var(--position);white-space:pre">(4)</span><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:87.41999999999999pt;position:var(--position);white-space:pre">&#160; </span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:93.41999999999999pt;position:var(--position);white-space:pre">16,843 BCE-2017-5 are exercisable subject to a service condition, which is fully fulfilled on the date hereof, and 16,844 BCE-2017-5 are </span></div><div style="line-height:8pt;position:var(--position);top:574.57pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">exercisable exclusively in the event of the achievement of qualitative objectives (non-market conditions) set by the Board. </span></div><div style="line-height:12pt;position:var(--position);top:583.53pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:78.1pt;position:var(--position);white-space:pre">(5)</span><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:87.41999999999999pt;position:var(--position);white-space:pre">&#160; </span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:93.41999999999999pt;position:var(--position);white-space:pre">8,422 BCE-2018-4 are exercisable subject to a service condition, which is fully fulfilled on the date hereof, and 8,421 BCE-2018-4 are </span></div><div style="line-height:8pt;position:var(--position);top:596.97pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">exercisable exclusively in the event of the achievement of qualitative objectives (non-market conditions) set by the Board. </span></div><div style="line-height:10pt;position:var(--position);top:619.73pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">General note: all of our BCE plans provide for specific cases of acceleration resulting in the exercise of said BCEs in </span></div><div style="line-height:10pt;position:var(--position);top:631.23pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">the event of the occurrence of specific events and in particular in the event of a change of control of us. </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">109</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Share Warrants (BSA)</span></div><div style="line-height:10pt;position:var(--position);top:90pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Share warrants (BSA) have historically been granted to our non-employee directors and consultants that </span></div><div style="line-height:10pt;position:var(--position);top:100pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regularly work in partnership with us. Similar to options, share warrants (BSA) entitle a holder to exercise the </span></div><div style="line-height:10pt;position:var(--position);top:110pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">warrant for the underlying vested shares at an exercise price per share determined by our Board and at least equal to </span></div><div style="line-height:10pt;position:var(--position);top:120pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the fair market value of an ordinary share on the date of grant. However, unlike options, the exercise price per share </span></div><div style="line-height:10pt;position:var(--position);top:130pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">is fixed as of the date of implementation of the plans pursuant to which the warrants may be granted, rather than as </span></div><div style="line-height:10pt;position:var(--position);top:140pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of the date of grant of the individual warrants.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:156pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">As of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.94pt;position:var(--position);text-decoration:none;white-space:pre">February</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:157.02pt;position:var(--position);text-decoration:none;white-space:pre"> 28, 2026, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:199.51999999999998pt;position:var(--position);white-space:pre">we had several types of share warrants (BSA) outstanding as follows: </span></div><div style="position:var(--position);top:179.44pt;width:612pt"><div style="font-size:0pt;left:108pt;position:var(--position);width:396pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:107.25pt"/><td style="padding:0;width:41.25pt"/><td style="padding:0;width:41.25pt"/><td style="padding:0;width:41.25pt"/><td style="padding:0;width:41.25pt"/><td style="padding:0;width:41.25pt"/><td style="padding:0;width:41.25pt"/><td style="padding:0;width:41.25pt"/></tr><tr style="height:15pt"><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:9.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:15pt;width:107.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:107.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Category</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:107.25pt;position:var(--position);top:15pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:4.55pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2018- 1</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:148.5pt;position:var(--position);top:15pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:41.25pt"><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:5.55pt;position:var(--position);white-space:pre">BSA 2024-1</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:15pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:41.25pt"><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:5.55pt;position:var(--position);white-space:pre">BSA 2024-2</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:15pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:41.25pt"><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:5.3pt;position:var(--position);white-space:pre">BSA-2025-1</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:272.25pt;position:var(--position);top:15pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:5.3pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2025-2</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:313.5pt;position:var(--position);top:15pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:5.55pt;position:var(--position);text-decoration:none;white-space:pre">BSA 2025-3</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:354.75pt;position:var(--position);top:15pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:5.55pt;position:var(--position);text-decoration:none;white-space:pre">BSA 2026-1</span></div></div></div></td></tr><tr style="height:9.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24.75pt;width:107.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:107.25pt"><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);white-space:pre">Date of general meeting</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:107.25pt;position:var(--position);top:24.75pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">23/06/2017</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:148.5pt;position:var(--position);top:24.75pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">5/6/2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:24.75pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">5/6/2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:24.75pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:41.25pt"><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">30/05/2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:272.25pt;position:var(--position);top:24.75pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:41.25pt"><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">30/05/2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:313.5pt;position:var(--position);top:24.75pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">30/05/2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:354.75pt;position:var(--position);top:24.75pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">06/06/2025</span></div></div></div></td></tr><tr style="height:9.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:34.5pt;width:107.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:107.25pt"><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);white-space:pre">Date of Board meeting</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:107.25pt;position:var(--position);top:34.5pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">22/01/2018</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:148.5pt;position:var(--position);top:34.5pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:41.25pt"><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">28/3/2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:34.5pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:41.25pt"><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">28/3/2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:34.5pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">8/1/2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:272.25pt;position:var(--position);top:34.5pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">8/1/2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:313.5pt;position:var(--position);top:34.5pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">01/05/2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:354.75pt;position:var(--position);top:34.5pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">05/02/2026</span></div></div></div></td></tr><tr style="height:17.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:44.25pt;width:107.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:107.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Date of decision of the Chief Executive </span></div><div style="line-height:6pt;position:var(--position);top:9.35pt;width:107.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Officer</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:148.5pt;position:var(--position);top:44.25pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:10.3pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">4/4/2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:44.25pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:10.3pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">4/4/2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:44.25pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:10.3pt;width:41.25pt"><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">13/01/2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:272.25pt;position:var(--position);top:44.25pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:10.3pt;width:41.25pt"><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">13/01/2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:313.5pt;position:var(--position);top:44.25pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:10.3pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">01/05/2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:354.75pt;position:var(--position);top:44.25pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:10.3pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">12/02/2026</span></div></div></div></td></tr><tr style="height:17.25pt"><td colspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:61.5pt;width:148.5pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:148.5pt"><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Total number of shares that may be subscribed or </span></div><div style="line-height:6pt;position:var(--position);top:9.35pt;width:148.5pt"><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">purchased (</span><span style="font-family:'Times New Roman', serif;font-size:3.9000000000000004pt;font-style:normal;font-weight:normal;left:30.419999999999998pt;position:var(--position);top:-1.456pt;vertical-align:super;white-space:pre">*</span><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:32.37pt;position:var(--position);white-space:pre">) :</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:9.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:107.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:107.25pt"><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Corinna zur Bonsen-Thomas</span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:76.88pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:77.46pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:77.53999999999999pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:77.56pt;position:var(--position);text-decoration:none;white-space:pre">..................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:148.5pt;position:var(--position);top:78.75pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.8pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">19,455</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:78.75pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.8pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">25,000</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:9.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:88.5pt;width:107.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:107.25pt"><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">June Lee</span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:25.77pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:26.349999999999998pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:26.5pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:26.54pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:26.55pt;position:var(--position);text-decoration:none;white-space:pre">....................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:148.5pt;position:var(--position);top:88.5pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.8pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">19,455</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:88.5pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.8pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">25,000</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:354.75pt;position:var(--position);top:88.5pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.8pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">7,414</span></div></div></div></td></tr><tr style="height:9.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:98.25pt;width:107.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:107.25pt"><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Troy Ignelzi</span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:34.09pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:34.11pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:34.12pt;position:var(--position);text-decoration:none;white-space:pre">...............................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:148.5pt;position:var(--position);top:98.25pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.8pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">19,455</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:98.25pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.8pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">25,000</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:9.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:108pt;width:107.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:107.25pt"><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Camilla Soenderby</span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:51.730000000000004pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:52.02pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:52.06pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:52.080000000000005pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:52.09pt;position:var(--position);text-decoration:none;white-space:pre">...................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:108pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.8pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">19455</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:108pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.8pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">25,000</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:354.75pt;position:var(--position);top:108pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.8pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">7,661</span></div></div></div></td></tr><tr style="height:9.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:117.75pt;width:107.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:107.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Dominik H&#246;chli</span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:43.400000000000006pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:43.980000000000004pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:44.27pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:44.42pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:44.5pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:44.52pt;position:var(--position);text-decoration:none;white-space:pre">........................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:313.5pt;position:var(--position);top:117.75pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.8pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">39,370</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:354.75pt;position:var(--position);top:117.75pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.8pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2,471</span></div></div></div></td></tr><tr style="height:9.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:127.5pt;width:107.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:107.25pt"><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Others</span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:20.259999999999998pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:20.55pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:20.59pt;position:var(--position);text-decoration:none;white-space:pre">........................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:107.25pt;position:var(--position);top:127.5pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">49,200</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:148.5pt;position:var(--position);top:127.5pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:127.5pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:272.25pt;position:var(--position);top:127.5pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.8pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">25,000</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:354.75pt;position:var(--position);top:127.5pt;width:41.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.8pt;width:41.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">5,931</span></div></div></div></td></tr></tbody></table></div></div></div><div style="line-height:12pt;position:var(--position);top:335.49pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">(*)</span><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:81.32pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:84.32pt;position:var(--position);white-space:pre">The number of shares to which the exercise of the BSAs and BCEs entitles the holder has been multiplied by 100 for all BSAs and BCEs </span></div><div style="line-height:8pt;position:var(--position);top:348.93pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">issued prior to the division by 100 of the nominal value of the shares, decided by our general meeting on February 20, 2015. Consequently, BSA </span></div><div style="line-height:8pt;position:var(--position);top:357.89pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">2014-3, BSA 2014-4 and BSA 2014-5 have a warrant to share ratio of 1:100. </span></div><div style="position:var(--position);top:366.85pt;width:612pt"><div style="font-size:0pt;left:83.62pt;position:var(--position);width:444.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:87.75pt"/><td style="padding:0;width:51pt"/><td style="padding:0;width:51pt"/><td style="padding:0;width:51pt"/><td style="padding:0;width:51pt"/><td style="padding:0;width:51pt"/><td style="padding:0;width:51pt"/><td style="padding:0;width:51pt"/></tr><tr style="height:15.75pt"><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:9.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:15.75pt;width:87.75pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:87.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Category</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:87.75pt;position:var(--position);top:15.75pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:10.18pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2018-1</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:138.75pt;position:var(--position);top:15.75pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:10.42pt;position:var(--position);white-space:pre">BSA 2024-1 </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:15.75pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:10.42pt;position:var(--position);white-space:pre">BSA 2024-2</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);top:15.75pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:10.18pt;position:var(--position);white-space:pre">BSA-2025-1</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:291.75pt;position:var(--position);top:15.75pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:10.18pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2025-2</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:342.75pt;position:var(--position);top:15.75pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:10.18pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2025-3</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:15.75pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:10.18pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2026-1</span></div></div></div></td></tr><tr style="height:17.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:25.5pt;width:87.75pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:87.75pt"><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Starting date for exercising </span></div><div style="line-height:6pt;position:var(--position);top:9.35pt;width:87.75pt"><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">options</span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:21.27pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:21.849999999999998pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:22pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:22.04pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:22.05pt;position:var(--position);text-decoration:none;white-space:pre">..........................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:87.75pt;position:var(--position);top:25.5pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:21.05pt;position:var(--position);text-decoration:none;white-space:pre">22/01/2018</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:138.75pt;position:var(--position);top:25.5pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:27.05pt;position:var(--position);text-decoration:none;white-space:pre">1/1/2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:25.5pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:27.05pt;position:var(--position);text-decoration:none;white-space:pre">1/4/2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);top:25.5pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:27.05pt;position:var(--position);text-decoration:none;white-space:pre">1/1/2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:291.75pt;position:var(--position);top:25.5pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:27.05pt;position:var(--position);text-decoration:none;white-space:pre">1/1/2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:342.75pt;position:var(--position);top:25.5pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:27.05pt;position:var(--position);text-decoration:none;white-space:pre">5/1/2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:25.5pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:27.05pt;position:var(--position);text-decoration:none;white-space:pre">2/1/2027</span></div></div></div></td></tr><tr style="height:9.75pt"><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:87.75pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:87.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Expiry date.</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:34.26pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:35.42pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:35.5pt;position:var(--position);text-decoration:none;white-space:pre">.................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:87.75pt;position:var(--position);top:42.75pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:21.05pt;position:var(--position);text-decoration:none;white-space:pre">22/01/2028</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:138.75pt;position:var(--position);top:42.75pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:27.05pt;position:var(--position);text-decoration:none;white-space:pre">4/4/2034</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:42.75pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:27.05pt;position:var(--position);text-decoration:none;white-space:pre">4/4/2034</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);top:42.75pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:21.05pt;position:var(--position);white-space:pre">13/01/2035</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:291.75pt;position:var(--position);top:42.75pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:21.05pt;position:var(--position);white-space:pre">13/01/2035</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:342.75pt;position:var(--position);top:42.75pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:27.05pt;position:var(--position);text-decoration:none;white-space:pre">5/1/2036</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:42.75pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:24.05pt;position:var(--position);text-decoration:none;white-space:pre">2/12/2036</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:17.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:68.25pt;width:87.75pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:87.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Subscription or purchase price </span></div><div style="line-height:6pt;position:var(--position);top:9.35pt;width:87.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(&#8364;)</span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:9.61pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:9.899999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:10.05pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:10.07pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:10.08pt;position:var(--position);text-decoration:none;white-space:pre">..................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:87.75pt;position:var(--position);top:68.25pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:40.87pt;position:var(--position);text-decoration:none;white-space:pre">0.9</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:138.75pt;position:var(--position);top:68.25pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:37.87pt;position:var(--position);text-decoration:none;white-space:pre">2.57</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:68.25pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:37.87pt;position:var(--position);text-decoration:none;white-space:pre">2.57</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);top:68.25pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:45.37pt;position:var(--position);text-decoration:none;white-space:pre">2</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:291.75pt;position:var(--position);top:68.25pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:45.37pt;position:var(--position);text-decoration:none;white-space:pre">2</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:342.75pt;position:var(--position);top:68.25pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:37.87pt;position:var(--position);text-decoration:none;white-space:pre">1.27</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:68.25pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:34.87pt;position:var(--position);text-decoration:none;white-space:pre">20.23</span></div></div></div></td></tr><tr style="height:9.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:85.5pt;width:87.75pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:87.75pt"><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Exercise price per share (&#8364;)</span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:72.83999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:72.99pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:73.07pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:73.11pt;position:var(--position);text-decoration:none;white-space:pre">........</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:87.75pt;position:var(--position);top:85.5pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:37.87pt;position:var(--position);text-decoration:none;white-space:pre">8.05</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:138.75pt;position:var(--position);top:85.5pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:37.87pt;position:var(--position);text-decoration:none;white-space:pre">13.1</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:85.5pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:37.87pt;position:var(--position);text-decoration:none;white-space:pre">13.1</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);top:85.5pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:37.87pt;position:var(--position);text-decoration:none;white-space:pre">6.63</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:291.75pt;position:var(--position);top:85.5pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:37.87pt;position:var(--position);text-decoration:none;white-space:pre">6.63</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:342.75pt;position:var(--position);top:85.5pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:37.87pt;position:var(--position);text-decoration:none;white-space:pre">6.40</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:85.5pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:34.87pt;position:var(--position);text-decoration:none;white-space:pre">99.63</span></div></div></div></td></tr><tr style="height:9.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:95.25pt;width:87.75pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:87.75pt"><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Terms of exercise</span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:47.550000000000004pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:47.59pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:47.61pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:47.620000000000005pt;position:var(--position);text-decoration:none;white-space:pre">.........................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:87.75pt;position:var(--position);top:95.25pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:28.24pt;position:var(--position);text-decoration:none;white-space:pre">Note (1)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:138.75pt;position:var(--position);top:95.25pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:28.24pt;position:var(--position);text-decoration:none;white-space:pre">Note (2)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:95.25pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:28.24pt;position:var(--position);text-decoration:none;white-space:pre">Note (3)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);top:95.25pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:28.24pt;position:var(--position);text-decoration:none;white-space:pre">Note (4)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:291.75pt;position:var(--position);top:95.25pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:28.24pt;position:var(--position);text-decoration:none;white-space:pre">Note (5)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:342.75pt;position:var(--position);top:95.25pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:28.24pt;position:var(--position);text-decoration:none;white-space:pre">Note (6)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:95.25pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:28.24pt;position:var(--position);text-decoration:none;white-space:pre">Note (7)</span></div></div></div></td></tr><tr style="height:9.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:105pt;width:87.75pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:87.75pt"><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Number of shares subscribed</span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:77.35pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:77.5pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:77.58pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:77.6pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:77.61pt;position:var(--position);text-decoration:none;white-space:pre">.....</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:87.75pt;position:var(--position);top:105pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:31.87pt;position:var(--position);text-decoration:none;white-space:pre">16,400</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:138.75pt;position:var(--position);top:105pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:34.87pt;position:var(--position);text-decoration:none;white-space:pre">4,863</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:105pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:45.37pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);top:105pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:45.37pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:291.75pt;position:var(--position);top:105pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:45.37pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:342.75pt;position:var(--position);top:105pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:45.37pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:105pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:45.37pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:17.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:114.75pt;width:87.75pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:87.75pt"><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cumulative number of BSA </span></div><div style="line-height:6pt;position:var(--position);top:9.35pt;width:87.75pt"><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">cancelled or lapsed</span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:51.220000000000006pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:51.800000000000004pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:51.95pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:52.03pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:52.050000000000004pt;position:var(--position);text-decoration:none;white-space:pre">......................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:87.75pt;position:var(--position);top:114.75pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:31.87pt;position:var(--position);text-decoration:none;white-space:pre">16,400</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:138.75pt;position:var(--position);top:114.75pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:45.37pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:114.75pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:45.37pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);top:114.75pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:45.37pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:291.75pt;position:var(--position);top:114.75pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:45.37pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:342.75pt;position:var(--position);top:114.75pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:45.37pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:114.75pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:45.37pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:9.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:132pt;width:87.75pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:87.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSAs as of February 28, 2026</span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:78.24pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:78.82pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:78.97pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:79.05pt;position:var(--position);text-decoration:none;white-space:pre">....</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:87.75pt;position:var(--position);top:132pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:31.87pt;position:var(--position);text-decoration:none;white-space:pre">16,400</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:138.75pt;position:var(--position);top:132pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.16pt;width:29.13pt"></span></span><span style="left:31.759999999999998pt;position:var(--position)">53,502<span style="display:inline-block;height:4.16pt;width:1.99pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:132pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.16pt;width:29.13pt"></span></span><span style="left:31.759999999999998pt;position:var(--position)">19,455<span style="display:inline-block;height:4.16pt;width:1.99pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);top:132pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.16pt;width:26.13pt"></span></span><span style="left:28.759999999999998pt;position:var(--position)">100,000<span style="display:inline-block;height:4.16pt;width:1.99pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:291.75pt;position:var(--position);top:132pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.16pt;width:29.13pt"></span></span><span style="left:31.759999999999998pt;position:var(--position)">25,000<span style="display:inline-block;height:4.16pt;width:1.99pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:342.75pt;position:var(--position);top:132pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.16pt;width:29.13pt"></span></span><span style="left:31.759999999999998pt;position:var(--position)">39,370<span style="display:inline-block;height:4.16pt;width:1.99pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:132pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.16pt;width:29.13pt"></span></span><span style="left:31.759999999999998pt;position:var(--position)">23,477<span style="display:inline-block;height:4.16pt;width:1.99pt"></span></span></span></div></div></div></td></tr><tr style="height:17.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:141.75pt;width:87.75pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:87.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA potentially exercisable as </span></div><div style="line-height:6pt;position:var(--position);top:9.35pt;width:87.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">of February 28 2026,*</span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:58.92pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:59.5pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:59.54pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:bold;left:59.56pt;position:var(--position);text-decoration:none;white-space:pre">.................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:87.75pt;position:var(--position);top:141.75pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:31.87pt;position:var(--position);text-decoration:none;white-space:pre">16,400</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:138.75pt;position:var(--position);top:141.75pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.16pt;width:29.13pt"></span></span><span style="left:31.759999999999998pt;position:var(--position)">24,318<span style="display:inline-block;height:4.16pt;width:1.99pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:141.75pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:34.87pt;position:var(--position);text-decoration:none;white-space:pre">4,863</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);top:141.75pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:33.37pt;position:var(--position);text-decoration:none;white-space:pre">25000</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:291.75pt;position:var(--position);top:141.75pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:34.87pt;position:var(--position);text-decoration:none;white-space:pre">6,250</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:342.75pt;position:var(--position);top:141.75pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:45.37pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:141.75pt;width:51pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:45.37pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr></tbody></table></div></div></div><div style="line-height:12pt;position:var(--position);top:539.81pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:78.1pt;position:var(--position);white-space:pre">(*)</span><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:87.41999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:90.41999999999999pt;position:var(--position);white-space:pre">The number of shares to which the exercise of the BSAs and BCEs entitles the holder has been multiplied by 100 for all BSAs and BCEs </span></div><div style="line-height:8pt;position:var(--position);top:553.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">issued prior to the division by 100 of the nominal value of the shares, decided by our general meeting on February 20, 2015. According to the </span></div><div style="line-height:8pt;position:var(--position);top:562.21pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">exercise conditions provided in the notes below and assuming that the objectives have been achieved. </span></div><div style="line-height:12pt;position:var(--position);top:571.17pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:78.1pt;position:var(--position);white-space:pre">(1)</span><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:87.41999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:90.41999999999999pt;position:var(--position);white-space:pre">Progressive vesting in time fully vested on the date hereof. </span></div><div style="line-height:8pt;position:var(--position);top:584.61pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:78.1pt;position:var(--position);white-space:pre">(2) Progressive vesting in time.</span></div><div style="line-height:8pt;position:var(--position);top:593.57pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:78.1pt;position:var(--position);white-space:pre">(3) Progressive vesting in time.</span></div><div style="line-height:8pt;position:var(--position);top:602.53pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:78.1pt;position:var(--position);white-space:pre">(4) Progressive vesting in time.</span></div><div style="line-height:8pt;position:var(--position);top:611.49pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:78.1pt;position:var(--position);white-space:pre">(5) Progressive vesting in time.</span></div><div style="line-height:8pt;position:var(--position);top:620.45pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:78.1pt;position:var(--position);white-space:pre">(6) Progressive vesting in time.</span></div><div style="line-height:8pt;position:var(--position);top:629.41pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:78.1pt;position:var(--position);white-space:pre">(7) Progressive vesting in time.</span></div><div style="line-height:10pt;position:var(--position);top:650.37pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">General note: all of our BSA plans provide for specific cases of acceleration resulting in the exercise of said BSAs in </span></div><div style="line-height:10pt;position:var(--position);top:662.37pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the event of the occurrence of specific events and in particular in the event of a change of control of us. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:686.37pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Free Shares (AGA)</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">110</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares (AGA) are employee equity incentive instruments pursuant to which the beneficiaries are </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">granted, for free, the possibility to receive our ordinary shares under certain conditions.</span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">As of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.94pt;position:var(--position);text-decoration:none;white-space:pre">February</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:157.02pt;position:var(--position);white-space:pre"> 28, 2026, we had </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:230.6pt;position:var(--position);text-decoration:none;white-space:pre">issued</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:255.58pt;position:var(--position);white-space:pre"> free shares (AGA) as follows:</span></div><div style="position:var(--position);top:130pt;width:612pt"><div style="font-size:0pt;left:96.5pt;position:var(--position);width:456pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:99.75pt"/><td style="padding:0;width:356.25pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:31.78pt;position:var(--position);white-space:pre">Plan name</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:113.17pt;position:var(--position);white-space:pre">Free ordinary share plan AGA 2023-1</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.8pt;position:var(--position);white-space:pre">General Meeting date</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:12pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">June 5, 2023</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.14pt;position:var(--position);white-space:pre">Board of Directors decision</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:24pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">July 11, 2023</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:36pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.02pt;position:var(--position);white-space:pre">granted by the Board of </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.89pt;position:var(--position);white-space:pre">Directors</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:36pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">1,382,796</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:68.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.45pt;position:var(--position);white-space:pre">Marc de Garidel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:68.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">1,382,796</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:80.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.34pt;position:var(--position);white-space:pre">Sylvie Gr&#233;goire</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:80.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:92.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.9pt;position:var(--position);white-space:pre">Didier Blondel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:92.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:104.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.45pt;position:var(--position);white-space:pre">Fabio Cataldi</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:104.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:116.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:38.11pt;position:var(--position);white-space:pre">Others</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:116.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:315.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:128.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.91pt;position:var(--position);white-space:pre">Duration of vesting period</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:128.25pt;width:356.25pt"><div><div style="line-height:12pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">212,738 Free Shares 2023-1 shall vest on July 11, 2024;</span></div><div style="line-height:12pt;position:var(--position);top:17.71pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">638,214 Free Shares 2023-1 shall progressively be definitively acquired on a monthly basis over a </span></div><div style="line-height:8pt;position:var(--position);top:32.71pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">period of three (3) years starting after July 11, 2024 (i.e. 17,728 Free Shares 2023-1 per month </span></div><div style="line-height:8pt;position:var(--position);top:47.71pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">except for the last month of the three-year period where 17,734 Free Shares 2023-1 shall be </span></div><div style="line-height:8pt;position:var(--position);top:62.71pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">acquired). The duration of the acquisition period of these Free Shares 2023-1 shall be calculated </span></div><div style="line-height:8pt;position:var(--position);top:77.71pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">accordingly;</span></div><div style="line-height:12pt;position:var(--position);top:92.79pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">212,738 Free Shares 2023-1 shall vest on the latest date between (i) July 11, 2024, and (ii) the </span></div><div style="line-height:8pt;position:var(--position);top:107.79pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">date of receipt by the Company of a Marketing Authorization for one of its products in a first </span></div><div style="line-height:8pt;position:var(--position);top:122.79pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">indication in the United States of America prior to June 30, 2026;</span></div><div style="line-height:12pt;position:var(--position);top:137.87pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">106,369 Free Shares 2023-1 shall vest on the latest date between (i) July 11, 2024, and (ii) the </span></div><div style="line-height:8pt;position:var(--position);top:152.87pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">date of the successful completion of the initial public offering of the Company&#8217;s shares (or </span></div><div style="line-height:8pt;position:var(--position);top:167.87pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">depositary receipts representing any such shares) on the NASDAQ stock exchange in New York </span></div><div style="line-height:8pt;position:var(--position);top:182.87pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">allowing the Company to raise an amount of gross proceeds at least equal to one hundred million </span></div><div style="line-height:8pt;position:var(--position);top:197.87pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">dollars ($100,000,000) on or before June 30, 2024;</span></div><div style="line-height:12pt;position:var(--position);top:212.95pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">106,369 Free Shares 2023-1 shall vest on the latest date between (i) July 11, 2024, and (ii) the </span></div><div style="line-height:8pt;position:var(--position);top:227.95pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">date on which that the market capitalization of the Company remains superior or equal to one </span></div><div style="line-height:8pt;position:var(--position);top:242.95pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">billion euros (&#8364;1,000,000,000) for a consecutive period of at least three (3) months prior to </span></div><div style="line-height:8pt;position:var(--position);top:257.95pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">December 31, 2024;</span></div><div style="line-height:12pt;position:var(--position);top:273.03pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">106,368 Free Shares 2023-1 shall vest on July 11, 2024 subject to the completion, prior to such </span></div><div style="line-height:8pt;position:var(--position);top:288.03pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">date, of a M&amp;A transaction in which the valuation of the Company is at least equal to one billion </span></div><div style="line-height:8pt;position:var(--position);top:303.03pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">euros (&#8364;1,000,000,000) on a fully diluted basis.</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:444pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.45pt;position:var(--position);white-space:pre">Date of availability</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:444pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">All ordinary shares vesting before July 11, 2025 shall be subject to a lock-up period ending on July 11, 2025. </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Ordinary shares vesting after July 11, 2025 are not subject to a lock-up period.</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:465.75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.36pt;position:var(--position);white-space:pre">Free ordinary shares fully </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:465.75pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">638,211</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:498pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.8pt;position:var(--position);white-space:pre">Free ordinary shares being </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:498pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">531,848</span></div></div></div></td></tr></tbody></table></div></div></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">111</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:var(--position);top:72pt;width:612pt"><div style="font-size:0pt;left:96.5pt;position:var(--position);width:456pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:99.75pt"/><td style="padding:0;width:356.25pt"/></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.9pt;position:var(--position);white-space:pre">lapsed as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">212,737</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:32.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.35pt;position:var(--position);white-space:pre">Employment conditions</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:32.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">For all of the ordinary shares, the vesting is subject to the beneficiary of the plan retaining, on an ongoing </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">basis, the status of corporate officer or employee of the Company and/or one of its direct and/or indirect </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">subsidiaries, as applicable.</span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:153pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:456pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:99.75pt"/><td style="padding:0;width:356.25pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:31.78pt;position:var(--position);white-space:pre">Plan name</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:113.17pt;position:var(--position);white-space:pre">Free ordinary share plan AGA 2023-2</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.8pt;position:var(--position);white-space:pre">General Meeting date</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:12pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">June 5, 2023</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.14pt;position:var(--position);white-space:pre">Board of Directors decision</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:24pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">July 11, 2023</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:36pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.02pt;position:var(--position);white-space:pre">granted by the Board of </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.89pt;position:var(--position);white-space:pre">Directors</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:36pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">100,000</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:68.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.45pt;position:var(--position);white-space:pre">Marc de Garidel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:68.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:80.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.34pt;position:var(--position);white-space:pre">Sylvie Gr&#233;goire</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:80.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:92.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.9pt;position:var(--position);white-space:pre">Didier Blondel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:92.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:104.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.45pt;position:var(--position);white-space:pre">Fabio Cataldi</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:104.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:116.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:38.11pt;position:var(--position);white-space:pre">Others</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:116.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">100,000</span></div></div></div></td></tr><tr style="height:90.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:128.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.91pt;position:var(--position);white-space:pre">Duration of vesting period</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:128.25pt;width:356.25pt"><div><div style="line-height:12pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">25% of the ordinary shares allocated shall vest on July 11, 2024; and</span></div><div style="line-height:12pt;position:var(--position);top:17.71pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">75% of the ordinary shares allocated shall vest on the latest date between (i) July 11, 2024, and </span></div><div style="line-height:8pt;position:var(--position);top:32.71pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">(ii) the date of receipt by the Company, prior to the June 30, 2025, of positive induction data </span></div><div style="line-height:8pt;position:var(--position);top:47.71pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">(positive primary endpoint and favorable safety as solely assessed by the Board of Directors) for </span></div><div style="line-height:8pt;position:var(--position);top:62.71pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">its phase 3 clinical trials for obefazimod in the field of ulcerative colitis allowing continuation of </span></div><div style="line-height:8pt;position:var(--position);top:77.71pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">the phase 3 trials towards NDA submission to the FDA.</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:219pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.45pt;position:var(--position);white-space:pre">Date of availability</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:219pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">All ordinary shares vesting before July 11, 2025 shall be subject to a lock-up period ending on July 11, 2025. </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Ordinary shares vesting after July 11, 2025 are not subject to a lock-up period.</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:240.75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.36pt;position:var(--position);white-space:pre">Free ordinary shares fully </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:240.75pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">25,000</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:273pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.8pt;position:var(--position);white-space:pre">Free ordinary shares being </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:273pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:305.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.9pt;position:var(--position);white-space:pre">lapsed as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:305.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">75,000</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:337.5pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.35pt;position:var(--position);white-space:pre">Employment conditions</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:337.5pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">None</span></div></div></div></td></tr></tbody></table></div></div></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">112</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:var(--position);top:72pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:456pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:99.75pt"/><td style="padding:0;width:356.25pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:31.78pt;position:var(--position);white-space:pre">Plan name</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:113.17pt;position:var(--position);white-space:pre">Free ordinary share plan AGA 2023-3</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.8pt;position:var(--position);white-space:pre">General Meeting date</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:12pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">June 5, 2023</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.14pt;position:var(--position);white-space:pre">Board of Directors decision</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:24pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">September 28, 2023</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:36pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.02pt;position:var(--position);white-space:pre">granted by the Board of </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.89pt;position:var(--position);white-space:pre">Directors</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:36pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">731,500</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:68.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.45pt;position:var(--position);white-space:pre">Marc de Garidel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:68.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:80.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.34pt;position:var(--position);white-space:pre">Sylvie Gr&#233;goire</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:80.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:92.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.9pt;position:var(--position);white-space:pre">Didier Blondel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:92.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">20,000</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:104.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.45pt;position:var(--position);white-space:pre">Fabio Cataldi</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:104.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:116.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:38.11pt;position:var(--position);white-space:pre">Others</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:116.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">711,500</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:128.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.91pt;position:var(--position);white-space:pre">Duration of vesting period</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:128.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">50% of the ordinary shares allocated shall vest on September 28, 2025;</span></div><div style="line-height:8pt;position:var(--position);top:12.71pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">25% of the ordinary shares allocated shall vest on September 28, 2026; and</span></div><div style="line-height:8pt;position:var(--position);top:22.79pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">25% of the ordinary shares allocated shall vest on September 28, 2027.</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:160.5pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.45pt;position:var(--position);white-space:pre">Date of availability</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:160.5pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">The ordinary shares are not subject to a lock-up period once vested.</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:172.5pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.36pt;position:var(--position);white-space:pre">Free ordinary shares fully </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:172.5pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">251,125</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:204.75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.8pt;position:var(--position);white-space:pre">Free ordinary shares being </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:204.75pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">200,000</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:237pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.9pt;position:var(--position);white-space:pre">lapsed as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:237pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">280,375</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:269.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.35pt;position:var(--position);white-space:pre">Employment conditions</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:269.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">For all of the ordinary shares, the vesting is subject to the beneficiary of the plan retaining, on an ongoing </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">basis, the status of corporate officer or employee of the Company and/or one of its direct and/or indirect </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">subsidiaries, as applicable.</span></div></div></div></td></tr></tbody></table></div></div></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">113</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:var(--position);top:72pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:456pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:99.75pt"/><td style="padding:0;width:356.25pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:31.78pt;position:var(--position);white-space:pre">Plan name</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:113.17pt;position:var(--position);white-space:pre">Free ordinary share plan AGA 2023-4</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.8pt;position:var(--position);white-space:pre">General Meeting date</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:12pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">June 5, 2023</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.14pt;position:var(--position);white-space:pre">Board of Directors decision</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:24pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">September 28, 2023</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:36pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.02pt;position:var(--position);white-space:pre">granted by the Board of </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.89pt;position:var(--position);white-space:pre">Directors</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:36pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">254,250</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:68.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.45pt;position:var(--position);white-space:pre">Marc de Garidel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:68.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:80.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.34pt;position:var(--position);white-space:pre">Sylvie Gr&#233;goire</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:80.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:92.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.9pt;position:var(--position);white-space:pre">Didier Blondel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:92.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">60,000</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:104.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.45pt;position:var(--position);white-space:pre">Fabio Cataldi</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:104.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:116.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:38.11pt;position:var(--position);white-space:pre">Others</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:116.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">194,250</span></div></div></div></td></tr><tr style="height:72pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:128.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.91pt;position:var(--position);white-space:pre">Duration of vesting period</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:128.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">50% of the ordinary shares allocated shall vest on September 28, 2025;</span></div><div style="line-height:8pt;position:var(--position);top:12.71pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">25% of the ordinary shares allocated shall vest on September 28, 2026; and</span></div><div style="line-height:8pt;position:var(--position);top:22.79pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">25% of the ordinary shares allocated shall vest on September 28, 2027.</span></div><div style="line-height:8pt;position:var(--position);top:32.87pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">The acquisition of the Free Shares 2023-4 is subject to the successful completion of the initial public offering </span></div><div style="line-height:8pt;position:var(--position);top:42.87pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">of the Company&#8217;s shares (or depositary receipts representing any such shares) on the NASDAQ stock </span></div><div style="line-height:8pt;position:var(--position);top:52.87pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">exchange in New York allowing the Company to raise an amount of gross proceeds at least equal to two </span></div><div style="line-height:8pt;position:var(--position);top:62.87pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">hundred million dollars ($200,000,000) on or before the first anniversary of the allocation date.</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:200.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.45pt;position:var(--position);white-space:pre">Date of availability</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:200.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">The ordinary shares are not subject to a lock-up period once vested.</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:212.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.36pt;position:var(--position);white-space:pre">Free ordinary shares fully </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:212.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">108,500</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:244.5pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.8pt;position:var(--position);white-space:pre">Free ordinary shares being </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:244.5pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">89,750</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:276.75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.9pt;position:var(--position);white-space:pre">lapsed as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:276.75pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">56,000</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:309pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.35pt;position:var(--position);white-space:pre">Employment conditions</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:309pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">For all of the ordinary shares, the vesting is subject to the beneficiary of the plan retaining, on an ongoing </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">basis, the status of corporate officer or employee of the Company and/or one of its direct and/or indirect </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">subsidiaries, as applicable.</span></div></div></div></td></tr></tbody></table></div></div></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">114</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:var(--position);top:72pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:456pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:99.75pt"/><td style="padding:0;width:356.25pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:31.78pt;position:var(--position);white-space:pre">Plan name</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:113.17pt;position:var(--position);white-space:pre">Free ordinary share plan AGA 2023-5</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.8pt;position:var(--position);white-space:pre">General Meeting date</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:12pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">June 5, 2023</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.14pt;position:var(--position);white-space:pre">Board of Directors decision</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:24pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">December 1, 2023</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:36pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.02pt;position:var(--position);white-space:pre">granted by the Board of </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.89pt;position:var(--position);white-space:pre">Directors</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:36pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">132,750</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:68.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.45pt;position:var(--position);white-space:pre">Marc de Garidel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:68.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:80.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.34pt;position:var(--position);white-space:pre">Sylvie Gr&#233;goire</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:80.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:92.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.9pt;position:var(--position);white-space:pre">Didier Blondel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:92.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:104.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.45pt;position:var(--position);white-space:pre">Fabio Cataldi</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:104.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:116.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:38.11pt;position:var(--position);white-space:pre">Others</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:116.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">132,750</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:128.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.91pt;position:var(--position);white-space:pre">Duration of vesting period</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:128.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">50% of the ordinary shares allocated shall vest on December 1, 2025;</span></div><div style="line-height:8pt;position:var(--position);top:12.71pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">25% of the ordinary shares allocated shall vest on December 1, 2026; and</span></div><div style="line-height:8pt;position:var(--position);top:22.79pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">25% of the ordinary shares allocated shall vest on December 1, 2027.</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:160.5pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.45pt;position:var(--position);white-space:pre">Date of availability</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:160.5pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">The ordinary shares are not subject to a lock-up period once vested.</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:172.5pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.36pt;position:var(--position);white-space:pre">Free ordinary shares fully </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:172.5pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">27,625</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:204.75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.8pt;position:var(--position);white-space:pre">Free ordinary shares being </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:204.75pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">27,625</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:237pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.9pt;position:var(--position);white-space:pre">lapsed as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:237pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">77,500</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:269.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.35pt;position:var(--position);white-space:pre">Employment conditions</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:269.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">For all of the ordinary shares, the vesting is subject to the beneficiary of the plan retaining, on an ongoing </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">basis, the status of corporate officer or employee of the Company and/or one of its direct and/or indirect </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">subsidiaries, as applicable.</span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:404.3pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:456pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:99.75pt"/><td style="padding:0;width:356.25pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:31.78pt;position:var(--position);text-decoration:none;white-space:pre">Plan name</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:113.17pt;position:var(--position);white-space:pre">Free ordinary share plan AGA 2024-1</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.8pt;position:var(--position);text-decoration:none;white-space:pre">General Meeting date</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:12pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">June 5, 2023</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.14pt;position:var(--position);text-decoration:none;white-space:pre">Board of Directors decision</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:24pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">February 1, 2024</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:36pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.02pt;position:var(--position);text-decoration:none;white-space:pre">granted by the Board of </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.89pt;position:var(--position);text-decoration:none;white-space:pre">Directors</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:36pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">1,549,125</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:68.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.45pt;position:var(--position);white-space:pre">Marc de Garidel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:68.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">400,000</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:80.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.34pt;position:var(--position);white-space:pre">Sylvie Gr&#233;goire</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:80.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:92.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.9pt;position:var(--position);white-space:pre">Didier Blondel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:92.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">120,000</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:104.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.45pt;position:var(--position);white-space:pre">Fabio Cataldi</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:104.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:116.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:38.11pt;position:var(--position);white-space:pre">Others</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:116.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">1,029,125</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:128.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.91pt;position:var(--position);text-decoration:none;white-space:pre">Duration of vesting period </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:128.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.33pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">50% of the ordinary shares allocated shall vest on February 1, 2026;</span></div><div style="line-height:8pt;position:var(--position);top:13.41pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">25% of the ordinary shares allocated shall vest on February 1, 2027; and</span></div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">25% of the ordinary shares allocated shall vest on February 1, 2028.</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:160.5pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.45pt;position:var(--position);text-decoration:none;white-space:pre">Date of availability</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:160.5pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">The ordinary shares are not subject to a lock-up period once vested.</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:172.5pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.36pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares fully </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);text-decoration:none;white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:172.5pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">610,752</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:204.75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.8pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares being </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);text-decoration:none;white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:204.75pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">610,478</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:237pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.9pt;position:var(--position);text-decoration:none;white-space:pre">lapsed as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:237pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">327,625</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:269.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.35pt;position:var(--position);text-decoration:none;white-space:pre">Employment conditions</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:269.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">For all of the ordinary shares, the vesting is subject to the beneficiary of the plan retaining, on an ongoing </span></div><div style="line-height:8pt;position:var(--position);top:13.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">basis, the status of corporate officer or employee of the Company and/or one of its direct and/or indirect </span></div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">subsidiaries, as applicable.</span></div></div></div></td></tr></tbody></table></div></div></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">115</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:var(--position);top:94pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:456pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:99.75pt"/><td style="padding:0;width:356.25pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:31.78pt;position:var(--position);text-decoration:none;white-space:pre">Plan name</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:113.17pt;position:var(--position);white-space:pre">Free ordinary share plan AGA 2024-2</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.8pt;position:var(--position);text-decoration:none;white-space:pre">General Meeting date</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:12pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">June 5, 2023</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.14pt;position:var(--position);text-decoration:none;white-space:pre">Board of Directors decision</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:24pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">March 28, 2024</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:36pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.02pt;position:var(--position);text-decoration:none;white-space:pre">granted by the Board of </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.89pt;position:var(--position);text-decoration:none;white-space:pre">Directors</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:36pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">22,500</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:68.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.45pt;position:var(--position);white-space:pre">Marc de Garidel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:68.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:80.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.34pt;position:var(--position);white-space:pre">Sylvie Gr&#233;goire</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:80.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:92.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.9pt;position:var(--position);white-space:pre">Didier Blondel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:92.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:104.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.45pt;position:var(--position);white-space:pre">Fabio Cataldi</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:104.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:116.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:38.11pt;position:var(--position);white-space:pre">Others</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:116.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">22,500</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:128.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.91pt;position:var(--position);text-decoration:none;white-space:pre">Duration of vesting period</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:128.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.33pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">50% of the ordinary shares allocated shall vest on March 28, 2026;</span></div><div style="line-height:8pt;position:var(--position);top:13.41pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">25% of the ordinary shares allocated shall vest on March 28, 2027; and</span></div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">25% of the ordinary shares allocated shall vest on March 28, 2028.</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:160.5pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.45pt;position:var(--position);text-decoration:none;white-space:pre">Date of availability</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:160.5pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">The ordinary shares are not subject to a lock-up period once vested.</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:172.5pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.36pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares fully </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);text-decoration:none;white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:172.5pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:204.75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.8pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares being </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);text-decoration:none;white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:204.75pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">22,500</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:237pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.9pt;position:var(--position);text-decoration:none;white-space:pre">lapsed as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:237pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:269.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.24pt;position:var(--position);text-decoration:none;white-space:pre">Performance and </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.24pt;position:var(--position);text-decoration:none;white-space:pre">employment conditions</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:269.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">For all of the ordinary shares, the vesting is subject to the beneficiary of the plan retaining, on an ongoing </span></div><div style="line-height:8pt;position:var(--position);top:13.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">basis, the status of corporate officer or employee of the Company and/or one of its direct and/or indirect </span></div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">subsidiaries, as applicable.</span></div></div></div></td></tr></tbody></table></div></div></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">116</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:var(--position);top:72pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:456pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:99.75pt"/><td style="padding:0;width:356.25pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:31.78pt;position:var(--position);text-decoration:none;white-space:pre">Plan name</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:113.17pt;position:var(--position);white-space:pre">Free ordinary share plan AGA 2024-3</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.8pt;position:var(--position);text-decoration:none;white-space:pre">General Meeting date</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:12pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">June 5, 2023</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.14pt;position:var(--position);text-decoration:none;white-space:pre">Board of Directors decision</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:24pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">May 23, 2024</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:36pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.02pt;position:var(--position);text-decoration:none;white-space:pre">granted by the Board of </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.89pt;position:var(--position);text-decoration:none;white-space:pre">Directors</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:36pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">38,500</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:68.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.45pt;position:var(--position);white-space:pre">Marc de Garidel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:68.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:80.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.34pt;position:var(--position);white-space:pre">Sylvie Gr&#233;goire</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:80.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:92.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.9pt;position:var(--position);white-space:pre">Didier Blondel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:92.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:104.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.45pt;position:var(--position);white-space:pre">Fabio Cataldi</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:104.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:116.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:38.11pt;position:var(--position);white-space:pre">Others</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:116.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">38,500</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:128.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.91pt;position:var(--position);text-decoration:none;white-space:pre">Duration of vesting period</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:128.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.33pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">50% of the ordinary shares allocated shall vest on May 23, 2026;</span></div><div style="line-height:8pt;position:var(--position);top:13.41pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">25% of the ordinary shares allocated shall vest on May 23, 2027; and</span></div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">25% of the ordinary shares allocated shall vest on May 23, 2028.</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:160.5pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.45pt;position:var(--position);text-decoration:none;white-space:pre">Date of availability</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:160.5pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">The ordinary shares are not subject to a lock-up period once vested.</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:172.5pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.36pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares fully </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);text-decoration:none;white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:172.5pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:204.75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.8pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares being </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);text-decoration:none;white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:204.75pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">25,500</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:237pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.9pt;position:var(--position);text-decoration:none;white-space:pre">lapsed as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:237pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">13,000</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:269.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.24pt;position:var(--position);text-decoration:none;white-space:pre">Performance and </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.24pt;position:var(--position);text-decoration:none;white-space:pre">employment conditions</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:269.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">For all of the ordinary shares, the vesting is subject to the beneficiary of the plan retaining, on an ongoing </span></div><div style="line-height:8pt;position:var(--position);top:13.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">basis, the status of corporate officer or employee of the Company and/or one of its direct and/or indirect </span></div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">subsidiaries, as applicable.</span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:390.5pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:456pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:99.75pt"/><td style="padding:0;width:356.25pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:31.78pt;position:var(--position);text-decoration:none;white-space:pre">Plan name</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:113.17pt;position:var(--position);white-space:pre">Free ordinary share plan AGA 2024-4</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.8pt;position:var(--position);text-decoration:none;white-space:pre">General Meeting date</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:12pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">May 30, 2024</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.14pt;position:var(--position);text-decoration:none;white-space:pre">Board of Directors decision</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:24pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">July 11, 2024</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:36pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.02pt;position:var(--position);text-decoration:none;white-space:pre">granted by the Board of </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.89pt;position:var(--position);text-decoration:none;white-space:pre">Directors</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:36pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">93,000</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:68.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.45pt;position:var(--position);white-space:pre">Marc de Garidel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:68.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:80.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.34pt;position:var(--position);white-space:pre">Sylvie Gr&#233;goire</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:80.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:92.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.9pt;position:var(--position);white-space:pre">Didier Blondel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:92.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:104.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.45pt;position:var(--position);white-space:pre">Fabio Cataldi</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:104.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:116.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:38.11pt;position:var(--position);white-space:pre">Others</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:116.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">93,000</span></div></div></div></td></tr><tr style="height:42pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:128.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:33.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.91pt;position:var(--position);text-decoration:none;white-space:pre">Duration of vesting period</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:128.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:13.08pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">50% of the ordinary shares allocated shall vest on July 11, 2026;</span></div><div style="line-height:8pt;position:var(--position);top:23.16pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">25% of the ordinary shares allocated shall vest on July 11, 2027; and</span></div><div style="line-height:8pt;position:var(--position);top:33.24pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">25% of the ordinary shares allocated shall vest on July 11, 2028.</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:170.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.45pt;position:var(--position);text-decoration:none;white-space:pre">Date of availability</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:170.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">The ordinary shares are not subject to a lock-up period once vested.</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:182.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.36pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares fully </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);text-decoration:none;white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:182.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:214.5pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.8pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares being </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);text-decoration:none;white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:214.5pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">93,000</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:246.75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.9pt;position:var(--position);text-decoration:none;white-space:pre">lapsed as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:246.75pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:279pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.24pt;position:var(--position);text-decoration:none;white-space:pre">Performance and </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.24pt;position:var(--position);text-decoration:none;white-space:pre">employment conditions</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:279pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">For all of the ordinary shares, the vesting is subject to the beneficiary of the plan retaining, on an ongoing </span></div><div style="line-height:8pt;position:var(--position);top:13.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">basis, the status of corporate officer or employee of the Company and/or one of its direct and/or indirect </span></div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">subsidiaries, as applicable.</span></div></div></div></td></tr></tbody></table></div></div></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">117</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:var(--position);top:138pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:456pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:99.75pt"/><td style="padding:0;width:356.25pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:31.78pt;position:var(--position);text-decoration:none;white-space:pre">Plan name</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:113.17pt;position:var(--position);white-space:pre">Free ordinary share plan AGA 2024-5</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.8pt;position:var(--position);text-decoration:none;white-space:pre">General Meeting date</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:12pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">May 30, 2024</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.14pt;position:var(--position);text-decoration:none;white-space:pre">Board of Directors decision</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:24pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">July 11, 2024</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:36pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.02pt;position:var(--position);text-decoration:none;white-space:pre">granted by the Board of </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.89pt;position:var(--position);text-decoration:none;white-space:pre">Directors</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:36pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">25,000</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:68.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.45pt;position:var(--position);white-space:pre">Marc de Garidel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:68.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:80.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.34pt;position:var(--position);white-space:pre">Sylvie Gr&#233;goire</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:80.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">25,000</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:92.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.9pt;position:var(--position);white-space:pre">Didier Blondel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:92.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:104.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.45pt;position:var(--position);white-space:pre">Fabio Cataldi</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:104.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:116.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:38.11pt;position:var(--position);white-space:pre">Others</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:116.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:128.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.91pt;position:var(--position);text-decoration:none;white-space:pre">Duration of vesting period</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:128.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.33pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">50% of the ordinary shares allocated shall vest on July 11, 2026;</span></div><div style="line-height:8pt;position:var(--position);top:13.41pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">25% of the ordinary shares allocated shall vest on July 11, 2027; and</span></div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">25% of the ordinary shares allocated shall vest on July 11, 2028.</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:160.5pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.45pt;position:var(--position);text-decoration:none;white-space:pre">Date of availability</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:160.5pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">The ordinary shares are not subject to a lock-up period once vested.</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:172.5pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.36pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares fully </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);text-decoration:none;white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:172.5pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:204.75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.8pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares being </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);text-decoration:none;white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:204.75pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">25,000</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:237pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.9pt;position:var(--position);text-decoration:none;white-space:pre">lapsed as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:237pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:269.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.24pt;position:var(--position);text-decoration:none;white-space:pre">Performance and </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.24pt;position:var(--position);text-decoration:none;white-space:pre">employment conditions</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:269.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">For all of the ordinary shares, the vesting is subject to the beneficiary of the plan retaining, on an ongoing </span></div><div style="line-height:8pt;position:var(--position);top:13.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">basis, the status of corporate officer or employee of the Company and/or one of its direct and/or indirect </span></div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">subsidiaries, as applicable.</span></div></div></div></td></tr></tbody></table></div></div></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">118</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:var(--position);top:72pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:456pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:99.75pt"/><td style="padding:0;width:356.25pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:31.78pt;position:var(--position);text-decoration:none;white-space:pre">Plan name</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:113.17pt;position:var(--position);white-space:pre">Free ordinary share plan AGA 2024-6</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.8pt;position:var(--position);text-decoration:none;white-space:pre">General Meeting date</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:12pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">May 30, 2024</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.14pt;position:var(--position);text-decoration:none;white-space:pre">Board of Directors decision</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:24pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">July 11, 2024</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:36pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.02pt;position:var(--position);text-decoration:none;white-space:pre">granted by the Board of </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.89pt;position:var(--position);text-decoration:none;white-space:pre">Directors</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:36pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">20,000</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:68.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.45pt;position:var(--position);white-space:pre">Marc de Garidel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:68.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:80.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.34pt;position:var(--position);white-space:pre">Sylvie Gr&#233;goire</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:80.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:92.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.9pt;position:var(--position);white-space:pre">Didier Blondel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:92.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:104.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.45pt;position:var(--position);white-space:pre">Fabio Cataldi</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:104.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:116.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:38.11pt;position:var(--position);white-space:pre">Others</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:116.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">20,000</span></div></div></div></td></tr><tr style="height:42pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:128.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:33.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.91pt;position:var(--position);text-decoration:none;white-space:pre">Duration of vesting period</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:128.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:13.16pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">50% of the ordinary shares allocated shall vest on July 11, 2025; and</span></div><div style="line-height:8pt;position:var(--position);top:23.24pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">50% of the ordinary shares allocated shall vest on the latest date between July 11, 2025 and the </span></div><div style="line-height:8pt;position:var(--position);top:33.24pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">date on which the performance condition is fulfilled</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:170.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:13.12pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.45pt;position:var(--position);text-decoration:none;white-space:pre">Date of availability</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:170.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.99pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Each ordinary share vesting before July 11, 2026 shall be subject to a lock-up period ending on July 11, </span></div><div style="line-height:8pt;position:var(--position);top:12.99pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">2026. Ordinary shares vesting after July 11, 2026 are not subject to a lock-up period.</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:192pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.36pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares fully </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);text-decoration:none;white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:192pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">10,000</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:224.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.8pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares being </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.13pt;position:var(--position);text-decoration:none;white-space:pre">vested as of February 28 </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:224.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">10,000</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:256.5pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.9pt;position:var(--position);text-decoration:none;white-space:pre">lapsed as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:256.5pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:288.75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.24pt;position:var(--position);text-decoration:none;white-space:pre">Performance and </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.24pt;position:var(--position);text-decoration:none;white-space:pre">employment conditions</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:288.75pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Performance condition to be fulfilled relates to the publication of a scientific article on obefazimod's </span></div><div style="line-height:8pt;position:var(--position);top:13.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">mechanism of action authored by the beneficiary in a reputable journal prior to July 11, 2027. No </span></div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">employment condition.</span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:410pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:456pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:99.75pt"/><td style="padding:0;width:356.25pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:31.78pt;position:var(--position);text-decoration:none;white-space:pre">Plan name</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:113.17pt;position:var(--position);white-space:pre">Free ordinary share plan AGA 2024-7</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.8pt;position:var(--position);text-decoration:none;white-space:pre">General Meeting date</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:12pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">May 30, 2024</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.14pt;position:var(--position);text-decoration:none;white-space:pre">Board of Directors decision</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:24pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">September 5, 2024</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:36pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.02pt;position:var(--position);text-decoration:none;white-space:pre">granted by the Board of </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.89pt;position:var(--position);text-decoration:none;white-space:pre">Directors</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:36pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">198,000</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:68.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.45pt;position:var(--position);white-space:pre">Marc de Garidel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:68.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:80.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.34pt;position:var(--position);white-space:pre">Sylvie Gr&#233;goire</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:80.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:92.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.9pt;position:var(--position);white-space:pre">Didier Blondel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:92.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:104.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.45pt;position:var(--position);white-space:pre">Fabio Cataldi</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:104.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">150,000</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:116.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:38.11pt;position:var(--position);white-space:pre">Others</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:116.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">48,000</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:128.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.91pt;position:var(--position);text-decoration:none;white-space:pre">Duration of vesting period</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:128.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.33pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">50% of the ordinary shares allocated shall vest on September 5, 2026;</span></div><div style="line-height:8pt;position:var(--position);top:13.41pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">25% of the ordinary shares allocated shall vest on September 5, 2027; and</span></div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">25% of the ordinary shares allocated shall vest on September 5, 2028.</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:160.5pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.45pt;position:var(--position);text-decoration:none;white-space:pre">Date of availability</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:160.5pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">The ordinary shares are not subject to a lock-up period once vested.</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:172.5pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.36pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares fully </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);text-decoration:none;white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:172.5pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:204.75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.8pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares being </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);text-decoration:none;white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:204.75pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">198,000</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:237pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.9pt;position:var(--position);text-decoration:none;white-space:pre">lapsed as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:237pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:269.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.24pt;position:var(--position);text-decoration:none;white-space:pre">Performance and </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.24pt;position:var(--position);text-decoration:none;white-space:pre">employment conditions</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:269.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">For all of the ordinary shares, the vesting is subject to the beneficiary of the plan retaining, on an ongoing </span></div><div style="line-height:8pt;position:var(--position);top:13.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">basis, the status of corporate officer or employee of the Company and/or one of its direct and/or indirect </span></div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">subsidiaries, as applicable.</span></div></div></div></td></tr></tbody></table></div></div></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">119</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:var(--position);top:72pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:456pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:99.75pt"/><td style="padding:0;width:356.25pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:31.78pt;position:var(--position);text-decoration:none;white-space:pre">Plan name</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:113.17pt;position:var(--position);white-space:pre">Free ordinary share plan AGA 2025-1</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.8pt;position:var(--position);text-decoration:none;white-space:pre">General Meeting date</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:12pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">May 30, 2024</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.14pt;position:var(--position);text-decoration:none;white-space:pre">Board of Directors decision</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:24pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">February 6, 2025</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:36pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.02pt;position:var(--position);text-decoration:none;white-space:pre">granted by the Board of </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.89pt;position:var(--position);text-decoration:none;white-space:pre">Directors</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:36pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">4,319,500</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:68.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.45pt;position:var(--position);white-space:pre">Marc de Garidel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:68.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">936,000</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:80.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.34pt;position:var(--position);white-space:pre">Sylvie Gr&#233;goire</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:80.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:92.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.9pt;position:var(--position);white-space:pre">Didier Blondel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:92.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">480,000</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:104.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.45pt;position:var(--position);white-space:pre">Fabio Cataldi</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:104.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">430,000</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:116.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:38.11pt;position:var(--position);white-space:pre">Others</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:116.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2,473,500</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:128.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.91pt;position:var(--position);text-decoration:none;white-space:pre">Duration of vesting period</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:128.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.33pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">50% of the ordinary shares allocated shall vest on February 6, 2027;</span></div><div style="line-height:8pt;position:var(--position);top:13.41pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">25% of the ordinary shares allocated shall vest on February 6, 2028; and</span></div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">25% of the ordinary shares allocated shall vest on February 6, 2029.</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:160.5pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.45pt;position:var(--position);text-decoration:none;white-space:pre">Date of availability</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:160.5pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">The ordinary shares are not subject to a lock-up period once vested.</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:172.5pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.36pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares fully </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);text-decoration:none;white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:172.5pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:204.75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.8pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares being </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);text-decoration:none;white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:204.75pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">4,102,000</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:237pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.9pt;position:var(--position);text-decoration:none;white-space:pre">lapsed as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:237pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">217,500</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:269.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.24pt;position:var(--position);text-decoration:none;white-space:pre">Performance and </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.24pt;position:var(--position);text-decoration:none;white-space:pre">employment conditions</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:269.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">For all of the ordinary shares, the vesting is subject to the beneficiary of the plan retaining, on an ongoing </span></div><div style="line-height:8pt;position:var(--position);top:13.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">basis, the status of corporate officer or employee of the Company and/or one of its direct and/or indirect </span></div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">subsidiaries, as applicable.</span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:390.5pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:456pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:99.75pt"/><td style="padding:0;width:356.25pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:31.78pt;position:var(--position);text-decoration:none;white-space:pre">Plan name</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:113.17pt;position:var(--position);white-space:pre">Free ordinary share plan AGA 2025-2</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.8pt;position:var(--position);text-decoration:none;white-space:pre">General Meeting date</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:12pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">May 30, 2024</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.14pt;position:var(--position);text-decoration:none;white-space:pre">Board of Directors decision</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:24pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">February 6, 2025</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:36pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.02pt;position:var(--position);text-decoration:none;white-space:pre">granted by the Board of </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.89pt;position:var(--position);text-decoration:none;white-space:pre">Directors</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:36pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">123,102</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:68.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.45pt;position:var(--position);white-space:pre">Marc de Garidel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:68.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">47,052</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:80.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.34pt;position:var(--position);white-space:pre">Sylvie Gr&#233;goire</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:80.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:92.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.9pt;position:var(--position);white-space:pre">Didier Blondel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:92.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">15,939</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:104.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.45pt;position:var(--position);white-space:pre">Fabio Cataldi</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:104.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">7,148</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:116.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:38.11pt;position:var(--position);white-space:pre">Others</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:116.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">52,963</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:128.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.91pt;position:var(--position);text-decoration:none;white-space:pre">Duration of vesting period</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:128.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">100% of the ordinary shares allocated shall vest on February 6, 2027.</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:140.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.45pt;position:var(--position);text-decoration:none;white-space:pre">Date of availability</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:140.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">The ordinary shares are not subject to a lock-up period once vested.</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:152.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.36pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares fully </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);text-decoration:none;white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:152.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:184.5pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.8pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares being </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);text-decoration:none;white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:184.5pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">123,102</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:216.75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.9pt;position:var(--position);text-decoration:none;white-space:pre">lapsed as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:216.75pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:249pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.24pt;position:var(--position);text-decoration:none;white-space:pre">Performance and </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.24pt;position:var(--position);text-decoration:none;white-space:pre">employment conditions</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:249pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">For all of the ordinary shares, the vesting is subject to the beneficiary of the plan retaining, on an ongoing </span></div><div style="line-height:8pt;position:var(--position);top:13.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">basis, the status of corporate officer or employee of the Company and/or one of its direct and/or indirect </span></div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">subsidiaries, as applicable.</span></div></div></div></td></tr></tbody></table></div></div></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">120</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:var(--position);top:72pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:456pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:99.75pt"/><td style="padding:0;width:356.25pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:31.78pt;position:var(--position);text-decoration:none;white-space:pre">Plan name</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:113.17pt;position:var(--position);white-space:pre">Free ordinary share plan AGA 2025-3</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.8pt;position:var(--position);text-decoration:none;white-space:pre">General Meeting date</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:12pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">May 30, 2024</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.14pt;position:var(--position);text-decoration:none;white-space:pre">Board of Directors decision</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:24pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">February 6, 2025</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:36pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.02pt;position:var(--position);text-decoration:none;white-space:pre">granted by the Board of </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.89pt;position:var(--position);text-decoration:none;white-space:pre">Directors</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:36pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">17,625</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:68.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.45pt;position:var(--position);white-space:pre">Marc de Garidel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:68.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:80.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.34pt;position:var(--position);white-space:pre">Sylvie Gr&#233;goire</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:80.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:92.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.9pt;position:var(--position);white-space:pre">Didier Blondel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:92.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:104.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.45pt;position:var(--position);white-space:pre">Fabio Cataldi</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:104.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:116.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:38.11pt;position:var(--position);white-space:pre">Others</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:116.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">17,625</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:128.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.91pt;position:var(--position);text-decoration:none;white-space:pre">Duration of vesting period</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:128.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.33pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">50% of the ordinary shares allocated shall vest on February 6, 2027;</span></div><div style="line-height:8pt;position:var(--position);top:13.41pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">25% of the ordinary shares allocated shall vest on February 6, 2028; and</span></div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">25% of the ordinary shares allocated shall vest on February 6, 2029.</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:160.5pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.45pt;position:var(--position);text-decoration:none;white-space:pre">Date of availability</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:160.5pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">The ordinary shares are not subject to a lock-up period once vested.</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:172.5pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.36pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares fully </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);text-decoration:none;white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:172.5pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:204.75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.8pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares being </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);text-decoration:none;white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:204.75pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">17,625</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:237pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.9pt;position:var(--position);text-decoration:none;white-space:pre">lapsed as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:237pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:269.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.24pt;position:var(--position);text-decoration:none;white-space:pre">Performance and </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.24pt;position:var(--position);text-decoration:none;white-space:pre">employment conditions</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:269.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">For all of the ordinary shares, the vesting is subject to the beneficiary of the plan retaining, on an ongoing </span></div><div style="line-height:8pt;position:var(--position);top:13.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">basis, the status of corporate officer or employee of the Company and/or one of its direct and/or indirect </span></div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">subsidiaries, as applicable.</span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:390.5pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:456pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:99.75pt"/><td style="padding:0;width:356.25pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:31.78pt;position:var(--position);text-decoration:none;white-space:pre">Plan name</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:113.17pt;position:var(--position);white-space:pre">Free ordinary share plan AGA 2025-4</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.8pt;position:var(--position);text-decoration:none;white-space:pre">General Meeting date</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:12pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">May 30, 2024</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.14pt;position:var(--position);text-decoration:none;white-space:pre">Board of Directors decision</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:24pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">February 6, 2025</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:36pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.02pt;position:var(--position);text-decoration:none;white-space:pre">granted by the Board of </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.89pt;position:var(--position);text-decoration:none;white-space:pre">Directors</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:36pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">30,500</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:68.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.45pt;position:var(--position);white-space:pre">Marc de Garidel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:68.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:80.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.34pt;position:var(--position);white-space:pre">Sylvie Gr&#233;goire</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:80.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">30,500</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:92.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.9pt;position:var(--position);white-space:pre">Didier Blondel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:92.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:104.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.45pt;position:var(--position);white-space:pre">Fabio Cataldi</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:104.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:116.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:38.11pt;position:var(--position);white-space:pre">Others</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:116.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:128.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.91pt;position:var(--position);text-decoration:none;white-space:pre">Duration of vesting period</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:128.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.33pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">50% of the ordinary shares allocated shall vest on February 6, 2027;</span></div><div style="line-height:8pt;position:var(--position);top:13.41pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">25% of the ordinary shares allocated shall vest on February 6, 2028; and</span></div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">25% of the ordinary shares allocated shall vest on February 6, 2029.</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:160.5pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.45pt;position:var(--position);text-decoration:none;white-space:pre">Date of availability</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:160.5pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">The ordinary shares are not subject to a lock-up period once vested.</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:172.5pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.36pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares fully </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);text-decoration:none;white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:172.5pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:204.75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.8pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares being </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);text-decoration:none;white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:204.75pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">30,500</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:237pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);text-decoration:none;white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.9pt;position:var(--position);text-decoration:none;white-space:pre">lapsed as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:237pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:269.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:13.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.24pt;position:var(--position);text-decoration:none;white-space:pre">Performance and </span></div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.24pt;position:var(--position);text-decoration:none;white-space:pre">employment conditions</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:269.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">For all of the ordinary shares, the vesting is subject to the beneficiary of the plan retaining, on an ongoing </span></div><div style="line-height:8pt;position:var(--position);top:13.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">basis, the status of corporate officer or employee of the Company and/or one of its direct and/or indirect </span></div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">subsidiaries, as applicable.</span></div></div></div></td></tr></tbody></table></div></div></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">121</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:var(--position);top:72pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:456pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:99.75pt"/><td style="padding:0;width:356.25pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:31.78pt;position:var(--position);white-space:pre">Plan name</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:113.17pt;position:var(--position);white-space:pre">Free ordinary share plan AGA 2025-5</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.8pt;position:var(--position);white-space:pre">General Meeting date</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:12pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">May 30, 2024</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.14pt;position:var(--position);white-space:pre">Board of Directors decision</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:24pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">March 20, 2025</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:36pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.02pt;position:var(--position);white-space:pre">granted by the Board of </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.89pt;position:var(--position);white-space:pre">Directors</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:36pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">50,000</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:68.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.45pt;position:var(--position);white-space:pre">Marc de Garidel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:68.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:80.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.34pt;position:var(--position);white-space:pre">Sylvie Gr&#233;goire</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:80.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:92.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.9pt;position:var(--position);white-space:pre">Didier Blondel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:92.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:104.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.45pt;position:var(--position);white-space:pre">Fabio Cataldi</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:104.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:116.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:38.11pt;position:var(--position);white-space:pre">Others</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:116.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">50,000</span></div></div></div></td></tr><tr style="height:60.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:128.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.91pt;position:var(--position);white-space:pre">Duration of vesting period</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:128.25pt;width:356.25pt"><div><div style="line-height:12pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">50% of the ordinary shares allocated shall vest on the earliest of March 20, 2026 and the </span></div><div style="line-height:8pt;position:var(--position);top:17.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">fulfillment of condition; and</span></div><div style="line-height:12pt;position:var(--position);top:32.71pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">50% of the ordinary shares allocated shall vest on the earliest of March 20, 2026 and the </span></div><div style="line-height:8pt;position:var(--position);top:47.71pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">fulfillment of condition.</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:189pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.45pt;position:var(--position);white-space:pre">Date of availability</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:189pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">The ordinary shares are not subject to a lock-up period once vested.</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:201pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.36pt;position:var(--position);white-space:pre">Free ordinary shares fully </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:201pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">0</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:233.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.8pt;position:var(--position);white-space:pre">Free ordinary shares being </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:233.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">0</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:265.5pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.9pt;position:var(--position);white-space:pre">lapsed as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:265.5pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">50,000</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:297.75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.24pt;position:var(--position);white-space:pre">Performance and </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.24pt;position:var(--position);white-space:pre">employment conditions</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:297.75pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">For all of the ordinary shares, the vesting is subject to the beneficiary of the plan retaining, on an ongoing </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">basis, the status of corporate officer or employee of the Company and/or one of its direct and/or indirect </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">subsidiaries, as applicable.</span></div></div></div></td></tr></tbody></table></div></div></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">122</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:var(--position);top:72pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:456pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:99.75pt"/><td style="padding:0;width:356.25pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:31.78pt;position:var(--position);white-space:pre">Plan name</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:113.17pt;position:var(--position);white-space:pre">Free ordinary share plan AGA 2025-6</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.8pt;position:var(--position);white-space:pre">General Meeting date</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:12pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">May 30, 2024</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.14pt;position:var(--position);white-space:pre">Board of Directors decision</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:24pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">May 28, 2025</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:36pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.02pt;position:var(--position);white-space:pre">granted by the Board of </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.89pt;position:var(--position);white-space:pre">Directors</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:36pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">25,000</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:68.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.45pt;position:var(--position);white-space:pre">Marc de Garidel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:68.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:80.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.34pt;position:var(--position);white-space:pre">Sylvie Gr&#233;goire</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:80.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:92.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.9pt;position:var(--position);white-space:pre">Didier Blondel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:92.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:104.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.45pt;position:var(--position);white-space:pre">Fabio Cataldi</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:104.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:116.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:38.11pt;position:var(--position);white-space:pre">Others</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:116.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">25,000</span></div></div></div></td></tr><tr style="height:60.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:128.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.91pt;position:var(--position);white-space:pre">Duration of vesting period</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:128.25pt;width:356.25pt"><div><div style="line-height:12pt;position:var(--position);top:17.71pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">50% of the ordinary shares allocated shall vest on May 28, 2027;</span></div><div style="line-height:12pt;position:var(--position);top:32.79pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">25% of the ordinary shares allocated shall vest on May 28 2028; and</span></div><div style="line-height:12pt;position:var(--position);top:47.87pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">25% of the ordinary shares allocated shall vest on May 28 2029.</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:189pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.45pt;position:var(--position);white-space:pre">Date of availability</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:189pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">The ordinary shares are not subject to a lock-up period once vested.</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:201pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.36pt;position:var(--position);white-space:pre">Free ordinary shares fully </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:201pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:349.62pt;position:var(--position);white-space:pre">0</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:233.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.8pt;position:var(--position);white-space:pre">Free ordinary shares being </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:233.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">25,000</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:265.5pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.9pt;position:var(--position);white-space:pre">lapsed as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:265.5pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:349.62pt;position:var(--position);white-space:pre">0</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:297.75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.24pt;position:var(--position);white-space:pre">Performance and </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.24pt;position:var(--position);white-space:pre">employment conditions</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:297.75pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">For all of the ordinary shares, the vesting is subject to the beneficiary of the plan retaining, on an ongoing </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">basis, the status of corporate officer or employee of the Company and/or one of its direct and/or indirect </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">subsidiaries, as applicable.</span></div></div></div></td></tr></tbody></table></div></div></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">123</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:var(--position);top:72pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:456pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:99.75pt"/><td style="padding:0;width:356.25pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:31.78pt;position:var(--position);white-space:pre">Plan name</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:113.17pt;position:var(--position);white-space:pre">Free ordinary share plan AGA 2025-7</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.8pt;position:var(--position);white-space:pre">General Meeting date</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:12pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">June 6, 2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.14pt;position:var(--position);white-space:pre">Board of Directors decision</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:24pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">August 1, 2025</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:36pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.02pt;position:var(--position);white-space:pre">granted by the Board of </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.89pt;position:var(--position);white-space:pre">Directors</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:36pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">1,711,000</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:68.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.45pt;position:var(--position);white-space:pre">Marc de Garidel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:68.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">100,000</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:80.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.34pt;position:var(--position);white-space:pre">Sylvie Gr&#233;goire</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:80.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:92.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.9pt;position:var(--position);white-space:pre">Didier Blondel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:92.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">130,000</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:104.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.45pt;position:var(--position);white-space:pre">Fabio Cataldi</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:104.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">50,000</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:116.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:38.11pt;position:var(--position);white-space:pre">Others</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:116.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">1,431,000</span></div></div></div></td></tr><tr style="height:60.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:128.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.91pt;position:var(--position);white-space:pre">Duration of vesting period</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:128.25pt;width:356.25pt"><div><div style="line-height:12pt;position:var(--position);top:17.71pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">50% of the ordinary shares allocated shall vest on August 1, 2027;</span></div><div style="line-height:12pt;position:var(--position);top:32.79pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">25% of the ordinary shares allocated shall vest on August 1 2028; and</span></div><div style="line-height:12pt;position:var(--position);top:47.87pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">25% of the ordinary shares allocated shall vest on August 1, 2029.</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:189pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.45pt;position:var(--position);white-space:pre">Date of availability</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:189pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">The ordinary shares are not subject to a lock-up period once vested.</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:201pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.36pt;position:var(--position);white-space:pre">Free ordinary shares fully </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:201pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:349.62pt;position:var(--position);white-space:pre">0</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:233.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.8pt;position:var(--position);white-space:pre">Free ordinary shares being </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:233.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">1,631,000</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:265.5pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.9pt;position:var(--position);white-space:pre">lapsed as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:265.5pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">80,000</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:297.75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.24pt;position:var(--position);white-space:pre">Performance and </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.24pt;position:var(--position);white-space:pre">employment conditions</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:297.75pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">For all of the ordinary shares, the vesting is subject to the beneficiary of the plan retaining, on an ongoing </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">basis, the status of corporate officer or employee of the Company and/or one of its direct and/or indirect </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">subsidiaries, as applicable.</span></div></div></div></td></tr></tbody></table></div></div></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">124</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:var(--position);top:72pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:456pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:99.75pt"/><td style="padding:0;width:356.25pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:31.78pt;position:var(--position);white-space:pre">Plan name</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:113.17pt;position:var(--position);white-space:pre">Free ordinary share plan AGA 2025-8</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.8pt;position:var(--position);white-space:pre">General Meeting date</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:12pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">June 6, 2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.14pt;position:var(--position);white-space:pre">Board of Directors decision</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:24pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">November 13, 2025</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:36pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.02pt;position:var(--position);white-space:pre">granted by the Board of </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.89pt;position:var(--position);white-space:pre">Directors</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:36pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">4,000</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:68.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.45pt;position:var(--position);white-space:pre">Marc de Garidel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:68.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:80.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.34pt;position:var(--position);white-space:pre">Sylvie Gr&#233;goire</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:80.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:92.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.9pt;position:var(--position);white-space:pre">Didier Blondel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:92.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:104.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.45pt;position:var(--position);white-space:pre">Fabio Cataldi</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:104.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:116.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:38.11pt;position:var(--position);white-space:pre">Others</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:116.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">4,000</span></div></div></div></td></tr><tr style="height:60.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:128.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.91pt;position:var(--position);white-space:pre">Duration of vesting period</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:128.25pt;width:356.25pt"><div><div style="line-height:12pt;position:var(--position);top:17.71pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">50% of the ordinary shares allocated shall vest on November 13, 2027;</span></div><div style="line-height:12pt;position:var(--position);top:32.79pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">25% of the ordinary shares allocated shall vest on November 13 2028; and</span></div><div style="line-height:12pt;position:var(--position);top:47.87pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">25% of the ordinary shares allocated shall vest on November 13, 2029.</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:189pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.45pt;position:var(--position);white-space:pre">Date of availability</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:189pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">The ordinary shares are not subject to a lock-up period once vested.</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:201pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.36pt;position:var(--position);white-space:pre">Free ordinary shares fully </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:201pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:349.62pt;position:var(--position);white-space:pre">0</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:233.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.8pt;position:var(--position);white-space:pre">Free ordinary shares being </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:233.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">4,000</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:265.5pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.9pt;position:var(--position);white-space:pre">lapsed as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:265.5pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:349.62pt;position:var(--position);white-space:pre">0</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:297.75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.24pt;position:var(--position);white-space:pre">Performance and </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.24pt;position:var(--position);white-space:pre">employment conditions</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:297.75pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">For all of the ordinary shares, the vesting is subject to the beneficiary of the plan retaining, on an ongoing </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">basis, the status of corporate officer or employee of the Company and/or one of its direct and/or indirect </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">subsidiaries, as applicable.</span></div></div></div></td></tr></tbody></table></div></div></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">125</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:var(--position);top:72pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:456pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:99.75pt"/><td style="padding:0;width:356.25pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:31.78pt;position:var(--position);white-space:pre">Plan name</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:113.17pt;position:var(--position);white-space:pre">Free ordinary share plan AGA 2026-1</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.8pt;position:var(--position);white-space:pre">General Meeting date</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:12pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">June 6, 2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.14pt;position:var(--position);white-space:pre">Board of Directors decision</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:24pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">February 5, 2026</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:36pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.02pt;position:var(--position);white-space:pre">granted by the Board of </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.89pt;position:var(--position);white-space:pre">Directors</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:36pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">47,500</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:68.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.45pt;position:var(--position);white-space:pre">Marc de Garidel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:68.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:80.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.34pt;position:var(--position);white-space:pre">Sylvie Gr&#233;goire</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:80.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:92.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.9pt;position:var(--position);white-space:pre">Didier Blondel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:92.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:104.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.45pt;position:var(--position);white-space:pre">Fabio Cataldi</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:104.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:116.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:38.11pt;position:var(--position);white-space:pre">Others</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:116.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">47,500</span></div></div></div></td></tr><tr style="height:60.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:128.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.91pt;position:var(--position);white-space:pre">Duration of vesting period</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:128.25pt;width:356.25pt"><div><div style="line-height:12pt;position:var(--position);top:17.71pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">50% of the ordinary shares allocated shall vest on February 5, 2028;</span></div><div style="line-height:12pt;position:var(--position);top:32.79pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">25% of the ordinary shares allocated shall vest on February 5, 2029; and</span></div><div style="line-height:12pt;position:var(--position);top:47.87pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:20.630000000000003pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.63pt;position:var(--position);white-space:pre">25% of the ordinary shares allocated shall vest on February 5, 2030.</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:189pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.45pt;position:var(--position);white-space:pre">Date of availability</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:189pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">The ordinary shares are not subject to a lock-up period once vested.</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:201pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.36pt;position:var(--position);white-space:pre">Free ordinary shares fully </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:201pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:349.62pt;position:var(--position);white-space:pre">0</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:233.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.8pt;position:var(--position);white-space:pre">Free ordinary shares being </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.13pt;position:var(--position);white-space:pre">vested as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:233.25pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">47,500</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:265.5pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.13pt;position:var(--position);white-space:pre">Free ordinary shares </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.9pt;position:var(--position);white-space:pre">lapsed as of February 28, </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.87pt;position:var(--position);white-space:pre">2026</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:265.5pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:349.62pt;position:var(--position);white-space:pre">0</span></div></div></div></td></tr><tr style="height:32.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:297.75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.24pt;position:var(--position);white-space:pre">Performance and </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:99.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.24pt;position:var(--position);white-space:pre">employment conditions</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:99.75pt;position:var(--position);top:297.75pt;width:356.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">For all of the ordinary shares, the vesting is subject to the beneficiary of the plan retaining, on an ongoing </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">basis, the status of corporate officer or employee of the Company and/or one of its direct and/or indirect </span></div><div style="line-height:8pt;position:var(--position);top:22.63pt;width:356.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">subsidiaries, as applicable.</span></div></div></div></td></tr></tbody></table></div></div></div><div style="line-height:10pt;position:var(--position);top:419pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">General note: all of our AGA plans provide for specific cases of acceleration resulting in the vesting of said AGAs </span></div><div style="line-height:10pt;position:var(--position);top:429pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">in the event of the occurrence of specific events and in particular in the event of a change of control of us. </span></div><div style="position:absolute;top:439pt" id="i7a006daedb3d4216a4128b76247285d7_91"></div><div style="line-height:10pt;position:var(--position);top:439pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">C.<span id="i31fb17b3491e46798f7c9cdefb8783db"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Board Practices</span></div><div style="line-height:10pt;position:var(--position);top:469pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Board Composition</span></div><div style="line-height:10pt;position:var(--position);top:485pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our Board currently consists of seven members. The rules of procedure of our Board set the principles guiding </span></div><div style="line-height:10pt;position:var(--position);top:495pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the composition of the Board. The most recent version of this document was adopted by our Board in April 2021 </span></div><div style="line-height:10pt;position:var(--position);top:505pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and subsequently amended in September 2023.The Board has established three permanent, specialized committees </span></div><div style="line-height:10pt;position:var(--position);top:515pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to assist the Board in its work: (1) the audit committee, (2) the remuneration committee and (3) the nomination and </span></div><div style="line-height:10pt;position:var(--position);top:525pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">governance committee. The Board has also established two ad hoc committees: (1) the scientific and clinical </span></div><div style="line-height:10pt;position:var(--position);top:535pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">committee and (2) the commercial committee. Subject to available exemptions, the composition and functioning of </span></div><div style="line-height:10pt;position:var(--position);top:545pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">all of our committees will comply with applicable requirements of the French Commercial Code, the Exchange Act, </span></div><div style="line-height:10pt;position:var(--position);top:555pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the Nasdaq Global Market and SEC rules and regulations.</span></div><div style="line-height:10pt;position:var(--position);top:571pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In accordance with French law, committees of our Board only have an advisory role and can only make </span></div><div style="line-height:10pt;position:var(--position);top:581pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">recommendations to our Board. As a result, decisions will be made by our Board taking into account non-binding </span></div><div style="line-height:10pt;position:var(--position);top:591pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">recommendations of the relevant Board committee. Since July 2024, our Board has been chaired by Dr. Gr&#233;goire. </span></div><div style="line-height:10pt;position:var(--position);top:601pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">Our Chief Executive Officer, Mr. de Garidel, represents us </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:309.5pt;position:var(--position);white-space:pre">vis-&#224;-vis</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:343.34pt;position:var(--position);white-space:pre"> third parties in his capacity as Chief Executive </span></div><div style="line-height:10pt;position:var(--position);top:611pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">Officer.</span></div><div style="line-height:10pt;position:var(--position);top:627pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">All members of the Board may serve for a maximum of four years, expiring at the end of the shareholders&#8217; </span></div><div style="line-height:10pt;position:var(--position);top:637pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">meeting called to approve the financial statements from the previous year and held during the year in which the term </span></div><div style="line-height:10pt;position:var(--position);top:647pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">expires. Members of the Board may be re-elected. They may be dismissed at any time by a decision of the ordinary </span></div><div style="line-height:10pt;position:var(--position);top:657pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">general meeting of shareholders. The composition of our Board is described below:</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">126</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:var(--position);top:72pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:469.5pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:209.25pt"/><td style="padding:0;width:85.5pt"/><td style="padding:0;width:99pt"/><td style="padding:0;width:75.75pt"/></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:209.25pt;position:var(--position);width:85.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:85.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14pt;position:var(--position);text-decoration:none;white-space:pre">Current Position</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:294.75pt;position:var(--position);width:99pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.3pt;position:var(--position);text-decoration:none;white-space:pre">Year of Initial</span></div><div style="line-height:8pt;position:var(--position);top:11.67pt;width:99pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.86pt;position:var(--position);text-decoration:none;white-space:pre">Appointment</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);width:75.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.9pt;position:var(--position);white-space:pre">Term Expiration </span></div><div style="line-height:8pt;position:var(--position);top:11.59pt;width:75.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.41pt;position:var(--position);white-space:pre">Year</span><span style="font-family:'Times New Roman', serif;font-size:5.2pt;font-style:normal;font-weight:bold;left:43.28pt;position:var(--position);top:-1.8935pt;vertical-align:super;white-space:pre">(1)</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21pt;width:209.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:209.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Sylvie Gr&#233;goire</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:209.25pt;position:var(--position);top:21pt;width:85.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:85.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:33.87pt;position:var(--position);text-decoration:none;white-space:pre">Chair</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:294.75pt;position:var(--position);top:21pt;width:99pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:41.5pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:21pt;width:75.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:29.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:33pt;width:209.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:209.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Marc de Garidel</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:209.25pt;position:var(--position);top:33pt;width:85.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:85.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:29.43pt;position:var(--position);white-space:pre">Director</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:294.75pt;position:var(--position);top:33pt;width:99pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:41.5pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:33pt;width:75.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:29.87pt;position:var(--position);text-decoration:none;white-space:pre">2029</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:45pt;width:209.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:209.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Corinna zur Bonsen-Thomas</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:209.25pt;position:var(--position);top:45pt;width:85.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:85.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:29.43pt;position:var(--position);text-decoration:none;white-space:pre">Director</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:294.75pt;position:var(--position);top:45pt;width:99pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:41.5pt;position:var(--position);text-decoration:none;white-space:pre">2017</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:45pt;width:75.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:29.87pt;position:var(--position);text-decoration:none;white-space:pre">2029</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:57pt;width:209.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:209.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">June Lee</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:209.25pt;position:var(--position);top:57pt;width:85.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:85.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:29.43pt;position:var(--position);text-decoration:none;white-space:pre">Director</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:294.75pt;position:var(--position);top:57pt;width:99pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:41.5pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:57pt;width:75.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:29.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:69pt;width:209.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:209.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Troy Ignelzi</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:209.25pt;position:var(--position);top:69pt;width:85.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:85.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:29.43pt;position:var(--position);text-decoration:none;white-space:pre">Director</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:294.75pt;position:var(--position);top:69pt;width:99pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:41.5pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:69pt;width:75.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:29.87pt;position:var(--position);text-decoration:none;white-space:pre">2026</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:81pt;width:209.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:209.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Camilla Soenderby</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:209.25pt;position:var(--position);top:81pt;width:85.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:85.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:29.43pt;position:var(--position);white-space:pre">Director</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:294.75pt;position:var(--position);top:81pt;width:99pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:41.5pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:81pt;width:75.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:29.87pt;position:var(--position);text-decoration:none;white-space:pre">2029</span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:93pt;width:209.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:209.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Dominik H</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.830000000000005pt;position:var(--position);text-decoration:none;white-space:pre">&#246;</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:42.830000000000005pt;position:var(--position);white-space:pre">chli</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:209.25pt;position:var(--position);top:93pt;width:85.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:85.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:29.43pt;position:var(--position);white-space:pre">Director</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:294.75pt;position:var(--position);top:93pt;width:99pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:99pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:41.5pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:93pt;width:75.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:75.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:29.87pt;position:var(--position);text-decoration:none;white-space:pre">2029</span></div></div></div></td></tr></tbody></table></div></div></div><div style="line-height:10pt;position:var(--position);top:182pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:6.5pt;font-style:italic;font-weight:normal;left:71.95pt;position:var(--position);top:-2.429pt;vertical-align:super;white-space:pre">(1) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:81.14pt;position:var(--position);white-space:pre">The mandates expire at the annual shareholders&#8217; meeting approving the financial statements closed on December </span></div><div style="line-height:10pt;position:var(--position);top:193.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);white-space:pre">31 of the previous year. </span></div><div style="line-height:10pt;position:var(--position);top:216.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">During the fiscal year ended December&#160;31, 2025, the Board met eleven times.</span></div><div style="line-height:10pt;position:var(--position);top:244.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Non-voting Board Members / Observers </span></div><div style="line-height:10pt;position:var(--position);top:260.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Pursuant to our by-laws, the General Meeting or the Board may appoint non-voting board members (or </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:270.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">observers</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:110.3pt;position:var(--position);text-decoration:none;white-space:pre">). There is currently no Board observer in office.</span></div><div style="line-height:10pt;position:var(--position);top:298.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Director Independence</span></div><div style="line-height:10pt;position:var(--position);top:314.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">As a foreign private issuer, under the listing requirements and rules of Nasdaq, we are not required to have </span></div><div style="line-height:10pt;position:var(--position);top:324.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">independent directors on our Board, except to the extent that our audit committee is required to be consistent with </span></div><div style="line-height:10pt;position:var(--position);top:334.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">independence requirements. In determining whether a director is an independent director, our Board considers the </span></div><div style="line-height:10pt;position:var(--position);top:344.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">relationships that each non-employee director has with the Board and all other facts and circumstances that our </span></div><div style="line-height:10pt;position:var(--position);top:354.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Board deems relevant in determining the director&#8217;s independence, including the number of ordinary shares </span></div><div style="line-height:10pt;position:var(--position);top:364.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">beneficially owned by the director and his or her affiliated entities, if any.</span></div><div style="line-height:10pt;position:var(--position);top:380.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Based upon information requested from, and provided by, each director concerning such director&#8217;s </span></div><div style="line-height:10pt;position:var(--position);top:390.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">background, employment and affiliations, including family relationships, our Board has determined that all of our </span></div><div style="line-height:10pt;position:var(--position);top:400.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">directors, except for Marc de Garidel, qualify as &#8220;independent directors&#8221; as defined under applicable rules of the </span></div><div style="line-height:10pt;position:var(--position);top:410.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Nasdaq Global Market and the independence requirements contemplated by the Exchange Act.</span></div><div style="line-height:10pt;position:var(--position);top:426.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Furthermore, our Board has determined that, under the criteria of the Middlenext Code of Corporate </span></div><div style="line-height:10pt;position:var(--position);top:436.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Governance, </span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:125.27000000000001pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">five</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.8pt;position:var(--position);text-decoration:none;white-space:pre"> of our directors are &#8220;independent directors&#8221;: Sylvie Gr&#233;goire, June Lee, Troy Ignelzi, Corinna zur </span></div><div style="line-height:10pt;position:var(--position);top:446.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Bonsen-Thomas, and Camilla Soenderby. The Middlenext Code sets out the five following criteria justifying the </span></div><div style="line-height:10pt;position:var(--position);top:456.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">independence of directors, characterized by the absence of any significant financial, contractual or family </span></div><div style="line-height:10pt;position:var(--position);top:466.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">relationship likely to affect their independence of judgment: </span></div><div style="line-height:10pt;position:var(--position);top:482.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">they must not be a salaried employee or corporate officer of us or our group and must not have held </span></span></div><div style="line-height:10pt;position:var(--position);top:492.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">such a position within the last five years; </span></div><div style="line-height:10pt;position:var(--position);top:508.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">they must not be in a significant business relationship with us or our group (e.g., client, supplier, </span></span></div><div style="line-height:10pt;position:var(--position);top:518.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">competitor, provider, creditor, banker, etc.) within the last two years; </span></div><div style="line-height:10pt;position:var(--position);top:534.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">they must not be a reference shareholder or hold a significant number of voting rights; </span></span></div><div style="line-height:10pt;position:var(--position);top:550.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">they must not have close relationships or family ties with any of our corporate officer or reference </span></span></div><div style="line-height:10pt;position:var(--position);top:560.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">shareholder; and </span></div><div style="line-height:10pt;position:var(--position);top:576.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">they must not have been our auditor within the last six years. </span></span></div><div style="line-height:10pt;position:var(--position);top:592.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Conflicts of Interest Among the Management and Supervisory Bodies and Executive Management </span></div><div style="line-height:10pt;position:var(--position);top:608.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our Chairperson and Chief Executive Officer, our Chief Financial Officer and Board Secretary and our </span></div><div style="line-height:10pt;position:var(--position);top:618.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">directors are direct </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:149.37pt;position:var(--position);white-space:pre">or</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:157.7pt;position:var(--position);text-decoration:none;white-space:pre"> indirect shareholders or holders of securities giving access to our share capital. See </span></div><div style="line-height:10pt;position:var(--position);top:628.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8220;Compensation and Benefits&#8212;Compensation of Chief Executive Officer.&#8221;</span></div><div style="line-height:10pt;position:var(--position);top:650.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);white-space:pre">Service Agreements Entered into with Board Members</span></div><div style="line-height:10pt;position:var(--position);top:667.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">There are no existing service contracts between the Company or its subsidiaries on the one hand, and any </span></div><div style="line-height:10pt;position:var(--position);top:677.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">Board member on </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:146.65pt;position:var(--position);text-decoration:none;white-space:pre">the</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.85pt;position:var(--position);white-space:pre"> other, providing for benefits upon termination of service as a board member.</span></div><div style="line-height:10pt;position:var(--position);top:693.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Board Committees</span></div><div style="line-height:10pt;position:var(--position);top:709.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Audit Committee</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">127</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Mission and Responsibilities </span></div><div style="line-height:10pt;position:var(--position);top:88pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The audit committee monitors issues relating to the elaboration and control of accounting and financial </span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">information as provided for by French law and by our by-laws and by the rules of procedure of the Board. It then </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">formulates recommendations to the Board in its task of permanent control of our management. It also issues </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">recommendations in relation to the proposed statutory auditors. </span></div><div style="line-height:10pt;position:var(--position);top:134pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The audit committee is responsible for: </span></div><div style="line-height:10pt;position:var(--position);top:150pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">monitoring the preparation and development of accounting and financial information and, where </span></span></div><div style="line-height:10pt;position:var(--position);top:160pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">appropriate, formulating recommendations in this respect to ensure its accuracy; </span></div><div style="line-height:10pt;position:var(--position);top:176pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">reviewing the efficiency of the internal control and risk management systems; </span></span></div><div style="line-height:10pt;position:var(--position);top:192pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">ensuring proper legal oversight of the preparation of the annual financial statements and financial </span></span></div><div style="line-height:10pt;position:var(--position);top:202pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">statements by the statutory auditors; and </span></div><div style="line-height:10pt;position:var(--position);top:218pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">selecting and ensuring the independence of the statutory auditors. </span></span></div><div style="line-height:10pt;position:var(--position);top:234pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The audit committee is also responsible for approving: </span></div><div style="line-height:10pt;position:var(--position);top:250pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">non-audit services provided by the statutory auditors (including the permitted level of fees); and </span></span></div><div style="line-height:10pt;position:var(--position);top:266pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">all budgets for statutory audits and other engagements provided by the statutory auditors. </span></span></div><div style="line-height:10pt;position:var(--position);top:282pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The audit committee further controls the services provided by the auditors in relation to what is permitted by </span></div><div style="line-height:10pt;position:var(--position);top:292pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">law or regulation. </span></div><div style="line-height:10pt;position:var(--position);top:308pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The audit committee is responsible for formulating recommendations regarding the statutory auditors </span></div><div style="line-height:10pt;position:var(--position);top:318pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">proposed for nomination by the General Meeting of Shareholders and/or during the renewal of their term. </span></div><div style="line-height:10pt;position:var(--position);top:334pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Within this context, the audit committee may examine our annual financial statements in the form that they are </span></div><div style="line-height:10pt;position:var(--position);top:344pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">presented to the Board, hear the opinions of the statutory auditors and the finance director and receive </span></div><div style="line-height:10pt;position:var(--position);top:354pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">communications in relation to their analysis work and their conclusions. </span></div><div style="line-height:10pt;position:var(--position);top:370pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The audit committee may use external experts at our expense, after approval of the chairperson of the Board or </span></div><div style="line-height:10pt;position:var(--position);top:380pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the audit committee or of the Chief Executive Officer, and render any expert reports to the Board. </span></div><div style="line-height:10pt;position:var(--position);top:396pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The audit committee may hear any director and carry out any internal or external audit on any subject it </span></div><div style="line-height:10pt;position:var(--position);top:406pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">considers relevant to its mission. The chairperson of the audit committee shall inform the Board in advance. In </span></div><div style="line-height:10pt;position:var(--position);top:416pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">particular, the audit committee has the power to interview the persons involved in the preparation of the accounts or </span></div><div style="line-height:10pt;position:var(--position);top:426pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">in their control (administrative and financial director and the main managers of the financial department). </span></div><div style="line-height:10pt;position:var(--position);top:454pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Composition and Compensation </span></div><div style="line-height:10pt;position:var(--position);top:470pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The audit committee and chairperson of the audit committee are appointed by the Board from members of the </span></div><div style="line-height:10pt;position:var(--position);top:480pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Board, excluding executive directors, with finance or accounting skills and at least one member must be independent </span></div><div style="line-height:10pt;position:var(--position);top:490pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">in accordance with the provisions of the Middlenext Code. Members of the audit committee are appointed for a </span></div><div style="line-height:10pt;position:var(--position);top:500pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">fixed period of time, which may not exceed the duration of their terms of office as director and may be revoked by </span></div><div style="line-height:10pt;position:var(--position);top:510pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the Board at any time and without reason. Appointments are renewable without limitation. The audit committee is </span></div><div style="line-height:10pt;position:var(--position);top:520pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">currently composed of three members and members receive no compensation other than attendance fees. Their </span></div><div style="line-height:10pt;position:var(--position);top:530pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">duties on the audit committee may be taken into account in determining the allocation of such attendance fees. </span></div><div style="line-height:10pt;position:var(--position);top:546pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The current members of the audit committee are Troy Ignelzi, Corinna zur Bonsen-Thomas and Sylvie </span></div><div style="line-height:10pt;position:var(--position);top:556pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">Gr&#233;goire</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:107.50999999999999pt;position:var(--position);text-decoration:none;white-space:pre">. The current chairperson of the audit committee is Mr. Ignelzi. </span></div><div style="line-height:10pt;position:var(--position);top:572pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The committee may invite any person, internal or external to us, to take part in its meetings and its work. </span></div><div style="line-height:10pt;position:var(--position);top:588pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our Board has determined that each of the members of our audit committee is independent within the meaning </span></div><div style="line-height:10pt;position:var(--position);top:598pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of the applicable listing rules and the independence requirements contemplated by Rule 10A-3. Committee members </span></div><div style="line-height:10pt;position:var(--position);top:608pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">must be competent in financial or accounting matters and at least one member must be independent in accordance </span></div><div style="line-height:10pt;position:var(--position);top:618pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">with the provisions of the Middlenext Code. Our Board has further determined that Mr. Ignelzi is an &#8220;audit </span></div><div style="line-height:10pt;position:var(--position);top:628pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">committee financial expert&#8221; as defined by SEC rules and regulations and that Mr. Ignelzi qualifies as financially </span></div><div style="line-height:10pt;position:var(--position);top:638pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">sophisticated under the applicable exchange listing rules. </span></div><div style="line-height:10pt;position:var(--position);top:666pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Conditions of Functioning </span></div><div style="line-height:10pt;position:var(--position);top:682pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The audit committee meets when the chairperson of the audit committee, at least two members of the audit </span></div><div style="line-height:10pt;position:var(--position);top:692pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">committee, the chairperson of the Board or the Chief Executive Officer deems useful and at least twice per year, </span></div><div style="line-height:10pt;position:var(--position);top:702pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">particularly before publication of the financial statements. The committee may be convened by any means 24&#160;hours </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">128</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">before the meeting by the chairperson of the audit committee or of the Board or any individual to whom one of them </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">shall have delegated the necessary authority. The committee meets at the registered office or in any other place </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">specified in the notice of the meeting. It may also meet by video conference or by any means of telecommunication </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">as specified in the internal regulation of the Board. </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">To deliberate validly, at least half of the members of the committee must be present. At meetings, one member </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of the audit committee may be represented by another audit committee member and the audit committee&#8217;s </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">recommendations are adopted by simple majority. Upon completion of each meeting, if the members deem it </span></div><div style="line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">necessary, meeting minutes may be prepared. The chairperson of the audit committee regularly reports to the Board </span></div><div style="line-height:10pt;position:var(--position);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">on the committee&#8217;s work and immediately report any difficulty encountered. </span></div><div style="line-height:10pt;position:var(--position);top:186pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Remuneration Committee </span></div><div style="line-height:10pt;position:var(--position);top:202pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Mission and Responsibilities </span></div><div style="line-height:10pt;position:var(--position);top:218pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The remuneration committee makes recommendations to the Board in relation to compensation for, executive </span></div><div style="line-height:10pt;position:var(--position);top:228pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">directors and the operational and functional management, and with regard to compensation policy and internal profit </span></div><div style="line-height:10pt;position:var(--position);top:238pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">sharing. In particular, the remuneration committee: </span></div><div style="line-height:10pt;position:var(--position);top:254pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">provides recommendations and proposals to the Board concerning compensation, retirement and </span></span></div><div style="line-height:10pt;position:var(--position);top:264pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">provident scheme, supplementary pension benefits, benefits in kind, various financial rights of our </span></div><div style="line-height:10pt;position:var(--position);top:274pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">managers and executive officers, the allocation of share warrants (BSA), founder&#8217;s share warrants </span></div><div style="line-height:10pt;position:var(--position);top:284pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">(BCE), free shares (AGA), share subscription or share purchase options, for the benefit of our </span></div><div style="line-height:10pt;position:var(--position);top:294pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">employees, managers or consultants and, where applicable, its subsidiaries, in accordance with legal </span></div><div style="line-height:10pt;position:var(--position);top:304pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">provisions; </span></div><div style="line-height:10pt;position:var(--position);top:320pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">defines the methods for determining the variable portion of the compensation of corporate officers and </span></span></div><div style="line-height:10pt;position:var(--position);top:330pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">monitors its application; </span></div><div style="line-height:10pt;position:var(--position);top:346pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">proposes a general policy for awarding share warrants (BSA), founder&#8217;s share warrants (BCE), free </span></span></div><div style="line-height:10pt;position:var(--position);top:356pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">shares (AGA) and options to subscribe or purchase shares, and determines the frequency thereof, </span></div><div style="line-height:10pt;position:var(--position);top:366pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">depending on the categories of beneficiaries; </span></div><div style="line-height:10pt;position:var(--position);top:382pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">examines the system of for the allocation of directors&#8217; fees among the members of the Board, </span></span></div><div style="line-height:10pt;position:var(--position);top:392pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">particularly according to their participation in our committees; and </span></div><div style="line-height:10pt;position:var(--position);top:408pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">expresses its opinion to senior management about the compensation of the principal senior executives. </span></span></div><div style="line-height:10pt;position:var(--position);top:436pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Composition and Compensation </span></div><div style="line-height:10pt;position:var(--position);top:452pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The remuneration committee is currently composed of three members. The chairperson of the remuneration </span></div><div style="line-height:10pt;position:var(--position);top:462pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">committee and the committee&#8217;s members are appointed by the Board from members of the Board. Members are </span></div><div style="line-height:10pt;position:var(--position);top:472pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">appointed for a fixed period of time, which may not exceed, as applicable, the duration of their term of office as </span></div><div style="line-height:10pt;position:var(--position);top:482pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">director and may be revoked by the Board at any time and without reason. Their appointments shall be renewable </span></div><div style="line-height:10pt;position:var(--position);top:492pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">without limitation. </span></div><div style="line-height:10pt;position:var(--position);top:508pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The chairperson of the Board, if not a member of the remuneration committee, may be invited to participate in </span></div><div style="line-height:10pt;position:var(--position);top:518pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the remuneration committee&#8217;s meetings. The remuneration committee shall invite him/her to present its proposals. </span></div><div style="line-height:10pt;position:var(--position);top:528pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">He/she shall not have the right to vote and shall not be present during the deliberations relating to his/her own </span></div><div style="line-height:10pt;position:var(--position);top:538pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">situation. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:554pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.03pt;position:var(--position);text-decoration:none;white-space:pre"> current members of the remuneration committee are June Lee, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:365.84pt;position:var(--position);white-space:pre">Camilla Soenderby, and Troy Ignelzi</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:514.28pt;position:var(--position);text-decoration:none;white-space:pre">. The </span></div><div style="line-height:10pt;position:var(--position);top:564pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">current chairperson of the remuneration committee is Dr. Lee. </span></div><div style="line-height:10pt;position:var(--position);top:580pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The remuneration committee may invite any person, internal or external to us, to take part in its meetings and </span></div><div style="line-height:10pt;position:var(--position);top:590pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">its work. </span></div><div style="line-height:10pt;position:var(--position);top:606pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Remuneration committee members shall receive no compensation other than attendance fees. Their duties on </span></div><div style="line-height:10pt;position:var(--position);top:616pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the remuneration committee may be taken into consideration in determining the allocation of such attendance fees. </span></div><div style="line-height:10pt;position:var(--position);top:644pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Conditions of Functioning </span></div><div style="line-height:10pt;position:var(--position);top:660pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The remuneration committee meets when the chairperson of the remuneration committee, at least two </span></div><div style="line-height:10pt;position:var(--position);top:670pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">members of the remuneration committee, the chairperson of the Board or the Chief Executive Officer deems useful </span></div><div style="line-height:10pt;position:var(--position);top:680pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and at least once a year. The remuneration committee may be convened by any means, 24 hours before the meeting, </span></div><div style="line-height:10pt;position:var(--position);top:690pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">by the chairperson of the remuneration committee or of the Board, or any individual to whom one of them shall have </span></div><div style="line-height:10pt;position:var(--position);top:700pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">delegated the authority necessary for the convocation. </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">129</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The committee meets at the registered office or in any other place specified in the notice of the meeting. It </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">may also meet by video conference or by any means of telecommunication, as specified in the internal regulation of </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the Board. </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">To deliberate validly, at least half of the members of the committee must be present. A member of the </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">remuneration committee may be represented by another remuneration committee member and the remuneration&#160; </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">committee&#8217;s recommendations are adopted by simple majority. Upon completion of each meeting, if the members </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">deem it necessary, meeting minutes may be prepared. </span></div><div style="line-height:10pt;position:var(--position);top:154pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The remuneration committee chairperson reports regularly to the Board on the remuneration committee&#8217;s </span></div><div style="line-height:10pt;position:var(--position);top:164pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">work and shall immediately report any difficulty encountered. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:186pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Nomination and Governance Committee</span></div><div style="line-height:10pt;position:var(--position);top:208.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Mission and Responsibilities</span></div><div style="line-height:10pt;position:var(--position);top:226.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The nomination and governance committee makes recommendations to the Board in relation to the nomination </span></div><div style="line-height:10pt;position:var(--position);top:236.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of executive directors and governance matters. In particular, the nomination and governance committee: </span></div><div style="line-height:10pt;position:var(--position);top:246.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">provides recommendations and proposals to the Board concerning the appointment, in particular in the </span></div><div style="line-height:10pt;position:var(--position);top:257.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">research of a balanced representation of men and women on the Board, of our managers and executive </span></div><div style="line-height:10pt;position:var(--position);top:268.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">officers, in accordance with legal provisions; </span></div><div style="line-height:10pt;position:var(--position);top:280pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">discusses each independent director&#8217;s qualifications upon his or her nomination and during the exercise of </span></div><div style="line-height:10pt;position:var(--position);top:291.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">his or her term of office, as applicable; and</span></div><div style="line-height:10pt;position:var(--position);top:302.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">oversees the Board&#8217;s governance policies and practices.</span></div><div style="line-height:10pt;position:var(--position);top:324.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Composition and Compensation</span></div><div style="line-height:10pt;position:var(--position);top:342.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The nomination and governance committee is currently composed of three members. The chairperson of the </span></div><div style="line-height:10pt;position:var(--position);top:352.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">nomination and governance and the committee&#8217;s members are appointed by the Board from members of the Board. </span></div><div style="line-height:10pt;position:var(--position);top:362.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Members are appointed for a fixed period of time, which may not exceed, as applicable, the duration of their term of </span></div><div style="line-height:10pt;position:var(--position);top:372.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">office as director and may be revoked by the Board at any time and without reason. Their appointments shall be </span></div><div style="line-height:10pt;position:var(--position);top:382.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">renewable without limitation. </span></div><div style="line-height:10pt;position:var(--position);top:398.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The chairperson of the Board, if not a member of the nomination and governance committee, may be invited </span></div><div style="line-height:10pt;position:var(--position);top:408.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to participate in the nomination and governance committee&#8217;s meetings. The nomination and governance committee </span></div><div style="line-height:10pt;position:var(--position);top:418.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">shall invite him/her to present its proposals. He/she shall not have the right to vote and shall not be present during </span></div><div style="line-height:10pt;position:var(--position);top:428.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the deliberations relating to his/her own situation. </span></div><div style="line-height:10pt;position:var(--position);top:444.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The current members of the nomination and governance committee are Sylvie Gregoire, Camilla Soenderby, </span></div><div style="line-height:10pt;position:var(--position);top:454.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and Corinna Thomas. The current chairperson of the nomination and governance committee is Dr. Gregoire. </span></div><div style="line-height:10pt;position:var(--position);top:470.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The nomination and governance committee may invite any person, internal or external to us, to take part in its </span></div><div style="line-height:10pt;position:var(--position);top:480.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">meetings and its work. </span></div><div style="line-height:10pt;position:var(--position);top:496.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Nomination and governance committee members shall receive no compensation other than attendance fees. </span></div><div style="line-height:10pt;position:var(--position);top:506.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Their duties on the nomination and governance committee may be taken into consideration in determining the </span></div><div style="line-height:10pt;position:var(--position);top:516.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">allocation of such attendance fees. </span></div><div style="line-height:10pt;position:var(--position);top:538pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);white-space:pre">Conditions of Functioning</span></div><div style="line-height:10pt;position:var(--position);top:555.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The nomination and governance committee meets when the chairperson of the nomination and governance </span></div><div style="line-height:10pt;position:var(--position);top:565.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">committee, at least two members of the nomination and governance committee, the chairperson of the Board or the </span></div><div style="line-height:10pt;position:var(--position);top:575.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Chief Executive Officer deems useful and at least once a year. The nomination and governance committee may be </span></div><div style="line-height:10pt;position:var(--position);top:585.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">convened by any means, 24 hours before the meeting, by the chairperson of the nomination and governance </span></div><div style="line-height:10pt;position:var(--position);top:595.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">committee or of the Board, or any individual to whom one of them shall have delegated the authority necessary for </span></div><div style="line-height:10pt;position:var(--position);top:605.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the convocation. </span></div><div style="line-height:10pt;position:var(--position);top:621.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The committee meets at the registered office or in any other place specified in the notice of the meeting. It </span></div><div style="line-height:10pt;position:var(--position);top:631.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">may also meet by video conference or by any means of telecommunication, as specified in the internal regulation of </span></div><div style="line-height:10pt;position:var(--position);top:641.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the Board. </span></div><div style="line-height:10pt;position:var(--position);top:657.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">To deliberate validly, at least half of the members of the committee must be present. A member of the </span></div><div style="line-height:10pt;position:var(--position);top:667.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">nomination and governance committee may be represented by another nomination and governance committee </span></div><div style="line-height:10pt;position:var(--position);top:677.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">member and the nomination and governance committee&#8217;s recommendations are adopted by simple majority. Upon </span></div><div style="line-height:10pt;position:var(--position);top:687.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">completion of each meeting, if the members deem it necessary, meeting minutes may be prepared. </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">130</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The nomination and governance committee chairperson reports regularly to the Board on the nomination and </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">governance committee&#8217;s work and shall immediately report any difficulty encountered.</span></div><div style="line-height:10pt;position:var(--position);top:105.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Scientific and Clinical Committee </span></div><div style="line-height:10pt;position:var(--position);top:121.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Mission and Responsibilities </span></div><div style="line-height:10pt;position:var(--position);top:137.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The scientific and clinical committee was created by a decision by the Board on September&#160;27, 2018. </span></div><div style="line-height:10pt;position:var(--position);top:153.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The role of the scientific and clinical committee is to: </span></div><div style="line-height:10pt;position:var(--position);top:169.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">examine specific scientific questions submitted to it; </span></span></div><div style="line-height:10pt;position:var(--position);top:185.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">make recommendations for determining the general guidelines to be adopted in the scientific field; and </span></span></div><div style="line-height:10pt;position:var(--position);top:201.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">make recommendations for defining our priorities in the field of research and development and the </span></span></div><div style="line-height:10pt;position:var(--position);top:211.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">means for achieving such objectives. </span></div><div style="line-height:10pt;position:var(--position);top:227.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The committee meets at least once a year. </span></div><div style="line-height:10pt;position:var(--position);top:243.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">It works in collaboration with the Chief Executive Officer, who may request its opinion on subjects related to </span></div><div style="line-height:10pt;position:var(--position);top:253.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">its mission. At the request of the Board, the chairperson of the scientific and clinical committee reports on the </span></div><div style="line-height:10pt;position:var(--position);top:263.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">committee&#8217;s work to the Board. </span></div><div style="line-height:10pt;position:var(--position);top:291.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Composition </span></div><div style="line-height:10pt;position:var(--position);top:307.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The scientific and clinical committee is composed of at least four members appointed by the Board upon </span></div><div style="line-height:10pt;position:var(--position);top:317.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">proposal of the Chief Executive Officer. The members of the scientific and clinical committee do not have to be </span></div><div style="line-height:10pt;position:var(--position);top:327.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">members of the Board. </span></div><div style="line-height:10pt;position:var(--position);top:343.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The current members of the scientific and clinical committee are June Lee, Camilla Soenderby, and Dominik </span></div><div style="line-height:10pt;position:var(--position);top:353.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">H&#246;chli. Dr. Lee is the current chair of the scientific and clinical committee. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:375.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Commercia</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:119.72pt;position:var(--position);white-space:pre">l Committee</span></div><div style="line-height:10pt;position:var(--position);top:397.9pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);white-space:pre">Mission and Responsibilities</span></div><div style="line-height:10pt;position:var(--position);top:415.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">The </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.53pt;position:var(--position);text-decoration:none;white-space:pre">commercial</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:161.66pt;position:var(--position);white-space:pre"> committee was created by a decision by the Board on December 11, 2025. </span></div><div style="line-height:10pt;position:var(--position);top:431.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">The </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.53pt;position:var(--position);text-decoration:none;white-space:pre">role</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:130.06pt;position:var(--position);white-space:pre"> of the commercial committee is to: </span></div><div style="line-height:10pt;position:var(--position);top:447.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05000000000001pt;position:var(--position);white-space:pre">Provide strategic advice on the overall commercialization strategy for Abivax' lead product candidate, </span></div><div style="line-height:10pt;position:var(--position);top:457.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);white-space:pre">obefazimod, and potential future products, from pre-launch planning through launch and subsequent </span></div><div style="line-height:10pt;position:var(--position);top:467.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);white-space:pre">lifecycle phases;</span></div><div style="line-height:10pt;position:var(--position);top:483.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05000000000001pt;position:var(--position);white-space:pre">Review and advise on launch readiness and execution plans, including market positioning, market </span></div><div style="line-height:10pt;position:var(--position);top:493.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);white-space:pre">access, pricing and reimbursement, distribution and channel strategy, patient services, commercial </span></div><div style="line-height:10pt;position:var(--position);top:503.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);white-space:pre">infrastructure, and sales and marketing;</span></div><div style="line-height:10pt;position:var(--position);top:519.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05000000000001pt;position:var(--position);white-space:pre">Review the capabilities of the commercial organization and the adequacy of the resources, systems, </span></div><div style="line-height:10pt;position:var(--position);top:529.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);white-space:pre">and infrastructure required to support successful product launch and commercialization;</span></div><div style="line-height:10pt;position:var(--position);top:545.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05000000000001pt;position:var(--position);white-space:pre">Review and advise on commercialization strategy in coordination with medical affairs, regulatory, </span></div><div style="line-height:10pt;position:var(--position);top:555.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);white-space:pre">manufacturing/supply and&#160; ensure that the commercialization approach is consistent with the </span></div><div style="line-height:10pt;position:var(--position);top:565.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);white-space:pre">company&#8217;s legal, medical, regulatory, and compliance framework;</span></div><div style="line-height:10pt;position:var(--position);top:581.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05000000000001pt;position:var(--position);white-space:pre">Review the principal assumptions, opportunities, and risks relating to commercialization, including the </span></div><div style="line-height:10pt;position:var(--position);top:591.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);white-space:pre">competitive landscape and market dynamics, and provide strategic guidance; and</span></div><div style="line-height:10pt;position:var(--position);top:607.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05000000000001pt;position:var(--position);white-space:pre">Advise the Board on strategic commercial matters and decisions requiring Board approval.</span></div><div style="line-height:10pt;position:var(--position);top:623.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">The committee meets when the chairperson of the commercial committee, the Board, or the Chief Executive </span></div><div style="line-height:10pt;position:var(--position);top:633.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">Officer deems useful </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.28pt;position:var(--position);text-decoration:none;white-space:pre">and</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:172.70999999999998pt;position:var(--position);white-space:pre"> meets at least twice a year.</span></div><div style="line-height:10pt;position:var(--position);top:649.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">It works in collaboration with the Chief Executive Officer, who may request its opinion on subjects related to </span></div><div style="line-height:10pt;position:var(--position);top:659.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">its mission. At the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:147.20999999999998pt;position:var(--position);text-decoration:none;white-space:pre">request</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:176.06pt;position:var(--position);white-space:pre"> of the Board, the chairperson of the commercial committee reports on the committee&#8217;s </span></div><div style="line-height:10pt;position:var(--position);top:669.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">work to the Board. The committee is advisory only unless the Board has delegated a specific power, and </span></div><div style="line-height:10pt;position:var(--position);top:679.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">management </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:125.53pt;position:var(--position);text-decoration:none;white-space:pre">remains</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:157.15pt;position:var(--position);white-space:pre"> responsible </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:207.66pt;position:var(--position);text-decoration:none;white-space:pre">for</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:219.32pt;position:var(--position);white-space:pre"> execution. </span></div><div style="line-height:10pt;position:var(--position);top:700.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);white-space:pre">Composition</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">131</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">The commercial committee is composed of at least two members appointed by the Board upon proposal of the </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">Chief </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.69pt;position:var(--position);text-decoration:none;white-space:pre">Executive</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:136.62pt;position:var(--position);white-space:pre"> Officer. The members of the commercial committee do not have to be members of the Board. </span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">The current members of the commercial committee are Camilla Soenderby and Dominik Hochli. Dr. </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">Soenderby is </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:126.41pt;position:var(--position);text-decoration:none;white-space:pre">the</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:138.61pt;position:var(--position);white-space:pre"> current chair of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:205.19pt;position:var(--position);text-decoration:none;white-space:pre">the</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:217.39pt;position:var(--position);white-space:pre"> commercial committee.</span></div><div style="position:absolute;top:132.5pt" id="i7a006daedb3d4216a4128b76247285d7_94"></div><div style="line-height:10pt;position:var(--position);top:132.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">D.<span id="ic3812253f6f74f55a21783abf17bfdc5"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Employees</span></div><div style="line-height:10pt;position:var(--position);top:150.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2025, we had 69 full-time employees, consisting of 49 within the research and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:160.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">development</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:123.6pt;position:var(--position);text-decoration:none;white-space:pre"> department 17 within the general administrative department and 3 within the sales and marketing </span></div><div style="line-height:10pt;position:var(--position);top:170.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">department. As of December 31, 2025, we had 42 employees located in France and 27 in the United States. Our </span></div><div style="line-height:10pt;position:var(--position);top:180.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">employees based in France are subject to the national collective bargaining agreement for the pharmaceutical </span></div><div style="line-height:10pt;position:var(--position);top:190.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">industry (the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:125.28999999999999pt;position:var(--position);text-decoration:none;white-space:pre">convention collective nationale de l&#8217;industrie pharmaceutique</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:373.58pt;position:var(--position);text-decoration:none;white-space:pre">). We believe that we maintain good </span></div><div style="line-height:10pt;position:var(--position);top:200.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">relations with our employees. </span></div><div style="line-height:10pt;position:var(--position);top:216.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We rely on skilled, experienced and innovative employees to conduct the operations of our company. We are </span></div><div style="line-height:10pt;position:var(--position);top:226.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">committed to building an outstanding, committed team and we focus on a culture that values a focus on scientific </span></div><div style="line-height:10pt;position:var(--position);top:236.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">innovation, inclusion, collaboration and equity. We focus on recruiting, retaining and developing employees from a </span></div><div style="line-height:10pt;position:var(--position);top:246.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">diverse range of backgrounds to conduct our research, development, clinical, commercial, marketing and market </span></div><div style="line-height:10pt;position:var(--position);top:256.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">access activities. We recognize that recruiting, motivating and retaining talented employees is vital to our success. </span></div><div style="line-height:10pt;position:var(--position);top:266.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the </span></div><div style="line-height:10pt;position:var(--position);top:276.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">granting of stock-based and cash-based compensation awards, in order to increase shareholder value and the success </span></div><div style="line-height:10pt;position:var(--position);top:286.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. </span></div><div style="line-height:10pt;position:var(--position);top:296.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">We aim to create an equitable, inclusive and empowering environment in which our employees can grow and </span></div><div style="line-height:10pt;position:var(--position);top:306.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">advance their careers, with the overall goal of developing, expanding and retaining our workforce to support our </span></div><div style="line-height:10pt;position:var(--position);top:316.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">current pipeline and future business goals. Employees are encouraged to attend scientific, clinical and technological </span></div><div style="line-height:10pt;position:var(--position);top:326.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">meetings and conferences and have access to broad resources they need to be successful. </span></div><div style="position:absolute;top:360.5pt" id="i7a006daedb3d4216a4128b76247285d7_97"></div><div style="line-height:10pt;position:var(--position);top:360.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">E.<span id="ic042ba9d4a39473eb915abff93068228"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Share Ownership</span></div><div style="line-height:10pt;position:var(--position);top:378.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For information regarding the share ownership of our directors and executive officers, see &#8220;Item 6.B&#8212;</span></div><div style="line-height:10pt;position:var(--position);top:388.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Compensation&#8221; and &#8220;Item 7.A&#8212;Major Shareholders and Related Party Transactions.&#8221;</span></div><div style="position:absolute;top:410.5pt" id="i7a006daedb3d4216a4128b76247285d7_100"></div><div style="line-height:10pt;position:var(--position);top:410.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">F.<span id="i2620225ddfa041dd83461d70f444648c"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Disclosure of a Registrant&#8217;s Action to Recover Erroneously Awarded Compensation</span></div><div style="line-height:10pt;position:var(--position);top:434.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">None.</span></div><div style="position:absolute;top:458.5pt" id="i7a006daedb3d4216a4128b76247285d7_103"></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">132</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_106"></div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">Item 7.<span style="display:inline-block;height:6.77pt;width:6.02pt"></span></span><span style="left:108pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:36pt"></span></span><span style="left:144pt;position:var(--position)">Major Shareholders and Related Party Transactions</span><span id="i221c3f04e7be4082a734a3bd88d62251"></span></span></div><div style="position:absolute;top:108pt" id="i7a006daedb3d4216a4128b76247285d7_109"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">A.<span id="i4b9d1e19577b4f93822f31892c83dca1"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Major Shareholders</span></div><div style="line-height:10pt;position:var(--position);top:126pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The following table and accompanying footnotes set forth information with respect to the beneficial ownership </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:136pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of our ordinary shares </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:162.49pt;position:var(--position);text-decoration:none;white-space:pre">as of February 28, 2026 </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:260.22pt;position:var(--position);text-decoration:none;white-space:pre">for: </span></div><div style="line-height:10pt;position:var(--position);top:152pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">each beneficial owner, known by us, of more than 5% of our outstanding ordinary shares; </span></span></div><div style="line-height:10pt;position:var(--position);top:168pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">each of our directors and executive officers individually; and </span></span></div><div style="line-height:10pt;position:var(--position);top:184pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">all of our directors and executive officers as a group. </span></span></div><div style="line-height:10pt;position:var(--position);top:200pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Beneficial ownership is determined in accordance with the rules of the SEC. These rules generally attribute </span></div><div style="line-height:10pt;position:var(--position);top:210pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">beneficial ownership of securities to persons who possess sole or shared voting power or investment power with </span></div><div style="line-height:10pt;position:var(--position);top:220pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">respect to those securities and include ordinary shares that can be acquired within 60 days of February 28, 2026. The </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:230pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">percentage ownership information shown in the table below is based upon </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:370.87pt;position:var(--position);text-decoration:none;white-space:pre">79,185,160</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:415.87pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares outstanding as </span></div><div style="line-height:10pt;position:var(--position);top:240pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of February 28, 2026. </span></div><div style="line-height:10pt;position:var(--position);top:256pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Except as otherwise indicated, all of the shares reflected in the table are ordinary shares and all persons listed </span></div><div style="line-height:10pt;position:var(--position);top:266pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">below have sole voting and investment power with respect to the shares beneficially owned by them, subject to </span></div><div style="line-height:10pt;position:var(--position);top:276pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">applicable community property laws. The information is not necessarily indicative of beneficial ownership for any </span></div><div style="line-height:10pt;position:var(--position);top:286pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">other purpose. </span></div><div style="line-height:10pt;position:var(--position);top:302pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In computing the number of ordinary shares beneficially owned by a person and the percentage ownership of </span></div><div style="line-height:10pt;position:var(--position);top:312pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">that person, we deemed outstanding ordinary shares subject to options and warrants held by that person that are </span></div><div style="line-height:10pt;position:var(--position);top:322pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">immediately exercisable or exercisable within 60 days of February 28, 2026. We did not deem these shares </span></div><div style="line-height:10pt;position:var(--position);top:332pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">outstanding, however, for the purpose of computing the percentage ownership of any other person. Beneficial </span></div><div style="line-height:10pt;position:var(--position);top:342pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ownership representing less than 1% is denoted with an asterisk (*). </span></div><div style="line-height:1pt;position:var(--position);top:361pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">133</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The information in the table below is based on information known to us or ascertained by us from public </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">filings made by the shareholders (which may be in the form of ADSs). Except as otherwise indicated in the table </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">below, addresses of the directors, executive officers and named beneficial owners are in care of Abivax SA, </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">7-11&#160;boulevard Haussmann, 75009 Paris, France. Our major shareholders do not have any special voting rights. </span></div><div style="line-height:12pt;position:var(--position);top:112pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="position:var(--position);top:124pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:459pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:254.25pt"/><td style="padding:0;width:68.25pt"/><td style="padding:0;width:68.25pt"/><td style="padding:0;width:68.25pt"/></tr><tr style="height:37.5pt"><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:254.25pt"><div><div style="line-height:10pt;position:var(--position);top:31.67pt;width:254.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Name of Beneficial Owner</span></div><div style="line-height:10pt;position:var(--position);top:42.67pt;width:254.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:125.87pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:254.25pt;position:var(--position);width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.67pt;width:68.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:10.94pt;position:var(--position);text-decoration:none;white-space:pre">Number&#160;of</span></div><div style="line-height:10pt;position:var(--position);top:12.67pt;width:68.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:13.86pt;position:var(--position);text-decoration:none;white-space:pre">Ordinary</span></div><div style="line-height:10pt;position:var(--position);top:22.67pt;width:68.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:19.69pt;position:var(--position);text-decoration:none;white-space:pre">Shares</span></div><div style="line-height:10pt;position:var(--position);top:32.67pt;width:68.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:9.16pt;position:var(--position);text-decoration:none;white-space:pre">Beneficially</span></div><div style="line-height:10pt;position:var(--position);top:42.67pt;width:68.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:18.85pt;position:var(--position);text-decoration:none;white-space:pre">Owned</span></div></div></div></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:322.5pt;position:var(--position);width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.67pt;width:68.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:5.14pt;position:var(--position);text-decoration:none;white-space:pre">Percentage&#160;of</span></div><div style="line-height:10pt;position:var(--position);top:12.67pt;width:68.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:13.86pt;position:var(--position);text-decoration:none;white-space:pre">Ordinary</span></div><div style="line-height:10pt;position:var(--position);top:22.67pt;width:68.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Shares&#160;Benefic</span></div><div style="line-height:10pt;position:var(--position);top:32.67pt;width:68.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:24.97pt;position:var(--position);text-decoration:none;white-space:pre">ially</span></div><div style="line-height:10pt;position:var(--position);top:42.67pt;width:68.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:18.85pt;position:var(--position);text-decoration:none;white-space:pre">Owned</span></div></div></div></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:390.75pt;position:var(--position);width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:22.83pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:5.14pt;position:var(--position);text-decoration:none;white-space:pre">Percentage of </span></div><div style="line-height:10pt;position:var(--position);top:32.83pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:19.68pt;position:var(--position);text-decoration:none;white-space:pre">Voting </span></div><div style="line-height:10pt;position:var(--position);top:42.83pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:17.69pt;position:var(--position);text-decoration:none;white-space:pre">Power+</span></div></div></div></td></tr><tr style="height:15.75pt"><td colspan="4" style="display:none"/></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:53.25pt;width:254.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:254.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">5% Shareholders:</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:254.25pt;position:var(--position);top:53.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:67.5pt;width:254.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:254.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">TCG Crossover(1)</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:77.3pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:78.46pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:78.75pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:78.89999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:78.94pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:78.96pt;position:var(--position);text-decoration:none;white-space:pre">.....................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:254.25pt;position:var(--position);top:67.5pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">6,456,596</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:322.5pt;position:var(--position);top:67.5pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:7.2pt;position:var(--position)">8.14<span style="display:inline-block;height:6.93pt;width:18.5pt"></span></span><span style="left:43.2pt;position:var(--position)">%</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:390.75pt;position:var(--position);top:67.5pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:7.2pt;position:var(--position)">7.92<span style="display:inline-block;height:6.93pt;width:18.5pt"></span></span><span style="left:43.2pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:81.75pt;width:254.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:254.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Invus(2)</span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:36.510000000000005pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:36.59pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:36.61pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36.620000000000005pt;position:var(--position);text-decoration:none;white-space:pre">......................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:254.25pt;position:var(--position);top:81.75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">6,765,569</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:322.5pt;position:var(--position);top:81.75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:7.2pt;position:var(--position)">8.54<span style="display:inline-block;height:6.93pt;width:18.5pt"></span></span><span style="left:43.2pt;position:var(--position)">%</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:390.75pt;position:var(--position);top:81.75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:7.2pt;position:var(--position)">8.30<span style="display:inline-block;height:6.93pt;width:18.5pt"></span></span><span style="left:43.2pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:96pt;width:254.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:254.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Darwin(3)</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:44.260000000000005pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:45.42pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:46pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:46.29pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:46.370000000000005pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:46.410000000000004pt;position:var(--position);text-decoration:none;white-space:pre">..................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:254.25pt;position:var(--position);top:96pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">4,260,015</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:322.5pt;position:var(--position);top:96pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:7.2pt;position:var(--position)">5.37<span style="display:inline-block;height:6.93pt;width:18.5pt"></span></span><span style="left:43.2pt;position:var(--position)">%</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:390.75pt;position:var(--position);top:96pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:7.2pt;position:var(--position)">5.22<span style="display:inline-block;height:6.93pt;width:18.5pt"></span></span><span style="left:43.2pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:6pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:110.25pt;width:254.25pt"><div><div style="line-height:1pt;position:var(--position);top:3.11pt;width:254.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:254.25pt;position:var(--position);top:110.25pt;width:68.25pt"><div><div style="line-height:1pt;position:var(--position);top:3.11pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:116.25pt;width:254.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:254.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Directors and Officers:</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:254.25pt;position:var(--position);top:116.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:130.5pt;width:254.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:254.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Marc de Garidel(4)</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:79.75pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:80.91pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:81.19999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:81.35pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:81.42999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:81.44999999999999pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:81.46pt;position:var(--position);text-decoration:none;white-space:pre">....................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:254.25pt;position:var(--position);top:130.5pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">929,540</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:322.5pt;position:var(--position);top:130.5pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">1.17%</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:390.75pt;position:var(--position);top:130.5pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">1.14%</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:144.75pt;width:254.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:254.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Didier Blondel(5)</span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:73.94pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:74.08999999999999pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:74.11pt;position:var(--position);text-decoration:none;white-space:pre">.......................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:254.25pt;position:var(--position);top:144.75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">121,578</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:322.5pt;position:var(--position);top:144.75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">*</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:390.75pt;position:var(--position);top:144.75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">*</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:159pt;width:254.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:254.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Fabio Cataldi</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:56.720000000000006pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:57.88pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:58.46pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:58.75pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:58.900000000000006pt;position:var(--position);text-decoration:none;white-space:pre">.............................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:254.25pt;position:var(--position);top:159pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:322.5pt;position:var(--position);top:159pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:390.75pt;position:var(--position);top:159pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:173.25pt;width:254.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:254.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Sylvie Gr&#233;goire</span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:66.17pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:66.46pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:66.53999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:66.58pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:66.59pt;position:var(--position);text-decoration:none;white-space:pre">..........................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:254.25pt;position:var(--position);top:173.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:322.5pt;position:var(--position);top:173.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:390.75pt;position:var(--position);top:173.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:187.5pt;width:254.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:254.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">June Lee(6) </span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:52.57pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:53.730000000000004pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:53.88pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:53.96pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:53.980000000000004pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:53.99pt;position:var(--position);text-decoration:none;white-space:pre">...............................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:254.25pt;position:var(--position);top:187.5pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">15,977</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:322.5pt;position:var(--position);top:187.5pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">*</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:390.75pt;position:var(--position);top:187.5pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">*</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:201.75pt;width:254.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:254.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Troy Ignelzi(7)</span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:63.95pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:64.1pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:64.11pt;position:var(--position);text-decoration:none;white-space:pre">...........................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:254.25pt;position:var(--position);top:201.75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">15,977</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:322.5pt;position:var(--position);top:201.75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">*</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:390.75pt;position:var(--position);top:201.75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">*</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:216pt;width:254.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:254.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Corinna zur Bonsen-Thomas(8)</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:129.74pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:130.9pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:131.19pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:131.34pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:131.42pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:131.46pt;position:var(--position);text-decoration:none;white-space:pre">................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:254.25pt;position:var(--position);top:216pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">15,976</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:322.5pt;position:var(--position);top:216pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">*</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:390.75pt;position:var(--position);top:216pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">*</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:230.25pt;width:254.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:254.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Camilla Soenderby(9)</span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:91.14pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:91.42999999999999pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.58pt;position:var(--position);text-decoration:none;white-space:pre">................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:254.25pt;position:var(--position);top:230.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">15,977</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:322.5pt;position:var(--position);top:230.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">*</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:390.75pt;position:var(--position);top:230.25pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">*</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:244.5pt;width:254.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:254.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Dominik H&#246;chli</span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:67.85pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:68.42999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:68.72pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:68.86999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:68.94999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:68.99pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:69.00999999999999pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:69.02pt;position:var(--position);text-decoration:none;white-space:pre">.........................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:254.25pt;position:var(--position);top:244.5pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:322.5pt;position:var(--position);top:244.5pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:390.75pt;position:var(--position);top:244.5pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:258.75pt;width:254.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:254.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">All directors and officers as a group (9&#160;persons)</span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:193.56pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:193.85pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:194pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:194.07999999999998pt;position:var(--position);text-decoration:none;white-space:pre">.......................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:254.25pt;position:var(--position);top:258.75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">1,115,025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:322.5pt;position:var(--position);top:258.75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">1.44%</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:390.75pt;position:var(--position);top:258.75pt;width:68.25pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">1.40%</span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:402pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:551.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:551.25pt"/></tr><tr style="height:12.75pt"><td style="border-bottom:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:551.25pt"><div><div style="line-height:6pt;position:var(--position);top:2.63pt;width:551.25pt"><span style="font-family:'Times New Roman', serif;font-size:6pt;font-style:normal;font-weight:normal;left:5.38pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr></tbody></table></div></div></div><div style="line-height:8pt;position:var(--position);top:419.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:78.1pt;position:var(--position)">*<span style="display:inline-block;height:5.54pt;width:14.35pt"></span></span><span style="left:96.44999999999999pt;position:var(--position)">Represents beneficial ownership of less than 1%. </span></span></div><div style="line-height:8pt;position:var(--position);top:427.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:78.1pt;position:var(--position)">+<span style="display:inline-block;height:5.54pt;width:13.84pt"></span></span><span style="left:96.44999999999999pt;position:var(--position)">A double voting right is attached to each registered ordinary share (except treasury share) that is held in the name of the same shareholder </span></span></div><div style="line-height:8pt;position:var(--position);top:435.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.45pt;position:var(--position);text-decoration:none;white-space:pre">for at least two years. </span></div><div style="line-height:8pt;position:var(--position);top:443.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:78.1pt;position:var(--position)">(1)<span style="display:inline-block;height:5.54pt;width:9.03pt"></span></span></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.44999999999999pt;position:var(--position);white-space:pre">The information in this footnote is based on a Schedule 13G filed with the SEC on November 14, 2025 by TCG Crossover GPI I, LLC </span></div><div style="line-height:8pt;position:var(--position);top:452.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.45pt;position:var(--position);white-space:pre">("TCG Crossover GP I"), TCG Crossover Fund I, L.P. ("TCG Crossover I"), TCG Crossover GPI II ("TCG Crossover GP II"), LLC, TCG </span></div><div style="line-height:8pt;position:var(--position);top:461.67pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.45pt;position:var(--position);white-space:pre">Crossover GPI II, L.P. ("TCG Crossover II") and Chen Yu. </span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:288.14pt;position:var(--position);text-decoration:none;white-space:pre">Consists of </span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:325.9pt;position:var(--position);white-space:pre">6,456,596 ordinary shares</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:408.96999999999997pt;position:var(--position);text-decoration:none;white-space:pre"> held by TCG Crossover I </span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:493.8pt;position:var(--position);white-space:pre">and 655,000 </span></div><div style="line-height:8pt;position:var(--position);top:470.63pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.45pt;position:var(--position);white-space:pre">ordinary shares held by TCG Crossover II</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:231.01pt;position:var(--position);text-decoration:none;white-space:pre">. TCG Crossover GP I is the general partner of TCG Crossover I and may be deemed to have </span></div><div style="line-height:8pt;position:var(--position);top:479.59pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.45pt;position:var(--position);text-decoration:none;white-space:pre">voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP I </span></div><div style="line-height:8pt;position:var(--position);top:488.55pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.45pt;position:var(--position);white-space:pre">and may be deemed to share voting, investment and dispositive power with respect to these securities</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:420.68pt;position:var(--position);text-decoration:none;white-space:pre">. TCG Crossover GP II is the general </span></div><div style="line-height:8pt;position:var(--position);top:497.51pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.45pt;position:var(--position);text-decoration:none;white-space:pre">partner of TCG Crossover II and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen </span></div><div style="line-height:8pt;position:var(--position);top:506.47pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.45pt;position:var(--position);text-decoration:none;white-space:pre">Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with </span></div><div style="line-height:8pt;position:var(--position);top:515.43pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.45pt;position:var(--position);text-decoration:none;white-space:pre">respect to these securities. The principal business address of each of TCG Crossover GP I, TCG Crossover I</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:442.15999999999997pt;position:var(--position);white-space:pre">, TCG Crossover GP II, TCG </span></div><div style="line-height:8pt;position:var(--position);top:524.39pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.45pt;position:var(--position);white-space:pre">Crossover II </span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:138.19pt;position:var(--position);text-decoration:none;white-space:pre"> and Dr. Yu is </span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:185.26999999999998pt;position:var(--position);white-space:pre">245 Lytton Ave., Suite 350, Palo Alto, CA 94301</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:343.86pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><div style="line-height:8pt;position:var(--position);top:533.35pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:78.1pt;position:var(--position)">(2)<span style="display:inline-block;height:5.54pt;width:9.03pt"></span></span><span style="left:96.44999999999999pt;position:var(--position)">Consists of 3,922,995 ordinary shares directly held by Invus Public Equities, L.P. (&#8220;Invus PE&#8221;). Invus Public Equities Advisors, LLC </span></span></div><div style="line-height:8pt;position:var(--position);top:542.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.45pt;position:var(--position);text-decoration:none;white-space:pre">(&#8220;Invus PE Advisors&#8221;), as the general partner of Invus PE, controls Invus PE and accordingly, may be deemed to beneficially own the </span></div><div style="line-height:8pt;position:var(--position);top:551.27pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.45pt;position:var(--position);text-decoration:none;white-space:pre">ordinary shares held by Invus PE. Invus Global Management, LLC (&#8220;Global Management&#8221;), as the managing member of Invus PE </span></div><div style="line-height:8pt;position:var(--position);top:560.23pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.45pt;position:var(--position);text-decoration:none;white-space:pre">Advisors, controls Invus PE Advisors and, accordingly, may be deemed to beneficially own the ordinary shares that Invus PE Advisors </span></div><div style="line-height:8pt;position:var(--position);top:569.19pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.45pt;position:var(--position);text-decoration:none;white-space:pre">may be deemed to beneficially own. Sire, L.L.C., (&#8220;Siren&#8221;), as the managing member of Global Management, controls Global </span></div><div style="line-height:8pt;position:var(--position);top:578.15pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.45pt;position:var(--position);text-decoration:none;white-space:pre">Management and, accordingly, may be deemed to beneficially own the ordinary shares that Global Management may be deemed to </span></div><div style="line-height:8pt;position:var(--position);top:587.11pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.45pt;position:var(--position);text-decoration:none;white-space:pre">beneficially own. Mr. Raymond Debbane, as the managing member of Siren, controls Siren and, accordingly, may be deemed to </span></div><div style="line-height:8pt;position:var(--position);top:596.07pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.45pt;position:var(--position);text-decoration:none;white-space:pre">beneficially own the ordinary shares that Siren may be deemed to beneficially own. The address of each of the entities and the individual </span></div><div style="line-height:8pt;position:var(--position);top:605.03pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.45pt;position:var(--position);text-decoration:none;white-space:pre">referenced in this footnote is 750 Lexington Avenue, 30th Floor, New York, NY 10022.&#160; </span></div><div style="line-height:8pt;position:var(--position);top:613.99pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:78.1pt;position:var(--position)">(3)<span style="display:inline-block;height:5.54pt;width:9.03pt"></span></span><span style="left:96.44999999999999pt;position:var(--position)">Consists of (i) 457,325 ordinary shares resulting from the holding of &#8220;right of use over ADR&#8221; contracts settled in cash, exercisable until </span></span></div><div style="line-height:8pt;position:var(--position);top:622.95pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.45pt;position:var(--position);text-decoration:none;white-space:pre">January 26, 2027, at a price of &#8364;63.85, and (ii) 2,036,688 ordinary shares resulting from the holding of cash-settled &#8220;right of use over </span></div><div style="line-height:8pt;position:var(--position);top:631.91pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.45pt;position:var(--position);text-decoration:none;white-space:pre">ADR&#8221; contracts, exercisable until August 26, 2027, at a price of &#8364;66.57.</span></div><div style="line-height:8pt;position:var(--position);top:640.87pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:78.1pt;position:var(--position)">(4)<span style="display:inline-block;height:5.54pt;width:9.03pt"></span></span><span style="left:96.44999999999999pt;position:var(--position)">Consists of (a) 894,084 ordinary shares held as of February 28, 2026 and (b) 35,456 free shares that vest within 60 days of February 28, </span></span></div><div style="line-height:8pt;position:var(--position);top:649.83pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.45pt;position:var(--position);text-decoration:none;white-space:pre">2026. </span></div><div style="line-height:8pt;position:var(--position);top:658.79pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:78.1pt;position:var(--position)">(5)<span style="display:inline-block;height:5.54pt;width:9.03pt"></span></span><span style="left:96.44999999999999pt;position:var(--position)">Consists of (a) 113,156 ordinary shares held as of February 28, 2026 and (b) up to 33,687 ordinary shares issuable upon the exercise of </span></span></div><div style="line-height:8pt;position:var(--position);top:666.79pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.45pt;position:var(--position);text-decoration:none;white-space:pre">warrants that are immediately exercisable or exercisable within 60 days of February 28, 2026. </span></div><div style="line-height:8pt;position:var(--position);top:674.79pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:78.1pt;position:var(--position)">(6)<span style="display:inline-block;height:5.54pt;width:9.03pt"></span></span><span style="left:96.44999999999999pt;position:var(--position)">Consists of up to 15,977 ordinary shares issuable upon the exercise of warrants that are immediately exercisable or exercisable within 60 </span></span></div><div style="line-height:8pt;position:var(--position);top:682.79pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.45pt;position:var(--position);text-decoration:none;white-space:pre">days of February 28, 2026. </span></div><div style="line-height:8pt;position:var(--position);top:690.79pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:78.1pt;position:var(--position)">(7)<span style="display:inline-block;height:5.54pt;width:9.03pt"></span></span><span style="left:96.44999999999999pt;position:var(--position)">Consists of up to 15,977 ordinary shares issuable upon the exercise of warrants that are immediately exercisable or exercisable within 60 </span></span></div><div style="line-height:8pt;position:var(--position);top:698.79pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.45pt;position:var(--position);text-decoration:none;white-space:pre">days of February 28, 2026. </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">134</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:8pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:78.1pt;position:var(--position)">(8)<span style="display:inline-block;height:5.54pt;width:9.03pt"></span></span><span style="left:96.44999999999999pt;position:var(--position)">Consists of (a) 4,863 ordinary shares held as of February 28, 2026 and (b) up to 11,113 ordinary shares issuable upon the exercise of </span></span></div><div style="line-height:8pt;position:var(--position);top:80pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.45pt;position:var(--position);text-decoration:none;white-space:pre">warrants that are immediately exercisable or exercisable within 60 days of February 28, 2026. </span></div><div style="line-height:8pt;position:var(--position);top:88pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:78.1pt;position:var(--position)">(9)<span style="display:inline-block;height:5.54pt;width:9.03pt"></span></span><span style="left:96.44999999999999pt;position:var(--position)">Consists of up to 15,977 ordinary shares issuable upon the exercise of options and warrants that are immediately exercisable or </span></span></div><div style="line-height:8pt;position:var(--position);top:96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.45pt;position:var(--position);text-decoration:none;white-space:pre">exercisable within 60 days of February 28, 2026.&#160; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:110pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">As of February 28, 2026, to the best of our knowledge, we estimate that 17,527,480 of our outstanding </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:120pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ordinary shares (including ordinary shares in the form of ADSs) were held by 4 shareholders of record in the United </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:130pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">States. The actual number of holders is greater than the number of record holders, and includes beneficial owners </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:140pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">whose ordinary shares or ADSs are held in street name by brokers and other nominees. This number of holders of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:150pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">record also does not include holders whose shares may be held in trust by other entities.</span></div><div style="position:absolute;top:184pt" id="i7a006daedb3d4216a4128b76247285d7_112"></div><div style="line-height:10pt;position:var(--position);top:184pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">B.<span id="iabc92b9f2d4547e39fb19821412137c5"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Related Party Transactions</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:202pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Since January&#160;1, 2025, we have engaged in the following transactions with our directors, executive officers </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:212pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and holders of more than 5% of our outstanding voting securities and their affiliates, which we refer to as to our </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:222pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">related parties. </span></div><div style="line-height:10pt;position:var(--position);top:238pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Arrangements with our Directors and Executive Officers </span></div><div style="line-height:10pt;position:var(--position);top:260pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Director and Executive Officer Compensation </span></div><div style="line-height:10pt;position:var(--position);top:278pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We are parties to employment agreements and other compensation arrangements, including equity </span></div><div style="line-height:10pt;position:var(--position);top:288pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">compensation arrangements, with our directors and executive officers in the ordinary course of business. See &#8220;Item </span></div><div style="line-height:10pt;position:var(--position);top:298pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">6.B Compensation and Benefits&#8221; for information regarding compensation of the Directors and Executive Officers.</span></div><div style="line-height:10pt;position:var(--position);top:326pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Related Person Transaction Policy </span></div><div style="line-height:10pt;position:var(--position);top:342pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We comply with French law regarding approval of transactions with related parties. In particular, in </span></div><div style="line-height:10pt;position:var(--position);top:352pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">accordance with article L.225-38 and seq. of the French Commercial Code, transactions with our general managers, </span></div><div style="line-height:10pt;position:var(--position);top:362pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">directors, shareholders holding more than 10% of the voting rights of the company and any company controlling a </span></div><div style="line-height:10pt;position:var(--position);top:372pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">shareholder holding more than 10% of our voting rights, other than transactions in the ordinary course of business </span></div><div style="line-height:10pt;position:var(--position);top:382pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and at arm&#8217;s length, are (i)&#160;subject to a prior approval by the Board, (ii)&#160;reported to the statutory auditors who must </span></div><div style="line-height:10pt;position:var(--position);top:392pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">then prepare a report on such transaction, and (iii)&#160;ratified by the our shareholders at the annual general meeting. </span></div><div style="line-height:10pt;position:var(--position);top:408pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In addition, we have adopted a related-party transaction policy that sets forth our procedures for the </span></div><div style="line-height:10pt;position:var(--position);top:418pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">identification, review, consideration and approval or ratification of related-party transactions. For purposes of our </span></div><div style="line-height:10pt;position:var(--position);top:428pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">policy only, a related-party transaction is defined as (1)&#160;any individual or series of financial transactions, </span></div><div style="line-height:10pt;position:var(--position);top:438pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">arrangements or relationships (including any indebtedness or guarantee of indebtedness), in which we and any </span></div><div style="line-height:10pt;position:var(--position);top:448pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">related parties are, were or will be participants, or otherwise have a direct or indirect interest, or (2)&#160;any agreement </span></div><div style="line-height:10pt;position:var(--position);top:458pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">or similar transaction under French law which falls within the scope of Article L. 225-38 of the French Commercial </span></div><div style="line-height:10pt;position:var(--position);top:468pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Code. For purposes of this policy, a related party is any person who is or at any time since the beginning of the our </span></div><div style="line-height:10pt;position:var(--position);top:478pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">last fiscal year was, a director, director nominee, executive officer, beneficial owner of more than 5% of any class of </span></div><div style="line-height:10pt;position:var(--position);top:488pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">our voting securities or any immediate family member(s) of the foregoing persons, or any firm, corporation or other </span></div><div style="line-height:10pt;position:var(--position);top:498pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">entity in which any of the foregoing persons is employed or is a partner or principal or in a similar position or in </span></div><div style="line-height:10pt;position:var(--position);top:508pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">which such person has more than a 5% beneficial ownership interest. Under the policy, related-party transactions </span></div><div style="line-height:10pt;position:var(--position);top:518pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">must be reported to us by the relevant related parties. If a transaction has been identified as a related-party </span></div><div style="line-height:10pt;position:var(--position);top:528pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">transaction, management must present information regarding the related-party transaction to our Board for review, </span></div><div style="line-height:10pt;position:var(--position);top:538pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">consideration and approval or ratification. Regarding certain transactions, our Board may appoint an independent </span></div><div style="line-height:10pt;position:var(--position);top:548pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">expert whenever the signing of a related person transaction is likely to have a material impact on our balance sheet </span></div><div style="line-height:10pt;position:var(--position);top:558pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">or results. In this case, this expert review will be mentioned in the special report of the statutory auditors and </span></div><div style="line-height:10pt;position:var(--position);top:568pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">disclosed to the public subject, as the case may be, to any information likely to adversely affect trade secret. Our </span></div><div style="line-height:10pt;position:var(--position);top:578pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Board may also seek the opinion of the audit committee and/or of the independent statutory auditors if there is any </span></div><div style="line-height:10pt;position:var(--position);top:588pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">doubt about the qualification of a related person transaction subject to his evaluation. When submitted to our </span></div><div style="line-height:10pt;position:var(--position);top:598pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Board&#8217;s review, the persons who have a direct or indirect interest in the transaction shall not participate in its review. </span></div><div style="position:absolute;top:632pt" id="i7a006daedb3d4216a4128b76247285d7_115"></div><div style="line-height:10pt;position:var(--position);top:632pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">C.<span id="i41488d34e8f54a8caab3af81fa0549a5"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Interests of Experts and Counsel</span></div><div style="line-height:10pt;position:var(--position);top:656pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">Not </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.99pt;position:var(--position);text-decoration:none;white-space:pre">applicable</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.02pt;position:var(--position);white-space:pre">.</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">135</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_118"></div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">Item 8.<span style="display:inline-block;height:6.77pt;width:6.02pt"></span></span><span style="left:108pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:36pt"></span></span><span style="left:144pt;position:var(--position)">Financial Information</span><span id="i6c7811576aae4cba9fc453dd4dfa1201"></span></span></div><div style="position:absolute;top:96pt" id="i7a006daedb3d4216a4128b76247285d7_121"></div><div style="line-height:10pt;position:var(--position);top:96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">A.<span id="icd0fa5bc323048fc80653a580fce7b12"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Consolidated Statements and Other Financial Information</span></div><div style="line-height:10pt;position:var(--position);top:120pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Financial Statements</span></div><div style="line-height:10pt;position:var(--position);top:142pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our consolidated financial statements are included at the end of this Annual Report on Form 20-F, starting at </span></div><div style="line-height:10pt;position:var(--position);top:152pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">page F-1.</span></div><div style="line-height:10pt;position:var(--position);top:174pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Legal Proceedings</span></div><div style="line-height:10pt;position:var(--position);top:190pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">From time to time, we may be involved in various claims and legal proceedings relating to claims arising out </span></div><div style="line-height:10pt;position:var(--position);top:200pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are </span></div><div style="line-height:10pt;position:var(--position);top:210pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse </span></div><div style="line-height:10pt;position:var(--position);top:220pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></div><div style="line-height:10pt;position:var(--position);top:242pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Dividend Policy </span></div><div style="line-height:10pt;position:var(--position);top:260pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We have never declared or paid any cash dividends on our ordinary shares. We do not have any present plan </span></div><div style="line-height:10pt;position:var(--position);top:270pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to pay any cash dividends on our equity securities in the foreseeable future. We currently intend to retain all of our </span></div><div style="line-height:10pt;position:var(--position);top:280pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">available funds and any future earnings to operate and expand our business. We do not anticipate paying cash </span></div><div style="line-height:10pt;position:var(--position);top:290pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">dividends on our equity securities in the foreseeable future and intend to retain all available funds and any future </span></div><div style="line-height:10pt;position:var(--position);top:300pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">earnings for use in the operation and expansion of our business, given our state of development. </span></div><div style="line-height:10pt;position:var(--position);top:316pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Subject to the requirements of French law and our by-laws, dividends may only be distributed from our </span></div><div style="line-height:10pt;position:var(--position);top:326pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">distributable profits, plus any amount held in our available reserves, which are those reserves other than the legal </span></div><div style="line-height:10pt;position:var(--position);top:336pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and statutory reserves and the revaluation surplus. </span></div><div style="line-height:10pt;position:var(--position);top:352pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">If we pay any dividends, we will pay our ADS holders to the same extent as holders of our ordinary shares, </span></div><div style="line-height:10pt;position:var(--position);top:362pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">subject to the terms of the deposit agreement, including deduction in respect of the fees and expenses payable </span></div><div style="line-height:10pt;position:var(--position);top:372pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">thereunder. See &#8220;Description of American Depositary Shares&#8221; for further information. Cash dividends on our </span></div><div style="line-height:10pt;position:var(--position);top:382pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ordinary shares, if any, will be paid in euros and converted into U.S. dollars with respect to ADSs, as provided in the </span></div><div style="line-height:10pt;position:var(--position);top:392pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">deposit agreement. </span></div><div style="position:absolute;top:414pt" id="i7a006daedb3d4216a4128b76247285d7_124"></div><div style="line-height:10pt;position:var(--position);top:414pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">B.<span id="i9eee21b00d194ec38f29086644b798ce"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Significant Changes</span></div><div style="line-height:10pt;position:var(--position);top:432pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">Except as disclosed </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:177.23000000000002pt;position:var(--position);text-decoration:none;white-space:pre">elsewhere</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:217.16pt;position:var(--position);white-space:pre"> in this Annual Report on Form 20-F, no significant changes have occurred.</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">136</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_127"></div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">Item 9.<span style="display:inline-block;height:6.77pt;width:6.02pt"></span></span><span style="left:108pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:36pt"></span></span><span style="left:144pt;position:var(--position)">The Offer and Listing</span><span id="i4293f704253543c3bf3137249451c700"></span></span></div><div style="line-height:10pt;position:var(--position);top:96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">A.<span id="i3a4f2ac68e0f4658a3302dc323f8f969"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Offer and Listing Details</span></div><div style="line-height:10pt;position:var(--position);top:114pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">Our ADSs have been listed on the Nasdaq Global Market under the symbol &#8220;ABVX&#8221; since October 20, 2023. </span></div><div style="line-height:10pt;position:var(--position);top:124pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">Prior to that date, there was no public trading market for our ADSs. Our ordinary shares have been trading on </span></div><div style="line-height:10pt;position:var(--position);top:134pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">Euronext Paris </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:133.61pt;position:var(--position);text-decoration:none;white-space:pre">under</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:156.37pt;position:var(--position);white-space:pre"> the symbol &#8220;ABVX&#8221; since June 2015. Prior to that date, there was no public trading market for </span></div><div style="line-height:10pt;position:var(--position);top:144pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">our ordinary shares.</span></div><div style="line-height:10pt;position:var(--position);top:166pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);white-space:pre">B.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);white-space:pre">Plan of Distribution</span></div><div style="line-height:10pt;position:var(--position);top:184pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">Not </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.99pt;position:var(--position);text-decoration:none;white-space:pre">applicable.</span></div><div style="line-height:10pt;position:var(--position);top:206pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);white-space:pre">C.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);white-space:pre">Markets</span></div><div style="line-height:10pt;position:var(--position);top:224pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">For information regarding the stock exchanges and regulated markets on which our ADSs and ordinary shares </span></div><div style="line-height:10pt;position:var(--position);top:234pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">are listed, see &#8220;Item 9.A. Offer and Listing Details".</span></div><div style="line-height:10pt;position:var(--position);top:256pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);white-space:pre">D.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);white-space:pre">Selling Shareholders</span></div><div style="line-height:10pt;position:var(--position);top:274pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">Not </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.99pt;position:var(--position);text-decoration:none;white-space:pre">applicable.</span></div><div style="line-height:10pt;position:var(--position);top:296pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);white-space:pre">E.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);white-space:pre">Dilution</span></div><div style="line-height:10pt;position:var(--position);top:314pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">Not </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.99pt;position:var(--position);text-decoration:none;white-space:pre">applicable.</span></div><div style="line-height:10pt;position:var(--position);top:336pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);white-space:pre">F.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);white-space:pre">Expenses of the Issue</span></div><div style="line-height:10pt;position:var(--position);top:354pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">Not </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.99pt;position:var(--position);text-decoration:none;white-space:pre">applicable.</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">137</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_130"></div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">Item 10.<span style="display:inline-block;height:6.77pt;width:1.02pt"></span></span><span style="left:108pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:36pt"></span></span><span style="left:144pt;position:var(--position)">Additional Information.</span><span id="i14117f6a019d493ea833e57b36a6fc1f"></span></span></div><div style="position:absolute;top:96pt" id="i7a006daedb3d4216a4128b76247285d7_133"></div><div style="line-height:10pt;position:var(--position);top:96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">A.<span id="i9bb6451ccfc344f385a89b5d9d00f280"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Share capital</span></div><div style="line-height:10pt;position:var(--position);top:114pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">Not </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.99pt;position:var(--position);text-decoration:none;white-space:pre">applicable.</span></div><div style="position:absolute;top:136pt" id="i7a006daedb3d4216a4128b76247285d7_136"></div><div style="line-height:10pt;position:var(--position);top:136pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">B.<span id="ie864456b5a6a46f899c933b91be73fa5"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Memorandum and articles of association</span></div><div style="line-height:10pt;position:var(--position);top:154pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">The information set forth in Exhibit 2.1 </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:256.9pt;position:var(--position);white-space:pre">is</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:263.56pt;position:var(--position);white-space:pre"> incorporated herein by reference.</span></div><div style="position:absolute;top:176pt" id="i7a006daedb3d4216a4128b76247285d7_139"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:176pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">C.<span id="i693ced088d844d50a6b754790ce4bbc7"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Material contracts</span></div><div style="line-height:10pt;position:var(--position);top:200pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);white-space:pre">ATM Agreement</span></div><div style="line-height:10pt;position:var(--position);top:218pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">On November 19, 2024, we entered into an Equity Distribution Agreement (the &#8220;ATM Agreement&#8221;) with </span></div><div style="line-height:10pt;position:var(--position);top:228pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Piper Sandler &amp; Co. (&#8220;Piper Sandler&#8221;) with respect to an equity offering program under which we may offer and sell </span></div><div style="line-height:10pt;position:var(--position);top:238pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ADSs from time to time, through Piper Sandler as sales agent, having an aggregate offering price of up to $150.0 </span></div><div style="line-height:10pt;position:var(--position);top:248pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">million (subject to French regulatory limits). Sales of the ADSs, if any, may be made in sales deemed to be an &#8220;at </span></div><div style="line-height:10pt;position:var(--position);top:258pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Act. The ATM Agreement will </span></div><div style="line-height:10pt;position:var(--position);top:268pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">terminate upon the earlier of (i) the sale of all ADSs subject to the ATM Agreement and (ii) the termination of the </span></div><div style="line-height:10pt;position:var(--position);top:278pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ATM Agreement as permitted therein. Piper Sandler may terminate the Agreement at any time, and we may </span></div><div style="line-height:10pt;position:var(--position);top:288pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">terminate the ATM Agreement at any time upon ten days&#8217; prior notice.</span></div><div style="position:absolute;top:322pt" id="i7a006daedb3d4216a4128b76247285d7_142"></div><div style="line-height:10pt;position:var(--position);top:322pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">D.<span id="i1261cc1079c349e6bb9e28fd00a2d510"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Exchange Controls</span></div><div style="line-height:10pt;position:var(--position);top:340pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Under current French foreign exchange control regulations there are no limitations on the amount of cash </span></div><div style="line-height:10pt;position:var(--position);top:350pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">payments that we may remit to residents of foreign countries. Laws and regulations concerning foreign exchange </span></div><div style="line-height:10pt;position:var(--position);top:360pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">controls do, however, require that all payments or transfers of funds made by a French resident to a non-resident </span></div><div style="line-height:10pt;position:var(--position);top:370pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">such as dividend payments be handled by an accredited intermediary. All registered banks and substantially all </span></div><div style="line-height:10pt;position:var(--position);top:380pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">credit institutions in France are accredited intermediaries. </span></div><div style="position:absolute;top:414pt" id="i7a006daedb3d4216a4128b76247285d7_145"></div><div style="line-height:10pt;position:var(--position);top:414pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">E.<span id="ieba5f14ba7c6442bab1c97818dbdaad0"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Taxation</span></div><div style="line-height:10pt;position:var(--position);top:438pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The summary set forth below describes certain French and U.S. federal income tax consequences relating to </span></div><div style="line-height:10pt;position:var(--position);top:448pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the purchase, ownership and disposition of the ADSs to U.S. Holders (as defined below) as of the date hereof. This </span></div><div style="line-height:10pt;position:var(--position);top:458pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">summary does not represent a detailed description of the tax consequences applicable to a U.S. Holder that is </span></div><div style="line-height:10pt;position:var(--position);top:468pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">subject to special treatment under the U.S. federal tax laws, including, without limitation: </span></div><div style="line-height:10pt;position:var(--position);top:484pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">certain financial institutions; </span></span></div><div style="line-height:10pt;position:var(--position);top:500pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">traders in securities who use a mark-to-market method of tax accounting; </span></span></div><div style="line-height:10pt;position:var(--position);top:516pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">dealers in securities or currencies; </span></span></div><div style="line-height:10pt;position:var(--position);top:532pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">persons holding ADSs as part of a hedging transaction, &#8220;straddle,&#8221; wash sale, conversion transaction or </span></span></div><div style="line-height:10pt;position:var(--position);top:542pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">integrated transaction or persons entering into a constructive sale with respect to the ADSs; </span></div><div style="line-height:10pt;position:var(--position);top:558pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">regulated investment companies; </span></span></div><div style="line-height:10pt;position:var(--position);top:574pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">insurance companies; </span></span></div><div style="line-height:10pt;position:var(--position);top:590pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">real estate investment trusts, grantor trusts or other trusts; </span></span></div><div style="line-height:10pt;position:var(--position);top:606pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">persons whose &#8220;functional currency&#8221; for U.S. federal income tax purposes is not the U.S. dollar; </span></span></div><div style="line-height:10pt;position:var(--position);top:622pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">expatriates of the United States; </span></span></div><div style="line-height:10pt;position:var(--position);top:638pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">tax exempt entities, including &#8220;individual retirement accounts&#8221; and &#8220;Roth IRAs&#8221;; </span></span></div><div style="line-height:10pt;position:var(--position);top:654pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">entities or arrangements classified as partnerships or other pass-through entities for U.S. federal </span></span></div><div style="line-height:10pt;position:var(--position);top:664pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">income tax purposes (and investors therein); </span></div><div style="line-height:10pt;position:var(--position);top:680pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">persons that received ADSs as compensation for the performance of services; </span></span></div><div style="line-height:10pt;position:var(--position);top:696pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">persons that own or are deemed to own ten percent or more of our shares (by vote or value); and </span></span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">138</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">persons holding ADSs in connection with a trade or business, permanent establishment, or fixed base </span></span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">outside the United States. </span></div><div style="line-height:10pt;position:var(--position);top:104pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">This summary is for general information only. Prospective Investors considering the purchase, </span></div><div style="line-height:10pt;position:var(--position);top:114pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ownership or disposition of the ADSs are advised to consult their own tax advisers concerning the French and </span></div><div style="line-height:10pt;position:var(--position);top:124pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">U.S. federal income tax consequences in light of their particular facts and circumstances, as well as any </span></div><div style="line-height:10pt;position:var(--position);top:134pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">consequences arising under the laws of any other taxing jurisdiction. </span></div><div style="line-height:10pt;position:var(--position);top:162pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">French Income Tax Considerations </span></div><div style="line-height:10pt;position:var(--position);top:178pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The following describes the material French income tax consequences to U.S. Holders (as defined below) of </span></div><div style="line-height:10pt;position:var(--position);top:188pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">purchasing, owning and disposing of our ADSs and, unless otherwise noted, this discussion is the opinion of </span></div><div style="line-height:10pt;position:var(--position);top:198pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Dechert, our French tax counsel, insofar as it relates to matters of French tax law and legal conclusions with respect </span></div><div style="line-height:10pt;position:var(--position);top:208pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to those matters. </span></div><div style="line-height:10pt;position:var(--position);top:224pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">This discussion does not purport to be a complete analysis or listing of all potential tax effects of the </span></div><div style="line-height:10pt;position:var(--position);top:234pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">acquisition, ownership or disposition of our ADSs to any particular investor, and does not discuss tax considerations </span></div><div style="line-height:10pt;position:var(--position);top:244pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">that arise from rules of general application or that are generally assumed to be known by investors. All of the </span></div><div style="line-height:10pt;position:var(--position);top:254pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">following is subject to change. Such changes could apply retroactively and could affect the consequences described </span></div><div style="line-height:10pt;position:var(--position);top:264pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">below. </span></div><div style="line-height:10pt;position:var(--position);top:280pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In 2011, France introduced a comprehensive set of new tax rules applicable to French assets that are held by or </span></div><div style="line-height:10pt;position:var(--position);top:290pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">in foreign trusts. These rules, among other things, provide for the inclusion of trust assets in the settlor&#8217;s net assets </span></div><div style="line-height:10pt;position:var(--position);top:300pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for purpose of applying the former French wealth tax (replaced by the French real estate wealth tax as from </span></div><div style="line-height:10pt;position:var(--position);top:310pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">January&#160;1, 2018), for the application of French gift and death duties to French assets held in trust, for a specific tax </span></div><div style="line-height:10pt;position:var(--position);top:320pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">on capital on the French assets of foreign trusts not already subject to the former French wealth tax (replaced by the </span></div><div style="line-height:10pt;position:var(--position);top:330pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">French real estate wealth tax as from January&#160;1, 2018) and for a number of French tax reporting and disclosure </span></div><div style="line-height:10pt;position:var(--position);top:340pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">obligations. The following discussion does not address the French tax consequences applicable to ADSs held in </span></div><div style="line-height:10pt;position:var(--position);top:350pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">trusts. If ADSs are held in trust, the grantor, trustee and beneficiary are urged to consult their own tax adviser </span></div><div style="line-height:10pt;position:var(--position);top:360pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regarding the specific tax consequences of acquiring, owning and disposing of ADSs. </span></div><div style="line-height:10pt;position:var(--position);top:376pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The description of the French income tax and real estate wealth tax consequences set forth below is based on </span></div><div style="line-height:10pt;position:var(--position);top:386pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the Convention Between the Government of the United States of America and the Government of the French </span></div><div style="line-height:10pt;position:var(--position);top:396pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Republic for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on </span></div><div style="line-height:10pt;position:var(--position);top:406pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Income and Capital of August&#160;31, 1994 which came into force on December&#160;30, 1995 (as amended by any </span></div><div style="line-height:10pt;position:var(--position);top:416pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">subsequent protocols, including the protocol of January&#160;13, 2009, or the "Treaty") and the tax guidelines issued by </span></div><div style="line-height:10pt;position:var(--position);top:426pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the French tax authorities in force as of the date of this Annual Report on Form 20-F. </span></div><div style="line-height:10pt;position:var(--position);top:442pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For the purposes of this discussion, the term &#8220;U.S. Holder&#8221; means a beneficial owner of ADSs that is (or is </span></div><div style="line-height:10pt;position:var(--position);top:452pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">treated as), for U.S. federal income tax purposes: (1)&#160;an individual who is a U.S. citizen or resident, (2)&#160;a corporation </span></div><div style="line-height:10pt;position:var(--position);top:462pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">or other entity that is treated as a corporation for U.S. federal income tax purposes, created or organized in or under </span></div><div style="line-height:10pt;position:var(--position);top:472pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the laws of the United States or any state thereof, including the District of Colombia, (3)&#160;otherwise subject to U.S. </span></div><div style="line-height:10pt;position:var(--position);top:482pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">federal income taxation or (4)&#160;a trust, if a court within the United States is able to exercise primary supervision over </span></div><div style="line-height:10pt;position:var(--position);top:492pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">its administration and one or more U.S. persons have the authority to control all of the substantial decisions of such </span></div><div style="line-height:10pt;position:var(--position);top:502pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">trust or has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a United States </span></div><div style="line-height:10pt;position:var(--position);top:512pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">person. </span></div><div style="line-height:10pt;position:var(--position);top:528pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">If a partnership (or any other entity treated as partnership for U.S. federal income tax purposes) holds ADSs, </span></div><div style="line-height:10pt;position:var(--position);top:538pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the tax treatment of the partnership and a partner in such partnership generally will depend upon the status of the </span></div><div style="line-height:10pt;position:var(--position);top:548pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">partner and the activities of the partnership. If a U.S. Holder is a partnership or a partner in a partnership that holds </span></div><div style="line-height:10pt;position:var(--position);top:558pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ADSs, such holder is urged to consult its own tax adviser regarding the specific tax consequences of acquiring, </span></div><div style="line-height:10pt;position:var(--position);top:568pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">owning and disposing of securities. </span></div><div style="line-height:10pt;position:var(--position);top:584pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">This discussion applies only to investors that hold our ADSs as capital assets that have the U.S. dollar as their </span></div><div style="line-height:10pt;position:var(--position);top:594pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">functional currency, that are entitled to Treaty benefits under the &#8220;Limitation on Benefits&#8221; provision contained in the </span></div><div style="line-height:10pt;position:var(--position);top:604pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Treaty, and whose ownership of the ADSs is not effectively connected to a permanent establishment or a fixed base </span></div><div style="line-height:10pt;position:var(--position);top:614pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">in France. Certain U.S. Holders (including, but not limited to, U.S. expatriates, partnerships or other entities </span></div><div style="line-height:10pt;position:var(--position);top:624pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">classified as partnerships for U.S. federal income tax purposes, banks, insurance companies, regulated investment </span></div><div style="line-height:10pt;position:var(--position);top:634pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">companies, tax-exempt organizations, financial institutions, persons subject to the alternative minimum tax, persons </span></div><div style="line-height:10pt;position:var(--position);top:644pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">who acquired the securities pursuant to the exercise of employee share options or otherwise as compensation, </span></div><div style="line-height:10pt;position:var(--position);top:654pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">persons that own (directly, indirectly or by attribution) 5% or more of our voting stock or 5% or more of our </span></div><div style="line-height:10pt;position:var(--position);top:664pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">outstanding share capital, dealers in securities or currencies, persons that elect to mark their securities to market for </span></div><div style="line-height:10pt;position:var(--position);top:674pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">U.S. federal income tax purposes and persons holding securities as a position in a synthetic security, straddle or </span></div><div style="line-height:10pt;position:var(--position);top:684pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">conversion transaction) may be subject to special rules not discussed below. </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">139</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">U.S. Holders are urged to consult their own tax advisers regarding the tax consequences of the purchase, </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ownership and disposition of securities in light of their particular circumstances, especially with regard to the </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8220;Limitations on Benefits&#8221; provision. </span></div><div style="line-height:10pt;position:var(--position);top:120pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Estate and Gift Taxes and Transfer Taxes </span></div><div style="line-height:10pt;position:var(--position);top:136pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In general, a transfer of securities by gift or by reason of death of a U.S. Holder that would otherwise be </span></div><div style="line-height:10pt;position:var(--position);top:146pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">subject to French gift or inheritance tax, respectively, will not be subject to such French tax by reason of the </span></div><div style="line-height:10pt;position:var(--position);top:156pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Convention between the Government of the United States of America and the Government of the French Republic </span></div><div style="line-height:10pt;position:var(--position);top:166pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Estates, </span></div><div style="line-height:10pt;position:var(--position);top:176pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Inheritances and Gifts, dated November&#160;24, 1978 (as amended by any subsequent protocols, including the protocol </span></div><div style="line-height:10pt;position:var(--position);top:186pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of December 8, 2004), unless (i)&#160;the donor or the transferor is domiciled in France at the time of making the gift or </span></div><div style="line-height:10pt;position:var(--position);top:196pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">at the time of his or her death, or (ii)&#160;the securities were used in, or held for use in, the conduct of a business through </span></div><div style="line-height:10pt;position:var(--position);top:206pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">a permanent establishment or a fixed base in France. </span></div><div style="line-height:1pt;position:var(--position);top:229.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="line-height:10pt;position:var(--position);top:230.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Financial Transactions Tax </span></div><div style="line-height:10pt;position:var(--position);top:258.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Pursuant to Article 235 ter ZD of the French Tax Code (</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:321.55pt;position:var(--position);text-decoration:none;white-space:pre">Code g&#233;n&#233;ral des imp&#244;ts</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:420.63pt;position:var(--position);text-decoration:none;white-space:pre">) (the &#8220;FTC&#8221;), purchases of </span></div><div style="line-height:10pt;position:var(--position);top:268.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">certain securities issued by a French company, including ordinary shares (which may be in the form of ADSs), </span></div><div style="line-height:10pt;position:var(--position);top:278.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">which are listed on a regulated market of the EU or an exchange market formally acknowledged by the AMF (in </span></div><div style="line-height:10pt;position:var(--position);top:288.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">each case within the meaning of the French Monetary and Financial Code (the &#8220;FMFC&#8221;)) are subject in France to a </span></div><div style="line-height:10pt;position:var(--position);top:298.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">0.3% tax </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:110.03pt;position:var(--position);white-space:pre">(increased to 0.4% as from April 1</span><span style="font-family:'Times New Roman', serif;font-size:6.474000000000001pt;font-style:normal;font-weight:normal;left:248.51pt;position:var(--position);top:-2.429pt;vertical-align:super;white-space:pre">st</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.81pt;position:var(--position);white-space:pre">, 2025) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:283.64pt;position:var(--position);text-decoration:none;white-space:pre">on financial transactions (the &#8220;TFT&#8221;), provided </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:474.79pt;position:var(--position);text-decoration:none;white-space:pre">inter alia</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:511.69pt;position:var(--position);text-decoration:none;white-space:pre"> that </span></div><div style="line-height:10pt;position:var(--position);top:308.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the issuer&#8217;s market capitalization exceeds &#8364;1&#160;billion as of December&#160;1 of the year preceding the taxation year. </span></div><div style="line-height:10pt;position:var(--position);top:324.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">A list of French relevant companies whose market capitalization exceeds &#8364;1&#160;billion as of December&#160;1 of the </span></div><div style="line-height:10pt;position:var(--position);top:334.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">year preceding the taxation year is published annually by the French State. The last version of such list was dated </span></div><div style="line-height:10pt;position:var(--position);top:344.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">December&#160;17, 2025 (BOI-ANNX-000467). It included Abivax SA as its market capitalization exceeded &#8364;1.0&#160;billion. </span></div><div style="line-height:10pt;position:var(--position);top:360.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">However, the Nasdaq Global Market, on which ADSs are listed, is not currently acknowledged by the AMF, </span></div><div style="line-height:10pt;position:var(--position);top:370.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">but it may change in the future.</span></div><div style="line-height:10pt;position:var(--position);top:386.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">As a result, the ADSs are not currently within the scope of the TFT. Under current law,&#160; purchases of our </span></div><div style="line-height:10pt;position:var(--position);top:396.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ADSs will not be subject to the TFT as long as&#160;the Nasdaq Global Market is not acknowledged by the AMF. </span></div><div style="line-height:10pt;position:var(--position);top:424.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Registration Duties </span></div><div style="line-height:10pt;position:var(--position);top:440.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In the case where the TFT is not applicable, (1)&#160;transfers of shares issued by a French company which are </span></div><div style="line-height:10pt;position:var(--position);top:450.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">listed on a regulated or organized market within the meaning of the FMFC are subject to uncapped registration </span></div><div style="line-height:10pt;position:var(--position);top:460.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">duties at the rate of 0.1% if the transfer is evidenced by a written statement (&#8220;acte&#8221;) executed either in France or </span></div><div style="line-height:10pt;position:var(--position);top:470.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">outside France, whereas (2)&#160;transfers of shares issued by a French company which are not listed on a regulated or </span></div><div style="line-height:10pt;position:var(--position);top:480.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">organized market within the meaning of the FMFC are subject to uncapped registration duties at the rate of 0.1% </span></div><div style="line-height:10pt;position:var(--position);top:490.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">notwithstanding the existence of a written statement. </span></div><div style="line-height:10pt;position:var(--position);top:506.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">As ordinary shares of Abivax SA are listed on Euronext Paris, which is a regulated market within the meaning </span></div><div style="line-height:10pt;position:var(--position);top:516.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of the FMFC, their transfer should be subject to uncapped registration duties at the rate of 0.1% only if such transfer </span></div><div style="line-height:10pt;position:var(--position);top:526.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">is evidenced by a written agreement. Although the official guidelines published by the French tax authorities are </span></div><div style="line-height:10pt;position:var(--position);top:536.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">silent on this point (BOI-ENR-DMTOM-40-10-10-24/04/2024), ADSs should remain outside of the scope of the </span></div><div style="line-height:10pt;position:var(--position);top:546.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">aforementioned 0.1% registration duties. </span></div><div style="line-height:10pt;position:var(--position);top:574.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Real Estate Wealth Tax </span></div><div style="line-height:10pt;position:var(--position);top:590.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Since January&#160;1, 2018, the French wealth tax (</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:281.87pt;position:var(--position);text-decoration:none;white-space:pre">imp&#244;t de solidarit&#233; sur la fortune</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:414.26pt;position:var(--position);text-decoration:none;white-space:pre">) has been repealed and </span></div><div style="line-height:10pt;position:var(--position);top:600.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">replaced by the French real estate wealth tax (</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:255.6pt;position:var(--position);text-decoration:none;white-space:pre">imp&#244;t sur la fortune immobili&#232;re</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:386.04pt;position:var(--position);text-decoration:none;white-space:pre">). </span></div><div style="line-height:10pt;position:var(--position);top:616.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The scope of such new tax is narrowed to real estate assets (and certain assets deemed to be real estate assets) </span></div><div style="line-height:10pt;position:var(--position);top:626.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">or rights, held directly or indirectly through one or more legal entities and whose net taxable assets amount at least </span></div><div style="line-height:10pt;position:var(--position);top:636.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to &#8364;1,300,000. </span></div><div style="line-height:10pt;position:var(--position);top:652.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Broadly, subject to provisions of double tax treaties and to certain exceptions, individuals who are not </span></div><div style="line-height:10pt;position:var(--position);top:662.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">residents of France for tax purposes within the meaning of Article 4 B of the FTC, are subject to real estate wealth </span></div><div style="line-height:10pt;position:var(--position);top:672.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">tax (</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:90.03pt;position:var(--position);text-decoration:none;white-space:pre">imp&#244;t sur la fortune immobili&#232;re</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:220.47pt;position:var(--position);text-decoration:none;white-space:pre">) in France in respect of the portion of the value of their shares of our company </span></div><div style="line-height:10pt;position:var(--position);top:682.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">representing real estate assets (Article 965, 2&#176; of the FTC). Some exceptions are provided by the FTC. For instance, </span></div><div style="line-height:10pt;position:var(--position);top:692.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">any participations representing less than 10% of the share capital of an operating company and shares representing </span></div><div style="line-height:10pt;position:var(--position);top:702.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">real estate for the professional use of the company considered shall not fall within the scope of the French real estate </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">140</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">wealth tax (</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:119.15pt;position:var(--position);text-decoration:none;white-space:pre">imp&#244;t sur la fortune immobili&#232;re</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:249.59pt;position:var(--position);text-decoration:none;white-space:pre">). Under the Treaty (the provisions of which should be applicable to this </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">new real estate wealth tax (</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:180.98000000000002pt;position:var(--position);text-decoration:none;white-space:pre">imp&#244;t sur la fortune immobili&#232;re</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:311.41999999999996pt;position:var(--position);text-decoration:none;white-space:pre">) in France), the French real estate wealth tax (</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:497.81pt;position:var(--position);text-decoration:none;white-space:pre">imp&#244;t sur </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">la fortune immobili&#232;re</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:161.9pt;position:var(--position);text-decoration:none;white-space:pre">) will however generally not apply to securities held by an eligible U.S. Holder who is a U.S. </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">resident, as defined pursuant to the provisions of the Treaty, provided that such (i) U.S. Holder (a)&#160;does not own </span></div><div style="line-height:10pt;position:var(--position);top:112pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">directly or indirectly more than 25% of the issuer&#8217;s financial rights and (b)&#160;that the ADSs do not form part of the </span></div><div style="line-height:10pt;position:var(--position);top:122pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">business property of a permanent establishment or fixed base in France and (ii) that the issuer&#8217;s assets do not consist </span></div><div style="line-height:10pt;position:var(--position);top:132pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">in at least 50 percent of real property located in France, or that the issuer&#8217;s shares do not derive at least 50 percent of </span></div><div style="line-height:10pt;position:var(--position);top:142pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">their value, directly or indirectly, from real property located in France. </span></div><div style="line-height:10pt;position:var(--position);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">U.S. Holders are advised to consult their own tax advisor regarding the specific tax consequences which may </span></div><div style="line-height:10pt;position:var(--position);top:168pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">apply to their particular situation with respect to such French real estate wealth tax (</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:407.64pt;position:var(--position);text-decoration:none;white-space:pre">imp&#244;t sur la fortune </span></div><div style="line-height:10pt;position:var(--position);top:178pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">immobili&#232;re</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.27000000000001pt;position:var(--position);text-decoration:none;white-space:pre">). </span></div><div style="line-height:10pt;position:var(--position);top:200pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);white-space:pre">Tax on Patrimonial Holding </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:194.70999999999998pt;position:var(--position);text-decoration:none;white-space:pre">Companies</span></div><div style="line-height:10pt;position:var(--position);top:216pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">The French Finance Act for 2026 introduced a tax on non&#8209;business assets held by patrimonial holding </span></div><div style="line-height:10pt;position:var(--position);top:226pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">companies that (i) have their registered office in France and are subject to corporate income tax, or (ii) have their </span></div><div style="line-height:10pt;position:var(--position);top:236pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">registered office </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:139.67000000000002pt;position:var(--position);text-decoration:none;white-space:pre">outside</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:168.53pt;position:var(--position);white-space:pre"> France and are either subject to a tax equivalent to corporate income tax or are companies </span></div><div style="line-height:10pt;position:var(--position);top:246pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">limited by shares. The tax base is </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:207.39pt;position:var(--position);text-decoration:none;white-space:pre">the</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:219.59pt;position:var(--position);white-space:pre"> sum of the fair market values of certain expressly enumerated assets held by </span></div><div style="line-height:10pt;position:var(--position);top:256pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">the company as of the close of the fiscal year for which the tax is due.</span></div><div style="line-height:10pt;position:var(--position);top:272pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">U.S. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:116.78pt;position:var(--position);text-decoration:none;white-space:pre">Holders</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:148.42000000000002pt;position:var(--position);white-space:pre"> are advised to consult their own tax advisor regarding the specific tax consequences which may </span></div><div style="line-height:10pt;position:var(--position);top:282pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">apply to their situation with respect </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:215.71pt;position:var(--position);text-decoration:none;white-space:pre">to</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:223.48pt;position:var(--position);white-space:pre"> such tax on patrimonial holding companies</span></div><div style="line-height:10pt;position:var(--position);top:312.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Taxation of Dividends </span></div><div style="line-height:10pt;position:var(--position);top:330.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Dividends paid by a French corporation</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:255.52pt;position:var(--position);white-space:pre">, when their beneficial owners are not French tax </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:453.61pt;position:var(--position);text-decoration:none;white-space:pre">residents, are </span></div><div style="line-height:10pt;position:var(--position);top:340.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">generally subject to French withholding tax at a rate of currently (i) 25% for dividends </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:420.23pt;position:var(--position);white-space:pre">the beneficial owners of </span></div><div style="line-height:10pt;position:var(--position);top:350.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">which are</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:111.11pt;position:var(--position);text-decoration:none;white-space:pre"> legal persons which are not French tax residents, and (ii) 12.8% for dividends </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:426.37pt;position:var(--position);white-space:pre">the beneficial owners of </span></div><div style="line-height:10pt;position:var(--position);top:360.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">which are</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:111.11pt;position:var(--position);text-decoration:none;white-space:pre"> individuals who are not French tax residents. Dividends paid by a French corporation in a non-cooperative </span></div><div style="line-height:10pt;position:var(--position);top:370.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">State or territory, as defined in Article 238-0 A of the FTC, other than those states or territories mentioned in 2&#176; of 2 </span></div><div style="line-height:10pt;position:var(--position);top:380.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">bis of the same Article 238-0 A will generally be subject to French withholding tax at a rate of 75%. However, </span></div><div style="line-height:10pt;position:var(--position);top:390.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">eligible U.S. Holders entitled to Treaty benefits under the &#8220;Limitation on Benefits&#8221; provision contained in the Treaty </span></div><div style="line-height:10pt;position:var(--position);top:400.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">who are U.S. residents, as defined pursuant to the provisions of the Treaty, will not be subject to this 12.8%, 25% or </span></div><div style="line-height:10pt;position:var(--position);top:410.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">75% withholding tax rate, but may be subject to the withholding tax at a reduced rate (as described below). </span></div><div style="line-height:10pt;position:var(--position);top:426.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Under the Treaty, the rate of French withholding tax on dividends paid to an eligible U.S. Holder who is a </span></div><div style="line-height:10pt;position:var(--position);top:436.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">U.S. resident as defined pursuant to the provisions of the Treaty and the beneficial owner of these dividends, and </span></div><div style="line-height:10pt;position:var(--position);top:446.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">whose ownership of the ordinary shares (which may be in the form of ADSs) is not effectively connected with a </span></div><div style="line-height:10pt;position:var(--position);top:456.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">permanent establishment or fixed base that such U.S. Holder has in France, is generally reduced to 15%, or to 5% if </span></div><div style="line-height:10pt;position:var(--position);top:466.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">such U.S. Holder is a corporation and owns directly or indirectly at least 10% of the share capital of the issuer; such </span></div><div style="line-height:10pt;position:var(--position);top:476.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">U.S. Holder may claim a refund from the French tax authorities of the amount withheld in excess of the Treaty rates </span></div><div style="line-height:10pt;position:var(--position);top:486.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of 15% or 5%, if any. </span></div><div style="line-height:10pt;position:var(--position);top:502.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For U.S. Holders that are not individuals but are U.S. residents, as defined pursuant to the provisions of the </span></div><div style="line-height:10pt;position:var(--position);top:512.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Treaty, the requirements for eligibility for Treaty benefits, including the reduced 5% or 15% withholding tax rates </span></div><div style="line-height:10pt;position:var(--position);top:522.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">contained in the &#8220;Limitation on Benefits&#8221; provision of the Treaty, are complicated, and certain technical changes </span></div><div style="line-height:10pt;position:var(--position);top:532.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">were made to these requirements by the protocol of January&#160;13, 2009. U.S. Holders are advised to consult their own </span></div><div style="line-height:10pt;position:var(--position);top:542.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">tax advisers regarding their eligibility for Treaty benefits in light of their own particular circumstances. </span></div><div style="line-height:10pt;position:var(--position);top:558.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Dividends paid to an eligible U.S. Holder may immediately be subject to the reduced rates of 5% or 15% </span></div><div style="line-height:10pt;position:var(--position);top:568.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">provided that: </span></div><div style="line-height:10pt;position:var(--position);top:584.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">such holder establishes before the date of payment that it is a U.S. resident under the Treaty by </span></span></div><div style="line-height:10pt;position:var(--position);top:594.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">completing and providing the depositary with a treaty form (Form 5000) in accordance with French </span></div><div style="line-height:10pt;position:var(--position);top:604.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">guidelines (BOI-INT-DG-20-20-20-20-12/09/2012); or </span></div><div style="line-height:10pt;position:var(--position);top:620.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">the depositary or other financial institution managing the securities account in the U.S. of such U.S. </span></span></div><div style="line-height:10pt;position:var(--position);top:630.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">Holder provides the French paying agent with a document listing certain information about the U.S. </span></div><div style="line-height:10pt;position:var(--position);top:640.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">Holder and its ordinary shares or ADSs and a certificate (BOI-LETTRE-000138-28/07/2014) whereby </span></div><div style="line-height:10pt;position:var(--position);top:650.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">the financial institution managing the U.S. Holder&#8217;s securities account in the United States takes full </span></div><div style="line-height:10pt;position:var(--position);top:660.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">responsibility for the accuracy of the information provided in the document. </span></div><div style="line-height:10pt;position:var(--position);top:676.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Otherwise, dividends paid to a U.S. Holder, if such U.S. Holder is a legal person, will be subject to French </span></div><div style="line-height:10pt;position:var(--position);top:686.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">withholding tax at the rate of 25%, or 75% if paid in a non-cooperative State or territory (as defined in Article 238-0 </span></div><div style="line-height:10pt;position:var(--position);top:696.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">A of the FTC, but other than those states or territories mentioned in 2&#176; of 2 bis of the same Article 238-0 A), and </span></div><div style="line-height:10pt;position:var(--position);top:706.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">then reduced at a later date to 5% or 15%, provided that such holder duly completes and provides the French tax </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">141</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">authorities with the treaty forms Form 5000 and Form 5001 before December&#160;31 of the year following the year </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">during which the dividend is paid </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:208.55pt;position:var(--position);white-space:pre">(due to recent case law regarding the statute of limitation for filing a withholding </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">tax claim: U.S. Holders are advised to consult their own tax advisor in this respect)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:403.85pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Certain qualifying pension funds and certain other tax-exempt entities are subject to the same general filing </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">requirements as other U.S. Holders except that they may have to supply additional documentation evidencing their </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">entitlement to these benefits. </span></div><div style="line-height:10pt;position:var(--position);top:144pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Since the withholding tax rate applicable under French domestic law to U.S. Holders who are individuals does </span></div><div style="line-height:10pt;position:var(--position);top:154pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">not exceed the cap provided in the Treaty (i.e., 15%), the 12.8% rate shall apply, without any reduction provided </span></div><div style="line-height:10pt;position:var(--position);top:164pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">under the Treaty. </span></div><div style="line-height:10pt;position:var(--position);top:180pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Besides, please note that pursuant to Article 235 </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:292.1pt;position:var(--position);text-decoration:none;white-space:pre">quater</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:318.19pt;position:var(--position);text-decoration:none;white-space:pre"> of the FTC (introduced by the French finance bill </span></div><div style="line-height:10pt;position:var(--position);top:190pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">No.&#160;2019-1479 for 2020) and under certain conditions, a corporate U.S. Holder which is in a tax loss position for the </span></div><div style="line-height:10pt;position:var(--position);top:200pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">fiscal year during which the dividend is received may be entitled to a deferral regime, and obtain a withholding tax </span></div><div style="line-height:10pt;position:var(--position);top:210pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">refund. The tax deferral ends in respect of the first financial year during which this U.S. Holder is in a profit making </span></div><div style="line-height:10pt;position:var(--position);top:220pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">position, as well as in the cases set out in Article 235 </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:285.91999999999996pt;position:var(--position);text-decoration:none;white-space:pre">quater</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:312.01pt;position:var(--position);text-decoration:none;white-space:pre"> of the FTC. Finance Bill for 2022 extended the deadline </span></div><div style="line-height:10pt;position:var(--position);top:230pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to claim the refund (December 31 of the second year following the year of payment instead of three months after the </span></div><div style="line-height:10pt;position:var(--position);top:240pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">end of the fiscal year following the payment of the income) and clarify the order in which the deferred taxes become </span></div><div style="line-height:10pt;position:var(--position);top:250pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">due (the forfeiture of the deferral applies in priority to the oldest withholding taxes). Also, pursuant to newly </span></div><div style="line-height:10pt;position:var(--position);top:260pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">introduced Article 235 </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:164.95pt;position:var(--position);text-decoration:none;white-space:pre">quinquies</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:203.81pt;position:var(--position);text-decoration:none;white-space:pre"> of the FTC and under certain conditions, a corporate U.S. Holder may be entitled </span></div><div style="line-height:10pt;position:var(--position);top:270pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to a refund of a fraction of the withholding tax, up to the difference between the withholding tax paid (on a gross </span></div><div style="line-height:10pt;position:var(--position);top:280pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">basis) and the withholding tax based on the dividend net of the expenses incurred for the acquisition and </span></div><div style="line-height:10pt;position:var(--position);top:290pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">conservation directly related to the income, provided (i)&#160;that these expenses would have been tax deductible had the </span></div><div style="line-height:10pt;position:var(--position);top:300pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">U.S. Holder been established in France, and (ii)&#160;that the tax rules in the United States do not allow the U.S. Holder </span></div><div style="line-height:10pt;position:var(--position);top:310pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to offset the withholding tax. </span></div><div style="line-height:10pt;position:var(--position);top:338pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Tax on Sale or Other Disposition </span></div><div style="line-height:10pt;position:var(--position);top:354pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In general, under the Treaty, a U.S. Holder who is a U.S. resident for purposes of the Treaty will not be </span></div><div style="line-height:10pt;position:var(--position);top:364pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">subject to French tax on any capital gain from the redemption (other than redemption proceeds characterized as </span></div><div style="line-height:10pt;position:var(--position);top:374pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">dividends under French domestic tax law or administrative guidelines), sale or exchange of ADSs unless the ADSs </span></div><div style="line-height:10pt;position:var(--position);top:384pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">form part of the business property of a permanent establishment or fixed base that the U.S. Holder has in France. </span></div><div style="line-height:10pt;position:var(--position);top:400pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Special rules apply to U.S. Holders who are residents of more than one country. </span></div><div style="line-height:10pt;position:var(--position);top:428pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Material U.S. Federal Income Tax Considerations for U.S. Holders </span></div><div style="line-height:10pt;position:var(--position);top:444pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The following is a description of the material U.S. federal income tax consequences to the U.S. Holders </span></div><div style="line-height:10pt;position:var(--position);top:454pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">described below of acquiring, owning and disposing of the ADSs. It is not a comprehensive description of all tax </span></div><div style="line-height:10pt;position:var(--position);top:464pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">considerations that may be relevant to a particular person&#8217;s decision to acquire securities. This discussion applies </span></div><div style="line-height:10pt;position:var(--position);top:474pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">only to a U.S. Holder that holds ADSs as &#8220;capital assets&#8221; (generally, property held for investment) under the U.S. </span></div><div style="line-height:10pt;position:var(--position);top:484pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;). In addition, it does not describe all of the tax </span></div><div style="line-height:10pt;position:var(--position);top:494pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">considerations that may be relevant in light of a U.S. Holder&#8217;s particular circumstances, including U.S. federal estate </span></div><div style="line-height:10pt;position:var(--position);top:504pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and gift taxes, the Medicare contribution tax on net investment income, the alternative minimum tax provisions of </span></div><div style="line-height:10pt;position:var(--position);top:514pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the Code, the special tax accounting rules under Section&#160;451(b) of the Code, any state, local, or non-U.S. tax </span></div><div style="line-height:10pt;position:var(--position);top:524pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">considerations, and tax considerations applicable to U.S. Holders subject to special rules, including, without </span></div><div style="line-height:10pt;position:var(--position);top:534pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">limitation:</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:113.59pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="line-height:10pt;position:var(--position);top:550pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">certain financial institutions; </span></span></div><div style="line-height:10pt;position:var(--position);top:566pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">traders in securities who use a mark-to-market method of tax accounting; </span></span></div><div style="line-height:10pt;position:var(--position);top:582pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">dealers in securities or currencies; </span></span></div><div style="line-height:1pt;position:var(--position);top:596.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="line-height:10pt;position:var(--position);top:597.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">persons holding ADSs as part of a hedging transaction, &#8220;straddle,&#8221; wash sale, conversion transaction or </span></span></div><div style="line-height:10pt;position:var(--position);top:607.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">integrated transaction or persons entering into a constructive sale with respect to the ADSs; </span></div><div style="line-height:10pt;position:var(--position);top:623.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">regulated investment companies; </span></span></div><div style="line-height:10pt;position:var(--position);top:639.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">insurance companies; </span></span></div><div style="line-height:10pt;position:var(--position);top:655.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">real estate investment trusts, grantor trusts or other trusts; </span></span></div><div style="line-height:10pt;position:var(--position);top:671.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">persons whose &#8220;functional currency&#8221; for U.S. federal income tax purposes is not the U.S. dollar; </span></span></div><div style="line-height:10pt;position:var(--position);top:687.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">expatriates of the United States; </span></span></div><div style="line-height:10pt;position:var(--position);top:703.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">tax exempt entities, including &#8220;individual retirement accounts&#8221; and &#8220;Roth IRAs&#8221;; </span></span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">142</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">entities or arrangements classified as partnerships or other pass-through entities for U.S. federal </span></span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">income tax purposes (and investors therein); </span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">persons that received ADSs as compensation for the performance of services; </span></span></div><div style="line-height:10pt;position:var(--position);top:114pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">persons that own or are deemed to own ten percent or more of our shares (by vote or value); and </span></span></div><div style="line-height:10pt;position:var(--position);top:130pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">persons holding ADSs in connection with a trade or business, permanent establishment, or fixed base </span></span></div><div style="line-height:10pt;position:var(--position);top:140pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">outside the United States. </span></div><div style="line-height:10pt;position:var(--position);top:156pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">If an entity or arrangement that is classified as a partnership for U.S. federal income tax purposes holds the </span></div><div style="line-height:10pt;position:var(--position);top:166pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ADSs, the U.S. federal income tax treatment of a partner in that partnership will generally depend on the status of </span></div><div style="line-height:10pt;position:var(--position);top:176pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the partner and the activities of the partnership. Partnerships holding the ADSs and partners in such partnerships are </span></div><div style="line-height:10pt;position:var(--position);top:186pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">encouraged to consult their own tax advisers as to the particular U.S. federal income tax consequences of acquiring, </span></div><div style="line-height:10pt;position:var(--position);top:196pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">owning, and disposing of the ADSs. </span></div><div style="line-height:10pt;position:var(--position);top:212pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">This description is based on the Code, existing, proposed and temporary U.S. Treasury Regulations </span></div><div style="line-height:10pt;position:var(--position);top:222pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">promulgated thereunder and administrative and judicial interpretations thereof, in each case as in effect and available </span></div><div style="line-height:10pt;position:var(--position);top:232pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">on the date hereof. All of the foregoing is subject to change, which change could apply retroactively, and to differing </span></div><div style="line-height:10pt;position:var(--position);top:242pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">interpretations, all of which could affect the tax considerations described below. No rulings have been sought from </span></div><div style="line-height:10pt;position:var(--position);top:252pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the U.S. Internal Revenue Service (the &#8220;IRS&#8221;), regarding the matters discussed herein and there can be no assurance </span></div><div style="line-height:10pt;position:var(--position);top:262pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">that the IRS will not take a contrary position concerning the tax consequences of the acquisition, ownership and </span></div><div style="line-height:10pt;position:var(--position);top:272pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">disposition of the ADSs or that such a position would not be sustained. U.S. Holders should consult their own tax </span></div><div style="line-height:10pt;position:var(--position);top:282pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">advisers concerning the U.S. federal, state, local and non-U.S. tax consequences of acquiring, owning, and disposing </span></div><div style="line-height:10pt;position:var(--position);top:292pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of the ADSs in their particular circumstances. </span></div><div style="line-height:10pt;position:var(--position);top:308pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">As used for purposes of this section &#8220;&#8212;Material U.S. Federal Income Tax Considerations for U.S. Holders&#8221;, a </span></div><div style="line-height:10pt;position:var(--position);top:318pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8220;U.S. Holder&#8221; is a holder who, for U.S. federal income tax purposes, is a beneficial owner of the ADSs that is an </span></div><div style="line-height:10pt;position:var(--position);top:328pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">initial purchaser of the ADSs sold in our initial public offering of our ADSs in the United States and is: </span></div><div style="line-height:10pt;position:var(--position);top:344pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">an individual who is a citizen or resident of the United States; </span></span></div><div style="line-height:10pt;position:var(--position);top:360pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the </span></span></div><div style="line-height:10pt;position:var(--position);top:370pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">United States, any state therein or the District of Columbia; </span></div><div style="line-height:10pt;position:var(--position);top:386pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">an estate whose income is eligible for inclusion in gross income for U.S. federal income tax purposes, </span></span></div><div style="line-height:10pt;position:var(--position);top:396pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">regardless of its source; or </span></div><div style="line-height:10pt;position:var(--position);top:412pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:127.05000000000001pt;position:var(--position)">a trust, if (A)&#160;a U.S. court is able to exercise primary supervision over the trust&#8217;s administration and </span></span></div><div style="line-height:10pt;position:var(--position);top:422pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">one or more United States persons (as such term is defined under the Code) have authority to control </span></div><div style="line-height:10pt;position:var(--position);top:432pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">all substantial decisions of the trust, or (B)&#160;the trust has a valid election in place under applicable U.S. </span></div><div style="line-height:10pt;position:var(--position);top:442pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">Treasury regulations to treat the trust as a United States person (as such term is defined under the </span></div><div style="line-height:10pt;position:var(--position);top:452pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.05pt;position:var(--position);text-decoration:none;white-space:pre">Code). </span></div><div style="line-height:10pt;position:var(--position);top:468pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The discussion below assumes that the representations contained in the depositary agreement are true and that </span></div><div style="line-height:10pt;position:var(--position);top:478pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the obligations in the deposit agreement and any related agreement will be complied with in accordance with its </span></div><div style="line-height:10pt;position:var(--position);top:488pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">terms. For U.S. federal income tax purposes, it is generally expected that a U.S. Holder of ADSs will be treated as </span></div><div style="line-height:10pt;position:var(--position);top:498pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the beneficial owner of the underlying ordinary shares represented by the ADSs. The remainder of this discussion </span></div><div style="line-height:10pt;position:var(--position);top:508pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">assumes that a U.S. Holder of our ADSs will be treated in this manner. Accordingly, deposits or withdrawals of </span></div><div style="line-height:10pt;position:var(--position);top:518pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ADSs for ordinary shares will generally not be subject to U.S. federal income tax. </span></div><div style="line-height:10pt;position:var(--position);top:540pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">U.S. Holders are encouraged to consult their own tax advisers concerning the U.S. federal, state, local </span></div><div style="line-height:10pt;position:var(--position);top:550pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and foreign tax consequences of acquiring, owning and disposing of the ADSs in their particular </span></div><div style="line-height:10pt;position:var(--position);top:560pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">circumstances. </span></div><div style="line-height:10pt;position:var(--position);top:588pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Taxation of Distributions </span></div><div style="line-height:10pt;position:var(--position);top:604pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Subject to the passive foreign investment company (&#8220;PFIC&#8221;) rules described below, distributions paid on the </span></div><div style="line-height:10pt;position:var(--position);top:614pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ADSs, other than certain pro rata distributions of the ADSs, will generally be treated as dividends to the extent paid </span></div><div style="line-height:10pt;position:var(--position);top:624pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). We </span></div><div style="line-height:10pt;position:var(--position);top:634pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">do not maintain calculations of our earnings and profits under U.S. federal income tax principles, and so we expect </span></div><div style="line-height:10pt;position:var(--position);top:644pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">that distributions generally will be reported to U.S. Holders as dividends. Subject to applicable limitations, dividends </span></div><div style="line-height:10pt;position:var(--position);top:654pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">paid by a &#8220;qualified foreign corporation&#8221; are eligible for taxation at a preferential capital gains rate rather than the </span></div><div style="line-height:10pt;position:var(--position);top:664pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">marginal tax rates generally applicable to ordinary income provided that certain requirements are met. However, if </span></div><div style="line-height:10pt;position:var(--position);top:674pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">we are a PFIC (or treated as a PFIC with respect to the U.S. Holder) for the taxable year in which the dividend is </span></div><div style="line-height:10pt;position:var(--position);top:684pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">paid or the preceding taxable year (see discussion below under &#8220;Passive Foreign Investment Company Rules&#8221;), we </span></div><div style="line-height:10pt;position:var(--position);top:694pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">will not be treated as a qualified foreign corporation, and therefore the preferential capital gains tax rate described </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">143</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">above will not apply. Each U.S. Holder is advised to consult its tax advisors regarding the availability of the </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">preferential tax rate on dividends with regard to its particular circumstances. </span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">A non-U.S. corporation (other than a corporation classified as a PFIC for the taxable year in which the </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">dividend is paid or the preceding taxable year) generally will be considered to be a qualified foreign corporation if: </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(i)&#160;it is eligible for the benefits of a comprehensive tax treaty with the United States, which the Secretary of Treasury </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of the United States determines is satisfactory for purposes of this provision, and which includes an exchange of </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">information provision; or (ii)&#160;with respect to any dividend it pays on shares that are readily tradable on an </span></div><div style="line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">established securities market in the United States. We believe that we qualify as a resident of France for the purposes </span></div><div style="line-height:10pt;position:var(--position);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of, and are eligible for the benefits of, the income tax treaty between France and the United States, which the IRS </span></div><div style="line-height:10pt;position:var(--position);top:168pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">has determined is satisfactory for purposes of the qualified dividend rules, and that it includes an exchange of </span></div><div style="line-height:10pt;position:var(--position);top:178pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">information provision, although there can be no assurance in this regard. Further, our ADSs will generally be </span></div><div style="line-height:10pt;position:var(--position);top:188pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">considered to be readily tradable on an established securities marked in the United States, including the Nasdaq </span></div><div style="line-height:10pt;position:var(--position);top:198pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Global Market. Therefore, subject to the discussion below under &#8220;Passive Foreign Investment Company Rules&#8221;, if </span></div><div style="line-height:10pt;position:var(--position);top:208pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the income tax treaty between France and the United States is applicable, or if the ADSs are readily tradable on an </span></div><div style="line-height:10pt;position:var(--position);top:218pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">established securities market in the United States, dividends paid on the ADSs will generally be &#8220;qualified dividend </span></div><div style="line-height:10pt;position:var(--position);top:228pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">income&#8221; in the hands of individual U.S. Holders, provided that certain conditions are met, including conditions </span></div><div style="line-height:10pt;position:var(--position);top:238pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">relating to the holding period and the absence of certain risk reduction transactions. </span></div><div style="line-height:10pt;position:var(--position);top:254pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">A U.S. Holder must include the gross amount of a dividend without reduction for amounts withheld by us in </span></div><div style="line-height:10pt;position:var(--position);top:264pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">respect of French income taxes (see &#8220;Material United States Federal Income and French Tax Considerations&#8212;</span></div><div style="line-height:10pt;position:var(--position);top:274pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Certain French Considerations&#8221;), even though the U.S. Holder did not in fact receive the amount associated with the </span></div><div style="line-height:10pt;position:var(--position);top:284pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">withheld French tax.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:154.41pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:156.91pt;position:var(--position);text-decoration:none;white-space:pre">The amount of the dividend will be treated as foreign-source dividend income to U.S. Holders </span></div><div style="line-height:10pt;position:var(--position);top:294pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and will not be eligible for the dividends-received deduction generally available to U.S. corporations under the </span></div><div style="line-height:10pt;position:var(--position);top:304pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Code. Dividends generally will be included in a U.S. Holder&#8217;s income on the date of the U.S. Holder&#8217;s receipt (or </span></div><div style="line-height:10pt;position:var(--position);top:314pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">deemed receipt) of the dividend. The amount of any distribution of property other than cash (excluding certain pro </span></div><div style="line-height:10pt;position:var(--position);top:324pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">rata distributions of ordinary shares or ADSs or rights to acquire ordinary shares or ADSs) will be the fair market </span></div><div style="line-height:10pt;position:var(--position);top:334pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">value of such property on the date of the distribution. The amount of any dividend income paid in euros will be the </span></div><div style="line-height:10pt;position:var(--position);top:344pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">U.S. dollar amount calculated by reference to the exchange rate in effect on the date of actual or constructive receipt, </span></div><div style="line-height:10pt;position:var(--position);top:354pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regardless of whether the payment is in fact converted into U.S. dollars. If the dividend is converted into U.S. dollars </span></div><div style="line-height:10pt;position:var(--position);top:364pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">on the date of receipt, a U.S. Holder should not be required to recognize foreign currency gain or loss in respect of </span></div><div style="line-height:10pt;position:var(--position);top:374pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the dividend income. A U.S. Holder may have foreign currency gain or loss if the dividend is converted into U.S. </span></div><div style="line-height:10pt;position:var(--position);top:384pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">dollars after the date of receipt. </span></div><div style="line-height:10pt;position:var(--position);top:400pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Subject to applicable limitations, some of which vary depending upon the U.S. Holder&#8217;s particular </span></div><div style="line-height:10pt;position:var(--position);top:410pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">circumstances, French income taxes withheld from dividends on the ADSs at a rate not exceeding the rate provided </span></div><div style="line-height:10pt;position:var(--position);top:420pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">by the income tax treaty between France and the United States generally will be creditable against the U.S. Holder&#8217;s </span></div><div style="line-height:10pt;position:var(--position);top:430pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">U.S. federal income tax liability. U.S. Treasury regulations may in some circumstances prohibit a U.S. Holder from </span></div><div style="line-height:10pt;position:var(--position);top:440pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">claiming a foreign tax credit with respect to certain foreign taxes that are not creditable under applicable tax treaties. </span></div><div style="line-height:10pt;position:var(--position);top:450pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Dividend distributions with respect to the ADSs generally will be treated as "passive category" income from sources </span></div><div style="line-height:10pt;position:var(--position);top:460pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">outside the United States for purposes of determining a U.S. Holder&#8217;s U.S. foreign tax credit limitation. The rules </span></div><div style="line-height:10pt;position:var(--position);top:470pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">governing foreign tax credits are complex and U.S. Holders should consult their tax advisers regarding the </span></div><div style="line-height:10pt;position:var(--position);top:480pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">creditability of foreign taxes in their particular circumstances. In lieu of claiming a foreign tax credit, U.S. Holders </span></div><div style="line-height:10pt;position:var(--position);top:490pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">may, at their election, deduct foreign taxes, including any French income tax, in computing their taxable income, </span></div><div style="line-height:10pt;position:var(--position);top:500pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">subject to generally applicable limitations under U.S. law. An election to deduct foreign taxes instead of claiming </span></div><div style="line-height:10pt;position:var(--position);top:510pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">foreign tax credits applies to all foreign taxes paid or accrued in the taxable year. </span></div><div style="line-height:10pt;position:var(--position);top:538pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Sale or Other Taxable Disposition of the ADSs </span></div><div style="line-height:10pt;position:var(--position);top:554pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">A U.S. Holder generally will recognize gain or loss for U.S. federal income tax purposes upon the sale, </span></div><div style="line-height:10pt;position:var(--position);top:564pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">exchange or other taxable disposition of the ADSs in an amount equal to the difference between the U.S. dollar </span></div><div style="line-height:10pt;position:var(--position);top:574pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">value of the amount realized from such sale or exchange and the U.S. Holder&#8217;s tax basis for those ADSs. Subject to </span></div><div style="line-height:10pt;position:var(--position);top:584pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the PFIC rules described below, this gain or loss generally will be a capital gain or loss. The adjusted tax basis in an </span></div><div style="line-height:10pt;position:var(--position);top:594pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ADS generally will be equal to the cost of such ADS. Capital gain from the sale, exchange or other taxable </span></div><div style="line-height:10pt;position:var(--position);top:604pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">disposition of ADSs of a non-corporate U.S. Holder is generally eligible for a preferential rate of taxation applicable </span></div><div style="line-height:10pt;position:var(--position);top:614pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to capital gains, if the non-corporate U.S. Holder&#8217;s holding period determined at the time of such sale, exchange or </span></div><div style="line-height:10pt;position:var(--position);top:624pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">other taxable disposition for such ADSs exceeds one year (</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:308.15pt;position:var(--position);text-decoration:none;white-space:pre">i.e.,</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:322.85pt;position:var(--position);text-decoration:none;white-space:pre"> such gain is long-term taxable gain). The </span></div><div style="line-height:10pt;position:var(--position);top:634pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">deductibility of capital losses for U.S. federal income tax purposes is subject to limitations under the Code. Any </span></div><div style="line-height:10pt;position:var(--position);top:644pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">such gain or loss that a U.S. Holder recognizes generally will be treated as U.S. source income or loss for foreign tax </span></div><div style="line-height:10pt;position:var(--position);top:654pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">credit limitation purposes. The deductibility of capital losses is subject to limitations.</span></div><div style="line-height:10pt;position:var(--position);top:670pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For a cash basis taxpayer, units of foreign currency paid or received are translated into U.S. dollars at the spot </span></div><div style="line-height:10pt;position:var(--position);top:680pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">rate on the settlement date of the purchase or sale. In that case, no foreign currency exchange gain or loss will result </span></div><div style="line-height:10pt;position:var(--position);top:690pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">from currency fluctuations between the trade date and the settlement date of such a purchase or sale. An accrual </span></div><div style="line-height:10pt;position:var(--position);top:700pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">basis taxpayer, however, may elect the same treatment required of cash basis taxpayers with respect to purchases </span></div><div style="line-height:10pt;position:var(--position);top:710pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and sales of the ADSs that are traded on an established securities market, provided the election is applied </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">144</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">consistently from year to year. Such election may not be changed without the consent of the IRS. For an accrual </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">basis taxpayer who does not make such an election, units of foreign currency paid or received are translated into </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">U.S. dollars at the spot rate on the trade date of the purchase or sale. Such an accrual basis taxpayer may recognize </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">exchange gain or loss based on currency fluctuations between the trade date and the settlement date. Any foreign </span></div><div style="line-height:10pt;position:var(--position);top:112pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">currency gain or loss a U.S. Holder realizes will be U.S. source ordinary income or loss. </span></div><div style="line-height:10pt;position:var(--position);top:140pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Passive Foreign Investment Company Rules </span></div><div style="line-height:10pt;position:var(--position);top:156pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Under the Code, we will be a PFIC for any taxable year in which, after the application of certain &#8220;look-</span></div><div style="line-height:10pt;position:var(--position);top:166pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">through&#8221; rules with respect to subsidiaries, either (i) 75% or more of our gross income consists of &#8220;passive </span></div><div style="line-height:10pt;position:var(--position);top:176pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">income,&#8221; (&#8220;income test&#8221;) or (ii) 50% or more of the average quarterly value of our assets (generally determined on </span></div><div style="line-height:10pt;position:var(--position);top:186pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the basis of a weighted quarterly average) consist of assets that produce, or are held for the production of, &#8220;passive </span></div><div style="line-height:10pt;position:var(--position);top:196pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">income.&#8221; Passive income generally includes dividends, interest, and gains from the sale or exchange of investment </span></div><div style="line-height:10pt;position:var(--position);top:206pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">property and rents or royalties other than rents or royalties which are received from unrelated parties in connection </span></div><div style="line-height:10pt;position:var(--position);top:216pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">with the active conduct of a trade or business. Passive assets include, among others, cash and assets readily </span></div><div style="line-height:10pt;position:var(--position);top:226pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">convertible into cash, while our goodwill and other unbooked intangibles associated with active business activities </span></div><div style="line-height:10pt;position:var(--position);top:236pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">may generally be treated as non-passive assets. In addition, for purposes of the above calculations, a non-U.S. </span></div><div style="line-height:10pt;position:var(--position);top:246pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">corporation that owns, directly or indirectly, at least 25% by value of the equity interests of another corporation is </span></div><div style="line-height:10pt;position:var(--position);top:256pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">treated as if it held its proportionate share of the assets of the other corporation, and received directly its </span></div><div style="line-height:10pt;position:var(--position);top:266pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">proportionate share of the income of the other corporation. If a corporation is treated as a PFIC with respect to a U.S. </span></div><div style="line-height:10pt;position:var(--position);top:276pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Holder for any taxable year, the corporation will continue to be treated as a PFIC with respect to that U.S. Holder in </span></div><div style="line-height:10pt;position:var(--position);top:286pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">all succeeding taxable years, regardless of whether the corporation continues to meet the PFIC requirements in such </span></div><div style="line-height:10pt;position:var(--position);top:296pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">years, unless certain elections are made. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:312pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Based on our analysis of our financial statements, activities and relevant market and shareholder data, we do </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:322pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">not believe that we were a PFIC for the taxable year ended December 31, 2025. The determination of whether we </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:332pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">are a PFIC is a fact-intensive determination made on an annual basis and the applicable law is subject to varying </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:342pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">interpretation. Whether we are a PFIC for any taxable year will depend on the composition of our income and the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:352pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">composition, nature and value of our assets from time to time (including the value or our goodwill, which may be </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:362pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">determined by reference to the value of our ADSs, which could fluctuate considerably). We currently do not </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:372pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">generate product revenues and therefore we may be a PFIC for any taxable year in which we do not generate </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:382pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">sufficient amounts of non-passive income to offset our passive income. As a result, there can be no assurance that </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:392pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">we will not be treated as a PFIC for the current or any future taxable year and our U.S. counsel expresses no opinion </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:402pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">with respect to our PFIC status for any prior, current or future taxable year. Even if we determine that we are not a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:412pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">PFIC for a taxable year, there can be no assurance that the IRS, will agree with our conclusion and that the IRS </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:422pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">would not successfully challenge our position.</span></div><div style="line-height:10pt;position:var(--position);top:438pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">If we are a PFIC for any taxable year during which a U.S. Holder holds the ADSs, the U.S. Holder may be </span></div><div style="line-height:10pt;position:var(--position);top:448pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">subject to adverse tax consequences, regardless of whether we remain a PFIC. Generally, gain recognized upon a </span></div><div style="line-height:10pt;position:var(--position);top:458pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">disposition (including, under certain circumstances, a pledge) of the ADSs by the U.S. Holder would be allocated </span></div><div style="line-height:10pt;position:var(--position);top:468pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ratably over the U.S. Holder&#8217;s holding period for such ADSs. The amounts allocated to the taxable year of </span></div><div style="line-height:10pt;position:var(--position);top:478pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">disposition and to years before we became a PFIC (&#8220;pre-PFIC Years&#8221;) would be taxed as ordinary income. The </span></div><div style="line-height:10pt;position:var(--position);top:488pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">amount allocated to each other taxable years would be subject to tax at the highest rate in effect for that taxable year </span></div><div style="line-height:10pt;position:var(--position);top:498pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for individuals or corporations, as appropriate, and would be subject to an interest charge on the resulting tax </span></div><div style="line-height:10pt;position:var(--position);top:508pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">deemed deferred with respect to each such other taxable year. Further, to the extent that any distribution received by </span></div><div style="line-height:10pt;position:var(--position);top:518pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">a U.S. Holder on its ADSs exceeds 125% of the average of the annual distributions on such ADSs received by the </span></div><div style="line-height:10pt;position:var(--position);top:528pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">U.S. Holder during the (i)&#160;preceding three years or (ii)&#160;the U.S. Holder&#8217;s holding period, whichever is shorter, that </span></div><div style="line-height:10pt;position:var(--position);top:538pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">distribution would be subject to taxation in the same manner described immediately above with respect to gain on </span></div><div style="line-height:10pt;position:var(--position);top:548pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">disposition. </span></div><div style="line-height:10pt;position:var(--position);top:564pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Alternatively, if we are a PFIC and if the ADSs are &#8220;regularly traded&#8221; on a &#8220;qualified exchange,&#8221; a U.S. </span></div><div style="line-height:10pt;position:var(--position);top:574pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Holder could make a mark-to-market election that would result in tax treatment different from the general tax </span></div><div style="line-height:10pt;position:var(--position);top:584pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">treatment described in the preceding paragraph. The ADSs would be treated as &#8220;regularly traded&#8221; in any calendar </span></div><div style="line-height:10pt;position:var(--position);top:594pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">year in which more than a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:178.54000000000002pt;position:var(--position);text-decoration:none;white-space:pre">de minimis </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:224.61pt;position:var(--position);text-decoration:none;white-space:pre">quantity of the ADSs are traded on a qualified exchange, including the Nasdaq </span></div><div style="line-height:10pt;position:var(--position);top:604pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Global Market, on at least 15 days during each calendar quarter. The ADSs are listed on the Nasdaq Global Market, </span></div><div style="line-height:10pt;position:var(--position);top:614pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and we expect, although no assurance can be given, that they will be regularly traded on the Nasdaq Global Market. </span></div><div style="line-height:10pt;position:var(--position);top:624pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">U.S. Holders should consult with their own tax advisors regarding potential availability of the mark-to-market </span></div><div style="line-height:10pt;position:var(--position);top:634pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">election. </span></div><div style="line-height:10pt;position:var(--position);top:650pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">If a U.S. Holder makes the mark-to-market election, the U.S. Holder generally will recognize as ordinary </span></div><div style="line-height:10pt;position:var(--position);top:660pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">income any excess of the fair market value of the ADSs at the end of each taxable year over their adjusted tax basis, </span></div><div style="line-height:10pt;position:var(--position);top:670pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of the ADSs over their fair </span></div><div style="line-height:10pt;position:var(--position);top:680pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">market value at the end of the taxable year (but only to the extent of the net amount of income previously included </span></div><div style="line-height:10pt;position:var(--position);top:690pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">as a result of the mark-to-market election). If a U.S. Holder makes the election, the U.S. Holder&#8217;s tax basis in the </span></div><div style="line-height:10pt;position:var(--position);top:700pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ADSs will be adjusted to reflect these income or loss amounts. Any gain recognized on the sale or other disposition </span></div><div style="line-height:10pt;position:var(--position);top:710pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of ADSs in a year when we are a PFIC will be treated as ordinary income and any loss will be treated as an ordinary </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">145</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">loss (but only to the extent of the net amount of income previously included as a result of the mark-to-market </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">election). If a U.S. Holder makes a mark-to-market election in respect of a corporation classified as a PFIC and such </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">corporation ceases to be classified as a PFIC, the holder will not be required to take into account the gain or loss </span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">described above during any period that such corporation is not classified as a PFIC. </span></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">A timely election to treat a PFIC as a qualified electing fund under Section&#160;1295 of the Code (&#8220;QEF Election&#8221;) </span></div><div style="line-height:10pt;position:var(--position);top:128pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">would result in alternative treatment. If a U.S. Holder makes a QEF Election for the first tax year of such U.S. </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Holder&#8217;s holding period in which we are classified as a PFIC, then such U.S. Holder generally would not be subject </span></div><div style="line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to the PFIC rules&#160;described above.&#160;Instead, a U.S. Holder that makes a timely and effective QEF Election will </span></div><div style="line-height:10pt;position:var(--position);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">currently include in gross income such U.S. Holder&#8217;s (a) pro rata share of our ordinary earnings as ordinary income </span></div><div style="line-height:10pt;position:var(--position);top:168pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and (b)&#160;pro rata share of our net capital gain as long-term capital gain, regardless of whether we have made any </span></div><div style="line-height:10pt;position:var(--position);top:178pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">distributions of such earnings or gain. The U.S. Holder&#8217;s basis in its ADSs would be increased to reflect the amount </span></div><div style="line-height:10pt;position:var(--position);top:188pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of such income inclusions.&#160;Generally, for this purpose, &#8220;ordinary earnings&#8221; are the excess of our (a) &#8220;earnings and </span></div><div style="line-height:10pt;position:var(--position);top:198pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">profits&#8221; over (b)&#160;net capital gain, and &#8220;net capital gain&#8221; is the excess of our (a)&#160;net long-term capital gain over (b)&#160;net </span></div><div style="line-height:10pt;position:var(--position);top:208pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">short-term capital loss.</span></div><div style="line-height:10pt;position:var(--position);top:224pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">A U.S. Holder that has made such a timely and effective QEF Election generally may receive a distribution </span></div><div style="line-height:10pt;position:var(--position);top:234pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">tax-free as a return of capital to the extent that such distribution represents &#8220;earnings and profits&#8221; that were </span></div><div style="line-height:10pt;position:var(--position);top:244pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">previously included in income by the U.S. Holder because of such QEF Election and such distribution&#160;will reduce </span></div><div style="line-height:10pt;position:var(--position);top:254pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">such U.S. holder&#8217;s adjusted tax basis in our ADSs to reflect the amount allowed as a tax free distribution because of </span></div><div style="line-height:10pt;position:var(--position);top:264pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">such QEF Election.&#160;A U.S. Holder that makes a QEF Election would generally recognize capital gain or loss on the </span></div><div style="line-height:10pt;position:var(--position);top:274pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">sale, exchange or other taxable disposition of its ADSs</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:290.94pt;position:var(--position);text-decoration:none;white-space:pre">.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:293.44pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="line-height:10pt;position:var(--position);top:290pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">However, a U.S. Holder will only be able to make a QEF Election if we provide such U.S. Holder with certain </span></div><div style="line-height:10pt;position:var(--position);top:300pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">tax information annually, and we may determine not to provide such information. Furthermore, if the IRS </span></div><div style="line-height:10pt;position:var(--position);top:310pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">determines that we were a PFIC for a year with respect to which we had determined that we were not (or believed </span></div><div style="line-height:10pt;position:var(--position);top:320pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">we were not) a PFIC, it might be too late for a U.S. Holder to make a timely QEF Election, unless the U.S. Holder </span></div><div style="line-height:10pt;position:var(--position);top:330pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">qualifies under the applicable Treasury Regulations to make a retroactive (late) election. U.S. Holders should consult </span></div><div style="line-height:10pt;position:var(--position);top:340pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">their own tax advisors regarding the making of any such QEF Election. </span></div><div style="line-height:10pt;position:var(--position);top:356pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In addition, if we are a PFIC or, with respect to particular U.S. Holders, are treated as a PFIC for the taxable </span></div><div style="line-height:10pt;position:var(--position);top:366pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">year in which we paid a dividend or for the prior taxable year, the preferential rates discussed above with respect to </span></div><div style="line-height:10pt;position:var(--position);top:376pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">dividends paid to certain non-corporate U.S. Holders would not apply. </span></div><div style="line-height:10pt;position:var(--position);top:392pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">If a U.S. Holder owns ADSs during any year in which we are a PFIC, the holder generally must file an IRS </span></div><div style="line-height:10pt;position:var(--position);top:402pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Form 8621, or such other form as is required by the U.S. Treasury Department, generally with the holder&#8217;s federal </span></div><div style="line-height:10pt;position:var(--position);top:412pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">income tax return for that year. </span></div><div style="line-height:10pt;position:var(--position);top:428pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">U.S. Holders should consult their tax advisers regarding whether we are or may become a PFIC and the </span></div><div style="line-height:10pt;position:var(--position);top:438pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">potential application of the PFIC rules.</span></div><div style="line-height:10pt;position:var(--position);top:466pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Information Reporting and Backup Withholding </span></div><div style="line-height:10pt;position:var(--position);top:482pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Payments of distributions and sales proceeds that are made within the United States or through certain U.S.-</span></div><div style="line-height:10pt;position:var(--position);top:492pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">related financial intermediaries generally are subject to information reporting, and may be subject to backup </span></div><div style="line-height:10pt;position:var(--position);top:502pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">withholding, unless (i)&#160;the U.S. Holder is a corporation or other exempt recipient or (ii)&#160;in the case of backup </span></div><div style="line-height:10pt;position:var(--position);top:512pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">withholding, the U.S. Holder provides a correct taxpayer identification number and certifies that it is not subject to </span></div><div style="line-height:10pt;position:var(--position);top:522pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">backup withholding. </span></div><div style="line-height:10pt;position:var(--position);top:544pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Backup withholding is not an additional tax. The amount of any backup withholding from a payment to a U.S. </span></div><div style="line-height:10pt;position:var(--position);top:554pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Holder will be allowed as a credit against the holder&#8217;s U.S. federal income tax liability and may entitle it to a refund, </span></div><div style="line-height:10pt;position:var(--position);top:564pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">provided that the required information is timely furnished to the IRS. </span></div><div style="line-height:1pt;position:var(--position);top:587.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="line-height:10pt;position:var(--position);top:588.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Information With Respect to Foreign Financial Assets </span></div><div style="line-height:10pt;position:var(--position);top:604.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Certain U.S. Holders who are individuals may be required to report information relating to their ownership of </span></div><div style="line-height:10pt;position:var(--position);top:614.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">an interest in certain foreign financial assets, including stock of a non-U.S. person, generally on Form 8938, subject </span></div><div style="line-height:10pt;position:var(--position);top:624.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to exceptions (including an exception for stock held through a U.S. financial institution). In addition, certain U.S. </span></div><div style="line-height:10pt;position:var(--position);top:634.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Holders may be required to file a FinCEN Form 114 (Report of Foreign Bank and Financial Accounts) with the U.S. </span></div><div style="line-height:10pt;position:var(--position);top:644.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Treasury Department each year to report their interest in the ADSs. U.S. Holders should consult their tax advisers </span></div><div style="line-height:10pt;position:var(--position);top:654.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">regarding their reporting obligations with respect to the ADSs. </span></div><div style="line-height:10pt;position:var(--position);top:676.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The above description is not intended to constitute a complete analysis of all tax consequences relating </span></div><div style="line-height:10pt;position:var(--position);top:686.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to acquisition, ownership and disposition of the ADSs. You should consult your tax advisor concerning the tax </span></div><div style="line-height:10pt;position:var(--position);top:696.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">consequences of your particular situation. </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">146</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_148"></div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">F.<span id="i0efa1778dbe94d8483dd1e7e15394a0d"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Dividends and Paying Agent</span></div><div style="line-height:10pt;position:var(--position);top:96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">Not </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.99pt;position:var(--position);text-decoration:none;white-space:pre">applicable.</span></div><div style="position:absolute;top:118pt" id="i7a006daedb3d4216a4128b76247285d7_151"></div><div style="line-height:10pt;position:var(--position);top:118pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">G.<span id="i3569837c4eed48f1b1fd86b2fbc5cb46"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Statement by Experts</span></div><div style="line-height:10pt;position:var(--position);top:142pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">Not </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.99pt;position:var(--position);text-decoration:none;white-space:pre">applicable.</span></div><div style="position:absolute;top:164pt" id="i7a006daedb3d4216a4128b76247285d7_154"></div><div style="line-height:10pt;position:var(--position);top:164pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">H.<span id="i963f8a7d822b441595205ee73d6c4559"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Documents on Display</span></div><div style="line-height:10pt;position:var(--position);top:182pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We are subject to the reporting requirements of the Exchange Act that are applicable to foreign private issuers. </span></div><div style="line-height:10pt;position:var(--position);top:192pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Under the Exchange Act, we file annual reports on Form 20-F and other information with the SEC. We also furnish </span></div><div style="line-height:10pt;position:var(--position);top:202pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to the SEC under cover of Form 6-K material information required to be made public in France, filed with and made </span></div><div style="line-height:10pt;position:var(--position);top:212pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">public by any stock exchange on which we are listed or distributed by us to our shareholders. As a foreign private </span></div><div style="line-height:10pt;position:var(--position);top:222pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">issuer, we are exempt from, among other things, the rules under the Exchange Act prescribing the furnishing and </span></div><div style="line-height:10pt;position:var(--position);top:232pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">content of proxy statements, and our principal shareholders are exempt from the reporting provisions contained in </span></div><div style="line-height:10pt;position:var(--position);top:242pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Section 16 of the Exchange Act.</span></div><div style="line-height:10pt;position:var(--position);top:258pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We maintain a corporate website at www.abivax.com. We make available free of charge on our website our </span></div><div style="line-height:10pt;position:var(--position);top:268pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Annual Reports on Form 20-F and Current Reports on Form 6-K as soon as reasonably practicable after we file them </span></div><div style="line-height:10pt;position:var(--position);top:278pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">with the SEC. Information contained on, or that can be accessed through, our website does not constitute a part of </span></div><div style="line-height:10pt;position:var(--position);top:288pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">this Annual Report. We have included our website address in this Annual Report solely as an inactive textual </span></div><div style="line-height:10pt;position:var(--position);top:298pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reference.</span></div><div style="line-height:10pt;position:var(--position);top:314pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The Securities and Exchange Commission maintains a website (www.sec.gov) that contains reports and other </span></div><div style="line-height:10pt;position:var(--position);top:324pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">information regarding foreign private issuers, such as us, that file electronically with the SEC.</span></div><div style="line-height:10pt;position:var(--position);top:340pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">With respect to references made in this Annual Report to any contract or other document of our company, </span></div><div style="line-height:10pt;position:var(--position);top:350pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">such references are not necessarily complete and you should refer to the exhibits attached or incorporated by </span></div><div style="line-height:10pt;position:var(--position);top:360pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reference to this Annual Report for copies of the actual contract or document.</span></div><div style="position:absolute;top:382pt" id="i7a006daedb3d4216a4128b76247285d7_157"></div><div style="line-height:10pt;position:var(--position);top:382pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">I.<span id="i0d9bbbf1076c4fadbbed3a5969040c09"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Subsidiary Information</span></div><div style="line-height:10pt;position:var(--position);top:400pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">Not </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.99pt;position:var(--position);text-decoration:none;white-space:pre">required</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:147.28pt;position:var(--position);white-space:pre">.</span></div><div style="position:absolute;top:422pt" id="i7a006daedb3d4216a4128b76247285d7_160"></div><div style="line-height:10pt;position:var(--position);top:422pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">J.<span id="i62f35ccc44854706a424a6ccc55e6364"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Annual Report to Security Holders</span></div><div style="line-height:10pt;position:var(--position);top:445.2pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">To the extent we furnish an annual report to security holders, we will furnish any such report under the cover </span></span></div><div style="line-height:10pt;position:var(--position);top:457.2pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">of Form 6-K</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:122.53999999999999pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">147</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_163"></div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">Item 11.<span style="display:inline-block;height:6.77pt;width:1.02pt"></span></span><span style="left:108pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:36pt"></span></span><span style="left:144pt;position:var(--position)">Quantitative and Qualitative Disclosures About Market Risk</span><span id="if89bd01dc74b40a1a7e3a5e16ee9e3c4"></span></span></div><div style="line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">A description of quantitative and qualitative disclosures about market risk is disclosed in Note 27 to our </span></div><div style="line-height:10pt;position:var(--position);top:112pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">financial statements as of and for the year ended December 31, 2025 appearing elsewhere in this Annual Report on </span></div><div style="line-height:10pt;position:var(--position);top:122pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Form 20-F. </span></div><div style="line-height:10pt;position:var(--position);top:138pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The principal financial instruments we hold are cash and cash equivalents. The purpose of holding these </span></div><div style="line-height:10pt;position:var(--position);top:148pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">instruments is to finance our ongoing business activities. It is not our policy to invest in financial instruments for </span></div><div style="line-height:10pt;position:var(--position);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">speculative purposes. We do not use derivative financial instruments for hedging purposes. </span></div><div style="line-height:10pt;position:var(--position);top:174pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The principal risks to which we are exposed are foreign currency exchange risk and credit risk. </span></div><div style="line-height:10pt;position:var(--position);top:202pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Foreign Currency Exchange Risk </span></div><div style="line-height:10pt;position:var(--position);top:218pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We are exposed to a risk of exchange rate fluctuations on commercial transactions performed in currencies </span></div><div style="line-height:10pt;position:var(--position);top:228pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">different from our functional currency in which we record the transactions. We have not adopted any other recurring </span></div><div style="line-height:10pt;position:var(--position);top:238pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">mechanism of hedging to protect against currency fluctuations. From time to time, we may nevertheless subscribe </span></div><div style="line-height:10pt;position:var(--position);top:248pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for currency term accounts in order to cover a commitment in currency. We may consider in the future using a </span></div><div style="line-height:10pt;position:var(--position);top:258pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">suitable policy to hedge exchange risks in a more significant manner, if needed. </span></div><div style="line-height:1pt;position:var(--position);top:277pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">148</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The following tables set forth the operating expenses we incurred in foreign currencies in the years ended </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">December 31, 2023, 2024 and 2025. Some figures have been rounded. Accordingly, the totals in the tables may not </span></div><div style="line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">be the exact sums of component items.</span></div><div style="line-height:12pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="position:var(--position);top:126pt;width:612pt"><div style="font-size:0pt;left:77.38pt;position:var(--position);width:462pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:102pt"/><td style="padding:0;width:60pt"/><td style="padding:0;width:60pt"/><td style="padding:0;width:60pt"/><td style="padding:0;width:60pt"/><td style="padding:0;width:60pt"/><td style="padding:0;width:60pt"/></tr><tr style="height:38.25pt"><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:102pt;position:var(--position);width:60pt"><div><div style="line-height:10pt;position:var(--position);top:2.73pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Year ended </span></div><div style="line-height:10pt;position:var(--position);top:15.23pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">December </span></div><div style="line-height:10pt;position:var(--position);top:27.73pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">31, 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:222pt;position:var(--position);width:60pt"><div><div style="line-height:10pt;position:var(--position);top:2.73pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Year ended </span></div><div style="line-height:10pt;position:var(--position);top:15.23pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">December </span></div><div style="line-height:10pt;position:var(--position);top:27.73pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">31, 2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:342pt;position:var(--position);width:60pt"><div><div style="line-height:10pt;position:var(--position);top:2.73pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Year ended </span></div><div style="line-height:10pt;position:var(--position);top:15.23pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">December </span></div><div style="line-height:10pt;position:var(--position);top:27.73pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">31, 2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:26.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:38.25pt;width:102pt"><div><div style="line-height:10pt;position:var(--position);top:9.23pt;width:102pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Currency (thousands)</span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:96.19999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:98.50999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:98.8pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:98.94999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:99.03pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:99.07pt;position:var(--position);white-space:pre"> </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:102pt;position:var(--position);top:38.25pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:2.98pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:13.35pt;position:var(--position);text-decoration:none;white-space:pre">Foreign </span></div><div style="line-height:10pt;position:var(--position);top:15.48pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:10.86pt;position:var(--position);text-decoration:none;white-space:pre">currency</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:162pt;position:var(--position);top:38.25pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:9.23pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:17.23pt;position:var(--position);text-decoration:none;white-space:pre">Euros</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:222pt;position:var(--position);top:38.25pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:2.98pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:13.35pt;position:var(--position);text-decoration:none;white-space:pre">Foreign </span></div><div style="line-height:10pt;position:var(--position);top:15.48pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:10.86pt;position:var(--position);text-decoration:none;white-space:pre">currency</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:282pt;position:var(--position);top:38.25pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:9.23pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:17.23pt;position:var(--position);text-decoration:none;white-space:pre">Euros</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:342pt;position:var(--position);top:38.25pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:2.98pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:13.35pt;position:var(--position);text-decoration:none;white-space:pre">Foreign </span></div><div style="line-height:10pt;position:var(--position);top:15.48pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:10.86pt;position:var(--position);text-decoration:none;white-space:pre">currency</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:402pt;position:var(--position);top:38.25pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:9.23pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:17.23pt;position:var(--position);text-decoration:none;white-space:pre">Euros</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:64.5pt;width:102pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:102pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Australian dollar</span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:70.03999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:72.35pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:73.50999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:73.8pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:73.94999999999999pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:73.96pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:102pt;position:var(--position);top:64.5pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:162pt;position:var(--position);top:64.5pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:222pt;position:var(--position);top:64.5pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:48.29pt"></span></span><span style="left:50.92pt;position:var(--position)">6<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:282pt;position:var(--position);top:64.5pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:48.29pt"></span></span><span style="left:50.92pt;position:var(--position)">3<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:342pt;position:var(--position);top:64.5pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:402pt;position:var(--position);top:64.5pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:102pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:102pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Brazilian real</span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:56.68pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:58.99pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:59.07pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:59.11pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:59.120000000000005pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:102pt;position:var(--position);top:78.75pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:162pt;position:var(--position);top:78.75pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:222pt;position:var(--position);top:78.75pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:282pt;position:var(--position);top:78.75pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:342pt;position:var(--position);top:78.75pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:402pt;position:var(--position);top:78.75pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:93pt;width:102pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:102pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Canadian dollar</span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:66.15pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:68.46pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:69.03999999999999pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:69.06pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:102pt;position:var(--position);top:93pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:162pt;position:var(--position);top:93pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:222pt;position:var(--position);top:93pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">32<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:282pt;position:var(--position);top:93pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">22<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:342pt;position:var(--position);top:93pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:39.96pt"></span></span><span style="left:42.59pt;position:var(--position)">(24)</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:402pt;position:var(--position);top:93pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:39.96pt"></span></span><span style="left:42.59pt;position:var(--position)">(15)</span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:107.25pt;width:102pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:102pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Chinese yuan renminbi</span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:95.31pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:97.61999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:98.78pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:98.92999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:98.97pt;position:var(--position);white-space:pre"> </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:102pt;position:var(--position);top:107.25pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">61<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:162pt;position:var(--position);top:107.25pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:48.29pt"></span></span><span style="left:50.92pt;position:var(--position)">8<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:222pt;position:var(--position);top:107.25pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:282pt;position:var(--position);top:107.25pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:342pt;position:var(--position);top:107.25pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:38.29pt"></span></span><span style="left:40.92pt;position:var(--position)">101<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:402pt;position:var(--position);top:107.25pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">12<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:121.5pt;width:102pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:102pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Czech crown</span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:55.06pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:57.370000000000005pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:58.53pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:58.82pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:58.900000000000006pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:58.940000000000005pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:58.96pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:58.970000000000006pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:102pt;position:var(--position);top:121.5pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:162pt;position:var(--position);top:121.5pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:222pt;position:var(--position);top:121.5pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">54<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:282pt;position:var(--position);top:121.5pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:48.29pt"></span></span><span style="left:50.92pt;position:var(--position)">2<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:342pt;position:var(--position);top:121.5pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">50<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:402pt;position:var(--position);top:121.5pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:48.29pt"></span></span><span style="left:50.92pt;position:var(--position)">2<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:135.75pt;width:102pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:102pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Danish kroner</span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:59.53pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:61.84pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:63pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:63.580000000000005pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:63.870000000000005pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:63.910000000000004pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:102pt;position:var(--position);top:135.75pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:38.29pt"></span></span><span style="left:40.92pt;position:var(--position)">120<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:162pt;position:var(--position);top:135.75pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">16<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:222pt;position:var(--position);top:135.75pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:48.29pt"></span></span><span style="left:50.92pt;position:var(--position)">4<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:282pt;position:var(--position);top:135.75pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:48.29pt"></span></span><span style="left:50.92pt;position:var(--position)">1<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:342pt;position:var(--position);top:135.75pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:402pt;position:var(--position);top:135.75pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:150pt;width:102pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:102pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Hungarian forints</span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:73.39999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:73.97999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:74.27pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:74.28pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:102pt;position:var(--position);top:150pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:30.79pt"></span></span><span style="left:33.42pt;position:var(--position)">3,517<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:162pt;position:var(--position);top:150pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:48.29pt"></span></span><span style="left:50.92pt;position:var(--position)">9<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:222pt;position:var(--position);top:150pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:38.29pt"></span></span><span style="left:40.92pt;position:var(--position)">408<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:282pt;position:var(--position);top:150pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:48.29pt"></span></span><span style="left:50.92pt;position:var(--position)">1<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:342pt;position:var(--position);top:150pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:402pt;position:var(--position);top:150pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:164.25pt;width:102pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:102pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Israeli shekel</span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:55.6pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:57.910000000000004pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:58.49pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:58.78pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:58.93pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:59.010000000000005pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:59.02pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:102pt;position:var(--position);top:164.25pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:162pt;position:var(--position);top:164.25pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:222pt;position:var(--position);top:164.25pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">26<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:282pt;position:var(--position);top:164.25pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:48.29pt"></span></span><span style="left:50.92pt;position:var(--position)">7<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:342pt;position:var(--position);top:164.25pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:48.29pt"></span></span><span style="left:50.92pt;position:var(--position)">6<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:402pt;position:var(--position);top:164.25pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:48.29pt"></span></span><span style="left:50.92pt;position:var(--position)">2<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:178.5pt;width:102pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:102pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Japanese yen</span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:55.06pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:57.370000000000005pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:58.53pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:58.82pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:58.900000000000006pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:58.940000000000005pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:58.96pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:58.970000000000006pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:102pt;position:var(--position);top:178.5pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:162pt;position:var(--position);top:178.5pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:222pt;position:var(--position);top:178.5pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:38.29pt"></span></span><span style="left:40.92pt;position:var(--position)">596<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:282pt;position:var(--position);top:178.5pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:48.29pt"></span></span><span style="left:50.92pt;position:var(--position)">3<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:342pt;position:var(--position);top:178.5pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:25.79pt"></span></span><span style="left:28.419999999999998pt;position:var(--position)">12,039<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:402pt;position:var(--position);top:178.5pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">65<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:192.75pt;width:102pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:102pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Pound sterling</span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:60.650000000000006pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:62.96pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:63.54pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:63.830000000000005pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:63.980000000000004pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:64.02pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:102pt;position:var(--position);top:192.75pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:38.29pt"></span></span><span style="left:40.92pt;position:var(--position)">359<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:162pt;position:var(--position);top:192.75pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:38.29pt"></span></span><span style="left:40.92pt;position:var(--position)">410<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:222pt;position:var(--position);top:192.75pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:30.79pt"></span></span><span style="left:33.42pt;position:var(--position)">1,016<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:282pt;position:var(--position);top:192.75pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:30.79pt"></span></span><span style="left:33.42pt;position:var(--position)">1,214<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:342pt;position:var(--position);top:192.75pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:30.79pt"></span></span><span style="left:33.42pt;position:var(--position)">2,286<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:402pt;position:var(--position);top:192.75pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:30.79pt"></span></span><span style="left:33.42pt;position:var(--position)">2,620<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:207pt;width:102pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:102pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Swedish krona</span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:61.760000000000005pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:64.07pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:64.11pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:64.12pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:102pt;position:var(--position);top:207pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:38.29pt"></span></span><span style="left:40.92pt;position:var(--position)">350<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:162pt;position:var(--position);top:207pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">30<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:222pt;position:var(--position);top:207pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:38.29pt"></span></span><span style="left:40.92pt;position:var(--position)">183<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:282pt;position:var(--position);top:207pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">16<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:342pt;position:var(--position);top:207pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:38.29pt"></span></span><span style="left:40.92pt;position:var(--position)">358<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:402pt;position:var(--position);top:207pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">33<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:221.25pt;width:102pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:102pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Swiss franc</span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:48.980000000000004pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:49.27pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:49.31pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:49.330000000000005pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:49.34pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:102pt;position:var(--position);top:221.25pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">49<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:162pt;position:var(--position);top:221.25pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:43.29pt"></span></span><span style="left:45.92pt;position:var(--position)">50<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:222pt;position:var(--position);top:221.25pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:38.29pt"></span></span><span style="left:40.92pt;position:var(--position)">234<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:282pt;position:var(--position);top:221.25pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:38.29pt"></span></span><span style="left:40.92pt;position:var(--position)">243<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:342pt;position:var(--position);top:221.25pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:38.29pt"></span></span><span style="left:40.92pt;position:var(--position)">557<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:402pt;position:var(--position);top:221.25pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:38.29pt"></span></span><span style="left:40.92pt;position:var(--position)">598<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:235.5pt;width:102pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:102pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">United States dollar</span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:81.97pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:83.13pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:83.71pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:84pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:84.14999999999999pt;position:var(--position);text-decoration:none;white-space:pre"> . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:102pt;position:var(--position);top:235.5pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:25.79pt"></span></span><span style="left:28.419999999999998pt;position:var(--position)">10,861<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:162pt;position:var(--position);top:235.5pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:25.79pt"></span></span><span style="left:28.419999999999998pt;position:var(--position)">10,112<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:222pt;position:var(--position);top:235.5pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:25.79pt"></span></span><span style="left:28.419999999999998pt;position:var(--position)">12,031<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:282pt;position:var(--position);top:235.5pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:25.79pt"></span></span><span style="left:28.419999999999998pt;position:var(--position)">10,547<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:342pt;position:var(--position);top:235.5pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:25.79pt"></span></span><span style="left:28.419999999999998pt;position:var(--position)">20,730<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:402pt;position:var(--position);top:235.5pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.15pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:25.79pt"></span></span><span style="left:28.419999999999998pt;position:var(--position)">18,356<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:249.75pt;width:102pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:102pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total</span><span style="font-family:'Times New Roman', serif;font-size:9.24pt;font-style:normal;font-weight:normal;left:25.39pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:27.7pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:28.86pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:28.939999999999998pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:28.98pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:29pt;position:var(--position);text-decoration:none;white-space:pre"> . . . . . . . . . . . . . .</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:102pt;position:var(--position);top:249.75pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:25.79pt"></span></span><span style="left:28.419999999999998pt;position:var(--position)">15,317<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:162pt;position:var(--position);top:249.75pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:25.79pt"></span></span><span style="left:28.419999999999998pt;position:var(--position)">10,636<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:222pt;position:var(--position);top:249.75pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:25.79pt"></span></span><span style="left:28.419999999999998pt;position:var(--position)">14,591<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:282pt;position:var(--position);top:249.75pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:25.79pt"></span></span><span style="left:28.419999999999998pt;position:var(--position)">12,060<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:342pt;position:var(--position);top:249.75pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:25.79pt"></span></span><span style="left:28.419999999999998pt;position:var(--position)">36,103<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:402pt;position:var(--position);top:249.75pt;width:60pt"><div><div style="line-height:10pt;position:var(--position);top:3.23pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:25.79pt"></span></span><span style="left:28.419999999999998pt;position:var(--position)">21,674<span style="display:inline-block;height:6.77pt;width:3.33pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:413pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);text-decoration:none;white-space:pre">, the total amount of operating expenses we incurred in foreign </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:423pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">currencies wa</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.19pt;position:var(--position);white-space:pre">s </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:133.57999999999998pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;21.7 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:187.43pt;position:var(--position);text-decoration:none;white-space:pre">, or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:203.26pt;position:var(--position);text-decoration:none;white-space:pre">9%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:216.59pt;position:var(--position);text-decoration:none;white-space:pre"> of our total operating expenses of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:355.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;250.6</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:383.12pt;position:var(--position);text-decoration:none;white-space:pre">&#160;million in that year. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:439pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);text-decoration:none;white-space:pre">, the total amount of operating expenses we incurred in foreign </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:449pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">currencies was </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:133.57999999999998pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.1 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:187.43pt;position:var(--position);text-decoration:none;white-space:pre">, or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:203.26pt;position:var(--position);text-decoration:none;white-space:pre">7%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:216.59pt;position:var(--position);text-decoration:none;white-space:pre"> of our total operating expenses of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:355.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;185.4</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:383.12pt;position:var(--position);text-decoration:none;white-space:pre">&#160;million in that year. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:465pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.59pt;position:var(--position);text-decoration:none;white-space:pre">year ended December 31, 2023</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.18pt;position:var(--position);text-decoration:none;white-space:pre">, the total amount of operating expenses we incurred in foreign </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:475pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">currencies was </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:133.57999999999998pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;10.6 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:187.43pt;position:var(--position);text-decoration:none;white-space:pre">, or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:203.26pt;position:var(--position);text-decoration:none;white-space:pre">8%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:216.59pt;position:var(--position);text-decoration:none;white-space:pre"> of our total operating expenses of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:355.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;132.0</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:383.12pt;position:var(--position);text-decoration:none;white-space:pre">&#160;million in that year. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:491pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For the years ended </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:177.53pt;position:var(--position);text-decoration:none;white-space:pre">December&#160;31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:256.07pt;position:var(--position);white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:261.07pt;position:var(--position);text-decoration:none;white-space:pre">December&#160;31, 2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:339.61pt;position:var(--position);white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:359.04pt;position:var(--position);text-decoration:none;white-space:pre">December&#160;31, 2023</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:437.58pt;position:var(--position);white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:442.58pt;position:var(--position);text-decoration:none;white-space:pre">expenses in U.S. dollars </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:501pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">totaled </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:101.67pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;18.4 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.51999999999998pt;position:var(--position);white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:160.51999999999998pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;10.5 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:214.37pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:216.87pt;position:var(--position);text-decoration:none;white-space:pre">and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:233.8pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;10.1 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:287.65pt;position:var(--position);text-decoration:none;white-space:pre"> respectively, based on the average annual exchange rate in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:511pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">effect as of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:118.87pt;position:var(--position);text-decoration:none;white-space:pre">December&#160;31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:197.41pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:202.41pt;position:var(--position);text-decoration:none;white-space:pre">December&#160;31, 2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:280.95pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:300.38pt;position:var(--position);text-decoration:none;white-space:pre">December&#160;31, 2023</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:378.92pt;position:var(--position);text-decoration:none;white-space:pre">. As a result, an adverse 10% change in </span></div><div style="line-height:10pt;position:var(--position);top:521pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the exchange rate for the U.S. dollar against the euro would have resulted in a foreign exchange rate loss of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:531pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">approximately </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:132.2pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;2.0 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:181.05pt;position:var(--position);white-space:pre"> for 2025, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:222.71pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0,3 million for 2024, &#8364;0.4 million for 2023.</span></div><div style="line-height:10pt;position:var(--position);top:559pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Credit Risk </span></div><div style="line-height:10pt;position:var(--position);top:575pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The credit risk related to our cash and cash equivalents is not significant in light of the quality of our co-</span></div><div style="line-height:10pt;position:var(--position);top:585pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">contracting financial institutions. As of December&#160;31, 2025, substantially all our cash and cash equivalents were </span></div><div style="line-height:10pt;position:var(--position);top:595pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">maintained with two financial institutions in France and in the United States. While our deposit accounts are insured </span></div><div style="line-height:10pt;position:var(--position);top:605pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">up to the legal limit, substantially all of our bank deposit balances exceed this insured limit. </span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:440.43pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">As of December </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:508.41pt;position:var(--position);white-space:pre">31, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:615pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">2025, we maintained </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.01999999999998pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;92.5&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:211.87pt;position:var(--position);white-space:pre"> in bank deposit accounts that are in excess of the legally insured limit in </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:505.12pt;position:var(--position);text-decoration:none;white-space:pre">five</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:520.65pt;position:var(--position);white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:625pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">legally insured financial institutions, in addition to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:276.2pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;437.0&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:335.05pt;position:var(--position);white-space:pre"> invested in mutual funds and structured notes. We </span></div><div style="line-height:10pt;position:var(--position);top:635pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">have not experienced any losses in such accounts and we do not believe we are exposed to any significant credit risk </span></div><div style="line-height:10pt;position:var(--position);top:645pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">related to these instruments.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:184.07pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="line-height:10pt;position:var(--position);top:661pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The credit risk related to our other receivables and related account is minimal. In particular, the credit risk </span></div><div style="line-height:10pt;position:var(--position);top:671pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">related to advances made to CROs is deemed insignificant due to their credit ratings. </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">149</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_166"></div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">Item 12.<span style="display:inline-block;height:6.77pt;width:1.02pt"></span></span><span style="left:108pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:36pt"></span></span><span style="left:144pt;position:var(--position)">Description of Securities Other than Equity Securities</span><span id="iaf9377f05838460298f4958d0f3b253c"></span></span></div><div style="position:absolute;top:96pt" id="i7a006daedb3d4216a4128b76247285d7_169"></div><div style="line-height:10pt;position:var(--position);top:96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">A.<span id="i8cade87ad8554addb647cc6528c6de4e"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Debt Securities</span></div><div style="line-height:10pt;position:var(--position);top:120pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">Not </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.99pt;position:var(--position);text-decoration:none;white-space:pre">applicable.</span></div><div style="position:absolute;top:142pt" id="i7a006daedb3d4216a4128b76247285d7_172"></div><div style="line-height:10pt;position:var(--position);top:142pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">B.<span id="i512159bf3a1d473b9fac6c5e3bad765a"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Warrants and Rights</span></div><div style="line-height:10pt;position:var(--position);top:166pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">Not </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.99pt;position:var(--position);text-decoration:none;white-space:pre">applicable.</span></div><div style="position:absolute;top:188pt" id="i7a006daedb3d4216a4128b76247285d7_175"></div><div style="line-height:10pt;position:var(--position);top:188pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">C.<span id="id8a2da598c4941ef96da9ce43befad8d"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Other Securities</span></div><div style="line-height:10pt;position:var(--position);top:212pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">Not </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.99pt;position:var(--position);text-decoration:none;white-space:pre">applicable.</span></div><div style="position:absolute;top:234pt" id="i7a006daedb3d4216a4128b76247285d7_178"></div><div style="line-height:10pt;position:var(--position);top:234pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90pt;position:var(--position);text-decoration:none;white-space:pre">D.<span id="ie6665c3165b74abfa851700744ed2c2c"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">American Depositary Shares</span></div><div style="line-height:10pt;position:var(--position);top:252pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Citibank, as depositary, registers and delivers our ADSs. Each ADS represents one ordinary share deposited </span></div><div style="line-height:10pt;position:var(--position);top:262pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">with Citibank Europe plc, located at 1 North Wall Quay, Dublin 1 Ireland, or any successor, as custodian for the </span></div><div style="line-height:10pt;position:var(--position);top:272pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">depositary. Each ADS will also represent any other securities, cash or other property that may be held by the </span></div><div style="line-height:10pt;position:var(--position);top:282pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">depositary. The depositary&#8217;s corporate trust offices at which the ADSs will be administered are located at 388 </span></div><div style="line-height:10pt;position:var(--position);top:292pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Greenwich Street, New York, New York 10013.</span></div><div style="line-height:10pt;position:var(--position);top:308pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">A deposit agreement among us, the depositary and the ADS holders sets out the ADS holder rights as well as </span></div><div style="line-height:10pt;position:var(--position);top:318pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the rights and obligations of the depositary. New York law governs the deposit agreement and the ADSs. A copy of </span></div><div style="line-height:10pt;position:var(--position);top:328pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the deposit agreement is incorporated by reference as an exhibit to this Annual Report on Form 20-F. </span></div><div style="line-height:10pt;position:var(--position);top:350pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);white-space:pre">Fees and Charges </span></div><div style="line-height:10pt;position:var(--position);top:366pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">As an ADS holder, you </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:192.57pt;position:var(--position);text-decoration:none;white-space:pre">will</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:208.1pt;position:var(--position);white-space:pre"> be required to pay the following fees under the terms of the deposit agreement: </span></div><div style="position:var(--position);top:387.2pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:469.5pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:241.5pt"/><td style="padding:0;width:228pt"/></tr><tr style="height:14.25pt"><td style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:241.5pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Service</span></div></div></div></td><td style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);width:228pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:228pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:104.57pt;position:var(--position);text-decoration:none;white-space:pre">Fees</span></div></div></div></td></tr><tr style="height:59.25pt"><td style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:14.25pt;width:241.5pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Issuance of ADSs (e.g., an issuance of ADS upon a </span></div><div style="line-height:10pt;position:var(--position);top:13.83pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">deposit of ordinary shares, upon a change in the ADS(s)-</span></div><div style="line-height:10pt;position:var(--position);top:25.03pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">to-ordinary share ratio, or for any other reason), excluding </span></div><div style="line-height:10pt;position:var(--position);top:36.23pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">ADS issuances as a result of distributions of ordinary </span></div><div style="line-height:10pt;position:var(--position);top:47.43pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">shares)</span></div></div></div></td><td style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:14.25pt;width:228pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:228pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Up to U.S. 5&#162; per ADS issued</span></div></div></div></td></tr><tr style="height:36pt"><td style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:73.5pt;width:241.5pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cancellation of ADSs (e.g., a cancellation of ADSs for </span></div><div style="line-height:10pt;position:var(--position);top:13.83pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">delivery of deposited property, upon a change in the </span></div><div style="line-height:10pt;position:var(--position);top:25.03pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">ADS(s)-to-ordinary share ratio, or for any other reason)</span></div></div></div></td><td style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:73.5pt;width:228pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:228pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Up to U.S. 5&#162; per ADS cancelled</span></div></div></div></td></tr><tr style="height:24.75pt"><td style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:109.5pt;width:241.5pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Distribution of cash dividends or other cash distributions </span></div><div style="line-height:10pt;position:var(--position);top:13.83pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(e.g., upon a sale of rights and other entitlements)</span></div></div></div></td><td style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:109.5pt;width:228pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:228pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Up to U.S. 5&#162; per ADS held</span></div></div></div></td></tr><tr style="height:36pt"><td style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:134.25pt;width:241.5pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Distribution of ADSs pursuant to (i) share dividends or </span></div><div style="line-height:10pt;position:var(--position);top:13.83pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">other free share distributions, or (ii) exercise of rights to </span></div><div style="line-height:10pt;position:var(--position);top:25.03pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">purchase additional ADSs</span></div></div></div></td><td style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:134.25pt;width:228pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:228pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Up to U.S. 5&#162; per ADS held</span></div></div></div></td></tr><tr style="height:24.75pt"><td style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:170.25pt;width:241.5pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Distribution of securities other than ADSs or rights to </span></div><div style="line-height:10pt;position:var(--position);top:13.83pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">purchase additional ADSs (e.g., upon a spin-off)</span></div></div></div></td><td style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:170.25pt;width:228pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:228pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Up to U.S. 5&#162; per ADS held</span></div></div></div></td></tr><tr style="height:24.75pt"><td style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:195pt;width:241.5pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">ADS Services</span></div></div></div></td><td style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:195pt;width:228pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:228pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Up to U.S. 5&#162; per ADS held on the applicable record </span></div><div style="line-height:10pt;position:var(--position);top:13.83pt;width:228pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">date(s) established by the depositary bank</span></div></div></div></td></tr><tr style="height:47.25pt"><td style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:219.75pt;width:241.5pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:241.5pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Registration of ADS transfers (e.g., upon a registration of </span></div><div style="line-height:10pt;position:var(--position);top:13.83pt;width:241.5pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">the transfer of registered ownership of ADSs, upon a </span></div><div style="line-height:10pt;position:var(--position);top:25.03pt;width:241.5pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">transfer of ADSs into DTC and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:130.31pt;position:var(--position);white-space:pre">vice versa</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:170.51pt;position:var(--position);white-space:pre">, or for any other </span></div><div style="line-height:10pt;position:var(--position);top:36.23pt;width:241.5pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">reason)</span></div></div></div></td><td style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:219.75pt;width:228pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:228pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Up to U.S. 5&#162; per ADS (or fraction thereof) transferred</span></div></div></div></td></tr><tr style="height:59.25pt"><td style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:267pt;width:241.5pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:241.5pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Conversion of ADSs of one series for ADSs of another </span></div><div style="line-height:10pt;position:var(--position);top:13.83pt;width:241.5pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">series (e.g., upon conversion of Partial Entitlement ADSs </span></div><div style="line-height:10pt;position:var(--position);top:25.03pt;width:241.5pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">for Full Entitlement ADSs, or upon conversion of </span></div><div style="line-height:10pt;position:var(--position);top:36.23pt;width:241.5pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Restricted ADSs (each as defined in the Deposit </span></div><div style="line-height:10pt;position:var(--position);top:47.43pt;width:241.5pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Agreement) into freely transferable ADSs, and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:192.13pt;position:var(--position);white-space:pre">vice versa</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:232.32999999999998pt;position:var(--position);white-space:pre">).</span></div></div></div></td><td style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:267pt;width:228pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:228pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Up to U.S. 5&#162; per ADS (or fraction thereof) converted</span></div></div></div></td></tr></tbody></table></div></div></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">150</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">As </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:110.11pt;position:var(--position);text-decoration:none;white-space:pre">an</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:119.53999999999999pt;position:var(--position);white-space:pre"> ADS holder, you will also be responsible to pay certain charges such as: </span></div><div style="line-height:10pt;position:var(--position);top:94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">taxes (including applicable interest and penalties) and other governmental charges; </span></div><div style="line-height:10pt;position:var(--position);top:105.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">the registration fees as may from time to time be in effect for the registration of ordinary shares on the share </span></div><div style="line-height:10pt;position:var(--position);top:117pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">register and applicable to transfers of ordinary shares to or from the name of the custodian, the depositary </span></div><div style="line-height:10pt;position:var(--position);top:128.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">bank or any nominees upon the making of deposits and withdrawals, respectively; </span></div><div style="line-height:10pt;position:var(--position);top:140pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">certain cable, telex and facsimile transmission and delivery expenses; </span></div><div style="line-height:10pt;position:var(--position);top:151.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">the fees, expenses, spreads, taxes and other charges of the depositary bank and/or service providers (which </span></div><div style="line-height:10pt;position:var(--position);top:163pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">may be a division, branch or affiliate of the depositary bank) in the conversion of foreign currency; </span></div><div style="line-height:10pt;position:var(--position);top:174.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">the reasonable and customary out-of-pocket expenses incurred by the depositary bank in connection with </span></div><div style="line-height:10pt;position:var(--position);top:186pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">compliance with exchange control regulations and other regulatory requirements applicable to ordinary </span></div><div style="line-height:10pt;position:var(--position);top:197.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">shares, ADSs and American Depositary Receipts ("ADRs"); and </span></div><div style="line-height:10pt;position:var(--position);top:209pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">the fees, charges, costs and expenses incurred by the depositary bank, the custodian, or any nominee in </span></div><div style="line-height:10pt;position:var(--position);top:220.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">connection with the ADR program. </span></div><div style="line-height:10pt;position:var(--position);top:238pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">ADS fees and charges for (i) the issuance of ADSs, and (ii) the cancellation of ADSs are charged to the person </span></div><div style="line-height:10pt;position:var(--position);top:248pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">for whom </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.65pt;position:var(--position);text-decoration:none;white-space:pre">the</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:125.85pt;position:var(--position);white-space:pre"> ADSs are issued (in the case of ADS issuances) and to the person for whom ADSs are cancelled (in </span></div><div style="line-height:10pt;position:var(--position);top:258pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">the case of ADS cancellations). In the case of ADSs issued by the depositary bank into DTC, the ADS issuance and </span></div><div style="line-height:10pt;position:var(--position);top:268pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">cancellation fees and charges may be </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:222.88pt;position:var(--position);text-decoration:none;white-space:pre">deducted</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:258.94pt;position:var(--position);white-space:pre"> from distributions made through DTC, and may be charged to the </span></div><div style="line-height:10pt;position:var(--position);top:278pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">DTC participant(s) receiving the ADSs being issued or the DTC participant(s) holding the ADSs being cancelled, as </span></div><div style="line-height:10pt;position:var(--position);top:288pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">the case may be, on behalf of the beneficial owner(s) and will be charged by the DTC participant(s) to the account of </span></div><div style="line-height:10pt;position:var(--position);top:298pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">the applicable beneficial owner(s) in accordance with the procedures and practices of the DTC participants as in </span></div><div style="line-height:10pt;position:var(--position);top:308pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">effect at the time. ADS fees and charges in respect of distributions and the ADS service fee are charged to the </span></div><div style="line-height:10pt;position:var(--position);top:318pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">holders as of the applicable ADS record date. In the case of distributions of cash, the amount of the applicable ADS </span></div><div style="line-height:10pt;position:var(--position);top:328pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">fees and charges is deducted from the funds being distributed. In the case of (i) distributions other than cash and (ii) </span></div><div style="line-height:10pt;position:var(--position);top:338pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">the ADS service fee, holders as of the ADS record date will be invoiced for the amount of the ADS fees and charges </span></div><div style="line-height:10pt;position:var(--position);top:348pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">and such ADS fees and charges may be deducted from distributions made to holders of ADSs. For ADSs held </span></div><div style="line-height:10pt;position:var(--position);top:358pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">through DTC, the ADS fees and charges for distributions other than cash and the ADS service fee may be deducted </span></div><div style="line-height:10pt;position:var(--position);top:368pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">from distributions made through DTC, and may be charged to the DTC participants in accordance with the </span></div><div style="line-height:10pt;position:var(--position);top:378pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">procedures and practices prescribed by DTC and the DTC participants in turn charge the amount of such ADS fees </span></div><div style="line-height:10pt;position:var(--position);top:388pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">and charges to the beneficial owners for whom they hold ADSs. In the case of (i) registration of ADS transfers, the </span></div><div style="line-height:10pt;position:var(--position);top:398pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">ADS transfer fee will be payable by the ADS Holder whose ADSs are being transferred or by the person to whom </span></div><div style="line-height:10pt;position:var(--position);top:408pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">the ADSs are transferred, and (ii) conversion of ADSs of one series for ADSs of another series, the ADS conversion </span></div><div style="line-height:10pt;position:var(--position);top:418pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">fee will be payable by the Holder whose ADSs are converted or by the person to whom the converted ADSs are </span></div><div style="line-height:10pt;position:var(--position);top:428pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">delivered. </span></div><div style="line-height:10pt;position:var(--position);top:444pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">In the event of refusal to pay the depositary bank fees, the depositary bank may, under the terms of the deposit </span></div><div style="line-height:10pt;position:var(--position);top:454pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">agreement, refuse the requested service until payment is received or may set off the amount of the depositary bank </span></div><div style="line-height:10pt;position:var(--position);top:464pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">fees from any distribution to be made to the ADS holder. Certain depositary fees and charges (such as the ADS </span></div><div style="line-height:10pt;position:var(--position);top:474pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">services fee) may become payable </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:211.51pt;position:var(--position);text-decoration:none;white-space:pre">shortly</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:239.27pt;position:var(--position);white-space:pre"> after the closing of the ADS offering. Note that the fees and charges you </span></div><div style="line-height:10pt;position:var(--position);top:484pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">may be required to pay may vary over time and may be changed by us and by the depositary bank. You will receive </span></div><div style="line-height:10pt;position:var(--position);top:494pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">prior notice of such changes. The depositary bank may reimburse us for certain expenses incurred by us in respect of </span></div><div style="line-height:10pt;position:var(--position);top:504pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">the ADR program, by making available a portion of the ADS fees charged in respect of the ADR program or </span></div><div style="line-height:10pt;position:var(--position);top:514pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">otherwise, upon such terms and conditions as we and the depositary bank agree from time to time.</span></div><div style="line-height:10pt;position:var(--position);top:536pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);white-space:pre">Taxes</span></div><div style="line-height:10pt;position:var(--position);top:552pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">As an </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:122.03999999999999pt;position:var(--position);text-decoration:none;white-space:pre">ADS</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:142.04pt;position:var(--position);white-space:pre"> holder, you will be responsible for the taxes and other governmental charges payable on the ADSs </span></div><div style="line-height:10pt;position:var(--position);top:562pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">and the securities represented by the ADSs. We, the depositary bank and the custodian may deduct from any </span></div><div style="line-height:10pt;position:var(--position);top:572pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">distribution the taxes and governmental charges payable by holders and may sell any and all property on deposit to </span></div><div style="line-height:10pt;position:var(--position);top:582pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">pay the taxes and governmental charges payable by holders. You will be liable for any deficiency if the sale </span></div><div style="line-height:10pt;position:var(--position);top:592pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">proceeds do not cover the taxes that are due.</span></div><div style="line-height:10pt;position:var(--position);top:614pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">The depositary bank may refuse to issue ADSs, to deliver, transfer, split and combine ADRs or to release </span></div><div style="line-height:10pt;position:var(--position);top:624pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">securities on deposit until all taxes and charges are paid by the applicable holder. The depositary bank and the </span></div><div style="line-height:10pt;position:var(--position);top:634pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">custodian may take reasonable administrative actions to obtain tax refunds and reduced tax withholding for any </span></div><div style="line-height:10pt;position:var(--position);top:644pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">distributions on your behalf. However, you may be required to provide to the depositary bank and to the custodian </span></div><div style="line-height:10pt;position:var(--position);top:654pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">proof of taxpayer status and residence and such other information as the depositary bank and the custodian may </span></div><div style="line-height:10pt;position:var(--position);top:664pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">require to fulfill legal obligations. You are required to indemnify us, the depositary bank and the custodian for any </span></div><div style="line-height:10pt;position:var(--position);top:674pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">claims with respect to taxes based on any tax benefit obtained for you. </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">151</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_181"></div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:287.26pt;position:var(--position);text-decoration:none;white-space:pre">PART II<span id="ia9786d3f07b147668722cff2baa4d714"></span></span></div><div style="position:absolute;top:108pt" id="i7a006daedb3d4216a4128b76247285d7_184"></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">Item 13.<span style="display:inline-block;height:6.77pt;width:1.02pt"></span></span><span style="left:108pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:36pt"></span></span><span style="left:144pt;position:var(--position)">Defaults, Dividend Arrearages and Delinquencies</span><span id="i916ad87a5ab840128257c67e003d2686"></span></span></div><div style="line-height:10pt;position:var(--position);top:126pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">Not applicable.</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">152</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_187"></div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">Item 14.<span style="display:inline-block;height:6.77pt;width:1.02pt"></span></span><span style="left:108pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:36pt"></span></span><span style="left:144pt;position:var(--position)">Material Modifications to the Rights of Security Holders and Use of Proceeds</span><span id="i4ea7fbbf56ad4bf094735d9b45bf2ac6"></span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:90pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Initial Public Offering</span></div><div style="line-height:10pt;position:var(--position);top:106pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">On October 24, 2023, we sold 20,325,500 new ordinary shares (the "New Shares"), consisting of a public </span></div><div style="line-height:10pt;position:var(--position);top:116pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">offering of 18,699,460 o</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:170.01999999999998pt;position:var(--position);white-space:pre">rdinary shares in the form of ADSs, each representing the right to receive one ordinary </span></div><div style="line-height:10pt;position:var(--position);top:126pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">share, in the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:123.05pt;position:var(--position);text-decoration:none;white-space:pre">United</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:150.24pt;position:var(--position);white-space:pre"> States</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:176.59pt;position:var(--position);white-space:pre"> (the "U.S. Offering") and a concurrent offering of 1,626,040 ordinary shares in certain </span></div><div style="line-height:10pt;position:var(--position);top:136pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">jurisdictions outside of the United States to certain investors (the "European Private Placement" and together with </span></div><div style="line-height:10pt;position:var(--position);top:146pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">the U.S. Offering, the "</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:165.17000000000002pt;position:var(--position);text-decoration:none;white-space:pre">Global</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:192.36pt;position:var(--position);white-space:pre"> Offering"). The offering price was set at $11.60 per ADS in the U.S. Offering and a </span></div><div style="line-height:10pt;position:var(--position);top:156pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">corresponding offering price of &#8364;10.9864 per ordinary share in the European Private Placement. The aggregate gross </span></div><div style="line-height:10pt;position:var(--position);top:166pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">proceeds amounted to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:162.18pt;position:var(--position);text-decoration:none;white-space:pre">approximately</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:219.88pt;position:var(--position);white-space:pre"> $235.8 million, equivalent to approximately &#8364;223.3 million (based on the </span></div><div style="line-height:10pt;position:var(--position);top:176pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">exchange rate then in effect), before deduction of underwriting commissions and expenses payable by us. All of the </span></div><div style="line-height:10pt;position:var(--position);top:186pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">ADSs and ordinary shares in the Global Offering were offered by Abivax.</span></div><div style="line-height:10pt;position:var(--position);top:202pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">We incurred </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:148.65pt;position:var(--position);white-space:pre">aggregate</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:187.47pt;position:var(--position);white-space:pre"> underwriting discounts of approximately $16.5 million and expenses of approximately </span></div><div style="line-height:10pt;position:var(--position);top:212pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">$7.0 million, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:125.85pt;position:var(--position);text-decoration:none;white-space:pre">resulting</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:160.81pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:163.31pt;position:var(--position);white-space:pre">in</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:171.07999999999998pt;position:var(--position);white-space:pre"> net proceeds to us of approximately $212.2 million. The effective date of the registration </span></div><div style="line-height:10pt;position:var(--position);top:222pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">statement, File No. 333-274780, for our initial public offering was October 19, 2023. </span></div><div style="line-height:10pt;position:var(--position);top:238pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">As of the date of this Annual Report on Form 20-F, we have applied all of the proceeds of our Global </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:248pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">Offering. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:111.41pt;position:var(--position);text-decoration:none;white-space:pre">There</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:134.7pt;position:var(--position);text-decoration:none;white-space:pre"> was </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.24pt;position:var(--position);text-decoration:none;white-space:pre">no</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:165.24pt;position:var(--position);text-decoration:none;white-space:pre"> material change in the use of proceeds from the Global Offering from that described in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:258pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">final prospectus related to the offering, which we filed with the SEC on October 23, 2023. </span></div><div style="line-height:10pt;position:var(--position);top:280pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);white-space:pre">2025 Follow-On Offering</span></div><div style="line-height:10pt;position:var(--position);top:296pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">On July 23, 2025, we entered into an Underwriting Agreement (the &#8220;Underwriting Agreement&#8221;) with Leerink </span></div><div style="line-height:10pt;position:var(--position);top:306pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">Partners LLC, Piper Sandler &amp; Co. and Guggenheim Securities, LLC, as representatives of the several underwriters </span></div><div style="line-height:10pt;position:var(--position);top:316pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">named therein, in connection </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:190.45999999999998pt;position:var(--position);text-decoration:none;white-space:pre">with</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:208.22pt;position:var(--position);white-space:pre"> the issuance and sale by the Company in a public offering of 11,679,400 ADSs at </span></div><div style="line-height:10pt;position:var(--position);top:326pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">a public offering price of $64.00 per ADS. The information contained in the Company&#8217;s Report on Form 6-K filed </span></div><div style="line-height:10pt;position:var(--position);top:336pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">on July 24, 2025 is incorporated by reference herein.</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">153</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_190"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">Item 15.<span style="display:inline-block;height:6.77pt;width:1.02pt"></span></span><span style="left:108pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:36pt"></span></span><span style="left:144pt;position:var(--position)">Controls and Procedures</span><span id="i7b73f7b395614f9e98f390ec15bcb896"></span></span></div><div style="position:absolute;top:108pt" id="i7a006daedb3d4216a4128b76247285d7_193"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Disc<span id="ib6c861854978412587e160d4914ad7bb"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:90.31pt;position:var(--position);text-decoration:none;white-space:pre">losure Controls and Proce</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:201.6pt;position:var(--position);white-space:pre">dures</span></div><div style="line-height:10pt;position:var(--position);top:124pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">Our Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial </span></div><div style="line-height:10pt;position:var(--position);top:134pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">officer), after evaluating the effectiveness of our &#8220;disclosure controls and procedures,&#8221; as such term is defined in </span></div><div style="line-height:10pt;position:var(--position);top:144pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">Rules 13a-15(e) and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.53pt;position:var(--position);text-decoration:none;white-space:pre">15d-15</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:183.86pt;position:var(--position);white-space:pre">(e) under the Exchange Act as of December 31, 2025, have concluded that, as of such </span></div><div style="line-height:10pt;position:var(--position);top:154pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">date, our disclosure controls and procedures were not effective as a result of the material weaknesses described </span></div><div style="line-height:10pt;position:var(--position);top:164pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">below. We are undertaking the remedial steps to address the material weaknesses in our disclosure controls and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:174pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">procedures as discussed </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:169.95999999999998pt;position:var(--position);text-decoration:none;white-space:pre">below</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:194.38pt;position:var(--position);white-space:pre">.</span></div><div style="position:absolute;top:196pt" id="i7a006daedb3d4216a4128b76247285d7_196"></div><div style="line-height:10pt;position:var(--position);top:196pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Management&#8217;s Annual Report on Internal Control Over Financial Reporting<span id="i4e2d6547883c4f839ff1d90f3c8c816c"></span></span></div><div style="line-height:10pt;position:var(--position);top:214pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">Our management is responsible for establishing and maintaining adequate internal control over financial </span></div><div style="line-height:10pt;position:var(--position);top:224pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) and for the assessment of the </span></div><div style="line-height:10pt;position:var(--position);top:234pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">effectiveness of our internal control over financial reporting. Our internal control over financial reporting is designed </span></div><div style="line-height:10pt;position:var(--position);top:244pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">to provide </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:115.3pt;position:var(--position);text-decoration:none;white-space:pre">reasonable</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.01pt;position:var(--position);white-space:pre"> assurance regarding the reliability of financial reporting and the preparation of consolidated </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:254pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">financial statements for external purposes in accordance with </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:318.88pt;position:var(--position);text-decoration:none;white-space:pre">International Financial Reporting Standards ("IFRS") </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:264pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">as issued by the International Accounting Standard board ("IASB") and IFRS as adopted by the European Union </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:274pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">("EU").</span></div><div style="line-height:10pt;position:var(--position);top:290pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">Because of its inherent limitations, internal control over financial reporting may not prevent or detect </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:300pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">misstatements</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:128.57999999999998pt;position:var(--position);text-decoration:none;white-space:pre">.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:131.07999999999998pt;position:var(--position);white-space:pre"> Also, projections of any evaluation of effectiveness to future periods are subject to the risk that </span></div><div style="line-height:10pt;position:var(--position);top:310pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies </span></div><div style="line-height:10pt;position:var(--position);top:320pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">or procedures may deteriorate. Effective internal controls can provide only reasonable assurance with respect to the </span></div><div style="line-height:10pt;position:var(--position);top:330pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">preparation and fair presentation of financial statements.</span></div><div style="line-height:10pt;position:var(--position);top:346pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, assessed </span></div><div style="line-height:10pt;position:var(--position);top:356pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">the design and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:132.22pt;position:var(--position);text-decoration:none;white-space:pre">effectiveness</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:184.35pt;position:var(--position);white-space:pre"> of our internal control over financial reporting as of December 31, 2025, using the </span></div><div style="line-height:10pt;position:var(--position);top:366pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">criteria established in the Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring </span></div><div style="line-height:10pt;position:var(--position);top:376pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">Organizations of the Treadway Commission (&#8220;COSO&#8221;). Based on this evaluation, management concluded that our </span></div><div style="line-height:10pt;position:var(--position);top:386pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">internal control over financial reporting was not effective as of December 31, 2025 due to material weaknesses </span></div><div style="line-height:10pt;position:var(--position);top:396pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">described below.</span></div><div style="line-height:10pt;position:var(--position);top:412pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial </span></div><div style="line-height:10pt;position:var(--position);top:422pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">reporting, such that there is a reasonable possibility that a material misstatement of our financial statements will not </span></div><div style="line-height:10pt;position:var(--position);top:432pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">be prevented or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:136.65pt;position:var(--position);text-decoration:none;white-space:pre">detected</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:169.91pt;position:var(--position);white-space:pre"> on a timely basis.</span></div><div style="line-height:10pt;position:var(--position);top:448pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">The material weaknesses are related to a lack of (i) design and implementation of effective risk assessment </span></div><div style="line-height:10pt;position:var(--position);top:458pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">process (Risk Assessment), (ii) formal, documented and implemented processes, controls and review procedures </span></div><div style="line-height:10pt;position:var(--position);top:468pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">(Control Activities), (iii) sufficient processes to identify, capture and communicate information necessary to support </span></div><div style="line-height:10pt;position:var(--position);top:478pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">the functioning of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:146.1pt;position:var(--position);text-decoration:none;white-space:pre">internal</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:176.6pt;position:var(--position);white-space:pre"> controls over financial reporting (Information and Communication) and (iv) process to </span></div><div style="line-height:10pt;position:var(--position);top:488pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">identify, maintain, and develop all control activities (Monitoring Activities). These material weaknesses are </span></div><div style="line-height:10pt;position:var(--position);top:498pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">specifically due to a lack of sufficient number of professionals with an appropriate level of internal control </span></div><div style="line-height:10pt;position:var(--position);top:508pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">knowledge, training and experience and the need to continue to reinforce our internal control governance (Control </span></div><div style="line-height:10pt;position:var(--position);top:518pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">Environment). </span></div><div style="line-height:10pt;position:var(--position);top:540pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Remediation Efforts<span id="if076c558137e445bb1bb31a8fe756e70"></span></span></div><div style="line-height:10pt;position:var(--position);top:556pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">In response to the identified material weaknesses, management took a number of actions to improve the </span></div><div style="line-height:10pt;position:var(--position);top:566pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">internal control </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:135.8pt;position:var(--position);text-decoration:none;white-space:pre">over</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:153.56pt;position:var(--position);white-space:pre"> financial reporting during the year ended December 31, 2025. </span></div><div style="line-height:10pt;position:var(--position);top:582pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">These actions </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:153.64pt;position:var(--position);text-decoration:none;white-space:pre">include</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:183.04000000000002pt;position:var(--position);white-space:pre">, but are not limited to, the following:</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:598pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">Reinforcing </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:146.72pt;position:var(--position);text-decoration:none;white-space:pre">further</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:173.91pt;position:var(--position);white-space:pre"> the finance and account</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:270.99pt;position:var(--position);text-decoration:none;white-space:pre">ing resources b</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:331.49pt;position:var(--position);white-space:pre">y: </span></div><div style="line-height:10pt;position:var(--position);top:619.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.5pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:144pt;position:var(--position);white-space:pre">Hiring additional qualified finance personnel, focusing on qualifications, certifications and </span></div><div style="line-height:10pt;position:var(--position);top:630.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">relevant industry experience; and</span></div><div style="line-height:10pt;position:var(--position);top:652.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.5pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:144pt;position:var(--position);white-space:pre">Providing a structured onboarding program for new hires, including an introduction to current </span></div><div style="line-height:10pt;position:var(--position);top:664pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">financial systems, company processes, and internal controls.</span></div><div style="line-height:10pt;position:var(--position);top:692.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">With the support of our </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:192.82pt;position:var(--position);text-decoration:none;white-space:pre">external</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:224.98pt;position:var(--position);white-space:pre"> advisors, we are in the process of designing and implementing measures to </span></div><div style="line-height:10pt;position:var(--position);top:702.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">enhance our internal control over financial reporting:</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">154</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:82.7pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">We are currently conducting&#160; a comprehensive risk assessment in all areas, including cash management, </span></div><div style="line-height:10pt;position:var(--position);top:93.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">financial reporting, compliance with regulations, fraud prevention and operational risks. The risk </span></div><div style="line-height:10pt;position:var(--position);top:104.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">assessment will be implemented as a framework, with specific objectives to identify new risks and update </span></div><div style="line-height:10pt;position:var(--position);top:114.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">regularly our processes based on emerging risks and/or changes in regulatory requirements,</span></div><div style="line-height:10pt;position:var(--position);top:136.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">We have started designing and implementing processes and controls, including segregation of duties, </span></div><div style="line-height:10pt;position:var(--position);top:146.9pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">approval workflows and reconciliation procedures. In particular, we are implementing additional review </span></div><div style="line-height:10pt;position:var(--position);top:157.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">activities within our finance department and introducing further standard operating procedures for the </span></div><div style="line-height:10pt;position:var(--position);top:168.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">preparation of the financial statements, </span></div><div style="line-height:10pt;position:var(--position);top:189.7pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">We are in the process of enhancing our information technology and the set of controls over the systems to </span></div><div style="line-height:10pt;position:var(--position);top:200.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">create a more effective control environment, which includes providing training to finance and accounting </span></div><div style="line-height:10pt;position:var(--position);top:211.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">personnel on the upgraded systems, focusing on new features, controls, and reporting capabilities.</span></div><div style="line-height:10pt;position:var(--position);top:232.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">We will deploy a more structured internal control governance with strong tone at the top communications </span></div><div style="line-height:10pt;position:var(--position);top:243.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">to drive a solid control environment throughout the organization and an annual testing plan that includes </span></div><div style="line-height:10pt;position:var(--position);top:253.9pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:var(--position);white-space:pre">monitoring of the operation of internal controls and addressing control deficiencies. </span></div><div style="line-height:10pt;position:var(--position);top:270.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">As of December 31, 2025, management has concluded that, while it has made significant progress to </span></div><div style="line-height:10pt;position:var(--position);top:280.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">remediate the previously disclosed </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:212.93pt;position:var(--position);text-decoration:none;white-space:pre">material</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:245.63pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:248.13pt;position:var(--position);text-decoration:none;white-space:pre">weaknesses</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:294.74pt;position:var(--position);white-space:pre">, they have not been remediated. With the oversight of senior </span></div><div style="line-height:10pt;position:var(--position);top:290.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">management </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:125.53pt;position:var(--position);text-decoration:none;white-space:pre">and</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:139.95999999999998pt;position:var(--position);white-space:pre"> our audit committee, we continue to strengthen our internal control over financial reporting and are </span></div><div style="line-height:10pt;position:var(--position);top:300.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">taking several remedial actions to address the material weaknesses that have been identified. </span></div><div style="line-height:10pt;position:var(--position);top:316.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">After giving full consideration to these material weaknesses, and the additional analyses and other procedures </span></div><div style="line-height:10pt;position:var(--position);top:326.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">that we performed to ensure that our consolidated financial statements included in this Annual Report on Form 20-F </span></div><div style="line-height:10pt;position:var(--position);top:336.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">were prepared in accordance with International Financial Reporting Standards (IFRS), management has concluded </span></div><div style="line-height:10pt;position:var(--position);top:346.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">that our consolidated financial statements present fairly, in all material respects, our financial position, results of </span></div><div style="line-height:10pt;position:var(--position);top:356.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">operations and cash flows for the periods disclosed in conformity with IFRS.</span></div><div style="line-height:10pt;position:var(--position);top:366.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre"> </span></div><div style="position:absolute;top:378.6pt" id="i7a006daedb3d4216a4128b76247285d7_199"></div><div style="line-height:10pt;position:var(--position);top:378.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Attestation Report of the Registered Public Accounting Firm<span id="ic3aa418b56794fc7851c31592dcccdcd"></span></span></div><div style="line-height:10pt;position:var(--position);top:396.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">This Annual Report </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:178.37pt;position:var(--position);white-space:pre">does</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:196.69pt;position:var(--position);text-decoration:none;white-space:pre"> not include an attestation report of our registered public accounting firm due to a </span></div><div style="line-height:10pt;position:var(--position);top:406.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">transition period </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.26pt;position:var(--position);white-space:pre">established</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:184.64pt;position:var(--position);text-decoration:none;white-space:pre"> by rules of the Securities and Exchange Commission for emerging growth companies </span></div><div style="line-height:10pt;position:var(--position);top:416.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(as defined in Rule 12b-2 under the Exchange Act).</span></div><div style="position:absolute;top:438.6pt" id="i7a006daedb3d4216a4128b76247285d7_202"></div><div style="line-height:10pt;position:var(--position);top:438.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Changes in Control over Financial Reporting<span id="ie841e5655cf74e0f95291982acfbf34a"></span></span></div><div style="line-height:10pt;position:var(--position);top:456.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">Except as described above in the section titled "</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:287.53999999999996pt;position:var(--position);text-decoration:none;white-space:pre">Management&#8217;s Annual Report on Internal Control Over <span id="i35220716b6e246a8967ffe954e32aee6"></span></span></div><div style="line-height:10pt;position:var(--position);top:466.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Financial </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:111.66pt;position:var(--position);text-decoration:none;white-space:pre">Reporting</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:151.62pt;position:var(--position);text-decoration:none;white-space:pre">" t<span id="ifbd065e0c3424fd7a2f298b5b17a9143"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:160.97pt;position:var(--position);white-space:pre">here has been no change in our </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:287.23pt;position:var(--position);text-decoration:none;white-space:pre">internal</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:317.73pt;position:var(--position);white-space:pre"> control over financial reporting during the year ended </span></div><div style="line-height:10pt;position:var(--position);top:476.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">December 31, 2025 that has materially affected, or is reasonably likely to materially affect, our internal control over </span></div><div style="line-height:10pt;position:var(--position);top:486.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">financial reporting.</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">155</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_205"></div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">Item 16.<span style="display:inline-block;height:6.77pt;width:1.02pt"></span></span><span style="left:108pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:36pt"></span></span><span style="left:144pt;position:var(--position)">[Reserved]</span><span id="i93a99af6c6324362a28db117160ebf43"></span></span></div><div style="position:absolute;top:96pt" id="i7a006daedb3d4216a4128b76247285d7_208"></div><div style="line-height:10pt;position:var(--position);top:96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">Item 16A.<span style="display:inline-block;height:6.77pt;width:29.8pt"></span></span><span style="left:144pt;position:var(--position)">Audit Committee Financial Expert</span><span id="i4f04e7552da04af7ba749682bdcc2685"></span></span></div><div style="line-height:10pt;position:var(--position);top:114pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our Board has determined that each of the members of our audit committee is independent within the meaning </span></div><div style="line-height:10pt;position:var(--position);top:124pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of the applicable listing rules of Nasdaq and the independence requirements contemplated by Rule 10A-3 under the </span></div><div style="line-height:10pt;position:var(--position);top:134pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Exchange Act. Committee members must be competent in financial or accounting matters and at least one member </span></div><div style="line-height:10pt;position:var(--position);top:144pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">must be independent in accordance with the provisions of the Middlenext Code. Our Board has further determined </span></div><div style="line-height:10pt;position:var(--position);top:154pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">that Mr. Ignelzi is an &#8220;audit committee financial expert&#8221; as defined by SEC rules and regulations and that Mr. </span></div><div style="line-height:10pt;position:var(--position);top:164pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Ignelzi qualifies as financially sophisticated under the listing rules of Nasdaq. </span></div><div style="position:absolute;top:186pt" id="i7a006daedb3d4216a4128b76247285d7_211"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:186pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">Item 16B.<span style="display:inline-block;height:6.77pt;width:30.36pt"></span></span><span style="left:144pt;position:var(--position)">Code of Ethics</span><span id="i8d421226ce09418182ea3e608ed6d1e6"></span></span></div><div style="line-height:10pt;position:var(--position);top:204pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We have adopted a Code of Business Conduct and Ethics, applicable to all of our employees, senior </span></div><div style="line-height:10pt;position:var(--position);top:214pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">management and directors, which is available on our website at www.abivax.com. We intend to promptly disclose </span></div><div style="line-height:10pt;position:var(--position);top:224pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(i) the nature of any amendment (other than technical, administrative or other non-substantive amendments) to the </span></div><div style="line-height:10pt;position:var(--position);top:234pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Code of Business Conduct and Ethics that applies to our principal executive officer, principal financial officer, </span></div><div style="line-height:10pt;position:var(--position);top:244pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">principal accounting officer or controller, or persons performing similar functions, and relates to any element of the </span></div><div style="line-height:10pt;position:var(--position);top:254pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">code of ethics definition enumerated in Item 16B(b) of Form 20-F and (ii) the nature of any waiver, including an </span></div><div style="line-height:10pt;position:var(--position);top:264pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">implicit waiver, from a provision of the Code of Business Conduct and Ethics that is granted to one of these </span></div><div style="line-height:10pt;position:var(--position);top:274pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">specified individuals that relates to one or more of the elements of the code of ethics definition enumerated in Item </span></div><div style="line-height:10pt;position:var(--position);top:284pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">16B(b) of Form 20-F, the name of such person who is granted the waiver and the date of the waiver. The reference </span></div><div style="line-height:10pt;position:var(--position);top:294pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to our website address does not constitute incorporation by reference of the information contained at or available </span></div><div style="line-height:10pt;position:var(--position);top:304pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">through our website, and you should not consider it to be a part of this Annual Report.</span></div><div style="position:absolute;top:326pt" id="i7a006daedb3d4216a4128b76247285d7_214"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:326pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">Item 16C.<span style="display:inline-block;height:6.77pt;width:29.8pt"></span></span><span style="left:144pt;position:var(--position)">Principal Accountant Fees and Ser</span><span id="i07d5b04f6c1d4fde95fa37694d9e3c37"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:292.2pt;position:var(--position);text-decoration:none;white-space:pre">vices</span></div><div style="position:var(--position);top:350pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:465.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:222.75pt"/><td style="padding:0;width:81pt"/><td style="padding:0;width:81pt"/><td style="padding:0;width:81pt"/></tr><tr style="height:34.5pt"><td style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:222.75pt"><div><div style="line-height:10pt;position:var(--position);top:13.27pt;width:222.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:46.95pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:222.75pt;position:var(--position);width:81pt"><div><div style="line-height:8pt;position:var(--position);top:4.65pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.19pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:14.25pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:23.85pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.5pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:303.75pt;position:var(--position);width:81pt"><div><div style="line-height:8pt;position:var(--position);top:4.65pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.19pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:14.25pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:23.85pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.5pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:384.75pt;position:var(--position);width:81pt"><div><div style="line-height:8pt;position:var(--position);top:4.65pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.19pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:14.25pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:23.85pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.5pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:15pt"><td style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:34.5pt;width:222.75pt"><div><div style="line-height:10pt;position:var(--position);top:4.42pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Audit fees</span></div></div></div></td><td style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:222.75pt;position:var(--position);top:34.5pt;width:81pt"><div><div style="line-height:10pt;position:var(--position);top:4.42pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:51.79pt"></span></span><span style="left:54.42pt;position:var(--position)">1,714<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:303.75pt;position:var(--position);top:34.5pt;width:81pt"><div><div style="line-height:10pt;position:var(--position);top:4.42pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:51.79pt"></span></span><span style="left:54.42pt;position:var(--position)">1,000<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:384.75pt;position:var(--position);top:34.5pt;width:81pt"><div><div style="line-height:10pt;position:var(--position);top:4.42pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:51.79pt"></span></span><span style="left:54.42pt;position:var(--position)">1,095<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td></tr><tr style="height:15pt"><td style="border-left:1pt solid #000000;border-right:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:49.5pt;width:222.75pt"><div><div style="line-height:10pt;position:var(--position);top:4.42pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Audit-related fees</span></div></div></div></td><td style="border-left:1pt solid #000000;border-right:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:222.75pt;position:var(--position);top:49.5pt;width:81pt"><div><div style="line-height:10pt;position:var(--position);top:4.42pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:64.29pt"></span></span><span style="left:66.92pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="border-left:1pt solid #000000;border-right:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:303.75pt;position:var(--position);top:49.5pt;width:81pt"><div><div style="line-height:10pt;position:var(--position);top:4.42pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:64.29pt"></span></span><span style="left:66.92pt;position:var(--position)">76<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="border-left:1pt solid #000;border-right:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:384.75pt;position:var(--position);top:49.5pt;width:81pt"><div><div style="line-height:10pt;position:var(--position);top:4.42pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:59.29pt"></span></span><span style="left:61.92pt;position:var(--position)">113<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td></tr><tr style="height:15pt"><td style="border-left:1pt solid #000000;border-right:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:64.5pt;width:222.75pt"><div><div style="line-height:10pt;position:var(--position);top:4.42pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Tax fees</span></div></div></div></td><td style="border-left:1pt solid #000000;border-right:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:222.75pt;position:var(--position);top:64.5pt;width:81pt"><div><div style="line-height:10pt;position:var(--position);top:4.42pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:64.29pt"></span></span><span style="left:66.92pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="border-left:1pt solid #000000;border-right:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:303.75pt;position:var(--position);top:64.5pt;width:81pt"><div><div style="line-height:10pt;position:var(--position);top:4.42pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:64.29pt"></span></span><span style="left:66.92pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="border-left:1pt solid #000;border-right:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:384.75pt;position:var(--position);top:64.5pt;width:81pt"><div><div style="line-height:10pt;position:var(--position);top:4.42pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:64.29pt"></span></span><span style="left:66.92pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td></tr><tr style="height:15pt"><td style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:79.5pt;width:222.75pt"><div><div style="line-height:10pt;position:var(--position);top:4.42pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">All other fees</span></div></div></div></td><td style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:222.75pt;position:var(--position);top:79.5pt;width:81pt"><div><div style="line-height:10pt;position:var(--position);top:4.42pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:59.29pt"></span></span><span style="left:61.92pt;position:var(--position)">492<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:303.75pt;position:var(--position);top:79.5pt;width:81pt"><div><div style="line-height:10pt;position:var(--position);top:4.42pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:69.29pt"></span></span><span style="left:71.92pt;position:var(--position)">7<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:384.75pt;position:var(--position);top:79.5pt;width:81pt"><div><div style="line-height:10pt;position:var(--position);top:4.42pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:64.29pt"></span></span><span style="left:66.92pt;position:var(--position)">32<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td></tr><tr style="height:15.75pt"><td style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:94.5pt;width:222.75pt"><div><div style="line-height:10pt;position:var(--position);top:5.17pt;width:222.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total</span></div></div></div></td><td style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:222.75pt;position:var(--position);top:94.5pt;width:81pt"><div><div style="line-height:10pt;position:var(--position);top:5.17pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:51.79pt"></span></span><span style="left:54.42pt;position:var(--position)">2,206<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:303.75pt;position:var(--position);top:94.5pt;width:81pt"><div><div style="line-height:10pt;position:var(--position);top:5.17pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:51.79pt"></span></span><span style="left:54.42pt;position:var(--position)">1,083<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td><td style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:384.75pt;position:var(--position);top:94.5pt;width:81pt"><div><div style="line-height:10pt;position:var(--position);top:5.17pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:51.79pt"></span></span><span style="left:54.42pt;position:var(--position)">1,161<span style="display:inline-block;height:6.93pt;width:3.33pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="line-height:10pt;position:var(--position);top:477.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);white-space:pre">Audit Fees</span></div><div style="line-height:10pt;position:var(--position);top:495.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">Audit fees include the standard audit work performed each fiscal year necessary to allow the auditor to issue </span></div><div style="line-height:10pt;position:var(--position);top:505.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">an opinion on our financial statements and to issue an opinion on the local statutory financial statements. Audit fees </span></div><div style="line-height:10pt;position:var(--position);top:515.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">also include services </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:157.16pt;position:var(--position);text-decoration:none;white-space:pre">that</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:172.13pt;position:var(--position);white-space:pre"> can be provided only by the external auditor such as reviews of quarterly financial results </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:525.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">and review of our securities offering documents.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:265.96000000000004pt;position:var(--position);text-decoration:none;white-space:pre"> Fees for the audit of our annual financial statements for the fiscal </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:535.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">years ended December 31, 2025 and 2024 were &#8364;1.1 million and &#8364;1.0 million, respectively.</span></div><div style="line-height:10pt;position:var(--position);top:557.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);white-space:pre">Audit-Related Fees</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:573.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">&#8220;Audit-related </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:156.68pt;position:var(--position);text-decoration:none;white-space:pre">Fees</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:174.99pt;position:var(--position);text-decoration:none;white-space:pre">&#8221; are the aggregate fees for assurance and related services that are reasonably related to the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:583.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">performance of the audit and are not reported under Audit Fees. The aggregate audit-related fees for the fiscal year </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:593.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ended December 31, 2025 and 2024 were &#8364;113 thousand and &#8364;76 thousand respectively. </span></div><div style="line-height:10pt;position:var(--position);top:615.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);white-space:pre">Tax Fees</span></div><div style="line-height:10pt;position:var(--position);top:639.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">None</span></div><div style="line-height:10pt;position:var(--position);top:661.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);white-space:pre">All Other Fees</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:679.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The aggregate fees for all other services for the fiscal year ended December 31, 2025 and 2024 were &#8364;0.1 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:689.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">million and &#8364;7 </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:132.78pt;position:var(--position);text-decoration:none;white-space:pre">thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:168.87pt;position:var(--position);text-decoration:none;white-space:pre"> respectively. Other fees relate to other non-audit assurance services. </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">156</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Audit Committee&#8217;s Pre-Approval Policies and Procedures</span></div><div style="line-height:10pt;position:var(--position);top:90pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">The Audit Committee is responsible for recommending the appointment, replacement, and compensation of </span></div><div style="line-height:10pt;position:var(--position);top:100pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">the independent auditors and monitoring the performance of the independent auditors. As part of this responsibility, </span></div><div style="line-height:10pt;position:var(--position);top:110pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">the Audit Committee pre-approves all audit and non-audit services performed by the independent auditors in order to </span></div><div style="line-height:10pt;position:var(--position);top:120pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">assure that they </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:136.64pt;position:var(--position);text-decoration:none;white-space:pre">do</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:146.64pt;position:var(--position);white-space:pre"> not impair the auditor&#8217;s independence from the Company in accordance with the Audit </span></div><div style="line-height:10pt;position:var(--position);top:130pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">Committee&#8217;s pre-approval policy.&#160; All fees described in this Item 16C above were pre-approved by the Audit </span></div><div style="line-height:10pt;position:var(--position);top:140pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">Committee.</span></div><div style="position:absolute;top:162pt" id="i7a006daedb3d4216a4128b76247285d7_217"></div><div style="line-height:10pt;position:var(--position);top:162pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">Item 16D.<span style="display:inline-block;height:6.77pt;width:29.8pt"></span></span><span style="left:144pt;position:var(--position)">Exemptions from the Listing Standards for Audit Committees</span><span id="i0ee554ab85064c87a702440c74e03176"></span></span></div><div style="line-height:10pt;position:var(--position);top:186pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.5pt;position:var(--position);white-space:pre">Not applicable.</span></div><div style="position:absolute;top:210pt" id="i7a006daedb3d4216a4128b76247285d7_220"></div><div style="line-height:10pt;position:var(--position);top:210pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">Item 16E.<span style="display:inline-block;height:6.77pt;width:30.36pt"></span></span><span style="left:144pt;position:var(--position)">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span><span id="ia8b8ac26e96945569ca28bd17a24670a"></span></span></div><div style="line-height:10pt;position:var(--position);top:234pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.5pt;position:var(--position);white-space:pre">None.</span></div><div style="position:absolute;top:258pt" id="i7a006daedb3d4216a4128b76247285d7_223"></div><div style="line-height:10pt;position:var(--position);top:258pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">Item 16F.<span style="display:inline-block;height:6.77pt;width:30.92pt"></span></span><span style="left:144pt;position:var(--position)">Change in Registrant&#8217;s Certifying Accountant</span><span id="i10ce1263950b4e8aa37013ff8539a1c3"></span></span></div><div style="line-height:10pt;position:var(--position);top:282pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.5pt;position:var(--position);white-space:pre">Not applicable.</span></div><div style="position:absolute;top:306pt" id="i7a006daedb3d4216a4128b76247285d7_226"></div><div style="line-height:10pt;position:var(--position);top:306pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">Item 16G.<span style="display:inline-block;height:6.77pt;width:29.25pt"></span></span><span style="left:144pt;position:var(--position)">Corporate Governance</span><span id="i64ffcd16ece64067895873399d959ae2"></span></span></div><div style="line-height:10pt;position:var(--position);top:324pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">As a French </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:147.29pt;position:var(--position);text-decoration:none;white-space:pre">soci&#233;t&#233; anonyme </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:216.09pt;position:var(--position);text-decoration:none;white-space:pre">(limited liability company) listed on Euronext Paris, we are subject to various </span></div><div style="line-height:10pt;position:var(--position);top:334pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">corporate governance requirements under French law. In particular, we refer to the Code of Corporate Governance </span></div><div style="line-height:10pt;position:var(--position);top:344pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">for small and medium-sized firms as published in September 2021 by Middlenext, as amended from time to time. In </span></div><div style="line-height:10pt;position:var(--position);top:354pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">addition, as a foreign private issuer listed on the Nasdaq Global Market, we are subject to Nasdaq&#8217;s corporate </span></div><div style="line-height:10pt;position:var(--position);top:364pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">governance listing standards. Nasdaq&#8217;s listing standards provide that foreign private issuers are permitted to follow </span></div><div style="line-height:10pt;position:var(--position);top:374pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">home country governance practices in lieu of Nasdaq rules, with certain exceptions. We currently rely on certain </span></div><div style="line-height:10pt;position:var(--position);top:384pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">exemptions for foreign private issuers and follow French corporate governance practices in lieu of Nasdaq corporate </span></div><div style="line-height:10pt;position:var(--position);top:394pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">governance rules, which would require that (i)&#160;a majority of our Board consists of independent directors and (ii)&#160;the </span></div><div style="line-height:10pt;position:var(--position);top:404pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">quorum for any meeting of the holders of ordinary shares be at least 33</span><span style="font-family:'Times New Roman', serif;font-size:4.875pt;font-style:normal;font-weight:normal;left:355.89pt;position:var(--position);text-decoration:none;top:-2.4254999999999995pt;vertical-align:super;white-space:pre">1</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:358.32pt;position:var(--position);text-decoration:none;white-space:pre">/</span><span style="font-family:'Times New Roman', serif;font-size:4.875pt;font-style:normal;font-weight:normal;left:361.09pt;position:var(--position);text-decoration:none;top:2.4254999999999995pt;vertical-align:sub;white-space:pre">3</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:363.52pt;position:var(--position);text-decoration:none;white-space:pre">&#160;% of the company's outstanding ordinary&#160; </span></div><div style="line-height:10pt;position:var(--position);top:414pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">shares. In addition, under French law, our shareholders, and not our Audit Committee, is directly responsible for the </span></div><div style="line-height:10pt;position:var(--position);top:424pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">appointment of our auditors. </span></div><div style="line-height:10pt;position:var(--position);top:440pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Nasdaq rules require that a listed company specify that the quorum for any meeting of the holders of ordinary </span></div><div style="line-height:10pt;position:var(--position);top:450pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">shares be at least 33</span><span style="font-family:'Times New Roman', serif;font-size:4.875pt;font-style:normal;font-weight:normal;left:151.89pt;position:var(--position);text-decoration:none;top:-2.4254999999999995pt;vertical-align:super;white-space:pre">1</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:154.32pt;position:var(--position);text-decoration:none;white-space:pre">/</span><span style="font-family:'Times New Roman', serif;font-size:4.875pt;font-style:normal;font-weight:normal;left:157.09pt;position:var(--position);text-decoration:none;top:2.4254999999999995pt;vertical-align:sub;white-space:pre">3</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:159.51999999999998pt;position:var(--position);text-decoration:none;white-space:pre">&#160;% of the company's outstanding ordinary shares. Consistent with French Law, our by-laws </span></div><div style="line-height:10pt;position:var(--position);top:460pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">provide that, for ordinary shareholders&#8217; meetings to be quorate, one-fifth of the holders of shares entitled to voting </span></div><div style="line-height:10pt;position:var(--position);top:470pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">rights must be present in person or vote by mail or by proxy or by authorized intermediary or by any means of </span></div><div style="line-height:10pt;position:var(--position);top:480pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">telecommunication permitting their identification. An extraordinary shareholders&#8217; meeting is quorate if one-fourth of </span></div><div style="line-height:10pt;position:var(--position);top:490pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the holders of shares entitled to voting rights are present or vote by mail or by proxy or by authorized intermediary </span></div><div style="line-height:10pt;position:var(--position);top:500pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">or by any means of telecommunication. As an exception, an extraordinary shareholders&#8217; meeting deciding upon a </span></div><div style="line-height:10pt;position:var(--position);top:510pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">share capital increase by capitalization of reserves, profits or share premium as the same quorum requirement as an </span></div><div style="line-height:10pt;position:var(--position);top:520pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ordinary shareholders&#8217; meeting. If the requirements for a quorum are not satisfied, the meeting is adjourned. When </span></div><div style="line-height:10pt;position:var(--position);top:530pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">an adjourned ordinary shareholders&#8217; meeting is resumed, there is no quorum requirement. When an adjourned </span></div><div style="line-height:10pt;position:var(--position);top:540pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">extraordinary shareholders&#8217; meeting is resumed, there is a quorum of one-fifth of the holders of shares entitled to </span></div><div style="line-height:10pt;position:var(--position);top:550pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">voting rights. If a quorum is not present, the reconvened extraordinary shareholders&#8217; meeting may be adjourned for a </span></div><div style="line-height:10pt;position:var(--position);top:560pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">maximum of two months. No deliberation by the shareholders may take place without a quorum. For special </span></div><div style="line-height:10pt;position:var(--position);top:570pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">meetings of holders of a certain class of shares, the quorum requirement is one-third of the certain class of shares </span></div><div style="line-height:10pt;position:var(--position);top:580pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">entitled to voting rights for the meeting convened on the first call, notice and one-fifth of the holders of shares </span></div><div style="line-height:10pt;position:var(--position);top:590pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">entitled to voting rights, should the meeting be reconvened.&#160; </span></div><div style="line-height:10pt;position:var(--position);top:606pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">In addition, we have opted out of shareholder approval requirements for the issuance of securities in </span></div><div style="line-height:10pt;position:var(--position);top:616pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">connection with certain events such as the acquisition of stock or assets of another company, the establishment of or </span></div><div style="line-height:10pt;position:var(--position);top:626pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">amendments to equity-based compensation plans for employees, a change of control of us and certain private </span></div><div style="line-height:10pt;position:var(--position);top:636pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">placements. To this </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:152.45pt;position:var(--position);white-space:pre">extent</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:176.85pt;position:var(--position);text-decoration:none;white-space:pre">, our practice varies from the requirements of Nasdaq Listing Rule 5635, which generally </span></div><div style="line-height:10pt;position:var(--position);top:646pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">requires an issuer </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:144.42000000000002pt;position:var(--position);white-space:pre">to</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:152.19pt;position:var(--position);text-decoration:none;white-space:pre"> obtain shareholder approval for the issuance of securities in connection with such events.</span></div><div style="line-height:10pt;position:var(--position);top:668pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Under French law, the committees of our Board of Directors are advisory only, and where Nasdaq listing rules </span></div><div style="line-height:10pt;position:var(--position);top:678pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">would permit or require certain decision-making powers to reside with specific committees of the Board of </span></div><div style="line-height:10pt;position:var(--position);top:688pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Directors, French law vests such authority in our Board of Directors or shareholders. Additionally, under French </span></div><div style="line-height:10pt;position:var(--position);top:698pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">corporate law, it is the shareholders vote at the annual general meeting that have the authority to appoint our auditors </span></div><div style="line-height:10pt;position:var(--position);top:708pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">upon consideration of the proposal of our Board of Directors, although the charter of the Audit Committee provides </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">157</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">that the Audit Committee will review and make recommendations to the Board of Directors with respect to proposed </span></div><div style="line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">engagements of the Company&#8217;s independent auditors, prior to the commencement of such engagements.</span></div><div style="line-height:10pt;position:var(--position);top:98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We may choose to take advantage of additional exemptions and follow home country practices in lieu of </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Nasdaq rules in the future.</span></div><div style="position:absolute;top:140pt" id="i7a006daedb3d4216a4128b76247285d7_229"></div><div style="line-height:10pt;position:var(--position);top:140pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">Item 16H.<span style="display:inline-block;height:6.77pt;width:29.25pt"></span></span><span style="left:144pt;position:var(--position)">Mine Safety Disclosure</span><span id="i18640a52a27d412d91865c66bc841e5b"></span></span></div><div style="line-height:10pt;position:var(--position);top:164pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.5pt;position:var(--position);white-space:pre">Not applicable.</span></div><div style="position:absolute;top:188pt" id="i7a006daedb3d4216a4128b76247285d7_232"></div><div style="line-height:10pt;position:var(--position);top:188pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">Item 16I.<span style="display:inline-block;height:6.77pt;width:33.13pt"></span></span><span style="left:144pt;position:var(--position)">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span><span id="i1d00a4ce11604ea38478030d23e246c5"></span></span></div><div style="line-height:10pt;position:var(--position);top:212pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.5pt;position:var(--position);white-space:pre">Not applicable.</span></div><div style="position:absolute;top:236pt" id="i7a006daedb3d4216a4128b76247285d7_235"></div><div style="line-height:10pt;position:var(--position);top:236pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">Item 16J.<span style="display:inline-block;height:6.77pt;width:32.02pt"></span></span><span style="left:144pt;position:var(--position)">Insider Trading Policies</span><span id="i3477383588404220960707720441ccc9"></span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:254pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our board </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:139.81pt;position:var(--position);white-space:pre">of</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:148.14pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:150.64pt;position:var(--position);white-space:pre">directors</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:185.59pt;position:var(--position);text-decoration:none;white-space:pre"> has </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:203.91pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-44">adopted</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:235.54pt;position:var(--position);text-decoration:none;white-space:pre"> a Code of Market Conduct that governs the purchase, sale, and other </span></div><div style="line-height:10pt;position:var(--position);top:264pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">dispositions of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:133.07999999999998pt;position:var(--position);white-space:pre">our</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:146.41pt;position:var(--position);text-decoration:none;white-space:pre"> securities by directors, senior management, and employees that is reasonably designed to </span></div><div style="line-height:10pt;position:var(--position);top:274pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">promote compliance with applicable insider trading laws, rules and regulations, and any listing standards applicable </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:284pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to us. A copy of our Code of Market Conduct is fil</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:274.63pt;position:var(--position);text-decoration:none;white-space:pre">ed as Exhibit 11.1 to this Annual Report on Form 20-F.</span></div><div style="position:absolute;top:306pt" id="i7a006daedb3d4216a4128b76247285d7_238"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:306pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">Item 16K.<span style="display:inline-block;height:6.77pt;width:29.25pt"></span></span><span id="id5656c62ef694bc8855e8fa9b7fd2901"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:144pt;position:var(--position);text-decoration:none;white-space:pre">Cybersecurity</span></div><div style="line-height:10pt;position:var(--position);top:330pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);white-space:pre">Risk Management and Strategy</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:348pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="f-45" continuedAt="f-45-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We have implemented and maintain various information security processes designed to identify, assess and </span></ix:nonNumeric></div><ix:continuation id="f-45-1"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:358pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">manage material </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.76pt;position:var(--position);text-decoration:none;white-space:pre">risks</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:159.64pt;position:var(--position);text-decoration:none;white-space:pre"> from cybersecurity threats to our critical information systems, third party hosted services, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:368pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">communications systems, hardware and software, and our critical data (including intellectual property, confidential </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:378pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">information that is proprietary, strategic or competitive in nature, and data related to our clinical trials and products) </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:388pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(collectively, &#8220;Information Systems and Data&#8221;).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:404pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our Chief Financial Officer as well as our external Data Protection Officer (&#8220;DPO&#8221;) and Information </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:414pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Technology Director (&#8220;IT Director&#8221;), and other independent service providers help identify, assess and manage the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:424pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">our cybersecurity threats and risks. Individuals in these roles identify and assess risks from cybersecurity threats by </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:434pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">monitoring and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:135.84pt;position:var(--position);text-decoration:none;white-space:pre">evaluating</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:177.44pt;position:var(--position);text-decoration:none;white-space:pre"> our threat environment using various methods including, for example, maintaining </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:444pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">manual and automated tools, conducting scans of our threat environment, and conducting vulnerability assessments.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:460pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="f-46" continuedAt="f-46-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Depending on the environment, we implement and maintain various technical, physical, and organizational </span></ix:nonNumeric></div><ix:continuation id="f-46-1"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:470pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:480pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">threats to our Information Systems and Data. These measures, processes, standards, and policies include, for </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:490pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">example: incident </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:145.76999999999998pt;position:var(--position);text-decoration:none;white-space:pre">response</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:180.74pt;position:var(--position);text-decoration:none;white-space:pre"> plans and policies, personnel training, phishing test campaigns, penetration testing, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:500pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">system backups, cybersecurity insurance, network security controls, segmentation for certain systems and data </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:510pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">access controls and physical security controls.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:526pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true" id="f-47" continuedAt="f-47-1"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.55pt;position:var(--position);text-decoration:none;white-space:pre">assessment</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.94pt;position:var(--position);text-decoration:none;white-space:pre"> and management of material risks from cybersecurity threats are integrated into our overall </span></ix:nonNumeric></div><ix:continuation id="f-47-1"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:536pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">risk management processes.&#160; For example, our external DPO and IT Director work with management in an effort to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:546pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:556pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">impact to our business.</span></div></ix:continuation></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:572pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true" id="f-48" continuedAt="f-48-1"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true" id="f-49" continuedAt="f-49-1"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We use independent service provider</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:244.65pt;position:var(--position);text-decoration:none;white-space:pre">s</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:248.54pt;position:var(--position);text-decoration:none;white-space:pre"> to assist us from time to time to identify, assess, and manage material </span></ix:nonNumeric></ix:nonNumeric></div><ix:continuation id="f-48-1"><ix:continuation id="f-49-1"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:582pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">risks from </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:115.31pt;position:var(--position);text-decoration:none;white-space:pre">cybersecurity</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:169.12pt;position:var(--position);text-decoration:none;white-space:pre"> threats, including for example: professional service firms, including legal counsel, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:592pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">penetration testing firms, dark web monitoring services, cybersecurity consultants, and cybersecurity software </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:602pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">providers.</span></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:624pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Further, we use independent service providers to perform a variety of functions throughout our business, such </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:634pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">as hosting companies and contract research organizations. We undertake efforts designed to manage cybersecurity </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:644pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">risks associated with our use of these providers.&#160; For certain vendors, these efforts include security questionnaires, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:654pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reviews of vendors&#8217; written security programs, reviews of security assessments, audits, and vulnerability scans </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:664pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">related to the vendors. Depending on the nature of the services provided, the sensitivity of the Information Systems </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:674pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and Data at issue, and the identity of the provider, our vendor management process may involve different levels of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:684pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">assessment designed to help identify cybersecurity risks associated with a provider and impose contractual </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:694pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">obligations related to cybersecurity on the provider.</span></div></ix:continuation></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">158</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:72pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false" id="f-50" continuedAt="f-50-1"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">For a description of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:177.54000000000002pt;position:var(--position);text-decoration:none;white-space:pre">the</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:189.74pt;position:var(--position);text-decoration:none;white-space:pre"> risks from cybersecurity threats that may materially affect the Company and how they </span></ix:nonNumeric></div><ix:continuation id="f-50-1"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">may do so, see our </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:149.17000000000002pt;position:var(--position);text-decoration:none;white-space:pre">risk</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:164.16pt;position:var(--position);text-decoration:none;white-space:pre"> factors under "Part I&#8212;Item 3D.&#8212;Risk Factors" in this Annual Report on Form 20-F, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">including &#8220;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:116.67pt;position:var(--position);text-decoration:none;white-space:pre">If our information technology systems or those of the third parties with whom we work, or our data are or </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:102pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">were compromised, we could experience adverse consequences resulting from such compromise, including but not </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:112pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">limited to: regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:122pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reputational harm; loss of revenue and profits; and other adverse consequences.&#8221;</span></div></ix:continuation><div style="line-height:10pt;position:var(--position);top:144pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:var(--position);white-space:pre">Governance</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:160pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="f-52" continuedAt="f-52-1" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-51" continuedAt="f-51-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our Board addresses our cybersecurity risk management as part of its general oversight function. The Board is </span></ix:nonNumeric></ix:nonNumeric></div><ix:continuation id="f-52-1"><ix:continuation id="f-51-1"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:170pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:180pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">from cybersecurity threats.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:179.36pt;position:var(--position);text-decoration:none;white-space:pre"> Our</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:197.41pt;position:var(--position);text-decoration:none;white-space:pre"> Committee of Executives (&#8220;COMEX&#8221;)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:355.54pt;position:var(--position);text-decoration:none;white-space:pre">, in addition to those identified below, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:190pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">provides </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108.92pt;position:var(--position);text-decoration:none;white-space:pre">input</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.46pt;position:var(--position);text-decoration:none;white-space:pre"> to the Board on cybersecurity threats. Our Committee of Executives consists of all our company's </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:200pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">officers along with our heads of manufacturing and quality.</span></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:216pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="f-54" continuedAt="f-54-1" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="f-53" continuedAt="f-53-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our cybersecurity risk assessment and management processes are implemented and maintained by certain </span></ix:nonNumeric></ix:nonNumeric></div><ix:continuation id="f-53-1"><ix:continuation id="f-54-1"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:226pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">management team members, including our</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:242.62pt;position:var(--position);text-decoration:none;white-space:pre"> <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true" id="f-55">Chief Financial Officer (&#8220;CFO&#8221;)</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:375.77pt;position:var(--position);text-decoration:none;white-space:pre"> who oversees our external </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.38pt;position:var(--position);text-decoration:none;white-space:pre">IT Director </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:236pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and DPO</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108.93pt;position:var(--position);text-decoration:none;white-space:pre">. </span><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="f-56" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.93pt;position:var(--position);text-decoration:none;white-space:pre">Our </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:131.98pt;position:var(--position);text-decoration:none;white-space:pre">CFO</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:151.42000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> has prior significant experience in strategic business operations</span></ix:nonNumeric><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:406.66pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:252pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our CFO as </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:147.31pt;position:var(--position);text-decoration:none;white-space:pre">well</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:164.5pt;position:var(--position);text-decoration:none;white-space:pre"> as our external IT Director and DPO are responsible for helping to integrate cybersecurity </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:262pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">risk considerations into our overall risk management strategy, and communicating key priorities to relevant </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:272pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">personnel. Our CFO is responsible for approving cybersecurity-related budgets, approving cybersecurity processes, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:282pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and reviewing security assessments and other security-related reports.</span></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:298pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="f-58" continuedAt="f-58-1" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-57" continuedAt="f-57-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our cybersecurity incident response procedures are designed to escalate certain cybersecurity incidents to </span></ix:nonNumeric></ix:nonNumeric></div><ix:continuation id="f-58-1"><ix:continuation id="f-57-1" continuedAt="f-57-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:308pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">members of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:121.95pt;position:var(--position);text-decoration:none;white-space:pre">management</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:172.98000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> depending on circumstances, including our CFO. Our CFO works with our incident </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:318pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">responders (such as the external IT Director and DPO) to help us mitigate and remediate cybersecurity incidents of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:328pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">which they are notified.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:166.88pt;position:var(--position);text-decoration:none;white-space:pre"> In addition, our incident response process includes reporting to the Board for certain </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:338pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">cybersecurity incidents.</span></div></ix:continuation></ix:continuation></ix:continuation><ix:continuation id="f-57-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:354pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true" id="f-59"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The Board </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:141.45pt;position:var(--position);text-decoration:none;white-space:pre">receives</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:174.16pt;position:var(--position);text-decoration:none;white-space:pre"> periodic communications from the CFO and others (such as the IT Director and DPO)</span></ix:nonNumeric><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:520.48pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:364pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">concerning our significant cybersecurity threats, risk and the processes we have implemented in an effort to address </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:374pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">them.</span></div></ix:continuation></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">159</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_241"></div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:285.31pt;position:var(--position);text-decoration:none;white-space:pre">PART III<span id="i8af2598290454e508a5b4a9567a69f9b"></span></span></div><div style="position:absolute;top:108pt" id="i7a006daedb3d4216a4128b76247285d7_244"></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">Item 17.<span style="display:inline-block;height:6.77pt;width:1.02pt"></span></span><span style="left:108pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:36pt"></span></span><span style="left:144pt;position:var(--position)">Financial Statements</span><span id="i08a771d6c5d34609b9358f3317868108"></span></span></div><div style="line-height:10pt;position:var(--position);top:126pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);white-space:pre">See </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.42pt;position:var(--position);text-decoration:none;white-space:pre">response</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:148.39pt;position:var(--position);white-space:pre"> to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:161.16pt;position:var(--position);text-decoration:none;white-space:pre">Item</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:179.45999999999998pt;position:var(--position);white-space:pre"> 18.</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">160</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_247"></div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">Item 18.<span style="display:inline-block;height:6.77pt;width:1.02pt"></span></span><span style="left:108pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:36pt"></span></span><span style="left:144pt;position:var(--position)">Financial Statements</span><span id="i5612c3da844146c6969843b8cdd93991"></span></span></div><div style="line-height:10pt;position:var(--position);top:96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.5pt;position:var(--position);white-space:pre">See pages F-1 through F-79 of this Annual Report on Form 20-F.</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="-sec-extract:summary;position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">161</span></div></div></div><div style="-sec-extract:summary;position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_250"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:72pt;position:var(--position)">Item 19.<span style="display:inline-block;height:6.77pt;width:1.02pt"></span></span><span style="left:108pt;position:var(--position)"><span style="display:inline-block;height:6.77pt;width:36pt"></span></span><span id="i358eba766ca24ae98940620872dbb5ed"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:144pt;position:var(--position);text-decoration:none;white-space:pre">Exhibits</span></div><div style="line-height:10pt;position:var(--position);top:96pt;width:612pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The following exhibits are filed herewith or incorporated herein by reference:</span></div><div style="position:var(--position);top:120pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:480pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:45.75pt"/><td style="padding:0;width:434.25pt"/></tr><tr style="height:26.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Exhibit </span></div><div style="line-height:10pt;position:var(--position);top:14.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Number</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:45.75pt;position:var(--position);width:434.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:434.25pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Description of Exhibit</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:26.25pt;width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">1.1*</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:45.75pt;position:var(--position);top:26.25pt;width:434.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="abivax-20xfxex11bylaws6feb.htm">By-laws (statuts) of the registrant (English translation)</a></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:40.5pt;width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2.1*</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:45.75pt;position:var(--position);top:40.5pt;width:434.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="abivax-20xfxex21descriptio.htm">Description of Securities</a></span></div></div></div></td></tr><tr style="height:24.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2.2</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:45.75pt;position:var(--position);top:54.75pt;width:434.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:434.25pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Form of Deposit Agreement (incorporated by reference to Exhibit (a) to the Form F-6 Registration </span></div><div style="line-height:10pt;position:var(--position);top:13.83pt;width:434.25pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Statement (File No. 333-274845), filed with the Commission on October 3, 2023)</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:79.5pt;width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2.3</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:45.75pt;position:var(--position);top:79.5pt;width:434.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:434.25pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Form of American Depositary Receipt (included in Exhibit 2.2)</span></div></div></div></td></tr><tr style="height:36pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:93.75pt;width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">4.1 &#x5E;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:45.75pt;position:var(--position);top:93.75pt;width:434.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="https://www.sec.gov/Archives/edgar/data/0001956827/000119312523247378/d609070dex107.htm">Terms and Conditions of the Royalty Certificates issued by Abivax SA dated August 31, 2022 </a></span></div><div style="line-height:10pt;position:var(--position);top:13.83pt;width:434.25pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(incorporated by reference to Exhibit 10.7 of the Company&#8217;s Registration Statement on Form F-1 (File No. </span></div><div style="line-height:10pt;position:var(--position);top:25.03pt;width:434.25pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">333-274780) filed with the Commission on September 29, 2023)</span></div></div></div></td></tr><tr style="height:36pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:129.75pt;width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">4.2 &#x5E;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:45.75pt;position:var(--position);top:129.75pt;width:434.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="https://www.sec.gov/Archives/edgar/data/0001956827/000119312523247378/d609070dex108.htm">Drug Discovery Services Agreement between Abivax SA and Evotec International GmbH dated </a></span></div><div style="line-height:10pt;position:var(--position);top:13.83pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="https://www.sec.gov/Archives/edgar/data/0001956827/000119312523247378/d609070dex108.htm">September 1, 2017 </a></span><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:80.35pt;position:var(--position);text-decoration:none;white-space:pre">(incorporated by reference to Exhibit 10.8 of the Company&#8217;s Registration Statement on </span></div><div style="line-height:10pt;position:var(--position);top:25.03pt;width:434.25pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Form F-1 (File No. 333-274780) filed with the Commission on September 29, 2023)</span></div></div></div></td></tr><tr style="height:36pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:165.75pt;width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">4.3 &#x5E;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:45.75pt;position:var(--position);top:165.75pt;width:434.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="https://www.sec.gov/Archives/edgar/data/0001956827/000119312523247378/d609070dex109.htm">Amendment No. 1 to Drug Discovery Services Agreement between Abivax SA and Evotec International </a></span></div><div style="line-height:10pt;position:var(--position);top:13.83pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="https://www.sec.gov/Archives/edgar/data/0001956827/000119312523247378/d609070dex109.htm">GmbH dated January 1, 2022 </a></span><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:122.55pt;position:var(--position);text-decoration:none;white-space:pre">(incorporated by reference to Exhibit 10.9 of the Company&#8217;s Registration </span></div><div style="line-height:10pt;position:var(--position);top:25.03pt;width:434.25pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Statement on Form F-1 (File No. 333-274780) filed with the Commission on September 29, 2023)</span></div></div></div></td></tr><tr style="height:36pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:201.75pt;width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">4.4 &#x5E;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:45.75pt;position:var(--position);top:201.75pt;width:434.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="https://www.sec.gov/Archives/edgar/data/0001956827/000119312523247378/d609070dex1010.htm">Manufacturing Agreement between Abivax SA and Delpharm Lille S.A.S. dated November 24, 2016 </a></span></div><div style="line-height:10pt;position:var(--position);top:13.83pt;width:434.25pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(incorporated by reference to Exhibit 10.10 of the Company&#8217;s Registration Statement on Form F-1 (File </span></div><div style="line-height:10pt;position:var(--position);top:25.03pt;width:434.25pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">No. 333-274780) filed with the Commission on September 29, 2023)</span></div></div></div></td></tr><tr style="height:47.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:237.75pt;width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">4.5 &#x5E;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:45.75pt;position:var(--position);top:237.75pt;width:434.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="https://www.sec.gov/Archives/edgar/data/0001956827/000119312523247378/d609070dex1011.htm">Clinical Batch and Development Production Agreement between Abivax SA and Produits Chimiques </a></span></div><div style="line-height:10pt;position:var(--position);top:13.83pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="https://www.sec.gov/Archives/edgar/data/0001956827/000119312523247378/d609070dex1011.htm">Auxiliaires et de Synth&#232;se dated March 11, 2016 </a></span><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:199.93pt;position:var(--position);text-decoration:none;white-space:pre">(incorporated by reference to Exhibit 10.11 of the </span></div><div style="line-height:10pt;position:var(--position);top:25.03pt;width:434.25pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Company&#8217;s Registration Statement on Form F-1 (File No. 333-274780) filed with the Commission on </span></div><div style="line-height:10pt;position:var(--position);top:36.23pt;width:434.25pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">September 29, 2023)</span></div></div></div></td></tr><tr style="height:47.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:285pt;width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">4.6 &#x5E;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:45.75pt;position:var(--position);top:285pt;width:434.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="https://www.sec.gov/Archives/edgar/data/0001956827/000119312523247378/d609070dex1012.htm">Amendment No. 1 to Clinical Batch and Development Production Agreement between Abivax SA and </a></span></div><div style="line-height:10pt;position:var(--position);top:13.83pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="https://www.sec.gov/Archives/edgar/data/0001956827/000119312523247378/d609070dex1012.htm">Produits Chimiques Auxiliaires et de Synth&#232;se dated March 2, 2021 </a></span><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:276.54pt;position:var(--position);text-decoration:none;white-space:pre">(incorporated by reference to Exhibit </span></div><div style="line-height:10pt;position:var(--position);top:25.03pt;width:434.25pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">10.12 of the Company&#8217;s Registration Statement on Form F-1 (File No. 333-274780) filed with the </span></div><div style="line-height:10pt;position:var(--position);top:36.23pt;width:434.25pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Commission on September 29, 2023)</span></div></div></div></td></tr><tr style="height:36pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:332.25pt;width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">4.7 &#x5E;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:45.75pt;position:var(--position);top:332.25pt;width:434.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="https://www.sec.gov/Archives/edgar/data/0001956827/000119312523247378/d609070dex1013.htm">State-guaranteed loan agreement between Abivax SA and Soci&#233;t&#233; General dated June 16, 2020 </a></span></div><div style="line-height:10pt;position:var(--position);top:13.83pt;width:434.25pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(incorporated by reference to Exhibit 10.13 of the Company&#8217;s Registration Statement on Form F-1 (File </span></div><div style="line-height:10pt;position:var(--position);top:25.03pt;width:434.25pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">No. 333-274780) filed with the Commission on September 29, 2023)</span></div></div></div></td></tr><tr style="height:36pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:368.25pt;width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">4.8 &#x5E;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:45.75pt;position:var(--position);top:368.25pt;width:434.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="https://www.sec.gov/Archives/edgar/data/0001956827/000119312523247378/d609070dex1014.htm">Amendment No.1 to State-guaranteed loan between Abivax SA and Soci&#233;t&#233; General dated March 15, 2021 </a></span></div><div style="line-height:10pt;position:var(--position);top:13.83pt;width:434.25pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(incorporated by reference to Exhibit 10.14 of the Company&#8217;s Registration Statement on Form F-1 (File </span></div><div style="line-height:10pt;position:var(--position);top:25.03pt;width:434.25pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">No. 333-274780) filed with the Commission on September 29, 2023)</span></div></div></div></td></tr><tr style="height:47.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:404.25pt;width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">4.9 &#x5E;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:45.75pt;position:var(--position);top:404.25pt;width:434.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="https://www.sec.gov/Archives/edgar/data/0001956827/000119312523247378/d609070dex1015.htm">Royalties Agreement with the French National Centre for Scientific Research, the University of </a></span></div><div style="line-height:10pt;position:var(--position);top:13.83pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="https://www.sec.gov/Archives/edgar/data/0001956827/000119312523247378/d609070dex1015.htm">Montpellier, and the Institut Curie dated December 18, 2008 </a></span><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:247.07999999999998pt;position:var(--position);text-decoration:none;white-space:pre">(incorporated by reference to Exhibit 10.15 of </span></div><div style="line-height:10pt;position:var(--position);top:25.03pt;width:434.25pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">the Company&#8217;s Registration Statement on Form F-1 (File No. 333-274780) filed with the Commission on </span></div><div style="line-height:10pt;position:var(--position);top:36.23pt;width:434.25pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">September 29, 2023)</span></div></div></div></td></tr><tr style="height:24.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:451.5pt;width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">4.10*</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:45.75pt;position:var(--position);top:451.5pt;width:434.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="abivax-20xfxex416summaryof.htm">Summary of BSA 2015-11, BSA 2015-12, BSA 2017-1, BSA 2018-1, BSA 2024-1, BSA 2024-2, </a></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:13.83pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="abivax-20xfxex416summaryof.htm">BSA-2025-1, BSA-2025-2, BSA-2025-3, and BSA 2026-1 Plans</a></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:476.25pt;width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">4.11*</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:45.75pt;position:var(--position);top:476.25pt;width:434.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="abivax-20xfxex417summaryof.htm">Summary of BCE 2017-1, BCE 2017-2, BCE 2017-4, BCE 2017-5 and BCE 2018-4 Plans</a></span></div></div></div></td></tr><tr style="height:47.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:490.5pt;width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">4.12*</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:45.75pt;position:var(--position);top:490.5pt;width:434.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="abivax-20xfxex418summaryof.htm">Summary of AGA-2023-1, AGA-2023-2, AGA-2023-3, AGA-2023-4, AGA-2023-5, AGA-2024-1, </a></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:13.83pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="abivax-20xfxex418summaryof.htm">AGA-2024-2, AGA-2024-3, AGA-2024-4, AGA-2024-5, AGA-2024-6, AGA-2024-7, AGA-2025-1, </a></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:25.03pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="abivax-20xfxex418summaryof.htm">AGA-2025-2, AGA 2025-3, AGA-2025-4, AGA-2025-5, AGA-2025-6, AGA-2025-7, AGA-2025-8, and </a></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:36.23pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="abivax-20xfxex418summaryof.htm">AGA-2026-1 Free Share Plans</a></span></div></div></div></td></tr><tr style="height:36pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:537.75pt;width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">4.13</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:45.75pt;position:var(--position);top:537.75pt;width:434.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:434.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Equity Distribution Agreement, dated as of November&#160; 19, 2024, by and between the registrant and Piper </span></div><div style="line-height:10pt;position:var(--position);top:13.83pt;width:434.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Sandler &amp; Co. (incorporated by reference to Exhibit 1.2 of the Company's Registration Statement on Form </span></div><div style="line-height:10pt;position:var(--position);top:25.03pt;width:434.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">F-3 (File No. 333-283336) filed with the Commission on November 19, 2025)</span></div></div></div></td></tr></tbody></table></div></div></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="-sec-extract:summary;position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">162</span></div></div></div><div style="-sec-extract:summary;position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:var(--position);top:72pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:480pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:45.75pt"/><td style="padding:0;width:434.25pt"/></tr><tr style="height:36pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">8.1</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:45.75pt;position:var(--position);width:434.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:434.25pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">List of subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 of the Company&#8217;s </span></div><div style="line-height:10pt;position:var(--position);top:13.83pt;width:434.25pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Registration Statement on Form F-1 (File No. 333-274780) filed with the Commission on September 29, </span></div><div style="line-height:10pt;position:var(--position);top:25.03pt;width:434.25pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2023)</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:36pt;width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">11.1*</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:45.75pt;position:var(--position);top:36pt;width:434.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="a03abivax-ipoxboardbookxco.htm">Abivax Code of Market Conduct</a></span></div></div></div></td></tr><tr style="height:24.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:50.25pt;width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">12.1*</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:45.75pt;position:var(--position);top:50.25pt;width:434.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="abivax-202520xfxex121ceo.htm">Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and </a></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:13.83pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="abivax-202520xfxex121ceo.htm">15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></div></div></td></tr><tr style="height:24.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:75pt;width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">12.2*</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:45.75pt;position:var(--position);top:75pt;width:434.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="abivax-202520xfxex122cfo.htm">Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and </a></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:13.83pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="abivax-202520xfxex122cfo.htm">15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></div></div></td></tr><tr style="height:24.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:99.75pt;width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">13.1**</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:45.75pt;position:var(--position);top:99.75pt;width:434.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="abivax-202520xfxex131ceo.htm">Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to </a></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:13.83pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="abivax-202520xfxex131ceo.htm">Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></div></div></td></tr><tr style="height:24.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:124.5pt;width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">13.2**</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:45.75pt;position:var(--position);top:124.5pt;width:434.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="abivax-202520xfxex132cfo.htm">Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to </a></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:13.83pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="abivax-202520xfxex132cfo.htm">Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:149.25pt;width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">15.1*</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:45.75pt;position:var(--position);top:149.25pt;width:434.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="pwc_consentx20-fxfy25.htm">Consent of PricewaterhouseCoopers Audit, independent registered accounting firm</a></span></div></div></div></td></tr><tr style="height:24.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:163.5pt;width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">97.1*</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:45.75pt;position:var(--position);top:163.5pt;width:434.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="https://www.sec.gov/Archives/edgar/data/1956827/000195682725000010/abivax-20xfxex971incentive.htm">Incentive Compensation Recoupment Policy (incorporated by reference to Exhibit 97.1 of the Company's </a></span></div><div style="line-height:10pt;position:var(--position);top:13.83pt;width:434.25pt"><span style="color:#0000ff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="https://www.sec.gov/Archives/edgar/data/1956827/000195682725000010/abivax-20xfxex971incentive.htm">Annual Report on Form 20-F (File No. 001-41842) filed with the Commission on March 24, 2025)</a></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:188.25pt;width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">101.INS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:45.75pt;position:var(--position);top:188.25pt;width:434.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:434.25pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Inline XBRL Instance Document</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:202.5pt;width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">101.SCH</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:45.75pt;position:var(--position);top:202.5pt;width:434.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:434.25pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">I</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:5.96pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">nline XBRL Taxonomy Extension Schema Document</span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:216.75pt;width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">101.CAL</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:45.75pt;position:var(--position);top:216.75pt;width:434.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:434.25pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:231pt;width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">101.DEF</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:45.75pt;position:var(--position);top:231pt;width:434.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:434.25pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:245.25pt;width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">101.LAB</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:45.75pt;position:var(--position);top:245.25pt;width:434.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:434.25pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Inline XBRL Taxonomy Extension Label Linkbase Document</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:259.5pt;width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">101.PRE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:45.75pt;position:var(--position);top:259.5pt;width:434.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:434.25pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:273.75pt;width:45.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:45.75pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">104</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:45.75pt;position:var(--position);top:273.75pt;width:434.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:434.25pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></div></div></div></td></tr></tbody></table></div></div></div><div style="line-height:10pt;position:var(--position);top:376.5pt;width:612pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">*&#160; &#160;  Filed herewith. </span></div><div style="line-height:10pt;position:var(--position);top:388.5pt;width:612pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">**&#160;  Furnished herewith.</span></div><div style="line-height:10pt;position:var(--position);top:400.5pt;width:612pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">#&#160; &#160;  Indicates a management contract or compensatory plan, contract or arrangement</span></div><div style="line-height:10pt;position:var(--position);top:412.5pt;width:612pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#x5E;&#160; &#160; &#160; &#160; &#160; &#160; Certain information has been excluded from this exhibit (indicated by &#8220;[***]&#8221;) because it is both not </span></div><div style="line-height:10pt;position:var(--position);top:423.7pt;width:612pt"><span style="color:#008080;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">material and is the type that the registrant treats as private or confidential.</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.5pt;position:var(--position);text-decoration:none;white-space:pre">163</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_253"></div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:273.51pt;position:var(--position);text-decoration:none;white-space:pre">SIGNATURES<span id="ibef2644fce1c434982fa363e312aa70a"></span></span></div><div style="line-height:10pt;position:var(--position);top:96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:99pt;position:var(--position);white-space:pre">The registrant hereby certifies that it meets all of the requirements for filing this Annual Report on Form 20-F </span></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.</span></div><div style="line-height:10pt;position:var(--position);top:132pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:351pt;position:var(--position);white-space:pre">ABIVAX SA</span></div><div style="line-height:10pt;position:var(--position);top:156pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:351pt;position:var(--position);white-space:pre">By: </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:367.93pt;position:var(--position);text-decoration:underline;white-space:pre">/s/ Marc de Garidel</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;white-space:pre"><span style="left:447.02pt;position:var(--position)"><span style="display:inline-block;height:6.94pt;width:11.98pt"></span></span><span style="left:459pt;position:var(--position)"><span style="display:inline-block;height:6.94pt;width:36pt"></span></span></span></div><div style="line-height:10pt;position:var(--position);top:168pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:351pt;position:var(--position);white-space:pre">&#160; &#160; &#160;  Marc de Garidel</span></div><div style="line-height:10pt;position:var(--position);top:180pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:351pt;position:var(--position);white-space:pre">&#160; &#160; &#160;  </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:368.5pt;position:var(--position);white-space:pre">Chief Executive Officer</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:204pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">Date: </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.12pt;position:var(--position);text-decoration:none;white-space:pre">March 23, 202</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:154.7pt;position:var(--position);white-space:pre">6</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:299.05pt;position:var(--position);white-space:pre">F-1</span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_256"></div><div style="position:absolute;top:102pt" id="i7a006daedb3d4216a4128b76247285d7_259"></div><div style="line-height:10pt;position:var(--position);top:103pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:174.68pt;position:var(--position);text-decoration:none;white-space:pre">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS<span id="ia53cad4fb38d40818f1bea8325c58d2b"></span></span></div><div style="position:var(--position);top:158.75pt;width:612pt"><span style="font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:523.45pt;position:var(--position);text-decoration:none;white-space:pre">&#8195;</span><div style="font-size:0pt;left:86.2pt;position:var(--position);width:437.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:395.25pt"/><td style="padding:0;width:42pt"/></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:395.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:3.67pt;width:395.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i7a006daedb3d4216a4128b76247285d7_262">Report of Independent Registered Public Accounting Firm</a></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:236.82999999999998pt;position:var(--position);text-decoration:none;white-space:pre"> (PCAOB ID No. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:308.75pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-60">1347</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:328.75pt;position:var(--position);text-decoration:none;white-space:pre">)</span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:332.08pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:332.37pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:332.52pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:332.56pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:332.58pt;position:var(--position);text-decoration:none;white-space:pre">........................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:395.25pt;position:var(--position);width:42pt"><div><div style="line-height:10pt;position:var(--position);top:3.67pt;width:42pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">F-</span><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:11.52pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i7a006daedb3d4216a4128b76247285d7_262">2</a></span></div></div></div></td></tr><tr style="height:35.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:14.25pt;width:395.25pt"><div><div style="line-height:10pt;position:var(--position);top:24.67pt;width:395.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i7a006daedb3d4216a4128b76247285d7_268">Consolidated Statements of Financial Position</a></span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:187.42pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:187.57pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:187.60999999999999pt;position:var(--position);text-decoration:none;white-space:pre">..................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:395.25pt;position:var(--position);top:14.25pt;width:42pt"><div><div style="line-height:10pt;position:var(--position);top:24.67pt;width:42pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">F-</span><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:11.52pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i7a006daedb3d4216a4128b76247285d7_268">3</a></span></div></div></div></td></tr><tr style="height:35.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:49.5pt;width:395.25pt"><div><div style="line-height:10pt;position:var(--position);top:24.67pt;width:395.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i7a006daedb3d4216a4128b76247285d7_271">Consolidated Statements of Income (Loss)</a></span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:173pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:174.16pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:174.74pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:174.89pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:174.93pt;position:var(--position);text-decoration:none;white-space:pre">.......................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:395.25pt;position:var(--position);top:49.5pt;width:42pt"><div><div style="line-height:10pt;position:var(--position);top:24.67pt;width:42pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">F-</span><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:11.52pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i7a006daedb3d4216a4128b76247285d7_271">4</a></span></div></div></div></td></tr><tr style="height:35.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:84.75pt;width:395.25pt"><div><div style="line-height:10pt;position:var(--position);top:24.67pt;width:395.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i7a006daedb3d4216a4128b76247285d7_274">Consolidated Statements of Comprehensive Income (Loss)</a></span><span style="font-family:'Times New Roman', serif;font-size:4.64pt;font-style:normal;font-weight:normal;left:238.21pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:239.37pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:239.66pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.32pt;font-style:normal;font-weight:normal;left:239.81pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:239.89pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:239.93pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:239.95pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:239.96pt;position:var(--position);text-decoration:none;white-space:pre">.............................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:395.25pt;position:var(--position);top:84.75pt;width:42pt"><div><div style="line-height:10pt;position:var(--position);top:24.67pt;width:42pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">F-</span><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:11.52pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i7a006daedb3d4216a4128b76247285d7_274">5</a></span></div></div></div></td></tr><tr style="height:35.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:120pt;width:395.25pt"><div><div style="line-height:10pt;position:var(--position);top:24.67pt;width:395.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i7a006daedb3d4216a4128b76247285d7_277">Consolidated Statements of Changes in Shareholders&#8217; Equity</a></span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:246.82pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:247.4pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:247.54999999999998pt;position:var(--position);text-decoration:none;white-space:pre">..........................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:395.25pt;position:var(--position);top:120pt;width:42pt"><div><div style="line-height:10pt;position:var(--position);top:24.67pt;width:42pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">F-</span><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:11.52pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i7a006daedb3d4216a4128b76247285d7_277">6</a></span></div></div></div></td></tr><tr style="height:35.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:155.25pt;width:395.25pt"><div><div style="line-height:10pt;position:var(--position);top:24.67pt;width:395.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i7a006daedb3d4216a4128b76247285d7_280">Consolidated Statements of Cash Flows</a></span><span style="font-family:'Times New Roman', serif;font-size:2.32pt;font-style:normal;font-weight:normal;left:161.92pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.16pt;font-style:normal;font-weight:normal;left:162.5pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:162.54pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:162.56pt;position:var(--position);text-decoration:none;white-space:pre">............................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:395.25pt;position:var(--position);top:155.25pt;width:42pt"><div><div style="line-height:10pt;position:var(--position);top:24.67pt;width:42pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">F-</span><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:11.52pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i7a006daedb3d4216a4128b76247285d7_280">7</a></span></div></div></div></td></tr><tr style="height:35.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:190.5pt;width:395.25pt"><div><div style="line-height:10pt;position:var(--position);top:24.67pt;width:395.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i7a006daedb3d4216a4128b76247285d7_283">Notes to the Consolidated Financial Statements</a></span><span style="font-family:'Times New Roman', serif;font-size:1.18pt;font-style:normal;font-weight:normal;left:192.10999999999999pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.6pt;font-style:normal;font-weight:normal;left:192.4pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.08pt;font-style:normal;font-weight:normal;left:192.54999999999998pt;position:var(--position);white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:0.04pt;font-style:normal;font-weight:normal;left:192.57pt;position:var(--position);white-space:pre"> </span><span style="color:#b4b4b4;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:192.57999999999998pt;position:var(--position);text-decoration:none;white-space:pre">................................................................................</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:395.25pt;position:var(--position);top:190.5pt;width:42pt"><div><div style="line-height:10pt;position:var(--position);top:24.67pt;width:42pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">F-</span><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:11.52pt;position:var(--position);text-decoration:none;white-space:pre"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#i7a006daedb3d4216a4128b76247285d7_283">8</a></span></div></div></div></td></tr></tbody></table></div></div></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:299.05pt;position:var(--position)">F-2<span style="display:inline-block;height:6.93pt;width:22.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_262"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:180.83pt;position:var(--position);text-decoration:none;white-space:pre">Report of Independent Registered Public Accounting Firm<span id="i1a98d94c305a4e40a6df83c8ed083a73"></span></span></div><div style="position:absolute;top:108pt" id="i7a006daedb3d4216a4128b76247285d7_265"></div><div style="line-height:10pt;position:var(--position);top:108pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">To the Board of Directors and Shareholders of Abivax SA</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:133pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);white-space:pre;width:52.21pt">Opinion on t</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:124.21000000000001pt;position:var(--position);text-decoration:none;white-space:pre;width:100.46pt">he Financial Statements</span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:158pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:467.9pt">We have audited the accompanying consolidated statements of financial position of Abivax SA and its subsidiary</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.9pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:169.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:467.91pt">(the &#8220;Company&#8221;) as of December 31, 2025, 2024 and 2023, and the related consolidated statements of income (loss),</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.9100000000001pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:180.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:467.9pt">comprehensive income (loss), changes in shareholders&#8217; equity and cash flows for each of the three years in the</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.9pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:191.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:467.97pt">period ended December 31, 2025, including the related notes (collectively referred to as the &#8220;consolidated financial</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.97pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:202.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:467.97pt">statements&#8221;).&#160; In our opinion, the consolidated financial statements present fairly, in all material respects, the</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.97pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:214pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:467.89pt">financial position of the Company as of December 31, 2025, 2024 and 2023, and the results of its operations and its</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.89pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:225.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:467.88pt">cash flows for each of the three years in the period ended December 31, 2025 in conformity with International</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.88pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:236.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:467.97pt">Financial Reporting Standards as issued by the International Accounting Standards Board and International</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.97pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:247.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:264.46pt">Financial Reporting Standards as adopted by the European Union.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:336.46pt;position:var(--position);white-space:pre;width:5pt">&#160; </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:270.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:72pt;position:var(--position);white-space:pre;width:73.31pt">Basis for Opinion</span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:293pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:467.89pt">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.89pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:304.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:467.87pt">to express an opinion on the Company&#8217;s consolidated financial statements based on our audits.&#160; We are a public</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.87pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:315.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:467.87pt">accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.87pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:326.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:467.9pt">required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.9pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:337.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:375.97pt">applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:360.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:467.98pt">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.98pt;position:var(--position);white-space:pre;width:5pt">&#160; </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:371.7pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:467.89pt">Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.89pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:382.9pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:467.87pt">consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.87pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:394.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:467.82pt">not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.&#160; As</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.8199999999999pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:405.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:468pt">part of our audits we are required to obtain an understanding of internal control over financial reporting but not for</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:540pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:416.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:467.96pt">the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.96pt;position:var(--position);white-space:pre;width:5pt">&#160; </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:427.7pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:167.93pt">Accordingly, we express no such opinion.</span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:450.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:468pt">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:540pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:461.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:467.84pt">statements, whether due to error or fraud, and performing procedures that respond to those risks.&#160; Such procedures</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.8399999999999pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:472.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:467.9pt">included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.9pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:484pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:467.91pt">statements.&#160; Our audits also included evaluating the accounting principles used and significant estimates made by</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.9100000000001pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:495.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:467.89pt">management, as well as evaluating the overall presentation of the consolidated financial statements.&#160; We believe that</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.89pt;position:var(--position);white-space:pre;width:2.5pt"> </span></div><div style="line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:506.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre;width:212.87pt">our audits provide a reasonable basis for our opinion.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:545.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">/s/ </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:83.93pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-61">PricewaterhouseCoopers Audit</ix:nonNumeric></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:556.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-62">Neuilly-sur-Seine, France</ix:nonNumeric></span></div><div style="line-height:10pt;position:var(--position);top:567.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">March 23, 2026</span></div><div style="line-height:10pt;position:var(--position);top:592.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);white-space:pre">We have served as the Company's auditor since 2013.</span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:299.05pt;position:var(--position)">F-3<span style="display:inline-block;height:6.93pt;width:22.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_268"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:138.03pt;position:var(--position);text-decoration:none;white-space:pre">ABIVAX SA CONSOLIDATED <span id="ifc01074a45774f568e3f5d92cd724799"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:278.81pt;position:var(--position);text-decoration:none;white-space:pre">STATEMENTS </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:349.6pt;position:var(--position);text-decoration:none;white-space:pre">OF </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:365.97pt;position:var(--position);text-decoration:none;white-space:pre">FINANCIAL POSITION</span></div><div style="position:var(--position);top:96pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:465pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:156pt"/><td style="padding:0;width:75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:75pt"/></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:156pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:25.58pt;position:var(--position);text-decoration:none;white-space:pre">(Amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:27.95pt;position:var(--position);text-decoration:none;white-space:pre">Notes</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.84pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.5pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.84pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.5pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.84pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.5pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:30.75pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">ASSETS</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-current assets</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Goodwill</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:35.5pt;position:var(--position);text-decoration:none;white-space:pre">6</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-63">18,419</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-64">18,419</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-65">18,419</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Intangible assets </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:35.5pt;position:var(--position);text-decoration:none;white-space:pre">7</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-66">6,604</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-67">6,606</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-68">6,605</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Property, plant and equipment </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:78.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:35.5pt;position:var(--position);text-decoration:none;white-space:pre">8</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:78.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-69">878</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:78.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-70">2,666</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:78.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-71">2,090</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90.75pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial assets</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:90.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:35.5pt;position:var(--position);text-decoration:none;white-space:pre">9</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:90.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:OtherNoncurrentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-72">12,870</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:90.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:OtherNoncurrentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-73">5,919</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:90.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:OtherNoncurrentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-74">5,358</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102.75pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other non-current assets</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:102.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.5pt;position:var(--position);text-decoration:none;white-space:pre">10</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:102.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:OtherNoncurrentNonfinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-75">2,320</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:102.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:OtherNoncurrentNonfinancialAssets" scale="3" id="f-76">948</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:102.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:OtherNoncurrentNonfinancialAssets" scale="3" id="f-77">625</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:114.75pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total non-current assets</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:114.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-78">41,090</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:114.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-79">34,558</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:114.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-80">33,097</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:126.75pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Current assets</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:139.5pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial assets</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:139.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:35.5pt;position:var(--position);text-decoration:none;white-space:pre">9</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:139.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:OtherCurrentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-81">9,186</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:139.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:OtherCurrentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-82">7,554</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:139.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:OtherCurrentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-83">21,415</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:151.5pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other receivables and assets</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:151.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.5pt;position:var(--position);text-decoration:none;white-space:pre">10</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:151.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="abvx:CurrentReceivablesAndCurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-84">24,845</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:151.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="abvx:CurrentReceivablesAndCurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-85">18,896</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:151.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="abvx:CurrentReceivablesAndCurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-86">13,144</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:163.5pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cash and cash equivalents</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:163.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.5pt;position:var(--position);text-decoration:none;white-space:pre">11</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:163.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.96pt"></span></span><span style="left:45.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-87">251,942</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:163.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.96pt"></span></span><span style="left:45.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-88">144,221</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:163.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.96pt"></span></span><span style="left:45.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-89">516,685</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:175.5pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total current assets</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:175.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.96pt"></span></span><span style="left:45.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-90">285,972</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:175.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.96pt"></span></span><span style="left:45.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-91">170,671</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:175.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.96pt"></span></span><span style="left:45.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-92">551,244</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:187.5pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">TOTAL ASSETS</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:187.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.96pt"></span></span><span style="left:45.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-93">327,062</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:187.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.96pt"></span></span><span style="left:45.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-94">205,228</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:187.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.96pt"></span></span><span style="left:45.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-95">584,341</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:199.5pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:3.07pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES AND SHAREHOLDERS' </span></div><div style="line-height:8pt;position:var(--position);top:12.67pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">EQUITY</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:221.25pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Shareholders&#8217; equity</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:233.25pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Share capital</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:233.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:IssuedCapital" scale="3" id="f-96">629</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:233.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:IssuedCapital" scale="3" id="f-97">633</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:233.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:IssuedCapital" scale="3" id="f-98">785</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:245.25pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Premiums related to share capital</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:245.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.96pt"></span></span><span style="left:45.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:SharePremium" format="ixt:num-dot-decimal" scale="3" id="f-99">478,218</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:245.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.96pt"></span></span><span style="left:45.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:SharePremium" format="ixt:num-dot-decimal" scale="3" id="f-100">478,905</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:245.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:SharePremium" format="ixt:num-dot-decimal" scale="3" id="f-101">1,190,593</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:257.25pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Translation reserve</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:257.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" scale="3" id="f-102">112</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:257.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.3pt"></span></span><span style="left:60.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" scale="3" id="f-103">75</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:257.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" format="ixt:num-dot-decimal" scale="3" id="f-104">2,309</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:269.25pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Retained earnings</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:269.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.3pt"></span></span><span style="left:42.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriod" format="ixt:num-dot-decimal" scale="3" id="f-105">135,209</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:269.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.3pt"></span></span><span style="left:42.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriod" format="ixt:num-dot-decimal" scale="3" id="f-106">262,637</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:269.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.3pt"></span></span><span style="left:42.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" sign="-" name="ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriod" format="ixt:num-dot-decimal" scale="3" id="f-107">402,380</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:281.25pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Net loss for the period</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:281.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.3pt"></span></span><span style="left:42.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:RetainedEarningsProfitLossForReportingPeriod" format="ixt:num-dot-decimal" scale="3" id="f-108">147,740</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:281.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.3pt"></span></span><span style="left:42.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:RetainedEarningsProfitLossForReportingPeriod" format="ixt:num-dot-decimal" scale="3" id="f-109">176,242</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:281.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.3pt"></span></span><span style="left:42.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" sign="-" name="ifrs-full:RetainedEarningsProfitLossForReportingPeriod" format="ixt:num-dot-decimal" scale="3" id="f-110">336,102</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:293.25pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total shareholders&#8217; equity</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:293.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.5pt;position:var(--position);text-decoration:none;white-space:pre">13</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:293.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.96pt"></span></span><span style="left:45.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-111">196,010</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:293.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-112">40,584</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:293.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.96pt"></span></span><span style="left:45.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-113">455,205</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:305.25pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-current liabilities</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:317.25pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Retirement benefit obligations</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:317.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.5pt;position:var(--position);text-decoration:none;white-space:pre">16</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:317.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:NoncurrentProvisionsForEmployeeBenefits" scale="3" id="f-114">629</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:317.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:NoncurrentProvisionsForEmployeeBenefits" scale="3" id="f-115">756</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:317.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:NoncurrentProvisionsForEmployeeBenefits" scale="3" id="f-116">627</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:329.25pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Provisions</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:329.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.5pt;position:var(--position);text-decoration:none;white-space:pre">14</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:329.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:OtherLongtermProvisions" scale="3" id="f-117">30</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:329.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:OtherLongtermProvisions" scale="3" id="f-118">819</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:329.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:OtherLongtermProvisions" format="ixt:num-dot-decimal" scale="3" id="f-119">28,849</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:341.25pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Borrowings</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:341.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.5pt;position:var(--position);text-decoration:none;white-space:pre">15</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:341.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:NoncurrentPortionOfOtherNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-120">2,563</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:341.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:NoncurrentPortionOfOtherNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-121">29,056</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:341.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:NoncurrentPortionOfOtherNoncurrentBorrowings" scale="3" id="f-122">554</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:353.25pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Convertible loan notes</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:353.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.5pt;position:var(--position);text-decoration:none;white-space:pre">15</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:353.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="abvx:NonCurrentConvertibleLoansNotes" format="ixt:num-dot-decimal" scale="3" id="f-123">21,643</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:353.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="abvx:NonCurrentConvertibleLoansNotes" format="ixt:num-dot-decimal" scale="3" id="f-124">23,370</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:353.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="abvx:NonCurrentConvertibleLoansNotes" format="ixt:fixed-zero" scale="3" id="f-125">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:365.25pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Derivative instruments</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:365.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.5pt;position:var(--position);text-decoration:none;white-space:pre">15</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:365.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:NoncurrentDerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-126">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:365.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:NoncurrentDerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-127">3,620</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:365.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:NoncurrentDerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-128">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:377.25pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Royalty certificates</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:377.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.5pt;position:var(--position);text-decoration:none;white-space:pre">15</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:377.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="abvx:NonCurrentRoyaltyCertificates" format="ixt:num-dot-decimal" scale="3" id="f-129">12,229</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:377.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="abvx:NonCurrentRoyaltyCertificates" format="ixt:num-dot-decimal" scale="3" id="f-130">13,023</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:377.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="abvx:NonCurrentRoyaltyCertificates" format="ixt:num-dot-decimal" scale="3" id="f-131">30,237</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:389.25pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial liabilities</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:389.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.5pt;position:var(--position);text-decoration:none;white-space:pre">15</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:389.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:OtherNoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-132">3,262</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:389.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:OtherNoncurrentFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-133">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:389.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:OtherNoncurrentFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-134">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:401.25pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Deferred tax liabilities</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:401.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.5pt;position:var(--position);text-decoration:none;white-space:pre">22</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:401.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="abvx:DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets" format="ixt:fixed-zero" scale="3" id="f-135">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:401.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="abvx:DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets" format="ixt:fixed-zero" scale="3" id="f-136">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:401.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="abvx:DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets" format="ixt:num-dot-decimal" scale="3" id="f-137">5,848</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:413.25pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total non-current liabilities</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:413.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:NoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-138">40,356</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:413.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:NoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-139">70,645</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:413.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:NoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-140">66,114</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:425.25pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Current liabilities</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:437.25pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Borrowings</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:437.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.5pt;position:var(--position);text-decoration:none;white-space:pre">15</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:437.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-141">1,655</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:437.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-142">22,195</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:437.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-143">1,302</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:449.25pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Convertible loan notes</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:449.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.5pt;position:var(--position);text-decoration:none;white-space:pre">15</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:449.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="abvx:CurrentPortionOfNonCurrentConvertibleLoansNotes" format="ixt:num-dot-decimal" scale="3" id="f-144">29,605</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:449.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="abvx:CurrentPortionOfNonCurrentConvertibleLoansNotes" format="ixt:num-dot-decimal" scale="3" id="f-145">21,574</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:449.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="abvx:CurrentPortionOfNonCurrentConvertibleLoansNotes" format="ixt:fixed-zero" scale="3" id="f-146">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:461.25pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Derivative instruments</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:461.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.5pt;position:var(--position);text-decoration:none;white-space:pre">15</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:461.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:CurrentDerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-147">2,579</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:461.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:CurrentDerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-148">1,166</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:461.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:CurrentDerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-149">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:473.25pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial liabilities</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:473.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.5pt;position:var(--position);text-decoration:none;white-space:pre">15</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:473.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:OtherCurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-150">3,509</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:473.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:OtherCurrentFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-151">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:473.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:OtherCurrentFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-152">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:485.25pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Provisions</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:485.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:33.5pt;position:var(--position);text-decoration:none;white-space:pre">14</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:485.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:OtherShorttermProvisions" format="ixt:fixed-zero" scale="3" id="f-153">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:485.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:OtherShorttermProvisions" scale="3" id="f-154">532</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:485.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:OtherShorttermProvisions" format="ixt:num-dot-decimal" scale="3" id="f-155">17,030</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:497.25pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Trade payables and other current liabilities</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:497.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:30.5pt;position:var(--position);text-decoration:none;white-space:pre">17.1</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:497.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-156">47,221</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:497.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-157">43,824</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:497.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-158">37,552</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:509.25pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Tax and employee-related payables</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:156pt;position:var(--position);top:509.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:30.5pt;position:var(--position);text-decoration:none;white-space:pre">17.2</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:509.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="abvx:CurrentTaxAndEmployeeBenefitLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-159">6,073</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:509.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="abvx:CurrentTaxAndEmployeeBenefitLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-160">4,709</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:509.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="abvx:CurrentTaxAndEmployeeBenefitLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-161">7,137</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:521.25pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Deferred income</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:521.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities" scale="3" id="f-162">52</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:521.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities" format="ixt:fixed-zero" scale="3" id="f-163">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:521.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities" format="ixt:fixed-zero" scale="3" id="f-164">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:533.25pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total current liabilities</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:533.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-165">90,695</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:533.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-166">93,999</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:533.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-167">63,021</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:545.25pt;width:156pt"><div><div style="line-height:8pt;position:var(--position);top:3.07pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">TOTAL LIABILITIES AND </span></div><div style="line-height:8pt;position:var(--position);top:12.67pt;width:156pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">SHAREHOLDERS' EQUITY</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:234pt;position:var(--position);top:545.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:7.87pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.96pt"></span></span><span style="left:45.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-168">327,062</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:545.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:7.87pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.96pt"></span></span><span style="left:45.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-169">205,228</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:390pt;position:var(--position);top:545.25pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:7.87pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.96pt"></span></span><span style="left:45.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-170">584,341</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:299.05pt;position:var(--position)">F-4<span style="display:inline-block;height:6.93pt;width:22.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:473pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_271"></div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:155.74pt;position:var(--position);text-decoration:none;white-space:pre">ABIVAX SA CONSOLIDATED STATEMENTS OF INCOME (LOSS)<span id="i6deca07919574684a79827242f67f037"></span></span></div><div style="position:var(--position);top:98.63pt;width:612pt"><div style="font-size:0pt;left:71.28pt;position:var(--position);width:473.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:191.25pt"/><td style="padding:0;width:68.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:68.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:68.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:68.25pt"/></tr><tr style="height:30.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.51pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:16.56pt;position:var(--position);text-decoration:none;white-space:pre">(Amounts in thousands of euros, except per share </span></div><div style="line-height:8pt;position:var(--position);top:17.11pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:80.74pt;position:var(--position);text-decoration:none;white-space:pre">amounts)</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.58pt;position:var(--position);text-decoration:none;white-space:pre">Notes</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.12pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.12pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:405pt;position:var(--position);width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.12pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:30.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other operating income</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:30.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:30.12pt;position:var(--position);text-decoration:none;white-space:pre">18</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:30.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.87pt"></span></span><span style="left:49.5pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-171">4,621</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:30.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.21pt"></span></span><span style="left:42.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-172">12,449</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:405pt;position:var(--position);top:30.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.21pt"></span></span><span style="left:46.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-173">4,570</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.63pt;position:var(--position);text-decoration:none;white-space:pre">Total operating income</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:42.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.87pt"></span></span><span style="left:49.5pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:RevenueAndOperatingIncome" format="ixt:num-dot-decimal" scale="3" id="f-174">4,621</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:42.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.21pt"></span></span><span style="left:42.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:RevenueAndOperatingIncome" format="ixt:num-dot-decimal" scale="3" id="f-175">12,449</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:405pt;position:var(--position);top:42.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:44.21pt"></span></span><span style="left:46.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:RevenueAndOperatingIncome" format="ixt:num-dot-decimal" scale="3" id="f-176">4,570</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Sales and marketing</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:54.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:27.12pt;position:var(--position);text-decoration:none;white-space:pre">19.1</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:54.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.55pt"></span></span><span style="left:44.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:SalesAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="f-177">6,431</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:54.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.55pt"></span></span><span style="left:44.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:SalesAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="f-178">5,954</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:405pt;position:var(--position);top:54.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.55pt"></span></span><span style="left:44.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:SalesAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="f-179">5,194</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Research and development</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:66.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:27.12pt;position:var(--position);text-decoration:none;white-space:pre">19.2</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:66.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.55pt"></span></span><span style="left:36.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-180">103,176</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:66.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.55pt"></span></span><span style="left:36.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-181">146,532</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:405pt;position:var(--position);top:66.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.55pt"></span></span><span style="left:36.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-182">177,761</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">General and administrative</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:78.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:27.12pt;position:var(--position);text-decoration:none;white-space:pre">19.3</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:78.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.55pt"></span></span><span style="left:40.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-183">22,390</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:78.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.55pt"></span></span><span style="left:40.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-184">32,946</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:405pt;position:var(--position);top:78.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.55pt"></span></span><span style="left:40.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-185">67,670</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.63pt;position:var(--position);text-decoration:none;white-space:pre">Total operating expenses</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:90.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:33.55pt"></span></span><span style="left:36.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-186">131,997</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:90.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:33.55pt"></span></span><span style="left:36.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-187">185,433</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:405pt;position:var(--position);top:90.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:33.55pt"></span></span><span style="left:36.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-188">250,626</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.63pt;position:var(--position);text-decoration:none;white-space:pre">Operating loss</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:102.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:33.55pt"></span></span><span style="left:36.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-189">127,376</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:102.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:33.55pt"></span></span><span style="left:36.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-190">172,984</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:405pt;position:var(--position);top:102.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:33.55pt"></span></span><span style="left:36.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-191">246,056</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:114.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial expenses </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:114.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.55pt"></span></span><span style="left:40.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-192">27,875</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:114.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.55pt"></span></span><span style="left:40.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-193">16,991</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:405pt;position:var(--position);top:114.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.55pt"></span></span><span style="left:36.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-194">111,743</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:126.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial income </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:126.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.87pt"></span></span><span style="left:49.5pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:FinanceIncome" format="ixt:num-dot-decimal" scale="3" id="f-195">7,511</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:126.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.21pt"></span></span><span style="left:42.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:FinanceIncome" format="ixt:num-dot-decimal" scale="3" id="f-196">13,732</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:405pt;position:var(--position);top:126.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.21pt"></span></span><span style="left:42.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:FinanceIncome" format="ixt:num-dot-decimal" scale="3" id="f-197">27,545</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:138.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial gain (loss)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:138.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:30.12pt;position:var(--position);text-decoration:none;white-space:pre">21</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:138.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:37.55pt"></span></span><span style="left:40.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:FinanceIncomeCost" format="ixt:num-dot-decimal" scale="3" id="f-198">20,364</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:138.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.55pt"></span></span><span style="left:44.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="ifrs-full:FinanceIncomeCost" format="ixt:num-dot-decimal" scale="3" id="f-199">3,258</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:405pt;position:var(--position);top:138.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:37.55pt"></span></span><span style="left:40.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:FinanceIncomeCost" format="ixt:num-dot-decimal" scale="3" id="f-200">84,198</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:150.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.63pt;position:var(--position);text-decoration:none;white-space:pre">Net loss before tax</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:150.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:33.55pt"></span></span><span style="left:36.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-201">147,740</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:150.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:33.55pt"></span></span><span style="left:36.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-202">176,242</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:405pt;position:var(--position);top:150.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:33.55pt"></span></span><span style="left:36.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-203">330,254</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:162.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Income tax</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:162.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:30.12pt;position:var(--position);text-decoration:none;white-space:pre">22</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:162.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.87pt"></span></span><span style="left:59.5pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:fixed-zero" scale="3" id="f-204">&#8212;</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:162.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.21pt"></span></span><span style="left:56.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:fixed-zero" scale="3" id="f-205">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:405pt;position:var(--position);top:162.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.55pt"></span></span><span style="left:44.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-206">5,848</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:174.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.63pt;position:var(--position);text-decoration:none;white-space:pre">Net loss for the period</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:174.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:33.55pt"></span></span><span style="left:36.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-207">147,740</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:174.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:33.55pt"></span></span><span style="left:36.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-208">176,242</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:405pt;position:var(--position);top:174.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:33.55pt"></span></span><span style="left:36.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-209">336,102</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:186.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.63pt;position:var(--position);text-decoration:none;white-space:pre">Loss per share (&#8364;/share)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:198.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Weighted average number of outstanding shares used for </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">computing basic/diluted loss per share</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:198.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:29.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-210"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-211">43,066,012</ix:nonFraction></ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:198.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:29.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-212"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-213">63,046,350</ix:nonFraction></ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:405pt;position:var(--position);top:198.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:29.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-214"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-215">69,527,315</ix:nonFraction></ix:nonFraction></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:219.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.63pt;position:var(--position);text-decoration:none;white-space:pre">Basic / diluted loss per share (&#8364;/share)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:219.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:30.12pt;position:var(--position);text-decoration:none;white-space:pre">23</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:219.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:45.55pt"></span></span><span style="left:48.18pt;position:var(--position)">(<ix:nonFraction unitRef="eurPerShare" contextRef="c-8" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-216"><ix:nonFraction unitRef="eurPerShare" contextRef="c-8" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-217">3.43</ix:nonFraction></ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:219.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:45.55pt"></span></span><span style="left:48.18pt;position:var(--position)">(<ix:nonFraction unitRef="eurPerShare" contextRef="c-9" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-218"><ix:nonFraction unitRef="eurPerShare" contextRef="c-9" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-219">2.80</ix:nonFraction></ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:405pt;position:var(--position);top:219.75pt;width:68.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:68.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:45.55pt"></span></span><span style="left:48.18pt;position:var(--position)">(<ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-220"><ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-221">4.83</ix:nonFraction></ix:nonFraction>)</span></span></div></div></div></td></tr></tbody></table></div></div></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:299.05pt;position:var(--position)">F-5<span style="display:inline-block;height:6.93pt;width:22.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_274"></div><div style="line-height:10pt;position:var(--position);top:84pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:107.64pt;position:var(--position);text-decoration:none;white-space:pre">ABIVAX SA CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)<span id="i92b5999ab3144ce4b22182f10000bee5"></span></span></div><div style="position:var(--position);top:120.83pt;width:612pt"><div style="font-size:0pt;left:72pt;position:var(--position);width:461.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:215.25pt"/><td style="padding:0;width:60pt"/><td style="padding:0;width:60pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:60pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:60pt"/></tr><tr style="height:41.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:215.25pt"><div><div style="line-height:8pt;position:var(--position);top:17.56pt;width:215.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:55.21pt;position:var(--position);text-decoration:none;white-space:pre">(Amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:215.25pt;position:var(--position);width:60pt"><div><div style="line-height:8pt;position:var(--position);top:17.62pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.45pt;position:var(--position);text-decoration:none;white-space:pre">Notes</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:275.25pt;position:var(--position);width:60pt"><div><div style="line-height:8pt;position:var(--position);top:8.02pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.69pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:17.62pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.91pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER </span></div><div style="line-height:8pt;position:var(--position);top:27.22pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16pt;position:var(--position);text-decoration:none;white-space:pre">31, 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:338.25pt;position:var(--position);width:60pt"><div><div style="line-height:8pt;position:var(--position);top:8.02pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.69pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:17.62pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.91pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER </span></div><div style="line-height:8pt;position:var(--position);top:27.22pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16pt;position:var(--position);text-decoration:none;white-space:pre">31, 2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:401.25pt;position:var(--position);width:60pt"><div><div style="line-height:8pt;position:var(--position);top:8.02pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.69pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:17.62pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.91pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER </span></div><div style="line-height:8pt;position:var(--position);top:27.22pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16pt;position:var(--position);text-decoration:none;white-space:pre">31, 2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:41.25pt;width:215.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:215.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Net loss for the period</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:215.25pt;position:var(--position);top:41.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:30pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:275.25pt;position:var(--position);top:41.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:25.3pt"></span></span><span style="left:27.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-222">147,740</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:338.25pt;position:var(--position);top:41.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:25.3pt"></span></span><span style="left:27.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-223">176,242</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:401.25pt;position:var(--position);top:41.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:25.3pt"></span></span><span style="left:27.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-224">336,102</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:53.25pt;width:215.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:215.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Items that will not be reclassified to profit or loss</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:215.25pt;position:var(--position);top:53.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:30pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:275.25pt;position:var(--position);top:53.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.96pt"></span></span><span style="left:44.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" scale="3" id="f-225">112</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:338.25pt;position:var(--position);top:53.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:43.3pt"></span></span><span style="left:45.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" scale="3" id="f-226">31</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:401.25pt;position:var(--position);top:53.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:45.96pt"></span></span><span style="left:48.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" scale="3" id="f-227">93</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:65.25pt;width:215.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:215.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Actuarial gains and losses on retirement benefit obligations</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:215.25pt;position:var(--position);top:65.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26pt;position:var(--position);text-decoration:none;white-space:pre">16</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:275.25pt;position:var(--position);top:65.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.96pt"></span></span><span style="left:44.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" scale="3" id="f-228">112</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:338.25pt;position:var(--position);top:65.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:43.3pt"></span></span><span style="left:45.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" scale="3" id="f-229">31</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:401.25pt;position:var(--position);top:65.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.96pt"></span></span><span style="left:48.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" scale="3" id="f-230">93</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:77.25pt;width:215.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:215.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Items that are or may be reclassified subsequently to profit </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:215.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">or loss</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:275.25pt;position:var(--position);top:77.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.96pt"></span></span><span style="left:44.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" scale="3" id="f-231">112</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:338.25pt;position:var(--position);top:77.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:39.3pt"></span></span><span style="left:41.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" scale="3" id="f-232">187</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:401.25pt;position:var(--position);top:77.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.96pt"></span></span><span style="left:38.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-233">2,384</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:98.25pt;width:215.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:215.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Foreign currency translation differences</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:275.25pt;position:var(--position);top:98.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.96pt"></span></span><span style="left:44.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="f-234">112</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:338.25pt;position:var(--position);top:98.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.3pt"></span></span><span style="left:41.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="f-235">187</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:401.25pt;position:var(--position);top:98.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.96pt"></span></span><span style="left:38.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" format="ixt:num-dot-decimal" scale="3" id="f-236">2,384</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:110.25pt;width:215.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:215.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other comprehensive income (loss) </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:215.25pt;position:var(--position);top:110.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:30pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:275.25pt;position:var(--position);top:110.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.96pt"></span></span><span style="left:44.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:OtherComprehensiveIncome" scale="3" id="f-237">225</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:338.25pt;position:var(--position);top:110.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:39.3pt"></span></span><span style="left:41.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="3" id="f-238">219</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:401.25pt;position:var(--position);top:110.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.96pt"></span></span><span style="left:38.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-239">2,477</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:122.25pt;width:215.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:215.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total comprehensive income (loss) for the period</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:215.25pt;position:var(--position);top:122.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:30pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:275.25pt;position:var(--position);top:122.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:25.3pt"></span></span><span style="left:27.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-240">147,516</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:338.25pt;position:var(--position);top:122.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:25.3pt"></span></span><span style="left:27.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-241">176,461</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:401.25pt;position:var(--position);top:122.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:25.3pt"></span></span><span style="left:27.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-242">333,625</ix:nonFraction>)</span></span></div></div></div></td></tr></tbody></table></div></div></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:299.05pt;position:var(--position)">F-6<span style="display:inline-block;height:6.93pt;width:22.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:583pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_277"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:84pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:94.99pt;position:var(--position);text-decoration:none;white-space:pre">ABIVAX SA CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; E<span id="i033e61d590274a87859424080ad3fa65"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:484.24pt;position:var(--position);text-decoration:none;white-space:pre">QUITY </span></div><div style="position:var(--position);top:108pt;width:612pt"><div style="font-size:0pt;left:14.4pt;position:var(--position);width:569.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:129.75pt"/><td style="padding:0;width:38.25pt"/><td style="padding:0;width:54.75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:54.75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:54.75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:54.75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:54.75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:54.75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:54.75pt"/></tr><tr style="height:36pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:19.73pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:italic;font-weight:normal;left:7.66pt;position:var(--position);text-decoration:none;white-space:pre">(In thousands of euros, except number of </span></div><div style="line-height:7pt;position:var(--position);top:28.13pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:italic;font-weight:normal;left:54.58pt;position:var(--position);text-decoration:none;white-space:pre">shares)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:129.75pt;position:var(--position);width:38.25pt"><div><div style="line-height:8pt;position:var(--position);top:15pt;width:38.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.58pt;position:var(--position);text-decoration:none;white-space:pre">Notes</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.04pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:6.11pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER OF </span></div><div style="line-height:7pt;position:var(--position);top:15.44pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:13.38pt;position:var(--position);text-decoration:none;white-space:pre">SHARES </span></div><div style="line-height:7pt;position:var(--position);top:23.84pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:14.74pt;position:var(--position);text-decoration:none;white-space:pre">ISSUED</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:11.24pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:15.33pt;position:var(--position);text-decoration:none;white-space:pre">SHARE </span></div><div style="line-height:7pt;position:var(--position);top:19.64pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:11.64pt;position:var(--position);text-decoration:none;white-space:pre">CAPITAL</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:2.84pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:7.95pt;position:var(--position);text-decoration:none;white-space:pre">PREMIUMS </span></div><div style="line-height:7pt;position:var(--position);top:11.24pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:4.55pt;position:var(--position);text-decoration:none;white-space:pre">RELATED TO </span></div><div style="line-height:7pt;position:var(--position);top:19.64pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:15.33pt;position:var(--position);text-decoration:none;white-space:pre">SHARE </span></div><div style="line-height:7pt;position:var(--position);top:28.04pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:11.64pt;position:var(--position);text-decoration:none;white-space:pre">CAPITAL</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:11.24pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:4.26pt;position:var(--position);text-decoration:none;white-space:pre">TRANSLATIO</span></div><div style="line-height:7pt;position:var(--position);top:19.64pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:7.46pt;position:var(--position);text-decoration:none;white-space:pre">N RESERVE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:11.24pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:8.92pt;position:var(--position);text-decoration:none;white-space:pre">RETAINED </span></div><div style="line-height:7pt;position:var(--position);top:19.64pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:8.92pt;position:var(--position);text-decoration:none;white-space:pre">EARNINGS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.04pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:10.37pt;position:var(--position);text-decoration:none;white-space:pre">NET LOSS </span></div><div style="line-height:7pt;position:var(--position);top:15.44pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:11.74pt;position:var(--position);text-decoration:none;white-space:pre">FOR THE </span></div><div style="line-height:7pt;position:var(--position);top:23.84pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:17.47pt;position:var(--position);text-decoration:none;white-space:pre">YEAR</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.04pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:15.14pt;position:var(--position);text-decoration:none;white-space:pre">TOTAL </span></div><div style="line-height:7pt;position:var(--position);top:15.44pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:2.7pt;position:var(--position);text-decoration:none;white-space:pre">SHAREHOLDE</span></div><div style="line-height:7pt;position:var(--position);top:23.84pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:7.27pt;position:var(--position);text-decoration:none;white-space:pre">RS' EQUITY</span></div></div></div></td></tr><tr style="height:20.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:36pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF JANUARY 1, 2023</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:36pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:17.54pt"></span></span><span style="left:20.169999999999998pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="0" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-243">22,313,185</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:36pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-11" decimals="-3" name="ifrs-full:Equity" scale="3" id="f-244">223</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:36pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:26.29pt"></span></span><span style="left:28.919999999999998pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-245">150,476</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:36pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-3" name="ifrs-full:Equity" format="ixt:fixed-zero" scale="3" id="f-246">&#8212;</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:36pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:27.46pt"></span></span><span style="left:30.09pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-247">82,770</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:36pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:27.46pt"></span></span><span style="left:30.09pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-248">60,740</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:36pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:33.29pt"></span></span><span style="left:35.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-249">7,189</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:56.25pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.39pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Net loss for the period</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:56.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:56.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:56.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:56.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:56.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:56.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:23.96pt"></span></span><span style="left:26.59pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-250">147,740</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:56.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:23.96pt"></span></span><span style="left:26.59pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-251">147,740</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:67.5pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other comprehensive income (loss) </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:129.75pt;position:var(--position);top:67.5pt;width:38.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:38.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.12pt;position:var(--position);text-decoration:none;white-space:pre">16</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:67.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:67.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:67.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:67.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-17" decimals="-3" name="ifrs-full:OtherComprehensiveIncome" scale="3" id="f-252">112</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:67.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-18" decimals="-3" name="ifrs-full:OtherComprehensiveIncome" scale="3" id="f-253">112</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:67.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:67.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:OtherComprehensiveIncome" scale="3" id="f-254">225</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total comprehensive loss for the period</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:78.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:78.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:78.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:78.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-17" decimals="-3" name="ifrs-full:ComprehensiveIncome" scale="3" id="f-255">112</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:78.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-18" decimals="-3" name="ifrs-full:ComprehensiveIncome" scale="3" id="f-256">112</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:78.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:23.96pt"></span></span><span style="left:26.59pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-257">147,740</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:78.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:23.96pt"></span></span><span style="left:26.59pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-258">147,516</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Appropriation of prior period net loss</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:90pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:90pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:90pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:90pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:90pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:27.46pt"></span></span><span style="left:30.09pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-18" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="f-259">60,740</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:90pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:29.79pt"></span></span><span style="left:32.42pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="f-260">60,740</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:90pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings" format="ixt:fixed-zero" scale="3" id="f-261">&#8212;</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:20.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:101.25pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.31pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Capital increase from issuance of ordinary </span></div><div style="line-height:7pt;position:var(--position);top:11.71pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">shares</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:129.75pt;position:var(--position);top:101.25pt;width:38.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.12pt;width:38.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.12pt;position:var(--position);text-decoration:none;white-space:pre">13.2</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:101.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.51pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:17.54pt"></span></span><span style="left:20.169999999999998pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="0" name="abvx:IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease" format="ixt:num-dot-decimal" scale="0" id="f-262">40,325,500</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:101.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.51pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-19" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="f-263">403</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:101.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.51pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:26.29pt"></span></span><span style="left:28.919999999999998pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-20" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-264">352,974</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:101.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.51pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:101.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.51pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:101.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.51pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:101.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.51pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:26.29pt"></span></span><span style="left:28.919999999999998pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-265">353,377</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:121.5pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Transaction costs related to capital increase </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:129.75pt;position:var(--position);top:121.5pt;width:38.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:38.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.12pt;position:var(--position);text-decoration:none;white-space:pre">13.2</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:121.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:121.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:121.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:27.46pt"></span></span><span style="left:30.09pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-20" decimals="-3" name="abvx:ShareIssueRelatedCostCredit" format="ixt:num-dot-decimal" scale="3" id="f-266">28,111</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:121.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:121.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:121.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:121.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:27.46pt"></span></span><span style="left:30.09pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:ShareIssueRelatedCostCredit" format="ixt:num-dot-decimal" scale="3" id="f-267">28,111</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:132.75pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Issue of convertible notes</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:129.75pt;position:var(--position);top:132.75pt;width:38.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:38.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.12pt;position:var(--position);text-decoration:none;white-space:pre">15</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:132.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:132.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:132.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:33.29pt"></span></span><span style="left:35.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-20" decimals="-3" name="ifrs-full:IssueOfConvertibleInstruments" format="ixt:num-dot-decimal" scale="3" id="f-268">1,030</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:132.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:132.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:132.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:132.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:33.29pt"></span></span><span style="left:35.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:IssueOfConvertibleInstruments" format="ixt:num-dot-decimal" scale="3" id="f-269">1,030</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:144pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Exercises of the Kreos share warrants</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:129.75pt;position:var(--position);top:144pt;width:38.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:38.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.12pt;position:var(--position);text-decoration:none;white-space:pre">13.2, 15</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:144pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:29.79pt"></span></span><span style="left:32.42pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="0" name="abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants" format="ixt:num-dot-decimal" scale="0" id="f-270">99,583</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:144pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:45.54pt"></span></span><span style="left:48.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-22" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" id="f-271">1</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:144pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:33.29pt"></span></span><span style="left:35.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-23" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" format="ixt:num-dot-decimal" scale="3" id="f-272">1,849</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:144pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:144pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:144pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:144pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:33.29pt"></span></span><span style="left:35.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-21" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" format="ixt:num-dot-decimal" scale="3" id="f-273">1,850</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:9.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:155.25pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:2.26pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Exercises of other share warrants</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:129.75pt;position:var(--position);top:155.25pt;width:38.25pt"><div><div style="line-height:8pt;position:var(--position);top:1.88pt;width:38.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.12pt;position:var(--position);text-decoration:none;white-space:pre">13.2, 14</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:155.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:2.26pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:26.29pt"></span></span><span style="left:28.919999999999998pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="0" name="abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants" format="ixt:num-dot-decimal" scale="0" id="f-274">190,550</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:155.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:2.26pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:45.54pt"></span></span><span style="left:48.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-25" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" id="f-275">2</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:155.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:2.26pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:155.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:2.26pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:155.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:2.26pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:155.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:2.26pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:155.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:2.26pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:45.54pt"></span></span><span style="left:48.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-24" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" id="f-276">2</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:165pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Shares based compensation expense</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:129.75pt;position:var(--position);top:165pt;width:38.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:38.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.12pt;position:var(--position);text-decoration:none;white-space:pre">14</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:165pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:165pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:165pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:165pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:165pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:33.29pt"></span></span><span style="left:35.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-18" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-277">8,179</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:165pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:165pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:33.29pt"></span></span><span style="left:35.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-278">8,179</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:176.25pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Transactions on treasury shares</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:129.75pt;position:var(--position);top:176.25pt;width:38.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:38.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.12pt;position:var(--position);text-decoration:none;white-space:pre">13.1</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:176.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:176.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:176.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:176.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:176.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-18" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" scale="3" id="f-279">10</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:176.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:176.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" scale="3" id="f-280">10</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:20.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:187.5pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:187.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:17.54pt"></span></span><span style="left:20.169999999999998pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-281">62,928,818</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:187.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-26" decimals="-3" name="ifrs-full:Equity" scale="3" id="f-282">629</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:187.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:26.29pt"></span></span><span style="left:28.919999999999998pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-27" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-283">478,218</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:187.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-28" decimals="-3" name="ifrs-full:Equity" scale="3" id="f-284">112</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:187.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:23.96pt"></span></span><span style="left:26.59pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-29" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-285">135,210</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:187.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:23.96pt"></span></span><span style="left:26.59pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-30" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-286">147,740</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:187.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:26.29pt"></span></span><span style="left:28.919999999999998pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-287">196,010</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1.5pt solid #000;font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:20.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:219pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF JANUARY 1, 2024</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:219pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:17.54pt"></span></span><span style="left:20.169999999999998pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-288">62,928,818</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:219pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-26" decimals="-3" name="ifrs-full:Equity" scale="3" id="f-289">629</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:219pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:26.29pt"></span></span><span style="left:28.919999999999998pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-27" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-290">478,218</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:219pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-28" decimals="-3" name="ifrs-full:Equity" scale="3" id="f-291">112</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:219pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:23.96pt"></span></span><span style="left:26.59pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-29" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-292">135,210</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:219pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:23.96pt"></span></span><span style="left:26.59pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-30" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-293">147,740</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:219pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:26.29pt"></span></span><span style="left:28.919999999999998pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-294">196,010</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:239.25pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.39pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Net loss for the period</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:239.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:239.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:239.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:239.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:239.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:239.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:23.96pt"></span></span><span style="left:26.59pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-31" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-295">176,242</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:239.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:23.96pt"></span></span><span style="left:26.59pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-296">176,242</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:250.5pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other comprehensive income (loss) </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:129.75pt;position:var(--position);top:250.5pt;width:38.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:38.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.12pt;position:var(--position);text-decoration:none;white-space:pre">16</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:250.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:250.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:250.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:250.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:36.21pt"></span></span><span style="left:38.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-32" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="3" id="f-297">187</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:250.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-33" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="3" id="f-298">31</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:250.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:250.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:36.21pt"></span></span><span style="left:38.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="3" id="f-299">219</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:261.75pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total comprehensive loss for the period</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:261.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:261.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:261.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:261.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:36.21pt"></span></span><span style="left:38.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-32" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" scale="3" id="f-300">187</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:261.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-33" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" scale="3" id="f-301">31</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:261.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:23.96pt"></span></span><span style="left:26.59pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-31" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-302">176,242</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:261.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:23.96pt"></span></span><span style="left:26.59pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-303">176,461</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:273pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Appropriation of prior period net loss</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:273pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:273pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:273pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:273pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:273pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:23.96pt"></span></span><span style="left:26.59pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-33" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="f-304">147,740</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:273pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:26.29pt"></span></span><span style="left:28.919999999999998pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-31" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="f-305">147,740</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:273pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings" format="ixt:fixed-zero" scale="3" id="f-306">&#8212;</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:284.25pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Transaction costs related to capital increase </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:129.75pt;position:var(--position);top:284.25pt;width:38.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:38.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.12pt;position:var(--position);text-decoration:none;white-space:pre">13.2</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:284.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:284.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:284.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-34" decimals="-3" sign="-" name="abvx:ShareIssueRelatedCostCredit" scale="3" id="f-307">446</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:284.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:284.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:284.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:284.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="abvx:ShareIssueRelatedCostCredit" scale="3" id="f-308">446</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:295.5pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Issue of share warrants </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:129.75pt;position:var(--position);top:295.5pt;width:38.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:38.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.12pt;position:var(--position);text-decoration:none;white-space:pre">14</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:295.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:295.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:295.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-34" decimals="-3" name="abvx:IncreaseDecreaseThroughIssuanceOfWarrantsEquity" scale="3" id="f-309">200</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:295.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:295.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:295.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:295.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:IncreaseDecreaseThroughIssuanceOfWarrantsEquity" scale="3" id="f-310">200</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:306.75pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Exercises of share warrants</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:129.75pt;position:var(--position);top:306.75pt;width:38.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:38.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.12pt;position:var(--position);text-decoration:none;white-space:pre">13.2, 14</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:306.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:33.29pt"></span></span><span style="left:35.92pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants" format="ixt:num-dot-decimal" scale="0" id="f-311">4,000</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:306.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:306.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-34" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" id="f-312">45</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:306.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:306.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:306.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:306.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" id="f-313">45</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:318pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Issue of free shares</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:129.75pt;position:var(--position);top:318pt;width:38.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:38.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:15.62pt;position:var(--position);text-decoration:none;white-space:pre">14</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:318pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:26.29pt"></span></span><span style="left:28.919999999999998pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="abvx:NumberOfFreeSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-314">415,019</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:318pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:45.54pt"></span></span><span style="left:48.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-3" name="abvx:IncreaseDecreaseFromFreeSharesIssued" scale="3" id="f-315">4</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:318pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:43.21pt"></span></span><span style="left:45.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-34" decimals="-3" sign="-" name="abvx:IncreaseDecreaseFromFreeSharesIssued" scale="3" id="f-316">4</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:318pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:318pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:318pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:318pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:45.54pt"></span></span><span style="left:48.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:IncreaseDecreaseFromFreeSharesIssued" scale="3" id="f-317">1</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:329.25pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Shares based compensation expense</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:129.75pt;position:var(--position);top:329.25pt;width:38.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:38.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.12pt;position:var(--position);text-decoration:none;white-space:pre">14</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:329.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:329.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:329.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:329.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:329.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:29.79pt"></span></span><span style="left:32.42pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-33" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-318">20,224</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:329.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:329.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:29.79pt"></span></span><span style="left:32.42pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-319">20,224</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:340.5pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Transactions on treasury shares</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:129.75pt;position:var(--position);top:340.5pt;width:38.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:38.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.12pt;position:var(--position);text-decoration:none;white-space:pre">13.1</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:340.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:340.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:340.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:340.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:340.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-33" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" scale="3" id="f-320">120</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:340.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:340.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" scale="3" id="f-321">120</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:20.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:351.75pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:129.75pt;position:var(--position);top:351.75pt;width:38.25pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:38.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">13.1</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:351.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:17.54pt"></span></span><span style="left:20.169999999999998pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-322">63,347,837</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:351.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-36" decimals="-3" name="ifrs-full:Equity" scale="3" id="f-323">633</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:351.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:26.29pt"></span></span><span style="left:28.919999999999998pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-37" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-324">478,905</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:351.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-38" decimals="-3" sign="-" name="ifrs-full:Equity" scale="3" id="f-325">75</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:351.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:23.96pt"></span></span><span style="left:26.59pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-39" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-326">262,638</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:351.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:23.96pt"></span></span><span style="left:26.59pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-40" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-327">176,242</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:351.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:29.79pt"></span></span><span style="left:32.42pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-328">40,584</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:20.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:383.25pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF JANUARY 1, 2025</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:383.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:17.54pt"></span></span><span style="left:20.169999999999998pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-329">63,347,837</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:383.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-36" decimals="-3" name="ifrs-full:Equity" scale="3" id="f-330">633</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:383.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:26.29pt"></span></span><span style="left:28.919999999999998pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-37" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-331">478,905</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:383.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-38" decimals="-3" sign="-" name="ifrs-full:Equity" scale="3" id="f-332">75</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:383.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:23.96pt"></span></span><span style="left:26.59pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-39" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-333">262,638</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:383.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:23.96pt"></span></span><span style="left:26.59pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-40" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-334">176,242</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:383.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:29.79pt"></span></span><span style="left:32.42pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-335">40,584</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:403.5pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.39pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Net loss for the period</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:403.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:403.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:403.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:403.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:403.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:403.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:23.96pt"></span></span><span style="left:26.59pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-41" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-336">336,102</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:403.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:23.96pt"></span></span><span style="left:26.59pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-337">336,102</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:414.75pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other comprehensive income (loss) </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:129.75pt;position:var(--position);top:414.75pt;width:38.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:38.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.12pt;position:var(--position);text-decoration:none;white-space:pre">16</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:414.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:414.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:414.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:414.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:33.29pt"></span></span><span style="left:35.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-42" decimals="-3" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-338">2,384</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:414.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-43" decimals="-3" name="ifrs-full:OtherComprehensiveIncome" scale="3" id="f-339">93</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:414.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:414.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:33.29pt"></span></span><span style="left:35.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-340">2,477</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:426pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:4.56pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total comprehensive loss for the period</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:426pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:4.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:426pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:4.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:426pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:4.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:426pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:4.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:33.29pt"></span></span><span style="left:35.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-42" decimals="-3" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-341">2,384</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:426pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:4.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-43" decimals="-3" name="ifrs-full:ComprehensiveIncome" scale="3" id="f-342">93</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:426pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:4.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:23.96pt"></span></span><span style="left:26.59pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-41" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-343">336,102</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:426pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:4.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:23.96pt"></span></span><span style="left:26.59pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-344">333,625</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:440.25pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Appropriation of prior period net loss</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:440.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:440.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:440.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:440.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:440.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:23.96pt"></span></span><span style="left:26.59pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-43" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="f-345">176,242</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:440.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:26.29pt"></span></span><span style="left:28.919999999999998pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-41" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="f-346">176,242</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:440.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings" format="ixt:fixed-zero" scale="3" id="f-347">&#8212;</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:14.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:14.25pt;overflow:hidden;position:var(--position);top:451.5pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:0.31pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Capital increase from issuance of ordinary </span></div><div style="line-height:7pt;position:var(--position);top:8.71pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">shares</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:129.75pt;position:var(--position);top:451.5pt;width:38.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.12pt;width:38.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.12pt;position:var(--position);text-decoration:none;white-space:pre">13.2</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:451.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:4.51pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:17.54pt"></span></span><span style="left:20.169999999999998pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="abvx:IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease" format="ixt:num-dot-decimal" scale="0" id="f-348">11,679,400</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:451.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:4.51pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-44" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="f-349">117</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:451.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:4.51pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:26.29pt"></span></span><span style="left:28.919999999999998pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-45" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-350">637,345</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:451.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:4.51pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:451.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:4.51pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:451.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:4.51pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:451.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:4.51pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:26.29pt"></span></span><span style="left:28.919999999999998pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-351">637,462</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:465.75pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Transaction costs related to capital increase </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:129.75pt;position:var(--position);top:465.75pt;width:38.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:38.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.12pt;position:var(--position);text-decoration:none;white-space:pre">13.2</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:465.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:465.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:465.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:27.46pt"></span></span><span style="left:30.09pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-45" decimals="-3" name="abvx:ShareIssueRelatedCostCredit" format="ixt:num-dot-decimal" scale="3" id="f-352">40,306</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:465.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:465.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:465.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:465.75pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:27.46pt"></span></span><span style="left:30.09pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:ShareIssueRelatedCostCredit" format="ixt:num-dot-decimal" scale="3" id="f-353">40,306</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:9pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:477pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:1.89pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Issue of share warrants </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:129.75pt;position:var(--position);top:477pt;width:38.25pt"><div><div style="line-height:8pt;position:var(--position);top:1.5pt;width:38.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.12pt;position:var(--position);text-decoration:none;white-space:pre">14</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:477pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:1.89pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:477pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:1.89pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:477pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:1.89pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-45" decimals="-3" name="abvx:IncreaseDecreaseThroughIssuanceOfWarrantsEquity" scale="3" id="f-354">300</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:477pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:1.89pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:477pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:1.89pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:477pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:1.89pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:477pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:1.89pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:IncreaseDecreaseThroughIssuanceOfWarrantsEquity" scale="3" id="f-355">300</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:486pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Exercises of the Kreos/Claret share warrants</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:129.75pt;position:var(--position);top:486pt;width:38.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:38.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.12pt;position:var(--position);text-decoration:none;white-space:pre">13.2, 15.1</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:486pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:26.29pt"></span></span><span style="left:28.919999999999998pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-46" decimals="0" name="abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants" format="ixt:num-dot-decimal" scale="0" id="f-356">525,913</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:486pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:45.54pt"></span></span><span style="left:48.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-44" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" id="f-357">5</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:486pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:29.79pt"></span></span><span style="left:32.42pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-47" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" format="ixt:num-dot-decimal" scale="3" id="f-358">33,763</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:486pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:486pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:486pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:486pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:29.79pt"></span></span><span style="left:32.42pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-46" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" format="ixt:num-dot-decimal" scale="3" id="f-359">33,768</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:497.25pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.38pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Exercises of other share warrants</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:129.75pt;position:var(--position);top:497.25pt;width:38.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:38.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.12pt;position:var(--position);text-decoration:none;white-space:pre">13.2, 14</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:497.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.38pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:26.29pt"></span></span><span style="left:28.919999999999998pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-48" decimals="0" name="abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants" format="ixt:num-dot-decimal" scale="0" id="f-360">257,087</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:497.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.38pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:45.54pt"></span></span><span style="left:48.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-49" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" id="f-361">3</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:497.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.38pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:33.29pt"></span></span><span style="left:35.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-50" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" format="ixt:num-dot-decimal" scale="3" id="f-362">3,343</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:497.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.38pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:497.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.38pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:497.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.38pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:497.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.38pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:33.29pt"></span></span><span style="left:35.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-48" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" format="ixt:num-dot-decimal" scale="3" id="f-363">3,346</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:509.25pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.38pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Conversion of the Kreos Claret OCABSA</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:129.75pt;position:var(--position);top:509.25pt;width:38.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:38.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.12pt;position:var(--position);text-decoration:none;white-space:pre">15.1</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:509.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.38pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:21.04pt"></span></span><span style="left:23.669999999999998pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-51" decimals="0" name="abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments" format="ixt:num-dot-decimal" scale="0" id="f-364">1,178,084</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:509.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.38pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-52" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" scale="3" id="f-365">12</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:509.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.38pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:29.79pt"></span></span><span style="left:32.42pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-53" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" format="ixt:num-dot-decimal" scale="3" id="f-366">23,338</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:509.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.38pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:509.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.38pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:33.29pt"></span></span><span style="left:35.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-54" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" format="ixt:num-dot-decimal" scale="3" id="f-367">1,009</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:509.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.38pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:509.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.38pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:29.79pt"></span></span><span style="left:32.42pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-51" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" format="ixt:num-dot-decimal" scale="3" id="f-368">24,359</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:521.25pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.38pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Conversion of the Heights notes</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:129.75pt;position:var(--position);top:521.25pt;width:38.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:38.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.12pt;position:var(--position);text-decoration:none;white-space:pre">15.2</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:521.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.38pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:26.29pt"></span></span><span style="left:28.919999999999998pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-55" decimals="0" name="abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments" format="ixt:num-dot-decimal" scale="0" id="f-369">920,377</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:521.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.38pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:45.54pt"></span></span><span style="left:48.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-56" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" scale="3" id="f-370">9</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:521.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.38pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:29.79pt"></span></span><span style="left:32.42pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-57" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" format="ixt:num-dot-decimal" scale="3" id="f-371">53,912</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:521.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.38pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:521.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.38pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:521.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.38pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:521.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.38pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:29.79pt"></span></span><span style="left:32.42pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-55" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" format="ixt:num-dot-decimal" scale="3" id="f-372">53,921</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:533.25pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.38pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Issue of free shares</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:129.75pt;position:var(--position);top:533.25pt;width:38.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:38.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.12pt;position:var(--position);text-decoration:none;white-space:pre">14</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:533.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.38pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:26.29pt"></span></span><span style="left:28.919999999999998pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="abvx:NumberOfFreeSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-373">627,714</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:533.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.38pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:45.54pt"></span></span><span style="left:48.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-44" decimals="-3" name="abvx:IncreaseDecreaseFromFreeSharesIssued" scale="3" id="f-374">6</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:533.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.38pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:43.21pt"></span></span><span style="left:45.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-45" decimals="-3" sign="-" name="abvx:IncreaseDecreaseFromFreeSharesIssued" scale="3" id="f-375">6</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:533.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.38pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:533.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.38pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:533.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.38pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:533.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.38pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:IncreaseDecreaseFromFreeSharesIssued" format="ixt:fixed-zero" scale="3" id="f-376">&#8212;</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:545.25pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Shares based compensation expense</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:129.75pt;position:var(--position);top:545.25pt;width:38.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:38.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.12pt;position:var(--position);text-decoration:none;white-space:pre">14</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:545.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:545.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:545.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:545.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:545.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:29.79pt"></span></span><span style="left:32.42pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-43" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-377">35,397</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:545.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:42.04pt"></span></span><span style="left:44.67pt;position:var(--position)">&#8212;<span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:545.25pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:29.79pt"></span></span><span style="left:32.42pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-378">35,397</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:20.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:556.5pt;width:129.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:129.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2025</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:129.75pt;position:var(--position);top:556.5pt;width:38.25pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:38.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:13pt;position:var(--position);text-decoration:none;white-space:pre">13.1</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168pt;position:var(--position);top:556.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:17.54pt"></span></span><span style="left:20.169999999999998pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-379">78,536,412</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:556.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-58" decimals="-3" name="ifrs-full:Equity" scale="3" id="f-380">785</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:556.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:21.04pt"></span></span><span style="left:23.669999999999998pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-59" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-381">1,190,593</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:341.25pt;position:var(--position);top:556.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:33.29pt"></span></span><span style="left:35.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-60" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-382">2,309</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:556.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:23.96pt"></span></span><span style="left:26.59pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-61" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-383">402,380</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:456.75pt;position:var(--position);top:556.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:23.96pt"></span></span><span style="left:26.59pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-62" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-384">336,102</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:514.5pt;position:var(--position);top:556.5pt;width:54.75pt"><div><div style="line-height:7pt;position:var(--position);top:7.56pt;width:54.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:26.29pt"></span></span><span style="left:28.919999999999998pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-385">455,205</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:299.05pt;position:var(--position)">F-7<span style="display:inline-block;height:6.93pt;width:22.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:583pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_280"></div><div style="line-height:10pt;position:var(--position);top:72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:158.85pt;position:var(--position);text-decoration:none;white-space:pre">ABIVAX SA CONSOLIDATED STATEMENTS OF CASH FLOWS<span id="i2d4f1c94cf034cb9953f124556200483"></span></span></div><div style="position:var(--position);top:84pt;width:612pt"><div style="font-size:0pt;left:31.5pt;position:var(--position);width:549pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:317.25pt"/><td style="padding:0;width:42.75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:60pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:60pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:60pt"/></tr><tr style="height:27.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:19.88pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:italic;font-weight:normal;left:113.15pt;position:var(--position);text-decoration:none;white-space:pre">(Amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:317.25pt;position:var(--position);width:42.75pt"><div><div style="line-height:7pt;position:var(--position);top:11.31pt;width:42.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:13.02pt;position:var(--position);text-decoration:none;white-space:pre">Notes</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);width:60pt"><div><div style="line-height:7pt;position:var(--position);top:2.91pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:6.98pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:7pt;position:var(--position);top:11.31pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:4.55pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:7pt;position:var(--position);top:19.71pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:23pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);width:60pt"><div><div style="line-height:7pt;position:var(--position);top:2.91pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:6.98pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:7pt;position:var(--position);top:11.31pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:4.55pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:7pt;position:var(--position);top:19.71pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:23pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);width:60pt"><div><div style="line-height:7pt;position:var(--position);top:2.91pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:6.98pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:7pt;position:var(--position);top:11.31pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:4.55pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:7pt;position:var(--position);top:19.71pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:23pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:9.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:27.75pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:2.32pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cash flows provided by (used in) operating activities</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:37.5pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Net loss for the period</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:37.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:29.21pt"></span></span><span style="left:31.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-386">147,740</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:37.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:29.21pt"></span></span><span style="left:31.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-387">176,242</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:37.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:29.21pt"></span></span><span style="left:31.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-388">336,102</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:48.75pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Adjustments for:</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:60pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Amortization of intangibles and depreciation of property, plant and equipment </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:60pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:43.79pt"></span></span><span style="left:46.42pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" id="f-389">707</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:60pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" format="ixt:num-dot-decimal" scale="3" id="f-390">1,100</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:60pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" format="ixt:num-dot-decimal" scale="3" id="f-391">1,072</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:71.25pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Retirement benefit obligations</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:317.25pt;position:var(--position);top:71.25pt;width:42.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.5pt;width:42.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:17.87pt;position:var(--position);text-decoration:none;white-space:pre">16</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:71.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:43.79pt"></span></span><span style="left:46.42pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" scale="3" id="f-392">109</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:71.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:47.29pt"></span></span><span style="left:49.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" scale="3" id="f-393">74</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:71.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" scale="3" id="f-394">65</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:82.5pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Share-based compensation expenses</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:317.25pt;position:var(--position);top:82.5pt;width:42.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.5pt;width:42.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:17.87pt;position:var(--position);text-decoration:none;white-space:pre">14</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:82.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="f-395">8,179</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:82.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:35.04pt"></span></span><span style="left:37.67pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="f-396">20,224</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:82.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:35.04pt"></span></span><span style="left:37.67pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="f-397">35,397</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:93.75pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Net gain on sale of treasury shares</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:93.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" sign="-" name="abvx:AdjustmentsForNetGainOnSaleOfTreasuryShares" scale="3" id="f-398">34</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:93.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="abvx:AdjustmentsForNetGainOnSaleOfTreasuryShares" scale="3" id="f-399">16</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:93.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:47.29pt"></span></span><span style="left:49.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:AdjustmentsForNetGainOnSaleOfTreasuryShares" format="ixt:fixed-zero" scale="3" id="f-400">&#8212;</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:105pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest expenses and other financial expenses</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:317.25pt;position:var(--position);top:105pt;width:42.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.5pt;width:42.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:17.87pt;position:var(--position);text-decoration:none;white-space:pre">21</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:105pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:35.04pt"></span></span><span style="left:37.67pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:AdjustmentsForOtherFinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-401">24,827</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:105pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:35.04pt"></span></span><span style="left:37.67pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:AdjustmentsForOtherFinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-402">14,203</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:105pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:35.04pt"></span></span><span style="left:37.67pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:AdjustmentsForOtherFinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-403">45,697</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:116.25pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial income </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:317.25pt;position:var(--position);top:116.25pt;width:42.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.5pt;width:42.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:17.87pt;position:var(--position);text-decoration:none;white-space:pre">21</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:116.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:36.21pt"></span></span><span style="left:38.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:AdjustmentsForOtherFinanceIncome" format="ixt:num-dot-decimal" scale="3" id="f-404">2,953</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:116.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:32.71pt"></span></span><span style="left:35.34pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:AdjustmentsForOtherFinanceIncome" format="ixt:num-dot-decimal" scale="3" id="f-405">11,609</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:116.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:32.71pt"></span></span><span style="left:35.34pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:AdjustmentsForOtherFinanceIncome" format="ixt:num-dot-decimal" scale="3" id="f-406">23,782</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:127.5pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Effect of unwinding the discount related to advances </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:317.25pt;position:var(--position);top:127.5pt;width:42.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.5pt;width:42.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:17.87pt;position:var(--position);text-decoration:none;white-space:pre">21</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:127.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:41.46pt"></span></span><span style="left:44.09pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" sign="-" name="abvx:AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances" scale="3" id="f-407">355</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:127.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:41.46pt"></span></span><span style="left:44.09pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="abvx:AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances" scale="3" id="f-408">710</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:127.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:41.46pt"></span></span><span style="left:44.09pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="abvx:AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances" scale="3" id="f-409">153</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:138.75pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Increase/(decrease) in derivatives and liabilities measured at fair value</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:317.25pt;position:var(--position);top:138.75pt;width:42.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.5pt;width:42.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:17.87pt;position:var(--position);text-decoration:none;white-space:pre">15</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:138.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:36.21pt"></span></span><span style="left:38.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForFairValueGainsLosses" format="ixt:num-dot-decimal" scale="3" id="f-410">1,158</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:138.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:AdjustmentsForFairValueGainsLosses" format="ixt:num-dot-decimal" scale="3" id="f-411">1,416</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:138.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:35.04pt"></span></span><span style="left:37.67pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForFairValueGainsLosses" format="ixt:num-dot-decimal" scale="3" id="f-412">62,330</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:150pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Forgiveness of conditional advances </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:317.25pt;position:var(--position);top:150pt;width:42.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.5pt;width:42.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:17.87pt;position:var(--position);text-decoration:none;white-space:pre">18</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:150pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:47.29pt"></span></span><span style="left:49.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:AdjustmentsForForgivenessOfConditionalAdvances" format="ixt:fixed-zero" scale="3" id="f-413">&#8212;</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:150pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:36.21pt"></span></span><span style="left:38.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="abvx:AdjustmentsForForgivenessOfConditionalAdvances" format="ixt:num-dot-decimal" scale="3" id="f-414">4,140</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:150pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:47.29pt"></span></span><span style="left:49.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:AdjustmentsForForgivenessOfConditionalAdvances" format="ixt:fixed-zero" scale="3" id="f-415">&#8212;</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:161.25pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Changes in provisions</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:317.25pt;position:var(--position);top:161.25pt;width:42.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.5pt;width:42.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:17.87pt;position:var(--position);text-decoration:none;white-space:pre">14</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:161.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:47.29pt"></span></span><span style="left:49.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:AdjustmentsForProvisions" format="ixt:fixed-zero" scale="3" id="f-416">&#8212;</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:161.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:47.29pt"></span></span><span style="left:49.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:AdjustmentsForProvisions" format="ixt:fixed-zero" scale="3" id="f-417">&#8212;</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:161.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:35.04pt"></span></span><span style="left:37.67pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForProvisions" format="ixt:num-dot-decimal" scale="3" id="f-418">44,706</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:172.5pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Current and deferred taxes expenses</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:317.25pt;position:var(--position);top:172.5pt;width:42.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.5pt;width:42.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:17.87pt;position:var(--position);text-decoration:none;white-space:pre">22</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:172.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:47.29pt"></span></span><span style="left:49.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:AdjustmentsForIncomeTaxExpense" format="ixt:fixed-zero" scale="3" id="f-419">&#8212;</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><span id="ifc0f34806ad143b380b96e001530f12f_16-5-1-1-177164"></span><div style="left:426pt;position:var(--position);top:172.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:47.29pt"></span></span><span style="left:49.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:AdjustmentsForIncomeTaxExpense" format="ixt:fixed-zero" scale="3" id="f-420">&#8212;</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:172.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForIncomeTaxExpense" format="ixt:num-dot-decimal" scale="3" id="f-421">5,848</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:183.75pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:183.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:47.29pt"></span></span><span style="left:49.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:OtherAdjustmentsForNoncashItems" scale="3" id="f-422">22</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:183.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:43.79pt"></span></span><span style="left:46.42pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:OtherAdjustmentsForNoncashItems" scale="3" id="f-423">204</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:183.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:43.79pt"></span></span><span style="left:46.42pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:OtherAdjustmentsForNoncashItems" scale="3" id="f-424">270</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:195pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cash flows provided by (used in) operating activities before change in working capital requirements </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:195pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:29.21pt"></span></span><span style="left:31.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-425">118,395</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:195pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:29.21pt"></span></span><span style="left:31.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-426">155,495</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:195pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:29.21pt"></span></span><span style="left:31.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-427">164,780</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:206.25pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Decrease / (increase) in other receivables and related accounts</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:206.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:32.71pt"></span></span><span style="left:35.34pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="f-428">14,231</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:206.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="f-429">4,591</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:206.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="f-430">7,042</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:217.5pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Increase / (decrease) in trade payables </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:217.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:35.04pt"></span></span><span style="left:37.67pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" format="ixt:num-dot-decimal" scale="3" id="f-431">31,757</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:217.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:36.21pt"></span></span><span style="left:38.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" format="ixt:num-dot-decimal" scale="3" id="f-432">3,444</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:217.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:36.21pt"></span></span><span style="left:38.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" format="ixt:num-dot-decimal" scale="3" id="f-433">6,210</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:228.75pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Increase / (decrease) in tax and social security liabilities </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:228.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-434">3,821</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:228.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:36.21pt"></span></span><span style="left:38.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="abvx:AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-435">1,487</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:228.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-436">2,110</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:240pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Changes in deferred income and other liabilities</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:240pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" sign="-" name="abvx:AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities" scale="3" id="f-437">81</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:240pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-438">1,763</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:240pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:43.79pt"></span></span><span style="left:46.42pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities" scale="3" id="f-439">710</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:251.25pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Changes in working capital requirements</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:251.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:35.04pt"></span></span><span style="left:37.67pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-440">21,265</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:251.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-441">1,423</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:251.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-442">3,651</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:262.5pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Income taxes paid</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:262.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:47.29pt"></span></span><span style="left:49.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" format="ixt:fixed-zero" scale="3" id="f-443">&#8212;</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:262.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:47.29pt"></span></span><span style="left:49.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" format="ixt:fixed-zero" scale="3" id="f-444">&#8212;</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:262.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:47.29pt"></span></span><span style="left:49.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" format="ixt:fixed-zero" scale="3" id="f-445">&#8212;</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:273.75pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cash flows provided by (used in) operating activities</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:273.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:32.71pt"></span></span><span style="left:35.34pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-446">97,130</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:273.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:29.21pt"></span></span><span style="left:31.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-447">154,072</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:273.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:29.21pt"></span></span><span style="left:31.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-448">161,129</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:285pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cash flows provided by (used in) investing activities</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:296.25pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Acquisitions of intangible assets</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:296.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:47.29pt"></span></span><span style="left:49.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-449">&#8212;</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:296.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:48.46pt"></span></span><span style="left:51.09pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="3" id="f-450">3</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:296.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:47.29pt"></span></span><span style="left:49.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-451">&#8212;</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:307.5pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Acquisitions of property, plant and equipment</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:307.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:41.46pt"></span></span><span style="left:44.09pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="f-452">265</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:307.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:41.46pt"></span></span><span style="left:44.09pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="f-453">640</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:307.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:41.46pt"></span></span><span style="left:44.09pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="f-454">142</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:318.75pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Advances reimbursed by / (made to) CROs </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:317.25pt;position:var(--position);top:318.75pt;width:42.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:42.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:17.87pt;position:var(--position);text-decoration:none;white-space:pre">10</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:318.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:36.21pt"></span></span><span style="left:38.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" sign="-" name="abvx:PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations" format="ixt:num-dot-decimal" scale="3" id="f-455">1,620</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:318.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:41.46pt"></span></span><span style="left:44.09pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="abvx:PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations" scale="3" id="f-456">231</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:318.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:47.29pt"></span></span><span style="left:49.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations" scale="3" id="f-457">71</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:330pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Increase in deposits</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:317.25pt;position:var(--position);top:330pt;width:42.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.5pt;width:42.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:19.62pt;position:var(--position);text-decoration:none;white-space:pre">9</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:330pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:36.21pt"></span></span><span style="left:38.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:CashPaymentsForDeposits" format="ixt:num-dot-decimal" scale="3" id="f-458">9,351</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:330pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:41.46pt"></span></span><span style="left:44.09pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:CashPaymentsForDeposits" scale="3" id="f-459">591</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:330pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:32.71pt"></span></span><span style="left:35.34pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:CashPaymentsForDeposits" format="ixt:num-dot-decimal" scale="3" id="f-460">14,152</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:341.25pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Decrease in deposits</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:317.25pt;position:var(--position);top:341.25pt;width:42.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.5pt;width:42.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:19.62pt;position:var(--position);text-decoration:none;white-space:pre">9</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:341.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:43.79pt"></span></span><span style="left:46.42pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:ProceedsFromReimbursementsOfDeposits" scale="3" id="f-461">741</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:341.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:ProceedsFromReimbursementsOfDeposits" format="ixt:num-dot-decimal" scale="3" id="f-462">9,050</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:341.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:43.79pt"></span></span><span style="left:46.42pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:ProceedsFromReimbursementsOfDeposits" scale="3" id="f-463">500</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:352.5pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest received</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:352.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:InterestReceivedClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-464">2,400</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:352.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:InterestReceivedClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-465">8,178</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:352.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:InterestReceivedClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-466">5,530</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:363.75pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cash flows provided by (used in) investing activities </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:363.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:36.21pt"></span></span><span style="left:38.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-467">8,095</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:363.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:35.04pt"></span></span><span style="left:37.67pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-468">15,762</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:363.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:36.21pt"></span></span><span style="left:38.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-469">8,193</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:375pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cash flows provided by (used in) financing activities</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:386.25pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Capital increases&#160; </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:317.25pt;position:var(--position);top:386.25pt;width:42.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.5pt;width:42.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:17.87pt;position:var(--position);text-decoration:none;white-space:pre">13</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:386.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:31.54pt"></span></span><span style="left:34.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="3" id="f-470">353,377</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:386.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:47.29pt"></span></span><span style="left:49.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:fixed-zero" scale="3" id="f-471">&#8212;</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:386.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:31.54pt"></span></span><span style="left:34.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="3" id="f-472">648,124</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:397.5pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Transaction costs related to capital increase&#160; </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:317.25pt;position:var(--position);top:397.5pt;width:42.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.5pt;width:42.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:17.87pt;position:var(--position);text-decoration:none;white-space:pre">13</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:397.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:32.71pt"></span></span><span style="left:35.34pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:PaymentsForProceedsFromShareIssueRelatedCostsCredit" format="ixt:num-dot-decimal" scale="3" id="f-473">28,111</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:397.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:43.79pt"></span></span><span style="left:46.42pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="abvx:PaymentsForProceedsFromShareIssueRelatedCostsCredit" scale="3" id="f-474">446</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:397.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:32.71pt"></span></span><span style="left:35.34pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:PaymentsForProceedsFromShareIssueRelatedCostsCredit" format="ixt:num-dot-decimal" scale="3" id="f-475">40,914</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:408.75pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Net proceeds from non-convertible bond loans</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:317.25pt;position:var(--position);top:408.75pt;width:42.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.5pt;width:42.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:17.87pt;position:var(--position);text-decoration:none;white-space:pre">15</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:408.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:47.29pt"></span></span><span style="left:49.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:NetProceedsFromNonConvertibleLoansNotes" format="ixt:fixed-zero" scale="3" id="f-476">&#8212;</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:408.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:35.04pt"></span></span><span style="left:37.67pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:NetProceedsFromNonConvertibleLoansNotes" format="ixt:num-dot-decimal" scale="3" id="f-477">47,944</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:408.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:47.29pt"></span></span><span style="left:49.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:NetProceedsFromNonConvertibleLoansNotes" format="ixt:fixed-zero" scale="3" id="f-478">&#8212;</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:420pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Repayments of non-convertible bond loans</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:317.25pt;position:var(--position);top:420pt;width:42.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.5pt;width:42.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:17.87pt;position:var(--position);text-decoration:none;white-space:pre">15</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:420pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:32.71pt"></span></span><span style="left:35.34pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:RepaymentsOfNonConvertibleLoansNotes" format="ixt:num-dot-decimal" scale="3" id="f-479">11,635</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:420pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:47.29pt"></span></span><span style="left:49.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:RepaymentsOfNonConvertibleLoansNotes" format="ixt:fixed-zero" scale="3" id="f-480">&#8212;</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:420pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:32.71pt"></span></span><span style="left:35.34pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:RepaymentsOfNonConvertibleLoansNotes" format="ixt:num-dot-decimal" scale="3" id="f-481">53,920</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:431.25pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Net proceeds from convertible loan notes</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:317.25pt;position:var(--position);top:431.25pt;width:42.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.5pt;width:42.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:17.87pt;position:var(--position);text-decoration:none;white-space:pre">15</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:431.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:35.04pt"></span></span><span style="left:37.67pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:NetProceedsFromConvertibleLoanNotes" format="ixt:num-dot-decimal" scale="3" id="f-482">55,841</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:431.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:47.29pt"></span></span><span style="left:49.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:NetProceedsFromConvertibleLoanNotes" format="ixt:fixed-zero" scale="3" id="f-483">&#8212;</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:431.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:47.29pt"></span></span><span style="left:49.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:NetProceedsFromConvertibleLoanNotes" format="ixt:fixed-zero" scale="3" id="f-484">&#8212;</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:442.5pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.39pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Repayments of convertible loan notes</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:317.25pt;position:var(--position);top:442.5pt;width:42.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.5pt;width:42.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:17.87pt;position:var(--position);text-decoration:none;white-space:pre">15</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:442.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:32.71pt"></span></span><span style="left:35.34pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:RepaymentsOfConvertibleLoansNotes" format="ixt:num-dot-decimal" scale="3" id="f-485">27,188</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:442.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:36.21pt"></span></span><span style="left:38.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:RepaymentsOfConvertibleLoansNotes" format="ixt:num-dot-decimal" scale="3" id="f-486">8,750</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:442.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:36.21pt"></span></span><span style="left:38.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:RepaymentsOfConvertibleLoansNotes" format="ixt:num-dot-decimal" scale="3" id="f-487">2,188</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:453.75pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Repayment of PGE</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:317.25pt;position:var(--position);top:453.75pt;width:42.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.5pt;width:42.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:17.87pt;position:var(--position);text-decoration:none;white-space:pre">15</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:453.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:36.21pt"></span></span><span style="left:38.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:RepaymentsOfPGE" format="ixt:num-dot-decimal" scale="3" id="f-488">1,250</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:453.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:36.21pt"></span></span><span style="left:38.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:RepaymentsOfPGE" format="ixt:num-dot-decimal" scale="3" id="f-489">1,250</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:453.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:36.21pt"></span></span><span style="left:38.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:RepaymentsOfPGE" format="ixt:num-dot-decimal" scale="3" id="f-490">2,514</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:465pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Repayments of conditional advances</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:317.25pt;position:var(--position);top:465pt;width:42.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.5pt;width:42.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:17.87pt;position:var(--position);text-decoration:none;white-space:pre">15</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:465pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:41.46pt"></span></span><span style="left:44.09pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:RepaymentsOfConditionalAdvances" scale="3" id="f-491">110</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:465pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:36.21pt"></span></span><span style="left:38.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:RepaymentsOfConditionalAdvances" format="ixt:num-dot-decimal" scale="3" id="f-492">2,708</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:465pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:47.29pt"></span></span><span style="left:49.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:RepaymentsOfConditionalAdvances" format="ixt:fixed-zero" scale="3" id="f-493">&#8212;</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:476.25pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Payments of the lease liabilities </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:317.25pt;position:var(--position);top:476.25pt;width:42.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.5pt;width:42.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:17.87pt;position:var(--position);text-decoration:none;white-space:pre">15</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:476.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:41.46pt"></span></span><span style="left:44.09pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="f-494">529</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:476.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:41.46pt"></span></span><span style="left:44.09pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="f-495">458</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:476.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:41.46pt"></span></span><span style="left:44.09pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="f-496">911</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:487.5pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Net proceeds from sale of treasury shares</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:487.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:47.29pt"></span></span><span style="left:49.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:ProceedsFromSaleOrIssueOfTreasuryShares" scale="3" id="f-497">10</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:487.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:43.79pt"></span></span><span style="left:46.42pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:ProceedsFromSaleOrIssueOfTreasuryShares" scale="3" id="f-498">434</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:487.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:47.29pt"></span></span><span style="left:49.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:ProceedsFromSaleOrIssueOfTreasuryShares" format="ixt:fixed-zero" scale="3" id="f-499">&#8212;</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:498.75pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest paid </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:317.25pt;position:var(--position);top:498.75pt;width:42.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:42.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:17.87pt;position:var(--position);text-decoration:none;white-space:pre">15</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:498.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:36.21pt"></span></span><span style="left:38.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-500">5,279</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:498.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:36.21pt"></span></span><span style="left:38.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-501">7,696</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:498.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:36.21pt"></span></span><span style="left:38.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-502">6,490</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:510pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Exercise of warrants</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:317.25pt;position:var(--position);top:510pt;width:42.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.5pt;width:42.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:15.25pt;position:var(--position);text-decoration:none;white-space:pre">15.1</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:510pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:47.29pt"></span></span><span style="left:49.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="f-503">&#8212;</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:510pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:47.29pt"></span></span><span style="left:49.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="f-504">&#8212;</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:510pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-505">5,820</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:521.25pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:521.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:43.79pt"></span></span><span style="left:46.42pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" scale="3" id="f-506">163</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:521.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:43.79pt"></span></span><span style="left:46.42pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" scale="3" id="f-507">245</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:521.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:43.79pt"></span></span><span style="left:46.42pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" scale="3" id="f-508">300</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:532.5pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cash flows provided by (used in) financing activities </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:532.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:31.54pt"></span></span><span style="left:34.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-509">335,290</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:532.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:35.04pt"></span></span><span style="left:37.67pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-510">28,207</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:532.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:31.54pt"></span></span><span style="left:34.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-511">547,307</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:12.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:543.75pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.76pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Effect of movements in exchange rates on cash held</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:317.25pt;position:var(--position);top:543.75pt;width:42.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.81pt;width:42.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:17.87pt;position:var(--position);text-decoration:none;white-space:pre">11</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:543.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.76pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:36.21pt"></span></span><span style="left:38.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-512">5,072</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:543.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.76pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-513">2,382</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:543.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.76pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:32.71pt"></span></span><span style="left:35.34pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-514">10,251</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:556.5pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Revaluation of cash equivalents measured at fair value</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:317.25pt;position:var(--position);top:556.5pt;width:42.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.5pt;width:42.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:9.71pt;position:var(--position);text-decoration:none;white-space:pre">11 &amp; 21</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:556.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:47.29pt"></span></span><span style="left:49.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:RevaluationOfCashEquivalentsMeasuredAtFairValue" format="ixt:fixed-zero" scale="3" id="f-515">&#8212;</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:556.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:47.29pt"></span></span><span style="left:49.92pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:RevaluationOfCashEquivalentsMeasuredAtFairValue" format="ixt:fixed-zero" scale="3" id="f-516">&#8212;</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:556.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:38.54pt"></span></span><span style="left:41.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:RevaluationOfCashEquivalentsMeasuredAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-517">4,730</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:567.75pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Increase (decrease) in cash and cash equivalents </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:567.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:31.54pt"></span></span><span style="left:34.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-518">224,992</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:567.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:29.21pt"></span></span><span style="left:31.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-519">107,720</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:567.75pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:31.54pt"></span></span><span style="left:34.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-520">372,464</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:579pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cash and cash equivalents at the beginning of the year</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:317.25pt;position:var(--position);top:579pt;width:42.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.5pt;width:42.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:17.87pt;position:var(--position);text-decoration:none;white-space:pre">11</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:579pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:35.04pt"></span></span><span style="left:37.67pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-521">26,950</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:579pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:31.54pt"></span></span><span style="left:34.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-522">251,942</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:579pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:31.54pt"></span></span><span style="left:34.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-523">144,221</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:590.25pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cash and cash equivalents at the end of the year</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:317.25pt;position:var(--position);top:590.25pt;width:42.75pt"><div><div style="line-height:7pt;position:var(--position);top:3.5pt;width:42.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:17.87pt;position:var(--position);text-decoration:none;white-space:pre">11</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:590.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:31.54pt"></span></span><span style="left:34.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-524">251,942</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:590.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:31.54pt"></span></span><span style="left:34.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-525">144,221</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:590.25pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.01pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.85pt;width:31.54pt"></span></span><span style="left:34.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-526">516,685</ix:nonFraction><span style="display:inline-block;height:4.85pt;width:2.33pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:601.5pt;width:317.25pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:317.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Increase (decrease) in cash and cash equivalents </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:363pt;position:var(--position);top:601.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:31.54pt"></span></span><span style="left:34.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-527">224,992</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:426pt;position:var(--position);top:601.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:29.21pt"></span></span><span style="left:31.84pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-528">107,720</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:489pt;position:var(--position);top:601.5pt;width:60pt"><div><div style="line-height:7pt;position:var(--position);top:3.06pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:4.74pt;width:31.54pt"></span></span><span style="left:34.17pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-529">372,464</ix:nonFraction><span style="display:inline-block;height:4.74pt;width:2.33pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:299.05pt;position:var(--position)">F-8<span style="display:inline-block;height:6.93pt;width:22.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><div style="position:absolute;top:70.56pt" id="i7a006daedb3d4216a4128b76247285d7_283"></div><div style="line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:175.23pt;position:var(--position);text-decoration:none;white-space:pre">ABIVAX SA NOTES TO THE FINANCIAL STATEMENTS </span></div><div style="position:absolute;top:92.56pt" id="i7a006daedb3d4216a4128b76247285d7_286"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:92.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 1. </span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" id="f-530" continuedAt="f-530-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:68.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">The Group </span></ix:nonNumeric></div><div style="position:absolute;top:108.56pt" id="i7a006daedb3d4216a4128b76247285d7_289"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:108.56pt;width:612pt"><ix:continuation id="f-530-1" continuedAt="f-530-2"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 1.1. Information on the Group and its business </span></ix:continuation></div><ix:continuation id="f-530-2" continuedAt="f-530-3"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:142.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">ABIVAX SA (the &#8220;Company&#8221;) is a soci&#233;t&#233; anonyme incorporated under the laws of France on December 4, 2013. Its registered office </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:152.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">is located at 7-11 Boulevard Haussmann&#8212;75009 Paris, France. The Company is developing therapeutics that harness the body&#8217;s </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:162.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:184.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">These consolidated financial statements as of and for the year ended December 31, 2025 comprise the Company and ABIVAX LLC </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:194.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(the &#8220;Subsidiary&#8221;), </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.97pt;position:var(--position);text-decoration:none;white-space:pre">the</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:126.17pt;position:var(--position);text-decoration:none;white-space:pre"> United States subsidiary of ABIVAX SA, created on March 20, 2023 under the laws of the State of Delaware </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:204.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(together referred to as the &#8220;Group&#8221;).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:226.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group has incurred losses since its inception and had shareholders&#8217; equity of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:363.17pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-531">455,205</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:400.67pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:403.17pt;position:var(--position);text-decoration:none;white-space:pre">thousand as of December 31, 2025. The </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:236.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Group anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its drug candidates </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:246.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">which are currently under development. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:198.03pt;position:var(--position);text-decoration:none;white-space:pre">Substantial additional financing will be needed by the Group to fund its operations and to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:256.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">commercially develop its drug candidates. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:278.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group's future operations are highly dependent on a combination of factors, including: (i)&#160;the success of its research and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:288.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">development activities; (ii)&#160;regulatory approval and market acceptance of its proposed future products; (iii)&#160;the timely and successful </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:298.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">completion of additional financing and (iv)&#160;the development of competitive therapies by other biotechnology and pharmaceutical </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:308.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">companies. As a result, the Group is, and expects to continue to be, in the short to mid-term, financed through the issuance of new </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:318.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">equity or debt instruments. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:340.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group is focusing its efforts on the following areas: </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:362.56pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Completion of the Phase 3 clinical trial program (ABTECT) for obefazimod in moderately to severely active ulcerative colitis </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:376pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(&#8220;UC&#8221;). </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:389.44pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Continuation of the Phase 2b clinical trial (ENHANCE-CD) of obefazimod in Crohn&#8217;s disease (&#8220;CD&#8221;). </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:402.88pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Evaluating combination therapy candidates with obefazimod in UC.</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:416.32pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Selecting a follow-on candidate for obefazimod. </span></div></ix:continuation><div style="position:absolute;top:459.76pt" id="i7a006daedb3d4216a4128b76247285d7_292"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:459.76pt;width:612pt"><ix:continuation id="f-530-3" continuedAt="f-530-4"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 1.2. Date of authorization of issuance </span></ix:continuation></div><ix:continuation id="f-530-4" continuedAt="f-530-5"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:475.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The consolidated financial statements and related notes (the &#8220;financial statements&#8221;) have been prepared under the responsibility of </span></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:485.76pt;width:612pt"><ix:continuation id="f-530-5" continuedAt="f-530-6"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">management of the Group and were approved and authorized for issuance by the Group&#8217;s board of directors on </span></ix:continuation><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:482.24pt;position:var(--position);text-decoration:none;white-space:pre"><ix:continuation id="f-530-6">March 19, 2026.</ix:continuation> </span></div><div style="position:absolute;top:513.76pt" id="i7a006daedb3d4216a4128b76247285d7_295"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:513.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 2. </span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" id="f-532" continuedAt="f-532-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:68.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Basis of preparation </span></ix:nonNumeric></div><ix:continuation id="f-532-1" continuedAt="f-532-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:535.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Except for share data and per share amounts, the financial statements are presented in thousands of euros. Amounts are rounded up or </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:546.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">down the nearest whole number for the calculation of certain financial data and other information contained in these accounts. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:558.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Accordingly, the total amounts presented in certain tables may not be the exact sum of the preceding figures. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:569.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:581.36pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="ifrs-full:StatementOfIFRSCompliance" id="f-533" continuedAt="f-533-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Statement of compliance </span></ix:nonNumeric></div><ix:continuation id="f-533-1" continuedAt="f-533-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:603.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The consolidated financial statements of the Group as of and for the years ended December 31, 2023, 2024 and 2025 have been </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:614.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">prepared in accordance with both International Financial Reporting Standards (&#8220;IFRS&#8221;) as issued by the International Accounting </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:625.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Standard Board (&#8220;IASB&#8221;) and IFRS as adopted by the European Union (&#8220;EU&#8221;) regulation n&#176;1606/2002 of July 19, 2002. The term </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:636.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8220;IFRS&#8221; refers collectively to International Accounting Standards (&#8220;IAS&#8221;) and IFRS as well as the interpretations issued by the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:648.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Standing Interpretations Committee (&#8220;SIC&#8221;) and the International Financial Reporting Interpretations Standards Committee (&#8220;IFRS </span></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:659.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><ix:continuation id="f-533-2">IC&#8221;), whose application is mandatory for the year ended December 31, 2025.</ix:continuation> </span></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:299.05pt;position:var(--position)">F-9<span style="display:inline-block;height:6.93pt;width:22.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><ix:continuation id="f-532-2" continuedAt="f-532-3"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Preparation of the financial statements </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:92.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The consolidated financial statements of the Group were prepared on a historical cost basis, with the exception of certain asset and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:103.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">liability categories and in accordance with the provisions set out in IFRS such as employee benefits measured using the projected unit </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:114.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">credit method, the Heights notes (classified under "Convertible loan notes") measured at fair value and derivative financial instruments </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">measured at fair value. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.47pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:155.36pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="abvx:DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock" id="f-534" continuedAt="f-534-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Going concern </span></ix:nonNumeric></div><ix:continuation id="f-534-1"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:177.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group has incurre</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:126.19pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">d substantial operating losses since inception and expects to continue to incur significant operating losses for the </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:189.36pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">foreseeab</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:74.27000000000001pt;position:var(--position);text-decoration:none;white-space:pre">le future and may never become profitable. For the year ended December 31, 2025, the Group had a net loss of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:519.9100000000001pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-535">336,102</ix:nonFraction> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:201.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72.09pt;position:var(--position);text-decoration:none;white-space:pre">.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:74.59pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:77.09pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:225.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Since inception, the Group has financed its operations through the issuance of ordinary shares with gross aggregate proceeds of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:237.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-63" decimals="-5" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="6" id="f-536">1,194.7</ix:nonFraction> million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:102.35pt;position:var(--position);text-decoration:none;white-space:pre">, of which </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:145.1pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-64" decimals="-6" name="ifrs-full:ProceedsFromIssuingShares" scale="6" id="f-537">130</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:196.45pt;position:var(--position);text-decoration:none;white-space:pre"> of gross proceeds were from offerings of its ordinary shares on Euronext Paris in February </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:249.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">2023, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:61pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-65" decimals="-5" name="ifrs-full:ProceedsFromIssuingShares" scale="6" id="f-538">223.3</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:119.85pt;position:var(--position);text-decoration:none;white-space:pre"> of gross proceeds were from its offering of ordinary shares in the form of American Depository Shares ("ADS") </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:261.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">on the Nasdaq Global Market as well as ordinary shares in Europe (including France) and countries outside of the United States in a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:273.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">private placement in October 2023, and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:196.64pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-66" decimals="-5" name="ifrs-full:ProceedsFromIssuingShares" scale="6" id="f-539">637.5</ix:nonFraction> million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:255.49pt;position:var(--position);text-decoration:none;white-space:pre"> of gross proceeds were from the offering of the Group's ordinary shares in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:285.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">form of ADS on the Nasdaq Global Market in July 2025 ("the Offering"), </span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:332.83pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">ba</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:342.26pt;position:var(--position);text-decoration:none;white-space:pre">nk borrowings and structured loans</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:483.27pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.77pt;position:var(--position);text-decoration:none;white-space:pre">for </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:499.93pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-63" decimals="-5" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" scale="6" id="f-540">175.0</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:558.78pt;position:var(--position);text-decoration:none;white-space:pre">, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:297.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">reimbursements of Research Tax Credits (Cr&#233;dit d&#8217;Imp&#244;t Recherche (&#8220;CIR&#8221;)) in an aggregate amo</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:430.47pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">unt of </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:456.57pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-63" decimals="-5" name="abvx:ProceedsFromResearchTaxCredit" scale="6" id="f-541">41.2</ix:nonFraction> million</span><span style="background-color:#ffff00;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:510.42pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">,</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:512.9200000000001pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> subsidies </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:309.36pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">received from Banque Publique d&#8217;Investissement (&#8220;Bpifrance&#8221;) (inclu</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:316.2pt;position:var(--position);text-decoration:none;white-space:pre">ding </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:336.47pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-67" decimals="-5" name="ifrs-full:ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities" scale="6" id="f-542">17.1</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:390.32pt;position:var(--position);text-decoration:none;white-space:pre"> of subsidies and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:459.72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-67" decimals="-5" name="abvx:ProceedsFromConditionalAdvances" scale="6" id="f-543">1.8</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:508.57pt;position:var(--position);text-decoration:none;white-space:pre"> of conditional </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:321.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">advances) and royalty certificates in an amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:237.95pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-63" decimals="-5" name="abvx:NetProceedsFromSaleOfRoyaltyCertificates" scale="6" id="f-544">2.9</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:286.8pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:345.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Based on the Group&#8217;s existing cash and cash equivalents </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:264.93pt;position:var(--position);text-decoration:none;white-space:pre">and other short-</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:328.21pt;position:var(--position);text-decoration:none;white-space:pre">term investments</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:396.73pt;position:var(--position);text-decoration:none;white-space:pre"> of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:410.06pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-5" name="abvx:CashAndCashEquivalentsAndOtherShortTermInvestments" scale="6" id="f-545">530.4</ix:nonFraction> million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:468.91pt;position:var(--position);text-decoration:none;white-space:pre"> a</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:475.84pt;position:var(--position);text-decoration:none;white-space:pre">s of December 31, 2025, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:356.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the Group expects, as of the date of issuance of these financial statements, to be able to fund its forecasted cash flow requirements into </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:368.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the fourth quarter of 20</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.25pt;position:var(--position);text-decoration:none;white-space:pre">27. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:144.25pt;position:var(--position);text-decoration:none;white-space:pre">This take</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:181.14pt;position:var(--position);text-decoration:none;white-space:pre">s into account management's assumptions</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:347.76pt;position:var(--position);text-decoration:none;white-space:pre"> of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:361.09pt;position:var(--position);text-decoration:none;white-space:pre">continued</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:400.49pt;position:var(--position);text-decoration:none;white-space:pre"> R&amp;D expenditure related to the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:379.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">continuation of the Phase 3 clinical trials of obefazimod in UC, progression of the Phase 2b clinical trials for CD and the initial stages </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:391.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of the scale up of the commercial organization as the Group prepares for a potential launch of obefazimod in UC.</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:488.78pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#160; </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:414.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Based on the above, these financial statements have been prepared on a going concern basis.</span></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:444.86pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="abvx:DisclosureOfImpactOfTheUkraineRussiaHostilitiesOnTheGroupPolicyTextBlock" id="f-546" continuedAt="f-546-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Impact of the Ukraine/Russia Hostilities on the Group </span></ix:nonNumeric></div><ix:continuation id="f-546-1" continuedAt="f-546-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:466.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In February 2022, Russia invaded Ukraine. The conflict has already had major implications for the global economy and the rate of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:478.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">inflation, particularly in relation to the supply of energy, raw materials and food products. It has also caused intense volatility on the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:489.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">financial markets, something that is still ongoing at the reporting date and has pushed down stock market prices around the world. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:511.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Given these developments, the Group has decided not to include Russia and Belarus in its global Phase 3 program for obefazimod in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:522.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">UC. However, the global scale of this conflict cannot be predicted at this stage. The Group, therefore, cannot rule out an adverse </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:534.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">impact of this conflict on its business, including in terms of access to raw materials, logistics, the performance of clinical studies and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:545.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in relation to any future financing the Group may seek. </span></div><div style="font-size:12pt;line-height:11pt;position:var(--position);top:567.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The long-term safety and efficacy extension of the</span><span style="color:#ff0000;font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:237.68pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:240.16pt;position:var(--position);text-decoration:none;white-space:pre">Phase 2b maintenance trial of obefazimod in moderately to severely active UC is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:579.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the Group&#8217;s only clinical trial with patients currently enrolled in Ukraine.&#160; The Phase 2b 12-month assessment was carried out in all </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:591.18pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the Ukrainian patients before the war broke out and these patients are therefore included in the one-year maintenance results that were </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:602.38pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">reported on April 6, 2022. Ukrainian patients who completed the two-year Phase 2b maintenance trial have been transitioned to the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:613.58pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">long-term safety and efficacy trial that is still on-going. The Group also has a few Ukrainian sites active in the western part of Ukraine </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:624.78pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in the ABTECT Phase 3 clinical trials.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:189.95pt;position:var(--position);text-decoration:none;white-space:pre"> None of these sites are located in the Crimea Region of Ukraine, the so-called Donetsk </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:635.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">People&#8217;s Republic, or the so-called Luhansk People&#8217;s Republic. We continue to monitor developments in the region, but any </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:647.18pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">instability as a result of the war may have material adverse impacts on these clinical sites, which could negatively impact our Phase 3 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:658.38pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">clinical trials.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:680.78pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Together with its contract research organizations ("</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:240.91pt;position:var(--position);text-decoration:none;white-space:pre">CROs")</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:272.75pt;position:var(--position);text-decoration:none;white-space:pre">, the Group is making considerable efforts to ensure the follow-up of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:691.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">patients who are unable to come to the study centers. Monitoring takes place through a remote monitoring system that was established </span></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:703.18pt;width:612pt"><ix:continuation id="f-546-2"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and used successfully during the COVID-19 pandemic.</span></ix:continuation><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:257.19pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:259.69pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div></div></ix:continuation></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-10<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-532-3" continuedAt="f-532-4"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="abvx:DisclosureOfAccountingPolicyForNewRevisedOrAmendedStandardsAndInterpretationsPolicyTextBlock" id="f-547" continuedAt="f-547-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">N</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:42.66pt;position:var(--position);text-decoration:none;white-space:pre">ew, revised or amended Standards and Interpreta</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:241.12pt;position:var(--position);text-decoration:none;white-space:pre">tions </span></ix:nonNumeric></div><ix:continuation id="f-547-1"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:92.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group applied the amendment to IAS 21 The Effects of Changes in Foreign Exchange Rates &#8211; Lack of Exchangeability that is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:103.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">effective as of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:95.07pt;position:var(--position);text-decoration:none;white-space:pre">December&#160;31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:173.61pt;position:var(--position);text-decoration:none;white-space:pre">.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:176.11pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:178.61pt;position:var(--position);text-decoration:none;white-space:pre">The Group assessed the impacts resulting from the application of this issued accounting </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:114.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">pronouncement and concluded that they are not material.</span></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:144.16pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="abvx:DisclosureOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedByIASBButNotYetMandatoryPolicyTextBlock" id="f-548" continuedAt="f-548-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">New standards, amendments and interpretations issued by IASB but not yet mandatory for financial years starting from January 1, </span></ix:nonNumeric></div><ix:continuation id="f-548-1" continuedAt="f-548-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:154.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">2025 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:170.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group did not elect for early application of the following new standards, amendments and interpretations, which were issued but </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:180.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">not mandatory as of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:118.15pt;position:var(--position);text-decoration:none;white-space:pre">December&#160;31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:196.69pt;position:var(--position);text-decoration:none;white-space:pre">: </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:201.66pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre">Amendments to IFRS 9 Financial Instruments and IFRS 7 Financial Instruments: Disclosures &#8211; Amendments to the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:215.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre">Classification and Measurement of Financial Instruments, whose application is for annual reporting periods beginning on </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:228.54pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre">or after January 1, 2026, as approved by the EU on May 27, 2025; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:241.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre">Amendments to IFRS 9 Financial Instruments and IFRS 7 Financial Instruments: Disclosures &#8211; Contracts Referencing </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:253.18pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre">Nature-dependent Electricity, whose application is for annual reporting periods beginning on or after January 1, 2026, as </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:264.38pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre">approved by the EU on June 30, 2025; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:275.58pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre">IFRS 18 Presentation and Disclosure in Financial Statements, whose application is for annual reporting periods </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:286.78pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre">beginning on or after January 1, 2027, as approved by the EU on February 16, 2026; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:297.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre">IFRS 19 Subsidiaries without Public Accountability: Disclosures, whose application is for annual reporting periods </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:309.18pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre">beginning on or after January 1, 2027 (not yet approved by the UE), and</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:320.38pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre;width:3.5pt">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre;width:485.99pt">Annual Improvements Volume 11, whose application is for annual reporting periods beginning on or after January 1,</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.99pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:331.38pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre;width:25pt">2026, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:115pt;position:var(--position);text-decoration:none;white-space:pre;width:157.69pt">as approved by the EU on July 9, 2025.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:355.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">These texts have not been early adopted. The application of the standards and interpretations issued respectively by the IASB and the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:367.02pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">IFRS IC that are not yet effective as of December 31, 2025 is not expected to have a material impact on the Group&#8217;s consolidated </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:378.22pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">financial statements. IFRS 18, issued in April 2024 and effective from January 1, 2027, will modify the presentation of the </span></div></ix:continuation></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:389.42pt;width:612pt"><ix:continuation id="f-548-2"><ix:continuation id="f-532-4"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Consolidated statements of income (loss) and the Consolidated statements of cash flows</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:388.1pt;position:var(--position);text-decoration:none;white-space:pre">.</span></ix:continuation></ix:continuation><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:390.6pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="position:absolute;top:418.62pt" id="i7a006daedb3d4216a4128b76247285d7_298"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:418.62pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:108pt;position:var(--position);text-decoration:none;white-space:pre">Note 3. </span><ix:nonNumeric contextRef="c-1" name="abvx:DisclosureOfSignificantEventsForThePeriodReportedAndEventsAfterReportingPeriodTextBlock" id="f-549" continuedAt="f-549-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:140.48pt;position:var(--position);text-decoration:none;white-space:pre">Significant events for the years ended</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:300.07pt;position:var(--position);text-decoration:none;white-space:pre"> December 31, 2023, 2024 and 2025 </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:451.95pt;position:var(--position);text-decoration:none;white-space:pre">and subsequent events </span></ix:nonNumeric></div><div style="position:absolute;top:446.62pt" id="i7a006daedb3d4216a4128b76247285d7_304"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:456.62pt;width:612pt"><ix:continuation id="f-549-1" continuedAt="f-549-2"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 3.1. For the year ended December 31, 2023 </span></ix:continuation></div><ix:continuation id="f-549-2" continuedAt="f-549-3"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:480.62pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Company announces successful oversubscribed </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:246.1pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-68" decimals="-5" name="abvx:FinancialAgreementAmount" scale="6" id="f-550">130.0</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:304.4pt;position:var(--position);text-decoration:none;white-space:pre"> cross-over financing at market price with top-tier U.S. and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:492.62pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">European Biotech investors &#8211; February 2023 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:510.62pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On February&#160;22, 2023, the Company announced the successful pricing of an oversubscribed </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:405.97pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-68" decimals="-5" name="abvx:FinancialAgreementAmount" scale="6" id="f-551">130.0</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:464.82pt;position:var(--position);text-decoration:none;white-space:pre"> financing with high-</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:520.62pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">quality U.S. and European biotech specialist investors, led by TCGX, with participation from existing investors Invus, Deep Track </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:530.62pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Capital, Sofinnova Partners, and Venrock Healthcare Capital Partners, as well as from new investors Great Point Partners, LLC, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:540.62pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Deerfield Management Company, Commodore Capital, Samsara BioCapital, Boxer Capital and others, by way of a reserved capital </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:550.62pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:82.03999999999999pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-69" decimals="-6" name="ifrs-full:IssueOfEquity" scale="6" id="f-552">130</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:133.39pt;position:var(--position);text-decoration:none;white-space:pre"> through the issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:231.36pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-69" decimals="0" name="abvx:IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease" format="ixt:num-dot-decimal" scale="0" id="f-553">20,000,000</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:276.36pt;position:var(--position);text-decoration:none;white-space:pre"> newly-issued ordinary shares with a nominal value of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:495.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-68" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-554">0.01</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:517.81pt;position:var(--position);text-decoration:none;white-space:pre"> per share, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:560.62pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">representing </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:87.88pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-70" decimals="3" name="abvx:EquityIssuancePercentageOfCurrentShareCapital" scale="-2" id="f-555">89.6</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.71pt;position:var(--position);text-decoration:none;white-space:pre"> of its current share capital, at a subscription price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:326.21pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-68" decimals="2" name="abvx:EquityIssuanceSubscriptionPricePerShare" scale="0" id="f-556">6.50</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:348.71pt;position:var(--position);text-decoration:none;white-space:pre"> per share. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:582.62pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Related transaction costs amounted to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:189.96pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-71" decimals="-5" name="ifrs-full:ShareIssueRelatedCost" scale="6" id="f-557">6.7</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:238.81pt;position:var(--position);text-decoration:none;white-space:pre"> and were deducted from the share premiums. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:610.62pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Change in governance and management &#8211; February-August 2023 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:626.62pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On April&#160;5, 2023, the Company announced the appointment of Marc de Garidel as Chief Executive Officer (&#8220;CEO&#8221;) and Interim </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:636.62pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Board Chair, effective May&#160;5, 2023. Corinna zur Bonsen-Thomas stepped down as acting Chair, a position she held since August </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:646.62pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">2022, and remains a Board Member. Prof. Hartmut J. Ehrlich, M.D., retired from the CEO position, which he held since the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:656.62pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Company&#8217;s founding in 2013, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.45pt;position:var(--position);text-decoration:none;white-space:pre">and stayed on as a strategic advisor during the transition period, which ended on December 31, 2023. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:678.62pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On February 17, 2023, and April 18, 2023, the Company respectively announced the appointments of Dr. Sheldon Sloan, M.D., M. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:689.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Bioethics as new Chief Medical Officer and Michael Ferguson as new Chief Commercial Officer. </span></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-11<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><ix:continuation id="f-549-3" continuedAt="f-549-4"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On July 11, 2023, the Group announced the appointments of June Lee, M.D. and Troy Ignelzi as new independent members of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:81.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Group&#8217;s Board of Directors, replacing Joy Amundson and Jean-Jacques Bertrand. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:104.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On August 23, 2023, the Group announced the appointment of Patrick Malloy as new Senior Vice President Investor Relations.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Creation of Abivax LLC &#8211; March 2023 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:144.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On March&#160;20, 2023, Abivax LLC (or the "Subsidiary&#8221;), was incorporated as a</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:347.31pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:349.81pt;position:var(--position);text-decoration:none;white-space:pre">limited liability company</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:450.77pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:453.27pt;position:var(--position);text-decoration:none;white-space:pre">under the laws of Delaware. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:154.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of the issuance of the financial statements, the Company has full ownership over the Subsidiary. The Subsidiary hosts the Group&#8217;s </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:164.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">operations in the United States. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:192.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Cashless exercise of the Kreos A&amp;B BSA &#8211; May 2023 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:214.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On May 24, 2023, Kreos Capital V UK Ltd (or &#8220;Kreos&#8221;) opted for the cashless exercise option of the share warrants they held (as </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:225.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">defined in Note 15.3), implemented through the repurchase by the Group of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:341.27pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-72" decimals="0" name="abvx:NumberOfOtherShareWarrantsRepurchased" format="ixt:num-dot-decimal" scale="0" id="f-558">43,070</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:368.77pt;position:var(--position);text-decoration:none;white-space:pre"> tranche A share warrants (&#8220;Kreos A BSA&#8221;) and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:236.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-73" decimals="0" name="abvx:NumberOfOtherShareWarrantsRepurchased" format="ixt:num-dot-decimal" scale="0" id="f-559">43,070</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:63.5pt;position:var(--position);text-decoration:none;white-space:pre"> tranche B share warrants (&#8220;Kreos B BSA&#8221;) and the issuance of respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:370.07pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-72" decimals="0" name="abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants" format="ixt:num-dot-decimal" scale="0" id="f-560">67,887</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:397.57pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:417pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-73" decimals="0" name="abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants" format="ixt:num-dot-decimal" scale="0" id="f-561">31,696</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:444.5pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares, as a result of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:248.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the exercise by Kreos of the outstanding Kreos A &amp; B BSA. The accounting treatment of the operation is set forth in </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:504.67pt;position:var(--position);text-decoration:none;white-space:pre">Note 15.3</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:544.0899999999999pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:270.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Free shares compensation plans &#8211; July-December 2023 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:292.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In July, September and December 2023, the Group issued </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:269.40999999999997pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="plan" contextRef="c-74" decimals="INF" name="abvx:NumberOfShareBasedCompensationPlansIssued" format="ixt-sec:numwordsen" scale="0" id="f-562">five</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:284.94pt;position:var(--position);text-decoration:none;white-space:pre"> free shares compensation plans (</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:417.84pt;position:var(--position);text-decoration:none;white-space:pre">attributions gratuites d&#8217;actions</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:542.1800000000001pt;position:var(--position);text-decoration:none;white-space:pre">, or </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:304.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8220;AGAs&#8221;) to certain of its officers and employees, representing a maximum of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:349.24pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-74" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-563">2,601,296</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:389.24pt;position:var(--position);text-decoration:none;white-space:pre"> shares in the aggregate. The detailed terms </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:315.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and conditions and the accounting treatment of these plans are presented in Note 14.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:337.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group secures financing up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:177.57pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-75" decimals="-6" name="abvx:FinancialAgreementAmount" scale="6" id="f-564">150</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:228.37pt;position:var(--position);text-decoration:none;white-space:pre"> from </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:252.25pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="transaction" contextRef="c-76" decimals="INF" name="abvx:FinancialAgreementNumberOfTransactions" format="ixt-sec:numwordsen" scale="0" id="f-565">two</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:266.68pt;position:var(--position);text-decoration:none;white-space:pre"> structured debt financing transactions &#8211; August 2023 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:360.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On August 20, 2023, the Group concurrently signed </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:246.43pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="transaction" contextRef="c-76" decimals="INF" name="abvx:FinancialAgreementNumberOfTransactions" format="ixt-sec:numwordsen" scale="0" id="f-566">two</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:261.41999999999996pt;position:var(--position);text-decoration:none;white-space:pre"> structured debt financing transactions for a total amount of up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:523.9100000000001pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-75" decimals="-6" name="abvx:FinancialAgreementAmount" scale="6" id="f-567">150</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.26pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:371.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">consisting of (i) up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:124.55pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-77" decimals="-6" name="abvx:BorrowingsMaximumBorrowingCapacity" scale="6" id="f-568">75</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:170.9pt;position:var(--position);text-decoration:none;white-space:pre"> from Kreos Capital and Claret European Growth Capital (the &#8220;Kreos / Claret Financing&#8221;) together </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:382.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">with the issuance of warrants (&#8220;the Kreos / Claret BSA&#8221;) exercisable to receive ordinary shares of the Company, for an aggregate </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:393.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">exercise price of up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.27pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-6" name="abvx:AggregateExercisePriceOtherEquityInstrumentsGranted" scale="6" id="f-569">8</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:168.62pt;position:var(--position);text-decoration:none;white-space:pre"> and (ii) up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:225.52pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-79" decimals="-6" name="abvx:BorrowingsMaximumBorrowingCapacity" scale="6" id="f-570">75</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:271.87pt;position:var(--position);text-decoration:none;white-space:pre"> from a fund advised by Heights Capital Management, Inc. (the &#8220;Heights </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:404.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Financing&#8221; and together with the Kreos / Claret Financing, the &#8220;Transaction&#8221;). The detailed structure and characteristics of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:416.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Transaction are set forth</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:133.36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> in Notes 15.1 and 15.2.</span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:438.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The first tranches of the Kreos / Claret Financing and the Heights Financing, for </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:359.25pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-80" decimals="-6" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" scale="6" id="f-571">25</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:405.6pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:425.03pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-81" decimals="-6" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" scale="6" id="f-572">35</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:471.38pt;position:var(--position);text-decoration:none;white-space:pre">, respectively, were </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:449.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">drawn on August 22, 2023, and August 24, 2023, respectively. In addition, the Group concurrently granted to Kreos and Claret, for no </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:460.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">additional consideration, warrants exercisable to receive ordinary shares of the Company for an aggregate exercise price of up to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:472.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-82" decimals="-6" name="abvx:AggregateExercisePriceOtherEquityInstrumentsGranted" scale="6" id="f-573">4</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:77.35pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:494.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As part of the Transaction, the Group is also repaying in full a total outstanding amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:399.52pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-83" decimals="-6" name="abvx:RepaymentsOfConvertibleLoansNotes" scale="6" id="f-574">33</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:445.87pt;position:var(--position);text-decoration:none;white-space:pre"> under (i) the pre-existing debt </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:505.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">agreements with Kreos for a total amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:215.24pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-84" decimals="-6" name="abvx:RepaymentsOfConvertibleLoansNotes" scale="6" id="f-575">8</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:256.59000000000003pt;position:var(--position);text-decoration:none;white-space:pre"> and (ii) the pre-existing OCEANE bonds for a total amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:509.68pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-85" decimals="-6" name="abvx:RepaymentsOfConvertibleLoansNotes" scale="6" id="f-576">25</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:556.03pt;position:var(--position);text-decoration:none;white-space:pre"> by </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:516.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">way of set-off with the Heights Financing, thereby fully repaying such pre-existing indebtedness. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:539.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The net proceeds of the drawdown of the first tranche of the Kreos / Claret Financing and of the Heights Financing which, net of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:550.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">refinancing of the existing indebtedness, amount to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:243pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-86" decimals="-6" name="abvx:ProceedsFromBorrowingsNetOfRefinancingOfExistingIndebteness" scale="6" id="f-577">27</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:289.35pt;position:var(--position);text-decoration:none;white-space:pre"> in the aggregate, are expected to be allocated mainly to the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:561.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">development of obefazimod for the treatment of adults with moderately to severely active UC and other potential chronic </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:572.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">inflammatory indications, as well for working capital and general corporate purposes of the Group. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:595.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On November 2, 2023, the Group granted additional warrants to Kreos and Claret, for an aggregate exercise price of up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:526.5899999999999pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-87" decimals="-6" name="abvx:IssuanceOfOtherShareWarrants" scale="6" id="f-578">4</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:567.94pt;position:var(--position);text-decoration:none;white-space:pre">, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:606.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in order to secure the future drawdown of the third tranche of the Kreos / Claret debt financing. The detailed characteristics of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:617.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">issuance is set forth in Note 15.1.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:640.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group announces closing of its Initial Public Offering on the Nasdaq Global Market &#8211; October 2023&#160;  </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:662.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On October 24, 2023, the Group announced the closing of its previously announced initial public offering on the Nasdaq Global </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:674.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Market by way of a capital increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:191.9pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-88" decimals="0" name="abvx:IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease" format="ixt:num-dot-decimal" scale="0" id="f-579">20,325,500</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:236.9pt;position:var(--position);text-decoration:none;white-space:pre"> new ordinary shares, consisting of a public offering of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:458.65pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-89" decimals="0" name="abvx:IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease" format="ixt:num-dot-decimal" scale="0" id="f-580">18,699,460</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:503.65pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:685.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in the form of American Depositary Shares (&#8220;ADSs&#8221;), each representing the right to receive </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:405.83pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-89" decimals="INF" name="abvx:NumberOfSharesReceivedPerADS" format="ixt-sec:numwordsen" scale="0" id="f-581">one</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:420.26pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary share, in the United States </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:697.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(the &#8220;U.S. Offering&#8221;), and a concurrent offering of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:240.51pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-90" decimals="0" name="abvx:IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease" format="ixt:num-dot-decimal" scale="0" id="f-582">1,626,040</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:280.51pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares in certain jurisdictions outside of the United States to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:708.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">certain investors (the &#8220;European Private Placement&#8221;, and together with the U.S. offering, the &#8220;Global Offering&#8221;). The offering price </span></div></div></ix:continuation></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-12<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-549-4" continuedAt="f-549-5"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">was set at </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:77.33pt;position:var(--position);text-decoration:none;white-space:pre">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-91" decimals="2" name="abvx:IssueOfEquityOfferingPricePerShare" scale="0" id="f-583">11.60</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:104.83pt;position:var(--position);text-decoration:none;white-space:pre"> per ADS in the U.S. Offering and a corresponding offering price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:378.77pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-92" decimals="4" name="abvx:IssueOfEquityOfferingPricePerShare" scale="0" id="f-584">10.9864</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:416.27pt;position:var(--position);text-decoration:none;white-space:pre"> per ordinary share in the European </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:82.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Private Placement. All of the ADSs and ordinary shares in the Global Offering were offered by the Group. The ADSs began trading on </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:93.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the Nasdaq Global Market on October 20, 2023. The aggregate gross proceeds were approximately </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:434.47pt;position:var(--position);text-decoration:none;white-space:pre">$<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="ifrs-full:ProceedsFromIssuingShares" scale="6" id="f-585">235.8</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:493.32pt;position:var(--position);text-decoration:none;white-space:pre">, equivalent to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:105.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">approximately </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.2pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-88" decimals="-5" name="ifrs-full:ProceedsFromIssuingShares" scale="6" id="f-586">223.3</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.05pt;position:var(--position);text-decoration:none;white-space:pre"> based on the exchange rate then in effect, before deduction of underwriting commissions and expenses </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:116.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">payable by the Group.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:140.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The net proceeds of the Global Offering were</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:218.28pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:220.78pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">$<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="abvx:ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants" scale="6" id="f-587">212.2</ix:nonFraction>&#160;million</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:279.63pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> (</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:285.46000000000004pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-88" decimals="-5" name="abvx:ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants" scale="6" id="f-588">202.0</ix:nonFraction>&#160;million</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:344.31pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">), after deducting </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:415.33pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">$<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="ifrs-full:PaymentsForShareIssueCosts" scale="6" id="f-589">23.6</ix:nonFraction>&#160;million</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:469.18pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> (</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:475.01pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-88" decimals="-5" name="ifrs-full:PaymentsForShareIssueCosts" scale="6" id="f-590">21.3</ix:nonFraction>&#160;million</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:528.86pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">) i</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:537.46pt;position:var(--position);text-decoration:none;white-space:pre">n </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:151.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">transaction costs. These costs were deducted from the share premiums.</span></div></ix:continuation><div style="position:absolute;top:217.06pt" id="i7a006daedb3d4216a4128b76247285d7_307"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:217.06pt;width:612pt"><ix:continuation id="f-549-5" continuedAt="f-549-6"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 3.2. For the year ended December 31, 2024 </span></ix:continuation></div><ix:continuation id="f-549-6" continuedAt="f-549-7"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:238.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Changes in governance &#8211; February-December 2024 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:263.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On February 7, 2024, the Group announced the appointment of Ana Sharma as Vice President, Global Head of Quality. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:289.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On April 2, 2024, the Group announced the appointment of Camilla Soenderby as Independent Board Member and also a member of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:299.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the Appointments and Compensation Committee. Ms. Soenderby replaces Sant&#233; Holdings S.R.L., represented by Mr. Paolo Rampulla, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:309.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">who will continue to contribute to the work of the Board of Directors as an observer alongside Mr. Maurizio PetitBon from Kreos </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:319.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Capital/Blackrock.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:339.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In July 2024, the Group announced the appointment of Sylvie Gr&#233;goire as Independent Board Member, Chairman of the Board and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:347.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">also a member of the Audit Committee. Dr. Gr&#233;goire replaces Ms. Brosgart as Director, Mr. de Garidel as Chairman, and Mr. Hong as </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:355.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">member of the Audit Committee. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:374.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On November 13, 2024, the Group announced the appointment of Mark Stenhouse as Board Observer &amp; Advisor to the Group.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:394.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On December 23, 2024, the Group announced the resignation of Dr. Philippe Pouletty, representative of Truffle Capital, as director of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:404.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the Group, effective on December 31, 2024. </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:427.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Share-based compensation plans</span><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:italic;font-weight:normal;left:168.14pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:174.14pt;position:var(--position);text-decoration:none;white-space:pre">&#8211; February-September 2024 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:456.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In February, March, May, July and September 2024, the Group issued </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:318.85pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="plan" contextRef="c-93" decimals="INF" name="abvx:NumberOfFreeSharesPlansIssued" format="ixt-sec:numwordsen" scale="0" id="f-591">seven</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:341.6pt;position:var(--position);text-decoration:none;white-space:pre"> free-share compensation plans to certain of its officers </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:466.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and employees, representing a maximum of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:213.3pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-94" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-592">1,946,125</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:253.3pt;position:var(--position);text-decoration:none;white-space:pre"> shares in the aggregate, the vesting of which is subject to the following service </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:476.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">condition: </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:79.00999999999999pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-95" decimals="2" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="f-593">50</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:97.34pt;position:var(--position);text-decoration:none;white-space:pre"> of the AGAs vest at the end of a </span><ix:nonNumeric contextRef="c-95" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-594"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:231.1pt;position:var(--position);text-decoration:none;white-space:pre">two</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:246.09pt;position:var(--position);text-decoration:none;white-space:pre">-year</span></ix:nonNumeric><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:266.61pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation date, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:397.27pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-96" decimals="2" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="f-595">25</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:415.6pt;position:var(--position);text-decoration:none;white-space:pre"> at the end of a </span><ix:nonNumeric contextRef="c-96" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-596"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:477.19pt;position:var(--position);text-decoration:none;white-space:pre">three</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:497.15pt;position:var(--position);text-decoration:none;white-space:pre">-year</span></ix:nonNumeric><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:517.6700000000001pt;position:var(--position);text-decoration:none;white-space:pre"> period from </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:486.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the allocation date and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:128.63pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-97" decimals="2" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="f-597">25</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:146.95999999999998pt;position:var(--position);text-decoration:none;white-space:pre"> at the end of a </span><ix:nonNumeric contextRef="c-97" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-598"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:208.55pt;position:var(--position);text-decoration:none;white-space:pre">four</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:225.21pt;position:var(--position);text-decoration:none;white-space:pre">-year</span></ix:nonNumeric><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:245.73pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation date (with the exception of the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:479.04pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-98" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-599">20,000</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:506.54pt;position:var(--position);text-decoration:none;white-space:pre"> 2024-6 AGAs, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:496.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">whose vesting conditions are set forth in Note 14).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:516.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In March 2024, the Group granted its independent Board members the right to subscribe up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:414.27pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-99" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-600">77,820</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:441.77pt;position:var(--position);text-decoration:none;white-space:pre"> share warrants (BSA) in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:526.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">aggregate, the vesting of which (if subscribed) is subject to a service condition of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:363.13pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-99" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-601">four years</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:403.37pt;position:var(--position);text-decoration:none;white-space:pre">, by tranches of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:467.48pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-99" decimals="2" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="f-602">25</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.81pt;position:var(--position);text-decoration:none;white-space:pre"> each, vested on each </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:536.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">anniversary date. All the BSAs have been subscribed.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:559.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Drawdown of Tranches B and C of the Kreos / Claret Financing &#8211; March-June 2024 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:585.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On March 28, 2024 and June 21, 2024, the Group drew down </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:284.5pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-100" decimals="-6" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" scale="6" id="f-603">25</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:330.85pt;position:var(--position);text-decoration:none;white-space:pre"> related to tranche B and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:431.26pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-101" decimals="-6" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" scale="6" id="f-604">25</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:477.61pt;position:var(--position);text-decoration:none;white-space:pre"> related to tranche C of </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:596.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">senior secured non-convertible bonds from the Kreos / Claret Financing.</span><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:325.7pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:331.7pt;position:var(--position);text-decoration:none;white-space:pre">These second and third tranches each consist of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:524.25pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-102" decimals="-3" name="abvx:BorrowingsMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="0" id="f-605">25,000,000</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:569.25pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:610.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">senior secured non-convertible bonds with a par value of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:265.49pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-102" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-606">1.00</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:287.99pt;position:var(--position);text-decoration:none;white-space:pre"> each, that will not be listed on any market.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:621.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The detailed characteristics of these bond loans and their accounting treatments are set forth in Note 15.1.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:646.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Bpifrance RNP-VIR and Carena conditional advances &#8211; June 2024</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:671.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In June 2024, the Group and Bpifrance renegotiated the RNP-VIR and CARENA conditional advances:</span></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-13<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><ix:continuation id="f-549-7" continuedAt="f-549-8"><div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Between September 2017 and November 2019, the Group had received repayable conditional advances amounting </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:84.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-103" decimals="-3" name="abvx:ProceedsFromConditionalAdvances" format="ixt:num-dot-decimal" scale="3" id="f-607">4,032</ix:nonFraction>&#160;thousands</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:141.98000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> and subsidies amounting to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:256.06pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-103" decimals="-3" name="ifrs-full:ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-608">1,123</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:322.15pt;position:var(--position);text-decoration:none;white-space:pre"> in relation to the RNP-VIR project, which aimed at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:98.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">discovering new molecules for the treatment of viral infectious diseases through the development of the &#8220;Modulation of RNA </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:111.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">biogenesis&#8221; platform. In June 2024, the Group and Bpifrance agreed to terminate the project due to technical failure, and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:125.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Bpifrance agreed to waive </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:179.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-104" decimals="2" name="abvx:PercentageOfConditionalAdvancesWaived" scale="-2" id="f-609">60</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:197.95pt;position:var(--position);text-decoration:none;white-space:pre"> of the remaining advances. See Note 15.7 "Conditional Advances".</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:153.36pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Between December 2013 and June 2016, the Group had received repayable conditional advances amounting </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:167.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-105" decimals="-3" name="abvx:ProceedsFromConditionalAdvances" format="ixt:num-dot-decimal" scale="3" id="f-610">2,187</ix:nonFraction>&#160;thousands</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:141.98000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> in relation to the CARENA project, which aimed at developing an anti-HIV-AIDS therapeutic program </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:180.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">with the compound ABX464 up to the Phase 2b study. In June 2024, the Group and Bpifrance agreed to terminate the project </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:194.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">due to technical failure, and Bpifrance agreed to waive </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:293.34000000000003pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-106" decimals="2" name="abvx:PercentageOfConditionalAdvancesWaived" scale="-2" id="f-611">60</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:311.66999999999996pt;position:var(--position);text-decoration:none;white-space:pre"> of the remaining conditional advance. See Note 15.7 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:208.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">"Conditional Advances".</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:233.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group fully reimbursed the remaining conditional advances for both programs during the last quarter of 2024. The subsidy </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:245.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">income recognized over the period, corresponding to the amounts waived by Bpifrance and related interests, amounts to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:256.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-107" decimals="-3" name="ifrs-full:RevenueFromGovernmentGrants" format="ixt:num-dot-decimal" scale="3" id="f-612">4,123</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:102.09pt;position:var(--position);text-decoration:none;white-space:pre"> in the aggregate (see Note 18).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:291.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Establishment of an At-the-Market ("ATM") Program on Nasdaq - November 2024</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:314.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On November 19, 2024, the Group announced the implementation of an At-The-Market program (&#8220;ATM Program&#8221;) allowing the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:325.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Group to issue and sell, including with unsolicited investors who have expressed an interest, ordinary shares in the form of ADSs, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:337.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">each ADS representing </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:131.17000000000002pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-108" decimals="INF" name="abvx:NumberOfADSPerOrdinaryShares" format="ixt-sec:numwordsen" scale="0" id="f-613">one</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:145.6pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary share, nominal value </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:269.90999999999997pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-108" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-614">0.01</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:292.41pt;position:var(--position);text-decoration:none;white-space:pre"> per share, of the Group, with aggregate gross sales proceeds of up to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:348.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">$<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="abvx:ExpectedProceedsFromShareIssuance" format="ixt:num-dot-decimal" scale="3" id="f-615">150,000</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.09pt;position:var(--position);text-decoration:none;white-space:pre"> (subject to French regulatory limits and within the limits of the investors&#8217; requests expressed in the context of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:360.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">program), from time to time, pursuant to the terms of an equity distribution agreement with Piper Sandler &amp; Co. (&#8220;Piper Sandler&#8221;), </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:371.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">acting as sales agent. The timing of any issuances in the form of ADSs will depend on a variety of factors. The ATM Program will be </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:383.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">effective until terminated in accordance with the equity distribution agreement or if ADSs representing the maximum gross sales </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:394.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">proceeds have been sold thereunder. To the extent that ADSs are sold pursuant to the ATM Program, the Group currently intends to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:406.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">use the net proceeds (after deduction of fees and expenses), if any, of sales of ADSs issued under the ATM Program primarily to fund </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:417.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the research and development of the Group's product candidates, for working capital and general corporate purposes, at its discretion.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:440.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">A shelf registration statement on Form F-3, including a base prospectus relating to the Group's securities and an equity distribution </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:452.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">agreement prospectus relating to the ATM Program, was filed with the SEC and went into effect during 2024. The base prospectus </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:463.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">provides for the potential sale of ADSs of the Group with aggregate gross sales proceeds of up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:426.75pt;position:var(--position);text-decoration:none;white-space:pre">$<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="abvx:ExpectedProceedsFromShareIssuanceShelfRegistration" format="ixt:num-dot-decimal" scale="3" id="f-616">350,000</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:502.84pt;position:var(--position);text-decoration:none;white-space:pre"> (including the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:475.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">$<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="abvx:ExpectedProceedsFromShareIssuance" format="ixt:num-dot-decimal" scale="3" id="f-617">150,000</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.09pt;position:var(--position);text-decoration:none;white-space:pre"> covered by the equity distribution agreement prospectus) to grant additional flexibility to the Group in connection </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:486.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">with its financing strategy. The specific terms of any securities to be offered pursuant to the base prospectus will be specified in one or </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:498.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">more prospectus supplements to the base prospectus. As of the date of issuance of these financial statements, the Group has not </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:509.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">utilized the ATM Program. </span></div></div></ix:continuation></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-14<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><ix:continuation id="f-549-8" continuedAt="f-549-9"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 3.3</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:70.42pt;position:var(--position);text-decoration:none;white-space:pre">. For the year ended December 31, 2025 </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:92.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Share-based compensation plans</span><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:italic;font-weight:normal;left:168.14pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:171.14pt;position:var(--position);text-decoration:none;white-space:pre">&#8211; January-</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:214.72pt;position:var(--position);text-decoration:none;white-space:pre">November </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:258.28pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:118.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In January 2025, the Group granted its independent Board members, as well as one of its Board Observers and Advisor, the right to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:130.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">subscribe up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:99.00999999999999pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-110" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-618">125,000</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:131.51pt;position:var(--position);text-decoration:none;white-space:pre"> share warrants (BSA) in the aggregate, the vesting of which is subject to a service condition of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:514.69pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-111" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-619">four years</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:554.93pt;position:var(--position);text-decoration:none;white-space:pre">, by </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:142.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">tranches of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:82.61pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-111" decimals="2" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="f-620">25</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:100.94pt;position:var(--position);text-decoration:none;white-space:pre"> each, vested on January 1 of each year.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:166.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In February, March, May, August and November 2025,</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:257.8pt;position:var(--position);text-decoration:none;white-space:pre"> the Group issued </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:330.53pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="plan" contextRef="c-112" decimals="INF" name="abvx:NumberOfFreeSharesPlansIssued" format="ixt-sec:numwordsen" scale="0" id="f-621">eight</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:350.5pt;position:var(--position);text-decoration:none;white-space:pre"> free-share compensation plans to certain of its officers </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:178.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and employees, representing a maximum o</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:207.47pt;position:var(--position);text-decoration:none;white-space:pre">f </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:213.3pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-113" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-622">6,280,727</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:253.3pt;position:var(--position);text-decoration:none;white-space:pre"> shares in the aggregate, the vesting of which is subject to the following service </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:190.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">condition: </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:79.00999999999999pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-114" decimals="2" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="f-623">50</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:97.34pt;position:var(--position);text-decoration:none;white-space:pre"> of the AGAs vest at the end of a </span><ix:nonNumeric contextRef="c-114" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-624"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:231.1pt;position:var(--position);text-decoration:none;white-space:pre">two</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:246.09pt;position:var(--position);text-decoration:none;white-space:pre">-year</span></ix:nonNumeric><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:266.61pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation date, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:397.27pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-115" decimals="2" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="f-625">25</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:415.6pt;position:var(--position);text-decoration:none;white-space:pre"> at the end of a </span><ix:nonNumeric contextRef="c-115" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-626"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:477.19pt;position:var(--position);text-decoration:none;white-space:pre">three</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:497.15pt;position:var(--position);text-decoration:none;white-space:pre">-year</span></ix:nonNumeric><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:517.6700000000001pt;position:var(--position);text-decoration:none;white-space:pre"> period from </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:202.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the allocation date and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:128.63pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-116" decimals="2" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="f-627">25</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:146.95999999999998pt;position:var(--position);text-decoration:none;white-space:pre"> at the end of a </span><ix:nonNumeric contextRef="c-116" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-628"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:208.55pt;position:var(--position);text-decoration:none;white-space:pre">four</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:225.21pt;position:var(--position);text-decoration:none;white-space:pre">-year</span></ix:nonNumeric><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:245.73pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation date (with the exception of the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:479.04pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-117" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-629">123,102</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:511.54pt;position:var(--position);text-decoration:none;white-space:pre"> 2025-2 AGAs, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:214.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">which vest at the end of a </span><ix:nonNumeric contextRef="c-117" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-630"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.6pt;position:var(--position);text-decoration:none;white-space:pre">two</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.59pt;position:var(--position);text-decoration:none;white-space:pre">-year</span></ix:nonNumeric><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:176.11pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation date, and the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:338.4pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-118" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-631">50,000</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:365.9pt;position:var(--position);text-decoration:none;white-space:pre"> 2025-5 AGAs , which vest only upon the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:226.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">achievement of milestones related to clinical studies). Moreover, the vesting of almost half of the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:426.88pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-119" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-632">4,319,500</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:466.88pt;position:var(--position);text-decoration:none;white-space:pre"> 2025-1 AGAs is subject to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:238.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the occurrence of a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.77pt;position:var(--position);text-decoration:none;white-space:pre">tender offer on the securities issued by the Group and resulting in a change of control of the Group</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:509.38pt;position:var(--position);text-decoration:none;white-space:pre"> before a certain </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:250.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">date. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:274.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In April 2025, the Group granted to one of its Board members the right to subscribe up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:395.98pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-120" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-633">39,370</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:423.48pt;position:var(--position);text-decoration:none;white-space:pre"> share warrants (BSA), the vesting of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:286.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">which is subject to a service condition of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:201.92pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-121" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-634">four years</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:242.16pt;position:var(--position);text-decoration:none;white-space:pre">, by tranches of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:306.27pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-121" decimals="2" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="f-635">25</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:324.6pt;position:var(--position);text-decoration:none;white-space:pre"> each, vested on May 1 of each year. The BSAs were </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:298.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">subscribed in May 2025.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:322.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The detailed terms and conditions of these plans are set forth in Note 14.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:346.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Change in management &#8211; April 2025</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:369.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On April 22, 2025, the Group announced the appointment of Dominik H&#246;chli, MD to the Board of Directors of Abivax, effective </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:381.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">immediately.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:405.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Completion of enrollment for the Phase 3 ABTECT trials in patients with moderately to severely active UC - April 2025</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:429.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On April 29, 2025, the Group announced the completion of enrollment for the Phase 3 ABTECT trials in patients with moderately to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:441.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">severely active UC.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:465.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Publication of positive Phase 3 results from both ABTECT 8-week induction trials investigating obefazimod, in moderate to severely </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:477.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">active UC </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:78.71000000000001pt;position:var(--position);text-decoration:none;white-space:pre">&#8211;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:83.71000000000001pt;position:var(--position);text-decoration:none;white-space:pre"> July 2025 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:501.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On July 22, 2025, the Group announced the positive results of the ABTECT-1 and ABTECT-2 induction trials in patients with </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:513.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">moderately to severely active UC. ABTECT-1 and 2 are global, multicenter, randomized, double-blind, placebo-controlled trials </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:525.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">assessing once-daily oral administration of obefazimod at 25 mg or 50 mg doses in adult patients with moderately to severely active </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:537.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">UC. Eligible participants had inadequate response, loss of response, or intolerance to conventional and/or advanced therapies.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:561.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Following this announcement and that of its Offering completed on July 28, 2025 (see </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:383.19pt;position:var(--position);text-decoration:none;white-space:pre">Completion of a public offering &#8211; July 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:558.31pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:573.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">within this section), the Group&#8217;s share price increased significantly, from </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:330.66pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-122" decimals="2" name="abvx:SharePrice1" scale="0" id="f-636">6.64</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:353.16pt;position:var(--position);text-decoration:none;white-space:pre"> as of June 30, 2025, to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:448.4pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-123" decimals="2" name="abvx:SharePrice1" scale="0" id="f-637">57.00</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:475.9pt;position:var(--position);text-decoration:none;white-space:pre"> as of July 28, 2025.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:584.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">At the same time, the Group reassessed the probability of success (&#8220;POS&#8221;) of obtaining a future market authorization for obefazimod </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:595.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in UC, to reflect a reduced level of uncertainty following positive Phase 3 results.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:618.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The main financial effects of this event on the Group&#8217;s financial statements are the following:</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:640.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">A significant increase in the carrying value of the royalty certificates, measured at amortized cost, reflecting an increase in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:652.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">projected probability-weighted cash flows of the instrument, following the reassessment of the POS (see Note 15.9),</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:674.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Significant changes in the carrying value of the Group&#8217;s financial liabilities measured at fair value through profit or loss, i.e. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:685.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the Kreos / Claret BSA, the Kreos / Claret MRI and the Heights convertible notes (the latter as well as the Kreos / Claret BSA </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:697.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">being converted into ordinary shares at the request of the noteholders in July and August 2025, see </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:468.85pt;position:var(--position);text-decoration:none;white-space:pre">Conversion of the Heights </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:708.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">convertible notes, Kreos / Claret OCABSA and Kreos / Claret BSA &#8211;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:346.71pt;position:var(--position);text-decoration:none;white-space:pre"> July-August 2025 below </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:448.29pt;position:var(--position);text-decoration:none;white-space:pre">and Notes 15.1 and 15.2</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:545.46pt;position:var(--position);text-decoration:none;white-space:pre">),</span></div></div></ix:continuation></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-15<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><ix:continuation id="f-549-9" continuedAt="f-549-10"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:82.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Significant changes in the disclosure of the fair values of other financial instruments measured at amortized cost (i.e. the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:93.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">royalty certificates, the debt components of (i) the Kreos / Claret OCABSA (Tranche A, converted into shares in August </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:104.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">2025) and (ii) Tranche B and C bond loans; these fair value changes are not expected directly to impact the future financial </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:115.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">position and net loss of the Group - see Note 15),</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:138.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">A significant increase in provisions related to employer contributions on AGAs (the contribution being based on the vesting </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:149.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">date share price - see Note 14).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:182.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Completion of a public offering </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:164.49pt;position:var(--position);text-decoration:none;white-space:pre">&#8211;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:169.49pt;position:var(--position);text-decoration:none;white-space:pre"> July 2025 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:206.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On July 28, 2025, the Group announced the completion of an underwritten public offering of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:409.86pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-124" decimals="INF" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-638">11,679,400</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:454.86pt;position:var(--position);text-decoration:none;white-space:pre"> ADSs (the &#8220;Offering&#8221;) at a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:218.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:69.28999999999999pt;position:var(--position);text-decoration:none;white-space:pre">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-125" decimals="2" name="abvx:IssueOfEquityOfferingPricePerShare" scale="0" id="f-639">64.00</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.78999999999999pt;position:var(--position);text-decoration:none;white-space:pre"> per ADS (corresponding to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:210.33pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-126" decimals="2" name="abvx:IssueOfEquityOfferingPricePerShare" scale="0" id="f-640">54.58</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:237.83pt;position:var(--position);text-decoration:none;white-space:pre"> per ordinary share, based on the exchange rate of &#8364;1.00 = $</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:477.12pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-127" decimals="4" name="ifrs-full:ClosingForeignExchangeRate" scale="0" id="f-641">1.1726</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:504.62pt;position:var(--position);text-decoration:none;white-space:pre"> as published by </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:230.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the European Central Bank on July 23, 2025). The aggregate gross proceeds amounted to approximately </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:455.3pt;position:var(--position);text-decoration:none;white-space:pre">$<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" scale="6" id="f-642">747.5</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:514.15pt;position:var(--position);text-decoration:none;white-space:pre">, equivalent to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:242.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">approximately </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.2pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-128" decimals="-5" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" scale="6" id="f-643">637.5</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.05pt;position:var(--position);text-decoration:none;white-space:pre">, before deduction of underwriting commissions and estimated expenses, and the net proceeds, after </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:254.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">deducting underwriting commissions and estimated offering expenses, were approximately </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:402.26pt;position:var(--position);text-decoration:none;white-space:pre">$<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="abvx:NetProceedsFromIssueOfOrdinaryShares" scale="6" id="f-644">700.3</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:461.11pt;position:var(--position);text-decoration:none;white-space:pre">, equivalent to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:266.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">approximately </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.2pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-128" decimals="-5" name="abvx:NetProceedsFromIssueOfOrdinaryShares" scale="6" id="f-645">597.2</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.05pt;position:var(--position);text-decoration:none;white-space:pre">. The net cash from the Offering of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:297.4pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-128" decimals="-5" name="ifrs-full:ProceedsFromIssuingOtherEquityInstruments" scale="6" id="f-646">607.2</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:324.9pt;position:var(--position);text-decoration:none;white-space:pre"> million presented within the Consolidated Statements of Cash </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:278.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Flows also includes the effect of a net foreign exchange gain </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:280.98pt;position:var(--position);text-decoration:none;white-space:pre">resulting from the favorable change in the euro to U.S. dollar exchange </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:290.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">rate between the closing of the Offering and the date of receipt of funds.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:314.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group believes that the net proceeds from the Offering, together with its current cash and cash equivalents, will allow it to finance </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:326.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">its operations into the fourth quarter of 2027, allowing it to reach 12 months of expected cash runway following the planned NDA </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:338.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">submission for UC, assuming positive results from its Phase 3 maintenance trial (see Note 2 above "Going concern").</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:374.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Conversion of the Heights convertible notes, Kreos OCABSA and Kreos / Claret BSA and prepayment of the Kreos / Claret Tranches </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:386.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">B and C bond loans &#8211;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:122.92pt;position:var(--position);text-decoration:none;white-space:pre"> July-December 2025 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:409.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On July 23 and July 30, 2025, the Group received notices from entities affiliated with Heights Capital Management, which hold </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:421.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">amortizing senior convertible notes of the Group issued in August 2023 (the &#8220;Height convertible notes&#8221;), for the immediate conversion </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:433.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:97.58pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="note" contextRef="c-129" decimals="INF" name="abvx:NumberOfConvertibleNotesConverted" scale="0" id="f-647">150</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.58pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:132.01pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="note" contextRef="c-130" decimals="INF" name="abvx:NumberOfConvertibleNotesConverted" scale="0" id="f-648">200</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:147.01pt;position:var(--position);text-decoration:none;white-space:pre"> convertible notes (corresponding to the entirety of the outstanding principal amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:497.47pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-130" decimals="-5" name="ifrs-full:NotionalAmount" scale="6" id="f-649">21.9</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:551.32pt;position:var(--position);text-decoration:none;white-space:pre">) into </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:445.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-131" decimals="INF" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-650">920,377</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:68.5pt;position:var(--position);text-decoration:none;white-space:pre"> new ordinary shares of the Group at a conversion price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:303.83pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-130" decimals="4" name="abvx:BorrowingsFixedConversionPrice" scale="0" id="f-651">23.7674</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:341.33pt;position:var(--position);text-decoration:none;white-space:pre"> per ordinary share in accordance with the terms and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:457.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">conditions of the convertible notes.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:481.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.96pt">On August 8, 2025, Kreos Capital VII (UK) Limited converted its portion of the Tranche A of the Kreos / Claret Financing (the Kreos</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.96pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:492.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:163.21pt">OCABSA), resulting in the issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:199.21pt;position:var(--position);text-decoration:none;white-space:pre;width:32.5pt"><ix:nonFraction unitRef="shares" contextRef="c-132" decimals="INF" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-652">785,389</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:231.71pt;position:var(--position);text-decoration:none;white-space:pre;width:344.2pt"> ordinary shares. In addition, on July 30, 2025, Kreos Capital VII Aggregator SCSp</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.91pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:503.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:414.04pt">exercised its share warrants (the tranche A-B BSA and tranche C BSA) resulting in the issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:450.04pt;position:var(--position);text-decoration:none;white-space:pre;width:32.5pt"><ix:nonFraction unitRef="shares" contextRef="c-133" decimals="INF" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-653">319,251</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:482.54pt;position:var(--position);text-decoration:none;white-space:pre;width:93.36pt"> ordinary shares of the</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.9pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:514.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:28.05pt">Group.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:537.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On August 28, 2025, Claret European Growth Capital Fund III SCSp exercised its share warrants (the tranche A-B BSA and tranche C </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:549.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">BSA) resulting in the issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:170.87pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-134" decimals="INF" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-654">206,662</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:203.37pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares of the Group.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:573.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On November 25, 2025, Claret European Growth Capital Fund III SCSp converted its portion of the Tranche A portion of the Kreos / </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:584.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Claret Financing (the Claret OCABSA), resulting in the issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:308.74pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-135" decimals="INF" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-655">392,695</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:341.24pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares of the Group. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:607.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On December 23, 2025, the Group completed the full prepayment of the outstanding balances of Tranches B and C of the Kreos / </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:619.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Claret Financing. The repayment amount, including end-of-loan exit fees and prepayment fees, amounts to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:465.22pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-136" decimals="-3" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-656">33,823</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:531.31pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:643.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Following these transactions, the Group no longer holds any debt related to the Kreos / Claret and Heights Financings.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:666.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The impacts of these operations on the Group's financial statements are set forth in Note 15.1 and 15.2.</span></div></div></ix:continuation></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-16<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-549-10" continuedAt="f-549-11"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Admission to the CAC Mid 60 and SBF 120 indices - September 2025</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:94.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Following the annual review of the Euronext Paris indices on September 11, 2025, the Scientific Council of the Indices has decided to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:106.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">admit the Company to the CAC Mid 60 and SBF 120 indices. This decision took effect on Friday, September 19, 2025, after market </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:118.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">close. The CAC Mid 60 and SBF 120 are key indices on the Euronext Paris exchange, representing mid-sized listed companies and a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:130.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">broader selection of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:117.84pt;position:var(--position);text-decoration:none;white-space:pre">120</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:132.84pt;position:var(--position);text-decoration:none;white-space:pre"> major securities, respectively.</span></div></ix:continuation><div style="position:absolute;top:190.56pt" id="i7a006daedb3d4216a4128b76247285d7_310"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:202.56pt;width:612pt"><ix:continuation id="f-549-11" continuedAt="f-549-12"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 3.4. Subsequent events&#160; </span></ix:continuation></div><ix:continuation id="f-549-12" continuedAt="f-549-13"><div style="font-size:12pt;line-height:12pt;position:var(--position);top:226.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Share-based compensation plans</span><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:italic;font-weight:normal;left:168.14pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:171.14pt;position:var(--position);text-decoration:none;white-space:pre">&#8211; February 2026</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:252.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In February 2026, the Group issued a new free-share compensation plan to certain of its officers and employees, representing a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:264.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">maximum of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:89.84pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-137" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-657">47,500</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:117.34pt;position:var(--position);text-decoration:none;white-space:pre"> shares in the aggregate, the vesting of which is subject to the following service condition: </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:479.98pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-138" decimals="2" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="f-658">50</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:498.31pt;position:var(--position);text-decoration:none;white-space:pre"> of the AGAs vest </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:276.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">at the end of a </span><ix:nonNumeric contextRef="c-138" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-659"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:95.09pt;position:var(--position);text-decoration:none;white-space:pre">two</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:110.08pt;position:var(--position);text-decoration:none;white-space:pre">-year</span></ix:nonNumeric><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:130.6pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation date, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:261.26pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-139" decimals="2" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="f-660">25</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:279.59000000000003pt;position:var(--position);text-decoration:none;white-space:pre"> at the end of a </span><ix:nonNumeric contextRef="c-139" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-661"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:341.18pt;position:var(--position);text-decoration:none;white-space:pre">three</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:361.14pt;position:var(--position);text-decoration:none;white-space:pre">-year</span></ix:nonNumeric><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:381.66pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation date and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:526.75pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-140" decimals="2" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="f-662">25</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:545.0799999999999pt;position:var(--position);text-decoration:none;white-space:pre"> at the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:288.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">end of a </span><ix:nonNumeric contextRef="c-140" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-663"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:70.69pt;position:var(--position);text-decoration:none;white-space:pre">four</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:87.35pt;position:var(--position);text-decoration:none;white-space:pre">-year</span></ix:nonNumeric><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:107.87pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation date.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:312.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In February 2026,</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:107.91pt;position:var(--position);text-decoration:none;white-space:pre"> the Group granted its independent Board members, as well as one of its Board Observers and Advisor, the right to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:324.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">subscribe up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:99.00999999999999pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-141" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-664">23,477</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:126.51pt;position:var(--position);text-decoration:none;white-space:pre"> share warrants (BSA) in the aggregate, the vesting of which (if subscribed) is subject to a service condition of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:336.36pt;width:612pt"><ix:nonNumeric contextRef="c-142" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-665"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">four</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:52.66pt;position:var(--position);text-decoration:none;white-space:pre"> years</span></ix:nonNumeric><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:76.24000000000001pt;position:var(--position);text-decoration:none;white-space:pre">, by tranches of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.35pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-142" decimals="2" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="f-666">25</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.68pt;position:var(--position);text-decoration:none;white-space:pre"> each, vested on each February 1st thereafter. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:360.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:underline;white-space:pre">Changes in Management - March</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:384.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In March 2026, the Group appointed Michael Nesrallah, MBA, as Chief Commercial Officer, Keith Fournier, Ph.D., as Senior Vice </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:395.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">President of Global Regulatory Affairs, and Maurus de la Rosa, Ph.D., Senior Vice President of Research.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:417.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In March 2026, Sofinnova Partners, represented by Dr. Kinam Hong, stepped down from the Group's Board of Directors.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:440.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In light of Mr. Didier Scherrer's departure from his role as Chief Scientific Officer, the Group entered into a settlement agreement </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:451.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">("protocole d&#8217;accord transactionnel") with Mr. Didier Scherrer under which:</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:462.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Mr. Scherrer received a balance of notice pay in the total gross amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:368.58pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-143" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits" scale="3" id="f-667">278</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:427.17pt;position:var(--position);text-decoration:none;white-space:pre">, together with a contractual </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:473.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">severance indemnity of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:167.70999999999998pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-143" decimals="-3" name="abvx:KeyManagementPersonnelCompensationContractualSeveranceIndemnity" scale="3" id="f-668">240</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:226.3pt;position:var(--position);text-decoration:none;white-space:pre"> (net);</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:485.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the Group waived the continued employment condition attached to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:341.41pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-144" decimals="INF" name="abvx:NumberOfSharesWaived" format="ixt:num-dot-decimal" scale="0" id="f-669">77,050</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:368.91pt;position:var(--position);text-decoration:none;white-space:pre"> free shares previously granted to Mr. Scherrer;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:496.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the Group waived the continued employment condition for a further </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:346.16pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-144" decimals="INF" name="abvx:NumberOfSharesWithPerformanceConditionsWaived" format="ixt:num-dot-decimal" scale="0" id="f-670">40,200</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:373.66pt;position:var(--position);text-decoration:none;white-space:pre"> free shares, subject to specific performance </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:507.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">conditions;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:518.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the remaining </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.7pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-144" decimals="INF" name="abvx:NumberOfSharesLapsed" format="ixt:num-dot-decimal" scale="0" id="f-671">217,750</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:162.2pt;position:var(--position);text-decoration:none;white-space:pre"> free shares previously granted to Mr. Scherrer are lapsed; and</span></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:529.96pt;width:612pt"><ix:continuation id="f-549-13" continuedAt="f-549-14"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span></ix:continuation><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"><ix:continuation id="f-549-14">Mr. Scherrer irrevocably waived all claims and renounced any legal action against the Group.</ix:continuation> </span></div><div style="position:absolute;top:559.16pt" id="i7a006daedb3d4216a4128b76247285d7_313"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:559.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 4. </span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory" id="f-672" continuedAt="f-672-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:68.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Accounting principles </span></ix:nonNumeric></div><div style="position:absolute;top:575.16pt" id="i7a006daedb3d4216a4128b76247285d7_316"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:575.16pt;width:612pt"><ix:continuation id="f-672-1" continuedAt="f-672-2"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 4.1. </span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForGoodwillExplanatory" id="f-673" continuedAt="f-673-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre">Goodwill </span></ix:nonNumeric></ix:continuation></div><ix:continuation id="f-672-2" continuedAt="f-672-3"><ix:continuation id="f-673-1" continuedAt="f-673-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:591.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Following initial recognition, goodwill is stated at cost less any accumulated impairment losses (see Note 4.4). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:613.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In respect of business combinations prior to January 1, 2020, in accordance with IFRS 1 exemption, goodwill is included on the basis </span></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:623.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><ix:continuation id="f-673-2">of its deemed cost, which represents the amount recorded under the prior basis of accounting, French GAAP, (&#8220;Previous GAAP&#8221;).</ix:continuation> </span></div></ix:continuation><div style="position:absolute;top:651.16pt" id="i7a006daedb3d4216a4128b76247285d7_319"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:651.16pt;width:612pt"><ix:continuation id="f-672-3" continuedAt="f-672-4"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 4.2. </span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" id="f-674" continuedAt="f-674-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre">Intangible assets </span></ix:nonNumeric></ix:continuation></div><ix:continuation id="f-674-1" continuedAt="f-674-2"><ix:continuation id="f-672-4" continuedAt="f-672-5"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:667.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Pursuant to IAS 38&#8212;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:122.36pt;position:var(--position);text-decoration:none;white-space:pre">Intangible Assets</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:190.9pt;position:var(--position);text-decoration:none;white-space:pre">, intangible assets acquired are recognized as assets on the statements of financial position at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:677.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">their acquisition cost. </span></div></ix:continuation></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-17<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-672-5" continuedAt="f-672-6"><ix:continuation id="f-674-2" continuedAt="f-674-3"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Licenses, patents and development costs </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:86.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Payments for separately acquired research and development are capitalized within &#8220;intangible assets&#8221; provided that they meet the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:96.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">definition of an intangible asset: a resource that is (i)&#160;controlled by the Group, (ii) expected to provide future economic benefits for the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:106.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Group and (iii)&#160;identifiable (i.e., it is either separable or arises from contractual or legal rights). In accordance with paragraph 25 of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:116.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">IAS 38&#8212;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:74.61pt;position:var(--position);text-decoration:none;white-space:pre">Intangible Assets</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:143.15pt;position:var(--position);text-decoration:none;white-space:pre">, the recognition criterion relating to the likelihood of future economic benefits generated by the intangible </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">asset, is presumed to be achieved for research and development activities when they are acquired separately. In this context, amounts </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:136.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">paid to third parties in the form of initial payments or milestone payments relating to pharmaceutical specialties that have not yet </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:146.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">obtained a marketing authorization are recognized as intangible assets. These rights will be amortized on a straight-line basis, after </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:156.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">obtaining the marketing authorization, over their useful life. Unamortized rights (before marketing authorization) are subject to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:166.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">impairment tests in accordance with the method defined in Note 4.4.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:188.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Research and development costs</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:206.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Pursuant to IAS 38 &#8211; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:122.36pt;position:var(--position);text-decoration:none;white-space:pre">Intangible Assets</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:190.9pt;position:var(--position);text-decoration:none;white-space:pre">, research costs are expensed in the period during which they are incurred. Development costs </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:216.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">are only recognized as intangible assets if the following criteria are met: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:232.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">it is technically feasible to complete the development of the project; </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:248.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">it is th</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:116.02000000000001pt;position:var(--position);text-decoration:none;white-space:pre">e Group&#8217;s intention to complete the project and to utilize it; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:264.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">it has capacity to utilize the intangible asset; </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:280.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">there is proof of the probability of future economic benefits associated with the asset </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:296.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">there is availability of the technical, financial and other resources for completing the project; and </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:312.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">there is a reliable evaluation of the development expenses. </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:334.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The initial measurement of the asset is the sum of expenses incurred starting on the date on which the development project meets the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:344.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">above criteria. Because of the risks and uncertainties related to regulatory authorizations and to the research and development process, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:354.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the Group believes that the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:146.14pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="criteria" contextRef="c-1" decimals="INF" name="abvx:ResearchAndDevelopmentCostsRecognitionInitialMeasurementNumberOfCriterias" format="ixt-sec:numwordsen" scale="0" id="f-675">six</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:157.8pt;position:var(--position);text-decoration:none;white-space:pre"> criteria stipulated by IAS 38 have not been fulfilled to date and the application of this principle has </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:364.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">resulted in all development costs being expensed as incurred in all periods presented. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:392.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Other intangible assets </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:408.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Other intangible assets mainly consist of acquired software. Costs related to the acquisition of software licenses are recognized as </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:418.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">assets based on the costs incurred to acquire and set up the related software. Other intangible assets are amortized using the straight-</span></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:428.56pt;width:612pt"><ix:continuation id="f-674-3" continuedAt="f-674-4"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">line method over a period of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:151.99pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-145" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:durwordsen" id="f-676">one year</ix:nonNumeric></span></ix:continuation><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:186.11pt;position:var(--position);text-decoration:none;white-space:pre"><ix:continuation id="f-674-4">.</ix:continuation> </span></div></ix:continuation><div style="position:absolute;top:456.56pt" id="i7a006daedb3d4216a4128b76247285d7_322"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:456.56pt;width:612pt"><ix:continuation id="f-672-6" continuedAt="f-672-7"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 4.3. </span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" id="f-677" continuedAt="f-677-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre">Property, plant and equipment </span></ix:nonNumeric></ix:continuation></div><ix:continuation id="f-677-1" continuedAt="f-677-2"><ix:continuation id="f-672-7" continuedAt="f-672-8"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:472.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Pursuant to IAS 16 &#8211; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:122.36pt;position:var(--position);text-decoration:none;white-space:pre">Property, Plant and Equipment</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:247.8pt;position:var(--position);text-decoration:none;white-space:pre">, property, plant and equipment are recognized at their acquisition cost (purchase </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:482.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">price and directly attributable costs) or at their production cost by the Group, as applicable. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:504.56pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" id="f-678" continuedAt="f-678-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Property, plant and equipment are depreciated using the straight-line method over the estimated useful life of the asset. The principal </span></ix:nonNumeric></div><ix:continuation id="f-678-1" continuedAt="f-678-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:514.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">useful lives applied are as follows: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:524.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="position:var(--position);top:534.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:324pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:150.75pt"/><td style="padding:0;width:95.25pt"/><td style="padding:0;width:78pt"/></tr><tr style="height:15.75pt"><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:15.75pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td colspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:15.75pt;width:173.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:173.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;position:var(--position);text-decoration:none;white-space:pre">DEPRECIATION PERIOD</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:30pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Buildings</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:30pt;width:95.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:30pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:44.25pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Office fixtures and fittings</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:44.25pt;width:95.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:3.67pt;width:95.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:45.13pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-146" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="f-679">3</ix:nonNumeric> years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:73.71pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span><span style="font-family:'Times New Roman', serif;font-size:6.5pt;font-style:normal;font-weight:normal;left:76.21pt;position:var(--position);text-decoration:none;top:-2.4254999999999995pt;vertical-align:super;white-space:pre">(1)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:44.25pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:58.5pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Equipment</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:58.5pt;width:95.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:58.5pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:72.75pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Industrial materials and equipment</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:72.75pt;width:95.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:21.95pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-147" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="f-680">5</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:26.95pt;position:var(--position);white-space:pre"> to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.72pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-148" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="f-681">10</ix:nonNumeric> years</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:72.75pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:87pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Technical facilities</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:87pt;width:95.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:21.95pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-149" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="f-682">5</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:26.95pt;position:var(--position);white-space:pre"> to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.72pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-150" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="f-683">10</ix:nonNumeric> years</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:87pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:101.25pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Furniture and computer equipment:</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:101.25pt;width:95.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:101.25pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:115.5pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Office equipment</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:115.5pt;width:95.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:21.95pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-151" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="f-684">5</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:26.95pt;position:var(--position);white-space:pre"> to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.72pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-152" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="f-685">10</ix:nonNumeric> years</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:115.5pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:129.75pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">IT equipment</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:129.75pt;width:95.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;  &#160;&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:45.13pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-153" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="f-686">3</ix:nonNumeric> years</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:129.75pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:144pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Furniture</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:144pt;width:95.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:22.08pt;position:var(--position);white-space:pre">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.58pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-154" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="f-687">10</ix:nonNumeric> years</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:144pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr></tbody></table></div></div></div></ix:continuation></ix:continuation></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-18<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-672-8" continuedAt="f-672-9"><ix:continuation id="f-677-2" continuedAt="f-677-3"><ix:continuation id="f-678-2" continuedAt="f-678-3"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:35.95pt;position:var(--position)">(1)<span style="display:inline-block;height:6.93pt;width:12.84pt"></span></span><span style="left:60.45pt;position:var(--position)">Office fixtures and fittings estimated useful lives correspond to the Paris headquarters and Boston offices residual estimated </span></span></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:80.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:60.45pt;position:var(--position);text-decoration:none;white-space:pre"><ix:continuation id="f-678-3">lease terms.</ix:continuation> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:102.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The useful lives of property, plant and equipment as well as any residual values are reviewed at each year-end and, in the event of a </span></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:112.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><ix:continuation id="f-677-3">significant change, the depreciation schedule is revised prospectively.</ix:continuation> </span></div></ix:continuation><div style="position:absolute;top:140.56pt" id="i7a006daedb3d4216a4128b76247285d7_328"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:140.56pt;width:612pt"><ix:continuation id="f-672-9" continuedAt="f-672-10"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 4.4. </span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" id="f-688" continuedAt="f-688-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre">Impairment of goodwill, intangible assets, property and plant and equipment </span></ix:nonNumeric></ix:continuation></div><ix:continuation id="f-672-10" continuedAt="f-672-11"><ix:continuation id="f-688-1" continuedAt="f-688-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:156.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Goodwill and intangible assets not yet available for use are not amortized and are tested for impairment annually. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:178.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In addition, the Group assesses at the end of each reporting period whether there is an indication that intangible assets and property, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:188.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">plant and equipment may be impaired. Pursuant to IAS 36&#8212;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:278.56pt;position:var(--position);text-decoration:none;white-space:pre">Impairment of Assets</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:362.93pt;position:var(--position);text-decoration:none;white-space:pre">, criteria for assessing indication of loss in value may </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:198.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">notably include performance levels lower than forecast, a significant change in market data or the regulatory environment, or </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:208.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">obsolescence or physical damage of the asset not included in the amortization/depreciation schedule. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:230.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">For the purpose of impairment testing, goodwill and intangible assets not yet available for use are allocated to each of the Group&#8217;s </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:240.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">CGUs expected to benefit from synergies arising from the business combination or from the use of the intangible assets. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:262.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">An impairment loss is recognized when the carrying amount of a CGU, including the goodwill, exceeds the recoverable amount of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:272.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">CGU. The recoverable amount of a CGU is the higher of the CGU&#8217;s fair value less cost to sell and value-in-use. The total impairment </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:282.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">loss of a CGU is allocated first to reduce the carrying amount of goodwill allocated to the CGU and then to the other assets of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:292.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">CGU pro-rata on the basis of the carrying amount of each asset in the CGU. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:314.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">An impairment loss on goodwill is not reversed in a subsequent period. Impairment losses on intangible assets and property, plant and </span></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:324.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><ix:continuation id="f-688-2">equipment shall be reversed subsequently if the impairment loss no longer exists or has decreased.</ix:continuation> </span></div></ix:continuation><div style="position:absolute;top:352.56pt" id="i7a006daedb3d4216a4128b76247285d7_331"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:352.56pt;width:612pt"><ix:continuation id="f-672-11" continuedAt="f-672-12"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 4.5. Financial assets </span></ix:continuation></div><ix:continuation id="f-672-12" continuedAt="f-672-13"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:368.56pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" id="f-689" continuedAt="f-689-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Financial assets at amortized cost </span></ix:nonNumeric></div><ix:continuation id="f-689-1" continuedAt="f-689-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:384.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Other financial assets (advances, loans and deposits granted to third parties and other short-term investments) and other receivables are </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:394.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">non-derivative financial assets with fixed or determinable payments that are not listed on an active market. They are initially </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:404.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">recognized at fair value plus transaction costs that are directly attributable to the acquisition or issue of the financial asset. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:420.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">IFRS 9 &#8211; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:74.61pt;position:var(--position);text-decoration:none;white-space:pre">Financial Instruments </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:165.64pt;position:var(--position);text-decoration:none;white-space:pre">requires an entity to recognize a loss allowance for expected credit losses on a financial asset at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:430.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">amortized cost at each statement of financial position date. The amount of the loss allowance for expected credit losses equal to: (i)&#160;the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:440.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">12&#8212;month expected credit losses or (ii)&#160;the full lifetime expected credit losses. The latter applies if credit risk has increased </span></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:450.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><ix:continuation id="f-689-2">significantly since initial recognition of the financial instrument.</ix:continuation> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:478.56pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" id="f-690" continuedAt="f-690-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Cash and cash equivalents </span></ix:nonNumeric></div><ix:continuation id="f-690-1" continuedAt="f-690-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:494.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group classifies investments as cash equivalents in the statements of financial position and statements of cash flows when they </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:504.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">meet the conditions of IAS 7&#8212;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:161.17000000000002pt;position:var(--position);text-decoration:none;white-space:pre">Statement of Cash Flows, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:265.8pt;position:var(--position);text-decoration:none;white-space:pre">i.e., when they are: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:520.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">held in order to face short-term cash commitments; and </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:536.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">short term and highly liquid assets at acquisition date, readily convertible into known amount of cash and not exposed to </span></span></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:546.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"><ix:continuation id="f-690-2">any material risk of change in value.</ix:continuation> </span></div></ix:continuation><div style="position:absolute;top:574.56pt" id="i7a006daedb3d4216a4128b76247285d7_334"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:574.56pt;width:612pt"><ix:continuation id="f-672-13" continuedAt="f-672-14"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 4.6. </span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" id="f-691" continuedAt="f-691-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre">Share capital </span></ix:nonNumeric></ix:continuation></div><ix:continuation id="f-672-14" continuedAt="f-672-15"><ix:continuation id="f-691-1" continuedAt="f-691-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:590.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Ordinary shares are classified in shareholders&#8217; equity. Costs associated with the issuance of new shares are directly accounted for in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:600.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">shareholders&#8217; equity in diminution of issuance premium. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:622.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group&#8217;s own shares bought in the context of a brokering/liquidity agreement entered with an independent broker are presented as </span></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:632.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><ix:continuation id="f-691-2">a reduction of shareholders&#8217; equity until their cancellation, their reissuance or their disposal.</ix:continuation> </span></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-19<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-672-15" continuedAt="f-672-16"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></ix:continuation><div style="position:absolute;top:80.56pt" id="i7a006daedb3d4216a4128b76247285d7_337"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:80.56pt;width:612pt"><ix:continuation id="f-672-16" continuedAt="f-672-17"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 4.7. </span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" id="f-692" continuedAt="f-692-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre">Share-based payments </span></ix:nonNumeric></ix:continuation></div><ix:continuation id="f-672-17" continuedAt="f-672-18"><ix:continuation id="f-692-1" continuedAt="f-692-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:96.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Since its inception, the Group has established several plans for compensation settled in equity instruments in the form of founders&#8217; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:106.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">share subscription warrants (&#8220;bons de souscription de parts de cr&#233;ateur d&#8217;entreprise&#8221; or &#8220;BCE&#8221;), share subscription warrants (&#8220;Bons de </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:116.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">souscription d&#8217;actions,&#8221; or &#8220;BSA&#8221;) and free shares (&#8220;Attributions gratuites d&#8217;actions,&#8221; or &#8220;AGA&#8221;), granted to its employees, corporate </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">officers and scientific consultants. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:148.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Pursuant to IFRS 2&#8212;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:122.36pt;position:var(--position);text-decoration:none;white-space:pre">Share-based Payment, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:214.78pt;position:var(--position);text-decoration:none;white-space:pre">these awards are measured at their fair value on the date of grant. The values of the equity </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:158.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">instruments are determined using the option pricing model (in particular, a Black and Scholes model for the BCE and BSA plans and a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:168.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Monte-Carlo simulation for the AGA plans which include market performance vesting conditions) based on the value of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:178.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">underlying equity instrument at grant date, the volatility observed in a sample of comparable listed companies and the estimated life of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:188.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the related equity instruments. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:210.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group recognizes the fair value of these awards as a share-based compensation expense over the period in which the related </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:220.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">services are received, i.e. over the vesting period, with a corresponding increase in shareholders&#8217; equity. Share-based compensation is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:230.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">recognized by installments in consistency with their graded vesting schedule, when applicable. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:252.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:262.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">performance conditions are expected to be met, such that the amount ultimately recognized is based on the number of awards that meet </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:272.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the related service and non-market performance conditions at the vesting date. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:294.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">For share-based payment awards with market vesting conditions and non-vesting conditions, the grant-date fair value of the share-</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:304.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">based payment is measured to reflect such conditions and there is no true-up for differences between expected and actual outcome. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:314.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The measurement of the fair value of BSA, BCE and AGA incorporates the market-based vesting conditions and non-vesting </span></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:324.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><ix:continuation id="f-692-2">conditions as described in Note 4.15 &#8220;Use of judgments and estimates&#8221;.</ix:continuation> </span></div></ix:continuation><div style="position:absolute;top:352.56pt" id="i7a006daedb3d4216a4128b76247285d7_340"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:352.56pt;width:612pt"><ix:continuation id="f-672-18" continuedAt="f-672-19"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 4.8. </span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" id="f-693" continuedAt="f-693-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre">Financial liabilities </span></ix:nonNumeric></ix:continuation></div><ix:continuation id="f-693-1" continuedAt="f-693-2"><ix:continuation id="f-672-19" continuedAt="f-672-20"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:374.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:underline;white-space:pre">Note 4.8.1. Financial liabilities at amortized cost</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:402.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Pursuant to IFRS 9 &#8211; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:122.36pt;position:var(--position);text-decoration:none;white-space:pre">Financial Instruments, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:215.89pt;position:var(--position);text-decoration:none;white-space:pre">the borrowings, the debt component of the Kreos / Claret OCABSA (classified as </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:412.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">convertible loan notes &#8211; see </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:149.47pt;position:var(--position);text-decoration:none;white-space:pre">Compound instruments </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:244.98pt;position:var(--position);text-decoration:none;white-space:pre">Compound instruments below), royalty certificates and Other financial liabilities </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:422.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(conditional advances) other than financial derivative liabilities are measured at amortized cost. They are initially recognized at fair </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:432.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">value and subsequently measured at amortized cost calculated using the effective interest rate (&#8220;EIR&#8221;) method. The transaction costs </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:442.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">that are directly attributable to the issue of the financial liability reduce that financial liability. These expenses are then amortized over </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:452.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the lifetime of the liability, on the basis of the EIR. The EIR is the rate that exactly discounts estimated future cash payments through </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:462.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the expected life of the financial liability to the amortized cost of a financial liability. Financial liabilities that are due within one year </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:472.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">are presented as current financial liabilities in the statements of financial position.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:500.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Royalty certificates </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:516.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Royalty certificates meet the definition of financial liabilities. The Group concluded that they do not include embedded derivatives </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:526.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">related to the variability of royalties that are based on future net sales. In addition, the Group concluded that the prepayment options </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:536.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">were separate derivative instruments as their redemption price did not reimburse holders for an amount up to the approximate present </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:546.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">value of lost interest for the remaining term of the host contracts. However, their value at inception and subsequent dates is nil and has </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:556.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">no impact on the financial statements. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:585.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Royalty certificates are initially measured at fair value (refer to note 15.9 for valuation model applied). They are subsequently </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:597.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">measured at amortized cost calculated using the EIR method. The EIR is calculated based on future cash flows, which are estimated on </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:609.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the basis of development and commercialization plans and budgets approved by the Board of Directors of the Group, and probability-</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:621.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">weighted to reflect the probability of success of clinical studies and any other uncertainty affecting them. If there is a change in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:633.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">timing or amount of estimated cash flows, then the gross carrying amount of the amortized cost of the financial liability is adjusted in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:645.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the period of change to reflect the revised actual and estimated cash flows, with a corresponding income or expense being recognized </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:657.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in profit or loss. The revised gross carrying amount of the amortized cost of the financial liability is calculated by discounting the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:669.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">future revised estimated cash flows at the original EIR. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:699.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Conditional advances and State guaranteed loan &#8211; &#8220;PGE&#8221; </span></div></ix:continuation></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-20<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-672-20" continuedAt="f-672-21"><ix:continuation id="f-693-2" continuedAt="f-693-3"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Accounting treatment for conditional advances and the State-guaranteed loan (Pr&#234;t garanti par l'Etat, or "PGE") is set forth in Note 4.9. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:98.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Leases </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:114.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Accounting treatment for lease liabilities is set forth in Note 4.12.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:146.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:underline;white-space:pre">Note 4.8.2. Financial liabilities measured at fair value through profit or loss </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:344.9pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:169.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Derivative instruments</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:127.27pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:186.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">BSA attached to Kreos 1 bonds, the conversion option of OCEANE, certain prepayment options of bonds, the Kreos / Claret warrants </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:196.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and the Kreos / Claret Minimum Return Indemnifications ("MRI") are derivatives instruments. Derivatives are recognized initially at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:206.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">fair value at the date the derivative contract is entered into and are subsequently remeasured to their fair value at each reporting date. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:216.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The resulting gain or loss from change in the fair value is recognized in profit or loss immediately, as financial expenses or income. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:244.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Hybrid instruments </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:272.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">OCEANE bonds </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:105.41pt;position:var(--position);text-decoration:none;white-space:pre">and Heights convertible notes (whose characteristics are described in Note 15.2 and Note 15.5)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.25pt;position:var(--position);text-decoration:none;white-space:pre"> are hybrid </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:282.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">instruments. A &#8220;hybrid contract&#8221; is a contract that includes both a non-derivative host contract and one or more embedded derivatives. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:292.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Embedded derivatives are required to be separated from the host contract (bifurcated) if: the economic characteristics and risks of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:302.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">embedded derivative are not closely related to those of the host, a separate instrument with the same terms as the embedded derivative </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:312.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">would meet the definition of a derivative, and the hybrid contract is not measured at fair value through profit or loss. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:334.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Separable embedded derivatives are required to be measured at fair value at each reporting date, with changes in fair value recognized </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:344.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in profit or loss. The initial bifurcation of a separable embedded derivative does not result in any gain or loss being recognized. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:354.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Because the embedded derivative component is measured at fair value on initial recognition, the carrying amount of the host contract </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:364.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">on initial recognition is the difference between the carrying amount of the hybrid instrument and the fair value of the embedded </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:374.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">derivative. If the fair values of the hybrid instrument and host contract are more reliably measurable than that of the derivative </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:384.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">component - e.g. because of the availability of quoted market prices - then it may be acceptable to use those values to determine the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:394.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">fair value of the derivative on initial recognition indirectly - i.e. as a residual amount. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:416.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Heights convertible notes issued on August 24, 2023 included embedded derivatives as detailed in Note 15. The Group concluded </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:428.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">that these features were embedded derivatives that would modify the cash flows required under the contract and require to be </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:439.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">bifurcated from their host contract. The Group being unable to reliably value each embedded derivative at issuance date and on </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:450.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">subsequent reporting dates, it measured the whole hybrid instrument at fair value through profit or loss (&#8220;FVTPL&#8221;) as permitted by </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:461.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">IFRS 9. Instruments measured at FVTPL under these conditions are measured at their fair value on issuance and on subsequent </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:472.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">reporting dates, with changes in fair value recognized in profit or loss.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:495.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Compound instruments </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:519.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Kreos / Claret OCABSA are compound instruments (whose characteristics are describ</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:398.62pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">ed in Note 15.1). </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:468.57pt;position:var(--position);text-decoration:none;white-space:pre">A &#8220;compound contract&#8221; is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:530.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">a contract that includes both a debt component and an equity component.&#160; The debt component (excluding the conversion option and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:542.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the attached OCABSA warrants) is initially recognized at fair value and subsequently measured at amortized cost calculated using the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:553.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">EIR method. The equity component corresponding to the conversion option and the attached OCABSA warrants is recorded in equity, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:564.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">for the difference between the whole instrument&#8217;s fair value (its nominal value) and the standalone fair value of the debt component.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:593.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Fair value measurement </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:609.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">When measuring the fair value of an asset or a liability, the Company uses market observable data as far as possible. Fair values are </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:619.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:635.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">level 1: fair value calculated using quoted prices in an active market for identical assets and liabilities; </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:651.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">level 2: fair value calculated using valuation techniques based on observable market data such as prices for assets and </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:661.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">liabilities or similar parameters quoted in an active market; &#160;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:671.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">level 3: fair value calculated using valuation techniques based in whole or in part on unobservable inputs such as prices </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:681.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">in an inactive market or a valuation based on multiples of unlisted securities. </span></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:703.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><ix:continuation id="f-693-3">See Note 12 Financial assets and liabilities and Note 15 Financial liabilities.</ix:continuation> </span></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-21<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><div style="position:absolute;top:70.56pt" id="i7a006daedb3d4216a4128b76247285d7_343"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><ix:continuation id="f-672-21" continuedAt="f-672-22"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 4.9. Research tax credit, subsidies and conditional advances </span></ix:continuation></div><ix:continuation id="f-672-22" continuedAt="f-672-23"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:86.56pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants" id="f-694" continuedAt="f-694-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Research tax credit </span></ix:nonNumeric></div><ix:continuation id="f-694-1" continuedAt="f-694-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:102.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group benefits from the provisions of Article 244 </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:255.53pt;position:var(--position);text-decoration:none;white-space:pre">quater </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:284.12pt;position:var(--position);text-decoration:none;white-space:pre">B of the French General Tax Code relating to the French research tax </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:112.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">credit (&#8220;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:68.99000000000001pt;position:var(--position);text-decoration:none;white-space:pre">Cr&#233;dit d&#8217;Imp&#244;t Recherche</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:173.3pt;position:var(--position);text-decoration:none;white-space:pre">&#8221; or &#8220;CIR&#8221;). The CIR is granted to companies in order to encourage them to conduct technical and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:122.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">scientific research. Companies that prove that they have expenditures which meet the required criteria (research expenditures located </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:132.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in France or, since January 1, 2005, within the European Union or in another state that is a party to the Agreement on the European </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:142.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Economic Area and has concluded a tax treaty with France that contains an administrative assistance clause) receive a tax credit that </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:152.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">can be used for the payment of the corporate tax due for the fiscal year in which the expenditures were made and the next three fiscal </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:162.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">years, or as applicable, companies may receive cash reimbursement for any excess portion at the three-year period following the fiscal </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:172.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">year of the expenditures. Only those companies meeting the EU definition of a small or medium-sized entity (&#8220;SME&#8221;) are eligible for </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:182.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">payment in cash of their research tax credit (to the extent not used to offset corporate tax payables) in the year following the request </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:192.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">for reimbursement. The expenditures taken into account for the calculation of the CIR involve only research expenses. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:214.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The CIR is presented under &#8220;Other operating income&#8221; in the statements of income (loss) as it is accounted for as a government grant </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:224.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">as defined in IAS 20 &#8211; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:128.16pt;position:var(--position);text-decoration:none;white-space:pre">Accounting for Government Grants and Disclosure of Government Assistanc</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:435.67pt;position:var(--position);text-decoration:none;white-space:pre">e, and as &#8220;Other receivables and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:234.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">assets&#8221; in the statement of financial position until its payment is received. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:262.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Subsidies </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:278.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Subsidies are non-repayable grants received by the Group and recognized in the financial statements when there exists reasonable </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:288.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">assurance that the Group will comply with the conditions attached to the subsidies and the subsidies will be received. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:310.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Subsidies that are upfront payments are presented as deferred income and recognized through &#8220;Other operating income&#8221; for the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:320.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">amount of the expenses incurred as part of the research program to which the subsidy relates. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:342.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">A subsidy that is to be received either as compensation for expenses or for losses already incurred, or for immediate financial support </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:352.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of the Group without associated future costs, is recognized in the Statements of income (loss) as &#8220;Other operating income&#8221; when there </span></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:362.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><ix:continuation id="f-694-2">exists reasonable assurance that the subsidies will be received.</ix:continuation> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:390.56pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForBorrowingsExplanatory" id="f-695" continuedAt="f-695-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Conditional advances and PGE </span></ix:nonNumeric></div><ix:continuation id="f-695-1" continuedAt="f-695-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:406.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group receives conditional advances to finance at below market interest rate research and development projects. Due to the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:416.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">innovative nature of its drug candidate development programs, the Group has benefited from certain sources of financial assistance </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:426.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">from Bpifrance. Bpifrance provides financial assistance and support to emerging French enterprises to facilitate the development and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:436.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">commercialization of innovative technologies. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:458.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Funds received from Bpifrance in the form of conditional advances are recognized as financial liabilities, as the Group has a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:468.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">contractual obligation to reimburse Bpifrance for such conditional advances in cash based on a repayment schedule. Each award of an </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:478.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">advance is made to help fund a specific development milestone. More de</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:327.3pt;position:var(--position);text-decoration:none;white-space:pre">tails </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:346.43pt;position:var(--position);text-decoration:none;white-space:pre">on conditional advances are provided in Note 15.7. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:488.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Receipts or reimbursements of conditional advances are reflected as financing transactions in the statements of cash flows. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:510.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The difference between the present value of the advance at market rate (i.e., present value of contractual cash flows including principal </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:520.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and interests, discounted using a market rate as effective interest rate in accordance with IFRS 9) and the amount received as cash </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:530.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">from the Bpifrance constitutes a subsidy within the meaning of IAS 20. Considering that these advances do not finance fixed assets, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:540.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">these subsidies are presented as &#8220;Deferred income&#8221; in the statement of financial position and recognized in the statement of net income </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:550.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(loss) as &#8220;Other operating income&#8220; on a systematic basis over the periods in which the Group recognizes as expenses the related costs </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:560.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">for which the grants are intended to compensate. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:582.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The incremental interest expense resulting from the difference between (a)&#160;the market interest rate and the (b)&#160;below-market rate is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:592.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">spread over the contractual period until the last repayment and recognized in the statement of income (loss) accordingly, using the EIR </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:602.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">method. In the event of a change in estimate of contractual cash flows due under the conditional advances, the Group recalculates the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:612.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">book value of the debt resulting from the discounting of the anticipated new future cash flows at the initial EIR. The adjustment is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:622.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">recognized in the statements of income (loss) for the period during which the modification is recognized. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:644.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In the statements of financial position, these conditional advances are recorded in &#8220;Other financial liabilities&#8221; as current or non-current </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:654.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">portion depending on their maturity. In the event Bpifrance waived the repayment of the advance, the corresponding liability is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:664.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">derecognized and treated as a subsidy in the statements of income (loss). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:686.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The benefit resulting from the low interest of PGE loans is also recognized as a subsidy corresponding to the difference between the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:696.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">present value of the PGE at market rate and the amount received as cash. The accounting treatment is therefore similar to the above-</span></div></ix:continuation></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-22<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-672-23" continuedAt="f-672-24"><ix:continuation id="f-695-2" continuedAt="f-695-3"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">mentioned accounting treatment for conditional advances. PGE are recorded in &#8220;Borrowings&#8221; as current or non-current portion </span></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:80.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><ix:continuation id="f-695-3">depending on their maturity.</ix:continuation> </span></div></ix:continuation><div style="position:absolute;top:108.56pt" id="i7a006daedb3d4216a4128b76247285d7_346"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:108.56pt;width:612pt"><ix:continuation id="f-672-24" continuedAt="f-672-25"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 4.10. </span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" id="f-696" continuedAt="f-696-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:80.42pt;position:var(--position);text-decoration:none;white-space:pre">Employee benefits </span></ix:nonNumeric></ix:continuation></div><ix:continuation id="f-672-25" continuedAt="f-672-26"><ix:continuation id="f-696-1" continuedAt="f-696-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:124.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group&#8217;s employees in France benefit from retirement benefits provided under French law, which consist in the following: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:140.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">compensation paid by the Group to employees upon their retirement (a defined benefit plan); and </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:156.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">payments of retirement pensions by the social security agencies, which are financed by the contributions made by the </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:166.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">Group and employees. As they meet the definition of a defined contribution plan, the liabilities are presented as Tax and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:176.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">employee-related payables in the statement of financial position. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:198.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In accordance with IAS 19 &#8211; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:153.11pt;position:var(--position);text-decoration:none;white-space:pre">Employee Benefits</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:227.15pt;position:var(--position);text-decoration:none;white-space:pre">, the liability with respect to defined benefit plans is estimated by using the projected </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:208.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">credit unit method. According to this method, the cost of the retirement benefit is recognized in the statements of income (loss). The </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:218.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">retirement benefit commitments are valued at the current value of the estimated future payments, discounted using the market rate for </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:228.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">high quality corporate bonds with a term and currency that correspond to that estimated for the payment of the benefits. The Group </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:238.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">applied the decision of the IFRS IC, published on May&#160;24, 2021, that concluded that, in the case that no rights were acquired in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:248.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">event of departure before retirement age and that the rights were capped after a certain number of years of seniority (&#8220;30 years&#8221;), the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:258.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">commitment would only be recognized for the last 30 years of the employee&#8217;s career within the Group. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:280.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The difference between the amount of the provision at the beginning of a period and at the close of that period is recognized through </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:290.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">operating expenses for the portion representing the costs of services rendered and financial expenses for the net interest costs, and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:300.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">through other comprehensive income (loss) for the portion representing the actuarial gains and losses due to changes in assumptions </span></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:310.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><ix:continuation id="f-696-2">and experience adjustments.</ix:continuation> </span></div></ix:continuation><div style="position:absolute;top:332.56pt" id="i7a006daedb3d4216a4128b76247285d7_349"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:332.56pt;width:612pt"><ix:continuation id="f-672-26" continuedAt="f-672-27"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 4.11. </span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory" id="f-697" continuedAt="f-697-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:80.42pt;position:var(--position);text-decoration:none;white-space:pre">Provisions </span></ix:nonNumeric></ix:continuation></div><ix:continuation id="f-672-27" continuedAt="f-672-28"><ix:continuation id="f-697-1" continuedAt="f-697-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:348.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Provisions correspond to commitments resulting from litigation and various risks to which the Group may face in the context of its </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:358.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">operations, as well as taxes and employer contributions related to AGAs that become due upon the vesting of the awards. In </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:368.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">accordance with IAS 37 &#8211; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:142.28pt;position:var(--position);text-decoration:none;white-space:pre">Provisions, Contingent Liabilities and</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:294.92pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:297.42pt;position:var(--position);text-decoration:none;white-space:pre">Contingent Assets, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:374.29pt;position:var(--position);text-decoration:none;white-space:pre">a provision is recorded when the Group has an </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:378.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">obligation to a third party resulting from a past event that will likely result in an outflow of resources to the third party, and for which </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:388.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">future cash outflows may be estimated reliably. The amount recorded as a provision is an estimate of the expenditure required to settle </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:398.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the obligation, discounted where necessary at year end. For AGA taxes, the taxes are based on the vesting date share price, and the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:408.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">provision is estimated based on the spot listed price at year-end multiplied by the number of AGAs which are expected to vest. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:418.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Contingent</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:80.4pt;position:var(--position);text-decoration:none;white-space:pre"> liabilities are not recognized, but are disclosed in the notes to the financial statements unless the possibility of an outflow </span></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:428.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><ix:continuation id="f-697-2">of economic resources is remote.</ix:continuation> </span></div></ix:continuation><div style="position:absolute;top:456.56pt" id="i7a006daedb3d4216a4128b76247285d7_352"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:456.56pt;width:612pt"><ix:continuation id="f-672-28" continuedAt="f-672-29"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 4.12. </span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory" id="f-698" continuedAt="f-698-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:80.42pt;position:var(--position);text-decoration:none;white-space:pre">Leases </span></ix:nonNumeric></ix:continuation></div><ix:continuation id="f-698-1" continuedAt="f-698-2"><ix:continuation id="f-672-29" continuedAt="f-672-30"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:472.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As lessee, the Group assesses whether a contract contains a lease at inception of a contract and upon the modification of a contract. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:482.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group elected to allocate the consideration in the contract to the lease and non-lease components on the basis of the relative </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:492.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">standalone price. The Group recognizes a right-of-use asset and a corresponding lease liability for all arrangements in which it is a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:502.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">lessee, except for leases with a term of 12 months or less (short-term leases) and low-value leases (value of the underlying asset below </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:512.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.0 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:92.09pt;position:var(--position);text-decoration:none;white-space:pre">). For these short-term and low-value leases, the Group recognizes the lease payments as an operating expense on a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:522.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">straight-line basis over the term of the lease. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:544.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The lease liability is initially measured at the present value of the future lease payments as from the commencement date of the lease </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:554.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">to the end of the lease term. The lease terms used by the Group reflect the non-cancellable terms of each contract, plus any extension </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:564.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">or termination options that the Group is reasonably certain to exercise or not exercise for all of the leases periods covered by the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:574.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">extension options. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:584.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Group incremental borrowing rate for the asset subject to the lease in the respective markets. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:606.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever there is a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:616.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">change to the lease terms or expected payments under the lease, or a modification that is not accounted for as a separate lease. The </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:626.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">portion of the lease payments attributable to the repayment of lease liabilities and the portion attributable to payment of interests are </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:636.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">recognized in cash flows used in financing activities. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:658.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Right-of-use assets are initially recognized on the balance sheet at cost, which comprises the amount of the initial measurement of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:668.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">corresponding lease liability, adjusted for any lease payments made at or prior to the commencement date of the lease, any lease </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:678.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">incentives received and any initial direct costs incurred by the Group, and expected costs for obligations to dismantle and remove </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:688.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">right-of-use assets when they are no longer used. </span></div></ix:continuation></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-23<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-672-30" continuedAt="f-672-31"><ix:continuation id="f-698-2" continuedAt="f-698-3"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Right-of-use assets are depreciated on a straight-line basis from the commencement date of the lease over the shorter of the useful life </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:80.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of the right-of-use asset or the end of the lease term. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:102.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Right-of-use assets are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be </span></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:112.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><ix:continuation id="f-698-3">recoverable using cash flow projections.</ix:continuation> </span></div></ix:continuation><div style="position:absolute;top:140.56pt" id="i7a006daedb3d4216a4128b76247285d7_355"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:140.56pt;width:612pt"><ix:continuation id="f-672-31" continuedAt="f-672-32"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 4.13. </span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" id="f-699" continuedAt="f-699-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:80.42pt;position:var(--position);text-decoration:none;white-space:pre">Translation of transactions denominated in foreign currency </span></ix:nonNumeric></ix:continuation></div><ix:continuation id="f-672-32" continuedAt="f-672-33"><ix:continuation id="f-699-1" continuedAt="f-699-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:156.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Pursuant to IAS 21</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.36pt;position:var(--position);text-decoration:none;white-space:pre"> &#8211; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:122.36pt;position:var(--position);text-decoration:none;white-space:pre">The Effects of Changes in Foreign Exchange Rates</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:326.3pt;position:var(--position);text-decoration:none;white-space:pre">, transactions performed by the Company and the Subsidiary </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:166.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in currencies other than their functional currencies, which are respectively the Euro and the U.S. dollar, are translated at the prevailing </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:176.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">exchange rate on the transaction date. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:198.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Trade receivables and payables and liabilities denominated in a currency other than the functional currency are translated at the </span></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:208.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><ix:continuation id="f-699-2">period-end exchange rate. Unrealized gains and losses arising on translation are recognized in net financial income / (loss).</ix:continuation> </span></div></ix:continuation><div style="position:absolute;top:230.56pt" id="i7a006daedb3d4216a4128b76247285d7_358"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:230.56pt;width:612pt"><ix:continuation id="f-672-33" continuedAt="f-672-34"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 4.14. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:80.42pt;position:var(--position);text-decoration:none;white-space:pre">Current and deferred tax </span></ix:continuation></div><ix:continuation id="f-672-34" continuedAt="f-672-35"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:246.56pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory" id="f-700" continuedAt="f-700-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to the </span></ix:nonNumeric></div><ix:continuation id="f-700-1" continuedAt="f-700-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:256.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">French tax authorities, using tax rates and tax laws enacted or substantively enacted at the end of the reporting period in accordance </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:266.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">with IAS 12 &#8211; Income Tax. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:288.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The income tax charge for the period comprises current tax due and the deferred tax charge. The tax expense is recognized in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:298.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">statement of income (loss) unless it relates to items recorded in other comprehensive income (loss) or directly in equity, in which case </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:308.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the tax is also recorded in other comprehensive income (loss) or directly in equity. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:336.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Current taxes </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:352.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The current tax expense is calculated based on taxable profit for the period, using tax rates enacted or substantively enacted at the </span></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:362.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><ix:continuation id="f-700-2">statement of financial position date. Considering the level of tax loss of the Group, no current tax expense is recognized.</ix:continuation> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:390.56pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" id="f-701" continuedAt="f-701-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Deferred taxes </span></ix:nonNumeric></div><ix:continuation id="f-701-1" continuedAt="f-701-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:406.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Deferred taxes are recognized when there are temporary differences between the carrying amount of assets and liabilities in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:416.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Group&#8217;s financial statements and the corresponding tax basis used to calculate taxable profit. Deferred taxes are not recognized if they </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:426.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">arise from the initial recognition of an asset or liability in a transaction other than a business combination which, at the time of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:436.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">transaction, does not affect either the accounting or the taxable profit (tax loss). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:446.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group applies the Amendments to IAS 12 &#8211; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:232.23pt;position:var(--position);text-decoration:none;white-space:pre">Deferred Tax related to Assets and Liabilities arising from a Single Transaction</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:552.79pt;position:var(--position);text-decoration:none;white-space:pre">, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:456.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">issued on May 7, 2021, and presents the deferred tax assets and liabilities arising from such transactions separately within Note 22 </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:559.6pt;position:var(--position);text-decoration:none;white-space:pre">- </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:466.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Income tax, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.11pt;position:var(--position);text-decoration:none;white-space:pre">rather than on a net basis. The Amendments have no impact on the Statements of financial position and the Statement of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:476.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">comprehensive income (loss) for the periods presented.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:504.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Deferred tax assets </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:520.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Deferred tax assets are recognized for all deductible temporary differences, unused tax losses and unused tax credits to the extent that </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:530.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">it is probable that the temporary difference will reverse in the foreseeable future and that taxable profit will be available against which </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:540.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the deductible temporary difference, unused tax losses or unused tax credits can be utilized. In this regard, the Group applies the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:550.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">decision of the IFRS IC, published on January 29, 2021, on the amount of deferred tax assets recognized from unused tax losses as a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:560.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">result of suitable taxable temporary differences, in the case when the use of such tax losses is restricted or limited by the tax law. See </span></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:570.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><ix:continuation id="f-701-2">Note 4.15. Use of judgments and estimates and Note 22 Income tax.</ix:continuation> </span></div></ix:continuation><div style="position:absolute;top:598.56pt" id="i7a006daedb3d4216a4128b76247285d7_364"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:598.56pt;width:612pt"><ix:continuation id="f-672-35" continuedAt="f-672-36"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 4.15. </span><ix:nonNumeric contextRef="c-1" name="abvx:DisclosureOfAccountingPolicyForAccountingJudgementsAndEstimatesExplanatoryPolicyTextBlock" id="f-702" continuedAt="f-702-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:80.42pt;position:var(--position);text-decoration:none;white-space:pre">Use of judgments and estimates </span></ix:nonNumeric></ix:continuation></div><ix:continuation id="f-702-1" continuedAt="f-702-2"><ix:continuation id="f-672-36" continuedAt="f-672-37"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:614.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In order to prepare financial statements in accordance with IFRS, estimates, judgments and assumptions were made by the Group&#8217;s </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:624.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">management which could affect the reported amounts of assets, liabilities, contingent liabilities, income and expenses. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:646.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">These estimates are based on the assumption of going concern and are prepared in accordance with information available at the date </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:656.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the financial statements were prepared. They are reviewed on an ongoing basis using past experience and various other factors </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:666.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">considered to be reasonable as the basis to measure the carrying amount of assets and liabilities. Estimates may be revised due to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:676.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">changes in the underlying circumstances or subsequent to new information. Actual results may differ significantly from these </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:686.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">estimates in line with assumptions or different conditions. </span></div></ix:continuation></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-24<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-702-2"><ix:continuation id="f-672-37"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">This note provides an overview of the areas that involved a higher degree of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:342.88pt;position:var(--position);text-decoration:none;white-space:pre">judgment </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:383.12pt;position:var(--position);text-decoration:none;white-space:pre">or complexity, and of items which are more </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:80.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">likely to be materially adjusted due to changes in estimates and assumptions. Detailed information about each of these estimates and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:90.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">judgments </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:80.13pt;position:var(--position);text-decoration:none;white-space:pre">is included in other notes together with information about the basis of calculation for each affected line item in the financial </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:100.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">statements. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:116.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Recognition and measurement of impairment of CGUs. The main assumptions used for the impairment test include </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">(a)&#160;the amount of cash flows that are set on the basis of the development and commercialization plans and budgets </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:136.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">approved by Board of Directors, (b)&#160;assumptions related to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:329.16pt;position:var(--position);text-decoration:none;white-space:pre">the</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:341.36pt;position:var(--position);text-decoration:none;white-space:pre"> achievement of the clinical trials and the launch of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:146.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">commercialization, (c)&#160;the discount rate, (d) assumptions on risk related to the development and (e)&#160;for the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:156.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">commercialization, selling price and volume of sales. The sensitivity analysis in respect of the recoverable amount of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:166.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">CGUs is presented in Note 6. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:182.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Measurement of share-based payments granted to employees, corporate officers and scientific consultants, such as BCE, </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:194.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">BSA and AGA, which is based on actuarial models; these models require the use by the Group of certain calculation </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:205.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">assumptions such as the estimated vesting, the occurrence dates of a change of control or a M&amp;A transaction dates, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:554.11pt;position:var(--position);text-decoration:none;white-space:pre">the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:217.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">percentage of success (&#8220;POS&#8221;) of obefazimod,</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:276.94pt;position:var(--position);text-decoration:none;white-space:pre"> the expected volatility and maturity of the underlying equity instrument </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:228.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">(see Note 4.7 and Note 14), </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:246.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Fair value measurement at inception and after of derivative financial instruments resulting from (i)&#160;the warrants issued </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:257.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">concomitantly with the issuance of the straight and convertible bonds to Kreos on July 24, 2018 (or &#8220;Kreos 1&#8221;), </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.25pt;position:var(--position);text-decoration:none;white-space:pre">(ii) the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:269.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">Kreos / Claret BSA issued on August 21, 2023 and November 2, 2023, related to tranches A-B and tranche C, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:280.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">respectively, and (iii) the Kreos / Claret Minimum Return Indemnifications related to tranches B and C, issued in March </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:292.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">2024 and June 2024, respectively,</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:309.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Amortized cost measurement a</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:215.04000000000002pt;position:var(--position);text-decoration:none;white-space:pre">nd fair value</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:265.53000000000003pt;position:var(--position);text-decoration:none;white-space:pre"> of royalty certificates, based on the following assumptions: (a)&#160;future cash </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:319.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">flows, estimated on the basis of development and commercialization plans and budgets approved by the Board of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:329.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">Directors, (b)&#160;the effective interest rate (for the amortized cost measurement) and (c) the discount rate (for the fair </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:339.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">value). The sensitivity analyses in respect of the amortized cost measurement and fair value of royalty certificates is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:349.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">presented in Note 15,&#160; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:365.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Fair value measurement of other financial liabilities at inception, </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:352.32pt;position:var(--position);text-decoration:none;white-space:pre">and after, for the Heights convertible notes measured at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:377.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">fair value at each reporting period, with fair value changes recognized in profit or loss, as well as for disclosure purposes </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:388.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">(see Note 15), </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:406.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Estimation of CIR, based on internal and external expenses, which meet the required criteria, incurred by the Group each </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:416.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">year (see Note 4.9), </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:432.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Recognition of deferred tax assets: availability and timing of future taxable profit against which deductible temporary </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:442.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">differences and tax losses carried forward can be utilized and whether sufficient evidence exists (see Note 22),</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:458.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72.69999999999999pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">Recognition of deferred tax assets: tax deductibility of future royalty payments related to the royalty certificates issued in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:470.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">September 2022 (see Notes 15 and 22),</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:488.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72.69999999999999pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">Determination of the terms of the leases, including whether the Group is reasonably certain to exercise extension and/or </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:500.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">termination options (see Note 15.8).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:536.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The main critical judgments made by the Group&#8217;s management impact the following items: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:564.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72.69999999999999pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">Accounting treatment of specific conditions of share-based compensation plans (see Notes 4.7 and 14),</span></div><div style="font-size:12pt;line-height:10.5pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:582.06pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:10.5pt;font-style:normal;font-weight:normal;left:72.69999999999999pt;position:var(--position);text-decoration:none;white-space:pre;width:3.67pt">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre;width:484.88pt">Accounting treatment of the royalty certificates and August 2023 Kreos / Claret and Heights Financings (see Notes 4.8</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.93pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:593.61pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre;width:32.76pt">and 15).</span></div></ix:continuation></ix:continuation><div style="position:absolute;top:647.16pt" id="i7a006daedb3d4216a4128b76247285d7_367"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:647.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 5. </span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory" id="f-703" continuedAt="f-703-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:68.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Segment information </span></ix:nonNumeric></div><ix:continuation id="f-703-1" continuedAt="f-703-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:663.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The assessment of the Group&#8217;s performance and the decisions about resources to be allocated are made by the chief operating decision </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:673.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">maker, based on the management reporting system of the Group. The Group identified the Chief Executive Officer of the Group as </span></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-25<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-703-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8220;chief operating decision maker&#8221;. The chief operating decision maker reviews on an aggregated basis the incurred expenses for </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:80.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">allocating and evaluating performance of the Group. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:102.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group operates in a single operating segment: R&amp;D of pharmaceutical products in order to market them in the future. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:124.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023 and 2024, substantially all operations, assets, liabilities, and losses of the Group were located in France. As </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:135.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of December 31, 2025, the U.S. Subsidiary's contributions to the Group&#8217;s l</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:334.53pt;position:var(--position);text-decoration:none;white-space:pre">iabilities and net losse</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:423.01pt;position:var(--position);text-decoration:none;white-space:pre">s </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:429.4pt;position:var(--position);text-decoration:none;white-space:pre">were less than </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:488.49pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-155" decimals="2" name="abvx:ContributionToGroupsLiabilitiesPercentage" scale="-2" id="f-704"><ix:nonFraction unitRef="number" contextRef="c-156" decimals="2" name="abvx:ContributionToGroupsNetProfitsLossesPercentage" scale="-2" id="f-705">10</ix:nonFraction></ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:506.82pt;position:var(--position);text-decoration:none;white-space:pre">, and its </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:146.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">contribution to the Group's assets were </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:193.76pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-157" decimals="2" name="abvx:ContributionToGroupsAssetsPercentage" scale="-2" id="f-706">29</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:212.09pt;position:var(--position);text-decoration:none;white-space:pre"> (consisting predominantly of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:332.54pt;position:var(--position);text-decoration:none;white-space:pre">cash and cash equivalents)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:438.79pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div></ix:continuation><div style="position:absolute;top:188.16pt" id="i7a006daedb3d4216a4128b76247285d7_373"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:188.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 6. </span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfGoodwillExplanatory" id="f-708" continuedAt="f-708-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:68.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Goodwill and impairment test </span></ix:nonNumeric></div><ix:continuation id="f-708-1" continuedAt="f-708-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:204.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Goodwill relates to the acquisition of Splicos SAS and Wittycel SAS that occurred in 2014 (i.e., prior the transition date to IFRS), </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:214.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">which were merged into the Group in the same year. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:236.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Goodwill from Splicos SAS and Wittycel SAS acquisition corresponds to the &#8220;Modulation of RNA biogenesis / splicing&#8221; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:246.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">technological platform and the &#8220;iNKT agonists&#8221; technological platform, respectively, from which derived the lead drug candidates of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:256.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the Group: ABX464 and ABX196, respectively. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:278.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">IFRS 3 was not applied to acquisitions of subsidiaries deemed to be a business within the meaning of IFRS, carried out before the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:288.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">IFRS transition date, i.e., January&#160;1 2020. Due to the application of this exemption, the previous accounting for business combinations </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:298.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in accordance with French GAAP remains unchanged (no identified Intellectual Property, Research&#160;&amp; Development (&#8220;IPR&amp;D&#8221;) assets </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:308.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">are recognized in the statement of financial position).</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:249.03pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:330.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The impairment test carried out as of December&#160;31, 2022 resulted in the full impairment of the goodwill resulting from the acquisition </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:340.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of Wittycell SAS and other assets included in the ABX196 CGU, i.e. an impairment loss of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:403.69pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-158" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-709">13,632</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:474.78pt;position:var(--position);text-decoration:none;white-space:pre"> as of December&#160;31, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:350.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">2022 (</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:61.83pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-158" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-710">13,586</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:132.92000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> related to goodwill and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:230.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-158" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" scale="3" id="f-711">45</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:283.9pt;position:var(--position);text-decoration:none;white-space:pre"> related to other assets). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:360.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Consequently, the carrying amount of the Group's goodwill of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:287.03999999999996pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-159" decimals="-3" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-712"><ix:nonFraction unitRef="eur" contextRef="c-160" decimals="-3" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-713"><ix:nonFraction unitRef="eur" contextRef="c-161" decimals="-3" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-714">18,419</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:358.13pt;position:var(--position);text-decoration:none;white-space:pre"> as of December&#160;31, 2023, 2024 and 2025 solely </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:372.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">relates to the acquisition of Splicos SAS. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:395.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In accordance with IAS 36, goodwill is allocated to CGUs at a level corresponding to the lead drug candidates. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:481.88pt;position:var(--position);text-decoration:none;white-space:pre">Thus, goodwill from </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:406.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Splicos SAS is allocated to the ABX464 CGU.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:429.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Goodwill impairment tests are undertaken annually or more frequently if events or changes in circumstances indicate a potential </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:439.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">impairment, in accordance with IAS 36. The carrying amount of goodwill is compared to the recoverable amount, which is the higher </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:449.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">value in use and the fair value less costs to disposal. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:471.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2025, the Group has not identified any indication of impairment loss related to goodwill, intangible or tangible </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:482.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">assets. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:505.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, 2024 and 2025 the recoverable amount used for the impairment test of each CGU was the value in use. This </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:517.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">value in use was based on a net present value calculation, using the following assumptions as of December 31, 2023, 2024 and 2025: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:535.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Cash flows are set on the basis of the development and commercialization plans and budgets approved by Board of </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:545.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">Directors; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:561.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05000000000001pt;position:var(--position);text-decoration:none;white-space:pre">A discount rate (or &#8220;WACC&#8221;) o</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:218.41000000000003pt;position:var(--position);text-decoration:none;white-space:pre">f</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:221.74pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:226.74pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="2" name="ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections" scale="-2" id="f-715">15</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:245.07pt;position:var(--position);text-decoration:none;white-space:pre"> as of December 31, 2023, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:352.76pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections" scale="-2" id="f-716">11.5</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:378.59pt;position:var(--position);text-decoration:none;white-space:pre"> as of December 31, 2024 and of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:511.53999999999996pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections" scale="-2" id="f-717">10.0</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:537.37pt;position:var(--position);text-decoration:none;white-space:pre"> as of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:572.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">December 31, 2025;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:590.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">A risk of development is taken into consideration by applying probabilities of success (or &#8220;POS&#8221;) of reaching future </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:600.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">phases of development to cash flows related to the commercialization phase. Those average probabilities of success of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:610.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">R&amp;D projects are based on public sources</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:259.2pt;position:var(--position);text-decoration:none;white-space:pre">;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:626.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">For the commercialization phase, selling price and sales volume are estimated on the basis of the potential market and </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:636.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">the observed performances of comparable drugs currently on the market. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:658.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The impairment tests resulted in </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:167.21pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" format="ixt:fixed-zero" scale="3" id="f-718"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" format="ixt:fixed-zero" scale="3" id="f-719"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" format="ixt:fixed-zero" scale="3" id="f-720">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:177.21pt;position:var(--position);text-decoration:none;white-space:pre"> impairment charges as of December 31, 2023, 2024, and 2025.</span></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-26<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-708-2" continuedAt="f-708-3"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Sensitivity testing as of December&#160;31, 2023, 2024 and 2025:</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:96.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As the product is currently under development, a clinical trial failure or a failure to obtain a marketing approval could result in an </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:107.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">impairment of the goodwill allocated to the ABX464 CGU. The results of the impairment test indicate a headroom level that is high </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:118.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">enough so that any reasonably possible change in any of the key assumptions (except clinical failure) would not lead to any </span></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:130.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><ix:continuation id="f-708-3">impairment.</ix:continuation> </span></div><div style="position:absolute;top:170.56pt" id="i7a006daedb3d4216a4128b76247285d7_376"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:170.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 7. </span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfIntangibleAssetsExplanatory" id="f-721" continuedAt="f-721-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:68.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Intangible assets </span></ix:nonNumeric></div><ix:continuation id="f-721-1" continuedAt="f-721-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:186.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Intangible assets are mainly comprised of the intellectual property underlying: </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:220.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:66.55pt;position:var(--position);text-decoration:none;white-space:pre">(i)</span><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:75.97999999999999pt;position:var(--position);text-decoration:none;white-space:pre">&#160; &#160;  </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90.97999999999999pt;position:var(--position);text-decoration:none;white-space:pre">The exclusive license agreement with the Scripps Research Institute, University of Chicago and Brigham Young </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:230.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">University for which the Group paid a milestone of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.35pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-162" decimals="-3" name="abvx:CollaborationAgreementsDevelopmentMilestonePaymentINDApproval" scale="3" id="f-722">45</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:351.94pt;position:var(--position);text-decoration:none;white-space:pre"> in September 2019 as a result of an IND filling of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:240.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">ABX196. The value in use and the fair value less costs to disposal of the ABX196 CGU being </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:470.43pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-163" decimals="-3" name="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLife" format="ixt:fixed-zero" scale="0" id="f-723">nil</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:480.97pt;position:var(--position);text-decoration:none;white-space:pre"> as of December 31, </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:250.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">2022, a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:122.97999999999999pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-158" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" scale="3" id="f-724">45</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:176.57pt;position:var(--position);text-decoration:none;white-space:pre"> impairment loss was recorded during the year ended December 31, 2022 (see Note 6).</span><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:522.87pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:266.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:66.55pt;position:var(--position)">(ii)<span style="display:inline-block;height:6.93pt;width:12.3pt"></span></span><span style="left:91.05pt;position:var(--position)">The collaboration and license agreement with the CNRS, Montpellier 2 university and the Curie for which the Group </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:276.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">paid a milestone of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:169.84pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-164" decimals="-3" name="abvx:CollaborationAgreementsDevelopmentMilestonePaymentPhase2" scale="3" id="f-725">40</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:223.43pt;position:var(--position);text-decoration:none;white-space:pre"> in September 2019 as a result of the entry in phase 2 of ABX464. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:292.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:66.55pt;position:var(--position)">(iii)<span style="display:inline-block;height:6.93pt;width:9.53pt"></span></span><span style="left:91.05pt;position:var(--position)">Patents acquired through the acquisition of Prosynergia SARL (or "Prosynergia") on April 1, 2022 and amounting to </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:302.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-165" decimals="-3" name="abvx:TechnologyBasedIntangibleAssetsAssetsAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-726">6,529</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:157.14pt;position:var(--position);text-decoration:none;white-space:pre">. Considering that Prosynergia only owned patent rights and did not enter into any employee contract, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:312.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">research agreement, collaboration agreement or out-licensed agreement, this</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:395.87pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:398.37pt;position:var(--position);text-decoration:none;white-space:pre">acquisition did not meet the definition of a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:322.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">business under IFRS 3. Consequently, the acquisition cost of this group of assets was mostly allocated to the acquired </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:332.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">patents, which cover alternative synthesis process for obefazimod and a family of close chemical analogues. They also </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:342.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">cover alternative forms of obefazimod (salts thereof and crystalline forms of said salts), the pharmaceutical composition </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:352.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">comprising them, that could be of interest to the Group for future development.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:362.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">The patents are not yet amortized, similarly to licenses, and are included in the ABX464 CGU for impairment test </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:372.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">purposes. All patents will expire in 2037.</span></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-27<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-721-2"><div style="font-size:12pt;line-height:1pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:71.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Licenses and patents recognized as Intangible assets are not amortized since they are not operating in a manner intended by the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:81.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">management. As a consequence, and in accordance with IAS 36, those assets were subject to an annual impairment test as of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:91.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">December 31, 2023, 2024 and 2025, which did </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:226.16pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-166" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="0" id="f-727"><ix:nonFraction unitRef="eur" contextRef="c-167" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="0" id="f-728"><ix:nonFraction unitRef="eur" contextRef="c-168" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="0" id="f-729">not</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:238.93pt;position:var(--position);text-decoration:none;white-space:pre"> result in any impairment loss being recognized</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:428.43pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><div style="position:var(--position);top:113.56pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" id="f-730" continuedAt="f-730-1" escape="true"><div style="font-size:0pt;left:36pt;position:var(--position);width:464.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:194.25pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:65.25pt"/></tr><tr style="height:32.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.48pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:45.59pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.86pt;position:var(--position);text-decoration:none;white-space:pre">LICENSES</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.75pt;position:var(--position);text-decoration:none;white-space:pre">SOFTWARE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.2pt;position:var(--position);text-decoration:none;white-space:pre">PATENTS</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.63pt;position:var(--position);text-decoration:none;white-space:pre">TOTAL</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:32.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">GROSS VALUES</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:44.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY 1, 2023</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:44.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.88pt"></span></span><span style="left:49.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-169" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-731">120</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:44.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-170" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-732">24</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:44.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-171" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-733">6,529</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:44.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-172" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-734">6,673</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:65.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:65.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.88pt"></span></span><span style="left:49.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-173" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-735">120</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:65.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-174" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-736">24</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:65.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-175" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-737">6,529</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:65.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-176" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-738">6,673</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:86.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Acquisition</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:86.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-177" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-739">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:86.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.88pt"></span></span><span style="left:57.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-178" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="f-740">3</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:86.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-179" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-741">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:86.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.88pt"></span></span><span style="left:57.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-180" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="f-742">3</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:23.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:98.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.02pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:98.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.88pt"></span></span><span style="left:49.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-181" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-743">120</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:98.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-182" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-744">27</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:98.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-183" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-745">6,529</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:98.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-184" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-746">6,677</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:23.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:121.5pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.82pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:13.42pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:121.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.88pt"></span></span><span style="left:49.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-185" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-747">120</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:121.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-186" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-748">27</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:121.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-187" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-749">6,529</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:121.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-188" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-750">6,677</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></ix:nonNumeric></div><ix:continuation id="f-730-1"><div style="position:var(--position);top:277.94pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:464.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:194.25pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:65.25pt"/></tr><tr style="height:35.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:26.48pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:45.59pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.8pt;position:var(--position);text-decoration:none;white-space:pre">LICENSES</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.69pt;position:var(--position);text-decoration:none;white-space:pre">SOFTWARE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.14pt;position:var(--position);text-decoration:none;white-space:pre">PATENTS</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:19.57pt;position:var(--position);text-decoration:none;white-space:pre">TOTAL</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:35.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AMORTIZATION</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:23.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:47.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.82pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:13.42pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY 1, 2023</span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:47.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.22pt"></span></span><span style="left:50.85pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-189" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-751">45</ix:nonFraction>)<span style="display:inline-block;height:5.41pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:47.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.55pt"></span></span><span style="left:51.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-190" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-752">21</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:47.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-191" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-753">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:47.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.55pt"></span></span><span style="left:51.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-192" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-754">66</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:70.5pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Increase </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:70.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-193" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-755">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:70.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.55pt"></span></span><span style="left:55.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-194" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-756">3</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:70.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-195" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-757">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:70.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.55pt"></span></span><span style="left:55.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-196" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-758">3</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:82.5pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:82.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.22pt"></span></span><span style="left:50.85pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-197" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-759">45</ix:nonFraction>)<span style="display:inline-block;height:5.41pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:82.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.55pt"></span></span><span style="left:51.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-198" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-760">24</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:82.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-199" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-761">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:82.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.55pt"></span></span><span style="left:51.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-200" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-762">70</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:103.5pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Increase </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:103.5pt;width:65.25pt"><div><div style="line-height:9pt;position:var(--position);top:2.35pt;width:65.25pt"><span style="color:#000000;font-family:'Arial', sans-serif;font-size:9pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.55pt;width:49.88pt"></span></span><span style="left:52.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-201" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-763">&#8212;</ix:nonFraction><span style="display:inline-block;height:6.55pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:103.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.55pt"></span></span><span style="left:55.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-202" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-764">1</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:103.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-203" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-765">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:103.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.55pt"></span></span><span style="left:55.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-204" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-766">1</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:24pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:115.5pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.2pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:13.8pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:115.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:15.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.22pt"></span></span><span style="left:50.85pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-205" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-767">45</ix:nonFraction>)<span style="display:inline-block;height:5.41pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:115.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:15.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.55pt"></span></span><span style="left:51.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-206" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-768">25</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:115.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:15.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-207" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-769">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:115.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:15.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.55pt"></span></span><span style="left:51.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-208" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-770">70</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:139.5pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.99pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Increase </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:139.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-209" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-771">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:139.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.55pt"></span></span><span style="left:55.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-210" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-772">1</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:139.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-211" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-773">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:139.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.55pt"></span></span><span style="left:55.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-212" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-774">1</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:24pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:152.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.2pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:13.8pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:152.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:15.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.22pt"></span></span><span style="left:50.85pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-213" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-775">45</ix:nonFraction>)<span style="display:inline-block;height:5.41pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:152.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:15.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.55pt"></span></span><span style="left:51.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-214" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-776">26</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:152.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:15.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-215" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-777">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:152.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:15.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.55pt"></span></span><span style="left:51.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-216" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-778">71</ix:nonFraction>)</span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:485.79pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:464.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:194.25pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:65.25pt"/></tr><tr style="height:35.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:26.48pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:45.59pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.8pt;position:var(--position);text-decoration:none;white-space:pre">LICENSES</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.69pt;position:var(--position);text-decoration:none;white-space:pre">SOFTWARE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.14pt;position:var(--position);text-decoration:none;white-space:pre">PATENTS</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:19.57pt;position:var(--position);text-decoration:none;white-space:pre">TOTAL</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:35.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">NET BOOK VALUES</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:47.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY 1, 2023</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:47.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-779">75</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:47.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-780">3</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:47.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-219" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-781">6,529</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:47.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-782">6,607</ix:nonFraction></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:68.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:68.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-220" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-783">75</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:68.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-221" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-784">0</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:68.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-222" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-785">6,529</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:68.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-786">6,604</ix:nonFraction></span></div></div></div></td></tr><tr style="height:29.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:89.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:6.82pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:16.42pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:89.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:11.56pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-223" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-787">75</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:89.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:11.56pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-224" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-788">3</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:89.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:11.56pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-225" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-789">6,529</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:89.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:11.56pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-790">6,606</ix:nonFraction></span></div></div></div></td></tr><tr style="height:29.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:118.5pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:6.82pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:16.42pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:118.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:11.56pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-226" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-791">75</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:118.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:11.56pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-227" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-792">2</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:118.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:11.56pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-228" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-793">6,529</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:118.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:11.56pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-794">6,605</ix:nonFraction></span></div></div></div></td></tr></tbody></table></div></div></div></ix:continuation></ix:continuation><div style="position:absolute;top:675.84pt" id="i7a006daedb3d4216a4128b76247285d7_379"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:675.84pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 8. <span id="ie7164015e32c41b1a5c08f257a969d6c"></span></span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory" id="f-795" continuedAt="f-795-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:68.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Property, plant and equipment</span></ix:nonNumeric></div><ix:continuation id="f-795-1" continuedAt="f-795-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:695.64pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfReconciliationOfChangesInPropertyPlantAndEquipmentIncludingRightofuseAssetsExplanatory" id="f-796" continuedAt="f-796-1" escape="true"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:44pt;position:var(--position);text-decoration:none;white-space:pre">The following tables present changes in property, plant and equipment including the right of use of assets (or &#8220;ROU&#8221;) as of </span></ix:nonNumeric></div><ix:continuation id="f-796-1" continuedAt="f-796-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:705.64pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:44pt;position:var(--position);text-decoration:none;white-space:pre">December 31, 2023, 2024 and 2025:</span></div></ix:continuation></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-28<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><ix:continuation id="f-796-2"><ix:continuation id="f-795-2" continuedAt="f-795-3"><div><div style="position:var(--position);top:85.19pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:525.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:213.75pt"/><td style="padding:0;width:60pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:60pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:60pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:60pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:60pt"/></tr><tr style="height:41.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:32.48pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:55.34pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);width:60pt"><div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.57pt;position:var(--position);text-decoration:none;white-space:pre">BUILDINGS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);width:60pt"><div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.35pt;position:var(--position);text-decoration:none;white-space:pre">EQUIPMENT</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3.82pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.25pt;position:var(--position);text-decoration:none;white-space:pre">FURNITURE </span></div><div style="line-height:8pt;position:var(--position);top:13.42pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.34pt;position:var(--position);text-decoration:none;white-space:pre">AND </span></div><div style="line-height:8pt;position:var(--position);top:23.02pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.69pt;position:var(--position);text-decoration:none;white-space:pre">COMPUTER </span></div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.35pt;position:var(--position);text-decoration:none;white-space:pre">EQUIPMENT</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);width:60pt"><div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.01pt;position:var(--position);text-decoration:none;white-space:pre">TOTAL</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);width:60pt"><div><div style="line-height:8pt;position:var(--position);top:23.02pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.79pt;position:var(--position);text-decoration:none;white-space:pre">OF WHICH </span></div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.12pt;position:var(--position);text-decoration:none;white-space:pre">ROU</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:41.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">GROSS VALUES</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:53.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY 1, 2023</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:53.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-229" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-797">1,618</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:53.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-230" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-798">436</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:53.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-799">346</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:53.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-232" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-800">2,400</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:53.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-233" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-801">1,561</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:74.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Acquisition</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:74.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-234" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-802">350</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:74.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-235" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-803">103</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:74.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-236" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-804">161</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:74.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-237" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-805">614</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:74.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-238" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-806">350</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:86.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Disposal</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:86.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.97pt"></span></span><span style="left:41.6pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-234" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-807">622</ix:nonFraction>)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:86.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.97pt"></span></span><span style="left:45.6pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-235" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-808">27</ix:nonFraction>)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:86.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.63pt"></span></span><span style="left:48.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-236" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:fixed-zero" scale="3" id="f-809">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:86.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.97pt"></span></span><span style="left:41.6pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-237" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-810">649</ix:nonFraction>)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:86.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.97pt"></span></span><span style="left:41.6pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-238" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-811">649</ix:nonFraction>)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:98.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:98.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-239" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-812">1,346</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:98.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-240" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-813">513</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:98.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-241" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-814">507</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:98.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-242" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-815">2,366</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:98.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-243" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-816">1,262</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:119.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Acquisition</span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:119.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-244" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-817">2,578</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:119.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.63pt"></span></span><span style="left:48.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-245" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:fixed-zero" scale="3" id="f-818">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:119.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-246" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-819">292</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:119.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-247" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-820">2,870</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:119.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-248" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-821">2,217</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:131.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Disposal</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:131.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.97pt"></span></span><span style="left:35.6pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-244" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-822">1,110</ix:nonFraction>)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:131.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.63pt"></span></span><span style="left:48.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-245" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:fixed-zero" scale="3" id="f-823">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:131.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.97pt"></span></span><span style="left:41.6pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-246" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-824">119</ix:nonFraction>)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:131.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.97pt"></span></span><span style="left:35.6pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-247" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-825">1,229</ix:nonFraction>)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:131.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.97pt"></span></span><span style="left:41.6pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-248" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-826">975</ix:nonFraction>)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:143.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Effect of the change in foreign currency exchange rates</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:143.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:49.63pt"></span></span><span style="left:52.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-244" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-827">4</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:143.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.63pt"></span></span><span style="left:48.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-245" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:fixed-zero" scale="3" id="f-828">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:143.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.63pt"></span></span><span style="left:48.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-246" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-829">17</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:143.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.63pt"></span></span><span style="left:48.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-247" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-830">22</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:143.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.63pt"></span></span><span style="left:48.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-248" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-831">22</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:155.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:155.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-249" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-832">2,818</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:155.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-250" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-833">513</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:155.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-251" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-834">698</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:155.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-252" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-835">4,029</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:155.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-253" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-836">2,526</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:176.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Acquisition</span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:176.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-254" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-837">436</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:176.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.63pt"></span></span><span style="left:48.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-255" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:fixed-zero" scale="3" id="f-838">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:176.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-256" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-839">123</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:176.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-257" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-840">559</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:176.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-258" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-841">424</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:188.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Disposal</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:188.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.63pt"></span></span><span style="left:48.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-254" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:fixed-zero" scale="3" id="f-842">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:188.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.97pt"></span></span><span style="left:45.6pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-255" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-843">49</ix:nonFraction>)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:188.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.97pt"></span></span><span style="left:41.6pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-256" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-844">203</ix:nonFraction>)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:188.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.97pt"></span></span><span style="left:41.6pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-257" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-845">252</ix:nonFraction>)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:188.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.97pt"></span></span><span style="left:45.6pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-258" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-846">34</ix:nonFraction>)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:200.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Effect of the change in foreign currency exchange rates</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:200.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.97pt"></span></span><span style="left:45.6pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-254" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-847">50</ix:nonFraction>)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:200.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.63pt"></span></span><span style="left:48.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-255" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:fixed-zero" scale="3" id="f-848">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:200.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.97pt"></span></span><span style="left:45.6pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-256" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-849">12</ix:nonFraction>)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:200.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.97pt"></span></span><span style="left:45.6pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-257" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-850">62</ix:nonFraction>)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:200.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.97pt"></span></span><span style="left:45.6pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-258" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-851">50</ix:nonFraction>)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:212.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:212.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-259" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-852">3,204</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:212.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-260" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-853">463</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:212.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-261" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-854">607</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:212.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-262" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-855">4,274</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:212.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-263" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-856">2,865</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:338.07pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:528.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:201.75pt"/><td style="padding:0;width:63pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:63pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:63pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:63pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:63pt"/></tr><tr style="height:41.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:32.48pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:49.34pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);width:63pt"><div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.07pt;position:var(--position);text-decoration:none;white-space:pre">BUILDINGS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);width:63pt"><div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.85pt;position:var(--position);text-decoration:none;white-space:pre">EQUIPMENT</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.82pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.75pt;position:var(--position);text-decoration:none;white-space:pre">FURNITURE </span></div><div style="line-height:8pt;position:var(--position);top:13.42pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.84pt;position:var(--position);text-decoration:none;white-space:pre">AND </span></div><div style="line-height:8pt;position:var(--position);top:23.02pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.19pt;position:var(--position);text-decoration:none;white-space:pre">COMPUTER </span></div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.85pt;position:var(--position);text-decoration:none;white-space:pre">EQUIPMENT</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);width:63pt"><div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.51pt;position:var(--position);text-decoration:none;white-space:pre">TOTAL</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);width:63pt"><div><div style="line-height:8pt;position:var(--position);top:23.02pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.29pt;position:var(--position);text-decoration:none;white-space:pre">OF WHICH </span></div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.62pt;position:var(--position);text-decoration:none;white-space:pre">ROU</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:41.25pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DEPRECIATION</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:53.25pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY 1, 2023</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);top:53.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-264" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-857">259</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:53.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-265" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-858">378</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:53.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-266" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-859">171</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:53.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-267" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-860">808</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:53.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-268" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-861">290</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:74.25pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Increase </span></div></div></div></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);top:74.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-269" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-862">578</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:74.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.3pt"></span></span><span style="left:48.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-270" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-863">36</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:74.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.3pt"></span></span><span style="left:48.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-271" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-864">94</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:74.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-272" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-865">707</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:74.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-273" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-866">498</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:86.25pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Disposal</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);top:86.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-269" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:fixed-zero" scale="3" id="f-867">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:86.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-270" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-868">27</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:86.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-271" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:fixed-zero" scale="3" id="f-869">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:86.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-272" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-870">27</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:86.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-273" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-871">27</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:98.25pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);top:98.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-274" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-872">837</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:98.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-275" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-873">387</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:98.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-276" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-874">265</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:98.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.3pt"></span></span><span style="left:38.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-277" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-875">1,488</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:98.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-278" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-876">761</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:119.25pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Increase </span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);top:119.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-279" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-877">886</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:119.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.3pt"></span></span><span style="left:48.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-280" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-878">32</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:119.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-281" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-879">171</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:119.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.3pt"></span></span><span style="left:38.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-282" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-880">1,089</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:119.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-283" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-881">788</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:131.25pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Disposal</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);top:131.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-279" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-882">1,111</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:131.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-280" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:fixed-zero" scale="3" id="f-883">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:131.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-281" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-884">104</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:131.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-282" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-885">1,215</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:131.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-283" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-886">975</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:143.25pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);top:143.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-284" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-887">613</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:143.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-285" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-888">419</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:143.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-286" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-889">332</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:143.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.3pt"></span></span><span style="left:38.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-287" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-890">1,363</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:143.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-288" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-891">575</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:164.25pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Increase </span></div></div></div></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);top:164.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-289" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-892">903</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:164.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.3pt"></span></span><span style="left:48.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-290" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-893">35</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:164.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-291" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-894">158</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:164.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.3pt"></span></span><span style="left:38.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-292" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-895">1,095</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:164.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-293" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-896">797</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:176.25pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Disposal</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);top:176.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-289" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:fixed-zero" scale="3" id="f-897">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:176.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-290" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-898">49</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:176.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-291" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-899">203</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:176.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-292" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-900">252</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:176.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-293" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-901">53</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:188.25pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Effect of the change in foreign currency exchange rates</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);top:188.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-289" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-902">17</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:188.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-290" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:fixed-zero" scale="3" id="f-903">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:188.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.96pt"></span></span><span style="left:55.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-291" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-904">5</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:188.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-292" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-905">22</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:188.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.99pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-293" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-906">17</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:201pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);top:201pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.3pt"></span></span><span style="left:38.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-294" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-907">1,498</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:201pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-295" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-908">404</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:201pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-296" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-909">281</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:201pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.3pt"></span></span><span style="left:38.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-297" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-910">2,184</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:201pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.3pt"></span></span><span style="left:38.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-298" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-911">1,302</ix:nonFraction>)</span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:577.07pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:529.5pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:200.25pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:56.25pt"/></tr><tr style="height:41.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:17.55pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:48.59pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:200.25pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.2pt;position:var(--position);text-decoration:none;white-space:pre">BUILDINGS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.98pt;position:var(--position);text-decoration:none;white-space:pre">EQUIPMENT</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:336.75pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.82pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.87pt;position:var(--position);text-decoration:none;white-space:pre">FURNITURE </span></div><div style="line-height:8pt;position:var(--position);top:13.42pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.97pt;position:var(--position);text-decoration:none;white-space:pre">AND </span></div><div style="line-height:8pt;position:var(--position);top:23.02pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.31pt;position:var(--position);text-decoration:none;white-space:pre">COMPUTER </span></div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.98pt;position:var(--position);text-decoration:none;white-space:pre">EQUIPMENT</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:405pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.63pt;position:var(--position);text-decoration:none;white-space:pre">TOTAL</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);width:56.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.02pt;width:56.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.91pt;position:var(--position);text-decoration:none;white-space:pre">OF WHICH </span></div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:56.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:19.24pt;position:var(--position);text-decoration:none;white-space:pre">ROU</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:41.25pt;width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">NET BOOK VALUES</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:53.25pt;width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY 1, 2023</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:200.25pt;position:var(--position);top:53.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-299" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-912">1,359</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:265.5pt;overflow:hidden;position:var(--position);top:53.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:53.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-300" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-913">59</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:333.75pt;overflow:hidden;position:var(--position);top:53.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:336.75pt;position:var(--position);top:53.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-301" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-914">175</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:402pt;overflow:hidden;position:var(--position);top:53.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:405pt;position:var(--position);top:53.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-302" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-915">1,592</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:470.25pt;overflow:hidden;position:var(--position);top:53.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:53.25pt;width:56.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:56.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.21pt"></span></span><span style="left:34.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-303" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-916">1,270</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:74.25pt;width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:200.25pt;position:var(--position);top:74.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-304" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-917">509</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:265.5pt;overflow:hidden;position:var(--position);top:74.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:74.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-305" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-918">126</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:333.75pt;overflow:hidden;position:var(--position);top:74.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:336.75pt;position:var(--position);top:74.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-306" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-919">242</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:402pt;overflow:hidden;position:var(--position);top:74.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:405pt;position:var(--position);top:74.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-307" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-920">878</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:470.25pt;overflow:hidden;position:var(--position);top:74.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:74.25pt;width:56.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:56.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.21pt"></span></span><span style="left:40.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-308" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-921">501</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:95.25pt;width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:200.25pt;position:var(--position);top:95.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-309" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-922">2,205</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:265.5pt;overflow:hidden;position:var(--position);top:95.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:95.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-310" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-923">94</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:333.75pt;overflow:hidden;position:var(--position);top:95.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:336.75pt;position:var(--position);top:95.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-311" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-924">366</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:402pt;overflow:hidden;position:var(--position);top:95.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:405pt;position:var(--position);top:95.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-312" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-925">2,666</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:470.25pt;overflow:hidden;position:var(--position);top:95.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:95.25pt;width:56.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:56.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.21pt"></span></span><span style="left:34.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-313" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-926">1,950</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:116.25pt;width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:200.25pt;position:var(--position);top:116.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-314" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-927">1,706</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:265.5pt;overflow:hidden;position:var(--position);top:116.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:116.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-315" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-928">59</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:333.75pt;overflow:hidden;position:var(--position);top:116.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:336.75pt;position:var(--position);top:116.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-316" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-929">325</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:402pt;overflow:hidden;position:var(--position);top:116.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:405pt;position:var(--position);top:116.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-317" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-930">2,090</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:470.25pt;overflow:hidden;position:var(--position);top:116.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:116.25pt;width:56.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:56.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.21pt"></span></span><span style="left:34.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-318" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-931">1,563</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div></div></ix:continuation></ix:continuation></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-29<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-795-3"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:83.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Right of use assets relate to buildings, vehicles and furniture. The net book value of right of use assets related to buildings amounted to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:95.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-319" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="f-932">453</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.59pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:99.59pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-320" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-933">1,846</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:165.68pt;position:var(--position);text-decoration:none;white-space:pre"> and</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:182.61pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:185.11pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-321" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-934">1,473</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:251.2pt;position:var(--position);text-decoration:none;white-space:pre"> as of December 31, 2023, 2024 and 2025 respectively. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:119.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Acquisitions over the year ended December 31, 2023 mainly include the right of use asset related to the new Boston offices entered </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:131.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">into in November 2023. Decreases mainly include the remeasurement of the right of use asset related to the reassessment of the Paris </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:143.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Headquarters lease term, for an amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:206.9pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-322" decimals="-3" name="abvx:DecreaseThroughReassessmentOfLeaseTermRightOfUseAssets" scale="3" id="f-935">622</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:265.49pt;position:var(--position);text-decoration:none;white-space:pre"> (see Note 15.8).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:167.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Acquisitions over the period ended December 31, 2024 mainly include the right of use assets related to the new Paris headquarters and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:179.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Montpellier offices entered into in May and April 2024 respectively, as well as the 1-year renewal of the Boston offices lease (see </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:191.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 15.8). Disposals over the period ended December 31, 2024 mainly include the right of use asset related to the former Paris </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:203.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">headquarters lease, which ended in June 2024.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:227.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Acquisitions over the period ended December 31, 2025 mainly include right of use assets related to the renewal of the hosting </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:239.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">agreement with the CNRS </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:143.65pt;position:var(--position);text-decoration:none;white-space:pre">(French National Centre for Scientific Research)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:338.09pt;position:var(--position);text-decoration:none;white-space:pre"> research laboratories based in Montpellier (which </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:251.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">previously fell under the IFRS 16 short-term lease exemption), as well as new office equipment leases. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:263.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Disposals over the period ended December 31, 2025 of the period mainly relate to the decommissioning of obsolete IT equipments.</span></div></ix:continuation><div style="position:absolute;top:299.86pt" id="i7a006daedb3d4216a4128b76247285d7_382"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:299.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 9. <span id="i5a946d8a495d4c27b7c705e925142ffc"></span></span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfOtherAssetsExplanatory" id="f-936" continuedAt="f-936-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:68.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Other financial assets</span></ix:nonNumeric></div><ix:continuation id="f-936-1" continuedAt="f-936-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:323.46pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinancialAssetsExplanatory" id="f-937" continuedAt="f-937-1" escape="true"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Other financial assets break down as follows:</span></ix:nonNumeric></div><ix:continuation id="f-937-1"><div style="font-size:12pt;line-height:11pt;position:var(--position);top:334.76pt;width:612pt"><span style="font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="position:var(--position);top:351.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:445.5pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:243.75pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:65.25pt"/></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:243.75pt"><div><div style="line-height:8pt;position:var(--position);top:21.98pt;width:243.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:70.34pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:243.75pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.97pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.97pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.97pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:30.75pt;width:243.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:243.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">OTHER FINANCIAL ASSETS</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:243.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:243.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Advances related to CRO contracts</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:243.75pt;position:var(--position);top:42.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.88pt"></span></span><span style="left:39.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="abvx:NonCurrentAdvancesToCROContractsUndiscountedAmount" format="ixt:num-dot-decimal" scale="3" id="f-938">12,172</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:309pt;overflow:hidden;position:var(--position);top:42.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:42.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="abvx:NonCurrentAdvancesToCROContractsUndiscountedAmount" format="ixt:num-dot-decimal" scale="3" id="f-939">4,929</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:377.25pt;overflow:hidden;position:var(--position);top:42.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:42.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="abvx:NonCurrentAdvancesToCROContractsUndiscountedAmount" format="ixt:num-dot-decimal" scale="3" id="f-940">4,665</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:243.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:243.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Deposits</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:243.75pt;position:var(--position);top:54.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.88pt"></span></span><span style="left:49.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:LongtermDeposits" scale="3" id="f-941">574</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:309pt;overflow:hidden;position:var(--position);top:54.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:54.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.88pt"></span></span><span style="left:49.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:LongtermDeposits" scale="3" id="f-942">863</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:377.25pt;overflow:hidden;position:var(--position);top:54.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:54.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.88pt"></span></span><span style="left:49.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:LongtermDeposits" scale="3" id="f-943">693</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:243.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:243.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:243.75pt;position:var(--position);top:66.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.88pt"></span></span><span style="left:49.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="abvx:OtherNonCurrentMiscellaneousFinancialAssets" scale="3" id="f-944">124</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:309pt;overflow:hidden;position:var(--position);top:66.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:66.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.88pt"></span></span><span style="left:49.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="abvx:OtherNonCurrentMiscellaneousFinancialAssets" scale="3" id="f-945">126</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:377.25pt;overflow:hidden;position:var(--position);top:66.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:66.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="abvx:OtherNonCurrentMiscellaneousFinancialAssets" format="ixt:fixed-zero" scale="3" id="f-946">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:243.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:243.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total other non-current financial assets</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:243.75pt;position:var(--position);top:78.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.88pt"></span></span><span style="left:39.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:OtherNoncurrentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-947">12,870</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:78.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:OtherNoncurrentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-948">5,919</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:78.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:OtherNoncurrentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-949">5,358</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90.75pt;width:243.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:243.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Advances related to CRO contracts</span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:243.75pt;position:var(--position);top:90.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="abvx:CurrentAdvancesToCROContracts" format="ixt:fixed-zero" scale="3" id="f-950">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:309pt;overflow:hidden;position:var(--position);top:90.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:90.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="abvx:CurrentAdvancesToCROContracts" format="ixt:num-dot-decimal" scale="3" id="f-951">7,418</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:377.25pt;overflow:hidden;position:var(--position);top:90.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:90.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="abvx:CurrentAdvancesToCROContracts" format="ixt:num-dot-decimal" scale="3" id="f-952">7,717</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102.75pt;width:243.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:243.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Deposits</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:243.75pt;position:var(--position);top:102.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.88pt"></span></span><span style="left:49.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents" scale="3" id="f-953">136</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:102.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.88pt"></span></span><span style="left:49.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents" scale="3" id="f-954">136</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:102.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-955">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:114.75pt;width:243.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:243.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other investments</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:243.75pt;position:var(--position);top:114.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="abvx:OtherCurrentInvestments" format="ixt:num-dot-decimal" scale="3" id="f-956">9,050</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:309pt;overflow:hidden;position:var(--position);top:114.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:114.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="abvx:OtherCurrentInvestments" format="ixt:fixed-zero" scale="3" id="f-957">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:377.25pt;overflow:hidden;position:var(--position);top:114.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:114.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.88pt"></span></span><span style="left:39.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="abvx:OtherCurrentInvestments" format="ixt:num-dot-decimal" scale="3" id="f-958">13,698</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:126.75pt;width:243.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:243.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total other current financial assets</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:243.75pt;position:var(--position);top:126.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:OtherCurrentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-959">9,186</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:126.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:OtherCurrentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-960">7,554</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:126.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.88pt"></span></span><span style="left:39.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:OtherCurrentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-961">21,415</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:138.75pt;width:243.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:243.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial assets</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:243.75pt;position:var(--position);top:138.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.88pt"></span></span><span style="left:39.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:OtherFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-962">22,055</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:138.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.88pt"></span></span><span style="left:39.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:OtherFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-963">13,473</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:138.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.88pt"></span></span><span style="left:39.510000000000005pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:OtherFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-964">26,772</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:531.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Advances related to CRO contracts </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:544.61pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">A</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43.22pt;position:var(--position);text-decoration:none;white-space:pre">dvances granted in 2022 for a total undiscounted amount of </span><span style="color:#008080;font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:283.55pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:289.55pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-3" name="abvx:NonCurrentAdvancesToCROContractsUndiscountedAmount" format="ixt:num-dot-decimal" scale="3" id="f-965">12,187</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:355.64pt;position:var(--position);text-decoration:none;white-space:pre"> f</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:361.47pt;position:var(--position);text-decoration:none;white-space:pre">or clinical studies are to be recovered at the end of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:558.05pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the studies after final reconciliation with pass-through costs, which are being invoiced and paid as studies are carried out. These long-</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:569.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">term advances were measured at fair value on initial recognition, using discount rates ranging from </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:434.4pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-323" decimals="4" name="abvx:DiscountRateAppliedToLongTermAdvances" scale="-2" id="f-966">0.19</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:460.23pt;position:var(--position);text-decoration:none;white-space:pre"> to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:473pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-324" decimals="4" name="abvx:DiscountRateAppliedToLongTermAdvances" scale="-2" id="f-967">7.16</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:498.83pt;position:var(--position);text-decoration:none;white-space:pre">, and are </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:580.45pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">subsequently measured at amortized cost.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:597.65pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">During the first half of 2023, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:153.97pt;position:var(--position);text-decoration:none;white-space:pre">additional advances related to CRO contracts</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:334.54pt;position:var(--position);text-decoration:none;white-space:pre"> amounting to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:392.55pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-325" decimals="-3" name="abvx:PaymentsForAdvancesMadeToContractResearchOrganizationsUndiscountedAmount" format="ixt:num-dot-decimal" scale="3" id="f-968">1,620</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:458.64pt;position:var(--position);text-decoration:none;white-space:pre"> were made (undiscounted </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:609.65pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">amount). These long-term advances were measured at fair value on initial recognition, using discount rates ranging from </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:520.15pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-326" decimals="4" name="abvx:DiscountRateAppliedToLongTermAdvances" scale="-2" id="f-969">7.09</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:545.98pt;position:var(--position);text-decoration:none;white-space:pre"> to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:621.65pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-327" decimals="4" name="abvx:DiscountRateAppliedToLongTermAdvances" scale="-2" id="f-970">7.59</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:61.83pt;position:var(--position);text-decoration:none;white-space:pre">, and are subsequently measured at amortized cost. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:639.65pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">At inception, a prepaid expenses asset was recognized for the difference between the advances&#8217; nominal value and fair value, and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:652.95pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">spread over the term of the advances, at the rate of recognition of the related R&amp;D expenses (see Note 10).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:672.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In March 2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:95.41pt;position:var(--position);text-decoration:none;white-space:pre">, a change order was signed with the CRO, extending the scope (addition of maintenance studies) and end date of one of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:684.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the studies to 2029, thus postponing the recovery date of the corresponding advance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:384.85pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-328" decimals="-3" name="abvx:PaymentsForAdvancesMadeToContractResearchOrganizationsUndiscountedAmount" format="ixt:num-dot-decimal" scale="3" id="f-971">5,538</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:450.94pt;position:var(--position);text-decoration:none;white-space:pre"> (undiscounted amount) from </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:696.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">June 2026 to June 2029. The Group considered that this asset modification met the criteria for derecognition, and recognized a new </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:708.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">financial asset at fair value on that date, using a discount rate of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:292.87pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-329" decimals="4" name="abvx:DiscountRateAppliedToLongTermAdvances" scale="-2" id="f-972">6.83</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:318.7pt;position:var(--position);text-decoration:none;white-space:pre">. Since the Group considers that these advances are made in </span></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-30<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-936-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">exchange for a discount on future services to be received from the CROs, a prepaid expense asset was also recognized for the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:82.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">difference between the derecognized asset carrying value and new asset fair value, and spread over </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:433.79pt;position:var(--position);text-decoration:none;white-space:pre">the term of the advanc</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:523.11pt;position:var(--position);text-decoration:none;white-space:pre">e </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:530.04pt;position:var(--position);text-decoration:none;white-space:pre">(equal to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:94.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the period of service) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:123.67pt;position:var(--position);text-decoration:none;white-space:pre">in a similar manner.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:112.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2025, the recovery dates of these advances are spread from 2026 to 2030.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:131.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The credit risk related to these advances is deemed insignificant</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:291.46000000000004pt;position:var(--position);text-decoration:none;white-space:pre"> due to the CROs' credit ratings.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:155.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Other investments</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:179.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, other investments consist of 6-month term deposits that do not qualify for a classification under cash and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:191.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">cash equivalents.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:215.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2025 other investments consist of 9-month and 12-month term deposits that do not qualify for a classification </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:227.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">under cash and cash equivalents.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:251.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Deposits</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:269.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Deposits include the Paris and Boston offices lease contracts, the ATM Program deposit, as well as other security deposits.</span></div></ix:continuation><div style="position:absolute;top:307.86pt" id="i7a006daedb3d4216a4128b76247285d7_385"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:307.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 10. <span id="ifc5ba91a0a07485b8b9e631ad3c37bc4"></span></span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory" id="f-973" continuedAt="f-973-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Other receivables and other assets</span></ix:nonNumeric></div><ix:continuation id="f-973-1" continuedAt="f-973-2"><div style="font-size:12pt;line-height:11pt;position:var(--position);top:328.96pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="abvx:DisclosureOfDetailedInformationAboutOtherReceivablesAndOtherAssetsTableTextBlock" id="f-974" continuedAt="f-974-1" escape="true"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:42pt;position:var(--position);text-decoration:none;white-space:pre">Other receivables and other assets break down as follows:</span><span style="font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:273.4pt;position:var(--position);text-decoration:none;white-space:pre"> </span></ix:nonNumeric></div><ix:continuation id="f-974-1"><div style="position:var(--position);top:340.84pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:435pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:233.25pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:65.25pt"/></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:233.25pt"><div><div style="line-height:8pt;position:var(--position);top:21.98pt;width:233.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:65.09pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:233.25pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.97pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:301.5pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.97pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:369.75pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.97pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:30.75pt;width:233.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:233.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">OTHER RECEIVABLES AND ASSETS</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:233.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:233.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Prepaid expenses - non current</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:233.25pt;position:var(--position);top:42.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="abvx:NonCurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-975">2,320</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:301.5pt;position:var(--position);top:42.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="abvx:NonCurrentPrepaidExpenses" scale="3" id="f-976">948</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:366.75pt;overflow:hidden;position:var(--position);top:42.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:369.75pt;position:var(--position);top:42.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="abvx:NonCurrentPrepaidExpenses" scale="3" id="f-977">625</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:233.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:233.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total other non-current assets</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:233.25pt;position:var(--position);top:54.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:OtherNoncurrentNonfinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-978">2,320</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:301.5pt;position:var(--position);top:54.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:OtherNoncurrentNonfinancialAssets" scale="3" id="f-979">948</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:369.75pt;position:var(--position);top:54.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:OtherNoncurrentNonfinancialAssets" scale="3" id="f-980">625</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:233.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:233.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Research tax credit ("CIR")</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:233.25pt;position:var(--position);top:66.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="abvx:CurrentResearchTaxCreditReceivables" format="ixt:num-dot-decimal" scale="3" id="f-981">4,600</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:301.5pt;position:var(--position);top:66.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="abvx:CurrentResearchTaxCreditReceivables" format="ixt:num-dot-decimal" scale="3" id="f-982">5,774</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:366.75pt;overflow:hidden;position:var(--position);top:66.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:369.75pt;position:var(--position);top:66.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="abvx:CurrentResearchTaxCreditReceivables" format="ixt:num-dot-decimal" scale="3" id="f-983">3,196</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:233.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:233.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">VAT receivables</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:233.25pt;position:var(--position);top:78.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:CurrentValueAddedTaxReceivables" format="ixt:num-dot-decimal" scale="3" id="f-984">14,439</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:301.5pt;position:var(--position);top:78.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:CurrentValueAddedTaxReceivables" format="ixt:num-dot-decimal" scale="3" id="f-985">9,841</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:366.75pt;overflow:hidden;position:var(--position);top:78.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:369.75pt;position:var(--position);top:78.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:CurrentValueAddedTaxReceivables" format="ixt:num-dot-decimal" scale="3" id="f-986">6,870</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90.75pt;width:233.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:233.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Prepaid expenses </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:233.25pt;position:var(--position);top:90.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-987">5,746</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:301.5pt;position:var(--position);top:90.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-988">3,233</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:366.75pt;overflow:hidden;position:var(--position);top:90.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:369.75pt;position:var(--position);top:90.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-989">2,649</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102.75pt;width:233.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:233.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Employee-related receivables</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:233.25pt;position:var(--position);top:102.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="abvx:CurrentReceivablesForEmployeeBenefits" format="ixt:fixed-zero" scale="3" id="f-990">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:301.5pt;position:var(--position);top:102.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="abvx:CurrentReceivablesForEmployeeBenefits" format="ixt:fixed-zero" scale="3" id="f-991">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:369.75pt;position:var(--position);top:102.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="abvx:CurrentReceivablesForEmployeeBenefits" scale="3" id="f-992">429</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:114.75pt;width:233.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:233.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Credit notes</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:233.25pt;position:var(--position);top:114.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="abvx:CurrentReceivablesFromCreditNotes" scale="3" id="f-993">60</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:301.5pt;position:var(--position);top:114.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="abvx:CurrentReceivablesFromCreditNotes" scale="3" id="f-994">48</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:369.75pt;position:var(--position);top:114.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="abvx:CurrentReceivablesFromCreditNotes" format="ixt:fixed-zero" scale="3" id="f-995">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:126.75pt;width:233.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:233.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total current other receivables and assets</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:233.25pt;position:var(--position);top:126.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="abvx:CurrentReceivablesAndCurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-996">24,845</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:301.5pt;position:var(--position);top:126.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="abvx:CurrentReceivablesAndCurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-997">18,896</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:369.75pt;position:var(--position);top:126.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="abvx:CurrentReceivablesAndCurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-998">13,144</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:138.75pt;width:233.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:233.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other receivables and assets</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:233.25pt;position:var(--position);top:138.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:OtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-999">27,164</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:301.5pt;position:var(--position);top:138.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:OtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-1000">19,843</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:369.75pt;position:var(--position);top:138.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:OtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-1001">13,769</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:506.59pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Research tax credit (&#8220;CIR&#8221;) </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:522.59pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The CIR is recognized as Other Operating Income (see note 4.9) in the year to which the eligible research expense relates. The Group </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:532.59pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">received the payments of the CIR for 2023 and 2024 tax years in the amount of respectively&#160; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:408.38pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:ProceedsFromResearchTaxCredit" format="ixt:num-dot-decimal" scale="3" id="f-1002">4,493</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:474.47pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:493.9pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:ProceedsFromResearchTaxCredit" format="ixt:num-dot-decimal" scale="3" id="f-1003">5,640</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:559.99pt;position:var(--position);text-decoration:none;white-space:pre"> in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:542.59pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">respectively 2024 and 2025 and expects to receive the CIR for the 2025 tax year o</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:364.25pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">f </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:370.08pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="abvx:CurrentResearchTaxCreditReceivables" format="ixt:num-dot-decimal" scale="3" id="f-1004">3,196</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:436.17pt;position:var(--position);text-decoration:none;white-space:pre"> in 2026. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:570.59pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">VAT Receivables </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:586.59pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Value-added tax (&#8220;VAT&#8221;) receivables relate primarily to the deductible VAT and VAT refunds claimed.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:620.59pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Prepaid expenses </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:644.59pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Prepaid expenses as of December 31, 2023 include prepaid expenses related to CRO contracts for an amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:484.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="abvx:CurrentPrepaidExpensesRelatedToCRO" format="ixt:num-dot-decimal" scale="3" id="f-1005">1,347</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:550.21pt;position:var(--position);text-decoration:none;white-space:pre"> (see </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:655.79pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 9) and deferred transactions costs related to tranches B and C of the Kreos / Claret financings for an amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:502.68pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-330" decimals="-3" sign="-" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1006">3,152</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:568.77pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:666.99pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(most of which represents the issuance date fair value of the tranche A-B and C Kreos / Claret BSA, representing origination fees for </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:678.19pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the future drawdowns of the tranches B and C of the Kreos / Claret Financing, See Note</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:387.57pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> 15.1) and other expenses from various </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:689.39pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">suppliers amounting to </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:130.09pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:CurrentAdvancesToSuppliers" format="ixt:num-dot-decimal" scale="3" id="f-1007">3,567</ix:nonFraction>&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:196.18pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">.</span></span></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-31<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-973-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Prepaid expenses as of December 31, 2024 include prepaid expenses related to CRO contracts for an amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:484.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="abvx:CurrentPrepaidExpensesRelatedToCRO" format="ixt:num-dot-decimal" scale="3" id="f-1008">1,577</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:550.21pt;position:var(--position);text-decoration:none;white-space:pre"> (see </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:81.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 9) </span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:68.75pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">and other expenses from various suppliers amounting to </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:295.22pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:CurrentAdvancesToSuppliers" format="ixt:num-dot-decimal" scale="3" id="f-1009">2,604</ix:nonFraction>&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:361.31pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">.</span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:104.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The decrease in prepaid expenses over the year ended December 31, 2024 mainly corresponds to the reclassification of the deferred </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:115.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">transaction costs of tranche B of the Kreos / Claret Financing, from prepaid expenses to a reduction of the initial carrying value of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">tranche B </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:77.05pt;position:var(--position);text-decoration:none;white-space:pre">debt </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.75pt;position:var(--position);text-decoration:none;white-space:pre">component, in accordance with the effective interest rate method, for an amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:429.92pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-331" decimals="-3" name="abvx:ReclassificationOfPrepaidExpensesToCarryingValueOfDebtComponent" format="ixt:num-dot-decimal" scale="3" id="f-1010">1,546</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:496.01pt;position:var(--position);text-decoration:none;white-space:pre">, and to the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:137.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">amortization of the deferred transaction costs related to tranche C (already fully amortized on the date of drawdown).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:160.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Prepaid expenses as of December 31, 2025 include prepaid expenses related to CRO contracts for an amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:484.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="abvx:CurrentPrepaidExpensesRelatedToCRO" format="ixt:num-dot-decimal" scale="3" id="f-1011">1,068</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:550.21pt;position:var(--position);text-decoration:none;white-space:pre"> (see </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:171.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 9) and other expenses from various suppliers amounting to</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:292.72pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:295.22pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:CurrentAdvancesToSuppliers" format="ixt:num-dot-decimal" scale="3" id="f-1012">2,207</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:361.31pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div></ix:continuation><div style="position:absolute;top:208pt" id="i7a006daedb3d4216a4128b76247285d7_388"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:208pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 11. <span id="ie73f73a187f84207a9b861ebeb4b0446"></span></span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory" id="f-1013" continuedAt="f-1013-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Cash and cash equivalents</span></ix:nonNumeric></div><ix:continuation id="f-1013-1" continuedAt="f-1013-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:227.8pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="abvx:DisclosureOfCompositionOfCashAndCashEquivalentsTableTextBlock" id="f-1014" continuedAt="f-1014-1" escape="true"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:41pt;position:var(--position);text-decoration:none;white-space:pre">Cash and cash equivalents break down as follows:</span></ix:nonNumeric></div><ix:continuation id="f-1014-1"><div style="position:var(--position);top:261.7pt;width:612pt"><div style="font-size:0pt;left:41pt;position:var(--position);width:474pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:243pt"/><td style="padding:0;width:75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:75pt"/></tr><tr style="height:30.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:243pt"><div><div style="line-height:8pt;position:var(--position);top:21.98pt;width:243pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:69.96pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:243pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.84pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.5pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:321pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.84pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.5pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.84pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.5pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:30.75pt;width:243pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:243pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">CASH AND CASH EQUIVALENTS</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:243pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:243pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cash equivalents</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:243pt;position:var(--position);top:42.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:50.37pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:CashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1015">18,105</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:321pt;position:var(--position);top:42.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:50.37pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:CashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1016">87,265</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:396pt;overflow:hidden;position:var(--position);top:42.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:42.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.37pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:CashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1017">478,541</ix:nonFraction></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:243pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:243pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cash</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:243pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.37pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:Cash" format="ixt:num-dot-decimal" scale="3" id="f-1018">233,837</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:321pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:50.37pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:Cash" format="ixt:num-dot-decimal" scale="3" id="f-1019">56,956</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:396pt;overflow:hidden;position:var(--position);top:54.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:50.37pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:Cash" format="ixt:num-dot-decimal" scale="3" id="f-1020">38,144</ix:nonFraction></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:243pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:243pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cash and cash equivalents</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:243pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:46.37pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1021">251,942</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:321pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:46.37pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1022">144,221</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:396pt;overflow:hidden;position:var(--position);top:66.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:46.37pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1023">516,685</ix:nonFraction></span></div></div></div></td></tr></tbody></table></div></div></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:356.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Cash equivalents mainly include term deposits with short-term maturities (measured at amortized cost) and highly liquid investments </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:368.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in mutual funds and structured notes (measured at fair value through profit or loss) denominated in euros and U.S. dollars.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:391.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, 2024 and 2025, in addition to the Group&#8217;s bank accounts, cash includes notice accounts amounting to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:402.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:OtherCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1024">231,562</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.09pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:117.09pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:OtherCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1025">44,239</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:188.18pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:207.61pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:OtherCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1026">5,744</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:273.7pt;position:var(--position);text-decoration:none;white-space:pre"> respectively. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:329.45pt;position:var(--position);text-decoration:none;white-space:pre">These funds are available on demand within 24 hours and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:414.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">without penalty.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:437.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The increase in cash and cash equivalents over the year ended December 31, 2025 is mainly explained by the proceeds from the&#160; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:448.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Offering completed on July 28, 2025 (see N</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:211.97pt;position:var(--position);text-decoration:none;white-space:pre">ote 3.3 - </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:247.5pt;position:var(--position);text-decoration:none;white-space:pre">Completion of a public offering </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:375.99pt;position:var(--position);text-decoration:none;white-space:pre">&#8211;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:380.99pt;position:var(--position);text-decoration:none;white-space:pre"> July 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:422.62pt;position:var(--position);text-decoration:none;white-space:pre">).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:472.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, 2024 and 2025, the impact of the revaluation of cash and cash equivalents held in U.S. dollars by the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:483.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Company into the its functional</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:162.53pt;position:var(--position);text-decoration:none;white-space:pre"> currency</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:199.98pt;position:var(--position);text-decoration:none;white-space:pre"> (euro) is a net financial expense of</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:340.63pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:343.13pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-332" decimals="-3" sign="-" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1027">3,196</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:409.22pt;position:var(--position);text-decoration:none;white-space:pre">, a net financial income of </span></div></ix:continuation><div style="font-size:12pt;line-height:11pt;position:var(--position);top:495.25pt;width:612pt"><ix:continuation id="f-1013-2"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-333" decimals="-3" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1028">2,035</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:102.09pt;position:var(--position);text-decoration:none;white-space:pre"> and a net financial expense of</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:223.59pt;position:var(--position);text-decoration:none;white-space:pre"> &#8364;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:231.09pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-334" decimals="-3" sign="-" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1029">8,639</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:292.18pt;position:var(--position);text-decoration:none;white-space:pre"> respectively.</span></ix:continuation><span style="font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:345.43pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="position:absolute;top:529.95pt" id="i7a006daedb3d4216a4128b76247285d7_391"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:529.95pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 12. <span id="i152bea964fdb44d1bbbe99758f4275cb"></span></span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory" id="f-1030" continuedAt="f-1030-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Financial assets and liabilities</span></ix:nonNumeric></div><ix:continuation id="f-1030-1" continuedAt="f-1030-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:549.75pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFairValueMeasurementOfAssetsExplanatory" id="f-1032" continuedAt="f-1032-1" escape="true"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" id="f-1031" continuedAt="f-1031-1" escape="true"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">The following table shows the carrying amounts and fair value of financial assets and financial liabilities, including their </span></ix:nonNumeric></ix:nonNumeric></div><ix:continuation id="f-1032-1" continuedAt="f-1032-2"><ix:continuation id="f-1031-1" continuedAt="f-1031-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:561.75pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">levels in the fair value hierarchy.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:573.75pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">Tax and employee-related payables are non-financial liabilities and are therefore excluded from the tables below. They are </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:585.75pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">presented in Note 17.2.</span></div></ix:continuation></ix:continuation></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-32<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><ix:continuation id="f-1032-2" continuedAt="f-1032-3"><ix:continuation id="f-1031-2" continuedAt="f-1031-3"><ix:continuation id="f-1030-2" continuedAt="f-1030-3"><div><div style="position:var(--position);top:70.56pt;width:612pt"><div style="font-size:0pt;left:39pt;position:var(--position);width:534pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:189.75pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:71.25pt"/></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"/><td colspan="9" style="font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);width:344.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:344.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:160.47pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:344.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:134.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td></tr><tr style="height:69pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:60.23pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:43.34pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.42pt;position:var(--position);text-decoration:none;white-space:pre">AMOUNT </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.31pt;position:var(--position);text-decoration:none;white-space:pre">RECOGNIZED </span></div><div style="line-height:8pt;position:var(--position);top:31.57pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.74pt;position:var(--position);text-decoration:none;white-space:pre">IN THE </span></div><div style="line-height:8pt;position:var(--position);top:41.17pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.53pt;position:var(--position);text-decoration:none;white-space:pre">STATEMENT </span></div><div style="line-height:8pt;position:var(--position);top:50.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.43pt;position:var(--position);text-decoration:none;white-space:pre">OF&#160;FINANCIAL </span></div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.08pt;position:var(--position);text-decoration:none;white-space:pre">POSITION</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.87pt;position:var(--position);text-decoration:none;white-space:pre">FAIR&#160;VALUE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.64pt;position:var(--position);text-decoration:none;white-space:pre">ASSETS/ </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.97pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.31pt;position:var(--position);text-decoration:none;white-space:pre">AT FAIR </span></div><div style="line-height:8pt;position:var(--position);top:31.57pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.64pt;position:var(--position);text-decoration:none;white-space:pre">VALUE </span></div><div style="line-height:8pt;position:var(--position);top:41.17pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.75pt;position:var(--position);text-decoration:none;white-space:pre">THROUGH </span></div><div style="line-height:8pt;position:var(--position);top:50.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.87pt;position:var(--position);text-decoration:none;white-space:pre">PROFIT&#160;AND </span></div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.41pt;position:var(--position);text-decoration:none;white-space:pre">LOSS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:41.17pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.2pt;position:var(--position);text-decoration:none;white-space:pre">ASSETS AT </span></div><div style="line-height:8pt;position:var(--position);top:50.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.53pt;position:var(--position);text-decoration:none;white-space:pre">AMORTIZED </span></div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.74pt;position:var(--position);text-decoration:none;white-space:pre">COST</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:21pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:41.17pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.97pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES </span></div><div style="line-height:8pt;position:var(--position);top:50.77pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.98pt;position:var(--position);text-decoration:none;white-space:pre">AT&#160;AMORTIZED </span></div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.74pt;position:var(--position);text-decoration:none;white-space:pre">COST</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial assets (2)</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-335" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1033">22,055</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-336" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1034">22,394</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-337" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:fixed-zero" scale="3" id="f-1035">&#8212;</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-338" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1036">22,394</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:90pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:60.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other receivables and assets (2)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:102pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-339" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1037">27,164</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:102pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-340" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1038">27,164</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:102pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-341" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:fixed-zero" scale="3" id="f-1039">&#8212;</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:102pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-342" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1040">27,164</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:102pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:60.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:114pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cash and cash equivalents (1)</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:114pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-343" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1041">251,942</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:114pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-344" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1042">251,942</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:114pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-345" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:fixed-zero" scale="3" id="f-1043">&#8212;</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:114pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-346" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1044">251,942</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:114pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:60.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:126pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial assets</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:126pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-347" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1045">301,161</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:126pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1046">301,500</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:126pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-348" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:fixed-zero" scale="3" id="f-1047">&#8212;</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:126pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-349" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1048">301,500</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:126pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:60.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:138pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial liabilities&#8212;non-current portion (4, Note 15)</span></div></div></div></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:138pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-350" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-1049">39,697</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:138pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-351" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1050">40,622</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:138pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-352" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1051">18,506</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:138pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:138pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-353" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1052">42,768</ix:nonFraction></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:150pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial liabilities&#8212;current portion (3, Note 15)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:150pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-354" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-1053">37,348</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:150pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-355" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1054">37,348</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:150pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-356" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1055">11,531</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:150pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:150pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:50.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-357" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1056">5,165</ix:nonFraction></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:162pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Trade payables and other current liabilities (3)</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:162pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-358" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-1057">47,221</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:162pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-359" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1058">47,221</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:162pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-360" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="3" id="f-1059">&#8212;</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:162pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:162pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-361" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1060">47,221</ix:nonFraction></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:174pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial liabilities</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:174pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-347" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-1061">124,266</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:174pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1062">125,191</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:174pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-362" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1063">30,037</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:174pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:174pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:46.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-363" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1064">95,154</ix:nonFraction></span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:273.56pt;width:612pt"><div style="font-size:0pt;left:39pt;position:var(--position);width:534pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:189.75pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:71.25pt"/></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"/><td colspan="9" style="font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);width:344.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:344.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:160.47pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:344.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:134.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td></tr><tr style="height:71.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:62.48pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:43.34pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.42pt;position:var(--position);text-decoration:none;white-space:pre">AMOUNT </span></div><div style="line-height:8pt;position:var(--position);top:24.22pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.31pt;position:var(--position);text-decoration:none;white-space:pre">RECOGNIZED </span></div><div style="line-height:8pt;position:var(--position);top:33.82pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.74pt;position:var(--position);text-decoration:none;white-space:pre">IN THE </span></div><div style="line-height:8pt;position:var(--position);top:43.42pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.53pt;position:var(--position);text-decoration:none;white-space:pre">STATEMENT </span></div><div style="line-height:8pt;position:var(--position);top:53.02pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.43pt;position:var(--position);text-decoration:none;white-space:pre">OF&#160;FINANCIAL </span></div><div style="line-height:8pt;position:var(--position);top:62.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.08pt;position:var(--position);text-decoration:none;white-space:pre">POSITION</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:62.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.87pt;position:var(--position);text-decoration:none;white-space:pre">FAIR&#160;VALUE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.02pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.64pt;position:var(--position);text-decoration:none;white-space:pre">ASSETS/ </span></div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.97pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES </span></div><div style="line-height:8pt;position:var(--position);top:24.22pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.31pt;position:var(--position);text-decoration:none;white-space:pre">AT FAIR </span></div><div style="line-height:8pt;position:var(--position);top:33.82pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.64pt;position:var(--position);text-decoration:none;white-space:pre">VALUE </span></div><div style="line-height:8pt;position:var(--position);top:43.42pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.75pt;position:var(--position);text-decoration:none;white-space:pre">THROUGH </span></div><div style="line-height:8pt;position:var(--position);top:53.02pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.87pt;position:var(--position);text-decoration:none;white-space:pre">PROFIT&#160;AND </span></div><div style="line-height:8pt;position:var(--position);top:62.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.41pt;position:var(--position);text-decoration:none;white-space:pre">LOSS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:43.42pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.2pt;position:var(--position);text-decoration:none;white-space:pre">ASSETS AT </span></div><div style="line-height:8pt;position:var(--position);top:53.02pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.53pt;position:var(--position);text-decoration:none;white-space:pre">AMORTIZED </span></div><div style="line-height:8pt;position:var(--position);top:62.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.74pt;position:var(--position);text-decoration:none;white-space:pre">COST</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:21pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:43.42pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.97pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES </span></div><div style="line-height:8pt;position:var(--position);top:53.02pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.98pt;position:var(--position);text-decoration:none;white-space:pre">AT&#160;AMORTIZED </span></div><div style="line-height:8pt;position:var(--position);top:62.62pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.74pt;position:var(--position);text-decoration:none;white-space:pre">COST</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:92.25pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial assets (2)</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:92.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-364" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1065">13,473</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:92.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-365" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1066">12,690</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:92.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-366" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:fixed-zero" scale="3" id="f-1067">&#8212;</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:92.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-367" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1068">12,690</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:92.25pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:60.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:104.25pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other receivables and assets (2)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:104.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-368" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1069">19,843</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:104.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-369" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1070">19,843</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:104.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-370" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:fixed-zero" scale="3" id="f-1071">&#8212;</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:104.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-371" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1072">19,843</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:104.25pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:60.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:116.25pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cash and cash equivalents (1)</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:116.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-372" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1073">144,221</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:116.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-373" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1074">144,221</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:116.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-374" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:fixed-zero" scale="3" id="f-1075">&#8212;</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:116.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-375" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1076">144,221</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:116.25pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:60.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:128.25pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial assets</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:128.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-376" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1077">177,537</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:128.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1078">176,754</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:128.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-377" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:fixed-zero" scale="3" id="f-1079">&#8212;</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:128.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-378" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1080">176,754</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:128.25pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:60.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:140.25pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial liabilities&#8212;non-current portion (4, Note 15)</span></div></div></div></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:140.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-379" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-1081">69,069</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:140.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-380" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1082">73,497</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:140.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-381" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1083">3,620</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:140.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:140.25pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-382" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1084">69,877</ix:nonFraction></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:152.25pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial liabilities&#8212;current portion (3, Note 15)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:152.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-383" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-1085">44,935</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:152.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-384" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1086">44,935</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:152.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-385" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1087">21,183</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:152.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:152.25pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-386" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1088">23,752</ix:nonFraction></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:164.25pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Trade payables and other current liabilities (3)</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:164.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-387" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-1089">43,824</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:164.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-388" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1090">43,824</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:164.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-389" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="3" id="f-1091">&#8212;</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:164.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:164.25pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-390" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1092">43,824</ix:nonFraction></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:176.25pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial liabilities</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:176.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-376" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-1093">157,828</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:176.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1094">162,256</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:176.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-391" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1095">24,803</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:176.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:176.25pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:42.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-392" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1096">137,453</ix:nonFraction></span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:478.81pt;width:612pt"><div style="font-size:0pt;left:40.12pt;position:var(--position);width:531.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:189.75pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:69pt"/></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"/><td colspan="9" style="font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);width:342pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:342pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:159.34pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:342pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:132.91pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td></tr><tr style="height:69pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:60.23pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:43.34pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.42pt;position:var(--position);text-decoration:none;white-space:pre">AMOUNT </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.31pt;position:var(--position);text-decoration:none;white-space:pre">RECOGNIZED </span></div><div style="line-height:8pt;position:var(--position);top:31.57pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.74pt;position:var(--position);text-decoration:none;white-space:pre">IN THE </span></div><div style="line-height:8pt;position:var(--position);top:41.17pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.53pt;position:var(--position);text-decoration:none;white-space:pre">STATEMENT </span></div><div style="line-height:8pt;position:var(--position);top:50.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.43pt;position:var(--position);text-decoration:none;white-space:pre">OF&#160;FINANCIAL </span></div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.08pt;position:var(--position);text-decoration:none;white-space:pre">POSITION</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.87pt;position:var(--position);text-decoration:none;white-space:pre">FAIR&#160;VALUE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.64pt;position:var(--position);text-decoration:none;white-space:pre">ASSETS/ </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.97pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.31pt;position:var(--position);text-decoration:none;white-space:pre">AT FAIR </span></div><div style="line-height:8pt;position:var(--position);top:31.57pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.64pt;position:var(--position);text-decoration:none;white-space:pre">VALUE </span></div><div style="line-height:8pt;position:var(--position);top:41.17pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.75pt;position:var(--position);text-decoration:none;white-space:pre">THROUGH </span></div><div style="line-height:8pt;position:var(--position);top:50.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.87pt;position:var(--position);text-decoration:none;white-space:pre">PROFIT&#160;AND </span></div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.41pt;position:var(--position);text-decoration:none;white-space:pre">LOSS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:41.17pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.2pt;position:var(--position);text-decoration:none;white-space:pre">ASSETS AT </span></div><div style="line-height:8pt;position:var(--position);top:50.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.53pt;position:var(--position);text-decoration:none;white-space:pre">AMORTIZED </span></div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.74pt;position:var(--position);text-decoration:none;white-space:pre">COST</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:21pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:41.17pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.85pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES </span></div><div style="line-height:8pt;position:var(--position);top:50.77pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.86pt;position:var(--position);text-decoration:none;white-space:pre">AT&#160;AMORTIZED </span></div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">COST</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial assets (2)</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-393" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1097">26,772</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-394" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1098">27,141</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-395" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:fixed-zero" scale="3" id="f-1099">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-396" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1100">27,141</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:90pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.96pt"></span></span><span style="left:57.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other receivables and assets (2)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:102pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-397" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1101">13,769</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:102pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-398" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1102">13,769</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:102pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-399" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:fixed-zero" scale="3" id="f-1103">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:102pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-400" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1104">13,769</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:102pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.96pt"></span></span><span style="left:57.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:114pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cash and cash equivalents (1)</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:114pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-401" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1105">516,685</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:114pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-402" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1106">516,685</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:114pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-403" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1107">437,031</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:114pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-404" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1108">79,654</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:114pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.96pt"></span></span><span style="left:57.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:126pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial assets</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:126pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-405" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1109">557,226</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:126pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1110">557,595</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:126pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-406" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1111">437,031</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:126pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-407" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1112">120,565</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:126pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:54.96pt"></span></span><span style="left:57.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:138pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial liabilities&#8212;non-current portion (4, Note 15)</span></div></div></div></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:138pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-408" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-1113">30,790</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:138pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-409" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1114">102,555</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:138pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-410" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="3" id="f-1115">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:138pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:138pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-411" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1116">102,555</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:150pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial liabilities&#8212;current portion (3, Note 15)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:150pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-412" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-1117">1,302</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:150pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-413" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1118">1,302</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:150pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-414" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="3" id="f-1119">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:150pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:150pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-415" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1120">1,302</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:162pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Trade payables and other current liabilities (3)</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:162pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-416" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-1121">37,552</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:162pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-417" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1122">37,552</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:162pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-418" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="3" id="f-1123">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:162pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:162pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.96pt"></span></span><span style="left:43.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-419" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1124">37,552</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:174pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial liabilities</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:174pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-405" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-1125">69,644</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:174pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1126">141,409</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:174pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-420" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="3" id="f-1127">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:174pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:174pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-421" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1128">141,409</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:681.81pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(1)&#160; &#160;  The fair value of cash and cash equivalents is determined based on Level 1 fair value measurement and corresponds to the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:693.81pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">market value of the assets. </span></div></div></ix:continuation></ix:continuation></ix:continuation></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-33<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-1032-3" continuedAt="f-1032-4"><ix:continuation id="f-1031-3" continuedAt="f-1031-4"><ix:continuation id="f-1030-3" continuedAt="f-1030-4"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(2)&#160; &#160;  The carrying amount of financial assets measured at amortized cost is deemed to be a reasonable estimate of fair value, except </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:82.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">for the long-term advances made to CROs, whose fair value is determined based on Level 3 fair value measurement and is estimated </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:93.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">based on future cash-flows discounted at market rates, using credit spreads ranging from </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:392.29pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-422" decimals="4" name="ifrs-full:SignificantUnobservableInputAssets" scale="-4" id="f-1129">104</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:407.29pt;position:var(--position);text-decoration:none;white-space:pre"> bp to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:432.56pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-423" decimals="4" name="ifrs-full:SignificantUnobservableInputAssets" scale="-4" id="f-1130">218</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:447.56pt;position:var(--position);text-decoration:none;white-space:pre"> bp as of December 31, 2023, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:105.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-424" decimals="4" name="ifrs-full:SignificantUnobservableInputAssets" scale="-4" id="f-1131">131</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:51pt;position:var(--position);text-decoration:none;white-space:pre"> bp to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:76.27000000000001pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-425" decimals="4" name="ifrs-full:SignificantUnobservableInputAssets" scale="-4" id="f-1132">271</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.27000000000001pt;position:var(--position);text-decoration:none;white-space:pre"> bp as of December 31, 2024 and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:225.89pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-426" decimals="4" name="ifrs-full:SignificantUnobservableInputAssets" scale="-4" id="f-1133">34</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:235.89pt;position:var(--position);text-decoration:none;white-space:pre"> bp to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:261.15999999999997pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-427" decimals="4" name="ifrs-full:SignificantUnobservableInputAssets" scale="-4" id="f-1134">131</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:276.15999999999997pt;position:var(--position);text-decoration:none;white-space:pre"> bp as of December 31, 2025. As of December 31, 2023, 2024, and 2025, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:116.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">an increase in the credit spread by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:174.42pt;position:var(--position);text-decoration:none;white-space:pre">+<ix:nonFraction unitRef="number" contextRef="c-428" decimals="4" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets" scale="-4" id="f-1135"><ix:nonFraction unitRef="number" contextRef="c-429" decimals="4" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets" scale="-4" id="f-1136"><ix:nonFraction unitRef="number" contextRef="c-430" decimals="4" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets" scale="-4" id="f-1137">100</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:195.05pt;position:var(--position);text-decoration:none;white-space:pre"> bp would result in a decrease in the advances fair value by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:433.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-431" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-1138">23</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:486.96pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:491.96pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-432" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-1139">235</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:550.55pt;position:var(--position);text-decoration:none;white-space:pre">, and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:128.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-433" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-1140">231</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.59pt;position:var(--position);text-decoration:none;white-space:pre">, respectively. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:151.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(3)&#160; &#160;  The carrying amount of short-term financial liabilities measured at amortized cost was deemed to be a reasonable estimate of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:163.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">fair value. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:187.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(4)&#160; &#160;  The fair value of the royalty certificates, Heights convertible notes, Kreos / Claret BSA and Minimum Return Indemnifications </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:199.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">is based on Level 3 fair value measurement and is estimated based on models and assumptions detailed in Note 15. The fair value of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:211.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">other long-term financial liabilities is determined based on Level 3 fair value measurement and is estimated based on future cash-flows </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:223.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">discounted at market rates, using the following assumptions: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:247.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">For the debt components of the Kreos / Claret OCABSA (tranche A) and the tranches B and C of the Kreos / Claret straight </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:259.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">bond loans, a credit spread of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:192.16pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-434" decimals="4" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-4" id="f-1141">960</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:207.16pt;position:var(--position);text-decoration:none;white-space:pre"> bp as of August 22, 2023, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:315.19pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-435" decimals="4" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-4" id="f-1142">900</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:330.19pt;position:var(--position);text-decoration:none;white-space:pre"> bp as of December 31, 2023 and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:464.81pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-436" decimals="4" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-4" id="f-1143">750</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:479.81pt;position:var(--position);text-decoration:none;white-space:pre"> bp as of December 31, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:271.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">2024. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:283.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">As of August 22, 2023, December 31, 2023 (tranche A) and December 31, 2024 (all </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:410.9pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="tranche" contextRef="c-437" decimals="INF" name="abvx:NumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="f-1144">three</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:430.86pt;position:var(--position);text-decoration:none;white-space:pre"> tranches), an increase in the credit </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:295.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">spread by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.08pt;position:var(--position);text-decoration:none;white-space:pre">+<ix:nonFraction unitRef="number" contextRef="c-438" decimals="4" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-4" id="f-1145"><ix:nonFraction unitRef="number" contextRef="c-439" decimals="4" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-4" id="f-1146"><ix:nonFraction unitRef="number" contextRef="c-440" decimals="4" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-4" id="f-1147">100</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:133.71pt;position:var(--position);text-decoration:none;white-space:pre"> bp would result in a decrease in the Kreos / Claret debt components fair value by respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:512.69pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-441" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="3" id="f-1148">624</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:571.28pt;position:var(--position);text-decoration:none;white-space:pre">,&#160; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:307.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-442" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="3" id="f-1149">538</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:130.59pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:150.01999999999998pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-443" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="3" id="f-1150">958</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:208.61pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:331.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">For the conditional advances and the PGE loan, a credit spread of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:336.42pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-444" decimals="4" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-4" id="f-1151">900</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:351.42pt;position:var(--position);text-decoration:none;white-space:pre"> bp as of December 31, 2023, and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:488.54pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-445" decimals="4" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-4" id="f-1152">730</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:503.54pt;position:var(--position);text-decoration:none;white-space:pre"> bp as of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:343.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">December 31, 2024. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.54000000000002pt;position:var(--position);text-decoration:none;white-space:pre">An i</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:173.03pt;position:var(--position);text-decoration:none;white-space:pre">ncrease in the credit spread by</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:294.25pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:296.75pt;position:var(--position);text-decoration:none;white-space:pre">+<ix:nonFraction unitRef="number" contextRef="c-430" decimals="4" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-4" id="f-1153">100</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:317.38pt;position:var(--position);text-decoration:none;white-space:pre"> bp w</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:339.6pt;position:var(--position);text-decoration:none;white-space:pre">ould result in the following: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:355.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:76.5pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.5pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, and 2024, a decrease in the PGE loan fair value by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:407.25pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-446" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="3" id="f-1154">39</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:460.84pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:480.27pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-447" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="3" id="f-1155">21</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:533.86pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:367.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.5pt;position:var(--position);text-decoration:none;white-space:pre">respectively. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:379.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:76.5pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.5pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, a decrease in the RNP-VIR conditional advance fair value by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:449.38pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-448" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="3" id="f-1156">15</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:502.97pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:391.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:76.5pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.5pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, a decrease in the CARENA conditional advance fair value by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:450.48pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-449" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="3" id="f-1157">37</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:504.07pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div></ix:continuation></ix:continuation></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:403.06pt;width:612pt"><ix:continuation id="f-1032-4" continuedAt="f-1032-5"><ix:continuation id="f-1031-4" continuedAt="f-1031-5"><ix:continuation id="f-1030-4" continuedAt="f-1030-5"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:76.5pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.5pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, a decrease in the Ebola conditional advance fair value by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:432.7pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-450" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="3" id="f-1158">1</ix:nonFraction>&#160;thousand</span></ix:continuation></ix:continuation></ix:continuation><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:481.29pt;position:var(--position);text-decoration:none;white-space:pre"><ix:continuation id="f-1032-5"><ix:continuation id="f-1031-5"><ix:continuation id="f-1030-5">.</ix:continuation></ix:continuation></ix:continuation> </span></div><div style="position:absolute;top:451.06pt" id="i7a006daedb3d4216a4128b76247285d7_394"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:451.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 13. <span id="i57f3d78aa8924e168a68604299c140f9"></span></span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" id="f-1159" continuedAt="f-1159-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Shareholders&#8217; equity</span></ix:nonNumeric></div><div style="position:absolute;top:471.91pt" id="i7a006daedb3d4216a4128b76247285d7_397"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:471.91pt;width:612pt"><ix:continuation id="f-1159-1" continuedAt="f-1159-2"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 13.1. Share capital issued<span id="i0fdb1d24fb1f4032bcb05504b8034ab4"></span></span></ix:continuation></div><ix:continuation id="f-1159-2" continuedAt="f-1159-3"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:490.76pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group manages its capital to ensure that the Group will be able to continue as a going concern while maximizing the return to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:502.76pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">shareholders through the optimization of the debt and equity balance.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:526.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, the Group&#8217;s share capital amounted to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.8pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:IssuedCapital" scale="3" id="f-1160">629</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:357.39pt;position:var(--position);text-decoration:none;white-space:pre"> divided into </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:410.4pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1161">62,928,818</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:455.4pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares issued with a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:540.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">par value of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:86.22pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-6" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-1162">0.01</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108.72pt;position:var(--position);text-decoration:none;white-space:pre"> each, fully paid up, after taking into account the various capital increases that took place since the inception (see </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:553.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 13.2). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:578.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2024, the Group&#8217;s share capital amounted to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.8pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:IssuedCapital" scale="3" id="f-1163">633</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:357.39pt;position:var(--position);text-decoration:none;white-space:pre"> divided into </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:410.4pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1164">63,347,837</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:455.4pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares issued with a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:589.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">par value of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:86.22pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-7" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-1165">0.01</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108.72pt;position:var(--position);text-decoration:none;white-space:pre"> each, fully paid up, after taking into account the various capital increases that took place since the inception (see </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:601.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 13.2). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:622.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2025, the Group&#8217;s share capital amounted to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.8pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:IssuedCapital" scale="3" id="f-1166">785</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:357.39pt;position:var(--position);text-decoration:none;white-space:pre"> divided into </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:410.4pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1167">78,536,412</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:455.4pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares issued with a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:633.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">par value of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:86.22pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-5" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-1168">0.01</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108.72pt;position:var(--position);text-decoration:none;white-space:pre"> each, fully paid up, after taking into account the various capital increases that took place since inception (see Note </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:644.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">13.2).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:667.96pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Share capital does not include founders&#8217; share subscription warrants (&#8220;Bons de souscription de parts de cr&#233;ateur d&#8217;entreprise&#8221; or </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:679.96pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8220;BCE&#8221;), share subscription warrants (&#8220;Bons de souscription d&#8217;actions,&#8221; or &#8220;BSA&#8221;) and free shares (&#8220;Attributions gratuites </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:691.96pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">d&#8217;actions,&#8221; or &#8220;AGA&#8221;) that have been granted to certain investors or natural persons, both employees and non-employees of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:703.96pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Group, but not yet exercised.</span></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-34<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-1159-3" continuedAt="f-1159-4"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:99.86pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Treasury shares</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:121.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group held </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:101.78pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="abvx:NumberOfTreasurySharesHeld" format="ixt:num-dot-decimal" scale="0" id="f-1169">11,339</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.28pt;position:var(--position);text-decoration:none;white-space:pre"> of its own shares as of December 31, 2023. The Group held </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:372.7pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="abvx:NumberOfTreasurySharesHeld" format="ixt:fixed-zero" scale="0" id="f-1170"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="abvx:NumberOfTreasurySharesHeld" format="ixt:fixed-zero" scale="0" id="f-1171">none</ix:nonFraction></ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:392.13pt;position:var(--position);text-decoration:none;white-space:pre"> of its own shares as of December 31, 2024 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:133.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and December 31, 2025.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:155.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The number of outstanding ordinary shares (excluding treasury shares held by the Group) was </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:414.55pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1172">62,928,818</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:459.55pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:464.55pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1173">63,347,837</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:509.55pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:512.05pt;position:var(--position);text-decoration:none;white-space:pre">and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:528.98pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1174">78,536,412</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:573.98pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:576.48pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:166.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">as of December 31, 2023, 2024 and 2025, respectively. </span></div></ix:continuation><div style="position:absolute;top:202.76pt" id="i7a006daedb3d4216a4128b76247285d7_403"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:202.76pt;width:612pt"><ix:continuation id="f-1159-4" continuedAt="f-1159-5"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 13.2. Change in share capital<span id="ie3ec27c85b104470b4ffdcd1d8b63baf"></span></span></ix:continuation></div><ix:continuation id="f-1159-5" continuedAt="f-1159-6"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:235.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The increases in the share capital for the year ended December 31, 2023 relate to: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:253.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The completion of a capital increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:230.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-451" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-1175">130,000</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:306.46000000000004pt;position:var(--position);text-decoration:none;white-space:pre"> on February 22, 2023 by issuing </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:440.86pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-451" decimals="0" name="abvx:IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease" format="ixt:num-dot-decimal" scale="0" id="f-1176">20,000,000</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.86pt;position:var(--position);text-decoration:none;white-space:pre"> new ordinary shares </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:264.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">with a par value of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:149.41pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-452" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-1177">0.01</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:171.91pt;position:var(--position);text-decoration:none;white-space:pre"> per share and a subscription price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:321.75pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-452" decimals="2" name="abvx:EquityIssuanceSubscriptionPricePerShare" scale="0" id="f-1178">6.50</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:344.25pt;position:var(--position);text-decoration:none;white-space:pre"> per share; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:281.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The cash-less exercise of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:174.63pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-453" decimals="0" name="abvx:NumberOfWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-1179">67,887</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:202.13pt;position:var(--position);text-decoration:none;white-space:pre"> Kreos A BSA and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:279.59000000000003pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-454" decimals="0" name="abvx:NumberOfWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-1180">31,696</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:307.09000000000003pt;position:var(--position);text-decoration:none;white-space:pre"> Kreos B BSA on</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:377.06pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> May 24, 20</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:425.38pt;position:var(--position);text-decoration:none;white-space:pre">23, resulting in a capital increase of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:292.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-455" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" format="ixt:num-dot-decimal" scale="3" id="f-1181">1,850</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:138.09pt;position:var(--position);text-decoration:none;white-space:pre"> by issuing </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:183.91pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-455" decimals="0" name="abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants" format="ixt:num-dot-decimal" scale="0" id="f-1182">99,583</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:211.41pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares with a par value of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:355.15pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-456" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-1183">0.01</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:377.65pt;position:var(--position);text-decoration:none;white-space:pre"> per share and an average subscription price of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:303.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-457" decimals="2" name="abvx:OtherShareWarrantsSubscriptionPricePerShare" scale="0" id="f-1184">18.57</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:99.5pt;position:var(--position);text-decoration:none;white-space:pre"> per share, which includes the impact of the derecognition of the BSA derivative financial liability; and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:321.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The completion of the Group&#8217;s Global Offering on the Nasdaq Global Market on October 24, 2023, by way of a capital </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:332.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:118.03999999999999pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-88" decimals="0" name="abvx:IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease" format="ixt:num-dot-decimal" scale="0" id="f-1185">20,325,500</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:163.04000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> new ordinary shares, consisting of the U.S. Offering of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:387.59pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-89" decimals="0" name="abvx:IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease" format="ixt:num-dot-decimal" scale="0" id="f-1186">18,699,460</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:432.59pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares in the form of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:343.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ADSs, and the European Private Placement of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:259.02pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-90" decimals="0" name="abvx:IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease" format="ixt:num-dot-decimal" scale="0" id="f-1187">1,626,040</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:299.02pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares, with a par value of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:445.26pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-458" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-1188">0.01</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:467.76pt;position:var(--position);text-decoration:none;white-space:pre"> per share and an offering </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:354.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">price set at </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:117.75pt;position:var(--position);text-decoration:none;white-space:pre">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-91" decimals="2" name="abvx:IssueOfEquityOfferingPricePerShare" scale="0" id="f-1189">11.60</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:145.25pt;position:var(--position);text-decoration:none;white-space:pre"> per ADS in the U.S. Offering and a corresponding offering price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:419.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-92" decimals="4" name="abvx:IssueOfEquityOfferingPricePerShare" scale="0" id="f-1190">10.9864</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:456.69pt;position:var(--position);text-decoration:none;white-space:pre"> per ordinary share in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:365.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">European Private Placement. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:383.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The exercise of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:136.07pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="0" name="abvx:NumberOfWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-1191">1,906</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.57pt;position:var(--position);text-decoration:none;white-space:pre"> other share warrants, by issuing </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:290.4pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="0" name="abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants" format="ixt:num-dot-decimal" scale="0" id="f-1192">190,550</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:322.9pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares with a par value of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:466.64pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-6" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-1193">0.01</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:489.14pt;position:var(--position);text-decoration:none;white-space:pre"> per share and an </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:394.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">average subscription price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:190.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-459" decimals="2" name="abvx:OtherShareWarrantsSubscriptionPricePerShare" scale="0" id="f-1194">0.01</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:212.69pt;position:var(--position);text-decoration:none;white-space:pre"> per share (see Note 14). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:411.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Incremental costs directly attributable to the issue of new shares, including underwriting commissions and offering expenses related to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:422.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the Global Offering, were classified as a deduction of shareholders&#8217; equity and amounted to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:405.3pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="3" id="f-1195">28,111</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:476.39pt;position:var(--position);text-decoration:none;white-space:pre"> for the period ended </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:433.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">December 31, 2023. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:456.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The increases in the share capital</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:168.28pt;position:var(--position);text-decoration:none;white-space:pre"> for the year ended December 31, 2024 relate to</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:359.16pt;position:var(--position);text-decoration:none;white-space:pre">:</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:467.56pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the issue and subscription by members of the Board of Directors of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:342.86pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-460" decimals="0" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1196">77,820</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:370.36pt;position:var(--position);text-decoration:none;white-space:pre"> share warrants, with a subscription price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:547.6700000000001pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-461" decimals="2" name="abvx:ShareWarrantsSubscriptionPricePerShare" scale="0" id="f-1197">2.57</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:570.1700000000001pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:481pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">each (see Note 14);</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:494.44pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">a credit note received for transaction fees related to the Global Offering, amounting to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:418.48pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="abvx:ShareIssueRelatedCostCredit" scale="3" id="f-1198">446</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:477.07pt;position:var(--position);text-decoration:none;white-space:pre"> and classified in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:507.88pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">share premiums; and</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:521.32pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the exercise of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:132.74pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-462" decimals="0" name="abvx:NumberOfWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-1199">4,000</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.24pt;position:var(--position);text-decoration:none;white-space:pre"> other share warrants, by issuing </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:287.07pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-462" decimals="0" name="abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants" format="ixt:num-dot-decimal" scale="0" id="f-1200">4,000</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:309.57pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares with a par value of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:453.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-7" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-1201">0.01</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:475.81pt;position:var(--position);text-decoration:none;white-space:pre"> per share and an </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:534.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">average subscription price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:190.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-463" decimals="2" name="abvx:OtherShareWarrantsSubscriptionPricePerShare" scale="0" id="f-1202">11.14</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:217.69pt;position:var(--position);text-decoration:none;white-space:pre"> per share (see Note 14).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:548.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the issue of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.00999999999999pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="abvx:NumberOfFreeSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1203">415,019</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:152.51pt;position:var(--position);text-decoration:none;white-space:pre"> vested free shares, as part of the AGA plans issued by the Group to certain of its officers and employees. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:570.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The increases in the share capital</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:168.28pt;position:var(--position);text-decoration:none;white-space:pre"> for the year ended December 31, 2025 relate to</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:359.16pt;position:var(--position);text-decoration:none;white-space:pre">:</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:581.8pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the completion of the July 28, 2025 Offering, by issuing </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:299.06pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-124" decimals="0" name="abvx:IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease" format="ixt:num-dot-decimal" scale="0" id="f-1204">11,679,400</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:344.06pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:346.56pt;position:var(--position);text-decoration:none;white-space:pre">ADSs</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:370.45pt;position:var(--position);text-decoration:none;white-space:pre"> a</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:377.38pt;position:var(--position);text-decoration:none;white-space:pre">t a price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:422.87pt;position:var(--position);text-decoration:none;white-space:pre">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-125" decimals="2" name="abvx:IssueOfEquityOfferingPricePerShare" scale="0" id="f-1205">64.00</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:450.37pt;position:var(--position);text-decoration:none;white-space:pre"> per ADS (corresponding to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:595.24pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-126" decimals="2" name="abvx:IssueOfEquityOfferingPricePerShare" scale="0" id="f-1206">54.58</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:99.5pt;position:var(--position);text-decoration:none;white-space:pre"> per ordinary share, based on the exchange rate of &#8364;1.00 = $</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:338.79pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-127" decimals="4" name="ifrs-full:ClosingForeignExchangeRate" scale="0" id="f-1207">1.1726</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:366.29pt;position:var(--position);text-decoration:none;white-space:pre"> as published by the European Central Bank on July </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:608.68pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">23, 2025);</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:625.12pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the conversion of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:143.88pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="note" contextRef="c-129" decimals="INF" name="abvx:NumberOfConvertibleNotesConverted" scale="0" id="f-1208">150</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.88pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:178.31pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="note" contextRef="c-130" decimals="INF" name="abvx:NumberOfConvertibleNotesConverted" scale="0" id="f-1209">200</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:193.31pt;position:var(--position);text-decoration:none;white-space:pre"> of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:206.64pt;position:var(--position);text-decoration:none;white-space:pre">Heights notes o</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:268.81pt;position:var(--position);text-decoration:none;white-space:pre">n respectively July 23 and July 30, 2025 (corresponding to the entirety of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:637.12pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the outstanding principal amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:217.13pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-130" decimals="-5" name="ifrs-full:NotionalAmount" scale="6" id="f-1210">21.9</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:270.98pt;position:var(--position);text-decoration:none;white-space:pre">). This conversion resulted in the issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:452.18pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-131" decimals="INF" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1211">920,377</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:484.68pt;position:var(--position);text-decoration:none;white-space:pre"> new ordinary shares </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:649.12pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of the Group at a conversion price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:221.85pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-130" decimals="4" name="abvx:BorrowingsFixedConversionPrice" scale="0" id="f-1212">23.7674</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:259.35pt;position:var(--position);text-decoration:none;white-space:pre"> per ordinary share in accordance with the terms and conditions of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:661.12pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">convertible notes;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:676.12pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:84.2pt;position:var(--position);text-decoration:none;white-space:pre"> conversion, on </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:148.05pt;position:var(--position);text-decoration:none;white-space:pre">August 8, 2025, by Kreos Capital VII (UK) Limited of its portion of the Tranche A of the Kreos / Claret </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:688.12pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Financing (the Kreos OCABSA), at a conversion price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:304pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-464" decimals="4" name="abvx:BorrowingsFixedConversionPrice" scale="0" id="f-1213">21.2209</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:341.5pt;position:var(--position);text-decoration:none;white-space:pre">,</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:344pt;position:var(--position);text-decoration:none;white-space:pre"> resulting in the issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:456.1pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-132" decimals="INF" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1214">785,389</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:488.6pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:700.12pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the Group, . </span></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-35<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-1159-6" continuedAt="f-1159-7"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the exercise, on July 30, 2025, by Kreos Capital VII Aggregator SCSp of its share warrants (the tranche A-B Kreos BSA and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:82.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">tranche C Kreos BSA) resulting in the issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:274.28999999999996pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-133" decimals="INF" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1215">319,251</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:306.78999999999996pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares of the Group;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:97.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the exercise, o</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.41pt;position:var(--position);text-decoration:none;white-space:pre">n August 28, 2025, by Claret European Growth Capital Fund III SCSp of its share warrants (the tranche A-B </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:109.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Claret BSA and tranche C Claret BSA) resulting in the issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:340.57pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-134" decimals="INF" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1216">206,662</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:373.07pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares of the Group;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:124.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the conversion, on November 25, 2025, by Claret European Growth Capital Fund III SCSp of its portion of the Tranche A of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:136.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the Kreos / Claret Financing (the Claret OCABSA), at a conversion price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:377.75pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-465" decimals="4" name="abvx:BorrowingsFixedConversionPrice" scale="0" id="f-1217">21.2209</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:415.25pt;position:var(--position);text-decoration:none;white-space:pre">,</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:417.75pt;position:var(--position);text-decoration:none;white-space:pre"> resulting in the issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:529.85pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-135" decimals="INF" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1218">392,695</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:562.35pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:148.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ordinary shares of the Group.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:163.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the issue of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.00999999999999pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="abvx:NumberOfFreeSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1219">627,714</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:152.51pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.01pt;position:var(--position);text-decoration:none;white-space:pre">vested free shares, as part of the AGA plans issued by the Group to certain of its officers and employees;</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:178.56pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the exercise of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:132.74pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-48" decimals="0" name="abvx:NumberOfWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-1220">257,087</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:165.24pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:167.74pt;position:var(--position);text-decoration:none;white-space:pre">other share warrants, by issuing </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:297.07pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-48" decimals="0" name="abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants" format="ixt:num-dot-decimal" scale="0" id="f-1221">257,087</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:329.57pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares with a par value of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:473.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-5" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-1222">0.01</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:495.81pt;position:var(--position);text-decoration:none;white-space:pre"> per share and an </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:192.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">average subscription price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:190.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-466" decimals="2" name="abvx:OtherShareWarrantsSubscriptionPricePerShare" scale="0" id="f-1223">13.02</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:217.69pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:220.19pt;position:var(--position);text-decoration:none;white-space:pre">per share (see Note 14).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:233.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Distribution of dividends </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:255.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group did not distribute any dividends for any of the periods presented, does not have any present plan to pay any cash dividends </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:267.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">on its equity securities in the foreseeable future and currently intends to retain all available funds and any future earnings to operate </span></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:278.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><ix:continuation id="f-1159-7">and expand our business.</ix:continuation> </span></div><div style="position:absolute;top:306.96pt" id="i7a006daedb3d4216a4128b76247285d7_406"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:306.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 14. <span id="ibe061045c5e544c095dba9bdc80c5a09"></span></span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" id="f-1224" continuedAt="f-1224-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Share-based payments</span></ix:nonNumeric></div><ix:continuation id="f-1224-1" continuedAt="f-1224-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:332.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group has granted BCEs, BSAs and free shares (</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:250.25pt;position:var(--position);text-decoration:none;white-space:pre">attributions gratuites d&#8217;actions</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:374.59pt;position:var(--position);text-decoration:none;white-space:pre">, or &#8220;AGAs&#8221;). These plans qualify as &#8220;equity </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:343.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">settled&#8221; under IFRS 2. The Group does not have any obligation to purchase these instruments in the event of departure or if a specific </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:354.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">event does not occur. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:375.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Valuation methods of BCEs, BSAs and AGAs </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:398.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The fair value of share-based awards was determined at grant date using the Black Scholes model for the BCEs and BSAs and the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:409.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Monte-Carlo simulation for AGAs plans with market performance conditions.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:431.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The assumptions used to estimate the fair value of the instruments are presented below and include: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:454.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Expected maturity of the options;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:465.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:60.1pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Expected volatility based on the historical market share price available; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:476.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:60.1pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Expected dividends based on management best estimate; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:487.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:60.1pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Risk-free interest rate based on French OAT rates measured at grant dates; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:499.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:60.1pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Share price</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:117.21000000000001pt;position:var(--position);text-decoration:none;white-space:pre">, including offered </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:193.8pt;position:var(--position);text-decoration:none;white-space:pre">in case of change of control (only for the market conditions applicable to the free-share plan </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:510.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-1</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:124.49000000000001pt;position:var(--position);text-decoration:none;white-space:pre">), i</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:135.59pt;position:var(--position);text-decoration:none;white-space:pre">s based on Monte-Carlo simulations and taking into account a change of control premium based on the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:521.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">management best estimate. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:543.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">BCEs </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:566.26pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" id="f-1225" continuedAt="f-1225-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The following tables summarize the data relating to BCEs as well as the assumptions used for the measurement thereof in accordance </span></ix:nonNumeric></div><ix:continuation id="f-1225-1" continuedAt="f-1225-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:577.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">with IFRS 2 &#8211; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:94.87pt;position:var(--position);text-decoration:none;white-space:pre">Share-based Payment</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:182.29pt;position:var(--position);text-decoration:none;white-space:pre">: </span></div></ix:continuation></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-36<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><ix:continuation id="f-1224-2" continuedAt="f-1224-3"><div><ix:continuation id="f-1225-2" continuedAt="f-1225-3"><div style="position:var(--position);top:70.56pt;width:612pt"><div style="font-size:0pt;left:43pt;position:var(--position);width:524.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:45pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:47.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:51pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:51pt"/><td style="padding:0;width:51pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:51pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:51pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:51pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:51pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:51pt"/></tr><tr style="height:89.25pt"><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:45pt"><div><div style="line-height:8pt;position:var(--position);top:52.2pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.18pt;position:var(--position);text-decoration:none;white-space:pre">GRANT&#160;D</span></div><div style="line-height:8pt;position:var(--position);top:61.8pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.28pt;position:var(--position);text-decoration:none;white-space:pre">ATE </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:48pt;position:var(--position);width:47.25pt"><div><div style="line-height:8pt;position:var(--position);top:57pt;width:47.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.97pt;position:var(--position);text-decoration:none;white-space:pre">TYPE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:98.25pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:47.4pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:57pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.18pt;position:var(--position);text-decoration:none;white-space:pre">OF BCEs </span></div><div style="line-height:8pt;position:var(--position);top:66.6pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.07pt;position:var(--position);text-decoration:none;white-space:pre">ISSUED</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:152.25pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:33pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:42.6pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.73pt;position:var(--position);text-decoration:none;white-space:pre">OF BCE </span></div><div style="line-height:8pt;position:var(--position);top:52.2pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.3pt;position:var(--position);text-decoration:none;white-space:pre">OUTSTAND</span></div><div style="line-height:8pt;position:var(--position);top:61.8pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.29pt;position:var(--position);text-decoration:none;white-space:pre">ING AS OF </span></div><div style="line-height:8pt;position:var(--position);top:71.4pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.19pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY </span></div><div style="line-height:8pt;position:var(--position);top:81pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.5pt;position:var(--position);text-decoration:none;white-space:pre">1, 2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:203.25pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:32.02pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:41.62pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.52pt;position:var(--position);text-decoration:none;white-space:pre">OF ISSUED </span></div><div style="line-height:8pt;position:var(--position);top:51.22pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.73pt;position:var(--position);text-decoration:none;white-space:pre">BCEs</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:257.25pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:32.02pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:41.62pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.19pt;position:var(--position);text-decoration:none;white-space:pre">OF LAPSED </span></div><div style="line-height:8pt;position:var(--position);top:51.22pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.73pt;position:var(--position);text-decoration:none;white-space:pre">BCEs</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:311.25pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:27.22pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:36.82pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:19.95pt;position:var(--position);text-decoration:none;white-space:pre">OF </span></div><div style="line-height:8pt;position:var(--position);top:46.42pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.07pt;position:var(--position);text-decoration:none;white-space:pre">EXERCISE</span></div><div style="line-height:8pt;position:var(--position);top:56.02pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.84pt;position:var(--position);text-decoration:none;white-space:pre">D BCEs</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:365.25pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:27.22pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:36.82pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.18pt;position:var(--position);text-decoration:none;white-space:pre">OF BCEs </span></div><div style="line-height:8pt;position:var(--position);top:46.42pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.3pt;position:var(--position);text-decoration:none;white-space:pre">OUTSTAND</span></div><div style="line-height:8pt;position:var(--position);top:56.02pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.95pt;position:var(--position);text-decoration:none;white-space:pre">ING </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:419.25pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:27.22pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:36.82pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.18pt;position:var(--position);text-decoration:none;white-space:pre">OF BCEs </span></div><div style="line-height:8pt;position:var(--position);top:46.42pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.85pt;position:var(--position);text-decoration:none;white-space:pre">EXERCISA</span></div><div style="line-height:8pt;position:var(--position);top:56.02pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.5pt;position:var(--position);text-decoration:none;white-space:pre">BLE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.22pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.96pt;position:var(--position);text-decoration:none;white-space:pre">MAXIMUM </span></div><div style="line-height:8pt;position:var(--position);top:12.82pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:22.42pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.96pt;position:var(--position);text-decoration:none;white-space:pre">OF SHARES </span></div><div style="line-height:8pt;position:var(--position);top:32.02pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.39pt;position:var(--position);text-decoration:none;white-space:pre">TO BE </span></div><div style="line-height:8pt;position:var(--position);top:41.62pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.07pt;position:var(--position);text-decoration:none;white-space:pre">ISSUED IF </span></div><div style="line-height:8pt;position:var(--position);top:51.22pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.28pt;position:var(--position);text-decoration:none;white-space:pre">ALL </span></div><div style="line-height:8pt;position:var(--position);top:60.82pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.85pt;position:var(--position);text-decoration:none;white-space:pre">CONDITIO</span></div><div style="line-height:8pt;position:var(--position);top:70.42pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.96pt;position:var(--position);text-decoration:none;white-space:pre">NS ARE </span></div><div style="line-height:8pt;position:var(--position);top:80.02pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.39pt;position:var(--position);text-decoration:none;white-space:pre">MET</span></div></div></div></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td colspan="5" style="font-size:0;text-align:left;vertical-align:top"><div style="left:203.25pt;position:var(--position);top:89.25pt;width:159pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:159pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.1pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED DECEMBER 31, 2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td colspan="5" style="font-size:0;text-align:left;vertical-align:top"><div style="left:365.25pt;position:var(--position);top:89.25pt;width:159pt"><div><div style="line-height:8pt;position:var(--position);top:7.57pt;width:159pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:67.84pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:17.17pt;width:159pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:120pt;width:45pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2016-11-07</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:48pt;position:var(--position);top:120pt;width:47.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:47.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BCE-2016-1</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:98.25pt;position:var(--position);top:120pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-467" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1226">84,000</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:152.25pt;position:var(--position);top:120pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-468" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1227">18,796</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:203.25pt;position:var(--position);top:120pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.62pt"></span></span><span style="left:42.25pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-469" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="f-1228">&#8212;</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:257.25pt;position:var(--position);top:120pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-469" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1229">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:311.25pt;position:var(--position);top:120pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:20.3pt"></span></span><span style="left:22.93pt;position:var(--position)">(<ix:nonFraction unitRef="shares" contextRef="c-469" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1230">18,796</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:365.25pt;position:var(--position);top:120pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-470" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1231">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:419.25pt;position:var(--position);top:120pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-470" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1232">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:120pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-470" decimals="INF" name="abvx:MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet" format="ixt:fixed-zero" scale="0" id="f-1233">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:132pt;width:45pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2017-01-23</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:48pt;position:var(--position);top:132pt;width:47.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:47.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BCE-2017-1</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:98.25pt;position:var(--position);top:132pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-471" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1234">67,374</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:152.25pt;position:var(--position);top:132pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-472" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1235">67,000</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:203.25pt;position:var(--position);top:132pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.62pt"></span></span><span style="left:42.25pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-473" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="f-1236">&#8212;</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:257.25pt;position:var(--position);top:132pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-473" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1237">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:311.25pt;position:var(--position);top:132pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:20.3pt"></span></span><span style="left:22.93pt;position:var(--position)">(<ix:nonFraction unitRef="shares" contextRef="c-473" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1238">33,313</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:365.25pt;position:var(--position);top:132pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-474" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1239">33,687</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:419.25pt;position:var(--position);top:132pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-474" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1240">33,687</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:132pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-474" decimals="INF" name="abvx:MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet" format="ixt:num-dot-decimal" scale="0" id="f-1241">33,687</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:144pt;width:45pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2017-11-20</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:48pt;position:var(--position);top:144pt;width:47.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:47.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BCE-2017-2</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:98.25pt;position:var(--position);top:144pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:21.62pt"></span></span><span style="left:24.25pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-475" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1242">150,000</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:152.25pt;position:var(--position);top:144pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:21.62pt"></span></span><span style="left:24.25pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-476" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1243">112,500</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:203.25pt;position:var(--position);top:144pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.62pt"></span></span><span style="left:42.25pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-477" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="f-1244">&#8212;</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:257.25pt;position:var(--position);top:144pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-477" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1245">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:311.25pt;position:var(--position);top:144pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-477" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1246">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:365.25pt;position:var(--position);top:144pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-478" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1247">112,500</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:419.25pt;position:var(--position);top:144pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-478" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1248">112,500</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:144pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-478" decimals="INF" name="abvx:MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet" format="ixt:num-dot-decimal" scale="0" id="f-1249">112,500</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:156pt;width:45pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2017-11-20</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:48pt;position:var(--position);top:156pt;width:47.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:47.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BCE-2017-4</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:98.25pt;position:var(--position);top:156pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-479" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1250">67,374</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:152.25pt;position:var(--position);top:156pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-480" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1251">67,373</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:203.25pt;position:var(--position);top:156pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.62pt"></span></span><span style="left:42.25pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-481" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="f-1252">&#8212;</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:257.25pt;position:var(--position);top:156pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-481" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1253">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:311.25pt;position:var(--position);top:156pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:20.3pt"></span></span><span style="left:22.93pt;position:var(--position)">(<ix:nonFraction unitRef="shares" contextRef="c-481" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1254">33,686</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:365.25pt;position:var(--position);top:156pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-482" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1255">33,687</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:419.25pt;position:var(--position);top:156pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-482" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1256">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:156pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-482" decimals="INF" name="abvx:MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet" format="ixt:num-dot-decimal" scale="0" id="f-1257">33,687</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:168pt;width:45pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2017-11-20</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:48pt;position:var(--position);top:168pt;width:47.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:47.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BCE-2017-5</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:98.25pt;position:var(--position);top:168pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-483" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1258">67,374</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:152.25pt;position:var(--position);top:168pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-484" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1259">33,687</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:203.25pt;position:var(--position);top:168pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.62pt"></span></span><span style="left:42.25pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-485" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="f-1260">&#8212;</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:257.25pt;position:var(--position);top:168pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-485" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1261">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:311.25pt;position:var(--position);top:168pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:20.3pt"></span></span><span style="left:22.93pt;position:var(--position)">(<ix:nonFraction unitRef="shares" contextRef="c-485" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1262">16,843</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:365.25pt;position:var(--position);top:168pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-486" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1263">16,844</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:419.25pt;position:var(--position);top:168pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-486" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1264">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:168pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-486" decimals="INF" name="abvx:MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet" format="ixt:num-dot-decimal" scale="0" id="f-1265">16,844</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:180pt;width:45pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2018-03-15</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:48pt;position:var(--position);top:180pt;width:47.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:47.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BCE-2018-1</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:98.25pt;position:var(--position);top:180pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-487" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1266">22,000</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:152.25pt;position:var(--position);top:180pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-488" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1267">11,980</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:203.25pt;position:var(--position);top:180pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.62pt"></span></span><span style="left:42.25pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-489" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="f-1268">&#8212;</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:257.25pt;position:var(--position);top:180pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-489" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1269">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:311.25pt;position:var(--position);top:180pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:24.3pt"></span></span><span style="left:26.93pt;position:var(--position)">(<ix:nonFraction unitRef="shares" contextRef="c-489" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1270">9,440</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:365.25pt;position:var(--position);top:180pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.96pt"></span></span><span style="left:29.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-490" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1271">2,540</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:419.25pt;position:var(--position);top:180pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.96pt"></span></span><span style="left:29.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-490" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1272">2,540</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:180pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.96pt"></span></span><span style="left:29.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-490" decimals="INF" name="abvx:MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet" format="ixt:num-dot-decimal" scale="0" id="f-1273">2,540</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:192pt;width:45pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2018-05-14</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:48pt;position:var(--position);top:192pt;width:47.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:47.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BCE-2018-4</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:98.25pt;position:var(--position);top:192pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-491" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1274">16,843</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:152.25pt;position:var(--position);top:192pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-492" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1275">16,843</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:203.25pt;position:var(--position);top:192pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.62pt"></span></span><span style="left:42.25pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-493" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="f-1276">&#8212;</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:257.25pt;position:var(--position);top:192pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-493" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1277">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:311.25pt;position:var(--position);top:192pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:24.3pt"></span></span><span style="left:26.93pt;position:var(--position)">(<ix:nonFraction unitRef="shares" contextRef="c-493" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1278">8,422</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:365.25pt;position:var(--position);top:192pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.96pt"></span></span><span style="left:29.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-494" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1279">8,421</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:419.25pt;position:var(--position);top:192pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.96pt"></span></span><span style="left:29.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-494" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1280">8,421</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:192pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.96pt"></span></span><span style="left:29.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-494" decimals="INF" name="abvx:MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet" format="ixt:num-dot-decimal" scale="0" id="f-1281">8,421</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:204pt;width:45pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2018-05-14</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:48pt;position:var(--position);top:204pt;width:47.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:47.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BCE-2018-5</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:98.25pt;position:var(--position);top:204pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-495" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1282">22,000</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:152.25pt;position:var(--position);top:204pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.62pt"></span></span><span style="left:32.25pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-496" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1283">2,000</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:203.25pt;position:var(--position);top:204pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.62pt"></span></span><span style="left:42.25pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-497" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="f-1284">&#8212;</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:257.25pt;position:var(--position);top:204pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-497" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1285">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:311.25pt;position:var(--position);top:204pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:24.3pt"></span></span><span style="left:26.93pt;position:var(--position)">(<ix:nonFraction unitRef="shares" contextRef="c-497" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1286">2,000</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:365.25pt;position:var(--position);top:204pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-498" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1287">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:419.25pt;position:var(--position);top:204pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-498" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1288">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:204pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-498" decimals="INF" name="abvx:MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet" format="ixt:fixed-zero" scale="0" id="f-1289">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:48pt;position:var(--position);top:216pt;width:47.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:47.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total BCEs</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:98.25pt;position:var(--position);top:216pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:21.62pt"></span></span><span style="left:24.25pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-499" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1290">496,965</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:152.25pt;position:var(--position);top:216pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:21.62pt"></span></span><span style="left:24.25pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-500" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1291">330,179</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:203.25pt;position:var(--position);top:216pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:39.62pt"></span></span><span style="left:42.25pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-501" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="f-1292">&#8212;</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:257.25pt;position:var(--position);top:216pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-501" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1293">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:311.25pt;position:var(--position);top:216pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:16.3pt"></span></span><span style="left:18.93pt;position:var(--position)">(<ix:nonFraction unitRef="shares" contextRef="c-501" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1294">122,500</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:365.25pt;position:var(--position);top:216pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-502" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1295">207,679</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:419.25pt;position:var(--position);top:216pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-502" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1296">157,148</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:216pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-502" decimals="INF" name="abvx:MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet" format="ixt:num-dot-decimal" scale="0" id="f-1297">207,679</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:338.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The BCEs include a service condition under which the beneficiary must still be an employee, a corporate officer or a scientific </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:349.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">consultant of the Group at the time of vesting. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:372.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The exercise rights for most of the BCEs are vested annually and have the following vesting terms: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:394.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-503" decimals="2" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="f-1298">25</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90.33pt;position:var(--position);text-decoration:none;white-space:pre"> of the award vests on the first anniversary of the date of grant for all currently issued BCEs; and </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:405.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">For the remaining </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:146.09pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-504" decimals="2" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="f-1299">75</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:164.42000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> of the award, the BCEs vest 1/48th per month over </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:372.56pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-504" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-1300">four years</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:412.8pt;position:var(--position);text-decoration:none;white-space:pre"> from the anniversary date of the grant. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:432.74pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Most of the BCEs plans include or partially include non-market performance conditions (obtaining financing of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:484.68pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-505" decimals="-6" name="abvx:VestingRequirementsForShareBasedPaymentArrangementPerformanceConditionsMinimumFinancing" scale="6" id="f-1301">100</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:536.03pt;position:var(--position);text-decoration:none;white-space:pre">, positive </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:443.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">results on clinic studies, signature of informed consent in a clinical phase, signing a license agreement, FDA authorization). The level </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:455.14pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of achievement of the non-market performance conditions are taken into account in determining the number of BCEs allocated </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:466.34pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">initially and reassessed at each closing date. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:488.74pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In the event of a change of control or a M&amp;A transaction, all the BCEs will become immediately exercisable. A change of control is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:499.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">defined as a new investor/company holding directly or indirectly more than </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:339.82pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-501" decimals="2" name="abvx:VestingRequirementsForShareBasedPaymentArrangementChangeOfControlMinimumThreshold" scale="-2" id="f-1302">50</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:358.15pt;position:var(--position);text-decoration:none;white-space:pre"> of the share capital or voting rights. As such the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:511.14pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">probable vesting date of each plan corresponds to the weighted average of probable change of control dates. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:535.24pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">BSAs</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:549.89pt;width:612pt"><ix:continuation id="f-1225-3" continuedAt="f-1225-4"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The following tables summarize the data relating to BSAs as well as the assumptions used for the measurement thereof in </span></ix:continuation></div><ix:continuation id="f-1225-4" continuedAt="f-1225-5"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:561.89pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">accordance with IFRS 2&#8212;</span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:142.28pt;position:var(--position);text-decoration:none;white-space:pre">Share-based Payment</span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:229.7pt;position:var(--position);text-decoration:none;white-space:pre">:</span></div></ix:continuation></div></ix:continuation></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-37<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><ix:continuation id="f-1224-3" continuedAt="f-1224-4"><div><ix:continuation id="f-1225-5" continuedAt="f-1225-6"><div style="position:var(--position);top:70.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:537pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:52.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:52.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:51pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:51pt"/><td style="padding:0;width:51pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:51pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:51pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:51pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:51pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:51pt"/></tr><tr style="height:69pt"><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:42.07pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.05pt;position:var(--position);text-decoration:none;white-space:pre">GRANT&#160;DA</span></div><div style="line-height:8pt;position:var(--position);top:51.67pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.92pt;position:var(--position);text-decoration:none;white-space:pre">TE </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:55.5pt;position:var(--position);width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:46.87pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.59pt;position:var(--position);text-decoration:none;white-space:pre">TYPE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:111pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:32.47pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.39pt;position:var(--position);text-decoration:none;white-space:pre">Total </span></div><div style="line-height:8pt;position:var(--position);top:42.07pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:51.67pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.62pt;position:var(--position);text-decoration:none;white-space:pre">OF BSAs </span></div><div style="line-height:8pt;position:var(--position);top:61.27pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.07pt;position:var(--position);text-decoration:none;white-space:pre">ISSUED</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:165pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:22.87pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:32.47pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.62pt;position:var(--position);text-decoration:none;white-space:pre">OF BSAs </span></div><div style="line-height:8pt;position:var(--position);top:42.07pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.3pt;position:var(--position);text-decoration:none;white-space:pre">OUTSTAND</span></div><div style="line-height:8pt;position:var(--position);top:51.67pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.29pt;position:var(--position);text-decoration:none;white-space:pre">ING AS OF </span></div><div style="line-height:8pt;position:var(--position);top:61.27pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.19pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY </span></div><div style="line-height:8pt;position:var(--position);top:70.87pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.5pt;position:var(--position);text-decoration:none;white-space:pre">1, 2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:21.9pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:31.5pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.52pt;position:var(--position);text-decoration:none;white-space:pre">OF ISSUED </span></div><div style="line-height:8pt;position:var(--position);top:41.1pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.17pt;position:var(--position);text-decoration:none;white-space:pre">BSAs</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:270pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:21.9pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:31.5pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.19pt;position:var(--position);text-decoration:none;white-space:pre">OF LAPSED </span></div><div style="line-height:8pt;position:var(--position);top:41.1pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.17pt;position:var(--position);text-decoration:none;white-space:pre">BSAs</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:324pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:17.1pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:26.7pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:19.95pt;position:var(--position);text-decoration:none;white-space:pre">OF </span></div><div style="line-height:8pt;position:var(--position);top:36.3pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.07pt;position:var(--position);text-decoration:none;white-space:pre">EXERCISE</span></div><div style="line-height:8pt;position:var(--position);top:45.9pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.29pt;position:var(--position);text-decoration:none;white-space:pre">D&#160; BSAs</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:17.1pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:26.7pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.62pt;position:var(--position);text-decoration:none;white-space:pre">OF BSAs </span></div><div style="line-height:8pt;position:var(--position);top:36.3pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.3pt;position:var(--position);text-decoration:none;white-space:pre">OUTSTAND</span></div><div style="line-height:8pt;position:var(--position);top:45.9pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.95pt;position:var(--position);text-decoration:none;white-space:pre">ING </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:432pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:17.1pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:26.7pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.62pt;position:var(--position);text-decoration:none;white-space:pre">OF BSAs </span></div><div style="line-height:8pt;position:var(--position);top:36.3pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.85pt;position:var(--position);text-decoration:none;white-space:pre">EXERCISA</span></div><div style="line-height:8pt;position:var(--position);top:45.9pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.5pt;position:var(--position);text-decoration:none;white-space:pre">BLE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="height:69pt;left:486pt;overflow:hidden;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:-6.9pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.96pt;position:var(--position);text-decoration:none;white-space:pre">MAXIMUM </span></div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.96pt;position:var(--position);text-decoration:none;white-space:pre">OF SHARES </span></div><div style="line-height:8pt;position:var(--position);top:21.9pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.39pt;position:var(--position);text-decoration:none;white-space:pre">TO BE </span></div><div style="line-height:8pt;position:var(--position);top:31.5pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.07pt;position:var(--position);text-decoration:none;white-space:pre">ISSUED IF </span></div><div style="line-height:8pt;position:var(--position);top:41.1pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.28pt;position:var(--position);text-decoration:none;white-space:pre">ALL </span></div><div style="line-height:8pt;position:var(--position);top:50.7pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.85pt;position:var(--position);text-decoration:none;white-space:pre">CONDITIO</span></div><div style="line-height:8pt;position:var(--position);top:60.3pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.96pt;position:var(--position);text-decoration:none;white-space:pre">NS ARE </span></div><div style="line-height:8pt;position:var(--position);top:69.9pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.39pt;position:var(--position);text-decoration:none;white-space:pre">MET</span></div></div></div></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td colspan="5" style="font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:69pt;width:159pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:159pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.1pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED DECEMBER 31, 2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td colspan="5" style="font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:69pt;width:159pt"><div><div style="line-height:8pt;position:var(--position);top:7.57pt;width:159pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:67.84pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:17.17pt;width:159pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:99.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2015-12-04</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:55.5pt;position:var(--position);top:99.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2015-11</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:111pt;position:var(--position);top:99.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-506" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1303">96,924</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:165pt;position:var(--position);top:99.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-507" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1304">96,924</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:99.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-508" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="f-1305">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:270pt;position:var(--position);top:99.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-508" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1306">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:324pt;position:var(--position);top:99.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:20.3pt"></span></span><span style="left:22.93pt;position:var(--position)">(<ix:nonFraction unitRef="shares" contextRef="c-508" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1307">96,924</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:99.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-509" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1308">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:432pt;position:var(--position);top:99.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-509" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1309">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:486pt;position:var(--position);top:99.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-509" decimals="INF" name="abvx:MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet" format="ixt:fixed-zero" scale="0" id="f-1310">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:111.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2015-12-04</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:55.5pt;position:var(--position);top:111.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2015-12</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:111pt;position:var(--position);top:111.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-510" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1311">82,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:165pt;position:var(--position);top:111.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-511" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1312">16,400</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:111.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-512" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="f-1313">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:270pt;position:var(--position);top:111.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-512" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1314">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:324pt;position:var(--position);top:111.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:20.3pt"></span></span><span style="left:22.93pt;position:var(--position)">(<ix:nonFraction unitRef="shares" contextRef="c-512" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1315">16,400</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:111.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-513" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1316">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:432pt;position:var(--position);top:111.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-513" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1317">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:486pt;position:var(--position);top:111.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-513" decimals="INF" name="abvx:MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet" format="ixt:fixed-zero" scale="0" id="f-1318">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:123.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2017-09-18</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:55.5pt;position:var(--position);top:123.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2017-1</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:111pt;position:var(--position);top:123.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-514" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1319">16,400</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:165pt;position:var(--position);top:123.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-515" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1320">16,400</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:123.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-516" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="f-1321">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:270pt;position:var(--position);top:123.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-516" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1322">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:324pt;position:var(--position);top:123.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:20.3pt"></span></span><span style="left:22.93pt;position:var(--position)">(<ix:nonFraction unitRef="shares" contextRef="c-516" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1323">16,400</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:123.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-517" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1324">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:432pt;position:var(--position);top:123.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-517" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1325">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:486pt;position:var(--position);top:123.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-517" decimals="INF" name="abvx:MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet" format="ixt:fixed-zero" scale="0" id="f-1326">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:135.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2018-01-22</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:55.5pt;position:var(--position);top:135.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2018-1</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:111pt;position:var(--position);top:135.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-518" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1327">49,200</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:165pt;position:var(--position);top:135.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-519" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1328">16,400</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:135.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-520" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="f-1329">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:270pt;position:var(--position);top:135.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-520" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1330">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:324pt;position:var(--position);top:135.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-520" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1331">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:135.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-521" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1332">16,400</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:432pt;position:var(--position);top:135.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-521" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1333">16,400</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:486pt;position:var(--position);top:135.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-521" decimals="INF" name="abvx:MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet" format="ixt:num-dot-decimal" scale="0" id="f-1334">16,400</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:147.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2024-04-04</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:55.5pt;position:var(--position);top:147.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2024-1</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:111pt;position:var(--position);top:147.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-522" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1335">58,365</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:165pt;position:var(--position);top:147.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-523" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1336">58,365</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:147.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-524" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="f-1337">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:270pt;position:var(--position);top:147.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-524" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1338">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:324pt;position:var(--position);top:147.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:24.3pt"></span></span><span style="left:26.93pt;position:var(--position)">(<ix:nonFraction unitRef="shares" contextRef="c-524" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1339">4,863</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:147.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-525" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1340">53,502</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:432pt;position:var(--position);top:147.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.96pt"></span></span><span style="left:29.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-525" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1341">9,726</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:486pt;position:var(--position);top:147.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-525" decimals="INF" name="abvx:MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet" format="ixt:num-dot-decimal" scale="0" id="f-1342">53,502</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:159.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2024-04-04</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:55.5pt;position:var(--position);top:159.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2024-2</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:111pt;position:var(--position);top:159.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-526" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1343">19,455</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:165pt;position:var(--position);top:159.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-527" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1344">19,455</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:159.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-528" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="f-1345">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:270pt;position:var(--position);top:159.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-528" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1346">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:324pt;position:var(--position);top:159.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-528" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1347">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:159.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-529" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1348">19,455</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:432pt;position:var(--position);top:159.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.96pt"></span></span><span style="left:29.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-529" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1349">4,863</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:486pt;position:var(--position);top:159.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-529" decimals="INF" name="abvx:MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet" format="ixt:num-dot-decimal" scale="0" id="f-1350">19,455</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:171.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2025-01-13</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:55.5pt;position:var(--position);top:171.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2025-1</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:111pt;position:var(--position);top:171.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-530" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1351">100,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:165pt;position:var(--position);top:171.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-531" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1352">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:171.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-532" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1353">100,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:270pt;position:var(--position);top:171.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-532" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1354">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:324pt;position:var(--position);top:171.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-532" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1355">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:171.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-533" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1356">100,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:432pt;position:var(--position);top:171.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-533" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1357">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:486pt;position:var(--position);top:171.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-533" decimals="INF" name="abvx:MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet" format="ixt:num-dot-decimal" scale="0" id="f-1358">100,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:183.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2025-01-13</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:55.5pt;position:var(--position);top:183.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2025-2</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:111pt;position:var(--position);top:183.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-534" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1359">25,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:165pt;position:var(--position);top:183.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-535" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1360">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:183.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-536" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1361">25,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:270pt;position:var(--position);top:183.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-536" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1362">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:324pt;position:var(--position);top:183.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-536" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1363">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:183.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-537" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1364">25,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:432pt;position:var(--position);top:183.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-537" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1365">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:486pt;position:var(--position);top:183.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-537" decimals="INF" name="abvx:MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet" format="ixt:num-dot-decimal" scale="0" id="f-1366">25,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:195.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2025-04-22</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:55.5pt;position:var(--position);top:195.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2025-3</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:111pt;position:var(--position);top:195.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-538" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1367">39,370</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:165pt;position:var(--position);top:195.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-539" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1368">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:195.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-540" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1369">39,370</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:270pt;position:var(--position);top:195.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-540" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1370">&#8212;</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:324pt;position:var(--position);top:195.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-540" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1371">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:195.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-541" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1372">39,370</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:11.25pt;left:429pt;overflow:hidden;position:var(--position);top:195.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:432pt;position:var(--position);top:195.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-541" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1373">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:11.25pt;left:483pt;overflow:hidden;position:var(--position);top:195.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:-45.51pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">3</span></div><div style="line-height:8pt;position:var(--position);top:-35.91pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">9</span></div><div style="line-height:8pt;position:var(--position);top:-26.31pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.63pt;position:var(--position);text-decoration:none;white-space:pre">,</span></div><div style="line-height:8pt;position:var(--position);top:-16.71pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">3</span></div><div style="line-height:8pt;position:var(--position);top:-7.11pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">7</span></div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:486pt;position:var(--position);top:195.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-541" decimals="INF" name="abvx:MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet" format="ixt:num-dot-decimal" scale="0" id="f-1374">39,370</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:55.5pt;position:var(--position);top:207pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total BSAs</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:111pt;position:var(--position);top:207pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-542" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1375">486,714</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:165pt;position:var(--position);top:207pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-543" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1376">223,944</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:207pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-544" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1377">164,370</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:11.25pt;left:267pt;overflow:hidden;position:var(--position);top:207pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:270pt;position:var(--position);top:207pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-544" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1378">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:324pt;position:var(--position);top:207pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:16.3pt"></span></span><span style="left:18.93pt;position:var(--position)">(<ix:nonFraction unitRef="shares" contextRef="c-544" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1379">134,587</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:207pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-545" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1380">253,727</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:11.25pt;left:429pt;overflow:hidden;position:var(--position);top:207pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:432pt;position:var(--position);top:207pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-545" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1381">30,989</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:11.25pt;left:483pt;overflow:hidden;position:var(--position);top:207pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:486pt;position:var(--position);top:207pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-545" decimals="INF" name="abvx:MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet" format="ixt:num-dot-decimal" scale="0" id="f-1382">253,727</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:307.11pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">BSAs issued prior to January 1, 2024</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:333.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">These BSAs include a service condition under which the beneficiary must still be an employee, a corporate officer or a scientific </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:344.91pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">consultant of the Group at the time of vesting. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:367.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The exercise rights for most of these BSAs are vested annually and have the following vesting terms: </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:378.51pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-546" decimals="2" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="f-1383">25</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90.33pt;position:var(--position);text-decoration:none;white-space:pre"> of the award vests on the first anniversary of the date of grant for all currently issued BSAs; and </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:391.95pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">For the remaining </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:146.09pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-547" decimals="2" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="f-1384">75</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:164.42000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> of the award, the BSAs vest 1/48th per month over </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:372.58pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-547" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-1385">four years</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:412.82pt;position:var(--position);text-decoration:none;white-space:pre"> from the anniversary date of the grant. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:418.69pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">All of these BSAs plans include or partially include non-market performance conditions (positive results on clinic studies, signature of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:429.89pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">informed consent in a clinical phase, signing a license agreement, FDA authorization). The level of achievement of the non-market </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:441.09pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">performance conditions are taken into account in determining the number of BSAs allocated initially and reassessed at each closing </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:452.29pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">date. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:474.69pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In the event of a change of control or a M&amp;A transaction, all these BSAs will become immediately exercisable. A change of control is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:485.89pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">defined as a new investor/company holding directly or indirectly more than </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:339.82pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-548" decimals="2" name="abvx:VestingRequirementsForShareBasedPaymentArrangementChangeOfControlMinimumThreshold" scale="-2" id="f-1386">50</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:358.15pt;position:var(--position);text-decoration:none;white-space:pre"> of the share capital or voting rights. As such the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:497.09pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">probable vesting date of each plan corresponds to the weighted average of probable change of control dates. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:519.49pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">BSAs granted in March 2024</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:544.49pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In March 2024, the Group granted its independent Board members the right to subscribe up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:414.27pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-460" decimals="0" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1387">77,820</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:441.77pt;position:var(--position);text-decoration:none;white-space:pre"> share warrants (BSA) in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:555.99pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">aggregate, the vesting of which is subject to a service condition of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:302.63pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-460" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-1388">four years</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:342.87pt;position:var(--position);text-decoration:none;white-space:pre">, by tranches of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:406.98pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-460" decimals="2" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="f-1389">25</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:425.31pt;position:var(--position);text-decoration:none;white-space:pre"> each, vested on each anniversary </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:567.49pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">date. Additionally, the BSAs are subject to a vesting acceleration condition in case of a tender offer on the securities issued by the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:578.99pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Group and resulting in a change of control of the Group. All of the granted BSAs were subscribed by the beneficiaries in April 2024.</span></div></div></ix:continuation></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-38<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><ix:continuation id="f-1224-4" continuedAt="f-1224-5"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">BSAs granted in January and April 2025</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:92.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In January 2025, the Group granted its independent Board members, as well as one of its Board Observers and Advisor, the right to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:104.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">subscribe up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:99.00999999999999pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-549" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1390">125,000</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:131.51pt;position:var(--position);text-decoration:none;white-space:pre"> BSAs in the aggregate, the vesting of which is subject to a service condition of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:451.44pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-549" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-1391">four years</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:491.68pt;position:var(--position);text-decoration:none;white-space:pre">, by tranches of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:555.79pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-549" decimals="2" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="f-1392">25</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:574.12pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:115.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">each, vested on January 1 of each year. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:194.7pt;position:var(--position);text-decoration:none;white-space:pre">All of the granted BSAs were subscribed by the beneficiaries in February 2025.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:137.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In April 2025, the Group granted to one of its Board members the right to subscribe up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:395.98pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-550" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1393">39,370</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:423.48pt;position:var(--position);text-decoration:none;white-space:pre"> BSAs, the vesting of which is subject </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:148.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">to a service condition of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:135.05pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-550" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-1394">four years</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:175.29pt;position:var(--position);text-decoration:none;white-space:pre">, by tranches of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:239.4pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-550" decimals="2" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="f-1395">25</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:257.73pt;position:var(--position);text-decoration:none;white-space:pre"> each, vested on May 1 of each year. The BSAs were subscribed in May 2025.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:171.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Additionally, the BSAs are subject to a vesting acceleration condition in case of a tender offer on the securities issued by the Group </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:182.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and resulting in a change of control of the Group.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:204.96pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory" id="f-1396" continuedAt="f-1396-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The fair value of the BSAs was determined at grant date using the Black Scholes model, with the following assumptions:</span></ix:nonNumeric></div><ix:continuation id="f-1396-1" continuedAt="f-1396-2"><div style="position:var(--position);top:227.36pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:540pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:51pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:60.75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:58.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:58.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:58.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:58.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:53.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:58.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:58.5pt"/></tr><tr style="height:41.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:51pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.84pt;position:var(--position);white-space:pre">TYPE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:54pt;position:var(--position);width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:60.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.62pt;position:var(--position);white-space:pre">FAIR VALUE </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:60.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.38pt;position:var(--position);white-space:pre">OF THE </span></div><div style="line-height:8pt;position:var(--position);top:21.83pt;width:60.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.07pt;position:var(--position);white-space:pre">UNDERLYING </span></div><div style="line-height:8pt;position:var(--position);top:31.43pt;width:60.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.61pt;position:var(--position);white-space:pre">SHARE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:117.75pt;position:var(--position);width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.5pt;position:var(--position);white-space:pre">FAIR VALUE </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.49pt;position:var(--position);white-space:pre">OF THE BSA</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:179.25pt;position:var(--position);width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.94pt;position:var(--position);white-space:pre">NUMBER OF </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:19.92pt;position:var(--position);white-space:pre">BSAs</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.27pt;position:var(--position);white-space:pre">SUBSCRIPTI</span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.82pt;position:var(--position);white-space:pre">ON PRICE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:302.25pt;position:var(--position);width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.15pt;position:var(--position);white-space:pre">STRIKE </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.83pt;position:var(--position);white-space:pre">PRICE PER </span></div><div style="line-height:8pt;position:var(--position);top:21.83pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.48pt;position:var(--position);white-space:pre">SHARE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:363.75pt;position:var(--position);width:53.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:53.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.2pt;position:var(--position);white-space:pre">RISK FREE </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:53.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.52pt;position:var(--position);white-space:pre">RATE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:420pt;position:var(--position);width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.49pt;position:var(--position);white-space:pre">EXPECTED </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.05pt;position:var(--position);white-space:pre">MATURITY</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:481.5pt;position:var(--position);width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.71pt;position:var(--position);white-space:pre">VOLATILITY</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:41.25pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA 2024-1</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:54pt;position:var(--position);top:41.25pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-522" decimals="2" name="abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1397">14.06</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:117.75pt;position:var(--position);top:41.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:11.26pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:13.92pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-551" decimals="1" name="abvx:EquityInstrumentFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1398">5.7</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:27.92pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:30.58pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-552" decimals="1" name="abvx:EquityInstrumentFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1399">6.5</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.58pt;position:var(--position);white-space:pre">]</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:179.25pt;position:var(--position);top:41.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:18.25pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-522" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1400">58,365</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);top:41.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-522" decimals="2" name="abvx:EquityInstrumentPriceOtherEquityInstrumentsGranted" scale="0" id="f-1401">2.57</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:302.25pt;position:var(--position);top:41.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:19.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-522" decimals="2" name="abvx:EquityInstrumentStrikePriceOtherEquityInstrumentsGranted" scale="0" id="f-1402">13.10</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:363.75pt;position:var(--position);top:41.25pt;width:53.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:53.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.23pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-522" decimals="4" name="abvx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="f-1403">4.30</ix:nonFraction>%</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:420pt;position:var(--position);top:41.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.15pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.8100000000000005pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-551" name="abvx:ExpectedMaturityOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="f-1404">5.4</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.810000000000002pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.47pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-552" name="abvx:ExpectedMaturityOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="f-1405">6.9</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:30.47pt;position:var(--position);white-space:pre"> years]</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:481.5pt;position:var(--position);top:41.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.86pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-522" decimals="4" name="abvx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="f-1406">60.41</ix:nonFraction>%</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:53.25pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:51pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA 2024-2</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:54pt;position:var(--position);top:53.25pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-526" decimals="2" name="abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1407">14.06</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:117.75pt;position:var(--position);top:53.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:11.26pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:13.92pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-553" decimals="1" name="abvx:EquityInstrumentFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1408">5.8</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:27.92pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:30.58pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-554" decimals="1" name="abvx:EquityInstrumentFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1409">6.6</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.58pt;position:var(--position);white-space:pre">]</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:179.25pt;position:var(--position);top:53.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:18.25pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-526" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1410">19,455</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);top:53.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-526" decimals="2" name="abvx:EquityInstrumentPriceOtherEquityInstrumentsGranted" scale="0" id="f-1411">2.57</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:302.25pt;position:var(--position);top:53.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:19.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-526" decimals="2" name="abvx:EquityInstrumentStrikePriceOtherEquityInstrumentsGranted" scale="0" id="f-1412">13.10</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:363.75pt;position:var(--position);top:53.25pt;width:53.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:53.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.23pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-526" decimals="4" name="abvx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="f-1413">4.30</ix:nonFraction>%</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:420pt;position:var(--position);top:53.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.15pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.8100000000000005pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-553" name="abvx:ExpectedMaturityOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="f-1414">5.5</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.810000000000002pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.47pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-554" name="abvx:ExpectedMaturityOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="f-1415">7.0</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:30.47pt;position:var(--position);white-space:pre"> years]</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:481.5pt;position:var(--position);top:53.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.86pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-526" decimals="4" name="abvx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="f-1416">60.41</ix:nonFraction>%</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:65.25pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2025-1</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:54pt;position:var(--position);top:65.25pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:22.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-530" decimals="2" name="abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1417">6.13</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:117.75pt;position:var(--position);top:65.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:11.26pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:13.92pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-555" decimals="1" name="abvx:EquityInstrumentFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1418">3.5</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:27.92pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:30.58pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-556" decimals="1" name="abvx:EquityInstrumentFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1419">3.9</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.58pt;position:var(--position);white-space:pre">]</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:179.25pt;position:var(--position);top:65.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:16.25pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-530" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1420">100,000</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);top:65.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-530" decimals="2" name="abvx:EquityInstrumentPriceOtherEquityInstrumentsGranted" scale="0" id="f-1421">2.00</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:302.25pt;position:var(--position);top:65.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-530" decimals="2" name="abvx:EquityInstrumentStrikePriceOtherEquityInstrumentsGranted" scale="0" id="f-1422">6.63</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:363.75pt;position:var(--position);top:65.25pt;width:53.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:53.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.23pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-530" decimals="4" name="abvx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="f-1423">4.65</ix:nonFraction>%</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:420pt;position:var(--position);top:65.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.15pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.8100000000000005pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-555" name="abvx:ExpectedMaturityOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="f-1424">5.5</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.810000000000002pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.47pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-556" name="abvx:ExpectedMaturityOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="f-1425">7.0</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:30.47pt;position:var(--position);white-space:pre"> years]</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:481.5pt;position:var(--position);top:65.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.86pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-530" decimals="4" name="abvx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="f-1426">60.88</ix:nonFraction>%</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:77.25pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2025-2</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:54pt;position:var(--position);top:77.25pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:22.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-534" decimals="2" name="abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1427">6.13</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:117.75pt;position:var(--position);top:77.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:11.26pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:13.92pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-557" decimals="1" name="abvx:EquityInstrumentFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1428">3.5</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:27.92pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:30.58pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-558" decimals="1" name="abvx:EquityInstrumentFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1429">3.9</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.58pt;position:var(--position);white-space:pre">]</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:179.25pt;position:var(--position);top:77.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:18.25pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-534" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1430">25,000</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);top:77.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-534" decimals="2" name="abvx:EquityInstrumentPriceOtherEquityInstrumentsGranted" scale="0" id="f-1431">2.00</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:302.25pt;position:var(--position);top:77.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-534" decimals="2" name="abvx:EquityInstrumentStrikePriceOtherEquityInstrumentsGranted" scale="0" id="f-1432">6.63</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:363.75pt;position:var(--position);top:77.25pt;width:53.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:53.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.23pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-534" decimals="4" name="abvx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="f-1433">4.65</ix:nonFraction>%</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:420pt;position:var(--position);top:77.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.15pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.8100000000000005pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-557" name="abvx:ExpectedMaturityOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="f-1434">5.5</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.810000000000002pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.47pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-558" name="abvx:ExpectedMaturityOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="f-1435">7.0</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:30.47pt;position:var(--position);white-space:pre"> years]</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:481.5pt;position:var(--position);top:77.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.86pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-534" decimals="4" name="abvx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="f-1436">60.88</ix:nonFraction>%</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:89.25pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2025-3</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:54pt;position:var(--position);top:89.25pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:22.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-538" decimals="2" name="abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1437">6.48</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:117.75pt;position:var(--position);top:89.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:11.26pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:13.92pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-559" decimals="1" name="abvx:EquityInstrumentFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1438">3.7</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:27.92pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:30.58pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-560" decimals="1" name="abvx:EquityInstrumentFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1439">4.1</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.58pt;position:var(--position);white-space:pre">]</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:179.25pt;position:var(--position);top:89.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:18.25pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-538" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1440">39,370</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);top:89.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-538" decimals="2" name="abvx:EquityInstrumentPriceOtherEquityInstrumentsGranted" scale="0" id="f-1441">1.27</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:302.25pt;position:var(--position);top:89.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-538" decimals="2" name="abvx:EquityInstrumentStrikePriceOtherEquityInstrumentsGranted" scale="0" id="f-1442">6.41</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:363.75pt;position:var(--position);top:89.25pt;width:53.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:53.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.23pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-538" decimals="4" name="abvx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="f-1443">3.92</ix:nonFraction>%</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:420pt;position:var(--position);top:89.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.15pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.8100000000000005pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-559" name="abvx:ExpectedMaturityOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="f-1444">5.5</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.810000000000002pt;position:var(--position);white-space:pre">- </span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.47pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-560" name="abvx:ExpectedMaturityOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="f-1445">7.0</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.47pt;position:var(--position);white-space:pre">years]</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:481.5pt;position:var(--position);top:89.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.86pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-538" decimals="4" name="abvx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="f-1446">60.69</ix:nonFraction>%</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/></tr></tbody></table></div></div></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:361.06pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">AGAs</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:379.56pt;width:612pt"><ix:continuation id="f-1225-6" continuedAt="f-1225-7"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">The following tables summarize the data relating to AGAs as well as the assumptions used for the measurement thereof in </span></ix:continuation></div><ix:continuation id="f-1225-7" continuedAt="f-1225-8"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:391.56pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">accordance with IFRS 2&#8212;</span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:149.28pt;position:var(--position);text-decoration:none;white-space:pre">Share-based Payment</span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:236.7pt;position:var(--position);text-decoration:none;white-space:pre">:</span></div></ix:continuation></div></ix:continuation></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-39<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><ix:continuation id="f-1225-8"><ix:continuation id="f-1224-5" continuedAt="f-1224-6"><div><div style="position:var(--position);top:70.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:537.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:64.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:64.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:64.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:64.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:64.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:64.5pt"/><td style="padding:0;width:5.25pt"/><td style="padding:0;width:65.25pt"/></tr><tr style="height:47.25pt"><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:38.25pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.72pt;position:var(--position);text-decoration:none;white-space:pre">GRANT&#160;DATE </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:38.25pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.59pt;position:var(--position);text-decoration:none;white-space:pre">TYPE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:28.65pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.38pt;position:var(--position);text-decoration:none;white-space:pre">Total NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:38.25pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.26pt;position:var(--position);text-decoration:none;white-space:pre">OF AGAs </span></div><div style="line-height:8pt;position:var(--position);top:47.85pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.82pt;position:var(--position);text-decoration:none;white-space:pre">ISSUED</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:25.87pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.31pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER OF </span></div><div style="line-height:8pt;position:var(--position);top:35.47pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.19pt;position:var(--position);text-decoration:none;white-space:pre">AGAs </span></div><div style="line-height:8pt;position:var(--position);top:45.07pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.87pt;position:var(--position);text-decoration:none;white-space:pre">OUTSTANDING </span></div><div style="line-height:8pt;position:var(--position);top:54.67pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.97pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:64.27pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.31pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY 1, </span></div><div style="line-height:8pt;position:var(--position);top:73.87pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:15.82pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.94pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER OF </span></div><div style="line-height:8pt;position:var(--position);top:25.42pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.38pt;position:var(--position);text-decoration:none;white-space:pre">ISSUED AGAs</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:15.82pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.94pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER OF </span></div><div style="line-height:8pt;position:var(--position);top:25.42pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.05pt;position:var(--position);text-decoration:none;white-space:pre">LAPSED AGAs</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:15.82pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.94pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER OF </span></div><div style="line-height:8pt;position:var(--position);top:25.42pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.83pt;position:var(--position);text-decoration:none;white-space:pre">VESTED AGAs</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:11.02pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.31pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER OF </span></div><div style="line-height:8pt;position:var(--position);top:20.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.19pt;position:var(--position);text-decoration:none;white-space:pre">AGAs </span></div><div style="line-height:8pt;position:var(--position);top:30.22pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.87pt;position:var(--position);text-decoration:none;white-space:pre">OUTSTANDING </span></div></div></div></td></tr><tr style="height:35.25pt"><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td colspan="6" style="font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:47.25pt;width:204.75pt"><div><div style="line-height:8pt;position:var(--position);top:26.62pt;width:204.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:37.92pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED DECEMBER 31, 2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:47.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:6.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.91pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:16.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.47pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.56pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:82.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">07/11/23</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:82.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2023-1</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:82.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.46pt"></span></span><span style="left:29.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-561" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1447">1,382,796</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:82.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-562" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1448">780,040</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:82.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-563" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="f-1449">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:82.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-563" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1450">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:82.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.8pt"></span></span><span style="left:32.43pt;position:var(--position)">(<ix:nonFraction unitRef="shares" contextRef="c-563" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1451">230,464</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:82.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-564" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1452">549,576</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:94.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">07/11/23</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:94.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2023-2</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:94.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.46pt"></span></span><span style="left:35.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-565" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1453">100,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:94.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-566" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1454">75,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:94.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-567" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="f-1455">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:94.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.8pt"></span></span><span style="left:36.43pt;position:var(--position)">(<ix:nonFraction unitRef="shares" contextRef="c-567" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1456">75,000</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:94.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-567" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1457">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:94.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-568" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1458">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:106.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">09/28/23</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:106.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2023-3</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:106.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.46pt"></span></span><span style="left:35.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-569" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1459">731,500</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:106.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-570" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1460">485,875</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:106.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-571" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="f-1461">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:106.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.8pt"></span></span><span style="left:36.43pt;position:var(--position)">(<ix:nonFraction unitRef="shares" contextRef="c-571" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1462">34,750</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:106.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.8pt"></span></span><span style="left:32.43pt;position:var(--position)">(<ix:nonFraction unitRef="shares" contextRef="c-571" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1463">251,125</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:106.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-572" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1464">200,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:118.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">09/28/23</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:118.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2023-4</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:118.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.46pt"></span></span><span style="left:35.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-573" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1465">254,250</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:118.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-574" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1466">213,250</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:118.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-575" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="f-1467">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:118.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.8pt"></span></span><span style="left:36.43pt;position:var(--position)">(<ix:nonFraction unitRef="shares" contextRef="c-575" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1468">15,000</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:118.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.8pt"></span></span><span style="left:32.43pt;position:var(--position)">(<ix:nonFraction unitRef="shares" contextRef="c-575" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1469">108,500</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:118.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-576" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1470">89,750</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:130.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">12/01/23</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:130.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2023-5</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:130.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.46pt"></span></span><span style="left:35.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-577" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1471">132,750</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:130.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-578" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1472">81,250</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:130.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-579" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="f-1473">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:130.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.8pt"></span></span><span style="left:36.43pt;position:var(--position)">(<ix:nonFraction unitRef="shares" contextRef="c-579" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1474">26,000</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:130.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.8pt"></span></span><span style="left:36.43pt;position:var(--position)">(<ix:nonFraction unitRef="shares" contextRef="c-579" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1475">27,625</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:130.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-580" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1476">27,625</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:142.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">02/01/24</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:142.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-1</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:142.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.46pt"></span></span><span style="left:29.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-581" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1477">1,549,125</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:142.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:27.21pt"></span></span><span style="left:29.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-582" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1478">1,355,625</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:142.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-583" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="f-1479">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:142.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.8pt"></span></span><span style="left:32.43pt;position:var(--position)">(<ix:nonFraction unitRef="shares" contextRef="c-583" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1480">134,125</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:142.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-583" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1481">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:142.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:27.21pt"></span></span><span style="left:29.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-584" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1482">1,221,500</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:154.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">03/28/24</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:154.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-2</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:154.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-585" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1483">22,500</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:154.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-586" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1484">22,500</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:154.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-587" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="f-1485">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:154.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-587" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1486">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:154.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-587" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1487">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:154.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-588" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1488">22,500</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:166.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">05/23/24</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:166.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-3</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:166.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-589" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1489">38,500</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:166.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-590" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1490">38,500</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:166.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-591" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="f-1491">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:166.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.8pt"></span></span><span style="left:36.43pt;position:var(--position)">(<ix:nonFraction unitRef="shares" contextRef="c-591" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1492">13,000</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:166.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-591" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1493">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:166.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-592" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1494">25,500</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:178.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">07/11/24</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:178.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-4</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:178.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-593" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1495">93,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:178.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-594" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1496">93,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:178.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-595" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="f-1497">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:178.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-595" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1498">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:178.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-595" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1499">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:178.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-596" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1500">93,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:190.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">07/11/24</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:190.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-5</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:190.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-597" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1501">25,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:190.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-598" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1502">25,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:190.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-599" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="f-1503">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:190.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-599" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1504">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:190.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-599" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1505">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:190.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-600" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1506">25,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:202.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">07/11/24</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:202.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-6</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:202.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-98" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1507">20,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:202.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-601" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1508">20,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:202.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-602" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="f-1509">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:202.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-602" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1510">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:202.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.8pt"></span></span><span style="left:36.43pt;position:var(--position)">(<ix:nonFraction unitRef="shares" contextRef="c-602" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1511">10,000</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:202.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-603" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1512">10,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:214.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">09/05/24</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:214.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-7</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:214.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.46pt"></span></span><span style="left:35.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-604" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1513">198,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:214.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-605" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1514">198,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:214.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-606" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="f-1515">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:214.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-606" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1516">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:214.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-606" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1517">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:214.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-607" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1518">198,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:226.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">02/06/25</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:226.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-1</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:226.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.46pt"></span></span><span style="left:29.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-608" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1519">4,319,500</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:226.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-609" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1520">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:226.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.46pt"></span></span><span style="left:29.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-610" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1521">4,319,500</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:226.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.8pt"></span></span><span style="left:32.43pt;position:var(--position)">(<ix:nonFraction unitRef="shares" contextRef="c-610" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1522">217,500</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:226.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-610" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1523">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:226.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:27.21pt"></span></span><span style="left:29.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-611" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1524">4,102,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:238.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">02/06/25</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:238.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-2</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:238.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.46pt"></span></span><span style="left:35.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-612" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1525">123,102</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:238.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-613" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1526">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:238.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.46pt"></span></span><span style="left:35.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-614" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1527">123,102</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:238.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-614" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1528">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:238.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-614" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1529">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:238.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-615" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1530">123,102</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:250.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">02/06/25</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:250.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-3</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:250.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-616" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1531">17,625</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:250.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-617" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1532">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:250.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-618" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1533">17,625</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:250.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-618" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1534">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:250.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-618" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1535">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:250.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-619" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1536">17,625</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:262.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">02/06/25</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:262.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-4</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:262.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-620" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1537">30,500</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:262.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-621" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1538">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:262.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-622" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1539">30,500</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:262.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-622" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1540">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:262.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-622" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1541">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:262.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-623" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1542">30,500</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:274.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">03/20/25</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:274.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-5</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:274.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-624" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1543">50,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:274.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-625" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1544">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:274.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-626" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1545">50,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:274.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.8pt"></span></span><span style="left:36.43pt;position:var(--position)">(<ix:nonFraction unitRef="shares" contextRef="c-626" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1546">50,000</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:274.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-626" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1547">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:274.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-627" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1548">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:286.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">05/30/25</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:286.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-6</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:286.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-628" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1549">25,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:286.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-629" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1550">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:286.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-630" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1551">25,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:286.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-630" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1552">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:286.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-630" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1553">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:286.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-631" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1554">25,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:298.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">08/01/25</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:298.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-7</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:298.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.46pt"></span></span><span style="left:29.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-632" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1555">1,711,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:298.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-633" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1556">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:298.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.46pt"></span></span><span style="left:29.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-634" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1557">1,711,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:298.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.8pt"></span></span><span style="left:36.43pt;position:var(--position)">(<ix:nonFraction unitRef="shares" contextRef="c-634" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1558">80,000</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:298.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-634" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1559">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:298.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:27.21pt"></span></span><span style="left:29.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-635" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1560">1,631,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:310.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">11/13/25</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:310.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-8</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:310.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.46pt"></span></span><span style="left:43.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-636" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1561">4,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:310.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-637" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1562">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:310.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.46pt"></span></span><span style="left:43.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-638" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1563">4,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:310.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-638" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1564">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:310.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-638" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1565">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:310.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-639" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1566">4,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:322.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total AGAs</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:132pt;overflow:hidden;position:var(--position);top:322.5pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:322.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:22.46pt"></span></span><span style="left:25.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-640" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1567">10,828,148</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:322.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:27.21pt"></span></span><span style="left:29.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-641" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1568">3,388,040</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:322.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:26.46pt"></span></span><span style="left:29.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-642" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1569">6,280,727</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:322.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.8pt"></span></span><span style="left:32.43pt;position:var(--position)">(<ix:nonFraction unitRef="shares" contextRef="c-642" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1570">645,375</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:322.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.8pt"></span></span><span style="left:32.43pt;position:var(--position)">(<ix:nonFraction unitRef="shares" contextRef="c-642" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1571">627,714</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:322.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:27.21pt"></span></span><span style="left:29.84pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-643" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1572">8,395,678</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div></div></ix:continuation></ix:continuation></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-40<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><ix:continuation id="f-1224-6" continuedAt="f-1224-7"><div><div style="position:var(--position);top:70.56pt;width:612pt"><ix:continuation id="f-1396-2" continuedAt="f-1396-3"><div style="font-size:0pt;left:36pt;position:var(--position);width:540pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:72pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:75pt"/></tr><tr style="height:41.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:17.62pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.84pt;position:var(--position);text-decoration:none;white-space:pre">TYPE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);width:72pt"><div><div style="line-height:8pt;position:var(--position);top:3.22pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.7pt;position:var(--position);text-decoration:none;white-space:pre">FAIR&#160;VALUE&#160;OF </span></div><div style="line-height:8pt;position:var(--position);top:12.82pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:27.56pt;position:var(--position);text-decoration:none;white-space:pre">THE </span></div><div style="line-height:8pt;position:var(--position);top:22.42pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.69pt;position:var(--position);text-decoration:none;white-space:pre">UNDERLYING </span></div><div style="line-height:8pt;position:var(--position);top:32.02pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.23pt;position:var(--position);text-decoration:none;white-space:pre">SHARE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:12.82pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.2pt;position:var(--position);text-decoration:none;white-space:pre">FAIR&#160;VALUE OF </span></div><div style="line-height:8pt;position:var(--position);top:22.42pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:19.18pt;position:var(--position);text-decoration:none;white-space:pre">THE AGA</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:17.62pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.19pt;position:var(--position);text-decoration:none;white-space:pre">AGA PRICE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:17.62pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.3pt;position:var(--position);text-decoration:none;white-space:pre">MATURITY</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:17.62pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.96pt;position:var(--position);text-decoration:none;white-space:pre">VOLATILITY </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:17.62pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.97pt;position:var(--position);text-decoration:none;white-space:pre">RISK&#160;FREE&#160;RATE</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:41.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:1.73pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-1 </span></div><div style="line-height:9pt;position:var(--position);top:12.98pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(Tranches 1-4)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:41.25pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-644" decimals="2" name="abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1573">15.98</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:41.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-644" decimals="2" name="abvx:EquityInstrumentFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1574">15.98</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:41.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-644" decimals="2" name="abvx:EquityInstrumentPriceOtherEquityInstrumentsGranted" scale="0" id="f-1575">0.00</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:41.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:41.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:41.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:63pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:1.73pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-1 </span></div><div style="line-height:9pt;position:var(--position);top:12.98pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(Tranche 5)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:63pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-645" decimals="2" name="abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1576">15.98</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:63pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-645" decimals="2" name="abvx:EquityInstrumentFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1577">3.62</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:63pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-645" decimals="2" name="abvx:EquityInstrumentPriceOtherEquityInstrumentsGranted" scale="0" id="f-1578">0.00</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:63pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:16.51pt;position:var(--position);text-decoration:none;white-space:pre">2024-12-31</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:63pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:26.82pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-645" decimals="3" name="abvx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="f-1579">67.2</ix:nonFraction>%</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:63pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:26.82pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-645" decimals="4" name="abvx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="f-1580">3.20</ix:nonFraction>%</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:84.75pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:1.73pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-1 </span></div><div style="line-height:9pt;position:var(--position);top:12.98pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(Tranche 6)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:84.75pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-646" decimals="2" name="abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1581">15.98</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:84.75pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-646" decimals="2" name="abvx:EquityInstrumentFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1582">0.74</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:84.75pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-646" decimals="2" name="abvx:EquityInstrumentPriceOtherEquityInstrumentsGranted" scale="0" id="f-1583">0.00</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:84.75pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:16.51pt;position:var(--position);text-decoration:none;white-space:pre">2024-07-11</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:84.75pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:26.82pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-646" decimals="3" name="abvx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="f-1584">67.2</ix:nonFraction>%</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:84.75pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:26.82pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-646" decimals="4" name="abvx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="f-1585">3.20</ix:nonFraction>%</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:106.5pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:1.73pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-2 </span></div><div style="line-height:9pt;position:var(--position);top:12.98pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(Tranche 1)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:106.5pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-647" decimals="2" name="abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1586">15.98</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:106.5pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-647" decimals="2" name="abvx:EquityInstrumentFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1587">15.98</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:106.5pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-647" decimals="2" name="abvx:EquityInstrumentPriceOtherEquityInstrumentsGranted" scale="0" id="f-1588">0.00</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:106.5pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:106.5pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:106.5pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:128.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:1.73pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-2 </span></div><div style="line-height:9pt;position:var(--position);top:12.98pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(Tranche 2)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:128.25pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-648" decimals="2" name="abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1589">15.98</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:128.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-648" decimals="2" name="abvx:EquityInstrumentFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1590">9.59</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:128.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-648" decimals="2" name="abvx:EquityInstrumentPriceOtherEquityInstrumentsGranted" scale="0" id="f-1591">0.00</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:128.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:128.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:128.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:150pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-3</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:150pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-569" decimals="2" name="abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1592">14.92</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:150pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-569" decimals="2" name="abvx:EquityInstrumentFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1593">14.92</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:150pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-569" decimals="2" name="abvx:EquityInstrumentPriceOtherEquityInstrumentsGranted" scale="0" id="f-1594">0.00</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:150pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:150pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:150pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:162pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-4</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:162pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-573" decimals="2" name="abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1595">14.92</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:162pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-573" decimals="2" name="abvx:EquityInstrumentFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1596">14.92</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:162pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-573" decimals="2" name="abvx:EquityInstrumentPriceOtherEquityInstrumentsGranted" scale="0" id="f-1597">0.00</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:162pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:162pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:162pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:174pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-5</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:174pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-577" decimals="2" name="abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1598">9.16</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:174pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-577" decimals="2" name="abvx:EquityInstrumentFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1599">9.16</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:174pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-577" decimals="2" name="abvx:EquityInstrumentPriceOtherEquityInstrumentsGranted" scale="0" id="f-1600">0.00</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:174pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:174pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:174pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:186pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2024-1</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:186pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-581" decimals="2" name="abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1601">12.26</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:186pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-581" decimals="2" name="abvx:EquityInstrumentFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1602">12.26</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:186pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-581" decimals="2" name="abvx:EquityInstrumentPriceOtherEquityInstrumentsGranted" scale="0" id="f-1603">0.00</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:186pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:186pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:186pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:198pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2024-2</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:198pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-585" decimals="2" name="abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1604">13.40</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:198pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-585" decimals="2" name="abvx:EquityInstrumentFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1605">13.40</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:198pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-585" decimals="2" name="abvx:EquityInstrumentPriceOtherEquityInstrumentsGranted" scale="0" id="f-1606">0.00</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:198pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:198pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:198pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:210pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-3</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:210pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-589" decimals="2" name="abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1607">12.76</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:210pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-589" decimals="2" name="abvx:EquityInstrumentFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1608">12.76</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:210pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-589" decimals="2" name="abvx:EquityInstrumentPriceOtherEquityInstrumentsGranted" scale="0" id="f-1609">0.00</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:210pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:210pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:210pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:222pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-4</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:222pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-593" decimals="2" name="abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1610">12.54</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:222pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-593" decimals="2" name="abvx:EquityInstrumentFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1611">12.54</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:222pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-593" decimals="2" name="abvx:EquityInstrumentPriceOtherEquityInstrumentsGranted" scale="0" id="f-1612">0.00</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:222pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:222pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:222pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:234pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-5</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:234pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-597" decimals="2" name="abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1613">12.54</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:234pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-597" decimals="2" name="abvx:EquityInstrumentFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1614">12.54</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:234pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-597" decimals="2" name="abvx:EquityInstrumentPriceOtherEquityInstrumentsGranted" scale="0" id="f-1615">0.00</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:234pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:234pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:234pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:246pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-6</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:246pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-98" decimals="2" name="abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1616">12.54</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:246pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-98" decimals="2" name="abvx:EquityInstrumentFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1617">12.54</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:246pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-98" decimals="2" name="abvx:EquityInstrumentPriceOtherEquityInstrumentsGranted" scale="0" id="f-1618">0.00</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:246pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:246pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:246pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:258pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-7</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:258pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-604" decimals="2" name="abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1619">10.80</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:258pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-604" decimals="2" name="abvx:EquityInstrumentFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1620">10.80</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:258pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-604" decimals="2" name="abvx:EquityInstrumentPriceOtherEquityInstrumentsGranted" scale="0" id="f-1621">0.00</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:258pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:258pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:258pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:270pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-1</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:270pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-608" decimals="2" name="abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1622">5.82</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:270pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-608" decimals="2" name="abvx:EquityInstrumentFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1623">5.82</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:270pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-608" decimals="2" name="abvx:EquityInstrumentPriceOtherEquityInstrumentsGranted" scale="0" id="f-1624">0.00</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:270pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:270pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:270pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:282pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-2</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:282pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-612" decimals="2" name="abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1625">5.82</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:282pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-612" decimals="2" name="abvx:EquityInstrumentFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1626">5.82</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:282pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-612" decimals="2" name="abvx:EquityInstrumentPriceOtherEquityInstrumentsGranted" scale="0" id="f-1627">0.00</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:282pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:282pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:282pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:294pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-3</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:294pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-616" decimals="2" name="abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1628">5.82</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:294pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-616" decimals="2" name="abvx:EquityInstrumentFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1629">5.82</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:294pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-616" decimals="2" name="abvx:EquityInstrumentPriceOtherEquityInstrumentsGranted" scale="0" id="f-1630">0.00</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:294pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:294pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:294pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:306pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-4</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:306pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-620" decimals="2" name="abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1631">5.82</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:306pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-620" decimals="2" name="abvx:EquityInstrumentFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1632">5.82</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:306pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-620" decimals="2" name="abvx:EquityInstrumentPriceOtherEquityInstrumentsGranted" scale="0" id="f-1633">0.00</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:306pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:306pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:306pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:318pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-5</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:318pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-624" decimals="2" name="abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1634">6.17</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:318pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-624" decimals="2" name="abvx:EquityInstrumentFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1635">6.17</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:318pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-624" decimals="2" name="abvx:EquityInstrumentPriceOtherEquityInstrumentsGranted" scale="0" id="f-1636">0.00</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:318pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:318pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:318pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:330pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-6</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:330pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-628" decimals="2" name="abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1637">5.17</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:330pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-628" decimals="2" name="abvx:EquityInstrumentFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1638">5.17</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:330pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-628" decimals="2" name="abvx:EquityInstrumentPriceOtherEquityInstrumentsGranted" scale="0" id="f-1639">0.00</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:330pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:330pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:330pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:342pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-7</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:342pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-632" decimals="2" name="abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1640">61.20</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:342pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-632" decimals="2" name="abvx:EquityInstrumentFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1641">61.20</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:342pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-632" decimals="2" name="abvx:EquityInstrumentPriceOtherEquityInstrumentsGranted" scale="0" id="f-1642">0.00</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:342pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:342pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:342pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:354pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-8</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:354pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-636" decimals="2" name="abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1643">89.40</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:354pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-636" decimals="2" name="abvx:EquityInstrumentFairValueOtherEquityInstrumentsGranted" scale="0" id="f-1644">89.40</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:354pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-636" decimals="2" name="abvx:EquityInstrumentPriceOtherEquityInstrumentsGranted" scale="0" id="f-1645">0.00</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:354pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:354pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:354pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr></tbody></table></div></div></ix:continuation></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:468.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">AGAs granted in July 2023</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:490.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(a) Pursuant to a Board decision on July 11, 2023, the Group allocated a total number of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:390.95pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-649" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1646">1,382,796</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:430.95pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs to Mr. Marc de Garidel, as </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:501.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the Group&#8217;s Chief Executive Officer, to which performance conditions and service conditions apply (AGA plan 2023-1):</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:524.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">For </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:88.39pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-650" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1647">212,738</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.89pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs 2023-1 (tranche 1): the acquisition period shall end on the first anniversary of the allocation date; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:535.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">For </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:88.39pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-651" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1648">638,214</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.89pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs 2023-1 (tranche 2): the AGAs 2023-1 shall progressively be definitively acquired on a monthly basis over </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:546.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">a period of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:117.78999999999999pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-651" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-1649">three years</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:161.32999999999998pt;position:var(--position);text-decoration:none;white-space:pre"> starting after the first anniversary of the allocation date;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:557.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">For </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:88.39pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-652" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1650">212,738</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.89pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs 2023-1 (tranche 3): the acquisition period shall end on the latest date between (i) the first anniversary of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:568.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the allocation date, and (ii) the date on which a specific performance condition related to regulatory approval is fulfilled; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:580.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">For </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:88.39pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-653" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1651">106,369</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.89pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs 2023-1 (tranche 4): the acquisition period shall end on the latest date between (i) the first anniversary of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:591.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the allocation date, and (ii) the date on which the Group successfully completes a public offering raising at least </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:521.4200000000001pt;position:var(--position);text-decoration:none;white-space:pre">$<ix:nonFraction unitRef="usd" contextRef="c-653" decimals="-6" name="abvx:VestingRequirementsForShareBasedPaymentArrangementPerformanceConditionsMinimumFinancing" scale="6" id="f-1652">100</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:572.77pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:602.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">in gross proceeds (the condition was met on October 24, 2023); </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:613.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">For </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:88.39pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-654" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1653">106,369</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.89pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs 2023-1 (tranche 5): the acquisition period shall end on the latest date between (i) the first anniversary of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:624.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the allocation date, and (ii) the date on which a specific performance condition related to the Group&#8217;s market capitalization is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:636.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">fulfilled; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:647.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">For </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:88.39pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-655" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1654">106,368</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.89pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs 2023-1 (tranche 6): the acquisition period shall end on the first anniversary of the allocation date subject </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:658.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to the completion, prior to such date, of a tender offer on the securities issued by the Group, at a predetermined minimum </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:669.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">price, and resulting in a change of control of the Group; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:680.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Additionally, AGAs related to tranches 1 to 5 are subject to a vesting acceleration condition in case of a tender offer on the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:692.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">securities issued by the Group and resulting in a change of control of the Group.</span></div></div></ix:continuation></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-41<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><ix:continuation id="f-1224-7" continuedAt="f-1224-8"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group qualified those conditions under IFRS 2 principles as follows:</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:92.96pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Conditions related to tranches 1 and 2 qualify as service conditions under IFRS 2 principles.</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:106.4pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Conditions related to tranches 3 and 4 qualify as service and non-market performance conditions. Their levels of achievement </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:119.84pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">are reflected in the number of instruments that are expected to vest and were estimated by management based on observable </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:133.28pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">industry-specific data.</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:146.72pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Conditions related to tranches 5 and 6 qualify as service and market performance conditions. The levels of achievement of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:160.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">market conditions are reflected in the unit fair value of the free shares and were estimated by management using the valuation </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:173.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">methods and assumptions set out above. The valuation of tranche 6 also incorporates management&#8217;s estimate of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:187.04pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">probability of a M&amp;A transaction prior to the limit date.</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:200.48pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The vesting acceleration condition in case of a tender offer on the securities issued by the Group and resulting in a change of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:213.92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">control of the Group qualifies as a non-market performance condition.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:241.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(b) Pursuant to a Board decision on July 11, 2023, the Group allocated a total number of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:391.52pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-656" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1655">100,000</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:424.02pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs to Mr. Hartmut Ehrlich, as the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:252.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Group&#8217;s former Chief Executive Officer, to which the following conditions apply (AGA plan 2023-2):</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:274.76pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">For </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:88.39pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-657" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1656">25,000</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:115.89pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs 2023-2 (tranche 1): the acquisition period shall end on the first anniversary of the allocation date, and is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:288.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">not subject to a future service condition; </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:301.64pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">For </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:88.39pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-658" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1657">75,000</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:115.89pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs 2023-2 (tranche 2): the acquisition period shall end on the latest date between (i) the first anniversary of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:315.08pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the allocation date, and (ii) the date on which a specific condition, related to positive results on clinical studies, is fulfilled. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:328.52pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The acquisition is not subject to a future service condition. Additionally, the tranche is subject to a vesting acceleration </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:341.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">condition in case of a tender offer on the securities issued by the Group and resulting in a change of control of the Group.&#160; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:355.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">This tranche qualifies as a non-vesting condition. Its level of achievement is reflected in the unit fair value of the free shares, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:368.84pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and was estimated by management based on observable industry-specific data.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:395.72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">AGAs granted in September and December 2023</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:418.12pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On September 28, 2023 and December 1, 2023, certain of the Group&#8217;s officers and employees were allocated respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:525.72pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-659" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1658">985,750</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:558.22pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:429.32pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">AGAs (AGA plans 2023-3 and 2023-4) and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:213.98pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-577" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1659">132,750</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:246.48pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs (AGA plan 2023-5) in the aggregate, the vesting of which is subject to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:440.52pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">certain conditions: </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:462.92pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Subject to remaining employed with the Group, each such officer or employee&#8217;s AGAs will be vested as follows: (i) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.28pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-660" decimals="2" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="f-1660">50</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:557.61pt;position:var(--position);text-decoration:none;white-space:pre"> at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:476.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the end of a </span><ix:nonNumeric contextRef="c-660" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-1661"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:121.39pt;position:var(--position);text-decoration:none;white-space:pre">two</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:136.38pt;position:var(--position);text-decoration:none;white-space:pre">-year</span></ix:nonNumeric><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:156.9pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation date, (ii) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:302.26pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-661" decimals="2" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="f-1662">25</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:320.59000000000003pt;position:var(--position);text-decoration:none;white-space:pre"> at the end of a </span><ix:nonNumeric contextRef="c-661" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-1663"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:382.18pt;position:var(--position);text-decoration:none;white-space:pre">three</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:402.14pt;position:var(--position);text-decoration:none;white-space:pre">-year</span></ix:nonNumeric><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:422.66pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation date and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:489.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(iii) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:89.47pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-662" decimals="2" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="f-1664">25</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:107.8pt;position:var(--position);text-decoration:none;white-space:pre"> at the end of a </span><ix:nonNumeric contextRef="c-662" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-1665"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:169.39pt;position:var(--position);text-decoration:none;white-space:pre">four</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:186.05pt;position:var(--position);text-decoration:none;white-space:pre">-year</span></ix:nonNumeric><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:206.57pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation date (service condition). </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:514.44pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Of the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:99.75pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-663" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1666">1,118,500</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:139.75pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:172.8pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-663" decimals="INF" name="abvx:NumberOfOtherEquityInstrumentsGrantedSubjectToNonMarketPerformanceCondition" format="ixt:num-dot-decimal" scale="0" id="f-1667">254,250</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:205.3pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs are subject to an additional non-market performance condition of the successful </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:527.88pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">completion of a public offering raising at least </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:259.53999999999996pt;position:var(--position);text-decoration:none;white-space:pre">$<ix:nonFraction unitRef="usd" contextRef="c-663" decimals="-6" name="abvx:VestingRequirementsForShareBasedPaymentArrangementPerformanceConditionsMinimumFinancing" scale="6" id="f-1668">200</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:310.89pt;position:var(--position);text-decoration:none;white-space:pre"> in gross proceeds. This condition was met on October 24, 2023.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:552.52pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Additionally, all the 2023-3, 2023-4 and 2023-5 AGAs are subject to a vesting acceleration condition in case of a tender offer on the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:564.52pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">securities issued by the Group and resulting in a change of control of the Group.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:589.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">AGAs granted in February, March, May, July and September 2024</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:612.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On February 1, 2024, March 28, 2024, May 23, 2024, July 11, 2024 and September 5, 2024 certain of the Group&#8217;s officers and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:623.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">employees were allocated respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:192.41pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-581" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1669">1,549,125</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:232.41pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs (AGA plans 2024-1), </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:350.7pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-585" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1670">22,500</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:378.2pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs (AGA plan 2024-2), </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:492.6pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-589" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1671">38,500</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:520.1pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs (AGA </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:634.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">plans 2024-3), </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.25pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-664" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1672">138,000</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:128.75pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs (AGA plans 2024-4, 5 and 6) and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:295.9pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-604" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1673">198,000</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:328.4pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs (AGA plans 2024-7), in the aggregate, the vesting of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:645.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">which is subject to certain conditions: </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:670.96pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Subject to remaining employed with the Group, each such officer or employee&#8217;s AGAs (with the exception of AGAs 2024-6) </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:684.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">will be vested as follows: (i) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:187.98000000000002pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-665" decimals="2" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="f-1674">50</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:206.31pt;position:var(--position);text-decoration:none;white-space:pre"> at the end of a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:267.9pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-665" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-1675">two years</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:306.47pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation date, (ii) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:451.83pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-666" decimals="2" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="f-1676">25</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:470.16pt;position:var(--position);text-decoration:none;white-space:pre"> at the end of a </span><ix:nonNumeric contextRef="c-666" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-1677"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:531.75pt;position:var(--position);text-decoration:none;white-space:pre">three</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:551.71pt;position:var(--position);text-decoration:none;white-space:pre">-year</span></ix:nonNumeric><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:572.23pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div></div></ix:continuation></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-42<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><ix:continuation id="f-1224-8" continuedAt="f-1224-9"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">period from the allocation date and (iii) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:232.06pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-667" decimals="2" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="f-1678">25</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:250.39pt;position:var(--position);text-decoration:none;white-space:pre"> at the end of a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:311.98pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-667" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-1679">four years</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:352.22pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation date (service condition).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:97.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90.03pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-668" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1680">20,000</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:117.53pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs 2024-6 granted to an employee are composed of (i) a first tranche of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:423.61pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-669" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1681">10,000</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:451.11pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs not subject to any </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:108.64pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">presence of performance condition and (ii) a second tranche of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:325.02pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-670" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1682">10,000</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:352.52pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs subject to a non-vesting condition, the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:119.84pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">achievement of which was deemed certain on grant date.</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:144.84pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Additionally, all the 2024-1 to 2024-7 AGA plans are subject to a vesting acceleration condition in case of a tender offer on </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:159.24pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the securities issued by the Group and resulting in a change of control of the Group.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:183.64pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">A</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:42.1pt;position:var(--position);text-decoration:none;white-space:pre">GAs granted in February, March, May, August and November 2025</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:206.04pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">From February to November 2025, certain of the Group&#8217;s officers and employees were allocated </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:424.75pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-119" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1683">4,319,500</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:464.75pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs (AGA plan </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:217.24pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">2025-1), </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72.66pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-117" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1684">123,102</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:105.16pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs (AGA plan 2025-2), </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:219.56pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-671" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1685">17,625</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:247.06pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs (AGA plans 2025-3), </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:365.35pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-672" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1686">30,500</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:392.85pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs (AGA plan 2025-4), </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:507.25pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-673" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1687">25,000</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:534.75pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:228.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(AGA plan 2025-6), </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:119.85pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-674" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1688">1,711,000</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:159.85pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs (AGA plan 2025-7) and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:288.68pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-675" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1689">4,000</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:311.18pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs (AGA plan 2025-8) in the aggregate, the vesting of which </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:239.64pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">is subject to certain conditions: </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:262.04pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Subject to remaining employed with the Group, each such officer or employee&#8217;s AGAs will be vested as follows: (i) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.28pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-676" decimals="2" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="f-1690">50</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:557.61pt;position:var(--position);text-decoration:none;white-space:pre"> at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:275.48pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the end of a </span><ix:nonNumeric contextRef="c-676" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-1691"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:121.39pt;position:var(--position);text-decoration:none;white-space:pre">two</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:136.38pt;position:var(--position);text-decoration:none;white-space:pre">-year</span></ix:nonNumeric><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:156.9pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation date, (ii) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:302.26pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-677" decimals="2" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="f-1692">25</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:320.59000000000003pt;position:var(--position);text-decoration:none;white-space:pre"> at the end of a </span><ix:nonNumeric contextRef="c-677" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-1693"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:382.18pt;position:var(--position);text-decoration:none;white-space:pre">three</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:402.14pt;position:var(--position);text-decoration:none;white-space:pre">-year</span></ix:nonNumeric><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:422.66pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation date and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:288.92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(iii) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:89.47pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-678" decimals="2" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="f-1694">25</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:107.8pt;position:var(--position);text-decoration:none;white-space:pre"> at the end of a </span><ix:nonNumeric contextRef="c-678" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-1695"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:169.39pt;position:var(--position);text-decoration:none;white-space:pre">four</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:186.05pt;position:var(--position);text-decoration:none;white-space:pre">-year</span></ix:nonNumeric><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:206.57pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation date (service condition). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:302.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">B</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:78.66pt;position:var(--position);text-decoration:none;white-space:pre">y exception to the above, the vesting of almost half of the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:310.9pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-119" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1696">4,319,500</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:350.9pt;position:var(--position);text-decoration:none;white-space:pre"> 2025-1 AGAs is subject to the occurrence of a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:541.27pt;position:var(--position);text-decoration:none;white-space:pre">tender </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:313.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">offer on the securities issued by the Group and resulting in a change of control of the Group</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:439.15pt;position:var(--position);text-decoration:none;white-space:pre"> before a certain date, and the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:324.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-117" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1697">123,102</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:104.5pt;position:var(--position);text-decoration:none;white-space:pre"> 2025-2 AGAs will vest entirely at the end of a </span><ix:nonNumeric contextRef="c-117" name="abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-1698"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:294.59000000000003pt;position:var(--position);text-decoration:none;white-space:pre">two</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:309.58000000000004pt;position:var(--position);text-decoration:none;white-space:pre">-year</span></ix:nonNumeric><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:330.1pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation dat</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:451.33pt;position:var(--position);text-decoration:none;white-space:pre">e, subject to future service </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:335.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">condition.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:347.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Additionally, all the AGA plans granted in 2025 are subject to a vesting acceleration condition in case of a tender offer on the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:359.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">securities issued by the Group and resulting in a change of control of the Group.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:383.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In March 2025, a Group employee was allocated </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:233.29pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-679" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1699">50,000</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:260.78999999999996pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs (AGA plan 2025-5),</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:372.69pt;position:var(--position);text-decoration:none;white-space:pre"> the vesting of which is subject to the achievement </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:394.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of certain milestones related to clinical studies and market authorization of ABX464 in UC and CD as well as future service.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:533.98pt;position:var(--position);text-decoration:none;white-space:pre"> These </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:405.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">AGAs are also s</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:101.22pt;position:var(--position);text-decoration:none;white-space:pre">ubject to a vesting acceleration condition in case of a tender offer on the securities issued by the Group and resulting </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:416.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in a change of control of the Group. Following the departure of the beneficiary during the period, the expense related to this plan has </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:427.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">been reversed.</span></div></div></ix:continuation></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-43<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-1224-9"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Social taxes related to AGAs</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:94.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">AGA plans granted to the Group's officers and employees are subject to employer's taxes, measured in accordance with the same </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:106.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">principles as the AGA plans. These taxes a</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:207.46pt;position:var(--position);text-decoration:none;white-space:pre">re paid </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:237.42pt;position:var(--position);text-decoration:none;white-space:pre">upon the vesting date of the awards and their amount is based on the fair value of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:118.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the underlying share at that date. They are therefore remeasured at every reporting date,</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:386.34pt;position:var(--position);text-decoration:none;white-space:pre"> using the listed share price at that date</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:541.6700000000001pt;position:var(--position);text-decoration:none;white-space:pre">. They </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:130.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">are classified as provisions before they are due.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:154.56pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss" id="f-1700" continuedAt="f-1700-1" escape="true"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre;width:439.91pt">Breakdown of the compensation expenses accounted for the period ended December 31, 2023, 2024 and 2025</span></ix:nonNumeric></div><ix:continuation id="f-1700-1"><div style="position:var(--position);top:177.91pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:321pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:119.25pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:65.25pt"/></tr><tr style="height:41.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.02pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">TYPE</span></div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:119.25pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:8.02pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.32pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:17.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:27.22pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:187.5pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:8.02pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.32pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:17.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:27.22pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:255.75pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:8.02pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.32pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:17.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:27.22pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:41.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BCEs</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:119.25pt;position:var(--position);top:41.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.55pt"></span></span><span style="left:47.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-680" decimals="-3" sign="-" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="f-1701">112</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:187.5pt;position:var(--position);top:41.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.55pt"></span></span><span style="left:47.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-681" decimals="-3" sign="-" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="f-1702">112</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:252.75pt;overflow:hidden;position:var(--position);top:41.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:255.75pt;position:var(--position);top:41.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-501" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="f-1703">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:53.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSAs</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:119.25pt;position:var(--position);top:53.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-548" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="f-1704">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:187.5pt;position:var(--position);top:53.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.55pt"></span></span><span style="left:47.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-682" decimals="-3" sign="-" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="f-1705">211</ix:nonFraction>)</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:252.75pt;overflow:hidden;position:var(--position);top:53.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:255.75pt;position:var(--position);top:53.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.55pt"></span></span><span style="left:47.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-544" decimals="-3" sign="-" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="f-1706">289</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:65.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGAs</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:119.25pt;position:var(--position);top:65.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.55pt"></span></span><span style="left:41.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-683" decimals="-3" sign="-" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="f-1707">8,067</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:187.5pt;position:var(--position);top:65.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:34.55pt"></span></span><span style="left:37.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-684" decimals="-3" sign="-" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="f-1708">19,900</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:252.75pt;overflow:hidden;position:var(--position);top:65.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:255.75pt;position:var(--position);top:65.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:35.3pt;position:var(--position);text-decoration:none;white-space:pre">(<ix:nonFraction unitRef="eur" contextRef="c-642" decimals="-3" sign="-" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="f-1709">35,108</ix:nonFraction>)</span></div></div></div></td></tr><tr style="height:12.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:77.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Social taxes related to AGAs</span></div></div></div></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:119.25pt;position:var(--position);top:77.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.55pt"></span></span><span style="left:47.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-683" decimals="-3" sign="-" name="abvx:ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes" scale="3" id="f-1710">426</ix:nonFraction>)</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:187.5pt;position:var(--position);top:77.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.55pt"></span></span><span style="left:47.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-684" decimals="-3" sign="-" name="abvx:ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes" scale="3" id="f-1711">717</ix:nonFraction>)</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="height:12.75pt;left:252.75pt;overflow:hidden;position:var(--position);top:77.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:255.75pt;position:var(--position);top:77.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:35.3pt;position:var(--position);text-decoration:none;white-space:pre">(<ix:nonFraction unitRef="eur" contextRef="c-642" decimals="-3" sign="-" name="abvx:ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes" format="ixt:num-dot-decimal" scale="3" id="f-1712">48,990</ix:nonFraction>)</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total</span></div></div></div></td><td style="background-color:#CCECFF;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:119.25pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:38.55pt"></span></span><span style="left:41.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="f-1713">8,605</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:187.5pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:34.55pt"></span></span><span style="left:37.18pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="f-1714">20,941</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:252.75pt;overflow:hidden;position:var(--position);top:90pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="background-color:#CCECFF;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:255.75pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:35.3pt;position:var(--position);text-decoration:none;white-space:pre">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="f-1715">84,387</ix:nonFraction>)</span></div></div></div></td></tr></tbody></table></div></div></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:294.91pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The significant amount of social taxes related to AGAs (and related provisions) for the year ended December 31, 2025 is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:304.91pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">predominantly attributable to the increase in the price of the underlying shares over the period.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:324.91pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Provisions for social taxes related to AGAs are classified within the Current Provisions and Non-current Provisions line items in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:334.91pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">balance sheet, which </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:121.43pt;position:var(--position);text-decoration:none;white-space:pre">amount</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:151.4pt;position:var(--position);text-decoration:none;white-space:pre"> to</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:161.67000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> respective</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:204.65pt;position:var(--position);text-decoration:none;white-space:pre">ly</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:212.42pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:214.92pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-643" decimals="-3" name="ifrs-full:OtherShorttermProvisions" format="ixt:num-dot-decimal" scale="3" id="f-1716">16,467</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:286.01pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:288.51pt;position:var(--position);text-decoration:none;white-space:pre">and</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:302.94pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:305.44pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-643" decimals="-3" name="ifrs-full:OtherLongtermProvisions" format="ixt:num-dot-decimal" scale="3" id="f-1717">28,718</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:376.53pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:379.03pt;position:var(--position);text-decoration:none;white-space:pre">as of December 31, 20</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:469.22pt;position:var(--position);text-decoration:none;white-space:pre">25.</span></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-44<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><div style="position:absolute;top:70.56pt" id="i7a006daedb3d4216a4128b76247285d7_412"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 15. <span id="id00cb1f7319c4d888d50dcea44a6cdb5"></span></span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory" id="f-1730" continuedAt="f-1730-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Financial liabilities</span></ix:nonNumeric></div><ix:continuation id="f-1730-1" continuedAt="f-1730-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:90.36pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory" id="f-1731" continuedAt="f-1731-1" escape="true"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:41pt;position:var(--position);text-decoration:none;white-space:pre">Financial liabilities break down as follows:</span></ix:nonNumeric></div><ix:continuation id="f-1731-1"><div style="font-size:12pt;line-height:11pt;position:var(--position);top:101.66pt;width:612pt"><span style="font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div><div style="position:var(--position);top:110.46pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:422.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:191.25pt"/><td style="padding:0;width:75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:75pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:44.09pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">FINANCIAL LIABILITIES&#160;</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:12pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.84pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.5pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:12pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.84pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.5pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:12pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.84pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.5pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos &amp; Claret bond loans </span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:42.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-691" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-1732">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:42.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-692" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1733">26,373</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:42.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-693" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-1734">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Lease liabilities</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-694" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" scale="3" id="f-1735">160</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-695" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1736">1,431</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-696" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" scale="3" id="f-1737">554</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">PGE</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-697" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1738">2,402</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-698" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1739">1,252</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-699" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-1740">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Borrowings</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:78.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-700" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1741">2,563</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:78.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-701" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1742">29,056</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:78.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-702" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" scale="3" id="f-1743">554</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos &amp; Claret convertible notes (OCABSA)</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:90.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-703" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1744">21,643</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:90.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-704" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1745">23,370</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:90.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-705" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-1746">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Convertible loan notes</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:102.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-706" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1747">21,643</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:102.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-707" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1748">23,370</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:102.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-708" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-1749">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:114.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos &amp; Claret minimal return indemnifications </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:114.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-709" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-1750">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:114.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-710" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1751">3,620</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:114.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-711" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-1752">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:126.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Derivative instruments</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:126.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-712" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-1753">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:126.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-713" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1754">3,620</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:126.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-714" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-1755">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:138.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Conditional advances Bpifrance</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:138.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-715" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1756">3,262</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:138.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-716" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-1757">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:138.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-717" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-1758">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:150.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Royalty certificates</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:150.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-718" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1759">12,229</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:150.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:50.37pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-719" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1760">13,023</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:150.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-720" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1761">30,237</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:162.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial liabilities</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:162.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-721" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1762">15,491</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:162.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-722" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1763">13,023</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:162.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-723" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1764">30,237</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:174.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total non-current financial liabilities</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:174.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1765">39,697</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:174.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1766">69,069</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:174.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1767">30,790</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:6.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:193.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos &amp; Claret bond loans </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:193.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-691" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-1768">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:193.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-692" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1769">20,028</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:193.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-693" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-1770">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:205.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Lease liabilities</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:205.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-694" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" scale="3" id="f-1771">379</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:205.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-695" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" scale="3" id="f-1772">932</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:205.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-696" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1773">1,302</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:217.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">PGE</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:217.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-697" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1774">1,276</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:217.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-698" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1775">1,235</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:217.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-699" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-1776">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:229.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Borrowings</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:229.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-700" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1777">1,655</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:229.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-701" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1778">22,195</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:229.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-702" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1779">1,302</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:241.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Heights convertible notes </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:241.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-724" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1780">29,605</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:241.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-725" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1781">21,574</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:241.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-726" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-1782">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:253.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Convertible loan notes</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:253.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-706" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1783">29,605</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:253.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-707" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1784">21,574</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:253.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-708" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-1785">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:265.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Conditional advances Bpifrance</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:265.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-715" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1786">3,509</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:265.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-716" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-1787">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:265.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-717" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-1788">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:277.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial liabilities</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:277.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-721" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1789">3,509</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:277.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-722" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-1790">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:277.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-723" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-1791">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:289.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos &amp; Claret BSA</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:289.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-727" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1792">2,579</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:289.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-728" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1793">1,166</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:289.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-729" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-1794">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:301.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Derivative instruments</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:301.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-712" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1795">2,579</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:301.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-713" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1796">1,166</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:301.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-714" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-1797">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:313.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total current financial liabilities</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:313.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1798">37,348</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:313.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1799">44,935</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:313.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1800">1,302</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:325.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial liabilities</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:325.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1801">77,045</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:325.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.96pt"></span></span><span style="left:45.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1802">114,004</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:325.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1803">32,093</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div></ix:continuation></ix:continuation><div style="position:absolute;top:507.6pt" id="i7a006daedb3d4216a4128b76247285d7_415"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:507.6pt;width:612pt"><ix:continuation id="f-1730-2" continuedAt="f-1730-3"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 15.1. Structured debt financing with </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:209.22pt;position:var(--position);text-decoration:none;white-space:pre">Kreos &amp; Claret subscribed in August 2023 &#8211; &#8220;Kreos / Claret Financing&#8221;</span></ix:continuation></div><ix:continuation id="f-1730-3" continuedAt="f-1730-4"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:530pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On August 20, 2023, the Group entered into a structured debt financing agreement with Kreos and Claret (the Kreos / Claret </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:541.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Financing), for up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:121.22pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-77" decimals="-3" name="abvx:BorrowingsMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="f-1804">75,000</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:192.31pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:563.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On August 22, 2023, the Group repaid in full the pre-existing debt agreements with Kreos for a total amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:482.81pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-730" decimals="-3" name="abvx:RepaymentsOfBondLoans" format="ixt:num-dot-decimal" scale="3" id="f-1805">7,661</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:548.9pt;position:var(--position);text-decoration:none;white-space:pre">. The </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:574.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">accounting treatment of this transaction is explained in Note 15.3.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:597.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Kreos / Claret Financing consists of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:199.99pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="tranche" contextRef="c-77" decimals="INF" name="abvx:BorrowingsNumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="f-1806">three</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:219.95pt;position:var(--position);text-decoration:none;white-space:pre"> tranches of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:269.06pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-77" decimals="-3" name="abvx:BorrowingsMaximumBorrowingCapacityPerTranche" format="ixt:num-dot-decimal" scale="3" id="f-1807">25,000</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:340.15pt;position:var(--position);text-decoration:none;white-space:pre"> each in aggregate principal amount:</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:619.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The first tranche (&#8220;tranche A&#8221;) in aggregate principal amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:330.53pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-80" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1808">25,000</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:401.62pt;position:var(--position);text-decoration:none;white-space:pre"> takes the form of senior secured </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:630.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">convertible bonds with warrants attached (the &#8220;Kreos / Claret OCABSA&#8221;) and was drawn on August 22, 2023. The Kreos / </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:642pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Claret OCABSA are convertible into ordinary shares at any time from their issuance at the request of their holders at a fixed </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:653.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">conversion price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:151.64pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-731" decimals="4" name="abvx:BorrowingsFixedConversionPrice" scale="0" id="f-1809">21.2209</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:189.14pt;position:var(--position);text-decoration:none;white-space:pre">, subject to standard adjustments, including anti-dilution and dividend protections. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:675.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Interest on the Kreos / Claret OCABSA accrues at a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:282.28999999999996pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-732" decimals="4" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-1810">9.00</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:308.12pt;position:var(--position);text-decoration:none;white-space:pre"> annual fixed interest rate, payable in quarterly installments. The </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:686.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Kreos / Claret OCBSA&#8217;s maturity date is March 31, 2027, it being specified that the scheduled date of final repayment is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:698pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">January 1, 2027.</span></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-45<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><ix:continuation id="f-1730-4" continuedAt="f-1730-5"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The Group is allowed to prepay the amounts due under the Kreos / Claret OCABSA at any time. In such case, the Group will </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:81.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">be required to pay a sum equal to (i) the principal outstanding at the time of the prepayment (plus accrued interests), plus (ii) </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:92.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">an aggregate of all remaining interest payments that would have been paid throughout the remainder of the term of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:104.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">tranche, discounted to present value by applying a discount rate of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:339.48pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-732" decimals="2" name="abvx:BorrowingsEarlyRepaymentDiscountRate" scale="-2" id="f-1811">4</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:352.81pt;position:var(--position);text-decoration:none;white-space:pre">, plus (iii) an end-of-loan exit fee equal to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:522.05pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-732" decimals="3" name="abvx:BorrowingsExitFeePercentage" scale="-2" id="f-1812">8.0</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:542.88pt;position:var(--position);text-decoration:none;white-space:pre"> of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:115.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">amounts drawn thereunder. In case of prepayment, the holders of the Kreos / Claret OCABSA will have the option to request </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">a conversion of their Kreos / Claret OCABSA instead of a cash repayment, in which case, the end-of-loan exit fee is not </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:137.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">payable by the Group.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:160.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The warrants included in the Kreos / Claret OCABSA will only become exercisable in case of prepayment in cash of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:171.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Kreos / Claret convertible bonds by the Group. Upon exercise of the warrants, their holders will be able to subscribe to the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:183.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">same number of ordinary shares (and at the same price conditions) as they would have been able to subscribe had they </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:194.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">converted the Kreos / Claret OCABSA which have been prepaid in cash. Any warrants not exercised on or prior to January 1, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:206.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">2027 will become automatically null and void. For the avoidance of doubt, if the Group does not prepay any Kreos / Claret </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:217.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">OCABSA in cash prior to their scheduled repayment dates, none of the warrants will be exercisable.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:240.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The second tranche (&#8220;tranche B&#8221;) in aggregate principal amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:341.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-100" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1813">25,000</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:412.72pt;position:var(--position);text-decoration:none;white-space:pre"> takes the form of senior secured non-</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:251.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">convertible bonds and was drawn on March 28, 2024. The drawdown of the second tranche was subject to a maximum </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:548.79pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-733" decimals="2" name="abvx:BorrowingsDebtToMarketCapitalizationRatio" scale="-2" id="f-1814">10</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:567.12pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:263.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Debt-To-Market Capitalization Ratio at the time of drawdown. The &#8220;Debt-To-Market Capitalization Ratio&#8221; is calculated on </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:274.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">any relevant date, by dividing (i) the indebtedness of the Group (including amounts due under the Kreos / Claret Financing </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:285.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">but excluding amounts due under the Heights Financing), by (ii) the market capitalization of the Group calculated by </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:296.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">multiplying the number of outstanding ordinary shares by the closing price of the ordinary shares on such relevant date. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:319.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The third tranche (&#8220;tranche C&#8221;) in aggregate principal amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:332.75pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-734" decimals="-3" name="abvx:BorrowingsMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="f-1815">25,000</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:403.84pt;position:var(--position);text-decoration:none;white-space:pre"> takes the form of senior secured non-</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:330.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">convertible bonds and was drawn on June 21, 2024. The drawdown of the third tranche was subject to a maximum </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:532.15pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-734" decimals="2" name="abvx:BorrowingsDebtToMarketCapitalizationRatio" scale="-2" id="f-1816">10</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:550.48pt;position:var(--position);text-decoration:none;white-space:pre"> Debt-</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:341.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">To-Market Capitalization Ratio at the time of drawdown (excluding the Heights Financing) and was conditional on the Group </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:352.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">raising a minimum of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:160.8pt;position:var(--position);text-decoration:none;white-space:pre">$<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="abvx:BorrowingsPerformanceConditionsMinimumFinancing" format="ixt:num-dot-decimal" scale="3" id="f-1817">125,000</ix:nonFraction>&#160;thousand</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:236.89pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> in gross proceeds through a listing on Nasdaq before June 30, 2024. This condition </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:363.86pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">was met on October 24, 2023 (see Note 3.3 - </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:253.52pt;position:var(--position);text-decoration:none;white-space:pre">Conversion of the Heights convertible notes, Kreos OCABSA and Kreos / Claret </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:375.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">BSA and prepayment of the Kreos / Claret Tranches B and C bond loans &#8211;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:370.12pt;position:var(--position);text-decoration:none;white-space:pre"> July-December 2025</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:456.13pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">).</span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:397.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">A variable interest rate of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:176.56pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-735" decimals="3" name="ifrs-full:BorrowingsAdjustmentToInterestRateBasis" scale="-2" id="f-1818">7.5</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:197.39pt;position:var(--position);text-decoration:none;white-space:pre"> + European Central Bank Base Rate (MRO) (with a floor at </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:441.07pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-736" decimals="3" name="abvx:BorrowingsBasisInterestRate" scale="-2" id="f-1819">2.5</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:461.9pt;position:var(--position);text-decoration:none;white-space:pre"> and a cap at </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:514.3199999999999pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-737" decimals="2" name="abvx:BorrowingsBasisInterestRate" scale="-2" id="f-1820">4</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:527.65pt;position:var(--position);text-decoration:none;white-space:pre">) applies to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:408.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the second and third tranche. These </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:215.99pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="tranche" contextRef="c-738" decimals="INF" name="abvx:BorrowingsNumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="f-1821">two</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:230.98pt;position:var(--position);text-decoration:none;white-space:pre"> tranches will be repaid monthly through March 31, 2027, after a deferred repayment </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:419.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of the principal until February 1, 2025.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:442.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The Group is allowed to prepay the amounts due under the second and third tranches of the Kreos / Claret Financing at any </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:453.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">time. In such case, The Group will be required to pay a sum equal to (i) the principal outstanding at the time of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:464.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">prepayment (plus accrued interests), plus (ii) an aggregate of all remaining interest payments that would have been paid </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:475.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">throughout the remainder of the term of the applicable tranche, discounted to present value by applying a discount rate of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:558.9300000000001pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-738" decimals="2" name="abvx:BorrowingsEarlyRepaymentDiscountRate" scale="-2" id="f-1822">4</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:572.26pt;position:var(--position);text-decoration:none;white-space:pre">, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:487.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">plus (iii) an end-of-loan exit fee equal to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:236.24pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-738" decimals="3" name="abvx:BorrowingsExitFeePercentage" scale="-2" id="f-1823">6.0</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:257.07pt;position:var(--position);text-decoration:none;white-space:pre"> of the amounts drawn under the applicable tranche.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:509.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Kreos / Claret Financing also provides for a Minimal Return Indemnification ("MRI") to the benefit of the bondholders. The </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:520.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Minimum Cash Return amount is defined as follows:</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:531.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(i) with respect to tranche A and tranche B, 1.4 times the amount of the cumulated principal drawn under the relevant </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:543.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">i</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:74.77pt;position:var(--position);text-decoration:none;white-space:pre">nstrument, and; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:554.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(ii) with respect to tranche C, 1.3 times the amount of the cumulated principal drawn under the relevant instrument.&#160; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:579.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In the event the amount of the cash generated by the tranche A (the Kreos / Claret OCABSA), tranche B or tranche C bond loans, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:590.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">including principal and interest payments, transaction fees, and the end-of-loan exit fees, (the &#8220;Actual Return&#8221; calculated as at the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:601.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">earlier of (i) March 31, 2027, or (ii) the date of any prepayment or acceleration of the tranche B and C bond loans or more generally </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:612.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">such earlier date as the same shall become repayable ("the Redemption Date")), is lower than the Minimum Cash Return, the Group </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:624.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">shall indemnify the bondholders for the difference between the Minimum Cash Return and the Actual Return (the &#8220;Minimal Return </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:635.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Indemnification"). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:646.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">If at the time of the Minimum Return Indemnification payment, the warrants related to both the OCABSA Bonds and the Tranche B </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:657.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">amortized bonds (the &#8220;Kreos / Claret A-B warrants&#8221;) or the Kreos / Claret Tranche C warrants are still outstanding, the exercise price </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:668.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">for such warrants shall be adjusted up by the amount of the Minimum Return Indemnification divided by the number of warrants </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:680.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">outstanding. For any Kreos / Claret A-B or C warrants that were exercised prior to the last Redemption Date, any capital gains made </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:691.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">from the exercise of such warrants will be added to the Minimum Cash Return amount.</span></div></div></ix:continuation></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-46<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><ix:continuation id="f-1730-5" continuedAt="f-1730-6"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Unless the repayment of the Tranche A and B bond loans results from a change of control (in which case the calculation of the Actual </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:81.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Return shall only include (i) interest accrued prior to conversion of any Tranche A OCABSA, (ii) transaction and end-of-loan exit </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:92.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">fees, and (iii) the net capital gain derived from the sale of shares underlying the Tranche A OCABSA within the framework of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:104.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">change of control transaction), neither the principal subscribed under Tranche A nor the Actual Return generated by Tranche A shall </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:115.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">be included in the calculation of the Minimum Return Indemnification (i.e. the Minimum Cash Return and the Actual Return shall </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">only be calculated, and the Minimum Return Indemnification shall only apply to Tranche B and Tranche C).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:137.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Kreos / Claret Financing provides for certain restrictive covenants (subject to customary exceptions) which include, among other </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:148.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">things, restrictions on the incurrence of indebtedness, cross-default, the distribution of dividends and the grant of security interests. As </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:160.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">security for the Kreos / Claret Financing, the lenders benefit from the grant of first-ranking collateral on The Group&#8217;s principal </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:171.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">tangible and intangible assets, including pledges over The Group&#8217;s business (</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:344.86pt;position:var(--position);text-decoration:none;white-space:pre">fonds de commerce</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:422pt;position:var(--position);text-decoration:none;white-space:pre">) as a going concern and intellectual </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:182.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">property rights in The Group's lead drug candidate, as well as pledges over The Group&#8217;s bank accounts and receivables. Such </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:193.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">securities apply to all tranches of the Kreos / Claret Financing.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:216.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In addition to the Kreos / Claret OCABSA, the Group has issued warrants (the &#8220;tranche A-B BSA&#8221;) for a global subscription price of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:227.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-739" decimals="2" name="abvx:OtherShareWarrantsSubscriptionPricePerShare" scale="0" id="f-1824">1.00</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:58.5pt;position:var(--position);text-decoration:none;white-space:pre">, giving Kreos and Claret the right to subscribe to up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:281.35pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-740" decimals="INF" name="abvx:NumberOfWarrantsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1825">214,198</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:313.85pt;position:var(--position);text-decoration:none;white-space:pre"> new ordinary shares at an exercise price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:489.46pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-739" decimals="4" name="abvx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="f-1826">18.6744</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:526.96pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:239.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(corresponding to a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:116.21pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-739" decimals="2" name="abvx:ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted" scale="-2" id="f-1827">10</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:134.54000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> premium over the 15-day VWAP prior to the date on which their issuance was decided). On November 2, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:250.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">2023, a second tranche of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.9pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-87" decimals="INF" name="abvx:NumberOfWarrantsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1828">405,832</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:173.4pt;position:var(--position);text-decoration:none;white-space:pre"> Kreos / Claret warrants (the &#8220;tranche C BSA&#8221;) was issued. The exercise price of the additional </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:262.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">warrants is equal to approximately </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:176.66pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-741" decimals="2" name="abvx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="f-1829">9.86</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:199.16pt;position:var(--position);text-decoration:none;white-space:pre"> (corresponding to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:274.94pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-741" decimals="2" name="abvx:ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted" scale="-2" id="f-1830">110</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.27pt;position:var(--position);text-decoration:none;white-space:pre"> of the 15-day VWAP prior to the date on which their issuance was </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:273.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">decided). The number of warrants issued corresponds to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:262.73pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-87" decimals="-6" name="abvx:IssuanceOfOtherShareWarrants" format="ixt:num-dot-decimal" scale="0" id="f-1831">4,000,000</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:307.73pt;position:var(--position);text-decoration:none;white-space:pre"> divided by the aforementioned exercise price (i.e. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:510.79pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-87" decimals="INF" name="abvx:NumberOfWarrantsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1832">405,832</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:543.29pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:285.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">warrants). Of these additional warrants, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:196.64pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-87" decimals="2" name="abvx:NumberOfInstrumentsGrantedOtherEquityInstrumentsPercentageExercisableImmediately" scale="-2" id="f-1833">50</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:214.97pt;position:var(--position);text-decoration:none;white-space:pre"> are exercisable immediately and the remaining </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:406.61pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-87" decimals="2" name="abvx:NumberOfInstrumentsGrantedOtherEquityInstrumentsRemainingPercentageExercisable" scale="-2" id="f-1834">50</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:424.94pt;position:var(--position);text-decoration:none;white-space:pre"> (&#8220;the conditional warrants&#8221;) shall </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:296.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">only be exercisable if the third tranche of the Kreos / Claret Financing is drawn by the Group.&#160; The Kreos / Claret warrants can be </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:308.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">exercised over a period of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:142.26pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-742" name="abvx:OtherShareWarrantsExercisePeriod" format="ixt-sec:duryear" id="f-1835">7</ix:nonNumeric> years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:170.84pt;position:var(--position);text-decoration:none;white-space:pre"> from their issuance date or up until the date of the successful closing of a tender offer for the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:319.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">ordinary shares, whichever is earlier. At the time of exercise of the Kreos / Claret warrants, the holders of the warrants are eligible to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:331.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">sell part of their warrants to the Group in accordance with a put option agreement to allow for a cashless exercise. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:353.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Settlement of the liabilities</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:377.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On August 8, 2025, Kreos Capital VII (UK) Limited converted the Tranche A portion of the Kreos / Claret Financing (the Kreos / </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:389.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Claret OCABSA), resulting in the issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:221.36pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-132" decimals="INF" name="abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments" format="ixt:num-dot-decimal" scale="0" id="f-1836">785,389</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:253.86pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares and an increase in equity by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:434.5pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-132" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" format="ixt:num-dot-decimal" scale="3" id="f-1837">16,058</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:505.59pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:413.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On July 30, 2025, Kreos Capital VII Aggregator SCSp opted for the cashless exercise of its share warrants (the tranche A-B BSA and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:425.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">tranche C BSA), implemented through the repurchase by the Group of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:319.61pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-743" decimals="INF" name="abvx:NumberOfWarrantsRepurchased" format="ixt:num-dot-decimal" scale="0" id="f-1838">94,117</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:347.11pt;position:var(--position);text-decoration:none;white-space:pre"> tranche A-B and C BSA and the issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:528.04pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-744" decimals="INF" name="abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants" format="ixt:num-dot-decimal" scale="0" id="f-1839">319,251</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:560.54pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:437.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">ordinary shares of the Group and an increase in equity by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:267.72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-744" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" format="ixt:num-dot-decimal" scale="3" id="f-1840">19,570</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:338.81pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:461.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On August 28, 2025, Claret European Growth Capital Fund III SCSp, exercised its share warrants (the tranche A-B BSA and tranche </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:473.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">C BSA), resulting in the issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:182.53pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-745" decimals="INF" name="abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants" format="ixt:num-dot-decimal" scale="0" id="f-1841">206,662</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:215.03pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:281.36pt;position:var(--position);text-decoration:none;white-space:pre">of the Group and an increase in equity by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:449.25pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-745" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" format="ixt:num-dot-decimal" scale="3" id="f-1842">14,198</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:520.3399999999999pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:497.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In August 2025, as a result of (i) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:168.41pt;position:var(--position);text-decoration:none;white-space:pre">the repayments of principal and interests </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:333.2pt;position:var(--position);text-decoration:none;white-space:pre">made until that date under the Kreos / Claret Financing, (ii) </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:509.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the exercise of the Tranche A-B and C BSA and (iii) the conversion of the Kreos OCABSA, the cash generated thereby met the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:521.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Minimum Cash Return due to the Kreos / Claret bondholders. Consequently, as no further payment could be due by the Group in </span></div></div></ix:continuation></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-47<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><ix:continuation id="f-1730-6" continuedAt="f-1730-7"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">relation to the Kreos / Claret Minimal Return Indemnification, the MRI derivatives were derecognized, resulting in a financial income </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:82.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:46.83pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-746" decimals="-3" name="abvx:AggregateFairValueOtherEquityInstrumentsOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-1843">3,620</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.92pt;position:var(--position);text-decoration:none;white-space:pre"> for the year ended December 31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:268.87pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:106.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On November 25, 2025, Claret European Growth Capital Fund III SCSp converted its portion of the Tranche A portion of the Kreos / </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:117.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Claret Financing (the Claret OCABSA), resulting in the issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:308.74pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-135" decimals="INF" name="abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments" format="ixt:num-dot-decimal" scale="0" id="f-1844">392,695</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:341.24pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares and an increase in equity by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:521.88pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-135" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" format="ixt:num-dot-decimal" scale="3" id="f-1845">8,296</ix:nonFraction> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:128.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72.09pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:152.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On November 28, 2025, the Group notified the bondholders of its intention to prepay in full the outstanding balances of Tranches B </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:164.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and C of the Kreos / Claret Financing. The transaction was completed on December 23, 2025. The total amount paid by the Group</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:556.83pt;position:var(--position);text-decoration:none;white-space:pre"> at</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:566.53pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:176.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">that date amounted to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:124.77pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-136" decimals="-3" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1846">33,823</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:195.86pt;position:var(--position);text-decoration:none;white-space:pre">, consisting of:</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:188.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the outstanding principal of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:184.66pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-747" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1847">29,903</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:255.75pt;position:var(--position);text-decoration:none;white-space:pre">, from which the deposit amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:398.96pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-747" decimals="-3" name="abvx:BorrowingsDeposit" format="ixt:num-dot-decimal" scale="3" id="f-1848">1,081</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:465.05pt;position:var(--position);text-decoration:none;white-space:pre"> initially paid by the Group </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:200.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to Kreos and Claret was deducted,</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:212.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">future interests discounted at a discount rate of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:261.21000000000004pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-747" decimals="2" name="abvx:BorrowingsDiscountRate" scale="-2" id="f-1849">4</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:274.53999999999996pt;position:var(--position);text-decoration:none;white-space:pre"> as</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:285.36pt;position:var(--position);text-decoration:none;white-space:pre"> per the terms of the prepayment option, amounting</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:490.98pt;position:var(--position);text-decoration:none;white-space:pre"> to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:503.75pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-136" decimals="-3" name="ifrs-full:InterestExpenseOnBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-1850">2,001</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:569.8399999999999pt;position:var(--position);text-decoration:none;white-space:pre">, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:224.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:236.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">end-of-loan exit fees of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:168pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-136" decimals="-3" name="abvx:BorrowingsExitFeeAmount" format="ixt:num-dot-decimal" scale="3" id="f-1851">3,000</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:234.09pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:260.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Following the aforementioned transactions, the Group no longer holds any debt related to the Kreos Claret Financing.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:283.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Accounting treatment</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:305.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">Kreos / Claret </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.53pt;position:var(--position);text-decoration:none;white-space:pre">OCABSA</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:328.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">The Kreos / Claret OCABSA are issued at market conditions: the net issuance proceeds reflect the fair value of the instruments at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:339.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">inception. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:361.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">The OCABSA are compound instruments, split between (i) a debt component (then measured at amortized cost) and (ii) an equity </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:372.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">component corresponding to the conversion option and the attached OCABSA warrants. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:395.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">As the adjustment provisions of the OCABSA conversion ratio are aimed at preserving the rights of the bondholders and are anti-</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:406.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">dilutive in nature rather than a down-round protection, the Group determined that the conversion option of the OCABSA is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:417.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">considered to result in the delivery of a fixed number of shares, and is therefore an equity instrument (the equity component of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:428.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">bonds).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:451.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">The OCABSA warrants were attached to each bond issued in the Tranche A closing and are not transferrable until after a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:462.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">prepayment. The OCABSA warrants become exercisable (i) upon the Group electing to prepay the bonds and (ii) in the event of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:473.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">the absence of the conversion notice from the bondholders for the full amount of the prepayment. As such, the warrants are not </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:484.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">freely transferable until the prepayment is made. Thus, the OCABSA warrants are considered as an embedded component of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:496.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">bonds rather than a separate stand-alone financial instrument. In all scenarios under which the exercisability conditions are </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:507.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">satisfied, and whereby the bondholder&#8217;s option to elect to convert the bonds was considered, the number of total ordinary shares </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:518.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">issuable upon warrant exercise as a result of prepayment and/or conversion option exercise remains fixed. Thus, the warrants </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:529.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">represent an equity-classified component of the bonds.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:552.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">The issuer prepayment option was deemed closely related to the host debt instrument and therefore does not meet the definition of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:563.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">a derivative instrument to be bifurcated.&#160; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:586.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">On their conversion dates, the carrying values of the debt components of the Kreos and Claret OCABSA, amounting to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:598.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:104.75pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-132" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" format="ixt:num-dot-decimal" scale="3" id="f-1852">16,058</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:175.84pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:195.27pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-135" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" format="ixt:num-dot-decimal" scale="3" id="f-1853">8,296</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:261.36pt;position:var(--position);text-decoration:none;white-space:pre">, were reclassified to equity.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:621.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">Kreos / Claret B and C tranches</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:643.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">The initial right granted to the Group to issue the amortized bonds under tranches B and C, upon meeting certain conditions, did </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:654.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">not meet the definition of a liability and was considered an off-balance sheet loan commitment received from the issuer as of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:665.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">December 31, 2023.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:688.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">The interest rate collars related to tranches B and C were determined to be closely related to the host debt instruments and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:699.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">therefore do not meet the definition of a derivative instrument to be bifurcated.</span></div></div></ix:continuation></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-48<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><ix:continuation id="f-1730-7" continuedAt="f-1730-8"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:84.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">The prepayment options related to tranches B and C were not determined to be closely related to the host debt instruments and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:95.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">therefore meet the definition of derivative instruments to be bifurcated. The Group determined that their fair value is insignificant </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:106.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">at issuance and as of December 31, 2024.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:131.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">The Minimum Return Indemnifications are embedded derivative instruments, which are not deemed closely related to the host </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:142.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">debt instruments and therefore meet the definition of derivative instruments to be bifurcated. They are classified as derivative </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:154.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">financial liabilities and measured at fair value through profit or loss.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:179.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">The Kreos / Claret second and third tranches are therefore hybrid instruments, split between (i) debt host contracts accounted for </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:190.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">at amortized cost and (ii) bifurcated embedded derivatives accounted for at fair value through profit and loss, corresponding to the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:201.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">Minimal Return Indemnifications and the prepayment options (the fair value of the prepayment options being deemed </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:212.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">insignificant at issuance and as of December 31, 2024).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:235.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">On December 23, 2025, the Group recognized a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:248.26pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-748" decimals="-3" sign="-" name="ifrs-full:GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid" format="ixt:num-dot-decimal" scale="3" id="f-1854">3,838</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:314.35pt;position:var(--position);text-decoration:none;white-space:pre"> loss on the derecognition </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:419.53pt;position:var(--position);text-decoration:none;white-space:pre">of Tranches B and C bonds as a result </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:247.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">of their redemption,</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:133.63pt;position:var(--position);text-decoration:none;white-space:pre"> corresponding to the difference between their carrying amount </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:388.6pt;position:var(--position);text-decoration:none;white-space:pre">on redemption date of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:479.06pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-747" decimals="-3" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-1855">29,985</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:550.15pt;position:var(--position);text-decoration:none;white-space:pre"> and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:259.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">the cash consideration of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:156.1pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-136" decimals="-3" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1856">33,823</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:227.19pt;position:var(--position);text-decoration:none;white-space:pre">. The difference is </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:302.36pt;position:var(--position);text-decoration:none;white-space:pre">primarily due to (i) the payment of future interests as per the terms </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:271.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">of the prepayment option and (ii) unamortized end-of-loan exit fees and issuance fees, reducing the carrying value of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:283.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">liabilities.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:308.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">Kreos / Claret BSA</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:331.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">As the A-B and C warrants (the Kreos / Claret BSA) are contractually transferable separately from the bonds and are redeemable </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:342.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">in a variable number of ordinary shares of the Group, they are classified as standalone derivative financial liabilities.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:364.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">As the A-B and C warrants (the Kreos / Claret BSA) represent compensation for the realized and future bond issuances of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:376.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">respectively tranches A-B and C and are an integral part of generating such bond issuances, the Group determined that they are in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:387.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">nature origination fees. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:412pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">As the A-B warrants are associated with both the OCABSA issued under tranche A and the amortized bonds issued under tranche </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:423.2pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">B, the Group allocated the initial fair value of the A-B warrants based on the pro-rata value of the proceeds to be received under </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:434.4pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">each tranche. At inception, the respective initial fair values of the A-B warrants allocated to tranche A and B were deferred and </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:445.6pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">subsequently accounted for as an adjustment to the EIR of the related debt components upon their drawdown (on August 20, 2023 </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:456.8pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">and March 28, 2024 for tranches A and B respectively). </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:279.34000000000003pt;position:var(--position);text-decoration:none;white-space:pre">Subsequent changes in the fair value will be recognized through profit or </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:468pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">loss. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:490.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">On November 2, 2023 (issuance date of the Kreos / Claret tranche C BSA), a derivative financial liability was recognized for their </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:501.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">initial fair value with a counterparty in prepaid expenses. On that date, the Group, based on management&#8217;s latest projections, did </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:512.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">not consider the drawdown of the tranche C bonds to be probable. Therefore, the amount of prepaid expenses allocated to the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:524pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">tranche C BSA </span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:116.99000000000001pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> has been amortized on a straight-line basis until the drawdown of the tranche C bonds.</span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:546.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">At the exercise dates of the BSA held by Kreos and Claret (respectively July 30, 2025 and August 28, 2025), the fair value of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:558.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">exercised warran</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:121.95pt;position:var(--position);text-decoration:none;white-space:pre">ts at the exercise dates </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:213.74pt;position:var(--position);text-decoration:none;white-space:pre">of respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:275.32pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-749" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" format="ixt:num-dot-decimal" scale="3" id="f-1857">15,143</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:346.41pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:365.84pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-750" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" format="ixt:num-dot-decimal" scale="3" id="f-1858">11,531</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:436.93pt;position:var(--position);text-decoration:none;white-space:pre"> was reclassified from derivative </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:570.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">financial liabilities to equity. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:594.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Measurement of the debt and equity components of the OCABSA</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:617.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">At inception, the fair value of the debt component of the OCABSA amounts to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:353.18pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-751" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1859">23,995</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:424.27pt;position:var(--position);text-decoration:none;white-space:pre">, using a market rate assumption of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:628.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-752" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1860">12.6</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:61.83pt;position:var(--position);text-decoration:none;white-space:pre">. The equity component amounts to the difference between the whole instrument&#8217;s fair value at inception (its nominal value of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:640pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-751" decimals="-3" name="abvx:ConvertibleLoansNotes" format="ixt:num-dot-decimal" scale="3" id="f-1861">25,000</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:107.09pt;position:var(--position);text-decoration:none;white-space:pre">) and the standalone fair value of the debt component. Therefore, the equity component amounts to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:504.97pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-751" decimals="-3" name="abvx:ConvertibleLoansNotesCarryingAmountOfTheEquityComponent" format="ixt:num-dot-decimal" scale="3" id="f-1862">1,005</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:571.06pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:651.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">It is not subsequently remeasured.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:673.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On the same date, using the same assumptions and an increase in market rate by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:358.39pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-753" decimals="4" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-4" id="f-1863">100</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:373.39pt;position:var(--position);text-decoration:none;white-space:pre"> bp would result in a decrease in the fair value of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:684.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the debt component and an increase in the value of the equity compone</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:320.1pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">nt by </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:342.87pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-754" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="3" id="f-1864">624</ix:nonFraction>&#160;thousand</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:401.46pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div></div></ix:continuation></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-49<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><ix:continuation id="f-1730-8" continuedAt="f-1730-9"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Measurement of the Kreos / Claret second and third tranches hybrid instruments</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:95.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">At inception, the net cash proceeds are the tranches' initial fair values. The fair values of the Minimal Return Indemnifications were </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:107.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">deducted from the initial carrying values of the debt components of each tranche, which were subsequently measured at amortized cost </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:119.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">using the EIR method.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:131.56pt;width:612pt"><ix:continuation id="f-1396-3" continuedAt="f-1396-4"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The fair value of the Minimum Return Indemnifications was measured using the following assumptions:</span></ix:continuation></div><ix:continuation id="f-1396-4" continuedAt="f-1396-5"><div style="position:var(--position);top:155.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:521.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:222.75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:146.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:146.25pt"/></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);white-space:pre">Tranche B Minimum Return Indemnification (issued in March </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);white-space:pre">2024)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.93pt;position:var(--position);text-decoration:none;white-space:pre">AS OF MARCH 28, 2024</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.38pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2024</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Final redemption scenario probability</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:21pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:128.18pt;position:var(--position)"></span><span style="left:128.18pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-755" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1865">95</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span><span style="left:138.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:21pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:128.18pt;position:var(--position)"></span><span style="left:128.18pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-756" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1866">95</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span><span style="left:138.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:33pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Minimal return</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:33pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:125.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-757" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-1867">1.40</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:139.62pt;position:var(--position);white-space:pre">x</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:33pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:125.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-758" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-1868">1.40</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:139.62pt;position:var(--position);white-space:pre">x</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:45pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Discount rate</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:45pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:128.18pt;position:var(--position)"></span><span style="left:128.18pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-759" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1869">13</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span><span style="left:138.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:45pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:132.18pt;position:var(--position)"></span><span style="left:132.18pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-760" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1870">8</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span><span style="left:138.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:57pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Probability-weighted present value of shortfall payment (in </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">thousands of &#8364;)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:57pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:63.45pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-761" decimals="-3" name="ifrs-full:SignificantUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1871">1,959</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.31pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:88.13pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-762" decimals="-3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="3" id="f-1872">68</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.13pt;position:var(--position);white-space:pre"> (Tender offer)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:57pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:63.45pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-763" decimals="-3" name="ifrs-full:SignificantUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1873">2,635</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.31pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:84.13pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-764" decimals="-3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="3" id="f-1874">136</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.13pt;position:var(--position);white-space:pre"> (Tender offer)</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Probability-weighted fair value of tranche A-B warrants with MRI </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">(in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:78.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:63.45pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-765" decimals="-3" name="ifrs-full:SignificantUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1875">1,066</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div></div></div></td><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:78.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:69.45pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-766" decimals="-3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="3" id="f-1876">104</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:99.75pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Probability-weighted fair value of tranche A-B warrants without </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">MRI (in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:99.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:63.45pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-767" decimals="-3" name="ifrs-full:SignificantUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1877">1,410</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:99.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:69.45pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-768" decimals="-3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="3" id="f-1878">241</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:120.75pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Total fair value of MRI (in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:120.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:29.41pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-769" decimals="-3" name="ifrs-full:SignificantUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1879">1,615</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:47.41pt;position:var(--position);white-space:pre"> (Final redemption, i.e. a+b-c)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.31pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:88.13pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-770" decimals="-3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="3" id="f-1880">68</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.13pt;position:var(--position);white-space:pre"> (Tender offer)</span></div></div></div></td><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:120.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:29.41pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-771" decimals="-3" name="ifrs-full:SignificantUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1881">2,499</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:47.41pt;position:var(--position);white-space:pre"> (Final redemption, i.e. a+b-c)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.31pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:84.13pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-772" decimals="-3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="3" id="f-1882">136</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.13pt;position:var(--position);white-space:pre"> (Tender offer)</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:142.5pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);white-space:pre">Fair value of Tranche B MRI (in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:142.5pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:115.55pt"></span></span><span style="left:118.17999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-773" decimals="-3" name="abvx:AggregateFairValueOtherEquityInstrumentsOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-1883">1,683</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:9.32pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:142.5pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:115.55pt"></span></span><span style="left:118.17999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-774" decimals="-3" name="abvx:AggregateFairValueOtherEquityInstrumentsOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-1884">2,636</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:9.32pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:342.66pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:521.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:222.75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:146.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:146.25pt"/></tr><tr style="height:21.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);white-space:pre">Tranche C Minimum Return Indemnification (issued in June </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);white-space:pre">2024)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:35.03pt;position:var(--position);text-decoration:none;white-space:pre">AS OF JUNE 21, 2024</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.38pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2024</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21.75pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Final redemption scenario probability</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:21.75pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:128.18pt;position:var(--position)"></span><span style="left:128.18pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-775" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1885">95</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span><span style="left:138.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:21.75pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:128.18pt;position:var(--position)"></span><span style="left:128.18pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-776" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1886">95</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span><span style="left:138.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:33.75pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Minimal return</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:33.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:125.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-777" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-1887">1.30</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:139.62pt;position:var(--position);white-space:pre">x</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:33.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:125.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-778" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-1888">1.30</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:139.62pt;position:var(--position);white-space:pre">x</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:45.75pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Discount rate</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:45.75pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:128.18pt;position:var(--position)"></span><span style="left:128.18pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-779" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1889">15</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span><span style="left:138.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:45.75pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:132.18pt;position:var(--position)"></span><span style="left:132.18pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-780" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1890">8</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span><span style="left:138.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:57.75pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">(a) Probability-weighted present value of shortfall payment (in </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">thousands of &#8364;)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:57.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:69.45pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-781" decimals="-3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="3" id="f-1891">741</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.31pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:92.13pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-782" decimals="-3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="3" id="f-1892">0</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.13pt;position:var(--position);white-space:pre"> (Tender offer)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:57.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:63.45pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-783" decimals="-3" name="ifrs-full:SignificantUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1893">1,160</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.31pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:88.13pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-784" decimals="-3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="3" id="f-1894">43</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.13pt;position:var(--position);white-space:pre"> (Tender offer)</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:79.5pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">(b) Probability-weighted fair value of tranche C warrants with MRI </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">(in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:79.5pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:63.45pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-785" decimals="-3" name="ifrs-full:SignificantUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1895">2,948</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div></div></div></td><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:79.5pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:69.45pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-786" decimals="-3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="3" id="f-1896">684</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:101.25pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">(c) Probability-weighted fair value of tranche C warrants without </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">MRI (in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:101.25pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:63.45pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-787" decimals="-3" name="ifrs-full:SignificantUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1897">3,250</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:101.25pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:69.45pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-788" decimals="-3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="3" id="f-1898">903</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:123pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Total fair value of MRI (in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:123pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:35.41pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-789" decimals="-3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="3" id="f-1899">475</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:47.41pt;position:var(--position);white-space:pre"> (Final redemption, i.e. a+b-c)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.31pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:92.13pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-790" decimals="-3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="3" id="f-1900">0</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.13pt;position:var(--position);white-space:pre"> (Tender offer)</span></div></div></div></td><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:123pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:35.41pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-791" decimals="-3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="3" id="f-1901">941</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:47.41pt;position:var(--position);white-space:pre"> (Final redemption, i.e. a+b-c)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.31pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:88.13pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-792" decimals="-3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="3" id="f-1902">43</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.13pt;position:var(--position);white-space:pre"> (Tender offer)</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:144.75pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);white-space:pre">Fair value of Tranche C MRI (in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:144.75pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:121.55pt"></span></span><span style="left:124.17999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-793" decimals="-3" name="abvx:AggregateFairValueOtherEquityInstrumentsOutstanding" scale="3" id="f-1903">475</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:9.32pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:144.75pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:121.55pt"></span></span><span style="left:124.17999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-794" decimals="-3" name="abvx:AggregateFairValueOtherEquityInstrumentsOutstanding" scale="3" id="f-1904">984</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:9.32pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:518.21pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">For the purpose of measuring the fair value of the MRI (shortfall payment), the fair value of the tranche A-B and C BSA was </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:530.21pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">measured with a Black Scholes model under the Final redemption scenario and with a Monte Carlo model under the Tender offer </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:542.21pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">scenario. As of March 28, 2024, the following assumptions were used: a share price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:384.57pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-795" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-1905">13.40</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:412.07pt;position:var(--position);text-decoration:none;white-space:pre">, a volatility of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:473.38pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-796" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1906">60.3</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:499.21pt;position:var(--position);text-decoration:none;white-space:pre"> (Black Scholes) </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:554.21pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:46.83pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-797" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1907">61.9</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72.66pt;position:var(--position);text-decoration:none;white-space:pre"> (Monte Carlo), and a risk-free rate of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:226.09pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-798" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1908">2.6</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:246.92pt;position:var(--position);text-decoration:none;white-space:pre"> (Black Scholes) or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:326.28pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-799" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1909">2.8</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:347.11pt;position:var(--position);text-decoration:none;white-space:pre"> (Monte Carlo).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:566.21pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of June 21, 2024, the following assumptions were used: a share price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:338.53pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-800" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-1910">12.94</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:366.03pt;position:var(--position);text-decoration:none;white-space:pre">, a volatility of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:427.34pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-801" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1911">60.1</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:453.17pt;position:var(--position);text-decoration:none;white-space:pre"> (Black Scholes) or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:532.53pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-802" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1912">59.9</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:558.36pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:578.21pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(Monte Carlo), and a risk-free rate of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:186.93pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-803" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1913">3.0</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:207.76pt;position:var(--position);text-decoration:none;white-space:pre"> (Black Scholes) or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:287.12pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-804" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1914">3.1</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:307.95pt;position:var(--position);text-decoration:none;white-space:pre"> (Monte Carlo).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:590.21pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The assumptions used for the valuations as of December 31, 2024 are set forth below:</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:616.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of March 28, 2024, using the same assumption with an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:317.15pt;position:var(--position);text-decoration:none;white-space:pre">+</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:322.78pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-805" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-1915">1</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:336.11pt;position:var(--position);text-decoration:none;white-space:pre"> volatility, &#8364;+</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:390.29pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eurPerShare" contextRef="c-806" decimals="INF" name="abvx:AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="0" id="f-1916">1</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:395.29pt;position:var(--position);text-decoration:none;white-space:pre"> share price, +</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:451.96pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-807" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-1917">1</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:465.29pt;position:var(--position);text-decoration:none;white-space:pre"> risk-free rate, +</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:529.72pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-808" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-1918">5</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:543.05pt;position:var(--position);text-decoration:none;white-space:pre"> in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:628.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">probability of achieving the Final redemption scenario and +</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:278.57pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-809" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-1919">1</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:291.9pt;position:var(--position);text-decoration:none;white-space:pre"> discount rate would result in changes of the MRI B value by </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:640.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">respectively &#8364;+</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:97.38pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-810" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-1920">4</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.97pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:145.97pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;-<ix:nonFraction unitRef="eur" contextRef="c-811" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-1921">30</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:202.89pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:207.89pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;-<ix:nonFraction unitRef="eur" contextRef="c-812" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-1922">3</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:259.81pt;position:var(--position);text-decoration:none;white-space:pre">, +</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:270.44pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-813" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-1923">35</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:319.03pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:338.46pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;-<ix:nonFraction unitRef="eur" contextRef="c-814" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-1924">53</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:395.38pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:665.81pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of June 21, 2024, using the same assumption with an increase of +</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:315.02pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-815" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-1925">1</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:328.35pt;position:var(--position);text-decoration:none;white-space:pre"> volatility, &#8364;+</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:382.53pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eurPerShare" contextRef="c-816" decimals="INF" name="abvx:AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="0" id="f-1926">1</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:387.53pt;position:var(--position);text-decoration:none;white-space:pre"> share price, +</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:444.2pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-817" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-1927">1</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:457.53pt;position:var(--position);text-decoration:none;white-space:pre"> risk-free rate, +</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:521.96pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-818" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-1928">5</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:535.29pt;position:var(--position);text-decoration:none;white-space:pre"> i</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:540.56pt;position:var(--position);text-decoration:none;white-space:pre">n the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:677.81pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">probability of achieving the Final redemption scenario and +</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:278.57pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-819" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-1929">1</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:291.9pt;position:var(--position);text-decoration:none;white-space:pre">discount rate would result in changes of the MRI C fair value by </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:689.81pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">respectively &#8364;+</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:97.38pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-820" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-1930">4</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.97pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:145.97pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;-<ix:nonFraction unitRef="eur" contextRef="c-821" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-1931">16</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:202.89pt;position:var(--position);text-decoration:none;white-space:pre">, &#8364;+</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:218.52pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-822" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-1932">8</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:262.11pt;position:var(--position);text-decoration:none;white-space:pre">, &#8364;+</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:277.74pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-823" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-1933">46</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:326.33pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:345.76pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;-<ix:nonFraction unitRef="eur" contextRef="c-824" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-1934">13</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:402.68pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div></div></ix:continuation></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-50<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><ix:continuation id="f-1730-9" continuedAt="f-1730-10"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2024, using the same assumption with an increase of +</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:337.74pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-825" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-1935">1</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:351.07pt;position:var(--position);text-decoration:none;white-space:pre"> volatility, &#8364;+</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:405.25pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eurPerShare" contextRef="c-826" decimals="INF" name="abvx:AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="0" id="f-1936">1</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:410.25pt;position:var(--position);text-decoration:none;white-space:pre"> share price, +</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:466.92pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-827" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-1937">1</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:480.25pt;position:var(--position);text-decoration:none;white-space:pre"> risk-free rate, +</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:544.6800000000001pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-828" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-1938">10</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:563.01pt;position:var(--position);text-decoration:none;white-space:pre"> in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:82.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the probability of achieving the Final redemption scenario and</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:285.14pt;position:var(--position);text-decoration:none;white-space:pre"> +</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:293.27pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-829" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-1939">1</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:306.6pt;position:var(--position);text-decoration:none;white-space:pre"> discount rate would result in changes of the MRI B and C fair </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:94.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">value by respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:123.38pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;-<ix:nonFraction unitRef="eur" contextRef="c-830" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-1940">1</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:175.3pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:180.3pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;-<ix:nonFraction unitRef="eur" contextRef="c-831" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-1941">3</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:232.22pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:237.22pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;-<ix:nonFraction unitRef="eur" contextRef="c-832" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-1942">3</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:289.14pt;position:var(--position);text-decoration:none;white-space:pre">, &#8364;+</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:304.77pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-833" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-1943">3</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:348.36pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:367.79pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;-<ix:nonFraction unitRef="eur" contextRef="c-834" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-1944">82</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:424.71pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:118.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Measurement of the Kreos / Claret tranche A-B-C BSA </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:140.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Kreos / Claret tranche A-B and tranche C BSA are measured at fair value using a Black-Scholes valuation model. The model </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:152.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">considers </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:76.24000000000001pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="scenario" contextRef="c-835" decimals="INF" name="abvx:NumberOfProbabilityWeightedScenarios" format="ixt-sec:numwordsen" scale="0" id="f-1945">two</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.22999999999999pt;position:var(--position);text-decoration:none;white-space:pre"> probability-weighted scenarios, i.e. (i) the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:263.52pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-835" name="abvx:ExpiryScenarioPeriodOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="f-1946">7</ix:nonNumeric> years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:292.1pt;position:var(--position);text-decoration:none;white-space:pre"> expiry of the BSA and (ii) an earlier exercise upon a tender offer. </span><ix:continuation id="f-1396-5" continuedAt="f-1396-6"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:558.17pt;position:var(--position);text-decoration:none;white-space:pre">The </span></ix:continuation></div><ix:continuation id="f-1396-6"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:163.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">main data and assumptions are the following:</span></div><div style="position:var(--position);top:211.46pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:522pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:137.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:125.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:125.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:125.25pt"/></tr><tr style="height:24pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.2pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos/Claret Tranche A-B BSA - </span></div><div style="line-height:8pt;position:var(--position);top:13.8pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">August 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.32pt;position:var(--position);text-decoration:none;white-space:pre">AS OF AUGUST 22, 2023 </span></div><div style="line-height:8pt;position:var(--position);top:14pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:37.65pt;position:var(--position);text-decoration:none;white-space:pre">(Tranche A-B)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:9pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.88pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:9pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.88pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2024</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Number of outstanding BSA</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:24pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-836" decimals="INF" name="abvx:NumberOfWarrantsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1947">214,198</ix:nonFraction></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:24pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-837" decimals="INF" name="abvx:NumberOfWarrantsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1948">214,198</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:24pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-838" decimals="INF" name="abvx:NumberOfWarrantsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1949">214,198</ix:nonFraction></span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:39.75pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Exercise price per share</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:39.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:100.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-839" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-1950">18.67</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:39.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:100.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-840" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-1951">18.67</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:39.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:100.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-841" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-1952">18.67</ix:nonFraction></span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:55.5pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Ordinary share price</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:55.5pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:100.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-842" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-1953">17.10</ix:nonFraction></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:55.5pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-843" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-1954">9.82</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:55.5pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-844" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-1955">6.76</ix:nonFraction></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:71.25pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Exercise date</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:71.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.44pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:19.99pt;position:var(--position);text-decoration:none;white-space:pre">19/08/2030 (expiry) 18/02/2027 </span></div><div style="line-height:8pt;position:var(--position);top:12.44pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:79.79pt;position:var(--position);text-decoration:none;white-space:pre">(tender offer)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:71.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.43pt;position:var(--position);text-decoration:none;white-space:pre">19/08/2030 (expiry)</span></div><div style="line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:41.35pt;position:var(--position);text-decoration:none;white-space:pre">18/02/2027 (tender offer)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:71.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.43pt;position:var(--position);text-decoration:none;white-space:pre">19/08/2030 (expiry)</span></div><div style="line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:41.35pt;position:var(--position);text-decoration:none;white-space:pre">18/02/2027 (tender offer)</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:92.25pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">7-year expiry scenario probability</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:92.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-845" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1956">50</ix:nonFraction></span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:92.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-846" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1957">95</ix:nonFraction></span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:92.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-847" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1958">95</ix:nonFraction></span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:108pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Volatility</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:108pt;width:125.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:74.21pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-848" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1959">71.9</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.86999999999999pt;position:var(--position);white-space:pre"> (expiry) </span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:57.13pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-849" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1960">65.2</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.79pt;position:var(--position);white-space:pre"> (tender offer)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:108pt;width:125.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:74.21pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-850" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1961">59.5</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.86999999999999pt;position:var(--position);white-space:pre"> (expiry)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:57.13pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-851" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1962">64.9</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.79pt;position:var(--position);white-space:pre"> (tender offer)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:108pt;width:125.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:74.21pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-852" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1963">44.3</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.86999999999999pt;position:var(--position);white-space:pre"> (expiry)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:57.13pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-853" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1964">44.3</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.79pt;position:var(--position);white-space:pre"> (tender offer)</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:129pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Dividend</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:129pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-854" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" format="ixt:fixed-zero" scale="-2" id="f-1965">&#8212;</ix:nonFraction></span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:129pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-855" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" format="ixt:fixed-zero" scale="-2" id="f-1966">&#8212;</ix:nonFraction></span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:129pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-856" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" format="ixt:fixed-zero" scale="-2" id="f-1967">&#8212;</ix:nonFraction></span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:144.75pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Risk-free rate</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:144.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-857" decimals="4" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1968">3.00</ix:nonFraction></span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:144.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-858" decimals="4" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1969">2.30</ix:nonFraction></span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="height:17.25pt;left:396.75pt;overflow:hidden;position:var(--position);top:144.75pt;width:125.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:0.52pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:78.21pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-859" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1970">2.9</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.86999999999999pt;position:var(--position);white-space:pre"> (expiry)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:10.6pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:61.13pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-860" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1971">2.9</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.79pt;position:var(--position);white-space:pre"> (tender offer)</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:162pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Fair value of issued Kreos/Claret </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Tranche A-B BSA</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:162pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:97.21pt"></span></span><span style="left:99.83999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-836" decimals="-3" name="abvx:AggregateFairValueOtherEquityInstrumentsOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-1972">2,092</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:6.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:162pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:103.21pt"></span></span><span style="left:105.83999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-837" decimals="-3" name="abvx:AggregateFairValueOtherEquityInstrumentsOutstanding" scale="3" id="f-1973">920</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:6.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:162pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:103.21pt"></span></span><span style="left:105.83999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-838" decimals="-3" name="abvx:AggregateFairValueOtherEquityInstrumentsOutstanding" scale="3" id="f-1974">243</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:6.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:421.86pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:522pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:137.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:125.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:125.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:125.25pt"/></tr><tr style="height:24pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.2pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos/Claret Tranche C BSA - </span></div><div style="line-height:8pt;position:var(--position);top:13.8pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">November 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:9pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.43pt;position:var(--position);text-decoration:none;white-space:pre">AS OF NOVEMBER 2, 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:9pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.88pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:9pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.88pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2024</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Number of outstanding BSA</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:24pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-861" decimals="INF" name="abvx:NumberOfWarrantsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1975">405,832</ix:nonFraction></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:24pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-862" decimals="INF" name="abvx:NumberOfWarrantsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1976">405,832</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:24pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-863" decimals="INF" name="abvx:NumberOfWarrantsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1977">405,832</ix:nonFraction></span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:39.75pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">of which, number of conditional BSA</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:39.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.8pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:96.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-861" decimals="INF" name="abvx:NumberOfWarrantsOutstandingSubjectToNonMarketPerformanceCondition" format="ixt:num-dot-decimal" scale="0" id="f-1978">202,915</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:39.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.8pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:96.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-862" decimals="INF" name="abvx:NumberOfWarrantsOutstandingSubjectToNonMarketPerformanceCondition" format="ixt:num-dot-decimal" scale="0" id="f-1979">202,916</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:39.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.8pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:118.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-863" decimals="INF" name="abvx:NumberOfWarrantsOutstandingSubjectToNonMarketPerformanceCondition" scale="0" id="f-1980">0</ix:nonFraction></span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:55.5pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Exercise price per share</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:55.5pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:6.99pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-864" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-1981">9.86</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:55.5pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:6.99pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-865" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-1982">9.86</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:55.5pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:6.99pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-866" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-1983">9.86</ix:nonFraction></span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:71.25pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Ordinary share price</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:71.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-867" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-1984">8.89</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:71.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-868" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-1985">9.82</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:71.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-869" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-1986">6.67</ix:nonFraction></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:87pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Exercise date</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:87pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.43pt;position:var(--position);white-space:pre">01/11/2030 (expiry) </span></div><div style="line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:41.35pt;position:var(--position);white-space:pre">18/02/2027 (tender offer)</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:87pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.43pt;position:var(--position);text-decoration:none;white-space:pre">01/11/2030 (expiry)</span></div><div style="line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:41.35pt;position:var(--position);text-decoration:none;white-space:pre">18/02/2027 (tender offer)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:87pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.43pt;position:var(--position);text-decoration:none;white-space:pre">01/11/2030 (expiry)</span></div><div style="line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:41.35pt;position:var(--position);text-decoration:none;white-space:pre">18/02/2027 (tender offer)</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:108pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">7-year expiry scenario probability</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:108pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-870" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1987">95</ix:nonFraction></span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:108pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-871" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1988">95</ix:nonFraction></span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:108pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-872" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1989">95</ix:nonFraction></span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:123.75pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Probability of Drawdown of Tranche C </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">credit facility</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:123.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-873" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1990">30</ix:nonFraction></span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:123.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-874" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1991">30</ix:nonFraction></span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:123.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.09pt;position:var(--position);text-decoration:none;white-space:pre">Drawn on June 21, 2024</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:144.75pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Volatility</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:144.75pt;width:125.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:74.21pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-875" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1992">67.3</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.86999999999999pt;position:var(--position);white-space:pre"> (expiry)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:57.13pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-876" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1993">64.3</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.79pt;position:var(--position);white-space:pre"> (tender offer)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:144.75pt;width:125.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:74.21pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-877" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1994">67.4</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.86999999999999pt;position:var(--position);white-space:pre"> (expiry)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:57.13pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-878" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1995">64.9</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.79pt;position:var(--position);white-space:pre"> (tender offer)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:144.75pt;width:125.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:74.21pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-879" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1996">44.3</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.86999999999999pt;position:var(--position);white-space:pre"> (expiry)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:57.13pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-880" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1997">44.3</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.79pt;position:var(--position);white-space:pre"> (tender offer)</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:165.75pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Dividend</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:165.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-881" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" format="ixt:fixed-zero" scale="-2" id="f-1998">&#8212;</ix:nonFraction></span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:165.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-882" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" format="ixt:fixed-zero" scale="-2" id="f-1999">&#8212;</ix:nonFraction></span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:165.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-883" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" format="ixt:fixed-zero" scale="-2" id="f-2000">&#8212;</ix:nonFraction></span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:24pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:181.5pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:8.93pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Risk-free rate</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:181.5pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:8.93pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-884" decimals="4" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2001">3.00</ix:nonFraction></span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:181.5pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:8.93pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-885" decimals="4" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2002">2.30</ix:nonFraction></span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:181.5pt;width:125.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:3.89pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:78.21pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-886" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2003">2.9</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.86999999999999pt;position:var(--position);white-space:pre"> (expiry)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:13.97pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:61.13pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-887" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2004">2.9</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.79pt;position:var(--position);white-space:pre"> (tender offer)</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:205.5pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:137.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Fair value of issued Kreos/Claret </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:137.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Tranche C BSA</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:205.5pt;width:125.25pt"><div><div style="line-height:9pt;position:var(--position);top:7.05pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.09pt;width:94.96pt"></span></span><span style="left:97.58999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-861" decimals="-3" name="abvx:AggregateFairValueOtherEquityInstrumentsOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-2005">1,493</ix:nonFraction><span style="display:inline-block;height:6.09pt;width:6.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:205.5pt;width:125.25pt"><div><div style="line-height:9pt;position:var(--position);top:7.05pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.09pt;width:94.96pt"></span></span><span style="left:97.58999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-862" decimals="-3" name="abvx:AggregateFairValueOtherEquityInstrumentsOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-2006">1,659</ix:nonFraction><span style="display:inline-block;height:6.09pt;width:6.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:205.5pt;width:125.25pt"><div><div style="line-height:9pt;position:var(--position);top:7.05pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.09pt;width:101.71pt"></span></span><span style="left:104.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-863" decimals="-3" name="abvx:AggregateFairValueOtherEquityInstrumentsOutstanding" scale="3" id="f-2007">923</ix:nonFraction><span style="display:inline-block;height:6.09pt;width:6.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:664.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of August 20, 2023 (date of issuance of the tranche A-B BSA), using the same assumption with an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:491.98pt;position:var(--position);text-decoration:none;white-space:pre">+<ix:nonFraction unitRef="number" contextRef="c-888" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-2008">1</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:510.94pt;position:var(--position);text-decoration:none;white-space:pre"> volatility, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:554.49pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:676.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">+<ix:nonFraction unitRef="eurPerShare" contextRef="c-889" decimals="INF" name="abvx:AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="0" id="f-2009">1</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:46.63pt;position:var(--position);text-decoration:none;white-space:pre">share price, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:95.17pt;position:var(--position);text-decoration:none;white-space:pre">+<ix:nonFraction unitRef="number" contextRef="c-890" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-2010">1</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.13pt;position:var(--position);text-decoration:none;white-space:pre"> risk-free rate or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:181.26pt;position:var(--position);text-decoration:none;white-space:pre">+<ix:nonFraction unitRef="number" contextRef="c-891" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-2011">5</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:200.22pt;position:var(--position);text-decoration:none;white-space:pre"> in the probability of achieving the</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:338.39pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:340.89pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-892" name="abvx:ExpiryScenarioPeriodOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="f-2012">7</ix:nonNumeric> years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:369.47pt;position:var(--position);text-decoration:none;white-space:pre"> expiry scenario would result in an increase of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:688.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">tranche A-B BSA fair value by respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:213.28pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-893" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-2013">48</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:266.87pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:271.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-894" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-2014">197</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:330.46pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:335.46pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-895" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-2015">64</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:389.05pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:408.48pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-896" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-2016">64</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:462.07pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div></div></ix:continuation></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-51<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-1730-10" continuedAt="f-1730-11"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of November 2, 2023 (date of issuance of the tranche C BSA), using the same assumption with an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:489.73pt;position:var(--position);text-decoration:none;white-space:pre">+<ix:nonFraction unitRef="number" contextRef="c-897" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-2017">1</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:508.69pt;position:var(--position);text-decoration:none;white-space:pre"> volatility, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:552.24pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:82.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">+<ix:nonFraction unitRef="eurPerShare" contextRef="c-898" decimals="INF" name="abvx:AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="0" id="f-2018">1</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:46.63pt;position:var(--position);text-decoration:none;white-space:pre">share price, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:95.17pt;position:var(--position);text-decoration:none;white-space:pre">+<ix:nonFraction unitRef="number" contextRef="c-899" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-2019">1</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.13pt;position:var(--position);text-decoration:none;white-space:pre"> risk-free rate or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:181.26pt;position:var(--position);text-decoration:none;white-space:pre">+<ix:nonFraction unitRef="number" contextRef="c-900" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-2020">5</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:200.22pt;position:var(--position);text-decoration:none;white-space:pre"> in the probability of achieving the </span><ix:nonNumeric contextRef="c-901" name="abvx:ExpiryScenarioPeriodOtherEquityInstrumentsGranted" format="ixt-sec:durwordsen" id="f-2021"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:340.89pt;position:var(--position);text-decoration:none;white-space:pre">7</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:345.89pt;position:var(--position);text-decoration:none;white-space:pre">-year</span></ix:nonNumeric><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:366.41pt;position:var(--position);text-decoration:none;white-space:pre"> expiry scenario would result in an increase of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:94.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">tranche A-B BSA fair value by respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:213.28pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-902" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-2022">28</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:266.87pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:271.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-903" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-2023">232</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:330.46pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:335.46pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-904" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-2024">42</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:389.05pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:408.48pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-905" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-2025">36</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:462.07pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:118.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, using the same assumption with an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:332.11pt;position:var(--position);text-decoration:none;white-space:pre">+<ix:nonFraction unitRef="number" contextRef="c-906" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-2026">1</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:351.07pt;position:var(--position);text-decoration:none;white-space:pre"> volatility, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:394.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;+<ix:nonFraction unitRef="eurPerShare" contextRef="c-907" decimals="INF" name="abvx:AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="0" id="f-2027">1</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:410.25pt;position:var(--position);text-decoration:none;white-space:pre">share price, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:458.79pt;position:var(--position);text-decoration:none;white-space:pre">+<ix:nonFraction unitRef="number" contextRef="c-908" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-2028">1</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:477.75pt;position:var(--position);text-decoration:none;white-space:pre"> risk-free rate and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:550.98pt;position:var(--position);text-decoration:none;white-space:pre">+<ix:nonFraction unitRef="number" contextRef="c-909" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-2029">5</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:569.94pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:130.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in the probability of achieving the </span><ix:nonNumeric contextRef="c-910" name="abvx:ExpiryScenarioPeriodOtherEquityInstrumentsGranted" format="ixt-sec:durwordsen" id="f-2030"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:174.17pt;position:var(--position);text-decoration:none;white-space:pre">7</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:179.17pt;position:var(--position);text-decoration:none;white-space:pre">-year</span></ix:nonNumeric><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:199.69pt;position:var(--position);text-decoration:none;white-space:pre"> expiry scenario would result in an increase of Kreos / Claret A-B and C BSA fair value by </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:142.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:86.75pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-911" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-2031">96</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.34pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:145.34pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-912" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-2032">401</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:203.93pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:208.93pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-913" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-2033">95</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:262.52pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:281.95pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-914" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-2034">76</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:335.54pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:166.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2024, using the same assumption with an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:332.11pt;position:var(--position);text-decoration:none;white-space:pre">+<ix:nonFraction unitRef="number" contextRef="c-825" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-2035">1</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:351.07pt;position:var(--position);text-decoration:none;white-space:pre"> volatility, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:394.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;+<ix:nonFraction unitRef="eurPerShare" contextRef="c-826" decimals="INF" name="abvx:AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="0" id="f-2036">1</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:410.25pt;position:var(--position);text-decoration:none;white-space:pre"> share price, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:461.29pt;position:var(--position);text-decoration:none;white-space:pre">+<ix:nonFraction unitRef="number" contextRef="c-827" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-2037">1</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:480.25pt;position:var(--position);text-decoration:none;white-space:pre"> risk-free rate and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:178.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">+</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:41.63pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-915" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-2038">10</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:59.96pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:62.46pt;position:var(--position);text-decoration:none;white-space:pre">in the probability of achieving the </span><ix:nonNumeric contextRef="c-916" name="abvx:ExpiryScenarioPeriodOtherEquityInstrumentsGranted" format="ixt-sec:durwordsen" id="f-2039"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:200.63pt;position:var(--position);text-decoration:none;white-space:pre">7</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:205.63pt;position:var(--position);text-decoration:none;white-space:pre">-year</span></ix:nonNumeric><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:226.15pt;position:var(--position);text-decoration:none;white-space:pre"> expiry scenario would result in an increase of Kreos / Claret A-B and C BSA fair </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:190.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">value by respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:123.38pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-917" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-2040">37</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:176.97pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:181.97pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-918" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-2041">350</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:240.56pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:245.56pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-919" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-2042">61</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:299.15pt;position:var(--position);text-decoration:none;white-space:pre"> and</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:316.08pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-920" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-2043">75</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:369.67pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:226.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of the exercise dates of the Kreos / Claret BSA (July 30, 2025 and August 28, 2025), due to the put options (allowing for a cashless </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:238.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">exercise) being exercised by the holders, the fair value of the BSAs is deemed equal to their intrinsic value, which is equal to the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:250.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">difference between the listed share price on the exercise dates and their exercise price.</span></div></ix:continuation><div style="position:absolute;top:292.56pt" id="i7a006daedb3d4216a4128b76247285d7_418"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:292.56pt;width:612pt"><ix:continuation id="f-1730-11" continuedAt="f-1730-12"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 15.2.&#160; Heights convertible notes&#160; </span></ix:continuation></div><ix:continuation id="f-1730-12" continuedAt="f-1730-13"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:314.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On August 20, 2023, the Group entered into a convertible notes subscription agreement with Heights, which provided for up to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:325.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-79" decimals="-3" name="abvx:BorrowingsMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="f-2044">75,000</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:107.09pt;position:var(--position);text-decoration:none;white-space:pre"> in financing, consisting of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:216.44pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="tranche" contextRef="c-79" decimals="INF" name="abvx:BorrowingsNumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="f-2045">two</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:231.43pt;position:var(--position);text-decoration:none;white-space:pre"> tranches: </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:348.16pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The first tranche (&#8220;tranche A&#8221;) of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:208.47pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-921" decimals="-3" name="abvx:NetProceedsFromConvertibleLoansNotes" format="ixt:num-dot-decimal" scale="3" id="f-2046">35,000</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:279.56pt;position:var(--position);text-decoration:none;white-space:pre"> in aggregate principal amount was drawn on August 24, 2023 and is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:361.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">composed of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:125.85pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-922" decimals="INF" name="abvx:NumberOfConvertibleNotesIssued" scale="0" id="f-2047">350</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.85pt;position:var(--position);text-decoration:none;white-space:pre"> amortizing senior convertible notes with a nominal value of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:384.45pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-922" decimals="INF" name="abvx:ConvertibleLoansNotesNominalValue" format="ixt:num-dot-decimal" scale="0" id="f-2048">100,000</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:421.95pt;position:var(--position);text-decoration:none;white-space:pre"> each and a fixed conversion price of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:375.04pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-922" decimals="4" name="abvx:BorrowingsFixedConversionPrice" scale="0" id="f-2049">23.7674</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:109.5pt;position:var(--position);text-decoration:none;white-space:pre"> (corresponding to a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:192.20999999999998pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-922" decimals="2" name="abvx:ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted" scale="-2" id="f-2050">40</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:210.54pt;position:var(--position);text-decoration:none;white-space:pre"> premium over the 15-day VWAP prior to the date on which their issuance is decided, and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:388.48pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">subject to standard adjustments, including anti-dilution and dividend protections).</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:413.12pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The second tranche (&#8220;tranche B&#8221;) of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:219.57pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-923" decimals="-3" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-2051">40,000</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:290.65999999999997pt;position:var(--position);text-decoration:none;white-space:pre"> in aggregate principal amount is composed of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:478.23pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-923" decimals="INF" name="abvx:NumberOfConvertibleNotesIssued" scale="0" id="f-2052">400</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:493.23pt;position:var(--position);text-decoration:none;white-space:pre"> amortizing senior </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:426.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">convertible notes with a nominal value of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:240.41pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-923" decimals="INF" name="abvx:ConvertibleLoansNotesNominalValue" format="ixt:num-dot-decimal" scale="0" id="f-2053">100,000</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:277.90999999999997pt;position:var(--position);text-decoration:none;white-space:pre"> each, and a conversion price (if any) that is be equal to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:501.52pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-923" decimals="2" name="abvx:ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted" scale="-2" id="f-2054">130</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:524.85pt;position:var(--position);text-decoration:none;white-space:pre"> of the 15-</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:440pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">day VWAP immediately preceding the date on which their issuance is decided.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:453.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">It may be drawn during the period from the date immediately following the </span><ix:nonNumeric contextRef="c-924" name="abvx:ConvertibleLoansNotesPeriod" format="ixt-sec:durwordsen" id="f-2055"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:375.27pt;position:var(--position);text-decoration:none;white-space:pre">three</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:395.23pt;position:var(--position);text-decoration:none;white-space:pre">-month</span></ix:nonNumeric><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:424.1pt;position:var(--position);text-decoration:none;white-space:pre"> anniversary of the issuance of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:464.64pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">first tranche to the first-year anniversary of the issuance of the first tranche (i.e. August 24, 2024), in up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:499.33pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="closing" contextRef="c-924" decimals="INF" name="abvx:ConvertibleLoansNotesNumberOfSeparateClosings" format="ixt-sec:numwordsen" scale="0" id="f-2056">two</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:514.3199999999999pt;position:var(--position);text-decoration:none;white-space:pre"> separate </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:475.84pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">closings to provide the Group with additional flexibility to request a partial drawdown.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:487.04pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">On the limit date for the drawdown of the second tranche of the Heights Financing (i.e. August 4, 2024), the Group had not </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:498.24pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">drawn down this tranche and has therefore forgone its right to do so in the future.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:531.84pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Interest on the Heights convertible notes accrues at a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:249.32pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-79" decimals="4" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-2057">6.00</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:275.15pt;position:var(--position);text-decoration:none;white-space:pre"> annual fixed interest rate payable in quarterly installments in cash or, at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:543.04pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the option of the Group, in ordinary shares.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:565.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Heights convertible notes will be repaid through </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:249.65pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="installment" contextRef="c-79" decimals="INF" name="abvx:BorrowingsNumberOfQuarterlyInstallments" format="ixt-sec:numwordsen" scale="0" id="f-2058">sixteen</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:277.94pt;position:var(--position);text-decoration:none;white-space:pre"> quarterly installment payments, beginning </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:451.63pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-925" name="abvx:BorrowingsMaturityDeferralPeriod" format="ixt-sec:durwordsen" id="f-2059">three months</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:503.52pt;position:var(--position);text-decoration:none;white-space:pre"> after their </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:576.64pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">issuance date (corresponding, for the first tranche, to a final repayment date on August 24, 2027). Installments are payable in cash or, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:587.84pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">at the option of the Group, in ordinary shares.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:610.24pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Any interest or installment payments in shares will be made on the basis of a share price equal to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:425.81pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-79" decimals="INF" name="abvx:BorrowingsPercentageOfMarketPrice" scale="-2" id="f-2060">90</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:444.14pt;position:var(--position);text-decoration:none;white-space:pre"> of the Market Price of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:621.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">ordinary shares at the time of payment, where &#8220;Market Price&#8221; refers to the arithmetic average of the daily volume weighted average </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:632.64pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">price (&#8220;VWAP&#8221;) for the ordinary shares on the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:225.8pt;position:var(--position);text-decoration:none;white-space:pre">two</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:240.79pt;position:var(--position);text-decoration:none;white-space:pre"> (</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:246.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-925" name="abvx:BorrowingsMarketPriceNumberOfDaysWithLowestDailyVWAP" format="ixt-sec:durday" id="f-2061">2</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:251.62pt;position:var(--position);text-decoration:none;white-space:pre">) days with the lowest daily VWAPs out of the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:440.9pt;position:var(--position);text-decoration:none;white-space:pre">five</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:456.43pt;position:var(--position);text-decoration:none;white-space:pre"> (</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:462.26pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-925" name="abvx:BorrowingsMarketPriceNumberOfTradingDays" format="ixt-sec:durday" id="f-2062">5</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:467.26pt;position:var(--position);text-decoration:none;white-space:pre">) trading days immediately </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:643.84pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">preceding the applicable date, but in no event greater than the VWAP of the ordinary shares on the applicable date. The Market Price </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:655.04pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">may not be higher than the applicable conversion price. Issuances of ordinary shares may not be made at a price lower than a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:537.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-926" decimals="2" name="abvx:IssuancePricePercentageOfDiscountTo15DayWVAP" scale="-2" id="f-2063">15</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:555.95pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:666.24pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">discount to the 15-day VWAP at the time of the decision to issue the Heights convertible notes (i.e., </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:438.06pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-79" decimals="4" name="abvx:EquityIssuanceSubscriptionPricePerShare" scale="0" id="f-2064">14.4303</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:475.56pt;position:var(--position);text-decoration:none;white-space:pre"> per ordinary share.).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:688.64pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Heights convertible notes include the following conversion and settlement options:</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:699.84pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Conversion at the option of the noteholders: the notes are convertible into the Group&#8217;s ordinary shares at the option of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:711.04pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">noteholders at any time during the period beginning on the tranche A notes closing until the fifth business day prior to the </span></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-52<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><ix:continuation id="f-1730-13" continuedAt="f-1730-14"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">maturity date. The ordinary shares issued would be equal to the product of (i) the conversion ratio in effect on the exercise </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:81.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">date, (ii) a fraction, the numerator of which is the outstanding principal amount per note and the denominator of which is the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:92.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">initial principal amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:179.07999999999998pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-79" decimals="INF" name="abvx:ConvertibleLoansNotesNominalValue" format="ixt:num-dot-decimal" scale="0" id="f-2065">100,000</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:216.58pt;position:var(--position);text-decoration:none;white-space:pre"> per note, and (iii) the number of notes for which the conversion right has been exercised.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:115.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Settlement in shares at the option of the Group: the Group has the option to settle any interest or principal due with its own </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:127.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ordinary shares (with respect to all but not some of the notes outstanding), subject to a price limit. The ordinary shares </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:139.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">issuable will be the lower of the conversion ratio or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:280.1pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-927" decimals="2" name="abvx:ConvertibleLoansNotesSettlementInSharesPercentageOfFairMarketValue" scale="-2" id="f-2066">90</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.43pt;position:var(--position);text-decoration:none;white-space:pre"> of the fair market value of the Group&#8217;s ordinary shares. </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:162.56pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Settlement in shares at the option of the noteholders (&#8220;SSO Investor Price Limit Option&#8221;): the noteholders may require a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:176pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">principal payment to be settled in shares in the event the share settlement price on any principal payment date is below the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:189.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">price limit in effect (initially </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:188.18pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-927" decimals="4" name="abvx:EquityIssuanceSubscriptionPricePerShare" scale="0" id="f-2067">14.4303</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:225.68pt;position:var(--position);text-decoration:none;white-space:pre">, subject to adjustments as described in the key terms below) and the Cash Carve-Out </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:202.88pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(i.e. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90.03pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-927" decimals="-3" name="abvx:EquityIssuanceCashCarveOut" scale="6" id="f-2068">13.125</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:153.88pt;position:var(--position);text-decoration:none;white-space:pre"> &#8211; the amount of cash permitted to be paid to Heights for principal payments) has been utilized such that </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:216.32pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">it does not allow payment in full of the principal payment. The majority noteholder may agree to waive the cash payment </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:229.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(which would otherwise be deferred until the original maturity date) and require the Group to exercise the share settlement </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:243.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">option for the principal payment required. A number of the ordinary shares issuable is based on the price limit in effect.</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:267.84pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Repayment of the notes upon an Event of Default (as defined below): the noteholder may notify the Group of their decision </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:281.28pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to cause the notes to become payable at a price equal to the Early Redemption Amount (as defined below) upon an Event of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:294.72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Default. The Early Redemption Amount means an amount equal to the greater of (a) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:411.86pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-928" decimals="2" name="abvx:ConvertibleLoansNotesEarlyRedemptionAmountPercentageOfOutstandongPrincipal" scale="-2" id="f-2069">120</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:435.19pt;position:var(--position);text-decoration:none;white-space:pre"> of the outstanding principal of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:308.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">note and (b) the market price of a number of shares issuable per note had the conversion right been exercised. Events of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:321.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Default include the following: default in any payment due on the notes, failure to deliver shares upon exercise of conversion </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:335.04pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">right or share settlement option, default of the Group on any obligation under the agreement, and other events.</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:359.68pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Repayment or purchase of the notes upon change of control, a delisting, or free float event (each, a &#8220;Put Event&#8221;): Upon a Put </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:373.12pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Event, the noteholder has an option to require the Group to redeem or, at the Group&#8217;s option, to purchase all of the notes at </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:386.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the total aggregate amount equal to the outstanding principal and interest accrued through the date of a Put Event.</span><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:526.15pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:413.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Heights Financing is a senior, unsecured financing. The terms and conditions of the Heights convertible notes include a standard </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:425pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">negative pledge providing that any security granted in favor of other borrowed debt or debt instruments should also be granted in favor </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:436.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of the Heights convertible notes on an equal basis (with the exception of the securities issued pursuant to the Kreos / Claret Financing, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:447.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">as detailed above).</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:469.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On August 24,</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.6pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> 2023, the Group repaid in full an outstanding amount of</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:320.81pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:323.81pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-85" decimals="-3" name="abvx:RepaymentsOfConvertibleLoansNotes" format="ixt:num-dot-decimal" scale="3" id="f-2070">25,102</ix:nonFraction>&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:394.9pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">, corresponding to the outstanding OCEANE </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:483.24pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">bonds, by way of set-off with the Heights Financing. The accounting treatment for this transaction is explained in Note 15.5.</span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:505.64pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On July 23 and July 30, 2025, the noteholders requested the conversion of respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:385.7pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="note" contextRef="c-129" decimals="INF" name="abvx:NumberOfConvertibleNotesConverted" scale="0" id="f-2071">150</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:400.7pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:420.13pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="note" contextRef="c-130" decimals="INF" name="abvx:NumberOfConvertibleNotesConverted" scale="0" id="f-2072">200</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:435.13pt;position:var(--position);text-decoration:none;white-space:pre"> convertible notes (corresponding </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:517.64pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">to the entirety of the outstanding principal amount of approximately </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:310.13pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-130" decimals="-5" name="ifrs-full:NotionalAmount" scale="6" id="f-2073">21.9</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:363.98pt;position:var(--position);text-decoration:none;white-space:pre">) into </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:387.85pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-131" decimals="INF" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-2074">920,377</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:420.35pt;position:var(--position);text-decoration:none;white-space:pre"> new ordinary shares of the Group at a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:529.64pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">conversion price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:115.64pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-130" decimals="4" name="abvx:BorrowingsFixedConversionPrice" scale="0" id="f-2075">23.7674</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:153.14pt;position:var(--position);text-decoration:none;white-space:pre"> per ordinary share (see Note 3.3 - </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:292.17pt;position:var(--position);text-decoration:none;white-space:pre">Conversion of the Heights convertible notes, Kreos OCABSA and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:541.64pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Kreos / Claret BSA and prepayment of the Kreos / Claret Tranches B and C bond loans &#8211;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:393.78pt;position:var(--position);text-decoration:none;white-space:pre"> July-December 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:479.79pt;position:var(--position);text-decoration:none;white-space:pre">).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:571.64pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Accounting treatment and measurement</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:593.64pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In application of the Amendments to IAS 1 Presentation of Financial Statements &#8211; Classification of Liabilities as Current or Non-</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:604.84pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">current, and Non-current Liabilities with Covenants, the Heights convertible notes are classified as current financial liabilities as of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:616.04pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">December 31, 2023 and 2024.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:638.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group concluded that, except for the repayment or purchase option of the notes upon a Put Event, the above-mentioned </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:649.64pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">conversion and settlement options represented embedded derivatives that required to be bifurcated from their host contract. The Group </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:660.84pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">being unable to reliably value each embedded derivative at issuance date and on subsequent reporting dates, it measured the whole </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:672.04pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">instrument at fair value through profit or loss (&#8220;FVTPL&#8221;) as permitted by IFRS 9. Instruments measured at FVTPL under these </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:683.24pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">conditions are measured at their fair value on issuance and on subsequent reporting dates, and the amount of change in the fair value of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:694.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the financial liability is presented in profit or loss.</span></div></div></ix:continuation></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-53<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-1730-14" continuedAt="f-1730-15"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">At inception, the Heights convertible notes were measured at fair value, which differs from the issuance procee</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:480.43pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">ds by </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:504.32pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-925" decimals="-3" name="abvx:GainsArisingFromRecognitionOfFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2076">2,359</ix:nonFraction>&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:570.41pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">. </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:81.76pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">Since the fair value measurement of the instrument is evidenced by a valuation technique that does not only use data from observable </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:92.96pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">markets, the carrying amount was adjusted to defer the difference between the fair value measurement and the transaction price, and </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:104.16pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">the day one gain is therefore recognized in financial income on a straight-line basis over the term of the instrument. </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:115.36pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">As of December 31, 2023 and 2024, the amounts by which the carrying value of the notes is adjusted to take into account the </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">unrecognized day one gain are </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:160.57pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-929" decimals="-3" name="abvx:UnrecognitionDayOneGainOfFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2077">2,147</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:226.66pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:246.09pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-930" decimals="-3" name="abvx:UnrecognitionDayOneGainOfFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2078">1,557</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:312.18pt;position:var(--position);text-decoration:none;white-space:pre">, respectively.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:148.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The fair value of the Heights convertible notes (including the embedded features) has been measured with a Monte Carlo model, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:160.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">considering </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.12pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="scenario" contextRef="c-55" decimals="INF" name="abvx:NumberOfProbabilityWeightedScenarios" format="ixt-sec:numwordsen" scale="0" id="f-2079">two</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:100.11pt;position:var(--position);text-decoration:none;white-space:pre"> probability-weighted scenarios: (i) a Put Event or Default/Dissolution scenario and (ii) a voluntary conversion at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:171.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">maturity scenario. </span><ix:nonNumeric contextRef="c-1" name="abvx:DisclosureOfIndirectMeasurementOfConvertibleLoansInstrumentsTableTextBlock" id="f-2080" continuedAt="f-2080-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:110.62pt;position:var(--position);text-decoration:none;white-space:pre">The main data and assumptions are the following: </span></ix:nonNumeric></div><ix:continuation id="f-2080-1"><div style="position:var(--position);top:193.76pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:519pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:143.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:128.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:119.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:119.25pt"/></tr><tr style="height:17.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.62pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Heights convertible notes - August 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.62pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:19.82pt;position:var(--position);text-decoration:none;white-space:pre">AS OF AUGUST 24, 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.62pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.88pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.62pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.88pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2024</span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:17.25pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Number of outstanding notes</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:17.25pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:113.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-931" decimals="INF" name="abvx:NumberOfConvertibleNotesOutstanding" scale="0" id="f-2081">350</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:17.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-932" decimals="INF" name="abvx:NumberOfConvertibleNotesOutstanding" scale="0" id="f-2082">350</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:17.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-933" decimals="INF" name="abvx:NumberOfConvertibleNotesOutstanding" scale="0" id="f-2083">350</ix:nonFraction></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:34.5pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Original principal amount (in thousands of </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:34.5pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:103.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-931" decimals="-3" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-2084">35,000</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:34.5pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-932" decimals="-3" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-2085">35,000</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:34.5pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-933" decimals="-3" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-2086">35,000</ix:nonFraction></span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:55.5pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest rate</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:55.5pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:116.84pt;position:var(--position)"></span><span style="left:116.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-934" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2087">6</ix:nonFraction></span><span style="left:120.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:55.5pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:107.84pt;position:var(--position)"></span><span style="left:107.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-935" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2088">6</ix:nonFraction></span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:55.5pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:107.84pt;position:var(--position)"></span><span style="left:107.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-936" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2089">6</ix:nonFraction></span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:72.75pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Conversion price per share</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:72.75pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:103.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-937" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-2090">23.77</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:72.75pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-938" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-2091">23.77</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:72.75pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-939" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-2092">23.77</ix:nonFraction></span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Ordinary share price</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:90pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:103.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-940" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-2093">16.74</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:90pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:98.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-941" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-2094">9.82</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:90pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:98.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-942" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-2095">6.76</ix:nonFraction></span></div></div></div></td></tr><tr style="height:27pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:107.25pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:10.43pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Maturity date</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:107.25pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.63pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:13.88pt;position:var(--position);text-decoration:none;white-space:pre">24/08/2025 (put event) 24/08/2027 </span></div><div style="line-height:8pt;position:var(--position);top:15.23pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:32.58pt;position:var(--position);text-decoration:none;white-space:pre">(HTM/voluntary conversion)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:27pt;left:277.5pt;overflow:hidden;position:var(--position);top:107.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:0.84pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:43.32pt;position:var(--position);text-decoration:none;white-space:pre">24/08/2025 (put event)</span></div><div style="line-height:8pt;position:var(--position);top:10.44pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:24.89pt;position:var(--position);text-decoration:none;white-space:pre">24/08/2027 (HTM/voluntary </span></div><div style="line-height:8pt;position:var(--position);top:20.04pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:78.87pt;position:var(--position);text-decoration:none;white-space:pre">conversion)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:27pt;left:399.75pt;overflow:hidden;position:var(--position);top:107.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:0.84pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:43.32pt;position:var(--position);text-decoration:none;white-space:pre">24/08/2025 (put event)</span></div><div style="line-height:8pt;position:var(--position);top:10.44pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:24.89pt;position:var(--position);text-decoration:none;white-space:pre">24/08/2027 (HTM/voluntary </span></div><div style="line-height:8pt;position:var(--position);top:20.04pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:78.87pt;position:var(--position);text-decoration:none;white-space:pre">conversion)</span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:17.25pt;overflow:hidden;position:var(--position);top:134.25pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:0.76pt;width:143.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Held to maturity / voluntary conversion </span></div><div style="line-height:8pt;position:var(--position);top:10.36pt;width:143.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">scenario probability</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:134.25pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:112.84pt;position:var(--position)"></span><span style="left:112.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-943" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2096">75</ix:nonFraction></span><span style="left:120.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:134.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-944" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2097">75</ix:nonFraction></span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:134.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-945" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2098">75</ix:nonFraction></span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:151.5pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Initial price limit</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:151.5pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:103.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-946" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-2099">14.43</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:151.5pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-947" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-2100">14.43</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:151.5pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-948" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-2101">14.43</ix:nonFraction></span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:168.75pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Early redemption amount (put event)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:168.75pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.84pt;position:var(--position)"></span><span style="left:108.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-949" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2102">120</ix:nonFraction></span><span style="left:120.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:168.75pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:99.84pt;position:var(--position)"></span><span style="left:99.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-950" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2103">120</ix:nonFraction></span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:168.75pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:99.84pt;position:var(--position)"></span><span style="left:99.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-951" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2104">120</ix:nonFraction></span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:186pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Volatility</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:186pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:112.84pt;position:var(--position)"></span><span style="left:112.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-952" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2105">50</ix:nonFraction></span><span style="left:120.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:186pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-953" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2106">50</ix:nonFraction></span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:186pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-954" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2107">50</ix:nonFraction></span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:203.25pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Credit spread</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:203.25pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:112.84pt;position:var(--position)"></span><span style="left:112.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-955" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2108">20</ix:nonFraction></span><span style="left:120.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:203.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-956" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2109">20</ix:nonFraction></span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:203.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-957" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2110">25</ix:nonFraction></span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:220.5pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Risk-free rate</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:220.5pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:110.84pt;position:var(--position)"></span><span style="left:110.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-958" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2111">2.9</ix:nonFraction></span><span style="left:120.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:220.5pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:101.84pt;position:var(--position)"></span><span style="left:101.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-959" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2112">2.3</ix:nonFraction></span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:220.5pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:101.84pt;position:var(--position)"></span><span style="left:101.84pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-960" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2113">2.9</ix:nonFraction></span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:237.75pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Fair value of Heights convertible notes </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:237.75pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:96.21pt"></span></span><span style="left:98.83999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-931" decimals="-3" name="abvx:AggregateFairValueConvertibleNotes" format="ixt:num-dot-decimal" scale="3" id="f-2114">32,641</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:6.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:237.75pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:87.21pt"></span></span><span style="left:89.83999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-932" decimals="-3" name="abvx:AggregateFairValueConvertibleNotes" format="ixt:num-dot-decimal" scale="3" id="f-2115">27,456</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:6.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:237.75pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:87.21pt"></span></span><span style="left:89.83999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-933" decimals="-3" name="abvx:AggregateFairValueConvertibleNotes" format="ixt:num-dot-decimal" scale="3" id="f-2116">20,017</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:6.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:468.71pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">As of August 24, 2023, using the same assumptions with an increase of </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:323.84pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">+<ix:nonFraction unitRef="number" contextRef="c-961" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-2117">1</ix:nonFraction>%</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:342.8pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> volatility, </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:386.35pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;+<ix:nonFraction unitRef="eurPerShare" contextRef="c-962" decimals="INF" name="abvx:AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="0" id="f-2118">1</ix:nonFraction></span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:401.98pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> share price, </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:453.02pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">+<ix:nonFraction unitRef="number" contextRef="c-963" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-2119">1</ix:nonFraction>%</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:471.98pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> risk-free rate and </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:545.21pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">+<ix:nonFraction unitRef="number" contextRef="c-964" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-2120">1</ix:nonFraction>%</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:564.17pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:479.91pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">probability of achieving the held to maturity scenario would result in a change in the Heights convertible notes fair value by </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:491.11pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">respectively </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:86.75pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;+<ix:nonFraction unitRef="eur" contextRef="c-965" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-2121">239</ix:nonFraction>&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:150.97pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">, </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.97pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;+<ix:nonFraction unitRef="eur" contextRef="c-966" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" format="ixt:num-dot-decimal" scale="3" id="f-2122">1,069</ix:nonFraction>&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:227.69pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">, </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:232.69pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;-<ix:nonFraction unitRef="eur" contextRef="c-967" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-2123">239</ix:nonFraction>&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:294.61pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> and </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:314.04pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;-<ix:nonFraction unitRef="eur" contextRef="c-968" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-2124">80</ix:nonFraction>&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:370.96pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">.</span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:513.51pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">As of December 31, 2023, using the same assumptions with an increase of </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:336pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">+<ix:nonFraction unitRef="number" contextRef="c-969" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-2125">1</ix:nonFraction>%</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:354.96pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> volatility, </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:398.51pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;+<ix:nonFraction unitRef="eurPerShare" contextRef="c-970" decimals="INF" name="abvx:AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="0" id="f-2126">1</ix:nonFraction></span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:414.14pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> share price, </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:465.18pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">+<ix:nonFraction unitRef="number" contextRef="c-971" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-2127">1</ix:nonFraction>%</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:484.14pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> risk-free rate and </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:524.71pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">+<ix:nonFraction unitRef="number" contextRef="c-972" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-2128">1</ix:nonFraction>%</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.96pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> probability of achieving the held to maturity scenario would result in a change in the Heights convertible notes fair value by </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:535.91pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">respectively </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:86.75pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;+<ix:nonFraction unitRef="eur" contextRef="c-973" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-2129">18</ix:nonFraction>&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:145.97pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">, </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:150.97pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;+<ix:nonFraction unitRef="eur" contextRef="c-974" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-2130">352</ix:nonFraction>&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:215.19pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">, </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:220.19pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;-<ix:nonFraction unitRef="eur" contextRef="c-975" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-2131">366</ix:nonFraction>&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:282.11pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> and </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301.54pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;-<ix:nonFraction unitRef="eur" contextRef="c-976" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-2132">364</ix:nonFraction>&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:363.46pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">.</span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:558.31pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">As of December 31, 2024, using the same assumptions with an increase of </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:336pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">+<ix:nonFraction unitRef="number" contextRef="c-906" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-2133">1</ix:nonFraction>%</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:354.96pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> volatility, </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:398.51pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;+<ix:nonFraction unitRef="eurPerShare" contextRef="c-907" decimals="INF" name="abvx:AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="0" id="f-2134">1</ix:nonFraction></span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:414.14pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> share price, </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:465.18pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">+<ix:nonFraction unitRef="number" contextRef="c-908" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-2135">1</ix:nonFraction>%</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:484.14pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> risk-free rate and </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:569.51pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">+<ix:nonFraction unitRef="number" contextRef="c-977" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-2136">10</ix:nonFraction>%</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:59.96pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> probability of achieving the held to maturity scenario would result in a change in the Heights convertible notes fair value by </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:580.71pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">respectively </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:86.75pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;+</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:97.38pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"><ix:nonFraction unitRef="eur" contextRef="c-978" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-2137">2</ix:nonFraction>&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.97pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">, </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:145.97pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;+</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:156.6pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"><ix:nonFraction unitRef="eur" contextRef="c-979" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-2138">39</ix:nonFraction>&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:205.19pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">, </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:210.19pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;-<ix:nonFraction unitRef="eur" contextRef="c-980" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-2139">219</ix:nonFraction>&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:272.11pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> and </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:291.53999999999996pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;-<ix:nonFraction unitRef="eur" contextRef="c-981" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-2140">631</ix:nonFraction>&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:353.46pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">.</span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:603.11pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">At the conversion dates of the Heights notes, the fair value of the converted notes of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:374.79pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-131" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" format="ixt:num-dot-decimal" scale="3" id="f-2141">53,921</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:445.88pt;position:var(--position);text-decoration:none;white-space:pre"> was reclassified from financial </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:614.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">liabilities to equity. On the conversion dates, due to the put option being exercised by the holders, the fair values of the Heights notes </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:625.51pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">were deemed equal to th</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:133.64pt;position:var(--position);text-decoration:none;white-space:pre">e listed market prices</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:218.78pt;position:var(--position);text-decoration:none;white-space:pre"> of the issued shares.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:636.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As a result of the derecognition of the Heights notes, the outstanding day-one gain was entirely amortized, resulting in a financial </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:648.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">income of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:78.72999999999999pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-131" decimals="-3" name="abvx:GainsArisingFromRecognitionOfFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2142">1,262</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:144.82pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:672.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">For the year ended December 31, 2025, changes in the fair value of the Heights notes (including the remeasurement at conversion </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:684.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">date) resulted in a financial expense of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:192.72pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-55" decimals="-3" sign="-" name="abvx:LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-2143">36,015</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:258.81pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-54<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><div style="position:absolute;top:70.56pt" id="i7a006daedb3d4216a4128b76247285d7_424"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><ix:continuation id="f-1730-15" continuedAt="f-1730-16"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 15.3</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre">. Structured debt financing with Kreos subscribed i</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:284.72pt;position:var(--position);text-decoration:none;white-space:pre">n July 2018 &#8211; &#8220;Kreos 1&#8221; </span></ix:continuation></div><ix:continuation id="f-1730-16" continuedAt="f-1730-17"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:93.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Kreos 1 bond loans</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:116.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On July 24, 2018, the Group entered into a Venture Loan Agreement, a Straight Bonds Issue Agreement and a Convertible Bonds </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:127.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Issue Agreement with Kreos Capital V (UK) Ltd., (or &#8220;Kreos&#8221;), which provided for up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:395.67pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-983" decimals="-3" name="abvx:BorrowingsMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="f-2146">20,000</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:466.76pt;position:var(--position);text-decoration:none;white-space:pre"> in financing. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:149.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Pursuant to the terms of the agreements, Kreos agreed to subscribe for </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:319.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-984" decimals="-3" name="abvx:BorrowingsMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="f-2147">16,000</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:390.4pt;position:var(--position);text-decoration:none;white-space:pre"> in non-convertible bonds and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:160.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-985" decimals="-3" name="abvx:BorrowingsMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="f-2148">4,000</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:102.09pt;position:var(--position);text-decoration:none;white-space:pre"> in convertible bonds, to be issued by the Group in </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:306.38pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="tranche" contextRef="c-983" decimals="INF" name="abvx:BorrowingsNumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="f-2149">two</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:321.37pt;position:var(--position);text-decoration:none;white-space:pre"> tranches of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:370.48pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-983" decimals="-3" name="abvx:BorrowingsMaximumBorrowingCapacityPerTranche" format="ixt:num-dot-decimal" scale="3" id="f-2150">10,000</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:441.57pt;position:var(--position);text-decoration:none;white-space:pre"> each. The tranches were issued </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:172.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in July 2018 and May 2019, respectively.&#160; The convertible bonds were convertible into new ordinary shares of the Group at any time </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:183.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">from their issuance and at the discretion of their holders. In October 2020, Kreos required the conversion of all the convertible bonds </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:194.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">they held and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:92.33pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-986" decimals="0" name="abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants" format="ixt:num-dot-decimal" scale="0" id="f-2151">464,309</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:124.83pt;position:var(--position);text-decoration:none;white-space:pre"> shares were issued. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:216.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The straight bond tranches were split between i) a debt component (then measured at amortized cost), and ii) a premium corresponding </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:228.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">to the initial fair value of attached BSA (then remeasured at fair value through profit and loss).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:251.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2022, the A tranche of the Kreos 1 bond loan has come to maturity and was repaid in full. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:273.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On August, 21, 2023, the B tranche of the Kreos 1 bond loan as well as the A &amp; B tranches of the Kreos 2 bond loan were repaid in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:284.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">full, for an amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:124.26pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-987" decimals="-3" name="abvx:RepaymentsOfConvertibleLoansNotes" format="ixt:num-dot-decimal" scale="3" id="f-2152">7,661</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:190.35pt;position:var(--position);text-decoration:none;white-space:pre">, using the proceeds from the new Kreos / Claret Fin</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:399.86pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">ancing (</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:432.32pt;position:var(--position);text-decoration:none;white-space:pre">see Note 3.1</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:481.99pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">). </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:307.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As the differences identified between the terms of the Kreos 1 &amp; 2 bond loans and the new Kreos / Claret Financing were considered </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:318.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">substantial, the repayment transaction on August 21, 2023 was accounted for as a debt extinguishment. The repayment of the Kreos 1 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:329.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&amp; 2 bond loans led to the recognition of a loss on extinguishment amounting to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:355.45pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-988" decimals="-3" sign="-" name="ifrs-full:GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid" scale="3" id="f-2153">170</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:414.04pt;position:var(--position);text-decoration:none;white-space:pre">, primarily due to (i) the payment of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:340.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">future interests as per the terms of the prepayment option and (ii) unamortized exit and issuance fees, reducing the carrying value of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:352.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the liabilities.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:385.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Kreos A &amp; B BSA</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:408.16pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">In connection with each tranche, the Group issued </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:238.83pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"><ix:nonFraction unitRef="shares" contextRef="c-989" decimals="INF" name="abvx:NumberOfShareWarrantsIssued" format="ixt:num-dot-decimal" scale="0" id="f-2154">110,957</ix:nonFraction></span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:271.33000000000004pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> tranche A share warrants (or &#8220;Kreos A BSA&#8221;) and </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:477.23pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"><ix:nonFraction unitRef="shares" contextRef="c-990" decimals="INF" name="abvx:NumberOfShareWarrantsIssued" format="ixt:num-dot-decimal" scale="0" id="f-2155">74,766</ix:nonFraction></span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:504.73pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> tranche B share </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:419.66pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">warrants (or &#8220;Kreos B BSA&#8221;), each, for a global subscription price of </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:315.71pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-991" decimals="0" name="abvx:ShareWarrantsSubscriptionPricePerShare" scale="0" id="f-2156">1</ix:nonFraction></span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:325.71pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">. Each Kreos A BSA and Kreos B BSA gives rights to </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:544.72pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"><ix:nonFraction unitRef="shares" contextRef="c-992" decimals="INF" name="abvx:NumberOfSharesPerShareWarrant" format="ixt-sec:numwordsen" scale="0" id="f-2157">one</ix:nonFraction></span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:559.15pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:431.16pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">new ordinary share at an exercise price of </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:205.22pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-989" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-2158">7.21</ix:nonFraction></span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:227.72pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> less a discount and </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:307.92pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-990" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-2159">10.70</ix:nonFraction></span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:335.42pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> less a discount, respectively. In addition, the Group granted </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:442.66pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">to the holders of the Kreos A BSA and the Kreos B </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:243.61pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">BSA the option to sell to the Group, upon each exercise of all or parts of the Kreos </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:454.16pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">A BSA, at the put price defined in the agreement, a proportion of the number of the warrants, for the sole purpose of implementing a </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:465.66pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">cash less exercise of the Kreos A BSA and Kreos B BSA</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:264.4pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">. </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:488.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The BSA attached to all tranches (both straight and convertible) did not meet the &#8220;fixed for fixed&#8221; criteria (non cash settlement option </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:499.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">which may result in exchanging a variable number of shares, for a variable price), and were accounted for as standalone derivative </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:511.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">instruments.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:533.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On May 24, 2023, the holders opted for the cashless exercise option of the share warrants they held, implemented through the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:544.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">repurchase by the Group of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:147.85pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-72" decimals="0" name="abvx:NumberOfOtherShareWarrantsRepurchased" format="ixt:num-dot-decimal" scale="0" id="f-2160">43,070</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:175.35pt;position:var(--position);text-decoration:none;white-space:pre"> Kreos A BSA and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.81pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-73" decimals="0" name="abvx:NumberOfOtherShareWarrantsRepurchased" format="ixt:num-dot-decimal" scale="0" id="f-2161">43,070</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:280.31pt;position:var(--position);text-decoration:none;white-space:pre"> Kreos B BSA and the issuance by the Group of respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:525.0799999999999pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-72" decimals="0" name="abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants" format="ixt:num-dot-decimal" scale="0" id="f-2162">67,887</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:552.58pt;position:var(--position);text-decoration:none;white-space:pre"> and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:555.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-73" decimals="0" name="abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants" format="ixt:num-dot-decimal" scale="0" id="f-2163">31,696</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:63.5pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares, as the result of the cashless exercise by Kreos of the outstanding </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:392.04pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-72" decimals="0" name="abvx:NumberOfOtherShareWarrantsConverted" format="ixt:num-dot-decimal" scale="0" id="f-2164">67,887</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:419.54pt;position:var(--position);text-decoration:none;white-space:pre"> Kreos A &amp; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:468.4pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-73" decimals="0" name="abvx:NumberOfOtherShareWarrantsConverted" format="ixt:num-dot-decimal" scale="0" id="f-2165">31,696</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:495.9pt;position:var(--position);text-decoration:none;white-space:pre"> B BSA. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:578.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">At this date, the fair value of exercised warrants of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:241.01pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-72" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" format="ixt:num-dot-decimal" scale="3" id="f-2166">1,850</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:307.1pt;position:var(--position);text-decoration:none;white-space:pre"> was reclassified from derivative financial liabilities to equity. As </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:589.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of this date, due to the put option being exercised by the holders, the fair value of the BSAs is deemed equal to their intrinsic value, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:600.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">which is equal to the difference between the share price on May 24, 2023 and their exercise price.</span></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-55<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><div style="position:absolute;top:70.56pt" id="i7a006daedb3d4216a4128b76247285d7_427"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><ix:continuation id="f-1730-17" continuedAt="f-1730-18"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 15.4 Structured debt financing with Kreos subscribed in October 2020 &#8211; &#8220;Kreos 2&#8221; </span></ix:continuation></div><ix:continuation id="f-1730-18" continuedAt="f-1730-19"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:92.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On October 13, 2020, the Group obtained a straight bond loan of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:297.47pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-993" decimals="-3" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-2167">15,000</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:368.56pt;position:var(--position);text-decoration:none;white-space:pre"> from Kreos corresponding to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:489.31pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="tranche" contextRef="c-993" decimals="INF" name="abvx:BorrowingsNumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="f-2168">two</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:504.3pt;position:var(--position);text-decoration:none;white-space:pre"> tranches of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:104.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-994" decimals="-3" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-2169">10,000</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:107.09pt;position:var(--position);text-decoration:none;white-space:pre"> (&#8220;Tranche A&#8221;) and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:186.98pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-995" decimals="-3" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-2170">5,000</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:253.07pt;position:var(--position);text-decoration:none;white-space:pre"> (&#8220;Tranche B&#8221;), with an option for an additional </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:446.73pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-993" decimals="-3" name="abvx:BorrowingsAdditionalTrancheAmount" format="ixt:num-dot-decimal" scale="3" id="f-2171">5,000</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:512.8199999999999pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Kreos 2 straight bonds were initially measured at fair value, which corresponds to the net cash proceeds, and subsequently </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:137.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">measured at amortized cost. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:160.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On August, 21, 2023, the B tranche of the Kreos 1 bond loan as well as the A &amp; B tranches of the Kreos 2 bond loan were repaid in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:171.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">full, for an amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:124.26pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-987" decimals="-3" name="abvx:RepaymentsOfConvertibleLoansNotes" format="ixt:num-dot-decimal" scale="3" id="f-2172">7,661</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:190.35pt;position:var(--position);text-decoration:none;white-space:pre">, using the proce</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:256.4pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">eds from the new Kreos / Claret Financing (</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:432.32pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">see Note 3.1 and 15.1)</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:522.25pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">. The </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:182.56pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">accounting treatment of the extinguishment of these liabilities is set forth in Note 15.3.</span></span></div></ix:continuation><div style="position:absolute;top:216.96pt" id="i7a006daedb3d4216a4128b76247285d7_430"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:216.96pt;width:612pt"><ix:continuation id="f-1730-19" continuedAt="f-1730-20"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 15.5. OCEANE </span></ix:continuation></div><ix:continuation id="f-1730-20" continuedAt="f-1730-21"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:234.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On July 30, 2021, the Group received a gross proceed of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:264.44pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-996" decimals="-3" name="abvx:ProceedsFromIssuingSharesAndConvertibleLoansNotes" format="ixt:num-dot-decimal" scale="3" id="f-2173">85,000</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:335.53pt;position:var(--position);text-decoration:none;white-space:pre"> through (i)&#160;the issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:445.43pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-996" decimals="0" name="abvx:IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease" format="ixt:num-dot-decimal" scale="0" id="f-2174">1,964,031</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.43pt;position:var(--position);text-decoration:none;white-space:pre"> shares with a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:244.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">subscription price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.64pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-997" decimals="2" name="abvx:EquityIssuanceSubscriptionPricePerShare" scale="0" id="f-2175">30.55</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:148.14pt;position:var(--position);text-decoration:none;white-space:pre"> per share (see Note 13.2 (changes in share capital)) for gross amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:438.67pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-996" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="3" id="f-2176">60,000</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:509.76pt;position:var(--position);text-decoration:none;white-space:pre">, and (ii)&#160;the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:254.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:83.17pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-996" decimals="-3" name="abvx:NetProceedsFromConvertibleLoansNotes" format="ixt:num-dot-decimal" scale="3" id="f-2177">25,000</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:154.26pt;position:var(--position);text-decoration:none;white-space:pre"> in OCEANE, maturing on July 30, 2026. The proceeds of the transaction mainly serve to finance the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:264.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">progress of ABX464 clinical trials in chronic inflammatory diseases.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:286.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The OCEANE were convertible into new ordinary shares and/or exchanged for existing ordinary shares of the group at any time from </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:296.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">their issuance and at the discretion of their holders. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:312.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As the conversion ratio was adjusted </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:185.29pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-998" name="abvx:ConversionPriceAdjustmentPeriod" format="ixt-sec:durmonth" id="f-2178">18</ix:nonNumeric> months</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:227.22pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:232.22pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-999" name="abvx:ConversionPriceAdjustmentPeriod" format="ixt-sec:durmonth" id="f-2179">24</ix:nonNumeric> months</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:274.15pt;position:var(--position);text-decoration:none;white-space:pre">, and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:296.08pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1000" name="abvx:ConversionPriceAdjustmentPeriod" format="ixt-sec:durmonth" id="f-2180">36</ix:nonNumeric> months</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:338.01pt;position:var(--position);text-decoration:none;white-space:pre"> after the issuance date of the OCEANE bond with the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:322.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">weighted average price of the shares and is subject to a floor and a cap, the conversion did not result in the delivery of a fixed number </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:332.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of shares. Consequently, the OCEANE bond was recorded as an hybrid instrument which includes i) a debt host contract accounted for </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:342.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">at amortized cost, and ii) a conversion option which was a embedded derivative accounted for at fair value through profit and loss. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:364.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">At inception, the net cash proceeds reflected the OCEANE initial fair value. The fair value of the bifurcated conversion option at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:374.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">inception has been measured with a Monte Carlo model using a Longstaff Schwartz algorithm, with a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:444.71pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1001" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2181">53</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:463.04pt;position:var(--position);text-decoration:none;white-space:pre"> share price volatility, a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:384.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1002" decimals="4" name="ifrs-full:SignificantUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="-4" id="f-2182">1,400</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:58.5pt;position:var(--position);text-decoration:none;white-space:pre"> bp credit spread assumption and a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:199.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-1003" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-2183">31.50</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:226.69pt;position:var(--position);text-decoration:none;white-space:pre"> share price. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:404.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of August 24, 2023, the date at which the OCEANE were repaid, the fair value of conversion option amounts to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:498.9pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1004" decimals="-3" name="abvx:AggregateFairValueConvertibleNotes" format="ixt:num-dot-decimal" scale="3" id="f-2184">1,762</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:564.99pt;position:var(--position);text-decoration:none;white-space:pre">, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:416.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">based on the same valuation model, a risk-free rate of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.67pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1005" decimals="4" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2185">3.22</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:278.5pt;position:var(--position);text-decoration:none;white-space:pre">, a credit spread assumption of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:403.09pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1006" decimals="4" name="ifrs-full:SignificantUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="-4" id="f-2186">1,398</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:425.59pt;position:var(--position);text-decoration:none;white-space:pre"> bp, a share price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:506.89pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-1007" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-2187">16.74</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:534.39pt;position:var(--position);text-decoration:none;white-space:pre">, and a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:427.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">price volatility of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:107.84pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1008" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2188">37</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:126.17pt;position:var(--position);text-decoration:none;white-space:pre">. As of August 24, 2023, using the same assumptions, an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:401.25pt;position:var(--position);text-decoration:none;white-space:pre">+<ix:nonFraction unitRef="number" contextRef="c-961" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-2189">1</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:420.21pt;position:var(--position);text-decoration:none;white-space:pre"> volatility, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:463.76pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;+<ix:nonFraction unitRef="eurPerShare" contextRef="c-962" decimals="INF" name="abvx:AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="0" id="f-2190">1</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:479.39pt;position:var(--position);text-decoration:none;white-space:pre"> share price and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:544.86pt;position:var(--position);text-decoration:none;white-space:pre">+<ix:nonFraction unitRef="number" contextRef="c-963" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-2191">1</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:563.82pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:438.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">risk free rate would result in an increase of the OCEANE conversion option fair value of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:392.82pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1009" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-2192">80</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:446.41pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:451.41pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1010" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-2193">364</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:510pt;position:var(--position);text-decoration:none;white-space:pre">, and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:449.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1011" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" scale="3" id="f-2194">121</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.59pt;position:var(--position);text-decoration:none;white-space:pre"> respectively. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:472.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On August 24, 2023, the outstanding OCEANE including accrued interests were repaid in full, for an amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:486.42pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-85" decimals="-3" name="abvx:RepaymentsOfConvertibleLoansNotes" format="ixt:num-dot-decimal" scale="3" id="f-2195">25,102</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:557.51pt;position:var(--position);text-decoration:none;white-space:pre">, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:483.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">using the proceeds from the new Heights Financings (see Note 3.1). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:494.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As the differences identified between the terms of the OCEANE and the new Heights convertible notes were considered substantial, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:505.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the transaction was accounted for as a debt extinguishment. The repayment of the OCEANE led to the recognition of a loss on </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:516.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">extinguishment amounting to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.61pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1012" decimals="-3" sign="-" name="ifrs-full:GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid" format="ixt:num-dot-decimal" scale="3" id="f-2196">3,069</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:221.7pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div></ix:continuation><div style="position:absolute;top:553.36pt" id="i7a006daedb3d4216a4128b76247285d7_433"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:553.36pt;width:612pt"><ix:continuation id="f-1730-21" continuedAt="f-1730-22"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 15.6. State guaranteed loan &#8211; &#8220;PGE&#8221;<span id="idf2ef93091c34d489c34e04dfef676a3"></span></span></ix:continuation></div><ix:continuation id="f-1730-22" continuedAt="f-1730-23"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:572.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In June 2020, the Group subscribed to a PGE from Soci&#233;t&#233; G&#233;n&#233;rale with an initial maturity of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:416.72pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1013" name="abvx:BorrowingsMaturityTerm" format="ixt-sec:durmonth" id="f-2197">12</ix:nonNumeric> months</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:458.65pt;position:var(--position);text-decoration:none;white-space:pre"> at </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:470.85pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1014" decimals="4" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-2198">0.25</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:496.68pt;position:var(--position);text-decoration:none;white-space:pre"> and a </span><ix:nonNumeric contextRef="c-1013" name="abvx:BorrowingsMaturityExtensionTerm" format="ixt-sec:durwordsen" id="f-2199"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:523.04pt;position:var(--position);text-decoration:none;white-space:pre">five</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:538.5699999999999pt;position:var(--position);text-decoration:none;white-space:pre">-year</span></ix:nonNumeric><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:559.09pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:582.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">extension option. In March 2021, the Group exercised the </span><ix:nonNumeric contextRef="c-1015" name="abvx:BorrowingsMaturityExtensionTerm" format="ixt-sec:durwordsen" id="f-2200"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:269.4pt;position:var(--position);text-decoration:none;white-space:pre">five</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:284.93pt;position:var(--position);text-decoration:none;white-space:pre">-year</span></ix:nonNumeric><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:305.45pt;position:var(--position);text-decoration:none;white-space:pre"> extension option with a </span><ix:nonNumeric contextRef="c-1015" name="abvx:BorrowingsMaturityDeferralPeriod" format="ixt-sec:durwordsen" id="f-2201"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:403.97pt;position:var(--position);text-decoration:none;white-space:pre">one</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:418.4pt;position:var(--position);text-decoration:none;white-space:pre">-year</span></ix:nonNumeric><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:438.92pt;position:var(--position);text-decoration:none;white-space:pre"> deferral of the principal </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:592.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">repayment, with the following conditions: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:608.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Rate: </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.61pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1016" decimals="4" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-2202">0.58</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.44pt;position:var(--position);text-decoration:none;white-space:pre"> per annum excluding insurance and state guaranteed premium, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:624.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">State guaranteed premium of </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:209.23000000000002pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1016" decimals="-3" name="abvx:BorrowingsStateGuaranteedPremium" scale="3" id="f-2203">138</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:267.82pt;position:var(--position);text-decoration:none;white-space:pre"> to be paid by installments over the contract period starting in June 2021, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:634.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:650.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Reimbursement by yearly installments from June 2021 to June 2026. </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:672.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The benefit resulting from the low interest nature of the award as a subsidy was recognized as other income during the period ended </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:682.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">December&#160;31, 2020 for an amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:186.43pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1017" decimals="-3" name="ifrs-full:RevenueFromGovernmentGrants" scale="3" id="f-2204">377</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:245.02pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-56<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-1730-23" continuedAt="f-1730-24"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The variation in the PGE loan over the periods ended December 31, 2023, 2024 is primarily related to the reimbursement of capital </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:81.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and interests. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:104.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">During the fourth quarter of 2025, the Group prepaid in full the outstanding principal of the PGE loan of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:456.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1018" decimals="-3" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2205">1,264</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:522.28pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div></ix:continuation><div style="position:absolute;top:127.36pt" id="i7a006daedb3d4216a4128b76247285d7_436"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:127.36pt;width:612pt"><ix:continuation id="f-1730-24" continuedAt="f-1730-25"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 15.7. Conditional advances<span id="i4379b0e22e6542cb9131970a4d5b89f6"></span></span></ix:continuation></div><ix:continuation id="f-1730-25" continuedAt="f-1730-26"><div style="font-size:12pt;line-height:11pt;position:var(--position);top:154.06pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfBorrowingsExplanatory" id="f-2206" continuedAt="f-2206-1" escape="true"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Conditional advances as of December 31, 2023, 2024 and 2025 are as </span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:317.41pt;position:var(--position);text-decoration:none;white-space:pre">follows</span><span style="font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:347.39pt;position:var(--position);text-decoration:none;white-space:pre">:</span></ix:nonNumeric></div><ix:continuation id="f-2206-1"><div style="font-size:12pt;line-height:11pt;position:var(--position);top:165.06pt;width:612pt"><span style="font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div><div style="position:var(--position);top:195.07pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:336pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:134.25pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:65.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:65.25pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:15.59pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">CONDITIONAL ADVANCES</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:134.25pt;position:var(--position);top:12pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.92pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.97pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.52pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:12pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.92pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.97pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.52pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:270.75pt;position:var(--position);top:12pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.92pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.97pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.52pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">RNP VIR &#8211; Bpifrance</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:134.25pt;position:var(--position);top:42.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1019" decimals="-3" name="abvx:ConditionalAdvances" format="ixt:num-dot-decimal" scale="3" id="f-2207">4,232</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:42.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1020" decimals="-3" name="abvx:ConditionalAdvances" format="ixt:fixed-zero" scale="3" id="f-2208">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:270.75pt;position:var(--position);top:42.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1021" decimals="-3" name="abvx:ConditionalAdvances" format="ixt:fixed-zero" scale="3" id="f-2209">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">CARENA &#8211; Bpifrance</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:134.25pt;position:var(--position);top:54.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1022" decimals="-3" name="abvx:ConditionalAdvances" format="ixt:num-dot-decimal" scale="3" id="f-2210">2,485</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:54.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1023" decimals="-3" name="abvx:ConditionalAdvances" format="ixt:fixed-zero" scale="3" id="f-2211">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:270.75pt;position:var(--position);top:54.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1024" decimals="-3" name="abvx:ConditionalAdvances" format="ixt:fixed-zero" scale="3" id="f-2212">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">EBOLA &#8211; Bpifrance</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:134.25pt;position:var(--position);top:66.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1025" decimals="-3" name="abvx:ConditionalAdvances" scale="3" id="f-2213">55</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:66.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1026" decimals="-3" name="abvx:ConditionalAdvances" format="ixt:fixed-zero" scale="3" id="f-2214">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:270.75pt;position:var(--position);top:66.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1027" decimals="-3" name="abvx:ConditionalAdvances" format="ixt:fixed-zero" scale="3" id="f-2215">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total conditional advances</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:134.25pt;position:var(--position);top:78.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="abvx:ConditionalAdvances" format="ixt:num-dot-decimal" scale="3" id="f-2216">6,771</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:78.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="abvx:ConditionalAdvances" format="ixt:fixed-zero" scale="3" id="f-2217">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:270.75pt;position:var(--position);top:78.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="abvx:ConditionalAdvances" format="ixt:fixed-zero" scale="3" id="f-2218">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:328.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">RNP-VIR &#8211; Bpifrance </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:344.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Under the RNP-VIR contract, the Group was eligible to receive up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:315.41pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1028" decimals="-5" name="abvx:OtherFinancialLiabilitiesMaximumDrawdownCapacity" scale="6" id="f-2219">6.3</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:364.26pt;position:var(--position);text-decoration:none;white-space:pre"> in conditional advances to further develop methods </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:354.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">for the discovery of new molecules for the treatment of viral infectious diseases through the development of the &#8220;Modulation of RNA </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:364.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">biogenesis&#8221; platform. As of December 31, 2022, the Group had received </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:328.49pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1029" decimals="-3" name="abvx:ProceedsFromConditionalAdvances" format="ixt:num-dot-decimal" scale="3" id="f-2220">4,032</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:394.58pt;position:var(--position);text-decoration:none;white-space:pre">, of which </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:437.33pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1030" decimals="-3" name="abvx:ProceedsFromConditionalAdvances" format="ixt:num-dot-decimal" scale="3" id="f-2221">1,756</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:503.42pt;position:var(--position);text-decoration:none;white-space:pre"> was received in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:374.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">September 2017, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:106.22pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1031" decimals="-3" name="abvx:ProceedsFromConditionalAdvances" scale="3" id="f-2222">346</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:164.81pt;position:var(--position);text-decoration:none;white-space:pre"> in August&#160;2018 and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:248.39pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1032" decimals="-3" name="abvx:ProceedsFromConditionalAdvances" format="ixt:num-dot-decimal" scale="3" id="f-2223">1,930</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:314.48pt;position:var(--position);text-decoration:none;white-space:pre"> in November 2019. The repayment of these funds is spread from </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:384.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the date on which the repayments are called by BPI. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:406.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In June 2024, the Group and Bpifrance agreed to terminate the project due to technical failure. Bpifrance claimed the reimbursement </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:418.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:46.83pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-104" decimals="-3" name="abvx:RepaymentOfExcessConditionalAdvancesClaimed" format="ixt:num-dot-decimal" scale="3" id="f-2224">1,241</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.92pt;position:var(--position);text-decoration:none;white-space:pre"> corresponding to overpayments of conditional advances and subsidies (for which the Group had not incurred the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:430.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">corresponding R&amp;D expenses) and agreed to waive </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:244.4pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-104" decimals="2" name="abvx:PercentageOfConditionalAdvancesWaived" scale="-2" id="f-2225">60</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:262.73pt;position:var(--position);text-decoration:none;white-space:pre"> of the remaining advances of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:383.7pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1033" decimals="-3" name="abvx:ConditionalAdvances" format="ixt:num-dot-decimal" scale="3" id="f-2226">2,945</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:449.79pt;position:var(--position);text-decoration:none;white-space:pre"> and accrued interests, which </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:442.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">resulted in a subsidy income of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:163.1pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-104" decimals="-3" name="ifrs-full:RevenueFromGovernmentGrants" format="ixt:num-dot-decimal" scale="3" id="f-2227">1,872</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:229.19pt;position:var(--position);text-decoration:none;white-space:pre"> in the aggregate (see Note 18). </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:356.81pt;position:var(--position);text-decoration:none;white-space:pre">The outstanding amount was fully repaid by the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:454.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Group during the second half of 2024.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:478.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">See Note 25.2. Commitments under BPI conditional advances. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:506.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">CARENA &#8211; Bpifrance </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:522.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Under the CARENA agreement, the Group was eligible to receive up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:325.94pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1034" decimals="-3" name="abvx:OtherFinancialLiabilitiesMaximumDrawdownCapacity" format="ixt:num-dot-decimal" scale="3" id="f-2228">3,840</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:392.03pt;position:var(--position);text-decoration:none;white-space:pre"> to develop a therapeutic HIV treatment </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:532.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">program with ABX464. As of December 31, 2022, the Group received </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:320.77pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1035" decimals="-3" name="abvx:ProceedsFromConditionalAdvances" format="ixt:num-dot-decimal" scale="3" id="f-2229">2,187</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:386.86pt;position:var(--position);text-decoration:none;white-space:pre">, of which </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:429.61pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1036" decimals="-3" name="abvx:ProceedsFromConditionalAdvances" format="ixt:num-dot-decimal" scale="3" id="f-2230">1,150</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:495.7pt;position:var(--position);text-decoration:none;white-space:pre"> was received in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:542.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">December 2013, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:104.54pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1037" decimals="-3" name="abvx:ProceedsFromConditionalAdvances" format="ixt:num-dot-decimal" scale="3" id="f-2231">1,008</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:170.63pt;position:var(--position);text-decoration:none;white-space:pre"> in September 2014 and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:268.05pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1038" decimals="-3" name="abvx:ProceedsFromConditionalAdvances" scale="3" id="f-2232">29</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:321.64pt;position:var(--position);text-decoration:none;white-space:pre"> received in June 2016. </span></div><div style="font-size:12pt;line-height:1pt;position:var(--position);top:564.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:566.02pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The repayment of the advance is spread from the date on which the repayments are called by Bpifrance. An additional repayment is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:576.02pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">provided for based on the income the Group generates through this research and development program.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:598.02pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In June 2024, the Group and Bpifrance agreed to terminate the project due to technical failure. Bpifrance granted an additional amount </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:609.52pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:46.83pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-106" decimals="-3" name="abvx:ProceedsFromConditionalAdvances" format="ixt:num-dot-decimal" scale="3" id="f-2233">1,068</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.92pt;position:var(--position);text-decoration:none;white-space:pre"> payable to the Group to reimburse additional expenses incurred as part of the project, and agreed to waive </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:541.3pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-106" decimals="2" name="abvx:PercentageOfConditionalAdvancesWaived" scale="-2" id="f-2234">60</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:559.63pt;position:var(--position);text-decoration:none;white-space:pre"> of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:621.02pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the remaining conditional advance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:187.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1039" decimals="-3" name="abvx:ConditionalAdvances" format="ixt:num-dot-decimal" scale="3" id="f-2235">3,255</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:253.28pt;position:var(--position);text-decoration:none;white-space:pre"> and accrued interests, which resulted in a subsidy income of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:498.56pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-106" decimals="-3" name="ifrs-full:RevenueFromGovernmentGrants" format="ixt:num-dot-decimal" scale="3" id="f-2236">2,251</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:564.65pt;position:var(--position);text-decoration:none;white-space:pre"> in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:632.52pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the aggregate (see Note 18).</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:148.35pt;position:var(--position);text-decoration:none;white-space:pre"> The outstanding amount was fully repaid by the Group during the second half of 2024.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:662.02pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">EBOLA &#8211; Bpifrance </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:678.02pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Under the Bpifrance and Occitanie region joint aid agreement, the Group received a total of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:404.94pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1040" decimals="-3" name="abvx:ProceedsFromConditionalAdvances" scale="3" id="f-2237">390</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:463.53pt;position:var(--position);text-decoration:none;white-space:pre"> (</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:469.36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1041" decimals="-3" name="abvx:ProceedsFromConditionalAdvances" scale="3" id="f-2238">300</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:527.95pt;position:var(--position);text-decoration:none;white-space:pre"> as of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:688.02pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">December 31, 2017 and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:133.97pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1042" decimals="-3" name="abvx:ProceedsFromConditionalAdvances" scale="3" id="f-2239">90</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:187.56pt;position:var(--position);text-decoration:none;white-space:pre"> as of December 31, 2019). The reimbursement was spread from 2019 to June 2024. </span></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-57<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><div style="position:absolute;top:94.56pt" id="i7a006daedb3d4216a4128b76247285d7_439"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:94.56pt;width:612pt"><ix:continuation id="f-1730-26" continuedAt="f-1730-27"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 15.8. Lease liabilities<span id="ifc3224d03a4e46d99a832b8e540a70e5"></span></span></ix:continuation></div><ix:continuation id="f-1730-27" continuedAt="f-1730-28"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:119.86pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="abvx:DisclosureOfLeasesForLesseeTableTextBlock" id="f-2240" continuedAt="f-2240-1" escape="true"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The variations in lease liabilities are set forth below:</span></ix:nonNumeric></div><ix:continuation id="f-2240-1"><div style="position:var(--position);top:133.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:301.5pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:216.75pt"/><td style="padding:0;width:84.75pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:216.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:56.84pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:216.75pt;position:var(--position);width:84.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:84.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.18pt;position:var(--position);text-decoration:none;white-space:pre"> LEASE LIABILITY</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:216.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY 1, 2023</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:216.75pt;position:var(--position);top:12pt;width:84.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:84.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.71pt"></span></span><span style="left:63.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2241">1,384</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:33pt;width:216.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(+) Increase </span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:216.75pt;position:var(--position);top:33pt;width:84.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:84.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.71pt"></span></span><span style="left:69.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:IncreaseInLeaseLiabilities" scale="3" id="f-2242">350</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:45pt;width:216.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(-) Decrease</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:216.75pt;position:var(--position);top:45pt;width:84.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:84.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.05pt"></span></span><span style="left:60.68pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:DecreaseInLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2243">1,194</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:57pt;width:216.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:216.75pt;position:var(--position);top:57pt;width:84.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:84.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:66.71pt"></span></span><span style="left:69.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:LeaseLiabilities" scale="3" id="f-2244">540</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78pt;width:216.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(+) Increase </span></div></div></div></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:216.75pt;position:var(--position);top:78pt;width:84.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:84.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.71pt"></span></span><span style="left:63.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:IncreaseInLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2245">2,221</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90pt;width:216.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(-) Decrease</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:216.75pt;position:var(--position);top:90pt;width:84.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:84.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:64.05pt"></span></span><span style="left:66.67999999999999pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:DecreaseInLeaseLiabilities" scale="3" id="f-2246">398</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102pt;width:216.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:216.75pt;position:var(--position);top:102pt;width:84.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:84.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.71pt"></span></span><span style="left:63.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2247">2,363</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:123pt;width:216.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(+) Increase </span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:216.75pt;position:var(--position);top:123pt;width:84.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:84.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.71pt"></span></span><span style="left:69.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:IncreaseInLeaseLiabilities" scale="3" id="f-2248">444</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:135pt;width:216.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(-) Decrease</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:216.75pt;position:var(--position);top:135pt;width:84.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:84.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:64.05pt"></span></span><span style="left:66.67999999999999pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:DecreaseInLeaseLiabilities" scale="3" id="f-2249">950</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:147pt;width:216.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:216.75pt;position:var(--position);top:147pt;width:84.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:84.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.71pt"></span></span><span style="left:63.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2250">1,856</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:318.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Lease liabilities mainly relate the Group&#8217;s headquarters in Paris, the Boston office entered into in November 2023, the Montpellier </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:329.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">offices entered into in April 2024, the new Paris headquarters entered into in May 2024 and to a lesser extent to vehicles, parking lots </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:340.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and printer</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:79.56pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">s (see Note 8).</span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:351.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The lease for the Group&#8217;s corporate headquarters in Paris, France at 7-11 Boulevard Haussmann, 75009 Paris started in July 2022. It </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:365.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">had a </span><ix:nonNumeric contextRef="c-1043" name="abvx:LeaseDurationPeriod" format="ixt-sec:durwordsen" id="f-2251"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:59.86pt;position:var(--position);text-decoration:none;white-space:pre">three</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:79.82pt;position:var(--position);text-decoration:none;white-space:pre">-year</span></ix:nonNumeric><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:100.34pt;position:var(--position);text-decoration:none;white-space:pre"> duration, with a tacit renewal option for approximately </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:324.51pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1043" name="abvx:LeaseTacitRenewalPeriod" format="ixt-sec:durwordsen" id="f-2252">two years</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:363.08pt;position:var(--position);text-decoration:none;white-space:pre"> and the possibility to break the contract </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:525.6600000000001pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1043" name="abvx:LeaseBreakClausePeriod" format="ixt-sec:durwordsen" id="f-2253">one year</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:559.78pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:378.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">before the end. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:98.15pt;position:var(--position);text-decoration:none;white-space:pre">In September 2023, the Group was notified by the lessor of its intention to exercise its option to terminate the contract </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:391.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">on June 30, 2024. Consequently, the Group reassessed the lease term and recorded a decrease in the related lease liability by </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:404.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1044" decimals="-3" name="abvx:DecreaseInLeaseLiabilitiesThroughModificationOfTerm" scale="3" id="f-2254">622</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.59pt;position:var(--position);text-decoration:none;white-space:pre"> and a corresponding decrease in the right of use asset for the same amount. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:417.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">A new lease for different premises within the same building was entered into on May 2, 2024. It has a </span><ix:nonNumeric contextRef="c-1045" name="abvx:LeaseDurationPeriod" format="ixt-sec:durwordsen" id="f-2255"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:445.58pt;position:var(--position);text-decoration:none;white-space:pre">three</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:465.54pt;position:var(--position);text-decoration:none;white-space:pre">-year</span></ix:nonNumeric><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:486.06pt;position:var(--position);text-decoration:none;white-space:pre"> duration, and no </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:431.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">renewal option. The Group also benefits from an initial eight-month rent-free period.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:455.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In November 2023, the Subsidiary entered a lease contract for its new Boston offices. It has a </span><ix:nonNumeric contextRef="c-1046" name="abvx:LeaseDurationPeriod" format="ixt-sec:durwordsen" id="f-2256"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:411.98pt;position:var(--position);text-decoration:none;white-space:pre">two</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:426.97pt;position:var(--position);text-decoration:none;white-space:pre">-year</span></ix:nonNumeric><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:447.49pt;position:var(--position);text-decoration:none;white-space:pre"> duration, with an option to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:466.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">renew the contract for an additional period of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:219.66pt;position:var(--position);text-decoration:none;white-space:pre"><span style="-sec-ix-hidden:f-2257">one</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:234.09pt;position:var(--position);text-decoration:none;white-space:pre"> or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:247.42pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1048" name="abvx:LeaseExtensionPeriod" format="ixt-sec:durwordsen" id="f-2258">two years</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:285.99pt;position:var(--position);text-decoration:none;white-space:pre">. In December 2024, the Group exercised its option to extend the lease </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:478.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">up until December 2026. P</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:143.41pt;position:var(--position);text-decoration:none;white-space:pre">er Management, additional renewal options are not reasonably certain due to the forecasted development of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:489.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the Subsidiary, which may lead it to relocate at the end of the current term.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:511.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In April 2024, the Company entered a lease contract for a new Montpellier office. It has an initial </span><ix:nonNumeric contextRef="c-1049" name="abvx:LeaseDurationPeriod" format="ixt-sec:durwordsen" id="f-2259"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:427.73pt;position:var(--position);text-decoration:none;white-space:pre">six</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:439.39pt;position:var(--position);text-decoration:none;white-space:pre">-year</span></ix:nonNumeric><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:459.91pt;position:var(--position);text-decoration:none;white-space:pre"> duration, with the option for </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:522.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the Company to terminate the lease at any time with a </span><ix:nonNumeric contextRef="c-1049" name="abvx:LeaseBreakClausePeriod" format="ixt-sec:durwordsen" id="f-2260"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:253.74pt;position:var(--position);text-decoration:none;white-space:pre">six</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:265.4pt;position:var(--position);text-decoration:none;white-space:pre">-month</span></ix:nonNumeric><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:294.27pt;position:var(--position);text-decoration:none;white-space:pre"> notice period, and a tacit renewal option for an additional period of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:534.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1049" name="abvx:LeaseTacitRenewalPeriod" format="ixt-sec:durwordsen" id="f-2261">six years</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:71.24000000000001pt;position:var(--position);text-decoration:none;white-space:pre">. Based on Management's estimate, the initial lease period of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:316.04pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1049" name="abvx:LeaseDurationPeriod" format="ixt-sec:durwordsen" id="f-2262">six years</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:351.28pt;position:var(--position);text-decoration:none;white-space:pre"> is considered reasonably certain and is therefore used </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:545.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">for the measurement of the lease&#160; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:567.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In December 2025, the Company renewed the lease contract with the CNRS </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:343.14pt;position:var(--position);text-decoration:none;white-space:pre">(French National Centre for Scientific Research)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:537.5799999999999pt;position:var(--position);text-decoration:none;white-space:pre"> research </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:578.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">laboratories based in Montpellier until December 31, 2026. A lease liability was recognized as of 31 December 2025.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:601.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, 2024 and 2025, the lease liabilities of the Paris headquarters and Boston offices represented </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:512.72pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1050" decimals="2" name="abvx:LeaseLiabilityPercentageOfTotal" scale="-2" id="f-2263">93</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:531.05pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:536.05pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1051" decimals="2" name="abvx:LeaseLiabilityPercentageOfTotal" scale="-2" id="f-2264">93</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:554.38pt;position:var(--position);text-decoration:none;white-space:pre"> and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:612.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1052" decimals="2" name="abvx:LeaseLiabilityPercentageOfTotal" scale="-2" id="f-2265">70</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.33pt;position:var(--position);text-decoration:none;white-space:pre"> of t</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:70.43pt;position:var(--position);text-decoration:none;white-space:pre">he total lease liability, respectively.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:634.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Lease expenses related to contracts for which a lease liability and right of use asset is recognized under IFRS 16 were </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:508.46pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:ExpenseOnLeaseLiabilities" scale="3" id="f-2266">548</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:567.05pt;position:var(--position);text-decoration:none;white-space:pre">, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:646.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:ExpenseOnLeaseLiabilities" scale="3" id="f-2267">730</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.59pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.02pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:ExpenseOnLeaseLiabilities" scale="3" id="f-2268">808</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:172.61pt;position:var(--position);text-decoration:none;white-space:pre"> for the years ended December 31, 2023, 2024 and 2025, respectively. They were recognized for (i) </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:657.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:DepreciationExpenseLease" scale="3" id="f-2269">498</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.59pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:99.59pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:DepreciationExpenseLease" scale="3" id="f-2270">788</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.18pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:177.61pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:DepreciationExpenseLease" scale="3" id="f-2271">744</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:236.2pt;position:var(--position);text-decoration:none;white-space:pre"> as Depreciation expenses and (ii) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:373.8pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="f-2272">13</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:427.39pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:432.39pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="f-2273">61</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.98pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:505.41pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="f-2274">64</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:559pt;position:var(--position);text-decoration:none;white-space:pre"> as </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:668.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Interest expenses, for the years ended December 31, 2023, 2024 and 2025, respectively.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:690.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Lease expenses related to short-term lease contracts and low value assets that are not included in the valuation of the lease liability </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:702.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">amount to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:78.74000000000001pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" scale="3" id="f-2275">334</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:137.32999999999998pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:142.32999999999998pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" scale="3" id="f-2276">352</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:200.92pt;position:var(--position);text-decoration:none;white-space:pre"> and</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:217.85pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:220.35pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" scale="3" id="f-2277">349</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:278.94pt;position:var(--position);text-decoration:none;white-space:pre"> for the years ended December 31, 2023, 2024 and 2025, respectively. </span></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-58<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><div style="position:absolute;top:82.56pt" id="i7a006daedb3d4216a4128b76247285d7_445"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:82.56pt;width:612pt"><ix:continuation id="f-1730-28" continuedAt="f-1730-29"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 15.9. Royalty certificates <span id="ib234ca1988eb4c919128d1c27cbc1aa4"></span></span></ix:continuation></div><ix:continuation id="f-1730-29" continuedAt="f-1730-30"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:107.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On September 2, 2022, the Group completed a financing of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:275.78pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1053" decimals="-3" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-2278">49,162</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:346.87pt;position:var(--position);text-decoration:none;white-space:pre">, consisting of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:405.72pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="transaction" contextRef="c-1053" decimals="INF" name="abvx:OtherLiabilitiesNumberOfTransactions" format="ixt-sec:numwordsen" scale="0" id="f-2279">two</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:420.71pt;position:var(--position);text-decoration:none;white-space:pre"> transactions: </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:130.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">a reserved capital increase of a gross amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:264.25pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1054" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-2280">46,231</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:335.34pt;position:var(--position);text-decoration:none;white-space:pre"> through the issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:433.31pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-1054" decimals="0" name="abvx:IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease" format="ixt:num-dot-decimal" scale="0" id="f-2281">5,530,000</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:473.31pt;position:var(--position);text-decoration:none;white-space:pre"> new shares with a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:143.7pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">nominal value of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:142.2pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-1053" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-2282">0.01</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:164.7pt;position:var(--position);text-decoration:none;white-space:pre"> per share at a subscription price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:307.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-1053" decimals="2" name="abvx:EquityIssuanceSubscriptionPricePerShare" scale="0" id="f-2283">8.36</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:329.81pt;position:var(--position);text-decoration:none;white-space:pre"> per share; and </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:157.14pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">an issue of royalty certificates with a subscription price amounting to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:350.83pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1055" decimals="-3" name="abvx:NetProceedsFromSaleOfRoyaltyCertificates" format="ixt:num-dot-decimal" scale="3" id="f-2284">2,931</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:416.92pt;position:var(--position);text-decoration:none;white-space:pre">. The royalty certificates give right to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:170.58pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">their holders to royalties equal to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:206.28pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1055" decimals="2" name="abvx:RoyaltyCertificatePercentageOfFutureSales" scale="-2" id="f-2285">2</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:219.61pt;position:var(--position);text-decoration:none;white-space:pre"> of the future net sales of obefazimod (worldwide and for all indications) as from the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:184.02pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">commercialization of such product. The amount of royalties that may be paid under the royalty certificates is capped at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:197.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1056" decimals="-3" name="abvx:RoyaltyCertificateMaximumAmount" format="ixt:num-dot-decimal" scale="3" id="f-2286">172,000</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:148.09pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:222.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Related transaction costs amounted to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:189.96pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1057" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="3" id="f-2287">3,280</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:256.05pt;position:var(--position);text-decoration:none;white-space:pre"> and are recorded in equity, since entirely related to the reserved capital </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:233.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">increase. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:255.7pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In April 2023, the Group reassessed its estimate of the probability of future royalty cash flows related to the royalty c</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:504.65pt;position:var(--position);text-decoration:none;white-space:pre">ertificates. </span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:549pt;position:var(--position);text-decoration:none;white-space:pre">This </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:266.9pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">change reflected the higher probability to reach the objectives of the development and commercialization plans following the recent </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:278.1pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">changes in management and governance, as well as results from its Phase 2b open-label maintenance trial in UC, as released in April </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:289.3pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">2023. Subsequently, in June 2023 and December 2023, the Group revised </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:333.01pt;position:var(--position);text-decoration:none;white-space:pre">the development and commercialization plans of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:300.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">obefazimod and reassessed its estimate of future royalty cash flows accordingly. These changes in estimates resulted in a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:311.7pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">remeasurement of the certificates&#8217; amortized costs, using the original EIR of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:343.91pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-718" decimals="2" name="abvx:RoyaltyCertificatesEIR" scale="-2" id="f-2288">34</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:362.24pt;position:var(--position);text-decoration:none;white-space:pre"> calculated at the date of issuance, which led to an </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:322.9pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">increase by</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:81.21000000000001pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:83.71000000000001pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1058" decimals="-3" name="abvx:IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2289">6,421</ix:nonFraction> thousand</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:149.8pt;position:var(--position);text-decoration:none;white-space:pre"> of the royalty certificates liability. The expense was recorded within the interest expenses in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:334.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Statements of Income (Loss).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:345.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Consequently, the total interest expense (including the unwinding of discount) related to royalty certificates amounts to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:356.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:InterestExpenseOnRoyaltyCertificatesIncludingTheUnwindingOfDiscount" format="ixt:num-dot-decimal" scale="3" id="f-2290">8,942</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:102.09pt;position:var(--position);text-decoration:none;white-space:pre"> for the year ended December 31, 2023.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:379.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In December 2024, the Group </span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.12pt;position:var(--position);text-decoration:none;white-space:pre">revised </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:189.47pt;position:var(--position);text-decoration:none;white-space:pre">the development and commercialization plans of obefazimod to take into account the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:391pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">progression in the ongoing clinical trials, reassessment of the commercial schedule and forecasts&#160; and reassessed its estimate of future </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:402.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">royalty cash flows accordingly.</span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:161.42000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> This</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:181.68pt;position:var(--position);text-decoration:none;white-space:pre"> change in estimate resulted in a remeasurement of the certificates&#8217; amortized costs, using the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:413.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">original EIR of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:98.99000000000001pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-719" decimals="2" name="abvx:RoyaltyCertificatesEIR" scale="-2" id="f-2291">34</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:117.32pt;position:var(--position);text-decoration:none;white-space:pre"> calculated at the date of issuance, which led to a decrease by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:364.17pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1059" decimals="-3" sign="-" name="abvx:IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2292">3,404</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:430.26pt;position:var(--position);text-decoration:none;white-space:pre"> of the royalty certificates liability. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:424.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The expense was recorded within the interest expenses in the Statements of Income (Loss).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:435.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Consequently, the total interest expense related to royalty certificates (including the effect of the unwinding of discount, amounting to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:447.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:UnwindingOfDiscountOnRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-2293">4,198</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:102.09pt;position:var(--position);text-decoration:none;white-space:pre">) amounts to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:154.55pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:InterestExpenseOnRoyaltyCertificatesIncludingTheUnwindingOfDiscount" scale="3" id="f-2294">794</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:213.14pt;position:var(--position);text-decoration:none;white-space:pre"> for the year ended December 31, 2024.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:470.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">During the third quarter of 2025, the Group revised the probability of success (&#8220;POS&#8221;) of the obefazimod clinical trials to take into </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:481.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">account the Phase 3 results announced in July 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:241.37pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:243.87pt;position:var(--position);text-decoration:none;white-space:pre">and reassessed its estimate of future royalty cash flows accordingly. This change </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:492.7pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in estimate resulted in a remeasurement of the certificates&#8217; amortized costs, using the original EIR of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:441.26pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1060" decimals="2" name="abvx:RoyaltyCertificatesEIR" scale="-2" id="f-2295">34</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:459.59pt;position:var(--position);text-decoration:none;white-space:pre"> calculated at the date of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:503.9pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">issuance, which led to an increase by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:186.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1061" decimals="-3" name="abvx:IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2296">11,286</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:257.46000000000004pt;position:var(--position);text-decoration:none;white-space:pre"> of the royalty certificates liability. The expense was recorded within the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:515.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">financial expenses in the Statements of Income (Los</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:244.9pt;position:var(--position);text-decoration:none;white-space:pre">s).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:537.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2025, using the same future royalty cash flows assumptions with an increase of +</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:443.75pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1062" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-4" id="f-2297">5</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:448.75pt;position:var(--position);text-decoration:none;white-space:pre"> points of POS and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:526.78pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1063" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-2298">+5</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:545.74pt;position:var(--position);text-decoration:none;white-space:pre"> of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:548.7pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">peak penetration (best case scenario) would result in an increase in the royalty certificates carrying value by respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:520.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:559.9pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-1064" decimals="-3" name="abvx:IncreaseDecreaseInCarryingValueDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="3" id="f-2299">+809</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:95.22pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.65pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;+<ix:nonFraction unitRef="eur" contextRef="c-1065" decimals="-3" name="abvx:IncreaseDecreaseInCarryingValueDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2300">2,616</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:186.37pt;position:var(--position);text-decoration:none;white-space:pre">. Using the same assumptions with a decrease of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:382.27pt;position:var(--position);text-decoration:none;white-space:pre">(<ix:nonFraction unitRef="number" contextRef="c-1062" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" scale="-4" id="f-2301">5</ix:nonFraction>)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:393.93pt;position:var(--position);text-decoration:none;white-space:pre"> points in POS and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:471.4pt;position:var(--position);text-decoration:none;white-space:pre">(<ix:nonFraction unitRef="number" contextRef="c-1063" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" scale="-2" id="f-2302">5</ix:nonFraction>)%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:491.39pt;position:var(--position);text-decoration:none;white-space:pre"> in peak penetration </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:571.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(worst case scenario) would result in a decrease in the royalty certificates carrying value by respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:454.3pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(<ix:nonFraction unitRef="eur" contextRef="c-1064" decimals="-3" sign="-" name="abvx:IncreaseDecreaseInCarryingValueDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2303">1,712</ix:nonFraction>)&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:527.05pt;position:var(--position);text-decoration:none;white-space:pre"> and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:582.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(<ix:nonFraction unitRef="eur" contextRef="c-1065" decimals="-3" sign="-" name="abvx:IncreaseDecreaseInCarryingValueDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2304">4,154</ix:nonFraction>)&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108.75pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:605.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Fair value </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:630.14pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The fair value of the royalty certificates amounts to</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:241.26pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:243.76pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-718" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-2305">12,395</ix:nonFraction> thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:314.85pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> as </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:328.17pt;position:var(--position);text-decoration:none;white-space:pre">of December 31, 2023, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:422.54pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-719" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-2306">7,313</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:488.63pt;position:var(--position);text-decoration:none;white-space:pre"> as of December 31, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:641.34pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">2024 and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:75.43pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-720" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-2307">102,001</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.93pt;position:var(--position);text-decoration:none;white-space:pre"> thousands as of December 31, 2025.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:663.74pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The fair value of the royalty certificates is based on the net present value of royalties, which depends on assumptions made by the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:674.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Group with regards to the probability of success of its studies (&#8220;POS&#8221;), the commercialization budget of obefazimod (&#8220;peak </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:686.14pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">penetration&#8221;) and the discount rate. In addition, as of December 31 2023 and 2024, royalty projections have been adjusted to reflect </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:697.34pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the significant difference between the Group&#8217;s value derived from management projections and the Group&#8217;s market capitalization. </span></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-59<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-1730-30" continuedAt="f-1730-31"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2025, following the increase in the Group's share price and the business plan update, such adjustment was no </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:82.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">longer required. Management ensured that the discount rate of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:287.37pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-720" decimals="3" name="abvx:UnobservableInputLiabilitiesDiscountRate" scale="-2" id="f-2308">7.5</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:308.2pt;position:var(--position);text-decoration:none;white-space:pre"> used at that date</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:375.32pt;position:var(--position);text-decoration:none;white-space:pre"> is reasonable based on the specific risk profile of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:93.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the royalties certificates.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:116.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The decrease in fair value of the royalty certificates over the year ended December 31, 2024 is mainly driven by the decrease in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:128.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Group's share price over the period, while the increase over the year ended December 31, 2025 is primarily explained by (i) the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:139.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">revised </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:67.35pt;position:var(--position);text-decoration:none;white-space:pre">POS</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.69pt;position:var(--position);text-decoration:none;white-space:pre">, reflecting the results of the Phase 3 trials, which resulted in the increase in the Group's share price during the second half </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:151.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of 2025, and (ii) a decrease in the discount rate consistent with the increase in the Group's market capitalization (see Note 3.3 </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:539.38pt;position:var(--position);text-decoration:none;white-space:pre">- </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:162.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Publication of positive Phase 3 results from both ABTECT 8-week induction trials investigating obefazimod, in moderate to severely </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:174.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">active UC </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:78.71000000000001pt;position:var(--position);text-decoration:none;white-space:pre">&#8211;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:83.71000000000001pt;position:var(--position);text-decoration:none;white-space:pre"> July 2025)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:128.67000000000002pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:196.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, using the same assumptions with an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:336pt;position:var(--position);text-decoration:none;white-space:pre">+<ix:nonFraction unitRef="number" contextRef="c-1066" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-4" id="f-2309">5</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:346.63pt;position:var(--position);text-decoration:none;white-space:pre"> points of POS, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:410.23pt;position:var(--position);text-decoration:none;white-space:pre">+<ix:nonFraction unitRef="number" contextRef="c-1067" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-2310">5</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:429.19pt;position:var(--position);text-decoration:none;white-space:pre"> of peak penetration (best case </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:207.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">scenario), </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:77.61pt;position:var(--position);text-decoration:none;white-space:pre">+<ix:nonFraction unitRef="number" contextRef="c-1068" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-2311">1</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.57pt;position:var(--position);text-decoration:none;white-space:pre"> WACC and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:148.47pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;+<ix:nonFraction unitRef="eurPerShare" contextRef="c-1069" decimals="INF" name="abvx:AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="0" id="f-2312">1</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:164.1pt;position:var(--position);text-decoration:none;white-space:pre"> share price would result in a change in the royalty certificates fair value by respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:518.6pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:219.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">+<ix:nonFraction unitRef="eur" contextRef="c-1070" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="3" id="f-2313">1104</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:100.22pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:105.22pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;+<ix:nonFraction unitRef="eur" contextRef="c-1071" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="3" id="f-2314">1757</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:174.44pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:179.44pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(<ix:nonFraction unitRef="eur" contextRef="c-1072" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="3" id="f-2315">577</ix:nonFraction>) thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:244.69pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:264.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;+<ix:nonFraction unitRef="eur" contextRef="c-1073" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="3" id="f-2316">1325</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:333.34pt;position:var(--position);text-decoration:none;white-space:pre">. Using the same assumptions with a decrease of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:529.24pt;position:var(--position);text-decoration:none;white-space:pre">(<ix:nonFraction unitRef="number" contextRef="c-1066" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" scale="-4" id="f-2317">5</ix:nonFraction>)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:540.9pt;position:var(--position);text-decoration:none;white-space:pre"> points </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:230.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of POS, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:70.17pt;position:var(--position);text-decoration:none;white-space:pre">(<ix:nonFraction unitRef="number" contextRef="c-1067" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" scale="-2" id="f-2318">5</ix:nonFraction>)%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90.16pt;position:var(--position);text-decoration:none;white-space:pre"> of peak penetration (worst case scenario) and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:276.03999999999996pt;position:var(--position);text-decoration:none;white-space:pre">(<ix:nonFraction unitRef="number" contextRef="c-1068" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" scale="-2" id="f-2319">1</ix:nonFraction>)%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:296.03pt;position:var(--position);text-decoration:none;white-space:pre"> WACC and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:347.93pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(<ix:nonFraction unitRef="eurPerShare" contextRef="c-1069" decimals="INF" name="abvx:AmountOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" scale="0" id="f-2320">1</ix:nonFraction>)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:364.59pt;position:var(--position);text-decoration:none;white-space:pre"> share price would result in a change in the royalty </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:241.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">certificates fair value by respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:186.02pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(<ix:nonFraction unitRef="eur" contextRef="c-1070" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2321">1,104</ix:nonFraction>) thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:258.77pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:263.77pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(<ix:nonFraction unitRef="eur" contextRef="c-1071" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2322">2,311</ix:nonFraction>) thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:336.52pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:341.52pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;+<ix:nonFraction unitRef="eur" contextRef="c-1072" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" scale="3" id="f-2323">612</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:405.74pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:425.17pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(<ix:nonFraction unitRef="eur" contextRef="c-1073" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2324">1,325</ix:nonFraction>) thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:497.92pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:263.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2024, using the same assumptions with an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:336pt;position:var(--position);text-decoration:none;white-space:pre">+<ix:nonFraction unitRef="number" contextRef="c-1074" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-4" id="f-2325">5</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:346.63pt;position:var(--position);text-decoration:none;white-space:pre"> points of POS, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:410.23pt;position:var(--position);text-decoration:none;white-space:pre">+<ix:nonFraction unitRef="number" contextRef="c-1075" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-2326">5</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:429.19pt;position:var(--position);text-decoration:none;white-space:pre"> of peak penetration (best case </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:275.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">scenario), </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:77.61pt;position:var(--position);text-decoration:none;white-space:pre">+<ix:nonFraction unitRef="number" contextRef="c-1076" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-2327">1</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.57pt;position:var(--position);text-decoration:none;white-space:pre"> WACC and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:148.47pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;+<ix:nonFraction unitRef="eurPerShare" contextRef="c-1077" decimals="INF" name="abvx:AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="0" id="f-2328">1</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:164.1pt;position:var(--position);text-decoration:none;white-space:pre"> share price would result in a change in the royalty certificates fair value by respectively &#8364;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:286.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">+</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:41.63pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-1078" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="3" id="f-2329">572</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:95.22pt;position:var(--position);text-decoration:none;white-space:pre">, &#8364;+</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:110.85pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-1079" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2330">1,735</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:171.94pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:176.94pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(<ix:nonFraction unitRef="eur" contextRef="c-1080" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="3" id="f-2331">314</ix:nonFraction>) thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:242.19pt;position:var(--position);text-decoration:none;white-space:pre"> and &#8364;+</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:272.25pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-1081" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2332">1,160</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:333.34pt;position:var(--position);text-decoration:none;white-space:pre">. Using the same assumptions with a decrease of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:529.24pt;position:var(--position);text-decoration:none;white-space:pre">(<ix:nonFraction unitRef="number" contextRef="c-1074" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" scale="-4" id="f-2333">5</ix:nonFraction>)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:540.9pt;position:var(--position);text-decoration:none;white-space:pre"> points </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:297.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of POS, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:70.17pt;position:var(--position);text-decoration:none;white-space:pre">(<ix:nonFraction unitRef="number" contextRef="c-1075" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" scale="-2" id="f-2334">5</ix:nonFraction>)%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90.16pt;position:var(--position);text-decoration:none;white-space:pre"> of peak penetration (worst case scenario) and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:276.03999999999996pt;position:var(--position);text-decoration:none;white-space:pre">(<ix:nonFraction unitRef="number" contextRef="c-1076" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" scale="-2" id="f-2335">1</ix:nonFraction>)%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:296.03pt;position:var(--position);text-decoration:none;white-space:pre"> WACC and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:347.93pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(<ix:nonFraction unitRef="eurPerShare" contextRef="c-1077" decimals="INF" name="abvx:AmountOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" scale="0" id="f-2336">1</ix:nonFraction>)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:364.59pt;position:var(--position);text-decoration:none;white-space:pre"> share price would result in a change in the royalty </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:308.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">certificates fair value by respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:186.02pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(<ix:nonFraction unitRef="eur" contextRef="c-1078" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" scale="3" id="f-2337">572</ix:nonFraction>) thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:251.27pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:256.27pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(<ix:nonFraction unitRef="eur" contextRef="c-1079" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2338">2,527</ix:nonFraction>) thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:329.02pt;position:var(--position);text-decoration:none;white-space:pre">, &#8364;+</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:344.65pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-1080" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" scale="3" id="f-2339">332</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:398.24pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:417.67pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(<ix:nonFraction unitRef="eur" contextRef="c-1081" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2340">1,160</ix:nonFraction>) thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:490.42pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:331.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2025, using the same assumptions with an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:336pt;position:var(--position);text-decoration:none;white-space:pre">+<ix:nonFraction unitRef="number" contextRef="c-1062" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-4" id="f-2341">5</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:346.63pt;position:var(--position);text-decoration:none;white-space:pre"> points of POS, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:410.23pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1063" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-2342">+5</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:429.19pt;position:var(--position);text-decoration:none;white-space:pre"> of peak penetration (best case </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:342.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">scenario) and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:92.03999999999999pt;position:var(--position);text-decoration:none;white-space:pre">+<ix:nonFraction unitRef="number" contextRef="c-1082" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-2343">1</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:111pt;position:var(--position);text-decoration:none;white-space:pre"> WACC would result in a change in the royalty certificates fair value by respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:451.93pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;+<ix:nonFraction unitRef="eur" contextRef="c-1064" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2344">5810</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:521.15pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:526.15pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:353.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">+<ix:nonFraction unitRef="eur" contextRef="c-1065" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2345">2830</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:100.22pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:119.65pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(<ix:nonFraction unitRef="eur" contextRef="c-1083" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2346">4,940</ix:nonFraction>) thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:192.4pt;position:var(--position);text-decoration:none;white-space:pre">. Using the same assumptions with a decrease of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:388.3pt;position:var(--position);text-decoration:none;white-space:pre">(<ix:nonFraction unitRef="number" contextRef="c-1062" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" scale="-4" id="f-2347">5</ix:nonFraction>)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:399.96pt;position:var(--position);text-decoration:none;white-space:pre"> points of POS, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:463.56pt;position:var(--position);text-decoration:none;white-space:pre">(<ix:nonFraction unitRef="number" contextRef="c-1063" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" scale="-2" id="f-2348">5</ix:nonFraction>)%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:483.55pt;position:var(--position);text-decoration:none;white-space:pre"> of peak penetration </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:364.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(worst case scenario) and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:139.76pt;position:var(--position);text-decoration:none;white-space:pre">(<ix:nonFraction unitRef="number" contextRef="c-1082" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" scale="-2" id="f-2349">1</ix:nonFraction>)%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:159.75pt;position:var(--position);text-decoration:none;white-space:pre"> WACC would result in a change in the royalty certificates fair value by respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:500.68pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(<ix:nonFraction unitRef="eur" contextRef="c-1064" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2350">5,810</ix:nonFraction>) thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:573.43pt;position:var(--position);text-decoration:none;white-space:pre">, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:375.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(<ix:nonFraction unitRef="eur" contextRef="c-1065" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2351">5,590</ix:nonFraction>) thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108.75pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:128.18pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;+<ix:nonFraction unitRef="eur" contextRef="c-1083" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2352">5,251</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:199.9pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div></ix:continuation><div style="position:absolute;top:410.36pt" id="i7a006daedb3d4216a4128b76247285d7_451"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:410.36pt;width:612pt"><ix:continuation id="f-1730-31" continuedAt="f-1730-32"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 15.10. Change in financial liabilities<span id="i9405cec2ec7c4be98c07cac8c184a2de"></span></span></ix:continuation></div><ix:continuation id="f-1730-32" continuedAt="f-1730-33"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:433.66pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" id="f-2353" continuedAt="f-2353-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:44pt;position:var(--position);text-decoration:none;white-space:pre">Changes in financial liabilities, excluding derivative instruments, are presented below as of December 31, 2023, 2024 and 2025:</span></ix:nonNumeric></div><ix:continuation id="f-2353-1" continuedAt="f-2353-2"><div style="position:var(--position);top:444.86pt;width:612pt"><div style="font-size:0pt;left:17pt;position:var(--position);width:558.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:96.75pt"/><td style="padding:0;width:43.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:43.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:43.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:43.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:43.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:43.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:43.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:43.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:43.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:43.5pt"/></tr><tr style="height:21.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:96.75pt"><div><div style="line-height:7pt;position:var(--position);top:13.88pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:italic;font-weight:normal;left:2.9pt;position:var(--position);text-decoration:none;white-space:pre">(Amounts in thousands of euros) </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:44.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21.75pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:9.52pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.73pt;position:var(--position);text-decoration:none;white-space:pre">FINANCIAL </span></div><div style="line-height:8pt;position:var(--position);top:19.12pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.96pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES (excluding </span></div><div style="line-height:8pt;position:var(--position);top:28.72pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.97pt;position:var(--position);text-decoration:none;white-space:pre">derivatives instruments)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:15.36pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:3.78pt;position:var(--position);text-decoration:none;white-space:pre">Kreos 1 &amp; 2 </span></div><div style="line-height:7pt;position:var(--position);top:23.76pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:5.51pt;position:var(--position);text-decoration:none;white-space:pre">bond loans</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:10.68pt;position:var(--position);text-decoration:none;white-space:pre">Oceane</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:2.76pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:11.85pt;position:var(--position);text-decoration:none;white-space:pre">Kreos/</span></div><div style="line-height:7pt;position:var(--position);top:11.16pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:12.24pt;position:var(--position);text-decoration:none;white-space:pre">Claret </span></div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:5.05pt;position:var(--position);text-decoration:none;white-space:pre">convertible </span></div><div style="line-height:7pt;position:var(--position);top:27.96pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:13.98pt;position:var(--position);text-decoration:none;white-space:pre">notes </span></div><div style="line-height:7pt;position:var(--position);top:36.36pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:4.85pt;position:var(--position);text-decoration:none;white-space:pre">(OCABSA)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:11.16pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:9.03pt;position:var(--position);text-decoration:none;white-space:pre">Kreos &amp; </span></div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:3.78pt;position:var(--position);text-decoration:none;white-space:pre">Claret bond </span></div><div style="line-height:7pt;position:var(--position);top:27.96pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:13.97pt;position:var(--position);text-decoration:none;white-space:pre">loans </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:11.16pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:10.29pt;position:var(--position);text-decoration:none;white-space:pre">Heights </span></div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:5.05pt;position:var(--position);text-decoration:none;white-space:pre">convertible </span></div><div style="line-height:7pt;position:var(--position);top:27.96pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:13.98pt;position:var(--position);text-decoration:none;white-space:pre">notes</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:14.56pt;position:var(--position);text-decoration:none;white-space:pre">PGE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:11.16pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:4.06pt;position:var(--position);text-decoration:none;white-space:pre">Conditional </span></div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:8.15pt;position:var(--position);text-decoration:none;white-space:pre">advances </span></div><div style="line-height:7pt;position:var(--position);top:27.96pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:15.92pt;position:var(--position);text-decoration:none;white-space:pre">BPI</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:15.36pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:13.21pt;position:var(--position);text-decoration:none;white-space:pre">Lease </span></div><div style="line-height:7pt;position:var(--position);top:23.76pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:8.16pt;position:var(--position);text-decoration:none;white-space:pre">liabilities</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:15.36pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:10.09pt;position:var(--position);text-decoration:none;white-space:pre">Royalty </span></div><div style="line-height:7pt;position:var(--position);top:23.76pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:5.45pt;position:var(--position);text-decoration:none;white-space:pre">certificates</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:13.78pt;position:var(--position);text-decoration:none;white-space:pre">Total </span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY 1, 2023</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1084" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2354">12,982</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1085" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2355">19,957</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1086" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2356">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1087" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2357">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1088" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2358">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1089" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2359">4,838</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1090" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2360">6,783</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1091" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2361">1,384</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1092" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2362">3,287</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2363">49,231</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:87pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Proceeds</span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1093" decimals="-3" name="abvx:IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2364">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1094" decimals="-3" name="abvx:IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2365">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1095" decimals="-3" name="abvx:IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2366">23,119</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1096" decimals="-3" name="abvx:IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2367">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1097" decimals="-3" name="abvx:IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2368">35,000</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1098" decimals="-3" name="abvx:IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2369">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1099" decimals="-3" name="abvx:IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2370">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1100" decimals="-3" name="abvx:IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2371">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1058" decimals="-3" name="abvx:IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2372">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2373">58,119</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:99pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Repayments </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:99pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:12.8pt"></span></span><span style="left:15.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1093" decimals="-3" name="abvx:DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2374">11,635</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:99pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:12.8pt"></span></span><span style="left:15.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1094" decimals="-3" name="abvx:DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2375">23,238</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:99pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1095" decimals="-3" name="abvx:DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2376">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:99pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1096" decimals="-3" name="abvx:DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2377">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:99pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1097" decimals="-3" name="abvx:DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2378">2,188</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:99pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1098" decimals="-3" name="abvx:DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2379">1,250</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:99pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.8pt"></span></span><span style="left:25.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1099" decimals="-3" name="abvx:DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2380">110</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:99pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.8pt"></span></span><span style="left:25.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1100" decimals="-3" name="abvx:DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2381">573</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:99pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1058" decimals="-3" name="abvx:DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2382">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:99pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:12.8pt"></span></span><span style="left:15.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2383">38,993</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:111pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest paid</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:111pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1093" decimals="-3" name="abvx:DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2384">2,278</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:111pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1094" decimals="-3" name="abvx:DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2385">1,602</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:111pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.8pt"></span></span><span style="left:25.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1095" decimals="-3" name="abvx:DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2386">818</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:111pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1096" decimals="-3" name="abvx:DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2387">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:111pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.8pt"></span></span><span style="left:25.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1097" decimals="-3" name="abvx:DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2388">525</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:111pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.8pt"></span></span><span style="left:29.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1098" decimals="-3" name="abvx:DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2389">43</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:111pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1099" decimals="-3" name="abvx:DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2390">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:111pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.8pt"></span></span><span style="left:29.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1100" decimals="-3" name="abvx:DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2391">12</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:111pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1058" decimals="-3" name="abvx:DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2392">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:111pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2393">5,278</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:50.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:123pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.09pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: </span></div><div style="line-height:8pt;position:var(--position);top:12.69pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">classification of embedded </span></div><div style="line-height:8pt;position:var(--position);top:22.29pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">derivatives as separate </span></div><div style="line-height:8pt;position:var(--position);top:31.89pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">derivative financial </span></div><div style="line-height:8pt;position:var(--position);top:41.49pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">instruments</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:123pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:22.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1093" decimals="-3" name="abvx:IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2394">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:123pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:22.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1094" decimals="-3" name="abvx:IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2395">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:123pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:22.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1095" decimals="-3" sign="-" name="abvx:IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2396">1,046</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:123pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:22.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1096" decimals="-3" name="abvx:IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2397">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:123pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:22.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1097" decimals="-3" name="abvx:IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2398">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:123pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:22.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1098" decimals="-3" name="abvx:IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2399">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:123pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:22.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1099" decimals="-3" name="abvx:IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2400">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:123pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:22.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1100" decimals="-3" name="abvx:IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2401">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:123pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:22.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1058" decimals="-3" name="abvx:IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2402">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:123pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:22.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" sign="-" name="abvx:IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2403">1,046</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:30.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:173.25pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.79pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: (gain)/</span></div><div style="line-height:8pt;position:var(--position);top:12.39pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">loss on recognition or </span></div><div style="line-height:8pt;position:var(--position);top:21.99pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">derecognition</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:173.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.46pt"></span></span><span style="left:28.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1093" decimals="-3" name="abvx:IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2404">170</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:173.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1094" decimals="-3" name="abvx:IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2405">3,069</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:173.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1095" decimals="-3" name="abvx:IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2406">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:173.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1096" decimals="-3" name="abvx:IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2407">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:173.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.8pt"></span></span><span style="left:25.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1097" decimals="-3" sign="-" name="abvx:IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2408">212</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:173.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1098" decimals="-3" name="abvx:IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2409">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:173.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1099" decimals="-3" name="abvx:IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2410">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:173.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1100" decimals="-3" name="abvx:IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2411">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:173.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1058" decimals="-3" name="abvx:IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2412">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:173.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2413">3,027</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:204pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.64pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: interest </span></div><div style="line-height:8pt;position:var(--position);top:12.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">expense and other</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:204pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.46pt"></span></span><span style="left:28.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1093" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2414">760</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:204pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1094" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2415">1,814</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:204pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1095" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2416">1,393</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:204pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1096" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2417">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:204pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.46pt"></span></span><span style="left:28.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1097" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2418">727</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:204pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.46pt"></span></span><span style="left:28.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1098" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2419">133</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:204pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1099" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2420">98</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:204pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1100" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2421">12</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:204pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1058" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2422">2,521</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:204pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2423">7,459</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:30.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:225pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.79pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: </span></div><div style="line-height:8pt;position:var(--position);top:12.39pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">recognition of earn-out </span></div><div style="line-height:8pt;position:var(--position);top:21.99pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">liability</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:225pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1093" decimals="-3" name="abvx:IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2424">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:225pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1094" decimals="-3" name="abvx:IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2425">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:225pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1095" decimals="-3" sign="-" name="abvx:IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2426">1,005</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:225pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1096" decimals="-3" name="abvx:IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2427">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:225pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1097" decimals="-3" name="abvx:IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2428">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:225pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1098" decimals="-3" name="abvx:IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2429">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:225pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1099" decimals="-3" name="abvx:IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2430">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:225pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1100" decimals="-3" name="abvx:IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2431">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:225pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1058" decimals="-3" name="abvx:IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2432">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:225pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" sign="-" name="abvx:IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2433">1,005</ix:nonFraction>)</span></span></div></div></div></td></tr></tbody></table></div></div></div></ix:continuation></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-60<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><ix:continuation id="f-2353-2"><ix:continuation id="f-1730-33" continuedAt="f-1730-34"><div><div style="position:var(--position);top:70.56pt;width:612pt"><div style="font-size:0pt;left:17pt;position:var(--position);width:558.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:96.75pt"/><td style="padding:0;width:43.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:43.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:43.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:43.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:43.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:43.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:43.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:43.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:43.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:43.5pt"/></tr><tr style="height:21.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:96.75pt"><div><div style="line-height:7pt;position:var(--position);top:13.88pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:italic;font-weight:normal;left:2.9pt;position:var(--position);text-decoration:none;white-space:pre">(Amounts in thousands of euros) </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:44.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21.75pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:9.52pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.73pt;position:var(--position);text-decoration:none;white-space:pre">FINANCIAL </span></div><div style="line-height:8pt;position:var(--position);top:19.12pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.96pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES (excluding </span></div><div style="line-height:8pt;position:var(--position);top:28.72pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.97pt;position:var(--position);text-decoration:none;white-space:pre">derivatives instruments)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:15.36pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:3.78pt;position:var(--position);text-decoration:none;white-space:pre">Kreos 1 &amp; 2 </span></div><div style="line-height:7pt;position:var(--position);top:23.76pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:5.51pt;position:var(--position);text-decoration:none;white-space:pre">bond loans</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:10.68pt;position:var(--position);text-decoration:none;white-space:pre">Oceane</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:2.76pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:11.85pt;position:var(--position);text-decoration:none;white-space:pre">Kreos/</span></div><div style="line-height:7pt;position:var(--position);top:11.16pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:12.24pt;position:var(--position);text-decoration:none;white-space:pre">Claret </span></div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:5.05pt;position:var(--position);text-decoration:none;white-space:pre">convertible </span></div><div style="line-height:7pt;position:var(--position);top:27.96pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:13.98pt;position:var(--position);text-decoration:none;white-space:pre">notes </span></div><div style="line-height:7pt;position:var(--position);top:36.36pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:4.85pt;position:var(--position);text-decoration:none;white-space:pre">(OCABSA)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:11.16pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:9.03pt;position:var(--position);text-decoration:none;white-space:pre">Kreos &amp; </span></div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:3.78pt;position:var(--position);text-decoration:none;white-space:pre">Claret bond </span></div><div style="line-height:7pt;position:var(--position);top:27.96pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:13.97pt;position:var(--position);text-decoration:none;white-space:pre">loans </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:11.16pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:10.29pt;position:var(--position);text-decoration:none;white-space:pre">Heights </span></div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:5.05pt;position:var(--position);text-decoration:none;white-space:pre">convertible </span></div><div style="line-height:7pt;position:var(--position);top:27.96pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:13.98pt;position:var(--position);text-decoration:none;white-space:pre">notes</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:14.56pt;position:var(--position);text-decoration:none;white-space:pre">PGE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:11.16pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:4.06pt;position:var(--position);text-decoration:none;white-space:pre">Conditional </span></div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:8.15pt;position:var(--position);text-decoration:none;white-space:pre">advances </span></div><div style="line-height:7pt;position:var(--position);top:27.96pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:15.92pt;position:var(--position);text-decoration:none;white-space:pre">BPI</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:15.36pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:13.21pt;position:var(--position);text-decoration:none;white-space:pre">Lease </span></div><div style="line-height:7pt;position:var(--position);top:23.76pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:8.16pt;position:var(--position);text-decoration:none;white-space:pre">liabilities</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:15.36pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:10.09pt;position:var(--position);text-decoration:none;white-space:pre">Royalty </span></div><div style="line-height:7pt;position:var(--position);top:23.76pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:5.45pt;position:var(--position);text-decoration:none;white-space:pre">certificates</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:13.78pt;position:var(--position);text-decoration:none;white-space:pre">Total </span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">amortized cost </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1093" decimals="-3" name="abvx:IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2434">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1094" decimals="-3" name="abvx:IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2435">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1095" decimals="-3" name="abvx:IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2436">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1096" decimals="-3" name="abvx:IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2437">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1097" decimals="-3" name="abvx:IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2438">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1098" decimals="-3" name="abvx:IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2439">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1099" decimals="-3" name="abvx:IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2440">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.8pt"></span></span><span style="left:25.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1100" decimals="-3" sign="-" name="abvx:IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2441">543</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1058" decimals="-3" name="abvx:IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2442">6,421</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2443">5,878</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:87pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.64pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: other </span></div><div style="line-height:8pt;position:var(--position);top:12.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">fair value remeasurement</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1093" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2444">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1094" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2445">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1095" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2446">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1096" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2447">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1097" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2448">3,198</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1098" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2449">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1099" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2450">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1100" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2451">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1058" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2452">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2453">3,198</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:108pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.64pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non cash changes: </span></div><div style="line-height:8pt;position:var(--position);top:12.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">additional leases</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:108pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1093" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2454">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:108pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1094" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2455">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:108pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1095" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2456">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:108pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1096" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2457">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:108pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1097" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2458">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:108pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1098" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2459">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:108pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1099" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2460">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:108pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.46pt"></span></span><span style="left:28.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1100" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2461">272</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:108pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1058" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2462">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:108pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.46pt"></span></span><span style="left:28.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2463">272</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:129pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:129pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1101" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2464">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:129pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1102" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2465">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:129pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1103" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2466">21,643</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:129pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1104" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2467">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:129pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1105" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2468">29,605</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:129pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1106" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2469">3,678</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:129pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1107" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2470">6,771</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:129pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:25.46pt"></span></span><span style="left:28.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1108" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" scale="3" id="f-2471">540</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:129pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1109" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2472">12,229</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:129pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2473">74,466</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:150pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Proceeds</span></div></div></div></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:150pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1110" decimals="-3" name="abvx:IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2474">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:150pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1111" decimals="-3" name="abvx:IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2475">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:150pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1112" decimals="-3" name="abvx:IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2476">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:150pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1113" decimals="-3" name="abvx:IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2477">47,444</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:150pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1114" decimals="-3" name="abvx:IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2478">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:150pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1115" decimals="-3" name="abvx:IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2479">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:150pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1116" decimals="-3" name="abvx:IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2480">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:150pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1117" decimals="-3" name="abvx:IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2481">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:150pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1059" decimals="-3" name="abvx:IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2482">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:150pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2483">47,444</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:162pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Repayments </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:162pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1110" decimals="-3" name="abvx:DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2484">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:162pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1111" decimals="-3" name="abvx:DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2485">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:162pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1112" decimals="-3" name="abvx:DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2486">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:162pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1113" decimals="-3" name="abvx:DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2487">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:162pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1114" decimals="-3" name="abvx:DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2488">8,750</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:162pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1115" decimals="-3" name="abvx:DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2489">1,250</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:162pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1116" decimals="-3" name="abvx:DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2490">2,708</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:162pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.8pt"></span></span><span style="left:25.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1117" decimals="-3" name="abvx:DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2491">459</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:162pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1059" decimals="-3" name="abvx:DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2492">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:162pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:12.8pt"></span></span><span style="left:15.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2493">13,167</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:174pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest paid</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:174pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1110" decimals="-3" name="abvx:DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2494">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:174pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1111" decimals="-3" name="abvx:DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2495">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:174pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1112" decimals="-3" name="abvx:DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2496">2,250</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:174pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1113" decimals="-3" name="abvx:DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2497">3,639</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:174pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1114" decimals="-3" name="abvx:DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2498">1,772</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:174pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.8pt"></span></span><span style="left:29.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1115" decimals="-3" name="abvx:DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2499">18</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:174pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1116" decimals="-3" name="abvx:DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2500">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:174pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.8pt"></span></span><span style="left:29.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1117" decimals="-3" name="abvx:DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2501">17</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:174pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1059" decimals="-3" name="abvx:DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2502">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:174pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2503">7,696</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:186pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">classification of embedded </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:186pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1110" decimals="-3" name="abvx:IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2504">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:186pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1111" decimals="-3" name="abvx:IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2505">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:186pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1112" decimals="-3" name="abvx:IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2506">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:186pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1113" decimals="-3" sign="-" name="abvx:IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2507">3,204</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:186pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1114" decimals="-3" name="abvx:IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2508">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:186pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1115" decimals="-3" name="abvx:IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2509">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:186pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1116" decimals="-3" name="abvx:IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2510">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:186pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1117" decimals="-3" name="abvx:IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2511">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:186pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1059" decimals="-3" name="abvx:IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2512">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:186pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="abvx:IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2513">3,204</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:207pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: (gain)/</span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">loss on recognition or </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:207pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1110" decimals="-3" name="abvx:IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2514">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:207pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1111" decimals="-3" name="abvx:IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2515">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:207pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1112" decimals="-3" name="abvx:IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2516">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:207pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1113" decimals="-3" name="abvx:IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2517">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:207pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.8pt"></span></span><span style="left:25.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1114" decimals="-3" sign="-" name="abvx:IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2518">590</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:207pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1115" decimals="-3" name="abvx:IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2519">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:207pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1116" decimals="-3" name="abvx:IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2520">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:207pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1117" decimals="-3" name="abvx:IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2521">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:207pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1059" decimals="-3" name="abvx:IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2522">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:207pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.8pt"></span></span><span style="left:25.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="abvx:IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2523">590</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:228pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.64pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: interest </span></div><div style="line-height:8pt;position:var(--position);top:12.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">expense and other</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:228pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1110" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2524">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:228pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1111" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2525">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:228pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1112" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2526">3,977</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:228pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1113" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2527">5,800</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:228pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1114" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2528">1,714</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:228pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1115" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2529">77</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:228pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.46pt"></span></span><span style="left:36.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1116" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2530">7</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:228pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1117" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2531">61</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:228pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1059" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2532">4,198</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:228pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2533">15,834</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:30.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:249pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.79pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: </span></div><div style="line-height:8pt;position:var(--position);top:12.39pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">amortized cost </span></div><div style="line-height:8pt;position:var(--position);top:21.99pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">remeasurement</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:249pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1110" decimals="-3" name="abvx:IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2534">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:249pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1111" decimals="-3" name="abvx:IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2535">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:249pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1112" decimals="-3" name="abvx:IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2536">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:249pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1113" decimals="-3" name="abvx:IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2537">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:249pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1114" decimals="-3" name="abvx:IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2538">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:249pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1115" decimals="-3" name="abvx:IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2539">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:249pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1116" decimals="-3" name="abvx:IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2540">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:249pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1117" decimals="-3" name="abvx:IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2541">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:249pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1059" decimals="-3" sign="-" name="abvx:IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2542">3,404</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:249pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="abvx:IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2543">3,404</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:279.75pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.64pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: other </span></div><div style="line-height:8pt;position:var(--position);top:12.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">fair value remeasurement</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:279.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1110" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2544">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:279.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1111" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2545">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:279.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1112" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2546">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:279.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1113" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2547">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:279.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1114" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2548">1,367</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:279.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1115" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2549">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:279.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1116" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2550">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:279.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1117" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2551">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:279.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1059" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2552">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:279.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2553">1,367</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:300.75pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.64pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes&#160;: </span></div><div style="line-height:8pt;position:var(--position);top:12.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">subsidies </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:300.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1110" decimals="-3" name="abvx:IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2554">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:300.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1111" decimals="-3" name="abvx:IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2555">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:300.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1112" decimals="-3" name="abvx:IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2556">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:300.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1113" decimals="-3" name="abvx:IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2557">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:300.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1114" decimals="-3" name="abvx:IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2558">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:300.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1115" decimals="-3" name="abvx:IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2559">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:300.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1116" decimals="-3" sign="-" name="abvx:IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2560">4,070</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:300.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1117" decimals="-3" name="abvx:IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2561">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:300.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1059" decimals="-3" name="abvx:IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2562">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:300.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="abvx:IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2563">4,070</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:321.75pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.64pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non cash changes: </span></div><div style="line-height:8pt;position:var(--position);top:12.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">additional leases</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:321.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1110" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2564">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:321.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1111" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2565">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:321.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1112" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2566">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:321.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1113" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2567">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:321.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1114" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2568">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:321.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1115" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2569">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:321.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1116" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2570">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:321.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1117" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2571">2,221</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:321.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1059" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2572">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:321.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2573">2,221</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:342.75pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non cash changes : Effect </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">of the change in foreign </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:342.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1110" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2574">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:342.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1111" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2575">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:342.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1112" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2576">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:342.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1113" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2577">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:342.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1114" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2578">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:342.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1115" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2579">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:342.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1116" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2580">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:342.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1117" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2581">17</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:342.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1059" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2582">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:342.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2583">17</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:363.75pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:363.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1118" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2584">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:363.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1119" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2585">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:363.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1120" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2586">23,370</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:363.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1121" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2587">46,401</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:363.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1122" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2588">21,574</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:363.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1123" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2589">2,488</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:363.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1124" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2590">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:363.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1125" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2591">2,363</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:363.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1126" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2592">13,023</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:363.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:11.46pt"></span></span><span style="left:14.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2593">109,218</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:384.75pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Proceeds</span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:384.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1127" decimals="-3" name="abvx:IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2594">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:384.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1128" decimals="-3" name="abvx:IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2595">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:384.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1129" decimals="-3" name="abvx:IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2596">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:384.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1130" decimals="-3" name="abvx:IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2597">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:384.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1131" decimals="-3" name="abvx:IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2598">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:384.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1132" decimals="-3" name="abvx:IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2599">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:384.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1133" decimals="-3" name="abvx:IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2600">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:384.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1134" decimals="-3" name="abvx:IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2601">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:384.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1061" decimals="-3" name="abvx:IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2602">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:384.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2603">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:396.75pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Repayments </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:396.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1127" decimals="-3" name="abvx:DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2604">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:396.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1128" decimals="-3" name="abvx:DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2605">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:396.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1129" decimals="-3" name="abvx:DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2606">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:396.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:12.8pt"></span></span><span style="left:15.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1130" decimals="-3" name="abvx:DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2607">53,920</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:396.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1131" decimals="-3" name="abvx:DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2608">2,188</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:396.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1132" decimals="-3" name="abvx:DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2609">2,514</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:396.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1133" decimals="-3" name="abvx:DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2610">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:396.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.8pt"></span></span><span style="left:25.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1134" decimals="-3" name="abvx:DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2611">910</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:396.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1061" decimals="-3" name="abvx:DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2612">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:396.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:12.8pt"></span></span><span style="left:15.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2613">59,532</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:408.75pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest paid</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:408.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1127" decimals="-3" name="abvx:DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2614">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:408.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1128" decimals="-3" name="abvx:DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2615">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:408.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1129" decimals="-3" name="abvx:DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2616">1,875</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:408.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1130" decimals="-3" name="abvx:DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2617">3,791</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:408.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.8pt"></span></span><span style="left:25.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1131" decimals="-3" name="abvx:DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2618">689</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:408.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.8pt"></span></span><span style="left:29.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1132" decimals="-3" name="abvx:DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2619">72</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:408.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1133" decimals="-3" name="abvx:DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2620">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:408.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.8pt"></span></span><span style="left:29.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1134" decimals="-3" name="abvx:DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2621">64</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:408.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1061" decimals="-3" name="abvx:DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2622">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:408.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2623">6,491</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:30.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:420.75pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.79pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: (gain)/</span></div><div style="line-height:8pt;position:var(--position);top:12.39pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">loss on recognition or </span></div><div style="line-height:8pt;position:var(--position);top:21.99pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">derecognition</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:420.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1127" decimals="-3" name="abvx:IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2624">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:420.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1128" decimals="-3" name="abvx:IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2625">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:420.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1129" decimals="-3" name="abvx:IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2626">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:420.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1130" decimals="-3" name="abvx:IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2627">3,838</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:420.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1131" decimals="-3" sign="-" name="abvx:IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2628">1,557</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:420.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1132" decimals="-3" name="abvx:IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2629">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:420.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1133" decimals="-3" name="abvx:IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2630">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:420.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1134" decimals="-3" name="abvx:IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2631">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:420.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1061" decimals="-3" name="abvx:IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2632">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:420.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2633">2,281</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:451.5pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.64pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: interest </span></div><div style="line-height:8pt;position:var(--position);top:12.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">expense and other</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:451.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1127" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2634">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:451.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1128" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2635">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:451.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1129" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2636">2,860</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:451.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1130" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2637">7,472</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:451.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.46pt"></span></span><span style="left:28.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1131" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2638">778</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:451.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1132" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2639">99</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:451.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1133" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2640">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:451.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1134" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2641">64</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:451.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1061" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2642">5,927</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:451.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2643">17,200</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:30.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:472.5pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.79pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: </span></div><div style="line-height:8pt;position:var(--position);top:12.39pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">amortized cost </span></div><div style="line-height:8pt;position:var(--position);top:21.99pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">remeasurement</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:472.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1127" decimals="-3" name="abvx:IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2644">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:472.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1128" decimals="-3" name="abvx:IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2645">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:472.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1129" decimals="-3" name="abvx:IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2646">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:472.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1130" decimals="-3" name="abvx:IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2647">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:472.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1131" decimals="-3" name="abvx:IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2648">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:472.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1132" decimals="-3" name="abvx:IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2649">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:472.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1133" decimals="-3" name="abvx:IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2650">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:472.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:30.8pt"></span></span><span style="left:33.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1134" decimals="-3" sign="-" name="abvx:IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2651">7</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:472.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1061" decimals="-3" name="abvx:IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2652">11,286</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:472.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2653">11,278</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:503.25pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.64pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: other </span></div><div style="line-height:8pt;position:var(--position);top:12.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">fair value remeasurement</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:503.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1127" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2654">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:503.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1128" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2655">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:503.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1129" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2656">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:503.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1130" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2657">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:503.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1131" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2658">36,002</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:503.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1132" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2659">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:503.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1133" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2660">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:503.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1134" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2661">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:503.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1061" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2662">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:503.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2663">36,002</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:524.25pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.64pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: </span></div><div style="line-height:8pt;position:var(--position);top:12.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">conversion into shares</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:524.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1127" decimals="-3" name="abvx:IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2664">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:524.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1128" decimals="-3" name="abvx:IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2665">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:524.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:12.8pt"></span></span><span style="left:15.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1129" decimals="-3" sign="-" name="abvx:IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2666">24,354</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:524.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1130" decimals="-3" name="abvx:IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2667">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:524.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:12.8pt"></span></span><span style="left:15.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1131" decimals="-3" sign="-" name="abvx:IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2668">53,921</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:524.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1132" decimals="-3" name="abvx:IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2669">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:524.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1133" decimals="-3" name="abvx:IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2670">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:524.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1134" decimals="-3" name="abvx:IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2671">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:524.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1061" decimals="-3" name="abvx:IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2672">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:524.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:12.8pt"></span></span><span style="left:15.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="abvx:IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2673">78,275</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:545.25pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.81pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non cash changes: </span></div><div style="line-height:8pt;position:var(--position);top:12.81pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">additional leases</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:545.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1127" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2674">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:545.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1128" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2675">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:545.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1129" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2676">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:545.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1130" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2677">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:545.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1131" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2678">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:545.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1132" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2679">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:545.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1133" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2680">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:545.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.46pt"></span></span><span style="left:28.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1134" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2681">444</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:545.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1061" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2682">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:545.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.46pt"></span></span><span style="left:28.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2683">444</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:32.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:567pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.49pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non cash changes : Effect </span></div><div style="line-height:8pt;position:var(--position);top:13.49pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">of the change in foreign </span></div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">currency exchange rates</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:567pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:13.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1127" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2684">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:567pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:13.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1128" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2685">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:567pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:13.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1129" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2686">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:567pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:13.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1130" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2687">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:567pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:13.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1131" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2688">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:567pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:13.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1132" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2689">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:567pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:13.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1133" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2690">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:567pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:13.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.8pt"></span></span><span style="left:29.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1134" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2691">33</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:567pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:13.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1061" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2692">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:567pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:13.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.8pt"></span></span><span style="left:29.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" scale="3" id="f-2693">33</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:599.25pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.52pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:13.12pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:599.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.87pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1135" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2694">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:599.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.87pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1136" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2695">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:599.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.87pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1137" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2696">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:599.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.87pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1138" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2697">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:599.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.87pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1139" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2698">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:599.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.87pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1140" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2699">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:599.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.87pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1141" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2700">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:599.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.87pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1142" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2701">1,856</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:599.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.87pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1143" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2702">30,237</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:599.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.87pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2703">32,093</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div></div></ix:continuation></ix:continuation></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-61<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-1730-34" continuedAt="f-1730-35"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">For the year ended December 31, 2023, proceeds from the issuance of the Kreos / Claret OCABSA are presented net of transaction </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:81.76pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">costs, amounting to </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:116.49pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1144" decimals="-3" name="ifrs-full:PaymentsForDebtIssueCosts" format="ixt:num-dot-decimal" scale="3" id="f-2704">1,881</ix:nonFraction>&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:182.58pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">. Net proceeds from convertible loan notes of </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:365.99pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:NetProceedsFromConvertibleLoansNotes" format="ixt:num-dot-decimal" scale="3" id="f-2705">55,841</ix:nonFraction></span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:398.49pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> disclosed in the Consolidated Statements of </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:92.96pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">Cash Flows also include transaction fees of (i) </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:223.57pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1145" decimals="-3" name="ifrs-full:PaymentsForDebtIssueCosts" scale="3" id="f-2706">750</ix:nonFraction>&#160;thousands</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:286.05pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> related to the Kreos / Claret B and C tranches and recorded in prepaid </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:104.16pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">expenses (see Note 10) and (ii) </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:162.53pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-929" decimals="-3" name="ifrs-full:PaymentsForDebtIssueCosts" format="ixt:num-dot-decimal" scale="3" id="f-2707">1,528</ix:nonFraction>&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:228.62pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> related to the Heights convertible notes.</span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">For the year ended December 31, 2023, repayments of the OCEANE are presented net of the repurchase of the conversion option, </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:137.76pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">value</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:57.629999999999995pt;position:var(--position);text-decoration:none;white-space:pre">d at </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:74.83pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1146" decimals="-3" name="abvx:RepurchaseOfDerivativeInstruments" format="ixt:num-dot-decimal" scale="3" id="f-2708">1,762</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.92000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> on the date of repayment, which is presented in Note 15.11. The aggregate repayment amounts to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:148.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1147" decimals="-3" name="abvx:RepaymentsOfConvertibleLoansNotes" format="ixt:num-dot-decimal" scale="3" id="f-2709">25,000</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:107.09pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:171.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">For the year ended December 31, 2024, proceeds from the issuance of the Kreos / Claret tranches B and C bond loans are presented </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:182.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">net of transaction costs and deposits (corresponding to the prepayments of half of the last debt installments on issuance date) included </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:193.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in the debt discount using the EIR method, and amounting to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:281.89pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-331" decimals="-3" name="ifrs-full:PaymentsForDebtIssueCosts" format="ixt:num-dot-decimal" scale="3" id="f-2710">1,475</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:347.98pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:367.41pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1148" decimals="-3" name="ifrs-full:PaymentsForDebtIssueCosts" format="ixt:num-dot-decimal" scale="3" id="f-2711">1,081</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:433.5pt;position:var(--position);text-decoration:none;white-space:pre"> respectively. Net proceeds from </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:204.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">non-convertible bond loans of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.68pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:GrossProceedsFromNonConvertibleLoansNotes" format="ixt:num-dot-decimal" scale="3" id="f-2712">48,544</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:191.18pt;position:var(--position);text-decoration:none;white-space:pre"> thousand disclosed in the Unaudited Condensed Consolidated Statements of Cash Flows do not </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:216.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">include transaction fees of (i) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.56pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1149" decimals="-3" name="ifrs-full:PaymentsForDebtIssueCosts" scale="3" id="f-2713">500</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:214.15pt;position:var(--position);text-decoration:none;white-space:pre"> related to the Kreos / Claret tranche A-B warrants classified as prepaid expenses as of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:227.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">December 31, 2023.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:249.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">For the year ended December 31,2025, repayments of the Kreos / Claret tranches B and C bond loans include end-of loan exit fees and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:260.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">future interests discounted at a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:160.56pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1150" decimals="2" name="abvx:BorrowingsDiscountRate" scale="-2" id="f-2714">4</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:173.89pt;position:var(--position);text-decoration:none;white-space:pre"> rate, as per the terms of the prepayment option </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:365.05pt;position:var(--position);text-decoration:none;white-space:pre">(see Note 15.1).</span></div></ix:continuation><div style="position:absolute;top:285.11pt" id="i7a006daedb3d4216a4128b76247285d7_454"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:285.11pt;width:612pt"><ix:continuation id="f-1730-35" continuedAt="f-1730-36"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 15.11. Change in derivative instruments<span id="ie479f271640a417bac703cd042645514"></span></span></ix:continuation></div><ix:continuation id="f-1730-36" continuedAt="f-1730-37"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:304.91pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="abvx:DisclosureOfChangesInDerivativeFinancialInstrumentsTableTextBlock" id="f-2715" continuedAt="f-2715-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Changes in derivative instruments, are presented below as of December 31, 2023, 2024 and 2025 :</span></ix:nonNumeric></div><ix:continuation id="f-2715-1"><div style="position:var(--position);top:326.91pt;width:612pt"><div style="font-size:0pt;left:44pt;position:var(--position);width:534.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:96pt"/><td style="padding:0;width:69.75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:69.75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:69.75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:69.75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:69.75pt"/></tr><tr style="height:24.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:96pt"><div><div style="line-height:8pt;position:var(--position);top:4.5pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:7.68pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of </span></div><div style="line-height:8pt;position:var(--position);top:14.1pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:37.78pt;position:var(--position);text-decoration:none;white-space:pre">euros)</span></div></div></div></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12pt;position:var(--position);text-decoration:none;white-space:pre">Kreos A BSA</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.22pt;position:var(--position);text-decoration:none;white-space:pre">Kreos B BSA</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:19.57pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.78pt;position:var(--position);text-decoration:none;white-space:pre">OCEANE </span></div><div style="line-height:8pt;position:var(--position);top:29.17pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.56pt;position:var(--position);text-decoration:none;white-space:pre">conversion option</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.53pt;position:var(--position);text-decoration:none;white-space:pre">Kreos/Claret BSA</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.67pt;position:var(--position);text-decoration:none;white-space:pre">Kreos/Claret </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.01pt;position:var(--position);text-decoration:none;white-space:pre">Minimal Return </span></div><div style="line-height:8pt;position:var(--position);top:33.97pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.01pt;position:var(--position);text-decoration:none;white-space:pre">Indemnifications</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.77pt;position:var(--position);text-decoration:none;white-space:pre">Total </span></div></div></div></td></tr><tr style="height:30pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.4pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DERIVATIVE </span></div><div style="line-height:8pt;position:var(--position);top:12pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">FINANCIAL </span></div><div style="line-height:8pt;position:var(--position);top:21.6pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">INSTRUMENTS</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY 1, 2023</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:54.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.71pt"></span></span><span style="left:54.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1151" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" scale="3" id="f-2716">275</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:54.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.71pt"></span></span><span style="left:54.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1152" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" scale="3" id="f-2717">149</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:54.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.71pt"></span></span><span style="left:54.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1153" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" scale="3" id="f-2718">142</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1154" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2719">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:54.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1155" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2720">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:54.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.71pt"></span></span><span style="left:54.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" scale="3" id="f-2721">566</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:75.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(+) Issuance</span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:75.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1156" decimals="-3" name="abvx:IssuanceOfDerivativeInstruments" format="ixt:fixed-zero" scale="3" id="f-2722">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:75.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1157" decimals="-3" name="abvx:IssuanceOfDerivativeInstruments" format="ixt:fixed-zero" scale="3" id="f-2723">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:75.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1146" decimals="-3" name="abvx:IssuanceOfDerivativeInstruments" format="ixt:fixed-zero" scale="3" id="f-2724">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:75.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1158" decimals="-3" name="abvx:IssuanceOfDerivativeInstruments" format="ixt:num-dot-decimal" scale="3" id="f-2725">3,585</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:75.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1159" decimals="-3" name="abvx:IssuanceOfDerivativeInstruments" format="ixt:fixed-zero" scale="3" id="f-2726">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:75.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:IssuanceOfDerivativeInstruments" format="ixt:num-dot-decimal" scale="3" id="f-2727">3,585</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:87.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(+) Increase in fair value</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:87.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.71pt"></span></span><span style="left:54.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1156" decimals="-3" name="ifrs-full:LossesOnChangeInFairValueOfDerivatives" scale="3" id="f-2728">986</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:87.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.71pt"></span></span><span style="left:54.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1157" decimals="-3" name="ifrs-full:LossesOnChangeInFairValueOfDerivatives" scale="3" id="f-2729">440</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:87.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1146" decimals="-3" name="ifrs-full:LossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-2730">1,620</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:87.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1158" decimals="-3" name="ifrs-full:LossesOnChangeInFairValueOfDerivatives" format="ixt:fixed-zero" scale="3" id="f-2731">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:87.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1159" decimals="-3" name="ifrs-full:LossesOnChangeInFairValueOfDerivatives" format="ixt:fixed-zero" scale="3" id="f-2732">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:87.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:LossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-2733">3,046</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:99.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(-) Decrease in fair value</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:99.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1156" decimals="-3" name="ifrs-full:GainsOnChangeInFairValueOfDerivatives" format="ixt:fixed-zero" scale="3" id="f-2734">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:99.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1157" decimals="-3" name="ifrs-full:GainsOnChangeInFairValueOfDerivatives" format="ixt:fixed-zero" scale="3" id="f-2735">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:99.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1146" decimals="-3" name="ifrs-full:GainsOnChangeInFairValueOfDerivatives" format="ixt:fixed-zero" scale="3" id="f-2736">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:99.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1158" decimals="-3" name="ifrs-full:GainsOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-2737">1,006</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:99.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1159" decimals="-3" name="ifrs-full:GainsOnChangeInFairValueOfDerivatives" format="ixt:fixed-zero" scale="3" id="f-2738">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:99.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:43.05pt"></span></span><span style="left:45.68pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:GainsOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-2739">1,006</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:111.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(-) Repurchases</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:111.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:49.05pt"></span></span><span style="left:51.68pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1156" decimals="-3" name="abvx:RepurchaseOfDerivativeInstruments" scale="3" id="f-2740">489</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:111.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:49.05pt"></span></span><span style="left:51.68pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1157" decimals="-3" name="abvx:RepurchaseOfDerivativeInstruments" scale="3" id="f-2741">339</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:111.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:43.05pt"></span></span><span style="left:45.68pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1146" decimals="-3" name="abvx:RepurchaseOfDerivativeInstruments" format="ixt:num-dot-decimal" scale="3" id="f-2742">1,762</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:111.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1158" decimals="-3" name="abvx:RepurchaseOfDerivativeInstruments" format="ixt:fixed-zero" scale="3" id="f-2743">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:111.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1159" decimals="-3" name="abvx:RepurchaseOfDerivativeInstruments" format="ixt:fixed-zero" scale="3" id="f-2744">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:111.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:43.05pt"></span></span><span style="left:45.68pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:RepurchaseOfDerivativeInstruments" format="ixt:num-dot-decimal" scale="3" id="f-2745">2,591</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:123.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(-) Exercises</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:123.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:49.05pt"></span></span><span style="left:51.68pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1156" decimals="-3" name="abvx:ExerciseOfDerivativeInstruments" scale="3" id="f-2746">771</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:123.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:49.05pt"></span></span><span style="left:51.68pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1157" decimals="-3" name="abvx:ExerciseOfDerivativeInstruments" scale="3" id="f-2747">250</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:123.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1146" decimals="-3" name="abvx:ExerciseOfDerivativeInstruments" format="ixt:fixed-zero" scale="3" id="f-2748">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:123.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1158" decimals="-3" name="abvx:ExerciseOfDerivativeInstruments" format="ixt:fixed-zero" scale="3" id="f-2749">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:123.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1159" decimals="-3" name="abvx:ExerciseOfDerivativeInstruments" format="ixt:fixed-zero" scale="3" id="f-2750">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:123.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:43.05pt"></span></span><span style="left:45.68pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:ExerciseOfDerivativeInstruments" format="ixt:num-dot-decimal" scale="3" id="f-2751">1,021</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:135.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:135.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1160" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2752">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:135.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1161" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2753">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:135.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1162" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2754">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:135.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-703" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2755">2,579</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:135.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-709" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2756">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:135.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2757">2,579</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:156.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(+) Issuance</span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:156.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1163" decimals="-3" name="abvx:IssuanceOfDerivativeInstruments" format="ixt:fixed-zero" scale="3" id="f-2758">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:156.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1164" decimals="-3" name="abvx:IssuanceOfDerivativeInstruments" format="ixt:fixed-zero" scale="3" id="f-2759">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:156.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1165" decimals="-3" name="abvx:IssuanceOfDerivativeInstruments" format="ixt:fixed-zero" scale="3" id="f-2760">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:156.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1166" decimals="-3" name="abvx:IssuanceOfDerivativeInstruments" format="ixt:fixed-zero" scale="3" id="f-2761">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:156.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1167" decimals="-3" name="abvx:IssuanceOfDerivativeInstruments" format="ixt:num-dot-decimal" scale="3" id="f-2762">2,158</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:156.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:IssuanceOfDerivativeInstruments" format="ixt:num-dot-decimal" scale="3" id="f-2763">2,158</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:168.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(+) Increase in fair value</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:168.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1163" decimals="-3" name="ifrs-full:LossesOnChangeInFairValueOfDerivatives" format="ixt:fixed-zero" scale="3" id="f-2764">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:168.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1164" decimals="-3" name="ifrs-full:LossesOnChangeInFairValueOfDerivatives" format="ixt:fixed-zero" scale="3" id="f-2765">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:168.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1165" decimals="-3" name="ifrs-full:LossesOnChangeInFairValueOfDerivatives" format="ixt:fixed-zero" scale="3" id="f-2766">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:168.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1166" decimals="-3" name="ifrs-full:LossesOnChangeInFairValueOfDerivatives" format="ixt:fixed-zero" scale="3" id="f-2767">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:168.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1167" decimals="-3" name="ifrs-full:LossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-2768">1,462</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:168.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:LossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-2769">1,462</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:180.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(-) Decrease in fair value</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:180.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1163" decimals="-3" name="ifrs-full:GainsOnChangeInFairValueOfDerivatives" format="ixt:fixed-zero" scale="3" id="f-2770">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:180.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1164" decimals="-3" name="ifrs-full:GainsOnChangeInFairValueOfDerivatives" format="ixt:fixed-zero" scale="3" id="f-2771">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:180.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1165" decimals="-3" name="ifrs-full:GainsOnChangeInFairValueOfDerivatives" format="ixt:fixed-zero" scale="3" id="f-2772">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:180.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1166" decimals="-3" name="ifrs-full:GainsOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-2773">1,413</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:180.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1167" decimals="-3" name="ifrs-full:GainsOnChangeInFairValueOfDerivatives" format="ixt:fixed-zero" scale="3" id="f-2774">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:180.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:43.05pt"></span></span><span style="left:45.68pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:GainsOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-2775">1,413</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:192.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:192.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1168" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2776">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:192.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1169" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2777">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:192.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1170" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2778">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:192.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-704" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2779">1,166</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:192.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-710" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2780">3,620</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:192.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2781">4,786</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:213.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(+) Increase in fair value</span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:213.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1171" decimals="-3" name="ifrs-full:LossesOnChangeInFairValueOfDerivatives" format="ixt:fixed-zero" scale="3" id="f-2782">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:213.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1172" decimals="-3" name="ifrs-full:LossesOnChangeInFairValueOfDerivatives" format="ixt:fixed-zero" scale="3" id="f-2783">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:213.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1173" decimals="-3" name="ifrs-full:LossesOnChangeInFairValueOfDerivatives" format="ixt:fixed-zero" scale="3" id="f-2784">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:213.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1174" decimals="-3" name="ifrs-full:LossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-2785">29,935</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:213.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1175" decimals="-3" name="ifrs-full:LossesOnChangeInFairValueOfDerivatives" format="ixt:fixed-zero" scale="3" id="f-2786">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:213.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.71pt"></span></span><span style="left:44.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:LossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-2787">29,935</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:225.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(-) Decrease in fair value</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:225.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1171" decimals="-3" name="ifrs-full:GainsOnChangeInFairValueOfDerivatives" format="ixt:fixed-zero" scale="3" id="f-2788">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:225.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1172" decimals="-3" name="ifrs-full:GainsOnChangeInFairValueOfDerivatives" format="ixt:fixed-zero" scale="3" id="f-2789">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:225.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1173" decimals="-3" name="ifrs-full:GainsOnChangeInFairValueOfDerivatives" format="ixt:fixed-zero" scale="3" id="f-2790">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:225.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1174" decimals="-3" name="ifrs-full:GainsOnChangeInFairValueOfDerivatives" format="ixt:fixed-zero" scale="3" id="f-2791">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:225.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:43.05pt"></span></span><span style="left:45.68pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1175" decimals="-3" name="ifrs-full:GainsOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-2792">3,620</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:225.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:43.05pt"></span></span><span style="left:45.68pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:GainsOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-2793">3,620</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:237.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(-) Repurchases</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:237.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1171" decimals="-3" name="abvx:RepurchaseOfDerivativeInstruments" format="ixt:fixed-zero" scale="3" id="f-2794">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:237.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1172" decimals="-3" name="abvx:RepurchaseOfDerivativeInstruments" format="ixt:fixed-zero" scale="3" id="f-2795">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:237.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1173" decimals="-3" name="abvx:RepurchaseOfDerivativeInstruments" format="ixt:fixed-zero" scale="3" id="f-2796">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:237.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1174" decimals="-3" name="abvx:RepurchaseOfDerivativeInstruments" format="ixt:num-dot-decimal" scale="3" id="f-2797">4,427</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:237.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1175" decimals="-3" name="abvx:RepurchaseOfDerivativeInstruments" format="ixt:fixed-zero" scale="3" id="f-2798">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:237.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:43.05pt"></span></span><span style="left:45.68pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:RepurchaseOfDerivativeInstruments" format="ixt:num-dot-decimal" scale="3" id="f-2799">4,427</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:249.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(-) Exercises</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:249.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1171" decimals="-3" name="abvx:ExerciseOfDerivativeInstruments" format="ixt:fixed-zero" scale="3" id="f-2800">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:249.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1172" decimals="-3" name="abvx:ExerciseOfDerivativeInstruments" format="ixt:fixed-zero" scale="3" id="f-2801">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:249.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1173" decimals="-3" name="abvx:ExerciseOfDerivativeInstruments" format="ixt:fixed-zero" scale="3" id="f-2802">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:249.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.3pt"></span></span><span style="left:46.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1174" decimals="-3" name="abvx:ExerciseOfDerivativeInstruments" format="ixt:num-dot-decimal" scale="3" id="f-2803">26,674</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:249.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1175" decimals="-3" name="abvx:ExerciseOfDerivativeInstruments" format="ixt:fixed-zero" scale="3" id="f-2804">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:249.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.05pt"></span></span><span style="left:41.68pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:ExerciseOfDerivativeInstruments" format="ixt:num-dot-decimal" scale="3" id="f-2805">26,674</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:261.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:261.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1176" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2806">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:261.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1177" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2807">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:261.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1178" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2808">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:261.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-705" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2809">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:261.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-711" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2810">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:261.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2811">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div></ix:continuation><div style="font-size:12pt;line-height:11pt;position:var(--position);top:614.66pt;width:612pt"><span style="font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:44pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:639.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Details related to these instruments' accounting treatments and terms and conditions are set forth in Notes 15.1 to 15.5.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:650.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The repurchases of the Kreos A&amp;B BSA (2023) and Kreos BSA (2025) were carried as part of the implementation of the cashless </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:661.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">exercises of these share warrants and were therefore not settled in cash.</span></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-62<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><div style="position:absolute;top:70.56pt" id="i7a006daedb3d4216a4128b76247285d7_457"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><ix:continuation id="f-1730-37" continuedAt="f-1730-38"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 15.12. Breakdown of financial liabilities by maturity<span id="i93807e77712e4fd38fa20547dc122790"></span></span></ix:continuation></div><ix:continuation id="f-1730-38"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:95.86pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="ifrs-full:MaturityAnalysisForDerivativeFinancialLiabilities" id="f-2813" continuedAt="f-2813-1" escape="true"><ix:nonNumeric contextRef="c-1" name="ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities" id="f-2812" continuedAt="f-2812-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The following are the remaining contractual maturities of financial liabilities as of December 31, 2023, 2024 and 2025. The amounts </span></ix:nonNumeric></ix:nonNumeric></div><ix:continuation id="f-2813-1"><ix:continuation id="f-2812-1"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:107.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">are gross and undiscounted, and include contractual interest payments. </span></div><div style="position:var(--position);top:128.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:543pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:147pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:63pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:69pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:63pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:60.75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:59.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:63pt"/></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:147pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.88pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td colspan="11" style="font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);width:393pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:393pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:145.75pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2023</span></div></div></div></td></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">CURRENT AND NON-CURRENT </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">FINANCIAL LIABILITIES</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:21pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.95pt;position:var(--position);text-decoration:none;white-space:pre">GROSS </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.29pt;position:var(--position);text-decoration:none;white-space:pre">AMOUNT </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:21pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.2pt;position:var(--position);text-decoration:none;white-space:pre">CONTRACTUAL </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.96pt;position:var(--position);text-decoration:none;white-space:pre">CASH FLOWS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:21pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.18pt;position:var(--position);text-decoration:none;white-space:pre">LESS THAN 1 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.18pt;position:var(--position);text-decoration:none;white-space:pre">YEAR</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:21pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.39pt;position:var(--position);text-decoration:none;white-space:pre">FROM 1 TO 2 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.83pt;position:var(--position);text-decoration:none;white-space:pre">YEARS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:21pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.64pt;position:var(--position);text-decoration:none;white-space:pre">FROM 2 TO 5 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.08pt;position:var(--position);text-decoration:none;white-space:pre">YEARS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:21pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:5.17pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.18pt;position:var(--position);text-decoration:none;white-space:pre">LONGER </span></div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.95pt;position:var(--position);text-decoration:none;white-space:pre">THAN 5 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.96pt;position:var(--position);text-decoration:none;white-space:pre">YEARS </span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Heights convertible notes</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:54pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.37pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-724" decimals="-3" name="abvx:ConvertibleLoansNotes" format="ixt:num-dot-decimal" scale="3" id="f-2814">29,605</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:54pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.96pt"></span></span><span style="left:43.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-724" decimals="-3" name="abvx:ConvertibleLoansNotesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2815">36,750</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:54pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:34.96pt"></span></span><span style="left:37.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1179" decimals="-3" name="abvx:ConvertibleLoansNotesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2816">10,522</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:54pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.71pt"></span></span><span style="left:39.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1180" decimals="-3" name="abvx:ConvertibleLoansNotesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2817">9,997</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:54pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:31.21pt"></span></span><span style="left:33.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1181" decimals="-3" name="abvx:ConvertibleLoansNotesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2818">16,231</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:54pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1182" decimals="-3" name="abvx:ConvertibleLoansNotesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-2819">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos/Claret convertible notes (OCABSA)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:66pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.37pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-703" decimals="-3" name="abvx:ConvertibleLoansNotes" format="ixt:num-dot-decimal" scale="3" id="f-2820">21,643</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:66pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.96pt"></span></span><span style="left:43.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-703" decimals="-3" name="abvx:ConvertibleLoansNotesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2821">30,903</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:66pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1183" decimals="-3" name="abvx:ConvertibleLoansNotesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2822">2,250</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:66pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.71pt"></span></span><span style="left:39.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1184" decimals="-3" name="abvx:ConvertibleLoansNotesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2823">2,250</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:66pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:31.21pt"></span></span><span style="left:33.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1185" decimals="-3" name="abvx:ConvertibleLoansNotesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2824">26,403</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:66pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1186" decimals="-3" name="abvx:ConvertibleLoansNotesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-2825">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">PGE</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:78pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:42.37pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-697" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-2826">3,678</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:78pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-697" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2827">3,880</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:78pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1187" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2828">1,293</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:78pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.71pt"></span></span><span style="left:39.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1188" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2829">1,293</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:78pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.21pt"></span></span><span style="left:37.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1189" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2830">1,293</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:78pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1190" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-2831">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Conditional advances Bpifrance</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:90pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:42.37pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="abvx:ConditionalAdvances" format="ixt:num-dot-decimal" scale="3" id="f-2832">6,771</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:90pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="abvx:ConditionalAdvancesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2833">6,813</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:90pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1191" decimals="-3" name="abvx:ConditionalAdvancesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2834">3,697</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:90pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.71pt"></span></span><span style="left:39.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1192" decimals="-3" name="abvx:ConditionalAdvancesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2835">1,490</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:90pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.21pt"></span></span><span style="left:37.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1193" decimals="-3" name="abvx:ConditionalAdvancesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2836">1,626</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:90pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1194" decimals="-3" name="abvx:ConditionalAdvancesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-2837">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Royalty certificates</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:102pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.37pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="abvx:NonCurrentRoyaltyCertificates" format="ixt:num-dot-decimal" scale="3" id="f-2838">12,229</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:102pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.96pt"></span></span><span style="left:57.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="abvx:RoyaltyCertificatesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-2839">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:102pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1191" decimals="-3" name="abvx:RoyaltyCertificatesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-2840">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:102pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.71pt"></span></span><span style="left:49.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1192" decimals="-3" name="abvx:RoyaltyCertificatesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-2841">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:102pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.21pt"></span></span><span style="left:47.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1193" decimals="-3" name="abvx:RoyaltyCertificatesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-2842">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:102pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1194" decimals="-3" name="abvx:RoyaltyCertificatesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-2843">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:114pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Lease liabilities</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:114pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:48.37pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:LeaseLiabilities" scale="3" id="f-2844">540</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:114pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" scale="3" id="f-2845">575</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:114pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1191" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" scale="3" id="f-2846">406</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:114pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.71pt"></span></span><span style="left:45.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1192" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" scale="3" id="f-2847">162</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:114pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:49.21pt"></span></span><span style="left:51.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1193" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" scale="3" id="f-2848">7</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:114pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1194" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:fixed-zero" scale="3" id="f-2849">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:126pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Derivative instruments</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:126pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:42.37pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2850">2,579</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:126pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2851">2,579</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:126pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1191" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2852">2,579</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:126pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.71pt"></span></span><span style="left:49.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1192" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-2853">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:126pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.21pt"></span></span><span style="left:47.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1193" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-2854">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:126pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1194" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-2855">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:138pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial liabilities </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:138pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:38.37pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2856">77,045</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:138pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.96pt"></span></span><span style="left:43.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="abvx:FinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2857">81,500</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:138pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:34.96pt"></span></span><span style="left:37.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1191" decimals="-3" name="abvx:FinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2858">20,747</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:138pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:32.71pt"></span></span><span style="left:35.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1192" decimals="-3" name="abvx:FinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2859">15,192</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:138pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:31.21pt"></span></span><span style="left:33.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1193" decimals="-3" name="abvx:FinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2860">45,561</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:138pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1194" decimals="-3" name="abvx:FinancialLiabilitiesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-2861">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:295.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:543pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:142.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:63.75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:69pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:63.75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:63.75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:60pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:62.25pt"/></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.63pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td colspan="11" style="font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);width:397.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:397.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:187.09pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:397.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:160.66pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">CURRENT AND NON-CURRENT </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">FINANCIAL LIABILITIES</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:21pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.33pt;position:var(--position);text-decoration:none;white-space:pre">GROSS </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.67pt;position:var(--position);text-decoration:none;white-space:pre">AMOUNT </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:21pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.2pt;position:var(--position);text-decoration:none;white-space:pre">CONTRACTUAL </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.96pt;position:var(--position);text-decoration:none;white-space:pre">CASH FLOWS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:21pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.56pt;position:var(--position);text-decoration:none;white-space:pre">LESS THAN 1 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.55pt;position:var(--position);text-decoration:none;white-space:pre">YEAR</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:21pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.89pt;position:var(--position);text-decoration:none;white-space:pre">FROM 1 TO 2 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.33pt;position:var(--position);text-decoration:none;white-space:pre">YEARS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:21pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.01pt;position:var(--position);text-decoration:none;white-space:pre">FROM 2 TO 5 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.46pt;position:var(--position);text-decoration:none;white-space:pre">YEARS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:21pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.17pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.8pt;position:var(--position);text-decoration:none;white-space:pre">LONGER </span></div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.58pt;position:var(--position);text-decoration:none;white-space:pre">THAN 5 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.58pt;position:var(--position);text-decoration:none;white-space:pre">YEARS </span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Heights convertible notes</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:54pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-725" decimals="-3" name="abvx:ConvertibleLoansNotes" format="ixt:num-dot-decimal" scale="3" id="f-2862">21,574</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:54pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.96pt"></span></span><span style="left:43.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-725" decimals="-3" name="abvx:ConvertibleLoansNotesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2863">24,063</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:54pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1195" decimals="-3" name="abvx:ConvertibleLoansNotesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2864">8,750</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:54pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1196" decimals="-3" name="abvx:ConvertibleLoansNotesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2865">8,750</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:54pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.96pt"></span></span><span style="left:38.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1197" decimals="-3" name="abvx:ConvertibleLoansNotesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2866">6,563</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:54pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1198" decimals="-3" name="abvx:ConvertibleLoansNotesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-2867">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:20.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.26pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos/Claret convertible notes </span></div><div style="line-height:8pt;position:var(--position);top:11.86pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(OCABSA)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:66pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.06pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-704" decimals="-3" name="abvx:ConvertibleLoansNotes" format="ixt:num-dot-decimal" scale="3" id="f-2868">23,370</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:66pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:7.06pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.96pt"></span></span><span style="left:43.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-704" decimals="-3" name="abvx:ConvertibleLoansNotesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2869">30,653</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:66pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.06pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1199" decimals="-3" name="abvx:ConvertibleLoansNotesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2870">2,250</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:66pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.06pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1200" decimals="-3" name="abvx:ConvertibleLoansNotesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2871">19,943</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:66pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.06pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.96pt"></span></span><span style="left:38.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1201" decimals="-3" name="abvx:ConvertibleLoansNotesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2872">8,460</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:66pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.06pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1202" decimals="-3" name="abvx:ConvertibleLoansNotesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-2873">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:86.25pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos/Claret bond loans</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:86.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1203" decimals="-3" name="abvx:ConvertibleLoansNotes" format="ixt:num-dot-decimal" scale="3" id="f-2874">46,401</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:86.25pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.96pt"></span></span><span style="left:43.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1203" decimals="-3" name="abvx:ConvertibleLoansNotesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2875">58,080</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:86.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1204" decimals="-3" name="abvx:ConvertibleLoansNotesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2876">24,016</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:86.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1205" decimals="-3" name="abvx:ConvertibleLoansNotesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2877">25,715</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:86.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.96pt"></span></span><span style="left:38.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1206" decimals="-3" name="abvx:ConvertibleLoansNotesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2878">8,348</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:86.25pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1207" decimals="-3" name="abvx:ConvertibleLoansNotesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-2879">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:98.25pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">PGE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:98.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-698" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-2880">2,488</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:98.25pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-698" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2881">2,586</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:98.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1208" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2882">1,293</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:98.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1209" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2883">1,293</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:98.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.96pt"></span></span><span style="left:48.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1210" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-2884">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:98.25pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1211" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-2885">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:110.25pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Royalty certificates (1)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:110.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="abvx:NonCurrentRoyaltyCertificates" format="ixt:num-dot-decimal" scale="3" id="f-2886">13,023</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:110.25pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.96pt"></span></span><span style="left:57.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="abvx:RoyaltyCertificatesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-2887">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:110.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:49.71pt"></span></span><span style="left:52.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1212" decimals="-3" name="abvx:RoyaltyCertificatesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-2888">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:110.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:49.71pt"></span></span><span style="left:52.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1213" decimals="-3" name="abvx:RoyaltyCertificatesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-2889">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:110.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.96pt"></span></span><span style="left:48.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1214" decimals="-3" name="abvx:RoyaltyCertificatesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-2890">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:110.25pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1215" decimals="-3" name="abvx:RoyaltyCertificatesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-2891">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:122.25pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Lease liabilities</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:122.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2892">2,363</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:122.25pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2893">2,512</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:122.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1212" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" scale="3" id="f-2894">993</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:122.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1213" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" scale="3" id="f-2895">996</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:122.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.96pt"></span></span><span style="left:44.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1214" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" scale="3" id="f-2896">516</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:122.25pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1215" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" scale="3" id="f-2897">7</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:134.25pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Derivative instruments</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:134.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2898">4,786</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:134.25pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2899">4,786</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:134.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1212" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2900">1,166</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:134.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:49.71pt"></span></span><span style="left:52.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1213" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-2901">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:134.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.96pt"></span></span><span style="left:38.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1214" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2902">3,620</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:134.25pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1215" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-2903">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:146.25pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial liabilities </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:146.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:31.71pt"></span></span><span style="left:34.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2904">114,004</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:146.25pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="abvx:FinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2905">122,680</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:146.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1212" decimals="-3" name="abvx:FinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2906">38,468</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:146.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1213" decimals="-3" name="abvx:FinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2907">56,698</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:146.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:31.96pt"></span></span><span style="left:34.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1214" decimals="-3" name="abvx:FinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2908">27,507</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:146.25pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1215" decimals="-3" name="abvx:FinancialLiabilitiesUndiscountedCashFlows" scale="3" id="f-2909">7</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:470.81pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:543pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:141.75pt"/><td style="padding:0;width:63pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:71.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:63pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:63pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:63pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:63pt"/></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:141.75pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:141.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.25pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td colspan="11" style="font-size:0;text-align:left;vertical-align:top"><div style="left:141.75pt;position:var(--position);width:401.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:401.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:149.88pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2025</span></div></div></div></td></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21pt;width:141.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:141.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">CURRENT AND NON-CURRENT </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:141.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">FINANCIAL LIABILITIES</span></div></div></div></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:141.75pt;position:var(--position);top:21pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.95pt;position:var(--position);text-decoration:none;white-space:pre">GROSS </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.29pt;position:var(--position);text-decoration:none;white-space:pre">AMOUNT </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:207.75pt;position:var(--position);top:21pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.32pt;position:var(--position);text-decoration:none;white-space:pre">CONTRACTUAL </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.09pt;position:var(--position);text-decoration:none;white-space:pre">CASH FLOWS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:282pt;position:var(--position);top:21pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.18pt;position:var(--position);text-decoration:none;white-space:pre">LESS THAN 1 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.18pt;position:var(--position);text-decoration:none;white-space:pre">YEAR</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:348pt;position:var(--position);top:21pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.51pt;position:var(--position);text-decoration:none;white-space:pre">FROM 1 TO 2 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.96pt;position:var(--position);text-decoration:none;white-space:pre">YEARS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:414pt;position:var(--position);top:21pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.51pt;position:var(--position);text-decoration:none;white-space:pre">FROM 2 TO 5 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.96pt;position:var(--position);text-decoration:none;white-space:pre">YEARS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:21pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:5.17pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.18pt;position:var(--position);text-decoration:none;white-space:pre">LONGER </span></div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.95pt;position:var(--position);text-decoration:none;white-space:pre">THAN 5 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.96pt;position:var(--position);text-decoration:none;white-space:pre">YEARS </span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66pt;width:141.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:141.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Royalty certificates</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:141.75pt;position:var(--position);top:66pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:34.96pt"></span></span><span style="left:37.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="abvx:NonCurrentRoyaltyCertificates" format="ixt:num-dot-decimal" scale="3" id="f-2910">30,237</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:207.75pt;position:var(--position);top:66pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:57.21pt"></span></span><span style="left:59.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="abvx:RoyaltyCertificatesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-2911">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282pt;position:var(--position);top:66pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1216" decimals="-3" name="abvx:RoyaltyCertificatesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-2912">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:348pt;position:var(--position);top:66pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1217" decimals="-3" name="abvx:RoyaltyCertificatesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-2913">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:414pt;position:var(--position);top:66pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1218" decimals="-3" name="abvx:RoyaltyCertificatesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-2914">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:66pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1219" decimals="-3" name="abvx:RoyaltyCertificatesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-2915">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78pt;width:141.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:141.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Lease liabilities</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:141.75pt;position:var(--position);top:78pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2916">1,856</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:207.75pt;position:var(--position);top:78pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2917">1,906</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282pt;position:var(--position);top:78pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1216" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2918">1,340</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:348pt;position:var(--position);top:78pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1217" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" scale="3" id="f-2919">450</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:414pt;position:var(--position);top:78pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1218" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" scale="3" id="f-2920">116</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:78pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1219" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:fixed-zero" scale="3" id="f-2921">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90.75pt;width:141.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:141.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial liabilities </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:141.75pt;position:var(--position);top:90.75pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:34.96pt"></span></span><span style="left:37.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2922">32,093</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:207.75pt;position:var(--position);top:90.75pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="abvx:FinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2923">1,906</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282pt;position:var(--position);top:90.75pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1216" decimals="-3" name="abvx:FinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-2924">1,340</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:348pt;position:var(--position);top:90.75pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1217" decimals="-3" name="abvx:FinancialLiabilitiesUndiscountedCashFlows" scale="3" id="f-2925">450</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:414pt;position:var(--position);top:90.75pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1218" decimals="-3" name="abvx:FinancialLiabilitiesUndiscountedCashFlows" scale="3" id="f-2926">116</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:90.75pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1219" decimals="-3" name="abvx:FinancialLiabilitiesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-2927">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div></ix:continuation></ix:continuation><div style="font-size:12pt;line-height:11pt;position:var(--position);top:578.56pt;width:612pt"><span style="font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:591.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The contractual cash flows above do not include potential future royalty payments related to the royalty certificates, amounting to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:556.99pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1054" decimals="2" name="abvx:RoyaltyCertificatePercentageOfFutureSales" scale="-2" id="f-2928">2</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:570.32pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:602.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of the future net sales of obefazimod (worldwide and for all indications). The amount of royalties that may be paid under the royalty </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:614.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">certificates is capped at </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:131.93pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1053" decimals="-5" name="abvx:RoyaltyCertificateMaximumAmount" scale="6" id="f-2929">172.0</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:190.78pt;position:var(--position);text-decoration:none;white-space:pre"> in the aggregate. Royalty payments are expected to take place before the expiry date of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:625.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">certificates, which is </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.86pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1053" name="abvx:RoyaltyCertificateExpirationPeriod" format="ixt-sec:duryear" id="f-2930">15</ix:nonNumeric> years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:154.44pt;position:var(--position);text-decoration:none;white-space:pre"> after their issuance date (September 2, 2037), and would be included in the "from 2 to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:502.88pt;position:var(--position);text-decoration:none;white-space:pre">5 years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:531.46pt;position:var(--position);text-decoration:none;white-space:pre">" and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:636.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">"longer than 5 years" maturity categories according to management's projections.</span></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:720pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:49.42pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-63<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:468pt"></div></div><div><div style="position:absolute;top:72pt" id="i7a006daedb3d4216a4128b76247285d7_2319"></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-64<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><div style="position:absolute;top:70.56pt" id="i7a006daedb3d4216a4128b76247285d7_460"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 16. <span id="ifa156fe53046409a924c34c12e30d889"></span></span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfEmployeeBenefitsExplanatory" id="f-2931" continuedAt="f-2931-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Retirement benefit obligations</span></ix:nonNumeric></div><ix:continuation id="f-2931-1"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:90.36pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:42pt;position:var(--position);text-decoration:none;white-space:pre">Retirement benefit obligations include the liability for the defined benefit plan, measured based on the provisions stipulated </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:102.36pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:42pt;position:var(--position);text-decoration:none;white-space:pre">under the applicable collective agreements, i.e. the French pharmaceutical industry&#8217;s collective agreement. This commitment </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:114.36pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:42pt;position:var(--position);text-decoration:none;white-space:pre">only applies to employees subject to French law. </span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory" id="f-2932" continuedAt="f-2932-1" escape="true"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:239.28pt;position:var(--position);text-decoration:none;white-space:pre">The main actuarial assumptions used to measure the retirement benefit </span></ix:nonNumeric></div><ix:continuation id="f-2932-1"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.36pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:42pt;position:var(--position);text-decoration:none;white-space:pre">obligations are as follows:</span></div><div style="position:var(--position);top:150.36pt;width:612pt"><div style="font-size:0pt;left:42pt;position:var(--position);width:480.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:159.75pt"/><td style="padding:0;width:105pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:105pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:105pt"/></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:159.75pt"><div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:159.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">ACTUARIAL ASSUMPTIONS</span></div></div></div></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:159.75pt;position:var(--position);width:105pt"><div><div style="line-height:8pt;position:var(--position);top:7.57pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.19pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:17.17pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);width:105pt"><div><div style="line-height:8pt;position:var(--position);top:7.57pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.19pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:17.17pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);width:105pt"><div><div style="line-height:8pt;position:var(--position);top:7.57pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.19pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:17.17pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td></tr><tr style="height:30.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:30.75pt;width:159.75pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:159.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Retirement age</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:159.75pt;position:var(--position);top:30.75pt;width:105pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:7.51pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:3.09pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1220" name="ifrs-full:ActuarialAssumptionOfRetirementAge2019" format="ixt-sec:duryear" id="f-2933">65</ix:nonNumeric> years</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:29.96pt;position:var(--position);text-decoration:none;white-space:pre"> for key management / </span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:17.11pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:6.09pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1221" name="ifrs-full:ActuarialAssumptionOfRetirementAge2019" format="ixt-sec:duryear" id="f-2934">63</ix:nonNumeric> years</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:32.96pt;position:var(--position);text-decoration:none;white-space:pre"> for other employees</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:30.75pt;width:105pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:7.51pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:3.09pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1222" name="ifrs-full:ActuarialAssumptionOfRetirementAge2019" format="ixt-sec:duryear" id="f-2935">65</ix:nonNumeric> years</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:29.96pt;position:var(--position);text-decoration:none;white-space:pre"> for key management / </span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:17.11pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:6.09pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1223" name="ifrs-full:ActuarialAssumptionOfRetirementAge2019" format="ixt-sec:duryear" id="f-2936">64</ix:nonNumeric> years</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:32.96pt;position:var(--position);text-decoration:none;white-space:pre"> for other employees</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:30.75pt;width:105pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:7.51pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:3.09pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1224" name="ifrs-full:ActuarialAssumptionOfRetirementAge2019" format="ixt-sec:duryear" id="f-2937">65</ix:nonNumeric> years</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:29.96pt;position:var(--position);text-decoration:none;white-space:pre"> for key management / </span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:17.11pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:6.09pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1225" name="ifrs-full:ActuarialAssumptionOfRetirementAge2019" format="ixt-sec:duryear" id="f-2938">64</ix:nonNumeric> years</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:32.96pt;position:var(--position);text-decoration:none;white-space:pre"> for other employees</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:61.5pt;width:159.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:159.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Collective agreement</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:159.75pt;position:var(--position);top:61.5pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:13.75pt;position:var(--position);text-decoration:none;white-space:pre">Pharmaceutical&#160;industry</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:61.5pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:13.75pt;position:var(--position);text-decoration:none;white-space:pre">Pharmaceutical&#160;industry</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:61.5pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:13.75pt;position:var(--position);text-decoration:none;white-space:pre">Pharmaceutical&#160;industry</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:73.5pt;width:159.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:159.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Discount Rate (IBoxx Corporates AA)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:159.75pt;position:var(--position);top:73.5pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:43.11pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="4" name="ifrs-full:ActuarialAssumptionOfDiscountRates" scale="-2" id="f-2939">0.90</ix:nonFraction>%</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:73.5pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:43.11pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="4" name="ifrs-full:ActuarialAssumptionOfDiscountRates" scale="-2" id="f-2940">3.34</ix:nonFraction>%</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:73.5pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:43.11pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="4" name="ifrs-full:ActuarialAssumptionOfDiscountRates" scale="-2" id="f-2941">3.70</ix:nonFraction>%</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:85.5pt;width:159.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:159.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Mortality rate table</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:159.75pt;position:var(--position);top:85.5pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:22.85pt;position:var(--position);text-decoration:none;white-space:pre">INSEE 2016-2018 </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:85.5pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:22.85pt;position:var(--position);text-decoration:none;white-space:pre">INSEE 2016-2018 </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:85.5pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:22.85pt;position:var(--position);text-decoration:none;white-space:pre">INSEE 2016-2018 </span></div></div></div></td></tr><tr style="height:42pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:97.5pt;width:159.75pt"><div><div style="line-height:8pt;position:var(--position);top:17.93pt;width:159.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Salary increase rate</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:159.75pt;position:var(--position);top:97.5pt;width:105pt"><div><div style="font-size:12pt;line-height:9pt;position:var(--position);top:11.85pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:6.04pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1226" decimals="2" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" scale="-2" id="f-2942">3</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:18.03pt;position:var(--position);white-space:pre"> for key management / </span></div><div style="font-size:12pt;line-height:9pt;position:var(--position);top:23.1pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:3.79pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1227" decimals="4" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" scale="-2" id="f-2943">2.55</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.029999999999998pt;position:var(--position);white-space:pre"> for other employees</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:97.5pt;width:105pt"><div><div style="font-size:12pt;line-height:9pt;position:var(--position);top:11.85pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:6.04pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1228" decimals="2" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" scale="-2" id="f-2944">3</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:18.03pt;position:var(--position);white-space:pre"> for key management / </span></div><div style="font-size:12pt;line-height:9pt;position:var(--position);top:23.1pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:3.79pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1229" decimals="4" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" scale="-2" id="f-2945">2.55</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.029999999999998pt;position:var(--position);white-space:pre"> for other employees</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:97.5pt;width:105pt"><div><div style="line-height:9pt;position:var(--position);top:17.47pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:41.82pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="4" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" scale="-2" id="f-2946">3.00</ix:nonFraction>%</span></div></div></div></td></tr><tr style="height:56.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:139.5pt;width:159.75pt"><div><div style="line-height:8pt;position:var(--position);top:25.06pt;width:159.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Turnover rate</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:159.75pt;position:var(--position);top:139.5pt;width:105pt"><div><div style="font-size:12pt;line-height:9pt;position:var(--position);top:13.35pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:5.3pt;position:var(--position);white-space:pre">Decreasing from </span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:67.72pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1230" decimals="4" name="abvx:ActuarialAssumptionOfExpectedRatesOfTurnover" scale="-2" id="f-2947">5.80</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:90.96pt;position:var(--position);white-space:pre"> at </span></div><div style="font-size:12pt;line-height:9pt;position:var(--position);top:24.6pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.91pt;position:var(--position);white-space:pre">20 years-old to </span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:59.120000000000005pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1231" decimals="4" name="abvx:ActuarialAssumptionOfExpectedRatesOfTurnover" scale="-2" id="f-2948">0.05</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:82.36pt;position:var(--position);white-space:pre"> from </span></div><div style="line-height:9pt;position:var(--position);top:35.85pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.14pt;position:var(--position);white-space:pre">55 years-old</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:139.5pt;width:105pt"><div><div style="line-height:9pt;position:var(--position);top:7.72pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:9.68pt;position:var(--position);white-space:pre">Decreasing rates by age </span></div><div style="font-size:12pt;line-height:9pt;position:var(--position);top:18.97pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:13.16pt;position:var(--position);white-space:pre">and </span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:28.4pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1232" decimals="4" name="abvx:ActuarialAssumptionOfExpectedRatesOfTurnover" format="ixt:fixed-zero" scale="-2" id="f-2949">zero</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:43.870000000000005pt;position:var(--position);white-space:pre"> from age 55, </span></div><div style="line-height:9pt;position:var(--position);top:30.22pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:5.18pt;position:var(--position);white-space:pre">generating an average exit </span></div><div style="font-size:12pt;line-height:9pt;position:var(--position);top:41.47pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:11.66pt;position:var(--position);white-space:pre">rate for 2025 of </span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:70.1pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="4" name="abvx:ActuarialAssumptionOfExpectedRatesOfTurnoverAverageExitRate" scale="-2" id="f-2950">2.05</ix:nonFraction>%</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:139.5pt;width:105pt"><div><div style="line-height:9pt;position:var(--position);top:7.72pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:9.68pt;position:var(--position);white-space:pre">Decreasing rates by age </span></div><div style="font-size:12pt;line-height:9pt;position:var(--position);top:18.97pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:13.16pt;position:var(--position);white-space:pre">and </span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:28.4pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1233" decimals="4" name="abvx:ActuarialAssumptionOfExpectedRatesOfTurnover" format="ixt:fixed-zero" scale="-2" id="f-2951">zero</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:43.870000000000005pt;position:var(--position);white-space:pre"> from age 55, </span></div><div style="line-height:9pt;position:var(--position);top:30.22pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:5.18pt;position:var(--position);white-space:pre">generating an average exit </span></div><div style="font-size:12pt;line-height:9pt;position:var(--position);top:41.47pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:10.53pt;position:var(--position);white-space:pre">rate for 2025 of </span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:68.97pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="4" name="abvx:ActuarialAssumptionOfExpectedRatesOfTurnoverAverageExitRate" scale="-2" id="f-2952">2.02</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:92.21000000000001pt;position:var(--position);white-space:pre">.</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:195.75pt;width:159.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:159.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Employee contribution rate</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:159.75pt;position:var(--position);top:195.75pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.11pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="2" name="abvx:ActuarialAssumptionOfEmployeeContributionRate" scale="-2" id="f-2953">45</ix:nonFraction>%</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:195.75pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.11pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-9" decimals="2" name="abvx:ActuarialAssumptionOfEmployeeContributionRate" scale="-2" id="f-2954">45</ix:nonFraction>%</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:195.75pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.11pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="abvx:ActuarialAssumptionOfEmployeeContributionRate" scale="-2" id="f-2955">45</ix:nonFraction>%</span></div></div></div></td></tr></tbody></table></div></div></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:374.41pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" id="f-2956" continuedAt="f-2956-1" escape="true"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:42pt;position:var(--position);text-decoration:none;white-space:pre">Changes in the projected benefit obligation for the periods presented were as follows:</span></ix:nonNumeric></div><ix:continuation id="f-2956-1"><div style="font-size:12pt;line-height:11pt;position:var(--position);top:393.71pt;width:612pt"><span style="font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="position:var(--position);top:402.51pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:321.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:153.75pt"/><td style="padding:0;width:168pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:39.67pt;position:var(--position);text-decoration:none;white-space:pre">(In thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);width:168pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.72pt;position:var(--position);text-decoration:none;white-space:pre">RETIREMENT BENEFIT OBLIGATIONS</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY 1, 2023</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:12pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:149.96pt"></span></span><span style="left:152.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1234" decimals="-3" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="3" id="f-2957">610</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:33pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Service cost </span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:33pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:149.96pt"></span></span><span style="left:152.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1235" decimals="-3" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" scale="3" id="f-2958">109</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:45pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.56pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest cost </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:45pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:2.56pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:153.96pt"></span></span><span style="left:156.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1235" decimals="-3" name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" scale="3" id="f-2959">23</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:56.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Actuarial gains and losses </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:56.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:147.3pt"></span></span><span style="left:149.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1235" decimals="-3" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="3" id="f-2960">112</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:68.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:68.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:149.96pt"></span></span><span style="left:152.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1236" decimals="-3" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="3" id="f-2961">629</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:89.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Service cost </span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:89.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:149.96pt"></span></span><span style="left:152.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1237" decimals="-3" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" scale="3" id="f-2962">115</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:101.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest cost </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:101.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:153.96pt"></span></span><span style="left:156.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1237" decimals="-3" name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" scale="3" id="f-2963">22</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:113.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Benefits paid</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:113.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:151.3pt"></span></span><span style="left:153.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1237" decimals="-3" name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" scale="3" id="f-2964">41</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:125.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Actuarial gains and losses </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:125.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:153.96pt"></span></span><span style="left:156.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1237" decimals="-3" sign="-" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="3" id="f-2965">31</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:137.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:137.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:149.96pt"></span></span><span style="left:152.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1238" decimals="-3" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="3" id="f-2966">756</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:158.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Current service cost </span></div></div></div></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:158.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:149.96pt"></span></span><span style="left:152.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1239" decimals="-3" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" scale="3" id="f-2967">141</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:170.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Past services cost</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:170.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:147.3pt"></span></span><span style="left:149.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1239" decimals="-3" sign="-" name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" scale="3" id="f-2968">205</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:182.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest cost </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:182.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:153.96pt"></span></span><span style="left:156.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1239" decimals="-3" name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" scale="3" id="f-2969">29</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:194.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Actuarial gains and losses </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:194.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:151.3pt"></span></span><span style="left:153.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1239" decimals="-3" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="3" id="f-2970">93</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:206.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:206.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:149.96pt"></span></span><span style="left:152.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1240" decimals="-3" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="3" id="f-2971">627</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:642.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Employees in the U.S. benefit from defined contribution plans (401(k)).</span></div></ix:continuation><div style="position:absolute;top:667.46pt" id="i7a006daedb3d4216a4128b76247285d7_463"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:667.46pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:42pt;position:var(--position);text-decoration:none;white-space:pre">Note 17. </span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory" id="f-2972" continuedAt="f-2972-1" escape="true"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:79.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Payables and other current liabilities</span></ix:nonNumeric></div><div style="position:absolute;top:685.96pt" id="i7a006daedb3d4216a4128b76247285d7_466"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:685.96pt;width:612pt"><ix:continuation id="f-2972-1" continuedAt="f-2972-2"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 17.1. Trade payables and other current liabilities<span id="ic8bc591b9eda49aa9427069a2f444203"></span></span></ix:continuation></div><ix:continuation id="f-2972-2" continuedAt="f-2972-3"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:705.76pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="abvx:DisclosureOfBreakdownOfTradeAndOtherPayablesTableTextBlock" id="f-2973" continuedAt="f-2973-1" escape="true"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:42pt;position:var(--position);text-decoration:none;white-space:pre">Trade payables and other current liabilities break down as follows:</span></ix:nonNumeric></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-65<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-2972-3" continuedAt="f-2972-4"><ix:continuation id="f-2973-1"><div style="position:var(--position);top:84.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:447pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:200.25pt"/><td style="padding:0;width:80.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:80.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:80.25pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:48.59pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">TRADE PAYABLES AND OTHER CURRENT </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:200.25pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:366.75pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:33pt;width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Trade payables </span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:200.25pt;position:var(--position);top:33pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" format="ixt:num-dot-decimal" scale="3" id="f-2974">21,953</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:280.5pt;overflow:hidden;position:var(--position);top:33pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:33pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" format="ixt:num-dot-decimal" scale="3" id="f-2975">30,748</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:363.75pt;overflow:hidden;position:var(--position);top:33pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:366.75pt;position:var(--position);top:33pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" format="ixt:num-dot-decimal" scale="3" id="f-2976">23,388</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:45pt;width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Accrued invoices</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:200.25pt;position:var(--position);top:45pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:AccrualsClassifiedAsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-2977">25,268</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:280.5pt;overflow:hidden;position:var(--position);top:45pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:45pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:AccrualsClassifiedAsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-2978">13,049</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:363.75pt;overflow:hidden;position:var(--position);top:45pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:366.75pt;position:var(--position);top:45pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:AccrualsClassifiedAsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-2979">14,159</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:57pt;width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:200.25pt;position:var(--position);top:57pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="abvx:OtherCurrentPayablesIncludingAdjustments" format="ixt:fixed-zero" scale="3" id="f-2980">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:280.5pt;overflow:hidden;position:var(--position);top:57pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:57pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="abvx:OtherCurrentPayablesIncludingAdjustments" scale="3" id="f-2981">26</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:363.75pt;overflow:hidden;position:var(--position);top:57pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:366.75pt;position:var(--position);top:57pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:70.21pt"></span></span><span style="left:72.83999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="abvx:OtherCurrentPayablesIncludingAdjustments" scale="3" id="f-2982">4</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:69pt;width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Trade payables and other current liabilities</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:200.25pt;position:var(--position);top:69pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-2983">47,221</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:280.5pt;overflow:hidden;position:var(--position);top:69pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:69pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-2984">43,824</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:363.75pt;overflow:hidden;position:var(--position);top:69pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:366.75pt;position:var(--position);top:69pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-2985">37,552</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:185.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">No discount was applied to payables and related accounts for which maturity does not exceed one year. As a result, their fair value </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:196.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">approximates their carrying amount. </span></div></ix:continuation><div style="position:absolute;top:237.1pt" id="i7a006daedb3d4216a4128b76247285d7_469"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:237.1pt;width:612pt"><ix:continuation id="f-2972-4" continuedAt="f-2972-5"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 17.2. Tax and employee-related payables<span id="i66385b0b949642f7af2ce7ab417684b3"></span></span></ix:continuation></div><ix:continuation id="f-2972-5"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:256.9pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="abvx:DisclosureOfTaxAndEmployeeRelatedPayablesExplanatoryTableTextBlock" id="f-2986" continuedAt="f-2986-1" escape="true"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">Tax and employee-related payables are presented below:</span></ix:nonNumeric></div><ix:continuation id="f-2986-1"><div style="font-size:12pt;line-height:11pt;position:var(--position);top:268.2pt;width:612pt"><span style="font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="position:var(--position);top:279.53pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:441.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:195pt"/><td style="padding:0;width:80.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:80.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:80.25pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:195pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:195pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:45.96pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:195pt"><div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:195pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">TAX AND EMPLOYEE-RELATED PAYABLES</span></div></div></div></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:195pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.92pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.52pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:278.25pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.92pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.52pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:361.5pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.92pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.52pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:195pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:195pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Employee-related payables</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:195pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.87pt"></span></span><span style="left:61.5pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:ShorttermEmployeeBenefitsAccruals" format="ixt:num-dot-decimal" scale="3" id="f-2987">3,694</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:278.25pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.87pt"></span></span><span style="left:61.5pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:ShorttermEmployeeBenefitsAccruals" format="ixt:num-dot-decimal" scale="3" id="f-2988">2,742</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:361.5pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:ShorttermEmployeeBenefitsAccruals" format="ixt:num-dot-decimal" scale="3" id="f-2989">4,816</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:195pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:195pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Social security and other</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:195pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.87pt"></span></span><span style="left:61.5pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" format="ixt:num-dot-decimal" scale="3" id="f-2990">2,251</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:278.25pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.87pt"></span></span><span style="left:61.5pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" format="ixt:num-dot-decimal" scale="3" id="f-2991">1,783</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:361.5pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" format="ixt:num-dot-decimal" scale="3" id="f-2992">2,304</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:195pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:195pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other tax and related payments</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:195pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:64.87pt"></span></span><span style="left:67.5pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="abvx:CurrentPayablesOnOtherTaxAndRelatedPayments" scale="3" id="f-2993">127</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:278.25pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:64.87pt"></span></span><span style="left:67.5pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="abvx:CurrentPayablesOnOtherTaxAndRelatedPayments" scale="3" id="f-2994">184</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:361.5pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="abvx:CurrentPayablesOnOtherTaxAndRelatedPayments" scale="3" id="f-2995">17</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:195pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:195pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">TAX AND EMPLOYEE-RELATED PAYABLES</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:195pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:58.87pt"></span></span><span style="left:61.5pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="abvx:CurrentTaxAndEmployeeBenefitLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2996">6,073</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:278.25pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:58.87pt"></span></span><span style="left:61.5pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="abvx:CurrentTaxAndEmployeeBenefitLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2997">4,709</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:361.5pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="abvx:CurrentTaxAndEmployeeBenefitLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2998">7,137</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:385.28pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43.1pt;position:var(--position);text-decoration:none;white-space:pre">The increase in employee-related, social security and other payables over the year ended December 31, 2025 is mainly related to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:396.48pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43.1pt;position:var(--position);text-decoration:none;white-space:pre">year-end bonus accruals.</span></div></ix:continuation><div style="position:absolute;top:432.98pt" id="i7a006daedb3d4216a4128b76247285d7_472"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:432.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 18. <span id="ica763b4400be4ef2928a4e8c28286e64"></span></span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory" id="f-2999" continuedAt="f-2999-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Other operating income</span></ix:nonNumeric></div><ix:continuation id="f-2999-1" continuedAt="f-2999-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:456.28pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="abvx:DisclosureOfDetailedInformationOfOperatingIncomeExplanatoryTableTextBlock" id="f-3000" continuedAt="f-3000-1" escape="true"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Other operating income is composed as below:</span></ix:nonNumeric></div><ix:continuation id="f-3000-1"><div style="font-size:12pt;position:var(--position);top:478.28pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"> </span><div style="font-size:0pt;left:38.5pt;position:var(--position);width:381pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:134.25pt"/><td style="padding:0;width:80.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:80.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:80.25pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:15.59pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">OPERATING INCOME</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:134.25pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:300.75pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Research tax credit ("CIR")</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:134.25pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:IncomeFromResearchTaxCredit" format="ixt:num-dot-decimal" scale="3" id="f-3001">4,493</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:IncomeFromResearchTaxCredit" format="ixt:num-dot-decimal" scale="3" id="f-3002">6,651</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:300.75pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:IncomeFromResearchTaxCredit" format="ixt:num-dot-decimal" scale="3" id="f-3003">3,061</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Subsidies</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:134.25pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:RevenueFromGovernmentGrants" scale="3" id="f-3004">81</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:RevenueFromGovernmentGrants" format="ixt:num-dot-decimal" scale="3" id="f-3005">4,140</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:300.75pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:RevenueFromGovernmentGrants" format="ixt:fixed-zero" scale="3" id="f-3006">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Depositary service fees</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:134.25pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:IncomeFromDepositaryServiceFees" format="ixt:fixed-zero" scale="3" id="f-3007">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:IncomeFromDepositaryServiceFees" format="ixt:num-dot-decimal" scale="3" id="f-3008">1,634</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:300.75pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:IncomeFromDepositaryServiceFees" format="ixt:num-dot-decimal" scale="3" id="f-3009">1,509</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:134.25pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="3" id="f-3010">47</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="3" id="f-3011">23</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:300.75pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:MiscellaneousOtherOperatingIncome" format="ixt:fixed-zero" scale="3" id="f-3012">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90.75pt;width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total operating income</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:134.25pt;position:var(--position);top:90.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-3013">4,621</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:90.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-3014">12,449</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:300.75pt;position:var(--position);top:90.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-3015">4,570</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:597.05pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Operating income is composed as follows: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:619.45pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Research tax credit (&#8220;CIR&#8221;) </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:641.85pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group carries out research and development projects. As such, it has benefited from a research tax credit for the years ended </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:653.05pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Decem</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:64.28pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">ber 31, 2023, 2024 and 2025 for an</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:205.06pt;position:var(--position);text-decoration:none;white-space:pre"> amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:250.86pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1241" decimals="-3" name="abvx:IncomeFromResearchTaxCredit" format="ixt:num-dot-decimal" scale="3" id="f-3016">4,493</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:316.95pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:321.95pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1242" decimals="-3" name="abvx:IncomeFromResearchTaxCredit" format="ixt:num-dot-decimal" scale="3" id="f-3017">5,668</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:388.04pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:407.47pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1243" decimals="-3" name="abvx:IncomeFromResearchTaxCredit" format="ixt:num-dot-decimal" scale="3" id="f-3018">3,197</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:473.56pt;position:var(--position);text-decoration:none;white-space:pre">, respectively (see Note </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:664.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">4.9). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:675.45pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">During the year ended December 31, 2024, the Group also received an additional tax credit payment related to the 2021 tax year for an </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:686.65pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:79.3pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1244" decimals="-3" name="abvx:IncomeFromResearchTaxCredit" scale="3" id="f-3019">984</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:137.89pt;position:var(--position);text-decoration:none;white-space:pre"> after a claim from the Group following a clarification of "public subsidy" definition.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:697.85pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The lower amount of CIR recognized in 2025 is mainly due to (i)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:296.85pt;position:var(--position);text-decoration:none;white-space:pre"> the maximum amount of eligible outsourced research and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:709.05pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">development expenses being capped, (ii) a decrease in internal research and development costs, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:420.21pt;position:var(--position);text-decoration:none;white-space:pre">(iii) the reimbursement of the </span></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-66<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-2999-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">CARENA and RNP-VIR conditional advances, deducted from the 2024 CIR calculation and (iv) a change in the CIR regulation </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:81.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">related to eligible expenses.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:104.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Subsidies</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Subsidies primarily relate to the Bpifrance RNP-VIR and CARENA conditional advances, the repayments of which were partly </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:137.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">waived by Bpifrance in June 2024, for </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:191.98pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-104" decimals="-3" name="ifrs-full:RevenueFromGovernmentGrants" format="ixt:num-dot-decimal" scale="3" id="f-3020">1,872</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:258.07pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:277.5pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-106" decimals="-3" name="ifrs-full:RevenueFromGovernmentGrants" format="ixt:num-dot-decimal" scale="3" id="f-3021">2,251</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:343.59pt;position:var(--position);text-decoration:none;white-space:pre"> respectively (see Notes 3.3 and 15.7).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:160.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Depositary services fees </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:182.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">For the years ended December 31, 2024 and 2025, this line item includes issuance, cancellation and depositary service fees collected </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:194.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">from ADS holders by Citibank, who is acting as the Group's exclusive depositary for its publicly listed ADSs. As part of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:205.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">depositary agreement between Citibank and the Group, the latter is entitled to receive a portion of the aforementioned fees collected </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:216.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">by Citibank. The amounts recognized for the years ended December 31, 2024 and 2025 reflect the large amounts of ADS transactions </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:227.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">following, respectively, (i) the Group's </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:193.48pt;position:var(--position);text-decoration:none;white-space:pre">Initial Public Offering on the Nasdaq Global Market</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:402.97pt;position:var(--position);text-decoration:none;white-space:pre"> in October 2023 and (ii) the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:238.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">announcement of Phase 3 results and the Group's Offering in July 2025.</span></div></ix:continuation><div style="position:absolute;top:284.46pt" id="i7a006daedb3d4216a4128b76247285d7_475"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:284.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 19. <span id="i08c1ed1414af45ec9f91acce289b5483"></span></span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory" id="f-3022" continuedAt="f-3022-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Operating expenses</span></ix:nonNumeric></div><div style="position:absolute;top:322.39pt" id="i7a006daedb3d4216a4128b76247285d7_478"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:322.39pt;width:612pt"><ix:continuation id="f-3022-1" continuedAt="f-3022-2"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 19.1. Sales and marketing<span id="i3c9108f67d8f42d7b78379593d90f92b"></span></span></ix:continuation></div><ix:continuation id="f-3022-2" continuedAt="f-3022-3"><div style="position:var(--position);top:355.69pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfExpensesByNatureExplanatory" id="f-3023" continuedAt="f-3023-1" escape="true"><div style="font-size:0pt;left:36pt;position:var(--position);width:474pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:224.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:80.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:80.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:80.25pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:60.59pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">SALES AND MARKETING</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Personnel costs</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1245" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-3024">1,710</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1246" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-3025">2,323</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1247" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-3026">3,347</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Consulting and professional fees </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:224.25pt;overflow:hidden;position:var(--position);top:54.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1245" decimals="-3" name="ifrs-full:ProfessionalFeesExpense" format="ixt:num-dot-decimal" scale="3" id="f-3027">4,012</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1246" decimals="-3" name="ifrs-full:ProfessionalFeesExpense" format="ixt:num-dot-decimal" scale="3" id="f-3028">2,699</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1247" decimals="-3" name="ifrs-full:ProfessionalFeesExpense" format="ixt:num-dot-decimal" scale="3" id="f-3029">1,623</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other sales and marketing expenses</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:224.25pt;overflow:hidden;position:var(--position);top:66.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1245" decimals="-3" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="3" id="f-3030">709</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1246" decimals="-3" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="3" id="f-3031">932</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1247" decimals="-3" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="3" id="f-3032">224</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Sales &amp; Marketing</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:224.25pt;overflow:hidden;position:var(--position);top:78.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1245" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-3033">6,431</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1246" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-3034">5,954</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1247" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-3035">5,194</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></ix:nonNumeric></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:461.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Sales and marketing expenses consist primarily of personnel expenses, including salaries, benefits, and share-based compensation </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:471.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">expenses, for employees engaged in sales and marketing activities, as well as consulting costs associated with market research in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:481.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">preparation for the Group's potential future sales and commercialization efforts in the U.S. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:503.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The decrease for the year ended was primarily </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:223.52pt;position:var(--position);text-decoration:none;white-space:pre">driven by the reduction in the headcount of the Group's sales and marketing department </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:515.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">part way through 2024. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:539.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The increase in personnel costs for the year ended December 31, 2025 is primarily driven by taxes and social contributions related to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:551.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">AGAs (see Note 14), while the decrease in consulting and professional fees is mainly explained by one-time costs that were incurred </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:563.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in 2024 for the Group's corporate re-branding, including its new website.</span></div></ix:continuation><div style="position:absolute;top:601.44pt" id="i7a006daedb3d4216a4128b76247285d7_481"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:601.44pt;width:612pt"><ix:continuation id="f-3022-3" continuedAt="f-3022-4"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 19.2. Research and development<span id="ic2e4d6b2de844eaa908459b8d08cd756"></span></span></ix:continuation></div><ix:continuation id="f-3022-4" continuedAt="f-3022-5"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:626.74pt;width:612pt"><ix:continuation id="f-3023-1" continuedAt="f-3023-2"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Research and development expenses break down as follows: </span></ix:continuation></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-67<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-3022-5" continuedAt="f-3022-6"><ix:continuation id="f-3023-2" continuedAt="f-3023-3"><div style="position:var(--position);top:70.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:474pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:224.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:80.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:80.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:80.25pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:60.59pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">RESEARCH AND DEVELOPMENT EXPENSES</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Sub-contracting, studies and research</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1248" decimals="-3" name="abvx:SubContractingStudiesAndResearchExpenses" format="ixt:num-dot-decimal" scale="3" id="f-3036">85,726</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1249" decimals="-3" name="abvx:SubContractingStudiesAndResearchExpenses" format="ixt:num-dot-decimal" scale="3" id="f-3037">110,993</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1250" decimals="-3" name="abvx:SubContractingStudiesAndResearchExpenses" format="ixt:num-dot-decimal" scale="3" id="f-3038">112,033</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Personnel costs</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1248" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-3039">8,048</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1249" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-3040">18,455</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1250" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-3041">49,616</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Consulting and professional fees </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1248" decimals="-3" name="ifrs-full:ProfessionalFeesExpense" format="ixt:num-dot-decimal" scale="3" id="f-3042">6,561</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1249" decimals="-3" name="ifrs-full:ProfessionalFeesExpense" format="ixt:num-dot-decimal" scale="3" id="f-3043">12,581</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1250" decimals="-3" name="ifrs-full:ProfessionalFeesExpense" format="ixt:num-dot-decimal" scale="3" id="f-3044">12,791</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Intellectual property fees</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1248" decimals="-3" name="abvx:IntellectualPropertyFees" format="ixt:num-dot-decimal" scale="3" id="f-3045">1,645</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1249" decimals="-3" name="abvx:IntellectualPropertyFees" format="ixt:num-dot-decimal" scale="3" id="f-3046">1,741</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1250" decimals="-3" name="abvx:IntellectualPropertyFees" format="ixt:num-dot-decimal" scale="3" id="f-3047">1,025</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other research and development expenses</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:90.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1248" decimals="-3" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-3048">1,196</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:90.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1249" decimals="-3" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-3049">2,761</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:90.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1250" decimals="-3" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-3050">2,297</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Research and development expenses </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:102.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1248" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-3051">103,176</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:102.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1249" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-3052">146,532</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:102.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1250" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-3053">177,761</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:224.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Research and development expenses consist primarily of the following items: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:240.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Personnel expenses, including salaries, benefits, and share-based compensation expenses, for employees engaged in </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:250.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">research and development activities; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:266.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Sub-contracting, collaboration and consultant expenses that primarily include the cost of third-party contractors such as </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:276.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">CROs who conduct our non-clinical studies and clinical trials, and research related to proprietary platforms, as well as </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:286.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">investigative sites and consultants that conduct our preclinical studies and clinical trials; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:302.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Expenses incurred under agreements with contract manufacturing organizations (&#8220;CMOs&#8221;), including manufacturing </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:312.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">scale-up expenses and the cost of acquiring and manufacturing preclinical study and clinical trial materials; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:328.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Expenses relating to preclinical studies and clinical trials; </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:344.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Expenses relating to regulatory affairs; </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:360.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Allocated expenses for facility costs, including rent, utilities and maintenance; and </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:376.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Expenses relating to the implementation of the quality assurance system. </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:409.51pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The increase in research and development expenses for the years ended December 31, 2024 and 2025 is primarily due to (i) the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:420.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">increase in UC expenses (of respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:201.34pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1249" decimals="-3" name="abvx:IncreaseDecreaseInUlcerativeColitisExpenses" format="ixt:num-dot-decimal" scale="3" id="f-3054">32,030</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:272.43pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:291.86pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1250" decimals="-3" name="abvx:IncreaseDecreaseInUlcerativeColitisExpenses" format="ixt:num-dot-decimal" scale="3" id="f-3055">1,587</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:319.36pt;position:var(--position);text-decoration:none;white-space:pre"> thousand), due to the progress of Phase 3 clinical trials for </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:431.91pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">obefazimod in UC, (ii) the increase in CD expenses (of respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:309.55pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1249" decimals="-3" name="abvx:IncreaseDecreaseInCrohnsDiseaseResearchExpenses" format="ixt:num-dot-decimal" scale="3" id="f-3056">4,620</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:375.64pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:395.07pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1250" decimals="-3" name="abvx:IncreaseDecreaseInCrohnsDiseaseResearchExpenses" format="ixt:num-dot-decimal" scale="3" id="f-3057">10,200</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:427.57pt;position:var(--position);text-decoration:none;white-space:pre"> thousand), due to the planning costs </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:443.11pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and progression of the Phase 2b CD trial, (iii) the increase in transversal activities of respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:426.89pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1249" decimals="-3" name="abvx:IncreaseDecreaseInTransversalActivities" format="ixt:num-dot-decimal" scale="3" id="f-3058">8,233</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:492.98pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:512.4100000000001pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1250" decimals="-3" name="abvx:IncreaseDecreaseInTransversalActivities" format="ixt:num-dot-decimal" scale="3" id="f-3059">12,987</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:544.9100000000001pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:454.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">thousand) related to (a) the overall expansion of the research and development headcount to support the Group's organizational growth </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:465.51pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and the issuance of new equity awards to officers and employees in research and development for the year ended December 31, 2024 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:476.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and (b) increased chemistry, manufacturing and controls ("CMC") and supply chain costs related to the progression of clinical trials </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:487.91pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and anticipation of future commercial launch for the year ended December 31, 2025, and (iv) the development of new indications for </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:499.11pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">obefazimod, including the combination therapy (increasing by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:287.38pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1250" decimals="-3" name="abvx:IncreaseDecreaseInTransversalActivitiesCombinationTherapy" format="ixt:num-dot-decimal" scale="3" id="f-3060">4,122</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:353.47pt;position:var(--position);text-decoration:none;white-space:pre"> for the year ended December 31, 2025).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:521.51pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">These increases for the year ended December 31, 2025 also resulted from increasing p</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:380.59pt;position:var(--position);text-decoration:none;white-space:pre">ersonnel costs, mainly explained by the rise in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:532.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">employer tax and social contributions related to AGAs by</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:266.86pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:269.36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1250" decimals="-3" name="abvx:IncreaseDecreaseInEmployerTaxAndSocialContributions" format="ixt:num-dot-decimal" scale="3" id="f-3061">20,131</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:340.45pt;position:var(--position);text-decoration:none;white-space:pre">, resulting predominantly from (i) the uptick in the Group's </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:543.91pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">share price during the second half of 2025 (see Note 14), and to a lesser extent by (ii) the increase in the employer contribution rate on </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:555.11pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">AGAs in France.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:566.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div></ix:continuation><div style="position:absolute;top:591.51pt" id="i7a006daedb3d4216a4128b76247285d7_484"></div><div style="font-size:12pt;line-height:11pt;position:var(--position);top:591.51pt;width:612pt"><ix:continuation id="f-3022-6" continuedAt="f-3022-7"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 19.3. General and administrative<span id="ia87a43e321ec4db3a0cdfb8251386316"></span></span><span style="font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:198.66pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></ix:continuation></div><ix:continuation id="f-3022-7" continuedAt="f-3022-8"><div style="position:var(--position);top:618.14pt;width:612pt"><ix:continuation id="f-3023-3"><div style="font-size:0pt;left:36pt;position:var(--position);width:474pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:224.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:80.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:80.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:80.25pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:60.59pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">GENERAL AND ADMINISTRATIVE EXPENSES</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Personnel costs</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1251" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-3062">13,105</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1252" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-3063">19,434</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1253" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-3064">52,817</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Consulting and professional fees </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1251" decimals="-3" name="ifrs-full:ProfessionalFeesExpense" format="ixt:num-dot-decimal" scale="3" id="f-3065">6,393</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1252" decimals="-3" name="ifrs-full:ProfessionalFeesExpense" format="ixt:num-dot-decimal" scale="3" id="f-3066">7,990</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1253" decimals="-3" name="ifrs-full:ProfessionalFeesExpense" format="ixt:num-dot-decimal" scale="3" id="f-3067">9,984</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other general and administrative expenses </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1251" decimals="-3" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-3068">2,893</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1252" decimals="-3" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-3069">5,522</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1253" decimals="-3" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-3070">4,870</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">General and administrative expenses </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1251" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-3071">22,391</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1252" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-3072">32,946</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1253" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-3073">67,670</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></ix:continuation></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-68<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-3022-8"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:94.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">General and administrative expenses consist primarily of personnel-related expenses, including salaries, benefits and share-based </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:104.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">compensation expenses, for personnel other than employees engaged in research and development activities. General and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:114.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">administrative expenses also include fees for professional services, mainly related to audit and legal services, consulting costs, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:124.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">communications and travel costs, allocated expenses for facility costs, including rent, utilities and maintenance, directors&#8217; attendance </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:134.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">fees, and insurance costs. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:156.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The increase in general and administrative expenses for the year ended December 31, 2024 was primarily due to the increase in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:167.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">personnel costs,</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:99.83pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:102.33pt;position:var(--position);text-decoration:none;white-space:pre">representing</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:151.70999999999998pt;position:var(--position);text-decoration:none;white-space:pre"> the full year impact of the build out of the Group's general and administrative organization (increased </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:178.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">headcount and equity based compensation costs), which started in late 2023 to support the expansion of the Group, as well as </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:190.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">increased legal and professional fees and other costs associated with operating as a dual-listed public company.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:212.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.94pt">The increase for the year ended December 31, 2025 was primarily due to an increase in personnel costs, mainly explained by the</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.94pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:223.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:280.6pt">increase in employer tax and social contributions related to AGAs by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:316.6pt;position:var(--position);text-decoration:none;white-space:pre;width:71.25pt">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1253" decimals="-3" name="abvx:IncreaseDecreaseInEmployerTaxAndSocialContributions" format="ixt:num-dot-decimal" scale="3" id="f-3074">27,299</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:387.85pt;position:var(--position);text-decoration:none;white-space:pre;width:8.49pt">, r</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:396.34pt;position:var(--position);text-decoration:none;white-space:pre;width:179.66pt">esulting predominantly from (i) the uptick in</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:576pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:234.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:297.46pt">the Group's share price during the second half of 2025 (see Note 14), </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:333.46pt;position:var(--position);text-decoration:none;white-space:pre;width:242.36pt">and to a lesser extent by (ii) the increase in the employer</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.82pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:246.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.84pt">contribution rate on AGAs in France, as well as an increase in legal and professional fees associated with building the Group's</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.84pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:257.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:222.57pt">infrastructure to support future growth in its operations.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:279.76pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="abvx:DisclosureOfPrincipalAuditFeesAndServicesTableTextBlock" id="f-3075" continuedAt="f-3075-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group's principal audit fees paid to its joint statutory auditors PricewaterhouseCoopers Audit and Agili3f, are set forth below:</span></ix:nonNumeric></div><ix:continuation id="f-3075-1"><div style="position:var(--position);top:303.76pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:524.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:275.25pt"/><td style="padding:0;width:81pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:81pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:81pt"/></tr><tr style="height:34.5pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:275.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.18pt;width:275.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:86.09pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:275.25pt;position:var(--position);width:81pt"><div><div style="line-height:8pt;position:var(--position);top:4.65pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.19pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:14.25pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:23.85pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.5pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:359.25pt;position:var(--position);width:81pt"><div><div style="line-height:8pt;position:var(--position);top:4.65pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.19pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:14.25pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:23.85pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.5pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:443.25pt;position:var(--position);width:81pt"><div><div style="line-height:8pt;position:var(--position);top:4.65pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.19pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:14.25pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:23.85pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.5pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:34.5pt;width:275.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:275.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Audit fees</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:275.25pt;position:var(--position);top:34.5pt;width:81pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:AuditorsRemunerationForAuditServices" format="ixt:num-dot-decimal" scale="3" id="f-3076">1,848</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:359.25pt;position:var(--position);top:34.5pt;width:81pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:AuditorsRemunerationForAuditServices" format="ixt:num-dot-decimal" scale="3" id="f-3077">1,144</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:443.25pt;position:var(--position);top:34.5pt;width:81pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:AuditorsRemunerationForAuditServices" format="ixt:num-dot-decimal" scale="3" id="f-3078">1,255</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:46.5pt;width:275.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:275.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Audit-related fees</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><ix:nonFraction unitRef="eur" contextRef="c-8" xsi:nil="true" name="abvx:AuditorsRemunerationForAuditRelatedFees" id="f-3079"></ix:nonFraction></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:359.25pt;position:var(--position);top:46.5pt;width:81pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:70.37pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:AuditorsRemunerationForAuditRelatedFees" scale="3" id="f-3080">82</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:443.25pt;position:var(--position);top:46.5pt;width:81pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.96pt"></span></span><span style="left:65.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:AuditorsRemunerationForAuditRelatedFees" scale="3" id="f-3081">129</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:58.5pt;width:275.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:275.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Tax fees</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><ix:nonFraction unitRef="eur" contextRef="c-8" xsi:nil="true" name="ifrs-full:AuditorsRemunerationForTaxServices" id="f-3082"></ix:nonFraction></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><ix:nonFraction unitRef="eur" contextRef="c-9" xsi:nil="true" name="ifrs-full:AuditorsRemunerationForTaxServices" id="f-3083"></ix:nonFraction></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><ix:nonFraction unitRef="eur" contextRef="c-1" xsi:nil="true" name="ifrs-full:AuditorsRemunerationForTaxServices" id="f-3084"></ix:nonFraction></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:70.5pt;width:275.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:275.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">All other fees</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:275.25pt;position:var(--position);top:70.5pt;width:81pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.96pt"></span></span><span style="left:65.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:AuditorsRemunerationForOtherServices" scale="3" id="f-3085">492</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:359.25pt;position:var(--position);top:70.5pt;width:81pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:70.96pt"></span></span><span style="left:73.58999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:AuditorsRemunerationForOtherServices" scale="3" id="f-3086">7</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:443.25pt;position:var(--position);top:70.5pt;width:81pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.96pt"></span></span><span style="left:69.58999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:AuditorsRemunerationForOtherServices" scale="3" id="f-3087">34</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:82.5pt;width:275.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.87pt;width:275.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:275.25pt;position:var(--position);top:82.5pt;width:81pt"><div><div style="line-height:8pt;position:var(--position);top:4.87pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:60.37pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:AuditorsRemuneration" format="ixt:num-dot-decimal" scale="3" id="f-3088">2,340</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:359.25pt;position:var(--position);top:82.5pt;width:81pt"><div><div style="line-height:8pt;position:var(--position);top:4.87pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:60.37pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:AuditorsRemuneration" format="ixt:num-dot-decimal" scale="3" id="f-3089">1,233</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:443.25pt;position:var(--position);top:82.5pt;width:81pt"><div><div style="line-height:8pt;position:var(--position);top:4.87pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:60.37pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:AuditorsRemuneration" format="ixt:num-dot-decimal" scale="3" id="f-3090">1,418</ix:nonFraction></span></div></div></div></td></tr></tbody></table></div></div></div></ix:continuation></ix:continuation><div style="position:absolute;top:431.01pt" id="i7a006daedb3d4216a4128b76247285d7_487"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:431.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 20. <span id="i4110fa439d034b6a8de82cb58e7a67e1"></span></span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory" id="f-3091" continuedAt="f-3091-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Employees</span></ix:nonNumeric></div><ix:continuation id="f-3091-1"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:450.51pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="abvx:DisclosureOfAverageNumberOfEmployeesTableTextBlock" id="f-3092" continuedAt="f-3092-1" escape="true"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">The Group&#8217;s average workforce during the periods ended December 31, 2023, 2024 and 2025 was as follows:</span></ix:nonNumeric></div><ix:continuation id="f-3092-1"><div style="position:var(--position);top:472.26pt;width:612pt"><div style="font-size:0pt;left:43pt;position:var(--position);width:360pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:88.5pt"/><td style="padding:0;width:88.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:88.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:88.5pt"/></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">HEADCOUNT</span></div></div></div></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:88.5pt;position:var(--position);width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.57pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.94pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:17.17pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.16pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:180pt;position:var(--position);width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.57pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.94pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:17.17pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.16pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:271.5pt;position:var(--position);width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.57pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.94pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:17.17pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.16pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:30.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">France </span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:88.5pt;position:var(--position);top:30.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.87pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="employee" contextRef="c-1254" decimals="0" name="ifrs-full:AverageNumberOfEmployees" scale="0" id="f-3093">28</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:180pt;position:var(--position);top:30.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.87pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="employee" contextRef="c-1255" decimals="0" name="ifrs-full:AverageNumberOfEmployees" scale="0" id="f-3094">38</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:271.5pt;position:var(--position);top:30.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.87pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="employee" contextRef="c-1256" decimals="0" name="ifrs-full:AverageNumberOfEmployees" scale="0" id="f-3095">41</ix:nonFraction></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">United States</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:88.5pt;position:var(--position);top:42.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.87pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="employee" contextRef="c-1257" decimals="0" name="ifrs-full:AverageNumberOfEmployees" scale="0" id="f-3096">12</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:180pt;position:var(--position);top:42.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.87pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="employee" contextRef="c-1258" decimals="0" name="ifrs-full:AverageNumberOfEmployees" scale="0" id="f-3097">29</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:271.5pt;position:var(--position);top:42.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.87pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="employee" contextRef="c-1259" decimals="0" name="ifrs-full:AverageNumberOfEmployees" scale="0" id="f-3098">27</ix:nonFraction></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:88.5pt;position:var(--position);top:54.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:77.87pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="employee" contextRef="c-8" decimals="0" name="ifrs-full:AverageNumberOfEmployees" scale="0" id="f-3099">40</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:180pt;position:var(--position);top:54.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:77.87pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="employee" contextRef="c-9" decimals="0" name="ifrs-full:AverageNumberOfEmployees" scale="0" id="f-3100">67</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:271.5pt;position:var(--position);top:54.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:77.87pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="employee" contextRef="c-1" decimals="0" name="ifrs-full:AverageNumberOfEmployees" scale="0" id="f-3101">68</ix:nonFraction></span></div></div></div></td></tr></tbody></table></div></div></div></ix:continuation></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-69<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><div style="position:absolute;top:70.56pt" id="i7a006daedb3d4216a4128b76247285d7_490"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 21. <span id="i23cd1f13af744bcdbd4e67d82d0b857d"></span></span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory" id="f-3102" continuedAt="f-3102-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Financial gain (loss)</span></ix:nonNumeric></div><ix:continuation id="f-3102-1" continuedAt="f-3102-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:90.06pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="abvx:DisclosureOfDetailedInformationAboutFinanceIncomeCostTableTextBlock" id="f-3103" continuedAt="f-3103-1" escape="true"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">The financial loss breaks down as follows:</span></ix:nonNumeric></div><ix:continuation id="f-3103-1"><div style="position:var(--position);top:112.66pt;width:612pt"><div style="font-size:0pt;left:43pt;position:var(--position);width:510pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:279pt"/><td style="padding:0;width:75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:75pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:279pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:87.96pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"> FINANCIAL GAIN (LOSS)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:12pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.19pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.5pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:12pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.19pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.5pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:12pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.19pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.5pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest on bond loans</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:42.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.3pt"></span></span><span style="left:56.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:InterestExpenseOnBonds" scale="3" id="f-3104">760</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:42.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:InterestExpenseOnBonds" format="ixt:num-dot-decimal" scale="3" id="f-3105">5,800</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:432pt;overflow:hidden;position:var(--position);top:42.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:42.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:InterestExpenseOnBonds" format="ixt:num-dot-decimal" scale="3" id="f-3106">7,472</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest on convertible loan notes</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:InterestExpenseOnDebtInstrumentsIssued" format="ixt:num-dot-decimal" scale="3" id="f-3107">3,935</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:InterestExpenseOnDebtInstrumentsIssued" format="ixt:num-dot-decimal" scale="3" id="f-3108">5,691</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:432pt;overflow:hidden;position:var(--position);top:54.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:InterestExpenseOnDebtInstrumentsIssued" format="ixt:num-dot-decimal" scale="3" id="f-3109">3,638</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest on conditional advances and PGE</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.3pt"></span></span><span style="left:56.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:InterestExpenseOnBorrowings" scale="3" id="f-3110">176</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.3pt"></span></span><span style="left:60.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:InterestExpenseOnBorrowings" scale="3" id="f-3111">85</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:432pt;overflow:hidden;position:var(--position);top:66.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.3pt"></span></span><span style="left:60.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:InterestExpenseOnBorrowings" scale="3" id="f-3112">95</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest on royalty certificates</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:78.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:InterestExpenseOnRoyaltyCertificates" format="ixt:num-dot-decimal" scale="3" id="f-3113">8,942</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:78.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.3pt"></span></span><span style="left:56.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:InterestExpenseOnRoyaltyCertificates" scale="3" id="f-3114">794</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:78.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.3pt"></span></span><span style="left:46.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:InterestExpenseOnRoyaltyCertificates" format="ixt:num-dot-decimal" scale="3" id="f-3115">17,213</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest on lease liabilities</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:90.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.3pt"></span></span><span style="left:60.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="f-3116">13</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:90.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.3pt"></span></span><span style="left:60.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="f-3117">61</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:90.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.3pt"></span></span><span style="left:60.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="f-3118">64</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(Increase) / decrease in derivatives fair value</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:102.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:LossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-3119">3,046</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:102.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:LossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-3120">1,462</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:102.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.3pt"></span></span><span style="left:46.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:LossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-3121">29,935</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:114.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(Increase) / decrease in other liabilities / (assets) at fair value through profit and loss</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:114.75pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.35pt;width:75pt"><span style="color:#000000;font-family:'Arial', sans-serif;font-size:9pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.55pt;width:56.62pt"></span></span><span style="left:59.25pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss" format="ixt:fixed-zero" scale="0" id="f-3122">&#8212;</ix:nonFraction></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:114.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-3123">1,367</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:114.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.3pt"></span></span><span style="left:46.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-3124">36,015</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:126.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Loss on derecognition of financial liabilities</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:126.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:LossesArisingFromDerecognitionOfFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-3125">3,431</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:126.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:LossesArisingFromDerecognitionOfFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-3126">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:126.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:LossesArisingFromDerecognitionOfFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-3127">3,838</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:138.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Transaction costs</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:138.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:TransactionCosts" format="ixt:num-dot-decimal" scale="3" id="f-3128">1,924</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:138.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:TransactionCosts" format="ixt:num-dot-decimal" scale="3" id="f-3129">1,615</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:138.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:TransactionCosts" format="ixt:fixed-zero" scale="3" id="f-3130">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:150.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Foreign exchange losses</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:150.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:ForeignExchangeLoss" format="ixt:num-dot-decimal" scale="3" id="f-3131">5,573</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:150.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.3pt"></span></span><span style="left:60.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:ForeignExchangeLoss" scale="3" id="f-3132">51</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:150.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.3pt"></span></span><span style="left:46.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:ForeignExchangeLoss" format="ixt:num-dot-decimal" scale="3" id="f-3133">13,444</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:162.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial expense</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:162.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.3pt"></span></span><span style="left:60.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:OtherFinanceCost" scale="3" id="f-3134">73</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:162.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.3pt"></span></span><span style="left:60.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:OtherFinanceCost" scale="3" id="f-3135">64</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:162.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.3pt"></span></span><span style="left:60.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:OtherFinanceCost" scale="3" id="f-3136">29</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:174.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial expenses</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:174.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:44.3pt"></span></span><span style="left:46.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-3137">27,875</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:174.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:44.3pt"></span></span><span style="left:46.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-3138">16,991</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:432pt;overflow:hidden;position:var(--position);top:174.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:174.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.3pt"></span></span><span style="left:42.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-3139">111,743</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:186.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest income</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:186.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:RevenueFromInterest" format="ixt:num-dot-decimal" scale="3" id="f-3140">2,418</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:186.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:RevenueFromInterest" format="ixt:num-dot-decimal" scale="3" id="f-3141">8,246</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:186.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:RevenueFromInterest" format="ixt:num-dot-decimal" scale="3" id="f-3142">5,600</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:198.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(Increase) / decrease in derivatives fair value</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:198.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:GainsOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-3143">1,006</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:198.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:GainsOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-3144">1,413</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:198.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:GainsOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-3145">3,620</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:210.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(Increase) / decrease in other liabilities / (assets) at fair value through profit and loss</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:210.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:GainsOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-3146">3,198</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:210.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:GainsOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" format="ixt:fixed-zero" scale="3" id="f-3147">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:210.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:GainsOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-3148">4,730</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:222.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Effect of unwinding the discount related to advances made to CROs</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:222.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:UnwindingEffectOfDiscountRelatedToAdvancesMadeToCROs" scale="3" id="f-3149">355</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:222.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:UnwindingEffectOfDiscountRelatedToAdvancesMadeToCROs" scale="3" id="f-3150">710</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:222.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:UnwindingEffectOfDiscountRelatedToAdvancesMadeToCROs" scale="3" id="f-3151">153</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:234.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Day-one gain on recognition of financial liabilities</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:234.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:GainsArisingFromRecognitionOfFinancialLiabilities" scale="3" id="f-3152">212</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:234.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:GainsArisingFromRecognitionOfFinancialLiabilities" scale="3" id="f-3153">590</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:234.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:GainsArisingFromRecognitionOfFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-3154">1,557</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:246.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Gain on derecognition of financial liabilities</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:246.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:GainsArisingFromDerecognitionOfFinancialLiabilities" scale="3" id="f-3155">192</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:246.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:GainsArisingFromDerecognitionOfFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-3156">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:246.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:GainsArisingFromDerecognitionOfFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-3157">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:258.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Foreign exchange gains </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:258.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:ForeignExchangeGain" format="ixt:fixed-zero" scale="0" id="f-3158">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:258.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:ForeignExchangeGain" format="ixt:num-dot-decimal" scale="3" id="f-3159">2,774</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:258.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:ForeignExchangeGain" format="ixt:num-dot-decimal" scale="3" id="f-3160">11,886</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:270.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial income</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:270.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:OtherFinanceIncome" scale="3" id="f-3161">130</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:270.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:OtherFinanceIncome" format="ixt:fixed-zero" scale="3" id="f-3162">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:270.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:OtherFinanceIncome" format="ixt:fixed-zero" scale="3" id="f-3163">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:282.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial income </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:282.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:FinanceIncome" format="ixt:num-dot-decimal" scale="3" id="f-3164">7,511</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:282.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:FinanceIncome" format="ixt:num-dot-decimal" scale="3" id="f-3165">13,732</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:282.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:FinanceIncome" format="ixt:num-dot-decimal" scale="3" id="f-3166">27,545</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:294.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial gain (loss)</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:294.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:44.3pt"></span></span><span style="left:46.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:FinanceIncomeCost" format="ixt:num-dot-decimal" scale="3" id="f-3167">20,364</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:294.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="ifrs-full:FinanceIncomeCost" format="ixt:num-dot-decimal" scale="3" id="f-3168">3,258</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:294.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:44.3pt"></span></span><span style="left:46.93pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:FinanceIncomeCost" format="ixt:num-dot-decimal" scale="3" id="f-3169">84,198</ix:nonFraction>)</span></span></div></div></div></td></tr></tbody></table></div></div></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:435.71pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Financial expenses</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:459.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Interest on bond loans consists of interests from the Kreos 1 and 2 bond loans redeemed in August 2023 (see Notes 15.3 and 15.4) and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:471.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">from </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:57.93pt;position:var(--position);text-decoration:none;white-space:pre">Kreos / Claret B and C tranches (non-convertible bonds),</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:286.3pt;position:var(--position);text-decoration:none;white-space:pre"> drawn down in March and June 2024, respectively and redeemed in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:483.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">December 2025 (see Note 15</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:152.54000000000002pt;position:var(--position);text-decoration:none;white-space:pre">.1). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:507.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Interests on convertible loan notes corresponds to interests from the OCEANE bond loans (see Note 15.5) converted in August 2023 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:519.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">as well as from the Kreos / Claret OCABSA (tranche A) and the Height notes converted in August 2025 (see Notes 15.1 and 15.2).</span></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-70<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-3102-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:82.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Interests on royalty certificates are detailed in Note 15.9.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:262.9pt;position:var(--position);text-decoration:none;white-space:pre"> They include the impacts of the remeasurements of the royalty certificates </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:94.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">following changes in the Group's estimates of future cash flows during the years ended December 31, 2023, 2024 and 2025 (see Note </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:106.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">15.9).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:130.56pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In</span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:44.33pt;position:var(--position);text-decoration:none;white-space:pre">creases and decreases in the fair value of derivatives are detailed </span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:304.75pt;position:var(--position);text-decoration:none;white-space:pre">in Notes 15.1, 15.3, 15.5 and 15.11. As of December 31, 2025, the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:142.56pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1260" decimals="-3" name="ifrs-full:LossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-3170">29,935</ix:nonFraction> thousand</span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:107.09pt;position:var(--position);text-decoration:none;white-space:pre"> expense relates to the increase in the fair value of the Kreos / Claret BSA following the increase in the Group's share </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:154.56pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">price in the third quarter of 2025.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:178.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Increases in other liabilities at FVTPL relate to t</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:229.04pt;position:var(--position);text-decoration:none;white-space:pre">he convertible Heights note</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:339.18pt;position:var(--position);text-decoration:none;white-space:pre">s for the years ended December 31, 2024 and 2025 (see </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:190.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 15.2). The notes were converted by the noteholders in July 2025.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:214.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Losses on the derecognition</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:147.82999999999998pt;position:var(--position);text-decoration:none;white-space:pre"> of financial liabilitie</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:231.84pt;position:var(--position);text-decoration:none;white-space:pre">s are detailed in Notes 15.1 to 15.5, and relate to the August 2023 refinancing for </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:226.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the year ended December 31, 2023 and to the redemption of the Kreos / Claret B and C tranches for the year ended December 31, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:238.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">2025.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:262.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Transaction costs for the year ended December 31, 2023 mainly</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:291.82pt;position:var(--position);text-decoration:none;white-space:pre"> related </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:323.98pt;position:var(--position);text-decoration:none;white-space:pre">to the Heights notes, and t</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:428.32pt;position:var(--position);text-decoration:none;white-space:pre">ransaction costs for the year ended </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:274.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">December 31, 2024 mainly </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:147.28pt;position:var(--position);text-decoration:none;white-space:pre">related</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:174.44pt;position:var(--position);text-decoration:none;white-space:pre"> to the amortization of the prepaid expenses related to the transaction costs of the Kreos / Claret </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:286.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">tranche C bond loans (see Note 15.1).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:310.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Foreign exchange losses for the year ended </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:211.09pt;position:var(--position);text-decoration:none;white-space:pre">December</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.13pt;position:var(--position);text-decoration:none;white-space:pre"> 31, 2023 mainly relate to the translation of cash and cash equivalents </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:532.9100000000001pt;position:var(--position);text-decoration:none;white-space:pre">held in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:321.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">U.S. dollars</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:83.47pt;position:var(--position);text-decoration:none;white-space:pre"> into the Company's functional currency as of December 31, 2023 (see Note 11), resulting in a loss of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:491.27pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-332" decimals="-3" name="ifrs-full:ForeignExchangeLoss" format="ixt:num-dot-decimal" scale="3" id="f-3171">3,196</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:557.36pt;position:var(--position);text-decoration:none;white-space:pre">, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:332.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and to a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:70.13pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-332" decimals="-3" sign="-" name="abvx:ForeignExchangeGainsLossesOnTranslationOfForeignOperations" format="ixt:num-dot-decimal" scale="3" id="f-3172">1,488</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:136.22pt;position:var(--position);text-decoration:none;white-space:pre"> loss resulting from foreign exchange transactions.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:344.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Foreign exchange losses for the year ended December 31, 2025 relate to the translation of cash and cash equivalents held in U.S. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:355.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">dollars into the Company's functional currency as of December 31, 2025, resulting in a net financial loss of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:466.79pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-334" decimals="-3" name="ifrs-full:ForeignExchangeLoss" format="ixt:num-dot-decimal" scale="3" id="f-3173">8,639</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:532.88pt;position:var(--position);text-decoration:none;white-space:pre">, and to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:366.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">other realized and unrealized losses on foreign exchange transactions (see Note 11).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:389.76pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Financial income</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:413.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Interest income mainly relates to the invested proceeds from </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:279.84000000000003pt;position:var(--position);text-decoration:none;white-space:pre">(i) the Group's </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:340.21pt;position:var(--position);text-decoration:none;white-space:pre">i</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:342.98pt;position:var(--position);text-decoration:none;white-space:pre">nitial public offering on the Nasdaq Global Market and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:425.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the concurrent European Private Placement from October 2023, (ii) the Kreos / Claret and Heights Financings and (iii) the Group's </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:437.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">public Offering from July 2025. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:461.76pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Incr</span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:52.09pt;position:var(--position);text-decoration:none;white-space:pre">eases and decreases in the fair value of derivatives are detailed in Notes 15.1, 15.3, 15.5 and 15.11. The </span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:468.29pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1261" decimals="-3" name="ifrs-full:GainsOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-3174">3,620</ix:nonFraction> thousand</span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:534.38pt;position:var(--position);text-decoration:none;white-space:pre"> income </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:473.76pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">for the year ended December 31, 2025 related to the extinguishment of the Kreos / Claret MRI following the conversion of the Kreos </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:485.76pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Tranche A and the exercises of the Kreos / Claret BSA in August 2025.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:509.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The decrease in other liabilities at FVTPL relates to t</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:248.17pt;position:var(--position);text-decoration:none;white-space:pre">he Height notes</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:310.88pt;position:var(--position);text-decoration:none;white-space:pre"> for the year ended December 31, 2023.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:521.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The increase in assets at FVTPL for the year ended December 31, 2025 relates to the revaluation of cash equivalents measured at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:533.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">FVTPL.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:557.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The day-one gain on recognition of financial liabilities relates to the Heights notes. The amount recorded for the year ended December </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:569.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">31, 2025 includes the amortization of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:187.79pt;position:var(--position);text-decoration:none;white-space:pre">the outstanding day-one gain</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:303.51pt;position:var(--position);text-decoration:none;white-space:pre"> upon the conversion of the notes (see Note 15.2).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:593.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Foreign exchange gains for the year ended December 31, 2024 mainly relate to the translation of cash and cash equivalents held in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:604.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">U.S. dollars into the Group's presentation currency as of December 31, 2024 (see Note 11), resulting in a gain of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:487.93pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-333" decimals="-3" name="ifrs-full:ForeignExchangeGain" format="ixt:num-dot-decimal" scale="3" id="f-3175">2,035</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:554.02pt;position:var(--position);text-decoration:none;white-space:pre">, and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:616.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">to a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:53.2pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-333" decimals="-3" name="abvx:ForeignExchangeGainsLossesOnTranslationOfForeignOperations" scale="3" id="f-3176">714</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:111.79pt;position:var(--position);text-decoration:none;white-space:pre"> gain resulting from foreign exchange transactions.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:639.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Foreign exchange gains for the year ended December 31, 2025 mainly relate to the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:369.22pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-334" decimals="-3" name="ifrs-full:ForeignExchangeGain" format="ixt:num-dot-decimal" scale="3" id="f-3177">10,663</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:440.31pt;position:var(--position);text-decoration:none;white-space:pre"> gain resulting from the favorable </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:651.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">change in the euro to U.S. dollar exchange rate between the closing of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:318.72pt;position:var(--position);text-decoration:none;white-space:pre">the Group's July 2025 Offering (date of recognition of the share </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:663.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">capital increase)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:101.14pt;position:var(--position);text-decoration:none;white-space:pre"> and the date of receipt of funds.</span></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-71<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><div style="position:absolute;top:70.56pt" id="i7a006daedb3d4216a4128b76247285d7_493"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 22. <span id="i441be68c5b784ec39f52d63fcc693a76"></span></span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="f-3178" continuedAt="f-3178-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Income tax</span></ix:nonNumeric></div><ix:continuation id="f-3178-1" continuedAt="f-3178-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:90.11pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The income tax rate applicable to the Company is the French corporate income tax rate, i.e. 25% for the years ended December 31, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:101.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">2023, 2024 and 2025. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:123.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The income tax rates applicable to the U.S. Subsidia</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:245.18pt;position:var(--position);text-decoration:none;white-space:pre">ry</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:253.51pt;position:var(--position);text-decoration:none;white-space:pre"> are the federal income tax rate of 21% and the State income tax rates of 4.35%, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:135.21pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">5.36% and 8.06% i.e. a total of 25.35%, 26.36% and 29.06% for the years ended December 31, 2023, 2024 and 2025 respectively.</span></div><div style="position:var(--position);top:158.71pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="abvx:DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock" id="f-3179" escape="true"><div style="font-size:0pt;left:36pt;position:var(--position);width:522.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:214.5pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:99.75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:99.75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:99.75pt"/></tr><tr style="height:26.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:17.48pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:39.07pt;position:var(--position);text-decoration:none;white-space:pre">(In thousands of euros, except percentage)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:5.32pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.57pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:14.92pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.78pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:5.32pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.57pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:14.92pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.78pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:5.32pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.57pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:14.92pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.78pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:26.25pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Loss before tax </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:26.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:65.05pt"></span></span><span style="left:67.67999999999999pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:AccountingProfit" format="ixt:num-dot-decimal" scale="3" id="f-3180">147,740</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);top:26.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:65.05pt"></span></span><span style="left:67.67999999999999pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="ifrs-full:AccountingProfit" format="ixt:num-dot-decimal" scale="3" id="f-3181">176,242</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:26.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:65.05pt"></span></span><span style="left:67.67999999999999pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AccountingProfit" format="ixt:num-dot-decimal" scale="3" id="f-3182">330,254</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:38.25pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:8.63pt;position:var(--position);text-decoration:none;white-space:pre">Statutory French tax rate</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:38.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:78.34pt;position:var(--position)"></span><span style="left:78.34pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="4" name="ifrs-full:ApplicableTaxRate" scale="-2" id="f-3183">25</ix:nonFraction></span><span style="left:86.34pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);top:38.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:78.34pt;position:var(--position)"></span><span style="left:78.34pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-9" decimals="4" name="ifrs-full:ApplicableTaxRate" scale="-2" id="f-3184">25</ix:nonFraction></span><span style="left:86.34pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:38.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:78.34pt;position:var(--position)"></span><span style="left:78.34pt;position:var(--position)"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="ifrs-full:ApplicableTaxRate" scale="-2" id="f-3185">25</ix:nonFraction></span><span style="left:86.34pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:12.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:50.25pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Nominal income tax using statutory French tax rate</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:50.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:71.71pt"></span></span><span style="left:74.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-3186">36,935</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);top:50.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:71.71pt"></span></span><span style="left:74.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-3187">44,061</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:50.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:71.71pt"></span></span><span style="left:74.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-3188">82,563</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:63pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Tax effect of:</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:75pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Tax rates in foreign jurisdictions</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:TaxEffectOfForeignTaxRates" format="ixt:fixed-zero" scale="3" id="f-3189">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);top:75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:TaxEffectOfForeignTaxRates" format="ixt:fixed-zero" scale="3" id="f-3190">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:79.05pt"></span></span><span style="left:81.67999999999999pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:TaxEffectOfForeignTaxRates" scale="3" id="f-3191">153</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:87pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Share-based payment</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:87pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:73.05pt"></span></span><span style="left:75.67999999999999pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" sign="-" name="abvx:TaxEffectOfShareBasedPayment" format="ixt:num-dot-decimal" scale="3" id="f-3192">2,045</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);top:87pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:73.05pt"></span></span><span style="left:75.67999999999999pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="abvx:TaxEffectOfShareBasedPayment" format="ixt:num-dot-decimal" scale="3" id="f-3193">5,056</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:87pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:73.05pt"></span></span><span style="left:75.67999999999999pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="abvx:TaxEffectOfShareBasedPayment" format="ixt:num-dot-decimal" scale="3" id="f-3194">8,849</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:99pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">CIR</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:99pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:75.71pt"></span></span><span style="left:78.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:TaxEffectOfResearchTaxCredit" format="ixt:num-dot-decimal" scale="3" id="f-3195">1,123</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);top:99pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:75.71pt"></span></span><span style="left:78.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:TaxEffectOfResearchTaxCredit" format="ixt:num-dot-decimal" scale="3" id="f-3196">1,663</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:99pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:TaxEffectOfResearchTaxCredit" scale="3" id="f-3197">765</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:111pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Transaction costs related to capital increase </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:111pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:75.71pt"></span></span><span style="left:78.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:TaxEffectOfTransactionCostsRelatedToCapitalIncrease" format="ixt:num-dot-decimal" scale="3" id="f-3198">3,073</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);top:111pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:79.05pt"></span></span><span style="left:81.67999999999999pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="abvx:TaxEffectOfTransactionCostsRelatedToCapitalIncrease" scale="3" id="f-3199">112</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:111pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:71.71pt"></span></span><span style="left:74.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:TaxEffectOfTransactionCostsRelatedToCapitalIncrease" format="ixt:num-dot-decimal" scale="3" id="f-3200">10,077</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:20.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:123pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:1.89pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Decrease / (increase) in derivatives and other liabilities measured </span></div><div style="line-height:8pt;position:var(--position);top:11.49pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">at FVTPL</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:123pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.06pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:TaxEffectOfChangesInDerivativeFairValueAndOtherLiabilitiesMeasuredAtFVTPL" scale="3" id="f-3201">748</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);top:123pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.06pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:79.05pt"></span></span><span style="left:81.67999999999999pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="abvx:TaxEffectOfChangesInDerivativeFairValueAndOtherLiabilitiesMeasuredAtFVTPL" scale="3" id="f-3202">207</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:123pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.06pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:69.05pt"></span></span><span style="left:71.67999999999999pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="abvx:TaxEffectOfChangesInDerivativeFairValueAndOtherLiabilitiesMeasuredAtFVTPL" format="ixt:num-dot-decimal" scale="3" id="f-3203">17,087</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:143.25pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.39pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-recognition of deferred tax assets related to tax losses and </span></div><div style="line-height:8pt;position:var(--position);top:12.99pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">temporary differences</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:143.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:69.05pt"></span></span><span style="left:71.67999999999999pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferences" format="ixt:num-dot-decimal" scale="3" id="f-3204">39,612</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);top:143.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:69.05pt"></span></span><span style="left:71.67999999999999pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferences" format="ixt:num-dot-decimal" scale="3" id="f-3205">40,399</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:143.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:69.05pt"></span></span><span style="left:71.67999999999999pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferences" format="ixt:num-dot-decimal" scale="3" id="f-3206">61,320</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:165pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:165pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:79.05pt"></span></span><span style="left:81.67999999999999pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="3" id="f-3207">222</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);top:165pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="3" id="f-3208">49</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:2pt solid #FFFFFF;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:165pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:79.05pt"></span></span><span style="left:81.67999999999999pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="3" id="f-3209">148</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:177pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Effective income tax (loss)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:177pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:fixed-zero" scale="3" id="f-3210">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);top:177pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:fixed-zero" scale="3" id="f-3211">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:177pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:73.05pt"></span></span><span style="left:75.67999999999999pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-3212">5,848</ix:nonFraction>)</span></span></div></div></div></td></tr></tbody></table></div></div></ix:nonNumeric></div><div style="position:var(--position);top:364.71pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" id="f-3213" escape="true"><div style="font-size:0pt;left:36pt;position:var(--position);width:522.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:216pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:99.75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:99.75pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:98.25pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:70.79pt;position:var(--position);text-decoration:none;white-space:pre">(In thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:27pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:5.7pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DEFERRED TAX ASSETS AND LIABILITIES BY </span></div><div style="line-height:8pt;position:var(--position);top:15.3pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">NATURE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:12pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:5.7pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:39.16pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:15.3pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.72pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:12pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:5.7pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:39.16pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:15.3pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.72pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:12pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.7pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.38pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:15.3pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.12pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:39pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Retirement benefit obligation</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:39pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1262" decimals="-3" name="ifrs-full:DeferredTaxAssets" scale="3" id="f-3214">157</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:39pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1263" decimals="-3" name="ifrs-full:DeferredTaxAssets" scale="3" id="f-3215">189</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:39pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:79.88pt"></span></span><span style="left:82.50999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1264" decimals="-3" name="ifrs-full:DeferredTaxAssets" scale="3" id="f-3216">157</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:51pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Leases</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:51pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1265" decimals="-3" name="ifrs-full:DeferredTaxAssets" scale="3" id="f-3217">135</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:51pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1266" decimals="-3" name="ifrs-full:DeferredTaxAssets" scale="3" id="f-3218">591</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:51pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:79.88pt"></span></span><span style="left:82.50999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1267" decimals="-3" name="ifrs-full:DeferredTaxAssets" scale="3" id="f-3219">476</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:63pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial liabilities</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:63pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:85.12pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-1268" decimals="-3" name="ifrs-full:DeferredTaxAssets" scale="3" id="f-3220">351</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:63pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:75.71pt"></span></span><span style="left:78.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1269" decimals="-3" name="ifrs-full:DeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-3221">1,678</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:63pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:83.88pt"></span></span><span style="left:86.50999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1270" decimals="-3" name="ifrs-full:DeferredTaxAssets" format="ixt:fixed-zero" scale="3" id="f-3222">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:75pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Provisions for AGA taxes</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:89.12pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-1271" decimals="-3" name="ifrs-full:DeferredTaxAssets" scale="3" id="f-3223">83</ix:nonFraction></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1272" decimals="-3" name="ifrs-full:DeferredTaxAssets" scale="3" id="f-3224">142</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:75pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:73.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-1273" decimals="-3" name="ifrs-full:DeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-3225">11,454</ix:nonFraction></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:87pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Tax losses carryforward</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:87pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:71.12pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-1274" decimals="-3" name="ifrs-full:DeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-3226">114,946</ix:nonFraction></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:87pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:67.71pt"></span></span><span style="left:70.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1275" decimals="-3" name="ifrs-full:DeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-3227">152,372</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:87pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:69.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-1276" decimals="-3" name="ifrs-full:DeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-3228">228,239</ix:nonFraction></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:99pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other items</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:99pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1277" decimals="-3" name="ifrs-full:DeferredTaxAssets" scale="3" id="f-3229">335</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:99pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1278" decimals="-3" name="ifrs-full:DeferredTaxAssets" scale="3" id="f-3230">744</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:99pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-1279" decimals="-3" name="ifrs-full:DeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-3231">1,568</ix:nonFraction></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:111pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Deferred tax assets</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:111pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:67.71pt"></span></span><span style="left:70.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:DeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-3232">116,006</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:111pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:67.71pt"></span></span><span style="left:70.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:DeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-3233">155,715</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:111pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:69.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:DeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-3234">241,894</ix:nonFraction></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:123pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Subsidies</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:123pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1280" decimals="-3" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="f-3235">24</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:123pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1281" decimals="-3" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="f-3236">12</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:123pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:83.88pt"></span></span><span style="left:86.50999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1282" decimals="-3" name="ifrs-full:DeferredTaxLiabilities" format="ixt:fixed-zero" scale="0" id="f-3237">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:135pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Leases</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:135pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1265" decimals="-3" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="f-3238">124</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:135pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1266" decimals="-3" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="f-3239">485</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:135pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:83.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-1267" decimals="-3" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="f-3240">396</ix:nonFraction></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:147pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Royalty certificates</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:147pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1283" decimals="-3" name="ifrs-full:DeferredTaxLiabilities" format="ixt:fixed-zero" scale="3" id="f-3241">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:147pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1284" decimals="-3" name="ifrs-full:DeferredTaxLiabilities" format="ixt:fixed-zero" scale="3" id="f-3242">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:147pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:73.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-1285" decimals="-3" name="ifrs-full:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-3243">17,208</ix:nonFraction></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:159pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial liabilities</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:159pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1268" decimals="-3" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="f-3244">285</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:159pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:75.71pt"></span></span><span style="left:78.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1269" decimals="-3" name="ifrs-full:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-3245">1,075</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:159pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:83.88pt"></span></span><span style="left:86.50999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1270" decimals="-3" name="ifrs-full:DeferredTaxLiabilities" format="ixt:fixed-zero" scale="0" id="f-3246">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:171pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other items</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:171pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1277" decimals="-3" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="f-3247">10</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:171pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1278" decimals="-3" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="f-3248">12</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:171pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:87.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-1279" decimals="-3" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="f-3249">11</ix:nonFraction></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:183pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Deferred tax liabilities</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:183pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="f-3250">444</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:183pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:75.71pt"></span></span><span style="left:78.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-3251">1,584</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:183pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:69.88pt"></span></span><span style="left:72.50999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-3252">17,616</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:195pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Deferred tax assets, net</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:195pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:67.71pt"></span></span><span style="left:70.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="f-3253">115,562</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:195pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:67.71pt"></span></span><span style="left:70.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="f-3254">154,131</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:195pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:69.62pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="f-3255">224,279</ix:nonFraction></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:207pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Unrecognized deferred tax assets</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:207pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:65.05pt"></span></span><span style="left:67.67999999999999pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="abvx:UnrecognizedDeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-3256">115,562</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:207pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:65.05pt"></span></span><span style="left:67.67999999999999pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="abvx:UnrecognizedDeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-3257">154,131</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:207pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:63.22pt"></span></span><span style="left:65.85pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="abvx:UnrecognizedDeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-3258">230,127</ix:nonFraction>)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:219pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total deferred taxes, net recognized in the statement of </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">financial position</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:219pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="abvx:NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition" format="ixt:fixed-zero" scale="3" id="f-3259">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:219pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="abvx:NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition" format="ixt:fixed-zero" scale="3" id="f-3260">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:219pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:71.22pt"></span></span><span style="left:73.85pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" sign="-" name="abvx:NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition" format="ixt:num-dot-decimal" scale="3" id="f-3261">5,848</ix:nonFraction>)<span style="display:inline-block;height:5.41pt;width:0.33pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></ix:nonNumeric></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:621.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group incurred tax losses in the reporting periods ended December 31, 2023, 2024 and 2025. As the recoverability of these tax </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:633.21pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">losses is not considered probable in subsequent periods due to the uncertainties inherent in the Group&#8217;s business, the Group has not </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:644.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">recognized deferred tax assets beyond deferred tax liabilities arising within the same taxable entity under the same taxable regime and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:656.21pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">with consistent timing of reversal, after considering, if applicable, limitations in the use of deductible tax losses carried forward from </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:667.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">prior periods applicable under tax laws in France and in the U.S..</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:691.21pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2025, the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.68pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1285" decimals="-3" name="ifrs-full:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-3262">17,208</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:229.77pt;position:var(--position);text-decoration:none;white-space:pre"> deferred tax liability on royalty certificates results from the difference between (i) the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:703.21pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">amount already deducted from the Company's taxable income as of December 31, 2025 (based on the certificates' fair value minus the </span></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-72<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-3178-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">subscription price) and (ii) the amount of the related financial liability recognized in the Group's Statements of Financial Position at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:82.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">that date (measured at amortized cost using the original EIR). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:94.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2024 and 2023, this difference resulted in a deferred tax asset of respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:428.61pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1284" decimals="-3" name="ifrs-full:DeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-3263">1,427</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:494.7pt;position:var(--position);text-decoration:none;white-space:pre"> (classified within </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:106.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the "Other financial liabilities" line item) and &#8364;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:224.15pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-1283" decimals="-3" name="ifrs-full:DeferredTaxAssets" scale="0" id="f-3264">0</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:229.15pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:130.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2025, the Group has assessed the expected reversal of temporary taxable and deductible differences existing at the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:142.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">reporting date. The timing of reversal of the taxable difference on royalty certificates was estimated under the same cash flow schedule </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:154.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and discount rate assumptions as the certificates' fair value as of December 31, 2025 (see Note 15.9).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:166.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Based on this assessment, under the above recoverability assumption and after taking into account the limitations on the use of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:178.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">deductible tax losses carried forward in France, the Group determined that deferred tax assets amounting to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:467.42pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1286" decimals="-3" name="ifrs-full:DeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-3265">11,720</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:538.51pt;position:var(--position);text-decoration:none;white-space:pre"> should </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:190.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">be recognized as the related deductible temporary differences and losses carried forward will reverse and be utilized against future </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:202.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">taxable temporary differences in the same periods in this jurisdiction.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:214.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As a result, the net deferred tax position of the Group as of December 31, 2025 is a deferred tax liability of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:465.53pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" sign="-" name="abvx:NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition" format="ixt:num-dot-decimal" scale="3" id="f-3266">5,848</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:531.62pt;position:var(--position);text-decoration:none;white-space:pre">, relating </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:226.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">to royalty certificates.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:250.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The accumulated tax loss carry</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:160.26pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> forwards for the Company amount to </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:313.75pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="f-3267">459,752</ix:nonFraction> thousand</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:389.84pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">,</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:392.34pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:394.84pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="f-3268">609,390</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:470.93pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:473.43pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">an</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:482.86pt;position:var(--position);text-decoration:none;white-space:pre">d </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:490.36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="f-3269">911,776</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:566.45pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:262.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">as of December 31, 2023, 2024 and 2025,</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:203.12pt;position:var(--position);text-decoration:none;white-space:pre"> respectively. In France, unused tax losses do not have any expiration date; however, their </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:274.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">annual utilization is limited to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.32pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:199.67pt;position:var(--position);text-decoration:none;white-space:pre"> plus </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:221.33pt;position:var(--position);text-decoration:none;white-space:pre">50%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:239.66pt;position:var(--position);text-decoration:none;white-space:pre"> of the taxable profit exceeding that amount.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:298.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The accumulated tax loss carry forwards for the U.S. Subsidiary consist of federal Net Operating Loss ("NOL") carry forwards and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:310.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">amount to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:78.74000000000001pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1287" decimals="-3" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" scale="3" id="f-3270">38</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:132.32999999999998pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:137.32999999999998pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1288" decimals="-3" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" scale="3" id="f-3271">112</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:195.92pt;position:var(--position);text-decoration:none;white-space:pre"> and</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:212.85pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:215.35pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1289" decimals="-3" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="f-3272">1,083</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:281.44pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:283.94pt;position:var(--position);text-decoration:none;white-space:pre">as of December 31, 2023, 2024 and 2025, respectively. They do not </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:322.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">have any expiration date.</span></div></ix:continuation><div style="position:absolute;top:358.56pt" id="i7a006daedb3d4216a4128b76247285d7_496"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:358.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 23. <span id="idab28a137a3745a6987b4d775e9098a4"></span></span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfEarningsPerShareExplanatory" id="f-3273" continuedAt="f-3273-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Income (loss) per share</span></ix:nonNumeric></div><ix:continuation id="f-3273-1" continuedAt="f-3273-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:378.11pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Basic losses per share is calculated by dividing income (loss) attributable to equity holders of the Group by the weighted-</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:390.11pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">average number of outstanding ordinary shares for the year.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:413.61pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Diluted losses per share are calculated by adjusting the weighted average number of ordinary outstanding shares to assume </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:425.61pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">conversion of all dilutive potential ordinary shares.</span></div><div style="position:var(--position);top:449.61pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="ifrs-full:EarningsPerShareExplanatory" id="f-3274" escape="true"><div style="font-size:0pt;left:36pt;position:var(--position);width:419.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:207pt"/><td style="padding:0;width:64.5pt"/><td style="padding:0;width:9.75pt"/><td style="padding:0;width:64.5pt"/><td style="padding:0;width:9pt"/><td style="padding:0;width:64.5pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:207pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:207pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:21.76pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros, except share data)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:207pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:207pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BASIC AND DILUTED LOSS PER SHARE</span></div></div></div></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:207pt;position:var(--position);top:12pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.94pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.16pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.25pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:281.25pt;position:var(--position);top:12pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.94pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.16pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.25pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:354.75pt;position:var(--position);top:12pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.94pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.16pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.25pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:207pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:207pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Weighted average number of outstanding shares</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:207pt;position:var(--position);top:42.75pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.46pt"></span></span><span style="left:25.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-3275"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-3276">43,066,012</ix:nonFraction></ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:281.25pt;position:var(--position);top:42.75pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.46pt"></span></span><span style="left:25.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-3277"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-3278">63,046,350</ix:nonFraction></ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:354.75pt;position:var(--position);top:42.75pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.46pt"></span></span><span style="left:25.09pt;position:var(--position)"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-3279"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-3280">69,527,315</ix:nonFraction></ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:207pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:207pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Net loss for the period</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:207pt;position:var(--position);top:54.75pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.8pt"></span></span><span style="left:32.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-3281">147,740</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:281.25pt;position:var(--position);top:54.75pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.8pt"></span></span><span style="left:32.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-3282">176,242</ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:354.75pt;position:var(--position);top:54.75pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.8pt"></span></span><span style="left:32.43pt;position:var(--position)">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-3283">336,102</ix:nonFraction>)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:207pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:207pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Basic and diluted loss per share (&#8364;/share) </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:207pt;position:var(--position);top:66.75pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.8pt"></span></span><span style="left:44.43pt;position:var(--position)">(<ix:nonFraction unitRef="eurPerShare" contextRef="c-8" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-3284"><ix:nonFraction unitRef="eurPerShare" contextRef="c-8" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-3285">3.43</ix:nonFraction></ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:281.25pt;position:var(--position);top:66.75pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.8pt"></span></span><span style="left:44.43pt;position:var(--position)">(<ix:nonFraction unitRef="eurPerShare" contextRef="c-9" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-3286"><ix:nonFraction unitRef="eurPerShare" contextRef="c-9" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-3287">2.80</ix:nonFraction></ix:nonFraction>)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:354.75pt;position:var(--position);top:66.75pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.8pt"></span></span><span style="left:44.43pt;position:var(--position)">(<ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-3288"><ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-3289">4.83</ix:nonFraction></ix:nonFraction>)</span></span></div></div></div></td></tr></tbody></table></div></div></ix:nonNumeric></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:557.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">Potential dilutive instruments (BCEs, BSAs, AGAs, BSA Kreos 1, OCEANE, Kreos/Claret BSA, Kreos/Claret OCABSA and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:568.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">Height notes) have been excluded from the computation of diluted weighted-average shares outstanding because such instruments </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:579.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">had an antidilutive impact due to the losses reported. As of December 31, 2023, 2024 and 2025, the number of potential dilutive </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:590.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">instruments were </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.03pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="0" name="ifrs-full:NumberOfInstrumentsThatAreAntidilutiveInPeriodPresented" format="ixt:num-dot-decimal" scale="0" id="f-3290">28,754,280</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:159.03pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:164.03pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="ifrs-full:NumberOfInstrumentsThatAreAntidilutiveInPeriodPresented" format="ixt:num-dot-decimal" scale="0" id="f-3291">29,570,132</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:209.03pt;position:var(--position);text-decoration:none;white-space:pre"> and</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:225.96pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:228.46pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ifrs-full:NumberOfInstrumentsThatAreAntidilutiveInPeriodPresented" format="ixt:num-dot-decimal" scale="0" id="f-3292">8,857,084</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:268.46000000000004pt;position:var(--position);text-decoration:none;white-space:pre"> respectively, giving rights to a maximum number of shares to be issued of </span></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:602.16pt;width:612pt"><ix:continuation id="f-3273-2" continuedAt="f-3273-3"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="abvx:MaximumNumberOfSharesToBeIssued" format="ixt:num-dot-decimal" scale="0" id="f-3293">6,510,658</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:83pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:88pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="abvx:MaximumNumberOfSharesToBeIssued" format="ixt:num-dot-decimal" scale="0" id="f-3294">6,760,392</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:128pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:147.43pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="abvx:MaximumNumberOfSharesToBeIssued" format="ixt:num-dot-decimal" scale="0" id="f-3295">8,857,084</ix:nonFraction></span></ix:continuation><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:187.43pt;position:var(--position);text-decoration:none;white-space:pre"><ix:continuation id="f-3273-3"> respectively.</ix:continuation> </span></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-73<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><div style="position:absolute;top:70.56pt" id="i7a006daedb3d4216a4128b76247285d7_499"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 24. <span id="i2bba0f79a1084c01bd54ebca90158d64"></span></span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfRelatedPartyExplanatory" id="f-3296" continuedAt="f-3296-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Related parties</span></ix:nonNumeric></div><ix:continuation id="f-3296-1"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:90.11pt;width:612pt"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" id="f-3297" continuedAt="f-3297-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">The aggregate compensation of the members of the Group&#8217;s Board of Directors and to the Chief Executive Officer includes the </span></ix:nonNumeric></div><ix:continuation id="f-3297-1"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:101.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">following: </span></div><div style="position:var(--position);top:122.51pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:488.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:241.5pt"/><td style="padding:0;width:80.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:80.25pt"/><td style="padding:0;width:3pt"/><td style="padding:0;width:80.25pt"/></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:241.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:83.54pt;position:var(--position);text-decoration:none;white-space:pre">(In thousands of euros)</span></div></div></div></td><td colspan="3" style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/><td style="font-size:0;text-align:left;vertical-align:top"/></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:241.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">COMPENSATION</span></div></div></div></td><td style="border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"/><td style="border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:408pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:241.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Fixed compensation owed </span></div></div></div></td><td style="background-color:#cceeff;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:KeyManagementPersonnelCompensationFixedCompensation" scale="3" id="f-3298">471</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:KeyManagementPersonnelCompensationFixedCompensation" scale="3" id="f-3299">578</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:408pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:KeyManagementPersonnelCompensationFixedCompensation" scale="3" id="f-3300">601</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:241.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Variable compensation owed </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:KeyManagementPersonnelCompensationVariableCompensation" scale="3" id="f-3301">282</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><ix:nonFraction unitRef="eur" contextRef="c-9" xsi:nil="true" name="abvx:KeyManagementPersonnelCompensationVariableCompensation" id="f-3302"></ix:nonFraction></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:408pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:KeyManagementPersonnelCompensationVariableCompensation" scale="3" id="f-3303">450</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:241.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Contributions in-kind </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:KeyManagementPersonnelCompensationInKindContributions" scale="3" id="f-3304">32</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:KeyManagementPersonnelCompensationInKindContributions" scale="3" id="f-3305">68</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:408pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:KeyManagementPersonnelCompensationInKindContributions" scale="3" id="f-3306">111</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:241.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Employer contributions </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" format="ixt:fixed-zero" scale="3" id="f-3307">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" format="ixt:fixed-zero" scale="3" id="f-3308">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:408pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" format="ixt:fixed-zero" scale="3" id="f-3309">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90.75pt;width:241.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Attendance fees&#8212;board of directors </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:90.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:KeyManagementPersonnelCompensationAttendanceFees" scale="3" id="f-3310">375</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);top:90.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:KeyManagementPersonnelCompensationAttendanceFees" scale="3" id="f-3311">495</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:408pt;position:var(--position);top:90.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:KeyManagementPersonnelCompensationAttendanceFees" scale="3" id="f-3312">608</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102.75pt;width:241.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Share-based payments </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:102.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" format="ixt:num-dot-decimal" scale="3" id="f-3313">6,561</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);top:102.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" format="ixt:num-dot-decimal" scale="3" id="f-3314">10,517</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:408pt;position:var(--position);top:102.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" format="ixt:num-dot-decimal" scale="3" id="f-3315">8,098</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:114.75pt;width:241.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Consulting fees </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:114.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="abvx:KeyManagementPersonnelCompensationConsultingFees" format="ixt:num-dot-decimal" scale="3" id="f-3316">1,210</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);top:114.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="abvx:KeyManagementPersonnelCompensationConsultingFees" format="ixt:fixed-zero" scale="3" id="f-3317">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:408pt;position:var(--position);top:114.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="abvx:KeyManagementPersonnelCompensationConsultingFees" format="ixt:fixed-zero" scale="3" id="f-3318">&#8212;</ix:nonFraction><span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:126.75pt;width:241.5pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:126.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensation" format="ixt:num-dot-decimal" scale="3" id="f-3319">8,930</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);top:126.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensation" format="ixt:num-dot-decimal" scale="3" id="f-3320">11,657</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:408pt;position:var(--position);top:126.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensation" format="ixt:num-dot-decimal" scale="3" id="f-3321">9,869</ix:nonFraction><span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:278.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, 2024 and 2025, there was <span id="i658c175374ed4bf5bd441dc128bb2ec4_1893"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:248.91pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-1290" decimals="-3" name="ifrs-full:RecognisedLiabilitiesDefinedBenefitPlan" format="ixt:fixed-zero" scale="0" id="f-3322"><ix:nonFraction unitRef="eur" contextRef="c-1291" decimals="-3" name="ifrs-full:RecognisedLiabilitiesDefinedBenefitPlan" format="ixt:fixed-zero" scale="0" id="f-3323"><ix:nonFraction unitRef="eur" contextRef="c-1292" decimals="-3" name="ifrs-full:RecognisedLiabilitiesDefinedBenefitPlan" format="ixt:fixed-zero" scale="0" id="f-3324">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:258.90999999999997pt;position:var(--position);text-decoration:none;white-space:pre"> liability related to post-employment defined benefit obligations for members </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:289.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of the Group&#8217;s Board of Directors and Chief Executive Officer. No other post-employment benefits are granted.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:311.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Other arrangements with our Directors and Executive Officers </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:334.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group entered into an intellectual property assignment agreement with CEO Hartmut Ehrlich on July 7, 2021. The purpose of this </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:345.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">agreement is to transfer to the Group all the intellectual property rights held by Hartmut Ehrlich on certain patents of which he is a co-</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:356.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">inventor. No compensation has been paid in respect of this transfer. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:367.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In connection with Dr. Hartmut Ehrlich&#8217;s retirement as CEO, the Group entered into a transition protocol with Dr. Ehrlich in April </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:379.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">2023. Pursuant to the transition protocol, Dr. Ehrlich remained a Group employee on a part-time basis until December 31, 2023 in a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:390.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">capacity as advisor to the new Chief Executive Officer against payment of a total compensation of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:431.59pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1293" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="3" id="f-3325">100</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:451.59pt;position:var(--position);text-decoration:none;white-space:pre"> thousand, and a departure </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:401.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">indemnity equal to&#160; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:115.91pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1293" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits" format="ixt:num-dot-decimal" scale="3" id="f-3326">1,210</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:143.41pt;position:var(--position);text-decoration:none;white-space:pre"> thousand was stated.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:412.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group entered into a management contract with CEO Marc de Garidel on April 18, 2023. In 2023, 2024 and 2025 the Group also </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:423.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">granted AGA plans to its CEO (see terms and conditions in Note 14).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:435.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group entered into a management contract with Chairman of the Board Sylvie Gr&#233;goire in July 2024. In 2024 and 2025, the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:446.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Group also granted BSA plans to its Chairman of the Board (see terms and conditions in Note 14).</span></div></ix:continuation><div style="position:absolute;top:481.46pt" id="i7a006daedb3d4216a4128b76247285d7_502"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:481.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 25. <span id="ifa1eef6a6e234e44a0434baadab6a3c0"></span></span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfCommitmentsExplanatory" id="f-3327" continuedAt="f-3327-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Off-balance sheet </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:150.63pt;position:var(--position);text-decoration:none;white-space:pre">commitments given</span></ix:nonNumeric></div><div style="position:absolute;top:507.01pt" id="i7a006daedb3d4216a4128b76247285d7_505"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:507.01pt;width:612pt"><ix:continuation id="f-3327-1" continuedAt="f-3327-2"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 25.1. Commitments under collaboration, research, service provision and licensing agreements granted by the Group </span></ix:continuation></div><ix:continuation id="f-3327-2" continuedAt="f-3327-3"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:523.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Collaboration, research and development, and licensing agreements, and licensing options related to the &#8220;Modulation of RNA </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:533.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">biogenesis&#8221; platform. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:549.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:91.05000000000001pt;position:var(--position);text-decoration:none;white-space:pre">Exclusive licensing agreement with the CNRS, the University of Montpellier and the Institut Curie</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:496.21pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:565.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">On December 4, 2008, the French National Centre for Scientific Research (CNRS), the University of Montpellier and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:575.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">the Institut Curie granted the Group </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:236.45pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="license" contextRef="c-1294" decimals="INF" name="abvx:NumberOfExclusiveLicenses" format="ixt-sec:numwordsen" scale="0" id="f-3328">four</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:253.11pt;position:var(--position);text-decoration:none;white-space:pre"> exclusive licenses. These licenses cover the use of their technology and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:585.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">products by the Group in the field of human and veterinary health relating to the use of synthetic products modifying </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:595.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">mRNA splicing, for research, diagnosis, prevention and treatment of any possible indication. The licensing agreement </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:605.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">includes low single-digit royalties based on future net sales to be paid by the Group. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:621.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72.7pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:76.2pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:91.05000000000001pt;position:var(--position);text-decoration:none;white-space:pre">Research and development contract with license option with the CNRS, the University of Montpellier and Theradiag</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:568.94pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:631.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">The CNRS, the University of Montpellier, the Group and Theradiag conducted since 2013 a collaborative project </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:642.51pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">notably in the fields of HIV and HTLV-1 called CARENA, in connection with a funding obtained through Bpifrance. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:654.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">The overall project provided for co-ownership and cross-licenses on the project's results through various instruments. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:665.51pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">The Group met all obligations and the project was closed in December 2024. </span></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-74<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-3327-3" continuedAt="f-3327-4"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Exclusive licensing contract with &#8220;The Scripps Research Institute, University of Chicago and Brigham Young University&#8221; with the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:80.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8220;Immune Stimulation&#8221; platform (ABX196 product) </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:96.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On 11&#160;November 2006, The Scripps Research Institute (La Jolla, California, USA), in agreement with the University of Chicago </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:106.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(Chicago, Illinois, USA) and Brigham Young University (Provo, Utah, USA), granted the Group an exclusive license in the field of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:116.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">human and veterinary health on its technology and products relating to the use of iNKT agonists for research, diagnosis, prevention </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and treatment of all possible indications. In consideration for the licensing rights granted to it under the agreement, the Group had to: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:142.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">pay The Scripps Research Institute milestones at different stages of clinical and regulatory development of the first </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:152.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">product (the milestones amount to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:230.07pt;position:var(--position);text-decoration:none;white-space:pre">$<ix:nonFraction unitRef="usd" contextRef="c-1295" decimals="-3" name="abvx:CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDFiling" scale="3" id="f-3329">50</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:283.66pt;position:var(--position);text-decoration:none;white-space:pre"> at IND filing, paid in September 2019 and capitalized, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:505.62pt;position:var(--position);text-decoration:none;white-space:pre">$<ix:nonFraction unitRef="usd" contextRef="c-1295" decimals="-3" name="abvx:CollaborationAgreementsPotentialDevelopmentMilestonePaymentPhase3" scale="3" id="f-3330">300</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:564.21pt;position:var(--position);text-decoration:none;white-space:pre"> at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:162.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">Phase 3 and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:141.29pt;position:var(--position);text-decoration:none;white-space:pre">$<ix:nonFraction unitRef="usd" contextRef="c-1295" decimals="-3" name="abvx:CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDApproval" scale="3" id="f-3331">500</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:199.88pt;position:var(--position);text-decoration:none;white-space:pre"> at IND approval) and low single-digit royalties for vaccines, diagnostic tests and therapeutic </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:172.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">products, according to the amount of net sales, and </span><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:296.67pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:188.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">give The Scripps Research Institute, University of Chicago and Brigham Young University an equitable interest in the </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:198.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">Group (as of the date of these financial statements, these </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:319.36pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="academic_institution" contextRef="c-1295" decimals="INF" name="abvx:NumberOfAcademicInstitutions" format="ixt-sec:numwordsen" scale="0" id="f-3332">three</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:339.32pt;position:var(--position);text-decoration:none;white-space:pre"> academic institutions hold </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:449.18pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1296" decimals="4" name="ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" scale="-2" id="f-3333">0.41</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:475.01pt;position:var(--position);text-decoration:none;white-space:pre"> of the Group&#8217;s </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:208.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">undiluted capital). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:230.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">During the year ended December 31, 2022, the Group made the decision to freeze the development program for ABX196 in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:240.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">treatment of hepatocellular cancer. Subsequently, in 2024, the licensing contract was terminated.</span></div></ix:continuation><div style="position:absolute;top:280.56pt" id="i7a006daedb3d4216a4128b76247285d7_508"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:280.56pt;width:612pt"><ix:continuation id="f-3327-4" continuedAt="f-3327-5"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 25.2. Commitments under BPI conditional advances </span></ix:continuation></div><ix:continuation id="f-3327-5" continuedAt="f-3327-6"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:296.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Bpifrance CARENA contract </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:312.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As part of the development of therapeutic and diagnostic solutions targeting alternative splicing and RNA interference in the fields of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:322.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">virology (HIV-AIDS, HTLV-1) and metabolism (obesity), SPLICOS (absorbed by the Group on 31&#160;October 2014) has entered into a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:332.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Master Support Agreement with Bpifrance as well as a conditional advance contract in the name of the &#8220;CARENA&#8221; Strategic </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:342.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Industrial Innovation Project dated December 16, 2013. The Group, acting as project leader for the CARENA project, was associated </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:352.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">as part of a consortium contract with Theradiag, a Group specializing in in vitro diagnostics and the development of theranostic tests </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:362.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">for monitoring biotherapies, as well as at the CNRS and the University of Montpellier. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:384.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The CARENA project aimed to develop the anti-HIV-AIDS therapeutic program with the compound ABX464 up to the Phase 2b </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:394.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">study, as well as a companion test set up by Theradiag simultaneously with the clinical development. Beyond the anti-HIV-AIDS </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:404.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">program, the CARENA project could extend its pharmacological investigations to another retrovirus that could be combated by the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:414.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">same approach: HTLV-1. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:436.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group is committed to reimbursing the received conditional advances up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:357.85pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1034" decimals="-3" name="abvx:OtherFinancialLiabilitiesMaximumDrawdownCapacityIncludingInterest" format="ixt:num-dot-decimal" scale="3" id="f-3334">3,840</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:423.94pt;position:var(--position);text-decoration:none;white-space:pre">. The Group will also have to pay an </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:448.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">annuity of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:79.3pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1034" decimals="2" name="abvx:OtherFinancialLiabilitiesAnnualPercentageOfProceedsFromSaleOfIntellectualPropertyRight" scale="-2" id="f-3335">50</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:97.63pt;position:var(--position);text-decoration:none;white-space:pre"> of the proceeds from the sale of the intellectual property rights resulting from the project, as well as the sale of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:460.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">prototypes, preproduction and models produced under the project; the sum due to Bpifrance under this provision will be deducted </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:472.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">from the repayment of the conditional advances. In addition, if the advance is repaid under the conditions outlined above, the Group </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:484.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">will pay to Bpifrance, over a period of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:191.66pt;position:var(--position);text-decoration:none;white-space:pre"><span style="-sec-ix-hidden:f-3336">five</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:207.19pt;position:var(--position);text-decoration:none;white-space:pre"> consecutive years after the date on which the repayment schedule ends and provided that </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:496.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the Group has reached cumulative pre-tax revenue greater than or equal to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:335.05pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1298" decimals="-6" name="abvx:OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDevelopedPreTaxRevenueThreshold" scale="6" id="f-3337">50</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:381.4pt;position:var(--position);text-decoration:none;white-space:pre">, an amount equal to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:465.2pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1034" decimals="4" name="abvx:OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDeveloped" scale="-2" id="f-3338">1.20</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:491.03pt;position:var(--position);text-decoration:none;white-space:pre"> of the annual </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:508.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">revenue generated from the sale of the products developed as part of the project. This supplementary payment amount is capped at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:520.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1299" decimals="-3" name="abvx:OtherFinancialLiabilitiesPayableAnnualRevenueFromSaleOfProductsDeveloped" format="ixt:num-dot-decimal" scale="3" id="f-3339">6,800</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:102.09pt;position:var(--position);text-decoration:none;white-space:pre">. The total period, including fixed payments and incentive payments, is limited to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:429.48pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1300" name="abvx:OtherFinancialLiabilitiesRepaymentPeriod" format="ixt-sec:duryear" id="f-3340">15</ix:nonNumeric> years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:463.06pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:544.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In June 2024, the Group and Bpifrance agreed to terminate the project due to technical failure. Termination became effective in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:556.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">December 2024 after the Group refunded&#160; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:206.1pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1301" decimals="-3" name="abvx:RepaymentsOfConditionalAdvances" scale="3" id="f-3341">234</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:264.69pt;position:var(--position);text-decoration:none;white-space:pre"> corresponding to a portion of the funding received. The Group is therefore </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:567.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">released of its obligations to pay an annuities on the proceeds from the sale of the intellectual property rights resulting from the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:579.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">project. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:608.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Bpifrance RNP-VIR contract </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:624.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In pursuit of the CARENA project, focused on the clinical development of a drug molecule and demonstrating the validity of an </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:634.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">innovative therapeutic approach targeting viral RNPs, the Group has entered into a Master Support Agreement with Bpifrance as well </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:644.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">as a beneficiary agreement with conditional advance for the &#8220;RNP-VIR&#8221; structuring research and development project for </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:654.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">competitiveness dated December 16, 2016. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:676.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The RNP-VIR project aimed to further the discovery of new molecules for the treatment of multiple infectious diseases by the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:686.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">development of the antiviral technology platform. The Group, acting as project leader of the RNP-VIR project, was associated in a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:696.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">consortium contract with the CNRS and the University of Montpellier. </span></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-75<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-3327-6" continuedAt="f-3327-7"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group is committed to reimburse the received conditional advances up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:349.51pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1028" decimals="-3" name="abvx:OtherFinancialLiabilitiesMaximumDrawdownCapacityIncludingInterest" format="ixt:num-dot-decimal" scale="3" id="f-3342">6,576</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:415.6pt;position:var(--position);text-decoration:none;white-space:pre">. If applicable, the Group will also have </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:80.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">to pay an annuity of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:118.43pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1028" decimals="2" name="abvx:OtherFinancialLiabilitiesAnnualPercentageOfProceedsFromSaleOfIntellectualPropertyRight" scale="-2" id="f-3343">50</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:136.76pt;position:var(--position);text-decoration:none;white-space:pre"> of the proceeds from the sale of the intellectual property rights resulting from the project, as well as the sale </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:90.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of the prototypes, preproduction and models produced under the project. The sum due to Bpifrance under this provision will be </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:100.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">deducted from the last payment (and if needed from the previous payments). </span></div><div style="font-size:12pt;line-height:1pt;position:var(--position);top:122.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:123.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">If the advance is repaid under the conditions outlined above, the Group will pay to Bpifrance, over a period of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:478.3pt;position:var(--position);text-decoration:none;white-space:pre"><span style="-sec-ix-hidden:f-3344">five</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:493.83pt;position:var(--position);text-decoration:none;white-space:pre"> consecutive years </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:133.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">following the date on which the repayment schedule ends and provided that the Group has reached cumulative pre-tax revenue greater </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:143.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">than or equal to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:100.93pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1303" decimals="-6" name="abvx:OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDevelopedPreTaxRevenueThreshold" scale="6" id="f-3345">25</ix:nonFraction>&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:147.28pt;position:var(--position);text-decoration:none;white-space:pre">, an amount equal to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:231.08pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1028" decimals="2" name="abvx:OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDeveloped" scale="-2" id="f-3346">3</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:244.41pt;position:var(--position);text-decoration:none;white-space:pre"> of the annual revenue generated from the sale of products developed as part of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:153.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">project. The supplementary payments amount is capped at </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:270.99pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1304" decimals="-3" name="abvx:OtherFinancialLiabilitiesPayableAnnualRevenueFromSaleOfProductsDeveloped" format="ixt:num-dot-decimal" scale="3" id="f-3347">5,500</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:337.08pt;position:var(--position);text-decoration:none;white-space:pre">. The total period, including fixed payments and incentive </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:163.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">payments, is limited to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.5pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1305" name="abvx:OtherFinancialLiabilitiesRepaymentPeriod" format="ixt-sec:duryear" id="f-3348">15</ix:nonNumeric> years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:163.07999999999998pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:185.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In June 2024, the Group and Bpifrance agreed to terminate the project due to technical failure. Termination became effective in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:197.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">December 2024. The Group is therefore released of its obligations to pay an annuities on the proceeds from the sale of the intellectual </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:208.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">property rights resulting from the project. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:238.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Bpifrance Ebola </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:254.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Bpifrance and Occitanie Region joint support agreement granted on June 2, 2017 consists of conditional advances to the Group </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:264.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">for a total amount of up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:143.4pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1306" decimals="-3" name="abvx:OtherFinancialLiabilitiesMaximumDrawdownCapacity" scale="3" id="f-3349">390</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:201.99pt;position:var(--position);text-decoration:none;white-space:pre">, based on the success of the program (respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:407.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1307" decimals="-3" name="abvx:OtherFinancialLiabilitiesMaximumDrawdownCapacity" scale="3" id="f-3350">130</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:466.46pt;position:var(--position);text-decoration:none;white-space:pre"> from the Languedoc </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:274.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Roussillon Midi Pyr&#233;n&#233;es Region and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:190.04pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1308" decimals="-3" name="abvx:OtherFinancialLiabilitiesMaximumDrawdownCapacity" scale="3" id="f-3351">260</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:248.63pt;position:var(--position);text-decoration:none;white-space:pre"> from Bpifrance). In September 2019, the Group decided to terminate this </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:284.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">program, due to the existence of a vaccine in the process of being licensed for this indication as well as changes in the macroeconomic </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:294.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">climate for public funding. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:316.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The reimbursement of the conditional advance was spread until June 2024. </span></div></ix:continuation><div style="position:absolute;top:344.26pt" id="i7a006daedb3d4216a4128b76247285d7_511"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:344.26pt;width:612pt"><ix:continuation id="f-3327-7" continuedAt="f-3327-8"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 25.3. Pledge assets to Kreos, Claret and Heights </span></ix:continuation></div><ix:continuation id="f-3327-8" continuedAt="f-3327-9"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:360.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As part of the KREOS 1 &amp; 2 bonds, Kreos benefits from first-rate collateral on the Group&#8217;s principal tangible and intangible assets, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:370.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">including its commercial fund, intellectual property rights in its principal drug candidates, as well as a pledge of the Group&#8217;s bank </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:380.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">accounts and claims. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:390.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On August 21, 2023, the outstanding Kreos 1 &amp; 2 bond loans were repaid in full, using the proceeds from the new Kreos / Claret </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:402.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Financing (see Note 3.1).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:425.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Kreos / Claret Financing provides for certain restrictive covenants (subject to customary exceptions) which include, among other </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:436.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">things, restrictions on the incurrence of indebtedness, cross-default, the distribution of dividends and the grant of security interests, and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:447.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">which would cause the bonds to become repayable on demand in case of breach. As of December 31, 2024, the Group complied with </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:459.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">these restrictive covenants.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:470.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As security for the Kreos / Claret Financing, the lenders benefit from the grant of first-ranking collateral on the Group&#8217;s principal </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:481.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">tangible and intangible assets, including pledges over the Group&#8217;s business (</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:341.53pt;position:var(--position);text-decoration:none;white-space:pre">fonds de commerce</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:418.67pt;position:var(--position);text-decoration:none;white-space:pre">) as a going concern and intellectual </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:492.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">property rights in the Group's lead drug candidate, as well as pledges over the Group&#8217;s bank accounts and receivables. Such securities </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:503.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">apply to all tranches of the Kreos / Claret Financing. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:515.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Following the conversion of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:151.47pt;position:var(--position);text-decoration:none;white-space:pre">Tranche A bonds</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:220.3pt;position:var(--position);text-decoration:none;white-space:pre"> in August and November 2025, the exercise of the Kreos / Claret BSA in August 2025 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:526.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and the repayment of Tranches B and C bonds in December 2025, the Group no longer holds any debt related to the Kreos / Claret </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:537.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Financin</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:70.96000000000001pt;position:var(--position);text-decoration:none;white-space:pre">g and is therefore released from the aforementioned commitments.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:559.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Heights Financing is a senior, unsecured financing. The terms and conditions of the Heights convertible notes include a standard </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:571.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">negative pledge providing that any security granted in favor of other borrowed debt or debt instruments should also be granted in favor </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:582.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of the Heights convertible notes on an equal basis (with the exception of the securities issued pursuant to the Kreos / Claret Financing, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:593.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">as detailed above).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:604.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Following the conversion of Tranche A in July 2025, the Group no longer holds any debt related to the Heights Financing and is </span></div></ix:continuation><div style="font-size:12pt;line-height:10pt;position:var(--position);top:615.86pt;width:612pt"><ix:continuation id="f-3327-9" continuedAt="f-3327-10"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">therefore released from the aforementioned commitment.</span></ix:continuation><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:264.56pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="position:absolute;top:645.06pt" id="i7a006daedb3d4216a4128b76247285d7_514"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:645.06pt;width:612pt"><ix:continuation id="f-3327-10" continuedAt="f-3327-11"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 25.4. Other commitments related to research and partnership arrangements </span></ix:continuation></div><ix:continuation id="f-3327-11" continuedAt="f-3327-12"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:661.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In the ordinary course of business, the Group regularly uses the services of subcontractors and enters into research and partnership </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:671.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">arrangements with various contract research organizations, or CROs, and with public- sector partners or subcontractors, who conduct </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:681.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">clinical trials and studies in relation to the drug candidates. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:691.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">At December 31, 2023, 2024, and 2025 the Group&#8217;s commitments amounted to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:355.47pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:CapitalCommitments" format="ixt:num-dot-decimal" scale="3" id="f-3352">201,777</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:431.56pt;position:var(--position);text-decoration:none;white-space:pre">,</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:434.06pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:436.56pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:CapitalCommitments" format="ixt:num-dot-decimal" scale="3" id="f-3353">234,908</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:512.65pt;position:var(--position);text-decoration:none;white-space:pre"> and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:703.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:CapitalCommitments" format="ixt:num-dot-decimal" scale="3" id="f-3354">205,131</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:107.09pt;position:var(--position);text-decoration:none;white-space:pre">. The cost of services performed by CROs is recognized as an operating expense as incurred.</span></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-76<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><div style="position:absolute;top:99.76pt" id="i7a006daedb3d4216a4128b76247285d7_517"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:99.76pt;width:612pt"><ix:continuation id="f-3327-12" continuedAt="f-3327-13"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 25.5. Leases </span></ix:continuation></div><ix:continuation id="f-3327-13"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:124.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Following the end (in December 31, 2021) of the Framework agreement with </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:347.64pt;position:var(--position);text-decoration:none;white-space:pre">CNRS </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:376.24pt;position:var(--position);text-decoration:none;white-space:pre">(French National Centre for Scientific Research) </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:135.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and the University of Montpellier for research collaboration to create a cooperative laboratory, a hosting agreement was signed in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:146.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">2022 with CNRS</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:104.86pt;position:var(--position);text-decoration:none;white-space:pre">, so that the Group can continue its research program at the CNRS</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:369.29pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:371.79pt;position:var(--position);text-decoration:none;white-space:pre">center for the year 2023, and was subsequently </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:157.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">renewed for 2024, 2025 and 2026. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:175.93pt;position:var(--position);text-decoration:none;white-space:pre">The lease fell under the IFRS 16 short-term lease exemption until the 2025 renewal. As of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:168.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">December 31, 2025 a right-of-use asset and a lease liability were recognized.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:192.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">I</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.33pt;position:var(--position);text-decoration:none;white-space:pre">n December 2022, following the end of the Research collaboration contract with the CNRS, the University of Montpellier and the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:204.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Institut Curie, the Company and the Institut Curie concluded a new contract for a duration of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:409.19pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonNumeric contextRef="c-1309" name="abvx:LeaseDurationPeriod" format="ixt-sec:durwordsen" id="f-3355">one year</ix:nonNumeric></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:443.31pt;position:var(--position);text-decoration:none;white-space:pre">, renewable by amendment, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:216.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">granting the Company access to some of the Institute&#8217;s equipment and consumables. The contract was subsequently renewed for 2024, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:228.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">2025 and 2026, under similar conditions.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:200.05pt;position:var(--position);text-decoration:none;white-space:pre"> Since the Group's right to use the equipment is non-exclusive, t</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:455.49pt;position:var(--position);text-decoration:none;white-space:pre">his agreement does not meet </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:240.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the definition of a lease under IFRS 16, and the related rental expenses are therefore recognized in operating expenses as incur</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:541.19pt;position:var(--position);text-decoration:none;white-space:pre">red. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:264.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group's commitments in relation to the above lease are not significant. Information on other ongoing leases recognized in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:276.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">balance sheet are set forth in Note 15.8 and 15.12.</span></div></ix:continuation><div style="position:absolute;top:300.16pt" id="i7a006daedb3d4216a4128b76247285d7_523"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:300.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 26. <span id="i5baa85baedb144a3974368774c59d7a6"></span></span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" id="f-3356" continuedAt="f-3356-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Off-balance sheet commitments received and contingent assets </span></ix:nonNumeric></div><ix:continuation id="f-3356-1"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:318.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The maximum amounts receivable by the Group after December 31, 2023 under the &#8220;RNP-VIR&#8221; and &#8220;CARENA&#8221; and innovation </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:328.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">agreements entered into with Bpifrance, subject to the provision of evidence to support the forecast expenses and the achievement of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:338.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">scientific milestones, are </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:137.5pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1019" decimals="-3" name="ifrs-full:UndrawnBorrowingFacilities" format="ixt:num-dot-decimal" scale="3" id="f-3357">3,255</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:203.59pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:223.02pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1022" decimals="-3" name="ifrs-full:UndrawnBorrowingFacilities" format="ixt:num-dot-decimal" scale="3" id="f-3358">1,853</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:289.11pt;position:var(--position);text-decoration:none;white-space:pre">, respectively. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:347.36pt;position:var(--position);text-decoration:none;white-space:pre">In June 2024, the Group and Bpifrance agreed to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:348.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">terminate the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90.9pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="project" contextRef="c-1310" decimals="INF" name="abvx:NumberOfProjectsTerminated" format="ixt-sec:numwordsen" scale="0" id="f-3359">two</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:105.89pt;position:var(--position);text-decoration:none;white-space:pre"> projects due to technical failures (see Note 15.7).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:370.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As part of the Kreos / Claret Financing agreement, the Group has received loan commitments from Kreos and Claret for the tranches B </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:382.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and C, of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1311" decimals="-3" name="ifrs-full:UndrawnBorrowingFacilities" format="ixt:num-dot-decimal" scale="3" id="f-3360">25,000</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:146.51pt;position:var(--position);text-decoration:none;white-space:pre"> in aggregate principal amount each (subject to the conditions set forth in Note 15.1.). The B and C </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:394.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">tranches were drawn in March 2024 and June 2024, respectively. The Group redeemed all the tranches drawn as part of the Kreos / </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:406.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Claret Financing agreement during the year ended December 31, 2025.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:418.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As part of the Heights Financing agreement, the Group has received a loan commitment from Heights for the tranche B, of up to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:430.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1312" decimals="-3" name="ifrs-full:UndrawnBorrowingFacilities" format="ixt:num-dot-decimal" scale="3" id="f-3361">40,000</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:107.09pt;position:var(--position);text-decoration:none;white-space:pre"> in aggregate principal amount (subject to the conditions set forth in Note 15.2.). </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:430.91pt;position:var(--position);text-decoration:none;white-space:pre">On the limit date for the drawdown </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:442.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of the second tranche of the Heights Financing (i.e. August 4, 2024), the Group had not drawn down this tranche and has therefore </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:454.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">forgone its right to do so in the future. Tranche A was converted by the noteholders in July 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:421.5pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:478.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group has not received any significant off-balance sheet commitment and has no significant contingent asset as of December 31, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:490.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">2025.</span></div></ix:continuation><div style="position:absolute;top:526.16pt" id="i7a006daedb3d4216a4128b76247285d7_526"></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:526.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 27. <span id="i4808277e01e342d0bfeeaa8cd889b49e"></span></span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinancialRiskManagementExplanatory" id="f-3362" continuedAt="f-3362-1" escape="true"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Management and assessment of financial risks </span></ix:nonNumeric></div><ix:continuation id="f-3362-1" continuedAt="f-3362-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:550.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The principal financial instruments held by the Group are cash and cash equivalents. The purpose of holding these instruments is to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:561.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">finance the ongoing business activities of the Group. It is not the Group&#8217;s policy to invest in financial instruments for speculative </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:572.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">purposes. The Group does not use derivative financial instruments for hedging purposes. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:594.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The principal risks to which the Group is exposed to are liquidity risk, foreign currency exchange risk and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:462.51pt;position:var(--position);text-decoration:none;white-space:pre">credit</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.24pt;position:var(--position);text-decoration:none;white-space:pre"> risk. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:624.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Liquidity risk </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:646.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Liquidity risk management aims to ensure that the Group disposes of sufficient liquidity and financial resources to be able to meet </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:657.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">present and future obligations. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:679.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group prepares short-term cash forecasts and annual operating cash flow forecasts as part of its budget procedures.</span></div></ix:continuation></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-family:Arial, sans-serif;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt;word-wrap:break-word"><div style="position:var(--position);top:721.44pt"><div style="width:468pt"><div style="line-height:10pt;position:var(--position);top:47.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;white-space:pre"><span style="left:296.55pt;position:var(--position)">F-77<span style="display:inline-block;height:6.93pt;width:17.11pt"></span></span></span></div></div></div><div style="position:var(--position)"><div style="width:540pt"></div></div><div><ix:continuation id="f-3362-2"><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Prudent liquidity risk management involves maintaining sufficient liquidity, having access to financial resources through appropriate </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:81.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">credit facilities and being able to unwind market positions.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:104.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group&#8217;s operations have consumed substantial amounts of cash since inception. Developing pharmaceutical drug candidates, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:115.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">including conducting clinical trials, is expensive, lengthy and risky, and the Group expects its research and development expenses to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">increase substantially in connection with its ongoing activities. Accordingly, the Group will continue to require substantial additional </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:137.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">capital to continue its clinical development activities and potentially engage in commercialization activities.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:160.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group's estimate of its cash runway as of the date of approval of these financial statements is set forth in Note 2</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:500.59pt;position:var(--position);text-decoration:none;white-space:pre"> - Going concern.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:189.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Interest rate risk </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:212.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, following the full repayment of the Kreos 1 bonds, all the Group&#8217;s non-derivative financial liabilities </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:224pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">accounted for at amortized cost bore fixed interest rates. Therefore, the Group had limited exposure.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:246.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Over the year ended December 31, 2024, the Group had drawn down the second and third tranches of the Kreos / Claret Financing, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:257.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">bearing variable interest rates (consisting of a fixed margin of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:285.13pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1313" decimals="3" name="ifrs-full:BorrowingsAdjustmentToInterestRateBasis" scale="-2" id="f-3363">7.5</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:305.96pt;position:var(--position);text-decoration:none;white-space:pre"> + European Central Bank Base Rate (MRO), with a floor at </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:548.81pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1314" decimals="3" name="abvx:BorrowingsBasisInterestRate" scale="-2" id="f-3364">2.5</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:569.64pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:268.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and a cap at </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.92pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1315" decimals="2" name="abvx:BorrowingsBasisInterestRate" scale="-2" id="f-3365">4</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:99.25pt;position:var(--position);text-decoration:none;white-space:pre">) and had therefore performed a reassessment of its exposure to interest rate risk. Due to the interest rate collar having </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:280pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">a range of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:78.45pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1313" decimals="4" name="abvx:InterestRateCollarRange" scale="-4" id="f-3366">150</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:93.45pt;position:var(--position);text-decoration:none;white-space:pre"> bp, the Group concluded that it still had limited exposure.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:302.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2025, the Group had reimbursed all its interest-bearing liabilities.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:313.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group's investments are short-term, highly liquid, and predominantly classified within Cash &amp; cash equivalents.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:324.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Accordingly, the Group has very limited exposure to interest rate risk.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:354pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Foreign currency risk</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:123.67pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:370pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group is exposed to a risk of exchange rates fluctuations on commercial transactions performed in currencies different from the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:380pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">functional currency of the Group entity recording the transactions. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:402pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:60.44pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:62.94pt;position:var(--position);text-decoration:none;white-space:pre">December 31, 2025, the monetary assets and liabilities denominated in U.S. dollars held by the Company amounted to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:414pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:86.75pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1316" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-3367">327,222</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:162.84pt;position:var(--position);text-decoration:none;white-space:pre"> (of which cash and cash equivalents of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:322.67pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1316" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-3368">143,180</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:398.76pt;position:var(--position);text-decoration:none;white-space:pre"> and intercompany receivables</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:520.53pt;position:var(--position);text-decoration:none;white-space:pre"> of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:533.86pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1316" decimals="-3" name="ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties" format="ixt:num-dot-decimal" scale="3" id="f-3369">194,712</ix:nonFraction> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:426pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72.09pt;position:var(--position);text-decoration:none;white-space:pre">) and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.85pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1316" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-3370">24,368</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:165.94pt;position:var(--position);text-decoration:none;white-space:pre"> (of which intercompany payables of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:315.23pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1316" decimals="-3" name="ifrs-full:TradeAndOtherPayablesToRelatedParties" format="ixt:num-dot-decimal" scale="3" id="f-3371">22,726</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:386.32pt;position:var(--position);text-decoration:none;white-space:pre">)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:389.65pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:438pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As a result, a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90.66pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1317" decimals="2" name="abvx:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent" scale="-2" id="f-3372">10</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108.99pt;position:var(--position);text-decoration:none;white-space:pre"> adverse change in the euro c</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:224.95pt;position:var(--position);text-decoration:none;white-space:pre">losing exchange rate </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:309.56pt;position:var(--position);text-decoration:none;white-space:pre">against the U.S. dollar would have resulted in a foreign exchange </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:450pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">loss of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:64.88pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1317" decimals="-3" sign="-" name="abvx:SensitivityAnalysisForTypesOfMarketRisk10AdverseChangeInExchangeRateImpactOnForeignExchangeGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-3373">29,747</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:135.97pt;position:var(--position);text-decoration:none;white-space:pre">, while a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:172.59pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="number" contextRef="c-1317" decimals="2" name="abvx:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent" scale="-2" id="f-3374">10</ix:nonFraction>%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:190.92pt;position:var(--position);text-decoration:none;white-space:pre"> favorable change would have resulted in a foreign exchange gain of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:466.71pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1317" decimals="-3" name="abvx:SensitivityAnalysisForTypesOfMarketRisk10FavorableChangeInExchangeRateImpactOnForeignExchangeGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-3375">36,358</ix:nonFraction> thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:537.8pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:462pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The U.S. Subsi</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.53pt;position:var(--position);text-decoration:none;white-space:pre">diar</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.06pt;position:var(--position);text-decoration:none;white-space:pre">y does not hold any monetary asset or liability denominated in currencies different from its functioning currency </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:474pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(the U.S. dollar).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:498pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">At this stage, the Group has not adopted any recurring mechanism of hedging to protect its activity against currency fluctuations. From </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:508pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">time to time, the Group may nevertheless subscribe currency term accounts in order to cover a commitment in currency as described </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:518pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">above. The Group may consider in the future using a suitable policy to hedge exchange risks in a more significant manner if needed. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:546pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Credit risk </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:568pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The credit risk related to the Group&#8217;s cash and cash equivalents is not significant in light of the quality of the co-contracting financial </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:579.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">institutions. As of December 31, 2025, substantially all of the Group&#8217;s cash and cash equivalents were maintained with </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:514.1pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="financial_institution" contextRef="c-1318" decimals="INF" name="abvx:NumberOfFinancialInstitutionsToMaintainCash" format="ixt-sec:numwordsen" scale="0" id="f-3376">five</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:529.63pt;position:var(--position);text-decoration:none;white-space:pre"> financial </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:590.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">institutions in France and in the United States. While the Group&#8217;s deposit accounts are i</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:386.43pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">nsured up to the legal limit, the maintained </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:601.6pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">balances may, at times, exceed this insured limit. As of December </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:302.31pt;position:var(--position);text-decoration:none;white-space:pre">31, 2025, the Group maintained</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:429.43pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:431.93pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1318" decimals="-3" name="abvx:BalancesWithBanksInExcessOfLegallyInsuredLimit" format="ixt:num-dot-decimal" scale="3" id="f-3377">92,482</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:503.02pt;position:var(--position);text-decoration:none;white-space:pre"> in bank deposit </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:612.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">accounts that are in excess of the legally insured limit in </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:263.19pt;position:var(--position);text-decoration:none;white-space:pre"><ix:nonFraction unitRef="financial_institution" contextRef="c-1318" decimals="INF" name="abvx:NumberOfFinancialInstitutionsToMaintainCash" format="ixt-sec:numwordsen" scale="0" id="f-3378">five</ix:nonFraction></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:278.72pt;position:var(--position);text-decoration:none;white-space:pre"> legally insured financial institutions, in addition to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.42pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1319" decimals="-3" name="abvx:InvestmentsInMutualFundsAndStructuredNotes" format="ixt:num-dot-decimal" scale="3" id="f-3379">437,032</ix:nonFraction>&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:561.51pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:624pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">invested in mutual funds and structured notes, all invested with well-established financial institutions. The Group has not experienced </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:635.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">any losses in such accounts and does not believe that it is exposed to any significant credit risk related to these instruments.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:657.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The credit risk related to the Group&#8217;s </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:186.65pt;position:var(--position);text-decoration:none;white-space:pre">O</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:193.87pt;position:var(--position);text-decoration:none;white-space:pre">ther</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:209.96pt;position:var(--position);text-decoration:none;white-space:pre"> receivables and related accounts</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:344.24pt;position:var(--position);text-decoration:none;white-space:pre"> is minimal. In particular, the credit risk related to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:668.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">advances made to C</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:116.17pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">ROs (see Note 9) is</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:194.43pt;position:var(--position);text-decoration:none;white-space:pre"> deemed insignificant due to their credit ratings.</span></div></ix:continuation></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>abivax-20xfxex11bylaws6feb.htm
<DESCRIPTION>EX-1.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i862154528f724c1192f623e908a5c93a_1"></div><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">ABIVAX</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">A French </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Soci&#233;t&#233; Anonyme</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> (limited company) with share capital of &#8364;633,832.93</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Registered office&#58; 7-11 Boulevard Haussmann</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">75009 Paris </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Paris Trade and Companies Register No 799 363 718 </font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">_______________________________<br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">MEMORANDUM AND ARTICLES OF ASSOCIATION </font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Updated on February 6, 2025</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Certified as true to the original </font></div><div style="margin-bottom:12pt;text-align:right"><font><br></font></div><div style="padding-left:360pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#91;Signature&#93;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">____________________________</font></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Chief Executive Officer</font></div><div><font><br></font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">SECTION I<br>LEGAL FORM &#8211; COMPANY NAME &#8211; OBJECTS &#8211; REGISTERED OFFICE &#8211; TERM OF INCORPORATION</font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">LEGAL FORM</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Abivax (hereinafter, the &#8216;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8217;) is a French </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">soci&#233;t&#233; anonyme</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> (limited company) with a Board of Directors, which is governed by the laws and regulations in force and by these Articles.</font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">COMPANY NAME </font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The name of the Company is&#58;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">ABIVAX</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In all instruments and documents issued by the Company and intended for third parties, the company name must always be preceded or followed immediately and clearly by the words &#8216;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Soci&#233;t&#233; Anonyme</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8217; or the initials &#8216;SA&#8217;, the amount of share capital, the Company&#8217;s registration number and the Trade and Companies Register in which it is registered.</font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">REGISTERED OFFICE</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The registered office is at&#58; </font></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">7-11 Boulevard Haussmann, 75009 Paris.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">It may be transferred to any location within the same or a neighbouring county (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">d&#233;partement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">) by ordinary decision of the Board of Directors, subject to ratification of that decision by the shareholders at their next Ordinary General Meeting, and to any other location by decision taken by the shareholders at an Extraordinary General Meeting. If a transfer is decided by the Board of Directors, the Board is authorised to vary these Articles accordingly.</font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">OBJECTS</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s objects, directly or indirectly, in France and other countries, is&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7pt">to engage in all research, development and marketing activities in relation to therapeutic and prophylactic vaccines and small therapeutic molecules administered primarily to combat infection&#59; to acquire, subscribe for, hold, manage and transfer, in any form whatsoever, all shares and all transferable securities in all existing or new French or foreign companies, and generally to manage equity interests in the Company&#8217;s area of business&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7pt">to take part, directly or indirectly, in all operations and transactions that relate to, or are likely to promote the achievement of, any of the above objects, through the creation of new companies, contributions or the subscription or purchase of securities or members&#8217; rights, mergers, business alliances, joint ventures or otherwise&#59; and </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7pt">generally, to engage in all personal property, real estate, industrial, commercial and financial operations and transactions that relate directly or indirectly to this object or to any similar or related objects, or that may be useful for, or facilitate the achievement of, such object. </font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">TERM OF INCORPORATION</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Company is incorporated for a term of ninety-nine (99) years from the date it is registered in the Trade and Companies Register, unless it is wound up early or its term of incorporation is extended.</font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Page 2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">SECTION II<br>SHARE CAPITAL &#8211; SHARES</font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">SHARE CAPITAL </font></div></td></tr></table></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Contributions &#8211; Formation of share capital</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Upon the Company&#8217;s incorporation, by virtue of a legal document dated 4&#160;December 2013, the Company received cash contributions totalling forty thousand euros (&#8364;40,000), corresponding to 40,000 ordinary shares.</font></div><div style="margin-bottom:12pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.1pt">By decisions taken by the shareholders at their Extraordinary General Meeting of 25&#160;April 2014&#58;</font></div><div style="margin-bottom:12pt;padding-left:70.9pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.08pt">the share capital was increased as a result of a cash contribution of nine thousand two hundred and fifty-nine euros (&#8364;9,259), from &#8364;40,000 to &#8364;49,259, through the creation of 9,259 new ordinary shares&#59;</font></div><div style="margin-bottom:12pt;padding-left:70.9pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.03pt">the share capital was increased as a result of a cash contribution of thirteen thousand seven hundred and sixty euros (&#8364;13,760), from &#8364;49,259 to &#8364;63,019, through the creation of 13,760&#160;new ordinary shares&#59;</font></div><div style="margin-bottom:12pt;padding-left:70.9pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.98pt">the share capital was increased as a result of a cash contribution of five hundred and seventy-six euros (&#8364;576), from &#8364;63,019 to &#8364;63,595, through the creation of 576 new ordinary shares&#59; and</font></div><div style="margin-bottom:12pt;padding-left:70.9pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.58pt">the share capital was increased as a result of a cash contribution of two thousand four hundred euros (&#8364;2,400), from &#8364;63,595 to &#8364;65,995 euros, through the creation of 2,400 new ordinary shares.</font></div><div style="margin-bottom:12pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.1pt">By decision taken by the Board of Directors on 21&#160;May 2014, pursuant to the authority delegated to the Board by the shareholders at their Combined General Meeting of 11&#160;March 2014, the share capital was increased by five hundred and fifty-five euros (&#8364;555), from &#8364;65,995 to &#8364;66,550, through the creation of 555 new ordinary shares.</font></div><div style="margin-bottom:12pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.1pt">By decisions taken by the shareholders at their Extraordinary General Meeting of 30&#160;July 2014, the share capital was increased in cash by three million two hundred and fifty thousand (3,250,000) euros, from sixty-six thousand five hundred and fifty (66,550) euros to sixty-nine thousand one hundred and fifty (69,150) euros, through the issue of 2,600 new ordinary shares.</font></div><div style="margin-bottom:12pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.1pt">By decision taken by the shareholders at their Extraordinary General Meeting of 20&#160;February 2015, the par value of the shares that made up the share capital of the Company was divided by 100, thus reducing the par value from one (1) euro to one (1) euro cent (&#8364;0.01).</font></div><div style="margin-bottom:12pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.1pt">As a result of the exercise of 28 &#8216;BCE-2014-5&#8217; founders&#8217; warrants on 24&#160;April 2015, which was recorded by the Board of Directors in a decision of 3&#160;June 2015, the share capital was increased by twenty-eight euros (&#8364;28), from sixty-nine thousand one hundred and fifty euros (&#8364;69,150) to sixty-nine thousand one hundred and seventy-eight euros (&#8364;69,178).</font></div><div style="margin-bottom:12pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.1pt">By decision taken by the Board of Directors on 23&#160;June 2015, pursuant to the authority delegated to the Board by the shareholders at their Combined General Meeting of 20&#160;February 2015, the share capital was increased on 25&#160;June 2015 by twenty-seven thousand and seventy euros and eighty-nine cents (&#8364;27,070.89), from sixty-nine thousand one hundred and seventy-eight euros (&#8364;69,178) to ninety-six thousand two hundred and forty-eight euros and eighty-nine cents (&#8364;96,248.89), through the issue of 2,707,089 new shares.</font></div><div style="margin-bottom:12pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.1pt">As a result of the exercise of 64 &#8216;BSA-2014-3&#8217; share warrants on 25&#160;September 2015 and of 448 &#8216;BSA-2014-2&#8217; share warrants on 26&#160;September 2015, which was recorded by the Board of Directors in </font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Page 3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:28.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">a decision of 4&#160;December 2015, the share capital was increased by five hundred and twelve euros (&#8364;512), from ninety-six thousand two hundred and forty-eight euros and eighty-nine cents (&#8364;96,248.89) to ninety-six thousand seven hundred and sixty euros and eighty-nine cents (&#8364;96,760.89).</font></div><div style="margin-bottom:12pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.1pt">As a result of the exercise of 208 &#8216;BCE-2014-3&#8217; founders&#8217; warrants on 22&#160;December 2015, which was recorded by the Board of Directors in a decision of 18&#160;January 2016, the share capital was increased by two hundred and eight euros (&#8364;208), from ninety-six thousand seven hundred and sixty euros and eighty-nine cents (&#8364;96,760.89) to ninety-six thousand nine hundred and sixty-eight euros and eighty-nine cents (&#8364;96,968.89).</font></div><div style="margin-bottom:12pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.1pt">As a result of the exercise of 52 &#8216;BSA-2014-6&#8217; share warrants on 11&#160;April 2016, which was recorded by the Board of Directors in a decision of 7&#160;November 2016, the share capital was increased by fifty-two euros (&#8364;52), from ninety-six thousand nine hundred and sixty-eight euros and eighty-nine cents (&#8364;96,968.89) to ninety-seven thousand and twenty euros and eighty-nine cents (&#8364;97,020.89).</font></div><div style="margin-bottom:12pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.6pt">As a result of the exercise of 394 &#8216;BSA-2014-1&#8217; share warrants on 17&#160;March 2017, 473 &#8216;BSA-2014-4&#8217; share warrants on 1&#160;August 2017, 100 &#8216;BCE-2014-4&#8217; founders&#8217; warrants on 1&#160;August 2017 and 400 &#8216;BCE-2014-2&#8217; founders&#8217; warrants on 28&#160;September 2017, and as a result of the exercise of 60,000 Kepler share warrants, which was recorded by the Board of Directors on 20&#160;November 2017, the share capital was increased by one thousand nine hundred and sixty-seven euros and forty cents (&#8364;1,967.40), from ninety-seven thousand and twenty euros and eighty-nine cents (&#8364;97,020.89) to ninety-eight thousand nine hundred and eighty-eight euros and twenty-nine cents (&#8364;98,988.29).</font></div><div style="margin-bottom:12pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.6pt">As a result of the exercise of 29 &#8216;BSA-2014-7&#8217; share warrants on 30&#160;October 2017 and 2,500 &#8216;BCE-2016-1&#8217; founders&#8217; warrants on 20&#160;December 2017, which was recorded by the Board of Directors on 22&#160;January 2018, the share capital was increased by fifty-four euros (&#8364;54), from ninety-eight thousand nine hundred and eighty-eight euros and twenty-nine cents (&#8364;98,988.29) to ninety-nine thousand and forty-two euros and twenty-nine cents (&#8364;99,042.29).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Share capital</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The share capital of the Company is set at six hundred and thirty-three thousand eight hundred and thirty-two euros and ninety-three cents (EUR 633,832.93).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">It is divided into sixty-three million three hundred and eighty-three thousand two hundred and ninety-three (63,383,293) fully subscribed and paid-up ordinary shares of the same class, with a par value of one euro cent (&#8364;0.01) each.</font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">ALTERATION OF SHARE CAPITAL</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">1 - The share capital may be increased by any method and on any terms provided for by law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The shareholders at an Extraordinary General Meeting have exclusive authority to decide, on the basis of a report by the Board of Directors, to increase the share capital and to delegate powers or authority to the Board of Directors in order to carry out the capital increase in one or more stages in accordance with applicable laws and regulations, set the applicable terms, record the completion thereof and vary these Articles accordingly. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The shareholders have a preferential right to subscribe for the shares issued for cash in the context of a capital increase, in proportion to the number of shares they already hold, and they may each waive their right. The shareholders at an Extraordinary General Meeting may decide to cancel this preferential subscription right in accordance with the law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">2 - A capital reduction must be authorised or decided by the shareholders at an Extraordinary General Meeting and must not affect shareholder equality under any circumstances.</font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Page 4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">A capital reduction to an amount less than the minimum required by law may be decided on the condition that the share capital is first increased to an amount at least equal to the amount required by law, unless the legal form of the Company is changed to a form that does not require a share capital higher than that after the reduction thereof.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Otherwise, any interested person may petition a court of law to wind up the Company. A decision to that effect may not be made if, on the day on which the Court decides on the merits of the application, the matter has been resolved.</font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">CAPITAL REDEMPTION</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The share capital may be redeemed in accordance with Article L.&#160;225-198 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">et seq</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">. of the French Commercial Code.</font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">PAYMENT FOR SHARES</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In the event of a capital increase, at least one quarter of the par value of the shares issued for cash must be paid up upon subscription, together with the entire share premium (if applicable).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The balance must be paid in one or more instalments further to a call made by the Board of Directors, within five (5) years of the date of completion of the capital increase.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Calls for monies unpaid must be sent to the relevant subscribers and shareholders at least fifteen (15) days before the due date for each payment, by registered letter (with acknowledgement of receipt requested).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Any shareholder that does not make the required payments in respect of their shares on the due date will be automatically liable, without notice, to pay the Company default interest calculated daily from the payment due date, at three (3) points above the statutory rate applicable in commercial matters.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In order to obtain monies unpaid, the Company has the right of enforcement and may impose the penalties provided for by Article L.&#160;228-27 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">et seq</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">. of the French Commercial Code.</font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">FORM OF SHARES </font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The shares may be bearer or registered shares, at the option of the shareholder and in accordance with the law. They shall be registered in an account in accordance with applicable laws and regulations. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Subject to compliance with the terms and conditions provided for by law, the shares shall be registered in the name of their holders and at their discretion, either in a registered account managed by the issuing company, in a registered account managed by an outside entity or in bearer form with an approved intermediary. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">However, if a shareholder does not have their registered address in French territory within the meaning of Article&#160;102 of the French Civil Code, any intermediary may be registered on behalf of that holder, either in a collective account or in several individual accounts, one for each holder.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The shares may be involved in transactions carried out by the relevant securities clearing house.</font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">SHARE TRANSFERS &#8211; NOTIFICATION OF MAJOR HOLDINGS &#8211; RIGHTS AND OBLIGATIONS ATTACHING TO SHARES </font></div></td></tr></table></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Share transfers</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The shares shall be freely negotiable upon issue, in accordance with the law.</font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Page 5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">They shall be registered in an account in accordance with the terms and conditions provided for by the laws and regulations in force.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Share transfers, irrespective of the form thereof, shall be carried out by way of a transfer from one account to another in accordance with the terms and conditions provided for by law. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Notification of major holdings </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In addition to the statutory obligations to disclose information, to give notice of major holdings and, where applicable, to declare their intent, any natural or legal person and any legal entity, acting alone or in concert, who directly or indirectly holds, by any means whatsoever within the meaning of Article L.&#160;233-7 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">et seq</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">. of the French Commercial Code, a number of shares that represents 2% of the share capital and&#47;or voting rights in the Company, is required to inform the Company of the total number of shares and voting rights or securities they hold directly or indirectly and that grant future access to the share capital of the Company. Such notice must be sent by registered letter (with acknowledgement of receipt requested) to the registered office or by any other equivalent means for the shareholders or securities holders who are resident outside France, within five (5) trading days of the date on which this threshold is exceeded. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Such notice must be given again for each additional 2% of the share capital or voting rights, without limitation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">This disclosure obligation applies on the above terms each time the fraction of share capital and&#47;or voting rights held by a shareholder falls below a multiple of 2% of the share capital or voting rights.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If no disclosure is duly made as stated above, further to a request made by one or more shareholders that hold at least 2% of the share capital or voting rights in the Company and that is recorded in the minutes of the General Meeting, the shares that exceed the percentage that should have been declared will be stripped of the right to vote at any Meeting of shareholders held within two (2) years of the date on which notice is given. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Rights and obligations associated with shares </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">1 - Each share entitles its holder to a portion of the Company&#8217;s profit, assets and liquidation surplus, in net proportion to the percentage of share capital it represents.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">It also entitles its holder to take part in General Meetings and to vote on resolutions in accordance with the law and these Articles.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">2 - Shareholder liability for the Company&#8217;s debts is limited to the amounts contributed by them. The rights and obligations attaching to shares shall remain attached thereto, irrespective of the holder.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Share ownership automatically entails acceptance of, and an agreement to comply with, these Articles and the decisions taken at General Meetings of the Company&#8217;s shareholders.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">3 - Whenever it is necessary to hold several shares in order to exercise a right of whatever kind (exchange, pooling, allotment of securities, capital increase or reduction, merger or any other corporate operation), the holders of single shares or of an insufficient number of shares may exercise this right on the condition that they arrange to pool and potentially purchase or sell the required number of securities.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Indivisibility of shares &#8211; Legal ownership &#8211; Beneficial ownership </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">1 - The Company recognises only one holder of each share.</font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Page 6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The joint owners of undivided shares must be represented at General Meetings by one of their number or by a single representative. In the event of a disagreement, a representative shall be appointed by a court of law at the request of the first joint owner to act.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">2 - Beneficial owners (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">usufruitiers</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">) have the right to vote at Ordinary General Meetings and legal owners (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">nus-propri&#233;taires</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">) have the right to vote at Extraordinary General Meetings. However, the shareholders may agree to allocate the right to vote at General Meetings differently, providing that the beneficial owner is not deprived of the right to vote on decisions concerning distributions of profit. In such event, they must inform the Company of their agreement by sending a registered letter (with acknowledgement of receipt requested) to the registered office. The Company must apply the agreement for any meeting held more than one (1) month after that letter was received.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Voting rights shall be exercised by the holder of the securities pledged.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Legal owners may always take part in General Meetings, even if they do not have the right to vote. </font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">DOUBLE VOTING RIGHT</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The voting right attached to capital shares and dividend shares is proportionate to the amount of share capital they represent. Each share carries one voting right. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">However, a double voting right compared to that attached to the other shares in view of the portion of share capital they represent is allocated to all fully paid-up shares that are proven to have been registered for at least two (2) years in the name of the same shareholder.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">This double voting right shall also be granted, upon the issue of shares issued in the context of a capital increase through the capitalisation of reserves, profit or share premiums, in respect of the registered shares allotted to a shareholder free of charge on the basis of their existing shares for which they hold a double voting right.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">A share transfer carried out as a result of an inheritance, division of marital property or </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">inter vivos </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">gift made to a spouse or relative entitled to inherit will not result in the loss of the right acquired and will not suspend the above period.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The foregoing shall also apply in the event of a share transfer carried out as a result of a merger or spin-off involving a corporate shareholder.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In addition, any merger or spin-off involving the Company will not affect the double voting right, which may be exercised within the beneficiary company or companies if so provided by the Articles of the relevant company or companies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">SECTION III<br>MANAGEMENT</font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">BOARD OF DIRECTORS</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Company shall be managed by a Board of Directors made up of no less than three (3) and no more than eighteen (18) members, subject to the exception provided for by law in the event of a merger. </font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">DIRECTORSHIPS</font></div></td></tr></table></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Page 7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Appointment of directors</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">During the Company&#8217;s existence, the directors shall be appointed by the shareholders at an Ordinary General Meeting. However, in the event of a merger or spin-off, they may be appointed by the shareholders at an Extraordinary General Meeting. The directors shall be appointed for a term of four (4) years. Their term of office shall end at the close of the Ordinary General Meeting of shareholders held in the year in which their term of office expires to decide on the financial statements for the previous financial year.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The directors may be re-elected. They may be removed at any time by decision of the shareholders taken at an Ordinary General Meeting.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">No individual over the age of eighty-five (85) may be a director. Any director who reaches this age limit whilst in office will be deemed to have automatically stepped down at the next General Meeting. Any appointment made in breach of the foregoing will be null and void, with the exception of interim appointments. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Upon their appointment and throughout their term of office, all natural person directors must comply with the law on the offices which an individual may concurrently hold in a limited company that has its registered office in mainland France, subject to the exceptions provided for by law. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">An employee of the Company may only be appointed as a director if their employment contract corresponds to an actual job position. No more than one third of the directors in office may have an employment contract with the Company.</font></div><div style="margin-bottom:12pt;padding-left:3.6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">14.2 Legal entity directors</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The directors may be natural persons or legal entities. Upon the appointment of a legal entity, the latter must appoint a permanent representative, who shall be bound by the same requirements and obligations and shall incur the same liability in civil and criminal law as though they were a director in their own name, without prejudice to the joint and several liability of the legal entity they represent. The permanent representative of a legal entity director shall be subject to the same age limit as that applicable to natural person directors. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The permanent representative appointed by a legal entity director shall be appointed for the term of the legal entity&#8217;s directorship. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If the legal entity removes its permanent representative from office, it must promptly notify the Company of the removal and of the identity of its new permanent representative by registered letter. The foregoing shall also apply if the permanent representative dies or resigns.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The appointment of a permanent representative and the termination of their office shall be subject to the same publicity formalities as would apply if the permanent representative were a director in their own name. </font></div><div style="margin-bottom:12pt;padding-left:3.6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">14.3 Board vacancies, death, resignation </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If one or more seats on the Board of Directors become vacant due to death or resignation, the Board may appoint interim directors between two General Meetings.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If the number of directors falls below the minimum required by law, the remaining directors must immediately convene an Ordinary General Meeting in order to fill the vacancies.</font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Page 8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Interim appointments made by the Board shall be subject to ratification by the shareholders at their next Ordinary General Meeting. In the absence of ratification, the decisions and steps taken previously by the Board shall nevertheless remain valid.</font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">ORGANISATION AND DECISIONS OF THE BOARD</font></div></td></tr></table></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Chairman of the Board</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Board of Directors shall elect a Chairman from among its members, who must be a natural person, failing which their appointment will be null and void. The Board of Directors shall determine the Chairman&#8217;s remuneration in accordance with applicable laws and regulations. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Chairman of the Board shall organise and oversee the work of the Board and report thereon to the shareholders at a General Meeting. The Chairman shall ensure that the Company&#8217;s bodies operate as required, and, in particular, that the directors are able to fulfil their duties.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Chairman of the Board must be less than eighty-five (85) years of age. If the Chairman reaches this age limit whilst in office, they will be deemed to have automatically stepped down and a new Chairman must be appointed in accordance with this Article.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Chairman shall be appointed for a term of office that must not exceed the term of their directorship, and they may be re-elected. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Board of Directors may remove the Chairman from office at any time. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If the Chairman is subject to a temporary impediment or dies, the Board of Directors may appoint a director to fulfil the duties of Chairman.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In the event of a temporary impediment, this authority shall be given for a limited period and may be renewed. If the Chairman dies, it shall apply until such time as a new Chairman has been elected. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Board meetings</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Board of Directors shall meet as often as required in the interests of the Company, further to a meeting notice sent by the Chairman or two directors.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If the Board has not met for more than two (2) months, a minimum of one third of Board members may ask the Chairman to convene a Board meeting to decide on a specific agenda. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Chief Executive Officer may also ask the Chairman to convene a Board meeting to decide on a specific agenda. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Chairman shall be bound by any requests made to them pursuant to the previous two paragraphs. Meetings may be convened by any means, including verbally. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Board shall meet at the registered office or at such other location (in France or another country) as may be stated in the meeting notice, and meetings shall be chaired by the Chairman of the Board or, if the Chairman is subject to an impediment, by a member appointed by the Board to act as Chairman. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Chairman of the Board shall chair meetings. If the Chairman is subject to an impediment, the Board shall appoint a member present at the meeting to act as Chairman.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">At each meeting, the Board may appoint a secretary, who may but need not be a member of the Board. </font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Page 9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">A register shall be kept and must be signed by the directors who take part in each Board meeting.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The directors, as well as any person who is invited to attend a Board meeting, shall be bound by a duty of discretion with regard to information and data that are designated as confidential by the Chairman.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Quorum and majority</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Board may only validly transact business if at least one half of the directors are present or deemed present, subject to the changes made by the Board&#8217;s rules of procedure for meetings held by video-conference or other method of telecommunication.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Unless these Articles state otherwise and subject to the changes made by the Board&#8217;s rules of procedure for meetings held by video-conference or other method of telecommunication, decisions must be taken by a majority of the votes cast by the members present, deemed present or represented. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In the event of a tie, the Chairman shall have a casting vote.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">For the purpose of calculating the quorum and majority, the directors who take part in a Board meeting by video-conference or method of telecommunication in accordance with the Board&#8217;s rules of procedure shall be deemed present. However, directors must be present in person or by proxy for all Board decisions concerning the approval of the annual and consolidated financial statements, the drafting of the management report and the group management report (if applicable) and decisions concerning the removal of the Chairman of the Board of Directors, the Chief Executive Officer and the Deputy Chief Executive Officer.</font></div><div><font><br></font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Page 10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Furthermore, one half of the directors in office may object to a Board meeting being held by video-conference or method of telecommunication. Notice of any such objection must be given in the form and within the time limit stated in the Board&#8217;s rules of procedure and&#47;or imposed by applicable law or regulations. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Representation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Any director may give another director written permission to represent them at a Board meeting. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">At any given meeting, each director may only hold one proxy form received pursuant to the previous paragraph. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">These provisions apply to the permanent representative of a legal entity director.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Written consultations </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Board of Directors may also make certain decisions within its remit by virtue of a written consultation, in accordance with the laws and regulations in force. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In the event of a written consultation, the Chairman of the Board must send, by any means, including electronically, each of the directors, the statutory auditors and any representatives of the Economic and Social Committee, such documents as are needed to make decisions concerning items included on the agenda of the consultation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The directors shall have such period of time as shall be stated in the relevant documents in which to cast their vote and to submit their observations to the Chairman, by any written means, including electronically.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Any director that does not respond within the specified time limit (which, if not stated in the relevant documents, shall be five (5) days from the date of transmission of the documents) shall be deemed to have abstained.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Minutes of written consultations shall be drawn up and signed by the Chairman&#59; they must then be sent along with each director&#8217;s response to the Company and retained in the same way as the minutes of Board meetings.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Minutes of decisions </font></div><div style="margin-bottom:12pt;padding-left:3.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Decisions taken by the Board of Directors shall be recorded in minutes entered in a special minute book, the pages of which must be initialled and signed, and which shall be held at the registered office as required by applicable regulations. </font></div><div><font><br></font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Page 11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">POWERS OF THE BOARD OF DIRECTORS &#8211; COMMITTEES &#8211; OBSERVERS</font></div></td></tr></table></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Powers of the Board of Directors</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Board of Directors shall determine and oversee the implementation of the Company&#8217;s business strategy in its corporate interests, with consideration to be given to the social and environmental challenges associated with its business.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Subject to the powers expressly conferred on the shareholders and within the limit of the Company&#8217;s objects, the Board of Directors shall attend to all matters relating to the smooth running of the Company and shall settle matters concerning the Company by virtue of its decisions. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In dealings with third parties, the Company shall be bound even by the acts of the Board of Directors that fall outside the scope of its objects, unless it can prove that the third party involved knew that a particular act was outside the scope of the Company&#8217;s objects or could not have disregarded such fact in view of the circumstances, on the understanding that the publication of these Articles alone will not be sufficient proof of the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Board of Directors shall carry out such controls and checks as it deems appropriate.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Chairman or the Chief Executive Officer is required to provide each director with the information needed to fulfil their duties. Each director may obtain such documents as they consider useful from the Chairman or the Chief Executive Officer.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to the decisions taken by the shareholders at their General Meeting of 19&#160;June 2020, the Board may vary these Articles as it sees fit in order to render them compliant with the laws and regulations in force, subject to ratification of the relevant decision by the shareholders at their next Extraordinary General Meeting. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Committees</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Board of Directors may decide to set up committees responsible for examining and issuing an opinion on matters put to them by the Board or its Chairman. These committees shall report to the Board on their work.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Board of Directors shall set the composition and duties of the committees, which shall operate under the responsibility of the Board. The Board shall set the remuneration of the committee members. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Observers</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">During the Company&#8217;s existence, the shareholders at an Ordinary General Meeting or the Board of Directors may appoint observers, who may but need not be shareholders.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">No more than three (3) observers may be appointed. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">They shall be appointed for a period of one (1) year. Their duties will end at the close of the Ordinary General Meeting held in the year in which their mandates expire in order for the shareholders to decide on the financial statements for the previous financial year.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Any outgoing observer may be re-elected providing that they fulfil the requirements imposed under this Article. Their mandates may be renewed by decision taken by the shareholders at an Ordinary General Meeting or by the Board of Directors.</font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Page 12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Page 13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The observers may be removed and replaced at any time by the shareholders at an Ordinary General Meeting or by the Board of Directors, in which case they will not be entitled to any compensation. The duties of observers will also end due to the death or incapacity of a natural person member or the winding-up or compulsory administration of a legal entity member, or their resignation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">They may be natural persons or legal entities. In the latter case, upon its appointment, the legal entity must appoint a permanent representative, who shall be bound by the same requirements and obligations and shall incur the same liability in civil and criminal law as though they were an observer in their own name, without prejudice to the joint and several liability of the legal entity they represent. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The observers must strictly enforce these Articles and put forward their observations at Board meetings. They shall generally provide an ongoing advisory and monitoring service to the Company. However, they must not interfere under any circumstances in the management of the Company or generally act in place of the Company&#8217;s statutory bodies. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In the context of their work, the observers may notably&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7pt">put forward observations to the Board of Directors&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7pt">ask to peruse any of the Company&#8217;s books, records, registers and documents at the registered office&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7pt">request and obtain such information as is useful for their work from senior management and the Company&#8217;s statutory auditor&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7pt">present a report on a specific matter to the shareholders at a General Meeting at the request of the Board. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The observers shall act both individually and collectively solely in an advisory capacity and shall not have the right to vote on the Board.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The observers may be invited to each Board meeting in the same way as the directors.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Decisions taken by the Board of Directors shall be valid notwithstanding any failure to invite an observer or members to a Board meeting or to provide them with documents prior to the meeting.</font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">SENIOR MANAGEMENT &#8211; DELEGATION OF POWERS </font></div></td></tr></table></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Senior management</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In accordance with the law, the Company shall be managed, under its responsibility, either by the Chairman of the Board of Directors or by another individual appointed by the Board of Directors with the title of Chief Executive Officer.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Board of Directors shall choose between the two management methods at any time and at least upon the expiry of the term of office of the Chief Executive Officer or of the Chairman of the Board of Directors if the latter is also the senior manager of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The shareholders and third parties must be informed of this decision in accordance with the applicable decree. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Board&#8217;s decision concerning the choice of management method must be taken by a majority of the directors present, represented or deemed present, on the understanding that the Chairman will not have a casting vote, subject to the specific provisions of Article 15.3 above if the directors take part in the Board meeting by video-conference or other method of telecommunication.</font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Page 14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If the Company is managed by the Chairman of the Board of Directors, the following provisions concerning the Chief Executive Officer shall apply to the Chairman.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Chief Executive Officer</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Chief Executive Officer has the broadest powers to act in all circumstances in the name of the Company. They shall exercise these powers within the limit of the Company&#8217;s objects and subject to the powers expressly conferred by law on the shareholders at a General Meeting and on the Board of Directors.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Chief Executive Officer shall represent the Company in its dealings with third parties. The Company shall be bound even by the acts of the Chief Executive Officer that do not come within the scope of its objects, unless it can prove that the third party concerned knew that a particular act was not within the scope of its objects or could not have disregarded such fact in view of the circumstances, on the understanding that the publication of these Articles alone will not be sufficient proof of the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If the Board of Directors chooses to separate the duties of Chairman and Chief Executive Officer, it shall appoint the Chief Executive Officer, set their term of office, determine their remuneration in accordance with the laws and regulations in force and, if applicable, set restrictions on their powers.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">No-one aged seventy-five (75) or over may be appointed as Chief Executive Officer. The Chief Executive Officer&#8217;s term of office will automatically end at the annual Ordinary General Meeting convened to approve the Company&#8217;s financial statements and held after the date on which the Chief Executive Officer reaches such age. Subject to this reservation, the Chief Executive Officer may be re-elected.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Chief Executive Officer may be removed from office at any time by the Board of Directors. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Deputy Chief Executive Officers </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">On a proposal by the Chief Executive Officer, whether they are also the Chairman of the Board of Directors or a different person, the Board of Directors may appoint one or more individuals as Deputy Chief Executive Officers &#8211; who may but need not be directors or shareholders &#8211; to assist the Chief Executive Officer.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">There may not be more than five (5) Deputy Chief Executive Officers. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If a Deputy Chief Executive Officer is a director, their term of office shall not exceed the term of their directorship.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">No-one aged seventy-five (75) or over may be appointed as Deputy Chief Executive Officer. The Deputy Chief Executive Officer&#8217;s term of office will automatically end at the annual Ordinary General Meeting convened to approve the Company&#8217;s financial statements and held after the date on which the Deputy Chief Executive Officer reaches such age. Subject to this reservation, the Deputy Chief Executive Officer may be re-elected.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Deputy Chief Executive Officers may be removed from office at any time by the Board of Directors, on a proposal by the Chief Executive Officer.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In agreement with the Chief Executive Officer, the Board of Directors shall determine the scope and term of validity of the powers conferred on the Deputy Chief Executive Officers. The Board of Directors shall determine their remuneration in accordance with the law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In dealings with third parties, the Deputy Chief Executive Officers shall have the same powers as the Chief Executive Officer.</font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Page 15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If the Chief Executive Officer ceases or is unable to perform their duties, unless the Board of Directors decides otherwise, the Deputy Chief Executive Officers shall retain their duties and responsibilities until a new Chief Executive Officer has been appointed.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Delegation of powers </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Board of Directors may appoint agents &#8211; who may but need not be directors &#8211; to perform such occasional or permanent tasks as shall be determined by the Board, delegate powers to those agents and set their remuneration as it sees fit.</font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">DIRECTORS&#8217; REMUNERATION </font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The shareholders at a General Meeting may allocate an annual fixed amount to the directors as remuneration for their work, which the shareholders shall determine without being bound by previous decisions. Any such remuneration shall be booked as operating expenses.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Board of Directors shall distribute the full allotted amount between its members as it sees fit. It may notably allot to the directors who are members of specialist committees an amount higher than that allotted to the other directors.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Board of Directors may allot exceptional fees in connection with the tasks or assignments allocated to directors.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Board may authorise the reimbursement of the travel and other expenses incurred by the directors in the Company&#8217;s interests.</font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">AGREEMENTS BETWEEN THE COMPANY AND A DIRECTOR, THE CHIEF EXECUTIVE OFFICER, A DEPUTY CHIEF EXECUTIVE OFFICER OR A SHAREHOLDER THAT HOLDS MORE THAN 10% OF VOTING RIGHTS</font></div></td></tr></table></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Agreements subject to authorisation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Any agreement other than those concerning ordinary transactions entered into under arm&#8217;s length conditions that is entered into directly or through an intermediary between the Company and one of its directors, the Chief Executive Officer, a Deputy Chief Executive Officer or a shareholder that holds more than 10% of voting rights in the Company or, in the case of a legal entity shareholder, the company that controls it within the meaning of Article L.&#160;233-3 of the French Commercial Code, are subject to the prior authorisation of the Board of Directors.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The foregoing also applies to agreements in which any of the persons referred to in the previous paragraph has an indirect interest.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Agreements entered into between the Company and an undertaking are also subject to prior authorisation if the Chief Executive Officer, a Deputy Chief Executive Officer or a director of the Company is the owner, a partner or shareholder with unlimited liability, a manager, a director, a Supervisory Board member or, generally, an executive of that undertaking.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">These agreements must be authorised and approved as required by law.</font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Page 16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Prohibited agreements</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The directors other than legal entity directors are prohibited from taking out any form of loan with the Company, from having the Company grant them an overdraft on a current account or otherwise, and from having the Company guarantee or endorse their commitments to third parties, failing which the relevant agreement will be null and void.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The same prohibition applies to the Chief Executive Officer, the Deputy Chief Executive Officers and the permanent representatives of legal entity directors. It also applies to the spouses, ascendants and descendants of the persons referred to in this Article and to any intermediary.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Ordinary agreements</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Agreements concerning ordinary operations that are entered into under arm&#8217;s length conditions are not subject to the statutory authorisation and approval procedure. </font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">SECTION IV<br>AUDITS OF THE COMPANY&#8217;S FINANCIAL STATEMENTS</font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">APPOINTMENT OF STATUTORY AUDITORS</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s financial statements shall be audited by one or more principal &#8211; and, if applicable, alternate &#8211; statutory auditors, who shall be appointed and who shall perform their duties as required by law. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">During the Company&#8217;s existence, the statutory auditors shall be appointed by the shareholders at an Ordinary General Meeting.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">For each principal statutory auditor, an alternate statutory auditor may be appointed. Any alternate statutory auditors shall be appointed at the same time as the principal statutory auditors and for the same term, and shall replace the principal statutory auditors if the latter refuse to act, are subject to an impediment, resign or die.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The statutory auditors shall be appointed for six (6) financial years by the shareholders at an Ordinary General Meeting. Their engagements will expire after the Ordinary General Meeting held to decide on the financial statements for the sixth financial year.</font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">STATUTORY AUDITORS&#8217; DUTIES</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The statutory auditors are vested with the duties and powers conferred on them by the laws and regulations in force. They may carry out such checks and audits as they consider appropriate at any time of the year. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The statutory auditors must be convened to all shareholder meetings at the latest at the same time as the shareholders themselves.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The statutory auditors&#8217; remuneration shall be determined in accordance with the regulations in force.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">They must be convened to the Board of Directors&#8217; meeting at which the Board approves the financial statements for the previous year and, if applicable, to any other Board meeting, at the same time as the directors themselves.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The statutory auditors must be convened by registered letter (with acknowledgement of receipt requested).</font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Page 17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">SECTION V<br>SHAREHOLDER MEETINGS</font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">QUORUM AND MAJORITY</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">At General Meetings, the shareholders shall transact business in accordance with the law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Ordinary and Extraordinary General Meetings shall be held when convened for the first &#8211; or second if applicable &#8211; time in accordance with the quorum requirements imposed by law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Decisions taken at General Meetings must be taken in accordance with the majority requirements imposed by law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The shareholders at an Ordinary General Meeting shall make all decisions other than those that are within the exclusive remit of the shareholders at an Extraordinary General Meeting according to the law and these Articles.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The shareholders at an Extraordinary General Meeting have exclusive remit to vary the provisions of these Articles, subject to the provisions of Articles 3 and 16 hereof.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If a meeting is held by video-conference or other method of telecommunication permitted by law in accordance with Article&#160;23 below, for the purpose of calculating the quorum and majority, the shareholders who take part in the meeting by video-conference or method of telecommunication will be deemed to be present.</font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">NOTICE OF GENERAL MEETINGS</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">General meetings shall be convened by the Board of Directors, by the statutory auditors or by an agent appointed by a court of law in accordance with the terms and conditions provided for by law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">They shall be held at the registered office or at such other location as may be stated in the meeting notice.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">For so long as the shares in the Company are admitted to trading on a regulated market or if the shares are not all registered shares, the Company is required, at least thirty-five (35) days before any meeting, to publish notice of the meeting &#8211; such notice to contain the information required by the laws and regulations in force &#8211; in the </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Bulletin des Annonces L&#233;gales Obligatoires</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> (BALO, the Gazette of Compulsory Legal Announcements).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">General Meetings must be convened through publication of a notice in a newspaper authorised to publish legal announcements in the county in which the registered office is located and in the </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Bulletin des Annonces L&#233;gales Obligatoires</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> (BALO).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">However, in place of the notices published as stated in the previous paragraph, notice may be given, at the Company&#8217;s expense, by letter sent by ordinary post or registered letter to each shareholder. Notice may also be given electronically in accordance with the regulations in force.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Any shareholder may also, if the Board so decides when a meeting is convened, take part in and vote at meetings held by video-conference or any method of telecommunication by which they can be identified, in accordance with the terms and conditions of the laws and regulations in force. </font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Page 18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Any meeting that is not convened as required may be cancelled. However, action to declare a meeting null and void will be inadmissible if all the shareholders were present or represented.</font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">MEETING AGENDA</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The agenda of a meeting shall be set by the person who convenes the meeting.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">However, one or more shareholders representing at least 5% of the share capital (or a group of shareholders that fulfil the requirements imposed by law) may, in accordance with the law, ask for draft resolutions to be added to the agenda of a meeting. Such requests must be sent along with the draft resolutions and may or may not be sent along with a brief explanation of the reasons for the request.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Such draft resolutions, of which the shareholders must be informed, shall be added to the agenda and put to the vote at the meeting. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">At the meeting, the shareholders may only discuss items included on the agenda.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Nonetheless, they may remove and replace one or more directors in any circumstances.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The agenda of a reconvened meeting must be identical to the agenda of the meeting originally convened.</font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">ADMISSION TO MEETINGS</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Any shareholder may take part, in person, by proxy or by correspondence, in all types of General Meetings.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In order to be entitled to take part in General Meetings, the shareholders must produce proof of the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7pt">for registered shares, that they were registered, within the time limit imposed by law prior to the Meeting, in the registered share accounts held by the Company&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7pt">for bearer shares, that they were registered, within the time limit imposed by law prior to the Meeting, in the bearer share accounts held by the authorised intermediary.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The booking or registration of securities in the bearer securities accounts kept by the authorised intermediary shall be recorded in a certificate issued by the said intermediary.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Any shareholder whose shares have not been fully paid-up may not attend meetings.</font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">SHAREHOLDER REPRESENTATION AND POSTAL BALLOTS</font></div></td></tr></table></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Shareholder representation </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">A shareholder may be represented by another shareholder, by their spouse or partner with whom they have entered into a civil partnership or by any person of their choosing.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Any shareholder may receive a proxy form in order to represent another shareholder at a meeting. In this respect, no limits apply other than those imposed by law that set the maximum number of votes that may be held by the same person, in their own name and as a proxy.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Postal ballots</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">When a meeting has been convened, a postal ballot form and its attachments must be delivered in person or sent, at the Company&#8217;s expense, to any shareholder who makes a written request to that effect.</font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Page 19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Company must accept any request deposited or received at the registered office at least six (6) days before the date of the meeting.</font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">MEETING OFFICERS</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Shareholder meetings must be chaired by the Chairman of the Board of Directors or, in their absence, by a director appointed for that purpose by the Board. Otherwise, the shareholders must elect a chairman themselves.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If a meeting is convened by the statutory auditors, a court-appointed agent or the liquidators, it must be chaired by the person or one of the persons who convened it.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The two consenting persons present at the meeting who hold the most votes shall act as tellers.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The meeting officers must appoint a secretary, who may but need not be a shareholder.</font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">MINUTES OF DECISIONS</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The decisions taken at shareholder meetings must be recorded in minutes drawn up and signed by the meeting officers.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">They must state the date and venue of the meeting, the method used to convene the meeting, the agenda, the meeting officers, the number of shares involved in the vote and the quorum reached, the documents and reports submitted to the shareholders, a summary of the discussions, the resolutions put to the vote and the results of the voting process.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Minutes must be entered in a special minute book kept at the registered office in accordance with the regulations in force.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If, in the absence of the required quorum, the shareholders cannot validly transact business, minutes must be drawn up by the officers of the meeting to record the foregoing.</font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">SHAREHOLDERS&#8217; RIGHT TO INFORMATION AND RIGHT OF SCRUTINY </font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Before each meeting, the Board of Directors must make available to the shareholders the documents they need to make informed decisions and to make an informed judgment on the management and running of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Following receipt of the above documents, any shareholder may submit written questions, in accordance with the laws and regulations in force, to which the Board of Directors must respond at the meeting.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Any shareholder has the right to obtain, at any time, the documents that the Board of Directors is required to make available to them at the registered office or to send to them in accordance with the laws and regulations in force.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">SECTION VI<br>FINANCIAL YEAR &#8211; ANNUAL FINANCIAL STATEMENTS &#8211; ACCOUNTING AND FINANCIAL INFORMATION &#8211; APPROPRIATION OF PROFIT&#47;LOSSES </font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">FINANCIAL YEAR</font></div></td></tr></table></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Page 20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The financial year has a term of twelve months. It begins on the first of January and ends on the thirty-first of December each year.</font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">ANNUAL FINANCIAL STATEMENTS</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">At the end of each financial year, the Board of Directors must prepare a statement of the Company&#8217;s assets and liabilities at year end, as well as the annual financial statements.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">It must draw up a management report on the Company&#8217;s position and business during the past year, its operating results, the progress made and difficulties encountered, its foreseeable development and future prospects, any significant events that have occurred between year end and the date of the report, and its research and development activities.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The annual financial statements, the management report and, where applicable, the consolidated financial statements and group management report must be made available to the statutory auditors at the registered office at least one month before the meeting at which the shareholders are to decide on the Company&#8217;s annual financial statements is convened.</font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">APPROPRIATION AND DISTRIBUTION OF PROFIT&#47;LOSSES</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If the annual financial statements approved by the shareholders at a General Meeting show that the Company has generated a distributable profit, as defined by law, the shareholders may decide to appropriate that profit to one or more reserves &#8211; in which case they must decide how it will be allocated or used &#8211;, carry the profit forward or distribute it.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The shareholders at a General Meeting may choose to receive the whole or part of any dividend or interim dividend in cash or shares, in accordance with the law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Following the approval of the financial statements by the shareholders at a General Meeting, any loss must be carried forward and set off against profit for future financial years until it has been cleared.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The portion of profit to which each shareholder is entitled and each shareholder&#8217;s liability for any loss shall be proportionate to its interest in the share capital.</font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">EQUITY LESS THAN ONE HALF OF SHARE CAPITAL </font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If, owing to losses recorded in the accounting documents, the Company&#8217;s equity falls below one half of its share capital, the Board of Directors is required, within four (4) months of the approval of the financial statements showing the loss, to convene an Extraordinary General Meeting of shareholders to decide whether to wind up the Company early.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If a decision is made not to wind up the Company, subject to the provisions of Article L.&#160;224-2 of the French Commercial Code, the Company is required, by the end of the second financial year following that in which the loss was recorded, to reduce its share capital at least by the amount of the loss that cannot be appropriated to the reserves unless, within that timeframe, it has rebuilt its equity to an amount equal to at least one half of its share capital. If these requirements are not met, any interested person may petition a court of law to wind up the Company. However, the Court may not make an order for the Company to be wound up if, on the day on which it decides the case, the situation has been remedied.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Page 21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">SECTION VII<br>WINDING-UP &#8211; LIQUIDATION &#8211; DISPUTES</font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">WINDING-UP &#8212; LIQUIDATION</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Upon the expiry of the term of incorporation set by the Company or if the Company is wound up early, the shareholders at a General Meeting must decide the terms of the liquidation proceedings and appoint one or more liquidators, whose powers shall be determined by the shareholders and who shall perform their duties as required by law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If all shares in the Company are held by a sole shareholder, the expiry of the term of incorporation of the Company or the winding-up of the Company for whatever reason shall entail the transfer of all of its assets and liabilities to the legal entity sole shareholder, without the need to liquidate the Company, subject to the creditors&#8217; right of opposition, in accordance with the provisions of Article 1844-5 of the French Civil Code.</font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.298%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.73pt">DISPUTES</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Any dispute that may arise during the Company&#8217;s existence or upon its liquidation between the Company and its shareholders or directors or between the shareholders themselves concerning the Company&#8217;s affairs shall be heard and decided in accordance with the law and referred to the competent courts.</font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Page 22</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>3
<FILENAME>abivax-20xfxex21descriptio.htm
<DESCRIPTION>EX-2.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i5f69cd8f9968441d97b67dac36857420_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Exhibit 2.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div><font><br></font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The following description of the ordinary shares, the American Depositary Shares and the articles of association, or bylaws, of Abivax SA (&#8220;Abivax,&#8221; the &#8220;Company,&#8221; &#8220;us&#8221; or &#8220;we&#8221;) is a summary and does not purport to be complete. This summary is subject to, and qualified in its entirety by reference to, the complete text of the Company&#8217;s bylaws, which are incorporated by reference as Exhibit 3.1 of the Company&#8217;s Annual Report on Form 20-F to which this description is also an exhibit. The Company encourages you to read the Company&#8217;s bylaws carefully.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2025, Abivax had the following series of securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended, or the Exchange Act&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.093%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Title of Each Class</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Trading Symbol</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Name of Each Exchange on Which Registered</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Ordinary shares, nominal value &#8364;0.01 per share</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">*</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Nasdaq Global Market*</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">American Depositary Shares, each representing one ordinary share, nominal value &#8364;0.01 per share</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">ABVX</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Nasdaq Global Market</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">* Not for trading, but only in connection with the registration of the American Depositary Shares.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">ORDINARY SHARES</font></div><div style="text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As of December 31, 2025, our issued share capital consisted of a total of 78,536,412 ordinary shares outstanding with a nominal value of &#8364;0.01 per share.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The description below reflects the terms of our bylaws and summarizes the material rights of holders of our ordinary shares under French law. Please note that this is only a summary and is not intended to be exhaustive. For further information, please refer to the full text of our bylaws, which are incorporated by reference as Exhibit 3.1 of the Company&#8217;s Annual Report on Form 20-F to which this description is also an exhibit.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders&#8217; Meetings and Voting Rights (Articles 12, 22, 23, 24, 25 and 26 of the By-Laws) </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">General </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In accordance with the French Commercial Code (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Code de Commerce</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">), there are three types of shareholders&#8217; meetings&#58; ordinary, extraordinary and special. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Ordinary shareholders&#8217; meetings are required to elect, replace or remove directors, appoint independent statutory auditors, approve the annual financial statements, approve share repurchase programs, declare dividends or authorizing dividends to be paid in shares and approve regulated agreements. In addition, pursuant to recommendation of the French Market Authority (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Autorit&#233; des March&#233;s Financiers</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">) (&#8220;AMF&#8221;), French listed companies may be required to conduct a consultation of the Ordinary Shareholders Meeting prior to the disposal of the majority of their assets, under certain conditions. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Extraordinary shareholders&#8217; meetings are required for approval of matters such as amendments to our by-laws, including amendments required in connection with extraordinary corporate actions (i.e., changing our name, corporate purpose or registered office, increasing or decreasing our share capital and creating a new class of equity securities (ordinary or preferred shares)). Shareholders&#8217; rights may be modified as allowed by French law. Only the extraordinary shareholders&#8217; meeting is authorized to amend any and all provisions of our by-laws. It may not, however, increase shareholder commitments without the prior approval of each shareholder. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Special meetings of holders of a certain category of shares or of securities giving access to our share capital are required for any modification of the rights relating to such categories of shares. The resolutions of the shareholders&#8217; meeting modifying these rights are effective only after they have been approved by the relevant special meeting. </font></div><div style="margin-top:13.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Special Voting Rights of Warrant Holders </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Under French law, the holders of warrants of the same class (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">i.e.,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> warrants that were issued at the same time and with the same rights), including founder&#8217;s share warrants (BCEs), are entitled to vote as a separate class at a general meeting of that class of warrant holders under certain circumstances, principally in connection with any proposed modification of the terms and conditions of the class of warrants or any proposed issuance of preferred shares or any modification of the rights of any outstanding class or series of preferred shares. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Shareholders&#8217; Meetings </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Our Board convenes an annual ordinary shareholders&#8217; meeting for the approval of the annual financial statements. This meeting is held within six months of the end of each fiscal year. This period may be extended by an order of the President of the French Commercial Court (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tribunal de Commerce</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">) at the request of the Board. The Board may also convene an ordinary or extraordinary shareholders&#8217; meeting upon proper notice at any time during the year. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If the Board fails to convene a shareholders&#8217; meeting at the shareholders&#8217; request, our statutory auditors may call the meeting. In the event of bankruptcy, the liquidator or court-appointed agent may also call a shareholders&#8217; meeting. In addition, any of the following may request the President of the French Commercial Court to appoint an agent to convene the shareholders&#8217; meeting&#58; one or several shareholders holding at least 5% of our share capital, any interested party in cases of urgency, the workers council in cases of urgency or duly qualified associations of shareholders who have held their shares in registered form for at least two years and who together hold a minimum number of the voting rights of our share capital. Shareholders holding a majority of the share capital or voting may also convene a shareholders&#8217; meeting after the filing of a public offer or sale of a controlling interest in our share capital. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; meetings shall be chaired by the chairperson of the Board or, in his or her absence, by a Deputy chairperson or by a director elected for this purpose. Failing that, the meeting itself shall elect a chairperson. Vote counting shall be performed by the two members of the meeting who are present and accept such duties, who represent, either on their own behalf or as proxies, the greatest number of votes. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Notice of Shareholders&#8217; Meeting </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We are subject to French law requirements in relation to notice of shareholders&#8217; meetings and announce shareholders&#8217; meetings at least 35 days in advance by means of a preliminary notice published in the </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bulletin des annonces l&#233;gales obligatoires</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> (BALO), as well as on our website at least 21&#160;days prior to the meeting. At least 15 days prior to the date set for a shareholders&#8217; meeting, or ten days if it is a second call, we must publish a final notice in accordance with French law requirements. In addition to the particulars relative to us, the final notice indicates, notably, the meeting&#8217;s agenda and the draft resolutions that will be presented. The requests for recording of issues or draft resolutions on the agenda must be addressed to the company under the conditions provided for in the current legislation. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In general, shareholders can only take action at shareholders&#8217; meetings on matters listed on the agenda for the meeting. As an exception to this rule, shareholders may take action, among other things, with respect to the dismissal of directors, even if these actions have not been included on the agenda. The Board must submit properly proposed resolutions to a vote of the shareholders. When a shareholder submits a blank proxy form without naming a representative, his vote is deemed to be in favor of the resolutions (or amendments) proposed or recommended by the Board and against all others. As of the date of the publication of the final notice of a meeting but no later than four business days before the shareholders&#8217; meeting, any shareholder may submit written questions to the Board relating to the agenda for the meeting. The Board must respond to these questions during the meeting. A common answer can be given to several questions if they have the same content or bear on the same topic. The answer to a written question is deemed to have been given insofar as it is published on our website in a section devoted to questions and answers. </font></div><div style="margin-top:13.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Agenda and Conduct of Annual Shareholders&#8217; Meetings. </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The agenda of the shareholders&#8217; meeting shall appear in the notice to convene the meeting and is set by the author of the notice. The shareholders&#8217; meeting may only deliberate on the items on the agenda except for the removal of directors and the appointment of their successors which may be put to vote by any shareholder during any shareholders&#8217; meeting. Pursuant to French law and our current share capital, one or more shareholders representing 5% of our share capital may request the inclusion of items or proposed resolutions on the agenda. Such request must be received at the latest on the 25th day preceding the date of the shareholders&#8217; meeting, and in any event no later than the 20th day following the date of the convening notice to the shareholders&#8217; meeting. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Attendance and Voting at Shareholders&#8217; Meetings </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Ownership of one share implies, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">ipso jure</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">, adherence to our by-laws and the decision of the shareholders&#8217; meeting. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The voting rights attached to equity or dividend shares are proportional to the percentage of the share capital they represent. Each share entitles the holder to one vote. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">However, a double voting right compared to that conferred to other shares with regard to the percentage of share capital they represent is allocated to all fully paid-up ordinary shares with proof of being held in registered form by the same owner for at least two (2)&#160;years. Under French law, treasury shares or ordinary shares held by entities controlled by us are not entitled to voting rights and do not count for quorum purposes. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In order to participate in any general meeting, shareholders are required to have their shares registered under the conditions and time limits provided for the applicable laws before such general meeting in their name or in the name of an intermediary registered on their behalf, either in the registered shares shareholder account or in the bearer shares shareholder account. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Proxies and Votes by Mail or Videoconference </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In general, all shareholders who have properly registered and fully paid their shares or duly presented a certificate from their accredited intermediary may participate in shareholders&#8217; meetings. Shareholders may participate in shareholders&#8217; meetings either in person, by proxy or by mail or, if provided for by the by-laws, by videoconference or by any means of telecommunications in accordance with applicable regulations, if the Board provides for such possibility when convening the meeting. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Proxies are sent to any shareholder upon request. In order to be counted, such proxies must be received at our registered office, or at any other address indicated on the notice convening the meeting, prior to the date of the meeting. A shareholder may grant proxies to his or her spouse, civil partner, to another shareholder or to any other person (individual or legal) of his&#47;her&#47;its choice. A shareholder that is a corporation may grant proxies to a legal representative. A shareholder who is a non-resident of France may be represented at a shareholders&#8217; meeting by an intermediary registered under the conditions set forth by French law. Alternatively, the shareholder may send a blank proxy to us without nominating a representative. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">With respect to votes by mail, we will send shareholders a voting form. The completed form must be returned to us at least three days prior to the date of the shareholders&#8217; meeting. The final date for returning votes by mail is disclosed in the notice of meeting published in accordance with French law requirements. Under our by-laws, shareholders&#8217; meetings by means of telecommunications permitting their identification are possible if the Board so determines in the preliminary or final notice of the meeting. Shareholders voting by proxy, mail, authorized intermediary or, if provided for in the preliminary or final notice of the meeting by any means of telecommunications permitting them to be identified, will be considered to be present at the meeting for the computation of the quorum and the majority. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">A shareholder who has voted by correspondence will no longer be able to participate directly in the meeting or to be represented. In the case of returning the proxy form and the voting by correspondence form, the proxy form is taken into account, subject to the votes cast in the voting by correspondence form. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Quorum </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">For an ordinary shareholders&#8217; meeting to be quorate, one-fifth of the holders of shares entitled to voting rights must be present in person or vote by mail or by proxy or by authorized intermediary or by any means of telecommunication permitting their identification. An extraordinary shareholders&#8217; meeting is quorate if one-fourth of the holders of shares entitled to voting rights are present or vote by mail or by proxy or by authorized intermediary or by any means of telecommunication. As an exception, an extraordinary shareholders&#8217; meeting deciding upon a share capital increase by capitalization of reserves, profits or share premium has the same quorum requirement as an ordinary shareholders&#8217; meeting. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If the requirements for a quorum are not satisfied, the meeting is adjourned. When an adjourned ordinary shareholders&#8217; meeting is resumed, there is no quorum requirement. Extraordinary shareholders&#8217; meetings require a quorum of one-fifth of the holders of shares entitled to voting rights. If a quorum is not present, the reconvened meeting may be adjourned for a maximum of two months. No deliberation by the shareholders may take place without a quorum. For special meetings of holders of a certain class of shares, the quorum requirement is one-third of the certain class of shares entitled to voting rights for the meeting convened on the first call. Should the special </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">meeting be reconvened, the quorum requirement is one-fifth of the certain class of shares entitled to voting rights for the meeting. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Majority </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">A simple majority of shareholders may pass a resolution at either an ordinary shareholders&#8217; meeting or an extraordinary shareholders&#8217; meeting deciding upon a share capital increase by capitalization of reserves, profits or share premium. At any other extraordinary shareholders&#8217; meeting, a two-thirds majority of the shareholder votes cast is required. A unanimous shareholder vote is required to increase shareholders&#8217; liabilities. Abstention from voting by those present either in person or by means of telecommunications if provided for by the by-laws, or those represented by proxy or voting by mail is counted as a vote against the resolution submitted to a shareholder vote. In general, each shareholder is entitled to one vote per share at any shareholders&#8217; meeting. Under the French Commercial Code, shares of a company held by it or by entities controlled directly or indirectly by that company are not entitled to voting rights and do not count for quorum or majority purposes. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Financial Statements and Other Communications with Shareholders </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In connection with the annual ordinary shareholders&#8217; meeting, we must provide or make available to any shareholder a set of documents including, among other things, our annual report, the annual and consolidated accounts, the statutory auditors&#8217; reports and a draft of the meeting&#8217;s resolutions. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The chairperson of the Board is required to deliver a special report to the annual ordinary shareholders&#8217; meeting regarding the composition of the Board, the representation of men and women in its composition, the status of the preparation and organization of the work of the Board, the status of the internal control procedures that we have implemented, including those in connection with the treatment of the accounting and financial statements and principles and rules that it establishes to determine management compensation and benefits. French law requires that a special report be provided annually to the ordinary shareholders&#8217; meeting regarding stock options authorized and&#47;or granted by the company. </font></div><div style="margin-top:13.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Rights, Preferences and Restrictions Attaching to Ordinary Shares (Articles&#160;7, 11, 30, 31 and 32 of the By-Laws) </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Dividends </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We only distribute dividends out of our &#8220;distributable profits,&#8221; plus any amounts filed in its reserves that the shareholders decide to make available for distribution, other than those reserves that are specifically required by French law or our by-laws. &#8220;Distributable profits&#8221; consist of our net profit in each fiscal year, as increased or reduced by any profit or loss carried forward from prior years, less any contributions to the reserve accounts pursuant to French law or our by-laws. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Legal Reserve </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Under French law, we are required to allocate 5% of our net income for each fiscal year, after reduction for losses carried forward from previous years, if any, to a legal reserve fund until the amount in the legal reserve is equal to 10% of the aggregate nominal value of the share capital. The legal reserve subject to this requirement may only be used to offset losses when other reserves cannot be used and, in particular, may not be distributed to shareholders until our liquidation. As of December&#160;31, 2025, our legal reserve was &#8364;0. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Approval of Dividends </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders may decide in an ordinary shareholders&#8217; meeting, upon proposal of the Board, to allocate all or part of the distributable profits to special or general reserves, to carry them forward to the following fiscal year as retained earnings, or to allocate them to the shareholders as dividends. Dividends may be paid in cash or as shares upon the option of the shareholders if such option is granted at the annual ordinary shareholders&#8217; meeting. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If we have earned distributable profits since the end of the preceding fiscal year, as reflected in an interim income statement certified by its auditors, the Board may distribute interim dividends to the extent of the distributable profits for the period covered by the interim income statement before approval of the annual financial statements. Subject to French law, the Board may declare interim dividends paid in cash without obtaining shareholder approval. For interim dividends paid in shares, prior authorization by an ordinary shareholders&#8217; meeting is required. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Distribution of Dividends and Timing of Payment </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In principle, dividends are distributed to shareholders pro rata according to their respective shareholdings. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Timing of Payment </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Under French law, we must pay any dividends within nine months of the end of our fiscal year, unless otherwise authorized by an order of the President of the French Commercial Court. Dividends on shares that are not claimed within five years of the date of declared payment revert to the French State. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In the case of interim dividends, distributions are made to shareholders on the date set by our Board during the meeting in which the distribution of interim dividends is approved. The actual dividend payment date is decided by the shareholders at an annual shareholders&#8217; meeting or by our Board in the absence of such a decision by the shareholders. Shareholders that own shares on the actual payment date are entitled to the dividend. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders may be granted an option to receive dividends in cash or in shares, in accordance with legal conditions. The conditions for payment of dividends in cash shall be set at the shareholders&#8217; meeting or, failing this, by the Board. </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Increases in Share Capital </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Our share capital may only be increased by obtaining the approval of the shareholders at an extraordinary shareholders&#8217; meeting upon the recommendation of the Board. The decision to increase share capital through increases in the nominal value of existing shares requires unanimous approval at an extraordinary shareholders&#8217; meeting. The decision to increase share capital through the capitalization of reserves, profits and&#47;or share premiums must be submitted to an extraordinary shareholders&#8217; meeting applying the quorum and majority requirements applicable to ordinary shareholders&#8217; meetings. In the case of an increase in share capital in connection with the payment of a share dividend the voting and quorum procedures of an ordinary shareholders&#8217; meetings apply. All other share capital increases require the approval of an extraordinary shareholders&#8217; meeting. See &#8220;Description of Share Capital&#8212;Shareholders&#8217; Meetings and Voting Rights (Articles 6, 12 and 22 of the By-Laws)&#8221; above. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Increases in our share capital may be effected by&#58; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;issuing additional shares&#59; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;increasing the par value of existing shares&#59; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;creating a new class of equity securities&#59; and </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;exercising the rights attached to securities giving access to the share capital. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Increases in share capital by issuing additional securities may be effected through one or a combination of the following&#58; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;in consideration for cash&#59; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;in consideration for assets contributed in kind&#59; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;through an exchange offer&#59; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;by conversion of previously issued debt instruments&#59; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;by capitalization of profits, reserves or share premium&#59; and </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;subject to certain conditions, by way of offset against debt incurred by us. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Subject to certain conditions, shareholders may delegate the authority (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">d&#233;l&#233;gation de comp&#233;tence</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">) or the powers (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">d&#233;l&#233;gation de pouvoirs</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">) to carry out certain increases in our share capital to the Board following approval at an extraordinary shareholders&#8217; meeting. The Board may further sub-delegate this right to the Chief Executive Officer. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Reduction in Share Capital </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Under French law, any reduction in our share capital requires approval of the shareholders at an extraordinary shareholders&#8217; meeting. The share capital may be reduced either by decreasing the nominal value of the outstanding shares or by reducing the number of outstanding shares. The number of outstanding shares may be reduced by the repurchase and cancellation of the shares. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Holders of each class of shares must be treated equally unless each affected shareholder agrees otherwise. As a general matter, reductions of capital occur pro rata among all shareholders, except (i)&#160;in the case of a share buyback program, or a public tender offer to repurchase shares, where such a reduction occurs pro rata only among tendering shareholders and (ii)&#160;in the case where all shareholders unanimously consent to a non-pro-rata reduction. In any case, we must not own more than 10% of our outstanding share capital. The extraordinary shareholders&#8217; meeting may authorize the buy-back program for a period not exceeding 18 months. In addition, we may not cancel more than 10% of our outstanding share capital over any 24-month period. </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Preferential Subscription Rights </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">According to French law, existing shareholders have preferential subscription rights to these securities on a pro rata basis if we issue certain kinds of additional securities. These preferential subscription rights require us to give priority treatment to existing shareholders. The rights entitle the individual or entity that holds them to subscribe to an issue of any securities that may increase our share capital by means of a cash payment or a settling of cash debts. Pursuant to applicable law, subscription rights are transferable during a period starting two days prior the opening of the subscription period (or, if such day is not a business day, the preceding trading day) and ending two days prior the closing of the subscription period (or, if such day is not a business day, the preceding trading day). </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">A two-thirds majority of the shares entitled to vote at an extraordinary shareholders&#8217; meeting may vote to waive preferential subscription rights with respect to any particular offering or a portion of that offering. French law requires that the Board and our statutory auditors present reports that specifically address any proposal to waive preferential subscription rights. In the event of a waiver, the issue of securities must be completed within the period prescribed by French law. The shareholders may also decide at an extraordinary shareholders&#8217; meeting to give existing shareholders a non-transferable priority right to subscribe to such new securities during a limited period of time. Shareholders also may notify us that they wish to waive their own preferential subscription rights with respect to any particular offering if they so choose. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In the event of a share capital increase without preferential subscription rights to existing shareholders to the benefit of qualified investors under Article L. 411-2 of the French Monetary and Financial Code, French law requires that the capital increase be made at a price equal to or exceeding the weighted-average market price of the shares in the three trading days preceding the setting of the price (such weighted-average-market price may be reduced by a maximum discount of 10%). However, within the limit of 10% of the share capital per year, the extraordinary shareholders&#8217; meeting may authorize the Board to set the issuing price in accordance with terms established by the extraordinary shareholders&#8217; meeting. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Form, Holding and Transfer of Shares (Articles 10 and 11 of the By-Laws) </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Form of Shares </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Our by-laws provide that the shares once fully paid may be held in registered or bearer form at the option of the shareholder, subject to applicable laws. Shares not fully paid must be nominal. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Holding of Shares </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In accordance with French law, shareholders&#8217; ownership rights are represented by book entries instead of share certificates. Shares issued are registered in individual accounts opened by us or any authorized intermediary, in the name of each shareholder and kept according to the terms and conditions laid down by the legal and regulatory provisions. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Any owner of our shares may elect to have its shares held in registered form and registered in its name in an account currently maintained by Uptevia, 12 place des Etats-Unis, CS 40083, 92549 Montrouge Cedex, France for and on our behalf or held in bearer form and recorded in its name in an account maintained by an accredited financial intermediary, such as a French broker, bank or other authorized financial institution. Any shareholder may, at its expense, change from one form of holding to the other. Both methods are operated through Euroclear. In addition, according to French law, shares held by any non-French resident may be held on the shareholder&#8217;s behalf in a collective account or in several individual accounts by an intermediary. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">When our shares are held in bearer form by a beneficial owner who is not a resident of France, Euroclear may agree to issue, upon our request, a bearer depository receipt with respect to such shares for use only outside France. In this case, the name of the holder is deleted from the accredited financial intermediary&#8217;s books. Title to the shares represented by a bearer depository receipt will pass upon delivery of the relevant receipt outside France. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In accordance with applicable laws, we may request the information referred to in Article&#160;L.228-2 of the French Commercial Code at any time from the central depository responsible for holding our shares. Thus, we are at any time entitled to request the name and year of birth or, in the case of a legal entity, the name and the year of incorporation, nationality and address of the holders of our shares or other securities granting immediate or future voting rights, held in bearer form, and the number of shares or other securities so held and, if applicable, the restrictions relating to such securities. Furthermore, under French law, any intermediary who acts on behalf of one or more persons who are not domiciled in France must declare that it is acting as an intermediary. We may also request the identity of the shareholders on whose behalf it is acting. Consequently, the owner of shares recorded in a collective account or in several individual accounts by an intermediary will be represented in the shareholders&#8217; meetings by this intermediary. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Transfer of Shares </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Our by-laws do not contain any restrictions relating to the transfer of shares. Shares are freely negotiable, subject to applicable legal and regulatory provisions. French and European law provide for standstill obligations and prohibition of insider trading. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Liquidation Rights </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If we are liquidated, any assets remaining after payment of our debts, liquidation expenses and all of our remaining obligations will be distributed first to repay in full the nominal value of our shares (up to the amount of the paid-up and non-liquidated share capital). Any surplus will be distributed pro rata among shareholders in proportion to the nominal value of their shareholdings, taking into account, where applicable, the rights attached to shares of different classes. Shareholders shall only bear losses up to the amount of their contributions. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Disclosure Requirements for Holdings Exceeding Certain Thresholds </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Declaration of Crossing of Ownership Thresholds (Article 11.2 of the By-laws) </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We are subject to certain disclosure requirements under French law. Any individual or entity, acting alone or in concert with others, that acquires, either directly or indirectly, shares representing more than 5%, 10%, 15%, 20%, 25%, 30%, 33</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">&#160;1</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:1.05pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%, 50%, 66</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">&#160;2</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:1.05pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%, 90% or 95% of our outstanding share capital or voting rights or that increases or decreases its shareholding or voting rights above or below any of those percentage thresholds, must notify us and the AMF, within four trading days of the date on which such threshold was crossed. French law and AMF regulations impose additional reporting requirements on persons who acquire more than 10%, 15%, 20% or 25% of the outstanding shares or voting rights of a listed company. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If a shareholder fails to comply with the notification requirements under French law, the shares or voting rights in excess of the relevant threshold will be deprived of voting rights until the end of a two-year period following the date on which the owner of such shares has complied with the notification requirements. They may also be suspended for up to five years and may be subject to criminal fines. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Our by-laws provide that any shareholder, acting alone or in concert, who comes into possession, in any manner whatsoever, either directly or indirectly, of a number of shares representing 2% of our share capital and&#47;or voting rights must, by registered letter with acknowledgment of receipt sent to the registered office, or any other equivalent means for the shareholders or security holders residing outside of France, within five trading days of crossing such threshold, notify us of the total number of shares and voting rights he or she owns and the number of securities he or she owns that give access to the capital and voting rights attached thereto. This disclosure requirement shall apply, under the conditions above, each time a new threshold of 2% of capital and&#47;or voting rights is met or exceeded, for whatever reason, including beyond the legal threshold of 5%. If the shares have not been reported under the above conditions, the shares exceeding the fraction that should have been reported are denied the right to vote in shareholders&#8217; meetings, if at a shareholders&#8217; meeting, the failure to report was recorded and if one or more shareholders holding together not less than 5% of capital or voting rights so request at that meeting. The denial of voting rights applies to any shareholders&#8217; meeting to be held until the expiration of a period of two years from the date of regularization of the reporting. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We are required to publish the total number of voting rights and shares composing the share capital (if such numbers vary from the numbers previously published) on a monthly basis. The AMF makes this information public. We are subject to AMF regulations regarding public tender offers. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Further, and subject to certain exemptions, any shareholder crossing, alone or acting in concert, the 30% threshold shall file a mandatory public tender offer with the AMF. Also, any shareholder holding directly or indirectly a number between 30% and 50% of the capital or voting rights and who, in less than 12 consecutive </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">months, increases his&#47;her&#47;its holding of capital or voting rights by at least 1% of the company&#8217;s capital or voting rights, shall file a mandatory public tender offer. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Treasury Shares and Purchases of our Own Shares </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We are not permitted to hold more than 10% of our share capital in treasury shares or to have more than 10% of our share capital to be held for us by our subsidiaries. Treasury shares are not entitled to dividends, voting rights or preferential subscription rights. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Repurchase and Redemption of Shares </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Under French law, we may acquire our own shares. Such acquisition may be challenged on the ground of market abuse regulations. However, EU Market Abuse Regulation 596&#47;2014 of April&#160;16, 2014 (&#8220;MAR&#8221;) provides for safe harbor exemptions when the acquisition is made for the following purposes only&#58; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;to decrease our share capital, provided that such a decision is not driven by losses and that a purchase offer is made to all shareholders on a&#160;pro rata&#160;basis, with the approval of the shareholders at an extraordinary meeting. In this case, the shares repurchased must be cancelled within one month from the expiry of the purchase offer&#59; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;to meet obligations arising from debt securities that are exchangeable into equity instruments&#59; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;to provide shares for distribution to employees or managers under a profit-sharing, free share or share option plan. In this case the shares repurchased must be distributed within 12 months from their repurchase failing which they must be cancelled&#59; or </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;under a buy-back program to be authorized by the shareholders in accordance with the provisions of Article L.&#160;22-10-62 of the French Commercial Code and in accordance with the general regulations of, and market practices accepted by the AMF. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">All other purposes, and especially share buy-backs made for external growth operations in pursuance of Article L. 22-10-62 of the French Commercial Code, while not forbidden, must be pursued in strict compliance of market manipulation and insider dealing rules. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Under MAR and in accordance with the general regulations (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">r&#233;glement g&#233;n&#233;ral</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">) of the AMF, or the General Regulations, a corporation shall report to the competent authority of the trading value on which the shares have been admitted to trading or are traded, no later than by the end of the seventh daily market session following the date of the execution of the transaction, all the transactions relating to the buy-back program, in a detailed form and in an aggregated form. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">No such repurchase of shares may result in us holding, directly or through a person acting on our behalf, more than 10% of our issued share capital. Shares repurchased by us continue to be deemed &#8220;issued&#8221; under French law but are not entitled to dividends or voting rights so long as we hold them directly or indirectly, and we may not exercise the preferential subscription rights attached to them. </font></div><div style="margin-top:13.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Ownership of Shares by Non-French Persons </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">EU and non-EU residents are required to file an administrative notice (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">d&#233;claration administrative</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">) with the French authorities in connection with certain direct or indirect investments in us, including through ownership of ADSs, on the date a binding purchase agreement is executed or a tender offer is made public. Under existing administrative rulings the following transactions qualify as foreign investments in us that require the filing of an administrative notice&#58; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;any transaction carried out on our capital by a non-French resident provided that after the transaction the cumulative amount of the capital or the voting rights held by non-French residents exceeds 1&#47;3 of our capital or voting rights&#59; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;any transaction mentioned above by a corporation incorporated under French law whose capital or voting rights are held for more than 33.33% by non-French residents&#59; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;any transaction carried out abroad resulting in a change of the controlling shareholder of a corporation incorporated under a foreign law that holds a shareholding or voting rights in us if our capital or voting rights are held for more than 33.33% by non-French residents&#59; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;loans and guarantees granted by the acquirer to us in amounts evidencing control over our financing&#59; and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;patent licenses granted by an acquirer or management or technical assistance agreements with such acquirer that place us in a dependent position </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">vis-&#224;-vis</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> such party or its group. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-French residents must file a declaration for statistical purposes with the Bank of France (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Banque de France</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">) within twenty working days following the date of certain direct foreign investments in us, including any purchase of our ADSs. In particular, such filings are required in connection with investments exceeding &#8364;15,000,000 that lead to the acquisition of at least 10% of our company&#8217;s share capital or voting rights or cross such 10% threshold. Violation of this filing requirement may be sanctioned by five years of imprisonment and a fine up to twice the amount of the relevant investment. This amount may be increased fivefold if the violation is made by a legal entity. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Differences in Corporate Law </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The laws applicable to French</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;soci&#233;t&#233;s anonymes</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;(limited liability companies) differ from laws applicable to U.S. corporations and their shareholders. Set forth below is a summary of certain differences between the provisions of the French Commercial Code applicable to us and the Delaware General Corporation Law relating to shareholders&#8217; rights and protections. This summary is not intended to be a complete discussion of the respective rights, and it is qualified in its entirety by reference to Delaware law and French law. </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:3.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:14.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.711%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.692%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:50%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.27pt;padding-right:2.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">FRANCE</font></div><div style="padding-left:2.27pt;padding-right:2.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:80%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.27pt;padding-right:2.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">DELAWARE</font></div><div style="padding-left:2.27pt;padding-right:2.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:80%">&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Number of Directors</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Under&#160;French&#160;law,&#160;a</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;soci&#233;t&#233;&#160;anonyme</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;must have at least three and may have up to 18 directors. The number of directors is fixed by or in the manner provided in the by-laws. The number of directors of each gender may not be less than 40%. In case a board of directors comprises up to eight members, the difference between the number of directors of each gender may not exceed two. Any appointment made in violation of this limit that is not remedied within six months of this appointment will be null and void and payment of directors&#8217; compensation will be suspended.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Under Delaware law, a corporation must have at least one director and the number of directors shall be fixed by or in the manner provided in the by-laws (unless specified in the certificate of incorporation of the corporation).</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Director Qualifications</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Under French law, a corporation may prescribe qualifications for directors under its by-laws. In addition, under French law, members of a board of directors may be legal entities, and such legal entities must designate an individual to represent them and to act on their behalf at meetings of the board of directors.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Under Delaware law, a corporation may prescribe qualifications for directors under its certificate of incorporation or by-laws.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Removal of Directors</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Under French law, directors may be removed from office, with or without cause, at any shareholders&#8217; meeting without notice or justification, by a simple majority vote of the shareholders present and voting at the meeting in person or by proxy.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Under Delaware law, unless otherwise provided in the certificate of incorporation, directors may be removed from office, with or without cause, by a majority stockholder vote, though in the case of a corporation whose board is classified, shareholders may effect such removal only for cause.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Vacancies on the board of directors</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Under&#160;French&#160;law,&#160;vacancies&#160;on&#160;the board of directors resulting from death or a resignation, provided that at least three directors remain in office, may be filled by a majority of the remaining directors pending ratification by the shareholders by the next shareholders&#8217; meeting.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Under Delaware law, vacancies on a corporation&#8217;s board of directors, including those caused by an increase in the number of directors, unless otherwise provided in the certificate of incorporation, may be filled by the board of directors or other governing body.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:3.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:14.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.711%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.692%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Annual Shareholders&#8217; Meeting</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Under French law, the annual shareholders&#8217; meeting shall be held at such place, on such date and at such time as decided each year by the board of directors and notified to the shareholders in the convening notice of the annual meeting, within six months after the close of the relevant fiscal year unless such period is extended by court order.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Under Delaware law, the annual meeting of stockholders shall be held at such place, on such date and at such time as may be designated from time to time by the board of directors or as provided in the certificate of incorporation or by the by-laws.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Shareholders&#8217; Meeting</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Under French law, shareholders&#8217; meetings may be called by the board of directors or, failing that, by the statutory auditors, or by a court appointed agent or liquidator in certain circumstances, or by the majority shareholder in capital or voting rights following a public tender offer or exchange offer or the transfer of a controlling block on the date decided by the board of directors or the relevant person.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Under Delaware law, special meetings of the stockholders may be called by the board of directors or by such person or persons as may be authorized by the certificate of incorporation or by the by-laws.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Notice of Shareholders&#8217; Meetings</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">A meeting notice (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">avis de r&#233;union</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">) is published in the </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bulletin des annonces l&#233;gales obligatoires </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(&#8220;BALO&#8221;), at least 35 days prior to a meeting and made available on the website of the company at least 21&#160;days prior to the meeting. Additionally, a convening notice (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">avis de convocation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">) is published at least 15&#160;days prior to the date of the meeting, in a legal announcement bulletin of the registered office department and in the BALO. Further, the holders of registered shares (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">actions nominatives</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">) for at least a month at the time of the convening notice shall be summoned individually, by regular letter (or by registered letter if they request it and include an advance of expenses) sent to their last known address. This notice may also be transmitted by electronic means of telecommunication, in lieu of any such mailing, to any shareholder requesting it beforehand by registered letter with acknowledgment of receipt in accordance with legal and regulatory requirements, specifying his e-mail address.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Under Delaware law, unless otherwise provided in the certificate of incorporation or by-laws, written notice of any meeting of the stockholders must be given to each stockholder entitled to vote at the meeting not less than ten nor more than 60 days before the date of the meeting and shall specify the place, date, hour, means of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in person and vote, the record date for voting if it is different from the record date determining notice and, in the case of a special meeting, purpose or purposes of the meeting.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:50%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">The meeting notice must also indicate the conditions under which the shareholders may vote by correspondence, the places and conditions in which they can obtain voting forms, and as the case may be, the e-mail address to which they may send written questions.</font></div></td><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:50%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:3.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:14.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.711%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.692%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Proxy</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Each shareholder has the right to attend the meetings and participate in the discussions (i)&#160;personally, (ii) by granting proxy to any individual or legal entity of his choosing, (iii)&#160;by sending a proxy to the company without indication of the mandate (in which case such proxy shall be cast in favor of the resolutions supported by the board of directors), (iv) by voting by correspondence or (v)&#160;by videoconference or another means of telecommunication allowing identification in accordance with applicable laws. The proxy is only valid for a single meeting or for successive meetings convened with the same agenda. It can also be granted for two meetings, one ordinary the other extraordinary, held on the same day or within a period of 15 days.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Under Delaware law, at any meeting of stockholders, a stockholder may designate another person to act for such stockholder by proxy, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Shareholder Action by Written Consent</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Under French law, shareholders&#8217; action by written consent is not permitted in a</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;soci&#233;t&#233; anonyme.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Under Delaware law, a corporation&#8217;s certificate of incorporation (i)&#160;may permit stockholders to act by written consent if such action is signed by all stockholders, (ii)&#160;may permit stockholders to act by written consent signed by stockholders having the minimum number of votes that would be necessary to take such action at a meeting or (iii)&#160;may prohibit actions by written consent.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Preferential Subscription Rights</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Under French law, in case of issuance of additional shares or other securities for cash or set-off against cash debts, the existing shareholders have preferential subscription rights to these securities on a pro rata basis unless such rights are waived by a two-thirds majority of the votes held by</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Under Delaware law, unless otherwise provided in a corporation&#8217;s certificate of incorporation, a stockholder does not, by operation of law, possess preemptive rights to subscribe to additional issuances of the corporation&#8217;s stock.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:50%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">the shareholders present at the extraordinary meeting deciding or authorizing the capital increase, voting in person or represented by proxy or voting by mail. In case such rights are not waived by the extraordinary general meeting, each shareholder may individually either exercise, assign or not exercise its preferential subscription rights.</font></div></td><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:50%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:3.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:14.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.711%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.692%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Sources of Dividends</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Under French law, dividends may only be paid by a French</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;soci&#233;t&#233; anonyme</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;out of &#8220;distributable profits,&#8221; plus any distributable reserves and &#8220;distributable premium&#8221; that the shareholders decide to make available for distribution, other than those reserves that are specifically required by-law. &#8220;Distributable profits&#8221; consist of the unconsolidated net profits of the relevant corporation for each fiscal year, as increased or reduced by any profit or loss carried forward from prior years, minus the amounts to be set aside to the statutory reserve (at least 5% of the profit until the reserve has reached 10% of the amount of the share capital) and to the reserve set forth in the company&#8217;s by-laws (if any).</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;Distributable premium&#8221; refers to the contribution paid by the shareholders in addition to the par value of their shares for their subscription that the shareholders decide to make available for distribution.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Except in the case of a share capital reduction, no distribution can be made to the shareholders when the net equity is, or would become, lower than the amount of the share capital plus the reserves which cannot be distributed in accordance with the law or the by-laws.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Under Delaware law, dividends may be paid by a Delaware corporation either out of (i)&#160;surplus, as defined in and computed in accordance with Delaware law, or (ii)&#160;in case there is no surplus, out of its net profits for the fiscal year in which the dividend is declared and&#47;or the preceding fiscal year, except when the capital is diminished by depreciation in the value of its property, or by losses or otherwise, to an amount less than the aggregate amount of capital represented by issued and outstanding stock having a preference on the distribution of assets.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Repurchase of Shares</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Under French law, a corporation may acquire its own shares. Such acquisition may be challenged on the ground of market abuse regulations. However, MAR provides for safe harbor exemptions when the acquisition is made for the following purposes only&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:1pt;padding-left:48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;to&#160;decrease&#160;its&#160;share&#160;capital, provided that such decision is not driven by losses and that a purchase offer is made to all shareholders on a pro rata basis, with the approval of the shareholders at the extraordinary general meeting deciding the capital reduction&#59; or to meet obligations arising from debt securities, that are exchangeable into equity instruments.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Under Delaware law, a corporation may generally redeem or repurchase shares of its stock unless the capital of the corporation is impaired or such redemption or repurchase would impair the capital of the corporation.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">No such repurchase of shares may result in the company holding, directly or through a person acting on its behalf, more than 10% of its issued share capital.</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.915%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.871%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:50%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.27pt;padding-right:2.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">FRANCE</font></div><div style="padding-left:2.27pt;padding-right:2.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:80%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.27pt;padding-right:2.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">DELAWARE</font></div><div style="padding-left:2.27pt;padding-right:2.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:80%">&#160;</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.915%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.871%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:50%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;with a view to distributing within one year of their repurchase the relevant shares to employees or managers under a profit-sharing, free share or share option plan&#59; or</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;under a buy-back program to be authorized by the shareholders in accordance with the provisions of Article L. 22-10-62 of the French Commercial Code and in accordance with the general regulations of the AMF.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">All other purposes, and especially share buy-backs for external growth operations by virtue of Article L. 22-10-62 of the French Commercial Code, while not forbidden, must be pursued in strict compliance of market manipulations and insider dealing rules.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">No such repurchase of shares may result in the company holding, directly or through a person acting on its behalf, more than 10% of its issued share capital.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Under MAR and in accordance with the General Regulations, a corporation shall report to the competent authority of the trading venue on which the shares have been admitted to trading or are traded, no later than by the end of the seventh daily market session following the date of the execution of the transaction, all the transactions relating to the buy-back program, in a detailed form and in an aggregated form.</font></div></td><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:50%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Liability of Directors and Officers</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Under French law, the by-laws may not include any provisions limiting the liability of directors.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Under Delaware law, a corporation&#8217;s certificate of incorporation may include a provision eliminating or limiting the personal liability of a director to the corporation and its stockholders for damages arising from a breach of fiduciary duty as a director. However, no provision can limit the liability of a director for&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders&#59;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law&#59;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;intentional or negligent payment of unlawful dividends or stock purchases or redemptions&#59; or</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:1pt;padding-left:48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;any transaction from which the director derives an improper personal benefit.</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.915%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.871%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Voting Rights</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">French law provides that, unless otherwise provided in the by-laws, each shareholder is entitled to one vote for each share of share capital held by such shareholder. Further, pursuant to the introduction of Law No.&#160;2014-384 dated March&#160;29, 2014 (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Loi Florange</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">), shares registered for more than two years in the name of the same shareholder are automatically be granted double voting rights from 2016, unless the by-laws expressly reject this measure.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Delaware law provides that, unless otherwise provided in the certificate of incorporation, each stockholder is entitled to one vote for each share of capital stock held by such stockholder.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Shareholder Vote on Certain Transactions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Generally, under French law, completion of a merger, dissolution or sale or exchange of all or substantially all of a corporation&#8217;s assets (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">apport partiel d&#8217;actifs</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">) requires&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;the approval of the board of directors&#59; and</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:1pt;padding-left:48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;approval by a two-thirds majority of the votes held by the shareholders present, represented by proxy or voting by mail at the relevant meeting or, in the case of a merger with a non-EU company, approval of all shareholders of the corporation.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Generally, under Delaware law, unless the certificate of incorporation pro</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">vides for the vote of a larger portion of shares, completion of a merger, consolidation, sale, lease or exchange of all or substantially all of a corporation&#8217;s assets or dissolution requires&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;the approval of the board of directors&#59; and</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:1pt;padding-left:48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;approval by the vote of the holders of a majority of the outstanding stock or, if the certificate of incorporation provides for more or less than one vote per share, a majority of the votes of the outstanding stock of a corporation entitled to vote on the matter.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Dissent or Dissenters Appraisal Rights</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">French law does not provide for any such right but provides that a merger is subject to shareholders&#8217; approval by a two-thirds majority vote, as stated above.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Under Delaware law, a holder of shares of any class or series has the right, in specified circumstances, to dissent from a merger or consolidation by demanding payment in cash for the stockholder&#8217;s shares equal to the fair value of those shares, as determined by the Delaware Chancery Court in an action timely brought by the corporation or a dissenting stockholder. Delaware law grants these appraisal rights only in the case of mergers or consolidations and not in the case of a sale or transfer of assets or a purchase of</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:50%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:50%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">assets for shares. Further, no appraisal rights are available for shares of any class or series that is listed on a national securities exchange or held of record by more than 2,000 stockholders, unless the agreement of merger or consolidation requires the holders to accept for their shares anything other than&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:1pt;padding-left:48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;shares of stock of the surviving corporation&#59;</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.915%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.871%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:50%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:50%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;shares of another corporation that are either listed on a national securities exchange or held of record by more than 2,000 stockholders&#59;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;cash in lieu of fractional shares of the stock described in the two preceding bullet points&#59; or</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;any combination of the above.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In addition, appraisal rights are not available to holders of shares of the surviving corporation in specified mergers that do not require the vote of the stockholders of the surviving corporation.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Standard of Conduct for Directors</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">French law does not contain specific provisions setting forth the standard of conduct of a director. However, directors have a duty to act without self-interest, on a well-informed basis, and not to take any decision against a corporation&#8217;s corporate interest (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">int&#233;r&#234;t social</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Delaware law does not contain specific provisions setting forth the standard of conduct of a director. The scope of the fiduciary duties of directors is generally determined by the courts of the State of Delaware. In general, directors have a duty to act without self-interest, on a well-informed basis and in a manner they reasonably believe to be in the best interest of the stockholders.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Shareholder Suits</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">French law provides that a shareholder, or a group of shareholders, may initiate a legal action to seek indemnification from the directors of a corporation in the corporation&#8217;s interest if it fails to bring such legal action itself. If so, any damages awarded by the court are paid to the corporation and any legal fees relating to such action are borne by the relevant shareholder or the group of shareholders.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The plaintiff must remain a shareholder through the duration of the legal action.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">There is no other case where shareholders may initiate a derivative action to enforce a right of a corporation.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">A shareholder may alternatively or cumulatively bring individual legal action against the directors, provided he has suffered distinct damages from those suffered by the corporation. In this case, any damages awarded by the court are paid to the relevant shareholder.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Under Delaware law, a stockholder may initiate a derivative action to enforce a right of a corporation if the corporation fails to enforce the right itself. The complaint must&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;state that the plaintiff was a stockholder at the time of the transaction of which the plaintiff complains or that the plaintiff&#8217;s shares thereafter devolved on the plaintiff by operation of law&#59; and</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;allege with particularity the efforts made by the plaintiff to obtain the action the plaintiff desires from the directors and the reasons for the plaintiff&#8217;s failure to obtain the action&#59; or</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;state the reasons for not making the effort.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:1pt;padding-left:48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;Additionally, the plaintiff must remain a stockholder through the duration of the derivative suit. The action will not be dismissed or compromised without the approval of the Delaware Court of Chancery.</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.915%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.871%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Amendment of Certificate of Incorporation</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unlike companies incorporated under Delaware law, the organizational documents, which comprise both a certificate of incorporation and by-laws, companies incorporated under French law only have by-laws (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">statuts</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">) as organizational documents.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As indicated in the paragraph below, only the extraordinary shareholders&#8217; meeting is authorized under French law to adopt or amend the by-laws.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Under Delaware law, generally a corporation may amend its certificate of incorporation if&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;its board of directors has adopted a resolution setting forth the amendment proposed and declared its advisability&#59; and</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:1pt;padding-left:48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;the amendment is adopted by the affirmative votes of a majority (or greater percentage as may be specified by the corporation) of the outstanding shares entitled to vote on the amendment and a majority (or greater percentage as may be specified by the corporation) of the outstanding shares of each class or series of stock, if any, entitled to vote on the amendment as a class or series.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Amendment of by-laws</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Under French law, only the extraordinary shareholders&#8217; meeting is authorized to adopt or amend the by-laws (two-thirds majority). The extraordinary shareholders&#8217; meeting may authorize the board of directors to amend the by-laws to comply with legal provisions, subject to the ratification of such amendments by the next extraordinary shareholders&#8217; meeting. The board of directors is authorized to amend the by-laws as a result of a decision to relocate the company&#8217;s registered office in France, subject to ratification by the next ordinary shareholders&#8217; meeting.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Under Delaware law, the stockholders entitled to vote have the power to adopt, amend or repeal by-laws. A corporation may also confer, in its certificate of incorporation, that power upon the board of directors.</font></div></td></tr></table></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">AMERICAN DEPOSITARY SHARES</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Citibank, N.A. (&#8220;Citibank&#8221;) is the depositary for the ADSs representing our ordinary shares pursuant to a deposit agreement. Citibank&#8217;s depositary offices are located at 388 Greenwich Street, New York, New York 10013. ADSs represent ownership interests in securities that are on deposit with the depositary bank. ADSs may be represented by certificates that are commonly known as &#8220;American Depositary Receipts&#8221; or &#8220;ADRs.&#8221; The depositary bank typically appoints a custodian to safekeep the securities on deposit. In this case, the custodian is Citibank Europe plc located at 1 North Wall Quay, Dublin 1, Ireland.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The form of the deposit agreement is on file with the SEC under cover of a registration statement on Form F-6. You may obtain a copy of the deposit agreement from the SEC&#8217;s website (www.sec.gov). Please refer to registration number 333-274845 when retrieving such copy. The portions of this summary description that are italicized describe matters that may be relevant to the ownership of ADSs but that may not be contained in the deposit agreement.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We are providing you with a summary description of the material terms of the ADSs and of your material rights as an owner of ADSs. Please remember that summaries by their nature lack the precision of the information summarized and that the rights and obligations of an owner of ADSs will be determined by reference to the terms of the deposit agreement and not by this summary. We urge you to review the deposit agreement in its entirety. The portions of this summary description that are italicized describe matters that may be relevant to the ownership of ADSs but that may not be contained in the deposit agreement. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Each ADS represents the right to receive, and to exercise the beneficial ownership interests in, one ordinary share that is on deposit with the depositary bank and&#47;or custodian. An ADS also represents the right to receive, and to exercise the beneficial interests in, any other property received by the depositary bank or the custodian on behalf of the owner of the ADS but that has not been distributed to the owners of ADSs because of legal restrictions or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">practical considerations. We and the depositary bank may agree to change the ADS-to-Share ratio by amending the deposit agreement. This amendment may give rise to, or change, the depositary fees payable by ADS owners. The custodian, the depositary bank and their respective nominees will hold all deposited property for the benefit of the holders and beneficial owners of ADSs. The deposited property does not constitute the proprietary assets of the depositary bank, the custodian or their nominees. Beneficial ownership in the deposited property will under the terms of the deposit agreement be vested in the beneficial owners of the ADSs. The depositary bank, the custodian and their respective nominees will be the record holders of the deposited property represented by the ADSs for the benefit of the holders and beneficial owners of the corresponding ADSs. A beneficial owner of ADSs may or may not be the holder of ADSs. Beneficial owners of ADSs will be able to receive, and to exercise beneficial ownership interests in, the deposited property only through the registered holders of the ADSs, the registered holders of the ADSs (on behalf of the applicable ADS owners) only through the depositary bank, and the depositary bank (on behalf of the owners of the corresponding ADSs) directly, or indirectly, through the custodian or their respective nominees, in each case upon the terms of the deposit agreement.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If you become an owner of ADSs, you will become a party to the deposit agreement and therefore will be bound to its terms and to the terms of any ADR that represents your ADSs. The deposit agreement and the ADR specify our rights and obligations as well as your rights and obligations as an owner of ADSs and those of the depositary bank. As an ADS holder you appoint the depositary bank to act on your behalf in certain circumstances. The deposit agreement and the ADRs are governed by New York law. However, our obligations to the holders of ordinary shares will continue to be governed by the laws of France, which may be different from the laws in the United States. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In addition, applicable laws and regulations may require you to satisfy reporting requirements and obtain regulatory approvals in certain circumstances. You are solely responsible for complying with such reporting requirements and obtaining such approvals. Neither the depositary bank, the custodian, us or any of their or our respective agents or affiliates shall be required to take any actions whatsoever on your behalf to satisfy such reporting requirements or obtain such regulatory approvals under applicable laws and regulations. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">As an owner of ADSs, we will not treat you as one of our shareholders and you will not have direct shareholder rights. The depositary bank will hold on your behalf the shareholder rights attached to the ordinary shares underlying your ADSs. As an owner of ADSs you will be able to exercise the shareholders rights for the ordinary shares represented by your ADSs through the depositary bank only to the extent contemplated in the deposit agreement. To exercise any shareholder rights not contemplated in the deposit agreement you will, as an ADS owner, need to arrange for the cancellation of your ADSs and become a direct shareholder.&#8195; </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The manner in which you own the ADSs (e.g., in a brokerage account vs. as registered holder, or as holder of certificated vs. uncertificated ADSs) may affect your rights and obligations, and the manner in which, and extent to which, the depositary bank&#8217;s services are made available to you. As an owner of ADSs, you may hold your ADSs either by means of an ADR registered in your name, through a brokerage or safekeeping account, or through an account established by the depositary bank in your name reflecting the registration of uncertificated ADSs directly on the books of the depositary bank (commonly referred to as the &#8220;direct registration system&#8221; or &#8220;DRS&#8221;). The direct registration system reflects the uncertificated (book-entry) registration of ownership of ADSs by the depositary bank. Under the direct registration system, ownership of ADSs is evidenced by periodic statements issued by the depositary bank to the holders of the ADSs. The direct registration system includes automated transfers between the depositary bank and The Depository Trust Company (&#8220;DTC&#8221;), the central book-entry clearing and settlement system for equity securities in the United States. If you decide to hold your ADSs through your brokerage or safekeeping account, you must rely on the procedures of your broker or bank to assert your rights as ADS owner. Banks and brokers typically hold securities such as the ADSs through clearing and settlement systems such as DTC. The procedures of such clearing and settlement systems may limit your ability to exercise your rights as an owner of ADSs. Please consult with your broker or bank if you have any questions concerning these limitations and procedures. All ADSs held through DTC will be registered in the name of a nominee of DTC. This summary description assumes you have opted to own the ADSs directly by means of an ADS registered in your name and, as such, we will refer to you as the &#8220;holder.&#8221; When we refer to &#8220;you,&#8221; we assume the reader owns ADSs and will own ADSs at the relevant time. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The registration of the ordinary shares in the name of the depositary bank or the custodian shall, to the maximum extent permitted by applicable law, vest in the depositary bank or the custodian the record ownership in the applicable ordinary shares with the beneficial ownership rights and interests in such ordinary shares being at all times vested with the beneficial owners of the ADSs representing the ordinary shares. The depositary bank or the custodian shall at all times be entitled to exercise the beneficial ownership rights in all deposited property, in each case only on behalf of the holders and beneficial owners of the ADSs representing the deposited property. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Dividends and Distributions </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As a holder of ADSs, you generally have the right to receive the distributions we make on the securities deposited with the custodian. Your receipt of these distributions may be limited, however, by practical considerations and legal limitations. Holders of ADSs will receive such distributions under the terms of the deposit agreement in proportion to the number of ADSs held as of the specified record date, after deduction of the applicable fees, taxes and expenses. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Distributions of Cash </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Whenever we make a cash distribution for the securities on deposit with the custodian, we will deposit the funds with the custodian. Upon receipt of confirmation of the deposit of the requisite funds, the depositary bank will arrange for the funds received in a currency other than U.S. dollars to be converted into U.S. dollars and for the distribution of the U.S. dollars to the holders, subject to the laws and regulations of France. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The conversion into U.S. dollars will take place only if practicable and if the U.S. dollars are transferable to the United States. The depositary bank will apply the same method for distributing the proceeds of the sale of any property (such as undistributed rights) held by the custodian in respect of securities on deposit. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The distribution of cash will be made net of the fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit agreement. The depositary bank will hold any cash amounts it is unable to distribute in a non-interest bearing account for the benefit of the applicable holders and beneficial owners of ADSs until the distribution can be effected or the funds that the depositary bank holds must be escheated as unclaimed property in accordance with the laws of the relevant states of the United States. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Distributions of Shares </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Whenever we make a free distribution of ordinary shares for the securities on deposit with the custodian, we will deposit the applicable number of ordinary shares with the custodian. Upon receipt of confirmation of such deposit, the depositary bank will </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">either</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> distribute to holders new ADSs representing the ordinary shares deposited </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> modify the ADS-to-ordinary shares ratio, in which case each ADS you hold will represent rights and interests in the additional ordinary shares so deposited. Only whole new ADSs will be distributed. Fractional entitlements will be sold and the proceeds of such sale will be distributed as in the case of a cash distribution. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The distribution of new ADSs or the modification of the ADS-to-ordinary shares ratio upon a distribution of ordinary shares will be made net of the fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit agreement. In order to pay such taxes or governmental charges, the depositary bank may sell all or a portion of the new ordinary shares so distributed. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">No such distribution of new ADSs will be made if it would violate a law (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">, the U.S. securities laws) or if it is not operationally practicable. If the depositary bank does not distribute new ADSs as described above, it may sell the ordinary shares received upon the terms described in the deposit agreement and will distribute the proceeds of the sale as in the case of a distribution of cash. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Distributions of Rights </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Whenever we intend to distribute rights to subscribe for additional ordinary shares, we will give prior notice to the depositary bank and we will assist the depositary bank in determining whether it is lawful and reasonably practicable to distribute rights to subscribe for additional ADSs to holders. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The depositary bank will establish procedures to distribute rights to subscribe for additional ADSs to holders and to enable such holders to exercise such rights if it is lawful and reasonably practicable to make the rights available to holders of ADSs, and if we provide all of the documentation contemplated in the deposit agreement (such as opinions to address the lawfulness of the transaction). You may have to pay fees, expenses, taxes and other governmental charges to subscribe for the new ADSs upon the exercise of your rights. The depositary bank is not obligated to establish procedures to facilitate the distribution and exercise by holders of rights to subscribe for new ordinary shares other than in the form of ADSs. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The depositary bank will </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">not</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> distribute the rights to you if&#58; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;We do not timely request that the rights be distributed to you or we request that the rights not be distributed to you&#59; or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;We fail to deliver satisfactory documents to the depositary bank&#59; or </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;It is not reasonably practicable to distribute the rights. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The depositary bank will sell the rights that are not exercised or not distributed if such sale is lawful and reasonably practicable. The proceeds of such sale will be distributed to holders as in the case of a cash distribution. If the depositary bank is unable to sell the rights, it will allow the rights to lapse. </font></div><div style="margin-top:13.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Elective Distributions </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Whenever we intend to distribute a dividend payable at the election of shareholders either in cash or in additional shares, we will give prior notice thereof to the depositary bank and will indicate whether we wish the elective distribution to be made available to you. In such case, we will assist the depositary bank in determining whether such distribution is lawful and reasonably practicable. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The depositary bank will make the election available to you only if it is reasonably practicable and if we have provided all of the documentation contemplated in the deposit agreement. In such case, the depositary bank will establish procedures to enable you to elect to receive either cash or additional ADSs, in each case as described in the deposit agreement. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If the election is not made available to you, you will receive either cash or additional ADSs, depending on what a shareholder in France would receive upon failing to make an election, as more fully described in the deposit agreement. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Other Distributions </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Whenever we intend to distribute property other than cash, ordinary shares or rights to subscribe for additional ordinary shares, we will notify the depositary bank in advance and will indicate whether we wish such distribution to be made to you. If so, we will assist the depositary bank in determining whether such distribution to holders is lawful and reasonably practicable. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If it is reasonably practicable to distribute such property to you and if we provide to the depositary bank all of the documentation contemplated in the deposit agreement, the depositary bank will distribute the property to the holders in a manner it deems practicable. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The distribution will be made net of fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit agreement. In order to pay such taxes and governmental charges, the depositary bank may sell all or a portion of the property received. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The depositary bank will </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">not</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> distribute the property to you and will sell the property if&#58; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;We do not request that the property be distributed to you or if we request that the property not be distributed to you&#59; or </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;We do not deliver satisfactory documents to the depositary bank&#59; or </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;The depositary bank determines that all or a portion of the distribution to you is not reasonably practicable. </font></div><div style="margin-top:12pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;The proceeds of such a sale will be distributed to holders as in the case of a cash distribution. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Redemption </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Whenever we decide to redeem any of the securities on deposit with the custodian, we will notify the depositary bank in advance. If it is practicable and if we provide all of the documentation contemplated in the deposit agreement, the depositary bank will provide notice of the redemption to the holders. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The custodian will be instructed to surrender the shares being redeemed against payment of the applicable redemption price. The depositary bank will convert into U.S. dollars upon the terms of the deposit agreement the redemption funds received in a currency other than U.S. dollars and will establish procedures to enable holders to receive the net proceeds from the redemption upon surrender of their ADSs to the depositary bank. You may have to pay fees, expenses, taxes and other governmental charges upon the redemption of your ADSs. If less than all ADSs are being redeemed, the ADSs to be retired will be selected by lot or on a </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">pro rata</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> basis, as the depositary bank may determine. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:13.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Changes Affecting Ordinary Shares </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The ordinary shares held on deposit for your ADSs may change from time to time. For example, there may be a change in nominal or par value, split-up, cancellation, consolidation or any other reclassification of such ordinary shares or a recapitalization, reorganization, merger, consolidation or sale of our assets. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If any such change were to occur, your ADSs would, to the extent permitted by law and the deposit agreement, represent the right to receive the property received or exchanged in respect of the ordinary shares held on deposit. The depositary bank may in such circumstances deliver new ADSs to you, amend the deposit agreement, the ADRs and the applicable Registration Statement(s) on Form F-6, call for the exchange of your existing ADSs for new ADSs and take any other actions that are appropriate to reflect as to the ADSs the change affecting the Shares. If the depositary bank may not lawfully distribute such property to you, the depositary bank may sell such property and distribute the net proceeds to you as in the case of a cash distribution. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Issuance of ADSs upon Deposit of Ordinary Shares </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The depositary bank may create ADSs on your behalf if you or your broker deposit ordinary shares with the custodian. The depositary bank will deliver these ADSs to the person you indicate only after you pay any applicable issuance fees and any charges and taxes payable for the transfer of the ordinary shares to the custodian. Your ability to deposit ordinary shares and receive ADSs may be limited by U.S. and French legal considerations applicable at the time of deposit. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The issuance of ADSs may be delayed until the depositary bank or the custodian receives confirmation that all required approvals have been given and that the ordinary shares have been duly transferred to the custodian. The depositary bank will only issue ADSs in whole numbers. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">When you make a deposit of ordinary shares, you will be responsible for transferring good and valid title to the depositary bank. As such, you will be deemed to represent and warrant that&#58; </font></div><div style="margin-top:6pt;padding-left:24.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The ordinary shares are duly authorized, validly issued, fully paid, non-assessable and legally obtained. </font></div><div style="margin-top:6pt;padding-left:24.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">All preemptive (and similar) rights, if any, with respect to such ordinary shares have been validly waived or exercised. </font></div><div style="margin-top:6pt;padding-left:24.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">You are duly authorized to deposit the ordinary shares. </font></div><div style="margin-top:6pt;padding-left:24.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The ordinary shares presented for deposit are free and clear of any lien, encumbrance, security interest, charge, mortgage or adverse claim, and are not, and the ADSs issuable upon such deposit will not be, &#8220;restricted securities&#8221; (as defined in the deposit agreement). </font></div><div style="margin-top:6pt;padding-left:24.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The ordinary shares presented for deposit have not been stripped of any rights or entitlements. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If any of the representations or warranties are incorrect in any way, we and the depositary bank may, at your cost and expense, take any and all actions necessary to correct the consequences of the misrepresentations. </font></div><div style="margin-top:13.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Transfer, Combination and Split Up of ADRs </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As an ADR holder, you will be entitled to transfer, combine or split up your ADRs and the ADSs evidenced thereby. For transfers of ADRs, you will have to surrender the ADRs to be transferred to the depositary bank and also must&#58; </font></div><div style="margin-top:6pt;padding-left:24.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">ensure that the surrendered ADR is properly endorsed or otherwise in proper form for transfer&#59; </font></div><div style="margin-top:6pt;padding-left:24.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">provide such proof of identity and genuineness of signatures as the depositary bank deems appropriate&#59; </font></div><div style="margin-top:6pt;padding-left:24.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">provide any transfer stamps required by the State of New York or the United States&#59; and </font></div><div style="margin-top:6pt;padding-left:24.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">pay all applicable fees, charges, expenses, taxes and other government charges payable by ADR holders pursuant to the terms of the deposit agreement, upon the transfer of ADRs. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">To have your ADRs either combined or split up, you must surrender the ADRs in question to the depositary bank with your request to have them combined or split up, and you must pay all applicable fees, charges and expenses payable by ADR holders, pursuant to the terms of the deposit agreement, upon a combination or split up of ADRs. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Withdrawal of Ordinary Shares Upon Cancellation of ADSs </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As a holder, you will be entitled to present your ADSs to the depositary bank for cancellation and then receive the corresponding number of underlying ordinary shares at the custodian&#8217;s offices. Your ability to withdraw the ordinary shares held in respect of the ADSs may be limited by U.S. and French law considerations applicable at the time of withdrawal. In order to withdraw the ordinary shares represented by your ADSs, you will be required to pay to the depositary bank the fees for cancellation of ADSs and any charges and taxes payable upon the transfer of the ordinary shares. You assume the risk for delivery of all funds and securities upon withdrawal. Once canceled, the ADSs will not have any rights under the deposit agreement. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If you hold ADSs registered in your name, the depositary bank may ask you to provide proof of identity and genuineness of any signature and such other documents as the depositary bank may deem appropriate before it will cancel your ADSs. The withdrawal of the ordinary shares represented by your ADSs may be delayed until the depositary bank receives satisfactory evidence of compliance with all applicable laws and regulations. Please keep in mind that the depositary bank will only accept ADSs for cancellation that represent a whole number of securities on deposit. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">You will have the right to withdraw the securities represented by your ADSs at any time except for&#58; </font></div><div style="margin-top:6pt;padding-left:24.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Temporary delays that may arise because (i)&#160;the transfer books for the ordinary shares or ADSs are closed, or (ii)&#160;ordinary shares are immobilized on account of a shareholders&#8217; meeting or a payment of dividends. </font></div><div style="margin-top:6pt;padding-left:24.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Obligations to pay fees, taxes and similar charges. </font></div><div style="margin-top:6pt;padding-left:24.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Restrictions imposed because of laws or regulations applicable to ADSs or the withdrawal of securities on deposit. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The deposit agreement may not be modified to impair your right to withdraw the securities represented by your ADSs except to comply with mandatory provisions of law. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Voting Rights </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As a holder, you generally have the right under the deposit agreement to instruct the depositary bank to exercise the voting rights for the ordinary shares represented by your ADSs. The voting rights of holders of ordinary shares are described in the section of this prospectus entitled &#8220;Description of Share Capital.&#8221; </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">At our request, the depositary bank will distribute to you any notice of shareholders&#8217; meeting received from us together with information explaining how to instruct the depositary bank to exercise the voting rights of the securities represented by ADSs. In lieu of distributing such materials, the depositary bank may distribute to holders of ADSs instructions on how to retrieve such materials upon request. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If the depositary bank timely receives voting instructions from a holder of ADSs, it will endeavor to vote the securities (in person or by proxy) represented by the holder&#8217;s ADSs in accordance with such voting instructions. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Securities for which no voting instructions have been received will not be voted (except as otherwise contemplated in the deposit agreement). Please note that the ability of the depositary bank to carry out voting instructions may be limited by practical and legal limitations and the terms of the securities on deposit. We cannot assure you that you will receive voting materials in time to enable you to return voting instructions to the depositary bank in a timely manner. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Fees and Charges </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As an ADS holder, you will be required to pay the following fees under the terms of the deposit agreement&#58; </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Service</font></div><div style="margin-top:1pt;padding-right:-1.32pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:80%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.27pt;padding-right:2.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fees</font></div><div style="padding-left:2.27pt;padding-right:2.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:80%">&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of ADSs (e.g., an issuance of ADS upon a deposit of ordinary shares, upon a change in the ADS(s)-to-ordinary share ratio, or for any other reason), excluding ADS issuances as a result of distributions of ordinary shares)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Up to U.S. 5&#162; per ADS issued</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cancellation of ADSs (e.g., a cancellation of ADSs for delivery of deposited property, upon a change in the ADS(s)-to-ordinary share ratio, or for any other reason)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Up to U.S. 5&#162; per ADS cancelled</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Distribution of cash dividends or other cash distributions (e.g., upon a sale of rights and other entitlements)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Up to U.S. 5&#162; per ADS held</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Distribution of ADSs pursuant to (i)&#160;share dividends or other free share distributions, or (ii)&#160;exercise of rights to purchase additional ADSs</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Up to U.S. 5&#162; per ADS held</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Distribution of securities other than ADSs or rights to purchase additional ADSs (e.g., upon a spin-off)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Up to U.S. 5&#162; per ADS held</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">ADS Services</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Up to U.S. 5&#162; per ADS held on the applicable record date(s) established by the depositary bank</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Registration of ADS transfers (e.g., upon a registration of the transfer of registered ownership of ADSs, upon a transfer of ADSs into DTC and </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">vice versa</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">, or for any other reason)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Up to U.S. 5&#162; per ADS (or fraction thereof) transferred</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:133%">&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Conversion of ADSs of one series for ADSs of another series (e.g., upon conversion of Partial Entitlement ADSs for Full Entitlement ADSs, or upon conversion of Restricted ADSs (each as defined in the Deposit Agreement) into freely transferable ADSs, and </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">vice versa</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Up to U.S. 5&#162; per ADS (or fraction thereof) converted</font></div></td></tr></table></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As an ADS holder you will also be responsible to pay certain charges such as&#58; </font></div><div style="margin-top:6pt;padding-left:24.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">taxes (including applicable interest and penalties) and other governmental charges&#59; </font></div><div style="margin-top:4.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:24.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">the registration fees as may from time to time be in effect for the registration of ordinary shares on the share register and applicable to transfers of ordinary shares to or from the name of the custodian, the depositary bank or any nominees upon the making of deposits and withdrawals, respectively&#59; </font></div><div style="margin-top:6pt;padding-left:24.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">certain cable, telex and facsimile transmission and delivery expenses&#59; </font></div><div style="margin-top:6pt;padding-left:24.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">the fees, expenses, spreads, taxes and other charges of the depositary bank and&#47;or service providers (which may be a division, branch or affiliate of the depositary bank) in the conversion of foreign currency&#59; </font></div><div style="margin-top:6pt;padding-left:24.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">the reasonable and customary out-of-pocket expenses incurred by the depositary bank in connection with compliance with exchange control regulations and other regulatory requirements applicable to ordinary shares, ADSs and ADRs&#59; and </font></div><div style="margin-top:6pt;padding-left:24.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">the fees, charges, costs and expenses incurred by the depositary bank, the custodian, or any nominee in connection with the ADR program. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">ADS fees and charges for (i)&#160;the issuance of ADSs, and (ii)&#160;the cancellation of ADSs are charged to the person for whom the ADSs are issued (in the case of ADS issuances) and to the person for whom ADSs are cancelled (in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">the case of ADS cancellations). In the case of ADSs issued by the depositary bank into DTC, the ADS issuance and cancellation fees and charges may be deducted from distributions made through DTC, and may be charged to the DTC participant(s) receiving the ADSs being issued or the DTC participant(s) holding the ADSs being cancelled, as the case may be, on behalf of the beneficial owner(s) and will be charged by the DTC participant(s) to the account of the applicable beneficial owner(s) in accordance with the procedures and practices of the DTC participants as in effect at the time. ADS fees and charges in respect of distributions and the ADS service fee are charged to the holders as of the applicable ADS record date. In the case of distributions of cash, the amount of the applicable ADS fees and charges is deducted from the funds being distributed. In the case of (i)&#160;distributions other than cash and (ii)&#160;the ADS service fee, holders as of the ADS record date will be invoiced for the amount of the ADS fees and charges and such ADS fees and charges may be deducted from distributions made to holders of ADSs. For ADSs held through DTC, the ADS fees and charges for distributions other than cash and the ADS service fee may be deducted from distributions made through DTC, and may be charged to the DTC participants in accordance with the procedures and practices prescribed by DTC and the DTC participants in turn charge the amount of such ADS fees and charges to the beneficial owners for whom they hold ADSs. In the case of (i)&#160;registration of ADS transfers, the ADS transfer fee will be payable by the ADS Holder whose ADSs are being transferred or by the person to whom the ADSs are transferred, and (ii)&#160;conversion of ADSs of one series for ADSs of another series, the ADS conversion fee will be payable by the Holder whose ADSs are converted or by the person to whom the converted ADSs are delivered. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In the event of refusal to pay the depositary bank fees, the depositary bank may, under the terms of the deposit agreement, refuse the requested service until payment is received or may set off the amount of the depositary bank fees from any distribution to be made to the ADS holder. You will receive prior notice of such changes. The depositary bank may reimburse us for certain expenses incurred by us in respect of the ADR program, by making available a portion of the ADS fees charged in respect of the ADR program or otherwise, upon such terms and conditions as we and the depositary bank agree from time to time. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Amendments and Termination </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We may agree with the depositary bank to modify the deposit agreement at any time without your consent. We undertake to give holders 30 days&#8217; prior notice of any modifications that would materially prejudice any of their substantial rights under the deposit agreement. We will not consider to be materially prejudicial to your substantial rights any modifications or supplements that are reasonably necessary for the ADSs to be registered under the Securities Act or to be eligible for book-entry settlement, in each case without imposing or increasing the fees and charges you are required to pay. In addition, we may not be able to provide you with prior notice of any modifications or supplements that are required to accommodate compliance with applicable provisions of law. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">You will be bound by the modifications to the deposit agreement if you continue to hold your ADSs after the modifications to the deposit agreement become effective. The deposit agreement cannot be amended to prevent you from withdrawing the ordinary shares represented by your ADSs (except as permitted by law). </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We have the right to direct the depositary bank to terminate the deposit agreement. Similarly, the depositary bank may in certain circumstances on its own initiative terminate the deposit agreement. In either case, the depositary bank must give notice to the holders at least 30 days before termination. Until termination, your rights under the deposit agreement will be unaffected. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">After termination, the depositary bank will continue to collect distributions received (but will not distribute any such property until you request the cancellation of your ADSs) and may sell the securities held on deposit. After the sale, the depositary bank will hold the proceeds from such sale and any other funds then held for the holders of ADSs in a non-interest bearing account. At that point, the depositary bank will have no further obligations to holders other than to account for the funds then held for the holders of ADSs still outstanding (after deduction of applicable fees, taxes and expenses). </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In connection with any termination of the deposit agreement, the depositary bank may make available to owners of ADSs a means to withdraw the ordinary shares represented by ADSs and to direct the depositary of such ordinary shares into an unsponsored American depositary share program established by the depositary bank. The ability to receive unsponsored American depositary shares upon termination of the deposit agreement would be subject to satisfaction of certain U.S. regulatory requirements applicable to the creation of unsponsored American depositary shares and the payment of applicable depositary fees. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Books of Depositary </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The depositary bank will maintain ADS holder records at its depositary office. You may inspect such records at such office during regular business hours but solely for the purpose of communicating with other holders in the interest of business matters relating to the ADSs and the deposit agreement. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The depositary bank will maintain in New York facilities to record and process the issuance, cancellation, combination, split-up and transfer of ADSs. These facilities may be closed from time to time, to the extent not prohibited by law. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Limitations on Obligations and Liabilities </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;The deposit agreement limits our obligations and the depositary bank&#8217;s obligations to you. Please note the following&#58; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;We and the depositary bank are obligated only to take the actions specifically stated in the deposit agreement without negligence or bad faith. </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;The depositary bank disclaims any liability for any failure to carry out voting instructions, for any manner in which a vote is cast or for the effect of any vote, provided it acts in good faith and in accordance with the terms of the deposit agreement. </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;The depositary bank disclaims any liability for any failure to determine the lawfulness or practicality of any action, for the content of any document forwarded to you on our behalf or for the accuracy of any translation of such a document, for the investment risks associated with investing in ordinary shares, for the validity or worth of the ordinary shares, for any tax consequences that result from the ownership of ADSs, for the credit-worthiness of any third party, for allowing any rights to lapse under the terms of the deposit agreement, for the timeliness of any of our notices or for our failure to give notice. </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;We and the depositary bank will not be obligated to perform any act that is inconsistent with the terms of the deposit agreement. </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;We and the depositary bank disclaim any liability if we or the depositary bank are prevented or forbidden from or subject to any civil or criminal penalty or restraint on account of, or delayed in, doing or performing any act or thing required by the terms of the deposit agreement, by reason of any provision, present or future of any law or regulation, or by reason of present or future provision of any provision of our by-laws, or any provision of or governing the securities on deposit, or by reason of any act of God or war or other circumstances beyond our control. </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;We and the depositary bank disclaim any liability by reason of any exercise of, or failure to exercise, any discretion provided for in the deposit agreement or in our by-laws or in any provisions of or governing the securities on deposit. </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;We and the depositary bank further disclaim any liability for any action or inaction in reliance on the advice or information received from legal counsel, accountants, any person presenting Shares for deposit, any holder of ADSs or authorized representatives thereof, or any other person believed by either of us in good faith to be competent to give such advice or information. </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;We and the depositary bank also disclaim liability for the inability by a holder to benefit from any distribution, offering, right or other benefit that is made available to holders of ordinary shares but is not, under the terms of the deposit agreement, made available to you. </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;We and the depositary bank may rely without any liability upon any written notice, request or other document believed to be genuine and to have been signed or presented by the proper parties. </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;We and the depositary bank also disclaim liability for any consequential or punitive damages for any breach of the terms of the deposit agreement. </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;No disclaimer of any Securities Act liability is intended by any provision of the deposit agreement. </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;Nothing in the deposit agreement gives rise to a partnership or joint venture, or establishes a fiduciary relationship, among us, the depositary bank and you as ADS holder. </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;Nothing in the deposit agreement precludes Citibank (or its affiliates) from engaging in transactions in which parties adverse to us or the ADS owners have interests, and nothing in the deposit agreement obligates Citibank to disclose those transactions, or any information obtained in the course of those transactions, to us or to the ADS owners, or to account for any payment received as part of those transactions. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">As the above limitations relate to our obligations and the depositary&#8217;s obligations to you under the deposit agreement, we believe that, as a matter of construction of the clause, such limitations would likely to continue to apply to ADS holders who withdraw the ordinary shares from the ADS facility with respect to obligations or liabilities incurred under the deposit agreement before the cancellation of the ADSs and the withdrawal of the ordinary shares, and such limitations would most likely not apply to ADS holders who withdraw the ordinary shares from the ADS facility with respect to obligations or liabilities incurred after the cancellation of the ADSs and the withdrawal of the ordinary shares and not under the deposit agreement. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">In any event, you will not be deemed, by agreeing to the terms of the deposit agreement, to have waived our or the depositary&#8217;s compliance with U.S. federal securities laws and the rules and regulations promulgated thereunder. In fact, you cannot waive our or the depositary&#8217;s compliance with U.S. federal securities laws and the rules and regulations promulgated thereunder. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Taxes </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">You will be responsible for the taxes and other governmental charges payable on the ADSs and the securities represented by the ADSs. We, the depositary bank and the custodian may deduct from any distribution the taxes and governmental charges payable by holders and may sell any and all property on deposit to pay the taxes and governmental charges payable by holders. You will be liable for any deficiency if the sale proceeds do not cover the taxes that are due. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The depositary bank may refuse to issue ADSs, to deliver, transfer, split and combine ADRs or to release securities on deposit until all taxes and charges are paid by the applicable holder. The depositary bank and the custodian may take reasonable administrative actions to obtain tax refunds and reduced tax withholding for any distributions on your behalf. However, you may be required to provide to the depositary bank and to the custodian proof of taxpayer status and residence and such other information as the depositary bank and the custodian may require to fulfill legal obligations. You are required to indemnify us, the depositary bank and the custodian for any claims with respect to taxes based on any tax benefit obtained for you. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Conversion </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The depositary bank will arrange for the conversion of all foreign currency received into U.S. dollars if such conversion is practical, and it will distribute the U.S. dollars in accordance with the terms of the deposit agreement. You may have to pay fees and expenses incurred in converting foreign currency, such as fees and expenses incurred in complying with currency exchange controls and other governmental requirements. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If the conversion of foreign currency is not practical or lawful, or if any required approvals are denied or not obtainable at a reasonable cost or within a reasonable period, the depositary bank may take the following actions in its discretion&#58; </font></div><div style="margin-top:6pt;padding-left:24.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Convert the foreign currency to the extent practical and lawful and distribute the U.S. dollars to the holders for whom the conversion and distribution is lawful and practical. </font></div><div style="margin-top:6pt;padding-left:24.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Distribute the foreign currency to holders for whom the distribution is lawful and practical. </font></div><div style="margin-top:6pt;padding-left:24.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Hold the foreign currency (without liability for interest) for the applicable holders. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Governing Law&#47;Waiver of Jury Trial </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The deposit agreement, the ADRs and the ADSs will be interpreted in accordance with the laws of the State of New York. The rights of holders of ordinary shares (including ordinary shares represented by ADSs) are governed by the laws of France. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As an owner of ADSs, you irrevocably agree that any legal action arising out of the Deposit Agreement, the ADSs or the ADRs involving us or the Depositary may only be instituted in a state or federal court in the city of New York. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">AS A PARTY TO THE DEPOSIT AGREEMENT, YOU IRREVOCABLY WAIVE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, YOUR RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF THE DEPOSIT AGREEMENT OR THE ADRs AGAINST US AND&#47;OR THE DEPOSITARY BANK. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The deposit agreement provides that, to the extent permitted by law, ADS holders waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our ordinary shares, the ADSs or the deposit agreement, including any claim under U.S. federal securities laws. If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable in the facts and circumstances of that case in accordance with applicable case law. However, you will not be deemed, by agreeing to the terms of the deposit agreement, to have waived our or the depositary&#8217;s compliance with U.S. federal securities laws and the rules and regulations promulgated thereunder.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.16
<SEQUENCE>4
<FILENAME>abivax-20xfxex416summaryof.htm
<DESCRIPTION>EX-4.16
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="if05733942a0b455c99356ed72933b841_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Exhibit 4.16</font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Summary of BSA Plans</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As at February 28, 2026, seven BSA share warrant plans were outstanding&#58; BSA 2015-11, BSA 2015-12, BSA 2017-1, BSA 2018-1, BSA 2024-1, BSA 2024-2, BSA-2025-1, BSA-2025-2 and BSA-2026-1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Share warrants (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">bons de souscription d&#8217;actions</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">), or BSAs, entitle a holder to exercise the warrant for the underlying vested shares at an exercise price per share determined by our board of directors and at least equal to the fair market value of an ordinary share on the date of grant. In addition to any exercise price payable by a holder upon the exercise of any share warrant, share warrants need to be subscribed for at a price which is determined by the board of directors at the time of the grant.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Administration</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">. Pursuant to delegations granted at our annual meeting, our board of directors determines the recipients, dates of grant and exercise price of share warrants, the number of share warrants to be granted and the terms and conditions of the share warrants, including their exercise period and their vesting period. In its discretion, the board of directors has the authority to extend the exercise period of share warrants post-termination.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Underlying shares</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">. Each BSA 2014-4, each BSA 2014-5, each BSA 2015-11, each BSA 2015-12, each BSA 2017-1, each BSA 2018-1, each BSA-2024-1, each BSA-2024-2, each BSA-2025-1, each BSA-2025-2 and each BSA-2026-1 gives the holder the right to purchase one (1)&#160;ordinary share. The number of shares to which the exercise of the BSAs entitles the holder has been multiplied by 100 for all BSAs issued prior to the division by 100 of the nominal value of the shares, decided by our general meeting on February 20, 2015. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Allocation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">. Our BSAs are generally subscribed by officers, directors,&#160;employees, consultants or partners of our company. BSAs 2024-1, BSAs 2024-2, BSAs 2025-1 and BSAs 2025-2 may not be transferred. BSAs 2017-1 and BSAs 2018-1 may not be transferred except specific authorization granted by the Board of the Company. BSAs 2014-4 and BSAs 2014-5 may not be transferred save in case (i) the board of directors expressly authorizes such transfer or (ii) of the holder&#8217;s death to his&#47;her heirs, who may exercise the exercisable BSAs as of the holder&#8217;s death and for a period of 6 months thereafter, failing which the BSAs will become null and void. BSAs 2015-12 may not be transferred save in case (i) the board of directors expressly authorizes such transfer or (ii) of the holder&#8217;s death.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Standard terms</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">. The conditions to exercise our BSAs are as follows&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.24pt">The BSAs 2015-11 will be exercisable </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">pro rata</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> to the number of months elapsed from their allocation over a total period of thirty-six (36) months, in one or several occasions. In any event, except in the event of dismissal for serious misconduct or gross negligence, the exercisable BSAs must be exercised by the holder within ninety (90) days of ceasing to be a member of the Company&#8217;s Board of Directors. If they are not exercised within this period or in the event of dismissal for serious misconduct or gross negligence, the exercisable BSAs will become null and void.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.67pt">The BSAs 2015-12 will be exercisable </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">pro rata</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> to the number of months elapsed from their allocation over a total period of forty-eight (48) months, in one or several occasions, it being specified that the beneficiary may only exercise the BSAs at the end of a period of one (1) year from their allocation. In any event, except in the event of dismissal for serious misconduct or gross negligence, the exercisable BSAs must be exercised by the holder within ninety (90) days of ceasing to be a member of the Company&#8217;s Scientific Committee. If they are not exercised within this period or in the event of dismissal for serious misconduct or gross negligence, the exercisable BSAs will become null and void.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.46pt">The BSAs 2017-1 will be exercisable for one third on the allocation date, for one third on March 18, 2018 and the balance on September 19, 2019, in one or several occasions. In any event, except in the event of dismissal for serious misconduct or gross negligence, the exercisable BSAs must be exercised by the holder within three (3) months of ceasing to be a member of the Company&#8217;s board of directors. If they are not exercised within this period or in the event of dismissal for serious misconduct or gross negligence, the exercisable BSAs will become null and void. Additionally, the BSAs will become fully exercisable (i) upon a change of control of the Company, (ii) if the Company is absorbed by another company or (iii) if the Company merges with one or several other companies resulting in the creation of a new entity or (iv) in case of a demerger. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:8.84pt">The BSAs 2018-1 will be exercisable for one third on the allocation date, for one third on July 22, 2018 and the balance on January 22, 2019, in one or several occasions. In any event, except in the event of dismissal for serious misconduct or gross negligence, the exercisable BSAs must be exercised by the holder within three (3) months of ceasing to be a member of the Company&#8217;s board of directors. If they are not exercised </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Exhibit 4.16</font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">within this period or in the event of dismissal for serious misconduct or gross negligence, the exercisable BSAs will become null and void. Additionally, the BSAs will become fully exercisable (i) upon a change of control of the Company, (ii) if the Company is absorbed by another company or (iii) if the Company merges with one or several other companies resulting in the creation of a new entity or (iv) in case of a demerger. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">e)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:9.46pt">The BSAs 2024-1 will be exercisable for one fourth on January 1st, 2025, for one fourth on January 1st, 2026, for one fourth on January 1st, 2027 and the balance on January 1st, 2028, in one or several occasions. In any event, except in the event of dismissal for serious misconduct or gross negligence, the exercisable BSAs must be exercised by the holder within three (3) months of ceasing to be a member of the Company&#8217;s board of directors. If they are not exercised within this period or in the event of dismissal for serious misconduct or gross negligence, the exercisable BSAs will become null and void. Additionally, the BSAs will become fully exercisable (i) upon a change of control of the Company, (ii) if the Company is absorbed by another company or (iii) if the Company merges with one or several other companies resulting in the creation of a new entity or (iv) in case of a demerger. </font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">f)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:11.34pt">The BSAs 2024-2 will be exercisable for one fourth on April 1st, 2025, for one fourth on April 1st, 2026, for one fourth on April 1st, 2027 and the balance on April 1st, 2028, in one or several occasions. In any event, except in the event of dismissal for serious misconduct or gross negligence, the exercisable BSAs must be exercised by the holder within three (3) months of ceasing to be a member of the Company&#8217;s board of directors. If they are not exercised within this period or in the event of dismissal for serious misconduct or gross negligence, the exercisable BSAs will become null and void. Additionally, the BSAs will become fully exercisable (i) upon a change of control of the Company, (ii) if the Company is absorbed by another company or (iii) if the Company merges with one or several other companies resulting in the creation of a new entity or (iv) in case of a demerger. </font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">g)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:9.67pt">The BSAs 2025-1 will be exercisable for one fourth on January 1st, 2026, for one fourth on January 1st, 2027, for one fourth on January 1st, 2028 and the balance on January 1st, 2029, in one or several occasions.  In any event, except in the event of dismissal for serious misconduct or gross negligence, the exercisable BSAs must be exercised by the holder within three (3) months of ceasing to be a member of the Company&#8217;s board of directors. If they are not exercised within this period or in the event of dismissal for serious misconduct or gross negligence, the exercisable BSAs will become null and void. Additionally, the BSAs will become fully exercisable (i) upon a change of control of the Company, (ii) if the Company is absorbed by another company or (iii) if the Company merges with one or several other companies resulting in the creation of a new entity or (iv) in case of a demerger. </font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">h)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:9.67pt">The BSAs 2025-2 will be exercisable for one fourth on January 1st, 2026, for one fourth on January 1st, 2027, for one fourth on January 1st, 2028 and the balance on January 1st, 2029, in one or several occasions.  In any event, except in the event of dismissal for serious misconduct or gross negligence, the exercisable BSAs must be exercised by the holder within three (3) months of ceasing to be a member of the Company&#8217;s board of directors. If they are not exercised within this period or in the event of dismissal for serious misconduct or gross negligence, the exercisable BSAs will become null and void. Additionally, the BSAs will become fully exercisable (i) upon a change of control of the Company, (ii) if the Company is absorbed by another company or (iii) if the Company merges with one or several other companies resulting in the creation of a new entity or (iv) in case of a demerger. </font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:11.9pt">The BSAs 2026-1 will be exercisable for one fourth on February 1st, 2027, for one fourth on February 1st, 2028, for one fourth on February 1st, 2029 and the balance on February 1st, 2030, in one or several occasions.  In any event, except in the event of dismissal for serious misconduct or gross negligence, the exercisable BSAs must be exercised by the holder within three (3) months of ceasing to be a member of the Company&#8217;s board of directors. If they are not exercised within this period or in the event of dismissal for serious misconduct or gross negligence, the exercisable BSAs will become null and void. Additionally, the BSAs will become fully exercisable (i) upon a change of control of the Company, (ii) if the Company is </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Exhibit 4.16</font></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">absorbed by another company or (iii) if the Company merges with one or several other companies resulting in the creation of a new entity or (iv) in case of a demerger.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Validity period. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">All BSAs have a maximum validity period of 10 years as from their issuance.</font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.17
<SEQUENCE>5
<FILENAME>abivax-20xfxex417summaryof.htm
<DESCRIPTION>EX-4.17
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ibcc6157aab6b461293dd1da7af053925_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Exhibit 4.17</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Summary of BCE Plans</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As at February 28, 2026, five BCE share warrant plans were outstanding&#58; BCE 2017-1, BCE 2017-2, BCE 2017-4, BCE 2017-5 and BCE 2018-4.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Founder&#8217;s share warrants (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">bons de souscription de parts de cr&#233;ateur d&#8217;entreprise</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">), or BCEs, entitle a holder to exercise the warrant for the underlying vested shares at an exercise price per share determined by our board of directors and at least equal to the fair market value of an ordinary share on the date of grant. Founder&#8217;s share warrants may only be issued by growth companies meeting certain criteria. Since our initial public offering in France, our eligibility to issue founder&#8217;s share warrants is subject to certain conditions, including that our market capitalization does not exceed &#8364;150M. Therefore, we are no longer eligible to issue founder&#8217;s share warrants.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Administration</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">. Pursuant to delegations granted at our annual meeting of shareholders, our board of directors determines the recipients, dates of grant and exercise price of founder&#8217;s share warrants, the number of founder&#8217;s share warrants to be granted and the terms and conditions of the founder&#8217;s share warrants, including the period of their exercisability and their vesting schedule.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Underlying shares.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;The securities to which the BCE 2017-1 issued on January 23, 2017, BCE 2017-2 issued on November 20, 2017, BCE 2017-4 issued on 20 November 2017, BCE 2017-5 issued on November 20, 2017, and BCE 2018-4 issued on May 14, 2018 (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">BCE</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) give rights are ordinary shares. Each BCE gives the holder the right to purchase one (1)&#160;ordinary share.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Allocation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">. Our founder&#8217;s share warrants are generally granted to executive officers, directors or employees of our company and its subsidiaries. Founder&#8217;s share warrants may not be transferred other than by inheritance.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Standard terms</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">. The vested BCE may be exercised in all or in part at the election of each holder as follows &#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.24pt">A portion of the BCEs 2017-1 and of the BCEs 2017-2 will be exercisable pro rata to the number of months elapsed from their allocation over a total period of 48 months, it being specified that the beneficiary may only exercise the BCEs at the end of a period of one year from their allocation, while the rest of the BCEs will be exercisable only if qualitative and&#47;or quantitative objective(s) set by the Board are met. In any event, except in the event of dismissal for serious misconduct or gross negligence, the exercisable BCEs must be exercised by the beneficiary within ninety (90) days of ceasing to be an employee. If they are not exercised within this period or in the event of dismissal for serious misconduct or gross negligence, the exercisable BCEs will become null and void.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.67pt">A portion of the BCEs 2017-4, BCEs 2017-5 and BCEs 2018-4 became exercisable as from a specific date specified in their terms and conditions, another portion will be exercisable pro rata to the number of months elapsed from their allocation over a total period of 24 months, it being specified that the beneficiary may only exercise the BCEs at the end of a period of one year from their allocation, while the rest of the BCEs will be exercisable only if qualitative and&#47;or quantitative objectives set by the Board are met. In any event, except in the event of dismissal for serious misconduct or gross negligence, the exercisable BCEs must be exercised by the beneficiary within ninety (90) days of ceasing to be an employee. If they are not exercised within this period or in the event of dismissal for serious misconduct or gross negligence, the exercisable BCEs will become null and void.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In addition, each beneficiary will be able to subscribe for and exercise all of such BCEs even if the above-mentioned conditions have not been met, in the event of a Change of Control of the Company, defined as the execution of an agreement under which an industrial company or a member of an industrial group, acting alone or in concert industrial group, within the meaning of Article L. 233-10 of the French Commercial Code, comes to hold, directly or indirectly, more than 50% of the Company's capital or voting rights.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Validity period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">. All BCEs have a maximum validity period of 10 years as from their issuance.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.18
<SEQUENCE>6
<FILENAME>abivax-20xfxex418summaryof.htm
<DESCRIPTION>EX-4.18
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i444804723c5746c48efbeeca9de743e7_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Exhibit 4.18</font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Summary of Free Share Plans</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">As at February 28, 2026, sixteen free share plans were outstanding&#58; AGA-2023-1, AGA-2023-2, AGA-2023-3, AGA-2023-4, AGA-2023-5, AGA-2024-1, AGA-2024-2, AGA-2024-3, AGA-2024-4, AGA-2024-5, AGA-2024-6, AGA-2024-7, AGA-2025-1, AGA-2025-2, AGA 2025-3, AGA-2025-4, AGA-2025-5, AGA-2025-6, AGA-2025-7, AGA-2025-8 and AGA-2026-1. Free Shares (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">actions gratuites</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">) are allotted for free to holders. The issuance of the Free Shares occurs automatically at the end of the vesting period (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">p&#233;riode d&#8217;acquisition</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">), subject to the fulfilment of the vesting conditions (if any), by way of a capital increase, which will be realized by debiting the unavailable reserve (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">r&#233;serve non disponible</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">) established for this matter.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Administration</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">. Pursuant to authorizations granted at our annual meeting, our board of directors determines the recipients, the number of free shares to be granted and the terms and conditions of the free shares, including their vesting calendar and conditions.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Underlying shares.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%"> Each Free Share gives the right to one (1)&#160;ordinary share.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Allocation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">. Our Free Shares are generally granted to executive officers, directors, employees, or consultants of our company or its subsidiaries.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Vesting periods and conditions</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">.&#160;The Free Shares vest as follows&#58;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.24pt">for the Free Shares 2023-1&#58;</font></div><div style="padding-left:53.45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">212,738 Free Shares 2023-1 shall vest one year from the grant (i.e., on July 11, 2024)&#59;</font></div><div style="padding-left:53.45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">638,214 Free Shares 2023-1 shall progressively vest on a monthly basis over a period of three (3) years starting one year from the grant (i.e., 17,728 Free Shares 2023-1 per month except for the last month of the three-year period where 17,734 Free Shares 2023-1 shall be acquired)&#59;</font></div><div style="padding-left:53.45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">212,738 Free Shares 2023-1 shall vest on the latest date between (i) one year from the grant (i.e., on July 11, 2024), and (ii) the date on which a performance condition related to regulatory approvals is fulfilled&#59;</font></div><div style="padding-left:53.45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">106,369 Free Shares 2023-1 shall vest on the latest date between (i) one year from the grant (i.e., on July 11, 2024), and (ii) the date on which the Group successfully completes a public offering raising at least $100 million in gross proceeds (the condition was met on October 24, 2023)&#59;</font></div><div style="padding-left:53.45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">106,369 Free Shares 2023-1 shall vest on the latest date between (i) one year from the grant (i.e., on July 11, 2024), and (ii) the date on which a specific performance condition related to the Group&#8217;s market capitalization is fulfilled&#59; and</font></div><div style="padding-left:53.45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">106,368 Free Shares 2023-1 shall vest one year from the grant (i.e., on July 11, 2024) subject to the completion, prior to such date, of a tender offer on the securities issued by the Group, at a predetermined minimum price, and resulting in a change of control of the Group.</font></div><div style="padding-left:53.45pt"><font><br></font></div><div style="padding-left:53.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">A condition of presence is applicable to all Free Shares 2023-1.</font></div><div style="padding-left:53.45pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.67pt">for the Free Shares 2023-2&#58;</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">25% of the Free Shares 2023-2 allocated shall vest one year from the grant (i.e., on July 11, 2024)&#59; and</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">75% of the Free Shares 2023-2 allocated shall vest on the latest date between (i) one year from the grant, on July 11, 2024, and (ii) the date on which a performance condition related to regulatory approvals is fulfilled.</font></div><div style="padding-left:53.45pt;text-align:justify"><font><br></font></div><div style="padding-left:53.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">There is no condition of presence applicable to the Free Shares 2023-2.</font></div><div style="padding-left:53.45pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.24pt">for the Free Shares 2023-3 and the Free Shares 2023-4&#58;</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">50% of the ordinary shares allocated shall vest two years from the grant (i.e., on September 28, 2025)&#59;</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">25% of the ordinary shares allocated shall vest three years from the grant, (i.e., on September 28, 2026)&#59; and</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">25% of the ordinary shares allocated shall vest four years from the grant, (i.e., on September 28, 2027).</font></div><div style="padding-left:53.45pt;text-align:justify"><font><br></font></div><div style="padding-left:53.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The Free Shares 2023-4 were subject to a performance condition of the successful completion of a public offering raising at least $200 million in gross proceeds. This condition was met on October 24, 2024.</font></div><div style="padding-left:53.45pt;text-align:justify"><font><br></font></div><div style="padding-left:53.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">A condition of presence is applicable to all Free Shares 2023-3 and 2023-4.</font></div><div style="padding-left:53.45pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.67pt">for the Free Shares 2024-1&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Exhibit 4.18</font></div></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">50% of the Free Shares 2024-1 allocated shall vest two years from the grant (i.e., on February 1, 2026)&#59;</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">25% of the Free Shares 2024-1 allocated shall vest two years from the grant (i.e., on February 1, 2027)&#59; and</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">25% of the Free Shares 2024-1 allocated shall vest two years from the grant (i.e., on February 1, 2028).</font></div><div style="padding-left:53.45pt;text-align:justify"><font><br></font></div><div style="padding-left:53.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">A condition of presence is applicable to all Free Shares 2024-1.</font></div><div style="margin-bottom:5pt;padding-left:53.45pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">e)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.24pt">for the Free Shares 2024-2&#58;</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">50% of the Free Shares 2024-2 allocated shall vest two years from the grant (i.e., on March 28, 2026)&#59;</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">25% of the Free Shares 2024-2 allocated shall vest three years from the grant (i.e., on March 28, 2027)&#59; and</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">25% of the Free Shares 2024-2 allocated shall vest four years from the grant (i.e., on March, 2028).</font></div><div style="padding-left:53.45pt;text-align:justify"><font><br></font></div><div style="padding-left:53.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">A condition of presence is applicable to all Free Shares 2024-2.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">f)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:11.34pt">for the Free Shares 2024-3&#58;</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">50% of the Free Shares 2024-3 allocated shall vest two years from the grant (i.e., on May 23, 2026)&#59;</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">25% of the Free Shares 2024-3 allocated shall vest three years from the grant (i.e., on May 23, 2027)&#59; and</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">25% of the Free Shares 2024-3 allocated shall vest four years from the grant (i.e., on May 23, 2028).</font></div><div style="padding-left:53.45pt;text-align:justify"><font><br></font></div><div style="padding-left:53.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">A condition of presence is applicable to all Free Shares 2024-3.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">g)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.67pt">for the Free Shares 2024-4&#58;</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">50% of the Free Shares 2024-4 allocated shall vest two years from the grant (i.e., on July 11, 2026)&#59;</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">25% of the Free Shares 2024-4 allocated shall vest three years from the grant (i.e., on July 11, 2027)&#59; and</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">25% of the Free Shares 2024-4 allocated shall vest four years from the grant (i.e., on July 11, 2028).</font></div><div style="padding-left:53.45pt;text-align:justify"><font><br></font></div><div style="padding-left:53.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">A condition of presence is applicable to all Free Shares 2024-4.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">h)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.67pt">for the Free Shares 2024-5&#58;</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">50% of the Free Shares 2024-5 allocated shall vest two years from the grant (i.e., on July 11, 2026)&#59;</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">25% of the Free Shares 2024-5 allocated shall vest three years from the grant (i.e., on July 11, 2027)&#59; and</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">25% of the Free Shares 2024-5 allocated shall vest four years from the grant (i.e., on July 11, 2028).</font></div><div style="padding-left:53.45pt;text-align:justify"><font><br></font></div><div style="padding-left:53.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">A condition of presence is applicable to all Free Shares 2024-5.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:11.9pt">for the Free Shares 2024-6&#58;</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">50% of the Free Shares 2024-6 allocated shall vest one year from the grant (i.e., on July 11, 2026)&#59; and</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">50% of the Free Shares 2024-6 allocated shall vest on the latest date between (i) one year from the grant (i.e., on July 11, 2026) and (ii) the date on which the performance condition is fulfilled.</font></div><div style="padding-left:53.45pt;text-align:justify"><font><br></font></div><div style="padding-left:53.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">A condition of presence is applicable to all Free Shares 2024-6.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">j)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:11.9pt">for the Free Shares 2024-7&#58;</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">50% of the Free Shares 2024-7 allocated shall vest two years from the grant (i.e., on September 5, 2026)&#59;</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">25% of the Free Shares 2024-7 allocated shall vest three years from the grant (i.e., on September 5, 2027)&#59; and</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">25% of the Free Shares 2024-7 allocated shall vest four years from the grant (i.e., on September 5, 2028).</font></div><div style="padding-left:53.45pt;text-align:justify"><font><br></font></div><div style="padding-left:53.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">A condition of presence is applicable to all Free Shares 2024-7.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">k)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.67pt">for the Free Shares 2025-1&#58;</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">50% of the Presence Free Shares 2025-1 allocated shall vest two years from the grant (i.e., on February 6, 2027)&#59;</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">25% of the Presence Free Shares 2025-1 allocated shall vest three years from the grant (i.e., on February 6, 2028)&#59; </font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">25% of the Presence Free Shares 2025-1 allocated shall vest four years from the grant (i.e., on February 6, 2029)&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Exhibit 4.18</font></div></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">The M&#38;A Free Shares shall vest on the latest date between (i) the second anniversary of the grant (i.e. on February 6, 2027), and (ii) the date on which M&#38;A Performance Condition is fulfilled.</font></div><div style="padding-left:53.45pt;text-align:justify"><font><br></font></div><div style="padding-left:53.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">A condition of presence is applicable to all Free Shares 2025-1.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">l)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:11.9pt">for the Free Shares 2025-2&#58; 100% of the Free Shares 2025-2 allocated shall vest two years from the grant (i.e., on February 6, 2027). A condition of presence is applicable to all Free Shares 2025-2.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">m)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:6.9pt">for the Free Shares 2025-3&#58;</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">50% of the Free Shares 2025-3 allocated shall vest two years from the grant (i.e., on February 6, 2027)&#59;</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">25% of the Free Shares 2025-3 allocated shall vest three years from the grant (i.e., on February 6, 2028)&#59; and</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">25% of the Free Shares 2025-3 allocated shall vest four years from the grant (i.e., on February 6, 2029).</font></div><div style="padding-left:53.45pt;text-align:justify"><font><br></font></div><div style="padding-left:53.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">A condition of presence is applicable to all Free Shares 2025-3.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">n)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.67pt">for the Free Shares 2025-4&#58;</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">50% of the Free Shares 2025-4 allocated shall vest two years from the grant (i.e., on February 6, 2027)&#59;</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">25% of the Free Shares 2025-4 allocated shall vest three years from the grant (i.e., on February 6, 2028)&#59; and</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">25% of the Free Shares 2025-4 allocated shall vest four years from the grant (i.e., on February 6, 2029).</font></div><div style="padding-left:53.45pt;text-align:justify"><font><br></font></div><div style="padding-left:53.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">A condition of presence is applicable to all Free Shares 2025-4.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">o)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.67pt">for the Free Shares 2025-5&#58;</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">50% of the Free Shares 2025-5 allocated shall vest on the latest date between (i) the first anniversary of the grant date (i.e., on March 20, 2026) and (ii) the date on which Performance Condition 1 is fuflilled&#59; and</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">50% of the Free Shares 2025-5 allocated shall vest on the latest date between (i) the first anniversary of the grant date (i.e., on March 20, 2026) and (ii) the date on which Performance Condition 2 is fuflilled</font></div><div style="padding-left:53.45pt;text-align:justify"><font><br></font></div><div style="padding-left:53.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">A condition of presence is applicable to all Free Shares 2025-5.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">p)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.67pt">for the Free Shares 2025-6&#58;</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">50% of the Free Shares 2025-6 allocated shall vest two years from the grant (i.e., on May 28, 2027)&#59;</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">25% of the Free Shares 2025-6 allocated shall vest three years from the grant (i.e., on May 28, 2028)&#59; and</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">25% of the Free Shares 2025-6 allocated shall vest four years from the grant (i.e., on May 28, 2029).</font></div><div style="padding-left:53.45pt;text-align:justify"><font><br></font></div><div style="padding-left:53.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">A condition of presence is applicable to all Free Shares 2025-6.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">q)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.67pt">for the Free Shares 2025-7&#58;</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">50% of the Free Shares 2025-7 allocated shall vest two years from the grant (i.e., on August 1, 2027)&#59;</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">25% of the Free Shares 2025-4 allocated shall vest three years from the grant (i.e., on August 1, 2028)&#59; and</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">25% of the Free Shares 2025-4 allocated shall vest four years from the grant (i.e., on August 1, 2029).</font></div><div style="padding-left:53.45pt;text-align:justify"><font><br></font></div><div style="padding-left:53.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">A condition of presence is applicable to all Free Shares 2025-7.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">r)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:11.34pt">for the Free Shares 2025-8&#58;</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">50% of the Free Shares 2025-8 allocated shall vest two years from the grant (i.e., on November 13, 2027)&#59;</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">25% of the Free Shares 2025-8 allocated shall vest three years from the grant (i.e., on November 13, 2028)&#59; and</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">25% of the Free Shares 2025-8 allocated shall vest four years from the grant (i.e., on November 13, 2028).</font></div><div style="padding-left:53.45pt;text-align:justify"><font><br></font></div><div style="padding-left:53.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">A condition of presence is applicable to all Free Shares 2025-8.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">s)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.78pt">for the Free Shares 2026-1&#58;</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">50% of the Free Shares 2026-1 allocated shall vest two years from the grant (i.e., on February 5, 2028)&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Exhibit 4.18</font></div></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">25% of the Free Shares 2026-1 allocated shall vest three years from the grant (i.e., on February 5, 2029)&#59; and</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">25% of the Free Shares 2026-1 allocated shall vest four years from the grant (i.e., on February 5, 2029).</font></div><div style="padding-left:53.45pt;text-align:justify"><font><br></font></div><div style="padding-left:53.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">A condition of presence is applicable to all Free Shares 2026-1.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Standard terms</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">Pursuant to Article L.225-197-3, if a holder deceases during the vesting period, heirs may request, within six (6) months of the holder&#8217;s death, the immediate allocation of the Free Shares for which the condition of presence and&#47;or the applicable performance condition(s), if any, have been met as of the date of the holder&#8217;s death.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">In the event that the vesting period expires prior to the second anniversary of the grant of the Free Shares, a lock-up period is applicable to the Free Shares until the date of the second anniversary of the grant. Free Shares vesting after the second anniversary of the grant are not subject to lock-up. </font></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">Additionally, all Free Shares are subject to a vesting acceleration condition in case of a tender offer on the securities issued by the company and resulting in a change of control of the company. </font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-11.1
<SEQUENCE>7
<FILENAME>a03abivax-ipoxboardbookxco.htm
<DESCRIPTION>EX-11.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i520ad6de13964bd8b3fd36baeaf79f6d_1"></div><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">ABIVAX </font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Code of Market Conduct</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">concerning the confidentiality of information <br>and the prevention of insider dealing </font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Note&#58; Translation into English for information purposes only</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Dated March 19, 2026</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Introduction</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Shares in Abivax SA (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Abivax</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) are admitted to trading on the regulated Euronext Paris market and in the form of American Depositary Shares&#47;Receipts (ADS), on the Nasdaq Global Market in the United States. The Company is therefore required to comply with the regulations applicable to&#58; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.34pt">the processing of &#8220;Inside Information&#8221;&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.34pt">the prevention of market offences by persons in possession of Inside Information&#59; and </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.34pt">Transactions in the Company&#8217;s securities. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s objective is to ensure compliance with all of these rules, the purpose of which is to protect market integrity, and to follow recommendations made by the market authorities concerning the management of risk associated with the possession, disclosure and use of Inside Information. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Therefore, this Code of Market Conduct (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Code</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) sets out the market regulations applicable to the Members of Abivax and, generally, to all other persons who need to be aware of it. It will be sent to all persons likely to be classed as &#8220;Occasional Insiders&#8221;, who will be informed of the reason why they have been classed as such. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Code therefore draws the attention of the Members of Abivax to&#58; </font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">the market laws and regulations in force as well as the administrative and criminal sanctions imposed for failure to comply with those laws and regulations&#59; and </font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.58pt">the preventive measures implemented to enable everyone to invest in Financial Instruments in accordance with the rules governing market integrity. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">These rules come mainly from (i) the European Regulation of 16&#160;April 2014 on market abuse, which came into force on 3&#160;July 2016</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Market Abuse Regulation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), the relevant implementing decrees, and the positions and recommendations of the ESMA and the AMF and (ii) the Securities Exchange Act of 1934, as amended, from its rules of application, as adopted by the Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">SEC</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and from the jurisprudence of the United States federal courts.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Capitalised terms that are not defined elsewhere in this Code have the meaning given to them in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Annex&#160;1</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:0.87pt;padding-right:0.87pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">IMPORTANT</font></div><div style="padding-left:0.87pt;padding-right:0.87pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Each Member of Abivax must read and comply with this Code and ensure that their investment activities and, generally, the Transactions executed by them in the Financial Instruments of the Company or third parties, comply with the regulations in force. </font></div><div style="padding-left:0.87pt;padding-right:0.87pt;text-align:justify"><font><br></font></div><div style="padding-left:0.87pt;padding-right:0.87pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Failure to comply with this Code or, generally, with the regulations in force, could result in criminal, administrative, civil or disciplinary sanctions. Individuals who do not work for Abivax are required to comply with market regulations but will not receive this Code.</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The actions of each and every Member of Abivax could affect the Company&#8217;s image in the eyes of our partners and members of the public. Furthermore, Members of Abivax may enter into management mandates in relation to the Company&#8217;s Financial Instruments in order to protect themselves against the risk of executing Transactions which do not comply with the regulations in force or with this Code.</font></div><div style="text-align:justify"><font><br></font></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"> Regulation (EU) No 596&#47;2014 of the European Parliament and of the Council of 16&#160;April 2014 on market abuse. </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Please do not hesitate to contact our designated &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Point of Contact</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;, Mr Didier Blondel (&#91;***&#93;), for any additional information concerning the interpretation, use or enforcement of this Code. </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.049%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.87pt;padding-right:0.87pt;text-align:center"><font><br></font></div><div style="padding-left:0.87pt;padding-right:0.87pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Contents</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">General principles of financial communication </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Company must </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">disclose to the public, &#8220;as soon as possible&#8221;, any Inside Information </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">which directly concerns the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">However, the Company may postpone the public disclosure of such information subject to the exceptions provided for by the Market Abuse Regulation, as set out in Section&#160;2.1 of this Code.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The purpose of Abivax&#8217;s financial communication policy is to ensure the effective, full and timely dissemination of accurate, precise and true information, which must be communicated to market players at the same time. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Only authorised persons within the Company are permitted to provide information concerning the Company to the financial market, either in the press or in any other media. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In addition to the non-disclosure obligation referred to in Section&#160;3 below, the Company implements quiet periods of 15&#160;days before publicly disclosing its annual and half-yearly results, and quarterly results, so as not to risk communicating fragmented financial information. During these periods, the Company generally refrains from contacting the financial community (financial analysts and investors), but is nevertheless required to provide the market with information pursuant to its ongoing information obligation during these quiet periods. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Inside Information </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">2.1</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">Definition</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Inside information (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Inside Information</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is information which directly or indirectly concerns the Company or one or more of its Financial Instruments&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.34pt">which is </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">of a precise nature</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.34pt">which </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">has not been made public</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.34pt">which, if it were made public, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">would be likely to have a significant effect on the price of those Financial Instruments or on the price of related derivative Financial Instruments</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.84pt;text-decoration:underline">Information is deemed to be &#8220;of a precise nature&#8221; if</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#58; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.34pt">it indicates a set of circumstances which exists or which may reasonably be expected to come into existence, or an event which has occurred or which may reasonably be expected to occur&#59; and </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.34pt">it is specific enough to enable a conclusion to be drawn as to the possible effect of that set of circumstances or event on the price of the relevant Financial Instruments. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.23pt;text-decoration:underline">Information must only be deemed &#8220;public&#8221;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> if it has been disclosed by the Company and&#47;or has been lawfully made public.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In compliance, in particular, with the dispositions of the Commission Implementing Regulation (EU) 2016&#47;1055 of June 29, 2016 laying down implementing technical standards with regard to the technical means for appropriate public disclosure of inside information and for delaying the public disclosure of inside information in accordance with Regulation (EU) No 596&#47;2014 of the European Parliament and of the Council.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Please be advised that the publication in the press or in any other media of rumours concerning information which has not been officially &#8220;publicly&#8221; confirmed by the Company remains inside information. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Company is required, as a matter of principle, to make public, as soon as possible, any Inside Information which concerns it. The Company may nevertheless decide to postpone the public disclosure of Inside Information, providing that each of the following three requirements are fulfilled&#58; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:53.4pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.29pt">an immediate public disclosure would potentially harm the Company&#8217;s legitimate interests&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:53.4pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.24pt">postponing a public disclosure would not be likely to mislead the public&#59; and </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:53.4pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">iii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.19pt">the Company is able to ensure that the information remains confidential. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In such scenario, the Company must estimate the date on which it must publicly disclose the Inside Information. The Company is therefore required to implement adequate internal procedures in order to protect the data which it may use in the future to prove that the requirements for postponing the public disclosure of Inside Information have indeed been satisfied.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If the requirements for postponing a public disclosure cease to be satisfied, the Company must make the information public and immediately notify the AMF of the public disclosure of Inside Information which it had previously decided to postpone. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:9.46pt;text-decoration:underline">Sensitive information, which is to say, information which is likely to have a significant effect on the price of the Financial Instruments or on the price of related derivative Financial Instruments</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> may be defined as information which a reasonable investor would be likely to use as part of the basis of their investment decisions.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">The Company will take appropriate steps in order to prevent the undue circulation of Inside Information and reduce the number of persons who have access to Inside Information, by limiting the number of people who attend meetings, using code names for transactions, regularly checking IT access rights and having the persons concerned sign non-disclosure letters. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">The Company also restricts data rooms solely to material transactions, as data rooms involve, or could potentially involve, the transmission of Inside Information. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Access to Inside Information is on a need-to-know basis, according to the duties and responsibilities of the relevant person. </font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">2.2</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">Examples of Inside Information</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In practice, and by way of a non-exhaustive guide, the following can be deemed Inside Information, provided that it has not been made public&#58; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.34pt">information which concerns the Company&#8217;s quarterly, half-yearly or annual results, forecasts concerning the Company&#8217;s cash runway and, generally, any anticipated change to a financial aggregate and any report which shows a significant discrepancy compared to the forecasts communicated by the Company or the market consensus&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.34pt">any plan to dispose of or acquire Company assets for &#8364;10 million or more, any plan for the Company to merge or enter into a material partnership (including any M&#38;A transaction), as well as any draft material agreement or contract (including any licence concerning any of the Company&#8217;s products)&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.34pt">any legal proceedings, dispute, financial transaction (such as a capital increase, bank financing or a bond issue) or restructuring likely to have a significant effect on the Company&#8217;s financial position&#59; </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.34pt">the results of a clinical trial conducted by the Company, a material change to the Company&#8217;s product portfolio, the chances of obtaining marketing authorisation for a product, any important notification from a regulatory authority concerning a clinical trial (such as a clinical hold) and any material information concerning the safety of the Company&#8217;s products&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.34pt">any plan to replace the Company&#8217;s Chief Executive Officer or material change to its management team or governing bodies. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">2.3</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">Defining Inside Information</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Company is responsible for determining whether information in its possession, and which concerns the Company directly or indirectly, is likely to constitute Inside Information.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">For this purpose, the Company has adopted internal procedures to ensure the reporting of Inside Information and has determined its own specific criteria, by defining materiality thresholds and identifying events which must be subject to close scrutiny in order to determine whether information is inside information or not.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Company has appointed a Point of Contact who is in charge of enforcing these criteria. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Anyone who receives information which is likely to be considered as inside information must immediately inform the Point of Contact who, following a discussion with the Board of Directors and (if necessary) the Company&#8217;s advisers, will issue an opinion as to whether he believes that the information is &#8220;inside&#8221; information, and will consider the consequences of disseminating the information. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Point of Contact will then inform the person concerned of his opinion. If the information is considered to be inside information, the Point of Contact will notify the person of their inclusion on the Company&#8217;s insider list. </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><div style="margin-bottom:8pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:125%">Information should only be classified as Inside Information if all of the criteria set out in Section&#160;2.1 above have been fulfilled. </font></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">2.4</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">Insider lists</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to the Market Abuse Regulation, the Company is required to draw up a list of all persons who have access to inside information and who work for the Company under a contract of employment, or otherwise perform tasks through which they have access to inside information, such as advisers or accountants. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">These insider lists are kept by the Company for at least five years after they were drawn up or updated, and are intended to protect market integrity and permit the monitoring of Inside Information within the Company. They are confidential, but must be provided to the AMF upon request.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to Regulation (EU) 2016&#47;679 of the European Parliament and of the Council of 27&#160;April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data (the General Data Protection Regulation), each person who is included on an insider list may exercise their right to access their personal data and to rectify any incorrect data by contacting the Data Protection Officer, Mr. Didier Blondel.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Each person who is included on an insider list will be notified by the Company of their inclusion and provided (if necessary) with information on the obligations and sanctions imposed on holders of Inside Information. </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">By countersigning this Code, you confirm that you have familiarised yourself with the Company&#8217;s obligations to draw up an insider list using the template attached as </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Annex&#160;2</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%"> to this Code. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">You agree to provide the information needed to include you on the Company&#8217;s insider list and therefore acknowledge that you are aware of the obligations imposed by law and regulations, and of the sanctions applicable to Insider Dealing and the unlawful disclosure of Inside Information. </font></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:24pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Non-disclosure obligations </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Any Member of Abivax who possesses Inside Information must </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">refrain from disclosing it to any other person</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">, including within the Company, other than in the ordinary course of their work, occupation or duties, providing that they first take steps to ensure that the recipient of Inside Information is bound by a legal, statutory, regulatory and&#47;or contractual non-disclosure obligation. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">The Inside Information must therefore not be disclosed to anyone</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">, including within the Company, who does not require such information in order to carry out their work or tasks.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Furthermore, it is </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">strictly prohibited to disseminate information or to spread rumours</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">, in the media or by any other means, which gives, or is likely to give, false or misleading information about the Financial Instruments and&#47;or the position, results or prospects of the Company. No interview, meeting or discussion with the press, investors or financial analysts may be held without the prior consent of a communications officer within the Company or the Point of Contact.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Furthermore, the Company is not required to respond to any rumours which concern it. Therefore, all Members of Abivax must </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">refrain from commenting on any rumour</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> which concerns the Company, if the rumour has not been confirmed or denied by the Company. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If the rumour is sufficiently precise and if it explicitly refers to Inside Information the public disclosure of which has been postponed, the Company must promptly disclose the Inside Information, as the confidentiality of the information is no longer guaranteed. </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><div style="margin-bottom:8pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:125%">All Members of Abivax are required to notify the Point of Contact immediately upon becoming aware of the disclosure or suspected disclosure of Inside Information (for example at an internal or external meeting). </font></div></td></tr></table></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Abstention obligations applicable to Insiders </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">4.1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.5pt">General abstention obligation</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Any Member of Abivax who possesses Inside Information must refrain from the following until the information has been made public&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:63.8pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:25.08pt">using or attempting to use the Inside Information by buying or selling, for their own account or for the account of a third party, directly or indirectly, Financial Instruments of the Company to which the Inside Information relates </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Insider Dealing</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Using Inside Information to cancel or amend an order concerning a Financial Instrument to which the Inside Information relates is also deemed to constitute Insider Dealing if the order was placed before the person concerned obtained the Inside Information&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:63.8pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.03pt">making a recommendation or inducing another person to engage in Insider Dealing</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">. Using a recommendation or inducement with the knowledge that it is based on Inside Information also constitutes Insider Dealing. </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If the third person to whom a recommendation is made is a legal person, the above abstention obligations also apply to the natural persons who decide to carry out the acquisition, disposal, cancellation or amendment of an order on behalf of the legal person concerned.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">All Members of Abivax must therefore refrain from executing any transaction and from using any recommendation or inducement for as long as the Inside Information in their possession remains Inside Information (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">e.g.,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%"> for as long as it has not been disclosed to the public or the project has not been abandoned). </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Any Member of Abivax who possesses Inside Information must notably refrain from imparting the Inside Information to persons close to them (including Persons Closely Associated) and, generally, to any person who, owing to their relationship with Members of Abivax, could be suspected of having relied on Inside Information.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Any Member of Abivax who has any doubts about the information which they are authorised to disclose, particularly during an oral presentation or in a written presentation, may seek advice from the Point of Contact. In case of doubt or if the Point of Contact does not reply immediately, the information must not be disclosed.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"> </font></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">4.2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.5pt">Blackout periods</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:78pt;text-align:justify;text-indent:-42.55pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">4.2.1</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.55pt">General rules </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In addition to the general abstention obligation described in Section&#160;4.1 above, and even if they are not in possession of Inside Information, every Person Discharging Managerial Responsibilities as well as every Permanent Insider and every Occasional Insider must </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">refrain from executing Transactions</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> in the Company&#8217;s Financial Instruments, for their own account or for the account of a third party, directly or indirectly&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:63.8pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.08pt">for a period of </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">30 calendar days</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">prior</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> to the date on which the Company publishes its annual and half-yearly results, including the date of publication&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:63.8pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.03pt">for a period of </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">15 calendar days</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">prior</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> to the date on which the Company voluntarily publishes quarterly financial information, including the date of publication.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">It should be noted that, under exceptional circumstances, these periods could begin earlier than the dates indicated above, in which case every Person Discharging Managerial Responsibilities as well as every Permanent Insider and every Occasional Insider would be so informed (this information could constitute Inside Information).</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The financial calendar containing the dates on which the Company plans to publish financial information is prepared annually by the Board of Directors and published on the Company&#8217;s website. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">A form of blackout notice is attached as </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Annex&#160;3</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> to this Code.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><div style="margin-bottom:8pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:125%">All persons who have regular or occasional access to Inside Information are required to fulfil these obligations of abstention during Blackout Periods.</font></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:78pt;text-align:justify;text-indent:-42.55pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">4.2.2</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.55pt">Exceptions </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Company may authorise a Person Discharging Managerial Responsibilities to trade during a Blackout Period, for their own account or for the account of a third party&#58; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.34pt">on a case-by-case basis due to exceptional circumstances</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">, on the understanding that circumstances are considered as exceptional if they are extremely urgent, unforeseeable and compelling, if they were not caused by the Person Discharging Managerial Responsibilities </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">concerned and if they are beyond the latter&#8217;s control (such as serious financial issues which require the immediate sale of shares)&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.34pt">due to the specific nature of the trade concerned </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">for transactions executed in the context of, or in relation to, a shareholding system or an employee savings scheme, the completion of formalities or the exercise of rights attached to the shares, or transactions that do not involve a change in ownership of the relevant security. In particular, the Company authorizes trades by a Person Discharging Managerial Responsibilities during a Blackout Period in the framework of a pre-established &#8220;sell to cover process&#8221; with the Company&#8217;s depositary (Uptevia) connected to the issuance of shares to such Person Discharging Managerial Responsibilities under a free share plan. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Person Discharging Managerial Responsibilities must submit their request in writing, give the reason for the request and describe the proposed Transaction. The request must be sent to the Point of Contact, who will issue his reply within eight business days of receipt of the request, following consultation with the Board of Directors and the Company&#8217;s advisers.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">When the Point of Contact determines whether the circumstances described in the written request are exceptional, he will determine whether and to what extent the Person Discharging Managerial Responsibilities&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.34pt">is bound, at the time of submitting their request, by a financial commitment or an enforceable claim&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.34pt">is required to make, or has put themselves in a situation prior to the beginning of the Blackout Period as a result of which they must make, a payment to a third party, including a tax liability, and cannot reasonably fulfil a financial commitment or claim other than by an immediate sale of shares. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In any case, the Person Discharging Managerial Responsibilities to whom permission is given must refrain from engaging in Insider Dealing under any circumstances. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Section&#160;4.2.2 of this Code also applies, in the same circumstances, to Permanent Insiders and Occasional Insiders, who must comply with the statutory Blackout Period pursuant to Section&#160;4.2.1 above. </font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">4.3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.5pt">Specific terms applicable to stock options (if applicable)</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Stock options may not be granted&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.34pt">less than 20 trading sessions after the detachment of the shares from a coupon which entitles its holder to a dividend or a capital increase&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.34pt">during the 10 trading sessions before and after the date on which the Company&#8217;s consolidated (annual or half-yearly) financial statements are made public&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.34pt">during the period between the date on which the Company&#8217;s corporate bodies become aware of Inside Information and the date on which the information was made public.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The foregoing provisions will apply solely in the event that the Company decides to implement a stock option plan in the future. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">4.4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.5pt">Specific terms applicable to free shares (if applicable) </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The periods of abstention referred to above are without prejudice to the specific period of abstention provided for by the regulations applicable to allotments of free shares, which state that free shares may not be transferred at the end of the lock-up period&#58;</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.34pt">for a period of </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">30 calendar days</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">prior</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> to the date on which the Company publishes its annual and half-yearly results, including the date of publication&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.34pt">during the period between the date on which the Company&#8217;s corporate bodies become aware of Inside Information and the date on which the information was made public</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">It is specified that the foregoing provisions shall not apply to sales of shares executed at the end of the acquisition period of free shares in the framework of a pre-established &#8220;sell to cover process&#8221; with the Company&#8217;s depositary (Uptevia).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Notification and lock-up obligations </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">5.1</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">Major shareholding notification to the Company and the AMF in relation to thresholds laid down by law</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Any Member of Abivax, acting alone or in concert, who acquires, by any means, directly or indirectly, a </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">number of shares representing more than 5%, 10%, 15%, 20</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">%</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">, 25%, 30%, 33.33%, 50%, 66.66%, 90% or 95% of the Company&#8217;s share capital or voting rights</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> is required to notify the Company and the AMF accordingly.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The notification made to the Company must state the nature of the transaction (purchase or sale) as a result of which the applicable threshold has been exceeded, as well as the total number of shares and voting rights held before and after the transaction. It must be sent by registered letter (with acknowledgement of receipt requested) to the registered office before the close of trading on the fourth trading day after the date on which the shareholding threshold was exceeded. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In order to make a notification to the AMF, the standard major shareholding notification and letter of intent must be completed (the Company may also complete it on the relevant person&#8217;s behalf). The form must be sent by e-mail, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">before close of trading on the fourth trading day</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> after the date on which the shareholding threshold was exceeded, to the following address&#58; </font><font style="color:#4472c4;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">declarationseuil&#64;amf-france.org</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If these obligations are not fulfilled, the person concerned will forfeit the voting rights attached to the number of shares over and above the percentage not notified as required, for any general shareholders&#8217; meeting held within two years of the date a notification is made.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">5.2</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">Major shareholding notification to the Company in relation to thresholds imposed under the Articles of Association </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Any Member of Abivax who is also a shareholder of the Company, acting alone or in concert, and who acquires, by any means, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">2% or more of the Company&#8217;s share capital or voting rights, or any multiple of that percentage</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">, must notify the Company accordingly. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The notification must state the nature of the transaction (purchase or sale) as a result of which the applicable threshold has been exceeded, as well as the total number of shares and voting rights held before and after the transaction. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The notification must be sent to the Company by registered letter (with acknowledgement of receipt requested) to the registered office </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">before close of trading on the fourth trading day</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> after the date on which the shareholding threshold was exceeded. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If this obligation is not fulfilled, the person concerned may forfeit the voting rights attached to the number of shares over and above the percentage not notified as required, for any general shareholders&#8217; meeting held within two years of the date a notification is made in accordance with the Company&#8217;s Articles of Association. </font></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"> Article L.&#160;22-10-59 of the French Commercial Code.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">5.3</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">Notifications made by Persons Discharging Managerial Responsibilities and persons closely associated to them </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Persons Discharging Managerial Responsibilities and persons closely associated to them </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(Persons Closely Associated) </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">are required to notify </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the Company and the AMF, by e-mail, of </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">any Transaction executed by them or by a third party acting on their behalf in the Company&#8217;s Financial Instruments </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(as listed in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Annex&#160;4</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to this Code), </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">within three business days</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> following the date of the Transaction, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">if the total amount of the Transactions executed in the relevant calendar year exceeds &#8364;50,000</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">It is not necessary to combine Transactions executed by Persons Discharging Managerial Responsibilities and Transactions executed by Persons Closely Associated to them in order to calculate this threshold. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The notification must be sent to the AMF within the above time limit, exclusively in electronic format, via an extranet system called &#8220;ONDE&#8221;, which is accessible on the AMF&#8217;s website at the following address&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#4472c4;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">https&#58;&#47;&#47;onde.amf-france.org&#47;RemiseInformationEmetteur&#47;Client&#47;PTRemiseInformationEmetteur.aspx</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The filing of information with the AMF via ONDE requires the use of an account and associated login details. Such details can be obtained by creating an account at the above address. Notifications may be sent by a third party on behalf of the persons required to make them. The identity of the third party must be clearly stated in the notification accessible on the AMF&#8217;s website.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Notifications must be completed under the responsibility of the person making them and are not examined by the AMF prior to publication. Notifications may be examined by the AMF in the future and are made public by the AMF.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Notifications made by Persons Discharging Managerial Responsibilities and Persons Closely Associated to them must also be sent to the Company within the same timeframe.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Persons Discharging Managerial Responsibilities must send the Company, and update, if necessary, a list of the Persons Closely Associated to them. They are also required to notify the Persons Closely Associated to them in writing of their notification obligations and to keep a copy of that notice. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Compliance with this Code</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">6.1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.5pt">The Point of Contact</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Point of Contact oversees compliance with this Code, on the understanding that each Permanent and Occasional Insider is ultimately responsible for complying with the applicable regulations.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In the context of his work, the Point of Contact is notably responsible for&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.34pt">informing Permanent and Occasional Insiders in advance of Blackout Periods resulting from the publication of the Company&#8217;s financial information, according to the specified annual publication dates&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.34pt">receiving notifications made pursuant to the notification obligations referred to in Section&#160;5 above&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.34pt">informing the Company&#8217;s Board of Directors as soon as possible of any breach of this Code and of market regulations&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.34pt">drawing up a list of Insiders, in the standard form attached as </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Annex&#160;2</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> to this Code, based on the information provided to him, ensuring that the list is kept up to date, sending it to the AMF upon request and keeping it for five years from the date it was drawn up and updated&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.34pt">informing Insiders of their inclusion in each section of the above list&#59;</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.34pt">drawing up and keeping up to date a list of Persons Discharging Managerial Responsibilities and Persons Closely Associated to them, based on the information provided to him&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.34pt">providing, upon request, an advisory opinion prior to any Transaction in the Company&#8217;s Financial Instruments.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In the performance of his work, the Point of Contact may, at his discretion, be assisted by the Company&#8217;s external legal adviser. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Any opinion given by the Point of Contact will be given solely in an advisory capacity, as the person concerned is ultimately responsible for deciding whether to execute a Transaction in the Company&#8217;s Financial Instruments. Sanctions could be imposed on the person concerned if they fail to fulfil their statutory obligations, irrespective of the opinion of the Point of Contact.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">6.2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.5pt">Information obligations </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">To ensure compliance with this Code within the Company, you must take steps to prevent a breach of the Code, in particular by&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.34pt">informing the Point of Contact of any project, which has not yet been made public and which could inherently constitute Inside Information and, in such scenario, providing him or having a third party provide him with a list of the persons informed as the project progresses&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.34pt">having all employees and third parties who work on sensitive matters or matters involving Inside Information sign a non-disclosure letter drawn up in agreement with the Point of Contact&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.34pt">informing the Members of Abivax who work on sensitive matters of the existence and content of this Code and having them sign a letter in which they agree to comply with this Code&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.34pt">promptly notifying the Point of Contact if any Inside Information has been transmitted to a person not included on an insider list.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In case of doubt, you are reminded that you must seek advice from the Point of Contact on the type of transactions you are planning to carry out in the Financial Instruments and seek his advice in advance. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Please also be aware that these preventive measures will not exempt you in any circumstances from criminal liability if an infringement is observed. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In addition to this Code, the Company will also provide regular training on the topic of Insider Dealing. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Sanctions</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Persons who do not comply with the rules relating to the use and disclosure of Inside Information risk, either administrative penalties handed down by the AMF and the SEC, or criminal penalties handed down by the French or American federal judicial authorities, as well as disciplinary sanctions within the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">7.1</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">French criminal sanctions for insider dealing</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Insider Dealing carries a penalty of </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">five years&#8217; imprisonment and a fine of &#8364;100 million</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">. The fine may be increased to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">ten times the illegal gain</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> and will not be less than the amount of such illegal gain</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The fine imposed on legal persons is capped at the higher of the following&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#8364;500 million, ten times the amount of the illegal gain or 15% of consolidated turnover</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">7.2</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">French administrative sanctions for insider dealing</font></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"> French Monetary and Financial Code, Articles L. 465-1 to L. 465-3. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"> French Monetary and Financial Code, Article L. 465-3-5.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Insider Dealing may carry a fine of </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#8364;100 million</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">, which may be increased to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">ten times the illegal gain if this can be established</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">6</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The fine imposed on legal persons may be increased to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">15% of the legal person&#8217;s consolidated turnover</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">7</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">7.3</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">Disciplinary sanctions </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Any violation of this Policy and of these rules or the law on insider trading or insider misconduct by a Member of Abivax, Permanent Insider, Occasional Insider, or Person Discharging Managerial Responsibilities (including Persons Closely Associated, in each case), may lead to measures up to the dismissal or discharge of the person concerned. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The commission of insider trading or insider misconduct is the responsibility of the one who commits it. Abivax may not be held liable in place of the person who committed such an act. In this regard, the Company is not intended to assume the fines to which its collaborators may be liable. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Anyone found in violation of the information contained in this Policy or having knowledge of the commission of such an offence by another person, must immediately inform the Point of Contact, who will take all appropriate measures internally and in relation to the market authorities.</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">*            *</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">*</font></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">6</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"> French Monetary and Financial Code, Article L. 621-15 III c). </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">7</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"> French Monetary and Financial Code, Article L. 621-15 III </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">bis</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Letter of agreement</font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">All Insiders and other recipients of this Code must complete and sign this letter and send it to Mr&#160;Didier Blondel</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">)</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">I, the undersigned, </font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">insert first name, surname and position</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">)</font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">have read Abivax&#8217;s Code of Market Conduct and agree to comply with the Code at all times.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Place&#58; &#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;. Date&#58;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Annex 1</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#58; Definitions </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">For the purposes of this Code, capitalised terms and expressions shall have the following meaning&#58;</font></div><div style="text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.412%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><div style="margin-bottom:8pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:125%">AMF </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">means the </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Autorit&#233; des March&#233;s Financiers </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(the French Financial Markets Authority).</font></div></td></tr><tr><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><div style="margin-bottom:8pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:125%">Blackout Period(s) </font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><div style="margin-bottom:8pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">has the meaning ascribed to it in Section&#160;4.2 of this Code. </font></div></td></tr><tr><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><div style="margin-bottom:8pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:125%">Corporate Officers</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><div style="margin-bottom:8pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">means the members of the Board of Directors.</font></div></td></tr><tr><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><div style="margin-bottom:8pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:125%">ESMA</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><div style="margin-bottom:8pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">means the European Securities and Markets Authority. </font></div></td></tr><tr><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><div style="margin-bottom:8pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:125%">Financial Instruments</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">means&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:38.77pt;padding-right:2.77pt;text-align:justify;text-indent:-39.05pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.68pt">the shares, bonds and transferable securities issued or to be issued by the Company, including founders&#8217; warrants (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">bons de souscription de parts de cr&#233;ateur d&#8217;entreprise</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">), share warrants (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">bons de souscription d&#8217;actions</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">) and free shares&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:38.77pt;padding-right:2.77pt;text-align:justify;text-indent:-39.05pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">the rights that may be separated from the securities referred to in point (i), particularly preferential subscription and allotment rights&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:38.77pt;padding-right:2.77pt;text-align:justify;text-indent:-39.05pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.58pt">any derivative or financial instrument linked to the rights or securities referred to in points (i) and (ii) above, particularly securities that give access to the Company&#8217;s share capital and futures (including equivalent cash-settled instruments, swaps and options, including stock options in particular).</font></div></td></tr><tr><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><div style="margin-bottom:8pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:125%">Inside Information </font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><div style="margin-bottom:8pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">has the meaning ascribed to in Section&#160;2 of this Code. </font></div></td></tr><tr><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><div style="margin-bottom:8pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:125%">Insider(s)</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><div style="margin-bottom:8pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">means any person who may or may not work for the Company, and who possesses Inside Information which concerns the Company. </font></div></td></tr><tr><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><div style="margin-bottom:8pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:125%">Insider Dealing </font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><div style="margin-bottom:8pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">has the meaning ascribed to it in Section&#160;4 of this Code. </font></div></td></tr><tr><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><div style="margin-bottom:8pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:125%">Member(s) of Abivax</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><div style="margin-bottom:8pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">means the Persons Discharging Managerial Responsibilities and any employee, including employees whose services are made available to another company and temporary employees, and any other agent of Abivax.</font></div></td></tr><tr><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><div style="margin-bottom:8pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:125%">Occasional Insider(s)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">means persons who occasionally have access to Inside Information which concerns the Company. These persons may belong to two categories&#58; </font></div><div style="margin-top:6pt;padding-left:38.77pt;padding-right:2.77pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.34pt">persons within the Company, such as employees, who have access to Inside Information due, for example, to their involvement in a project or transaction&#59;</font></div><div style="padding-left:38.77pt;padding-right:2.77pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;padding-left:38.77pt;padding-right:2.77pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.34pt">third parties acting in the name or on behalf of the Company, who have access to Inside Information in the context of their business relationships with the Company at the time of preparation or performance of an occasional transaction, such as service providers, including lawyers and financing and investment banks, who, for example, work with the Company on a transaction or proposed transaction, or a communications agency appointed in respect of the transaction. </font></div></td></tr></table></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.412%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><div style="margin-bottom:8pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:125%">Permanent Insider(s)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">means all persons who, owing to the nature of their duties or position, have permanent access to Inside Information which concerns the Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div></td></tr><tr><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><div style="margin-bottom:8pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:125%">Persons Closely Associated</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">means the persons who have close personal links to a Member of Abivax, namely&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:38.77pt;padding-right:2.77pt;text-align:justify;text-indent:-39.05pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.68pt">their spouse who shares the same household or their civil partner&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:38.77pt;padding-right:2.77pt;text-align:justify;text-indent:-39.05pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">children over whom they exercise parental authority or who live with them permanently or alternately, or for whom they are effectively and permanently responsible&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:38.77pt;padding-right:2.77pt;text-align:justify;text-indent:-39.05pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.58pt">blood relatives and relatives by marriage who have shared the same household for at least one year on the date of the transaction concerned&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:38.77pt;padding-right:2.77pt;text-align:justify;text-indent:-39.05pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">legal persons, trusts or partnerships, the managerial responsibilities of which are discharged by them or by a person referred to in point (i), (ii) or (iii) above&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:38.77pt;padding-right:2.77pt;text-align:justify;text-indent:-39.05pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:26.23pt">legal persons, trusts or partnerships that are controlled, directly or indirectly, by them or by a person referred to in point (i), (ii) or (iii) above&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:38.77pt;padding-right:2.77pt;text-align:justify;text-indent:-39.05pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">legal persons, trusts or partnerships that haven been incorporated or set up for their benefit or for the benefit of a person referred to in point (i), (ii) or (iii) above&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:38.77pt;padding-right:2.77pt;text-align:justify;text-indent:-39.05pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.13pt">legal persons, trusts or partnerships whose economic interests are substantially the same as their own or as those of a person referred to in point (i), (ii) or (iii) above. </font></div></td></tr><tr><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><div style="margin-bottom:8pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:125%">Persons Discharging Managerial Responsibilities&#160;</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><div style="margin-bottom:8pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">means Corporate Officers and Similar Persons.</font></div></td></tr><tr><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><div style="margin-bottom:8pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:125%">Point of Contact</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><div style="margin-bottom:8pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">has the meaning ascribed to it in the Introduction and in Section&#160;2.3 of this Code.</font></div></td></tr><tr><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><div style="margin-bottom:8pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:125%">Similar Person(s) </font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><div style="margin-bottom:8pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">means any person similar to a Corporate Officer who, on the one hand, has the power within the Company to make management decisions concerning the Company&#8217;s development and strategy and who, on the other hand, has regular access to Inside Information which directly or indirectly concerns the Company.</font></div></td></tr><tr><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><div style="margin-bottom:8pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:125%">Transaction</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">means, in particular, any acquisition, disposal, subscription, exchange or conversion of Financial Instruments, immediately or in the future, on the market or over the counter, the entering into of an undertaking to acquire or dispose of Financial Instruments, any derivatives transaction for which the underlying assets are Financial Instruments, any hedging transaction that results in the acquisition or transfer of the economic risk associated with Financial Instruments, which is executed directly or indirectly by a person for their own account or for the account of a third party.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The foregoing also applies to the exercise of stock options and the sale of securities resulting from the exercise of stock options and, generally, all transactions covered by the regulations in force. </font></div></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i520ad6de13964bd8b3fd36baeaf79f6d_4"></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Annex&#160;2</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#58; Template sections of insider list<br>in accordance with Commission Implementing Regulation (EU) 2016&#47;347 of 10 March 2016 laying down implementing technical standards with regard to the precise format of insider lists and for updating insider lists </font></div><div><font><br></font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i520ad6de13964bd8b3fd36baeaf79f6d_7"></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Annex&#160;3</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#58; Form of blackout notice </font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Annex&#160;4</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#58; Excerpt from Commission Delegated Regulation (EU) 2016&#47;522 of 17 December 2015 supplementing Regulation (EU) No 596&#47;2014 of the European Parliament and of the Council as regards &#8230; the competent authority for notifications of delays, the permission for trading during closed periods and types of notifiable managers&#8217; transactions </font></div><div><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>8
<FILENAME>abivax-202520xfxex121ceo.htm
<DESCRIPTION>EX-12.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="idd882b67a708410a90cd3924a08fbc39_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Exhibit 12.1</font></div></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER<br>PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED<br>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">I, Marc de Garidel, certify that&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">I have reviewed this annual report on Form 20-F of Abivax SA&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">The company&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">Evaluated the effectiveness of the company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">Disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">The company&#8217;s other certifying officer and have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the audit committee of the company&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 23, 2026</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Marc de Garidel&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Marc de Garidel</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Chief Executive Officer and Chairman <br>(Principal Executive Officer)</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>9
<FILENAME>abivax-202520xfxex122cfo.htm
<DESCRIPTION>EX-12.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i56abf88c55a24211bd88c6b798b579f6_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Exhibit 12.2</font></div></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER<br>PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED<br>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">I, Didier Blondel, certify that&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">I have reviewed this annual report on Form 20-F of Abivax SA&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">The company&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">Evaluated the effectiveness of the company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">Disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">The company&#8217;s other certifying officer and have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the audit committee of the company&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 23, 2026</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Didier Blondel&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Didier Blondel</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Executive Vice President and Chief Financial Officer <br>(Principal Financial Officer)</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>10
<FILENAME>abivax-202520xfxex131ceo.htm
<DESCRIPTION>EX-13.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="if76fb94b725f47a595e26c95a07d1976_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Exhibit 13.1</font></div></div><div><font><br></font></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Certification by the Principal Executive Officer<br>Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In connection with the Annual Report of Abivax SA (the &#8220;Company&#8221;) on Form 20-F for the fiscal year ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Marc de Garidel, Chief Executive Officer and Chairman of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div style="margin-bottom:12pt;padding-left:64.8pt;text-align:justify;text-indent:-28.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:17.14pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:12pt;padding-left:64.8pt;text-align:justify;text-indent:-28.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:17.14pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 23, 2026</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Marc de Garidel&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Marc de Garidel</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Chief Executive Officer and Chairman<br>(Principal Executive Officer)</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">This certification accompanies the Report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of this Report), irrespective of any general incorporation language contained in such filing.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>11
<FILENAME>abivax-202520xfxex132cfo.htm
<DESCRIPTION>EX-13.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="if6b78709e4f54faa92a5c48e242f9834_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Exhibit 13.2</font></div></div><div><font><br></font></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Certification by the Principal Financial Officer<br>Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In connection with the Annual Report of Abivax SA (the &#8220;Company&#8221;) on Form 20-F for the fiscal year ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Didier Blondel, Chief Financial Officer and Board Secretary of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div style="margin-bottom:12pt;padding-left:64.8pt;text-align:justify;text-indent:-28.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:17.14pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:12pt;padding-left:64.8pt;text-align:justify;text-indent:-28.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:17.14pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 23, 2026</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Didier Blondel&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Didier Blondel</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Executive Vice President, Chief Financial Officer and Board Secretary<br>(Principal Financial Officer)</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">This certification accompanies the Report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of this Report), irrespective of any general incorporation language contained in such filing.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>12
<FILENAME>pwc_consentx20-fxfy25.htm
<DESCRIPTION>EX-15.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i2edac790b2234f349efb9a78332c59ac_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Georgia',serif;font-size:11pt;font-weight:400;line-height:125%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Georgia',serif;font-size:11pt;font-weight:400;line-height:125%">We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (File Nos. 333-283336 and 333-288884) and Form S-8 (File No. 333-286069) of Abivax SA of our report dated March 23, 2026, relating to the financial statements, which appears in this Form 20-F.</font></div><div><font style="color:#000000;font-family:'Georgia',serif;font-size:11pt;font-weight:400;line-height:125%">&#47;s&#47; PricewaterhouseCoopers Audit</font></div><div><font style="color:#000000;font-family:'Georgia',serif;font-size:11pt;font-weight:400;line-height:125%">Neuilly-sur-Seine, France</font></div><div><font style="color:#000000;font-family:'Georgia',serif;font-size:11pt;font-weight:400;line-height:125%">March 23, 2026</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>abvx-20251231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:3ade1e9c-8754-4bce-84b9-83231d17b989,g:c324a16d-aca9-45c2-8b50-8666bee7377b-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:abvx="http://www.abivax.com/20251231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.abivax.com/20251231">
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2025" schemaLocation="https://xbrl.sec.gov/currency/2025/currency-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af-sub/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd"/>
  <xs:import namespace="https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abvx-20251231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abvx-20251231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abvx-20251231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abvx-20251231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Coverpage" roleURI="http://www.abivax.com/role/Coverpage">
        <link:definition>0000001 - Document - Cover page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Auditorinformation" roleURI="http://www.abivax.com/role/Auditorinformation">
        <link:definition>0000002 - Document - Auditor information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" roleURI="http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION">
        <link:definition>9952151 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFINCOMELOSS" roleURI="http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS">
        <link:definition>9952152 - Statement - CONSOLIDATED STATEMENTS OF INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" roleURI="http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS">
        <link:definition>9952153 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" roleURI="http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY">
        <link:definition>9952154 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheGroup" roleURI="http://www.abivax.com/role/TheGroup">
        <link:definition>9952156 - Disclosure - The Group</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Basisofpreparation" roleURI="http://www.abivax.com/role/Basisofpreparation">
        <link:definition>9952157 - Disclosure - Basis of preparation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequentevents" roleURI="http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequentevents">
        <link:definition>9952158 - Disclosure - Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Accountingprinciples" roleURI="http://www.abivax.com/role/Accountingprinciples">
        <link:definition>9952159 - Disclosure - Accounting principles</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Segmentinformation" roleURI="http://www.abivax.com/role/Segmentinformation">
        <link:definition>9952160 - Disclosure - Segment information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Goodwillandimpairmenttest" roleURI="http://www.abivax.com/role/Goodwillandimpairmenttest">
        <link:definition>9952161 - Disclosure - Goodwill and impairment test</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Intangibleassets" roleURI="http://www.abivax.com/role/Intangibleassets">
        <link:definition>9952162 - Disclosure - Intangible assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Propertyplantandequipment" roleURI="http://www.abivax.com/role/Propertyplantandequipment">
        <link:definition>9952163 - Disclosure - Property, plant and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Otherfinancialassets" roleURI="http://www.abivax.com/role/Otherfinancialassets">
        <link:definition>9952164 - Disclosure - Other financial assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Otherreceivablesandotherassets" roleURI="http://www.abivax.com/role/Otherreceivablesandotherassets">
        <link:definition>9952165 - Disclosure - Other receivables and other assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Cashandcashequivalents" roleURI="http://www.abivax.com/role/Cashandcashequivalents">
        <link:definition>9952166 - Disclosure - Cash and cash equivalents</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Financialassetsandliabilities" roleURI="http://www.abivax.com/role/Financialassetsandliabilities">
        <link:definition>9952167 - Disclosure - Financial assets and liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Shareholdersequity" roleURI="http://www.abivax.com/role/Shareholdersequity">
        <link:definition>9952168 - Disclosure - Shareholders&#8217; equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Sharebasedpayments" roleURI="http://www.abivax.com/role/Sharebasedpayments">
        <link:definition>9952169 - Disclosure - Share-based payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Financialliabilities" roleURI="http://www.abivax.com/role/Financialliabilities">
        <link:definition>9952170 - Disclosure - Financial liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Retirementbenefitobligations" roleURI="http://www.abivax.com/role/Retirementbenefitobligations">
        <link:definition>9952171 - Disclosure - Retirement benefit obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Payablesandothercurrentliabilities" roleURI="http://www.abivax.com/role/Payablesandothercurrentliabilities">
        <link:definition>9952172 - Disclosure - Payables and other current liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Otheroperatingincome" roleURI="http://www.abivax.com/role/Otheroperatingincome">
        <link:definition>9952173 - Disclosure - Other operating income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Operatingexpenses" roleURI="http://www.abivax.com/role/Operatingexpenses">
        <link:definition>9952174 - Disclosure - Operating expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Employees" roleURI="http://www.abivax.com/role/Employees">
        <link:definition>9952175 - Disclosure - Employees</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Financialgainloss" roleURI="http://www.abivax.com/role/Financialgainloss">
        <link:definition>9952176 - Disclosure - Financial gain (loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Incometax" roleURI="http://www.abivax.com/role/Incometax">
        <link:definition>9952177 - Disclosure - Income tax</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Incomelosspershare" roleURI="http://www.abivax.com/role/Incomelosspershare">
        <link:definition>9952178 - Disclosure - Income (loss) per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Relatedparties" roleURI="http://www.abivax.com/role/Relatedparties">
        <link:definition>9952179 - Disclosure - Related parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Offbalancesheetcommitmentsgiven" roleURI="http://www.abivax.com/role/Offbalancesheetcommitmentsgiven">
        <link:definition>9952180 - Disclosure - Off-balance sheet commitments given</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Offbalancesheetcommitmentsreceivedandcontingentassets" roleURI="http://www.abivax.com/role/Offbalancesheetcommitmentsreceivedandcontingentassets">
        <link:definition>9952181 - Disclosure - Off-balance sheet commitments received and contingent assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Managementandassessmentoffinancialrisks" roleURI="http://www.abivax.com/role/Managementandassessmentoffinancialrisks">
        <link:definition>9952182 - Disclosure - Management and assessment of financial risks</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountingprinciplesPolicies" roleURI="http://www.abivax.com/role/AccountingprinciplesPolicies">
        <link:definition>9955511 - Disclosure - Accounting principles (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountingprinciplesTables" roleURI="http://www.abivax.com/role/AccountingprinciplesTables">
        <link:definition>9955512 - Disclosure - Accounting principles (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsTables" roleURI="http://www.abivax.com/role/IntangibleassetsTables">
        <link:definition>9955513 - Disclosure - Intangible assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentTables" roleURI="http://www.abivax.com/role/PropertyplantandequipmentTables">
        <link:definition>9955514 - Disclosure - Property, plant and equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherfinancialassetsTables" roleURI="http://www.abivax.com/role/OtherfinancialassetsTables">
        <link:definition>9955515 - Disclosure - Other financial assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherreceivablesandotherassetsTables" roleURI="http://www.abivax.com/role/OtherreceivablesandotherassetsTables">
        <link:definition>9955516 - Disclosure - Other receivables and other assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandcashequivalentsTables" roleURI="http://www.abivax.com/role/CashandcashequivalentsTables">
        <link:definition>9955517 - Disclosure - Cash and cash equivalents (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialassetsandliabilitiesTables" roleURI="http://www.abivax.com/role/FinancialassetsandliabilitiesTables">
        <link:definition>9955518 - Disclosure - Financial assets and liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedpaymentsTables" roleURI="http://www.abivax.com/role/SharebasedpaymentsTables">
        <link:definition>9955519 - Disclosure - Share-based payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesTables" roleURI="http://www.abivax.com/role/FinancialliabilitiesTables">
        <link:definition>9955520 - Disclosure - Financial liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementbenefitobligationsTables" roleURI="http://www.abivax.com/role/RetirementbenefitobligationsTables">
        <link:definition>9955521 - Disclosure - Retirement benefit obligations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PayablesandothercurrentliabilitiesTables" roleURI="http://www.abivax.com/role/PayablesandothercurrentliabilitiesTables">
        <link:definition>9955522 - Disclosure - Payables and other current liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtheroperatingincomeTables" roleURI="http://www.abivax.com/role/OtheroperatingincomeTables">
        <link:definition>9955523 - Disclosure - Other operating income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingexpensesTables" roleURI="http://www.abivax.com/role/OperatingexpensesTables">
        <link:definition>9955524 - Disclosure - Operating expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeesTables" roleURI="http://www.abivax.com/role/EmployeesTables">
        <link:definition>9955525 - Disclosure - Employees (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialgainlossTables" roleURI="http://www.abivax.com/role/FinancialgainlossTables">
        <link:definition>9955526 - Disclosure - Financial gain (loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxTables" roleURI="http://www.abivax.com/role/IncometaxTables">
        <link:definition>9955527 - Disclosure - Income tax (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomelosspershareTables" roleURI="http://www.abivax.com/role/IncomelosspershareTables">
        <link:definition>9955528 - Disclosure - Income (loss) per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartiesTables" roleURI="http://www.abivax.com/role/RelatedpartiesTables">
        <link:definition>9955529 - Disclosure - Related parties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheGroupDetails" roleURI="http://www.abivax.com/role/TheGroupDetails">
        <link:definition>9955530 - Disclosure - The Group (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpreparationDetails" roleURI="http://www.abivax.com/role/BasisofpreparationDetails">
        <link:definition>9955531 - Disclosure - Basis of preparation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" roleURI="http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details">
        <link:definition>9955532 - Disclosure - Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events - For the year ended 2023 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details" roleURI="http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details">
        <link:definition>9955533 - Disclosure - Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events - For the year ended 2024 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details" roleURI="http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details">
        <link:definition>9955534 - Disclosure - Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events - For the year ended 2025 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails" roleURI="http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails">
        <link:definition>9955535 - Disclosure - Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events - Subsequent events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountingprinciplesIntangibleassetsDetails" roleURI="http://www.abivax.com/role/AccountingprinciplesIntangibleassetsDetails">
        <link:definition>9955536 - Disclosure - Accounting principles - Intangible assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails" roleURI="http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails">
        <link:definition>9955537 - Disclosure - Accounting principles - Disclosure of depreciation period of property, plant and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentinformationDetails" roleURI="http://www.abivax.com/role/SegmentinformationDetails">
        <link:definition>9955538 - Disclosure - Segment information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandimpairmenttestDetails" roleURI="http://www.abivax.com/role/GoodwillandimpairmenttestDetails">
        <link:definition>9955539 - Disclosure - Goodwill and impairment test (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsNarrativeDetails" roleURI="http://www.abivax.com/role/IntangibleassetsNarrativeDetails">
        <link:definition>9955540 - Disclosure - Intangible assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails" roleURI="http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails">
        <link:definition>9955541 - Disclosure - Intangible assets - Disclosure of reconciliation of intangible assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" roleURI="http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails">
        <link:definition>9955542 - Disclosure - Property, plant and equipment - Disclosure of reconciliation of property, plant and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentNarrativeDetails" roleURI="http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails">
        <link:definition>9955543 - Disclosure - Property, plant and equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherfinancialassetsDisclosureofotherfinancialassetsDetails" roleURI="http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails">
        <link:definition>9955544 - Disclosure - Other financial assets - Disclosure of other financial assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherfinancialassetsNarrativeDetails" roleURI="http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails">
        <link:definition>9955545 - Disclosure - Other financial assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails" roleURI="http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails">
        <link:definition>9955546 - Disclosure - Other receivables and other assets - Disclosure of other receivables and other assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherreceivablesandotherassetsNarrativeDetails" roleURI="http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails">
        <link:definition>9955547 - Disclosure - Other receivables and other assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandcashequivalentsDisclosureofcompositionofcashandcashequivalentsDetails" roleURI="http://www.abivax.com/role/CashandcashequivalentsDisclosureofcompositionofcashandcashequivalentsDetails">
        <link:definition>9955548 - Disclosure - Cash and cash equivalents - Disclosure of composition of cash and cash equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandcashequivalentsNarrativeDetails" roleURI="http://www.abivax.com/role/CashandcashequivalentsNarrativeDetails">
        <link:definition>9955549 - Disclosure - Cash and cash equivalents - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialassetsandliabilitiesDetails" roleURI="http://www.abivax.com/role/FinancialassetsandliabilitiesDetails">
        <link:definition>9955550 - Disclosure - Financial assets and liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersequitySharecapitalissuedDetails" roleURI="http://www.abivax.com/role/ShareholdersequitySharecapitalissuedDetails">
        <link:definition>9955551 - Disclosure - Shareholders&#8217; equity - Share capital issued (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersequityChangeinsharecapitalDetails" roleURI="http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails">
        <link:definition>9955552 - Disclosure - Shareholders&#8217; equity - Change in share capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedpaymentsDisclosureofreconciliationofBCEsDetails" roleURI="http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails">
        <link:definition>9955553 - Disclosure - Share-based payments - Disclosure of reconciliation of BCEs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedpaymentsNarrativeDetails" roleURI="http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails">
        <link:definition>9955554 - Disclosure - Share-based payments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedpaymentsDisclosureofreconciliationofBSAsDetails" roleURI="http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails">
        <link:definition>9955555 - Disclosure - Share-based payments - Disclosure of reconciliation of BSAs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails" roleURI="http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails">
        <link:definition>9955556 - Disclosure - Share-based payments - Disclosure of assumptions used for the measurement of BSAs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedpaymentsDisclosureofreconciliationofAGAsDetails" roleURI="http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails">
        <link:definition>9955557 - Disclosure - Share-based payments - Disclosure of reconciliation of AGAs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails" roleURI="http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails">
        <link:definition>9955558 - Disclosure - Share-based payments - Disclosure of assumptions used for the measurement of AGAs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails" roleURI="http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails">
        <link:definition>9955559 - Disclosure - Share-based payments - Disclosure of breakdown of the compensation expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails" roleURI="http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails">
        <link:definition>9955560 - Disclosure - Financial liabilities - Disclosure of financial liabilities breakdown (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesKreosClaretFinancingDetails" roleURI="http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails">
        <link:definition>9955561 - Disclosure - Financial liabilities - Kreos / Claret Financing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails" roleURI="http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails">
        <link:definition>9955562 - Disclosure - Financial liabilities - Disclosure of the main data and assumptions, Kreos / Claret minimum return indemnifications (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails" roleURI="http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails">
        <link:definition>9955563 - Disclosure - Financial liabilities - Disclosure of the main data and assumptions, Kreos / Claret BSA (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesHeightsconvertiblenotesDetails" roleURI="http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails">
        <link:definition>9955564 - Disclosure - Financial liabilities - Heights convertible notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails" roleURI="http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails">
        <link:definition>9955565 - Disclosure - Financial liabilities - Disclosure of the main data and assumptions, Heights convertible loan notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesKreos1Details" roleURI="http://www.abivax.com/role/FinancialliabilitiesKreos1Details">
        <link:definition>9955566 - Disclosure - Financial liabilities - Kreos 1 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails" roleURI="http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails">
        <link:definition>9955567 - Disclosure - Financial liabilities - Disclosure of the main data and assumptions, Kreos BSA (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesKreos2Details" roleURI="http://www.abivax.com/role/FinancialliabilitiesKreos2Details">
        <link:definition>9955568 - Disclosure - Financial liabilities - Kreos 2 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesOCEANEDetails" roleURI="http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails">
        <link:definition>9955569 - Disclosure - Financial liabilities - OCEANE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesStateguaranteedloanPGEDetails" roleURI="http://www.abivax.com/role/FinancialliabilitiesStateguaranteedloanPGEDetails">
        <link:definition>9955570 - Disclosure - Financial liabilities - State guaranteed loan &#8211; &#8220;PGE&#8221; (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesDisclosureofconditionaladvancesDetails" roleURI="http://www.abivax.com/role/FinancialliabilitiesDisclosureofconditionaladvancesDetails">
        <link:definition>9955571 - Disclosure - Financial liabilities - Disclosure of conditional advances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesConditionaladvancesDetails" roleURI="http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails">
        <link:definition>9955572 - Disclosure - Financial liabilities - Conditional advances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesDisclosureofvariationinleaseliabilitiesDetails" roleURI="http://www.abivax.com/role/FinancialliabilitiesDisclosureofvariationinleaseliabilitiesDetails">
        <link:definition>9955573 - Disclosure - Financial liabilities - Disclosure of variation in lease liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesLeaseliabilitiesDetails" roleURI="http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails">
        <link:definition>9955574 - Disclosure - Financial liabilities - Lease liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesRoyaltycertificatesDetails" roleURI="http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails">
        <link:definition>9955575 - Disclosure - Financial liabilities - Royalty certificates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" roleURI="http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails">
        <link:definition>9955576 - Disclosure - Financial liabilities - Disclosure of reconciliation of liabilities arising from financing activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesChangeinfinancialliabilitiesDetails" roleURI="http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails">
        <link:definition>9955577 - Disclosure - Financial liabilities - Change in financial liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails" roleURI="http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails">
        <link:definition>9955578 - Disclosure - Financial liabilities - Disclosure of changes in derivative instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" roleURI="http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails">
        <link:definition>9955579 - Disclosure - Financial liabilities - Disclosure of remaining contractual maturities of financial liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesBreakdownoffinancialliabilitiesbymaturityDetails" roleURI="http://www.abivax.com/role/FinancialliabilitiesBreakdownoffinancialliabilitiesbymaturityDetails">
        <link:definition>9955580 - Disclosure - Financial liabilities - Breakdown of financial liabilities by maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails" roleURI="http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails">
        <link:definition>9955581 - Disclosure - Retirement benefit obligations - Disclosure of main actuarial assumptions used to measure the retirement benefit obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementbenefitobligationsDisclosureofchangesinprojectedbenefitobligationDetails" roleURI="http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofchangesinprojectedbenefitobligationDetails">
        <link:definition>9955582 - Disclosure - Retirement benefit obligations - Disclosure of changes in projected benefit obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails" roleURI="http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails">
        <link:definition>9955583 - Disclosure - Payables and other current liabilities - Disclosure of breakdown of trade and other payables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails" roleURI="http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails">
        <link:definition>9955584 - Disclosure - Payables and other current liabilities - Disclosure of tax and employee-related payables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtheroperatingincomeDisclosureofbreakdownofoperatingincomeDetails" roleURI="http://www.abivax.com/role/OtheroperatingincomeDisclosureofbreakdownofoperatingincomeDetails">
        <link:definition>9955585 - Disclosure - Other operating income - Disclosure of breakdown of operating income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtheroperatingincomeNarrativeDetails" roleURI="http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails">
        <link:definition>9955586 - Disclosure - Other operating income - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingexpensesDisclosureofsalesandmarketingexpensesDetails" roleURI="http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails">
        <link:definition>9955587 - Disclosure - Operating expenses - Disclosure of sales and marketing expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails" roleURI="http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails">
        <link:definition>9955588 - Disclosure - Operating expenses - Disclosure of research and development expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingexpensesNarrativeDetails" roleURI="http://www.abivax.com/role/OperatingexpensesNarrativeDetails">
        <link:definition>9955589 - Disclosure - Operating expenses - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails" roleURI="http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails">
        <link:definition>9955590 - Disclosure - Operating expenses - Disclosure of general and administrative expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingexpensesDisclosureofprincipalauditfeesandservicesDetails" roleURI="http://www.abivax.com/role/OperatingexpensesDisclosureofprincipalauditfeesandservicesDetails">
        <link:definition>9955591 - Disclosure - Operating expenses - Disclosure of principal audit fees and services (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeesDetails" roleURI="http://www.abivax.com/role/EmployeesDetails">
        <link:definition>9955592 - Disclosure - Employees (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialgainlossDisclosureofnetfinancialincomelossDetails" roleURI="http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails">
        <link:definition>9955593 - Disclosure - Financial gain (loss) - Disclosure of net financial income (loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialgainlossNarrativeDetails" roleURI="http://www.abivax.com/role/FinancialgainlossNarrativeDetails">
        <link:definition>9955594 - Disclosure - Financial gain (loss) - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails" roleURI="http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails">
        <link:definition>9955595 - Disclosure - Income tax - Disclosure of reconciliation of effective income tax (loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails" roleURI="http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails">
        <link:definition>9955596 - Disclosure - Income tax - Disclosure of deferred tax assets and liabilities by nature (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxNarrativeDetails" roleURI="http://www.abivax.com/role/IncometaxNarrativeDetails">
        <link:definition>9955597 - Disclosure - Income tax - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomelosspershareScheduleofearningspershareDetails" roleURI="http://www.abivax.com/role/IncomelosspershareScheduleofearningspershareDetails">
        <link:definition>9955598 - Disclosure - Income (loss) per share - Schedule of earnings per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomelosspershareNarrativeDetails" roleURI="http://www.abivax.com/role/IncomelosspershareNarrativeDetails">
        <link:definition>9955599 - Disclosure - Income (loss) per share - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails" roleURI="http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails">
        <link:definition>9955600 - Disclosure - Related parties - Disclosure of aggregate compensation of the members of the Group&#8217;s Board of Directors and CEO (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartiesNarrativeDetails" roleURI="http://www.abivax.com/role/RelatedpartiesNarrativeDetails">
        <link:definition>9955601 - Disclosure - Related parties - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OffbalancesheetcommitmentsgivenDetails" roleURI="http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails">
        <link:definition>9955602 - Disclosure - Off-balance sheet commitments given (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OffbalancesheetcommitmentsreceivedandcontingentassetsDetails" roleURI="http://www.abivax.com/role/OffbalancesheetcommitmentsreceivedandcontingentassetsDetails">
        <link:definition>9955603 - Disclosure - Off-balance sheet commitments received and contingent assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ManagementandassessmentoffinancialrisksDetails" roleURI="http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails">
        <link:definition>9955604 - Disclosure - Management and assessment of financial risks (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="abvx_AmericanDepositorySharesNASDAQGlobalMarketMember" abstract="true" name="AmericanDepositorySharesNASDAQGlobalMarketMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_OrdinarySharesNASDAQGlobalMarketMember" abstract="true" name="OrdinarySharesNASDAQGlobalMarketMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abvx_CurrentReceivablesAndCurrentPrepaidExpenses" abstract="false" name="CurrentReceivablesAndCurrentPrepaidExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_NonCurrentConvertibleLoansNotes" abstract="false" name="NonCurrentConvertibleLoansNotes" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_NonCurrentRoyaltyCertificates" abstract="false" name="NonCurrentRoyaltyCertificates" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets" abstract="false" name="DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_CurrentPortionOfNonCurrentConvertibleLoansNotes" abstract="false" name="CurrentPortionOfNonCurrentConvertibleLoansNotes" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_CurrentTaxAndEmployeeBenefitLiabilities" abstract="false" name="CurrentTaxAndEmployeeBenefitLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_FinancialAgreementAxis" abstract="true" name="FinancialAgreementAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="abvx_FinancialAgreementDomain" abstract="true" name="FinancialAgreementDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_Kreos1Member" abstract="true" name="Kreos1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_KreosClaretFinancingMember" abstract="true" name="KreosClaretFinancingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_OtherEquityAgreementsMember" abstract="true" name="OtherEquityAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_KreosOCABSAMember" abstract="true" name="KreosOCABSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_HeightsConvertibleNotesMember" abstract="true" name="HeightsConvertibleNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease" abstract="false" name="IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants" abstract="false" name="IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments" abstract="false" name="IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="abvx_NumberOfFreeSharesIssued" abstract="false" name="NumberOfFreeSharesIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="abvx_ShareIssueRelatedCostCredit" abstract="false" name="ShareIssueRelatedCostCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_IncreaseDecreaseThroughIssuanceOfWarrantsEquity" abstract="false" name="IncreaseDecreaseThroughIssuanceOfWarrantsEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_IncreaseDecreaseFromFreeSharesIssued" abstract="false" name="IncreaseDecreaseFromFreeSharesIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_AdjustmentsForNetGainOnSaleOfTreasuryShares" abstract="false" name="AdjustmentsForNetGainOnSaleOfTreasuryShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_AdjustmentsForOtherFinanceCosts" abstract="false" name="AdjustmentsForOtherFinanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_AdjustmentsForOtherFinanceIncome" abstract="false" name="AdjustmentsForOtherFinanceIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances" abstract="false" name="AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_AdjustmentsForForgivenessOfConditionalAdvances" abstract="false" name="AdjustmentsForForgivenessOfConditionalAdvances" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities" abstract="false" name="AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities" abstract="false" name="AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations" abstract="false" name="PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_CashPaymentsForDeposits" abstract="false" name="CashPaymentsForDeposits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_ProceedsFromReimbursementsOfDeposits" abstract="false" name="ProceedsFromReimbursementsOfDeposits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_PaymentsForProceedsFromShareIssueRelatedCostsCredit" abstract="false" name="PaymentsForProceedsFromShareIssueRelatedCostsCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_NetProceedsFromNonConvertibleLoansNotes" abstract="false" name="NetProceedsFromNonConvertibleLoansNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_RepaymentsOfNonConvertibleLoansNotes" abstract="false" name="RepaymentsOfNonConvertibleLoansNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_NetProceedsFromConvertibleLoanNotes" abstract="false" name="NetProceedsFromConvertibleLoanNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_RepaymentsOfConvertibleLoansNotes" abstract="false" name="RepaymentsOfConvertibleLoansNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_RepaymentsOfPGE" abstract="false" name="RepaymentsOfPGE" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_RepaymentsOfConditionalAdvances" abstract="false" name="RepaymentsOfConditionalAdvances" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_RevaluationOfCashEquivalentsMeasuredAtFairValue" abstract="false" name="RevaluationOfCashEquivalentsMeasuredAtFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_AccountingPrinciplesAbstract" abstract="true" name="AccountingPrinciplesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abvx_DisclosureOfSignificantEventsForThePeriodReportedAndEventsAfterReportingPeriodTextBlock" abstract="false" name="DisclosureOfSignificantEventsForThePeriodReportedAndEventsAfterReportingPeriodTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="abvx_FairValueMeasurementAbstract" abstract="true" name="FairValueMeasurementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abvx_ShareBasedPaymentArrangementsAbstract" abstract="true" name="ShareBasedPaymentArrangementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abvx_FinancialIncomeLossAbstract" abstract="true" name="FinancialIncomeLossAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abvx_OffBalanceSheetCommitmentsAbstract" abstract="true" name="OffBalanceSheetCommitmentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abvx_FinancialRiskManagementAbstract" abstract="true" name="FinancialRiskManagementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abvx_DisclosureOfAccountingPolicyForAssetsAcquisitionsPolicyTextBlock" abstract="false" name="DisclosureOfAccountingPolicyForAssetsAcquisitionsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="abvx_DisclosureOfAccountingPolicyForAccountingJudgementsAndEstimatesExplanatoryPolicyTextBlock" abstract="false" name="DisclosureOfAccountingPolicyForAccountingJudgementsAndEstimatesExplanatoryPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="abvx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock" abstract="false" name="DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="abvx_DisclosureOfImpactOfTheUkraineRussiaHostilitiesOnTheGroupPolicyTextBlock" abstract="false" name="DisclosureOfImpactOfTheUkraineRussiaHostilitiesOnTheGroupPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="abvx_DisclosureOfAccountingPolicyForNewRevisedOrAmendedStandardsAndInterpretationsPolicyTextBlock" abstract="false" name="DisclosureOfAccountingPolicyForNewRevisedOrAmendedStandardsAndInterpretationsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="abvx_DisclosureOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedByIASBButNotYetMandatoryPolicyTextBlock" abstract="false" name="DisclosureOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedByIASBButNotYetMandatoryPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="abvx_DisclosureOfDetailedInformationAboutAssetsAcquisitionsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutAssetsAcquisitionsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="abvx_DisclosureOfDetailedInformationAboutOtherReceivablesAndOtherAssetsTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutOtherReceivablesAndOtherAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="abvx_DisclosureOfCompositionOfCashAndCashEquivalentsTableTextBlock" abstract="false" name="DisclosureOfCompositionOfCashAndCashEquivalentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="abvx_DisclosureOfIndirectMeasurementOfConvertibleLoansInstrumentsTableTextBlock" abstract="false" name="DisclosureOfIndirectMeasurementOfConvertibleLoansInstrumentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="abvx_DisclosureOfLeasesForLesseeTableTextBlock" abstract="false" name="DisclosureOfLeasesForLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="abvx_DisclosureOfChangesInDerivativeFinancialInstrumentsTableTextBlock" abstract="false" name="DisclosureOfChangesInDerivativeFinancialInstrumentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="abvx_DisclosureOfBreakdownOfTradeAndOtherPayablesTableTextBlock" abstract="false" name="DisclosureOfBreakdownOfTradeAndOtherPayablesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="abvx_DisclosureOfTaxAndEmployeeRelatedPayablesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfTaxAndEmployeeRelatedPayablesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="abvx_DisclosureOfDetailedInformationOfOperatingIncomeExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationOfOperatingIncomeExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="abvx_DisclosureOfPrincipalAuditFeesAndServicesTableTextBlock" abstract="false" name="DisclosureOfPrincipalAuditFeesAndServicesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="abvx_DisclosureOfAverageNumberOfEmployeesTableTextBlock" abstract="false" name="DisclosureOfAverageNumberOfEmployeesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="abvx_DisclosureOfDetailedInformationAboutFinanceIncomeCostTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutFinanceIncomeCostTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="abvx_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock" abstract="false" name="DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="abvx_SaleOfStockAxis" abstract="true" name="SaleOfStockAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="abvx_SaleOfStockDomain" abstract="true" name="SaleOfStockDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_RegisteredDirectOfferingMember" abstract="true" name="RegisteredDirectOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_BanquePubliqueDInvestissementBPIMember" abstract="true" name="BanquePubliqueDInvestissementBPIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_ProceedsFromResearchTaxCredit" abstract="false" name="ProceedsFromResearchTaxCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_ProceedsFromConditionalAdvances" abstract="false" name="ProceedsFromConditionalAdvances" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_NetProceedsFromSaleOfRoyaltyCertificates" abstract="false" name="NetProceedsFromSaleOfRoyaltyCertificates" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_CashAndCashEquivalentsAndOtherShortTermInvestments" abstract="false" name="CashAndCashEquivalentsAndOtherShortTermInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_A130.0MillionCrossOverFinancingFebruary2023Member" abstract="true" name="A130.0MillionCrossOverFinancingFebruary2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_A49.2MillionCrossOverFinancingSeptember2022Member" abstract="true" name="A49.2MillionCrossOverFinancingSeptember2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_A150.0MillionFinancingAugust2023Member" abstract="true" name="A150.0MillionFinancingAugust2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_Kreos1ConvertibleBondLoansTrancheAMember" abstract="true" name="Kreos1ConvertibleBondLoansTrancheAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_Kreos1ConvertibleBondLoansTrancheBMember" abstract="true" name="Kreos1ConvertibleBondLoansTrancheBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_KreosClaretFinancingTrancheAMember" abstract="true" name="KreosClaretFinancingTrancheAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_OCEANEMember" abstract="true" name="OCEANEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_KreosClaretFinancingAndHeightsConvertibleNotesMember" abstract="true" name="KreosClaretFinancingAndHeightsConvertibleNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_AmericanDepositorySharesMember" abstract="true" name="AmericanDepositorySharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_WarrantsAxis" abstract="true" name="WarrantsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="abvx_WarrantsDomain" abstract="true" name="WarrantsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_KreosCBSAMember" abstract="true" name="KreosCBSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_FreeSharesAGAMember" abstract="true" name="FreeSharesAGAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_FinancialAgreementAmount" abstract="false" name="FinancialAgreementAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_EquityIssuancePercentageOfCurrentShareCapital" abstract="false" name="EquityIssuancePercentageOfCurrentShareCapital" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="abvx_EquityIssuanceSubscriptionPricePerShare" abstract="false" name="EquityIssuanceSubscriptionPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="abvx_NumberOfOtherShareWarrantsRepurchased" abstract="false" name="NumberOfOtherShareWarrantsRepurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="abvx_NumberOfShareBasedCompensationPlansIssued" abstract="false" name="NumberOfShareBasedCompensationPlansIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abvx_FinancialAgreementNumberOfTransactions" abstract="false" name="FinancialAgreementNumberOfTransactions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abvx_BorrowingsMaximumBorrowingCapacity" abstract="false" name="BorrowingsMaximumBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_AggregateExercisePriceOtherEquityInstrumentsGranted" abstract="false" name="AggregateExercisePriceOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_ProceedsFromBorrowingsNetOfRefinancingOfExistingIndebteness" abstract="false" name="ProceedsFromBorrowingsNetOfRefinancingOfExistingIndebteness" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_IssuanceOfOtherShareWarrants" abstract="false" name="IssuanceOfOtherShareWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_NumberOfSharesReceivedPerADS" abstract="false" name="NumberOfSharesReceivedPerADS" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="abvx_IssueOfEquityOfferingPricePerShare" abstract="false" name="IssueOfEquityOfferingPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="abvx_ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants" abstract="false" name="ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_AGA2024Member" abstract="true" name="AGA2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_AGA20246Member" abstract="true" name="AGA20246Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_BSA20241Member" abstract="true" name="BSA20241Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_TranchesAxis" abstract="true" name="TranchesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="abvx_TranchesDomain" abstract="true" name="TranchesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_TrancheOneMember" abstract="true" name="TrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_TrancheTwoMember" abstract="true" name="TrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_TrancheThreeMember" abstract="true" name="TrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_KreosClaretFinancingTrancheBMember" abstract="true" name="KreosClaretFinancingTrancheBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_KreosClaretFinancingTrancheCMember" abstract="true" name="KreosClaretFinancingTrancheCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_KreosClaretFinancingTrancheBAndCMember" abstract="true" name="KreosClaretFinancingTrancheBAndCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_RNPVIRConditionalAdvanceBPIMember" abstract="true" name="RNPVIRConditionalAdvanceBPIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_CARENAConditionalAdvanceBPIMember" abstract="true" name="CARENAConditionalAdvanceBPIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_RNPVIRConditionalAdvanceBPIAndCARENAConditionalAdvanceBPIMember" abstract="true" name="RNPVIRConditionalAdvanceBPIAndCARENAConditionalAdvanceBPIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_AtTheMarketATMProgramMember" abstract="true" name="AtTheMarketATMProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_NumberOfFreeSharesPlansIssued" abstract="false" name="NumberOfFreeSharesPlansIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" abstract="false" name="VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" abstract="false" name="VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="abvx_PercentageOfConditionalAdvancesWaived" abstract="false" name="PercentageOfConditionalAdvancesWaived" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="abvx_NumberOfADSPerOrdinaryShares" abstract="false" name="NumberOfADSPerOrdinaryShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abvx_ExpectedProceedsFromShareIssuance" abstract="false" name="ExpectedProceedsFromShareIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_ExpectedProceedsFromShareIssuanceShelfRegistration" abstract="false" name="ExpectedProceedsFromShareIssuanceShelfRegistration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_ShareSubscriptionWarrantsBSAMember" abstract="true" name="ShareSubscriptionWarrantsBSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_AGA2025Member" abstract="true" name="AGA2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_AGA20252Member" abstract="true" name="AGA20252Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_AGA20255Member" abstract="true" name="AGA20255Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_AGA20251Member" abstract="true" name="AGA20251Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_BoardMemberMember" abstract="true" name="BoardMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_KreosABCBSAMember" abstract="true" name="KreosABCBSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_KreosClaretFinancingBAndCMember" abstract="true" name="KreosClaretFinancingBAndCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_SharePrice1" abstract="false" name="SharePrice1" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="abvx_NetProceedsFromIssueOfOrdinaryShares" abstract="false" name="NetProceedsFromIssueOfOrdinaryShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_NumberOfConvertibleNotesConverted" abstract="false" name="NumberOfConvertibleNotesConverted" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abvx_BorrowingsFixedConversionPrice" abstract="false" name="BorrowingsFixedConversionPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="abvx_MajorShareBasedTransactionsMember" abstract="true" name="MajorShareBasedTransactionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_CSOSettlementAgreementMember" abstract="true" name="CSOSettlementAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_KeyManagementPersonnelCompensationContractualSeveranceIndemnity" abstract="false" name="KeyManagementPersonnelCompensationContractualSeveranceIndemnity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_NumberOfSharesWaived" abstract="false" name="NumberOfSharesWaived" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="abvx_NumberOfSharesWithPerformanceConditionsWaived" abstract="false" name="NumberOfSharesWithPerformanceConditionsWaived" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="abvx_NumberOfSharesLapsed" abstract="false" name="NumberOfSharesLapsed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="abvx_ResearchAndDevelopmentCostsRecognitionInitialMeasurementNumberOfCriterias" abstract="false" name="ResearchAndDevelopmentCostsRecognitionInitialMeasurementNumberOfCriterias" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abvx_IndustrialMaterialsAndEquipmentMember" abstract="true" name="IndustrialMaterialsAndEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_TechnicalFacilitiesMember" abstract="true" name="TechnicalFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_FurnitureMember" abstract="true" name="FurnitureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_ContributionToGroupsLiabilitiesPercentage" abstract="false" name="ContributionToGroupsLiabilitiesPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="abvx_ContributionToGroupsNetProfitsLossesPercentage" abstract="false" name="ContributionToGroupsNetProfitsLossesPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="abvx_ContributionToGroupsAssetsPercentage" abstract="false" name="ContributionToGroupsAssetsPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="abvx_NumberOfOperatingSegment" abstract="false" name="NumberOfOperatingSegment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abvx_WittycelSASABX196Member" abstract="true" name="WittycelSASABX196Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_SplicosSASABX464Member" abstract="true" name="SplicosSASABX464Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_PrincipalAgreementsAxis" abstract="true" name="PrincipalAgreementsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="abvx_PrincipalAgreementsDomain" abstract="true" name="PrincipalAgreementsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember" abstract="true" name="ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember" abstract="true" name="ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_AssetsAcquisitionsAxis" abstract="true" name="AssetsAcquisitionsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="abvx_AssetsAcquisitionsDomain" abstract="true" name="AssetsAcquisitionsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_ProsynergiaMember" abstract="true" name="ProsynergiaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_CollaborationAgreementsDevelopmentMilestonePaymentINDApproval" abstract="false" name="CollaborationAgreementsDevelopmentMilestonePaymentINDApproval" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_CollaborationAgreementsDevelopmentMilestonePaymentPhase2" abstract="false" name="CollaborationAgreementsDevelopmentMilestonePaymentPhase2" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_TechnologyBasedIntangibleAssetsAssetsAcquisitions" abstract="false" name="TechnologyBasedIntangibleAssetsAssetsAcquisitions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_FurnitureAndComputerEquipmentMember" abstract="true" name="FurnitureAndComputerEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_LeaseFacilitiesParisMember" abstract="true" name="LeaseFacilitiesParisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_DecreaseThroughReassessmentOfLeaseTermRightOfUseAssets" abstract="false" name="DecreaseThroughReassessmentOfLeaseTermRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_NonCurrentAdvancesToCROContractsUndiscountedAmount" abstract="false" name="NonCurrentAdvancesToCROContractsUndiscountedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_OtherNonCurrentMiscellaneousFinancialAssets" abstract="false" name="OtherNonCurrentMiscellaneousFinancialAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_CurrentAdvancesToCROContracts" abstract="false" name="CurrentAdvancesToCROContracts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_OtherCurrentInvestments" abstract="false" name="OtherCurrentInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_DiscountRateAppliedToLongTermAdvances" abstract="false" name="DiscountRateAppliedToLongTermAdvances" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="abvx_PaymentsForAdvancesMadeToContractResearchOrganizationsUndiscountedAmount" abstract="false" name="PaymentsForAdvancesMadeToContractResearchOrganizationsUndiscountedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_NonCurrentPrepaidExpenses" abstract="false" name="NonCurrentPrepaidExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_CurrentResearchTaxCreditReceivables" abstract="false" name="CurrentResearchTaxCreditReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_CurrentReceivablesForEmployeeBenefits" abstract="false" name="CurrentReceivablesForEmployeeBenefits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_CurrentReceivablesFromCreditNotes" abstract="false" name="CurrentReceivablesFromCreditNotes" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_DisclosureOfOtherReceivablesAndOtherAssetsTable" abstract="true" name="DisclosureOfOtherReceivablesAndOtherAssetsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="abvx_DeferredFinancingCostsNettingMember" abstract="true" name="DeferredFinancingCostsNettingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems" abstract="true" name="DisclosureOfOtherReceivablesAndOtherAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abvx_CurrentPrepaidExpensesRelatedToCRO" abstract="false" name="CurrentPrepaidExpensesRelatedToCRO" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_ReclassificationOfPrepaidExpensesToCarryingValueOfDebtComponent" abstract="false" name="ReclassificationOfPrepaidExpensesToCarryingValueOfDebtComponent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_DisclosureOfCashAndCashEquivalentsTable" abstract="true" name="DisclosureOfCashAndCashEquivalentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="abvx_DisclosureOfCashAndCashEquivalentsLineItems" abstract="true" name="DisclosureOfCashAndCashEquivalentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable" abstract="true" name="DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="abvx_OtherFinancialAssetsMember" abstract="true" name="OtherFinancialAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_OtherReceivablesAndAssetsMember" abstract="true" name="OtherReceivablesAndAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_CashAndCashEquivalentMember" abstract="true" name="CashAndCashEquivalentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_NonCurrentAdvancesToCROContractsMember" abstract="true" name="NonCurrentAdvancesToCROContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_NonCurrentFinancialLiabilitiesMember" abstract="true" name="NonCurrentFinancialLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_KreosClaretFinancingTrancheABAndCMember" abstract="true" name="KreosClaretFinancingTrancheABAndCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_ConditionalAdvancesAndPGELoanMember" abstract="true" name="ConditionalAdvancesAndPGELoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_PretGarantiParLEtatPGEMember" abstract="true" name="PretGarantiParLEtatPGEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_EbolaConditionalAdvanceBPIMember" abstract="true" name="EbolaConditionalAdvanceBPIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_CurrentFinancialLiabilitiesMember" abstract="true" name="CurrentFinancialLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_TradePayablesAndOtherCurrentLiabilitiesMember" abstract="true" name="TradePayablesAndOtherCurrentLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems" abstract="true" name="DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abvx_NumberOfTranches" abstract="false" name="NumberOfTranches" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abvx_NumberOfTreasurySharesHeld" abstract="false" name="NumberOfTreasurySharesHeld" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="abvx_KreosABSAMember" abstract="true" name="KreosABSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_KreosBBSAMember" abstract="true" name="KreosBBSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_BSA20241AndBSA20242Member" abstract="true" name="BSA20241AndBSA20242Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_NumberOfWarrantsExercised" abstract="false" name="NumberOfWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="abvx_OtherShareWarrantsSubscriptionPricePerShare" abstract="false" name="OtherShareWarrantsSubscriptionPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="abvx_ShareWarrantsSubscriptionPricePerShare" abstract="false" name="ShareWarrantsSubscriptionPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="abvx_FoundersShareSubscriptionWarrantsBCEMember" abstract="true" name="FoundersShareSubscriptionWarrantsBCEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_BCE20161Member" abstract="true" name="BCE20161Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_BCE20171Member" abstract="true" name="BCE20171Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_BCE20172Member" abstract="true" name="BCE20172Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_BCE20174Member" abstract="true" name="BCE20174Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_BCE20175Member" abstract="true" name="BCE20175Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_BCE20181Member" abstract="true" name="BCE20181Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_BCE20184Member" abstract="true" name="BCE20184Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_BCE20185Member" abstract="true" name="BCE20185Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet" abstract="false" name="MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="abvx_TrancheFourMember" abstract="true" name="TrancheFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_TrancheFiveMember" abstract="true" name="TrancheFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_TrancheSixMember" abstract="true" name="TrancheSixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_BCEExceptBCE20142Member" abstract="true" name="BCEExceptBCE20142Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_BSA20251AndBSA20252Member" abstract="true" name="BSA20251AndBSA20252Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_BSA20253Member" abstract="true" name="BSA20253Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_AGA20231Member" abstract="true" name="AGA20231Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_AGA20232Member" abstract="true" name="AGA20232Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_AGA20233AGA20234AndAGA20235Member" abstract="true" name="AGA20233AGA20234AndAGA20235Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_AGA20233AndAGA20234Member" abstract="true" name="AGA20233AndAGA20234Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_AGA20235Member" abstract="true" name="AGA20235Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_AGA20241Member" abstract="true" name="AGA20241Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_AGA20242Member" abstract="true" name="AGA20242Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_AGA20243Member" abstract="true" name="AGA20243Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_AGA20244AGA20245AndAGA20246Member" abstract="true" name="AGA20244AGA20245AndAGA20246Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_AGA20247Member" abstract="true" name="AGA20247Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_AGA20241AGE20242AGA20243AGA20244AGA20245AndAGA20247Member" abstract="true" name="AGA20241AGE20242AGA20243AGA20244AGA20245AndAGA20247Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_AGA20253Member" abstract="true" name="AGA20253Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_AGA20254Member" abstract="true" name="AGA20254Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_AGA20256Member" abstract="true" name="AGA20256Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_AGA20257Member" abstract="true" name="AGA20257Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_AGA20258Member" abstract="true" name="AGA20258Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_AGA20251AGA20253AGA20254AGA20256AGA20257AndAGA20258Member" abstract="true" name="AGA20251AGA20253AGA20254AGA20256AGA20257AndAGA20258Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_FormerChiefExecutiveOfficerMember" abstract="true" name="FormerChiefExecutiveOfficerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_EmployeeMember" abstract="true" name="EmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentagePerMonth" abstract="false" name="VestingRequirementsForShareBasedPaymentArrangementVestingPercentagePerMonth" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="abvx_VestingRequirementsForShareBasedPaymentArrangementPerformanceConditionsMinimumFinancing" abstract="false" name="VestingRequirementsForShareBasedPaymentArrangementPerformanceConditionsMinimumFinancing" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_VestingRequirementsForShareBasedPaymentArrangementChangeOfControlMinimumThreshold" abstract="false" name="VestingRequirementsForShareBasedPaymentArrangementChangeOfControlMinimumThreshold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="abvx_NumberOfOtherEquityInstrumentsGrantedSubjectToNonMarketPerformanceCondition" abstract="false" name="NumberOfOtherEquityInstrumentsGrantedSubjectToNonMarketPerformanceCondition" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="abvx_VestingRequirementsForShareBasedPaymentArrangementServicePeriod" abstract="false" name="VestingRequirementsForShareBasedPaymentArrangementServicePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="abvx_BSA201511Member" abstract="true" name="BSA201511Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_BSA201512Member" abstract="true" name="BSA201512Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_BSA20171Member" abstract="true" name="BSA20171Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_BSA20181Member" abstract="true" name="BSA20181Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_BSA20242Member" abstract="true" name="BSA20242Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_BSA20251Member" abstract="true" name="BSA20251Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_BSA20252Member" abstract="true" name="BSA20252Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted" abstract="false" name="UnderlyingShareFairValueOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted" abstract="false" name="EquityInstrumentFairValueOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted" abstract="false" name="EquityInstrumentPriceOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="abvx_EquityInstrumentStrikePriceOtherEquityInstrumentsGranted" abstract="false" name="EquityInstrumentStrikePriceOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted" abstract="false" name="RiskFreeInterestRateOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="abvx_ExpectedMaturityOtherEquityInstrumentsGranted" abstract="false" name="ExpectedMaturityOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="abvx_ExpectedVolatilityOtherEquityInstrumentsGranted" abstract="false" name="ExpectedVolatilityOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="abvx_AGA20233Member" abstract="true" name="AGA20233Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_AGA20234Member" abstract="true" name="AGA20234Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_AGA20244Member" abstract="true" name="AGA20244Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_AGA20245Member" abstract="true" name="AGA20245Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_TranchesOneToFourMember" abstract="true" name="TranchesOneToFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes" abstract="false" name="ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_Borrowings1Member" abstract="true" name="Borrowings1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_Kreos1ClaretBondLoansMember" abstract="true" name="Kreos1ClaretBondLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_ConvertibleLoansNotesMember" abstract="true" name="ConvertibleLoansNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_KreosClaretMinimumReturnIndemnificationsMember" abstract="true" name="KreosClaretMinimumReturnIndemnificationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_KreosClaretFinancingBSAMember" abstract="true" name="KreosClaretFinancingBSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_OtherFinancialLiabilitiesMember" abstract="true" name="OtherFinancialLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_ConditionalAdvancesMember" abstract="true" name="ConditionalAdvancesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_RoyaltyCertificatesMember" abstract="true" name="RoyaltyCertificatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember" abstract="true" name="KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_Kreos1BondLoansMember" abstract="true" name="Kreos1BondLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_EuropeanCentralBankBaseRateMember" abstract="true" name="EuropeanCentralBankBaseRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_KreosABBSAMember" abstract="true" name="KreosABBSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_MarketRateMeasurementInputMember" abstract="true" name="MarketRateMeasurementInputMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_SharePriceMeasurementInputMember" abstract="true" name="SharePriceMeasurementInputMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_RiskFreeInterestRateMeasurementInputMember" abstract="true" name="RiskFreeInterestRateMeasurementInputMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_FinalRedemptionScenarioProbabilityMeasurementInputMember" abstract="true" name="FinalRedemptionScenarioProbabilityMeasurementInputMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_ExpiryScenarioProbablityMeasurementInputMember" abstract="true" name="ExpiryScenarioProbablityMeasurementInputMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_BlackScholesModelMember" abstract="true" name="BlackScholesModelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_MonteCarloModel1Member" abstract="true" name="MonteCarloModel1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_RepaymentsOfBondLoans" abstract="false" name="RepaymentsOfBondLoans" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_BorrowingsNumberOfTranches" abstract="false" name="BorrowingsNumberOfTranches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abvx_BorrowingsMaximumBorrowingCapacityPerTranche" abstract="false" name="BorrowingsMaximumBorrowingCapacityPerTranche" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_BorrowingsEarlyRepaymentDiscountRate" abstract="false" name="BorrowingsEarlyRepaymentDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="abvx_BorrowingsExitFeePercentage" abstract="false" name="BorrowingsExitFeePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="abvx_BorrowingsDebtToMarketCapitalizationRatio" abstract="false" name="BorrowingsDebtToMarketCapitalizationRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="abvx_BorrowingsPerformanceConditionsMinimumFinancing" abstract="false" name="BorrowingsPerformanceConditionsMinimumFinancing" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_BorrowingsBasisInterestRate" abstract="false" name="BorrowingsBasisInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="abvx_NumberOfWarrantsGranted" abstract="false" name="NumberOfWarrantsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="abvx_ExercisePriceOtherEquityInstrumentsGranted" abstract="false" name="ExercisePriceOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="abvx_ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted" abstract="false" name="ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="abvx_ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted" abstract="false" name="ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsPercentageExercisableImmediately" abstract="false" name="NumberOfInstrumentsGrantedOtherEquityInstrumentsPercentageExercisableImmediately" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsRemainingPercentageExercisable" abstract="false" name="NumberOfInstrumentsGrantedOtherEquityInstrumentsRemainingPercentageExercisable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="abvx_OtherShareWarrantsExercisePeriod" abstract="false" name="OtherShareWarrantsExercisePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="abvx_NumberOfWarrantsRepurchased" abstract="false" name="NumberOfWarrantsRepurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="abvx_AggregateFairValueOtherEquityInstrumentsOutstanding" abstract="false" name="AggregateFairValueOtherEquityInstrumentsOutstanding" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_BorrowingsDeposit" abstract="false" name="BorrowingsDeposit" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_BorrowingsDiscountRate" abstract="false" name="BorrowingsDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abvx_BorrowingsExitFeeAmount" abstract="false" name="BorrowingsExitFeeAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_ConvertibleLoansNotes" abstract="false" name="ConvertibleLoansNotes" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_ConvertibleLoansNotesCarryingAmountOfTheEquityComponent" abstract="false" name="ConvertibleLoansNotesCarryingAmountOfTheEquityComponent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" abstract="false" name="AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted" abstract="false" name="ExpiryScenarioPeriodOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="abvx_MinimalReturnMeasurementInputMember" abstract="true" name="MinimalReturnMeasurementInputMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember" abstract="true" name="FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember" abstract="true" name="TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember" abstract="true" name="FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember" abstract="true" name="FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_FinalRedemptionFairValueOfMRIMeasurementInputMember" abstract="true" name="FinalRedemptionFairValueOfMRIMeasurementInputMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_TenderOfferFairValueOfMRIMeasurementInputMember" abstract="true" name="TenderOfferFairValueOfMRIMeasurementInputMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_AmortizedCostEIRMethodMember" abstract="true" name="AmortizedCostEIRMethodMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_TrancheBMember" abstract="true" name="TrancheBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_TrancheCMember" abstract="true" name="TrancheCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_DisclosureOfWarrantsArrangementsTable" abstract="true" name="DisclosureOfWarrantsArrangementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="abvx_ExercisePricePerShareMeasurementInputMember" abstract="true" name="ExercisePricePerShareMeasurementInputMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_DrawdownProbablityMeasurementInputMember" abstract="true" name="DrawdownProbablityMeasurementInputMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_VolatilityForSharesMeasurementInputExpiryMember" abstract="true" name="VolatilityForSharesMeasurementInputExpiryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_VolatilityForSharesMeasurementInputTenderOfferMember" abstract="true" name="VolatilityForSharesMeasurementInputTenderOfferMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_ExpectedDividendMeasurementInputMember" abstract="true" name="ExpectedDividendMeasurementInputMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_RiskFreeInterestRateMeasurementInputExpiryMember" abstract="true" name="RiskFreeInterestRateMeasurementInputExpiryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_RiskFreeInterestRateMeasurementInputTenderOfferMember" abstract="true" name="RiskFreeInterestRateMeasurementInputTenderOfferMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_DisclosureOfWarrantsArrangementsLineItems" abstract="true" name="DisclosureOfWarrantsArrangementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abvx_NumberOfProbabilityWeightedScenarios" abstract="false" name="NumberOfProbabilityWeightedScenarios" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abvx_NumberOfWarrantsOutstanding" abstract="false" name="NumberOfWarrantsOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="abvx_NumberOfWarrantsOutstandingSubjectToNonMarketPerformanceCondition" abstract="false" name="NumberOfWarrantsOutstandingSubjectToNonMarketPerformanceCondition" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="abvx_HeightsConvertibleNotesTrancheAMember" abstract="true" name="HeightsConvertibleNotesTrancheAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_HeightsConvertibleNotesTrancheBMember" abstract="true" name="HeightsConvertibleNotesTrancheBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_VoluntaryConversionScenarioProbabilityMeasurementInputMember" abstract="true" name="VoluntaryConversionScenarioProbabilityMeasurementInputMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_NetProceedsFromConvertibleLoansNotes" abstract="false" name="NetProceedsFromConvertibleLoansNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_NumberOfConvertibleNotesIssued" abstract="false" name="NumberOfConvertibleNotesIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abvx_ConvertibleLoansNotesNominalValue" abstract="false" name="ConvertibleLoansNotesNominalValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_ConvertibleLoansNotesPeriod" abstract="false" name="ConvertibleLoansNotesPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="abvx_ConvertibleLoansNotesNumberOfSeparateClosings" abstract="false" name="ConvertibleLoansNotesNumberOfSeparateClosings" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abvx_BorrowingsNumberOfQuarterlyInstallments" abstract="false" name="BorrowingsNumberOfQuarterlyInstallments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abvx_BorrowingsMaturityDeferralPeriod" abstract="false" name="BorrowingsMaturityDeferralPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="abvx_BorrowingsPercentageOfMarketPrice" abstract="false" name="BorrowingsPercentageOfMarketPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="abvx_BorrowingsMarketPriceNumberOfDaysWithLowestDailyVWAP" abstract="false" name="BorrowingsMarketPriceNumberOfDaysWithLowestDailyVWAP" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="abvx_BorrowingsMarketPriceNumberOfTradingDays" abstract="false" name="BorrowingsMarketPriceNumberOfTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="abvx_IssuancePricePercentageOfDiscountTo15DayWVAP" abstract="false" name="IssuancePricePercentageOfDiscountTo15DayWVAP" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="abvx_ConvertibleLoansNotesSettlementInSharesPercentageOfFairMarketValue" abstract="false" name="ConvertibleLoansNotesSettlementInSharesPercentageOfFairMarketValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="abvx_EquityIssuanceCashCarveOut" abstract="false" name="EquityIssuanceCashCarveOut" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_ConvertibleLoansNotesEarlyRedemptionAmountPercentageOfOutstandongPrincipal" abstract="false" name="ConvertibleLoansNotesEarlyRedemptionAmountPercentageOfOutstandongPrincipal" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="abvx_GainsArisingFromRecognitionOfFinancialLiabilities" abstract="false" name="GainsArisingFromRecognitionOfFinancialLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_UnrecognitionDayOneGainOfFinancialLiabilities" abstract="false" name="UnrecognitionDayOneGainOfFinancialLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_ConvertibleLoansNotesConversionOptionMaximumPeriodPriorToMaturityDate" abstract="false" name="ConvertibleLoansNotesConversionOptionMaximumPeriodPriorToMaturityDate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss" abstract="false" name="LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_ConversionPricePerShareMeasurementInputMember" abstract="true" name="ConversionPricePerShareMeasurementInputMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_InitialPriceLimitMeasurementInputMember" abstract="true" name="InitialPriceLimitMeasurementInputMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_EarlyRedemptionAmountMeasurementInputMember" abstract="true" name="EarlyRedemptionAmountMeasurementInputMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_MonteCarloModelIFRSMember" abstract="true" name="MonteCarloModelIFRSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_NumberOfConvertibleNotesOutstanding" abstract="false" name="NumberOfConvertibleNotesOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abvx_AggregateFairValueConvertibleNotes" abstract="false" name="AggregateFairValueConvertibleNotes" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_Kreos1NonConvertibleBondLoansMember" abstract="true" name="Kreos1NonConvertibleBondLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_Kreos1ConvertibleBondLoansMember" abstract="true" name="Kreos1ConvertibleBondLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_Kreos12BondLoansMember" abstract="true" name="Kreos12BondLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_NumberOfShareWarrantsIssued" abstract="false" name="NumberOfShareWarrantsIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="abvx_NumberOfSharesPerShareWarrant" abstract="false" name="NumberOfSharesPerShareWarrant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="abvx_NumberOfOtherShareWarrantsConverted" abstract="false" name="NumberOfOtherShareWarrantsConverted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="abvx_Kreos2Member" abstract="true" name="Kreos2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_Kreos2TrancheAMember" abstract="true" name="Kreos2TrancheAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_Kreos2TrancheBMember" abstract="true" name="Kreos2TrancheBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_BorrowingsAdditionalTrancheAmount" abstract="false" name="BorrowingsAdditionalTrancheAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_RemeasurementPeriodAxis" abstract="true" name="RemeasurementPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="abvx_RemeasurementPeriodDomain" abstract="true" name="RemeasurementPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_After18MonthsMember" abstract="true" name="After18MonthsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_After24MonthsMember" abstract="true" name="After24MonthsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_After36MonthsMember" abstract="true" name="After36MonthsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_ProceedsFromIssuingSharesAndConvertibleLoansNotes" abstract="false" name="ProceedsFromIssuingSharesAndConvertibleLoansNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_ConversionPriceAdjustmentPeriod" abstract="false" name="ConversionPriceAdjustmentPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="abvx_BorrowingsMaturityTerm" abstract="false" name="BorrowingsMaturityTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="abvx_BorrowingsMaturityExtensionTerm" abstract="false" name="BorrowingsMaturityExtensionTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="abvx_BorrowingsStateGuaranteedPremium" abstract="false" name="BorrowingsStateGuaranteedPremium" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_ConditionalAdvances" abstract="false" name="ConditionalAdvances" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity" abstract="false" name="OtherFinancialLiabilitiesMaximumDrawdownCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_RepaymentOfExcessConditionalAdvancesClaimed" abstract="false" name="RepaymentOfExcessConditionalAdvancesClaimed" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_IncreaseInLeaseLiabilities" abstract="false" name="IncreaseInLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_DecreaseInLeaseLiabilities" abstract="false" name="DecreaseInLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_DisclosureOfLeaseLiabilitiesTable" abstract="true" name="DisclosureOfLeaseLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="abvx_LeaseFacilitiesBostonMember" abstract="true" name="LeaseFacilitiesBostonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_LeaseFacilitiesMontpellierMember" abstract="true" name="LeaseFacilitiesMontpellierMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_LeaseFacilitiesMember" abstract="true" name="LeaseFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_DisclosureOfLeaseLiabilitiesLineItems" abstract="true" name="DisclosureOfLeaseLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abvx_LeaseDurationPeriod" abstract="false" name="LeaseDurationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="abvx_LeaseTacitRenewalPeriod" abstract="false" name="LeaseTacitRenewalPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="abvx_LeaseBreakClausePeriod" abstract="false" name="LeaseBreakClausePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="abvx_DecreaseInLeaseLiabilitiesThroughModificationOfTerm" abstract="false" name="DecreaseInLeaseLiabilitiesThroughModificationOfTerm" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_LeaseExtensionPeriod" abstract="false" name="LeaseExtensionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="abvx_LeaseLiabilityPercentageOfTotal" abstract="false" name="LeaseLiabilityPercentageOfTotal" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="abvx_ExpenseOnLeaseLiabilities" abstract="false" name="ExpenseOnLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_DepreciationExpenseLease" abstract="false" name="DepreciationExpenseLease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" abstract="false" name="ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_ProbabilityOfSuccessMeasurementInputMember" abstract="true" name="ProbabilityOfSuccessMeasurementInputMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_PeakPenetrationMeasurementInputMember" abstract="true" name="PeakPenetrationMeasurementInputMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_OtherLiabilitiesNumberOfTransactions" abstract="false" name="OtherLiabilitiesNumberOfTransactions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abvx_RoyaltyCertificatePercentageOfFutureSales" abstract="false" name="RoyaltyCertificatePercentageOfFutureSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="abvx_RoyaltyCertificateMaximumAmount" abstract="false" name="RoyaltyCertificateMaximumAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_RoyaltyCertificatesEIR" abstract="false" name="RoyaltyCertificatesEIR" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" abstract="false" name="IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_InterestExpenseOnRoyaltyCertificatesIncludingTheUnwindingOfDiscount" abstract="false" name="InterestExpenseOnRoyaltyCertificatesIncludingTheUnwindingOfDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_UnwindingOfDiscountOnRoyalties" abstract="false" name="UnwindingOfDiscountOnRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" abstract="false" name="IncreaseDecreaseInCarryingValueDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" abstract="false" name="IncreaseDecreaseInCarryingValueDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_UnobservableInputLiabilitiesDiscountRate" abstract="false" name="UnobservableInputLiabilitiesDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abvx_AmountOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" abstract="false" name="AmountOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="abvx_IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" abstract="false" name="IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" abstract="false" name="DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" abstract="false" name="DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities" abstract="false" name="IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" abstract="false" name="IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities" abstract="false" name="IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities" abstract="false" name="IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities" abstract="false" name="IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_KreosClaretFinancingTrancheABMember" abstract="true" name="KreosClaretFinancingTrancheABMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_OceaneConversionOptionMember" abstract="true" name="OceaneConversionOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_RepurchaseOfDerivativeInstruments" abstract="false" name="RepurchaseOfDerivativeInstruments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_GrossProceedsFromNonConvertibleLoansNotes" abstract="false" name="GrossProceedsFromNonConvertibleLoansNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_IssuanceOfDerivativeInstruments" abstract="false" name="IssuanceOfDerivativeInstruments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_ExerciseOfDerivativeInstruments" abstract="false" name="ExerciseOfDerivativeInstruments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_KreosClaretBondLoansMember" abstract="true" name="KreosClaretBondLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_ConvertibleLoansNotesUndiscountedCashFlows" abstract="false" name="ConvertibleLoansNotesUndiscountedCashFlows" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_ConditionalAdvancesUndiscountedCashFlows" abstract="false" name="ConditionalAdvancesUndiscountedCashFlows" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_RoyaltyCertificatesUndiscountedCashFlows" abstract="false" name="RoyaltyCertificatesUndiscountedCashFlows" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_FinancialLiabilitiesUndiscountedCashFlows" abstract="false" name="FinancialLiabilitiesUndiscountedCashFlows" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_RoyaltyCertificateExpirationPeriod" abstract="false" name="RoyaltyCertificateExpirationPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="abvx_OtherEmployeesMember" abstract="true" name="OtherEmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_ActuarialAssumptionOfExpectedRatesOfTurnover" abstract="false" name="ActuarialAssumptionOfExpectedRatesOfTurnover" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="abvx_ActuarialAssumptionOfExpectedRatesOfTurnoverAverageExitRate" abstract="false" name="ActuarialAssumptionOfExpectedRatesOfTurnoverAverageExitRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="abvx_ActuarialAssumptionOfEmployeeContributionRate" abstract="false" name="ActuarialAssumptionOfEmployeeContributionRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="abvx_OtherCurrentPayablesIncludingAdjustments" abstract="false" name="OtherCurrentPayablesIncludingAdjustments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_CurrentPayablesOnOtherTaxAndRelatedPayments" abstract="false" name="CurrentPayablesOnOtherTaxAndRelatedPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_IncomeFromResearchTaxCredit" abstract="false" name="IncomeFromResearchTaxCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_IncomeFromDepositaryServiceFees" abstract="false" name="IncomeFromDepositaryServiceFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_DisclosureOfOperatingIncomeTable" abstract="true" name="DisclosureOfOperatingIncomeTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="abvx_CIRTaxYearAxis" abstract="true" name="CIRTaxYearAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="abvx_CIRTaxYearDomain" abstract="true" name="CIRTaxYearDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_A2021TaxYearMember" abstract="true" name="A2021TaxYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_A2022TaxYearMember" abstract="true" name="A2022TaxYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_A2023TaxYearMember" abstract="true" name="A2023TaxYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_A2024TaxYearMember" abstract="true" name="A2024TaxYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_DisclosureOfOperatingIncomeLineItems" abstract="true" name="DisclosureOfOperatingIncomeLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abvx_SalesAndMarketingExpenseMember" abstract="true" name="SalesAndMarketingExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_ResearchAndDevelopmentExpensesMember" abstract="true" name="ResearchAndDevelopmentExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_SubContractingStudiesAndResearchExpenses" abstract="false" name="SubContractingStudiesAndResearchExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_IntellectualPropertyFees" abstract="false" name="IntellectualPropertyFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_GeneralAndAdministrativeExpensesMember" abstract="true" name="GeneralAndAdministrativeExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_IncreaseDecreaseInUlcerativeColitisExpenses" abstract="false" name="IncreaseDecreaseInUlcerativeColitisExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_IncreaseDecreaseInCrohnsDiseaseResearchExpenses" abstract="false" name="IncreaseDecreaseInCrohnsDiseaseResearchExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_IncreaseDecreaseInTransversalActivities" abstract="false" name="IncreaseDecreaseInTransversalActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_IncreaseDecreaseInTransversalActivitiesCombinationTherapy" abstract="false" name="IncreaseDecreaseInTransversalActivitiesCombinationTherapy" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_IncreaseDecreaseInEmployerTaxAndSocialContributions" abstract="false" name="IncreaseDecreaseInEmployerTaxAndSocialContributions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_AuditorsRemunerationForAuditRelatedFees" abstract="false" name="AuditorsRemunerationForAuditRelatedFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_DisclosureOfEmployeeWorkforceTable" abstract="true" name="DisclosureOfEmployeeWorkforceTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="abvx_DisclosureOfEmployeeWorkforceLineItems" abstract="true" name="DisclosureOfEmployeeWorkforceLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abvx_InterestExpenseOnRoyaltyCertificates" abstract="false" name="InterestExpenseOnRoyaltyCertificates" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_LossesArisingFromDerecognitionOfFinancialLiabilities" abstract="false" name="LossesArisingFromDerecognitionOfFinancialLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_TransactionCosts" abstract="false" name="TransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_GainsOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" abstract="false" name="GainsOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_UnwindingEffectOfDiscountRelatedToAdvancesMadeToCROs" abstract="false" name="UnwindingEffectOfDiscountRelatedToAdvancesMadeToCROs" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_GainsArisingFromDerecognitionOfFinancialLiabilities" abstract="false" name="GainsArisingFromDerecognitionOfFinancialLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_DisclosureOfFinancialGainLossTable" abstract="true" name="DisclosureOfFinancialGainLossTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="abvx_DisclosureOfFinancialGainLossLineItems" abstract="true" name="DisclosureOfFinancialGainLossLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abvx_ForeignExchangeGainsLossesOnTranslationOfForeignOperations" abstract="false" name="ForeignExchangeGainsLossesOnTranslationOfForeignOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_TaxEffectOfShareBasedPayment" abstract="false" name="TaxEffectOfShareBasedPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_TaxEffectOfResearchTaxCredit" abstract="false" name="TaxEffectOfResearchTaxCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_TaxEffectOfTransactionCostsRelatedToCapitalIncrease" abstract="false" name="TaxEffectOfTransactionCostsRelatedToCapitalIncrease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_TaxEffectOfChangesInDerivativeFairValueAndOtherLiabilitiesMeasuredAtFVTPL" abstract="false" name="TaxEffectOfChangesInDerivativeFairValueAndOtherLiabilitiesMeasuredAtFVTPL" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferences" abstract="false" name="TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferences" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_RetirementBenefitObligationsRelatedTemporaryDifferencesMember" abstract="true" name="RetirementBenefitObligationsRelatedTemporaryDifferencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_SubsidiesRelatedTemporaryDifferencesMember" abstract="true" name="SubsidiesRelatedTemporaryDifferencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_LeasesRelatedTemporaryDifferencesMember" abstract="true" name="LeasesRelatedTemporaryDifferencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_RoyaltyCertificatesRelatedTemporaryDifferencesMember" abstract="true" name="RoyaltyCertificatesRelatedTemporaryDifferencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_OtherFinancialLiabilitiesRelatedTemporaryDifferencesMember" abstract="true" name="OtherFinancialLiabilitiesRelatedTemporaryDifferencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_ProvisionsForAGATaxesRelatedTemporaryDifferencesMember" abstract="true" name="ProvisionsForAGATaxesRelatedTemporaryDifferencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_UnrecognizedDeferredTaxAssets" abstract="false" name="UnrecognizedDeferredTaxAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition" abstract="false" name="NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_AbivaxLLCMember" abstract="true" name="AbivaxLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_MaximumNumberOfSharesToBeIssued" abstract="false" name="MaximumNumberOfSharesToBeIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="abvx_KeyManagementPersonnelCompensationFixedCompensation" abstract="false" name="KeyManagementPersonnelCompensationFixedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_KeyManagementPersonnelCompensationVariableCompensation" abstract="false" name="KeyManagementPersonnelCompensationVariableCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_KeyManagementPersonnelCompensationInKindContributions" abstract="false" name="KeyManagementPersonnelCompensationInKindContributions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_KeyManagementPersonnelCompensationAttendanceFees" abstract="false" name="KeyManagementPersonnelCompensationAttendanceFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_KeyManagementPersonnelCompensationConsultingFees" abstract="false" name="KeyManagementPersonnelCompensationConsultingFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_BoardOfDirectorsAndChiefExecutiveOfficerMember" abstract="true" name="BoardOfDirectorsAndChiefExecutiveOfficerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_AdvisorToTheChiefExecutiveOfficerMember" abstract="true" name="AdvisorToTheChiefExecutiveOfficerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_DisclosureOfOffBalanceSheetCommitmentsTable" abstract="true" name="DisclosureOfOffBalanceSheetCommitmentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="abvx_ResearchAndCollaborationAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember" abstract="true" name="ResearchAndCollaborationAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_TheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember" abstract="true" name="TheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_EbolaConditionalAdvanceBPILanguedocRoussillonMember" abstract="true" name="EbolaConditionalAdvanceBPILanguedocRoussillonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_EbolaConditionalAdvanceBPIFranceMember" abstract="true" name="EbolaConditionalAdvanceBPIFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems" abstract="true" name="DisclosureOfOffBalanceSheetCommitmentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abvx_NumberOfExclusiveLicenses" abstract="false" name="NumberOfExclusiveLicenses" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abvx_AgreementPeriod" abstract="false" name="AgreementPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDFiling" abstract="false" name="CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDFiling" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentPhase3" abstract="false" name="CollaborationAgreementsPotentialDevelopmentMilestonePaymentPhase3" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDApproval" abstract="false" name="CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDApproval" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_NumberOfAcademicInstitutions" abstract="false" name="NumberOfAcademicInstitutions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacityIncludingInterest" abstract="false" name="OtherFinancialLiabilitiesMaximumDrawdownCapacityIncludingInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_OtherFinancialLiabilitiesAnnualPercentageOfProceedsFromSaleOfIntellectualPropertyRight" abstract="false" name="OtherFinancialLiabilitiesAnnualPercentageOfProceedsFromSaleOfIntellectualPropertyRight" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="abvx_OtherFinancialLiabilitiesAnnualRevenueFromSaleOfProductsDevelopedPeriod" abstract="false" name="OtherFinancialLiabilitiesAnnualRevenueFromSaleOfProductsDevelopedPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDevelopedPreTaxRevenueThreshold" abstract="false" name="OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDevelopedPreTaxRevenueThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDeveloped" abstract="false" name="OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDeveloped" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="abvx_OtherFinancialLiabilitiesPayableAnnualRevenueFromSaleOfProductsDeveloped" abstract="false" name="OtherFinancialLiabilitiesPayableAnnualRevenueFromSaleOfProductsDeveloped" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_OtherFinancialLiabilitiesRepaymentPeriod" abstract="false" name="OtherFinancialLiabilitiesRepaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="abvx_DisclosureOfCommitmentsReceivedTable" abstract="true" name="DisclosureOfCommitmentsReceivedTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="abvx_DisclosureOfCommitmentsReceivedLineItems" abstract="true" name="DisclosureOfCommitmentsReceivedLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abvx_NumberOfProjectsTerminated" abstract="false" name="NumberOfProjectsTerminated" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abvx_InterestRateCollarRange" abstract="false" name="InterestRateCollarRange" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="abvx_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent" abstract="false" name="SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="abvx_SensitivityAnalysisForTypesOfMarketRisk10AdverseChangeInExchangeRateImpactOnForeignExchangeGainLoss" abstract="false" name="SensitivityAnalysisForTypesOfMarketRisk10AdverseChangeInExchangeRateImpactOnForeignExchangeGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_SensitivityAnalysisForTypesOfMarketRisk10FavorableChangeInExchangeRateImpactOnForeignExchangeGainLoss" abstract="false" name="SensitivityAnalysisForTypesOfMarketRisk10FavorableChangeInExchangeRateImpactOnForeignExchangeGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_NumberOfFinancialInstitutionsToMaintainCash" abstract="false" name="NumberOfFinancialInstitutionsToMaintainCash" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abvx_BalancesWithBanksInExcessOfLegallyInsuredLimit" abstract="false" name="BalancesWithBanksInExcessOfLegallyInsuredLimit" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abvx_InvestmentsInMutualFundsAndStructuredNotes" abstract="false" name="InvestmentsInMutualFundsAndStructuredNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>abvx-20251231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:3ade1e9c-8754-4bce-84b9-83231d17b989,g:c324a16d-aca9-45c2-8b50-8666bee7377b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item"/>
  <link:roleRef roleURI="http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="simple" xlink:href="abvx-20251231.xsd#CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"/>
  <link:calculationLink xlink:role="http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_1a0a215f-d596-4199-8eab-5ee0371382c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_57894d5e-af4a-435e-9f5d-c63a717c3dfd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Goodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_1a0a215f-d596-4199-8eab-5ee0371382c9" xlink:to="loc_ifrs-full_Goodwill_57894d5e-af4a-435e-9f5d-c63a717c3dfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_58820b33-f48a-4cc1-8586-9ca7364d35ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_1a0a215f-d596-4199-8eab-5ee0371382c9" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_58820b33-f48a-4cc1-8586-9ca7364d35ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentNonfinancialAssets_1e5e8d11-1a06-45f8-8010-10ef85ed3c5e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_1a0a215f-d596-4199-8eab-5ee0371382c9" xlink:to="loc_ifrs-full_OtherNoncurrentNonfinancialAssets_1e5e8d11-1a06-45f8-8010-10ef85ed3c5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_aa7f2fe3-0cb6-4eb0-a982-e9fccfcb5313" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_1a0a215f-d596-4199-8eab-5ee0371382c9" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_aa7f2fe3-0cb6-4eb0-a982-e9fccfcb5313" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentFinancialAssets_b32df0ea-601c-4f11-9604-2039215f4b31" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_1a0a215f-d596-4199-8eab-5ee0371382c9" xlink:to="loc_ifrs-full_OtherNoncurrentFinancialAssets_b32df0ea-601c-4f11-9604-2039215f4b31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_00021c08-83c6-4884-991a-8bade7cf92ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits_4e16c246-130e-4852-a8b7-2583ec5c28ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentProvisionsForEmployeeBenefits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_00021c08-83c6-4884-991a-8bade7cf92ad" xlink:to="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits_4e16c246-130e-4852-a8b7-2583ec5c28ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherLongtermProvisions_4a12e8ea-add9-40a7-af75-340d88306fab" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherLongtermProvisions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_00021c08-83c6-4884-991a-8bade7cf92ad" xlink:to="loc_ifrs-full_OtherLongtermProvisions_4a12e8ea-add9-40a7-af75-340d88306fab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings_4952df81-badf-4f18-ac0b-d7af580b9c1f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_00021c08-83c6-4884-991a-8bade7cf92ad" xlink:to="loc_ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings_4952df81-badf-4f18-ac0b-d7af580b9c1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NonCurrentConvertibleLoansNotes_c8c07fa3-00ed-41d4-99f3-a139a1fa7dcd" xlink:href="abvx-20251231.xsd#abvx_NonCurrentConvertibleLoansNotes"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_00021c08-83c6-4884-991a-8bade7cf92ad" xlink:to="loc_abvx_NonCurrentConvertibleLoansNotes_c8c07fa3-00ed-41d4-99f3-a139a1fa7dcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_1dc8fc1d-f740-4cd9-8ac0-553325259d86" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_00021c08-83c6-4884-991a-8bade7cf92ad" xlink:to="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_1dc8fc1d-f740-4cd9-8ac0-553325259d86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NonCurrentRoyaltyCertificates_1c0053cb-7838-4e28-9b1c-ad7c92dafc8c" xlink:href="abvx-20251231.xsd#abvx_NonCurrentRoyaltyCertificates"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_00021c08-83c6-4884-991a-8bade7cf92ad" xlink:to="loc_abvx_NonCurrentRoyaltyCertificates_1c0053cb-7838-4e28-9b1c-ad7c92dafc8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentFinancialLiabilities_04318a76-5391-4279-9e5b-fec025fded92" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_00021c08-83c6-4884-991a-8bade7cf92ad" xlink:to="loc_ifrs-full_OtherNoncurrentFinancialLiabilities_04318a76-5391-4279-9e5b-fec025fded92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets_019d00b7-1d10-7c57-bb88-76523fb2cf39" xlink:href="abvx-20251231.xsd#abvx_DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_00021c08-83c6-4884-991a-8bade7cf92ad" xlink:to="loc_abvx_DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets_019d00b7-1d10-7c57-bb88-76523fb2cf39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_46a39518-2e9a-4425-9d4d-969484bff333" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremium_1f3560af-53d1-420f-b8a6-78c014d5fae7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharePremium"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_46a39518-2e9a-4425-9d4d-969484bff333" xlink:to="loc_ifrs-full_SharePremium_1f3560af-53d1-420f-b8a6-78c014d5fae7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsProfitLossForReportingPeriod_4bc6f9b9-9ab4-4f67-8689-712a6ac0f1bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarningsProfitLossForReportingPeriod"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_46a39518-2e9a-4425-9d4d-969484bff333" xlink:to="loc_ifrs-full_RetainedEarningsProfitLossForReportingPeriod_4bc6f9b9-9ab4-4f67-8689-712a6ac0f1bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod_33ac5abb-f9f1-41e3-a49e-1437ce038e09" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_46a39518-2e9a-4425-9d4d-969484bff333" xlink:to="loc_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod_33ac5abb-f9f1-41e3-a49e-1437ce038e09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslation_07adb58a-0087-4b7b-a458-f2b0865a46d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_46a39518-2e9a-4425-9d4d-969484bff333" xlink:to="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslation_07adb58a-0087-4b7b-a458-f2b0865a46d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_3ffd560a-9d49-421b-ae2a-37d7f0096644" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapital"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_46a39518-2e9a-4425-9d4d-969484bff333" xlink:to="loc_ifrs-full_IssuedCapital_3ffd560a-9d49-421b-ae2a-37d7f0096644" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_763ce727-075b-4cee-9842-eb49e9a2a8bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentPortionOfNonCurrentConvertibleLoansNotes_77a9d594-3c86-4823-a2e3-7eef94a6eb18" xlink:href="abvx-20251231.xsd#abvx_CurrentPortionOfNonCurrentConvertibleLoansNotes"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_763ce727-075b-4cee-9842-eb49e9a2a8bc" xlink:to="loc_abvx_CurrentPortionOfNonCurrentConvertibleLoansNotes_77a9d594-3c86-4823-a2e3-7eef94a6eb18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_b58f941c-a268-4e13-81f2-eab1a51a30e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_763ce727-075b-4cee-9842-eb49e9a2a8bc" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_b58f941c-a268-4e13-81f2-eab1a51a30e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentTaxAndEmployeeBenefitLiabilities_fcc6d4fa-4f99-40b4-86a7-546546d424ae" xlink:href="abvx-20251231.xsd#abvx_CurrentTaxAndEmployeeBenefitLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_763ce727-075b-4cee-9842-eb49e9a2a8bc" xlink:to="loc_abvx_CurrentTaxAndEmployeeBenefitLiabilities_fcc6d4fa-4f99-40b4-86a7-546546d424ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings_f1f0c055-c9a3-4cd7-84b2-04380131ae78" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_763ce727-075b-4cee-9842-eb49e9a2a8bc" xlink:to="loc_ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings_f1f0c055-c9a3-4cd7-84b2-04380131ae78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentFinancialLiabilities_821645ad-50b7-4228-bc57-41a7ac0f1209" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentFinancialLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_763ce727-075b-4cee-9842-eb49e9a2a8bc" xlink:to="loc_ifrs-full_OtherCurrentFinancialLiabilities_821645ad-50b7-4228-bc57-41a7ac0f1209" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_ead11161-a769-47a7-85ee-790c4266a643" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_763ce727-075b-4cee-9842-eb49e9a2a8bc" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_ead11161-a769-47a7-85ee-790c4266a643" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherShorttermProvisions_1292346d-3f21-4242-9141-2df14d53f507" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherShorttermProvisions"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_763ce727-075b-4cee-9842-eb49e9a2a8bc" xlink:to="loc_ifrs-full_OtherShorttermProvisions_1292346d-3f21-4242-9141-2df14d53f507" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities_54bb2a87-21a2-4fd8-bcda-840637844151" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_763ce727-075b-4cee-9842-eb49e9a2a8bc" xlink:to="loc_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities_54bb2a87-21a2-4fd8-bcda-840637844151" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_71b5a913-f611-4809-98b9-c7f5eeb1164b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_7a3f8828-abdb-46ad-ac96-2685aafb42c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_71b5a913-f611-4809-98b9-c7f5eeb1164b" xlink:to="loc_ifrs-full_NoncurrentLiabilities_7a3f8828-abdb-46ad-ac96-2685aafb42c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_74a3ac4e-afe3-47a2-9453-94eb53dde8f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_71b5a913-f611-4809-98b9-c7f5eeb1164b" xlink:to="loc_ifrs-full_CurrentLiabilities_74a3ac4e-afe3-47a2-9453-94eb53dde8f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_f4cde2b6-5790-4e10-b82a-7afd71ac9996" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_71b5a913-f611-4809-98b9-c7f5eeb1164b" xlink:to="loc_ifrs-full_Equity_f4cde2b6-5790-4e10-b82a-7afd71ac9996" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_352f43bd-d368-4df5-9612-69f6d327f584" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_4fd187ec-fb39-4235-b14a-d9c67ec122e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_352f43bd-d368-4df5-9612-69f6d327f584" xlink:to="loc_ifrs-full_CurrentAssets_4fd187ec-fb39-4235-b14a-d9c67ec122e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_b178c482-65e2-4b58-bd57-73e1b2a1e703" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_352f43bd-d368-4df5-9612-69f6d327f584" xlink:to="loc_ifrs-full_NoncurrentAssets_b178c482-65e2-4b58-bd57-73e1b2a1e703" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_9348bf99-2be7-4f0d-8ecd-7eb45ad34443" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentFinancialAssets_c4274c35-6e12-4518-8631-03c0ba091a5e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_9348bf99-2be7-4f0d-8ecd-7eb45ad34443" xlink:to="loc_ifrs-full_OtherCurrentFinancialAssets_c4274c35-6e12-4518-8631-03c0ba091a5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_db99b2a9-2d9d-48c8-8198-1c006be0fba8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_9348bf99-2be7-4f0d-8ecd-7eb45ad34443" xlink:to="loc_ifrs-full_CashAndCashEquivalents_db99b2a9-2d9d-48c8-8198-1c006be0fba8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentReceivablesAndCurrentPrepaidExpenses_f2cc6777-ac6f-435f-86ac-26dad7ea02d8" xlink:href="abvx-20251231.xsd#abvx_CurrentReceivablesAndCurrentPrepaidExpenses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_9348bf99-2be7-4f0d-8ecd-7eb45ad34443" xlink:to="loc_abvx_CurrentReceivablesAndCurrentPrepaidExpenses_f2cc6777-ac6f-435f-86ac-26dad7ea02d8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS" xlink:type="simple" xlink:href="abvx-20251231.xsd#CONSOLIDATEDSTATEMENTSOFINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_298f364c-76a8-4225-8d28-4abdc7d2568d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_2a13a178-98ef-4cc7-a5bb-e76c219a7b60" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_298f364c-76a8-4225-8d28-4abdc7d2568d" xlink:to="loc_ifrs-full_FinanceCosts_2a13a178-98ef-4cc7-a5bb-e76c219a7b60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_82aa1da2-6f4f-4b9d-a30c-20e8e495e70f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_298f364c-76a8-4225-8d28-4abdc7d2568d" xlink:to="loc_ifrs-full_FinanceIncome_82aa1da2-6f4f-4b9d-a30c-20e8e495e70f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_ba59e3ad-9b23-43c8-9168-9df69251caf3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAndOperatingIncome_950c636b-9974-445b-b761-afeceaad89b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueAndOperatingIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_ba59e3ad-9b23-43c8-9168-9df69251caf3" xlink:to="loc_ifrs-full_RevenueAndOperatingIncome_950c636b-9974-445b-b761-afeceaad89b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_ca602634-0162-40c8-a2a3-1fde6980a9a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OperatingExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_ba59e3ad-9b23-43c8-9168-9df69251caf3" xlink:to="loc_ifrs-full_OperatingExpense_ca602634-0162-40c8-a2a3-1fde6980a9a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAndOperatingIncome_3fba9221-daf6-44d9-8805-16635b516f45" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueAndOperatingIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIncome_6fcedd10-4c97-4114-b60e-980b3eb7150d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_RevenueAndOperatingIncome_3fba9221-daf6-44d9-8805-16635b516f45" xlink:to="loc_ifrs-full_OtherIncome_6fcedd10-4c97-4114-b60e-980b3eb7150d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_4bb21527-45f0-4ab9-9276-c0da5d842993" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OperatingExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_205081c9-c7f8-428a-8c4d-fbfc6724c885" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_4bb21527-45f0-4ab9-9276-c0da5d842993" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_205081c9-c7f8-428a-8c4d-fbfc6724c885" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_af88be1e-29ad-48de-b04a-55417daa5cdf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_4bb21527-45f0-4ab9-9276-c0da5d842993" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_af88be1e-29ad-48de-b04a-55417daa5cdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SalesAndMarketingExpense_3fc346ea-2768-4b9e-8da9-8fa53891af6f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_4bb21527-45f0-4ab9-9276-c0da5d842993" xlink:to="loc_ifrs-full_SalesAndMarketingExpense_3fc346ea-2768-4b9e-8da9-8fa53891af6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_bb1058e5-f5c9-42b2-900d-9601f2dd933f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_f02bf33e-90e3-490b-9107-f39ee8d849bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_bb1058e5-f5c9-42b2-900d-9601f2dd933f" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_f02bf33e-90e3-490b-9107-f39ee8d849bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_83579e2e-8c49-456e-aef8-e891023e8333" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_bb1058e5-f5c9-42b2-900d-9601f2dd933f" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_83579e2e-8c49-456e-aef8-e891023e8333" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_bd2c3342-ee9a-4078-8eab-4d0f514e7bba" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_9fb9e3db-4021-4a85-bc49-73a2e9069c04" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_bd2c3342-ee9a-4078-8eab-4d0f514e7bba" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_9fb9e3db-4021-4a85-bc49-73a2e9069c04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_3dc39d37-c2d4-4ddf-8bcd-37ff1a7d7b87" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_bd2c3342-ee9a-4078-8eab-4d0f514e7bba" xlink:to="loc_ifrs-full_FinanceIncomeCost_3dc39d37-c2d4-4ddf-8bcd-37ff1a7d7b87" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="abvx-20251231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_0e5f92ce-1721-47cc-873f-db547a9cdf1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_8bf03ffa-375c-4090-9045-00953cce8f94" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_0e5f92ce-1721-47cc-873f-db547a9cdf1d" xlink:to="loc_ifrs-full_ProfitLoss_8bf03ffa-375c-4090-9045-00953cce8f94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_1130630a-e0df-4adb-87a5-fb331ea97713" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_0e5f92ce-1721-47cc-873f-db547a9cdf1d" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_1130630a-e0df-4adb-87a5-fb331ea97713" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_53536679-d2c3-4c7b-9947-daea037ecb0d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_094c8b79-2f19-4044-aca3-4fefab720724" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_53536679-d2c3-4c7b-9947-daea037ecb0d" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_094c8b79-2f19-4044-aca3-4fefab720724" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_3772683c-85d2-451f-b066-3b71549305c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_33d49f7d-8743-4902-aac9-07263b01ffe0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncome_3772683c-85d2-451f-b066-3b71549305c2" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_33d49f7d-8743-4902-aac9-07263b01ffe0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_0652ce91-b947-4031-a4cb-9715e87b1a41" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncome_3772683c-85d2-451f-b066-3b71549305c2" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_0652ce91-b947-4031-a4cb-9715e87b1a41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_3a07c76d-8c96-48fe-a0f6-17e2b5c78e7f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_cf9b53f1-2882-4782-a9e5-3661e40e4781" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_3a07c76d-8c96-48fe-a0f6-17e2b5c78e7f" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_cf9b53f1-2882-4782-a9e5-3661e40e4781" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="abvx-20251231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_b0f93242-7bba-40a9-90b5-3e263235b3b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_0c26cefd-4a94-464d-a264-d016968c2632" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_b0f93242-7bba-40a9-90b5-3e263235b3b1" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_0c26cefd-4a94-464d-a264-d016968c2632" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PaymentsForProceedsFromShareIssueRelatedCostsCredit_573e9a75-1565-4c6c-9db2-99784f472099" xlink:href="abvx-20251231.xsd#abvx_PaymentsForProceedsFromShareIssueRelatedCostsCredit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_b0f93242-7bba-40a9-90b5-3e263235b3b1" xlink:to="loc_abvx_PaymentsForProceedsFromShareIssueRelatedCostsCredit_573e9a75-1565-4c6c-9db2-99784f472099" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NetProceedsFromNonConvertibleLoansNotes_886c6497-cf9a-48da-bf9a-5b18900bc741" xlink:href="abvx-20251231.xsd#abvx_NetProceedsFromNonConvertibleLoansNotes"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_b0f93242-7bba-40a9-90b5-3e263235b3b1" xlink:to="loc_abvx_NetProceedsFromNonConvertibleLoansNotes_886c6497-cf9a-48da-bf9a-5b18900bc741" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepaymentsOfNonConvertibleLoansNotes_2258a27f-798b-469a-a001-96604162ea1c" xlink:href="abvx-20251231.xsd#abvx_RepaymentsOfNonConvertibleLoansNotes"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_b0f93242-7bba-40a9-90b5-3e263235b3b1" xlink:to="loc_abvx_RepaymentsOfNonConvertibleLoansNotes_2258a27f-798b-469a-a001-96604162ea1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NetProceedsFromConvertibleLoanNotes_686445c6-566c-4997-86e9-3214887fd6b2" xlink:href="abvx-20251231.xsd#abvx_NetProceedsFromConvertibleLoanNotes"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_b0f93242-7bba-40a9-90b5-3e263235b3b1" xlink:to="loc_abvx_NetProceedsFromConvertibleLoanNotes_686445c6-566c-4997-86e9-3214887fd6b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepaymentsOfConvertibleLoansNotes_435f5410-52cc-4ed2-9272-4ac9831c5d1d" xlink:href="abvx-20251231.xsd#abvx_RepaymentsOfConvertibleLoansNotes"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_b0f93242-7bba-40a9-90b5-3e263235b3b1" xlink:to="loc_abvx_RepaymentsOfConvertibleLoansNotes_435f5410-52cc-4ed2-9272-4ac9831c5d1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepaymentsOfPGE_55890adc-7652-46bf-a3a4-20a64c0d0617" xlink:href="abvx-20251231.xsd#abvx_RepaymentsOfPGE"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_b0f93242-7bba-40a9-90b5-3e263235b3b1" xlink:to="loc_abvx_RepaymentsOfPGE_55890adc-7652-46bf-a3a4-20a64c0d0617" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepaymentsOfConditionalAdvances_b36b4037-f0c5-490f-93c7-78a7fa5af1c4" xlink:href="abvx-20251231.xsd#abvx_RepaymentsOfConditionalAdvances"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_b0f93242-7bba-40a9-90b5-3e263235b3b1" xlink:to="loc_abvx_RepaymentsOfConditionalAdvances_b36b4037-f0c5-490f-93c7-78a7fa5af1c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_6921ce70-8e0e-4e76-9518-fbabbd49bf1e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_b0f93242-7bba-40a9-90b5-3e263235b3b1" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_6921ce70-8e0e-4e76-9518-fbabbd49bf1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares_a4cefc94-7b6c-4602-9ccb-373c6fb6c5e5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_b0f93242-7bba-40a9-90b5-3e263235b3b1" xlink:to="loc_ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares_a4cefc94-7b6c-4602-9ccb-373c6fb6c5e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsFinancingActivities_5f6fd735-350a-48e0-8de7-cc392753c682" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_b0f93242-7bba-40a9-90b5-3e263235b3b1" xlink:to="loc_ifrs-full_InterestPaidClassifiedAsFinancingActivities_5f6fd735-350a-48e0-8de7-cc392753c682" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants_f360d2b7-1695-406a-a111-34f41339f8a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_b0f93242-7bba-40a9-90b5-3e263235b3b1" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfWarrants_f360d2b7-1695-406a-a111-34f41339f8a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_70c6451b-94fe-41eb-8158-e89639d31818" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_b0f93242-7bba-40a9-90b5-3e263235b3b1" xlink:to="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_70c6451b-94fe-41eb-8158-e89639d31818" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_54a9eb16-6f59-4fa4-81f9-5f2625fd7b7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_01841c7c-6713-4bf7-93ab-0f17f0ab4077" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_54a9eb16-6f59-4fa4-81f9-5f2625fd7b7b" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_01841c7c-6713-4bf7-93ab-0f17f0ab4077" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_64d1e546-c62d-4699-9f5a-c7bc96501a24" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_54a9eb16-6f59-4fa4-81f9-5f2625fd7b7b" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_64d1e546-c62d-4699-9f5a-c7bc96501a24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_e3b305c5-6650-44a9-9dda-cb7deb20d673" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_54a9eb16-6f59-4fa4-81f9-5f2625fd7b7b" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_e3b305c5-6650-44a9-9dda-cb7deb20d673" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_037a08fa-4d57-40c4-b3e9-aabfe249bac3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_54a9eb16-6f59-4fa4-81f9-5f2625fd7b7b" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_037a08fa-4d57-40c4-b3e9-aabfe249bac3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RevaluationOfCashEquivalentsMeasuredAtFairValue_019c4343-1b4e-7421-bb9e-e6380e9946fa" xlink:href="abvx-20251231.xsd#abvx_RevaluationOfCashEquivalentsMeasuredAtFairValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_54a9eb16-6f59-4fa4-81f9-5f2625fd7b7b" xlink:to="loc_abvx_RevaluationOfCashEquivalentsMeasuredAtFairValue_019c4343-1b4e-7421-bb9e-e6380e9946fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_9c8095a1-71fc-4ae4-a149-7bc04277d5c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_de0148fb-3649-4ab0-af37-58511e48dafb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_9c8095a1-71fc-4ae4-a149-7bc04277d5c4" xlink:to="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_de0148fb-3649-4ab0-af37-58511e48dafb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_b0ce4ec9-94dc-4d52-b00c-579c69c94702" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_9c8095a1-71fc-4ae4-a149-7bc04277d5c4" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_b0ce4ec9-94dc-4d52-b00c-579c69c94702" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations_5aff8165-3880-41fb-9558-1c4c7c4a943b" xlink:href="abvx-20251231.xsd#abvx_PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_9c8095a1-71fc-4ae4-a149-7bc04277d5c4" xlink:to="loc_abvx_PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations_5aff8165-3880-41fb-9558-1c4c7c4a943b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CashPaymentsForDeposits_943d4f5c-d0dd-47a8-a000-bc1651d31e1d" xlink:href="abvx-20251231.xsd#abvx_CashPaymentsForDeposits"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_9c8095a1-71fc-4ae4-a149-7bc04277d5c4" xlink:to="loc_abvx_CashPaymentsForDeposits_943d4f5c-d0dd-47a8-a000-bc1651d31e1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ProceedsFromReimbursementsOfDeposits_a7541bf9-2732-4df4-9813-a7ae08c35747" xlink:href="abvx-20251231.xsd#abvx_ProceedsFromReimbursementsOfDeposits"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_9c8095a1-71fc-4ae4-a149-7bc04277d5c4" xlink:to="loc_abvx_ProceedsFromReimbursementsOfDeposits_a7541bf9-2732-4df4-9813-a7ae08c35747" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsInvestingActivities_019cc35e-6e25-7932-8a52-49882ea978ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestReceivedClassifiedAsInvestingActivities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_9c8095a1-71fc-4ae4-a149-7bc04277d5c4" xlink:to="loc_ifrs-full_InterestReceivedClassifiedAsInvestingActivities_019cc35e-6e25-7932-8a52-49882ea978ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_9803d7f0-e121-4f8a-992c-63f8b6b12c00" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_4f265301-8ad6-4738-84c7-55b30a03993d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_9803d7f0-e121-4f8a-992c-63f8b6b12c00" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_4f265301-8ad6-4738-84c7-55b30a03993d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities_ec42f451-ac7c-4187-99b6-b2d15ba6f427" xlink:href="abvx-20251231.xsd#abvx_AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_9803d7f0-e121-4f8a-992c-63f8b6b12c00" xlink:to="loc_abvx_AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities_ec42f451-ac7c-4187-99b6-b2d15ba6f427" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities_3a4dde3c-8e81-4e04-bc2e-fe5bbd34f399" xlink:href="abvx-20251231.xsd#abvx_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_9803d7f0-e121-4f8a-992c-63f8b6b12c00" xlink:to="loc_abvx_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities_3a4dde3c-8e81-4e04-bc2e-fe5bbd34f399" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_f314464e-49d1-4489-959e-8d8a3b3811b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_9803d7f0-e121-4f8a-992c-63f8b6b12c00" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_f314464e-49d1-4489-959e-8d8a3b3811b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_4d378074-3945-48ea-bcb1-1cf5ea721355" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_2a226ba9-cb0e-4598-8697-a1e3ef22b062" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_4d378074-3945-48ea-bcb1-1cf5ea721355" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_2a226ba9-cb0e-4598-8697-a1e3ef22b062" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_ef4ddd86-83e6-42f1-ab34-ef6ee3a4b7bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_4d378074-3945-48ea-bcb1-1cf5ea721355" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_ef4ddd86-83e6-42f1-ab34-ef6ee3a4b7bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_019c4337-ce39-7c2a-a1b0-85bac35660fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_4d378074-3945-48ea-bcb1-1cf5ea721355" xlink:to="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_019c4337-ce39-7c2a-a1b0-85bac35660fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_804705af-6a32-4e1b-bf4e-20394b01eeef" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_0105beeb-09c8-4964-86fa-fa8faba1127b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_804705af-6a32-4e1b-bf4e-20394b01eeef" xlink:to="loc_ifrs-full_ProfitLoss_0105beeb-09c8-4964-86fa-fa8faba1127b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_99a0f1c0-c15e-4a58-b8c0-28e5a488e9c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_804705af-6a32-4e1b-bf4e-20394b01eeef" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_99a0f1c0-c15e-4a58-b8c0-28e5a488e9c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_9d073ba4-23e9-41a4-b804-9a81d1fa867d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_804705af-6a32-4e1b-bf4e-20394b01eeef" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_9d073ba4-23e9-41a4-b804-9a81d1fa867d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_b43cd687-56e1-447b-b1b6-9355ea991dc2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_804705af-6a32-4e1b-bf4e-20394b01eeef" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_b43cd687-56e1-447b-b1b6-9355ea991dc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AdjustmentsForNetGainOnSaleOfTreasuryShares_64964408-7f92-4daf-a836-a7067c3ec127" xlink:href="abvx-20251231.xsd#abvx_AdjustmentsForNetGainOnSaleOfTreasuryShares"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_804705af-6a32-4e1b-bf4e-20394b01eeef" xlink:to="loc_abvx_AdjustmentsForNetGainOnSaleOfTreasuryShares_64964408-7f92-4daf-a836-a7067c3ec127" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AdjustmentsForOtherFinanceCosts_cd32ac61-3545-496c-92b2-b25b42fb4e9e" xlink:href="abvx-20251231.xsd#abvx_AdjustmentsForOtherFinanceCosts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_804705af-6a32-4e1b-bf4e-20394b01eeef" xlink:to="loc_abvx_AdjustmentsForOtherFinanceCosts_cd32ac61-3545-496c-92b2-b25b42fb4e9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AdjustmentsForOtherFinanceIncome_d1b9faf8-870d-498d-9ec8-16205b3d7f92" xlink:href="abvx-20251231.xsd#abvx_AdjustmentsForOtherFinanceIncome"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_804705af-6a32-4e1b-bf4e-20394b01eeef" xlink:to="loc_abvx_AdjustmentsForOtherFinanceIncome_d1b9faf8-870d-498d-9ec8-16205b3d7f92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances_15ddbd18-ffd7-4ba4-a715-62b64057deb7" xlink:href="abvx-20251231.xsd#abvx_AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_804705af-6a32-4e1b-bf4e-20394b01eeef" xlink:to="loc_abvx_AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances_15ddbd18-ffd7-4ba4-a715-62b64057deb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFairValueGainsLosses_c44339ba-a64d-4c74-984b-4b2190345978" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForFairValueGainsLosses"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_804705af-6a32-4e1b-bf4e-20394b01eeef" xlink:to="loc_ifrs-full_AdjustmentsForFairValueGainsLosses_c44339ba-a64d-4c74-984b-4b2190345978" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AdjustmentsForForgivenessOfConditionalAdvances_55f83264-8d3a-45cb-969b-1e71ad47452e" xlink:href="abvx-20251231.xsd#abvx_AdjustmentsForForgivenessOfConditionalAdvances"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_804705af-6a32-4e1b-bf4e-20394b01eeef" xlink:to="loc_abvx_AdjustmentsForForgivenessOfConditionalAdvances_55f83264-8d3a-45cb-969b-1e71ad47452e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForProvisions_dbd3b86b-d6a1-4abf-aaaf-6cffcbccfc49" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForProvisions"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_804705af-6a32-4e1b-bf4e-20394b01eeef" xlink:to="loc_ifrs-full_AdjustmentsForProvisions_dbd3b86b-d6a1-4abf-aaaf-6cffcbccfc49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncomeTaxExpense_019c4335-e812-7fbe-9733-e0607c762160" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncomeTaxExpense"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_804705af-6a32-4e1b-bf4e-20394b01eeef" xlink:to="loc_ifrs-full_AdjustmentsForIncomeTaxExpense_019c4335-e812-7fbe-9733-e0607c762160" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAdjustmentsForNoncashItems_019cc302-c048-7243-b923-5fb2c7ac6bb8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherAdjustmentsForNoncashItems"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_804705af-6a32-4e1b-bf4e-20394b01eeef" xlink:to="loc_ifrs-full_OtherAdjustmentsForNoncashItems_019cc302-c048-7243-b923-5fb2c7ac6bb8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#OtherfinancialassetsDisclosureofotherfinancialassetsDetails"/>
  <link:calculationLink xlink:role="http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentFinancialAssets_e8ef0847-4bd1-4587-acbb-eddcfb35f380" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentAdvancesToCROContracts_eaa2c329-ed14-4cff-92de-c8f72425e7f2" xlink:href="abvx-20251231.xsd#abvx_CurrentAdvancesToCROContracts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentFinancialAssets_e8ef0847-4bd1-4587-acbb-eddcfb35f380" xlink:to="loc_abvx_CurrentAdvancesToCROContracts_eaa2c329-ed14-4cff-92de-c8f72425e7f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherCurrentInvestments_4b284c70-4dde-446c-a980-12c3b09934de" xlink:href="abvx-20251231.xsd#abvx_OtherCurrentInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentFinancialAssets_e8ef0847-4bd1-4587-acbb-eddcfb35f380" xlink:to="loc_abvx_OtherCurrentInvestments_4b284c70-4dde-446c-a980-12c3b09934de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_88b5d0eb-fa63-402a-83c8-4d22623eacf4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentFinancialAssets_e8ef0847-4bd1-4587-acbb-eddcfb35f380" xlink:to="loc_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_88b5d0eb-fa63-402a-83c8-4d22623eacf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinancialAssets_59b80f17-1656-4e11-85c3-bffc8184e1ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherFinancialAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentFinancialAssets_989c186a-f410-4c9c-971f-9f5f79319677" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherFinancialAssets_59b80f17-1656-4e11-85c3-bffc8184e1ae" xlink:to="loc_ifrs-full_OtherCurrentFinancialAssets_989c186a-f410-4c9c-971f-9f5f79319677" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentFinancialAssets_777b1083-2bd1-4772-a1a5-04583ea9555a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherFinancialAssets_59b80f17-1656-4e11-85c3-bffc8184e1ae" xlink:to="loc_ifrs-full_OtherNoncurrentFinancialAssets_777b1083-2bd1-4772-a1a5-04583ea9555a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentFinancialAssets_3be988e9-db9d-40e8-904d-4b4bf452f134" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NonCurrentAdvancesToCROContractsUndiscountedAmount_987d8699-ca41-4908-ab8f-ae144c6944bd" xlink:href="abvx-20251231.xsd#abvx_NonCurrentAdvancesToCROContractsUndiscountedAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNoncurrentFinancialAssets_3be988e9-db9d-40e8-904d-4b4bf452f134" xlink:to="loc_abvx_NonCurrentAdvancesToCROContractsUndiscountedAmount_987d8699-ca41-4908-ab8f-ae144c6944bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermDeposits_75d7c02b-066e-424d-b40b-71c2a4be5286" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LongtermDeposits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNoncurrentFinancialAssets_3be988e9-db9d-40e8-904d-4b4bf452f134" xlink:to="loc_ifrs-full_LongtermDeposits_75d7c02b-066e-424d-b40b-71c2a4be5286" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherNonCurrentMiscellaneousFinancialAssets_0a8b8102-389d-4b47-b151-f7b4abc86731" xlink:href="abvx-20251231.xsd#abvx_OtherNonCurrentMiscellaneousFinancialAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNoncurrentFinancialAssets_3be988e9-db9d-40e8-904d-4b4bf452f134" xlink:to="loc_abvx_OtherNonCurrentMiscellaneousFinancialAssets_0a8b8102-389d-4b47-b151-f7b4abc86731" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails"/>
  <link:calculationLink xlink:role="http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentNonfinancialAssets_5231efb6-f7fb-465c-84e6-83a9370023ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NonCurrentPrepaidExpenses_c8d63c1e-eaf2-41fa-a452-2da8394cabc3" xlink:href="abvx-20251231.xsd#abvx_NonCurrentPrepaidExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNoncurrentNonfinancialAssets_5231efb6-f7fb-465c-84e6-83a9370023ed" xlink:to="loc_abvx_NonCurrentPrepaidExpenses_c8d63c1e-eaf2-41fa-a452-2da8394cabc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentReceivablesAndCurrentPrepaidExpenses_a5a1d729-d55f-443e-aa6d-36bc7cb207bd" xlink:href="abvx-20251231.xsd#abvx_CurrentReceivablesAndCurrentPrepaidExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentResearchTaxCreditReceivables_9414f96f-f65f-4ccc-8593-601aeeaf634c" xlink:href="abvx-20251231.xsd#abvx_CurrentResearchTaxCreditReceivables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_abvx_CurrentReceivablesAndCurrentPrepaidExpenses_a5a1d729-d55f-443e-aa6d-36bc7cb207bd" xlink:to="loc_abvx_CurrentResearchTaxCreditReceivables_9414f96f-f65f-4ccc-8593-601aeeaf634c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentValueAddedTaxReceivables_535ef682-c986-4511-b9a2-ad408ff70adb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentValueAddedTaxReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_abvx_CurrentReceivablesAndCurrentPrepaidExpenses_a5a1d729-d55f-443e-aa6d-36bc7cb207bd" xlink:to="loc_ifrs-full_CurrentValueAddedTaxReceivables_535ef682-c986-4511-b9a2-ad408ff70adb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_c19ca7d3-9740-47c7-9b3e-68441679a48b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_abvx_CurrentReceivablesAndCurrentPrepaidExpenses_a5a1d729-d55f-443e-aa6d-36bc7cb207bd" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_c19ca7d3-9740-47c7-9b3e-68441679a48b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentReceivablesForEmployeeBenefits_169f0826-2716-48c8-a0f8-360cc1fed1c8" xlink:href="abvx-20251231.xsd#abvx_CurrentReceivablesForEmployeeBenefits"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_abvx_CurrentReceivablesAndCurrentPrepaidExpenses_a5a1d729-d55f-443e-aa6d-36bc7cb207bd" xlink:to="loc_abvx_CurrentReceivablesForEmployeeBenefits_169f0826-2716-48c8-a0f8-360cc1fed1c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentReceivablesFromCreditNotes_019cc31b-8131-795b-be9b-754101dddba1" xlink:href="abvx-20251231.xsd#abvx_CurrentReceivablesFromCreditNotes"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_abvx_CurrentReceivablesAndCurrentPrepaidExpenses_a5a1d729-d55f-443e-aa6d-36bc7cb207bd" xlink:to="loc_abvx_CurrentReceivablesFromCreditNotes_019cc31b-8131-795b-be9b-754101dddba1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAssets_97ba5e63-5d76-4e06-bcd8-306c6d2103ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentReceivablesAndCurrentPrepaidExpenses_fbaae523-f4ba-4865-a01b-57b75575a8ec" xlink:href="abvx-20251231.xsd#abvx_CurrentReceivablesAndCurrentPrepaidExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherAssets_97ba5e63-5d76-4e06-bcd8-306c6d2103ce" xlink:to="loc_abvx_CurrentReceivablesAndCurrentPrepaidExpenses_fbaae523-f4ba-4865-a01b-57b75575a8ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentNonfinancialAssets_3240fe0d-5b83-4b90-bfa4-f2dc54dc691d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherAssets_97ba5e63-5d76-4e06-bcd8-306c6d2103ce" xlink:to="loc_ifrs-full_OtherNoncurrentNonfinancialAssets_3240fe0d-5b83-4b90-bfa4-f2dc54dc691d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/CashandcashequivalentsDisclosureofcompositionofcashandcashequivalentsDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#CashandcashequivalentsDisclosureofcompositionofcashandcashequivalentsDetails"/>
  <link:calculationLink xlink:role="http://www.abivax.com/role/CashandcashequivalentsDisclosureofcompositionofcashandcashequivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_c62e8d5e-d01d-4aea-a143-29b24f2dd60f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashEquivalents_ebc80dc5-986c-4207-b3ce-a8772eaf9e4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashAndCashEquivalents_c62e8d5e-d01d-4aea-a143-29b24f2dd60f" xlink:to="loc_ifrs-full_CashEquivalents_ebc80dc5-986c-4207-b3ce-a8772eaf9e4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Cash_6ffb8f41-b19d-4b5a-9064-cde9a9eebff4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Cash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashAndCashEquivalents_c62e8d5e-d01d-4aea-a143-29b24f2dd60f" xlink:to="loc_ifrs-full_Cash_6ffb8f41-b19d-4b5a-9064-cde9a9eebff4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails"/>
  <link:calculationLink xlink:role="http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_217e268d-c612-464e-a1b5-487a212fc75f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_22ed356b-6090-479f-9ab1-37b48860549b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_217e268d-c612-464e-a1b5-487a212fc75f" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_22ed356b-6090-479f-9ab1-37b48860549b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes_d7909269-52f6-4606-9fae-ec996ca03849" xlink:href="abvx-20251231.xsd#abvx_ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_217e268d-c612-464e-a1b5-487a212fc75f" xlink:to="loc_abvx_ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes_d7909269-52f6-4606-9fae-ec996ca03849" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities_65f725bc-ae89-4140-9b44-6f6e9c88b6c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotes_71dee305-d8bd-4cbf-981f-03c8a182d15f" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotes"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialLiabilities_65f725bc-ae89-4140-9b44-6f6e9c88b6c6" xlink:to="loc_abvx_ConvertibleLoansNotes_71dee305-d8bd-4cbf-981f-03c8a182d15f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_66a26922-632f-4d45-bf1d-9d9003eef906" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Borrowings"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialLiabilities_65f725bc-ae89-4140-9b44-6f6e9c88b6c6" xlink:to="loc_ifrs-full_Borrowings_66a26922-632f-4d45-bf1d-9d9003eef906" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConditionalAdvances_8320ba3c-023f-4f7e-99b8-283be10becdb" xlink:href="abvx-20251231.xsd#abvx_ConditionalAdvances"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialLiabilities_65f725bc-ae89-4140-9b44-6f6e9c88b6c6" xlink:to="loc_abvx_ConditionalAdvances_8320ba3c-023f-4f7e-99b8-283be10becdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NonCurrentRoyaltyCertificates_3bc51300-6c97-40ff-9003-4c471c146a41" xlink:href="abvx-20251231.xsd#abvx_NonCurrentRoyaltyCertificates"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialLiabilities_65f725bc-ae89-4140-9b44-6f6e9c88b6c6" xlink:to="loc_abvx_NonCurrentRoyaltyCertificates_3bc51300-6c97-40ff-9003-4c471c146a41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_5c5a4425-6904-4dea-8b49-0f89d8c17e20" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialLiabilities_65f725bc-ae89-4140-9b44-6f6e9c88b6c6" xlink:to="loc_ifrs-full_LeaseLiabilities_5c5a4425-6904-4dea-8b49-0f89d8c17e20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities_64820b68-84be-45a0-aaf2-2b640b42f504" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialLiabilities_65f725bc-ae89-4140-9b44-6f6e9c88b6c6" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilities_64820b68-84be-45a0-aaf2-2b640b42f504" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialLiabilitiesUndiscountedCashFlows_86541526-d85a-482a-8fec-5187611ec3f9" xlink:href="abvx-20251231.xsd#abvx_FinancialLiabilitiesUndiscountedCashFlows"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotesUndiscountedCashFlows_ba5588a4-8a85-4616-8fc2-4d233c83fc88" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotesUndiscountedCashFlows"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_abvx_FinancialLiabilitiesUndiscountedCashFlows_86541526-d85a-482a-8fec-5187611ec3f9" xlink:to="loc_abvx_ConvertibleLoansNotesUndiscountedCashFlows_ba5588a4-8a85-4616-8fc2-4d233c83fc88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows_f2f59a93-250f-4b95-a51c-a62a91384c30" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BankBorrowingsUndiscountedCashFlows"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_abvx_FinancialLiabilitiesUndiscountedCashFlows_86541526-d85a-482a-8fec-5187611ec3f9" xlink:to="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows_f2f59a93-250f-4b95-a51c-a62a91384c30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLeaseLiabilities_9868e899-cf88-48b0-8486-729ad6fe5e20" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_abvx_FinancialLiabilitiesUndiscountedCashFlows_86541526-d85a-482a-8fec-5187611ec3f9" xlink:to="loc_ifrs-full_GrossLeaseLiabilities_9868e899-cf88-48b0-8486-729ad6fe5e20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificatesUndiscountedCashFlows_44c9bf7b-706c-4844-bfed-b5c448cdb728" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificatesUndiscountedCashFlows"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_abvx_FinancialLiabilitiesUndiscountedCashFlows_86541526-d85a-482a-8fec-5187611ec3f9" xlink:to="loc_abvx_RoyaltyCertificatesUndiscountedCashFlows_44c9bf7b-706c-4844-bfed-b5c448cdb728" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows_e0d2df14-788b-42bb-8cdc-055bc9585b4c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_abvx_FinancialLiabilitiesUndiscountedCashFlows_86541526-d85a-482a-8fec-5187611ec3f9" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows_e0d2df14-788b-42bb-8cdc-055bc9585b4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConditionalAdvancesUndiscountedCashFlows_a3763f70-a038-499e-a852-fce3ffbfad53" xlink:href="abvx-20251231.xsd#abvx_ConditionalAdvancesUndiscountedCashFlows"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_abvx_FinancialLiabilitiesUndiscountedCashFlows_86541526-d85a-482a-8fec-5187611ec3f9" xlink:to="loc_abvx_ConditionalAdvancesUndiscountedCashFlows_a3763f70-a038-499e-a852-fce3ffbfad53" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails"/>
  <link:calculationLink xlink:role="http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_4e653ed0-10f9-40cd-8ea8-14507b136d7f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_eb3efaf0-663d-43cd-9c73-095d4c250c17" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables_4e653ed0-10f9-40cd-8ea8-14507b136d7f" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_eb3efaf0-663d-43cd-9c73-095d4c250c17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccrualsClassifiedAsCurrent_a8dc1a74-a095-49e3-b000-acbd38835a90" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccrualsClassifiedAsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables_4e653ed0-10f9-40cd-8ea8-14507b136d7f" xlink:to="loc_ifrs-full_AccrualsClassifiedAsCurrent_a8dc1a74-a095-49e3-b000-acbd38835a90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherCurrentPayablesIncludingAdjustments_1ef06be1-9fa6-462e-898f-88b2b07d6736" xlink:href="abvx-20251231.xsd#abvx_OtherCurrentPayablesIncludingAdjustments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables_4e653ed0-10f9-40cd-8ea8-14507b136d7f" xlink:to="loc_abvx_OtherCurrentPayablesIncludingAdjustments_1ef06be1-9fa6-462e-898f-88b2b07d6736" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails"/>
  <link:calculationLink xlink:role="http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentTaxAndEmployeeBenefitLiabilities_26629b98-732a-475c-9fbf-a41cf923a73b" xlink:href="abvx-20251231.xsd#abvx_CurrentTaxAndEmployeeBenefitLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_bd4fd21b-8c3e-42d3-9f94-28fcd3c03c5a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_abvx_CurrentTaxAndEmployeeBenefitLiabilities_26629b98-732a-475c-9fbf-a41cf923a73b" xlink:to="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_bd4fd21b-8c3e-42d3-9f94-28fcd3c03c5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentPayablesOnOtherTaxAndRelatedPayments_7baeac73-ac67-46f1-8f2a-7046c8d155b7" xlink:href="abvx-20251231.xsd#abvx_CurrentPayablesOnOtherTaxAndRelatedPayments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_abvx_CurrentTaxAndEmployeeBenefitLiabilities_26629b98-732a-475c-9fbf-a41cf923a73b" xlink:to="loc_abvx_CurrentPayablesOnOtherTaxAndRelatedPayments_7baeac73-ac67-46f1-8f2a-7046c8d155b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsAccruals_61e6a02f-4587-477a-bafe-66f3daa70084" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_abvx_CurrentTaxAndEmployeeBenefitLiabilities_26629b98-732a-475c-9fbf-a41cf923a73b" xlink:to="loc_ifrs-full_ShorttermEmployeeBenefitsAccruals_61e6a02f-4587-477a-bafe-66f3daa70084" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/OtheroperatingincomeDisclosureofbreakdownofoperatingincomeDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#OtheroperatingincomeDisclosureofbreakdownofoperatingincomeDetails"/>
  <link:calculationLink xlink:role="http://www.abivax.com/role/OtheroperatingincomeDisclosureofbreakdownofoperatingincomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIncome_30b7d1a7-5ee0-4bc3-8c71-575de2a81ec8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncomeFromResearchTaxCredit_5030a1ed-68c7-4b53-ba91-472afdab850e" xlink:href="abvx-20251231.xsd#abvx_IncomeFromResearchTaxCredit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherIncome_30b7d1a7-5ee0-4bc3-8c71-575de2a81ec8" xlink:to="loc_abvx_IncomeFromResearchTaxCredit_5030a1ed-68c7-4b53-ba91-472afdab850e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromGovernmentGrants_250ddfbb-713f-4c78-a0dc-6ca626ceedbf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherIncome_30b7d1a7-5ee0-4bc3-8c71-575de2a81ec8" xlink:to="loc_ifrs-full_RevenueFromGovernmentGrants_250ddfbb-713f-4c78-a0dc-6ca626ceedbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncomeFromDepositaryServiceFees_fa8d4a0f-d2ab-43e7-930e-a69acd1ece94" xlink:href="abvx-20251231.xsd#abvx_IncomeFromDepositaryServiceFees"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherIncome_30b7d1a7-5ee0-4bc3-8c71-575de2a81ec8" xlink:to="loc_abvx_IncomeFromDepositaryServiceFees_fa8d4a0f-d2ab-43e7-930e-a69acd1ece94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_019c5755-40d9-753b-9090-c5d9565154ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherIncome_30b7d1a7-5ee0-4bc3-8c71-575de2a81ec8" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_019c5755-40d9-753b-9090-c5d9565154ba" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails"/>
  <link:calculationLink xlink:role="http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_280bcc0a-793b-4a8d-a485-d574241810e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OperatingExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SubContractingStudiesAndResearchExpenses_334f8268-a4ed-40cd-bcb0-b8077edd748d" xlink:href="abvx-20251231.xsd#abvx_SubContractingStudiesAndResearchExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_280bcc0a-793b-4a8d-a485-d574241810e6" xlink:to="loc_abvx_SubContractingStudiesAndResearchExpenses_334f8268-a4ed-40cd-bcb0-b8077edd748d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_262905c4-8d6b-40cf-a6a6-25b14dbc8adc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_280bcc0a-793b-4a8d-a485-d574241810e6" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_262905c4-8d6b-40cf-a6a6-25b14dbc8adc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfessionalFeesExpense_8898fefc-feec-4140-81ee-3e4090f1f868" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfessionalFeesExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_280bcc0a-793b-4a8d-a485-d574241810e6" xlink:to="loc_ifrs-full_ProfessionalFeesExpense_8898fefc-feec-4140-81ee-3e4090f1f868" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IntellectualPropertyFees_d7bda7e6-c37f-4274-8970-8437efe3c076" xlink:href="abvx-20251231.xsd#abvx_IntellectualPropertyFees"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_280bcc0a-793b-4a8d-a485-d574241810e6" xlink:to="loc_abvx_IntellectualPropertyFees_d7bda7e6-c37f-4274-8970-8437efe3c076" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_5d35d35d-df58-41c2-982b-c38af81d003a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_280bcc0a-793b-4a8d-a485-d574241810e6" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_5d35d35d-df58-41c2-982b-c38af81d003a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/OperatingexpensesDisclosureofprincipalauditfeesandservicesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#OperatingexpensesDisclosureofprincipalauditfeesandservicesDetails"/>
  <link:calculationLink xlink:role="http://www.abivax.com/role/OperatingexpensesDisclosureofprincipalauditfeesandservicesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemuneration_43d85c88-8c63-47d8-883b-3f85ad9c99c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AuditorsRemuneration"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemunerationForAuditServices_d20d511f-9f37-4c83-a69d-7260afcdacba" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AuditorsRemunerationForAuditServices"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_AuditorsRemuneration_43d85c88-8c63-47d8-883b-3f85ad9c99c6" xlink:to="loc_ifrs-full_AuditorsRemunerationForAuditServices_d20d511f-9f37-4c83-a69d-7260afcdacba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AuditorsRemunerationForAuditRelatedFees_f710ccd4-6bb6-44e6-b65e-75a679690521" xlink:href="abvx-20251231.xsd#abvx_AuditorsRemunerationForAuditRelatedFees"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_AuditorsRemuneration_43d85c88-8c63-47d8-883b-3f85ad9c99c6" xlink:to="loc_abvx_AuditorsRemunerationForAuditRelatedFees_f710ccd4-6bb6-44e6-b65e-75a679690521" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemunerationForTaxServices_019cfc0d-9d3e-793b-82d7-c3dba2f86310" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AuditorsRemunerationForTaxServices"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_AuditorsRemuneration_43d85c88-8c63-47d8-883b-3f85ad9c99c6" xlink:to="loc_ifrs-full_AuditorsRemunerationForTaxServices_019cfc0d-9d3e-793b-82d7-c3dba2f86310" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemunerationForOtherServices_019cfc16-8157-7b37-a197-94f95bf22b23" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AuditorsRemunerationForOtherServices"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_AuditorsRemuneration_43d85c88-8c63-47d8-883b-3f85ad9c99c6" xlink:to="loc_ifrs-full_AuditorsRemunerationForOtherServices_019cfc16-8157-7b37-a197-94f95bf22b23" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialgainlossDisclosureofnetfinancialincomelossDetails"/>
  <link:calculationLink xlink:role="http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_50f2e0ab-55c9-448a-9d78-9ce0ca7cef19" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromInterest_7a870975-ec2e-455c-ad4f-1cdced678ade" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome_50f2e0ab-55c9-448a-9d78-9ce0ca7cef19" xlink:to="loc_ifrs-full_RevenueFromInterest_7a870975-ec2e-455c-ad4f-1cdced678ade" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives_9e0c821d-d92b-4d3e-bdd2-be18e44b4f1c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsOnChangeInFairValueOfDerivatives"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome_50f2e0ab-55c9-448a-9d78-9ce0ca7cef19" xlink:to="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives_9e0c821d-d92b-4d3e-bdd2-be18e44b4f1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_GainsOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss_025f43b0-cac5-45ec-a320-095a5a08167c" xlink:href="abvx-20251231.xsd#abvx_GainsOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome_50f2e0ab-55c9-448a-9d78-9ce0ca7cef19" xlink:to="loc_abvx_GainsOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss_025f43b0-cac5-45ec-a320-095a5a08167c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_UnwindingEffectOfDiscountRelatedToAdvancesMadeToCROs_ce6b62d8-552e-4286-940e-cccc129f912f" xlink:href="abvx-20251231.xsd#abvx_UnwindingEffectOfDiscountRelatedToAdvancesMadeToCROs"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome_50f2e0ab-55c9-448a-9d78-9ce0ca7cef19" xlink:to="loc_abvx_UnwindingEffectOfDiscountRelatedToAdvancesMadeToCROs_ce6b62d8-552e-4286-940e-cccc129f912f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_GainsArisingFromRecognitionOfFinancialLiabilities_79937936-7e13-44cb-bcdb-b0de247623c5" xlink:href="abvx-20251231.xsd#abvx_GainsArisingFromRecognitionOfFinancialLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome_50f2e0ab-55c9-448a-9d78-9ce0ca7cef19" xlink:to="loc_abvx_GainsArisingFromRecognitionOfFinancialLiabilities_79937936-7e13-44cb-bcdb-b0de247623c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_GainsArisingFromDerecognitionOfFinancialLiabilities_01840243-bbe0-4df6-823b-e3f9322df3b1" xlink:href="abvx-20251231.xsd#abvx_GainsArisingFromDerecognitionOfFinancialLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome_50f2e0ab-55c9-448a-9d78-9ce0ca7cef19" xlink:to="loc_abvx_GainsArisingFromDerecognitionOfFinancialLiabilities_01840243-bbe0-4df6-823b-e3f9322df3b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ForeignExchangeGain_1c229168-c88a-4ab7-835e-2ffbd882ebbb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ForeignExchangeGain"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome_50f2e0ab-55c9-448a-9d78-9ce0ca7cef19" xlink:to="loc_ifrs-full_ForeignExchangeGain_1c229168-c88a-4ab7-835e-2ffbd882ebbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinanceIncome_9097ea52-39ca-448c-8c18-fa047af40d69" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherFinanceIncome"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome_50f2e0ab-55c9-448a-9d78-9ce0ca7cef19" xlink:to="loc_ifrs-full_OtherFinanceIncome_9097ea52-39ca-448c-8c18-fa047af40d69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_9dda8b68-48c7-4b07-804c-cc69c4e148c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBonds_62c426b2-4c04-495f-92ee-103c660f5fff" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnBonds"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_9dda8b68-48c7-4b07-804c-cc69c4e148c7" xlink:to="loc_ifrs-full_InterestExpenseOnBonds_62c426b2-4c04-495f-92ee-103c660f5fff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnDebtInstrumentsIssued_a8670cd0-f38e-4c7a-bbed-c53fad1dde5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnDebtInstrumentsIssued"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_9dda8b68-48c7-4b07-804c-cc69c4e148c7" xlink:to="loc_ifrs-full_InterestExpenseOnDebtInstrumentsIssued_a8670cd0-f38e-4c7a-bbed-c53fad1dde5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_dc545983-c2c8-492b-b171-0b5f6b315f8f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_9dda8b68-48c7-4b07-804c-cc69c4e148c7" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_dc545983-c2c8-492b-b171-0b5f6b315f8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_InterestExpenseOnRoyaltyCertificates_52aec1a9-294e-4668-b18f-e6ea055a3cd1" xlink:href="abvx-20251231.xsd#abvx_InterestExpenseOnRoyaltyCertificates"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_9dda8b68-48c7-4b07-804c-cc69c4e148c7" xlink:to="loc_abvx_InterestExpenseOnRoyaltyCertificates_52aec1a9-294e-4668-b18f-e6ea055a3cd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_67f808db-18e8-4846-8ec0-1ec7181d73b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_9dda8b68-48c7-4b07-804c-cc69c4e148c7" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_67f808db-18e8-4846-8ec0-1ec7181d73b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LossesOnChangeInFairValueOfDerivatives_842e2a4e-6cce-49c3-87a4-ff9a6bdb49fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LossesOnChangeInFairValueOfDerivatives"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_9dda8b68-48c7-4b07-804c-cc69c4e148c7" xlink:to="loc_ifrs-full_LossesOnChangeInFairValueOfDerivatives_842e2a4e-6cce-49c3-87a4-ff9a6bdb49fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss_458ac3db-aba6-4306-89f6-b750568110bb" xlink:href="abvx-20251231.xsd#abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_9dda8b68-48c7-4b07-804c-cc69c4e148c7" xlink:to="loc_abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss_458ac3db-aba6-4306-89f6-b750568110bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LossesArisingFromDerecognitionOfFinancialLiabilities_12e84bbf-ee6d-4938-a210-9f1e5397d87e" xlink:href="abvx-20251231.xsd#abvx_LossesArisingFromDerecognitionOfFinancialLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_9dda8b68-48c7-4b07-804c-cc69c4e148c7" xlink:to="loc_abvx_LossesArisingFromDerecognitionOfFinancialLiabilities_12e84bbf-ee6d-4938-a210-9f1e5397d87e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TransactionCosts_7e57464c-1df7-41bc-813b-02cb8282e03f" xlink:href="abvx-20251231.xsd#abvx_TransactionCosts"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_9dda8b68-48c7-4b07-804c-cc69c4e148c7" xlink:to="loc_abvx_TransactionCosts_7e57464c-1df7-41bc-813b-02cb8282e03f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ForeignExchangeLoss_ebc8e989-3f8c-4ba1-814c-ac73e39a7cf5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ForeignExchangeLoss"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_9dda8b68-48c7-4b07-804c-cc69c4e148c7" xlink:to="loc_ifrs-full_ForeignExchangeLoss_ebc8e989-3f8c-4ba1-814c-ac73e39a7cf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinanceCost_ee4367c2-01a8-4d68-81e8-fd1c67348037" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherFinanceCost"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_9dda8b68-48c7-4b07-804c-cc69c4e148c7" xlink:to="loc_ifrs-full_OtherFinanceCost_ee4367c2-01a8-4d68-81e8-fd1c67348037" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails"/>
  <link:calculationLink xlink:role="http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_1d489419-dc22-413d-9510-bfb721595d9e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_03126f4e-8db3-48b8-8cd5-3d2aee79da86" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_1d489419-dc22-413d-9510-bfb721595d9e" xlink:to="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_03126f4e-8db3-48b8-8cd5-3d2aee79da86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfForeignTaxRates_07913736-09c4-40a0-b3ce-59300d70d9ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TaxEffectOfForeignTaxRates"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_1d489419-dc22-413d-9510-bfb721595d9e" xlink:to="loc_ifrs-full_TaxEffectOfForeignTaxRates_07913736-09c4-40a0-b3ce-59300d70d9ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TaxEffectOfShareBasedPayment_3212c8ae-7825-48b3-9eb7-c50bf37a6e5c" xlink:href="abvx-20251231.xsd#abvx_TaxEffectOfShareBasedPayment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_1d489419-dc22-413d-9510-bfb721595d9e" xlink:to="loc_abvx_TaxEffectOfShareBasedPayment_3212c8ae-7825-48b3-9eb7-c50bf37a6e5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TaxEffectOfResearchTaxCredit_44464565-ca1b-43ae-8a31-ef9746c91dd4" xlink:href="abvx-20251231.xsd#abvx_TaxEffectOfResearchTaxCredit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_1d489419-dc22-413d-9510-bfb721595d9e" xlink:to="loc_abvx_TaxEffectOfResearchTaxCredit_44464565-ca1b-43ae-8a31-ef9746c91dd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TaxEffectOfTransactionCostsRelatedToCapitalIncrease_905b5190-9617-4abb-82eb-5e92ae0218a1" xlink:href="abvx-20251231.xsd#abvx_TaxEffectOfTransactionCostsRelatedToCapitalIncrease"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_1d489419-dc22-413d-9510-bfb721595d9e" xlink:to="loc_abvx_TaxEffectOfTransactionCostsRelatedToCapitalIncrease_905b5190-9617-4abb-82eb-5e92ae0218a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TaxEffectOfChangesInDerivativeFairValueAndOtherLiabilitiesMeasuredAtFVTPL_42810e56-723d-4b35-8627-27f587a3eb42" xlink:href="abvx-20251231.xsd#abvx_TaxEffectOfChangesInDerivativeFairValueAndOtherLiabilitiesMeasuredAtFVTPL"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_1d489419-dc22-413d-9510-bfb721595d9e" xlink:to="loc_abvx_TaxEffectOfChangesInDerivativeFairValueAndOtherLiabilitiesMeasuredAtFVTPL_42810e56-723d-4b35-8627-27f587a3eb42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferences_6bdb2aa0-962f-4573-b2cc-745c7978c2fa" xlink:href="abvx-20251231.xsd#abvx_TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferences"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_1d489419-dc22-413d-9510-bfb721595d9e" xlink:to="loc_abvx_TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferences_6bdb2aa0-962f-4573-b2cc-745c7978c2fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_76f285b6-c722-4f66-b99c-34d4296fa800" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_1d489419-dc22-413d-9510-bfb721595d9e" xlink:to="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_76f285b6-c722-4f66-b99c-34d4296fa800" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails"/>
  <link:calculationLink xlink:role="http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition_9fd35fc7-b4c3-4c76-bb96-8b6b526f21be" xlink:href="abvx-20251231.xsd#abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_UnrecognizedDeferredTaxAssets_1ef4c352-d799-49e3-95f2-adf84980343b" xlink:href="abvx-20251231.xsd#abvx_UnrecognizedDeferredTaxAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition_9fd35fc7-b4c3-4c76-bb96-8b6b526f21be" xlink:to="loc_abvx_UnrecognizedDeferredTaxAssets_1ef4c352-d799-49e3-95f2-adf84980343b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset_f22b94ef-0be8-4303-a469-8118f7597940" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition_9fd35fc7-b4c3-4c76-bb96-8b6b526f21be" xlink:to="loc_ifrs-full_DeferredTaxLiabilityAsset_f22b94ef-0be8-4303-a469-8118f7597940" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset_909a60c7-d0a6-4fbb-b17f-43799eaa5639" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilities_857da34c-8a78-4f0c-b04d-d633c2db1591" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredTaxLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_DeferredTaxLiabilityAsset_909a60c7-d0a6-4fbb-b17f-43799eaa5639" xlink:to="loc_ifrs-full_DeferredTaxLiabilities_857da34c-8a78-4f0c-b04d-d633c2db1591" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets_9a4f265d-2247-4920-8c2e-8b366ad1b1c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_DeferredTaxLiabilityAsset_909a60c7-d0a6-4fbb-b17f-43799eaa5639" xlink:to="loc_ifrs-full_DeferredTaxAssets_9a4f265d-2247-4920-8c2e-8b366ad1b1c5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails"/>
  <link:calculationLink xlink:role="http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_cea0fa84-c6f8-434a-a9fc-a5cd9d678dc0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KeyManagementPersonnelCompensationInKindContributions_bf09e938-6e4e-4e57-ba2c-ffb856f434e2" xlink:href="abvx-20251231.xsd#abvx_KeyManagementPersonnelCompensationInKindContributions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_cea0fa84-c6f8-434a-a9fc-a5cd9d678dc0" xlink:to="loc_abvx_KeyManagementPersonnelCompensationInKindContributions_bf09e938-6e4e-4e57-ba2c-ffb856f434e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KeyManagementPersonnelCompensationAttendanceFees_7d406fc2-06ad-4d3e-bbd2-15dd511db5a2" xlink:href="abvx-20251231.xsd#abvx_KeyManagementPersonnelCompensationAttendanceFees"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_cea0fa84-c6f8-434a-a9fc-a5cd9d678dc0" xlink:to="loc_abvx_KeyManagementPersonnelCompensationAttendanceFees_7d406fc2-06ad-4d3e-bbd2-15dd511db5a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_b8b53873-6f7b-4f79-add5-efba2590c613" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_cea0fa84-c6f8-434a-a9fc-a5cd9d678dc0" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_b8b53873-6f7b-4f79-add5-efba2590c613" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KeyManagementPersonnelCompensationVariableCompensation_3c866dd6-75c7-4932-954e-2d5b9cb4d4f9" xlink:href="abvx-20251231.xsd#abvx_KeyManagementPersonnelCompensationVariableCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_cea0fa84-c6f8-434a-a9fc-a5cd9d678dc0" xlink:to="loc_abvx_KeyManagementPersonnelCompensationVariableCompensation_3c866dd6-75c7-4932-954e-2d5b9cb4d4f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KeyManagementPersonnelCompensationFixedCompensation_c73f7522-f911-4559-b77f-98a6e365ff5d" xlink:href="abvx-20251231.xsd#abvx_KeyManagementPersonnelCompensationFixedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_cea0fa84-c6f8-434a-a9fc-a5cd9d678dc0" xlink:to="loc_abvx_KeyManagementPersonnelCompensationFixedCompensation_c73f7522-f911-4559-b77f-98a6e365ff5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KeyManagementPersonnelCompensationConsultingFees_15638610-7881-4fa7-8778-46672b3c2df7" xlink:href="abvx-20251231.xsd#abvx_KeyManagementPersonnelCompensationConsultingFees"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_cea0fa84-c6f8-434a-a9fc-a5cd9d678dc0" xlink:to="loc_abvx_KeyManagementPersonnelCompensationConsultingFees_15638610-7881-4fa7-8778-46672b3c2df7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_a7ecd82f-49fe-4a0a-be2f-55b37ecb35d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_cea0fa84-c6f8-434a-a9fc-a5cd9d678dc0" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_a7ecd82f-49fe-4a0a-be2f-55b37ecb35d8" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>abvx-20251231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:3ade1e9c-8754-4bce-84b9-83231d17b989,g:c324a16d-aca9-45c2-8b50-8666bee7377b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.abivax.com/role/Coverpage" xlink:type="simple" xlink:href="abvx-20251231.xsd#Coverpage"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/Coverpage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_3683f404-bf42-4fab-9fdf-9658d3fcae93" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntitiesTable_3683f404-bf42-4fab-9fdf-9658d3fcae93" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_9b371dcd-3173-44c8-96ae-407bfda4e9c7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityListingsExchangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_3683f404-bf42-4fab-9fdf-9658d3fcae93" xlink:to="loc_dei_EntityListingsExchangeAxis_9b371dcd-3173-44c8-96ae-407bfda4e9c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_9b371dcd-3173-44c8-96ae-407bfda4e9c7_default" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityListingsExchangeAxis_9b371dcd-3173-44c8-96ae-407bfda4e9c7" xlink:to="loc_dei_ExchangeDomain_9b371dcd-3173-44c8-96ae-407bfda4e9c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_d6773f1b-50d0-4911-886b-d40ecbca0f02" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityListingsExchangeAxis_9b371dcd-3173-44c8-96ae-407bfda4e9c7" xlink:to="loc_dei_ExchangeDomain_d6773f1b-50d0-4911-886b-d40ecbca0f02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AmericanDepositorySharesNASDAQGlobalMarketMember_7705cdaa-90b8-4635-9a6d-85127451d266" xlink:href="abvx-20251231.xsd#abvx_AmericanDepositorySharesNASDAQGlobalMarketMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain_d6773f1b-50d0-4911-886b-d40ecbca0f02" xlink:to="loc_abvx_AmericanDepositorySharesNASDAQGlobalMarketMember_7705cdaa-90b8-4635-9a6d-85127451d266" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OrdinarySharesNASDAQGlobalMarketMember_58096e37-81b7-4e7d-8a3a-a80fdf46b1ec" xlink:href="abvx-20251231.xsd#abvx_OrdinarySharesNASDAQGlobalMarketMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain_d6773f1b-50d0-4911-886b-d40ecbca0f02" xlink:to="loc_abvx_OrdinarySharesNASDAQGlobalMarketMember_58096e37-81b7-4e7d-8a3a-a80fdf46b1ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_3e8c3ed0-6ee8-4dfc-ba9e-c8b054c86634" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_3683f404-bf42-4fab-9fdf-9658d3fcae93" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_3e8c3ed0-6ee8-4dfc-ba9e-c8b054c86634" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_3e8c3ed0-6ee8-4dfc-ba9e-c8b054c86634_default" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_3e8c3ed0-6ee8-4dfc-ba9e-c8b054c86634" xlink:to="loc_dei_AddressTypeDomain_3e8c3ed0-6ee8-4dfc-ba9e-c8b054c86634_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_3d4c9cbc-bbd3-4033-ba6f-032913516eb3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_3e8c3ed0-6ee8-4dfc-ba9e-c8b054c86634" xlink:to="loc_dei_AddressTypeDomain_3d4c9cbc-bbd3-4033-ba6f-032913516eb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember_289dbd96-b92a-4337-9685-e37de3cf7b1a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_BusinessContactMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_3d4c9cbc-bbd3-4033-ba6f-032913516eb3" xlink:to="loc_dei_BusinessContactMember_289dbd96-b92a-4337-9685-e37de3cf7b1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9e9f4308-a9df-4a66-acb0-ec65b88fe5e4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_DocumentType_9e9f4308-a9df-4a66-acb0-ec65b88fe5e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement_951bf81b-8727-4ef0-9a45-1ea5c7a4d9a9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_DocumentRegistrationStatement_951bf81b-8727-4ef0-9a45-1ea5c7a4d9a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_42769bf8-d95e-4ae5-b044-9cf9f60ca3e5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_DocumentAnnualReport_42769bf8-d95e-4ae5-b044-9cf9f60ca3e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_8e035edb-f360-430b-ab5c-0283169c52f9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_DocumentPeriodEndDate_8e035edb-f360-430b-ab5c-0283169c52f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_fc021916-1a5e-446e-aba3-c5d1fdb05ce5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_CurrentFiscalYearEndDate_fc021916-1a5e-446e-aba3-c5d1fdb05ce5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_a067fac4-2f93-4865-9704-c4dd7141580b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_DocumentTransitionReport_a067fac4-2f93-4865-9704-c4dd7141580b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport_94fb1c4b-89fc-47cc-b597-d0b5008c9ce1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_DocumentShellCompanyReport_94fb1c4b-89fc-47cc-b597-d0b5008c9ce1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_193ff3d9-ef6e-4ed7-9d8b-35e07410a58e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityFileNumber_193ff3d9-ef6e-4ed7-9d8b-35e07410a58e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_4bf0fbf9-2aaf-49cc-867e-84da6c96e7d8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityRegistrantName_4bf0fbf9-2aaf-49cc-867e-84da6c96e7d8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b66571b1-9926-49f9-ab37-d353dc23666b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b66571b1-9926-49f9-ab37-d353dc23666b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName_3aa9dd95-0708-4b18-95b8-0dada626724d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_ContactPersonnelName_3aa9dd95-0708-4b18-95b8-0dada626724d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_1775d9c6-40e9-46a2-85d4-19f98b52c482" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityAddressAddressLine1_1775d9c6-40e9-46a2-85d4-19f98b52c482" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_eec7737a-a827-4685-bd53-2fbe1bfef887" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityAddressPostalZipCode_eec7737a-a827-4685-bd53-2fbe1bfef887" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_293d4492-a60e-4a0c-8081-ecdb6d4ef31d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityAddressCityOrTown_293d4492-a60e-4a0c-8081-ecdb6d4ef31d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_ce4ac6f5-3f1e-421a-99d8-29ea9962f6ef" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityAddressCountry_ce4ac6f5-3f1e-421a-99d8-29ea9962f6ef" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_70a392c5-9d0f-41ef-9f22-cb59f9e64d85" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_CityAreaCode_70a392c5-9d0f-41ef-9f22-cb59f9e64d85" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_03349789-3959-4262-a8cd-eb8cf6d5b998" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_LocalPhoneNumber_03349789-3959-4262-a8cd-eb8cf6d5b998" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_14b72046-ef28-4cb3-aa79-e66f9b5ef6e0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_Security12bTitle_14b72046-ef28-4cb3-aa79-e66f9b5ef6e0" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_2d42f606-70ad-493f-87f9-85a8ca69486a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_TradingSymbol_2d42f606-70ad-493f-87f9-85a8ca69486a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_f7b9b7e1-62ac-4d40-a4de-68903994ff4d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_SecurityExchangeName_f7b9b7e1-62ac-4d40-a4de-68903994ff4d" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8df04137-de20-4774-8c71-a9ac1ef47c5b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_8df04137-de20-4774-8c71-a9ac1ef47c5b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_c9c528ae-379c-418e-b180-0a842a803974" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_c9c528ae-379c-418e-b180-0a842a803974" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_df28ca70-4a7a-4592-bf32-8e0b5f9a22b4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityVoluntaryFilers_df28ca70-4a7a-4592-bf32-8e0b5f9a22b4" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_20ed84de-ec19-4ebb-b3d5-832b4ac0335d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityCurrentReportingStatus_20ed84de-ec19-4ebb-b3d5-832b4ac0335d" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_7ad61ce1-64e0-49dc-b440-eb0c2f2d4053" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityInteractiveDataCurrent_7ad61ce1-64e0-49dc-b440-eb0c2f2d4053" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_a2d496dc-c791-436d-b318-e8b9e16a7f93" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityFilerCategory_a2d496dc-c791-436d-b318-e8b9e16a7f93" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_88c612ec-0aa7-4674-8ae8-166139320459" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityEmergingGrowthCompany_88c612ec-0aa7-4674-8ae8-166139320459" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_303b20f8-9689-4277-a36b-d70ab5a50cc1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityExTransitionPeriod_303b20f8-9689-4277-a36b-d70ab5a50cc1" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_1de8821d-dd2a-479f-b6e4-03daf5b1ab15" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_IcfrAuditorAttestationFlag_1de8821d-dd2a-479f-b6e4-03daf5b1ab15" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_76008dc1-bf36-4866-aa77-5e3b982c4bc0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_76008dc1-bf36-4866-aa77-5e3b982c4bc0" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard_04b2dc15-df35-4df4-b87b-fefd28ab63c9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_DocumentAccountingStandard_04b2dc15-df35-4df4-b87b-fefd28ab63c9" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_3a4ba0d0-1ec6-439f-b462-0a0ace98522d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityShellCompany_3a4ba0d0-1ec6-439f-b462-0a0ace98522d" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3d340220-a749-486d-aec9-362c05614707" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_AmendmentFlag_3d340220-a749-486d-aec9-362c05614707" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_31e4af00-e5c6-4647-b79c-59ff991bbd6b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_DocumentFiscalYearFocus_31e4af00-e5c6-4647-b79c-59ff991bbd6b" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_e2de3586-98c9-4ef6-8a17-a152b0405207" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_e2de3586-98c9-4ef6-8a17-a152b0405207" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a615e093-6886-4a48-93b5-755e6a409a14" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityCentralIndexKey_a615e093-6886-4a48-93b5-755e6a409a14" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_NoTradingSymbolFlag_10924dd2-5460-4fb4-a2aa-5321f0a365c2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_NoTradingSymbolFlag_10924dd2-5460-4fb4-a2aa-5321f0a365c2" xlink:type="arc" order="36"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="abvx-20251231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_023018de-2d00-40f0-9b6f-3a54ea3e380e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_d00a493c-cb99-445c-837a-1e3427d39b07" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_023018de-2d00-40f0-9b6f-3a54ea3e380e" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_d00a493c-cb99-445c-837a-1e3427d39b07" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_e3ea0d07-2c87-4e1a-a8e6-0481a8872c8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_d00a493c-cb99-445c-837a-1e3427d39b07" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_e3ea0d07-2c87-4e1a-a8e6-0481a8872c8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_e3ea0d07-2c87-4e1a-a8e6-0481a8872c8b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_e3ea0d07-2c87-4e1a-a8e6-0481a8872c8b" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_e3ea0d07-2c87-4e1a-a8e6-0481a8872c8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_d67da622-71de-4eef-8b04-f38112f010fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_e3ea0d07-2c87-4e1a-a8e6-0481a8872c8b" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_d67da622-71de-4eef-8b04-f38112f010fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_cac0207c-84fc-431e-9190-61d7dc6043f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_d67da622-71de-4eef-8b04-f38112f010fa" xlink:to="loc_ifrs-full_IssuedCapitalMember_cac0207c-84fc-431e-9190-61d7dc6043f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_854d164e-1809-4d61-96ce-da34d3f037ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_d67da622-71de-4eef-8b04-f38112f010fa" xlink:to="loc_ifrs-full_SharePremiumMember_854d164e-1809-4d61-96ce-da34d3f037ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_6fe9dda0-afec-4e5a-bed8-e6c07383d136" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_d67da622-71de-4eef-8b04-f38112f010fa" xlink:to="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_6fe9dda0-afec-4e5a-bed8-e6c07383d136" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember_e069f920-2e19-425a-8156-69a5ac442516" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_d67da622-71de-4eef-8b04-f38112f010fa" xlink:to="loc_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember_e069f920-2e19-425a-8156-69a5ac442516" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_5c185867-b2a4-4f23-9448-28e5382d9b2b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_d67da622-71de-4eef-8b04-f38112f010fa" xlink:to="loc_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_5c185867-b2a4-4f23-9448-28e5382d9b2b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialAgreementAxis_96504be2-b918-46f6-8638-0b4ccc2274e6" xlink:href="abvx-20251231.xsd#abvx_FinancialAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_d00a493c-cb99-445c-837a-1e3427d39b07" xlink:to="loc_abvx_FinancialAgreementAxis_96504be2-b918-46f6-8638-0b4ccc2274e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialAgreementDomain_96504be2-b918-46f6-8638-0b4ccc2274e6_default" xlink:href="abvx-20251231.xsd#abvx_FinancialAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_abvx_FinancialAgreementAxis_96504be2-b918-46f6-8638-0b4ccc2274e6" xlink:to="loc_abvx_FinancialAgreementDomain_96504be2-b918-46f6-8638-0b4ccc2274e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialAgreementDomain_d84c840d-b88b-40cb-9dab-07cce24bc517" xlink:href="abvx-20251231.xsd#abvx_FinancialAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_abvx_FinancialAgreementAxis_96504be2-b918-46f6-8638-0b4ccc2274e6" xlink:to="loc_abvx_FinancialAgreementDomain_d84c840d-b88b-40cb-9dab-07cce24bc517" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1Member_019cc2f3-bb23-77de-a9e7-25c4c1873464" xlink:href="abvx-20251231.xsd#abvx_Kreos1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FinancialAgreementDomain_d84c840d-b88b-40cb-9dab-07cce24bc517" xlink:to="loc_abvx_Kreos1Member_019cc2f3-bb23-77de-a9e7-25c4c1873464" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingMember_019c4326-72ec-77dc-8079-3eeb481efbff" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FinancialAgreementDomain_d84c840d-b88b-40cb-9dab-07cce24bc517" xlink:to="loc_abvx_KreosClaretFinancingMember_019c4326-72ec-77dc-8079-3eeb481efbff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherEquityAgreementsMember_019cc2f3-fb30-7c47-8500-ae95d7ff5f1c" xlink:href="abvx-20251231.xsd#abvx_OtherEquityAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FinancialAgreementDomain_d84c840d-b88b-40cb-9dab-07cce24bc517" xlink:to="loc_abvx_OtherEquityAgreementsMember_019cc2f3-fb30-7c47-8500-ae95d7ff5f1c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_019c4327-ff74-7493-8d9c-ce605a7ab130" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_d00a493c-cb99-445c-837a-1e3427d39b07" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_019c4327-ff74-7493-8d9c-ce605a7ab130" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_019c4327-ff74-7493-8d9c-ce605a7ab130_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_019c4327-ff74-7493-8d9c-ce605a7ab130" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_019c4327-ff74-7493-8d9c-ce605a7ab130_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_019c4327-ff74-7050-bb5e-55a56c78fc5a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_019c4327-ff74-7493-8d9c-ce605a7ab130" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_019c4327-ff74-7050-bb5e-55a56c78fc5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosOCABSAMember_019c4328-2d72-7643-a937-e304693e0682" xlink:href="abvx-20251231.xsd#abvx_KreosOCABSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_019c4327-ff74-7050-bb5e-55a56c78fc5a" xlink:to="loc_abvx_KreosOCABSAMember_019c4328-2d72-7643-a937-e304693e0682" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_019c4328-803a-7fe7-9447-f522113dc268" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_d00a493c-cb99-445c-837a-1e3427d39b07" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_019c4328-803a-7fe7-9447-f522113dc268" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019c4328-803a-7fe7-9447-f522113dc268_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019c4328-803a-7fe7-9447-f522113dc268" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019c4328-803a-7fe7-9447-f522113dc268_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019c4328-803a-76b9-ba47-f702bd6206c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019c4328-803a-7fe7-9447-f522113dc268" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019c4328-803a-76b9-ba47-f702bd6206c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_HeightsConvertibleNotesMember_019c4328-aa77-7ebf-9397-3ebb8d0728e3" xlink:href="abvx-20251231.xsd#abvx_HeightsConvertibleNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019c4328-803a-76b9-ba47-f702bd6206c9" xlink:to="loc_abvx_HeightsConvertibleNotesMember_019c4328-aa77-7ebf-9397-3ebb8d0728e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_2efdbd89-d5f1-47d6-a514-9413333ac0fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_023018de-2d00-40f0-9b6f-3a54ea3e380e" xlink:to="loc_ifrs-full_NumberOfSharesIssued_2efdbd89-d5f1-47d6-a514-9413333ac0fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_1bd1f087-6147-4445-b545-efb07cdc3259" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_023018de-2d00-40f0-9b6f-3a54ea3e380e" xlink:to="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_1bd1f087-6147-4445-b545-efb07cdc3259" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease_997cd59e-2f4a-46ac-9480-007e5f92971d" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_1bd1f087-6147-4445-b545-efb07cdc3259" xlink:to="loc_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease_997cd59e-2f4a-46ac-9480-007e5f92971d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants_54aebae5-07c1-47a6-b495-034af3c1479f" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_1bd1f087-6147-4445-b545-efb07cdc3259" xlink:to="loc_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants_54aebae5-07c1-47a6-b495-034af3c1479f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments_019c4327-404a-7d2e-bb32-556bb67a5e60" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_1bd1f087-6147-4445-b545-efb07cdc3259" xlink:to="loc_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments_019c4327-404a-7d2e-bb32-556bb67a5e60" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfFreeSharesIssued_267fb8ab-f60b-4b3a-bc7f-7ee61a6cb399" xlink:href="abvx-20251231.xsd#abvx_NumberOfFreeSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_1bd1f087-6147-4445-b545-efb07cdc3259" xlink:to="loc_abvx_NumberOfFreeSharesIssued_267fb8ab-f60b-4b3a-bc7f-7ee61a6cb399" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_704f8c32-a4c9-465d-ac4d-a009634d34d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_d415f447-a573-4978-a1b5-9f5d1d5ad65d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_023018de-2d00-40f0-9b6f-3a54ea3e380e" xlink:to="loc_ifrs-full_Equity_d415f447-a573-4978-a1b5-9f5d1d5ad65d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInEquityAbstract_840ca2eb-2780-4e09-ab18-0a451c76abf0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ChangesInEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_023018de-2d00-40f0-9b6f-3a54ea3e380e" xlink:to="loc_ifrs-full_ChangesInEquityAbstract_840ca2eb-2780-4e09-ab18-0a451c76abf0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_dea1978d-1268-462c-a19d-666c37057732" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_840ca2eb-2780-4e09-ab18-0a451c76abf0" xlink:to="loc_ifrs-full_ProfitLoss_dea1978d-1268-462c-a19d-666c37057732" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_5950f862-1629-4df2-8620-69b7888e57e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_840ca2eb-2780-4e09-ab18-0a451c76abf0" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_5950f862-1629-4df2-8620-69b7888e57e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_4447ceaa-79c4-4340-b6b6-df4b671b1a30" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_840ca2eb-2780-4e09-ab18-0a451c76abf0" xlink:to="loc_ifrs-full_ComprehensiveIncome_4447ceaa-79c4-4340-b6b6-df4b671b1a30" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings_bd0d9050-9e02-497a-8427-368a041b8812" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_840ca2eb-2780-4e09-ab18-0a451c76abf0" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings_bd0d9050-9e02-497a-8427-368a041b8812" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_99dd4952-5d32-44f7-a127-a0991ad246ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_840ca2eb-2780-4e09-ab18-0a451c76abf0" xlink:to="loc_ifrs-full_IssueOfEquity_99dd4952-5d32-44f7-a127-a0991ad246ca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ShareIssueRelatedCostCredit_3905a2b2-20c4-4021-913f-950c3ac3774f" xlink:href="abvx-20251231.xsd#abvx_ShareIssueRelatedCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_840ca2eb-2780-4e09-ab18-0a451c76abf0" xlink:to="loc_abvx_ShareIssueRelatedCostCredit_3905a2b2-20c4-4021-913f-950c3ac3774f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfConvertibleInstruments_019cc2ef-dc2f-7479-b54d-e834b738a92a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssueOfConvertibleInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_840ca2eb-2780-4e09-ab18-0a451c76abf0" xlink:to="loc_ifrs-full_IssueOfConvertibleInstruments_019cc2ef-dc2f-7479-b54d-e834b738a92a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseThroughIssuanceOfWarrantsEquity_898a034e-8b3c-4a0f-9b07-6cfaf2b9f19a" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseThroughIssuanceOfWarrantsEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_840ca2eb-2780-4e09-ab18-0a451c76abf0" xlink:to="loc_abvx_IncreaseDecreaseThroughIssuanceOfWarrantsEquity_898a034e-8b3c-4a0f-9b07-6cfaf2b9f19a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_245361c1-f6e3-4a76-9218-276e2a85af41" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_840ca2eb-2780-4e09-ab18-0a451c76abf0" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_245361c1-f6e3-4a76-9218-276e2a85af41" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_019c4327-849d-76ff-ad76-73d6c12b22e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_840ca2eb-2780-4e09-ab18-0a451c76abf0" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_019c4327-849d-76ff-ad76-73d6c12b22e0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseFromFreeSharesIssued_3748677d-9c78-4973-9149-62fa6d0b2e00" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseFromFreeSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_840ca2eb-2780-4e09-ab18-0a451c76abf0" xlink:to="loc_abvx_IncreaseDecreaseFromFreeSharesIssued_3748677d-9c78-4973-9149-62fa6d0b2e00" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_304ea5cb-1bb1-407a-aec6-ac0e31a8101f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_840ca2eb-2780-4e09-ab18-0a451c76abf0" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_304ea5cb-1bb1-407a-aec6-ac0e31a8101f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_41fce087-6514-446c-918e-739a726a6ddb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_840ca2eb-2780-4e09-ab18-0a451c76abf0" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_41fce087-6514-446c-918e-739a726a6ddb" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_13cb43dd-3c02-4c7d-b120-06c027396258" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/BasisofpreparationDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#BasisofpreparationDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/BasisofpreparationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3727c861-3787-40da-8ee4-8557a018979d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_5a04552b-e148-4136-bb64-1022dc6d3aa2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3727c861-3787-40da-8ee4-8557a018979d" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_5a04552b-e148-4136-bb64-1022dc6d3aa2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SaleOfStockAxis_9636aa04-a03c-4fe6-979f-e883570254bf" xlink:href="abvx-20251231.xsd#abvx_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_5a04552b-e148-4136-bb64-1022dc6d3aa2" xlink:to="loc_abvx_SaleOfStockAxis_9636aa04-a03c-4fe6-979f-e883570254bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SaleOfStockDomain_9636aa04-a03c-4fe6-979f-e883570254bf_default" xlink:href="abvx-20251231.xsd#abvx_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_abvx_SaleOfStockAxis_9636aa04-a03c-4fe6-979f-e883570254bf" xlink:to="loc_abvx_SaleOfStockDomain_9636aa04-a03c-4fe6-979f-e883570254bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SaleOfStockDomain_af5a6cb4-a79d-443d-8a0d-0af5895ce4ae" xlink:href="abvx-20251231.xsd#abvx_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_abvx_SaleOfStockAxis_9636aa04-a03c-4fe6-979f-e883570254bf" xlink:to="loc_abvx_SaleOfStockDomain_af5a6cb4-a79d-443d-8a0d-0af5895ce4ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RegisteredDirectOfferingMember_020d0650-0103-47b7-bd8c-f4904537c382" xlink:href="abvx-20251231.xsd#abvx_RegisteredDirectOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_SaleOfStockDomain_af5a6cb4-a79d-443d-8a0d-0af5895ce4ae" xlink:to="loc_abvx_RegisteredDirectOfferingMember_020d0650-0103-47b7-bd8c-f4904537c382" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d00be8d3-5d44-403c-ae3d-bfd6a731b144" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_5a04552b-e148-4136-bb64-1022dc6d3aa2" xlink:to="loc_srt_CounterpartyNameAxis_d00be8d3-5d44-403c-ae3d-bfd6a731b144" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d00be8d3-5d44-403c-ae3d-bfd6a731b144_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d00be8d3-5d44-403c-ae3d-bfd6a731b144" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d00be8d3-5d44-403c-ae3d-bfd6a731b144_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fc9eb33-2169-4d10-ba48-eca99716d298" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d00be8d3-5d44-403c-ae3d-bfd6a731b144" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fc9eb33-2169-4d10-ba48-eca99716d298" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BanquePubliqueDInvestissementBPIMember_9cd4ef0c-c5fe-4f1b-90c1-21e4b2428b63" xlink:href="abvx-20251231.xsd#abvx_BanquePubliqueDInvestissementBPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fc9eb33-2169-4d10-ba48-eca99716d298" xlink:to="loc_abvx_BanquePubliqueDInvestissementBPIMember_9cd4ef0c-c5fe-4f1b-90c1-21e4b2428b63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_aec0127e-6b8d-4fde-b41a-e249987e3005" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3727c861-3787-40da-8ee4-8557a018979d" xlink:to="loc_ifrs-full_ProfitLoss_aec0127e-6b8d-4fde-b41a-e249987e3005" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_1802063c-a58b-4ef5-b865-7fd025a35499" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3727c861-3787-40da-8ee4-8557a018979d" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_1802063c-a58b-4ef5-b865-7fd025a35499" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_bf28e84e-a047-46ba-bfb9-2f77bb98f8a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3727c861-3787-40da-8ee4-8557a018979d" xlink:to="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_bf28e84e-a047-46ba-bfb9-2f77bb98f8a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ProceedsFromResearchTaxCredit_024b1391-8e72-4a5f-aa7e-14b2be6b3fcd" xlink:href="abvx-20251231.xsd#abvx_ProceedsFromResearchTaxCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3727c861-3787-40da-8ee4-8557a018979d" xlink:to="loc_abvx_ProceedsFromResearchTaxCredit_024b1391-8e72-4a5f-aa7e-14b2be6b3fcd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities_d77a7f93-dee1-4d27-9526-594ddf93ce3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3727c861-3787-40da-8ee4-8557a018979d" xlink:to="loc_ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities_d77a7f93-dee1-4d27-9526-594ddf93ce3c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ProceedsFromConditionalAdvances_b2d623d7-d526-4b71-b1ff-8589a311367e" xlink:href="abvx-20251231.xsd#abvx_ProceedsFromConditionalAdvances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3727c861-3787-40da-8ee4-8557a018979d" xlink:to="loc_abvx_ProceedsFromConditionalAdvances_b2d623d7-d526-4b71-b1ff-8589a311367e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NetProceedsFromSaleOfRoyaltyCertificates_963602ec-79bf-45e0-891c-cc9d3049705d" xlink:href="abvx-20251231.xsd#abvx_NetProceedsFromSaleOfRoyaltyCertificates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3727c861-3787-40da-8ee4-8557a018979d" xlink:to="loc_abvx_NetProceedsFromSaleOfRoyaltyCertificates_963602ec-79bf-45e0-891c-cc9d3049705d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CashAndCashEquivalentsAndOtherShortTermInvestments_019cd7eb-73d9-7d8a-a7c3-7e8550ba39b4" xlink:href="abvx-20251231.xsd#abvx_CashAndCashEquivalentsAndOtherShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3727c861-3787-40da-8ee4-8557a018979d" xlink:to="loc_abvx_CashAndCashEquivalentsAndOtherShortTermInvestments_019cd7eb-73d9-7d8a-a7c3-7e8550ba39b4" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" xlink:type="simple" xlink:href="abvx-20251231.xsd#SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_4f2160ed-9398-4159-8a3e-9431996a786a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_4f2160ed-9398-4159-8a3e-9431996a786a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialAgreementAxis_f11ee1aa-c644-4aa9-8db1-a9a44aaaa2c5" xlink:href="abvx-20251231.xsd#abvx_FinancialAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_4f2160ed-9398-4159-8a3e-9431996a786a" xlink:to="loc_abvx_FinancialAgreementAxis_f11ee1aa-c644-4aa9-8db1-a9a44aaaa2c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialAgreementDomain_f11ee1aa-c644-4aa9-8db1-a9a44aaaa2c5_default" xlink:href="abvx-20251231.xsd#abvx_FinancialAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_abvx_FinancialAgreementAxis_f11ee1aa-c644-4aa9-8db1-a9a44aaaa2c5" xlink:to="loc_abvx_FinancialAgreementDomain_f11ee1aa-c644-4aa9-8db1-a9a44aaaa2c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialAgreementDomain_3b33e393-8817-49f5-9e37-1ec0ea3c494b" xlink:href="abvx-20251231.xsd#abvx_FinancialAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_abvx_FinancialAgreementAxis_f11ee1aa-c644-4aa9-8db1-a9a44aaaa2c5" xlink:to="loc_abvx_FinancialAgreementDomain_3b33e393-8817-49f5-9e37-1ec0ea3c494b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_A130.0MillionCrossOverFinancingFebruary2023Member_a14ac1d7-8642-4bae-bc5e-a3894ba31a70" xlink:href="abvx-20251231.xsd#abvx_A130.0MillionCrossOverFinancingFebruary2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FinancialAgreementDomain_3b33e393-8817-49f5-9e37-1ec0ea3c494b" xlink:to="loc_abvx_A130.0MillionCrossOverFinancingFebruary2023Member_a14ac1d7-8642-4bae-bc5e-a3894ba31a70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_A49.2MillionCrossOverFinancingSeptember2022Member_41e98ff5-e04f-403a-8337-77b2894369cf" xlink:href="abvx-20251231.xsd#abvx_A49.2MillionCrossOverFinancingSeptember2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FinancialAgreementDomain_3b33e393-8817-49f5-9e37-1ec0ea3c494b" xlink:to="loc_abvx_A49.2MillionCrossOverFinancingSeptember2022Member_41e98ff5-e04f-403a-8337-77b2894369cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_A150.0MillionFinancingAugust2023Member_98153e11-2c37-4328-badf-0aa3439029d7" xlink:href="abvx-20251231.xsd#abvx_A150.0MillionFinancingAugust2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FinancialAgreementDomain_3b33e393-8817-49f5-9e37-1ec0ea3c494b" xlink:to="loc_abvx_A150.0MillionFinancingAugust2023Member_98153e11-2c37-4328-badf-0aa3439029d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_5f01a384-9b1d-4582-8120-8d317e191fa1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_4f2160ed-9398-4159-8a3e-9431996a786a" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_5f01a384-9b1d-4582-8120-8d317e191fa1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_5f01a384-9b1d-4582-8120-8d317e191fa1_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_5f01a384-9b1d-4582-8120-8d317e191fa1" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_5f01a384-9b1d-4582-8120-8d317e191fa1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_8f94ca90-8cc8-4ed0-8ddb-d2ba0dd08270" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_5f01a384-9b1d-4582-8120-8d317e191fa1" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_8f94ca90-8cc8-4ed0-8ddb-d2ba0dd08270" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_a69ad1b5-6e98-4a9e-8387-072f37eb9f01" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_8f94ca90-8cc8-4ed0-8ddb-d2ba0dd08270" xlink:to="loc_ifrs-full_SharePremiumMember_a69ad1b5-6e98-4a9e-8387-072f37eb9f01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_5726150b-87b1-4d15-8a09-1533f91009d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_4f2160ed-9398-4159-8a3e-9431996a786a" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_5726150b-87b1-4d15-8a09-1533f91009d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_5726150b-87b1-4d15-8a09-1533f91009d5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_5726150b-87b1-4d15-8a09-1533f91009d5" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_5726150b-87b1-4d15-8a09-1533f91009d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_c57574e1-a77d-4d91-969f-45c36e6ebac7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_5726150b-87b1-4d15-8a09-1533f91009d5" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_c57574e1-a77d-4d91-969f-45c36e6ebac7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1ConvertibleBondLoansTrancheAMember_ba072001-3e39-4199-a98c-3cb4698fb05a" xlink:href="abvx-20251231.xsd#abvx_Kreos1ConvertibleBondLoansTrancheAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c57574e1-a77d-4d91-969f-45c36e6ebac7" xlink:to="loc_abvx_Kreos1ConvertibleBondLoansTrancheAMember_ba072001-3e39-4199-a98c-3cb4698fb05a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1ConvertibleBondLoansTrancheBMember_3934b5a4-7f21-4ad2-a2e1-fd3bcfcd9406" xlink:href="abvx-20251231.xsd#abvx_Kreos1ConvertibleBondLoansTrancheBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c57574e1-a77d-4d91-969f-45c36e6ebac7" xlink:to="loc_abvx_Kreos1ConvertibleBondLoansTrancheBMember_3934b5a4-7f21-4ad2-a2e1-fd3bcfcd9406" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingMember_a319e854-9496-44b1-9444-288f19675070" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c57574e1-a77d-4d91-969f-45c36e6ebac7" xlink:to="loc_abvx_KreosClaretFinancingMember_a319e854-9496-44b1-9444-288f19675070" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_HeightsConvertibleNotesMember_dd5efce1-7e89-4334-876d-e9eacb337606" xlink:href="abvx-20251231.xsd#abvx_HeightsConvertibleNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c57574e1-a77d-4d91-969f-45c36e6ebac7" xlink:to="loc_abvx_HeightsConvertibleNotesMember_dd5efce1-7e89-4334-876d-e9eacb337606" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheAMember_103ae38f-be96-4337-bda7-0064012edca5" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c57574e1-a77d-4d91-969f-45c36e6ebac7" xlink:to="loc_abvx_KreosClaretFinancingTrancheAMember_103ae38f-be96-4337-bda7-0064012edca5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OCEANEMember_5e75d5f5-6358-4c46-917c-0b3c73c2054c" xlink:href="abvx-20251231.xsd#abvx_OCEANEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c57574e1-a77d-4d91-969f-45c36e6ebac7" xlink:to="loc_abvx_OCEANEMember_5e75d5f5-6358-4c46-917c-0b3c73c2054c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingAndHeightsConvertibleNotesMember_f243d714-df1d-428f-89d9-fbc96c1b18bc" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingAndHeightsConvertibleNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c57574e1-a77d-4d91-969f-45c36e6ebac7" xlink:to="loc_abvx_KreosClaretFinancingAndHeightsConvertibleNotesMember_f243d714-df1d-428f-89d9-fbc96c1b18bc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_cd16f4b3-1b22-4b3f-9dfe-e5111ba16182" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_4f2160ed-9398-4159-8a3e-9431996a786a" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_cd16f4b3-1b22-4b3f-9dfe-e5111ba16182" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_cd16f4b3-1b22-4b3f-9dfe-e5111ba16182_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_cd16f4b3-1b22-4b3f-9dfe-e5111ba16182" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_cd16f4b3-1b22-4b3f-9dfe-e5111ba16182_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_81ecfecb-581f-4359-a6d7-61262160381e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_cd16f4b3-1b22-4b3f-9dfe-e5111ba16182" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_81ecfecb-581f-4359-a6d7-61262160381e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AmericanDepositorySharesMember_2c67ba44-c9bf-4bdf-ae80-7b7db54b6688" xlink:href="abvx-20251231.xsd#abvx_AmericanDepositorySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_81ecfecb-581f-4359-a6d7-61262160381e" xlink:to="loc_abvx_AmericanDepositorySharesMember_2c67ba44-c9bf-4bdf-ae80-7b7db54b6688" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_b5e97169-a592-4021-8a0a-c608bcc82a0e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_81ecfecb-581f-4359-a6d7-61262160381e" xlink:to="loc_ifrs-full_OrdinarySharesMember_b5e97169-a592-4021-8a0a-c608bcc82a0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c90e2a2b-44f6-4074-9954-7b566f0415fa" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_4f2160ed-9398-4159-8a3e-9431996a786a" xlink:to="loc_srt_RangeAxis_c90e2a2b-44f6-4074-9954-7b566f0415fa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c90e2a2b-44f6-4074-9954-7b566f0415fa_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c90e2a2b-44f6-4074-9954-7b566f0415fa" xlink:to="loc_srt_RangeMember_c90e2a2b-44f6-4074-9954-7b566f0415fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_684911bb-2078-4c7a-a060-3f6a33f68d0d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c90e2a2b-44f6-4074-9954-7b566f0415fa" xlink:to="loc_srt_RangeMember_684911bb-2078-4c7a-a060-3f6a33f68d0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c2d9ed35-330c-44cd-b1da-548f59f3e756" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_684911bb-2078-4c7a-a060-3f6a33f68d0d" xlink:to="loc_srt_MaximumMember_c2d9ed35-330c-44cd-b1da-548f59f3e756" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_WarrantsAxis_86a16f4d-4222-47d4-9c03-7af3a2907e78" xlink:href="abvx-20251231.xsd#abvx_WarrantsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_4f2160ed-9398-4159-8a3e-9431996a786a" xlink:to="loc_abvx_WarrantsAxis_86a16f4d-4222-47d4-9c03-7af3a2907e78" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_WarrantsDomain_86a16f4d-4222-47d4-9c03-7af3a2907e78_default" xlink:href="abvx-20251231.xsd#abvx_WarrantsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_abvx_WarrantsAxis_86a16f4d-4222-47d4-9c03-7af3a2907e78" xlink:to="loc_abvx_WarrantsDomain_86a16f4d-4222-47d4-9c03-7af3a2907e78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_WarrantsDomain_12ca03ff-7503-4b90-b035-ad5c5bd817e8" xlink:href="abvx-20251231.xsd#abvx_WarrantsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_abvx_WarrantsAxis_86a16f4d-4222-47d4-9c03-7af3a2907e78" xlink:to="loc_abvx_WarrantsDomain_12ca03ff-7503-4b90-b035-ad5c5bd817e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosCBSAMember_0cdb8b2c-ea25-4a43-9ab7-7a0b8d7dfeb6" xlink:href="abvx-20251231.xsd#abvx_KreosCBSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_WarrantsDomain_12ca03ff-7503-4b90-b035-ad5c5bd817e8" xlink:to="loc_abvx_KreosCBSAMember_0cdb8b2c-ea25-4a43-9ab7-7a0b8d7dfeb6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_df586d1b-804e-4766-9c05-0db5c0a86db3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_4f2160ed-9398-4159-8a3e-9431996a786a" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_df586d1b-804e-4766-9c05-0db5c0a86db3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_df586d1b-804e-4766-9c05-0db5c0a86db3_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_df586d1b-804e-4766-9c05-0db5c0a86db3" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_df586d1b-804e-4766-9c05-0db5c0a86db3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_975fb03d-6e10-4856-ae7f-a5497e046654" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_df586d1b-804e-4766-9c05-0db5c0a86db3" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_975fb03d-6e10-4856-ae7f-a5497e046654" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FreeSharesAGAMember_5b7be167-3091-4d36-ad73-eaa0b67eb602" xlink:href="abvx-20251231.xsd#abvx_FreeSharesAGAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_975fb03d-6e10-4856-ae7f-a5497e046654" xlink:to="loc_abvx_FreeSharesAGAMember_5b7be167-3091-4d36-ad73-eaa0b67eb602" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialAgreementAmount_8f1d6b61-436e-41ef-80fb-6163177198be" xlink:href="abvx-20251231.xsd#abvx_FinancialAgreementAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_abvx_FinancialAgreementAmount_8f1d6b61-436e-41ef-80fb-6163177198be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_2d7f681a-ff9b-42b0-a7fe-a52137b538e5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_ifrs-full_IssueOfEquity_2d7f681a-ff9b-42b0-a7fe-a52137b538e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease_b5054313-4b5f-4822-8cff-09e6825f611d" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease_b5054313-4b5f-4822-8cff-09e6825f611d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_408e3784-b477-4830-be11-49444bc76dd6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_ifrs-full_ParValuePerShare_408e3784-b477-4830-be11-49444bc76dd6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EquityIssuancePercentageOfCurrentShareCapital_8be79708-cc76-47ab-ae73-01e0e6f515c2" xlink:href="abvx-20251231.xsd#abvx_EquityIssuancePercentageOfCurrentShareCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_abvx_EquityIssuancePercentageOfCurrentShareCapital_8be79708-cc76-47ab-ae73-01e0e6f515c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EquityIssuanceSubscriptionPricePerShare_0cfede77-0f98-487d-8d3c-7194f452586d" xlink:href="abvx-20251231.xsd#abvx_EquityIssuanceSubscriptionPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_abvx_EquityIssuanceSubscriptionPricePerShare_0cfede77-0f98-487d-8d3c-7194f452586d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_0aad9077-dc6e-4ae8-9718-e333ee2b5cbc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_0aad9077-dc6e-4ae8-9718-e333ee2b5cbc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfOtherShareWarrantsRepurchased_1931ed97-a3d6-4f31-bb45-7ce49ff73834" xlink:href="abvx-20251231.xsd#abvx_NumberOfOtherShareWarrantsRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_abvx_NumberOfOtherShareWarrantsRepurchased_1931ed97-a3d6-4f31-bb45-7ce49ff73834" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants_1e2cb7bc-f329-454e-a1a5-80d58010348f" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants_1e2cb7bc-f329-454e-a1a5-80d58010348f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfShareBasedCompensationPlansIssued_b3df8840-47a9-4c3b-a74a-d336f0ae0c7d" xlink:href="abvx-20251231.xsd#abvx_NumberOfShareBasedCompensationPlansIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_abvx_NumberOfShareBasedCompensationPlansIssued_b3df8840-47a9-4c3b-a74a-d336f0ae0c7d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_b71d0cc6-61b9-4e20-a592-3909efb31778" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_b71d0cc6-61b9-4e20-a592-3909efb31778" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialAgreementNumberOfTransactions_9b2dc97f-ac6f-4133-9bb8-e440853393dd" xlink:href="abvx-20251231.xsd#abvx_FinancialAgreementNumberOfTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_abvx_FinancialAgreementNumberOfTransactions_9b2dc97f-ac6f-4133-9bb8-e440853393dd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsMaximumBorrowingCapacity_9cb21027-4e5a-4508-abe2-e69dd0d00f91" xlink:href="abvx-20251231.xsd#abvx_BorrowingsMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_abvx_BorrowingsMaximumBorrowingCapacity_9cb21027-4e5a-4508-abe2-e69dd0d00f91" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AggregateExercisePriceOtherEquityInstrumentsGranted_87fb5006-fc49-4dac-9608-d4fc67a58812" xlink:href="abvx-20251231.xsd#abvx_AggregateExercisePriceOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_abvx_AggregateExercisePriceOtherEquityInstrumentsGranted_87fb5006-fc49-4dac-9608-d4fc67a58812" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_db06c5d7-9d0d-415d-8e4f-aa7f20b848f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_db06c5d7-9d0d-415d-8e4f-aa7f20b848f7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepaymentsOfConvertibleLoansNotes_d49bdc38-9303-47b7-ae8a-94f53cfe5308" xlink:href="abvx-20251231.xsd#abvx_RepaymentsOfConvertibleLoansNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_abvx_RepaymentsOfConvertibleLoansNotes_d49bdc38-9303-47b7-ae8a-94f53cfe5308" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ProceedsFromBorrowingsNetOfRefinancingOfExistingIndebteness_62cf4cec-17aa-431a-b8d7-9a4982ad07f6" xlink:href="abvx-20251231.xsd#abvx_ProceedsFromBorrowingsNetOfRefinancingOfExistingIndebteness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_abvx_ProceedsFromBorrowingsNetOfRefinancingOfExistingIndebteness_62cf4cec-17aa-431a-b8d7-9a4982ad07f6" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IssuanceOfOtherShareWarrants_ae4e37bb-78f5-4e2b-b08d-fa1f4509bb75" xlink:href="abvx-20251231.xsd#abvx_IssuanceOfOtherShareWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_abvx_IssuanceOfOtherShareWarrants_ae4e37bb-78f5-4e2b-b08d-fa1f4509bb75" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfSharesReceivedPerADS_6267e321-f19d-4382-b743-6cc6e7365ff4" xlink:href="abvx-20251231.xsd#abvx_NumberOfSharesReceivedPerADS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_abvx_NumberOfSharesReceivedPerADS_6267e321-f19d-4382-b743-6cc6e7365ff4" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IssueOfEquityOfferingPricePerShare_a351f9af-52e4-441b-97bb-b460e515d994" xlink:href="abvx-20251231.xsd#abvx_IssueOfEquityOfferingPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_abvx_IssueOfEquityOfferingPricePerShare_a351f9af-52e4-441b-97bb-b460e515d994" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_caaf49b4-b8ae-4d51-887e-37a6895c2e72" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_caaf49b4-b8ae-4d51-887e-37a6895c2e72" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants_301d71dd-5f07-4e85-8589-c05a4c915690" xlink:href="abvx-20251231.xsd#abvx_ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_abvx_ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants_301d71dd-5f07-4e85-8589-c05a4c915690" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts_1ca917fa-0b76-4fd5-b189-7a6f113c6011" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_ifrs-full_PaymentsForShareIssueCosts_1ca917fa-0b76-4fd5-b189-7a6f113c6011" xlink:type="arc" order="22"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details" xlink:type="simple" xlink:href="abvx-20251231.xsd#SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_5fc8bf59-7fd4-47e0-b270-ecd573debcdf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_8ac2c0c6-1416-45a2-8c01-ebe7609ccfec" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_5fc8bf59-7fd4-47e0-b270-ecd573debcdf" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_8ac2c0c6-1416-45a2-8c01-ebe7609ccfec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_51582bdc-32ef-4749-aa04-d5b2cae0beb4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_8ac2c0c6-1416-45a2-8c01-ebe7609ccfec" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_51582bdc-32ef-4749-aa04-d5b2cae0beb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_51582bdc-32ef-4749-aa04-d5b2cae0beb4_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_51582bdc-32ef-4749-aa04-d5b2cae0beb4" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_51582bdc-32ef-4749-aa04-d5b2cae0beb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_01f2dc4b-0792-4a7a-a0be-20232fa9a1b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_51582bdc-32ef-4749-aa04-d5b2cae0beb4" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_01f2dc4b-0792-4a7a-a0be-20232fa9a1b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA2024Member_7dc4b2d8-d003-4493-a44c-55374801634f" xlink:href="abvx-20251231.xsd#abvx_AGA2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_01f2dc4b-0792-4a7a-a0be-20232fa9a1b0" xlink:to="loc_abvx_AGA2024Member_7dc4b2d8-d003-4493-a44c-55374801634f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20246Member_1a5794d5-2d46-46d3-8156-3735deb4ffa6" xlink:href="abvx-20251231.xsd#abvx_AGA20246Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_01f2dc4b-0792-4a7a-a0be-20232fa9a1b0" xlink:to="loc_abvx_AGA20246Member_1a5794d5-2d46-46d3-8156-3735deb4ffa6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20241Member_f02ff7ef-f028-4f3a-b73d-c2b1783a35b9" xlink:href="abvx-20251231.xsd#abvx_BSA20241Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_01f2dc4b-0792-4a7a-a0be-20232fa9a1b0" xlink:to="loc_abvx_BSA20241Member_f02ff7ef-f028-4f3a-b73d-c2b1783a35b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesAxis_fb6ef457-c6fd-459a-b68d-205708d2c7cb" xlink:href="abvx-20251231.xsd#abvx_TranchesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_8ac2c0c6-1416-45a2-8c01-ebe7609ccfec" xlink:to="loc_abvx_TranchesAxis_fb6ef457-c6fd-459a-b68d-205708d2c7cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesDomain_fb6ef457-c6fd-459a-b68d-205708d2c7cb_default" xlink:href="abvx-20251231.xsd#abvx_TranchesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_abvx_TranchesAxis_fb6ef457-c6fd-459a-b68d-205708d2c7cb" xlink:to="loc_abvx_TranchesDomain_fb6ef457-c6fd-459a-b68d-205708d2c7cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesDomain_a99b33ce-454e-4d90-9f38-5b9ae17cc668" xlink:href="abvx-20251231.xsd#abvx_TranchesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_abvx_TranchesAxis_fb6ef457-c6fd-459a-b68d-205708d2c7cb" xlink:to="loc_abvx_TranchesDomain_a99b33ce-454e-4d90-9f38-5b9ae17cc668" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheOneMember_ca613633-c968-4916-888c-f38a14e7da1e" xlink:href="abvx-20251231.xsd#abvx_TrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_TranchesDomain_a99b33ce-454e-4d90-9f38-5b9ae17cc668" xlink:to="loc_abvx_TrancheOneMember_ca613633-c968-4916-888c-f38a14e7da1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheTwoMember_4adaa04d-2473-4958-ba28-d5b6c013f823" xlink:href="abvx-20251231.xsd#abvx_TrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_TranchesDomain_a99b33ce-454e-4d90-9f38-5b9ae17cc668" xlink:to="loc_abvx_TrancheTwoMember_4adaa04d-2473-4958-ba28-d5b6c013f823" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheThreeMember_5a4f1005-5aef-40a2-91fa-0ee8525dd5ae" xlink:href="abvx-20251231.xsd#abvx_TrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_TranchesDomain_a99b33ce-454e-4d90-9f38-5b9ae17cc668" xlink:to="loc_abvx_TrancheThreeMember_5a4f1005-5aef-40a2-91fa-0ee8525dd5ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_f737c7c6-4827-445e-9e72-40045f243f8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_8ac2c0c6-1416-45a2-8c01-ebe7609ccfec" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_f737c7c6-4827-445e-9e72-40045f243f8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_f737c7c6-4827-445e-9e72-40045f243f8a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_f737c7c6-4827-445e-9e72-40045f243f8a" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_f737c7c6-4827-445e-9e72-40045f243f8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_891bce34-cc65-40a8-b2f0-15f836783a74" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_f737c7c6-4827-445e-9e72-40045f243f8a" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_891bce34-cc65-40a8-b2f0-15f836783a74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheBMember_d25eee13-9de1-43ec-9d7a-66db54ae1f58" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_891bce34-cc65-40a8-b2f0-15f836783a74" xlink:to="loc_abvx_KreosClaretFinancingTrancheBMember_d25eee13-9de1-43ec-9d7a-66db54ae1f58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheCMember_89ef56c2-1aac-4a7c-b49d-bfff813b9cb5" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_891bce34-cc65-40a8-b2f0-15f836783a74" xlink:to="loc_abvx_KreosClaretFinancingTrancheCMember_89ef56c2-1aac-4a7c-b49d-bfff813b9cb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheBAndCMember_64fc0902-24d7-43a8-ad55-e5a8f3a459a1" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheBAndCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_891bce34-cc65-40a8-b2f0-15f836783a74" xlink:to="loc_abvx_KreosClaretFinancingTrancheBAndCMember_64fc0902-24d7-43a8-ad55-e5a8f3a459a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_51c3c5e1-78c2-4fd0-a8e6-d4c176341d36" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_8ac2c0c6-1416-45a2-8c01-ebe7609ccfec" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_51c3c5e1-78c2-4fd0-a8e6-d4c176341d36" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_51c3c5e1-78c2-4fd0-a8e6-d4c176341d36_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_51c3c5e1-78c2-4fd0-a8e6-d4c176341d36" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_51c3c5e1-78c2-4fd0-a8e6-d4c176341d36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_159a014c-d774-4d09-bb2c-892fabbfa1a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_51c3c5e1-78c2-4fd0-a8e6-d4c176341d36" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_159a014c-d774-4d09-bb2c-892fabbfa1a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RNPVIRConditionalAdvanceBPIMember_cd27b71f-f3f2-4aed-9347-6cecaae4fd63" xlink:href="abvx-20251231.xsd#abvx_RNPVIRConditionalAdvanceBPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_159a014c-d774-4d09-bb2c-892fabbfa1a8" xlink:to="loc_abvx_RNPVIRConditionalAdvanceBPIMember_cd27b71f-f3f2-4aed-9347-6cecaae4fd63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CARENAConditionalAdvanceBPIMember_ce919239-7900-4ce4-858e-c39e3257b9cc" xlink:href="abvx-20251231.xsd#abvx_CARENAConditionalAdvanceBPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_159a014c-d774-4d09-bb2c-892fabbfa1a8" xlink:to="loc_abvx_CARENAConditionalAdvanceBPIMember_ce919239-7900-4ce4-858e-c39e3257b9cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RNPVIRConditionalAdvanceBPIAndCARENAConditionalAdvanceBPIMember_23e63341-60d4-49ca-ba60-1479122b9848" xlink:href="abvx-20251231.xsd#abvx_RNPVIRConditionalAdvanceBPIAndCARENAConditionalAdvanceBPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_159a014c-d774-4d09-bb2c-892fabbfa1a8" xlink:to="loc_abvx_RNPVIRConditionalAdvanceBPIAndCARENAConditionalAdvanceBPIMember_23e63341-60d4-49ca-ba60-1479122b9848" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SaleOfStockAxis_5bf3019f-0075-482b-b9fd-2e655f146f40" xlink:href="abvx-20251231.xsd#abvx_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_8ac2c0c6-1416-45a2-8c01-ebe7609ccfec" xlink:to="loc_abvx_SaleOfStockAxis_5bf3019f-0075-482b-b9fd-2e655f146f40" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SaleOfStockDomain_5bf3019f-0075-482b-b9fd-2e655f146f40_default" xlink:href="abvx-20251231.xsd#abvx_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_abvx_SaleOfStockAxis_5bf3019f-0075-482b-b9fd-2e655f146f40" xlink:to="loc_abvx_SaleOfStockDomain_5bf3019f-0075-482b-b9fd-2e655f146f40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SaleOfStockDomain_857307c1-09d7-4d8c-9027-1103349efa34" xlink:href="abvx-20251231.xsd#abvx_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_abvx_SaleOfStockAxis_5bf3019f-0075-482b-b9fd-2e655f146f40" xlink:to="loc_abvx_SaleOfStockDomain_857307c1-09d7-4d8c-9027-1103349efa34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AtTheMarketATMProgramMember_38e54fc7-4a55-4735-a288-e520dc42b723" xlink:href="abvx-20251231.xsd#abvx_AtTheMarketATMProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_SaleOfStockDomain_857307c1-09d7-4d8c-9027-1103349efa34" xlink:to="loc_abvx_AtTheMarketATMProgramMember_38e54fc7-4a55-4735-a288-e520dc42b723" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfFreeSharesPlansIssued_f0704c72-c7d7-4ddc-8bfd-f0bc87a8fb9a" xlink:href="abvx-20251231.xsd#abvx_NumberOfFreeSharesPlansIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_5fc8bf59-7fd4-47e0-b270-ecd573debcdf" xlink:to="loc_abvx_NumberOfFreeSharesPlansIssued_f0704c72-c7d7-4ddc-8bfd-f0bc87a8fb9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_9a6d37bd-d97b-462b-943c-ee08bff4e0c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_5fc8bf59-7fd4-47e0-b270-ecd573debcdf" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_9a6d37bd-d97b-462b-943c-ee08bff4e0c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage_a01f4d89-4f36-4c4d-a4fb-42063d7b9931" xlink:href="abvx-20251231.xsd#abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_5fc8bf59-7fd4-47e0-b270-ecd573debcdf" xlink:to="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage_a01f4d89-4f36-4c4d-a4fb-42063d7b9931" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_5946f9e7-6930-4e9a-9a75-7f27d12c884e" xlink:href="abvx-20251231.xsd#abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_5fc8bf59-7fd4-47e0-b270-ecd573debcdf" xlink:to="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_5946f9e7-6930-4e9a-9a75-7f27d12c884e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_9a251a40-7208-4585-b741-f55f4ee80e90" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_5fc8bf59-7fd4-47e0-b270-ecd573debcdf" xlink:to="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_9a251a40-7208-4585-b741-f55f4ee80e90" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsMaximumBorrowingCapacity_42a531ce-1383-4cb5-ba7a-48aaaf026381" xlink:href="abvx-20251231.xsd#abvx_BorrowingsMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_5fc8bf59-7fd4-47e0-b270-ecd573debcdf" xlink:to="loc_abvx_BorrowingsMaximumBorrowingCapacity_42a531ce-1383-4cb5-ba7a-48aaaf026381" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_c3abb54a-46a6-4913-90a1-e3d54d62c619" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_5fc8bf59-7fd4-47e0-b270-ecd573debcdf" xlink:to="loc_ifrs-full_ParValuePerShare_c3abb54a-46a6-4913-90a1-e3d54d62c619" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ProceedsFromConditionalAdvances_120e7152-b9fb-4807-88ad-12d2d6025d7e" xlink:href="abvx-20251231.xsd#abvx_ProceedsFromConditionalAdvances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_5fc8bf59-7fd4-47e0-b270-ecd573debcdf" xlink:to="loc_abvx_ProceedsFromConditionalAdvances_120e7152-b9fb-4807-88ad-12d2d6025d7e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities_ba95cc77-a0e5-45a5-bf9d-cf6e3baacc8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_5fc8bf59-7fd4-47e0-b270-ecd573debcdf" xlink:to="loc_ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities_ba95cc77-a0e5-45a5-bf9d-cf6e3baacc8a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PercentageOfConditionalAdvancesWaived_9981f06a-0dba-495c-93a8-288699cfe73d" xlink:href="abvx-20251231.xsd#abvx_PercentageOfConditionalAdvancesWaived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_5fc8bf59-7fd4-47e0-b270-ecd573debcdf" xlink:to="loc_abvx_PercentageOfConditionalAdvancesWaived_9981f06a-0dba-495c-93a8-288699cfe73d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromGovernmentGrants_4edcf9cf-48fd-44da-b7b6-a577eb90f592" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_5fc8bf59-7fd4-47e0-b270-ecd573debcdf" xlink:to="loc_ifrs-full_RevenueFromGovernmentGrants_4edcf9cf-48fd-44da-b7b6-a577eb90f592" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfADSPerOrdinaryShares_4ec551c6-67d8-4e64-93a6-e1cb190b2c6b" xlink:href="abvx-20251231.xsd#abvx_NumberOfADSPerOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_5fc8bf59-7fd4-47e0-b270-ecd573debcdf" xlink:to="loc_abvx_NumberOfADSPerOrdinaryShares_4ec551c6-67d8-4e64-93a6-e1cb190b2c6b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpectedProceedsFromShareIssuance_e3438e42-66e8-4fed-a5b7-a25049a33b13" xlink:href="abvx-20251231.xsd#abvx_ExpectedProceedsFromShareIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_5fc8bf59-7fd4-47e0-b270-ecd573debcdf" xlink:to="loc_abvx_ExpectedProceedsFromShareIssuance_e3438e42-66e8-4fed-a5b7-a25049a33b13" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpectedProceedsFromShareIssuanceShelfRegistration_e2757e53-8000-4aa9-aa8b-3f73f6c176b6" xlink:href="abvx-20251231.xsd#abvx_ExpectedProceedsFromShareIssuanceShelfRegistration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_5fc8bf59-7fd4-47e0-b270-ecd573debcdf" xlink:to="loc_abvx_ExpectedProceedsFromShareIssuanceShelfRegistration_e2757e53-8000-4aa9-aa8b-3f73f6c176b6" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details" xlink:type="simple" xlink:href="abvx-20251231.xsd#SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019beae7-6ccc-7a24-8454-790efec75929" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019beae7-6ccc-7a24-8454-790efec75929" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019beae7-6ccc-72c2-bc77-4407f8420694" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019beae7-6ccc-7a24-8454-790efec75929" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019beae7-6ccc-72c2-bc77-4407f8420694" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019beae7-6ccc-72c2-bc77-4407f8420694_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019beae7-6ccc-72c2-bc77-4407f8420694" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019beae7-6ccc-72c2-bc77-4407f8420694_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019beae7-6ccc-78b8-962b-256576f0b913" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019beae7-6ccc-72c2-bc77-4407f8420694" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019beae7-6ccc-78b8-962b-256576f0b913" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ShareSubscriptionWarrantsBSAMember_019beae7-6ccc-783a-977a-6180c16723b3" xlink:href="abvx-20251231.xsd#abvx_ShareSubscriptionWarrantsBSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019beae7-6ccc-78b8-962b-256576f0b913" xlink:to="loc_abvx_ShareSubscriptionWarrantsBSAMember_019beae7-6ccc-783a-977a-6180c16723b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA2025Member_019beae7-6ccc-78a9-a5bf-e0d9be16f179" xlink:href="abvx-20251231.xsd#abvx_AGA2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019beae7-6ccc-78b8-962b-256576f0b913" xlink:to="loc_abvx_AGA2025Member_019beae7-6ccc-78a9-a5bf-e0d9be16f179" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20252Member_019beae7-6ccc-7672-be26-7289d0b37b10" xlink:href="abvx-20251231.xsd#abvx_AGA20252Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019beae7-6ccc-78b8-962b-256576f0b913" xlink:to="loc_abvx_AGA20252Member_019beae7-6ccc-7672-be26-7289d0b37b10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20255Member_019beae7-6ccc-777d-8748-a2c3221cba69" xlink:href="abvx-20251231.xsd#abvx_AGA20255Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019beae7-6ccc-78b8-962b-256576f0b913" xlink:to="loc_abvx_AGA20255Member_019beae7-6ccc-777d-8748-a2c3221cba69" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20251Member_019beae7-6ccc-7dd0-b7e7-8f8cd4aea026" xlink:href="abvx-20251231.xsd#abvx_AGA20251Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019beae7-6ccc-78b8-962b-256576f0b913" xlink:to="loc_abvx_AGA20251Member_019beae7-6ccc-7dd0-b7e7-8f8cd4aea026" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_019beae7-6ccc-737f-9858-58742dc2ad97" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019beae7-6ccc-7a24-8454-790efec75929" xlink:to="loc_srt_TitleOfIndividualAxis_019beae7-6ccc-737f-9858-58742dc2ad97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019beae7-6ccc-737f-9858-58742dc2ad97_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_019beae7-6ccc-737f-9858-58742dc2ad97" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019beae7-6ccc-737f-9858-58742dc2ad97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019beae7-6ccc-7454-9dd1-9b51a83a2bb7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_019beae7-6ccc-737f-9858-58742dc2ad97" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019beae7-6ccc-7454-9dd1-9b51a83a2bb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BoardMemberMember_019beae7-6ccc-78b3-aaf5-037e9eb4142e" xlink:href="abvx-20251231.xsd#abvx_BoardMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019beae7-6ccc-7454-9dd1-9b51a83a2bb7" xlink:to="loc_abvx_BoardMemberMember_019beae7-6ccc-78b3-aaf5-037e9eb4142e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesAxis_019beae7-6ccc-779f-a3da-d8d1e3ccb0e5" xlink:href="abvx-20251231.xsd#abvx_TranchesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019beae7-6ccc-7a24-8454-790efec75929" xlink:to="loc_abvx_TranchesAxis_019beae7-6ccc-779f-a3da-d8d1e3ccb0e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesDomain_019beae7-6ccc-779f-a3da-d8d1e3ccb0e5_default" xlink:href="abvx-20251231.xsd#abvx_TranchesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_abvx_TranchesAxis_019beae7-6ccc-779f-a3da-d8d1e3ccb0e5" xlink:to="loc_abvx_TranchesDomain_019beae7-6ccc-779f-a3da-d8d1e3ccb0e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesDomain_019beae7-6ccc-7910-aced-3fef8e457739" xlink:href="abvx-20251231.xsd#abvx_TranchesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_abvx_TranchesAxis_019beae7-6ccc-779f-a3da-d8d1e3ccb0e5" xlink:to="loc_abvx_TranchesDomain_019beae7-6ccc-7910-aced-3fef8e457739" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheOneMember_019beae7-6ccc-792b-8deb-6a3ec85d5b1b" xlink:href="abvx-20251231.xsd#abvx_TrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_TranchesDomain_019beae7-6ccc-7910-aced-3fef8e457739" xlink:to="loc_abvx_TrancheOneMember_019beae7-6ccc-792b-8deb-6a3ec85d5b1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheTwoMember_019beae7-6ccc-7e88-988d-657b9a66a580" xlink:href="abvx-20251231.xsd#abvx_TrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_TranchesDomain_019beae7-6ccc-7910-aced-3fef8e457739" xlink:to="loc_abvx_TrancheTwoMember_019beae7-6ccc-7e88-988d-657b9a66a580" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheThreeMember_019beae7-6ccc-77e9-928c-153784076a25" xlink:href="abvx-20251231.xsd#abvx_TrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_TranchesDomain_019beae7-6ccc-7910-aced-3fef8e457739" xlink:to="loc_abvx_TrancheThreeMember_019beae7-6ccc-77e9-928c-153784076a25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_019beae9-d416-74d2-bbf7-dec2ee122c9d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019beae7-6ccc-7a24-8454-790efec75929" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_019beae9-d416-74d2-bbf7-dec2ee122c9d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019beae9-d416-74d2-bbf7-dec2ee122c9d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019beae9-d416-74d2-bbf7-dec2ee122c9d" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019beae9-d416-74d2-bbf7-dec2ee122c9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019beae9-d416-70a6-b96e-afe18a5d5960" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019beae9-d416-74d2-bbf7-dec2ee122c9d" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019beae9-d416-70a6-b96e-afe18a5d5960" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_HeightsConvertibleNotesMember_019beae9-d416-7e5b-8ef9-6455466c0467" xlink:href="abvx-20251231.xsd#abvx_HeightsConvertibleNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019beae9-d416-70a6-b96e-afe18a5d5960" xlink:to="loc_abvx_HeightsConvertibleNotesMember_019beae9-d416-7e5b-8ef9-6455466c0467" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheAMember_019beae9-d416-740a-b00a-8208ac4028bc" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019beae9-d416-70a6-b96e-afe18a5d5960" xlink:to="loc_abvx_KreosClaretFinancingTrancheAMember_019beae9-d416-740a-b00a-8208ac4028bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosABCBSAMember_019beae9-d416-7d0c-949a-b843769e76d0" xlink:href="abvx-20251231.xsd#abvx_KreosABCBSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019beae9-d416-70a6-b96e-afe18a5d5960" xlink:to="loc_abvx_KreosABCBSAMember_019beae9-d416-7d0c-949a-b843769e76d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingBAndCMember_019c4350-fd31-774c-9664-d81f4883a6c6" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingBAndCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019beae9-d416-70a6-b96e-afe18a5d5960" xlink:to="loc_abvx_KreosClaretFinancingBAndCMember_019c4350-fd31-774c-9664-d81f4883a6c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_019beae9-d416-7faf-9ada-fd3445ec4c3f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019beae7-6ccc-7a24-8454-790efec75929" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_019beae9-d416-7faf-9ada-fd3445ec4c3f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_019beae9-d416-7faf-9ada-fd3445ec4c3f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_019beae9-d416-7faf-9ada-fd3445ec4c3f" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_019beae9-d416-7faf-9ada-fd3445ec4c3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_019beae9-d416-79d4-8672-2b4c73b1be67" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_019beae9-d416-7faf-9ada-fd3445ec4c3f" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_019beae9-d416-79d4-8672-2b4c73b1be67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AmericanDepositorySharesMember_019beae9-f264-7bb7-ad1e-0bf70a0ac702" xlink:href="abvx-20251231.xsd#abvx_AmericanDepositorySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_019beae9-d416-79d4-8672-2b4c73b1be67" xlink:to="loc_abvx_AmericanDepositorySharesMember_019beae9-f264-7bb7-ad1e-0bf70a0ac702" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_019beae9-d416-77e2-b903-c9f9d88e741b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_019beae9-d416-79d4-8672-2b4c73b1be67" xlink:to="loc_ifrs-full_OrdinarySharesMember_019beae9-d416-77e2-b903-c9f9d88e741b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_019beae7-6ccc-75a5-bbca-241480c59f9c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_019beae7-6ccc-75a5-bbca-241480c59f9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_019beae7-6ccc-70db-8b79-1ae3c2fe19c8" xlink:href="abvx-20251231.xsd#abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:to="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_019beae7-6ccc-70db-8b79-1ae3c2fe19c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage_019beae7-6ccc-731a-bbf7-999e4ec5b59b" xlink:href="abvx-20251231.xsd#abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:to="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage_019beae7-6ccc-731a-bbf7-999e4ec5b59b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfFreeSharesPlansIssued_019beae7-6ccc-726f-93b1-2c039ca9687c" xlink:href="abvx-20251231.xsd#abvx_NumberOfFreeSharesPlansIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:to="loc_abvx_NumberOfFreeSharesPlansIssued_019beae7-6ccc-726f-93b1-2c039ca9687c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SharePrice1_019beae9-0f2a-7f6d-ba93-f956cc92553b" xlink:href="abvx-20251231.xsd#abvx_SharePrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:to="loc_abvx_SharePrice1_019beae9-0f2a-7f6d-ba93-f956cc92553b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_019beae9-d416-7e0c-9018-d43e5dd65a71" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:to="loc_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_019beae9-d416-7e0c-9018-d43e5dd65a71" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IssueOfEquityOfferingPricePerShare_019beae9-f264-77df-ba76-a04a73f703b1" xlink:href="abvx-20251231.xsd#abvx_IssueOfEquityOfferingPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:to="loc_abvx_IssueOfEquityOfferingPricePerShare_019beae9-f264-77df-ba76-a04a73f703b1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate_019beae9-f264-7b75-a9f6-cc32ec1cf61d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClosingForeignExchangeRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:to="loc_ifrs-full_ClosingForeignExchangeRate_019beae9-f264-7b75-a9f6-cc32ec1cf61d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_019beae9-f264-7e53-8306-72dda9862dee" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_019beae9-f264-7e53-8306-72dda9862dee" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NetProceedsFromIssueOfOrdinaryShares_019beae9-f264-78f3-b9cd-b6618fd09ce2" xlink:href="abvx-20251231.xsd#abvx_NetProceedsFromIssueOfOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:to="loc_abvx_NetProceedsFromIssueOfOrdinaryShares_019beae9-f264-78f3-b9cd-b6618fd09ce2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingOtherEquityInstruments_019beae9-f264-7c52-ac40-d6241b5e91e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssuingOtherEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:to="loc_ifrs-full_ProceedsFromIssuingOtherEquityInstruments_019beae9-f264-7c52-ac40-d6241b5e91e8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfConvertibleNotesConverted_019beae9-d416-7ba4-97d7-6cc889342499" xlink:href="abvx-20251231.xsd#abvx_NumberOfConvertibleNotesConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:to="loc_abvx_NumberOfConvertibleNotesConverted_019beae9-d416-7ba4-97d7-6cc889342499" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_019beae9-d416-7008-a8e9-02a31311f8d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:to="loc_ifrs-full_NotionalAmount_019beae9-d416-7008-a8e9-02a31311f8d0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsFixedConversionPrice_019beae9-d416-7539-a8fd-7b723075c344" xlink:href="abvx-20251231.xsd#abvx_BorrowingsFixedConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:to="loc_abvx_BorrowingsFixedConversionPrice_019beae9-d416-7539-a8fd-7b723075c344" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_019c434f-4789-7cd8-8089-4fd76d189379" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:to="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_019c434f-4789-7cd8-8089-4fd76d189379" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019cc310-7e3e-732d-9556-fdae2a74f98b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019cc310-7e3e-7fa3-99c2-f893b022fa45" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019cc310-7e3e-732d-9556-fdae2a74f98b" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019cc310-7e3e-7fa3-99c2-f893b022fa45" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_019cc310-7e3e-75be-a2fd-6c43d009b905" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019cc310-7e3e-7fa3-99c2-f893b022fa45" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_019cc310-7e3e-75be-a2fd-6c43d009b905" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_019cc310-7e3e-75be-a2fd-6c43d009b905_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_019cc310-7e3e-75be-a2fd-6c43d009b905" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_019cc310-7e3e-75be-a2fd-6c43d009b905_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_019cc310-7e3e-7831-9c77-e4dc45955268" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_019cc310-7e3e-75be-a2fd-6c43d009b905" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_019cc310-7e3e-7831-9c77-e4dc45955268" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_MajorShareBasedTransactionsMember_019cc310-7e3e-7fcc-a08c-9776db2751e1" xlink:href="abvx-20251231.xsd#abvx_MajorShareBasedTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_019cc310-7e3e-7831-9c77-e4dc45955268" xlink:to="loc_abvx_MajorShareBasedTransactionsMember_019cc310-7e3e-7fcc-a08c-9776db2751e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CSOSettlementAgreementMember_019cf67d-61f0-7afa-aa51-54e74e204290" xlink:href="abvx-20251231.xsd#abvx_CSOSettlementAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_019cc310-7e3e-7831-9c77-e4dc45955268" xlink:to="loc_abvx_CSOSettlementAgreementMember_019cf67d-61f0-7afa-aa51-54e74e204290" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019cc310-7e3e-7e57-822a-268a31b83ac6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019cc310-7e3e-7fa3-99c2-f893b022fa45" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019cc310-7e3e-7e57-822a-268a31b83ac6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019cc310-7e3e-7e57-822a-268a31b83ac6_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019cc310-7e3e-7e57-822a-268a31b83ac6" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019cc310-7e3e-7e57-822a-268a31b83ac6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019cc310-7e3e-7a7f-a7df-4a3a7e02ace7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019cc310-7e3e-7e57-822a-268a31b83ac6" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019cc310-7e3e-7a7f-a7df-4a3a7e02ace7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FreeSharesAGAMember_019cc311-13dd-7262-a8bd-33d9223aa097" xlink:href="abvx-20251231.xsd#abvx_FreeSharesAGAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019cc310-7e3e-7a7f-a7df-4a3a7e02ace7" xlink:to="loc_abvx_FreeSharesAGAMember_019cc311-13dd-7262-a8bd-33d9223aa097" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ShareSubscriptionWarrantsBSAMember_019cfbac-e289-7246-a765-ceab850e49c7" xlink:href="abvx-20251231.xsd#abvx_ShareSubscriptionWarrantsBSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019cc310-7e3e-7a7f-a7df-4a3a7e02ace7" xlink:to="loc_abvx_ShareSubscriptionWarrantsBSAMember_019cfbac-e289-7246-a765-ceab850e49c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesAxis_019cc310-7e3e-79c4-970b-b8c4fab8a7e2" xlink:href="abvx-20251231.xsd#abvx_TranchesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019cc310-7e3e-7fa3-99c2-f893b022fa45" xlink:to="loc_abvx_TranchesAxis_019cc310-7e3e-79c4-970b-b8c4fab8a7e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesDomain_019cc310-7e3e-79c4-970b-b8c4fab8a7e2_default" xlink:href="abvx-20251231.xsd#abvx_TranchesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_abvx_TranchesAxis_019cc310-7e3e-79c4-970b-b8c4fab8a7e2" xlink:to="loc_abvx_TranchesDomain_019cc310-7e3e-79c4-970b-b8c4fab8a7e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesDomain_019cc310-7e3e-7ba1-9bdd-7fe3cf8977d7" xlink:href="abvx-20251231.xsd#abvx_TranchesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_abvx_TranchesAxis_019cc310-7e3e-79c4-970b-b8c4fab8a7e2" xlink:to="loc_abvx_TranchesDomain_019cc310-7e3e-7ba1-9bdd-7fe3cf8977d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheOneMember_019cc310-7e3e-7c17-ae22-024a7b8a6722" xlink:href="abvx-20251231.xsd#abvx_TrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_TranchesDomain_019cc310-7e3e-7ba1-9bdd-7fe3cf8977d7" xlink:to="loc_abvx_TrancheOneMember_019cc310-7e3e-7c17-ae22-024a7b8a6722" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheTwoMember_019cc310-7e3e-71db-966a-1b4eed96bdf8" xlink:href="abvx-20251231.xsd#abvx_TrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_TranchesDomain_019cc310-7e3e-7ba1-9bdd-7fe3cf8977d7" xlink:to="loc_abvx_TrancheTwoMember_019cc310-7e3e-71db-966a-1b4eed96bdf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheThreeMember_019cc310-7e3e-7e20-8304-6ec61f0a64c7" xlink:href="abvx-20251231.xsd#abvx_TrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_TranchesDomain_019cc310-7e3e-7ba1-9bdd-7fe3cf8977d7" xlink:to="loc_abvx_TrancheThreeMember_019cc310-7e3e-7e20-8304-6ec61f0a64c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_019cfbad-625a-742f-9a0b-aace8ce1ae5d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019cc310-7e3e-7fa3-99c2-f893b022fa45" xlink:to="loc_srt_TitleOfIndividualAxis_019cfbad-625a-742f-9a0b-aace8ce1ae5d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019cfbad-625a-742f-9a0b-aace8ce1ae5d_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_019cfbad-625a-742f-9a0b-aace8ce1ae5d" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019cfbad-625a-742f-9a0b-aace8ce1ae5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019cfbad-625a-7c94-b2de-94355fb80ccb" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_019cfbad-625a-742f-9a0b-aace8ce1ae5d" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019cfbad-625a-7c94-b2de-94355fb80ccb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BoardMemberMember_019cfbad-625a-7984-ba13-57d9adde4a01" xlink:href="abvx-20251231.xsd#abvx_BoardMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019cfbad-625a-7c94-b2de-94355fb80ccb" xlink:to="loc_abvx_BoardMemberMember_019cfbad-625a-7984-ba13-57d9adde4a01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_019cc310-7e3e-719d-a9c7-6a8d629f6630" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019cc310-7e3e-732d-9556-fdae2a74f98b" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_019cc310-7e3e-719d-a9c7-6a8d629f6630" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage_019cc310-7e3e-7140-a5c2-96c572e08186" xlink:href="abvx-20251231.xsd#abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019cc310-7e3e-732d-9556-fdae2a74f98b" xlink:to="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage_019cc310-7e3e-7140-a5c2-96c572e08186" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_019cc310-7e3e-7f77-83f3-b8ce3e0220cd" xlink:href="abvx-20251231.xsd#abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019cc310-7e3e-732d-9556-fdae2a74f98b" xlink:to="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_019cc310-7e3e-7f77-83f3-b8ce3e0220cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_019cf692-b2c9-788f-9afd-70706d534515" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019cc310-7e3e-732d-9556-fdae2a74f98b" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_019cf692-b2c9-788f-9afd-70706d534515" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KeyManagementPersonnelCompensationContractualSeveranceIndemnity_019cf693-fc6e-7752-a36b-9462fa231094" xlink:href="abvx-20251231.xsd#abvx_KeyManagementPersonnelCompensationContractualSeveranceIndemnity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019cc310-7e3e-732d-9556-fdae2a74f98b" xlink:to="loc_abvx_KeyManagementPersonnelCompensationContractualSeveranceIndemnity_019cf693-fc6e-7752-a36b-9462fa231094" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfSharesWaived_019cf6b6-35b3-77f4-88cd-83527ac778c4" xlink:href="abvx-20251231.xsd#abvx_NumberOfSharesWaived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019cc310-7e3e-732d-9556-fdae2a74f98b" xlink:to="loc_abvx_NumberOfSharesWaived_019cf6b6-35b3-77f4-88cd-83527ac778c4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfSharesWithPerformanceConditionsWaived_019cf6b7-2230-7d0c-9761-7eb5fb6494bd" xlink:href="abvx-20251231.xsd#abvx_NumberOfSharesWithPerformanceConditionsWaived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019cc310-7e3e-732d-9556-fdae2a74f98b" xlink:to="loc_abvx_NumberOfSharesWithPerformanceConditionsWaived_019cf6b7-2230-7d0c-9761-7eb5fb6494bd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfSharesLapsed_019cf6b9-29dd-7f86-baef-2520c7ddc7c0" xlink:href="abvx-20251231.xsd#abvx_NumberOfSharesLapsed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019cc310-7e3e-732d-9556-fdae2a74f98b" xlink:to="loc_abvx_NumberOfSharesLapsed_019cf6b9-29dd-7f86-baef-2520c7ddc7c0" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/AccountingprinciplesIntangibleassetsDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#AccountingprinciplesIntangibleassetsDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/AccountingprinciplesIntangibleassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_e064fabd-e523-4374-848b-4f9a0a9a7e73" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_6c5d5940-be46-40bd-b86d-70d08e719a8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_e064fabd-e523-4374-848b-4f9a0a9a7e73" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_6c5d5940-be46-40bd-b86d-70d08e719a8b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_9b41661c-896a-4fbf-99f0-faa541b6185f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_6c5d5940-be46-40bd-b86d-70d08e719a8b" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_9b41661c-896a-4fbf-99f0-faa541b6185f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_9b41661c-896a-4fbf-99f0-faa541b6185f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_9b41661c-896a-4fbf-99f0-faa541b6185f" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_9b41661c-896a-4fbf-99f0-faa541b6185f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_2defbb06-2e9a-4199-b517-7a5cb73b2f3d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_9b41661c-896a-4fbf-99f0-faa541b6185f" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_2defbb06-2e9a-4199-b517-7a5cb73b2f3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIntangibleAssetsMember_77d96577-9a77-441b-bef6-a41c9cc50170" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_2defbb06-2e9a-4199-b517-7a5cb73b2f3d" xlink:to="loc_ifrs-full_OtherIntangibleAssetsMember_77d96577-9a77-441b-bef6-a41c9cc50170" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ResearchAndDevelopmentCostsRecognitionInitialMeasurementNumberOfCriterias_3b9228f6-ab28-441d-b3d2-1232041967d4" xlink:href="abvx-20251231.xsd#abvx_ResearchAndDevelopmentCostsRecognitionInitialMeasurementNumberOfCriterias"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_e064fabd-e523-4374-848b-4f9a0a9a7e73" xlink:to="loc_abvx_ResearchAndDevelopmentCostsRecognitionInitialMeasurementNumberOfCriterias_3b9228f6-ab28-441d-b3d2-1232041967d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_23283892-3cc7-4657-8468-5ebc839797ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_e064fabd-e523-4374-848b-4f9a0a9a7e73" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_23283892-3cc7-4657-8468-5ebc839797ab" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_9a14ee8e-0c9b-4c76-9b2e-9ec7e7f2e32c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_a9711434-40d6-4c3f-b0d1-1bd63fae70a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_9a14ee8e-0c9b-4c76-9b2e-9ec7e7f2e32c" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_a9711434-40d6-4c3f-b0d1-1bd63fae70a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_99e7c1c8-10db-4252-9a21-6fba0d752284" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_a9711434-40d6-4c3f-b0d1-1bd63fae70a5" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_99e7c1c8-10db-4252-9a21-6fba0d752284" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_99e7c1c8-10db-4252-9a21-6fba0d752284_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_99e7c1c8-10db-4252-9a21-6fba0d752284" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_99e7c1c8-10db-4252-9a21-6fba0d752284_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_8ec3e1c6-7dc2-4567-848b-e61f35835d4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_99e7c1c8-10db-4252-9a21-6fba0d752284" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_8ec3e1c6-7dc2-4567-848b-e61f35835d4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixturesAndFittingsMember_db567e9a-93d9-4447-980c-9f6845cd9196" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FixturesAndFittingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_8ec3e1c6-7dc2-4567-848b-e61f35835d4d" xlink:to="loc_ifrs-full_FixturesAndFittingsMember_db567e9a-93d9-4447-980c-9f6845cd9196" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IndustrialMaterialsAndEquipmentMember_720e5de2-db2d-4f63-9d17-c51cbe140000" xlink:href="abvx-20251231.xsd#abvx_IndustrialMaterialsAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_8ec3e1c6-7dc2-4567-848b-e61f35835d4d" xlink:to="loc_abvx_IndustrialMaterialsAndEquipmentMember_720e5de2-db2d-4f63-9d17-c51cbe140000" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TechnicalFacilitiesMember_b60907f4-b276-4ca7-afaf-1394bebe1dca" xlink:href="abvx-20251231.xsd#abvx_TechnicalFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_8ec3e1c6-7dc2-4567-848b-e61f35835d4d" xlink:to="loc_abvx_TechnicalFacilitiesMember_b60907f4-b276-4ca7-afaf-1394bebe1dca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember_3624c457-131e-45fe-9e69-94b0c29f3ab4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_8ec3e1c6-7dc2-4567-848b-e61f35835d4d" xlink:to="loc_ifrs-full_OfficeEquipmentMember_3624c457-131e-45fe-9e69-94b0c29f3ab4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_2a80fcbd-f2e3-4302-9645-eb4862cc780d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_8ec3e1c6-7dc2-4567-848b-e61f35835d4d" xlink:to="loc_ifrs-full_ComputerEquipmentMember_2a80fcbd-f2e3-4302-9645-eb4862cc780d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FurnitureMember_1bf3218b-c756-42a0-adbb-14b56fc8d3f1" xlink:href="abvx-20251231.xsd#abvx_FurnitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_8ec3e1c6-7dc2-4567-848b-e61f35835d4d" xlink:to="loc_abvx_FurnitureMember_1bf3218b-c756-42a0-adbb-14b56fc8d3f1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_31015c94-1bc7-4bec-9346-61d21ecdf749" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_a9711434-40d6-4c3f-b0d1-1bd63fae70a5" xlink:to="loc_ifrs-full_RangeAxis_31015c94-1bc7-4bec-9346-61d21ecdf749" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_31015c94-1bc7-4bec-9346-61d21ecdf749_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_31015c94-1bc7-4bec-9346-61d21ecdf749" xlink:to="loc_ifrs-full_RangeDomain_31015c94-1bc7-4bec-9346-61d21ecdf749_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_a030bbfd-23ff-4837-8c8c-68754dfd5ce3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_31015c94-1bc7-4bec-9346-61d21ecdf749" xlink:to="loc_ifrs-full_RangeDomain_a030bbfd-23ff-4837-8c8c-68754dfd5ce3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_455d53a5-e8df-4434-9629-21bcdbd92cc1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_a030bbfd-23ff-4837-8c8c-68754dfd5ce3" xlink:to="loc_ifrs-full_BottomOfRangeMember_455d53a5-e8df-4434-9629-21bcdbd92cc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_39f9b38d-0d3e-46a3-8c44-f208e441f061" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_a030bbfd-23ff-4837-8c8c-68754dfd5ce3" xlink:to="loc_ifrs-full_TopOfRangeMember_39f9b38d-0d3e-46a3-8c44-f208e441f061" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_68c97c13-57c1-4fc1-a8d2-93773336f811" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_9a14ee8e-0c9b-4c76-9b2e-9ec7e7f2e32c" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_68c97c13-57c1-4fc1-a8d2-93773336f811" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/SegmentinformationDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#SegmentinformationDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/SegmentinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_f71c2eb6-4ae0-4e54-8129-85d92ab001f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable_0a68bcb0-f54b-457c-8750-4669cb8c581e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_f71c2eb6-4ae0-4e54-8129-85d92ab001f7" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasTable_0a68bcb0-f54b-457c-8750-4669cb8c581e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_75667292-e3e6-498d-9bc4-324be3ac294a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_0a68bcb0-f54b-457c-8750-4669cb8c581e" xlink:to="loc_ifrs-full_GeographicalAreasAxis_75667292-e3e6-498d-9bc4-324be3ac294a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_75667292-e3e6-498d-9bc4-324be3ac294a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_75667292-e3e6-498d-9bc4-324be3ac294a" xlink:to="loc_ifrs-full_GeographicalAreasDomain_75667292-e3e6-498d-9bc4-324be3ac294a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_ca416f49-4d64-4d0e-9b6e-f40273a0846c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_75667292-e3e6-498d-9bc4-324be3ac294a" xlink:to="loc_ifrs-full_GeographicalAreasDomain_ca416f49-4d64-4d0e-9b6e-f40273a0846c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_e11111b1-10fa-489e-bd42-c26e897edae8" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasDomain_ca416f49-4d64-4d0e-9b6e-f40273a0846c" xlink:to="loc_country_US_e11111b1-10fa-489e-bd42-c26e897edae8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_c71f8361-be41-44ff-ad70-a45f525d02e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_0a68bcb0-f54b-457c-8750-4669cb8c581e" xlink:to="loc_ifrs-full_RangeAxis_c71f8361-be41-44ff-ad70-a45f525d02e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_c71f8361-be41-44ff-ad70-a45f525d02e8_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_c71f8361-be41-44ff-ad70-a45f525d02e8" xlink:to="loc_ifrs-full_RangeDomain_c71f8361-be41-44ff-ad70-a45f525d02e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_97166769-1703-43e5-850b-6205a75a1d66" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_c71f8361-be41-44ff-ad70-a45f525d02e8" xlink:to="loc_ifrs-full_RangeDomain_97166769-1703-43e5-850b-6205a75a1d66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_bc73afa5-0da8-4ad1-a1e5-ca2cd877b941" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_97166769-1703-43e5-850b-6205a75a1d66" xlink:to="loc_ifrs-full_TopOfRangeMember_bc73afa5-0da8-4ad1-a1e5-ca2cd877b941" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ContributionToGroupsLiabilitiesPercentage_3d193556-f525-4c94-ba60-0a4634272b92" xlink:href="abvx-20251231.xsd#abvx_ContributionToGroupsLiabilitiesPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_f71c2eb6-4ae0-4e54-8129-85d92ab001f7" xlink:to="loc_abvx_ContributionToGroupsLiabilitiesPercentage_3d193556-f525-4c94-ba60-0a4634272b92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ContributionToGroupsNetProfitsLossesPercentage_c8ccff63-2288-406e-830b-f7b74e9a1b2f" xlink:href="abvx-20251231.xsd#abvx_ContributionToGroupsNetProfitsLossesPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_f71c2eb6-4ae0-4e54-8129-85d92ab001f7" xlink:to="loc_abvx_ContributionToGroupsNetProfitsLossesPercentage_c8ccff63-2288-406e-830b-f7b74e9a1b2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ContributionToGroupsAssetsPercentage_0b3a4e60-e7f6-4dfc-82b7-2ad76fc8d404" xlink:href="abvx-20251231.xsd#abvx_ContributionToGroupsAssetsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_f71c2eb6-4ae0-4e54-8129-85d92ab001f7" xlink:to="loc_abvx_ContributionToGroupsAssetsPercentage_0b3a4e60-e7f6-4dfc-82b7-2ad76fc8d404" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfOperatingSegment_3e08ce28-397d-4e72-9eef-02554cb14e0a" xlink:href="abvx-20251231.xsd#abvx_NumberOfOperatingSegment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_f71c2eb6-4ae0-4e54-8129-85d92ab001f7" xlink:to="loc_abvx_NumberOfOperatingSegment_3e08ce28-397d-4e72-9eef-02554cb14e0a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/GoodwillandimpairmenttestDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#GoodwillandimpairmenttestDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/GoodwillandimpairmenttestDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems_ad67da6e-dc15-452b-a71a-def6af7158fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesTable_7ce07f24-7153-4d8a-a356-fa579588be69" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems_ad67da6e-dc15-452b-a71a-def6af7158fa" xlink:to="loc_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesTable_7ce07f24-7153-4d8a-a356-fa579588be69" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis_291b2ca0-ac9f-462b-9ec4-d2e1dda6c0a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesTable_7ce07f24-7153-4d8a-a356-fa579588be69" xlink:to="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis_291b2ca0-ac9f-462b-9ec4-d2e1dda6c0a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain_291b2ca0-ac9f-462b-9ec4-d2e1dda6c0a3_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis_291b2ca0-ac9f-462b-9ec4-d2e1dda6c0a3" xlink:to="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain_291b2ca0-ac9f-462b-9ec4-d2e1dda6c0a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain_2c01f794-721a-4c46-95b1-ddc61f0e49b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis_291b2ca0-ac9f-462b-9ec4-d2e1dda6c0a3" xlink:to="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain_2c01f794-721a-4c46-95b1-ddc61f0e49b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_WittycelSASABX196Member_91b7cd22-5ee7-4a5b-be88-290e9cff83a9" xlink:href="abvx-20251231.xsd#abvx_WittycelSASABX196Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain_2c01f794-721a-4c46-95b1-ddc61f0e49b7" xlink:to="loc_abvx_WittycelSASABX196Member_91b7cd22-5ee7-4a5b-be88-290e9cff83a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SplicosSASABX464Member_cf042855-ca2c-47ea-924b-5c910a397ef5" xlink:href="abvx-20251231.xsd#abvx_SplicosSASABX464Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain_2c01f794-721a-4c46-95b1-ddc61f0e49b7" xlink:to="loc_abvx_SplicosSASABX464Member_cf042855-ca2c-47ea-924b-5c910a397ef5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill_29c6cfd4-bcd2-4d7a-9bbb-430de6fa6229" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems_ad67da6e-dc15-452b-a71a-def6af7158fa" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill_29c6cfd4-bcd2-4d7a-9bbb-430de6fa6229" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_390420e1-ebb5-403e-a5b6-7684ebfe94dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems_ad67da6e-dc15-452b-a71a-def6af7158fa" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_390420e1-ebb5-403e-a5b6-7684ebfe94dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_61668205-f84a-4d2f-9d5b-4d6e491cd8e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems_ad67da6e-dc15-452b-a71a-def6af7158fa" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_61668205-f84a-4d2f-9d5b-4d6e491cd8e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_18ca5e2f-5e26-4846-83e7-3dbbf4ff037a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems_ad67da6e-dc15-452b-a71a-def6af7158fa" xlink:to="loc_ifrs-full_Goodwill_18ca5e2f-5e26-4846-83e7-3dbbf4ff037a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections_d9a131eb-661c-401e-b05a-bbea18c85042" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems_ad67da6e-dc15-452b-a71a-def6af7158fa" xlink:to="loc_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections_d9a131eb-661c-401e-b05a-bbea18c85042" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/IntangibleassetsNarrativeDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#IntangibleassetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/IntangibleassetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_c34c5875-f0c5-410c-b869-f38dbd456720" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_45262169-2d94-4001-bcb2-4dc85757dc4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_c34c5875-f0c5-410c-b869-f38dbd456720" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_45262169-2d94-4001-bcb2-4dc85757dc4f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis_395b4aea-6b13-4e2e-906a-b3d771928bf9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_45262169-2d94-4001-bcb2-4dc85757dc4f" xlink:to="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis_395b4aea-6b13-4e2e-906a-b3d771928bf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain_395b4aea-6b13-4e2e-906a-b3d771928bf9_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis_395b4aea-6b13-4e2e-906a-b3d771928bf9" xlink:to="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain_395b4aea-6b13-4e2e-906a-b3d771928bf9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain_81cd9d1a-ec6c-4bda-a7ea-4dc16a59ab46" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis_395b4aea-6b13-4e2e-906a-b3d771928bf9" xlink:to="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain_81cd9d1a-ec6c-4bda-a7ea-4dc16a59ab46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_WittycelSASABX196Member_96049b93-2ddc-478c-a8b8-eea114c3dc0a" xlink:href="abvx-20251231.xsd#abvx_WittycelSASABX196Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain_81cd9d1a-ec6c-4bda-a7ea-4dc16a59ab46" xlink:to="loc_abvx_WittycelSASABX196Member_96049b93-2ddc-478c-a8b8-eea114c3dc0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PrincipalAgreementsAxis_0290f461-e78b-4104-8909-29cf81e34b10" xlink:href="abvx-20251231.xsd#abvx_PrincipalAgreementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_45262169-2d94-4001-bcb2-4dc85757dc4f" xlink:to="loc_abvx_PrincipalAgreementsAxis_0290f461-e78b-4104-8909-29cf81e34b10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PrincipalAgreementsDomain_0290f461-e78b-4104-8909-29cf81e34b10_default" xlink:href="abvx-20251231.xsd#abvx_PrincipalAgreementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_abvx_PrincipalAgreementsAxis_0290f461-e78b-4104-8909-29cf81e34b10" xlink:to="loc_abvx_PrincipalAgreementsDomain_0290f461-e78b-4104-8909-29cf81e34b10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PrincipalAgreementsDomain_ffd8649a-8948-41dc-a0d5-6958057aa0f4" xlink:href="abvx-20251231.xsd#abvx_PrincipalAgreementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_abvx_PrincipalAgreementsAxis_0290f461-e78b-4104-8909-29cf81e34b10" xlink:to="loc_abvx_PrincipalAgreementsDomain_ffd8649a-8948-41dc-a0d5-6958057aa0f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember_90fca1cd-a9e5-4082-8adb-4d056e106d40" xlink:href="abvx-20251231.xsd#abvx_ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_PrincipalAgreementsDomain_ffd8649a-8948-41dc-a0d5-6958057aa0f4" xlink:to="loc_abvx_ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember_90fca1cd-a9e5-4082-8adb-4d056e106d40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember_fddab8b1-338c-4372-a1f1-1dd4580e7ff7" xlink:href="abvx-20251231.xsd#abvx_ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_PrincipalAgreementsDomain_ffd8649a-8948-41dc-a0d5-6958057aa0f4" xlink:to="loc_abvx_ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember_fddab8b1-338c-4372-a1f1-1dd4580e7ff7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AssetsAcquisitionsAxis_5e9b01eb-45f8-4afd-8cae-43c85efa5a19" xlink:href="abvx-20251231.xsd#abvx_AssetsAcquisitionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_45262169-2d94-4001-bcb2-4dc85757dc4f" xlink:to="loc_abvx_AssetsAcquisitionsAxis_5e9b01eb-45f8-4afd-8cae-43c85efa5a19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AssetsAcquisitionsDomain_5e9b01eb-45f8-4afd-8cae-43c85efa5a19_default" xlink:href="abvx-20251231.xsd#abvx_AssetsAcquisitionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_abvx_AssetsAcquisitionsAxis_5e9b01eb-45f8-4afd-8cae-43c85efa5a19" xlink:to="loc_abvx_AssetsAcquisitionsDomain_5e9b01eb-45f8-4afd-8cae-43c85efa5a19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AssetsAcquisitionsDomain_726b1c97-3830-410b-a88b-3f6ebc2087ee" xlink:href="abvx-20251231.xsd#abvx_AssetsAcquisitionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_abvx_AssetsAcquisitionsAxis_5e9b01eb-45f8-4afd-8cae-43c85efa5a19" xlink:to="loc_abvx_AssetsAcquisitionsDomain_726b1c97-3830-410b-a88b-3f6ebc2087ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ProsynergiaMember_100463fc-1573-4373-bbe2-4cec7c5484c0" xlink:href="abvx-20251231.xsd#abvx_ProsynergiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_AssetsAcquisitionsDomain_726b1c97-3830-410b-a88b-3f6ebc2087ee" xlink:to="loc_abvx_ProsynergiaMember_100463fc-1573-4373-bbe2-4cec7c5484c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CollaborationAgreementsDevelopmentMilestonePaymentINDApproval_ffbc8671-5dce-47f4-91df-3412c3949170" xlink:href="abvx-20251231.xsd#abvx_CollaborationAgreementsDevelopmentMilestonePaymentINDApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_c34c5875-f0c5-410c-b869-f38dbd456720" xlink:to="loc_abvx_CollaborationAgreementsDevelopmentMilestonePaymentINDApproval_ffbc8671-5dce-47f4-91df-3412c3949170" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife_d53f55ea-d771-4bb0-8ce5-7490b101be20" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_c34c5875-f0c5-410c-b869-f38dbd456720" xlink:to="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife_d53f55ea-d771-4bb0-8ce5-7490b101be20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_8eafd51c-14c8-4b28-9ddd-568f2a51f9a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_c34c5875-f0c5-410c-b869-f38dbd456720" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_8eafd51c-14c8-4b28-9ddd-568f2a51f9a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CollaborationAgreementsDevelopmentMilestonePaymentPhase2_a5e433a1-1a87-4429-bf48-813281cc84e4" xlink:href="abvx-20251231.xsd#abvx_CollaborationAgreementsDevelopmentMilestonePaymentPhase2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_c34c5875-f0c5-410c-b869-f38dbd456720" xlink:to="loc_abvx_CollaborationAgreementsDevelopmentMilestonePaymentPhase2_a5e433a1-1a87-4429-bf48-813281cc84e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TechnologyBasedIntangibleAssetsAssetsAcquisitions_0c95c135-aca9-432f-a6d6-7ca4cde97a46" xlink:href="abvx-20251231.xsd#abvx_TechnologyBasedIntangibleAssetsAssetsAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_c34c5875-f0c5-410c-b869-f38dbd456720" xlink:to="loc_abvx_TechnologyBasedIntangibleAssetsAssetsAcquisitions_0c95c135-aca9-432f-a6d6-7ca4cde97a46" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_2b328002-ff56-48ff-820b-14f1cf8ea1b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_9dddb4ec-a016-4402-85bd-fbd0e40d9355" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_2b328002-ff56-48ff-820b-14f1cf8ea1b3" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_9dddb4ec-a016-4402-85bd-fbd0e40d9355" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_58ecf613-e94d-4ef1-99ff-ca1477076fac" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_9dddb4ec-a016-4402-85bd-fbd0e40d9355" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_58ecf613-e94d-4ef1-99ff-ca1477076fac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_58ecf613-e94d-4ef1-99ff-ca1477076fac_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_58ecf613-e94d-4ef1-99ff-ca1477076fac" xlink:to="loc_ifrs-full_CarryingAmountMember_58ecf613-e94d-4ef1-99ff-ca1477076fac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_256e4d0c-8163-417f-91fd-5cc8ca23359b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_58ecf613-e94d-4ef1-99ff-ca1477076fac" xlink:to="loc_ifrs-full_CarryingAmountMember_256e4d0c-8163-417f-91fd-5cc8ca23359b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_b0256efb-6ae9-4283-bdb1-41623c290b0c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_256e4d0c-8163-417f-91fd-5cc8ca23359b" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_b0256efb-6ae9-4283-bdb1-41623c290b0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_8ba98db0-db2d-4e0f-b67b-c8ca07a760da" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_256e4d0c-8163-417f-91fd-5cc8ca23359b" xlink:to="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_8ba98db0-db2d-4e0f-b67b-c8ca07a760da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_ee3d7914-6651-4f24-ac0b-1cf4a7c2a8f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_9dddb4ec-a016-4402-85bd-fbd0e40d9355" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_ee3d7914-6651-4f24-ac0b-1cf4a7c2a8f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_ee3d7914-6651-4f24-ac0b-1cf4a7c2a8f7_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_ee3d7914-6651-4f24-ac0b-1cf4a7c2a8f7" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_ee3d7914-6651-4f24-ac0b-1cf4a7c2a8f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_013f4f13-c0e7-4563-be7e-ac0c80d6eb71" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_ee3d7914-6651-4f24-ac0b-1cf4a7c2a8f7" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_013f4f13-c0e7-4563-be7e-ac0c80d6eb71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LicencesMember_428fd6b0-0733-4a24-8c84-cc57897cada2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LicencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_013f4f13-c0e7-4563-be7e-ac0c80d6eb71" xlink:to="loc_ifrs-full_LicencesMember_428fd6b0-0733-4a24-8c84-cc57897cada2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember_a8e76dc5-4d1d-4ce6-90d3-1bf3f809c9b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_013f4f13-c0e7-4563-be7e-ac0c80d6eb71" xlink:to="loc_ifrs-full_ComputerSoftwareMember_a8e76dc5-4d1d-4ce6-90d3-1bf3f809c9b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_d6755779-c8a6-4f8f-8973-305fcfbe73f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_013f4f13-c0e7-4563-be7e-ac0c80d6eb71" xlink:to="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_d6755779-c8a6-4f8f-8973-305fcfbe73f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_9216e72d-1f7c-4454-af69-a3b14d63be1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_2b328002-ff56-48ff-820b-14f1cf8ea1b3" xlink:to="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_9216e72d-1f7c-4454-af69-a3b14d63be1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_e2a0cdb9-214b-4be3-bff4-07a1fdefa283" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_9216e72d-1f7c-4454-af69-a3b14d63be1d" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_e2a0cdb9-214b-4be3-bff4-07a1fdefa283" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_2bf9776c-efb7-41f6-a143-cf3a501c82a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_9216e72d-1f7c-4454-af69-a3b14d63be1d" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_2bf9776c-efb7-41f6-a143-cf3a501c82a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_94b8b45f-e34e-4f4b-a5e8-a6569347cdd9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_9216e72d-1f7c-4454-af69-a3b14d63be1d" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_94b8b45f-e34e-4f4b-a5e8-a6569347cdd9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_72fc40f6-6d80-4d83-86a3-133023fa630c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_7152fb62-7ec2-44c5-a7f7-0aacfe877d3f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_4a773fee-a2bb-4eb8-8a4e-73054c5f62d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_7152fb62-7ec2-44c5-a7f7-0aacfe877d3f" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_4a773fee-a2bb-4eb8-8a4e-73054c5f62d2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fc04495c-5dad-4a83-bc92-d04ee0d96365" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_4a773fee-a2bb-4eb8-8a4e-73054c5f62d2" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fc04495c-5dad-4a83-bc92-d04ee0d96365" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_fc04495c-5dad-4a83-bc92-d04ee0d96365_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fc04495c-5dad-4a83-bc92-d04ee0d96365" xlink:to="loc_ifrs-full_CarryingAmountMember_fc04495c-5dad-4a83-bc92-d04ee0d96365_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_edd4f8cf-d5e4-466f-b12c-2d3225384740" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fc04495c-5dad-4a83-bc92-d04ee0d96365" xlink:to="loc_ifrs-full_CarryingAmountMember_edd4f8cf-d5e4-466f-b12c-2d3225384740" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_13e98174-83a8-45e9-9657-49e52b508a99" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_edd4f8cf-d5e4-466f-b12c-2d3225384740" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_13e98174-83a8-45e9-9657-49e52b508a99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_71b6b4e4-86a2-48a8-95f9-0a0804bb61e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_edd4f8cf-d5e4-466f-b12c-2d3225384740" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_71b6b4e4-86a2-48a8-95f9-0a0804bb61e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_03fd40e3-8bb2-4904-81d7-ca4146cf5b5a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_4a773fee-a2bb-4eb8-8a4e-73054c5f62d2" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_03fd40e3-8bb2-4904-81d7-ca4146cf5b5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_03fd40e3-8bb2-4904-81d7-ca4146cf5b5a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_03fd40e3-8bb2-4904-81d7-ca4146cf5b5a" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_03fd40e3-8bb2-4904-81d7-ca4146cf5b5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_0ae40ba1-1397-48a5-9957-8d9f6241106a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_03fd40e3-8bb2-4904-81d7-ca4146cf5b5a" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_0ae40ba1-1397-48a5-9957-8d9f6241106a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BuildingsMember_1c5bd328-8425-443d-95fa-df76e3ce57ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BuildingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_0ae40ba1-1397-48a5-9957-8d9f6241106a" xlink:to="loc_ifrs-full_BuildingsMember_1c5bd328-8425-443d-95fa-df76e3ce57ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember_019bf9cc-506f-72d9-a9fa-f2872638d9b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_0ae40ba1-1397-48a5-9957-8d9f6241106a" xlink:to="loc_ifrs-full_OfficeEquipmentMember_019bf9cc-506f-72d9-a9fa-f2872638d9b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FurnitureAndComputerEquipmentMember_59c71fef-fb02-4bfd-86bb-ce3f2b0ec6b5" xlink:href="abvx-20251231.xsd#abvx_FurnitureAndComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_0ae40ba1-1397-48a5-9957-8d9f6241106a" xlink:to="loc_abvx_FurnitureAndComputerEquipmentMember_59c71fef-fb02-4bfd-86bb-ce3f2b0ec6b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis_4d42dd46-ce68-46a1-85f0-85b34701623e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_4a773fee-a2bb-4eb8-8a4e-73054c5f62d2" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis_4d42dd46-ce68-46a1-85f0-85b34701623e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain_4d42dd46-ce68-46a1-85f0-85b34701623e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis_4d42dd46-ce68-46a1-85f0-85b34701623e" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain_4d42dd46-ce68-46a1-85f0-85b34701623e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain_5c73695b-b942-4b6d-a62c-b4ca3d380771" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis_4d42dd46-ce68-46a1-85f0-85b34701623e" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain_5c73695b-b942-4b6d-a62c-b4ca3d380771" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_019bf9cf-a8a5-755f-99bf-38d49debd4c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain_5c73695b-b942-4b6d-a62c-b4ca3d380771" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_019bf9cf-a8a5-755f-99bf-38d49debd4c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssetsMember_dbc0249b-d617-4f78-8505-f959a384a0c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RightofuseAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain_5c73695b-b942-4b6d-a62c-b4ca3d380771" xlink:to="loc_ifrs-full_RightofuseAssetsMember_dbc0249b-d617-4f78-8505-f959a384a0c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_41788080-0be5-413d-b967-609226b88b2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_7152fb62-7ec2-44c5-a7f7-0aacfe877d3f" xlink:to="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_41788080-0be5-413d-b967-609226b88b2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_f6c16bb2-e86c-432d-a8f0-6d9763b844fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_41788080-0be5-413d-b967-609226b88b2f" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_f6c16bb2-e86c-432d-a8f0-6d9763b844fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets_e36731a8-afc8-4c15-b8d3-d778db8fe1ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_41788080-0be5-413d-b967-609226b88b2f" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets_e36731a8-afc8-4c15-b8d3-d778db8fe1ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets_d1099089-5263-4b32-8e02-9f8d3c262827" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_41788080-0be5-413d-b967-609226b88b2f" xlink:to="loc_ifrs-full_DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets_d1099089-5263-4b32-8e02-9f8d3c262827" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets_bb9c32d2-c390-4f3a-ac91-2cf6a45b8aea" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_41788080-0be5-413d-b967-609226b88b2f" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets_bb9c32d2-c390-4f3a-ac91-2cf6a45b8aea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets_5b780b77-defb-4387-847e-208f359b7c7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_41788080-0be5-413d-b967-609226b88b2f" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets_5b780b77-defb-4387-847e-208f359b7c7a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_eeeed366-6400-4baa-907a-2838807d2be7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#PropertyplantandequipmentNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_35a4ee22-cbe8-47f3-a69f-d7931ad28cc0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_08aee887-2ab3-4357-b034-3f2bdecf5feb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_35a4ee22-cbe8-47f3-a69f-d7931ad28cc0" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_08aee887-2ab3-4357-b034-3f2bdecf5feb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_daf30111-89c6-4824-a6af-498c8b0c2bb0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_08aee887-2ab3-4357-b034-3f2bdecf5feb" xlink:to="loc_ifrs-full_TypesOfContractsAxis_daf30111-89c6-4824-a6af-498c8b0c2bb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_daf30111-89c6-4824-a6af-498c8b0c2bb0_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfContractsAxis_daf30111-89c6-4824-a6af-498c8b0c2bb0" xlink:to="loc_ifrs-full_TypesOfContractsDomain_daf30111-89c6-4824-a6af-498c8b0c2bb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_88778690-4275-4314-b1a9-be9238e60c25" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfContractsAxis_daf30111-89c6-4824-a6af-498c8b0c2bb0" xlink:to="loc_ifrs-full_TypesOfContractsDomain_88778690-4275-4314-b1a9-be9238e60c25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LeaseFacilitiesParisMember_114f8aff-80ac-4470-899f-fb9bebdd3da9" xlink:href="abvx-20251231.xsd#abvx_LeaseFacilitiesParisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsDomain_88778690-4275-4314-b1a9-be9238e60c25" xlink:to="loc_abvx_LeaseFacilitiesParisMember_114f8aff-80ac-4470-899f-fb9bebdd3da9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_566b6da6-2bf9-4383-8f73-d4f3862922e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_08aee887-2ab3-4357-b034-3f2bdecf5feb" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_566b6da6-2bf9-4383-8f73-d4f3862922e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_566b6da6-2bf9-4383-8f73-d4f3862922e4_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_566b6da6-2bf9-4383-8f73-d4f3862922e4" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_566b6da6-2bf9-4383-8f73-d4f3862922e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_752cadfa-34a6-4f76-9d43-3aedc2cc6b6b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_566b6da6-2bf9-4383-8f73-d4f3862922e4" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_752cadfa-34a6-4f76-9d43-3aedc2cc6b6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BuildingsMember_f99aaf2b-64db-4855-bb50-6efddde1b200" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BuildingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_752cadfa-34a6-4f76-9d43-3aedc2cc6b6b" xlink:to="loc_ifrs-full_BuildingsMember_f99aaf2b-64db-4855-bb50-6efddde1b200" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_8126817a-e5ac-4aea-9942-1752729e2ba7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_35a4ee22-cbe8-47f3-a69f-d7931ad28cc0" xlink:to="loc_ifrs-full_RightofuseAssets_8126817a-e5ac-4aea-9942-1752729e2ba7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DecreaseThroughReassessmentOfLeaseTermRightOfUseAssets_cdfabcc5-8f86-4974-a7e7-fc4b5ca8e57c" xlink:href="abvx-20251231.xsd#abvx_DecreaseThroughReassessmentOfLeaseTermRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_35a4ee22-cbe8-47f3-a69f-d7931ad28cc0" xlink:to="loc_abvx_DecreaseThroughReassessmentOfLeaseTermRightOfUseAssets_cdfabcc5-8f86-4974-a7e7-fc4b5ca8e57c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#OtherfinancialassetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_0cc33eb0-c14a-43bd-b056-8af83102661f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsTable_69b1b92c-7f1d-4521-bb64-5a1d0d5010fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_0cc33eb0-c14a-43bd-b056-8af83102661f" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsTable_69b1b92c-7f1d-4521-bb64-5a1d0d5010fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_5f9b5b2b-d1f7-468c-be6b-c4ea4684b74b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_69b1b92c-7f1d-4521-bb64-5a1d0d5010fe" xlink:to="loc_ifrs-full_RangeAxis_5f9b5b2b-d1f7-468c-be6b-c4ea4684b74b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_5f9b5b2b-d1f7-468c-be6b-c4ea4684b74b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_5f9b5b2b-d1f7-468c-be6b-c4ea4684b74b" xlink:to="loc_ifrs-full_RangeDomain_5f9b5b2b-d1f7-468c-be6b-c4ea4684b74b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_b2e4cb60-6f1e-42a5-88fb-5031c364b9b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_5f9b5b2b-d1f7-468c-be6b-c4ea4684b74b" xlink:to="loc_ifrs-full_RangeDomain_b2e4cb60-6f1e-42a5-88fb-5031c364b9b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_cba50796-5cf0-4466-aca7-e67d78555d93" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_b2e4cb60-6f1e-42a5-88fb-5031c364b9b3" xlink:to="loc_ifrs-full_BottomOfRangeMember_cba50796-5cf0-4466-aca7-e67d78555d93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_a65283db-6d71-4512-9a92-181696bba450" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_b2e4cb60-6f1e-42a5-88fb-5031c364b9b3" xlink:to="loc_ifrs-full_TopOfRangeMember_a65283db-6d71-4512-9a92-181696bba450" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NonCurrentAdvancesToCROContractsUndiscountedAmount_019c524e-b46b-78c9-b595-00fa1e57fdea" xlink:href="abvx-20251231.xsd#abvx_NonCurrentAdvancesToCROContractsUndiscountedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_0cc33eb0-c14a-43bd-b056-8af83102661f" xlink:to="loc_abvx_NonCurrentAdvancesToCROContractsUndiscountedAmount_019c524e-b46b-78c9-b595-00fa1e57fdea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DiscountRateAppliedToLongTermAdvances_e6c6270c-ba89-4748-9812-f5c16bf00974" xlink:href="abvx-20251231.xsd#abvx_DiscountRateAppliedToLongTermAdvances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_0cc33eb0-c14a-43bd-b056-8af83102661f" xlink:to="loc_abvx_DiscountRateAppliedToLongTermAdvances_e6c6270c-ba89-4748-9812-f5c16bf00974" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PaymentsForAdvancesMadeToContractResearchOrganizationsUndiscountedAmount_6986fa31-f4eb-4a18-bab5-6ba6ab864bc1" xlink:href="abvx-20251231.xsd#abvx_PaymentsForAdvancesMadeToContractResearchOrganizationsUndiscountedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_0cc33eb0-c14a-43bd-b056-8af83102661f" xlink:to="loc_abvx_PaymentsForAdvancesMadeToContractResearchOrganizationsUndiscountedAmount_6986fa31-f4eb-4a18-bab5-6ba6ab864bc1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#OtherreceivablesandotherassetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems_a10b0bc7-6763-48f3-b274-5caeb6dabfef" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfOtherReceivablesAndOtherAssetsTable_5c5aad94-551e-4f9e-9a94-ff9ef4e2b063" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfOtherReceivablesAndOtherAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems_a10b0bc7-6763-48f3-b274-5caeb6dabfef" xlink:to="loc_abvx_DisclosureOfOtherReceivablesAndOtherAssetsTable_5c5aad94-551e-4f9e-9a94-ff9ef4e2b063" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_b93ba26b-e70f-4cd9-a5b1-a5d87d3de075" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abvx_DisclosureOfOtherReceivablesAndOtherAssetsTable_5c5aad94-551e-4f9e-9a94-ff9ef4e2b063" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_b93ba26b-e70f-4cd9-a5b1-a5d87d3de075" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_b93ba26b-e70f-4cd9-a5b1-a5d87d3de075_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_b93ba26b-e70f-4cd9-a5b1-a5d87d3de075" xlink:to="loc_ifrs-full_CarryingAmountMember_b93ba26b-e70f-4cd9-a5b1-a5d87d3de075_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_833fccbc-8669-405e-a07c-f2c483941600" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_b93ba26b-e70f-4cd9-a5b1-a5d87d3de075" xlink:to="loc_ifrs-full_CarryingAmountMember_833fccbc-8669-405e-a07c-f2c483941600" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DeferredFinancingCostsNettingMember_3e25dc6b-48ae-4fb8-b80a-6a6d13f835d7" xlink:href="abvx-20251231.xsd#abvx_DeferredFinancingCostsNettingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_833fccbc-8669-405e-a07c-f2c483941600" xlink:to="loc_abvx_DeferredFinancingCostsNettingMember_3e25dc6b-48ae-4fb8-b80a-6a6d13f835d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_b071abbf-d0fa-4f99-942c-54566e18526c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abvx_DisclosureOfOtherReceivablesAndOtherAssetsTable_5c5aad94-551e-4f9e-9a94-ff9ef4e2b063" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_b071abbf-d0fa-4f99-942c-54566e18526c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_b071abbf-d0fa-4f99-942c-54566e18526c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_b071abbf-d0fa-4f99-942c-54566e18526c" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_b071abbf-d0fa-4f99-942c-54566e18526c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_f260e9ef-cec9-4dcc-858b-7833a7efcc00" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_b071abbf-d0fa-4f99-942c-54566e18526c" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_f260e9ef-cec9-4dcc-858b-7833a7efcc00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheBMember_735eb06a-4e28-4578-bb1c-c19d659b6822" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_f260e9ef-cec9-4dcc-858b-7833a7efcc00" xlink:to="loc_abvx_KreosClaretFinancingTrancheBMember_735eb06a-4e28-4578-bb1c-c19d659b6822" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ProceedsFromResearchTaxCredit_504ee738-644c-481c-a49d-e1c743e578f0" xlink:href="abvx-20251231.xsd#abvx_ProceedsFromResearchTaxCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems_a10b0bc7-6763-48f3-b274-5caeb6dabfef" xlink:to="loc_abvx_ProceedsFromResearchTaxCredit_504ee738-644c-481c-a49d-e1c743e578f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentResearchTaxCreditReceivables_0e229e10-28b1-49af-b5c7-199566907aa9" xlink:href="abvx-20251231.xsd#abvx_CurrentResearchTaxCreditReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems_a10b0bc7-6763-48f3-b274-5caeb6dabfef" xlink:to="loc_abvx_CurrentResearchTaxCreditReceivables_0e229e10-28b1-49af-b5c7-199566907aa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentPrepaidExpensesRelatedToCRO_80bbd16b-062b-43fa-8a9d-495ed5ad0da4" xlink:href="abvx-20251231.xsd#abvx_CurrentPrepaidExpensesRelatedToCRO"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems_a10b0bc7-6763-48f3-b274-5caeb6dabfef" xlink:to="loc_abvx_CurrentPrepaidExpensesRelatedToCRO_80bbd16b-062b-43fa-8a9d-495ed5ad0da4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_c3185b92-2916-47a4-97fc-8b69c439a376" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems_a10b0bc7-6763-48f3-b274-5caeb6dabfef" xlink:to="loc_ifrs-full_Borrowings_c3185b92-2916-47a4-97fc-8b69c439a376" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAdvancesToSuppliers_f71fa34d-86f0-410b-b587-955b8b15c706" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAdvancesToSuppliers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems_a10b0bc7-6763-48f3-b274-5caeb6dabfef" xlink:to="loc_ifrs-full_CurrentAdvancesToSuppliers_f71fa34d-86f0-410b-b587-955b8b15c706" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ReclassificationOfPrepaidExpensesToCarryingValueOfDebtComponent_988a8a53-840e-427b-96c7-78ea09eeef8c" xlink:href="abvx-20251231.xsd#abvx_ReclassificationOfPrepaidExpensesToCarryingValueOfDebtComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems_a10b0bc7-6763-48f3-b274-5caeb6dabfef" xlink:to="loc_abvx_ReclassificationOfPrepaidExpensesToCarryingValueOfDebtComponent_988a8a53-840e-427b-96c7-78ea09eeef8c" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/CashandcashequivalentsNarrativeDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#CashandcashequivalentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/CashandcashequivalentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfCashAndCashEquivalentsLineItems_1fb3d627-69b2-443f-8dc7-bb23dc886c7b" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfCashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfCashAndCashEquivalentsTable_92e45cfb-5e34-45be-95fc-2d4fcd9f0eb0" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_abvx_DisclosureOfCashAndCashEquivalentsLineItems_1fb3d627-69b2-443f-8dc7-bb23dc886c7b" xlink:to="loc_abvx_DisclosureOfCashAndCashEquivalentsTable_92e45cfb-5e34-45be-95fc-2d4fcd9f0eb0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_b8d1da64-528f-44f0-8f8c-8bc25677364c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abvx_DisclosureOfCashAndCashEquivalentsTable_92e45cfb-5e34-45be-95fc-2d4fcd9f0eb0" xlink:to="loc_srt_CurrencyAxis_b8d1da64-528f-44f0-8f8c-8bc25677364c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_b8d1da64-528f-44f0-8f8c-8bc25677364c_default" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_b8d1da64-528f-44f0-8f8c-8bc25677364c" xlink:to="loc_currency_AllCurrenciesDomain_b8d1da64-528f-44f0-8f8c-8bc25677364c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_84b6cee6-f74b-4a90-a7a4-1f7fda518047" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_b8d1da64-528f-44f0-8f8c-8bc25677364c" xlink:to="loc_currency_AllCurrenciesDomain_84b6cee6-f74b-4a90-a7a4-1f7fda518047" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_ba51e457-528f-4306-8510-a7cd5767b17b" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_84b6cee6-f74b-4a90-a7a4-1f7fda518047" xlink:to="loc_currency_USD_ba51e457-528f-4306-8510-a7cd5767b17b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCashAndCashEquivalents_45877975-8261-4cf9-9c7f-fc43dc3e9626" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfCashAndCashEquivalentsLineItems_1fb3d627-69b2-443f-8dc7-bb23dc886c7b" xlink:to="loc_ifrs-full_OtherCashAndCashEquivalents_45877975-8261-4cf9-9c7f-fc43dc3e9626" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_56a6888a-64a7-4df9-966d-588a97d18f23" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfCashAndCashEquivalentsLineItems_1fb3d627-69b2-443f-8dc7-bb23dc886c7b" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_56a6888a-64a7-4df9-966d-588a97d18f23" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialassetsandliabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems_09e7ea9e-0422-4834-b492-4b2471c70545" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_eb61362b-324b-4ae6-93ae-5aeda5474a21" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems_09e7ea9e-0422-4834-b492-4b2471c70545" xlink:to="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_eb61362b-324b-4ae6-93ae-5aeda5474a21" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_f49f844c-df61-4c3b-91f8-f4d99b28aa96" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_eb61362b-324b-4ae6-93ae-5aeda5474a21" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_f49f844c-df61-4c3b-91f8-f4d99b28aa96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_f49f844c-df61-4c3b-91f8-f4d99b28aa96_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_f49f844c-df61-4c3b-91f8-f4d99b28aa96" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_f49f844c-df61-4c3b-91f8-f4d99b28aa96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_4a466881-bf6b-4ef5-9313-b424dee5d840" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_f49f844c-df61-4c3b-91f8-f4d99b28aa96" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_4a466881-bf6b-4ef5-9313-b424dee5d840" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialAssetsMember_52644017-b6c3-4db6-a7d6-aa6c382b333e" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_4a466881-bf6b-4ef5-9313-b424dee5d840" xlink:to="loc_abvx_OtherFinancialAssetsMember_52644017-b6c3-4db6-a7d6-aa6c382b333e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherReceivablesAndAssetsMember_65c16dce-0677-4055-8a5d-d31f636ea10d" xlink:href="abvx-20251231.xsd#abvx_OtherReceivablesAndAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_4a466881-bf6b-4ef5-9313-b424dee5d840" xlink:to="loc_abvx_OtherReceivablesAndAssetsMember_65c16dce-0677-4055-8a5d-d31f636ea10d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CashAndCashEquivalentMember_dd1ef532-48ee-438b-9397-a6d8213b2dae" xlink:href="abvx-20251231.xsd#abvx_CashAndCashEquivalentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_4a466881-bf6b-4ef5-9313-b424dee5d840" xlink:to="loc_abvx_CashAndCashEquivalentMember_dd1ef532-48ee-438b-9397-a6d8213b2dae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NonCurrentAdvancesToCROContractsMember_1b75357c-dc00-4a9e-bd22-72a116a3053c" xlink:href="abvx-20251231.xsd#abvx_NonCurrentAdvancesToCROContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_4a466881-bf6b-4ef5-9313-b424dee5d840" xlink:to="loc_abvx_NonCurrentAdvancesToCROContractsMember_1b75357c-dc00-4a9e-bd22-72a116a3053c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_2ac3fedd-b0a3-4ce8-bb8e-fd5cb702e443" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_eb61362b-324b-4ae6-93ae-5aeda5474a21" xlink:to="loc_ifrs-full_MeasurementAxis_2ac3fedd-b0a3-4ce8-bb8e-fd5cb702e443" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_2ac3fedd-b0a3-4ce8-bb8e-fd5cb702e443_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_2ac3fedd-b0a3-4ce8-bb8e-fd5cb702e443" xlink:to="loc_ifrs-full_MeasurementDomain_2ac3fedd-b0a3-4ce8-bb8e-fd5cb702e443_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_1fe30cca-a5d5-42d8-a66d-1cbab2bdb2fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_2ac3fedd-b0a3-4ce8-bb8e-fd5cb702e443" xlink:to="loc_ifrs-full_MeasurementDomain_1fe30cca-a5d5-42d8-a66d-1cbab2bdb2fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RecurringFairValueMeasurementMember_c5f4c64a-8663-4063-a37f-9cba071bd895" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RecurringFairValueMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MeasurementDomain_1fe30cca-a5d5-42d8-a66d-1cbab2bdb2fc" xlink:to="loc_ifrs-full_RecurringFairValueMeasurementMember_c5f4c64a-8663-4063-a37f-9cba071bd895" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_320f166b-17c7-484f-8f79-c1ba0e0b747b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_eb61362b-324b-4ae6-93ae-5aeda5474a21" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_320f166b-17c7-484f-8f79-c1ba0e0b747b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_320f166b-17c7-484f-8f79-c1ba0e0b747b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_320f166b-17c7-484f-8f79-c1ba0e0b747b" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_320f166b-17c7-484f-8f79-c1ba0e0b747b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_79352162-f667-41e6-9571-c040c8740d83" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_320f166b-17c7-484f-8f79-c1ba0e0b747b" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_79352162-f667-41e6-9571-c040c8740d83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_1bf2b0af-8068-436c-97b4-ea8dddc5dfdb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_79352162-f667-41e6-9571-c040c8740d83" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_1bf2b0af-8068-436c-97b4-ea8dddc5dfdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_ee1ad156-1c91-4578-a410-557d5de7de3d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_79352162-f667-41e6-9571-c040c8740d83" xlink:to="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_ee1ad156-1c91-4578-a410-557d5de7de3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2e93b70b-a581-462d-b88a-b6655a93ef56" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_eb61362b-324b-4ae6-93ae-5aeda5474a21" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2e93b70b-a581-462d-b88a-b6655a93ef56" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_2e93b70b-a581-462d-b88a-b6655a93ef56_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2e93b70b-a581-462d-b88a-b6655a93ef56" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_2e93b70b-a581-462d-b88a-b6655a93ef56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_d609931c-8eb2-464a-8409-3ac7dbb4901b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2e93b70b-a581-462d-b88a-b6655a93ef56" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_d609931c-8eb2-464a-8409-3ac7dbb4901b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_37433730-c52a-4f43-ae66-951373fd042c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_d609931c-8eb2-464a-8409-3ac7dbb4901b" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_37433730-c52a-4f43-ae66-951373fd042c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_8466749d-8c8e-4db4-83ed-1571e66de446" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_d609931c-8eb2-464a-8409-3ac7dbb4901b" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_8466749d-8c8e-4db4-83ed-1571e66de446" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_f7327d89-bb6e-4b22-b236-a79f498c395e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_eb61362b-324b-4ae6-93ae-5aeda5474a21" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_f7327d89-bb6e-4b22-b236-a79f498c395e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_f7327d89-bb6e-4b22-b236-a79f498c395e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_f7327d89-bb6e-4b22-b236-a79f498c395e" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_f7327d89-bb6e-4b22-b236-a79f498c395e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_26b8a9a8-439f-4fd7-87c6-3b65978a4891" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_f7327d89-bb6e-4b22-b236-a79f498c395e" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_26b8a9a8-439f-4fd7-87c6-3b65978a4891" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NonCurrentFinancialLiabilitiesMember_344a8d31-5afc-4e57-a9a2-ba69aede40cf" xlink:href="abvx-20251231.xsd#abvx_NonCurrentFinancialLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_26b8a9a8-439f-4fd7-87c6-3b65978a4891" xlink:to="loc_abvx_NonCurrentFinancialLiabilitiesMember_344a8d31-5afc-4e57-a9a2-ba69aede40cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheABAndCMember_ec1e8066-b74c-4e6f-b197-dea2ab89057e" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheABAndCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_NonCurrentFinancialLiabilitiesMember_344a8d31-5afc-4e57-a9a2-ba69aede40cf" xlink:to="loc_abvx_KreosClaretFinancingTrancheABAndCMember_ec1e8066-b74c-4e6f-b197-dea2ab89057e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheAMember_88dff9eb-fc96-4731-812e-97d206956a4d" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_NonCurrentFinancialLiabilitiesMember_344a8d31-5afc-4e57-a9a2-ba69aede40cf" xlink:to="loc_abvx_KreosClaretFinancingTrancheAMember_88dff9eb-fc96-4731-812e-97d206956a4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConditionalAdvancesAndPGELoanMember_2adc2b84-a6ff-4a79-b9f6-fda6896c8838" xlink:href="abvx-20251231.xsd#abvx_ConditionalAdvancesAndPGELoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_NonCurrentFinancialLiabilitiesMember_344a8d31-5afc-4e57-a9a2-ba69aede40cf" xlink:to="loc_abvx_ConditionalAdvancesAndPGELoanMember_2adc2b84-a6ff-4a79-b9f6-fda6896c8838" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PretGarantiParLEtatPGEMember_73f63775-754b-4651-853d-c1e485841b98" xlink:href="abvx-20251231.xsd#abvx_PretGarantiParLEtatPGEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_ConditionalAdvancesAndPGELoanMember_2adc2b84-a6ff-4a79-b9f6-fda6896c8838" xlink:to="loc_abvx_PretGarantiParLEtatPGEMember_73f63775-754b-4651-853d-c1e485841b98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RNPVIRConditionalAdvanceBPIMember_bcd5a293-0052-43e9-9d69-e0a4b801c4f4" xlink:href="abvx-20251231.xsd#abvx_RNPVIRConditionalAdvanceBPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_ConditionalAdvancesAndPGELoanMember_2adc2b84-a6ff-4a79-b9f6-fda6896c8838" xlink:to="loc_abvx_RNPVIRConditionalAdvanceBPIMember_bcd5a293-0052-43e9-9d69-e0a4b801c4f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CARENAConditionalAdvanceBPIMember_011df764-fb31-4911-8002-8a796bf51aeb" xlink:href="abvx-20251231.xsd#abvx_CARENAConditionalAdvanceBPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_ConditionalAdvancesAndPGELoanMember_2adc2b84-a6ff-4a79-b9f6-fda6896c8838" xlink:to="loc_abvx_CARENAConditionalAdvanceBPIMember_011df764-fb31-4911-8002-8a796bf51aeb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EbolaConditionalAdvanceBPIMember_6d73250c-5742-45ec-ae45-35540b8ecbd0" xlink:href="abvx-20251231.xsd#abvx_EbolaConditionalAdvanceBPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_ConditionalAdvancesAndPGELoanMember_2adc2b84-a6ff-4a79-b9f6-fda6896c8838" xlink:to="loc_abvx_EbolaConditionalAdvanceBPIMember_6d73250c-5742-45ec-ae45-35540b8ecbd0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentFinancialLiabilitiesMember_734b574c-24b1-4813-b05e-c07f763900ab" xlink:href="abvx-20251231.xsd#abvx_CurrentFinancialLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_26b8a9a8-439f-4fd7-87c6-3b65978a4891" xlink:to="loc_abvx_CurrentFinancialLiabilitiesMember_734b574c-24b1-4813-b05e-c07f763900ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TradePayablesAndOtherCurrentLiabilitiesMember_c77d82f8-2e89-4b62-a28a-8ce9b66c6e47" xlink:href="abvx-20251231.xsd#abvx_TradePayablesAndOtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_26b8a9a8-439f-4fd7-87c6-3b65978a4891" xlink:to="loc_abvx_TradePayablesAndOtherCurrentLiabilitiesMember_c77d82f8-2e89-4b62-a28a-8ce9b66c6e47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_44534e52-e837-4f59-b4c8-ecb6ffa66694" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_eb61362b-324b-4ae6-93ae-5aeda5474a21" xlink:to="loc_ifrs-full_RangeAxis_44534e52-e837-4f59-b4c8-ecb6ffa66694" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_44534e52-e837-4f59-b4c8-ecb6ffa66694_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_44534e52-e837-4f59-b4c8-ecb6ffa66694" xlink:to="loc_ifrs-full_RangeDomain_44534e52-e837-4f59-b4c8-ecb6ffa66694_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_55f71d54-bb2f-42fb-ad11-eb6bc4ac3eee" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_44534e52-e837-4f59-b4c8-ecb6ffa66694" xlink:to="loc_ifrs-full_RangeDomain_55f71d54-bb2f-42fb-ad11-eb6bc4ac3eee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_df361df7-8a85-430a-87ff-6726fc49d742" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_55f71d54-bb2f-42fb-ad11-eb6bc4ac3eee" xlink:to="loc_ifrs-full_BottomOfRangeMember_df361df7-8a85-430a-87ff-6726fc49d742" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_dd6fc551-5ef8-4e2d-b85d-cb93db53f34c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_55f71d54-bb2f-42fb-ad11-eb6bc4ac3eee" xlink:to="loc_ifrs-full_TopOfRangeMember_dd6fc551-5ef8-4e2d-b85d-cb93db53f34c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_59168bdf-9890-47b7-8ea8-a51a8742e2df" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_eb61362b-324b-4ae6-93ae-5aeda5474a21" xlink:to="loc_ifrs-full_UnobservableInputsAxis_59168bdf-9890-47b7-8ea8-a51a8742e2df" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain_59168bdf-9890-47b7-8ea8-a51a8742e2df_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_UnobservableInputsAxis_59168bdf-9890-47b7-8ea8-a51a8742e2df" xlink:to="loc_ifrs-full_UnobservableInputsDomain_59168bdf-9890-47b7-8ea8-a51a8742e2df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain_3396ecb8-4f80-4b36-a18e-773a7959d8b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_UnobservableInputsAxis_59168bdf-9890-47b7-8ea8-a51a8742e2df" xlink:to="loc_ifrs-full_UnobservableInputsDomain_3396ecb8-4f80-4b36-a18e-773a7959d8b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CreditSpreadMeasurementInputMember_e62bd654-e27b-4784-9d0a-5626f3152f9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CreditSpreadMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_3396ecb8-4f80-4b36-a18e-773a7959d8b1" xlink:to="loc_ifrs-full_CreditSpreadMeasurementInputMember_e62bd654-e27b-4784-9d0a-5626f3152f9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_96a573e2-ce6a-4ace-b3ef-c8670f34f270" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_eb61362b-324b-4ae6-93ae-5aeda5474a21" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_96a573e2-ce6a-4ace-b3ef-c8670f34f270" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_96a573e2-ce6a-4ace-b3ef-c8670f34f270_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_96a573e2-ce6a-4ace-b3ef-c8670f34f270" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_96a573e2-ce6a-4ace-b3ef-c8670f34f270_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_f616dca6-9df4-48f5-884c-647b1a2e7bcc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_96a573e2-ce6a-4ace-b3ef-c8670f34f270" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_f616dca6-9df4-48f5-884c-647b1a2e7bcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DiscountedCashFlowMember_bd0b2db0-e34a-4e62-abf5-e9804a98ae6f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DiscountedCashFlowMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_f616dca6-9df4-48f5-884c-647b1a2e7bcc" xlink:to="loc_ifrs-full_DiscountedCashFlowMember_bd0b2db0-e34a-4e62-abf5-e9804a98ae6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_d92189f6-06fa-4059-9d21-1642d0854fbf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems_09e7ea9e-0422-4834-b492-4b2471c70545" xlink:to="loc_ifrs-full_Assets_d92189f6-06fa-4059-9d21-1642d0854fbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValue_fd86ecdf-126d-411f-af99-ab599cfc0514" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialAssetsAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems_09e7ea9e-0422-4834-b492-4b2471c70545" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValue_fd86ecdf-126d-411f-af99-ab599cfc0514" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_aefe6fe9-db2f-4404-b92d-50bb09210d9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems_09e7ea9e-0422-4834-b492-4b2471c70545" xlink:to="loc_ifrs-full_Liabilities_aefe6fe9-db2f-4404-b92d-50bb09210d9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValue_ccaf4fdb-9836-4fac-a9d2-d7f1dedebb0a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems_09e7ea9e-0422-4834-b492-4b2471c70545" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValue_ccaf4fdb-9836-4fac-a9d2-d7f1dedebb0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputAssets_0976d20f-af14-4716-8fdc-d15bcf5bed09" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantUnobservableInputAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems_09e7ea9e-0422-4834-b492-4b2471c70545" xlink:to="loc_ifrs-full_SignificantUnobservableInputAssets_0976d20f-af14-4716-8fdc-d15bcf5bed09" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets_daf67fd2-92b3-4adf-b4cf-6382bd9383e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems_09e7ea9e-0422-4834-b492-4b2471c70545" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets_daf67fd2-92b3-4adf-b4cf-6382bd9383e6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets_46c7c057-2d32-4e53-b096-a5179dbc1b07" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems_09e7ea9e-0422-4834-b492-4b2471c70545" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets_46c7c057-2d32-4e53-b096-a5179dbc1b07" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities_87435302-63e7-48d0-8713-d6c3c9e7e5f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems_09e7ea9e-0422-4834-b492-4b2471c70545" xlink:to="loc_ifrs-full_SignificantUnobservableInputLiabilities_87435302-63e7-48d0-8713-d6c3c9e7e5f5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfTranches_019cfb72-9017-7599-b97d-e6ba1101d67d" xlink:href="abvx-20251231.xsd#abvx_NumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems_09e7ea9e-0422-4834-b492-4b2471c70545" xlink:to="loc_abvx_NumberOfTranches_019cfb72-9017-7599-b97d-e6ba1101d67d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_ef643c7b-a0de-44ff-a148-05cacc40c4f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems_09e7ea9e-0422-4834-b492-4b2471c70545" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_ef643c7b-a0de-44ff-a148-05cacc40c4f9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities_a201f1e3-45b9-4da1-bc07-c2feff04be1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems_09e7ea9e-0422-4834-b492-4b2471c70545" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities_a201f1e3-45b9-4da1-bc07-c2feff04be1d" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#ShareholdersequityChangeinsharecapitalDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e58e1ca9-d480-4e76-8910-39b5321d45d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e58e1ca9-d480-4e76-8910-39b5321d45d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialAgreementAxis_019bfa86-24aa-7a99-807a-d360dc28c9ca" xlink:href="abvx-20251231.xsd#abvx_FinancialAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e58e1ca9-d480-4e76-8910-39b5321d45d0" xlink:to="loc_abvx_FinancialAgreementAxis_019bfa86-24aa-7a99-807a-d360dc28c9ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialAgreementDomain_019bfa86-24aa-7a99-807a-d360dc28c9ca_default" xlink:href="abvx-20251231.xsd#abvx_FinancialAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_abvx_FinancialAgreementAxis_019bfa86-24aa-7a99-807a-d360dc28c9ca" xlink:to="loc_abvx_FinancialAgreementDomain_019bfa86-24aa-7a99-807a-d360dc28c9ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialAgreementDomain_019bfa86-24aa-7309-b759-b7d0c6955d10" xlink:href="abvx-20251231.xsd#abvx_FinancialAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_abvx_FinancialAgreementAxis_019bfa86-24aa-7a99-807a-d360dc28c9ca" xlink:to="loc_abvx_FinancialAgreementDomain_019bfa86-24aa-7309-b759-b7d0c6955d10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1Member_019bfa86-24aa-74f0-8ac6-a8ccf4ff066e" xlink:href="abvx-20251231.xsd#abvx_Kreos1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FinancialAgreementDomain_019bfa86-24aa-7309-b759-b7d0c6955d10" xlink:to="loc_abvx_Kreos1Member_019bfa86-24aa-74f0-8ac6-a8ccf4ff066e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherEquityAgreementsMember_019bfa86-24aa-7b4a-9311-fbbaa02d1da0" xlink:href="abvx-20251231.xsd#abvx_OtherEquityAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FinancialAgreementDomain_019bfa86-24aa-7309-b759-b7d0c6955d10" xlink:to="loc_abvx_OtherEquityAgreementsMember_019bfa86-24aa-7b4a-9311-fbbaa02d1da0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019bfa86-24aa-74f7-9e66-58e0ed68f5dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e58e1ca9-d480-4e76-8910-39b5321d45d0" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019bfa86-24aa-74f7-9e66-58e0ed68f5dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019bfa86-24aa-74f7-9e66-58e0ed68f5dd_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019bfa86-24aa-74f7-9e66-58e0ed68f5dd" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019bfa86-24aa-74f7-9e66-58e0ed68f5dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019bfa86-24aa-7417-b9e8-6ad522db4ee4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019bfa86-24aa-74f7-9e66-58e0ed68f5dd" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019bfa86-24aa-7417-b9e8-6ad522db4ee4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosABSAMember_019bfa86-24aa-7a20-b8de-d2bd0510a5e7" xlink:href="abvx-20251231.xsd#abvx_KreosABSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019bfa86-24aa-7417-b9e8-6ad522db4ee4" xlink:to="loc_abvx_KreosABSAMember_019bfa86-24aa-7a20-b8de-d2bd0510a5e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosBBSAMember_019bfa86-24aa-78f8-bf4b-a2736bb05fae" xlink:href="abvx-20251231.xsd#abvx_KreosBBSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019bfa86-24aa-7417-b9e8-6ad522db4ee4" xlink:to="loc_abvx_KreosBBSAMember_019bfa86-24aa-78f8-bf4b-a2736bb05fae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20241AndBSA20242Member_019bfa86-53a9-786a-8bf1-3598b5e96816" xlink:href="abvx-20251231.xsd#abvx_BSA20241AndBSA20242Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019bfa86-24aa-7417-b9e8-6ad522db4ee4" xlink:to="loc_abvx_BSA20241AndBSA20242Member_019bfa86-53a9-786a-8bf1-3598b5e96816" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_019bfa86-24aa-7b29-b9f9-0570086cc6c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e58e1ca9-d480-4e76-8910-39b5321d45d0" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_019bfa86-24aa-7b29-b9f9-0570086cc6c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_019bfa86-24aa-7b29-b9f9-0570086cc6c1_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_019bfa86-24aa-7b29-b9f9-0570086cc6c1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_019bfa86-24aa-7b29-b9f9-0570086cc6c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_019bfa86-24aa-7612-9513-2ed08055a57d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_019bfa86-24aa-7b29-b9f9-0570086cc6c1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_019bfa86-24aa-7612-9513-2ed08055a57d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AmericanDepositorySharesMember_019bfa86-24aa-717d-8d8f-fc352e81dfd0" xlink:href="abvx-20251231.xsd#abvx_AmericanDepositorySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_019bfa86-24aa-7612-9513-2ed08055a57d" xlink:to="loc_abvx_AmericanDepositorySharesMember_019bfa86-24aa-717d-8d8f-fc352e81dfd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_019bfa86-24aa-7f1b-8424-ba3339af547a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_019bfa86-24aa-7612-9513-2ed08055a57d" xlink:to="loc_ifrs-full_OrdinarySharesMember_019bfa86-24aa-7f1b-8424-ba3339af547a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_019bfa87-4537-7631-8dcb-be1b4b0b138f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e58e1ca9-d480-4e76-8910-39b5321d45d0" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_019bfa87-4537-7631-8dcb-be1b4b0b138f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019bfa87-4537-7631-8dcb-be1b4b0b138f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019bfa87-4537-7631-8dcb-be1b4b0b138f" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019bfa87-4537-7631-8dcb-be1b4b0b138f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019bfa87-4537-7834-afdb-3de0a17312a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019bfa87-4537-7631-8dcb-be1b4b0b138f" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019bfa87-4537-7834-afdb-3de0a17312a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_HeightsConvertibleNotesMember_019bfa87-4537-7fd9-beab-622facff8b44" xlink:href="abvx-20251231.xsd#abvx_HeightsConvertibleNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019bfa87-4537-7834-afdb-3de0a17312a3" xlink:to="loc_abvx_HeightsConvertibleNotesMember_019bfa87-4537-7fd9-beab-622facff8b44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheAMember_019bfa87-4537-7bd7-b6c0-39825bc503b2" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019bfa87-4537-7834-afdb-3de0a17312a3" xlink:to="loc_abvx_KreosClaretFinancingTrancheAMember_019bfa87-4537-7bd7-b6c0-39825bc503b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosABCBSAMember_019bfa88-8029-721f-a4ac-420aa8082b1d" xlink:href="abvx-20251231.xsd#abvx_KreosABCBSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019bfa87-4537-7834-afdb-3de0a17312a3" xlink:to="loc_abvx_KreosABCBSAMember_019bfa88-8029-721f-a4ac-420aa8082b1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_019bfa86-24aa-7170-99d9-a6614e5871b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_ifrs-full_IssueOfEquity_019bfa86-24aa-7170-99d9-a6614e5871b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease_019bfa86-24aa-70b1-ad69-bb12227cab73" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease_019bfa86-24aa-70b1-ad69-bb12227cab73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_019bfa86-24aa-71cc-9cf7-cbf492ca3ef2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_ifrs-full_ParValuePerShare_019bfa86-24aa-71cc-9cf7-cbf492ca3ef2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EquityIssuanceSubscriptionPricePerShare_019bfa86-24aa-7916-b09b-f5d54b23010e" xlink:href="abvx-20251231.xsd#abvx_EquityIssuanceSubscriptionPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_abvx_EquityIssuanceSubscriptionPricePerShare_019bfa86-24aa-7916-b09b-f5d54b23010e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfWarrantsExercised_019bfa86-24aa-727c-88ac-df13439d1caf" xlink:href="abvx-20251231.xsd#abvx_NumberOfWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_abvx_NumberOfWarrantsExercised_019bfa86-24aa-727c-88ac-df13439d1caf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_019bfa86-24aa-7762-8795-b4b2baa39cd9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_019bfa86-24aa-7762-8795-b4b2baa39cd9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants_019bfa86-24aa-7868-b504-a1ad9d323300" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants_019bfa86-24aa-7868-b504-a1ad9d323300" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherShareWarrantsSubscriptionPricePerShare_019bfa86-24aa-70ca-95e2-de80b709d09b" xlink:href="abvx-20251231.xsd#abvx_OtherShareWarrantsSubscriptionPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_abvx_OtherShareWarrantsSubscriptionPricePerShare_019bfa86-24aa-70ca-95e2-de80b709d09b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IssueOfEquityOfferingPricePerShare_019bfa86-24aa-7a22-87c1-f4a838ccf2ef" xlink:href="abvx-20251231.xsd#abvx_IssueOfEquityOfferingPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_abvx_IssueOfEquityOfferingPricePerShare_019bfa86-24aa-7a22-87c1-f4a838ccf2ef" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_019bfa86-53a9-758c-86a4-ecedaf1b42fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_019bfa86-53a9-758c-86a4-ecedaf1b42fd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_019bfa86-53a9-7b13-8f4a-90235824e616" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_019bfa86-53a9-7b13-8f4a-90235824e616" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ShareWarrantsSubscriptionPricePerShare_019bfa86-53a9-713c-aa78-cf030ab56c03" xlink:href="abvx-20251231.xsd#abvx_ShareWarrantsSubscriptionPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_abvx_ShareWarrantsSubscriptionPricePerShare_019bfa86-53a9-713c-aa78-cf030ab56c03" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ShareIssueRelatedCostCredit_019bfa86-53a9-7237-af8e-4cc5d7abffc6" xlink:href="abvx-20251231.xsd#abvx_ShareIssueRelatedCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_abvx_ShareIssueRelatedCostCredit_019bfa86-53a9-7237-af8e-4cc5d7abffc6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfFreeSharesIssued_019bfa86-53a9-77d3-bbbc-41053cd91fee" xlink:href="abvx-20251231.xsd#abvx_NumberOfFreeSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_abvx_NumberOfFreeSharesIssued_019bfa86-53a9-77d3-bbbc-41053cd91fee" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate_019bfa87-4537-77c5-a40d-1c6bb036aeee" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClosingForeignExchangeRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_ifrs-full_ClosingForeignExchangeRate_019bfa87-4537-77c5-a40d-1c6bb036aeee" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfConvertibleNotesConverted_019bfa87-4537-705d-815a-8d80be363531" xlink:href="abvx-20251231.xsd#abvx_NumberOfConvertibleNotesConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_abvx_NumberOfConvertibleNotesConverted_019bfa87-4537-705d-815a-8d80be363531" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_019bfa87-4537-7384-ac02-81da5da547d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_ifrs-full_NotionalAmount_019bfa87-4537-7384-ac02-81da5da547d7" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_019bfa87-4537-7436-aca3-e0c8fa71edad" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_019bfa87-4537-7436-aca3-e0c8fa71edad" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsFixedConversionPrice_019bfa87-4537-7e91-823a-f534e01b47d0" xlink:href="abvx-20251231.xsd#abvx_BorrowingsFixedConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_abvx_BorrowingsFixedConversionPrice_019bfa87-4537-7e91-823a-f534e01b47d0" xlink:type="arc" order="18"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#SharebasedpaymentsDisclosureofreconciliationofBCEsDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1d70bcfd-e943-4d77-aa94-f5740d0584dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_47dea508-c7ee-486d-a2c3-c3ddd34011a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1d70bcfd-e943-4d77-aa94-f5740d0584dc" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_47dea508-c7ee-486d-a2c3-c3ddd34011a9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_6f35c44f-488b-436d-9391-01650ef7dbdd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_47dea508-c7ee-486d-a2c3-c3ddd34011a9" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_6f35c44f-488b-436d-9391-01650ef7dbdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6f35c44f-488b-436d-9391-01650ef7dbdd_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_6f35c44f-488b-436d-9391-01650ef7dbdd" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6f35c44f-488b-436d-9391-01650ef7dbdd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_2ac46ceb-b144-458e-a0b0-e10964858a9b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_6f35c44f-488b-436d-9391-01650ef7dbdd" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_2ac46ceb-b144-458e-a0b0-e10964858a9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FoundersShareSubscriptionWarrantsBCEMember_61ca9cc3-1332-45a6-b1dc-f0c7b0d89e26" xlink:href="abvx-20251231.xsd#abvx_FoundersShareSubscriptionWarrantsBCEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_2ac46ceb-b144-458e-a0b0-e10964858a9b" xlink:to="loc_abvx_FoundersShareSubscriptionWarrantsBCEMember_61ca9cc3-1332-45a6-b1dc-f0c7b0d89e26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BCE20161Member_498a3203-7d46-4df9-baf6-6f5a77cfa1c9" xlink:href="abvx-20251231.xsd#abvx_BCE20161Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FoundersShareSubscriptionWarrantsBCEMember_61ca9cc3-1332-45a6-b1dc-f0c7b0d89e26" xlink:to="loc_abvx_BCE20161Member_498a3203-7d46-4df9-baf6-6f5a77cfa1c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BCE20171Member_4ecb7f9b-29c7-4cc3-9ae6-ced313e7775a" xlink:href="abvx-20251231.xsd#abvx_BCE20171Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FoundersShareSubscriptionWarrantsBCEMember_61ca9cc3-1332-45a6-b1dc-f0c7b0d89e26" xlink:to="loc_abvx_BCE20171Member_4ecb7f9b-29c7-4cc3-9ae6-ced313e7775a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BCE20172Member_36a5a6a5-a800-4e7f-bad4-95470f301f86" xlink:href="abvx-20251231.xsd#abvx_BCE20172Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FoundersShareSubscriptionWarrantsBCEMember_61ca9cc3-1332-45a6-b1dc-f0c7b0d89e26" xlink:to="loc_abvx_BCE20172Member_36a5a6a5-a800-4e7f-bad4-95470f301f86" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BCE20174Member_c46a2a79-5ba7-4e7b-9883-bc7efd32bb48" xlink:href="abvx-20251231.xsd#abvx_BCE20174Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FoundersShareSubscriptionWarrantsBCEMember_61ca9cc3-1332-45a6-b1dc-f0c7b0d89e26" xlink:to="loc_abvx_BCE20174Member_c46a2a79-5ba7-4e7b-9883-bc7efd32bb48" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BCE20175Member_55fead39-06f1-4186-a01a-51742757defd" xlink:href="abvx-20251231.xsd#abvx_BCE20175Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FoundersShareSubscriptionWarrantsBCEMember_61ca9cc3-1332-45a6-b1dc-f0c7b0d89e26" xlink:to="loc_abvx_BCE20175Member_55fead39-06f1-4186-a01a-51742757defd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BCE20181Member_ce1065e6-7182-463c-9cbf-7930431cf5a4" xlink:href="abvx-20251231.xsd#abvx_BCE20181Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FoundersShareSubscriptionWarrantsBCEMember_61ca9cc3-1332-45a6-b1dc-f0c7b0d89e26" xlink:to="loc_abvx_BCE20181Member_ce1065e6-7182-463c-9cbf-7930431cf5a4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BCE20184Member_e9aa6b70-2b6c-4e15-b44d-f19389dc9c79" xlink:href="abvx-20251231.xsd#abvx_BCE20184Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FoundersShareSubscriptionWarrantsBCEMember_61ca9cc3-1332-45a6-b1dc-f0c7b0d89e26" xlink:to="loc_abvx_BCE20184Member_e9aa6b70-2b6c-4e15-b44d-f19389dc9c79" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BCE20185Member_1a57f2f6-d4fe-450a-b50b-20d1fe96ce00" xlink:href="abvx-20251231.xsd#abvx_BCE20185Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FoundersShareSubscriptionWarrantsBCEMember_61ca9cc3-1332-45a6-b1dc-f0c7b0d89e26" xlink:to="loc_abvx_BCE20185Member_1a57f2f6-d4fe-450a-b50b-20d1fe96ce00" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_42b01723-aa96-4940-a89f-f1447502cac2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1d70bcfd-e943-4d77-aa94-f5740d0584dc" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_42b01723-aa96-4940-a89f-f1447502cac2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_290de5b4-eb4e-499c-90f3-438f7b0c5061" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1d70bcfd-e943-4d77-aa94-f5740d0584dc" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_290de5b4-eb4e-499c-90f3-438f7b0c5061" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_96d33b93-56d7-45e8-8a5b-413116a0a6a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1d70bcfd-e943-4d77-aa94-f5740d0584dc" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_96d33b93-56d7-45e8-8a5b-413116a0a6a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_c6cb33c8-6cb5-4224-ad30-5447a6bb2c63" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1d70bcfd-e943-4d77-aa94-f5740d0584dc" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_c6cb33c8-6cb5-4224-ad30-5447a6bb2c63" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_882fddcb-be7a-4f48-a5a3-1c4b62612f54" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_9a200f7b-3c9d-4a9d-b84e-9a9c21216d4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1d70bcfd-e943-4d77-aa94-f5740d0584dc" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_9a200f7b-3c9d-4a9d-b84e-9a9c21216d4d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet_96c6d517-0ab9-4ad8-b56e-f948a27c24e4" xlink:href="abvx-20251231.xsd#abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1d70bcfd-e943-4d77-aa94-f5740d0584dc" xlink:to="loc_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet_96c6d517-0ab9-4ad8-b56e-f948a27c24e4" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#SharebasedpaymentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019bfb19-cfb8-7bdc-b888-cd33594b4482" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_9a4168f3-5cd7-4898-92d5-32efd93d22ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019bfb19-cfb8-7bdc-b888-cd33594b4482" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_9a4168f3-5cd7-4898-92d5-32efd93d22ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesAxis_019bfb19-cfb8-7f14-8c83-e80db55db7bb" xlink:href="abvx-20251231.xsd#abvx_TranchesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_9a4168f3-5cd7-4898-92d5-32efd93d22ec" xlink:to="loc_abvx_TranchesAxis_019bfb19-cfb8-7f14-8c83-e80db55db7bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesDomain_019bfb19-cfb8-7f14-8c83-e80db55db7bb_default" xlink:href="abvx-20251231.xsd#abvx_TranchesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_abvx_TranchesAxis_019bfb19-cfb8-7f14-8c83-e80db55db7bb" xlink:to="loc_abvx_TranchesDomain_019bfb19-cfb8-7f14-8c83-e80db55db7bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesDomain_019bfb19-cfb8-716f-bb26-edacd9711228" xlink:href="abvx-20251231.xsd#abvx_TranchesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_abvx_TranchesAxis_019bfb19-cfb8-7f14-8c83-e80db55db7bb" xlink:to="loc_abvx_TranchesDomain_019bfb19-cfb8-716f-bb26-edacd9711228" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheOneMember_019bfb19-cfb8-7ced-a345-7726767b6e22" xlink:href="abvx-20251231.xsd#abvx_TrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_TranchesDomain_019bfb19-cfb8-716f-bb26-edacd9711228" xlink:to="loc_abvx_TrancheOneMember_019bfb19-cfb8-7ced-a345-7726767b6e22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheTwoMember_019bfb19-cfb8-7abf-983e-3bfbd749f314" xlink:href="abvx-20251231.xsd#abvx_TrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_TranchesDomain_019bfb19-cfb8-716f-bb26-edacd9711228" xlink:to="loc_abvx_TrancheTwoMember_019bfb19-cfb8-7abf-983e-3bfbd749f314" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheThreeMember_019bfb1a-6596-7278-a0f4-9e910b437217" xlink:href="abvx-20251231.xsd#abvx_TrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_TranchesDomain_019bfb19-cfb8-716f-bb26-edacd9711228" xlink:to="loc_abvx_TrancheThreeMember_019bfb1a-6596-7278-a0f4-9e910b437217" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheFourMember_019bfb1a-6596-7dc5-adde-72d66cca39d9" xlink:href="abvx-20251231.xsd#abvx_TrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_TranchesDomain_019bfb19-cfb8-716f-bb26-edacd9711228" xlink:to="loc_abvx_TrancheFourMember_019bfb1a-6596-7dc5-adde-72d66cca39d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheFiveMember_019bfb1a-6596-733e-ae7d-82d66176bd78" xlink:href="abvx-20251231.xsd#abvx_TrancheFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_TranchesDomain_019bfb19-cfb8-716f-bb26-edacd9711228" xlink:to="loc_abvx_TrancheFiveMember_019bfb1a-6596-733e-ae7d-82d66176bd78" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheSixMember_019bfb1a-6596-7047-8b7e-3e3e8a995f8c" xlink:href="abvx-20251231.xsd#abvx_TrancheSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_TranchesDomain_019bfb19-cfb8-716f-bb26-edacd9711228" xlink:to="loc_abvx_TrancheSixMember_019bfb1a-6596-7047-8b7e-3e3e8a995f8c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019bfb19-cfb8-7e04-92ff-fad51b249078" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_9a4168f3-5cd7-4898-92d5-32efd93d22ec" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019bfb19-cfb8-7e04-92ff-fad51b249078" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019bfb19-cfb8-7e04-92ff-fad51b249078_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019bfb19-cfb8-7e04-92ff-fad51b249078" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019bfb19-cfb8-7e04-92ff-fad51b249078_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019bfb19-cfb8-73e5-9124-e484181a565a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019bfb19-cfb8-7e04-92ff-fad51b249078" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019bfb19-cfb8-73e5-9124-e484181a565a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FoundersShareSubscriptionWarrantsBCEMember_019bfb19-cfb8-7d69-9df0-e21350266eba" xlink:href="abvx-20251231.xsd#abvx_FoundersShareSubscriptionWarrantsBCEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019bfb19-cfb8-73e5-9124-e484181a565a" xlink:to="loc_abvx_FoundersShareSubscriptionWarrantsBCEMember_019bfb19-cfb8-7d69-9df0-e21350266eba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BCEExceptBCE20142Member_019bfb19-cfb8-7d99-8c0b-d850fa892a85" xlink:href="abvx-20251231.xsd#abvx_BCEExceptBCE20142Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FoundersShareSubscriptionWarrantsBCEMember_019bfb19-cfb8-7d69-9df0-e21350266eba" xlink:to="loc_abvx_BCEExceptBCE20142Member_019bfb19-cfb8-7d99-8c0b-d850fa892a85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ShareSubscriptionWarrantsBSAMember_019bfb19-ffde-700f-bf2a-d7e8e0543807" xlink:href="abvx-20251231.xsd#abvx_ShareSubscriptionWarrantsBSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019bfb19-cfb8-73e5-9124-e484181a565a" xlink:to="loc_abvx_ShareSubscriptionWarrantsBSAMember_019bfb19-ffde-700f-bf2a-d7e8e0543807" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20241AndBSA20242Member_019bfb19-ffde-73c4-bb5b-fdd052f7f560" xlink:href="abvx-20251231.xsd#abvx_BSA20241AndBSA20242Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_ShareSubscriptionWarrantsBSAMember_019bfb19-ffde-700f-bf2a-d7e8e0543807" xlink:to="loc_abvx_BSA20241AndBSA20242Member_019bfb19-ffde-73c4-bb5b-fdd052f7f560" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20251AndBSA20252Member_019cfca6-e954-7cc4-af1a-50d187713e4f" xlink:href="abvx-20251231.xsd#abvx_BSA20251AndBSA20252Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_ShareSubscriptionWarrantsBSAMember_019bfb19-ffde-700f-bf2a-d7e8e0543807" xlink:to="loc_abvx_BSA20251AndBSA20252Member_019cfca6-e954-7cc4-af1a-50d187713e4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20253Member_019cfca7-11b1-7957-9736-d8d9439463d6" xlink:href="abvx-20251231.xsd#abvx_BSA20253Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_ShareSubscriptionWarrantsBSAMember_019bfb19-ffde-700f-bf2a-d7e8e0543807" xlink:to="loc_abvx_BSA20253Member_019cfca7-11b1-7957-9736-d8d9439463d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:href="abvx-20251231.xsd#abvx_FreeSharesAGAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019bfb19-cfb8-73e5-9124-e484181a565a" xlink:to="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20231Member_019bfb1a-6596-7e1d-8857-dadfbad3540e" xlink:href="abvx-20251231.xsd#abvx_AGA20231Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20231Member_019bfb1a-6596-7e1d-8857-dadfbad3540e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20232Member_019bfb1a-9ecc-7c8d-abf9-8ec3a724dc19" xlink:href="abvx-20251231.xsd#abvx_AGA20232Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20232Member_019bfb1a-9ecc-7c8d-abf9-8ec3a724dc19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20233AGA20234AndAGA20235Member_019bfb1a-9ecc-7273-b1dc-22738c7dd6c1" xlink:href="abvx-20251231.xsd#abvx_AGA20233AGA20234AndAGA20235Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20233AGA20234AndAGA20235Member_019bfb1a-9ecc-7273-b1dc-22738c7dd6c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20233AndAGA20234Member_019bfb1a-9ecc-75b3-8e84-bd99ad3724b7" xlink:href="abvx-20251231.xsd#abvx_AGA20233AndAGA20234Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_AGA20233AGA20234AndAGA20235Member_019bfb1a-9ecc-7273-b1dc-22738c7dd6c1" xlink:to="loc_abvx_AGA20233AndAGA20234Member_019bfb1a-9ecc-75b3-8e84-bd99ad3724b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20235Member_019bfb1a-9ecc-7962-a059-e83010e81e35" xlink:href="abvx-20251231.xsd#abvx_AGA20235Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_AGA20233AGA20234AndAGA20235Member_019bfb1a-9ecc-7273-b1dc-22738c7dd6c1" xlink:to="loc_abvx_AGA20235Member_019bfb1a-9ecc-7962-a059-e83010e81e35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20241Member_019bfb1a-c1ca-799b-808f-cf0ea4e9958d" xlink:href="abvx-20251231.xsd#abvx_AGA20241Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20241Member_019bfb1a-c1ca-799b-808f-cf0ea4e9958d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20242Member_019bfb1a-c1ca-70e5-8efa-6fedf1943926" xlink:href="abvx-20251231.xsd#abvx_AGA20242Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20242Member_019bfb1a-c1ca-70e5-8efa-6fedf1943926" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20243Member_019bfb1a-c1ca-7812-a457-ceff09f8665e" xlink:href="abvx-20251231.xsd#abvx_AGA20243Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20243Member_019bfb1a-c1ca-7812-a457-ceff09f8665e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20244AGA20245AndAGA20246Member_019bfb1a-c1ca-76fe-80a0-22b94d947eac" xlink:href="abvx-20251231.xsd#abvx_AGA20244AGA20245AndAGA20246Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20244AGA20245AndAGA20246Member_019bfb1a-c1ca-76fe-80a0-22b94d947eac" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20247Member_019bfb1a-c1ca-74f5-a5ec-9ca29f46bc53" xlink:href="abvx-20251231.xsd#abvx_AGA20247Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20247Member_019bfb1a-c1ca-74f5-a5ec-9ca29f46bc53" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20241AGE20242AGA20243AGA20244AGA20245AndAGA20247Member_019bfb1a-ecc0-7e9a-9bff-84d460153dfb" xlink:href="abvx-20251231.xsd#abvx_AGA20241AGE20242AGA20243AGA20244AGA20245AndAGA20247Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20241AGE20242AGA20243AGA20244AGA20245AndAGA20247Member_019bfb1a-ecc0-7e9a-9bff-84d460153dfb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20246Member_019bfb1a-ecc0-7dd8-99df-83e27c86b936" xlink:href="abvx-20251231.xsd#abvx_AGA20246Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20246Member_019bfb1a-ecc0-7dd8-99df-83e27c86b936" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20251Member_019bfb1b-2608-7a81-9ce5-8a31a8f4f904" xlink:href="abvx-20251231.xsd#abvx_AGA20251Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20251Member_019bfb1b-2608-7a81-9ce5-8a31a8f4f904" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20252Member_019bfb1b-2608-73da-ad7e-294b5a7fd7b0" xlink:href="abvx-20251231.xsd#abvx_AGA20252Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20252Member_019bfb1b-2608-73da-ad7e-294b5a7fd7b0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20253Member_019bfb1b-2608-792e-8965-7e86c4ab9f12" xlink:href="abvx-20251231.xsd#abvx_AGA20253Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20253Member_019bfb1b-2608-792e-8965-7e86c4ab9f12" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20254Member_019bfb1b-2608-7182-b0a6-dde36dbc0779" xlink:href="abvx-20251231.xsd#abvx_AGA20254Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20254Member_019bfb1b-2608-7182-b0a6-dde36dbc0779" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20256Member_019bfb1b-2608-7e24-89ca-ddc6be2ae4f3" xlink:href="abvx-20251231.xsd#abvx_AGA20256Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20256Member_019bfb1b-2608-7e24-89ca-ddc6be2ae4f3" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20257Member_019bfb1b-2608-72a0-8281-5d521eb13a98" xlink:href="abvx-20251231.xsd#abvx_AGA20257Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20257Member_019bfb1b-2608-72a0-8281-5d521eb13a98" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20258Member_019bfb1b-2608-7d70-9a0a-017c7b24c302" xlink:href="abvx-20251231.xsd#abvx_AGA20258Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20258Member_019bfb1b-2608-7d70-9a0a-017c7b24c302" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20251AGA20253AGA20254AGA20256AGA20257AndAGA20258Member_019bfb1b-2608-7462-8e98-f1d5ed173a96" xlink:href="abvx-20251231.xsd#abvx_AGA20251AGA20253AGA20254AGA20256AGA20257AndAGA20258Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20251AGA20253AGA20254AGA20256AGA20257AndAGA20258Member_019bfb1b-2608-7462-8e98-f1d5ed173a96" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20255Member_019bfb1b-2608-709f-af24-dbe111b5e67f" xlink:href="abvx-20251231.xsd#abvx_AGA20255Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20255Member_019bfb1b-2608-709f-af24-dbe111b5e67f" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_019bfb1a-35f5-7b16-80e0-18b961afac81" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_9a4168f3-5cd7-4898-92d5-32efd93d22ec" xlink:to="loc_srt_TitleOfIndividualAxis_019bfb1a-35f5-7b16-80e0-18b961afac81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019bfb1a-35f5-7b16-80e0-18b961afac81_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_019bfb1a-35f5-7b16-80e0-18b961afac81" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019bfb1a-35f5-7b16-80e0-18b961afac81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019bfb1a-35f5-7452-b953-1ca7edba1eee" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_019bfb1a-35f5-7b16-80e0-18b961afac81" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019bfb1a-35f5-7452-b953-1ca7edba1eee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_019bfb1a-6596-70c3-bb9c-f9f9159d7884" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019bfb1a-35f5-7452-b953-1ca7edba1eee" xlink:to="loc_srt_ChiefExecutiveOfficerMember_019bfb1a-6596-70c3-bb9c-f9f9159d7884" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FormerChiefExecutiveOfficerMember_019bfb1a-9ecc-7fc6-8c12-68166810e396" xlink:href="abvx-20251231.xsd#abvx_FormerChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019bfb1a-35f5-7452-b953-1ca7edba1eee" xlink:to="loc_abvx_FormerChiefExecutiveOfficerMember_019bfb1a-9ecc-7fc6-8c12-68166810e396" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EmployeeMember_019bfb1a-ecc0-7419-897c-a4485c752907" xlink:href="abvx-20251231.xsd#abvx_EmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019bfb1a-35f5-7452-b953-1ca7edba1eee" xlink:to="loc_abvx_EmployeeMember_019bfb1a-ecc0-7419-897c-a4485c752907" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019c003f-1ea0-7383-892d-3ee631562258" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_9a4168f3-5cd7-4898-92d5-32efd93d22ec" xlink:to="loc_srt_RangeAxis_019c003f-1ea0-7383-892d-3ee631562258" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019c003f-1ea0-7383-892d-3ee631562258_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_019c003f-1ea0-7383-892d-3ee631562258" xlink:to="loc_srt_RangeMember_019c003f-1ea0-7383-892d-3ee631562258_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019c003f-1ea0-71ee-95e7-2364dce30b77" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_019c003f-1ea0-7383-892d-3ee631562258" xlink:to="loc_srt_RangeMember_019c003f-1ea0-71ee-95e7-2364dce30b77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019c003f-1ea0-7315-bf2f-bdaea9a2a338" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019c003f-1ea0-71ee-95e7-2364dce30b77" xlink:to="loc_srt_MaximumMember_019c003f-1ea0-7315-bf2f-bdaea9a2a338" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage_019bfb19-cfb8-7d4c-82b8-d01782bc92a0" xlink:href="abvx-20251231.xsd#abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019bfb19-cfb8-7bdc-b888-cd33594b4482" xlink:to="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage_019bfb19-cfb8-7d4c-82b8-d01782bc92a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_019bfb19-cfb8-73bb-be84-74d1b2bd6dfd" xlink:href="abvx-20251231.xsd#abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019bfb19-cfb8-7bdc-b888-cd33594b4482" xlink:to="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_019bfb19-cfb8-73bb-be84-74d1b2bd6dfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentagePerMonth_019c003f-1ea0-741d-936d-2591217db816" xlink:href="abvx-20251231.xsd#abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentagePerMonth"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019bfb19-cfb8-7bdc-b888-cd33594b4482" xlink:to="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentagePerMonth_019c003f-1ea0-741d-936d-2591217db816" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementPerformanceConditionsMinimumFinancing_019bfb19-cfb8-7200-84ea-ed39355e284e" xlink:href="abvx-20251231.xsd#abvx_VestingRequirementsForShareBasedPaymentArrangementPerformanceConditionsMinimumFinancing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019bfb19-cfb8-7bdc-b888-cd33594b4482" xlink:to="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementPerformanceConditionsMinimumFinancing_019bfb19-cfb8-7200-84ea-ed39355e284e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementChangeOfControlMinimumThreshold_019bfb19-cfb8-70cb-a7b9-e7cd4e80df92" xlink:href="abvx-20251231.xsd#abvx_VestingRequirementsForShareBasedPaymentArrangementChangeOfControlMinimumThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019bfb19-cfb8-7bdc-b888-cd33594b4482" xlink:to="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementChangeOfControlMinimumThreshold_019bfb19-cfb8-70cb-a7b9-e7cd4e80df92" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_019bfb19-ffde-7065-af49-483278da772c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019bfb19-cfb8-7bdc-b888-cd33594b4482" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_019bfb19-ffde-7065-af49-483278da772c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfOtherEquityInstrumentsGrantedSubjectToNonMarketPerformanceCondition_019bfb1a-9ecc-7cb6-b681-019e1960914e" xlink:href="abvx-20251231.xsd#abvx_NumberOfOtherEquityInstrumentsGrantedSubjectToNonMarketPerformanceCondition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019bfb19-cfb8-7bdc-b888-cd33594b4482" xlink:to="loc_abvx_NumberOfOtherEquityInstrumentsGrantedSubjectToNonMarketPerformanceCondition_019bfb1a-9ecc-7cb6-b681-019e1960914e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherShorttermProvisions_019bfb1b-530a-7bae-8355-94f5d2dc56df" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherShorttermProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019bfb19-cfb8-7bdc-b888-cd33594b4482" xlink:to="loc_ifrs-full_OtherShorttermProvisions_019bfb1b-530a-7bae-8355-94f5d2dc56df" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherLongtermProvisions_019bfb1b-530a-741c-b825-572d1e3314ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherLongtermProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019bfb19-cfb8-7bdc-b888-cd33594b4482" xlink:to="loc_ifrs-full_OtherLongtermProvisions_019bfb1b-530a-741c-b825-572d1e3314ae" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementServicePeriod_019c003f-1ea0-7e35-affe-c5e8e9a7fbeb" xlink:href="abvx-20251231.xsd#abvx_VestingRequirementsForShareBasedPaymentArrangementServicePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019bfb19-cfb8-7bdc-b888-cd33594b4482" xlink:to="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementServicePeriod_019c003f-1ea0-7e35-affe-c5e8e9a7fbeb" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#SharebasedpaymentsDisclosureofreconciliationofBSAsDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_8ed354f7-adab-4275-a35c-87a9f9aa4244" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3fcb40b1-6499-4202-8d89-edcafd8fb34f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_8ed354f7-adab-4275-a35c-87a9f9aa4244" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3fcb40b1-6499-4202-8d89-edcafd8fb34f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f606e404-67e1-44c5-835a-311bee9e4692" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3fcb40b1-6499-4202-8d89-edcafd8fb34f" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f606e404-67e1-44c5-835a-311bee9e4692" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f606e404-67e1-44c5-835a-311bee9e4692_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f606e404-67e1-44c5-835a-311bee9e4692" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f606e404-67e1-44c5-835a-311bee9e4692_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_d787b95a-8181-48bc-8679-eb961a9b5a7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f606e404-67e1-44c5-835a-311bee9e4692" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_d787b95a-8181-48bc-8679-eb961a9b5a7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ShareSubscriptionWarrantsBSAMember_86827a7c-0da6-4a99-8bf0-6ba3f8a0722b" xlink:href="abvx-20251231.xsd#abvx_ShareSubscriptionWarrantsBSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_d787b95a-8181-48bc-8679-eb961a9b5a7a" xlink:to="loc_abvx_ShareSubscriptionWarrantsBSAMember_86827a7c-0da6-4a99-8bf0-6ba3f8a0722b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA201511Member_5145e119-555e-45b8-92d6-477edd40d794" xlink:href="abvx-20251231.xsd#abvx_BSA201511Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_ShareSubscriptionWarrantsBSAMember_86827a7c-0da6-4a99-8bf0-6ba3f8a0722b" xlink:to="loc_abvx_BSA201511Member_5145e119-555e-45b8-92d6-477edd40d794" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA201512Member_953c6161-1140-4bde-94f9-1aa77579036e" xlink:href="abvx-20251231.xsd#abvx_BSA201512Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_ShareSubscriptionWarrantsBSAMember_86827a7c-0da6-4a99-8bf0-6ba3f8a0722b" xlink:to="loc_abvx_BSA201512Member_953c6161-1140-4bde-94f9-1aa77579036e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20171Member_b871846b-d010-4b1d-871e-0bdeca850833" xlink:href="abvx-20251231.xsd#abvx_BSA20171Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_ShareSubscriptionWarrantsBSAMember_86827a7c-0da6-4a99-8bf0-6ba3f8a0722b" xlink:to="loc_abvx_BSA20171Member_b871846b-d010-4b1d-871e-0bdeca850833" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20181Member_6421f5ba-ed88-4263-ad6f-56e7cd2df058" xlink:href="abvx-20251231.xsd#abvx_BSA20181Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_ShareSubscriptionWarrantsBSAMember_86827a7c-0da6-4a99-8bf0-6ba3f8a0722b" xlink:to="loc_abvx_BSA20181Member_6421f5ba-ed88-4263-ad6f-56e7cd2df058" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20241Member_0f8c245f-6182-41ac-9bc7-8a516fea38f7" xlink:href="abvx-20251231.xsd#abvx_BSA20241Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_ShareSubscriptionWarrantsBSAMember_86827a7c-0da6-4a99-8bf0-6ba3f8a0722b" xlink:to="loc_abvx_BSA20241Member_0f8c245f-6182-41ac-9bc7-8a516fea38f7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20242Member_8e31b790-0927-40b5-afcb-d40365f990e7" xlink:href="abvx-20251231.xsd#abvx_BSA20242Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_ShareSubscriptionWarrantsBSAMember_86827a7c-0da6-4a99-8bf0-6ba3f8a0722b" xlink:to="loc_abvx_BSA20242Member_8e31b790-0927-40b5-afcb-d40365f990e7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20251Member_019c5687-aadc-7f29-aedf-6355a3bb6308" xlink:href="abvx-20251231.xsd#abvx_BSA20251Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_ShareSubscriptionWarrantsBSAMember_86827a7c-0da6-4a99-8bf0-6ba3f8a0722b" xlink:to="loc_abvx_BSA20251Member_019c5687-aadc-7f29-aedf-6355a3bb6308" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20252Member_019c5687-d130-7872-8cc5-d48403a0d1d0" xlink:href="abvx-20251231.xsd#abvx_BSA20252Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_ShareSubscriptionWarrantsBSAMember_86827a7c-0da6-4a99-8bf0-6ba3f8a0722b" xlink:to="loc_abvx_BSA20252Member_019c5687-d130-7872-8cc5-d48403a0d1d0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20253Member_019c5687-f206-79f2-bbfd-90327dcae5ad" xlink:href="abvx-20251231.xsd#abvx_BSA20253Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_ShareSubscriptionWarrantsBSAMember_86827a7c-0da6-4a99-8bf0-6ba3f8a0722b" xlink:to="loc_abvx_BSA20253Member_019c5687-f206-79f2-bbfd-90327dcae5ad" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_8707e9c3-9c03-47c9-8cf9-9843c0e68fb1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_8ed354f7-adab-4275-a35c-87a9f9aa4244" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_8707e9c3-9c03-47c9-8cf9-9843c0e68fb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_ff6367f1-7763-4e11-bbb2-96b824c79ff0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_8ed354f7-adab-4275-a35c-87a9f9aa4244" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_ff6367f1-7763-4e11-bbb2-96b824c79ff0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_9aba2688-3a5d-441f-80b2-52607984ad21" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_8ed354f7-adab-4275-a35c-87a9f9aa4244" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_9aba2688-3a5d-441f-80b2-52607984ad21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_9b61b9e8-6862-4ca5-b205-2746782ac62a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_8ed354f7-adab-4275-a35c-87a9f9aa4244" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_9b61b9e8-6862-4ca5-b205-2746782ac62a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_aff8bb19-ef3f-4d66-a621-7c29870824c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_c39eb5ae-d3ac-4566-95c8-cf9012596de9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_8ed354f7-adab-4275-a35c-87a9f9aa4244" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_c39eb5ae-d3ac-4566-95c8-cf9012596de9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet_f348720e-3dda-4406-893f-3fac7b466bfa" xlink:href="abvx-20251231.xsd#abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_8ed354f7-adab-4275-a35c-87a9f9aa4244" xlink:to="loc_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet_f348720e-3dda-4406-893f-3fac7b466bfa" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a945d3e7-b261-4cc0-bffe-2347aca1e7a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3e97a34d-b635-406e-927e-055e2b234f01" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a945d3e7-b261-4cc0-bffe-2347aca1e7a3" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3e97a34d-b635-406e-927e-055e2b234f01" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1e07aac0-dadb-4077-9f62-53a9e503aa28" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3e97a34d-b635-406e-927e-055e2b234f01" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1e07aac0-dadb-4077-9f62-53a9e503aa28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_1e07aac0-dadb-4077-9f62-53a9e503aa28_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1e07aac0-dadb-4077-9f62-53a9e503aa28" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_1e07aac0-dadb-4077-9f62-53a9e503aa28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_bd36689e-de41-4630-b393-ac5df24aae67" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1e07aac0-dadb-4077-9f62-53a9e503aa28" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_bd36689e-de41-4630-b393-ac5df24aae67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20241Member_185c4c31-817a-48fd-b512-5e1253949228" xlink:href="abvx-20251231.xsd#abvx_BSA20241Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_bd36689e-de41-4630-b393-ac5df24aae67" xlink:to="loc_abvx_BSA20241Member_185c4c31-817a-48fd-b512-5e1253949228" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20242Member_62ad543a-0251-4574-859f-c7c31f3eae7e" xlink:href="abvx-20251231.xsd#abvx_BSA20242Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_bd36689e-de41-4630-b393-ac5df24aae67" xlink:to="loc_abvx_BSA20242Member_62ad543a-0251-4574-859f-c7c31f3eae7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20251Member_019bfaed-ae59-7133-a193-a5ffe6656b89" xlink:href="abvx-20251231.xsd#abvx_BSA20251Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_bd36689e-de41-4630-b393-ac5df24aae67" xlink:to="loc_abvx_BSA20251Member_019bfaed-ae59-7133-a193-a5ffe6656b89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20252Member_019bfaed-dcc8-72ca-a67a-612816ceccc1" xlink:href="abvx-20251231.xsd#abvx_BSA20252Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_bd36689e-de41-4630-b393-ac5df24aae67" xlink:to="loc_abvx_BSA20252Member_019bfaed-dcc8-72ca-a67a-612816ceccc1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20253Member_019bfaee-2775-7033-81fd-50d0a3fb96b4" xlink:href="abvx-20251231.xsd#abvx_BSA20253Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_bd36689e-de41-4630-b393-ac5df24aae67" xlink:to="loc_abvx_BSA20253Member_019bfaee-2775-7033-81fd-50d0a3fb96b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_8b5c9c89-3de1-4737-bf67-803efd0dc22f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3e97a34d-b635-406e-927e-055e2b234f01" xlink:to="loc_ifrs-full_RangeAxis_8b5c9c89-3de1-4737-bf67-803efd0dc22f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_8b5c9c89-3de1-4737-bf67-803efd0dc22f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_8b5c9c89-3de1-4737-bf67-803efd0dc22f" xlink:to="loc_ifrs-full_RangeDomain_8b5c9c89-3de1-4737-bf67-803efd0dc22f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_508f69b5-53fd-476d-8930-f6027a178b79" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_8b5c9c89-3de1-4737-bf67-803efd0dc22f" xlink:to="loc_ifrs-full_RangeDomain_508f69b5-53fd-476d-8930-f6027a178b79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5b9e5b0f-1b3a-4187-bfe9-dfa5291284f7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_508f69b5-53fd-476d-8930-f6027a178b79" xlink:to="loc_srt_MinimumMember_5b9e5b0f-1b3a-4187-bfe9-dfa5291284f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a839e7dc-4847-40eb-b2f9-1f8d96012b50" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_508f69b5-53fd-476d-8930-f6027a178b79" xlink:to="loc_srt_MaximumMember_a839e7dc-4847-40eb-b2f9-1f8d96012b50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted_f7f75781-682e-4860-9114-6e4726e61e18" xlink:href="abvx-20251231.xsd#abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a945d3e7-b261-4cc0-bffe-2347aca1e7a3" xlink:to="loc_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted_f7f75781-682e-4860-9114-6e4726e61e18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted_be06938d-ea73-414e-a6f1-e25d51f24fee" xlink:href="abvx-20251231.xsd#abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a945d3e7-b261-4cc0-bffe-2347aca1e7a3" xlink:to="loc_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted_be06938d-ea73-414e-a6f1-e25d51f24fee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_b71452a0-8180-438e-8c53-43b27751e232" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a945d3e7-b261-4cc0-bffe-2347aca1e7a3" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_b71452a0-8180-438e-8c53-43b27751e232" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted_6f59ccd3-869f-42d2-be50-a013a34cceb5" xlink:href="abvx-20251231.xsd#abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a945d3e7-b261-4cc0-bffe-2347aca1e7a3" xlink:to="loc_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted_6f59ccd3-869f-42d2-be50-a013a34cceb5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EquityInstrumentStrikePriceOtherEquityInstrumentsGranted_9f868d05-8da8-4c05-936e-dc696efbe5ef" xlink:href="abvx-20251231.xsd#abvx_EquityInstrumentStrikePriceOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a945d3e7-b261-4cc0-bffe-2347aca1e7a3" xlink:to="loc_abvx_EquityInstrumentStrikePriceOtherEquityInstrumentsGranted_9f868d05-8da8-4c05-936e-dc696efbe5ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted_6426209c-6057-46e7-a4bd-2ea7f4528435" xlink:href="abvx-20251231.xsd#abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a945d3e7-b261-4cc0-bffe-2347aca1e7a3" xlink:to="loc_abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted_6426209c-6057-46e7-a4bd-2ea7f4528435" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpectedMaturityOtherEquityInstrumentsGranted_701456f7-b201-42c7-83b8-92dc2abf3125" xlink:href="abvx-20251231.xsd#abvx_ExpectedMaturityOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a945d3e7-b261-4cc0-bffe-2347aca1e7a3" xlink:to="loc_abvx_ExpectedMaturityOtherEquityInstrumentsGranted_701456f7-b201-42c7-83b8-92dc2abf3125" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpectedVolatilityOtherEquityInstrumentsGranted_69b7111b-bf82-4014-9d5c-bce6e1f15853" xlink:href="abvx-20251231.xsd#abvx_ExpectedVolatilityOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a945d3e7-b261-4cc0-bffe-2347aca1e7a3" xlink:to="loc_abvx_ExpectedVolatilityOtherEquityInstrumentsGranted_69b7111b-bf82-4014-9d5c-bce6e1f15853" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#SharebasedpaymentsDisclosureofreconciliationofAGAsDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_105b6e0b-1b27-4fb0-8566-495f1a329c4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_0988986e-9d00-4e8d-bb69-1d92affdd4c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_105b6e0b-1b27-4fb0-8566-495f1a329c4f" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_0988986e-9d00-4e8d-bb69-1d92affdd4c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_9cda77e9-331c-42ee-a122-135bb0f2e68f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_0988986e-9d00-4e8d-bb69-1d92affdd4c1" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_9cda77e9-331c-42ee-a122-135bb0f2e68f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_9cda77e9-331c-42ee-a122-135bb0f2e68f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_9cda77e9-331c-42ee-a122-135bb0f2e68f" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_9cda77e9-331c-42ee-a122-135bb0f2e68f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_3be2ac57-5908-4673-b25d-b24285875322" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_9cda77e9-331c-42ee-a122-135bb0f2e68f" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_3be2ac57-5908-4673-b25d-b24285875322" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:href="abvx-20251231.xsd#abvx_FreeSharesAGAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_3be2ac57-5908-4673-b25d-b24285875322" xlink:to="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20231Member_957c1a0a-a143-4c82-9a37-57da96c03383" xlink:href="abvx-20251231.xsd#abvx_AGA20231Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20231Member_957c1a0a-a143-4c82-9a37-57da96c03383" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20232Member_52aac868-4b55-4cb0-88e3-aee965019447" xlink:href="abvx-20251231.xsd#abvx_AGA20232Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20232Member_52aac868-4b55-4cb0-88e3-aee965019447" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20233Member_e77bc2a4-c84d-4639-bc3f-02bce9b9b2cd" xlink:href="abvx-20251231.xsd#abvx_AGA20233Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20233Member_e77bc2a4-c84d-4639-bc3f-02bce9b9b2cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20234Member_0dc37682-3285-4975-b9c7-7eb139482202" xlink:href="abvx-20251231.xsd#abvx_AGA20234Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20234Member_0dc37682-3285-4975-b9c7-7eb139482202" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20235Member_14e73a1c-e2ea-4128-92c8-746dec075028" xlink:href="abvx-20251231.xsd#abvx_AGA20235Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20235Member_14e73a1c-e2ea-4128-92c8-746dec075028" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20241Member_2e010280-d2df-43ee-b9fb-07afa98e50b2" xlink:href="abvx-20251231.xsd#abvx_AGA20241Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20241Member_2e010280-d2df-43ee-b9fb-07afa98e50b2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20242Member_d8b97919-4a46-4085-92f1-4ca2dd5549c0" xlink:href="abvx-20251231.xsd#abvx_AGA20242Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20242Member_d8b97919-4a46-4085-92f1-4ca2dd5549c0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20243Member_6cc205c1-7829-4001-9c85-c71f5c80ea9d" xlink:href="abvx-20251231.xsd#abvx_AGA20243Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20243Member_6cc205c1-7829-4001-9c85-c71f5c80ea9d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20244Member_a7114653-b4ec-45af-b8cb-832e22fbbc1a" xlink:href="abvx-20251231.xsd#abvx_AGA20244Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20244Member_a7114653-b4ec-45af-b8cb-832e22fbbc1a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20245Member_15b20233-c70f-4505-8c3d-4f5dee3de02e" xlink:href="abvx-20251231.xsd#abvx_AGA20245Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20245Member_15b20233-c70f-4505-8c3d-4f5dee3de02e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20246Member_a9a9fa34-8e60-4ddc-84f9-3eefce1b95aa" xlink:href="abvx-20251231.xsd#abvx_AGA20246Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20246Member_a9a9fa34-8e60-4ddc-84f9-3eefce1b95aa" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20247Member_ac59c67b-b278-4cf2-ab67-56deb3126df8" xlink:href="abvx-20251231.xsd#abvx_AGA20247Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20247Member_ac59c67b-b278-4cf2-ab67-56deb3126df8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20251Member_019c5692-5e4c-7297-baf5-0654e9287a2b" xlink:href="abvx-20251231.xsd#abvx_AGA20251Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20251Member_019c5692-5e4c-7297-baf5-0654e9287a2b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20252Member_019c5692-7d39-7919-bae3-8dc7300f7c9d" xlink:href="abvx-20251231.xsd#abvx_AGA20252Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20252Member_019c5692-7d39-7919-bae3-8dc7300f7c9d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20253Member_019c5693-156e-7d9b-9d8c-0de4c80fa9ba" xlink:href="abvx-20251231.xsd#abvx_AGA20253Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20253Member_019c5693-156e-7d9b-9d8c-0de4c80fa9ba" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20254Member_019c5693-156e-7374-a494-49dc8e97742c" xlink:href="abvx-20251231.xsd#abvx_AGA20254Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20254Member_019c5693-156e-7374-a494-49dc8e97742c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20255Member_019c5693-156e-78da-ada1-a407ba424dfe" xlink:href="abvx-20251231.xsd#abvx_AGA20255Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20255Member_019c5693-156e-78da-ada1-a407ba424dfe" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20256Member_019c5693-156e-7fd2-8a37-a2204acfd74c" xlink:href="abvx-20251231.xsd#abvx_AGA20256Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20256Member_019c5693-156e-7fd2-8a37-a2204acfd74c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20257Member_019c5693-156e-751d-8f50-5f3014d2f8c9" xlink:href="abvx-20251231.xsd#abvx_AGA20257Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20257Member_019c5693-156e-751d-8f50-5f3014d2f8c9" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20258Member_019c5693-156e-7f34-977e-59bb5f265164" xlink:href="abvx-20251231.xsd#abvx_AGA20258Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20258Member_019c5693-156e-7f34-977e-59bb5f265164" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_04363a92-f910-4196-aecf-cd3887bea24f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_105b6e0b-1b27-4fb0-8566-495f1a329c4f" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_04363a92-f910-4196-aecf-cd3887bea24f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_e0da9dc1-b61d-47a8-850e-20e42cdb9f1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_105b6e0b-1b27-4fb0-8566-495f1a329c4f" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_e0da9dc1-b61d-47a8-850e-20e42cdb9f1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_dfd0361b-c554-414c-a29b-195905bb5a39" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_105b6e0b-1b27-4fb0-8566-495f1a329c4f" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_dfd0361b-c554-414c-a29b-195905bb5a39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_eccaf176-0d8d-431f-aac1-9b93b99accb7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_105b6e0b-1b27-4fb0-8566-495f1a329c4f" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_eccaf176-0d8d-431f-aac1-9b93b99accb7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_9aa5df59-22c1-40db-a46c-399a1f95a467" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_b3ca2a2e-c90d-4d1c-9bf9-de9711b84c9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_e440733e-c619-46da-a594-be39ed72163e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_b3ca2a2e-c90d-4d1c-9bf9-de9711b84c9f" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_e440733e-c619-46da-a594-be39ed72163e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_6c6b36a4-23ff-4291-8831-1f50fc2b09d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_e440733e-c619-46da-a594-be39ed72163e" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_6c6b36a4-23ff-4291-8831-1f50fc2b09d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6c6b36a4-23ff-4291-8831-1f50fc2b09d1_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_6c6b36a4-23ff-4291-8831-1f50fc2b09d1" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6c6b36a4-23ff-4291-8831-1f50fc2b09d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_6c6b36a4-23ff-4291-8831-1f50fc2b09d1" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20231Member_49dafe01-6f1b-4ba7-bbb6-1313ad94c7a4" xlink:href="abvx-20251231.xsd#abvx_AGA20231Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20231Member_49dafe01-6f1b-4ba7-bbb6-1313ad94c7a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20232Member_839267f9-4505-48d0-811a-45d21184c399" xlink:href="abvx-20251231.xsd#abvx_AGA20232Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20232Member_839267f9-4505-48d0-811a-45d21184c399" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20233Member_f4224785-3a69-4c35-8fe6-5cfc54420e8f" xlink:href="abvx-20251231.xsd#abvx_AGA20233Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20233Member_f4224785-3a69-4c35-8fe6-5cfc54420e8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20234Member_f220248a-fa96-4f48-a67d-0cc088f48ef4" xlink:href="abvx-20251231.xsd#abvx_AGA20234Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20234Member_f220248a-fa96-4f48-a67d-0cc088f48ef4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20235Member_faf3ace0-28cc-457a-a848-121969810a84" xlink:href="abvx-20251231.xsd#abvx_AGA20235Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20235Member_faf3ace0-28cc-457a-a848-121969810a84" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20241Member_22cec87c-bfbf-457f-9fbc-44ac368a9153" xlink:href="abvx-20251231.xsd#abvx_AGA20241Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20241Member_22cec87c-bfbf-457f-9fbc-44ac368a9153" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20242Member_df90699a-2710-4cb6-be44-871c7e55b255" xlink:href="abvx-20251231.xsd#abvx_AGA20242Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20242Member_df90699a-2710-4cb6-be44-871c7e55b255" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20243Member_551d2e37-2680-4485-a76a-880d6faf8edb" xlink:href="abvx-20251231.xsd#abvx_AGA20243Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20243Member_551d2e37-2680-4485-a76a-880d6faf8edb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20244Member_d449e3a6-b423-4c0a-9c8d-05d898e96827" xlink:href="abvx-20251231.xsd#abvx_AGA20244Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20244Member_d449e3a6-b423-4c0a-9c8d-05d898e96827" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20245Member_c2a480d6-0052-48d7-a6f6-7cba92444f98" xlink:href="abvx-20251231.xsd#abvx_AGA20245Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20245Member_c2a480d6-0052-48d7-a6f6-7cba92444f98" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20246Member_32d88de7-36ec-42b2-a6a4-808afe736443" xlink:href="abvx-20251231.xsd#abvx_AGA20246Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20246Member_32d88de7-36ec-42b2-a6a4-808afe736443" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20247Member_f9fad285-039d-41d3-8369-a1525e64d368" xlink:href="abvx-20251231.xsd#abvx_AGA20247Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20247Member_f9fad285-039d-41d3-8369-a1525e64d368" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20251Member_019bfaf5-15ee-7c3c-b433-8a2d55bcbccd" xlink:href="abvx-20251231.xsd#abvx_AGA20251Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20251Member_019bfaf5-15ee-7c3c-b433-8a2d55bcbccd" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20252Member_019bfaf5-3a27-743f-9e7d-76c284967e3a" xlink:href="abvx-20251231.xsd#abvx_AGA20252Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20252Member_019bfaf5-3a27-743f-9e7d-76c284967e3a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20253Member_019bfaf6-28ef-7590-8b1c-8564f1c3a08d" xlink:href="abvx-20251231.xsd#abvx_AGA20253Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20253Member_019bfaf6-28ef-7590-8b1c-8564f1c3a08d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20254Member_019bfaf6-508e-7cd4-9c2d-9bd58109086d" xlink:href="abvx-20251231.xsd#abvx_AGA20254Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20254Member_019bfaf6-508e-7cd4-9c2d-9bd58109086d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20255Member_019bfaf6-6be7-7b43-8199-263a9a99589d" xlink:href="abvx-20251231.xsd#abvx_AGA20255Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20255Member_019bfaf6-6be7-7b43-8199-263a9a99589d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20256Member_019bfaf7-9523-7304-bde2-53ff6d310451" xlink:href="abvx-20251231.xsd#abvx_AGA20256Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20256Member_019bfaf7-9523-7304-bde2-53ff6d310451" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20257Member_019bfaf7-c34f-791b-b82a-5318dc0e92b5" xlink:href="abvx-20251231.xsd#abvx_AGA20257Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20257Member_019bfaf7-c34f-791b-b82a-5318dc0e92b5" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20258Member_019bfaf7-ee30-75cd-a998-17888b5d557b" xlink:href="abvx-20251231.xsd#abvx_AGA20258Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20258Member_019bfaf7-ee30-75cd-a998-17888b5d557b" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesAxis_09b7b9df-4e33-40b6-8a8a-6657b6fa0ef1" xlink:href="abvx-20251231.xsd#abvx_TranchesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_e440733e-c619-46da-a594-be39ed72163e" xlink:to="loc_abvx_TranchesAxis_09b7b9df-4e33-40b6-8a8a-6657b6fa0ef1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesDomain_09b7b9df-4e33-40b6-8a8a-6657b6fa0ef1_default" xlink:href="abvx-20251231.xsd#abvx_TranchesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_abvx_TranchesAxis_09b7b9df-4e33-40b6-8a8a-6657b6fa0ef1" xlink:to="loc_abvx_TranchesDomain_09b7b9df-4e33-40b6-8a8a-6657b6fa0ef1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesDomain_3de17878-cffd-468d-a372-d10fd82267dd" xlink:href="abvx-20251231.xsd#abvx_TranchesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_abvx_TranchesAxis_09b7b9df-4e33-40b6-8a8a-6657b6fa0ef1" xlink:to="loc_abvx_TranchesDomain_3de17878-cffd-468d-a372-d10fd82267dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesOneToFourMember_be82ef3d-f04e-4ee5-a585-82d5aca8125e" xlink:href="abvx-20251231.xsd#abvx_TranchesOneToFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_TranchesDomain_3de17878-cffd-468d-a372-d10fd82267dd" xlink:to="loc_abvx_TranchesOneToFourMember_be82ef3d-f04e-4ee5-a585-82d5aca8125e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheFiveMember_9f707d3c-f0ab-49c7-9a5f-01126d97dde8" xlink:href="abvx-20251231.xsd#abvx_TrancheFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_TranchesDomain_3de17878-cffd-468d-a372-d10fd82267dd" xlink:to="loc_abvx_TrancheFiveMember_9f707d3c-f0ab-49c7-9a5f-01126d97dde8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheSixMember_d1f95c06-03f8-4b3c-a2a2-c73fe949d771" xlink:href="abvx-20251231.xsd#abvx_TrancheSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_TranchesDomain_3de17878-cffd-468d-a372-d10fd82267dd" xlink:to="loc_abvx_TrancheSixMember_d1f95c06-03f8-4b3c-a2a2-c73fe949d771" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheOneMember_827db1be-c912-4b8b-8ab6-b6af511af08e" xlink:href="abvx-20251231.xsd#abvx_TrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_TranchesDomain_3de17878-cffd-468d-a372-d10fd82267dd" xlink:to="loc_abvx_TrancheOneMember_827db1be-c912-4b8b-8ab6-b6af511af08e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheTwoMember_7a1bcec3-926d-4231-b5e7-513d6fc81ac8" xlink:href="abvx-20251231.xsd#abvx_TrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_TranchesDomain_3de17878-cffd-468d-a372-d10fd82267dd" xlink:to="loc_abvx_TrancheTwoMember_7a1bcec3-926d-4231-b5e7-513d6fc81ac8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted_0c990f3d-cc1b-4596-a2bb-a502430bef02" xlink:href="abvx-20251231.xsd#abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_b3ca2a2e-c90d-4d1c-9bf9-de9711b84c9f" xlink:to="loc_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted_0c990f3d-cc1b-4596-a2bb-a502430bef02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted_0aeaf74b-20e8-4115-9e2c-7338fea6bc5b" xlink:href="abvx-20251231.xsd#abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_b3ca2a2e-c90d-4d1c-9bf9-de9711b84c9f" xlink:to="loc_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted_0aeaf74b-20e8-4115-9e2c-7338fea6bc5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted_43227f63-d871-4b05-9d00-5ad12f8d7d80" xlink:href="abvx-20251231.xsd#abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_b3ca2a2e-c90d-4d1c-9bf9-de9711b84c9f" xlink:to="loc_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted_43227f63-d871-4b05-9d00-5ad12f8d7d80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpectedVolatilityOtherEquityInstrumentsGranted_01aa0598-f4a7-4117-819b-2b397fb0f248" xlink:href="abvx-20251231.xsd#abvx_ExpectedVolatilityOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_b3ca2a2e-c90d-4d1c-9bf9-de9711b84c9f" xlink:to="loc_abvx_ExpectedVolatilityOtherEquityInstrumentsGranted_01aa0598-f4a7-4117-819b-2b397fb0f248" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted_1534f37d-db18-44c8-8fa5-8793f15a2ca0" xlink:href="abvx-20251231.xsd#abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_b3ca2a2e-c90d-4d1c-9bf9-de9711b84c9f" xlink:to="loc_abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted_1534f37d-db18-44c8-8fa5-8793f15a2ca0" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_3be04068-1f23-42a2-ab9e-a0bc2b5c7cf0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_822bc12a-13be-4a39-bfff-1a841397c162" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_3be04068-1f23-42a2-ab9e-a0bc2b5c7cf0" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_822bc12a-13be-4a39-bfff-1a841397c162" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_e67d9f5f-1c2d-4626-91aa-ab6319e8c3c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_822bc12a-13be-4a39-bfff-1a841397c162" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_e67d9f5f-1c2d-4626-91aa-ab6319e8c3c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_e67d9f5f-1c2d-4626-91aa-ab6319e8c3c2_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_e67d9f5f-1c2d-4626-91aa-ab6319e8c3c2" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_e67d9f5f-1c2d-4626-91aa-ab6319e8c3c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_16980579-7140-49dd-b956-4701d3b58e5e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_e67d9f5f-1c2d-4626-91aa-ab6319e8c3c2" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_16980579-7140-49dd-b956-4701d3b58e5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FoundersShareSubscriptionWarrantsBCEMember_adf84893-6f18-4db4-9941-563d31e999ed" xlink:href="abvx-20251231.xsd#abvx_FoundersShareSubscriptionWarrantsBCEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_16980579-7140-49dd-b956-4701d3b58e5e" xlink:to="loc_abvx_FoundersShareSubscriptionWarrantsBCEMember_adf84893-6f18-4db4-9941-563d31e999ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ShareSubscriptionWarrantsBSAMember_72c50e5e-f9fb-41b1-aa6f-b8097494c77e" xlink:href="abvx-20251231.xsd#abvx_ShareSubscriptionWarrantsBSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_16980579-7140-49dd-b956-4701d3b58e5e" xlink:to="loc_abvx_ShareSubscriptionWarrantsBSAMember_72c50e5e-f9fb-41b1-aa6f-b8097494c77e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FreeSharesAGAMember_285603fd-4072-4769-bbda-ec66366d383f" xlink:href="abvx-20251231.xsd#abvx_FreeSharesAGAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_16980579-7140-49dd-b956-4701d3b58e5e" xlink:to="loc_abvx_FreeSharesAGAMember_285603fd-4072-4769-bbda-ec66366d383f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_8fb6c5d8-17a0-4a80-9776-679994e3c0f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_3be04068-1f23-42a2-ab9e-a0bc2b5c7cf0" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_8fb6c5d8-17a0-4a80-9776-679994e3c0f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes_8b5629ba-1a6b-453a-a173-01547b2fbc0e" xlink:href="abvx-20251231.xsd#abvx_ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_3be04068-1f23-42a2-ab9e-a0bc2b5c7cf0" xlink:to="loc_abvx_ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes_8b5629ba-1a6b-453a-a173-01547b2fbc0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_39f7dc0f-4999-4436-8806-49f07908940a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_3be04068-1f23-42a2-ab9e-a0bc2b5c7cf0" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_39f7dc0f-4999-4436-8806-49f07908940a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_f988ba67-7836-40ed-804f-c775cc9451ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_b4ca613f-d6b8-42d9-a4a1-381e6b751182" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_f988ba67-7836-40ed-804f-c775cc9451ae" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_b4ca613f-d6b8-42d9-a4a1-381e6b751182" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_3c062d8d-0f33-4a06-84fc-c32d7757ebc5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_b4ca613f-d6b8-42d9-a4a1-381e6b751182" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_3c062d8d-0f33-4a06-84fc-c32d7757ebc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_3c062d8d-0f33-4a06-84fc-c32d7757ebc5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_3c062d8d-0f33-4a06-84fc-c32d7757ebc5" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_3c062d8d-0f33-4a06-84fc-c32d7757ebc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_8164547c-f892-4c72-ac89-3660ffe4a95b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_3c062d8d-0f33-4a06-84fc-c32d7757ebc5" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_8164547c-f892-4c72-ac89-3660ffe4a95b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Borrowings1Member_32df8845-b5b8-472e-a979-f0a5fd829e54" xlink:href="abvx-20251231.xsd#abvx_Borrowings1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_8164547c-f892-4c72-ac89-3660ffe4a95b" xlink:to="loc_abvx_Borrowings1Member_32df8845-b5b8-472e-a979-f0a5fd829e54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1ClaretBondLoansMember_842e9057-8a21-46d3-8bb6-e13732adea47" xlink:href="abvx-20251231.xsd#abvx_Kreos1ClaretBondLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_Borrowings1Member_32df8845-b5b8-472e-a979-f0a5fd829e54" xlink:to="loc_abvx_Kreos1ClaretBondLoansMember_842e9057-8a21-46d3-8bb6-e13732adea47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_ec3ee55c-1b57-4ca3-ad52-1b7db5eabef5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_Borrowings1Member_32df8845-b5b8-472e-a979-f0a5fd829e54" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_ec3ee55c-1b57-4ca3-ad52-1b7db5eabef5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PretGarantiParLEtatPGEMember_270cae6d-821f-4510-b3d0-df1b51677dda" xlink:href="abvx-20251231.xsd#abvx_PretGarantiParLEtatPGEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_Borrowings1Member_32df8845-b5b8-472e-a979-f0a5fd829e54" xlink:to="loc_abvx_PretGarantiParLEtatPGEMember_270cae6d-821f-4510-b3d0-df1b51677dda" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotesMember_8cf103b1-8abd-437b-93c8-eb0dc18deb30" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_8164547c-f892-4c72-ac89-3660ffe4a95b" xlink:to="loc_abvx_ConvertibleLoansNotesMember_8cf103b1-8abd-437b-93c8-eb0dc18deb30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheAMember_288d002c-69e3-4117-ad71-56c015eeb977" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_ConvertibleLoansNotesMember_8cf103b1-8abd-437b-93c8-eb0dc18deb30" xlink:to="loc_abvx_KreosClaretFinancingTrancheAMember_288d002c-69e3-4117-ad71-56c015eeb977" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_HeightsConvertibleNotesMember_2b2cb042-56a2-4b43-ba7f-5042cb4e99b6" xlink:href="abvx-20251231.xsd#abvx_HeightsConvertibleNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_ConvertibleLoansNotesMember_8cf103b1-8abd-437b-93c8-eb0dc18deb30" xlink:to="loc_abvx_HeightsConvertibleNotesMember_2b2cb042-56a2-4b43-ba7f-5042cb4e99b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativesMember_e378ff87-67ef-4be6-b035-dc1671b48702" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_8164547c-f892-4c72-ac89-3660ffe4a95b" xlink:to="loc_ifrs-full_DerivativesMember_e378ff87-67ef-4be6-b035-dc1671b48702" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretMinimumReturnIndemnificationsMember_6156b6c6-61cb-4c6c-b8ae-7a6beb8b6818" xlink:href="abvx-20251231.xsd#abvx_KreosClaretMinimumReturnIndemnificationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DerivativesMember_e378ff87-67ef-4be6-b035-dc1671b48702" xlink:to="loc_abvx_KreosClaretMinimumReturnIndemnificationsMember_6156b6c6-61cb-4c6c-b8ae-7a6beb8b6818" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingBSAMember_8a156ce0-2b52-4d12-818a-641f5e60375a" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingBSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DerivativesMember_e378ff87-67ef-4be6-b035-dc1671b48702" xlink:to="loc_abvx_KreosClaretFinancingBSAMember_8a156ce0-2b52-4d12-818a-641f5e60375a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialLiabilitiesMember_f98bd28e-99e2-4080-b110-4b53bbb21327" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_8164547c-f892-4c72-ac89-3660ffe4a95b" xlink:to="loc_abvx_OtherFinancialLiabilitiesMember_f98bd28e-99e2-4080-b110-4b53bbb21327" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConditionalAdvancesMember_170b5755-c9d8-4c51-bb5b-60de31a6195d" xlink:href="abvx-20251231.xsd#abvx_ConditionalAdvancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_OtherFinancialLiabilitiesMember_f98bd28e-99e2-4080-b110-4b53bbb21327" xlink:to="loc_abvx_ConditionalAdvancesMember_170b5755-c9d8-4c51-bb5b-60de31a6195d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificatesMember_3d29cb2b-7ec9-40f9-bfc9-f1c473ff024b" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_OtherFinancialLiabilitiesMember_f98bd28e-99e2-4080-b110-4b53bbb21327" xlink:to="loc_abvx_RoyaltyCertificatesMember_3d29cb2b-7ec9-40f9-bfc9-f1c473ff024b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialLiabilities_5ad64c42-5834-415e-be80-b3ecc28bc68b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_f988ba67-7836-40ed-804f-c775cc9451ae" xlink:to="loc_ifrs-full_NoncurrentFinancialLiabilities_5ad64c42-5834-415e-be80-b3ecc28bc68b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentFinancialLiabilities_2209f43e-e657-4cd6-b302-86bb3e0ca748" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_f988ba67-7836-40ed-804f-c775cc9451ae" xlink:to="loc_ifrs-full_CurrentFinancialLiabilities_2209f43e-e657-4cd6-b302-86bb3e0ca748" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities_a2efd26d-f298-4fa2-a282-9bb9549aa3ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_f988ba67-7836-40ed-804f-c775cc9451ae" xlink:to="loc_ifrs-full_FinancialLiabilities_a2efd26d-f298-4fa2-a282-9bb9549aa3ae" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesKreosClaretFinancingDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2d725804-2b58-4529-b3a8-ded122e8fe7d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2d725804-2b58-4529-b3a8-ded122e8fe7d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_019bfefd-f0b7-71e3-8e09-e45b9e1155a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2d725804-2b58-4529-b3a8-ded122e8fe7d" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_019bfefd-f0b7-71e3-8e09-e45b9e1155a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019bfefd-f0b7-71e3-8e09-e45b9e1155a9_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019bfefd-f0b7-71e3-8e09-e45b9e1155a9" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019bfefd-f0b7-71e3-8e09-e45b9e1155a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019bfefd-f0b7-7397-a01e-9c0fb982c54a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019bfefd-f0b7-71e3-8e09-e45b9e1155a9" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019bfefd-f0b7-7397-a01e-9c0fb982c54a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingMember_019bfefd-f0b7-7391-bf9a-cd0f45659582" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019bfefd-f0b7-7397-a01e-9c0fb982c54a" xlink:to="loc_abvx_KreosClaretFinancingMember_019bfefd-f0b7-7391-bf9a-cd0f45659582" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheAMember_019bfefe-190c-72bd-9735-f8ac34d3c33b" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019bfefd-f0b7-7397-a01e-9c0fb982c54a" xlink:to="loc_abvx_KreosClaretFinancingTrancheAMember_019bfefe-190c-72bd-9735-f8ac34d3c33b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheBMember_019bfefe-58cf-70b4-a0cd-d87c56d2329d" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019bfefd-f0b7-7397-a01e-9c0fb982c54a" xlink:to="loc_abvx_KreosClaretFinancingTrancheBMember_019bfefe-58cf-70b4-a0cd-d87c56d2329d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheCMember_019bfefe-58cf-7759-bb29-652ca1ad0273" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019bfefd-f0b7-7397-a01e-9c0fb982c54a" xlink:to="loc_abvx_KreosClaretFinancingTrancheCMember_019bfefe-58cf-7759-bb29-652ca1ad0273" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember_019bfefe-58cf-7f61-bbc3-9c0c638dfd0b" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019bfefd-f0b7-7397-a01e-9c0fb982c54a" xlink:to="loc_abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember_019bfefe-58cf-7f61-bbc3-9c0c638dfd0b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1BondLoansMember_019bfefe-b216-7a7a-8ea8-066bc2005562" xlink:href="abvx-20251231.xsd#abvx_Kreos1BondLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019bfefd-f0b7-7397-a01e-9c0fb982c54a" xlink:to="loc_abvx_Kreos1BondLoansMember_019bfefe-b216-7a7a-8ea8-066bc2005562" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosABCBSAMember_019bfefe-d819-729b-a6a4-002f3b950783" xlink:href="abvx-20251231.xsd#abvx_KreosABCBSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019bfefd-f0b7-7397-a01e-9c0fb982c54a" xlink:to="loc_abvx_KreosABCBSAMember_019bfefe-d819-729b-a6a4-002f3b950783" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingBAndCMember_019c56b3-373e-76b3-9eef-e54272a17ad2" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingBAndCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019bfefd-f0b7-7397-a01e-9c0fb982c54a" xlink:to="loc_abvx_KreosClaretFinancingBAndCMember_019c56b3-373e-76b3-9eef-e54272a17ad2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_019bfefe-58cf-796a-bda2-c3981ef6873f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2d725804-2b58-4529-b3a8-ded122e8fe7d" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_019bfefe-58cf-796a-bda2-c3981ef6873f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesDomain_019bfefe-58cf-796a-bda2-c3981ef6873f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_019bfefe-58cf-796a-bda2-c3981ef6873f" xlink:to="loc_ifrs-full_TypesOfInterestRatesDomain_019bfefe-58cf-796a-bda2-c3981ef6873f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesDomain_019bfefe-58cf-7677-aacc-088b4ee88027" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_019bfefe-58cf-796a-bda2-c3981ef6873f" xlink:to="loc_ifrs-full_TypesOfInterestRatesDomain_019bfefe-58cf-7677-aacc-088b4ee88027" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EuropeanCentralBankBaseRateMember_019bfefe-58cf-70c0-a40e-616974249b76" xlink:href="abvx-20251231.xsd#abvx_EuropeanCentralBankBaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfInterestRatesDomain_019bfefe-58cf-7677-aacc-088b4ee88027" xlink:to="loc_abvx_EuropeanCentralBankBaseRateMember_019bfefe-58cf-70c0-a40e-616974249b76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_019bfefe-58cf-79af-a4de-c092ef8acb89" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2d725804-2b58-4529-b3a8-ded122e8fe7d" xlink:to="loc_ifrs-full_RangeAxis_019bfefe-58cf-79af-a4de-c092ef8acb89" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_019bfefe-58cf-79af-a4de-c092ef8acb89_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_019bfefe-58cf-79af-a4de-c092ef8acb89" xlink:to="loc_ifrs-full_RangeDomain_019bfefe-58cf-79af-a4de-c092ef8acb89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_019bfefe-58cf-72e6-ad11-9a7e73d10db2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_019bfefe-58cf-79af-a4de-c092ef8acb89" xlink:to="loc_ifrs-full_RangeDomain_019bfefe-58cf-72e6-ad11-9a7e73d10db2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_019bfefe-58cf-7af5-bfa9-8750052b5593" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_019bfefe-58cf-72e6-ad11-9a7e73d10db2" xlink:to="loc_ifrs-full_BottomOfRangeMember_019bfefe-58cf-7af5-bfa9-8750052b5593" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_019bfefe-58cf-7caf-95ab-e480c33f258a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_019bfefe-58cf-72e6-ad11-9a7e73d10db2" xlink:to="loc_ifrs-full_TopOfRangeMember_019bfefe-58cf-7caf-95ab-e480c33f258a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_WarrantsAxis_019bfefe-b216-7673-bdca-49cc018560d8" xlink:href="abvx-20251231.xsd#abvx_WarrantsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2d725804-2b58-4529-b3a8-ded122e8fe7d" xlink:to="loc_abvx_WarrantsAxis_019bfefe-b216-7673-bdca-49cc018560d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_WarrantsDomain_019bfefe-b216-7673-bdca-49cc018560d8_default" xlink:href="abvx-20251231.xsd#abvx_WarrantsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_abvx_WarrantsAxis_019bfefe-b216-7673-bdca-49cc018560d8" xlink:to="loc_abvx_WarrantsDomain_019bfefe-b216-7673-bdca-49cc018560d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_WarrantsDomain_019bfefe-b216-7d04-9853-b555dccd1d3a" xlink:href="abvx-20251231.xsd#abvx_WarrantsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_abvx_WarrantsAxis_019bfefe-b216-7673-bdca-49cc018560d8" xlink:to="loc_abvx_WarrantsDomain_019bfefe-b216-7d04-9853-b555dccd1d3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosABBSAMember_019bfefe-b216-7699-ae9b-f37c49e2ebf7" xlink:href="abvx-20251231.xsd#abvx_KreosABBSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_WarrantsDomain_019bfefe-b216-7d04-9853-b555dccd1d3a" xlink:to="loc_abvx_KreosABBSAMember_019bfefe-b216-7699-ae9b-f37c49e2ebf7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosCBSAMember_019bfefe-b216-71cc-93a4-d4e15399dacc" xlink:href="abvx-20251231.xsd#abvx_KreosCBSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_WarrantsDomain_019bfefe-b216-7d04-9853-b555dccd1d3a" xlink:to="loc_abvx_KreosCBSAMember_019bfefe-b216-71cc-93a4-d4e15399dacc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosABCBSAMember_019bff0c-e052-7dbd-b0f9-89eb141b253e" xlink:href="abvx-20251231.xsd#abvx_KreosABCBSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_WarrantsDomain_019bfefe-b216-7d04-9853-b555dccd1d3a" xlink:to="loc_abvx_KreosABCBSAMember_019bff0c-e052-7dbd-b0f9-89eb141b253e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_019bfefe-d819-7682-8ce4-1914ffc84f44" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2d725804-2b58-4529-b3a8-ded122e8fe7d" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_019bfefe-d819-7682-8ce4-1914ffc84f44" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_019bfefe-d819-7682-8ce4-1914ffc84f44_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_019bfefe-d819-7682-8ce4-1914ffc84f44" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_019bfefe-d819-7682-8ce4-1914ffc84f44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_019bfefe-d819-749d-837f-1fc3f9a2df8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_019bfefe-d819-7682-8ce4-1914ffc84f44" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_019bfefe-d819-749d-837f-1fc3f9a2df8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_019bfefe-d819-751f-a0bb-1685db38888c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_019bfefe-d819-749d-837f-1fc3f9a2df8b" xlink:to="loc_ifrs-full_OrdinarySharesMember_019bfefe-d819-751f-a0bb-1685db38888c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialAgreementAxis_019bfefe-d819-70bc-8553-91dd2e61485f" xlink:href="abvx-20251231.xsd#abvx_FinancialAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2d725804-2b58-4529-b3a8-ded122e8fe7d" xlink:to="loc_abvx_FinancialAgreementAxis_019bfefe-d819-70bc-8553-91dd2e61485f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialAgreementDomain_019bfefe-d819-70bc-8553-91dd2e61485f_default" xlink:href="abvx-20251231.xsd#abvx_FinancialAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_abvx_FinancialAgreementAxis_019bfefe-d819-70bc-8553-91dd2e61485f" xlink:to="loc_abvx_FinancialAgreementDomain_019bfefe-d819-70bc-8553-91dd2e61485f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialAgreementDomain_019bfefe-d819-7ca6-bcb1-1d318ea29161" xlink:href="abvx-20251231.xsd#abvx_FinancialAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_abvx_FinancialAgreementAxis_019bfefe-d819-70bc-8553-91dd2e61485f" xlink:to="loc_abvx_FinancialAgreementDomain_019bfefe-d819-7ca6-bcb1-1d318ea29161" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingMember_019bff03-0eb3-7320-89fe-3b4cb0b9edab" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_FinancialAgreementDomain_019bfefe-d819-7ca6-bcb1-1d318ea29161" xlink:to="loc_abvx_KreosClaretFinancingMember_019bff03-0eb3-7320-89fe-3b4cb0b9edab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesAxis_019bfeff-00b5-72ed-9122-7bef7f97b596" xlink:href="abvx-20251231.xsd#abvx_TranchesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2d725804-2b58-4529-b3a8-ded122e8fe7d" xlink:to="loc_abvx_TranchesAxis_019bfeff-00b5-72ed-9122-7bef7f97b596" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesDomain_019bfeff-00b5-72ed-9122-7bef7f97b596_default" xlink:href="abvx-20251231.xsd#abvx_TranchesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_abvx_TranchesAxis_019bfeff-00b5-72ed-9122-7bef7f97b596" xlink:to="loc_abvx_TranchesDomain_019bfeff-00b5-72ed-9122-7bef7f97b596_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesDomain_019bfeff-00b5-76de-a855-2d9bc1d77a55" xlink:href="abvx-20251231.xsd#abvx_TranchesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_abvx_TranchesAxis_019bfeff-00b5-72ed-9122-7bef7f97b596" xlink:to="loc_abvx_TranchesDomain_019bfeff-00b5-76de-a855-2d9bc1d77a55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheABAndCMember_019bfeff-00b5-78fd-9345-78ebef8844a2" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheABAndCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_TranchesDomain_019bfeff-00b5-76de-a855-2d9bc1d77a55" xlink:to="loc_abvx_KreosClaretFinancingTrancheABAndCMember_019bfeff-00b5-78fd-9345-78ebef8844a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_019bfeff-00b5-7080-be53-dcd7dac7f3c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2d725804-2b58-4529-b3a8-ded122e8fe7d" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_019bfeff-00b5-7080-be53-dcd7dac7f3c9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_019bfeff-00b5-7080-be53-dcd7dac7f3c9_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_019bfeff-00b5-7080-be53-dcd7dac7f3c9" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_019bfeff-00b5-7080-be53-dcd7dac7f3c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_019bfeff-00b5-72d4-ad89-08d6cad5c0a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_019bfeff-00b5-7080-be53-dcd7dac7f3c9" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_019bfeff-00b5-72d4-ad89-08d6cad5c0a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretMinimumReturnIndemnificationsMember_019bfeff-00b5-7247-b73a-3e32e6de1bf5" xlink:href="abvx-20251231.xsd#abvx_KreosClaretMinimumReturnIndemnificationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_019bfeff-00b5-72d4-ad89-08d6cad5c0a6" xlink:to="loc_abvx_KreosClaretMinimumReturnIndemnificationsMember_019bfeff-00b5-7247-b73a-3e32e6de1bf5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019bfeff-82d5-7a4c-8385-489519e6b09f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2d725804-2b58-4529-b3a8-ded122e8fe7d" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019bfeff-82d5-7a4c-8385-489519e6b09f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019bfeff-82d5-7a4c-8385-489519e6b09f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019bfeff-82d5-7a4c-8385-489519e6b09f" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019bfeff-82d5-7a4c-8385-489519e6b09f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019bfeff-82d5-7c33-9511-39844f218df2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019bfeff-82d5-7a4c-8385-489519e6b09f" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019bfeff-82d5-7c33-9511-39844f218df2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosABBSAMember_019bfeff-82d5-73de-9562-4afcbd11f6af" xlink:href="abvx-20251231.xsd#abvx_KreosABBSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019bfeff-82d5-7c33-9511-39844f218df2" xlink:to="loc_abvx_KreosABBSAMember_019bfeff-82d5-73de-9562-4afcbd11f6af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretMinimumReturnIndemnificationsMember_019bfeff-b745-7feb-9264-1834b1a0be71" xlink:href="abvx-20251231.xsd#abvx_KreosClaretMinimumReturnIndemnificationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019bfeff-82d5-7c33-9511-39844f218df2" xlink:to="loc_abvx_KreosClaretMinimumReturnIndemnificationsMember_019bfeff-b745-7feb-9264-1834b1a0be71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosABCBSAMember_019bff0c-e052-7c62-95ab-804715793a0d" xlink:href="abvx-20251231.xsd#abvx_KreosABCBSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019bfeff-82d5-7c33-9511-39844f218df2" xlink:to="loc_abvx_KreosABCBSAMember_019bff0c-e052-7c62-95ab-804715793a0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosCBSAMember_019c0047-c5e4-73fa-b949-2eaea9cdc692" xlink:href="abvx-20251231.xsd#abvx_KreosCBSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019bfeff-82d5-7c33-9511-39844f218df2" xlink:to="loc_abvx_KreosCBSAMember_019c0047-c5e4-73fa-b949-2eaea9cdc692" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_019bfeff-82d5-74c4-b079-e7d00424261e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2d725804-2b58-4529-b3a8-ded122e8fe7d" xlink:to="loc_ifrs-full_UnobservableInputsAxis_019bfeff-82d5-74c4-b079-e7d00424261e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain_019bfeff-82d5-74c4-b079-e7d00424261e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_UnobservableInputsAxis_019bfeff-82d5-74c4-b079-e7d00424261e" xlink:to="loc_ifrs-full_UnobservableInputsDomain_019bfeff-82d5-74c4-b079-e7d00424261e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain_019bfeff-82d5-7be8-9d48-6d4f77fd898a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_UnobservableInputsAxis_019bfeff-82d5-74c4-b079-e7d00424261e" xlink:to="loc_ifrs-full_UnobservableInputsDomain_019bfeff-82d5-7be8-9d48-6d4f77fd898a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_MarketRateMeasurementInputMember_019bfeff-82d5-7523-9de9-3cbb04860cd9" xlink:href="abvx-20251231.xsd#abvx_MarketRateMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019bfeff-82d5-7be8-9d48-6d4f77fd898a" xlink:to="loc_abvx_MarketRateMeasurementInputMember_019bfeff-82d5-7523-9de9-3cbb04860cd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SharePriceMeasurementInputMember_019bfeff-b745-7890-bc29-434581939a82" xlink:href="abvx-20251231.xsd#abvx_SharePriceMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019bfeff-82d5-7be8-9d48-6d4f77fd898a" xlink:to="loc_abvx_SharePriceMeasurementInputMember_019bfeff-b745-7890-bc29-434581939a82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_019bfeff-b745-705d-8e84-9245cc16e966" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019bfeff-82d5-7be8-9d48-6d4f77fd898a" xlink:to="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_019bfeff-b745-705d-8e84-9245cc16e966" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RiskFreeInterestRateMeasurementInputMember_019bfeff-b745-77f5-80fc-36a6aded56d1" xlink:href="abvx-20251231.xsd#abvx_RiskFreeInterestRateMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019bfeff-82d5-7be8-9d48-6d4f77fd898a" xlink:to="loc_abvx_RiskFreeInterestRateMeasurementInputMember_019bfeff-b745-77f5-80fc-36a6aded56d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinalRedemptionScenarioProbabilityMeasurementInputMember_019bfeff-dc24-7392-8855-650ee886ba89" xlink:href="abvx-20251231.xsd#abvx_FinalRedemptionScenarioProbabilityMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019bfeff-82d5-7be8-9d48-6d4f77fd898a" xlink:to="loc_abvx_FinalRedemptionScenarioProbabilityMeasurementInputMember_019bfeff-dc24-7392-8855-650ee886ba89" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DiscountRateMeasurementInputMember_019bfeff-dc24-7e70-830c-e64ff90ebba0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DiscountRateMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019bfeff-82d5-7be8-9d48-6d4f77fd898a" xlink:to="loc_ifrs-full_DiscountRateMeasurementInputMember_019bfeff-dc24-7e70-830c-e64ff90ebba0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpiryScenarioProbablityMeasurementInputMember_019bff0c-e052-72de-83bc-12d8873a63ba" xlink:href="abvx-20251231.xsd#abvx_ExpiryScenarioProbablityMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019bfeff-82d5-7be8-9d48-6d4f77fd898a" xlink:to="loc_abvx_ExpiryScenarioProbablityMeasurementInputMember_019bff0c-e052-72de-83bc-12d8873a63ba" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_019bfeff-b745-7bad-b8eb-647b237b05e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2d725804-2b58-4529-b3a8-ded122e8fe7d" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_019bfeff-b745-7bad-b8eb-647b237b05e0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_019bfeff-b745-7bad-b8eb-647b237b05e0_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_019bfeff-b745-7bad-b8eb-647b237b05e0" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_019bfeff-b745-7bad-b8eb-647b237b05e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_019bfeff-b745-7968-bfb8-80711a1ca811" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_019bfeff-b745-7bad-b8eb-647b237b05e0" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_019bfeff-b745-7968-bfb8-80711a1ca811" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BlackScholesModelMember_019bfeff-b745-7140-af40-8b22666e9e35" xlink:href="abvx-20251231.xsd#abvx_BlackScholesModelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_019bfeff-b745-7968-bfb8-80711a1ca811" xlink:to="loc_abvx_BlackScholesModelMember_019bfeff-b745-7140-af40-8b22666e9e35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_MonteCarloModel1Member_019bfeff-b745-7518-b21b-e7c80bc398f9" xlink:href="abvx-20251231.xsd#abvx_MonteCarloModel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_019bfeff-b745-7968-bfb8-80711a1ca811" xlink:to="loc_abvx_MonteCarloModel1Member_019bfeff-b745-7518-b21b-e7c80bc398f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_019c56bf-5b1e-7528-936a-5999fe4b05aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2d725804-2b58-4529-b3a8-ded122e8fe7d" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_019c56bf-5b1e-7528-936a-5999fe4b05aa" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_019c56bf-5b1e-7528-936a-5999fe4b05aa_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_019c56bf-5b1e-7528-936a-5999fe4b05aa" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_019c56bf-5b1e-7528-936a-5999fe4b05aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_019c56bf-5b1e-7d91-a183-c5deb96b764e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_019c56bf-5b1e-7528-936a-5999fe4b05aa" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_019c56bf-5b1e-7d91-a183-c5deb96b764e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1ClaretBondLoansMember_019c56bf-5b1e-74da-a130-5cd79b88b1f6" xlink:href="abvx-20251231.xsd#abvx_Kreos1ClaretBondLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_019c56bf-5b1e-7d91-a183-c5deb96b764e" xlink:to="loc_abvx_Kreos1ClaretBondLoansMember_019c56bf-5b1e-74da-a130-5cd79b88b1f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsMaximumBorrowingCapacity_019bfefd-f0b7-790e-a120-38adabf2252a" xlink:href="abvx-20251231.xsd#abvx_BorrowingsMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_BorrowingsMaximumBorrowingCapacity_019bfefd-f0b7-790e-a120-38adabf2252a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepaymentsOfBondLoans_019bfefe-b216-7ea3-9dd6-11e37f6e7e4d" xlink:href="abvx-20251231.xsd#abvx_RepaymentsOfBondLoans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_RepaymentsOfBondLoans_019bfefe-b216-7ea3-9dd6-11e37f6e7e4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsNumberOfTranches_019bfefd-f0b7-7398-bf8b-76b2676d1733" xlink:href="abvx-20251231.xsd#abvx_BorrowingsNumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_BorrowingsNumberOfTranches_019bfefd-f0b7-7398-bf8b-76b2676d1733" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsMaximumBorrowingCapacityPerTranche_019bfefd-f0b7-7cd6-9dbb-576ae92b1802" xlink:href="abvx-20251231.xsd#abvx_BorrowingsMaximumBorrowingCapacityPerTranche"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_BorrowingsMaximumBorrowingCapacityPerTranche_019bfefd-f0b7-7cd6-9dbb-576ae92b1802" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_019bfefe-190c-72a2-a7a4-6da1222d670e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_019bfefe-190c-72a2-a7a4-6da1222d670e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsFixedConversionPrice_019bfefe-190c-706b-b789-746eaa3a0546" xlink:href="abvx-20251231.xsd#abvx_BorrowingsFixedConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_BorrowingsFixedConversionPrice_019bfefe-190c-706b-b789-746eaa3a0546" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_019bfefe-190c-75c6-b12c-59d045c6bc61" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_ifrs-full_BorrowingsInterestRate_019bfefe-190c-75c6-b12c-59d045c6bc61" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsEarlyRepaymentDiscountRate_019bfefe-190c-7555-a078-76edd7de7f1f" xlink:href="abvx-20251231.xsd#abvx_BorrowingsEarlyRepaymentDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_BorrowingsEarlyRepaymentDiscountRate_019bfefe-190c-7555-a078-76edd7de7f1f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsExitFeePercentage_019bfefe-190c-7cf8-a383-946861fee68a" xlink:href="abvx-20251231.xsd#abvx_BorrowingsExitFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_BorrowingsExitFeePercentage_019bfefe-190c-7cf8-a383-946861fee68a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsDebtToMarketCapitalizationRatio_019bfefe-58cf-708d-b262-d0572d6c8076" xlink:href="abvx-20251231.xsd#abvx_BorrowingsDebtToMarketCapitalizationRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_BorrowingsDebtToMarketCapitalizationRatio_019bfefe-58cf-708d-b262-d0572d6c8076" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsPerformanceConditionsMinimumFinancing_019bfefe-58cf-73a3-8bd8-00fb5e5ed461" xlink:href="abvx-20251231.xsd#abvx_BorrowingsPerformanceConditionsMinimumFinancing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_BorrowingsPerformanceConditionsMinimumFinancing_019bfefe-58cf-73a3-8bd8-00fb5e5ed461" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsAdjustmentToInterestRateBasis_019bfefe-58cf-734d-b3bb-6794ac3b9883" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsAdjustmentToInterestRateBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_ifrs-full_BorrowingsAdjustmentToInterestRateBasis_019bfefe-58cf-734d-b3bb-6794ac3b9883" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsBasisInterestRate_019bfefe-58cf-711d-9b0b-60d2d4526d7a" xlink:href="abvx-20251231.xsd#abvx_BorrowingsBasisInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_BorrowingsBasisInterestRate_019bfefe-58cf-711d-9b0b-60d2d4526d7a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherShareWarrantsSubscriptionPricePerShare_019bfefe-b216-7fca-9cf5-95e4d057b916" xlink:href="abvx-20251231.xsd#abvx_OtherShareWarrantsSubscriptionPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_OtherShareWarrantsSubscriptionPricePerShare_019bfefe-b216-7fca-9cf5-95e4d057b916" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfWarrantsGranted_019bfefe-b216-7334-9654-7b14b85d0646" xlink:href="abvx-20251231.xsd#abvx_NumberOfWarrantsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_NumberOfWarrantsGranted_019bfefe-b216-7334-9654-7b14b85d0646" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExercisePriceOtherEquityInstrumentsGranted_019bfefe-b216-77b8-8ee6-95a7f8b51e9d" xlink:href="abvx-20251231.xsd#abvx_ExercisePriceOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_ExercisePriceOtherEquityInstrumentsGranted_019bfefe-b216-77b8-8ee6-95a7f8b51e9d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted_019bfefe-b216-731b-8247-c79689f4a7ee" xlink:href="abvx-20251231.xsd#abvx_ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted_019bfefe-b216-731b-8247-c79689f4a7ee" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted_019bfefe-b216-7b22-9451-68ac6e300cdb" xlink:href="abvx-20251231.xsd#abvx_ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted_019bfefe-b216-7b22-9451-68ac6e300cdb" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IssuanceOfOtherShareWarrants_019bfefe-b216-7a76-bc7d-57c7484c3888" xlink:href="abvx-20251231.xsd#abvx_IssuanceOfOtherShareWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_IssuanceOfOtherShareWarrants_019bfefe-b216-7a76-bc7d-57c7484c3888" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsPercentageExercisableImmediately_019bfefe-b216-7f5d-aba3-d1b1e0ef67b6" xlink:href="abvx-20251231.xsd#abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsPercentageExercisableImmediately"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsPercentageExercisableImmediately_019bfefe-b216-7f5d-aba3-d1b1e0ef67b6" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsRemainingPercentageExercisable_019bfefe-b216-7319-b927-50206565ca44" xlink:href="abvx-20251231.xsd#abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsRemainingPercentageExercisable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsRemainingPercentageExercisable_019bfefe-b216-7319-b927-50206565ca44" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherShareWarrantsExercisePeriod_019bfefe-b216-7970-8ef6-0426d1d6929c" xlink:href="abvx-20251231.xsd#abvx_OtherShareWarrantsExercisePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_OtherShareWarrantsExercisePeriod_019bfefe-b216-7970-8ef6-0426d1d6929c" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments_019bfefe-d819-7e34-9eca-c12f279daaa5" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments_019bfefe-d819-7e34-9eca-c12f279daaa5" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_019bfefe-d819-7ec0-a72a-1b4c9d30aba1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_019bfefe-d819-7ec0-a72a-1b4c9d30aba1" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfWarrantsRepurchased_019bfefe-d819-78dd-b858-386bfe8107a0" xlink:href="abvx-20251231.xsd#abvx_NumberOfWarrantsRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_NumberOfWarrantsRepurchased_019bfefe-d819-78dd-b858-386bfe8107a0" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants_019bfefe-d819-76b6-853c-da7f044c3269" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants_019bfefe-d819-76b6-853c-da7f044c3269" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_019cfcce-9713-73cb-a6dc-5cecf1a7dceb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_019cfcce-9713-73cb-a6dc-5cecf1a7dceb" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding_019bfeff-00b5-7325-8631-ade5906ff8ce" xlink:href="abvx-20251231.xsd#abvx_AggregateFairValueOtherEquityInstrumentsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding_019bfeff-00b5-7325-8631-ade5906ff8ce" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_019c56b3-373e-7d6b-9806-84dd9630a285" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_019c56b3-373e-7d6b-9806-84dd9630a285" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_019c56bb-c8ad-7a1d-aa49-105f5750d0fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_ifrs-full_Borrowings_019c56bb-c8ad-7a1d-aa49-105f5750d0fd" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsDeposit_019c56b4-da50-7300-a5b4-9fe89fb33835" xlink:href="abvx-20251231.xsd#abvx_BorrowingsDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_BorrowingsDeposit_019c56b4-da50-7300-a5b4-9fe89fb33835" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsDiscountRate_019c56bd-58fc-7f8e-828e-1a4251c5a793" xlink:href="abvx-20251231.xsd#abvx_BorrowingsDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_BorrowingsDiscountRate_019c56bd-58fc-7f8e-828e-1a4251c5a793" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_019c56ba-78b5-71cb-af61-30c8b159f573" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_019c56ba-78b5-71cb-af61-30c8b159f573" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsExitFeeAmount_019c57ec-2964-7cc1-a9c1-aa3bdeac1ba4" xlink:href="abvx-20251231.xsd#abvx_BorrowingsExitFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_BorrowingsExitFeeAmount_019c57ec-2964-7cc1-a9c1-aa3bdeac1ba4" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid_019c56c6-6e6f-7865-b098-1eee8ae22e25" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid_019c56c6-6e6f-7865-b098-1eee8ae22e25" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_019c56d5-139c-7bf5-a5fb-32d5ee832f4a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_ifrs-full_NotionalAmount_019c56d5-139c-7bf5-a5fb-32d5ee832f4a" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValue_019bfeff-82d5-7687-91e5-b85640ccec44" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValue_019bfeff-82d5-7687-91e5-b85640ccec44" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities_019bfeff-82d5-7e60-af27-9c7bb84a1892" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_ifrs-full_SignificantUnobservableInputLiabilities_019bfeff-82d5-7e60-af27-9c7bb84a1892" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotes_019bfeff-82d5-79dd-84ce-297e6d15e1d9" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_ConvertibleLoansNotes_019bfeff-82d5-79dd-84ce-297e6d15e1d9" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotesCarryingAmountOfTheEquityComponent_019bfeff-82d5-7b04-ac27-3d08313b0bd6" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotesCarryingAmountOfTheEquityComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_ConvertibleLoansNotesCarryingAmountOfTheEquityComponent_019bfeff-82d5-7b04-ac27-3d08313b0bd6" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bfeff-82d5-72b5-83b6-cbd5d8a5b024" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bfeff-82d5-72b5-83b6-cbd5d8a5b024" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bfeff-82d5-7fb2-9fd3-3b35ba90d069" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bfeff-82d5-7fb2-9fd3-3b35ba90d069" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bfeff-dc24-7094-8820-4c4406c53691" xlink:href="abvx-20251231.xsd#abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bfeff-dc24-7094-8820-4c4406c53691" xlink:type="arc" order="42"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets_019bfeff-dc24-704e-856f-eebc0671514d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets_019bfeff-dc24-704e-856f-eebc0671514d" xlink:type="arc" order="43"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted_019bff0c-e052-708d-a4c3-19905e9ff88e" xlink:href="abvx-20251231.xsd#abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted_019bff0c-e052-708d-a4c3-19905e9ff88e" xlink:type="arc" order="44"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities_019c56bf-5b1e-73fb-baa0-823b1300875f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities_019c56bf-5b1e-73fb-baa0-823b1300875f" xlink:type="arc" order="45"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_9872e8ad-dc13-43ab-a0f3-9d170405ce0f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_36cd83a0-7931-48fc-b0df-94f3b271081f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_9872e8ad-dc13-43ab-a0f3-9d170405ce0f" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_36cd83a0-7931-48fc-b0df-94f3b271081f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_a84674cd-1a26-4dd5-b547-078dee1358fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_36cd83a0-7931-48fc-b0df-94f3b271081f" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_a84674cd-1a26-4dd5-b547-078dee1358fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_a84674cd-1a26-4dd5-b547-078dee1358fa_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_a84674cd-1a26-4dd5-b547-078dee1358fa" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_a84674cd-1a26-4dd5-b547-078dee1358fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_06bcadf2-00bd-4f1d-9716-8b1820858b45" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_a84674cd-1a26-4dd5-b547-078dee1358fa" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_06bcadf2-00bd-4f1d-9716-8b1820858b45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretMinimumReturnIndemnificationsMember_94e984e7-b7d7-43b3-b648-fec3925fc43e" xlink:href="abvx-20251231.xsd#abvx_KreosClaretMinimumReturnIndemnificationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_06bcadf2-00bd-4f1d-9716-8b1820858b45" xlink:to="loc_abvx_KreosClaretMinimumReturnIndemnificationsMember_94e984e7-b7d7-43b3-b648-fec3925fc43e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_768050a3-57f8-487a-b829-3f09a7798321" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_36cd83a0-7931-48fc-b0df-94f3b271081f" xlink:to="loc_ifrs-full_UnobservableInputsAxis_768050a3-57f8-487a-b829-3f09a7798321" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain_768050a3-57f8-487a-b829-3f09a7798321_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_UnobservableInputsAxis_768050a3-57f8-487a-b829-3f09a7798321" xlink:to="loc_ifrs-full_UnobservableInputsDomain_768050a3-57f8-487a-b829-3f09a7798321_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain_13497e69-3221-4bae-849d-162e23accfba" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_UnobservableInputsAxis_768050a3-57f8-487a-b829-3f09a7798321" xlink:to="loc_ifrs-full_UnobservableInputsDomain_13497e69-3221-4bae-849d-162e23accfba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinalRedemptionScenarioProbabilityMeasurementInputMember_68a89ecb-c5e5-408f-91ef-0c48f92e9f24" xlink:href="abvx-20251231.xsd#abvx_FinalRedemptionScenarioProbabilityMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_13497e69-3221-4bae-849d-162e23accfba" xlink:to="loc_abvx_FinalRedemptionScenarioProbabilityMeasurementInputMember_68a89ecb-c5e5-408f-91ef-0c48f92e9f24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_MinimalReturnMeasurementInputMember_00eb163c-99bf-48c5-8ab6-4f7ff4e202b2" xlink:href="abvx-20251231.xsd#abvx_MinimalReturnMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_13497e69-3221-4bae-849d-162e23accfba" xlink:to="loc_abvx_MinimalReturnMeasurementInputMember_00eb163c-99bf-48c5-8ab6-4f7ff4e202b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DiscountRateMeasurementInputMember_d977269c-5c93-4964-b1d0-d54ee84527c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DiscountRateMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_13497e69-3221-4bae-849d-162e23accfba" xlink:to="loc_ifrs-full_DiscountRateMeasurementInputMember_d977269c-5c93-4964-b1d0-d54ee84527c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember_65d80013-b519-4c4b-9df2-9bab15aa222a" xlink:href="abvx-20251231.xsd#abvx_FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_13497e69-3221-4bae-849d-162e23accfba" xlink:to="loc_abvx_FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember_65d80013-b519-4c4b-9df2-9bab15aa222a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember_916024b2-f762-4677-b25a-a0995c10ef93" xlink:href="abvx-20251231.xsd#abvx_TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_13497e69-3221-4bae-849d-162e23accfba" xlink:to="loc_abvx_TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember_916024b2-f762-4677-b25a-a0995c10ef93" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember_f36618a9-1e2f-43c6-9250-d6c668797a3a" xlink:href="abvx-20251231.xsd#abvx_FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_13497e69-3221-4bae-849d-162e23accfba" xlink:to="loc_abvx_FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember_f36618a9-1e2f-43c6-9250-d6c668797a3a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember_8af5ce17-404c-41a9-837f-6de6b0d11ffb" xlink:href="abvx-20251231.xsd#abvx_FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_13497e69-3221-4bae-849d-162e23accfba" xlink:to="loc_abvx_FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember_8af5ce17-404c-41a9-837f-6de6b0d11ffb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinalRedemptionFairValueOfMRIMeasurementInputMember_7265268a-6add-4bf4-aa1a-9745fb699b8c" xlink:href="abvx-20251231.xsd#abvx_FinalRedemptionFairValueOfMRIMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_13497e69-3221-4bae-849d-162e23accfba" xlink:to="loc_abvx_FinalRedemptionFairValueOfMRIMeasurementInputMember_7265268a-6add-4bf4-aa1a-9745fb699b8c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TenderOfferFairValueOfMRIMeasurementInputMember_c97f3eb8-8833-497e-84cd-8c302e4372ac" xlink:href="abvx-20251231.xsd#abvx_TenderOfferFairValueOfMRIMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_13497e69-3221-4bae-849d-162e23accfba" xlink:to="loc_abvx_TenderOfferFairValueOfMRIMeasurementInputMember_c97f3eb8-8833-497e-84cd-8c302e4372ac" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_b1590cdc-d247-4ac7-b801-bc3a84f5656a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_36cd83a0-7931-48fc-b0df-94f3b271081f" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_b1590cdc-d247-4ac7-b801-bc3a84f5656a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_b1590cdc-d247-4ac7-b801-bc3a84f5656a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_b1590cdc-d247-4ac7-b801-bc3a84f5656a" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_b1590cdc-d247-4ac7-b801-bc3a84f5656a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_7b61290a-2065-40b2-a3b2-447e5ccd344d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_b1590cdc-d247-4ac7-b801-bc3a84f5656a" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_7b61290a-2065-40b2-a3b2-447e5ccd344d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AmortizedCostEIRMethodMember_70cbd0d6-8c2b-4de2-9475-3c8240d70e3a" xlink:href="abvx-20251231.xsd#abvx_AmortizedCostEIRMethodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_7b61290a-2065-40b2-a3b2-447e5ccd344d" xlink:to="loc_abvx_AmortizedCostEIRMethodMember_70cbd0d6-8c2b-4de2-9475-3c8240d70e3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesAxis_e182b80b-b796-4c25-96ea-19da86e25baa" xlink:href="abvx-20251231.xsd#abvx_TranchesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_36cd83a0-7931-48fc-b0df-94f3b271081f" xlink:to="loc_abvx_TranchesAxis_e182b80b-b796-4c25-96ea-19da86e25baa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesDomain_e182b80b-b796-4c25-96ea-19da86e25baa_default" xlink:href="abvx-20251231.xsd#abvx_TranchesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_abvx_TranchesAxis_e182b80b-b796-4c25-96ea-19da86e25baa" xlink:to="loc_abvx_TranchesDomain_e182b80b-b796-4c25-96ea-19da86e25baa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesDomain_9e1e2092-4488-4e98-a620-1a08d01656e9" xlink:href="abvx-20251231.xsd#abvx_TranchesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_abvx_TranchesAxis_e182b80b-b796-4c25-96ea-19da86e25baa" xlink:to="loc_abvx_TranchesDomain_9e1e2092-4488-4e98-a620-1a08d01656e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheBMember_1d4d516c-bdf6-4262-a8f2-8df550cb4c07" xlink:href="abvx-20251231.xsd#abvx_TrancheBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_TranchesDomain_9e1e2092-4488-4e98-a620-1a08d01656e9" xlink:to="loc_abvx_TrancheBMember_1d4d516c-bdf6-4262-a8f2-8df550cb4c07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheCMember_d26ff512-170d-4682-a733-23c6fbb3fa7e" xlink:href="abvx-20251231.xsd#abvx_TrancheCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_TranchesDomain_9e1e2092-4488-4e98-a620-1a08d01656e9" xlink:to="loc_abvx_TrancheCMember_d26ff512-170d-4682-a733-23c6fbb3fa7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities_7d715588-af4a-4813-bc29-c81392ee0579" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_9872e8ad-dc13-43ab-a0f3-9d170405ce0f" xlink:to="loc_ifrs-full_SignificantUnobservableInputLiabilities_7d715588-af4a-4813-bc29-c81392ee0579" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding_efc7bee9-461d-4579-8450-73a957fd4c73" xlink:href="abvx-20251231.xsd#abvx_AggregateFairValueOtherEquityInstrumentsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_9872e8ad-dc13-43ab-a0f3-9d170405ce0f" xlink:to="loc_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding_efc7bee9-461d-4579-8450-73a957fd4c73" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfWarrantsArrangementsLineItems_d7994492-1e50-4fc6-a2ab-b3d7fe738371" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfWarrantsArrangementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfWarrantsArrangementsTable_10900a4b-72f0-4dcd-bef1-1eb16b6a3947" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfWarrantsArrangementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsLineItems_d7994492-1e50-4fc6-a2ab-b3d7fe738371" xlink:to="loc_abvx_DisclosureOfWarrantsArrangementsTable_10900a4b-72f0-4dcd-bef1-1eb16b6a3947" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_WarrantsAxis_3a452a7e-63be-45fc-b642-9950260545a1" xlink:href="abvx-20251231.xsd#abvx_WarrantsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsTable_10900a4b-72f0-4dcd-bef1-1eb16b6a3947" xlink:to="loc_abvx_WarrantsAxis_3a452a7e-63be-45fc-b642-9950260545a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_WarrantsDomain_3a452a7e-63be-45fc-b642-9950260545a1_default" xlink:href="abvx-20251231.xsd#abvx_WarrantsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_abvx_WarrantsAxis_3a452a7e-63be-45fc-b642-9950260545a1" xlink:to="loc_abvx_WarrantsDomain_3a452a7e-63be-45fc-b642-9950260545a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_WarrantsDomain_1c2ea615-bac9-47b1-8434-1019915c82fc" xlink:href="abvx-20251231.xsd#abvx_WarrantsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_abvx_WarrantsAxis_3a452a7e-63be-45fc-b642-9950260545a1" xlink:to="loc_abvx_WarrantsDomain_1c2ea615-bac9-47b1-8434-1019915c82fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosABBSAMember_ceaea5e7-c61b-47d9-ae14-dc7208568f89" xlink:href="abvx-20251231.xsd#abvx_KreosABBSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_WarrantsDomain_1c2ea615-bac9-47b1-8434-1019915c82fc" xlink:to="loc_abvx_KreosABBSAMember_ceaea5e7-c61b-47d9-ae14-dc7208568f89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosCBSAMember_bff0f80f-1b07-45cd-b25c-326601e5f69d" xlink:href="abvx-20251231.xsd#abvx_KreosCBSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_WarrantsDomain_1c2ea615-bac9-47b1-8434-1019915c82fc" xlink:to="loc_abvx_KreosCBSAMember_bff0f80f-1b07-45cd-b25c-326601e5f69d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_b8db9b02-bb20-4132-8c72-1ef096aa02f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsTable_10900a4b-72f0-4dcd-bef1-1eb16b6a3947" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_b8db9b02-bb20-4132-8c72-1ef096aa02f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_b8db9b02-bb20-4132-8c72-1ef096aa02f8_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_b8db9b02-bb20-4132-8c72-1ef096aa02f8" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_b8db9b02-bb20-4132-8c72-1ef096aa02f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_05b99197-9573-442b-9fe4-36ba04f9521f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_b8db9b02-bb20-4132-8c72-1ef096aa02f8" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_05b99197-9573-442b-9fe4-36ba04f9521f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosABBSAMember_4b51b439-eee7-4bd9-a318-05419921d67b" xlink:href="abvx-20251231.xsd#abvx_KreosABBSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_05b99197-9573-442b-9fe4-36ba04f9521f" xlink:to="loc_abvx_KreosABBSAMember_4b51b439-eee7-4bd9-a318-05419921d67b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosCBSAMember_6e097aea-66dc-455d-bda3-1cb2ee73ca38" xlink:href="abvx-20251231.xsd#abvx_KreosCBSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_05b99197-9573-442b-9fe4-36ba04f9521f" xlink:to="loc_abvx_KreosCBSAMember_6e097aea-66dc-455d-bda3-1cb2ee73ca38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_9b25b42f-6eca-4b28-bb28-f138c05e5663" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsTable_10900a4b-72f0-4dcd-bef1-1eb16b6a3947" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_9b25b42f-6eca-4b28-bb28-f138c05e5663" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_9b25b42f-6eca-4b28-bb28-f138c05e5663_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_9b25b42f-6eca-4b28-bb28-f138c05e5663" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_9b25b42f-6eca-4b28-bb28-f138c05e5663_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_af52823c-9cf6-41b3-932e-3af301f83a22" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_9b25b42f-6eca-4b28-bb28-f138c05e5663" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_af52823c-9cf6-41b3-932e-3af301f83a22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OptionPricingModelMember_8ba5ca94-62fd-4787-ae19-a8980c39b5ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OptionPricingModelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_af52823c-9cf6-41b3-932e-3af301f83a22" xlink:to="loc_ifrs-full_OptionPricingModelMember_8ba5ca94-62fd-4787-ae19-a8980c39b5ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_e1b99aac-5813-4b22-bc78-03c11c715f48" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsTable_10900a4b-72f0-4dcd-bef1-1eb16b6a3947" xlink:to="loc_ifrs-full_UnobservableInputsAxis_e1b99aac-5813-4b22-bc78-03c11c715f48" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain_e1b99aac-5813-4b22-bc78-03c11c715f48_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_UnobservableInputsAxis_e1b99aac-5813-4b22-bc78-03c11c715f48" xlink:to="loc_ifrs-full_UnobservableInputsDomain_e1b99aac-5813-4b22-bc78-03c11c715f48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain_1ea3f684-57da-4869-b3e6-ff6b1f8ca68f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_UnobservableInputsAxis_e1b99aac-5813-4b22-bc78-03c11c715f48" xlink:to="loc_ifrs-full_UnobservableInputsDomain_1ea3f684-57da-4869-b3e6-ff6b1f8ca68f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExercisePricePerShareMeasurementInputMember_c83ed6e0-32cf-435a-b205-89e9d907a641" xlink:href="abvx-20251231.xsd#abvx_ExercisePricePerShareMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_1ea3f684-57da-4869-b3e6-ff6b1f8ca68f" xlink:to="loc_abvx_ExercisePricePerShareMeasurementInputMember_c83ed6e0-32cf-435a-b205-89e9d907a641" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SharePriceMeasurementInputMember_e7a442ae-d47e-4d92-b400-087cd5f747e3" xlink:href="abvx-20251231.xsd#abvx_SharePriceMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_1ea3f684-57da-4869-b3e6-ff6b1f8ca68f" xlink:to="loc_abvx_SharePriceMeasurementInputMember_e7a442ae-d47e-4d92-b400-087cd5f747e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpiryScenarioProbablityMeasurementInputMember_bff38aa4-36ac-41d3-9bd6-f725b81a0941" xlink:href="abvx-20251231.xsd#abvx_ExpiryScenarioProbablityMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_1ea3f684-57da-4869-b3e6-ff6b1f8ca68f" xlink:to="loc_abvx_ExpiryScenarioProbablityMeasurementInputMember_bff38aa4-36ac-41d3-9bd6-f725b81a0941" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DrawdownProbablityMeasurementInputMember_33e6a508-5ca8-41f7-ad6c-dcf230cf1d22" xlink:href="abvx-20251231.xsd#abvx_DrawdownProbablityMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_1ea3f684-57da-4869-b3e6-ff6b1f8ca68f" xlink:to="loc_abvx_DrawdownProbablityMeasurementInputMember_33e6a508-5ca8-41f7-ad6c-dcf230cf1d22" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VolatilityForSharesMeasurementInputExpiryMember_c980c27c-a675-47dc-b0e4-3024763d6706" xlink:href="abvx-20251231.xsd#abvx_VolatilityForSharesMeasurementInputExpiryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_1ea3f684-57da-4869-b3e6-ff6b1f8ca68f" xlink:to="loc_abvx_VolatilityForSharesMeasurementInputExpiryMember_c980c27c-a675-47dc-b0e4-3024763d6706" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VolatilityForSharesMeasurementInputTenderOfferMember_43c9b57c-bc26-4b05-98df-a9e374ca5d8b" xlink:href="abvx-20251231.xsd#abvx_VolatilityForSharesMeasurementInputTenderOfferMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_1ea3f684-57da-4869-b3e6-ff6b1f8ca68f" xlink:to="loc_abvx_VolatilityForSharesMeasurementInputTenderOfferMember_43c9b57c-bc26-4b05-98df-a9e374ca5d8b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpectedDividendMeasurementInputMember_d24025c8-ede3-4660-b0ec-a39ff6ea81cb" xlink:href="abvx-20251231.xsd#abvx_ExpectedDividendMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_1ea3f684-57da-4869-b3e6-ff6b1f8ca68f" xlink:to="loc_abvx_ExpectedDividendMeasurementInputMember_d24025c8-ede3-4660-b0ec-a39ff6ea81cb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RiskFreeInterestRateMeasurementInputMember_72b958c6-3b1d-400e-b260-cbfd799b326a" xlink:href="abvx-20251231.xsd#abvx_RiskFreeInterestRateMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_1ea3f684-57da-4869-b3e6-ff6b1f8ca68f" xlink:to="loc_abvx_RiskFreeInterestRateMeasurementInputMember_72b958c6-3b1d-400e-b260-cbfd799b326a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RiskFreeInterestRateMeasurementInputExpiryMember_ae5061f2-98a8-470e-a975-c236f86a8c7a" xlink:href="abvx-20251231.xsd#abvx_RiskFreeInterestRateMeasurementInputExpiryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_1ea3f684-57da-4869-b3e6-ff6b1f8ca68f" xlink:to="loc_abvx_RiskFreeInterestRateMeasurementInputExpiryMember_ae5061f2-98a8-470e-a975-c236f86a8c7a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RiskFreeInterestRateMeasurementInputTenderOfferMember_e490440b-84f5-406f-8654-0847580de6cc" xlink:href="abvx-20251231.xsd#abvx_RiskFreeInterestRateMeasurementInputTenderOfferMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_1ea3f684-57da-4869-b3e6-ff6b1f8ca68f" xlink:to="loc_abvx_RiskFreeInterestRateMeasurementInputTenderOfferMember_e490440b-84f5-406f-8654-0847580de6cc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfProbabilityWeightedScenarios_4946f6e1-9293-4db8-9933-1415b1d8f7ec" xlink:href="abvx-20251231.xsd#abvx_NumberOfProbabilityWeightedScenarios"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsLineItems_d7994492-1e50-4fc6-a2ab-b3d7fe738371" xlink:to="loc_abvx_NumberOfProbabilityWeightedScenarios_4946f6e1-9293-4db8-9933-1415b1d8f7ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted_9cf42215-b004-4674-aa40-a31f52568d2a" xlink:href="abvx-20251231.xsd#abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsLineItems_d7994492-1e50-4fc6-a2ab-b3d7fe738371" xlink:to="loc_abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted_9cf42215-b004-4674-aa40-a31f52568d2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfWarrantsOutstanding_9369da01-f1f2-4660-95b9-9617be73e253" xlink:href="abvx-20251231.xsd#abvx_NumberOfWarrantsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsLineItems_d7994492-1e50-4fc6-a2ab-b3d7fe738371" xlink:to="loc_abvx_NumberOfWarrantsOutstanding_9369da01-f1f2-4660-95b9-9617be73e253" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfWarrantsOutstandingSubjectToNonMarketPerformanceCondition_f2719dee-12dc-4188-b8de-9093f8b9bc30" xlink:href="abvx-20251231.xsd#abvx_NumberOfWarrantsOutstandingSubjectToNonMarketPerformanceCondition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsLineItems_d7994492-1e50-4fc6-a2ab-b3d7fe738371" xlink:to="loc_abvx_NumberOfWarrantsOutstandingSubjectToNonMarketPerformanceCondition_f2719dee-12dc-4188-b8de-9093f8b9bc30" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities_0548aa26-b075-4d10-af03-ddb2486b8ab6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsLineItems_d7994492-1e50-4fc6-a2ab-b3d7fe738371" xlink:to="loc_ifrs-full_SignificantUnobservableInputLiabilities_0548aa26-b075-4d10-af03-ddb2486b8ab6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding_9d9e1fa2-1111-4bb8-9ea7-f0efd382e810" xlink:href="abvx-20251231.xsd#abvx_AggregateFairValueOtherEquityInstrumentsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsLineItems_d7994492-1e50-4fc6-a2ab-b3d7fe738371" xlink:to="loc_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding_9d9e1fa2-1111-4bb8-9ea7-f0efd382e810" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesHeightsconvertiblenotesDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_b068f566-e3c9-4f43-b0cd-3ff8579756cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_b068f566-e3c9-4f43-b0cd-3ff8579756cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_019bff12-946a-7a51-bd9a-32e2f3205c7f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_b068f566-e3c9-4f43-b0cd-3ff8579756cd" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_019bff12-946a-7a51-bd9a-32e2f3205c7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019bff12-946a-7a51-bd9a-32e2f3205c7f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019bff12-946a-7a51-bd9a-32e2f3205c7f" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019bff12-946a-7a51-bd9a-32e2f3205c7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019bff12-946a-72c0-859d-d805b393d44a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019bff12-946a-7a51-bd9a-32e2f3205c7f" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019bff12-946a-72c0-859d-d805b393d44a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_HeightsConvertibleNotesMember_019bff12-946a-7472-a528-1e5927176811" xlink:href="abvx-20251231.xsd#abvx_HeightsConvertibleNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019bff12-946a-72c0-859d-d805b393d44a" xlink:to="loc_abvx_HeightsConvertibleNotesMember_019bff12-946a-7472-a528-1e5927176811" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_HeightsConvertibleNotesTrancheAMember_019bff12-946a-779e-bf7c-43680d555e8c" xlink:href="abvx-20251231.xsd#abvx_HeightsConvertibleNotesTrancheAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019bff12-946a-72c0-859d-d805b393d44a" xlink:to="loc_abvx_HeightsConvertibleNotesTrancheAMember_019bff12-946a-779e-bf7c-43680d555e8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_HeightsConvertibleNotesTrancheBMember_019bff12-946a-7c20-824a-7644194ca7d3" xlink:href="abvx-20251231.xsd#abvx_HeightsConvertibleNotesTrancheBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019bff12-946a-72c0-859d-d805b393d44a" xlink:to="loc_abvx_HeightsConvertibleNotesTrancheBMember_019bff12-946a-7c20-824a-7644194ca7d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OCEANEMember_019bff13-18dc-7fa8-b908-2ce651b29da5" xlink:href="abvx-20251231.xsd#abvx_OCEANEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019bff12-946a-72c0-859d-d805b393d44a" xlink:to="loc_abvx_OCEANEMember_019bff13-18dc-7fa8-b908-2ce651b29da5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019bff12-946a-74cc-8a70-bd34e286ed55" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_b068f566-e3c9-4f43-b0cd-3ff8579756cd" xlink:to="loc_srt_RangeAxis_019bff12-946a-74cc-8a70-bd34e286ed55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019bff12-946a-74cc-8a70-bd34e286ed55_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_019bff12-946a-74cc-8a70-bd34e286ed55" xlink:to="loc_srt_RangeMember_019bff12-946a-74cc-8a70-bd34e286ed55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019bff12-946a-71b0-8b53-e3a0cbd35648" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_019bff12-946a-74cc-8a70-bd34e286ed55" xlink:to="loc_srt_RangeMember_019bff12-946a-71b0-8b53-e3a0cbd35648" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019bff12-946a-7500-a636-2f0ee1fd3944" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019bff12-946a-71b0-8b53-e3a0cbd35648" xlink:to="loc_srt_MinimumMember_019bff12-946a-7500-a636-2f0ee1fd3944" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019bff12-ec92-7c6e-8239-d37362a7659c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019bff12-946a-71b0-8b53-e3a0cbd35648" xlink:to="loc_srt_MaximumMember_019bff12-ec92-7c6e-8239-d37362a7659c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_019bff13-a23c-71b7-a9c0-541434254536" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_b068f566-e3c9-4f43-b0cd-3ff8579756cd" xlink:to="loc_ifrs-full_UnobservableInputsAxis_019bff13-a23c-71b7-a9c0-541434254536" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain_019bff13-a23c-71b7-a9c0-541434254536_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_UnobservableInputsAxis_019bff13-a23c-71b7-a9c0-541434254536" xlink:to="loc_ifrs-full_UnobservableInputsDomain_019bff13-a23c-71b7-a9c0-541434254536_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain_019bff13-a23c-7f06-b1ba-b956d500f3d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_UnobservableInputsAxis_019bff13-a23c-71b7-a9c0-541434254536" xlink:to="loc_ifrs-full_UnobservableInputsDomain_019bff13-a23c-7f06-b1ba-b956d500f3d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_019bff13-a23c-7aaf-8965-46974d5e78f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019bff13-a23c-7f06-b1ba-b956d500f3d7" xlink:to="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_019bff13-a23c-7aaf-8965-46974d5e78f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SharePriceMeasurementInputMember_019bff13-a23c-7480-8cdb-a47093bbe6e3" xlink:href="abvx-20251231.xsd#abvx_SharePriceMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019bff13-a23c-7f06-b1ba-b956d500f3d7" xlink:to="loc_abvx_SharePriceMeasurementInputMember_019bff13-a23c-7480-8cdb-a47093bbe6e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RiskFreeInterestRateMeasurementInputMember_019bff13-a23c-710d-b8d9-ecfcbe68b08c" xlink:href="abvx-20251231.xsd#abvx_RiskFreeInterestRateMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019bff13-a23c-7f06-b1ba-b956d500f3d7" xlink:to="loc_abvx_RiskFreeInterestRateMeasurementInputMember_019bff13-a23c-710d-b8d9-ecfcbe68b08c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VoluntaryConversionScenarioProbabilityMeasurementInputMember_019bff13-a23c-7c66-8400-debadf55571b" xlink:href="abvx-20251231.xsd#abvx_VoluntaryConversionScenarioProbabilityMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019bff13-a23c-7f06-b1ba-b956d500f3d7" xlink:to="loc_abvx_VoluntaryConversionScenarioProbabilityMeasurementInputMember_019bff13-a23c-7c66-8400-debadf55571b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019bff13-a23c-7b01-9cac-3b84fd31dbef" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_b068f566-e3c9-4f43-b0cd-3ff8579756cd" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019bff13-a23c-7b01-9cac-3b84fd31dbef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019bff13-a23c-7b01-9cac-3b84fd31dbef_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019bff13-a23c-7b01-9cac-3b84fd31dbef" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019bff13-a23c-7b01-9cac-3b84fd31dbef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019bff13-a23c-7887-8253-60037e437a8f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019bff13-a23c-7b01-9cac-3b84fd31dbef" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019bff13-a23c-7887-8253-60037e437a8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_HeightsConvertibleNotesTrancheAMember_019bff13-a23c-7a80-b4b9-b278b97ac4ac" xlink:href="abvx-20251231.xsd#abvx_HeightsConvertibleNotesTrancheAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019bff13-a23c-7887-8253-60037e437a8f" xlink:to="loc_abvx_HeightsConvertibleNotesTrancheAMember_019bff13-a23c-7a80-b4b9-b278b97ac4ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsMaximumBorrowingCapacity_019bff12-946a-7a65-a938-28ef01967da8" xlink:href="abvx-20251231.xsd#abvx_BorrowingsMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_BorrowingsMaximumBorrowingCapacity_019bff12-946a-7a65-a938-28ef01967da8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsNumberOfTranches_019bff12-946a-7458-a4d3-4c1302c63185" xlink:href="abvx-20251231.xsd#abvx_BorrowingsNumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_BorrowingsNumberOfTranches_019bff12-946a-7458-a4d3-4c1302c63185" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NetProceedsFromConvertibleLoansNotes_019bff12-946a-7c12-a2a1-368622ea9a9e" xlink:href="abvx-20251231.xsd#abvx_NetProceedsFromConvertibleLoansNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_NetProceedsFromConvertibleLoansNotes_019bff12-946a-7c12-a2a1-368622ea9a9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfConvertibleNotesIssued_019bff12-946a-7457-8a27-5bbb0f6e8a3a" xlink:href="abvx-20251231.xsd#abvx_NumberOfConvertibleNotesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_NumberOfConvertibleNotesIssued_019bff12-946a-7457-8a27-5bbb0f6e8a3a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotesNominalValue_019bff12-946a-7ceb-9448-a605232adf11" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotesNominalValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_ConvertibleLoansNotesNominalValue_019bff12-946a-7ceb-9448-a605232adf11" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsFixedConversionPrice_019bff12-946a-786b-9995-408d0936a74d" xlink:href="abvx-20251231.xsd#abvx_BorrowingsFixedConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_BorrowingsFixedConversionPrice_019bff12-946a-786b-9995-408d0936a74d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted_019bff12-946a-7b13-a6fc-04560f7c1f9a" xlink:href="abvx-20251231.xsd#abvx_ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted_019bff12-946a-7b13-a6fc-04560f7c1f9a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_019bff12-946a-7bf8-88b6-1b4ab6e7bfb6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_ifrs-full_NotionalAmount_019bff12-946a-7bf8-88b6-1b4ab6e7bfb6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted_019bff12-946a-707b-bfcf-192831e0d9c1" xlink:href="abvx-20251231.xsd#abvx_ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted_019bff12-946a-707b-bfcf-192831e0d9c1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotesPeriod_019bff12-946a-7550-a7c6-c121120a3ca5" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotesPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_ConvertibleLoansNotesPeriod_019bff12-946a-7550-a7c6-c121120a3ca5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotesNumberOfSeparateClosings_019bff12-946a-719d-9b3d-7799e5eba37c" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotesNumberOfSeparateClosings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_ConvertibleLoansNotesNumberOfSeparateClosings_019bff12-946a-719d-9b3d-7799e5eba37c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_019bff12-c4b9-7a05-b178-450221629cd9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_ifrs-full_BorrowingsInterestRate_019bff12-c4b9-7a05-b178-450221629cd9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsNumberOfQuarterlyInstallments_019bff12-c4b9-7528-8ce5-0e50e2edd844" xlink:href="abvx-20251231.xsd#abvx_BorrowingsNumberOfQuarterlyInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_BorrowingsNumberOfQuarterlyInstallments_019bff12-c4b9-7528-8ce5-0e50e2edd844" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsMaturityDeferralPeriod_019bff12-c4b9-72f9-aa91-ea09f34c8860" xlink:href="abvx-20251231.xsd#abvx_BorrowingsMaturityDeferralPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_BorrowingsMaturityDeferralPeriod_019bff12-c4b9-72f9-aa91-ea09f34c8860" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsPercentageOfMarketPrice_019bff12-c4b9-7ac1-b548-51b2f25ff480" xlink:href="abvx-20251231.xsd#abvx_BorrowingsPercentageOfMarketPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_BorrowingsPercentageOfMarketPrice_019bff12-c4b9-7ac1-b548-51b2f25ff480" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsMarketPriceNumberOfDaysWithLowestDailyVWAP_019bff12-c4b9-7d89-8118-7438cd5e8bf9" xlink:href="abvx-20251231.xsd#abvx_BorrowingsMarketPriceNumberOfDaysWithLowestDailyVWAP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_BorrowingsMarketPriceNumberOfDaysWithLowestDailyVWAP_019bff12-c4b9-7d89-8118-7438cd5e8bf9" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsMarketPriceNumberOfTradingDays_019bff12-c4b9-76da-8d4f-7c5d6430c47b" xlink:href="abvx-20251231.xsd#abvx_BorrowingsMarketPriceNumberOfTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_BorrowingsMarketPriceNumberOfTradingDays_019bff12-c4b9-76da-8d4f-7c5d6430c47b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IssuancePricePercentageOfDiscountTo15DayWVAP_019bff12-c4b9-7caf-b8e4-27b3b0c66c51" xlink:href="abvx-20251231.xsd#abvx_IssuancePricePercentageOfDiscountTo15DayWVAP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_IssuancePricePercentageOfDiscountTo15DayWVAP_019bff12-c4b9-7caf-b8e4-27b3b0c66c51" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EquityIssuanceSubscriptionPricePerShare_019bff12-c4b9-797e-a06f-eb5c2e59cad1" xlink:href="abvx-20251231.xsd#abvx_EquityIssuanceSubscriptionPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_EquityIssuanceSubscriptionPricePerShare_019bff12-c4b9-797e-a06f-eb5c2e59cad1" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotesSettlementInSharesPercentageOfFairMarketValue_019bff12-ec92-7d04-aace-5bb9c13dbc50" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotesSettlementInSharesPercentageOfFairMarketValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_ConvertibleLoansNotesSettlementInSharesPercentageOfFairMarketValue_019bff12-ec92-7d04-aace-5bb9c13dbc50" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EquityIssuanceCashCarveOut_019bff12-ec92-71c0-9fd1-c08682ad0bb5" xlink:href="abvx-20251231.xsd#abvx_EquityIssuanceCashCarveOut"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_EquityIssuanceCashCarveOut_019bff12-ec92-71c0-9fd1-c08682ad0bb5" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotesEarlyRedemptionAmountPercentageOfOutstandongPrincipal_019bff13-18dc-78bf-8644-4b9125257829" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotesEarlyRedemptionAmountPercentageOfOutstandongPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_ConvertibleLoansNotesEarlyRedemptionAmountPercentageOfOutstandongPrincipal_019bff13-18dc-78bf-8644-4b9125257829" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepaymentsOfConvertibleLoansNotes_019bff13-18dc-7a39-aa91-8443d6d056aa" xlink:href="abvx-20251231.xsd#abvx_RepaymentsOfConvertibleLoansNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_RepaymentsOfConvertibleLoansNotes_019bff13-18dc-7a39-aa91-8443d6d056aa" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfConvertibleNotesConverted_019bff13-3e5b-7e10-b6a3-94c78f8a82ea" xlink:href="abvx-20251231.xsd#abvx_NumberOfConvertibleNotesConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_NumberOfConvertibleNotesConverted_019bff13-3e5b-7e10-b6a3-94c78f8a82ea" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_019bff13-3e5b-73e8-8a05-e983be0b2719" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_019bff13-3e5b-73e8-8a05-e983be0b2719" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_GainsArisingFromRecognitionOfFinancialLiabilities_019bff13-6356-79b4-9788-8c6469a8a18f" xlink:href="abvx-20251231.xsd#abvx_GainsArisingFromRecognitionOfFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_GainsArisingFromRecognitionOfFinancialLiabilities_019bff13-6356-79b4-9788-8c6469a8a18f" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_UnrecognitionDayOneGainOfFinancialLiabilities_019bff13-6356-7aa1-a865-65ca279d5cbf" xlink:href="abvx-20251231.xsd#abvx_UnrecognitionDayOneGainOfFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_UnrecognitionDayOneGainOfFinancialLiabilities_019bff13-6356-7aa1-a865-65ca279d5cbf" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfProbabilityWeightedScenarios_019cfba1-980d-7a8e-8fd6-98b0a11a56bc" xlink:href="abvx-20251231.xsd#abvx_NumberOfProbabilityWeightedScenarios"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_NumberOfProbabilityWeightedScenarios_019cfba1-980d-7a8e-8fd6-98b0a11a56bc" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bff13-a23c-7f3f-a0da-d75585e988f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bff13-a23c-7f3f-a0da-d75585e988f2" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bff13-a23c-7bf0-b00a-532cfc13e21a" xlink:href="abvx-20251231.xsd#abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bff13-a23c-7bf0-b00a-532cfc13e21a" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets_019bff13-a23c-7b5a-802c-64b3e29cd8cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets_019bff13-a23c-7b5a-802c-64b3e29cd8cb" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_019bff13-a23c-7d93-9021-98c761240786" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_019bff13-a23c-7d93-9021-98c761240786" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotesConversionOptionMaximumPeriodPriorToMaturityDate_019c0044-9e8d-7861-a998-2c6f72f53d40" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotesConversionOptionMaximumPeriodPriorToMaturityDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_ConvertibleLoansNotesConversionOptionMaximumPeriodPriorToMaturityDate_019c0044-9e8d-7861-a998-2c6f72f53d40" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss_019cf6c5-e6dc-7754-b236-f928272ffd2e" xlink:href="abvx-20251231.xsd#abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss_019cf6c5-e6dc-7754-b236-f928272ffd2e" xlink:type="arc" order="33"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_d337f439-0521-46ad-80b2-95d6ff073461" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_24ccb8fc-d0dc-4297-bc7e-6503ac2e3749" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_d337f439-0521-46ad-80b2-95d6ff073461" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_24ccb8fc-d0dc-4297-bc7e-6503ac2e3749" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_4bbdda24-5dae-4f0d-a518-1770da543fca" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_24ccb8fc-d0dc-4297-bc7e-6503ac2e3749" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_4bbdda24-5dae-4f0d-a518-1770da543fca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_4bbdda24-5dae-4f0d-a518-1770da543fca_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_4bbdda24-5dae-4f0d-a518-1770da543fca" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_4bbdda24-5dae-4f0d-a518-1770da543fca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_ba61a51c-f384-4ed5-bdfe-c4d01dde5ff4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_4bbdda24-5dae-4f0d-a518-1770da543fca" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_ba61a51c-f384-4ed5-bdfe-c4d01dde5ff4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_HeightsConvertibleNotesTrancheAMember_7b351cf3-5294-48c4-bc8a-9699e27a5426" xlink:href="abvx-20251231.xsd#abvx_HeightsConvertibleNotesTrancheAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_ba61a51c-f384-4ed5-bdfe-c4d01dde5ff4" xlink:to="loc_abvx_HeightsConvertibleNotesTrancheAMember_7b351cf3-5294-48c4-bc8a-9699e27a5426" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_e3b939c6-993d-45c3-b1a4-b6d3c9a36309" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_24ccb8fc-d0dc-4297-bc7e-6503ac2e3749" xlink:to="loc_ifrs-full_UnobservableInputsAxis_e3b939c6-993d-45c3-b1a4-b6d3c9a36309" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain_e3b939c6-993d-45c3-b1a4-b6d3c9a36309_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_UnobservableInputsAxis_e3b939c6-993d-45c3-b1a4-b6d3c9a36309" xlink:to="loc_ifrs-full_UnobservableInputsDomain_e3b939c6-993d-45c3-b1a4-b6d3c9a36309_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain_697203e3-7f0c-40ea-8d83-109b440d3879" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_UnobservableInputsAxis_e3b939c6-993d-45c3-b1a4-b6d3c9a36309" xlink:to="loc_ifrs-full_UnobservableInputsDomain_697203e3-7f0c-40ea-8d83-109b440d3879" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateMeasurementInputMember_23790f53-4d92-4693-9490-f89248714796" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestRateMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_697203e3-7f0c-40ea-8d83-109b440d3879" xlink:to="loc_ifrs-full_InterestRateMeasurementInputMember_23790f53-4d92-4693-9490-f89248714796" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConversionPricePerShareMeasurementInputMember_db23499f-198e-4408-b2e9-dd0f560116df" xlink:href="abvx-20251231.xsd#abvx_ConversionPricePerShareMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_697203e3-7f0c-40ea-8d83-109b440d3879" xlink:to="loc_abvx_ConversionPricePerShareMeasurementInputMember_db23499f-198e-4408-b2e9-dd0f560116df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SharePriceMeasurementInputMember_299bee0c-563f-4ba9-81a8-08ce4ec3f828" xlink:href="abvx-20251231.xsd#abvx_SharePriceMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_697203e3-7f0c-40ea-8d83-109b440d3879" xlink:to="loc_abvx_SharePriceMeasurementInputMember_299bee0c-563f-4ba9-81a8-08ce4ec3f828" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VoluntaryConversionScenarioProbabilityMeasurementInputMember_8e580454-3d5a-40b0-9305-3f14274a64ab" xlink:href="abvx-20251231.xsd#abvx_VoluntaryConversionScenarioProbabilityMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_697203e3-7f0c-40ea-8d83-109b440d3879" xlink:to="loc_abvx_VoluntaryConversionScenarioProbabilityMeasurementInputMember_8e580454-3d5a-40b0-9305-3f14274a64ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_InitialPriceLimitMeasurementInputMember_97cd79a9-ff97-4b9e-b274-7208f63efd6a" xlink:href="abvx-20251231.xsd#abvx_InitialPriceLimitMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_697203e3-7f0c-40ea-8d83-109b440d3879" xlink:to="loc_abvx_InitialPriceLimitMeasurementInputMember_97cd79a9-ff97-4b9e-b274-7208f63efd6a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EarlyRedemptionAmountMeasurementInputMember_3a4b60bb-0150-4de0-8714-8789c4478718" xlink:href="abvx-20251231.xsd#abvx_EarlyRedemptionAmountMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_697203e3-7f0c-40ea-8d83-109b440d3879" xlink:to="loc_abvx_EarlyRedemptionAmountMeasurementInputMember_3a4b60bb-0150-4de0-8714-8789c4478718" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_c3cc9604-dd17-4414-847b-0c1d72b3eeb9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_697203e3-7f0c-40ea-8d83-109b440d3879" xlink:to="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_c3cc9604-dd17-4414-847b-0c1d72b3eeb9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CreditSpreadMeasurementInputMember_5c66691a-1f09-44d9-b7e7-5b3af049283c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CreditSpreadMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_697203e3-7f0c-40ea-8d83-109b440d3879" xlink:to="loc_ifrs-full_CreditSpreadMeasurementInputMember_5c66691a-1f09-44d9-b7e7-5b3af049283c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RiskFreeInterestRateMeasurementInputMember_077bf4c7-df59-47d8-8e79-4eba84787eb5" xlink:href="abvx-20251231.xsd#abvx_RiskFreeInterestRateMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_697203e3-7f0c-40ea-8d83-109b440d3879" xlink:to="loc_abvx_RiskFreeInterestRateMeasurementInputMember_077bf4c7-df59-47d8-8e79-4eba84787eb5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_431db341-8e53-4721-9728-c8f1aa9432b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_24ccb8fc-d0dc-4297-bc7e-6503ac2e3749" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_431db341-8e53-4721-9728-c8f1aa9432b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_431db341-8e53-4721-9728-c8f1aa9432b8_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_431db341-8e53-4721-9728-c8f1aa9432b8" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_431db341-8e53-4721-9728-c8f1aa9432b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_c180f943-6c01-45af-9948-018bd227344c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_431db341-8e53-4721-9728-c8f1aa9432b8" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_c180f943-6c01-45af-9948-018bd227344c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_MonteCarloModelIFRSMember_a9f21e00-afe2-4118-b799-89e8c14e4834" xlink:href="abvx-20251231.xsd#abvx_MonteCarloModelIFRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_c180f943-6c01-45af-9948-018bd227344c" xlink:to="loc_abvx_MonteCarloModelIFRSMember_a9f21e00-afe2-4118-b799-89e8c14e4834" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfConvertibleNotesOutstanding_19aa7b31-69b0-4d2d-8675-67a4744929c9" xlink:href="abvx-20251231.xsd#abvx_NumberOfConvertibleNotesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_d337f439-0521-46ad-80b2-95d6ff073461" xlink:to="loc_abvx_NumberOfConvertibleNotesOutstanding_19aa7b31-69b0-4d2d-8675-67a4744929c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_693d56dd-8700-4a39-a61a-bb29f1d5b721" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_d337f439-0521-46ad-80b2-95d6ff073461" xlink:to="loc_ifrs-full_NotionalAmount_693d56dd-8700-4a39-a61a-bb29f1d5b721" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities_8afef000-f6ed-40e4-8215-bd8e9a831773" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_d337f439-0521-46ad-80b2-95d6ff073461" xlink:to="loc_ifrs-full_SignificantUnobservableInputLiabilities_8afef000-f6ed-40e4-8215-bd8e9a831773" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AggregateFairValueConvertibleNotes_076facea-3161-41c0-9724-90f5624af683" xlink:href="abvx-20251231.xsd#abvx_AggregateFairValueConvertibleNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_d337f439-0521-46ad-80b2-95d6ff073461" xlink:to="loc_abvx_AggregateFairValueConvertibleNotes_076facea-3161-41c0-9724-90f5624af683" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesKreos1Details" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesKreos1Details"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesKreos1Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56eb-f87d-7f70-8309-6889b8b13ee2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_d79094d2-00f4-4224-9d4b-0bfd16a7f8f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56eb-f87d-7f70-8309-6889b8b13ee2" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_d79094d2-00f4-4224-9d4b-0bfd16a7f8f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_019c56eb-f87d-70b1-b721-9421cfb2104b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_d79094d2-00f4-4224-9d4b-0bfd16a7f8f4" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_019c56eb-f87d-70b1-b721-9421cfb2104b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019c56eb-f87d-70b1-b721-9421cfb2104b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019c56eb-f87d-70b1-b721-9421cfb2104b" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019c56eb-f87d-70b1-b721-9421cfb2104b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019c56eb-f87d-766c-b6fa-a7df6fee600f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019c56eb-f87d-70b1-b721-9421cfb2104b" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019c56eb-f87d-766c-b6fa-a7df6fee600f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1Member_019c56eb-f87d-7b6e-b66a-662dc4eefe28" xlink:href="abvx-20251231.xsd#abvx_Kreos1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019c56eb-f87d-766c-b6fa-a7df6fee600f" xlink:to="loc_abvx_Kreos1Member_019c56eb-f87d-7b6e-b66a-662dc4eefe28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1NonConvertibleBondLoansMember_019c56eb-f87d-7d54-b4eb-46985852d6e1" xlink:href="abvx-20251231.xsd#abvx_Kreos1NonConvertibleBondLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019c56eb-f87d-766c-b6fa-a7df6fee600f" xlink:to="loc_abvx_Kreos1NonConvertibleBondLoansMember_019c56eb-f87d-7d54-b4eb-46985852d6e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1ConvertibleBondLoansMember_019c56eb-f87d-7ce2-9196-e78aaf4dfed1" xlink:href="abvx-20251231.xsd#abvx_Kreos1ConvertibleBondLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019c56eb-f87d-766c-b6fa-a7df6fee600f" xlink:to="loc_abvx_Kreos1ConvertibleBondLoansMember_019c56eb-f87d-7ce2-9196-e78aaf4dfed1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1ConvertibleBondLoansTrancheBMember_019c56eb-f87d-720d-8a4d-6f944d66b548" xlink:href="abvx-20251231.xsd#abvx_Kreos1ConvertibleBondLoansTrancheBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019c56eb-f87d-766c-b6fa-a7df6fee600f" xlink:to="loc_abvx_Kreos1ConvertibleBondLoansTrancheBMember_019c56eb-f87d-720d-8a4d-6f944d66b548" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos12BondLoansMember_019c56eb-f87d-7d7e-ab9c-2f0ff9d99960" xlink:href="abvx-20251231.xsd#abvx_Kreos12BondLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019c56eb-f87d-766c-b6fa-a7df6fee600f" xlink:to="loc_abvx_Kreos12BondLoansMember_019c56eb-f87d-7d7e-ab9c-2f0ff9d99960" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1ConvertibleBondLoansTrancheAMember_019c56eb-f87d-7566-a4c1-132a80d333c2" xlink:href="abvx-20251231.xsd#abvx_Kreos1ConvertibleBondLoansTrancheAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019c56eb-f87d-766c-b6fa-a7df6fee600f" xlink:to="loc_abvx_Kreos1ConvertibleBondLoansTrancheAMember_019c56eb-f87d-7566-a4c1-132a80d333c2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_WarrantsAxis_019c56eb-f87d-7849-831d-cb3c5a041e9b" xlink:href="abvx-20251231.xsd#abvx_WarrantsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_d79094d2-00f4-4224-9d4b-0bfd16a7f8f4" xlink:to="loc_abvx_WarrantsAxis_019c56eb-f87d-7849-831d-cb3c5a041e9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_WarrantsDomain_019c56eb-f87d-7849-831d-cb3c5a041e9b_default" xlink:href="abvx-20251231.xsd#abvx_WarrantsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_abvx_WarrantsAxis_019c56eb-f87d-7849-831d-cb3c5a041e9b" xlink:to="loc_abvx_WarrantsDomain_019c56eb-f87d-7849-831d-cb3c5a041e9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_WarrantsDomain_019c56eb-f87d-72a1-9713-b8aa41ded0a8" xlink:href="abvx-20251231.xsd#abvx_WarrantsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_abvx_WarrantsAxis_019c56eb-f87d-7849-831d-cb3c5a041e9b" xlink:to="loc_abvx_WarrantsDomain_019c56eb-f87d-72a1-9713-b8aa41ded0a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosABSAMember_019c56eb-f87d-7ad1-aac5-5c14dc91c7ec" xlink:href="abvx-20251231.xsd#abvx_KreosABSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_WarrantsDomain_019c56eb-f87d-72a1-9713-b8aa41ded0a8" xlink:to="loc_abvx_KreosABSAMember_019c56eb-f87d-7ad1-aac5-5c14dc91c7ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosBBSAMember_019c56eb-f87d-7ff6-97b4-72952900d8b9" xlink:href="abvx-20251231.xsd#abvx_KreosBBSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_WarrantsDomain_019c56eb-f87d-72a1-9713-b8aa41ded0a8" xlink:to="loc_abvx_KreosBBSAMember_019c56eb-f87d-7ff6-97b4-72952900d8b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosABBSAMember_019c56eb-f87d-72a5-b4cc-4e60ca083296" xlink:href="abvx-20251231.xsd#abvx_KreosABBSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_WarrantsDomain_019c56eb-f87d-72a1-9713-b8aa41ded0a8" xlink:to="loc_abvx_KreosABBSAMember_019c56eb-f87d-72a5-b4cc-4e60ca083296" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_019c56eb-f87d-76bd-80e9-f3899b2326cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_d79094d2-00f4-4224-9d4b-0bfd16a7f8f4" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_019c56eb-f87d-76bd-80e9-f3899b2326cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_019c56eb-f87d-76bd-80e9-f3899b2326cb_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_019c56eb-f87d-76bd-80e9-f3899b2326cb" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_019c56eb-f87d-76bd-80e9-f3899b2326cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_019c56eb-f87d-76c7-9ca3-8e65b983c033" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_019c56eb-f87d-76bd-80e9-f3899b2326cb" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_019c56eb-f87d-76c7-9ca3-8e65b983c033" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_019c56eb-f87d-7eb2-b71e-0be9fdb8a8ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_019c56eb-f87d-76c7-9ca3-8e65b983c033" xlink:to="loc_ifrs-full_OrdinarySharesMember_019c56eb-f87d-7eb2-b71e-0be9fdb8a8ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsMaximumBorrowingCapacity_019c56eb-f87d-7b79-9d5e-46585ad1474b" xlink:href="abvx-20251231.xsd#abvx_BorrowingsMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56eb-f87d-7f70-8309-6889b8b13ee2" xlink:to="loc_abvx_BorrowingsMaximumBorrowingCapacity_019c56eb-f87d-7b79-9d5e-46585ad1474b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsNumberOfTranches_019c56eb-f87d-7292-b04e-9dce2756154f" xlink:href="abvx-20251231.xsd#abvx_BorrowingsNumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56eb-f87d-7f70-8309-6889b8b13ee2" xlink:to="loc_abvx_BorrowingsNumberOfTranches_019c56eb-f87d-7292-b04e-9dce2756154f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsMaximumBorrowingCapacityPerTranche_019c56eb-f87d-76ff-9d46-7fd2cb5c368f" xlink:href="abvx-20251231.xsd#abvx_BorrowingsMaximumBorrowingCapacityPerTranche"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56eb-f87d-7f70-8309-6889b8b13ee2" xlink:to="loc_abvx_BorrowingsMaximumBorrowingCapacityPerTranche_019c56eb-f87d-76ff-9d46-7fd2cb5c368f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants_019c56eb-f87d-7cb6-8ad4-dde1695e1564" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56eb-f87d-7f70-8309-6889b8b13ee2" xlink:to="loc_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants_019c56eb-f87d-7cb6-8ad4-dde1695e1564" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepaymentsOfConvertibleLoansNotes_019c56eb-f87d-735c-958a-e4575c0d7fc9" xlink:href="abvx-20251231.xsd#abvx_RepaymentsOfConvertibleLoansNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56eb-f87d-7f70-8309-6889b8b13ee2" xlink:to="loc_abvx_RepaymentsOfConvertibleLoansNotes_019c56eb-f87d-735c-958a-e4575c0d7fc9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid_019c56eb-f87d-7b77-8087-8c3c2ddd67f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56eb-f87d-7f70-8309-6889b8b13ee2" xlink:to="loc_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid_019c56eb-f87d-7b77-8087-8c3c2ddd67f9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfShareWarrantsIssued_019c56eb-f87d-7a8c-ae11-16b4b4a8cccb" xlink:href="abvx-20251231.xsd#abvx_NumberOfShareWarrantsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56eb-f87d-7f70-8309-6889b8b13ee2" xlink:to="loc_abvx_NumberOfShareWarrantsIssued_019c56eb-f87d-7a8c-ae11-16b4b4a8cccb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ShareWarrantsSubscriptionPricePerShare_019c56eb-f87d-7a8b-98f2-7cb08c0af0b2" xlink:href="abvx-20251231.xsd#abvx_ShareWarrantsSubscriptionPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56eb-f87d-7f70-8309-6889b8b13ee2" xlink:to="loc_abvx_ShareWarrantsSubscriptionPricePerShare_019c56eb-f87d-7a8b-98f2-7cb08c0af0b2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfSharesPerShareWarrant_019c56eb-f87d-790e-a524-e604f3dc9eb8" xlink:href="abvx-20251231.xsd#abvx_NumberOfSharesPerShareWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56eb-f87d-7f70-8309-6889b8b13ee2" xlink:to="loc_abvx_NumberOfSharesPerShareWarrant_019c56eb-f87d-790e-a524-e604f3dc9eb8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_019c56eb-f87d-71d6-aec2-4e27a502366a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56eb-f87d-7f70-8309-6889b8b13ee2" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_019c56eb-f87d-71d6-aec2-4e27a502366a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfOtherShareWarrantsRepurchased_019c56eb-f87d-7453-8fbd-478dc64cf59e" xlink:href="abvx-20251231.xsd#abvx_NumberOfOtherShareWarrantsRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56eb-f87d-7f70-8309-6889b8b13ee2" xlink:to="loc_abvx_NumberOfOtherShareWarrantsRepurchased_019c56eb-f87d-7453-8fbd-478dc64cf59e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfOtherShareWarrantsConverted_019c56eb-f87d-7dcb-b1c5-d482103a18e0" xlink:href="abvx-20251231.xsd#abvx_NumberOfOtherShareWarrantsConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56eb-f87d-7f70-8309-6889b8b13ee2" xlink:to="loc_abvx_NumberOfOtherShareWarrantsConverted_019c56eb-f87d-7dcb-b1c5-d482103a18e0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_019c56eb-f87d-750c-b5a8-df791801209a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56eb-f87d-7f70-8309-6889b8b13ee2" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_019c56eb-f87d-750c-b5a8-df791801209a" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfWarrantsArrangementsLineItems_e022a2b0-7017-48b3-90a4-1464412daac2" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfWarrantsArrangementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfWarrantsArrangementsTable_94ab92ee-a296-44e7-a3af-51bb336d2413" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfWarrantsArrangementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsLineItems_e022a2b0-7017-48b3-90a4-1464412daac2" xlink:to="loc_abvx_DisclosureOfWarrantsArrangementsTable_94ab92ee-a296-44e7-a3af-51bb336d2413" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_WarrantsAxis_31c19bc1-4aaf-4928-9af4-e7da6ee3ffea" xlink:href="abvx-20251231.xsd#abvx_WarrantsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsTable_94ab92ee-a296-44e7-a3af-51bb336d2413" xlink:to="loc_abvx_WarrantsAxis_31c19bc1-4aaf-4928-9af4-e7da6ee3ffea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_WarrantsDomain_31c19bc1-4aaf-4928-9af4-e7da6ee3ffea_default" xlink:href="abvx-20251231.xsd#abvx_WarrantsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_abvx_WarrantsAxis_31c19bc1-4aaf-4928-9af4-e7da6ee3ffea" xlink:to="loc_abvx_WarrantsDomain_31c19bc1-4aaf-4928-9af4-e7da6ee3ffea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_WarrantsDomain_0d8c9e4f-3f9b-4273-843c-0397e2b7e9ef" xlink:href="abvx-20251231.xsd#abvx_WarrantsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_abvx_WarrantsAxis_31c19bc1-4aaf-4928-9af4-e7da6ee3ffea" xlink:to="loc_abvx_WarrantsDomain_0d8c9e4f-3f9b-4273-843c-0397e2b7e9ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosABSAMember_c3aaac39-29d8-49c6-9dc5-df378d5c4b3e" xlink:href="abvx-20251231.xsd#abvx_KreosABSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_WarrantsDomain_0d8c9e4f-3f9b-4273-843c-0397e2b7e9ef" xlink:to="loc_abvx_KreosABSAMember_c3aaac39-29d8-49c6-9dc5-df378d5c4b3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosBBSAMember_510ac62c-6b44-41cb-92fb-bd9d6841d527" xlink:href="abvx-20251231.xsd#abvx_KreosBBSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_WarrantsDomain_0d8c9e4f-3f9b-4273-843c-0397e2b7e9ef" xlink:to="loc_abvx_KreosBBSAMember_510ac62c-6b44-41cb-92fb-bd9d6841d527" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_df9006e3-6bdf-47aa-b426-dca35a705327" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsTable_94ab92ee-a296-44e7-a3af-51bb336d2413" xlink:to="loc_ifrs-full_UnobservableInputsAxis_df9006e3-6bdf-47aa-b426-dca35a705327" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain_df9006e3-6bdf-47aa-b426-dca35a705327_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_UnobservableInputsAxis_df9006e3-6bdf-47aa-b426-dca35a705327" xlink:to="loc_ifrs-full_UnobservableInputsDomain_df9006e3-6bdf-47aa-b426-dca35a705327_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain_a3a41e96-1515-4d6c-90c4-5ef60ef6ae60" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_UnobservableInputsAxis_df9006e3-6bdf-47aa-b426-dca35a705327" xlink:to="loc_ifrs-full_UnobservableInputsDomain_a3a41e96-1515-4d6c-90c4-5ef60ef6ae60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExercisePricePerShareMeasurementInputMember_815b56cc-d1ab-4e9e-af58-f1ecf1711104" xlink:href="abvx-20251231.xsd#abvx_ExercisePricePerShareMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_a3a41e96-1515-4d6c-90c4-5ef60ef6ae60" xlink:to="loc_abvx_ExercisePricePerShareMeasurementInputMember_815b56cc-d1ab-4e9e-af58-f1ecf1711104" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SharePriceMeasurementInputMember_a62b75ca-3c5f-4ac4-a39a-c9e6012742c1" xlink:href="abvx-20251231.xsd#abvx_SharePriceMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_a3a41e96-1515-4d6c-90c4-5ef60ef6ae60" xlink:to="loc_abvx_SharePriceMeasurementInputMember_a62b75ca-3c5f-4ac4-a39a-c9e6012742c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_729bd8a8-d893-4e34-bf75-824b0d930139" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsTable_94ab92ee-a296-44e7-a3af-51bb336d2413" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_729bd8a8-d893-4e34-bf75-824b0d930139" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_729bd8a8-d893-4e34-bf75-824b0d930139_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_729bd8a8-d893-4e34-bf75-824b0d930139" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_729bd8a8-d893-4e34-bf75-824b0d930139_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_8f43a780-eaf3-4628-8a4a-76d325daeff8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_729bd8a8-d893-4e34-bf75-824b0d930139" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_8f43a780-eaf3-4628-8a4a-76d325daeff8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OptionPricingModelMember_0acfedaf-fd25-46d9-9ba9-0c7f2e597426" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OptionPricingModelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_8f43a780-eaf3-4628-8a4a-76d325daeff8" xlink:to="loc_ifrs-full_OptionPricingModelMember_0acfedaf-fd25-46d9-9ba9-0c7f2e597426" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfWarrantsOutstanding_708db23d-c912-4aa1-a9b4-fe2c6171b978" xlink:href="abvx-20251231.xsd#abvx_NumberOfWarrantsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsLineItems_e022a2b0-7017-48b3-90a4-1464412daac2" xlink:to="loc_abvx_NumberOfWarrantsOutstanding_708db23d-c912-4aa1-a9b4-fe2c6171b978" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities_2420e6e4-9a23-4e9f-931d-3b5f8f1d7d44" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsLineItems_e022a2b0-7017-48b3-90a4-1464412daac2" xlink:to="loc_ifrs-full_SignificantUnobservableInputLiabilities_2420e6e4-9a23-4e9f-931d-3b5f8f1d7d44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding_862bf3c3-dd15-45e5-bc2e-e10347da9258" xlink:href="abvx-20251231.xsd#abvx_AggregateFairValueOtherEquityInstrumentsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsLineItems_e022a2b0-7017-48b3-90a4-1464412daac2" xlink:to="loc_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding_862bf3c3-dd15-45e5-bc2e-e10347da9258" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesKreos2Details" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesKreos2Details"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesKreos2Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f5-9d35-7bf9-9931-9c1fc6ceebaf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_44d45666-828b-41c2-b946-3c4604f70488" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f5-9d35-7bf9-9931-9c1fc6ceebaf" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_44d45666-828b-41c2-b946-3c4604f70488" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_019c56f5-9d35-7331-aedd-bdecfb838337" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_44d45666-828b-41c2-b946-3c4604f70488" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_019c56f5-9d35-7331-aedd-bdecfb838337" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019c56f5-9d35-7331-aedd-bdecfb838337_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019c56f5-9d35-7331-aedd-bdecfb838337" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019c56f5-9d35-7331-aedd-bdecfb838337_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019c56f5-9d35-7b94-b36a-52aeabf359aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019c56f5-9d35-7331-aedd-bdecfb838337" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019c56f5-9d35-7b94-b36a-52aeabf359aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos2Member_019c56f5-9d35-7e06-940a-c9a3fd5ab0d5" xlink:href="abvx-20251231.xsd#abvx_Kreos2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019c56f5-9d35-7b94-b36a-52aeabf359aa" xlink:to="loc_abvx_Kreos2Member_019c56f5-9d35-7e06-940a-c9a3fd5ab0d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos2TrancheAMember_019c56f5-9d35-7b8e-875a-fee1818ac367" xlink:href="abvx-20251231.xsd#abvx_Kreos2TrancheAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019c56f5-9d35-7b94-b36a-52aeabf359aa" xlink:to="loc_abvx_Kreos2TrancheAMember_019c56f5-9d35-7b8e-875a-fee1818ac367" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos2TrancheBMember_019c56f5-9d35-7e86-a797-6d3324ac2855" xlink:href="abvx-20251231.xsd#abvx_Kreos2TrancheBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019c56f5-9d35-7b94-b36a-52aeabf359aa" xlink:to="loc_abvx_Kreos2TrancheBMember_019c56f5-9d35-7e86-a797-6d3324ac2855" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1ConvertibleBondLoansTrancheBMember_019c56f5-9d35-79d1-968f-00f21ab12342" xlink:href="abvx-20251231.xsd#abvx_Kreos1ConvertibleBondLoansTrancheBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019c56f5-9d35-7b94-b36a-52aeabf359aa" xlink:to="loc_abvx_Kreos1ConvertibleBondLoansTrancheBMember_019c56f5-9d35-79d1-968f-00f21ab12342" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_019c56f5-9d35-7d42-9584-a17aaebd06d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f5-9d35-7bf9-9931-9c1fc6ceebaf" xlink:to="loc_ifrs-full_NotionalAmount_019c56f5-9d35-7d42-9584-a17aaebd06d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsNumberOfTranches_019c56f5-9d35-7017-a1ec-120e54ab2246" xlink:href="abvx-20251231.xsd#abvx_BorrowingsNumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f5-9d35-7bf9-9931-9c1fc6ceebaf" xlink:to="loc_abvx_BorrowingsNumberOfTranches_019c56f5-9d35-7017-a1ec-120e54ab2246" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsAdditionalTrancheAmount_019c56f5-9d35-7f60-9de7-5cc983486576" xlink:href="abvx-20251231.xsd#abvx_BorrowingsAdditionalTrancheAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f5-9d35-7bf9-9931-9c1fc6ceebaf" xlink:to="loc_abvx_BorrowingsAdditionalTrancheAmount_019c56f5-9d35-7f60-9de7-5cc983486576" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepaymentsOfConvertibleLoansNotes_019c56f5-9d35-70d1-be55-1596967dc743" xlink:href="abvx-20251231.xsd#abvx_RepaymentsOfConvertibleLoansNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f5-9d35-7bf9-9931-9c1fc6ceebaf" xlink:to="loc_abvx_RepaymentsOfConvertibleLoansNotes_019c56f5-9d35-70d1-be55-1596967dc743" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesOCEANEDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f4-89fe-7f94-9f8f-aab28713fd5c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_feb8fe6e-32b2-4c27-b55a-59e41b01fc45" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f4-89fe-7f94-9f8f-aab28713fd5c" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_feb8fe6e-32b2-4c27-b55a-59e41b01fc45" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_019c56f4-89fe-7e02-87a0-ffb7ca2821c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_feb8fe6e-32b2-4c27-b55a-59e41b01fc45" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_019c56f4-89fe-7e02-87a0-ffb7ca2821c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019c56f4-89fe-7e02-87a0-ffb7ca2821c4_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019c56f4-89fe-7e02-87a0-ffb7ca2821c4" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019c56f4-89fe-7e02-87a0-ffb7ca2821c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019c56f4-89fe-7e80-84c6-0194a64aa635" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019c56f4-89fe-7e02-87a0-ffb7ca2821c4" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019c56f4-89fe-7e80-84c6-0194a64aa635" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OCEANEMember_019c56f4-89fe-7479-a5f4-07fa01f3d5d1" xlink:href="abvx-20251231.xsd#abvx_OCEANEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019c56f4-89fe-7e80-84c6-0194a64aa635" xlink:to="loc_abvx_OCEANEMember_019c56f4-89fe-7479-a5f4-07fa01f3d5d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RemeasurementPeriodAxis_019c56f4-89fe-73d8-a605-d79f5761ebba" xlink:href="abvx-20251231.xsd#abvx_RemeasurementPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_feb8fe6e-32b2-4c27-b55a-59e41b01fc45" xlink:to="loc_abvx_RemeasurementPeriodAxis_019c56f4-89fe-73d8-a605-d79f5761ebba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RemeasurementPeriodDomain_019c56f4-89fe-73d8-a605-d79f5761ebba_default" xlink:href="abvx-20251231.xsd#abvx_RemeasurementPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_abvx_RemeasurementPeriodAxis_019c56f4-89fe-73d8-a605-d79f5761ebba" xlink:to="loc_abvx_RemeasurementPeriodDomain_019c56f4-89fe-73d8-a605-d79f5761ebba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RemeasurementPeriodDomain_019c56f4-89fe-731b-83a5-5a752c3dd36c" xlink:href="abvx-20251231.xsd#abvx_RemeasurementPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_abvx_RemeasurementPeriodAxis_019c56f4-89fe-73d8-a605-d79f5761ebba" xlink:to="loc_abvx_RemeasurementPeriodDomain_019c56f4-89fe-731b-83a5-5a752c3dd36c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_After18MonthsMember_019c56f4-89fe-7b48-bdf7-2c7ccf456bac" xlink:href="abvx-20251231.xsd#abvx_After18MonthsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_RemeasurementPeriodDomain_019c56f4-89fe-731b-83a5-5a752c3dd36c" xlink:to="loc_abvx_After18MonthsMember_019c56f4-89fe-7b48-bdf7-2c7ccf456bac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_After24MonthsMember_019c56f4-89fe-78fe-a722-d7a2e0f8dabd" xlink:href="abvx-20251231.xsd#abvx_After24MonthsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_RemeasurementPeriodDomain_019c56f4-89fe-731b-83a5-5a752c3dd36c" xlink:to="loc_abvx_After24MonthsMember_019c56f4-89fe-78fe-a722-d7a2e0f8dabd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_After36MonthsMember_019c56f4-89fe-76cd-a5e4-339c00c555fb" xlink:href="abvx-20251231.xsd#abvx_After36MonthsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_RemeasurementPeriodDomain_019c56f4-89fe-731b-83a5-5a752c3dd36c" xlink:to="loc_abvx_After36MonthsMember_019c56f4-89fe-76cd-a5e4-339c00c555fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019c56f4-89fe-7bdb-8c68-f89d080bb082" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_feb8fe6e-32b2-4c27-b55a-59e41b01fc45" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019c56f4-89fe-7bdb-8c68-f89d080bb082" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019c56f4-89fe-7bdb-8c68-f89d080bb082_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019c56f4-89fe-7bdb-8c68-f89d080bb082" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019c56f4-89fe-7bdb-8c68-f89d080bb082_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019c56f4-89fe-7e2a-8d8d-8614c09eefd8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019c56f4-89fe-7bdb-8c68-f89d080bb082" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019c56f4-89fe-7e2a-8d8d-8614c09eefd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OCEANEMember_019c56f4-89fe-761e-bd49-a28a646847aa" xlink:href="abvx-20251231.xsd#abvx_OCEANEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019c56f4-89fe-7e2a-8d8d-8614c09eefd8" xlink:to="loc_abvx_OCEANEMember_019c56f4-89fe-761e-bd49-a28a646847aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_019c56f4-89fe-7868-80bb-aad993484364" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_feb8fe6e-32b2-4c27-b55a-59e41b01fc45" xlink:to="loc_ifrs-full_UnobservableInputsAxis_019c56f4-89fe-7868-80bb-aad993484364" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain_019c56f4-89fe-7868-80bb-aad993484364_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_UnobservableInputsAxis_019c56f4-89fe-7868-80bb-aad993484364" xlink:to="loc_ifrs-full_UnobservableInputsDomain_019c56f4-89fe-7868-80bb-aad993484364_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain_019c56f4-89fe-79d4-b762-f3da1e11b194" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_UnobservableInputsAxis_019c56f4-89fe-7868-80bb-aad993484364" xlink:to="loc_ifrs-full_UnobservableInputsDomain_019c56f4-89fe-79d4-b762-f3da1e11b194" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_019c56f4-89fe-73bf-9359-6d7a7d7f9636" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019c56f4-89fe-79d4-b762-f3da1e11b194" xlink:to="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_019c56f4-89fe-73bf-9359-6d7a7d7f9636" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CreditSpreadMeasurementInputMember_019c56f4-89fe-7ee7-ac5b-ec486aa07f2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CreditSpreadMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019c56f4-89fe-79d4-b762-f3da1e11b194" xlink:to="loc_ifrs-full_CreditSpreadMeasurementInputMember_019c56f4-89fe-7ee7-ac5b-ec486aa07f2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SharePriceMeasurementInputMember_019c56f4-89fe-7360-ab3a-064074067392" xlink:href="abvx-20251231.xsd#abvx_SharePriceMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019c56f4-89fe-79d4-b762-f3da1e11b194" xlink:to="loc_abvx_SharePriceMeasurementInputMember_019c56f4-89fe-7360-ab3a-064074067392" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RiskFreeInterestRateMeasurementInputMember_019c56f4-89fe-7d19-9cc2-1f8e0848f4b1" xlink:href="abvx-20251231.xsd#abvx_RiskFreeInterestRateMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019c56f4-89fe-79d4-b762-f3da1e11b194" xlink:to="loc_abvx_RiskFreeInterestRateMeasurementInputMember_019c56f4-89fe-7d19-9cc2-1f8e0848f4b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_019c56f4-89fe-710e-8842-d28121d41df5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_feb8fe6e-32b2-4c27-b55a-59e41b01fc45" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_019c56f4-89fe-710e-8842-d28121d41df5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_019c56f4-89fe-710e-8842-d28121d41df5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_019c56f4-89fe-710e-8842-d28121d41df5" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_019c56f4-89fe-710e-8842-d28121d41df5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_019c56f4-89fe-772f-996e-7d28a81f340e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_019c56f4-89fe-710e-8842-d28121d41df5" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_019c56f4-89fe-772f-996e-7d28a81f340e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_MonteCarloModelIFRSMember_019c56f4-89fe-7afb-9ba2-6d4679defc30" xlink:href="abvx-20251231.xsd#abvx_MonteCarloModelIFRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_019c56f4-89fe-772f-996e-7d28a81f340e" xlink:to="loc_abvx_MonteCarloModelIFRSMember_019c56f4-89fe-7afb-9ba2-6d4679defc30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ProceedsFromIssuingSharesAndConvertibleLoansNotes_019c56f4-89fe-7828-be5a-f3525c08cf0f" xlink:href="abvx-20251231.xsd#abvx_ProceedsFromIssuingSharesAndConvertibleLoansNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f4-89fe-7f94-9f8f-aab28713fd5c" xlink:to="loc_abvx_ProceedsFromIssuingSharesAndConvertibleLoansNotes_019c56f4-89fe-7828-be5a-f3525c08cf0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease_019c56f4-89fe-77a0-82da-bf2bc678e0f2" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f4-89fe-7f94-9f8f-aab28713fd5c" xlink:to="loc_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease_019c56f4-89fe-77a0-82da-bf2bc678e0f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EquityIssuanceSubscriptionPricePerShare_019c56f4-89fe-7758-a880-e84014382883" xlink:href="abvx-20251231.xsd#abvx_EquityIssuanceSubscriptionPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f4-89fe-7f94-9f8f-aab28713fd5c" xlink:to="loc_abvx_EquityIssuanceSubscriptionPricePerShare_019c56f4-89fe-7758-a880-e84014382883" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_019c56f4-89fe-77e1-9697-0b8c2c106419" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f4-89fe-7f94-9f8f-aab28713fd5c" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_019c56f4-89fe-77e1-9697-0b8c2c106419" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NetProceedsFromConvertibleLoansNotes_019c56f4-89fe-758e-a9bd-3681ab066299" xlink:href="abvx-20251231.xsd#abvx_NetProceedsFromConvertibleLoansNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f4-89fe-7f94-9f8f-aab28713fd5c" xlink:to="loc_abvx_NetProceedsFromConvertibleLoansNotes_019c56f4-89fe-758e-a9bd-3681ab066299" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConversionPriceAdjustmentPeriod_019c56f4-89fe-70cc-b4eb-04feb9e73a0e" xlink:href="abvx-20251231.xsd#abvx_ConversionPriceAdjustmentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f4-89fe-7f94-9f8f-aab28713fd5c" xlink:to="loc_abvx_ConversionPriceAdjustmentPeriod_019c56f4-89fe-70cc-b4eb-04feb9e73a0e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities_019c56f4-89fe-7078-b1dc-fbbd8514817c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f4-89fe-7f94-9f8f-aab28713fd5c" xlink:to="loc_ifrs-full_SignificantUnobservableInputLiabilities_019c56f4-89fe-7078-b1dc-fbbd8514817c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AggregateFairValueConvertibleNotes_019c56f4-89fe-782b-a659-6e4ada9daefc" xlink:href="abvx-20251231.xsd#abvx_AggregateFairValueConvertibleNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f4-89fe-7f94-9f8f-aab28713fd5c" xlink:to="loc_abvx_AggregateFairValueConvertibleNotes_019c56f4-89fe-782b-a659-6e4ada9daefc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_019c56f4-89fe-7da1-b5d7-a6fca9c276e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f4-89fe-7f94-9f8f-aab28713fd5c" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_019c56f4-89fe-7da1-b5d7-a6fca9c276e0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_019c56f4-89fe-7197-bf4f-33a65f6be7b8" xlink:href="abvx-20251231.xsd#abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f4-89fe-7f94-9f8f-aab28713fd5c" xlink:to="loc_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_019c56f4-89fe-7197-bf4f-33a65f6be7b8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets_019c56f4-89fe-7591-af78-1a3413155698" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f4-89fe-7f94-9f8f-aab28713fd5c" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets_019c56f4-89fe-7591-af78-1a3413155698" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepaymentsOfConvertibleLoansNotes_019c56f4-89fe-77c0-9355-239d34bfcbf3" xlink:href="abvx-20251231.xsd#abvx_RepaymentsOfConvertibleLoansNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f4-89fe-7f94-9f8f-aab28713fd5c" xlink:to="loc_abvx_RepaymentsOfConvertibleLoansNotes_019c56f4-89fe-77c0-9355-239d34bfcbf3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid_019c56f4-89fe-7a0c-977e-aa206502b6a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f4-89fe-7f94-9f8f-aab28713fd5c" xlink:to="loc_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid_019c56f4-89fe-7a0c-977e-aa206502b6a7" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesStateguaranteedloanPGEDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesStateguaranteedloanPGEDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesStateguaranteedloanPGEDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_47c997b2-20b4-4ccb-ba02-014aa5dacbcf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_12c38cae-fae0-467d-aca8-c83d9af261fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_47c997b2-20b4-4ccb-ba02-014aa5dacbcf" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_12c38cae-fae0-467d-aca8-c83d9af261fa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_cb9cd544-3883-4089-8111-b8f93c9b1c54" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_12c38cae-fae0-467d-aca8-c83d9af261fa" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_cb9cd544-3883-4089-8111-b8f93c9b1c54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_cb9cd544-3883-4089-8111-b8f93c9b1c54_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_cb9cd544-3883-4089-8111-b8f93c9b1c54" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_cb9cd544-3883-4089-8111-b8f93c9b1c54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_2c0fa645-5dfd-4659-900a-b18dc776400e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_cb9cd544-3883-4089-8111-b8f93c9b1c54" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_2c0fa645-5dfd-4659-900a-b18dc776400e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PretGarantiParLEtatPGEMember_3df1dc0a-138a-4bce-988d-0ff37c982b30" xlink:href="abvx-20251231.xsd#abvx_PretGarantiParLEtatPGEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_2c0fa645-5dfd-4659-900a-b18dc776400e" xlink:to="loc_abvx_PretGarantiParLEtatPGEMember_3df1dc0a-138a-4bce-988d-0ff37c982b30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsMaturityTerm_a857c880-a58a-46a0-9dd1-30e29abc33c2" xlink:href="abvx-20251231.xsd#abvx_BorrowingsMaturityTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_47c997b2-20b4-4ccb-ba02-014aa5dacbcf" xlink:to="loc_abvx_BorrowingsMaturityTerm_a857c880-a58a-46a0-9dd1-30e29abc33c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_d7042f2b-09be-4f04-aa01-a17b7ce9b1cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_47c997b2-20b4-4ccb-ba02-014aa5dacbcf" xlink:to="loc_ifrs-full_BorrowingsInterestRate_d7042f2b-09be-4f04-aa01-a17b7ce9b1cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsMaturityExtensionTerm_1549860c-9773-401b-9bd0-c58db631edfe" xlink:href="abvx-20251231.xsd#abvx_BorrowingsMaturityExtensionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_47c997b2-20b4-4ccb-ba02-014aa5dacbcf" xlink:to="loc_abvx_BorrowingsMaturityExtensionTerm_1549860c-9773-401b-9bd0-c58db631edfe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsMaturityDeferralPeriod_a3557aa1-a742-4229-911e-8c6a98b794de" xlink:href="abvx-20251231.xsd#abvx_BorrowingsMaturityDeferralPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_47c997b2-20b4-4ccb-ba02-014aa5dacbcf" xlink:to="loc_abvx_BorrowingsMaturityDeferralPeriod_a3557aa1-a742-4229-911e-8c6a98b794de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsStateGuaranteedPremium_720299d8-31e4-41a7-8d42-453505d93e53" xlink:href="abvx-20251231.xsd#abvx_BorrowingsStateGuaranteedPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_47c997b2-20b4-4ccb-ba02-014aa5dacbcf" xlink:to="loc_abvx_BorrowingsStateGuaranteedPremium_720299d8-31e4-41a7-8d42-453505d93e53" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromGovernmentGrants_55a9fd97-506f-4b35-9e54-74f2fd49e4d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_47c997b2-20b4-4ccb-ba02-014aa5dacbcf" xlink:to="loc_ifrs-full_RevenueFromGovernmentGrants_55a9fd97-506f-4b35-9e54-74f2fd49e4d2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_019cfd00-dead-7593-831e-7f92c598802c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_47c997b2-20b4-4ccb-ba02-014aa5dacbcf" xlink:to="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_019cfd00-dead-7593-831e-7f92c598802c" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesDisclosureofconditionaladvancesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesDisclosureofconditionaladvancesDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesDisclosureofconditionaladvancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_d5c1e78b-a09f-4b20-800a-7dceefeb27eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_0dde3b7b-9ebd-4ff9-b341-9eaa156746e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_d5c1e78b-a09f-4b20-800a-7dceefeb27eb" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_0dde3b7b-9ebd-4ff9-b341-9eaa156746e0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_1512a780-f378-40ad-91d5-26d86d28a163" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_0dde3b7b-9ebd-4ff9-b341-9eaa156746e0" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_1512a780-f378-40ad-91d5-26d86d28a163" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_1512a780-f378-40ad-91d5-26d86d28a163_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_1512a780-f378-40ad-91d5-26d86d28a163" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_1512a780-f378-40ad-91d5-26d86d28a163_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_74400510-9cfd-44f5-a78e-314dd5058b2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_1512a780-f378-40ad-91d5-26d86d28a163" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_74400510-9cfd-44f5-a78e-314dd5058b2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RNPVIRConditionalAdvanceBPIMember_56ea95fa-14f2-4d54-b87c-7860015747a1" xlink:href="abvx-20251231.xsd#abvx_RNPVIRConditionalAdvanceBPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_74400510-9cfd-44f5-a78e-314dd5058b2e" xlink:to="loc_abvx_RNPVIRConditionalAdvanceBPIMember_56ea95fa-14f2-4d54-b87c-7860015747a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CARENAConditionalAdvanceBPIMember_40906cfa-579f-4069-a20d-cfc599e68fd2" xlink:href="abvx-20251231.xsd#abvx_CARENAConditionalAdvanceBPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_74400510-9cfd-44f5-a78e-314dd5058b2e" xlink:to="loc_abvx_CARENAConditionalAdvanceBPIMember_40906cfa-579f-4069-a20d-cfc599e68fd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EbolaConditionalAdvanceBPIMember_85a3eb3c-1921-4d36-959e-6e64c423e464" xlink:href="abvx-20251231.xsd#abvx_EbolaConditionalAdvanceBPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_74400510-9cfd-44f5-a78e-314dd5058b2e" xlink:to="loc_abvx_EbolaConditionalAdvanceBPIMember_85a3eb3c-1921-4d36-959e-6e64c423e464" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConditionalAdvances_dd46eddd-0d44-4d65-a6e8-34740071014e" xlink:href="abvx-20251231.xsd#abvx_ConditionalAdvances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_d5c1e78b-a09f-4b20-800a-7dceefeb27eb" xlink:to="loc_abvx_ConditionalAdvances_dd46eddd-0d44-4d65-a6e8-34740071014e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesConditionaladvancesDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fe4daff4-1733-4154-a906-16629ff5fa3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_6f4460f0-d988-4d01-bd8e-2757931c12b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fe4daff4-1733-4154-a906-16629ff5fa3c" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_6f4460f0-d988-4d01-bd8e-2757931c12b5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_8d892f5a-c9b4-493d-9fb7-2b9116e7141c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_6f4460f0-d988-4d01-bd8e-2757931c12b5" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_8d892f5a-c9b4-493d-9fb7-2b9116e7141c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_8d892f5a-c9b4-493d-9fb7-2b9116e7141c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_8d892f5a-c9b4-493d-9fb7-2b9116e7141c" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_8d892f5a-c9b4-493d-9fb7-2b9116e7141c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f92c6b63-42de-4e4d-893e-81e1bb6ba342" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_8d892f5a-c9b4-493d-9fb7-2b9116e7141c" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f92c6b63-42de-4e4d-893e-81e1bb6ba342" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RNPVIRConditionalAdvanceBPIMember_a23d6645-428f-46ae-8e37-1f6350f2ca59" xlink:href="abvx-20251231.xsd#abvx_RNPVIRConditionalAdvanceBPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f92c6b63-42de-4e4d-893e-81e1bb6ba342" xlink:to="loc_abvx_RNPVIRConditionalAdvanceBPIMember_a23d6645-428f-46ae-8e37-1f6350f2ca59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CARENAConditionalAdvanceBPIMember_81c2ca5d-6b5a-42ca-8d2e-e475ac1ce075" xlink:href="abvx-20251231.xsd#abvx_CARENAConditionalAdvanceBPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f92c6b63-42de-4e4d-893e-81e1bb6ba342" xlink:to="loc_abvx_CARENAConditionalAdvanceBPIMember_81c2ca5d-6b5a-42ca-8d2e-e475ac1ce075" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EbolaConditionalAdvanceBPIMember_d3494ba1-9878-43c3-83d7-62d67d8d1744" xlink:href="abvx-20251231.xsd#abvx_EbolaConditionalAdvanceBPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f92c6b63-42de-4e4d-893e-81e1bb6ba342" xlink:to="loc_abvx_EbolaConditionalAdvanceBPIMember_d3494ba1-9878-43c3-83d7-62d67d8d1744" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity_93586da5-d530-417d-874c-903f538f7c6b" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fe4daff4-1733-4154-a906-16629ff5fa3c" xlink:to="loc_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity_93586da5-d530-417d-874c-903f538f7c6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ProceedsFromConditionalAdvances_17ecd6f5-a1e6-474b-940d-f287c15aff9e" xlink:href="abvx-20251231.xsd#abvx_ProceedsFromConditionalAdvances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fe4daff4-1733-4154-a906-16629ff5fa3c" xlink:to="loc_abvx_ProceedsFromConditionalAdvances_17ecd6f5-a1e6-474b-940d-f287c15aff9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepaymentOfExcessConditionalAdvancesClaimed_844a21c4-b1e7-4d98-8a33-65ada243005f" xlink:href="abvx-20251231.xsd#abvx_RepaymentOfExcessConditionalAdvancesClaimed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fe4daff4-1733-4154-a906-16629ff5fa3c" xlink:to="loc_abvx_RepaymentOfExcessConditionalAdvancesClaimed_844a21c4-b1e7-4d98-8a33-65ada243005f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PercentageOfConditionalAdvancesWaived_5e106c9c-ecf7-4311-9ba0-9931f66878af" xlink:href="abvx-20251231.xsd#abvx_PercentageOfConditionalAdvancesWaived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fe4daff4-1733-4154-a906-16629ff5fa3c" xlink:to="loc_abvx_PercentageOfConditionalAdvancesWaived_5e106c9c-ecf7-4311-9ba0-9931f66878af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConditionalAdvances_2b90c9cb-550a-40f5-a520-85b294bc5642" xlink:href="abvx-20251231.xsd#abvx_ConditionalAdvances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fe4daff4-1733-4154-a906-16629ff5fa3c" xlink:to="loc_abvx_ConditionalAdvances_2b90c9cb-550a-40f5-a520-85b294bc5642" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromGovernmentGrants_24982f23-2603-4d52-93fa-2e9fb3654c62" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fe4daff4-1733-4154-a906-16629ff5fa3c" xlink:to="loc_ifrs-full_RevenueFromGovernmentGrants_24982f23-2603-4d52-93fa-2e9fb3654c62" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesLeaseliabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfLeaseLiabilitiesLineItems_3ce3eef7-3f85-4c91-a089-66af04cd3665" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfLeaseLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfLeaseLiabilitiesTable_90179b54-69e9-496c-ab74-817e7d9e4f63" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfLeaseLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_abvx_DisclosureOfLeaseLiabilitiesLineItems_3ce3eef7-3f85-4c91-a089-66af04cd3665" xlink:to="loc_abvx_DisclosureOfLeaseLiabilitiesTable_90179b54-69e9-496c-ab74-817e7d9e4f63" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_e33b131f-937a-409e-a626-a69c8b74c07d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abvx_DisclosureOfLeaseLiabilitiesTable_90179b54-69e9-496c-ab74-817e7d9e4f63" xlink:to="loc_ifrs-full_TypesOfContractsAxis_e33b131f-937a-409e-a626-a69c8b74c07d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_e33b131f-937a-409e-a626-a69c8b74c07d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfContractsAxis_e33b131f-937a-409e-a626-a69c8b74c07d" xlink:to="loc_ifrs-full_TypesOfContractsDomain_e33b131f-937a-409e-a626-a69c8b74c07d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_97674617-d0ab-490d-9c5c-c5e74c323ea0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfContractsAxis_e33b131f-937a-409e-a626-a69c8b74c07d" xlink:to="loc_ifrs-full_TypesOfContractsDomain_97674617-d0ab-490d-9c5c-c5e74c323ea0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LeaseFacilitiesParisMember_4a89ae34-eeca-4181-98e3-51d148e535dd" xlink:href="abvx-20251231.xsd#abvx_LeaseFacilitiesParisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsDomain_97674617-d0ab-490d-9c5c-c5e74c323ea0" xlink:to="loc_abvx_LeaseFacilitiesParisMember_4a89ae34-eeca-4181-98e3-51d148e535dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LeaseFacilitiesBostonMember_a1cbcce2-3e76-414d-b6a3-b69badbe6c25" xlink:href="abvx-20251231.xsd#abvx_LeaseFacilitiesBostonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsDomain_97674617-d0ab-490d-9c5c-c5e74c323ea0" xlink:to="loc_abvx_LeaseFacilitiesBostonMember_a1cbcce2-3e76-414d-b6a3-b69badbe6c25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LeaseFacilitiesMontpellierMember_4bfd11f5-80a5-41e6-9c49-00f26b6a25f5" xlink:href="abvx-20251231.xsd#abvx_LeaseFacilitiesMontpellierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsDomain_97674617-d0ab-490d-9c5c-c5e74c323ea0" xlink:to="loc_abvx_LeaseFacilitiesMontpellierMember_4bfd11f5-80a5-41e6-9c49-00f26b6a25f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LeaseFacilitiesMember_edbd71fc-7f11-4c0a-a766-7488ae6c73f7" xlink:href="abvx-20251231.xsd#abvx_LeaseFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsDomain_97674617-d0ab-490d-9c5c-c5e74c323ea0" xlink:to="loc_abvx_LeaseFacilitiesMember_edbd71fc-7f11-4c0a-a766-7488ae6c73f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_f12f6201-73a8-40c9-ae35-e515234d081f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abvx_DisclosureOfLeaseLiabilitiesTable_90179b54-69e9-496c-ab74-817e7d9e4f63" xlink:to="loc_ifrs-full_RangeAxis_f12f6201-73a8-40c9-ae35-e515234d081f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_f12f6201-73a8-40c9-ae35-e515234d081f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_f12f6201-73a8-40c9-ae35-e515234d081f" xlink:to="loc_ifrs-full_RangeDomain_f12f6201-73a8-40c9-ae35-e515234d081f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_e403825c-8b2c-42d0-a5de-829d6bda500d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_f12f6201-73a8-40c9-ae35-e515234d081f" xlink:to="loc_ifrs-full_RangeDomain_e403825c-8b2c-42d0-a5de-829d6bda500d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f50f22cf-387f-4388-85cb-015842be2b90" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_e403825c-8b2c-42d0-a5de-829d6bda500d" xlink:to="loc_srt_MinimumMember_f50f22cf-387f-4388-85cb-015842be2b90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6eb94a93-26f8-4c9d-9ce3-599ca2d178de" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_e403825c-8b2c-42d0-a5de-829d6bda500d" xlink:to="loc_srt_MaximumMember_6eb94a93-26f8-4c9d-9ce3-599ca2d178de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LeaseDurationPeriod_1e0c8955-8a6b-46b2-b4a4-39c1d979646b" xlink:href="abvx-20251231.xsd#abvx_LeaseDurationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfLeaseLiabilitiesLineItems_3ce3eef7-3f85-4c91-a089-66af04cd3665" xlink:to="loc_abvx_LeaseDurationPeriod_1e0c8955-8a6b-46b2-b4a4-39c1d979646b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LeaseTacitRenewalPeriod_0898cda7-4946-485d-9d23-09e011157c89" xlink:href="abvx-20251231.xsd#abvx_LeaseTacitRenewalPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfLeaseLiabilitiesLineItems_3ce3eef7-3f85-4c91-a089-66af04cd3665" xlink:to="loc_abvx_LeaseTacitRenewalPeriod_0898cda7-4946-485d-9d23-09e011157c89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LeaseBreakClausePeriod_c333363e-1cf8-45ba-98ef-5c3c79cd4f2f" xlink:href="abvx-20251231.xsd#abvx_LeaseBreakClausePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfLeaseLiabilitiesLineItems_3ce3eef7-3f85-4c91-a089-66af04cd3665" xlink:to="loc_abvx_LeaseBreakClausePeriod_c333363e-1cf8-45ba-98ef-5c3c79cd4f2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DecreaseInLeaseLiabilitiesThroughModificationOfTerm_dd1fe94e-4176-41bb-b74e-3eb8b59215c8" xlink:href="abvx-20251231.xsd#abvx_DecreaseInLeaseLiabilitiesThroughModificationOfTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfLeaseLiabilitiesLineItems_3ce3eef7-3f85-4c91-a089-66af04cd3665" xlink:to="loc_abvx_DecreaseInLeaseLiabilitiesThroughModificationOfTerm_dd1fe94e-4176-41bb-b74e-3eb8b59215c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LeaseExtensionPeriod_29f0aec0-12b0-4493-8a9f-36a9eb40b020" xlink:href="abvx-20251231.xsd#abvx_LeaseExtensionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfLeaseLiabilitiesLineItems_3ce3eef7-3f85-4c91-a089-66af04cd3665" xlink:to="loc_abvx_LeaseExtensionPeriod_29f0aec0-12b0-4493-8a9f-36a9eb40b020" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LeaseLiabilityPercentageOfTotal_b600d7c7-fa0c-45e0-b93a-d68222509182" xlink:href="abvx-20251231.xsd#abvx_LeaseLiabilityPercentageOfTotal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfLeaseLiabilitiesLineItems_3ce3eef7-3f85-4c91-a089-66af04cd3665" xlink:to="loc_abvx_LeaseLiabilityPercentageOfTotal_b600d7c7-fa0c-45e0-b93a-d68222509182" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpenseOnLeaseLiabilities_763d7c17-55c2-4c27-a09a-c8ac6b304787" xlink:href="abvx-20251231.xsd#abvx_ExpenseOnLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfLeaseLiabilitiesLineItems_3ce3eef7-3f85-4c91-a089-66af04cd3665" xlink:to="loc_abvx_ExpenseOnLeaseLiabilities_763d7c17-55c2-4c27-a09a-c8ac6b304787" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DepreciationExpenseLease_d5c85315-27d7-4af5-b1d7-2c80a9708152" xlink:href="abvx-20251231.xsd#abvx_DepreciationExpenseLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfLeaseLiabilitiesLineItems_3ce3eef7-3f85-4c91-a089-66af04cd3665" xlink:to="loc_abvx_DepreciationExpenseLease_d5c85315-27d7-4af5-b1d7-2c80a9708152" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_703d05b3-f0eb-4df3-86e6-7b59cf150ca9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfLeaseLiabilitiesLineItems_3ce3eef7-3f85-4c91-a089-66af04cd3665" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_703d05b3-f0eb-4df3-86e6-7b59cf150ca9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed_cf18d510-0fb4-4a37-b8c4-9dd3b2e62f02" xlink:href="abvx-20251231.xsd#abvx_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfLeaseLiabilitiesLineItems_3ce3eef7-3f85-4c91-a089-66af04cd3665" xlink:to="loc_abvx_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed_cf18d510-0fb4-4a37-b8c4-9dd3b2e62f02" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesRoyaltycertificatesDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_29aeafb0-99bb-41d3-a620-494d837525ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_29aeafb0-99bb-41d3-a620-494d837525ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019bffa7-38ad-7881-aa13-56ccfbd47f07" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_29aeafb0-99bb-41d3-a620-494d837525ee" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019bffa7-38ad-7881-aa13-56ccfbd47f07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019bffa7-38ad-7881-aa13-56ccfbd47f07_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019bffa7-38ad-7881-aa13-56ccfbd47f07" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019bffa7-38ad-7881-aa13-56ccfbd47f07_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019bffa7-38ad-7163-bcce-d128c8e34d9d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019bffa7-38ad-7881-aa13-56ccfbd47f07" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019bffa7-38ad-7163-bcce-d128c8e34d9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificatesMember_019bffa7-38ad-756a-af6e-4f182497d06f" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019bffa7-38ad-7163-bcce-d128c8e34d9d" xlink:to="loc_abvx_RoyaltyCertificatesMember_019bffa7-38ad-756a-af6e-4f182497d06f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_019bffa7-38ad-74e1-924b-0fdfae1eff24" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_29aeafb0-99bb-41d3-a620-494d837525ee" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_019bffa7-38ad-74e1-924b-0fdfae1eff24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_019bffa7-38ad-74e1-924b-0fdfae1eff24_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_019bffa7-38ad-74e1-924b-0fdfae1eff24" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_019bffa7-38ad-74e1-924b-0fdfae1eff24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_019bffa7-38ad-7be3-950a-e9c64fac0d26" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_019bffa7-38ad-74e1-924b-0fdfae1eff24" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_019bffa7-38ad-7be3-950a-e9c64fac0d26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_019bffa7-38ad-742c-ae99-e1b725a7138e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_019bffa7-38ad-7be3-950a-e9c64fac0d26" xlink:to="loc_ifrs-full_SharePremiumMember_019bffa7-38ad-742c-ae99-e1b725a7138e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_019bffa7-38ad-7647-b202-c388f5137ebd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_29aeafb0-99bb-41d3-a620-494d837525ee" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_019bffa7-38ad-7647-b202-c388f5137ebd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_019bffa7-38ad-7647-b202-c388f5137ebd_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_019bffa7-38ad-7647-b202-c388f5137ebd" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_019bffa7-38ad-7647-b202-c388f5137ebd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_019bffa7-38ad-7e8b-8a6f-cf9bf4adbea9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_019bffa7-38ad-7647-b202-c388f5137ebd" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_019bffa7-38ad-7e8b-8a6f-cf9bf4adbea9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificatesMember_019bffa7-38ad-7a64-9a71-82af63b506b4" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_019bffa7-38ad-7e8b-8a6f-cf9bf4adbea9" xlink:to="loc_abvx_RoyaltyCertificatesMember_019bffa7-38ad-7a64-9a71-82af63b506b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_019bffa7-9b9e-7b9c-b770-f7b82339cae6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_29aeafb0-99bb-41d3-a620-494d837525ee" xlink:to="loc_ifrs-full_UnobservableInputsAxis_019bffa7-9b9e-7b9c-b770-f7b82339cae6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain_019bffa7-9b9e-7b9c-b770-f7b82339cae6_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_UnobservableInputsAxis_019bffa7-9b9e-7b9c-b770-f7b82339cae6" xlink:to="loc_ifrs-full_UnobservableInputsDomain_019bffa7-9b9e-7b9c-b770-f7b82339cae6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain_019bffa7-9b9e-7a0c-a352-5876d295342b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_UnobservableInputsAxis_019bffa7-9b9e-7b9c-b770-f7b82339cae6" xlink:to="loc_ifrs-full_UnobservableInputsDomain_019bffa7-9b9e-7a0c-a352-5876d295342b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ProbabilityOfSuccessMeasurementInputMember_019bffa7-9b9e-7c7f-afed-329a082d1291" xlink:href="abvx-20251231.xsd#abvx_ProbabilityOfSuccessMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019bffa7-9b9e-7a0c-a352-5876d295342b" xlink:to="loc_abvx_ProbabilityOfSuccessMeasurementInputMember_019bffa7-9b9e-7c7f-afed-329a082d1291" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PeakPenetrationMeasurementInputMember_019bffa7-9b9e-79f1-a4ae-cdfe6557697d" xlink:href="abvx-20251231.xsd#abvx_PeakPenetrationMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019bffa7-9b9e-7a0c-a352-5876d295342b" xlink:to="loc_abvx_PeakPenetrationMeasurementInputMember_019bffa7-9b9e-79f1-a4ae-cdfe6557697d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DiscountRateMeasurementInputMember_019bffa7-d5df-7c58-aefe-54d001ca1ce9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DiscountRateMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019bffa7-9b9e-7a0c-a352-5876d295342b" xlink:to="loc_ifrs-full_DiscountRateMeasurementInputMember_019bffa7-d5df-7c58-aefe-54d001ca1ce9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageCostOfCapitalMeasurementInputMember_019bffa8-5859-7c48-ac7a-c5e9a15ba52a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageCostOfCapitalMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019bffa7-9b9e-7a0c-a352-5876d295342b" xlink:to="loc_ifrs-full_WeightedAverageCostOfCapitalMeasurementInputMember_019bffa8-5859-7c48-ac7a-c5e9a15ba52a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SharePriceMeasurementInputMember_019bffa8-5859-7f7c-bd51-2fbd6b84bd4b" xlink:href="abvx-20251231.xsd#abvx_SharePriceMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019bffa7-9b9e-7a0c-a352-5876d295342b" xlink:to="loc_abvx_SharePriceMeasurementInputMember_019bffa8-5859-7f7c-bd51-2fbd6b84bd4b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_019bffa7-38ad-7d14-896c-5ddfb393aae8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_ifrs-full_NotionalAmount_019bffa7-38ad-7d14-896c-5ddfb393aae8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherLiabilitiesNumberOfTransactions_019bffa7-38ad-721a-a548-7b128cfd9db5" xlink:href="abvx-20251231.xsd#abvx_OtherLiabilitiesNumberOfTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_abvx_OtherLiabilitiesNumberOfTransactions_019bffa7-38ad-721a-a548-7b128cfd9db5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_019bffa7-38ad-7e94-9d92-605ae4e29f41" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_ifrs-full_IssueOfEquity_019bffa7-38ad-7e94-9d92-605ae4e29f41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease_019bffa7-38ad-7564-bdd7-846176f57c71" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease_019bffa7-38ad-7564-bdd7-846176f57c71" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_019bffa7-38ad-7e09-8581-cde59c963300" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_ifrs-full_ParValuePerShare_019bffa7-38ad-7e09-8581-cde59c963300" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EquityIssuanceSubscriptionPricePerShare_019bffa7-38ad-7810-a567-aa8a1f8680f5" xlink:href="abvx-20251231.xsd#abvx_EquityIssuanceSubscriptionPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_abvx_EquityIssuanceSubscriptionPricePerShare_019bffa7-38ad-7810-a567-aa8a1f8680f5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NetProceedsFromSaleOfRoyaltyCertificates_019bffa7-38ad-7fe4-ae90-8fed5a98a807" xlink:href="abvx-20251231.xsd#abvx_NetProceedsFromSaleOfRoyaltyCertificates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_abvx_NetProceedsFromSaleOfRoyaltyCertificates_019bffa7-38ad-7fe4-ae90-8fed5a98a807" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificatePercentageOfFutureSales_019bffa7-38ad-73fa-9c4f-452751285f40" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificatePercentageOfFutureSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_abvx_RoyaltyCertificatePercentageOfFutureSales_019bffa7-38ad-73fa-9c4f-452751285f40" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificateMaximumAmount_019bffa7-38ad-73b8-8eee-db78ab00ecd0" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificateMaximumAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_abvx_RoyaltyCertificateMaximumAmount_019bffa7-38ad-73b8-8eee-db78ab00ecd0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_019bffa7-38ad-7227-bc08-bb6da64a836d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_019bffa7-38ad-7227-bc08-bb6da64a836d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificatesEIR_019bffa7-38ad-77fe-945d-ae258c83a886" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificatesEIR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_abvx_RoyaltyCertificatesEIR_019bffa7-38ad-77fe-945d-ae258c83a886" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities_019bffa7-38ad-712a-ad7e-d61049b171cd" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities_019bffa7-38ad-712a-ad7e-d61049b171cd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_InterestExpenseOnRoyaltyCertificatesIncludingTheUnwindingOfDiscount_019cc355-1afa-75a6-b67b-c756b4814935" xlink:href="abvx-20251231.xsd#abvx_InterestExpenseOnRoyaltyCertificatesIncludingTheUnwindingOfDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_abvx_InterestExpenseOnRoyaltyCertificatesIncludingTheUnwindingOfDiscount_019cc355-1afa-75a6-b67b-c756b4814935" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_UnwindingOfDiscountOnRoyalties_019bffa7-38ad-7d1f-969c-4879e029870f" xlink:href="abvx-20251231.xsd#abvx_UnwindingOfDiscountOnRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_abvx_UnwindingOfDiscountOnRoyalties_019bffa7-38ad-7d1f-969c-4879e029870f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bffa7-9b9e-7aa2-8dad-d3d373ac91c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bffa7-9b9e-7aa2-8dad-d3d373ac91c3" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bffa7-9b9e-7c62-9256-61085e1a7395" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bffa7-9b9e-7c62-9256-61085e1a7395" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities_019bffa7-9b9e-7fe4-9b1b-44ece0a3f912" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities_019bffa7-9b9e-7fe4-9b1b-44ece0a3f912" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities_019bffa7-9b9e-7282-b713-e584e8928c63" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities_019bffa7-9b9e-7282-b713-e584e8928c63" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValue_019bffa7-d5df-7ae5-be28-907032db5d3b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValue_019bffa7-d5df-7ae5-be28-907032db5d3b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_UnobservableInputLiabilitiesDiscountRate_019cfd0f-9f4a-733f-bef7-84fa815ccf7f" xlink:href="abvx-20251231.xsd#abvx_UnobservableInputLiabilitiesDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_abvx_UnobservableInputLiabilitiesDiscountRate_019cfd0f-9f4a-733f-bef7-84fa815ccf7f" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bffa8-5859-780e-928d-33a887c1b159" xlink:href="abvx-20251231.xsd#abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bffa8-5859-780e-928d-33a887c1b159" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bffa8-5859-7b0b-932b-d4022ee61264" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bffa8-5859-7b0b-932b-d4022ee61264" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AmountOfReasonablyPossibleDecreaseInUnobservableInputLiabilities_019bffa8-5859-7763-82c3-105310a28740" xlink:href="abvx-20251231.xsd#abvx_AmountOfReasonablyPossibleDecreaseInUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_abvx_AmountOfReasonablyPossibleDecreaseInUnobservableInputLiabilities_019bffa8-5859-7763-82c3-105310a28740" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities_019bffa8-5859-7122-83b6-3f32d58cec9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities_019bffa8-5859-7122-83b6-3f32d58cec9a" xlink:type="arc" order="23"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_75f23386-f6a4-40c2-896d-b4fed2d770cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_fd50bf14-1f81-44a8-856c-5728ed8fe292" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_75f23386-f6a4-40c2-896d-b4fed2d770cb" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_fd50bf14-1f81-44a8-856c-5728ed8fe292" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_b9a6a222-0ab5-4235-a39c-2f44b045df5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_fd50bf14-1f81-44a8-856c-5728ed8fe292" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_b9a6a222-0ab5-4235-a39c-2f44b045df5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_b9a6a222-0ab5-4235-a39c-2f44b045df5b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_b9a6a222-0ab5-4235-a39c-2f44b045df5b" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_b9a6a222-0ab5-4235-a39c-2f44b045df5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_a6de3721-e5dd-4c7a-b311-d842bb5dcbfa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_b9a6a222-0ab5-4235-a39c-2f44b045df5b" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_a6de3721-e5dd-4c7a-b311-d842bb5dcbfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos12BondLoansMember_2444bc7c-0cc7-41b6-9cb7-6492a736b687" xlink:href="abvx-20251231.xsd#abvx_Kreos12BondLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_a6de3721-e5dd-4c7a-b311-d842bb5dcbfa" xlink:to="loc_abvx_Kreos12BondLoansMember_2444bc7c-0cc7-41b6-9cb7-6492a736b687" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OCEANEMember_de55bdc7-bdb6-4afd-85ad-d365ff2be4db" xlink:href="abvx-20251231.xsd#abvx_OCEANEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_a6de3721-e5dd-4c7a-b311-d842bb5dcbfa" xlink:to="loc_abvx_OCEANEMember_de55bdc7-bdb6-4afd-85ad-d365ff2be4db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheAMember_e96e63c0-f448-4116-afdb-65b6840c369c" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_a6de3721-e5dd-4c7a-b311-d842bb5dcbfa" xlink:to="loc_abvx_KreosClaretFinancingTrancheAMember_e96e63c0-f448-4116-afdb-65b6840c369c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1ClaretBondLoansMember_f0f39668-ae05-4710-84d4-6bd0d5c6708f" xlink:href="abvx-20251231.xsd#abvx_Kreos1ClaretBondLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_a6de3721-e5dd-4c7a-b311-d842bb5dcbfa" xlink:to="loc_abvx_Kreos1ClaretBondLoansMember_f0f39668-ae05-4710-84d4-6bd0d5c6708f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_HeightsConvertibleNotesMember_6f8f511e-b6a9-4e12-b939-0940a66f37c0" xlink:href="abvx-20251231.xsd#abvx_HeightsConvertibleNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_a6de3721-e5dd-4c7a-b311-d842bb5dcbfa" xlink:to="loc_abvx_HeightsConvertibleNotesMember_6f8f511e-b6a9-4e12-b939-0940a66f37c0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PretGarantiParLEtatPGEMember_08633a4a-8a55-42ae-a17b-fceaeaba9199" xlink:href="abvx-20251231.xsd#abvx_PretGarantiParLEtatPGEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_a6de3721-e5dd-4c7a-b311-d842bb5dcbfa" xlink:to="loc_abvx_PretGarantiParLEtatPGEMember_08633a4a-8a55-42ae-a17b-fceaeaba9199" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConditionalAdvancesMember_4effc3a7-7520-4256-943f-728033e84f49" xlink:href="abvx-20251231.xsd#abvx_ConditionalAdvancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_a6de3721-e5dd-4c7a-b311-d842bb5dcbfa" xlink:to="loc_abvx_ConditionalAdvancesMember_4effc3a7-7520-4256-943f-728033e84f49" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_9e2f4a58-ca9e-441f-9314-6328394f38b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_a6de3721-e5dd-4c7a-b311-d842bb5dcbfa" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_9e2f4a58-ca9e-441f-9314-6328394f38b7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificatesMember_541b547f-1bca-4e7e-b52b-3f03327f0cd5" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_a6de3721-e5dd-4c7a-b311-d842bb5dcbfa" xlink:to="loc_abvx_RoyaltyCertificatesMember_541b547f-1bca-4e7e-b52b-3f03327f0cd5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_77655021-90d9-445e-b733-fb009709bdd3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_75f23386-f6a4-40c2-896d-b4fed2d770cb" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_77655021-90d9-445e-b733-fb009709bdd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities_32b1894e-aca4-46e0-91c9-fd8ab718d3ed" xlink:href="abvx-20251231.xsd#abvx_IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_75f23386-f6a4-40c2-896d-b4fed2d770cb" xlink:to="loc_abvx_IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities_32b1894e-aca4-46e0-91c9-fd8ab718d3ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities_f83a13ea-01b7-42fd-93ec-056e02845d7d" xlink:href="abvx-20251231.xsd#abvx_DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_75f23386-f6a4-40c2-896d-b4fed2d770cb" xlink:to="loc_abvx_DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities_f83a13ea-01b7-42fd-93ec-056e02845d7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities_927733f9-50fa-45f4-92f5-46c6683f864d" xlink:href="abvx-20251231.xsd#abvx_DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_75f23386-f6a4-40c2-896d-b4fed2d770cb" xlink:to="loc_abvx_DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities_927733f9-50fa-45f4-92f5-46c6683f864d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities_9fbf257d-7ea5-4e1b-ad97-4cfc6aa897d9" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_75f23386-f6a4-40c2-896d-b4fed2d770cb" xlink:to="loc_abvx_IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities_9fbf257d-7ea5-4e1b-ad97-4cfc6aa897d9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities_3b4cd96f-b533-4ab5-a5dc-65dc7ad9cb27" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_75f23386-f6a4-40c2-896d-b4fed2d770cb" xlink:to="loc_abvx_IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities_3b4cd96f-b533-4ab5-a5dc-65dc7ad9cb27" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_43fa501c-3d10-446b-b9bc-bee4ee9c9de7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_75f23386-f6a4-40c2-896d-b4fed2d770cb" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_43fa501c-3d10-446b-b9bc-bee4ee9c9de7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities_349580da-da7b-4521-aefd-89513f8bc6e6" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_75f23386-f6a4-40c2-896d-b4fed2d770cb" xlink:to="loc_abvx_IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities_349580da-da7b-4521-aefd-89513f8bc6e6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities_d5ce1524-7c50-4146-b767-353427d5dfcf" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_75f23386-f6a4-40c2-896d-b4fed2d770cb" xlink:to="loc_abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities_d5ce1524-7c50-4146-b767-353427d5dfcf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities_41f36a07-4647-42d4-8054-d87ea063625d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_75f23386-f6a4-40c2-896d-b4fed2d770cb" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities_41f36a07-4647-42d4-8054-d87ea063625d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities_652a1c84-6123-4462-98d4-9452c40662c5" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_75f23386-f6a4-40c2-896d-b4fed2d770cb" xlink:to="loc_abvx_IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities_652a1c84-6123-4462-98d4-9452c40662c5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities_019c5738-0ffd-7187-af60-eca22b6709d2" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_75f23386-f6a4-40c2-896d-b4fed2d770cb" xlink:to="loc_abvx_IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities_019c5738-0ffd-7187-af60-eca22b6709d2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_703b5c5e-be92-4805-bef4-2d232d095e58" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_75f23386-f6a4-40c2-896d-b4fed2d770cb" xlink:to="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_703b5c5e-be92-4805-bef4-2d232d095e58" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_b027fe05-2a2c-4657-b2bc-38fedd5840a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_75f23386-f6a4-40c2-896d-b4fed2d770cb" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_b027fe05-2a2c-4657-b2bc-38fedd5840a0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_c2bd0a5e-33c1-4cc9-8022-15b45bc34a83" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesChangeinfinancialliabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_1991fa2a-be1c-4870-9876-5d351d3a7ec1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_e8f93a72-6a5d-45d9-95e0-0c82001df9bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_1991fa2a-be1c-4870-9876-5d351d3a7ec1" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_e8f93a72-6a5d-45d9-95e0-0c82001df9bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_3b57197d-14b5-47b2-aa7b-479fa7e361f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_e8f93a72-6a5d-45d9-95e0-0c82001df9bc" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_3b57197d-14b5-47b2-aa7b-479fa7e361f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_3b57197d-14b5-47b2-aa7b-479fa7e361f8_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_3b57197d-14b5-47b2-aa7b-479fa7e361f8" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_3b57197d-14b5-47b2-aa7b-479fa7e361f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_c73c5a1e-8035-4a0c-ae6b-1ae46fa059dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_3b57197d-14b5-47b2-aa7b-479fa7e361f8" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_c73c5a1e-8035-4a0c-ae6b-1ae46fa059dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheAMember_bdef2de1-96d9-4070-90b5-b55be137a853" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c73c5a1e-8035-4a0c-ae6b-1ae46fa059dc" xlink:to="loc_abvx_KreosClaretFinancingTrancheAMember_bdef2de1-96d9-4070-90b5-b55be137a853" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember_b7d5eba2-5c57-4d0c-9552-bd86dfbae26a" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c73c5a1e-8035-4a0c-ae6b-1ae46fa059dc" xlink:to="loc_abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember_b7d5eba2-5c57-4d0c-9552-bd86dfbae26a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_HeightsConvertibleNotesMember_ab8dcd51-05bc-4c53-8989-365c4304afde" xlink:href="abvx-20251231.xsd#abvx_HeightsConvertibleNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c73c5a1e-8035-4a0c-ae6b-1ae46fa059dc" xlink:to="loc_abvx_HeightsConvertibleNotesMember_ab8dcd51-05bc-4c53-8989-365c4304afde" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OCEANEMember_e196ca6b-d192-43eb-983e-3a6126027d7d" xlink:href="abvx-20251231.xsd#abvx_OCEANEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c73c5a1e-8035-4a0c-ae6b-1ae46fa059dc" xlink:to="loc_abvx_OCEANEMember_e196ca6b-d192-43eb-983e-3a6126027d7d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheBMember_ea5144cb-2889-407b-a1ef-e365ab344db2" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c73c5a1e-8035-4a0c-ae6b-1ae46fa059dc" xlink:to="loc_abvx_KreosClaretFinancingTrancheBMember_ea5144cb-2889-407b-a1ef-e365ab344db2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheCMember_ddba5ac9-d2bb-4e9a-ba4c-3b2c3ee40b70" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c73c5a1e-8035-4a0c-ae6b-1ae46fa059dc" xlink:to="loc_abvx_KreosClaretFinancingTrancheCMember_ddba5ac9-d2bb-4e9a-ba4c-3b2c3ee40b70" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheABMember_6a33c444-7471-4690-a2b6-0310b9093661" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheABMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c73c5a1e-8035-4a0c-ae6b-1ae46fa059dc" xlink:to="loc_abvx_KreosClaretFinancingTrancheABMember_6a33c444-7471-4690-a2b6-0310b9093661" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_8eca8f20-3b00-4783-b0a8-c0fa8b3e4a8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_e8f93a72-6a5d-45d9-95e0-0c82001df9bc" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_8eca8f20-3b00-4783-b0a8-c0fa8b3e4a8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_8eca8f20-3b00-4783-b0a8-c0fa8b3e4a8b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_8eca8f20-3b00-4783-b0a8-c0fa8b3e4a8b" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_8eca8f20-3b00-4783-b0a8-c0fa8b3e4a8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_9ce61c2e-d6dd-4fd6-bdf7-2b6718d3c28c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_8eca8f20-3b00-4783-b0a8-c0fa8b3e4a8b" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_9ce61c2e-d6dd-4fd6-bdf7-2b6718d3c28c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OceaneConversionOptionMember_4afaca7c-0471-4245-b697-abad4dcfa032" xlink:href="abvx-20251231.xsd#abvx_OceaneConversionOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_9ce61c2e-d6dd-4fd6-bdf7-2b6718d3c28c" xlink:to="loc_abvx_OceaneConversionOptionMember_4afaca7c-0471-4245-b697-abad4dcfa032" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForDebtIssueCosts_00e5c24e-09f6-4add-859e-19985cfd53c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsForDebtIssueCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_1991fa2a-be1c-4870-9876-5d351d3a7ec1" xlink:to="loc_ifrs-full_PaymentsForDebtIssueCosts_00e5c24e-09f6-4add-859e-19985cfd53c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NetProceedsFromConvertibleLoansNotes_c514cc74-8df9-4898-91f3-23e4908458cb" xlink:href="abvx-20251231.xsd#abvx_NetProceedsFromConvertibleLoansNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_1991fa2a-be1c-4870-9876-5d351d3a7ec1" xlink:to="loc_abvx_NetProceedsFromConvertibleLoansNotes_c514cc74-8df9-4898-91f3-23e4908458cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepurchaseOfDerivativeInstruments_bfeced63-29c5-4619-80ac-a9180e07c1a9" xlink:href="abvx-20251231.xsd#abvx_RepurchaseOfDerivativeInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_1991fa2a-be1c-4870-9876-5d351d3a7ec1" xlink:to="loc_abvx_RepurchaseOfDerivativeInstruments_bfeced63-29c5-4619-80ac-a9180e07c1a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepaymentsOfConvertibleLoansNotes_5c40627c-eefa-4d99-a428-2ddf16c6a979" xlink:href="abvx-20251231.xsd#abvx_RepaymentsOfConvertibleLoansNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_1991fa2a-be1c-4870-9876-5d351d3a7ec1" xlink:to="loc_abvx_RepaymentsOfConvertibleLoansNotes_5c40627c-eefa-4d99-a428-2ddf16c6a979" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_GrossProceedsFromNonConvertibleLoansNotes_bbc3aa11-7581-4ed8-bf6e-1c81609ffb86" xlink:href="abvx-20251231.xsd#abvx_GrossProceedsFromNonConvertibleLoansNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_1991fa2a-be1c-4870-9876-5d351d3a7ec1" xlink:to="loc_abvx_GrossProceedsFromNonConvertibleLoansNotes_bbc3aa11-7581-4ed8-bf6e-1c81609ffb86" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsDiscountRate_019c5742-3d2a-70df-9dd5-08d040c2001b" xlink:href="abvx-20251231.xsd#abvx_BorrowingsDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_1991fa2a-be1c-4870-9876-5d351d3a7ec1" xlink:to="loc_abvx_BorrowingsDiscountRate_019c5742-3d2a-70df-9dd5-08d040c2001b" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_7afa4347-ce99-4133-8623-b24af27cbadd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_e4c41bb0-a1d8-4fdd-ad1d-1b7f8ce1a4ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_7afa4347-ce99-4133-8623-b24af27cbadd" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_e4c41bb0-a1d8-4fdd-ad1d-1b7f8ce1a4ff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_1c56de6b-1a1a-4efa-9fb4-aae7eec8524d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_e4c41bb0-a1d8-4fdd-ad1d-1b7f8ce1a4ff" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_1c56de6b-1a1a-4efa-9fb4-aae7eec8524d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_1c56de6b-1a1a-4efa-9fb4-aae7eec8524d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_1c56de6b-1a1a-4efa-9fb4-aae7eec8524d" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_1c56de6b-1a1a-4efa-9fb4-aae7eec8524d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_b3c58368-7fe8-4cdb-9ee4-d272bd430e44" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_1c56de6b-1a1a-4efa-9fb4-aae7eec8524d" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_b3c58368-7fe8-4cdb-9ee4-d272bd430e44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosABSAMember_566ace77-5fb6-4623-b504-306f6c00db52" xlink:href="abvx-20251231.xsd#abvx_KreosABSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_b3c58368-7fe8-4cdb-9ee4-d272bd430e44" xlink:to="loc_abvx_KreosABSAMember_566ace77-5fb6-4623-b504-306f6c00db52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosBBSAMember_4d7649f3-cd43-4f8c-9fa1-df10e9f9491e" xlink:href="abvx-20251231.xsd#abvx_KreosBBSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_b3c58368-7fe8-4cdb-9ee4-d272bd430e44" xlink:to="loc_abvx_KreosBBSAMember_4d7649f3-cd43-4f8c-9fa1-df10e9f9491e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OceaneConversionOptionMember_b9b6fa8d-3cb8-4fef-9ea5-147e29cdd19e" xlink:href="abvx-20251231.xsd#abvx_OceaneConversionOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_b3c58368-7fe8-4cdb-9ee4-d272bd430e44" xlink:to="loc_abvx_OceaneConversionOptionMember_b9b6fa8d-3cb8-4fef-9ea5-147e29cdd19e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheAMember_1d558002-759d-4da6-9586-365b5b154f35" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_b3c58368-7fe8-4cdb-9ee4-d272bd430e44" xlink:to="loc_abvx_KreosClaretFinancingTrancheAMember_1d558002-759d-4da6-9586-365b5b154f35" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretMinimumReturnIndemnificationsMember_bbf812be-bbdd-40ee-bd8b-ca195c98c497" xlink:href="abvx-20251231.xsd#abvx_KreosClaretMinimumReturnIndemnificationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_b3c58368-7fe8-4cdb-9ee4-d272bd430e44" xlink:to="loc_abvx_KreosClaretMinimumReturnIndemnificationsMember_bbf812be-bbdd-40ee-bd8b-ca195c98c497" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities_8d6b56ff-debc-46ee-b1be-b3cad6903a33" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_7afa4347-ce99-4133-8623-b24af27cbadd" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilities_8d6b56ff-debc-46ee-b1be-b3cad6903a33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IssuanceOfDerivativeInstruments_6cb447ec-a701-4b75-9148-e2c76e919001" xlink:href="abvx-20251231.xsd#abvx_IssuanceOfDerivativeInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_7afa4347-ce99-4133-8623-b24af27cbadd" xlink:to="loc_abvx_IssuanceOfDerivativeInstruments_6cb447ec-a701-4b75-9148-e2c76e919001" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LossesOnChangeInFairValueOfDerivatives_4bceff72-93eb-40cd-beb7-68f0fdb7eb8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LossesOnChangeInFairValueOfDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_7afa4347-ce99-4133-8623-b24af27cbadd" xlink:to="loc_ifrs-full_LossesOnChangeInFairValueOfDerivatives_4bceff72-93eb-40cd-beb7-68f0fdb7eb8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives_8b5f7ce6-8089-4e2f-bc66-aa94235b0dd3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsOnChangeInFairValueOfDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_7afa4347-ce99-4133-8623-b24af27cbadd" xlink:to="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives_8b5f7ce6-8089-4e2f-bc66-aa94235b0dd3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepurchaseOfDerivativeInstruments_1362e66b-da37-4c33-9759-2652a43cc95d" xlink:href="abvx-20251231.xsd#abvx_RepurchaseOfDerivativeInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_7afa4347-ce99-4133-8623-b24af27cbadd" xlink:to="loc_abvx_RepurchaseOfDerivativeInstruments_1362e66b-da37-4c33-9759-2652a43cc95d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExerciseOfDerivativeInstruments_56ec67d3-a9f4-4554-a3ac-ed163fa70994" xlink:href="abvx-20251231.xsd#abvx_ExerciseOfDerivativeInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_7afa4347-ce99-4133-8623-b24af27cbadd" xlink:to="loc_abvx_ExerciseOfDerivativeInstruments_56ec67d3-a9f4-4554-a3ac-ed163fa70994" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities_5ae8dc8d-e4ed-4fa0-b27b-bc490bb5de42" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_61d0bb6e-49e7-4306-b424-edce15fba592" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_78c0728d-f42e-412b-a2bd-f6711359ebf2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_61d0bb6e-49e7-4306-b424-edce15fba592" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_78c0728d-f42e-412b-a2bd-f6711359ebf2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ea3aec78-05b5-4326-bf18-ac5f6556da84" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_78c0728d-f42e-412b-a2bd-f6711359ebf2" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ea3aec78-05b5-4326-bf18-ac5f6556da84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_ea3aec78-05b5-4326-bf18-ac5f6556da84_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ea3aec78-05b5-4326-bf18-ac5f6556da84" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_ea3aec78-05b5-4326-bf18-ac5f6556da84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_33e69911-32d6-4c73-b5fe-afd0aee5d5d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ea3aec78-05b5-4326-bf18-ac5f6556da84" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_33e69911-32d6-4c73-b5fe-afd0aee5d5d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_HeightsConvertibleNotesMember_daf64d0d-24d6-4715-afe6-fb8ca41e81c6" xlink:href="abvx-20251231.xsd#abvx_HeightsConvertibleNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_33e69911-32d6-4c73-b5fe-afd0aee5d5d8" xlink:to="loc_abvx_HeightsConvertibleNotesMember_daf64d0d-24d6-4715-afe6-fb8ca41e81c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheAMember_7a522bae-aed3-4d89-a688-04d92aaea1a9" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_33e69911-32d6-4c73-b5fe-afd0aee5d5d8" xlink:to="loc_abvx_KreosClaretFinancingTrancheAMember_7a522bae-aed3-4d89-a688-04d92aaea1a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretBondLoansMember_01e3ef08-07b5-446d-a0a1-d9ab70126131" xlink:href="abvx-20251231.xsd#abvx_KreosClaretBondLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_33e69911-32d6-4c73-b5fe-afd0aee5d5d8" xlink:to="loc_abvx_KreosClaretBondLoansMember_01e3ef08-07b5-446d-a0a1-d9ab70126131" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PretGarantiParLEtatPGEMember_4e01771a-2520-4921-a2b8-531749c18041" xlink:href="abvx-20251231.xsd#abvx_PretGarantiParLEtatPGEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_33e69911-32d6-4c73-b5fe-afd0aee5d5d8" xlink:to="loc_abvx_PretGarantiParLEtatPGEMember_4e01771a-2520-4921-a2b8-531749c18041" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_af598c98-c654-492d-81be-aa3ce82e2313" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_78c0728d-f42e-412b-a2bd-f6711359ebf2" xlink:to="loc_ifrs-full_MaturityAxis_af598c98-c654-492d-81be-aa3ce82e2313" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_af598c98-c654-492d-81be-aa3ce82e2313_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_af598c98-c654-492d-81be-aa3ce82e2313" xlink:to="loc_ifrs-full_MaturityDomain_af598c98-c654-492d-81be-aa3ce82e2313_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_2cb635f9-1f42-4f48-baae-2ffbabf23ecd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_af598c98-c654-492d-81be-aa3ce82e2313" xlink:to="loc_ifrs-full_MaturityDomain_2cb635f9-1f42-4f48-baae-2ffbabf23ecd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_6cae0916-883c-4d54-837e-033031636171" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_2cb635f9-1f42-4f48-baae-2ffbabf23ecd" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_6cae0916-883c-4d54-837e-033031636171" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_6537d6e5-99c3-4248-8abf-3743bc74a6b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_2cb635f9-1f42-4f48-baae-2ffbabf23ecd" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_6537d6e5-99c3-4248-8abf-3743bc74a6b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember_82d5900f-9af5-4847-a885-8bf62529b823" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_2cb635f9-1f42-4f48-baae-2ffbabf23ecd" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember_82d5900f-9af5-4847-a885-8bf62529b823" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_be58fe9a-951f-4bb0-beff-b53cc2d0a77b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_2cb635f9-1f42-4f48-baae-2ffbabf23ecd" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_be58fe9a-951f-4bb0-beff-b53cc2d0a77b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotes_fa315cb3-6f4a-4822-9cb1-7ccd0db304db" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_61d0bb6e-49e7-4306-b424-edce15fba592" xlink:to="loc_abvx_ConvertibleLoansNotes_fa315cb3-6f4a-4822-9cb1-7ccd0db304db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotesUndiscountedCashFlows_61207533-2845-4a39-9be6-c6197f7b103e" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotesUndiscountedCashFlows"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_61d0bb6e-49e7-4306-b424-edce15fba592" xlink:to="loc_abvx_ConvertibleLoansNotesUndiscountedCashFlows_61207533-2845-4a39-9be6-c6197f7b103e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_46d583cd-28a0-4e31-ba44-3e79e560b86d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_61d0bb6e-49e7-4306-b424-edce15fba592" xlink:to="loc_ifrs-full_Borrowings_46d583cd-28a0-4e31-ba44-3e79e560b86d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows_f629d02e-96bf-4abc-8c5c-62a31ead7e30" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BankBorrowingsUndiscountedCashFlows"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_61d0bb6e-49e7-4306-b424-edce15fba592" xlink:to="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows_f629d02e-96bf-4abc-8c5c-62a31ead7e30" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConditionalAdvances_f99e1dee-1ac3-48bd-9574-adf1bb7beb71" xlink:href="abvx-20251231.xsd#abvx_ConditionalAdvances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_61d0bb6e-49e7-4306-b424-edce15fba592" xlink:to="loc_abvx_ConditionalAdvances_f99e1dee-1ac3-48bd-9574-adf1bb7beb71" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConditionalAdvancesUndiscountedCashFlows_4a11b72c-4a07-4a2a-a205-9e195aa996ff" xlink:href="abvx-20251231.xsd#abvx_ConditionalAdvancesUndiscountedCashFlows"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_61d0bb6e-49e7-4306-b424-edce15fba592" xlink:to="loc_abvx_ConditionalAdvancesUndiscountedCashFlows_4a11b72c-4a07-4a2a-a205-9e195aa996ff" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NonCurrentRoyaltyCertificates_4a1c6903-f5af-45bf-9f4e-c95dab965f67" xlink:href="abvx-20251231.xsd#abvx_NonCurrentRoyaltyCertificates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_61d0bb6e-49e7-4306-b424-edce15fba592" xlink:to="loc_abvx_NonCurrentRoyaltyCertificates_4a1c6903-f5af-45bf-9f4e-c95dab965f67" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificatesUndiscountedCashFlows_2258445e-c758-4575-ace5-880f2c9c3a0a" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificatesUndiscountedCashFlows"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_61d0bb6e-49e7-4306-b424-edce15fba592" xlink:to="loc_abvx_RoyaltyCertificatesUndiscountedCashFlows_2258445e-c758-4575-ace5-880f2c9c3a0a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_dc7fa830-86a7-4f99-beba-9f4f91abd249" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_61d0bb6e-49e7-4306-b424-edce15fba592" xlink:to="loc_ifrs-full_LeaseLiabilities_dc7fa830-86a7-4f99-beba-9f4f91abd249" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLeaseLiabilities_5fb4362d-09e3-4c23-a3f5-b1aab072f7b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_61d0bb6e-49e7-4306-b424-edce15fba592" xlink:to="loc_ifrs-full_GrossLeaseLiabilities_5fb4362d-09e3-4c23-a3f5-b1aab072f7b2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities_6a855fd7-7aaf-4b48-a80d-44e43e89638a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_61d0bb6e-49e7-4306-b424-edce15fba592" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilities_6a855fd7-7aaf-4b48-a80d-44e43e89638a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows_877fd5c3-7060-4e96-bda2-979d672c239f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_61d0bb6e-49e7-4306-b424-edce15fba592" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows_877fd5c3-7060-4e96-bda2-979d672c239f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities_ff47ff04-ec85-4b62-8600-cf904663e180" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_61d0bb6e-49e7-4306-b424-edce15fba592" xlink:to="loc_ifrs-full_FinancialLiabilities_ff47ff04-ec85-4b62-8600-cf904663e180" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialLiabilitiesUndiscountedCashFlows_09f0839f-90d6-4cc4-9c2d-6252144c91cb" xlink:href="abvx-20251231.xsd#abvx_FinancialLiabilitiesUndiscountedCashFlows"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_61d0bb6e-49e7-4306-b424-edce15fba592" xlink:to="loc_abvx_FinancialLiabilitiesUndiscountedCashFlows_09f0839f-90d6-4cc4-9c2d-6252144c91cb" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesBreakdownoffinancialliabilitiesbymaturityDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesBreakdownoffinancialliabilitiesbymaturityDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesBreakdownoffinancialliabilitiesbymaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c290df7-624d-45a2-af97-1e900ae3601a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_69933053-a9a4-4d0c-b6f7-e6d69c3f8541" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c290df7-624d-45a2-af97-1e900ae3601a" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_69933053-a9a4-4d0c-b6f7-e6d69c3f8541" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_980f766a-2fcd-4c79-a127-573f62590fd1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_69933053-a9a4-4d0c-b6f7-e6d69c3f8541" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_980f766a-2fcd-4c79-a127-573f62590fd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_980f766a-2fcd-4c79-a127-573f62590fd1_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_980f766a-2fcd-4c79-a127-573f62590fd1" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_980f766a-2fcd-4c79-a127-573f62590fd1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_dab8e3f9-642c-4545-9372-fb9b3315ddb7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_980f766a-2fcd-4c79-a127-573f62590fd1" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_dab8e3f9-642c-4545-9372-fb9b3315ddb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificatesMember_28fe38d4-9104-468e-abaf-cd874d5fbd04" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_dab8e3f9-642c-4545-9372-fb9b3315ddb7" xlink:to="loc_abvx_RoyaltyCertificatesMember_28fe38d4-9104-468e-abaf-cd874d5fbd04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificatePercentageOfFutureSales_00f49b25-2e5a-4acf-9f90-4473e61bd9b1" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificatePercentageOfFutureSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c290df7-624d-45a2-af97-1e900ae3601a" xlink:to="loc_abvx_RoyaltyCertificatePercentageOfFutureSales_00f49b25-2e5a-4acf-9f90-4473e61bd9b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificateMaximumAmount_656392d4-65dd-421d-a8e0-f8ada648d47c" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificateMaximumAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c290df7-624d-45a2-af97-1e900ae3601a" xlink:to="loc_abvx_RoyaltyCertificateMaximumAmount_656392d4-65dd-421d-a8e0-f8ada648d47c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificateExpirationPeriod_b293b72a-6f01-463c-b9f3-7fb7ecc249bc" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificateExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c290df7-624d-45a2-af97-1e900ae3601a" xlink:to="loc_abvx_RoyaltyCertificateExpirationPeriod_b293b72a-6f01-463c-b9f3-7fb7ecc249bc" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_448a5ca1-db79-4f97-a27a-0bf0dea7c8c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_aba9a28c-3fa5-48f4-a0bf-bf15343e09ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_448a5ca1-db79-4f97-a27a-0bf0dea7c8c9" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_aba9a28c-3fa5-48f4-a0bf-bf15343e09ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_501f46a2-d6d6-4aaf-a203-286b1aee64b9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_aba9a28c-3fa5-48f4-a0bf-bf15343e09ee" xlink:to="loc_srt_TitleOfIndividualAxis_501f46a2-d6d6-4aaf-a203-286b1aee64b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_501f46a2-d6d6-4aaf-a203-286b1aee64b9_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_501f46a2-d6d6-4aaf-a203-286b1aee64b9" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_501f46a2-d6d6-4aaf-a203-286b1aee64b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1ef1e6c0-bb21-456e-9c31-43a13210feba" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_501f46a2-d6d6-4aaf-a203-286b1aee64b9" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1ef1e6c0-bb21-456e-9c31-43a13210feba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ManagementMember_96284b31-0d04-4b44-b52d-6058279c61a3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1ef1e6c0-bb21-456e-9c31-43a13210feba" xlink:to="loc_srt_ManagementMember_96284b31-0d04-4b44-b52d-6058279c61a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherEmployeesMember_8dc302c4-0756-4d25-9510-3f3eb4a2abcf" xlink:href="abvx-20251231.xsd#abvx_OtherEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1ef1e6c0-bb21-456e-9c31-43a13210feba" xlink:to="loc_abvx_OtherEmployeesMember_8dc302c4-0756-4d25-9510-3f3eb4a2abcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1c5dbe2b-29b1-4067-b5af-262e3e1476d8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_aba9a28c-3fa5-48f4-a0bf-bf15343e09ee" xlink:to="loc_srt_RangeAxis_1c5dbe2b-29b1-4067-b5af-262e3e1476d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1c5dbe2b-29b1-4067-b5af-262e3e1476d8_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1c5dbe2b-29b1-4067-b5af-262e3e1476d8" xlink:to="loc_srt_RangeMember_1c5dbe2b-29b1-4067-b5af-262e3e1476d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1e0b7bf8-5c7e-47ef-9719-4b889bc1073c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1c5dbe2b-29b1-4067-b5af-262e3e1476d8" xlink:to="loc_srt_RangeMember_1e0b7bf8-5c7e-47ef-9719-4b889bc1073c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_0fbfd571-11ae-4a45-901c-09aad3443838" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1e0b7bf8-5c7e-47ef-9719-4b889bc1073c" xlink:to="loc_ifrs-full_TopOfRangeMember_0fbfd571-11ae-4a45-901c-09aad3443838" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_25ea520a-50a1-4104-8926-2f4f85c10ed8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1e0b7bf8-5c7e-47ef-9719-4b889bc1073c" xlink:to="loc_ifrs-full_BottomOfRangeMember_25ea520a-50a1-4104-8926-2f4f85c10ed8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfRetirementAge2019_77ac4d3b-0b90-4a60-9167-3be35f153f04" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ActuarialAssumptionOfRetirementAge2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_448a5ca1-db79-4f97-a27a-0bf0dea7c8c9" xlink:to="loc_ifrs-full_ActuarialAssumptionOfRetirementAge2019_77ac4d3b-0b90-4a60-9167-3be35f153f04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRates_ddd886f1-9db6-4155-a7dd-f428ff91d637" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_448a5ca1-db79-4f97-a27a-0bf0dea7c8c9" xlink:to="loc_ifrs-full_ActuarialAssumptionOfDiscountRates_ddd886f1-9db6-4155-a7dd-f428ff91d637" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_86063ad2-6c0a-45a7-9120-8f8ee717bafd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_448a5ca1-db79-4f97-a27a-0bf0dea7c8c9" xlink:to="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_86063ad2-6c0a-45a7-9120-8f8ee717bafd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ActuarialAssumptionOfExpectedRatesOfTurnover_1ca547d8-b47c-4909-85be-9fe4a9c9e98b" xlink:href="abvx-20251231.xsd#abvx_ActuarialAssumptionOfExpectedRatesOfTurnover"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_448a5ca1-db79-4f97-a27a-0bf0dea7c8c9" xlink:to="loc_abvx_ActuarialAssumptionOfExpectedRatesOfTurnover_1ca547d8-b47c-4909-85be-9fe4a9c9e98b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ActuarialAssumptionOfExpectedRatesOfTurnoverAverageExitRate_015444ef-74a1-4220-8dca-9fa2a70b13e3" xlink:href="abvx-20251231.xsd#abvx_ActuarialAssumptionOfExpectedRatesOfTurnoverAverageExitRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_448a5ca1-db79-4f97-a27a-0bf0dea7c8c9" xlink:to="loc_abvx_ActuarialAssumptionOfExpectedRatesOfTurnoverAverageExitRate_015444ef-74a1-4220-8dca-9fa2a70b13e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ActuarialAssumptionOfEmployeeContributionRate_7afa45db-841e-4f8e-a0c9-2074ec1b8e28" xlink:href="abvx-20251231.xsd#abvx_ActuarialAssumptionOfEmployeeContributionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_448a5ca1-db79-4f97-a27a-0bf0dea7c8c9" xlink:to="loc_abvx_ActuarialAssumptionOfEmployeeContributionRate_7afa45db-841e-4f8e-a0c9-2074ec1b8e28" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofchangesinprojectedbenefitobligationDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#RetirementbenefitobligationsDisclosureofchangesinprojectedbenefitobligationDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofchangesinprojectedbenefitobligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_c68624e3-f0c9-4545-ab15-b13051cc1aeb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_c6baee42-b9f3-4915-aca0-fa880a01cb59" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_c68624e3-f0c9-4545-ab15-b13051cc1aeb" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_c6baee42-b9f3-4915-aca0-fa880a01cb59" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_c53aa916-97d8-47bb-8a7c-d31d1f02bee2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_c6baee42-b9f3-4915-aca0-fa880a01cb59" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_c53aa916-97d8-47bb-8a7c-d31d1f02bee2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_c53aa916-97d8-47bb-8a7c-d31d1f02bee2_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_c53aa916-97d8-47bb-8a7c-d31d1f02bee2" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_c53aa916-97d8-47bb-8a7c-d31d1f02bee2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_c9500674-0774-435e-ae96-2c38a8bc8f40" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_c53aa916-97d8-47bb-8a7c-d31d1f02bee2" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_c9500674-0774-435e-ae96-2c38a8bc8f40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember_91ec1a10-5e7b-478a-8ba0-4578d29ba950" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PresentValueOfDefinedBenefitObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_c9500674-0774-435e-ae96-2c38a8bc8f40" xlink:to="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember_91ec1a10-5e7b-478a-8ba0-4578d29ba950" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_a7edb470-00f2-48c0-86b5-df461c113bc8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_c68624e3-f0c9-4545-ab15-b13051cc1aeb" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_a7edb470-00f2-48c0-86b5-df461c113bc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_4e0286b3-22b9-4f7f-b84e-aa186fc0e4db" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_c68624e3-f0c9-4545-ab15-b13051cc1aeb" xlink:to="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_4e0286b3-22b9-4f7f-b84e-aa186fc0e4db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset_019c574f-b20b-71d4-9d35-26f20dc47f7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_c68624e3-f0c9-4545-ab15-b13051cc1aeb" xlink:to="loc_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset_019c574f-b20b-71d4-9d35-26f20dc47f7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_07a1dffe-7d45-42d5-a9af-473ce0d11b3d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_c68624e3-f0c9-4545-ab15-b13051cc1aeb" xlink:to="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_07a1dffe-7d45-42d5-a9af-473ce0d11b3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_d4476b4b-7310-405e-a248-b530bd24ad7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_c68624e3-f0c9-4545-ab15-b13051cc1aeb" xlink:to="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_d4476b4b-7310-405e-a248-b530bd24ad7a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_a2ffc485-43bf-41ca-952f-af87a3d013e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_c68624e3-f0c9-4545-ab15-b13051cc1aeb" xlink:to="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_a2ffc485-43bf-41ca-952f-af87a3d013e9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_f5560863-0c60-4f86-94d8-701ae2d667c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#OtheroperatingincomeNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfOperatingIncomeLineItems_6a0c878d-703a-4f1a-a96f-6d5a25197c25" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfOperatingIncomeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfOperatingIncomeTable_56f401eb-af87-4f50-af47-20ad9c7fc2c3" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfOperatingIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_abvx_DisclosureOfOperatingIncomeLineItems_6a0c878d-703a-4f1a-a96f-6d5a25197c25" xlink:to="loc_abvx_DisclosureOfOperatingIncomeTable_56f401eb-af87-4f50-af47-20ad9c7fc2c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CIRTaxYearAxis_d092d1c5-2054-4df4-88e7-ce84bda2ea84" xlink:href="abvx-20251231.xsd#abvx_CIRTaxYearAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abvx_DisclosureOfOperatingIncomeTable_56f401eb-af87-4f50-af47-20ad9c7fc2c3" xlink:to="loc_abvx_CIRTaxYearAxis_d092d1c5-2054-4df4-88e7-ce84bda2ea84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CIRTaxYearDomain_d092d1c5-2054-4df4-88e7-ce84bda2ea84_default" xlink:href="abvx-20251231.xsd#abvx_CIRTaxYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_abvx_CIRTaxYearAxis_d092d1c5-2054-4df4-88e7-ce84bda2ea84" xlink:to="loc_abvx_CIRTaxYearDomain_d092d1c5-2054-4df4-88e7-ce84bda2ea84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CIRTaxYearDomain_af3ad0be-0b56-4461-9b92-0e300f1f613f" xlink:href="abvx-20251231.xsd#abvx_CIRTaxYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_abvx_CIRTaxYearAxis_d092d1c5-2054-4df4-88e7-ce84bda2ea84" xlink:to="loc_abvx_CIRTaxYearDomain_af3ad0be-0b56-4461-9b92-0e300f1f613f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_A2021TaxYearMember_019c57c7-c3d0-786c-94c7-1114b0062dca" xlink:href="abvx-20251231.xsd#abvx_A2021TaxYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_CIRTaxYearDomain_af3ad0be-0b56-4461-9b92-0e300f1f613f" xlink:to="loc_abvx_A2021TaxYearMember_019c57c7-c3d0-786c-94c7-1114b0062dca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_A2022TaxYearMember_93df0bc2-2ec9-4ffe-9001-e1c2969b230f" xlink:href="abvx-20251231.xsd#abvx_A2022TaxYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_CIRTaxYearDomain_af3ad0be-0b56-4461-9b92-0e300f1f613f" xlink:to="loc_abvx_A2022TaxYearMember_93df0bc2-2ec9-4ffe-9001-e1c2969b230f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_A2023TaxYearMember_ce3fbb32-0da5-41df-8a60-0cc00df080a9" xlink:href="abvx-20251231.xsd#abvx_A2023TaxYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_CIRTaxYearDomain_af3ad0be-0b56-4461-9b92-0e300f1f613f" xlink:to="loc_abvx_A2023TaxYearMember_ce3fbb32-0da5-41df-8a60-0cc00df080a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_A2024TaxYearMember_019c5757-3845-71f1-9aec-29380bc8b04a" xlink:href="abvx-20251231.xsd#abvx_A2024TaxYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_CIRTaxYearDomain_af3ad0be-0b56-4461-9b92-0e300f1f613f" xlink:to="loc_abvx_A2024TaxYearMember_019c5757-3845-71f1-9aec-29380bc8b04a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_3ea93f68-e7c8-42b7-8726-2bc7c3d01b9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abvx_DisclosureOfOperatingIncomeTable_56f401eb-af87-4f50-af47-20ad9c7fc2c3" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_3ea93f68-e7c8-42b7-8726-2bc7c3d01b9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_3ea93f68-e7c8-42b7-8726-2bc7c3d01b9f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_3ea93f68-e7c8-42b7-8726-2bc7c3d01b9f" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_3ea93f68-e7c8-42b7-8726-2bc7c3d01b9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_fedc0c49-3215-404e-9fd4-b3cf4ee44644" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_3ea93f68-e7c8-42b7-8726-2bc7c3d01b9f" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_fedc0c49-3215-404e-9fd4-b3cf4ee44644" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RNPVIRConditionalAdvanceBPIMember_86f1976a-b7f4-4625-a63f-c234b3bb52e7" xlink:href="abvx-20251231.xsd#abvx_RNPVIRConditionalAdvanceBPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_fedc0c49-3215-404e-9fd4-b3cf4ee44644" xlink:to="loc_abvx_RNPVIRConditionalAdvanceBPIMember_86f1976a-b7f4-4625-a63f-c234b3bb52e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CARENAConditionalAdvanceBPIMember_c644d6eb-0924-44cf-81e8-31983ab6df4e" xlink:href="abvx-20251231.xsd#abvx_CARENAConditionalAdvanceBPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_fedc0c49-3215-404e-9fd4-b3cf4ee44644" xlink:to="loc_abvx_CARENAConditionalAdvanceBPIMember_c644d6eb-0924-44cf-81e8-31983ab6df4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncomeFromResearchTaxCredit_b9e38762-16bc-4f93-aa64-53aa7e2c4972" xlink:href="abvx-20251231.xsd#abvx_IncomeFromResearchTaxCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfOperatingIncomeLineItems_6a0c878d-703a-4f1a-a96f-6d5a25197c25" xlink:to="loc_abvx_IncomeFromResearchTaxCredit_b9e38762-16bc-4f93-aa64-53aa7e2c4972" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromGovernmentGrants_03c31e27-ef28-403e-b47e-99b6ebaeb707" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfOperatingIncomeLineItems_6a0c878d-703a-4f1a-a96f-6d5a25197c25" xlink:to="loc_ifrs-full_RevenueFromGovernmentGrants_03c31e27-ef28-403e-b47e-99b6ebaeb707" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_019bffc0-2d78-748f-96ec-5054c2cd9d89" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfOperatingIncomeLineItems_6a0c878d-703a-4f1a-a96f-6d5a25197c25" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_019bffc0-2d78-748f-96ec-5054c2cd9d89" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#OperatingexpensesDisclosureofsalesandmarketingexpensesDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_d47287a5-cf04-4bc9-8d4a-39275498515f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_e111342d-013e-4844-a178-daa2197c24ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_d47287a5-cf04-4bc9-8d4a-39275498515f" xlink:to="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_e111342d-013e-4844-a178-daa2197c24ea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_4f16b5af-f063-4f2d-a194-14df8d4a6cfc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_e111342d-013e-4844-a178-daa2197c24ea" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_4f16b5af-f063-4f2d-a194-14df8d4a6cfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_4f16b5af-f063-4f2d-a194-14df8d4a6cfc_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_4f16b5af-f063-4f2d-a194-14df8d4a6cfc" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_4f16b5af-f063-4f2d-a194-14df8d4a6cfc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_9531b110-6d5f-4ecb-ba58-f875b10d44fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_4f16b5af-f063-4f2d-a194-14df8d4a6cfc" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_9531b110-6d5f-4ecb-ba58-f875b10d44fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SalesAndMarketingExpenseMember_75edeee1-5f58-4fd0-a85a-bdb601c3229d" xlink:href="abvx-20251231.xsd#abvx_SalesAndMarketingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_9531b110-6d5f-4ecb-ba58-f875b10d44fd" xlink:to="loc_abvx_SalesAndMarketingExpenseMember_75edeee1-5f58-4fd0-a85a-bdb601c3229d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_ab5e663b-24cf-4bd9-8703-31dbf6268b8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_d47287a5-cf04-4bc9-8d4a-39275498515f" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_ab5e663b-24cf-4bd9-8703-31dbf6268b8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfessionalFeesExpense_49e3bac6-7400-49f9-901b-e8bc8560611d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfessionalFeesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_d47287a5-cf04-4bc9-8d4a-39275498515f" xlink:to="loc_ifrs-full_ProfessionalFeesExpense_49e3bac6-7400-49f9-901b-e8bc8560611d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_670a5238-641c-4cc5-9436-54016aef2cfb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_d47287a5-cf04-4bc9-8d4a-39275498515f" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_670a5238-641c-4cc5-9436-54016aef2cfb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_00b9cb9a-08b9-48d8-9e48-843059004191" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_d47287a5-cf04-4bc9-8d4a-39275498515f" xlink:to="loc_ifrs-full_OperatingExpense_00b9cb9a-08b9-48d8-9e48-843059004191" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_ebd76308-81a8-4890-a9a5-bb4c0da2b8a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_dbb757cd-2a1a-402f-a41c-adf77445c2c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_ebd76308-81a8-4890-a9a5-bb4c0da2b8a4" xlink:to="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_dbb757cd-2a1a-402f-a41c-adf77445c2c6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_9bdb8aea-2421-470c-91c9-54e0c163388e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_dbb757cd-2a1a-402f-a41c-adf77445c2c6" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_9bdb8aea-2421-470c-91c9-54e0c163388e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_9bdb8aea-2421-470c-91c9-54e0c163388e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_9bdb8aea-2421-470c-91c9-54e0c163388e" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_9bdb8aea-2421-470c-91c9-54e0c163388e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_7e494e66-8f52-4d81-aebf-b6a1f3d91264" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_9bdb8aea-2421-470c-91c9-54e0c163388e" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_7e494e66-8f52-4d81-aebf-b6a1f3d91264" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ResearchAndDevelopmentExpensesMember_4b42726e-4c5f-45ea-8f2e-f322303d054b" xlink:href="abvx-20251231.xsd#abvx_ResearchAndDevelopmentExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_7e494e66-8f52-4d81-aebf-b6a1f3d91264" xlink:to="loc_abvx_ResearchAndDevelopmentExpensesMember_4b42726e-4c5f-45ea-8f2e-f322303d054b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SubContractingStudiesAndResearchExpenses_fd69e967-b49c-4161-8420-76146b330684" xlink:href="abvx-20251231.xsd#abvx_SubContractingStudiesAndResearchExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_ebd76308-81a8-4890-a9a5-bb4c0da2b8a4" xlink:to="loc_abvx_SubContractingStudiesAndResearchExpenses_fd69e967-b49c-4161-8420-76146b330684" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_4fc9f15f-2910-4fe3-a3a6-95d65638429e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_ebd76308-81a8-4890-a9a5-bb4c0da2b8a4" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_4fc9f15f-2910-4fe3-a3a6-95d65638429e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfessionalFeesExpense_0ee7937b-bdc4-45b7-a980-3195ecd124a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfessionalFeesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_ebd76308-81a8-4890-a9a5-bb4c0da2b8a4" xlink:to="loc_ifrs-full_ProfessionalFeesExpense_0ee7937b-bdc4-45b7-a980-3195ecd124a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IntellectualPropertyFees_1728d476-5f76-4529-a4ab-e1b0724560fc" xlink:href="abvx-20251231.xsd#abvx_IntellectualPropertyFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_ebd76308-81a8-4890-a9a5-bb4c0da2b8a4" xlink:to="loc_abvx_IntellectualPropertyFees_1728d476-5f76-4529-a4ab-e1b0724560fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_15616933-d9db-40c4-ad78-9a8e8de310e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_ebd76308-81a8-4890-a9a5-bb4c0da2b8a4" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_15616933-d9db-40c4-ad78-9a8e8de310e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_b96692b8-f591-4329-8217-ecb641ae7bbc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_ebd76308-81a8-4890-a9a5-bb4c0da2b8a4" xlink:to="loc_ifrs-full_OperatingExpense_b96692b8-f591-4329-8217-ecb641ae7bbc" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/OperatingexpensesNarrativeDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#OperatingexpensesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/OperatingexpensesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_5ff4f599-2f10-4b78-b031-a824a56c98d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_77e3b522-ca3c-4180-8026-b656f35ce963" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_5ff4f599-2f10-4b78-b031-a824a56c98d4" xlink:to="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_77e3b522-ca3c-4180-8026-b656f35ce963" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_8b608cc6-7531-49f1-8888-0b03b54577b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_77e3b522-ca3c-4180-8026-b656f35ce963" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_8b608cc6-7531-49f1-8888-0b03b54577b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_8b608cc6-7531-49f1-8888-0b03b54577b3_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_8b608cc6-7531-49f1-8888-0b03b54577b3" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_8b608cc6-7531-49f1-8888-0b03b54577b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_9f8d028c-4e32-4b10-8589-ce1aa236b6da" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_8b608cc6-7531-49f1-8888-0b03b54577b3" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_9f8d028c-4e32-4b10-8589-ce1aa236b6da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ResearchAndDevelopmentExpensesMember_7411fda6-cede-4123-98cc-e1b4256d701c" xlink:href="abvx-20251231.xsd#abvx_ResearchAndDevelopmentExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_9f8d028c-4e32-4b10-8589-ce1aa236b6da" xlink:to="loc_abvx_ResearchAndDevelopmentExpensesMember_7411fda6-cede-4123-98cc-e1b4256d701c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_GeneralAndAdministrativeExpensesMember_019c57c8-2813-7d73-9d97-2b9a73ab9be8" xlink:href="abvx-20251231.xsd#abvx_GeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_9f8d028c-4e32-4b10-8589-ce1aa236b6da" xlink:to="loc_abvx_GeneralAndAdministrativeExpensesMember_019c57c8-2813-7d73-9d97-2b9a73ab9be8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInUlcerativeColitisExpenses_128d9b10-b818-4c7d-afd7-f1b0040e0348" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInUlcerativeColitisExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_5ff4f599-2f10-4b78-b031-a824a56c98d4" xlink:to="loc_abvx_IncreaseDecreaseInUlcerativeColitisExpenses_128d9b10-b818-4c7d-afd7-f1b0040e0348" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInCrohnsDiseaseResearchExpenses_f3da0fc1-a68d-4e75-85fe-46cc481c91b0" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInCrohnsDiseaseResearchExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_5ff4f599-2f10-4b78-b031-a824a56c98d4" xlink:to="loc_abvx_IncreaseDecreaseInCrohnsDiseaseResearchExpenses_f3da0fc1-a68d-4e75-85fe-46cc481c91b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInTransversalActivities_2caf2588-4072-4c77-a905-1a77bd76517f" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInTransversalActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_5ff4f599-2f10-4b78-b031-a824a56c98d4" xlink:to="loc_abvx_IncreaseDecreaseInTransversalActivities_2caf2588-4072-4c77-a905-1a77bd76517f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInTransversalActivitiesCombinationTherapy_019cd7fb-00dd-7629-8b23-1c7eeb03b411" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInTransversalActivitiesCombinationTherapy"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_5ff4f599-2f10-4b78-b031-a824a56c98d4" xlink:to="loc_abvx_IncreaseDecreaseInTransversalActivitiesCombinationTherapy_019cd7fb-00dd-7629-8b23-1c7eeb03b411" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInEmployerTaxAndSocialContributions_019c5760-de97-7279-9745-69b6019c74e4" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInEmployerTaxAndSocialContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_5ff4f599-2f10-4b78-b031-a824a56c98d4" xlink:to="loc_abvx_IncreaseDecreaseInEmployerTaxAndSocialContributions_019c5760-de97-7279-9745-69b6019c74e4" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_359e8ed5-8025-433a-9192-4365c1486c4c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_8f36584e-cdc2-4ce2-a60c-d495cb54271b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_359e8ed5-8025-433a-9192-4365c1486c4c" xlink:to="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_8f36584e-cdc2-4ce2-a60c-d495cb54271b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_b4f5791e-7bf4-4f5b-8bc8-b6f627e90fa7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_8f36584e-cdc2-4ce2-a60c-d495cb54271b" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_b4f5791e-7bf4-4f5b-8bc8-b6f627e90fa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_b4f5791e-7bf4-4f5b-8bc8-b6f627e90fa7_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_b4f5791e-7bf4-4f5b-8bc8-b6f627e90fa7" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_b4f5791e-7bf4-4f5b-8bc8-b6f627e90fa7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_f09a4a39-0b42-4999-9bd4-12a46f053748" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_b4f5791e-7bf4-4f5b-8bc8-b6f627e90fa7" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_f09a4a39-0b42-4999-9bd4-12a46f053748" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_GeneralAndAdministrativeExpensesMember_feb1d90b-a3c4-49ae-828d-028e8090aaf7" xlink:href="abvx-20251231.xsd#abvx_GeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_f09a4a39-0b42-4999-9bd4-12a46f053748" xlink:to="loc_abvx_GeneralAndAdministrativeExpensesMember_feb1d90b-a3c4-49ae-828d-028e8090aaf7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_a7d95776-9139-4222-a491-0c5d9779b0f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_359e8ed5-8025-433a-9192-4365c1486c4c" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_a7d95776-9139-4222-a491-0c5d9779b0f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfessionalFeesExpense_ebb36c3c-e025-4bbd-819d-b0c8b8fddb0a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfessionalFeesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_359e8ed5-8025-433a-9192-4365c1486c4c" xlink:to="loc_ifrs-full_ProfessionalFeesExpense_ebb36c3c-e025-4bbd-819d-b0c8b8fddb0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_e99eca0f-c97c-4c70-8e40-7c3ea8f6d611" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_359e8ed5-8025-433a-9192-4365c1486c4c" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_e99eca0f-c97c-4c70-8e40-7c3ea8f6d611" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_0bd5f6f2-56d1-471b-9738-652c19b30a0f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_359e8ed5-8025-433a-9192-4365c1486c4c" xlink:to="loc_ifrs-full_OperatingExpense_0bd5f6f2-56d1-471b-9738-652c19b30a0f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/EmployeesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#EmployeesDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/EmployeesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfEmployeeWorkforceLineItems_44f1647b-9cbb-4213-b2b4-b8a3447bc51b" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfEmployeeWorkforceLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfEmployeeWorkforceTable_b0f5829c-995d-4b09-b256-9f247c94176e" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfEmployeeWorkforceTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_abvx_DisclosureOfEmployeeWorkforceLineItems_44f1647b-9cbb-4213-b2b4-b8a3447bc51b" xlink:to="loc_abvx_DisclosureOfEmployeeWorkforceTable_b0f5829c-995d-4b09-b256-9f247c94176e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_577fa728-3dfc-488b-a7ff-5a5ab3f35d2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abvx_DisclosureOfEmployeeWorkforceTable_b0f5829c-995d-4b09-b256-9f247c94176e" xlink:to="loc_ifrs-full_GeographicalAreasAxis_577fa728-3dfc-488b-a7ff-5a5ab3f35d2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_577fa728-3dfc-488b-a7ff-5a5ab3f35d2e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_577fa728-3dfc-488b-a7ff-5a5ab3f35d2e" xlink:to="loc_ifrs-full_GeographicalAreasDomain_577fa728-3dfc-488b-a7ff-5a5ab3f35d2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_ba565072-5408-4efc-9aa3-62b1c7644aea" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_577fa728-3dfc-488b-a7ff-5a5ab3f35d2e" xlink:to="loc_ifrs-full_GeographicalAreasDomain_ba565072-5408-4efc-9aa3-62b1c7644aea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_ab53a958-b7cc-4ea1-8d00-470171dec908" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasDomain_ba565072-5408-4efc-9aa3-62b1c7644aea" xlink:to="loc_country_FR_ab53a958-b7cc-4ea1-8d00-470171dec908" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_99c01d91-dd40-499b-a9be-8b7259c957a1" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasDomain_ba565072-5408-4efc-9aa3-62b1c7644aea" xlink:to="loc_country_US_99c01d91-dd40-499b-a9be-8b7259c957a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageNumberOfEmployees_27ee2524-90a1-4a9b-8c84-4a13365f7409" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AverageNumberOfEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfEmployeeWorkforceLineItems_44f1647b-9cbb-4213-b2b4-b8a3447bc51b" xlink:to="loc_ifrs-full_AverageNumberOfEmployees_27ee2524-90a1-4a9b-8c84-4a13365f7409" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialgainlossNarrativeDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialgainlossNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/FinancialgainlossNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfFinancialGainLossLineItems_4e1da471-5df4-4efb-bd5e-4187070ccabd" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfFinancialGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfFinancialGainLossTable_0fcf66de-1125-412e-acd8-6b33fe527f75" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfFinancialGainLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_abvx_DisclosureOfFinancialGainLossLineItems_4e1da471-5df4-4efb-bd5e-4187070ccabd" xlink:to="loc_abvx_DisclosureOfFinancialGainLossTable_0fcf66de-1125-412e-acd8-6b33fe527f75" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_6f343a6a-f9a3-4c85-b478-874ed8fc6d07" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abvx_DisclosureOfFinancialGainLossTable_0fcf66de-1125-412e-acd8-6b33fe527f75" xlink:to="loc_srt_CurrencyAxis_6f343a6a-f9a3-4c85-b478-874ed8fc6d07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_6f343a6a-f9a3-4c85-b478-874ed8fc6d07_default" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_6f343a6a-f9a3-4c85-b478-874ed8fc6d07" xlink:to="loc_currency_AllCurrenciesDomain_6f343a6a-f9a3-4c85-b478-874ed8fc6d07_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_3f5f37fa-3993-4559-ac29-b36cfacad49c" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_6f343a6a-f9a3-4c85-b478-874ed8fc6d07" xlink:to="loc_currency_AllCurrenciesDomain_3f5f37fa-3993-4559-ac29-b36cfacad49c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_e51b2326-8f4c-45a8-80b1-bb1fae735932" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_3f5f37fa-3993-4559-ac29-b36cfacad49c" xlink:to="loc_currency_USD_e51b2326-8f4c-45a8-80b1-bb1fae735932" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_019d0058-fb69-713d-abcf-d4e1e3a7a672" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abvx_DisclosureOfFinancialGainLossTable_0fcf66de-1125-412e-acd8-6b33fe527f75" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_019d0058-fb69-713d-abcf-d4e1e3a7a672" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_019d0058-fb69-713d-abcf-d4e1e3a7a672_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_019d0058-fb69-713d-abcf-d4e1e3a7a672" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_019d0058-fb69-713d-abcf-d4e1e3a7a672_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_019d0058-fb69-7e0d-904f-0090cd8dd3ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_019d0058-fb69-713d-abcf-d4e1e3a7a672" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_019d0058-fb69-7e0d-904f-0090cd8dd3ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingBSAMember_019d0059-395f-7f81-b0c5-2ae1b6047179" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingBSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_019d0058-fb69-7e0d-904f-0090cd8dd3ed" xlink:to="loc_abvx_KreosClaretFinancingBSAMember_019d0059-395f-7f81-b0c5-2ae1b6047179" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretMinimumReturnIndemnificationsMember_019d005b-137d-7ea1-8b6e-9d6097a97088" xlink:href="abvx-20251231.xsd#abvx_KreosClaretMinimumReturnIndemnificationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_019d0058-fb69-7e0d-904f-0090cd8dd3ed" xlink:to="loc_abvx_KreosClaretMinimumReturnIndemnificationsMember_019d005b-137d-7ea1-8b6e-9d6097a97088" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LossesOnChangeInFairValueOfDerivatives_019d005a-712b-7990-9b8a-b680da436521" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LossesOnChangeInFairValueOfDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfFinancialGainLossLineItems_4e1da471-5df4-4efb-bd5e-4187070ccabd" xlink:to="loc_ifrs-full_LossesOnChangeInFairValueOfDerivatives_019d005a-712b-7990-9b8a-b680da436521" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ForeignExchangeLoss_019d005c-ecef-7e97-bec8-a8b539a0fdf5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ForeignExchangeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfFinancialGainLossLineItems_4e1da471-5df4-4efb-bd5e-4187070ccabd" xlink:to="loc_ifrs-full_ForeignExchangeLoss_019d005c-ecef-7e97-bec8-a8b539a0fdf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ForeignExchangeGainsLossesOnTranslationOfForeignOperations_d185c057-1ec9-4625-8a95-3a8615d61ab9" xlink:href="abvx-20251231.xsd#abvx_ForeignExchangeGainsLossesOnTranslationOfForeignOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfFinancialGainLossLineItems_4e1da471-5df4-4efb-bd5e-4187070ccabd" xlink:to="loc_abvx_ForeignExchangeGainsLossesOnTranslationOfForeignOperations_d185c057-1ec9-4625-8a95-3a8615d61ab9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives_019c5773-68de-7e7d-986b-8b2d83e5b934" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsOnChangeInFairValueOfDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfFinancialGainLossLineItems_4e1da471-5df4-4efb-bd5e-4187070ccabd" xlink:to="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives_019c5773-68de-7e7d-986b-8b2d83e5b934" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ForeignExchangeGain_019d005c-bf9c-7a85-a9e2-c618a72ff557" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ForeignExchangeGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfFinancialGainLossLineItems_4e1da471-5df4-4efb-bd5e-4187070ccabd" xlink:to="loc_ifrs-full_ForeignExchangeGain_019d005c-bf9c-7a85-a9e2-c618a72ff557" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_724dafcd-6b35-428d-9c1d-20654bcbbd40" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_cfdc0a50-9734-48fc-bc1c-e0dd043a75b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_724dafcd-6b35-428d-9c1d-20654bcbbd40" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_cfdc0a50-9734-48fc-bc1c-e0dd043a75b1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_0782f2f4-8046-4980-9854-000917ee463f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_cfdc0a50-9734-48fc-bc1c-e0dd043a75b1" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_0782f2f4-8046-4980-9854-000917ee463f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_0782f2f4-8046-4980-9854-000917ee463f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_0782f2f4-8046-4980-9854-000917ee463f" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_0782f2f4-8046-4980-9854-000917ee463f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_e59ca16d-8b29-4770-b961-8149e0ce2b90" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_0782f2f4-8046-4980-9854-000917ee463f" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_e59ca16d-8b29-4770-b961-8149e0ce2b90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RetirementBenefitObligationsRelatedTemporaryDifferencesMember_8b77ae7b-0cfd-4b2b-8753-21fb74f70af6" xlink:href="abvx-20251231.xsd#abvx_RetirementBenefitObligationsRelatedTemporaryDifferencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_e59ca16d-8b29-4770-b961-8149e0ce2b90" xlink:to="loc_abvx_RetirementBenefitObligationsRelatedTemporaryDifferencesMember_8b77ae7b-0cfd-4b2b-8753-21fb74f70af6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SubsidiesRelatedTemporaryDifferencesMember_74255e77-d2cb-4f22-bb09-a49b7e921fd0" xlink:href="abvx-20251231.xsd#abvx_SubsidiesRelatedTemporaryDifferencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_e59ca16d-8b29-4770-b961-8149e0ce2b90" xlink:to="loc_abvx_SubsidiesRelatedTemporaryDifferencesMember_74255e77-d2cb-4f22-bb09-a49b7e921fd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LeasesRelatedTemporaryDifferencesMember_3d814b11-ffba-4d11-ba62-831dcd4ab64c" xlink:href="abvx-20251231.xsd#abvx_LeasesRelatedTemporaryDifferencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_e59ca16d-8b29-4770-b961-8149e0ce2b90" xlink:to="loc_abvx_LeasesRelatedTemporaryDifferencesMember_3d814b11-ffba-4d11-ba62-831dcd4ab64c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificatesRelatedTemporaryDifferencesMember_019c5797-a063-70d5-aab8-947b780c1504" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificatesRelatedTemporaryDifferencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_e59ca16d-8b29-4770-b961-8149e0ce2b90" xlink:to="loc_abvx_RoyaltyCertificatesRelatedTemporaryDifferencesMember_019c5797-a063-70d5-aab8-947b780c1504" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialLiabilitiesRelatedTemporaryDifferencesMember_73dc6f37-5229-4e55-9a88-7da81167d79e" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialLiabilitiesRelatedTemporaryDifferencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_e59ca16d-8b29-4770-b961-8149e0ce2b90" xlink:to="loc_abvx_OtherFinancialLiabilitiesRelatedTemporaryDifferencesMember_73dc6f37-5229-4e55-9a88-7da81167d79e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ProvisionsForAGATaxesRelatedTemporaryDifferencesMember_019c5785-c419-71fd-8f09-e69d0f3f7482" xlink:href="abvx-20251231.xsd#abvx_ProvisionsForAGATaxesRelatedTemporaryDifferencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_e59ca16d-8b29-4770-b961-8149e0ce2b90" xlink:to="loc_abvx_ProvisionsForAGATaxesRelatedTemporaryDifferencesMember_019c5785-c419-71fd-8f09-e69d0f3f7482" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_c1092b3d-fa04-4484-9946-0b7656afaeb3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnusedTaxLossesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_e59ca16d-8b29-4770-b961-8149e0ce2b90" xlink:to="loc_ifrs-full_UnusedTaxLossesMember_c1092b3d-fa04-4484-9946-0b7656afaeb3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTemporaryDifferencesMember_6055f67d-dc28-48c1-b6ec-42b6f16dab44" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherTemporaryDifferencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_e59ca16d-8b29-4770-b961-8149e0ce2b90" xlink:to="loc_ifrs-full_OtherTemporaryDifferencesMember_6055f67d-dc28-48c1-b6ec-42b6f16dab44" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets_2af54b0e-e48b-441d-8bc1-4ab5a954ba45" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_724dafcd-6b35-428d-9c1d-20654bcbbd40" xlink:to="loc_ifrs-full_DeferredTaxAssets_2af54b0e-e48b-441d-8bc1-4ab5a954ba45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilities_c5bfc3e7-5c5c-41c6-b78d-162faa0f633c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_724dafcd-6b35-428d-9c1d-20654bcbbd40" xlink:to="loc_ifrs-full_DeferredTaxLiabilities_c5bfc3e7-5c5c-41c6-b78d-162faa0f633c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset_dd222ca8-6373-44b2-b0dc-4c49fcef96a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_724dafcd-6b35-428d-9c1d-20654bcbbd40" xlink:to="loc_ifrs-full_DeferredTaxLiabilityAsset_dd222ca8-6373-44b2-b0dc-4c49fcef96a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_UnrecognizedDeferredTaxAssets_bffb9a41-fee1-45f6-8f63-2e5aaf832785" xlink:href="abvx-20251231.xsd#abvx_UnrecognizedDeferredTaxAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_724dafcd-6b35-428d-9c1d-20654bcbbd40" xlink:to="loc_abvx_UnrecognizedDeferredTaxAssets_bffb9a41-fee1-45f6-8f63-2e5aaf832785" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition_23de28d8-93e6-4680-b46c-32aef586ed00" xlink:href="abvx-20251231.xsd#abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_724dafcd-6b35-428d-9c1d-20654bcbbd40" xlink:to="loc_abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition_23de28d8-93e6-4680-b46c-32aef586ed00" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/IncometaxNarrativeDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#IncometaxNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/IncometaxNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_d6ec99ae-7a90-4adf-8579-a3b9016101f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_ef2984d7-7624-46ec-b486-63bdc1f2a554" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_d6ec99ae-7a90-4adf-8579-a3b9016101f1" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_ef2984d7-7624-46ec-b486-63bdc1f2a554" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_49bd88e9-f46d-4937-b8e4-a7284155e959" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_ef2984d7-7624-46ec-b486-63bdc1f2a554" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_49bd88e9-f46d-4937-b8e4-a7284155e959" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_49bd88e9-f46d-4937-b8e4-a7284155e959_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_49bd88e9-f46d-4937-b8e4-a7284155e959" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_49bd88e9-f46d-4937-b8e4-a7284155e959_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_df20d9d7-911d-4a9c-9e7e-6584a2452da1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_49bd88e9-f46d-4937-b8e4-a7284155e959" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_df20d9d7-911d-4a9c-9e7e-6584a2452da1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AbivaxLLCMember_16fd3d7c-d6b3-4efa-8736-c40d322d180f" xlink:href="abvx-20251231.xsd#abvx_AbivaxLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_df20d9d7-911d-4a9c-9e7e-6584a2452da1" xlink:to="loc_abvx_AbivaxLLCMember_16fd3d7c-d6b3-4efa-8736-c40d322d180f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_019c578c-c80d-74e2-8e50-a03d59e94f77" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_ef2984d7-7624-46ec-b486-63bdc1f2a554" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_019c578c-c80d-74e2-8e50-a03d59e94f77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_019c578c-c80d-74e2-8e50-a03d59e94f77_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_019c578c-c80d-74e2-8e50-a03d59e94f77" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_019c578c-c80d-74e2-8e50-a03d59e94f77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_019c578c-c80d-7315-99f3-b5cd938ebeff" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_019c578c-c80d-74e2-8e50-a03d59e94f77" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_019c578c-c80d-7315-99f3-b5cd938ebeff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificatesRelatedTemporaryDifferencesMember_019c5798-1a07-7e2a-a362-5fe66606b72a" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificatesRelatedTemporaryDifferencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_019c578c-c80d-7315-99f3-b5cd938ebeff" xlink:to="loc_abvx_RoyaltyCertificatesRelatedTemporaryDifferencesMember_019c5798-1a07-7e2a-a362-5fe66606b72a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_019c5799-5262-7f8a-9711-ac7088a3b584" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_ef2984d7-7624-46ec-b486-63bdc1f2a554" xlink:to="loc_srt_StatementGeographicalAxis_019c5799-5262-7f8a-9711-ac7088a3b584" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_019c5799-5262-7f8a-9711-ac7088a3b584_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_019c5799-5262-7f8a-9711-ac7088a3b584" xlink:to="loc_srt_SegmentGeographicalDomain_019c5799-5262-7f8a-9711-ac7088a3b584_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_019c5799-5262-7060-8e3d-4276003be93f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_019c5799-5262-7f8a-9711-ac7088a3b584" xlink:to="loc_srt_SegmentGeographicalDomain_019c5799-5262-7060-8e3d-4276003be93f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_019c579a-18cf-7016-b0d8-d54640000e0f" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_019c5799-5262-7060-8e3d-4276003be93f" xlink:to="loc_country_FR_019c579a-18cf-7016-b0d8-d54640000e0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilities_019c578c-c80d-7167-8408-14f32fe0795e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_d6ec99ae-7a90-4adf-8579-a3b9016101f1" xlink:to="loc_ifrs-full_DeferredTaxLiabilities_019c578c-c80d-7167-8408-14f32fe0795e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets_019c5793-a379-7aaa-84c5-f147bde633de" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_d6ec99ae-7a90-4adf-8579-a3b9016101f1" xlink:to="loc_ifrs-full_DeferredTaxAssets_019c5793-a379-7aaa-84c5-f147bde633de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition_019d0069-a760-7a4b-a34a-f201bc976ba9" xlink:href="abvx-20251231.xsd#abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_d6ec99ae-7a90-4adf-8579-a3b9016101f1" xlink:to="loc_abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition_019d0069-a760-7a4b-a34a-f201bc976ba9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_06606862-9bbc-4bb3-a8f3-e2c6fe3971c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_d6ec99ae-7a90-4adf-8579-a3b9016101f1" xlink:to="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_06606862-9bbc-4bb3-a8f3-e2c6fe3971c4" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/RelatedpartiesNarrativeDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#RelatedpartiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/RelatedpartiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_548bb043-bf17-43fe-9369-18043bd76570" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_5351c6f2-c7fe-4196-8b19-c45cfbab0be9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_548bb043-bf17-43fe-9369-18043bd76570" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_5351c6f2-c7fe-4196-8b19-c45cfbab0be9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_4a89241a-3065-48d6-a921-488e9c752be6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_5351c6f2-c7fe-4196-8b19-c45cfbab0be9" xlink:to="loc_srt_TitleOfIndividualAxis_4a89241a-3065-48d6-a921-488e9c752be6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4a89241a-3065-48d6-a921-488e9c752be6_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_4a89241a-3065-48d6-a921-488e9c752be6" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4a89241a-3065-48d6-a921-488e9c752be6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c02fddb3-2ad6-47a9-830d-1f3515d02ab9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_4a89241a-3065-48d6-a921-488e9c752be6" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c02fddb3-2ad6-47a9-830d-1f3515d02ab9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BoardOfDirectorsAndChiefExecutiveOfficerMember_839bfe3d-37b8-4698-829f-f14137e12e10" xlink:href="abvx-20251231.xsd#abvx_BoardOfDirectorsAndChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c02fddb3-2ad6-47a9-830d-1f3515d02ab9" xlink:to="loc_abvx_BoardOfDirectorsAndChiefExecutiveOfficerMember_839bfe3d-37b8-4698-829f-f14137e12e10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AdvisorToTheChiefExecutiveOfficerMember_b5daffd5-2a07-471c-8b89-a9177ce39c65" xlink:href="abvx-20251231.xsd#abvx_AdvisorToTheChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c02fddb3-2ad6-47a9-830d-1f3515d02ab9" xlink:to="loc_abvx_AdvisorToTheChiefExecutiveOfficerMember_b5daffd5-2a07-471c-8b89-a9177ce39c65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_8e8401fa-fa5e-4e63-aa4d-3cc95bab2fdc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_5351c6f2-c7fe-4196-8b19-c45cfbab0be9" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_8e8401fa-fa5e-4e63-aa4d-3cc95bab2fdc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_8e8401fa-fa5e-4e63-aa4d-3cc95bab2fdc_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_8e8401fa-fa5e-4e63-aa4d-3cc95bab2fdc" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_8e8401fa-fa5e-4e63-aa4d-3cc95bab2fdc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_0e2a4be7-51dd-4cf8-8a2f-e778c88fbb47" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_8e8401fa-fa5e-4e63-aa4d-3cc95bab2fdc" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_0e2a4be7-51dd-4cf8-8a2f-e778c88fbb47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_0bac730b-459b-49a2-ab91-0d3d2f22e1fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_0e2a4be7-51dd-4cf8-8a2f-e778c88fbb47" xlink:to="loc_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_0bac730b-459b-49a2-ab91-0d3d2f22e1fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan_22092d6d-410c-4768-9073-1c0f48b26794" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_548bb043-bf17-43fe-9369-18043bd76570" xlink:to="loc_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan_22092d6d-410c-4768-9073-1c0f48b26794" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_16315341-3db1-49ff-9d7c-fa5a247aafa0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_548bb043-bf17-43fe-9369-18043bd76570" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_16315341-3db1-49ff-9d7c-fa5a247aafa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_6482c5d3-6789-4139-8844-5ddcd1146bf5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_548bb043-bf17-43fe-9369-18043bd76570" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_6482c5d3-6789-4139-8844-5ddcd1146bf5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#OffbalancesheetcommitmentsgivenDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsTable_6a773e1d-176a-4b41-9cba-88d5eb6ee40f" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfOffBalanceSheetCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsTable_6a773e1d-176a-4b41-9cba-88d5eb6ee40f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PrincipalAgreementsAxis_019c0012-0441-791e-a402-f17846f7739e" xlink:href="abvx-20251231.xsd#abvx_PrincipalAgreementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsTable_6a773e1d-176a-4b41-9cba-88d5eb6ee40f" xlink:to="loc_abvx_PrincipalAgreementsAxis_019c0012-0441-791e-a402-f17846f7739e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PrincipalAgreementsDomain_019c0012-0441-791e-a402-f17846f7739e_default" xlink:href="abvx-20251231.xsd#abvx_PrincipalAgreementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_abvx_PrincipalAgreementsAxis_019c0012-0441-791e-a402-f17846f7739e" xlink:to="loc_abvx_PrincipalAgreementsDomain_019c0012-0441-791e-a402-f17846f7739e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PrincipalAgreementsDomain_019c0012-0441-7e92-9ee0-1c3da7db140e" xlink:href="abvx-20251231.xsd#abvx_PrincipalAgreementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_abvx_PrincipalAgreementsAxis_019c0012-0441-791e-a402-f17846f7739e" xlink:to="loc_abvx_PrincipalAgreementsDomain_019c0012-0441-7e92-9ee0-1c3da7db140e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember_019c0012-0441-7c2d-9a8f-89f9e9b42c5a" xlink:href="abvx-20251231.xsd#abvx_ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_PrincipalAgreementsDomain_019c0012-0441-7e92-9ee0-1c3da7db140e" xlink:to="loc_abvx_ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember_019c0012-0441-7c2d-9a8f-89f9e9b42c5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ResearchAndCollaborationAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember_019c0012-286d-7c14-a54c-7d1a6b1a86d3" xlink:href="abvx-20251231.xsd#abvx_ResearchAndCollaborationAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_PrincipalAgreementsDomain_019c0012-0441-7e92-9ee0-1c3da7db140e" xlink:to="loc_abvx_ResearchAndCollaborationAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember_019c0012-286d-7c14-a54c-7d1a6b1a86d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember_019c0012-286d-76bd-9d5b-9d2af1576d6b" xlink:href="abvx-20251231.xsd#abvx_ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_PrincipalAgreementsDomain_019c0012-0441-7e92-9ee0-1c3da7db140e" xlink:to="loc_abvx_ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember_019c0012-286d-76bd-9d5b-9d2af1576d6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_019c0012-286d-7de1-89e3-698c32d87830" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsTable_6a773e1d-176a-4b41-9cba-88d5eb6ee40f" xlink:to="loc_dei_LegalEntityAxis_019c0012-286d-7de1-89e3-698c32d87830" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019c0012-286d-7de1-89e3-698c32d87830_default" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_019c0012-286d-7de1-89e3-698c32d87830" xlink:to="loc_dei_EntityDomain_019c0012-286d-7de1-89e3-698c32d87830_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019c0012-286d-7fa3-9471-f15a6be5653b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_019c0012-286d-7de1-89e3-698c32d87830" xlink:to="loc_dei_EntityDomain_019c0012-286d-7fa3-9471-f15a6be5653b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember_019c0012-286d-7d6f-9655-20f95ac8ad53" xlink:href="abvx-20251231.xsd#abvx_TheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_019c0012-286d-7fa3-9471-f15a6be5653b" xlink:to="loc_abvx_TheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember_019c0012-286d-7d6f-9655-20f95ac8ad53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019c0012-66f4-7709-ab1a-fc9868985fd6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsTable_6a773e1d-176a-4b41-9cba-88d5eb6ee40f" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019c0012-66f4-7709-ab1a-fc9868985fd6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019c0012-66f4-7709-ab1a-fc9868985fd6_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019c0012-66f4-7709-ab1a-fc9868985fd6" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019c0012-66f4-7709-ab1a-fc9868985fd6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019c0012-66f4-739b-a1a4-edb123ebe044" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019c0012-66f4-7709-ab1a-fc9868985fd6" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019c0012-66f4-739b-a1a4-edb123ebe044" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CARENAConditionalAdvanceBPIMember_019c0012-66f4-71f6-9301-3e0e44ade71f" xlink:href="abvx-20251231.xsd#abvx_CARENAConditionalAdvanceBPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019c0012-66f4-739b-a1a4-edb123ebe044" xlink:to="loc_abvx_CARENAConditionalAdvanceBPIMember_019c0012-66f4-71f6-9301-3e0e44ade71f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RNPVIRConditionalAdvanceBPIMember_019c0012-8a04-79bd-ad0d-b20c30ee5aea" xlink:href="abvx-20251231.xsd#abvx_RNPVIRConditionalAdvanceBPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019c0012-66f4-739b-a1a4-edb123ebe044" xlink:to="loc_abvx_RNPVIRConditionalAdvanceBPIMember_019c0012-8a04-79bd-ad0d-b20c30ee5aea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EbolaConditionalAdvanceBPIMember_019c0012-8a04-7921-90e1-26e11bade272" xlink:href="abvx-20251231.xsd#abvx_EbolaConditionalAdvanceBPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019c0012-66f4-739b-a1a4-edb123ebe044" xlink:to="loc_abvx_EbolaConditionalAdvanceBPIMember_019c0012-8a04-7921-90e1-26e11bade272" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EbolaConditionalAdvanceBPILanguedocRoussillonMember_019c0012-8a04-70f3-a660-a5e4350a2490" xlink:href="abvx-20251231.xsd#abvx_EbolaConditionalAdvanceBPILanguedocRoussillonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019c0012-66f4-739b-a1a4-edb123ebe044" xlink:to="loc_abvx_EbolaConditionalAdvanceBPILanguedocRoussillonMember_019c0012-8a04-70f3-a660-a5e4350a2490" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EbolaConditionalAdvanceBPIFranceMember_019c0012-8a04-75d2-bb8d-cb5c37d0b971" xlink:href="abvx-20251231.xsd#abvx_EbolaConditionalAdvanceBPIFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019c0012-66f4-739b-a1a4-edb123ebe044" xlink:to="loc_abvx_EbolaConditionalAdvanceBPIFranceMember_019c0012-8a04-75d2-bb8d-cb5c37d0b971" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019c0012-66f4-71de-abb7-714cffddd6d0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsTable_6a773e1d-176a-4b41-9cba-88d5eb6ee40f" xlink:to="loc_srt_RangeAxis_019c0012-66f4-71de-abb7-714cffddd6d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019c0012-66f4-71de-abb7-714cffddd6d0_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_019c0012-66f4-71de-abb7-714cffddd6d0" xlink:to="loc_srt_RangeMember_019c0012-66f4-71de-abb7-714cffddd6d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019c0012-66f4-7191-8c9f-a9df2f0cc899" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_019c0012-66f4-71de-abb7-714cffddd6d0" xlink:to="loc_srt_RangeMember_019c0012-66f4-7191-8c9f-a9df2f0cc899" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019c0012-66f4-7af9-8f34-b2f7fe54f121" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019c0012-66f4-7191-8c9f-a9df2f0cc899" xlink:to="loc_srt_MinimumMember_019c0012-66f4-7af9-8f34-b2f7fe54f121" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019c0012-66f4-7195-839e-dfc08339060c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019c0012-66f4-7191-8c9f-a9df2f0cc899" xlink:to="loc_srt_MaximumMember_019c0012-66f4-7195-839e-dfc08339060c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfExclusiveLicenses_019c0012-0441-75cd-9a54-1f3986ee0591" xlink:href="abvx-20251231.xsd#abvx_NumberOfExclusiveLicenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_abvx_NumberOfExclusiveLicenses_019c0012-0441-75cd-9a54-1f3986ee0591" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AgreementPeriod_019c0012-286d-7e5c-8a2a-3a22ac161f55" xlink:href="abvx-20251231.xsd#abvx_AgreementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_abvx_AgreementPeriod_019c0012-286d-7e5c-8a2a-3a22ac161f55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDFiling_019c0012-286d-78e7-b2d4-2fb036be0158" xlink:href="abvx-20251231.xsd#abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDFiling"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDFiling_019c0012-286d-78e7-b2d4-2fb036be0158" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentPhase3_019c0012-286d-71f1-b769-e3840b396196" xlink:href="abvx-20251231.xsd#abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentPhase3"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentPhase3_019c0012-286d-71f1-b769-e3840b396196" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDApproval_019c0012-286d-7916-85d2-3412baca3be9" xlink:href="abvx-20251231.xsd#abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDApproval_019c0012-286d-7916-85d2-3412baca3be9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfAcademicInstitutions_019c0012-286d-7e63-a407-ab61d04cfaa0" xlink:href="abvx-20251231.xsd#abvx_NumberOfAcademicInstitutions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_abvx_NumberOfAcademicInstitutions_019c0012-286d-7e63-a407-ab61d04cfaa0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_019c0012-286d-77ae-be8c-d7f95f5277f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_019c0012-286d-77ae-be8c-d7f95f5277f5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacityIncludingInterest_019c0012-66f4-730e-8200-628bdd816b5f" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacityIncludingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacityIncludingInterest_019c0012-66f4-730e-8200-628bdd816b5f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialLiabilitiesAnnualPercentageOfProceedsFromSaleOfIntellectualPropertyRight_019c0012-66f4-7dde-8c33-20d9c80185b9" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialLiabilitiesAnnualPercentageOfProceedsFromSaleOfIntellectualPropertyRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_abvx_OtherFinancialLiabilitiesAnnualPercentageOfProceedsFromSaleOfIntellectualPropertyRight_019c0012-66f4-7dde-8c33-20d9c80185b9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialLiabilitiesAnnualRevenueFromSaleOfProductsDevelopedPeriod_019c0012-66f4-7ad1-b8b3-3dd19346a160" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialLiabilitiesAnnualRevenueFromSaleOfProductsDevelopedPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_abvx_OtherFinancialLiabilitiesAnnualRevenueFromSaleOfProductsDevelopedPeriod_019c0012-66f4-7ad1-b8b3-3dd19346a160" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDevelopedPreTaxRevenueThreshold_019c0012-66f4-7f95-ab55-240902ed5e13" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDevelopedPreTaxRevenueThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDevelopedPreTaxRevenueThreshold_019c0012-66f4-7f95-ab55-240902ed5e13" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDeveloped_019c0012-66f4-7f91-8c25-6f9587d58a0f" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDeveloped"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDeveloped_019c0012-66f4-7f91-8c25-6f9587d58a0f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialLiabilitiesPayableAnnualRevenueFromSaleOfProductsDeveloped_019c0012-66f4-7720-ade6-b22fb965c580" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialLiabilitiesPayableAnnualRevenueFromSaleOfProductsDeveloped"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_abvx_OtherFinancialLiabilitiesPayableAnnualRevenueFromSaleOfProductsDeveloped_019c0012-66f4-7720-ade6-b22fb965c580" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialLiabilitiesRepaymentPeriod_019c0012-66f4-709b-8b43-4cc13043ac96" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialLiabilitiesRepaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_abvx_OtherFinancialLiabilitiesRepaymentPeriod_019c0012-66f4-709b-8b43-4cc13043ac96" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepaymentsOfConditionalAdvances_019c0012-66f4-7ae4-916e-555657b9c3a8" xlink:href="abvx-20251231.xsd#abvx_RepaymentsOfConditionalAdvances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_abvx_RepaymentsOfConditionalAdvances_019c0012-66f4-7ae4-916e-555657b9c3a8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity_019c0012-8a04-712f-93da-9d795cd525b2" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity_019c0012-8a04-712f-93da-9d795cd525b2" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CapitalCommitments_019c0012-b574-74a5-a0ed-0eb7695f6602" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CapitalCommitments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_ifrs-full_CapitalCommitments_019c0012-b574-74a5-a0ed-0eb7695f6602" xlink:type="arc" order="16"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/OffbalancesheetcommitmentsreceivedandcontingentassetsDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#OffbalancesheetcommitmentsreceivedandcontingentassetsDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/OffbalancesheetcommitmentsreceivedandcontingentassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfCommitmentsReceivedLineItems_8d67ee55-0750-4d48-816a-daa2f019e7d4" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfCommitmentsReceivedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfCommitmentsReceivedTable_93a78c3e-0433-4e6d-b335-49c4132d7b23" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfCommitmentsReceivedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_abvx_DisclosureOfCommitmentsReceivedLineItems_8d67ee55-0750-4d48-816a-daa2f019e7d4" xlink:to="loc_abvx_DisclosureOfCommitmentsReceivedTable_93a78c3e-0433-4e6d-b335-49c4132d7b23" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_d388beee-94fb-4600-ba3d-da1850cca49a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abvx_DisclosureOfCommitmentsReceivedTable_93a78c3e-0433-4e6d-b335-49c4132d7b23" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_d388beee-94fb-4600-ba3d-da1850cca49a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_d388beee-94fb-4600-ba3d-da1850cca49a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_d388beee-94fb-4600-ba3d-da1850cca49a" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_d388beee-94fb-4600-ba3d-da1850cca49a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_c8f353ce-8653-41e0-a11d-048c9626cbb9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_d388beee-94fb-4600-ba3d-da1850cca49a" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_c8f353ce-8653-41e0-a11d-048c9626cbb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RNPVIRConditionalAdvanceBPIMember_297920cf-1823-4f19-920e-2a0b76bd1553" xlink:href="abvx-20251231.xsd#abvx_RNPVIRConditionalAdvanceBPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_c8f353ce-8653-41e0-a11d-048c9626cbb9" xlink:to="loc_abvx_RNPVIRConditionalAdvanceBPIMember_297920cf-1823-4f19-920e-2a0b76bd1553" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CARENAConditionalAdvanceBPIMember_29a6f2b9-bf98-4a30-8e92-65e906fb3762" xlink:href="abvx-20251231.xsd#abvx_CARENAConditionalAdvanceBPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_c8f353ce-8653-41e0-a11d-048c9626cbb9" xlink:to="loc_abvx_CARENAConditionalAdvanceBPIMember_29a6f2b9-bf98-4a30-8e92-65e906fb3762" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_46a90a92-70ed-4168-94b5-92ce803b0153" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abvx_DisclosureOfCommitmentsReceivedTable_93a78c3e-0433-4e6d-b335-49c4132d7b23" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_46a90a92-70ed-4168-94b5-92ce803b0153" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_46a90a92-70ed-4168-94b5-92ce803b0153_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_46a90a92-70ed-4168-94b5-92ce803b0153" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_46a90a92-70ed-4168-94b5-92ce803b0153_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_be095b72-f9c6-4013-8c65-48539d324618" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_46a90a92-70ed-4168-94b5-92ce803b0153" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_be095b72-f9c6-4013-8c65-48539d324618" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingMember_98641ada-cdb0-4ef5-a125-1f3337d982ef" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_be095b72-f9c6-4013-8c65-48539d324618" xlink:to="loc_abvx_KreosClaretFinancingMember_98641ada-cdb0-4ef5-a125-1f3337d982ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_HeightsConvertibleNotesTrancheBMember_cc95cbb3-5316-4e20-9246-04dd75ca917d" xlink:href="abvx-20251231.xsd#abvx_HeightsConvertibleNotesTrancheBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_be095b72-f9c6-4013-8c65-48539d324618" xlink:to="loc_abvx_HeightsConvertibleNotesTrancheBMember_cc95cbb3-5316-4e20-9246-04dd75ca917d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UndrawnBorrowingFacilities_0b0d3d49-885c-4029-9ee0-72ad23d3d7f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UndrawnBorrowingFacilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfCommitmentsReceivedLineItems_8d67ee55-0750-4d48-816a-daa2f019e7d4" xlink:to="loc_ifrs-full_UndrawnBorrowingFacilities_0b0d3d49-885c-4029-9ee0-72ad23d3d7f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfProjectsTerminated_f4614113-362e-4b19-afc8-36852878cc99" xlink:href="abvx-20251231.xsd#abvx_NumberOfProjectsTerminated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abvx_DisclosureOfCommitmentsReceivedLineItems_8d67ee55-0750-4d48-816a-daa2f019e7d4" xlink:to="loc_abvx_NumberOfProjectsTerminated_f4614113-362e-4b19-afc8-36852878cc99" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#ManagementandassessmentoffinancialrisksDetails"/>
  <link:definitionLink xlink:role="http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_019c001b-755b-7d1b-b305-7cdd2e05533d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfCreditRiskExposureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCreditRiskExposureTable_a02a0791-7ac7-4072-a071-ded250bb9e86" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfCreditRiskExposureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_019c001b-755b-7d1b-b305-7cdd2e05533d" xlink:to="loc_ifrs-full_DisclosureOfCreditRiskExposureTable_a02a0791-7ac7-4072-a071-ded250bb9e86" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_019c001b-755b-7f02-b92a-b8d22b20f3e3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureTable_a02a0791-7ac7-4072-a071-ded250bb9e86" xlink:to="loc_srt_CurrencyAxis_019c001b-755b-7f02-b92a-b8d22b20f3e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_019c001b-755b-7f02-b92a-b8d22b20f3e3_default" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_019c001b-755b-7f02-b92a-b8d22b20f3e3" xlink:to="loc_currency_AllCurrenciesDomain_019c001b-755b-7f02-b92a-b8d22b20f3e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_019c001b-755b-73f7-bcfa-58d352aeb2de" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_019c001b-755b-7f02-b92a-b8d22b20f3e3" xlink:to="loc_currency_AllCurrenciesDomain_019c001b-755b-73f7-bcfa-58d352aeb2de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_019c001b-755b-774b-8c0b-5b10122c36b7" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_019c001b-755b-73f7-bcfa-58d352aeb2de" xlink:to="loc_currency_USD_019c001b-755b-774b-8c0b-5b10122c36b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_019c001b-755b-7b70-9678-ecd25b58f54e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureTable_a02a0791-7ac7-4072-a071-ded250bb9e86" xlink:to="loc_ifrs-full_TypesOfRisksAxis_019c001b-755b-7b70-9678-ecd25b58f54e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksDomain_019c001b-755b-7b70-9678-ecd25b58f54e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfRisksDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_019c001b-755b-7b70-9678-ecd25b58f54e" xlink:to="loc_ifrs-full_TypesOfRisksDomain_019c001b-755b-7b70-9678-ecd25b58f54e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksDomain_019c001b-755b-7982-a493-bf18707f0f1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfRisksDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_019c001b-755b-7b70-9678-ecd25b58f54e" xlink:to="loc_ifrs-full_TypesOfRisksDomain_019c001b-755b-7982-a493-bf18707f0f1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember_019c001b-755b-7ffb-82a8-5acb8b8aa732" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksDomain_019c001b-755b-7982-a493-bf18707f0f1d" xlink:to="loc_ifrs-full_CurrencyRiskMember_019c001b-755b-7ffb-82a8-5acb8b8aa732" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CreditRiskMember_019c001b-755b-768d-9fef-fc9bb7577084" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CreditRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksDomain_019c001b-755b-7982-a493-bf18707f0f1d" xlink:to="loc_ifrs-full_CreditRiskMember_019c001b-755b-768d-9fef-fc9bb7577084" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_019c57a0-fcda-72b4-8b39-7df9565179fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureTable_a02a0791-7ac7-4072-a071-ded250bb9e86" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_019c57a0-fcda-72b4-8b39-7df9565179fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019c57a0-fcda-72b4-8b39-7df9565179fd_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019c57a0-fcda-72b4-8b39-7df9565179fd" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019c57a0-fcda-72b4-8b39-7df9565179fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019c57a0-fcda-7474-96a1-1ecfb3dd81b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019c57a0-fcda-72b4-8b39-7df9565179fd" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019c57a0-fcda-7474-96a1-1ecfb3dd81b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember_019c57a0-fcda-7da6-bdbe-8d302be58654" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019c57a0-fcda-7474-96a1-1ecfb3dd81b6" xlink:to="loc_abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember_019c57a0-fcda-7da6-bdbe-8d302be58654" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_019c57a1-2af3-7567-a68f-2b60a1f9b8cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureTable_a02a0791-7ac7-4072-a071-ded250bb9e86" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_019c57a1-2af3-7567-a68f-2b60a1f9b8cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesDomain_019c57a1-2af3-7567-a68f-2b60a1f9b8cd_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_019c57a1-2af3-7567-a68f-2b60a1f9b8cd" xlink:to="loc_ifrs-full_TypesOfInterestRatesDomain_019c57a1-2af3-7567-a68f-2b60a1f9b8cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesDomain_019c57a1-2af3-7fb6-a9af-00f3ce1829d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_019c57a1-2af3-7567-a68f-2b60a1f9b8cd" xlink:to="loc_ifrs-full_TypesOfInterestRatesDomain_019c57a1-2af3-7fb6-a9af-00f3ce1829d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EuropeanCentralBankBaseRateMember_019c57a1-2af3-7e5f-ab04-30a62d146e6e" xlink:href="abvx-20251231.xsd#abvx_EuropeanCentralBankBaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfInterestRatesDomain_019c57a1-2af3-7fb6-a9af-00f3ce1829d5" xlink:to="loc_abvx_EuropeanCentralBankBaseRateMember_019c57a1-2af3-7e5f-ab04-30a62d146e6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_019c57a2-ee66-7099-809b-1cd6bd829546" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureTable_a02a0791-7ac7-4072-a071-ded250bb9e86" xlink:to="loc_ifrs-full_RangeAxis_019c57a2-ee66-7099-809b-1cd6bd829546" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_019c57a2-ee66-7099-809b-1cd6bd829546_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_019c57a2-ee66-7099-809b-1cd6bd829546" xlink:to="loc_ifrs-full_RangeDomain_019c57a2-ee66-7099-809b-1cd6bd829546_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_019c57a2-ee66-7df4-a11d-cd921bdca89b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_019c57a2-ee66-7099-809b-1cd6bd829546" xlink:to="loc_ifrs-full_RangeDomain_019c57a2-ee66-7df4-a11d-cd921bdca89b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_019c57a3-3799-77ea-8119-2fffa3df4b7c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_019c57a2-ee66-7df4-a11d-cd921bdca89b" xlink:to="loc_ifrs-full_TopOfRangeMember_019c57a3-3799-77ea-8119-2fffa3df4b7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_019c57a4-25e6-73de-99de-d97edf4deb0a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_019c57a2-ee66-7df4-a11d-cd921bdca89b" xlink:to="loc_ifrs-full_BottomOfRangeMember_019c57a4-25e6-73de-99de-d97edf4deb0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsAdjustmentToInterestRateBasis_019c57a0-fcda-7da3-a60c-105bcb711921" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsAdjustmentToInterestRateBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_019c001b-755b-7d1b-b305-7cdd2e05533d" xlink:to="loc_ifrs-full_BorrowingsAdjustmentToInterestRateBasis_019c57a0-fcda-7da3-a60c-105bcb711921" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsBasisInterestRate_019c57a1-a8d9-7158-9227-d36a8b41f9ea" xlink:href="abvx-20251231.xsd#abvx_BorrowingsBasisInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_019c001b-755b-7d1b-b305-7cdd2e05533d" xlink:to="loc_abvx_BorrowingsBasisInterestRate_019c57a1-a8d9-7158-9227-d36a8b41f9ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_InterestRateCollarRange_019c57a3-9b2d-78d8-adf7-e65b67c6e845" xlink:href="abvx-20251231.xsd#abvx_InterestRateCollarRange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_019c001b-755b-7d1b-b305-7cdd2e05533d" xlink:to="loc_abvx_InterestRateCollarRange_019c57a3-9b2d-78d8-adf7-e65b67c6e845" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_019c001b-755b-7645-9c0a-b523c6ac2ee6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_019c001b-755b-7d1b-b305-7cdd2e05533d" xlink:to="loc_ifrs-full_Assets_019c001b-755b-7645-9c0a-b523c6ac2ee6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_019c001b-755b-733b-b249-6e3a9eebbfab" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_019c001b-755b-7d1b-b305-7cdd2e05533d" xlink:to="loc_ifrs-full_CashAndCashEquivalents_019c001b-755b-733b-b249-6e3a9eebbfab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties_019cfba9-a6ba-702f-8244-77b539395e81" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_019c001b-755b-7d1b-b305-7cdd2e05533d" xlink:to="loc_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties_019cfba9-a6ba-702f-8244-77b539395e81" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_019c001b-755b-7b0d-a4b1-1d016d37648f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_019c001b-755b-7d1b-b305-7cdd2e05533d" xlink:to="loc_ifrs-full_Liabilities_019c001b-755b-7b0d-a4b1-1d016d37648f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherPayablesToRelatedParties_019d1a27-a695-72fd-bf88-efe81dfbb18b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherPayablesToRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_019c001b-755b-7d1b-b305-7cdd2e05533d" xlink:to="loc_ifrs-full_TradeAndOtherPayablesToRelatedParties_019d1a27-a695-72fd-bf88-efe81dfbb18b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent_019c001b-755b-77dd-91cc-e55af5618188" xlink:href="abvx-20251231.xsd#abvx_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_019c001b-755b-7d1b-b305-7cdd2e05533d" xlink:to="loc_abvx_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent_019c001b-755b-77dd-91cc-e55af5618188" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SensitivityAnalysisForTypesOfMarketRisk10AdverseChangeInExchangeRateImpactOnForeignExchangeGainLoss_019c001b-755b-7b3d-8ece-fca866f0036c" xlink:href="abvx-20251231.xsd#abvx_SensitivityAnalysisForTypesOfMarketRisk10AdverseChangeInExchangeRateImpactOnForeignExchangeGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_019c001b-755b-7d1b-b305-7cdd2e05533d" xlink:to="loc_abvx_SensitivityAnalysisForTypesOfMarketRisk10AdverseChangeInExchangeRateImpactOnForeignExchangeGainLoss_019c001b-755b-7b3d-8ece-fca866f0036c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SensitivityAnalysisForTypesOfMarketRisk10FavorableChangeInExchangeRateImpactOnForeignExchangeGainLoss_019c001b-755b-74fe-af00-fc9eeee58bf7" xlink:href="abvx-20251231.xsd#abvx_SensitivityAnalysisForTypesOfMarketRisk10FavorableChangeInExchangeRateImpactOnForeignExchangeGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_019c001b-755b-7d1b-b305-7cdd2e05533d" xlink:to="loc_abvx_SensitivityAnalysisForTypesOfMarketRisk10FavorableChangeInExchangeRateImpactOnForeignExchangeGainLoss_019c001b-755b-74fe-af00-fc9eeee58bf7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfFinancialInstitutionsToMaintainCash_019c001b-755b-7d6e-b62f-f7e794d1a25c" xlink:href="abvx-20251231.xsd#abvx_NumberOfFinancialInstitutionsToMaintainCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_019c001b-755b-7d1b-b305-7cdd2e05533d" xlink:to="loc_abvx_NumberOfFinancialInstitutionsToMaintainCash_019c001b-755b-7d6e-b62f-f7e794d1a25c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BalancesWithBanksInExcessOfLegallyInsuredLimit_019c001b-755b-7abd-ac82-b565f790d5a6" xlink:href="abvx-20251231.xsd#abvx_BalancesWithBanksInExcessOfLegallyInsuredLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_019c001b-755b-7d1b-b305-7cdd2e05533d" xlink:to="loc_abvx_BalancesWithBanksInExcessOfLegallyInsuredLimit_019c001b-755b-7abd-ac82-b565f790d5a6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_InvestmentsInMutualFundsAndStructuredNotes_019c57ac-9c30-7ef0-95ed-c507deb20efb" xlink:href="abvx-20251231.xsd#abvx_InvestmentsInMutualFundsAndStructuredNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_019c001b-755b-7d1b-b305-7cdd2e05533d" xlink:to="loc_abvx_InvestmentsInMutualFundsAndStructuredNotes_019c57ac-9c30-7ef0-95ed-c507deb20efb" xlink:type="arc" order="13"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>abvx-20251231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:3ade1e9c-8754-4bce-84b9-83231d17b989,g:c324a16d-aca9-45c2-8b50-8666bee7377b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_abvx_NumberOfWarrantsOutstandingSubjectToNonMarketPerformanceCondition_919cdb05-5fde-4ef5-8695-c3a171589322_terseLabel_en-US" xlink:label="lab_abvx_NumberOfWarrantsOutstandingSubjectToNonMarketPerformanceCondition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of outstanding warrants subject to non-market performance condition (in shares)</link:label>
    <link:label id="lab_abvx_NumberOfWarrantsOutstandingSubjectToNonMarketPerformanceCondition_label_en-US" xlink:label="lab_abvx_NumberOfWarrantsOutstandingSubjectToNonMarketPerformanceCondition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Warrants Outstanding Subject To Non-Market Performance Condition</link:label>
    <link:label id="lab_abvx_NumberOfWarrantsOutstandingSubjectToNonMarketPerformanceCondition_documentation_en-US" xlink:label="lab_abvx_NumberOfWarrantsOutstandingSubjectToNonMarketPerformanceCondition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Warrants Outstanding Subject To Non-Market Performance Condition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfWarrantsOutstandingSubjectToNonMarketPerformanceCondition" xlink:href="abvx-20251231.xsd#abvx_NumberOfWarrantsOutstandingSubjectToNonMarketPerformanceCondition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NumberOfWarrantsOutstandingSubjectToNonMarketPerformanceCondition" xlink:to="lab_abvx_NumberOfWarrantsOutstandingSubjectToNonMarketPerformanceCondition" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems_d4d41f5f-02ed-4d33-b667-1b1e0d0bdb59_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of geographical areas [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of geographical areas [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:to="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BorrowingsExitFeeAmount_cc3bde9e-8b7d-4616-abd9-3f709c658706_terseLabel_en-US" xlink:label="lab_abvx_BorrowingsExitFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, exit fee amount</link:label>
    <link:label id="lab_abvx_BorrowingsExitFeeAmount_label_en-US" xlink:label="lab_abvx_BorrowingsExitFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, Exit Fee Amount</link:label>
    <link:label id="lab_abvx_BorrowingsExitFeeAmount_documentation_en-US" xlink:label="lab_abvx_BorrowingsExitFeeAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowings, Exit Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsExitFeeAmount" xlink:href="abvx-20251231.xsd#abvx_BorrowingsExitFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BorrowingsExitFeeAmount" xlink:to="lab_abvx_BorrowingsExitFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_CurrentReceivablesForEmployeeBenefits_019cc31a-6424-7f4c-aadc-706554da77e1_terseLabel_en-US" xlink:label="lab_abvx_CurrentReceivablesForEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee-related receivables</link:label>
    <link:label id="lab_abvx_CurrentReceivablesForEmployeeBenefits_label_en-US" xlink:label="lab_abvx_CurrentReceivablesForEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Receivables for Employee Benefits</link:label>
    <link:label id="lab_abvx_CurrentReceivablesForEmployeeBenefits_documentation_en-US" xlink:label="lab_abvx_CurrentReceivablesForEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current Receivables for Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentReceivablesForEmployeeBenefits" xlink:href="abvx-20251231.xsd#abvx_CurrentReceivablesForEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_CurrentReceivablesForEmployeeBenefits" xlink:to="lab_abvx_CurrentReceivablesForEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_d6edd7da-2067-4749-b9db-d046138f262d_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_SubContractingStudiesAndResearchExpenses_7633f550-ef91-4dbb-a403-f58993e36400_terseLabel_en-US" xlink:label="lab_abvx_SubContractingStudiesAndResearchExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sub-contracting, studies and research</link:label>
    <link:label id="lab_abvx_SubContractingStudiesAndResearchExpenses_label_en-US" xlink:label="lab_abvx_SubContractingStudiesAndResearchExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sub-Contracting, Studies And Research Expenses</link:label>
    <link:label id="lab_abvx_SubContractingStudiesAndResearchExpenses_documentation_en-US" xlink:label="lab_abvx_SubContractingStudiesAndResearchExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sub-Contracting, Studies And Research Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SubContractingStudiesAndResearchExpenses" xlink:href="abvx-20251231.xsd#abvx_SubContractingStudiesAndResearchExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_SubContractingStudiesAndResearchExpenses" xlink:to="lab_abvx_SubContractingStudiesAndResearchExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NumberOfWarrantsExercised_4d5585d4-6393-4006-a75b-9b92e223e3a7_terseLabel_en-US" xlink:label="lab_abvx_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of warrants exercised (in shares)</link:label>
    <link:label id="lab_abvx_NumberOfWarrantsExercised_label_en-US" xlink:label="lab_abvx_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Warrants Exercised</link:label>
    <link:label id="lab_abvx_NumberOfWarrantsExercised_documentation_en-US" xlink:label="lab_abvx_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfWarrantsExercised" xlink:href="abvx-20251231.xsd#abvx_NumberOfWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NumberOfWarrantsExercised" xlink:to="lab_abvx_NumberOfWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityListingsExchangeAxis_9edea8b0-8b6f-4f78-8614-488505b3f62f_terseLabel_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:label id="lab_dei_EntityListingsExchangeAxis_label_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityListingsExchangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityListingsExchangeAxis" xlink:to="lab_dei_EntityListingsExchangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_692531d9-db2e-4f40-8cb5-8855f2504bcf_terseLabel_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proportion of ownership interests held by non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_label_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proportion of ownership interests held by non-controlling interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xlink:to="lab_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NumberOfSharesWaived_019cf6b6-35b3-7b1f-9110-6c5a199d31cd_terseLabel_en-US" xlink:label="lab_abvx_NumberOfSharesWaived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares waived (in shares)</link:label>
    <link:label id="lab_abvx_NumberOfSharesWaived_label_en-US" xlink:label="lab_abvx_NumberOfSharesWaived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Waived</link:label>
    <link:label id="lab_abvx_NumberOfSharesWaived_documentation_en-US" xlink:label="lab_abvx_NumberOfSharesWaived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Shares Waived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfSharesWaived" xlink:href="abvx-20251231.xsd#abvx_NumberOfSharesWaived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NumberOfSharesWaived" xlink:to="lab_abvx_NumberOfSharesWaived" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b724e2db-1ffd-4855-84d6-41e686e4dcba_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_019beaf8-c9e1-771e-af42-6adc034bf2b5_verboseLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, intangible assets other than goodwill</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherFinanceIncome_effe337f-db26-4c1b-b1a1-1b792a8b435d_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherFinanceIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial income</link:label>
    <link:label id="lab_ifrs-full_OtherFinanceIncome_label_en-US" xlink:label="lab_ifrs-full_OtherFinanceIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other finance income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherFinanceIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherFinanceIncome" xlink:to="lab_ifrs-full_OtherFinanceIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_30f5bccb-8110-4287-823f-0e4a6c93a84a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of intangible assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings_077f027c-f730-4a1f-9e7e-fb71b41b148c_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Appropriation of prior period net loss</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through appropriation of retained earnings, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_A2021TaxYearMember_7c00f66a-b745-4aa2-9d6c-26e4008f7f76_terseLabel_en-US" xlink:label="lab_abvx_A2021TaxYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Year 2021</link:label>
    <link:label id="lab_abvx_A2021TaxYearMember_label_en-US" xlink:label="lab_abvx_A2021TaxYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2021, Tax Year [Member]</link:label>
    <link:label id="lab_abvx_A2021TaxYearMember_documentation_en-US" xlink:label="lab_abvx_A2021TaxYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Year 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_A2021TaxYearMember" xlink:href="abvx-20251231.xsd#abvx_A2021TaxYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_A2021TaxYearMember" xlink:to="lab_abvx_A2021TaxYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_db012e2b-07d9-404e-81ea-ebc9af0b65f0_terseLabel_en-US" xlink:label="lab_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net defined benefit liability (asset) [axis]</link:label>
    <link:label id="lab_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_label_en-US" xlink:label="lab_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net defined benefit liability (asset) [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:to="lab_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="lab_ifrs-full_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_8cc29238-f2a0-47a8-b683-31ea85e4bb3b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of liabilities arising from financing activities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of liabilities arising from financing activities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BSA20181Member_a8b868ee-883b-43eb-b3c7-10d85118a1b4_terseLabel_en-US" xlink:label="lab_abvx_BSA20181Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSA-2018-1</link:label>
    <link:label id="lab_abvx_BSA20181Member_label_en-US" xlink:label="lab_abvx_BSA20181Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSA-2018-1 [Member]</link:label>
    <link:label id="lab_abvx_BSA20181Member_documentation_en-US" xlink:label="lab_abvx_BSA20181Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BSA-2018-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20181Member" xlink:href="abvx-20251231.xsd#abvx_BSA20181Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BSA20181Member" xlink:to="lab_abvx_BSA20181Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_d83065ab-69b7-40b5-a0e1-eb6b766ac10f_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_label_en-US" xlink:label="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other tax effects for reconciliation between accounting profit and tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:to="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_TaxEffectOfResearchTaxCredit_d812ef2d-482c-4c12-aab8-10587dd0b7c7_terseLabel_en-US" xlink:label="lab_abvx_TaxEffectOfResearchTaxCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CIR</link:label>
    <link:label id="lab_abvx_TaxEffectOfResearchTaxCredit_label_en-US" xlink:label="lab_abvx_TaxEffectOfResearchTaxCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Effect Of Research Tax Credit</link:label>
    <link:label id="lab_abvx_TaxEffectOfResearchTaxCredit_documentation_en-US" xlink:label="lab_abvx_TaxEffectOfResearchTaxCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Effect Of Research Tax Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TaxEffectOfResearchTaxCredit" xlink:href="abvx-20251231.xsd#abvx_TaxEffectOfResearchTaxCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_TaxEffectOfResearchTaxCredit" xlink:to="lab_abvx_TaxEffectOfResearchTaxCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_KreosClaretMinimumReturnIndemnificationsMember_11aed01f-dd8e-4482-8171-a4d053113171_terseLabel_en-US" xlink:label="lab_abvx_KreosClaretMinimumReturnIndemnificationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret minimal return indemnifications</link:label>
    <link:label id="lab_abvx_KreosClaretMinimumReturnIndemnificationsMember_3b00d2f4-41b9-4c0e-8f1e-2e65d8ed982f_verboseLabel_en-US" xlink:label="lab_abvx_KreosClaretMinimumReturnIndemnificationsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Kreos/Claret Minimal Return Indemnifications</link:label>
    <link:label id="lab_abvx_KreosClaretMinimumReturnIndemnificationsMember_label_en-US" xlink:label="lab_abvx_KreosClaretMinimumReturnIndemnificationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret Minimum Return Indemnifications [Member]</link:label>
    <link:label id="lab_abvx_KreosClaretMinimumReturnIndemnificationsMember_documentation_en-US" xlink:label="lab_abvx_KreosClaretMinimumReturnIndemnificationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret Minimum Return Indemnifications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretMinimumReturnIndemnificationsMember" xlink:href="abvx-20251231.xsd#abvx_KreosClaretMinimumReturnIndemnificationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_KreosClaretMinimumReturnIndemnificationsMember" xlink:to="lab_abvx_KreosClaretMinimumReturnIndemnificationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BCE20185Member_8ac5487e-7818-4be3-a29c-0cb6e3a6abc9_terseLabel_en-US" xlink:label="lab_abvx_BCE20185Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BCE-2018-5</link:label>
    <link:label id="lab_abvx_BCE20185Member_label_en-US" xlink:label="lab_abvx_BCE20185Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BCE-2018-5 [Member]</link:label>
    <link:label id="lab_abvx_BCE20185Member_documentation_en-US" xlink:label="lab_abvx_BCE20185Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BCE-2018-5</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BCE20185Member" xlink:href="abvx-20251231.xsd#abvx_BCE20185Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BCE20185Member" xlink:to="lab_abvx_BCE20185Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceIncomeCost_514d15d4-ad31-455a-a10a-a5db0b130244_totalLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncomeCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Financial gain (loss)</link:label>
    <link:label id="lab_ifrs-full_FinanceIncomeCost_label_en-US" xlink:label="lab_ifrs-full_FinanceIncomeCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance income (cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceIncomeCost" xlink:to="lab_ifrs-full_FinanceIncomeCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_de18c648-b22d-459c-8744-72ee8eb7a9a7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_a694dd0f-2859-41f5-a7a9-0ce54b07d972_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Number of instruments exercised (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments exercised or vested in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_KreosClaretBondLoansMember_6f85004d-69ef-4173-834e-f05f646a0592_terseLabel_en-US" xlink:label="lab_abvx_KreosClaretBondLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kreos/Claret bond loans</link:label>
    <link:label id="lab_abvx_KreosClaretBondLoansMember_label_en-US" xlink:label="lab_abvx_KreosClaretBondLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret bond loans [Member]</link:label>
    <link:label id="lab_abvx_KreosClaretBondLoansMember_documentation_en-US" xlink:label="lab_abvx_KreosClaretBondLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret bond loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretBondLoansMember" xlink:href="abvx-20251231.xsd#abvx_KreosClaretBondLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_KreosClaretBondLoansMember" xlink:to="lab_abvx_KreosClaretBondLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherPayablesToRelatedParties_019d1a27-a695-7474-b421-de451269f342_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherPayablesToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payables to related parties</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherPayablesToRelatedParties_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherPayablesToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables to related parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherPayablesToRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherPayablesToRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherPayablesToRelatedParties" xlink:to="lab_ifrs-full_TradeAndOtherPayablesToRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of comprehensive income [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_51758bed-4211-4460-8606-1866c7ba0cf5_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent_2c0860b1-9e9c-4c1f-b202-1469718316cf_terseLabel_en-US" xlink:label="lab_abvx_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reasonably possible change in risk variable, percent</link:label>
    <link:label id="lab_abvx_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent_label_en-US" xlink:label="lab_abvx_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Percent</link:label>
    <link:label id="lab_abvx_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent_documentation_en-US" xlink:label="lab_abvx_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent" xlink:href="abvx-20251231.xsd#abvx_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent" xlink:to="lab_abvx_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueFromGovernmentGrants_170d3709-2465-4033-b399-5344a0e57e2d_verboseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromGovernmentGrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income from government grants</link:label>
    <link:label id="lab_ifrs-full_RevenueFromGovernmentGrants_fc3b4f1d-fb03-4e06-9ccf-388aab41b8fc_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromGovernmentGrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidies</link:label>
    <link:label id="lab_ifrs-full_RevenueFromGovernmentGrants_label_en-US" xlink:label="lab_ifrs-full_RevenueFromGovernmentGrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income from government grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromGovernmentGrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromGovernmentGrants" xlink:to="lab_ifrs-full_RevenueFromGovernmentGrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarningsProfitLossForReportingPeriod_a5cf5646-b5c6-4301-9d35-3be8a52eebef_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarningsProfitLossForReportingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss for the period</link:label>
    <link:label id="lab_ifrs-full_RetainedEarningsProfitLossForReportingPeriod_label_en-US" xlink:label="lab_ifrs-full_RetainedEarningsProfitLossForReportingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings, profit (loss) for reporting period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsProfitLossForReportingPeriod" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarningsProfitLossForReportingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsProfitLossForReportingPeriod" xlink:to="lab_ifrs-full_RetainedEarningsProfitLossForReportingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_RevaluationOfCashEquivalentsMeasuredAtFairValue_019c4341-3515-7e88-b107-9e988a904b19_terseLabel_en-US" xlink:label="lab_abvx_RevaluationOfCashEquivalentsMeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revaluation of cash equivalents measured at fair value</link:label>
    <link:label id="lab_abvx_RevaluationOfCashEquivalentsMeasuredAtFairValue_label_en-US" xlink:label="lab_abvx_RevaluationOfCashEquivalentsMeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revaluation Of Cash Equivalents Measured At Fair Value</link:label>
    <link:label id="lab_abvx_RevaluationOfCashEquivalentsMeasuredAtFairValue_documentation_en-US" xlink:label="lab_abvx_RevaluationOfCashEquivalentsMeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revaluation Of Cash Equivalents Measured At Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RevaluationOfCashEquivalentsMeasuredAtFairValue" xlink:href="abvx-20251231.xsd#abvx_RevaluationOfCashEquivalentsMeasuredAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_RevaluationOfCashEquivalentsMeasuredAtFairValue" xlink:to="lab_abvx_RevaluationOfCashEquivalentsMeasuredAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_f150a755-e04d-44fc-93e8-6f25456b473b_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Number of instruments lapsed (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments expired in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bff98-0c03-727c-a674-008d9dbaf32b_terseLabel_en-US" xlink:label="lab_abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in carrying value due to reasonably possible increase in unobservable input liabilities</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities_label_en-US" xlink:label="lab_abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Carrying Value Due To Reasonably Possible Increase In Unobservable Input Liabilities</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities_documentation_en-US" xlink:label="lab_abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Carrying Value Due To Reasonably Possible Increase In Unobservable Input Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:to="lab_abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasTable_4b0b51b8-9e2d-4293-80e1-3a8afa6d6093_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of geographical areas [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of geographical areas [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:to="lab_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ContributionToGroupsLiabilitiesPercentage_73c21fa2-6031-46c6-9bae-4074716d218c_terseLabel_en-US" xlink:label="lab_abvx_ContributionToGroupsLiabilitiesPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contribution to Group's liabilities, percentage</link:label>
    <link:label id="lab_abvx_ContributionToGroupsLiabilitiesPercentage_label_en-US" xlink:label="lab_abvx_ContributionToGroupsLiabilitiesPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contribution To Group's Liabilities, Percentage</link:label>
    <link:label id="lab_abvx_ContributionToGroupsLiabilitiesPercentage_documentation_en-US" xlink:label="lab_abvx_ContributionToGroupsLiabilitiesPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contribution To Group's Liabilities, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ContributionToGroupsLiabilitiesPercentage" xlink:href="abvx-20251231.xsd#abvx_ContributionToGroupsLiabilitiesPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ContributionToGroupsLiabilitiesPercentage" xlink:to="lab_abvx_ContributionToGroupsLiabilitiesPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_A2022TaxYearMember_5a4f0654-8b03-4d41-8018-7df7cf6ac930_terseLabel_en-US" xlink:label="lab_abvx_A2022TaxYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Year 2022</link:label>
    <link:label id="lab_abvx_A2022TaxYearMember_label_en-US" xlink:label="lab_abvx_A2022TaxYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2022, Tax Year [Member]</link:label>
    <link:label id="lab_abvx_A2022TaxYearMember_documentation_en-US" xlink:label="lab_abvx_A2022TaxYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Year 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_A2022TaxYearMember" xlink:href="abvx-20251231.xsd#abvx_A2022TaxYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_A2022TaxYearMember" xlink:to="lab_abvx_A2022TaxYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentDerivativeFinancialLiabilities_c75e41be-0b95-44c0-a598-6c67ced0fb95_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative instruments</link:label>
    <link:label id="lab_ifrs-full_CurrentDerivativeFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current derivative financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:to="lab_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_4d539d30-effc-4aa8-9d1e-9853d40c23d9_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS AT FAIR VALUE THROUGH PROFIT&#160;AND LOSS</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets at fair value through profit or loss, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:to="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BCE20172Member_dc3b8f2c-920e-4dff-904a-cf276e06bc1b_terseLabel_en-US" xlink:label="lab_abvx_BCE20172Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BCE-2017-2</link:label>
    <link:label id="lab_abvx_BCE20172Member_label_en-US" xlink:label="lab_abvx_BCE20172Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BCE-2017-2 [Member]</link:label>
    <link:label id="lab_abvx_BCE20172Member_documentation_en-US" xlink:label="lab_abvx_BCE20172Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BCE-2017-2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BCE20172Member" xlink:href="abvx-20251231.xsd#abvx_BCE20172Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BCE20172Member" xlink:to="lab_abvx_BCE20172Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_6d8b358a-1674-48cf-bf64-7755fca4bcc1_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ProceedsFromConditionalAdvances_1713a0d1-c0f3-435f-b650-bfa049663ec8_terseLabel_en-US" xlink:label="lab_abvx_ProceedsFromConditionalAdvances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from conditional advances</link:label>
    <link:label id="lab_abvx_ProceedsFromConditionalAdvances_label_en-US" xlink:label="lab_abvx_ProceedsFromConditionalAdvances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Conditional Advances</link:label>
    <link:label id="lab_abvx_ProceedsFromConditionalAdvances_documentation_en-US" xlink:label="lab_abvx_ProceedsFromConditionalAdvances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Conditional Advances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ProceedsFromConditionalAdvances" xlink:href="abvx-20251231.xsd#abvx_ProceedsFromConditionalAdvances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ProceedsFromConditionalAdvances" xlink:to="lab_abvx_ProceedsFromConditionalAdvances" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_26995cd1-4515-483e-afee-cfda44321f7b_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for provisions [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_bb9847b8-418b-4ef0-9980-1f6bd25d7490_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_KreosClaretFinancingTrancheAMember_cba1a1c0-b206-46ee-a0be-278d8b90438e_terseLabel_en-US" xlink:label="lab_abvx_KreosClaretFinancingTrancheAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret convertible notes (OCABSA)</link:label>
    <link:label id="lab_abvx_KreosClaretFinancingTrancheAMember_4a45b5c9-3cb3-4d2b-9e29-59c4e89a16db_netLabel_en-US" xlink:label="lab_abvx_KreosClaretFinancingTrancheAMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Kreos/Claret BSA</link:label>
    <link:label id="lab_abvx_KreosClaretFinancingTrancheAMember_label_en-US" xlink:label="lab_abvx_KreosClaretFinancingTrancheAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret Financing, Tranche A [Member]</link:label>
    <link:label id="lab_abvx_KreosClaretFinancingTrancheAMember_documentation_en-US" xlink:label="lab_abvx_KreosClaretFinancingTrancheAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret Financing, Tranche A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheAMember" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_KreosClaretFinancingTrancheAMember" xlink:to="lab_abvx_KreosClaretFinancingTrancheAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AGA2024Member_89543410-7a7e-4123-8303-8518c0b5b15e_terseLabel_en-US" xlink:label="lab_abvx_AGA2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA-2024</link:label>
    <link:label id="lab_abvx_AGA2024Member_label_en-US" xlink:label="lab_abvx_AGA2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA-2024 [Member]</link:label>
    <link:label id="lab_abvx_AGA2024Member_documentation_en-US" xlink:label="lab_abvx_AGA2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA-2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA2024Member" xlink:href="abvx-20251231.xsd#abvx_AGA2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AGA2024Member" xlink:to="lab_abvx_AGA2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BSA20253Member_019bfaee-2775-7635-b2f8-b24a75076be2_terseLabel_en-US" xlink:label="lab_abvx_BSA20253Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSA-2025-3</link:label>
    <link:label id="lab_abvx_BSA20253Member_label_en-US" xlink:label="lab_abvx_BSA20253Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSA-2025-3 [Member]</link:label>
    <link:label id="lab_abvx_BSA20253Member_documentation_en-US" xlink:label="lab_abvx_BSA20253Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BSA-2025-3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20253Member" xlink:href="abvx-20251231.xsd#abvx_BSA20253Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BSA20253Member" xlink:to="lab_abvx_BSA20253Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_IncreaseDecreaseInCrohnsDiseaseResearchExpenses_b30b5e42-5112-4007-b9bc-39299432b802_terseLabel_en-US" xlink:label="lab_abvx_IncreaseDecreaseInCrohnsDiseaseResearchExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in Crohn's Disease research expenses</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseInCrohnsDiseaseResearchExpenses_label_en-US" xlink:label="lab_abvx_IncreaseDecreaseInCrohnsDiseaseResearchExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Crohn's Disease Research Expenses</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseInCrohnsDiseaseResearchExpenses_documentation_en-US" xlink:label="lab_abvx_IncreaseDecreaseInCrohnsDiseaseResearchExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Crohn's Disease Research Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInCrohnsDiseaseResearchExpenses" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInCrohnsDiseaseResearchExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_IncreaseDecreaseInCrohnsDiseaseResearchExpenses" xlink:to="lab_abvx_IncreaseDecreaseInCrohnsDiseaseResearchExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_3c105bbc-c8b8-4c4c-914b-1e7f15806dc5_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharePremium_f17cb039-a8db-4e4d-afa9-e3f9203c99a5_terseLabel_en-US" xlink:label="lab_ifrs-full_SharePremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Premiums related to share capital</link:label>
    <link:label id="lab_ifrs-full_SharePremium_label_en-US" xlink:label="lab_ifrs-full_SharePremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharePremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharePremium" xlink:to="lab_ifrs-full_SharePremium" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_ab0dcd0f-7b9d-436e-9b94-ea9aa8c64d71_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows provided by (used in) financing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AGA20258Member_019bfaf7-ee30-78a3-bb5d-ce8ceedaa87c_terseLabel_en-US" xlink:label="lab_abvx_AGA20258Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA-2025-8</link:label>
    <link:label id="lab_abvx_AGA20258Member_label_en-US" xlink:label="lab_abvx_AGA20258Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA-2025-8 [Member]</link:label>
    <link:label id="lab_abvx_AGA20258Member_documentation_en-US" xlink:label="lab_abvx_AGA20258Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA-2025-8</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20258Member" xlink:href="abvx-20251231.xsd#abvx_AGA20258Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AGA20258Member" xlink:to="lab_abvx_AGA20258Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ShareWarrantsSubscriptionPricePerShare_7e3489d1-4f2b-4650-a8ae-69a31bd6bd72_terseLabel_en-US" xlink:label="lab_abvx_ShareWarrantsSubscriptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share warrants, subscription price (in euro per share)</link:label>
    <link:label id="lab_abvx_ShareWarrantsSubscriptionPricePerShare_label_en-US" xlink:label="lab_abvx_ShareWarrantsSubscriptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Warrants, Subscription Price Per Share</link:label>
    <link:label id="lab_abvx_ShareWarrantsSubscriptionPricePerShare_documentation_en-US" xlink:label="lab_abvx_ShareWarrantsSubscriptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Warrants, Subscription Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ShareWarrantsSubscriptionPricePerShare" xlink:href="abvx-20251231.xsd#abvx_ShareWarrantsSubscriptionPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ShareWarrantsSubscriptionPricePerShare" xlink:to="lab_abvx_ShareWarrantsSubscriptionPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesDomain_f53b592c-cf7d-466d-a557-7bddf0f602be_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of liabilities [domain]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of liabilities [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain" xlink:to="lab_ifrs-full_ClassesOfLiabilitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_273660c3-e9d7-45ff-bed6-f6cf2e025c31_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Actuarial gains and losses</link:label>
    <link:label id="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BorrowingsMaturityTerm_88c568cb-70ca-47ea-a65e-5d40730bcbd9_terseLabel_en-US" xlink:label="lab_abvx_BorrowingsMaturityTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, maturity term</link:label>
    <link:label id="lab_abvx_BorrowingsMaturityTerm_label_en-US" xlink:label="lab_abvx_BorrowingsMaturityTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings Maturity, Term</link:label>
    <link:label id="lab_abvx_BorrowingsMaturityTerm_documentation_en-US" xlink:label="lab_abvx_BorrowingsMaturityTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowings Maturity, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsMaturityTerm" xlink:href="abvx-20251231.xsd#abvx_BorrowingsMaturityTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BorrowingsMaturityTerm" xlink:to="lab_abvx_BorrowingsMaturityTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ConvertibleLoansNotesSettlementInSharesPercentageOfFairMarketValue_25d5f57f-f4cf-484c-bdea-7018fe33c8c8_terseLabel_en-US" xlink:label="lab_abvx_ConvertibleLoansNotesSettlementInSharesPercentageOfFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlement in shares, percentage of fair market value</link:label>
    <link:label id="lab_abvx_ConvertibleLoansNotesSettlementInSharesPercentageOfFairMarketValue_label_en-US" xlink:label="lab_abvx_ConvertibleLoansNotesSettlementInSharesPercentageOfFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Loans Notes, Settlement In Shares, Percentage Of Fair Market Value</link:label>
    <link:label id="lab_abvx_ConvertibleLoansNotesSettlementInSharesPercentageOfFairMarketValue_documentation_en-US" xlink:label="lab_abvx_ConvertibleLoansNotesSettlementInSharesPercentageOfFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Loans Notes, Settlement In Shares, Percentage Of Fair Market Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotesSettlementInSharesPercentageOfFairMarketValue" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotesSettlementInSharesPercentageOfFairMarketValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ConvertibleLoansNotesSettlementInSharesPercentageOfFairMarketValue" xlink:to="lab_abvx_ConvertibleLoansNotesSettlementInSharesPercentageOfFairMarketValue" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_EquityIssuancePercentageOfCurrentShareCapital_6af7c011-fa0a-4800-9c71-06b3dddefac7_terseLabel_en-US" xlink:label="lab_abvx_EquityIssuancePercentageOfCurrentShareCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity issuance, percentage of current share capital</link:label>
    <link:label id="lab_abvx_EquityIssuancePercentageOfCurrentShareCapital_label_en-US" xlink:label="lab_abvx_EquityIssuancePercentageOfCurrentShareCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Issuance, Percentage Of Current Share Capital</link:label>
    <link:label id="lab_abvx_EquityIssuancePercentageOfCurrentShareCapital_documentation_en-US" xlink:label="lab_abvx_EquityIssuancePercentageOfCurrentShareCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Issuance, Percentage Of Current Share Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EquityIssuancePercentageOfCurrentShareCapital" xlink:href="abvx-20251231.xsd#abvx_EquityIssuancePercentageOfCurrentShareCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_EquityIssuancePercentageOfCurrentShareCapital" xlink:to="lab_abvx_EquityIssuancePercentageOfCurrentShareCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_f593b5ac-4c03-4983-a531-e7ced9374744_totalLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive income (loss) for the period</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="lab_ifrs-full_ComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_SaleOfStockDomain_fc3b98da-daa6-44b6-b926-6764b5a1c053_terseLabel_en-US" xlink:label="lab_abvx_SaleOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Domain]</link:label>
    <link:label id="lab_abvx_SaleOfStockDomain_label_en-US" xlink:label="lab_abvx_SaleOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Domain]</link:label>
    <link:label id="lab_abvx_SaleOfStockDomain_documentation_en-US" xlink:label="lab_abvx_SaleOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SaleOfStockDomain" xlink:href="abvx-20251231.xsd#abvx_SaleOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_SaleOfStockDomain" xlink:to="lab_abvx_SaleOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_IncomeFromResearchTaxCredit_037249f0-678b-42e0-b8da-f9c0c9b0ebf1_terseLabel_en-US" xlink:label="lab_abvx_IncomeFromResearchTaxCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research tax credit ("CIR")</link:label>
    <link:label id="lab_abvx_IncomeFromResearchTaxCredit_label_en-US" xlink:label="lab_abvx_IncomeFromResearchTaxCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income From Research Tax Credit</link:label>
    <link:label id="lab_abvx_IncomeFromResearchTaxCredit_documentation_en-US" xlink:label="lab_abvx_IncomeFromResearchTaxCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income From Research Tax Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncomeFromResearchTaxCredit" xlink:href="abvx-20251231.xsd#abvx_IncomeFromResearchTaxCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_IncomeFromResearchTaxCredit" xlink:to="lab_abvx_IncomeFromResearchTaxCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities_5b36cdea-4f2d-47a6-a556-e5a00151bcd4_negatedTerseLabel_en-US" xlink:label="lab_abvx_DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_abvx_DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_abvx_DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease Through Interest Paid, Liabilities Arising From Financing Activities</link:label>
    <link:label id="lab_abvx_DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities_documentation_en-US" xlink:label="lab_abvx_DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Decrease Through Interest Paid, Liabilities Arising From Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" xlink:href="abvx-20251231.xsd#abvx_DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" xlink:to="lab_abvx_DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_23526c37-8f36-4daf-b113-4e08856d5267_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of changes in projected benefit obligation</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_384d7dd7-dabb-4e97-b239-b8cf838f4af7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of preparation</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NumberOfConvertibleNotesIssued_f9f4d5d1-47ac-4cb9-af52-a5aef42d96da_terseLabel_en-US" xlink:label="lab_abvx_NumberOfConvertibleNotesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of convertible notes issued (in shares)</link:label>
    <link:label id="lab_abvx_NumberOfConvertibleNotesIssued_label_en-US" xlink:label="lab_abvx_NumberOfConvertibleNotesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Convertible Notes Issued</link:label>
    <link:label id="lab_abvx_NumberOfConvertibleNotesIssued_documentation_en-US" xlink:label="lab_abvx_NumberOfConvertibleNotesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Convertible Notes Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfConvertibleNotesIssued" xlink:href="abvx-20251231.xsd#abvx_NumberOfConvertibleNotesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NumberOfConvertibleNotesIssued" xlink:to="lab_abvx_NumberOfConvertibleNotesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_RoyaltyCertificateMaximumAmount_ed016f15-4600-4809-bc8c-c36cba1e2063_terseLabel_en-US" xlink:label="lab_abvx_RoyaltyCertificateMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty certificate, maximum amount</link:label>
    <link:label id="lab_abvx_RoyaltyCertificateMaximumAmount_label_en-US" xlink:label="lab_abvx_RoyaltyCertificateMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Certificate, Maximum Amount</link:label>
    <link:label id="lab_abvx_RoyaltyCertificateMaximumAmount_documentation_en-US" xlink:label="lab_abvx_RoyaltyCertificateMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Certificate, Maximum Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificateMaximumAmount" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificateMaximumAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_RoyaltyCertificateMaximumAmount" xlink:to="lab_abvx_RoyaltyCertificateMaximumAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AGA20245Member_3042c19b-6a8d-410d-b7d3-80b55edac48c_terseLabel_en-US" xlink:label="lab_abvx_AGA20245Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA-2024-5</link:label>
    <link:label id="lab_abvx_AGA20245Member_label_en-US" xlink:label="lab_abvx_AGA20245Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA-2024-5 [Member]</link:label>
    <link:label id="lab_abvx_AGA20245Member_documentation_en-US" xlink:label="lab_abvx_AGA20245Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA-2024-5</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20245Member" xlink:href="abvx-20251231.xsd#abvx_AGA20245Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AGA20245Member" xlink:to="lab_abvx_AGA20245Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_84cd4a1c-7530-4480-b711-d4c2ea1b15aa_terseLabel_en-US" xlink:label="lab_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deposits</link:label>
    <link:label id="lab_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term deposits, not classified as cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:to="lab_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_SharePrice1_019beae9-0f2a-74cb-ab06-c3cf27201c14_terseLabel_en-US" xlink:label="lab_abvx_SharePrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share price (euro per share)</link:label>
    <link:label id="lab_abvx_SharePrice1_label_en-US" xlink:label="lab_abvx_SharePrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price1</link:label>
    <link:label id="lab_abvx_SharePrice1_documentation_en-US" xlink:label="lab_abvx_SharePrice1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Price1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SharePrice1" xlink:href="abvx-20251231.xsd#abvx_SharePrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_SharePrice1" xlink:to="lab_abvx_SharePrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ResearchAndDevelopmentExpensesMember_cbfeae62-24a7-40c4-af21-e6ae20288498_terseLabel_en-US" xlink:label="lab_abvx_ResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_abvx_ResearchAndDevelopmentExpensesMember_label_en-US" xlink:label="lab_abvx_ResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Expenses [Member]</link:label>
    <link:label id="lab_abvx_ResearchAndDevelopmentExpensesMember_documentation_en-US" xlink:label="lab_abvx_ResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ResearchAndDevelopmentExpensesMember" xlink:href="abvx-20251231.xsd#abvx_ResearchAndDevelopmentExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ResearchAndDevelopmentExpensesMember" xlink:to="lab_abvx_ResearchAndDevelopmentExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_087d4cd1-e568-47d2-a5fc-b24beac61ff5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_GrossProceedsFromNonConvertibleLoansNotes_a73e7ab1-7d8e-41d3-a49e-c51345c37310_terseLabel_en-US" xlink:label="lab_abvx_GrossProceedsFromNonConvertibleLoansNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the issuance of non-convertible bond loans</link:label>
    <link:label id="lab_abvx_GrossProceedsFromNonConvertibleLoansNotes_label_en-US" xlink:label="lab_abvx_GrossProceedsFromNonConvertibleLoansNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Proceeds From Non-Convertible Loans Notes</link:label>
    <link:label id="lab_abvx_GrossProceedsFromNonConvertibleLoansNotes_documentation_en-US" xlink:label="lab_abvx_GrossProceedsFromNonConvertibleLoansNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gross Proceeds From Non-Convertible Loans Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_GrossProceedsFromNonConvertibleLoansNotes" xlink:href="abvx-20251231.xsd#abvx_GrossProceedsFromNonConvertibleLoansNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_GrossProceedsFromNonConvertibleLoansNotes" xlink:to="lab_abvx_GrossProceedsFromNonConvertibleLoansNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Assets_9e01d199-46fa-4649-8c5c-8fca40d09e12_totalLabel_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:label id="lab_ifrs-full_Assets_1a27b26b-7cc4-458e-b83c-1e3f6cd033d0_terseLabel_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_ifrs-full_Assets_019c001c-650e-7c5e-ad0c-d45303ec7a37_verboseLabel_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_ifrs-full_Assets_label_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Assets" xlink:to="lab_ifrs-full_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AdjustmentsForForgivenessOfConditionalAdvances_de3cbac7-d240-4aea-a38b-b9b128f55775_terseLabel_en-US" xlink:label="lab_abvx_AdjustmentsForForgivenessOfConditionalAdvances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgiveness of conditional advances</link:label>
    <link:label id="lab_abvx_AdjustmentsForForgivenessOfConditionalAdvances_label_en-US" xlink:label="lab_abvx_AdjustmentsForForgivenessOfConditionalAdvances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Forgiveness Of Conditional Advances</link:label>
    <link:label id="lab_abvx_AdjustmentsForForgivenessOfConditionalAdvances_documentation_en-US" xlink:label="lab_abvx_AdjustmentsForForgivenessOfConditionalAdvances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments For Forgiveness Of Conditional Advances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AdjustmentsForForgivenessOfConditionalAdvances" xlink:href="abvx-20251231.xsd#abvx_AdjustmentsForForgivenessOfConditionalAdvances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AdjustmentsForForgivenessOfConditionalAdvances" xlink:to="lab_abvx_AdjustmentsForForgivenessOfConditionalAdvances" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_UnrecognizedDeferredTaxAssets_e5a3a1c5-ec2d-450d-9e70-58f02dec3878_negatedTerseLabel_en-US" xlink:label="lab_abvx_UnrecognizedDeferredTaxAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized deferred tax assets</link:label>
    <link:label id="lab_abvx_UnrecognizedDeferredTaxAssets_label_en-US" xlink:label="lab_abvx_UnrecognizedDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Deferred Tax Assets</link:label>
    <link:label id="lab_abvx_UnrecognizedDeferredTaxAssets_documentation_en-US" xlink:label="lab_abvx_UnrecognizedDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrecognized Deferred Tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_UnrecognizedDeferredTaxAssets" xlink:href="abvx-20251231.xsd#abvx_UnrecognizedDeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_UnrecognizedDeferredTaxAssets" xlink:to="lab_abvx_UnrecognizedDeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_18fb6eba-a176-4375-9635-ea22998ae6da_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current taxes</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for income tax [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_b5d590c1-95ff-4d83-9aeb-7d0223edeabb_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Number of instruments outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_c349402f-d473-406e-a613-e7727f2c2d53_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Number of instruments outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory_3f833752-8358-4ee5-9c42-bb5825bcde74_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for goodwill [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CreditRiskMember_a59486e5-78ad-435c-a5f0-94bc2e4279ec_terseLabel_en-US" xlink:label="lab_ifrs-full_CreditRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit risk</link:label>
    <link:label id="lab_ifrs-full_CreditRiskMember_label_en-US" xlink:label="lab_ifrs-full_CreditRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit risk [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CreditRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CreditRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CreditRiskMember" xlink:to="lab_ifrs-full_CreditRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_62799bc6-bd5a-471e-a54c-580f171e56cb_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfInterestRatesAxis_9874f063-6cca-40e4-a85f-5c60781fdfb1_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfInterestRatesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of interest rates [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfInterestRatesAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfInterestRatesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of interest rates [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis" xlink:to="lab_ifrs-full_TypesOfInterestRatesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_LossesArisingFromDerecognitionOfFinancialLiabilities_6bb1984c-0e8e-4f0e-9ac6-8736ed5a909d_negatedTerseLabel_en-US" xlink:label="lab_abvx_LossesArisingFromDerecognitionOfFinancialLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on derecognition of financial liabilities</link:label>
    <link:label id="lab_abvx_LossesArisingFromDerecognitionOfFinancialLiabilities_label_en-US" xlink:label="lab_abvx_LossesArisingFromDerecognitionOfFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Losses Arising From Derecognition Of Financial Liabilities</link:label>
    <link:label id="lab_abvx_LossesArisingFromDerecognitionOfFinancialLiabilities_documentation_en-US" xlink:label="lab_abvx_LossesArisingFromDerecognitionOfFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Losses Arising From Derecognition Of Financial Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LossesArisingFromDerecognitionOfFinancialLiabilities" xlink:href="abvx-20251231.xsd#abvx_LossesArisingFromDerecognitionOfFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_LossesArisingFromDerecognitionOfFinancialLiabilities" xlink:to="lab_abvx_LossesArisingFromDerecognitionOfFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDApproval_3079a76b-8ea2-4bb6-8876-f344075e845f_terseLabel_en-US" xlink:label="lab_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDApproval" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential development milestone payment, IND approval</link:label>
    <link:label id="lab_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDApproval_label_en-US" xlink:label="lab_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDApproval" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Potential Development Milestone Payment, IND Approval</link:label>
    <link:label id="lab_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDApproval_documentation_en-US" xlink:label="lab_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDApproval" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Potential Development Milestone Payment, IND Approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDApproval" xlink:href="abvx-20251231.xsd#abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDApproval"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDApproval" xlink:to="lab_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDApproval" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_4f4326b3-226a-44ad-838a-887627adf5e2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember_8e771fb1-41d9-412f-87c6-dcc703c17251_terseLabel_en-US" xlink:label="lab_abvx_FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Probability-weighted present value of shortfall payment, final redemption</link:label>
    <link:label id="lab_abvx_FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember_label_en-US" xlink:label="lab_abvx_FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Final Redemption, Probability-Weighted Present Value Of Shortfall Payment, Measurement Input [Member]</link:label>
    <link:label id="lab_abvx_FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember_documentation_en-US" xlink:label="lab_abvx_FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Final Redemption,Probability-Weighted Present Value Of Shortfall Payment, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember" xlink:href="abvx-20251231.xsd#abvx_FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember" xlink:to="lab_abvx_FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBorrowingsExplanatory_00748fbd-b6e0-4425-be65-d6c31dfc82b6_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of conditional advances</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBorrowingsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of borrowings [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBorrowingsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_41a077e1-7dfb-4abc-b0ff-3abb101bd4b5_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SHARE CAPITAL</link:label>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_label_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapitalMember" xlink:to="lab_ifrs-full_IssuedCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory_82d82a7f-12a3-4f14-9834-8415cf673dd7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employees</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of information about employees [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_LeaseFacilitiesMontpellierMember_410f583a-a4fb-45f1-95bf-7e4900dd929a_terseLabel_en-US" xlink:label="lab_abvx_LeaseFacilitiesMontpellierMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease facilities, Montpellier</link:label>
    <link:label id="lab_abvx_LeaseFacilitiesMontpellierMember_label_en-US" xlink:label="lab_abvx_LeaseFacilitiesMontpellierMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Facilities, Montpellier [Member]</link:label>
    <link:label id="lab_abvx_LeaseFacilitiesMontpellierMember_documentation_en-US" xlink:label="lab_abvx_LeaseFacilitiesMontpellierMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Facilities, Montpellier</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LeaseFacilitiesMontpellierMember" xlink:href="abvx-20251231.xsd#abvx_LeaseFacilitiesMontpellierMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_LeaseFacilitiesMontpellierMember" xlink:to="lab_abvx_LeaseFacilitiesMontpellierMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_KreosClaretFinancingTrancheBAndCMember_fd498438-98b4-4a90-91c8-ad34885639a7_terseLabel_en-US" xlink:label="lab_abvx_KreosClaretFinancingTrancheBAndCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret financing, tranche B and C</link:label>
    <link:label id="lab_abvx_KreosClaretFinancingTrancheBAndCMember_label_en-US" xlink:label="lab_abvx_KreosClaretFinancingTrancheBAndCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret Financing, Tranche B and C [Member]</link:label>
    <link:label id="lab_abvx_KreosClaretFinancingTrancheBAndCMember_documentation_en-US" xlink:label="lab_abvx_KreosClaretFinancingTrancheBAndCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret Financing, Tranche B and C</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheBAndCMember" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheBAndCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_KreosClaretFinancingTrancheBAndCMember" xlink:to="lab_abvx_KreosClaretFinancingTrancheBAndCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_LeaseBreakClausePeriod_2391c209-6e31-444b-b486-b46ff7c0ee42_terseLabel_en-US" xlink:label="lab_abvx_LeaseBreakClausePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease, break clause period</link:label>
    <link:label id="lab_abvx_LeaseBreakClausePeriod_label_en-US" xlink:label="lab_abvx_LeaseBreakClausePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Break Clause Period</link:label>
    <link:label id="lab_abvx_LeaseBreakClausePeriod_documentation_en-US" xlink:label="lab_abvx_LeaseBreakClausePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease, Break Clause Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LeaseBreakClausePeriod" xlink:href="abvx-20251231.xsd#abvx_LeaseBreakClausePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_LeaseBreakClausePeriod" xlink:to="lab_abvx_LeaseBreakClausePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_166bd955-d4c9-415d-851b-c2355e291909_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7450d42b-2e30-401e-9d05-51cbc3e48d25_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NumberOfWarrantsRepurchased_019bfef3-92c1-7b0f-87bf-cb2e44d736a6_terseLabel_en-US" xlink:label="lab_abvx_NumberOfWarrantsRepurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of warrants repurchased (in shares)</link:label>
    <link:label id="lab_abvx_NumberOfWarrantsRepurchased_label_en-US" xlink:label="lab_abvx_NumberOfWarrantsRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Warrants Repurchased</link:label>
    <link:label id="lab_abvx_NumberOfWarrantsRepurchased_documentation_en-US" xlink:label="lab_abvx_NumberOfWarrantsRepurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Warrants Repurchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfWarrantsRepurchased" xlink:href="abvx-20251231.xsd#abvx_NumberOfWarrantsRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NumberOfWarrantsRepurchased" xlink:to="lab_abvx_NumberOfWarrantsRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_019beae9-d416-763c-b588-d95c4f0efd78_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in number of ordinary shares issued (in shares)</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in number of ordinary shares issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:to="lab_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_CurrentAdvancesToCROContracts_fa27b510-efc3-4b83-9d66-b7e1bd9453f2_terseLabel_en-US" xlink:label="lab_abvx_CurrentAdvancesToCROContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advances related to CRO contracts</link:label>
    <link:label id="lab_abvx_CurrentAdvancesToCROContracts_label_en-US" xlink:label="lab_abvx_CurrentAdvancesToCROContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Advances To CRO Contracts</link:label>
    <link:label id="lab_abvx_CurrentAdvancesToCROContracts_documentation_en-US" xlink:label="lab_abvx_CurrentAdvancesToCROContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current Advances To CRO Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentAdvancesToCROContracts" xlink:href="abvx-20251231.xsd#abvx_CurrentAdvancesToCROContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_CurrentAdvancesToCROContracts" xlink:to="lab_abvx_CurrentAdvancesToCROContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_c710d7b9-414a-4f71-a855-3083c4091ac7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Group</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of general information about financial statements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities_833144f4-85a0-46c3-91ad-318912b83a30_verboseLabel_en-US" xlink:label="lab_abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) through amortization cost remeasurement</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities_dfc79374-e66a-41c6-8ea2-f7dbea8dc908_terseLabel_en-US" xlink:label="lab_abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash changes: amortized cost remeasurement</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Amortization Cost Remeasurement, Liabilities Arising From Financing Activities</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities_documentation_en-US" xlink:label="lab_abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Amortization Cost Remeasurement, Liabilities Arising From Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" xlink:to="lab_abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember_0d65deaf-616d-4661-ba98-84c150a64dc6_terseLabel_en-US" xlink:label="lab_abvx_FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Final redemption, probability-weighted fair value without MRI</link:label>
    <link:label id="lab_abvx_FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember_label_en-US" xlink:label="lab_abvx_FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Final Redemption, Probability-Weighted Fair Value Without MRI , Measurement Input [Member]</link:label>
    <link:label id="lab_abvx_FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember_documentation_en-US" xlink:label="lab_abvx_FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Final Redemption, Probability-Weighted Fair Value Without MRI , Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember" xlink:href="abvx-20251231.xsd#abvx_FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember" xlink:to="lab_abvx_FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherNoncurrentNonfinancialAssets_493c8806-b62d-4f63-a305-36ba59980410_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_ifrs-full_OtherNoncurrentNonfinancialAssets_019bfa02-2c58-7dd6-b29f-0bd60bf7b11e_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other non-current assets</link:label>
    <link:label id="lab_ifrs-full_OtherNoncurrentNonfinancialAssets_label_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current non-financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:to="lab_ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_33ffa5e5-d76a-43d1-afdb-f53f8ed7b62a_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nominal income tax using statutory French tax rate</link:label>
    <link:label id="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_label_en-US" xlink:label="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax expense (income) at applicable tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:to="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_2a0d5f93-4302-4395-a46b-5baacd22ba01_terseLabel_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chief Executive Officer</link:label>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember" xlink:to="lab_srt_ChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_A2023TaxYearMember_163b7f0f-3cb4-4efe-bf9d-ff1a243d4bfc_terseLabel_en-US" xlink:label="lab_abvx_A2023TaxYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Year 2023</link:label>
    <link:label id="lab_abvx_A2023TaxYearMember_label_en-US" xlink:label="lab_abvx_A2023TaxYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023, Tax Year [Member]</link:label>
    <link:label id="lab_abvx_A2023TaxYearMember_documentation_en-US" xlink:label="lab_abvx_A2023TaxYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Year 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_A2023TaxYearMember" xlink:href="abvx-20251231.xsd#abvx_A2023TaxYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_A2023TaxYearMember" xlink:to="lab_abvx_A2023TaxYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_IncomeFromDepositaryServiceFees_019c5754-bc2a-78f4-b436-ca8c1d1b59e0_terseLabel_en-US" xlink:label="lab_abvx_IncomeFromDepositaryServiceFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depositary service fees</link:label>
    <link:label id="lab_abvx_IncomeFromDepositaryServiceFees_label_en-US" xlink:label="lab_abvx_IncomeFromDepositaryServiceFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income From Depositary Service Fees</link:label>
    <link:label id="lab_abvx_IncomeFromDepositaryServiceFees_documentation_en-US" xlink:label="lab_abvx_IncomeFromDepositaryServiceFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income From Depositary Service Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncomeFromDepositaryServiceFees" xlink:href="abvx-20251231.xsd#abvx_IncomeFromDepositaryServiceFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_IncomeFromDepositaryServiceFees" xlink:to="lab_abvx_IncomeFromDepositaryServiceFees" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentPrepaidExpenses_f5ba4455-abef-4006-bdf7-da166dc2bc22_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_ifrs-full_CurrentPrepaidExpenses_label_en-US" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPrepaidExpenses" xlink:to="lab_ifrs-full_CurrentPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AssetsAbstract_61feeebd-b417-45f2-bfd1-b26a0f3b767e_terseLabel_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_ifrs-full_AssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAbstract" xlink:to="lab_ifrs-full_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AGA20241AGE20242AGA20243AGA20244AGA20245AndAGA20247Member_68ded199-e84f-4d9f-ae3d-f253cc22a299_terseLabel_en-US" xlink:label="lab_abvx_AGA20241AGE20242AGA20243AGA20244AGA20245AndAGA20247Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA-2024-1, AGE-2024-2, AGA-2024-3, AGA-2024-4, AGA-2024-5 and AGA-2024-7</link:label>
    <link:label id="lab_abvx_AGA20241AGE20242AGA20243AGA20244AGA20245AndAGA20247Member_label_en-US" xlink:label="lab_abvx_AGA20241AGE20242AGA20243AGA20244AGA20245AndAGA20247Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA-2024-1, AGE-2024-2, AGA-2024-3, AGA-2024-4, AGA-2024-5 and AGA-2024-7 [Member]</link:label>
    <link:label id="lab_abvx_AGA20241AGE20242AGA20243AGA20244AGA20245AndAGA20247Member_documentation_en-US" xlink:label="lab_abvx_AGA20241AGE20242AGA20243AGA20244AGA20245AndAGA20247Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA-2024-1, AGE-2024-2, AGA-2024-3, AGA-2024-4, AGA-2024-5 and AGA-2024-7</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20241AGE20242AGA20243AGA20244AGA20245AndAGA20247Member" xlink:href="abvx-20251231.xsd#abvx_AGA20241AGE20242AGA20243AGA20244AGA20245AndAGA20247Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AGA20241AGE20242AGA20243AGA20244AGA20245AndAGA20247Member" xlink:to="lab_abvx_AGA20241AGE20242AGA20243AGA20244AGA20245AndAGA20247Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_RNPVIRConditionalAdvanceBPIAndCARENAConditionalAdvanceBPIMember_84d3b999-869d-435f-afe5-e0620d11b943_terseLabel_en-US" xlink:label="lab_abvx_RNPVIRConditionalAdvanceBPIAndCARENAConditionalAdvanceBPIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RNP-VIR conditional advance and CARENA conditional advance</link:label>
    <link:label id="lab_abvx_RNPVIRConditionalAdvanceBPIAndCARENAConditionalAdvanceBPIMember_label_en-US" xlink:label="lab_abvx_RNPVIRConditionalAdvanceBPIAndCARENAConditionalAdvanceBPIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RNP-VIR Conditional Advance, BPI And CARENA Conditional Advance, BPI [Member]</link:label>
    <link:label id="lab_abvx_RNPVIRConditionalAdvanceBPIAndCARENAConditionalAdvanceBPIMember_documentation_en-US" xlink:label="lab_abvx_RNPVIRConditionalAdvanceBPIAndCARENAConditionalAdvanceBPIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">RNP-VIR Conditional Advance, BPI And CARENA Conditional Advance, BPI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RNPVIRConditionalAdvanceBPIAndCARENAConditionalAdvanceBPIMember" xlink:href="abvx-20251231.xsd#abvx_RNPVIRConditionalAdvanceBPIAndCARENAConditionalAdvanceBPIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_RNPVIRConditionalAdvanceBPIAndCARENAConditionalAdvanceBPIMember" xlink:to="lab_abvx_RNPVIRConditionalAdvanceBPIAndCARENAConditionalAdvanceBPIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AmericanDepositorySharesNASDAQGlobalMarketMember_d7863426-edd0-40c3-ba50-a3d58b394b8d_terseLabel_en-US" xlink:label="lab_abvx_AmericanDepositorySharesNASDAQGlobalMarketMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">American Depositary Shares, each representing one ordinary share, nominal value &#8364;0.01 per share</link:label>
    <link:label id="lab_abvx_AmericanDepositorySharesNASDAQGlobalMarketMember_label_en-US" xlink:label="lab_abvx_AmericanDepositorySharesNASDAQGlobalMarketMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">American Depository Shares, NASDAQ Global Market [Member]</link:label>
    <link:label id="lab_abvx_AmericanDepositorySharesNASDAQGlobalMarketMember_documentation_en-US" xlink:label="lab_abvx_AmericanDepositorySharesNASDAQGlobalMarketMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">American Depository Shares, NASDAQ Global Select Market [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AmericanDepositorySharesNASDAQGlobalMarketMember" xlink:href="abvx-20251231.xsd#abvx_AmericanDepositorySharesNASDAQGlobalMarketMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AmericanDepositorySharesNASDAQGlobalMarketMember" xlink:to="lab_abvx_AmericanDepositorySharesNASDAQGlobalMarketMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RightofuseAssetsMember_df36b1f4-ed65-48a5-a114-c000c2f2009e_terseLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ROU</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssetsMember_label_en-US" xlink:label="lab_ifrs-full_RightofuseAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-use assets [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RightofuseAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RightofuseAssetsMember" xlink:to="lab_ifrs-full_RightofuseAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CreditSpreadMeasurementInputMember_9b1c211b-e0ee-4b82-809f-45c364424a4e_terseLabel_en-US" xlink:label="lab_ifrs-full_CreditSpreadMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit spread</link:label>
    <link:label id="lab_ifrs-full_CreditSpreadMeasurementInputMember_label_en-US" xlink:label="lab_ifrs-full_CreditSpreadMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit spread, measurement input [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CreditSpreadMeasurementInputMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CreditSpreadMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CreditSpreadMeasurementInputMember" xlink:to="lab_ifrs-full_CreditSpreadMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod_d6125054-7f73-415d-8903-aa36b4dda422_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod_label_en-US" xlink:label="lab_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings, excluding profit (loss) for reporting period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod" xlink:to="lab_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_RegisteredDirectOfferingMember_693c75ee-2132-48b5-a803-3c8b3b4c0ded_terseLabel_en-US" xlink:label="lab_abvx_RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Registered direct offering</link:label>
    <link:label id="lab_abvx_RegisteredDirectOfferingMember_label_en-US" xlink:label="lab_abvx_RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Registered Direct Offering [Member]</link:label>
    <link:label id="lab_abvx_RegisteredDirectOfferingMember_documentation_en-US" xlink:label="lab_abvx_RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Registered Direct Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RegisteredDirectOfferingMember" xlink:href="abvx-20251231.xsd#abvx_RegisteredDirectOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_RegisteredDirectOfferingMember" xlink:to="lab_abvx_RegisteredDirectOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_943461fc-3a9b-4711-a6f9-df53dfbf0a5a_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssetsAbstract" xlink:to="lab_ifrs-full_CurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_0d3f894d-9062-456f-b995-8d5a1c6a1be6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueAbstract_label_en-US" xlink:label="lab_ifrs-full_RevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueAbstract" xlink:to="lab_ifrs-full_RevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_b873a436-d737-43b1-af4f-d01e82db762c_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:to="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_KreosABBSAMember_796fbe2e-38b0-4031-b2de-ba9988b7a046_terseLabel_en-US" xlink:label="lab_abvx_KreosABBSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kreos A &amp; B BSA</link:label>
    <link:label id="lab_abvx_KreosABBSAMember_label_en-US" xlink:label="lab_abvx_KreosABBSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kreos A &amp; B BSA [Member]</link:label>
    <link:label id="lab_abvx_KreosABBSAMember_documentation_en-US" xlink:label="lab_abvx_KreosABBSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kreos A &amp; B BSA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosABBSAMember" xlink:href="abvx-20251231.xsd#abvx_KreosABBSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_KreosABBSAMember" xlink:to="lab_abvx_KreosABBSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AuditorsRemunerationForOtherServices_6dbf501c-8415-492a-951a-e10692c9cfa8_terseLabel_en-US" xlink:label="lab_ifrs-full_AuditorsRemunerationForOtherServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All other fees</link:label>
    <link:label id="lab_ifrs-full_AuditorsRemunerationForOtherServices_label_en-US" xlink:label="lab_ifrs-full_AuditorsRemunerationForOtherServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor's remuneration for other services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemunerationForOtherServices" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AuditorsRemunerationForOtherServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AuditorsRemunerationForOtherServices" xlink:to="lab_ifrs-full_AuditorsRemunerationForOtherServices" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets_0a4c0a04-f252-4edc-a78e-d6ec896744e6_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment including right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GeneralAndAdministrativeExpense_afa78b4c-51ba-4a16-8bbb-3dfe17ceeac5_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_ifrs-full_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_ifrs-full_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeneralAndAdministrativeExpense" xlink:to="lab_ifrs-full_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_IncreaseDecreaseInTransversalActivities_66544015-c6e0-4dd0-8b7f-d74d1767df3a_terseLabel_en-US" xlink:label="lab_abvx_IncreaseDecreaseInTransversalActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in transversal activities</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseInTransversalActivities_label_en-US" xlink:label="lab_abvx_IncreaseDecreaseInTransversalActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Transversal Activities</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseInTransversalActivities_documentation_en-US" xlink:label="lab_abvx_IncreaseDecreaseInTransversalActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Transversal Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInTransversalActivities" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInTransversalActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_IncreaseDecreaseInTransversalActivities" xlink:to="lab_abvx_IncreaseDecreaseInTransversalActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_7ce74f7a-2ccf-41cf-b4fe-6fccea57a906_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of income tax [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsForShareIssueCosts_479fad46-1f90-4d5a-974d-820c776713a8_terseLabel_en-US" xlink:label="lab_ifrs-full_PaymentsForShareIssueCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for share issue costs</link:label>
    <link:label id="lab_ifrs-full_PaymentsForShareIssueCosts_label_en-US" xlink:label="lab_ifrs-full_PaymentsForShareIssueCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for share issue costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsForShareIssueCosts" xlink:to="lab_ifrs-full_PaymentsForShareIssueCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_7883fe50-c6be-4fe1-9cd2-bd01e2c11d97_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of defined benefit plans [abstract]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of defined benefit plans [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lab_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_EarlyRedemptionAmountMeasurementInputMember_25780523-6162-4cb5-bc06-eac4a606defe_terseLabel_en-US" xlink:label="lab_abvx_EarlyRedemptionAmountMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Early redemption amount (put event)</link:label>
    <link:label id="lab_abvx_EarlyRedemptionAmountMeasurementInputMember_label_en-US" xlink:label="lab_abvx_EarlyRedemptionAmountMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Early Redemption Amount, Measurement Input [Member]</link:label>
    <link:label id="lab_abvx_EarlyRedemptionAmountMeasurementInputMember_documentation_en-US" xlink:label="lab_abvx_EarlyRedemptionAmountMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Early Redemption Amount, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EarlyRedemptionAmountMeasurementInputMember" xlink:href="abvx-20251231.xsd#abvx_EarlyRedemptionAmountMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_EarlyRedemptionAmountMeasurementInputMember" xlink:to="lab_abvx_EarlyRedemptionAmountMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfDetailedInformationAboutOtherReceivablesAndOtherAssetsTableTextBlock_1028cec5-e6fe-4d4e-88a8-efef3d6badaa_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfDetailedInformationAboutOtherReceivablesAndOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of other receivables and other assets</link:label>
    <link:label id="lab_abvx_DisclosureOfDetailedInformationAboutOtherReceivablesAndOtherAssetsTableTextBlock_label_en-US" xlink:label="lab_abvx_DisclosureOfDetailedInformationAboutOtherReceivablesAndOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Other Receivables And Other Assets [Table Text Block]</link:label>
    <link:label id="lab_abvx_DisclosureOfDetailedInformationAboutOtherReceivablesAndOtherAssetsTableTextBlock_documentation_en-US" xlink:label="lab_abvx_DisclosureOfDetailedInformationAboutOtherReceivablesAndOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Other Receivables And Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfDetailedInformationAboutOtherReceivablesAndOtherAssetsTableTextBlock" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfDetailedInformationAboutOtherReceivablesAndOtherAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfDetailedInformationAboutOtherReceivablesAndOtherAssetsTableTextBlock" xlink:to="lab_abvx_DisclosureOfDetailedInformationAboutOtherReceivablesAndOtherAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestPaidClassifiedAsFinancingActivities_93d83e06-8852-432c-87cb-079b761103e7_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_ifrs-full_InterestPaidClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest paid, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed_ce0a2786-1dc6-4a65-abf4-4fe9de8c0977_terseLabel_en-US" xlink:label="lab_abvx_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense relating to short-term leases</link:label>
    <link:label id="lab_abvx_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed_label_en-US" xlink:label="lab_abvx_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense Relating To Short-Term Leases And Low Value Assets For Which Recognition Exemption Has Been Used</link:label>
    <link:label id="lab_abvx_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed_documentation_en-US" xlink:label="lab_abvx_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expense Relating To Short-Term Leases And Low Value Assets For Which Recognition Exemption Has Been Used</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:href="abvx-20251231.xsd#abvx_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:to="lab_abvx_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_InterestExpenseOnRoyaltyCertificates_c8db3a9e-ab86-4bca-bdbd-dd86431b16b5_negatedTerseLabel_en-US" xlink:label="lab_abvx_InterestExpenseOnRoyaltyCertificates" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest on royalty certificates</link:label>
    <link:label id="lab_abvx_InterestExpenseOnRoyaltyCertificates_label_en-US" xlink:label="lab_abvx_InterestExpenseOnRoyaltyCertificates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense On Royalty Certificates</link:label>
    <link:label id="lab_abvx_InterestExpenseOnRoyaltyCertificates_documentation_en-US" xlink:label="lab_abvx_InterestExpenseOnRoyaltyCertificates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Expense On Royalty Certificates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_InterestExpenseOnRoyaltyCertificates" xlink:href="abvx-20251231.xsd#abvx_InterestExpenseOnRoyaltyCertificates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_InterestExpenseOnRoyaltyCertificates" xlink:to="lab_abvx_InterestExpenseOnRoyaltyCertificates" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_InitialPriceLimitMeasurementInputMember_e9dba606-49d6-4a53-aa1a-ce9817a9a07b_terseLabel_en-US" xlink:label="lab_abvx_InitialPriceLimitMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial price limit (in euro per share)</link:label>
    <link:label id="lab_abvx_InitialPriceLimitMeasurementInputMember_label_en-US" xlink:label="lab_abvx_InitialPriceLimitMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Price Limit, Measurement Input [Member]</link:label>
    <link:label id="lab_abvx_InitialPriceLimitMeasurementInputMember_documentation_en-US" xlink:label="lab_abvx_InitialPriceLimitMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initial Price Limit, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_InitialPriceLimitMeasurementInputMember" xlink:href="abvx-20251231.xsd#abvx_InitialPriceLimitMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_InitialPriceLimitMeasurementInputMember" xlink:to="lab_abvx_InitialPriceLimitMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ForeignExchangeLoss_ae03b3e7-eba0-4097-8d08-8e8d527b3bdf_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ForeignExchangeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange losses</link:label>
    <link:label id="lab_ifrs-full_ForeignExchangeLoss_558531dd-b666-4655-b4f0-6042a9dcdd52_terseLabel_en-US" xlink:label="lab_ifrs-full_ForeignExchangeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange loss</link:label>
    <link:label id="lab_ifrs-full_ForeignExchangeLoss_label_en-US" xlink:label="lab_ifrs-full_ForeignExchangeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign exchange loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ForeignExchangeLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ForeignExchangeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ForeignExchangeLoss" xlink:to="lab_ifrs-full_ForeignExchangeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComputerSoftwareMember_83fb612b-9b0a-4e2f-8c18-ee3c2863bb1e_terseLabel_en-US" xlink:label="lab_ifrs-full_ComputerSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SOFTWARE</link:label>
    <link:label id="lab_ifrs-full_ComputerSoftwareMember_label_en-US" xlink:label="lab_ifrs-full_ComputerSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer software [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComputerSoftwareMember" xlink:to="lab_ifrs-full_ComputerSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ConvertibleLoansNotesNominalValue_0e259445-1178-4a5e-9604-400e5f896de2_terseLabel_en-US" xlink:label="lab_abvx_ConvertibleLoansNotesNominalValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible loan notes, nominal value</link:label>
    <link:label id="lab_abvx_ConvertibleLoansNotesNominalValue_label_en-US" xlink:label="lab_abvx_ConvertibleLoansNotesNominalValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Loans Notes, Nominal Value</link:label>
    <link:label id="lab_abvx_ConvertibleLoansNotesNominalValue_documentation_en-US" xlink:label="lab_abvx_ConvertibleLoansNotesNominalValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Loans Notes, Nominal Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotesNominalValue" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotesNominalValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ConvertibleLoansNotesNominalValue" xlink:to="lab_abvx_ConvertibleLoansNotesNominalValue" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NumberOfWarrantsOutstanding_1e6da927-1f74-46ca-aa29-fdead75b32e7_terseLabel_en-US" xlink:label="lab_abvx_NumberOfWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of outstanding warrants (in shares)</link:label>
    <link:label id="lab_abvx_NumberOfWarrantsOutstanding_label_en-US" xlink:label="lab_abvx_NumberOfWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Warrants Outstanding</link:label>
    <link:label id="lab_abvx_NumberOfWarrantsOutstanding_documentation_en-US" xlink:label="lab_abvx_NumberOfWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Warrants Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfWarrantsOutstanding" xlink:href="abvx-20251231.xsd#abvx_NumberOfWarrantsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NumberOfWarrantsOutstanding" xlink:to="lab_abvx_NumberOfWarrantsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Cash_d2136a20-d866-45c5-b284-98dd4e282a9b_terseLabel_en-US" xlink:label="lab_ifrs-full_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_ifrs-full_Cash_label_en-US" xlink:label="lab_ifrs-full_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Cash" xlink:to="lab_ifrs-full_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RelatedPartyTransactionsAbstract_79e9e5e2-6dad-427f-980c-85e7b57eb91d_terseLabel_en-US" xlink:label="lab_ifrs-full_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party transactions [abstract]</link:label>
    <link:label id="lab_ifrs-full_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_ifrs-full_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related party transactions [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="lab_ifrs-full_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ConvertibleLoansNotesMember_f33b762e-5143-43c4-9ddb-b0490a49f515_terseLabel_en-US" xlink:label="lab_abvx_ConvertibleLoansNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible loan notes</link:label>
    <link:label id="lab_abvx_ConvertibleLoansNotesMember_label_en-US" xlink:label="lab_abvx_ConvertibleLoansNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Loans Notes [Member]</link:label>
    <link:label id="lab_abvx_ConvertibleLoansNotesMember_documentation_en-US" xlink:label="lab_abvx_ConvertibleLoansNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Loans Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotesMember" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ConvertibleLoansNotesMember" xlink:to="lab_abvx_ConvertibleLoansNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentPhase3_78fbebe7-b0cf-4a39-b5c5-adfb20063016_terseLabel_en-US" xlink:label="lab_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentPhase3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential development milestone payment, phase 3</link:label>
    <link:label id="lab_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentPhase3_label_en-US" xlink:label="lab_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentPhase3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Potential Development Milestone Payment, Phase 3</link:label>
    <link:label id="lab_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentPhase3_documentation_en-US" xlink:label="lab_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentPhase3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Potential Development Milestone Payment, Phase 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentPhase3" xlink:href="abvx-20251231.xsd#abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentPhase3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentPhase3" xlink:to="lab_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentPhase3" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted_a1c0d3e0-861a-4930-bf00-51f76613b99a_verboseLabel_en-US" xlink:label="lab_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">FAIR VALUE OF THE BSA (in euro per share)</link:label>
    <link:label id="lab_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted_23d47c0d-5735-4f25-ad3e-28cdcebec3a3_terseLabel_en-US" xlink:label="lab_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAIR VALUE OF THE AGA (in euro per share)</link:label>
    <link:label id="lab_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Instrument Fair Value, Other Equity Instruments Granted</link:label>
    <link:label id="lab_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Instrument Fair Value, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted" xlink:href="abvx-20251231.xsd#abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted" xlink:to="lab_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ResearchAndCollaborationAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember_9fe7ca8b-ff92-4e74-8e79-42312a6a7d1d_terseLabel_en-US" xlink:label="lab_abvx_ResearchAndCollaborationAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and collaboration agreement with CNRS, University of Montpellier and Institut Curie</link:label>
    <link:label id="lab_abvx_ResearchAndCollaborationAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember_label_en-US" xlink:label="lab_abvx_ResearchAndCollaborationAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Collaboration Agreement With CNRS, University Of Montpellier And Institut Curie [Member]</link:label>
    <link:label id="lab_abvx_ResearchAndCollaborationAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember_documentation_en-US" xlink:label="lab_abvx_ResearchAndCollaborationAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Collaboration Agreement With CNRS, University Of Montpellier And Institut Curie</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ResearchAndCollaborationAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember" xlink:href="abvx-20251231.xsd#abvx_ResearchAndCollaborationAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ResearchAndCollaborationAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember" xlink:to="lab_abvx_ResearchAndCollaborationAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_c378d50d-c8ed-4429-8081-36ac1883d258_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows provided by (used in) investing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_1fd0fd1e-66ed-4cf0-9055-79ca1b5d4523_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Off-Balance Sheet Commitments [Line Items]</link:label>
    <link:label id="lab_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_label_en-US" xlink:label="lab_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Off-Balance Sheet Commitments [Line Items]</link:label>
    <link:label id="lab_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_documentation_en-US" xlink:label="lab_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Off-Balance Sheet Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems" xlink:to="lab_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities_019bff99-d057-7f5e-8fe7-6b824ff93af8_terseLabel_en-US" xlink:label="lab_abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in carrying value due to reasonably possible decrease in unobservable input liabilities</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities_label_en-US" xlink:label="lab_abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Carrying Value Due To Reasonably Possible Decrease In Unobservable Input Liabilities</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities_documentation_en-US" xlink:label="lab_abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Carrying Value Due To Reasonably Possible Decrease In Unobservable Input Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:to="lab_abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AGA20241Member_96fc11c3-989b-4476-93d7-e88fddde5d3c_terseLabel_en-US" xlink:label="lab_abvx_AGA20241Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA-2024-1</link:label>
    <link:label id="lab_abvx_AGA20241Member_label_en-US" xlink:label="lab_abvx_AGA20241Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA-2024-1 [Member]</link:label>
    <link:label id="lab_abvx_AGA20241Member_documentation_en-US" xlink:label="lab_abvx_AGA20241Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA-2024-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20241Member" xlink:href="abvx-20251231.xsd#abvx_AGA20241Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AGA20241Member" xlink:to="lab_abvx_AGA20241Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BorrowingsMaturityExtensionTerm_a31528da-56b8-4fb9-9675-eb3e1b68f35b_terseLabel_en-US" xlink:label="lab_abvx_BorrowingsMaturityExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings maturity, extension term</link:label>
    <link:label id="lab_abvx_BorrowingsMaturityExtensionTerm_label_en-US" xlink:label="lab_abvx_BorrowingsMaturityExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings Maturity, Extension Term</link:label>
    <link:label id="lab_abvx_BorrowingsMaturityExtensionTerm_documentation_en-US" xlink:label="lab_abvx_BorrowingsMaturityExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowings Maturity, Extension Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsMaturityExtensionTerm" xlink:href="abvx-20251231.xsd#abvx_BorrowingsMaturityExtensionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BorrowingsMaturityExtensionTerm" xlink:to="lab_abvx_BorrowingsMaturityExtensionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_24a7ca7b-832f-464c-bf67-e952607ce563_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for determining components of cash and cash equivalents [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_EquityIssuanceCashCarveOut_f94e7268-24fe-4911-9602-b37bbe43cde7_terseLabel_en-US" xlink:label="lab_abvx_EquityIssuanceCashCarveOut" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity issuance, cash carve-out</link:label>
    <link:label id="lab_abvx_EquityIssuanceCashCarveOut_label_en-US" xlink:label="lab_abvx_EquityIssuanceCashCarveOut" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Issuance, Cash Carve-Out</link:label>
    <link:label id="lab_abvx_EquityIssuanceCashCarveOut_documentation_en-US" xlink:label="lab_abvx_EquityIssuanceCashCarveOut" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Issuance, Cash Carve-Out</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EquityIssuanceCashCarveOut" xlink:href="abvx-20251231.xsd#abvx_EquityIssuanceCashCarveOut"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_EquityIssuanceCashCarveOut" xlink:to="lab_abvx_EquityIssuanceCashCarveOut" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities_019c5737-bd84-71e2-805e-5a6345b3c2a6_terseLabel_en-US" xlink:label="lab_abvx_IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash changes: conversion into shares</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_abvx_IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Conversion Into Shares, Liabilities Arising From Financing Activities</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities_documentation_en-US" xlink:label="lab_abvx_IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Conversion Into Shares, Liabilities Arising From Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities" xlink:to="lab_abvx_IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_KreosClaretFinancingTrancheABMember_377216f6-c37f-4431-8cc1-d68446578b32_terseLabel_en-US" xlink:label="lab_abvx_KreosClaretFinancingTrancheABMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret financing, tranche A-B</link:label>
    <link:label id="lab_abvx_KreosClaretFinancingTrancheABMember_label_en-US" xlink:label="lab_abvx_KreosClaretFinancingTrancheABMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret Financing, Tranche A-B [Member]</link:label>
    <link:label id="lab_abvx_KreosClaretFinancingTrancheABMember_documentation_en-US" xlink:label="lab_abvx_KreosClaretFinancingTrancheABMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret Financing, Tranche A-B</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheABMember" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheABMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_KreosClaretFinancingTrancheABMember" xlink:to="lab_abvx_KreosClaretFinancingTrancheABMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AGA20233Member_95a65209-d818-4b18-b24e-303dbcbd031c_terseLabel_en-US" xlink:label="lab_abvx_AGA20233Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA-2023-3</link:label>
    <link:label id="lab_abvx_AGA20233Member_label_en-US" xlink:label="lab_abvx_AGA20233Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA-2023-3 [Member]</link:label>
    <link:label id="lab_abvx_AGA20233Member_documentation_en-US" xlink:label="lab_abvx_AGA20233Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA-2023-3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20233Member" xlink:href="abvx-20251231.xsd#abvx_AGA20233Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AGA20233Member" xlink:to="lab_abvx_AGA20233Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_cf73366d-8757-4bed-9010-3d603d8122ea_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares based compensation expense</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_8eda72b9-b86a-46b2-864b-1659d878f6ab_terseLabel_en-US" xlink:label="lab_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of number of shares outstanding [abstract]</link:label>
    <link:label id="lab_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of number of shares outstanding [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract" xlink:to="lab_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DecreaseInLeaseLiabilities_ec4c2e3f-e51d-4583-a95a-ac62a3d54cdb_negatedTerseLabel_en-US" xlink:label="lab_abvx_DecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease</link:label>
    <link:label id="lab_abvx_DecreaseInLeaseLiabilities_label_en-US" xlink:label="lab_abvx_DecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease In Lease Liabilities</link:label>
    <link:label id="lab_abvx_DecreaseInLeaseLiabilities_documentation_en-US" xlink:label="lab_abvx_DecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Decrease In Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DecreaseInLeaseLiabilities" xlink:href="abvx-20251231.xsd#abvx_DecreaseInLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DecreaseInLeaseLiabilities" xlink:to="lab_abvx_DecreaseInLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_bfdbc614-3356-4529-9f9c-b38fcd4bcd4a_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ConvertibleLoansNotesNumberOfSeparateClosings_20b64415-5e1a-4b4f-a4d1-5a22eb2fc696_terseLabel_en-US" xlink:label="lab_abvx_ConvertibleLoansNotesNumberOfSeparateClosings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible loan notes, number of separate closings</link:label>
    <link:label id="lab_abvx_ConvertibleLoansNotesNumberOfSeparateClosings_label_en-US" xlink:label="lab_abvx_ConvertibleLoansNotesNumberOfSeparateClosings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Loans Notes, Number Of Separate Closings</link:label>
    <link:label id="lab_abvx_ConvertibleLoansNotesNumberOfSeparateClosings_documentation_en-US" xlink:label="lab_abvx_ConvertibleLoansNotesNumberOfSeparateClosings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Loans Notes, Number Of Separate Closings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotesNumberOfSeparateClosings" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotesNumberOfSeparateClosings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ConvertibleLoansNotesNumberOfSeparateClosings" xlink:to="lab_abvx_ConvertibleLoansNotesNumberOfSeparateClosings" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfAccountingPolicyForAccountingJudgementsAndEstimatesExplanatoryPolicyTextBlock_3e3869a4-aa79-4ae4-a141-4f27430b345a_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfAccountingPolicyForAccountingJudgementsAndEstimatesExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of judgments and estimates</link:label>
    <link:label id="lab_abvx_DisclosureOfAccountingPolicyForAccountingJudgementsAndEstimatesExplanatoryPolicyTextBlock_label_en-US" xlink:label="lab_abvx_DisclosureOfAccountingPolicyForAccountingJudgementsAndEstimatesExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Accounting Policy For Accounting Judgements And Estimates Explanatory [Policy Text Block]</link:label>
    <link:label id="lab_abvx_DisclosureOfAccountingPolicyForAccountingJudgementsAndEstimatesExplanatoryPolicyTextBlock_documentation_en-US" xlink:label="lab_abvx_DisclosureOfAccountingPolicyForAccountingJudgementsAndEstimatesExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Accounting Policy For Accounting Judgements And Estimates Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfAccountingPolicyForAccountingJudgementsAndEstimatesExplanatoryPolicyTextBlock" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfAccountingPolicyForAccountingJudgementsAndEstimatesExplanatoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfAccountingPolicyForAccountingJudgementsAndEstimatesExplanatoryPolicyTextBlock" xlink:to="lab_abvx_DisclosureOfAccountingPolicyForAccountingJudgementsAndEstimatesExplanatoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_b5e01f26-cdc7-45a8-a434-b9ecf68951de_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation differences</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, exchange differences on translation of foreign operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssets_d01715b1-7a4a-4558-9f7f-c059af992a31_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="lab_ifrs-full_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_e2291a62-f250-4547-9da2-683ca26d2a60_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis for derivative financial liabilities [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis for derivative financial liabilities [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AGA20233AndAGA20234Member_5a5c69ec-0912-4c5d-a826-992452de42a8_terseLabel_en-US" xlink:label="lab_abvx_AGA20233AndAGA20234Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA-2023-3 and AGA-2023-4</link:label>
    <link:label id="lab_abvx_AGA20233AndAGA20234Member_label_en-US" xlink:label="lab_abvx_AGA20233AndAGA20234Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA-2023-3 And AGA-2023-4 [Member]</link:label>
    <link:label id="lab_abvx_AGA20233AndAGA20234Member_documentation_en-US" xlink:label="lab_abvx_AGA20233AndAGA20234Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA-2023-3 And AGA-2023-4</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20233AndAGA20234Member" xlink:href="abvx-20251231.xsd#abvx_AGA20233AndAGA20234Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AGA20233AndAGA20234Member" xlink:to="lab_abvx_AGA20233AndAGA20234Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_4a324c7d-0e5f-4ce2-96fd-cf5f9db8ee41_terseLabel_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share issue related cost</link:label>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_label_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share issue related cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareIssueRelatedCost" xlink:to="lab_ifrs-full_ShareIssueRelatedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDefinedBenefitPlansTable_4c89f4c5-66d1-4f24-9b68-d370c166e905_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of defined benefit plans [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDefinedBenefitPlansTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of defined benefit plans [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:to="lab_ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_RemeasurementPeriodDomain_e2c93f56-efa5-4e38-911b-1d848d3e3ecd_terseLabel_en-US" xlink:label="lab_abvx_RemeasurementPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remeasurement Period [Domain]</link:label>
    <link:label id="lab_abvx_RemeasurementPeriodDomain_label_en-US" xlink:label="lab_abvx_RemeasurementPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remeasurement Period [Domain]</link:label>
    <link:label id="lab_abvx_RemeasurementPeriodDomain_documentation_en-US" xlink:label="lab_abvx_RemeasurementPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Remeasurement Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RemeasurementPeriodDomain" xlink:href="abvx-20251231.xsd#abvx_RemeasurementPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_RemeasurementPeriodDomain" xlink:to="lab_abvx_RemeasurementPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NonCurrentConvertibleLoansNotes_75b09e4b-c978-4b1a-aa8c-091e7b735834_terseLabel_en-US" xlink:label="lab_abvx_NonCurrentConvertibleLoansNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible loan notes</link:label>
    <link:label id="lab_abvx_NonCurrentConvertibleLoansNotes_label_en-US" xlink:label="lab_abvx_NonCurrentConvertibleLoansNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Current Convertible Loans Notes</link:label>
    <link:label id="lab_abvx_NonCurrentConvertibleLoansNotes_documentation_en-US" xlink:label="lab_abvx_NonCurrentConvertibleLoansNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Current Convertible Loans Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NonCurrentConvertibleLoansNotes" xlink:href="abvx-20251231.xsd#abvx_NonCurrentConvertibleLoansNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NonCurrentConvertibleLoansNotes" xlink:to="lab_abvx_NonCurrentConvertibleLoansNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_18a95d1a-0cae-4c78-8adb-17bd88de5595_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromExerciseOfWarrants_50f66e46-0bb4-4149-b146-85c426d46379_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of warrants</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromExerciseOfWarrants_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromExerciseOfWarrants" xlink:to="lab_ifrs-full_ProceedsFromExerciseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis_ce9e5aae-2d1d-4e70-b9e9-e7d0dd293c92_terseLabel_en-US" xlink:label="lab_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash-generating units [axis]</link:label>
    <link:label id="lab_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis_label_en-US" xlink:label="lab_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash-generating units [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis" xlink:to="lab_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_20e31a10-6967-4cc8-a828-967b6b127dcf_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [domain]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfOtherReceivablesAndOtherAssetsTable_d9ea72ce-f325-4867-a418-d422f77c52fa_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfOtherReceivablesAndOtherAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Receivables And Other Assets [Table]</link:label>
    <link:label id="lab_abvx_DisclosureOfOtherReceivablesAndOtherAssetsTable_label_en-US" xlink:label="lab_abvx_DisclosureOfOtherReceivablesAndOtherAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Receivables And Other Assets [Table]</link:label>
    <link:label id="lab_abvx_DisclosureOfOtherReceivablesAndOtherAssetsTable_documentation_en-US" xlink:label="lab_abvx_DisclosureOfOtherReceivablesAndOtherAssetsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Receivables And Other Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfOtherReceivablesAndOtherAssetsTable" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfOtherReceivablesAndOtherAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfOtherReceivablesAndOtherAssetsTable" xlink:to="lab_abvx_DisclosureOfOtherReceivablesAndOtherAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_455ed4e3-bca3-4028-abdc-539cd9d2f503_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_IncreaseDecreaseInTransversalActivitiesCombinationTherapy_019cd7fb-00dd-7d57-85ad-079432419311_terseLabel_en-US" xlink:label="lab_abvx_IncreaseDecreaseInTransversalActivitiesCombinationTherapy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in transversal activities, combination therapy</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseInTransversalActivitiesCombinationTherapy_label_en-US" xlink:label="lab_abvx_IncreaseDecreaseInTransversalActivitiesCombinationTherapy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Transversal Activities, Combination Therapy</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseInTransversalActivitiesCombinationTherapy_documentation_en-US" xlink:label="lab_abvx_IncreaseDecreaseInTransversalActivitiesCombinationTherapy" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Transversal Activities, Combination Therapy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInTransversalActivitiesCombinationTherapy" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInTransversalActivitiesCombinationTherapy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_IncreaseDecreaseInTransversalActivitiesCombinationTherapy" xlink:to="lab_abvx_IncreaseDecreaseInTransversalActivitiesCombinationTherapy" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ConvertibleLoansNotesUndiscountedCashFlows_0d379166-4e16-4ae5-854a-284b0c11294d_terseLabel_en-US" xlink:label="lab_abvx_ConvertibleLoansNotesUndiscountedCashFlows" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible loans notes, undiscounted cash flows</link:label>
    <link:label id="lab_abvx_ConvertibleLoansNotesUndiscountedCashFlows_label_en-US" xlink:label="lab_abvx_ConvertibleLoansNotesUndiscountedCashFlows" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Loans Notes, Undiscounted Cash Flows</link:label>
    <link:label id="lab_abvx_ConvertibleLoansNotesUndiscountedCashFlows_documentation_en-US" xlink:label="lab_abvx_ConvertibleLoansNotesUndiscountedCashFlows" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Loans Notes, Undiscounted Cash Flows</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotesUndiscountedCashFlows" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotesUndiscountedCashFlows"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ConvertibleLoansNotesUndiscountedCashFlows" xlink:to="lab_abvx_ConvertibleLoansNotesUndiscountedCashFlows" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_578c9d46-3255-4525-972c-a2f2ba43ab20_terseLabel_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in intangible assets other than goodwill [abstract]</link:label>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_label_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in intangible assets other than goodwill [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract" xlink:to="lab_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants_71344c5c-8c1f-4234-8545-a96b3d6e6371_terseLabel_en-US" xlink:label="lab_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercises of share warrants (in shares)</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants_label_en-US" xlink:label="lab_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Number Of Shares Issued Through Exercise Of Share Warrants</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants_documentation_en-US" xlink:label="lab_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Number Of Shares Issued Through Exercise Of Share Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants" xlink:to="lab_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_InterestExpenseOnRoyaltyCertificatesIncludingTheUnwindingOfDiscount_019cc355-1afa-702a-b245-c3c773f3a866_terseLabel_en-US" xlink:label="lab_abvx_InterestExpenseOnRoyaltyCertificatesIncludingTheUnwindingOfDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense on royalty certificates, including the unwinding of discount</link:label>
    <link:label id="lab_abvx_InterestExpenseOnRoyaltyCertificatesIncludingTheUnwindingOfDiscount_label_en-US" xlink:label="lab_abvx_InterestExpenseOnRoyaltyCertificatesIncludingTheUnwindingOfDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense On Royalty Certificates, Including The Unwinding Of Discount</link:label>
    <link:label id="lab_abvx_InterestExpenseOnRoyaltyCertificatesIncludingTheUnwindingOfDiscount_documentation_en-US" xlink:label="lab_abvx_InterestExpenseOnRoyaltyCertificatesIncludingTheUnwindingOfDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Expense On Royalty Certificates, Including The Unwinding Of Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_InterestExpenseOnRoyaltyCertificatesIncludingTheUnwindingOfDiscount" xlink:href="abvx-20251231.xsd#abvx_InterestExpenseOnRoyaltyCertificatesIncludingTheUnwindingOfDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_InterestExpenseOnRoyaltyCertificatesIncludingTheUnwindingOfDiscount" xlink:to="lab_abvx_InterestExpenseOnRoyaltyCertificatesIncludingTheUnwindingOfDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_TrancheCMember_b9cbd895-a950-47a5-9fd5-786cd0fdadc5_terseLabel_en-US" xlink:label="lab_abvx_TrancheCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche C</link:label>
    <link:label id="lab_abvx_TrancheCMember_label_en-US" xlink:label="lab_abvx_TrancheCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche C [Member]</link:label>
    <link:label id="lab_abvx_TrancheCMember_documentation_en-US" xlink:label="lab_abvx_TrancheCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche C</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheCMember" xlink:href="abvx-20251231.xsd#abvx_TrancheCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_TrancheCMember" xlink:to="lab_abvx_TrancheCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ConvertibleLoansNotesPeriod_999a5aec-5074-4265-b8e8-4530888bc527_terseLabel_en-US" xlink:label="lab_abvx_ConvertibleLoansNotesPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible loan notes, period</link:label>
    <link:label id="lab_abvx_ConvertibleLoansNotesPeriod_label_en-US" xlink:label="lab_abvx_ConvertibleLoansNotesPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Loans Notes, Period</link:label>
    <link:label id="lab_abvx_ConvertibleLoansNotesPeriod_documentation_en-US" xlink:label="lab_abvx_ConvertibleLoansNotesPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Loans Notes, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotesPeriod" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotesPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ConvertibleLoansNotesPeriod" xlink:to="lab_abvx_ConvertibleLoansNotesPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_a9d10946-b407-4923-bcd9-c96062742db5_terseLabel_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of movements in exchange rates on cash held</link:label>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestReceivedClassifiedAsInvestingActivities_df9f0197-14a0-437e-b5c6-d4ecf381e254_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest received</link:label>
    <link:label id="lab_ifrs-full_InterestReceivedClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest received, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestReceivedClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_Kreos1ConvertibleBondLoansMember_a2d5a2cb-5a39-4ac3-83b2-11b78fde8e01_terseLabel_en-US" xlink:label="lab_abvx_Kreos1ConvertibleBondLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kreos 1, convertible bond loans</link:label>
    <link:label id="lab_abvx_Kreos1ConvertibleBondLoansMember_label_en-US" xlink:label="lab_abvx_Kreos1ConvertibleBondLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kreos 1, Convertible Bond Loans [Member]</link:label>
    <link:label id="lab_abvx_Kreos1ConvertibleBondLoansMember_documentation_en-US" xlink:label="lab_abvx_Kreos1ConvertibleBondLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kreos 1, Convertible Bond Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1ConvertibleBondLoansMember" xlink:href="abvx-20251231.xsd#abvx_Kreos1ConvertibleBondLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_Kreos1ConvertibleBondLoansMember" xlink:to="lab_abvx_Kreos1ConvertibleBondLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_VoluntaryConversionScenarioProbabilityMeasurementInputMember_ce861958-de94-4075-bd7b-70ddfbbd98ed_terseLabel_en-US" xlink:label="lab_abvx_VoluntaryConversionScenarioProbabilityMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Held to maturity / voluntary conversion scenario probability</link:label>
    <link:label id="lab_abvx_VoluntaryConversionScenarioProbabilityMeasurementInputMember_label_en-US" xlink:label="lab_abvx_VoluntaryConversionScenarioProbabilityMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Voluntary Conversion Scenario Probability, Measurement Input [Member]</link:label>
    <link:label id="lab_abvx_VoluntaryConversionScenarioProbabilityMeasurementInputMember_documentation_en-US" xlink:label="lab_abvx_VoluntaryConversionScenarioProbabilityMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Voluntary Conversion Scenario Probability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VoluntaryConversionScenarioProbabilityMeasurementInputMember" xlink:href="abvx-20251231.xsd#abvx_VoluntaryConversionScenarioProbabilityMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_VoluntaryConversionScenarioProbabilityMeasurementInputMember" xlink:to="lab_abvx_VoluntaryConversionScenarioProbabilityMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_ffe5be31-bae8-4cfa-9106-f1f22b7f48cc_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Translation of transactions denominated in foreign currency</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ForeignExchangeGainsLossesOnTranslationOfForeignOperations_6eb0af04-9005-46db-8cbc-1eba16c2e979_terseLabel_en-US" xlink:label="lab_abvx_ForeignExchangeGainsLossesOnTranslationOfForeignOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation differences gains (loss)</link:label>
    <link:label id="lab_abvx_ForeignExchangeGainsLossesOnTranslationOfForeignOperations_label_en-US" xlink:label="lab_abvx_ForeignExchangeGainsLossesOnTranslationOfForeignOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Gains (Losses) On Translation Of Foreign Operations</link:label>
    <link:label id="lab_abvx_ForeignExchangeGainsLossesOnTranslationOfForeignOperations_documentation_en-US" xlink:label="lab_abvx_ForeignExchangeGainsLossesOnTranslationOfForeignOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign Exchange Gains (Losses) On Translation Of Foreign Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ForeignExchangeGainsLossesOnTranslationOfForeignOperations" xlink:href="abvx-20251231.xsd#abvx_ForeignExchangeGainsLossesOnTranslationOfForeignOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ForeignExchangeGainsLossesOnTranslationOfForeignOperations" xlink:to="lab_abvx_ForeignExchangeGainsLossesOnTranslationOfForeignOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsForDebtIssueCosts_8d2211b0-3b2b-45cb-9a57-2bcbf848512e_terseLabel_en-US" xlink:label="lab_ifrs-full_PaymentsForDebtIssueCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for debt issue costs</link:label>
    <link:label id="lab_ifrs-full_PaymentsForDebtIssueCosts_label_en-US" xlink:label="lab_ifrs-full_PaymentsForDebtIssueCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for debt issue costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForDebtIssueCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsForDebtIssueCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsForDebtIssueCosts" xlink:to="lab_ifrs-full_PaymentsForDebtIssueCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets_019d007f-c848-7009-9e3d-e0a52b4bfcbe_verboseLabel_en-US" xlink:label="lab_abvx_DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_abvx_DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets_label_en-US" xlink:label="lab_abvx_DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities (Assets) Net of Unrecognized Liabilities (Assets)</link:label>
    <link:label id="lab_abvx_DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets_documentation_en-US" xlink:label="lab_abvx_DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities (Assets) Net of Unrecognized Liabilities (Assets)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets" xlink:href="abvx-20251231.xsd#abvx_DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets" xlink:to="lab_abvx_DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_dd826aae-2b13-4ea1-b340-47c8d87058a1_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_9cf86263-dd21-41f5-9cf0-0a1f1fdebb2b_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_RoyaltyCertificatesEIR_bfdbb5fd-2289-4392-b3fe-301a134dce62_terseLabel_en-US" xlink:label="lab_abvx_RoyaltyCertificatesEIR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty certificates, EIR</link:label>
    <link:label id="lab_abvx_RoyaltyCertificatesEIR_label_en-US" xlink:label="lab_abvx_RoyaltyCertificatesEIR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Certificates, EIR</link:label>
    <link:label id="lab_abvx_RoyaltyCertificatesEIR_documentation_en-US" xlink:label="lab_abvx_RoyaltyCertificatesEIR" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Certificates, EIR</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificatesEIR" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificatesEIR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_RoyaltyCertificatesEIR" xlink:to="lab_abvx_RoyaltyCertificatesEIR" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_KreosClaretFinancingMember_7f71f12c-f86f-4e0a-a06b-008c9e3792b3_terseLabel_en-US" xlink:label="lab_abvx_KreosClaretFinancingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret financing</link:label>
    <link:label id="lab_abvx_KreosClaretFinancingMember_label_en-US" xlink:label="lab_abvx_KreosClaretFinancingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret Financing [Member]</link:label>
    <link:label id="lab_abvx_KreosClaretFinancingMember_documentation_en-US" xlink:label="lab_abvx_KreosClaretFinancingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret Financing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingMember" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_KreosClaretFinancingMember" xlink:to="lab_abvx_KreosClaretFinancingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BSA20241Member_2745b57e-3a95-4724-a52c-f64e3daac4e5_terseLabel_en-US" xlink:label="lab_abvx_BSA20241Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSA-2024-1</link:label>
    <link:label id="lab_abvx_BSA20241Member_label_en-US" xlink:label="lab_abvx_BSA20241Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSA-2024-1 [Member]</link:label>
    <link:label id="lab_abvx_BSA20241Member_documentation_en-US" xlink:label="lab_abvx_BSA20241Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BSA-2024-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20241Member" xlink:href="abvx-20251231.xsd#abvx_BSA20241Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BSA20241Member" xlink:to="lab_abvx_BSA20241Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable_9769b816-b0c4-4b50-bff5-7cf29964a2be_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GeographicalAreasDomain_162ee1c8-7d8f-4c01-9c1e-54487119c231_terseLabel_en-US" xlink:label="lab_ifrs-full_GeographicalAreasDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical areas [domain]</link:label>
    <link:label id="lab_ifrs-full_GeographicalAreasDomain_label_en-US" xlink:label="lab_ifrs-full_GeographicalAreasDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical areas [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeographicalAreasDomain" xlink:to="lab_ifrs-full_GeographicalAreasDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInPropertyPlantAndEquipmentIncludingRightofuseAssetsExplanatory_f47735e0-0dba-44bb-8298-33dbe320503f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInPropertyPlantAndEquipmentIncludingRightofuseAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInPropertyPlantAndEquipmentIncludingRightofuseAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInPropertyPlantAndEquipmentIncludingRightofuseAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in property, plant and equipment, including right-of-use assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInPropertyPlantAndEquipmentIncludingRightofuseAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInPropertyPlantAndEquipmentIncludingRightofuseAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInPropertyPlantAndEquipmentIncludingRightofuseAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfChangesInPropertyPlantAndEquipmentIncludingRightofuseAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BorrowingsStateGuaranteedPremium_2ef4f3c6-5922-47f0-a146-d3feecfc5351_terseLabel_en-US" xlink:label="lab_abvx_BorrowingsStateGuaranteedPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, state guaranteed premium</link:label>
    <link:label id="lab_abvx_BorrowingsStateGuaranteedPremium_label_en-US" xlink:label="lab_abvx_BorrowingsStateGuaranteedPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, State Guaranteed Premium</link:label>
    <link:label id="lab_abvx_BorrowingsStateGuaranteedPremium_documentation_en-US" xlink:label="lab_abvx_BorrowingsStateGuaranteedPremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowings, State Guaranteed Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsStateGuaranteedPremium" xlink:href="abvx-20251231.xsd#abvx_BorrowingsStateGuaranteedPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BorrowingsStateGuaranteedPremium" xlink:to="lab_abvx_BorrowingsStateGuaranteedPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_a03289d6-1979-4b2a-abc9-8998e2cb539b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Management and assessment of financial risks</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial risk management [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_9bcba3f9-77d2-418f-a814-25bcf8c9c192_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_SensitivityAnalysisForTypesOfMarketRisk10FavorableChangeInExchangeRateImpactOnForeignExchangeGainLoss_019c0018-ca0c-71c6-87b4-10b381a7d329_terseLabel_en-US" xlink:label="lab_abvx_SensitivityAnalysisForTypesOfMarketRisk10FavorableChangeInExchangeRateImpactOnForeignExchangeGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Favorable change in exchange rate, impact on foreign exchange gain</link:label>
    <link:label id="lab_abvx_SensitivityAnalysisForTypesOfMarketRisk10FavorableChangeInExchangeRateImpactOnForeignExchangeGainLoss_label_en-US" xlink:label="lab_abvx_SensitivityAnalysisForTypesOfMarketRisk10FavorableChangeInExchangeRateImpactOnForeignExchangeGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, 10% Favorable Change in Exchange Rate, Impact On Foreign Exchange Gain (Loss)</link:label>
    <link:label id="lab_abvx_SensitivityAnalysisForTypesOfMarketRisk10FavorableChangeInExchangeRateImpactOnForeignExchangeGainLoss_documentation_en-US" xlink:label="lab_abvx_SensitivityAnalysisForTypesOfMarketRisk10FavorableChangeInExchangeRateImpactOnForeignExchangeGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, 10% Favorable Change in Exchange Rate, Impact On Foreign Exchange Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SensitivityAnalysisForTypesOfMarketRisk10FavorableChangeInExchangeRateImpactOnForeignExchangeGainLoss" xlink:href="abvx-20251231.xsd#abvx_SensitivityAnalysisForTypesOfMarketRisk10FavorableChangeInExchangeRateImpactOnForeignExchangeGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_SensitivityAnalysisForTypesOfMarketRisk10FavorableChangeInExchangeRateImpactOnForeignExchangeGainLoss" xlink:to="lab_abvx_SensitivityAnalysisForTypesOfMarketRisk10FavorableChangeInExchangeRateImpactOnForeignExchangeGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties_019d0074-4039-7e6a-a992-321d2a836127_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivables due from related parties</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables due from related parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" xlink:to="lab_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities_a8fb3425-46b7-4c16-bfc6-3c7e27d517e4_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease in financial liabilities at fair value</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bff09-52d7-7c00-800b-d03e0462a176_verboseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, liabilities</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities_325b5103-7596-4175-aae1-58628a630480_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in financial liabilities at fair value due to reasonably possible increase in unobservable input</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:to="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_f2c19729-b0fb-429e-94a4-a79fdc5abd6d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of attribution of expenses by nature to their function [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of attribution of expenses by nature to their function [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:to="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceCosts_f756f90d-b5c8-4782-b664-d78f56918b52_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Financial expenses</link:label>
    <link:label id="lab_ifrs-full_FinanceCosts_c85aa36f-a987-42d2-9877-364be047b08b_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Financial expenses</link:label>
    <link:label id="lab_ifrs-full_FinanceCosts_label_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceCosts" xlink:to="lab_ifrs-full_FinanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory_5eafc711-7b41-407c-b323-396f06b3d84e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of other financial assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities_89e1a597-232c-4d56-9fc8-7ec8dcc5db24_terseLabel_en-US" xlink:label="lab_abvx_IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash changes&#160;: subsidies</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_abvx_IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Subsidies, Liabilities Arising From Financing Activities</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities_documentation_en-US" xlink:label="lab_abvx_IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Subsidies, Liabilities Arising From Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities" xlink:to="lab_abvx_IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncomeTaxExpense_019c4335-5d20-7195-a624-03c27203a877_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current and deferred taxes expenses</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncomeTaxExpense_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for income tax expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncomeTaxExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:to="lab_ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCreditRiskExposureTable_a3e51ccd-6cbb-4095-8ed0-498ec67a0042_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCreditRiskExposureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of credit risk exposure [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCreditRiskExposureTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCreditRiskExposureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of credit risk exposure [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCreditRiskExposureTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfCreditRiskExposureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureTable" xlink:to="lab_ifrs-full_DisclosureOfCreditRiskExposureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_cb511e16-406d-42ab-a963-778548e23b1b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting principles</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of material accounting policy information [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:to="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity_87a09615-8033-40f3-8d77-8ffbb34cdd32_terseLabel_en-US" xlink:label="lab_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum drawdown capacity</link:label>
    <link:label id="lab_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity_label_en-US" xlink:label="lab_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Financial Liabilities, Maximum Drawdown Capacity</link:label>
    <link:label id="lab_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity_documentation_en-US" xlink:label="lab_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Financial Liabilities, Maximum Drawdown Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity" xlink:to="lab_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ConvertibleLoansNotesEarlyRedemptionAmountPercentageOfOutstandongPrincipal_d15ac14c-b9c0-4e95-9ba1-e50f676f9f92_terseLabel_en-US" xlink:label="lab_abvx_ConvertibleLoansNotesEarlyRedemptionAmountPercentageOfOutstandongPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Early redemption amount, percentage of outstandong principal</link:label>
    <link:label id="lab_abvx_ConvertibleLoansNotesEarlyRedemptionAmountPercentageOfOutstandongPrincipal_label_en-US" xlink:label="lab_abvx_ConvertibleLoansNotesEarlyRedemptionAmountPercentageOfOutstandongPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Loans Notes, Early Redemption Amount, Percentage Of Outstandong Principal</link:label>
    <link:label id="lab_abvx_ConvertibleLoansNotesEarlyRedemptionAmountPercentageOfOutstandongPrincipal_documentation_en-US" xlink:label="lab_abvx_ConvertibleLoansNotesEarlyRedemptionAmountPercentageOfOutstandongPrincipal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Loans Notes, Early Redemption Amount, Percentage Of Outstandong Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotesEarlyRedemptionAmountPercentageOfOutstandongPrincipal" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotesEarlyRedemptionAmountPercentageOfOutstandongPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ConvertibleLoansNotesEarlyRedemptionAmountPercentageOfOutstandongPrincipal" xlink:to="lab_abvx_ConvertibleLoansNotesEarlyRedemptionAmountPercentageOfOutstandongPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_LeaseDurationPeriod_c3960768-d1a2-46d8-9260-deaa78325d93_terseLabel_en-US" xlink:label="lab_abvx_LeaseDurationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease, duration period</link:label>
    <link:label id="lab_abvx_LeaseDurationPeriod_label_en-US" xlink:label="lab_abvx_LeaseDurationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Duration Period</link:label>
    <link:label id="lab_abvx_LeaseDurationPeriod_documentation_en-US" xlink:label="lab_abvx_LeaseDurationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease, Duration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LeaseDurationPeriod" xlink:href="abvx-20251231.xsd#abvx_LeaseDurationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_LeaseDurationPeriod" xlink:to="lab_abvx_LeaseDurationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_3eed97e3-16e0-40f2-8156-b4e0dfe77381_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacityIncludingInterest_55a351ea-8729-4704-9df9-9d1e438071db_terseLabel_en-US" xlink:label="lab_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacityIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum drawdown capacity including interest</link:label>
    <link:label id="lab_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacityIncludingInterest_label_en-US" xlink:label="lab_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacityIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Financial Liabilities, Maximum Drawdown Capacity Including Interest</link:label>
    <link:label id="lab_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacityIncludingInterest_documentation_en-US" xlink:label="lab_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacityIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Financial Liabilities, Maximum Drawdown Capacity Including Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacityIncludingInterest" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacityIncludingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacityIncludingInterest" xlink:to="lab_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacityIncludingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NumberOfConvertibleNotesOutstanding_4ca51f48-7df8-4d3a-955d-389ea0db2210_terseLabel_en-US" xlink:label="lab_abvx_NumberOfConvertibleNotesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of outstanding notes (in shares)</link:label>
    <link:label id="lab_abvx_NumberOfConvertibleNotesOutstanding_label_en-US" xlink:label="lab_abvx_NumberOfConvertibleNotesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Convertible Notes Outstanding</link:label>
    <link:label id="lab_abvx_NumberOfConvertibleNotesOutstanding_documentation_en-US" xlink:label="lab_abvx_NumberOfConvertibleNotesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Convertible Notes Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfConvertibleNotesOutstanding" xlink:href="abvx-20251231.xsd#abvx_NumberOfConvertibleNotesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NumberOfConvertibleNotesOutstanding" xlink:to="lab_abvx_NumberOfConvertibleNotesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AGA20232Member_91c7cabd-cf73-411f-aa6a-90c7695e2b0d_terseLabel_en-US" xlink:label="lab_abvx_AGA20232Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA-2023-2</link:label>
    <link:label id="lab_abvx_AGA20232Member_label_en-US" xlink:label="lab_abvx_AGA20232Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA-2023-2 [Member]</link:label>
    <link:label id="lab_abvx_AGA20232Member_documentation_en-US" xlink:label="lab_abvx_AGA20232Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA-2023-2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20232Member" xlink:href="abvx-20251231.xsd#abvx_AGA20232Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AGA20232Member" xlink:to="lab_abvx_AGA20232Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_SensitivityAnalysisForTypesOfMarketRisk10AdverseChangeInExchangeRateImpactOnForeignExchangeGainLoss_019c001b-ee21-7917-b4f0-c1f9eb904b8f_negatedTerseLabel_en-US" xlink:label="lab_abvx_SensitivityAnalysisForTypesOfMarketRisk10AdverseChangeInExchangeRateImpactOnForeignExchangeGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Adverse change in exchange rate, impact on foreign exchange loss</link:label>
    <link:label id="lab_abvx_SensitivityAnalysisForTypesOfMarketRisk10AdverseChangeInExchangeRateImpactOnForeignExchangeGainLoss_label_en-US" xlink:label="lab_abvx_SensitivityAnalysisForTypesOfMarketRisk10AdverseChangeInExchangeRateImpactOnForeignExchangeGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, 10% Adverse Change in Exchange Rate, Impact On Foreign Exchange Gain (Loss)</link:label>
    <link:label id="lab_abvx_SensitivityAnalysisForTypesOfMarketRisk10AdverseChangeInExchangeRateImpactOnForeignExchangeGainLoss_documentation_en-US" xlink:label="lab_abvx_SensitivityAnalysisForTypesOfMarketRisk10AdverseChangeInExchangeRateImpactOnForeignExchangeGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, 10% Adverse Change in Exchange Rate, Impact On Foreign Exchange Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SensitivityAnalysisForTypesOfMarketRisk10AdverseChangeInExchangeRateImpactOnForeignExchangeGainLoss" xlink:href="abvx-20251231.xsd#abvx_SensitivityAnalysisForTypesOfMarketRisk10AdverseChangeInExchangeRateImpactOnForeignExchangeGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_SensitivityAnalysisForTypesOfMarketRisk10AdverseChangeInExchangeRateImpactOnForeignExchangeGainLoss" xlink:to="lab_abvx_SensitivityAnalysisForTypesOfMarketRisk10AdverseChangeInExchangeRateImpactOnForeignExchangeGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_ee2d5ecb-7326-4aa1-9805-f824e6daad05_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ReclassificationOfPrepaidExpensesToCarryingValueOfDebtComponent_d2c95820-1295-41da-a50e-a349926aed56_terseLabel_en-US" xlink:label="lab_abvx_ReclassificationOfPrepaidExpensesToCarryingValueOfDebtComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of prepaid expenses to carrying value of debt component</link:label>
    <link:label id="lab_abvx_ReclassificationOfPrepaidExpensesToCarryingValueOfDebtComponent_label_en-US" xlink:label="lab_abvx_ReclassificationOfPrepaidExpensesToCarryingValueOfDebtComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification of Prepaid Expenses to Carrying Value of Debt Component</link:label>
    <link:label id="lab_abvx_ReclassificationOfPrepaidExpensesToCarryingValueOfDebtComponent_documentation_en-US" xlink:label="lab_abvx_ReclassificationOfPrepaidExpensesToCarryingValueOfDebtComponent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reclassification of Prepaid Expenses to Carrying Value of Debt Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ReclassificationOfPrepaidExpensesToCarryingValueOfDebtComponent" xlink:href="abvx-20251231.xsd#abvx_ReclassificationOfPrepaidExpensesToCarryingValueOfDebtComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ReclassificationOfPrepaidExpensesToCarryingValueOfDebtComponent" xlink:to="lab_abvx_ReclassificationOfPrepaidExpensesToCarryingValueOfDebtComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_3161ac11-e65c-4835-8e0c-62ef2f231295_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Items that are or may be reclassified subsequently to profit or loss</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income that will be reclassified to profit or loss, net of tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_bc4fcaf4-ca2b-4e21-948d-f683c9587e38_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of cash and cash equivalents [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NonCurrentPrepaidExpenses_33e04ca5-2aad-451c-a057-24cae8518271_terseLabel_en-US" xlink:label="lab_abvx_NonCurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses - non current</link:label>
    <link:label id="lab_abvx_NonCurrentPrepaidExpenses_label_en-US" xlink:label="lab_abvx_NonCurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Current Prepaid Expenses</link:label>
    <link:label id="lab_abvx_NonCurrentPrepaidExpenses_documentation_en-US" xlink:label="lab_abvx_NonCurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Current Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NonCurrentPrepaidExpenses" xlink:href="abvx-20251231.xsd#abvx_NonCurrentPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NonCurrentPrepaidExpenses" xlink:to="lab_abvx_NonCurrentPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfessionalFeesExpense_e18eeea1-ddec-460e-bf2c-083347297c4c_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfessionalFeesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consulting and professional fees</link:label>
    <link:label id="lab_ifrs-full_ProfessionalFeesExpense_label_en-US" xlink:label="lab_ifrs-full_ProfessionalFeesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Professional fees expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfessionalFeesExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfessionalFeesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfessionalFeesExpense" xlink:to="lab_ifrs-full_ProfessionalFeesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_df840f38-4f8d-4593-9f0e-49f5de8c02dd_terseLabel_en-US" xlink:label="lab_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation techniques used in fair value measurement [axis]</link:label>
    <link:label id="lab_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_label_en-US" xlink:label="lab_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation techniques used in fair value measurement [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis" xlink:to="lab_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_CashPaymentsForDeposits_74125794-130f-4f57-aa6f-ee08fbc3da2c_negatedTerseLabel_en-US" xlink:label="lab_abvx_CashPaymentsForDeposits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Increase in deposits</link:label>
    <link:label id="lab_abvx_CashPaymentsForDeposits_label_en-US" xlink:label="lab_abvx_CashPaymentsForDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Payments For Deposits</link:label>
    <link:label id="lab_abvx_CashPaymentsForDeposits_documentation_en-US" xlink:label="lab_abvx_CashPaymentsForDeposits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Payments For Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CashPaymentsForDeposits" xlink:href="abvx-20251231.xsd#abvx_CashPaymentsForDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_CashPaymentsForDeposits" xlink:to="lab_abvx_CashPaymentsForDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsRemainingPercentageExercisable_e136f540-523f-477d-a86d-cf186579d4aa_terseLabel_en-US" xlink:label="lab_abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsRemainingPercentageExercisable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of instruments granted, remaining percentage exercisable</link:label>
    <link:label id="lab_abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsRemainingPercentageExercisable_label_en-US" xlink:label="lab_abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsRemainingPercentageExercisable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Instruments Granted, Other Equity Instruments, Remaining Percentage Exercisable</link:label>
    <link:label id="lab_abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsRemainingPercentageExercisable_documentation_en-US" xlink:label="lab_abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsRemainingPercentageExercisable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Instruments Granted, Other Equity Instruments, Remaining Percentage Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsRemainingPercentageExercisable" xlink:href="abvx-20251231.xsd#abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsRemainingPercentageExercisable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsRemainingPercentageExercisable" xlink:to="lab_abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsRemainingPercentageExercisable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseOnDebtInstrumentsIssued_91ba7a8b-1b25-48b1-aa6c-be0ea6cb7b4f_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnDebtInstrumentsIssued" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest on convertible loan notes</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnDebtInstrumentsIssued_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnDebtInstrumentsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense on debt instruments issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnDebtInstrumentsIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnDebtInstrumentsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnDebtInstrumentsIssued" xlink:to="lab_ifrs-full_InterestExpenseOnDebtInstrumentsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_KreosBBSAMember_4a674e5e-d869-49a8-9bab-9140ded0e1d2_terseLabel_en-US" xlink:label="lab_abvx_KreosBBSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kreos B BSA</link:label>
    <link:label id="lab_abvx_KreosBBSAMember_label_en-US" xlink:label="lab_abvx_KreosBBSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kreos B BSA [Member]</link:label>
    <link:label id="lab_abvx_KreosBBSAMember_documentation_en-US" xlink:label="lab_abvx_KreosBBSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kreos B BSA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosBBSAMember" xlink:href="abvx-20251231.xsd#abvx_KreosBBSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_KreosBBSAMember" xlink:to="lab_abvx_KreosBBSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ProceedsFromBorrowingsNetOfRefinancingOfExistingIndebteness_5a562be5-babc-4d77-98ff-466d5f09c7c7_terseLabel_en-US" xlink:label="lab_abvx_ProceedsFromBorrowingsNetOfRefinancingOfExistingIndebteness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from borrowings, net of refinancing of existing indebteness</link:label>
    <link:label id="lab_abvx_ProceedsFromBorrowingsNetOfRefinancingOfExistingIndebteness_label_en-US" xlink:label="lab_abvx_ProceedsFromBorrowingsNetOfRefinancingOfExistingIndebteness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Borrowings, Net Of Refinancing Of Existing Indebteness</link:label>
    <link:label id="lab_abvx_ProceedsFromBorrowingsNetOfRefinancingOfExistingIndebteness_documentation_en-US" xlink:label="lab_abvx_ProceedsFromBorrowingsNetOfRefinancingOfExistingIndebteness" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Borrowings, Net Of Refinancing Of Existing Indebteness</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ProceedsFromBorrowingsNetOfRefinancingOfExistingIndebteness" xlink:href="abvx-20251231.xsd#abvx_ProceedsFromBorrowingsNetOfRefinancingOfExistingIndebteness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ProceedsFromBorrowingsNetOfRefinancingOfExistingIndebteness" xlink:to="lab_abvx_ProceedsFromBorrowingsNetOfRefinancingOfExistingIndebteness" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfAverageNumberOfEmployeesTableTextBlock_d3a5431d-d88e-4f86-ab10-5e2638580024_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfAverageNumberOfEmployeesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of average workforce during the periods</link:label>
    <link:label id="lab_abvx_DisclosureOfAverageNumberOfEmployeesTableTextBlock_label_en-US" xlink:label="lab_abvx_DisclosureOfAverageNumberOfEmployeesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Average Number Of Employees [Table Text Block]</link:label>
    <link:label id="lab_abvx_DisclosureOfAverageNumberOfEmployeesTableTextBlock_documentation_en-US" xlink:label="lab_abvx_DisclosureOfAverageNumberOfEmployeesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Average Number Of Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfAverageNumberOfEmployeesTableTextBlock" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfAverageNumberOfEmployeesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfAverageNumberOfEmployeesTableTextBlock" xlink:to="lab_abvx_DisclosureOfAverageNumberOfEmployeesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_a9e81f43-4f88-4150-a9e7-74f6a6ecc823_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for deferred income tax [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_f98866fd-19f6-4b64-9fb1-4ef7e0fdc3b5_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities_1db370ba-2b33-4235-9a4a-ad03e31ecf5e_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from government grants</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from government grants, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_OtherFinancialLiabilitiesRepaymentPeriod_3312c029-316b-4f1e-8ada-5eef9310e2b3_terseLabel_en-US" xlink:label="lab_abvx_OtherFinancialLiabilitiesRepaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayment period</link:label>
    <link:label id="lab_abvx_OtherFinancialLiabilitiesRepaymentPeriod_label_en-US" xlink:label="lab_abvx_OtherFinancialLiabilitiesRepaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Financial Liabilities, Repayment Period</link:label>
    <link:label id="lab_abvx_OtherFinancialLiabilitiesRepaymentPeriod_documentation_en-US" xlink:label="lab_abvx_OtherFinancialLiabilitiesRepaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Financial Liabilities, Repayment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialLiabilitiesRepaymentPeriod" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialLiabilitiesRepaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_OtherFinancialLiabilitiesRepaymentPeriod" xlink:to="lab_abvx_OtherFinancialLiabilitiesRepaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_d9fe2e16-d72b-4a71-88a4-9b9fe263180b_terseLabel_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in property, plant and equipment [abstract]</link:label>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in property, plant and equipment [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:to="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_1edebf50-34ce-4d0b-93fb-a3f7b52dc1be_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DiscountedCashFlowMember_98992cb3-2303-4c02-aa13-78f7d869ac3e_terseLabel_en-US" xlink:label="lab_ifrs-full_DiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discounted cash flow</link:label>
    <link:label id="lab_ifrs-full_DiscountedCashFlowMember_label_en-US" xlink:label="lab_ifrs-full_DiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discounted cash flow [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DiscountedCashFlowMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DiscountedCashFlowMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DiscountedCashFlowMember" xlink:to="lab_ifrs-full_DiscountedCashFlowMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ExpectedProceedsFromShareIssuance_49222828-b135-4677-936a-d8590da62969_terseLabel_en-US" xlink:label="lab_abvx_ExpectedProceedsFromShareIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected proceeds from share issuance</link:label>
    <link:label id="lab_abvx_ExpectedProceedsFromShareIssuance_label_en-US" xlink:label="lab_abvx_ExpectedProceedsFromShareIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Proceeds From Share Issuance</link:label>
    <link:label id="lab_abvx_ExpectedProceedsFromShareIssuance_documentation_en-US" xlink:label="lab_abvx_ExpectedProceedsFromShareIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected Proceeds From Share Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpectedProceedsFromShareIssuance" xlink:href="abvx-20251231.xsd#abvx_ExpectedProceedsFromShareIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ExpectedProceedsFromShareIssuance" xlink:to="lab_abvx_ExpectedProceedsFromShareIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember_42b1bb35-dbf6-41be-96e3-ae1f0cf51cae_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FROM 2 TO 5 YEARS</link:label>
    <link:label id="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than two years and not later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_18276956-1b92-4397-a6c4-dcff6cc4b97b_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_OtherShareWarrantsSubscriptionPricePerShare_52b5dc19-7359-4eef-b4e9-831406bf3ded_terseLabel_en-US" xlink:label="lab_abvx_OtherShareWarrantsSubscriptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other share warrants, subscripion price per share (in euro per share)</link:label>
    <link:label id="lab_abvx_OtherShareWarrantsSubscriptionPricePerShare_label_en-US" xlink:label="lab_abvx_OtherShareWarrantsSubscriptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Share Warrants, Subscription Price Per Share</link:label>
    <link:label id="lab_abvx_OtherShareWarrantsSubscriptionPricePerShare_documentation_en-US" xlink:label="lab_abvx_OtherShareWarrantsSubscriptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Share Warrants, Subscription Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherShareWarrantsSubscriptionPricePerShare" xlink:href="abvx-20251231.xsd#abvx_OtherShareWarrantsSubscriptionPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_OtherShareWarrantsSubscriptionPricePerShare" xlink:to="lab_abvx_OtherShareWarrantsSubscriptionPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BCE20181Member_366b7cb3-cf36-48b6-82b3-20a1593d22b9_terseLabel_en-US" xlink:label="lab_abvx_BCE20181Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BCE-2018-1</link:label>
    <link:label id="lab_abvx_BCE20181Member_label_en-US" xlink:label="lab_abvx_BCE20181Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BCE-2018-1 [Member]</link:label>
    <link:label id="lab_abvx_BCE20181Member_documentation_en-US" xlink:label="lab_abvx_BCE20181Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BCE-2018-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BCE20181Member" xlink:href="abvx-20251231.xsd#abvx_BCE20181Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BCE20181Member" xlink:to="lab_abvx_BCE20181Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_04135c15-20d3-43ee-85c7-a4e7ba36b884_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:to="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_RoyaltyCertificatesUndiscountedCashFlows_a10a6f9a-b06e-4b06-8600-9030dabdb828_terseLabel_en-US" xlink:label="lab_abvx_RoyaltyCertificatesUndiscountedCashFlows" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty certificates, undiscounted cash flows</link:label>
    <link:label id="lab_abvx_RoyaltyCertificatesUndiscountedCashFlows_label_en-US" xlink:label="lab_abvx_RoyaltyCertificatesUndiscountedCashFlows" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Certificates, Undiscounted Cash Flows</link:label>
    <link:label id="lab_abvx_RoyaltyCertificatesUndiscountedCashFlows_documentation_en-US" xlink:label="lab_abvx_RoyaltyCertificatesUndiscountedCashFlows" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Certificates, Undiscounted Cash Flows</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificatesUndiscountedCashFlows" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificatesUndiscountedCashFlows"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_RoyaltyCertificatesUndiscountedCashFlows" xlink:to="lab_abvx_RoyaltyCertificatesUndiscountedCashFlows" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife_eb9f7165-60d7-42a1-b8e5-c0acc58a36c2_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets with indefinite useful life</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets with indefinite useful life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife" xlink:to="lab_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AuditorsRemunerationForAuditServices_ad9d87c9-26b8-4a03-b623-fdc882a2bc89_terseLabel_en-US" xlink:label="lab_ifrs-full_AuditorsRemunerationForAuditServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Audit fees</link:label>
    <link:label id="lab_ifrs-full_AuditorsRemunerationForAuditServices_label_en-US" xlink:label="lab_ifrs-full_AuditorsRemunerationForAuditServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor's remuneration for audit services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemunerationForAuditServices" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AuditorsRemunerationForAuditServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AuditorsRemunerationForAuditServices" xlink:to="lab_ifrs-full_AuditorsRemunerationForAuditServices" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NonCurrentAdvancesToCROContractsMember_0ea8fadd-8f4b-412b-9dd7-7eff6e483bd6_terseLabel_en-US" xlink:label="lab_abvx_NonCurrentAdvancesToCROContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term advances made to CROs</link:label>
    <link:label id="lab_abvx_NonCurrentAdvancesToCROContractsMember_label_en-US" xlink:label="lab_abvx_NonCurrentAdvancesToCROContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Current Advances To CRO Contracts [Member]</link:label>
    <link:label id="lab_abvx_NonCurrentAdvancesToCROContractsMember_documentation_en-US" xlink:label="lab_abvx_NonCurrentAdvancesToCROContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Current Advances To CRO Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NonCurrentAdvancesToCROContractsMember" xlink:href="abvx-20251231.xsd#abvx_NonCurrentAdvancesToCROContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NonCurrentAdvancesToCROContractsMember" xlink:to="lab_abvx_NonCurrentAdvancesToCROContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities_6222d528-ab51-4eb6-9631-59ac67ebfec1_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Percentage of reasonably possible decrease in unobservable input, liabilities</link:label>
    <link:label id="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities_label_en-US" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of reasonably possible decrease in unobservable input, liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:to="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_eac1650a-487d-450a-8f1a-5824b7b00a75_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_FairValueMeasurementAbstract_label_en-US" xlink:label="lab_abvx_FairValueMeasurementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Abstract]</link:label>
    <link:label id="lab_abvx_FairValueMeasurementAbstract_documentation_en-US" xlink:label="lab_abvx_FairValueMeasurementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FairValueMeasurementAbstract" xlink:href="abvx-20251231.xsd#abvx_FairValueMeasurementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_FairValueMeasurementAbstract" xlink:to="lab_abvx_FairValueMeasurementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_IssuanceOfDerivativeInstruments_c8e7933d-636d-4083-a4a5-dd1edaccc5b7_terseLabel_en-US" xlink:label="lab_abvx_IssuanceOfDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance</link:label>
    <link:label id="lab_abvx_IssuanceOfDerivativeInstruments_label_en-US" xlink:label="lab_abvx_IssuanceOfDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance Of Derivative Instruments</link:label>
    <link:label id="lab_abvx_IssuanceOfDerivativeInstruments_documentation_en-US" xlink:label="lab_abvx_IssuanceOfDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance Of Derivative Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IssuanceOfDerivativeInstruments" xlink:href="abvx-20251231.xsd#abvx_IssuanceOfDerivativeInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_IssuanceOfDerivativeInstruments" xlink:to="lab_abvx_IssuanceOfDerivativeInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_8288c799-e953-482a-b1d3-3b34b3430cd3_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement benefit obligations</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in employee benefit liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BanquePubliqueDInvestissementBPIMember_61d37a4c-7dc8-49ef-94fd-5e4a543c14bc_terseLabel_en-US" xlink:label="lab_abvx_BanquePubliqueDInvestissementBPIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conditional advances Bpifrance</link:label>
    <link:label id="lab_abvx_BanquePubliqueDInvestissementBPIMember_label_en-US" xlink:label="lab_abvx_BanquePubliqueDInvestissementBPIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Banque Publique d&#8217;Investissement (BPI) [Member]</link:label>
    <link:label id="lab_abvx_BanquePubliqueDInvestissementBPIMember_documentation_en-US" xlink:label="lab_abvx_BanquePubliqueDInvestissementBPIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Banque Publique d&#8217;Investissement (BPI)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BanquePubliqueDInvestissementBPIMember" xlink:href="abvx-20251231.xsd#abvx_BanquePubliqueDInvestissementBPIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BanquePubliqueDInvestissementBPIMember" xlink:to="lab_abvx_BanquePubliqueDInvestissementBPIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss_6534264c-eca0-4c31-8d12-cdb3a8f7be1a_terseLabel_en-US" xlink:label="lab_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of breakdown of the compensation expenses</link:label>
    <link:label id="lab_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Explanation of effect of share-based payments on entity's profit or loss [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss" xlink:to="lab_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NumberOfOperatingSegment_6511bc2f-e4b8-4089-97cb-4a8ea37d707b_terseLabel_en-US" xlink:label="lab_abvx_NumberOfOperatingSegment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_abvx_NumberOfOperatingSegment_label_en-US" xlink:label="lab_abvx_NumberOfOperatingSegment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segment</link:label>
    <link:label id="lab_abvx_NumberOfOperatingSegment_documentation_en-US" xlink:label="lab_abvx_NumberOfOperatingSegment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Operating Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfOperatingSegment" xlink:href="abvx-20251231.xsd#abvx_NumberOfOperatingSegment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NumberOfOperatingSegment" xlink:to="lab_abvx_NumberOfOperatingSegment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:to="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsTable_d749372e-89cd-431a-907a-a0a248ee2928_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet_1671abeb-0a25-498b-a277-1558d50f5eb4_terseLabel_en-US" xlink:label="lab_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum number of shares to be issued if all conditions are met (in shares)</link:label>
    <link:label id="lab_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet_label_en-US" xlink:label="lab_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Number Of Other Equity Instruments To Be Issued In Share-Based Payment Arrangement If All Conditions Are Met</link:label>
    <link:label id="lab_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet_documentation_en-US" xlink:label="lab_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum Number Of Other Equity Instruments To Be Issued In Share-Based Payment Arrangement If All Conditions Are Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet" xlink:href="abvx-20251231.xsd#abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet" xlink:to="lab_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_669f4454-673c-45f6-990c-ec1574cc748b_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_5dafd707-d30d-4dc9-b5ba-fb962e1b2d40_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of instruments exercisable (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_TransactionCosts_e08d3a3f-bc9c-4498-9788-15a6b529c5b6_negatedLabel_en-US" xlink:label="lab_abvx_TransactionCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_abvx_TransactionCosts_label_en-US" xlink:label="lab_abvx_TransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction Costs</link:label>
    <link:label id="lab_abvx_TransactionCosts_documentation_en-US" xlink:label="lab_abvx_TransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TransactionCosts" xlink:href="abvx-20251231.xsd#abvx_TransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_TransactionCosts" xlink:to="lab_abvx_TransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_aaae6988-ea16-4123-abfe-0fd1a573eb1d_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfOffBalanceSheetCommitmentsTable_87ce3039-fbbb-40a6-9810-7e98162cac89_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfOffBalanceSheetCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Off-Balance Sheet Commitments [Table]</link:label>
    <link:label id="lab_abvx_DisclosureOfOffBalanceSheetCommitmentsTable_label_en-US" xlink:label="lab_abvx_DisclosureOfOffBalanceSheetCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Off-Balance Sheet Commitments [Table]</link:label>
    <link:label id="lab_abvx_DisclosureOfOffBalanceSheetCommitmentsTable_documentation_en-US" xlink:label="lab_abvx_DisclosureOfOffBalanceSheetCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Off-Balance Sheet Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsTable" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfOffBalanceSheetCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsTable" xlink:to="lab_abvx_DisclosureOfOffBalanceSheetCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NumberOfShareWarrantsIssued_37ef2f05-95c2-43f9-b53a-46900b6ce676_terseLabel_en-US" xlink:label="lab_abvx_NumberOfShareWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued (in shares)</link:label>
    <link:label id="lab_abvx_NumberOfShareWarrantsIssued_label_en-US" xlink:label="lab_abvx_NumberOfShareWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Share Warrants Issued</link:label>
    <link:label id="lab_abvx_NumberOfShareWarrantsIssued_documentation_en-US" xlink:label="lab_abvx_NumberOfShareWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Share Warrants Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfShareWarrantsIssued" xlink:href="abvx-20251231.xsd#abvx_NumberOfShareWarrantsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NumberOfShareWarrantsIssued" xlink:to="lab_abvx_NumberOfShareWarrantsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxEffectOfForeignTaxRates_dca6eb4e-4cfb-4e2a-82b1-6fda70a8955f_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxEffectOfForeignTaxRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax rates in foreign jurisdictions</link:label>
    <link:label id="lab_ifrs-full_TaxEffectOfForeignTaxRates_label_en-US" xlink:label="lab_ifrs-full_TaxEffectOfForeignTaxRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax effect of foreign tax rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfForeignTaxRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TaxEffectOfForeignTaxRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectOfForeignTaxRates" xlink:to="lab_ifrs-full_TaxEffectOfForeignTaxRates" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BSA20252Member_019bfaed-dcc8-7cff-b717-39910bb045da_terseLabel_en-US" xlink:label="lab_abvx_BSA20252Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSA-2025-2</link:label>
    <link:label id="lab_abvx_BSA20252Member_label_en-US" xlink:label="lab_abvx_BSA20252Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSA-2025-2 [Member]</link:label>
    <link:label id="lab_abvx_BSA20252Member_documentation_en-US" xlink:label="lab_abvx_BSA20252Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BSA-2025-2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20252Member" xlink:href="abvx-20251231.xsd#abvx_BSA20252Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BSA20252Member" xlink:to="lab_abvx_BSA20252Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_TaxEffectOfTransactionCostsRelatedToCapitalIncrease_0cc2b4a3-8a9f-4a9d-9cca-4329634c3564_terseLabel_en-US" xlink:label="lab_abvx_TaxEffectOfTransactionCostsRelatedToCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs related to capital increase</link:label>
    <link:label id="lab_abvx_TaxEffectOfTransactionCostsRelatedToCapitalIncrease_label_en-US" xlink:label="lab_abvx_TaxEffectOfTransactionCostsRelatedToCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Effect Of Transaction Costs Related To Capital Increase</link:label>
    <link:label id="lab_abvx_TaxEffectOfTransactionCostsRelatedToCapitalIncrease_documentation_en-US" xlink:label="lab_abvx_TaxEffectOfTransactionCostsRelatedToCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Effect Of Transaction Costs Related To Capital Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TaxEffectOfTransactionCostsRelatedToCapitalIncrease" xlink:href="abvx-20251231.xsd#abvx_TaxEffectOfTransactionCostsRelatedToCapitalIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_TaxEffectOfTransactionCostsRelatedToCapitalIncrease" xlink:to="lab_abvx_TaxEffectOfTransactionCostsRelatedToCapitalIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_7719665f-e826-4ff3-a56e-7007349159a7_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_OtherFinancialAssetsMember_dbe8f5db-9e00-43d9-8e6c-cc8f9bf622f8_terseLabel_en-US" xlink:label="lab_abvx_OtherFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial assets</link:label>
    <link:label id="lab_abvx_OtherFinancialAssetsMember_label_en-US" xlink:label="lab_abvx_OtherFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Financial Assets [Member]</link:label>
    <link:label id="lab_abvx_OtherFinancialAssetsMember_documentation_en-US" xlink:label="lab_abvx_OtherFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Financial Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialAssetsMember" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_OtherFinancialAssetsMember" xlink:to="lab_abvx_OtherFinancialAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LongtermDeposits_1a46b09e-3b52-4530-a1cd-ae41b0dadb96_terseLabel_en-US" xlink:label="lab_ifrs-full_LongtermDeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deposits</link:label>
    <link:label id="lab_ifrs-full_LongtermDeposits_label_en-US" xlink:label="lab_ifrs-full_LongtermDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermDeposits" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LongtermDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LongtermDeposits" xlink:to="lab_ifrs-full_LongtermDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BorrowingsFixedConversionPrice_bc31d8b4-7810-4632-88ce-65969c43c59a_terseLabel_en-US" xlink:label="lab_abvx_BorrowingsFixedConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, fixed conversion price (in euro per share)</link:label>
    <link:label id="lab_abvx_BorrowingsFixedConversionPrice_label_en-US" xlink:label="lab_abvx_BorrowingsFixedConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, Fixed Conversion Price</link:label>
    <link:label id="lab_abvx_BorrowingsFixedConversionPrice_documentation_en-US" xlink:label="lab_abvx_BorrowingsFixedConversionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowings, Fixed Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsFixedConversionPrice" xlink:href="abvx-20251231.xsd#abvx_BorrowingsFixedConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BorrowingsFixedConversionPrice" xlink:to="lab_abvx_BorrowingsFixedConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ProceedsFromResearchTaxCredit_cc75e151-920f-4c36-a9ee-56c0dfaf4436_terseLabel_en-US" xlink:label="lab_abvx_ProceedsFromResearchTaxCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from research tax credit</link:label>
    <link:label id="lab_abvx_ProceedsFromResearchTaxCredit_label_en-US" xlink:label="lab_abvx_ProceedsFromResearchTaxCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Research Tax Credit</link:label>
    <link:label id="lab_abvx_ProceedsFromResearchTaxCredit_documentation_en-US" xlink:label="lab_abvx_ProceedsFromResearchTaxCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Research Tax Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ProceedsFromResearchTaxCredit" xlink:href="abvx-20251231.xsd#abvx_ProceedsFromResearchTaxCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ProceedsFromResearchTaxCredit" xlink:to="lab_abvx_ProceedsFromResearchTaxCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_CurrentPayablesOnOtherTaxAndRelatedPayments_0295011e-3e68-42f8-807d-7f8f96f2e3d1_terseLabel_en-US" xlink:label="lab_abvx_CurrentPayablesOnOtherTaxAndRelatedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other tax and related payments</link:label>
    <link:label id="lab_abvx_CurrentPayablesOnOtherTaxAndRelatedPayments_label_en-US" xlink:label="lab_abvx_CurrentPayablesOnOtherTaxAndRelatedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Payables On Other Tax And Related Payments</link:label>
    <link:label id="lab_abvx_CurrentPayablesOnOtherTaxAndRelatedPayments_documentation_en-US" xlink:label="lab_abvx_CurrentPayablesOnOtherTaxAndRelatedPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current Payables On Other Tax And Related Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentPayablesOnOtherTaxAndRelatedPayments" xlink:href="abvx-20251231.xsd#abvx_CurrentPayablesOnOtherTaxAndRelatedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_CurrentPayablesOnOtherTaxAndRelatedPayments" xlink:to="lab_abvx_CurrentPayablesOnOtherTaxAndRelatedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentFinancialLiabilities_0f761d60-6e84-4df9-9619-8f1e18862117_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial liabilities</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="lab_ifrs-full_OtherCurrentFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_2505f578-e74b-4385-a4b1-97831da33426_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NetProceedsFromConvertibleLoansNotes_54f81959-27ad-44b8-b007-3f52ce0d450a_terseLabel_en-US" xlink:label="lab_abvx_NetProceedsFromConvertibleLoansNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from convertible loan notes</link:label>
    <link:label id="lab_abvx_NetProceedsFromConvertibleLoansNotes_label_en-US" xlink:label="lab_abvx_NetProceedsFromConvertibleLoansNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Proceeds From Convertible Loans Notes</link:label>
    <link:label id="lab_abvx_NetProceedsFromConvertibleLoansNotes_documentation_en-US" xlink:label="lab_abvx_NetProceedsFromConvertibleLoansNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Proceeds From Convertible Loans Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NetProceedsFromConvertibleLoansNotes" xlink:href="abvx-20251231.xsd#abvx_NetProceedsFromConvertibleLoansNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NetProceedsFromConvertibleLoansNotes" xlink:to="lab_abvx_NetProceedsFromConvertibleLoansNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_TranchesAxis_f8e17a35-5b7a-4393-87b5-24f486e03f31_terseLabel_en-US" xlink:label="lab_abvx_TranchesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranches [Axis]</link:label>
    <link:label id="lab_abvx_TranchesAxis_label_en-US" xlink:label="lab_abvx_TranchesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranches [Axis]</link:label>
    <link:label id="lab_abvx_TranchesAxis_documentation_en-US" xlink:label="lab_abvx_TranchesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesAxis" xlink:href="abvx-20251231.xsd#abvx_TranchesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_TranchesAxis" xlink:to="lab_abvx_TranchesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalDomain_7dada834-03a1-488a-a1d4-047bfcdd78bd_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of share capital [domain]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of share capital [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain" xlink:to="lab_ifrs-full_ClassesOfShareCapitalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_bba104e2-d776-4969-9713-1182748dd5c6_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Salary increase rate</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of expected rates of salary increases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:to="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AdjustmentsForOtherFinanceIncome_0415166f-e248-4f20-9f90-e6e71920b139_negatedTerseLabel_en-US" xlink:label="lab_abvx_AdjustmentsForOtherFinanceIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Financial income</link:label>
    <link:label id="lab_abvx_AdjustmentsForOtherFinanceIncome_label_en-US" xlink:label="lab_abvx_AdjustmentsForOtherFinanceIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Other Finance Income</link:label>
    <link:label id="lab_abvx_AdjustmentsForOtherFinanceIncome_documentation_en-US" xlink:label="lab_abvx_AdjustmentsForOtherFinanceIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments For Other Finance Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AdjustmentsForOtherFinanceIncome" xlink:href="abvx-20251231.xsd#abvx_AdjustmentsForOtherFinanceIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AdjustmentsForOtherFinanceIncome" xlink:to="lab_abvx_AdjustmentsForOtherFinanceIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AgreementPeriod_9fa802c1-09e3-4253-ba62-62b1ea9240a7_terseLabel_en-US" xlink:label="lab_abvx_AgreementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement, period</link:label>
    <link:label id="lab_abvx_AgreementPeriod_label_en-US" xlink:label="lab_abvx_AgreementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement, Period</link:label>
    <link:label id="lab_abvx_AgreementPeriod_documentation_en-US" xlink:label="lab_abvx_AgreementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AgreementPeriod" xlink:href="abvx-20251231.xsd#abvx_AgreementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AgreementPeriod" xlink:to="lab_abvx_AgreementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_KreosCBSAMember_b1b37e8d-e691-4937-8b20-5fb41c846eb3_terseLabel_en-US" xlink:label="lab_abvx_KreosCBSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kreos C BSA</link:label>
    <link:label id="lab_abvx_KreosCBSAMember_label_en-US" xlink:label="lab_abvx_KreosCBSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kreos C BSA [Member]</link:label>
    <link:label id="lab_abvx_KreosCBSAMember_documentation_en-US" xlink:label="lab_abvx_KreosCBSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kreos C BSA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosCBSAMember" xlink:href="abvx-20251231.xsd#abvx_KreosCBSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_KreosCBSAMember" xlink:to="lab_abvx_KreosCBSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares_019beae9-f264-7252-b020-b47f303de43c_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issue of ordinary shares</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issue of ordinary shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:to="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfOperatingIncomeLineItems_634e3ffc-64f4-4634-86da-70b7fc0053bd_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfOperatingIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Operating Income [Line Items]</link:label>
    <link:label id="lab_abvx_DisclosureOfOperatingIncomeLineItems_label_en-US" xlink:label="lab_abvx_DisclosureOfOperatingIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Operating Income [Line Items]</link:label>
    <link:label id="lab_abvx_DisclosureOfOperatingIncomeLineItems_documentation_en-US" xlink:label="lab_abvx_DisclosureOfOperatingIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Operating Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfOperatingIncomeLineItems" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfOperatingIncomeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfOperatingIncomeLineItems" xlink:to="lab_abvx_DisclosureOfOperatingIncomeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceIncome_2f429ecb-5c02-4736-a5ff-a21366f37537_terseLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial income</link:label>
    <link:label id="lab_ifrs-full_FinanceIncome_510e00a1-05ab-4f31-a012-27e395333433_totalLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Financial income</link:label>
    <link:label id="lab_ifrs-full_FinanceIncome_label_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceIncome" xlink:to="lab_ifrs-full_FinanceIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_TrancheBMember_4ab615c3-b0c1-4707-bf4f-e35296e25158_terseLabel_en-US" xlink:label="lab_abvx_TrancheBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche B</link:label>
    <link:label id="lab_abvx_TrancheBMember_label_en-US" xlink:label="lab_abvx_TrancheBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche B [Member]</link:label>
    <link:label id="lab_abvx_TrancheBMember_documentation_en-US" xlink:label="lab_abvx_TrancheBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche B</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheBMember" xlink:href="abvx-20251231.xsd#abvx_TrancheBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_TrancheBMember" xlink:to="lab_abvx_TrancheBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis_2a114755-1726-40fc-9c8d-3e2c7f3c825c_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of financial liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialLiabilitiesDomain_01e6e350-f562-49cf-9868-84d95792666f_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of financial liabilities [domain]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialLiabilitiesDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial liabilities [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:to="lab_ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentShellCompanyReport_71b31444-f4bb-4cce-b2c5-ac9fa3132bc9_terseLabel_en-US" xlink:label="lab_dei_DocumentShellCompanyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Shell Company Report</link:label>
    <link:label id="lab_dei_DocumentShellCompanyReport_label_en-US" xlink:label="lab_dei_DocumentShellCompanyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Shell Company Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentShellCompanyReport" xlink:to="lab_dei_DocumentShellCompanyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AdjustmentsForOtherFinanceCosts_b5444a69-bff9-4a52-96fe-0d49f285526c_terseLabel_en-US" xlink:label="lab_abvx_AdjustmentsForOtherFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expenses and other financial expenses</link:label>
    <link:label id="lab_abvx_AdjustmentsForOtherFinanceCosts_label_en-US" xlink:label="lab_abvx_AdjustmentsForOtherFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Other Finance Costs</link:label>
    <link:label id="lab_abvx_AdjustmentsForOtherFinanceCosts_documentation_en-US" xlink:label="lab_abvx_AdjustmentsForOtherFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments For Other Finance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AdjustmentsForOtherFinanceCosts" xlink:href="abvx-20251231.xsd#abvx_AdjustmentsForOtherFinanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AdjustmentsForOtherFinanceCosts" xlink:to="lab_abvx_AdjustmentsForOtherFinanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities_702942a7-9882-43c6-b2ec-a0b74e11d320_terseLabel_en-US" xlink:label="lab_abvx_IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash changes: recognition of earn-out liability</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_abvx_IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Recognition of Earn Out Liability, Liabilities Arising From Financing Activities</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities_documentation_en-US" xlink:label="lab_abvx_IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Recognition of Earn Out Liability, Liabilities Arising From Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities" xlink:to="lab_abvx_IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsAdjustmentToInterestRateBasis_6edb313c-5b81-4a98-9edf-f392b668170a_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsAdjustmentToInterestRateBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, adjustment to interest rate basis</link:label>
    <link:label id="lab_ifrs-full_BorrowingsAdjustmentToInterestRateBasis_label_en-US" xlink:label="lab_ifrs-full_BorrowingsAdjustmentToInterestRateBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, adjustment to interest rate basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsAdjustmentToInterestRateBasis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsAdjustmentToInterestRateBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsAdjustmentToInterestRateBasis" xlink:to="lab_ifrs-full_BorrowingsAdjustmentToInterestRateBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted_9ae6a558-d8fd-416b-adf7-fec82b189b2b_terseLabel_en-US" xlink:label="lab_abvx_ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price, percentage of 15-day WVAP</link:label>
    <link:label id="lab_abvx_ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_abvx_ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price, Percentage Of 15-Day WVAP, Other Equity Instruments Granted</link:label>
    <link:label id="lab_abvx_ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_abvx_ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price, Percentage Of 15-Day WVAP, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted" xlink:href="abvx-20251231.xsd#abvx_ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted" xlink:to="lab_abvx_ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BCE20171Member_f418567e-e1ec-451c-8494-97d81ac979c3_terseLabel_en-US" xlink:label="lab_abvx_BCE20171Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BCE-2017-1</link:label>
    <link:label id="lab_abvx_BCE20171Member_label_en-US" xlink:label="lab_abvx_BCE20171Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BCE-2017-1 [Member]</link:label>
    <link:label id="lab_abvx_BCE20171Member_documentation_en-US" xlink:label="lab_abvx_BCE20171Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BCE-2017-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BCE20171Member" xlink:href="abvx-20251231.xsd#abvx_BCE20171Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BCE20171Member" xlink:to="lab_abvx_BCE20171Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NumberOfFreeSharesIssued_70eb3fc9-8dc1-48d8-a2d3-79c71bbf9207_terseLabel_en-US" xlink:label="lab_abvx_NumberOfFreeSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issue of free shares (in shares)</link:label>
    <link:label id="lab_abvx_NumberOfFreeSharesIssued_label_en-US" xlink:label="lab_abvx_NumberOfFreeSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Free Shares Issued</link:label>
    <link:label id="lab_abvx_NumberOfFreeSharesIssued_documentation_en-US" xlink:label="lab_abvx_NumberOfFreeSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Free Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfFreeSharesIssued" xlink:href="abvx-20251231.xsd#abvx_NumberOfFreeSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NumberOfFreeSharesIssued" xlink:to="lab_abvx_NumberOfFreeSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedByIASBButNotYetMandatoryPolicyTextBlock_5351f0d2-df34-47ed-a545-c28efee45c65_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedByIASBButNotYetMandatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New standards, amendments and interpretations issued by IASB but not yet mandatory for financial years starting from January 1, 2023</link:label>
    <link:label id="lab_abvx_DisclosureOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedByIASBButNotYetMandatoryPolicyTextBlock_label_en-US" xlink:label="lab_abvx_DisclosureOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedByIASBButNotYetMandatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Accounting Policy For New Standards, Amendments And Interpretations Issued By IASB But Not Yet Mandatory [Policy Text Block]</link:label>
    <link:label id="lab_abvx_DisclosureOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedByIASBButNotYetMandatoryPolicyTextBlock_documentation_en-US" xlink:label="lab_abvx_DisclosureOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedByIASBButNotYetMandatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Accounting Policy For New Standards, Amendments And For Financial Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedByIASBButNotYetMandatoryPolicyTextBlock" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedByIASBButNotYetMandatoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedByIASBButNotYetMandatoryPolicyTextBlock" xlink:to="lab_abvx_DisclosureOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedByIASBButNotYetMandatoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_EquityIssuanceSubscriptionPricePerShare_7f69999e-f714-4590-8dea-c546eaef01e3_terseLabel_en-US" xlink:label="lab_abvx_EquityIssuanceSubscriptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity issuance, subscripion price per share (in euro per share)</link:label>
    <link:label id="lab_abvx_EquityIssuanceSubscriptionPricePerShare_label_en-US" xlink:label="lab_abvx_EquityIssuanceSubscriptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Issuance, Subscription Price Per Share</link:label>
    <link:label id="lab_abvx_EquityIssuanceSubscriptionPricePerShare_documentation_en-US" xlink:label="lab_abvx_EquityIssuanceSubscriptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Issuance, Subscription Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EquityIssuanceSubscriptionPricePerShare" xlink:href="abvx-20251231.xsd#abvx_EquityIssuanceSubscriptionPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_EquityIssuanceSubscriptionPricePerShare" xlink:to="lab_abvx_EquityIssuanceSubscriptionPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AverageNumberOfEmployees_809b362c-1676-4ec4-bd47-e31b096889b2_terseLabel_en-US" xlink:label="lab_ifrs-full_AverageNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average number of employees</link:label>
    <link:label id="lab_ifrs-full_AverageNumberOfEmployees_label_en-US" xlink:label="lab_ifrs-full_AverageNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average number of employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageNumberOfEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AverageNumberOfEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AverageNumberOfEmployees" xlink:to="lab_ifrs-full_AverageNumberOfEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BCE20184Member_b8494789-eb21-49ab-b59d-eaf15d4e763e_terseLabel_en-US" xlink:label="lab_abvx_BCE20184Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BCE-2018-4</link:label>
    <link:label id="lab_abvx_BCE20184Member_label_en-US" xlink:label="lab_abvx_BCE20184Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BCE-2018-4 [Member]</link:label>
    <link:label id="lab_abvx_BCE20184Member_documentation_en-US" xlink:label="lab_abvx_BCE20184Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BCE-2018-4</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BCE20184Member" xlink:href="abvx-20251231.xsd#abvx_BCE20184Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BCE20184Member" xlink:to="lab_abvx_BCE20184Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NumberOfTreasurySharesHeld_d1c66e38-eb8d-4157-b349-dc7d1845f51e_terseLabel_en-US" xlink:label="lab_abvx_NumberOfTreasurySharesHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of treasury shares held (in shares)</link:label>
    <link:label id="lab_abvx_NumberOfTreasurySharesHeld_label_en-US" xlink:label="lab_abvx_NumberOfTreasurySharesHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Treasury Shares Held</link:label>
    <link:label id="lab_abvx_NumberOfTreasurySharesHeld_documentation_en-US" xlink:label="lab_abvx_NumberOfTreasurySharesHeld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Treasury Shares Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfTreasurySharesHeld" xlink:href="abvx-20251231.xsd#abvx_NumberOfTreasurySharesHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NumberOfTreasurySharesHeld" xlink:to="lab_abvx_NumberOfTreasurySharesHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_SaleOfStockAxis_0e97877f-93b3-4ab2-802d-80d0baf002ae_terseLabel_en-US" xlink:label="lab_abvx_SaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Axis]</link:label>
    <link:label id="lab_abvx_SaleOfStockAxis_label_en-US" xlink:label="lab_abvx_SaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Axis]</link:label>
    <link:label id="lab_abvx_SaleOfStockAxis_documentation_en-US" xlink:label="lab_abvx_SaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SaleOfStockAxis" xlink:href="abvx-20251231.xsd#abvx_SaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_SaleOfStockAxis" xlink:to="lab_abvx_SaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_CurrentReceivablesAndCurrentPrepaidExpenses_cb07197f-b970-4ba1-a1d9-861c5e9939b5_terseLabel_en-US" xlink:label="lab_abvx_CurrentReceivablesAndCurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables and assets</link:label>
    <link:label id="lab_abvx_CurrentReceivablesAndCurrentPrepaidExpenses_012713f2-74fe-4ff3-878a-047454f8293c_totalLabel_en-US" xlink:label="lab_abvx_CurrentReceivablesAndCurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current other receivables and assets</link:label>
    <link:label id="lab_abvx_CurrentReceivablesAndCurrentPrepaidExpenses_label_en-US" xlink:label="lab_abvx_CurrentReceivablesAndCurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Receivables And Current Prepaid Expenses</link:label>
    <link:label id="lab_abvx_CurrentReceivablesAndCurrentPrepaidExpenses_documentation_en-US" xlink:label="lab_abvx_CurrentReceivablesAndCurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current Receivables And Current Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentReceivablesAndCurrentPrepaidExpenses" xlink:href="abvx-20251231.xsd#abvx_CurrentReceivablesAndCurrentPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_CurrentReceivablesAndCurrentPrepaidExpenses" xlink:to="lab_abvx_CurrentReceivablesAndCurrentPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilities_e0954a8b-7ed0-425e-ac0f-d96b915e89dd_periodStartLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities at beginning of period</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_13e23940-f87b-46b8-be7a-9b1c4463cb99_periodEndLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities at end of period</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_1736e7f0-931c-4ea9-b789-9ef44313e63b_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilities" xlink:to="lab_ifrs-full_LeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_Kreos1ConvertibleBondLoansTrancheBMember_ec1597fd-77ea-45e8-9537-4e1520a61074_terseLabel_en-US" xlink:label="lab_abvx_Kreos1ConvertibleBondLoansTrancheBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kreos 1, convertible bond loans, tranche B</link:label>
    <link:label id="lab_abvx_Kreos1ConvertibleBondLoansTrancheBMember_label_en-US" xlink:label="lab_abvx_Kreos1ConvertibleBondLoansTrancheBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kreos 1, Convertible Bond Loans, Tranche B [Member]</link:label>
    <link:label id="lab_abvx_Kreos1ConvertibleBondLoansTrancheBMember_documentation_en-US" xlink:label="lab_abvx_Kreos1ConvertibleBondLoansTrancheBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kreos 1, Convertible Bond Loans, Tranche B</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1ConvertibleBondLoansTrancheBMember" xlink:href="abvx-20251231.xsd#abvx_Kreos1ConvertibleBondLoansTrancheBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_Kreos1ConvertibleBondLoansTrancheBMember" xlink:to="lab_abvx_Kreos1ConvertibleBondLoansTrancheBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_1309c441-05c6-4410-bba5-883c094ecc08_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transactions on treasury shares</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through treasury share transactions, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_EmployeeMember_73546eca-1155-4f09-a177-dd2f3c796b84_terseLabel_en-US" xlink:label="lab_abvx_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee</link:label>
    <link:label id="lab_abvx_EmployeeMember_label_en-US" xlink:label="lab_abvx_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee [Member]</link:label>
    <link:label id="lab_abvx_EmployeeMember_documentation_en-US" xlink:label="lab_abvx_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EmployeeMember" xlink:href="abvx-20251231.xsd#abvx_EmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_EmployeeMember" xlink:to="lab_abvx_EmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_8d4999ac-d2b4-4457-a3b2-1b6b40815ad7_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash changes: interest expense and other</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through other changes, liabilities arising from financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations_019c4339-09ae-72d7-ae0b-e857ca1c0812_terseLabel_en-US" xlink:label="lab_abvx_PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advances reimbursed by / (made to) CROs</link:label>
    <link:label id="lab_abvx_PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations_label_en-US" xlink:label="lab_abvx_PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For Advances Reimbursed (Made to) Contract Research Organizations</link:label>
    <link:label id="lab_abvx_PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations_documentation_en-US" xlink:label="lab_abvx_PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments For Advances Reimbursed (Made to) Contract Research Organizations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations" xlink:href="abvx-20251231.xsd#abvx_PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations" xlink:to="lab_abvx_PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfDiscountRates_c27bced6-1134-4690-87e6-a55c8457ebf4_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount Rate (IBoxx Corporates AA)</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfDiscountRates_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of discount rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:to="lab_ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_LeaseLiabilityPercentageOfTotal_764a76cc-dc94-48e5-a085-83541e7499eb_terseLabel_en-US" xlink:label="lab_abvx_LeaseLiabilityPercentageOfTotal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability, percentage of total</link:label>
    <link:label id="lab_abvx_LeaseLiabilityPercentageOfTotal_label_en-US" xlink:label="lab_abvx_LeaseLiabilityPercentageOfTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Liability, Percentage Of Total</link:label>
    <link:label id="lab_abvx_LeaseLiabilityPercentageOfTotal_documentation_en-US" xlink:label="lab_abvx_LeaseLiabilityPercentageOfTotal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Liability, Percentage Of Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LeaseLiabilityPercentageOfTotal" xlink:href="abvx-20251231.xsd#abvx_LeaseLiabilityPercentageOfTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_LeaseLiabilityPercentageOfTotal" xlink:to="lab_abvx_LeaseLiabilityPercentageOfTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AGA20257Member_019bfaf7-c34f-7481-9714-38cc1f93c2e5_terseLabel_en-US" xlink:label="lab_abvx_AGA20257Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA-2025-7</link:label>
    <link:label id="lab_abvx_AGA20257Member_label_en-US" xlink:label="lab_abvx_AGA20257Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA-2025-7 [Member]</link:label>
    <link:label id="lab_abvx_AGA20257Member_documentation_en-US" xlink:label="lab_abvx_AGA20257Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA-2025-7</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20257Member" xlink:href="abvx-20251231.xsd#abvx_AGA20257Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AGA20257Member" xlink:to="lab_abvx_AGA20257Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_OffBalanceSheetCommitmentsAbstract_label_en-US" xlink:label="lab_abvx_OffBalanceSheetCommitmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Off-Balance Sheet Commitments [Abstract]</link:label>
    <link:label id="lab_abvx_OffBalanceSheetCommitmentsAbstract_documentation_en-US" xlink:label="lab_abvx_OffBalanceSheetCommitmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Off-Balance Sheet Commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OffBalanceSheetCommitmentsAbstract" xlink:href="abvx-20251231.xsd#abvx_OffBalanceSheetCommitmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_OffBalanceSheetCommitmentsAbstract" xlink:to="lab_abvx_OffBalanceSheetCommitmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_bb9862d9-912c-4eff-9574-698425a4ff0c_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_6a4252fe-7753-4895-89d2-51dbecc2dd65_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities arising from financing activities [domain]</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities arising from financing activities [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:to="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_PrincipalAgreementsAxis_960ecab2-3106-4936-9d3a-fd882830398f_terseLabel_en-US" xlink:label="lab_abvx_PrincipalAgreementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal Agreements [Axis]</link:label>
    <link:label id="lab_abvx_PrincipalAgreementsAxis_label_en-US" xlink:label="lab_abvx_PrincipalAgreementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal Agreements [Axis]</link:label>
    <link:label id="lab_abvx_PrincipalAgreementsAxis_documentation_en-US" xlink:label="lab_abvx_PrincipalAgreementsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Principal Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PrincipalAgreementsAxis" xlink:href="abvx-20251231.xsd#abvx_PrincipalAgreementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_PrincipalAgreementsAxis" xlink:to="lab_abvx_PrincipalAgreementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_47d547a6-10f1-4aaf-9fc5-d1b013fc101b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of other equity instruments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average exercise prices of other equity instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_CSOSettlementAgreementMember_019cf67d-61f0-73fc-ba9c-69628a1cf856_terseLabel_en-US" xlink:label="lab_abvx_CSOSettlementAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CSO, settlement agreement</link:label>
    <link:label id="lab_abvx_CSOSettlementAgreementMember_label_en-US" xlink:label="lab_abvx_CSOSettlementAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CSO, Settlement Agreement [Member]</link:label>
    <link:label id="lab_abvx_CSOSettlementAgreementMember_documentation_en-US" xlink:label="lab_abvx_CSOSettlementAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CSO, Settlement Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CSOSettlementAgreementMember" xlink:href="abvx-20251231.xsd#abvx_CSOSettlementAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_CSOSettlementAgreementMember" xlink:to="lab_abvx_CSOSettlementAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementServicePeriod_09bd5fff-8374-437f-af51-baf982aa9873_terseLabel_en-US" xlink:label="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementServicePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service period</link:label>
    <link:label id="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementServicePeriod_label_en-US" xlink:label="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementServicePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Service Period</link:label>
    <link:label id="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementServicePeriod_documentation_en-US" xlink:label="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementServicePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementServicePeriod" xlink:href="abvx-20251231.xsd#abvx_VestingRequirementsForShareBasedPaymentArrangementServicePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementServicePeriod" xlink:to="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementServicePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_After24MonthsMember_20c874ca-5630-4ec2-94be-daf18a326ef1_terseLabel_en-US" xlink:label="lab_abvx_After24MonthsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After 24 months</link:label>
    <link:label id="lab_abvx_After24MonthsMember_label_en-US" xlink:label="lab_abvx_After24MonthsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">After 24 Months [Member]</link:label>
    <link:label id="lab_abvx_After24MonthsMember_documentation_en-US" xlink:label="lab_abvx_After24MonthsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">After 24 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_After24MonthsMember" xlink:href="abvx-20251231.xsd#abvx_After24MonthsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_After24MonthsMember" xlink:to="lab_abvx_After24MonthsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_OrdinarySharesNASDAQGlobalMarketMember_8958b445-ea33-4973-a91d-8cb10372689d_terseLabel_en-US" xlink:label="lab_abvx_OrdinarySharesNASDAQGlobalMarketMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, nominal value &#8364;0.01 per share</link:label>
    <link:label id="lab_abvx_OrdinarySharesNASDAQGlobalMarketMember_label_en-US" xlink:label="lab_abvx_OrdinarySharesNASDAQGlobalMarketMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary Shares, NASDAQ Global Market [Member]</link:label>
    <link:label id="lab_abvx_OrdinarySharesNASDAQGlobalMarketMember_documentation_en-US" xlink:label="lab_abvx_OrdinarySharesNASDAQGlobalMarketMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ordinary Shares, NASDAQ Global Market [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OrdinarySharesNASDAQGlobalMarketMember" xlink:href="abvx-20251231.xsd#abvx_OrdinarySharesNASDAQGlobalMarketMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_OrdinarySharesNASDAQGlobalMarketMember" xlink:to="lab_abvx_OrdinarySharesNASDAQGlobalMarketMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapital_9133667f-a697-4b9f-aece-9e219378162d_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapital_label_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapital" xlink:to="lab_ifrs-full_IssuedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_b311fe5c-bc67-4133-8fe1-144230e24a76_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of liabilities arising from financing activities [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of liabilities arising from financing activities [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_c6735906-b1cd-4ac3-944b-b0c0181a4d4c_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unused tax losses for which no deferred tax asset recognised</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused tax losses for which no deferred tax asset recognised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:to="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherIntangibleAssetsMember_0096ea64-7307-4af1-8b9d-ef649aad8774_verboseLabel_en-US" xlink:label="lab_ifrs-full_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets</link:label>
    <link:label id="lab_ifrs-full_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_ifrs-full_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other intangible assets [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIntangibleAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherIntangibleAssetsMember" xlink:to="lab_ifrs-full_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialAssetsAxis_6929af7d-7ed4-4e06-982c-acd38b7e1a98_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Categories of financial assets [axis]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of financial assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_CIRTaxYearDomain_d2f79ae8-8904-4f72-908e-a403aa14493c_terseLabel_en-US" xlink:label="lab_abvx_CIRTaxYearDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CIR Tax Year [Domain]</link:label>
    <link:label id="lab_abvx_CIRTaxYearDomain_label_en-US" xlink:label="lab_abvx_CIRTaxYearDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CIR Tax Year [Domain]</link:label>
    <link:label id="lab_abvx_CIRTaxYearDomain_documentation_en-US" xlink:label="lab_abvx_CIRTaxYearDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CIR Tax Year [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CIRTaxYearDomain" xlink:href="abvx-20251231.xsd#abvx_CIRTaxYearDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_CIRTaxYearDomain" xlink:to="lab_abvx_CIRTaxYearDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExercisePriceShareOptionsGranted2019_019c56e7-6a50-7cbf-9797-125601bcaab6_terseLabel_en-US" xlink:label="lab_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price, share options granted (in euro per share)</link:label>
    <link:label id="lab_ifrs-full_ExercisePriceShareOptionsGranted2019_label_en-US" xlink:label="lab_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="lab_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_IncreaseDecreaseThroughIssuanceOfWarrantsEquity_835482da-9988-48e2-9b17-b417acd025fc_terseLabel_en-US" xlink:label="lab_abvx_IncreaseDecreaseThroughIssuanceOfWarrantsEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issue of share warrants</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseThroughIssuanceOfWarrantsEquity_label_en-US" xlink:label="lab_abvx_IncreaseDecreaseThroughIssuanceOfWarrantsEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Issuance of Warrants, Equity</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseThroughIssuanceOfWarrantsEquity_documentation_en-US" xlink:label="lab_abvx_IncreaseDecreaseThroughIssuanceOfWarrantsEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Issuance of Warrants, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseThroughIssuanceOfWarrantsEquity" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseThroughIssuanceOfWarrantsEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_IncreaseDecreaseThroughIssuanceOfWarrantsEquity" xlink:to="lab_abvx_IncreaseDecreaseThroughIssuanceOfWarrantsEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_77d9b8e9-ea05-46ef-ae7b-721b7087b2a9_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase / (decrease) in trade payables</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in trade accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherTemporaryDifferencesMember_7a0d818d-f8b7-4969-9d38-2851eec7cca2_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other items</link:label>
    <link:label id="lab_ifrs-full_OtherTemporaryDifferencesMember_label_en-US" xlink:label="lab_ifrs-full_OtherTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other temporary differences [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTemporaryDifferencesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherTemporaryDifferencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherTemporaryDifferencesMember" xlink:to="lab_ifrs-full_OtherTemporaryDifferencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilities_3ea780a6-f39e-45f7-9daf-646dfab3a5c7_totalLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total financial liabilities</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilities" xlink:to="lab_ifrs-full_FinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_b52154ef-2f77-4b48-972e-d51be174dcd6_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_019cd872-9778-7798-b02d-2b5dec88a9b7_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Effective income tax (loss)</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SignificantUnobservableInputLiabilities_be6eea6a-36cd-4ce7-8d80-792429ebccfc_terseLabel_en-US" xlink:label="lab_ifrs-full_SignificantUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant unobservable input, liabilities</link:label>
    <link:label id="lab_ifrs-full_SignificantUnobservableInputLiabilities_label_en-US" xlink:label="lab_ifrs-full_SignificantUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant unobservable input, liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantUnobservableInputLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SignificantUnobservableInputLiabilities" xlink:to="lab_ifrs-full_SignificantUnobservableInputLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain_f8c57f69-dd31-479a-b5d5-150c4106493d_terseLabel_en-US" xlink:label="lab_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash-generating units [domain]</link:label>
    <link:label id="lab_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain_label_en-US" xlink:label="lab_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash-generating units [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain" xlink:to="lab_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_CurrentPortionOfNonCurrentConvertibleLoansNotes_d19ac90b-3c43-4a1c-9255-e9c7a3f8f9c1_terseLabel_en-US" xlink:label="lab_abvx_CurrentPortionOfNonCurrentConvertibleLoansNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible loan notes</link:label>
    <link:label id="lab_abvx_CurrentPortionOfNonCurrentConvertibleLoansNotes_label_en-US" xlink:label="lab_abvx_CurrentPortionOfNonCurrentConvertibleLoansNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Portion Of Non-Current Convertible Loans Notes</link:label>
    <link:label id="lab_abvx_CurrentPortionOfNonCurrentConvertibleLoansNotes_documentation_en-US" xlink:label="lab_abvx_CurrentPortionOfNonCurrentConvertibleLoansNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current Portion Of Non-Current Convertible Loans Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentPortionOfNonCurrentConvertibleLoansNotes" xlink:href="abvx-20251231.xsd#abvx_CurrentPortionOfNonCurrentConvertibleLoansNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_CurrentPortionOfNonCurrentConvertibleLoansNotes" xlink:to="lab_abvx_CurrentPortionOfNonCurrentConvertibleLoansNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_RepaymentsOfPGE_2b7e0170-f9a9-4b4a-ace3-de58bcfdc69e_negatedTerseLabel_en-US" xlink:label="lab_abvx_RepaymentsOfPGE" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of PGE</link:label>
    <link:label id="lab_abvx_RepaymentsOfPGE_label_en-US" xlink:label="lab_abvx_RepaymentsOfPGE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments Of PGE</link:label>
    <link:label id="lab_abvx_RepaymentsOfPGE_documentation_en-US" xlink:label="lab_abvx_RepaymentsOfPGE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Repayments Of PGE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepaymentsOfPGE" xlink:href="abvx-20251231.xsd#abvx_RepaymentsOfPGE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_RepaymentsOfPGE" xlink:to="lab_abvx_RepaymentsOfPGE" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_OtherCurrentPayablesIncludingAdjustments_e05f3f63-a88d-45dc-bb28-3186cc6f00d4_terseLabel_en-US" xlink:label="lab_abvx_OtherCurrentPayablesIncludingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_abvx_OtherCurrentPayablesIncludingAdjustments_label_en-US" xlink:label="lab_abvx_OtherCurrentPayablesIncludingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Payables, Including Adjustments</link:label>
    <link:label id="lab_abvx_OtherCurrentPayablesIncludingAdjustments_documentation_en-US" xlink:label="lab_abvx_OtherCurrentPayablesIncludingAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Current Payables, Including Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherCurrentPayablesIncludingAdjustments" xlink:href="abvx-20251231.xsd#abvx_OtherCurrentPayablesIncludingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_OtherCurrentPayablesIncludingAdjustments" xlink:to="lab_abvx_OtherCurrentPayablesIncludingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_4d6d6979-19f4-4265-baec-9c7cdd8ca57e_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_HeightsConvertibleNotesTrancheBMember_75ee4944-bbfe-438f-860a-238c28eb911d_terseLabel_en-US" xlink:label="lab_abvx_HeightsConvertibleNotesTrancheBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Heights convertible notes, tranche B</link:label>
    <link:label id="lab_abvx_HeightsConvertibleNotesTrancheBMember_label_en-US" xlink:label="lab_abvx_HeightsConvertibleNotesTrancheBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Heights Convertible Notes, Tranche B [Member]</link:label>
    <link:label id="lab_abvx_HeightsConvertibleNotesTrancheBMember_documentation_en-US" xlink:label="lab_abvx_HeightsConvertibleNotesTrancheBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Heights Convertible Notes, Tranche B</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_HeightsConvertibleNotesTrancheBMember" xlink:href="abvx-20251231.xsd#abvx_HeightsConvertibleNotesTrancheBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_HeightsConvertibleNotesTrancheBMember" xlink:to="lab_abvx_HeightsConvertibleNotesTrancheBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9aadf5ad-4a90-41a0-85f6-4635de7aa0bb_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows provided by (used in) operating activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory_2fde2d63-6db0-4b8d-98a7-8fa9a2760eac_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Off-balance sheet commitments received and contingent assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other provisions, contingent liabilities and contingent assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_004c14e7-8469-44c0-a127-fdd507a4e1ba_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Fair Value Measurement Of Assets And Liabilities [Table]</link:label>
    <link:label id="lab_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_label_en-US" xlink:label="lab_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Fair Value Measurement Of Assets And Liabilities [Table]</link:label>
    <link:label id="lab_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_documentation_en-US" xlink:label="lab_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Fair Value Measurement Of Assets And Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable" xlink:to="lab_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ExpectedDividendMeasurementInputMember_23d4b61c-bbef-4101-ad27-5a2fa8b0b441_terseLabel_en-US" xlink:label="lab_abvx_ExpectedDividendMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend</link:label>
    <link:label id="lab_abvx_ExpectedDividendMeasurementInputMember_label_en-US" xlink:label="lab_abvx_ExpectedDividendMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Dividend, Measurement Input [Member]</link:label>
    <link:label id="lab_abvx_ExpectedDividendMeasurementInputMember_documentation_en-US" xlink:label="lab_abvx_ExpectedDividendMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected Dividend, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpectedDividendMeasurementInputMember" xlink:href="abvx-20251231.xsd#abvx_ExpectedDividendMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ExpectedDividendMeasurementInputMember" xlink:to="lab_abvx_ExpectedDividendMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_0f62008a-2a78-4a9a-bed3-b27e1bc1a100_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of defined benefit plans [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of defined benefit plans [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lab_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_dd511789-3827-4aae-bd7f-eeb91e4a5717_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_9351f0fe-f5df-4f1a-b11f-949961be758f_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [domain]</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:to="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ExpiryScenarioProbablityMeasurementInputMember_d348afc2-e10b-44d8-8635-18417fe176c0_terseLabel_en-US" xlink:label="lab_abvx_ExpiryScenarioProbablityMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">7-year expiry scenario probability</link:label>
    <link:label id="lab_abvx_ExpiryScenarioProbablityMeasurementInputMember_label_en-US" xlink:label="lab_abvx_ExpiryScenarioProbablityMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expiry Scenario Probablity, Measurement Input [Member]</link:label>
    <link:label id="lab_abvx_ExpiryScenarioProbablityMeasurementInputMember_documentation_en-US" xlink:label="lab_abvx_ExpiryScenarioProbablityMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expiry Scenario Probablity, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpiryScenarioProbablityMeasurementInputMember" xlink:href="abvx-20251231.xsd#abvx_ExpiryScenarioProbablityMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ExpiryScenarioProbablityMeasurementInputMember" xlink:to="lab_abvx_ExpiryScenarioProbablityMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_48c608f6-56c1-4f9d-9a42-94502f268f8d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_CollaborationAgreementsDevelopmentMilestonePaymentPhase2_bfa79d97-aed8-4ab7-9790-044cfec04ed6_terseLabel_en-US" xlink:label="lab_abvx_CollaborationAgreementsDevelopmentMilestonePaymentPhase2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreements, development milestone payment, Phase 2</link:label>
    <link:label id="lab_abvx_CollaborationAgreementsDevelopmentMilestonePaymentPhase2_label_en-US" xlink:label="lab_abvx_CollaborationAgreementsDevelopmentMilestonePaymentPhase2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Development Milestone Payment, Phase 2</link:label>
    <link:label id="lab_abvx_CollaborationAgreementsDevelopmentMilestonePaymentPhase2_documentation_en-US" xlink:label="lab_abvx_CollaborationAgreementsDevelopmentMilestonePaymentPhase2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Development Milestone Payment, Phase 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CollaborationAgreementsDevelopmentMilestonePaymentPhase2" xlink:href="abvx-20251231.xsd#abvx_CollaborationAgreementsDevelopmentMilestonePaymentPhase2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_CollaborationAgreementsDevelopmentMilestonePaymentPhase2" xlink:to="lab_abvx_CollaborationAgreementsDevelopmentMilestonePaymentPhase2" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_Kreos1NonConvertibleBondLoansMember_329fe783-08e2-41a2-b434-cc5ea0987afb_terseLabel_en-US" xlink:label="lab_abvx_Kreos1NonConvertibleBondLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kreos 1, non-convertible bond loans</link:label>
    <link:label id="lab_abvx_Kreos1NonConvertibleBondLoansMember_label_en-US" xlink:label="lab_abvx_Kreos1NonConvertibleBondLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kreos 1, Non-Convertible Bond Loans [Member]</link:label>
    <link:label id="lab_abvx_Kreos1NonConvertibleBondLoansMember_documentation_en-US" xlink:label="lab_abvx_Kreos1NonConvertibleBondLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kreos 1, Non-Convertible Bond Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1NonConvertibleBondLoansMember" xlink:href="abvx-20251231.xsd#abvx_Kreos1NonConvertibleBondLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_Kreos1NonConvertibleBondLoansMember" xlink:to="lab_abvx_Kreos1NonConvertibleBondLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGoodwillExplanatory_ebd0568f-d8d0-4f12-99b3-58b52f75fb7e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and impairment test</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGoodwillExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of goodwill [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGoodwillExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGoodwillExplanatory" xlink:to="lab_ifrs-full_DisclosureOfGoodwillExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities_4e047385-d0fb-40e9-88f9-a4240f97dfab_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income</link:label>
    <link:label id="lab_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current deferred income other than current contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities" xlink:to="lab_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_UnwindingEffectOfDiscountRelatedToAdvancesMadeToCROs_75ac6e77-71e9-4842-9cbb-f591e6cc7494_terseLabel_en-US" xlink:label="lab_abvx_UnwindingEffectOfDiscountRelatedToAdvancesMadeToCROs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of unwinding the discount related to advances made to CROs</link:label>
    <link:label id="lab_abvx_UnwindingEffectOfDiscountRelatedToAdvancesMadeToCROs_label_en-US" xlink:label="lab_abvx_UnwindingEffectOfDiscountRelatedToAdvancesMadeToCROs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unwinding Effect Of Discount Related To Advances Made To CROs</link:label>
    <link:label id="lab_abvx_UnwindingEffectOfDiscountRelatedToAdvancesMadeToCROs_documentation_en-US" xlink:label="lab_abvx_UnwindingEffectOfDiscountRelatedToAdvancesMadeToCROs" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unwinding Effect Of Discount Related To Advances Made To CROs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_UnwindingEffectOfDiscountRelatedToAdvancesMadeToCROs" xlink:href="abvx-20251231.xsd#abvx_UnwindingEffectOfDiscountRelatedToAdvancesMadeToCROs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_UnwindingEffectOfDiscountRelatedToAdvancesMadeToCROs" xlink:to="lab_abvx_UnwindingEffectOfDiscountRelatedToAdvancesMadeToCROs" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaturityAxis_ef661cdd-c4d4-4af2-b8ea-e5e27b7b69cf_terseLabel_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity [axis]</link:label>
    <link:label id="lab_ifrs-full_MaturityAxis_label_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityAxis" xlink:to="lab_ifrs-full_MaturityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_b904ab58-f1c8-45b7-bee3-f294382e863d_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other inflows (outflows) of cash, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis_019c4327-ff74-79b0-8982-b0064da5a63b_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of financial instruments [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial instruments [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BorrowingsEarlyRepaymentDiscountRate_d897f4c6-fbc9-48d0-89e7-88b590f46019_terseLabel_en-US" xlink:label="lab_abvx_BorrowingsEarlyRepaymentDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, early repayment, discount rate</link:label>
    <link:label id="lab_abvx_BorrowingsEarlyRepaymentDiscountRate_label_en-US" xlink:label="lab_abvx_BorrowingsEarlyRepaymentDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, Early Repayment, Discount Rate</link:label>
    <link:label id="lab_abvx_BorrowingsEarlyRepaymentDiscountRate_documentation_en-US" xlink:label="lab_abvx_BorrowingsEarlyRepaymentDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowings, Early Repayment, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsEarlyRepaymentDiscountRate" xlink:href="abvx-20251231.xsd#abvx_BorrowingsEarlyRepaymentDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BorrowingsEarlyRepaymentDiscountRate" xlink:to="lab_abvx_BorrowingsEarlyRepaymentDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Goodwill_f24eab33-ad5e-43dc-ad0a-5cec6af491de_terseLabel_en-US" xlink:label="lab_ifrs-full_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_ifrs-full_Goodwill_label_en-US" xlink:label="lab_ifrs-full_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Goodwill" xlink:to="lab_ifrs-full_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_OtherFinancialLiabilitiesMember_31b3e102-1436-4157-832d-f6afcc1e39f2_terseLabel_en-US" xlink:label="lab_abvx_OtherFinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_abvx_OtherFinancialLiabilitiesMember_label_en-US" xlink:label="lab_abvx_OtherFinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Financial Liabilities [Member]</link:label>
    <link:label id="lab_abvx_OtherFinancialLiabilitiesMember_documentation_en-US" xlink:label="lab_abvx_OtherFinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Financial Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialLiabilitiesMember" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_OtherFinancialLiabilitiesMember" xlink:to="lab_abvx_OtherFinancialLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BSA20251AndBSA20252Member_019cfca6-e954-79c7-b3d1-bf7d66291cf6_terseLabel_en-US" xlink:label="lab_abvx_BSA20251AndBSA20252Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSA-2025-1 and BSA-2025-2</link:label>
    <link:label id="lab_abvx_BSA20251AndBSA20252Member_label_en-US" xlink:label="lab_abvx_BSA20251AndBSA20252Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSA-2025-1 And BSA-2025-2 [Member]</link:label>
    <link:label id="lab_abvx_BSA20251AndBSA20252Member_documentation_en-US" xlink:label="lab_abvx_BSA20251AndBSA20252Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BSA-2025-1 And BSA-2025-2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20251AndBSA20252Member" xlink:href="abvx-20251231.xsd#abvx_BSA20251AndBSA20252Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BSA20251AndBSA20252Member" xlink:to="lab_abvx_BSA20251AndBSA20252Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_a14c5b46-ea57-489f-a43e-a25a9e8ca2a5_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GrossLeaseLiabilities_2b61477c-d99a-479d-8657-913ac9b61e4e_terseLabel_en-US" xlink:label="lab_ifrs-full_GrossLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross lease liabilities</link:label>
    <link:label id="lab_ifrs-full_GrossLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_GrossLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossLeaseLiabilities" xlink:to="lab_ifrs-full_GrossLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_OtherFinancialLiabilitiesRelatedTemporaryDifferencesMember_5cce82af-a924-4334-ae06-939793ee83ed_terseLabel_en-US" xlink:label="lab_abvx_OtherFinancialLiabilitiesRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial liabilities</link:label>
    <link:label id="lab_abvx_OtherFinancialLiabilitiesRelatedTemporaryDifferencesMember_label_en-US" xlink:label="lab_abvx_OtherFinancialLiabilitiesRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Financial Liabilities Related Temporary Differences [Member]</link:label>
    <link:label id="lab_abvx_OtherFinancialLiabilitiesRelatedTemporaryDifferencesMember_documentation_en-US" xlink:label="lab_abvx_OtherFinancialLiabilitiesRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Financial Liabilities Related Temporary Differences</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialLiabilitiesRelatedTemporaryDifferencesMember" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialLiabilitiesRelatedTemporaryDifferencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_OtherFinancialLiabilitiesRelatedTemporaryDifferencesMember" xlink:to="lab_abvx_OtherFinancialLiabilitiesRelatedTemporaryDifferencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AccountingPrinciplesAbstract_c7a61dbd-7032-42e9-abc8-c2a2e77c39d8_terseLabel_en-US" xlink:label="lab_abvx_AccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Principles [Abstract]</link:label>
    <link:label id="lab_abvx_AccountingPrinciplesAbstract_label_en-US" xlink:label="lab_abvx_AccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Principles [Abstract]</link:label>
    <link:label id="lab_abvx_AccountingPrinciplesAbstract_documentation_en-US" xlink:label="lab_abvx_AccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounting Principles [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AccountingPrinciplesAbstract" xlink:href="abvx-20251231.xsd#abvx_AccountingPrinciplesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AccountingPrinciplesAbstract" xlink:to="lab_abvx_AccountingPrinciplesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeStatementAbstract_label_en-US" xlink:label="lab_ifrs-full_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit or loss [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeStatementAbstract" xlink:to="lab_ifrs-full_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_18a5de54-65ac-49c7-bb9b-bb16d6b85aa0_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_a1a6beb6-57b3-44c5-8a8f-b2e085dc3021_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [abstract]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="lab_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_TechnologyBasedIntangibleAssetsAssetsAcquisitions_d413cae9-3e2d-4aef-81d4-4fc562de8af0_terseLabel_en-US" xlink:label="lab_abvx_TechnologyBasedIntangibleAssetsAssetsAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_abvx_TechnologyBasedIntangibleAssetsAssetsAcquisitions_label_en-US" xlink:label="lab_abvx_TechnologyBasedIntangibleAssetsAssetsAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technology-Based Intangible Assets, Assets Acquisitions</link:label>
    <link:label id="lab_abvx_TechnologyBasedIntangibleAssetsAssetsAcquisitions_documentation_en-US" xlink:label="lab_abvx_TechnologyBasedIntangibleAssetsAssetsAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Technology-Based Intangible Assets, Assets Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TechnologyBasedIntangibleAssetsAssetsAcquisitions" xlink:href="abvx-20251231.xsd#abvx_TechnologyBasedIntangibleAssetsAssetsAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_TechnologyBasedIntangibleAssetsAssetsAcquisitions" xlink:to="lab_abvx_TechnologyBasedIntangibleAssetsAssetsAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NetProceedsFromIssueOfOrdinaryShares_019beae9-f264-75c0-afdf-4440cf7fd6a2_terseLabel_en-US" xlink:label="lab_abvx_NetProceedsFromIssueOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from issue of ordinary shares</link:label>
    <link:label id="lab_abvx_NetProceedsFromIssueOfOrdinaryShares_label_en-US" xlink:label="lab_abvx_NetProceedsFromIssueOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Proceeds From Issue Of Ordinary Shares</link:label>
    <link:label id="lab_abvx_NetProceedsFromIssueOfOrdinaryShares_documentation_en-US" xlink:label="lab_abvx_NetProceedsFromIssueOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Proceeds From Issue Of Ordinary Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NetProceedsFromIssueOfOrdinaryShares" xlink:href="abvx-20251231.xsd#abvx_NetProceedsFromIssueOfOrdinaryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NetProceedsFromIssueOfOrdinaryShares" xlink:to="lab_abvx_NetProceedsFromIssueOfOrdinaryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments_019bfef1-7a8f-713d-b1d3-480d9c4836ef_terseLabel_en-US" xlink:label="lab_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible instruments (in shares)</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments_label_en-US" xlink:label="lab_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Number Of Shares Issued Through Conversion Of Convertible Instruments</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments_documentation_en-US" xlink:label="lab_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Number Of Shares Issued Through Conversion Of Convertible Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments" xlink:to="lab_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfAssetsAxis_c4f8853c-4c5f-48a1-aa66-a590cb966c60_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of assets [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis" xlink:to="lab_ifrs-full_ClassesOfAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ConditionalAdvancesUndiscountedCashFlows_ec1e6891-9f45-439f-8933-a36e5599fce5_terseLabel_en-US" xlink:label="lab_abvx_ConditionalAdvancesUndiscountedCashFlows" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conditional advances, undiscounted cash flows</link:label>
    <link:label id="lab_abvx_ConditionalAdvancesUndiscountedCashFlows_label_en-US" xlink:label="lab_abvx_ConditionalAdvancesUndiscountedCashFlows" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conditional Advances, Undiscounted Cash Flows</link:label>
    <link:label id="lab_abvx_ConditionalAdvancesUndiscountedCashFlows_documentation_en-US" xlink:label="lab_abvx_ConditionalAdvancesUndiscountedCashFlows" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conditional Advances, Undiscounted Cash Flows</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConditionalAdvancesUndiscountedCashFlows" xlink:href="abvx-20251231.xsd#abvx_ConditionalAdvancesUndiscountedCashFlows"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ConditionalAdvancesUndiscountedCashFlows" xlink:to="lab_abvx_ConditionalAdvancesUndiscountedCashFlows" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfChangesInDerivativeFinancialInstrumentsTableTextBlock_7195d222-8b96-4c41-a488-a19dbab182cd_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfChangesInDerivativeFinancialInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of changes in derivative instruments</link:label>
    <link:label id="lab_abvx_DisclosureOfChangesInDerivativeFinancialInstrumentsTableTextBlock_label_en-US" xlink:label="lab_abvx_DisclosureOfChangesInDerivativeFinancialInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Changes In Derivative Financial Instruments [Table Text Block]</link:label>
    <link:label id="lab_abvx_DisclosureOfChangesInDerivativeFinancialInstrumentsTableTextBlock_documentation_en-US" xlink:label="lab_abvx_DisclosureOfChangesInDerivativeFinancialInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Changes In Derivative Financial Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfChangesInDerivativeFinancialInstrumentsTableTextBlock" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfChangesInDerivativeFinancialInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfChangesInDerivativeFinancialInstrumentsTableTextBlock" xlink:to="lab_abvx_DisclosureOfChangesInDerivativeFinancialInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_ba69cd2c-0eaa-409b-b1a1-7d83e3a4ab21_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [domain]</link:label>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_label_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_OtherEquityAgreementsMember_5e80e620-2e18-4181-8c51-5903ce2c1825_terseLabel_en-US" xlink:label="lab_abvx_OtherEquityAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other equity agreement</link:label>
    <link:label id="lab_abvx_OtherEquityAgreementsMember_label_en-US" xlink:label="lab_abvx_OtherEquityAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Equity Agreements [Member]</link:label>
    <link:label id="lab_abvx_OtherEquityAgreementsMember_documentation_en-US" xlink:label="lab_abvx_OtherEquityAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Equity Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherEquityAgreementsMember" xlink:href="abvx-20251231.xsd#abvx_OtherEquityAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_OtherEquityAgreementsMember" xlink:to="lab_abvx_OtherEquityAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_8499d48d-875f-4748-b55e-783cd445ba2e_terseLabel_en-US" xlink:label="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_label_en-US" xlink:label="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Vesting Period</link:label>
    <link:label id="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_documentation_en-US" xlink:label="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" xlink:href="abvx-20251231.xsd#abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" xlink:to="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_country_FR_2d91aab0-2206-470d-9fc0-c8339df60622_terseLabel_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">France</link:label>
    <link:label id="lab_country_FR_label_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FRANCE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_FR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_FR" xlink:to="lab_country_FR" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareAbstract_c26e700f-c1b4-452d-8602-1218be6460c9_terseLabel_en-US" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss per share (&#8364;/share)</link:label>
    <link:label id="lab_ifrs-full_EarningsPerShareAbstract_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareAbstract" xlink:to="lab_ifrs-full_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangeAxis_08bca0bb-9392-4299-82c7-82803f3c1540_terseLabel_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [axis]</link:label>
    <link:label id="lab_ifrs-full_RangeAxis_label_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeAxis" xlink:to="lab_ifrs-full_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_e17c39ce-e0ad-4924-8940-f84006757335_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis" xlink:to="lab_ifrs-full_ComponentsOfEquityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_ce919279-789a-44c1-aa0b-4dffa531cf3d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities breakdown</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_68545da8-54d2-448a-bb55-3bf4c173dea3_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_d413b9d7-f62c-4912-9642-2eca9972a898_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfPrincipalAuditFeesAndServicesTableTextBlock_f5d973a4-7703-43be-ab99-d5658972bf32_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfPrincipalAuditFeesAndServicesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of principal audit fees and services</link:label>
    <link:label id="lab_abvx_DisclosureOfPrincipalAuditFeesAndServicesTableTextBlock_label_en-US" xlink:label="lab_abvx_DisclosureOfPrincipalAuditFeesAndServicesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Principal Audit Fees And Services [Table Text Block]</link:label>
    <link:label id="lab_abvx_DisclosureOfPrincipalAuditFeesAndServicesTableTextBlock_documentation_en-US" xlink:label="lab_abvx_DisclosureOfPrincipalAuditFeesAndServicesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Principal Audit Fees And Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfPrincipalAuditFeesAndServicesTableTextBlock" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfPrincipalAuditFeesAndServicesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfPrincipalAuditFeesAndServicesTableTextBlock" xlink:to="lab_abvx_DisclosureOfPrincipalAuditFeesAndServicesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_f165d0b1-81fa-4c6e-b85c-2b2617c5d050_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss before tax</link:label>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_label_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) before tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="lab_ifrs-full_ProfitLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_OtherFinancialLiabilitiesAnnualRevenueFromSaleOfProductsDevelopedPeriod_9130b334-a7c8-4ef8-9bb6-030e104422fc_terseLabel_en-US" xlink:label="lab_abvx_OtherFinancialLiabilitiesAnnualRevenueFromSaleOfProductsDevelopedPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual revenue from sale of products developed, period</link:label>
    <link:label id="lab_abvx_OtherFinancialLiabilitiesAnnualRevenueFromSaleOfProductsDevelopedPeriod_label_en-US" xlink:label="lab_abvx_OtherFinancialLiabilitiesAnnualRevenueFromSaleOfProductsDevelopedPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Financial Liabilities, Annual Revenue From Sale Of Products Developed, Period</link:label>
    <link:label id="lab_abvx_OtherFinancialLiabilitiesAnnualRevenueFromSaleOfProductsDevelopedPeriod_documentation_en-US" xlink:label="lab_abvx_OtherFinancialLiabilitiesAnnualRevenueFromSaleOfProductsDevelopedPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Financial Liabilities, Annual Revenue From Sale Of Products Developed, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialLiabilitiesAnnualRevenueFromSaleOfProductsDevelopedPeriod" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialLiabilitiesAnnualRevenueFromSaleOfProductsDevelopedPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_OtherFinancialLiabilitiesAnnualRevenueFromSaleOfProductsDevelopedPeriod" xlink:to="lab_abvx_OtherFinancialLiabilitiesAnnualRevenueFromSaleOfProductsDevelopedPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_After18MonthsMember_62d135e5-132f-4da6-b591-c9e63ec72098_terseLabel_en-US" xlink:label="lab_abvx_After18MonthsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After 18 months</link:label>
    <link:label id="lab_abvx_After18MonthsMember_label_en-US" xlink:label="lab_abvx_After18MonthsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">After 18 Months [Member]</link:label>
    <link:label id="lab_abvx_After18MonthsMember_documentation_en-US" xlink:label="lab_abvx_After18MonthsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">After 18 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_After18MonthsMember" xlink:href="abvx-20251231.xsd#abvx_After18MonthsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_After18MonthsMember" xlink:to="lab_abvx_After18MonthsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ConditionalAdvances_3f7b7c4c-4fd2-4021-927f-ebc6ee64ecf5_terseLabel_en-US" xlink:label="lab_abvx_ConditionalAdvances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conditional advances</link:label>
    <link:label id="lab_abvx_ConditionalAdvances_label_en-US" xlink:label="lab_abvx_ConditionalAdvances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conditional Advances</link:label>
    <link:label id="lab_abvx_ConditionalAdvances_documentation_en-US" xlink:label="lab_abvx_ConditionalAdvances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conditional Advances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConditionalAdvances" xlink:href="abvx-20251231.xsd#abvx_ConditionalAdvances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ConditionalAdvances" xlink:to="lab_abvx_ConditionalAdvances" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_57f18d29-0e3e-41e3-80a9-ebcc31da63dd_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders&#8217; equity</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_8fa2c07b-cd12-4dc6-b6ff-6f9f085c0932_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other operating income</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other operating income [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfRelatedPartiesDomain_5f3e2513-15c7-4897-98a3-1282b9c2bd66_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Categories of related parties [domain]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfRelatedPartiesDomain_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of related parties [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="lab_ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherLongtermProvisions_16bc194e-15eb-4813-8b13-010df25a279b_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherLongtermProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions</link:label>
    <link:label id="lab_ifrs-full_OtherLongtermProvisions_019bfb1b-7623-71c6-abf1-a91a6d9175f0_verboseLabel_en-US" xlink:label="lab_ifrs-full_OtherLongtermProvisions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other non-current provisions</link:label>
    <link:label id="lab_ifrs-full_OtherLongtermProvisions_label_en-US" xlink:label="lab_ifrs-full_OtherLongtermProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherLongtermProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherLongtermProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherLongtermProvisions" xlink:to="lab_ifrs-full_OtherLongtermProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_RiskFreeInterestRateMeasurementInputMember_33adebb8-020f-4f2e-a779-c01167d55125_terseLabel_en-US" xlink:label="lab_abvx_RiskFreeInterestRateMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free rate</link:label>
    <link:label id="lab_abvx_RiskFreeInterestRateMeasurementInputMember_label_en-US" xlink:label="lab_abvx_RiskFreeInterestRateMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk-Free Interest Rate, Measurement Input [Member]</link:label>
    <link:label id="lab_abvx_RiskFreeInterestRateMeasurementInputMember_documentation_en-US" xlink:label="lab_abvx_RiskFreeInterestRateMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Risk-Free Interest Rate, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RiskFreeInterestRateMeasurementInputMember" xlink:href="abvx-20251231.xsd#abvx_RiskFreeInterestRateMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_RiskFreeInterestRateMeasurementInputMember" xlink:to="lab_abvx_RiskFreeInterestRateMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_64faf6d1-bd0e-4a62-a960-51983920b1c3_terseLabel_en-US" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of reasonably possible increase in unobservable input, liabilities</link:label>
    <link:label id="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_label_en-US" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of reasonably possible increase in unobservable input, liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:to="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsDomain_019c4327-ff74-7de1-9571-76ec934c69bf_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of financial instruments [domain]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial instruments [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:to="lab_ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets_781a13c1-bb1a-43c9-a734-fdd817b8000b_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of the change in foreign currency exchange rates</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, property, plant and equipment including right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_962709b8-dc80-437f-921a-2ed622d7c425_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AmericanDepositorySharesMember_8faba20f-2496-4519-8417-42420f969e3d_terseLabel_en-US" xlink:label="lab_abvx_AmericanDepositorySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ADS</link:label>
    <link:label id="lab_abvx_AmericanDepositorySharesMember_label_en-US" xlink:label="lab_abvx_AmericanDepositorySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">American Depository Shares [Member]</link:label>
    <link:label id="lab_abvx_AmericanDepositorySharesMember_documentation_en-US" xlink:label="lab_abvx_AmericanDepositorySharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">American Depository Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AmericanDepositorySharesMember" xlink:href="abvx-20251231.xsd#abvx_AmericanDepositorySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AmericanDepositorySharesMember" xlink:to="lab_abvx_AmericanDepositorySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_MarketRateMeasurementInputMember_56beabdb-9f65-4357-9e0e-684533a73824_terseLabel_en-US" xlink:label="lab_abvx_MarketRateMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market rate</link:label>
    <link:label id="lab_abvx_MarketRateMeasurementInputMember_label_en-US" xlink:label="lab_abvx_MarketRateMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Rate, Measurement Input [Member]</link:label>
    <link:label id="lab_abvx_MarketRateMeasurementInputMember_documentation_en-US" xlink:label="lab_abvx_MarketRateMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market Rate, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_MarketRateMeasurementInputMember" xlink:href="abvx-20251231.xsd#abvx_MarketRateMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_MarketRateMeasurementInputMember" xlink:to="lab_abvx_MarketRateMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NumberOfSharesPerShareWarrant_019c56e4-cd83-7b06-8701-290a508b4b45_terseLabel_en-US" xlink:label="lab_abvx_NumberOfSharesPerShareWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares (in shares)</link:label>
    <link:label id="lab_abvx_NumberOfSharesPerShareWarrant_label_en-US" xlink:label="lab_abvx_NumberOfSharesPerShareWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares per Share Warrant</link:label>
    <link:label id="lab_abvx_NumberOfSharesPerShareWarrant_documentation_en-US" xlink:label="lab_abvx_NumberOfSharesPerShareWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Shares per Share Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfSharesPerShareWarrant" xlink:href="abvx-20251231.xsd#abvx_NumberOfSharesPerShareWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NumberOfSharesPerShareWarrant" xlink:to="lab_abvx_NumberOfSharesPerShareWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_FreeSharesAGAMember_7376330f-7fbe-4ae0-802a-14b0f4162f5f_terseLabel_en-US" xlink:label="lab_abvx_FreeSharesAGAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total AGAs</link:label>
    <link:label id="lab_abvx_FreeSharesAGAMember_019cc311-8bca-72e2-8ed0-e83c1e9fbf4f_netLabel_en-US" xlink:label="lab_abvx_FreeSharesAGAMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Free shares (AGA)</link:label>
    <link:label id="lab_abvx_FreeSharesAGAMember_6a9c8747-eff8-490b-978c-9a86e87a3515_verboseLabel_en-US" xlink:label="lab_abvx_FreeSharesAGAMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">AGAs</link:label>
    <link:label id="lab_abvx_FreeSharesAGAMember_label_en-US" xlink:label="lab_abvx_FreeSharesAGAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Free Shares (AGA) [Member]</link:label>
    <link:label id="lab_abvx_FreeSharesAGAMember_documentation_en-US" xlink:label="lab_abvx_FreeSharesAGAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Free Shares (AGA)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FreeSharesAGAMember" xlink:href="abvx-20251231.xsd#abvx_FreeSharesAGAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_FreeSharesAGAMember" xlink:to="lab_abvx_FreeSharesAGAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageShares_40afd3df-7704-4cce-bd53-c2c50d2797b0_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of outstanding shares used for computing basic loss per share (in shares)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageShares_c7aeaf1e-e644-41d3-a1fa-84fabd4f7d64_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of outstanding shares, basic loss per share (in shares)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares" xlink:to="lab_ifrs-full_WeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NumberOfExclusiveLicenses_9e30bab5-4138-4c0c-8641-d18cc4cb0415_terseLabel_en-US" xlink:label="lab_abvx_NumberOfExclusiveLicenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of exclusive licenses</link:label>
    <link:label id="lab_abvx_NumberOfExclusiveLicenses_label_en-US" xlink:label="lab_abvx_NumberOfExclusiveLicenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Exclusive Licenses</link:label>
    <link:label id="lab_abvx_NumberOfExclusiveLicenses_documentation_en-US" xlink:label="lab_abvx_NumberOfExclusiveLicenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Exclusive Licenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfExclusiveLicenses" xlink:href="abvx-20251231.xsd#abvx_NumberOfExclusiveLicenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NumberOfExclusiveLicenses" xlink:to="lab_abvx_NumberOfExclusiveLicenses" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BorrowingsMaximumBorrowingCapacity_6005898c-ad51-4367-b1fb-24158b5985f4_terseLabel_en-US" xlink:label="lab_abvx_BorrowingsMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, maximum borrowing capacity</link:label>
    <link:label id="lab_abvx_BorrowingsMaximumBorrowingCapacity_label_en-US" xlink:label="lab_abvx_BorrowingsMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, Maximum Borrowing Capacity</link:label>
    <link:label id="lab_abvx_BorrowingsMaximumBorrowingCapacity_documentation_en-US" xlink:label="lab_abvx_BorrowingsMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowings, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsMaximumBorrowingCapacity" xlink:href="abvx-20251231.xsd#abvx_BorrowingsMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BorrowingsMaximumBorrowingCapacity" xlink:to="lab_abvx_BorrowingsMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_320ba4c8-84db-4025-bc56-c6b82b3e7516_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of deferred tax assets and liabilities by nature</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAdvancesToSuppliers_6e862293-6b66-418f-9594-cdb051315e54_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAdvancesToSuppliers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current advances to suppliers</link:label>
    <link:label id="lab_ifrs-full_CurrentAdvancesToSuppliers_label_en-US" xlink:label="lab_ifrs-full_CurrentAdvancesToSuppliers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current advances to suppliers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAdvancesToSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAdvancesToSuppliers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAdvancesToSuppliers" xlink:to="lab_ifrs-full_CurrentAdvancesToSuppliers" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_b60094cb-54f7-476b-87e2-c4701a9c3193_terseLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, goodwill</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsTable_dd07fcd0-4c79-4800-ab37-03be2b77a927_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_011baf59-3c0b-4740-833b-26832e4ff8b7_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payments</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, share-based payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfBreakdownOfTradeAndOtherPayablesTableTextBlock_b1751e75-71d0-4ec6-9a70-800fc13bdb4a_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfBreakdownOfTradeAndOtherPayablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of breakdown of trade and other payables</link:label>
    <link:label id="lab_abvx_DisclosureOfBreakdownOfTradeAndOtherPayablesTableTextBlock_label_en-US" xlink:label="lab_abvx_DisclosureOfBreakdownOfTradeAndOtherPayablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Breakdown Of Trade And Other Payables [Table Text Block]</link:label>
    <link:label id="lab_abvx_DisclosureOfBreakdownOfTradeAndOtherPayablesTableTextBlock_documentation_en-US" xlink:label="lab_abvx_DisclosureOfBreakdownOfTradeAndOtherPayablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Breakdown Of Trade And Other Payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfBreakdownOfTradeAndOtherPayablesTableTextBlock" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfBreakdownOfTradeAndOtherPayablesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfBreakdownOfTradeAndOtherPayablesTableTextBlock" xlink:to="lab_abvx_DisclosureOfBreakdownOfTradeAndOtherPayablesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Borrowings_731bad71-853d-4b8a-b7ea-d5c91d362464_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_ifrs-full_Borrowings_05321124-b087-41de-917a-a73402f51dce_terseLabel_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_ifrs-full_Borrowings_label_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Borrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Borrowings" xlink:to="lab_ifrs-full_Borrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_e6a8d48f-8250-42c9-ac1d-2c0e007c2fbb_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfCommitmentsReceivedLineItems_ea07598e-cd0c-4808-b737-5751b1f36536_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfCommitmentsReceivedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Commitments Received [Line Items]</link:label>
    <link:label id="lab_abvx_DisclosureOfCommitmentsReceivedLineItems_label_en-US" xlink:label="lab_abvx_DisclosureOfCommitmentsReceivedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Commitments Received [Line Items]</link:label>
    <link:label id="lab_abvx_DisclosureOfCommitmentsReceivedLineItems_documentation_en-US" xlink:label="lab_abvx_DisclosureOfCommitmentsReceivedLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Commitments Received [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfCommitmentsReceivedLineItems" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfCommitmentsReceivedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfCommitmentsReceivedLineItems" xlink:to="lab_abvx_DisclosureOfCommitmentsReceivedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BorrowingsMarketPriceNumberOfDaysWithLowestDailyVWAP_c3b7a528-a624-435a-a77e-6938b36b1b86_terseLabel_en-US" xlink:label="lab_abvx_BorrowingsMarketPriceNumberOfDaysWithLowestDailyVWAP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, market price, number of days with lowest daily VWAP</link:label>
    <link:label id="lab_abvx_BorrowingsMarketPriceNumberOfDaysWithLowestDailyVWAP_label_en-US" xlink:label="lab_abvx_BorrowingsMarketPriceNumberOfDaysWithLowestDailyVWAP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, Market Price, Number Of Days With Lowest Daily VWAP</link:label>
    <link:label id="lab_abvx_BorrowingsMarketPriceNumberOfDaysWithLowestDailyVWAP_documentation_en-US" xlink:label="lab_abvx_BorrowingsMarketPriceNumberOfDaysWithLowestDailyVWAP" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowings, Market Price, Number Of Days With Lowest Daily VWAP</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsMarketPriceNumberOfDaysWithLowestDailyVWAP" xlink:href="abvx-20251231.xsd#abvx_BorrowingsMarketPriceNumberOfDaysWithLowestDailyVWAP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BorrowingsMarketPriceNumberOfDaysWithLowestDailyVWAP" xlink:to="lab_abvx_BorrowingsMarketPriceNumberOfDaysWithLowestDailyVWAP" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_KeyManagementPersonnelCompensationVariableCompensation_860b3d10-e17b-4a0c-9ea5-058f97c26c1e_terseLabel_en-US" xlink:label="lab_abvx_KeyManagementPersonnelCompensationVariableCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable compensation owed</link:label>
    <link:label id="lab_abvx_KeyManagementPersonnelCompensationVariableCompensation_label_en-US" xlink:label="lab_abvx_KeyManagementPersonnelCompensationVariableCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key Management Personnel Compensation, Variable Compensation</link:label>
    <link:label id="lab_abvx_KeyManagementPersonnelCompensationVariableCompensation_documentation_en-US" xlink:label="lab_abvx_KeyManagementPersonnelCompensationVariableCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Key Management Personnel Compensation, Variable Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KeyManagementPersonnelCompensationVariableCompensation" xlink:href="abvx-20251231.xsd#abvx_KeyManagementPersonnelCompensationVariableCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_KeyManagementPersonnelCompensationVariableCompensation" xlink:to="lab_abvx_KeyManagementPersonnelCompensationVariableCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherFinancialAssets_2b62ad4f-f31b-4c92-88f1-0b5950b6a38a_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other financial assets</link:label>
    <link:label id="lab_ifrs-full_OtherFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_OtherFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherFinancialAssets" xlink:to="lab_ifrs-full_OtherFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_HeightsConvertibleNotesTrancheAMember_742ffc4a-2e18-4f87-b67d-e51d970f3027_terseLabel_en-US" xlink:label="lab_abvx_HeightsConvertibleNotesTrancheAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Heights convertible notes, tranche A</link:label>
    <link:label id="lab_abvx_HeightsConvertibleNotesTrancheAMember_label_en-US" xlink:label="lab_abvx_HeightsConvertibleNotesTrancheAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Heights Convertible Notes, Tranche A [Member]</link:label>
    <link:label id="lab_abvx_HeightsConvertibleNotesTrancheAMember_documentation_en-US" xlink:label="lab_abvx_HeightsConvertibleNotesTrancheAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Heights Convertible Notes, Tranche A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_HeightsConvertibleNotesTrancheAMember" xlink:href="abvx-20251231.xsd#abvx_HeightsConvertibleNotesTrancheAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_HeightsConvertibleNotesTrancheAMember" xlink:to="lab_abvx_HeightsConvertibleNotesTrancheAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComputerEquipmentMember_18f452e9-ecbe-4403-9105-9c46cd5b6041_verboseLabel_en-US" xlink:label="lab_ifrs-full_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">IT equipment</link:label>
    <link:label id="lab_ifrs-full_ComputerEquipmentMember_label_en-US" xlink:label="lab_ifrs-full_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer equipment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComputerEquipmentMember" xlink:to="lab_ifrs-full_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_fe56941f-b23b-4d85-a4bc-16cace761474_totalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and cash equivalents after effect of exchange rate changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_KreosABCBSAMember_734b4556-ebaa-4a93-b063-e79563b8bfd0_terseLabel_en-US" xlink:label="lab_abvx_KreosABCBSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kreos A &amp; B &amp; C BSA</link:label>
    <link:label id="lab_abvx_KreosABCBSAMember_label_en-US" xlink:label="lab_abvx_KreosABCBSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kreos A &amp; B &amp; C BSA [Member]</link:label>
    <link:label id="lab_abvx_KreosABCBSAMember_documentation_en-US" xlink:label="lab_abvx_KreosABCBSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kreos A &amp; B &amp; C BSA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosABCBSAMember" xlink:href="abvx-20251231.xsd#abvx_KreosABCBSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_KreosABCBSAMember" xlink:to="lab_abvx_KreosABCBSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems_dfe8f602-6fa2-45e6-9f7c-61ec80e18271_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of information for cash-generating units [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of information for cash-generating units [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems" xlink:to="lab_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset_019c574f-b20b-71a8-bbcb-6c7a0af26e2e_terseLabel_en-US" xlink:label="lab_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Past services cost</link:label>
    <link:label id="lab_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in net defined benefit liability (asset) resulting from past service cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_94281688-a575-4f48-b130-66139f17f8ba_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash flows provided by (used in) financing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_IssueOfEquityOfferingPricePerShare_492eebd1-2d39-4c9c-b073-7aa9ebc09097_terseLabel_en-US" xlink:label="lab_abvx_IssueOfEquityOfferingPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issue of equity, offering price per share (in dollar/euro per share)</link:label>
    <link:label id="lab_abvx_IssueOfEquityOfferingPricePerShare_label_en-US" xlink:label="lab_abvx_IssueOfEquityOfferingPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue Of Equity, Offering Price Per Share</link:label>
    <link:label id="lab_abvx_IssueOfEquityOfferingPricePerShare_documentation_en-US" xlink:label="lab_abvx_IssueOfEquityOfferingPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issue Of Equity, Offering Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IssueOfEquityOfferingPricePerShare" xlink:href="abvx-20251231.xsd#abvx_IssueOfEquityOfferingPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_IssueOfEquityOfferingPricePerShare" xlink:to="lab_abvx_IssueOfEquityOfferingPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NumberOfSharesLapsed_019cf6b9-29dd-7c73-9c14-43fbb74f0400_terseLabel_en-US" xlink:label="lab_abvx_NumberOfSharesLapsed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares lapsed (in shares)</link:label>
    <link:label id="lab_abvx_NumberOfSharesLapsed_label_en-US" xlink:label="lab_abvx_NumberOfSharesLapsed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Lapsed</link:label>
    <link:label id="lab_abvx_NumberOfSharesLapsed_documentation_en-US" xlink:label="lab_abvx_NumberOfSharesLapsed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Shares Lapsed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfSharesLapsed" xlink:href="abvx-20251231.xsd#abvx_NumberOfSharesLapsed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NumberOfSharesLapsed" xlink:to="lab_abvx_NumberOfSharesLapsed" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_1e828027-b8be-49c7-bd97-eabb059d602b_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AMORTIZATION</link:label>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated depreciation, amortisation and impairment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:to="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_0951412a-8e06-4d99-860d-8ca1173a6f42_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets at amortized cost</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_428e9438-b6d7-4864-9486-fbebf288b10a_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BorrowingsMarketPriceNumberOfTradingDays_1a814085-5a40-483c-87ba-347b4c5e631f_terseLabel_en-US" xlink:label="lab_abvx_BorrowingsMarketPriceNumberOfTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, market price, number of trading days</link:label>
    <link:label id="lab_abvx_BorrowingsMarketPriceNumberOfTradingDays_label_en-US" xlink:label="lab_abvx_BorrowingsMarketPriceNumberOfTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, Market Price, Number Of Trading Days</link:label>
    <link:label id="lab_abvx_BorrowingsMarketPriceNumberOfTradingDays_documentation_en-US" xlink:label="lab_abvx_BorrowingsMarketPriceNumberOfTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowings, Market Price, Number Of Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsMarketPriceNumberOfTradingDays" xlink:href="abvx-20251231.xsd#abvx_BorrowingsMarketPriceNumberOfTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BorrowingsMarketPriceNumberOfTradingDays" xlink:to="lab_abvx_BorrowingsMarketPriceNumberOfTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AGA2025Member_1a3ad859-67d4-4a77-8c23-93154e5d7956_terseLabel_en-US" xlink:label="lab_abvx_AGA2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA-2025</link:label>
    <link:label id="lab_abvx_AGA2025Member_label_en-US" xlink:label="lab_abvx_AGA2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA-2025 [Member]</link:label>
    <link:label id="lab_abvx_AGA2025Member_documentation_en-US" xlink:label="lab_abvx_AGA2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA-2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA2025Member" xlink:href="abvx-20251231.xsd#abvx_AGA2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AGA2025Member" xlink:to="lab_abvx_AGA2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_325fdd5d-d068-4261-aa2e-771b2b767045_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:to="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_45735487-f60b-413e-9c57-8184f3ae6bc3_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Key management personnel</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel of entity or parent [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lab_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_OCEANEMember_6b8d862d-c2ef-4e71-b14a-4d9bc88cf052_terseLabel_en-US" xlink:label="lab_abvx_OCEANEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OCEANE</link:label>
    <link:label id="lab_abvx_OCEANEMember_label_en-US" xlink:label="lab_abvx_OCEANEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCEANE [Member]</link:label>
    <link:label id="lab_abvx_OCEANEMember_documentation_en-US" xlink:label="lab_abvx_OCEANEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OCEANE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OCEANEMember" xlink:href="abvx-20251231.xsd#abvx_OCEANEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_OCEANEMember" xlink:to="lab_abvx_OCEANEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities_a4ed55bf-0d2a-44b2-bf17-a06a2ce692c8_terseLabel_en-US" xlink:label="lab_abvx_AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in deferred income and other liabilities</link:label>
    <link:label id="lab_abvx_AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities_label_en-US" xlink:label="lab_abvx_AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Increase (Decrease) In Deferred Income And Other Liabilities</link:label>
    <link:label id="lab_abvx_AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities_documentation_en-US" xlink:label="lab_abvx_AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments For Increase (Decrease) In Deferred Income And Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities" xlink:href="abvx-20251231.xsd#abvx_AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities" xlink:to="lab_abvx_AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NumberOfSharesWithPerformanceConditionsWaived_019cf6b7-2230-71c8-9354-04642524799e_terseLabel_en-US" xlink:label="lab_abvx_NumberOfSharesWithPerformanceConditionsWaived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares with performance conditions waived (in shares)</link:label>
    <link:label id="lab_abvx_NumberOfSharesWithPerformanceConditionsWaived_label_en-US" xlink:label="lab_abvx_NumberOfSharesWithPerformanceConditionsWaived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares With Performance Conditions Waived</link:label>
    <link:label id="lab_abvx_NumberOfSharesWithPerformanceConditionsWaived_documentation_en-US" xlink:label="lab_abvx_NumberOfSharesWithPerformanceConditionsWaived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Shares With Performance Conditions Waived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfSharesWithPerformanceConditionsWaived" xlink:href="abvx-20251231.xsd#abvx_NumberOfSharesWithPerformanceConditionsWaived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NumberOfSharesWithPerformanceConditionsWaived" xlink:to="lab_abvx_NumberOfSharesWithPerformanceConditionsWaived" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DrawdownProbablityMeasurementInputMember_f273075f-3ec4-4356-98ae-490517e9ef8d_terseLabel_en-US" xlink:label="lab_abvx_DrawdownProbablityMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Probability of Drawdown of Tranche C credit facility</link:label>
    <link:label id="lab_abvx_DrawdownProbablityMeasurementInputMember_label_en-US" xlink:label="lab_abvx_DrawdownProbablityMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Drawdown Probablity, Measurement Input [Member]</link:label>
    <link:label id="lab_abvx_DrawdownProbablityMeasurementInputMember_documentation_en-US" xlink:label="lab_abvx_DrawdownProbablityMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Drawdown Probablity, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DrawdownProbablityMeasurementInputMember" xlink:href="abvx-20251231.xsd#abvx_DrawdownProbablityMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DrawdownProbablityMeasurementInputMember" xlink:to="lab_abvx_DrawdownProbablityMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_A2024TaxYearMember_019c5757-3845-7d93-b699-835e2ee162b7_terseLabel_en-US" xlink:label="lab_abvx_A2024TaxYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Year 2024</link:label>
    <link:label id="lab_abvx_A2024TaxYearMember_label_en-US" xlink:label="lab_abvx_A2024TaxYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2024, Tax Year [Member]</link:label>
    <link:label id="lab_abvx_A2024TaxYearMember_documentation_en-US" xlink:label="lab_abvx_A2024TaxYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2024, Tax Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_A2024TaxYearMember" xlink:href="abvx-20251231.xsd#abvx_A2024TaxYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_A2024TaxYearMember" xlink:to="lab_abvx_A2024TaxYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfWarrantsArrangementsTable_ede3375b-80eb-4f6f-89ff-c5306b94faaf_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfWarrantsArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Warrants Arrangements [Table]</link:label>
    <link:label id="lab_abvx_DisclosureOfWarrantsArrangementsTable_label_en-US" xlink:label="lab_abvx_DisclosureOfWarrantsArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Warrants Arrangements [Table]</link:label>
    <link:label id="lab_abvx_DisclosureOfWarrantsArrangementsTable_documentation_en-US" xlink:label="lab_abvx_DisclosureOfWarrantsArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Warrants Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfWarrantsArrangementsTable" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfWarrantsArrangementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsTable" xlink:to="lab_abvx_DisclosureOfWarrantsArrangementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_6fd269a9-63b0-4d47-bb5e-e69b129dfe39_terseLabel_en-US" xlink:label="lab_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_label_en-US" xlink:label="lab_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Historical volatility for shares, measurement input [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:to="lab_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_CashAndCashEquivalentsAndOtherShortTermInvestments_019cd7eb-73d9-7baa-941b-14346731dcdd_terseLabel_en-US" xlink:label="lab_abvx_CashAndCashEquivalentsAndOtherShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents and other short-term investments</link:label>
    <link:label id="lab_abvx_CashAndCashEquivalentsAndOtherShortTermInvestments_label_en-US" xlink:label="lab_abvx_CashAndCashEquivalentsAndOtherShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents And Other Short-Term Investments</link:label>
    <link:label id="lab_abvx_CashAndCashEquivalentsAndOtherShortTermInvestments_documentation_en-US" xlink:label="lab_abvx_CashAndCashEquivalentsAndOtherShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents And Other Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CashAndCashEquivalentsAndOtherShortTermInvestments" xlink:href="abvx-20251231.xsd#abvx_CashAndCashEquivalentsAndOtherShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_CashAndCashEquivalentsAndOtherShortTermInvestments" xlink:to="lab_abvx_CashAndCashEquivalentsAndOtherShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfAssetsDomain_4de080d3-5366-4201-8b04-49b440f30007_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of assets [domain]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfAssetsDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of assets [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain" xlink:to="lab_ifrs-full_ClassesOfAssetsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_302951bb-2340-4349-a088-4e28e055c4b9_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NetProceedsFromSaleOfRoyaltyCertificates_3a95d9ea-11fc-4f99-b365-284ab94a08c8_terseLabel_en-US" xlink:label="lab_abvx_NetProceedsFromSaleOfRoyaltyCertificates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from sale of royalty certificates</link:label>
    <link:label id="lab_abvx_NetProceedsFromSaleOfRoyaltyCertificates_label_en-US" xlink:label="lab_abvx_NetProceedsFromSaleOfRoyaltyCertificates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Proceeds From Sale Of Royalty Certificates</link:label>
    <link:label id="lab_abvx_NetProceedsFromSaleOfRoyaltyCertificates_documentation_en-US" xlink:label="lab_abvx_NetProceedsFromSaleOfRoyaltyCertificates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Proceeds From Sale Of Royalty Certificates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NetProceedsFromSaleOfRoyaltyCertificates" xlink:href="abvx-20251231.xsd#abvx_NetProceedsFromSaleOfRoyaltyCertificates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NetProceedsFromSaleOfRoyaltyCertificates" xlink:to="lab_abvx_NetProceedsFromSaleOfRoyaltyCertificates" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AggregateFairValueConvertibleNotes_34a708e3-f210-413f-905c-2b4c83fd56c1_terseLabel_en-US" xlink:label="lab_abvx_AggregateFairValueConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of convertible notes</link:label>
    <link:label id="lab_abvx_AggregateFairValueConvertibleNotes_label_en-US" xlink:label="lab_abvx_AggregateFairValueConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Fair Value, Convertible Notes</link:label>
    <link:label id="lab_abvx_AggregateFairValueConvertibleNotes_documentation_en-US" xlink:label="lab_abvx_AggregateFairValueConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate Fair Value, Convertible Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AggregateFairValueConvertibleNotes" xlink:href="abvx-20251231.xsd#abvx_AggregateFairValueConvertibleNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AggregateFairValueConvertibleNotes" xlink:to="lab_abvx_AggregateFairValueConvertibleNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfLeaseLiabilitiesTable_5ccba557-3751-4e05-90b4-c5dfa14557fa_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfLeaseLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Lease Liabilities [Table]</link:label>
    <link:label id="lab_abvx_DisclosureOfLeaseLiabilitiesTable_label_en-US" xlink:label="lab_abvx_DisclosureOfLeaseLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Lease Liabilities [Table]</link:label>
    <link:label id="lab_abvx_DisclosureOfLeaseLiabilitiesTable_documentation_en-US" xlink:label="lab_abvx_DisclosureOfLeaseLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Lease Liabilities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfLeaseLiabilitiesTable" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfLeaseLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfLeaseLiabilitiesTable" xlink:to="lab_abvx_DisclosureOfLeaseLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashEquivalents_56027e01-7e36-42a4-af3b-5b95265b2f24_terseLabel_en-US" xlink:label="lab_ifrs-full_CashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashEquivalents_label_en-US" xlink:label="lab_ifrs-full_CashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashEquivalents" xlink:to="lab_ifrs-full_CashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_0d464420-1f4f-4b7e-83ff-e10099d8400f_terseLabel_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bottom of range</link:label>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bottom of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BottomOfRangeMember" xlink:to="lab_ifrs-full_BottomOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition_1b0c79dc-d1b8-4445-9efd-a07a0e044723_totalLabel_en-US" xlink:label="lab_abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred taxes, net recognized in the statement of financial position</link:label>
    <link:label id="lab_abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition_019d006a-5b30-77f7-90cf-31be8de00233_negatedTerseLabel_en-US" xlink:label="lab_abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:label id="lab_abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition_label_en-US" xlink:label="lab_abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Deferred Tax Assets (Liabilities) Recognised In Financial Position</link:label>
    <link:label id="lab_abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition_documentation_en-US" xlink:label="lab_abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Deferred Tax Assets (Liabilities) Recognised In Financial Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition" xlink:href="abvx-20251231.xsd#abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition" xlink:to="lab_abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_IssuancePricePercentageOfDiscountTo15DayWVAP_b4f000e1-e038-40ff-bb49-b8ccaa2e1b73_terseLabel_en-US" xlink:label="lab_abvx_IssuancePricePercentageOfDiscountTo15DayWVAP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance price, percentage of discount to 15-day WVAP</link:label>
    <link:label id="lab_abvx_IssuancePricePercentageOfDiscountTo15DayWVAP_label_en-US" xlink:label="lab_abvx_IssuancePricePercentageOfDiscountTo15DayWVAP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance Price, Percentage Of Discount To 15-Day WVAP</link:label>
    <link:label id="lab_abvx_IssuancePricePercentageOfDiscountTo15DayWVAP_documentation_en-US" xlink:label="lab_abvx_IssuancePricePercentageOfDiscountTo15DayWVAP" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance Price, Percentage Of Discount To 15-Day WVAP</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IssuancePricePercentageOfDiscountTo15DayWVAP" xlink:href="abvx-20251231.xsd#abvx_IssuancePricePercentageOfDiscountTo15DayWVAP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_IssuancePricePercentageOfDiscountTo15DayWVAP" xlink:to="lab_abvx_IssuancePricePercentageOfDiscountTo15DayWVAP" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfRelatedPartiesAxis_e79d43c2-b60b-42b6-b685-4c8b4436b407_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Categories of related parties [axis]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfRelatedPartiesAxis_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of related parties [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_5ee7af59-81a1-4085-bdf6-0cd1b62ef7e3_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AT&#160;AMORTIZED COST</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities at amortised cost, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_cdad755d-8947-40d9-84e0-fa614a60ef02_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of goodwill, intangible assets, property and plant and equipment</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for impairment of non-financial assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_dee12e89-47bf-4119-bbc4-3ddbe0a84e13_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ExercisePriceOtherEquityInstrumentsGranted_bae03535-9e32-4b6f-9019-14453903ccdb_terseLabel_en-US" xlink:label="lab_abvx_ExercisePriceOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price, other equity instruments granted (in euro per share)</link:label>
    <link:label id="lab_abvx_ExercisePriceOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_abvx_ExercisePriceOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price, Other Equity Instruments Granted</link:label>
    <link:label id="lab_abvx_ExercisePriceOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_abvx_ExercisePriceOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExercisePriceOtherEquityInstrumentsGranted" xlink:href="abvx-20251231.xsd#abvx_ExercisePriceOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ExercisePriceOtherEquityInstrumentsGranted" xlink:to="lab_abvx_ExercisePriceOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss_019d0116-c961-7d94-9c5d-5862ab13eceb_negatedLabel_en-US" xlink:label="lab_abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Losses on financial liabilities</link:label>
    <link:label id="lab_abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss_4982f2e0-a220-44d0-b69e-8d61b81bcaa1_negatedTerseLabel_en-US" xlink:label="lab_abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">(Increase) / decrease in other liabilities / (assets) at fair value through profit and loss</link:label>
    <link:label id="lab_abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss_label_en-US" xlink:label="lab_abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Losses On Financial Liabilities (Assets) At Fair Value Through Profit Or Loss</link:label>
    <link:label id="lab_abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss_documentation_en-US" xlink:label="lab_abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Losses On Financial Liabilities (Assets) At Fair Value Through Profit Or Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss" xlink:href="abvx-20251231.xsd#abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss" xlink:to="lab_abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLoss_a9b4116e-f278-4235-ba9b-381cde2e4cae_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss for the period</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_c2c57acb-02bc-4bef-a703-74bde1b43264_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss for the period</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_ca38392b-ce8d-4368-abb8-301eb6e17231_negatedLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_label_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss" xlink:to="lab_ifrs-full_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_670e6cd1-aa11-4ea3-ab81-8ea629dbbee5_terseLabel_en-US" xlink:label="lab_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of reasonably possible increase in unobservable input, liabilities (in euro per share)</link:label>
    <link:label id="lab_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_label_en-US" xlink:label="lab_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount Of Reasonably Possible Increase In Unobservable Input, Liabilities</link:label>
    <link:label id="lab_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_documentation_en-US" xlink:label="lab_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount Of Reasonably Possible Increase In Unobservable Input, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:href="abvx-20251231.xsd#abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:to="lab_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_KeyManagementPersonnelCompensationContractualSeveranceIndemnity_019cf693-fc6e-7ac7-84ab-f54eb3b660e6_terseLabel_en-US" xlink:label="lab_abvx_KeyManagementPersonnelCompensationContractualSeveranceIndemnity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual severance indemnity</link:label>
    <link:label id="lab_abvx_KeyManagementPersonnelCompensationContractualSeveranceIndemnity_label_en-US" xlink:label="lab_abvx_KeyManagementPersonnelCompensationContractualSeveranceIndemnity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key Management Personnel Compensation, Contractual Severance Indemnity</link:label>
    <link:label id="lab_abvx_KeyManagementPersonnelCompensationContractualSeveranceIndemnity_documentation_en-US" xlink:label="lab_abvx_KeyManagementPersonnelCompensationContractualSeveranceIndemnity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Key Management Personnel Compensation, Contractual Severance Indemnity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KeyManagementPersonnelCompensationContractualSeveranceIndemnity" xlink:href="abvx-20251231.xsd#abvx_KeyManagementPersonnelCompensationContractualSeveranceIndemnity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_KeyManagementPersonnelCompensationContractualSeveranceIndemnity" xlink:to="lab_abvx_KeyManagementPersonnelCompensationContractualSeveranceIndemnity" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_A150.0MillionFinancingAugust2023Member_48f6812b-024b-4eea-bfc8-6ddc49d1d1c7_terseLabel_en-US" xlink:label="lab_abvx_A150.0MillionFinancingAugust2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">&#8364;150.0&#160;million financing, august 2023</link:label>
    <link:label id="lab_abvx_A150.0MillionFinancingAugust2023Member_label_en-US" xlink:label="lab_abvx_A150.0MillionFinancingAugust2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">&#8364;150.0&#160;Million Financing, August 2023 [Member]</link:label>
    <link:label id="lab_abvx_A150.0MillionFinancingAugust2023Member_documentation_en-US" xlink:label="lab_abvx_A150.0MillionFinancingAugust2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">&#8364;150.0&#160;Million Financing, August 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_A150.0MillionFinancingAugust2023Member" xlink:href="abvx-20251231.xsd#abvx_A150.0MillionFinancingAugust2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_A150.0MillionFinancingAugust2023Member" xlink:to="lab_abvx_A150.0MillionFinancingAugust2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_MonteCarloModel1Member_db51edef-b5a6-4fd3-88b7-0a45e2b01702_terseLabel_en-US" xlink:label="lab_abvx_MonteCarloModel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Monte Carlo Model</link:label>
    <link:label id="lab_abvx_MonteCarloModel1Member_label_en-US" xlink:label="lab_abvx_MonteCarloModel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Monte Carlo Model1 [Member]</link:label>
    <link:label id="lab_abvx_MonteCarloModel1Member_documentation_en-US" xlink:label="lab_abvx_MonteCarloModel1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Monte Carlo Model</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_MonteCarloModel1Member" xlink:href="abvx-20251231.xsd#abvx_MonteCarloModel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_MonteCarloModel1Member" xlink:to="lab_abvx_MonteCarloModel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NumberOfShareBasedCompensationPlansIssued_7b00c4aa-e0e5-411b-8c7a-cb14f9e2b5c7_terseLabel_en-US" xlink:label="lab_abvx_NumberOfShareBasedCompensationPlansIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of share-based compensation plans issued</link:label>
    <link:label id="lab_abvx_NumberOfShareBasedCompensationPlansIssued_label_en-US" xlink:label="lab_abvx_NumberOfShareBasedCompensationPlansIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Share-Based Compensation Plans Issued</link:label>
    <link:label id="lab_abvx_NumberOfShareBasedCompensationPlansIssued_documentation_en-US" xlink:label="lab_abvx_NumberOfShareBasedCompensationPlansIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Share-Based Compensation Plans Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfShareBasedCompensationPlansIssued" xlink:href="abvx-20251231.xsd#abvx_NumberOfShareBasedCompensationPlansIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NumberOfShareBasedCompensationPlansIssued" xlink:to="lab_abvx_NumberOfShareBasedCompensationPlansIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NonCurrentAdvancesToCROContractsUndiscountedAmount_a5ea21bc-78a0-437c-97a0-ddc8150a8488_terseLabel_en-US" xlink:label="lab_abvx_NonCurrentAdvancesToCROContractsUndiscountedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advances related to CRO contracts</link:label>
    <link:label id="lab_abvx_NonCurrentAdvancesToCROContractsUndiscountedAmount_label_en-US" xlink:label="lab_abvx_NonCurrentAdvancesToCROContractsUndiscountedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Current Advances To CRO Contracts, Undiscounted Amount</link:label>
    <link:label id="lab_abvx_NonCurrentAdvancesToCROContractsUndiscountedAmount_documentation_en-US" xlink:label="lab_abvx_NonCurrentAdvancesToCROContractsUndiscountedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Current Advances To CRO Contracts, Undiscounted Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NonCurrentAdvancesToCROContractsUndiscountedAmount" xlink:href="abvx-20251231.xsd#abvx_NonCurrentAdvancesToCROContractsUndiscountedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NonCurrentAdvancesToCROContractsUndiscountedAmount" xlink:to="lab_abvx_NonCurrentAdvancesToCROContractsUndiscountedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_42510868-0e0e-4d05-b751-4b52bec54eb4_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="lab_ifrs-full_NoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClosingForeignExchangeRate_019beae9-f264-7252-a110-7b541ba1bd84_terseLabel_en-US" xlink:label="lab_ifrs-full_ClosingForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Closing foreign exchange rate</link:label>
    <link:label id="lab_ifrs-full_ClosingForeignExchangeRate_label_en-US" xlink:label="lab_ifrs-full_ClosingForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Closing foreign exchange rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClosingForeignExchangeRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClosingForeignExchangeRate" xlink:to="lab_ifrs-full_ClosingForeignExchangeRate" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_OtherCurrentInvestments_98b10c07-89dd-453f-95cb-4ad861087ba0_terseLabel_en-US" xlink:label="lab_abvx_OtherCurrentInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other investments</link:label>
    <link:label id="lab_abvx_OtherCurrentInvestments_label_en-US" xlink:label="lab_abvx_OtherCurrentInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Investments</link:label>
    <link:label id="lab_abvx_OtherCurrentInvestments_documentation_en-US" xlink:label="lab_abvx_OtherCurrentInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Current Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherCurrentInvestments" xlink:href="abvx-20251231.xsd#abvx_OtherCurrentInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_OtherCurrentInvestments" xlink:to="lab_abvx_OtherCurrentInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AGA20255Member_019beae7-6ccc-7432-93c2-8306dac3f689_terseLabel_en-US" xlink:label="lab_abvx_AGA20255Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA-2025-5</link:label>
    <link:label id="lab_abvx_AGA20255Member_label_en-US" xlink:label="lab_abvx_AGA20255Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA-2025-5 [Member]</link:label>
    <link:label id="lab_abvx_AGA20255Member_documentation_en-US" xlink:label="lab_abvx_AGA20255Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA-2025-5</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20255Member" xlink:href="abvx-20251231.xsd#abvx_AGA20255Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AGA20255Member" xlink:to="lab_abvx_AGA20255Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentRegistrationStatement_b425be70-634a-462f-b1f0-8a450db6c487_terseLabel_en-US" xlink:label="lab_dei_DocumentRegistrationStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Registration Statement</link:label>
    <link:label id="lab_dei_DocumentRegistrationStatement_label_en-US" xlink:label="lab_dei_DocumentRegistrationStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Registration Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentRegistrationStatement" xlink:to="lab_dei_DocumentRegistrationStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_0cf5e7af-34e0-442d-bb57-55aa2b3137cc_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued at beginning of period (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_588c221d-580e-4b61-8e74-9380ebb22ada_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued at end of period (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_020902c2-0d05-42d9-9186-538253730222_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssued" xlink:to="lab_ifrs-full_NumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_62e028c2-8a58-4a64-8aad-e00c3ac946ce_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment information</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of entity's operating segments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_LeaseFacilitiesBostonMember_73901dc6-ebec-4ab4-84f5-9497c3087985_terseLabel_en-US" xlink:label="lab_abvx_LeaseFacilitiesBostonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease facilities, Boston</link:label>
    <link:label id="lab_abvx_LeaseFacilitiesBostonMember_label_en-US" xlink:label="lab_abvx_LeaseFacilitiesBostonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Facilities, Boston [Member]</link:label>
    <link:label id="lab_abvx_LeaseFacilitiesBostonMember_documentation_en-US" xlink:label="lab_abvx_LeaseFacilitiesBostonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Facilities, Boston</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LeaseFacilitiesBostonMember" xlink:href="abvx-20251231.xsd#abvx_LeaseFacilitiesBostonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_LeaseFacilitiesBostonMember" xlink:to="lab_abvx_LeaseFacilitiesBostonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BorrowingsDebtToMarketCapitalizationRatio_d6d5f879-74ea-4dd7-b520-4dc80f4a5c35_terseLabel_en-US" xlink:label="lab_abvx_BorrowingsDebtToMarketCapitalizationRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, debt-to-market capitalization ratio</link:label>
    <link:label id="lab_abvx_BorrowingsDebtToMarketCapitalizationRatio_label_en-US" xlink:label="lab_abvx_BorrowingsDebtToMarketCapitalizationRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, Debt-To-Market Capitalization Ratio</link:label>
    <link:label id="lab_abvx_BorrowingsDebtToMarketCapitalizationRatio_documentation_en-US" xlink:label="lab_abvx_BorrowingsDebtToMarketCapitalizationRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowings, Debt-To-Market Capitalization Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsDebtToMarketCapitalizationRatio" xlink:href="abvx-20251231.xsd#abvx_BorrowingsDebtToMarketCapitalizationRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BorrowingsDebtToMarketCapitalizationRatio" xlink:to="lab_abvx_BorrowingsDebtToMarketCapitalizationRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_731817e3-4e0f-47df-af14-a6f32c3b5e63_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [domain]</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CapitalCommitments_b60113e1-6dd8-4858-a206-42cb3d6d937d_terseLabel_en-US" xlink:label="lab_ifrs-full_CapitalCommitments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital commitments</link:label>
    <link:label id="lab_ifrs-full_CapitalCommitments_label_en-US" xlink:label="lab_ifrs-full_CapitalCommitments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CapitalCommitments" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CapitalCommitments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CapitalCommitments" xlink:to="lab_ifrs-full_CapitalCommitments" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AGA20252Member_06fc4e5c-8bb5-469f-8df1-51d842212a86_terseLabel_en-US" xlink:label="lab_abvx_AGA20252Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA-2025-2</link:label>
    <link:label id="lab_abvx_AGA20252Member_label_en-US" xlink:label="lab_abvx_AGA20252Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA-2025-2 [Member]</link:label>
    <link:label id="lab_abvx_AGA20252Member_documentation_en-US" xlink:label="lab_abvx_AGA20252Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA-2025-2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20252Member" xlink:href="abvx-20251231.xsd#abvx_AGA20252Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AGA20252Member" xlink:to="lab_abvx_AGA20252Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayablesAbstract_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other current payables [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_495eb2a6-9962-4c1d-a748-e4572a3a61c9_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DEPRECIATION</link:label>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated depreciation and amortisation [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:to="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_c84985bf-0ffd-45ad-a681-45264ddde727_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial gain (loss)</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of finance income (cost) [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities_a2598cdf-10a4-4e7b-8e22-68a593dfbf70_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in financial liabilities at fair value due to reasonably possible decrease in unobservable input</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:to="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfCompositionOfCashAndCashEquivalentsTableTextBlock_28b35bb2-c9d9-407a-ada3-3af8649ea829_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfCompositionOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of composition of cash and cash equivalents</link:label>
    <link:label id="lab_abvx_DisclosureOfCompositionOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_abvx_DisclosureOfCompositionOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Composition Of Cash And Cash Equivalents [Table Text Block]</link:label>
    <link:label id="lab_abvx_DisclosureOfCompositionOfCashAndCashEquivalentsTableTextBlock_documentation_en-US" xlink:label="lab_abvx_DisclosureOfCompositionOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Composition Of Cash And Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfCompositionOfCashAndCashEquivalentsTableTextBlock" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfCompositionOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfCompositionOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_abvx_DisclosureOfCompositionOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_019c4331-b65b-7037-8020-ba25f79eb8a2_verboseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Kreos Claret OCABSA and Heights notes</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_3f700033-4fc4-4824-ae8f-f4fa8902c579_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) through conversion of convertible instruments, equity</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through conversion of convertible instruments, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_a87b0659-825c-493e-8459-cc6ae9baca6d_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FROM 1 TO 2 YEARS</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year and not later than two years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:to="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PresentValueOfDefinedBenefitObligationMember_2dec451a-23b8-4921-887e-44bc6326a83f_terseLabel_en-US" xlink:label="lab_ifrs-full_PresentValueOfDefinedBenefitObligationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RETIREMENT BENEFIT OBLIGATIONS</link:label>
    <link:label id="lab_ifrs-full_PresentValueOfDefinedBenefitObligationMember_label_en-US" xlink:label="lab_ifrs-full_PresentValueOfDefinedBenefitObligationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Present value of defined benefit obligation [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PresentValueOfDefinedBenefitObligationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember" xlink:to="lab_ifrs-full_PresentValueOfDefinedBenefitObligationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_8ad2b0e6-cfb9-4738-b63d-09624a8ed97e_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for leases [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_BusinessContactMember_1511029b-26a0-4d03-9b3f-8828ea30dabc_terseLabel_en-US" xlink:label="lab_dei_BusinessContactMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Contact</link:label>
    <link:label id="lab_dei_BusinessContactMember_label_en-US" xlink:label="lab_dei_BusinessContactMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Contact [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_BusinessContactMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember" xlink:to="lab_dei_BusinessContactMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_TrancheSixMember_ede8c5ea-5c53-4814-a50b-453c3692cf82_terseLabel_en-US" xlink:label="lab_abvx_TrancheSixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche 6</link:label>
    <link:label id="lab_abvx_TrancheSixMember_label_en-US" xlink:label="lab_abvx_TrancheSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche Six [Member]</link:label>
    <link:label id="lab_abvx_TrancheSixMember_documentation_en-US" xlink:label="lab_abvx_TrancheSixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche Six</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheSixMember" xlink:href="abvx-20251231.xsd#abvx_TrancheSixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_TrancheSixMember" xlink:to="lab_abvx_TrancheSixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_KreosClaretFinancingBAndCMember_019c4350-fd31-7846-a626-9490b59cae31_terseLabel_en-US" xlink:label="lab_abvx_KreosClaretFinancingBAndCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kreos/Claret financing B and C</link:label>
    <link:label id="lab_abvx_KreosClaretFinancingBAndCMember_label_en-US" xlink:label="lab_abvx_KreosClaretFinancingBAndCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kreos/Claret Financing B And C [Member]</link:label>
    <link:label id="lab_abvx_KreosClaretFinancingBAndCMember_documentation_en-US" xlink:label="lab_abvx_KreosClaretFinancingBAndCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kreos/Claret Financing B And C</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingBAndCMember" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingBAndCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_KreosClaretFinancingBAndCMember" xlink:to="lab_abvx_KreosClaretFinancingBAndCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_d66254da-c3f1-49fa-abab-52a9d3630957_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from payments from plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_TranchesOneToFourMember_a4abd2f6-6bab-488f-9931-754c054a6568_terseLabel_en-US" xlink:label="lab_abvx_TranchesOneToFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranches 1-4</link:label>
    <link:label id="lab_abvx_TranchesOneToFourMember_label_en-US" xlink:label="lab_abvx_TranchesOneToFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranches One To Four [Member]</link:label>
    <link:label id="lab_abvx_TranchesOneToFourMember_documentation_en-US" xlink:label="lab_abvx_TranchesOneToFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranches One To Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesOneToFourMember" xlink:href="abvx-20251231.xsd#abvx_TranchesOneToFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_TranchesOneToFourMember" xlink:to="lab_abvx_TranchesOneToFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BorrowingsBasisInterestRate_8a3dd2ee-debe-4e38-9735-e8854050abbc_terseLabel_en-US" xlink:label="lab_abvx_BorrowingsBasisInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, interest rate basis</link:label>
    <link:label id="lab_abvx_BorrowingsBasisInterestRate_label_en-US" xlink:label="lab_abvx_BorrowingsBasisInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, Basis Interest Rate</link:label>
    <link:label id="lab_abvx_BorrowingsBasisInterestRate_documentation_en-US" xlink:label="lab_abvx_BorrowingsBasisInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowings, Basis Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsBasisInterestRate" xlink:href="abvx-20251231.xsd#abvx_BorrowingsBasisInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BorrowingsBasisInterestRate" xlink:to="lab_abvx_BorrowingsBasisInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AGA20253Member_019bfaf6-28ef-748f-a102-478012e205d6_terseLabel_en-US" xlink:label="lab_abvx_AGA20253Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA-2025-3</link:label>
    <link:label id="lab_abvx_AGA20253Member_label_en-US" xlink:label="lab_abvx_AGA20253Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA-2025-3 [Member]</link:label>
    <link:label id="lab_abvx_AGA20253Member_documentation_en-US" xlink:label="lab_abvx_AGA20253Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA-2025-3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20253Member" xlink:href="abvx-20251231.xsd#abvx_AGA20253Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AGA20253Member" xlink:to="lab_abvx_AGA20253Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialAssetsDomain_8170f5a0-29d4-4137-9512-61c946658b4e_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Categories of financial assets [domain]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialAssetsDomain_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of financial assets [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:to="lab_ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_TrancheOneMember_74e134f6-befc-49e1-be3e-c9b1193c33b7_terseLabel_en-US" xlink:label="lab_abvx_TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche 1</link:label>
    <link:label id="lab_abvx_TrancheOneMember_label_en-US" xlink:label="lab_abvx_TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche One [Member]</link:label>
    <link:label id="lab_abvx_TrancheOneMember_documentation_en-US" xlink:label="lab_abvx_TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheOneMember" xlink:href="abvx-20251231.xsd#abvx_TrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_TrancheOneMember" xlink:to="lab_abvx_TrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountMember_17161518-4049-40ec-8e3a-6ca15010c7e3_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying amount [member]</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountMember" xlink:to="lab_ifrs-full_CarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets_fb6d5708-81d4-4e85-bc28-014ae04f532a_terseLabel_en-US" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of reasonably possible increase in unobservable input, assets</link:label>
    <link:label id="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets_label_en-US" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of reasonably possible increase in unobservable input, assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets" xlink:to="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnobservableInputsDomain_f1fc877f-25c8-4e4d-aa9c-bd7fdaefe73c_terseLabel_en-US" xlink:label="lab_ifrs-full_UnobservableInputsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unobservable inputs [domain]</link:label>
    <link:label id="lab_ifrs-full_UnobservableInputsDomain_label_en-US" xlink:label="lab_ifrs-full_UnobservableInputsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unobservable inputs [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnobservableInputsDomain" xlink:to="lab_ifrs-full_UnobservableInputsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ChangesInEquityAbstract_6d27481e-d641-4b92-90b1-2b6edecc0498_terseLabel_en-US" xlink:label="lab_ifrs-full_ChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in equity [abstract]</link:label>
    <link:label id="lab_ifrs-full_ChangesInEquityAbstract_label_en-US" xlink:label="lab_ifrs-full_ChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ChangesInEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ChangesInEquityAbstract" xlink:to="lab_ifrs-full_ChangesInEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_d6644b41-7dde-4e13-8b7f-164ef103d310_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total compensation</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_37c91932-a8a7-4ca6-bd38-8c71a73f5fcd_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_45d0a4d0-bd2e-4d64-a607-a6139be8f0f5_periodStartLabel_en-US" xlink:label="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Net defined benefit liability (asset) at beginning of period</link:label>
    <link:label id="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_fed50ee3-ca0a-4e37-a168-4d14b08e167f_periodEndLabel_en-US" xlink:label="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Net defined benefit liability (asset) at end of period</link:label>
    <link:label id="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_label_en-US" xlink:label="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net defined benefit liability (asset)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:to="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_FinancialRiskManagementAbstract_label_en-US" xlink:label="lab_abvx_FinancialRiskManagementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Risk Management [Abstract]</link:label>
    <link:label id="lab_abvx_FinancialRiskManagementAbstract_documentation_en-US" xlink:label="lab_abvx_FinancialRiskManagementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Risk Management [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialRiskManagementAbstract" xlink:href="abvx-20251231.xsd#abvx_FinancialRiskManagementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_FinancialRiskManagementAbstract" xlink:to="lab_abvx_FinancialRiskManagementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings_930f2088-6e0d-4338-b2ae-1862748d2fa2_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current borrowings and current portion of other non-current borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings" xlink:to="lab_ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory_887bf7ff-b70f-4009-a4c7-4dd07834970b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of main data and assumptions used for the measurement of other equity instruments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of indirect measurement of fair value of goods or services received, other equity instruments granted during period [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares_9416e326-7fe8-4cc6-b5b2-4c2f3a3844d3_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from sale of treasury shares</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sale or issue of treasury shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares" xlink:to="lab_ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDevelopedPreTaxRevenueThreshold_1e58af21-e5d4-40fd-894c-867aa44a34ca_terseLabel_en-US" xlink:label="lab_abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDevelopedPreTaxRevenueThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-tax revenue threshold</link:label>
    <link:label id="lab_abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDevelopedPreTaxRevenueThreshold_label_en-US" xlink:label="lab_abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDevelopedPreTaxRevenueThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Financial Liabilities, Percentage Of Annual Revenue From Sale Of Products Developed, Pre-Tax Revenue Threshold</link:label>
    <link:label id="lab_abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDevelopedPreTaxRevenueThreshold_documentation_en-US" xlink:label="lab_abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDevelopedPreTaxRevenueThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Financial Liabilities, Percentage Of Annual Revenue From Sale Of Products Developed, Pre-Tax Revenue Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDevelopedPreTaxRevenueThreshold" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDevelopedPreTaxRevenueThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDevelopedPreTaxRevenueThreshold" xlink:to="lab_abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDevelopedPreTaxRevenueThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentProvisionsForEmployeeBenefits_fa5097a0-9212-44c0-9b54-fd40c1c8c551_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement benefit obligations</link:label>
    <link:label id="lab_ifrs-full_NoncurrentProvisionsForEmployeeBenefits_label_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current provisions for employee benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentProvisionsForEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:to="lab_ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RightofuseAssets_5c80f070-ad39-48e6-a494-3a692f7b0564_terseLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RightofuseAssets" xlink:to="lab_ifrs-full_RightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_FinancialAgreementAmount_66a7e624-d942-4ab1-9dba-c8f709cead43_terseLabel_en-US" xlink:label="lab_abvx_FinancialAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial agreement, amount</link:label>
    <link:label id="lab_abvx_FinancialAgreementAmount_label_en-US" xlink:label="lab_abvx_FinancialAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Agreement, Amount</link:label>
    <link:label id="lab_abvx_FinancialAgreementAmount_documentation_en-US" xlink:label="lab_abvx_FinancialAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Agreement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialAgreementAmount" xlink:href="abvx-20251231.xsd#abvx_FinancialAgreementAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_FinancialAgreementAmount" xlink:to="lab_abvx_FinancialAgreementAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage_5ff6fa20-aa2e-4c98-9802-a8bd5cc22991_terseLabel_en-US" xlink:label="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage_label_en-US" xlink:label="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Vesting Percentage</link:label>
    <link:label id="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage_documentation_en-US" xlink:label="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Vesting Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" xlink:href="abvx-20251231.xsd#abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" xlink:to="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ContactPersonnelName_a09fa2d9-a4c7-4201-9469-30b884aeb4ff_terseLabel_en-US" xlink:label="lab_dei_ContactPersonnelName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contact Personnel Name</link:label>
    <link:label id="lab_dei_ContactPersonnelName_label_en-US" xlink:label="lab_dei_ContactPersonnelName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contact Personnel Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName" xlink:to="lab_dei_ContactPersonnelName" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_KreosClaretFinancingTrancheABAndCMember_cf937791-4fbb-4afe-bbd8-8ff91c366913_terseLabel_en-US" xlink:label="lab_abvx_KreosClaretFinancingTrancheABAndCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret Financing, Tranche A,B and C</link:label>
    <link:label id="lab_abvx_KreosClaretFinancingTrancheABAndCMember_label_en-US" xlink:label="lab_abvx_KreosClaretFinancingTrancheABAndCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret Financing, Tranche A,B and C [Member]</link:label>
    <link:label id="lab_abvx_KreosClaretFinancingTrancheABAndCMember_documentation_en-US" xlink:label="lab_abvx_KreosClaretFinancingTrancheABAndCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret Financing, Tranche A,B and C</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheABAndCMember" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheABAndCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_KreosClaretFinancingTrancheABAndCMember" xlink:to="lab_abvx_KreosClaretFinancingTrancheABAndCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NumberOfOtherShareWarrantsRepurchased_96f2815d-bb02-4820-ad74-c85c2d86665b_terseLabel_en-US" xlink:label="lab_abvx_NumberOfOtherShareWarrantsRepurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of other share warrants repurchased (in shares)</link:label>
    <link:label id="lab_abvx_NumberOfOtherShareWarrantsRepurchased_label_en-US" xlink:label="lab_abvx_NumberOfOtherShareWarrantsRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Other Share Warrants Repurchased</link:label>
    <link:label id="lab_abvx_NumberOfOtherShareWarrantsRepurchased_documentation_en-US" xlink:label="lab_abvx_NumberOfOtherShareWarrantsRepurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Other Share Warrants Repurchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfOtherShareWarrantsRepurchased" xlink:href="abvx-20251231.xsd#abvx_NumberOfOtherShareWarrantsRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NumberOfOtherShareWarrantsRepurchased" xlink:to="lab_abvx_NumberOfOtherShareWarrantsRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfAccountingPolicyForNewRevisedOrAmendedStandardsAndInterpretationsPolicyTextBlock_b8841b46-2dc0-4ce5-8496-bf8d3cddca38_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfAccountingPolicyForNewRevisedOrAmendedStandardsAndInterpretationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New, revised or amended Standards and Interpretations</link:label>
    <link:label id="lab_abvx_DisclosureOfAccountingPolicyForNewRevisedOrAmendedStandardsAndInterpretationsPolicyTextBlock_label_en-US" xlink:label="lab_abvx_DisclosureOfAccountingPolicyForNewRevisedOrAmendedStandardsAndInterpretationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Accounting Policy For New, Revised Or Amended Standards And Interpretations [Policy Text Block]</link:label>
    <link:label id="lab_abvx_DisclosureOfAccountingPolicyForNewRevisedOrAmendedStandardsAndInterpretationsPolicyTextBlock_documentation_en-US" xlink:label="lab_abvx_DisclosureOfAccountingPolicyForNewRevisedOrAmendedStandardsAndInterpretationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Accounting Policy For New, Revised Or Amended Standards And Interpretations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfAccountingPolicyForNewRevisedOrAmendedStandardsAndInterpretationsPolicyTextBlock" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfAccountingPolicyForNewRevisedOrAmendedStandardsAndInterpretationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfAccountingPolicyForNewRevisedOrAmendedStandardsAndInterpretationsPolicyTextBlock" xlink:to="lab_abvx_DisclosureOfAccountingPolicyForNewRevisedOrAmendedStandardsAndInterpretationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_RoyaltyCertificateExpirationPeriod_814fea03-bf40-4f17-b6b2-9f938e717aff_terseLabel_en-US" xlink:label="lab_abvx_RoyaltyCertificateExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty certificate, expiration period</link:label>
    <link:label id="lab_abvx_RoyaltyCertificateExpirationPeriod_label_en-US" xlink:label="lab_abvx_RoyaltyCertificateExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Certificate, Expiration Period</link:label>
    <link:label id="lab_abvx_RoyaltyCertificateExpirationPeriod_documentation_en-US" xlink:label="lab_abvx_RoyaltyCertificateExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Certificate, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificateExpirationPeriod" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificateExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_RoyaltyCertificateExpirationPeriod" xlink:to="lab_abvx_RoyaltyCertificateExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_LeasesRelatedTemporaryDifferencesMember_4020f538-8c53-4465-a960-f2d114191b42_terseLabel_en-US" xlink:label="lab_abvx_LeasesRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_abvx_LeasesRelatedTemporaryDifferencesMember_label_en-US" xlink:label="lab_abvx_LeasesRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases Related Temporary Differences [Member]</link:label>
    <link:label id="lab_abvx_LeasesRelatedTemporaryDifferencesMember_documentation_en-US" xlink:label="lab_abvx_LeasesRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Leases Related Temporary Differences</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LeasesRelatedTemporaryDifferencesMember" xlink:href="abvx-20251231.xsd#abvx_LeasesRelatedTemporaryDifferencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_LeasesRelatedTemporaryDifferencesMember" xlink:to="lab_abvx_LeasesRelatedTemporaryDifferencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ActuarialAssumptionOfEmployeeContributionRate_5c2d7332-53e2-4952-b80f-dc4b505bc43a_terseLabel_en-US" xlink:label="lab_abvx_ActuarialAssumptionOfEmployeeContributionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee contribution rate</link:label>
    <link:label id="lab_abvx_ActuarialAssumptionOfEmployeeContributionRate_label_en-US" xlink:label="lab_abvx_ActuarialAssumptionOfEmployeeContributionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial Assumption Of Employee Contribution Rate</link:label>
    <link:label id="lab_abvx_ActuarialAssumptionOfEmployeeContributionRate_documentation_en-US" xlink:label="lab_abvx_ActuarialAssumptionOfEmployeeContributionRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Actuarial Assumption Of Employee Contribution Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ActuarialAssumptionOfEmployeeContributionRate" xlink:href="abvx-20251231.xsd#abvx_ActuarialAssumptionOfEmployeeContributionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ActuarialAssumptionOfEmployeeContributionRate" xlink:to="lab_abvx_ActuarialAssumptionOfEmployeeContributionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ConversionPriceAdjustmentPeriod_ceaa9772-1ffe-4077-beb7-1a4497c81073_terseLabel_en-US" xlink:label="lab_abvx_ConversionPriceAdjustmentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion price, adjustment, period</link:label>
    <link:label id="lab_abvx_ConversionPriceAdjustmentPeriod_label_en-US" xlink:label="lab_abvx_ConversionPriceAdjustmentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion Price, Adjustment, Period</link:label>
    <link:label id="lab_abvx_ConversionPriceAdjustmentPeriod_documentation_en-US" xlink:label="lab_abvx_ConversionPriceAdjustmentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion Price, Adjustment, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConversionPriceAdjustmentPeriod" xlink:href="abvx-20251231.xsd#abvx_ConversionPriceAdjustmentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ConversionPriceAdjustmentPeriod" xlink:to="lab_abvx_ConversionPriceAdjustmentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NumberOfWarrantsGranted_b697c193-dc13-44e8-b175-ef0f611bd4f4_terseLabel_en-US" xlink:label="lab_abvx_NumberOfWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of warrants granted (in shares)</link:label>
    <link:label id="lab_abvx_NumberOfWarrantsGranted_label_en-US" xlink:label="lab_abvx_NumberOfWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Warrants Granted</link:label>
    <link:label id="lab_abvx_NumberOfWarrantsGranted_documentation_en-US" xlink:label="lab_abvx_NumberOfWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Warrants Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfWarrantsGranted" xlink:href="abvx-20251231.xsd#abvx_NumberOfWarrantsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NumberOfWarrantsGranted" xlink:to="lab_abvx_NumberOfWarrantsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AGA20254Member_019bfaf6-508e-7754-b7d5-17da09ed541c_terseLabel_en-US" xlink:label="lab_abvx_AGA20254Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA-2025-4</link:label>
    <link:label id="lab_abvx_AGA20254Member_label_en-US" xlink:label="lab_abvx_AGA20254Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA-2025-4 [Member]</link:label>
    <link:label id="lab_abvx_AGA20254Member_documentation_en-US" xlink:label="lab_abvx_AGA20254Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA-2025-4</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20254Member" xlink:href="abvx-20251231.xsd#abvx_AGA20254Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AGA20254Member" xlink:to="lab_abvx_AGA20254Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_IncreaseDecreaseInUlcerativeColitisExpenses_8e96fd6b-341c-4c51-a06b-6d6553b80468_terseLabel_en-US" xlink:label="lab_abvx_IncreaseDecreaseInUlcerativeColitisExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in Ulcerative Colitis expenses</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseInUlcerativeColitisExpenses_label_en-US" xlink:label="lab_abvx_IncreaseDecreaseInUlcerativeColitisExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Ulcerative Colitis Expenses</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseInUlcerativeColitisExpenses_documentation_en-US" xlink:label="lab_abvx_IncreaseDecreaseInUlcerativeColitisExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Ulcerative Colitis Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInUlcerativeColitisExpenses" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInUlcerativeColitisExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_IncreaseDecreaseInUlcerativeColitisExpenses" xlink:to="lab_abvx_IncreaseDecreaseInUlcerativeColitisExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DerivativesMember_6aa419d4-038c-4820-9ed7-02e78530fdd1_terseLabel_en-US" xlink:label="lab_ifrs-full_DerivativesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative instruments</link:label>
    <link:label id="lab_ifrs-full_DerivativesMember_label_en-US" xlink:label="lab_ifrs-full_DerivativesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DerivativesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DerivativesMember" xlink:to="lab_ifrs-full_DerivativesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValue_96106743-b403-4f9a-b5da-6771c520ed22_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets, at fair value</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValue_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets, at fair value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValue" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialAssetsAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtFairValue" xlink:to="lab_ifrs-full_FinancialAssetsAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_bd48cd74-74f6-4889-9c62-5a3a7c2e527b_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageCostOfCapitalMeasurementInputMember_0afe6e87-d192-45f9-88d3-7e278bd38018_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageCostOfCapitalMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">WACC</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageCostOfCapitalMeasurementInputMember_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageCostOfCapitalMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average cost of capital, measurement input [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageCostOfCapitalMeasurementInputMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageCostOfCapitalMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageCostOfCapitalMeasurementInputMember" xlink:to="lab_ifrs-full_WeightedAverageCostOfCapitalMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings_e5aa1aa7-bec9-4f6c-9bb5-8c017ec31212_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings_label_en-US" xlink:label="lab_ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current portion of other non-current borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings" xlink:to="lab_ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_PrincipalAgreementsDomain_d645d159-ba9a-404e-82f5-34e36ddee45d_terseLabel_en-US" xlink:label="lab_abvx_PrincipalAgreementsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal Agreements [Domain]</link:label>
    <link:label id="lab_abvx_PrincipalAgreementsDomain_label_en-US" xlink:label="lab_abvx_PrincipalAgreementsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal Agreements [Domain]</link:label>
    <link:label id="lab_abvx_PrincipalAgreementsDomain_documentation_en-US" xlink:label="lab_abvx_PrincipalAgreementsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Principal Agreements [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PrincipalAgreementsDomain" xlink:href="abvx-20251231.xsd#abvx_PrincipalAgreementsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_PrincipalAgreementsDomain" xlink:to="lab_abvx_PrincipalAgreementsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BSA201512Member_4bd2665c-b51d-40ac-94a0-87cbe1f0c59f_terseLabel_en-US" xlink:label="lab_abvx_BSA201512Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSA-2015-12</link:label>
    <link:label id="lab_abvx_BSA201512Member_label_en-US" xlink:label="lab_abvx_BSA201512Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSA-2015-12 [Member]</link:label>
    <link:label id="lab_abvx_BSA201512Member_documentation_en-US" xlink:label="lab_abvx_BSA201512Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BSA-2015-12</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA201512Member" xlink:href="abvx-20251231.xsd#abvx_BSA201512Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BSA201512Member" xlink:to="lab_abvx_BSA201512Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_OtherEmployeesMember_318121fb-24a1-4d40-b8ad-750b183a3971_terseLabel_en-US" xlink:label="lab_abvx_OtherEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other employees</link:label>
    <link:label id="lab_abvx_OtherEmployeesMember_label_en-US" xlink:label="lab_abvx_OtherEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Employees [Member]</link:label>
    <link:label id="lab_abvx_OtherEmployeesMember_documentation_en-US" xlink:label="lab_abvx_OtherEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherEmployeesMember" xlink:href="abvx-20251231.xsd#abvx_OtherEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_OtherEmployeesMember" xlink:to="lab_abvx_OtherEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedTaxLossesMember_6230caf7-7b08-4905-b9b5-4de9d7b1a5be_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax losses carryforward</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxLossesMember_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused tax losses [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnusedTaxLossesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxLossesMember" xlink:to="lab_ifrs-full_UnusedTaxLossesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AssetsAcquisitionsAxis_0e45ef6f-061b-44b0-9da0-24b2904bcacc_terseLabel_en-US" xlink:label="lab_abvx_AssetsAcquisitionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets Acquisitions [Axis]</link:label>
    <link:label id="lab_abvx_AssetsAcquisitionsAxis_label_en-US" xlink:label="lab_abvx_AssetsAcquisitionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets Acquisitions [Axis]</link:label>
    <link:label id="lab_abvx_AssetsAcquisitionsAxis_documentation_en-US" xlink:label="lab_abvx_AssetsAcquisitionsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AssetsAcquisitionsAxis" xlink:href="abvx-20251231.xsd#abvx_AssetsAcquisitionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AssetsAcquisitionsAxis" xlink:to="lab_abvx_AssetsAcquisitionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_1eb9114d-f5e7-4b44-ac95-84ebcae099ed_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase in net defined benefit liability (asset) resulting from current service cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_GainsArisingFromRecognitionOfFinancialLiabilities_09ec5313-3671-4fca-99ba-15324ca5411e_terseLabel_en-US" xlink:label="lab_abvx_GainsArisingFromRecognitionOfFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Day-one gain on recognition of financial liabilities</link:label>
    <link:label id="lab_abvx_GainsArisingFromRecognitionOfFinancialLiabilities_label_en-US" xlink:label="lab_abvx_GainsArisingFromRecognitionOfFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains Arising From Recognition Of Financial Liabilities</link:label>
    <link:label id="lab_abvx_GainsArisingFromRecognitionOfFinancialLiabilities_documentation_en-US" xlink:label="lab_abvx_GainsArisingFromRecognitionOfFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gains Arising From Recognition Of Financial Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_GainsArisingFromRecognitionOfFinancialLiabilities" xlink:href="abvx-20251231.xsd#abvx_GainsArisingFromRecognitionOfFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_GainsArisingFromRecognitionOfFinancialLiabilities" xlink:to="lab_abvx_GainsArisingFromRecognitionOfFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_40f1a5d1-59c8-42ff-ab37-422c9e624480_terseLabel_en-US" xlink:label="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TRANSLATION RESERVE</link:label>
    <link:label id="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_label_en-US" xlink:label="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve of exchange differences on translation [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:to="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_2d3e4f8f-4081-4140-8d22-f8dcd8b2a662_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities arising from financing activities [axis]</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities arising from financing activities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ProvisionsForAGATaxesRelatedTemporaryDifferencesMember_019c5785-c419-7239-831a-4af700fa0cb2_terseLabel_en-US" xlink:label="lab_abvx_ProvisionsForAGATaxesRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for AGA taxes</link:label>
    <link:label id="lab_abvx_ProvisionsForAGATaxesRelatedTemporaryDifferencesMember_label_en-US" xlink:label="lab_abvx_ProvisionsForAGATaxesRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions For AGA Taxes Related Temporary Differences [Member]</link:label>
    <link:label id="lab_abvx_ProvisionsForAGATaxesRelatedTemporaryDifferencesMember_documentation_en-US" xlink:label="lab_abvx_ProvisionsForAGATaxesRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provisions For AGA Taxes Related Temporary Differences</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ProvisionsForAGATaxesRelatedTemporaryDifferencesMember" xlink:href="abvx-20251231.xsd#abvx_ProvisionsForAGATaxesRelatedTemporaryDifferencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ProvisionsForAGATaxesRelatedTemporaryDifferencesMember" xlink:to="lab_abvx_ProvisionsForAGATaxesRelatedTemporaryDifferencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_KeyManagementPersonnelCompensationConsultingFees_019c579c-ae7e-713d-9ebe-4460f096550d_verboseLabel_en-US" xlink:label="lab_abvx_KeyManagementPersonnelCompensationConsultingFees" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Consulting fees</link:label>
    <link:label id="lab_abvx_KeyManagementPersonnelCompensationConsultingFees_label_en-US" xlink:label="lab_abvx_KeyManagementPersonnelCompensationConsultingFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key Management Personnel Compensation, Consulting Fees</link:label>
    <link:label id="lab_abvx_KeyManagementPersonnelCompensationConsultingFees_documentation_en-US" xlink:label="lab_abvx_KeyManagementPersonnelCompensationConsultingFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Key Management Personnel Compensation, Consulting Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KeyManagementPersonnelCompensationConsultingFees" xlink:href="abvx-20251231.xsd#abvx_KeyManagementPersonnelCompensationConsultingFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_KeyManagementPersonnelCompensationConsultingFees" xlink:to="lab_abvx_KeyManagementPersonnelCompensationConsultingFees" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherNoncurrentFinancialAssets_c288c0e5-7ee3-445b-b3e3-83280c51e983_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial assets</link:label>
    <link:label id="lab_ifrs-full_OtherNoncurrentFinancialAssets_5701b85a-0e5f-4156-89ec-43847b2da40b_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other non-current financial assets</link:label>
    <link:label id="lab_ifrs-full_OtherNoncurrentFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNoncurrentFinancialAssets" xlink:to="lab_ifrs-full_OtherNoncurrentFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_FinancialAgreementNumberOfTransactions_100288e5-667d-4cd1-a980-12c4e0d7da8d_terseLabel_en-US" xlink:label="lab_abvx_FinancialAgreementNumberOfTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial agreement, number of transactions</link:label>
    <link:label id="lab_abvx_FinancialAgreementNumberOfTransactions_label_en-US" xlink:label="lab_abvx_FinancialAgreementNumberOfTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Agreement, Number Of Transactions</link:label>
    <link:label id="lab_abvx_FinancialAgreementNumberOfTransactions_documentation_en-US" xlink:label="lab_abvx_FinancialAgreementNumberOfTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Agreement, Number Of Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialAgreementNumberOfTransactions" xlink:href="abvx-20251231.xsd#abvx_FinancialAgreementNumberOfTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_FinancialAgreementNumberOfTransactions" xlink:to="lab_abvx_FinancialAgreementNumberOfTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_RepaymentsOfNonConvertibleLoansNotes_019c4341-b7c1-7a57-b83f-3114af59a442_negatedTerseLabel_en-US" xlink:label="lab_abvx_RepaymentsOfNonConvertibleLoansNotes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayments of non-convertible bond loans</link:label>
    <link:label id="lab_abvx_RepaymentsOfNonConvertibleLoansNotes_label_en-US" xlink:label="lab_abvx_RepaymentsOfNonConvertibleLoansNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments Of Non-Convertible Loans Notes</link:label>
    <link:label id="lab_abvx_RepaymentsOfNonConvertibleLoansNotes_documentation_en-US" xlink:label="lab_abvx_RepaymentsOfNonConvertibleLoansNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Repayments Of Non-Convertible Loans Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepaymentsOfNonConvertibleLoansNotes" xlink:href="abvx-20251231.xsd#abvx_RepaymentsOfNonConvertibleLoansNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_RepaymentsOfNonConvertibleLoansNotes" xlink:to="lab_abvx_RepaymentsOfNonConvertibleLoansNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OperatingExpense_3f934e9b-d60f-459a-9848-26c6194e7086_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_OperatingExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_ifrs-full_OperatingExpense_d8b49319-51e9-4f14-817f-640b91cc9074_totalLabel_en-US" xlink:label="lab_ifrs-full_OperatingExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_ifrs-full_OperatingExpense_label_en-US" xlink:label="lab_ifrs-full_OperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OperatingExpense" xlink:to="lab_ifrs-full_OperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_TradePayablesAndOtherCurrentLiabilitiesMember_f3a679bc-a117-4ebb-8fa8-05e3ff6240e0_terseLabel_en-US" xlink:label="lab_abvx_TradePayablesAndOtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade payables and other current liabilities</link:label>
    <link:label id="lab_abvx_TradePayablesAndOtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_abvx_TradePayablesAndOtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade Payables And Other Current Liabilities [Member]</link:label>
    <link:label id="lab_abvx_TradePayablesAndOtherCurrentLiabilitiesMember_documentation_en-US" xlink:label="lab_abvx_TradePayablesAndOtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Trade Payables And Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TradePayablesAndOtherCurrentLiabilitiesMember" xlink:href="abvx-20251231.xsd#abvx_TradePayablesAndOtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_TradePayablesAndOtherCurrentLiabilitiesMember" xlink:to="lab_abvx_TradePayablesAndOtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_2900e019-1d5f-4f24-a1e3-f598baf3f3f0_terseLabel_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful life measured as period of time, intangible assets other than goodwill</link:label>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Useful life measured as period of time, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_280596fd-d212-4f07-a633-ba408c6fb73e_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis" xlink:to="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AssetsAcquisitionsDomain_4a43180c-0fbc-4c65-ae90-f3a0e2a66f94_terseLabel_en-US" xlink:label="lab_abvx_AssetsAcquisitionsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets Acquisitions [Domain]</link:label>
    <link:label id="lab_abvx_AssetsAcquisitionsDomain_label_en-US" xlink:label="lab_abvx_AssetsAcquisitionsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets Acquisitions [Domain]</link:label>
    <link:label id="lab_abvx_AssetsAcquisitionsDomain_documentation_en-US" xlink:label="lab_abvx_AssetsAcquisitionsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets Acquisitions [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AssetsAcquisitionsDomain" xlink:href="abvx-20251231.xsd#abvx_AssetsAcquisitionsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AssetsAcquisitionsDomain" xlink:to="lab_abvx_AssetsAcquisitionsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes_c1ddf67d-7655-4bfc-a29c-3e42522a7c44_terseLabel_en-US" xlink:label="lab_abvx_ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Social taxes related to AGAs</link:label>
    <link:label id="lab_abvx_ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes_label_en-US" xlink:label="lab_abvx_ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense From Equity-Settled Share-Based Payment Transactions, Social Taxes</link:label>
    <link:label id="lab_abvx_ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes_documentation_en-US" xlink:label="lab_abvx_ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expense From Equity-Settled Share-Based Payment Transactions, Social Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes" xlink:href="abvx-20251231.xsd#abvx_ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes" xlink:to="lab_abvx_ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsThatAreAntidilutiveInPeriodPresented_b64451e5-bcf8-453e-8f9a-fd4703f8101a_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsThatAreAntidilutiveInPeriodPresented" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of instruments that are antidilutive in period presented (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsThatAreAntidilutiveInPeriodPresented_label_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsThatAreAntidilutiveInPeriodPresented" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of instruments that are antidilutive in period presented</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsThatAreAntidilutiveInPeriodPresented" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfInstrumentsThatAreAntidilutiveInPeriodPresented"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfInstrumentsThatAreAntidilutiveInPeriodPresented" xlink:to="lab_ifrs-full_NumberOfInstrumentsThatAreAntidilutiveInPeriodPresented" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_MajorShareBasedTransactionsMember_45ea45fa-ad63-4783-a6fa-ac7cd2263931_terseLabel_en-US" xlink:label="lab_abvx_MajorShareBasedTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major share-based transactions</link:label>
    <link:label id="lab_abvx_MajorShareBasedTransactionsMember_label_en-US" xlink:label="lab_abvx_MajorShareBasedTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Share-Based Transactions [Member]</link:label>
    <link:label id="lab_abvx_MajorShareBasedTransactionsMember_documentation_en-US" xlink:label="lab_abvx_MajorShareBasedTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Major Share-Based Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_MajorShareBasedTransactionsMember" xlink:href="abvx-20251231.xsd#abvx_MajorShareBasedTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_MajorShareBasedTransactionsMember" xlink:to="lab_abvx_MajorShareBasedTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Equity_33830fdd-9f47-4061-a02f-556e10600993_totalLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_ifrs-full_Equity_659580f9-2471-4635-ba8e-1a0b429ca3f9_periodStartLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Equity at beginning of period</link:label>
    <link:label id="lab_ifrs-full_Equity_976681de-c564-4dca-885b-164f33cb26a4_periodEndLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Equity at end of period</link:label>
    <link:label id="lab_ifrs-full_Equity_3e74d43f-0c67-4dab-9cf6-d271bd0ceec7_terseLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_ifrs-full_Equity_label_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity" xlink:to="lab_ifrs-full_Equity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_04ba6837-a2a9-422d-9564-ec159e4dc33f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_label_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDFiling_1a7930bd-0b81-457b-9483-ecd4875c28aa_terseLabel_en-US" xlink:label="lab_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDFiling" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential development milestone payment, IND filing</link:label>
    <link:label id="lab_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDFiling_label_en-US" xlink:label="lab_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDFiling" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Potential Development Milestone Payment, IND Filing</link:label>
    <link:label id="lab_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDFiling_documentation_en-US" xlink:label="lab_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDFiling" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Potential Development Milestone Payment, IND Filing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDFiling" xlink:href="abvx-20251231.xsd#abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDFiling"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDFiling" xlink:to="lab_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDFiling" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCommitmentsExplanatory_7ab5dc04-a94d-4564-830b-9b6fc280290f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Off-balance sheet commitments given</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCommitmentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of commitments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_LeaseExtensionPeriod_23bcadd2-33fe-4ad8-b95b-a24c47d01650_terseLabel_en-US" xlink:label="lab_abvx_LeaseExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease, extension period</link:label>
    <link:label id="lab_abvx_LeaseExtensionPeriod_label_en-US" xlink:label="lab_abvx_LeaseExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Extension Period</link:label>
    <link:label id="lab_abvx_LeaseExtensionPeriod_documentation_en-US" xlink:label="lab_abvx_LeaseExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease, Extension Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LeaseExtensionPeriod" xlink:href="abvx-20251231.xsd#abvx_LeaseExtensionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_LeaseExtensionPeriod" xlink:to="lab_abvx_LeaseExtensionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AGA20256Member_019bfaf7-9523-7021-9517-91bd2ad66942_terseLabel_en-US" xlink:label="lab_abvx_AGA20256Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA-2025-6</link:label>
    <link:label id="lab_abvx_AGA20256Member_label_en-US" xlink:label="lab_abvx_AGA20256Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA-2025-6 [Member]</link:label>
    <link:label id="lab_abvx_AGA20256Member_documentation_en-US" xlink:label="lab_abvx_AGA20256Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA-2025-6</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20256Member" xlink:href="abvx-20251231.xsd#abvx_AGA20256Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AGA20256Member" xlink:to="lab_abvx_AGA20256Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NumberOfFinancialInstitutionsToMaintainCash_8efed09c-6d77-4f92-8dd3-bc525496618e_terseLabel_en-US" xlink:label="lab_abvx_NumberOfFinancialInstitutionsToMaintainCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of financial institutions to maintain cash</link:label>
    <link:label id="lab_abvx_NumberOfFinancialInstitutionsToMaintainCash_label_en-US" xlink:label="lab_abvx_NumberOfFinancialInstitutionsToMaintainCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Financial Institutions To Maintain Cash</link:label>
    <link:label id="lab_abvx_NumberOfFinancialInstitutionsToMaintainCash_documentation_en-US" xlink:label="lab_abvx_NumberOfFinancialInstitutionsToMaintainCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Financial Institutions To Maintain Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfFinancialInstitutionsToMaintainCash" xlink:href="abvx-20251231.xsd#abvx_NumberOfFinancialInstitutionsToMaintainCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NumberOfFinancialInstitutionsToMaintainCash" xlink:to="lab_abvx_NumberOfFinancialInstitutionsToMaintainCash" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_LeaseTacitRenewalPeriod_53993054-87c0-4025-98c9-41160de77021_terseLabel_en-US" xlink:label="lab_abvx_LeaseTacitRenewalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease, tacit renewal period</link:label>
    <link:label id="lab_abvx_LeaseTacitRenewalPeriod_label_en-US" xlink:label="lab_abvx_LeaseTacitRenewalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Tacit Renewal Period</link:label>
    <link:label id="lab_abvx_LeaseTacitRenewalPeriod_documentation_en-US" xlink:label="lab_abvx_LeaseTacitRenewalPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease, Tacit Renewal Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LeaseTacitRenewalPeriod" xlink:href="abvx-20251231.xsd#abvx_LeaseTacitRenewalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_LeaseTacitRenewalPeriod" xlink:to="lab_abvx_LeaseTacitRenewalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems_06c05cf1-fce9-481b-ab95-011eff00ad81_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</link:label>
    <link:label id="lab_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems_label_en-US" xlink:label="lab_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</link:label>
    <link:label id="lab_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems_documentation_en-US" xlink:label="lab_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Fair Value Measurement Of Assets And Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems" xlink:to="lab_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows_7b010c68-5230-42d0-97c1-b0c24f14aac0_terseLabel_en-US" xlink:label="lab_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative financial liabilities, undiscounted cash flows</link:label>
    <link:label id="lab_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows_label_en-US" xlink:label="lab_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial liabilities, undiscounted cash flows</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:to="lab_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherAssets_abf56ec3-4f63-4c05-865a-3b2819bfa610_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other receivables and assets</link:label>
    <link:label id="lab_ifrs-full_OtherAssets_label_en-US" xlink:label="lab_ifrs-full_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherAssets" xlink:to="lab_ifrs-full_OtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfContractsDomain_83281e3b-3c02-49d1-8011-05256c4b33d4_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfContractsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of contracts [domain]</link:label>
    <link:label id="lab_ifrs-full_TypesOfContractsDomain_label_en-US" xlink:label="lab_ifrs-full_TypesOfContractsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of contracts [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfContractsDomain" xlink:to="lab_ifrs-full_TypesOfContractsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_label_en-US" xlink:label="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate information and statement of IFRS compliance [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:to="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_e68da29e-13de-4c03-b2de-a5c892ed0baf_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_SalesAndMarketingExpenseMember_950a07eb-b4ba-42a4-a96c-a145545a5a46_terseLabel_en-US" xlink:label="lab_abvx_SalesAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales and marketing expenses</link:label>
    <link:label id="lab_abvx_SalesAndMarketingExpenseMember_label_en-US" xlink:label="lab_abvx_SalesAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales And Marketing Expense [Member]</link:label>
    <link:label id="lab_abvx_SalesAndMarketingExpenseMember_documentation_en-US" xlink:label="lab_abvx_SalesAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales And Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SalesAndMarketingExpenseMember" xlink:href="abvx-20251231.xsd#abvx_SalesAndMarketingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_SalesAndMarketingExpenseMember" xlink:to="lab_abvx_SalesAndMarketingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UndrawnBorrowingFacilities_7df80237-09f7-40e2-b419-f6bc64038193_terseLabel_en-US" xlink:label="lab_ifrs-full_UndrawnBorrowingFacilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undrawn borrowing facilities</link:label>
    <link:label id="lab_ifrs-full_UndrawnBorrowingFacilities_label_en-US" xlink:label="lab_ifrs-full_UndrawnBorrowingFacilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undrawn borrowing facilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UndrawnBorrowingFacilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UndrawnBorrowingFacilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UndrawnBorrowingFacilities" xlink:to="lab_ifrs-full_UndrawnBorrowingFacilities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_EquityInstrumentStrikePriceOtherEquityInstrumentsGranted_33fb5934-b2d5-4dc6-b684-2d08c2c9a61a_terseLabel_en-US" xlink:label="lab_abvx_EquityInstrumentStrikePriceOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STRIKE PRICE PER SHARE ( in euro per share)</link:label>
    <link:label id="lab_abvx_EquityInstrumentStrikePriceOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_abvx_EquityInstrumentStrikePriceOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Instrument Strike Price, Other Equity Instruments Granted</link:label>
    <link:label id="lab_abvx_EquityInstrumentStrikePriceOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_abvx_EquityInstrumentStrikePriceOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Instrument Strike Price, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EquityInstrumentStrikePriceOtherEquityInstrumentsGranted" xlink:href="abvx-20251231.xsd#abvx_EquityInstrumentStrikePriceOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_EquityInstrumentStrikePriceOtherEquityInstrumentsGranted" xlink:to="lab_abvx_EquityInstrumentStrikePriceOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DiscountRateMeasurementInputMember_e57486d5-9c70-411d-ae50-f4579fa36abc_terseLabel_en-US" xlink:label="lab_ifrs-full_DiscountRateMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_ifrs-full_DiscountRateMeasurementInputMember_label_en-US" xlink:label="lab_ifrs-full_DiscountRateMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discount rate, measurement input [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DiscountRateMeasurementInputMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DiscountRateMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DiscountRateMeasurementInputMember" xlink:to="lab_ifrs-full_DiscountRateMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NumberOfADSPerOrdinaryShares_bc6b026f-8d3e-4ef9-9059-2cd2b0accc14_terseLabel_en-US" xlink:label="lab_abvx_NumberOfADSPerOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of ADS per ordinary shares (in shares)</link:label>
    <link:label id="lab_abvx_NumberOfADSPerOrdinaryShares_label_en-US" xlink:label="lab_abvx_NumberOfADSPerOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of ADS per Ordinary Shares</link:label>
    <link:label id="lab_abvx_NumberOfADSPerOrdinaryShares_documentation_en-US" xlink:label="lab_abvx_NumberOfADSPerOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of ADS per Ordinary Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfADSPerOrdinaryShares" xlink:href="abvx-20251231.xsd#abvx_NumberOfADSPerOrdinaryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NumberOfADSPerOrdinaryShares" xlink:to="lab_abvx_NumberOfADSPerOrdinaryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_SubsidiesRelatedTemporaryDifferencesMember_4814767f-4285-475a-b824-54c00e47b01e_terseLabel_en-US" xlink:label="lab_abvx_SubsidiesRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidies</link:label>
    <link:label id="lab_abvx_SubsidiesRelatedTemporaryDifferencesMember_label_en-US" xlink:label="lab_abvx_SubsidiesRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidies Related Temporary Differences [Member]</link:label>
    <link:label id="lab_abvx_SubsidiesRelatedTemporaryDifferencesMember_documentation_en-US" xlink:label="lab_abvx_SubsidiesRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Subsidies Related Temporary Differences</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SubsidiesRelatedTemporaryDifferencesMember" xlink:href="abvx-20251231.xsd#abvx_SubsidiesRelatedTemporaryDifferencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_SubsidiesRelatedTemporaryDifferencesMember" xlink:to="lab_abvx_SubsidiesRelatedTemporaryDifferencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ConversionPricePerShareMeasurementInputMember_b45137f1-68dc-4f7a-9c80-f0b6f35a4822_terseLabel_en-US" xlink:label="lab_abvx_ConversionPricePerShareMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion price per share (in euro per share)</link:label>
    <link:label id="lab_abvx_ConversionPricePerShareMeasurementInputMember_label_en-US" xlink:label="lab_abvx_ConversionPricePerShareMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion Price Per Share, Measurement Input [Member]</link:label>
    <link:label id="lab_abvx_ConversionPricePerShareMeasurementInputMember_documentation_en-US" xlink:label="lab_abvx_ConversionPricePerShareMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion Price Per Share, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConversionPricePerShareMeasurementInputMember" xlink:href="abvx-20251231.xsd#abvx_ConversionPricePerShareMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ConversionPricePerShareMeasurementInputMember" xlink:to="lab_abvx_ConversionPricePerShareMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FixturesAndFittingsMember_2dd676e1-ad7e-4dbd-9370-b34551bf9402_terseLabel_en-US" xlink:label="lab_ifrs-full_FixturesAndFittingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office fixtures and fittings</link:label>
    <link:label id="lab_ifrs-full_FixturesAndFittingsMember_label_en-US" xlink:label="lab_ifrs-full_FixturesAndFittingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixtures and fittings [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixturesAndFittingsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FixturesAndFittingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FixturesAndFittingsMember" xlink:to="lab_ifrs-full_FixturesAndFittingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_PeakPenetrationMeasurementInputMember_57d1d524-59b2-42ec-980f-75bb55aeab32_terseLabel_en-US" xlink:label="lab_abvx_PeakPenetrationMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peak penetration</link:label>
    <link:label id="lab_abvx_PeakPenetrationMeasurementInputMember_label_en-US" xlink:label="lab_abvx_PeakPenetrationMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peak Penetration, Measurement Input [Member]</link:label>
    <link:label id="lab_abvx_PeakPenetrationMeasurementInputMember_documentation_en-US" xlink:label="lab_abvx_PeakPenetrationMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Peak Penetration, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PeakPenetrationMeasurementInputMember" xlink:href="abvx-20251231.xsd#abvx_PeakPenetrationMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_PeakPenetrationMeasurementInputMember" xlink:to="lab_abvx_PeakPenetrationMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock_27ebaf52-90e2-4084-804a-9bd5df96c84e_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of effective income tax (loss)</link:label>
    <link:label id="lab_abvx_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock_label_en-US" xlink:label="lab_abvx_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Reconciliation Of Accounting Profit Multiplied By Applicable Tax Rates And Average Effective Tax Rate [Table Text Block]</link:label>
    <link:label id="lab_abvx_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock_documentation_en-US" xlink:label="lab_abvx_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Reconciliation Of Accounting Profit Multiplied By Applicable Tax Rates And Average Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock" xlink:to="lab_abvx_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DepreciationExpenseLease_d40af09e-5e4d-436c-a09b-a3404239c6d5_terseLabel_en-US" xlink:label="lab_abvx_DepreciationExpenseLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense, lease</link:label>
    <link:label id="lab_abvx_DepreciationExpenseLease_label_en-US" xlink:label="lab_abvx_DepreciationExpenseLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation Expense, Lease</link:label>
    <link:label id="lab_abvx_DepreciationExpenseLease_documentation_en-US" xlink:label="lab_abvx_DepreciationExpenseLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Depreciation Expense, Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DepreciationExpenseLease" xlink:href="abvx-20251231.xsd#abvx_DepreciationExpenseLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DepreciationExpenseLease" xlink:to="lab_abvx_DepreciationExpenseLease" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_TheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember_876ce387-6119-4a0f-95b3-631a585aa024_terseLabel_en-US" xlink:label="lab_abvx_TheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Scripps Research Institute, University of Chicago and Brigham Young University</link:label>
    <link:label id="lab_abvx_TheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember_label_en-US" xlink:label="lab_abvx_TheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Scripps Research Institute, University Of Chicago And Brigham Young University [Member]</link:label>
    <link:label id="lab_abvx_TheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember_documentation_en-US" xlink:label="lab_abvx_TheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Scripps Research Institute, University Of Chicago And Brigham Young University</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember" xlink:href="abvx-20251231.xsd#abvx_TheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_TheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember" xlink:to="lab_abvx_TheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SalesAndMarketingExpense_7bbba9bf-83ce-45d1-9c69-e72aa0c99aca_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_SalesAndMarketingExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_ifrs-full_SalesAndMarketingExpense_label_en-US" xlink:label="lab_ifrs-full_SalesAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales and marketing expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SalesAndMarketingExpense" xlink:to="lab_ifrs-full_SalesAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForProvisions_019cc302-0be4-747a-9eaf-c5fa6ca146e8_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in provisions</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForProvisions_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForProvisions" xlink:to="lab_ifrs-full_AdjustmentsForProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfAccountingPolicyForAssetsAcquisitionsPolicyTextBlock_a6df2b91-6df4-40c2-9d4c-251eb05f017d_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfAccountingPolicyForAssetsAcquisitionsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting of Prosynergia acquisition</link:label>
    <link:label id="lab_abvx_DisclosureOfAccountingPolicyForAssetsAcquisitionsPolicyTextBlock_label_en-US" xlink:label="lab_abvx_DisclosureOfAccountingPolicyForAssetsAcquisitionsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Accounting Policy For Assets Acquisitions [Policy Text Block]</link:label>
    <link:label id="lab_abvx_DisclosureOfAccountingPolicyForAssetsAcquisitionsPolicyTextBlock_documentation_en-US" xlink:label="lab_abvx_DisclosureOfAccountingPolicyForAssetsAcquisitionsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Accounting Policy For Assets Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfAccountingPolicyForAssetsAcquisitionsPolicyTextBlock" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfAccountingPolicyForAssetsAcquisitionsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfAccountingPolicyForAssetsAcquisitionsPolicyTextBlock" xlink:to="lab_abvx_DisclosureOfAccountingPolicyForAssetsAcquisitionsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_OtherFinancialLiabilitiesPayableAnnualRevenueFromSaleOfProductsDeveloped_2efe48c6-387d-47fd-bf18-fd378f0cc58f_terseLabel_en-US" xlink:label="lab_abvx_OtherFinancialLiabilitiesPayableAnnualRevenueFromSaleOfProductsDeveloped" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual revenue from sale of products developed</link:label>
    <link:label id="lab_abvx_OtherFinancialLiabilitiesPayableAnnualRevenueFromSaleOfProductsDeveloped_label_en-US" xlink:label="lab_abvx_OtherFinancialLiabilitiesPayableAnnualRevenueFromSaleOfProductsDeveloped" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Financial Liabilities, Payable, Annual Revenue From Sale Of Products Developed</link:label>
    <link:label id="lab_abvx_OtherFinancialLiabilitiesPayableAnnualRevenueFromSaleOfProductsDeveloped_documentation_en-US" xlink:label="lab_abvx_OtherFinancialLiabilitiesPayableAnnualRevenueFromSaleOfProductsDeveloped" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Financial Liabilities, Payable, Annual Revenue From Sale Of Products Developed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialLiabilitiesPayableAnnualRevenueFromSaleOfProductsDeveloped" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialLiabilitiesPayableAnnualRevenueFromSaleOfProductsDeveloped"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_OtherFinancialLiabilitiesPayableAnnualRevenueFromSaleOfProductsDeveloped" xlink:to="lab_abvx_OtherFinancialLiabilitiesPayableAnnualRevenueFromSaleOfProductsDeveloped" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ExercisePricePerShareMeasurementInputMember_0eb3a5f1-73d3-4e64-a0c0-cf7d73ddec6f_terseLabel_en-US" xlink:label="lab_abvx_ExercisePricePerShareMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price per share (in euro per share)</link:label>
    <link:label id="lab_abvx_ExercisePricePerShareMeasurementInputMember_label_en-US" xlink:label="lab_abvx_ExercisePricePerShareMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Per Share, Measurement Input [Member]</link:label>
    <link:label id="lab_abvx_ExercisePricePerShareMeasurementInputMember_documentation_en-US" xlink:label="lab_abvx_ExercisePricePerShareMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Per Share, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExercisePricePerShareMeasurementInputMember" xlink:href="abvx-20251231.xsd#abvx_ExercisePricePerShareMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ExercisePricePerShareMeasurementInputMember" xlink:to="lab_abvx_ExercisePricePerShareMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilityAsset_3d42bcff-5939-4083-940a-adb351909d9a_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilityAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liability (asset)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxLiabilityAsset" xlink:to="lab_ifrs-full_DeferredTaxLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherAdjustmentsForNoncashItems_80684c55-bbfa-4a87-84ac-2cc97b4766d5_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherAdjustmentsForNoncashItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ifrs-full_OtherAdjustmentsForNoncashItems_label_en-US" xlink:label="lab_ifrs-full_OtherAdjustmentsForNoncashItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other adjustments for non-cash items</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAdjustmentsForNoncashItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherAdjustmentsForNoncashItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherAdjustmentsForNoncashItems" xlink:to="lab_ifrs-full_OtherAdjustmentsForNoncashItems" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_LeaseFacilitiesMember_a437e704-20d8-4ae0-a206-f177188ffef5_terseLabel_en-US" xlink:label="lab_abvx_LeaseFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease facilities</link:label>
    <link:label id="lab_abvx_LeaseFacilitiesMember_label_en-US" xlink:label="lab_abvx_LeaseFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Facilities [Member]</link:label>
    <link:label id="lab_abvx_LeaseFacilitiesMember_documentation_en-US" xlink:label="lab_abvx_LeaseFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Facilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LeaseFacilitiesMember" xlink:href="abvx-20251231.xsd#abvx_LeaseFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_LeaseFacilitiesMember" xlink:to="lab_abvx_LeaseFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilities_fac761f2-70e2-4273-a910-157d9720eb94_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="lab_ifrs-full_CurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AGA20251Member_019beae7-6ccc-7181-be08-f73b56d4b411_terseLabel_en-US" xlink:label="lab_abvx_AGA20251Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA-2025-1</link:label>
    <link:label id="lab_abvx_AGA20251Member_label_en-US" xlink:label="lab_abvx_AGA20251Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA-2025-1 [Member]</link:label>
    <link:label id="lab_abvx_AGA20251Member_documentation_en-US" xlink:label="lab_abvx_AGA20251Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA-2025-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20251Member" xlink:href="abvx-20251231.xsd#abvx_AGA20251Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AGA20251Member" xlink:to="lab_abvx_AGA20251Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherReceivablesAbstract_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other receivables [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="lab_ifrs-full_TradeAndOtherReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseByNatureAbstract_label_en-US" xlink:label="lab_ifrs-full_ExpenseByNatureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expenses by nature [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseByNatureAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseByNatureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract" xlink:to="lab_ifrs-full_ExpenseByNatureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxAssets_7a918e02-eaf0-423e-8608-2ccc28d3ba7f_terseLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxAssets_019c579a-6656-7d4e-98c5-e5214d0d7c2d_verboseLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxAssets_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxAssets" xlink:to="lab_ifrs-full_DeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DecreaseThroughReassessmentOfLeaseTermRightOfUseAssets_71d34997-eead-48f9-b8fa-fb5720d38a4c_terseLabel_en-US" xlink:label="lab_abvx_DecreaseThroughReassessmentOfLeaseTermRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease through reassessment of lease term</link:label>
    <link:label id="lab_abvx_DecreaseThroughReassessmentOfLeaseTermRightOfUseAssets_label_en-US" xlink:label="lab_abvx_DecreaseThroughReassessmentOfLeaseTermRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease Through Reassessment Of Lease Term, Right-Of-Use Assets</link:label>
    <link:label id="lab_abvx_DecreaseThroughReassessmentOfLeaseTermRightOfUseAssets_documentation_en-US" xlink:label="lab_abvx_DecreaseThroughReassessmentOfLeaseTermRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Decrease Through Reassessment Of Lease Term, Right-Of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DecreaseThroughReassessmentOfLeaseTermRightOfUseAssets" xlink:href="abvx-20251231.xsd#abvx_DecreaseThroughReassessmentOfLeaseTermRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DecreaseThroughReassessmentOfLeaseTermRightOfUseAssets" xlink:to="lab_abvx_DecreaseThroughReassessmentOfLeaseTermRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ProceedsFromReimbursementsOfDeposits_fa91d58d-5e65-4c1d-bc7c-3b9dc65f8bb6_terseLabel_en-US" xlink:label="lab_abvx_ProceedsFromReimbursementsOfDeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in deposits</link:label>
    <link:label id="lab_abvx_ProceedsFromReimbursementsOfDeposits_label_en-US" xlink:label="lab_abvx_ProceedsFromReimbursementsOfDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Reimbursements Of Deposits</link:label>
    <link:label id="lab_abvx_ProceedsFromReimbursementsOfDeposits_documentation_en-US" xlink:label="lab_abvx_ProceedsFromReimbursementsOfDeposits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Reimbursements Of Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ProceedsFromReimbursementsOfDeposits" xlink:href="abvx-20251231.xsd#abvx_ProceedsFromReimbursementsOfDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ProceedsFromReimbursementsOfDeposits" xlink:to="lab_abvx_ProceedsFromReimbursementsOfDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAccountingStandard_1aea010d-ba79-4ab2-9358-901d6c8d11b8_terseLabel_en-US" xlink:label="lab_dei_DocumentAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Accounting Standard</link:label>
    <link:label id="lab_dei_DocumentAccountingStandard_label_en-US" xlink:label="lab_dei_DocumentAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Accounting Standard</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAccountingStandard" xlink:to="lab_dei_DocumentAccountingStandard" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_dc759f48-16e0-4026-bae1-fa1413479892_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Social security and other</link:label>
    <link:label id="lab_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_label_en-US" xlink:label="lab_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current payables on social security and taxes other than income tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:to="lab_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_212184eb-b932-47c8-9b2d-3d5ee40d8a1c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ExpenseOnLeaseLiabilities_433b4332-9941-42d0-96b1-f3f86ed06328_terseLabel_en-US" xlink:label="lab_abvx_ExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense on lease liabilities</link:label>
    <link:label id="lab_abvx_ExpenseOnLeaseLiabilities_label_en-US" xlink:label="lab_abvx_ExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense On Lease Liabilities</link:label>
    <link:label id="lab_abvx_ExpenseOnLeaseLiabilities_documentation_en-US" xlink:label="lab_abvx_ExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expense On Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpenseOnLeaseLiabilities" xlink:href="abvx-20251231.xsd#abvx_ExpenseOnLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ExpenseOnLeaseLiabilities" xlink:to="lab_abvx_ExpenseOnLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid_e7766aa5-b75e-4117-b32a-2664544d58f9_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss of extinguishment</link:label>
    <link:label id="lab_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid_label_en-US" xlink:label="lab_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (loss) arising from difference between carrying amount of financial liability extinguished and consideration paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid" xlink:to="lab_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_56eaf68e-c9c3-4015-add6-cb743404ce56_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_4317139f-c032-4b77-8f4e-675816811269_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other operating expense [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfFinancialGainLossLineItems_0bdbf036-dee0-4dd2-8751-dab1b2c96e17_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfFinancialGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Financial Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_abvx_DisclosureOfFinancialGainLossLineItems_label_en-US" xlink:label="lab_abvx_DisclosureOfFinancialGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Financial Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_abvx_DisclosureOfFinancialGainLossLineItems_documentation_en-US" xlink:label="lab_abvx_DisclosureOfFinancialGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Financial Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfFinancialGainLossLineItems" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfFinancialGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfFinancialGainLossLineItems" xlink:to="lab_abvx_DisclosureOfFinancialGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_GeneralAndAdministrativeExpensesMember_88e8bef0-eadb-4c0d-81c0-f5d6f04b7298_terseLabel_en-US" xlink:label="lab_abvx_GeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_abvx_GeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_abvx_GeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General And Administrative Expenses [Member]</link:label>
    <link:label id="lab_abvx_GeneralAndAdministrativeExpensesMember_documentation_en-US" xlink:label="lab_abvx_GeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">General And Administrative Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_GeneralAndAdministrativeExpensesMember" xlink:href="abvx-20251231.xsd#abvx_GeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_GeneralAndAdministrativeExpensesMember" xlink:to="lab_abvx_GeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_8578fca8-4a2c-40c2-8cef-2a37e9cce7c7_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payments</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for share-based payment transactions [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_PretGarantiParLEtatPGEMember_bba446fc-aa05-4b73-9bc6-683e6b375bd2_terseLabel_en-US" xlink:label="lab_abvx_PretGarantiParLEtatPGEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PGE</link:label>
    <link:label id="lab_abvx_PretGarantiParLEtatPGEMember_label_en-US" xlink:label="lab_abvx_PretGarantiParLEtatPGEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pr&#234;t Garanti Par l'Etat (PGE) [Member]</link:label>
    <link:label id="lab_abvx_PretGarantiParLEtatPGEMember_documentation_en-US" xlink:label="lab_abvx_PretGarantiParLEtatPGEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pr&#234;t Garanti Par l'Etat (PGE)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PretGarantiParLEtatPGEMember" xlink:href="abvx-20251231.xsd#abvx_PretGarantiParLEtatPGEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_PretGarantiParLEtatPGEMember" xlink:to="lab_abvx_PretGarantiParLEtatPGEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AdvisorToTheChiefExecutiveOfficerMember_e3cdb635-5619-433d-83aa-7e29339112c9_terseLabel_en-US" xlink:label="lab_abvx_AdvisorToTheChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advisor to the Chief Executive Officer</link:label>
    <link:label id="lab_abvx_AdvisorToTheChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_abvx_AdvisorToTheChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advisor To The Chief Executive Officer [Member]</link:label>
    <link:label id="lab_abvx_AdvisorToTheChiefExecutiveOfficerMember_documentation_en-US" xlink:label="lab_abvx_AdvisorToTheChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Advisor To The Chief Executive Officer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AdvisorToTheChiefExecutiveOfficerMember" xlink:href="abvx-20251231.xsd#abvx_AdvisorToTheChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AdvisorToTheChiefExecutiveOfficerMember" xlink:to="lab_abvx_AdvisorToTheChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MeasurementDomain_7c8df89a-e337-4ba1-b311-81bbbd7690a8_terseLabel_en-US" xlink:label="lab_ifrs-full_MeasurementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement [domain]</link:label>
    <link:label id="lab_ifrs-full_MeasurementDomain_label_en-US" xlink:label="lab_ifrs-full_MeasurementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MeasurementDomain" xlink:to="lab_ifrs-full_MeasurementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_KreosABSAMember_c3062b82-68b1-4be8-9c6d-771d73fbfb7e_terseLabel_en-US" xlink:label="lab_abvx_KreosABSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kreos A BSA</link:label>
    <link:label id="lab_abvx_KreosABSAMember_label_en-US" xlink:label="lab_abvx_KreosABSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kreos A BSA [Member]</link:label>
    <link:label id="lab_abvx_KreosABSAMember_documentation_en-US" xlink:label="lab_abvx_KreosABSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kreos A BSA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosABSAMember" xlink:href="abvx-20251231.xsd#abvx_KreosABSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_KreosABSAMember" xlink:to="lab_abvx_KreosABSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ConvertibleLoansNotes_971fdd46-d125-4832-a82b-09b9e3e7efa9_terseLabel_en-US" xlink:label="lab_abvx_ConvertibleLoansNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible loans notes</link:label>
    <link:label id="lab_abvx_ConvertibleLoansNotes_label_en-US" xlink:label="lab_abvx_ConvertibleLoansNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Loans Notes</link:label>
    <link:label id="lab_abvx_ConvertibleLoansNotes_documentation_en-US" xlink:label="lab_abvx_ConvertibleLoansNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Loans Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotes" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ConvertibleLoansNotes" xlink:to="lab_abvx_ConvertibleLoansNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AGA20235Member_4650dc99-5ae5-40d1-b91b-9f6029735c37_terseLabel_en-US" xlink:label="lab_abvx_AGA20235Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA-2023-5</link:label>
    <link:label id="lab_abvx_AGA20235Member_label_en-US" xlink:label="lab_abvx_AGA20235Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA-2023-5 [Member]</link:label>
    <link:label id="lab_abvx_AGA20235Member_documentation_en-US" xlink:label="lab_abvx_AGA20235Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA-2023-5</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20235Member" xlink:href="abvx-20251231.xsd#abvx_AGA20235Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AGA20235Member" xlink:to="lab_abvx_AGA20235Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfEmployeeWorkforceLineItems_fa9a282e-a28f-40c1-89b1-1f356254fb49_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfEmployeeWorkforceLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Employee Workforce [Line Items]</link:label>
    <link:label id="lab_abvx_DisclosureOfEmployeeWorkforceLineItems_label_en-US" xlink:label="lab_abvx_DisclosureOfEmployeeWorkforceLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Employee Workforce [Line Items]</link:label>
    <link:label id="lab_abvx_DisclosureOfEmployeeWorkforceLineItems_documentation_en-US" xlink:label="lab_abvx_DisclosureOfEmployeeWorkforceLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Employee Workforce [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfEmployeeWorkforceLineItems" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfEmployeeWorkforceLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfEmployeeWorkforceLineItems" xlink:to="lab_abvx_DisclosureOfEmployeeWorkforceLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_OtherLiabilitiesNumberOfTransactions_20fe7e5e-1e34-49c6-abfe-c390fdf5f389_terseLabel_en-US" xlink:label="lab_abvx_OtherLiabilitiesNumberOfTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities, number of transactions</link:label>
    <link:label id="lab_abvx_OtherLiabilitiesNumberOfTransactions_label_en-US" xlink:label="lab_abvx_OtherLiabilitiesNumberOfTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Number Of Transactions</link:label>
    <link:label id="lab_abvx_OtherLiabilitiesNumberOfTransactions_documentation_en-US" xlink:label="lab_abvx_OtherLiabilitiesNumberOfTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Liabilities, Number Of Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherLiabilitiesNumberOfTransactions" xlink:href="abvx-20251231.xsd#abvx_OtherLiabilitiesNumberOfTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_OtherLiabilitiesNumberOfTransactions" xlink:to="lab_abvx_OtherLiabilitiesNumberOfTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_FoundersShareSubscriptionWarrantsBCEMember_588fa141-7b1e-460b-b66a-df64251cd6c6_terseLabel_en-US" xlink:label="lab_abvx_FoundersShareSubscriptionWarrantsBCEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total BCEs</link:label>
    <link:label id="lab_abvx_FoundersShareSubscriptionWarrantsBCEMember_7192e5f8-8f5e-41ba-9838-c8923e27dfea_verboseLabel_en-US" xlink:label="lab_abvx_FoundersShareSubscriptionWarrantsBCEMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">BCEs</link:label>
    <link:label id="lab_abvx_FoundersShareSubscriptionWarrantsBCEMember_label_en-US" xlink:label="lab_abvx_FoundersShareSubscriptionWarrantsBCEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Founders&#8217; Share Subscription Warrants (BCE) [Member]</link:label>
    <link:label id="lab_abvx_FoundersShareSubscriptionWarrantsBCEMember_documentation_en-US" xlink:label="lab_abvx_FoundersShareSubscriptionWarrantsBCEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Founders&#8217; Share Subscription Warrants (BCE)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FoundersShareSubscriptionWarrantsBCEMember" xlink:href="abvx-20251231.xsd#abvx_FoundersShareSubscriptionWarrantsBCEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_FoundersShareSubscriptionWarrantsBCEMember" xlink:to="lab_abvx_FoundersShareSubscriptionWarrantsBCEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_38f3dd40-2bdd-42b0-b28b-56a950e0d2af_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SignificantUnobservableInputAssets_5070d19b-7873-4c4e-9dff-20dd9b4b8dba_terseLabel_en-US" xlink:label="lab_ifrs-full_SignificantUnobservableInputAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant unobservable input, assets</link:label>
    <link:label id="lab_ifrs-full_SignificantUnobservableInputAssets_label_en-US" xlink:label="lab_ifrs-full_SignificantUnobservableInputAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant unobservable input, assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantUnobservableInputAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SignificantUnobservableInputAssets" xlink:to="lab_ifrs-full_SignificantUnobservableInputAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BuildingsMember_98945325-5fdf-43a4-aab4-b6339e5da7be_terseLabel_en-US" xlink:label="lab_ifrs-full_BuildingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BUILDINGS</link:label>
    <link:label id="lab_ifrs-full_BuildingsMember_b9f1a113-a19d-49e8-8424-c44d8644763e_verboseLabel_en-US" xlink:label="lab_ifrs-full_BuildingsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_ifrs-full_BuildingsMember_label_en-US" xlink:label="lab_ifrs-full_BuildingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Buildings [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BuildingsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BuildingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BuildingsMember" xlink:to="lab_ifrs-full_BuildingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_03ebcf9a-2164-45fb-ac82-b5cee9b7c273_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of instruments issued (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_25d003ed-58a6-4bb4-a37e-e55817cf6b52_verboseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">NUMBE OF BSAs ( in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfRisksDomain_ab38d2ed-3e9d-45b0-917a-98a46d31fdad_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfRisksDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of risks [domain]</link:label>
    <link:label id="lab_ifrs-full_TypesOfRisksDomain_label_en-US" xlink:label="lab_ifrs-full_TypesOfRisksDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of risks [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfRisksDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksDomain" xlink:to="lab_ifrs-full_TypesOfRisksDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_c42771fd-356c-45f2-ba5d-8f868da5d09f_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease / (increase) in other receivables and related accounts</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in trade and other receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_6e0ceec1-b518-4bc0-b250-af6fccb76909_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BSA20251Member_2281c9fc-47d4-4044-8d3d-613d070f4e1b_terseLabel_en-US" xlink:label="lab_abvx_BSA20251Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSA-2025-1</link:label>
    <link:label id="lab_abvx_BSA20251Member_label_en-US" xlink:label="lab_abvx_BSA20251Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSA-2025-1 [Member]</link:label>
    <link:label id="lab_abvx_BSA20251Member_documentation_en-US" xlink:label="lab_abvx_BSA20251Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BSA-2025-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20251Member" xlink:href="abvx-20251231.xsd#abvx_BSA20251Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BSA20251Member" xlink:to="lab_abvx_BSA20251Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_45095624-a60c-4685-aa8a-f4b4afe1a075_terseLabel_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiaries [axis]</link:label>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_label_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiaries [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_A49.2MillionCrossOverFinancingSeptember2022Member_55755966-f1a2-4df6-8e46-22816d5c967e_terseLabel_en-US" xlink:label="lab_abvx_A49.2MillionCrossOverFinancingSeptember2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">&#8364;49.2 million cross-over financing, september 2022</link:label>
    <link:label id="lab_abvx_A49.2MillionCrossOverFinancingSeptember2022Member_label_en-US" xlink:label="lab_abvx_A49.2MillionCrossOverFinancingSeptember2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">&#8364;49.2&#160;Million Cross-Over Financing, September 2022 [Member]</link:label>
    <link:label id="lab_abvx_A49.2MillionCrossOverFinancingSeptember2022Member_documentation_en-US" xlink:label="lab_abvx_A49.2MillionCrossOverFinancingSeptember2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">&#8364;49.2&#160;Million Cross-Over Financing, September 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_A49.2MillionCrossOverFinancingSeptember2022Member" xlink:href="abvx-20251231.xsd#abvx_A49.2MillionCrossOverFinancingSeptember2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_A49.2MillionCrossOverFinancingSeptember2022Member" xlink:to="lab_abvx_A49.2MillionCrossOverFinancingSeptember2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_KreosClaretFinancingTrancheCMember_d2741472-9057-40c8-b5af-df96128afd67_terseLabel_en-US" xlink:label="lab_abvx_KreosClaretFinancingTrancheCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret financing, tranche C</link:label>
    <link:label id="lab_abvx_KreosClaretFinancingTrancheCMember_label_en-US" xlink:label="lab_abvx_KreosClaretFinancingTrancheCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret Financing, Tranche C [Member]</link:label>
    <link:label id="lab_abvx_KreosClaretFinancingTrancheCMember_documentation_en-US" xlink:label="lab_abvx_KreosClaretFinancingTrancheCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret Financing, Tranche C</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheCMember" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_KreosClaretFinancingTrancheCMember" xlink:to="lab_abvx_KreosClaretFinancingTrancheCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ManagementMember_6a4c1521-16be-473b-9f89-9099e60962d1_terseLabel_en-US" xlink:label="lab_srt_ManagementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Key magement</link:label>
    <link:label id="lab_srt_ManagementMember_label_en-US" xlink:label="lab_srt_ManagementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Management [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ManagementMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ManagementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ManagementMember" xlink:to="lab_srt_ManagementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted_cbadcf66-d3d0-4d6c-b86c-cfb82bc508e9_terseLabel_en-US" xlink:label="lab_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAIR VALUE OF THE UNDERLYING SHARE (in euro per share)</link:label>
    <link:label id="lab_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Share Fair Value, Other Equity Instruments Granted</link:label>
    <link:label id="lab_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Underlying Share Fair Value, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted" xlink:href="abvx-20251231.xsd#abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted" xlink:to="lab_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_019c5799-5262-7139-971a-fe5efce59a69_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesTable_74b72536-76c8-4531-ab22-2c97aa0e2307_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfIndirectMeasurementOfConvertibleLoansInstrumentsTableTextBlock_0fea1238-5a83-484b-8291-962c043a49d4_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfIndirectMeasurementOfConvertibleLoansInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of main data and assumptions used for the measurement of convertible loan notes</link:label>
    <link:label id="lab_abvx_DisclosureOfIndirectMeasurementOfConvertibleLoansInstrumentsTableTextBlock_label_en-US" xlink:label="lab_abvx_DisclosureOfIndirectMeasurementOfConvertibleLoansInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Indirect Measurement Of Convertible Loans Instruments [Table Text Block]</link:label>
    <link:label id="lab_abvx_DisclosureOfIndirectMeasurementOfConvertibleLoansInstrumentsTableTextBlock_documentation_en-US" xlink:label="lab_abvx_DisclosureOfIndirectMeasurementOfConvertibleLoansInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfIndirectMeasurementOfConvertibleLoansInstrumentsTableTextBlock" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfIndirectMeasurementOfConvertibleLoansInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfIndirectMeasurementOfConvertibleLoansInstrumentsTableTextBlock" xlink:to="lab_abvx_DisclosureOfIndirectMeasurementOfConvertibleLoansInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfDetailedInformationOfOperatingIncomeExplanatoryTableTextBlock_80df87b1-d2c1-4563-aba7-317e8ae7e322_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfDetailedInformationOfOperatingIncomeExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of breakdown of operating income</link:label>
    <link:label id="lab_abvx_DisclosureOfDetailedInformationOfOperatingIncomeExplanatoryTableTextBlock_label_en-US" xlink:label="lab_abvx_DisclosureOfDetailedInformationOfOperatingIncomeExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information Of Operating Income Explanatory [Table Text Block]</link:label>
    <link:label id="lab_abvx_DisclosureOfDetailedInformationOfOperatingIncomeExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_abvx_DisclosureOfDetailedInformationOfOperatingIncomeExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information Of Operating Income Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfDetailedInformationOfOperatingIncomeExplanatoryTableTextBlock" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfDetailedInformationOfOperatingIncomeExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfDetailedInformationOfOperatingIncomeExplanatoryTableTextBlock" xlink:to="lab_abvx_DisclosureOfDetailedInformationOfOperatingIncomeExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember_22ff5953-2895-46e0-adfe-babf34b72eec_terseLabel_en-US" xlink:label="lab_abvx_FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Final redemption, probability-weighted fair value with MRI</link:label>
    <link:label id="lab_abvx_FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember_label_en-US" xlink:label="lab_abvx_FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Final Redemption, Probability-Weighted Fair Value With MRI , Measurement Input [Member]</link:label>
    <link:label id="lab_abvx_FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember_documentation_en-US" xlink:label="lab_abvx_FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Final Redemption, Probability-Weighted Fair Value With MRI , Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember" xlink:href="abvx-20251231.xsd#abvx_FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember" xlink:to="lab_abvx_FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GeographicalAreasAxis_7c7187bd-94b8-49c3-8b62-ec0a01b31c92_terseLabel_en-US" xlink:label="lab_ifrs-full_GeographicalAreasAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical areas [axis]</link:label>
    <link:label id="lab_ifrs-full_GeographicalAreasAxis_label_en-US" xlink:label="lab_ifrs-full_GeographicalAreasAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical areas [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeographicalAreasAxis" xlink:to="lab_ifrs-full_GeographicalAreasAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_b6b8d70e-109a-472e-a2c1-8a4d62404657_terseLabel_en-US" xlink:label="lab_ifrs-full_NetDefinedBenefitLiabilityAssetDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net defined benefit liability (asset) [domain]</link:label>
    <link:label id="lab_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_label_en-US" xlink:label="lab_ifrs-full_NetDefinedBenefitLiabilityAssetDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net defined benefit liability (asset) [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain" xlink:to="lab_ifrs-full_NetDefinedBenefitLiabilityAssetDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AGA20243Member_1f63e4fb-ef7a-497f-88e5-c2ef084d2d3c_terseLabel_en-US" xlink:label="lab_abvx_AGA20243Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA-2024-3</link:label>
    <link:label id="lab_abvx_AGA20243Member_label_en-US" xlink:label="lab_abvx_AGA20243Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA-2024-3 [Member]</link:label>
    <link:label id="lab_abvx_AGA20243Member_documentation_en-US" xlink:label="lab_abvx_AGA20243Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA-2024-3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20243Member" xlink:href="abvx-20251231.xsd#abvx_AGA20243Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AGA20243Member" xlink:to="lab_abvx_AGA20243Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities_becdab4c-f27c-489e-ae77-5868b4e3fc44_periodStartLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Liabilities arising from financing activities at beginning of period</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities_acaa2b35-87d7-47de-8f33-b807e96e3826_periodEndLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Liabilities arising from financing activities at end of period</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities arising from financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:to="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_Kreos2TrancheAMember_9cd7405a-877c-4cc5-8b72-f9616b9593d9_terseLabel_en-US" xlink:label="lab_abvx_Kreos2TrancheAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kreos 2, tranche A</link:label>
    <link:label id="lab_abvx_Kreos2TrancheAMember_label_en-US" xlink:label="lab_abvx_Kreos2TrancheAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kreos 2, Tranche A [Member]</link:label>
    <link:label id="lab_abvx_Kreos2TrancheAMember_documentation_en-US" xlink:label="lab_abvx_Kreos2TrancheAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kreos 2, Tranche A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos2TrancheAMember" xlink:href="abvx-20251231.xsd#abvx_Kreos2TrancheAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_Kreos2TrancheAMember" xlink:to="lab_abvx_Kreos2TrancheAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NumberOfSharesReceivedPerADS_d5c7d372-5e1d-4a68-9541-c89b2884752b_terseLabel_en-US" xlink:label="lab_abvx_NumberOfSharesReceivedPerADS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares received per ADS (in shares)</link:label>
    <link:label id="lab_abvx_NumberOfSharesReceivedPerADS_label_en-US" xlink:label="lab_abvx_NumberOfSharesReceivedPerADS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Received Per ADS</link:label>
    <link:label id="lab_abvx_NumberOfSharesReceivedPerADS_documentation_en-US" xlink:label="lab_abvx_NumberOfSharesReceivedPerADS" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Shares Received Per ADS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfSharesReceivedPerADS" xlink:href="abvx-20251231.xsd#abvx_NumberOfSharesReceivedPerADS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NumberOfSharesReceivedPerADS" xlink:to="lab_abvx_NumberOfSharesReceivedPerADS" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_CIRTaxYearAxis_e6905148-faa6-41bf-b105-16002c679f73_terseLabel_en-US" xlink:label="lab_abvx_CIRTaxYearAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CIR Tax Year [Axis]</link:label>
    <link:label id="lab_abvx_CIRTaxYearAxis_label_en-US" xlink:label="lab_abvx_CIRTaxYearAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CIR Tax Year [Axis]</link:label>
    <link:label id="lab_abvx_CIRTaxYearAxis_documentation_en-US" xlink:label="lab_abvx_CIRTaxYearAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CIR Tax Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CIRTaxYearAxis" xlink:href="abvx-20251231.xsd#abvx_CIRTaxYearAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_CIRTaxYearAxis" xlink:to="lab_abvx_CIRTaxYearAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_94a94dd2-bc97-4d90-8c14-82a23320fea2_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCashAndCashEquivalents_124b87fb-38d2-4cdc-adae-6d5dd11f8d36_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notice accounts</link:label>
    <link:label id="lab_ifrs-full_OtherCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_OtherCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCashAndCashEquivalents" xlink:to="lab_ifrs-full_OtherCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_FurnitureAndComputerEquipmentMember_72bf2afa-ea1b-470d-aacd-138148546c94_terseLabel_en-US" xlink:label="lab_abvx_FurnitureAndComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FURNITURE AND COMPUTER EQUIPMENT</link:label>
    <link:label id="lab_abvx_FurnitureAndComputerEquipmentMember_label_en-US" xlink:label="lab_abvx_FurnitureAndComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture And Computer Equipment [Member]</link:label>
    <link:label id="lab_abvx_FurnitureAndComputerEquipmentMember_documentation_en-US" xlink:label="lab_abvx_FurnitureAndComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Furniture And Computer Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FurnitureAndComputerEquipmentMember" xlink:href="abvx-20251231.xsd#abvx_FurnitureAndComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_FurnitureAndComputerEquipmentMember" xlink:to="lab_abvx_FurnitureAndComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_b53ec30d-5b7a-490e-9b39-07621a8234af_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_fa363456-591b-465e-8111-8e197448db78_periodStartLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill at beginning of period</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_6e6502ae-2cfc-4196-a25c-d6e399e4e53d_periodEndLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill at end of period</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_e0df6fdd-a945-40fd-a87a-e989db43d323_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_IncreaseDecreaseInEmployerTaxAndSocialContributions_019c5760-de97-7d0a-af76-8462bafb535b_terseLabel_en-US" xlink:label="lab_abvx_IncreaseDecreaseInEmployerTaxAndSocialContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in employer tax and social contributions</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseInEmployerTaxAndSocialContributions_label_en-US" xlink:label="lab_abvx_IncreaseDecreaseInEmployerTaxAndSocialContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Employer Tax And Social Contributions</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseInEmployerTaxAndSocialContributions_documentation_en-US" xlink:label="lab_abvx_IncreaseDecreaseInEmployerTaxAndSocialContributions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Employer Tax And Social Contributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInEmployerTaxAndSocialContributions" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInEmployerTaxAndSocialContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_IncreaseDecreaseInEmployerTaxAndSocialContributions" xlink:to="lab_abvx_IncreaseDecreaseInEmployerTaxAndSocialContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentDerivativeFinancialLiabilities_ddcda890-4d57-4bd9-9782-989e9edc3b16_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative instruments</link:label>
    <link:label id="lab_ifrs-full_NoncurrentDerivativeFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current derivative financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:to="lab_ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AuditorInformationAbstract_label_en-US" xlink:label="lab_abvx_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_abvx_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_abvx_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Auditor Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AuditorInformationAbstract" xlink:href="abvx-20251231.xsd#abvx_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AuditorInformationAbstract" xlink:to="lab_abvx_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_739f1db8-3c51-455f-a1f7-2778a4252e44_terseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_e980a0f8-a3fa-499e-b41b-3ee1ac7b599d_periodStartLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at the beginning of the year</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_7e36d6ce-0051-4b68-806e-c9c7bbbf21cd_periodEndLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at the end of the year</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_a8545cee-02c8-4695-8552-2915cc73a6c3_totalLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents" xlink:to="lab_ifrs-full_CashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_RoyaltyCertificatesRelatedTemporaryDifferencesMember_019c5789-a340-7ccd-9d5b-48111f820bd1_terseLabel_en-US" xlink:label="lab_abvx_RoyaltyCertificatesRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty certificates</link:label>
    <link:label id="lab_abvx_RoyaltyCertificatesRelatedTemporaryDifferencesMember_label_en-US" xlink:label="lab_abvx_RoyaltyCertificatesRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Certificates Related Temporary Differences [Member]</link:label>
    <link:label id="lab_abvx_RoyaltyCertificatesRelatedTemporaryDifferencesMember_documentation_en-US" xlink:label="lab_abvx_RoyaltyCertificatesRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Certificates Related Temporary Differences</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificatesRelatedTemporaryDifferencesMember" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificatesRelatedTemporaryDifferencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_RoyaltyCertificatesRelatedTemporaryDifferencesMember" xlink:to="lab_abvx_RoyaltyCertificatesRelatedTemporaryDifferencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_281e8f05-cd32-4935-83ad-a48d496c8b8f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis for derivative financial liabilities [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis for derivative financial liabilities [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslation_ee014f2a-7949-4e51-a3ab-678faa556bef_terseLabel_en-US" xlink:label="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Translation reserve</link:label>
    <link:label id="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslation_label_en-US" xlink:label="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve of exchange differences on translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:to="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_96c34318-2ce1-4389-bfb0-9db13dc19d94_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_58425eb2-2dfa-4e3d-b0df-8baecae32342_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of aggregate compensation of the members of the Group&#8217;s Board of Directors and CEO</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_2fa1a96e-84a6-4c77-ad17-0fedb9605516_totalLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilities" xlink:to="lab_ifrs-full_EquityAndLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_58f1b54d-dfd3-4f97-a1b6-a263de36d6b2_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_MonteCarloModelIFRSMember_6021e5a6-5efb-4379-a6f9-f5bdfee4b0af_terseLabel_en-US" xlink:label="lab_abvx_MonteCarloModelIFRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Monte Carlo model</link:label>
    <link:label id="lab_abvx_MonteCarloModelIFRSMember_label_en-US" xlink:label="lab_abvx_MonteCarloModelIFRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Monte Carlo Model IFRS [Member]</link:label>
    <link:label id="lab_abvx_MonteCarloModelIFRSMember_documentation_en-US" xlink:label="lab_abvx_MonteCarloModelIFRSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Monte Carlo Model IFRS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_MonteCarloModelIFRSMember" xlink:href="abvx-20251231.xsd#abvx_MonteCarloModelIFRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_MonteCarloModelIFRSMember" xlink:to="lab_abvx_MonteCarloModelIFRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AGA20244AGA20245AndAGA20246Member_cb60e2a7-0079-44b9-941f-1cd6cb1a2c64_terseLabel_en-US" xlink:label="lab_abvx_AGA20244AGA20245AndAGA20246Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA-2024-4, AGA-2024-5 and AGA-2024-6</link:label>
    <link:label id="lab_abvx_AGA20244AGA20245AndAGA20246Member_label_en-US" xlink:label="lab_abvx_AGA20244AGA20245AndAGA20246Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA-2024-4, AGA-2024-5 and AGA-2024-6 [Member]</link:label>
    <link:label id="lab_abvx_AGA20244AGA20245AndAGA20246Member_documentation_en-US" xlink:label="lab_abvx_AGA20244AGA20245AndAGA20246Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA-2024-4, AGA-2024-5 and AGA-2024-6</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20244AGA20245AndAGA20246Member" xlink:href="abvx-20251231.xsd#abvx_AGA20244AGA20245AndAGA20246Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AGA20244AGA20245AndAGA20246Member" xlink:to="lab_abvx_AGA20244AGA20245AndAGA20246Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BoardMemberMember_019beae7-6ccc-7cba-a0f6-ec7c780de3f6_terseLabel_en-US" xlink:label="lab_abvx_BoardMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Board member</link:label>
    <link:label id="lab_abvx_BoardMemberMember_label_en-US" xlink:label="lab_abvx_BoardMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Board Member [Member]</link:label>
    <link:label id="lab_abvx_BoardMemberMember_documentation_en-US" xlink:label="lab_abvx_BoardMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Board Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BoardMemberMember" xlink:href="abvx-20251231.xsd#abvx_BoardMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BoardMemberMember" xlink:to="lab_abvx_BoardMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_TaxEffectOfChangesInDerivativeFairValueAndOtherLiabilitiesMeasuredAtFVTPL_efd60ff7-e309-42dc-8b24-01ba9eee71fc_terseLabel_en-US" xlink:label="lab_abvx_TaxEffectOfChangesInDerivativeFairValueAndOtherLiabilitiesMeasuredAtFVTPL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease / (increase) in derivatives and other liabilities measured at FVTPL</link:label>
    <link:label id="lab_abvx_TaxEffectOfChangesInDerivativeFairValueAndOtherLiabilitiesMeasuredAtFVTPL_label_en-US" xlink:label="lab_abvx_TaxEffectOfChangesInDerivativeFairValueAndOtherLiabilitiesMeasuredAtFVTPL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Effect Of Changes In Derivative Fair Value And Other Liabilities Measured At FVTPL</link:label>
    <link:label id="lab_abvx_TaxEffectOfChangesInDerivativeFairValueAndOtherLiabilitiesMeasuredAtFVTPL_documentation_en-US" xlink:label="lab_abvx_TaxEffectOfChangesInDerivativeFairValueAndOtherLiabilitiesMeasuredAtFVTPL" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Effect Of Changes In Derivative Fair Value And Other Liabilities Measured At FVTPL</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TaxEffectOfChangesInDerivativeFairValueAndOtherLiabilitiesMeasuredAtFVTPL" xlink:href="abvx-20251231.xsd#abvx_TaxEffectOfChangesInDerivativeFairValueAndOtherLiabilitiesMeasuredAtFVTPL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_TaxEffectOfChangesInDerivativeFairValueAndOtherLiabilitiesMeasuredAtFVTPL" xlink:to="lab_abvx_TaxEffectOfChangesInDerivativeFairValueAndOtherLiabilitiesMeasuredAtFVTPL" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_CurrentFinancialLiabilitiesMember_8c6480f0-0060-4ac9-b90f-a7c9ae31a116_terseLabel_en-US" xlink:label="lab_abvx_CurrentFinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities-current portion</link:label>
    <link:label id="lab_abvx_CurrentFinancialLiabilitiesMember_label_en-US" xlink:label="lab_abvx_CurrentFinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Financial Liabilities [Member]</link:label>
    <link:label id="lab_abvx_CurrentFinancialLiabilitiesMember_documentation_en-US" xlink:label="lab_abvx_CurrentFinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current Financial Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentFinancialLiabilitiesMember" xlink:href="abvx-20251231.xsd#abvx_CurrentFinancialLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_CurrentFinancialLiabilitiesMember" xlink:to="lab_abvx_CurrentFinancialLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestRateMeasurementInputMember_339869f3-e81a-4900-80e9-806d65e8e0e1_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestRateMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_ifrs-full_InterestRateMeasurementInputMember_label_en-US" xlink:label="lab_ifrs-full_InterestRateMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest rate, measurement input [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateMeasurementInputMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestRateMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestRateMeasurementInputMember" xlink:to="lab_ifrs-full_InterestRateMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_CurrentTaxAndEmployeeBenefitLiabilities_620bf5ef-a35a-47d8-825f-8c173a2623ce_terseLabel_en-US" xlink:label="lab_abvx_CurrentTaxAndEmployeeBenefitLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax and employee-related payables</link:label>
    <link:label id="lab_abvx_CurrentTaxAndEmployeeBenefitLiabilities_f5741bf4-3ba4-46da-84f2-491148b22be1_totalLabel_en-US" xlink:label="lab_abvx_CurrentTaxAndEmployeeBenefitLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TAX AND EMPLOYEE-RELATED PAYABLES</link:label>
    <link:label id="lab_abvx_CurrentTaxAndEmployeeBenefitLiabilities_label_en-US" xlink:label="lab_abvx_CurrentTaxAndEmployeeBenefitLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Tax And Employee Benefit Liabilities</link:label>
    <link:label id="lab_abvx_CurrentTaxAndEmployeeBenefitLiabilities_documentation_en-US" xlink:label="lab_abvx_CurrentTaxAndEmployeeBenefitLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current Tax And Employee Benefit Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentTaxAndEmployeeBenefitLiabilities" xlink:href="abvx-20251231.xsd#abvx_CurrentTaxAndEmployeeBenefitLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_CurrentTaxAndEmployeeBenefitLiabilities" xlink:to="lab_abvx_CurrentTaxAndEmployeeBenefitLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_OtherShareWarrantsExercisePeriod_f6627264-1e61-4b4e-bb8e-afc26d670482_terseLabel_en-US" xlink:label="lab_abvx_OtherShareWarrantsExercisePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other share warrants, exercise period</link:label>
    <link:label id="lab_abvx_OtherShareWarrantsExercisePeriod_label_en-US" xlink:label="lab_abvx_OtherShareWarrantsExercisePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Share Warrants, Exercise Period</link:label>
    <link:label id="lab_abvx_OtherShareWarrantsExercisePeriod_documentation_en-US" xlink:label="lab_abvx_OtherShareWarrantsExercisePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Share Warrants, Exercise Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherShareWarrantsExercisePeriod" xlink:href="abvx-20251231.xsd#abvx_OtherShareWarrantsExercisePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_OtherShareWarrantsExercisePeriod" xlink:to="lab_abvx_OtherShareWarrantsExercisePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfDetailedInformationAboutAssetsAcquisitionsExplanatoryTableTextBlock_d66a007a-4918-4d3d-ae24-96ce600e3e80_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfDetailedInformationAboutAssetsAcquisitionsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of allocation of acquisition cost</link:label>
    <link:label id="lab_abvx_DisclosureOfDetailedInformationAboutAssetsAcquisitionsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_abvx_DisclosureOfDetailedInformationAboutAssetsAcquisitionsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Assets Acquisitions Explanatory [Table Text Block]</link:label>
    <link:label id="lab_abvx_DisclosureOfDetailedInformationAboutAssetsAcquisitionsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_abvx_DisclosureOfDetailedInformationAboutAssetsAcquisitionsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Assets Acquisitions Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfDetailedInformationAboutAssetsAcquisitionsExplanatoryTableTextBlock" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfDetailedInformationAboutAssetsAcquisitionsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfDetailedInformationAboutAssetsAcquisitionsExplanatoryTableTextBlock" xlink:to="lab_abvx_DisclosureOfDetailedInformationAboutAssetsAcquisitionsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_6f3e011f-643f-4613-92e3-fee770f2a88a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of attribution of expenses by nature to their function [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of attribution of expenses by nature to their function [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xlink:to="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsOnChangeInFairValueOfDerivatives_309422ac-4180-4be0-bbfb-81d8f8aeb0e8_negatedLabel_en-US" xlink:label="lab_ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Decrease in fair value</link:label>
    <link:label id="lab_ifrs-full_GainsOnChangeInFairValueOfDerivatives_70992b3c-4df4-484e-8d6b-51e528e59459_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Increase) / decrease in derivatives fair value</link:label>
    <link:label id="lab_ifrs-full_GainsOnChangeInFairValueOfDerivatives_9f9ad201-4ae5-4d69-9ad0-35a7afbb8d06_verboseLabel_en-US" xlink:label="lab_ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gains on change in fair value of derivatives</link:label>
    <link:label id="lab_ifrs-full_GainsOnChangeInFairValueOfDerivatives_label_en-US" xlink:label="lab_ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains on change in fair value of derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsOnChangeInFairValueOfDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:to="lab_ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BSA20171Member_4b2df595-cccc-41d9-b475-c3f6344827f0_terseLabel_en-US" xlink:label="lab_abvx_BSA20171Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSA-2017-1</link:label>
    <link:label id="lab_abvx_BSA20171Member_label_en-US" xlink:label="lab_abvx_BSA20171Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSA-2017-1 [Member]</link:label>
    <link:label id="lab_abvx_BSA20171Member_documentation_en-US" xlink:label="lab_abvx_BSA20171Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BSA-2017-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20171Member" xlink:href="abvx-20251231.xsd#abvx_BSA20171Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BSA20171Member" xlink:to="lab_abvx_BSA20171Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_abb5920f-9f9f-4ccb-974c-0afac3b3d9b3_terseLabel_en-US" xlink:label="lab_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of remaining contractual maturities of non-derivative financial liabilities</link:label>
    <link:label id="lab_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:to="lab_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BSA20242Member_d6ff7eb1-8e1e-4862-8eb9-3b82107f1c9f_terseLabel_en-US" xlink:label="lab_abvx_BSA20242Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSA-2024-2</link:label>
    <link:label id="lab_abvx_BSA20242Member_label_en-US" xlink:label="lab_abvx_BSA20242Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSA-2024-2 [Member]</link:label>
    <link:label id="lab_abvx_BSA20242Member_documentation_en-US" xlink:label="lab_abvx_BSA20242Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BSA-2024-2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20242Member" xlink:href="abvx-20251231.xsd#abvx_BSA20242Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BSA20242Member" xlink:to="lab_abvx_BSA20242Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_FurnitureMember_f05ac4af-a75b-4d3c-b140-1916c1734221_terseLabel_en-US" xlink:label="lab_abvx_FurnitureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture</link:label>
    <link:label id="lab_abvx_FurnitureMember_label_en-US" xlink:label="lab_abvx_FurnitureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture [Member]</link:label>
    <link:label id="lab_abvx_FurnitureMember_documentation_en-US" xlink:label="lab_abvx_FurnitureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Furniture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FurnitureMember" xlink:href="abvx-20251231.xsd#abvx_FurnitureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_FurnitureMember" xlink:to="lab_abvx_FurnitureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_HeightsConvertibleNotesMember_e37a3053-5c2c-4fdf-8e50-9a564fe60ecc_terseLabel_en-US" xlink:label="lab_abvx_HeightsConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Heights convertible notes</link:label>
    <link:label id="lab_abvx_HeightsConvertibleNotesMember_label_en-US" xlink:label="lab_abvx_HeightsConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Heights Convertible Notes [Member]</link:label>
    <link:label id="lab_abvx_HeightsConvertibleNotesMember_documentation_en-US" xlink:label="lab_abvx_HeightsConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Heights Convertible Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_HeightsConvertibleNotesMember" xlink:href="abvx-20251231.xsd#abvx_HeightsConvertibleNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_HeightsConvertibleNotesMember" xlink:to="lab_abvx_HeightsConvertibleNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_PaymentsForAdvancesMadeToContractResearchOrganizationsUndiscountedAmount_7543d049-e700-4a17-9029-4a4d941d344a_terseLabel_en-US" xlink:label="lab_abvx_PaymentsForAdvancesMadeToContractResearchOrganizationsUndiscountedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash advances and loans made to CRO</link:label>
    <link:label id="lab_abvx_PaymentsForAdvancesMadeToContractResearchOrganizationsUndiscountedAmount_label_en-US" xlink:label="lab_abvx_PaymentsForAdvancesMadeToContractResearchOrganizationsUndiscountedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For Advances Made to Contract Research Organizations, Undiscounted Amount</link:label>
    <link:label id="lab_abvx_PaymentsForAdvancesMadeToContractResearchOrganizationsUndiscountedAmount_documentation_en-US" xlink:label="lab_abvx_PaymentsForAdvancesMadeToContractResearchOrganizationsUndiscountedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments For Advances Made to Contract Research Organizations, Undiscounted Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PaymentsForAdvancesMadeToContractResearchOrganizationsUndiscountedAmount" xlink:href="abvx-20251231.xsd#abvx_PaymentsForAdvancesMadeToContractResearchOrganizationsUndiscountedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_PaymentsForAdvancesMadeToContractResearchOrganizationsUndiscountedAmount" xlink:to="lab_abvx_PaymentsForAdvancesMadeToContractResearchOrganizationsUndiscountedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BorrowingsMaturityDeferralPeriod_aa3ac10d-164c-4f6e-8a33-5e5ddb6f332f_terseLabel_en-US" xlink:label="lab_abvx_BorrowingsMaturityDeferralPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings maturity, deferral period</link:label>
    <link:label id="lab_abvx_BorrowingsMaturityDeferralPeriod_label_en-US" xlink:label="lab_abvx_BorrowingsMaturityDeferralPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings Maturity, Deferral Period</link:label>
    <link:label id="lab_abvx_BorrowingsMaturityDeferralPeriod_documentation_en-US" xlink:label="lab_abvx_BorrowingsMaturityDeferralPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowings Maturity, Deferral Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsMaturityDeferralPeriod" xlink:href="abvx-20251231.xsd#abvx_BorrowingsMaturityDeferralPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BorrowingsMaturityDeferralPeriod" xlink:to="lab_abvx_BorrowingsMaturityDeferralPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShorttermEmployeeBenefitsAccruals_e0daaa18-b9e5-495a-a907-1812ccb22a6e_terseLabel_en-US" xlink:label="lab_ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee-related payables</link:label>
    <link:label id="lab_ifrs-full_ShorttermEmployeeBenefitsAccruals_label_en-US" xlink:label="lab_ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term employee benefits accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:to="lab_ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_7164b2f6-a1a8-46d3-9afe-d1dd8cfcd399_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non cash changes : Effect of the change in foreign currency exchange rates</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_CurrentReceivablesFromCreditNotes_02c3f0f0-3b86-44f0-bfc8-de82784db350_terseLabel_en-US" xlink:label="lab_abvx_CurrentReceivablesFromCreditNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit notes</link:label>
    <link:label id="lab_abvx_CurrentReceivablesFromCreditNotes_label_en-US" xlink:label="lab_abvx_CurrentReceivablesFromCreditNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Receivables From Credit Notes</link:label>
    <link:label id="lab_abvx_CurrentReceivablesFromCreditNotes_documentation_en-US" xlink:label="lab_abvx_CurrentReceivablesFromCreditNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current Receivables From Credit Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentReceivablesFromCreditNotes" xlink:href="abvx-20251231.xsd#abvx_CurrentReceivablesFromCreditNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_CurrentReceivablesFromCreditNotes" xlink:to="lab_abvx_CurrentReceivablesFromCreditNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfCommitmentsReceivedTable_137a2b0b-a96c-4bb7-a6c5-7305601156c9_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfCommitmentsReceivedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Commitments Received [Table]</link:label>
    <link:label id="lab_abvx_DisclosureOfCommitmentsReceivedTable_label_en-US" xlink:label="lab_abvx_DisclosureOfCommitmentsReceivedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Commitments Received [Table]</link:label>
    <link:label id="lab_abvx_DisclosureOfCommitmentsReceivedTable_documentation_en-US" xlink:label="lab_abvx_DisclosureOfCommitmentsReceivedTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Commitments Received [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfCommitmentsReceivedTable" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfCommitmentsReceivedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfCommitmentsReceivedTable" xlink:to="lab_abvx_DisclosureOfCommitmentsReceivedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_ef9b1add-820f-4f8f-bb98-a520cf15b666_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_USD_506b2275-3451-4c83-a234-259e17e8709b_terseLabel_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States of America, Dollars</link:label>
    <link:label id="lab_currency_USD_label_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United States of America, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_USD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_USD" xlink:to="lab_currency_USD" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_b8215c2d-22f3-4098-879a-4e55d330c739_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets and liabilities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value of financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NumberOfProbabilityWeightedScenarios_91058c59-e017-4bc7-b725-068cb487f9c8_terseLabel_en-US" xlink:label="lab_abvx_NumberOfProbabilityWeightedScenarios" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of probability-weighted scenarios</link:label>
    <link:label id="lab_abvx_NumberOfProbabilityWeightedScenarios_label_en-US" xlink:label="lab_abvx_NumberOfProbabilityWeightedScenarios" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Probability-Weighted Scenarios</link:label>
    <link:label id="lab_abvx_NumberOfProbabilityWeightedScenarios_documentation_en-US" xlink:label="lab_abvx_NumberOfProbabilityWeightedScenarios" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Probability-Weighted Scenarios</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfProbabilityWeightedScenarios" xlink:href="abvx-20251231.xsd#abvx_NumberOfProbabilityWeightedScenarios"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NumberOfProbabilityWeightedScenarios" xlink:to="lab_abvx_NumberOfProbabilityWeightedScenarios" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_d9696dcf-eb34-4534-b152-bdaf27067b13_terseLabel_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful life measured as period of time, property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Useful life measured as period of time, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:to="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_CashAndCashEquivalentMember_041656e8-26eb-45ec-8bc9-26953522e8b4_terseLabel_en-US" xlink:label="lab_abvx_CashAndCashEquivalentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_abvx_CashAndCashEquivalentMember_label_en-US" xlink:label="lab_abvx_CashAndCashEquivalentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalent [Member]</link:label>
    <link:label id="lab_abvx_CashAndCashEquivalentMember_documentation_en-US" xlink:label="lab_abvx_CashAndCashEquivalentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CashAndCashEquivalentMember" xlink:href="abvx-20251231.xsd#abvx_CashAndCashEquivalentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_CashAndCashEquivalentMember" xlink:to="lab_abvx_CashAndCashEquivalentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_7d3711db-169a-449a-8298-d9258df3c7c7_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Categories of financial liabilities [domain]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of financial liabilities [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:to="lab_ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_06bbe6ba-bafe-4337-90cb-f2c15328df5e_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LONGER THAN 5 YEARS</link:label>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_SplicosSASABX464Member_709a6c84-dafe-422b-8a4a-f7bc27076cb4_terseLabel_en-US" xlink:label="lab_abvx_SplicosSASABX464Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Splicos SAS</link:label>
    <link:label id="lab_abvx_SplicosSASABX464Member_label_en-US" xlink:label="lab_abvx_SplicosSASABX464Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Splicos SAS - ABX464 [Member]</link:label>
    <link:label id="lab_abvx_SplicosSASABX464Member_documentation_en-US" xlink:label="lab_abvx_SplicosSASABX464Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Splicos SAS - ABX464</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SplicosSASABX464Member" xlink:href="abvx-20251231.xsd#abvx_SplicosSASABX464Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_SplicosSASABX464Member" xlink:to="lab_abvx_SplicosSASABX464Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_OceaneConversionOptionMember_bfdc7a28-87cb-4564-bef6-dc71d97dacc4_terseLabel_en-US" xlink:label="lab_abvx_OceaneConversionOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Oceane conversion option</link:label>
    <link:label id="lab_abvx_OceaneConversionOptionMember_54b5631c-fe0e-4e24-8f4f-41803ae959dc_verboseLabel_en-US" xlink:label="lab_abvx_OceaneConversionOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">OCEANE conversion option</link:label>
    <link:label id="lab_abvx_OceaneConversionOptionMember_label_en-US" xlink:label="lab_abvx_OceaneConversionOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oceane Conversion Option [Member]</link:label>
    <link:label id="lab_abvx_OceaneConversionOptionMember_documentation_en-US" xlink:label="lab_abvx_OceaneConversionOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Oceane Conversion Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OceaneConversionOptionMember" xlink:href="abvx-20251231.xsd#abvx_OceaneConversionOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_OceaneConversionOptionMember" xlink:to="lab_abvx_OceaneConversionOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_c48ec8a8-5cb9-47a7-9821-80c41b3a23ee_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related parties</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of related party [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill_a39fa774-d689-4799-90a3-323082a4a457_terseLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, intangible assets and goodwill</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, intangible assets and goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_5ea8d396-dd03-4dd7-ac38-96b334add50f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of intangible assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BorrowingsDiscountRate_019c56bd-58fc-7ea8-ab05-be1c2210dcdb_terseLabel_en-US" xlink:label="lab_abvx_BorrowingsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, discount rate</link:label>
    <link:label id="lab_abvx_BorrowingsDiscountRate_label_en-US" xlink:label="lab_abvx_BorrowingsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, Discount Rate</link:label>
    <link:label id="lab_abvx_BorrowingsDiscountRate_documentation_en-US" xlink:label="lab_abvx_BorrowingsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowings, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsDiscountRate" xlink:href="abvx-20251231.xsd#abvx_BorrowingsDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BorrowingsDiscountRate" xlink:to="lab_abvx_BorrowingsDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfIFRSCompliance_419bbdd8-3df1-4574-a608-f614681f892e_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfIFRSCompliance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of compliance</link:label>
    <link:label id="lab_ifrs-full_StatementOfIFRSCompliance_label_en-US" xlink:label="lab_ifrs-full_StatementOfIFRSCompliance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of IFRS compliance [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfIFRSCompliance" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfIFRSCompliance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfIFRSCompliance" xlink:to="lab_ifrs-full_StatementOfIFRSCompliance" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentValueAddedTaxReceivables_2569f169-bd25-4765-a580-e37e286a598c_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentValueAddedTaxReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">VAT receivables</link:label>
    <link:label id="lab_ifrs-full_CurrentValueAddedTaxReceivables_label_en-US" xlink:label="lab_ifrs-full_CurrentValueAddedTaxReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current value added tax receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentValueAddedTaxReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentValueAddedTaxReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentValueAddedTaxReceivables" xlink:to="lab_ifrs-full_CurrentValueAddedTaxReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets_23c0f0da-8540-4376-9668-e16dba18c29d_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Disposal</link:label>
    <link:label id="lab_ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals, property, plant and equipment including right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:to="lab_ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_3cc9a2ad-dd82-4da3-a4b4-d8692f8c701f_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense on lease liabilities</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_73f9ec2a-25f6-4471-a05b-e118d36540f2_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense on lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NumberOfFreeSharesPlansIssued_924339b5-a651-4884-a90d-7c74b25ad847_terseLabel_en-US" xlink:label="lab_abvx_NumberOfFreeSharesPlansIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of free shares plans issued</link:label>
    <link:label id="lab_abvx_NumberOfFreeSharesPlansIssued_label_en-US" xlink:label="lab_abvx_NumberOfFreeSharesPlansIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Free Shares Plans Issued</link:label>
    <link:label id="lab_abvx_NumberOfFreeSharesPlansIssued_documentation_en-US" xlink:label="lab_abvx_NumberOfFreeSharesPlansIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Free Shares Plans Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfFreeSharesPlansIssued" xlink:href="abvx-20251231.xsd#abvx_NumberOfFreeSharesPlansIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NumberOfFreeSharesPlansIssued" xlink:to="lab_abvx_NumberOfFreeSharesPlansIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_119e5313-878e-489e-ab2d-bb20f4aa61da_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnobservableInputsAxis_57182409-6d9f-4a78-abb7-50076f0e215f_terseLabel_en-US" xlink:label="lab_ifrs-full_UnobservableInputsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unobservable inputs [axis]</link:label>
    <link:label id="lab_ifrs-full_UnobservableInputsAxis_label_en-US" xlink:label="lab_ifrs-full_UnobservableInputsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unobservable inputs [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnobservableInputsAxis" xlink:to="lab_ifrs-full_UnobservableInputsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_f816f4f0-9f71-455e-84a7-d18b9780150f_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_FormerChiefExecutiveOfficerMember_bc8ec72c-d5df-4d33-9456-ed9a94dc2d76_terseLabel_en-US" xlink:label="lab_abvx_FormerChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Former Chief Executive Officer</link:label>
    <link:label id="lab_abvx_FormerChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_abvx_FormerChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Former Chief Executive Officer [Member]</link:label>
    <link:label id="lab_abvx_FormerChiefExecutiveOfficerMember_documentation_en-US" xlink:label="lab_abvx_FormerChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Former Chief Executive Officer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FormerChiefExecutiveOfficerMember" xlink:href="abvx-20251231.xsd#abvx_FormerChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_FormerChiefExecutiveOfficerMember" xlink:to="lab_abvx_FormerChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_FinancialAgreementDomain_9cd33b67-22ac-417b-8dd6-828d5188307a_terseLabel_en-US" xlink:label="lab_abvx_FinancialAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Agreement [Domain]</link:label>
    <link:label id="lab_abvx_FinancialAgreementDomain_label_en-US" xlink:label="lab_abvx_FinancialAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Agreement [Domain]</link:label>
    <link:label id="lab_abvx_FinancialAgreementDomain_documentation_en-US" xlink:label="lab_abvx_FinancialAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Agreement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialAgreementDomain" xlink:href="abvx-20251231.xsd#abvx_FinancialAgreementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_FinancialAgreementDomain" xlink:to="lab_abvx_FinancialAgreementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_InvestmentsInMutualFundsAndStructuredNotes_019c57ac-9c30-7f7b-9741-8645143e410d_terseLabel_en-US" xlink:label="lab_abvx_InvestmentsInMutualFundsAndStructuredNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in mutual funds and structured notes</link:label>
    <link:label id="lab_abvx_InvestmentsInMutualFundsAndStructuredNotes_label_en-US" xlink:label="lab_abvx_InvestmentsInMutualFundsAndStructuredNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments In Mutual Funds And Structured Notes</link:label>
    <link:label id="lab_abvx_InvestmentsInMutualFundsAndStructuredNotes_documentation_en-US" xlink:label="lab_abvx_InvestmentsInMutualFundsAndStructuredNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments In Mutual Funds And Structured Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_InvestmentsInMutualFundsAndStructuredNotes" xlink:href="abvx-20251231.xsd#abvx_InvestmentsInMutualFundsAndStructuredNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_InvestmentsInMutualFundsAndStructuredNotes" xlink:to="lab_abvx_InvestmentsInMutualFundsAndStructuredNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_MinimalReturnMeasurementInputMember_9583bf12-bad3-432b-a166-472e5782b6b5_terseLabel_en-US" xlink:label="lab_abvx_MinimalReturnMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimal return</link:label>
    <link:label id="lab_abvx_MinimalReturnMeasurementInputMember_label_en-US" xlink:label="lab_abvx_MinimalReturnMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimal Return, Measurement Input [Member]</link:label>
    <link:label id="lab_abvx_MinimalReturnMeasurementInputMember_documentation_en-US" xlink:label="lab_abvx_MinimalReturnMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimal Return, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_MinimalReturnMeasurementInputMember" xlink:href="abvx-20251231.xsd#abvx_MinimalReturnMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_MinimalReturnMeasurementInputMember" xlink:to="lab_abvx_MinimalReturnMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ContributionToGroupsNetProfitsLossesPercentage_2419237a-b904-4b74-80dc-a1674dc22a9f_terseLabel_en-US" xlink:label="lab_abvx_ContributionToGroupsNetProfitsLossesPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contribution to Group's net profits (losses), percentage</link:label>
    <link:label id="lab_abvx_ContributionToGroupsNetProfitsLossesPercentage_label_en-US" xlink:label="lab_abvx_ContributionToGroupsNetProfitsLossesPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contribution To Group's Net Profits (Losses), Percentage</link:label>
    <link:label id="lab_abvx_ContributionToGroupsNetProfitsLossesPercentage_documentation_en-US" xlink:label="lab_abvx_ContributionToGroupsNetProfitsLossesPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contribution To Group's Net Profits (Losses), Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ContributionToGroupsNetProfitsLossesPercentage" xlink:href="abvx-20251231.xsd#abvx_ContributionToGroupsNetProfitsLossesPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ContributionToGroupsNetProfitsLossesPercentage" xlink:to="lab_abvx_ContributionToGroupsNetProfitsLossesPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AGA20251AGA20253AGA20254AGA20256AGA20257AndAGA20258Member_019bfb11-cfe8-78b6-9816-d8fdb4977e64_terseLabel_en-US" xlink:label="lab_abvx_AGA20251AGA20253AGA20254AGA20256AGA20257AndAGA20258Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA-2025-1, AGA-2025-3, AGA-2025-4, AGA-2025-6, AGA-2025-7 and AGA-2025-8</link:label>
    <link:label id="lab_abvx_AGA20251AGA20253AGA20254AGA20256AGA20257AndAGA20258Member_label_en-US" xlink:label="lab_abvx_AGA20251AGA20253AGA20254AGA20256AGA20257AndAGA20258Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA-2025-1, AGA-2025-3, AGA-2025-4, AGA-2025-6, AGA-2025-7 and AGA-2025-8 [Member]</link:label>
    <link:label id="lab_abvx_AGA20251AGA20253AGA20254AGA20256AGA20257AndAGA20258Member_documentation_en-US" xlink:label="lab_abvx_AGA20251AGA20253AGA20254AGA20256AGA20257AndAGA20258Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA-2025-1, AGA-2025-3, AGA-2025-4, AGA-2025-6, AGA-2025-7 and AGA-2025-8</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20251AGA20253AGA20254AGA20256AGA20257AndAGA20258Member" xlink:href="abvx-20251231.xsd#abvx_AGA20251AGA20253AGA20254AGA20256AGA20257AndAGA20258Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AGA20251AGA20253AGA20254AGA20256AGA20257AndAGA20258Member" xlink:to="lab_abvx_AGA20251AGA20253AGA20254AGA20256AGA20257AndAGA20258Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_306f52c8-91cb-47e5-ba30-d51ed7048830_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables and other assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of trade and other receivables [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentFinancialAssets_71cc4b21-3722-4980-8466-c66002120dca_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial assets</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentFinancialAssets_c3d89214-8dda-4476-9046-afa128e0d204_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other current financial assets</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentFinancialAssets" xlink:to="lab_ifrs-full_OtherCurrentFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_IndustrialMaterialsAndEquipmentMember_25099a4f-585b-4a1d-ab6c-7463b48a7a2b_terseLabel_en-US" xlink:label="lab_abvx_IndustrialMaterialsAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Industrial materials and equipment</link:label>
    <link:label id="lab_abvx_IndustrialMaterialsAndEquipmentMember_label_en-US" xlink:label="lab_abvx_IndustrialMaterialsAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Industrial Materials And Equipment [Member]</link:label>
    <link:label id="lab_abvx_IndustrialMaterialsAndEquipmentMember_documentation_en-US" xlink:label="lab_abvx_IndustrialMaterialsAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Industrial Materials And Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IndustrialMaterialsAndEquipmentMember" xlink:href="abvx-20251231.xsd#abvx_IndustrialMaterialsAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_IndustrialMaterialsAndEquipmentMember" xlink:to="lab_abvx_IndustrialMaterialsAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_WittycelSASABX196Member_a6454a6a-98b4-4592-ae9f-1c097b44dad0_terseLabel_en-US" xlink:label="lab_abvx_WittycelSASABX196Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Wittycel SAS</link:label>
    <link:label id="lab_abvx_WittycelSASABX196Member_label_en-US" xlink:label="lab_abvx_WittycelSASABX196Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Wittycel SAS - ABX196 [Member]</link:label>
    <link:label id="lab_abvx_WittycelSASABX196Member_documentation_en-US" xlink:label="lab_abvx_WittycelSASABX196Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Wittycel SAS - ABX196</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_WittycelSASABX196Member" xlink:href="abvx-20251231.xsd#abvx_WittycelSASABX196Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_WittycelSASABX196Member" xlink:to="lab_abvx_WittycelSASABX196Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AmountOfReasonablyPossibleDecreaseInUnobservableInputLiabilities_0dcc43af-d7e6-44e0-980d-61181516dd6e_negatedTerseLabel_en-US" xlink:label="lab_abvx_AmountOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amount of reasonably possible decrease in unobservable input, liabilities (in euro per share)</link:label>
    <link:label id="lab_abvx_AmountOfReasonablyPossibleDecreaseInUnobservableInputLiabilities_label_en-US" xlink:label="lab_abvx_AmountOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount Of Reasonably Possible Decrease In Unobservable Input, Liabilities</link:label>
    <link:label id="lab_abvx_AmountOfReasonablyPossibleDecreaseInUnobservableInputLiabilities_documentation_en-US" xlink:label="lab_abvx_AmountOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount Of Reasonably Possible Decrease In Unobservable Input, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AmountOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:href="abvx-20251231.xsd#abvx_AmountOfReasonablyPossibleDecreaseInUnobservableInputLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AmountOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:to="lab_abvx_AmountOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AGA20234Member_2dcb6619-89ba-4a1a-b05a-a221c9058c56_terseLabel_en-US" xlink:label="lab_abvx_AGA20234Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA-2023-4</link:label>
    <link:label id="lab_abvx_AGA20234Member_label_en-US" xlink:label="lab_abvx_AGA20234Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA-2023-4 [Member]</link:label>
    <link:label id="lab_abvx_AGA20234Member_documentation_en-US" xlink:label="lab_abvx_AGA20234Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA-2023-4</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20234Member" xlink:href="abvx-20251231.xsd#abvx_AGA20234Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AGA20234Member" xlink:to="lab_abvx_AGA20234Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_4e9b0d17-b331-4105-a727-ef00ddb096d4_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash flows provided by (used in) operating activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_85228bd6-b66f-4da6-8f70-544722764cca_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLiabilitiesAbstract_c362dbcf-c437-4285-9999-52d26af22c64_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_3b69bb20-4b19-47cc-87d1-b0ebfcb807f9_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities_334c2bcd-cc95-4bcd-bf9b-966ce9f49415_terseLabel_en-US" xlink:label="lab_abvx_IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash changes: classification of embedded derivatives as separate derivative financial instruments</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_abvx_IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Classification of Embedded Derivatives as Separate Financial Instruments, Liabilities Arising From Financing Activities</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities_documentation_en-US" xlink:label="lab_abvx_IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Classification of Embedded Derivatives as Separate Financial Instruments, Liabilities Arising From Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities" xlink:to="lab_abvx_IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_KreosClaretFinancingBSAMember_e7400904-da24-4db2-a686-632567ad7801_terseLabel_en-US" xlink:label="lab_abvx_KreosClaretFinancingBSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret BSA</link:label>
    <link:label id="lab_abvx_KreosClaretFinancingBSAMember_label_en-US" xlink:label="lab_abvx_KreosClaretFinancingBSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret Financing, BSA [Member]</link:label>
    <link:label id="lab_abvx_KreosClaretFinancingBSAMember_documentation_en-US" xlink:label="lab_abvx_KreosClaretFinancingBSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret Financing, BSA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingBSAMember" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingBSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_KreosClaretFinancingBSAMember" xlink:to="lab_abvx_KreosClaretFinancingBSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_5283aa16-e545-4be5-b890-fb08539adf3c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingIncome_2281ab72-0241-4ba5-9db4-93594467c987_terseLabel_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingIncome_label_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Miscellaneous other operating income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:to="lab_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherNoncurrentFinancialLiabilities_6c31f8b7-e197-4a0f-9758-199b9da975ad_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial liabilities</link:label>
    <link:label id="lab_ifrs-full_OtherNoncurrentFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:to="lab_ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_IntellectualPropertyFees_3f2b794c-24d2-483a-b0a7-39eb7207b323_terseLabel_en-US" xlink:label="lab_abvx_IntellectualPropertyFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intellectual property fees</link:label>
    <link:label id="lab_abvx_IntellectualPropertyFees_label_en-US" xlink:label="lab_abvx_IntellectualPropertyFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intellectual Property Fees</link:label>
    <link:label id="lab_abvx_IntellectualPropertyFees_documentation_en-US" xlink:label="lab_abvx_IntellectualPropertyFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intellectual Property Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IntellectualPropertyFees" xlink:href="abvx-20251231.xsd#abvx_IntellectualPropertyFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_IntellectualPropertyFees" xlink:to="lab_abvx_IntellectualPropertyFees" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_RoyaltyCertificatesMember_ae71a6d9-3853-425b-9436-4e8f8d1386ee_terseLabel_en-US" xlink:label="lab_abvx_RoyaltyCertificatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty certificates</link:label>
    <link:label id="lab_abvx_RoyaltyCertificatesMember_label_en-US" xlink:label="lab_abvx_RoyaltyCertificatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Certificates [Member]</link:label>
    <link:label id="lab_abvx_RoyaltyCertificatesMember_documentation_en-US" xlink:label="lab_abvx_RoyaltyCertificatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Certificates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificatesMember" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_RoyaltyCertificatesMember" xlink:to="lab_abvx_RoyaltyCertificatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NetProceedsFromConvertibleLoanNotes_019c4341-ab5f-7e1c-b559-da43236318db_terseLabel_en-US" xlink:label="lab_abvx_NetProceedsFromConvertibleLoanNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from convertible loan notes</link:label>
    <link:label id="lab_abvx_NetProceedsFromConvertibleLoanNotes_label_en-US" xlink:label="lab_abvx_NetProceedsFromConvertibleLoanNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Proceeds From Convertible Loan Notes</link:label>
    <link:label id="lab_abvx_NetProceedsFromConvertibleLoanNotes_documentation_en-US" xlink:label="lab_abvx_NetProceedsFromConvertibleLoanNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Proceeds From Convertible Loan Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NetProceedsFromConvertibleLoanNotes" xlink:href="abvx-20251231.xsd#abvx_NetProceedsFromConvertibleLoanNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NetProceedsFromConvertibleLoanNotes" xlink:to="lab_abvx_NetProceedsFromConvertibleLoanNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_5979502e-0b8d-439d-8cfc-f66320760996_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_31163ad3-6cd2-440d-80e0-9c5622b3eeac_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for:</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile profit (loss) [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BorrowingsNumberOfTranches_6b899c49-492f-4070-96f4-bee88f33fb3f_terseLabel_en-US" xlink:label="lab_abvx_BorrowingsNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, number of tranches</link:label>
    <link:label id="lab_abvx_BorrowingsNumberOfTranches_label_en-US" xlink:label="lab_abvx_BorrowingsNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, Number Of Tranches</link:label>
    <link:label id="lab_abvx_BorrowingsNumberOfTranches_documentation_en-US" xlink:label="lab_abvx_BorrowingsNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowings, Number Of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsNumberOfTranches" xlink:href="abvx-20251231.xsd#abvx_BorrowingsNumberOfTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BorrowingsNumberOfTranches" xlink:to="lab_abvx_BorrowingsNumberOfTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_UnobservableInputLiabilitiesDiscountRate_019cfd0f-9f4a-7f59-b292-17e9c65d78f2_terseLabel_en-US" xlink:label="lab_abvx_UnobservableInputLiabilitiesDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unobservable input, liabilities, discount rate</link:label>
    <link:label id="lab_abvx_UnobservableInputLiabilitiesDiscountRate_label_en-US" xlink:label="lab_abvx_UnobservableInputLiabilitiesDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unobservable Input, Liabilities, Discount Rate</link:label>
    <link:label id="lab_abvx_UnobservableInputLiabilitiesDiscountRate_documentation_en-US" xlink:label="lab_abvx_UnobservableInputLiabilitiesDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unobservable Input, Liabilities, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_UnobservableInputLiabilitiesDiscountRate" xlink:href="abvx-20251231.xsd#abvx_UnobservableInputLiabilitiesDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_UnobservableInputLiabilitiesDiscountRate" xlink:to="lab_abvx_UnobservableInputLiabilitiesDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ShareIssueRelatedCostCredit_a8a235b3-2720-4c9b-9765-f2021e82b52d_negatedTerseLabel_en-US" xlink:label="lab_abvx_ShareIssueRelatedCostCredit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs related to capital increase</link:label>
    <link:label id="lab_abvx_ShareIssueRelatedCostCredit_label_en-US" xlink:label="lab_abvx_ShareIssueRelatedCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Issue Related Cost (Credit)</link:label>
    <link:label id="lab_abvx_ShareIssueRelatedCostCredit_documentation_en-US" xlink:label="lab_abvx_ShareIssueRelatedCostCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Issue Related Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ShareIssueRelatedCostCredit" xlink:href="abvx-20251231.xsd#abvx_ShareIssueRelatedCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ShareIssueRelatedCostCredit" xlink:to="lab_abvx_ShareIssueRelatedCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfRetirementAge2019_32ac0707-dba0-46c7-9bda-62b907261468_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfRetirementAge2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement age</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfRetirementAge2019_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfRetirementAge2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of retirement age</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfRetirementAge2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ActuarialAssumptionOfRetirementAge2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionOfRetirementAge2019" xlink:to="lab_ifrs-full_ActuarialAssumptionOfRetirementAge2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentFinancialLiabilities_191f721e-ba05-4754-8afb-906f70839908_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current financial liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentFinancialLiabilities" xlink:to="lab_ifrs-full_CurrentFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ExpectedVolatilityOtherEquityInstrumentsGranted_d82c8f03-a738-41d2-8772-6f1a8f21196e_terseLabel_en-US" xlink:label="lab_abvx_ExpectedVolatilityOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">VOLATILITY</link:label>
    <link:label id="lab_abvx_ExpectedVolatilityOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_abvx_ExpectedVolatilityOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Volatility, Other Equity Instruments Granted</link:label>
    <link:label id="lab_abvx_ExpectedVolatilityOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_abvx_ExpectedVolatilityOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected Volatility, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpectedVolatilityOtherEquityInstrumentsGranted" xlink:href="abvx-20251231.xsd#abvx_ExpectedVolatilityOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ExpectedVolatilityOtherEquityInstrumentsGranted" xlink:to="lab_abvx_ExpectedVolatilityOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfInterestRatesDomain_c0576ab3-f92a-4763-8d71-d8094c01716e_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfInterestRatesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of interest rates [domain]</link:label>
    <link:label id="lab_ifrs-full_TypesOfInterestRatesDomain_label_en-US" xlink:label="lab_ifrs-full_TypesOfInterestRatesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of interest rates [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfInterestRatesDomain" xlink:to="lab_ifrs-full_TypesOfInterestRatesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_OtherReceivablesAndAssetsMember_b0c0de84-208b-4c27-a81d-78ffa8e5b009_terseLabel_en-US" xlink:label="lab_abvx_OtherReceivablesAndAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables and assets</link:label>
    <link:label id="lab_abvx_OtherReceivablesAndAssetsMember_label_en-US" xlink:label="lab_abvx_OtherReceivablesAndAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Receivables And Assets [Member]</link:label>
    <link:label id="lab_abvx_OtherReceivablesAndAssetsMember_documentation_en-US" xlink:label="lab_abvx_OtherReceivablesAndAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Receivables And Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherReceivablesAndAssetsMember" xlink:href="abvx-20251231.xsd#abvx_OtherReceivablesAndAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_OtherReceivablesAndAssetsMember" xlink:to="lab_abvx_OtherReceivablesAndAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherIncome_a3b715ec-d5cd-4a9f-81f4-dba935818a46_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other operating income</link:label>
    <link:label id="lab_ifrs-full_OtherIncome_e6f26e19-dada-4052-a3d4-1f6966ce12a4_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating income</link:label>
    <link:label id="lab_ifrs-full_OtherIncome_label_en-US" xlink:label="lab_ifrs-full_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherIncome" xlink:to="lab_ifrs-full_OtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NumberOfAcademicInstitutions_bcde57b6-aa8c-4d45-9ab7-b1f9ed5be93b_terseLabel_en-US" xlink:label="lab_abvx_NumberOfAcademicInstitutions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of academic institutions</link:label>
    <link:label id="lab_abvx_NumberOfAcademicInstitutions_label_en-US" xlink:label="lab_abvx_NumberOfAcademicInstitutions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Academic Institutions</link:label>
    <link:label id="lab_abvx_NumberOfAcademicInstitutions_documentation_en-US" xlink:label="lab_abvx_NumberOfAcademicInstitutions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Academic Institutions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfAcademicInstitutions" xlink:href="abvx-20251231.xsd#abvx_NumberOfAcademicInstitutions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NumberOfAcademicInstitutions" xlink:to="lab_abvx_NumberOfAcademicInstitutions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssueOfConvertibleInstruments_b7116a38-b8ab-476b-893f-9e0b5973eeef_terseLabel_en-US" xlink:label="lab_ifrs-full_IssueOfConvertibleInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issue of convertible notes</link:label>
    <link:label id="lab_ifrs-full_IssueOfConvertibleInstruments_label_en-US" xlink:label="lab_ifrs-full_IssueOfConvertibleInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue of convertible instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfConvertibleInstruments" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssueOfConvertibleInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssueOfConvertibleInstruments" xlink:to="lab_ifrs-full_IssueOfConvertibleInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ForeignExchangeGain_204937a5-83fe-40d7-a49c-839f597a8a54_terseLabel_en-US" xlink:label="lab_ifrs-full_ForeignExchangeGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange gains</link:label>
    <link:label id="lab_ifrs-full_ForeignExchangeGain_label_en-US" xlink:label="lab_ifrs-full_ForeignExchangeGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign exchange gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ForeignExchangeGain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ForeignExchangeGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ForeignExchangeGain" xlink:to="lab_ifrs-full_ForeignExchangeGain" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NumberOfProjectsTerminated_8707ffc3-f83a-4003-9cab-510e140f0d45_terseLabel_en-US" xlink:label="lab_abvx_NumberOfProjectsTerminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of projects terminated</link:label>
    <link:label id="lab_abvx_NumberOfProjectsTerminated_label_en-US" xlink:label="lab_abvx_NumberOfProjectsTerminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Projects Terminated</link:label>
    <link:label id="lab_abvx_NumberOfProjectsTerminated_documentation_en-US" xlink:label="lab_abvx_NumberOfProjectsTerminated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Projects Terminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfProjectsTerminated" xlink:href="abvx-20251231.xsd#abvx_NumberOfProjectsTerminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NumberOfProjectsTerminated" xlink:to="lab_abvx_NumberOfProjectsTerminated" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ExchangeDomain_5326f368-1beb-49ce-83a5-f2b5d3d7b06b_terseLabel_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:label id="lab_dei_ExchangeDomain_label_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ExchangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ExchangeDomain" xlink:to="lab_dei_ExchangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_0c9f0914-44db-4110-98ae-3baa998ecb1b_verboseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Trade payables</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current trade payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensation_f7db6737-7ae4-46ab-aaa7-2b4ebf070dad_totalLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensation_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_Kreos1ConvertibleBondLoansTrancheAMember_ca36fa5c-f291-465b-ad3e-5ae76d65db86_terseLabel_en-US" xlink:label="lab_abvx_Kreos1ConvertibleBondLoansTrancheAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kreos 1, convertible bond loans, tranche A</link:label>
    <link:label id="lab_abvx_Kreos1ConvertibleBondLoansTrancheAMember_label_en-US" xlink:label="lab_abvx_Kreos1ConvertibleBondLoansTrancheAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kreos 1, Convertible Bond Loans, Tranche A [Member]</link:label>
    <link:label id="lab_abvx_Kreos1ConvertibleBondLoansTrancheAMember_documentation_en-US" xlink:label="lab_abvx_Kreos1ConvertibleBondLoansTrancheAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kreos 1, Convertible Bond Loans, Tranche A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1ConvertibleBondLoansTrancheAMember" xlink:href="abvx-20251231.xsd#abvx_Kreos1ConvertibleBondLoansTrancheAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_Kreos1ConvertibleBondLoansTrancheAMember" xlink:to="lab_abvx_Kreos1ConvertibleBondLoansTrancheAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_WarrantsDomain_ec9e1f87-7c1a-48fd-bea9-cbbd973265f6_terseLabel_en-US" xlink:label="lab_abvx_WarrantsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants [Domain]</link:label>
    <link:label id="lab_abvx_WarrantsDomain_label_en-US" xlink:label="lab_abvx_WarrantsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants [Domain]</link:label>
    <link:label id="lab_abvx_WarrantsDomain_documentation_en-US" xlink:label="lab_abvx_WarrantsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_WarrantsDomain" xlink:href="abvx-20251231.xsd#abvx_WarrantsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_WarrantsDomain" xlink:to="lab_abvx_WarrantsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherFinanceCost_26455b2a-6b0b-4e12-99c7-6e99954476c4_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_OtherFinanceCost" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other financial expense</link:label>
    <link:label id="lab_ifrs-full_OtherFinanceCost_label_en-US" xlink:label="lab_ifrs-full_OtherFinanceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other finance cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinanceCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherFinanceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherFinanceCost" xlink:to="lab_ifrs-full_OtherFinanceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DerivativeFinancialLiabilities_46824816-ac21-4850-9bdc-7758acfbd1eb_periodStartLabel_en-US" xlink:label="lab_ifrs-full_DerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Derivative financial liabilities at beginning of period</link:label>
    <link:label id="lab_ifrs-full_DerivativeFinancialLiabilities_a5a964b5-9055-4744-9f5f-b86225ffb84f_periodEndLabel_en-US" xlink:label="lab_ifrs-full_DerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Derivative financial liabilities at end of period</link:label>
    <link:label id="lab_ifrs-full_DerivativeFinancialLiabilities_d92fc835-2002-44cc-923f-e74afb5f381a_terseLabel_en-US" xlink:label="lab_ifrs-full_DerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative financial liabilities</link:label>
    <link:label id="lab_ifrs-full_DerivativeFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_DerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DerivativeFinancialLiabilities" xlink:to="lab_ifrs-full_DerivativeFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCreditRiskExposureLineItems_f528c449-5b3d-4e66-966f-d38397399e88_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of credit risk exposure [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCreditRiskExposureLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of credit risk exposure [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfCreditRiskExposureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:to="lab_ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory_e4ebe671-3807-476e-9575-585f2a8d2689_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of main actuarial assumptions used to measure the retirement benefit obligations</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of defined benefit plans [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ContributionToGroupsAssetsPercentage_b0c6606e-8da3-467d-b3ac-001107476155_terseLabel_en-US" xlink:label="lab_abvx_ContributionToGroupsAssetsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contribution to Group's assets, percentage</link:label>
    <link:label id="lab_abvx_ContributionToGroupsAssetsPercentage_label_en-US" xlink:label="lab_abvx_ContributionToGroupsAssetsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contribution To Group's Assets, Percentage</link:label>
    <link:label id="lab_abvx_ContributionToGroupsAssetsPercentage_documentation_en-US" xlink:label="lab_abvx_ContributionToGroupsAssetsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contribution To Group's Assets, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ContributionToGroupsAssetsPercentage" xlink:href="abvx-20251231.xsd#abvx_ContributionToGroupsAssetsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ContributionToGroupsAssetsPercentage" xlink:to="lab_abvx_ContributionToGroupsAssetsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OrdinarySharesMember_3f822d6b-013f-4574-bd07-c56614a7e50d_terseLabel_en-US" xlink:label="lab_ifrs-full_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares</link:label>
    <link:label id="lab_ifrs-full_OrdinarySharesMember_label_en-US" xlink:label="lab_ifrs-full_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary shares [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OrdinarySharesMember" xlink:to="lab_ifrs-full_OrdinarySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ProbabilityOfSuccessMeasurementInputMember_3a5e980e-a3f0-480e-900f-85ba4c8a65fd_terseLabel_en-US" xlink:label="lab_abvx_ProbabilityOfSuccessMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">POS</link:label>
    <link:label id="lab_abvx_ProbabilityOfSuccessMeasurementInputMember_label_en-US" xlink:label="lab_abvx_ProbabilityOfSuccessMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Probability Of Success, Measurement Input [Member]</link:label>
    <link:label id="lab_abvx_ProbabilityOfSuccessMeasurementInputMember_documentation_en-US" xlink:label="lab_abvx_ProbabilityOfSuccessMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Probability Of Success, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ProbabilityOfSuccessMeasurementInputMember" xlink:href="abvx-20251231.xsd#abvx_ProbabilityOfSuccessMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ProbabilityOfSuccessMeasurementInputMember" xlink:to="lab_abvx_ProbabilityOfSuccessMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_33d021c4-5188-4d1f-9249-955d91ea124c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income (loss) per share</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_8385bd9e-df4b-4367-bf16-c75f5df6572a_terseLabel_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GROSS VALUES</link:label>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossCarryingAmountMember" xlink:to="lab_ifrs-full_GrossCarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_0e4cd252-0944-4079-a506-9b043ce57681_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade payables and other current liabilities</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_d7c007c7-87cf-4a4d-96de-644f2b302e9a_totalLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Trade payables and other current liabilities</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other current payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_RepaymentsOfBondLoans_a6e5eb6d-8f95-4170-ba8e-5a3e5af2bb08_terseLabel_en-US" xlink:label="lab_abvx_RepaymentsOfBondLoans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of bond loans</link:label>
    <link:label id="lab_abvx_RepaymentsOfBondLoans_label_en-US" xlink:label="lab_abvx_RepaymentsOfBondLoans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments Of Bond Loans</link:label>
    <link:label id="lab_abvx_RepaymentsOfBondLoans_documentation_en-US" xlink:label="lab_abvx_RepaymentsOfBondLoans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Repayments Of Bond Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepaymentsOfBondLoans" xlink:href="abvx-20251231.xsd#abvx_RepaymentsOfBondLoans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_RepaymentsOfBondLoans" xlink:to="lab_abvx_RepaymentsOfBondLoans" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ApplicableTaxRate_1ca5e987-0f1e-4e8a-838d-60452ed01daf_terseLabel_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statutory French tax rate</link:label>
    <link:label id="lab_ifrs-full_ApplicableTaxRate_label_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Applicable tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ApplicableTaxRate" xlink:to="lab_ifrs-full_ApplicableTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_WarrantsAxis_d25ed583-8790-4634-b201-2a4f3f0ff184_terseLabel_en-US" xlink:label="lab_abvx_WarrantsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants [Axis]</link:label>
    <link:label id="lab_abvx_WarrantsAxis_label_en-US" xlink:label="lab_abvx_WarrantsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants [Axis]</link:label>
    <link:label id="lab_abvx_WarrantsAxis_documentation_en-US" xlink:label="lab_abvx_WarrantsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_WarrantsAxis" xlink:href="abvx-20251231.xsd#abvx_WarrantsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_WarrantsAxis" xlink:to="lab_abvx_WarrantsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_EbolaConditionalAdvanceBPIMember_3315f1a7-c746-42cd-81a0-f95748232456_terseLabel_en-US" xlink:label="lab_abvx_EbolaConditionalAdvanceBPIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ebola conditional advance</link:label>
    <link:label id="lab_abvx_EbolaConditionalAdvanceBPIMember_763346f8-425e-4eab-99dd-21fd2793eb39_verboseLabel_en-US" xlink:label="lab_abvx_EbolaConditionalAdvanceBPIMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">EBOLA &#8211; Bpifrance</link:label>
    <link:label id="lab_abvx_EbolaConditionalAdvanceBPIMember_label_en-US" xlink:label="lab_abvx_EbolaConditionalAdvanceBPIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ebola Conditional Advance, BPI [Member]</link:label>
    <link:label id="lab_abvx_EbolaConditionalAdvanceBPIMember_documentation_en-US" xlink:label="lab_abvx_EbolaConditionalAdvanceBPIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ebola Conditional Advance, BPI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EbolaConditionalAdvanceBPIMember" xlink:href="abvx-20251231.xsd#abvx_EbolaConditionalAdvanceBPIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_EbolaConditionalAdvanceBPIMember" xlink:to="lab_abvx_EbolaConditionalAdvanceBPIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccrualsClassifiedAsCurrent_63ff0823-3119-4253-85a5-2c758542d1fa_terseLabel_en-US" xlink:label="lab_ifrs-full_AccrualsClassifiedAsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued invoices</link:label>
    <link:label id="lab_ifrs-full_AccrualsClassifiedAsCurrent_label_en-US" xlink:label="lab_ifrs-full_AccrualsClassifiedAsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accruals classified as current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccrualsClassifiedAsCurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccrualsClassifiedAsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccrualsClassifiedAsCurrent" xlink:to="lab_ifrs-full_AccrualsClassifiedAsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_eb8b592c-1dcd-4141-83a2-0c04599e900c_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_410cddac-3b8d-401d-8b2c-95ebda19b9c0_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital increases</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuing shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssuingShares" xlink:to="lab_ifrs-full_ProceedsFromIssuingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_93a7a6ba-a3b6-4bb2-8abc-a958ed976727_terseLabel_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LESS THAN 1 YEAR</link:label>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_label_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not later than one year [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotLaterThanOneYearMember" xlink:to="lab_ifrs-full_NotLaterThanOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ProsynergiaMember_8d6fc40d-9a43-4470-8f45-476fa5f3237e_terseLabel_en-US" xlink:label="lab_abvx_ProsynergiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prosynergia</link:label>
    <link:label id="lab_abvx_ProsynergiaMember_label_en-US" xlink:label="lab_abvx_ProsynergiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prosynergia [Member]</link:label>
    <link:label id="lab_abvx_ProsynergiaMember_documentation_en-US" xlink:label="lab_abvx_ProsynergiaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prosynergia</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ProsynergiaMember" xlink:href="abvx-20251231.xsd#abvx_ProsynergiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ProsynergiaMember" xlink:to="lab_abvx_ProsynergiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_RetirementBenefitObligationsRelatedTemporaryDifferencesMember_0d50d0dc-4374-464b-9834-f6561ea8a4b8_terseLabel_en-US" xlink:label="lab_abvx_RetirementBenefitObligationsRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement benefit obligation</link:label>
    <link:label id="lab_abvx_RetirementBenefitObligationsRelatedTemporaryDifferencesMember_label_en-US" xlink:label="lab_abvx_RetirementBenefitObligationsRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefit Obligations Related Temporary Differences [Member]</link:label>
    <link:label id="lab_abvx_RetirementBenefitObligationsRelatedTemporaryDifferencesMember_documentation_en-US" xlink:label="lab_abvx_RetirementBenefitObligationsRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Retirement Benefit Obligations Related Temporary Differences</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RetirementBenefitObligationsRelatedTemporaryDifferencesMember" xlink:href="abvx-20251231.xsd#abvx_RetirementBenefitObligationsRelatedTemporaryDifferencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_RetirementBenefitObligationsRelatedTemporaryDifferencesMember" xlink:to="lab_abvx_RetirementBenefitObligationsRelatedTemporaryDifferencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ConvertibleLoansNotesCarryingAmountOfTheEquityComponent_5fd4d5a5-e411-44a4-b17d-8c55945fe0ae_terseLabel_en-US" xlink:label="lab_abvx_ConvertibleLoansNotesCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying amount of the equity component</link:label>
    <link:label id="lab_abvx_ConvertibleLoansNotesCarryingAmountOfTheEquityComponent_label_en-US" xlink:label="lab_abvx_ConvertibleLoansNotesCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Loans Notes, Carrying Amount Of The Equity Component</link:label>
    <link:label id="lab_abvx_ConvertibleLoansNotesCarryingAmountOfTheEquityComponent_documentation_en-US" xlink:label="lab_abvx_ConvertibleLoansNotesCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Loans Notes, Carrying Amount Of The Equity Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotesCarryingAmountOfTheEquityComponent" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotesCarryingAmountOfTheEquityComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ConvertibleLoansNotesCarryingAmountOfTheEquityComponent" xlink:to="lab_abvx_ConvertibleLoansNotesCarryingAmountOfTheEquityComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AuditorsRemunerationForAuditRelatedFees_019cfc16-3e60-75ce-98e3-ed7bf9b13ba7_terseLabel_en-US" xlink:label="lab_abvx_AuditorsRemunerationForAuditRelatedFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Audit-related fees</link:label>
    <link:label id="lab_abvx_AuditorsRemunerationForAuditRelatedFees_label_en-US" xlink:label="lab_abvx_AuditorsRemunerationForAuditRelatedFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor's Remuneration For Audit-Related Fees</link:label>
    <link:label id="lab_abvx_AuditorsRemunerationForAuditRelatedFees_documentation_en-US" xlink:label="lab_abvx_AuditorsRemunerationForAuditRelatedFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Auditor's Remuneration For Audit-Related Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AuditorsRemunerationForAuditRelatedFees" xlink:href="abvx-20251231.xsd#abvx_AuditorsRemunerationForAuditRelatedFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AuditorsRemunerationForAuditRelatedFees" xlink:to="lab_abvx_AuditorsRemunerationForAuditRelatedFees" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BCE20174Member_4cf68c45-e9de-4347-9392-a0ff73e46106_terseLabel_en-US" xlink:label="lab_abvx_BCE20174Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BCE-2017-4</link:label>
    <link:label id="lab_abvx_BCE20174Member_label_en-US" xlink:label="lab_abvx_BCE20174Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BCE-2017-4 [Member]</link:label>
    <link:label id="lab_abvx_BCE20174Member_documentation_en-US" xlink:label="lab_abvx_BCE20174Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BCE-2017-4</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BCE20174Member" xlink:href="abvx-20251231.xsd#abvx_BCE20174Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BCE20174Member" xlink:to="lab_abvx_BCE20174Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_MaximumNumberOfSharesToBeIssued_e4cf55f4-03c2-4f91-8d2b-f79488fff0ec_terseLabel_en-US" xlink:label="lab_abvx_MaximumNumberOfSharesToBeIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum number of shares to be issued (in shares)</link:label>
    <link:label id="lab_abvx_MaximumNumberOfSharesToBeIssued_label_en-US" xlink:label="lab_abvx_MaximumNumberOfSharesToBeIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Number Of Shares To Be Issued</link:label>
    <link:label id="lab_abvx_MaximumNumberOfSharesToBeIssued_documentation_en-US" xlink:label="lab_abvx_MaximumNumberOfSharesToBeIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum Number Of Shares To Be Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_MaximumNumberOfSharesToBeIssued" xlink:href="abvx-20251231.xsd#abvx_MaximumNumberOfSharesToBeIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_MaximumNumberOfSharesToBeIssued" xlink:to="lab_abvx_MaximumNumberOfSharesToBeIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_1dddfb9d-ce7c-407f-b6e6-23cd5055bde4_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AT FAIR VALUE THROUGH PROFIT&#160;AND LOSS</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities at fair value through profit or loss, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AggregateExercisePriceOtherEquityInstrumentsGranted_15609e59-8b51-459a-9551-d6b6054eb76f_terseLabel_en-US" xlink:label="lab_abvx_AggregateExercisePriceOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate exercise price</link:label>
    <link:label id="lab_abvx_AggregateExercisePriceOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_abvx_AggregateExercisePriceOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Exercise Price, Other Equity Instruments Granted</link:label>
    <link:label id="lab_abvx_AggregateExercisePriceOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_abvx_AggregateExercisePriceOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate Exercise Price, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AggregateExercisePriceOtherEquityInstrumentsGranted" xlink:href="abvx-20251231.xsd#abvx_AggregateExercisePriceOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AggregateExercisePriceOtherEquityInstrumentsGranted" xlink:to="lab_abvx_AggregateExercisePriceOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AuditorsRemuneration_105059cb-1451-4f39-b88b-04ad97c13532_totalLabel_en-US" xlink:label="lab_ifrs-full_AuditorsRemuneration" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total auditor's remuneration</link:label>
    <link:label id="lab_ifrs-full_AuditorsRemuneration_label_en-US" xlink:label="lab_ifrs-full_AuditorsRemuneration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor's remuneration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemuneration" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AuditorsRemuneration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AuditorsRemuneration" xlink:to="lab_ifrs-full_AuditorsRemuneration" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_EuropeanCentralBankBaseRateMember_2a178c76-23f7-4325-8ac7-c24f2d44a959_terseLabel_en-US" xlink:label="lab_abvx_EuropeanCentralBankBaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">European Central Bank base rate</link:label>
    <link:label id="lab_abvx_EuropeanCentralBankBaseRateMember_label_en-US" xlink:label="lab_abvx_EuropeanCentralBankBaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">European Central Bank Base Rate [Member]</link:label>
    <link:label id="lab_abvx_EuropeanCentralBankBaseRateMember_documentation_en-US" xlink:label="lab_abvx_EuropeanCentralBankBaseRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">European Central Bank Base Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EuropeanCentralBankBaseRateMember" xlink:href="abvx-20251231.xsd#abvx_EuropeanCentralBankBaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_EuropeanCentralBankBaseRateMember" xlink:to="lab_abvx_EuropeanCentralBankBaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NonCurrentFinancialLiabilitiesMember_2dcdc6c5-0437-4d51-88d1-3ed9780670a8_terseLabel_en-US" xlink:label="lab_abvx_NonCurrentFinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities-non current portion</link:label>
    <link:label id="lab_abvx_NonCurrentFinancialLiabilitiesMember_label_en-US" xlink:label="lab_abvx_NonCurrentFinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Current Financial Liabilities [Member]</link:label>
    <link:label id="lab_abvx_NonCurrentFinancialLiabilitiesMember_documentation_en-US" xlink:label="lab_abvx_NonCurrentFinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Current Financial Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NonCurrentFinancialLiabilitiesMember" xlink:href="abvx-20251231.xsd#abvx_NonCurrentFinancialLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NonCurrentFinancialLiabilitiesMember" xlink:to="lab_abvx_NonCurrentFinancialLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems_71eab15b-cbda-4f92-b19e-bbaa7255861c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentMember_019bf9cf-a8a5-7a78-99ca-fe4519d15cee_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentMember_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_8d849534-b094-4b91-b96f-c9b8f5affe26_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BorrowingsPercentageOfMarketPrice_6aaa0ec1-0db0-4df2-9896-9157195fd1ae_terseLabel_en-US" xlink:label="lab_abvx_BorrowingsPercentageOfMarketPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, percentage of market price</link:label>
    <link:label id="lab_abvx_BorrowingsPercentageOfMarketPrice_label_en-US" xlink:label="lab_abvx_BorrowingsPercentageOfMarketPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, Percentage Of Market Price</link:label>
    <link:label id="lab_abvx_BorrowingsPercentageOfMarketPrice_documentation_en-US" xlink:label="lab_abvx_BorrowingsPercentageOfMarketPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowings, Percentage Of Market Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsPercentageOfMarketPrice" xlink:href="abvx-20251231.xsd#abvx_BorrowingsPercentageOfMarketPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BorrowingsPercentageOfMarketPrice" xlink:to="lab_abvx_BorrowingsPercentageOfMarketPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_118029ae-3e30-4dd6-a314-8512cb9ae7f3_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from borrowings</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from borrowings, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_883b7ad2-ba81-4e90-b4a4-ca2dddc9c498_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments of the lease liabilities</link:label>
    <link:label id="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of lease liabilities, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_ffa22226-6c3d-4733-8c54-0ead9cbd7847_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AuditorsRemunerationForTaxServices_019cc32c-c755-7a4c-bf5f-fb3b0c63c128_terseLabel_en-US" xlink:label="lab_ifrs-full_AuditorsRemunerationForTaxServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax fees</link:label>
    <link:label id="lab_ifrs-full_AuditorsRemunerationForTaxServices_label_en-US" xlink:label="lab_ifrs-full_AuditorsRemunerationForTaxServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor's remuneration for tax services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemunerationForTaxServices" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AuditorsRemunerationForTaxServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AuditorsRemunerationForTaxServices" xlink:to="lab_ifrs-full_AuditorsRemunerationForTaxServices" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NumberOfOtherShareWarrantsConverted_b03ec54a-5f70-4a61-ad1f-444887816283_terseLabel_en-US" xlink:label="lab_abvx_NumberOfOtherShareWarrantsConverted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of other share warrants converted (in shares)</link:label>
    <link:label id="lab_abvx_NumberOfOtherShareWarrantsConverted_label_en-US" xlink:label="lab_abvx_NumberOfOtherShareWarrantsConverted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Other Share Warrants Converted</link:label>
    <link:label id="lab_abvx_NumberOfOtherShareWarrantsConverted_documentation_en-US" xlink:label="lab_abvx_NumberOfOtherShareWarrantsConverted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Other Share Warrants Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfOtherShareWarrantsConverted" xlink:href="abvx-20251231.xsd#abvx_NumberOfOtherShareWarrantsConverted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NumberOfOtherShareWarrantsConverted" xlink:to="lab_abvx_NumberOfOtherShareWarrantsConverted" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsPercentageExercisableImmediately_44e0dbbc-5bd5-49c9-953f-c995ed67c2f3_terseLabel_en-US" xlink:label="lab_abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsPercentageExercisableImmediately" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of instruments granted, percentage exercisable immediately</link:label>
    <link:label id="lab_abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsPercentageExercisableImmediately_label_en-US" xlink:label="lab_abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsPercentageExercisableImmediately" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Instruments Granted, Other Equity Instruments, Percentage Exercisable Immediately</link:label>
    <link:label id="lab_abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsPercentageExercisableImmediately_documentation_en-US" xlink:label="lab_abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsPercentageExercisableImmediately" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Instruments Granted, Other Equity Instruments, Percentage Exercisable Immediately</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsPercentageExercisableImmediately" xlink:href="abvx-20251231.xsd#abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsPercentageExercisableImmediately"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsPercentageExercisableImmediately" xlink:to="lab_abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsPercentageExercisableImmediately" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities_47a21996-22b9-4ad5-b77a-8c89f3b253d5_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash changes: other fair value remeasurement</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through changes in fair values, liabilities arising from financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances_ba724e01-b752-490f-846e-e2fa71a87f37_terseLabel_en-US" xlink:label="lab_abvx_AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of unwinding the discount related to advances</link:label>
    <link:label id="lab_abvx_AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances_label_en-US" xlink:label="lab_abvx_AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Unwinding Of Discount Related To Conditional Advances</link:label>
    <link:label id="lab_abvx_AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances_documentation_en-US" xlink:label="lab_abvx_AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments For Unwinding Of Discount Related To Conditional Advances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances" xlink:href="abvx-20251231.xsd#abvx_AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances" xlink:to="lab_abvx_AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LossesOnChangeInFairValueOfDerivatives_3e3ca9d1-1e77-4d02-b8c6-7180e1a25068_verboseLabel_en-US" xlink:label="lab_ifrs-full_LossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase in fair value</link:label>
    <link:label id="lab_ifrs-full_LossesOnChangeInFairValueOfDerivatives_abc9e34c-3a64-4392-9cb7-b2e34ce167e5_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_LossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">(Increase) / decrease in derivatives fair value</link:label>
    <link:label id="lab_ifrs-full_LossesOnChangeInFairValueOfDerivatives_019d005a-91d9-7b46-8ff1-77bcf46bbeda_netLabel_en-US" xlink:label="lab_ifrs-full_LossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Losses on change in fair value of derivatives</link:label>
    <link:label id="lab_ifrs-full_LossesOnChangeInFairValueOfDerivatives_label_en-US" xlink:label="lab_ifrs-full_LossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Losses on change in fair value of derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LossesOnChangeInFairValueOfDerivatives" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LossesOnChangeInFairValueOfDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LossesOnChangeInFairValueOfDerivatives" xlink:to="lab_ifrs-full_LossesOnChangeInFairValueOfDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BorrowingsExitFeePercentage_2c19ce71-36f9-4a95-bd12-8c07bb2e6618_terseLabel_en-US" xlink:label="lab_abvx_BorrowingsExitFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, exit fee percentage</link:label>
    <link:label id="lab_abvx_BorrowingsExitFeePercentage_label_en-US" xlink:label="lab_abvx_BorrowingsExitFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, Exit Fee Percentage</link:label>
    <link:label id="lab_abvx_BorrowingsExitFeePercentage_documentation_en-US" xlink:label="lab_abvx_BorrowingsExitFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowings, Exit Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsExitFeePercentage" xlink:href="abvx-20251231.xsd#abvx_BorrowingsExitFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BorrowingsExitFeePercentage" xlink:to="lab_abvx_BorrowingsExitFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DecreaseInLeaseLiabilitiesThroughModificationOfTerm_403f1ffc-fc0d-4992-b571-e361dcfdc892_terseLabel_en-US" xlink:label="lab_abvx_DecreaseInLeaseLiabilitiesThroughModificationOfTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in lease liabilities through modification of term</link:label>
    <link:label id="lab_abvx_DecreaseInLeaseLiabilitiesThroughModificationOfTerm_label_en-US" xlink:label="lab_abvx_DecreaseInLeaseLiabilitiesThroughModificationOfTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease In Lease Liabilities Through Modification Of Term</link:label>
    <link:label id="lab_abvx_DecreaseInLeaseLiabilitiesThroughModificationOfTerm_documentation_en-US" xlink:label="lab_abvx_DecreaseInLeaseLiabilitiesThroughModificationOfTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Decrease In Lease Liabilities Through Modification Of Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DecreaseInLeaseLiabilitiesThroughModificationOfTerm" xlink:href="abvx-20251231.xsd#abvx_DecreaseInLeaseLiabilitiesThroughModificationOfTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DecreaseInLeaseLiabilitiesThroughModificationOfTerm" xlink:to="lab_abvx_DecreaseInLeaseLiabilitiesThroughModificationOfTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ShareBasedPaymentArrangementsAbstract_0b01269a-f5d5-49a9-afcc-f83e90408ab9_terseLabel_en-US" xlink:label="lab_abvx_ShareBasedPaymentArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangements [Abstract]</link:label>
    <link:label id="lab_abvx_ShareBasedPaymentArrangementsAbstract_label_en-US" xlink:label="lab_abvx_ShareBasedPaymentArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangements [Abstract]</link:label>
    <link:label id="lab_abvx_ShareBasedPaymentArrangementsAbstract_documentation_en-US" xlink:label="lab_abvx_ShareBasedPaymentArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ShareBasedPaymentArrangementsAbstract" xlink:href="abvx-20251231.xsd#abvx_ShareBasedPaymentArrangementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ShareBasedPaymentArrangementsAbstract" xlink:to="lab_abvx_ShareBasedPaymentArrangementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_SharePriceMeasurementInputMember_14a4f493-0c7f-45de-bacd-2afef32a23b5_terseLabel_en-US" xlink:label="lab_abvx_SharePriceMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary share price (in euro per share)</link:label>
    <link:label id="lab_abvx_SharePriceMeasurementInputMember_label_en-US" xlink:label="lab_abvx_SharePriceMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price, Measurement Input [Member]</link:label>
    <link:label id="lab_abvx_SharePriceMeasurementInputMember_documentation_en-US" xlink:label="lab_abvx_SharePriceMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Price, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SharePriceMeasurementInputMember" xlink:href="abvx-20251231.xsd#abvx_SharePriceMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_SharePriceMeasurementInputMember" xlink:to="lab_abvx_SharePriceMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BCE20175Member_e4cb0796-f7f8-45d7-96e1-88c857b81155_terseLabel_en-US" xlink:label="lab_abvx_BCE20175Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BCE-2017-5</link:label>
    <link:label id="lab_abvx_BCE20175Member_label_en-US" xlink:label="lab_abvx_BCE20175Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BCE-2017-5 [Member]</link:label>
    <link:label id="lab_abvx_BCE20175Member_documentation_en-US" xlink:label="lab_abvx_BCE20175Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BCE-2017-5</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BCE20175Member" xlink:href="abvx-20251231.xsd#abvx_BCE20175Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BCE20175Member" xlink:to="lab_abvx_BCE20175Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_93a512da-faf8-467e-8e0b-fcfc52735bce_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_c4f9ba00-2a74-4277-ae95-71c2cd8af0b2_terseLabel_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic loss per share (in euro per share)</link:label>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsLossPerShare" xlink:to="lab_ifrs-full_BasicEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AGA20231Member_75f062a7-016e-46c1-b097-9d1c1bde0944_terseLabel_en-US" xlink:label="lab_abvx_AGA20231Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA-2023-1</link:label>
    <link:label id="lab_abvx_AGA20231Member_label_en-US" xlink:label="lab_abvx_AGA20231Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA-2023-1 [Member]</link:label>
    <link:label id="lab_abvx_AGA20231Member_documentation_en-US" xlink:label="lab_abvx_AGA20231Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA-2023-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20231Member" xlink:href="abvx-20251231.xsd#abvx_AGA20231Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AGA20231Member" xlink:to="lab_abvx_AGA20231Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MeasurementAxis_1aaf48cc-664c-4b10-86cd-e3ff7d3b34ea_terseLabel_en-US" xlink:label="lab_ifrs-full_MeasurementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement [axis]</link:label>
    <link:label id="lab_ifrs-full_MeasurementAxis_label_en-US" xlink:label="lab_ifrs-full_MeasurementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MeasurementAxis" xlink:to="lab_ifrs-full_MeasurementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfOperatingIncomeTable_9620b43f-f8a3-4f55-a2b8-066b851f4940_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfOperatingIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Operating Income [Table]</link:label>
    <link:label id="lab_abvx_DisclosureOfOperatingIncomeTable_label_en-US" xlink:label="lab_abvx_DisclosureOfOperatingIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Operating Income [Table]</link:label>
    <link:label id="lab_abvx_DisclosureOfOperatingIncomeTable_documentation_en-US" xlink:label="lab_abvx_DisclosureOfOperatingIncomeTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Operating Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfOperatingIncomeTable" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfOperatingIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfOperatingIncomeTable" xlink:to="lab_abvx_DisclosureOfOperatingIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_ae97829e-b603-4b55-8608-44bfede8d59e_verboseLabel_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of outstanding shares used for computing diluted loss per share (in shares)</link:label>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_c28bf2a3-dd49-439d-8374-60736b9a03c1_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of outstanding shares, diluted loss per share (in shares)</link:label>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares used in calculating diluted earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:to="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_After36MonthsMember_6d2e5ee8-64fc-46b1-9cce-be9310d058b4_terseLabel_en-US" xlink:label="lab_abvx_After36MonthsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After 36 months</link:label>
    <link:label id="lab_abvx_After36MonthsMember_label_en-US" xlink:label="lab_abvx_After36MonthsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">After 36 Months [Member]</link:label>
    <link:label id="lab_abvx_After36MonthsMember_documentation_en-US" xlink:label="lab_abvx_After36MonthsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">After 36 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_After36MonthsMember" xlink:href="abvx-20251231.xsd#abvx_After36MonthsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_After36MonthsMember" xlink:to="lab_abvx_After36MonthsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ActuarialAssumptionOfExpectedRatesOfTurnover_0180f35c-878c-4e3b-8109-0168093308a7_terseLabel_en-US" xlink:label="lab_abvx_ActuarialAssumptionOfExpectedRatesOfTurnover" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Turnover rate</link:label>
    <link:label id="lab_abvx_ActuarialAssumptionOfExpectedRatesOfTurnover_label_en-US" xlink:label="lab_abvx_ActuarialAssumptionOfExpectedRatesOfTurnover" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial Assumption Of Expected Rates Of Turnover</link:label>
    <link:label id="lab_abvx_ActuarialAssumptionOfExpectedRatesOfTurnover_documentation_en-US" xlink:label="lab_abvx_ActuarialAssumptionOfExpectedRatesOfTurnover" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Actuarial Assumption Of Expected Rates Of Turnover</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ActuarialAssumptionOfExpectedRatesOfTurnover" xlink:href="abvx-20251231.xsd#abvx_ActuarialAssumptionOfExpectedRatesOfTurnover"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ActuarialAssumptionOfExpectedRatesOfTurnover" xlink:to="lab_abvx_ActuarialAssumptionOfExpectedRatesOfTurnover" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_KeyManagementPersonnelCompensationInKindContributions_6687e57d-43ad-454e-89d3-785b5ebf9413_terseLabel_en-US" xlink:label="lab_abvx_KeyManagementPersonnelCompensationInKindContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contributions in-kind</link:label>
    <link:label id="lab_abvx_KeyManagementPersonnelCompensationInKindContributions_label_en-US" xlink:label="lab_abvx_KeyManagementPersonnelCompensationInKindContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key Management Personnel Compensation, In-Kind Contributions</link:label>
    <link:label id="lab_abvx_KeyManagementPersonnelCompensationInKindContributions_documentation_en-US" xlink:label="lab_abvx_KeyManagementPersonnelCompensationInKindContributions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Key Management Personnel Compensation, In-Kind Contributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KeyManagementPersonnelCompensationInKindContributions" xlink:href="abvx-20251231.xsd#abvx_KeyManagementPersonnelCompensationInKindContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_KeyManagementPersonnelCompensationInKindContributions" xlink:to="lab_abvx_KeyManagementPersonnelCompensationInKindContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_UnrecognitionDayOneGainOfFinancialLiabilities_61ec6ab1-92f3-4a9a-9e1a-2237f3f4acdf_terseLabel_en-US" xlink:label="lab_abvx_UnrecognitionDayOneGainOfFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognition day-one gain of financial liabilities</link:label>
    <link:label id="lab_abvx_UnrecognitionDayOneGainOfFinancialLiabilities_label_en-US" xlink:label="lab_abvx_UnrecognitionDayOneGainOfFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognition Day-One Gain Of Financial Liabilities</link:label>
    <link:label id="lab_abvx_UnrecognitionDayOneGainOfFinancialLiabilities_documentation_en-US" xlink:label="lab_abvx_UnrecognitionDayOneGainOfFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrecognition Day-One Gain Of Financial Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_UnrecognitionDayOneGainOfFinancialLiabilities" xlink:href="abvx-20251231.xsd#abvx_UnrecognitionDayOneGainOfFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_UnrecognitionDayOneGainOfFinancialLiabilities" xlink:to="lab_abvx_UnrecognitionDayOneGainOfFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets_351f8779-2686-4bb8-b313-d4a9fc16bbe8_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease in financial assets at fair value</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets_4ddf4937-b6e5-4b30-8c54-92cc39b2518d_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" xlink:to="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_73bf48bd-b62b-4e8e-b4d6-bdbb0e142133_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [domain]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:to="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_de70e344-210d-4cc0-9b4c-8ea62ebc4d78_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expenses</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for share-based payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BorrowingsNumberOfQuarterlyInstallments_cc459b66-79ff-48cf-85a5-f0ad7a1e593c_terseLabel_en-US" xlink:label="lab_abvx_BorrowingsNumberOfQuarterlyInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, number of quarterly installments</link:label>
    <link:label id="lab_abvx_BorrowingsNumberOfQuarterlyInstallments_label_en-US" xlink:label="lab_abvx_BorrowingsNumberOfQuarterlyInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, Number Of Quarterly Installments</link:label>
    <link:label id="lab_abvx_BorrowingsNumberOfQuarterlyInstallments_documentation_en-US" xlink:label="lab_abvx_BorrowingsNumberOfQuarterlyInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowings, Number Of Quarterly Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsNumberOfQuarterlyInstallments" xlink:href="abvx-20251231.xsd#abvx_BorrowingsNumberOfQuarterlyInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BorrowingsNumberOfQuarterlyInstallments" xlink:to="lab_abvx_BorrowingsNumberOfQuarterlyInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_KreosClaretFinancingAndHeightsConvertibleNotesMember_6d99dc1b-7ba8-4ff5-aa10-3c30b187badd_terseLabel_en-US" xlink:label="lab_abvx_KreosClaretFinancingAndHeightsConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret financing and Heights convertible notes</link:label>
    <link:label id="lab_abvx_KreosClaretFinancingAndHeightsConvertibleNotesMember_label_en-US" xlink:label="lab_abvx_KreosClaretFinancingAndHeightsConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret Financing And Heights Convertible Notes [Member]</link:label>
    <link:label id="lab_abvx_KreosClaretFinancingAndHeightsConvertibleNotesMember_documentation_en-US" xlink:label="lab_abvx_KreosClaretFinancingAndHeightsConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret Financing And Heights Convertible Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingAndHeightsConvertibleNotesMember" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingAndHeightsConvertibleNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_KreosClaretFinancingAndHeightsConvertibleNotesMember" xlink:to="lab_abvx_KreosClaretFinancingAndHeightsConvertibleNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ConditionalAdvancesAndPGELoanMember_65aae74b-2e9c-4042-a963-98ba4f260db8_terseLabel_en-US" xlink:label="lab_abvx_ConditionalAdvancesAndPGELoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conditional advances and PGE loan</link:label>
    <link:label id="lab_abvx_ConditionalAdvancesAndPGELoanMember_label_en-US" xlink:label="lab_abvx_ConditionalAdvancesAndPGELoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conditional Advances And PGE Loan [Member]</link:label>
    <link:label id="lab_abvx_ConditionalAdvancesAndPGELoanMember_documentation_en-US" xlink:label="lab_abvx_ConditionalAdvancesAndPGELoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conditional Advances And PGE Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConditionalAdvancesAndPGELoanMember" xlink:href="abvx-20251231.xsd#abvx_ConditionalAdvancesAndPGELoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ConditionalAdvancesAndPGELoanMember" xlink:to="lab_abvx_ConditionalAdvancesAndPGELoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_TechnicalFacilitiesMember_482cb0a2-fb57-4a1b-b8b9-d86f817ccc59_terseLabel_en-US" xlink:label="lab_abvx_TechnicalFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Technical facilities</link:label>
    <link:label id="lab_abvx_TechnicalFacilitiesMember_label_en-US" xlink:label="lab_abvx_TechnicalFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technical Facilities [Member]</link:label>
    <link:label id="lab_abvx_TechnicalFacilitiesMember_documentation_en-US" xlink:label="lab_abvx_TechnicalFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Technical Facilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TechnicalFacilitiesMember" xlink:href="abvx-20251231.xsd#abvx_TechnicalFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_TechnicalFacilitiesMember" xlink:to="lab_abvx_TechnicalFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BlackScholesModelMember_6701756d-b2f0-4031-a72f-478766c46db5_terseLabel_en-US" xlink:label="lab_abvx_BlackScholesModelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Black Scholes Model</link:label>
    <link:label id="lab_abvx_BlackScholesModelMember_label_en-US" xlink:label="lab_abvx_BlackScholesModelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Black Scholes Model [Member]</link:label>
    <link:label id="lab_abvx_BlackScholesModelMember_documentation_en-US" xlink:label="lab_abvx_BlackScholesModelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Black Scholes Model</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BlackScholesModelMember" xlink:href="abvx-20251231.xsd#abvx_BlackScholesModelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BlackScholesModelMember" xlink:to="lab_abvx_BlackScholesModelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_9f8b1b50-bf2e-4bf9-bfd8-886334cb9483_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement benefit obligations</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of employee benefits [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementPerformanceConditionsMinimumFinancing_9e5091c0-3c0b-4b5c-a158-10c34e4813fb_terseLabel_en-US" xlink:label="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementPerformanceConditionsMinimumFinancing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance conditions, minimum financing</link:label>
    <link:label id="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementPerformanceConditionsMinimumFinancing_label_en-US" xlink:label="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementPerformanceConditionsMinimumFinancing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Performance Conditions, Minimum Financing</link:label>
    <link:label id="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementPerformanceConditionsMinimumFinancing_documentation_en-US" xlink:label="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementPerformanceConditionsMinimumFinancing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Performance Conditions, Minimum Financing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementPerformanceConditionsMinimumFinancing" xlink:href="abvx-20251231.xsd#abvx_VestingRequirementsForShareBasedPaymentArrangementPerformanceConditionsMinimumFinancing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementPerformanceConditionsMinimumFinancing" xlink:to="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementPerformanceConditionsMinimumFinancing" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_GainsOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss_4e6a781c-f421-44a4-aaa1-0533aa8c61bb_terseLabel_en-US" xlink:label="lab_abvx_GainsOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Increase) / decrease in other liabilities / (assets) at fair value through profit and loss</link:label>
    <link:label id="lab_abvx_GainsOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss_label_en-US" xlink:label="lab_abvx_GainsOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains On Financial Liabilities At Fair Value Through Profit Or Loss</link:label>
    <link:label id="lab_abvx_GainsOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss_documentation_en-US" xlink:label="lab_abvx_GainsOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gains On Financial Liabilities At Fair Value Through Profit Or Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_GainsOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:href="abvx-20251231.xsd#abvx_GainsOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_GainsOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:to="lab_abvx_GainsOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_ef402685-798c-490d-b264-dbe77e8828d9_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAbstract_6bc98789-5b99-48a3-8972-59b10f42b470_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders&#8217; equity</link:label>
    <link:label id="lab_ifrs-full_EquityAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAbstract" xlink:to="lab_ifrs-full_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_IssuanceOfOtherShareWarrants_b9235ee0-4dfe-45f3-91ef-418f12a31190_terseLabel_en-US" xlink:label="lab_abvx_IssuanceOfOtherShareWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of other share warrants</link:label>
    <link:label id="lab_abvx_IssuanceOfOtherShareWarrants_label_en-US" xlink:label="lab_abvx_IssuanceOfOtherShareWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance Of Other Share Warrants</link:label>
    <link:label id="lab_abvx_IssuanceOfOtherShareWarrants_documentation_en-US" xlink:label="lab_abvx_IssuanceOfOtherShareWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance Of Other Share Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IssuanceOfOtherShareWarrants" xlink:href="abvx-20251231.xsd#abvx_IssuanceOfOtherShareWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_IssuanceOfOtherShareWarrants" xlink:to="lab_abvx_IssuanceOfOtherShareWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory_3ead2f84-dfb5-42e2-9a08-0dca7d015fcc_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of carrying amounts and fair value of financial assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDeveloped_fb270103-7183-46c7-9672-d95b5b64da45_terseLabel_en-US" xlink:label="lab_abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDeveloped" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of annual revenue from sale of products developed</link:label>
    <link:label id="lab_abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDeveloped_label_en-US" xlink:label="lab_abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDeveloped" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Financial Liabilities, Percentage Of Annual Revenue From Sale Of Products Developed</link:label>
    <link:label id="lab_abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDeveloped_documentation_en-US" xlink:label="lab_abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDeveloped" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Financial Liabilities, Percentage Of Annual Revenue From Sale Of Products Developed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDeveloped" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDeveloped"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDeveloped" xlink:to="lab_abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDeveloped" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_EbolaConditionalAdvanceBPILanguedocRoussillonMember_8db212be-0c33-4351-8c8e-4329b74db9fc_terseLabel_en-US" xlink:label="lab_abvx_EbolaConditionalAdvanceBPILanguedocRoussillonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ebola conditional advance, BPI Languedoc-Roussillon</link:label>
    <link:label id="lab_abvx_EbolaConditionalAdvanceBPILanguedocRoussillonMember_label_en-US" xlink:label="lab_abvx_EbolaConditionalAdvanceBPILanguedocRoussillonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ebola Conditional Advance, BPI Languedoc-Roussillon [Member]</link:label>
    <link:label id="lab_abvx_EbolaConditionalAdvanceBPILanguedocRoussillonMember_documentation_en-US" xlink:label="lab_abvx_EbolaConditionalAdvanceBPILanguedocRoussillonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ebola Conditional Advance, BPI Languedoc-Roussillon</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EbolaConditionalAdvanceBPILanguedocRoussillonMember" xlink:href="abvx-20251231.xsd#abvx_EbolaConditionalAdvanceBPILanguedocRoussillonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_EbolaConditionalAdvanceBPILanguedocRoussillonMember" xlink:to="lab_abvx_EbolaConditionalAdvanceBPILanguedocRoussillonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_KeyManagementPersonnelCompensationFixedCompensation_157b04df-23e7-4546-8199-995808c36967_terseLabel_en-US" xlink:label="lab_abvx_KeyManagementPersonnelCompensationFixedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed compensation owed</link:label>
    <link:label id="lab_abvx_KeyManagementPersonnelCompensationFixedCompensation_label_en-US" xlink:label="lab_abvx_KeyManagementPersonnelCompensationFixedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key Management Personnel Compensation, Fixed Compensation</link:label>
    <link:label id="lab_abvx_KeyManagementPersonnelCompensationFixedCompensation_documentation_en-US" xlink:label="lab_abvx_KeyManagementPersonnelCompensationFixedCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Key Management Personnel Compensation, Fixed Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KeyManagementPersonnelCompensationFixedCompensation" xlink:href="abvx-20251231.xsd#abvx_KeyManagementPersonnelCompensationFixedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_KeyManagementPersonnelCompensationFixedCompensation" xlink:to="lab_abvx_KeyManagementPersonnelCompensationFixedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_Kreos1BondLoansMember_79e8f06d-f184-4a89-9742-04ff7affc6e1_terseLabel_en-US" xlink:label="lab_abvx_Kreos1BondLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kreos 1 bond loans</link:label>
    <link:label id="lab_abvx_Kreos1BondLoansMember_label_en-US" xlink:label="lab_abvx_Kreos1BondLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kreos 1 Bond Loans [Member]</link:label>
    <link:label id="lab_abvx_Kreos1BondLoansMember_documentation_en-US" xlink:label="lab_abvx_Kreos1BondLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kreos 1 Bond Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1BondLoansMember" xlink:href="abvx-20251231.xsd#abvx_Kreos1BondLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_Kreos1BondLoansMember" xlink:to="lab_abvx_Kreos1BondLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AmortizedCostEIRMethodMember_a0526e68-608a-4383-841f-41cc0ebda8be_terseLabel_en-US" xlink:label="lab_abvx_AmortizedCostEIRMethodMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized cost (EIR method)</link:label>
    <link:label id="lab_abvx_AmortizedCostEIRMethodMember_label_en-US" xlink:label="lab_abvx_AmortizedCostEIRMethodMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortized Cost (EIR Method) [Member]</link:label>
    <link:label id="lab_abvx_AmortizedCostEIRMethodMember_documentation_en-US" xlink:label="lab_abvx_AmortizedCostEIRMethodMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortized Cost (EIR Method)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AmortizedCostEIRMethodMember" xlink:href="abvx-20251231.xsd#abvx_AmortizedCostEIRMethodMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AmortizedCostEIRMethodMember" xlink:to="lab_abvx_AmortizedCostEIRMethodMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_CollaborationAgreementsDevelopmentMilestonePaymentINDApproval_0f53c96b-576f-42df-b899-f3360f12a9d0_terseLabel_en-US" xlink:label="lab_abvx_CollaborationAgreementsDevelopmentMilestonePaymentINDApproval" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreements, development milestone payment, IND approval</link:label>
    <link:label id="lab_abvx_CollaborationAgreementsDevelopmentMilestonePaymentINDApproval_label_en-US" xlink:label="lab_abvx_CollaborationAgreementsDevelopmentMilestonePaymentINDApproval" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Development Milestone Payment, IND Approval</link:label>
    <link:label id="lab_abvx_CollaborationAgreementsDevelopmentMilestonePaymentINDApproval_documentation_en-US" xlink:label="lab_abvx_CollaborationAgreementsDevelopmentMilestonePaymentINDApproval" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Development Milestone Payment, IND Approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CollaborationAgreementsDevelopmentMilestonePaymentINDApproval" xlink:href="abvx-20251231.xsd#abvx_CollaborationAgreementsDevelopmentMilestonePaymentINDApproval"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_CollaborationAgreementsDevelopmentMilestonePaymentINDApproval" xlink:to="lab_abvx_CollaborationAgreementsDevelopmentMilestonePaymentINDApproval" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AGA20244Member_80fc25f1-fd61-4cb3-9546-24bba50724b2_terseLabel_en-US" xlink:label="lab_abvx_AGA20244Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA-2024-4</link:label>
    <link:label id="lab_abvx_AGA20244Member_label_en-US" xlink:label="lab_abvx_AGA20244Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA-2024-4 [Member]</link:label>
    <link:label id="lab_abvx_AGA20244Member_documentation_en-US" xlink:label="lab_abvx_AGA20244Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA-2024-4</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20244Member" xlink:href="abvx-20251231.xsd#abvx_AGA20244Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AGA20244Member" xlink:to="lab_abvx_AGA20244Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember_f755cf3f-e61a-45c3-9d5f-d30d92904ea8_terseLabel_en-US" xlink:label="lab_abvx_TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Probability-weighted present value of shortfall payment, tender offer</link:label>
    <link:label id="lab_abvx_TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember_label_en-US" xlink:label="lab_abvx_TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tender Offer, Probability-Weighted Present Value Of Shortfall Payment, Measurement Input [Member]</link:label>
    <link:label id="lab_abvx_TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember_documentation_en-US" xlink:label="lab_abvx_TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tender Offer, Probability-Weighted Present Value Of Shortfall Payment, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember" xlink:href="abvx-20251231.xsd#abvx_TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember" xlink:to="lab_abvx_TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_2187163f-741a-4c87-bdff-a3958f4c1c43_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions other than through business combinations, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_7798dfb8-d853-4721-bcc1-a235c9febdf7_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_KreosClaretFinancingTrancheBMember_f7d099af-b579-46a6-b864-4c1576d706ca_terseLabel_en-US" xlink:label="lab_abvx_KreosClaretFinancingTrancheBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret financing, tranche B</link:label>
    <link:label id="lab_abvx_KreosClaretFinancingTrancheBMember_label_en-US" xlink:label="lab_abvx_KreosClaretFinancingTrancheBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret Financing, Tranche B [Member]</link:label>
    <link:label id="lab_abvx_KreosClaretFinancingTrancheBMember_documentation_en-US" xlink:label="lab_abvx_KreosClaretFinancingTrancheBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret Financing, Tranche B</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheBMember" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_KreosClaretFinancingTrancheBMember" xlink:to="lab_abvx_KreosClaretFinancingTrancheBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_4674a095-ea70-4b7a-b06e-247f0fa2810b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_UnwindingOfDiscountOnRoyalties_88944887-1100-4961-bcbf-f857c4470e85_terseLabel_en-US" xlink:label="lab_abvx_UnwindingOfDiscountOnRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unwinding of discount on royalties</link:label>
    <link:label id="lab_abvx_UnwindingOfDiscountOnRoyalties_label_en-US" xlink:label="lab_abvx_UnwindingOfDiscountOnRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unwinding Of Discount On Royalties</link:label>
    <link:label id="lab_abvx_UnwindingOfDiscountOnRoyalties_documentation_en-US" xlink:label="lab_abvx_UnwindingOfDiscountOnRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unwinding Of Discount On Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_UnwindingOfDiscountOnRoyalties" xlink:href="abvx-20251231.xsd#abvx_UnwindingOfDiscountOnRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_UnwindingOfDiscountOnRoyalties" xlink:to="lab_abvx_UnwindingOfDiscountOnRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_04fe5c45-b687-4e74-947a-579f6104e1fc_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_184f814c-f63b-45bd-8bdb-0ae69ef9bcc3_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employer contributions</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, post-employment benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfContractsAxis_84f2ebbb-fe3f-4e3e-bdb0-0aff34f4f655_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfContractsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of contracts [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfContractsAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfContractsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of contracts [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfContractsAxis" xlink:to="lab_ifrs-full_TypesOfContractsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharePremiumMember_5650fb5e-64ae-45f3-a72f-00220d195eb4_terseLabel_en-US" xlink:label="lab_ifrs-full_SharePremiumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PREMIUMS RELATED TO SHARE CAPITAL</link:label>
    <link:label id="lab_ifrs-full_SharePremiumMember_4a1719e5-b16e-4556-a4d9-b107b5fe2046_verboseLabel_en-US" xlink:label="lab_ifrs-full_SharePremiumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share premium</link:label>
    <link:label id="lab_ifrs-full_SharePremiumMember_label_en-US" xlink:label="lab_ifrs-full_SharePremiumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share premium [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharePremiumMember" xlink:to="lab_ifrs-full_SharePremiumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BorrowingsAdditionalTrancheAmount_eb3e73d0-e246-4b10-aebe-3dd343c6a2a4_terseLabel_en-US" xlink:label="lab_abvx_BorrowingsAdditionalTrancheAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, additional tranche mount</link:label>
    <link:label id="lab_abvx_BorrowingsAdditionalTrancheAmount_label_en-US" xlink:label="lab_abvx_BorrowingsAdditionalTrancheAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, Additional Tranche Amount</link:label>
    <link:label id="lab_abvx_BorrowingsAdditionalTrancheAmount_documentation_en-US" xlink:label="lab_abvx_BorrowingsAdditionalTrancheAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowings, Additional Tranche Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsAdditionalTrancheAmount" xlink:href="abvx-20251231.xsd#abvx_BorrowingsAdditionalTrancheAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BorrowingsAdditionalTrancheAmount" xlink:to="lab_abvx_BorrowingsAdditionalTrancheAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DiscountRateAppliedToLongTermAdvances_fbf6c39a-4890-430f-94aa-277822f0971c_terseLabel_en-US" xlink:label="lab_abvx_DiscountRateAppliedToLongTermAdvances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disount rate applied to long-term advances</link:label>
    <link:label id="lab_abvx_DiscountRateAppliedToLongTermAdvances_label_en-US" xlink:label="lab_abvx_DiscountRateAppliedToLongTermAdvances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discount Rate Applied To Long-Term Advances</link:label>
    <link:label id="lab_abvx_DiscountRateAppliedToLongTermAdvances_documentation_en-US" xlink:label="lab_abvx_DiscountRateAppliedToLongTermAdvances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Discount Rate Applied To Long-Term Advances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DiscountRateAppliedToLongTermAdvances" xlink:href="abvx-20251231.xsd#abvx_DiscountRateAppliedToLongTermAdvances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DiscountRateAppliedToLongTermAdvances" xlink:to="lab_abvx_DiscountRateAppliedToLongTermAdvances" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NonCurrentRoyaltyCertificates_cd4dda9c-17ad-4f38-89b8-7cd2c558d9f2_terseLabel_en-US" xlink:label="lab_abvx_NonCurrentRoyaltyCertificates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty certificates</link:label>
    <link:label id="lab_abvx_NonCurrentRoyaltyCertificates_label_en-US" xlink:label="lab_abvx_NonCurrentRoyaltyCertificates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Current Royalty Certificates</link:label>
    <link:label id="lab_abvx_NonCurrentRoyaltyCertificates_documentation_en-US" xlink:label="lab_abvx_NonCurrentRoyaltyCertificates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Current Royalty Certificates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NonCurrentRoyaltyCertificates" xlink:href="abvx-20251231.xsd#abvx_NonCurrentRoyaltyCertificates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NonCurrentRoyaltyCertificates" xlink:to="lab_abvx_NonCurrentRoyaltyCertificates" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementChangeOfControlMinimumThreshold_8c2efb17-6a6f-4905-8c21-54d6a2bef945_terseLabel_en-US" xlink:label="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementChangeOfControlMinimumThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change of control, minimum percentage</link:label>
    <link:label id="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementChangeOfControlMinimumThreshold_label_en-US" xlink:label="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementChangeOfControlMinimumThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Change Of Control, Minimum Threshold</link:label>
    <link:label id="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementChangeOfControlMinimumThreshold_documentation_en-US" xlink:label="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementChangeOfControlMinimumThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Change Of Control, Minimum Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementChangeOfControlMinimumThreshold" xlink:href="abvx-20251231.xsd#abvx_VestingRequirementsForShareBasedPaymentArrangementChangeOfControlMinimumThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementChangeOfControlMinimumThreshold" xlink:to="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementChangeOfControlMinimumThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_VolatilityForSharesMeasurementInputExpiryMember_98a05966-c5a0-4d0f-9cb8-0657e7c1661d_terseLabel_en-US" xlink:label="lab_abvx_VolatilityForSharesMeasurementInputExpiryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility, expiry</link:label>
    <link:label id="lab_abvx_VolatilityForSharesMeasurementInputExpiryMember_label_en-US" xlink:label="lab_abvx_VolatilityForSharesMeasurementInputExpiryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Volatility For Shares Measurement Input, Expiry [Member]</link:label>
    <link:label id="lab_abvx_VolatilityForSharesMeasurementInputExpiryMember_documentation_en-US" xlink:label="lab_abvx_VolatilityForSharesMeasurementInputExpiryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Volatility For Shares Measurement Input, Expiry</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VolatilityForSharesMeasurementInputExpiryMember" xlink:href="abvx-20251231.xsd#abvx_VolatilityForSharesMeasurementInputExpiryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_VolatilityForSharesMeasurementInputExpiryMember" xlink:to="lab_abvx_VolatilityForSharesMeasurementInputExpiryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Liabilities_f9107033-cae2-43f7-a7af-ed4366255d53_terseLabel_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities</link:label>
    <link:label id="lab_ifrs-full_Liabilities_019c001c-7ddc-7e2f-8bd4-5dbf69d2df56_verboseLabel_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_ifrs-full_Liabilities_label_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Liabilities" xlink:to="lab_ifrs-full_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_784d95f3-909d-4060-beae-145af4b3c802_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research tax credit and subsidies</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for government grants [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OfficeEquipmentMember_0ffee452-8f00-46f6-b946-e197d1a96332_terseLabel_en-US" xlink:label="lab_ifrs-full_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_ifrs-full_OfficeEquipmentMember_019bf9cc-c880-7cd0-a9de-057a50a9bc6a_verboseLabel_en-US" xlink:label="lab_ifrs-full_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">EQUIPMENT</link:label>
    <link:label id="lab_ifrs-full_OfficeEquipmentMember_label_en-US" xlink:label="lab_ifrs-full_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office equipment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OfficeEquipmentMember" xlink:to="lab_ifrs-full_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_PercentageOfConditionalAdvancesWaived_383a1fe7-1cbf-4d77-93c0-e02326839a0d_terseLabel_en-US" xlink:label="lab_abvx_PercentageOfConditionalAdvancesWaived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of conditional advances waived</link:label>
    <link:label id="lab_abvx_PercentageOfConditionalAdvancesWaived_label_en-US" xlink:label="lab_abvx_PercentageOfConditionalAdvancesWaived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Conditional Advances Waived</link:label>
    <link:label id="lab_abvx_PercentageOfConditionalAdvancesWaived_documentation_en-US" xlink:label="lab_abvx_PercentageOfConditionalAdvancesWaived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Conditional Advances Waived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PercentageOfConditionalAdvancesWaived" xlink:href="abvx-20251231.xsd#abvx_PercentageOfConditionalAdvancesWaived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_PercentageOfConditionalAdvancesWaived" xlink:to="lab_abvx_PercentageOfConditionalAdvancesWaived" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember_73cdcbe5-89b4-4f12-bd31-1015f22f9874_terseLabel_en-US" xlink:label="lab_abvx_ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exclusive licensing agreement with CNRS, University of Montpellier and Institut Curie</link:label>
    <link:label id="lab_abvx_ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember_label_en-US" xlink:label="lab_abvx_ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exclusive Licensing Agreement With CNRS, University Of Montpellier And Institut Curie [Member]</link:label>
    <link:label id="lab_abvx_ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember_documentation_en-US" xlink:label="lab_abvx_ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exclusive Licensing Agreement With CNRS, University Of Montpellier And Institut Curie</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember" xlink:href="abvx-20251231.xsd#abvx_ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember" xlink:to="lab_abvx_ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities_d26ef364-9f26-4a91-aef3-32c57fd818aa_terseLabel_en-US" xlink:label="lab_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of remaining contractual maturities of derivative financial liabilities</link:label>
    <link:label id="lab_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis for derivative financial liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities" xlink:to="lab_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_d1d7d564-c6c8-47f0-9570-f6c1b1802bda_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BorrowingsMaximumBorrowingCapacityPerTranche_4e6e37c5-d212-43bb-b41c-69709b6d1a85_terseLabel_en-US" xlink:label="lab_abvx_BorrowingsMaximumBorrowingCapacityPerTranche" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, maximum borrowing capacity per tranche</link:label>
    <link:label id="lab_abvx_BorrowingsMaximumBorrowingCapacityPerTranche_label_en-US" xlink:label="lab_abvx_BorrowingsMaximumBorrowingCapacityPerTranche" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, Maximum Borrowing Capacity Per Tranche</link:label>
    <link:label id="lab_abvx_BorrowingsMaximumBorrowingCapacityPerTranche_documentation_en-US" xlink:label="lab_abvx_BorrowingsMaximumBorrowingCapacityPerTranche" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowings, Maximum Borrowing Capacity Per Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsMaximumBorrowingCapacityPerTranche" xlink:href="abvx-20251231.xsd#abvx_BorrowingsMaximumBorrowingCapacityPerTranche"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BorrowingsMaximumBorrowingCapacityPerTranche" xlink:to="lab_abvx_BorrowingsMaximumBorrowingCapacityPerTranche" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ShareSubscriptionWarrantsBSAMember_7ecdc29f-c698-4ed0-83e1-19e347b06a2a_terseLabel_en-US" xlink:label="lab_abvx_ShareSubscriptionWarrantsBSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total BSAs</link:label>
    <link:label id="lab_abvx_ShareSubscriptionWarrantsBSAMember_ada6061f-1b35-4715-aa07-367d0e3685f7_verboseLabel_en-US" xlink:label="lab_abvx_ShareSubscriptionWarrantsBSAMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">BSAs</link:label>
    <link:label id="lab_abvx_ShareSubscriptionWarrantsBSAMember_label_en-US" xlink:label="lab_abvx_ShareSubscriptionWarrantsBSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Subscription Warrants (BSA) [Member]</link:label>
    <link:label id="lab_abvx_ShareSubscriptionWarrantsBSAMember_documentation_en-US" xlink:label="lab_abvx_ShareSubscriptionWarrantsBSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Subscription Warrants (BSA)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ShareSubscriptionWarrantsBSAMember" xlink:href="abvx-20251231.xsd#abvx_ShareSubscriptionWarrantsBSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ShareSubscriptionWarrantsBSAMember" xlink:to="lab_abvx_ShareSubscriptionWarrantsBSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_5bd35b77-de22-40f8-8f9a-2735e163400c_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for intangible assets other than goodwill [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_NoTradingSymbolFlag_56a9f42b-d271-477a-bb56-f622f37dfb05_terseLabel_en-US" xlink:label="lab_dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">No Trading Symbol Flag</link:label>
    <link:label id="lab_dei_NoTradingSymbolFlag_label_en-US" xlink:label="lab_dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">No Trading Symbol Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_NoTradingSymbolFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_NoTradingSymbolFlag" xlink:to="lab_dei_NoTradingSymbolFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections_3ffd92ee-1504-47fd-9ec4-1c01d0897fa9_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate (WACC)</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discount rate applied to cash flow projections</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:to="lab_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherAssetsExplanatory_23a71188-1b99-40bb-b265-e72c6d1a9b48_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesTable_f3456fb6-8056-4bc2-907f-a59d9d544b88_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of information for cash-generating units [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of information for cash-generating units [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesTable" xlink:to="lab_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseOnBonds_5500b8e7-e840-4da4-b63b-137e4906d8c6_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnBonds" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest on bond loans</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnBonds_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnBonds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense on bonds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBonds" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnBonds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnBonds" xlink:to="lab_ifrs-full_InterestExpenseOnBonds" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ActuarialAssumptionOfExpectedRatesOfTurnoverAverageExitRate_03f268c6-cb87-4cad-a0dc-0b881443207e_terseLabel_en-US" xlink:label="lab_abvx_ActuarialAssumptionOfExpectedRatesOfTurnoverAverageExitRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Turnover rate, average exit rate</link:label>
    <link:label id="lab_abvx_ActuarialAssumptionOfExpectedRatesOfTurnoverAverageExitRate_label_en-US" xlink:label="lab_abvx_ActuarialAssumptionOfExpectedRatesOfTurnoverAverageExitRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial Assumption Of Expected Rates Of Turnover, Average Exit Rate</link:label>
    <link:label id="lab_abvx_ActuarialAssumptionOfExpectedRatesOfTurnoverAverageExitRate_documentation_en-US" xlink:label="lab_abvx_ActuarialAssumptionOfExpectedRatesOfTurnoverAverageExitRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Actuarial Assumption Of Expected Rates Of Turnover, Average Exit Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ActuarialAssumptionOfExpectedRatesOfTurnoverAverageExitRate" xlink:href="abvx-20251231.xsd#abvx_ActuarialAssumptionOfExpectedRatesOfTurnoverAverageExitRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ActuarialAssumptionOfExpectedRatesOfTurnoverAverageExitRate" xlink:to="lab_abvx_ActuarialAssumptionOfExpectedRatesOfTurnoverAverageExitRate" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_RepaymentsOfConvertibleLoansNotes_2b9a768e-71f2-4f51-871c-ef61d4f83ecd_negatedTerseLabel_en-US" xlink:label="lab_abvx_RepaymentsOfConvertibleLoansNotes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayments of convertible loan notes</link:label>
    <link:label id="lab_abvx_RepaymentsOfConvertibleLoansNotes_762574c4-a764-4ef1-ba77-2cfec6a1f567_terseLabel_en-US" xlink:label="lab_abvx_RepaymentsOfConvertibleLoansNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of convertible loan notes</link:label>
    <link:label id="lab_abvx_RepaymentsOfConvertibleLoansNotes_label_en-US" xlink:label="lab_abvx_RepaymentsOfConvertibleLoansNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments Of Convertible Loans Notes</link:label>
    <link:label id="lab_abvx_RepaymentsOfConvertibleLoansNotes_documentation_en-US" xlink:label="lab_abvx_RepaymentsOfConvertibleLoansNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Repayments Of Convertible Loans Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepaymentsOfConvertibleLoansNotes" xlink:href="abvx-20251231.xsd#abvx_RepaymentsOfConvertibleLoansNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_RepaymentsOfConvertibleLoansNotes" xlink:to="lab_abvx_RepaymentsOfConvertibleLoansNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilitiesMember_91818f62-aa40-4541-8a11-c0fa393fbcd1_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilitiesMember_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilitiesMember" xlink:to="lab_ifrs-full_LeaseLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted_369414bb-945f-4d0f-86f1-31c89796f56f_verboseLabel_en-US" xlink:label="lab_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">BSA SUBSCRIPTION PRICE (in euro per share)</link:label>
    <link:label id="lab_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted_250e4598-441f-44ce-a6e0-c0d34c650a96_terseLabel_en-US" xlink:label="lab_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA PRICE (in euro per share)</link:label>
    <link:label id="lab_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Instrument Price, Other Equity Instruments Granted</link:label>
    <link:label id="lab_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Instrument Price, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted" xlink:href="abvx-20251231.xsd#abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted" xlink:to="lab_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfSignificantEventsForThePeriodReportedAndEventsAfterReportingPeriodTextBlock_56617b2d-d718-4989-ae7a-32704aea0276_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfSignificantEventsForThePeriodReportedAndEventsAfterReportingPeriodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent event</link:label>
    <link:label id="lab_abvx_DisclosureOfSignificantEventsForThePeriodReportedAndEventsAfterReportingPeriodTextBlock_label_en-US" xlink:label="lab_abvx_DisclosureOfSignificantEventsForThePeriodReportedAndEventsAfterReportingPeriodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Significant Events For The Period Reported And Events After Reporting Period [Text Block]</link:label>
    <link:label id="lab_abvx_DisclosureOfSignificantEventsForThePeriodReportedAndEventsAfterReportingPeriodTextBlock_documentation_en-US" xlink:label="lab_abvx_DisclosureOfSignificantEventsForThePeriodReportedAndEventsAfterReportingPeriodTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Significant Events For The Period Reported And Events After Reporting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfSignificantEventsForThePeriodReportedAndEventsAfterReportingPeriodTextBlock" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfSignificantEventsForThePeriodReportedAndEventsAfterReportingPeriodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfSignificantEventsForThePeriodReportedAndEventsAfterReportingPeriodTextBlock" xlink:to="lab_abvx_DisclosureOfSignificantEventsForThePeriodReportedAndEventsAfterReportingPeriodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfLeasesForLesseeTableTextBlock_ca7ef7ea-aae8-41b0-8a46-f73290a14be9_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfLeasesForLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of variation in lease liabilities</link:label>
    <link:label id="lab_abvx_DisclosureOfLeasesForLesseeTableTextBlock_label_en-US" xlink:label="lab_abvx_DisclosureOfLeasesForLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Leases For Lessee [Table Text Block]</link:label>
    <link:label id="lab_abvx_DisclosureOfLeasesForLesseeTableTextBlock_documentation_en-US" xlink:label="lab_abvx_DisclosureOfLeasesForLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Leases For Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfLeasesForLesseeTableTextBlock" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfLeasesForLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfLeasesForLesseeTableTextBlock" xlink:to="lab_abvx_DisclosureOfLeasesForLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BSA201511Member_b5a448da-bc0f-4f49-b5fd-31dc6882e6fc_terseLabel_en-US" xlink:label="lab_abvx_BSA201511Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSA-2015-11</link:label>
    <link:label id="lab_abvx_BSA201511Member_label_en-US" xlink:label="lab_abvx_BSA201511Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSA-2015-11 [Member]</link:label>
    <link:label id="lab_abvx_BSA201511Member_documentation_en-US" xlink:label="lab_abvx_BSA201511Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BSA-2015-11</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA201511Member" xlink:href="abvx-20251231.xsd#abvx_BSA201511Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BSA201511Member" xlink:to="lab_abvx_BSA201511Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities_47538bf6-f0f9-4603-b840-a331096023ea_terseLabel_en-US" xlink:label="lab_abvx_IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash changes: (gain)/loss on recognition or derecognition</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_abvx_IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Gain (Loss) On Recognition/Derecognition, Liabilities Arising From Financing Activities</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities_documentation_en-US" xlink:label="lab_abvx_IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Gain (Loss) On Recognition/Derecognition, Liabilities Arising From Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" xlink:to="lab_abvx_IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_556b7411-bcba-48d0-9b4e-d715bb89b511_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_561dff32-16d1-40f0-b25d-876b982f2a66_periodStartLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment including right-of-use assets at beginning of period</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_9655a155-f36a-478b-8417-33bb4d717f87_periodEndLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment including right-of-use assets at end of period</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment including right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtFairValue_7806a78a-59de-4e1d-a603-dbf2b62677ef_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities, at fair value</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtFairValue_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities, at fair value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValue" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesAtFairValue" xlink:to="lab_ifrs-full_FinancialLiabilitiesAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BorrowingsDeposit_019c56b4-da50-7649-af15-6bfd3d661474_terseLabel_en-US" xlink:label="lab_abvx_BorrowingsDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deposit paid, borrowing</link:label>
    <link:label id="lab_abvx_BorrowingsDeposit_label_en-US" xlink:label="lab_abvx_BorrowingsDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, Deposit</link:label>
    <link:label id="lab_abvx_BorrowingsDeposit_documentation_en-US" xlink:label="lab_abvx_BorrowingsDeposit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowings, Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsDeposit" xlink:href="abvx-20251231.xsd#abvx_BorrowingsDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BorrowingsDeposit" xlink:to="lab_abvx_BorrowingsDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_ebb13f7b-7634-43fc-8fb6-c23ba8b6f3cd_verboseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_label_en-US" xlink:label="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense from equity-settled share-based payment transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_2a5a834c-6e16-438a-8235-2ce54d5d59de_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_Kreos2TrancheBMember_a7059197-906a-4860-ab26-93589aa4c1c2_terseLabel_en-US" xlink:label="lab_abvx_Kreos2TrancheBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kreos 2, tranche B</link:label>
    <link:label id="lab_abvx_Kreos2TrancheBMember_label_en-US" xlink:label="lab_abvx_Kreos2TrancheBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kreos 2, Tranche B [Member]</link:label>
    <link:label id="lab_abvx_Kreos2TrancheBMember_documentation_en-US" xlink:label="lab_abvx_Kreos2TrancheBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kreos 2, Tranche B</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos2TrancheBMember" xlink:href="abvx-20251231.xsd#abvx_Kreos2TrancheBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_Kreos2TrancheBMember" xlink:to="lab_abvx_Kreos2TrancheBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_a38a2dbe-7a17-4dbf-92ba-a486243932c8_terseLabel_en-US" xlink:label="lab_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation techniques used in fair value measurement [domain]</link:label>
    <link:label id="lab_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_label_en-US" xlink:label="lab_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation techniques used in fair value measurement [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain" xlink:to="lab_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TopOfRangeMember_e881301d-c5f5-4894-b23d-d2ecb91deed0_terseLabel_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Top of range</link:label>
    <link:label id="lab_ifrs-full_TopOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Top of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TopOfRangeMember" xlink:to="lab_ifrs-full_TopOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsAndGoodwillAbstract_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="lab_ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_04e9afc6-ae82-47de-bb13-11cb930cb6fe_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:to="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfImpactOfTheUkraineRussiaHostilitiesOnTheGroupPolicyTextBlock_c5c3615f-828b-4111-8291-56e3f12ae07b_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfImpactOfTheUkraineRussiaHostilitiesOnTheGroupPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of the Ukraine/Russia Hostilities on the Group</link:label>
    <link:label id="lab_abvx_DisclosureOfImpactOfTheUkraineRussiaHostilitiesOnTheGroupPolicyTextBlock_label_en-US" xlink:label="lab_abvx_DisclosureOfImpactOfTheUkraineRussiaHostilitiesOnTheGroupPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Impact Of The Ukraine/Russia Hostilities On The Group [Policy Text Block]</link:label>
    <link:label id="lab_abvx_DisclosureOfImpactOfTheUkraineRussiaHostilitiesOnTheGroupPolicyTextBlock_documentation_en-US" xlink:label="lab_abvx_DisclosureOfImpactOfTheUkraineRussiaHostilitiesOnTheGroupPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Impact Of The Ukraine/Russia Hostilities On The Group</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfImpactOfTheUkraineRussiaHostilitiesOnTheGroupPolicyTextBlock" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfImpactOfTheUkraineRussiaHostilitiesOnTheGroupPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfImpactOfTheUkraineRussiaHostilitiesOnTheGroupPolicyTextBlock" xlink:to="lab_abvx_DisclosureOfImpactOfTheUkraineRussiaHostilitiesOnTheGroupPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities_564e8b34-5df6-4213-8799-943856d8d197_terseLabel_en-US" xlink:label="lab_abvx_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase / (decrease) in tax and social security liabilities</link:label>
    <link:label id="lab_abvx_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities_label_en-US" xlink:label="lab_abvx_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Increase (Decrease) In Tax And Social Security Liabilities</link:label>
    <link:label id="lab_abvx_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities_documentation_en-US" xlink:label="lab_abvx_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments For Increase (Decrease) In Tax And Social Security Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities" xlink:href="abvx-20251231.xsd#abvx_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities" xlink:to="lab_abvx_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_be1076d5-fc76-4e08-948c-52331faf5ed4_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial gains and losses on retirement benefit obligations</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_RoyaltyCertificatePercentageOfFutureSales_24c0c267-f9e8-49c7-b88e-a010b5c7cc3d_terseLabel_en-US" xlink:label="lab_abvx_RoyaltyCertificatePercentageOfFutureSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty certificate, percentage of future sales</link:label>
    <link:label id="lab_abvx_RoyaltyCertificatePercentageOfFutureSales_label_en-US" xlink:label="lab_abvx_RoyaltyCertificatePercentageOfFutureSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Certificate, Percentage Of Future Sales</link:label>
    <link:label id="lab_abvx_RoyaltyCertificatePercentageOfFutureSales_documentation_en-US" xlink:label="lab_abvx_RoyaltyCertificatePercentageOfFutureSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Certificate, Percentage Of Future Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificatePercentageOfFutureSales" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificatePercentageOfFutureSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_RoyaltyCertificatePercentageOfFutureSales" xlink:to="lab_abvx_RoyaltyCertificatePercentageOfFutureSales" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_KeyManagementPersonnelCompensationAttendanceFees_a2f0e7e0-65cc-4540-8e86-cbc616393f99_terseLabel_en-US" xlink:label="lab_abvx_KeyManagementPersonnelCompensationAttendanceFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attendance fees&#8212;board of directors</link:label>
    <link:label id="lab_abvx_KeyManagementPersonnelCompensationAttendanceFees_label_en-US" xlink:label="lab_abvx_KeyManagementPersonnelCompensationAttendanceFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key Management Personnel Compensation, Attendance Fees</link:label>
    <link:label id="lab_abvx_KeyManagementPersonnelCompensationAttendanceFees_documentation_en-US" xlink:label="lab_abvx_KeyManagementPersonnelCompensationAttendanceFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Key Management Personnel Compensation, Attendance Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KeyManagementPersonnelCompensationAttendanceFees" xlink:href="abvx-20251231.xsd#abvx_KeyManagementPersonnelCompensationAttendanceFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_KeyManagementPersonnelCompensationAttendanceFees" xlink:to="lab_abvx_KeyManagementPersonnelCompensationAttendanceFees" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingExpense_019d000d-df0b-7d8d-973a-77aa3c454afb_netLabel_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Other sales and marketing expenses</link:label>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingExpense_ed0adeeb-fadc-4d37-b3f8-4241e0e732f8_terseLabel_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other research and development expenses</link:label>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingExpense_79e62c1a-1184-48c5-b6ec-1090e3035bbd_verboseLabel_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other general and administrative expenses</link:label>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingExpense_label_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Miscellaneous other operating expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:to="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NetProceedsFromNonConvertibleLoansNotes_31cbecd9-ffa9-43ff-8afa-0e7aaa13d7e2_terseLabel_en-US" xlink:label="lab_abvx_NetProceedsFromNonConvertibleLoansNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from non-convertible bond loans</link:label>
    <link:label id="lab_abvx_NetProceedsFromNonConvertibleLoansNotes_label_en-US" xlink:label="lab_abvx_NetProceedsFromNonConvertibleLoansNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Proceeds From Non-Convertible Loans Notes</link:label>
    <link:label id="lab_abvx_NetProceedsFromNonConvertibleLoansNotes_documentation_en-US" xlink:label="lab_abvx_NetProceedsFromNonConvertibleLoansNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Proceeds From Non-Convertible Loans Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NetProceedsFromNonConvertibleLoansNotes" xlink:href="abvx-20251231.xsd#abvx_NetProceedsFromNonConvertibleLoansNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NetProceedsFromNonConvertibleLoansNotes" xlink:to="lab_abvx_NetProceedsFromNonConvertibleLoansNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_FinancialAgreementAxis_d49088b5-f12f-439d-8c5e-3970d83824e9_terseLabel_en-US" xlink:label="lab_abvx_FinancialAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Agreement [Axis]</link:label>
    <link:label id="lab_abvx_FinancialAgreementAxis_label_en-US" xlink:label="lab_abvx_FinancialAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Agreement [Axis]</link:label>
    <link:label id="lab_abvx_FinancialAgreementAxis_documentation_en-US" xlink:label="lab_abvx_FinancialAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialAgreementAxis" xlink:href="abvx-20251231.xsd#abvx_FinancialAgreementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_FinancialAgreementAxis" xlink:to="lab_abvx_FinancialAgreementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_ab839e9c-36a2-4c22-8819-7dd472fe496c_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Items that will not be reclassified to profit or loss</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income that will not be reclassified to profit or loss, net of tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfCashAndCashEquivalentsLineItems_0dfaf15a-a80f-4434-b883-5720ffa10fa6_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfCashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Cash And Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_abvx_DisclosureOfCashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_abvx_DisclosureOfCashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Cash And Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_abvx_DisclosureOfCashAndCashEquivalentsLineItems_documentation_en-US" xlink:label="lab_abvx_DisclosureOfCashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Cash And Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfCashAndCashEquivalentsLineItems" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfCashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfCashAndCashEquivalentsLineItems" xlink:to="lab_abvx_DisclosureOfCashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ConvertibleLoansNotesConversionOptionMaximumPeriodPriorToMaturityDate_131aa84a-3a8a-4c73-93b2-b233b6e23797_terseLabel_en-US" xlink:label="lab_abvx_ConvertibleLoansNotesConversionOptionMaximumPeriodPriorToMaturityDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion option, maximum period prior to maturity date</link:label>
    <link:label id="lab_abvx_ConvertibleLoansNotesConversionOptionMaximumPeriodPriorToMaturityDate_label_en-US" xlink:label="lab_abvx_ConvertibleLoansNotesConversionOptionMaximumPeriodPriorToMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Loans Notes, Conversion Option, Maximum Period Prior To Maturity Date</link:label>
    <link:label id="lab_abvx_ConvertibleLoansNotesConversionOptionMaximumPeriodPriorToMaturityDate_documentation_en-US" xlink:label="lab_abvx_ConvertibleLoansNotesConversionOptionMaximumPeriodPriorToMaturityDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Loans Notes, Conversion Option, Maximum Period Prior To Maturity Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotesConversionOptionMaximumPeriodPriorToMaturityDate" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotesConversionOptionMaximumPeriodPriorToMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ConvertibleLoansNotesConversionOptionMaximumPeriodPriorToMaturityDate" xlink:to="lab_abvx_ConvertibleLoansNotesConversionOptionMaximumPeriodPriorToMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_43cf9212-d527-4b72-a531-1388233a6dbc_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsByNameDomain_70f741b5-7c8e-4dfd-91af-14933227e205_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings by name [domain]</link:label>
    <link:label id="lab_ifrs-full_BorrowingsByNameDomain_label_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings by name [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsByNameDomain" xlink:to="lab_ifrs-full_BorrowingsByNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrencyRiskMember_bb7b5440-c541-44c9-ae39-614769ce3125_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrencyRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency risk</link:label>
    <link:label id="lab_ifrs-full_CurrencyRiskMember_label_en-US" xlink:label="lab_ifrs-full_CurrencyRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency risk [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrencyRiskMember" xlink:to="lab_ifrs-full_CurrencyRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ConditionalAdvancesMember_067e4504-9eeb-4ada-b511-9bb8e17ca6e4_terseLabel_en-US" xlink:label="lab_abvx_ConditionalAdvancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conditional advances Bpifrance</link:label>
    <link:label id="lab_abvx_ConditionalAdvancesMember_label_en-US" xlink:label="lab_abvx_ConditionalAdvancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conditional Advances [Member]</link:label>
    <link:label id="lab_abvx_ConditionalAdvancesMember_documentation_en-US" xlink:label="lab_abvx_ConditionalAdvancesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conditional Advances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConditionalAdvancesMember" xlink:href="abvx-20251231.xsd#abvx_ConditionalAdvancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ConditionalAdvancesMember" xlink:to="lab_abvx_ConditionalAdvancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_CARENAConditionalAdvanceBPIMember_1eb8f0fe-c4a1-482a-97a8-f307f4f76da8_terseLabel_en-US" xlink:label="lab_abvx_CARENAConditionalAdvanceBPIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CARENA conditional advance</link:label>
    <link:label id="lab_abvx_CARENAConditionalAdvanceBPIMember_ff50341f-d7bc-4bba-8e76-134eccb6709d_verboseLabel_en-US" xlink:label="lab_abvx_CARENAConditionalAdvanceBPIMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">CARENA &#8211; Bpifrance</link:label>
    <link:label id="lab_abvx_CARENAConditionalAdvanceBPIMember_label_en-US" xlink:label="lab_abvx_CARENAConditionalAdvanceBPIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CARENA Conditional Advance, BPI [Member]</link:label>
    <link:label id="lab_abvx_CARENAConditionalAdvanceBPIMember_documentation_en-US" xlink:label="lab_abvx_CARENAConditionalAdvanceBPIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CARENA Conditional Advance, BPI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CARENAConditionalAdvanceBPIMember" xlink:href="abvx-20251231.xsd#abvx_CARENAConditionalAdvanceBPIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_CARENAConditionalAdvanceBPIMember" xlink:to="lab_abvx_CARENAConditionalAdvanceBPIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AGA20233AGA20234AndAGA20235Member_33c2c68a-d97f-436e-a009-70525f9537f5_terseLabel_en-US" xlink:label="lab_abvx_AGA20233AGA20234AndAGA20235Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA-2023-3 , AGA-2023-4 and AGA-2023-5</link:label>
    <link:label id="lab_abvx_AGA20233AGA20234AndAGA20235Member_label_en-US" xlink:label="lab_abvx_AGA20233AGA20234AndAGA20235Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA-2023-3 , AGA-2023-4 And AGA-2023-5 [Member]</link:label>
    <link:label id="lab_abvx_AGA20233AGA20234AndAGA20235Member_documentation_en-US" xlink:label="lab_abvx_AGA20233AGA20234AndAGA20235Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA-2023-3 , AGA-2023-4 And AGA-2023-5</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20233AGA20234AndAGA20235Member" xlink:href="abvx-20251231.xsd#abvx_AGA20233AGA20234AndAGA20235Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AGA20233AGA20234AndAGA20235Member" xlink:to="lab_abvx_AGA20233AGA20234AndAGA20235Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilities_019c4314-18c4-7d3d-9f2e-43b1959e375b_verboseLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilities_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxLiabilities" xlink:to="lab_ifrs-full_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_019c5799-5262-715a-bc9d-3368be4e3feb_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis_8931d811-9a37-4e27-b549-15a7d323df86_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment including right-of-use assets [axis]</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment including right-of-use assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_019c4337-3064-7d1f-9a7b-01fae11d8195_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes paid (refund), classified as operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncome_f0e360f3-ded3-4156-92c4-358c59e2681b_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncome_322a9f16-e09f-4b0b-ad3c-215849010018_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncome" xlink:to="lab_ifrs-full_OtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesAxis_63d098e9-d1ef-42a3-ab4b-84057cf3c929_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AGA20242Member_aa7d6e9b-ed6d-47d6-9391-3509d4b26f3c_terseLabel_en-US" xlink:label="lab_abvx_AGA20242Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA-2024-2</link:label>
    <link:label id="lab_abvx_AGA20242Member_label_en-US" xlink:label="lab_abvx_AGA20242Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA-2024-2 [Member]</link:label>
    <link:label id="lab_abvx_AGA20242Member_documentation_en-US" xlink:label="lab_abvx_AGA20242Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA-2024-2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20242Member" xlink:href="abvx-20251231.xsd#abvx_AGA20242Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AGA20242Member" xlink:to="lab_abvx_AGA20242Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding_b3c20222-0b79-4ac2-a37a-162cc61114e5_terseLabel_en-US" xlink:label="lab_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of other equity instruments</link:label>
    <link:label id="lab_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding_label_en-US" xlink:label="lab_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Fair Value, Other Equity Instruments Outstanding</link:label>
    <link:label id="lab_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding_documentation_en-US" xlink:label="lab_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate Fair Value, Other Equity Instruments Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding" xlink:href="abvx-20251231.xsd#abvx_AggregateFairValueOtherEquityInstrumentsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding" xlink:to="lab_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfCashAndCashEquivalentsTable_c8ed062d-d788-45ae-9d86-a79394ac6409_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Cash And Cash Equivalents [Table]</link:label>
    <link:label id="lab_abvx_DisclosureOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_abvx_DisclosureOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Cash And Cash Equivalents [Table]</link:label>
    <link:label id="lab_abvx_DisclosureOfCashAndCashEquivalentsTable_documentation_en-US" xlink:label="lab_abvx_DisclosureOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Cash And Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfCashAndCashEquivalentsTable" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfCashAndCashEquivalentsTable" xlink:to="lab_abvx_DisclosureOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherShorttermProvisions_cf0d8d31-d4a3-423c-a901-dfc133a3a2f9_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherShorttermProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions</link:label>
    <link:label id="lab_ifrs-full_OtherShorttermProvisions_label_en-US" xlink:label="lab_ifrs-full_OtherShorttermProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherShorttermProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherShorttermProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherShorttermProvisions" xlink:to="lab_ifrs-full_OtherShorttermProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_KreosOCABSAMember_019c4328-2d72-7e33-b5cb-ede83a6aaa59_terseLabel_en-US" xlink:label="lab_abvx_KreosOCABSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kreos OCABSA</link:label>
    <link:label id="lab_abvx_KreosOCABSAMember_label_en-US" xlink:label="lab_abvx_KreosOCABSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kreos OCABSA [Member]</link:label>
    <link:label id="lab_abvx_KreosOCABSAMember_documentation_en-US" xlink:label="lab_abvx_KreosOCABSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kreos OCABSA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosOCABSAMember" xlink:href="abvx-20251231.xsd#abvx_KreosOCABSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_KreosOCABSAMember" xlink:to="lab_abvx_KreosOCABSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_OtherNonCurrentMiscellaneousFinancialAssets_425828a4-8411-430e-acb8-a154502d8f8b_terseLabel_en-US" xlink:label="lab_abvx_OtherNonCurrentMiscellaneousFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_abvx_OtherNonCurrentMiscellaneousFinancialAssets_label_en-US" xlink:label="lab_abvx_OtherNonCurrentMiscellaneousFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Non-Current Miscellaneous Financial Assets</link:label>
    <link:label id="lab_abvx_OtherNonCurrentMiscellaneousFinancialAssets_documentation_en-US" xlink:label="lab_abvx_OtherNonCurrentMiscellaneousFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Non-Current Miscellaneous Financial Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherNonCurrentMiscellaneousFinancialAssets" xlink:href="abvx-20251231.xsd#abvx_OtherNonCurrentMiscellaneousFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_OtherNonCurrentMiscellaneousFinancialAssets" xlink:to="lab_abvx_OtherNonCurrentMiscellaneousFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_829741a4-d1ef-4ee6-9b13-2445cefbd020_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_3ea55cb1-34ab-496a-b4d7-7e3813a0bada_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangibles and depreciation of property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for depreciation and amortisation expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseOnBorrowings_019c56ba-78b5-7f2c-9981-6de3a602af0b_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense on borrowings</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnBorrowings_583e9e53-58e6-4e1c-955a-83bfc6f5d617_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnBorrowings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest on conditional advances and PGE</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnBorrowings_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense on borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnBorrowings" xlink:to="lab_ifrs-full_InterestExpenseOnBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_8ae2ec76-5aa1-48e3-97d7-905721b9744d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems_894c50a0-3964-4ed4-abca-1bdf03b13b46_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Receivables And Other Assets [Line Items]</link:label>
    <link:label id="lab_abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems_label_en-US" xlink:label="lab_abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Receivables And Other Assets [Line Items]</link:label>
    <link:label id="lab_abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems_documentation_en-US" xlink:label="lab_abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Receivables And Other Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems" xlink:to="lab_abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AbivaxLLCMember_cbaa3a4c-4d4a-4320-afa6-3c8a71f8bc95_terseLabel_en-US" xlink:label="lab_abvx_AbivaxLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Abivax LLC</link:label>
    <link:label id="lab_abvx_AbivaxLLCMember_label_en-US" xlink:label="lab_abvx_AbivaxLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Abivax LLC [Member]</link:label>
    <link:label id="lab_abvx_AbivaxLLCMember_documentation_en-US" xlink:label="lab_abvx_AbivaxLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Abivax LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AbivaxLLCMember" xlink:href="abvx-20251231.xsd#abvx_AbivaxLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AbivaxLLCMember" xlink:to="lab_abvx_AbivaxLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfLeaseLiabilitiesLineItems_fa98dfc3-836e-4972-a70f-f704de941726_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfLeaseLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Lease Liabilities [Line Items]</link:label>
    <link:label id="lab_abvx_DisclosureOfLeaseLiabilitiesLineItems_label_en-US" xlink:label="lab_abvx_DisclosureOfLeaseLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Lease Liabilities [Line Items]</link:label>
    <link:label id="lab_abvx_DisclosureOfLeaseLiabilitiesLineItems_documentation_en-US" xlink:label="lab_abvx_DisclosureOfLeaseLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Lease Liabilities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfLeaseLiabilitiesLineItems" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfLeaseLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfLeaseLiabilitiesLineItems" xlink:to="lab_abvx_DisclosureOfLeaseLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_0cfece15-63c4-45bd-9e5a-ef688ba50f89_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of carrying amounts and fair value of financial liabilities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssueOfEquity_a58a3ab4-fd46-49bb-8be3-cac75a0861fb_terseLabel_en-US" xlink:label="lab_ifrs-full_IssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital increase from issuance of ordinary shares</link:label>
    <link:label id="lab_ifrs-full_IssueOfEquity_label_en-US" xlink:label="lab_ifrs-full_IssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue of equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssueOfEquity" xlink:to="lab_ifrs-full_IssueOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities_ec137276-f723-48c8-8f4a-fa0eb7445bc3_terseLabel_en-US" xlink:label="lab_abvx_IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds</link:label>
    <link:label id="lab_abvx_IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_abvx_IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Through Proceeds, Liabilities Arising From Financing Activities</link:label>
    <link:label id="lab_abvx_IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities_documentation_en-US" xlink:label="lab_abvx_IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase Through Proceeds, Liabilities Arising From Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" xlink:href="abvx-20251231.xsd#abvx_IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" xlink:to="lab_abvx_IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BankBorrowingsUndiscountedCashFlows_a3ecfe13-db68-4950-887c-4957528159c8_terseLabel_en-US" xlink:label="lab_ifrs-full_BankBorrowingsUndiscountedCashFlows" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, undiscounted cash flows</link:label>
    <link:label id="lab_ifrs-full_BankBorrowingsUndiscountedCashFlows_label_en-US" xlink:label="lab_ifrs-full_BankBorrowingsUndiscountedCashFlows" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bank borrowings, undiscounted cash flows</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BankBorrowingsUndiscountedCashFlows"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows" xlink:to="lab_ifrs-full_BankBorrowingsUndiscountedCashFlows" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember_d3211b4a-927b-4eca-af54-d976de267551_terseLabel_en-US" xlink:label="lab_abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret financing, tranche B and C</link:label>
    <link:label id="lab_abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember_label_en-US" xlink:label="lab_abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret Financing, Senior Secured Non-Convertible Loans [Member]</link:label>
    <link:label id="lab_abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember_documentation_en-US" xlink:label="lab_abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret Financing, Senior Secured Non-Convertible Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember" xlink:to="lab_abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_TrancheFourMember_bd54bf3f-8b81-46e4-b25b-4dbfd17e89a1_terseLabel_en-US" xlink:label="lab_abvx_TrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche 4</link:label>
    <link:label id="lab_abvx_TrancheFourMember_label_en-US" xlink:label="lab_abvx_TrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche Four [Member]</link:label>
    <link:label id="lab_abvx_TrancheFourMember_documentation_en-US" xlink:label="lab_abvx_TrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheFourMember" xlink:href="abvx-20251231.xsd#abvx_TrancheFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_TrancheFourMember" xlink:to="lab_abvx_TrancheFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_RepaymentOfExcessConditionalAdvancesClaimed_45c18fa6-b8e2-4504-a8be-ac81aad2efbc_terseLabel_en-US" xlink:label="lab_abvx_RepaymentOfExcessConditionalAdvancesClaimed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Excess conditional advances claimed</link:label>
    <link:label id="lab_abvx_RepaymentOfExcessConditionalAdvancesClaimed_label_en-US" xlink:label="lab_abvx_RepaymentOfExcessConditionalAdvancesClaimed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayment Of Excess Conditional Advances Claimed</link:label>
    <link:label id="lab_abvx_RepaymentOfExcessConditionalAdvancesClaimed_documentation_en-US" xlink:label="lab_abvx_RepaymentOfExcessConditionalAdvancesClaimed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Repayment Of Excess Conditional Advances Claimed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepaymentOfExcessConditionalAdvancesClaimed" xlink:href="abvx-20251231.xsd#abvx_RepaymentOfExcessConditionalAdvancesClaimed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_RepaymentOfExcessConditionalAdvancesClaimed" xlink:to="lab_abvx_RepaymentOfExcessConditionalAdvancesClaimed" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AdjustmentsForNetGainOnSaleOfTreasuryShares_01fe83d2-5415-4019-aee9-76c0f0e2f5c9_terseLabel_en-US" xlink:label="lab_abvx_AdjustmentsForNetGainOnSaleOfTreasuryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net gain on sale of treasury shares</link:label>
    <link:label id="lab_abvx_AdjustmentsForNetGainOnSaleOfTreasuryShares_label_en-US" xlink:label="lab_abvx_AdjustmentsForNetGainOnSaleOfTreasuryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Net Gain On Sale Of Treasury Shares</link:label>
    <link:label id="lab_abvx_AdjustmentsForNetGainOnSaleOfTreasuryShares_documentation_en-US" xlink:label="lab_abvx_AdjustmentsForNetGainOnSaleOfTreasuryShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments For Net Gain On Sale Of Treasury Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AdjustmentsForNetGainOnSaleOfTreasuryShares" xlink:href="abvx-20251231.xsd#abvx_AdjustmentsForNetGainOnSaleOfTreasuryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AdjustmentsForNetGainOnSaleOfTreasuryShares" xlink:to="lab_abvx_AdjustmentsForNetGainOnSaleOfTreasuryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_RiskFreeInterestRateMeasurementInputExpiryMember_fec6cd15-3070-4048-a00c-7b3dd059a84e_terseLabel_en-US" xlink:label="lab_abvx_RiskFreeInterestRateMeasurementInputExpiryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free rate, expiry</link:label>
    <link:label id="lab_abvx_RiskFreeInterestRateMeasurementInputExpiryMember_label_en-US" xlink:label="lab_abvx_RiskFreeInterestRateMeasurementInputExpiryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk-Free Interest Rate, Measurement Input, Expiry [Member]</link:label>
    <link:label id="lab_abvx_RiskFreeInterestRateMeasurementInputExpiryMember_documentation_en-US" xlink:label="lab_abvx_RiskFreeInterestRateMeasurementInputExpiryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Risk-Free Interest Rate, Measurement Input, Expiry</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RiskFreeInterestRateMeasurementInputExpiryMember" xlink:href="abvx-20251231.xsd#abvx_RiskFreeInterestRateMeasurementInputExpiryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_RiskFreeInterestRateMeasurementInputExpiryMember" xlink:to="lab_abvx_RiskFreeInterestRateMeasurementInputExpiryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_A130.0MillionCrossOverFinancingFebruary2023Member_0412b587-4675-4f60-b5a3-dca8f20f277d_terseLabel_en-US" xlink:label="lab_abvx_A130.0MillionCrossOverFinancingFebruary2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">&#8364;130.0&#160;million cross-over financing, february 2023</link:label>
    <link:label id="lab_abvx_A130.0MillionCrossOverFinancingFebruary2023Member_label_en-US" xlink:label="lab_abvx_A130.0MillionCrossOverFinancingFebruary2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">&#8364;130.0&#160;Million Cross-Over Financing, February 2023 [Member]</link:label>
    <link:label id="lab_abvx_A130.0MillionCrossOverFinancingFebruary2023Member_documentation_en-US" xlink:label="lab_abvx_A130.0MillionCrossOverFinancingFebruary2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">&#8364;130.0&#160;Million Cross-Over Financing, February 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_A130.0MillionCrossOverFinancingFebruary2023Member" xlink:href="abvx-20251231.xsd#abvx_A130.0MillionCrossOverFinancingFebruary2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_A130.0MillionCrossOverFinancingFebruary2023Member" xlink:to="lab_abvx_A130.0MillionCrossOverFinancingFebruary2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ExpectedProceedsFromShareIssuanceShelfRegistration_1d43bd0c-59b2-48f7-a82a-47f60b0b42ef_terseLabel_en-US" xlink:label="lab_abvx_ExpectedProceedsFromShareIssuanceShelfRegistration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected proceeds from share issuance, shelf registration</link:label>
    <link:label id="lab_abvx_ExpectedProceedsFromShareIssuanceShelfRegistration_label_en-US" xlink:label="lab_abvx_ExpectedProceedsFromShareIssuanceShelfRegistration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Proceeds From Share Issuance, Shelf Registration</link:label>
    <link:label id="lab_abvx_ExpectedProceedsFromShareIssuanceShelfRegistration_documentation_en-US" xlink:label="lab_abvx_ExpectedProceedsFromShareIssuanceShelfRegistration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected Proceeds From Share Issuance, Shelf Registration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpectedProceedsFromShareIssuanceShelfRegistration" xlink:href="abvx-20251231.xsd#abvx_ExpectedProceedsFromShareIssuanceShelfRegistration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ExpectedProceedsFromShareIssuanceShelfRegistration" xlink:to="lab_abvx_ExpectedProceedsFromShareIssuanceShelfRegistration" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_3fb7df5a-014d-43ca-b592-a456d01b727e_terseLabel_en-US" xlink:label="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attribution of expenses by nature to their function [domain]</link:label>
    <link:label id="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_label_en-US" xlink:label="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Attribution of expenses by nature to their function [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:to="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_IncreaseInLeaseLiabilities_772fbf6f-4d8e-4c1d-9105-4a6adf0295e5_terseLabel_en-US" xlink:label="lab_abvx_IncreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase</link:label>
    <link:label id="lab_abvx_IncreaseInLeaseLiabilities_label_en-US" xlink:label="lab_abvx_IncreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase In Lease Liabilities</link:label>
    <link:label id="lab_abvx_IncreaseInLeaseLiabilities_documentation_en-US" xlink:label="lab_abvx_IncreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase In Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseInLeaseLiabilities" xlink:href="abvx-20251231.xsd#abvx_IncreaseInLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_IncreaseInLeaseLiabilities" xlink:to="lab_abvx_IncreaseInLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccountingProfit_6cc63424-022b-4d85-8867-7c4ab9599cc9_terseLabel_en-US" xlink:label="lab_ifrs-full_AccountingProfit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss before tax</link:label>
    <link:label id="lab_ifrs-full_AccountingProfit_label_en-US" xlink:label="lab_ifrs-full_AccountingProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccountingProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccountingProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccountingProfit" xlink:to="lab_ifrs-full_AccountingProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets_019bf9d2-b4d6-7e55-9242-3557429f4ed5_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Increase</link:label>
    <link:label id="lab_ifrs-full_DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, property, plant and equipment including right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:to="lab_ifrs-full_DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferences_5b7cf8ab-d993-4f81-8a34-0afff657049b_negatedTerseLabel_en-US" xlink:label="lab_abvx_TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferences" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-recognition of deferred tax assets related to tax losses and temporary differences</link:label>
    <link:label id="lab_abvx_TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferences_label_en-US" xlink:label="lab_abvx_TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferences" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Effect Of Non-Recognition Of Deferred Tax Assets Related To Tax Losses And Temporary Differences</link:label>
    <link:label id="lab_abvx_TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferences_documentation_en-US" xlink:label="lab_abvx_TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferences" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Effect Of Non-Recognition Of Deferred Tax Assets Related To Tax Losses And Temporary Differences</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferences" xlink:href="abvx-20251231.xsd#abvx_TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferences"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferences" xlink:to="lab_abvx_TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferences" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain_f159a4ff-3cc3-4ddf-9032-baff268d192d_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment including right-of-use assets [domain]</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment including right-of-use assets [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_b3ff1b9f-095c-4fcf-a82c-5afe71bdfdf2_terseLabel_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiaries [domain]</link:label>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_label_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiaries [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="lab_ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_019c434f-4789-7904-9e4a-f5d004e4d173_terseLabel_en-US" xlink:label="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of borrowings, classified as financing activities</link:label>
    <link:label id="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of borrowings, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_TrancheFiveMember_c481b170-0076-4e8d-86eb-e829cc6026d2_terseLabel_en-US" xlink:label="lab_abvx_TrancheFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche 5</link:label>
    <link:label id="lab_abvx_TrancheFiveMember_label_en-US" xlink:label="lab_abvx_TrancheFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche Five [Member]</link:label>
    <link:label id="lab_abvx_TrancheFiveMember_documentation_en-US" xlink:label="lab_abvx_TrancheFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheFiveMember" xlink:href="abvx-20251231.xsd#abvx_TrancheFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_TrancheFiveMember" xlink:to="lab_abvx_TrancheFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsByNameAxis_f93524ee-89dc-416c-92a3-fca583d18a09_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings by name [axis]</link:label>
    <link:label id="lab_ifrs-full_BorrowingsByNameAxis_label_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings by name [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsByNameAxis" xlink:to="lab_ifrs-full_BorrowingsByNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants_1dcf4a9d-2f9a-4d3f-8896-6e6dce63b124_terseLabel_en-US" xlink:label="lab_abvx_ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital increases</link:label>
    <link:label id="lab_abvx_ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants_label_en-US" xlink:label="lab_abvx_ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Issuing Shares Other Than Through Exercise Of Warrants</link:label>
    <link:label id="lab_abvx_ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants_documentation_en-US" xlink:label="lab_abvx_ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Issuing Shares Other Than Through Exercise Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants" xlink:href="abvx-20251231.xsd#abvx_ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants" xlink:to="lab_abvx_ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember_d1c0b8aa-3a83-4390-8537-6bce6ba0526a_terseLabel_en-US" xlink:label="lab_abvx_ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exclusive licensing contract with the Scripps Research Institute, University of Chicago and Brigham Young University</link:label>
    <link:label id="lab_abvx_ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember_label_en-US" xlink:label="lab_abvx_ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exclusive Licensing Contract With The Scripps Research Institute, University Of Chicago And Brigham Young University [Member]</link:label>
    <link:label id="lab_abvx_ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember_documentation_en-US" xlink:label="lab_abvx_ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exclusive Licensing Contract With The Scripps Research Institute, University Of Chicago And Brigham Young University</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember" xlink:href="abvx-20251231.xsd#abvx_ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember" xlink:to="lab_abvx_ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_7a87ec39-1824-4668-8b4b-9f6d69af9bf2_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payables and other current liabilities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of trade and other payables [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_InterestRateCollarRange_1220ca67-af75-4063-97a6-7b6308047ed3_terseLabel_en-US" xlink:label="lab_abvx_InterestRateCollarRange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate collar range</link:label>
    <link:label id="lab_abvx_InterestRateCollarRange_label_en-US" xlink:label="lab_abvx_InterestRateCollarRange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Collar Range</link:label>
    <link:label id="lab_abvx_InterestRateCollarRange_documentation_en-US" xlink:label="lab_abvx_InterestRateCollarRange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Rate Collar Range</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_InterestRateCollarRange" xlink:href="abvx-20251231.xsd#abvx_InterestRateCollarRange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_InterestRateCollarRange" xlink:to="lab_abvx_InterestRateCollarRange" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_TrancheTwoMember_e5d9cf61-ea27-40a5-9c32-6cd0ba05f577_terseLabel_en-US" xlink:label="lab_abvx_TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche 2</link:label>
    <link:label id="lab_abvx_TrancheTwoMember_label_en-US" xlink:label="lab_abvx_TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche Two [Member]</link:label>
    <link:label id="lab_abvx_TrancheTwoMember_documentation_en-US" xlink:label="lab_abvx_TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheTwoMember" xlink:href="abvx-20251231.xsd#abvx_TrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_TrancheTwoMember" xlink:to="lab_abvx_TrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AGA20247Member_348224ea-ec88-4a11-a28e-f261c5716ed2_terseLabel_en-US" xlink:label="lab_abvx_AGA20247Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA-2024-7</link:label>
    <link:label id="lab_abvx_AGA20247Member_label_en-US" xlink:label="lab_abvx_AGA20247Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA-2024-7 [Member]</link:label>
    <link:label id="lab_abvx_AGA20247Member_documentation_en-US" xlink:label="lab_abvx_AGA20247Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA-2024-7</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20247Member" xlink:href="abvx-20251231.xsd#abvx_AGA20247Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AGA20247Member" xlink:to="lab_abvx_AGA20247Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfExpensesByNatureExplanatory_0eef1844-7cc4-42f4-9700-3b87476f4d58_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of expenses by nature</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfExpensesByNatureExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of expenses by nature [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:to="lab_ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory_9c30c6a0-e439-479d-adc3-490ed812a225_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conditional advances and PGE</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for borrowings [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfTaxAndEmployeeRelatedPayablesExplanatoryTableTextBlock_fdd178ec-cade-423f-9313-5b1bff7ca290_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfTaxAndEmployeeRelatedPayablesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of tax and employee-related payables</link:label>
    <link:label id="lab_abvx_DisclosureOfTaxAndEmployeeRelatedPayablesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_abvx_DisclosureOfTaxAndEmployeeRelatedPayablesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Tax And Employee-Related Payables Explanatory [Table Text Block]</link:label>
    <link:label id="lab_abvx_DisclosureOfTaxAndEmployeeRelatedPayablesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_abvx_DisclosureOfTaxAndEmployeeRelatedPayablesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Tax And Employee-Related Payables Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfTaxAndEmployeeRelatedPayablesExplanatoryTableTextBlock" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfTaxAndEmployeeRelatedPayablesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfTaxAndEmployeeRelatedPayablesExplanatoryTableTextBlock" xlink:to="lab_abvx_DisclosureOfTaxAndEmployeeRelatedPayablesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_be4aca95-cad3-4e75-85c5-3658043bc527_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NET LOSS FOR THE YEAR</link:label>
    <link:label id="lab_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_label_en-US" xlink:label="lab_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings, profit (loss) for reporting period [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember" xlink:to="lab_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_a3b65676-f488-4a2c-bb43-3bf089a20c87_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_5d131cb4-9298-4411-b5ed-56106ed7219e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of depreciation period of property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ExerciseOfDerivativeInstruments_60831577-ffa6-4c73-a67e-0a636b81ec7e_negatedTerseLabel_en-US" xlink:label="lab_abvx_ExerciseOfDerivativeInstruments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercises</link:label>
    <link:label id="lab_abvx_ExerciseOfDerivativeInstruments_label_en-US" xlink:label="lab_abvx_ExerciseOfDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Of Derivative Instruments</link:label>
    <link:label id="lab_abvx_ExerciseOfDerivativeInstruments_documentation_en-US" xlink:label="lab_abvx_ExerciseOfDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Of Derivative Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExerciseOfDerivativeInstruments" xlink:href="abvx-20251231.xsd#abvx_ExerciseOfDerivativeInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ExerciseOfDerivativeInstruments" xlink:to="lab_abvx_ExerciseOfDerivativeInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LicencesMember_f36f2a64-4e25-4690-93c0-a519b442d8b2_terseLabel_en-US" xlink:label="lab_ifrs-full_LicencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LICENSES</link:label>
    <link:label id="lab_ifrs-full_LicencesMember_label_en-US" xlink:label="lab_ifrs-full_LicencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licences [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LicencesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LicencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LicencesMember" xlink:to="lab_ifrs-full_LicencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsInterestRate_cf9c5d22-cb13-43e6-bf65-8b90b9b7b90d_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, interest rate</link:label>
    <link:label id="lab_ifrs-full_BorrowingsInterestRate_label_en-US" xlink:label="lab_ifrs-full_BorrowingsInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, interest rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsInterestRate" xlink:to="lab_ifrs-full_BorrowingsInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_ed752d7d-8dc5-4232-946e-59f86c68970e_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash flows provided by (used in) investing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_FinalRedemptionScenarioProbabilityMeasurementInputMember_348eba4c-ea56-4a98-8645-3f3b29357929_terseLabel_en-US" xlink:label="lab_abvx_FinalRedemptionScenarioProbabilityMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Final redemption scenario probability</link:label>
    <link:label id="lab_abvx_FinalRedemptionScenarioProbabilityMeasurementInputMember_label_en-US" xlink:label="lab_abvx_FinalRedemptionScenarioProbabilityMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Final Redemption Scenario Probability, Measurement Input [Member]</link:label>
    <link:label id="lab_abvx_FinalRedemptionScenarioProbabilityMeasurementInputMember_documentation_en-US" xlink:label="lab_abvx_FinalRedemptionScenarioProbabilityMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Final Redemption Scenario Probability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinalRedemptionScenarioProbabilityMeasurementInputMember" xlink:href="abvx-20251231.xsd#abvx_FinalRedemptionScenarioProbabilityMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_FinalRedemptionScenarioProbabilityMeasurementInputMember" xlink:to="lab_abvx_FinalRedemptionScenarioProbabilityMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems_194ae4bc-856f-43d3-b629-973888ec5f75_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EmployeeBenefitsExpense_e552ec5b-680f-41be-af08-4bfc03955fc9_terseLabel_en-US" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Personnel costs</link:label>
    <link:label id="lab_ifrs-full_EmployeeBenefitsExpense_label_en-US" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee benefits expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense" xlink:to="lab_ifrs-full_EmployeeBenefitsExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_Kreos1ClaretBondLoansMember_df043c57-4e0f-499f-acbc-b1e6b5cb92ee_terseLabel_en-US" xlink:label="lab_abvx_Kreos1ClaretBondLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kreos &amp; Claret bond loans</link:label>
    <link:label id="lab_abvx_Kreos1ClaretBondLoansMember_label_en-US" xlink:label="lab_abvx_Kreos1ClaretBondLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kreos 1 &amp; Claret Bond Loans [Member]</link:label>
    <link:label id="lab_abvx_Kreos1ClaretBondLoansMember_documentation_en-US" xlink:label="lab_abvx_Kreos1ClaretBondLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kreos 1 &amp; Claret Bond Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1ClaretBondLoansMember" xlink:href="abvx-20251231.xsd#abvx_Kreos1ClaretBondLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_Kreos1ClaretBondLoansMember" xlink:to="lab_abvx_Kreos1ClaretBondLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BalancesWithBanksInExcessOfLegallyInsuredLimit_1aa35fe5-a68c-46db-9193-bf8b21b5049d_terseLabel_en-US" xlink:label="lab_abvx_BalancesWithBanksInExcessOfLegallyInsuredLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balances with banks in excess of legally insured limit</link:label>
    <link:label id="lab_abvx_BalancesWithBanksInExcessOfLegallyInsuredLimit_label_en-US" xlink:label="lab_abvx_BalancesWithBanksInExcessOfLegallyInsuredLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balances With Banks In Excess Of Legally Insured Limit</link:label>
    <link:label id="lab_abvx_BalancesWithBanksInExcessOfLegallyInsuredLimit_documentation_en-US" xlink:label="lab_abvx_BalancesWithBanksInExcessOfLegallyInsuredLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Balances With Banks In Excess Of Legally Insured Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BalancesWithBanksInExcessOfLegallyInsuredLimit" xlink:href="abvx-20251231.xsd#abvx_BalancesWithBanksInExcessOfLegallyInsuredLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BalancesWithBanksInExcessOfLegallyInsuredLimit" xlink:to="lab_abvx_BalancesWithBanksInExcessOfLegallyInsuredLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_019bf9c1-b3be-7e41-899f-839b985a77e8_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Increase</link:label>
    <link:label id="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortisation, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_RepurchaseOfDerivativeInstruments_e22a6115-e00e-4ec9-ba2c-96e89ba67eae_terseLabel_en-US" xlink:label="lab_abvx_RepurchaseOfDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchases</link:label>
    <link:label id="lab_abvx_RepurchaseOfDerivativeInstruments_91168e68-43e6-48a5-a5aa-634029429d70_negatedLabel_en-US" xlink:label="lab_abvx_RepurchaseOfDerivativeInstruments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchases</link:label>
    <link:label id="lab_abvx_RepurchaseOfDerivativeInstruments_label_en-US" xlink:label="lab_abvx_RepurchaseOfDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repurchase Of Derivative Instruments</link:label>
    <link:label id="lab_abvx_RepurchaseOfDerivativeInstruments_documentation_en-US" xlink:label="lab_abvx_RepurchaseOfDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Repurchase Of Derivative Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepurchaseOfDerivativeInstruments" xlink:href="abvx-20251231.xsd#abvx_RepurchaseOfDerivativeInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_RepurchaseOfDerivativeInstruments" xlink:to="lab_abvx_RepurchaseOfDerivativeInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_EbolaConditionalAdvanceBPIFranceMember_b252c710-c308-425f-a347-2158f8205dd0_terseLabel_en-US" xlink:label="lab_abvx_EbolaConditionalAdvanceBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ebola conditional advance, BPI France</link:label>
    <link:label id="lab_abvx_EbolaConditionalAdvanceBPIFranceMember_label_en-US" xlink:label="lab_abvx_EbolaConditionalAdvanceBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ebola Conditional Advance, BPI France [Member]</link:label>
    <link:label id="lab_abvx_EbolaConditionalAdvanceBPIFranceMember_documentation_en-US" xlink:label="lab_abvx_EbolaConditionalAdvanceBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ebola Conditional Advance, BPI France</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EbolaConditionalAdvanceBPIFranceMember" xlink:href="abvx-20251231.xsd#abvx_EbolaConditionalAdvanceBPIFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_EbolaConditionalAdvanceBPIFranceMember" xlink:to="lab_abvx_EbolaConditionalAdvanceBPIFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingOtherEquityInstruments_019beae9-f264-764c-904c-b7f0e8faffbd_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuing other equity instruments</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingOtherEquityInstruments_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuing other equity instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssuingOtherEquityInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:to="lab_ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_9d5efaa8-1df8-4126-afe6-32ef209ce36f_terseLabel_en-US" xlink:label="lab_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PATENTS</link:label>
    <link:label id="lab_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_label_en-US" xlink:label="lab_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Copyrights, patents and other industrial property rights, service and operating rights [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember" xlink:to="lab_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BCE20161Member_c1ede980-b9f5-4380-a033-676406fd8ddb_terseLabel_en-US" xlink:label="lab_abvx_BCE20161Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BCE-2016-1</link:label>
    <link:label id="lab_abvx_BCE20161Member_label_en-US" xlink:label="lab_abvx_BCE20161Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BCE-2016-1 [Member]</link:label>
    <link:label id="lab_abvx_BCE20161Member_documentation_en-US" xlink:label="lab_abvx_BCE20161Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BCE-2016-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BCE20161Member" xlink:href="abvx-20251231.xsd#abvx_BCE20161Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BCE20161Member" xlink:to="lab_abvx_BCE20161Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_1cda4514-542f-4bcb-bdc9-1d94aea847bb_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Changes in working capital requirements</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in working capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:to="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssets_64ec3735-8b9d-4a58-9cdc-fad1d8b2f097_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssets_label_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="lab_ifrs-full_CurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_Borrowings1Member_09023576-df7c-4ba6-bc6f-92ce715c52ab_terseLabel_en-US" xlink:label="lab_abvx_Borrowings1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_abvx_Borrowings1Member_label_en-US" xlink:label="lab_abvx_Borrowings1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings1 [Member]</link:label>
    <link:label id="lab_abvx_Borrowings1Member_documentation_en-US" xlink:label="lab_abvx_Borrowings1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowings by name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Borrowings1Member" xlink:href="abvx-20251231.xsd#abvx_Borrowings1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_Borrowings1Member" xlink:to="lab_abvx_Borrowings1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentagePerMonth_a780fa5e-c242-425b-abdd-183af7c85fe8_terseLabel_en-US" xlink:label="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentagePerMonth" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting percentage per month</link:label>
    <link:label id="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentagePerMonth_label_en-US" xlink:label="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentagePerMonth" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Vesting Percentage Per Month</link:label>
    <link:label id="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentagePerMonth_documentation_en-US" xlink:label="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentagePerMonth" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Vesting Percentage Per Month</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentagePerMonth" xlink:href="abvx-20251231.xsd#abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentagePerMonth"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentagePerMonth" xlink:to="lab_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentagePerMonth" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember_33d03428-0cb3-4d85-9358-cca06db735c8_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RETAINED EARNINGS</link:label>
    <link:label id="lab_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember_label_en-US" xlink:label="lab_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings, excluding profit (loss) for reporting period [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember" xlink:to="lab_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_RNPVIRConditionalAdvanceBPIMember_da6803a8-897c-4423-8b38-46823474b89a_terseLabel_en-US" xlink:label="lab_abvx_RNPVIRConditionalAdvanceBPIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RNP-VIR conditional advance</link:label>
    <link:label id="lab_abvx_RNPVIRConditionalAdvanceBPIMember_c81fa341-d404-4039-a3b4-3d138fb699e5_verboseLabel_en-US" xlink:label="lab_abvx_RNPVIRConditionalAdvanceBPIMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">RNP VIR &#8211; Bpifrance</link:label>
    <link:label id="lab_abvx_RNPVIRConditionalAdvanceBPIMember_label_en-US" xlink:label="lab_abvx_RNPVIRConditionalAdvanceBPIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RNP-VIR Conditional Advance, BPI [Member]</link:label>
    <link:label id="lab_abvx_RNPVIRConditionalAdvanceBPIMember_documentation_en-US" xlink:label="lab_abvx_RNPVIRConditionalAdvanceBPIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">RNP-VIR Conditional Advance, BPI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RNPVIRConditionalAdvanceBPIMember" xlink:href="abvx-20251231.xsd#abvx_RNPVIRConditionalAdvanceBPIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_RNPVIRConditionalAdvanceBPIMember" xlink:to="lab_abvx_RNPVIRConditionalAdvanceBPIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_201a151a-2cf2-4294-84a7-8005bd8ba607_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash flows provided by (used in) operating activities before change in working capital requirements</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operations before changes in working capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_IncreaseDecreaseFromFreeSharesIssued_286bd104-7ebf-493f-9099-7081f9652a6c_terseLabel_en-US" xlink:label="lab_abvx_IncreaseDecreaseFromFreeSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issue of free shares</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseFromFreeSharesIssued_label_en-US" xlink:label="lab_abvx_IncreaseDecreaseFromFreeSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) From Free Shares Issued</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseFromFreeSharesIssued_documentation_en-US" xlink:label="lab_abvx_IncreaseDecreaseFromFreeSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) From Free Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseFromFreeSharesIssued" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseFromFreeSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_IncreaseDecreaseFromFreeSharesIssued" xlink:to="lab_abvx_IncreaseDecreaseFromFreeSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_CurrentResearchTaxCreditReceivables_067788e7-94a4-4689-b9fb-07338fdb4e7c_terseLabel_en-US" xlink:label="lab_abvx_CurrentResearchTaxCreditReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research tax credit ("CIR")</link:label>
    <link:label id="lab_abvx_CurrentResearchTaxCreditReceivables_label_en-US" xlink:label="lab_abvx_CurrentResearchTaxCreditReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Research Tax Credit Receivables</link:label>
    <link:label id="lab_abvx_CurrentResearchTaxCreditReceivables_documentation_en-US" xlink:label="lab_abvx_CurrentResearchTaxCreditReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current Research Tax Credit Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentResearchTaxCreditReceivables" xlink:href="abvx-20251231.xsd#abvx_CurrentResearchTaxCreditReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_CurrentResearchTaxCreditReceivables" xlink:to="lab_abvx_CurrentResearchTaxCreditReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfRisksAxis_292e009d-6570-4795-8737-26ba763469ab_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfRisksAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of risks [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfRisksAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfRisksAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of risks [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksAxis" xlink:to="lab_ifrs-full_TypesOfRisksAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_LeaseFacilitiesParisMember_8dd9ab0e-64f2-4cf5-80b1-a63881c526ef_terseLabel_en-US" xlink:label="lab_abvx_LeaseFacilitiesParisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease facilities, Paris</link:label>
    <link:label id="lab_abvx_LeaseFacilitiesParisMember_label_en-US" xlink:label="lab_abvx_LeaseFacilitiesParisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Facilities, Paris [Member]</link:label>
    <link:label id="lab_abvx_LeaseFacilitiesParisMember_documentation_en-US" xlink:label="lab_abvx_LeaseFacilitiesParisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Facilities, Paris</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LeaseFacilitiesParisMember" xlink:href="abvx-20251231.xsd#abvx_LeaseFacilitiesParisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_LeaseFacilitiesParisMember" xlink:to="lab_abvx_LeaseFacilitiesParisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfDetailedInformationAboutFinanceIncomeCostTableTextBlock_a75a22c3-c892-4605-baf2-baab9f2e41e0_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfDetailedInformationAboutFinanceIncomeCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of net financial income (loss)</link:label>
    <link:label id="lab_abvx_DisclosureOfDetailedInformationAboutFinanceIncomeCostTableTextBlock_label_en-US" xlink:label="lab_abvx_DisclosureOfDetailedInformationAboutFinanceIncomeCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Finance Income (Cost) [Table Text Block]</link:label>
    <link:label id="lab_abvx_DisclosureOfDetailedInformationAboutFinanceIncomeCostTableTextBlock_documentation_en-US" xlink:label="lab_abvx_DisclosureOfDetailedInformationAboutFinanceIncomeCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Finance Income (Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfDetailedInformationAboutFinanceIncomeCostTableTextBlock" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfDetailedInformationAboutFinanceIncomeCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfDetailedInformationAboutFinanceIncomeCostTableTextBlock" xlink:to="lab_abvx_DisclosureOfDetailedInformationAboutFinanceIncomeCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock_2c36dd18-eaa6-47e4-8e41-28d524ae3472_terseLabel_en-US" xlink:label="lab_abvx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Going concern</link:label>
    <link:label id="lab_abvx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock_label_en-US" xlink:label="lab_abvx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description Of Accounting Policy For Going Concern [Policy Text Block]</link:label>
    <link:label id="lab_abvx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock_documentation_en-US" xlink:label="lab_abvx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description Of Accounting Policy For Going Concern</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock" xlink:href="abvx-20251231.xsd#abvx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock" xlink:to="lab_abvx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_TaxEffectOfShareBasedPayment_2d2a5cae-e193-421c-aeb8-02daa09a3cd2_terseLabel_en-US" xlink:label="lab_abvx_TaxEffectOfShareBasedPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment</link:label>
    <link:label id="lab_abvx_TaxEffectOfShareBasedPayment_label_en-US" xlink:label="lab_abvx_TaxEffectOfShareBasedPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Effect Of Share-Based Payment</link:label>
    <link:label id="lab_abvx_TaxEffectOfShareBasedPayment_documentation_en-US" xlink:label="lab_abvx_TaxEffectOfShareBasedPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Effect Of Share-Based Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TaxEffectOfShareBasedPayment" xlink:href="abvx-20251231.xsd#abvx_TaxEffectOfShareBasedPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_TaxEffectOfShareBasedPayment" xlink:to="lab_abvx_TaxEffectOfShareBasedPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BSA20241AndBSA20242Member_a795242e-d2ae-41cf-b7e2-6e78c8264fcb_terseLabel_en-US" xlink:label="lab_abvx_BSA20241AndBSA20242Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSA-2024-1 and BSA-2024-2</link:label>
    <link:label id="lab_abvx_BSA20241AndBSA20242Member_label_en-US" xlink:label="lab_abvx_BSA20241AndBSA20242Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSA-2024-1 And BSA-2024-2 [Member]</link:label>
    <link:label id="lab_abvx_BSA20241AndBSA20242Member_documentation_en-US" xlink:label="lab_abvx_BSA20241AndBSA20242Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BSA-2024-1 And BSA-2024-2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20241AndBSA20242Member" xlink:href="abvx-20251231.xsd#abvx_BSA20241AndBSA20242Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BSA20241AndBSA20242Member" xlink:to="lab_abvx_BSA20241AndBSA20242Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AGA20246Member_2137c8d3-2df9-4512-9344-eca68c674645_terseLabel_en-US" xlink:label="lab_abvx_AGA20246Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA-2024-6</link:label>
    <link:label id="lab_abvx_AGA20246Member_label_en-US" xlink:label="lab_abvx_AGA20246Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA-2024-6 [Member]</link:label>
    <link:label id="lab_abvx_AGA20246Member_documentation_en-US" xlink:label="lab_abvx_AGA20246Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA-2024-6</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20246Member" xlink:href="abvx-20251231.xsd#abvx_AGA20246Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AGA20246Member" xlink:to="lab_abvx_AGA20246Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_c7e65284-b9b9-463f-8c53-657f81fead46_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfEmployeeWorkforceTable_ae20b1c9-17ec-4295-a0a0-8b3b37293acd_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfEmployeeWorkforceTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Employee Workforce [Table]</link:label>
    <link:label id="lab_abvx_DisclosureOfEmployeeWorkforceTable_label_en-US" xlink:label="lab_abvx_DisclosureOfEmployeeWorkforceTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Employee Workforce [Table]</link:label>
    <link:label id="lab_abvx_DisclosureOfEmployeeWorkforceTable_documentation_en-US" xlink:label="lab_abvx_DisclosureOfEmployeeWorkforceTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Employee Workforce [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfEmployeeWorkforceTable" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfEmployeeWorkforceTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfEmployeeWorkforceTable" xlink:to="lab_abvx_DisclosureOfEmployeeWorkforceTable" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_FinancialLiabilitiesUndiscountedCashFlows_b57d1974-8fd0-4296-8ae6-42e7f17dbebc_totalLabel_en-US" xlink:label="lab_abvx_FinancialLiabilitiesUndiscountedCashFlows" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities, undiscounted cash flows</link:label>
    <link:label id="lab_abvx_FinancialLiabilitiesUndiscountedCashFlows_label_en-US" xlink:label="lab_abvx_FinancialLiabilitiesUndiscountedCashFlows" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Liabilities, Undiscounted Cash Flows</link:label>
    <link:label id="lab_abvx_FinancialLiabilitiesUndiscountedCashFlows_documentation_en-US" xlink:label="lab_abvx_FinancialLiabilitiesUndiscountedCashFlows" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Liabilities, Undiscounted Cash Flows</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialLiabilitiesUndiscountedCashFlows" xlink:href="abvx-20251231.xsd#abvx_FinancialLiabilitiesUndiscountedCashFlows"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_FinancialLiabilitiesUndiscountedCashFlows" xlink:to="lab_abvx_FinancialLiabilitiesUndiscountedCashFlows" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NumberOfOtherEquityInstrumentsGrantedSubjectToNonMarketPerformanceCondition_eac9d0d8-33c0-4ac0-bfa3-6da12501d545_terseLabel_en-US" xlink:label="lab_abvx_NumberOfOtherEquityInstrumentsGrantedSubjectToNonMarketPerformanceCondition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of instruments issued subject to non-market performance condition (in shares)</link:label>
    <link:label id="lab_abvx_NumberOfOtherEquityInstrumentsGrantedSubjectToNonMarketPerformanceCondition_label_en-US" xlink:label="lab_abvx_NumberOfOtherEquityInstrumentsGrantedSubjectToNonMarketPerformanceCondition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Other Equity Instruments Granted Subject To Non-Market Performance Condition</link:label>
    <link:label id="lab_abvx_NumberOfOtherEquityInstrumentsGrantedSubjectToNonMarketPerformanceCondition_documentation_en-US" xlink:label="lab_abvx_NumberOfOtherEquityInstrumentsGrantedSubjectToNonMarketPerformanceCondition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Other Equity Instruments Granted Subject To Non-Market Performance Condition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfOtherEquityInstrumentsGrantedSubjectToNonMarketPerformanceCondition" xlink:href="abvx-20251231.xsd#abvx_NumberOfOtherEquityInstrumentsGrantedSubjectToNonMarketPerformanceCondition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NumberOfOtherEquityInstrumentsGrantedSubjectToNonMarketPerformanceCondition" xlink:to="lab_abvx_NumberOfOtherEquityInstrumentsGrantedSubjectToNonMarketPerformanceCondition" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_TrancheThreeMember_fe1358b2-5111-428a-a0f1-a43838c12400_terseLabel_en-US" xlink:label="lab_abvx_TrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche 3</link:label>
    <link:label id="lab_abvx_TrancheThreeMember_label_en-US" xlink:label="lab_abvx_TrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche Three [Member]</link:label>
    <link:label id="lab_abvx_TrancheThreeMember_documentation_en-US" xlink:label="lab_abvx_TrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheThreeMember" xlink:href="abvx-20251231.xsd#abvx_TrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_TrancheThreeMember" xlink:to="lab_abvx_TrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForFairValueGainsLosses_d6bbc82b-1035-447a-84fc-caf94b79ed15_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase/(decrease) in derivatives and liabilities measured at fair value</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForFairValueGainsLosses_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for fair value losses (gains)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForFairValueGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:to="lab_ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease_c48aa58d-a970-43cb-975b-2f62351eea1b_terseLabel_en-US" xlink:label="lab_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital increase from issuance of ordinary shares (in shares)</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease_label_en-US" xlink:label="lab_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Number Of Ordinary Shares Issued Through Capital Increase</link:label>
    <link:label id="lab_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease_documentation_en-US" xlink:label="lab_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Number Of Ordinary Shares Issued Through Capital Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease" xlink:to="lab_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted_44cde602-6523-40fc-ba68-b0c50c474ce4_terseLabel_en-US" xlink:label="lab_abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RISK&#160;FREE&#160;RATE</link:label>
    <link:label id="lab_abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk Free Interest Rate, Other Equity Instruments Granted</link:label>
    <link:label id="lab_abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Risk Free Interest Rate, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:href="abvx-20251231.xsd#abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:to="lab_abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_PaymentsForProceedsFromShareIssueRelatedCostsCredit_45408126-3235-410f-8c5e-89bf01d8bab8_negatedTerseLabel_en-US" xlink:label="lab_abvx_PaymentsForProceedsFromShareIssueRelatedCostsCredit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs related to capital increase</link:label>
    <link:label id="lab_abvx_PaymentsForProceedsFromShareIssueRelatedCostsCredit_label_en-US" xlink:label="lab_abvx_PaymentsForProceedsFromShareIssueRelatedCostsCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For (Proceeds From) Share Issue Related Costs (Credit)</link:label>
    <link:label id="lab_abvx_PaymentsForProceedsFromShareIssueRelatedCostsCredit_documentation_en-US" xlink:label="lab_abvx_PaymentsForProceedsFromShareIssueRelatedCostsCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments For (Proceeds From) Share Issue Related Costs (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PaymentsForProceedsFromShareIssueRelatedCostsCredit" xlink:href="abvx-20251231.xsd#abvx_PaymentsForProceedsFromShareIssueRelatedCostsCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_PaymentsForProceedsFromShareIssueRelatedCostsCredit" xlink:to="lab_abvx_PaymentsForProceedsFromShareIssueRelatedCostsCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_4715f7d0-a693-48f0-810d-702f85baa050_terseLabel_en-US" xlink:label="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attribution of expenses by nature to their function [axis]</link:label>
    <link:label id="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_label_en-US" xlink:label="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Attribution of expenses by nature to their function [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefundAbstract_db69af8d-caba-4d09-8ce3-928748ee7a9e_terseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes paid (refund) [abstract]</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefundAbstract_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes paid (refund) [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="lab_ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_700a5037-6577-42b5-b876-b5b31e676a0a_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS AT AMORTIZED COST</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets at amortised cost, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:to="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ParValuePerShare_37beb323-9f4c-4c49-a31a-ff208602280e_terseLabel_en-US" xlink:label="lab_ifrs-full_ParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Par value per share (in euro per share)</link:label>
    <link:label id="lab_ifrs-full_ParValuePerShare_label_en-US" xlink:label="lab_ifrs-full_ParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Par value per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ParValuePerShare" xlink:to="lab_ifrs-full_ParValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_9b6a9dad-5c91-4bde-b295-827654a90329_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_59f0c552-193a-42be-8a6f-feb4a70421e0_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities_68be8f33-8ceb-464c-a822-1e5b23828fd2_negatedTerseLabel_en-US" xlink:label="lab_abvx_DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayments</link:label>
    <link:label id="lab_abvx_DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_abvx_DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease Through Repayments, Liabilities Arising From Financing Activities</link:label>
    <link:label id="lab_abvx_DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities_documentation_en-US" xlink:label="lab_abvx_DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Decrease Through Repayments, Liabilities Arising From Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" xlink:href="abvx-20251231.xsd#abvx_DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" xlink:to="lab_abvx_DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_e0fee66b-cee8-4884-875e-f6a0dc412539_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfEquityDomain_3af5bfc6-153a-46bc-99a4-43ee25f8d929_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of equity [domain]</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfEquityDomain_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of equity [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain" xlink:to="lab_ifrs-full_ComponentsOfEquityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_RiskFreeInterestRateMeasurementInputTenderOfferMember_bdb91c8b-b257-4d01-bc77-ccf123892d17_terseLabel_en-US" xlink:label="lab_abvx_RiskFreeInterestRateMeasurementInputTenderOfferMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free rate, tender offer</link:label>
    <link:label id="lab_abvx_RiskFreeInterestRateMeasurementInputTenderOfferMember_label_en-US" xlink:label="lab_abvx_RiskFreeInterestRateMeasurementInputTenderOfferMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk-Free Interest Rate, Measurement Input, Tender Offer [Member]</link:label>
    <link:label id="lab_abvx_RiskFreeInterestRateMeasurementInputTenderOfferMember_documentation_en-US" xlink:label="lab_abvx_RiskFreeInterestRateMeasurementInputTenderOfferMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Risk-Free Interest Rate, Measurement Input, Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RiskFreeInterestRateMeasurementInputTenderOfferMember" xlink:href="abvx-20251231.xsd#abvx_RiskFreeInterestRateMeasurementInputTenderOfferMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_RiskFreeInterestRateMeasurementInputTenderOfferMember" xlink:to="lab_abvx_RiskFreeInterestRateMeasurementInputTenderOfferMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberAndAverageNumberOfEmployeesAbstract_label_en-US" xlink:label="lab_ifrs-full_NumberAndAverageNumberOfEmployeesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number and average number of employees [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberAndAverageNumberOfEmployeesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberAndAverageNumberOfEmployeesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberAndAverageNumberOfEmployeesAbstract" xlink:to="lab_ifrs-full_NumberAndAverageNumberOfEmployeesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_VolatilityForSharesMeasurementInputTenderOfferMember_fe2a1a2c-1474-4eee-9816-fefa0ec85081_terseLabel_en-US" xlink:label="lab_abvx_VolatilityForSharesMeasurementInputTenderOfferMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility, tender offer</link:label>
    <link:label id="lab_abvx_VolatilityForSharesMeasurementInputTenderOfferMember_label_en-US" xlink:label="lab_abvx_VolatilityForSharesMeasurementInputTenderOfferMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Volatility For Shares Measurement Input, Tender Offer [Member]</link:label>
    <link:label id="lab_abvx_VolatilityForSharesMeasurementInputTenderOfferMember_documentation_en-US" xlink:label="lab_abvx_VolatilityForSharesMeasurementInputTenderOfferMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Volatility For Shares Measurement Input, Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VolatilityForSharesMeasurementInputTenderOfferMember" xlink:href="abvx-20251231.xsd#abvx_VolatilityForSharesMeasurementInputTenderOfferMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_VolatilityForSharesMeasurementInputTenderOfferMember" xlink:to="lab_abvx_VolatilityForSharesMeasurementInputTenderOfferMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_383383e4-c3e8-4005-9822-f7ba6cb9d02d_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee benefits</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for employee benefits [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NumberOfConvertibleNotesConverted_019beae9-d416-74cc-952b-f5b06b679707_terseLabel_en-US" xlink:label="lab_abvx_NumberOfConvertibleNotesConverted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of convertible notes converted</link:label>
    <link:label id="lab_abvx_NumberOfConvertibleNotesConverted_label_en-US" xlink:label="lab_abvx_NumberOfConvertibleNotesConverted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Convertible Notes Converted</link:label>
    <link:label id="lab_abvx_NumberOfConvertibleNotesConverted_documentation_en-US" xlink:label="lab_abvx_NumberOfConvertibleNotesConverted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Convertible Notes Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfConvertibleNotesConverted" xlink:href="abvx-20251231.xsd#abvx_NumberOfConvertibleNotesConverted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NumberOfConvertibleNotesConverted" xlink:to="lab_abvx_NumberOfConvertibleNotesConverted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_29e35502-3db1-41a4-8fb7-0794c7af44aa_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non cash changes: additional leases</link:label>
    <link:label id="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase through new leases, liabilities arising from financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:to="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueAndOperatingIncome_4dc85175-aab2-4381-b172-1f239d19fadf_totalLabel_en-US" xlink:label="lab_ifrs-full_RevenueAndOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating income</link:label>
    <link:label id="lab_ifrs-full_RevenueAndOperatingIncome_label_en-US" xlink:label="lab_ifrs-full_RevenueAndOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue and other operating income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAndOperatingIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueAndOperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueAndOperatingIncome" xlink:to="lab_ifrs-full_RevenueAndOperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_3e9944f2-532e-473e-b80f-01c8f9594a94_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_GainsArisingFromDerecognitionOfFinancialLiabilities_eb11ffc2-46de-4d12-87fc-041b7877ee22_terseLabel_en-US" xlink:label="lab_abvx_GainsArisingFromDerecognitionOfFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on derecognition of financial liabilities</link:label>
    <link:label id="lab_abvx_GainsArisingFromDerecognitionOfFinancialLiabilities_label_en-US" xlink:label="lab_abvx_GainsArisingFromDerecognitionOfFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains Arising From Derecognition Of Financial Liabilities</link:label>
    <link:label id="lab_abvx_GainsArisingFromDerecognitionOfFinancialLiabilities_documentation_en-US" xlink:label="lab_abvx_GainsArisingFromDerecognitionOfFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gains Arising From Derecognition Of Financial Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_GainsArisingFromDerecognitionOfFinancialLiabilities" xlink:href="abvx-20251231.xsd#abvx_GainsArisingFromDerecognitionOfFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_GainsArisingFromDerecognitionOfFinancialLiabilities" xlink:to="lab_abvx_GainsArisingFromDerecognitionOfFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_Kreos12BondLoansMember_463a8a44-a652-465d-ada7-4f354a3fe5ef_terseLabel_en-US" xlink:label="lab_abvx_Kreos12BondLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kreos 1 &amp; 2 bond loans</link:label>
    <link:label id="lab_abvx_Kreos12BondLoansMember_label_en-US" xlink:label="lab_abvx_Kreos12BondLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kreos 1 &amp; 2 Bond Loans [Member]</link:label>
    <link:label id="lab_abvx_Kreos12BondLoansMember_documentation_en-US" xlink:label="lab_abvx_Kreos12BondLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kreos 1 &amp; 2 Bond Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos12BondLoansMember" xlink:href="abvx-20251231.xsd#abvx_Kreos12BondLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_Kreos12BondLoansMember" xlink:to="lab_abvx_Kreos12BondLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangeDomain_06582968-935f-414e-80ae-7427f767e91f_terseLabel_en-US" xlink:label="lab_ifrs-full_RangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [domain]</link:label>
    <link:label id="lab_ifrs-full_RangeDomain_label_en-US" xlink:label="lab_ifrs-full_RangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeDomain" xlink:to="lab_ifrs-full_RangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_1ece65b1-5ffd-41a6-9332-f668262d20e0_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination benefits</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, termination benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_TranchesDomain_c1ab4454-1269-4ab1-8bd4-ffb47266f197_terseLabel_en-US" xlink:label="lab_abvx_TranchesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranches [Domain]</link:label>
    <link:label id="lab_abvx_TranchesDomain_label_en-US" xlink:label="lab_abvx_TranchesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranches [Domain]</link:label>
    <link:label id="lab_abvx_TranchesDomain_documentation_en-US" xlink:label="lab_abvx_TranchesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranches [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesDomain" xlink:href="abvx-20251231.xsd#abvx_TranchesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_TranchesDomain" xlink:to="lab_abvx_TranchesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfFinancialGainLossTable_9ba1ffa6-c982-48e9-8aa2-dd308acbbd77_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfFinancialGainLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Financial Gain (Loss) [Table]</link:label>
    <link:label id="lab_abvx_DisclosureOfFinancialGainLossTable_label_en-US" xlink:label="lab_abvx_DisclosureOfFinancialGainLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Financial Gain (Loss) [Table]</link:label>
    <link:label id="lab_abvx_DisclosureOfFinancialGainLossTable_documentation_en-US" xlink:label="lab_abvx_DisclosureOfFinancialGainLossTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Financial Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfFinancialGainLossTable" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfFinancialGainLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfFinancialGainLossTable" xlink:to="lab_abvx_DisclosureOfFinancialGainLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueFromInterest_fb2e4406-c3d8-4bc9-9ced-25612ec6ccae_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_ifrs-full_RevenueFromInterest_label_en-US" xlink:label="lab_ifrs-full_RevenueFromInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromInterest" xlink:to="lab_ifrs-full_RevenueFromInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RecurringFairValueMeasurementMember_248851d6-5542-4383-ad17-22647985fae4_terseLabel_en-US" xlink:label="lab_ifrs-full_RecurringFairValueMeasurementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recurring fair value measurement</link:label>
    <link:label id="lab_ifrs-full_RecurringFairValueMeasurementMember_label_en-US" xlink:label="lab_ifrs-full_RecurringFairValueMeasurementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recurring fair value measurement [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RecurringFairValueMeasurementMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RecurringFairValueMeasurementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RecurringFairValueMeasurementMember" xlink:to="lab_ifrs-full_RecurringFairValueMeasurementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ExpectedMaturityOtherEquityInstrumentsGranted_75efd712-19e3-4d13-9a6a-31cc989ca322_terseLabel_en-US" xlink:label="lab_abvx_ExpectedMaturityOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EXPECTED MATURITY</link:label>
    <link:label id="lab_abvx_ExpectedMaturityOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_abvx_ExpectedMaturityOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Maturity, Other Equity Instruments Granted</link:label>
    <link:label id="lab_abvx_ExpectedMaturityOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_abvx_ExpectedMaturityOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected Maturity, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpectedMaturityOtherEquityInstrumentsGranted" xlink:href="abvx-20251231.xsd#abvx_ExpectedMaturityOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ExpectedMaturityOtherEquityInstrumentsGranted" xlink:to="lab_abvx_ExpectedMaturityOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BCEExceptBCE20142Member_7284d7d5-e59f-46d9-b630-a6003d3ad787_terseLabel_en-US" xlink:label="lab_abvx_BCEExceptBCE20142Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BCE except BCE 2014-2</link:label>
    <link:label id="lab_abvx_BCEExceptBCE20142Member_label_en-US" xlink:label="lab_abvx_BCEExceptBCE20142Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BCE Except BCE 2014-2 [Member]</link:label>
    <link:label id="lab_abvx_BCEExceptBCE20142Member_documentation_en-US" xlink:label="lab_abvx_BCEExceptBCE20142Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BCE Except BCE 2014-2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BCEExceptBCE20142Member" xlink:href="abvx-20251231.xsd#abvx_BCEExceptBCE20142Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BCEExceptBCE20142Member" xlink:to="lab_abvx_BCEExceptBCE20142Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted_b721e38b-5812-4e40-9c85-aa53caa8a5d7_terseLabel_en-US" xlink:label="lab_abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiry scenario period, other equity instruments granted</link:label>
    <link:label id="lab_abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expiry Scenario Period, Other Equity Instruments Granted</link:label>
    <link:label id="lab_abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expiry Scenario Period, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted" xlink:href="abvx-20251231.xsd#abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted" xlink:to="lab_abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentFinancialLiabilities_a4867f0b-a3cb-4d46-b06c-4ef67cacf6c3_verboseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-current financial liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentFinancialLiabilities" xlink:to="lab_ifrs-full_NoncurrentFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_c3c63814-c621-478a-b0db-add8ccb1bbd1_totalLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_label_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense from share-based payment transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_019cfb43-117c-7a8a-bcb7-3883af84c0da_verboseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercises of shares warrants</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_b4fff8a2-4fbd-478b-9d55-9e30494f30a7_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercises of the Kreos/Claret and other share warrants</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through exercise of warrants, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_FinalRedemptionFairValueOfMRIMeasurementInputMember_b633d2ca-6a65-4f87-a412-1b0672f57db7_terseLabel_en-US" xlink:label="lab_abvx_FinalRedemptionFairValueOfMRIMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value of MRI, final redemption</link:label>
    <link:label id="lab_abvx_FinalRedemptionFairValueOfMRIMeasurementInputMember_label_en-US" xlink:label="lab_abvx_FinalRedemptionFairValueOfMRIMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Final Redemption, Fair Value Of MRI , Measurement Input [Member]</link:label>
    <link:label id="lab_abvx_FinalRedemptionFairValueOfMRIMeasurementInputMember_documentation_en-US" xlink:label="lab_abvx_FinalRedemptionFairValueOfMRIMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Final Redemption, Fair Value Of MRI , Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinalRedemptionFairValueOfMRIMeasurementInputMember" xlink:href="abvx-20251231.xsd#abvx_FinalRedemptionFairValueOfMRIMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_FinalRedemptionFairValueOfMRIMeasurementInputMember" xlink:to="lab_abvx_FinalRedemptionFairValueOfMRIMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_Kreos1Member_b22b525c-40c7-44cd-87eb-f1c775b3701c_terseLabel_en-US" xlink:label="lab_abvx_Kreos1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kreos A &amp; B BSA</link:label>
    <link:label id="lab_abvx_Kreos1Member_label_en-US" xlink:label="lab_abvx_Kreos1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kreos 1 [Member]</link:label>
    <link:label id="lab_abvx_Kreos1Member_documentation_en-US" xlink:label="lab_abvx_Kreos1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kreos 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1Member" xlink:href="abvx-20251231.xsd#abvx_Kreos1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_Kreos1Member" xlink:to="lab_abvx_Kreos1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_FinancialIncomeLossAbstract_label_en-US" xlink:label="lab_abvx_FinancialIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Income (Loss) [Abstract]</link:label>
    <link:label id="lab_abvx_FinancialIncomeLossAbstract_documentation_en-US" xlink:label="lab_abvx_FinancialIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialIncomeLossAbstract" xlink:href="abvx-20251231.xsd#abvx_FinancialIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_FinancialIncomeLossAbstract" xlink:to="lab_abvx_FinancialIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DeferredFinancingCostsNettingMember_e2f9fc5f-3398-4b0e-bd64-ed435c3cfcba_terseLabel_en-US" xlink:label="lab_abvx_DeferredFinancingCostsNettingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_abvx_DeferredFinancingCostsNettingMember_label_en-US" xlink:label="lab_abvx_DeferredFinancingCostsNettingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Financing Costs, Netting [Member]</link:label>
    <link:label id="lab_abvx_DeferredFinancingCostsNettingMember_documentation_en-US" xlink:label="lab_abvx_DeferredFinancingCostsNettingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Financing Costs, Netting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DeferredFinancingCostsNettingMember" xlink:href="abvx-20251231.xsd#abvx_DeferredFinancingCostsNettingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DeferredFinancingCostsNettingMember" xlink:to="lab_abvx_DeferredFinancingCostsNettingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AddressTypeDomain_f9ba9e31-403c-4ae1-99ed-4341d753a08c_terseLabel_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:label id="lab_dei_AddressTypeDomain_label_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NotionalAmount_1fa6fc93-971b-4968-85f0-17a2f88694f9_terseLabel_en-US" xlink:label="lab_ifrs-full_NotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notional amount</link:label>
    <link:label id="lab_ifrs-full_NotionalAmount_42b383f3-a6ec-4e7e-8d5b-62abe2fe8fb4_verboseLabel_en-US" xlink:label="lab_ifrs-full_NotionalAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Original principal amount</link:label>
    <link:label id="lab_ifrs-full_NotionalAmount_label_en-US" xlink:label="lab_ifrs-full_NotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notional amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotionalAmount" xlink:to="lab_ifrs-full_NotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_NumberOfTranches_019cfb6f-e310-7d23-aae0-9ea18ce3af98_terseLabel_en-US" xlink:label="lab_abvx_NumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of tranches</link:label>
    <link:label id="lab_abvx_NumberOfTranches_label_en-US" xlink:label="lab_abvx_NumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Tranches</link:label>
    <link:label id="lab_abvx_NumberOfTranches_documentation_en-US" xlink:label="lab_abvx_NumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfTranches" xlink:href="abvx-20251231.xsd#abvx_NumberOfTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_NumberOfTranches" xlink:to="lab_abvx_NumberOfTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ResearchAndDevelopmentCostsRecognitionInitialMeasurementNumberOfCriterias_97ae26e3-3951-42c2-bb00-cb01e7eeb62f_terseLabel_en-US" xlink:label="lab_abvx_ResearchAndDevelopmentCostsRecognitionInitialMeasurementNumberOfCriterias" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development costs recognition, initial measurement, number of criterias</link:label>
    <link:label id="lab_abvx_ResearchAndDevelopmentCostsRecognitionInitialMeasurementNumberOfCriterias_label_en-US" xlink:label="lab_abvx_ResearchAndDevelopmentCostsRecognitionInitialMeasurementNumberOfCriterias" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Costs Recognition, Initial Measurement, Number Of Criterias</link:label>
    <link:label id="lab_abvx_ResearchAndDevelopmentCostsRecognitionInitialMeasurementNumberOfCriterias_documentation_en-US" xlink:label="lab_abvx_ResearchAndDevelopmentCostsRecognitionInitialMeasurementNumberOfCriterias" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Costs Recognition, Initial Measurement, Number Of Criterias</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ResearchAndDevelopmentCostsRecognitionInitialMeasurementNumberOfCriterias" xlink:href="abvx-20251231.xsd#abvx_ResearchAndDevelopmentCostsRecognitionInitialMeasurementNumberOfCriterias"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ResearchAndDevelopmentCostsRecognitionInitialMeasurementNumberOfCriterias" xlink:to="lab_abvx_ResearchAndDevelopmentCostsRecognitionInitialMeasurementNumberOfCriterias" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_AtTheMarketATMProgramMember_c05edbb4-5bb9-46ef-9b61-4953094a2f52_terseLabel_en-US" xlink:label="lab_abvx_AtTheMarketATMProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At-The-Market (ATM) Program</link:label>
    <link:label id="lab_abvx_AtTheMarketATMProgramMember_label_en-US" xlink:label="lab_abvx_AtTheMarketATMProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At-The-Market (ATM) Program [Member]</link:label>
    <link:label id="lab_abvx_AtTheMarketATMProgramMember_documentation_en-US" xlink:label="lab_abvx_AtTheMarketATMProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At-The-Market (ATM) Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AtTheMarketATMProgramMember" xlink:href="abvx-20251231.xsd#abvx_AtTheMarketATMProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_AtTheMarketATMProgramMember" xlink:to="lab_abvx_AtTheMarketATMProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BorrowingsPerformanceConditionsMinimumFinancing_7ef3a19f-f0fa-4029-b4e9-94b41be58aab_terseLabel_en-US" xlink:label="lab_abvx_BorrowingsPerformanceConditionsMinimumFinancing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance conditions, minimum financing</link:label>
    <link:label id="lab_abvx_BorrowingsPerformanceConditionsMinimumFinancing_label_en-US" xlink:label="lab_abvx_BorrowingsPerformanceConditionsMinimumFinancing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, Performance Conditions, Minimum Financing</link:label>
    <link:label id="lab_abvx_BorrowingsPerformanceConditionsMinimumFinancing_documentation_en-US" xlink:label="lab_abvx_BorrowingsPerformanceConditionsMinimumFinancing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowings, Performance Conditions, Minimum Financing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsPerformanceConditionsMinimumFinancing" xlink:href="abvx-20251231.xsd#abvx_BorrowingsPerformanceConditionsMinimumFinancing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BorrowingsPerformanceConditionsMinimumFinancing" xlink:to="lab_abvx_BorrowingsPerformanceConditionsMinimumFinancing" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_b509831e-ad69-42f0-8ecb-f3ab0cc577a0_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_OtherFinancialLiabilitiesAnnualPercentageOfProceedsFromSaleOfIntellectualPropertyRight_2eb23f8a-d344-4953-870f-421140e00f9f_terseLabel_en-US" xlink:label="lab_abvx_OtherFinancialLiabilitiesAnnualPercentageOfProceedsFromSaleOfIntellectualPropertyRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual percentage of proceeds from sale of intellectual property right</link:label>
    <link:label id="lab_abvx_OtherFinancialLiabilitiesAnnualPercentageOfProceedsFromSaleOfIntellectualPropertyRight_label_en-US" xlink:label="lab_abvx_OtherFinancialLiabilitiesAnnualPercentageOfProceedsFromSaleOfIntellectualPropertyRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Financial Liabilities, Annual Percentage Of Proceeds From Sale Of Intellectual Property Right</link:label>
    <link:label id="lab_abvx_OtherFinancialLiabilitiesAnnualPercentageOfProceedsFromSaleOfIntellectualPropertyRight_documentation_en-US" xlink:label="lab_abvx_OtherFinancialLiabilitiesAnnualPercentageOfProceedsFromSaleOfIntellectualPropertyRight" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Financial Liabilities, Annual Percentage Of Proceeds From Sale Of Intellectual Property Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialLiabilitiesAnnualPercentageOfProceedsFromSaleOfIntellectualPropertyRight" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialLiabilitiesAnnualPercentageOfProceedsFromSaleOfIntellectualPropertyRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_OtherFinancialLiabilitiesAnnualPercentageOfProceedsFromSaleOfIntellectualPropertyRight" xlink:to="lab_abvx_OtherFinancialLiabilitiesAnnualPercentageOfProceedsFromSaleOfIntellectualPropertyRight" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_89a5fec5-f261-406c-b0fa-29792efbc1ee_terseLabel_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted loss per share (in euro per share)</link:label>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:to="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaturityDomain_71d556ea-b3b6-45a5-b728-f4100ec2168e_terseLabel_en-US" xlink:label="lab_ifrs-full_MaturityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity [domain]</link:label>
    <link:label id="lab_ifrs-full_MaturityDomain_label_en-US" xlink:label="lab_ifrs-full_MaturityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityDomain" xlink:to="lab_ifrs-full_MaturityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_405b0eea-2b18-4502-a499-18b05e5355b0_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for issued capital [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_edceeef9-339b-448f-808a-f04f859b33ca_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Categories of financial liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of financial liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3aa1e09b-c6ea-4d59-9181-daadab5b17cb_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_CurrentPrepaidExpensesRelatedToCRO_d808b340-7ccf-4b64-9dd7-2924b8624f5a_terseLabel_en-US" xlink:label="lab_abvx_CurrentPrepaidExpensesRelatedToCRO" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current prepaid expenses related to CRO</link:label>
    <link:label id="lab_abvx_CurrentPrepaidExpensesRelatedToCRO_label_en-US" xlink:label="lab_abvx_CurrentPrepaidExpensesRelatedToCRO" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Prepaid Expenses Related To CRO</link:label>
    <link:label id="lab_abvx_CurrentPrepaidExpensesRelatedToCRO_documentation_en-US" xlink:label="lab_abvx_CurrentPrepaidExpensesRelatedToCRO" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current Prepaid Expenses Related To CRO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentPrepaidExpensesRelatedToCRO" xlink:href="abvx-20251231.xsd#abvx_CurrentPrepaidExpensesRelatedToCRO"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_CurrentPrepaidExpensesRelatedToCRO" xlink:to="lab_abvx_CurrentPrepaidExpensesRelatedToCRO" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_Kreos2Member_822a070c-3aee-4cd7-8c36-464c77fa8c6d_terseLabel_en-US" xlink:label="lab_abvx_Kreos2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kreos 2</link:label>
    <link:label id="lab_abvx_Kreos2Member_label_en-US" xlink:label="lab_abvx_Kreos2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kreos 2 [Member]</link:label>
    <link:label id="lab_abvx_Kreos2Member_documentation_en-US" xlink:label="lab_abvx_Kreos2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kreos 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos2Member" xlink:href="abvx-20251231.xsd#abvx_Kreos2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_Kreos2Member" xlink:to="lab_abvx_Kreos2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_BoardOfDirectorsAndChiefExecutiveOfficerMember_e9749ff8-4131-4bb3-bc36-3f1957c7244c_terseLabel_en-US" xlink:label="lab_abvx_BoardOfDirectorsAndChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Board of Directors and Chief Executive Officer</link:label>
    <link:label id="lab_abvx_BoardOfDirectorsAndChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_abvx_BoardOfDirectorsAndChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Board Of Directors And Chief Executive Officer [Member]</link:label>
    <link:label id="lab_abvx_BoardOfDirectorsAndChiefExecutiveOfficerMember_documentation_en-US" xlink:label="lab_abvx_BoardOfDirectorsAndChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Board Of Directors And Chief Executive Officer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BoardOfDirectorsAndChiefExecutiveOfficerMember" xlink:href="abvx-20251231.xsd#abvx_BoardOfDirectorsAndChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_BoardOfDirectorsAndChiefExecutiveOfficerMember" xlink:to="lab_abvx_BoardOfDirectorsAndChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_5f1e2c56-4c0b-461a-961f-51420fa4eeb0_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of liabilities arising from financing activities [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of liabilities arising from financing activities [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_RemeasurementPeriodAxis_97462efc-f48f-4f75-afd3-d0bee44ddae0_terseLabel_en-US" xlink:label="lab_abvx_RemeasurementPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remeasurement Period [Axis]</link:label>
    <link:label id="lab_abvx_RemeasurementPeriodAxis_label_en-US" xlink:label="lab_abvx_RemeasurementPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remeasurement Period [Axis]</link:label>
    <link:label id="lab_abvx_RemeasurementPeriodAxis_documentation_en-US" xlink:label="lab_abvx_RemeasurementPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Remeasurement Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RemeasurementPeriodAxis" xlink:href="abvx-20251231.xsd#abvx_RemeasurementPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_RemeasurementPeriodAxis" xlink:to="lab_abvx_RemeasurementPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_RepaymentsOfConditionalAdvances_6fb392ec-1769-4777-bc22-dc829703739e_negatedTerseLabel_en-US" xlink:label="lab_abvx_RepaymentsOfConditionalAdvances" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayments of conditional advances</link:label>
    <link:label id="lab_abvx_RepaymentsOfConditionalAdvances_2df3fccd-f57c-4aa5-ac92-8742b5b63573_terseLabel_en-US" xlink:label="lab_abvx_RepaymentsOfConditionalAdvances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of conditional advances</link:label>
    <link:label id="lab_abvx_RepaymentsOfConditionalAdvances_label_en-US" xlink:label="lab_abvx_RepaymentsOfConditionalAdvances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments Of Conditional Advances</link:label>
    <link:label id="lab_abvx_RepaymentsOfConditionalAdvances_documentation_en-US" xlink:label="lab_abvx_RepaymentsOfConditionalAdvances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Repayments Of Conditional Advances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepaymentsOfConditionalAdvances" xlink:href="abvx-20251231.xsd#abvx_RepaymentsOfConditionalAdvances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_RepaymentsOfConditionalAdvances" xlink:to="lab_abvx_RepaymentsOfConditionalAdvances" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted_5c192dd1-2a8f-4e5e-8f30-acfbaa7619d0_terseLabel_en-US" xlink:label="lab_abvx_ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price, percentage of premium</link:label>
    <link:label id="lab_abvx_ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_abvx_ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price, Percentage Of Premium Over 15-Day VWAP, Other Equity Instruments Granted</link:label>
    <link:label id="lab_abvx_ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_abvx_ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price, Percentage Of Premium Over 15-Day VWAP, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted" xlink:href="abvx-20251231.xsd#abvx_ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted" xlink:to="lab_abvx_ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_TenderOfferFairValueOfMRIMeasurementInputMember_cb966186-c809-4a47-a819-f8b9dec51d37_terseLabel_en-US" xlink:label="lab_abvx_TenderOfferFairValueOfMRIMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value of MRI, tender offer</link:label>
    <link:label id="lab_abvx_TenderOfferFairValueOfMRIMeasurementInputMember_label_en-US" xlink:label="lab_abvx_TenderOfferFairValueOfMRIMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tender Offer, Fair Value Of MRI , Measurement Input [Member]</link:label>
    <link:label id="lab_abvx_TenderOfferFairValueOfMRIMeasurementInputMember_documentation_en-US" xlink:label="lab_abvx_TenderOfferFairValueOfMRIMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tender Offer, Fair Value Of MRI , Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TenderOfferFairValueOfMRIMeasurementInputMember" xlink:href="abvx-20251231.xsd#abvx_TenderOfferFairValueOfMRIMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_TenderOfferFairValueOfMRIMeasurementInputMember" xlink:to="lab_abvx_TenderOfferFairValueOfMRIMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareExplanatory_f762efa4-8efa-42b0-90dc-b52dbb6adac2_terseLabel_en-US" xlink:label="lab_ifrs-full_EarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of earnings per share</link:label>
    <link:label id="lab_ifrs-full_EarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareExplanatory" xlink:to="lab_ifrs-full_EarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_DisclosureOfWarrantsArrangementsLineItems_e7a7d5be-c9e8-4e62-af5b-9fb90a137f86_terseLabel_en-US" xlink:label="lab_abvx_DisclosureOfWarrantsArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Warrants Arrangements [Line Items]</link:label>
    <link:label id="lab_abvx_DisclosureOfWarrantsArrangementsLineItems_label_en-US" xlink:label="lab_abvx_DisclosureOfWarrantsArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Warrants Arrangements [Line Items]</link:label>
    <link:label id="lab_abvx_DisclosureOfWarrantsArrangementsLineItems_documentation_en-US" xlink:label="lab_abvx_DisclosureOfWarrantsArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Warrants Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfWarrantsArrangementsLineItems" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfWarrantsArrangementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsLineItems" xlink:to="lab_abvx_DisclosureOfWarrantsArrangementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_20b6d6ca-bec7-48b0-8e73-6bd7f2e59d0d_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OptionPricingModelMember_1bd75f0e-7307-42a5-bb5e-6d85dac34cd7_terseLabel_en-US" xlink:label="lab_ifrs-full_OptionPricingModelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option pricing model</link:label>
    <link:label id="lab_ifrs-full_OptionPricingModelMember_label_en-US" xlink:label="lab_ifrs-full_OptionPricingModelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option pricing model [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OptionPricingModelMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OptionPricingModelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OptionPricingModelMember" xlink:to="lab_ifrs-full_OptionPricingModelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_484f7c70-583e-4404-a9d6-83ea39124363_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan_84c00b35-82c7-42f5-af75-ec0a80ed1605_terseLabel_en-US" xlink:label="lab_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net defined benefit liability</link:label>
    <link:label id="lab_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan_label_en-US" xlink:label="lab_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net defined benefit liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan" xlink:to="lab_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_019cd7e9-4e68-739f-bfbc-bf5eba977a4d_negatedLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of intangible assets</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of intangible assets, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_abvx_ProceedsFromIssuingSharesAndConvertibleLoansNotes_695d3cdf-6b8a-4be0-991f-e7b3977e2731_terseLabel_en-US" xlink:label="lab_abvx_ProceedsFromIssuingSharesAndConvertibleLoansNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuing shares and convertible loan notes</link:label>
    <link:label id="lab_abvx_ProceedsFromIssuingSharesAndConvertibleLoansNotes_label_en-US" xlink:label="lab_abvx_ProceedsFromIssuingSharesAndConvertibleLoansNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Issuing Shares And Convertible Loans Notes</link:label>
    <link:label id="lab_abvx_ProceedsFromIssuingSharesAndConvertibleLoansNotes_documentation_en-US" xlink:label="lab_abvx_ProceedsFromIssuingSharesAndConvertibleLoansNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Issuing Shares And Convertible Loans Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ProceedsFromIssuingSharesAndConvertibleLoansNotes" xlink:href="abvx-20251231.xsd#abvx_ProceedsFromIssuingSharesAndConvertibleLoansNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abvx_ProceedsFromIssuingSharesAndConvertibleLoansNotes" xlink:to="lab_abvx_ProceedsFromIssuingSharesAndConvertibleLoansNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f86db0ac-b9e4-4cf5-a3a9-7f9f80e3fa7d_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>abvx-20251231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:3ade1e9c-8754-4bce-84b9-83231d17b989,g:c324a16d-aca9-45c2-8b50-8666bee7377b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.abivax.com/role/Coverpage" xlink:type="simple" xlink:href="abvx-20251231.xsd#Coverpage"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/Coverpage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_3cec7069-177d-42b6-9ada-bd157188fb1c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_3683f404-bf42-4fab-9fdf-9658d3fcae93" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3cec7069-177d-42b6-9ada-bd157188fb1c" xlink:to="loc_dei_EntitiesTable_3683f404-bf42-4fab-9fdf-9658d3fcae93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_9b371dcd-3173-44c8-96ae-407bfda4e9c7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityListingsExchangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_3683f404-bf42-4fab-9fdf-9658d3fcae93" xlink:to="loc_dei_EntityListingsExchangeAxis_9b371dcd-3173-44c8-96ae-407bfda4e9c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_d6773f1b-50d0-4911-886b-d40ecbca0f02" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ExchangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsExchangeAxis_9b371dcd-3173-44c8-96ae-407bfda4e9c7" xlink:to="loc_dei_ExchangeDomain_d6773f1b-50d0-4911-886b-d40ecbca0f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AmericanDepositorySharesNASDAQGlobalMarketMember_7705cdaa-90b8-4635-9a6d-85127451d266" xlink:href="abvx-20251231.xsd#abvx_AmericanDepositorySharesNASDAQGlobalMarketMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain_d6773f1b-50d0-4911-886b-d40ecbca0f02" xlink:to="loc_abvx_AmericanDepositorySharesNASDAQGlobalMarketMember_7705cdaa-90b8-4635-9a6d-85127451d266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OrdinarySharesNASDAQGlobalMarketMember_58096e37-81b7-4e7d-8a3a-a80fdf46b1ec" xlink:href="abvx-20251231.xsd#abvx_OrdinarySharesNASDAQGlobalMarketMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain_d6773f1b-50d0-4911-886b-d40ecbca0f02" xlink:to="loc_abvx_OrdinarySharesNASDAQGlobalMarketMember_58096e37-81b7-4e7d-8a3a-a80fdf46b1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_3e8c3ed0-6ee8-4dfc-ba9e-c8b054c86634" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_3683f404-bf42-4fab-9fdf-9658d3fcae93" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_3e8c3ed0-6ee8-4dfc-ba9e-c8b054c86634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_3d4c9cbc-bbd3-4033-ba6f-032913516eb3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_3e8c3ed0-6ee8-4dfc-ba9e-c8b054c86634" xlink:to="loc_dei_AddressTypeDomain_3d4c9cbc-bbd3-4033-ba6f-032913516eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember_289dbd96-b92a-4337-9685-e37de3cf7b1a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_BusinessContactMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_3d4c9cbc-bbd3-4033-ba6f-032913516eb3" xlink:to="loc_dei_BusinessContactMember_289dbd96-b92a-4337-9685-e37de3cf7b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_3683f404-bf42-4fab-9fdf-9658d3fcae93" xlink:to="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9e9f4308-a9df-4a66-acb0-ec65b88fe5e4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_DocumentType_9e9f4308-a9df-4a66-acb0-ec65b88fe5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement_951bf81b-8727-4ef0-9a45-1ea5c7a4d9a9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_DocumentRegistrationStatement_951bf81b-8727-4ef0-9a45-1ea5c7a4d9a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_42769bf8-d95e-4ae5-b044-9cf9f60ca3e5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_DocumentAnnualReport_42769bf8-d95e-4ae5-b044-9cf9f60ca3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_8e035edb-f360-430b-ab5c-0283169c52f9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_DocumentPeriodEndDate_8e035edb-f360-430b-ab5c-0283169c52f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_fc021916-1a5e-446e-aba3-c5d1fdb05ce5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_CurrentFiscalYearEndDate_fc021916-1a5e-446e-aba3-c5d1fdb05ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_a067fac4-2f93-4865-9704-c4dd7141580b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_DocumentTransitionReport_a067fac4-2f93-4865-9704-c4dd7141580b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport_94fb1c4b-89fc-47cc-b597-d0b5008c9ce1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_DocumentShellCompanyReport_94fb1c4b-89fc-47cc-b597-d0b5008c9ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_193ff3d9-ef6e-4ed7-9d8b-35e07410a58e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityFileNumber_193ff3d9-ef6e-4ed7-9d8b-35e07410a58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_4bf0fbf9-2aaf-49cc-867e-84da6c96e7d8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityRegistrantName_4bf0fbf9-2aaf-49cc-867e-84da6c96e7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b66571b1-9926-49f9-ab37-d353dc23666b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b66571b1-9926-49f9-ab37-d353dc23666b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName_3aa9dd95-0708-4b18-95b8-0dada626724d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelName"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_ContactPersonnelName_3aa9dd95-0708-4b18-95b8-0dada626724d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_1775d9c6-40e9-46a2-85d4-19f98b52c482" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityAddressAddressLine1_1775d9c6-40e9-46a2-85d4-19f98b52c482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_eec7737a-a827-4685-bd53-2fbe1bfef887" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityAddressPostalZipCode_eec7737a-a827-4685-bd53-2fbe1bfef887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_293d4492-a60e-4a0c-8081-ecdb6d4ef31d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityAddressCityOrTown_293d4492-a60e-4a0c-8081-ecdb6d4ef31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_ce4ac6f5-3f1e-421a-99d8-29ea9962f6ef" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityAddressCountry_ce4ac6f5-3f1e-421a-99d8-29ea9962f6ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_70a392c5-9d0f-41ef-9f22-cb59f9e64d85" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_CityAreaCode_70a392c5-9d0f-41ef-9f22-cb59f9e64d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_03349789-3959-4262-a8cd-eb8cf6d5b998" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_LocalPhoneNumber_03349789-3959-4262-a8cd-eb8cf6d5b998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_14b72046-ef28-4cb3-aa79-e66f9b5ef6e0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_Security12bTitle_14b72046-ef28-4cb3-aa79-e66f9b5ef6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_2d42f606-70ad-493f-87f9-85a8ca69486a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_TradingSymbol_2d42f606-70ad-493f-87f9-85a8ca69486a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_f7b9b7e1-62ac-4d40-a4de-68903994ff4d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_SecurityExchangeName_f7b9b7e1-62ac-4d40-a4de-68903994ff4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8df04137-de20-4774-8c71-a9ac1ef47c5b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_8df04137-de20-4774-8c71-a9ac1ef47c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_c9c528ae-379c-418e-b180-0a842a803974" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_c9c528ae-379c-418e-b180-0a842a803974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_df28ca70-4a7a-4592-bf32-8e0b5f9a22b4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityVoluntaryFilers_df28ca70-4a7a-4592-bf32-8e0b5f9a22b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_20ed84de-ec19-4ebb-b3d5-832b4ac0335d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityCurrentReportingStatus_20ed84de-ec19-4ebb-b3d5-832b4ac0335d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_7ad61ce1-64e0-49dc-b440-eb0c2f2d4053" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityInteractiveDataCurrent_7ad61ce1-64e0-49dc-b440-eb0c2f2d4053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_a2d496dc-c791-436d-b318-e8b9e16a7f93" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityFilerCategory_a2d496dc-c791-436d-b318-e8b9e16a7f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_88c612ec-0aa7-4674-8ae8-166139320459" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityEmergingGrowthCompany_88c612ec-0aa7-4674-8ae8-166139320459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_303b20f8-9689-4277-a36b-d70ab5a50cc1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityExTransitionPeriod_303b20f8-9689-4277-a36b-d70ab5a50cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_1de8821d-dd2a-479f-b6e4-03daf5b1ab15" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_IcfrAuditorAttestationFlag_1de8821d-dd2a-479f-b6e4-03daf5b1ab15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_76008dc1-bf36-4866-aa77-5e3b982c4bc0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_76008dc1-bf36-4866-aa77-5e3b982c4bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard_04b2dc15-df35-4df4-b87b-fefd28ab63c9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_DocumentAccountingStandard_04b2dc15-df35-4df4-b87b-fefd28ab63c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_3a4ba0d0-1ec6-439f-b462-0a0ace98522d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityShellCompany_3a4ba0d0-1ec6-439f-b462-0a0ace98522d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3d340220-a749-486d-aec9-362c05614707" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_AmendmentFlag_3d340220-a749-486d-aec9-362c05614707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_31e4af00-e5c6-4647-b79c-59ff991bbd6b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_DocumentFiscalYearFocus_31e4af00-e5c6-4647-b79c-59ff991bbd6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_e2de3586-98c9-4ef6-8a17-a152b0405207" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_e2de3586-98c9-4ef6-8a17-a152b0405207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a615e093-6886-4a48-93b5-755e6a409a14" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_EntityCentralIndexKey_a615e093-6886-4a48-93b5-755e6a409a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_NoTradingSymbolFlag_10924dd2-5460-4fb4-a2aa-5321f0a365c2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_576d111d-9ba0-4fab-bb6c-dfd7141fd6d4" xlink:to="loc_dei_NoTradingSymbolFlag_10924dd2-5460-4fb4-a2aa-5321f0a365c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/Auditorinformation" xlink:type="simple" xlink:href="abvx-20251231.xsd#Auditorinformation"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/Auditorinformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AuditorInformationAbstract_0596c5d8-46fa-48bd-add8-f0b60c6491b6" xlink:href="abvx-20251231.xsd#abvx_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_9886ceb4-903c-453d-ae51-efad49bcae2d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AuditorInformationAbstract_0596c5d8-46fa-48bd-add8-f0b60c6491b6" xlink:to="loc_dei_AuditorName_9886ceb4-903c-453d-ae51-efad49bcae2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_6f021e6a-97dd-4a61-be67-a0f0f439773d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AuditorInformationAbstract_0596c5d8-46fa-48bd-add8-f0b60c6491b6" xlink:to="loc_dei_AuditorLocation_6f021e6a-97dd-4a61-be67-a0f0f439773d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_7470d851-7191-4119-89ad-a947057de34e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AuditorInformationAbstract_0596c5d8-46fa-48bd-add8-f0b60c6491b6" xlink:to="loc_dei_AuditorFirmId_7470d851-7191-4119-89ad-a947057de34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="simple" xlink:href="abvx-20251231.xsd#CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_208ecaad-9f90-4e6b-adba-7eea5a1814dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract_632bac75-3f6c-4f29-a406-f5ffa3acfcc0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_208ecaad-9f90-4e6b-adba-7eea5a1814dc" xlink:to="loc_ifrs-full_AssetsAbstract_632bac75-3f6c-4f29-a406-f5ffa3acfcc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract_49e810ee-4c50-4408-bc5c-f2e36dfd18f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_632bac75-3f6c-4f29-a406-f5ffa3acfcc0" xlink:to="loc_ifrs-full_NoncurrentAssetsAbstract_49e810ee-4c50-4408-bc5c-f2e36dfd18f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_163b072b-2407-4ca7-9c7b-1386a9ce0489" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_49e810ee-4c50-4408-bc5c-f2e36dfd18f2" xlink:to="loc_ifrs-full_Goodwill_163b072b-2407-4ca7-9c7b-1386a9ce0489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_1c0f2f3f-c597-4807-ae9f-8f7e7c78d2f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_49e810ee-4c50-4408-bc5c-f2e36dfd18f2" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_1c0f2f3f-c597-4807-ae9f-8f7e7c78d2f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_1a5e1134-99b5-4c6e-bd75-c10d14fb7fec" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_49e810ee-4c50-4408-bc5c-f2e36dfd18f2" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_1a5e1134-99b5-4c6e-bd75-c10d14fb7fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentFinancialAssets_e52e1a43-eed6-4040-bc1b-8706ab28d762" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_49e810ee-4c50-4408-bc5c-f2e36dfd18f2" xlink:to="loc_ifrs-full_OtherNoncurrentFinancialAssets_e52e1a43-eed6-4040-bc1b-8706ab28d762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentNonfinancialAssets_75cd1b92-c84f-4f2a-9c2c-e57a58743fc6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_49e810ee-4c50-4408-bc5c-f2e36dfd18f2" xlink:to="loc_ifrs-full_OtherNoncurrentNonfinancialAssets_75cd1b92-c84f-4f2a-9c2c-e57a58743fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_0bcc176f-4e1a-4cb5-9eea-b885b20eba37" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_49e810ee-4c50-4408-bc5c-f2e36dfd18f2" xlink:to="loc_ifrs-full_NoncurrentAssets_0bcc176f-4e1a-4cb5-9eea-b885b20eba37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_4e9f993b-0931-419f-8029-67a05e353d64" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_632bac75-3f6c-4f29-a406-f5ffa3acfcc0" xlink:to="loc_ifrs-full_CurrentAssetsAbstract_4e9f993b-0931-419f-8029-67a05e353d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentFinancialAssets_9f7ac058-94f6-4efc-8a5a-68e0c4e16602" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_4e9f993b-0931-419f-8029-67a05e353d64" xlink:to="loc_ifrs-full_OtherCurrentFinancialAssets_9f7ac058-94f6-4efc-8a5a-68e0c4e16602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentReceivablesAndCurrentPrepaidExpenses_bf94d585-1084-4e91-b34a-c169aa4fa325" xlink:href="abvx-20251231.xsd#abvx_CurrentReceivablesAndCurrentPrepaidExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_4e9f993b-0931-419f-8029-67a05e353d64" xlink:to="loc_abvx_CurrentReceivablesAndCurrentPrepaidExpenses_bf94d585-1084-4e91-b34a-c169aa4fa325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_774a5420-515a-4582-a12e-6a79f04d3111" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_4e9f993b-0931-419f-8029-67a05e353d64" xlink:to="loc_ifrs-full_CashAndCashEquivalents_774a5420-515a-4582-a12e-6a79f04d3111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_32f98164-a22d-4d13-b00e-bcec696827e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_4e9f993b-0931-419f-8029-67a05e353d64" xlink:to="loc_ifrs-full_CurrentAssets_32f98164-a22d-4d13-b00e-bcec696827e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_9d6384f5-9942-4281-bcdf-3cea9cfc21b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_632bac75-3f6c-4f29-a406-f5ffa3acfcc0" xlink:to="loc_ifrs-full_Assets_9d6384f5-9942-4281-bcdf-3cea9cfc21b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract_5901676a-48dc-4ffa-97e9-70a3ea2c7c34" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_208ecaad-9f90-4e6b-adba-7eea5a1814dc" xlink:to="loc_ifrs-full_EquityAndLiabilitiesAbstract_5901676a-48dc-4ffa-97e9-70a3ea2c7c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract_baa8e3cc-4618-4a97-b1cf-7f52e9df11c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_5901676a-48dc-4ffa-97e9-70a3ea2c7c34" xlink:to="loc_ifrs-full_EquityAbstract_baa8e3cc-4618-4a97-b1cf-7f52e9df11c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_07f9c169-949d-40ca-86d3-438a370b2beb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_baa8e3cc-4618-4a97-b1cf-7f52e9df11c4" xlink:to="loc_ifrs-full_IssuedCapital_07f9c169-949d-40ca-86d3-438a370b2beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremium_9e454fba-1b63-4d65-aceb-4bc737c91011" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharePremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_baa8e3cc-4618-4a97-b1cf-7f52e9df11c4" xlink:to="loc_ifrs-full_SharePremium_9e454fba-1b63-4d65-aceb-4bc737c91011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslation_17c762b2-b24e-4b4b-a36a-7560afe57850" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_baa8e3cc-4618-4a97-b1cf-7f52e9df11c4" xlink:to="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslation_17c762b2-b24e-4b4b-a36a-7560afe57850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod_e5b491e3-64e0-4969-8a1c-b7c0f21f0707" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_baa8e3cc-4618-4a97-b1cf-7f52e9df11c4" xlink:to="loc_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod_e5b491e3-64e0-4969-8a1c-b7c0f21f0707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsProfitLossForReportingPeriod_99355beb-4556-45a4-b9aa-c2295d932ab3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarningsProfitLossForReportingPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_baa8e3cc-4618-4a97-b1cf-7f52e9df11c4" xlink:to="loc_ifrs-full_RetainedEarningsProfitLossForReportingPeriod_99355beb-4556-45a4-b9aa-c2295d932ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_5b278bf8-548f-41cc-ae5f-a0e896f00be7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_baa8e3cc-4618-4a97-b1cf-7f52e9df11c4" xlink:to="loc_ifrs-full_Equity_5b278bf8-548f-41cc-ae5f-a0e896f00be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract_998eb392-31a8-4bbe-8464-50bd0829d9be" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_5901676a-48dc-4ffa-97e9-70a3ea2c7c34" xlink:to="loc_ifrs-full_NoncurrentLiabilitiesAbstract_998eb392-31a8-4bbe-8464-50bd0829d9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits_c6e26515-0c3e-4209-8a6a-2b2f905d2a3e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentProvisionsForEmployeeBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_998eb392-31a8-4bbe-8464-50bd0829d9be" xlink:to="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits_c6e26515-0c3e-4209-8a6a-2b2f905d2a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherLongtermProvisions_541fbcf1-29be-42a3-9681-150e5ad60c33" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherLongtermProvisions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_998eb392-31a8-4bbe-8464-50bd0829d9be" xlink:to="loc_ifrs-full_OtherLongtermProvisions_541fbcf1-29be-42a3-9681-150e5ad60c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings_ff11f2a2-0e42-41fd-b409-e6fe3ce90c86" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_998eb392-31a8-4bbe-8464-50bd0829d9be" xlink:to="loc_ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings_ff11f2a2-0e42-41fd-b409-e6fe3ce90c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NonCurrentConvertibleLoansNotes_ee581d73-bb53-4be3-8629-65e8d8562a83" xlink:href="abvx-20251231.xsd#abvx_NonCurrentConvertibleLoansNotes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_998eb392-31a8-4bbe-8464-50bd0829d9be" xlink:to="loc_abvx_NonCurrentConvertibleLoansNotes_ee581d73-bb53-4be3-8629-65e8d8562a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_5ebf3280-6963-4f77-8008-6a2a63cf3135" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_998eb392-31a8-4bbe-8464-50bd0829d9be" xlink:to="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_5ebf3280-6963-4f77-8008-6a2a63cf3135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NonCurrentRoyaltyCertificates_196f1ef2-9ed3-4a8d-acf9-01b2c10f8490" xlink:href="abvx-20251231.xsd#abvx_NonCurrentRoyaltyCertificates"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_998eb392-31a8-4bbe-8464-50bd0829d9be" xlink:to="loc_abvx_NonCurrentRoyaltyCertificates_196f1ef2-9ed3-4a8d-acf9-01b2c10f8490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentFinancialLiabilities_7160e603-6dd6-40ae-8046-d5b7bb7f2166" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_998eb392-31a8-4bbe-8464-50bd0829d9be" xlink:to="loc_ifrs-full_OtherNoncurrentFinancialLiabilities_7160e603-6dd6-40ae-8046-d5b7bb7f2166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets_019c4313-0784-7466-9c6d-88cff6e57bf7" xlink:href="abvx-20251231.xsd#abvx_DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_998eb392-31a8-4bbe-8464-50bd0829d9be" xlink:to="loc_abvx_DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets_019c4313-0784-7466-9c6d-88cff6e57bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_fd1946f1-1498-4f3a-a679-75e3493f3c24" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_998eb392-31a8-4bbe-8464-50bd0829d9be" xlink:to="loc_ifrs-full_NoncurrentLiabilities_fd1946f1-1498-4f3a-a679-75e3493f3c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract_97e2486c-1c3e-4a73-a167-c2d904f4c569" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_5901676a-48dc-4ffa-97e9-70a3ea2c7c34" xlink:to="loc_ifrs-full_CurrentLiabilitiesAbstract_97e2486c-1c3e-4a73-a167-c2d904f4c569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings_d3dbca60-2539-41d3-9eac-5861be77f59b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_97e2486c-1c3e-4a73-a167-c2d904f4c569" xlink:to="loc_ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings_d3dbca60-2539-41d3-9eac-5861be77f59b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentPortionOfNonCurrentConvertibleLoansNotes_2d260141-502a-4850-9883-04d2f378e54b" xlink:href="abvx-20251231.xsd#abvx_CurrentPortionOfNonCurrentConvertibleLoansNotes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_97e2486c-1c3e-4a73-a167-c2d904f4c569" xlink:to="loc_abvx_CurrentPortionOfNonCurrentConvertibleLoansNotes_2d260141-502a-4850-9883-04d2f378e54b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_8189dd8d-7143-4ff1-8648-90f920e3a728" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_97e2486c-1c3e-4a73-a167-c2d904f4c569" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_8189dd8d-7143-4ff1-8648-90f920e3a728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentFinancialLiabilities_53d0550f-d332-4d1e-b45e-92a77789681f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentFinancialLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_97e2486c-1c3e-4a73-a167-c2d904f4c569" xlink:to="loc_ifrs-full_OtherCurrentFinancialLiabilities_53d0550f-d332-4d1e-b45e-92a77789681f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherShorttermProvisions_d0fc5e5f-ead8-4d08-bcc0-0a26f6caf582" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherShorttermProvisions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_97e2486c-1c3e-4a73-a167-c2d904f4c569" xlink:to="loc_ifrs-full_OtherShorttermProvisions_d0fc5e5f-ead8-4d08-bcc0-0a26f6caf582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_9032fefb-538e-411c-8ebb-587cba58eb09" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_97e2486c-1c3e-4a73-a167-c2d904f4c569" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_9032fefb-538e-411c-8ebb-587cba58eb09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentTaxAndEmployeeBenefitLiabilities_aa41744c-4393-43e5-9470-bf40630edc00" xlink:href="abvx-20251231.xsd#abvx_CurrentTaxAndEmployeeBenefitLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_97e2486c-1c3e-4a73-a167-c2d904f4c569" xlink:to="loc_abvx_CurrentTaxAndEmployeeBenefitLiabilities_aa41744c-4393-43e5-9470-bf40630edc00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities_cb547cf1-fd7a-4791-844b-5c696fdd8587" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_97e2486c-1c3e-4a73-a167-c2d904f4c569" xlink:to="loc_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities_cb547cf1-fd7a-4791-844b-5c696fdd8587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_d5b17baa-a6e5-4b61-b7df-21f9b44dd8d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_97e2486c-1c3e-4a73-a167-c2d904f4c569" xlink:to="loc_ifrs-full_CurrentLiabilities_d5b17baa-a6e5-4b61-b7df-21f9b44dd8d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_1eab5e28-c397-4a59-8b80-fed477cf55ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_5901676a-48dc-4ffa-97e9-70a3ea2c7c34" xlink:to="loc_ifrs-full_EquityAndLiabilities_1eab5e28-c397-4a59-8b80-fed477cf55ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS" xlink:type="simple" xlink:href="abvx-20251231.xsd#CONSOLIDATEDSTATEMENTSOFINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeStatementAbstract_5b1cc6c5-e0a8-4aba-a8b2-60d294ff159b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIncome_3f305207-41f8-43ea-af89-73e5bd17880f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_5b1cc6c5-e0a8-4aba-a8b2-60d294ff159b" xlink:to="loc_ifrs-full_OtherIncome_3f305207-41f8-43ea-af89-73e5bd17880f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAndOperatingIncome_a4e1702e-e723-4f7e-9b16-fbe397fda484" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueAndOperatingIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_5b1cc6c5-e0a8-4aba-a8b2-60d294ff159b" xlink:to="loc_ifrs-full_RevenueAndOperatingIncome_a4e1702e-e723-4f7e-9b16-fbe397fda484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SalesAndMarketingExpense_c2d5a60e-7b45-4aa8-b637-f226c251593b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_5b1cc6c5-e0a8-4aba-a8b2-60d294ff159b" xlink:to="loc_ifrs-full_SalesAndMarketingExpense_c2d5a60e-7b45-4aa8-b637-f226c251593b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_a655a01e-8f55-434d-bd37-a3a2f0ea075f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_5b1cc6c5-e0a8-4aba-a8b2-60d294ff159b" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_a655a01e-8f55-434d-bd37-a3a2f0ea075f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_855f7da3-7daf-402b-b509-7ff308231d5a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_5b1cc6c5-e0a8-4aba-a8b2-60d294ff159b" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_855f7da3-7daf-402b-b509-7ff308231d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_317cdc02-753e-4e54-b1fc-6e13346954a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OperatingExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_5b1cc6c5-e0a8-4aba-a8b2-60d294ff159b" xlink:to="loc_ifrs-full_OperatingExpense_317cdc02-753e-4e54-b1fc-6e13346954a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_f1b163d9-6039-4619-b799-c6da426973bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_5b1cc6c5-e0a8-4aba-a8b2-60d294ff159b" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_f1b163d9-6039-4619-b799-c6da426973bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_b6323772-bbe2-47c2-b057-fbdbb34e4a82" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_5b1cc6c5-e0a8-4aba-a8b2-60d294ff159b" xlink:to="loc_ifrs-full_FinanceCosts_b6323772-bbe2-47c2-b057-fbdbb34e4a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_5626f287-aeea-4e9b-819c-93798e32818b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_5b1cc6c5-e0a8-4aba-a8b2-60d294ff159b" xlink:to="loc_ifrs-full_FinanceIncome_5626f287-aeea-4e9b-819c-93798e32818b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_bac73eb6-3464-424e-b847-96c3750792c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_5b1cc6c5-e0a8-4aba-a8b2-60d294ff159b" xlink:to="loc_ifrs-full_FinanceIncomeCost_bac73eb6-3464-424e-b847-96c3750792c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_77d9adb8-a2d8-4d11-9ecf-4c2455b7c937" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_5b1cc6c5-e0a8-4aba-a8b2-60d294ff159b" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_77d9adb8-a2d8-4d11-9ecf-4c2455b7c937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_fd0c257a-097c-4986-b017-19b3213bd8f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_5b1cc6c5-e0a8-4aba-a8b2-60d294ff159b" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_fd0c257a-097c-4986-b017-19b3213bd8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_094c1880-42f3-4464-8d63-c7de1b5f455f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_5b1cc6c5-e0a8-4aba-a8b2-60d294ff159b" xlink:to="loc_ifrs-full_ProfitLoss_094c1880-42f3-4464-8d63-c7de1b5f455f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_72c5f0ad-7017-4934-84a7-caa36d9ce695" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_5b1cc6c5-e0a8-4aba-a8b2-60d294ff159b" xlink:to="loc_ifrs-full_EarningsPerShareAbstract_72c5f0ad-7017-4934-84a7-caa36d9ce695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_042e557c-73ca-4ab5-a135-bf1e5bdb9741" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_72c5f0ad-7017-4934-84a7-caa36d9ce695" xlink:to="loc_ifrs-full_WeightedAverageShares_042e557c-73ca-4ab5-a135-bf1e5bdb9741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_84c7b809-adbd-4082-ae13-299461294cd0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_72c5f0ad-7017-4934-84a7-caa36d9ce695" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_84c7b809-adbd-4082-ae13-299461294cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_0228382d-864f-4a5b-8529-6599e80f1358" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_72c5f0ad-7017-4934-84a7-caa36d9ce695" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_0228382d-864f-4a5b-8529-6599e80f1358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_e5527854-2872-499d-86e7-fe14a63bcb69" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_72c5f0ad-7017-4934-84a7-caa36d9ce695" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_e5527854-2872-499d-86e7-fe14a63bcb69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="abvx-20251231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_822d774a-0a2f-42cd-a062-a59828933177" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_5092c555-be34-4f0e-8c07-a9a55833d26e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_822d774a-0a2f-42cd-a062-a59828933177" xlink:to="loc_ifrs-full_ProfitLoss_5092c555-be34-4f0e-8c07-a9a55833d26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_12e2da24-0d94-4d23-975b-89b604416c35" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_822d774a-0a2f-42cd-a062-a59828933177" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_12e2da24-0d94-4d23-975b-89b604416c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_fcf20ad7-8edc-4650-9a56-7b3a97343d74" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_822d774a-0a2f-42cd-a062-a59828933177" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_fcf20ad7-8edc-4650-9a56-7b3a97343d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_58500c01-3eee-4b09-b3b1-a40b49f04cab" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_822d774a-0a2f-42cd-a062-a59828933177" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_58500c01-3eee-4b09-b3b1-a40b49f04cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_beb3e1f8-9f67-4964-9f7c-1d41704ccafa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_822d774a-0a2f-42cd-a062-a59828933177" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_beb3e1f8-9f67-4964-9f7c-1d41704ccafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_446425ae-c97c-42cd-b80f-9d9ed753647e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_822d774a-0a2f-42cd-a062-a59828933177" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_446425ae-c97c-42cd-b80f-9d9ed753647e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_bdda8da4-3305-4657-80a0-320d06d7872a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_822d774a-0a2f-42cd-a062-a59828933177" xlink:to="loc_ifrs-full_ComprehensiveIncome_bdda8da4-3305-4657-80a0-320d06d7872a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="abvx-20251231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_a552c7a1-7a9e-4607-8692-b64fa82a3992" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_d00a493c-cb99-445c-837a-1e3427d39b07" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_a552c7a1-7a9e-4607-8692-b64fa82a3992" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_d00a493c-cb99-445c-837a-1e3427d39b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_e3ea0d07-2c87-4e1a-a8e6-0481a8872c8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_d00a493c-cb99-445c-837a-1e3427d39b07" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_e3ea0d07-2c87-4e1a-a8e6-0481a8872c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_d67da622-71de-4eef-8b04-f38112f010fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_e3ea0d07-2c87-4e1a-a8e6-0481a8872c8b" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_d67da622-71de-4eef-8b04-f38112f010fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_cac0207c-84fc-431e-9190-61d7dc6043f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_d67da622-71de-4eef-8b04-f38112f010fa" xlink:to="loc_ifrs-full_IssuedCapitalMember_cac0207c-84fc-431e-9190-61d7dc6043f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_854d164e-1809-4d61-96ce-da34d3f037ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_d67da622-71de-4eef-8b04-f38112f010fa" xlink:to="loc_ifrs-full_SharePremiumMember_854d164e-1809-4d61-96ce-da34d3f037ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_6fe9dda0-afec-4e5a-bed8-e6c07383d136" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_d67da622-71de-4eef-8b04-f38112f010fa" xlink:to="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_6fe9dda0-afec-4e5a-bed8-e6c07383d136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember_e069f920-2e19-425a-8156-69a5ac442516" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_d67da622-71de-4eef-8b04-f38112f010fa" xlink:to="loc_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember_e069f920-2e19-425a-8156-69a5ac442516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_5c185867-b2a4-4f23-9448-28e5382d9b2b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_d67da622-71de-4eef-8b04-f38112f010fa" xlink:to="loc_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_5c185867-b2a4-4f23-9448-28e5382d9b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialAgreementAxis_96504be2-b918-46f6-8638-0b4ccc2274e6" xlink:href="abvx-20251231.xsd#abvx_FinancialAgreementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_d00a493c-cb99-445c-837a-1e3427d39b07" xlink:to="loc_abvx_FinancialAgreementAxis_96504be2-b918-46f6-8638-0b4ccc2274e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialAgreementDomain_d84c840d-b88b-40cb-9dab-07cce24bc517" xlink:href="abvx-20251231.xsd#abvx_FinancialAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialAgreementAxis_96504be2-b918-46f6-8638-0b4ccc2274e6" xlink:to="loc_abvx_FinancialAgreementDomain_d84c840d-b88b-40cb-9dab-07cce24bc517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1Member_019cc2f3-bb23-77de-a9e7-25c4c1873464" xlink:href="abvx-20251231.xsd#abvx_Kreos1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialAgreementDomain_d84c840d-b88b-40cb-9dab-07cce24bc517" xlink:to="loc_abvx_Kreos1Member_019cc2f3-bb23-77de-a9e7-25c4c1873464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingMember_019c4326-72ec-77dc-8079-3eeb481efbff" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialAgreementDomain_d84c840d-b88b-40cb-9dab-07cce24bc517" xlink:to="loc_abvx_KreosClaretFinancingMember_019c4326-72ec-77dc-8079-3eeb481efbff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherEquityAgreementsMember_019cc2f3-fb30-7c47-8500-ae95d7ff5f1c" xlink:href="abvx-20251231.xsd#abvx_OtherEquityAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialAgreementDomain_d84c840d-b88b-40cb-9dab-07cce24bc517" xlink:to="loc_abvx_OtherEquityAgreementsMember_019cc2f3-fb30-7c47-8500-ae95d7ff5f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_019c4327-ff74-7493-8d9c-ce605a7ab130" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_d00a493c-cb99-445c-837a-1e3427d39b07" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_019c4327-ff74-7493-8d9c-ce605a7ab130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_019c4327-ff74-7050-bb5e-55a56c78fc5a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_019c4327-ff74-7493-8d9c-ce605a7ab130" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_019c4327-ff74-7050-bb5e-55a56c78fc5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosOCABSAMember_019c4328-2d72-7643-a937-e304693e0682" xlink:href="abvx-20251231.xsd#abvx_KreosOCABSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_019c4327-ff74-7050-bb5e-55a56c78fc5a" xlink:to="loc_abvx_KreosOCABSAMember_019c4328-2d72-7643-a937-e304693e0682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_019c4328-803a-7fe7-9447-f522113dc268" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_d00a493c-cb99-445c-837a-1e3427d39b07" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_019c4328-803a-7fe7-9447-f522113dc268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019c4328-803a-76b9-ba47-f702bd6206c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019c4328-803a-7fe7-9447-f522113dc268" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019c4328-803a-76b9-ba47-f702bd6206c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_HeightsConvertibleNotesMember_019c4328-aa77-7ebf-9397-3ebb8d0728e3" xlink:href="abvx-20251231.xsd#abvx_HeightsConvertibleNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019c4328-803a-76b9-ba47-f702bd6206c9" xlink:to="loc_abvx_HeightsConvertibleNotesMember_019c4328-aa77-7ebf-9397-3ebb8d0728e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_023018de-2d00-40f0-9b6f-3a54ea3e380e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_d00a493c-cb99-445c-837a-1e3427d39b07" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_023018de-2d00-40f0-9b6f-3a54ea3e380e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_2efdbd89-d5f1-47d6-a514-9413333ac0fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_023018de-2d00-40f0-9b6f-3a54ea3e380e" xlink:to="loc_ifrs-full_NumberOfSharesIssued_2efdbd89-d5f1-47d6-a514-9413333ac0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_1bd1f087-6147-4445-b545-efb07cdc3259" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_023018de-2d00-40f0-9b6f-3a54ea3e380e" xlink:to="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_1bd1f087-6147-4445-b545-efb07cdc3259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease_997cd59e-2f4a-46ac-9480-007e5f92971d" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_1bd1f087-6147-4445-b545-efb07cdc3259" xlink:to="loc_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease_997cd59e-2f4a-46ac-9480-007e5f92971d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants_54aebae5-07c1-47a6-b495-034af3c1479f" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_1bd1f087-6147-4445-b545-efb07cdc3259" xlink:to="loc_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants_54aebae5-07c1-47a6-b495-034af3c1479f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments_019c4327-404a-7d2e-bb32-556bb67a5e60" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_1bd1f087-6147-4445-b545-efb07cdc3259" xlink:to="loc_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments_019c4327-404a-7d2e-bb32-556bb67a5e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfFreeSharesIssued_267fb8ab-f60b-4b3a-bc7f-7ee61a6cb399" xlink:href="abvx-20251231.xsd#abvx_NumberOfFreeSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_1bd1f087-6147-4445-b545-efb07cdc3259" xlink:to="loc_abvx_NumberOfFreeSharesIssued_267fb8ab-f60b-4b3a-bc7f-7ee61a6cb399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_704f8c32-a4c9-465d-ac4d-a009634d34d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_023018de-2d00-40f0-9b6f-3a54ea3e380e" xlink:to="loc_ifrs-full_NumberOfSharesIssued_704f8c32-a4c9-465d-ac4d-a009634d34d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_d415f447-a573-4978-a1b5-9f5d1d5ad65d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_023018de-2d00-40f0-9b6f-3a54ea3e380e" xlink:to="loc_ifrs-full_Equity_d415f447-a573-4978-a1b5-9f5d1d5ad65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInEquityAbstract_840ca2eb-2780-4e09-ab18-0a451c76abf0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ChangesInEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_023018de-2d00-40f0-9b6f-3a54ea3e380e" xlink:to="loc_ifrs-full_ChangesInEquityAbstract_840ca2eb-2780-4e09-ab18-0a451c76abf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_dea1978d-1268-462c-a19d-666c37057732" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_840ca2eb-2780-4e09-ab18-0a451c76abf0" xlink:to="loc_ifrs-full_ProfitLoss_dea1978d-1268-462c-a19d-666c37057732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_5950f862-1629-4df2-8620-69b7888e57e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_840ca2eb-2780-4e09-ab18-0a451c76abf0" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_5950f862-1629-4df2-8620-69b7888e57e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_4447ceaa-79c4-4340-b6b6-df4b671b1a30" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_840ca2eb-2780-4e09-ab18-0a451c76abf0" xlink:to="loc_ifrs-full_ComprehensiveIncome_4447ceaa-79c4-4340-b6b6-df4b671b1a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings_bd0d9050-9e02-497a-8427-368a041b8812" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_840ca2eb-2780-4e09-ab18-0a451c76abf0" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings_bd0d9050-9e02-497a-8427-368a041b8812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_99dd4952-5d32-44f7-a127-a0991ad246ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_840ca2eb-2780-4e09-ab18-0a451c76abf0" xlink:to="loc_ifrs-full_IssueOfEquity_99dd4952-5d32-44f7-a127-a0991ad246ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ShareIssueRelatedCostCredit_3905a2b2-20c4-4021-913f-950c3ac3774f" xlink:href="abvx-20251231.xsd#abvx_ShareIssueRelatedCostCredit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_840ca2eb-2780-4e09-ab18-0a451c76abf0" xlink:to="loc_abvx_ShareIssueRelatedCostCredit_3905a2b2-20c4-4021-913f-950c3ac3774f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfConvertibleInstruments_019cc2ef-dc2f-7479-b54d-e834b738a92a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssueOfConvertibleInstruments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_840ca2eb-2780-4e09-ab18-0a451c76abf0" xlink:to="loc_ifrs-full_IssueOfConvertibleInstruments_019cc2ef-dc2f-7479-b54d-e834b738a92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseThroughIssuanceOfWarrantsEquity_898a034e-8b3c-4a0f-9b07-6cfaf2b9f19a" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseThroughIssuanceOfWarrantsEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_840ca2eb-2780-4e09-ab18-0a451c76abf0" xlink:to="loc_abvx_IncreaseDecreaseThroughIssuanceOfWarrantsEquity_898a034e-8b3c-4a0f-9b07-6cfaf2b9f19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_245361c1-f6e3-4a76-9218-276e2a85af41" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_840ca2eb-2780-4e09-ab18-0a451c76abf0" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_245361c1-f6e3-4a76-9218-276e2a85af41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_019c4327-849d-76ff-ad76-73d6c12b22e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_840ca2eb-2780-4e09-ab18-0a451c76abf0" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_019c4327-849d-76ff-ad76-73d6c12b22e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseFromFreeSharesIssued_3748677d-9c78-4973-9149-62fa6d0b2e00" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseFromFreeSharesIssued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_840ca2eb-2780-4e09-ab18-0a451c76abf0" xlink:to="loc_abvx_IncreaseDecreaseFromFreeSharesIssued_3748677d-9c78-4973-9149-62fa6d0b2e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_304ea5cb-1bb1-407a-aec6-ac0e31a8101f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_840ca2eb-2780-4e09-ab18-0a451c76abf0" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_304ea5cb-1bb1-407a-aec6-ac0e31a8101f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_41fce087-6514-446c-918e-739a726a6ddb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_840ca2eb-2780-4e09-ab18-0a451c76abf0" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_41fce087-6514-446c-918e-739a726a6ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_13cb43dd-3c02-4c7d-b120-06c027396258" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_023018de-2d00-40f0-9b6f-3a54ea3e380e" xlink:to="loc_ifrs-full_Equity_13cb43dd-3c02-4c7d-b120-06c027396258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="abvx-20251231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_5a5c7818-40e1-43ac-93fd-34ef4616345c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_3237a8f7-7a9d-433d-a63c-d8c32acadac7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_5a5c7818-40e1-43ac-93fd-34ef4616345c" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_3237a8f7-7a9d-433d-a63c-d8c32acadac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_3c383b8d-d7fe-46e6-b986-fc4602e98a6f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_3237a8f7-7a9d-433d-a63c-d8c32acadac7" xlink:to="loc_ifrs-full_ProfitLoss_3c383b8d-d7fe-46e6-b986-fc4602e98a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_ed4a6930-26bd-4d39-9516-788df430d49a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_3237a8f7-7a9d-433d-a63c-d8c32acadac7" xlink:to="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_ed4a6930-26bd-4d39-9516-788df430d49a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_3054a624-2b81-4b70-ab9f-d6234822fd93" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_ed4a6930-26bd-4d39-9516-788df430d49a" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_3054a624-2b81-4b70-ab9f-d6234822fd93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_36e20f6f-be8c-4a5e-ad41-81fae1c0444f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_ed4a6930-26bd-4d39-9516-788df430d49a" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_36e20f6f-be8c-4a5e-ad41-81fae1c0444f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_a57c91db-c586-45f1-af47-eab00238f8fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_ed4a6930-26bd-4d39-9516-788df430d49a" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_a57c91db-c586-45f1-af47-eab00238f8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AdjustmentsForNetGainOnSaleOfTreasuryShares_e548ec64-3209-4725-be62-91d48085ab84" xlink:href="abvx-20251231.xsd#abvx_AdjustmentsForNetGainOnSaleOfTreasuryShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_ed4a6930-26bd-4d39-9516-788df430d49a" xlink:to="loc_abvx_AdjustmentsForNetGainOnSaleOfTreasuryShares_e548ec64-3209-4725-be62-91d48085ab84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AdjustmentsForOtherFinanceCosts_6e948b9e-de44-4b01-b41a-f0f9755ea61b" xlink:href="abvx-20251231.xsd#abvx_AdjustmentsForOtherFinanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_ed4a6930-26bd-4d39-9516-788df430d49a" xlink:to="loc_abvx_AdjustmentsForOtherFinanceCosts_6e948b9e-de44-4b01-b41a-f0f9755ea61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AdjustmentsForOtherFinanceIncome_d92efe5d-0c1f-4148-95a4-c08163d1c016" xlink:href="abvx-20251231.xsd#abvx_AdjustmentsForOtherFinanceIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_ed4a6930-26bd-4d39-9516-788df430d49a" xlink:to="loc_abvx_AdjustmentsForOtherFinanceIncome_d92efe5d-0c1f-4148-95a4-c08163d1c016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances_3d3dd988-4760-45ee-8858-2301f906646c" xlink:href="abvx-20251231.xsd#abvx_AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_ed4a6930-26bd-4d39-9516-788df430d49a" xlink:to="loc_abvx_AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances_3d3dd988-4760-45ee-8858-2301f906646c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFairValueGainsLosses_55feb332-14ed-4154-a674-d8d6f75fb650" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForFairValueGainsLosses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_ed4a6930-26bd-4d39-9516-788df430d49a" xlink:to="loc_ifrs-full_AdjustmentsForFairValueGainsLosses_55feb332-14ed-4154-a674-d8d6f75fb650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AdjustmentsForForgivenessOfConditionalAdvances_5dd1a521-a0c6-4316-a1fc-89982d81301e" xlink:href="abvx-20251231.xsd#abvx_AdjustmentsForForgivenessOfConditionalAdvances"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_ed4a6930-26bd-4d39-9516-788df430d49a" xlink:to="loc_abvx_AdjustmentsForForgivenessOfConditionalAdvances_5dd1a521-a0c6-4316-a1fc-89982d81301e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForProvisions_019cc302-0be4-7ad7-93ac-57a34af9bd3d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForProvisions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_ed4a6930-26bd-4d39-9516-788df430d49a" xlink:to="loc_ifrs-full_AdjustmentsForProvisions_019cc302-0be4-7ad7-93ac-57a34af9bd3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncomeTaxExpense_019c4335-5d20-789a-95e5-f34fcf52e2dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncomeTaxExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_ed4a6930-26bd-4d39-9516-788df430d49a" xlink:to="loc_ifrs-full_AdjustmentsForIncomeTaxExpense_019c4335-5d20-789a-95e5-f34fcf52e2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAdjustmentsForNoncashItems_13137a43-f8ed-48cc-ba91-5629ca84b487" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherAdjustmentsForNoncashItems"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_ed4a6930-26bd-4d39-9516-788df430d49a" xlink:to="loc_ifrs-full_OtherAdjustmentsForNoncashItems_13137a43-f8ed-48cc-ba91-5629ca84b487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_ac109caf-f5d5-4870-ad9a-dad1b23b1da5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_ed4a6930-26bd-4d39-9516-788df430d49a" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_ac109caf-f5d5-4870-ad9a-dad1b23b1da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_a6816e92-0e0b-4d9c-899f-418e4651e39c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_ed4a6930-26bd-4d39-9516-788df430d49a" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_a6816e92-0e0b-4d9c-899f-418e4651e39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_4f0ad401-b3bc-446b-8666-e6cdef23eb42" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_ed4a6930-26bd-4d39-9516-788df430d49a" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_4f0ad401-b3bc-446b-8666-e6cdef23eb42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities_4f4f9a6a-6828-46f8-a733-ad360ae67988" xlink:href="abvx-20251231.xsd#abvx_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_ed4a6930-26bd-4d39-9516-788df430d49a" xlink:to="loc_abvx_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities_4f4f9a6a-6828-46f8-a733-ad360ae67988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities_de5ee013-1d7c-4ced-80d6-32226e26cc7d" xlink:href="abvx-20251231.xsd#abvx_AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_ed4a6930-26bd-4d39-9516-788df430d49a" xlink:to="loc_abvx_AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities_de5ee013-1d7c-4ced-80d6-32226e26cc7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_6cb0450a-22be-4c66-b271-5b287bc7d533" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_3237a8f7-7a9d-433d-a63c-d8c32acadac7" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_6cb0450a-22be-4c66-b271-5b287bc7d533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_019c4337-003b-76c2-9bb8-fbde5f3158dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_3237a8f7-7a9d-433d-a63c-d8c32acadac7" xlink:to="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_019c4337-003b-76c2-9bb8-fbde5f3158dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_432ecd88-c2f6-43e4-b749-c41caad0b61b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_3237a8f7-7a9d-433d-a63c-d8c32acadac7" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_432ecd88-c2f6-43e4-b749-c41caad0b61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_0abdf462-a489-4614-bf2e-beb435c94a2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_5a5c7818-40e1-43ac-93fd-34ef4616345c" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_0abdf462-a489-4614-bf2e-beb435c94a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_019cc35e-02e8-7d93-bd16-e844ce75b2a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_0abdf462-a489-4614-bf2e-beb435c94a2f" xlink:to="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_019cc35e-02e8-7d93-bd16-e844ce75b2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_ef2e4a4d-5119-437b-addb-b1161be22bcf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_0abdf462-a489-4614-bf2e-beb435c94a2f" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_ef2e4a4d-5119-437b-addb-b1161be22bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations_019c4339-09ae-7d48-a921-b22e7e4cedd8" xlink:href="abvx-20251231.xsd#abvx_PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_0abdf462-a489-4614-bf2e-beb435c94a2f" xlink:to="loc_abvx_PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations_019c4339-09ae-7d48-a921-b22e7e4cedd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CashPaymentsForDeposits_cd2c9a76-3397-4c33-bec3-3b4d352861a6" xlink:href="abvx-20251231.xsd#abvx_CashPaymentsForDeposits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_0abdf462-a489-4614-bf2e-beb435c94a2f" xlink:to="loc_abvx_CashPaymentsForDeposits_cd2c9a76-3397-4c33-bec3-3b4d352861a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ProceedsFromReimbursementsOfDeposits_9bbfeaa4-6cdc-415b-95f2-62483aeda5c4" xlink:href="abvx-20251231.xsd#abvx_ProceedsFromReimbursementsOfDeposits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_0abdf462-a489-4614-bf2e-beb435c94a2f" xlink:to="loc_abvx_ProceedsFromReimbursementsOfDeposits_9bbfeaa4-6cdc-415b-95f2-62483aeda5c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsInvestingActivities_4084f40d-617f-4979-b92b-db91de85c055" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestReceivedClassifiedAsInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_0abdf462-a489-4614-bf2e-beb435c94a2f" xlink:to="loc_ifrs-full_InterestReceivedClassifiedAsInvestingActivities_4084f40d-617f-4979-b92b-db91de85c055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_4916d776-47f1-4f52-9d8a-b0e9512ae33b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_0abdf462-a489-4614-bf2e-beb435c94a2f" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_4916d776-47f1-4f52-9d8a-b0e9512ae33b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_e00e718f-3eae-404e-9d5b-801fe6ea24dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_5a5c7818-40e1-43ac-93fd-34ef4616345c" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_e00e718f-3eae-404e-9d5b-801fe6ea24dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_b6ce065e-7039-45f2-93d5-2e6023ae9c12" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_e00e718f-3eae-404e-9d5b-801fe6ea24dc" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_b6ce065e-7039-45f2-93d5-2e6023ae9c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PaymentsForProceedsFromShareIssueRelatedCostsCredit_0a709729-13fb-47d2-a4a6-22410eaaa0b7" xlink:href="abvx-20251231.xsd#abvx_PaymentsForProceedsFromShareIssueRelatedCostsCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_e00e718f-3eae-404e-9d5b-801fe6ea24dc" xlink:to="loc_abvx_PaymentsForProceedsFromShareIssueRelatedCostsCredit_0a709729-13fb-47d2-a4a6-22410eaaa0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NetProceedsFromNonConvertibleLoansNotes_c55483c4-6f2d-4084-b8db-ca9e22b2e533" xlink:href="abvx-20251231.xsd#abvx_NetProceedsFromNonConvertibleLoansNotes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_e00e718f-3eae-404e-9d5b-801fe6ea24dc" xlink:to="loc_abvx_NetProceedsFromNonConvertibleLoansNotes_c55483c4-6f2d-4084-b8db-ca9e22b2e533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepaymentsOfNonConvertibleLoansNotes_019c433d-1ca9-76c8-b7b9-54b040655bd8" xlink:href="abvx-20251231.xsd#abvx_RepaymentsOfNonConvertibleLoansNotes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_e00e718f-3eae-404e-9d5b-801fe6ea24dc" xlink:to="loc_abvx_RepaymentsOfNonConvertibleLoansNotes_019c433d-1ca9-76c8-b7b9-54b040655bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NetProceedsFromConvertibleLoanNotes_0e43b643-f634-49a7-926f-e788cc54ce9c" xlink:href="abvx-20251231.xsd#abvx_NetProceedsFromConvertibleLoanNotes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_e00e718f-3eae-404e-9d5b-801fe6ea24dc" xlink:to="loc_abvx_NetProceedsFromConvertibleLoanNotes_0e43b643-f634-49a7-926f-e788cc54ce9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepaymentsOfConvertibleLoansNotes_2cec1bfa-6095-46e0-929e-ccc42335e624" xlink:href="abvx-20251231.xsd#abvx_RepaymentsOfConvertibleLoansNotes"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_e00e718f-3eae-404e-9d5b-801fe6ea24dc" xlink:to="loc_abvx_RepaymentsOfConvertibleLoansNotes_2cec1bfa-6095-46e0-929e-ccc42335e624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepaymentsOfPGE_0d7a2209-9f87-4ae3-8cc4-db1da3773b02" xlink:href="abvx-20251231.xsd#abvx_RepaymentsOfPGE"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_e00e718f-3eae-404e-9d5b-801fe6ea24dc" xlink:to="loc_abvx_RepaymentsOfPGE_0d7a2209-9f87-4ae3-8cc4-db1da3773b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepaymentsOfConditionalAdvances_ad83d022-f5fa-4a1c-88dc-fe008d43044c" xlink:href="abvx-20251231.xsd#abvx_RepaymentsOfConditionalAdvances"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_e00e718f-3eae-404e-9d5b-801fe6ea24dc" xlink:to="loc_abvx_RepaymentsOfConditionalAdvances_ad83d022-f5fa-4a1c-88dc-fe008d43044c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_84660fc7-debe-435e-acaf-0e75185f1cc9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_e00e718f-3eae-404e-9d5b-801fe6ea24dc" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_84660fc7-debe-435e-acaf-0e75185f1cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares_a59de7b6-64e6-41c0-b2f8-ea3e9d85ec5f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_e00e718f-3eae-404e-9d5b-801fe6ea24dc" xlink:to="loc_ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares_a59de7b6-64e6-41c0-b2f8-ea3e9d85ec5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsFinancingActivities_0b209a37-46c3-4a06-98fa-938530a0a7e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_e00e718f-3eae-404e-9d5b-801fe6ea24dc" xlink:to="loc_ifrs-full_InterestPaidClassifiedAsFinancingActivities_0b209a37-46c3-4a06-98fa-938530a0a7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants_019c4340-78da-7519-b5c7-c7e0c8e4d859" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_e00e718f-3eae-404e-9d5b-801fe6ea24dc" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfWarrants_019c4340-78da-7519-b5c7-c7e0c8e4d859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_7a1ba4f3-53d4-4854-84d3-9421d0d3cce5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_e00e718f-3eae-404e-9d5b-801fe6ea24dc" xlink:to="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_7a1ba4f3-53d4-4854-84d3-9421d0d3cce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_d2326d8a-5729-4099-9eae-b691fc28d62f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_e00e718f-3eae-404e-9d5b-801fe6ea24dc" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_d2326d8a-5729-4099-9eae-b691fc28d62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_14c88d01-90bc-4079-82e8-3bfaffd76b3a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_5a5c7818-40e1-43ac-93fd-34ef4616345c" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_14c88d01-90bc-4079-82e8-3bfaffd76b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RevaluationOfCashEquivalentsMeasuredAtFairValue_019c4341-3515-73fd-826f-f4a83c4b877f" xlink:href="abvx-20251231.xsd#abvx_RevaluationOfCashEquivalentsMeasuredAtFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_5a5c7818-40e1-43ac-93fd-34ef4616345c" xlink:to="loc_abvx_RevaluationOfCashEquivalentsMeasuredAtFairValue_019c4341-3515-73fd-826f-f4a83c4b877f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_aa304d0d-5b87-4a97-bdf0-6b9b41fc2e62" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_5a5c7818-40e1-43ac-93fd-34ef4616345c" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_aa304d0d-5b87-4a97-bdf0-6b9b41fc2e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_d5399aad-8b62-4ae8-a0d1-475c14345473" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_5a5c7818-40e1-43ac-93fd-34ef4616345c" xlink:to="loc_ifrs-full_CashAndCashEquivalents_d5399aad-8b62-4ae8-a0d1-475c14345473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_76880c6a-5760-4080-a4fa-ab308458fb12" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_5a5c7818-40e1-43ac-93fd-34ef4616345c" xlink:to="loc_ifrs-full_CashAndCashEquivalents_76880c6a-5760-4080-a4fa-ab308458fb12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_019cfb2f-ddce-7f74-af93-7a2e4edd1a33" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/TheGroup" xlink:type="simple" xlink:href="abvx-20251231.xsd#TheGroup"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/TheGroup" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_33ab8dfa-1658-4c61-8de4-5c390499707b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_39a22ba9-b59a-4ae7-868f-16f47a050206" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_33ab8dfa-1658-4c61-8de4-5c390499707b" xlink:to="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_39a22ba9-b59a-4ae7-868f-16f47a050206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/Basisofpreparation" xlink:type="simple" xlink:href="abvx-20251231.xsd#Basisofpreparation"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/Basisofpreparation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_ada8caa2-2990-4668-be9e-1ca7ded917f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_ef884470-e508-4c12-89db-91c987e6b3f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_ada8caa2-2990-4668-be9e-1ca7ded917f5" xlink:to="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_ef884470-e508-4c12-89db-91c987e6b3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequentevents" xlink:type="simple" xlink:href="abvx-20251231.xsd#SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequentevents"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequentevents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AccountingPrinciplesAbstract_4ecebd69-cb7f-46ac-941b-f5dfba7da629" xlink:href="abvx-20251231.xsd#abvx_AccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfSignificantEventsForThePeriodReportedAndEventsAfterReportingPeriodTextBlock_d8703fdc-99d2-4d64-b76a-45db46c28d6b" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfSignificantEventsForThePeriodReportedAndEventsAfterReportingPeriodTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_4ecebd69-cb7f-46ac-941b-f5dfba7da629" xlink:to="loc_abvx_DisclosureOfSignificantEventsForThePeriodReportedAndEventsAfterReportingPeriodTextBlock_d8703fdc-99d2-4d64-b76a-45db46c28d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/Accountingprinciples" xlink:type="simple" xlink:href="abvx-20251231.xsd#Accountingprinciples"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/Accountingprinciples" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AccountingPrinciplesAbstract_52fb0d4e-84bb-429e-9bd1-f86664b46b68" xlink:href="abvx-20251231.xsd#abvx_AccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_d881081e-b74f-4420-9915-d9fadd9a24c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_52fb0d4e-84bb-429e-9bd1-f86664b46b68" xlink:to="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_d881081e-b74f-4420-9915-d9fadd9a24c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/Segmentinformation" xlink:type="simple" xlink:href="abvx-20251231.xsd#Segmentinformation"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/Segmentinformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_411ce158-6354-4803-99d1-659927babe5d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_b4b4fad7-bb3b-4934-ae5c-c76846742814" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_411ce158-6354-4803-99d1-659927babe5d" xlink:to="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_b4b4fad7-bb3b-4934-ae5c-c76846742814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/Goodwillandimpairmenttest" xlink:type="simple" xlink:href="abvx-20251231.xsd#Goodwillandimpairmenttest"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/Goodwillandimpairmenttest" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_a36cf083-13d9-427c-91c6-3ed6d4c3b147" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGoodwillExplanatory_d9c03b01-8340-44da-8eb1-4252469c4a47" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGoodwillExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_a36cf083-13d9-427c-91c6-3ed6d4c3b147" xlink:to="loc_ifrs-full_DisclosureOfGoodwillExplanatory_d9c03b01-8340-44da-8eb1-4252469c4a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/Intangibleassets" xlink:type="simple" xlink:href="abvx-20251231.xsd#Intangibleassets"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/Intangibleassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_fa64b0df-b7a9-4faf-87cc-26fb870eda1b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_b7464972-31fd-4306-bbe3-3bc14570b39b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_fa64b0df-b7a9-4faf-87cc-26fb870eda1b" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_b7464972-31fd-4306-bbe3-3bc14570b39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/Propertyplantandequipment" xlink:type="simple" xlink:href="abvx-20251231.xsd#Propertyplantandequipment"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/Propertyplantandequipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_6869e41b-44f5-4b7e-86c8-412d3c0a006c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_96536154-54ae-44cb-b5c0-e814e5dc4434" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_6869e41b-44f5-4b7e-86c8-412d3c0a006c" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_96536154-54ae-44cb-b5c0-e814e5dc4434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/Otherfinancialassets" xlink:type="simple" xlink:href="abvx-20251231.xsd#Otherfinancialassets"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/Otherfinancialassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract_81e1ab69-f63e-4b71-9d90-dbc23a660021" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherAssetsExplanatory_642d5276-4efd-4b3b-97b5-83f564e65433" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract_81e1ab69-f63e-4b71-9d90-dbc23a660021" xlink:to="loc_ifrs-full_DisclosureOfOtherAssetsExplanatory_642d5276-4efd-4b3b-97b5-83f564e65433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/Otherreceivablesandotherassets" xlink:type="simple" xlink:href="abvx-20251231.xsd#Otherreceivablesandotherassets"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/Otherreceivablesandotherassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesAbstract_eaa1b087-a7f1-4dcc-852b-4f1cdabbd3d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_77b824f2-847d-4e78-85f0-4f6db8779f87" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_eaa1b087-a7f1-4dcc-852b-4f1cdabbd3d3" xlink:to="loc_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_77b824f2-847d-4e78-85f0-4f6db8779f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/Cashandcashequivalents" xlink:type="simple" xlink:href="abvx-20251231.xsd#Cashandcashequivalents"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/Cashandcashequivalents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_c091f5ff-c2e1-40f8-a22a-d458e38fce58" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_8ee29a51-21b1-4ddf-956d-4e7687d2cb8d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_c091f5ff-c2e1-40f8-a22a-d458e38fce58" xlink:to="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_8ee29a51-21b1-4ddf-956d-4e7687d2cb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/Financialassetsandliabilities" xlink:type="simple" xlink:href="abvx-20251231.xsd#Financialassetsandliabilities"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/Financialassetsandliabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FairValueMeasurementAbstract_c07e31e9-1039-4018-9640-21860c2270b7" xlink:href="abvx-20251231.xsd#abvx_FairValueMeasurementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_fd6b64c7-b57d-439e-9c38-236293cbdc06" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FairValueMeasurementAbstract_c07e31e9-1039-4018-9640-21860c2270b7" xlink:to="loc_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_fd6b64c7-b57d-439e-9c38-236293cbdc06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/Shareholdersequity" xlink:type="simple" xlink:href="abvx-20251231.xsd#Shareholdersequity"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/Shareholdersequity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract_26553fd4-8d94-47bd-b77a-f1e748f15616" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_11b8a6d9-1b62-4274-8a62-8b2592b1b6d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_26553fd4-8d94-47bd-b77a-f1e748f15616" xlink:to="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_11b8a6d9-1b62-4274-8a62-8b2592b1b6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/Sharebasedpayments" xlink:type="simple" xlink:href="abvx-20251231.xsd#Sharebasedpayments"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/Sharebasedpayments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ShareBasedPaymentArrangementsAbstract_295c22e8-2eac-4ebd-9a89-275b31d93e66" xlink:href="abvx-20251231.xsd#abvx_ShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_106d79b2-9baa-4105-b025-b61bb100c0d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_ShareBasedPaymentArrangementsAbstract_295c22e8-2eac-4ebd-9a89-275b31d93e66" xlink:to="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_106d79b2-9baa-4105-b025-b61bb100c0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/Financialliabilities" xlink:type="simple" xlink:href="abvx-20251231.xsd#Financialliabilities"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/Financialliabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_e8595590-2a52-483d-b1ca-7763a11c2718" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_81cb0523-9af8-423f-9f27-0f987e4a1250" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_e8595590-2a52-483d-b1ca-7763a11c2718" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_81cb0523-9af8-423f-9f27-0f987e4a1250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/Retirementbenefitobligations" xlink:type="simple" xlink:href="abvx-20251231.xsd#Retirementbenefitobligations"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/Retirementbenefitobligations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_c0afca56-b182-4443-ac8c-22f4482d6edf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_8be8a93b-3e9e-4cb2-81e7-46e84f902f77" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_c0afca56-b182-4443-ac8c-22f4482d6edf" xlink:to="loc_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_8be8a93b-3e9e-4cb2-81e7-46e84f902f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/Payablesandothercurrentliabilities" xlink:type="simple" xlink:href="abvx-20251231.xsd#Payablesandothercurrentliabilities"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/Payablesandothercurrentliabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_2893b4e7-5f6b-423a-a2b0-496b1d623e83" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_b142651e-eaba-4433-b3e4-eaa3cbc01957" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_2893b4e7-5f6b-423a-a2b0-496b1d623e83" xlink:to="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_b142651e-eaba-4433-b3e4-eaa3cbc01957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/Otheroperatingincome" xlink:type="simple" xlink:href="abvx-20251231.xsd#Otheroperatingincome"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/Otheroperatingincome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract_c87713be-9f20-46d0-9dda-d96233481710" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_2191dc96-ba82-42f8-98f3-c5732290338f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_c87713be-9f20-46d0-9dda-d96233481710" xlink:to="loc_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_2191dc96-ba82-42f8-98f3-c5732290338f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/Operatingexpenses" xlink:type="simple" xlink:href="abvx-20251231.xsd#Operatingexpenses"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/Operatingexpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseByNatureAbstract_9425533a-3971-42d6-9218-278095b34a23" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseByNatureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_3392a12b-44da-4103-9f39-d64ea0b34062" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_9425533a-3971-42d6-9218-278095b34a23" xlink:to="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_3392a12b-44da-4103-9f39-d64ea0b34062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/Employees" xlink:type="simple" xlink:href="abvx-20251231.xsd#Employees"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/Employees" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberAndAverageNumberOfEmployeesAbstract_285621aa-ca1c-4fe1-8fd3-5e6132550085" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberAndAverageNumberOfEmployeesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory_93ae5c5f-b1ee-46c1-b47f-28a0fc5ce3df" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NumberAndAverageNumberOfEmployeesAbstract_285621aa-ca1c-4fe1-8fd3-5e6132550085" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory_93ae5c5f-b1ee-46c1-b47f-28a0fc5ce3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/Financialgainloss" xlink:type="simple" xlink:href="abvx-20251231.xsd#Financialgainloss"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/Financialgainloss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialIncomeLossAbstract_3f24e421-4e8e-4783-9857-b2f8f990c8e6" xlink:href="abvx-20251231.xsd#abvx_FinancialIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_9484ae21-014f-4c23-a0a2-ac9573aceb80" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialIncomeLossAbstract_3f24e421-4e8e-4783-9857-b2f8f990c8e6" xlink:to="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_9484ae21-014f-4c23-a0a2-ac9573aceb80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/Incometax" xlink:type="simple" xlink:href="abvx-20251231.xsd#Incometax"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/Incometax" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_7931a8bf-3f06-4094-bc48-07333296f2df" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_2f561125-8e0b-4d3c-9d33-44798156f776" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_7931a8bf-3f06-4094-bc48-07333296f2df" xlink:to="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_2f561125-8e0b-4d3c-9d33-44798156f776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/Incomelosspershare" xlink:type="simple" xlink:href="abvx-20251231.xsd#Incomelosspershare"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/Incomelosspershare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_0d778b0c-9228-4303-a0e0-5be64a8f21fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_354ad7eb-0f25-4542-b1ad-6d2680eb7b47" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_0d778b0c-9228-4303-a0e0-5be64a8f21fe" xlink:to="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_354ad7eb-0f25-4542-b1ad-6d2680eb7b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/Relatedparties" xlink:type="simple" xlink:href="abvx-20251231.xsd#Relatedparties"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/Relatedparties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract_782d2a04-a4cc-499e-af1f-6435eff3b32a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_89763d1a-cc8e-4326-805f-0453525f4dff" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_782d2a04-a4cc-499e-af1f-6435eff3b32a" xlink:to="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_89763d1a-cc8e-4326-805f-0453525f4dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/Offbalancesheetcommitmentsgiven" xlink:type="simple" xlink:href="abvx-20251231.xsd#Offbalancesheetcommitmentsgiven"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/Offbalancesheetcommitmentsgiven" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OffBalanceSheetCommitmentsAbstract_6ae60267-f427-4cc8-bbc7-452753a6c31c" xlink:href="abvx-20251231.xsd#abvx_OffBalanceSheetCommitmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_fb1bbd18-0d67-4340-942a-89f2c7258612" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_OffBalanceSheetCommitmentsAbstract_6ae60267-f427-4cc8-bbc7-452753a6c31c" xlink:to="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_fb1bbd18-0d67-4340-942a-89f2c7258612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/Offbalancesheetcommitmentsreceivedandcontingentassets" xlink:type="simple" xlink:href="abvx-20251231.xsd#Offbalancesheetcommitmentsreceivedandcontingentassets"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/Offbalancesheetcommitmentsreceivedandcontingentassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OffBalanceSheetCommitmentsAbstract_aea1a003-2abf-4c52-b333-f3a29d9a756d" xlink:href="abvx-20251231.xsd#abvx_OffBalanceSheetCommitmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory_50611028-5ed3-4635-a17b-91648ee5e9c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_OffBalanceSheetCommitmentsAbstract_aea1a003-2abf-4c52-b333-f3a29d9a756d" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory_50611028-5ed3-4635-a17b-91648ee5e9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/Managementandassessmentoffinancialrisks" xlink:type="simple" xlink:href="abvx-20251231.xsd#Managementandassessmentoffinancialrisks"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/Managementandassessmentoffinancialrisks" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialRiskManagementAbstract_40e1111d-93d1-4d6e-a3b8-af536c32c782" xlink:href="abvx-20251231.xsd#abvx_FinancialRiskManagementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_cea7e2da-9303-4e95-a0d5-c3a27c9abcb7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialRiskManagementAbstract_40e1111d-93d1-4d6e-a3b8-af536c32c782" xlink:to="loc_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_cea7e2da-9303-4e95-a0d5-c3a27c9abcb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/AccountingprinciplesPolicies" xlink:type="simple" xlink:href="abvx-20251231.xsd#AccountingprinciplesPolicies"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/AccountingprinciplesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AccountingPrinciplesAbstract_8cc8207d-f9a7-4144-a525-85ca5b93e445" xlink:href="abvx-20251231.xsd#abvx_AccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory_f61c00b3-2873-4b41-b617-462ab41baf2b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_8cc8207d-f9a7-4144-a525-85ca5b93e445" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory_f61c00b3-2873-4b41-b617-462ab41baf2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_c6b504ea-b027-479d-8dd1-b0687f8c1bfa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_8cc8207d-f9a7-4144-a525-85ca5b93e445" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_c6b504ea-b027-479d-8dd1-b0687f8c1bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_ddfe48dd-d315-4477-86e9-a3bd7a21d7a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_8cc8207d-f9a7-4144-a525-85ca5b93e445" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_ddfe48dd-d315-4477-86e9-a3bd7a21d7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_aaed29b8-3f16-45ae-8431-4ac24992bbd2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_8cc8207d-f9a7-4144-a525-85ca5b93e445" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_aaed29b8-3f16-45ae-8431-4ac24992bbd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_7c277e60-df1f-42da-a8fc-fd5d24bca9de" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_8cc8207d-f9a7-4144-a525-85ca5b93e445" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_7c277e60-df1f-42da-a8fc-fd5d24bca9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_43a9d7b8-d531-4aef-8247-080e9f85f3ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_8cc8207d-f9a7-4144-a525-85ca5b93e445" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_43a9d7b8-d531-4aef-8247-080e9f85f3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_0ea28ead-588c-40f7-b6d8-9290d4f98802" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_8cc8207d-f9a7-4144-a525-85ca5b93e445" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_0ea28ead-588c-40f7-b6d8-9290d4f98802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_e7d3b853-6144-467d-aaf8-eb69e49465be" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_8cc8207d-f9a7-4144-a525-85ca5b93e445" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_e7d3b853-6144-467d-aaf8-eb69e49465be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_1647c675-ed20-40a2-ad4b-e1d9f7a818da" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_8cc8207d-f9a7-4144-a525-85ca5b93e445" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_1647c675-ed20-40a2-ad4b-e1d9f7a818da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_7be9b375-0416-4f50-9d6e-7e80c27a024e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_8cc8207d-f9a7-4144-a525-85ca5b93e445" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_7be9b375-0416-4f50-9d6e-7e80c27a024e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory_03a9014d-64b7-4092-819b-a5d112895c14" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_8cc8207d-f9a7-4144-a525-85ca5b93e445" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory_03a9014d-64b7-4092-819b-a5d112895c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_8d741351-cee1-4c49-8af1-8400c29d0976" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_8cc8207d-f9a7-4144-a525-85ca5b93e445" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_8d741351-cee1-4c49-8af1-8400c29d0976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_f3294322-e512-46cf-9461-f0b8c1631122" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_8cc8207d-f9a7-4144-a525-85ca5b93e445" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_f3294322-e512-46cf-9461-f0b8c1631122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_2c82de79-ab5b-4f9a-a1f5-ac6e557536e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_8cc8207d-f9a7-4144-a525-85ca5b93e445" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_2c82de79-ab5b-4f9a-a1f5-ac6e557536e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_64fdb4d7-9988-48c3-bdef-61680e9afaff" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_8cc8207d-f9a7-4144-a525-85ca5b93e445" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_64fdb4d7-9988-48c3-bdef-61680e9afaff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_91be4bd1-5b66-40a1-b502-064840870067" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_8cc8207d-f9a7-4144-a525-85ca5b93e445" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_91be4bd1-5b66-40a1-b502-064840870067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_44b8b11b-a425-4dbe-ba2c-f93a80a20a0f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_8cc8207d-f9a7-4144-a525-85ca5b93e445" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_44b8b11b-a425-4dbe-ba2c-f93a80a20a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfAccountingPolicyForAssetsAcquisitionsPolicyTextBlock_8bed40ae-362c-433f-b2f4-008b266d6511" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfAccountingPolicyForAssetsAcquisitionsPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_8cc8207d-f9a7-4144-a525-85ca5b93e445" xlink:to="loc_abvx_DisclosureOfAccountingPolicyForAssetsAcquisitionsPolicyTextBlock_8bed40ae-362c-433f-b2f4-008b266d6511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfAccountingPolicyForAccountingJudgementsAndEstimatesExplanatoryPolicyTextBlock_37102cff-3624-4d02-aa47-7f50075fc3b9" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfAccountingPolicyForAccountingJudgementsAndEstimatesExplanatoryPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_8cc8207d-f9a7-4144-a525-85ca5b93e445" xlink:to="loc_abvx_DisclosureOfAccountingPolicyForAccountingJudgementsAndEstimatesExplanatoryPolicyTextBlock_37102cff-3624-4d02-aa47-7f50075fc3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfIFRSCompliance_5472678c-bef3-466a-8bd7-1ad1b0a28d58" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfIFRSCompliance"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_8cc8207d-f9a7-4144-a525-85ca5b93e445" xlink:to="loc_ifrs-full_StatementOfIFRSCompliance_5472678c-bef3-466a-8bd7-1ad1b0a28d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock_f46753f7-0220-4ad0-9530-977f0609540b" xlink:href="abvx-20251231.xsd#abvx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_8cc8207d-f9a7-4144-a525-85ca5b93e445" xlink:to="loc_abvx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock_f46753f7-0220-4ad0-9530-977f0609540b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfImpactOfTheUkraineRussiaHostilitiesOnTheGroupPolicyTextBlock_c4a41cd8-3a6a-4863-ada5-e105b4c6c54d" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfImpactOfTheUkraineRussiaHostilitiesOnTheGroupPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_8cc8207d-f9a7-4144-a525-85ca5b93e445" xlink:to="loc_abvx_DisclosureOfImpactOfTheUkraineRussiaHostilitiesOnTheGroupPolicyTextBlock_c4a41cd8-3a6a-4863-ada5-e105b4c6c54d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfAccountingPolicyForNewRevisedOrAmendedStandardsAndInterpretationsPolicyTextBlock_e50ed2ed-d934-495e-8b15-245102d4992c" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfAccountingPolicyForNewRevisedOrAmendedStandardsAndInterpretationsPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_8cc8207d-f9a7-4144-a525-85ca5b93e445" xlink:to="loc_abvx_DisclosureOfAccountingPolicyForNewRevisedOrAmendedStandardsAndInterpretationsPolicyTextBlock_e50ed2ed-d934-495e-8b15-245102d4992c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedByIASBButNotYetMandatoryPolicyTextBlock_f16ea994-d1e4-427c-8320-39f6f07d2c9b" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedByIASBButNotYetMandatoryPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_8cc8207d-f9a7-4144-a525-85ca5b93e445" xlink:to="loc_abvx_DisclosureOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedByIASBButNotYetMandatoryPolicyTextBlock_f16ea994-d1e4-427c-8320-39f6f07d2c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/AccountingprinciplesTables" xlink:type="simple" xlink:href="abvx-20251231.xsd#AccountingprinciplesTables"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/AccountingprinciplesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AccountingPrinciplesAbstract_d8c0aeb7-3075-47d0-9ce5-d94dd0dbf687" xlink:href="abvx-20251231.xsd#abvx_AccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_6cf48d56-33b1-402b-a720-2cf76917b9ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_d8c0aeb7-3075-47d0-9ce5-d94dd0dbf687" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_6cf48d56-33b1-402b-a720-2cf76917b9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfDetailedInformationAboutAssetsAcquisitionsExplanatoryTableTextBlock_0efee742-5d53-4cf1-b931-062ca5d7aaf9" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfDetailedInformationAboutAssetsAcquisitionsExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_d8c0aeb7-3075-47d0-9ce5-d94dd0dbf687" xlink:to="loc_abvx_DisclosureOfDetailedInformationAboutAssetsAcquisitionsExplanatoryTableTextBlock_0efee742-5d53-4cf1-b931-062ca5d7aaf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/IntangibleassetsTables" xlink:type="simple" xlink:href="abvx-20251231.xsd#IntangibleassetsTables"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/IntangibleassetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_52a56546-cc85-492c-b8d3-1f59178a24fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_9ee88009-a621-4898-a994-277bc7efe5b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_52a56546-cc85-492c-b8d3-1f59178a24fc" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_9ee88009-a621-4898-a994-277bc7efe5b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/PropertyplantandequipmentTables" xlink:type="simple" xlink:href="abvx-20251231.xsd#PropertyplantandequipmentTables"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/PropertyplantandequipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_0bfa9b70-d4dc-47d3-903b-35c396743f2a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInPropertyPlantAndEquipmentIncludingRightofuseAssetsExplanatory_a33ab6c7-6a57-4321-a9b7-389d2db9688b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInPropertyPlantAndEquipmentIncludingRightofuseAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_0bfa9b70-d4dc-47d3-903b-35c396743f2a" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInPropertyPlantAndEquipmentIncludingRightofuseAssetsExplanatory_a33ab6c7-6a57-4321-a9b7-389d2db9688b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/OtherfinancialassetsTables" xlink:type="simple" xlink:href="abvx-20251231.xsd#OtherfinancialassetsTables"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/OtherfinancialassetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract_5e125f17-3885-4bf3-92f1-f47a98e43eda" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory_0b8257a8-f6f9-400b-826b-7a32005d8801" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract_5e125f17-3885-4bf3-92f1-f47a98e43eda" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory_0b8257a8-f6f9-400b-826b-7a32005d8801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/OtherreceivablesandotherassetsTables" xlink:type="simple" xlink:href="abvx-20251231.xsd#OtherreceivablesandotherassetsTables"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/OtherreceivablesandotherassetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesAbstract_cf42fba4-8a72-4e63-bd54-c3740a02b959" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfDetailedInformationAboutOtherReceivablesAndOtherAssetsTableTextBlock_f7508ae0-11a9-4289-af5a-e873843c88e7" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfDetailedInformationAboutOtherReceivablesAndOtherAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_cf42fba4-8a72-4e63-bd54-c3740a02b959" xlink:to="loc_abvx_DisclosureOfDetailedInformationAboutOtherReceivablesAndOtherAssetsTableTextBlock_f7508ae0-11a9-4289-af5a-e873843c88e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/CashandcashequivalentsTables" xlink:type="simple" xlink:href="abvx-20251231.xsd#CashandcashequivalentsTables"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/CashandcashequivalentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_52c467f9-52a7-4736-9187-c4ba6a9b5ada" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfCompositionOfCashAndCashEquivalentsTableTextBlock_4a4be44c-4da3-44b4-9eb0-8724e84e4006" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfCompositionOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_52c467f9-52a7-4736-9187-c4ba6a9b5ada" xlink:to="loc_abvx_DisclosureOfCompositionOfCashAndCashEquivalentsTableTextBlock_4a4be44c-4da3-44b4-9eb0-8724e84e4006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialassetsandliabilitiesTables" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialassetsandliabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/FinancialassetsandliabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FairValueMeasurementAbstract_9532b6f5-7340-4a9f-af9b-1a5c02684d21" xlink:href="abvx-20251231.xsd#abvx_FairValueMeasurementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory_923bbf02-74b3-4589-aade-afc83ff5ca61" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FairValueMeasurementAbstract_9532b6f5-7340-4a9f-af9b-1a5c02684d21" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory_923bbf02-74b3-4589-aade-afc83ff5ca61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_aabe8b67-d410-4544-ab4d-708c05664a15" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FairValueMeasurementAbstract_9532b6f5-7340-4a9f-af9b-1a5c02684d21" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_aabe8b67-d410-4544-ab4d-708c05664a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/SharebasedpaymentsTables" xlink:type="simple" xlink:href="abvx-20251231.xsd#SharebasedpaymentsTables"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/SharebasedpaymentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ShareBasedPaymentArrangementsAbstract_2272ae49-431a-48fb-9cf4-f5dd4adf0a7e" xlink:href="abvx-20251231.xsd#abvx_ShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_ef71d489-fd0f-4f35-900c-b1b63f93b485" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_ShareBasedPaymentArrangementsAbstract_2272ae49-431a-48fb-9cf4-f5dd4adf0a7e" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_ef71d489-fd0f-4f35-900c-b1b63f93b485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory_c570158d-1a8d-4266-8238-c9a231bd12bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_ShareBasedPaymentArrangementsAbstract_2272ae49-431a-48fb-9cf4-f5dd4adf0a7e" xlink:to="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory_c570158d-1a8d-4266-8238-c9a231bd12bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss_c55e6633-94d4-4bc5-961b-6664482e2bc3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_ShareBasedPaymentArrangementsAbstract_2272ae49-431a-48fb-9cf4-f5dd4adf0a7e" xlink:to="loc_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss_c55e6633-94d4-4bc5-961b-6664482e2bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesTables" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_a6c6b24b-5a63-415e-b373-3611f5c9d84c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_cb82388e-fd09-47d6-bca6-e7ebcf150da5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_a6c6b24b-5a63-415e-b373-3611f5c9d84c" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_cb82388e-fd09-47d6-bca6-e7ebcf150da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory_fc5657bc-9cb9-4a51-9c0b-68e2ae5712d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_a6c6b24b-5a63-415e-b373-3611f5c9d84c" xlink:to="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory_fc5657bc-9cb9-4a51-9c0b-68e2ae5712d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfIndirectMeasurementOfConvertibleLoansInstrumentsTableTextBlock_a6a82e25-bb44-4c43-b7db-e0f1a3a0d033" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfIndirectMeasurementOfConvertibleLoansInstrumentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_a6c6b24b-5a63-415e-b373-3611f5c9d84c" xlink:to="loc_abvx_DisclosureOfIndirectMeasurementOfConvertibleLoansInstrumentsTableTextBlock_a6a82e25-bb44-4c43-b7db-e0f1a3a0d033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBorrowingsExplanatory_92b2d676-a979-4432-bd0a-64e96858c7e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBorrowingsExplanatory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_a6c6b24b-5a63-415e-b373-3611f5c9d84c" xlink:to="loc_ifrs-full_DisclosureOfBorrowingsExplanatory_92b2d676-a979-4432-bd0a-64e96858c7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfLeasesForLesseeTableTextBlock_d7f7dbd9-650b-47b7-bafb-19672ba95a8c" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfLeasesForLesseeTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_a6c6b24b-5a63-415e-b373-3611f5c9d84c" xlink:to="loc_abvx_DisclosureOfLeasesForLesseeTableTextBlock_d7f7dbd9-650b-47b7-bafb-19672ba95a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_0e1aff9e-1dad-45be-993f-05729b41c052" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_a6c6b24b-5a63-415e-b373-3611f5c9d84c" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_0e1aff9e-1dad-45be-993f-05729b41c052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfChangesInDerivativeFinancialInstrumentsTableTextBlock_554bc8ea-a5c6-4a03-b643-da10ccefaa2b" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfChangesInDerivativeFinancialInstrumentsTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_a6c6b24b-5a63-415e-b373-3611f5c9d84c" xlink:to="loc_abvx_DisclosureOfChangesInDerivativeFinancialInstrumentsTableTextBlock_554bc8ea-a5c6-4a03-b643-da10ccefaa2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities_7c3ea4ca-fcff-4c32-8658-6a8338eeefc7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_a6c6b24b-5a63-415e-b373-3611f5c9d84c" xlink:to="loc_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities_7c3ea4ca-fcff-4c32-8658-6a8338eeefc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_3032955e-7f95-405e-8fef-70ca95c88e5a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_a6c6b24b-5a63-415e-b373-3611f5c9d84c" xlink:to="loc_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_3032955e-7f95-405e-8fef-70ca95c88e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/RetirementbenefitobligationsTables" xlink:type="simple" xlink:href="abvx-20251231.xsd#RetirementbenefitobligationsTables"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/RetirementbenefitobligationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_5cd2aa5e-d4cd-42b4-8b04-7e05b73f6195" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory_085df8c7-7ce5-44e9-82b1-88dcfb6e8259" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_5cd2aa5e-d4cd-42b4-8b04-7e05b73f6195" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory_085df8c7-7ce5-44e9-82b1-88dcfb6e8259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_81d90440-812b-4a8a-8fc7-18d51b9f7466" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_5cd2aa5e-d4cd-42b4-8b04-7e05b73f6195" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_81d90440-812b-4a8a-8fc7-18d51b9f7466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/PayablesandothercurrentliabilitiesTables" xlink:type="simple" xlink:href="abvx-20251231.xsd#PayablesandothercurrentliabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/PayablesandothercurrentliabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_8ca2e06e-1ebc-4aa3-898d-b3c9f3e2813f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfBreakdownOfTradeAndOtherPayablesTableTextBlock_36bcb0dd-a421-4c46-b132-93f852c437fd" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfBreakdownOfTradeAndOtherPayablesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_8ca2e06e-1ebc-4aa3-898d-b3c9f3e2813f" xlink:to="loc_abvx_DisclosureOfBreakdownOfTradeAndOtherPayablesTableTextBlock_36bcb0dd-a421-4c46-b132-93f852c437fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfTaxAndEmployeeRelatedPayablesExplanatoryTableTextBlock_3ac2600f-f22a-4eb4-a0d2-a37f3483b09a" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfTaxAndEmployeeRelatedPayablesExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_8ca2e06e-1ebc-4aa3-898d-b3c9f3e2813f" xlink:to="loc_abvx_DisclosureOfTaxAndEmployeeRelatedPayablesExplanatoryTableTextBlock_3ac2600f-f22a-4eb4-a0d2-a37f3483b09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/OtheroperatingincomeTables" xlink:type="simple" xlink:href="abvx-20251231.xsd#OtheroperatingincomeTables"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/OtheroperatingincomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract_84ff25bf-2bb5-40e1-8e87-fbca034315f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfDetailedInformationOfOperatingIncomeExplanatoryTableTextBlock_f3fe88f5-c02a-465e-bb87-233fe4131211" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfDetailedInformationOfOperatingIncomeExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_84ff25bf-2bb5-40e1-8e87-fbca034315f6" xlink:to="loc_abvx_DisclosureOfDetailedInformationOfOperatingIncomeExplanatoryTableTextBlock_f3fe88f5-c02a-465e-bb87-233fe4131211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/OperatingexpensesTables" xlink:type="simple" xlink:href="abvx-20251231.xsd#OperatingexpensesTables"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/OperatingexpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseByNatureAbstract_3dfb52f4-b7e2-43f3-ab50-0dd1df214b6d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseByNatureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfExpensesByNatureExplanatory_6ee2b495-e405-4932-920f-b9664d3f8496" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_3dfb52f4-b7e2-43f3-ab50-0dd1df214b6d" xlink:to="loc_ifrs-full_DisclosureOfExpensesByNatureExplanatory_6ee2b495-e405-4932-920f-b9664d3f8496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfPrincipalAuditFeesAndServicesTableTextBlock_417b139d-bfb8-4929-bc45-86a3cc48266e" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfPrincipalAuditFeesAndServicesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_3dfb52f4-b7e2-43f3-ab50-0dd1df214b6d" xlink:to="loc_abvx_DisclosureOfPrincipalAuditFeesAndServicesTableTextBlock_417b139d-bfb8-4929-bc45-86a3cc48266e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/EmployeesTables" xlink:type="simple" xlink:href="abvx-20251231.xsd#EmployeesTables"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/EmployeesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberAndAverageNumberOfEmployeesAbstract_00f43a43-308f-4344-861e-acafcfb73238" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberAndAverageNumberOfEmployeesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfAverageNumberOfEmployeesTableTextBlock_0cb20388-1910-4809-89c9-dd63b26a8f6c" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfAverageNumberOfEmployeesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NumberAndAverageNumberOfEmployeesAbstract_00f43a43-308f-4344-861e-acafcfb73238" xlink:to="loc_abvx_DisclosureOfAverageNumberOfEmployeesTableTextBlock_0cb20388-1910-4809-89c9-dd63b26a8f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialgainlossTables" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialgainlossTables"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/FinancialgainlossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialIncomeLossAbstract_d05791d4-b8ce-4b95-aeb9-870778f1d05e" xlink:href="abvx-20251231.xsd#abvx_FinancialIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfDetailedInformationAboutFinanceIncomeCostTableTextBlock_47443c0e-e959-4bf9-ae66-4760da24cd29" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfDetailedInformationAboutFinanceIncomeCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialIncomeLossAbstract_d05791d4-b8ce-4b95-aeb9-870778f1d05e" xlink:to="loc_abvx_DisclosureOfDetailedInformationAboutFinanceIncomeCostTableTextBlock_47443c0e-e959-4bf9-ae66-4760da24cd29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/IncometaxTables" xlink:type="simple" xlink:href="abvx-20251231.xsd#IncometaxTables"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/IncometaxTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_22086e53-67f0-40eb-95d6-444ed7b1df7d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock_a0a1dc97-ce6a-424f-9e68-bc9667750cc0" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_22086e53-67f0-40eb-95d6-444ed7b1df7d" xlink:to="loc_abvx_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock_a0a1dc97-ce6a-424f-9e68-bc9667750cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_c087123d-db17-479d-bce4-6e3a85ff55ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_22086e53-67f0-40eb-95d6-444ed7b1df7d" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_c087123d-db17-479d-bce4-6e3a85ff55ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/IncomelosspershareTables" xlink:type="simple" xlink:href="abvx-20251231.xsd#IncomelosspershareTables"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/IncomelosspershareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_bfab5e74-fd7d-4523-be26-2f1376d8e23f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareExplanatory_a668d19f-fc05-4b1a-bd9e-6444f7a5b2f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_bfab5e74-fd7d-4523-be26-2f1376d8e23f" xlink:to="loc_ifrs-full_EarningsPerShareExplanatory_a668d19f-fc05-4b1a-bd9e-6444f7a5b2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/RelatedpartiesTables" xlink:type="simple" xlink:href="abvx-20251231.xsd#RelatedpartiesTables"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/RelatedpartiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract_207616b5-ed08-428a-9548-44d8f2930019" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_d6c88cb3-b42f-4ced-938e-fe4abccb7a9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_207616b5-ed08-428a-9548-44d8f2930019" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_d6c88cb3-b42f-4ced-938e-fe4abccb7a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/TheGroupDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#TheGroupDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/TheGroupDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_38ed3578-962f-44cf-9681-0c9b64a211bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_67369893-c654-49e8-8880-e8ea174f7732" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_38ed3578-962f-44cf-9681-0c9b64a211bc" xlink:to="loc_ifrs-full_Equity_67369893-c654-49e8-8880-e8ea174f7732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/BasisofpreparationDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#BasisofpreparationDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/BasisofpreparationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_4947c53e-ce8f-4362-aea1-06c098f26a82" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_5a04552b-e148-4136-bb64-1022dc6d3aa2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_4947c53e-ce8f-4362-aea1-06c098f26a82" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_5a04552b-e148-4136-bb64-1022dc6d3aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SaleOfStockAxis_9636aa04-a03c-4fe6-979f-e883570254bf" xlink:href="abvx-20251231.xsd#abvx_SaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_5a04552b-e148-4136-bb64-1022dc6d3aa2" xlink:to="loc_abvx_SaleOfStockAxis_9636aa04-a03c-4fe6-979f-e883570254bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SaleOfStockDomain_af5a6cb4-a79d-443d-8a0d-0af5895ce4ae" xlink:href="abvx-20251231.xsd#abvx_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_SaleOfStockAxis_9636aa04-a03c-4fe6-979f-e883570254bf" xlink:to="loc_abvx_SaleOfStockDomain_af5a6cb4-a79d-443d-8a0d-0af5895ce4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RegisteredDirectOfferingMember_020d0650-0103-47b7-bd8c-f4904537c382" xlink:href="abvx-20251231.xsd#abvx_RegisteredDirectOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_SaleOfStockDomain_af5a6cb4-a79d-443d-8a0d-0af5895ce4ae" xlink:to="loc_abvx_RegisteredDirectOfferingMember_020d0650-0103-47b7-bd8c-f4904537c382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d00be8d3-5d44-403c-ae3d-bfd6a731b144" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_5a04552b-e148-4136-bb64-1022dc6d3aa2" xlink:to="loc_srt_CounterpartyNameAxis_d00be8d3-5d44-403c-ae3d-bfd6a731b144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fc9eb33-2169-4d10-ba48-eca99716d298" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d00be8d3-5d44-403c-ae3d-bfd6a731b144" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fc9eb33-2169-4d10-ba48-eca99716d298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BanquePubliqueDInvestissementBPIMember_9cd4ef0c-c5fe-4f1b-90c1-21e4b2428b63" xlink:href="abvx-20251231.xsd#abvx_BanquePubliqueDInvestissementBPIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fc9eb33-2169-4d10-ba48-eca99716d298" xlink:to="loc_abvx_BanquePubliqueDInvestissementBPIMember_9cd4ef0c-c5fe-4f1b-90c1-21e4b2428b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3727c861-3787-40da-8ee4-8557a018979d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_5a04552b-e148-4136-bb64-1022dc6d3aa2" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3727c861-3787-40da-8ee4-8557a018979d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_aec0127e-6b8d-4fde-b41a-e249987e3005" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3727c861-3787-40da-8ee4-8557a018979d" xlink:to="loc_ifrs-full_ProfitLoss_aec0127e-6b8d-4fde-b41a-e249987e3005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_1802063c-a58b-4ef5-b865-7fd025a35499" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3727c861-3787-40da-8ee4-8557a018979d" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_1802063c-a58b-4ef5-b865-7fd025a35499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_bf28e84e-a047-46ba-bfb9-2f77bb98f8a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3727c861-3787-40da-8ee4-8557a018979d" xlink:to="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_bf28e84e-a047-46ba-bfb9-2f77bb98f8a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ProceedsFromResearchTaxCredit_024b1391-8e72-4a5f-aa7e-14b2be6b3fcd" xlink:href="abvx-20251231.xsd#abvx_ProceedsFromResearchTaxCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3727c861-3787-40da-8ee4-8557a018979d" xlink:to="loc_abvx_ProceedsFromResearchTaxCredit_024b1391-8e72-4a5f-aa7e-14b2be6b3fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities_d77a7f93-dee1-4d27-9526-594ddf93ce3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3727c861-3787-40da-8ee4-8557a018979d" xlink:to="loc_ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities_d77a7f93-dee1-4d27-9526-594ddf93ce3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ProceedsFromConditionalAdvances_b2d623d7-d526-4b71-b1ff-8589a311367e" xlink:href="abvx-20251231.xsd#abvx_ProceedsFromConditionalAdvances"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3727c861-3787-40da-8ee4-8557a018979d" xlink:to="loc_abvx_ProceedsFromConditionalAdvances_b2d623d7-d526-4b71-b1ff-8589a311367e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NetProceedsFromSaleOfRoyaltyCertificates_963602ec-79bf-45e0-891c-cc9d3049705d" xlink:href="abvx-20251231.xsd#abvx_NetProceedsFromSaleOfRoyaltyCertificates"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3727c861-3787-40da-8ee4-8557a018979d" xlink:to="loc_abvx_NetProceedsFromSaleOfRoyaltyCertificates_963602ec-79bf-45e0-891c-cc9d3049705d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CashAndCashEquivalentsAndOtherShortTermInvestments_019cd7eb-73d9-7d8a-a7c3-7e8550ba39b4" xlink:href="abvx-20251231.xsd#abvx_CashAndCashEquivalentsAndOtherShortTermInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3727c861-3787-40da-8ee4-8557a018979d" xlink:to="loc_abvx_CashAndCashEquivalentsAndOtherShortTermInvestments_019cd7eb-73d9-7d8a-a7c3-7e8550ba39b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" xlink:type="simple" xlink:href="abvx-20251231.xsd#SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AccountingPrinciplesAbstract_397e48a5-fae8-4a9c-9838-17ea4c9c4eaf" xlink:href="abvx-20251231.xsd#abvx_AccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_4f2160ed-9398-4159-8a3e-9431996a786a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_397e48a5-fae8-4a9c-9838-17ea4c9c4eaf" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_4f2160ed-9398-4159-8a3e-9431996a786a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialAgreementAxis_f11ee1aa-c644-4aa9-8db1-a9a44aaaa2c5" xlink:href="abvx-20251231.xsd#abvx_FinancialAgreementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_4f2160ed-9398-4159-8a3e-9431996a786a" xlink:to="loc_abvx_FinancialAgreementAxis_f11ee1aa-c644-4aa9-8db1-a9a44aaaa2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialAgreementDomain_3b33e393-8817-49f5-9e37-1ec0ea3c494b" xlink:href="abvx-20251231.xsd#abvx_FinancialAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialAgreementAxis_f11ee1aa-c644-4aa9-8db1-a9a44aaaa2c5" xlink:to="loc_abvx_FinancialAgreementDomain_3b33e393-8817-49f5-9e37-1ec0ea3c494b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_A130.0MillionCrossOverFinancingFebruary2023Member_a14ac1d7-8642-4bae-bc5e-a3894ba31a70" xlink:href="abvx-20251231.xsd#abvx_A130.0MillionCrossOverFinancingFebruary2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialAgreementDomain_3b33e393-8817-49f5-9e37-1ec0ea3c494b" xlink:to="loc_abvx_A130.0MillionCrossOverFinancingFebruary2023Member_a14ac1d7-8642-4bae-bc5e-a3894ba31a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_A49.2MillionCrossOverFinancingSeptember2022Member_41e98ff5-e04f-403a-8337-77b2894369cf" xlink:href="abvx-20251231.xsd#abvx_A49.2MillionCrossOverFinancingSeptember2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialAgreementDomain_3b33e393-8817-49f5-9e37-1ec0ea3c494b" xlink:to="loc_abvx_A49.2MillionCrossOverFinancingSeptember2022Member_41e98ff5-e04f-403a-8337-77b2894369cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_A150.0MillionFinancingAugust2023Member_98153e11-2c37-4328-badf-0aa3439029d7" xlink:href="abvx-20251231.xsd#abvx_A150.0MillionFinancingAugust2023Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialAgreementDomain_3b33e393-8817-49f5-9e37-1ec0ea3c494b" xlink:to="loc_abvx_A150.0MillionFinancingAugust2023Member_98153e11-2c37-4328-badf-0aa3439029d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_5f01a384-9b1d-4582-8120-8d317e191fa1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_4f2160ed-9398-4159-8a3e-9431996a786a" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_5f01a384-9b1d-4582-8120-8d317e191fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_8f94ca90-8cc8-4ed0-8ddb-d2ba0dd08270" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_5f01a384-9b1d-4582-8120-8d317e191fa1" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_8f94ca90-8cc8-4ed0-8ddb-d2ba0dd08270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_a69ad1b5-6e98-4a9e-8387-072f37eb9f01" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_8f94ca90-8cc8-4ed0-8ddb-d2ba0dd08270" xlink:to="loc_ifrs-full_SharePremiumMember_a69ad1b5-6e98-4a9e-8387-072f37eb9f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_5726150b-87b1-4d15-8a09-1533f91009d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_4f2160ed-9398-4159-8a3e-9431996a786a" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_5726150b-87b1-4d15-8a09-1533f91009d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_c57574e1-a77d-4d91-969f-45c36e6ebac7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_5726150b-87b1-4d15-8a09-1533f91009d5" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_c57574e1-a77d-4d91-969f-45c36e6ebac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1ConvertibleBondLoansTrancheAMember_ba072001-3e39-4199-a98c-3cb4698fb05a" xlink:href="abvx-20251231.xsd#abvx_Kreos1ConvertibleBondLoansTrancheAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c57574e1-a77d-4d91-969f-45c36e6ebac7" xlink:to="loc_abvx_Kreos1ConvertibleBondLoansTrancheAMember_ba072001-3e39-4199-a98c-3cb4698fb05a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1ConvertibleBondLoansTrancheBMember_3934b5a4-7f21-4ad2-a2e1-fd3bcfcd9406" xlink:href="abvx-20251231.xsd#abvx_Kreos1ConvertibleBondLoansTrancheBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c57574e1-a77d-4d91-969f-45c36e6ebac7" xlink:to="loc_abvx_Kreos1ConvertibleBondLoansTrancheBMember_3934b5a4-7f21-4ad2-a2e1-fd3bcfcd9406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingMember_a319e854-9496-44b1-9444-288f19675070" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c57574e1-a77d-4d91-969f-45c36e6ebac7" xlink:to="loc_abvx_KreosClaretFinancingMember_a319e854-9496-44b1-9444-288f19675070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_HeightsConvertibleNotesMember_dd5efce1-7e89-4334-876d-e9eacb337606" xlink:href="abvx-20251231.xsd#abvx_HeightsConvertibleNotesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c57574e1-a77d-4d91-969f-45c36e6ebac7" xlink:to="loc_abvx_HeightsConvertibleNotesMember_dd5efce1-7e89-4334-876d-e9eacb337606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheAMember_103ae38f-be96-4337-bda7-0064012edca5" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheAMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c57574e1-a77d-4d91-969f-45c36e6ebac7" xlink:to="loc_abvx_KreosClaretFinancingTrancheAMember_103ae38f-be96-4337-bda7-0064012edca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OCEANEMember_5e75d5f5-6358-4c46-917c-0b3c73c2054c" xlink:href="abvx-20251231.xsd#abvx_OCEANEMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c57574e1-a77d-4d91-969f-45c36e6ebac7" xlink:to="loc_abvx_OCEANEMember_5e75d5f5-6358-4c46-917c-0b3c73c2054c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingAndHeightsConvertibleNotesMember_f243d714-df1d-428f-89d9-fbc96c1b18bc" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingAndHeightsConvertibleNotesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c57574e1-a77d-4d91-969f-45c36e6ebac7" xlink:to="loc_abvx_KreosClaretFinancingAndHeightsConvertibleNotesMember_f243d714-df1d-428f-89d9-fbc96c1b18bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_cd16f4b3-1b22-4b3f-9dfe-e5111ba16182" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_4f2160ed-9398-4159-8a3e-9431996a786a" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_cd16f4b3-1b22-4b3f-9dfe-e5111ba16182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_81ecfecb-581f-4359-a6d7-61262160381e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_cd16f4b3-1b22-4b3f-9dfe-e5111ba16182" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_81ecfecb-581f-4359-a6d7-61262160381e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AmericanDepositorySharesMember_2c67ba44-c9bf-4bdf-ae80-7b7db54b6688" xlink:href="abvx-20251231.xsd#abvx_AmericanDepositorySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_81ecfecb-581f-4359-a6d7-61262160381e" xlink:to="loc_abvx_AmericanDepositorySharesMember_2c67ba44-c9bf-4bdf-ae80-7b7db54b6688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_b5e97169-a592-4021-8a0a-c608bcc82a0e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_81ecfecb-581f-4359-a6d7-61262160381e" xlink:to="loc_ifrs-full_OrdinarySharesMember_b5e97169-a592-4021-8a0a-c608bcc82a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c90e2a2b-44f6-4074-9954-7b566f0415fa" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_4f2160ed-9398-4159-8a3e-9431996a786a" xlink:to="loc_srt_RangeAxis_c90e2a2b-44f6-4074-9954-7b566f0415fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_684911bb-2078-4c7a-a060-3f6a33f68d0d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c90e2a2b-44f6-4074-9954-7b566f0415fa" xlink:to="loc_srt_RangeMember_684911bb-2078-4c7a-a060-3f6a33f68d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c2d9ed35-330c-44cd-b1da-548f59f3e756" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_684911bb-2078-4c7a-a060-3f6a33f68d0d" xlink:to="loc_srt_MaximumMember_c2d9ed35-330c-44cd-b1da-548f59f3e756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_WarrantsAxis_86a16f4d-4222-47d4-9c03-7af3a2907e78" xlink:href="abvx-20251231.xsd#abvx_WarrantsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_4f2160ed-9398-4159-8a3e-9431996a786a" xlink:to="loc_abvx_WarrantsAxis_86a16f4d-4222-47d4-9c03-7af3a2907e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_WarrantsDomain_12ca03ff-7503-4b90-b035-ad5c5bd817e8" xlink:href="abvx-20251231.xsd#abvx_WarrantsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_WarrantsAxis_86a16f4d-4222-47d4-9c03-7af3a2907e78" xlink:to="loc_abvx_WarrantsDomain_12ca03ff-7503-4b90-b035-ad5c5bd817e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosCBSAMember_0cdb8b2c-ea25-4a43-9ab7-7a0b8d7dfeb6" xlink:href="abvx-20251231.xsd#abvx_KreosCBSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_WarrantsDomain_12ca03ff-7503-4b90-b035-ad5c5bd817e8" xlink:to="loc_abvx_KreosCBSAMember_0cdb8b2c-ea25-4a43-9ab7-7a0b8d7dfeb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_df586d1b-804e-4766-9c05-0db5c0a86db3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_4f2160ed-9398-4159-8a3e-9431996a786a" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_df586d1b-804e-4766-9c05-0db5c0a86db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_975fb03d-6e10-4856-ae7f-a5497e046654" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_df586d1b-804e-4766-9c05-0db5c0a86db3" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_975fb03d-6e10-4856-ae7f-a5497e046654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FreeSharesAGAMember_5b7be167-3091-4d36-ad73-eaa0b67eb602" xlink:href="abvx-20251231.xsd#abvx_FreeSharesAGAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_975fb03d-6e10-4856-ae7f-a5497e046654" xlink:to="loc_abvx_FreeSharesAGAMember_5b7be167-3091-4d36-ad73-eaa0b67eb602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_4f2160ed-9398-4159-8a3e-9431996a786a" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialAgreementAmount_8f1d6b61-436e-41ef-80fb-6163177198be" xlink:href="abvx-20251231.xsd#abvx_FinancialAgreementAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_abvx_FinancialAgreementAmount_8f1d6b61-436e-41ef-80fb-6163177198be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_2d7f681a-ff9b-42b0-a7fe-a52137b538e5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_ifrs-full_IssueOfEquity_2d7f681a-ff9b-42b0-a7fe-a52137b538e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease_b5054313-4b5f-4822-8cff-09e6825f611d" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease_b5054313-4b5f-4822-8cff-09e6825f611d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_408e3784-b477-4830-be11-49444bc76dd6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_ifrs-full_ParValuePerShare_408e3784-b477-4830-be11-49444bc76dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EquityIssuancePercentageOfCurrentShareCapital_8be79708-cc76-47ab-ae73-01e0e6f515c2" xlink:href="abvx-20251231.xsd#abvx_EquityIssuancePercentageOfCurrentShareCapital"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_abvx_EquityIssuancePercentageOfCurrentShareCapital_8be79708-cc76-47ab-ae73-01e0e6f515c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EquityIssuanceSubscriptionPricePerShare_0cfede77-0f98-487d-8d3c-7194f452586d" xlink:href="abvx-20251231.xsd#abvx_EquityIssuanceSubscriptionPricePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_abvx_EquityIssuanceSubscriptionPricePerShare_0cfede77-0f98-487d-8d3c-7194f452586d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_0aad9077-dc6e-4ae8-9718-e333ee2b5cbc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_0aad9077-dc6e-4ae8-9718-e333ee2b5cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfOtherShareWarrantsRepurchased_1931ed97-a3d6-4f31-bb45-7ce49ff73834" xlink:href="abvx-20251231.xsd#abvx_NumberOfOtherShareWarrantsRepurchased"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_abvx_NumberOfOtherShareWarrantsRepurchased_1931ed97-a3d6-4f31-bb45-7ce49ff73834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants_1e2cb7bc-f329-454e-a1a5-80d58010348f" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants_1e2cb7bc-f329-454e-a1a5-80d58010348f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfShareBasedCompensationPlansIssued_b3df8840-47a9-4c3b-a74a-d336f0ae0c7d" xlink:href="abvx-20251231.xsd#abvx_NumberOfShareBasedCompensationPlansIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_abvx_NumberOfShareBasedCompensationPlansIssued_b3df8840-47a9-4c3b-a74a-d336f0ae0c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_b71d0cc6-61b9-4e20-a592-3909efb31778" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_b71d0cc6-61b9-4e20-a592-3909efb31778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialAgreementNumberOfTransactions_9b2dc97f-ac6f-4133-9bb8-e440853393dd" xlink:href="abvx-20251231.xsd#abvx_FinancialAgreementNumberOfTransactions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_abvx_FinancialAgreementNumberOfTransactions_9b2dc97f-ac6f-4133-9bb8-e440853393dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsMaximumBorrowingCapacity_9cb21027-4e5a-4508-abe2-e69dd0d00f91" xlink:href="abvx-20251231.xsd#abvx_BorrowingsMaximumBorrowingCapacity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_abvx_BorrowingsMaximumBorrowingCapacity_9cb21027-4e5a-4508-abe2-e69dd0d00f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AggregateExercisePriceOtherEquityInstrumentsGranted_87fb5006-fc49-4dac-9608-d4fc67a58812" xlink:href="abvx-20251231.xsd#abvx_AggregateExercisePriceOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_abvx_AggregateExercisePriceOtherEquityInstrumentsGranted_87fb5006-fc49-4dac-9608-d4fc67a58812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_db06c5d7-9d0d-415d-8e4f-aa7f20b848f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_db06c5d7-9d0d-415d-8e4f-aa7f20b848f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepaymentsOfConvertibleLoansNotes_d49bdc38-9303-47b7-ae8a-94f53cfe5308" xlink:href="abvx-20251231.xsd#abvx_RepaymentsOfConvertibleLoansNotes"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_abvx_RepaymentsOfConvertibleLoansNotes_d49bdc38-9303-47b7-ae8a-94f53cfe5308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ProceedsFromBorrowingsNetOfRefinancingOfExistingIndebteness_62cf4cec-17aa-431a-b8d7-9a4982ad07f6" xlink:href="abvx-20251231.xsd#abvx_ProceedsFromBorrowingsNetOfRefinancingOfExistingIndebteness"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_abvx_ProceedsFromBorrowingsNetOfRefinancingOfExistingIndebteness_62cf4cec-17aa-431a-b8d7-9a4982ad07f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IssuanceOfOtherShareWarrants_ae4e37bb-78f5-4e2b-b08d-fa1f4509bb75" xlink:href="abvx-20251231.xsd#abvx_IssuanceOfOtherShareWarrants"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_abvx_IssuanceOfOtherShareWarrants_ae4e37bb-78f5-4e2b-b08d-fa1f4509bb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfSharesReceivedPerADS_6267e321-f19d-4382-b743-6cc6e7365ff4" xlink:href="abvx-20251231.xsd#abvx_NumberOfSharesReceivedPerADS"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_abvx_NumberOfSharesReceivedPerADS_6267e321-f19d-4382-b743-6cc6e7365ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IssueOfEquityOfferingPricePerShare_a351f9af-52e4-441b-97bb-b460e515d994" xlink:href="abvx-20251231.xsd#abvx_IssueOfEquityOfferingPricePerShare"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_abvx_IssueOfEquityOfferingPricePerShare_a351f9af-52e4-441b-97bb-b460e515d994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_caaf49b4-b8ae-4d51-887e-37a6895c2e72" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_caaf49b4-b8ae-4d51-887e-37a6895c2e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants_301d71dd-5f07-4e85-8589-c05a4c915690" xlink:href="abvx-20251231.xsd#abvx_ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_abvx_ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants_301d71dd-5f07-4e85-8589-c05a4c915690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts_1ca917fa-0b76-4fd5-b189-7a6f113c6011" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cafd87af-5da2-4641-a0b0-39392db3550b" xlink:to="loc_ifrs-full_PaymentsForShareIssueCosts_1ca917fa-0b76-4fd5-b189-7a6f113c6011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details" xlink:type="simple" xlink:href="abvx-20251231.xsd#SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AccountingPrinciplesAbstract_e6d8e56a-b4b7-467f-9e17-0ba7b75ac90b" xlink:href="abvx-20251231.xsd#abvx_AccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_8ac2c0c6-1416-45a2-8c01-ebe7609ccfec" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_e6d8e56a-b4b7-467f-9e17-0ba7b75ac90b" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_8ac2c0c6-1416-45a2-8c01-ebe7609ccfec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_51582bdc-32ef-4749-aa04-d5b2cae0beb4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_8ac2c0c6-1416-45a2-8c01-ebe7609ccfec" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_51582bdc-32ef-4749-aa04-d5b2cae0beb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_01f2dc4b-0792-4a7a-a0be-20232fa9a1b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_51582bdc-32ef-4749-aa04-d5b2cae0beb4" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_01f2dc4b-0792-4a7a-a0be-20232fa9a1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA2024Member_7dc4b2d8-d003-4493-a44c-55374801634f" xlink:href="abvx-20251231.xsd#abvx_AGA2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_01f2dc4b-0792-4a7a-a0be-20232fa9a1b0" xlink:to="loc_abvx_AGA2024Member_7dc4b2d8-d003-4493-a44c-55374801634f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20246Member_1a5794d5-2d46-46d3-8156-3735deb4ffa6" xlink:href="abvx-20251231.xsd#abvx_AGA20246Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_01f2dc4b-0792-4a7a-a0be-20232fa9a1b0" xlink:to="loc_abvx_AGA20246Member_1a5794d5-2d46-46d3-8156-3735deb4ffa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20241Member_f02ff7ef-f028-4f3a-b73d-c2b1783a35b9" xlink:href="abvx-20251231.xsd#abvx_BSA20241Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_01f2dc4b-0792-4a7a-a0be-20232fa9a1b0" xlink:to="loc_abvx_BSA20241Member_f02ff7ef-f028-4f3a-b73d-c2b1783a35b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesAxis_fb6ef457-c6fd-459a-b68d-205708d2c7cb" xlink:href="abvx-20251231.xsd#abvx_TranchesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_8ac2c0c6-1416-45a2-8c01-ebe7609ccfec" xlink:to="loc_abvx_TranchesAxis_fb6ef457-c6fd-459a-b68d-205708d2c7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesDomain_a99b33ce-454e-4d90-9f38-5b9ae17cc668" xlink:href="abvx-20251231.xsd#abvx_TranchesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_TranchesAxis_fb6ef457-c6fd-459a-b68d-205708d2c7cb" xlink:to="loc_abvx_TranchesDomain_a99b33ce-454e-4d90-9f38-5b9ae17cc668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheOneMember_ca613633-c968-4916-888c-f38a14e7da1e" xlink:href="abvx-20251231.xsd#abvx_TrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_TranchesDomain_a99b33ce-454e-4d90-9f38-5b9ae17cc668" xlink:to="loc_abvx_TrancheOneMember_ca613633-c968-4916-888c-f38a14e7da1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheTwoMember_4adaa04d-2473-4958-ba28-d5b6c013f823" xlink:href="abvx-20251231.xsd#abvx_TrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_TranchesDomain_a99b33ce-454e-4d90-9f38-5b9ae17cc668" xlink:to="loc_abvx_TrancheTwoMember_4adaa04d-2473-4958-ba28-d5b6c013f823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheThreeMember_5a4f1005-5aef-40a2-91fa-0ee8525dd5ae" xlink:href="abvx-20251231.xsd#abvx_TrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_TranchesDomain_a99b33ce-454e-4d90-9f38-5b9ae17cc668" xlink:to="loc_abvx_TrancheThreeMember_5a4f1005-5aef-40a2-91fa-0ee8525dd5ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_f737c7c6-4827-445e-9e72-40045f243f8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_8ac2c0c6-1416-45a2-8c01-ebe7609ccfec" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_f737c7c6-4827-445e-9e72-40045f243f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_891bce34-cc65-40a8-b2f0-15f836783a74" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_f737c7c6-4827-445e-9e72-40045f243f8a" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_891bce34-cc65-40a8-b2f0-15f836783a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheBMember_d25eee13-9de1-43ec-9d7a-66db54ae1f58" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheBMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_891bce34-cc65-40a8-b2f0-15f836783a74" xlink:to="loc_abvx_KreosClaretFinancingTrancheBMember_d25eee13-9de1-43ec-9d7a-66db54ae1f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheCMember_89ef56c2-1aac-4a7c-b49d-bfff813b9cb5" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_891bce34-cc65-40a8-b2f0-15f836783a74" xlink:to="loc_abvx_KreosClaretFinancingTrancheCMember_89ef56c2-1aac-4a7c-b49d-bfff813b9cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheBAndCMember_64fc0902-24d7-43a8-ad55-e5a8f3a459a1" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheBAndCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_891bce34-cc65-40a8-b2f0-15f836783a74" xlink:to="loc_abvx_KreosClaretFinancingTrancheBAndCMember_64fc0902-24d7-43a8-ad55-e5a8f3a459a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_51c3c5e1-78c2-4fd0-a8e6-d4c176341d36" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_8ac2c0c6-1416-45a2-8c01-ebe7609ccfec" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_51c3c5e1-78c2-4fd0-a8e6-d4c176341d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_159a014c-d774-4d09-bb2c-892fabbfa1a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_51c3c5e1-78c2-4fd0-a8e6-d4c176341d36" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_159a014c-d774-4d09-bb2c-892fabbfa1a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RNPVIRConditionalAdvanceBPIMember_cd27b71f-f3f2-4aed-9347-6cecaae4fd63" xlink:href="abvx-20251231.xsd#abvx_RNPVIRConditionalAdvanceBPIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_159a014c-d774-4d09-bb2c-892fabbfa1a8" xlink:to="loc_abvx_RNPVIRConditionalAdvanceBPIMember_cd27b71f-f3f2-4aed-9347-6cecaae4fd63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CARENAConditionalAdvanceBPIMember_ce919239-7900-4ce4-858e-c39e3257b9cc" xlink:href="abvx-20251231.xsd#abvx_CARENAConditionalAdvanceBPIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_159a014c-d774-4d09-bb2c-892fabbfa1a8" xlink:to="loc_abvx_CARENAConditionalAdvanceBPIMember_ce919239-7900-4ce4-858e-c39e3257b9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RNPVIRConditionalAdvanceBPIAndCARENAConditionalAdvanceBPIMember_23e63341-60d4-49ca-ba60-1479122b9848" xlink:href="abvx-20251231.xsd#abvx_RNPVIRConditionalAdvanceBPIAndCARENAConditionalAdvanceBPIMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_159a014c-d774-4d09-bb2c-892fabbfa1a8" xlink:to="loc_abvx_RNPVIRConditionalAdvanceBPIAndCARENAConditionalAdvanceBPIMember_23e63341-60d4-49ca-ba60-1479122b9848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SaleOfStockAxis_5bf3019f-0075-482b-b9fd-2e655f146f40" xlink:href="abvx-20251231.xsd#abvx_SaleOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_8ac2c0c6-1416-45a2-8c01-ebe7609ccfec" xlink:to="loc_abvx_SaleOfStockAxis_5bf3019f-0075-482b-b9fd-2e655f146f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SaleOfStockDomain_857307c1-09d7-4d8c-9027-1103349efa34" xlink:href="abvx-20251231.xsd#abvx_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_SaleOfStockAxis_5bf3019f-0075-482b-b9fd-2e655f146f40" xlink:to="loc_abvx_SaleOfStockDomain_857307c1-09d7-4d8c-9027-1103349efa34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AtTheMarketATMProgramMember_38e54fc7-4a55-4735-a288-e520dc42b723" xlink:href="abvx-20251231.xsd#abvx_AtTheMarketATMProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_SaleOfStockDomain_857307c1-09d7-4d8c-9027-1103349efa34" xlink:to="loc_abvx_AtTheMarketATMProgramMember_38e54fc7-4a55-4735-a288-e520dc42b723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_5fc8bf59-7fd4-47e0-b270-ecd573debcdf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_8ac2c0c6-1416-45a2-8c01-ebe7609ccfec" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_5fc8bf59-7fd4-47e0-b270-ecd573debcdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfFreeSharesPlansIssued_f0704c72-c7d7-4ddc-8bfd-f0bc87a8fb9a" xlink:href="abvx-20251231.xsd#abvx_NumberOfFreeSharesPlansIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_5fc8bf59-7fd4-47e0-b270-ecd573debcdf" xlink:to="loc_abvx_NumberOfFreeSharesPlansIssued_f0704c72-c7d7-4ddc-8bfd-f0bc87a8fb9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_9a6d37bd-d97b-462b-943c-ee08bff4e0c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_5fc8bf59-7fd4-47e0-b270-ecd573debcdf" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_9a6d37bd-d97b-462b-943c-ee08bff4e0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage_a01f4d89-4f36-4c4d-a4fb-42063d7b9931" xlink:href="abvx-20251231.xsd#abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_5fc8bf59-7fd4-47e0-b270-ecd573debcdf" xlink:to="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage_a01f4d89-4f36-4c4d-a4fb-42063d7b9931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_5946f9e7-6930-4e9a-9a75-7f27d12c884e" xlink:href="abvx-20251231.xsd#abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_5fc8bf59-7fd4-47e0-b270-ecd573debcdf" xlink:to="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_5946f9e7-6930-4e9a-9a75-7f27d12c884e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_9a251a40-7208-4585-b741-f55f4ee80e90" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_5fc8bf59-7fd4-47e0-b270-ecd573debcdf" xlink:to="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_9a251a40-7208-4585-b741-f55f4ee80e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsMaximumBorrowingCapacity_42a531ce-1383-4cb5-ba7a-48aaaf026381" xlink:href="abvx-20251231.xsd#abvx_BorrowingsMaximumBorrowingCapacity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_5fc8bf59-7fd4-47e0-b270-ecd573debcdf" xlink:to="loc_abvx_BorrowingsMaximumBorrowingCapacity_42a531ce-1383-4cb5-ba7a-48aaaf026381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_c3abb54a-46a6-4913-90a1-e3d54d62c619" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_5fc8bf59-7fd4-47e0-b270-ecd573debcdf" xlink:to="loc_ifrs-full_ParValuePerShare_c3abb54a-46a6-4913-90a1-e3d54d62c619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ProceedsFromConditionalAdvances_120e7152-b9fb-4807-88ad-12d2d6025d7e" xlink:href="abvx-20251231.xsd#abvx_ProceedsFromConditionalAdvances"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_5fc8bf59-7fd4-47e0-b270-ecd573debcdf" xlink:to="loc_abvx_ProceedsFromConditionalAdvances_120e7152-b9fb-4807-88ad-12d2d6025d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities_ba95cc77-a0e5-45a5-bf9d-cf6e3baacc8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_5fc8bf59-7fd4-47e0-b270-ecd573debcdf" xlink:to="loc_ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities_ba95cc77-a0e5-45a5-bf9d-cf6e3baacc8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PercentageOfConditionalAdvancesWaived_9981f06a-0dba-495c-93a8-288699cfe73d" xlink:href="abvx-20251231.xsd#abvx_PercentageOfConditionalAdvancesWaived"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_5fc8bf59-7fd4-47e0-b270-ecd573debcdf" xlink:to="loc_abvx_PercentageOfConditionalAdvancesWaived_9981f06a-0dba-495c-93a8-288699cfe73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromGovernmentGrants_4edcf9cf-48fd-44da-b7b6-a577eb90f592" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_5fc8bf59-7fd4-47e0-b270-ecd573debcdf" xlink:to="loc_ifrs-full_RevenueFromGovernmentGrants_4edcf9cf-48fd-44da-b7b6-a577eb90f592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfADSPerOrdinaryShares_4ec551c6-67d8-4e64-93a6-e1cb190b2c6b" xlink:href="abvx-20251231.xsd#abvx_NumberOfADSPerOrdinaryShares"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_5fc8bf59-7fd4-47e0-b270-ecd573debcdf" xlink:to="loc_abvx_NumberOfADSPerOrdinaryShares_4ec551c6-67d8-4e64-93a6-e1cb190b2c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpectedProceedsFromShareIssuance_e3438e42-66e8-4fed-a5b7-a25049a33b13" xlink:href="abvx-20251231.xsd#abvx_ExpectedProceedsFromShareIssuance"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_5fc8bf59-7fd4-47e0-b270-ecd573debcdf" xlink:to="loc_abvx_ExpectedProceedsFromShareIssuance_e3438e42-66e8-4fed-a5b7-a25049a33b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpectedProceedsFromShareIssuanceShelfRegistration_e2757e53-8000-4aa9-aa8b-3f73f6c176b6" xlink:href="abvx-20251231.xsd#abvx_ExpectedProceedsFromShareIssuanceShelfRegistration"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_5fc8bf59-7fd4-47e0-b270-ecd573debcdf" xlink:to="loc_abvx_ExpectedProceedsFromShareIssuanceShelfRegistration_e2757e53-8000-4aa9-aa8b-3f73f6c176b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details" xlink:type="simple" xlink:href="abvx-20251231.xsd#SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AccountingPrinciplesAbstract_6669a25f-9141-49b2-862b-38f5669ac5ff" xlink:href="abvx-20251231.xsd#abvx_AccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019beae7-6ccc-7a24-8454-790efec75929" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_6669a25f-9141-49b2-862b-38f5669ac5ff" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019beae7-6ccc-7a24-8454-790efec75929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019beae7-6ccc-72c2-bc77-4407f8420694" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019beae7-6ccc-7a24-8454-790efec75929" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019beae7-6ccc-72c2-bc77-4407f8420694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019beae7-6ccc-78b8-962b-256576f0b913" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019beae7-6ccc-72c2-bc77-4407f8420694" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019beae7-6ccc-78b8-962b-256576f0b913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ShareSubscriptionWarrantsBSAMember_019beae7-6ccc-783a-977a-6180c16723b3" xlink:href="abvx-20251231.xsd#abvx_ShareSubscriptionWarrantsBSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019beae7-6ccc-78b8-962b-256576f0b913" xlink:to="loc_abvx_ShareSubscriptionWarrantsBSAMember_019beae7-6ccc-783a-977a-6180c16723b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA2025Member_019beae7-6ccc-78a9-a5bf-e0d9be16f179" xlink:href="abvx-20251231.xsd#abvx_AGA2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019beae7-6ccc-78b8-962b-256576f0b913" xlink:to="loc_abvx_AGA2025Member_019beae7-6ccc-78a9-a5bf-e0d9be16f179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20252Member_019beae7-6ccc-7672-be26-7289d0b37b10" xlink:href="abvx-20251231.xsd#abvx_AGA20252Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019beae7-6ccc-78b8-962b-256576f0b913" xlink:to="loc_abvx_AGA20252Member_019beae7-6ccc-7672-be26-7289d0b37b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20255Member_019beae7-6ccc-777d-8748-a2c3221cba69" xlink:href="abvx-20251231.xsd#abvx_AGA20255Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019beae7-6ccc-78b8-962b-256576f0b913" xlink:to="loc_abvx_AGA20255Member_019beae7-6ccc-777d-8748-a2c3221cba69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20251Member_019beae7-6ccc-7dd0-b7e7-8f8cd4aea026" xlink:href="abvx-20251231.xsd#abvx_AGA20251Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019beae7-6ccc-78b8-962b-256576f0b913" xlink:to="loc_abvx_AGA20251Member_019beae7-6ccc-7dd0-b7e7-8f8cd4aea026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_019beae7-6ccc-737f-9858-58742dc2ad97" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019beae7-6ccc-7a24-8454-790efec75929" xlink:to="loc_srt_TitleOfIndividualAxis_019beae7-6ccc-737f-9858-58742dc2ad97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019beae7-6ccc-7454-9dd1-9b51a83a2bb7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_019beae7-6ccc-737f-9858-58742dc2ad97" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019beae7-6ccc-7454-9dd1-9b51a83a2bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BoardMemberMember_019beae7-6ccc-78b3-aaf5-037e9eb4142e" xlink:href="abvx-20251231.xsd#abvx_BoardMemberMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019beae7-6ccc-7454-9dd1-9b51a83a2bb7" xlink:to="loc_abvx_BoardMemberMember_019beae7-6ccc-78b3-aaf5-037e9eb4142e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesAxis_019beae7-6ccc-779f-a3da-d8d1e3ccb0e5" xlink:href="abvx-20251231.xsd#abvx_TranchesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019beae7-6ccc-7a24-8454-790efec75929" xlink:to="loc_abvx_TranchesAxis_019beae7-6ccc-779f-a3da-d8d1e3ccb0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesDomain_019beae7-6ccc-7910-aced-3fef8e457739" xlink:href="abvx-20251231.xsd#abvx_TranchesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_TranchesAxis_019beae7-6ccc-779f-a3da-d8d1e3ccb0e5" xlink:to="loc_abvx_TranchesDomain_019beae7-6ccc-7910-aced-3fef8e457739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheOneMember_019beae7-6ccc-792b-8deb-6a3ec85d5b1b" xlink:href="abvx-20251231.xsd#abvx_TrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_TranchesDomain_019beae7-6ccc-7910-aced-3fef8e457739" xlink:to="loc_abvx_TrancheOneMember_019beae7-6ccc-792b-8deb-6a3ec85d5b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheTwoMember_019beae7-6ccc-7e88-988d-657b9a66a580" xlink:href="abvx-20251231.xsd#abvx_TrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_TranchesDomain_019beae7-6ccc-7910-aced-3fef8e457739" xlink:to="loc_abvx_TrancheTwoMember_019beae7-6ccc-7e88-988d-657b9a66a580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheThreeMember_019beae7-6ccc-77e9-928c-153784076a25" xlink:href="abvx-20251231.xsd#abvx_TrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_TranchesDomain_019beae7-6ccc-7910-aced-3fef8e457739" xlink:to="loc_abvx_TrancheThreeMember_019beae7-6ccc-77e9-928c-153784076a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_019beae9-d416-74d2-bbf7-dec2ee122c9d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019beae7-6ccc-7a24-8454-790efec75929" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_019beae9-d416-74d2-bbf7-dec2ee122c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019beae9-d416-70a6-b96e-afe18a5d5960" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019beae9-d416-74d2-bbf7-dec2ee122c9d" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019beae9-d416-70a6-b96e-afe18a5d5960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_HeightsConvertibleNotesMember_019beae9-d416-7e5b-8ef9-6455466c0467" xlink:href="abvx-20251231.xsd#abvx_HeightsConvertibleNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019beae9-d416-70a6-b96e-afe18a5d5960" xlink:to="loc_abvx_HeightsConvertibleNotesMember_019beae9-d416-7e5b-8ef9-6455466c0467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheAMember_019beae9-d416-740a-b00a-8208ac4028bc" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019beae9-d416-70a6-b96e-afe18a5d5960" xlink:to="loc_abvx_KreosClaretFinancingTrancheAMember_019beae9-d416-740a-b00a-8208ac4028bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosABCBSAMember_019beae9-d416-7d0c-949a-b843769e76d0" xlink:href="abvx-20251231.xsd#abvx_KreosABCBSAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019beae9-d416-70a6-b96e-afe18a5d5960" xlink:to="loc_abvx_KreosABCBSAMember_019beae9-d416-7d0c-949a-b843769e76d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingBAndCMember_019c4350-fd31-774c-9664-d81f4883a6c6" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingBAndCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019beae9-d416-70a6-b96e-afe18a5d5960" xlink:to="loc_abvx_KreosClaretFinancingBAndCMember_019c4350-fd31-774c-9664-d81f4883a6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_019beae9-d416-7faf-9ada-fd3445ec4c3f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019beae7-6ccc-7a24-8454-790efec75929" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_019beae9-d416-7faf-9ada-fd3445ec4c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_019beae9-d416-79d4-8672-2b4c73b1be67" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_019beae9-d416-7faf-9ada-fd3445ec4c3f" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_019beae9-d416-79d4-8672-2b4c73b1be67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AmericanDepositorySharesMember_019beae9-f264-7bb7-ad1e-0bf70a0ac702" xlink:href="abvx-20251231.xsd#abvx_AmericanDepositorySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_019beae9-d416-79d4-8672-2b4c73b1be67" xlink:to="loc_abvx_AmericanDepositorySharesMember_019beae9-f264-7bb7-ad1e-0bf70a0ac702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_019beae9-d416-77e2-b903-c9f9d88e741b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_019beae9-d416-79d4-8672-2b4c73b1be67" xlink:to="loc_ifrs-full_OrdinarySharesMember_019beae9-d416-77e2-b903-c9f9d88e741b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019beae7-6ccc-7a24-8454-790efec75929" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_019beae7-6ccc-75a5-bbca-241480c59f9c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_019beae7-6ccc-75a5-bbca-241480c59f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_019beae7-6ccc-70db-8b79-1ae3c2fe19c8" xlink:href="abvx-20251231.xsd#abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:to="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_019beae7-6ccc-70db-8b79-1ae3c2fe19c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage_019beae7-6ccc-731a-bbf7-999e4ec5b59b" xlink:href="abvx-20251231.xsd#abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:to="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage_019beae7-6ccc-731a-bbf7-999e4ec5b59b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfFreeSharesPlansIssued_019beae7-6ccc-726f-93b1-2c039ca9687c" xlink:href="abvx-20251231.xsd#abvx_NumberOfFreeSharesPlansIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:to="loc_abvx_NumberOfFreeSharesPlansIssued_019beae7-6ccc-726f-93b1-2c039ca9687c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SharePrice1_019beae9-0f2a-7f6d-ba93-f956cc92553b" xlink:href="abvx-20251231.xsd#abvx_SharePrice1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:to="loc_abvx_SharePrice1_019beae9-0f2a-7f6d-ba93-f956cc92553b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_019beae9-d416-7e0c-9018-d43e5dd65a71" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:to="loc_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_019beae9-d416-7e0c-9018-d43e5dd65a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IssueOfEquityOfferingPricePerShare_019beae9-f264-77df-ba76-a04a73f703b1" xlink:href="abvx-20251231.xsd#abvx_IssueOfEquityOfferingPricePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:to="loc_abvx_IssueOfEquityOfferingPricePerShare_019beae9-f264-77df-ba76-a04a73f703b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate_019beae9-f264-7b75-a9f6-cc32ec1cf61d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClosingForeignExchangeRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:to="loc_ifrs-full_ClosingForeignExchangeRate_019beae9-f264-7b75-a9f6-cc32ec1cf61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_019beae9-f264-7e53-8306-72dda9862dee" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_019beae9-f264-7e53-8306-72dda9862dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NetProceedsFromIssueOfOrdinaryShares_019beae9-f264-78f3-b9cd-b6618fd09ce2" xlink:href="abvx-20251231.xsd#abvx_NetProceedsFromIssueOfOrdinaryShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:to="loc_abvx_NetProceedsFromIssueOfOrdinaryShares_019beae9-f264-78f3-b9cd-b6618fd09ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingOtherEquityInstruments_019beae9-f264-7c52-ac40-d6241b5e91e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssuingOtherEquityInstruments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:to="loc_ifrs-full_ProceedsFromIssuingOtherEquityInstruments_019beae9-f264-7c52-ac40-d6241b5e91e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfConvertibleNotesConverted_019beae9-d416-7ba4-97d7-6cc889342499" xlink:href="abvx-20251231.xsd#abvx_NumberOfConvertibleNotesConverted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:to="loc_abvx_NumberOfConvertibleNotesConverted_019beae9-d416-7ba4-97d7-6cc889342499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_019beae9-d416-7008-a8e9-02a31311f8d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotionalAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:to="loc_ifrs-full_NotionalAmount_019beae9-d416-7008-a8e9-02a31311f8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsFixedConversionPrice_019beae9-d416-7539-a8fd-7b723075c344" xlink:href="abvx-20251231.xsd#abvx_BorrowingsFixedConversionPrice"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:to="loc_abvx_BorrowingsFixedConversionPrice_019beae9-d416-7539-a8fd-7b723075c344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_019c434f-4789-7cd8-8089-4fd76d189379" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019beae7-6ccc-709e-afbd-8db8e488e804" xlink:to="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_019c434f-4789-7cd8-8089-4fd76d189379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AccountingPrinciplesAbstract_019cc30e-da52-7913-b17c-4dfa1ccdbdb5" xlink:href="abvx-20251231.xsd#abvx_AccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019cc310-7e3e-7fa3-99c2-f893b022fa45" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_019cc30e-da52-7913-b17c-4dfa1ccdbdb5" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019cc310-7e3e-7fa3-99c2-f893b022fa45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_019cc310-7e3e-75be-a2fd-6c43d009b905" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019cc310-7e3e-7fa3-99c2-f893b022fa45" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_019cc310-7e3e-75be-a2fd-6c43d009b905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_019cc310-7e3e-7831-9c77-e4dc45955268" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_019cc310-7e3e-75be-a2fd-6c43d009b905" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_019cc310-7e3e-7831-9c77-e4dc45955268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_MajorShareBasedTransactionsMember_019cc310-7e3e-7fcc-a08c-9776db2751e1" xlink:href="abvx-20251231.xsd#abvx_MajorShareBasedTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_019cc310-7e3e-7831-9c77-e4dc45955268" xlink:to="loc_abvx_MajorShareBasedTransactionsMember_019cc310-7e3e-7fcc-a08c-9776db2751e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CSOSettlementAgreementMember_019cf67d-61f0-7afa-aa51-54e74e204290" xlink:href="abvx-20251231.xsd#abvx_CSOSettlementAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_019cc310-7e3e-7831-9c77-e4dc45955268" xlink:to="loc_abvx_CSOSettlementAgreementMember_019cf67d-61f0-7afa-aa51-54e74e204290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019cc310-7e3e-7e57-822a-268a31b83ac6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019cc310-7e3e-7fa3-99c2-f893b022fa45" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019cc310-7e3e-7e57-822a-268a31b83ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019cc310-7e3e-7a7f-a7df-4a3a7e02ace7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019cc310-7e3e-7e57-822a-268a31b83ac6" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019cc310-7e3e-7a7f-a7df-4a3a7e02ace7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FreeSharesAGAMember_019cc311-13dd-7262-a8bd-33d9223aa097" xlink:href="abvx-20251231.xsd#abvx_FreeSharesAGAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019cc310-7e3e-7a7f-a7df-4a3a7e02ace7" xlink:to="loc_abvx_FreeSharesAGAMember_019cc311-13dd-7262-a8bd-33d9223aa097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ShareSubscriptionWarrantsBSAMember_019cfbac-e289-7246-a765-ceab850e49c7" xlink:href="abvx-20251231.xsd#abvx_ShareSubscriptionWarrantsBSAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019cc310-7e3e-7a7f-a7df-4a3a7e02ace7" xlink:to="loc_abvx_ShareSubscriptionWarrantsBSAMember_019cfbac-e289-7246-a765-ceab850e49c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesAxis_019cc310-7e3e-79c4-970b-b8c4fab8a7e2" xlink:href="abvx-20251231.xsd#abvx_TranchesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019cc310-7e3e-7fa3-99c2-f893b022fa45" xlink:to="loc_abvx_TranchesAxis_019cc310-7e3e-79c4-970b-b8c4fab8a7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesDomain_019cc310-7e3e-7ba1-9bdd-7fe3cf8977d7" xlink:href="abvx-20251231.xsd#abvx_TranchesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_TranchesAxis_019cc310-7e3e-79c4-970b-b8c4fab8a7e2" xlink:to="loc_abvx_TranchesDomain_019cc310-7e3e-7ba1-9bdd-7fe3cf8977d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheOneMember_019cc310-7e3e-7c17-ae22-024a7b8a6722" xlink:href="abvx-20251231.xsd#abvx_TrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_TranchesDomain_019cc310-7e3e-7ba1-9bdd-7fe3cf8977d7" xlink:to="loc_abvx_TrancheOneMember_019cc310-7e3e-7c17-ae22-024a7b8a6722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheTwoMember_019cc310-7e3e-71db-966a-1b4eed96bdf8" xlink:href="abvx-20251231.xsd#abvx_TrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_TranchesDomain_019cc310-7e3e-7ba1-9bdd-7fe3cf8977d7" xlink:to="loc_abvx_TrancheTwoMember_019cc310-7e3e-71db-966a-1b4eed96bdf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheThreeMember_019cc310-7e3e-7e20-8304-6ec61f0a64c7" xlink:href="abvx-20251231.xsd#abvx_TrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_TranchesDomain_019cc310-7e3e-7ba1-9bdd-7fe3cf8977d7" xlink:to="loc_abvx_TrancheThreeMember_019cc310-7e3e-7e20-8304-6ec61f0a64c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_019cfbad-625a-742f-9a0b-aace8ce1ae5d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019cc310-7e3e-7fa3-99c2-f893b022fa45" xlink:to="loc_srt_TitleOfIndividualAxis_019cfbad-625a-742f-9a0b-aace8ce1ae5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019cfbad-625a-7c94-b2de-94355fb80ccb" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_019cfbad-625a-742f-9a0b-aace8ce1ae5d" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019cfbad-625a-7c94-b2de-94355fb80ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BoardMemberMember_019cfbad-625a-7984-ba13-57d9adde4a01" xlink:href="abvx-20251231.xsd#abvx_BoardMemberMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019cfbad-625a-7c94-b2de-94355fb80ccb" xlink:to="loc_abvx_BoardMemberMember_019cfbad-625a-7984-ba13-57d9adde4a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019cc310-7e3e-732d-9556-fdae2a74f98b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019cc310-7e3e-7fa3-99c2-f893b022fa45" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019cc310-7e3e-732d-9556-fdae2a74f98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_019cc310-7e3e-719d-a9c7-6a8d629f6630" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019cc310-7e3e-732d-9556-fdae2a74f98b" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_019cc310-7e3e-719d-a9c7-6a8d629f6630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage_019cc310-7e3e-7140-a5c2-96c572e08186" xlink:href="abvx-20251231.xsd#abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019cc310-7e3e-732d-9556-fdae2a74f98b" xlink:to="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage_019cc310-7e3e-7140-a5c2-96c572e08186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_019cc310-7e3e-7f77-83f3-b8ce3e0220cd" xlink:href="abvx-20251231.xsd#abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019cc310-7e3e-732d-9556-fdae2a74f98b" xlink:to="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_019cc310-7e3e-7f77-83f3-b8ce3e0220cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_019cf692-b2c9-788f-9afd-70706d534515" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019cc310-7e3e-732d-9556-fdae2a74f98b" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_019cf692-b2c9-788f-9afd-70706d534515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KeyManagementPersonnelCompensationContractualSeveranceIndemnity_019cf693-fc6e-7752-a36b-9462fa231094" xlink:href="abvx-20251231.xsd#abvx_KeyManagementPersonnelCompensationContractualSeveranceIndemnity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019cc310-7e3e-732d-9556-fdae2a74f98b" xlink:to="loc_abvx_KeyManagementPersonnelCompensationContractualSeveranceIndemnity_019cf693-fc6e-7752-a36b-9462fa231094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfSharesWaived_019cf6b6-35b3-77f4-88cd-83527ac778c4" xlink:href="abvx-20251231.xsd#abvx_NumberOfSharesWaived"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019cc310-7e3e-732d-9556-fdae2a74f98b" xlink:to="loc_abvx_NumberOfSharesWaived_019cf6b6-35b3-77f4-88cd-83527ac778c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfSharesWithPerformanceConditionsWaived_019cf6b7-2230-7d0c-9761-7eb5fb6494bd" xlink:href="abvx-20251231.xsd#abvx_NumberOfSharesWithPerformanceConditionsWaived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019cc310-7e3e-732d-9556-fdae2a74f98b" xlink:to="loc_abvx_NumberOfSharesWithPerformanceConditionsWaived_019cf6b7-2230-7d0c-9761-7eb5fb6494bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfSharesLapsed_019cf6b9-29dd-7f86-baef-2520c7ddc7c0" xlink:href="abvx-20251231.xsd#abvx_NumberOfSharesLapsed"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019cc310-7e3e-732d-9556-fdae2a74f98b" xlink:to="loc_abvx_NumberOfSharesLapsed_019cf6b9-29dd-7f86-baef-2520c7ddc7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/AccountingprinciplesIntangibleassetsDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#AccountingprinciplesIntangibleassetsDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/AccountingprinciplesIntangibleassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AccountingPrinciplesAbstract_59adc869-3734-4fa2-b6df-fd3b100e4bf7" xlink:href="abvx-20251231.xsd#abvx_AccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_6c5d5940-be46-40bd-b86d-70d08e719a8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_59adc869-3734-4fa2-b6df-fd3b100e4bf7" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_6c5d5940-be46-40bd-b86d-70d08e719a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_9b41661c-896a-4fbf-99f0-faa541b6185f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_6c5d5940-be46-40bd-b86d-70d08e719a8b" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_9b41661c-896a-4fbf-99f0-faa541b6185f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_2defbb06-2e9a-4199-b517-7a5cb73b2f3d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_9b41661c-896a-4fbf-99f0-faa541b6185f" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_2defbb06-2e9a-4199-b517-7a5cb73b2f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIntangibleAssetsMember_77d96577-9a77-441b-bef6-a41c9cc50170" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_2defbb06-2e9a-4199-b517-7a5cb73b2f3d" xlink:to="loc_ifrs-full_OtherIntangibleAssetsMember_77d96577-9a77-441b-bef6-a41c9cc50170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_e064fabd-e523-4374-848b-4f9a0a9a7e73" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_6c5d5940-be46-40bd-b86d-70d08e719a8b" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_e064fabd-e523-4374-848b-4f9a0a9a7e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ResearchAndDevelopmentCostsRecognitionInitialMeasurementNumberOfCriterias_3b9228f6-ab28-441d-b3d2-1232041967d4" xlink:href="abvx-20251231.xsd#abvx_ResearchAndDevelopmentCostsRecognitionInitialMeasurementNumberOfCriterias"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_e064fabd-e523-4374-848b-4f9a0a9a7e73" xlink:to="loc_abvx_ResearchAndDevelopmentCostsRecognitionInitialMeasurementNumberOfCriterias_3b9228f6-ab28-441d-b3d2-1232041967d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_23283892-3cc7-4657-8468-5ebc839797ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_e064fabd-e523-4374-848b-4f9a0a9a7e73" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_23283892-3cc7-4657-8468-5ebc839797ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AccountingPrinciplesAbstract_78811b9d-3a24-46a4-a34d-70f4b50d518c" xlink:href="abvx-20251231.xsd#abvx_AccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_a9711434-40d6-4c3f-b0d1-1bd63fae70a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AccountingPrinciplesAbstract_78811b9d-3a24-46a4-a34d-70f4b50d518c" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_a9711434-40d6-4c3f-b0d1-1bd63fae70a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_99e7c1c8-10db-4252-9a21-6fba0d752284" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_a9711434-40d6-4c3f-b0d1-1bd63fae70a5" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_99e7c1c8-10db-4252-9a21-6fba0d752284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_8ec3e1c6-7dc2-4567-848b-e61f35835d4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_99e7c1c8-10db-4252-9a21-6fba0d752284" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_8ec3e1c6-7dc2-4567-848b-e61f35835d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixturesAndFittingsMember_db567e9a-93d9-4447-980c-9f6845cd9196" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FixturesAndFittingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_8ec3e1c6-7dc2-4567-848b-e61f35835d4d" xlink:to="loc_ifrs-full_FixturesAndFittingsMember_db567e9a-93d9-4447-980c-9f6845cd9196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IndustrialMaterialsAndEquipmentMember_720e5de2-db2d-4f63-9d17-c51cbe140000" xlink:href="abvx-20251231.xsd#abvx_IndustrialMaterialsAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_8ec3e1c6-7dc2-4567-848b-e61f35835d4d" xlink:to="loc_abvx_IndustrialMaterialsAndEquipmentMember_720e5de2-db2d-4f63-9d17-c51cbe140000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TechnicalFacilitiesMember_b60907f4-b276-4ca7-afaf-1394bebe1dca" xlink:href="abvx-20251231.xsd#abvx_TechnicalFacilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_8ec3e1c6-7dc2-4567-848b-e61f35835d4d" xlink:to="loc_abvx_TechnicalFacilitiesMember_b60907f4-b276-4ca7-afaf-1394bebe1dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember_3624c457-131e-45fe-9e69-94b0c29f3ab4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_8ec3e1c6-7dc2-4567-848b-e61f35835d4d" xlink:to="loc_ifrs-full_OfficeEquipmentMember_3624c457-131e-45fe-9e69-94b0c29f3ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_2a80fcbd-f2e3-4302-9645-eb4862cc780d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_8ec3e1c6-7dc2-4567-848b-e61f35835d4d" xlink:to="loc_ifrs-full_ComputerEquipmentMember_2a80fcbd-f2e3-4302-9645-eb4862cc780d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FurnitureMember_1bf3218b-c756-42a0-adbb-14b56fc8d3f1" xlink:href="abvx-20251231.xsd#abvx_FurnitureMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_8ec3e1c6-7dc2-4567-848b-e61f35835d4d" xlink:to="loc_abvx_FurnitureMember_1bf3218b-c756-42a0-adbb-14b56fc8d3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_31015c94-1bc7-4bec-9346-61d21ecdf749" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_a9711434-40d6-4c3f-b0d1-1bd63fae70a5" xlink:to="loc_ifrs-full_RangeAxis_31015c94-1bc7-4bec-9346-61d21ecdf749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_a030bbfd-23ff-4837-8c8c-68754dfd5ce3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_31015c94-1bc7-4bec-9346-61d21ecdf749" xlink:to="loc_ifrs-full_RangeDomain_a030bbfd-23ff-4837-8c8c-68754dfd5ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_455d53a5-e8df-4434-9629-21bcdbd92cc1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_a030bbfd-23ff-4837-8c8c-68754dfd5ce3" xlink:to="loc_ifrs-full_BottomOfRangeMember_455d53a5-e8df-4434-9629-21bcdbd92cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_39f9b38d-0d3e-46a3-8c44-f208e441f061" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_a030bbfd-23ff-4837-8c8c-68754dfd5ce3" xlink:to="loc_ifrs-full_TopOfRangeMember_39f9b38d-0d3e-46a3-8c44-f208e441f061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_9a14ee8e-0c9b-4c76-9b2e-9ec7e7f2e32c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_a9711434-40d6-4c3f-b0d1-1bd63fae70a5" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_9a14ee8e-0c9b-4c76-9b2e-9ec7e7f2e32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_68c97c13-57c1-4fc1-a8d2-93773336f811" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_9a14ee8e-0c9b-4c76-9b2e-9ec7e7f2e32c" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_68c97c13-57c1-4fc1-a8d2-93773336f811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/SegmentinformationDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#SegmentinformationDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/SegmentinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_65220c51-449a-4988-9adf-9946ea262ecf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable_0a68bcb0-f54b-457c-8750-4669cb8c581e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_65220c51-449a-4988-9adf-9946ea262ecf" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasTable_0a68bcb0-f54b-457c-8750-4669cb8c581e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_75667292-e3e6-498d-9bc4-324be3ac294a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_0a68bcb0-f54b-457c-8750-4669cb8c581e" xlink:to="loc_ifrs-full_GeographicalAreasAxis_75667292-e3e6-498d-9bc4-324be3ac294a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_ca416f49-4d64-4d0e-9b6e-f40273a0846c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_75667292-e3e6-498d-9bc4-324be3ac294a" xlink:to="loc_ifrs-full_GeographicalAreasDomain_ca416f49-4d64-4d0e-9b6e-f40273a0846c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_e11111b1-10fa-489e-bd42-c26e897edae8" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasDomain_ca416f49-4d64-4d0e-9b6e-f40273a0846c" xlink:to="loc_country_US_e11111b1-10fa-489e-bd42-c26e897edae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_c71f8361-be41-44ff-ad70-a45f525d02e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_0a68bcb0-f54b-457c-8750-4669cb8c581e" xlink:to="loc_ifrs-full_RangeAxis_c71f8361-be41-44ff-ad70-a45f525d02e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_97166769-1703-43e5-850b-6205a75a1d66" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_c71f8361-be41-44ff-ad70-a45f525d02e8" xlink:to="loc_ifrs-full_RangeDomain_97166769-1703-43e5-850b-6205a75a1d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_bc73afa5-0da8-4ad1-a1e5-ca2cd877b941" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_97166769-1703-43e5-850b-6205a75a1d66" xlink:to="loc_ifrs-full_TopOfRangeMember_bc73afa5-0da8-4ad1-a1e5-ca2cd877b941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_f71c2eb6-4ae0-4e54-8129-85d92ab001f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_0a68bcb0-f54b-457c-8750-4669cb8c581e" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_f71c2eb6-4ae0-4e54-8129-85d92ab001f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ContributionToGroupsLiabilitiesPercentage_3d193556-f525-4c94-ba60-0a4634272b92" xlink:href="abvx-20251231.xsd#abvx_ContributionToGroupsLiabilitiesPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_f71c2eb6-4ae0-4e54-8129-85d92ab001f7" xlink:to="loc_abvx_ContributionToGroupsLiabilitiesPercentage_3d193556-f525-4c94-ba60-0a4634272b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ContributionToGroupsNetProfitsLossesPercentage_c8ccff63-2288-406e-830b-f7b74e9a1b2f" xlink:href="abvx-20251231.xsd#abvx_ContributionToGroupsNetProfitsLossesPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_f71c2eb6-4ae0-4e54-8129-85d92ab001f7" xlink:to="loc_abvx_ContributionToGroupsNetProfitsLossesPercentage_c8ccff63-2288-406e-830b-f7b74e9a1b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ContributionToGroupsAssetsPercentage_0b3a4e60-e7f6-4dfc-82b7-2ad76fc8d404" xlink:href="abvx-20251231.xsd#abvx_ContributionToGroupsAssetsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_f71c2eb6-4ae0-4e54-8129-85d92ab001f7" xlink:to="loc_abvx_ContributionToGroupsAssetsPercentage_0b3a4e60-e7f6-4dfc-82b7-2ad76fc8d404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfOperatingSegment_3e08ce28-397d-4e72-9eef-02554cb14e0a" xlink:href="abvx-20251231.xsd#abvx_NumberOfOperatingSegment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_f71c2eb6-4ae0-4e54-8129-85d92ab001f7" xlink:to="loc_abvx_NumberOfOperatingSegment_3e08ce28-397d-4e72-9eef-02554cb14e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/GoodwillandimpairmenttestDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#GoodwillandimpairmenttestDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/GoodwillandimpairmenttestDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_62d5ddef-ba84-451f-a0e1-253f1cdcce0e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesTable_7ce07f24-7153-4d8a-a356-fa579588be69" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_62d5ddef-ba84-451f-a0e1-253f1cdcce0e" xlink:to="loc_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesTable_7ce07f24-7153-4d8a-a356-fa579588be69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis_291b2ca0-ac9f-462b-9ec4-d2e1dda6c0a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesTable_7ce07f24-7153-4d8a-a356-fa579588be69" xlink:to="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis_291b2ca0-ac9f-462b-9ec4-d2e1dda6c0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain_2c01f794-721a-4c46-95b1-ddc61f0e49b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis_291b2ca0-ac9f-462b-9ec4-d2e1dda6c0a3" xlink:to="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain_2c01f794-721a-4c46-95b1-ddc61f0e49b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_WittycelSASABX196Member_91b7cd22-5ee7-4a5b-be88-290e9cff83a9" xlink:href="abvx-20251231.xsd#abvx_WittycelSASABX196Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain_2c01f794-721a-4c46-95b1-ddc61f0e49b7" xlink:to="loc_abvx_WittycelSASABX196Member_91b7cd22-5ee7-4a5b-be88-290e9cff83a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SplicosSASABX464Member_cf042855-ca2c-47ea-924b-5c910a397ef5" xlink:href="abvx-20251231.xsd#abvx_SplicosSASABX464Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain_2c01f794-721a-4c46-95b1-ddc61f0e49b7" xlink:to="loc_abvx_SplicosSASABX464Member_cf042855-ca2c-47ea-924b-5c910a397ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems_ad67da6e-dc15-452b-a71a-def6af7158fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesTable_7ce07f24-7153-4d8a-a356-fa579588be69" xlink:to="loc_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems_ad67da6e-dc15-452b-a71a-def6af7158fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill_29c6cfd4-bcd2-4d7a-9bbb-430de6fa6229" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems_ad67da6e-dc15-452b-a71a-def6af7158fa" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill_29c6cfd4-bcd2-4d7a-9bbb-430de6fa6229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_390420e1-ebb5-403e-a5b6-7684ebfe94dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems_ad67da6e-dc15-452b-a71a-def6af7158fa" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_390420e1-ebb5-403e-a5b6-7684ebfe94dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_61668205-f84a-4d2f-9d5b-4d6e491cd8e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems_ad67da6e-dc15-452b-a71a-def6af7158fa" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_61668205-f84a-4d2f-9d5b-4d6e491cd8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_18ca5e2f-5e26-4846-83e7-3dbbf4ff037a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems_ad67da6e-dc15-452b-a71a-def6af7158fa" xlink:to="loc_ifrs-full_Goodwill_18ca5e2f-5e26-4846-83e7-3dbbf4ff037a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections_d9a131eb-661c-401e-b05a-bbea18c85042" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems_ad67da6e-dc15-452b-a71a-def6af7158fa" xlink:to="loc_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections_d9a131eb-661c-401e-b05a-bbea18c85042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/IntangibleassetsNarrativeDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#IntangibleassetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/IntangibleassetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_a397dc02-197f-4eb6-957f-f70b786ae91a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_45262169-2d94-4001-bcb2-4dc85757dc4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_a397dc02-197f-4eb6-957f-f70b786ae91a" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_45262169-2d94-4001-bcb2-4dc85757dc4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis_395b4aea-6b13-4e2e-906a-b3d771928bf9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_45262169-2d94-4001-bcb2-4dc85757dc4f" xlink:to="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis_395b4aea-6b13-4e2e-906a-b3d771928bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain_81cd9d1a-ec6c-4bda-a7ea-4dc16a59ab46" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis_395b4aea-6b13-4e2e-906a-b3d771928bf9" xlink:to="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain_81cd9d1a-ec6c-4bda-a7ea-4dc16a59ab46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_WittycelSASABX196Member_96049b93-2ddc-478c-a8b8-eea114c3dc0a" xlink:href="abvx-20251231.xsd#abvx_WittycelSASABX196Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain_81cd9d1a-ec6c-4bda-a7ea-4dc16a59ab46" xlink:to="loc_abvx_WittycelSASABX196Member_96049b93-2ddc-478c-a8b8-eea114c3dc0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PrincipalAgreementsAxis_0290f461-e78b-4104-8909-29cf81e34b10" xlink:href="abvx-20251231.xsd#abvx_PrincipalAgreementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_45262169-2d94-4001-bcb2-4dc85757dc4f" xlink:to="loc_abvx_PrincipalAgreementsAxis_0290f461-e78b-4104-8909-29cf81e34b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PrincipalAgreementsDomain_ffd8649a-8948-41dc-a0d5-6958057aa0f4" xlink:href="abvx-20251231.xsd#abvx_PrincipalAgreementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_PrincipalAgreementsAxis_0290f461-e78b-4104-8909-29cf81e34b10" xlink:to="loc_abvx_PrincipalAgreementsDomain_ffd8649a-8948-41dc-a0d5-6958057aa0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember_90fca1cd-a9e5-4082-8adb-4d056e106d40" xlink:href="abvx-20251231.xsd#abvx_ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_PrincipalAgreementsDomain_ffd8649a-8948-41dc-a0d5-6958057aa0f4" xlink:to="loc_abvx_ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember_90fca1cd-a9e5-4082-8adb-4d056e106d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember_fddab8b1-338c-4372-a1f1-1dd4580e7ff7" xlink:href="abvx-20251231.xsd#abvx_ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_PrincipalAgreementsDomain_ffd8649a-8948-41dc-a0d5-6958057aa0f4" xlink:to="loc_abvx_ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember_fddab8b1-338c-4372-a1f1-1dd4580e7ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AssetsAcquisitionsAxis_5e9b01eb-45f8-4afd-8cae-43c85efa5a19" xlink:href="abvx-20251231.xsd#abvx_AssetsAcquisitionsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_45262169-2d94-4001-bcb2-4dc85757dc4f" xlink:to="loc_abvx_AssetsAcquisitionsAxis_5e9b01eb-45f8-4afd-8cae-43c85efa5a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AssetsAcquisitionsDomain_726b1c97-3830-410b-a88b-3f6ebc2087ee" xlink:href="abvx-20251231.xsd#abvx_AssetsAcquisitionsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AssetsAcquisitionsAxis_5e9b01eb-45f8-4afd-8cae-43c85efa5a19" xlink:to="loc_abvx_AssetsAcquisitionsDomain_726b1c97-3830-410b-a88b-3f6ebc2087ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ProsynergiaMember_100463fc-1573-4373-bbe2-4cec7c5484c0" xlink:href="abvx-20251231.xsd#abvx_ProsynergiaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AssetsAcquisitionsDomain_726b1c97-3830-410b-a88b-3f6ebc2087ee" xlink:to="loc_abvx_ProsynergiaMember_100463fc-1573-4373-bbe2-4cec7c5484c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_c34c5875-f0c5-410c-b869-f38dbd456720" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_45262169-2d94-4001-bcb2-4dc85757dc4f" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_c34c5875-f0c5-410c-b869-f38dbd456720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CollaborationAgreementsDevelopmentMilestonePaymentINDApproval_ffbc8671-5dce-47f4-91df-3412c3949170" xlink:href="abvx-20251231.xsd#abvx_CollaborationAgreementsDevelopmentMilestonePaymentINDApproval"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_c34c5875-f0c5-410c-b869-f38dbd456720" xlink:to="loc_abvx_CollaborationAgreementsDevelopmentMilestonePaymentINDApproval_ffbc8671-5dce-47f4-91df-3412c3949170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife_d53f55ea-d771-4bb0-8ce5-7490b101be20" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_c34c5875-f0c5-410c-b869-f38dbd456720" xlink:to="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife_d53f55ea-d771-4bb0-8ce5-7490b101be20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_8eafd51c-14c8-4b28-9ddd-568f2a51f9a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_c34c5875-f0c5-410c-b869-f38dbd456720" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_8eafd51c-14c8-4b28-9ddd-568f2a51f9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CollaborationAgreementsDevelopmentMilestonePaymentPhase2_a5e433a1-1a87-4429-bf48-813281cc84e4" xlink:href="abvx-20251231.xsd#abvx_CollaborationAgreementsDevelopmentMilestonePaymentPhase2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_c34c5875-f0c5-410c-b869-f38dbd456720" xlink:to="loc_abvx_CollaborationAgreementsDevelopmentMilestonePaymentPhase2_a5e433a1-1a87-4429-bf48-813281cc84e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TechnologyBasedIntangibleAssetsAssetsAcquisitions_0c95c135-aca9-432f-a6d6-7ca4cde97a46" xlink:href="abvx-20251231.xsd#abvx_TechnologyBasedIntangibleAssetsAssetsAcquisitions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_c34c5875-f0c5-410c-b869-f38dbd456720" xlink:to="loc_abvx_TechnologyBasedIntangibleAssetsAssetsAcquisitions_0c95c135-aca9-432f-a6d6-7ca4cde97a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_a3347e21-d22d-4396-a11f-3525762b3654" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_9dddb4ec-a016-4402-85bd-fbd0e40d9355" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_a3347e21-d22d-4396-a11f-3525762b3654" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_9dddb4ec-a016-4402-85bd-fbd0e40d9355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_58ecf613-e94d-4ef1-99ff-ca1477076fac" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_9dddb4ec-a016-4402-85bd-fbd0e40d9355" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_58ecf613-e94d-4ef1-99ff-ca1477076fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_256e4d0c-8163-417f-91fd-5cc8ca23359b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_58ecf613-e94d-4ef1-99ff-ca1477076fac" xlink:to="loc_ifrs-full_CarryingAmountMember_256e4d0c-8163-417f-91fd-5cc8ca23359b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_b0256efb-6ae9-4283-bdb1-41623c290b0c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_256e4d0c-8163-417f-91fd-5cc8ca23359b" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_b0256efb-6ae9-4283-bdb1-41623c290b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_8ba98db0-db2d-4e0f-b67b-c8ca07a760da" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_256e4d0c-8163-417f-91fd-5cc8ca23359b" xlink:to="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_8ba98db0-db2d-4e0f-b67b-c8ca07a760da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_ee3d7914-6651-4f24-ac0b-1cf4a7c2a8f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_9dddb4ec-a016-4402-85bd-fbd0e40d9355" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_ee3d7914-6651-4f24-ac0b-1cf4a7c2a8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_013f4f13-c0e7-4563-be7e-ac0c80d6eb71" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_ee3d7914-6651-4f24-ac0b-1cf4a7c2a8f7" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_013f4f13-c0e7-4563-be7e-ac0c80d6eb71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LicencesMember_428fd6b0-0733-4a24-8c84-cc57897cada2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LicencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_013f4f13-c0e7-4563-be7e-ac0c80d6eb71" xlink:to="loc_ifrs-full_LicencesMember_428fd6b0-0733-4a24-8c84-cc57897cada2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember_a8e76dc5-4d1d-4ce6-90d3-1bf3f809c9b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_013f4f13-c0e7-4563-be7e-ac0c80d6eb71" xlink:to="loc_ifrs-full_ComputerSoftwareMember_a8e76dc5-4d1d-4ce6-90d3-1bf3f809c9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_d6755779-c8a6-4f8f-8973-305fcfbe73f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_013f4f13-c0e7-4563-be7e-ac0c80d6eb71" xlink:to="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_d6755779-c8a6-4f8f-8973-305fcfbe73f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_2b328002-ff56-48ff-820b-14f1cf8ea1b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_9dddb4ec-a016-4402-85bd-fbd0e40d9355" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_2b328002-ff56-48ff-820b-14f1cf8ea1b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_9216e72d-1f7c-4454-af69-a3b14d63be1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_2b328002-ff56-48ff-820b-14f1cf8ea1b3" xlink:to="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_9216e72d-1f7c-4454-af69-a3b14d63be1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_e2a0cdb9-214b-4be3-bff4-07a1fdefa283" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_9216e72d-1f7c-4454-af69-a3b14d63be1d" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_e2a0cdb9-214b-4be3-bff4-07a1fdefa283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_2bf9776c-efb7-41f6-a143-cf3a501c82a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_9216e72d-1f7c-4454-af69-a3b14d63be1d" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_2bf9776c-efb7-41f6-a143-cf3a501c82a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_94b8b45f-e34e-4f4b-a5e8-a6569347cdd9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_9216e72d-1f7c-4454-af69-a3b14d63be1d" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_94b8b45f-e34e-4f4b-a5e8-a6569347cdd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_72fc40f6-6d80-4d83-86a3-133023fa630c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_9216e72d-1f7c-4454-af69-a3b14d63be1d" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_72fc40f6-6d80-4d83-86a3-133023fa630c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_67bc8254-c6ba-47b5-9352-fb90ac217fd5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_4a773fee-a2bb-4eb8-8a4e-73054c5f62d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_67bc8254-c6ba-47b5-9352-fb90ac217fd5" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_4a773fee-a2bb-4eb8-8a4e-73054c5f62d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fc04495c-5dad-4a83-bc92-d04ee0d96365" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_4a773fee-a2bb-4eb8-8a4e-73054c5f62d2" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fc04495c-5dad-4a83-bc92-d04ee0d96365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_edd4f8cf-d5e4-466f-b12c-2d3225384740" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fc04495c-5dad-4a83-bc92-d04ee0d96365" xlink:to="loc_ifrs-full_CarryingAmountMember_edd4f8cf-d5e4-466f-b12c-2d3225384740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_13e98174-83a8-45e9-9657-49e52b508a99" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_edd4f8cf-d5e4-466f-b12c-2d3225384740" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_13e98174-83a8-45e9-9657-49e52b508a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_71b6b4e4-86a2-48a8-95f9-0a0804bb61e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_edd4f8cf-d5e4-466f-b12c-2d3225384740" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_71b6b4e4-86a2-48a8-95f9-0a0804bb61e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_03fd40e3-8bb2-4904-81d7-ca4146cf5b5a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_4a773fee-a2bb-4eb8-8a4e-73054c5f62d2" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_03fd40e3-8bb2-4904-81d7-ca4146cf5b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_0ae40ba1-1397-48a5-9957-8d9f6241106a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_03fd40e3-8bb2-4904-81d7-ca4146cf5b5a" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_0ae40ba1-1397-48a5-9957-8d9f6241106a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BuildingsMember_1c5bd328-8425-443d-95fa-df76e3ce57ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BuildingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_0ae40ba1-1397-48a5-9957-8d9f6241106a" xlink:to="loc_ifrs-full_BuildingsMember_1c5bd328-8425-443d-95fa-df76e3ce57ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember_019bf9cc-506f-72d9-a9fa-f2872638d9b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_0ae40ba1-1397-48a5-9957-8d9f6241106a" xlink:to="loc_ifrs-full_OfficeEquipmentMember_019bf9cc-506f-72d9-a9fa-f2872638d9b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FurnitureAndComputerEquipmentMember_59c71fef-fb02-4bfd-86bb-ce3f2b0ec6b5" xlink:href="abvx-20251231.xsd#abvx_FurnitureAndComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_0ae40ba1-1397-48a5-9957-8d9f6241106a" xlink:to="loc_abvx_FurnitureAndComputerEquipmentMember_59c71fef-fb02-4bfd-86bb-ce3f2b0ec6b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis_4d42dd46-ce68-46a1-85f0-85b34701623e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_4a773fee-a2bb-4eb8-8a4e-73054c5f62d2" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis_4d42dd46-ce68-46a1-85f0-85b34701623e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain_5c73695b-b942-4b6d-a62c-b4ca3d380771" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis_4d42dd46-ce68-46a1-85f0-85b34701623e" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain_5c73695b-b942-4b6d-a62c-b4ca3d380771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_019bf9cf-a8a5-755f-99bf-38d49debd4c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain_5c73695b-b942-4b6d-a62c-b4ca3d380771" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_019bf9cf-a8a5-755f-99bf-38d49debd4c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssetsMember_dbc0249b-d617-4f78-8505-f959a384a0c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RightofuseAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain_5c73695b-b942-4b6d-a62c-b4ca3d380771" xlink:to="loc_ifrs-full_RightofuseAssetsMember_dbc0249b-d617-4f78-8505-f959a384a0c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_7152fb62-7ec2-44c5-a7f7-0aacfe877d3f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_4a773fee-a2bb-4eb8-8a4e-73054c5f62d2" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_7152fb62-7ec2-44c5-a7f7-0aacfe877d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_41788080-0be5-413d-b967-609226b88b2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_7152fb62-7ec2-44c5-a7f7-0aacfe877d3f" xlink:to="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_41788080-0be5-413d-b967-609226b88b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_f6c16bb2-e86c-432d-a8f0-6d9763b844fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_41788080-0be5-413d-b967-609226b88b2f" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_f6c16bb2-e86c-432d-a8f0-6d9763b844fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets_e36731a8-afc8-4c15-b8d3-d778db8fe1ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_41788080-0be5-413d-b967-609226b88b2f" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets_e36731a8-afc8-4c15-b8d3-d778db8fe1ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets_d1099089-5263-4b32-8e02-9f8d3c262827" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_41788080-0be5-413d-b967-609226b88b2f" xlink:to="loc_ifrs-full_DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets_d1099089-5263-4b32-8e02-9f8d3c262827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets_bb9c32d2-c390-4f3a-ac91-2cf6a45b8aea" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_41788080-0be5-413d-b967-609226b88b2f" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets_bb9c32d2-c390-4f3a-ac91-2cf6a45b8aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets_5b780b77-defb-4387-847e-208f359b7c7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_41788080-0be5-413d-b967-609226b88b2f" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets_5b780b77-defb-4387-847e-208f359b7c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_eeeed366-6400-4baa-907a-2838807d2be7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_41788080-0be5-413d-b967-609226b88b2f" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_eeeed366-6400-4baa-907a-2838807d2be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#PropertyplantandequipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_ed70adb7-6daf-4f61-9fc2-db9b30149b3a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_08aee887-2ab3-4357-b034-3f2bdecf5feb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_ed70adb7-6daf-4f61-9fc2-db9b30149b3a" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_08aee887-2ab3-4357-b034-3f2bdecf5feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_daf30111-89c6-4824-a6af-498c8b0c2bb0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_08aee887-2ab3-4357-b034-3f2bdecf5feb" xlink:to="loc_ifrs-full_TypesOfContractsAxis_daf30111-89c6-4824-a6af-498c8b0c2bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_88778690-4275-4314-b1a9-be9238e60c25" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsAxis_daf30111-89c6-4824-a6af-498c8b0c2bb0" xlink:to="loc_ifrs-full_TypesOfContractsDomain_88778690-4275-4314-b1a9-be9238e60c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LeaseFacilitiesParisMember_114f8aff-80ac-4470-899f-fb9bebdd3da9" xlink:href="abvx-20251231.xsd#abvx_LeaseFacilitiesParisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsDomain_88778690-4275-4314-b1a9-be9238e60c25" xlink:to="loc_abvx_LeaseFacilitiesParisMember_114f8aff-80ac-4470-899f-fb9bebdd3da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_566b6da6-2bf9-4383-8f73-d4f3862922e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_08aee887-2ab3-4357-b034-3f2bdecf5feb" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_566b6da6-2bf9-4383-8f73-d4f3862922e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_752cadfa-34a6-4f76-9d43-3aedc2cc6b6b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_566b6da6-2bf9-4383-8f73-d4f3862922e4" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_752cadfa-34a6-4f76-9d43-3aedc2cc6b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BuildingsMember_f99aaf2b-64db-4855-bb50-6efddde1b200" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BuildingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_752cadfa-34a6-4f76-9d43-3aedc2cc6b6b" xlink:to="loc_ifrs-full_BuildingsMember_f99aaf2b-64db-4855-bb50-6efddde1b200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_35a4ee22-cbe8-47f3-a69f-d7931ad28cc0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_08aee887-2ab3-4357-b034-3f2bdecf5feb" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_35a4ee22-cbe8-47f3-a69f-d7931ad28cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_8126817a-e5ac-4aea-9942-1752729e2ba7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_35a4ee22-cbe8-47f3-a69f-d7931ad28cc0" xlink:to="loc_ifrs-full_RightofuseAssets_8126817a-e5ac-4aea-9942-1752729e2ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DecreaseThroughReassessmentOfLeaseTermRightOfUseAssets_cdfabcc5-8f86-4974-a7e7-fc4b5ca8e57c" xlink:href="abvx-20251231.xsd#abvx_DecreaseThroughReassessmentOfLeaseTermRightOfUseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_35a4ee22-cbe8-47f3-a69f-d7931ad28cc0" xlink:to="loc_abvx_DecreaseThroughReassessmentOfLeaseTermRightOfUseAssets_cdfabcc5-8f86-4974-a7e7-fc4b5ca8e57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#OtherfinancialassetsDisclosureofotherfinancialassetsDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract_9fb465f2-d1d0-449a-9247-878419272496" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NonCurrentAdvancesToCROContractsUndiscountedAmount_8fab24d5-fd14-4181-a724-2f59e4a2861c" xlink:href="abvx-20251231.xsd#abvx_NonCurrentAdvancesToCROContractsUndiscountedAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract_9fb465f2-d1d0-449a-9247-878419272496" xlink:to="loc_abvx_NonCurrentAdvancesToCROContractsUndiscountedAmount_8fab24d5-fd14-4181-a724-2f59e4a2861c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermDeposits_1e971687-9951-465b-9308-f11dbb850e01" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LongtermDeposits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract_9fb465f2-d1d0-449a-9247-878419272496" xlink:to="loc_ifrs-full_LongtermDeposits_1e971687-9951-465b-9308-f11dbb850e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherNonCurrentMiscellaneousFinancialAssets_889189a6-5477-442b-99e9-7290efec524e" xlink:href="abvx-20251231.xsd#abvx_OtherNonCurrentMiscellaneousFinancialAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract_9fb465f2-d1d0-449a-9247-878419272496" xlink:to="loc_abvx_OtherNonCurrentMiscellaneousFinancialAssets_889189a6-5477-442b-99e9-7290efec524e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentFinancialAssets_2c7730af-19e0-4924-abd5-82a4f243fa94" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract_9fb465f2-d1d0-449a-9247-878419272496" xlink:to="loc_ifrs-full_OtherNoncurrentFinancialAssets_2c7730af-19e0-4924-abd5-82a4f243fa94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentAdvancesToCROContracts_2bf7765d-5083-455b-8410-294924c87559" xlink:href="abvx-20251231.xsd#abvx_CurrentAdvancesToCROContracts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract_9fb465f2-d1d0-449a-9247-878419272496" xlink:to="loc_abvx_CurrentAdvancesToCROContracts_2bf7765d-5083-455b-8410-294924c87559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_a03f0448-b96c-4cd7-a137-ab57fcbf0f22" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract_9fb465f2-d1d0-449a-9247-878419272496" xlink:to="loc_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_a03f0448-b96c-4cd7-a137-ab57fcbf0f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherCurrentInvestments_231589b1-901d-4ed9-b4db-67bc4798399f" xlink:href="abvx-20251231.xsd#abvx_OtherCurrentInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract_9fb465f2-d1d0-449a-9247-878419272496" xlink:to="loc_abvx_OtherCurrentInvestments_231589b1-901d-4ed9-b4db-67bc4798399f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentFinancialAssets_9a890c32-5cb5-4f18-8c59-ecc797c61bf4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract_9fb465f2-d1d0-449a-9247-878419272496" xlink:to="loc_ifrs-full_OtherCurrentFinancialAssets_9a890c32-5cb5-4f18-8c59-ecc797c61bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinancialAssets_953b92b7-2037-4faf-80b2-3f194a8a5116" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherFinancialAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract_9fb465f2-d1d0-449a-9247-878419272496" xlink:to="loc_ifrs-full_OtherFinancialAssets_953b92b7-2037-4faf-80b2-3f194a8a5116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#OtherfinancialassetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract_411b737e-f4cb-48af-afae-cfaa20340d52" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsTable_69b1b92c-7f1d-4521-bb64-5a1d0d5010fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract_411b737e-f4cb-48af-afae-cfaa20340d52" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsTable_69b1b92c-7f1d-4521-bb64-5a1d0d5010fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_5f9b5b2b-d1f7-468c-be6b-c4ea4684b74b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_69b1b92c-7f1d-4521-bb64-5a1d0d5010fe" xlink:to="loc_ifrs-full_RangeAxis_5f9b5b2b-d1f7-468c-be6b-c4ea4684b74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_b2e4cb60-6f1e-42a5-88fb-5031c364b9b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_5f9b5b2b-d1f7-468c-be6b-c4ea4684b74b" xlink:to="loc_ifrs-full_RangeDomain_b2e4cb60-6f1e-42a5-88fb-5031c364b9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_cba50796-5cf0-4466-aca7-e67d78555d93" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_b2e4cb60-6f1e-42a5-88fb-5031c364b9b3" xlink:to="loc_ifrs-full_BottomOfRangeMember_cba50796-5cf0-4466-aca7-e67d78555d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_a65283db-6d71-4512-9a92-181696bba450" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_b2e4cb60-6f1e-42a5-88fb-5031c364b9b3" xlink:to="loc_ifrs-full_TopOfRangeMember_a65283db-6d71-4512-9a92-181696bba450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_0cc33eb0-c14a-43bd-b056-8af83102661f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_69b1b92c-7f1d-4521-bb64-5a1d0d5010fe" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_0cc33eb0-c14a-43bd-b056-8af83102661f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NonCurrentAdvancesToCROContractsUndiscountedAmount_019c524e-b46b-78c9-b595-00fa1e57fdea" xlink:href="abvx-20251231.xsd#abvx_NonCurrentAdvancesToCROContractsUndiscountedAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_0cc33eb0-c14a-43bd-b056-8af83102661f" xlink:to="loc_abvx_NonCurrentAdvancesToCROContractsUndiscountedAmount_019c524e-b46b-78c9-b595-00fa1e57fdea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DiscountRateAppliedToLongTermAdvances_e6c6270c-ba89-4748-9812-f5c16bf00974" xlink:href="abvx-20251231.xsd#abvx_DiscountRateAppliedToLongTermAdvances"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_0cc33eb0-c14a-43bd-b056-8af83102661f" xlink:to="loc_abvx_DiscountRateAppliedToLongTermAdvances_e6c6270c-ba89-4748-9812-f5c16bf00974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PaymentsForAdvancesMadeToContractResearchOrganizationsUndiscountedAmount_6986fa31-f4eb-4a18-bab5-6ba6ab864bc1" xlink:href="abvx-20251231.xsd#abvx_PaymentsForAdvancesMadeToContractResearchOrganizationsUndiscountedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_0cc33eb0-c14a-43bd-b056-8af83102661f" xlink:to="loc_abvx_PaymentsForAdvancesMadeToContractResearchOrganizationsUndiscountedAmount_6986fa31-f4eb-4a18-bab5-6ba6ab864bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesAbstract_6c7b59fd-b67b-4aeb-a416-74927a7d47a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NonCurrentPrepaidExpenses_0a392557-4836-477b-9f41-cd6e1e89b8b9" xlink:href="abvx-20251231.xsd#abvx_NonCurrentPrepaidExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_6c7b59fd-b67b-4aeb-a416-74927a7d47a6" xlink:to="loc_abvx_NonCurrentPrepaidExpenses_0a392557-4836-477b-9f41-cd6e1e89b8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentNonfinancialAssets_019c5253-f16d-7272-8768-d779e572c95f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_6c7b59fd-b67b-4aeb-a416-74927a7d47a6" xlink:to="loc_ifrs-full_OtherNoncurrentNonfinancialAssets_019c5253-f16d-7272-8768-d779e572c95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentResearchTaxCreditReceivables_6f2f7f15-45bc-4b39-8a94-afb9fed3a6ab" xlink:href="abvx-20251231.xsd#abvx_CurrentResearchTaxCreditReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_6c7b59fd-b67b-4aeb-a416-74927a7d47a6" xlink:to="loc_abvx_CurrentResearchTaxCreditReceivables_6f2f7f15-45bc-4b39-8a94-afb9fed3a6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentValueAddedTaxReceivables_df857b24-646c-443b-a119-ee33be169495" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentValueAddedTaxReceivables"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_6c7b59fd-b67b-4aeb-a416-74927a7d47a6" xlink:to="loc_ifrs-full_CurrentValueAddedTaxReceivables_df857b24-646c-443b-a119-ee33be169495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_9885e9fd-d0ce-481b-903a-acfe978276c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_6c7b59fd-b67b-4aeb-a416-74927a7d47a6" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_9885e9fd-d0ce-481b-903a-acfe978276c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentReceivablesForEmployeeBenefits_019cc31a-6424-7422-9dc5-357044744edd" xlink:href="abvx-20251231.xsd#abvx_CurrentReceivablesForEmployeeBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_6c7b59fd-b67b-4aeb-a416-74927a7d47a6" xlink:to="loc_abvx_CurrentReceivablesForEmployeeBenefits_019cc31a-6424-7422-9dc5-357044744edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentReceivablesFromCreditNotes_888568c5-7645-4f44-b307-d5c206205151" xlink:href="abvx-20251231.xsd#abvx_CurrentReceivablesFromCreditNotes"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_6c7b59fd-b67b-4aeb-a416-74927a7d47a6" xlink:to="loc_abvx_CurrentReceivablesFromCreditNotes_888568c5-7645-4f44-b307-d5c206205151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentReceivablesAndCurrentPrepaidExpenses_2aaee750-6df8-4fa4-9a6a-b88fb6f13ec0" xlink:href="abvx-20251231.xsd#abvx_CurrentReceivablesAndCurrentPrepaidExpenses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_6c7b59fd-b67b-4aeb-a416-74927a7d47a6" xlink:to="loc_abvx_CurrentReceivablesAndCurrentPrepaidExpenses_2aaee750-6df8-4fa4-9a6a-b88fb6f13ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAssets_7f206f40-f151-4b49-8ab6-2a39e61a5343" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_6c7b59fd-b67b-4aeb-a416-74927a7d47a6" xlink:to="loc_ifrs-full_OtherAssets_7f206f40-f151-4b49-8ab6-2a39e61a5343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#OtherreceivablesandotherassetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesAbstract_12b07c7a-301f-40eb-84c0-aecbfb488fac" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfOtherReceivablesAndOtherAssetsTable_5c5aad94-551e-4f9e-9a94-ff9ef4e2b063" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfOtherReceivablesAndOtherAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_12b07c7a-301f-40eb-84c0-aecbfb488fac" xlink:to="loc_abvx_DisclosureOfOtherReceivablesAndOtherAssetsTable_5c5aad94-551e-4f9e-9a94-ff9ef4e2b063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_b93ba26b-e70f-4cd9-a5b1-a5d87d3de075" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOtherReceivablesAndOtherAssetsTable_5c5aad94-551e-4f9e-9a94-ff9ef4e2b063" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_b93ba26b-e70f-4cd9-a5b1-a5d87d3de075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_833fccbc-8669-405e-a07c-f2c483941600" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_b93ba26b-e70f-4cd9-a5b1-a5d87d3de075" xlink:to="loc_ifrs-full_CarryingAmountMember_833fccbc-8669-405e-a07c-f2c483941600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DeferredFinancingCostsNettingMember_3e25dc6b-48ae-4fb8-b80a-6a6d13f835d7" xlink:href="abvx-20251231.xsd#abvx_DeferredFinancingCostsNettingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_833fccbc-8669-405e-a07c-f2c483941600" xlink:to="loc_abvx_DeferredFinancingCostsNettingMember_3e25dc6b-48ae-4fb8-b80a-6a6d13f835d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_b071abbf-d0fa-4f99-942c-54566e18526c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOtherReceivablesAndOtherAssetsTable_5c5aad94-551e-4f9e-9a94-ff9ef4e2b063" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_b071abbf-d0fa-4f99-942c-54566e18526c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_f260e9ef-cec9-4dcc-858b-7833a7efcc00" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_b071abbf-d0fa-4f99-942c-54566e18526c" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_f260e9ef-cec9-4dcc-858b-7833a7efcc00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheBMember_735eb06a-4e28-4578-bb1c-c19d659b6822" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheBMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_f260e9ef-cec9-4dcc-858b-7833a7efcc00" xlink:to="loc_abvx_KreosClaretFinancingTrancheBMember_735eb06a-4e28-4578-bb1c-c19d659b6822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems_a10b0bc7-6763-48f3-b274-5caeb6dabfef" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOtherReceivablesAndOtherAssetsTable_5c5aad94-551e-4f9e-9a94-ff9ef4e2b063" xlink:to="loc_abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems_a10b0bc7-6763-48f3-b274-5caeb6dabfef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ProceedsFromResearchTaxCredit_504ee738-644c-481c-a49d-e1c743e578f0" xlink:href="abvx-20251231.xsd#abvx_ProceedsFromResearchTaxCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems_a10b0bc7-6763-48f3-b274-5caeb6dabfef" xlink:to="loc_abvx_ProceedsFromResearchTaxCredit_504ee738-644c-481c-a49d-e1c743e578f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentResearchTaxCreditReceivables_0e229e10-28b1-49af-b5c7-199566907aa9" xlink:href="abvx-20251231.xsd#abvx_CurrentResearchTaxCreditReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems_a10b0bc7-6763-48f3-b274-5caeb6dabfef" xlink:to="loc_abvx_CurrentResearchTaxCreditReceivables_0e229e10-28b1-49af-b5c7-199566907aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentPrepaidExpensesRelatedToCRO_80bbd16b-062b-43fa-8a9d-495ed5ad0da4" xlink:href="abvx-20251231.xsd#abvx_CurrentPrepaidExpensesRelatedToCRO"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems_a10b0bc7-6763-48f3-b274-5caeb6dabfef" xlink:to="loc_abvx_CurrentPrepaidExpensesRelatedToCRO_80bbd16b-062b-43fa-8a9d-495ed5ad0da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_c3185b92-2916-47a4-97fc-8b69c439a376" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems_a10b0bc7-6763-48f3-b274-5caeb6dabfef" xlink:to="loc_ifrs-full_Borrowings_c3185b92-2916-47a4-97fc-8b69c439a376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAdvancesToSuppliers_f71fa34d-86f0-410b-b587-955b8b15c706" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAdvancesToSuppliers"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems_a10b0bc7-6763-48f3-b274-5caeb6dabfef" xlink:to="loc_ifrs-full_CurrentAdvancesToSuppliers_f71fa34d-86f0-410b-b587-955b8b15c706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ReclassificationOfPrepaidExpensesToCarryingValueOfDebtComponent_988a8a53-840e-427b-96c7-78ea09eeef8c" xlink:href="abvx-20251231.xsd#abvx_ReclassificationOfPrepaidExpensesToCarryingValueOfDebtComponent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems_a10b0bc7-6763-48f3-b274-5caeb6dabfef" xlink:to="loc_abvx_ReclassificationOfPrepaidExpensesToCarryingValueOfDebtComponent_988a8a53-840e-427b-96c7-78ea09eeef8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/CashandcashequivalentsDisclosureofcompositionofcashandcashequivalentsDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#CashandcashequivalentsDisclosureofcompositionofcashandcashequivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/CashandcashequivalentsDisclosureofcompositionofcashandcashequivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_18d47a2e-a5c4-4807-a284-babf1ba3573c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashEquivalents_4397954f-d11b-41e5-b530-2239518c55d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_18d47a2e-a5c4-4807-a284-babf1ba3573c" xlink:to="loc_ifrs-full_CashEquivalents_4397954f-d11b-41e5-b530-2239518c55d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Cash_6595a23f-d435-4ebd-b2bd-5d5edbfdf593" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Cash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_18d47a2e-a5c4-4807-a284-babf1ba3573c" xlink:to="loc_ifrs-full_Cash_6595a23f-d435-4ebd-b2bd-5d5edbfdf593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_fe883be4-b9c6-4973-ab9d-6a8217f86421" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_18d47a2e-a5c4-4807-a284-babf1ba3573c" xlink:to="loc_ifrs-full_CashAndCashEquivalents_fe883be4-b9c6-4973-ab9d-6a8217f86421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/CashandcashequivalentsNarrativeDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#CashandcashequivalentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/CashandcashequivalentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_3421182e-3363-4c44-a3cb-b815a0391277" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfCashAndCashEquivalentsTable_92e45cfb-5e34-45be-95fc-2d4fcd9f0eb0" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_3421182e-3363-4c44-a3cb-b815a0391277" xlink:to="loc_abvx_DisclosureOfCashAndCashEquivalentsTable_92e45cfb-5e34-45be-95fc-2d4fcd9f0eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_b8d1da64-528f-44f0-8f8c-8bc25677364c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfCashAndCashEquivalentsTable_92e45cfb-5e34-45be-95fc-2d4fcd9f0eb0" xlink:to="loc_srt_CurrencyAxis_b8d1da64-528f-44f0-8f8c-8bc25677364c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_84b6cee6-f74b-4a90-a7a4-1f7fda518047" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_b8d1da64-528f-44f0-8f8c-8bc25677364c" xlink:to="loc_currency_AllCurrenciesDomain_84b6cee6-f74b-4a90-a7a4-1f7fda518047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_ba51e457-528f-4306-8510-a7cd5767b17b" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_USD"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_84b6cee6-f74b-4a90-a7a4-1f7fda518047" xlink:to="loc_currency_USD_ba51e457-528f-4306-8510-a7cd5767b17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfCashAndCashEquivalentsLineItems_1fb3d627-69b2-443f-8dc7-bb23dc886c7b" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfCashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfCashAndCashEquivalentsTable_92e45cfb-5e34-45be-95fc-2d4fcd9f0eb0" xlink:to="loc_abvx_DisclosureOfCashAndCashEquivalentsLineItems_1fb3d627-69b2-443f-8dc7-bb23dc886c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCashAndCashEquivalents_45877975-8261-4cf9-9c7f-fc43dc3e9626" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfCashAndCashEquivalentsLineItems_1fb3d627-69b2-443f-8dc7-bb23dc886c7b" xlink:to="loc_ifrs-full_OtherCashAndCashEquivalents_45877975-8261-4cf9-9c7f-fc43dc3e9626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_56a6888a-64a7-4df9-966d-588a97d18f23" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfCashAndCashEquivalentsLineItems_1fb3d627-69b2-443f-8dc7-bb23dc886c7b" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_56a6888a-64a7-4df9-966d-588a97d18f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialassetsandliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FairValueMeasurementAbstract_fe5ba2e0-4321-43c3-95d1-4792c019447b" xlink:href="abvx-20251231.xsd#abvx_FairValueMeasurementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_eb61362b-324b-4ae6-93ae-5aeda5474a21" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FairValueMeasurementAbstract_fe5ba2e0-4321-43c3-95d1-4792c019447b" xlink:to="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_eb61362b-324b-4ae6-93ae-5aeda5474a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_f49f844c-df61-4c3b-91f8-f4d99b28aa96" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_eb61362b-324b-4ae6-93ae-5aeda5474a21" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_f49f844c-df61-4c3b-91f8-f4d99b28aa96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_4a466881-bf6b-4ef5-9313-b424dee5d840" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_f49f844c-df61-4c3b-91f8-f4d99b28aa96" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_4a466881-bf6b-4ef5-9313-b424dee5d840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialAssetsMember_52644017-b6c3-4db6-a7d6-aa6c382b333e" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_4a466881-bf6b-4ef5-9313-b424dee5d840" xlink:to="loc_abvx_OtherFinancialAssetsMember_52644017-b6c3-4db6-a7d6-aa6c382b333e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherReceivablesAndAssetsMember_65c16dce-0677-4055-8a5d-d31f636ea10d" xlink:href="abvx-20251231.xsd#abvx_OtherReceivablesAndAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_4a466881-bf6b-4ef5-9313-b424dee5d840" xlink:to="loc_abvx_OtherReceivablesAndAssetsMember_65c16dce-0677-4055-8a5d-d31f636ea10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CashAndCashEquivalentMember_dd1ef532-48ee-438b-9397-a6d8213b2dae" xlink:href="abvx-20251231.xsd#abvx_CashAndCashEquivalentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_4a466881-bf6b-4ef5-9313-b424dee5d840" xlink:to="loc_abvx_CashAndCashEquivalentMember_dd1ef532-48ee-438b-9397-a6d8213b2dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NonCurrentAdvancesToCROContractsMember_1b75357c-dc00-4a9e-bd22-72a116a3053c" xlink:href="abvx-20251231.xsd#abvx_NonCurrentAdvancesToCROContractsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_4a466881-bf6b-4ef5-9313-b424dee5d840" xlink:to="loc_abvx_NonCurrentAdvancesToCROContractsMember_1b75357c-dc00-4a9e-bd22-72a116a3053c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_2ac3fedd-b0a3-4ce8-bb8e-fd5cb702e443" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_eb61362b-324b-4ae6-93ae-5aeda5474a21" xlink:to="loc_ifrs-full_MeasurementAxis_2ac3fedd-b0a3-4ce8-bb8e-fd5cb702e443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_1fe30cca-a5d5-42d8-a66d-1cbab2bdb2fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_2ac3fedd-b0a3-4ce8-bb8e-fd5cb702e443" xlink:to="loc_ifrs-full_MeasurementDomain_1fe30cca-a5d5-42d8-a66d-1cbab2bdb2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RecurringFairValueMeasurementMember_c5f4c64a-8663-4063-a37f-9cba071bd895" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RecurringFairValueMeasurementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementDomain_1fe30cca-a5d5-42d8-a66d-1cbab2bdb2fc" xlink:to="loc_ifrs-full_RecurringFairValueMeasurementMember_c5f4c64a-8663-4063-a37f-9cba071bd895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_320f166b-17c7-484f-8f79-c1ba0e0b747b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_eb61362b-324b-4ae6-93ae-5aeda5474a21" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_320f166b-17c7-484f-8f79-c1ba0e0b747b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_79352162-f667-41e6-9571-c040c8740d83" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_320f166b-17c7-484f-8f79-c1ba0e0b747b" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_79352162-f667-41e6-9571-c040c8740d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_1bf2b0af-8068-436c-97b4-ea8dddc5dfdb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_79352162-f667-41e6-9571-c040c8740d83" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_1bf2b0af-8068-436c-97b4-ea8dddc5dfdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_ee1ad156-1c91-4578-a410-557d5de7de3d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_79352162-f667-41e6-9571-c040c8740d83" xlink:to="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_ee1ad156-1c91-4578-a410-557d5de7de3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2e93b70b-a581-462d-b88a-b6655a93ef56" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_eb61362b-324b-4ae6-93ae-5aeda5474a21" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2e93b70b-a581-462d-b88a-b6655a93ef56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_d609931c-8eb2-464a-8409-3ac7dbb4901b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2e93b70b-a581-462d-b88a-b6655a93ef56" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_d609931c-8eb2-464a-8409-3ac7dbb4901b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_37433730-c52a-4f43-ae66-951373fd042c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_d609931c-8eb2-464a-8409-3ac7dbb4901b" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_37433730-c52a-4f43-ae66-951373fd042c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_8466749d-8c8e-4db4-83ed-1571e66de446" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_d609931c-8eb2-464a-8409-3ac7dbb4901b" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_8466749d-8c8e-4db4-83ed-1571e66de446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_f7327d89-bb6e-4b22-b236-a79f498c395e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_eb61362b-324b-4ae6-93ae-5aeda5474a21" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_f7327d89-bb6e-4b22-b236-a79f498c395e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_26b8a9a8-439f-4fd7-87c6-3b65978a4891" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_f7327d89-bb6e-4b22-b236-a79f498c395e" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_26b8a9a8-439f-4fd7-87c6-3b65978a4891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NonCurrentFinancialLiabilitiesMember_344a8d31-5afc-4e57-a9a2-ba69aede40cf" xlink:href="abvx-20251231.xsd#abvx_NonCurrentFinancialLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_26b8a9a8-439f-4fd7-87c6-3b65978a4891" xlink:to="loc_abvx_NonCurrentFinancialLiabilitiesMember_344a8d31-5afc-4e57-a9a2-ba69aede40cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheABAndCMember_ec1e8066-b74c-4e6f-b197-dea2ab89057e" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheABAndCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_NonCurrentFinancialLiabilitiesMember_344a8d31-5afc-4e57-a9a2-ba69aede40cf" xlink:to="loc_abvx_KreosClaretFinancingTrancheABAndCMember_ec1e8066-b74c-4e6f-b197-dea2ab89057e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheAMember_88dff9eb-fc96-4731-812e-97d206956a4d" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_NonCurrentFinancialLiabilitiesMember_344a8d31-5afc-4e57-a9a2-ba69aede40cf" xlink:to="loc_abvx_KreosClaretFinancingTrancheAMember_88dff9eb-fc96-4731-812e-97d206956a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConditionalAdvancesAndPGELoanMember_2adc2b84-a6ff-4a79-b9f6-fda6896c8838" xlink:href="abvx-20251231.xsd#abvx_ConditionalAdvancesAndPGELoanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_NonCurrentFinancialLiabilitiesMember_344a8d31-5afc-4e57-a9a2-ba69aede40cf" xlink:to="loc_abvx_ConditionalAdvancesAndPGELoanMember_2adc2b84-a6ff-4a79-b9f6-fda6896c8838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PretGarantiParLEtatPGEMember_73f63775-754b-4651-853d-c1e485841b98" xlink:href="abvx-20251231.xsd#abvx_PretGarantiParLEtatPGEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_ConditionalAdvancesAndPGELoanMember_2adc2b84-a6ff-4a79-b9f6-fda6896c8838" xlink:to="loc_abvx_PretGarantiParLEtatPGEMember_73f63775-754b-4651-853d-c1e485841b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RNPVIRConditionalAdvanceBPIMember_bcd5a293-0052-43e9-9d69-e0a4b801c4f4" xlink:href="abvx-20251231.xsd#abvx_RNPVIRConditionalAdvanceBPIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_ConditionalAdvancesAndPGELoanMember_2adc2b84-a6ff-4a79-b9f6-fda6896c8838" xlink:to="loc_abvx_RNPVIRConditionalAdvanceBPIMember_bcd5a293-0052-43e9-9d69-e0a4b801c4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CARENAConditionalAdvanceBPIMember_011df764-fb31-4911-8002-8a796bf51aeb" xlink:href="abvx-20251231.xsd#abvx_CARENAConditionalAdvanceBPIMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_ConditionalAdvancesAndPGELoanMember_2adc2b84-a6ff-4a79-b9f6-fda6896c8838" xlink:to="loc_abvx_CARENAConditionalAdvanceBPIMember_011df764-fb31-4911-8002-8a796bf51aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EbolaConditionalAdvanceBPIMember_6d73250c-5742-45ec-ae45-35540b8ecbd0" xlink:href="abvx-20251231.xsd#abvx_EbolaConditionalAdvanceBPIMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_ConditionalAdvancesAndPGELoanMember_2adc2b84-a6ff-4a79-b9f6-fda6896c8838" xlink:to="loc_abvx_EbolaConditionalAdvanceBPIMember_6d73250c-5742-45ec-ae45-35540b8ecbd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentFinancialLiabilitiesMember_734b574c-24b1-4813-b05e-c07f763900ab" xlink:href="abvx-20251231.xsd#abvx_CurrentFinancialLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_26b8a9a8-439f-4fd7-87c6-3b65978a4891" xlink:to="loc_abvx_CurrentFinancialLiabilitiesMember_734b574c-24b1-4813-b05e-c07f763900ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TradePayablesAndOtherCurrentLiabilitiesMember_c77d82f8-2e89-4b62-a28a-8ce9b66c6e47" xlink:href="abvx-20251231.xsd#abvx_TradePayablesAndOtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_26b8a9a8-439f-4fd7-87c6-3b65978a4891" xlink:to="loc_abvx_TradePayablesAndOtherCurrentLiabilitiesMember_c77d82f8-2e89-4b62-a28a-8ce9b66c6e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_44534e52-e837-4f59-b4c8-ecb6ffa66694" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_eb61362b-324b-4ae6-93ae-5aeda5474a21" xlink:to="loc_ifrs-full_RangeAxis_44534e52-e837-4f59-b4c8-ecb6ffa66694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_55f71d54-bb2f-42fb-ad11-eb6bc4ac3eee" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_44534e52-e837-4f59-b4c8-ecb6ffa66694" xlink:to="loc_ifrs-full_RangeDomain_55f71d54-bb2f-42fb-ad11-eb6bc4ac3eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_df361df7-8a85-430a-87ff-6726fc49d742" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_55f71d54-bb2f-42fb-ad11-eb6bc4ac3eee" xlink:to="loc_ifrs-full_BottomOfRangeMember_df361df7-8a85-430a-87ff-6726fc49d742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_dd6fc551-5ef8-4e2d-b85d-cb93db53f34c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_55f71d54-bb2f-42fb-ad11-eb6bc4ac3eee" xlink:to="loc_ifrs-full_TopOfRangeMember_dd6fc551-5ef8-4e2d-b85d-cb93db53f34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_59168bdf-9890-47b7-8ea8-a51a8742e2df" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_eb61362b-324b-4ae6-93ae-5aeda5474a21" xlink:to="loc_ifrs-full_UnobservableInputsAxis_59168bdf-9890-47b7-8ea8-a51a8742e2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain_3396ecb8-4f80-4b36-a18e-773a7959d8b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsAxis_59168bdf-9890-47b7-8ea8-a51a8742e2df" xlink:to="loc_ifrs-full_UnobservableInputsDomain_3396ecb8-4f80-4b36-a18e-773a7959d8b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CreditSpreadMeasurementInputMember_e62bd654-e27b-4784-9d0a-5626f3152f9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CreditSpreadMeasurementInputMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_3396ecb8-4f80-4b36-a18e-773a7959d8b1" xlink:to="loc_ifrs-full_CreditSpreadMeasurementInputMember_e62bd654-e27b-4784-9d0a-5626f3152f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_96a573e2-ce6a-4ace-b3ef-c8670f34f270" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_eb61362b-324b-4ae6-93ae-5aeda5474a21" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_96a573e2-ce6a-4ace-b3ef-c8670f34f270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_f616dca6-9df4-48f5-884c-647b1a2e7bcc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_96a573e2-ce6a-4ace-b3ef-c8670f34f270" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_f616dca6-9df4-48f5-884c-647b1a2e7bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DiscountedCashFlowMember_bd0b2db0-e34a-4e62-abf5-e9804a98ae6f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DiscountedCashFlowMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_f616dca6-9df4-48f5-884c-647b1a2e7bcc" xlink:to="loc_ifrs-full_DiscountedCashFlowMember_bd0b2db0-e34a-4e62-abf5-e9804a98ae6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems_09e7ea9e-0422-4834-b492-4b2471c70545" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_eb61362b-324b-4ae6-93ae-5aeda5474a21" xlink:to="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems_09e7ea9e-0422-4834-b492-4b2471c70545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_d92189f6-06fa-4059-9d21-1642d0854fbf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Assets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems_09e7ea9e-0422-4834-b492-4b2471c70545" xlink:to="loc_ifrs-full_Assets_d92189f6-06fa-4059-9d21-1642d0854fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValue_fd86ecdf-126d-411f-af99-ab599cfc0514" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialAssetsAtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems_09e7ea9e-0422-4834-b492-4b2471c70545" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValue_fd86ecdf-126d-411f-af99-ab599cfc0514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_aefe6fe9-db2f-4404-b92d-50bb09210d9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems_09e7ea9e-0422-4834-b492-4b2471c70545" xlink:to="loc_ifrs-full_Liabilities_aefe6fe9-db2f-4404-b92d-50bb09210d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValue_ccaf4fdb-9836-4fac-a9d2-d7f1dedebb0a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems_09e7ea9e-0422-4834-b492-4b2471c70545" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValue_ccaf4fdb-9836-4fac-a9d2-d7f1dedebb0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputAssets_0976d20f-af14-4716-8fdc-d15bcf5bed09" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantUnobservableInputAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems_09e7ea9e-0422-4834-b492-4b2471c70545" xlink:to="loc_ifrs-full_SignificantUnobservableInputAssets_0976d20f-af14-4716-8fdc-d15bcf5bed09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets_daf67fd2-92b3-4adf-b4cf-6382bd9383e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems_09e7ea9e-0422-4834-b492-4b2471c70545" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets_daf67fd2-92b3-4adf-b4cf-6382bd9383e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets_46c7c057-2d32-4e53-b096-a5179dbc1b07" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems_09e7ea9e-0422-4834-b492-4b2471c70545" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets_46c7c057-2d32-4e53-b096-a5179dbc1b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities_87435302-63e7-48d0-8713-d6c3c9e7e5f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantUnobservableInputLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems_09e7ea9e-0422-4834-b492-4b2471c70545" xlink:to="loc_ifrs-full_SignificantUnobservableInputLiabilities_87435302-63e7-48d0-8713-d6c3c9e7e5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfTranches_019cfb72-9017-7599-b97d-e6ba1101d67d" xlink:href="abvx-20251231.xsd#abvx_NumberOfTranches"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems_09e7ea9e-0422-4834-b492-4b2471c70545" xlink:to="loc_abvx_NumberOfTranches_019cfb72-9017-7599-b97d-e6ba1101d67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_ef643c7b-a0de-44ff-a148-05cacc40c4f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems_09e7ea9e-0422-4834-b492-4b2471c70545" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_ef643c7b-a0de-44ff-a148-05cacc40c4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities_a201f1e3-45b9-4da1-bc07-c2feff04be1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems_09e7ea9e-0422-4834-b492-4b2471c70545" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities_a201f1e3-45b9-4da1-bc07-c2feff04be1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/ShareholdersequitySharecapitalissuedDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#ShareholdersequitySharecapitalissuedDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/ShareholdersequitySharecapitalissuedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract_913d7027-dd62-475f-8408-47e2aa6c465f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_019c5806-3bc8-7d8b-bab4-afd1ae0181b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_913d7027-dd62-475f-8408-47e2aa6c465f" xlink:to="loc_ifrs-full_IssuedCapital_019c5806-3bc8-7d8b-bab4-afd1ae0181b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_019c5806-3bc8-72aa-84f3-b9ec5d18d400" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_913d7027-dd62-475f-8408-47e2aa6c465f" xlink:to="loc_ifrs-full_NumberOfSharesIssued_019c5806-3bc8-72aa-84f3-b9ec5d18d400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_019c5806-3bc8-71db-a9a1-fbcb84d01058" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_913d7027-dd62-475f-8408-47e2aa6c465f" xlink:to="loc_ifrs-full_ParValuePerShare_019c5806-3bc8-71db-a9a1-fbcb84d01058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfTreasurySharesHeld_019c580c-a812-7cad-8f99-090bdcb20e43" xlink:href="abvx-20251231.xsd#abvx_NumberOfTreasurySharesHeld"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_913d7027-dd62-475f-8408-47e2aa6c465f" xlink:to="loc_abvx_NumberOfTreasurySharesHeld_019c580c-a812-7cad-8f99-090bdcb20e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#ShareholdersequityChangeinsharecapitalDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract_27a91953-0117-4c35-a697-dfa9777eb3d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e58e1ca9-d480-4e76-8910-39b5321d45d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_27a91953-0117-4c35-a697-dfa9777eb3d1" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e58e1ca9-d480-4e76-8910-39b5321d45d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialAgreementAxis_019bfa86-24aa-7a99-807a-d360dc28c9ca" xlink:href="abvx-20251231.xsd#abvx_FinancialAgreementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e58e1ca9-d480-4e76-8910-39b5321d45d0" xlink:to="loc_abvx_FinancialAgreementAxis_019bfa86-24aa-7a99-807a-d360dc28c9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialAgreementDomain_019bfa86-24aa-7309-b759-b7d0c6955d10" xlink:href="abvx-20251231.xsd#abvx_FinancialAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialAgreementAxis_019bfa86-24aa-7a99-807a-d360dc28c9ca" xlink:to="loc_abvx_FinancialAgreementDomain_019bfa86-24aa-7309-b759-b7d0c6955d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1Member_019bfa86-24aa-74f0-8ac6-a8ccf4ff066e" xlink:href="abvx-20251231.xsd#abvx_Kreos1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialAgreementDomain_019bfa86-24aa-7309-b759-b7d0c6955d10" xlink:to="loc_abvx_Kreos1Member_019bfa86-24aa-74f0-8ac6-a8ccf4ff066e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherEquityAgreementsMember_019bfa86-24aa-7b4a-9311-fbbaa02d1da0" xlink:href="abvx-20251231.xsd#abvx_OtherEquityAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialAgreementDomain_019bfa86-24aa-7309-b759-b7d0c6955d10" xlink:to="loc_abvx_OtherEquityAgreementsMember_019bfa86-24aa-7b4a-9311-fbbaa02d1da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019bfa86-24aa-74f7-9e66-58e0ed68f5dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e58e1ca9-d480-4e76-8910-39b5321d45d0" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019bfa86-24aa-74f7-9e66-58e0ed68f5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019bfa86-24aa-7417-b9e8-6ad522db4ee4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019bfa86-24aa-74f7-9e66-58e0ed68f5dd" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019bfa86-24aa-7417-b9e8-6ad522db4ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosABSAMember_019bfa86-24aa-7a20-b8de-d2bd0510a5e7" xlink:href="abvx-20251231.xsd#abvx_KreosABSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019bfa86-24aa-7417-b9e8-6ad522db4ee4" xlink:to="loc_abvx_KreosABSAMember_019bfa86-24aa-7a20-b8de-d2bd0510a5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosBBSAMember_019bfa86-24aa-78f8-bf4b-a2736bb05fae" xlink:href="abvx-20251231.xsd#abvx_KreosBBSAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019bfa86-24aa-7417-b9e8-6ad522db4ee4" xlink:to="loc_abvx_KreosBBSAMember_019bfa86-24aa-78f8-bf4b-a2736bb05fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20241AndBSA20242Member_019bfa86-53a9-786a-8bf1-3598b5e96816" xlink:href="abvx-20251231.xsd#abvx_BSA20241AndBSA20242Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019bfa86-24aa-7417-b9e8-6ad522db4ee4" xlink:to="loc_abvx_BSA20241AndBSA20242Member_019bfa86-53a9-786a-8bf1-3598b5e96816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_019bfa86-24aa-7b29-b9f9-0570086cc6c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e58e1ca9-d480-4e76-8910-39b5321d45d0" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_019bfa86-24aa-7b29-b9f9-0570086cc6c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_019bfa86-24aa-7612-9513-2ed08055a57d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_019bfa86-24aa-7b29-b9f9-0570086cc6c1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_019bfa86-24aa-7612-9513-2ed08055a57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AmericanDepositorySharesMember_019bfa86-24aa-717d-8d8f-fc352e81dfd0" xlink:href="abvx-20251231.xsd#abvx_AmericanDepositorySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_019bfa86-24aa-7612-9513-2ed08055a57d" xlink:to="loc_abvx_AmericanDepositorySharesMember_019bfa86-24aa-717d-8d8f-fc352e81dfd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_019bfa86-24aa-7f1b-8424-ba3339af547a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_019bfa86-24aa-7612-9513-2ed08055a57d" xlink:to="loc_ifrs-full_OrdinarySharesMember_019bfa86-24aa-7f1b-8424-ba3339af547a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_019bfa87-4537-7631-8dcb-be1b4b0b138f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e58e1ca9-d480-4e76-8910-39b5321d45d0" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_019bfa87-4537-7631-8dcb-be1b4b0b138f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019bfa87-4537-7834-afdb-3de0a17312a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019bfa87-4537-7631-8dcb-be1b4b0b138f" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019bfa87-4537-7834-afdb-3de0a17312a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_HeightsConvertibleNotesMember_019bfa87-4537-7fd9-beab-622facff8b44" xlink:href="abvx-20251231.xsd#abvx_HeightsConvertibleNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019bfa87-4537-7834-afdb-3de0a17312a3" xlink:to="loc_abvx_HeightsConvertibleNotesMember_019bfa87-4537-7fd9-beab-622facff8b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheAMember_019bfa87-4537-7bd7-b6c0-39825bc503b2" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019bfa87-4537-7834-afdb-3de0a17312a3" xlink:to="loc_abvx_KreosClaretFinancingTrancheAMember_019bfa87-4537-7bd7-b6c0-39825bc503b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosABCBSAMember_019bfa88-8029-721f-a4ac-420aa8082b1d" xlink:href="abvx-20251231.xsd#abvx_KreosABCBSAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019bfa87-4537-7834-afdb-3de0a17312a3" xlink:to="loc_abvx_KreosABCBSAMember_019bfa88-8029-721f-a4ac-420aa8082b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e58e1ca9-d480-4e76-8910-39b5321d45d0" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_019bfa86-24aa-7170-99d9-a6614e5871b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_ifrs-full_IssueOfEquity_019bfa86-24aa-7170-99d9-a6614e5871b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease_019bfa86-24aa-70b1-ad69-bb12227cab73" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease_019bfa86-24aa-70b1-ad69-bb12227cab73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_019bfa86-24aa-71cc-9cf7-cbf492ca3ef2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_ifrs-full_ParValuePerShare_019bfa86-24aa-71cc-9cf7-cbf492ca3ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EquityIssuanceSubscriptionPricePerShare_019bfa86-24aa-7916-b09b-f5d54b23010e" xlink:href="abvx-20251231.xsd#abvx_EquityIssuanceSubscriptionPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_abvx_EquityIssuanceSubscriptionPricePerShare_019bfa86-24aa-7916-b09b-f5d54b23010e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfWarrantsExercised_019bfa86-24aa-727c-88ac-df13439d1caf" xlink:href="abvx-20251231.xsd#abvx_NumberOfWarrantsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_abvx_NumberOfWarrantsExercised_019bfa86-24aa-727c-88ac-df13439d1caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_019bfa86-24aa-7762-8795-b4b2baa39cd9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_019bfa86-24aa-7762-8795-b4b2baa39cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants_019bfa86-24aa-7868-b504-a1ad9d323300" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants_019bfa86-24aa-7868-b504-a1ad9d323300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherShareWarrantsSubscriptionPricePerShare_019bfa86-24aa-70ca-95e2-de80b709d09b" xlink:href="abvx-20251231.xsd#abvx_OtherShareWarrantsSubscriptionPricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_abvx_OtherShareWarrantsSubscriptionPricePerShare_019bfa86-24aa-70ca-95e2-de80b709d09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IssueOfEquityOfferingPricePerShare_019bfa86-24aa-7a22-87c1-f4a838ccf2ef" xlink:href="abvx-20251231.xsd#abvx_IssueOfEquityOfferingPricePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_abvx_IssueOfEquityOfferingPricePerShare_019bfa86-24aa-7a22-87c1-f4a838ccf2ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_019bfa86-53a9-758c-86a4-ecedaf1b42fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_019bfa86-53a9-758c-86a4-ecedaf1b42fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_019bfa86-53a9-7b13-8f4a-90235824e616" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_019bfa86-53a9-7b13-8f4a-90235824e616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ShareWarrantsSubscriptionPricePerShare_019bfa86-53a9-713c-aa78-cf030ab56c03" xlink:href="abvx-20251231.xsd#abvx_ShareWarrantsSubscriptionPricePerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_abvx_ShareWarrantsSubscriptionPricePerShare_019bfa86-53a9-713c-aa78-cf030ab56c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ShareIssueRelatedCostCredit_019bfa86-53a9-7237-af8e-4cc5d7abffc6" xlink:href="abvx-20251231.xsd#abvx_ShareIssueRelatedCostCredit"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_abvx_ShareIssueRelatedCostCredit_019bfa86-53a9-7237-af8e-4cc5d7abffc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfFreeSharesIssued_019bfa86-53a9-77d3-bbbc-41053cd91fee" xlink:href="abvx-20251231.xsd#abvx_NumberOfFreeSharesIssued"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_abvx_NumberOfFreeSharesIssued_019bfa86-53a9-77d3-bbbc-41053cd91fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate_019bfa87-4537-77c5-a40d-1c6bb036aeee" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClosingForeignExchangeRate"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_ifrs-full_ClosingForeignExchangeRate_019bfa87-4537-77c5-a40d-1c6bb036aeee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfConvertibleNotesConverted_019bfa87-4537-705d-815a-8d80be363531" xlink:href="abvx-20251231.xsd#abvx_NumberOfConvertibleNotesConverted"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_abvx_NumberOfConvertibleNotesConverted_019bfa87-4537-705d-815a-8d80be363531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_019bfa87-4537-7384-ac02-81da5da547d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotionalAmount"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_ifrs-full_NotionalAmount_019bfa87-4537-7384-ac02-81da5da547d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_019bfa87-4537-7436-aca3-e0c8fa71edad" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_019bfa87-4537-7436-aca3-e0c8fa71edad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsFixedConversionPrice_019bfa87-4537-7e91-823a-f534e01b47d0" xlink:href="abvx-20251231.xsd#abvx_BorrowingsFixedConversionPrice"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019bfa86-24aa-7469-b7d9-5c60420ce7f8" xlink:to="loc_abvx_BorrowingsFixedConversionPrice_019bfa87-4537-7e91-823a-f534e01b47d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#SharebasedpaymentsDisclosureofreconciliationofBCEsDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ShareBasedPaymentArrangementsAbstract_570a93af-19f6-46c7-8f88-7b85ea901d53" xlink:href="abvx-20251231.xsd#abvx_ShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_47dea508-c7ee-486d-a2c3-c3ddd34011a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_ShareBasedPaymentArrangementsAbstract_570a93af-19f6-46c7-8f88-7b85ea901d53" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_47dea508-c7ee-486d-a2c3-c3ddd34011a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_6f35c44f-488b-436d-9391-01650ef7dbdd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_47dea508-c7ee-486d-a2c3-c3ddd34011a9" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_6f35c44f-488b-436d-9391-01650ef7dbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_2ac46ceb-b144-458e-a0b0-e10964858a9b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_6f35c44f-488b-436d-9391-01650ef7dbdd" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_2ac46ceb-b144-458e-a0b0-e10964858a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FoundersShareSubscriptionWarrantsBCEMember_61ca9cc3-1332-45a6-b1dc-f0c7b0d89e26" xlink:href="abvx-20251231.xsd#abvx_FoundersShareSubscriptionWarrantsBCEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_2ac46ceb-b144-458e-a0b0-e10964858a9b" xlink:to="loc_abvx_FoundersShareSubscriptionWarrantsBCEMember_61ca9cc3-1332-45a6-b1dc-f0c7b0d89e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BCE20161Member_498a3203-7d46-4df9-baf6-6f5a77cfa1c9" xlink:href="abvx-20251231.xsd#abvx_BCE20161Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FoundersShareSubscriptionWarrantsBCEMember_61ca9cc3-1332-45a6-b1dc-f0c7b0d89e26" xlink:to="loc_abvx_BCE20161Member_498a3203-7d46-4df9-baf6-6f5a77cfa1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BCE20171Member_4ecb7f9b-29c7-4cc3-9ae6-ced313e7775a" xlink:href="abvx-20251231.xsd#abvx_BCE20171Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FoundersShareSubscriptionWarrantsBCEMember_61ca9cc3-1332-45a6-b1dc-f0c7b0d89e26" xlink:to="loc_abvx_BCE20171Member_4ecb7f9b-29c7-4cc3-9ae6-ced313e7775a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BCE20172Member_36a5a6a5-a800-4e7f-bad4-95470f301f86" xlink:href="abvx-20251231.xsd#abvx_BCE20172Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FoundersShareSubscriptionWarrantsBCEMember_61ca9cc3-1332-45a6-b1dc-f0c7b0d89e26" xlink:to="loc_abvx_BCE20172Member_36a5a6a5-a800-4e7f-bad4-95470f301f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BCE20174Member_c46a2a79-5ba7-4e7b-9883-bc7efd32bb48" xlink:href="abvx-20251231.xsd#abvx_BCE20174Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FoundersShareSubscriptionWarrantsBCEMember_61ca9cc3-1332-45a6-b1dc-f0c7b0d89e26" xlink:to="loc_abvx_BCE20174Member_c46a2a79-5ba7-4e7b-9883-bc7efd32bb48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BCE20175Member_55fead39-06f1-4186-a01a-51742757defd" xlink:href="abvx-20251231.xsd#abvx_BCE20175Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FoundersShareSubscriptionWarrantsBCEMember_61ca9cc3-1332-45a6-b1dc-f0c7b0d89e26" xlink:to="loc_abvx_BCE20175Member_55fead39-06f1-4186-a01a-51742757defd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BCE20181Member_ce1065e6-7182-463c-9cbf-7930431cf5a4" xlink:href="abvx-20251231.xsd#abvx_BCE20181Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FoundersShareSubscriptionWarrantsBCEMember_61ca9cc3-1332-45a6-b1dc-f0c7b0d89e26" xlink:to="loc_abvx_BCE20181Member_ce1065e6-7182-463c-9cbf-7930431cf5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BCE20184Member_e9aa6b70-2b6c-4e15-b44d-f19389dc9c79" xlink:href="abvx-20251231.xsd#abvx_BCE20184Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FoundersShareSubscriptionWarrantsBCEMember_61ca9cc3-1332-45a6-b1dc-f0c7b0d89e26" xlink:to="loc_abvx_BCE20184Member_e9aa6b70-2b6c-4e15-b44d-f19389dc9c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BCE20185Member_1a57f2f6-d4fe-450a-b50b-20d1fe96ce00" xlink:href="abvx-20251231.xsd#abvx_BCE20185Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FoundersShareSubscriptionWarrantsBCEMember_61ca9cc3-1332-45a6-b1dc-f0c7b0d89e26" xlink:to="loc_abvx_BCE20185Member_1a57f2f6-d4fe-450a-b50b-20d1fe96ce00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1d70bcfd-e943-4d77-aa94-f5740d0584dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_47dea508-c7ee-486d-a2c3-c3ddd34011a9" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1d70bcfd-e943-4d77-aa94-f5740d0584dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_42b01723-aa96-4940-a89f-f1447502cac2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1d70bcfd-e943-4d77-aa94-f5740d0584dc" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_42b01723-aa96-4940-a89f-f1447502cac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_290de5b4-eb4e-499c-90f3-438f7b0c5061" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1d70bcfd-e943-4d77-aa94-f5740d0584dc" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_290de5b4-eb4e-499c-90f3-438f7b0c5061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_96d33b93-56d7-45e8-8a5b-413116a0a6a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1d70bcfd-e943-4d77-aa94-f5740d0584dc" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_96d33b93-56d7-45e8-8a5b-413116a0a6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_c6cb33c8-6cb5-4224-ad30-5447a6bb2c63" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1d70bcfd-e943-4d77-aa94-f5740d0584dc" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_c6cb33c8-6cb5-4224-ad30-5447a6bb2c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_882fddcb-be7a-4f48-a5a3-1c4b62612f54" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1d70bcfd-e943-4d77-aa94-f5740d0584dc" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_882fddcb-be7a-4f48-a5a3-1c4b62612f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_9a200f7b-3c9d-4a9d-b84e-9a9c21216d4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1d70bcfd-e943-4d77-aa94-f5740d0584dc" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_9a200f7b-3c9d-4a9d-b84e-9a9c21216d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet_96c6d517-0ab9-4ad8-b56e-f948a27c24e4" xlink:href="abvx-20251231.xsd#abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1d70bcfd-e943-4d77-aa94-f5740d0584dc" xlink:to="loc_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet_96c6d517-0ab9-4ad8-b56e-f948a27c24e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#SharebasedpaymentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ShareBasedPaymentArrangementsAbstract_677b1760-56a7-4283-bf77-b165dc32ff70" xlink:href="abvx-20251231.xsd#abvx_ShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_9a4168f3-5cd7-4898-92d5-32efd93d22ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_ShareBasedPaymentArrangementsAbstract_677b1760-56a7-4283-bf77-b165dc32ff70" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_9a4168f3-5cd7-4898-92d5-32efd93d22ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesAxis_019bfb19-cfb8-7f14-8c83-e80db55db7bb" xlink:href="abvx-20251231.xsd#abvx_TranchesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_9a4168f3-5cd7-4898-92d5-32efd93d22ec" xlink:to="loc_abvx_TranchesAxis_019bfb19-cfb8-7f14-8c83-e80db55db7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesDomain_019bfb19-cfb8-716f-bb26-edacd9711228" xlink:href="abvx-20251231.xsd#abvx_TranchesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_TranchesAxis_019bfb19-cfb8-7f14-8c83-e80db55db7bb" xlink:to="loc_abvx_TranchesDomain_019bfb19-cfb8-716f-bb26-edacd9711228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheOneMember_019bfb19-cfb8-7ced-a345-7726767b6e22" xlink:href="abvx-20251231.xsd#abvx_TrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_TranchesDomain_019bfb19-cfb8-716f-bb26-edacd9711228" xlink:to="loc_abvx_TrancheOneMember_019bfb19-cfb8-7ced-a345-7726767b6e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheTwoMember_019bfb19-cfb8-7abf-983e-3bfbd749f314" xlink:href="abvx-20251231.xsd#abvx_TrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_TranchesDomain_019bfb19-cfb8-716f-bb26-edacd9711228" xlink:to="loc_abvx_TrancheTwoMember_019bfb19-cfb8-7abf-983e-3bfbd749f314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheThreeMember_019bfb1a-6596-7278-a0f4-9e910b437217" xlink:href="abvx-20251231.xsd#abvx_TrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_TranchesDomain_019bfb19-cfb8-716f-bb26-edacd9711228" xlink:to="loc_abvx_TrancheThreeMember_019bfb1a-6596-7278-a0f4-9e910b437217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheFourMember_019bfb1a-6596-7dc5-adde-72d66cca39d9" xlink:href="abvx-20251231.xsd#abvx_TrancheFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_TranchesDomain_019bfb19-cfb8-716f-bb26-edacd9711228" xlink:to="loc_abvx_TrancheFourMember_019bfb1a-6596-7dc5-adde-72d66cca39d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheFiveMember_019bfb1a-6596-733e-ae7d-82d66176bd78" xlink:href="abvx-20251231.xsd#abvx_TrancheFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_TranchesDomain_019bfb19-cfb8-716f-bb26-edacd9711228" xlink:to="loc_abvx_TrancheFiveMember_019bfb1a-6596-733e-ae7d-82d66176bd78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheSixMember_019bfb1a-6596-7047-8b7e-3e3e8a995f8c" xlink:href="abvx-20251231.xsd#abvx_TrancheSixMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_TranchesDomain_019bfb19-cfb8-716f-bb26-edacd9711228" xlink:to="loc_abvx_TrancheSixMember_019bfb1a-6596-7047-8b7e-3e3e8a995f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019bfb19-cfb8-7e04-92ff-fad51b249078" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_9a4168f3-5cd7-4898-92d5-32efd93d22ec" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019bfb19-cfb8-7e04-92ff-fad51b249078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019bfb19-cfb8-73e5-9124-e484181a565a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019bfb19-cfb8-7e04-92ff-fad51b249078" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019bfb19-cfb8-73e5-9124-e484181a565a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FoundersShareSubscriptionWarrantsBCEMember_019bfb19-cfb8-7d69-9df0-e21350266eba" xlink:href="abvx-20251231.xsd#abvx_FoundersShareSubscriptionWarrantsBCEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019bfb19-cfb8-73e5-9124-e484181a565a" xlink:to="loc_abvx_FoundersShareSubscriptionWarrantsBCEMember_019bfb19-cfb8-7d69-9df0-e21350266eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BCEExceptBCE20142Member_019bfb19-cfb8-7d99-8c0b-d850fa892a85" xlink:href="abvx-20251231.xsd#abvx_BCEExceptBCE20142Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FoundersShareSubscriptionWarrantsBCEMember_019bfb19-cfb8-7d69-9df0-e21350266eba" xlink:to="loc_abvx_BCEExceptBCE20142Member_019bfb19-cfb8-7d99-8c0b-d850fa892a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ShareSubscriptionWarrantsBSAMember_019bfb19-ffde-700f-bf2a-d7e8e0543807" xlink:href="abvx-20251231.xsd#abvx_ShareSubscriptionWarrantsBSAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019bfb19-cfb8-73e5-9124-e484181a565a" xlink:to="loc_abvx_ShareSubscriptionWarrantsBSAMember_019bfb19-ffde-700f-bf2a-d7e8e0543807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20241AndBSA20242Member_019bfb19-ffde-73c4-bb5b-fdd052f7f560" xlink:href="abvx-20251231.xsd#abvx_BSA20241AndBSA20242Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_ShareSubscriptionWarrantsBSAMember_019bfb19-ffde-700f-bf2a-d7e8e0543807" xlink:to="loc_abvx_BSA20241AndBSA20242Member_019bfb19-ffde-73c4-bb5b-fdd052f7f560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20251AndBSA20252Member_019cfca6-e954-7cc4-af1a-50d187713e4f" xlink:href="abvx-20251231.xsd#abvx_BSA20251AndBSA20252Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_ShareSubscriptionWarrantsBSAMember_019bfb19-ffde-700f-bf2a-d7e8e0543807" xlink:to="loc_abvx_BSA20251AndBSA20252Member_019cfca6-e954-7cc4-af1a-50d187713e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20253Member_019cfca7-11b1-7957-9736-d8d9439463d6" xlink:href="abvx-20251231.xsd#abvx_BSA20253Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_ShareSubscriptionWarrantsBSAMember_019bfb19-ffde-700f-bf2a-d7e8e0543807" xlink:to="loc_abvx_BSA20253Member_019cfca7-11b1-7957-9736-d8d9439463d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:href="abvx-20251231.xsd#abvx_FreeSharesAGAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019bfb19-cfb8-73e5-9124-e484181a565a" xlink:to="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20231Member_019bfb1a-6596-7e1d-8857-dadfbad3540e" xlink:href="abvx-20251231.xsd#abvx_AGA20231Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20231Member_019bfb1a-6596-7e1d-8857-dadfbad3540e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20232Member_019bfb1a-9ecc-7c8d-abf9-8ec3a724dc19" xlink:href="abvx-20251231.xsd#abvx_AGA20232Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20232Member_019bfb1a-9ecc-7c8d-abf9-8ec3a724dc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20233AGA20234AndAGA20235Member_019bfb1a-9ecc-7273-b1dc-22738c7dd6c1" xlink:href="abvx-20251231.xsd#abvx_AGA20233AGA20234AndAGA20235Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20233AGA20234AndAGA20235Member_019bfb1a-9ecc-7273-b1dc-22738c7dd6c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20233AndAGA20234Member_019bfb1a-9ecc-75b3-8e84-bd99ad3724b7" xlink:href="abvx-20251231.xsd#abvx_AGA20233AndAGA20234Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AGA20233AGA20234AndAGA20235Member_019bfb1a-9ecc-7273-b1dc-22738c7dd6c1" xlink:to="loc_abvx_AGA20233AndAGA20234Member_019bfb1a-9ecc-75b3-8e84-bd99ad3724b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20235Member_019bfb1a-9ecc-7962-a059-e83010e81e35" xlink:href="abvx-20251231.xsd#abvx_AGA20235Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_AGA20233AGA20234AndAGA20235Member_019bfb1a-9ecc-7273-b1dc-22738c7dd6c1" xlink:to="loc_abvx_AGA20235Member_019bfb1a-9ecc-7962-a059-e83010e81e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20241Member_019bfb1a-c1ca-799b-808f-cf0ea4e9958d" xlink:href="abvx-20251231.xsd#abvx_AGA20241Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20241Member_019bfb1a-c1ca-799b-808f-cf0ea4e9958d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20242Member_019bfb1a-c1ca-70e5-8efa-6fedf1943926" xlink:href="abvx-20251231.xsd#abvx_AGA20242Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20242Member_019bfb1a-c1ca-70e5-8efa-6fedf1943926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20243Member_019bfb1a-c1ca-7812-a457-ceff09f8665e" xlink:href="abvx-20251231.xsd#abvx_AGA20243Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20243Member_019bfb1a-c1ca-7812-a457-ceff09f8665e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20244AGA20245AndAGA20246Member_019bfb1a-c1ca-76fe-80a0-22b94d947eac" xlink:href="abvx-20251231.xsd#abvx_AGA20244AGA20245AndAGA20246Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20244AGA20245AndAGA20246Member_019bfb1a-c1ca-76fe-80a0-22b94d947eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20247Member_019bfb1a-c1ca-74f5-a5ec-9ca29f46bc53" xlink:href="abvx-20251231.xsd#abvx_AGA20247Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20247Member_019bfb1a-c1ca-74f5-a5ec-9ca29f46bc53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20241AGE20242AGA20243AGA20244AGA20245AndAGA20247Member_019bfb1a-ecc0-7e9a-9bff-84d460153dfb" xlink:href="abvx-20251231.xsd#abvx_AGA20241AGE20242AGA20243AGA20244AGA20245AndAGA20247Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20241AGE20242AGA20243AGA20244AGA20245AndAGA20247Member_019bfb1a-ecc0-7e9a-9bff-84d460153dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20246Member_019bfb1a-ecc0-7dd8-99df-83e27c86b936" xlink:href="abvx-20251231.xsd#abvx_AGA20246Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20246Member_019bfb1a-ecc0-7dd8-99df-83e27c86b936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20251Member_019bfb1b-2608-7a81-9ce5-8a31a8f4f904" xlink:href="abvx-20251231.xsd#abvx_AGA20251Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20251Member_019bfb1b-2608-7a81-9ce5-8a31a8f4f904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20252Member_019bfb1b-2608-73da-ad7e-294b5a7fd7b0" xlink:href="abvx-20251231.xsd#abvx_AGA20252Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20252Member_019bfb1b-2608-73da-ad7e-294b5a7fd7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20253Member_019bfb1b-2608-792e-8965-7e86c4ab9f12" xlink:href="abvx-20251231.xsd#abvx_AGA20253Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20253Member_019bfb1b-2608-792e-8965-7e86c4ab9f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20254Member_019bfb1b-2608-7182-b0a6-dde36dbc0779" xlink:href="abvx-20251231.xsd#abvx_AGA20254Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20254Member_019bfb1b-2608-7182-b0a6-dde36dbc0779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20256Member_019bfb1b-2608-7e24-89ca-ddc6be2ae4f3" xlink:href="abvx-20251231.xsd#abvx_AGA20256Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20256Member_019bfb1b-2608-7e24-89ca-ddc6be2ae4f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20257Member_019bfb1b-2608-72a0-8281-5d521eb13a98" xlink:href="abvx-20251231.xsd#abvx_AGA20257Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20257Member_019bfb1b-2608-72a0-8281-5d521eb13a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20258Member_019bfb1b-2608-7d70-9a0a-017c7b24c302" xlink:href="abvx-20251231.xsd#abvx_AGA20258Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20258Member_019bfb1b-2608-7d70-9a0a-017c7b24c302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20251AGA20253AGA20254AGA20256AGA20257AndAGA20258Member_019bfb1b-2608-7462-8e98-f1d5ed173a96" xlink:href="abvx-20251231.xsd#abvx_AGA20251AGA20253AGA20254AGA20256AGA20257AndAGA20258Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20251AGA20253AGA20254AGA20256AGA20257AndAGA20258Member_019bfb1b-2608-7462-8e98-f1d5ed173a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20255Member_019bfb1b-2608-709f-af24-dbe111b5e67f" xlink:href="abvx-20251231.xsd#abvx_AGA20255Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_019cf672-bed8-7b05-85fa-789b45d227fc" xlink:to="loc_abvx_AGA20255Member_019bfb1b-2608-709f-af24-dbe111b5e67f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_019bfb1a-35f5-7b16-80e0-18b961afac81" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_9a4168f3-5cd7-4898-92d5-32efd93d22ec" xlink:to="loc_srt_TitleOfIndividualAxis_019bfb1a-35f5-7b16-80e0-18b961afac81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019bfb1a-35f5-7452-b953-1ca7edba1eee" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_019bfb1a-35f5-7b16-80e0-18b961afac81" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019bfb1a-35f5-7452-b953-1ca7edba1eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_019bfb1a-6596-70c3-bb9c-f9f9159d7884" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019bfb1a-35f5-7452-b953-1ca7edba1eee" xlink:to="loc_srt_ChiefExecutiveOfficerMember_019bfb1a-6596-70c3-bb9c-f9f9159d7884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FormerChiefExecutiveOfficerMember_019bfb1a-9ecc-7fc6-8c12-68166810e396" xlink:href="abvx-20251231.xsd#abvx_FormerChiefExecutiveOfficerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019bfb1a-35f5-7452-b953-1ca7edba1eee" xlink:to="loc_abvx_FormerChiefExecutiveOfficerMember_019bfb1a-9ecc-7fc6-8c12-68166810e396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EmployeeMember_019bfb1a-ecc0-7419-897c-a4485c752907" xlink:href="abvx-20251231.xsd#abvx_EmployeeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019bfb1a-35f5-7452-b953-1ca7edba1eee" xlink:to="loc_abvx_EmployeeMember_019bfb1a-ecc0-7419-897c-a4485c752907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019c003f-1ea0-7383-892d-3ee631562258" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_9a4168f3-5cd7-4898-92d5-32efd93d22ec" xlink:to="loc_srt_RangeAxis_019c003f-1ea0-7383-892d-3ee631562258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019c003f-1ea0-71ee-95e7-2364dce30b77" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_019c003f-1ea0-7383-892d-3ee631562258" xlink:to="loc_srt_RangeMember_019c003f-1ea0-71ee-95e7-2364dce30b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019c003f-1ea0-7315-bf2f-bdaea9a2a338" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019c003f-1ea0-71ee-95e7-2364dce30b77" xlink:to="loc_srt_MaximumMember_019c003f-1ea0-7315-bf2f-bdaea9a2a338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019bfb19-cfb8-7bdc-b888-cd33594b4482" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_9a4168f3-5cd7-4898-92d5-32efd93d22ec" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019bfb19-cfb8-7bdc-b888-cd33594b4482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage_019bfb19-cfb8-7d4c-82b8-d01782bc92a0" xlink:href="abvx-20251231.xsd#abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019bfb19-cfb8-7bdc-b888-cd33594b4482" xlink:to="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage_019bfb19-cfb8-7d4c-82b8-d01782bc92a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_019bfb19-cfb8-73bb-be84-74d1b2bd6dfd" xlink:href="abvx-20251231.xsd#abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019bfb19-cfb8-7bdc-b888-cd33594b4482" xlink:to="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_019bfb19-cfb8-73bb-be84-74d1b2bd6dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentagePerMonth_019c003f-1ea0-741d-936d-2591217db816" xlink:href="abvx-20251231.xsd#abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentagePerMonth"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019bfb19-cfb8-7bdc-b888-cd33594b4482" xlink:to="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentagePerMonth_019c003f-1ea0-741d-936d-2591217db816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementPerformanceConditionsMinimumFinancing_019bfb19-cfb8-7200-84ea-ed39355e284e" xlink:href="abvx-20251231.xsd#abvx_VestingRequirementsForShareBasedPaymentArrangementPerformanceConditionsMinimumFinancing"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019bfb19-cfb8-7bdc-b888-cd33594b4482" xlink:to="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementPerformanceConditionsMinimumFinancing_019bfb19-cfb8-7200-84ea-ed39355e284e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementChangeOfControlMinimumThreshold_019bfb19-cfb8-70cb-a7b9-e7cd4e80df92" xlink:href="abvx-20251231.xsd#abvx_VestingRequirementsForShareBasedPaymentArrangementChangeOfControlMinimumThreshold"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019bfb19-cfb8-7bdc-b888-cd33594b4482" xlink:to="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementChangeOfControlMinimumThreshold_019bfb19-cfb8-70cb-a7b9-e7cd4e80df92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_019bfb19-ffde-7065-af49-483278da772c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019bfb19-cfb8-7bdc-b888-cd33594b4482" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_019bfb19-ffde-7065-af49-483278da772c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfOtherEquityInstrumentsGrantedSubjectToNonMarketPerformanceCondition_019bfb1a-9ecc-7cb6-b681-019e1960914e" xlink:href="abvx-20251231.xsd#abvx_NumberOfOtherEquityInstrumentsGrantedSubjectToNonMarketPerformanceCondition"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019bfb19-cfb8-7bdc-b888-cd33594b4482" xlink:to="loc_abvx_NumberOfOtherEquityInstrumentsGrantedSubjectToNonMarketPerformanceCondition_019bfb1a-9ecc-7cb6-b681-019e1960914e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherShorttermProvisions_019bfb1b-530a-7bae-8355-94f5d2dc56df" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherShorttermProvisions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019bfb19-cfb8-7bdc-b888-cd33594b4482" xlink:to="loc_ifrs-full_OtherShorttermProvisions_019bfb1b-530a-7bae-8355-94f5d2dc56df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherLongtermProvisions_019bfb1b-530a-741c-b825-572d1e3314ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherLongtermProvisions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019bfb19-cfb8-7bdc-b888-cd33594b4482" xlink:to="loc_ifrs-full_OtherLongtermProvisions_019bfb1b-530a-741c-b825-572d1e3314ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementServicePeriod_019c003f-1ea0-7e35-affe-c5e8e9a7fbeb" xlink:href="abvx-20251231.xsd#abvx_VestingRequirementsForShareBasedPaymentArrangementServicePeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019bfb19-cfb8-7bdc-b888-cd33594b4482" xlink:to="loc_abvx_VestingRequirementsForShareBasedPaymentArrangementServicePeriod_019c003f-1ea0-7e35-affe-c5e8e9a7fbeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#SharebasedpaymentsDisclosureofreconciliationofBSAsDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ShareBasedPaymentArrangementsAbstract_970c67c2-b3c1-4851-a92e-7e0c76a3813f" xlink:href="abvx-20251231.xsd#abvx_ShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3fcb40b1-6499-4202-8d89-edcafd8fb34f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_ShareBasedPaymentArrangementsAbstract_970c67c2-b3c1-4851-a92e-7e0c76a3813f" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3fcb40b1-6499-4202-8d89-edcafd8fb34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f606e404-67e1-44c5-835a-311bee9e4692" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3fcb40b1-6499-4202-8d89-edcafd8fb34f" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f606e404-67e1-44c5-835a-311bee9e4692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_d787b95a-8181-48bc-8679-eb961a9b5a7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f606e404-67e1-44c5-835a-311bee9e4692" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_d787b95a-8181-48bc-8679-eb961a9b5a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ShareSubscriptionWarrantsBSAMember_86827a7c-0da6-4a99-8bf0-6ba3f8a0722b" xlink:href="abvx-20251231.xsd#abvx_ShareSubscriptionWarrantsBSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_d787b95a-8181-48bc-8679-eb961a9b5a7a" xlink:to="loc_abvx_ShareSubscriptionWarrantsBSAMember_86827a7c-0da6-4a99-8bf0-6ba3f8a0722b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA201511Member_5145e119-555e-45b8-92d6-477edd40d794" xlink:href="abvx-20251231.xsd#abvx_BSA201511Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_ShareSubscriptionWarrantsBSAMember_86827a7c-0da6-4a99-8bf0-6ba3f8a0722b" xlink:to="loc_abvx_BSA201511Member_5145e119-555e-45b8-92d6-477edd40d794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA201512Member_953c6161-1140-4bde-94f9-1aa77579036e" xlink:href="abvx-20251231.xsd#abvx_BSA201512Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_ShareSubscriptionWarrantsBSAMember_86827a7c-0da6-4a99-8bf0-6ba3f8a0722b" xlink:to="loc_abvx_BSA201512Member_953c6161-1140-4bde-94f9-1aa77579036e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20171Member_b871846b-d010-4b1d-871e-0bdeca850833" xlink:href="abvx-20251231.xsd#abvx_BSA20171Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_ShareSubscriptionWarrantsBSAMember_86827a7c-0da6-4a99-8bf0-6ba3f8a0722b" xlink:to="loc_abvx_BSA20171Member_b871846b-d010-4b1d-871e-0bdeca850833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20181Member_6421f5ba-ed88-4263-ad6f-56e7cd2df058" xlink:href="abvx-20251231.xsd#abvx_BSA20181Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_ShareSubscriptionWarrantsBSAMember_86827a7c-0da6-4a99-8bf0-6ba3f8a0722b" xlink:to="loc_abvx_BSA20181Member_6421f5ba-ed88-4263-ad6f-56e7cd2df058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20241Member_0f8c245f-6182-41ac-9bc7-8a516fea38f7" xlink:href="abvx-20251231.xsd#abvx_BSA20241Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_ShareSubscriptionWarrantsBSAMember_86827a7c-0da6-4a99-8bf0-6ba3f8a0722b" xlink:to="loc_abvx_BSA20241Member_0f8c245f-6182-41ac-9bc7-8a516fea38f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20242Member_8e31b790-0927-40b5-afcb-d40365f990e7" xlink:href="abvx-20251231.xsd#abvx_BSA20242Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_ShareSubscriptionWarrantsBSAMember_86827a7c-0da6-4a99-8bf0-6ba3f8a0722b" xlink:to="loc_abvx_BSA20242Member_8e31b790-0927-40b5-afcb-d40365f990e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20251Member_019c5687-aadc-7f29-aedf-6355a3bb6308" xlink:href="abvx-20251231.xsd#abvx_BSA20251Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_ShareSubscriptionWarrantsBSAMember_86827a7c-0da6-4a99-8bf0-6ba3f8a0722b" xlink:to="loc_abvx_BSA20251Member_019c5687-aadc-7f29-aedf-6355a3bb6308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20252Member_019c5687-d130-7872-8cc5-d48403a0d1d0" xlink:href="abvx-20251231.xsd#abvx_BSA20252Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_ShareSubscriptionWarrantsBSAMember_86827a7c-0da6-4a99-8bf0-6ba3f8a0722b" xlink:to="loc_abvx_BSA20252Member_019c5687-d130-7872-8cc5-d48403a0d1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20253Member_019c5687-f206-79f2-bbfd-90327dcae5ad" xlink:href="abvx-20251231.xsd#abvx_BSA20253Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_ShareSubscriptionWarrantsBSAMember_86827a7c-0da6-4a99-8bf0-6ba3f8a0722b" xlink:to="loc_abvx_BSA20253Member_019c5687-f206-79f2-bbfd-90327dcae5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_8ed354f7-adab-4275-a35c-87a9f9aa4244" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3fcb40b1-6499-4202-8d89-edcafd8fb34f" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_8ed354f7-adab-4275-a35c-87a9f9aa4244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_8707e9c3-9c03-47c9-8cf9-9843c0e68fb1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_8ed354f7-adab-4275-a35c-87a9f9aa4244" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_8707e9c3-9c03-47c9-8cf9-9843c0e68fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_ff6367f1-7763-4e11-bbb2-96b824c79ff0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_8ed354f7-adab-4275-a35c-87a9f9aa4244" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_ff6367f1-7763-4e11-bbb2-96b824c79ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_9aba2688-3a5d-441f-80b2-52607984ad21" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_8ed354f7-adab-4275-a35c-87a9f9aa4244" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_9aba2688-3a5d-441f-80b2-52607984ad21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_9b61b9e8-6862-4ca5-b205-2746782ac62a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_8ed354f7-adab-4275-a35c-87a9f9aa4244" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_9b61b9e8-6862-4ca5-b205-2746782ac62a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_aff8bb19-ef3f-4d66-a621-7c29870824c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_8ed354f7-adab-4275-a35c-87a9f9aa4244" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_aff8bb19-ef3f-4d66-a621-7c29870824c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_c39eb5ae-d3ac-4566-95c8-cf9012596de9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_8ed354f7-adab-4275-a35c-87a9f9aa4244" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_c39eb5ae-d3ac-4566-95c8-cf9012596de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet_f348720e-3dda-4406-893f-3fac7b466bfa" xlink:href="abvx-20251231.xsd#abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_8ed354f7-adab-4275-a35c-87a9f9aa4244" xlink:to="loc_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet_f348720e-3dda-4406-893f-3fac7b466bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ShareBasedPaymentArrangementsAbstract_019cfc55-c45f-7e0d-a6de-a4b5390ec464" xlink:href="abvx-20251231.xsd#abvx_ShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3e97a34d-b635-406e-927e-055e2b234f01" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_ShareBasedPaymentArrangementsAbstract_019cfc55-c45f-7e0d-a6de-a4b5390ec464" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3e97a34d-b635-406e-927e-055e2b234f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1e07aac0-dadb-4077-9f62-53a9e503aa28" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3e97a34d-b635-406e-927e-055e2b234f01" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1e07aac0-dadb-4077-9f62-53a9e503aa28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_bd36689e-de41-4630-b393-ac5df24aae67" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1e07aac0-dadb-4077-9f62-53a9e503aa28" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_bd36689e-de41-4630-b393-ac5df24aae67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20241Member_185c4c31-817a-48fd-b512-5e1253949228" xlink:href="abvx-20251231.xsd#abvx_BSA20241Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_bd36689e-de41-4630-b393-ac5df24aae67" xlink:to="loc_abvx_BSA20241Member_185c4c31-817a-48fd-b512-5e1253949228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20242Member_62ad543a-0251-4574-859f-c7c31f3eae7e" xlink:href="abvx-20251231.xsd#abvx_BSA20242Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_bd36689e-de41-4630-b393-ac5df24aae67" xlink:to="loc_abvx_BSA20242Member_62ad543a-0251-4574-859f-c7c31f3eae7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20251Member_019bfaed-ae59-7133-a193-a5ffe6656b89" xlink:href="abvx-20251231.xsd#abvx_BSA20251Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_bd36689e-de41-4630-b393-ac5df24aae67" xlink:to="loc_abvx_BSA20251Member_019bfaed-ae59-7133-a193-a5ffe6656b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20252Member_019bfaed-dcc8-72ca-a67a-612816ceccc1" xlink:href="abvx-20251231.xsd#abvx_BSA20252Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_bd36689e-de41-4630-b393-ac5df24aae67" xlink:to="loc_abvx_BSA20252Member_019bfaed-dcc8-72ca-a67a-612816ceccc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BSA20253Member_019bfaee-2775-7033-81fd-50d0a3fb96b4" xlink:href="abvx-20251231.xsd#abvx_BSA20253Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_bd36689e-de41-4630-b393-ac5df24aae67" xlink:to="loc_abvx_BSA20253Member_019bfaee-2775-7033-81fd-50d0a3fb96b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_8b5c9c89-3de1-4737-bf67-803efd0dc22f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3e97a34d-b635-406e-927e-055e2b234f01" xlink:to="loc_ifrs-full_RangeAxis_8b5c9c89-3de1-4737-bf67-803efd0dc22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_508f69b5-53fd-476d-8930-f6027a178b79" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_8b5c9c89-3de1-4737-bf67-803efd0dc22f" xlink:to="loc_ifrs-full_RangeDomain_508f69b5-53fd-476d-8930-f6027a178b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5b9e5b0f-1b3a-4187-bfe9-dfa5291284f7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_508f69b5-53fd-476d-8930-f6027a178b79" xlink:to="loc_srt_MinimumMember_5b9e5b0f-1b3a-4187-bfe9-dfa5291284f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a839e7dc-4847-40eb-b2f9-1f8d96012b50" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_508f69b5-53fd-476d-8930-f6027a178b79" xlink:to="loc_srt_MaximumMember_a839e7dc-4847-40eb-b2f9-1f8d96012b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a945d3e7-b261-4cc0-bffe-2347aca1e7a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3e97a34d-b635-406e-927e-055e2b234f01" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a945d3e7-b261-4cc0-bffe-2347aca1e7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted_f7f75781-682e-4860-9114-6e4726e61e18" xlink:href="abvx-20251231.xsd#abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a945d3e7-b261-4cc0-bffe-2347aca1e7a3" xlink:to="loc_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted_f7f75781-682e-4860-9114-6e4726e61e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted_be06938d-ea73-414e-a6f1-e25d51f24fee" xlink:href="abvx-20251231.xsd#abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a945d3e7-b261-4cc0-bffe-2347aca1e7a3" xlink:to="loc_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted_be06938d-ea73-414e-a6f1-e25d51f24fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_b71452a0-8180-438e-8c53-43b27751e232" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a945d3e7-b261-4cc0-bffe-2347aca1e7a3" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_b71452a0-8180-438e-8c53-43b27751e232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted_6f59ccd3-869f-42d2-be50-a013a34cceb5" xlink:href="abvx-20251231.xsd#abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a945d3e7-b261-4cc0-bffe-2347aca1e7a3" xlink:to="loc_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted_6f59ccd3-869f-42d2-be50-a013a34cceb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EquityInstrumentStrikePriceOtherEquityInstrumentsGranted_9f868d05-8da8-4c05-936e-dc696efbe5ef" xlink:href="abvx-20251231.xsd#abvx_EquityInstrumentStrikePriceOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a945d3e7-b261-4cc0-bffe-2347aca1e7a3" xlink:to="loc_abvx_EquityInstrumentStrikePriceOtherEquityInstrumentsGranted_9f868d05-8da8-4c05-936e-dc696efbe5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted_6426209c-6057-46e7-a4bd-2ea7f4528435" xlink:href="abvx-20251231.xsd#abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a945d3e7-b261-4cc0-bffe-2347aca1e7a3" xlink:to="loc_abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted_6426209c-6057-46e7-a4bd-2ea7f4528435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpectedMaturityOtherEquityInstrumentsGranted_701456f7-b201-42c7-83b8-92dc2abf3125" xlink:href="abvx-20251231.xsd#abvx_ExpectedMaturityOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a945d3e7-b261-4cc0-bffe-2347aca1e7a3" xlink:to="loc_abvx_ExpectedMaturityOtherEquityInstrumentsGranted_701456f7-b201-42c7-83b8-92dc2abf3125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpectedVolatilityOtherEquityInstrumentsGranted_69b7111b-bf82-4014-9d5c-bce6e1f15853" xlink:href="abvx-20251231.xsd#abvx_ExpectedVolatilityOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a945d3e7-b261-4cc0-bffe-2347aca1e7a3" xlink:to="loc_abvx_ExpectedVolatilityOtherEquityInstrumentsGranted_69b7111b-bf82-4014-9d5c-bce6e1f15853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#SharebasedpaymentsDisclosureofreconciliationofAGAsDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ShareBasedPaymentArrangementsAbstract_9d425745-00a0-446e-854f-d89b5362d9db" xlink:href="abvx-20251231.xsd#abvx_ShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_0988986e-9d00-4e8d-bb69-1d92affdd4c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_ShareBasedPaymentArrangementsAbstract_9d425745-00a0-446e-854f-d89b5362d9db" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_0988986e-9d00-4e8d-bb69-1d92affdd4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_9cda77e9-331c-42ee-a122-135bb0f2e68f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_0988986e-9d00-4e8d-bb69-1d92affdd4c1" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_9cda77e9-331c-42ee-a122-135bb0f2e68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_3be2ac57-5908-4673-b25d-b24285875322" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_9cda77e9-331c-42ee-a122-135bb0f2e68f" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_3be2ac57-5908-4673-b25d-b24285875322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:href="abvx-20251231.xsd#abvx_FreeSharesAGAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_3be2ac57-5908-4673-b25d-b24285875322" xlink:to="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20231Member_957c1a0a-a143-4c82-9a37-57da96c03383" xlink:href="abvx-20251231.xsd#abvx_AGA20231Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20231Member_957c1a0a-a143-4c82-9a37-57da96c03383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20232Member_52aac868-4b55-4cb0-88e3-aee965019447" xlink:href="abvx-20251231.xsd#abvx_AGA20232Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20232Member_52aac868-4b55-4cb0-88e3-aee965019447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20233Member_e77bc2a4-c84d-4639-bc3f-02bce9b9b2cd" xlink:href="abvx-20251231.xsd#abvx_AGA20233Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20233Member_e77bc2a4-c84d-4639-bc3f-02bce9b9b2cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20234Member_0dc37682-3285-4975-b9c7-7eb139482202" xlink:href="abvx-20251231.xsd#abvx_AGA20234Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20234Member_0dc37682-3285-4975-b9c7-7eb139482202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20235Member_14e73a1c-e2ea-4128-92c8-746dec075028" xlink:href="abvx-20251231.xsd#abvx_AGA20235Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20235Member_14e73a1c-e2ea-4128-92c8-746dec075028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20241Member_2e010280-d2df-43ee-b9fb-07afa98e50b2" xlink:href="abvx-20251231.xsd#abvx_AGA20241Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20241Member_2e010280-d2df-43ee-b9fb-07afa98e50b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20242Member_d8b97919-4a46-4085-92f1-4ca2dd5549c0" xlink:href="abvx-20251231.xsd#abvx_AGA20242Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20242Member_d8b97919-4a46-4085-92f1-4ca2dd5549c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20243Member_6cc205c1-7829-4001-9c85-c71f5c80ea9d" xlink:href="abvx-20251231.xsd#abvx_AGA20243Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20243Member_6cc205c1-7829-4001-9c85-c71f5c80ea9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20244Member_a7114653-b4ec-45af-b8cb-832e22fbbc1a" xlink:href="abvx-20251231.xsd#abvx_AGA20244Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20244Member_a7114653-b4ec-45af-b8cb-832e22fbbc1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20245Member_15b20233-c70f-4505-8c3d-4f5dee3de02e" xlink:href="abvx-20251231.xsd#abvx_AGA20245Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20245Member_15b20233-c70f-4505-8c3d-4f5dee3de02e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20246Member_a9a9fa34-8e60-4ddc-84f9-3eefce1b95aa" xlink:href="abvx-20251231.xsd#abvx_AGA20246Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20246Member_a9a9fa34-8e60-4ddc-84f9-3eefce1b95aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20247Member_ac59c67b-b278-4cf2-ab67-56deb3126df8" xlink:href="abvx-20251231.xsd#abvx_AGA20247Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20247Member_ac59c67b-b278-4cf2-ab67-56deb3126df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20251Member_019c5692-5e4c-7297-baf5-0654e9287a2b" xlink:href="abvx-20251231.xsd#abvx_AGA20251Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20251Member_019c5692-5e4c-7297-baf5-0654e9287a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20252Member_019c5692-7d39-7919-bae3-8dc7300f7c9d" xlink:href="abvx-20251231.xsd#abvx_AGA20252Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20252Member_019c5692-7d39-7919-bae3-8dc7300f7c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20253Member_019c5693-156e-7d9b-9d8c-0de4c80fa9ba" xlink:href="abvx-20251231.xsd#abvx_AGA20253Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20253Member_019c5693-156e-7d9b-9d8c-0de4c80fa9ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20254Member_019c5693-156e-7374-a494-49dc8e97742c" xlink:href="abvx-20251231.xsd#abvx_AGA20254Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20254Member_019c5693-156e-7374-a494-49dc8e97742c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20255Member_019c5693-156e-78da-ada1-a407ba424dfe" xlink:href="abvx-20251231.xsd#abvx_AGA20255Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20255Member_019c5693-156e-78da-ada1-a407ba424dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20256Member_019c5693-156e-7fd2-8a37-a2204acfd74c" xlink:href="abvx-20251231.xsd#abvx_AGA20256Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20256Member_019c5693-156e-7fd2-8a37-a2204acfd74c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20257Member_019c5693-156e-751d-8f50-5f3014d2f8c9" xlink:href="abvx-20251231.xsd#abvx_AGA20257Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20257Member_019c5693-156e-751d-8f50-5f3014d2f8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20258Member_019c5693-156e-7f34-977e-59bb5f265164" xlink:href="abvx-20251231.xsd#abvx_AGA20258Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FreeSharesAGAMember_959f8758-fa1b-43c1-854c-b8efc69ad91a" xlink:to="loc_abvx_AGA20258Member_019c5693-156e-7f34-977e-59bb5f265164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_105b6e0b-1b27-4fb0-8566-495f1a329c4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_0988986e-9d00-4e8d-bb69-1d92affdd4c1" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_105b6e0b-1b27-4fb0-8566-495f1a329c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_04363a92-f910-4196-aecf-cd3887bea24f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_105b6e0b-1b27-4fb0-8566-495f1a329c4f" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_04363a92-f910-4196-aecf-cd3887bea24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_e0da9dc1-b61d-47a8-850e-20e42cdb9f1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_105b6e0b-1b27-4fb0-8566-495f1a329c4f" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_e0da9dc1-b61d-47a8-850e-20e42cdb9f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_dfd0361b-c554-414c-a29b-195905bb5a39" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_105b6e0b-1b27-4fb0-8566-495f1a329c4f" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_dfd0361b-c554-414c-a29b-195905bb5a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_eccaf176-0d8d-431f-aac1-9b93b99accb7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_105b6e0b-1b27-4fb0-8566-495f1a329c4f" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_eccaf176-0d8d-431f-aac1-9b93b99accb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_9aa5df59-22c1-40db-a46c-399a1f95a467" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_105b6e0b-1b27-4fb0-8566-495f1a329c4f" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_9aa5df59-22c1-40db-a46c-399a1f95a467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ShareBasedPaymentArrangementsAbstract_26febae8-91ff-4b30-84d8-e248a2d16585" xlink:href="abvx-20251231.xsd#abvx_ShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_e440733e-c619-46da-a594-be39ed72163e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_ShareBasedPaymentArrangementsAbstract_26febae8-91ff-4b30-84d8-e248a2d16585" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_e440733e-c619-46da-a594-be39ed72163e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_6c6b36a4-23ff-4291-8831-1f50fc2b09d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_e440733e-c619-46da-a594-be39ed72163e" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_6c6b36a4-23ff-4291-8831-1f50fc2b09d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_6c6b36a4-23ff-4291-8831-1f50fc2b09d1" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20231Member_49dafe01-6f1b-4ba7-bbb6-1313ad94c7a4" xlink:href="abvx-20251231.xsd#abvx_AGA20231Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20231Member_49dafe01-6f1b-4ba7-bbb6-1313ad94c7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20232Member_839267f9-4505-48d0-811a-45d21184c399" xlink:href="abvx-20251231.xsd#abvx_AGA20232Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20232Member_839267f9-4505-48d0-811a-45d21184c399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20233Member_f4224785-3a69-4c35-8fe6-5cfc54420e8f" xlink:href="abvx-20251231.xsd#abvx_AGA20233Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20233Member_f4224785-3a69-4c35-8fe6-5cfc54420e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20234Member_f220248a-fa96-4f48-a67d-0cc088f48ef4" xlink:href="abvx-20251231.xsd#abvx_AGA20234Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20234Member_f220248a-fa96-4f48-a67d-0cc088f48ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20235Member_faf3ace0-28cc-457a-a848-121969810a84" xlink:href="abvx-20251231.xsd#abvx_AGA20235Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20235Member_faf3ace0-28cc-457a-a848-121969810a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20241Member_22cec87c-bfbf-457f-9fbc-44ac368a9153" xlink:href="abvx-20251231.xsd#abvx_AGA20241Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20241Member_22cec87c-bfbf-457f-9fbc-44ac368a9153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20242Member_df90699a-2710-4cb6-be44-871c7e55b255" xlink:href="abvx-20251231.xsd#abvx_AGA20242Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20242Member_df90699a-2710-4cb6-be44-871c7e55b255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20243Member_551d2e37-2680-4485-a76a-880d6faf8edb" xlink:href="abvx-20251231.xsd#abvx_AGA20243Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20243Member_551d2e37-2680-4485-a76a-880d6faf8edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20244Member_d449e3a6-b423-4c0a-9c8d-05d898e96827" xlink:href="abvx-20251231.xsd#abvx_AGA20244Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20244Member_d449e3a6-b423-4c0a-9c8d-05d898e96827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20245Member_c2a480d6-0052-48d7-a6f6-7cba92444f98" xlink:href="abvx-20251231.xsd#abvx_AGA20245Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20245Member_c2a480d6-0052-48d7-a6f6-7cba92444f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20246Member_32d88de7-36ec-42b2-a6a4-808afe736443" xlink:href="abvx-20251231.xsd#abvx_AGA20246Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20246Member_32d88de7-36ec-42b2-a6a4-808afe736443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20247Member_f9fad285-039d-41d3-8369-a1525e64d368" xlink:href="abvx-20251231.xsd#abvx_AGA20247Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20247Member_f9fad285-039d-41d3-8369-a1525e64d368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20251Member_019bfaf5-15ee-7c3c-b433-8a2d55bcbccd" xlink:href="abvx-20251231.xsd#abvx_AGA20251Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20251Member_019bfaf5-15ee-7c3c-b433-8a2d55bcbccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20252Member_019bfaf5-3a27-743f-9e7d-76c284967e3a" xlink:href="abvx-20251231.xsd#abvx_AGA20252Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20252Member_019bfaf5-3a27-743f-9e7d-76c284967e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20253Member_019bfaf6-28ef-7590-8b1c-8564f1c3a08d" xlink:href="abvx-20251231.xsd#abvx_AGA20253Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20253Member_019bfaf6-28ef-7590-8b1c-8564f1c3a08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20254Member_019bfaf6-508e-7cd4-9c2d-9bd58109086d" xlink:href="abvx-20251231.xsd#abvx_AGA20254Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20254Member_019bfaf6-508e-7cd4-9c2d-9bd58109086d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20255Member_019bfaf6-6be7-7b43-8199-263a9a99589d" xlink:href="abvx-20251231.xsd#abvx_AGA20255Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20255Member_019bfaf6-6be7-7b43-8199-263a9a99589d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20256Member_019bfaf7-9523-7304-bde2-53ff6d310451" xlink:href="abvx-20251231.xsd#abvx_AGA20256Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20256Member_019bfaf7-9523-7304-bde2-53ff6d310451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20257Member_019bfaf7-c34f-791b-b82a-5318dc0e92b5" xlink:href="abvx-20251231.xsd#abvx_AGA20257Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20257Member_019bfaf7-c34f-791b-b82a-5318dc0e92b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AGA20258Member_019bfaf7-ee30-75cd-a998-17888b5d557b" xlink:href="abvx-20251231.xsd#abvx_AGA20258Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_989786a7-0a3e-4ad1-a9f6-8a77d006dbc7" xlink:to="loc_abvx_AGA20258Member_019bfaf7-ee30-75cd-a998-17888b5d557b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesAxis_09b7b9df-4e33-40b6-8a8a-6657b6fa0ef1" xlink:href="abvx-20251231.xsd#abvx_TranchesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_e440733e-c619-46da-a594-be39ed72163e" xlink:to="loc_abvx_TranchesAxis_09b7b9df-4e33-40b6-8a8a-6657b6fa0ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesDomain_3de17878-cffd-468d-a372-d10fd82267dd" xlink:href="abvx-20251231.xsd#abvx_TranchesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_TranchesAxis_09b7b9df-4e33-40b6-8a8a-6657b6fa0ef1" xlink:to="loc_abvx_TranchesDomain_3de17878-cffd-468d-a372-d10fd82267dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesOneToFourMember_be82ef3d-f04e-4ee5-a585-82d5aca8125e" xlink:href="abvx-20251231.xsd#abvx_TranchesOneToFourMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_TranchesDomain_3de17878-cffd-468d-a372-d10fd82267dd" xlink:to="loc_abvx_TranchesOneToFourMember_be82ef3d-f04e-4ee5-a585-82d5aca8125e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheFiveMember_9f707d3c-f0ab-49c7-9a5f-01126d97dde8" xlink:href="abvx-20251231.xsd#abvx_TrancheFiveMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_TranchesDomain_3de17878-cffd-468d-a372-d10fd82267dd" xlink:to="loc_abvx_TrancheFiveMember_9f707d3c-f0ab-49c7-9a5f-01126d97dde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheSixMember_d1f95c06-03f8-4b3c-a2a2-c73fe949d771" xlink:href="abvx-20251231.xsd#abvx_TrancheSixMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_TranchesDomain_3de17878-cffd-468d-a372-d10fd82267dd" xlink:to="loc_abvx_TrancheSixMember_d1f95c06-03f8-4b3c-a2a2-c73fe949d771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheOneMember_827db1be-c912-4b8b-8ab6-b6af511af08e" xlink:href="abvx-20251231.xsd#abvx_TrancheOneMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_TranchesDomain_3de17878-cffd-468d-a372-d10fd82267dd" xlink:to="loc_abvx_TrancheOneMember_827db1be-c912-4b8b-8ab6-b6af511af08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheTwoMember_7a1bcec3-926d-4231-b5e7-513d6fc81ac8" xlink:href="abvx-20251231.xsd#abvx_TrancheTwoMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_TranchesDomain_3de17878-cffd-468d-a372-d10fd82267dd" xlink:to="loc_abvx_TrancheTwoMember_7a1bcec3-926d-4231-b5e7-513d6fc81ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_b3ca2a2e-c90d-4d1c-9bf9-de9711b84c9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_e440733e-c619-46da-a594-be39ed72163e" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_b3ca2a2e-c90d-4d1c-9bf9-de9711b84c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted_0c990f3d-cc1b-4596-a2bb-a502430bef02" xlink:href="abvx-20251231.xsd#abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_b3ca2a2e-c90d-4d1c-9bf9-de9711b84c9f" xlink:to="loc_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted_0c990f3d-cc1b-4596-a2bb-a502430bef02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted_0aeaf74b-20e8-4115-9e2c-7338fea6bc5b" xlink:href="abvx-20251231.xsd#abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_b3ca2a2e-c90d-4d1c-9bf9-de9711b84c9f" xlink:to="loc_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted_0aeaf74b-20e8-4115-9e2c-7338fea6bc5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted_43227f63-d871-4b05-9d00-5ad12f8d7d80" xlink:href="abvx-20251231.xsd#abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_b3ca2a2e-c90d-4d1c-9bf9-de9711b84c9f" xlink:to="loc_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted_43227f63-d871-4b05-9d00-5ad12f8d7d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpectedVolatilityOtherEquityInstrumentsGranted_01aa0598-f4a7-4117-819b-2b397fb0f248" xlink:href="abvx-20251231.xsd#abvx_ExpectedVolatilityOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_b3ca2a2e-c90d-4d1c-9bf9-de9711b84c9f" xlink:to="loc_abvx_ExpectedVolatilityOtherEquityInstrumentsGranted_01aa0598-f4a7-4117-819b-2b397fb0f248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted_1534f37d-db18-44c8-8fa5-8793f15a2ca0" xlink:href="abvx-20251231.xsd#abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_b3ca2a2e-c90d-4d1c-9bf9-de9711b84c9f" xlink:to="loc_abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted_1534f37d-db18-44c8-8fa5-8793f15a2ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ShareBasedPaymentArrangementsAbstract_84cd3e08-5be8-49fa-a91f-bbcdfb9d7531" xlink:href="abvx-20251231.xsd#abvx_ShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_822bc12a-13be-4a39-bfff-1a841397c162" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_ShareBasedPaymentArrangementsAbstract_84cd3e08-5be8-49fa-a91f-bbcdfb9d7531" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_822bc12a-13be-4a39-bfff-1a841397c162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_e67d9f5f-1c2d-4626-91aa-ab6319e8c3c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_822bc12a-13be-4a39-bfff-1a841397c162" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_e67d9f5f-1c2d-4626-91aa-ab6319e8c3c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_16980579-7140-49dd-b956-4701d3b58e5e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_e67d9f5f-1c2d-4626-91aa-ab6319e8c3c2" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_16980579-7140-49dd-b956-4701d3b58e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FoundersShareSubscriptionWarrantsBCEMember_adf84893-6f18-4db4-9941-563d31e999ed" xlink:href="abvx-20251231.xsd#abvx_FoundersShareSubscriptionWarrantsBCEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_16980579-7140-49dd-b956-4701d3b58e5e" xlink:to="loc_abvx_FoundersShareSubscriptionWarrantsBCEMember_adf84893-6f18-4db4-9941-563d31e999ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ShareSubscriptionWarrantsBSAMember_72c50e5e-f9fb-41b1-aa6f-b8097494c77e" xlink:href="abvx-20251231.xsd#abvx_ShareSubscriptionWarrantsBSAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_16980579-7140-49dd-b956-4701d3b58e5e" xlink:to="loc_abvx_ShareSubscriptionWarrantsBSAMember_72c50e5e-f9fb-41b1-aa6f-b8097494c77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FreeSharesAGAMember_285603fd-4072-4769-bbda-ec66366d383f" xlink:href="abvx-20251231.xsd#abvx_FreeSharesAGAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_16980579-7140-49dd-b956-4701d3b58e5e" xlink:to="loc_abvx_FreeSharesAGAMember_285603fd-4072-4769-bbda-ec66366d383f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_3be04068-1f23-42a2-ab9e-a0bc2b5c7cf0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_822bc12a-13be-4a39-bfff-1a841397c162" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_3be04068-1f23-42a2-ab9e-a0bc2b5c7cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_8fb6c5d8-17a0-4a80-9776-679994e3c0f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_3be04068-1f23-42a2-ab9e-a0bc2b5c7cf0" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_8fb6c5d8-17a0-4a80-9776-679994e3c0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes_8b5629ba-1a6b-453a-a173-01547b2fbc0e" xlink:href="abvx-20251231.xsd#abvx_ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_3be04068-1f23-42a2-ab9e-a0bc2b5c7cf0" xlink:to="loc_abvx_ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes_8b5629ba-1a6b-453a-a173-01547b2fbc0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_39f7dc0f-4999-4436-8806-49f07908940a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_3be04068-1f23-42a2-ab9e-a0bc2b5c7cf0" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_39f7dc0f-4999-4436-8806-49f07908940a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_07b91915-f963-4e07-b6d2-b55dd0c0a956" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_b4ca613f-d6b8-42d9-a4a1-381e6b751182" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_07b91915-f963-4e07-b6d2-b55dd0c0a956" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_b4ca613f-d6b8-42d9-a4a1-381e6b751182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_3c062d8d-0f33-4a06-84fc-c32d7757ebc5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_b4ca613f-d6b8-42d9-a4a1-381e6b751182" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_3c062d8d-0f33-4a06-84fc-c32d7757ebc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_8164547c-f892-4c72-ac89-3660ffe4a95b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_3c062d8d-0f33-4a06-84fc-c32d7757ebc5" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_8164547c-f892-4c72-ac89-3660ffe4a95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Borrowings1Member_32df8845-b5b8-472e-a979-f0a5fd829e54" xlink:href="abvx-20251231.xsd#abvx_Borrowings1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_8164547c-f892-4c72-ac89-3660ffe4a95b" xlink:to="loc_abvx_Borrowings1Member_32df8845-b5b8-472e-a979-f0a5fd829e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1ClaretBondLoansMember_842e9057-8a21-46d3-8bb6-e13732adea47" xlink:href="abvx-20251231.xsd#abvx_Kreos1ClaretBondLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_Borrowings1Member_32df8845-b5b8-472e-a979-f0a5fd829e54" xlink:to="loc_abvx_Kreos1ClaretBondLoansMember_842e9057-8a21-46d3-8bb6-e13732adea47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_ec3ee55c-1b57-4ca3-ad52-1b7db5eabef5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_Borrowings1Member_32df8845-b5b8-472e-a979-f0a5fd829e54" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_ec3ee55c-1b57-4ca3-ad52-1b7db5eabef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PretGarantiParLEtatPGEMember_270cae6d-821f-4510-b3d0-df1b51677dda" xlink:href="abvx-20251231.xsd#abvx_PretGarantiParLEtatPGEMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_Borrowings1Member_32df8845-b5b8-472e-a979-f0a5fd829e54" xlink:to="loc_abvx_PretGarantiParLEtatPGEMember_270cae6d-821f-4510-b3d0-df1b51677dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotesMember_8cf103b1-8abd-437b-93c8-eb0dc18deb30" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_8164547c-f892-4c72-ac89-3660ffe4a95b" xlink:to="loc_abvx_ConvertibleLoansNotesMember_8cf103b1-8abd-437b-93c8-eb0dc18deb30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheAMember_288d002c-69e3-4117-ad71-56c015eeb977" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_ConvertibleLoansNotesMember_8cf103b1-8abd-437b-93c8-eb0dc18deb30" xlink:to="loc_abvx_KreosClaretFinancingTrancheAMember_288d002c-69e3-4117-ad71-56c015eeb977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_HeightsConvertibleNotesMember_2b2cb042-56a2-4b43-ba7f-5042cb4e99b6" xlink:href="abvx-20251231.xsd#abvx_HeightsConvertibleNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_ConvertibleLoansNotesMember_8cf103b1-8abd-437b-93c8-eb0dc18deb30" xlink:to="loc_abvx_HeightsConvertibleNotesMember_2b2cb042-56a2-4b43-ba7f-5042cb4e99b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativesMember_e378ff87-67ef-4be6-b035-dc1671b48702" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DerivativesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_8164547c-f892-4c72-ac89-3660ffe4a95b" xlink:to="loc_ifrs-full_DerivativesMember_e378ff87-67ef-4be6-b035-dc1671b48702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretMinimumReturnIndemnificationsMember_6156b6c6-61cb-4c6c-b8ae-7a6beb8b6818" xlink:href="abvx-20251231.xsd#abvx_KreosClaretMinimumReturnIndemnificationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DerivativesMember_e378ff87-67ef-4be6-b035-dc1671b48702" xlink:to="loc_abvx_KreosClaretMinimumReturnIndemnificationsMember_6156b6c6-61cb-4c6c-b8ae-7a6beb8b6818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingBSAMember_8a156ce0-2b52-4d12-818a-641f5e60375a" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingBSAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DerivativesMember_e378ff87-67ef-4be6-b035-dc1671b48702" xlink:to="loc_abvx_KreosClaretFinancingBSAMember_8a156ce0-2b52-4d12-818a-641f5e60375a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialLiabilitiesMember_f98bd28e-99e2-4080-b110-4b53bbb21327" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_8164547c-f892-4c72-ac89-3660ffe4a95b" xlink:to="loc_abvx_OtherFinancialLiabilitiesMember_f98bd28e-99e2-4080-b110-4b53bbb21327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConditionalAdvancesMember_170b5755-c9d8-4c51-bb5b-60de31a6195d" xlink:href="abvx-20251231.xsd#abvx_ConditionalAdvancesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_OtherFinancialLiabilitiesMember_f98bd28e-99e2-4080-b110-4b53bbb21327" xlink:to="loc_abvx_ConditionalAdvancesMember_170b5755-c9d8-4c51-bb5b-60de31a6195d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificatesMember_3d29cb2b-7ec9-40f9-bfc9-f1c473ff024b" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificatesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_OtherFinancialLiabilitiesMember_f98bd28e-99e2-4080-b110-4b53bbb21327" xlink:to="loc_abvx_RoyaltyCertificatesMember_3d29cb2b-7ec9-40f9-bfc9-f1c473ff024b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_f988ba67-7836-40ed-804f-c775cc9451ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_b4ca613f-d6b8-42d9-a4a1-381e6b751182" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_f988ba67-7836-40ed-804f-c775cc9451ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialLiabilities_5ad64c42-5834-415e-be80-b3ecc28bc68b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentFinancialLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_f988ba67-7836-40ed-804f-c775cc9451ae" xlink:to="loc_ifrs-full_NoncurrentFinancialLiabilities_5ad64c42-5834-415e-be80-b3ecc28bc68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentFinancialLiabilities_2209f43e-e657-4cd6-b302-86bb3e0ca748" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentFinancialLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_f988ba67-7836-40ed-804f-c775cc9451ae" xlink:to="loc_ifrs-full_CurrentFinancialLiabilities_2209f43e-e657-4cd6-b302-86bb3e0ca748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities_a2efd26d-f298-4fa2-a282-9bb9549aa3ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_f988ba67-7836-40ed-804f-c775cc9451ae" xlink:to="loc_ifrs-full_FinancialLiabilities_a2efd26d-f298-4fa2-a282-9bb9549aa3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesKreosClaretFinancingDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_f47e6c5d-d202-4a9e-9574-852e467b5df5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2d725804-2b58-4529-b3a8-ded122e8fe7d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_f47e6c5d-d202-4a9e-9574-852e467b5df5" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2d725804-2b58-4529-b3a8-ded122e8fe7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_019bfefd-f0b7-71e3-8e09-e45b9e1155a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2d725804-2b58-4529-b3a8-ded122e8fe7d" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_019bfefd-f0b7-71e3-8e09-e45b9e1155a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019bfefd-f0b7-7397-a01e-9c0fb982c54a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019bfefd-f0b7-71e3-8e09-e45b9e1155a9" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019bfefd-f0b7-7397-a01e-9c0fb982c54a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingMember_019bfefd-f0b7-7391-bf9a-cd0f45659582" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019bfefd-f0b7-7397-a01e-9c0fb982c54a" xlink:to="loc_abvx_KreosClaretFinancingMember_019bfefd-f0b7-7391-bf9a-cd0f45659582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheAMember_019bfefe-190c-72bd-9735-f8ac34d3c33b" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019bfefd-f0b7-7397-a01e-9c0fb982c54a" xlink:to="loc_abvx_KreosClaretFinancingTrancheAMember_019bfefe-190c-72bd-9735-f8ac34d3c33b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheBMember_019bfefe-58cf-70b4-a0cd-d87c56d2329d" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheBMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019bfefd-f0b7-7397-a01e-9c0fb982c54a" xlink:to="loc_abvx_KreosClaretFinancingTrancheBMember_019bfefe-58cf-70b4-a0cd-d87c56d2329d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheCMember_019bfefe-58cf-7759-bb29-652ca1ad0273" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019bfefd-f0b7-7397-a01e-9c0fb982c54a" xlink:to="loc_abvx_KreosClaretFinancingTrancheCMember_019bfefe-58cf-7759-bb29-652ca1ad0273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember_019bfefe-58cf-7f61-bbc3-9c0c638dfd0b" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019bfefd-f0b7-7397-a01e-9c0fb982c54a" xlink:to="loc_abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember_019bfefe-58cf-7f61-bbc3-9c0c638dfd0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1BondLoansMember_019bfefe-b216-7a7a-8ea8-066bc2005562" xlink:href="abvx-20251231.xsd#abvx_Kreos1BondLoansMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019bfefd-f0b7-7397-a01e-9c0fb982c54a" xlink:to="loc_abvx_Kreos1BondLoansMember_019bfefe-b216-7a7a-8ea8-066bc2005562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosABCBSAMember_019bfefe-d819-729b-a6a4-002f3b950783" xlink:href="abvx-20251231.xsd#abvx_KreosABCBSAMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019bfefd-f0b7-7397-a01e-9c0fb982c54a" xlink:to="loc_abvx_KreosABCBSAMember_019bfefe-d819-729b-a6a4-002f3b950783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingBAndCMember_019c56b3-373e-76b3-9eef-e54272a17ad2" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingBAndCMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019bfefd-f0b7-7397-a01e-9c0fb982c54a" xlink:to="loc_abvx_KreosClaretFinancingBAndCMember_019c56b3-373e-76b3-9eef-e54272a17ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_019bfefe-58cf-796a-bda2-c3981ef6873f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2d725804-2b58-4529-b3a8-ded122e8fe7d" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_019bfefe-58cf-796a-bda2-c3981ef6873f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesDomain_019bfefe-58cf-7677-aacc-088b4ee88027" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_019bfefe-58cf-796a-bda2-c3981ef6873f" xlink:to="loc_ifrs-full_TypesOfInterestRatesDomain_019bfefe-58cf-7677-aacc-088b4ee88027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EuropeanCentralBankBaseRateMember_019bfefe-58cf-70c0-a40e-616974249b76" xlink:href="abvx-20251231.xsd#abvx_EuropeanCentralBankBaseRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInterestRatesDomain_019bfefe-58cf-7677-aacc-088b4ee88027" xlink:to="loc_abvx_EuropeanCentralBankBaseRateMember_019bfefe-58cf-70c0-a40e-616974249b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_019bfefe-58cf-79af-a4de-c092ef8acb89" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2d725804-2b58-4529-b3a8-ded122e8fe7d" xlink:to="loc_ifrs-full_RangeAxis_019bfefe-58cf-79af-a4de-c092ef8acb89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_019bfefe-58cf-72e6-ad11-9a7e73d10db2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_019bfefe-58cf-79af-a4de-c092ef8acb89" xlink:to="loc_ifrs-full_RangeDomain_019bfefe-58cf-72e6-ad11-9a7e73d10db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_019bfefe-58cf-7af5-bfa9-8750052b5593" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_019bfefe-58cf-72e6-ad11-9a7e73d10db2" xlink:to="loc_ifrs-full_BottomOfRangeMember_019bfefe-58cf-7af5-bfa9-8750052b5593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_019bfefe-58cf-7caf-95ab-e480c33f258a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_019bfefe-58cf-72e6-ad11-9a7e73d10db2" xlink:to="loc_ifrs-full_TopOfRangeMember_019bfefe-58cf-7caf-95ab-e480c33f258a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_WarrantsAxis_019bfefe-b216-7673-bdca-49cc018560d8" xlink:href="abvx-20251231.xsd#abvx_WarrantsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2d725804-2b58-4529-b3a8-ded122e8fe7d" xlink:to="loc_abvx_WarrantsAxis_019bfefe-b216-7673-bdca-49cc018560d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_WarrantsDomain_019bfefe-b216-7d04-9853-b555dccd1d3a" xlink:href="abvx-20251231.xsd#abvx_WarrantsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_WarrantsAxis_019bfefe-b216-7673-bdca-49cc018560d8" xlink:to="loc_abvx_WarrantsDomain_019bfefe-b216-7d04-9853-b555dccd1d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosABBSAMember_019bfefe-b216-7699-ae9b-f37c49e2ebf7" xlink:href="abvx-20251231.xsd#abvx_KreosABBSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_WarrantsDomain_019bfefe-b216-7d04-9853-b555dccd1d3a" xlink:to="loc_abvx_KreosABBSAMember_019bfefe-b216-7699-ae9b-f37c49e2ebf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosCBSAMember_019bfefe-b216-71cc-93a4-d4e15399dacc" xlink:href="abvx-20251231.xsd#abvx_KreosCBSAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_WarrantsDomain_019bfefe-b216-7d04-9853-b555dccd1d3a" xlink:to="loc_abvx_KreosCBSAMember_019bfefe-b216-71cc-93a4-d4e15399dacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosABCBSAMember_019bff0c-e052-7dbd-b0f9-89eb141b253e" xlink:href="abvx-20251231.xsd#abvx_KreosABCBSAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_WarrantsDomain_019bfefe-b216-7d04-9853-b555dccd1d3a" xlink:to="loc_abvx_KreosABCBSAMember_019bff0c-e052-7dbd-b0f9-89eb141b253e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_019bfefe-d819-7682-8ce4-1914ffc84f44" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2d725804-2b58-4529-b3a8-ded122e8fe7d" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_019bfefe-d819-7682-8ce4-1914ffc84f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_019bfefe-d819-749d-837f-1fc3f9a2df8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_019bfefe-d819-7682-8ce4-1914ffc84f44" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_019bfefe-d819-749d-837f-1fc3f9a2df8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_019bfefe-d819-751f-a0bb-1685db38888c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_019bfefe-d819-749d-837f-1fc3f9a2df8b" xlink:to="loc_ifrs-full_OrdinarySharesMember_019bfefe-d819-751f-a0bb-1685db38888c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialAgreementAxis_019bfefe-d819-70bc-8553-91dd2e61485f" xlink:href="abvx-20251231.xsd#abvx_FinancialAgreementAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2d725804-2b58-4529-b3a8-ded122e8fe7d" xlink:to="loc_abvx_FinancialAgreementAxis_019bfefe-d819-70bc-8553-91dd2e61485f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialAgreementDomain_019bfefe-d819-7ca6-bcb1-1d318ea29161" xlink:href="abvx-20251231.xsd#abvx_FinancialAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialAgreementAxis_019bfefe-d819-70bc-8553-91dd2e61485f" xlink:to="loc_abvx_FinancialAgreementDomain_019bfefe-d819-7ca6-bcb1-1d318ea29161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingMember_019bff03-0eb3-7320-89fe-3b4cb0b9edab" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialAgreementDomain_019bfefe-d819-7ca6-bcb1-1d318ea29161" xlink:to="loc_abvx_KreosClaretFinancingMember_019bff03-0eb3-7320-89fe-3b4cb0b9edab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesAxis_019bfeff-00b5-72ed-9122-7bef7f97b596" xlink:href="abvx-20251231.xsd#abvx_TranchesAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2d725804-2b58-4529-b3a8-ded122e8fe7d" xlink:to="loc_abvx_TranchesAxis_019bfeff-00b5-72ed-9122-7bef7f97b596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesDomain_019bfeff-00b5-76de-a855-2d9bc1d77a55" xlink:href="abvx-20251231.xsd#abvx_TranchesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_TranchesAxis_019bfeff-00b5-72ed-9122-7bef7f97b596" xlink:to="loc_abvx_TranchesDomain_019bfeff-00b5-76de-a855-2d9bc1d77a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheABAndCMember_019bfeff-00b5-78fd-9345-78ebef8844a2" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheABAndCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_TranchesDomain_019bfeff-00b5-76de-a855-2d9bc1d77a55" xlink:to="loc_abvx_KreosClaretFinancingTrancheABAndCMember_019bfeff-00b5-78fd-9345-78ebef8844a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_019bfeff-00b5-7080-be53-dcd7dac7f3c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2d725804-2b58-4529-b3a8-ded122e8fe7d" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_019bfeff-00b5-7080-be53-dcd7dac7f3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_019bfeff-00b5-72d4-ad89-08d6cad5c0a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_019bfeff-00b5-7080-be53-dcd7dac7f3c9" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_019bfeff-00b5-72d4-ad89-08d6cad5c0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretMinimumReturnIndemnificationsMember_019bfeff-00b5-7247-b73a-3e32e6de1bf5" xlink:href="abvx-20251231.xsd#abvx_KreosClaretMinimumReturnIndemnificationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_019bfeff-00b5-72d4-ad89-08d6cad5c0a6" xlink:to="loc_abvx_KreosClaretMinimumReturnIndemnificationsMember_019bfeff-00b5-7247-b73a-3e32e6de1bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019bfeff-82d5-7a4c-8385-489519e6b09f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2d725804-2b58-4529-b3a8-ded122e8fe7d" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019bfeff-82d5-7a4c-8385-489519e6b09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019bfeff-82d5-7c33-9511-39844f218df2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019bfeff-82d5-7a4c-8385-489519e6b09f" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019bfeff-82d5-7c33-9511-39844f218df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosABBSAMember_019bfeff-82d5-73de-9562-4afcbd11f6af" xlink:href="abvx-20251231.xsd#abvx_KreosABBSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019bfeff-82d5-7c33-9511-39844f218df2" xlink:to="loc_abvx_KreosABBSAMember_019bfeff-82d5-73de-9562-4afcbd11f6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretMinimumReturnIndemnificationsMember_019bfeff-b745-7feb-9264-1834b1a0be71" xlink:href="abvx-20251231.xsd#abvx_KreosClaretMinimumReturnIndemnificationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019bfeff-82d5-7c33-9511-39844f218df2" xlink:to="loc_abvx_KreosClaretMinimumReturnIndemnificationsMember_019bfeff-b745-7feb-9264-1834b1a0be71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosABCBSAMember_019bff0c-e052-7c62-95ab-804715793a0d" xlink:href="abvx-20251231.xsd#abvx_KreosABCBSAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019bfeff-82d5-7c33-9511-39844f218df2" xlink:to="loc_abvx_KreosABCBSAMember_019bff0c-e052-7c62-95ab-804715793a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosCBSAMember_019c0047-c5e4-73fa-b949-2eaea9cdc692" xlink:href="abvx-20251231.xsd#abvx_KreosCBSAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019bfeff-82d5-7c33-9511-39844f218df2" xlink:to="loc_abvx_KreosCBSAMember_019c0047-c5e4-73fa-b949-2eaea9cdc692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_019bfeff-82d5-74c4-b079-e7d00424261e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2d725804-2b58-4529-b3a8-ded122e8fe7d" xlink:to="loc_ifrs-full_UnobservableInputsAxis_019bfeff-82d5-74c4-b079-e7d00424261e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain_019bfeff-82d5-7be8-9d48-6d4f77fd898a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsAxis_019bfeff-82d5-74c4-b079-e7d00424261e" xlink:to="loc_ifrs-full_UnobservableInputsDomain_019bfeff-82d5-7be8-9d48-6d4f77fd898a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_MarketRateMeasurementInputMember_019bfeff-82d5-7523-9de9-3cbb04860cd9" xlink:href="abvx-20251231.xsd#abvx_MarketRateMeasurementInputMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019bfeff-82d5-7be8-9d48-6d4f77fd898a" xlink:to="loc_abvx_MarketRateMeasurementInputMember_019bfeff-82d5-7523-9de9-3cbb04860cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SharePriceMeasurementInputMember_019bfeff-b745-7890-bc29-434581939a82" xlink:href="abvx-20251231.xsd#abvx_SharePriceMeasurementInputMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019bfeff-82d5-7be8-9d48-6d4f77fd898a" xlink:to="loc_abvx_SharePriceMeasurementInputMember_019bfeff-b745-7890-bc29-434581939a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_019bfeff-b745-705d-8e84-9245cc16e966" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019bfeff-82d5-7be8-9d48-6d4f77fd898a" xlink:to="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_019bfeff-b745-705d-8e84-9245cc16e966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RiskFreeInterestRateMeasurementInputMember_019bfeff-b745-77f5-80fc-36a6aded56d1" xlink:href="abvx-20251231.xsd#abvx_RiskFreeInterestRateMeasurementInputMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019bfeff-82d5-7be8-9d48-6d4f77fd898a" xlink:to="loc_abvx_RiskFreeInterestRateMeasurementInputMember_019bfeff-b745-77f5-80fc-36a6aded56d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinalRedemptionScenarioProbabilityMeasurementInputMember_019bfeff-dc24-7392-8855-650ee886ba89" xlink:href="abvx-20251231.xsd#abvx_FinalRedemptionScenarioProbabilityMeasurementInputMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019bfeff-82d5-7be8-9d48-6d4f77fd898a" xlink:to="loc_abvx_FinalRedemptionScenarioProbabilityMeasurementInputMember_019bfeff-dc24-7392-8855-650ee886ba89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DiscountRateMeasurementInputMember_019bfeff-dc24-7e70-830c-e64ff90ebba0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DiscountRateMeasurementInputMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019bfeff-82d5-7be8-9d48-6d4f77fd898a" xlink:to="loc_ifrs-full_DiscountRateMeasurementInputMember_019bfeff-dc24-7e70-830c-e64ff90ebba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpiryScenarioProbablityMeasurementInputMember_019bff0c-e052-72de-83bc-12d8873a63ba" xlink:href="abvx-20251231.xsd#abvx_ExpiryScenarioProbablityMeasurementInputMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019bfeff-82d5-7be8-9d48-6d4f77fd898a" xlink:to="loc_abvx_ExpiryScenarioProbablityMeasurementInputMember_019bff0c-e052-72de-83bc-12d8873a63ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_019bfeff-b745-7bad-b8eb-647b237b05e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2d725804-2b58-4529-b3a8-ded122e8fe7d" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_019bfeff-b745-7bad-b8eb-647b237b05e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_019bfeff-b745-7968-bfb8-80711a1ca811" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_019bfeff-b745-7bad-b8eb-647b237b05e0" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_019bfeff-b745-7968-bfb8-80711a1ca811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BlackScholesModelMember_019bfeff-b745-7140-af40-8b22666e9e35" xlink:href="abvx-20251231.xsd#abvx_BlackScholesModelMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_019bfeff-b745-7968-bfb8-80711a1ca811" xlink:to="loc_abvx_BlackScholesModelMember_019bfeff-b745-7140-af40-8b22666e9e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_MonteCarloModel1Member_019bfeff-b745-7518-b21b-e7c80bc398f9" xlink:href="abvx-20251231.xsd#abvx_MonteCarloModel1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_019bfeff-b745-7968-bfb8-80711a1ca811" xlink:to="loc_abvx_MonteCarloModel1Member_019bfeff-b745-7518-b21b-e7c80bc398f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_019c56bf-5b1e-7528-936a-5999fe4b05aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2d725804-2b58-4529-b3a8-ded122e8fe7d" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_019c56bf-5b1e-7528-936a-5999fe4b05aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_019c56bf-5b1e-7d91-a183-c5deb96b764e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_019c56bf-5b1e-7528-936a-5999fe4b05aa" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_019c56bf-5b1e-7d91-a183-c5deb96b764e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1ClaretBondLoansMember_019c56bf-5b1e-74da-a130-5cd79b88b1f6" xlink:href="abvx-20251231.xsd#abvx_Kreos1ClaretBondLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_019c56bf-5b1e-7d91-a183-c5deb96b764e" xlink:to="loc_abvx_Kreos1ClaretBondLoansMember_019c56bf-5b1e-74da-a130-5cd79b88b1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2d725804-2b58-4529-b3a8-ded122e8fe7d" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsMaximumBorrowingCapacity_019bfefd-f0b7-790e-a120-38adabf2252a" xlink:href="abvx-20251231.xsd#abvx_BorrowingsMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_BorrowingsMaximumBorrowingCapacity_019bfefd-f0b7-790e-a120-38adabf2252a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepaymentsOfBondLoans_019bfefe-b216-7ea3-9dd6-11e37f6e7e4d" xlink:href="abvx-20251231.xsd#abvx_RepaymentsOfBondLoans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_RepaymentsOfBondLoans_019bfefe-b216-7ea3-9dd6-11e37f6e7e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsNumberOfTranches_019bfefd-f0b7-7398-bf8b-76b2676d1733" xlink:href="abvx-20251231.xsd#abvx_BorrowingsNumberOfTranches"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_BorrowingsNumberOfTranches_019bfefd-f0b7-7398-bf8b-76b2676d1733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsMaximumBorrowingCapacityPerTranche_019bfefd-f0b7-7cd6-9dbb-576ae92b1802" xlink:href="abvx-20251231.xsd#abvx_BorrowingsMaximumBorrowingCapacityPerTranche"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_BorrowingsMaximumBorrowingCapacityPerTranche_019bfefd-f0b7-7cd6-9dbb-576ae92b1802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_019bfefe-190c-72a2-a7a4-6da1222d670e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_019bfefe-190c-72a2-a7a4-6da1222d670e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsFixedConversionPrice_019bfefe-190c-706b-b789-746eaa3a0546" xlink:href="abvx-20251231.xsd#abvx_BorrowingsFixedConversionPrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_BorrowingsFixedConversionPrice_019bfefe-190c-706b-b789-746eaa3a0546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_019bfefe-190c-75c6-b12c-59d045c6bc61" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_ifrs-full_BorrowingsInterestRate_019bfefe-190c-75c6-b12c-59d045c6bc61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsEarlyRepaymentDiscountRate_019bfefe-190c-7555-a078-76edd7de7f1f" xlink:href="abvx-20251231.xsd#abvx_BorrowingsEarlyRepaymentDiscountRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_BorrowingsEarlyRepaymentDiscountRate_019bfefe-190c-7555-a078-76edd7de7f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsExitFeePercentage_019bfefe-190c-7cf8-a383-946861fee68a" xlink:href="abvx-20251231.xsd#abvx_BorrowingsExitFeePercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_BorrowingsExitFeePercentage_019bfefe-190c-7cf8-a383-946861fee68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsDebtToMarketCapitalizationRatio_019bfefe-58cf-708d-b262-d0572d6c8076" xlink:href="abvx-20251231.xsd#abvx_BorrowingsDebtToMarketCapitalizationRatio"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_BorrowingsDebtToMarketCapitalizationRatio_019bfefe-58cf-708d-b262-d0572d6c8076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsPerformanceConditionsMinimumFinancing_019bfefe-58cf-73a3-8bd8-00fb5e5ed461" xlink:href="abvx-20251231.xsd#abvx_BorrowingsPerformanceConditionsMinimumFinancing"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_BorrowingsPerformanceConditionsMinimumFinancing_019bfefe-58cf-73a3-8bd8-00fb5e5ed461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsAdjustmentToInterestRateBasis_019bfefe-58cf-734d-b3bb-6794ac3b9883" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsAdjustmentToInterestRateBasis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_ifrs-full_BorrowingsAdjustmentToInterestRateBasis_019bfefe-58cf-734d-b3bb-6794ac3b9883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsBasisInterestRate_019bfefe-58cf-711d-9b0b-60d2d4526d7a" xlink:href="abvx-20251231.xsd#abvx_BorrowingsBasisInterestRate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_BorrowingsBasisInterestRate_019bfefe-58cf-711d-9b0b-60d2d4526d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherShareWarrantsSubscriptionPricePerShare_019bfefe-b216-7fca-9cf5-95e4d057b916" xlink:href="abvx-20251231.xsd#abvx_OtherShareWarrantsSubscriptionPricePerShare"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_OtherShareWarrantsSubscriptionPricePerShare_019bfefe-b216-7fca-9cf5-95e4d057b916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfWarrantsGranted_019bfefe-b216-7334-9654-7b14b85d0646" xlink:href="abvx-20251231.xsd#abvx_NumberOfWarrantsGranted"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_NumberOfWarrantsGranted_019bfefe-b216-7334-9654-7b14b85d0646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExercisePriceOtherEquityInstrumentsGranted_019bfefe-b216-77b8-8ee6-95a7f8b51e9d" xlink:href="abvx-20251231.xsd#abvx_ExercisePriceOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_ExercisePriceOtherEquityInstrumentsGranted_019bfefe-b216-77b8-8ee6-95a7f8b51e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted_019bfefe-b216-731b-8247-c79689f4a7ee" xlink:href="abvx-20251231.xsd#abvx_ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted_019bfefe-b216-731b-8247-c79689f4a7ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted_019bfefe-b216-7b22-9451-68ac6e300cdb" xlink:href="abvx-20251231.xsd#abvx_ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted_019bfefe-b216-7b22-9451-68ac6e300cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IssuanceOfOtherShareWarrants_019bfefe-b216-7a76-bc7d-57c7484c3888" xlink:href="abvx-20251231.xsd#abvx_IssuanceOfOtherShareWarrants"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_IssuanceOfOtherShareWarrants_019bfefe-b216-7a76-bc7d-57c7484c3888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsPercentageExercisableImmediately_019bfefe-b216-7f5d-aba3-d1b1e0ef67b6" xlink:href="abvx-20251231.xsd#abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsPercentageExercisableImmediately"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsPercentageExercisableImmediately_019bfefe-b216-7f5d-aba3-d1b1e0ef67b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsRemainingPercentageExercisable_019bfefe-b216-7319-b927-50206565ca44" xlink:href="abvx-20251231.xsd#abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsRemainingPercentageExercisable"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsRemainingPercentageExercisable_019bfefe-b216-7319-b927-50206565ca44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherShareWarrantsExercisePeriod_019bfefe-b216-7970-8ef6-0426d1d6929c" xlink:href="abvx-20251231.xsd#abvx_OtherShareWarrantsExercisePeriod"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_OtherShareWarrantsExercisePeriod_019bfefe-b216-7970-8ef6-0426d1d6929c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments_019bfefe-d819-7e34-9eca-c12f279daaa5" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments_019bfefe-d819-7e34-9eca-c12f279daaa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_019bfefe-d819-7ec0-a72a-1b4c9d30aba1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_019bfefe-d819-7ec0-a72a-1b4c9d30aba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfWarrantsRepurchased_019bfefe-d819-78dd-b858-386bfe8107a0" xlink:href="abvx-20251231.xsd#abvx_NumberOfWarrantsRepurchased"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_NumberOfWarrantsRepurchased_019bfefe-d819-78dd-b858-386bfe8107a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants_019bfefe-d819-76b6-853c-da7f044c3269" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants_019bfefe-d819-76b6-853c-da7f044c3269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_019cfcce-9713-73cb-a6dc-5cecf1a7dceb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_019cfcce-9713-73cb-a6dc-5cecf1a7dceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding_019bfeff-00b5-7325-8631-ade5906ff8ce" xlink:href="abvx-20251231.xsd#abvx_AggregateFairValueOtherEquityInstrumentsOutstanding"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding_019bfeff-00b5-7325-8631-ade5906ff8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_019c56b3-373e-7d6b-9806-84dd9630a285" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_019c56b3-373e-7d6b-9806-84dd9630a285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_019c56bb-c8ad-7a1d-aa49-105f5750d0fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_ifrs-full_Borrowings_019c56bb-c8ad-7a1d-aa49-105f5750d0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsDeposit_019c56b4-da50-7300-a5b4-9fe89fb33835" xlink:href="abvx-20251231.xsd#abvx_BorrowingsDeposit"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_BorrowingsDeposit_019c56b4-da50-7300-a5b4-9fe89fb33835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsDiscountRate_019c56bd-58fc-7f8e-828e-1a4251c5a793" xlink:href="abvx-20251231.xsd#abvx_BorrowingsDiscountRate"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_BorrowingsDiscountRate_019c56bd-58fc-7f8e-828e-1a4251c5a793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_019c56ba-78b5-71cb-af61-30c8b159f573" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_019c56ba-78b5-71cb-af61-30c8b159f573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsExitFeeAmount_019c57ec-2964-7cc1-a9c1-aa3bdeac1ba4" xlink:href="abvx-20251231.xsd#abvx_BorrowingsExitFeeAmount"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_BorrowingsExitFeeAmount_019c57ec-2964-7cc1-a9c1-aa3bdeac1ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid_019c56c6-6e6f-7865-b098-1eee8ae22e25" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid_019c56c6-6e6f-7865-b098-1eee8ae22e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_019c56d5-139c-7bf5-a5fb-32d5ee832f4a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotionalAmount"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_ifrs-full_NotionalAmount_019c56d5-139c-7bf5-a5fb-32d5ee832f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValue_019bfeff-82d5-7687-91e5-b85640ccec44" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValue"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValue_019bfeff-82d5-7687-91e5-b85640ccec44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities_019bfeff-82d5-7e60-af27-9c7bb84a1892" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantUnobservableInputLiabilities"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_ifrs-full_SignificantUnobservableInputLiabilities_019bfeff-82d5-7e60-af27-9c7bb84a1892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotes_019bfeff-82d5-79dd-84ce-297e6d15e1d9" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotes"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_ConvertibleLoansNotes_019bfeff-82d5-79dd-84ce-297e6d15e1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotesCarryingAmountOfTheEquityComponent_019bfeff-82d5-7b04-ac27-3d08313b0bd6" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotesCarryingAmountOfTheEquityComponent"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_ConvertibleLoansNotesCarryingAmountOfTheEquityComponent_019bfeff-82d5-7b04-ac27-3d08313b0bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bfeff-82d5-72b5-83b6-cbd5d8a5b024" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bfeff-82d5-72b5-83b6-cbd5d8a5b024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bfeff-82d5-7fb2-9fd3-3b35ba90d069" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bfeff-82d5-7fb2-9fd3-3b35ba90d069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bfeff-dc24-7094-8820-4c4406c53691" xlink:href="abvx-20251231.xsd#abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bfeff-dc24-7094-8820-4c4406c53691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets_019bfeff-dc24-704e-856f-eebc0671514d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets"/>
    <link:presentationArc order="44" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets_019bfeff-dc24-704e-856f-eebc0671514d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted_019bff0c-e052-708d-a4c3-19905e9ff88e" xlink:href="abvx-20251231.xsd#abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="45" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted_019bff0c-e052-708d-a4c3-19905e9ff88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities_019c56bf-5b1e-73fb-baa0-823b1300875f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="46" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bfefd-f0b7-755e-8458-c5a0425f953a" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities_019c56bf-5b1e-73fb-baa0-823b1300875f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_68757f29-cf47-4c73-be26-beffe2af9c50" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_36cd83a0-7931-48fc-b0df-94f3b271081f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_68757f29-cf47-4c73-be26-beffe2af9c50" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_36cd83a0-7931-48fc-b0df-94f3b271081f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_a84674cd-1a26-4dd5-b547-078dee1358fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_36cd83a0-7931-48fc-b0df-94f3b271081f" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_a84674cd-1a26-4dd5-b547-078dee1358fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_06bcadf2-00bd-4f1d-9716-8b1820858b45" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_a84674cd-1a26-4dd5-b547-078dee1358fa" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_06bcadf2-00bd-4f1d-9716-8b1820858b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretMinimumReturnIndemnificationsMember_94e984e7-b7d7-43b3-b648-fec3925fc43e" xlink:href="abvx-20251231.xsd#abvx_KreosClaretMinimumReturnIndemnificationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_06bcadf2-00bd-4f1d-9716-8b1820858b45" xlink:to="loc_abvx_KreosClaretMinimumReturnIndemnificationsMember_94e984e7-b7d7-43b3-b648-fec3925fc43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_768050a3-57f8-487a-b829-3f09a7798321" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_36cd83a0-7931-48fc-b0df-94f3b271081f" xlink:to="loc_ifrs-full_UnobservableInputsAxis_768050a3-57f8-487a-b829-3f09a7798321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain_13497e69-3221-4bae-849d-162e23accfba" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsAxis_768050a3-57f8-487a-b829-3f09a7798321" xlink:to="loc_ifrs-full_UnobservableInputsDomain_13497e69-3221-4bae-849d-162e23accfba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinalRedemptionScenarioProbabilityMeasurementInputMember_68a89ecb-c5e5-408f-91ef-0c48f92e9f24" xlink:href="abvx-20251231.xsd#abvx_FinalRedemptionScenarioProbabilityMeasurementInputMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_13497e69-3221-4bae-849d-162e23accfba" xlink:to="loc_abvx_FinalRedemptionScenarioProbabilityMeasurementInputMember_68a89ecb-c5e5-408f-91ef-0c48f92e9f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_MinimalReturnMeasurementInputMember_00eb163c-99bf-48c5-8ab6-4f7ff4e202b2" xlink:href="abvx-20251231.xsd#abvx_MinimalReturnMeasurementInputMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_13497e69-3221-4bae-849d-162e23accfba" xlink:to="loc_abvx_MinimalReturnMeasurementInputMember_00eb163c-99bf-48c5-8ab6-4f7ff4e202b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DiscountRateMeasurementInputMember_d977269c-5c93-4964-b1d0-d54ee84527c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DiscountRateMeasurementInputMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_13497e69-3221-4bae-849d-162e23accfba" xlink:to="loc_ifrs-full_DiscountRateMeasurementInputMember_d977269c-5c93-4964-b1d0-d54ee84527c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember_65d80013-b519-4c4b-9df2-9bab15aa222a" xlink:href="abvx-20251231.xsd#abvx_FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_13497e69-3221-4bae-849d-162e23accfba" xlink:to="loc_abvx_FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember_65d80013-b519-4c4b-9df2-9bab15aa222a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember_916024b2-f762-4677-b25a-a0995c10ef93" xlink:href="abvx-20251231.xsd#abvx_TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_13497e69-3221-4bae-849d-162e23accfba" xlink:to="loc_abvx_TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember_916024b2-f762-4677-b25a-a0995c10ef93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember_f36618a9-1e2f-43c6-9250-d6c668797a3a" xlink:href="abvx-20251231.xsd#abvx_FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_13497e69-3221-4bae-849d-162e23accfba" xlink:to="loc_abvx_FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember_f36618a9-1e2f-43c6-9250-d6c668797a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember_8af5ce17-404c-41a9-837f-6de6b0d11ffb" xlink:href="abvx-20251231.xsd#abvx_FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_13497e69-3221-4bae-849d-162e23accfba" xlink:to="loc_abvx_FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember_8af5ce17-404c-41a9-837f-6de6b0d11ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinalRedemptionFairValueOfMRIMeasurementInputMember_7265268a-6add-4bf4-aa1a-9745fb699b8c" xlink:href="abvx-20251231.xsd#abvx_FinalRedemptionFairValueOfMRIMeasurementInputMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_13497e69-3221-4bae-849d-162e23accfba" xlink:to="loc_abvx_FinalRedemptionFairValueOfMRIMeasurementInputMember_7265268a-6add-4bf4-aa1a-9745fb699b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TenderOfferFairValueOfMRIMeasurementInputMember_c97f3eb8-8833-497e-84cd-8c302e4372ac" xlink:href="abvx-20251231.xsd#abvx_TenderOfferFairValueOfMRIMeasurementInputMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_13497e69-3221-4bae-849d-162e23accfba" xlink:to="loc_abvx_TenderOfferFairValueOfMRIMeasurementInputMember_c97f3eb8-8833-497e-84cd-8c302e4372ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_b1590cdc-d247-4ac7-b801-bc3a84f5656a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_36cd83a0-7931-48fc-b0df-94f3b271081f" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_b1590cdc-d247-4ac7-b801-bc3a84f5656a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_7b61290a-2065-40b2-a3b2-447e5ccd344d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_b1590cdc-d247-4ac7-b801-bc3a84f5656a" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_7b61290a-2065-40b2-a3b2-447e5ccd344d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AmortizedCostEIRMethodMember_70cbd0d6-8c2b-4de2-9475-3c8240d70e3a" xlink:href="abvx-20251231.xsd#abvx_AmortizedCostEIRMethodMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_7b61290a-2065-40b2-a3b2-447e5ccd344d" xlink:to="loc_abvx_AmortizedCostEIRMethodMember_70cbd0d6-8c2b-4de2-9475-3c8240d70e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesAxis_e182b80b-b796-4c25-96ea-19da86e25baa" xlink:href="abvx-20251231.xsd#abvx_TranchesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_36cd83a0-7931-48fc-b0df-94f3b271081f" xlink:to="loc_abvx_TranchesAxis_e182b80b-b796-4c25-96ea-19da86e25baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TranchesDomain_9e1e2092-4488-4e98-a620-1a08d01656e9" xlink:href="abvx-20251231.xsd#abvx_TranchesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_TranchesAxis_e182b80b-b796-4c25-96ea-19da86e25baa" xlink:to="loc_abvx_TranchesDomain_9e1e2092-4488-4e98-a620-1a08d01656e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheBMember_1d4d516c-bdf6-4262-a8f2-8df550cb4c07" xlink:href="abvx-20251231.xsd#abvx_TrancheBMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_TranchesDomain_9e1e2092-4488-4e98-a620-1a08d01656e9" xlink:to="loc_abvx_TrancheBMember_1d4d516c-bdf6-4262-a8f2-8df550cb4c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TrancheCMember_d26ff512-170d-4682-a733-23c6fbb3fa7e" xlink:href="abvx-20251231.xsd#abvx_TrancheCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_TranchesDomain_9e1e2092-4488-4e98-a620-1a08d01656e9" xlink:to="loc_abvx_TrancheCMember_d26ff512-170d-4682-a733-23c6fbb3fa7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_9872e8ad-dc13-43ab-a0f3-9d170405ce0f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_36cd83a0-7931-48fc-b0df-94f3b271081f" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_9872e8ad-dc13-43ab-a0f3-9d170405ce0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities_7d715588-af4a-4813-bc29-c81392ee0579" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantUnobservableInputLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_9872e8ad-dc13-43ab-a0f3-9d170405ce0f" xlink:to="loc_ifrs-full_SignificantUnobservableInputLiabilities_7d715588-af4a-4813-bc29-c81392ee0579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding_efc7bee9-461d-4579-8450-73a957fd4c73" xlink:href="abvx-20251231.xsd#abvx_AggregateFairValueOtherEquityInstrumentsOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_9872e8ad-dc13-43ab-a0f3-9d170405ce0f" xlink:to="loc_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding_efc7bee9-461d-4579-8450-73a957fd4c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_5819dbd7-4017-4d64-ad24-1165c29de7a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfWarrantsArrangementsTable_10900a4b-72f0-4dcd-bef1-1eb16b6a3947" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfWarrantsArrangementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_5819dbd7-4017-4d64-ad24-1165c29de7a2" xlink:to="loc_abvx_DisclosureOfWarrantsArrangementsTable_10900a4b-72f0-4dcd-bef1-1eb16b6a3947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_WarrantsAxis_3a452a7e-63be-45fc-b642-9950260545a1" xlink:href="abvx-20251231.xsd#abvx_WarrantsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsTable_10900a4b-72f0-4dcd-bef1-1eb16b6a3947" xlink:to="loc_abvx_WarrantsAxis_3a452a7e-63be-45fc-b642-9950260545a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_WarrantsDomain_1c2ea615-bac9-47b1-8434-1019915c82fc" xlink:href="abvx-20251231.xsd#abvx_WarrantsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_WarrantsAxis_3a452a7e-63be-45fc-b642-9950260545a1" xlink:to="loc_abvx_WarrantsDomain_1c2ea615-bac9-47b1-8434-1019915c82fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosABBSAMember_ceaea5e7-c61b-47d9-ae14-dc7208568f89" xlink:href="abvx-20251231.xsd#abvx_KreosABBSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_WarrantsDomain_1c2ea615-bac9-47b1-8434-1019915c82fc" xlink:to="loc_abvx_KreosABBSAMember_ceaea5e7-c61b-47d9-ae14-dc7208568f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosCBSAMember_bff0f80f-1b07-45cd-b25c-326601e5f69d" xlink:href="abvx-20251231.xsd#abvx_KreosCBSAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_WarrantsDomain_1c2ea615-bac9-47b1-8434-1019915c82fc" xlink:to="loc_abvx_KreosCBSAMember_bff0f80f-1b07-45cd-b25c-326601e5f69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_b8db9b02-bb20-4132-8c72-1ef096aa02f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsTable_10900a4b-72f0-4dcd-bef1-1eb16b6a3947" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_b8db9b02-bb20-4132-8c72-1ef096aa02f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_05b99197-9573-442b-9fe4-36ba04f9521f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_b8db9b02-bb20-4132-8c72-1ef096aa02f8" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_05b99197-9573-442b-9fe4-36ba04f9521f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosABBSAMember_4b51b439-eee7-4bd9-a318-05419921d67b" xlink:href="abvx-20251231.xsd#abvx_KreosABBSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_05b99197-9573-442b-9fe4-36ba04f9521f" xlink:to="loc_abvx_KreosABBSAMember_4b51b439-eee7-4bd9-a318-05419921d67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosCBSAMember_6e097aea-66dc-455d-bda3-1cb2ee73ca38" xlink:href="abvx-20251231.xsd#abvx_KreosCBSAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_05b99197-9573-442b-9fe4-36ba04f9521f" xlink:to="loc_abvx_KreosCBSAMember_6e097aea-66dc-455d-bda3-1cb2ee73ca38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_9b25b42f-6eca-4b28-bb28-f138c05e5663" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsTable_10900a4b-72f0-4dcd-bef1-1eb16b6a3947" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_9b25b42f-6eca-4b28-bb28-f138c05e5663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_af52823c-9cf6-41b3-932e-3af301f83a22" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_9b25b42f-6eca-4b28-bb28-f138c05e5663" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_af52823c-9cf6-41b3-932e-3af301f83a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OptionPricingModelMember_8ba5ca94-62fd-4787-ae19-a8980c39b5ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OptionPricingModelMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_af52823c-9cf6-41b3-932e-3af301f83a22" xlink:to="loc_ifrs-full_OptionPricingModelMember_8ba5ca94-62fd-4787-ae19-a8980c39b5ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_e1b99aac-5813-4b22-bc78-03c11c715f48" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsTable_10900a4b-72f0-4dcd-bef1-1eb16b6a3947" xlink:to="loc_ifrs-full_UnobservableInputsAxis_e1b99aac-5813-4b22-bc78-03c11c715f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain_1ea3f684-57da-4869-b3e6-ff6b1f8ca68f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsAxis_e1b99aac-5813-4b22-bc78-03c11c715f48" xlink:to="loc_ifrs-full_UnobservableInputsDomain_1ea3f684-57da-4869-b3e6-ff6b1f8ca68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExercisePricePerShareMeasurementInputMember_c83ed6e0-32cf-435a-b205-89e9d907a641" xlink:href="abvx-20251231.xsd#abvx_ExercisePricePerShareMeasurementInputMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_1ea3f684-57da-4869-b3e6-ff6b1f8ca68f" xlink:to="loc_abvx_ExercisePricePerShareMeasurementInputMember_c83ed6e0-32cf-435a-b205-89e9d907a641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SharePriceMeasurementInputMember_e7a442ae-d47e-4d92-b400-087cd5f747e3" xlink:href="abvx-20251231.xsd#abvx_SharePriceMeasurementInputMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_1ea3f684-57da-4869-b3e6-ff6b1f8ca68f" xlink:to="loc_abvx_SharePriceMeasurementInputMember_e7a442ae-d47e-4d92-b400-087cd5f747e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpiryScenarioProbablityMeasurementInputMember_bff38aa4-36ac-41d3-9bd6-f725b81a0941" xlink:href="abvx-20251231.xsd#abvx_ExpiryScenarioProbablityMeasurementInputMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_1ea3f684-57da-4869-b3e6-ff6b1f8ca68f" xlink:to="loc_abvx_ExpiryScenarioProbablityMeasurementInputMember_bff38aa4-36ac-41d3-9bd6-f725b81a0941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DrawdownProbablityMeasurementInputMember_33e6a508-5ca8-41f7-ad6c-dcf230cf1d22" xlink:href="abvx-20251231.xsd#abvx_DrawdownProbablityMeasurementInputMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_1ea3f684-57da-4869-b3e6-ff6b1f8ca68f" xlink:to="loc_abvx_DrawdownProbablityMeasurementInputMember_33e6a508-5ca8-41f7-ad6c-dcf230cf1d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VolatilityForSharesMeasurementInputExpiryMember_c980c27c-a675-47dc-b0e4-3024763d6706" xlink:href="abvx-20251231.xsd#abvx_VolatilityForSharesMeasurementInputExpiryMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_1ea3f684-57da-4869-b3e6-ff6b1f8ca68f" xlink:to="loc_abvx_VolatilityForSharesMeasurementInputExpiryMember_c980c27c-a675-47dc-b0e4-3024763d6706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VolatilityForSharesMeasurementInputTenderOfferMember_43c9b57c-bc26-4b05-98df-a9e374ca5d8b" xlink:href="abvx-20251231.xsd#abvx_VolatilityForSharesMeasurementInputTenderOfferMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_1ea3f684-57da-4869-b3e6-ff6b1f8ca68f" xlink:to="loc_abvx_VolatilityForSharesMeasurementInputTenderOfferMember_43c9b57c-bc26-4b05-98df-a9e374ca5d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpectedDividendMeasurementInputMember_d24025c8-ede3-4660-b0ec-a39ff6ea81cb" xlink:href="abvx-20251231.xsd#abvx_ExpectedDividendMeasurementInputMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_1ea3f684-57da-4869-b3e6-ff6b1f8ca68f" xlink:to="loc_abvx_ExpectedDividendMeasurementInputMember_d24025c8-ede3-4660-b0ec-a39ff6ea81cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RiskFreeInterestRateMeasurementInputMember_72b958c6-3b1d-400e-b260-cbfd799b326a" xlink:href="abvx-20251231.xsd#abvx_RiskFreeInterestRateMeasurementInputMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_1ea3f684-57da-4869-b3e6-ff6b1f8ca68f" xlink:to="loc_abvx_RiskFreeInterestRateMeasurementInputMember_72b958c6-3b1d-400e-b260-cbfd799b326a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RiskFreeInterestRateMeasurementInputExpiryMember_ae5061f2-98a8-470e-a975-c236f86a8c7a" xlink:href="abvx-20251231.xsd#abvx_RiskFreeInterestRateMeasurementInputExpiryMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_1ea3f684-57da-4869-b3e6-ff6b1f8ca68f" xlink:to="loc_abvx_RiskFreeInterestRateMeasurementInputExpiryMember_ae5061f2-98a8-470e-a975-c236f86a8c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RiskFreeInterestRateMeasurementInputTenderOfferMember_e490440b-84f5-406f-8654-0847580de6cc" xlink:href="abvx-20251231.xsd#abvx_RiskFreeInterestRateMeasurementInputTenderOfferMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_1ea3f684-57da-4869-b3e6-ff6b1f8ca68f" xlink:to="loc_abvx_RiskFreeInterestRateMeasurementInputTenderOfferMember_e490440b-84f5-406f-8654-0847580de6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfWarrantsArrangementsLineItems_d7994492-1e50-4fc6-a2ab-b3d7fe738371" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfWarrantsArrangementsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsTable_10900a4b-72f0-4dcd-bef1-1eb16b6a3947" xlink:to="loc_abvx_DisclosureOfWarrantsArrangementsLineItems_d7994492-1e50-4fc6-a2ab-b3d7fe738371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfProbabilityWeightedScenarios_4946f6e1-9293-4db8-9933-1415b1d8f7ec" xlink:href="abvx-20251231.xsd#abvx_NumberOfProbabilityWeightedScenarios"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsLineItems_d7994492-1e50-4fc6-a2ab-b3d7fe738371" xlink:to="loc_abvx_NumberOfProbabilityWeightedScenarios_4946f6e1-9293-4db8-9933-1415b1d8f7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted_9cf42215-b004-4674-aa40-a31f52568d2a" xlink:href="abvx-20251231.xsd#abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsLineItems_d7994492-1e50-4fc6-a2ab-b3d7fe738371" xlink:to="loc_abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted_9cf42215-b004-4674-aa40-a31f52568d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfWarrantsOutstanding_9369da01-f1f2-4660-95b9-9617be73e253" xlink:href="abvx-20251231.xsd#abvx_NumberOfWarrantsOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsLineItems_d7994492-1e50-4fc6-a2ab-b3d7fe738371" xlink:to="loc_abvx_NumberOfWarrantsOutstanding_9369da01-f1f2-4660-95b9-9617be73e253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfWarrantsOutstandingSubjectToNonMarketPerformanceCondition_f2719dee-12dc-4188-b8de-9093f8b9bc30" xlink:href="abvx-20251231.xsd#abvx_NumberOfWarrantsOutstandingSubjectToNonMarketPerformanceCondition"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsLineItems_d7994492-1e50-4fc6-a2ab-b3d7fe738371" xlink:to="loc_abvx_NumberOfWarrantsOutstandingSubjectToNonMarketPerformanceCondition_f2719dee-12dc-4188-b8de-9093f8b9bc30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities_0548aa26-b075-4d10-af03-ddb2486b8ab6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantUnobservableInputLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsLineItems_d7994492-1e50-4fc6-a2ab-b3d7fe738371" xlink:to="loc_ifrs-full_SignificantUnobservableInputLiabilities_0548aa26-b075-4d10-af03-ddb2486b8ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding_9d9e1fa2-1111-4bb8-9ea7-f0efd382e810" xlink:href="abvx-20251231.xsd#abvx_AggregateFairValueOtherEquityInstrumentsOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsLineItems_d7994492-1e50-4fc6-a2ab-b3d7fe738371" xlink:to="loc_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding_9d9e1fa2-1111-4bb8-9ea7-f0efd382e810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesHeightsconvertiblenotesDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_864b3882-a7c8-4d34-b771-85bdd5209931" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_b068f566-e3c9-4f43-b0cd-3ff8579756cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_864b3882-a7c8-4d34-b771-85bdd5209931" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_b068f566-e3c9-4f43-b0cd-3ff8579756cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_019bff12-946a-7a51-bd9a-32e2f3205c7f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_b068f566-e3c9-4f43-b0cd-3ff8579756cd" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_019bff12-946a-7a51-bd9a-32e2f3205c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019bff12-946a-72c0-859d-d805b393d44a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019bff12-946a-7a51-bd9a-32e2f3205c7f" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019bff12-946a-72c0-859d-d805b393d44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_HeightsConvertibleNotesMember_019bff12-946a-7472-a528-1e5927176811" xlink:href="abvx-20251231.xsd#abvx_HeightsConvertibleNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019bff12-946a-72c0-859d-d805b393d44a" xlink:to="loc_abvx_HeightsConvertibleNotesMember_019bff12-946a-7472-a528-1e5927176811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_HeightsConvertibleNotesTrancheAMember_019bff12-946a-779e-bf7c-43680d555e8c" xlink:href="abvx-20251231.xsd#abvx_HeightsConvertibleNotesTrancheAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019bff12-946a-72c0-859d-d805b393d44a" xlink:to="loc_abvx_HeightsConvertibleNotesTrancheAMember_019bff12-946a-779e-bf7c-43680d555e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_HeightsConvertibleNotesTrancheBMember_019bff12-946a-7c20-824a-7644194ca7d3" xlink:href="abvx-20251231.xsd#abvx_HeightsConvertibleNotesTrancheBMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019bff12-946a-72c0-859d-d805b393d44a" xlink:to="loc_abvx_HeightsConvertibleNotesTrancheBMember_019bff12-946a-7c20-824a-7644194ca7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OCEANEMember_019bff13-18dc-7fa8-b908-2ce651b29da5" xlink:href="abvx-20251231.xsd#abvx_OCEANEMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019bff12-946a-72c0-859d-d805b393d44a" xlink:to="loc_abvx_OCEANEMember_019bff13-18dc-7fa8-b908-2ce651b29da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019bff12-946a-74cc-8a70-bd34e286ed55" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_b068f566-e3c9-4f43-b0cd-3ff8579756cd" xlink:to="loc_srt_RangeAxis_019bff12-946a-74cc-8a70-bd34e286ed55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019bff12-946a-71b0-8b53-e3a0cbd35648" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_019bff12-946a-74cc-8a70-bd34e286ed55" xlink:to="loc_srt_RangeMember_019bff12-946a-71b0-8b53-e3a0cbd35648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019bff12-946a-7500-a636-2f0ee1fd3944" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019bff12-946a-71b0-8b53-e3a0cbd35648" xlink:to="loc_srt_MinimumMember_019bff12-946a-7500-a636-2f0ee1fd3944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019bff12-ec92-7c6e-8239-d37362a7659c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019bff12-946a-71b0-8b53-e3a0cbd35648" xlink:to="loc_srt_MaximumMember_019bff12-ec92-7c6e-8239-d37362a7659c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_019bff13-a23c-71b7-a9c0-541434254536" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_b068f566-e3c9-4f43-b0cd-3ff8579756cd" xlink:to="loc_ifrs-full_UnobservableInputsAxis_019bff13-a23c-71b7-a9c0-541434254536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain_019bff13-a23c-7f06-b1ba-b956d500f3d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsAxis_019bff13-a23c-71b7-a9c0-541434254536" xlink:to="loc_ifrs-full_UnobservableInputsDomain_019bff13-a23c-7f06-b1ba-b956d500f3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_019bff13-a23c-7aaf-8965-46974d5e78f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019bff13-a23c-7f06-b1ba-b956d500f3d7" xlink:to="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_019bff13-a23c-7aaf-8965-46974d5e78f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SharePriceMeasurementInputMember_019bff13-a23c-7480-8cdb-a47093bbe6e3" xlink:href="abvx-20251231.xsd#abvx_SharePriceMeasurementInputMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019bff13-a23c-7f06-b1ba-b956d500f3d7" xlink:to="loc_abvx_SharePriceMeasurementInputMember_019bff13-a23c-7480-8cdb-a47093bbe6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RiskFreeInterestRateMeasurementInputMember_019bff13-a23c-710d-b8d9-ecfcbe68b08c" xlink:href="abvx-20251231.xsd#abvx_RiskFreeInterestRateMeasurementInputMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019bff13-a23c-7f06-b1ba-b956d500f3d7" xlink:to="loc_abvx_RiskFreeInterestRateMeasurementInputMember_019bff13-a23c-710d-b8d9-ecfcbe68b08c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VoluntaryConversionScenarioProbabilityMeasurementInputMember_019bff13-a23c-7c66-8400-debadf55571b" xlink:href="abvx-20251231.xsd#abvx_VoluntaryConversionScenarioProbabilityMeasurementInputMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019bff13-a23c-7f06-b1ba-b956d500f3d7" xlink:to="loc_abvx_VoluntaryConversionScenarioProbabilityMeasurementInputMember_019bff13-a23c-7c66-8400-debadf55571b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019bff13-a23c-7b01-9cac-3b84fd31dbef" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_b068f566-e3c9-4f43-b0cd-3ff8579756cd" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019bff13-a23c-7b01-9cac-3b84fd31dbef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019bff13-a23c-7887-8253-60037e437a8f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019bff13-a23c-7b01-9cac-3b84fd31dbef" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019bff13-a23c-7887-8253-60037e437a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_HeightsConvertibleNotesTrancheAMember_019bff13-a23c-7a80-b4b9-b278b97ac4ac" xlink:href="abvx-20251231.xsd#abvx_HeightsConvertibleNotesTrancheAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019bff13-a23c-7887-8253-60037e437a8f" xlink:to="loc_abvx_HeightsConvertibleNotesTrancheAMember_019bff13-a23c-7a80-b4b9-b278b97ac4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_b068f566-e3c9-4f43-b0cd-3ff8579756cd" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsMaximumBorrowingCapacity_019bff12-946a-7a65-a938-28ef01967da8" xlink:href="abvx-20251231.xsd#abvx_BorrowingsMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_BorrowingsMaximumBorrowingCapacity_019bff12-946a-7a65-a938-28ef01967da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsNumberOfTranches_019bff12-946a-7458-a4d3-4c1302c63185" xlink:href="abvx-20251231.xsd#abvx_BorrowingsNumberOfTranches"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_BorrowingsNumberOfTranches_019bff12-946a-7458-a4d3-4c1302c63185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NetProceedsFromConvertibleLoansNotes_019bff12-946a-7c12-a2a1-368622ea9a9e" xlink:href="abvx-20251231.xsd#abvx_NetProceedsFromConvertibleLoansNotes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_NetProceedsFromConvertibleLoansNotes_019bff12-946a-7c12-a2a1-368622ea9a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfConvertibleNotesIssued_019bff12-946a-7457-8a27-5bbb0f6e8a3a" xlink:href="abvx-20251231.xsd#abvx_NumberOfConvertibleNotesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_NumberOfConvertibleNotesIssued_019bff12-946a-7457-8a27-5bbb0f6e8a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotesNominalValue_019bff12-946a-7ceb-9448-a605232adf11" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotesNominalValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_ConvertibleLoansNotesNominalValue_019bff12-946a-7ceb-9448-a605232adf11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsFixedConversionPrice_019bff12-946a-786b-9995-408d0936a74d" xlink:href="abvx-20251231.xsd#abvx_BorrowingsFixedConversionPrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_BorrowingsFixedConversionPrice_019bff12-946a-786b-9995-408d0936a74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted_019bff12-946a-7b13-a6fc-04560f7c1f9a" xlink:href="abvx-20251231.xsd#abvx_ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted_019bff12-946a-7b13-a6fc-04560f7c1f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_019bff12-946a-7bf8-88b6-1b4ab6e7bfb6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotionalAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_ifrs-full_NotionalAmount_019bff12-946a-7bf8-88b6-1b4ab6e7bfb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted_019bff12-946a-707b-bfcf-192831e0d9c1" xlink:href="abvx-20251231.xsd#abvx_ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted_019bff12-946a-707b-bfcf-192831e0d9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotesPeriod_019bff12-946a-7550-a7c6-c121120a3ca5" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotesPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_ConvertibleLoansNotesPeriod_019bff12-946a-7550-a7c6-c121120a3ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotesNumberOfSeparateClosings_019bff12-946a-719d-9b3d-7799e5eba37c" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotesNumberOfSeparateClosings"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_ConvertibleLoansNotesNumberOfSeparateClosings_019bff12-946a-719d-9b3d-7799e5eba37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_019bff12-c4b9-7a05-b178-450221629cd9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_ifrs-full_BorrowingsInterestRate_019bff12-c4b9-7a05-b178-450221629cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsNumberOfQuarterlyInstallments_019bff12-c4b9-7528-8ce5-0e50e2edd844" xlink:href="abvx-20251231.xsd#abvx_BorrowingsNumberOfQuarterlyInstallments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_BorrowingsNumberOfQuarterlyInstallments_019bff12-c4b9-7528-8ce5-0e50e2edd844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsMaturityDeferralPeriod_019bff12-c4b9-72f9-aa91-ea09f34c8860" xlink:href="abvx-20251231.xsd#abvx_BorrowingsMaturityDeferralPeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_BorrowingsMaturityDeferralPeriod_019bff12-c4b9-72f9-aa91-ea09f34c8860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsPercentageOfMarketPrice_019bff12-c4b9-7ac1-b548-51b2f25ff480" xlink:href="abvx-20251231.xsd#abvx_BorrowingsPercentageOfMarketPrice"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_BorrowingsPercentageOfMarketPrice_019bff12-c4b9-7ac1-b548-51b2f25ff480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsMarketPriceNumberOfDaysWithLowestDailyVWAP_019bff12-c4b9-7d89-8118-7438cd5e8bf9" xlink:href="abvx-20251231.xsd#abvx_BorrowingsMarketPriceNumberOfDaysWithLowestDailyVWAP"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_BorrowingsMarketPriceNumberOfDaysWithLowestDailyVWAP_019bff12-c4b9-7d89-8118-7438cd5e8bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsMarketPriceNumberOfTradingDays_019bff12-c4b9-76da-8d4f-7c5d6430c47b" xlink:href="abvx-20251231.xsd#abvx_BorrowingsMarketPriceNumberOfTradingDays"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_BorrowingsMarketPriceNumberOfTradingDays_019bff12-c4b9-76da-8d4f-7c5d6430c47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IssuancePricePercentageOfDiscountTo15DayWVAP_019bff12-c4b9-7caf-b8e4-27b3b0c66c51" xlink:href="abvx-20251231.xsd#abvx_IssuancePricePercentageOfDiscountTo15DayWVAP"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_IssuancePricePercentageOfDiscountTo15DayWVAP_019bff12-c4b9-7caf-b8e4-27b3b0c66c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EquityIssuanceSubscriptionPricePerShare_019bff12-c4b9-797e-a06f-eb5c2e59cad1" xlink:href="abvx-20251231.xsd#abvx_EquityIssuanceSubscriptionPricePerShare"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_EquityIssuanceSubscriptionPricePerShare_019bff12-c4b9-797e-a06f-eb5c2e59cad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotesSettlementInSharesPercentageOfFairMarketValue_019bff12-ec92-7d04-aace-5bb9c13dbc50" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotesSettlementInSharesPercentageOfFairMarketValue"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_ConvertibleLoansNotesSettlementInSharesPercentageOfFairMarketValue_019bff12-ec92-7d04-aace-5bb9c13dbc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EquityIssuanceCashCarveOut_019bff12-ec92-71c0-9fd1-c08682ad0bb5" xlink:href="abvx-20251231.xsd#abvx_EquityIssuanceCashCarveOut"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_EquityIssuanceCashCarveOut_019bff12-ec92-71c0-9fd1-c08682ad0bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotesEarlyRedemptionAmountPercentageOfOutstandongPrincipal_019bff13-18dc-78bf-8644-4b9125257829" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotesEarlyRedemptionAmountPercentageOfOutstandongPrincipal"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_ConvertibleLoansNotesEarlyRedemptionAmountPercentageOfOutstandongPrincipal_019bff13-18dc-78bf-8644-4b9125257829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepaymentsOfConvertibleLoansNotes_019bff13-18dc-7a39-aa91-8443d6d056aa" xlink:href="abvx-20251231.xsd#abvx_RepaymentsOfConvertibleLoansNotes"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_RepaymentsOfConvertibleLoansNotes_019bff13-18dc-7a39-aa91-8443d6d056aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfConvertibleNotesConverted_019bff13-3e5b-7e10-b6a3-94c78f8a82ea" xlink:href="abvx-20251231.xsd#abvx_NumberOfConvertibleNotesConverted"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_NumberOfConvertibleNotesConverted_019bff13-3e5b-7e10-b6a3-94c78f8a82ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_019bff13-3e5b-73e8-8a05-e983be0b2719" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_019bff13-3e5b-73e8-8a05-e983be0b2719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_GainsArisingFromRecognitionOfFinancialLiabilities_019bff13-6356-79b4-9788-8c6469a8a18f" xlink:href="abvx-20251231.xsd#abvx_GainsArisingFromRecognitionOfFinancialLiabilities"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_GainsArisingFromRecognitionOfFinancialLiabilities_019bff13-6356-79b4-9788-8c6469a8a18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_UnrecognitionDayOneGainOfFinancialLiabilities_019bff13-6356-7aa1-a865-65ca279d5cbf" xlink:href="abvx-20251231.xsd#abvx_UnrecognitionDayOneGainOfFinancialLiabilities"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_UnrecognitionDayOneGainOfFinancialLiabilities_019bff13-6356-7aa1-a865-65ca279d5cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfProbabilityWeightedScenarios_019cfba1-980d-7a8e-8fd6-98b0a11a56bc" xlink:href="abvx-20251231.xsd#abvx_NumberOfProbabilityWeightedScenarios"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_NumberOfProbabilityWeightedScenarios_019cfba1-980d-7a8e-8fd6-98b0a11a56bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bff13-a23c-7f3f-a0da-d75585e988f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bff13-a23c-7f3f-a0da-d75585e988f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bff13-a23c-7bf0-b00a-532cfc13e21a" xlink:href="abvx-20251231.xsd#abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bff13-a23c-7bf0-b00a-532cfc13e21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets_019bff13-a23c-7b5a-802c-64b3e29cd8cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets_019bff13-a23c-7b5a-802c-64b3e29cd8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_019bff13-a23c-7d93-9021-98c761240786" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_019bff13-a23c-7d93-9021-98c761240786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotesConversionOptionMaximumPeriodPriorToMaturityDate_019c0044-9e8d-7861-a998-2c6f72f53d40" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotesConversionOptionMaximumPeriodPriorToMaturityDate"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_ConvertibleLoansNotesConversionOptionMaximumPeriodPriorToMaturityDate_019c0044-9e8d-7861-a998-2c6f72f53d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss_019cf6c5-e6dc-7754-b236-f928272ffd2e" xlink:href="abvx-20251231.xsd#abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bff12-946a-7f72-9612-caf5436cd585" xlink:to="loc_abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss_019cf6c5-e6dc-7754-b236-f928272ffd2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_9dd23bf8-dabf-4ff5-aacb-060b3c7fe744" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_24ccb8fc-d0dc-4297-bc7e-6503ac2e3749" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_9dd23bf8-dabf-4ff5-aacb-060b3c7fe744" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_24ccb8fc-d0dc-4297-bc7e-6503ac2e3749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_4bbdda24-5dae-4f0d-a518-1770da543fca" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_24ccb8fc-d0dc-4297-bc7e-6503ac2e3749" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_4bbdda24-5dae-4f0d-a518-1770da543fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_ba61a51c-f384-4ed5-bdfe-c4d01dde5ff4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_4bbdda24-5dae-4f0d-a518-1770da543fca" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_ba61a51c-f384-4ed5-bdfe-c4d01dde5ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_HeightsConvertibleNotesTrancheAMember_7b351cf3-5294-48c4-bc8a-9699e27a5426" xlink:href="abvx-20251231.xsd#abvx_HeightsConvertibleNotesTrancheAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_ba61a51c-f384-4ed5-bdfe-c4d01dde5ff4" xlink:to="loc_abvx_HeightsConvertibleNotesTrancheAMember_7b351cf3-5294-48c4-bc8a-9699e27a5426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_e3b939c6-993d-45c3-b1a4-b6d3c9a36309" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_24ccb8fc-d0dc-4297-bc7e-6503ac2e3749" xlink:to="loc_ifrs-full_UnobservableInputsAxis_e3b939c6-993d-45c3-b1a4-b6d3c9a36309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain_697203e3-7f0c-40ea-8d83-109b440d3879" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsAxis_e3b939c6-993d-45c3-b1a4-b6d3c9a36309" xlink:to="loc_ifrs-full_UnobservableInputsDomain_697203e3-7f0c-40ea-8d83-109b440d3879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateMeasurementInputMember_23790f53-4d92-4693-9490-f89248714796" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestRateMeasurementInputMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_697203e3-7f0c-40ea-8d83-109b440d3879" xlink:to="loc_ifrs-full_InterestRateMeasurementInputMember_23790f53-4d92-4693-9490-f89248714796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConversionPricePerShareMeasurementInputMember_db23499f-198e-4408-b2e9-dd0f560116df" xlink:href="abvx-20251231.xsd#abvx_ConversionPricePerShareMeasurementInputMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_697203e3-7f0c-40ea-8d83-109b440d3879" xlink:to="loc_abvx_ConversionPricePerShareMeasurementInputMember_db23499f-198e-4408-b2e9-dd0f560116df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SharePriceMeasurementInputMember_299bee0c-563f-4ba9-81a8-08ce4ec3f828" xlink:href="abvx-20251231.xsd#abvx_SharePriceMeasurementInputMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_697203e3-7f0c-40ea-8d83-109b440d3879" xlink:to="loc_abvx_SharePriceMeasurementInputMember_299bee0c-563f-4ba9-81a8-08ce4ec3f828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_VoluntaryConversionScenarioProbabilityMeasurementInputMember_8e580454-3d5a-40b0-9305-3f14274a64ab" xlink:href="abvx-20251231.xsd#abvx_VoluntaryConversionScenarioProbabilityMeasurementInputMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_697203e3-7f0c-40ea-8d83-109b440d3879" xlink:to="loc_abvx_VoluntaryConversionScenarioProbabilityMeasurementInputMember_8e580454-3d5a-40b0-9305-3f14274a64ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_InitialPriceLimitMeasurementInputMember_97cd79a9-ff97-4b9e-b274-7208f63efd6a" xlink:href="abvx-20251231.xsd#abvx_InitialPriceLimitMeasurementInputMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_697203e3-7f0c-40ea-8d83-109b440d3879" xlink:to="loc_abvx_InitialPriceLimitMeasurementInputMember_97cd79a9-ff97-4b9e-b274-7208f63efd6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EarlyRedemptionAmountMeasurementInputMember_3a4b60bb-0150-4de0-8714-8789c4478718" xlink:href="abvx-20251231.xsd#abvx_EarlyRedemptionAmountMeasurementInputMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_697203e3-7f0c-40ea-8d83-109b440d3879" xlink:to="loc_abvx_EarlyRedemptionAmountMeasurementInputMember_3a4b60bb-0150-4de0-8714-8789c4478718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_c3cc9604-dd17-4414-847b-0c1d72b3eeb9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_697203e3-7f0c-40ea-8d83-109b440d3879" xlink:to="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_c3cc9604-dd17-4414-847b-0c1d72b3eeb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CreditSpreadMeasurementInputMember_5c66691a-1f09-44d9-b7e7-5b3af049283c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CreditSpreadMeasurementInputMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_697203e3-7f0c-40ea-8d83-109b440d3879" xlink:to="loc_ifrs-full_CreditSpreadMeasurementInputMember_5c66691a-1f09-44d9-b7e7-5b3af049283c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RiskFreeInterestRateMeasurementInputMember_077bf4c7-df59-47d8-8e79-4eba84787eb5" xlink:href="abvx-20251231.xsd#abvx_RiskFreeInterestRateMeasurementInputMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_697203e3-7f0c-40ea-8d83-109b440d3879" xlink:to="loc_abvx_RiskFreeInterestRateMeasurementInputMember_077bf4c7-df59-47d8-8e79-4eba84787eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_431db341-8e53-4721-9728-c8f1aa9432b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_24ccb8fc-d0dc-4297-bc7e-6503ac2e3749" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_431db341-8e53-4721-9728-c8f1aa9432b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_c180f943-6c01-45af-9948-018bd227344c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_431db341-8e53-4721-9728-c8f1aa9432b8" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_c180f943-6c01-45af-9948-018bd227344c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_MonteCarloModelIFRSMember_a9f21e00-afe2-4118-b799-89e8c14e4834" xlink:href="abvx-20251231.xsd#abvx_MonteCarloModelIFRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_c180f943-6c01-45af-9948-018bd227344c" xlink:to="loc_abvx_MonteCarloModelIFRSMember_a9f21e00-afe2-4118-b799-89e8c14e4834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_d337f439-0521-46ad-80b2-95d6ff073461" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_24ccb8fc-d0dc-4297-bc7e-6503ac2e3749" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_d337f439-0521-46ad-80b2-95d6ff073461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfConvertibleNotesOutstanding_19aa7b31-69b0-4d2d-8675-67a4744929c9" xlink:href="abvx-20251231.xsd#abvx_NumberOfConvertibleNotesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_d337f439-0521-46ad-80b2-95d6ff073461" xlink:to="loc_abvx_NumberOfConvertibleNotesOutstanding_19aa7b31-69b0-4d2d-8675-67a4744929c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_693d56dd-8700-4a39-a61a-bb29f1d5b721" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_d337f439-0521-46ad-80b2-95d6ff073461" xlink:to="loc_ifrs-full_NotionalAmount_693d56dd-8700-4a39-a61a-bb29f1d5b721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities_8afef000-f6ed-40e4-8215-bd8e9a831773" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantUnobservableInputLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_d337f439-0521-46ad-80b2-95d6ff073461" xlink:to="loc_ifrs-full_SignificantUnobservableInputLiabilities_8afef000-f6ed-40e4-8215-bd8e9a831773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AggregateFairValueConvertibleNotes_076facea-3161-41c0-9724-90f5624af683" xlink:href="abvx-20251231.xsd#abvx_AggregateFairValueConvertibleNotes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_d337f439-0521-46ad-80b2-95d6ff073461" xlink:to="loc_abvx_AggregateFairValueConvertibleNotes_076facea-3161-41c0-9724-90f5624af683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesKreos1Details" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesKreos1Details"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesKreos1Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_0f64000c-7a34-4279-a079-d1b8ae3cc2f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_d79094d2-00f4-4224-9d4b-0bfd16a7f8f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_0f64000c-7a34-4279-a079-d1b8ae3cc2f9" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_d79094d2-00f4-4224-9d4b-0bfd16a7f8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_019c56eb-f87d-70b1-b721-9421cfb2104b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_d79094d2-00f4-4224-9d4b-0bfd16a7f8f4" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_019c56eb-f87d-70b1-b721-9421cfb2104b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019c56eb-f87d-766c-b6fa-a7df6fee600f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019c56eb-f87d-70b1-b721-9421cfb2104b" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019c56eb-f87d-766c-b6fa-a7df6fee600f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1Member_019c56eb-f87d-7b6e-b66a-662dc4eefe28" xlink:href="abvx-20251231.xsd#abvx_Kreos1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019c56eb-f87d-766c-b6fa-a7df6fee600f" xlink:to="loc_abvx_Kreos1Member_019c56eb-f87d-7b6e-b66a-662dc4eefe28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1NonConvertibleBondLoansMember_019c56eb-f87d-7d54-b4eb-46985852d6e1" xlink:href="abvx-20251231.xsd#abvx_Kreos1NonConvertibleBondLoansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019c56eb-f87d-766c-b6fa-a7df6fee600f" xlink:to="loc_abvx_Kreos1NonConvertibleBondLoansMember_019c56eb-f87d-7d54-b4eb-46985852d6e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1ConvertibleBondLoansMember_019c56eb-f87d-7ce2-9196-e78aaf4dfed1" xlink:href="abvx-20251231.xsd#abvx_Kreos1ConvertibleBondLoansMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019c56eb-f87d-766c-b6fa-a7df6fee600f" xlink:to="loc_abvx_Kreos1ConvertibleBondLoansMember_019c56eb-f87d-7ce2-9196-e78aaf4dfed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1ConvertibleBondLoansTrancheBMember_019c56eb-f87d-720d-8a4d-6f944d66b548" xlink:href="abvx-20251231.xsd#abvx_Kreos1ConvertibleBondLoansTrancheBMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019c56eb-f87d-766c-b6fa-a7df6fee600f" xlink:to="loc_abvx_Kreos1ConvertibleBondLoansTrancheBMember_019c56eb-f87d-720d-8a4d-6f944d66b548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos12BondLoansMember_019c56eb-f87d-7d7e-ab9c-2f0ff9d99960" xlink:href="abvx-20251231.xsd#abvx_Kreos12BondLoansMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019c56eb-f87d-766c-b6fa-a7df6fee600f" xlink:to="loc_abvx_Kreos12BondLoansMember_019c56eb-f87d-7d7e-ab9c-2f0ff9d99960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1ConvertibleBondLoansTrancheAMember_019c56eb-f87d-7566-a4c1-132a80d333c2" xlink:href="abvx-20251231.xsd#abvx_Kreos1ConvertibleBondLoansTrancheAMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019c56eb-f87d-766c-b6fa-a7df6fee600f" xlink:to="loc_abvx_Kreos1ConvertibleBondLoansTrancheAMember_019c56eb-f87d-7566-a4c1-132a80d333c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_WarrantsAxis_019c56eb-f87d-7849-831d-cb3c5a041e9b" xlink:href="abvx-20251231.xsd#abvx_WarrantsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_d79094d2-00f4-4224-9d4b-0bfd16a7f8f4" xlink:to="loc_abvx_WarrantsAxis_019c56eb-f87d-7849-831d-cb3c5a041e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_WarrantsDomain_019c56eb-f87d-72a1-9713-b8aa41ded0a8" xlink:href="abvx-20251231.xsd#abvx_WarrantsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_WarrantsAxis_019c56eb-f87d-7849-831d-cb3c5a041e9b" xlink:to="loc_abvx_WarrantsDomain_019c56eb-f87d-72a1-9713-b8aa41ded0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosABSAMember_019c56eb-f87d-7ad1-aac5-5c14dc91c7ec" xlink:href="abvx-20251231.xsd#abvx_KreosABSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_WarrantsDomain_019c56eb-f87d-72a1-9713-b8aa41ded0a8" xlink:to="loc_abvx_KreosABSAMember_019c56eb-f87d-7ad1-aac5-5c14dc91c7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosBBSAMember_019c56eb-f87d-7ff6-97b4-72952900d8b9" xlink:href="abvx-20251231.xsd#abvx_KreosBBSAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_WarrantsDomain_019c56eb-f87d-72a1-9713-b8aa41ded0a8" xlink:to="loc_abvx_KreosBBSAMember_019c56eb-f87d-7ff6-97b4-72952900d8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosABBSAMember_019c56eb-f87d-72a5-b4cc-4e60ca083296" xlink:href="abvx-20251231.xsd#abvx_KreosABBSAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_WarrantsDomain_019c56eb-f87d-72a1-9713-b8aa41ded0a8" xlink:to="loc_abvx_KreosABBSAMember_019c56eb-f87d-72a5-b4cc-4e60ca083296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_019c56eb-f87d-76bd-80e9-f3899b2326cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_d79094d2-00f4-4224-9d4b-0bfd16a7f8f4" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_019c56eb-f87d-76bd-80e9-f3899b2326cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_019c56eb-f87d-76c7-9ca3-8e65b983c033" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_019c56eb-f87d-76bd-80e9-f3899b2326cb" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_019c56eb-f87d-76c7-9ca3-8e65b983c033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_019c56eb-f87d-7eb2-b71e-0be9fdb8a8ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_019c56eb-f87d-76c7-9ca3-8e65b983c033" xlink:to="loc_ifrs-full_OrdinarySharesMember_019c56eb-f87d-7eb2-b71e-0be9fdb8a8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56eb-f87d-7f70-8309-6889b8b13ee2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_d79094d2-00f4-4224-9d4b-0bfd16a7f8f4" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56eb-f87d-7f70-8309-6889b8b13ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsMaximumBorrowingCapacity_019c56eb-f87d-7b79-9d5e-46585ad1474b" xlink:href="abvx-20251231.xsd#abvx_BorrowingsMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56eb-f87d-7f70-8309-6889b8b13ee2" xlink:to="loc_abvx_BorrowingsMaximumBorrowingCapacity_019c56eb-f87d-7b79-9d5e-46585ad1474b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsNumberOfTranches_019c56eb-f87d-7292-b04e-9dce2756154f" xlink:href="abvx-20251231.xsd#abvx_BorrowingsNumberOfTranches"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56eb-f87d-7f70-8309-6889b8b13ee2" xlink:to="loc_abvx_BorrowingsNumberOfTranches_019c56eb-f87d-7292-b04e-9dce2756154f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsMaximumBorrowingCapacityPerTranche_019c56eb-f87d-76ff-9d46-7fd2cb5c368f" xlink:href="abvx-20251231.xsd#abvx_BorrowingsMaximumBorrowingCapacityPerTranche"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56eb-f87d-7f70-8309-6889b8b13ee2" xlink:to="loc_abvx_BorrowingsMaximumBorrowingCapacityPerTranche_019c56eb-f87d-76ff-9d46-7fd2cb5c368f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants_019c56eb-f87d-7cb6-8ad4-dde1695e1564" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56eb-f87d-7f70-8309-6889b8b13ee2" xlink:to="loc_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants_019c56eb-f87d-7cb6-8ad4-dde1695e1564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepaymentsOfConvertibleLoansNotes_019c56eb-f87d-735c-958a-e4575c0d7fc9" xlink:href="abvx-20251231.xsd#abvx_RepaymentsOfConvertibleLoansNotes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56eb-f87d-7f70-8309-6889b8b13ee2" xlink:to="loc_abvx_RepaymentsOfConvertibleLoansNotes_019c56eb-f87d-735c-958a-e4575c0d7fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid_019c56eb-f87d-7b77-8087-8c3c2ddd67f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56eb-f87d-7f70-8309-6889b8b13ee2" xlink:to="loc_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid_019c56eb-f87d-7b77-8087-8c3c2ddd67f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfShareWarrantsIssued_019c56eb-f87d-7a8c-ae11-16b4b4a8cccb" xlink:href="abvx-20251231.xsd#abvx_NumberOfShareWarrantsIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56eb-f87d-7f70-8309-6889b8b13ee2" xlink:to="loc_abvx_NumberOfShareWarrantsIssued_019c56eb-f87d-7a8c-ae11-16b4b4a8cccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ShareWarrantsSubscriptionPricePerShare_019c56eb-f87d-7a8b-98f2-7cb08c0af0b2" xlink:href="abvx-20251231.xsd#abvx_ShareWarrantsSubscriptionPricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56eb-f87d-7f70-8309-6889b8b13ee2" xlink:to="loc_abvx_ShareWarrantsSubscriptionPricePerShare_019c56eb-f87d-7a8b-98f2-7cb08c0af0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfSharesPerShareWarrant_019c56eb-f87d-790e-a524-e604f3dc9eb8" xlink:href="abvx-20251231.xsd#abvx_NumberOfSharesPerShareWarrant"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56eb-f87d-7f70-8309-6889b8b13ee2" xlink:to="loc_abvx_NumberOfSharesPerShareWarrant_019c56eb-f87d-790e-a524-e604f3dc9eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_019c56eb-f87d-71d6-aec2-4e27a502366a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56eb-f87d-7f70-8309-6889b8b13ee2" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_019c56eb-f87d-71d6-aec2-4e27a502366a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfOtherShareWarrantsRepurchased_019c56eb-f87d-7453-8fbd-478dc64cf59e" xlink:href="abvx-20251231.xsd#abvx_NumberOfOtherShareWarrantsRepurchased"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56eb-f87d-7f70-8309-6889b8b13ee2" xlink:to="loc_abvx_NumberOfOtherShareWarrantsRepurchased_019c56eb-f87d-7453-8fbd-478dc64cf59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfOtherShareWarrantsConverted_019c56eb-f87d-7dcb-b1c5-d482103a18e0" xlink:href="abvx-20251231.xsd#abvx_NumberOfOtherShareWarrantsConverted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56eb-f87d-7f70-8309-6889b8b13ee2" xlink:to="loc_abvx_NumberOfOtherShareWarrantsConverted_019c56eb-f87d-7dcb-b1c5-d482103a18e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_019c56eb-f87d-750c-b5a8-df791801209a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56eb-f87d-7f70-8309-6889b8b13ee2" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_019c56eb-f87d-750c-b5a8-df791801209a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_9d6fab82-c84e-4823-a0fa-e432a6a5182e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfWarrantsArrangementsTable_94ab92ee-a296-44e7-a3af-51bb336d2413" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfWarrantsArrangementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_9d6fab82-c84e-4823-a0fa-e432a6a5182e" xlink:to="loc_abvx_DisclosureOfWarrantsArrangementsTable_94ab92ee-a296-44e7-a3af-51bb336d2413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_WarrantsAxis_31c19bc1-4aaf-4928-9af4-e7da6ee3ffea" xlink:href="abvx-20251231.xsd#abvx_WarrantsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsTable_94ab92ee-a296-44e7-a3af-51bb336d2413" xlink:to="loc_abvx_WarrantsAxis_31c19bc1-4aaf-4928-9af4-e7da6ee3ffea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_WarrantsDomain_0d8c9e4f-3f9b-4273-843c-0397e2b7e9ef" xlink:href="abvx-20251231.xsd#abvx_WarrantsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_WarrantsAxis_31c19bc1-4aaf-4928-9af4-e7da6ee3ffea" xlink:to="loc_abvx_WarrantsDomain_0d8c9e4f-3f9b-4273-843c-0397e2b7e9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosABSAMember_c3aaac39-29d8-49c6-9dc5-df378d5c4b3e" xlink:href="abvx-20251231.xsd#abvx_KreosABSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_WarrantsDomain_0d8c9e4f-3f9b-4273-843c-0397e2b7e9ef" xlink:to="loc_abvx_KreosABSAMember_c3aaac39-29d8-49c6-9dc5-df378d5c4b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosBBSAMember_510ac62c-6b44-41cb-92fb-bd9d6841d527" xlink:href="abvx-20251231.xsd#abvx_KreosBBSAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_WarrantsDomain_0d8c9e4f-3f9b-4273-843c-0397e2b7e9ef" xlink:to="loc_abvx_KreosBBSAMember_510ac62c-6b44-41cb-92fb-bd9d6841d527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_df9006e3-6bdf-47aa-b426-dca35a705327" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsTable_94ab92ee-a296-44e7-a3af-51bb336d2413" xlink:to="loc_ifrs-full_UnobservableInputsAxis_df9006e3-6bdf-47aa-b426-dca35a705327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain_a3a41e96-1515-4d6c-90c4-5ef60ef6ae60" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsAxis_df9006e3-6bdf-47aa-b426-dca35a705327" xlink:to="loc_ifrs-full_UnobservableInputsDomain_a3a41e96-1515-4d6c-90c4-5ef60ef6ae60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExercisePricePerShareMeasurementInputMember_815b56cc-d1ab-4e9e-af58-f1ecf1711104" xlink:href="abvx-20251231.xsd#abvx_ExercisePricePerShareMeasurementInputMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_a3a41e96-1515-4d6c-90c4-5ef60ef6ae60" xlink:to="loc_abvx_ExercisePricePerShareMeasurementInputMember_815b56cc-d1ab-4e9e-af58-f1ecf1711104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SharePriceMeasurementInputMember_a62b75ca-3c5f-4ac4-a39a-c9e6012742c1" xlink:href="abvx-20251231.xsd#abvx_SharePriceMeasurementInputMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_a3a41e96-1515-4d6c-90c4-5ef60ef6ae60" xlink:to="loc_abvx_SharePriceMeasurementInputMember_a62b75ca-3c5f-4ac4-a39a-c9e6012742c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_729bd8a8-d893-4e34-bf75-824b0d930139" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsTable_94ab92ee-a296-44e7-a3af-51bb336d2413" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_729bd8a8-d893-4e34-bf75-824b0d930139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_8f43a780-eaf3-4628-8a4a-76d325daeff8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_729bd8a8-d893-4e34-bf75-824b0d930139" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_8f43a780-eaf3-4628-8a4a-76d325daeff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OptionPricingModelMember_0acfedaf-fd25-46d9-9ba9-0c7f2e597426" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OptionPricingModelMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_8f43a780-eaf3-4628-8a4a-76d325daeff8" xlink:to="loc_ifrs-full_OptionPricingModelMember_0acfedaf-fd25-46d9-9ba9-0c7f2e597426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfWarrantsArrangementsLineItems_e022a2b0-7017-48b3-90a4-1464412daac2" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfWarrantsArrangementsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsTable_94ab92ee-a296-44e7-a3af-51bb336d2413" xlink:to="loc_abvx_DisclosureOfWarrantsArrangementsLineItems_e022a2b0-7017-48b3-90a4-1464412daac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfWarrantsOutstanding_708db23d-c912-4aa1-a9b4-fe2c6171b978" xlink:href="abvx-20251231.xsd#abvx_NumberOfWarrantsOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsLineItems_e022a2b0-7017-48b3-90a4-1464412daac2" xlink:to="loc_abvx_NumberOfWarrantsOutstanding_708db23d-c912-4aa1-a9b4-fe2c6171b978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities_2420e6e4-9a23-4e9f-931d-3b5f8f1d7d44" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantUnobservableInputLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsLineItems_e022a2b0-7017-48b3-90a4-1464412daac2" xlink:to="loc_ifrs-full_SignificantUnobservableInputLiabilities_2420e6e4-9a23-4e9f-931d-3b5f8f1d7d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding_862bf3c3-dd15-45e5-bc2e-e10347da9258" xlink:href="abvx-20251231.xsd#abvx_AggregateFairValueOtherEquityInstrumentsOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfWarrantsArrangementsLineItems_e022a2b0-7017-48b3-90a4-1464412daac2" xlink:to="loc_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding_862bf3c3-dd15-45e5-bc2e-e10347da9258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesKreos2Details" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesKreos2Details"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesKreos2Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_324b9849-6ae0-4d90-86ae-fea2ce43887e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_44d45666-828b-41c2-b946-3c4604f70488" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_324b9849-6ae0-4d90-86ae-fea2ce43887e" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_44d45666-828b-41c2-b946-3c4604f70488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_019c56f5-9d35-7331-aedd-bdecfb838337" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_44d45666-828b-41c2-b946-3c4604f70488" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_019c56f5-9d35-7331-aedd-bdecfb838337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019c56f5-9d35-7b94-b36a-52aeabf359aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019c56f5-9d35-7331-aedd-bdecfb838337" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019c56f5-9d35-7b94-b36a-52aeabf359aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos2Member_019c56f5-9d35-7e06-940a-c9a3fd5ab0d5" xlink:href="abvx-20251231.xsd#abvx_Kreos2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019c56f5-9d35-7b94-b36a-52aeabf359aa" xlink:to="loc_abvx_Kreos2Member_019c56f5-9d35-7e06-940a-c9a3fd5ab0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos2TrancheAMember_019c56f5-9d35-7b8e-875a-fee1818ac367" xlink:href="abvx-20251231.xsd#abvx_Kreos2TrancheAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019c56f5-9d35-7b94-b36a-52aeabf359aa" xlink:to="loc_abvx_Kreos2TrancheAMember_019c56f5-9d35-7b8e-875a-fee1818ac367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos2TrancheBMember_019c56f5-9d35-7e86-a797-6d3324ac2855" xlink:href="abvx-20251231.xsd#abvx_Kreos2TrancheBMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019c56f5-9d35-7b94-b36a-52aeabf359aa" xlink:to="loc_abvx_Kreos2TrancheBMember_019c56f5-9d35-7e86-a797-6d3324ac2855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1ConvertibleBondLoansTrancheBMember_019c56f5-9d35-79d1-968f-00f21ab12342" xlink:href="abvx-20251231.xsd#abvx_Kreos1ConvertibleBondLoansTrancheBMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019c56f5-9d35-7b94-b36a-52aeabf359aa" xlink:to="loc_abvx_Kreos1ConvertibleBondLoansTrancheBMember_019c56f5-9d35-79d1-968f-00f21ab12342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f5-9d35-7bf9-9931-9c1fc6ceebaf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_44d45666-828b-41c2-b946-3c4604f70488" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f5-9d35-7bf9-9931-9c1fc6ceebaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_019c56f5-9d35-7d42-9584-a17aaebd06d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f5-9d35-7bf9-9931-9c1fc6ceebaf" xlink:to="loc_ifrs-full_NotionalAmount_019c56f5-9d35-7d42-9584-a17aaebd06d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsNumberOfTranches_019c56f5-9d35-7017-a1ec-120e54ab2246" xlink:href="abvx-20251231.xsd#abvx_BorrowingsNumberOfTranches"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f5-9d35-7bf9-9931-9c1fc6ceebaf" xlink:to="loc_abvx_BorrowingsNumberOfTranches_019c56f5-9d35-7017-a1ec-120e54ab2246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsAdditionalTrancheAmount_019c56f5-9d35-7f60-9de7-5cc983486576" xlink:href="abvx-20251231.xsd#abvx_BorrowingsAdditionalTrancheAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f5-9d35-7bf9-9931-9c1fc6ceebaf" xlink:to="loc_abvx_BorrowingsAdditionalTrancheAmount_019c56f5-9d35-7f60-9de7-5cc983486576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepaymentsOfConvertibleLoansNotes_019c56f5-9d35-70d1-be55-1596967dc743" xlink:href="abvx-20251231.xsd#abvx_RepaymentsOfConvertibleLoansNotes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f5-9d35-7bf9-9931-9c1fc6ceebaf" xlink:to="loc_abvx_RepaymentsOfConvertibleLoansNotes_019c56f5-9d35-70d1-be55-1596967dc743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesOCEANEDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_db87271b-250c-4412-bdb3-f0262fa3bb46" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_feb8fe6e-32b2-4c27-b55a-59e41b01fc45" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_db87271b-250c-4412-bdb3-f0262fa3bb46" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_feb8fe6e-32b2-4c27-b55a-59e41b01fc45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_019c56f4-89fe-7e02-87a0-ffb7ca2821c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_feb8fe6e-32b2-4c27-b55a-59e41b01fc45" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_019c56f4-89fe-7e02-87a0-ffb7ca2821c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019c56f4-89fe-7e80-84c6-0194a64aa635" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019c56f4-89fe-7e02-87a0-ffb7ca2821c4" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019c56f4-89fe-7e80-84c6-0194a64aa635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OCEANEMember_019c56f4-89fe-7479-a5f4-07fa01f3d5d1" xlink:href="abvx-20251231.xsd#abvx_OCEANEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019c56f4-89fe-7e80-84c6-0194a64aa635" xlink:to="loc_abvx_OCEANEMember_019c56f4-89fe-7479-a5f4-07fa01f3d5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RemeasurementPeriodAxis_019c56f4-89fe-73d8-a605-d79f5761ebba" xlink:href="abvx-20251231.xsd#abvx_RemeasurementPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_feb8fe6e-32b2-4c27-b55a-59e41b01fc45" xlink:to="loc_abvx_RemeasurementPeriodAxis_019c56f4-89fe-73d8-a605-d79f5761ebba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RemeasurementPeriodDomain_019c56f4-89fe-731b-83a5-5a752c3dd36c" xlink:href="abvx-20251231.xsd#abvx_RemeasurementPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_RemeasurementPeriodAxis_019c56f4-89fe-73d8-a605-d79f5761ebba" xlink:to="loc_abvx_RemeasurementPeriodDomain_019c56f4-89fe-731b-83a5-5a752c3dd36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_After18MonthsMember_019c56f4-89fe-7b48-bdf7-2c7ccf456bac" xlink:href="abvx-20251231.xsd#abvx_After18MonthsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_RemeasurementPeriodDomain_019c56f4-89fe-731b-83a5-5a752c3dd36c" xlink:to="loc_abvx_After18MonthsMember_019c56f4-89fe-7b48-bdf7-2c7ccf456bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_After24MonthsMember_019c56f4-89fe-78fe-a722-d7a2e0f8dabd" xlink:href="abvx-20251231.xsd#abvx_After24MonthsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_RemeasurementPeriodDomain_019c56f4-89fe-731b-83a5-5a752c3dd36c" xlink:to="loc_abvx_After24MonthsMember_019c56f4-89fe-78fe-a722-d7a2e0f8dabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_After36MonthsMember_019c56f4-89fe-76cd-a5e4-339c00c555fb" xlink:href="abvx-20251231.xsd#abvx_After36MonthsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_RemeasurementPeriodDomain_019c56f4-89fe-731b-83a5-5a752c3dd36c" xlink:to="loc_abvx_After36MonthsMember_019c56f4-89fe-76cd-a5e4-339c00c555fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019c56f4-89fe-7bdb-8c68-f89d080bb082" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_feb8fe6e-32b2-4c27-b55a-59e41b01fc45" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019c56f4-89fe-7bdb-8c68-f89d080bb082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019c56f4-89fe-7e2a-8d8d-8614c09eefd8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019c56f4-89fe-7bdb-8c68-f89d080bb082" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019c56f4-89fe-7e2a-8d8d-8614c09eefd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OCEANEMember_019c56f4-89fe-761e-bd49-a28a646847aa" xlink:href="abvx-20251231.xsd#abvx_OCEANEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019c56f4-89fe-7e2a-8d8d-8614c09eefd8" xlink:to="loc_abvx_OCEANEMember_019c56f4-89fe-761e-bd49-a28a646847aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_019c56f4-89fe-7868-80bb-aad993484364" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_feb8fe6e-32b2-4c27-b55a-59e41b01fc45" xlink:to="loc_ifrs-full_UnobservableInputsAxis_019c56f4-89fe-7868-80bb-aad993484364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain_019c56f4-89fe-79d4-b762-f3da1e11b194" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsAxis_019c56f4-89fe-7868-80bb-aad993484364" xlink:to="loc_ifrs-full_UnobservableInputsDomain_019c56f4-89fe-79d4-b762-f3da1e11b194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_019c56f4-89fe-73bf-9359-6d7a7d7f9636" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019c56f4-89fe-79d4-b762-f3da1e11b194" xlink:to="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_019c56f4-89fe-73bf-9359-6d7a7d7f9636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CreditSpreadMeasurementInputMember_019c56f4-89fe-7ee7-ac5b-ec486aa07f2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CreditSpreadMeasurementInputMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019c56f4-89fe-79d4-b762-f3da1e11b194" xlink:to="loc_ifrs-full_CreditSpreadMeasurementInputMember_019c56f4-89fe-7ee7-ac5b-ec486aa07f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SharePriceMeasurementInputMember_019c56f4-89fe-7360-ab3a-064074067392" xlink:href="abvx-20251231.xsd#abvx_SharePriceMeasurementInputMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019c56f4-89fe-79d4-b762-f3da1e11b194" xlink:to="loc_abvx_SharePriceMeasurementInputMember_019c56f4-89fe-7360-ab3a-064074067392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RiskFreeInterestRateMeasurementInputMember_019c56f4-89fe-7d19-9cc2-1f8e0848f4b1" xlink:href="abvx-20251231.xsd#abvx_RiskFreeInterestRateMeasurementInputMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019c56f4-89fe-79d4-b762-f3da1e11b194" xlink:to="loc_abvx_RiskFreeInterestRateMeasurementInputMember_019c56f4-89fe-7d19-9cc2-1f8e0848f4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_019c56f4-89fe-710e-8842-d28121d41df5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_feb8fe6e-32b2-4c27-b55a-59e41b01fc45" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_019c56f4-89fe-710e-8842-d28121d41df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_019c56f4-89fe-772f-996e-7d28a81f340e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_019c56f4-89fe-710e-8842-d28121d41df5" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_019c56f4-89fe-772f-996e-7d28a81f340e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_MonteCarloModelIFRSMember_019c56f4-89fe-7afb-9ba2-6d4679defc30" xlink:href="abvx-20251231.xsd#abvx_MonteCarloModelIFRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain_019c56f4-89fe-772f-996e-7d28a81f340e" xlink:to="loc_abvx_MonteCarloModelIFRSMember_019c56f4-89fe-7afb-9ba2-6d4679defc30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f4-89fe-7f94-9f8f-aab28713fd5c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_feb8fe6e-32b2-4c27-b55a-59e41b01fc45" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f4-89fe-7f94-9f8f-aab28713fd5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ProceedsFromIssuingSharesAndConvertibleLoansNotes_019c56f4-89fe-7828-be5a-f3525c08cf0f" xlink:href="abvx-20251231.xsd#abvx_ProceedsFromIssuingSharesAndConvertibleLoansNotes"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f4-89fe-7f94-9f8f-aab28713fd5c" xlink:to="loc_abvx_ProceedsFromIssuingSharesAndConvertibleLoansNotes_019c56f4-89fe-7828-be5a-f3525c08cf0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease_019c56f4-89fe-77a0-82da-bf2bc678e0f2" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f4-89fe-7f94-9f8f-aab28713fd5c" xlink:to="loc_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease_019c56f4-89fe-77a0-82da-bf2bc678e0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EquityIssuanceSubscriptionPricePerShare_019c56f4-89fe-7758-a880-e84014382883" xlink:href="abvx-20251231.xsd#abvx_EquityIssuanceSubscriptionPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f4-89fe-7f94-9f8f-aab28713fd5c" xlink:to="loc_abvx_EquityIssuanceSubscriptionPricePerShare_019c56f4-89fe-7758-a880-e84014382883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_019c56f4-89fe-77e1-9697-0b8c2c106419" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f4-89fe-7f94-9f8f-aab28713fd5c" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_019c56f4-89fe-77e1-9697-0b8c2c106419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NetProceedsFromConvertibleLoansNotes_019c56f4-89fe-758e-a9bd-3681ab066299" xlink:href="abvx-20251231.xsd#abvx_NetProceedsFromConvertibleLoansNotes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f4-89fe-7f94-9f8f-aab28713fd5c" xlink:to="loc_abvx_NetProceedsFromConvertibleLoansNotes_019c56f4-89fe-758e-a9bd-3681ab066299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConversionPriceAdjustmentPeriod_019c56f4-89fe-70cc-b4eb-04feb9e73a0e" xlink:href="abvx-20251231.xsd#abvx_ConversionPriceAdjustmentPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f4-89fe-7f94-9f8f-aab28713fd5c" xlink:to="loc_abvx_ConversionPriceAdjustmentPeriod_019c56f4-89fe-70cc-b4eb-04feb9e73a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities_019c56f4-89fe-7078-b1dc-fbbd8514817c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantUnobservableInputLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f4-89fe-7f94-9f8f-aab28713fd5c" xlink:to="loc_ifrs-full_SignificantUnobservableInputLiabilities_019c56f4-89fe-7078-b1dc-fbbd8514817c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AggregateFairValueConvertibleNotes_019c56f4-89fe-782b-a659-6e4ada9daefc" xlink:href="abvx-20251231.xsd#abvx_AggregateFairValueConvertibleNotes"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f4-89fe-7f94-9f8f-aab28713fd5c" xlink:to="loc_abvx_AggregateFairValueConvertibleNotes_019c56f4-89fe-782b-a659-6e4ada9daefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_019c56f4-89fe-7da1-b5d7-a6fca9c276e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f4-89fe-7f94-9f8f-aab28713fd5c" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_019c56f4-89fe-7da1-b5d7-a6fca9c276e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_019c56f4-89fe-7197-bf4f-33a65f6be7b8" xlink:href="abvx-20251231.xsd#abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f4-89fe-7f94-9f8f-aab28713fd5c" xlink:to="loc_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_019c56f4-89fe-7197-bf4f-33a65f6be7b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets_019c56f4-89fe-7591-af78-1a3413155698" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f4-89fe-7f94-9f8f-aab28713fd5c" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets_019c56f4-89fe-7591-af78-1a3413155698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepaymentsOfConvertibleLoansNotes_019c56f4-89fe-77c0-9355-239d34bfcbf3" xlink:href="abvx-20251231.xsd#abvx_RepaymentsOfConvertibleLoansNotes"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f4-89fe-7f94-9f8f-aab28713fd5c" xlink:to="loc_abvx_RepaymentsOfConvertibleLoansNotes_019c56f4-89fe-77c0-9355-239d34bfcbf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid_019c56f4-89fe-7a0c-977e-aa206502b6a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019c56f4-89fe-7f94-9f8f-aab28713fd5c" xlink:to="loc_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid_019c56f4-89fe-7a0c-977e-aa206502b6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesStateguaranteedloanPGEDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesStateguaranteedloanPGEDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesStateguaranteedloanPGEDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_e796895c-3e8a-4675-883a-a575d8c98b60" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_12c38cae-fae0-467d-aca8-c83d9af261fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_e796895c-3e8a-4675-883a-a575d8c98b60" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_12c38cae-fae0-467d-aca8-c83d9af261fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_cb9cd544-3883-4089-8111-b8f93c9b1c54" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_12c38cae-fae0-467d-aca8-c83d9af261fa" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_cb9cd544-3883-4089-8111-b8f93c9b1c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_2c0fa645-5dfd-4659-900a-b18dc776400e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_cb9cd544-3883-4089-8111-b8f93c9b1c54" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_2c0fa645-5dfd-4659-900a-b18dc776400e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PretGarantiParLEtatPGEMember_3df1dc0a-138a-4bce-988d-0ff37c982b30" xlink:href="abvx-20251231.xsd#abvx_PretGarantiParLEtatPGEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_2c0fa645-5dfd-4659-900a-b18dc776400e" xlink:to="loc_abvx_PretGarantiParLEtatPGEMember_3df1dc0a-138a-4bce-988d-0ff37c982b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_47c997b2-20b4-4ccb-ba02-014aa5dacbcf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_12c38cae-fae0-467d-aca8-c83d9af261fa" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_47c997b2-20b4-4ccb-ba02-014aa5dacbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsMaturityTerm_a857c880-a58a-46a0-9dd1-30e29abc33c2" xlink:href="abvx-20251231.xsd#abvx_BorrowingsMaturityTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_47c997b2-20b4-4ccb-ba02-014aa5dacbcf" xlink:to="loc_abvx_BorrowingsMaturityTerm_a857c880-a58a-46a0-9dd1-30e29abc33c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_d7042f2b-09be-4f04-aa01-a17b7ce9b1cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_47c997b2-20b4-4ccb-ba02-014aa5dacbcf" xlink:to="loc_ifrs-full_BorrowingsInterestRate_d7042f2b-09be-4f04-aa01-a17b7ce9b1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsMaturityExtensionTerm_1549860c-9773-401b-9bd0-c58db631edfe" xlink:href="abvx-20251231.xsd#abvx_BorrowingsMaturityExtensionTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_47c997b2-20b4-4ccb-ba02-014aa5dacbcf" xlink:to="loc_abvx_BorrowingsMaturityExtensionTerm_1549860c-9773-401b-9bd0-c58db631edfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsMaturityDeferralPeriod_a3557aa1-a742-4229-911e-8c6a98b794de" xlink:href="abvx-20251231.xsd#abvx_BorrowingsMaturityDeferralPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_47c997b2-20b4-4ccb-ba02-014aa5dacbcf" xlink:to="loc_abvx_BorrowingsMaturityDeferralPeriod_a3557aa1-a742-4229-911e-8c6a98b794de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsStateGuaranteedPremium_720299d8-31e4-41a7-8d42-453505d93e53" xlink:href="abvx-20251231.xsd#abvx_BorrowingsStateGuaranteedPremium"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_47c997b2-20b4-4ccb-ba02-014aa5dacbcf" xlink:to="loc_abvx_BorrowingsStateGuaranteedPremium_720299d8-31e4-41a7-8d42-453505d93e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromGovernmentGrants_55a9fd97-506f-4b35-9e54-74f2fd49e4d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_47c997b2-20b4-4ccb-ba02-014aa5dacbcf" xlink:to="loc_ifrs-full_RevenueFromGovernmentGrants_55a9fd97-506f-4b35-9e54-74f2fd49e4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_019cfd00-dead-7593-831e-7f92c598802c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_47c997b2-20b4-4ccb-ba02-014aa5dacbcf" xlink:to="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_019cfd00-dead-7593-831e-7f92c598802c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesDisclosureofconditionaladvancesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesDisclosureofconditionaladvancesDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesDisclosureofconditionaladvancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_0d7081c6-e94a-49fc-bbff-0979c292b575" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_0dde3b7b-9ebd-4ff9-b341-9eaa156746e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_0d7081c6-e94a-49fc-bbff-0979c292b575" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_0dde3b7b-9ebd-4ff9-b341-9eaa156746e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_1512a780-f378-40ad-91d5-26d86d28a163" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_0dde3b7b-9ebd-4ff9-b341-9eaa156746e0" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_1512a780-f378-40ad-91d5-26d86d28a163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_74400510-9cfd-44f5-a78e-314dd5058b2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_1512a780-f378-40ad-91d5-26d86d28a163" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_74400510-9cfd-44f5-a78e-314dd5058b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RNPVIRConditionalAdvanceBPIMember_56ea95fa-14f2-4d54-b87c-7860015747a1" xlink:href="abvx-20251231.xsd#abvx_RNPVIRConditionalAdvanceBPIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_74400510-9cfd-44f5-a78e-314dd5058b2e" xlink:to="loc_abvx_RNPVIRConditionalAdvanceBPIMember_56ea95fa-14f2-4d54-b87c-7860015747a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CARENAConditionalAdvanceBPIMember_40906cfa-579f-4069-a20d-cfc599e68fd2" xlink:href="abvx-20251231.xsd#abvx_CARENAConditionalAdvanceBPIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_74400510-9cfd-44f5-a78e-314dd5058b2e" xlink:to="loc_abvx_CARENAConditionalAdvanceBPIMember_40906cfa-579f-4069-a20d-cfc599e68fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EbolaConditionalAdvanceBPIMember_85a3eb3c-1921-4d36-959e-6e64c423e464" xlink:href="abvx-20251231.xsd#abvx_EbolaConditionalAdvanceBPIMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_74400510-9cfd-44f5-a78e-314dd5058b2e" xlink:to="loc_abvx_EbolaConditionalAdvanceBPIMember_85a3eb3c-1921-4d36-959e-6e64c423e464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_d5c1e78b-a09f-4b20-800a-7dceefeb27eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_0dde3b7b-9ebd-4ff9-b341-9eaa156746e0" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_d5c1e78b-a09f-4b20-800a-7dceefeb27eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConditionalAdvances_dd46eddd-0d44-4d65-a6e8-34740071014e" xlink:href="abvx-20251231.xsd#abvx_ConditionalAdvances"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_d5c1e78b-a09f-4b20-800a-7dceefeb27eb" xlink:to="loc_abvx_ConditionalAdvances_dd46eddd-0d44-4d65-a6e8-34740071014e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesConditionaladvancesDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_6029b81a-1b10-41ac-8c0e-fd82d87034b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_6f4460f0-d988-4d01-bd8e-2757931c12b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_6029b81a-1b10-41ac-8c0e-fd82d87034b2" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_6f4460f0-d988-4d01-bd8e-2757931c12b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_8d892f5a-c9b4-493d-9fb7-2b9116e7141c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_6f4460f0-d988-4d01-bd8e-2757931c12b5" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_8d892f5a-c9b4-493d-9fb7-2b9116e7141c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f92c6b63-42de-4e4d-893e-81e1bb6ba342" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_8d892f5a-c9b4-493d-9fb7-2b9116e7141c" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f92c6b63-42de-4e4d-893e-81e1bb6ba342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RNPVIRConditionalAdvanceBPIMember_a23d6645-428f-46ae-8e37-1f6350f2ca59" xlink:href="abvx-20251231.xsd#abvx_RNPVIRConditionalAdvanceBPIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f92c6b63-42de-4e4d-893e-81e1bb6ba342" xlink:to="loc_abvx_RNPVIRConditionalAdvanceBPIMember_a23d6645-428f-46ae-8e37-1f6350f2ca59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CARENAConditionalAdvanceBPIMember_81c2ca5d-6b5a-42ca-8d2e-e475ac1ce075" xlink:href="abvx-20251231.xsd#abvx_CARENAConditionalAdvanceBPIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f92c6b63-42de-4e4d-893e-81e1bb6ba342" xlink:to="loc_abvx_CARENAConditionalAdvanceBPIMember_81c2ca5d-6b5a-42ca-8d2e-e475ac1ce075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EbolaConditionalAdvanceBPIMember_d3494ba1-9878-43c3-83d7-62d67d8d1744" xlink:href="abvx-20251231.xsd#abvx_EbolaConditionalAdvanceBPIMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f92c6b63-42de-4e4d-893e-81e1bb6ba342" xlink:to="loc_abvx_EbolaConditionalAdvanceBPIMember_d3494ba1-9878-43c3-83d7-62d67d8d1744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fe4daff4-1733-4154-a906-16629ff5fa3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_6f4460f0-d988-4d01-bd8e-2757931c12b5" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fe4daff4-1733-4154-a906-16629ff5fa3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity_93586da5-d530-417d-874c-903f538f7c6b" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fe4daff4-1733-4154-a906-16629ff5fa3c" xlink:to="loc_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity_93586da5-d530-417d-874c-903f538f7c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ProceedsFromConditionalAdvances_17ecd6f5-a1e6-474b-940d-f287c15aff9e" xlink:href="abvx-20251231.xsd#abvx_ProceedsFromConditionalAdvances"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fe4daff4-1733-4154-a906-16629ff5fa3c" xlink:to="loc_abvx_ProceedsFromConditionalAdvances_17ecd6f5-a1e6-474b-940d-f287c15aff9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepaymentOfExcessConditionalAdvancesClaimed_844a21c4-b1e7-4d98-8a33-65ada243005f" xlink:href="abvx-20251231.xsd#abvx_RepaymentOfExcessConditionalAdvancesClaimed"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fe4daff4-1733-4154-a906-16629ff5fa3c" xlink:to="loc_abvx_RepaymentOfExcessConditionalAdvancesClaimed_844a21c4-b1e7-4d98-8a33-65ada243005f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PercentageOfConditionalAdvancesWaived_5e106c9c-ecf7-4311-9ba0-9931f66878af" xlink:href="abvx-20251231.xsd#abvx_PercentageOfConditionalAdvancesWaived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fe4daff4-1733-4154-a906-16629ff5fa3c" xlink:to="loc_abvx_PercentageOfConditionalAdvancesWaived_5e106c9c-ecf7-4311-9ba0-9931f66878af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConditionalAdvances_2b90c9cb-550a-40f5-a520-85b294bc5642" xlink:href="abvx-20251231.xsd#abvx_ConditionalAdvances"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fe4daff4-1733-4154-a906-16629ff5fa3c" xlink:to="loc_abvx_ConditionalAdvances_2b90c9cb-550a-40f5-a520-85b294bc5642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromGovernmentGrants_24982f23-2603-4d52-93fa-2e9fb3654c62" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fe4daff4-1733-4154-a906-16629ff5fa3c" xlink:to="loc_ifrs-full_RevenueFromGovernmentGrants_24982f23-2603-4d52-93fa-2e9fb3654c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesDisclosureofvariationinleaseliabilitiesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesDisclosureofvariationinleaseliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesDisclosureofvariationinleaseliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_74fc31f9-e2fe-40c4-aa5c-8362a65f8bc4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_821c51ca-8477-4f15-a8ff-73cff57caf1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_74fc31f9-e2fe-40c4-aa5c-8362a65f8bc4" xlink:to="loc_ifrs-full_LeaseLiabilities_821c51ca-8477-4f15-a8ff-73cff57caf1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseInLeaseLiabilities_451a8266-c84d-4087-8182-ec31f5b48a1a" xlink:href="abvx-20251231.xsd#abvx_IncreaseInLeaseLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_74fc31f9-e2fe-40c4-aa5c-8362a65f8bc4" xlink:to="loc_abvx_IncreaseInLeaseLiabilities_451a8266-c84d-4087-8182-ec31f5b48a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DecreaseInLeaseLiabilities_d7432bd1-cba7-423d-8755-0df6b8bb3315" xlink:href="abvx-20251231.xsd#abvx_DecreaseInLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_74fc31f9-e2fe-40c4-aa5c-8362a65f8bc4" xlink:to="loc_abvx_DecreaseInLeaseLiabilities_d7432bd1-cba7-423d-8755-0df6b8bb3315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_24badead-14e7-4db5-bd02-5da1efedd938" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_74fc31f9-e2fe-40c4-aa5c-8362a65f8bc4" xlink:to="loc_ifrs-full_LeaseLiabilities_24badead-14e7-4db5-bd02-5da1efedd938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesLeaseliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_f650e01f-3b04-446e-b3b6-ecaccbf0fedc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfLeaseLiabilitiesTable_90179b54-69e9-496c-ab74-817e7d9e4f63" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfLeaseLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_f650e01f-3b04-446e-b3b6-ecaccbf0fedc" xlink:to="loc_abvx_DisclosureOfLeaseLiabilitiesTable_90179b54-69e9-496c-ab74-817e7d9e4f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_e33b131f-937a-409e-a626-a69c8b74c07d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfLeaseLiabilitiesTable_90179b54-69e9-496c-ab74-817e7d9e4f63" xlink:to="loc_ifrs-full_TypesOfContractsAxis_e33b131f-937a-409e-a626-a69c8b74c07d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_97674617-d0ab-490d-9c5c-c5e74c323ea0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsAxis_e33b131f-937a-409e-a626-a69c8b74c07d" xlink:to="loc_ifrs-full_TypesOfContractsDomain_97674617-d0ab-490d-9c5c-c5e74c323ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LeaseFacilitiesParisMember_4a89ae34-eeca-4181-98e3-51d148e535dd" xlink:href="abvx-20251231.xsd#abvx_LeaseFacilitiesParisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsDomain_97674617-d0ab-490d-9c5c-c5e74c323ea0" xlink:to="loc_abvx_LeaseFacilitiesParisMember_4a89ae34-eeca-4181-98e3-51d148e535dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LeaseFacilitiesBostonMember_a1cbcce2-3e76-414d-b6a3-b69badbe6c25" xlink:href="abvx-20251231.xsd#abvx_LeaseFacilitiesBostonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsDomain_97674617-d0ab-490d-9c5c-c5e74c323ea0" xlink:to="loc_abvx_LeaseFacilitiesBostonMember_a1cbcce2-3e76-414d-b6a3-b69badbe6c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LeaseFacilitiesMontpellierMember_4bfd11f5-80a5-41e6-9c49-00f26b6a25f5" xlink:href="abvx-20251231.xsd#abvx_LeaseFacilitiesMontpellierMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsDomain_97674617-d0ab-490d-9c5c-c5e74c323ea0" xlink:to="loc_abvx_LeaseFacilitiesMontpellierMember_4bfd11f5-80a5-41e6-9c49-00f26b6a25f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LeaseFacilitiesMember_edbd71fc-7f11-4c0a-a766-7488ae6c73f7" xlink:href="abvx-20251231.xsd#abvx_LeaseFacilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsDomain_97674617-d0ab-490d-9c5c-c5e74c323ea0" xlink:to="loc_abvx_LeaseFacilitiesMember_edbd71fc-7f11-4c0a-a766-7488ae6c73f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_f12f6201-73a8-40c9-ae35-e515234d081f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfLeaseLiabilitiesTable_90179b54-69e9-496c-ab74-817e7d9e4f63" xlink:to="loc_ifrs-full_RangeAxis_f12f6201-73a8-40c9-ae35-e515234d081f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_e403825c-8b2c-42d0-a5de-829d6bda500d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_f12f6201-73a8-40c9-ae35-e515234d081f" xlink:to="loc_ifrs-full_RangeDomain_e403825c-8b2c-42d0-a5de-829d6bda500d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f50f22cf-387f-4388-85cb-015842be2b90" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_e403825c-8b2c-42d0-a5de-829d6bda500d" xlink:to="loc_srt_MinimumMember_f50f22cf-387f-4388-85cb-015842be2b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6eb94a93-26f8-4c9d-9ce3-599ca2d178de" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_e403825c-8b2c-42d0-a5de-829d6bda500d" xlink:to="loc_srt_MaximumMember_6eb94a93-26f8-4c9d-9ce3-599ca2d178de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfLeaseLiabilitiesLineItems_3ce3eef7-3f85-4c91-a089-66af04cd3665" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfLeaseLiabilitiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfLeaseLiabilitiesTable_90179b54-69e9-496c-ab74-817e7d9e4f63" xlink:to="loc_abvx_DisclosureOfLeaseLiabilitiesLineItems_3ce3eef7-3f85-4c91-a089-66af04cd3665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LeaseDurationPeriod_1e0c8955-8a6b-46b2-b4a4-39c1d979646b" xlink:href="abvx-20251231.xsd#abvx_LeaseDurationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfLeaseLiabilitiesLineItems_3ce3eef7-3f85-4c91-a089-66af04cd3665" xlink:to="loc_abvx_LeaseDurationPeriod_1e0c8955-8a6b-46b2-b4a4-39c1d979646b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LeaseTacitRenewalPeriod_0898cda7-4946-485d-9d23-09e011157c89" xlink:href="abvx-20251231.xsd#abvx_LeaseTacitRenewalPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfLeaseLiabilitiesLineItems_3ce3eef7-3f85-4c91-a089-66af04cd3665" xlink:to="loc_abvx_LeaseTacitRenewalPeriod_0898cda7-4946-485d-9d23-09e011157c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LeaseBreakClausePeriod_c333363e-1cf8-45ba-98ef-5c3c79cd4f2f" xlink:href="abvx-20251231.xsd#abvx_LeaseBreakClausePeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfLeaseLiabilitiesLineItems_3ce3eef7-3f85-4c91-a089-66af04cd3665" xlink:to="loc_abvx_LeaseBreakClausePeriod_c333363e-1cf8-45ba-98ef-5c3c79cd4f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DecreaseInLeaseLiabilitiesThroughModificationOfTerm_dd1fe94e-4176-41bb-b74e-3eb8b59215c8" xlink:href="abvx-20251231.xsd#abvx_DecreaseInLeaseLiabilitiesThroughModificationOfTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfLeaseLiabilitiesLineItems_3ce3eef7-3f85-4c91-a089-66af04cd3665" xlink:to="loc_abvx_DecreaseInLeaseLiabilitiesThroughModificationOfTerm_dd1fe94e-4176-41bb-b74e-3eb8b59215c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LeaseExtensionPeriod_29f0aec0-12b0-4493-8a9f-36a9eb40b020" xlink:href="abvx-20251231.xsd#abvx_LeaseExtensionPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfLeaseLiabilitiesLineItems_3ce3eef7-3f85-4c91-a089-66af04cd3665" xlink:to="loc_abvx_LeaseExtensionPeriod_29f0aec0-12b0-4493-8a9f-36a9eb40b020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LeaseLiabilityPercentageOfTotal_b600d7c7-fa0c-45e0-b93a-d68222509182" xlink:href="abvx-20251231.xsd#abvx_LeaseLiabilityPercentageOfTotal"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfLeaseLiabilitiesLineItems_3ce3eef7-3f85-4c91-a089-66af04cd3665" xlink:to="loc_abvx_LeaseLiabilityPercentageOfTotal_b600d7c7-fa0c-45e0-b93a-d68222509182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpenseOnLeaseLiabilities_763d7c17-55c2-4c27-a09a-c8ac6b304787" xlink:href="abvx-20251231.xsd#abvx_ExpenseOnLeaseLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfLeaseLiabilitiesLineItems_3ce3eef7-3f85-4c91-a089-66af04cd3665" xlink:to="loc_abvx_ExpenseOnLeaseLiabilities_763d7c17-55c2-4c27-a09a-c8ac6b304787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DepreciationExpenseLease_d5c85315-27d7-4af5-b1d7-2c80a9708152" xlink:href="abvx-20251231.xsd#abvx_DepreciationExpenseLease"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfLeaseLiabilitiesLineItems_3ce3eef7-3f85-4c91-a089-66af04cd3665" xlink:to="loc_abvx_DepreciationExpenseLease_d5c85315-27d7-4af5-b1d7-2c80a9708152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_703d05b3-f0eb-4df3-86e6-7b59cf150ca9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfLeaseLiabilitiesLineItems_3ce3eef7-3f85-4c91-a089-66af04cd3665" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_703d05b3-f0eb-4df3-86e6-7b59cf150ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed_cf18d510-0fb4-4a37-b8c4-9dd3b2e62f02" xlink:href="abvx-20251231.xsd#abvx_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfLeaseLiabilitiesLineItems_3ce3eef7-3f85-4c91-a089-66af04cd3665" xlink:to="loc_abvx_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed_cf18d510-0fb4-4a37-b8c4-9dd3b2e62f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesRoyaltycertificatesDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_7e9250ec-fb34-425f-b91c-7a2abd5353a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_29aeafb0-99bb-41d3-a620-494d837525ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_7e9250ec-fb34-425f-b91c-7a2abd5353a6" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_29aeafb0-99bb-41d3-a620-494d837525ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019bffa7-38ad-7881-aa13-56ccfbd47f07" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_29aeafb0-99bb-41d3-a620-494d837525ee" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019bffa7-38ad-7881-aa13-56ccfbd47f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019bffa7-38ad-7163-bcce-d128c8e34d9d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019bffa7-38ad-7881-aa13-56ccfbd47f07" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019bffa7-38ad-7163-bcce-d128c8e34d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificatesMember_019bffa7-38ad-756a-af6e-4f182497d06f" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019bffa7-38ad-7163-bcce-d128c8e34d9d" xlink:to="loc_abvx_RoyaltyCertificatesMember_019bffa7-38ad-756a-af6e-4f182497d06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_019bffa7-38ad-74e1-924b-0fdfae1eff24" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_29aeafb0-99bb-41d3-a620-494d837525ee" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_019bffa7-38ad-74e1-924b-0fdfae1eff24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_019bffa7-38ad-7be3-950a-e9c64fac0d26" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_019bffa7-38ad-74e1-924b-0fdfae1eff24" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_019bffa7-38ad-7be3-950a-e9c64fac0d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_019bffa7-38ad-742c-ae99-e1b725a7138e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_019bffa7-38ad-7be3-950a-e9c64fac0d26" xlink:to="loc_ifrs-full_SharePremiumMember_019bffa7-38ad-742c-ae99-e1b725a7138e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_019bffa7-38ad-7647-b202-c388f5137ebd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_29aeafb0-99bb-41d3-a620-494d837525ee" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_019bffa7-38ad-7647-b202-c388f5137ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_019bffa7-38ad-7e8b-8a6f-cf9bf4adbea9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_019bffa7-38ad-7647-b202-c388f5137ebd" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_019bffa7-38ad-7e8b-8a6f-cf9bf4adbea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificatesMember_019bffa7-38ad-7a64-9a71-82af63b506b4" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_019bffa7-38ad-7e8b-8a6f-cf9bf4adbea9" xlink:to="loc_abvx_RoyaltyCertificatesMember_019bffa7-38ad-7a64-9a71-82af63b506b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_019bffa7-9b9e-7b9c-b770-f7b82339cae6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_29aeafb0-99bb-41d3-a620-494d837525ee" xlink:to="loc_ifrs-full_UnobservableInputsAxis_019bffa7-9b9e-7b9c-b770-f7b82339cae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain_019bffa7-9b9e-7a0c-a352-5876d295342b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsAxis_019bffa7-9b9e-7b9c-b770-f7b82339cae6" xlink:to="loc_ifrs-full_UnobservableInputsDomain_019bffa7-9b9e-7a0c-a352-5876d295342b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ProbabilityOfSuccessMeasurementInputMember_019bffa7-9b9e-7c7f-afed-329a082d1291" xlink:href="abvx-20251231.xsd#abvx_ProbabilityOfSuccessMeasurementInputMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019bffa7-9b9e-7a0c-a352-5876d295342b" xlink:to="loc_abvx_ProbabilityOfSuccessMeasurementInputMember_019bffa7-9b9e-7c7f-afed-329a082d1291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PeakPenetrationMeasurementInputMember_019bffa7-9b9e-79f1-a4ae-cdfe6557697d" xlink:href="abvx-20251231.xsd#abvx_PeakPenetrationMeasurementInputMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019bffa7-9b9e-7a0c-a352-5876d295342b" xlink:to="loc_abvx_PeakPenetrationMeasurementInputMember_019bffa7-9b9e-79f1-a4ae-cdfe6557697d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DiscountRateMeasurementInputMember_019bffa7-d5df-7c58-aefe-54d001ca1ce9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DiscountRateMeasurementInputMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019bffa7-9b9e-7a0c-a352-5876d295342b" xlink:to="loc_ifrs-full_DiscountRateMeasurementInputMember_019bffa7-d5df-7c58-aefe-54d001ca1ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageCostOfCapitalMeasurementInputMember_019bffa8-5859-7c48-ac7a-c5e9a15ba52a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageCostOfCapitalMeasurementInputMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019bffa7-9b9e-7a0c-a352-5876d295342b" xlink:to="loc_ifrs-full_WeightedAverageCostOfCapitalMeasurementInputMember_019bffa8-5859-7c48-ac7a-c5e9a15ba52a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SharePriceMeasurementInputMember_019bffa8-5859-7f7c-bd51-2fbd6b84bd4b" xlink:href="abvx-20251231.xsd#abvx_SharePriceMeasurementInputMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_019bffa7-9b9e-7a0c-a352-5876d295342b" xlink:to="loc_abvx_SharePriceMeasurementInputMember_019bffa8-5859-7f7c-bd51-2fbd6b84bd4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_29aeafb0-99bb-41d3-a620-494d837525ee" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_019bffa7-38ad-7d14-896c-5ddfb393aae8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_ifrs-full_NotionalAmount_019bffa7-38ad-7d14-896c-5ddfb393aae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherLiabilitiesNumberOfTransactions_019bffa7-38ad-721a-a548-7b128cfd9db5" xlink:href="abvx-20251231.xsd#abvx_OtherLiabilitiesNumberOfTransactions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_abvx_OtherLiabilitiesNumberOfTransactions_019bffa7-38ad-721a-a548-7b128cfd9db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_019bffa7-38ad-7e94-9d92-605ae4e29f41" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_ifrs-full_IssueOfEquity_019bffa7-38ad-7e94-9d92-605ae4e29f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease_019bffa7-38ad-7564-bdd7-846176f57c71" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease_019bffa7-38ad-7564-bdd7-846176f57c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_019bffa7-38ad-7e09-8581-cde59c963300" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_ifrs-full_ParValuePerShare_019bffa7-38ad-7e09-8581-cde59c963300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EquityIssuanceSubscriptionPricePerShare_019bffa7-38ad-7810-a567-aa8a1f8680f5" xlink:href="abvx-20251231.xsd#abvx_EquityIssuanceSubscriptionPricePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_abvx_EquityIssuanceSubscriptionPricePerShare_019bffa7-38ad-7810-a567-aa8a1f8680f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NetProceedsFromSaleOfRoyaltyCertificates_019bffa7-38ad-7fe4-ae90-8fed5a98a807" xlink:href="abvx-20251231.xsd#abvx_NetProceedsFromSaleOfRoyaltyCertificates"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_abvx_NetProceedsFromSaleOfRoyaltyCertificates_019bffa7-38ad-7fe4-ae90-8fed5a98a807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificatePercentageOfFutureSales_019bffa7-38ad-73fa-9c4f-452751285f40" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificatePercentageOfFutureSales"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_abvx_RoyaltyCertificatePercentageOfFutureSales_019bffa7-38ad-73fa-9c4f-452751285f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificateMaximumAmount_019bffa7-38ad-73b8-8eee-db78ab00ecd0" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificateMaximumAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_abvx_RoyaltyCertificateMaximumAmount_019bffa7-38ad-73b8-8eee-db78ab00ecd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_019bffa7-38ad-7227-bc08-bb6da64a836d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_019bffa7-38ad-7227-bc08-bb6da64a836d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificatesEIR_019bffa7-38ad-77fe-945d-ae258c83a886" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificatesEIR"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_abvx_RoyaltyCertificatesEIR_019bffa7-38ad-77fe-945d-ae258c83a886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities_019bffa7-38ad-712a-ad7e-d61049b171cd" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities_019bffa7-38ad-712a-ad7e-d61049b171cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_InterestExpenseOnRoyaltyCertificatesIncludingTheUnwindingOfDiscount_019cc355-1afa-75a6-b67b-c756b4814935" xlink:href="abvx-20251231.xsd#abvx_InterestExpenseOnRoyaltyCertificatesIncludingTheUnwindingOfDiscount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_abvx_InterestExpenseOnRoyaltyCertificatesIncludingTheUnwindingOfDiscount_019cc355-1afa-75a6-b67b-c756b4814935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_UnwindingOfDiscountOnRoyalties_019bffa7-38ad-7d1f-969c-4879e029870f" xlink:href="abvx-20251231.xsd#abvx_UnwindingOfDiscountOnRoyalties"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_abvx_UnwindingOfDiscountOnRoyalties_019bffa7-38ad-7d1f-969c-4879e029870f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bffa7-9b9e-7aa2-8dad-d3d373ac91c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bffa7-9b9e-7aa2-8dad-d3d373ac91c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bffa7-9b9e-7c62-9256-61085e1a7395" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bffa7-9b9e-7c62-9256-61085e1a7395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities_019bffa7-9b9e-7fe4-9b1b-44ece0a3f912" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities_019bffa7-9b9e-7fe4-9b1b-44ece0a3f912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities_019bffa7-9b9e-7282-b713-e584e8928c63" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities_019bffa7-9b9e-7282-b713-e584e8928c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValue_019bffa7-d5df-7ae5-be28-907032db5d3b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValue_019bffa7-d5df-7ae5-be28-907032db5d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_UnobservableInputLiabilitiesDiscountRate_019cfd0f-9f4a-733f-bef7-84fa815ccf7f" xlink:href="abvx-20251231.xsd#abvx_UnobservableInputLiabilitiesDiscountRate"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_abvx_UnobservableInputLiabilitiesDiscountRate_019cfd0f-9f4a-733f-bef7-84fa815ccf7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bffa8-5859-780e-928d-33a887c1b159" xlink:href="abvx-20251231.xsd#abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bffa8-5859-780e-928d-33a887c1b159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bffa8-5859-7b0b-932b-d4022ee61264" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities_019bffa8-5859-7b0b-932b-d4022ee61264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AmountOfReasonablyPossibleDecreaseInUnobservableInputLiabilities_019bffa8-5859-7763-82c3-105310a28740" xlink:href="abvx-20251231.xsd#abvx_AmountOfReasonablyPossibleDecreaseInUnobservableInputLiabilities"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_abvx_AmountOfReasonablyPossibleDecreaseInUnobservableInputLiabilities_019bffa8-5859-7763-82c3-105310a28740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities_019bffa8-5859-7122-83b6-3f32d58cec9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019bffa7-38ad-7c0c-8ddf-b8d1f1b55258" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities_019bffa8-5859-7122-83b6-3f32d58cec9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_8bcf7960-004f-4608-a38e-d47453d47a2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_fd50bf14-1f81-44a8-856c-5728ed8fe292" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_8bcf7960-004f-4608-a38e-d47453d47a2c" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_fd50bf14-1f81-44a8-856c-5728ed8fe292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_b9a6a222-0ab5-4235-a39c-2f44b045df5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_fd50bf14-1f81-44a8-856c-5728ed8fe292" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_b9a6a222-0ab5-4235-a39c-2f44b045df5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_a6de3721-e5dd-4c7a-b311-d842bb5dcbfa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_b9a6a222-0ab5-4235-a39c-2f44b045df5b" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_a6de3721-e5dd-4c7a-b311-d842bb5dcbfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos12BondLoansMember_2444bc7c-0cc7-41b6-9cb7-6492a736b687" xlink:href="abvx-20251231.xsd#abvx_Kreos12BondLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_a6de3721-e5dd-4c7a-b311-d842bb5dcbfa" xlink:to="loc_abvx_Kreos12BondLoansMember_2444bc7c-0cc7-41b6-9cb7-6492a736b687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OCEANEMember_de55bdc7-bdb6-4afd-85ad-d365ff2be4db" xlink:href="abvx-20251231.xsd#abvx_OCEANEMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_a6de3721-e5dd-4c7a-b311-d842bb5dcbfa" xlink:to="loc_abvx_OCEANEMember_de55bdc7-bdb6-4afd-85ad-d365ff2be4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheAMember_e96e63c0-f448-4116-afdb-65b6840c369c" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_a6de3721-e5dd-4c7a-b311-d842bb5dcbfa" xlink:to="loc_abvx_KreosClaretFinancingTrancheAMember_e96e63c0-f448-4116-afdb-65b6840c369c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_Kreos1ClaretBondLoansMember_f0f39668-ae05-4710-84d4-6bd0d5c6708f" xlink:href="abvx-20251231.xsd#abvx_Kreos1ClaretBondLoansMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_a6de3721-e5dd-4c7a-b311-d842bb5dcbfa" xlink:to="loc_abvx_Kreos1ClaretBondLoansMember_f0f39668-ae05-4710-84d4-6bd0d5c6708f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_HeightsConvertibleNotesMember_6f8f511e-b6a9-4e12-b939-0940a66f37c0" xlink:href="abvx-20251231.xsd#abvx_HeightsConvertibleNotesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_a6de3721-e5dd-4c7a-b311-d842bb5dcbfa" xlink:to="loc_abvx_HeightsConvertibleNotesMember_6f8f511e-b6a9-4e12-b939-0940a66f37c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PretGarantiParLEtatPGEMember_08633a4a-8a55-42ae-a17b-fceaeaba9199" xlink:href="abvx-20251231.xsd#abvx_PretGarantiParLEtatPGEMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_a6de3721-e5dd-4c7a-b311-d842bb5dcbfa" xlink:to="loc_abvx_PretGarantiParLEtatPGEMember_08633a4a-8a55-42ae-a17b-fceaeaba9199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConditionalAdvancesMember_4effc3a7-7520-4256-943f-728033e84f49" xlink:href="abvx-20251231.xsd#abvx_ConditionalAdvancesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_a6de3721-e5dd-4c7a-b311-d842bb5dcbfa" xlink:to="loc_abvx_ConditionalAdvancesMember_4effc3a7-7520-4256-943f-728033e84f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_9e2f4a58-ca9e-441f-9314-6328394f38b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_a6de3721-e5dd-4c7a-b311-d842bb5dcbfa" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_9e2f4a58-ca9e-441f-9314-6328394f38b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificatesMember_541b547f-1bca-4e7e-b52b-3f03327f0cd5" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificatesMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_a6de3721-e5dd-4c7a-b311-d842bb5dcbfa" xlink:to="loc_abvx_RoyaltyCertificatesMember_541b547f-1bca-4e7e-b52b-3f03327f0cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_75f23386-f6a4-40c2-896d-b4fed2d770cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_fd50bf14-1f81-44a8-856c-5728ed8fe292" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_75f23386-f6a4-40c2-896d-b4fed2d770cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_77655021-90d9-445e-b733-fb009709bdd3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_75f23386-f6a4-40c2-896d-b4fed2d770cb" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_77655021-90d9-445e-b733-fb009709bdd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities_32b1894e-aca4-46e0-91c9-fd8ab718d3ed" xlink:href="abvx-20251231.xsd#abvx_IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_75f23386-f6a4-40c2-896d-b4fed2d770cb" xlink:to="loc_abvx_IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities_32b1894e-aca4-46e0-91c9-fd8ab718d3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities_f83a13ea-01b7-42fd-93ec-056e02845d7d" xlink:href="abvx-20251231.xsd#abvx_DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_75f23386-f6a4-40c2-896d-b4fed2d770cb" xlink:to="loc_abvx_DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities_f83a13ea-01b7-42fd-93ec-056e02845d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities_927733f9-50fa-45f4-92f5-46c6683f864d" xlink:href="abvx-20251231.xsd#abvx_DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_75f23386-f6a4-40c2-896d-b4fed2d770cb" xlink:to="loc_abvx_DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities_927733f9-50fa-45f4-92f5-46c6683f864d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities_9fbf257d-7ea5-4e1b-ad97-4cfc6aa897d9" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_75f23386-f6a4-40c2-896d-b4fed2d770cb" xlink:to="loc_abvx_IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities_9fbf257d-7ea5-4e1b-ad97-4cfc6aa897d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities_3b4cd96f-b533-4ab5-a5dc-65dc7ad9cb27" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_75f23386-f6a4-40c2-896d-b4fed2d770cb" xlink:to="loc_abvx_IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities_3b4cd96f-b533-4ab5-a5dc-65dc7ad9cb27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_43fa501c-3d10-446b-b9bc-bee4ee9c9de7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_75f23386-f6a4-40c2-896d-b4fed2d770cb" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_43fa501c-3d10-446b-b9bc-bee4ee9c9de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities_349580da-da7b-4521-aefd-89513f8bc6e6" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_75f23386-f6a4-40c2-896d-b4fed2d770cb" xlink:to="loc_abvx_IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities_349580da-da7b-4521-aefd-89513f8bc6e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities_d5ce1524-7c50-4146-b767-353427d5dfcf" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_75f23386-f6a4-40c2-896d-b4fed2d770cb" xlink:to="loc_abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities_d5ce1524-7c50-4146-b767-353427d5dfcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities_41f36a07-4647-42d4-8054-d87ea063625d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_75f23386-f6a4-40c2-896d-b4fed2d770cb" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities_41f36a07-4647-42d4-8054-d87ea063625d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities_652a1c84-6123-4462-98d4-9452c40662c5" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_75f23386-f6a4-40c2-896d-b4fed2d770cb" xlink:to="loc_abvx_IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities_652a1c84-6123-4462-98d4-9452c40662c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities_019c5738-0ffd-7187-af60-eca22b6709d2" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_75f23386-f6a4-40c2-896d-b4fed2d770cb" xlink:to="loc_abvx_IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities_019c5738-0ffd-7187-af60-eca22b6709d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_703b5c5e-be92-4805-bef4-2d232d095e58" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_75f23386-f6a4-40c2-896d-b4fed2d770cb" xlink:to="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_703b5c5e-be92-4805-bef4-2d232d095e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_b027fe05-2a2c-4657-b2bc-38fedd5840a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_75f23386-f6a4-40c2-896d-b4fed2d770cb" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_b027fe05-2a2c-4657-b2bc-38fedd5840a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_c2bd0a5e-33c1-4cc9-8022-15b45bc34a83" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_75f23386-f6a4-40c2-896d-b4fed2d770cb" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_c2bd0a5e-33c1-4cc9-8022-15b45bc34a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesChangeinfinancialliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_a7c0e831-341b-49df-a81f-98a53204da1e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_e8f93a72-6a5d-45d9-95e0-0c82001df9bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_a7c0e831-341b-49df-a81f-98a53204da1e" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_e8f93a72-6a5d-45d9-95e0-0c82001df9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_3b57197d-14b5-47b2-aa7b-479fa7e361f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_e8f93a72-6a5d-45d9-95e0-0c82001df9bc" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_3b57197d-14b5-47b2-aa7b-479fa7e361f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_c73c5a1e-8035-4a0c-ae6b-1ae46fa059dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_3b57197d-14b5-47b2-aa7b-479fa7e361f8" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_c73c5a1e-8035-4a0c-ae6b-1ae46fa059dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheAMember_bdef2de1-96d9-4070-90b5-b55be137a853" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c73c5a1e-8035-4a0c-ae6b-1ae46fa059dc" xlink:to="loc_abvx_KreosClaretFinancingTrancheAMember_bdef2de1-96d9-4070-90b5-b55be137a853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember_b7d5eba2-5c57-4d0c-9552-bd86dfbae26a" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c73c5a1e-8035-4a0c-ae6b-1ae46fa059dc" xlink:to="loc_abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember_b7d5eba2-5c57-4d0c-9552-bd86dfbae26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_HeightsConvertibleNotesMember_ab8dcd51-05bc-4c53-8989-365c4304afde" xlink:href="abvx-20251231.xsd#abvx_HeightsConvertibleNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c73c5a1e-8035-4a0c-ae6b-1ae46fa059dc" xlink:to="loc_abvx_HeightsConvertibleNotesMember_ab8dcd51-05bc-4c53-8989-365c4304afde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OCEANEMember_e196ca6b-d192-43eb-983e-3a6126027d7d" xlink:href="abvx-20251231.xsd#abvx_OCEANEMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c73c5a1e-8035-4a0c-ae6b-1ae46fa059dc" xlink:to="loc_abvx_OCEANEMember_e196ca6b-d192-43eb-983e-3a6126027d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheBMember_ea5144cb-2889-407b-a1ef-e365ab344db2" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheBMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c73c5a1e-8035-4a0c-ae6b-1ae46fa059dc" xlink:to="loc_abvx_KreosClaretFinancingTrancheBMember_ea5144cb-2889-407b-a1ef-e365ab344db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheCMember_ddba5ac9-d2bb-4e9a-ba4c-3b2c3ee40b70" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheCMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c73c5a1e-8035-4a0c-ae6b-1ae46fa059dc" xlink:to="loc_abvx_KreosClaretFinancingTrancheCMember_ddba5ac9-d2bb-4e9a-ba4c-3b2c3ee40b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheABMember_6a33c444-7471-4690-a2b6-0310b9093661" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheABMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c73c5a1e-8035-4a0c-ae6b-1ae46fa059dc" xlink:to="loc_abvx_KreosClaretFinancingTrancheABMember_6a33c444-7471-4690-a2b6-0310b9093661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_8eca8f20-3b00-4783-b0a8-c0fa8b3e4a8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_e8f93a72-6a5d-45d9-95e0-0c82001df9bc" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_8eca8f20-3b00-4783-b0a8-c0fa8b3e4a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_9ce61c2e-d6dd-4fd6-bdf7-2b6718d3c28c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_8eca8f20-3b00-4783-b0a8-c0fa8b3e4a8b" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_9ce61c2e-d6dd-4fd6-bdf7-2b6718d3c28c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OceaneConversionOptionMember_4afaca7c-0471-4245-b697-abad4dcfa032" xlink:href="abvx-20251231.xsd#abvx_OceaneConversionOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_9ce61c2e-d6dd-4fd6-bdf7-2b6718d3c28c" xlink:to="loc_abvx_OceaneConversionOptionMember_4afaca7c-0471-4245-b697-abad4dcfa032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_1991fa2a-be1c-4870-9876-5d351d3a7ec1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_e8f93a72-6a5d-45d9-95e0-0c82001df9bc" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_1991fa2a-be1c-4870-9876-5d351d3a7ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForDebtIssueCosts_00e5c24e-09f6-4add-859e-19985cfd53c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsForDebtIssueCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_1991fa2a-be1c-4870-9876-5d351d3a7ec1" xlink:to="loc_ifrs-full_PaymentsForDebtIssueCosts_00e5c24e-09f6-4add-859e-19985cfd53c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NetProceedsFromConvertibleLoansNotes_c514cc74-8df9-4898-91f3-23e4908458cb" xlink:href="abvx-20251231.xsd#abvx_NetProceedsFromConvertibleLoansNotes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_1991fa2a-be1c-4870-9876-5d351d3a7ec1" xlink:to="loc_abvx_NetProceedsFromConvertibleLoansNotes_c514cc74-8df9-4898-91f3-23e4908458cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepurchaseOfDerivativeInstruments_bfeced63-29c5-4619-80ac-a9180e07c1a9" xlink:href="abvx-20251231.xsd#abvx_RepurchaseOfDerivativeInstruments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_1991fa2a-be1c-4870-9876-5d351d3a7ec1" xlink:to="loc_abvx_RepurchaseOfDerivativeInstruments_bfeced63-29c5-4619-80ac-a9180e07c1a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepaymentsOfConvertibleLoansNotes_5c40627c-eefa-4d99-a428-2ddf16c6a979" xlink:href="abvx-20251231.xsd#abvx_RepaymentsOfConvertibleLoansNotes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_1991fa2a-be1c-4870-9876-5d351d3a7ec1" xlink:to="loc_abvx_RepaymentsOfConvertibleLoansNotes_5c40627c-eefa-4d99-a428-2ddf16c6a979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_GrossProceedsFromNonConvertibleLoansNotes_bbc3aa11-7581-4ed8-bf6e-1c81609ffb86" xlink:href="abvx-20251231.xsd#abvx_GrossProceedsFromNonConvertibleLoansNotes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_1991fa2a-be1c-4870-9876-5d351d3a7ec1" xlink:to="loc_abvx_GrossProceedsFromNonConvertibleLoansNotes_bbc3aa11-7581-4ed8-bf6e-1c81609ffb86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsDiscountRate_019c5742-3d2a-70df-9dd5-08d040c2001b" xlink:href="abvx-20251231.xsd#abvx_BorrowingsDiscountRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_1991fa2a-be1c-4870-9876-5d351d3a7ec1" xlink:to="loc_abvx_BorrowingsDiscountRate_019c5742-3d2a-70df-9dd5-08d040c2001b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_4490fc8f-a246-4d78-b7c4-b63901ec4f1f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_e4c41bb0-a1d8-4fdd-ad1d-1b7f8ce1a4ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_4490fc8f-a246-4d78-b7c4-b63901ec4f1f" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_e4c41bb0-a1d8-4fdd-ad1d-1b7f8ce1a4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_1c56de6b-1a1a-4efa-9fb4-aae7eec8524d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_e4c41bb0-a1d8-4fdd-ad1d-1b7f8ce1a4ff" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_1c56de6b-1a1a-4efa-9fb4-aae7eec8524d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_b3c58368-7fe8-4cdb-9ee4-d272bd430e44" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_1c56de6b-1a1a-4efa-9fb4-aae7eec8524d" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_b3c58368-7fe8-4cdb-9ee4-d272bd430e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosABSAMember_566ace77-5fb6-4623-b504-306f6c00db52" xlink:href="abvx-20251231.xsd#abvx_KreosABSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_b3c58368-7fe8-4cdb-9ee4-d272bd430e44" xlink:to="loc_abvx_KreosABSAMember_566ace77-5fb6-4623-b504-306f6c00db52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosBBSAMember_4d7649f3-cd43-4f8c-9fa1-df10e9f9491e" xlink:href="abvx-20251231.xsd#abvx_KreosBBSAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_b3c58368-7fe8-4cdb-9ee4-d272bd430e44" xlink:to="loc_abvx_KreosBBSAMember_4d7649f3-cd43-4f8c-9fa1-df10e9f9491e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OceaneConversionOptionMember_b9b6fa8d-3cb8-4fef-9ea5-147e29cdd19e" xlink:href="abvx-20251231.xsd#abvx_OceaneConversionOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_b3c58368-7fe8-4cdb-9ee4-d272bd430e44" xlink:to="loc_abvx_OceaneConversionOptionMember_b9b6fa8d-3cb8-4fef-9ea5-147e29cdd19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheAMember_1d558002-759d-4da6-9586-365b5b154f35" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_b3c58368-7fe8-4cdb-9ee4-d272bd430e44" xlink:to="loc_abvx_KreosClaretFinancingTrancheAMember_1d558002-759d-4da6-9586-365b5b154f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretMinimumReturnIndemnificationsMember_bbf812be-bbdd-40ee-bd8b-ca195c98c497" xlink:href="abvx-20251231.xsd#abvx_KreosClaretMinimumReturnIndemnificationsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_b3c58368-7fe8-4cdb-9ee4-d272bd430e44" xlink:to="loc_abvx_KreosClaretMinimumReturnIndemnificationsMember_bbf812be-bbdd-40ee-bd8b-ca195c98c497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_7afa4347-ce99-4133-8623-b24af27cbadd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_e4c41bb0-a1d8-4fdd-ad1d-1b7f8ce1a4ff" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_7afa4347-ce99-4133-8623-b24af27cbadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities_8d6b56ff-debc-46ee-b1be-b3cad6903a33" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_7afa4347-ce99-4133-8623-b24af27cbadd" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilities_8d6b56ff-debc-46ee-b1be-b3cad6903a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IssuanceOfDerivativeInstruments_6cb447ec-a701-4b75-9148-e2c76e919001" xlink:href="abvx-20251231.xsd#abvx_IssuanceOfDerivativeInstruments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_7afa4347-ce99-4133-8623-b24af27cbadd" xlink:to="loc_abvx_IssuanceOfDerivativeInstruments_6cb447ec-a701-4b75-9148-e2c76e919001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LossesOnChangeInFairValueOfDerivatives_4bceff72-93eb-40cd-beb7-68f0fdb7eb8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LossesOnChangeInFairValueOfDerivatives"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_7afa4347-ce99-4133-8623-b24af27cbadd" xlink:to="loc_ifrs-full_LossesOnChangeInFairValueOfDerivatives_4bceff72-93eb-40cd-beb7-68f0fdb7eb8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives_8b5f7ce6-8089-4e2f-bc66-aa94235b0dd3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsOnChangeInFairValueOfDerivatives"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_7afa4347-ce99-4133-8623-b24af27cbadd" xlink:to="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives_8b5f7ce6-8089-4e2f-bc66-aa94235b0dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepurchaseOfDerivativeInstruments_1362e66b-da37-4c33-9759-2652a43cc95d" xlink:href="abvx-20251231.xsd#abvx_RepurchaseOfDerivativeInstruments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_7afa4347-ce99-4133-8623-b24af27cbadd" xlink:to="loc_abvx_RepurchaseOfDerivativeInstruments_1362e66b-da37-4c33-9759-2652a43cc95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExerciseOfDerivativeInstruments_56ec67d3-a9f4-4554-a3ac-ed163fa70994" xlink:href="abvx-20251231.xsd#abvx_ExerciseOfDerivativeInstruments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_7afa4347-ce99-4133-8623-b24af27cbadd" xlink:to="loc_abvx_ExerciseOfDerivativeInstruments_56ec67d3-a9f4-4554-a3ac-ed163fa70994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities_5ae8dc8d-e4ed-4fa0-b27b-bc490bb5de42" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_7afa4347-ce99-4133-8623-b24af27cbadd" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilities_5ae8dc8d-e4ed-4fa0-b27b-bc490bb5de42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_0e1191d1-25b9-47ef-a1d6-e5aa6cab04e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_78c0728d-f42e-412b-a2bd-f6711359ebf2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_0e1191d1-25b9-47ef-a1d6-e5aa6cab04e9" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_78c0728d-f42e-412b-a2bd-f6711359ebf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ea3aec78-05b5-4326-bf18-ac5f6556da84" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_78c0728d-f42e-412b-a2bd-f6711359ebf2" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ea3aec78-05b5-4326-bf18-ac5f6556da84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_33e69911-32d6-4c73-b5fe-afd0aee5d5d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ea3aec78-05b5-4326-bf18-ac5f6556da84" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_33e69911-32d6-4c73-b5fe-afd0aee5d5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_HeightsConvertibleNotesMember_daf64d0d-24d6-4715-afe6-fb8ca41e81c6" xlink:href="abvx-20251231.xsd#abvx_HeightsConvertibleNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_33e69911-32d6-4c73-b5fe-afd0aee5d5d8" xlink:to="loc_abvx_HeightsConvertibleNotesMember_daf64d0d-24d6-4715-afe6-fb8ca41e81c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingTrancheAMember_7a522bae-aed3-4d89-a688-04d92aaea1a9" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingTrancheAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_33e69911-32d6-4c73-b5fe-afd0aee5d5d8" xlink:to="loc_abvx_KreosClaretFinancingTrancheAMember_7a522bae-aed3-4d89-a688-04d92aaea1a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretBondLoansMember_01e3ef08-07b5-446d-a0a1-d9ab70126131" xlink:href="abvx-20251231.xsd#abvx_KreosClaretBondLoansMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_33e69911-32d6-4c73-b5fe-afd0aee5d5d8" xlink:to="loc_abvx_KreosClaretBondLoansMember_01e3ef08-07b5-446d-a0a1-d9ab70126131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PretGarantiParLEtatPGEMember_4e01771a-2520-4921-a2b8-531749c18041" xlink:href="abvx-20251231.xsd#abvx_PretGarantiParLEtatPGEMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_33e69911-32d6-4c73-b5fe-afd0aee5d5d8" xlink:to="loc_abvx_PretGarantiParLEtatPGEMember_4e01771a-2520-4921-a2b8-531749c18041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_af598c98-c654-492d-81be-aa3ce82e2313" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_78c0728d-f42e-412b-a2bd-f6711359ebf2" xlink:to="loc_ifrs-full_MaturityAxis_af598c98-c654-492d-81be-aa3ce82e2313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_2cb635f9-1f42-4f48-baae-2ffbabf23ecd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_af598c98-c654-492d-81be-aa3ce82e2313" xlink:to="loc_ifrs-full_MaturityDomain_2cb635f9-1f42-4f48-baae-2ffbabf23ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_6cae0916-883c-4d54-837e-033031636171" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_2cb635f9-1f42-4f48-baae-2ffbabf23ecd" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_6cae0916-883c-4d54-837e-033031636171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_6537d6e5-99c3-4248-8abf-3743bc74a6b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_2cb635f9-1f42-4f48-baae-2ffbabf23ecd" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_6537d6e5-99c3-4248-8abf-3743bc74a6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember_82d5900f-9af5-4847-a885-8bf62529b823" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_2cb635f9-1f42-4f48-baae-2ffbabf23ecd" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember_82d5900f-9af5-4847-a885-8bf62529b823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_be58fe9a-951f-4bb0-beff-b53cc2d0a77b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_2cb635f9-1f42-4f48-baae-2ffbabf23ecd" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_be58fe9a-951f-4bb0-beff-b53cc2d0a77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_61d0bb6e-49e7-4306-b424-edce15fba592" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_78c0728d-f42e-412b-a2bd-f6711359ebf2" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_61d0bb6e-49e7-4306-b424-edce15fba592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotes_fa315cb3-6f4a-4822-9cb1-7ccd0db304db" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotes"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_61d0bb6e-49e7-4306-b424-edce15fba592" xlink:to="loc_abvx_ConvertibleLoansNotes_fa315cb3-6f4a-4822-9cb1-7ccd0db304db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConvertibleLoansNotesUndiscountedCashFlows_61207533-2845-4a39-9be6-c6197f7b103e" xlink:href="abvx-20251231.xsd#abvx_ConvertibleLoansNotesUndiscountedCashFlows"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_61d0bb6e-49e7-4306-b424-edce15fba592" xlink:to="loc_abvx_ConvertibleLoansNotesUndiscountedCashFlows_61207533-2845-4a39-9be6-c6197f7b103e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_46d583cd-28a0-4e31-ba44-3e79e560b86d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_61d0bb6e-49e7-4306-b424-edce15fba592" xlink:to="loc_ifrs-full_Borrowings_46d583cd-28a0-4e31-ba44-3e79e560b86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows_f629d02e-96bf-4abc-8c5c-62a31ead7e30" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BankBorrowingsUndiscountedCashFlows"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_61d0bb6e-49e7-4306-b424-edce15fba592" xlink:to="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows_f629d02e-96bf-4abc-8c5c-62a31ead7e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConditionalAdvances_f99e1dee-1ac3-48bd-9574-adf1bb7beb71" xlink:href="abvx-20251231.xsd#abvx_ConditionalAdvances"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_61d0bb6e-49e7-4306-b424-edce15fba592" xlink:to="loc_abvx_ConditionalAdvances_f99e1dee-1ac3-48bd-9574-adf1bb7beb71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ConditionalAdvancesUndiscountedCashFlows_4a11b72c-4a07-4a2a-a205-9e195aa996ff" xlink:href="abvx-20251231.xsd#abvx_ConditionalAdvancesUndiscountedCashFlows"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_61d0bb6e-49e7-4306-b424-edce15fba592" xlink:to="loc_abvx_ConditionalAdvancesUndiscountedCashFlows_4a11b72c-4a07-4a2a-a205-9e195aa996ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NonCurrentRoyaltyCertificates_4a1c6903-f5af-45bf-9f4e-c95dab965f67" xlink:href="abvx-20251231.xsd#abvx_NonCurrentRoyaltyCertificates"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_61d0bb6e-49e7-4306-b424-edce15fba592" xlink:to="loc_abvx_NonCurrentRoyaltyCertificates_4a1c6903-f5af-45bf-9f4e-c95dab965f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificatesUndiscountedCashFlows_2258445e-c758-4575-ace5-880f2c9c3a0a" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificatesUndiscountedCashFlows"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_61d0bb6e-49e7-4306-b424-edce15fba592" xlink:to="loc_abvx_RoyaltyCertificatesUndiscountedCashFlows_2258445e-c758-4575-ace5-880f2c9c3a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_dc7fa830-86a7-4f99-beba-9f4f91abd249" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_61d0bb6e-49e7-4306-b424-edce15fba592" xlink:to="loc_ifrs-full_LeaseLiabilities_dc7fa830-86a7-4f99-beba-9f4f91abd249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLeaseLiabilities_5fb4362d-09e3-4c23-a3f5-b1aab072f7b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_61d0bb6e-49e7-4306-b424-edce15fba592" xlink:to="loc_ifrs-full_GrossLeaseLiabilities_5fb4362d-09e3-4c23-a3f5-b1aab072f7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities_6a855fd7-7aaf-4b48-a80d-44e43e89638a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_61d0bb6e-49e7-4306-b424-edce15fba592" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilities_6a855fd7-7aaf-4b48-a80d-44e43e89638a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows_877fd5c3-7060-4e96-bda2-979d672c239f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_61d0bb6e-49e7-4306-b424-edce15fba592" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows_877fd5c3-7060-4e96-bda2-979d672c239f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities_ff47ff04-ec85-4b62-8600-cf904663e180" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_61d0bb6e-49e7-4306-b424-edce15fba592" xlink:to="loc_ifrs-full_FinancialLiabilities_ff47ff04-ec85-4b62-8600-cf904663e180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialLiabilitiesUndiscountedCashFlows_09f0839f-90d6-4cc4-9c2d-6252144c91cb" xlink:href="abvx-20251231.xsd#abvx_FinancialLiabilitiesUndiscountedCashFlows"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_61d0bb6e-49e7-4306-b424-edce15fba592" xlink:to="loc_abvx_FinancialLiabilitiesUndiscountedCashFlows_09f0839f-90d6-4cc4-9c2d-6252144c91cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialliabilitiesBreakdownoffinancialliabilitiesbymaturityDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialliabilitiesBreakdownoffinancialliabilitiesbymaturityDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/FinancialliabilitiesBreakdownoffinancialliabilitiesbymaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_4c470e15-fe41-4267-b43a-74af02fc698b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_69933053-a9a4-4d0c-b6f7-e6d69c3f8541" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_4c470e15-fe41-4267-b43a-74af02fc698b" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_69933053-a9a4-4d0c-b6f7-e6d69c3f8541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_980f766a-2fcd-4c79-a127-573f62590fd1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_69933053-a9a4-4d0c-b6f7-e6d69c3f8541" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_980f766a-2fcd-4c79-a127-573f62590fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_dab8e3f9-642c-4545-9372-fb9b3315ddb7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_980f766a-2fcd-4c79-a127-573f62590fd1" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_dab8e3f9-642c-4545-9372-fb9b3315ddb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificatesMember_28fe38d4-9104-468e-abaf-cd874d5fbd04" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_dab8e3f9-642c-4545-9372-fb9b3315ddb7" xlink:to="loc_abvx_RoyaltyCertificatesMember_28fe38d4-9104-468e-abaf-cd874d5fbd04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c290df7-624d-45a2-af97-1e900ae3601a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_69933053-a9a4-4d0c-b6f7-e6d69c3f8541" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c290df7-624d-45a2-af97-1e900ae3601a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificatePercentageOfFutureSales_00f49b25-2e5a-4acf-9f90-4473e61bd9b1" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificatePercentageOfFutureSales"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c290df7-624d-45a2-af97-1e900ae3601a" xlink:to="loc_abvx_RoyaltyCertificatePercentageOfFutureSales_00f49b25-2e5a-4acf-9f90-4473e61bd9b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificateMaximumAmount_656392d4-65dd-421d-a8e0-f8ada648d47c" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificateMaximumAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c290df7-624d-45a2-af97-1e900ae3601a" xlink:to="loc_abvx_RoyaltyCertificateMaximumAmount_656392d4-65dd-421d-a8e0-f8ada648d47c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificateExpirationPeriod_b293b72a-6f01-463c-b9f3-7fb7ecc249bc" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificateExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c290df7-624d-45a2-af97-1e900ae3601a" xlink:to="loc_abvx_RoyaltyCertificateExpirationPeriod_b293b72a-6f01-463c-b9f3-7fb7ecc249bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_ed9a615f-a88d-428d-8981-d02289ad52dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_aba9a28c-3fa5-48f4-a0bf-bf15343e09ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_ed9a615f-a88d-428d-8981-d02289ad52dc" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_aba9a28c-3fa5-48f4-a0bf-bf15343e09ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_501f46a2-d6d6-4aaf-a203-286b1aee64b9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_aba9a28c-3fa5-48f4-a0bf-bf15343e09ee" xlink:to="loc_srt_TitleOfIndividualAxis_501f46a2-d6d6-4aaf-a203-286b1aee64b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1ef1e6c0-bb21-456e-9c31-43a13210feba" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_501f46a2-d6d6-4aaf-a203-286b1aee64b9" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1ef1e6c0-bb21-456e-9c31-43a13210feba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ManagementMember_96284b31-0d04-4b44-b52d-6058279c61a3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ManagementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1ef1e6c0-bb21-456e-9c31-43a13210feba" xlink:to="loc_srt_ManagementMember_96284b31-0d04-4b44-b52d-6058279c61a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherEmployeesMember_8dc302c4-0756-4d25-9510-3f3eb4a2abcf" xlink:href="abvx-20251231.xsd#abvx_OtherEmployeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1ef1e6c0-bb21-456e-9c31-43a13210feba" xlink:to="loc_abvx_OtherEmployeesMember_8dc302c4-0756-4d25-9510-3f3eb4a2abcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1c5dbe2b-29b1-4067-b5af-262e3e1476d8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_aba9a28c-3fa5-48f4-a0bf-bf15343e09ee" xlink:to="loc_srt_RangeAxis_1c5dbe2b-29b1-4067-b5af-262e3e1476d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1e0b7bf8-5c7e-47ef-9719-4b889bc1073c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1c5dbe2b-29b1-4067-b5af-262e3e1476d8" xlink:to="loc_srt_RangeMember_1e0b7bf8-5c7e-47ef-9719-4b889bc1073c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_0fbfd571-11ae-4a45-901c-09aad3443838" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1e0b7bf8-5c7e-47ef-9719-4b889bc1073c" xlink:to="loc_ifrs-full_TopOfRangeMember_0fbfd571-11ae-4a45-901c-09aad3443838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_25ea520a-50a1-4104-8926-2f4f85c10ed8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1e0b7bf8-5c7e-47ef-9719-4b889bc1073c" xlink:to="loc_ifrs-full_BottomOfRangeMember_25ea520a-50a1-4104-8926-2f4f85c10ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_448a5ca1-db79-4f97-a27a-0bf0dea7c8c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_aba9a28c-3fa5-48f4-a0bf-bf15343e09ee" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_448a5ca1-db79-4f97-a27a-0bf0dea7c8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfRetirementAge2019_77ac4d3b-0b90-4a60-9167-3be35f153f04" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ActuarialAssumptionOfRetirementAge2019"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_448a5ca1-db79-4f97-a27a-0bf0dea7c8c9" xlink:to="loc_ifrs-full_ActuarialAssumptionOfRetirementAge2019_77ac4d3b-0b90-4a60-9167-3be35f153f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRates_ddd886f1-9db6-4155-a7dd-f428ff91d637" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_448a5ca1-db79-4f97-a27a-0bf0dea7c8c9" xlink:to="loc_ifrs-full_ActuarialAssumptionOfDiscountRates_ddd886f1-9db6-4155-a7dd-f428ff91d637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_86063ad2-6c0a-45a7-9120-8f8ee717bafd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_448a5ca1-db79-4f97-a27a-0bf0dea7c8c9" xlink:to="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_86063ad2-6c0a-45a7-9120-8f8ee717bafd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ActuarialAssumptionOfExpectedRatesOfTurnover_1ca547d8-b47c-4909-85be-9fe4a9c9e98b" xlink:href="abvx-20251231.xsd#abvx_ActuarialAssumptionOfExpectedRatesOfTurnover"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_448a5ca1-db79-4f97-a27a-0bf0dea7c8c9" xlink:to="loc_abvx_ActuarialAssumptionOfExpectedRatesOfTurnover_1ca547d8-b47c-4909-85be-9fe4a9c9e98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ActuarialAssumptionOfExpectedRatesOfTurnoverAverageExitRate_015444ef-74a1-4220-8dca-9fa2a70b13e3" xlink:href="abvx-20251231.xsd#abvx_ActuarialAssumptionOfExpectedRatesOfTurnoverAverageExitRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_448a5ca1-db79-4f97-a27a-0bf0dea7c8c9" xlink:to="loc_abvx_ActuarialAssumptionOfExpectedRatesOfTurnoverAverageExitRate_015444ef-74a1-4220-8dca-9fa2a70b13e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ActuarialAssumptionOfEmployeeContributionRate_7afa45db-841e-4f8e-a0c9-2074ec1b8e28" xlink:href="abvx-20251231.xsd#abvx_ActuarialAssumptionOfEmployeeContributionRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_448a5ca1-db79-4f97-a27a-0bf0dea7c8c9" xlink:to="loc_abvx_ActuarialAssumptionOfEmployeeContributionRate_7afa45db-841e-4f8e-a0c9-2074ec1b8e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofchangesinprojectedbenefitobligationDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#RetirementbenefitobligationsDisclosureofchangesinprojectedbenefitobligationDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofchangesinprojectedbenefitobligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_52e02790-1b4e-40c0-ad37-61e984205a8d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_c6baee42-b9f3-4915-aca0-fa880a01cb59" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_52e02790-1b4e-40c0-ad37-61e984205a8d" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_c6baee42-b9f3-4915-aca0-fa880a01cb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_c53aa916-97d8-47bb-8a7c-d31d1f02bee2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_c6baee42-b9f3-4915-aca0-fa880a01cb59" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_c53aa916-97d8-47bb-8a7c-d31d1f02bee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_c9500674-0774-435e-ae96-2c38a8bc8f40" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_c53aa916-97d8-47bb-8a7c-d31d1f02bee2" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_c9500674-0774-435e-ae96-2c38a8bc8f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember_91ec1a10-5e7b-478a-8ba0-4578d29ba950" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PresentValueOfDefinedBenefitObligationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_c9500674-0774-435e-ae96-2c38a8bc8f40" xlink:to="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember_91ec1a10-5e7b-478a-8ba0-4578d29ba950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_c68624e3-f0c9-4545-ab15-b13051cc1aeb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_c6baee42-b9f3-4915-aca0-fa880a01cb59" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_c68624e3-f0c9-4545-ab15-b13051cc1aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_a7edb470-00f2-48c0-86b5-df461c113bc8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_c68624e3-f0c9-4545-ab15-b13051cc1aeb" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_a7edb470-00f2-48c0-86b5-df461c113bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_4e0286b3-22b9-4f7f-b84e-aa186fc0e4db" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_c68624e3-f0c9-4545-ab15-b13051cc1aeb" xlink:to="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_4e0286b3-22b9-4f7f-b84e-aa186fc0e4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset_019c574f-b20b-71d4-9d35-26f20dc47f7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_c68624e3-f0c9-4545-ab15-b13051cc1aeb" xlink:to="loc_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset_019c574f-b20b-71d4-9d35-26f20dc47f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_07a1dffe-7d45-42d5-a9af-473ce0d11b3d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_c68624e3-f0c9-4545-ab15-b13051cc1aeb" xlink:to="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_07a1dffe-7d45-42d5-a9af-473ce0d11b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_d4476b4b-7310-405e-a248-b530bd24ad7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_c68624e3-f0c9-4545-ab15-b13051cc1aeb" xlink:to="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_d4476b4b-7310-405e-a248-b530bd24ad7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_a2ffc485-43bf-41ca-952f-af87a3d013e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_c68624e3-f0c9-4545-ab15-b13051cc1aeb" xlink:to="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_a2ffc485-43bf-41ca-952f-af87a3d013e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_f5560863-0c60-4f86-94d8-701ae2d667c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_c68624e3-f0c9-4545-ab15-b13051cc1aeb" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_f5560863-0c60-4f86-94d8-701ae2d667c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_71d5520b-cf6f-42e7-95f4-c7e1d701df4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_a952b310-0928-4c1f-9720-06d08a2b9d12" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_71d5520b-cf6f-42e7-95f4-c7e1d701df4f" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_a952b310-0928-4c1f-9720-06d08a2b9d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccrualsClassifiedAsCurrent_91434129-e6e1-4cc8-acdf-75ed8fe5fcfe" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccrualsClassifiedAsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_71d5520b-cf6f-42e7-95f4-c7e1d701df4f" xlink:to="loc_ifrs-full_AccrualsClassifiedAsCurrent_91434129-e6e1-4cc8-acdf-75ed8fe5fcfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherCurrentPayablesIncludingAdjustments_18234d86-dc98-4b0f-b55a-ff48ecdaca4d" xlink:href="abvx-20251231.xsd#abvx_OtherCurrentPayablesIncludingAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_71d5520b-cf6f-42e7-95f4-c7e1d701df4f" xlink:to="loc_abvx_OtherCurrentPayablesIncludingAdjustments_18234d86-dc98-4b0f-b55a-ff48ecdaca4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_b7f34689-d69f-490a-8b43-173f97c89c96" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_71d5520b-cf6f-42e7-95f4-c7e1d701df4f" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_b7f34689-d69f-490a-8b43-173f97c89c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_74ad1d85-093a-4f65-ad79-07a5ffeb9cbc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsAccruals_6f10c233-431a-4162-8fc7-da18721129f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_74ad1d85-093a-4f65-ad79-07a5ffeb9cbc" xlink:to="loc_ifrs-full_ShorttermEmployeeBenefitsAccruals_6f10c233-431a-4162-8fc7-da18721129f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_eb962066-a05c-47a1-a457-a761d2e5b245" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_74ad1d85-093a-4f65-ad79-07a5ffeb9cbc" xlink:to="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_eb962066-a05c-47a1-a457-a761d2e5b245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentPayablesOnOtherTaxAndRelatedPayments_d0975afa-772c-44a8-8620-194fcc2cc128" xlink:href="abvx-20251231.xsd#abvx_CurrentPayablesOnOtherTaxAndRelatedPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_74ad1d85-093a-4f65-ad79-07a5ffeb9cbc" xlink:to="loc_abvx_CurrentPayablesOnOtherTaxAndRelatedPayments_d0975afa-772c-44a8-8620-194fcc2cc128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CurrentTaxAndEmployeeBenefitLiabilities_0cb42b6b-03ea-4752-9ecb-e4661566fecf" xlink:href="abvx-20251231.xsd#abvx_CurrentTaxAndEmployeeBenefitLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_74ad1d85-093a-4f65-ad79-07a5ffeb9cbc" xlink:to="loc_abvx_CurrentTaxAndEmployeeBenefitLiabilities_0cb42b6b-03ea-4752-9ecb-e4661566fecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/OtheroperatingincomeDisclosureofbreakdownofoperatingincomeDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#OtheroperatingincomeDisclosureofbreakdownofoperatingincomeDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/OtheroperatingincomeDisclosureofbreakdownofoperatingincomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract_77a9c690-281f-4224-8f37-7a2b38ecbf73" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncomeFromResearchTaxCredit_824e3867-f122-461c-93d8-d7f52fe8dcec" xlink:href="abvx-20251231.xsd#abvx_IncomeFromResearchTaxCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_77a9c690-281f-4224-8f37-7a2b38ecbf73" xlink:to="loc_abvx_IncomeFromResearchTaxCredit_824e3867-f122-461c-93d8-d7f52fe8dcec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromGovernmentGrants_73f34c29-6d94-4020-9f23-e6875627026c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_77a9c690-281f-4224-8f37-7a2b38ecbf73" xlink:to="loc_ifrs-full_RevenueFromGovernmentGrants_73f34c29-6d94-4020-9f23-e6875627026c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncomeFromDepositaryServiceFees_019c5754-bc2a-709a-b535-836f9b32779f" xlink:href="abvx-20251231.xsd#abvx_IncomeFromDepositaryServiceFees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_77a9c690-281f-4224-8f37-7a2b38ecbf73" xlink:to="loc_abvx_IncomeFromDepositaryServiceFees_019c5754-bc2a-709a-b535-836f9b32779f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_cd143c3c-1ae7-4b3a-b076-c5e698cf608f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_77a9c690-281f-4224-8f37-7a2b38ecbf73" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_cd143c3c-1ae7-4b3a-b076-c5e698cf608f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIncome_9c3c87b6-05c2-4555-ae63-4a33e2a9bd3f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_77a9c690-281f-4224-8f37-7a2b38ecbf73" xlink:to="loc_ifrs-full_OtherIncome_9c3c87b6-05c2-4555-ae63-4a33e2a9bd3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#OtheroperatingincomeNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract_2dc8362f-7a5a-401c-855d-ef150d463ff9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfOperatingIncomeTable_56f401eb-af87-4f50-af47-20ad9c7fc2c3" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfOperatingIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_2dc8362f-7a5a-401c-855d-ef150d463ff9" xlink:to="loc_abvx_DisclosureOfOperatingIncomeTable_56f401eb-af87-4f50-af47-20ad9c7fc2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CIRTaxYearAxis_d092d1c5-2054-4df4-88e7-ce84bda2ea84" xlink:href="abvx-20251231.xsd#abvx_CIRTaxYearAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOperatingIncomeTable_56f401eb-af87-4f50-af47-20ad9c7fc2c3" xlink:to="loc_abvx_CIRTaxYearAxis_d092d1c5-2054-4df4-88e7-ce84bda2ea84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CIRTaxYearDomain_af3ad0be-0b56-4461-9b92-0e300f1f613f" xlink:href="abvx-20251231.xsd#abvx_CIRTaxYearDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_CIRTaxYearAxis_d092d1c5-2054-4df4-88e7-ce84bda2ea84" xlink:to="loc_abvx_CIRTaxYearDomain_af3ad0be-0b56-4461-9b92-0e300f1f613f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_A2021TaxYearMember_019c57c7-c3d0-786c-94c7-1114b0062dca" xlink:href="abvx-20251231.xsd#abvx_A2021TaxYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_CIRTaxYearDomain_af3ad0be-0b56-4461-9b92-0e300f1f613f" xlink:to="loc_abvx_A2021TaxYearMember_019c57c7-c3d0-786c-94c7-1114b0062dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_A2022TaxYearMember_93df0bc2-2ec9-4ffe-9001-e1c2969b230f" xlink:href="abvx-20251231.xsd#abvx_A2022TaxYearMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_CIRTaxYearDomain_af3ad0be-0b56-4461-9b92-0e300f1f613f" xlink:to="loc_abvx_A2022TaxYearMember_93df0bc2-2ec9-4ffe-9001-e1c2969b230f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_A2023TaxYearMember_ce3fbb32-0da5-41df-8a60-0cc00df080a9" xlink:href="abvx-20251231.xsd#abvx_A2023TaxYearMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_CIRTaxYearDomain_af3ad0be-0b56-4461-9b92-0e300f1f613f" xlink:to="loc_abvx_A2023TaxYearMember_ce3fbb32-0da5-41df-8a60-0cc00df080a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_A2024TaxYearMember_019c5757-3845-71f1-9aec-29380bc8b04a" xlink:href="abvx-20251231.xsd#abvx_A2024TaxYearMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_CIRTaxYearDomain_af3ad0be-0b56-4461-9b92-0e300f1f613f" xlink:to="loc_abvx_A2024TaxYearMember_019c5757-3845-71f1-9aec-29380bc8b04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_3ea93f68-e7c8-42b7-8726-2bc7c3d01b9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOperatingIncomeTable_56f401eb-af87-4f50-af47-20ad9c7fc2c3" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_3ea93f68-e7c8-42b7-8726-2bc7c3d01b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_fedc0c49-3215-404e-9fd4-b3cf4ee44644" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_3ea93f68-e7c8-42b7-8726-2bc7c3d01b9f" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_fedc0c49-3215-404e-9fd4-b3cf4ee44644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RNPVIRConditionalAdvanceBPIMember_86f1976a-b7f4-4625-a63f-c234b3bb52e7" xlink:href="abvx-20251231.xsd#abvx_RNPVIRConditionalAdvanceBPIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_fedc0c49-3215-404e-9fd4-b3cf4ee44644" xlink:to="loc_abvx_RNPVIRConditionalAdvanceBPIMember_86f1976a-b7f4-4625-a63f-c234b3bb52e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CARENAConditionalAdvanceBPIMember_c644d6eb-0924-44cf-81e8-31983ab6df4e" xlink:href="abvx-20251231.xsd#abvx_CARENAConditionalAdvanceBPIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_fedc0c49-3215-404e-9fd4-b3cf4ee44644" xlink:to="loc_abvx_CARENAConditionalAdvanceBPIMember_c644d6eb-0924-44cf-81e8-31983ab6df4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfOperatingIncomeLineItems_6a0c878d-703a-4f1a-a96f-6d5a25197c25" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfOperatingIncomeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOperatingIncomeTable_56f401eb-af87-4f50-af47-20ad9c7fc2c3" xlink:to="loc_abvx_DisclosureOfOperatingIncomeLineItems_6a0c878d-703a-4f1a-a96f-6d5a25197c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncomeFromResearchTaxCredit_b9e38762-16bc-4f93-aa64-53aa7e2c4972" xlink:href="abvx-20251231.xsd#abvx_IncomeFromResearchTaxCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOperatingIncomeLineItems_6a0c878d-703a-4f1a-a96f-6d5a25197c25" xlink:to="loc_abvx_IncomeFromResearchTaxCredit_b9e38762-16bc-4f93-aa64-53aa7e2c4972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromGovernmentGrants_03c31e27-ef28-403e-b47e-99b6ebaeb707" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOperatingIncomeLineItems_6a0c878d-703a-4f1a-a96f-6d5a25197c25" xlink:to="loc_ifrs-full_RevenueFromGovernmentGrants_03c31e27-ef28-403e-b47e-99b6ebaeb707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_019bffc0-2d78-748f-96ec-5054c2cd9d89" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOperatingIncomeLineItems_6a0c878d-703a-4f1a-a96f-6d5a25197c25" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_019bffc0-2d78-748f-96ec-5054c2cd9d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#OperatingexpensesDisclosureofsalesandmarketingexpensesDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseByNatureAbstract_e90ca2a2-bce3-43f1-b489-4612dd6344d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseByNatureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_e111342d-013e-4844-a178-daa2197c24ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_e90ca2a2-bce3-43f1-b489-4612dd6344d5" xlink:to="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_e111342d-013e-4844-a178-daa2197c24ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_4f16b5af-f063-4f2d-a194-14df8d4a6cfc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_e111342d-013e-4844-a178-daa2197c24ea" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_4f16b5af-f063-4f2d-a194-14df8d4a6cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_9531b110-6d5f-4ecb-ba58-f875b10d44fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_4f16b5af-f063-4f2d-a194-14df8d4a6cfc" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_9531b110-6d5f-4ecb-ba58-f875b10d44fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SalesAndMarketingExpenseMember_75edeee1-5f58-4fd0-a85a-bdb601c3229d" xlink:href="abvx-20251231.xsd#abvx_SalesAndMarketingExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_9531b110-6d5f-4ecb-ba58-f875b10d44fd" xlink:to="loc_abvx_SalesAndMarketingExpenseMember_75edeee1-5f58-4fd0-a85a-bdb601c3229d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_d47287a5-cf04-4bc9-8d4a-39275498515f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_e111342d-013e-4844-a178-daa2197c24ea" xlink:to="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_d47287a5-cf04-4bc9-8d4a-39275498515f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_ab5e663b-24cf-4bd9-8703-31dbf6268b8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_d47287a5-cf04-4bc9-8d4a-39275498515f" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_ab5e663b-24cf-4bd9-8703-31dbf6268b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfessionalFeesExpense_49e3bac6-7400-49f9-901b-e8bc8560611d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfessionalFeesExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_d47287a5-cf04-4bc9-8d4a-39275498515f" xlink:to="loc_ifrs-full_ProfessionalFeesExpense_49e3bac6-7400-49f9-901b-e8bc8560611d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_670a5238-641c-4cc5-9436-54016aef2cfb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_d47287a5-cf04-4bc9-8d4a-39275498515f" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_670a5238-641c-4cc5-9436-54016aef2cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_00b9cb9a-08b9-48d8-9e48-843059004191" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OperatingExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_d47287a5-cf04-4bc9-8d4a-39275498515f" xlink:to="loc_ifrs-full_OperatingExpense_00b9cb9a-08b9-48d8-9e48-843059004191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseByNatureAbstract_64b1cd2b-2697-4f18-aed4-60f912d81ced" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseByNatureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_dbb757cd-2a1a-402f-a41c-adf77445c2c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_64b1cd2b-2697-4f18-aed4-60f912d81ced" xlink:to="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_dbb757cd-2a1a-402f-a41c-adf77445c2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_9bdb8aea-2421-470c-91c9-54e0c163388e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_dbb757cd-2a1a-402f-a41c-adf77445c2c6" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_9bdb8aea-2421-470c-91c9-54e0c163388e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_7e494e66-8f52-4d81-aebf-b6a1f3d91264" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_9bdb8aea-2421-470c-91c9-54e0c163388e" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_7e494e66-8f52-4d81-aebf-b6a1f3d91264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ResearchAndDevelopmentExpensesMember_4b42726e-4c5f-45ea-8f2e-f322303d054b" xlink:href="abvx-20251231.xsd#abvx_ResearchAndDevelopmentExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_7e494e66-8f52-4d81-aebf-b6a1f3d91264" xlink:to="loc_abvx_ResearchAndDevelopmentExpensesMember_4b42726e-4c5f-45ea-8f2e-f322303d054b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_ebd76308-81a8-4890-a9a5-bb4c0da2b8a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_dbb757cd-2a1a-402f-a41c-adf77445c2c6" xlink:to="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_ebd76308-81a8-4890-a9a5-bb4c0da2b8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SubContractingStudiesAndResearchExpenses_fd69e967-b49c-4161-8420-76146b330684" xlink:href="abvx-20251231.xsd#abvx_SubContractingStudiesAndResearchExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_ebd76308-81a8-4890-a9a5-bb4c0da2b8a4" xlink:to="loc_abvx_SubContractingStudiesAndResearchExpenses_fd69e967-b49c-4161-8420-76146b330684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_4fc9f15f-2910-4fe3-a3a6-95d65638429e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_ebd76308-81a8-4890-a9a5-bb4c0da2b8a4" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_4fc9f15f-2910-4fe3-a3a6-95d65638429e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfessionalFeesExpense_0ee7937b-bdc4-45b7-a980-3195ecd124a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfessionalFeesExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_ebd76308-81a8-4890-a9a5-bb4c0da2b8a4" xlink:to="loc_ifrs-full_ProfessionalFeesExpense_0ee7937b-bdc4-45b7-a980-3195ecd124a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IntellectualPropertyFees_1728d476-5f76-4529-a4ab-e1b0724560fc" xlink:href="abvx-20251231.xsd#abvx_IntellectualPropertyFees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_ebd76308-81a8-4890-a9a5-bb4c0da2b8a4" xlink:to="loc_abvx_IntellectualPropertyFees_1728d476-5f76-4529-a4ab-e1b0724560fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_15616933-d9db-40c4-ad78-9a8e8de310e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_ebd76308-81a8-4890-a9a5-bb4c0da2b8a4" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_15616933-d9db-40c4-ad78-9a8e8de310e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_b96692b8-f591-4329-8217-ecb641ae7bbc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OperatingExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_ebd76308-81a8-4890-a9a5-bb4c0da2b8a4" xlink:to="loc_ifrs-full_OperatingExpense_b96692b8-f591-4329-8217-ecb641ae7bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/OperatingexpensesNarrativeDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#OperatingexpensesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/OperatingexpensesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseByNatureAbstract_c35a59d2-c29e-4e28-a239-d184f1630263" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseByNatureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_77e3b522-ca3c-4180-8026-b656f35ce963" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_c35a59d2-c29e-4e28-a239-d184f1630263" xlink:to="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_77e3b522-ca3c-4180-8026-b656f35ce963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_8b608cc6-7531-49f1-8888-0b03b54577b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_77e3b522-ca3c-4180-8026-b656f35ce963" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_8b608cc6-7531-49f1-8888-0b03b54577b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_9f8d028c-4e32-4b10-8589-ce1aa236b6da" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_8b608cc6-7531-49f1-8888-0b03b54577b3" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_9f8d028c-4e32-4b10-8589-ce1aa236b6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ResearchAndDevelopmentExpensesMember_7411fda6-cede-4123-98cc-e1b4256d701c" xlink:href="abvx-20251231.xsd#abvx_ResearchAndDevelopmentExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_9f8d028c-4e32-4b10-8589-ce1aa236b6da" xlink:to="loc_abvx_ResearchAndDevelopmentExpensesMember_7411fda6-cede-4123-98cc-e1b4256d701c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_GeneralAndAdministrativeExpensesMember_019c57c8-2813-7d73-9d97-2b9a73ab9be8" xlink:href="abvx-20251231.xsd#abvx_GeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_9f8d028c-4e32-4b10-8589-ce1aa236b6da" xlink:to="loc_abvx_GeneralAndAdministrativeExpensesMember_019c57c8-2813-7d73-9d97-2b9a73ab9be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_5ff4f599-2f10-4b78-b031-a824a56c98d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_77e3b522-ca3c-4180-8026-b656f35ce963" xlink:to="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_5ff4f599-2f10-4b78-b031-a824a56c98d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInUlcerativeColitisExpenses_128d9b10-b818-4c7d-afd7-f1b0040e0348" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInUlcerativeColitisExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_5ff4f599-2f10-4b78-b031-a824a56c98d4" xlink:to="loc_abvx_IncreaseDecreaseInUlcerativeColitisExpenses_128d9b10-b818-4c7d-afd7-f1b0040e0348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInCrohnsDiseaseResearchExpenses_f3da0fc1-a68d-4e75-85fe-46cc481c91b0" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInCrohnsDiseaseResearchExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_5ff4f599-2f10-4b78-b031-a824a56c98d4" xlink:to="loc_abvx_IncreaseDecreaseInCrohnsDiseaseResearchExpenses_f3da0fc1-a68d-4e75-85fe-46cc481c91b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInTransversalActivities_2caf2588-4072-4c77-a905-1a77bd76517f" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInTransversalActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_5ff4f599-2f10-4b78-b031-a824a56c98d4" xlink:to="loc_abvx_IncreaseDecreaseInTransversalActivities_2caf2588-4072-4c77-a905-1a77bd76517f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInTransversalActivitiesCombinationTherapy_019cd7fb-00dd-7629-8b23-1c7eeb03b411" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInTransversalActivitiesCombinationTherapy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_5ff4f599-2f10-4b78-b031-a824a56c98d4" xlink:to="loc_abvx_IncreaseDecreaseInTransversalActivitiesCombinationTherapy_019cd7fb-00dd-7629-8b23-1c7eeb03b411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_IncreaseDecreaseInEmployerTaxAndSocialContributions_019c5760-de97-7279-9745-69b6019c74e4" xlink:href="abvx-20251231.xsd#abvx_IncreaseDecreaseInEmployerTaxAndSocialContributions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_5ff4f599-2f10-4b78-b031-a824a56c98d4" xlink:to="loc_abvx_IncreaseDecreaseInEmployerTaxAndSocialContributions_019c5760-de97-7279-9745-69b6019c74e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseByNatureAbstract_508b118a-7645-466b-b15d-bf8eb996841e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseByNatureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_8f36584e-cdc2-4ce2-a60c-d495cb54271b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_508b118a-7645-466b-b15d-bf8eb996841e" xlink:to="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_8f36584e-cdc2-4ce2-a60c-d495cb54271b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_b4f5791e-7bf4-4f5b-8bc8-b6f627e90fa7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_8f36584e-cdc2-4ce2-a60c-d495cb54271b" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_b4f5791e-7bf4-4f5b-8bc8-b6f627e90fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_f09a4a39-0b42-4999-9bd4-12a46f053748" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_b4f5791e-7bf4-4f5b-8bc8-b6f627e90fa7" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_f09a4a39-0b42-4999-9bd4-12a46f053748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_GeneralAndAdministrativeExpensesMember_feb1d90b-a3c4-49ae-828d-028e8090aaf7" xlink:href="abvx-20251231.xsd#abvx_GeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_f09a4a39-0b42-4999-9bd4-12a46f053748" xlink:to="loc_abvx_GeneralAndAdministrativeExpensesMember_feb1d90b-a3c4-49ae-828d-028e8090aaf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_359e8ed5-8025-433a-9192-4365c1486c4c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_8f36584e-cdc2-4ce2-a60c-d495cb54271b" xlink:to="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_359e8ed5-8025-433a-9192-4365c1486c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_a7d95776-9139-4222-a491-0c5d9779b0f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_359e8ed5-8025-433a-9192-4365c1486c4c" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_a7d95776-9139-4222-a491-0c5d9779b0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfessionalFeesExpense_ebb36c3c-e025-4bbd-819d-b0c8b8fddb0a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfessionalFeesExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_359e8ed5-8025-433a-9192-4365c1486c4c" xlink:to="loc_ifrs-full_ProfessionalFeesExpense_ebb36c3c-e025-4bbd-819d-b0c8b8fddb0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_e99eca0f-c97c-4c70-8e40-7c3ea8f6d611" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_359e8ed5-8025-433a-9192-4365c1486c4c" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_e99eca0f-c97c-4c70-8e40-7c3ea8f6d611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_0bd5f6f2-56d1-471b-9738-652c19b30a0f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OperatingExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_359e8ed5-8025-433a-9192-4365c1486c4c" xlink:to="loc_ifrs-full_OperatingExpense_0bd5f6f2-56d1-471b-9738-652c19b30a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/OperatingexpensesDisclosureofprincipalauditfeesandservicesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#OperatingexpensesDisclosureofprincipalauditfeesandservicesDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/OperatingexpensesDisclosureofprincipalauditfeesandservicesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseByNatureAbstract_0c71d059-0dbb-431b-957c-9fa48019b856" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseByNatureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemunerationForAuditServices_8469e33e-4855-404e-9d00-0a2cd7bf5e45" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AuditorsRemunerationForAuditServices"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_0c71d059-0dbb-431b-957c-9fa48019b856" xlink:to="loc_ifrs-full_AuditorsRemunerationForAuditServices_8469e33e-4855-404e-9d00-0a2cd7bf5e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AuditorsRemunerationForAuditRelatedFees_019cfc16-3e60-75ce-8a58-19975c9ccbf3" xlink:href="abvx-20251231.xsd#abvx_AuditorsRemunerationForAuditRelatedFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_0c71d059-0dbb-431b-957c-9fa48019b856" xlink:to="loc_abvx_AuditorsRemunerationForAuditRelatedFees_019cfc16-3e60-75ce-8a58-19975c9ccbf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemunerationForTaxServices_019cc330-ba72-7d29-9728-eda16c6da3ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AuditorsRemunerationForTaxServices"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_0c71d059-0dbb-431b-957c-9fa48019b856" xlink:to="loc_ifrs-full_AuditorsRemunerationForTaxServices_019cc330-ba72-7d29-9728-eda16c6da3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemunerationForOtherServices_783057d7-76a8-49b0-ae6b-9594f8f2cc26" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AuditorsRemunerationForOtherServices"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_0c71d059-0dbb-431b-957c-9fa48019b856" xlink:to="loc_ifrs-full_AuditorsRemunerationForOtherServices_783057d7-76a8-49b0-ae6b-9594f8f2cc26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemuneration_f865e646-3b7b-411a-8b2e-dd31aa27c3b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AuditorsRemuneration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_0c71d059-0dbb-431b-957c-9fa48019b856" xlink:to="loc_ifrs-full_AuditorsRemuneration_f865e646-3b7b-411a-8b2e-dd31aa27c3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/EmployeesDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#EmployeesDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/EmployeesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberAndAverageNumberOfEmployeesAbstract_3b8f546c-64c4-4c33-8e5e-13a67dd374a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberAndAverageNumberOfEmployeesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfEmployeeWorkforceTable_b0f5829c-995d-4b09-b256-9f247c94176e" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfEmployeeWorkforceTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NumberAndAverageNumberOfEmployeesAbstract_3b8f546c-64c4-4c33-8e5e-13a67dd374a9" xlink:to="loc_abvx_DisclosureOfEmployeeWorkforceTable_b0f5829c-995d-4b09-b256-9f247c94176e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_577fa728-3dfc-488b-a7ff-5a5ab3f35d2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfEmployeeWorkforceTable_b0f5829c-995d-4b09-b256-9f247c94176e" xlink:to="loc_ifrs-full_GeographicalAreasAxis_577fa728-3dfc-488b-a7ff-5a5ab3f35d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_ba565072-5408-4efc-9aa3-62b1c7644aea" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_577fa728-3dfc-488b-a7ff-5a5ab3f35d2e" xlink:to="loc_ifrs-full_GeographicalAreasDomain_ba565072-5408-4efc-9aa3-62b1c7644aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_ab53a958-b7cc-4ea1-8d00-470171dec908" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_FR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasDomain_ba565072-5408-4efc-9aa3-62b1c7644aea" xlink:to="loc_country_FR_ab53a958-b7cc-4ea1-8d00-470171dec908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_99c01d91-dd40-499b-a9be-8b7259c957a1" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasDomain_ba565072-5408-4efc-9aa3-62b1c7644aea" xlink:to="loc_country_US_99c01d91-dd40-499b-a9be-8b7259c957a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfEmployeeWorkforceLineItems_44f1647b-9cbb-4213-b2b4-b8a3447bc51b" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfEmployeeWorkforceLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfEmployeeWorkforceTable_b0f5829c-995d-4b09-b256-9f247c94176e" xlink:to="loc_abvx_DisclosureOfEmployeeWorkforceLineItems_44f1647b-9cbb-4213-b2b4-b8a3447bc51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageNumberOfEmployees_27ee2524-90a1-4a9b-8c84-4a13365f7409" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AverageNumberOfEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfEmployeeWorkforceLineItems_44f1647b-9cbb-4213-b2b4-b8a3447bc51b" xlink:to="loc_ifrs-full_AverageNumberOfEmployees_27ee2524-90a1-4a9b-8c84-4a13365f7409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialgainlossDisclosureofnetfinancialincomelossDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialIncomeLossAbstract_03c0cb5d-323d-4bb0-9174-c4739bf40d9c" xlink:href="abvx-20251231.xsd#abvx_FinancialIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBonds_1d99e2c8-be00-42c5-8489-3e4a4077c4dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnBonds"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialIncomeLossAbstract_03c0cb5d-323d-4bb0-9174-c4739bf40d9c" xlink:to="loc_ifrs-full_InterestExpenseOnBonds_1d99e2c8-be00-42c5-8489-3e4a4077c4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnDebtInstrumentsIssued_c4aa229c-0d0a-493a-b0cf-e37b2e6723e5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnDebtInstrumentsIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialIncomeLossAbstract_03c0cb5d-323d-4bb0-9174-c4739bf40d9c" xlink:to="loc_ifrs-full_InterestExpenseOnDebtInstrumentsIssued_c4aa229c-0d0a-493a-b0cf-e37b2e6723e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_c4796812-c80c-4cb4-a724-8f5675283066" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialIncomeLossAbstract_03c0cb5d-323d-4bb0-9174-c4739bf40d9c" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_c4796812-c80c-4cb4-a724-8f5675283066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_InterestExpenseOnRoyaltyCertificates_8f60b03e-98b7-4465-8bd1-d3017d208d6c" xlink:href="abvx-20251231.xsd#abvx_InterestExpenseOnRoyaltyCertificates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialIncomeLossAbstract_03c0cb5d-323d-4bb0-9174-c4739bf40d9c" xlink:to="loc_abvx_InterestExpenseOnRoyaltyCertificates_8f60b03e-98b7-4465-8bd1-d3017d208d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_66b2c8b2-2e0d-48fc-9618-020cc67dd878" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialIncomeLossAbstract_03c0cb5d-323d-4bb0-9174-c4739bf40d9c" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_66b2c8b2-2e0d-48fc-9618-020cc67dd878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LossesOnChangeInFairValueOfDerivatives_019c5769-e904-7efc-a024-310e39a14ecd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LossesOnChangeInFairValueOfDerivatives"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialIncomeLossAbstract_03c0cb5d-323d-4bb0-9174-c4739bf40d9c" xlink:to="loc_ifrs-full_LossesOnChangeInFairValueOfDerivatives_019c5769-e904-7efc-a024-310e39a14ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss_1bf6df60-691b-404d-8ca9-f76a259668c3" xlink:href="abvx-20251231.xsd#abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialIncomeLossAbstract_03c0cb5d-323d-4bb0-9174-c4739bf40d9c" xlink:to="loc_abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss_1bf6df60-691b-404d-8ca9-f76a259668c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LossesArisingFromDerecognitionOfFinancialLiabilities_fe29eeb3-005f-4849-890e-9cfcc7e4cff9" xlink:href="abvx-20251231.xsd#abvx_LossesArisingFromDerecognitionOfFinancialLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialIncomeLossAbstract_03c0cb5d-323d-4bb0-9174-c4739bf40d9c" xlink:to="loc_abvx_LossesArisingFromDerecognitionOfFinancialLiabilities_fe29eeb3-005f-4849-890e-9cfcc7e4cff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TransactionCosts_704543e3-a6fc-4940-9443-c8283f035734" xlink:href="abvx-20251231.xsd#abvx_TransactionCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialIncomeLossAbstract_03c0cb5d-323d-4bb0-9174-c4739bf40d9c" xlink:to="loc_abvx_TransactionCosts_704543e3-a6fc-4940-9443-c8283f035734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ForeignExchangeLoss_ed46f2f3-bb79-4371-9964-e3087f150ae3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ForeignExchangeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialIncomeLossAbstract_03c0cb5d-323d-4bb0-9174-c4739bf40d9c" xlink:to="loc_ifrs-full_ForeignExchangeLoss_ed46f2f3-bb79-4371-9964-e3087f150ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinanceCost_d0022efa-8a45-4005-861e-8a36ca20de39" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherFinanceCost"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialIncomeLossAbstract_03c0cb5d-323d-4bb0-9174-c4739bf40d9c" xlink:to="loc_ifrs-full_OtherFinanceCost_d0022efa-8a45-4005-861e-8a36ca20de39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_2cba0d94-670b-402c-84ad-03be6013b508" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialIncomeLossAbstract_03c0cb5d-323d-4bb0-9174-c4739bf40d9c" xlink:to="loc_ifrs-full_FinanceCosts_2cba0d94-670b-402c-84ad-03be6013b508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromInterest_d930dc1a-aeaf-44d9-9976-571af974c57f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialIncomeLossAbstract_03c0cb5d-323d-4bb0-9174-c4739bf40d9c" xlink:to="loc_ifrs-full_RevenueFromInterest_d930dc1a-aeaf-44d9-9976-571af974c57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives_60e08ebb-e0c8-4172-9e1b-ca9fdc3e0de9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsOnChangeInFairValueOfDerivatives"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialIncomeLossAbstract_03c0cb5d-323d-4bb0-9174-c4739bf40d9c" xlink:to="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives_60e08ebb-e0c8-4172-9e1b-ca9fdc3e0de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_GainsOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss_dcc37172-0988-48f3-aae7-7c35fb3168f8" xlink:href="abvx-20251231.xsd#abvx_GainsOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialIncomeLossAbstract_03c0cb5d-323d-4bb0-9174-c4739bf40d9c" xlink:to="loc_abvx_GainsOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss_dcc37172-0988-48f3-aae7-7c35fb3168f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_UnwindingEffectOfDiscountRelatedToAdvancesMadeToCROs_4eb03ef9-640c-43b7-a2bf-00e957c105f6" xlink:href="abvx-20251231.xsd#abvx_UnwindingEffectOfDiscountRelatedToAdvancesMadeToCROs"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialIncomeLossAbstract_03c0cb5d-323d-4bb0-9174-c4739bf40d9c" xlink:to="loc_abvx_UnwindingEffectOfDiscountRelatedToAdvancesMadeToCROs_4eb03ef9-640c-43b7-a2bf-00e957c105f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_GainsArisingFromRecognitionOfFinancialLiabilities_c9a816c0-33ce-4b86-b760-b0f69f018601" xlink:href="abvx-20251231.xsd#abvx_GainsArisingFromRecognitionOfFinancialLiabilities"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialIncomeLossAbstract_03c0cb5d-323d-4bb0-9174-c4739bf40d9c" xlink:to="loc_abvx_GainsArisingFromRecognitionOfFinancialLiabilities_c9a816c0-33ce-4b86-b760-b0f69f018601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_GainsArisingFromDerecognitionOfFinancialLiabilities_4cd69e9a-a0e8-473f-8c5a-07fb26cd9f4f" xlink:href="abvx-20251231.xsd#abvx_GainsArisingFromDerecognitionOfFinancialLiabilities"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialIncomeLossAbstract_03c0cb5d-323d-4bb0-9174-c4739bf40d9c" xlink:to="loc_abvx_GainsArisingFromDerecognitionOfFinancialLiabilities_4cd69e9a-a0e8-473f-8c5a-07fb26cd9f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ForeignExchangeGain_21f292e8-03cd-4bba-86f7-9b294a4cc531" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ForeignExchangeGain"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialIncomeLossAbstract_03c0cb5d-323d-4bb0-9174-c4739bf40d9c" xlink:to="loc_ifrs-full_ForeignExchangeGain_21f292e8-03cd-4bba-86f7-9b294a4cc531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinanceIncome_528ab21a-f657-480f-8990-31fb590d26e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherFinanceIncome"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialIncomeLossAbstract_03c0cb5d-323d-4bb0-9174-c4739bf40d9c" xlink:to="loc_ifrs-full_OtherFinanceIncome_528ab21a-f657-480f-8990-31fb590d26e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_bf8ec911-5657-44a2-9e13-8778d681fec0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialIncomeLossAbstract_03c0cb5d-323d-4bb0-9174-c4739bf40d9c" xlink:to="loc_ifrs-full_FinanceIncome_bf8ec911-5657-44a2-9e13-8778d681fec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_4358192b-55b0-4207-99ad-344b175db715" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialIncomeLossAbstract_03c0cb5d-323d-4bb0-9174-c4739bf40d9c" xlink:to="loc_ifrs-full_FinanceIncomeCost_4358192b-55b0-4207-99ad-344b175db715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/FinancialgainlossNarrativeDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#FinancialgainlossNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/FinancialgainlossNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialIncomeLossAbstract_f003c3d4-d959-4611-b251-f4442626172c" xlink:href="abvx-20251231.xsd#abvx_FinancialIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfFinancialGainLossTable_0fcf66de-1125-412e-acd8-6b33fe527f75" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfFinancialGainLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialIncomeLossAbstract_f003c3d4-d959-4611-b251-f4442626172c" xlink:to="loc_abvx_DisclosureOfFinancialGainLossTable_0fcf66de-1125-412e-acd8-6b33fe527f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_6f343a6a-f9a3-4c85-b478-874ed8fc6d07" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfFinancialGainLossTable_0fcf66de-1125-412e-acd8-6b33fe527f75" xlink:to="loc_srt_CurrencyAxis_6f343a6a-f9a3-4c85-b478-874ed8fc6d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_3f5f37fa-3993-4559-ac29-b36cfacad49c" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_6f343a6a-f9a3-4c85-b478-874ed8fc6d07" xlink:to="loc_currency_AllCurrenciesDomain_3f5f37fa-3993-4559-ac29-b36cfacad49c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_e51b2326-8f4c-45a8-80b1-bb1fae735932" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_USD"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_3f5f37fa-3993-4559-ac29-b36cfacad49c" xlink:to="loc_currency_USD_e51b2326-8f4c-45a8-80b1-bb1fae735932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_019d0058-fb69-713d-abcf-d4e1e3a7a672" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfFinancialGainLossTable_0fcf66de-1125-412e-acd8-6b33fe527f75" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_019d0058-fb69-713d-abcf-d4e1e3a7a672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_019d0058-fb69-7e0d-904f-0090cd8dd3ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_019d0058-fb69-713d-abcf-d4e1e3a7a672" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_019d0058-fb69-7e0d-904f-0090cd8dd3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingBSAMember_019d0059-395f-7f81-b0c5-2ae1b6047179" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingBSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_019d0058-fb69-7e0d-904f-0090cd8dd3ed" xlink:to="loc_abvx_KreosClaretFinancingBSAMember_019d0059-395f-7f81-b0c5-2ae1b6047179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretMinimumReturnIndemnificationsMember_019d005b-137d-7ea1-8b6e-9d6097a97088" xlink:href="abvx-20251231.xsd#abvx_KreosClaretMinimumReturnIndemnificationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_019d0058-fb69-7e0d-904f-0090cd8dd3ed" xlink:to="loc_abvx_KreosClaretMinimumReturnIndemnificationsMember_019d005b-137d-7ea1-8b6e-9d6097a97088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfFinancialGainLossLineItems_4e1da471-5df4-4efb-bd5e-4187070ccabd" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfFinancialGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfFinancialGainLossTable_0fcf66de-1125-412e-acd8-6b33fe527f75" xlink:to="loc_abvx_DisclosureOfFinancialGainLossLineItems_4e1da471-5df4-4efb-bd5e-4187070ccabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LossesOnChangeInFairValueOfDerivatives_019d005a-712b-7990-9b8a-b680da436521" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LossesOnChangeInFairValueOfDerivatives"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfFinancialGainLossLineItems_4e1da471-5df4-4efb-bd5e-4187070ccabd" xlink:to="loc_ifrs-full_LossesOnChangeInFairValueOfDerivatives_019d005a-712b-7990-9b8a-b680da436521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ForeignExchangeLoss_019d005c-ecef-7e97-bec8-a8b539a0fdf5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ForeignExchangeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfFinancialGainLossLineItems_4e1da471-5df4-4efb-bd5e-4187070ccabd" xlink:to="loc_ifrs-full_ForeignExchangeLoss_019d005c-ecef-7e97-bec8-a8b539a0fdf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ForeignExchangeGainsLossesOnTranslationOfForeignOperations_d185c057-1ec9-4625-8a95-3a8615d61ab9" xlink:href="abvx-20251231.xsd#abvx_ForeignExchangeGainsLossesOnTranslationOfForeignOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfFinancialGainLossLineItems_4e1da471-5df4-4efb-bd5e-4187070ccabd" xlink:to="loc_abvx_ForeignExchangeGainsLossesOnTranslationOfForeignOperations_d185c057-1ec9-4625-8a95-3a8615d61ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives_019c5773-68de-7e7d-986b-8b2d83e5b934" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsOnChangeInFairValueOfDerivatives"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfFinancialGainLossLineItems_4e1da471-5df4-4efb-bd5e-4187070ccabd" xlink:to="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives_019c5773-68de-7e7d-986b-8b2d83e5b934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ForeignExchangeGain_019d005c-bf9c-7a85-a9e2-c618a72ff557" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ForeignExchangeGain"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfFinancialGainLossLineItems_4e1da471-5df4-4efb-bd5e-4187070ccabd" xlink:to="loc_ifrs-full_ForeignExchangeGain_019d005c-bf9c-7a85-a9e2-c618a72ff557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_d8e8d6c7-e720-43cf-917c-ec173d31cd17" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccountingProfit_8da6ea83-6bf0-489b-baee-c3d7b87b0a60" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccountingProfit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_d8e8d6c7-e720-43cf-917c-ec173d31cd17" xlink:to="loc_ifrs-full_AccountingProfit_8da6ea83-6bf0-489b-baee-c3d7b87b0a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate_cc6777f8-3387-4c19-95ef-752ed9b7ef12" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_d8e8d6c7-e720-43cf-917c-ec173d31cd17" xlink:to="loc_ifrs-full_ApplicableTaxRate_cc6777f8-3387-4c19-95ef-752ed9b7ef12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_4d11083a-5756-4dac-84a6-c7ac74c49f4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_d8e8d6c7-e720-43cf-917c-ec173d31cd17" xlink:to="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_4d11083a-5756-4dac-84a6-c7ac74c49f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfForeignTaxRates_b5b5b531-9c03-47c0-9bd9-aafd8663450a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TaxEffectOfForeignTaxRates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_d8e8d6c7-e720-43cf-917c-ec173d31cd17" xlink:to="loc_ifrs-full_TaxEffectOfForeignTaxRates_b5b5b531-9c03-47c0-9bd9-aafd8663450a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TaxEffectOfShareBasedPayment_d49866db-8d2a-4910-9426-7cd71d0c56c9" xlink:href="abvx-20251231.xsd#abvx_TaxEffectOfShareBasedPayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_d8e8d6c7-e720-43cf-917c-ec173d31cd17" xlink:to="loc_abvx_TaxEffectOfShareBasedPayment_d49866db-8d2a-4910-9426-7cd71d0c56c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TaxEffectOfResearchTaxCredit_ee6dad8e-d78f-4487-b6b8-95586b727784" xlink:href="abvx-20251231.xsd#abvx_TaxEffectOfResearchTaxCredit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_d8e8d6c7-e720-43cf-917c-ec173d31cd17" xlink:to="loc_abvx_TaxEffectOfResearchTaxCredit_ee6dad8e-d78f-4487-b6b8-95586b727784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TaxEffectOfTransactionCostsRelatedToCapitalIncrease_e1b4cdd7-3b10-4a8e-ad6d-f6b9e6b6d151" xlink:href="abvx-20251231.xsd#abvx_TaxEffectOfTransactionCostsRelatedToCapitalIncrease"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_d8e8d6c7-e720-43cf-917c-ec173d31cd17" xlink:to="loc_abvx_TaxEffectOfTransactionCostsRelatedToCapitalIncrease_e1b4cdd7-3b10-4a8e-ad6d-f6b9e6b6d151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TaxEffectOfChangesInDerivativeFairValueAndOtherLiabilitiesMeasuredAtFVTPL_c2e0b2b9-dcfc-4e79-ad87-495eb1ebc80f" xlink:href="abvx-20251231.xsd#abvx_TaxEffectOfChangesInDerivativeFairValueAndOtherLiabilitiesMeasuredAtFVTPL"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_d8e8d6c7-e720-43cf-917c-ec173d31cd17" xlink:to="loc_abvx_TaxEffectOfChangesInDerivativeFairValueAndOtherLiabilitiesMeasuredAtFVTPL_c2e0b2b9-dcfc-4e79-ad87-495eb1ebc80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferences_d89647fb-0cf5-4fe2-b666-12118e7c59d0" xlink:href="abvx-20251231.xsd#abvx_TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferences"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_d8e8d6c7-e720-43cf-917c-ec173d31cd17" xlink:to="loc_abvx_TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferences_d89647fb-0cf5-4fe2-b666-12118e7c59d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_5e1c154e-0834-4696-9412-88021e51e120" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_d8e8d6c7-e720-43cf-917c-ec173d31cd17" xlink:to="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_5e1c154e-0834-4696-9412-88021e51e120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_2e2bc62d-b755-4c07-b8b9-e70e75c34533" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_d8e8d6c7-e720-43cf-917c-ec173d31cd17" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_2e2bc62d-b755-4c07-b8b9-e70e75c34533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_4ebce28f-7379-4b38-94c0-870f9c76ffd2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_cfdc0a50-9734-48fc-bc1c-e0dd043a75b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_4ebce28f-7379-4b38-94c0-870f9c76ffd2" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_cfdc0a50-9734-48fc-bc1c-e0dd043a75b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_0782f2f4-8046-4980-9854-000917ee463f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_cfdc0a50-9734-48fc-bc1c-e0dd043a75b1" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_0782f2f4-8046-4980-9854-000917ee463f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_e59ca16d-8b29-4770-b961-8149e0ce2b90" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_0782f2f4-8046-4980-9854-000917ee463f" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_e59ca16d-8b29-4770-b961-8149e0ce2b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RetirementBenefitObligationsRelatedTemporaryDifferencesMember_8b77ae7b-0cfd-4b2b-8753-21fb74f70af6" xlink:href="abvx-20251231.xsd#abvx_RetirementBenefitObligationsRelatedTemporaryDifferencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_e59ca16d-8b29-4770-b961-8149e0ce2b90" xlink:to="loc_abvx_RetirementBenefitObligationsRelatedTemporaryDifferencesMember_8b77ae7b-0cfd-4b2b-8753-21fb74f70af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SubsidiesRelatedTemporaryDifferencesMember_74255e77-d2cb-4f22-bb09-a49b7e921fd0" xlink:href="abvx-20251231.xsd#abvx_SubsidiesRelatedTemporaryDifferencesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_e59ca16d-8b29-4770-b961-8149e0ce2b90" xlink:to="loc_abvx_SubsidiesRelatedTemporaryDifferencesMember_74255e77-d2cb-4f22-bb09-a49b7e921fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_LeasesRelatedTemporaryDifferencesMember_3d814b11-ffba-4d11-ba62-831dcd4ab64c" xlink:href="abvx-20251231.xsd#abvx_LeasesRelatedTemporaryDifferencesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_e59ca16d-8b29-4770-b961-8149e0ce2b90" xlink:to="loc_abvx_LeasesRelatedTemporaryDifferencesMember_3d814b11-ffba-4d11-ba62-831dcd4ab64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificatesRelatedTemporaryDifferencesMember_019c5797-a063-70d5-aab8-947b780c1504" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificatesRelatedTemporaryDifferencesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_e59ca16d-8b29-4770-b961-8149e0ce2b90" xlink:to="loc_abvx_RoyaltyCertificatesRelatedTemporaryDifferencesMember_019c5797-a063-70d5-aab8-947b780c1504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialLiabilitiesRelatedTemporaryDifferencesMember_73dc6f37-5229-4e55-9a88-7da81167d79e" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialLiabilitiesRelatedTemporaryDifferencesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_e59ca16d-8b29-4770-b961-8149e0ce2b90" xlink:to="loc_abvx_OtherFinancialLiabilitiesRelatedTemporaryDifferencesMember_73dc6f37-5229-4e55-9a88-7da81167d79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ProvisionsForAGATaxesRelatedTemporaryDifferencesMember_019c5785-c419-71fd-8f09-e69d0f3f7482" xlink:href="abvx-20251231.xsd#abvx_ProvisionsForAGATaxesRelatedTemporaryDifferencesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_e59ca16d-8b29-4770-b961-8149e0ce2b90" xlink:to="loc_abvx_ProvisionsForAGATaxesRelatedTemporaryDifferencesMember_019c5785-c419-71fd-8f09-e69d0f3f7482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_c1092b3d-fa04-4484-9946-0b7656afaeb3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnusedTaxLossesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_e59ca16d-8b29-4770-b961-8149e0ce2b90" xlink:to="loc_ifrs-full_UnusedTaxLossesMember_c1092b3d-fa04-4484-9946-0b7656afaeb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTemporaryDifferencesMember_6055f67d-dc28-48c1-b6ec-42b6f16dab44" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherTemporaryDifferencesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_e59ca16d-8b29-4770-b961-8149e0ce2b90" xlink:to="loc_ifrs-full_OtherTemporaryDifferencesMember_6055f67d-dc28-48c1-b6ec-42b6f16dab44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_724dafcd-6b35-428d-9c1d-20654bcbbd40" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_cfdc0a50-9734-48fc-bc1c-e0dd043a75b1" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_724dafcd-6b35-428d-9c1d-20654bcbbd40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets_2af54b0e-e48b-441d-8bc1-4ab5a954ba45" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_724dafcd-6b35-428d-9c1d-20654bcbbd40" xlink:to="loc_ifrs-full_DeferredTaxAssets_2af54b0e-e48b-441d-8bc1-4ab5a954ba45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilities_c5bfc3e7-5c5c-41c6-b78d-162faa0f633c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredTaxLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_724dafcd-6b35-428d-9c1d-20654bcbbd40" xlink:to="loc_ifrs-full_DeferredTaxLiabilities_c5bfc3e7-5c5c-41c6-b78d-162faa0f633c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset_dd222ca8-6373-44b2-b0dc-4c49fcef96a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_724dafcd-6b35-428d-9c1d-20654bcbbd40" xlink:to="loc_ifrs-full_DeferredTaxLiabilityAsset_dd222ca8-6373-44b2-b0dc-4c49fcef96a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_UnrecognizedDeferredTaxAssets_bffb9a41-fee1-45f6-8f63-2e5aaf832785" xlink:href="abvx-20251231.xsd#abvx_UnrecognizedDeferredTaxAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_724dafcd-6b35-428d-9c1d-20654bcbbd40" xlink:to="loc_abvx_UnrecognizedDeferredTaxAssets_bffb9a41-fee1-45f6-8f63-2e5aaf832785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition_23de28d8-93e6-4680-b46c-32aef586ed00" xlink:href="abvx-20251231.xsd#abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_724dafcd-6b35-428d-9c1d-20654bcbbd40" xlink:to="loc_abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition_23de28d8-93e6-4680-b46c-32aef586ed00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/IncometaxNarrativeDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#IncometaxNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/IncometaxNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_ee8f2f51-a703-48de-8cca-fdf1c7ef9918" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_ef2984d7-7624-46ec-b486-63bdc1f2a554" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_ee8f2f51-a703-48de-8cca-fdf1c7ef9918" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_ef2984d7-7624-46ec-b486-63bdc1f2a554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_49bd88e9-f46d-4937-b8e4-a7284155e959" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_ef2984d7-7624-46ec-b486-63bdc1f2a554" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_49bd88e9-f46d-4937-b8e4-a7284155e959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_df20d9d7-911d-4a9c-9e7e-6584a2452da1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_49bd88e9-f46d-4937-b8e4-a7284155e959" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_df20d9d7-911d-4a9c-9e7e-6584a2452da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AbivaxLLCMember_16fd3d7c-d6b3-4efa-8736-c40d322d180f" xlink:href="abvx-20251231.xsd#abvx_AbivaxLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_df20d9d7-911d-4a9c-9e7e-6584a2452da1" xlink:to="loc_abvx_AbivaxLLCMember_16fd3d7c-d6b3-4efa-8736-c40d322d180f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_019c578c-c80d-74e2-8e50-a03d59e94f77" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_ef2984d7-7624-46ec-b486-63bdc1f2a554" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_019c578c-c80d-74e2-8e50-a03d59e94f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_019c578c-c80d-7315-99f3-b5cd938ebeff" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_019c578c-c80d-74e2-8e50-a03d59e94f77" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_019c578c-c80d-7315-99f3-b5cd938ebeff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RoyaltyCertificatesRelatedTemporaryDifferencesMember_019c5798-1a07-7e2a-a362-5fe66606b72a" xlink:href="abvx-20251231.xsd#abvx_RoyaltyCertificatesRelatedTemporaryDifferencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_019c578c-c80d-7315-99f3-b5cd938ebeff" xlink:to="loc_abvx_RoyaltyCertificatesRelatedTemporaryDifferencesMember_019c5798-1a07-7e2a-a362-5fe66606b72a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_019c5799-5262-7f8a-9711-ac7088a3b584" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_ef2984d7-7624-46ec-b486-63bdc1f2a554" xlink:to="loc_srt_StatementGeographicalAxis_019c5799-5262-7f8a-9711-ac7088a3b584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_019c5799-5262-7060-8e3d-4276003be93f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_019c5799-5262-7f8a-9711-ac7088a3b584" xlink:to="loc_srt_SegmentGeographicalDomain_019c5799-5262-7060-8e3d-4276003be93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_019c579a-18cf-7016-b0d8-d54640000e0f" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_FR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_019c5799-5262-7060-8e3d-4276003be93f" xlink:to="loc_country_FR_019c579a-18cf-7016-b0d8-d54640000e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_d6ec99ae-7a90-4adf-8579-a3b9016101f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_ef2984d7-7624-46ec-b486-63bdc1f2a554" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_d6ec99ae-7a90-4adf-8579-a3b9016101f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilities_019c578c-c80d-7167-8408-14f32fe0795e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredTaxLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_d6ec99ae-7a90-4adf-8579-a3b9016101f1" xlink:to="loc_ifrs-full_DeferredTaxLiabilities_019c578c-c80d-7167-8408-14f32fe0795e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets_019c5793-a379-7aaa-84c5-f147bde633de" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_d6ec99ae-7a90-4adf-8579-a3b9016101f1" xlink:to="loc_ifrs-full_DeferredTaxAssets_019c5793-a379-7aaa-84c5-f147bde633de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition_019d0069-a760-7a4b-a34a-f201bc976ba9" xlink:href="abvx-20251231.xsd#abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_d6ec99ae-7a90-4adf-8579-a3b9016101f1" xlink:to="loc_abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition_019d0069-a760-7a4b-a34a-f201bc976ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_06606862-9bbc-4bb3-a8f3-e2c6fe3971c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_d6ec99ae-7a90-4adf-8579-a3b9016101f1" xlink:to="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_06606862-9bbc-4bb3-a8f3-e2c6fe3971c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/IncomelosspershareScheduleofearningspershareDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#IncomelosspershareScheduleofearningspershareDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/IncomelosspershareScheduleofearningspershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_a2869e02-681b-4840-b541-2506e20ee92e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_1ae675ff-934e-4bf1-a147-a6ccd51527b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_a2869e02-681b-4840-b541-2506e20ee92e" xlink:to="loc_ifrs-full_WeightedAverageShares_1ae675ff-934e-4bf1-a147-a6ccd51527b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_a827d6de-724c-415c-8bc6-974f4709e2ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_a2869e02-681b-4840-b541-2506e20ee92e" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_a827d6de-724c-415c-8bc6-974f4709e2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_bd39d335-2d9d-462c-b20b-1a5308e32564" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_a2869e02-681b-4840-b541-2506e20ee92e" xlink:to="loc_ifrs-full_ProfitLoss_bd39d335-2d9d-462c-b20b-1a5308e32564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_54ef6971-4bc1-4f92-826a-cf1fab3e759d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_a2869e02-681b-4840-b541-2506e20ee92e" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_54ef6971-4bc1-4f92-826a-cf1fab3e759d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_5cc17eba-f45c-49b6-80f8-56ea71514cc0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_a2869e02-681b-4840-b541-2506e20ee92e" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_5cc17eba-f45c-49b6-80f8-56ea71514cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/IncomelosspershareNarrativeDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#IncomelosspershareNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/IncomelosspershareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_024e1336-1c17-42bb-b25d-ce1641f3e8f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsThatAreAntidilutiveInPeriodPresented_e4ddd2a9-a609-4699-9987-436da33a7bdf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfInstrumentsThatAreAntidilutiveInPeriodPresented"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_024e1336-1c17-42bb-b25d-ce1641f3e8f7" xlink:to="loc_ifrs-full_NumberOfInstrumentsThatAreAntidilutiveInPeriodPresented_e4ddd2a9-a609-4699-9987-436da33a7bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_MaximumNumberOfSharesToBeIssued_e71175d4-97d1-4688-862d-3ed6365004dc" xlink:href="abvx-20251231.xsd#abvx_MaximumNumberOfSharesToBeIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_024e1336-1c17-42bb-b25d-ce1641f3e8f7" xlink:to="loc_abvx_MaximumNumberOfSharesToBeIssued_e71175d4-97d1-4688-862d-3ed6365004dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract_7349b62f-349d-44a3-aa05-524dd4135c31" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KeyManagementPersonnelCompensationFixedCompensation_523bf3bd-a3c2-413e-be73-07985bcf883d" xlink:href="abvx-20251231.xsd#abvx_KeyManagementPersonnelCompensationFixedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_7349b62f-349d-44a3-aa05-524dd4135c31" xlink:to="loc_abvx_KeyManagementPersonnelCompensationFixedCompensation_523bf3bd-a3c2-413e-be73-07985bcf883d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KeyManagementPersonnelCompensationVariableCompensation_a5f53b3a-d076-4b6b-9735-159699533c60" xlink:href="abvx-20251231.xsd#abvx_KeyManagementPersonnelCompensationVariableCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_7349b62f-349d-44a3-aa05-524dd4135c31" xlink:to="loc_abvx_KeyManagementPersonnelCompensationVariableCompensation_a5f53b3a-d076-4b6b-9735-159699533c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KeyManagementPersonnelCompensationInKindContributions_4c3aac62-6d48-4465-aaf2-ce615917271c" xlink:href="abvx-20251231.xsd#abvx_KeyManagementPersonnelCompensationInKindContributions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_7349b62f-349d-44a3-aa05-524dd4135c31" xlink:to="loc_abvx_KeyManagementPersonnelCompensationInKindContributions_4c3aac62-6d48-4465-aaf2-ce615917271c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_cb6c2e98-34ba-41f4-976c-f38eaf0954ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_7349b62f-349d-44a3-aa05-524dd4135c31" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_cb6c2e98-34ba-41f4-976c-f38eaf0954ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KeyManagementPersonnelCompensationAttendanceFees_dac24c95-6a43-424d-9df1-fbaf4849325f" xlink:href="abvx-20251231.xsd#abvx_KeyManagementPersonnelCompensationAttendanceFees"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_7349b62f-349d-44a3-aa05-524dd4135c31" xlink:to="loc_abvx_KeyManagementPersonnelCompensationAttendanceFees_dac24c95-6a43-424d-9df1-fbaf4849325f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_1f08c3ec-8bf0-4dbc-9350-516d2a83b35c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_7349b62f-349d-44a3-aa05-524dd4135c31" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_1f08c3ec-8bf0-4dbc-9350-516d2a83b35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KeyManagementPersonnelCompensationConsultingFees_917e37ea-0e98-44b4-9552-9c535eee8752" xlink:href="abvx-20251231.xsd#abvx_KeyManagementPersonnelCompensationConsultingFees"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_7349b62f-349d-44a3-aa05-524dd4135c31" xlink:to="loc_abvx_KeyManagementPersonnelCompensationConsultingFees_917e37ea-0e98-44b4-9552-9c535eee8752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_b7850640-9378-4684-810e-a630d46100d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_7349b62f-349d-44a3-aa05-524dd4135c31" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensation_b7850640-9378-4684-810e-a630d46100d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/RelatedpartiesNarrativeDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#RelatedpartiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/RelatedpartiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract_dc3dcc33-f241-4445-868b-90bca8075809" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_5351c6f2-c7fe-4196-8b19-c45cfbab0be9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_dc3dcc33-f241-4445-868b-90bca8075809" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_5351c6f2-c7fe-4196-8b19-c45cfbab0be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_4a89241a-3065-48d6-a921-488e9c752be6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_5351c6f2-c7fe-4196-8b19-c45cfbab0be9" xlink:to="loc_srt_TitleOfIndividualAxis_4a89241a-3065-48d6-a921-488e9c752be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c02fddb3-2ad6-47a9-830d-1f3515d02ab9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_4a89241a-3065-48d6-a921-488e9c752be6" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c02fddb3-2ad6-47a9-830d-1f3515d02ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BoardOfDirectorsAndChiefExecutiveOfficerMember_839bfe3d-37b8-4698-829f-f14137e12e10" xlink:href="abvx-20251231.xsd#abvx_BoardOfDirectorsAndChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c02fddb3-2ad6-47a9-830d-1f3515d02ab9" xlink:to="loc_abvx_BoardOfDirectorsAndChiefExecutiveOfficerMember_839bfe3d-37b8-4698-829f-f14137e12e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AdvisorToTheChiefExecutiveOfficerMember_b5daffd5-2a07-471c-8b89-a9177ce39c65" xlink:href="abvx-20251231.xsd#abvx_AdvisorToTheChiefExecutiveOfficerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c02fddb3-2ad6-47a9-830d-1f3515d02ab9" xlink:to="loc_abvx_AdvisorToTheChiefExecutiveOfficerMember_b5daffd5-2a07-471c-8b89-a9177ce39c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_8e8401fa-fa5e-4e63-aa4d-3cc95bab2fdc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_5351c6f2-c7fe-4196-8b19-c45cfbab0be9" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_8e8401fa-fa5e-4e63-aa4d-3cc95bab2fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_0e2a4be7-51dd-4cf8-8a2f-e778c88fbb47" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_8e8401fa-fa5e-4e63-aa4d-3cc95bab2fdc" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_0e2a4be7-51dd-4cf8-8a2f-e778c88fbb47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_0bac730b-459b-49a2-ab91-0d3d2f22e1fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_0e2a4be7-51dd-4cf8-8a2f-e778c88fbb47" xlink:to="loc_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_0bac730b-459b-49a2-ab91-0d3d2f22e1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_548bb043-bf17-43fe-9369-18043bd76570" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_5351c6f2-c7fe-4196-8b19-c45cfbab0be9" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_548bb043-bf17-43fe-9369-18043bd76570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan_22092d6d-410c-4768-9073-1c0f48b26794" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_548bb043-bf17-43fe-9369-18043bd76570" xlink:to="loc_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan_22092d6d-410c-4768-9073-1c0f48b26794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_16315341-3db1-49ff-9d7c-fa5a247aafa0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_548bb043-bf17-43fe-9369-18043bd76570" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_16315341-3db1-49ff-9d7c-fa5a247aafa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_6482c5d3-6789-4139-8844-5ddcd1146bf5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_548bb043-bf17-43fe-9369-18043bd76570" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_6482c5d3-6789-4139-8844-5ddcd1146bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#OffbalancesheetcommitmentsgivenDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OffBalanceSheetCommitmentsAbstract_5be06b3a-b920-419d-bbad-45ec322dbad0" xlink:href="abvx-20251231.xsd#abvx_OffBalanceSheetCommitmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsTable_6a773e1d-176a-4b41-9cba-88d5eb6ee40f" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfOffBalanceSheetCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_OffBalanceSheetCommitmentsAbstract_5be06b3a-b920-419d-bbad-45ec322dbad0" xlink:to="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsTable_6a773e1d-176a-4b41-9cba-88d5eb6ee40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PrincipalAgreementsAxis_019c0012-0441-791e-a402-f17846f7739e" xlink:href="abvx-20251231.xsd#abvx_PrincipalAgreementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsTable_6a773e1d-176a-4b41-9cba-88d5eb6ee40f" xlink:to="loc_abvx_PrincipalAgreementsAxis_019c0012-0441-791e-a402-f17846f7739e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_PrincipalAgreementsDomain_019c0012-0441-7e92-9ee0-1c3da7db140e" xlink:href="abvx-20251231.xsd#abvx_PrincipalAgreementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_PrincipalAgreementsAxis_019c0012-0441-791e-a402-f17846f7739e" xlink:to="loc_abvx_PrincipalAgreementsDomain_019c0012-0441-7e92-9ee0-1c3da7db140e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember_019c0012-0441-7c2d-9a8f-89f9e9b42c5a" xlink:href="abvx-20251231.xsd#abvx_ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_PrincipalAgreementsDomain_019c0012-0441-7e92-9ee0-1c3da7db140e" xlink:to="loc_abvx_ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember_019c0012-0441-7c2d-9a8f-89f9e9b42c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ResearchAndCollaborationAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember_019c0012-286d-7c14-a54c-7d1a6b1a86d3" xlink:href="abvx-20251231.xsd#abvx_ResearchAndCollaborationAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_PrincipalAgreementsDomain_019c0012-0441-7e92-9ee0-1c3da7db140e" xlink:to="loc_abvx_ResearchAndCollaborationAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember_019c0012-286d-7c14-a54c-7d1a6b1a86d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember_019c0012-286d-76bd-9d5b-9d2af1576d6b" xlink:href="abvx-20251231.xsd#abvx_ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_PrincipalAgreementsDomain_019c0012-0441-7e92-9ee0-1c3da7db140e" xlink:to="loc_abvx_ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember_019c0012-286d-76bd-9d5b-9d2af1576d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_019c0012-286d-7de1-89e3-698c32d87830" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsTable_6a773e1d-176a-4b41-9cba-88d5eb6ee40f" xlink:to="loc_dei_LegalEntityAxis_019c0012-286d-7de1-89e3-698c32d87830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019c0012-286d-7fa3-9471-f15a6be5653b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_019c0012-286d-7de1-89e3-698c32d87830" xlink:to="loc_dei_EntityDomain_019c0012-286d-7fa3-9471-f15a6be5653b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_TheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember_019c0012-286d-7d6f-9655-20f95ac8ad53" xlink:href="abvx-20251231.xsd#abvx_TheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_019c0012-286d-7fa3-9471-f15a6be5653b" xlink:to="loc_abvx_TheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember_019c0012-286d-7d6f-9655-20f95ac8ad53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019c0012-66f4-7709-ab1a-fc9868985fd6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsTable_6a773e1d-176a-4b41-9cba-88d5eb6ee40f" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019c0012-66f4-7709-ab1a-fc9868985fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019c0012-66f4-739b-a1a4-edb123ebe044" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_019c0012-66f4-7709-ab1a-fc9868985fd6" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019c0012-66f4-739b-a1a4-edb123ebe044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CARENAConditionalAdvanceBPIMember_019c0012-66f4-71f6-9301-3e0e44ade71f" xlink:href="abvx-20251231.xsd#abvx_CARENAConditionalAdvanceBPIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019c0012-66f4-739b-a1a4-edb123ebe044" xlink:to="loc_abvx_CARENAConditionalAdvanceBPIMember_019c0012-66f4-71f6-9301-3e0e44ade71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RNPVIRConditionalAdvanceBPIMember_019c0012-8a04-79bd-ad0d-b20c30ee5aea" xlink:href="abvx-20251231.xsd#abvx_RNPVIRConditionalAdvanceBPIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019c0012-66f4-739b-a1a4-edb123ebe044" xlink:to="loc_abvx_RNPVIRConditionalAdvanceBPIMember_019c0012-8a04-79bd-ad0d-b20c30ee5aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EbolaConditionalAdvanceBPIMember_019c0012-8a04-7921-90e1-26e11bade272" xlink:href="abvx-20251231.xsd#abvx_EbolaConditionalAdvanceBPIMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019c0012-66f4-739b-a1a4-edb123ebe044" xlink:to="loc_abvx_EbolaConditionalAdvanceBPIMember_019c0012-8a04-7921-90e1-26e11bade272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EbolaConditionalAdvanceBPILanguedocRoussillonMember_019c0012-8a04-70f3-a660-a5e4350a2490" xlink:href="abvx-20251231.xsd#abvx_EbolaConditionalAdvanceBPILanguedocRoussillonMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019c0012-66f4-739b-a1a4-edb123ebe044" xlink:to="loc_abvx_EbolaConditionalAdvanceBPILanguedocRoussillonMember_019c0012-8a04-70f3-a660-a5e4350a2490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EbolaConditionalAdvanceBPIFranceMember_019c0012-8a04-75d2-bb8d-cb5c37d0b971" xlink:href="abvx-20251231.xsd#abvx_EbolaConditionalAdvanceBPIFranceMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_019c0012-66f4-739b-a1a4-edb123ebe044" xlink:to="loc_abvx_EbolaConditionalAdvanceBPIFranceMember_019c0012-8a04-75d2-bb8d-cb5c37d0b971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019c0012-66f4-71de-abb7-714cffddd6d0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsTable_6a773e1d-176a-4b41-9cba-88d5eb6ee40f" xlink:to="loc_srt_RangeAxis_019c0012-66f4-71de-abb7-714cffddd6d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019c0012-66f4-7191-8c9f-a9df2f0cc899" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_019c0012-66f4-71de-abb7-714cffddd6d0" xlink:to="loc_srt_RangeMember_019c0012-66f4-7191-8c9f-a9df2f0cc899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019c0012-66f4-7af9-8f34-b2f7fe54f121" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019c0012-66f4-7191-8c9f-a9df2f0cc899" xlink:to="loc_srt_MinimumMember_019c0012-66f4-7af9-8f34-b2f7fe54f121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019c0012-66f4-7195-839e-dfc08339060c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019c0012-66f4-7191-8c9f-a9df2f0cc899" xlink:to="loc_srt_MaximumMember_019c0012-66f4-7195-839e-dfc08339060c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsTable_6a773e1d-176a-4b41-9cba-88d5eb6ee40f" xlink:to="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfExclusiveLicenses_019c0012-0441-75cd-9a54-1f3986ee0591" xlink:href="abvx-20251231.xsd#abvx_NumberOfExclusiveLicenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_abvx_NumberOfExclusiveLicenses_019c0012-0441-75cd-9a54-1f3986ee0591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_AgreementPeriod_019c0012-286d-7e5c-8a2a-3a22ac161f55" xlink:href="abvx-20251231.xsd#abvx_AgreementPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_abvx_AgreementPeriod_019c0012-286d-7e5c-8a2a-3a22ac161f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDFiling_019c0012-286d-78e7-b2d4-2fb036be0158" xlink:href="abvx-20251231.xsd#abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDFiling"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDFiling_019c0012-286d-78e7-b2d4-2fb036be0158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentPhase3_019c0012-286d-71f1-b769-e3840b396196" xlink:href="abvx-20251231.xsd#abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentPhase3"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentPhase3_019c0012-286d-71f1-b769-e3840b396196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDApproval_019c0012-286d-7916-85d2-3412baca3be9" xlink:href="abvx-20251231.xsd#abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDApproval"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDApproval_019c0012-286d-7916-85d2-3412baca3be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfAcademicInstitutions_019c0012-286d-7e63-a407-ab61d04cfaa0" xlink:href="abvx-20251231.xsd#abvx_NumberOfAcademicInstitutions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_abvx_NumberOfAcademicInstitutions_019c0012-286d-7e63-a407-ab61d04cfaa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_019c0012-286d-77ae-be8c-d7f95f5277f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_019c0012-286d-77ae-be8c-d7f95f5277f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacityIncludingInterest_019c0012-66f4-730e-8200-628bdd816b5f" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacityIncludingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacityIncludingInterest_019c0012-66f4-730e-8200-628bdd816b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialLiabilitiesAnnualPercentageOfProceedsFromSaleOfIntellectualPropertyRight_019c0012-66f4-7dde-8c33-20d9c80185b9" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialLiabilitiesAnnualPercentageOfProceedsFromSaleOfIntellectualPropertyRight"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_abvx_OtherFinancialLiabilitiesAnnualPercentageOfProceedsFromSaleOfIntellectualPropertyRight_019c0012-66f4-7dde-8c33-20d9c80185b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialLiabilitiesAnnualRevenueFromSaleOfProductsDevelopedPeriod_019c0012-66f4-7ad1-b8b3-3dd19346a160" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialLiabilitiesAnnualRevenueFromSaleOfProductsDevelopedPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_abvx_OtherFinancialLiabilitiesAnnualRevenueFromSaleOfProductsDevelopedPeriod_019c0012-66f4-7ad1-b8b3-3dd19346a160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDevelopedPreTaxRevenueThreshold_019c0012-66f4-7f95-ab55-240902ed5e13" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDevelopedPreTaxRevenueThreshold"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDevelopedPreTaxRevenueThreshold_019c0012-66f4-7f95-ab55-240902ed5e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDeveloped_019c0012-66f4-7f91-8c25-6f9587d58a0f" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDeveloped"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDeveloped_019c0012-66f4-7f91-8c25-6f9587d58a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialLiabilitiesPayableAnnualRevenueFromSaleOfProductsDeveloped_019c0012-66f4-7720-ade6-b22fb965c580" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialLiabilitiesPayableAnnualRevenueFromSaleOfProductsDeveloped"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_abvx_OtherFinancialLiabilitiesPayableAnnualRevenueFromSaleOfProductsDeveloped_019c0012-66f4-7720-ade6-b22fb965c580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialLiabilitiesRepaymentPeriod_019c0012-66f4-709b-8b43-4cc13043ac96" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialLiabilitiesRepaymentPeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_abvx_OtherFinancialLiabilitiesRepaymentPeriod_019c0012-66f4-709b-8b43-4cc13043ac96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RepaymentsOfConditionalAdvances_019c0012-66f4-7ae4-916e-555657b9c3a8" xlink:href="abvx-20251231.xsd#abvx_RepaymentsOfConditionalAdvances"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_abvx_RepaymentsOfConditionalAdvances_019c0012-66f4-7ae4-916e-555657b9c3a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity_019c0012-8a04-712f-93da-9d795cd525b2" xlink:href="abvx-20251231.xsd#abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity_019c0012-8a04-712f-93da-9d795cd525b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CapitalCommitments_019c0012-b574-74a5-a0ed-0eb7695f6602" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CapitalCommitments"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems_019c0012-0441-7e13-b19e-b2809ee93f74" xlink:to="loc_ifrs-full_CapitalCommitments_019c0012-b574-74a5-a0ed-0eb7695f6602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/OffbalancesheetcommitmentsreceivedandcontingentassetsDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#OffbalancesheetcommitmentsreceivedandcontingentassetsDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/OffbalancesheetcommitmentsreceivedandcontingentassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_OffBalanceSheetCommitmentsAbstract_7ebde8c7-808a-470a-aae5-15f0a6615221" xlink:href="abvx-20251231.xsd#abvx_OffBalanceSheetCommitmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfCommitmentsReceivedTable_93a78c3e-0433-4e6d-b335-49c4132d7b23" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfCommitmentsReceivedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_OffBalanceSheetCommitmentsAbstract_7ebde8c7-808a-470a-aae5-15f0a6615221" xlink:to="loc_abvx_DisclosureOfCommitmentsReceivedTable_93a78c3e-0433-4e6d-b335-49c4132d7b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_d388beee-94fb-4600-ba3d-da1850cca49a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfCommitmentsReceivedTable_93a78c3e-0433-4e6d-b335-49c4132d7b23" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_d388beee-94fb-4600-ba3d-da1850cca49a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_c8f353ce-8653-41e0-a11d-048c9626cbb9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_d388beee-94fb-4600-ba3d-da1850cca49a" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_c8f353ce-8653-41e0-a11d-048c9626cbb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_RNPVIRConditionalAdvanceBPIMember_297920cf-1823-4f19-920e-2a0b76bd1553" xlink:href="abvx-20251231.xsd#abvx_RNPVIRConditionalAdvanceBPIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_c8f353ce-8653-41e0-a11d-048c9626cbb9" xlink:to="loc_abvx_RNPVIRConditionalAdvanceBPIMember_297920cf-1823-4f19-920e-2a0b76bd1553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_CARENAConditionalAdvanceBPIMember_29a6f2b9-bf98-4a30-8e92-65e906fb3762" xlink:href="abvx-20251231.xsd#abvx_CARENAConditionalAdvanceBPIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_c8f353ce-8653-41e0-a11d-048c9626cbb9" xlink:to="loc_abvx_CARENAConditionalAdvanceBPIMember_29a6f2b9-bf98-4a30-8e92-65e906fb3762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_46a90a92-70ed-4168-94b5-92ce803b0153" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfCommitmentsReceivedTable_93a78c3e-0433-4e6d-b335-49c4132d7b23" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_46a90a92-70ed-4168-94b5-92ce803b0153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_be095b72-f9c6-4013-8c65-48539d324618" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_46a90a92-70ed-4168-94b5-92ce803b0153" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_be095b72-f9c6-4013-8c65-48539d324618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingMember_98641ada-cdb0-4ef5-a125-1f3337d982ef" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_be095b72-f9c6-4013-8c65-48539d324618" xlink:to="loc_abvx_KreosClaretFinancingMember_98641ada-cdb0-4ef5-a125-1f3337d982ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_HeightsConvertibleNotesTrancheBMember_cc95cbb3-5316-4e20-9246-04dd75ca917d" xlink:href="abvx-20251231.xsd#abvx_HeightsConvertibleNotesTrancheBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_be095b72-f9c6-4013-8c65-48539d324618" xlink:to="loc_abvx_HeightsConvertibleNotesTrancheBMember_cc95cbb3-5316-4e20-9246-04dd75ca917d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_DisclosureOfCommitmentsReceivedLineItems_8d67ee55-0750-4d48-816a-daa2f019e7d4" xlink:href="abvx-20251231.xsd#abvx_DisclosureOfCommitmentsReceivedLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfCommitmentsReceivedTable_93a78c3e-0433-4e6d-b335-49c4132d7b23" xlink:to="loc_abvx_DisclosureOfCommitmentsReceivedLineItems_8d67ee55-0750-4d48-816a-daa2f019e7d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UndrawnBorrowingFacilities_0b0d3d49-885c-4029-9ee0-72ad23d3d7f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UndrawnBorrowingFacilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfCommitmentsReceivedLineItems_8d67ee55-0750-4d48-816a-daa2f019e7d4" xlink:to="loc_ifrs-full_UndrawnBorrowingFacilities_0b0d3d49-885c-4029-9ee0-72ad23d3d7f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfProjectsTerminated_f4614113-362e-4b19-afc8-36852878cc99" xlink:href="abvx-20251231.xsd#abvx_NumberOfProjectsTerminated"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_DisclosureOfCommitmentsReceivedLineItems_8d67ee55-0750-4d48-816a-daa2f019e7d4" xlink:to="loc_abvx_NumberOfProjectsTerminated_f4614113-362e-4b19-afc8-36852878cc99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" xlink:type="simple" xlink:href="abvx-20251231.xsd#ManagementandassessmentoffinancialrisksDetails"/>
  <link:presentationLink xlink:role="http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abvx_FinancialRiskManagementAbstract_adaef3f2-6818-41bf-ab9f-c4beaaa30028" xlink:href="abvx-20251231.xsd#abvx_FinancialRiskManagementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCreditRiskExposureTable_a02a0791-7ac7-4072-a071-ded250bb9e86" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfCreditRiskExposureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abvx_FinancialRiskManagementAbstract_adaef3f2-6818-41bf-ab9f-c4beaaa30028" xlink:to="loc_ifrs-full_DisclosureOfCreditRiskExposureTable_a02a0791-7ac7-4072-a071-ded250bb9e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_019c001b-755b-7f02-b92a-b8d22b20f3e3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureTable_a02a0791-7ac7-4072-a071-ded250bb9e86" xlink:to="loc_srt_CurrencyAxis_019c001b-755b-7f02-b92a-b8d22b20f3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_019c001b-755b-73f7-bcfa-58d352aeb2de" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_019c001b-755b-7f02-b92a-b8d22b20f3e3" xlink:to="loc_currency_AllCurrenciesDomain_019c001b-755b-73f7-bcfa-58d352aeb2de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_019c001b-755b-774b-8c0b-5b10122c36b7" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_USD"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_019c001b-755b-73f7-bcfa-58d352aeb2de" xlink:to="loc_currency_USD_019c001b-755b-774b-8c0b-5b10122c36b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_019c001b-755b-7b70-9678-ecd25b58f54e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureTable_a02a0791-7ac7-4072-a071-ded250bb9e86" xlink:to="loc_ifrs-full_TypesOfRisksAxis_019c001b-755b-7b70-9678-ecd25b58f54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksDomain_019c001b-755b-7982-a493-bf18707f0f1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfRisksDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_019c001b-755b-7b70-9678-ecd25b58f54e" xlink:to="loc_ifrs-full_TypesOfRisksDomain_019c001b-755b-7982-a493-bf18707f0f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember_019c001b-755b-7ffb-82a8-5acb8b8aa732" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksDomain_019c001b-755b-7982-a493-bf18707f0f1d" xlink:to="loc_ifrs-full_CurrencyRiskMember_019c001b-755b-7ffb-82a8-5acb8b8aa732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CreditRiskMember_019c001b-755b-768d-9fef-fc9bb7577084" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CreditRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksDomain_019c001b-755b-7982-a493-bf18707f0f1d" xlink:to="loc_ifrs-full_CreditRiskMember_019c001b-755b-768d-9fef-fc9bb7577084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_019c57a0-fcda-72b4-8b39-7df9565179fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureTable_a02a0791-7ac7-4072-a071-ded250bb9e86" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_019c57a0-fcda-72b4-8b39-7df9565179fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019c57a0-fcda-7474-96a1-1ecfb3dd81b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019c57a0-fcda-72b4-8b39-7df9565179fd" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019c57a0-fcda-7474-96a1-1ecfb3dd81b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember_019c57a0-fcda-7da6-bdbe-8d302be58654" xlink:href="abvx-20251231.xsd#abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019c57a0-fcda-7474-96a1-1ecfb3dd81b6" xlink:to="loc_abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember_019c57a0-fcda-7da6-bdbe-8d302be58654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_019c57a1-2af3-7567-a68f-2b60a1f9b8cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureTable_a02a0791-7ac7-4072-a071-ded250bb9e86" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_019c57a1-2af3-7567-a68f-2b60a1f9b8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesDomain_019c57a1-2af3-7fb6-a9af-00f3ce1829d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_019c57a1-2af3-7567-a68f-2b60a1f9b8cd" xlink:to="loc_ifrs-full_TypesOfInterestRatesDomain_019c57a1-2af3-7fb6-a9af-00f3ce1829d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_EuropeanCentralBankBaseRateMember_019c57a1-2af3-7e5f-ab04-30a62d146e6e" xlink:href="abvx-20251231.xsd#abvx_EuropeanCentralBankBaseRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInterestRatesDomain_019c57a1-2af3-7fb6-a9af-00f3ce1829d5" xlink:to="loc_abvx_EuropeanCentralBankBaseRateMember_019c57a1-2af3-7e5f-ab04-30a62d146e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_019c57a2-ee66-7099-809b-1cd6bd829546" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureTable_a02a0791-7ac7-4072-a071-ded250bb9e86" xlink:to="loc_ifrs-full_RangeAxis_019c57a2-ee66-7099-809b-1cd6bd829546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_019c57a2-ee66-7df4-a11d-cd921bdca89b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_019c57a2-ee66-7099-809b-1cd6bd829546" xlink:to="loc_ifrs-full_RangeDomain_019c57a2-ee66-7df4-a11d-cd921bdca89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_019c57a3-3799-77ea-8119-2fffa3df4b7c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_019c57a2-ee66-7df4-a11d-cd921bdca89b" xlink:to="loc_ifrs-full_TopOfRangeMember_019c57a3-3799-77ea-8119-2fffa3df4b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_019c57a4-25e6-73de-99de-d97edf4deb0a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_019c57a2-ee66-7df4-a11d-cd921bdca89b" xlink:to="loc_ifrs-full_BottomOfRangeMember_019c57a4-25e6-73de-99de-d97edf4deb0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_019c001b-755b-7d1b-b305-7cdd2e05533d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfCreditRiskExposureLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureTable_a02a0791-7ac7-4072-a071-ded250bb9e86" xlink:to="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_019c001b-755b-7d1b-b305-7cdd2e05533d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsAdjustmentToInterestRateBasis_019c57a0-fcda-7da3-a60c-105bcb711921" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsAdjustmentToInterestRateBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_019c001b-755b-7d1b-b305-7cdd2e05533d" xlink:to="loc_ifrs-full_BorrowingsAdjustmentToInterestRateBasis_019c57a0-fcda-7da3-a60c-105bcb711921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BorrowingsBasisInterestRate_019c57a1-a8d9-7158-9227-d36a8b41f9ea" xlink:href="abvx-20251231.xsd#abvx_BorrowingsBasisInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_019c001b-755b-7d1b-b305-7cdd2e05533d" xlink:to="loc_abvx_BorrowingsBasisInterestRate_019c57a1-a8d9-7158-9227-d36a8b41f9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_InterestRateCollarRange_019c57a3-9b2d-78d8-adf7-e65b67c6e845" xlink:href="abvx-20251231.xsd#abvx_InterestRateCollarRange"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_019c001b-755b-7d1b-b305-7cdd2e05533d" xlink:to="loc_abvx_InterestRateCollarRange_019c57a3-9b2d-78d8-adf7-e65b67c6e845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_019c001b-755b-7645-9c0a-b523c6ac2ee6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_019c001b-755b-7d1b-b305-7cdd2e05533d" xlink:to="loc_ifrs-full_Assets_019c001b-755b-7645-9c0a-b523c6ac2ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_019c001b-755b-733b-b249-6e3a9eebbfab" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_019c001b-755b-7d1b-b305-7cdd2e05533d" xlink:to="loc_ifrs-full_CashAndCashEquivalents_019c001b-755b-733b-b249-6e3a9eebbfab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties_019cfba9-a6ba-702f-8244-77b539395e81" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_019c001b-755b-7d1b-b305-7cdd2e05533d" xlink:to="loc_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties_019cfba9-a6ba-702f-8244-77b539395e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_019c001b-755b-7b0d-a4b1-1d016d37648f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_019c001b-755b-7d1b-b305-7cdd2e05533d" xlink:to="loc_ifrs-full_Liabilities_019c001b-755b-7b0d-a4b1-1d016d37648f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherPayablesToRelatedParties_019d1a27-a695-72fd-bf88-efe81dfbb18b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherPayablesToRelatedParties"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_019c001b-755b-7d1b-b305-7cdd2e05533d" xlink:to="loc_ifrs-full_TradeAndOtherPayablesToRelatedParties_019d1a27-a695-72fd-bf88-efe81dfbb18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent_019c001b-755b-77dd-91cc-e55af5618188" xlink:href="abvx-20251231.xsd#abvx_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_019c001b-755b-7d1b-b305-7cdd2e05533d" xlink:to="loc_abvx_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent_019c001b-755b-77dd-91cc-e55af5618188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SensitivityAnalysisForTypesOfMarketRisk10AdverseChangeInExchangeRateImpactOnForeignExchangeGainLoss_019c001b-755b-7b3d-8ece-fca866f0036c" xlink:href="abvx-20251231.xsd#abvx_SensitivityAnalysisForTypesOfMarketRisk10AdverseChangeInExchangeRateImpactOnForeignExchangeGainLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_019c001b-755b-7d1b-b305-7cdd2e05533d" xlink:to="loc_abvx_SensitivityAnalysisForTypesOfMarketRisk10AdverseChangeInExchangeRateImpactOnForeignExchangeGainLoss_019c001b-755b-7b3d-8ece-fca866f0036c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_SensitivityAnalysisForTypesOfMarketRisk10FavorableChangeInExchangeRateImpactOnForeignExchangeGainLoss_019c001b-755b-74fe-af00-fc9eeee58bf7" xlink:href="abvx-20251231.xsd#abvx_SensitivityAnalysisForTypesOfMarketRisk10FavorableChangeInExchangeRateImpactOnForeignExchangeGainLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_019c001b-755b-7d1b-b305-7cdd2e05533d" xlink:to="loc_abvx_SensitivityAnalysisForTypesOfMarketRisk10FavorableChangeInExchangeRateImpactOnForeignExchangeGainLoss_019c001b-755b-74fe-af00-fc9eeee58bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_NumberOfFinancialInstitutionsToMaintainCash_019c001b-755b-7d6e-b62f-f7e794d1a25c" xlink:href="abvx-20251231.xsd#abvx_NumberOfFinancialInstitutionsToMaintainCash"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_019c001b-755b-7d1b-b305-7cdd2e05533d" xlink:to="loc_abvx_NumberOfFinancialInstitutionsToMaintainCash_019c001b-755b-7d6e-b62f-f7e794d1a25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_BalancesWithBanksInExcessOfLegallyInsuredLimit_019c001b-755b-7abd-ac82-b565f790d5a6" xlink:href="abvx-20251231.xsd#abvx_BalancesWithBanksInExcessOfLegallyInsuredLimit"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_019c001b-755b-7d1b-b305-7cdd2e05533d" xlink:to="loc_abvx_BalancesWithBanksInExcessOfLegallyInsuredLimit_019c001b-755b-7abd-ac82-b565f790d5a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abvx_InvestmentsInMutualFundsAndStructuredNotes_019c57ac-9c30-7ef0-95ed-c507deb20efb" xlink:href="abvx-20251231.xsd#abvx_InvestmentsInMutualFundsAndStructuredNotes"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_019c001b-755b-7d1b-b305-7cdd2e05533d" xlink:to="loc_abvx_InvestmentsInMutualFundsAndStructuredNotes_019c57ac-9c30-7ef0-95ed-c507deb20efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>abvx-20251231_g1.gif
<TEXT>
begin 644 abvx-20251231_g1.gif
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MY]"C2Y].O;KUZ]BS:__?SKV[]^_@PXL?3[Z\^?/HTZM?S[Z]^_?PY0IP)D
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M".LF_\G??6QIC&R<RPIQ]T($3F4? [['@(=T7]2,Y8=0/B,%'\@:P$/FQR<
M!CY&O$TVO9$U_)C)?/#VR3=B\920OB S]WP"T$SQE'S;))A.@.?3_664C!GD
M 8#YZCN2^]T'X/4EJ7(3HL!GDM25LER:]4"T6>'ZB/H!D.+GPFYL6^!65*/
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M=]>/Z2<%[$!U*2(%FZ<B!SDFN*8/[R@094>&B!-)T:AT"\8[](IW &@P%1D
M*.*>\"IVQ>8,V_B1XWIU 0 %LJ*0')EWZ:>0%9EW7!> [ZHBX[H/[IEW"SB1
M'.D 9_4]&3H0K<JB33F6'+JDP%E[P7BK#!&"X%:<-XMF>TJJO->KNQF3?TB6
M7CJ67E9GZJ:8&K$&KQF7:C9Q2BEIWW"S2*JK5=:G<+8&_"9N;"9N-%MF3IL
M,[F57Y:JV#JK+GNE4X9N5LFF.AL \$";"">%F,F3;&:!QN%C16!E!C=F1SAF
M^N:DL:F26E80_W&+MM)JB)[9>TEX$:0HJ'4KLW>+MHI'A4=& );)FIG0@L!I
M<9U)AP#) 3'(?%<6HS"YB3T& R,WD__&904 >J)'B '@A&RJ9$H+G =AHBL'
M>8_V<AVHMT9+E@8!JDW9N<?*NR'Q;[+WJ!-X>0/!<M,*FU48N#R*$!^GDB+Q
MC*>4?L560 %8?@&(?OQH'Z)6:R(K$*>& .(7  ]@'\XP:ZQFC7E'CJF6?E#
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M <9PC=. 1Z5F;=A#"Z.,-\E_!F6;YJ(X.[GF9HL\V6]M+!R8W))FV6?\61
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M__,+B*58B?7C0 ;D0?[C0A9D0R;D0U;D1&9D1';D17[D1H;D29;D@M4')T"
M-0C+$VT"^.WDKTS1KY11K_SDPT2 3WY145;?3I;93^9DKS1E5 YE4EYE]'7E
M4X9E4@9E]GU3Q0S3SJS@HR7, T;1C*W,K2V&R_3EIY7@_VW,7O;,GB7:9M[,
M8,99!=[:%EW3<,#@ L#@#O[F9.[F;^9F;Q;GTB3G<"YG;_;F<M[F<6YG=89G
M<#;G=4[G>IYG=R;ATKQ;NBT 1)U;?P9H?I[;@19HQCWH@";<?T;HA39HAV[H
M@HYHAE9HB:YHBN94W@S=C1[=CN;HC_9HCRY5RQ4K*O]NJNRJ1'F2I--+735.
M':_JLL;)K6!"Q_D"+\CRI],K8^R*.J RZ>EB)Z!&/^WAHS0Z-F5C.(!,B_%E
MZJ9VZJ>&ZJB6ZJD.RP=HAP?09/0]T95=T8\E6I@M3/4-:Z]VTHS]:K ^V:\<
M:YG]:K-.V:U.ZY#56+;>6,2,3)R5S,/DT<8L4S7]WQ1MTE]V:VTF8,4<YF)H
MT</66,+F:V4&9@9>4D/M6&KPX'8N5 WVX&Z^;!/.[ _&;'9.X<_6[ X6;<_F
M;-#>; _N[-#&X,HF[7G(6[F5AKI-8D758=OV8=P68MTV8MZN;7[>;>#N;>'^
M;<V%XN-&[B:N7 (HOT;KG_[_>:E,VRWYLBTMY*D\XF*6.B(J)B.*:S1:JJE]
M3!T%).HQ=,9Z>FZR,J?TUK0NKB<,7&I*CN3YEN_ZKF3ZOF_[QN_]UN_^SN__
MYF\ ]V]#7@.KCH),1G"P3-&Z5E_X95^PK.M-%LL&;U_T_5@)QW 'U_ +)TL6
M%<W^E6"<9=-P>--A[M_1+&85O5@2+^R?%?'$[-DJO=(JE4PZ_>N,3> E!5H)
M+G%N#F%P]O%Z)DP@7U,AY^8C+_)M'G(D__%D7G)P;G+%)/(H?_(@5_(CC^<V
M1>=P6.@N!VY&S5LP_V$O%W/=)O-&#7,T'_,T]V<S9W,OG^T"D.+(#6F0MO,Z
MQ_,[_U_NW,P 5*)"/^=N[C(,W7N7X[HC[-&.T, ''RP8JV,F\H% S1IC;FNR
MR@L]]QH8\5&VQ/I&A0JC%&)%I^)I/Y(U!2"XN3.H@C+TJ+M0JG;U5X?U6)?U
M6:=J)[!J3;YJ3$8 74_?6_;PN$YE(UWEL+;?5([1\_7*4![V^37V7U=?98=1
M4Q9K+$U1R1[K9EYP:4Y,OZY,HRV 8=Y3P?[J"7Y1OU[P#C[L:G=:$X_, )93
M'^5KO39-&B9GT"[A>5_M>]]R>Z_A?>]F?6]G?O]W$_[W?@_X@C=AMD7WRD94
M'>[;AG?4?H#XAP=NV:YXO9UXBW]4B;]XCM_XC,?XCI_XD/_G<R;.S9%&>=U,
M^9-7^99G^9<G59>/>9A?^9FW^9H?:8W6S5[ZKO*#JBX[##8;.&J#/D5;&XO!
M!\BXNST*JWVR(WCA1?7SME!L'MO"(9JRF E$#RDP]94^'+&Y+KH"1+>*[E(7
ME^@2=8KCXSX^5W%U^W!]^Z^$^[F7^[IO>[J_>[N/^[SG^[WW>[S_>[T'_,$7
M_,+O>\(_?,,/_,1G_,5W?,1_?,6'_,F7_,IO?,J_?,N/_,SG_,WW?,S_?,T'
M?;PO\'8X< 30ATS.==0W_:M&=K4NV?]EZU$V=HR%X%8N60AV\,'6:L0^ZT_.
M6-T_7]['7RR]Y4X66?T]S!#W7QK_9]J=/7$$?E)GOM&G_64*-LR<G>::=5+'
M5%H:[_%BSMDA-^:\%N<?+TT?#_("4/]W/N?V/_]RAO_V9W_WI__Y?^?ZC_]W
M5O\F (@"Q0J$*R"P@+1^!> 99+A0(3R("A\N1#@Q(D6*#!,VE-BQ(D>-%R%:
M_(A18TF1% D0R,"R)4R7,F/2G&FS)LZ;.G/RW.D3)P%^_/8)(,IN']*C1=D5
MW><,Z5,!1Z-*E?HN@ *B1K<V?9I4*M*F3ND%P <E #T!:HT6K<K4*52D^Y2^
M#1#%*U.Z5>5.==KVZ%RP2KFRBQ) KE>D4M8HB)H7[E^[@8U*"8 @@!2X89-^
MW7ITS>&^_UW?0HX;EFF U*I7L[:,X/5KU[!CSX8M>_9MV[5I[\[-N[;OR[N%
M]QX>_+CQY,67 U?>G#ENY]&AZZ;^>_KS[-BW5]?>G?OU[^+#DR?NO3QRZ^;!
MKQ_?'KUT]^G/OZ\_G_U]]TX0M+/<[@%L3N@S6W^S%? :-:\UD6"""#2!8#&O
MA3,;-<4T6!N#"&2H(0(17G@AA[MEN&&"'L+V880(PF:B@Q,>&$X3$\)8(34Q
MQM@A-31:>*"%/=88SCP(\$@C O,D*)".0<+8XXTO%A/DBQTJV:*-+B(PX3P^
M_MB$CP7,0] \!3UIT)= P@@FF6D^6="77JH9IIMQ?KFFG&^RF?^FFW2VN:=
M;1J4YY=P,M2/0X-*TQ"BA1;03S\)*>HHHHQ""A*AD39:*:6*2HKI1IPN>JFB
M%0WZDDLOF7HJJJFJNBJKK;KZ*JJE]L664>6HU@1@IDU6564*Y-6674VDUHT
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MXN*0OKC&-+[QC',L=..6#"57*Q6 ^F3(EB5JY7TPU(Q:_;K PO;P,-Y:@S,
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M _\(P%@YU1FB!3L("Q0@T!%5$%BDD)$=F@)1#  1$ )(1:\D(>NQ3V>4AEO
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MQ5_ZH6O\QD=ZQ%^\QH<\Q7>\I&>ZR)?\R*,\HZ<\QI,\QR-ZH:-\Q1?ZRP^
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M2^[@CKABL#_D SW$CC_@\3[:XSW@,6" RPGXY;ALK8;<S=O8B?7PJ[^@[<(
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M0]8Q@U+0XW:YN^ MU0DDM]=;<]ME9)(']5;_ ^.9\3_HI;;*/5!3]9A5#5Z
M53/88((%@N*<(@I P!DGW+%3$B/ H0$> $.&G!LH?$,C:2OH@08* L.Q_];9
M&+I(AEZ'R"$J?A49;NWE4?A7);=[1^]G\+6$<&_>^I A&F"]"1F%HT BF'[E
M;Q?I*T/IF^5V[4$#6 RW!4+L*4/I'P =E%5&DPM'NRN.WD9?UW6%DM*=</)D
MR'FYJ%4*03KQ/$2@H4N@%2^G^!5ZIQ6@H00B$-&/DBHK ^41/PP67V6J+$<
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M7ZUFIP%W>,Y]@2,<!/B].O;PQEZX(8%*F?4WTQW Y.O>0[D9ZKZYO1"^0X)
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M'6+C5B)7ABL1$A605Q*!5(2%;\^A5N"@4C(!B[%15(QA4OQ4$2S!&"O5$MB
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MMMV,9 @ G-L 5YFE>4=E3D#I "22-Z<([6P:N;-1P/%A\;#A+3LI7)>7@C)
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M*U&YCP"LP9'E,B3C%<".#'?#](L/ !2Z!:P,GY[Q,W:R,TK,__H-9]CU"@@
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M$ERK& \I&O'(#+<JG3_["\H JN]('=WQCGU+-W+R,IIY,Y((@(\:LQ $&7N
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M0R/T/R=T,3CT/!AT$S@T-1#T13>T/X>S1%MT1 _T13]T04-T-Q^T0!? /!1
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M0XDB==H3:%2H38&RVR=@G[-]5ZWNPQ< ;).N6+5NS;K5_RJ] ,4"0-D7X$$
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MZ&9\H91[1CJ$JSE&YC(%8V<6Q396=A!M46@1=A@403HB%GL)4V>.ZS%SIC)
M:3IOMC$0-A'M5&6NE&295AB$NT\>\3D7F3A#\1=-]G]6QJ0083-<@6(?29"R
M9#*.(XZ#9C+MY#@GR6EXD[D$:;K].#$2ADPAUJ@SYJ2-%KU R6;!EZ6B6S6#
M!Q9=46DZ03%^IFE5TS6#,[I$%D^,]C"#!I.%,QT1IA0^@1D]&6?>^Q+^XB^
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MZ$:V*:G28QS;&[TH,XJDB+[+N+4E_#?\6"+\V2#80;=LR[8TR9 %$B 0\3<
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M6 ZUNM1RY@'-V)%B#2D$F-R!Q-CIJQL!;,-'/+\@7\TRZA9W##3'Z-',&>]
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MQ^3PX8QU.(8=MNL+%/81ER;@]'6\<5YC+@,=S@7&&?=SP'7L8IO!X$8WA5N
M:02#M] X(3G3$1YDM).7YB1O+VR%77*<XS?AA<<Z?C-K==BRO>WMJ4 _6E.
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M_XB-0"3!+(OH0K;>3CB%X[.*NZCI- 4^ZI4WQS- F>[L8HY__/-"V, >[&$
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MVVVW&<64$DTHK?0N3O+*"U.[.ME[$TOZDJ0O32V=Q57_6ELA1M193X7%EV*
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M\P5R1MA<A:&;GCFM89%'^^7!Y673MA0%0R&'4K .\"4 \[I),LROYNH7$AL
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M.Y_/%MVF#0W1ZP>GD.7.-5D_<?5^B$JJ!B@LK+)95+E71,GA6B4GU4N5ZEL
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MD*UACXC.RAJSB:CD!C!D;A1G5KQ1@#X>\(#<A'G_RF2V\@"P,:L'%*,!L[H
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MW)*N>)F7 ?.C,8PZ9U&6MU$8">N+AMBQ"TB)"NB-"1BOD<$79<$O5.JML)
M>W"++QL Y)HQ 9.;7 &;K9"6#%NBB3$6LZ"7F=,8H$C_,8/[+PSA%M4 )/Z:
M%H=8@PFPAPE(EI&IBR,D!T_,&:!8FR-\@,^3@(^)PP&H@.7ZK>?BK;E!+PUS
MEW.AF8?HQ&)0""?X,N4;@ E8EHR2CPI8B"BP #"#0F4AL0E#K]W"EJ?)0W_9
M"J-@%\]@&J PBI'P#*3HE9$)%G#,FK7)F+K(%F:A!@38L>\8M  @CEG!!B,#
M@2%[@-\#APL8LCU),XUJ@G""/C(;,H]"CNI@ _F(J),*/I/:$S/#CVOP)]H
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M8P-P.)9@%*G!39X+D+(,K3(WL)"(*C+B  'H/;, * 8@0P=^_%. L@:%G V
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M$^AC'3E\/6#! !>LX?( Z@YDS4?V8"-5RKI%H=D !%M3DA-.D$Q#.R M5F
M00^@P+@$.S30!0$_=,VFV;'!4TEK+'2-OPACG!784&55K\?MS@OP2\,!1;&Y
M;+!!@U0/+,3-3R0CTTYK3TB5G6H/G+SI-0/IY=5*#Z'L,$TW58WO33YCMQ,"
M)(.\AA-11&TA-AGK8][?3]CSD#67M^,W>P-8,+?_3Q:P ;,3?J^F<<:PEXV
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MJ4=($J24K$3(*25ID($44I6HI*1%0I*0C0RDFH)5)C%Y"4QKTA:COB0F^"G
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M&/)0@Y[T(&C%:$T4VA6!JG5<CK&'!?(2US5$H38N$<A,:-*:W?P5K#73&^J
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M2,&=: DK'=.I.,,:! "CX(FJ.<,XT4.FB <UO1*GS1H[X1.TJ!*P.,,[1(L
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MP\-.&#:%PS,:)S'K(BXTF#BF[LG6HP@E+S?T@_)46#\A]C=:)I)^"199(SZ
MKH/#;C02LS?!6+F(0S%S W#J<SG@;IGV-2\ 2IRB<RA,22OR*#IN&).,8@F#
M8SCO*SH0S&,5)#CIM3H<!+Y 9*>6I/5@STK>9ZHBJM $\JE8:I-]K_F*;W*-
M%'TJK:46ET0:*GEF),]FBD,C5'V8SW=F.4?W]FW?L:E<_VI'U6?TFO',BH>
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M;^[6/0F'6(<EF*=5A?B&5SDH6.>P(X*%#P%P#HU56?)V'JEJ($U J2^B@P*
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M!3<_8ZEN)A@_E;H  H(>3: @)Q19'X26E]65^T.JK^4,30 !R]N7 J C^#!
M68( B-5 8_(^!H(>K+H&!1< :Z"I?'4C/!)'Y1$%P7HC\B$AZ!$ 3;"_M6HB
M7W!:!"R\R)JL661QJL2;K$2;U-E*@^*@BG*<$M=XRR1)X 1&,Q1WHF)S\>*<
MG32:>$1SS:HH5W=S@(@P"=9VOO28FM1X_>F?_Z$T0[822EA48G1WH,ID1JGD
M1K8D12[\+5.T++@43:\40P?J<R\\P]I9B;\B3:52AD=7G-NTF762F:RY+U:G
M*)*41,:TFL/TFCN&+==I*"^<Q(-G0S+$=ANV=5:')F8WFRW<FBT<P2_<>#.$
MPM.X1I G>3%',D[D329RQU4T2G(4>* X*AAC<B:'3V$6M5][9F=6M^PX955V
M,[X7%A.53X\<3BVQ>O>H-+YG,P.U9B U-::L-1_U?3>U419*4+/74&X3HUCS
M3Q_ED N%43O:RJ;,C\0G%N_W4F:*%>/7?BKE-W1Q4X61?U(J.8?!S&(*%_;G
M.#E5?GY3%NK74Z?A?O^-,X%CI:;!$5:]T8!KBH"WUAKE7&Q5A<[$)E5W2KI6
M9:@7B)55>6W? ;RXZX%T]:?W7*C((PTGY)>-JEEPR;SC]F]%6,"&B:D*P XW
MTJN8):D&5V\HU#_S1JJ%-6]2<F_JLUA*<B)&Z#X$O;SNL='H$2 :4!]+ B.(
MA5<WT@VLFA\7H@'_YB'WT:OH,4("9*KJ<\ !4(8+%L> -"S@Y6(=RXOSE5L_
M5D2H2"@CVZW*VF'/PD;UVF :]C*<Y+(">RW3I8KJ]6$0$UZ\DM4PUHVS(B>?
M2"KX^DS>HBG-U(H: S LAF"]<C".U["(AXQ:YRBUB,6.R2J8QWC0LBS9-8W_
MWK*P$@9>2AU<M')?X9B&,D,N?"(J=?VQ]_*&QSAB#A:PS^JP##%<@CW(B!0Q
MV.4GWCC6E#UX5D1<V[A;0,V@;U1AR;(R!K'"L2DGM%)<1B1-8T1?5OP14RM.
M:79E7D:B6/NUJ(?<[-@S,L$U(,IZIE<3^+2BN/<5";F/<WO=:AMG>#NW93ND
M@Y8U82&DQ9=.@C.1=(M07.-0PL=]KZQ\2SJWQG<:TYRX1Z6X(XFXSER2AW.Y
MG$:3D0:Y+KDXD?%I .Y^=3%IFI,XL,:3QS8;M?&3$FAK2QF4KAO.->F3.TGA
M0TELN":G!1!7N9L]4YG/@2KBB%H]?7J[\JP<_" -_QEPEZE%A1;=EN>[#P%R
M(^? #LYK(-[+XQ&" /R1J0"2J3B.'T_BOS82(=W /N61Y/@@ *P:!?O@O/^;
MXP9R#ONQ) $@6!'2! *0Y+4*Y>O!JEHBOGW%JN;;'TMBOO,6!0%@0DHNY1+B
M'_1&6NP YU#@O# "!?ZK'W0>  ZMJH#9E;#E(P>\13>'R.1H8<<B2ZA$7#RT
M1B^\KP.JZ(*WA=$)20Y:QD$<=TYGPN^I<JS$GY:9G'C<=1Z!Q.,BM$-$=$AW
MF10G+5B'G*U418!D=UJ<=),YPA:\B.\YC9?"1KN2+37,=X <1'3'UG77FU/D
MFE\7<;RD*;-DQ[=)Z7=LP?^ U$C.V4+IZ2X "D=PY"Y?3')HA$NY]<5<O,B"
M37=SM$P.ZJ"2I$U+IA!V-&%W)T,V)'&MI#*2U$DXU$>+CG/+U)L9X<CO*#6P
MU[5&(Q-'DZ)%,V6FY\@HP?#%?:$@L:(CRC.OYWM)2E!ZMF8*]6<+236:_$^_
M1U))JLELIE-2HS59H=[?%WQ&^GNP7+8*B<K6['_Z9VI7>J5[H5/"3'Y.NJ5/
M2FKZ1QAE6A>JYJ3T%U25RSEYX3=?M500J,[B#%8(6(%5O_6N$3M1E?5I"H%U
MBE4#R!K>46V RE:#VKNVZ\^W>Y7[W%;),;Q">..$5>, $BGIX><-3;^Y*N0W
M B/_,@(C]]$$0#X@4G*I1 [GXX/C1*XC0_XDY-$?]. ,ZP E&XV_Z=&JSL"J
MM;K1]P$C<-[Y1&+F44Y:K.H@ Q?Z 4#3_N,,!_%90B( "-(?-)WW2][E 0(C
M&X+X]-$@'XTD4S)"Q;JK!SS;NO(O21:A\!)A?_(L@_Q$00LG IK9[LI>?R)T
M3DWK$Z=>U-@JJ DP?'V*^Q+7V<*S\_*%RS\MONC\=@UCL+VT+C..7^TFG)(R
M.<2P!+/K ($@2KN!"!"T>] .@3Z%:Q825!A (8*$41 X9.ADX4*-!A%T](CP
MHD>&!=<\T!B (D2/!O4Y40CRY<6$$UU.['@2H4B.'B4^_Z#IT2%+B0-SMCQ)
MTF;0EAL_&AR*DNG#@0FM^E3($.A.!#]'.@1+D*9&ASV3ZF-:-BO(I!*[-I1:
M%FK(@BK%8CQ8UZ!%N0:!1FT'4RI#C@@U)ARILN]+KH0--FE)#4$X!)*+23:(
M&0%D:I<A&Z0\V6.3SID1S*O,^7'+8AY;BV8MF71EVAXE2T8MV_9FV_,NH_:-
MH$!ES^%(%QM.F9IO:DV,4Q[._+=HZ9.;0\<M_+3HYZ<OBT[N'+QVRI?-+Q\?
MO4"X>04*S&./_'U\][[CAWN/W/C[]NS7VW^O/N1\<\\_]P+$3[[Y[",0O@#S
M\Z]!_1K$K[,"X"F@GPL+D$;##O_[Z7!###<,L40-1\00GA/=0W'%#2_T\,40
M74R1QA-7!)%&$3W\A@ ?,R  R!^#)+)('X<\,DDC@13RR":-)))))Z-<$LHG
MJ40R2W[V86<?9_818!\PV1& S#'#%+-+,<,LL\Q]I A  2Z;"* < :"($Y\
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MK1>9V3:F;!KJK9B=+9]E[*#EQ MQ6E5$$J([4*@E[0@U.J#_>T73-A)^4+'
MS63I.I>Z93&O%4:Z75'9;DA9=N2P15S ]5K0,]L0M5'<!KWC9F2]%>[!->4S
ML5M';FYH >6PW44V^B[9%MRJE=*GL^0TT>4]J3.UL1E>,YA3*TR(B9O1M4DY
M2\$F([7D)8BZ,;+.%:K#H#%J\C2><C6*24N=_-[1^;/"+)U9*E;[?1G#&<G
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M03QR7US71]2ECKJH'V)?5..G/0("<$H 9* ,BXK!KE+HJW5=DO]P33\&VFA
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MZH"?1-]3B5.[9]0(7>_3W2,?^ STH;GVZ-AR?3^2,/3M ^E/2P"T/X[D%?\
MFZ]QB+'=E98<VY+DSUV-R(C0GXV@B6#U4/U,EIN@$)K<R6.MR:!(U@G!T 6"
M8*"$8&&)H& E2@<&5F>Y%FF=2F@ED6<IT:@LD:8\$<#-X!758+^YBKYE2A+!
M5@[V0W&)_Q'%!9<1)MP801P:&=<1"M<:'2&O\(.N-(R[.)(=1<0HB0L[^$O"
M#%UT,80?25)"7-?%P%S1.=<>95(FD5(B2=(=X4M]K2'%W O&85++^=R[>!+
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M,"N;!."TU@@))>N1Z-^99*NU^LF,!"".& J;+*!DZ=J.:( &K .ZKO\KND)
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M:N@$TZ:1STA+FH=TE99CC_Q0C_A))$0VD-A[FHF8Y$26?8E(9/7P5;+YFHO
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MGGX*@*?.?J2AT\XZ[^23SSG[M#-//ONQ4U! !QW44#W]!-10)AWU<] ^%2U
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M2]AJLX^N.$4O4A" !NK"CJ@LP"]C3L!)%%BJF\X$8"B,HXL3G#&9L^FE&,Y
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M/=V8<T*_]S-*GE2_H6RT]V._I6&HG90_&=2TIW2-J[0T_NO+I>1+W2FWCYI
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M T)/L.--<36XM*-?W6K/->(BR&0@"BHZ.'(B_+RC\^K- ,6/=N"&Q%Z#**
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M']BZ$Y[#=4=Z U#._?1WM?/4SQX'3.!/P'$'[03P/8?CWWR"MQ(V2,! #"K
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M8ECCH ZF$@SNM!CV(>H&  0H&IJU#*;@-.CBX!+RI^AF*"LY@SYD[JJGFA/
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M'-EFC6T)CZ&8BY'_FL@FCX51;<[8C!TTHB]GW3KT_N-_H@,$ 8$9!!8D6)
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M:-N8Y6Z^QQ>7%#9\W@9'8*I5,YYY2^\U;03C&CWE1C"B,8N!-+#-#:S_1W#
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M@.NLA6"T!0$B*1.!R9=<R5]&B5QTR<,\Z93@+I6<4Y2P,SI1*9CDI>]:Z>U
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MG,-1F>BXXHJKTC17DU0P:8U'D73KH\/3G%1^7%4S/CI\86-Z*:":8]I)>FL
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M>U>\ @S@X[^;(36^40 %= :7ZOO>SN]C ?Q!#PHIZ%YVJ/!$F,]A@^H+^@!
M04'YB6H!H\0.%K)CO4I",@VA9,+W*( ="2Y@=QKT8RT&P '.,+X00[B -?0G
MP37\_7['&*$&_/]H#>MP4'QV:'H:@<>)X-GB%#\?  U,*0#; 1F*Q*2E]O<0
M/$<&,I)+='XEF\E:0P771<L&U((D:E91@U.DLDUBPQ!Q5BJM]$D_]33;5%:!
M=%$+F%2CY"AZA$F68E6L4E;P<DVK!%0/5Q",5"G\9RF=8D@-@PYV5%(#0 -V
M0@&ZX@3Z5!36X&S@T"]1!2Q$@8+X)! L90'Z\&T-48.FPFJ)DDX-^&F#4BZ
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MPU<C A!5Y*$!V[%Z$4(>TA<A_8%[0Z8>%$8>'(*6$ 1]@LD.0D(>4* ="!0
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M!=92(72;E<"OTZF+VG2OPZBHU3J*T72;FM>\L_YC5W9RG:CNWZAO47:>VJ@
M44#@P +P"O0S*-"@06D'I2$L&+%?@880(UY,:!#B1(T9'4I<B/$@1X4?^U7T
M&!%>PX03";S,0"!FS)<U9<*\B7,FSIH[:?+<J=/F3YL\BQKM>33IRWU-V345
MP$Y TWW.]DG=%U5KU:Q8IV*UZI1KUJY<GTZ-ZG3KU+!LK[:]*@ MU*=QR7X=
M&Q<L7;12O5[EBA?J8,%NR=I=^W>N5:QER?[=>[BNVL:-K6YE/#7 9LZ=/0=
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MSC\<KYFK.3C^P_!\)#TB.IS%6?G,3Y"P3Y.H"%$Z):@3I:AC)?\R9*LK3WB
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M2,U!-UE4Z:,K0EFH@#+H_= JA3+K.!6WQR=H3HL1&A1!K0J^HNI -P?5.]G
MPK<H;ZL^BDR/N'YJI7818,7J/2NKW+/]3<40S ^J<C7^32\JQV_6H_HIR-D>
M">G6MJ)51MTGC(P3S0<JBL*]6XUV9P\YNP:(< @04!M(\.! :DT**F1H<.#"
M@PXG/J16S.#$B DE(MSH$&-'!$W"640PKYC%@N%&(A X#T&Q B:+D439Q*1"
MERAMEI1Y$N9+GRT7TFR8DN7))C*II8PYD]K+>4W_H1(\*?-J :CA3FZ-.:]
M@:];P7H-%Q:LV'E;QWXM8%9M5J\TK9[M:A?M7+=<OT)UFW6O7KIEVQ:0UJ]?
MX7[2"L!##(\Q8\=@#1= 3+DQ9,B8&U^6G/GQ8\N2$7\&&YIRY\2)%8LN_*T
M@=@$,LR6;;LV[=NX8]/.S7MW;M^[?P._[5MX;]G)B3,GP,_9/NC[]K&+OD]
M=0'6M5N_S@[[=.Q1 GR!$B" ,W8!G+"3<G[Z^GU2UBC8IR" !OD!I.PS7]\Z
M._?EMT8 V#T0 #[GX<-. P'0(\!]4CC31 #=[$.@  D^((!Y33"(8(#[[3->
M=.L)T,UYVF''80 >NJ>!_P :[,>=,PFV"!Z+4@C@8'OGZ2@ =NY!D:"'UW77
MW8K>33>==,Z UV1XTU7WG7?G67DEEN<-Y$0[#ZR!P)<#>=EE.U^VHP^8"#@Q
MD)EH?NEEF@:%J>:9"+3#YD/M1-%.EW.F^2:7#[03* )HJHEGGVK"J6>=9.Z)
MY@,#[1FIG0$8M&:=>R(@*)Q_;GIGFI%BNJ>ECM8IJ*6;^GGHETX(^I"=KR(J
MZ)Z8=EIIK ,9"BN93KB9JZH&48JFK[&NBF:=>$YZ**-;[JIHF*[V2JR@K6Z)
M*Z.)?DHJ GN::2FMC!J*JD%D0@OKEWO6Z>JA:;KZ)K*I;EMFL.>"NN6BG,Y)
M;O^W]WX:::F&#AKIH[Q.>F<[J3)::L'X]HKGI_+Z*>V<=\H*Y[MXIBNNHHTN
M6RC$Q?IY*YU[%@PJR8)F;*>FL&)T$4$HP03233 7]+)!,#_T4DHS/Z2SS3)O
M)-! .A=TD\](OP31S"K!RM!.4A44% (R%?.20 *E]!)*:NW4LU187PTV4T-E
MW83,)UDD%4M+"53 U2;%S!1+*U&STMLR-P4W6?.T)17<7@L.U]7A%'YUWV85
MKI3B:(T5EN%PG7762)-'#CE8;B%>%^-G?25XYHI!AMAHE2W63VBI:V8:ZX^-
M?KKKJJ.>.6BF5U9[[+>;[MEIHUTVF32UV9;<<K\5K]S_\+HE+_SRS"-_'/+-
M,U<\;?P04!UU0!I))7C98X\D@"=:2>$[SJ!HZ7C?V=@B= JL(45[:S0!G1,!
M1($]=A0J"&$ "CCCWH8H=)_^36D\[X'.^A[P'?/T;T)6P@=TWG&>!Z0O22BB
M!SLH!+_Y> @\[KG2_00PG_-41W_C:]\$O].]*3&IA=X1@'2HLR3M4"E\*OK.
M=[*D0RNMJ5 ]W-2:PK0&6@$Q5T/4TT/\-,0>,HI22^Q2$%\5@#NM21\_!%.D
MOJ0/61UQ4D'4%:CTT24Y%0J*=YKBGRC5Q#5Q,4X__-(2\23&ELF1C% TB!6Q
MF$0LKLE2<'P &Q%@*3&&BU5._XR3#]D$L#&R+$UYO&.8QGC'1BJ2CW9*8[.&
M.) [YA&+9V2D&*6514[AL5G-(B2?2#D0-!*2C)L$F"?E!$@IB@E,=\IC%O,4
MJ6:A$6)FZI8E"?G%2,9)4$C,(QR!%<M>-C&3>EPEJ,BTRRB4T9->+"8;HYA(
M1IF,45&DXK5NB;(X'5&0H.JA)A^"3)8U$V2*Y!(PS:FI2::JB_Y"B$9N9K.8
M#60E')F(T"HR-X)$9&H[@]5-''(1K4E$:#V[F4CZ292-\,PI;Y,;WD:BT:V5
MI"$VJ<G:")J3M>VD:BT9:=6<AK>9R$TE6Z/)4XI!E*-D%"IIT4M,]*+3ND#N
M<V@!R_]6 (/3NE@%;T2-R5WXMI*CAL4KF;,(4(L*&+H81C*UB\SO5+.8T.P.
M,JG):NX^TQJP5N9UK=F,8\9J5=<8SWG)$TY;H5><Y4"/KL9QJUSM:M?E52])
MX7,A=%34'1Q&23OIH<YA80C#-=PO.HK%WO<("Z3 ;L<ZT+FL#*OCC 9U@[ M
M=%)V,.M8PTII1=EA!VC!!R3-8N=[F'V29K?W).R EK!3,NT+K],]Z>"0.]E[
M878RNSWP[7"'JO24PXI%+XSYLEW%,E:_J'7+4 UJ7-),%*;8Y:Y=!NQ2^!)B
MQ\IU()?9*6,)P]6MI%4KE>E+6.<EV<KL1"TQ5;=CU$R6PY#_]9!%'0Q?EWI5
M(4'5*F-2*EAW]%9T.R8O9L&I96;2U(!7)2V)N9=A9V1GQ#)L$#\B\E-X$N7&
M[A7A32JQF)N45[&Z^:Q:.4Q=U?+PF]K5S325BE+L5=-\_72P[E)SD\MJ\'G[
M-<8)O_*ZR$H9QQK%J?J&JU-PFM.H+/:F097W5J\B<I EA;!%:9>;^+7CJSX"
MT:5])*(095K.*J(WERW-91!]:$#/;&:!'E3."1D)2H1BM91,Y6L?)0C<[C;3
MF=[-SSQKB-7P;-*=L.1KU)!)Y$S*,Y8\NB4M]3-4(V<6O6CZ<'#!,^$>[>G'
M;8YP:B',J 4WEL(!-7!O>36K^Y85_U>+)7.V.XWN7J>[V:VU=H<Y756![;MA
MCRYWK%%=L5E7&EZ[;G;!4Q[Q='.\YL&5VM!NZ_.$)U>W$H=ZO"$M_FHXV.XA
MB; QY$Z&WD.D&/XVL#4$#_9X>Z0EA8=*&0P %%3$[BA%=DDUY)Z]:<B=WJJP
MM$KR-PV-Y+WA(KRP@B5M;A.N<--"'-S:2]+ 8;B/XNKP3EK\X8R?E<B1>Y*(
M> Q4-"VY84:N,I%STN0:J/RJ52FR6>TJ8S?I&,<ABE&9*JNY.4>)W"\B:L;O
MA/$S:WY%F/O8Y;J2YRFKB,2@?S.75J3R@\5)7XL)TL=-C.74J0[&EH.,YH#4
MH\W!2,V7T_^WQP_III<7V<,YACU:4^_DM?[8]%+N'94]GB,B.ZE%7DZ2C#'_
M>Q(GV7---M/+MAP[F9 X^*8G<TYXOWH9S[XI&DM24X(/Y[*F",C(+ZOGP\RE
M,@>_]EB)<;J]U-4WZ5BSHD%49QQ!2,_L=I V&R0B/*,]I2%"M(BJ620%T=L^
M]UE[IYWY)Y!.Z4(V&OV&8.TI)EV;14BB49S(+"Y3F=K6N$\5JOUY*3!5VT+;
M=GV>?6XO.?V;X^@"?[ \VG(C.35-E-*6KD2UJ3]]JE5,U5SD!5Y@SO_9Q4F@
M5628E6J$U6-DE5?Q3E?U#@-N1NM(X *Z#FKX3FEP5;0%QULYSP?_3D]QD*"W
M28^T14\)BJ!M/,<,;4=LM9"*= _&(9RY#1 )*0EE_=:3&,G *1QP49QWT$,
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M(5ZJE@O=4)(H)K\=893X90_^U<:5X95XG:9<D:$LGA0URQLM69'!DYN<7:0
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MN3O?YDG^\Q/<IC@<]&V?^!L?]"]?ZIO^P'\<^!M_];N#Z0$B  )] =H)/(A
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M&)MSR>/->?MO3AIMF@VHU&+)=6<;?[,=-Z!XV>WVU58_1845A5EMA2%4616
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M[JZ,W,9M.@1Y4A/UHFT6(D0"$-2*"0PGD%J3<$V*(9@WD!K#@P4%(F18K(#
M A;GA2LPKT !C@W#B6QX\>/(8AP_(MQ8$B7()AU'?J0IL&3'E"QGJO3XLF-&
MDS]_[A0*KX#1?D>5)H7']&-3I5"E.DTJS6G4HU2M8NVW%:G7 M(*5'UZ%>I6
ML5*52OM&( ,!N''=SH7[]FU=N7?IXM6;=^]=NW+Y[L7K-[#@P'WM[F.WS[&
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M@@@\E?NBRNI1-^^$"<)?BV2%;B#*T*:\,Y(!@=>I']['BBUDDIG*C: FDA"
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MDN'$24P[F]&8IR$ J%D*NLLQ;(*Q&T,*6EP+& .+JJFQ7 R:J'%%&KL:&BN
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M[4M\,[2+_+1<R>PLN2$<[9]3SI]42]OHZ5/>%W[)]=OLL6X5BO<]Y6Z'7#:
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MK!*,'04@4^ OLP3 )P!ZD%H+L; $0&L?#0*08JW!"LNJK+,&PRJ*Q[XJ*NP
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M)5DB*</JD5H"">^"Q9)B15F0Y5BD!<."Q<+PD54,<E9@+)!N*<A@S/34Q<;
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MB!9$1X].X(:CWMY3B,0-@01N@G"(/E@41BFG'-N.4,9H[,[.[/RDC/JK&P=
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M[<SQ@7]@',IV*6ND'&\"OAMU!0&DL%L0@#OTY/2 AX]S^*V#W'+[*!"?<\Z
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MT^I-"-C5 VA0R"XQZTT7N*036#6 -+&KD4@RDX;_Z+-'Y5=;6CJPHE"&- N
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M1XAR+END:U931)0'32 #33YS)2&F;#0#*0F&+B 9,V;B)R>S:[1V-!AC#Q3
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MZQ(P4>";LU2*F!0SH51[.!0&+J!>R\N':,N/R+7YQCLOY[:<2!:U^!3&(UB
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M2SW55%<Y;1764%T]-59594W5F7UV94< =O;150!?A>VU5V!WU74? 8[M58H
MGI5BGUZ???97? ( [=D%UGBV' &N5:K;86/"UM@H NCUG #P$8"> )IX5@%I
M]WEV#7B[\579?<YE!X)WZSU6WU^7?=8!!0+HAAUGI?BUUW?*C2E898M==M=A
M?]67UWR#K9C992LVMEAF)T966@%T92?99(U-%EANJ84YYF=;B@R!QZ[S2:..
M6%J#)XQ@(^D:KWX>* H+^)M@HC60^8ZB@R002)^&O*+ ) KL84,C;NRQIX('
M_RH8NF>?+F#C&)DT6J.A":(@"VR'++#9.9][%HKNC6R&KB*?MB/HJ9QY3FRV
MXP1ZJJ2:%2MI\([\?NUFOX6Z>:#>$D--9\)K[OFY@1[CZ>FS;*:AO@G.$MMO
ML:,6"H'"3]HM=>3J'N@JXTZBO'*\.:>)I+AM3IWQCU3G>26\JTH=ML&7BIHB
MU".3RW*"7AM*HMDZNGDIW6]V?G/:4S\]>NDJ%XKON%,72B/:/^);Y^EWX]NP
M\H=*K:+%X,_9==BD5U_GI[H3F_C-]^[.WGAW/_25A'&L,TF U#,?_2@P0..Q
M!WT@Z![QP = Z;G@>##X'@JNAS[EL<]_)' @$9$P1O\[ E&.)O2A&I6H1"EL
M$XD<5(P4HLA!+%S1AG#8( ;- T@2RE$X&L3#!3WH0"'RX8H6Q$(*R0A$2VH2
MBHC4)"@*:1X^-)*3?$@D*+X)2ULDDY%@1$4UM0F,4XS2DKBTQ2BQ48QFI&(Q
MQ)C%/$5J3X*Z8QWU:"D]2B-2>"R 'P.YQT@)4DZ+BI0=':5'0%J*4H8L)" 5
M><@"M(I4M0*5JF*5*E9U4E:KRN0G+PG*6XWR5J#BA\F,U;&!#8QD ?O5RO:Q
M+88=#%_8DM:YG'&M-3BC&P6[EA-V^2Q\L .7 GB6KLZ5RP#XZ@'K<H;J-,".
M<^%C7]!\UCLDYHR8"."745#_V+MX=2QG)O-@$ BG ECVK"8(X 'GZI:Q2*:K
M9%7,&</*6+Y$-D]\DG-7R/J8*_]I,8R5S* R0RBU?E.<WP0P?(4I3%N6 Q.J
M7,0:#@G)=9PP-?U<A ((B0C7KF$5_B"M*P]IQP0.PHUV?#0AUW$(-_+6CJUE
MHQT&<: &H-.<YLA/+GIC'T-O\CF-HHT@TYM*;99CEJ$T1F<ZTXWEK'.:ZYSE
MH7=K#?>P@Y:=.D2G37T 3E^ZG(FP#ZQ1,\[T6C,5AG:F)NQ;#$TZ A>.($6J
MU+D.2XIC5Y9H!C'Q4]Y"8<.^WF EJY83C$>V*IR%1J<I$=7K35P'5(RP)GS-
MZ0W[_Y0S$YL ]B>%->I;T?<YSKJFLKCY"U"+%QSM:.0YP3F,Y; BO,I6M:Q/
MK<J!OE,?]'2P/^@)$'P^^%O^#*B!##1/? "D7.."(SP/U(\]!N20YU[P($D3
M" DY1 T4_7!$.(10EVAX(P_)2$7A+88.5S2A#DVH2PI:+X?8&R/WENA%*]21
M$D^4HQ!YB8M2$E*0"A!&+O;W2D*R8H#7Y"8IM0F*3()2EF D7A^N:4D-UA*8
ML.3@ F.)BIB"U*(>%:A$52K$=YH3B1N52$DV2I(G=B2F6+QB%/?CDYG$)"<Q
MN2I;<7)6.J95*$GYJEGQ&%>NJJ<J3Z:O92498Q\SF;)4A_\Q74EA#0P3@)6E
M *Y]7.L!]PS  [X5 'K<$UY06$  -+ K9VE  -W<A[O8]4QVP0L?#@ASK\XL
M,F0&P)?O&B8]>L5*>*EY'[;,\AK423!B1C, #./7DC/V3Y15;&/S$I:^DDSI
M@59ZG$U6<L8\/2^3)32AP:O?<PIW.\.@VH L6;5&A!;"KCW@HVRP1A3 !@ZX
M;2UK3CB(-5(ZM  @PRM@:0@% O"?"3Q@ O: &V"BX!4)G$1^%[6'/J[AD*1-
M&]J1R9S>N)>8Q_#O;G5+S%P"J(_4/:9\?(F=Y@9;;JKX;'=Q"V#IYD<_=JN;
M(.B^&[TW(S[UP4]G<S&?5(I';_[_^:S@SRO>_=P7F-U)!'?*BQS=ZF?6G5H;
M@/0#C.Q"OK?C:6=WA<.-;?^'LXW?K-\131[P!BNVU%0<X,?1F\9IGC/8=&]_
ML$8.YS9SN;F6Y"Q^VPW.-(ZW M[-9D"E=TG8K=E6^XS=QS$ZSP?(\/'Y3WDZ
M'P@#]6/!\GP0%R#$3P0E2,'A:K ]'G2/?-P^GSODAX$E50_;![ .@=!00=E-
MKQ 5%*,8VJB$&W)0@S!40R4V$;P'VM$-*02D"EE(\4$$T1*;P"(DMI=&2@Q\
M&+$()RV^$4ZFY[ 5HT@F*M&1C4Z*8AE_9/HMI4F.K;_PZ+%D^MNOWDD$V*.D
M"#G\0-T1_Y*/,N2( 7FI0BKR^/"P(XO]2"D^BACZ@K(DD6U5Y"-ODONB-+*0
M1YDJ'Q?9Q]OG5"H#Y@QYEHS*JXQEE(&U3) =;,WI!!<[\.P$:243SPB0%ELZ
MF'70%0T(  40@',I)WQP!CIC!W>!@FMI F!I@ "  B:CI@#8!W]Y '8(IDKK
ME8,1)W8X)X6Y,F!1G4<K)V"!%PCX)XK9IXLAF8 :F9&1)969&'O2&("*09/)
M%U\Q-83Z#<"HJY3XG-;8JZ'[".*XJ 6"")4:G8G !GM(B*L9 (7PBI'*!GN0
MJ;&!-J,9@ FH 'O80IMRB J8BC5PB&O8"8YH0@2PAH.H (EH"/]L8"K%T S
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M(/,46>*T@EJ6@MHT&8P)!C29-(N6?3# +0NS8?HR>D&7:Q$T 3BSA?D5*UL
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M"O:9K>EXN/P$++(5+<4JQ^#4C4\T4,Q*JT9L"D[4PXBS#;TZPMB]+.IP\-B
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M*C7B',B7X1CLX-]7<-7<?BQZBH^CX5K_4;9#(K6&Q)C&WMI3"T>Y+XIA-3=
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MX0CI?(B%CL2HM5BN-9_-AL;(->OG5FWW!K'_304K\]@V3G=A[GA/;KY>A(5
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M7PQ^ 1(GH(#\%4.?:_71I]V"^QE88'W^(8A?. O2)^%_Q/5'X(0'TB=-/P7
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AYQUU;N=WCN=YKN=[SN=][N=_#NB!+NB#3NB%#N0! 0 [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>abvx-20251231_g10.gif
<TEXT>
begin 644 abvx-20251231_g10.gif
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M#<2#(#0R]J80:R8833A"^8I4_3 <'W#BTB CTQD WA4SH4U#(4H\MD)^:1W
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MP Z'G<Q]&^%ZK^A[__=^'_A]/_B(+OB%3_B(COA\?_B,G_B-O_B.'_F0/_F
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MR0"-*'@.N9"-GK>1X1$,(08YI4" D<I4FM)!)6CE*E\92U8.!!_]T, (<K0
M#>!R QU+)2__I]&@:6A@ 3.XR +Z,<Q:-DB6""K(!8S9 E4>)2(&\  O^[&
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MNW^8MB>2RNIJM0)#5A>H*J4J+>XMG;N9Z@ZVNX^94".%:JV&$4(DM$,>+AQ
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M^1\G;"]TJHCVBHCBX1#V80?_'$'"#%'0];I&%I$F#]BX[AK#CFM- &L( 36
M_+PN^-I#\KJ'"KC%?A@(,,0NB36 #=@F[((O-3P#7OHE;'PO7F*";#)%^+J
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MS;_J3!JNCY8T_VYV:CZW/KI]-5V/":I'GP&@8'XLJ%[UK"H>\I (0:)V7G/
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MU#(QXRWXH.[IL+(#-H )IF'ZW#(0\V\:S/\! +P2]O;2%^WP]1RS):J/]3S
M'$XP&3=0,<>-Z\R/ C[/(5'B VHN)>CQ!:-1&!E1)7ZOZ%@N_5;B @@/'#P
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MJH1]UC)<I,^L,&"Q/5VL8QGP#,>6P1 I4/]J82_+H&5X8!>WQ*QG/ZN59<R
M YV5BKY.BUI^P$>UJK78:5F+VMBZUK6MA:UM+=;:U<[VM4#)[6YQR]O@PE:V
MP.5M;8FKV^/ZMK?,12YSA^O;W!H 3K8I$&BO:RK$;L6Q^W!L9!\+7@:P8 ?8
M+6]DEO'4TIIWO>9%+P=PQU[*3+<GHXJO?3V$6'E>94+#Z"\[,I "%&# $,J
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MUF/9]>/SF3*=K_OD^WZ6?[SG?__X[[_^_<]__R>  4B  &B  WB !8B "ZB
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MR915B953:954J959>95&^9,[:),]1X).@0'AP  /T))J](XN&89W(9-+\0!
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M$K_R%)_R$U_Q#Y]WMYGR:)<,]G;S_YS+.=Y=SZ9+"?W62U&J0@[1<LZ^_ML
M8W7I\Z,4&E#%&7P4(SSG'= "\!#3$VVB1]\4X%"T ,#U:,VJ#A#3KT !00T
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MSX!"(#%\T0Q?!HO80VC KX<HH!\&.]ES*F2A?8'LHS1+S<( $-,H-@""_=
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MI&"O4( "S('@%D1  VG=" TT8&%XA(>CH5E "U[A@8?E5#Q=FT8#(M""\&B
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M)H&&3P- _QPI*T<4P)H&5,B!^%II3JT!<J&SE#\AK6).$1Z!FXJP'3E?*1+
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ML0^RD2@=A).DJ)*.'S8$ \\8E1 +_YF9\Y'G%1XP%O84 KY'-@ "(\A?0EH
M ?!Y0 (PH,9!1! "\"T -0TIP?=RXQS8,<%8"[A :, CKAE,2UT "(&Z-G#)
MWSP/ -!(Y6]H!2V%G($"$3!6)CT3'H2 1U:&7.9#<ID0)D!G!^J"ID70L;^%
MT"-D6C)9WA:4L)F8)2K?[$@X3S+.QTWHG(?Q6EC^]BATJK%H( ,,J!""!*'4
M,R'9]!D5?=0ILA5$  CQG\JTF4^$9%, XU#(1S( @!6P+)[KU!+"ZG2SE[US
MH@4K*$G&V<T'M7-G;((0.KN2-;[9PZ',7"E+,\..M)@)1P7-$8?^>;A')69!
M 'J91RTJ3O^; 72C!I/H2'5V*;D]A2> )! @ 8"$&0U5@@8#C)TZ55&H4O6B
M6>592"F(T1;-]*ID$T!.$6=5I!H)C#DZJL,VE%*(8,!RF&LI71L2O[KB=3P+
M8%5>ZWK7"_"+!@MX'@6<J3_Y*$0!,2V36I1DF*IT[&PP/915"BA9-;+,2R/#
MD58P>)?*@I5E_7$*01B"CH,Q)$OX60F/OMB_'_GI)*"ZIPY/B!\6#B2UZ6C:
M0F0+@&Q.%H.2+9EK(1M!O>QIN+B]R6U/&B0MLLP^4GF1%[W8U+YBEZY(T-11
MBP@YE'0V4B4,8Y[0TC;DEM>**@KHUZ[XVN"2L494_$_;BGJ2Z_[_I*E(")0(
MLR*3UIZP0DF*;8!A&\8P!2C!;663DEHKE@,I^,'K7<R (G03HRCI/ALZF&,E
M?*),T65+2TIK%:^;$%&A +'9I6L)5+SB%YMG>S!>)B(18@ *>,  3*  ##Q
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MT0B%$)?_ZJ^@+ ;IO2#_@HFO<N1]PJO(!!Z)GACOI:WR'I+ 4? %DUWQQ2<
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M!(,>   ,?8:0$!06 $S;P& 5(H$76A8&",G8B310@9?@E:$(V2M1&X+0$LS
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MG?@ F8 / D,ZK[P"+C5A1&B@V),W(-@5G3 ,"NO"(L5L!-:(P,U.U%AIBYD
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M)U]364XG-1LBR8GBI7B&][V44PDOA5? @ UED-E+3N2D#%-1^;<" #OX!R
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MO9&H?9&#!- ;$@!TP D $D -). ;+= !W=@<UQ":$B"?&I ;.T!U)AB"+=
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MKF*0YOD*NL+]9WM)G-1^NB$"A?_5<<N" *&!R84(YAHP 0!@![$0!!U&N&
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MO;M\:T^F@0 8 1\CE7PM->;VY+-//___!#1000<EM%!##T4T4447%0Z#?1A
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MV\,[O ZH@4.*D_^M$2-0=T)$VZ  34Q*<*B165FQL-0ULYO0C^C038S$S-"
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MW!C>SD\>XUP&8UW&XE[^8E\6XUT69F#.8$?*J5E]%'+:SP/IK&&I"];R#O'
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M'7"ZD#E1)>Z)#8"'H,"3#QV_YS6[$XT DM" N"2*O=B '4 Y[!T,E&MPMM
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MHP:1#FW(5&E3D?]1EQ9U6O7H5:I2H3ZUNM5K4K!3HX;]V$*@!'P/+2)4,,)
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M_L<IIC^":1)0&\"$V3,8< ::'Z61=D^KN;G:*JNU#91:;$A\)JMJM/&:@*D
M+/>9!CL-A YQQB5[W6O/)4#7&9]%8!RLG57[*FDL1;@DM]UZ^RVXX<K$8GH#
M*+D2.Q:99%]#E#%$V4/N&@3OO!;12X"\^*ZK_^^[^^9[[[_^VBMPO_$.;##"
MGFY$0E EFM17@*)"+!6I$XL:$4(/.KR026KM*]B@"XT 8(@6#P7PP?46K'*]
M!J_,;\LLZ^MRS##/+#/*+Z-\TI 022HNT$$+W5.Z0(:4KWSRK;4OJ4H[;>72
M43_=--13,WVUU%5K33776%N===<G ?DQ12,SU!?'"D^\5D4C/Z3611LP?&/
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MOD(+K*8,4M-*KJ1*4,!K"HM,P@XU2 =G;@NR,4$IPD,+R*!9A4#8B< $"I-
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M"&IIL\' L#*! 9A#LTE /ZSD!FS@&51K\VD -80 /E"J2L2JBMW)^%$#!)"
M1MX#!RKR-,2#=^HJ^EDR)M-L<=KQ!GK =Q R*(NRA/1P V>NC$EI ^"QAL0A
M!WH Z[ $B4XC/H"@!D3 HQC '5^ &BONDJ0O%4^S;;4#!D3#-6<S-F^S-F.
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M\NFE4U@9I=V'L7EZ;!OB6ICEBJN%"[MB)W53V_9A#[J'\S:ZQSN)D[,YUU!
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M% A2"%&088-I!0TT&%%0@4  &QH8*!BA@00 (SH6I!#R0H.$&0LV6 A PTH
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M#"?K_PNU1YWZ[J80.LA)R(+<U(Z@&:#$J $(/-A@@94H@#(EXX*T#2<%.FA
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M2%0M9%[!:!A"30SBB:H.)W; !'W$")N& BVJ'7YJI_XDFZI&RVY- N1! 21
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MK_GZK_W:K.,7K/TXBL=!D NB9066*19(1R:B.,JTZ"CBAHJ#9!A8 V0,/&8
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M8%4L*0M?/'"/LDQ* 4Z9R+_B8<'U*4 J#MS45B(@JZZ@"BP_"8$%Y?&!>VQ
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MT5>1:=1]$ZF1&"E^%K-&&*@8CS%Q[7: WY$"HY22 _B!BC$,!4B HV0>T"<
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M0"HT''_X7\Q,_PM  ?2_%;@:M8(2>X"[L6D' VA !WQ "'Q !C2 ":S !K1
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M35557556;557_WU56(U569U56JU56[U57,U57=U57NU57_U58 U681W63%4
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MG+9R*"_S,6=O-,]R,L]G,_=R,6?S9IYJ=W[G(I9FW\T 9J5='^]S/Z>1CQZ
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M4 ^CB$/,,(1VJAMB$57G1!<:IB A8-P.IJBO=1W&(43\ ' FDSWB%*0$D]#
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MR <<3H$/JP[,&?A Y4!\C8(H&0+,)T$1F;_$!=0%!O),.!*LH;KC@X'A+\Z
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MX(9GC82$)41(!!%8@9@^+0X)+(0^F?_B8!@@$PE$63'!D>A3O94 $36/7GT
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MWXF5%CVT #?)V>+04V:Z'Y#AI>KHV80E4FCPHX_0'F'LGFJ\91I]D87%A7K
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M@DI/[ZK4WK;PUIH#OD(*0(#JI')M($G 7W; 7$!S 2I <. #!DB 7T@ .&!
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M\G/N8K6Q*,;.=V-I\2L:4! 6@2Z!K"_G<P%_/";_6W$YT6!\<B\/J!9YH@$
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M0[@D0"6LR?T\0XW[J/Q$O%;-D%"E42," Q])2&M$$V%%H17M2Y9HT-4Q4*!
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M\W9FQ[-LU[1SGPYQ1_9ZM_=[Q_=\U_=]Y_=^]_=_!_B %_B!)_B"-WBU#0@
!.P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>abvx-20251231_g11.gif
<TEXT>
begin 644 abvx-20251231_g11.gif
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M2A#F>Q"U>^_6M5J,K8Q:[[6MO>_>2AF,>^^$YN\9YJ6MM6-:WN^UYN]*YA
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M2//ZU[X.-JQ[/6Q@%UO8LB9VLHV];&336MG/9G:HU08HYI:PE2AT"-;>T)8
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M$);CR: ?:J'A":+S*9XE_^J=CEA@B#>85.55+9.=;3%W#,&%#G.)Y2,FRX6
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MEEMJ+L:Q^(VT9 W1D>TDY9QC1A-C95)<ON(6I%(85')<1-:W"!XS%SDQ1\U
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MV,G+IU$<MS".2IS! UQF  3B(![?'Y62 USE0## !A3#/$A!B!#F('+**SR
M$+S:.2)$/\HGFZ$/15"B7RZ;B(3G&82(6RR#!&C%8.VA>2R#!\#9&]68+A;/
MZ D$6H9I/K;H0V:I634&&DB#Q(A)C_96?ZW?K+!4\\0,W=WH@8D;"'%+2=E6
M7SP*876- TD1C+ZICG0>;&9J3ZR5 [G7ZA#=H[*C78VDGWT51D7&C$*%VB$5
M+8X;UHPJ Q;*5U&?:_7%*W3 DSK F@9 *TK DW)$(_IJB&P4J",.(GGIP@-
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M*[?D1,VVK]XJZU!=]J0(4S(5[:U-JW"3T#^-S$-I&0PRI.4!I9SB*(!EI'G
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MSH*MK.9\^DC8RN6XE*,_(BTMXB960DM:8N5OQJY"T$)"T,GQ,N2<A. A9J1
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MK/>*NJA7!; +E2A]I@@ G#A^@JA_F*B,6@B-BA6+U"<.#O  ]) !$@ !2Y$
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M  7,L $1@ '.@ V_< 01( S.0 3_^3 -K0  VY &)N ,(6 !$1"T<%6?=<4
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M:26K:6"M_P-@ I4* -?@#(=,!\.;L24@Q^>P'N)P!)(\ !1@ LD 5Q5K5PS
M >.H#Q%@ !N0 239PHB%#';@QP-0#0U<R(ZLR&NURNA  0-P"(A 3\< QW(L
M!%9; ],PR:AJR1I@K9H\RXJEPH6ENL+7"Q(P#1. #2U)#P$*#1DP =B,P@V
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M5EW+K?;\JP. S120 52.0ZWZ% T0R$SA#8H:%7NN5J9*P-\ Z4UQ! Z0J45
MP&QEX'-E <H- -J TRR)#P\P ?"@6.*P ,/;%)0>5\%@J$\QZU'5 *] P-<@
M!*<YYW_XA0,^-H8-5F$KL'4"@QX*#@&>YV03L'22X*^WX'1%FM4Z /;L  .
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M23K19I!%_BB=]3J&#]($."CP@ WL_ZG (P8H@)2D!R;@;^JIBW# :JL=D*!
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M>E2H33,#$-CA63'-S8VW[7C&ML 73#5Z<JY4B%OT  '8!GY:!H"61>,:X0!
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M6,#+_[(N(%,>!6B2"KB&V>N(!PS"'*PK"MPKV$,2BHB&))P)HA,?HCN ?0@
MV+N #5@Z+&Q'8=RM6^P9=2.E7X#'90"R!2@58P2)(GB  /$&-%B4# @<_8%!
M1Y3!98P^&QP].(+&47M&98HM3903/!J #_@>#VB+CL@>C.L2/+!(C@K%?](/
M/'0 <<A# ^@%K!@TV!.?P]B !V  F]2'9;A)!K@*/LK'IZK% \I(5D(&-&"
M=X@(\1"R !HT#9B&3T,&"7@ LA&]L>)"+5$ AWS(Y[.',)PWB@P4E*2CU..9
M"QB !U@O"1@ *?"(U9.F;P0M-SRK<4Q$%J$(NU3%=+0>C/\3DE4T '"H"*6X
MO>(R08(#2D<*/IF   LH$ZTSAKF(B P( 9:L" C AGQ )ZS,$@C82JYLO@]@
M@$DTR;#4BTNL)U,3KP/2'G#0@ ?0GZ;Q.;L8RW@:17&<R?R@B"8<QP,0(XO
M$O- 0OUJDN(22D$B2E("!RD@C(YKR0U8!_WQ!JM9 *HTCPN8@&>(#%<$ &1<
M&<_\S )L%!XL30RA32T:L+7C&0C@@+1$&@[@I$]$IC&4M&5#K%YX!YQ1$)UP
M ..[0PC().NQ"?;#.SNT0[H3@L)$3O<QSAK:AL28/7  LB7AB(/#.ZK\S0R@
MAP?( *GQB*OK0[501O"LP69DDZ[_(T]5(\U?DC/C<8"?^)X-6)' 8Z^U!- @
M5%&(,L]X&L<7X<0D@3%5W ?Q:8#,U$M5U"4%0%)Q^"-:1$SHN<<+ @>05,5Z
M_(C#^#0'(".!X% -5 ]_7 8?FA,1'=$!\$HU 4L4E1,=M:*RM)EK2$AH.,@(
M&$GX>+X(D,VX@#374RP,Q, Q4\4$ (!?<*\#V,;?7#]RG E%)3G>@M) "41O
M4H!>2,(RBZ4SN%#!Q,(260 YRH_;TST)"!(Q_<[/E,2'P]$T#8O3Y#;M<U(K
MB88'J :ET,H(T(G*\T<!>(#N<X\U]2;;M*OQ&[\ $+U!0Y*6.0#WJXAT:#KR
MRP]B30EQE\  :&$V5W4>1W6@,Y&)"-VZ9ZC#D&@ JBP+")!%/(R *DF2CFO$
M+!G3$:4 :*"^5)T3:;PW:E10+?&&# "!BS 4<KT(?5!#7IW/YZK/O?J% QBA
MC]A+C-@/5534)%54JZM6FS),*V+0"TH "4@3ZER .)2 :^N("\ & 7 \W N'
M1-P #7@BDP%1L6!7\(S(AW.H>)63\1S_I]04'G&0  X8#62@AUH-R5U%CYJU
MJ5X=)P48UCG<3SM<S">BA7$03(I(1:D=LVFE-(D]/'MMI'I)DPW0!XM@2I"X
M@ Y8@!7Y'W-@  R(  E('N0953)M/C,]0%2=6:HHVEZR+HN5"PBHA@^8@ ?X
MB:.*S\ 00G"<2[&"O52\!]V,6EL=I73P %6\NPL0DKM+@&&]6I:ZUCV!U&R"
M@)N\@'XL"YS\(==Y!22L@ F8@ P0C=3:3"MQV5(5S5.EV^N;2-BJN*QU1 G0
M@ AX )\"0BOQFKG]IU^M*QXMBQHK"W.LTHJ@!4QC4FHMN=RE(Z21@ V8  _0
M"=?Y6(ZX1I>Y_T9:N#N/6-DYT<JW;;X2'5[:=8EY%3"\Q=Q V0" 10_=^JMP
M!-9,VI=H@( &B 9D\ H%2(=>8%X%21.=&&  ^, DO0<6(<Q&G5[ER=L*4@!M
MV ^!R,+]8-F/:%LYZ<SS'0"8S0J"7=\4_:B*LZ0?#%KY-"_U34D#\0;(/%IQ
MV-^*"  %MIXBH.#\"-0JC-Q4JEK4DN! T5P%4H!KH(5MR$(:6\60<5WW,-_S
MC=L)L5L2]@@JWJ"=8[OY76%E,S07T<)_$H?VVXH9:U@CO<8'2L^/@-[6HE@H
MXEQLHF!_]%:](%\Y@5VN-%49JN(L6=6T\ZUU:J<L,ZP6IB?;M"5NL=H4#<:F
MY95# "@"XUL  PE? +@&E85< PB' X@&>!"2I</#]8)?E!)B/B%B!7K))MDZ
M!%IDP7!B],!CKGS7BZB%0N;CY;GBWZI7!Z0 #I2F$2Y<#6H2]2#(#!8J X ]
M&C-CY"V1HQ4?!S * WB'J W,_,N/WA3ECC)EQL+F*XJ&7K@ (1""/ )CDE#7
MUR75/&8 0YTL6PZ,H;6G5E5-!Q+)1\-E99JF7P!BH<) !6@+HF,1I3B #TQ6
M '@U&CE',[ZZXN3FX^PH'YO<N+#C.('E991B!['G=L9HH_]2B;^;YRT>W%J.
M)TJ\" 70YW&"L6@03I$8/P@X P/(0P#X7U5$,@*6,9GH36>=:56TDP0U)#C.
M)F_ E0^S"PZ>:'1^R! 6PW9V#S_NP4QL)QOMXY FI^)-X*=MB;(P@*V882@J
MLXRQE>T43)T 4F76+Q#DB'00 $FE4BJ%,:4(DX667H J(7\4L@78ATZ,"HG^
M$HI>QF9\YZ6>BO;-)C2\H&Y4L1,EJOL53),.":+#0@BXATKM:K+QV/T(:VO&
MPDH.S L(S$(</^N!"Y5.0G$XHL+LZ"8BY08Z$RF @%X AP$./N[]BJ+FZZ->
M1CT6P\0.[*\ [&OR02W&TY;@Q!C_0:'!9BD]F6%%=&MU1KB#$[E?1#@LA.XK
M<F6+&&#)55J\,Q (&.2+.(,.F&F[TXETL+OU:LLFE6M]"H!J(3[,OA+K#@PH
M?EN+!H#ZY>TIFVHVI4:&M@CB_F]YCHNW5(MC1ES86[-[&>G"S8^^D1V\41S(
M=$)RKJI8*G"S0-;0GA'EG1!Q@(?^5BL(-IZ?IB:D\58DW !158N]]A(//M^D
MGB##Q6^Q:&IRPLB\$&,#WX<<)^"PB$V[4,$-R#T@"QV-_J62]-0Y!K(B2/(%
M6 <(R&O+G'#:HJ5@A8!?^&95S"3O)6"@\5^V_F<Q;HK&WK0/!QEMGAYQ@,<%
M> 5,.8-U_Z@6*0^)VO:2^7[;KV1G&<_3(F^@-A4+>%!=#>!=WHT 0<^ ]Y:*
M ?\* RB1!H%I_Z:1$-NKP[K52IKC)5]R?QRESZIF!B'H"A*'^,Z/H2BS8W8O
MEA%4+-QDZTF3FQ[U"S#']=L ]+;'$"\>U6Z@7XC#J6F  /#TI0KUO^CK+[0'
M?8#7/#=-_8:BU(1RJ B "!B :7B HV0 --B :M\ !K8+P86*>GF J;R\J/%V
M;_< #Y" 0"5<T-J(7E!R);]T=@>R47J'<&@OI!6\Z6ZB4$=@Q^9R1$62BIB]
MLKB ,B^U@1_B6F>C:]R&R([SD5CQ+G3Q9J3E8Z^S9&\B]-0+,V&3!GKP  >8
MTK](]*6"Q)38<U)2J#A\]TK'=$R?4/WR4B9/<BDX X:WF?@V &_P._R@0YW@
MC)5\H+H( )5)7,9E8]1R8Z0J> FZ1J Y2I2XA]UNB3E_>/J67?EY^HEO"1JW
M_]EX_HM[Z$D.Y9^9'PG@K8H&@$2O(/E(8HH#P/24KW2WE^3/^K&73_)7X"^$
M*\5T#/N\Z#B\9TZ$FU0FQH@!-D( 4%P\9-S\X#OK*:-]+% "Q<,T0WI,5.]Z
M2O,%P!2;!+)J\?6I,&?W$'8OI(#TO7JY..YKZG.]J#P)R !L>).\V/96XH8O
M'/FX%*O0NE5W;WNW[W6,\#1V=_?<OP!#[7T5Q$G=8^6X.  AV+IBQ+W<,W[<
MJTP&.=Y%54*B$RF&%8D+6(>>IJ-;OY\S<0!="G^DD8+ 5'%@-Y/;AL071WO:
M]6UJ8E'*<P 0 .'AT_:/AHI7^(#9!P" *. / ,&"!O\/(DRH<"'#A@X?0HPH
M\2">@0=H+5A0).-&CAHS0D!HX)7'C28_9CPCCF$O8P<<,(!PX(""B39O%MS&
MX,*% Q#.' "7[D" "S(9; "'\, % $S%/57@ ("X"]YH(DQ71$'(7ETAB/O5
M5 $#?3C/HDVK=FU$!PO8PHW+<,%4N7;OHH6 IBD !1L8 "BR(:3=,PP.X+UY
M8,* QHX?0X[\V!Z#F@4K)LZL>3/GSG']#?0L6C1=AZ4YO]R0(4($#PL@6,:[
M@0)?N XDXYX*.MKHWKXA[K)8\N/)C@$0*L!(?/G)5[$90G#P_+?#! MX-X2P
M8+K3XPIZ]56J #& 7N.Y.Y#_?J_O.P#@VBLX+DZ?$.KV[YNNBW^T@+?[_S]T
M %+&B./  PX@8P$#R-P%$WG[+8:;A+AQ4)E!P0&8H88;WE7 +MAQ&")";CF4
MCG^):?< :R%L< $R(&;&P !GR-7 !Q,^-I5 (O+(%FA.=50<2AV!==!(0P[7
MT07<):0=DQI"($%(#A@#@ ,01,,3 -H8M<"#!<TD#F\*C$F0 35Q!2-!)CX$
M004]PMG@B7'"=1J=_VF#E 4;>.F !=NHR58ZAP&H &,X(MJ8A07]>*>CC]X7
M3:.09FCG0B2BR,$ TRSCP#TS!0"!J$^RA<8 M;'E #>)#J#;+I3"BM"/!WB$
MY$D+_QQWD%1)UKK1*X$FM,UV<.8)'C(K(8,F> K\XN1!XH!S0 -3(N8I %I&
ME] 9#_35T[6(>6N4-G/&6FY""Z1C+DZ8JCL:4Z_5)%-BAGUY'P2'LBIAA088
M-&F[_P(LT8X!^\;N0I;:!4$$ U0S#0<?<$ !-S=R@*I=#- FUP44L"H   ,3
M3.=NO0A9\@+K$'802;S>NF2;P_96DP'1B)G= MZ@J913!'E#T 6+&C230^.M
M=!!,!&&5=$TTN1FRN@8[K1#"46NF *EK.5@HOOGB!LUS&%(=-L'^BIW8U".2
M*]=+;F74-MO2939.QG'=QJIN_@!;]G[^%.!4VT(.*42N!O;MRAQSZYSQ2T)H
M L";-@XLVY?DF4' $Y?;7*#-U=I5[M14"BP ;1$,;H &=S[UA9@W5<8'P"\T
M!8#>YZZO%(UEED&M-YQGE]V?[HE)Y3)>@]9K7X1<4P@T /[@\;OSD'J8]_-H
MY8Z01F'+^(I<#FB:J(ZA38]?-!@>$"3+("6T\JWF9W1!T81S&?\V;ED>O[>)
M;4/+!0LL<X'^Q1M$.^;IBP)6HA1QD.E:RB-(+YIR 'A 92SI L V9L*O@Z1#
M  UTB@.7)!77_25\/:I>V7@GPH=P17]<NL \)'"EJYV%7@ Z'O(B0YGG^&,7
M%SPA#_\C*?#U$"W_)BP("3FC@'O ,"T6.-7V\N6J(%*';]&@E>&6DY'!%:1P
MY@/<*Q1WD -(H6UB'&-& &@7 4'D9XA)VAK7R!68%<0 0G,=08J&'=MAQ6BS
M^T5-^$@5W*T#BAH:(M6**,BE;& "$J#+ B;P@'P(;WN$^@\-:_B8??4+B(?<
M9&= QDF)&)(@ O!88@X@)3 ]R $1L)A<,,;*M*3C1HGRF"<_J9D?D<QP@"N2
MRLYWDD@6I!=D_-L8S:@VP+3IE ZH5D@N0*-M:$,[Q>L%4>(5KYZYA(,)P=0%
MB^;%E5SC3;:T3RBC1DA;:D,"#XA)+_X"F^%-$D);LZ1CE$>V<>(3+O?,_Z?4
M]',P?]IE8Z140 8D0,2*968VKZ2>$Y>G27[*A6\ "  QK6B2=6"1(%I$$DH6
MD+BE,!(C12C.27HA/;A  )G5@>-"G&40 UQ%7A=0R@7 (RH &..5Z?! M\"%
MF H"( $0L Y$>X.N\/FNJ%\4 )\@P*<=%B:>^*DD/0=0(1R^2JE:O4GTMKK-
MM*$- %"-"P0XX!\%1& "!P5H*YD8EP9T#U'?\RI<QF>1+:X#<*]!B#C.D%=?
M+N 5[POF^3I:);R "!PJ+0BPI'F ,Q%F+.]<P *=8L8=GB>L"?$B;R!0'[IJ
MIIQ..R<^?Y;(RMI&JO>A*CUOR-A:@C:V!OFA;/\+<LZC)N8"'Z@+6@U*D 58
M8Z&E&H V&,*O"XY5(77SWO(^5%NT2)2*ZV..X)"C').AY*-?)";@.F+,L_A$
M5.)UP ;"*UXD(F1<HI+C6&C1+3*AX1FG<R!8#E!<!4AV)EXT2'J@DKK_CJ<O
M"Q#G<^5"VI")%I^](*\V3@I+U1IOGO3$)*/P5N "PY:NY4P/Y<RJT0APBR#<
MHU%B9"1<RQZ@%U>9XT(ND"]:/O3"$,$E^Z:+/H2(M%=6=!]"A,E1P'T7)PQ@
M@ 08P+]Q5& 9?-K DB< 3 "X%#H+ ,\7NW( VX6$*U1)\6.SL@!PA 1UJ!,+
M088L8[J!M81L]:K5%)#_7+C(\#^&JBIDO&:0#)]9J_OTZFW3S!;=.D <9P*Q
M6 &P (0FQE3"I961)< G!JR9OZMB[I[SO!#F^:V*0@K 8/MB(ET21PC. :FF
MA_1=QJ'I%V_.8DRL=B:9];&  -@ E0.( 9]>ZSC0A+*HOGR0*3ZHTXWKRS[V
M6Q!:^!,[@ZV*GRTMD0,3+*G.IAN$J7,O.COFJIF<-EV[6ML-1YHM9=6 .2;
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M+3'  ^A%&RI93TH$S]U?Z '=%_;?8NH. "J5 *Y% "0@<DQC04@ !Y ' W#
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M+P4!+MP#X" G:  7( " X)-B@P< "A\0=R$G;-,0+F.]J@^>;=TD6>[V35(
MS-_#B4L,X$! @PNO'$"@:?', ^&L+42(X&X"ZJ<,G!;'>$!@5/$(.3 P(-%?
M >_KV;=WC[7 KFCOZ5=U,/VB@+\>+TR00/L=" )\[B(&."B-. 8&T,ZAH80Z
M:I^C:"M*J/,F.@.=\0IJJ8"(ZOO0O?]H((JF%[GX8@M!B<2A)2R[[#JCK(G
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MY2TM AP+CNPV-[GX:"(&,-J8) , A$6L>!#8P(VTD9-.SF8VE(.+OFXD&]E
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M(*!^Y$;FU +F)(*SVJ9:V$*:'")'^"(>=Z0(*"(:U@%:8L37)H*V0N9P7D4
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MHL'$BB<0(^BON%7Z?BRQP,5OZ@?9GD(X%&!E$^;%HN$Q3I-@E3.'#NH^OL0
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M6#Y !._4-^H( ZHW(S8@ X)U)!Z#O$YB 2* &\(2HL%2HMM+HL-2HCG CB1
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M)H '1X+E!T"Y)D((*0)8$,Q@SS7V^&JJ4;XCX*4HI1LIJ0D@%DC8L(#! @,
M$BI<R+"APX<0(?KS%^W @HM%%F3<J/'B@@ -%=#RV+&(D(X=7REH:+$D2HX7
M>['$J/$DQXWK'(1D -( 0H?B # XT!#" @@0*EX0I\ !4P<K-S!8R?  4:H
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M<AMD^="F31I =J@9M\0F2A^%A-=+5J8$[T(MG0G3 C)5Y5&5<-,2DCYW$>6
M=]IH!X'A$WRF35Y9+<GD2D$9A>A5CP-PI.,'P+<06.)X9^F4('TNGQ"[:K6D
M61!8 -<[?Z$(P8EW5:"7 0TPT,L[/;?6^HD><WS6 NGX+GQ#N0YOO&7R87#
M,QO\PH $QCS)JEGB"$EB:DB=^ ZTU;YFU5D0<!OT^+UY]9]B"ABF.63280 U
M6@9@9[5#W(G]6$$'+\3 -' V]D[!WF"/PN;F&&_,YWT).8"Q>/4!"_A'.,>+
M(&B*5R"![4H"$>@*_PC, 0 !5&-^:(& S"#P@6>$BR$+&,#\4(,[:TWK-.M+
MR 7&=YN020DT]8E&+RP(  ,0T"&EL<H& B"IB$QC !G(0 22.($D:B #&M!
MBT@'$:/@Q2!X@0 "'Q,C'6;$3%_B&P1B"  NV8UM*A%3W#+B)IJTC2'@< G<
MP@BQA;CL'@HQP/HTUZ^B2, [%R#*!4 " 7@H"BD+V!&Z5E*G1A*E+C\,#0\?
M H$*Z.IP%TC2!1P0R(A @ &!E)6I7K./>[QC5?JX$T/XXA>W5"LUA9FD!/<B
MRUGNJG>VS*59GA< !O1K \I[DFCRMR33& -WQSS-J6CEPE+ZJ%X*$!\-O?\%
M+O^0*S+TL0R+), PB!@  QGPFUFTL2_*X.\L#*A&+=-R@ P8S"P)F :]*&.
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MY Y7B96C&#';&!W\M!+_Q)CPJ3&MJ)Y8F:&OT(R*$@'! QD6X7L;0 'S SO
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MBG\6$<NVC9*9I-JFQR^M$)O9QY,T0]IV 8*L$ ]@#SK- 65ILI%\-S;V"V=
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M:A?8,<4-012WW Y=,S===5F;"JD#C(&*T0[/Z"^U=@63UEAOC?ILLGXAZ.4
M%*F\+D>#<P2O(#PT5$@!?008^+7T,%6M 0XDB)@U##)X9;4+ -MM@7I38\ =
M,WG+@.+4$N  /MT87%2U ]"X(!K=W-N H&C$6[=GG_%"-[6.?.YE@@D80!II
M*4KU</\#%AU*]CEJ^7T'LHD<X.9@[0;B&0#W3IZ(GFE@6F@9*55[8)I"%8+
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M4H\:?SS%-ZY0C@YY0)'1C\I=[/$ 4NZ(*!N4=0BD09J<0OH(1'*(2.*RG3B
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M$^0RQV&X+<N<EF L];LDLG 0E/ &!3 /,F-'NMA%S8J)&KF J.@E2@D _FH
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MB-U"Q2?49:;!&BT>4@Z010G"2QP=JVK Q85(Q-I3*Q[[46 TK8Q^46),4M3
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MO7?&%#I,Z!1"1XA8D1V(IO+ A %BQY(M:Y8L.BG_1@?Z\T?2V[H&!G1"B/#
MFTH''#"LM:E 0H9M+2](@7#4P3.E*AE4&YD3@@8/>%->J+;AJ (&#N:F/,#@
MPM$%'"P0]%? Z]'4JE?CE-C2-6?6LH\RH ":I,, '+'>VVC5I-ZS9T<6<#OP
MP@!]L4].X-!W((8/"51ZX&"89 !G KY6>V R0H37 VJ21$X>I7F3#SXH1FF.
M SB"Q0$<6+"@B'W\0O#SMW^]HCAGY'<?@03BM\ 9SP'0RX#[#=C? @&4!,Z
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M!PB@%RTR!F@PFK21_&(#4RP)DSAE-WIU2J=B^A55'H(FTBW_)&\E"0 TPG&
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M%N'/"FW=?*!0A:@%^DA8)")K@Y=)V:X(IJV>=8$X^B#J[5*7WI&S((ZI5A!
MQ@%.?! (M-K5.FDB09XH)SJY^(Q-83#LI +@(H1PT=<#)MRP+UY&I>3IE0IQ
M\ :@W9$)CS2.GIKCF_"@=:S_83U"QN[T8M(G$ /\+$S3%=H!WO@*7<E.Q2@6
M5BLG^8$ ]8[&2^5D3::!C1R3,KD\-OR/"_*M'9KC X4'0"V(@JY@M@>7XCB#
M9./5V$/:2YCL^N;%D&S8@!FDC1^AR0%>63+MU],QYX$F4(S6,;DT0 C\>P@$
M2(9^<1P PU]^D$'6J8"''2!9].\83M& 8?BXC'5B:@F1N(];[FF>:N4 $*V?
M7$9$E(8D0F*@>.3N=,B(6.3_1@+;-LSR)$^&,G #U0GPU$=6HBXD@FB#2*0D
M*J-,K*\CV*[M<@)N4JHHCD+O$N)N8FIO9/ @K (K!&?=+,P#08PLS +9%D(;
M(H#9_RXBJ2PG[0IL #; CH:" UMEZK["PSC-=.!L(&(";#SO,G0D,U),UFIG
M(=C*(':'!P6"-:AL*>!M!MV!WD+)WA)"KPS"-_2MKPP"L([#&I(C^*[,^::,
M^G8)>[AC 5Y!"2%+$)\//"A.7@YB(V3+ 2! '."AF[II GRDYJ!I0N+$Y')I
M*?8G5IY"+@R@Y7CHC6;NS@3$-7H!>.9#0/*A C@D 120NX#.Z7A. %%KA"Y#
MYPZ G^Y'NH;H1LQD1Y:N(,0!TN;#@E;DZ:2P:IIQ \D+"K7NTRZJM<H.H$@(
MZF+FZ5:BM:!MOE@P)]HDU@K@Q":G 6Y0[>P..*0B\1)"'/\$+*?"Z"[0P&@6
M L$&;\%R"G*\0L*F"%H:;S XX!E,8]JDD4HH#S0P,-,6P[8(PAB::Z'$ZE8,
M(I%(+^X:2?_^#<8*8@-DC/5PZ2QNC'AF#RILCR"ZY?:VY0%8:2.!HER"3Y:B
M+!+G,/G$YY>**<K681#34 &&#V"2J2CZ R(\[IJRA2,N8)NZZ3$2<2#.3LVN
M[_HXPAL2P!0/@Q2!(BFNP>:6BP*9AF:2:P!%1&A&0B1\,75\YO]RD23,+KOF
M<"-R,2:XY+TL[0(/LB&H\"XGBNNH[R/(KKGTJ27(,JS$J:7 ,1P' -;@3J4$
MI (JQ]9@2B%D*AW!Z6]^+46";3#_?' @BDTI D (9<,:=.T(G6VDFDJ,F###
M]')*I/ 9,VVK NF]@(:05 =O8H=M.F/%?B2M; =W#$+=E.5W#.(SJRXAWD%:
M[@IY!,8!\.V*[+ @GF?(DJ-ZC$FRGF,=>I)[!JXY&BY6UL,ZW<,\H"L\9#)?
M,F\@-N A-$9 Y$,;**0KABV#H*E"OB]#R.QBWB$I?R2V]B%;'@8"SE,@TJ$V
M!J07#  >T".;9#$!@BL8=<:X2F(T!\+G;&1L .I%BJZ?(JC_(J-$> 2%D%%(
MG(YUA,XUHS O)2\A5Y.JT*LCQ&F$6 *U7$1G2M"(ZDR^5I %W^Y-=%,@O$$*
M@M+6],2__R*G(@"E[^31#"%" #;351HE'Q_ ][X(<M)I(MKH'Q&"_2Z3(3Z%
MCN*&,5<T,514G<J"[JB- 4Y'Q'!F1FGS_;@EQ1@)6!C 3 % L-#S RX3DYKE
MNPZ )(UGE$QRQ]0J)7-/R%K)]Y0#S=@#/,T#EW0I?/+%L=(#/*,O>]*#X,QG
M)YVC" YB&1X"@0P@'*;)M[:A^KIOG # 'I_B*=Q2;= N*<0!5NTBXQ3@'MY(
M(ZJ,)L!!5WGU&O9L_YSKHX3(&Y9AT' $)LC2 !/& JZ!NF(F%PG*'@D":;X&
M:,J&H^KRAL:4 TTT3&^(&KW&)!80,&WD9DC0) H331!S)TYJ(/]><&YB</!N
MK08E=(MZ+4##4DFYM$D/)'',0@.$*B&4S:C8Z"B^D2ZJ5&J8$"BFREL10PIG
M[B"?@3&&4S"W:T7"#33&[2)IAS?%L#1^L_6\):X*8JZ^"P*0L]YRHSD%@J_J
M4'CZ[>X* N ^0^#:8U&S,SNV ^*@PY<<3F>;[#R\,\H"D4ZHKP+ZTUT1PN,6
M1B8.('!(KG(80'-$3)  8(5&L2NBP6E])&*QLIS2!8(N ^I$E)XND2O*DDLD
M@Q8S]'X80(1")"9 1$>NBR , -)^QH6&CD2ZU52PRF$!(!H!M[SXLBBLT84F
M*-#Z;U8"X$Q&*D?;SK[@KASG9O'P9!W_H2+O,(+OMA2,]'4A"H<A+.!)J4@?
M#0]RE##"+#=+ _(B+JR.!A<QQC1;-Q!- _0 4,):S6162B+T1H]M%FE4@.7T
M7-)8/J"K$D)/U68-L]1/0PE0\^@D4VE0<8\@'H "AFQ2C"QH!]%1F0P1%P G
M"4(]P)<[]L5>RK<Y!,8 UD%CD'*; @0"'B8  C9U/G$([Q<\%,@CZL0G(>8C
M9,X!D"$KN D  F!B_!<>-9(@T& ;XBDF=(X7 Q EN8("$VIG$@88@[4E H"@
M]@5(YJ--G4[@'&HA):]O8S=K6O2B0)#4W*M6+#@%'W==<T(Q57-"'),R9V1>
M)=,&E>(J.C<S_UV77QG '4RX6>KW(!)@&I9!A^>F-*'E-.^""9."<\ TA0<C
MP2)6&K?J"@5"B)*.)/8V8[?N"\]JZSQ6(="-#$76(-HM>!;B.-V0((X'.%CV
M1Y[3.9W'WR(I.6KA7 QC$?_0& /9)@=14L$'4MNC%]+N$(<O0)?))%[)0\[%
M-1CD #S@;#D"*G_K:N=#:-4&NOK2%(7#+@Q@+^RH =PI 3QONX3N%@G"YRYC
M[,!X']H6+1-0Z$8H%W<D?S4/;SW/Z?86A4F%F*EM6[$XAYI4 <3I'<"NO<I6
M+F5S'\2)3@\S''>4>@H"&?1+7H<T<XW02./1\.;Q4!!&=*<!11TC O\\0)11
M\L'8:'4/0DOE*%2^-)D!8W;Y" H;4L1D-*'Z#V]$C]Q*C\46&"'L5" H:?62
MMXT/X/5&RGGI&'J=4U![K'H'X@&X8?=Z;R#P@ ]_LE$/Z7MO=CK.P$? @5*I
MP_GNX5*C;%V"%,14 Y4%8B^2PN.*-5L2M*4?PX"9\NX^(ILN($$YXAJZ(@"*
MDR#2 0URBY/5#!Q\56PKU-1&0K4F&-A.;49CY@#=UD.**-!,PH/?,H0_A,2"
MB'9C")DST)CQV50*=VZ^QEP'J;K$]4;(I+56#7+;S@6?$%X?\W(C,X\T]R)^
MX6_P%1>]H@A(:R&*^(B7-XD-(@'<(9R-5!\,XL)RQ"AS3*-AVUK3_[18G<T+
M-AVCK,NU%LTD,S86-P>K8XUM#$^# ]XJ(= 0CF4C9=]P9??JCLD*9EN26/00
MELC3D)VC.J@/X;2#/-AC'>IB:*5OLI@[.E3Z.?!5RZ+A'A["?[W! ;RAY)@6
MP!1&M*(!&0*@<4L+ M!CH\Z%H0FB >9L0#AB&XAZ*2 @''ZU(V5QTG+N1NHU
M6^Y)=9*N1(SA+,?,9[!Q%U&+&$$4+H/9O=B:-4';Z@2WL^]HA;/D<'.F@]@T
M"[<0B=:.AG%B'"?WQ*XT5H549B/DO_IFG"FEG(>XIP2O="4EI]C"*Z[4FEO7
M(KH4=B7<2HP-K25OV\"#U/YY=TOBD"[ 'O\(&B/EE$X3&@ \,K810GEK;"1!
M::)UK/:H=R7!Y5#KZ,@4F5V*[_@&D:2Y0WP'@GQ?FCO2$'V;>Q#7-XY0AB/$
MH1?LPFB8MJ<'))>R8D Z[AF>#(E$JO*"0O,$PC3$(1K@ 1;A@]2B;E; <C^X
MPJ['54P$W("A(1R"=266JRTKX.ZH-9CQZ69\_'/4^H0??,=)!5P1@IE?9.R$
M9FF<;H1IT[Q1-4OTFKYL^)[A%2F\>8<F<W-[+8@_5W2(& @Q@G%VB*@HFR(F
MYZ^SM*G<,7J;4" X&]4A F)//:N /'5$I(/DB9>],,G]P8["4(U]\[65](W?
M+:D/XAZF88X'HH[_[VTY=3M"\G@@Q@7U@-N8D#L[ J"/%" 0VUP(ECN1M[,Y
MQG,1T8?ZV&<O.+'6:LW)I50@X$%?T*X547$^: (L?&0?NNG\2,8;RL+] GC]
M3(9?3N8I%J"^"0(#(F@DV,O48!FKN1!&OT0"H(M&3D)M!5-('* 8[39$RZZL
M[Z'!I>1O';;4K;U4WCJQOD9NBV2]O)VY'!=:;KVDLKF@!Z+9(]XB^@N<$Q8B
M<K!S6=PBF!2)\-'6VGD?B]1(Y1F.MA1T![(@KWCIH:+'RY2?!P"GP"-N2TA&
MF^M6T2')=7-XF9PC6U[U9BPDF7>>(T#V_O3*WS3+O67+-U)[8U)G-36Y_PEL
ML5YZ 1!Y?!7YL%PZR?PEI@?"$6.K*Q* $I=B A+F$VVZG.1"8<BG/D"O%_KS
M%[IB_5"F(! NS]=38YKINC> 90RB@6\FUGWH(ZX:,Y.5<6VETB&  ?P,9TJ0
M++.; >X.;V/T0:O: K75L:W.Z.T>,2A\U:TQGOP/; "J_24#K]75PP>@78.B
MKV?-V1^%AQ-"I@!"'("!! L:/&@ 0P9:!P]>8 "AH42)"Q@<F$A0BK4%&#L"
M.)#AP46,"3AL4. 1HX(* @1B/(#F0K24$QT,V$"PEC^:/'OZ_ DT*( %#CPZ
M*"HTJ5*>&RA<. @!P@$(QJ3>>S<5PKT 4AO:'/\ -JQ8L47]%2#H@ /'COBF
M_3JXC$-$C ^F!3@($NE$"-4>-(R0P:, ;GH)TB+<T69A@N8XC)PX@0/*@68!
M!%BPH$AF(9D[:RXBY*Y!!0XP>\;\.?.Z"Y,+'D!].K7F!8\)OH8=N_,"AJ,7
M&%,@T!M*!<,G;^AU4-N&NZP!7+@8%0!6" M:#XQVX !Q ),5&. ^'(+U@4=3
M4F^X(0'7J>RC!K@G==EX -H@<H4_=>N]?>\WU!X( 1I2#5C55.]!@$QIR!GD
M  ,*0,!?A.^]MP]UBRV%X4!$9<AAAQ@)L):'(HY((HEG6-21 KU,Q1^$ 53(
M(H7OQ7A/C2M^]]($8^W_R"./'##P%D%FS420-_DX@&-0$$3P@#>)?7"24 I(
MD,$V'ET@Q5Q"5?1?0PQ4<V%/$&C@@9,875!-E%(R@&1'!S#P5%(+<("&D/X0
M66*>>O)4FD>8[0GH1 P,$*=K$!R(7U0'; 5CD@2E\T&/.Q95P$X#73   WA*
M%-E\&'"@34<>R(57!F&Z-HU?!T40@5$#A$@0IK V)&M##SC646/@7+?+3KW(
M=IIN"VA9$"W! HO9&?/U IL01:R#+&T'_9K;L6&.4]2# '*GG64 H&@0!"AV
MVRTX%WG3"W5=]F+,!1$YL \  ACCW%,0A.F !-QU!0%R_0(@%3SY-!135ED-
M_\C> 1AT^1#"\+U(U:$*=RGN<UQ!^#",!S1H)D$&O,( ,A=/"%^%[_T9J$]]
MILQR1QNV#'/,'C;8Y6C9Z1?Q@%2]LY567$$\E3?=YBAIT3O:XV!!_EA*T$H"
MS"=F!-C47%!:$D!-DS@;9'#&E1 IQ:5'#$PSJT\!A$0U0?"8A#5-1CK0]D P
M%1J431M\%\W2,N\]XLL8E<>WGF@0>E#)+QZ8U8$!U/R5T6"5Q71:91\4@CN.
M#O1I J)6\PY4IG:TI*H& 6848@P.<"I:J#<46=H#1=;QD+?E!JQH!2E@+.V<
MS79!D*[!EIINGW5Y&[#(%M'0,ASMDZT#XI!&'-S@%O]T374'C7>!]049(/1V
MO7QW@$#>$_LH3K_\!C!*[Z"470*3;Z#-5%7Q!Q_/ZUWM$$0]TT\A5?<<!Q4&
MQ,]%ZXE*@1R0C_$8H $,\(;_]N._&5DH<!/Q&P59MK(+:K!E"CC !;31MG1,
M3R(*$)I6\F.P$[IH/XJ3F.ODIB/'.>Y'CJK,[=AT.9^$KF,220L&XM81 U")
M;A+!$OE^XH!Q+ @C:(A ZLRC@0?LZDQI\AU0%(!#-\$);!QX!I'TML$P]B2#
M%>1(#L4H% 8X!2]<J0JC#@4C_.2P 1R0X0 $ (!*Q2I39RQ(IPZR@0_ 0U2D
M,D@ G(''E_3E+ZU*S*L<PHW_R17D I&TE3U>^$?*[.0 LPE>)S&SCB-^##>?
M3 TM7%(0<#CK6,&R'4&HQ4KA.<\@!JC 7":#RB2-$$ .N$#OF/<+!51'F+WX
MQ0;4Y)J[;&<['QD(<896K"<2Z0)"0$\"WHBX >WC !)@&$0.L(^>U:B !_ /
M5"QPC46]YQYNA%B"\L'#@=#"(D [%#;W@3(TDA&-);(@/_^9H5]<P /2F, &
MCCB0$[U01>ITD<\<JI\#&>.-R("F1 X00SL6+6D$Z=5H*@"WI(3NA73$7U"B
M0:57> VA8[3 "P&@$4G2!"0BZ4@"K($!5%Z1)3IM"$RT844D4F #+@$C0(]*
M$']Z_R4=2%4*--88KAJ]8Z+VQ!E[O*+1LNP"+6KQ2%N""@ )%'(B=7'E0/;Q
M.8Q 8!H>^$M@.C*8"]%B=7^CJT$ZP(%X'B23 *A,\6BG&[-RIS3 JQ90\6*:
M3H(F6$NT#?!6B2S>;$\?4T%)5[+SD8L@0P)ZU<8">H$2<8QDM/)<QWP.P-1[
M&>!>)>0(:;(#UJ/TXBD>M QK2,.=#;QO@.N$V'T69]*"U.=0]FQ/HLP9+@'2
M:*H/DXH#*J! !J8K8BR$ST0O\T2^+8"I3141B+H+WI] X $9P, #(L!1!NWR
M>MEAK@1;= \6K9!G55G<2S&JT:+]R#K^P(-!WB:./IJ'22QZ91 '<BJE(5XI
M2V!;[T&^E%W0D:G DTS3IG[BC2R^9(MRX@ TA%2 "X=W@__[](I,1RRH :C4
M( >8$(Q6"#&IY!!3=BS+62XU 'T(^'62.0@&/J YC(SJB" Y\4<6N:I&UK5L
MM<+(*RIYD =\ )-Y[>B=J.7)!4 6,Q  ZRL *ZPS]!0 S*I6\!8@6"P##UJR
M])('+^(N@#TE -?XR-0"B!)P?&>9PUGM O2*68\UK6GA.T@ZG'>1#G(+ *+5
M$ ,(MHT7X2=C^N&F-WU6(9T9:&('"<!!Y8=IJP0@017H$LB\44^)8BR?8BPQ
MBH.BU%?+6D,9J(XW'C !A(KPA09HKW[>\5 #V7,]C*I1]U*4T?P>+;T \.CM
M6+)CCXRT(R4%(D8,L(P,$)%67Y/_DX,-,C8C=^1L-<6(-J8AGZ0HX$A G)M2
M;(*&(!EUUA>,M4'L36^##(Z(!JB0R:RKE:E&C''<J'%?(]?5CE0NAW%A*4$\
MP#G/97>MHBL(Z1)CNJIEO(=V]2.N,,)7OR86S&B^'F%EP^;4O.*TA<T,LAHK
MMY:7<@'KN) P'5Z0D$%% N^ZB /N42_G1$5[!!&'N0Z G'U8EGT7.4"H#K(R
M!<RD.WO^Q7E\K)X!%=!_VPQNK+XY<$5IA3\ 3.X Z??KJVP,NK1D(#+LJ4V2
M8?>?^,ZW4<1M=X!.J=P+T$"8%)JB#H+3&-ML<7RMLJC$(VQQ*_((?I7M(P;4
MD&G.!*D!_Z*M5@(GYL"8GTA"M.V1^@C6)P+X=D&:&&&,[","'ICB1+21ILY/
M1 'ZX.Z&M^V3.3T#Q'FGH*L9A'=ZJW';+?8?PJP"(1D?Y!61DJ&-]_CHCO"5
M(($<I)#':AMG9/< 2!Z=DFOR2(,T>2*4G-RM7JBKZ^B1DZ2LUA'%<08V=V;+
MO%M683^IFRZ!8^;'FZ5!=/L1V=(["L : H5%%*-SP $>"T@<ZC(MBN(<< 8=
M$0$!N-< ?D& X?,< ' &%Q%IV_ ^P99\V&1IR0$1^S _!F0_5(%<!0$!%K -
M\F,_X70X":(/R !U])0H^V,5K!9&O]=[&%%W0?A/4])- Y$ Z/^%$HY",P"
M(]U!:,)&7,F7@L8 ;(H#'U(Q$DL8#>(P=3 $>3V27GEC*3CB#2S1&M^AAD[(
MAFOH*.\0 >: '%XH$&_1&M4F:&[8AGN((PJQ8C.AAETX3=VV)2CRA&S8&@S@
M#K#B$E#('<X$B1^!-@  B$XHB  R#0BFAYO(A\[$)I.QADLH-QPV$'0HB*9(
MAP!@178S$V2()S@B>T0(-A$VA'8W#E!5=/=!/Q  ;/75,XR350?'5>+V50<A
M5C@' &4E<1VQ#QS05JOR5A^R<?(TC5#7<8SQ<9!199J$'??7?B4W&KES/*BQ
M#F< 5G]%<L3CC3,G606Q 0S1"W5F=?O_ AQ=ME[N PY.HF@ HXHCT2 *)#24
MR&@#$23=85'DL1:.J(#1H  )4$V -$  1U7SPTWST3!R5R$3Q1[+H%?BD@ H
M]%!5X5RF96@.XE#T4Q7S4XLRLY*R.!#?Y9+@-270L"!+\FAO<DS'5% 2D),]
MZ9,\*0%!*902L Q#:91&B0$;P),^R91B%88\@@\^62E)F9/+, $=P)0^:0%9
MF9-H( $#H %4R95H\  #D %<B98^F6T<\ !IN0%D20]M695SV9/+0)=O.0$3
ML)1HB089\ $@T)-B>4QHD)9HX $4$ %N299FZ9:-B0%YV9C9)I<;()@YR0!I
MR0 Z$@(Y62E9_RD!N!>3&0*$:!%\LS8H7<-B/5,@VO1&!S!'=>1\?75CSL%'
MTM=C__<!3S<10U8J1L9]%4<0K.(J3!9^Y =E!O$ EV2;K:$39/89]!<L$#!F
MN0-8O#-F968\K30M,A<L2F4 ZT OD6@  G%Y [%>]Z(-K+$QQ+$ S^, %W%,
MIQ41%04 X !TVB(.[[ B\]$GQ;& CP@ SX4>VN P"&,_)2A^]D&#DW8QY82
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M!G@ -HI;8P"$6BG^UEE] :9%XGT'AA5==4E^[8 ((&CMVFKUM4<:<O?UN#6
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MZ&%N?HA2#@@1B13@9M'R>4^<I1"H0S5<=!2P  E\Y *HBDXX?I2!_P'M QP
M9W6\\0#]E%.<$Z#0.JNCC1]-H $B!8X!],$0#WR1J$5#I*Z*L-:]'8"A#87
M#8NWQM0HH*[!.4!-<Q,-",SU7 $0[+GV^K< $,Q7!U1-7_%J&W'< QG!T6M%
M7]-/R[[&&W[-36"#XXW"KJ:R?-T'4W]S6-\8P+.&@X!IN=96N/^B1G>QI>T#
M+[ .(5P@L[TYZ@0DL!T'A/8WX-C E28@5.8P$B,;4"MTA, 8!NS6</KHC%>A
MHP , &6LT;G  _#Q3<[6=E(_5<ULR2I>YL"O:<K+&GNQYEZMQ5>^3T-O?>TK
M/_+"%;;W7:L"A. !"8!D <*ES3L>((%[(.H"\R"=,QSP6.,L ,#.D$!SG7,
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MZ^Z=C[1BXAS  ;K-ZP(V ($%S,73P;G  J:8FG$RX ",CFYQHG$!!UCXQ!>
M0 <BL(!L@RVXJCGQ'1\ 2>.(F]RH^46(O;$ &,.9V,T9L^TF?G&,9USC0V4F
M?V>[<;'UMMX8_Y8WH0>\@7H+1P&GP6Z,60.X!Q!85VKR0' WA:YE*. "BKF
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MW@B ]^" J-H;!N( $O,-8:$0//26'QD (4 B,'F X;L-"AH =/@ZWP"8ANA
M(G0'"AG"UY#%+\R-"R"38&0<,)& @&L AIB !.,MKK(&Z^HL,*&IR\F/#\A
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M59H 69J B/04#F/,\U* "?" >1@ K>JL:>@?#BC$VWB[$,K&VXB^'14DFYH
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MNHR&I#I=W*VVS-@ B1-'VI$E<VACB+N_;A&'0@, ",B :E#8I<T,:^T6 ?B
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MH-)K)FE#*NYP  T@1TT<NH?U#4X.L52M9:R-C0T(!XP5+0RCX:& !\-C "D
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M!TPP@&?R3=!80@8H<$]$83V@W&L?:5F0 9(2= T'$5QXP 8:O-G1 51R%9^
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M @\ N=16$:!YD+CFM/O3/O.$0.RV'L!-=D\7.//SQ&A,$'=0"M"R 087Z)J
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M$=YV@ $5:*R($C"!>71  IF%,J5GTM2$:++2%XF. XH$@;&HT0#26#!*E#6
MJ  %&MP1B6S5(L<&))4V,C;@TAB" 8YJDS\GPT@# $@;T%# ,PJ8JV/X9F,
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MH]!9!I!96!0HI=WI#HYHG2Y1#.Y$BNC#5/Q( UR PUG <&+- H1 %'W0*V0
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MF"A  $CP3S@ !ULP&E &..Q#+R;%7BR  *#-GTA-I_$CAG )/:#!V"V /DR
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M041 !YS>SCK-I%P%_5F&%6W%UUQ(;YRX8P">CSL5C7^EC-OY"F8'<*A%BWA
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MW   9YD-O)E+@R.%@F !ZCHZ0 (.-%C -*%D>B!/AR"08 )L/&C SY_NBV
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M "M3N=A;&  ";*RN7K)IB 4<)#5,O0DB?B&(-#C@ ;\M[@ ,,$>?(/(_@2C
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M[%O*?>@T4YJ'G%4B"SA7!A@0*;@,_"4O[ND)0Q"WP(#TZ0.CB',MH*R'P&,
M \B'K@% +9!(IWL39B*7]@8\GT3#A[V0P <&EIG,1N0:&1B F BBFSQYH_(0
M44U/!4!A*.K#UC+D+^)O1Y A&@X ']#JZH1C(,2A/0JB0R#.'L*A(N3N1L(&
MRJ1&9MS-(;1A_F8C-!YD+E[B  1@:3BB.S*@D !@JMIO69I%UIIBT;@! _1%
M :"A&L0)A68#-NPNC_Q$&R0/BO(A-V8D* S_0.[@2TD,8*1R!^@ZJ#](Q$^H
M)  <H%P\[?: ) M[@MVVT N5I#>,JU62C1LFX.)8!:JJ+2C2P5\X#S0>(,^&
M@FN@YUT" -I2;BD40!O@ 3>8Q> R0W54Y:[<\ L+T>^,XN] 1R:VR_2ZHRS,
MBZ\P12ORHAK4:BO\(F[LI2&PH>Q(:P/H80.PP6G.B +P@1O8KOLBX(XD(%*T
MR4@H(MR0Q1UD39H*K_'ZJ -&2EV$P/_TCR[FJDIP1!IDJ2(H*DPHQW(< FN"
MS,V8KK)RZB$RA)ETPU9 HDLF1Q<EP@'R820.@%-R Q\RHPL!(*B*"B+H0G=^
MBV.V8@".I%9X#@#@_\%?2F6?_.07Y"]$?L$F_((Z+&#N3(4!%:T($@4 S.\M
M$@?$5D@L>HHOS*&'MJ?F/(4/F^NF)&(:UH:.<FCD%F!R*N!&T !KZL+T#!%9
M.) D'>*V3E(E?>0":*95A&4"]BNWN&,J8$("/* B=P*-4(@0+65R9!*3-N !
M\+!URN)*$G$H?@%3SG E55+P(&KW0$>9B.4!OI$@-@I6YDXK^N()^TJ.(N2Z
MJ.4S]A&_(((7(=#"PB+[-J 50P-4*@ B&,!H3(IJWNQ4&F\^/B!(\",M(R+,
M/.#+%&T"["$;(Z(!.%$:Y$@#S.$A)@1 3$HH S,Y),.U\(%:-DP!I, #1/]B
M*RB'6&1%'%!+>P;@&7*)2S[ ^@3()*H2(LQFTJ)#5-8%(RH@;@9K+4X%5.)C
M#K?+4OS%49[%[1C-W#C 'C)*I9YA;G (?ZXAVACLM 9@QB#"="AB_28 'SX@
M)EUK ,JJ*:4F*KUP'+M3/'5" 49224 "*'/+ &2"'A)%)KZS(SZ$0!3@VE;P
M^KRF1["%:?;&UB! ]#P@552%6;IM/$DR/&E,MNXABURF"&!QR"K"0*Q/</2R
M_A1+P70N[LP1NWRO(C)B(*(C+?MB'<"C&AP &1* (CAH>]:%:2KEA#8L\.)(
M723@%"7")_(B JZ!'GPP+3@T+KEA;QP 'A^L(^;_@P&LP7(@$+=J)2L.8"+5
M1=FZ;_X:D1NFXU$\(GRPK*4<@B[2<^U&$0"\01KL 9GZ(J/> 0)&,APVYD6^
M"C?NPU@60 -D3:5J;W.TH5A(30HR($ A8APX0"&N3!S:S!P, !DF '#&\T!/
M\BD+U%$?54AX[0% 0 ).QTX]HDF08QOH@7G2X6W,,R@*@AXH]3ML:'(\@"F3
MY#Y8$U*]L%&],[>*PU^J81P@( %5;I-R8_Z$4Z9P@UIN9 '0IB7J9#Z,,S,>
MXBK&X<%:4K],@TJ>X:S0#94XX - X%W612 B2RQZ1GHV:K$: @+D*$)#9!DT
M+K7PR;PX: (^8&\D8"YUC\(#!B "U,4ZNB<!,'1=VN5&7D1A!@ -U&4^'J,7
MEI$V\,FYEF6S?H\A/<(W&!-'#J1[OD4<QV$!8B3^,, <GI @8-.D>G$KM$$-
MX^<=[F0 :+-@I^^M;,.'',(X^N-2714^LW!16Y5F:]9\+L !4+1'7FIU9*(#
M3 45?43]O*92'XLKH"%Z9D6;#@!4;=;4_V8V+$Q2HB   [ B A".)2;I1#@$
M0WEBO,3! ":+1XUB (P5(JXA N*C5N;N3IZA*L0"1L]V(Z3"; =B&Z0C(O("
M+7#4),"/():F4FIDFMBU2+2/+TY'/8;,.)C+(VJ#.],&4[KG J;A.P)@:>ZD
M1.LOPX*DS:0/7^)F/F2E2<JB.\RAP ;" R* ^_(V9Z!TY/;C.0RD&K0%*@)
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M[N>>[NO>[A\ &^Y>[_4^[]>^[]7^[R<G\/&>[0??\ L?\=?>-RQ@S_G\>07
MW,M>\B>?WB/?WN>=\G\D+^:N6<;(\S\?]$-?]$>?]$O?]$\?]5-?]3M?]5O?
M]:OE\V'?\V5_C&B_/*YV]G&_]G7_]F.?]VF_6D*EZ_F\LS/?^(]?O#&_U,@>
M^9>BPU0" A( 'J)_^J6?^J_?^K._^K<?^[E?^[M@'_R_7_R]G_S#O_S''_R]
M/P&N(0':W_W?'_[C7_[GG_[;?_JG'P*J_QJB/__['R @P(.0X!I!@0@1%CPX
M<*!"@PD0.ARX,*$^#AL4 -C(L:/'CR!#BAQ)LJ3)DRA3EES@_V!E2Y4P8\J<
M&5(CS9LX<^HT^0MEM)U 3QHH.32HT:,FBW8TH!2ITZ<;;4)%R7*J59@.%ES=
MRK6KUYD0-&!H^K6LV;-H.5ZH]NQGVK=PLY9,IY4LW+,*'D"XRS<HA M4#_1%
M>:'!2&]:![]=('6C PF"%:-EP*#Q6;F2GU;-S+GSV0 :/(#S3+KTV[493:N>
MN7DDYM53O5'8"WOU:Y(*&$2&??OC@0VUIRI(W9%!AMW!D8)X8+?L@G3):0I(
M'+VZ]8\0(DBP?+V[=X\7.##X?KTWR-;D;RK@0#L]WPLO2XIC<"^X@R(C>P%W
MCY,XQP7.(,=?3!YL%Q=U YX77X(,]O^5W0,"-B@A9Q<,X-^$G:$7DGD8CK3>
M/@!$(TXT0VDD(HD F#ABB2&NF&*+**H8(XPLGOBBC3;U!,"(._[$XX\^!MGC
MD$ 2*6212![IXT87X&>2 OI$9M.4457YXI548FEEEEQNZ>65''+T&T==:FEF
MF6A^F>:9:K;)YI4IHF$9 _0(-I2+>**8YYUZ]LGGGSWR*<Z+(PZJ4:&$BIBH
MH3TRBNBABD+*Z$8/>.!66AI.&&:'G$[UVP*7=BIJ6A L8]BHDFWZGP"H>HA1
M5@),Q]("T\D**ZT+S%IKKK?:BJNON\Z*J["^#MOKK\CNJFRRN<KJ;+/0#ONL
MM-$N4 0:")+_M $#O'8K;%;?>@ONN.*6&^ZYY,Z:51$+2+#@1WFE*Z^Y\Z)+
M[[WVYEOOOM[&FNL"'EBV0 8,@+OLP<PBK#"SR![K<,,0[_JPQ,;F>D8&!KZE
MZH"9MNKQ3@IP]_'(4(5,\ET=>[3QJ.LY  $$!KTL\\PTUVSSS3CG?'/,.O?L
M\\\]7Y/R1]&@X< ]0">MM,_;R&Q0/N]ZY(T$2U=M]=58SRR!CO]EX'+68,_,
M\\MCPTQSV6B?K;;-$T@PZ&)12SC=R737;??=>*\\=*OKM8=W3A=D*Y(!^418
M6@."=Z3?W=&,(_ $AG\L0< 'BKKWWYAGKOGFJET.P,JB>L/!.YS3)P3?20I4
M$+EG#L0M)AIWB[,!UQM5 /G=#TC0W%?/B0IZZ< '+_SP1__I[63="MCC-_$E
M!8XZ R#6INJ8=U\(P#H91%^W!P^(_-7OY'G._/CDEV_^1IZ#WV%NWI^_T0'+
MCW1!^YW=4Y]("@!F=S07T [ -0Z@'ZI:AS+7,6AN[DN@ A?(N97%BH$0C* $
M/:8^[XAO@AC,H 9AX[D+;O"#( PAW'R7.!&:\(0HY,K*Y+*[%+KPA3"<206[
MX\$80E <X#B 5**A !VBI(<")!,0=0+$%MI00AV$SA&7R,0F?J1WG4*@$S.8
M/PM(0 (;<  R4M2N^(%$ 8]Q5Q !<  &6&!U*KG ,AQ@Q"FF9X4&=*,<YXC!
M&5ZGAG0,GC@<0(\(3. !$8C &?/_,H X<L0;$QC !!BS$:4$J2CZH1H VLB1
M4'ED 1_(6!XY9D@ Y&J";_M(*%$RRI.44B>G/(IE_#>35)K$E:XT2PLI&1-:
MAD0IMMRD)SOI'COJ,G,0F, TT& 0!S@C @XXP ,&L #XS"\J\%G 7A2P#@YP
M@&H*@$!6'+ /<7B#7! XP )T<P!GM@X9!SB#-&U23I9 H"CY<\ %-F"A,?Y2
M>B7L" $C"+]P2B6;[[!GBEXF4#)"8#0@@T  "@J3;.ZFA_=@*+P.$%"5 '1*
M-B'H2."W1?BA43T0>$<H/3I0+WK$9"<AJ4H,H%'X230E/21H01TJ49)ZU'O9
MA(!&-%H=65]6!X_WS-P"./" 7G!$ -60P 4DH,@'9&"1"C#  AXP@3\V  (2
ML(<]'G"!I5858\8(P 9 , $-1( !7@VI-#) 57PL8ZQL!<P!)/!4MK8D-QE@
M:R(U&50+_W;RDPOLX0.F,8 !<  #M+E ! 9@SWMDP+#0^&$B\QD3" P@ MYX
M"@,&\  Q/59_8(D !S[ZD7L,( ,!\&0']G* :7S I!N9P <8L\S]',6R QA/
MBI@*G")P( ,D&1AI-X*,1.HV)0>P9D SP '*T@2,B2QL!!AYDJ$"UZ++' \]
MER&2[(P6 (_E98;$2QXI]G5\"I# -(2@% CDM0$>4.0"-N#' %PC ]KQ  <\
MD  A3 .9XGS ,Q@@6BVV3@+<L(<T\0N!;6C 'E@4K3GR(4PA#(<"$\@'!C2@
MEP94PQIH,$X]S_L=O9$7> =8;#4R@ \.#$ #@,D.8U-4RI#9Q/\ 0CBM-*.B
M$8S:V":!$TS(#.7CCHA( 8KJR$XO.]R9;+:S44DD+:)"Y)-&=90F"PM[A&B
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MN7( 8W8<8T9N9]!B I ;*DAQ!]!'$:%L 84-=B9NK@@/TF - F   ?  UN
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MX %E-0 &F2+T% %'=YA:T6]PN&*D8XF=]8&)04@7L$R)$0 CZ!1E"64IDDB
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MA*P;,VG!'& 88:$\ & .S$1(U:!LIW4_.E$AU6 3FW64E@A<T:L1'^L-OQ"
MVT&&S)4] % ! MF=%UL9&XA?7FRCM$RC&N -!T !'Z!#.4B#.KH3!] !3"RM
MXA"8T"&N@C&1"V /3"M=(5"30Y6&$5 -LW68;;@U))L!*_R]TT !@K%8TU"&
MM\-!2L0IF4G$\CS/BO^A-X Z/ '   7" ''[&T( #QN@=SJB<UKW3$LUH':G
M&QM =5<T.1B7$5.%NQ*0;[V  =!@5 ==(H_A 0Q0N1'G 6B0  L=D281#>$
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M5MLF-0< ,VPS/?<LZJB#\EQS@'T,C* ^B%YD$P .;%04O/O$A# XJUKC#X!
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M!U*^/1(I_GKC/).C^W:N2?;3^\)RO0:*IH8CX%9-QCH5T>FL"!V6KA@@$K;
M]Y6ZHGLS*?2L(C1.K.@\\,Y)#*SZD=KS>0*N[E$>X_JWQ/7[Z:ZI/&$ ];B]
M#&1TRTA<MH^F;&3-B,FU48'%;)^IY,"YBV J#H[4FZF<U^)Z@Q=!E6C:@%R1
M*5IK>;Y[@/1LA59125N1^ +]>APO=]6KZP0Q];IY8Y^IN>C\K)#Y$HP-983V
M! >NL[>K(%^A0D*I $\\#2[_+*I/*N[B+AEBLI^7)TU_J,(IK\S(PZ);D4L^
M9+1$RZ1S/%[9.<0QY!'2]EBJU6;RF63V2' WP;W/BN.7./L!"M;Z*_YKK>L
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M*L&9"R%2LBCYQ"I7,6=\H%2:B3Q(*4I,#'-DI+J[=-%F?P2>[1CR$9_H8W6
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B)J1"+B1#-J1#/B1$1J1$3B1%5J1%7B1&9J1&;B1G!00 .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>abvx-20251231_g12.gif
<TEXT>
begin 644 abvx-20251231_g12.gif
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MYBH/<'"S9'($]5RG,\>T2FUN=)PC7>@\Q_G-ZR1SJ+=<ZDVG>M"%._1/%9U
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M<C#4(W<*+E$9=1,;M*E0T@6URA^C$%J]N4+JQ, _LN@E]ZB4R\OXW;,4!&Q
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M%Z)2S?JBB-'%' RUD3OJK\J@(&_5W=TU#&SBM)?CE^P*RH=,R**JD7;56/-
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M__ ;XPR'=B$/!*TALC'!C@ME(:IU++_/^F"*4<A_%I+ ]EFX<:&D(U>MO&O
MGF\12O&4WM_$#FM)DFX5W])7LAJX8"]=-FG"&7*E1NEZ2Q'06"&>+HVF6!(9
M]=V^_O"N4>53[L!+<W OEZ%P3KP1!N\U_T<:\ED0G&_,RCU.^HPZSV _)EI(
MD^7D+KR^ONB.YO,D?_*X[G,DAW*P W2G]I>$RFH@YVH1[!?9:O0,%&NEC@O$
M>VH(WPPP-71$P4 8!] ^(] VJA%I CRSV;@1XL&A65>Z4*T^S!%X8XQ4;I,A
M.EY.:U2\!AF?VD\4E_/\!F6G^>04!IC^-$1/K_71UO]L6AYU87]Q(RF2$)'V
M&B_V&$EOPMX3:6IO)Y[)O4FG&LT16\==Y:[@ >6I5 _UM1'7'&?N;ZYVQ8-S
M<!68LH1/5)^9"W^YAZ1R'[N,(LG9SD;PG]H(-B=X^HRI*]XQMVG7NMY@=TV(
MGFWT6$Z7&R_QA8;4%%.YBE=+??_G.X1W>2]AU<9M<3]EU/+KC9-T"N_/ALPN
MN7%EU/+9G+U"Y6+PF1K:Y&;EW]GXROWLE=_VM[[NABSQ4X+S'LUC9+?X+^>Q
MC!_+<C:8F.,QAPY>AC339R?KZ!I!T7#QI7[ST3[V$!Q!-NHL]YEQMX$B<TZ1
M%,U/NHKH  LP?RH;, ^?;*7_<>;>\\QXPRT!WT[_[[Y?+>#%]%M/5QB9ZSZ)
M(#B'\3K7!;7'9K$_5V7?ZA=!>*QV^QTJ(-'00N4>RX+G?(!D=;]O^*X^=;J^
M62 +\JX&H9CC$<86TS)[Y<QG2$ D='/&_,/F:Z^<<!FO>Q9Q<8I>^YV]:$AZ
MZ=;?(1,B4Z0>ZT(O?<GNX)6O)+O^I3%-=_[$&S<#>47W%^#_^Y@6_?[\-#>K
M>!NG(>,F&(+T8X0?<_(_>A*D=S\GN.F'=_-^;K)F&VZSQ:?6PU@9]K%)*64!
M"!$! N@::*]@@$(#"0Y4>'"@0((*$2X<6%!;1(0(,V@ 82"%@7X@-%!DF)!A
M1HL3_PUJ;%C19,&2,56^9*BK4$F&#P-$'*C-8[\4:V#6)+J3X,.C16^:#& O
MI<2%,RTZ97I2:E.IA91.+:@P*\*>N@"0+6OV+-JT:M>R;>OV+=RX<N?2K=MV
M7,V6%1%^M=F7Z<&)?0/3S)D5K,J2 J?N=5E1,-:D!95237F3+^*B1*'ZI:J7
M:4Z])OLZ+BW1,-:3%Q<+GFRX[P#+$#U77?E2IN2JC8DVE6G;\.7:N;'&)(WU
M+]7>2K\6S&@<)VVJ$W>"WGJ3,.C1FEN65$&ZI\VY5C7:0SK;:E/H7Y$;UU4^
M]-[RZ[VZYQDUH7O1[G&65YV<86O)30?@0HOAMYUC_!V&&_]!VB1HD@@.OB06
M<0V19U, #EYD'D6,8;B4A0<RUQ]IHODDW7\9FJ:58S.I5Y."I758E('X]:=A
MBDNIMU]]]3UV7W!@V0.=3^@1N)""/5:6ET4[$8FDDOZI=M0X=EEY)999:KDE
MEV\%AQF+J96X&YG_^?BB?8T9-YMFX&$(W8Q]O=CCFN:5F>9Y:9*FH6U2#8GD
M;4/2)Q^3]"UIHGU6)5F3A!,Z""=1$M89'X=H B>HH*7QMZE,1:VT9H_O?>5F
M<O"A)Z>/I<I(79-7Y=5?B^\=E5^+646T)I'ZO31744Z&-J:JG>IT75AESJ14
MHX>Y.JMV+U%VE6O(:0;3F*C=9Q__8;25U&APR1[YHZNZ#>;5M8 "BFA>S*&$
M8&:[=87GAR!F%R)BZRG+DFWM:64MK0=R9BUT7%4$WHR!/3MA;63.>]N= G7Y
M,,012SQQ7>#J2G!63[;$@+H5<=QN<<FEQ.J!.!HYK:ZNA@QF3D\^R?#"YJ;V
M[K,K3[J0@P_='%.V&4*EUU&@+KFN1$XRK!ID2 G;8=#D)I897V#VUK&YJ,WD
MFH@PPPCSJ'NMA/6T.:[$*H4OR<DFKRXR"-_-4";8[XE7O=QJD$O[16=CABX:
M+X>[Y:HRF_O:F**2:T:(:+%B7CW:C)?)*MV[C&?ZV7$X\_8C>A%%&*Z".-;$
M&8AF.\T8B)&0TOUTCI=+J2*,B5.DKK37CN?K@:<Q:3;=<[_\),6]^_X[\%>6
M2N*T/?TF'P.UDOOEG>'ZZ5)]5(=K*( M%XHR@3>IT/=QUM:^>(Q08JJZTB&&
MY;G(]Z8&+K!$H1GV\QZF'OJ*ZZM?>^SR5\X\M#0%VG>00F0Z4G7H9I#1FX]
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M7G,\$S"]!"A %OU;239)N&DQIY\CE*,Z=4:5;.U461J+"A9CJ,6%E* > ^&
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M+G4NF^(@)<=/@CY';3.6'4R@[ AM$!K)#/5<G#Z8)A&HP $7B(B6C3&0*BS
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M "-IQ) -1'>A'> H3D40%QE%E*<AQ&,1!)150$$LE$=]P?.]%4/YG0-(64'
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M4%>Q4-*,17D^*[2F4@PE6K>AR!?.H[XQD'7<"9Y>J9@HFNZ43S;6DRK&9$4
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MSJB$S"9!F.A +.9DANC8!D!W+=EX3*:$]*CJ-8IF6@1SJ4"+6<3P:>V4<<
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MV35%C@F<&2OD1VXBNB;_Z$8Q1#W@)92AZJRZWX4J]68KG-;QFWMO;<$JQ!<
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MO;,V'W0WU_-$431%571%6;1%7?1%831&971&:?0C[($!\ 0? @!/[.$=\&$
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M JJ@"DK  _RZL$7;!JS!M/<! -[A T: ,U3@L8]:3"C 'BH: Q:@ 3Q@J1D
MN!?@ ;Y:!3"["CR@!$S@ N3A SY/!>2! R!@ 4(@LEG;M24BM5_[ON_8OO$[
M(_3[D0> MFO[O *@ 4A &C   TB  SIZ!$C !C   KP! WP[ CC@P!]@&DS
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MDI-9%IF55E8FEM9AIB1U6,N[C/)XH4%<%?6(E?D]SP8>"J4D1RE,%C&@,R7
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M$)Z'*4!RE^7B)]1HDFMDEUJ!=/+(C=;1' \0E6[36QY =Q$Q#A3P#A^P#Q'
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M!ZI1-8A*Q?@7,OYE.&24:4P0:I@2: H#$"#F6,M*5@B8-:UHQ4!935" %=J
MF'-%*UWM6E>TIM4NOIS: /BZPZ%"[%F!A>40.;.V/C("*A^]3TBIRA"2/O8]
MD97LOZQE)"4M-:O=6DG[TJA #&A1::,E;6E-2UJ:2N.TJV4M:4D @5).3:?P
MK"SUBDI 627U)'LL25-KVYBP_/9'4ZVM57>#K3(.SY:<S%1-W48!"HPCNN90
MP'2K.P[J6E>[M5F@=*$;).C^J[KBG<L"RSO>!2J@NOOD(&T+4KO8X4[_=WUS
MKT"(MA4*B+-9##DG]7CV,Y\M%0R^C0DW", /!"=8P0C> THA*EP=/1C""ZG6
MV3 K8&V5L:LO>1LV)]R:V<;74V_:77TE.AX22X2] ^FOU-)9KSV^M"83I7&-
MO8,0QQ[$"=&0+'$_C!H?(VL<*>**<6&CEQ@+#X:=/8HG?]PA0V*$LH:2[T3K
M&[FLG#@G84LBCF\KDUKV1:D;'1!-<GQ!-%OE!3Q^[)2?')F37JX=/^1&!+Q2
M+=U<&,-:E=> -NP2-#KWS:()\6,=-Q&!5&%QB1Z=0EK<D)#N): QS*J9^_0[
MKNRXQ_4=]&J"+*C#C, #T'UD"3S @!43I!T#__A KZIH9-.I)*L!-N-/OMKI
MR'2P(:=\[%#>Q&@+=^H!"WDT?YDR:W4&A['ONG2:C[)FR>((U_B1-N7&L:\"
MO /;< HL/7J* 0=PH,L*J; 8![JD]"#[SRWI\+331%B!?/I4%/"7"1TP;H0H
MN@&*SHJB\_R.\=#8L#%9JMK4R=2!FQ/3+SFP@@],@(=#'.+\:/B"$?Q+';K;
M89PF5C3$.8(O+$@B(:2P/3A @@MXH J:D@M#8-U"6DN:SR)A;D]NK7&U0%7"
MF%,Q XBRS:HF!9)9F4"C?;X5@6N&*0?LHWK0O0M+:\4G%)?XPRE^]89'/.)7
M_Z6;<6XNS$5$6B72:R0!\IP0!I9 &A,0%02F$2<*3\/"L$'NM@X8&&2;9-T?
M:<=GOX[_ET);C]\,2'$!4NVT#?&;T7D6-K&_?%@E&RCJ=_1)Q)$@\<M#//,$
MR#S5+\_U7<K[[UX1/9H^"(%[=L<#'^CB2H'X#GSL0R!"X=A"S.$QF"=W?:HC
M#.L$/7JR' =K\JL,!T[\@%;R#CXEEL>B >!OQR?</-J2IJQF/F#IRV?J5>=^
M][TO<7YT'=[ -TN<KT:/Q<E#*"1400.<KQ#I_G !9C,*0PN"^V>^<)VHV[M'
MWO9[\O.*P(N=[F" ^]J0H8"G<<()B1B NB"AZ%.Z='HII4*)R3N*,].\[_N^
MS>.\ \.X#PE 3PM!NH$&%$">T.J:$; !L^L(!5"'*+F,<= V_U;:B4K2LPJ,
MN5KS"2<3P;* *OC*GNXP&L,+&\.[",43B/DJ@&4CB&(C-IXIG%KABZ?KBWN1
M0,KK">Z[/">@."[DAP[@P@[X/O'S0=3PNC;)+V^0".]Y!*?! 'R;C,H@ ;A+
MF@7A'"T"FP(H@:N:BN#@K$L2@)JKB6LR0[##B-(3%,61"(Y@1(Q(PMECQ*%Z
M0D<S*MY++@O,OAFK/.[K # D@ [PQ#$$1:H[,"< /XP++D/,-8X+%D4I 2W"
M@"I@@)4S&"EK@+!Y@%49B*,;I[,S'=Z*N:SJ/X^XN54$KN&3'RS+B?XA"TK<
MF1?+K#]$MP+ABPM\#R_L "<810+81O_-&\4Q1((Q_,3+*\-C9 PTM)'R&HAL
M*(%UD(=H8#5XQ B/FX:-*0@&"!NPV4<&V<.K&@R."LA ' YBQ(AV.T>N&$#K
ML8]4*XW'([@<E+63N,;LJ+HQ#,-0O+R+/$5X> &("\.JP[A61,C&&,D_"8 1
M6)5Q4 %Y^((J<(1>&0&8K*]]J(*WVD,2%(AV8"458(  4($;/+) E,A**4B,
M,$:2E)V<9 A>$\%GQ+'_VI;,PBK0H$CJJ#IQM,BJ^\1.],9?JK:D3 OS$ZS0
MH0UK<(!UV!(JP8"H68@1X)L%&#_\0PWDBI6F*QPF\XF^ T .48!HX(:_#$S
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MB,Z"5K-!\6OFV"80_VG1BE=-K42XN#JBD6LCJ"N)25<RF-W(#JT499=E,1(
M>_3VDKV[) 6J@ $)J(D$%QC!P$AP/!:6-G_? 0\@H3)#I50I*-HDQ"&A\C?R
MX52GX=V-> ,3'R&BCZ@+@>L;!U %!V G!'AMR >>50*NC>!9'J!?3Y+*D"HX
M0AZ."/" "_Q9 1N8P 0^X4^:ZM>T1=4G5LSB0*TJRY^XAJOB0EH71;*:!O+F
M\7N,/=Q9#Q7<AK#WQ+I+,?JB@0$22. MY7D V%)*MF;BL3O^?&%G1&--(T$
M!4XQ1ZQ>Y2I670/)UN.ND9/\JB+W[2<:HUJC8%(7JID5+^>K((L5,EQE<D!
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M9=A!7V7:X"6**0*J39E2Y2 /E!(R)QBU1J,9+D_U7$$*1NR!:IX"L<F@K\E
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M>' BR>[CL"X:P*VI-BMC5YW$*3H$'B*U+TTH;@'L.3/UO-CUNS2Q,?!'!6"
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MGK;[#E'(RB-O*2Y#Y#4A%3\#JT4K^C!M\:I08YS1VFRU;<@>4+?]%B$*2%A
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MN:7M@IK?XJK5XI\QN:H?S:!A>BXT>*81&G#K<81SB)4;XJ$+(9)C8I8==[)
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M0N$;7CM6;"R[O< %4QPI" UG3\&GNS9Q3 X[R*-'*;7=76@PO2%<.],IP /
MLS%&H 24SC7_2F AP%XP!H #,(#L+5VWK1XN@)V42\#?X<8#(& !U(&&^4X5
MQZW@;Y;/(\GU<+>G?K[NA[ZLHL^6+VG&26T_)0]:J +1*+?>"#]HX+W-T33\
M IXNS.&ND)\N<K4[ZPMBGE;-M=[2J;_?.( $OEX@/, &, #L]0P%G+= _^8"
M_X;\I<,9BN0:4)S]V]_]WQ_^V7\57-P%I,;^[Q__[=\%7(#<!P(@Q@VIUN%%
MAX,'"2(D2."@080%%W;@!J"BQ8L8*U+(R+&CQX\@0W8<P$"DQ0 #3*I<R;*E
MRY<P8X*D,*& 37DR/6*PN:! RIP>J]C\ * = P8;@6(L48##!P@VJCDH_<C
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MKRS_P=QCS1GB>C;HNQ[@=$_E]D<^-RXYY"DN#$!/(4S%#8HE-&U/UEMA;3D
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M(U7 LACFBX8:!FZG+PSJ86=I *U"BGDH\ $,<.#5+!EQJZ!=YF+CD]KM;8?
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M]X/4R <"M]\5*4A@\V$*8'="@I^X&$7_F90)LP\Z0F,2&<Z0AQ#VLP^2?6!
M AYX^EO%\@$)I(Q@(UA 6VP?%FCTQ ,[P8"T(EK-K!LCE@Q@XEQ$R  4Y \%
M). ! O<VGJ5<E<9L=X8F/[$TT8=J!8!C%V%0/01EK99_^M)HQ <3(V1H[; T
MYC,V:7)H7G-FC,=]CC. %D8!^H%09K4H6F<5 0!Z62$P&  I)3!##_  -I"!
M6V$G*(!U6X,!#]" @%41\B!_='%P 2B#0$$!W* .<U1Z24<R#P!.@*=+\76
M4$$@0.13.%=W+#$FYY8PY^82I]-@%N$U_G)@+[$3'* "7BA1;(<A<3B"UU<S
M)HAF5(=IYL  _QA0 KE5!0ZP#@R0=2K0>JG'$E\F%Z]% B7  4SA (DX3E\@
M >N@=]K&1Z'# *HR:;)U.+53 BHPB6W'  TP 1OAA[7G" VP=HZ0#:3X.QU6
M=B@862-4 0Z0:WF$AO70>R[!,E&1$6B7$VD",A<A3#&T2A0X/@GU  ZS$SQ8
M?!)S:$Q4BS95@GF8$]BH9G83-A>0$O(@#?>  57 B250 F(W-AM! 5]@ R0
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M81+:$P'X4U]0(Y&9%=S@""1@ E<A>@(B#?@0#?3  (H:%A7@27=Z$7:C; $
M?R[3B@+'B<JFF4%IB@]XD.A$=B;!H[[U#HDDF43%7"<6;P?5$>15J"917T#G
M#:"3?H[9=E"1%/P#:P60:\/VH8_*6=G(  X C\[49!R@*&2:$^T3%?A0!19D
M>?8U DG3J%.A#C:PH&AAI?D)?X]H/ (G5N58$0CR;"CF#8[8G0D4IT3&1/(
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M$/ Z9.' ]XF\83'&K_(7% !S#K  AK]?(^"08<.6#G*@=X$7NDX!J\G=8O4
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MVP<.H).@ 2NW,"+8F2YK<%T5  @ )/K&%NNXG$064MJ27X0EN;C'PRB5K@(
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MC([Z#*V86=$-:3?_B]$GE!VE#%F"/(JC^0MN@$D_F^GJZ&>^'&K1"XJRV0V
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BG7KZ*:BABCHJJ:6:>BJJJ:JZ*JNMNOHJK+'*.JN  0$ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>abvx-20251231_g13.jpg
<TEXT>
begin 644 abvx-20251231_g13.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '* Y4# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW_XU1]1Q7_/J7W,#Z*S1FOG7_AOCX0?]!/6/_!#>_P#QJC_AOCX0?]!/6/\
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M:,U\Z_\ #?'P@_Z">L?^"&]_^-4?\-\?"#_H)ZQ_X(;W_P"-4?4<5_SZE]S
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M;X^$'_03UC_P0WO_ ,:H^HXK_GT_N8'T26HW5\Z_\-[_  A_Z">L?^"&\_\
MC52Z?^W;\)-2O[:TCU75$DN)4A0S:+=HNYF"KEC'@<D<FI>"Q45=TVODP/H:
MEIBMD<\4^N, HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS2O^05:?]<4_D*_3N"/CK>B$RS1117ZT2%%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M04444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH Y;XI?\ )-?%G_8)N_\ T2]?CYI7_(*M/^N*?R%?L'\4?^2;
M>+/^P3=_^B7K\?-*_P"05:?]<4_D*_3N"/CK>B$RS1117ZT2%%%% !1110 4
M444 %%%% !1110 4444#-WP/X3N/'/BS3-#M6\N2\E$?F$9">K'V S72:1\&
M]7\:>*]>TCPCMUB'26/F7%Q)';90-MW?,V.H]:Z3]EZW5?%VNZAP9;'1KJ6,
M'^\4(!_"M3]F^&RU3P_\44U:^.G64VD+Y]VL32F,&3);:.3SZ5\7F.8UZ-6M
M[)V4$E\V_P#(M11YSXZ^$?B3X<VMM<:W!:PQ7#F.,P7D,Q) R>$8D?C7&?3D
M=F[5Z/\ \(EX.C\5>'K31_$;^)8+J\2*ZA>QEM-J%@,<XSGIQ74?%G_A -#\
M:7GA#1O!UP6M[Y4EU!+MS<-R-T<<9XQS@9YK6CFU2FHTY)SG:[TMI?S%8\0]
M<<^E'8XY_ECUKZMM_@WIOB3P[K8NOAK)X1@M[&2XM=2;4B]UN0942Q$X&X>@
MKSGX=Z-X.T_X.:QXJ\1:$^KWUIJ4=O!$EPT(?<OW6(Z+GK@9JX<04JD)/D;L
M[6]0Y3QCMD<^W2C_  S7LGCWP?X=\0^"_!_BCPYI?_"/R:M>MIL^GK,\T:NI
M WJS?-W[UI>/9/A]\+]<G\(R>"SK=Q:Q*ESJTM])'-YK+R50?+@$]Q6T<\4E
M&,(-R=[K2ZMN'*>$]\=^^>U;_@+P[:>+O%FG:/>7S:=%>2^2+@1A]K$<9!(X
M)P/QKWGP+\$K>U^'.D>(8_!T7C2]U9VD\FZU+[+%;0@X4 @@LQ_*N*^-'@&R
M^&_CGPY=Z7;G3XKY([HZ<TXF-M('&Y-P/(ST[XKG_MRGB92PU--/6STW0<IY
M;XBT.X\,Z[?Z5=J5N+.9H7]R#BLZO6OVH+6.#XN7LJ*J&ZM;>Y< ?Q-&"?UK
MR6O?P-:6)PU.I/=HE[A1117>(**** "BBB@ HHHH **** "BBB@ J:Q_Y"NE
M?]A"U_\ 1Z5#4UC_ ,A72O\ L(6O_H]*\[,O]SJ>C&?LTOW!]*?3%^X/I3Z_
MF<H****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKXL_[!-W_P"B7K\?-*_Y!5I_UQ3^0K]@_BC_ ,DV\6?]@F[_ /1+U^/FE?\
M(*M/^N*?R%?IW!'QUO1"99HHHK]:)"BBB@ HHHH **** "BBB@ HHHH ****
M "BBBA:; %%%% !1110 4444 %%%% !1110M-@"BBB@ HHHH **** "BBB@
MHHHH **** "IK'_D*Z5_V$+7_P!'I4-36/\ R%=*_P"PA:_^CTKSLR_W.IZ,
M9^S2_<'TI],7[@^E/K^9R@HHHI@%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!RWQ2_Y)KXL_P"P3=_^B7K\?-*_
MY!5I_P!<4_D*_8/XH_\ )-O%G_8)N_\ T2]?CYI7_(*M/^N*?R%?IW!'QUO1
M"99HHHK]:)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "I;'_D*Z5_V$+7
M_P!'I452V/\ R%=*_P"PA:_^CTKSLQ_W.IZ/\AG[-K]P?2GTQ?N#Z4^OYG*"
MBBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%)0!R_Q1/_%M?%G_ &";O_T2]?CYI7_(+M/^N*?R%?L-\1+6?4/
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS0!Z'2UX5\?OC7XG\(^*_"7@#P%IVGWWC;Q.9'AGU9V6TLK>,?O)I OS-C.
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=5COY[Z\*;5),?RJB@GJ<FOJ?RUYZ]<]:3R5]_6@#Y!\+^!_C1^SCK'C'0/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 444E "-SD5\3_#!?^,\/
M% _VKO\ ] 6OK'XB>,G\!^$=0UU=/FU-;-/,>WM\;RHZD9]*_/GPA\?K#0?V
MB]5^(+:7=SVE^TWEV<>WS1O4  \XSD5]%E.#KXBE7E3C?W1GZ6JU+GFLGPWK
M4NN:'8W\UG)8R7,2RFVE(+1Y&<''&:UJ^=E>+L]Q"T444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 444E $;2XSR!]:7S/<8
MKG/B--)9_#_Q-<02/#/%IEU)')&Q5E81,001T(-?/?A'X8Z/JGA/1;RZO/$,
MMS<64,TLG_"2ZD-SM&I)P+C Y)Z5I"GS=27*Q]4;_<4;_<5\V_\ "H= _P"?
MGQ#_ .%-J?\ \D4?\*AT#_GY\0_^%/J?_P D5K['^]^!'.?26_W%&_W%?-O_
M  J'0/\ GY\0_P#A3ZG_ /)%'_"H= _Y^?$/_A3ZG_\ )%'L?[WX!SGTEO\
M<4;_ '%?-O\ PJ'0/^?GQ#_X4^I__)%'_"H= _Y^?$/_ (4^I_\ R11['^]^
M <Y]);_<4;_<5\V_\*AT#_GY\0_^%/J?_P D4?\ "H= _P"?GQ#_ .%/J?\
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M^(?_  I]3_\ DBCV/]X.<^DMX]:C:4C_ .N*^</^%0Z!_P _/B+_ ,*?4O\
MY(KG/B)X'L?"/A"ZU?2K_7[?4+6:W:*1O$-_( 3/&#E7G*D8)&"#UI.C;[17
M,CZU5RV*?357%.KG+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSJ&]111708!1110 4444 %%%% !1110 4444 %%%% !11@\_TYI,\X[_ )T
M+11_.B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *X?XT_\DWU3_KI;?^E$5=Q7#_&G_DF^J?\ 72V_]*(J?0N.Y]++VIU-7M3J
M\XZ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\,?$7C_0?$IAN;6Z\.RSF:RE"8>.6**1#CT;!%+W@T/6$_:QLH/A!K?BV_\
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MT!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM_Z415W%</\ &G_DF^J?]=+;_P!*(J?0N.Y]++VIU-7M3J\XZ HHHH ****
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MH **** "BBB@ HHHH **** "BBB@ HHHH Y7XG_\DW\5_P#8)N__ $2]>5^
M?^1%\.?]@VV_]%+7JGQ/_P"2;^*_^P3=_P#HEZ\K\ _\B+X<_P"P;;?^BEKH
MH[&=0WJ***Z# **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X?XT_\DWU3
M_KI;?^E$5=O7#_&D_P#%M]3_ .NEM_Z41T^A<=SZ77M3J:O:G5YQT!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]M .0I<>OZ4<>OZ5=_X9E\ _\^FM?^%)J7_R11_PS+X!_P"?36O_  I-2_\
MDBCVL Y"EQZUPWQJPOPUU0YY$EMU_P"OB.O1?^&9? /_ #Z:S_X4FI?_ "11
M_P ,Q_#UI(VDTW5+@1NL@CN-?U"6,LK!ERC3E3@@'!&.*/:QM9#43U%&R!3Z
M;M%.KE- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ I,4M% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
%110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>abvx-20251231_g2.gif
<TEXT>
begin 644 abvx-20251231_g2.gif
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M00 .J1%& N"/!\&D1"Q9INT5<0 :R]J80!*! 7KE 7R<9 5>4) 0!&  %)E
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M.= "'EB'9Y!&502L&B04%](:<<"T;>N433N6"9"!;<&X.SP7'0 '4J 9!9@
M6[0(<=!"BY '4D 2H5& >  '@T1(!4B'7)R\R)B4<(%(!/24"5"S"@0]%\ "
M8?]<1"GDAU)(16 1!R,L0@9\1B.<O(\L%3/4.4;XQ&!1@'"8 R]8A$5 @T60
MR3D(!XDD1]=YP6O[*5S#HY4C*D/Y-)HQ@#\\%%)@!Y14"$^;KX6$"PA)@!3
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M"#-VS);/? '_-(@(F"-VP I 4TW@@%*KF("EA%(*^31 4PX#&#<H-0FO.,I
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M,-733 F*955P8X<0N%JGQ%6'" %IE%K_P%K#@%AE.4I9]8K0) U6E5B#,%6
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MUFF>'@!5%A2_SE&#V.#<#H<):-=M8  #.%;LXU88RUSGK9K/WBX(=Z3O]XD
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M>MM1)Y!,$YB$F0'28;>BB*Q11M"0XLT7I&SQX!5= +9-,0"*.(X46D($$F1
M>@DX(""277KY)9C(U79;A0- $T]7 FVC389$"1<FG''*R9)X!"4P@7\%.1#-
M<@4)E,!IV/]9LUP&U)"$#(X"D;+C0#U2@UV><XJEVF0@Y36 @I*2Y4!Z/0HD
M':<XTH0=?')%QY:4X*7$I::MNOHJK H9  V9!0QPC0,Z'+2A41W&^BNP(!K
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MZZ+'N:)(;7NN?"4L8RG+64*D>Q>9BNJVOZ2P-T8-=K3\)3"#*<QA5HY6J1O
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M\Z8,_><[,WN1MO+#KSCP*S\ D([:ZHX@X C!%&J+@V00)!V;]2M?#T*CO^*
M'YA]"%6SVM8$6$NV9;&ME@[2&+_V%C+1M2Z$CAO5/U&UK]0=RG<5DMZ5@+:[
M? OJ2@@WQY1V4RC40"QX)[)=W8%6M/\$048"0E" ]28$M/8:B .:FX"> .
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MO&]1P#92@(-W+ <'(1B)#O8+ &@P/L&![PSC=< .?DQ!SG,?]&89K&B0\[D
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M1\->(@.PEC(-Q+>J:KAF+=D^U,N6K7J\6#[-$48)1,&V1+NBK=S.+;;*;$0
MK9F\6=BVQ(/2K=\.%-;^;82T8\!:"#@HSMNVQ,<*+N.&TZ(V;L!D[*TR98T)
MC\1"+N:^TN5FKE@PZ^!DTX6@ZO1 U#)<P"?8P0(L@!U\0CDL ^>.1>F>;NJN
M;NN^[@ TPR0\@01(P!-,@A*<6;P"["7:_PK*#NW"G"T\:<,%H.X",((_I&[S
M/N\"7,#K*H7R,J_S0F_V3J_((HD"4(,$P$/X[B[YDJ\Y@*J_VFW3TNRZ]M)
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M6ZO$XH(3-8!V/Z\Q\Z)O.8"T_UYRZG["6(B#"-  8(,"&J2#$ P ,D #!WR
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M@RHO""PX=!8K ?K^-A:/+RS  D4S[0Y74+=NCJ,?!/?!DS_,@PK[ T@[\0+
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M(&J6&\A>>&#)6_'%?3. 4#PCT#,>8;?Y,R=J4F1<\YOL82I&IM($>)OW%K@
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M$7C@ *3H1SI"  HUJ&%_^VM!L*0(G  &3 &3P)<$8 $(X>C@'DHP$T%V8+U
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M!"P !5:@]$YO$*J0">% ]." ]4[@!\31#,+Q!,Q1''_@&T./]*I0$$[O#,P
M!39  T"N/AI"!^0!YYZ1(W3/P2)G /8$8"P')S!G'SU*',[@$)C@I^3J=;2"
MM%#&M% LUJ"!UH9."X)G;)0I0L9""_+BZ>!""](B+\(E:"K2*JP.5G3I0DQ
M')(G_YX-N4: _T9 !)! 2PS_,B<58@1H(!O4X)Q<L7R0P2S.:1:II*S0:S9Z
M[.[P#<T\D+WZ3@=& +Y.T!9YQ003[RKGZ&UH  I @.R<42?'(QXV3P6N$?60
M$ RX\1M/P S<4A+@4A)X02YY@1=Z 0$0H!=Z@2[-8"[ATBW%L1O9<1"H$ RN
M4 -B &_$TB8JBM(*X((DS#S2<#$[:!M:@'5>1ZZXQ2%E299>K99<1@^%CNAH
MBG?4HBUB(P9XX"W"81W@8F0F)%60YR3S B/A(AS60!S<@ $^D;B("[F62-I6
M 0]$0!\I,]+>\ 'O0,O<#.[631;/2'[(AA9O\4FH! 188!=[D;T\@"IS8QBU
MTGV,_W$\9T#Q" $9:* %_*S3C#,G&\:]D(#UM/'T1*\<W7(N\1,O"8  \!("
M_!,O 10!_A,O-P! ZY(7W)(<?P -!+,*50\)5 ",VO,X*2("M(/2O&-/^B33
M<B*4*%2*=  )#@$-1HL4A"#ZYK"&J,^T3.REW #[MJ\L2$68\D+]+$ +VB(<
M>* VM(#'B@M5CDH+GJ$M1@8L:NI"@HRI]F\FBXO_:/(&/@ +H>=#26X$5B%K
M3&-3A/)\QF8H7[&, &$=8K'=J.1)SLRM\(T$B]%G-$ $@''?:,,$\TFOY/08
M/: \;X 0-( &;*":!NY"=;)/&B8>H $%D&#TV!$,Q+$MX?^2%P+4/PD 4O43
M0"$@0!%@/R^5/_M30"%@/PG 4?]209E0".%1&FI/%:F4(>H$LK[#]U:.HR8S
M537G2L^@\TY4 ^*J\TQ&EFIH*_80M:["Q6;JUG* 96!EMGA(UZ(I'-IB'7CL
M+I+(5M;!!.A"6=V 63DE'$8$VF#RZ_;O29$!!?#@*V75R4#F#K)!:]R4K(22
M L>JK*Y"Z,@!$&)&;>HUK]+&.MT*&41@#H3-"^9 "%X#!+PF/.O,3NVT//$4
M3PF!!6A@"5"5L29T '\1!I" "8E0+7_@!.(R+SDU4STU4RUU9$E60/NS4SLU
M4D,6 >J2'$_@#$;U'7-!0B/V0\'_$)-,@A2N87)^[R9<KERE1P1&=!4T0 @Z
MSP0T<^+JT(9D;89&I2N$-1!;)6:(2)D^($D@!"Y&DD:3)VNA(4GRPD<MY"6=
M[6N:=":== 9N0 .R93V!EK$. !32%116 8S*AP7$B 7$9DO%9NY&D[5J"ESL
MKJWH"1?E# 2$0,?08+=Z:P[2:DZU$BO'4RO[2I_4EJ]$  I$8.#",O(:IO.0
M@/2(L#XEP0S@DE(%E#\K]5(GU5)7UV1'UC\K=78WE3]5-E)7MRY+E_5&E?3.
M(!<L .1J=C$G[>2Z8P(F@ PQS0QM @W?-GK@4 V0H/-PE5NX13-ER YIZ$ :
M)-;<P ]QHHVF;$4NQK?'?*U#C@IY2,16O*Z9?O-]GTG_T/9)?:4XG[>Q#( T
MMN8JD %O\3:]@O++RFH$_/ (7FQ>![=MI$2!0:"N"%8#ALH 5,,#.,  B"I*
M%$\\CW&#^8F?5'"O]FF?1F )W"7;.G?@&F;B4"!1V=)T)>$N/U93 ]1V65>&
M77=39W=U:1>'-[6&4[93619!S: ;>_=W7V-BB=?D\.1XH?]!Y1:BDX!/@>YW
M:12 !LY@(4W :#4 :2<.5U-L5VUI=F*@4S!$;\?&+FP%2.>"08Y'J<!B1-8O
MCH,(+I+H-YW)-[D5VIQ-_YQTVL9UBJ>*";(A#E8!*TCP;K&""SP.&4QURP[@
MR^0U^]:!7,ST7%A !<1+;;1@$<#(GCS@ZB#7?>(T<A&VKT)8;?>IKVR@!=XE
MTF#0"[>!4#4 ](!!$+KQ#-IR+E.WARGU=6>X=7N8=G/89/^SF(GY8ROU=O?S
M/^V2'!FT"5= "\5A>)^Q'W&V8)(W,GTV5@$Y8%  4[8NZ[88::G7BTO&0;QW
M=L("0<["=V;&54:%R#S1 H[*V([_R&>$BYF8J36<C6>,RX[S.&WY[VW$U12[
MV9JDP8OJ!F_[MZ&#\N)FSUVQ@H"'#A!G:AW4YJY P$17H:-1 .M,( _2(<[F
M%!H UGJYKFZZ1:4GMZ\45D[YBA (P09L8 G<]J C2#-((72?4"W#T73[,U)+
M=J@UU89A]U%)=H>5VF1M%V4YU5.%&@)*=XB9L K/8 5" 420^!0;TW@UJ8DI
M9R";-_AP6F*0 5/"H6CE2C-Q=9Q+9@Y/#.BV8HQC)RU@YF=&97AZ;,B B(YU
M!E7:]R65;?T NKAF\I_[3Z#7%@]4H*Q'21R\J%M(\+WNMFYL@P0QKANZ%))K
M[0^SC[7H_[6MW*C\2'L1O$#\O( !Z@N?:&,=W _^YL =UD&V:5MA^\J#.YB"
M8R"5^<H#EJ"F50 $XH&:)^F$^ZN]H"$71F\;O]%T'=67A_JH?QF8>?AU:9>&
M59=UC5FH-369439E/;52Y_)E>QH8X)%K>-9FI3@C4&X",*J@F-<F?M:QYV4;
MG$^M3_1$.R\(N-@.>]5%Y1JUW.*FF,U#+L0MVBB.CXJ9?.9X8F:ID@=HH,F(
MY$N/G<VPCTN@I0TTII2^HXCM\*#P%IH$_[>A^_>0>P"=S(B\P'=82T +VLG,
MU,8 YF =(N %V"$<&, 2YVM-W6<.PD$(5D$+3M0 IM6?1&MR1?\XA'GEMO>I
MS:2!II=@"8+[;BYK^;)-T:IQN;N149][AV\8=4F6/WFAJ&L80)MZ4FDXF6LX
MN[W;AR\54N4<JO%2$MJR=TG/#%1@KXA[X&YVB1F %"8 BI_8N#&B(#U\7E!
M(8N6>K&.K1U2>R<2- V$06IF;,*"5-Q"TX&&?8OMK^=B5;@VC9'J0EP272C<
MF<B6W_;"__PO;4F!&' RT25(!PY!#4:<,QBZQ,VHG,:HN_XV$/.-@6%#3$?
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M(+6=E/CO%LJ;-__!38P8T-JO@?8!&H<//2R$0D$,R0H;:%;X9X)$?TRL,""
MQ,"@Q4$YS/!!@P["!\T(,7PPPGSS-3@"A0YFR. ,'LXP@H<WB("'!LN=B&**
M*J[(8E-XW"$""]+(R$*-)-V(#!<Q"!1##SS_\@B"13$DB% )Y*S#$ A**CF1
MDNM8A!%$#)@@$40/83."!\@\"0(T*GFTCD?0F.!1F5G&Y,$-:,K$4YLW;,,3
M4(3\1 @ A/2@0CPM[DG;;7S^B>(V-UB PAE@C 7'"6;P8E=;C3[*UEQL#>8H
M G(%!IBE:OF%F&">"J87J)Y>:BEC>R&&ZF"\\&*&&2=4-@AF/Q C0DR> 8KK
MGP9 $]HV!C PP 0*P';4-MH0BUP_]XQF0 A4_7;4"_TT%8)QN5Z+[8D*T* &
M"D)4)X(&0HBK@77876>"!>6>9X$;[;[K!C3LE2?O&APT9*$%Q/CG'Q)(P( "
M# )O(((*,!@L,, HV" Q!SD(]2#1!Q8VV%"&&&HX7X8@;4RAQB&&>$,,**"@
M9[8FGXQRR@" <LB,+&A@(S+(D/(R,C&0Q 5)!/TX4,\&(:1$">LL5"4'##T$
M40P>0+30"$V7R8%'6(Z C$=4>W1 U2-DK69#/:QG94UICGU#FSK-20B<00%U
M PO8J*QRR7#/C91LXL0@ A*' E/66;W\E=;?D ZNZ5N2WH7XIZ%RJFE>H_:E
MV*F+=6KJ88NGBFI:K+IJ*#"Q_H"$"A;,M,UG ( F&NJ@K7ZZ4[/1S94!TZ36
M#[#0./_P>MVY'R=//WZ&]H"U2CT00O%^0AO<"\09UVQ2U0[@;/'5(L6 ]-,>
ME1OLVA]'RB%HF/#MM^1BUYT)YI.2KG?=!>$=N^;%X&X,:[#W@07P$:J?OP$+
ML8$&,!"\ 16(8 ,'^Y\  RB".1PD:"58 1)R$0J+Q2<^$K*8A3*4L8MY[$,?
MNH$T2K2]$(IPA$[1P1W4(".:=0,9+)C.*D2PBB60Q$<["M*."(+#(!$)(4?J
MF=$FXA"("+%)&YO(1[!D)I# I$PO&4@\%  4<1SM)3=)4]G*!J>>].1L.Y%3
M#UB .A+N"5EBS-4,D $#O<4!46:1A.#L\K<W$LY1?*G47##_=4='!28QH**4
MXS!EN5.52G*)*:1A"F,8S 4F,I/I7!S(LH(?Y$($%H@!!\1Q TQJ,I.<%,<(
M/"F."+6G/> 9'W;H%8_9A+&,S[I&:GX5K&$I19;*B<#OMN* $!2 *2]0'@ *
M$(+;(.\%PG.><7*Y2P! SP$3" $[A!G,7X8 '$>9'@!"X$M6:I,I"CB#&E8A
M+NV(3PC@T\ZY-! $=;'+#>ERESOAQ9X86& ^H="/ Y' /_\1$ 8%XZ? ^ME/
M@VU "PXKTLB8P 08] "##M+@ABCF,0UMC(,SX  >1""W;6ITHWN"QAU:4",5
MO$Q&(D#& 3P@#F2L0F<V[!F0<"B-_R4L849*"N+1;CI$B$2M0DL; 1)!$K6=
M@L!,'MBIU0BBNJ,(16DVX<D5TX:V+JX-*%PP"D>ONCW8[&Z6\8!&W@XU"+XE
MR@R28-0<Y2@X.0(N4G99G*5"M9B[8&IPAZDKY5!U.;S@U:Z*Q*OFSO*#$QQJ
MC9C)S ]^P"\SG&$%9J !8Q?K'\2>8;*3M<P6#C&(1Q;6,HA%P75BX)E58O4H
M!IA KU;3&G&L\C-;I8VR1)-+TRHEE[\+'@"&F<WA6<L<$3A*!)37S-\5!P"V
M)2UP1KM19*CA#.$3U[C&=<[KD()]Y1M/NMS7+OFYJUT<L$#^_@4##8C@GP4T
MV '-6\ ":O] "PP\"#FT8+"%K0 %%L#0A!AJH0QJ2*(,^AB(/$0B4B!WP 0.
MC33NP(04UD@#TM! FF80#QW$8$8L' @+>K8SEZI &M+0T9*2Q"0KZ92('AEJ
ME<HTU#/UE*A94M+J7GR4>$1-;%ALTT[4QL6S?;' Q[DECT-C-V1L@ EG$ 0;
M%766MAP. 6EELI,#]Q8Y+ADN=YSR'D=5N+^V2E%H(.L/OF&(#)AA4Y,K9!\G
ME\A "J9RJ5+,JB3C*LI8)JQ@,+(@+N,Y8 B"SD8^E)__3&<_WWD0@MB"( 3Q
M2,UXMB011NZN4A.! @3KB;,D(VUL"=L0#& I!6!'"(CGZ=X,LYC_2+&F-*NY
MRV;*S1S3<J:KV7'<'X]P&RL PRJ>6QURC9.<Y&N?!=A''G@)>SWR(52_"DA
M]!ILO /TI[*3_;\@P$ ).3B(%@*X@8#I1P43DIB#](O!"D640Q3Z[PQB<%'1
MRGK=LJ;!'42J@6[4:#H@$ <F/10/#7!;9C;D61!O^&&C5>D#.(T($:UD1(D
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M?K^-(8])?P0HP ,R+H]]Y&XC!8>@V8Q@)HU:B<,C\9C!#4! 4YNY%,,]J^E
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M$B5F1 C7<$"1 TVP4$M4)LC0$U,5@#1F17&"-G/2173B<9?I%(0G:ZQU ]"
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M!"! X!)H $V-X+4S -# X$C!6J[+^ DOKZM@HQ6^:V-9':,W+OT*'HKX:RI
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MB;LD\R[*<L$6L+=:)? Y>VHVBR2P=Q0Q9P:<2U<ZHI4NO=#<]@1Q(,;'-V*
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MT@"N$@RU?>F7"9@ !1!!3Q,.4!._D&S-C(@'4%B!Z/@GVHP.$TA'&=0 =[2
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MG/X?9/0&RZS,0DN'=%B'=7"'HPX'QS #.(B#00B%&SAD)C. :QCHCGBG 7
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M5!>VPA &;*VK@OYS5P81$XK]$2 4\H(,O90PAY+"=#$N1"$*8UC3A?U/HF:
M@ZYR0@P+[(B<+3' -7AC  -P3 '_(?L(R*33#^4(-:I2=<XRZ]8#*99G21JH
MF16I&(3M6&"+Q/AB?$@$M%R8]4-@.^,&5)".&LB@ FV4VH$,Q!<T:(@',N!!
MV380-D&J#6V"%5O0Z!.T$:FUH$%H9-W6\,A&0J-&+[* "E; A*5.-;.:C8X"
M[@"*)(%22<L$9>2<Q"54:@X$^&2!EI"AI1BP$@0 /0,-:+ FU*V EJ9;4S**
MP#09]!:NOZP!*&S !$#90%#)M5TS!^4[@AQDFAP8@0ZJ"X#J3DHC$K%(I; !
M!61L%DCB"&]*0$:*,VQA$&!09U%ZT<X?O/,0\K2!")#Q*'Y:,B7_7 4>X)>K
M'RA4*!=5_U8,#:B:H7R%6@,6(< (?*V-KD4M^4,PA2N#KYE>F#$PQ6!E3N@L
MBL90HEX9,0QY,2N<".(,Q(@!9LF;FPD8M0 #., 0B3-.YKP JB[>,8^E@0=$
M0A&K5-S.!LBS51-H)\DBX&(72=1D%! -D+D(@1>"M@*X&HBN4O-/'.>S 29L
M#4)C@X$>-:.V,]\1L&5+&Q*0$ 09?0"R4(0DC*)H 2'0  4\WC.?3R*$.S!!
M!)Y40>*0) TH(0D9*IB2Y'I BD97#G-9@JTKM30"%JC"MFG*D9HZW8(0K$ _
MPBU"+X=;@^4.<YB!0B:AE$FHW2V*!0KA "&N>]WJ$F*:W,0(=_\Y!<X^-T?'
MP ; -J"!!(?II'L(0(H[=56^%:! UO$(:G-TX %DH* %P<*5_8@R+03#D%DD
M3-:'#<S@"S;K?]5"=[P0K)AXQ32F'+:P3#4,XF>)$*7]*V%J3,Q30<3A#$N
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MW$W=X),%%%0!_Z1?"V;2-AS"(1R:H26)"M2@-(P=HYV2DT@:EDA.;%':Y[
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M6-=O_=ZO*?ECB[#6S[I6S\(2#13G *,XIZU ,O1U'!G(/NRR+:E)G/",#:R
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MN:-TN $9/-#8XHXMMH@C#ET.">6&!G<S )JI%#"  5*NB6>;H+;1)D7F(G#
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MDH=!W0U5 % TIJ/N/^L [D7>Y,U+3[_VV@N/ON\0""4]ZMT%V(SLBQ\>C$/
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M$CMFX&1VF+J?\S 5JL?S)(! R3TP@((G+2"&-$!P@U2J4H#H2\<A='&'.'
MK./R&,<,, !H[*\YO02.QGQ:_]=#0N,,+<C4!C3 5Q7 K$<U$]("<P9-(JW
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M4P^HP ;QK3)2L#5I2P>E8?$  3)6@8?!4&<Z:K"J?D<=ZN^)FJ@TP ,,2'$
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MH#^=U=DE?.1!\@++!P '(#&]ZBT?$AP$X $@*<#J38]Z +C>\E-8R01>'_L
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M3HPH-ZP2P/NF#'O"*A$!!QO%7-S%7DPU\]NFOXJA^A>^,/S%:.R>8YO&1+/
M%=HG7G1=4*S%;%S') S%=HPD]0=PZ+)A(0&^]#:L>3S(THO'A)PA6!AR1;G5
MBHR%Q2FAOX<<R>3JR)(\)RJ,>!FF>!D*P97<R4GZ<IX\+AG\N]]67102=JUV
MQJ&\RD27MJPL*T6\O7W<PAJJRJ]\RREGR+@<0&N\$L Y9>+6P[L\S'.GR\1\
M&;&,P_VPP7&\:JY<$TM\S-)<=: \S74RQ2FA -30=:]$</@K%W1LS>),=.DV
MSG3BQFTZD#M<QA5BR^;\SMEFS/"\%]R6- 6PSO?;A7,1SO/<SQK7OOZ\(=B,
M$L [ :QEF4\N',T!O= (Y\X,S1=A3+;%YL?Y+'0/?='Y5LX832 #_<1DZ<$E
M!<6"O-$DW6SR7-(S$=';"\?VB\IW(<(H'=/ YM R76K5C&.^.DJ,K,^E1M,U
M_=-,)<1 ?1FC3+\<3-&-O+9#O=18=M),G1*73,I*<PT@G4#R)JP^_=1:O=7
MUM$FP77@=E3?K%1;S-5FC5E9?=9P-Z[UA,^GQ,EJ'=<2)M>!X=4E4<6=_X=
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M6  S<^<!<!SL;E;AY>X'I4\7&X L@,< R#L/# !'^.T M#O_;E!]B/(+WQL
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MZ@X#<#JG-,3N^"J%V*!M"X RJLF2E+\BZ;=5N9LH*;=*!*<WN:K_$X^TDI#
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MH7@!\(PF@V"'\VR(!%7/!X50&&'/X!G04G&9DM&,US2*T+J2 +@D8!F9J'F
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MA?@K>J%?[7 W;:=$SPV:$C\616\U1C_9<J?HM[Z(?@&R( : O=#NA<!-X=3
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MI 3 0ELT8I2Q!C(<@!<2!#E:RT%^5$PN94\^I9ETI!WX""Q(@%-")82  SP
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M1RXY3CJXHSHX46OZS=#U#?,F7KL )MUFHX\SE,-#=MCN<3I =9>F9YJ#HUX
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MES^??GW[]_'GU[^??W___P$,4+[SR"KP/ (1Q.Q !1DTL,$%'8P0P@0E;%#
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MRRG.<[I3GO!DYSRY6<]UOG.?]<3CNNPBCLC\AESRH*!)=$ 7@TA&@Y(9:&3
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M:/-[V!D/=L0A+>PP0]O8[B;YLD7N\6F7/-LG=WG(58YR-2\8S0 P:$(.*I&
#   [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>abvx-20251231_g3.gif
<TEXT>
begin 644 abvx-20251231_g3.gif
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M: +G]FCSB([NF%@&H% %18?KL@/*Y8[U^&<!&5ZTN(?_ ' .<3B0_[AG#D.
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MM_=^4(160&C41BW2T/9//HM[*NA/9M9I;46>9P,_Y(DVE6**A'L0A&EY_5O
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M)AD"745_&C%?\40",7N>;'@-0Z+0=M4Y U!U53E:'$L8,AY0*N@U5#+!#@9
M,KTV9%S0F9RF<OH1Y=3KA8EKV:2.M*J+]>4<S[P?[$SEI-%A3694W4$Z@F2
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M#:T8#Q4Q(::9Q/O*1%$4Q4],IL!+0G!2MEXLC&9\)XD9NJ+3H=+J$U\#L\L
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M/+J;?S[Z:Y7I3CL&Z.-U^O&7!+#C0GX >:G1/L>P1_I(,,4MI/"YY\% !!(
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MI@ N_N:0SB*RSF((K,"%7@ (]*0&6,0.8*.M<H0)M", U ++X=1+I$.XLH!
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M9 "A/0UL0-(](U8P8@HC.L!BA!"PZ""$*['$<@HLK8320 %!,"(HI/_ B2&
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MX7"9 8H0(Z8+GA?XTD.%Q3RN2\-^35ZL"BS_$M #BBIZ0WBX020XN>:M$)$
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M8EA &2+@414!<%90$C!/>M:C 1B(X#WMZ=W=Y./1_RBH/H$;W/1PQC@(%:A
M'$+G"X11#W_8HG,70J>!VGE.#TV.1.X,G6/F$#K,)4 &*Z $@?5G "OL *@U
M@)V/ZB&[(./'$P4-CPAF@&2\:6 037K2ECHPI>)E"4NZP)(1F <\&P!. QW
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MXX[D;N(C/J1) _1F< 2G/@*D0T3 Q$#@!6C !=S "+R@#W0P$&8G$'2P#XR
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M=@_7D"4 Z$$!LJ%\!X$>!N'_? ^6?15 /@^V*MSW8 ?A8-&W? \V?[\5$3Q
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MW:01N H\0#*BG1X:?EQ->* WPS!E0 J\8$E/W..4"4:11"1E5 0B%<GHPYI
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M.M(1Q((,(*9,;:I3XQ*TJ/V'8V1<C7J>MC2II<P5<V195A5TG_%$-:P BN,
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M\"TEMA428 -[T W^AX.@D0XW0 TSA@ #8'.1)!CS(!C@T !]8 0?,63Y) (
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M47W@ B^84B=E4E]Q 5[A%7NP C&6A2WY%DAU RNT0BR0-Q@0 #(2&#K6#8%
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M@85W;SNE7=-,6]>S=M_5U]W1?!!"7>[.N>TT>.'E%[8:?'CW7G[W75<+B+7
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M5*8RI<9,26I3G(HTIBJ-Z4Q9FE.7]A2H+2WI3X?ZT@&T@Z4F%:I+"9,7 S3
M&SN CP'$=9$VNK$&2Y.//B+$U0-A+:OD0AI]O!:?"XVM'6$+P(3T@(&T!3(;
M=0-E+B%ID!D8;D0J0,1!F 0WNK9-F7![$45XY#@0N<USK2LL8NNF.1F1"&Y^
M%5/O;#01A+1H3:B44>W>EEC'"7.N3GIL[2;+(LB%%B&WLR4]C* "P9&H2IJK
MPNU.J8!M8,%W2C*(9FU9D"J E/\ !$!"-;9I$1?\P W=T,!*+&42&:S$)!.P
M 775Z1+M>:H/I^+)"KH+SY]\+Q $*('[VI<46N$A!LCH0$*C,C^Q:.6@!LW?
M_>X7EK'$UPA[*& !H26!9['E66V10 ?ZT V0)EC!"V9P@QULP0LFE:4I96%*
M5WIA'[+P.1GV888EG-25^G##&"XIB#L<X@N7^#DI/7&)6XQB#\?8PF4#\4]?
M3.,3O[C"''9Q4@U@X@MC.,0]5BJ0+5SA%&,XQRNEP'K06%6,1*B!7[-C8KY:
M( '1AP%C'5=9(=0.^D (D&E-&]C0AK:VYBF6BCT4E@)'#SFY"$B"PQ*+$KM)
M(@V"((G_+0B/)$LF+.69(,(D)9/(E$PL#,)0BMT3D/)VNX(D>M"*-?1C'ZL0
M/0\JL7QN4ITEZ:+6&;J6;H/E)06E9DI/MM,CFA%(39"%?F2! %:@PP[JT\T.
M:"!Z+I")#%#B EZ'D[K#OMX,.O #H7AW55,0BJI:%8BE)"56[(M!#/#0"2ND
MH%<I<$&O=M6K^1(KO@:E'_Y6U8%CK6 /$WA+6P8Q+8JRY=@:>'"][>VMJ%H!
M#D7@][Z1T8]N</G> _\H45&,9 \?&<0B57C#:\SPAR<9R0]?JL0?'F.+.QS)
M1]XXQ3V.\9]VO.,)7[C(A8SP)'O8XNW82U2-5H-Y&*".479@_QP+<X,!( #+
M4@OK<<OUM:]>J&M]).2&--36<YS#D7@"U)_\I((_\74AN!  1+SD(Z@S_>F
M:KH$$&!U+S4=3]!\^I\2C8 91 1/ _'1T\L^=B@,@AJ#(+M#LK[TJ \$$8-
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MS<,>[- 6/5&>'%&R%-$2C<D9_=&V9$L?==$=-=$<C=$AI<N8#-(IX\L&,('
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MR6UB*-:Q@WSB\(SB*89<*^[5"9PJ*(/6S?66 M76K=$/"!G=1P&ZKXHY,.M
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MIIL)B1D1FF&>Z267NAG00#4[N",22SU)F9M/Z5!S P( B.323P&T8P "A!K
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MMK&D0"XYTLN09'-?X#Q'"UG"$C\]BG7'M!WO!G#_ ]X]2IHND8DULUD3;09
M']955#>I&92;J$YYR6-*.9L2@,4(H'H$O H_!+ .K!  "57Y)_G&1X#I2:^^
M D565>* A/K&93):26EG<A4_=I$&6?FS@KH(N!=7'70SW0J@5";H%L2$BS0
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MJ24$"Y1 $Y0 *J)Q)S9$#<C !0W"1L),"&BHRIW#Y0X. 9 - = T;C%Q4@\
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MONQ0_A#+->A>? ;&?6N8RD ;O.\6JZ_Z.M4.'=E-PD 0Z:AV<"3*JG,[GU%
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M\=UN\-AW#Q<)D"A2U_HZUT)2.+ ZWTM^21RX4CLJJU:B4$<.;C\X._=H=]C
M''2#Y*KJMT^Q2V-X ]1+%K3!4Y]Q;\&^1$PU+U%C'3N)2"#K<[4X2XPUZ3JC
MH4"CL4:K[Y__+JZK1%N_UZ^ZA.\EDR-/$_3]A._B!#B!([!MZZET\I,O6/JH
MC\7%)T>-"\41@+WU2L0A0#]X= 000,CSZTDI2[J4JYD7D/+B\ELD HXLYGR6
MLO+"REP A($$ A#H$2!00()V"=LA&"A 0$.#!R6X$*$!AA$C(SC"&&2# <2&
M QT*,/A0H<.%(B,"</D29DR9,VG6M'D3Y\QT1NQ,L>&BFPT-0XEJ<%&TZ" -
M(@;!N+5GR@HC4CM,F6+$:M8.5;=V[<!1AJX1'<2&" NCJ]BM84-@(3MVA%LC
M(3:&&!'"JI$?'90J%4%# Z6A@D5<7/>F04[%BQDW=OP8<F3)DRG?_TPG[ &Y
M!P^$I7.,(!T" Z,-L# 0P,"Y1!%8L[:G0T>3'$W$Z:AM.P?KW*U9)Z[\&WAP
MX<.)#Q] 84"[X\F7(T>NW'GSY="9/Y=.W7KVZ=NQ;X^.?  EI3:,8+D; GV(
M#C8DB)#^O?K[^/#IRX??G7H[Y T2$4!2O[OZZ&O,@ :JJ88!U& BK3@#   -
M0@ <O(&:T$(#8  )-=0'PP<[=!!$#1U$0,0- :@0M!)/F^DT ]+)T$4#]'D1
M@0%$$XVT'/48#8-V1F.AG1Y;1(W(T\Z9!S6(]$  (A.0@.@())A\R*0JVT%I
MH24A@FA*EK1,R*0VFBBBGRFOW++*@0;2<O\B-1,RP"0$5JHR(3D38!),A1*
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M)[98#3\C-)>\_ZO5('@-T(*^H8R5%O:P'59%TMCQ-$_^F40;  <):C0"XB
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M2", 0D_A0(X%SG9K_\]*;*@F^GY9;93,--P&_BPOF(DD7_P,<A$ !MP !)8
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M 5B%+T?)\^A-80=VL(/!O-&X\((+9*"Z_"WA!WW@P62]D.45U %$=3CGF>B
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MR6VP#FB8R3,1P;9\R[B<R[K\J#1\.#^H4Y;S@Q@\5,/FG<0LS!G,A,Y9*C4
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MIG3&3VE>0<Q(7%\>(WA.BV$VBR]G0R4W9VGJ#61YENL@U)#6BCILX"W1#@X
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M5S#IQ80 5L .]-H'+P,(; <,.P<!=!"3<>%K<'! 1B]W$P!YC*L=TFL#NN
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M!'3JWPE(PKYN4'OE&NK]F(CUG#JUIJO)EE"[Z'G!^S6K9)?B?(#_"%&$=13
M&&B"UG<#GZ\WP/.K01Y-!\?"'2#L]E2WR48CR!J!L3!H O/@<'A3U)1.YWJT
M>3J.H(UL9)ML^JTUV<@H<(0F-.$(L04_'8&K?68_V]G4AY!HM2W'=OBL&O(
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MKM'Q+<D2?IL2R7X:K@&X%T"2-8:3A0@2A2BX=3YM\]+ B," .2D)A5YHCS.
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M.UD.\Y>Q[91:<M06;^R  8.AIZM<(CSA$M=]UT(>CW[#&[Q8*S6KD97S9&,
MRX0 !"Y1#?&<JYMS^ 8  6",:9Z+FM/<@%O6))>L^F( V5!C5_6L7_[JI\\
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MO!D3,BE378C1JY &8OB*#_K(KO@*MU1E>E&EM1C (,Q ",2*\\2&$)Z32P0
MM\A*:437\ZR3K3R7 ;@38L1/7O &&*[<;9R+8-"!"2#!+#1''0+=POP=!4D1
M!%W0!9G'T0P0TTB8>W 4C'!=S_$,R:Q -S0=AH' 'BPB#_1!(ZZ %ZS !8Q8
M'62(>V04!*%,TU!(>_!=>/@43DV!$:@=VXEB"$S!_R!X "5H4'EHU TIC0(M
M)D79QQ_RRRS>(G$6IW'N204&"4OH :U% !R\(]DP7Q'4H^X%VO<=A Z,&DE<
MF9S%35F)#=F89 28%438S40((V 1#IH<!-<LA* =&_?)&4& V2$%WT%P9Z<%
M'V#IP.P5@?LI%O?AFGD&@!60'O8]ISXZG_"5U;G(T3;.ISO:IZE9)T&PWBRP
MGIR1)T'H >\!5A'PU>?!I_[MV4<R'X+JP1LUP3C^FIS!XZ!,%LNI)$0@5IRX
M%9(XX)K88G(.B0,@ 1UL#DS$ED_B%I&^H)'"VTV>()*2&PD>Z6HQZ2WQ1+WQ
M5K[1!<?-Q&!\9:R8TP_2QO\0&L#S+!S"5:$$N, @6.%3]@7TG(989MQS)=SS
MP&D6<@\"9(MM:-.VP"4^"4<Y#09RD.$LO!P&OAQ_'=$%-5C#X"$#*<R_(%UA
M+MB%2)&)$*9\F,@'N8",/=T%],$/_  C-N+5T0")6< %!";26(B2 9EHP@=T
M4,(@_%3:S:9LLMT4:  W6<@<!N?8O>%Z3 @?IJ85C=%Q#BNQ%BM"P"17(5*P
MG6,^\IDR7J,QM@-%8I\_0D0SCF,[W-%UHDNE04D^ I(.; E&<,V8;:L;K6B;
M$,ZD_1$& "!"WE$;$$0[F%X[ I\;64$W0@G86,DYM,$ODIJ:>5E(!D :21*J
MQ0W_0A+L]QW@1M())%&:"6! !!Q2-R(DX<R"OT6 /) D272?'-UGM4Y;Y.0)
M7'5)'O75)]'11; DG%0;%NUHD!P!(1" $\3 $=BD":I@DN;DI@1E5PSI;:4%
MT/+D,+5;+Q&MJ>B6O>&;- G7Y<P/6HZ38)2&5((I:D276<I&M0S/!$3<^EP+
MG%)+M.#%$R(&"XR77O!*>G4A:9"E;2B&=.DI7HRDR=W&[ZU>'&2K 5QHO+#,
MJMI07XX,S_'<B1U-BS%5?4!40XTFTY@,B]&(;HK %,@ AC6=9?Y '_# #X J
M9W[F#81F44F0T?4,S375BRA- C! 9PQ"VG4 %H3 "*Q=_P@8P<R( ,(@T4/I
M9I$5+L1TD*12U' :J_ .K^'!;(^P!"3IP'.>0_1A6CNPGJ_-G[DB0Q,H1.=]
M7OPAA F(0^1%)X4BQ-P$P.<-FPX('WLV'H0.TM949T2XV?*5 #((!-APWJD5
M@3U@;!LT@?'!@31@ (#63<16VD"4%8R29/<.Q%Q]S?;9S;EPS;DH%IXU:(06
MUO#1W_HY"?P1*/4E*.'XVNU!< 1@K/.>*\$V@4!<[]C$7A<EX#DXX.$8A$J:
MB>)(CI+(**$0DBAYVSDX0&B=&]%&J<XRZ9(^:= 6Z;F5V[H5L0M":>S\#H[L
M#ES(A4Q<SA:6SY<V+8\@!UI^Y?_7*F&OH$:LJ _[&"%WZ04#7)=+>.%>8%>:
M9J4T?>E;YH5<! ?9^H89FB'^'($:P@M].<>D7I =%AUATB$A]VK7/5$%B5VC
MNJ)BGJH$[($+6!A(@8 ;>.KF]H%F7MT%U $\;-U$?4<@TV&*Q0=]'!T"E&DW
MR8 1=, (L)TNC,"-488$=)3H$J:BXA# Y&&E1M%U!"_Q_C(POZ0NKL2\8EGN
MD;!TH@N7P8VYAEH$$*2<*5I9D?"; 9KVKIJI81D!5%LVQB])D"C&.O.K,1]\
MYMK$.C.9%00<[)D\+%J\?O";=<W 7B-]*2/S[F/XMM' 0I)B<9JF#49[9NRH
M^?,S(\3_/*2:JXTCES5!$52DP0H:F3GDMWXCK4'SFXWC)VE)VSP;2M9HCJKL
M&34;G(A)V42.RP;*U1C%3)2.$OLP"QXM$1MQ+2'Q3\;T3#?QIP33"!9I52#E
MO2DE\.0* F  &*=7/0');H IPHDI8^!%.H6E5Q+7\Y"&R8TE;BSA^R2<,REU
M.N#*;%PMQ463_-CQGQI <)3UY\3 R^FE6!U=%2FNPPPNI4)N84Y0;@(FO_BF
M>OC+0_V+ <! A2V!"]# $ECF%'1J'_2#I\K "]2!!8#N[@;=*U;J*VKBB1RA
M3]E !ZSR*M^8$=@ "'0#/(S,7 _,XH;=J3(4(?MR,+>V:W>1A?'N2)((Q#D"
MEI6H\)]2A$!$FY_8**#896-UA&^S!&"I<$3$'D;425M9B:#4"8Q:!(PB!'+[
M3>SQL4=O:+PXCKP>R4D7Q$ARTMD4]T:? VXG#@UW-"B5B8S:,.58SM6H=1S0
MP2P$J4O7#A#?=,X2$U'B=-'B=TWK++@9I9(.):GH" *X13O_N]=H^,52;G53
M8_$T'89Q,;5M& _["(_5?BWT#%=RH(:5]L469^53;F%S85>=A@MH[ ;^]-/*
M];$W($$<',$1G*,$(0P!)1AJ+U!?2Y@(V "-Y90$Z >NOF)X]&$CTZ$!4$*%
MN4#3$?8*6/(/4,$4E-0<T, LD^YHMD@'4;:+L$A[V&%TP(Q/K4!GKW(E!,C-
M< C@$3*8$U"'X.;8>1UKOS:=USERQK:N-%E&:W2.)DER3Q)5M;"=[PE*JJR;
M@#2A*]N2D+2RH3?@2&!*>%)(/QF>\\@LT $.'(&WL322^H15X 0%4$ [A+JH
MDWJHC_JHX\2HFWJIMSJIK[JKASJH_[,ZK,/ZJ9.ZJK\ZKJ>ZK+<ZJM\ZL+LZ
MK]MZ" KX$3=I3N-$#,Z".V"QP,&$:]0&W.H##B(U7A1AK\B*M\0*:O!%_7CX
M$D[+\P#<6([&KTRX=-E&%THQ5?.%^I33K>"/]_Q&O,1+<N!E#<0?>=OKD;=A
MXS(4X/4U1TE'%-B !$2!@(A(B%3B8 9GPZ3,;Q)F=3# '@BV!A#V2<F %UB!
M&VC !9S4"<D F"-13=%U(I_NA@C R]"8",! !W0 B(! 3OT<Q,RU(I,,$CF\
MX#+-G ^ZS__\L?;\%Z4$>&\1>Q]$=*N$#1\]T&>1HXN$F?1-K'55M'F)C(HT
MZLDHT1MW:/]83M!+S2QLX%ZN-$V+>A.3%MJG_6F)F]JWO=MKQ=N__5*H_:?$
M?=P'!=H#A:>?H,\2N'WGUA.GR@Z  P;DRFP$]>%O:30)R?Q8$[I[L6Y0 _W
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M7[4K40,:\&:'&O]B \XFSQ9[+#8 8DN.A43_BNTSSZBYX;/6$,!-6-GFF0Z
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MA9J^Y3B<A1,_<9B:17F$Q;BNA3)N@YJ6J=; AUR>:YAR+5MD+SG.H5J$8SD
M1GO:P1OBX!RP SOD1MF\C;S.HV#&C=TLS#T0  0&000T8 KX*02P  NNK8%
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ME7B:0)0% K\;W'O=7"?#5'4/,XR&7.9L6>4:4N6*X'#C5)3GX2I_ER+G 1E
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M2U [=930/Z<$--%-.]7S4T"])))44E=%0558E2565EZ!Q17:8ZW]-D<J#]"
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M5[$2.3,2_T%V=^WP8V"8=&Z#="I##4:&-WT%4.LW$5[V9(-3.'W1&9\8&?-
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M1+-A@]BC1?HS=*B&6).(+T&&-NJ(.68V:#.)E8B)>P=D<\,6U=")@X>4+ H
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MFKW(2];V5\@L>+SY&;VZ/%<;J,JZZZ&&#(#>.Z D>M?'EI'*BX/.V]>/TH)
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M G0D#Y;TCB0:Y:60 O"\)"'I!DC21Y$^BA(O$4^D2Y(> LX1IR&)*4PW*-,
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MV$WZ/FJL ^XO4,;BX%(#M;\="GI2%015#U%E5PP"&H#,6M7_#MBJC42!6!(
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MCSH48[DJ7$RJKE*J^MF4_ $4 EJK27$644LK2OM%1+L@";J4_U&5"UJ419&
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MN\#,T\%T6BX-2Z-=*#H[IB8TQ"J%*+GM.QL1DAP)/((U@!O@G7TDDN;)$N(
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MS)W-T7N25@T:P&@T7(5=XFQI 8 !-V@ #F(K8_S.X%/>4LLA"&)=_88@3!8
M2G!O(WB($,""5[<U&P !$5 U L\?YY3&0KETWT268TW> $]IZ-2]-KAG'="!
M1,@(X&PL"6]V9W]PM8;2A*D*)"+F5\(O(8Q?^OMPLP;"FREQN$ ]:S\O6EI2
M"H__(__%7_3=WO*M=G0/W['N7LHR=V]CUWW6FJ#K&M'&4L$N2RV$N6ENVO7X
M2RS/8#%4 @80G+IDTP-)$#9=> -)$#C=NC+-8+5\.J@U.G66IJ2%8*(+1,;D
M.<H,6HG:X18A@!S0@1P@P'M_;2&QG2)F $<=Z#NWQ.3&LX3^"DE-!U$<'NK)
M^5 -@%,,'RHNDO#1$@0X^B]^[C)F'^G>,\"@U7; (Q:0JG,<H*R2M&N$@0:@
M@3F@ 1N0H$KGH7.<Z59)1U31 Y]L@C9@[Z/F(!.ZE1D8!)V.(5WP%<'B*PEH
M*E[[Q0PBUZ$&H!.2*ES_$U^KJTNCE!URF9=Q<Z.>9&-Y_W;)GWQ0-HN1#(H8
MATI?OFO.9])JRV6;P'" /+EA#E]CH^67PWQ8YN40SU^7V_SRU:QKAZQ?/HO<
MT/'X8YV@-9WJ8$Q!/5HM=5H,Z/*G3>>T;$NU_#!4R.85.QS%81  D4NY+!#%
MT8)UZCHKU\NS% K\F,.@<UK!-,RUXU+K*%HXKUMZ)GD"<!DK<&V*"M6+JH$X
MB1+-S$?A*1Y*9?1!)XG=,4V , #  ,$ !@( 2*AP(4.%Z0(@2(<  ((!-P80
M3$=-7T6"'C_J,=#.  N">DJ&/!GRG)X *@,(2- N 0*9,07@3( S)TX],F1H
M %'GQ84+W63 H"2SIH"9._4TU?^I\^G.FS';,<791D<C'?82T;2Y$P%4G#7;
M"8"*  $,#1I@3#'284J'$2-@#)+A-"I?G65C&A +56?@JSO]IK7:E"=BPU/)
M5D70)(>.RN*H"H <MFG#SIX_@PXM>C3ITJ9/HTZM>C7KUJY%!X@M>S;MV@'.
MT68I&[?MWK5U^^9->][MW;OU8)@MO#?+Y,QSQQ8.7/?RZ,B-WVZYG#=NY\I]
M@[==/7SQX.2SES_N'?OY[.MS7V\O'_SX^;]]O\[?<," =@,H_!>@?^<,0" +
M+!18((+G',@@"PXZ6$.#2F# 0@T8*!$ "QEFB&$HKN#!!!-X*!&*$B666$,H
M^(3(1@U,*(;R8HPGFHAAB:@P@4H 2KCCH8P8OGB.$B_N:"$+%5[8X(-*+JF@
MDPP.4 -_%+  ((#^71F@E0)RF>666:;#GY;]_7>: 0UXL\,.!O\Q1)!^IAU$
M43H"Z:/1G"N%1M   % C9T0&A!0G:@;I,Y ^U&Q$C40&#'"H/AAYU,X\)!DP
M3SLKB712.^<<Q"F#[00 *@(QC7K33(&A!94>I:X#0E&N@O#"/'7,\0((+1PV
MZEZDIII6J:HB,-.H-JW:A#A-5!9.J33]U5.N/$D@PPQOQ177.C8,HD$4SG*+
M%F8\>6L56HU5U1=@Y_8TK &&):8593E$T ]/[2YVTYOWXINOOOORVZ^_G]GW
M7'0!YX:!'KA5AQMQW]EV,,.S+3PP=.T9W)UL&$AGGGCA.4RP;2PX7/%Y]4E<
MF\CW"4QR>RI;QW)O'7<<GL@S@^IQ;P+__9O:F%X&6.6# QS8(-!++BDA"QHB
MJ<2#2F,\)) G[LA&CB%BH&( <HC(A!)9BZA$B((0PX0@6H32=8BHA)@UCB1B
ML#8&&%;]MH5O9SCWT0<JP2"$0O_<-X _?[DSF3P3/B:6 ?)'X.#]F=E -=7$
M9D Z"[F9<YL147,1GQ<A4!+.GQ&4^9Z%"D0-I0BA%KKDHL^) *,W,.KZ1R+1
M'I+G!G%J4 "6)C=/<P'8)--2CTVUDPCK+ $")904=<$+1#UOP0M*]4J83N.6
MV^QA6#V&;&4Z-!%5N*I2->Y,6$7A@@ANP= !##.(,$@E6;7+%+F)%8:8L,6?
M)?Q9F97E+\7#_\Q4"B,  A2A"?(RU4Z<LA0]6"Z"$IP@!2MH086(!SDJ<YE]
MVI$<X%S,8QQ4CWSJD["6S.8] ?L=>ZRCG/C0!X491-D+,4:>$<90A=;1X<;"
MD[")P:<\($P/$8&X0QQ>4#3\:0?/$I0@*B4(2GICTH.09#<A'<UI2@L AG:$
M#ZRQ 4>HN%&.E("*,;8(0V=;FQ8$,2(6Y>B+9<1 BY2 -4'LZ$)#XI"1A%0A
MI4G(043;FX(6]$0$\8R)BSM<X0['2#(I+G 4.,T &M" '=2 393[7 3=5*@^
M80X %PD);#YIIS_IHR"I.8A%J+$GUW'N4!:97:4\1Y)+'80@&)"4[O]8TBF0
MG6-8R^)+ &," S> ('E/N("KF/>\.=0*'A>@Q%^PYY1K%F\PUV2@ -I &1WD
MH!\U&5:XN,7-J3 @!!H00?SBMTY=*08JJ?I556A2SNLEH##C^M6PRI48IPSF
M*?WT%4W6<BYRK6HG25PH0QOJT(<^)V8V.UD1:>@2'/:&HAH3F&PDRM'8>'2%
M%P7B#VT6&QM6U(@6;>'#.,H;D;E,.!J-#<A\.%/GO-1A&+V81%EVLH=V!DN2
M3!Q1#40@HP%M;TNJ4(4TE*0M[I%#+WJCU/!@HJYAP!T4^AH+W/&U&HB(!5A#
M!1W+*$:MXD@.KF ",3;THKCEC8]YNQO2ICC_R*0>B (&,F3@'ME7P?EU<0!:
M9(!.@P#'.6 'D^)DY22X.CL)1"(:\0AL!J"HB&"63[3C9&D,<EG)541T!I =
M+24UDD!YSI>APIT!SG$.XH#*,.=C5U4,L )*:& )E* !\YSGVQ=(SP+PN,$\
M7B 5 12&*5F!3%.R8CVK],-8_9C*\&[2K.K:TR\BL $,D"("!OCO@8?YEO"P
M5]ZL.-"<UTM,6?Z'DUZU2WO'5>]X(0C4^^(WO_I=S<ADB)X=TL=F'(S81U.J
M'A-J4*3NB>'1"EQ"V1RDO\&!X6\2G$/X?/"&VNEAA0V\8 !/>*4KV_#+&LRP
M<^P7 %/J$E%]1B6?_QU(07O3D)&<>J0A97%'5<NB$MPXQE"TB 4B>M&+O,8$
M-B@!CF@46XB2/%8YCA%#(O)QD76,8RQJ"(N!/-"6!QEC T5Q2@88JB,%ET@6
M%^Y+E$13-S+)V<9&$"&9%0B=!P)GSP3@!GZR$^ERN4H,;*25!N <G25'RTEY
M#I<G:2W(&JT28.Z2,<*\BO $((';/F%YNG5>K&I5JQO PP(WN,$<UG7<V19S
M7J<2%ZDR0XU)KW=\B\%GL 98JIS0LRH)W=5UHS),7@<+,]JC5SX'*%!*OY=>
MOMHF3E+L[&=#&[\K.ZE.C1,SDLV4/$4@@&\:$ ':9'ND :[-MHO(DIWBIO^G
M(2UB"4H0 &]3VV(F#<"V,Q;1Y<";B.L6HDK'/>Z3./B'^_:P@J<]&SWO%TN/
M],]_ $2@AQ>R;WNK$)>MB"$&Q;5J>\0:UY@@!WR("&XJJJ.1!<&"M;W1R&,4
MXXX"$**PC4WC+3]1TUYT-Z7-54D0PNO/I+2@ $@IS805>B,-M\C&56,'[AC)
MY^H\0820;B!2IS/J\J2HS$EV(I"Z,VD0$ "-W,"5G)N31T@[NY 8I"0@.ZU(
M0'804+6V)>W:9GMU<EB@4&()3W!545XP!^=)#P&A'K4>UIM<8_-E+_B\"7/%
M%3SKCI<I3ND?>ZU2O,;LA;G]XQY?#-CX^U%>@-C_"WT#S1)0 B+WN/:--NM;
M[_I_U="'SV&A>$P0@=M#KAWE[HWN"5"SR.F@!.> MP&"7S*&\?#=MU]^!'1@
M@-W3Q@'-EXWMF:^#V92 ^;?G]H5ET^[A1^#<QSD^<RA\#CAPO\+OV4Z^E;.>
MG;8L @T /WVR;P+@:__^!(,_@*<S'WO[!F?AUXKQS#E $9@YB(PQR12=PXXQ
M5=U(E<9AB)!I#89(#1.T38X$P!G!$1V<R-E(B-KDS1>8E<?9G!L-62A8F834
MW)$LS=TP2)8%#2$9X)<52 R"PU^1F='MX)8L7)F8Q@VPF9NUB0#ZBYN\4M:I
M&.Q4'6@@Q)[T29U%!-JI_X9!6)9$#  "/(H66L36>02G@(1(Y X+@,JF.%H#
MBDJZ*$9\2< >+$%N+<\RO8 &N$$?[($,7$!PB9H%;,948%-Z^8ICZ(I86,5@
MJ$NK!6)9T 2QK4L#$4N]S$NS"-#_9)<Y:0_YE%X@9E<Y,0:] %2I8 \DOMXH
MDF(IML;$R)1]I%M]>)L#!, .N!N]<1O)0-]L'$2^11AY=$Q)F8#SK58MQD8)
MZ( )-$$NR@8+%$$_&&-LU%L*^5L M)OR551U',Q,<8=L .-W#)RW<5"X951L
MR!_]]<8.1$ OZA\7U4S[Q9LJ_A][#%Q[>%2?I-B5!(Z8* X"#LV+*971N."%
M8/^<D/@1A1 )RU%(R=5 VK"-U,0",905DAD9$[C56.U(UB 9"X3-&$$-AT!@
M<M@-C1F-T0B24275T!C(I3# #D1! -"C8 $6BP568%D)TBG=2!0*Y4R0FV#6
MY-29Z6@2:+! Y@P$V($=I#2A:8 , #B*Z(B.ZY@=+8$AIRQ:2K@=2[0#,,&$
M(J;>W+W7"FA "^16\KR &U !%?! 6?* "UA 6H[:!<B39NS3]32>6BR>_6#%
M=5E3?)6>)&Z/W0W0>>EE^3@7 (U7LC5+_V1% %A!%E@!+N :^:!*KA!B>J77
MZIEB95KF92X$>?Q>=;! &S2!L<1 "XE? -B>+>K \A'_ /C=7@/<!OJ=IOS%
M!AP<@33*(C0N7Q'$1O6%H_*M)FT80"_NAFO>GBM&C@F( WQX&^3D!OJ-GT&\
M)O?I)FL:P/?EFVXJ9W9DW_3A1CG>WO7EYNW! 3"6  &<YOQ%)_Y%  %\6^_%
M!BX6P>W%XGF^XO+='W"$H[=YD&_,0Q.<HVSH7BSRVT:IGPGY1H;11G[6!H&U
M5$_N%P$*B,,ESH)(Z,,MX('86 .ZU0LVH![MB$9FTH8<R /2S02^U8GHD5M-
M(-,PU8;LR-ETB!Y=")'-C=(("0NZ( -**-$4R &ZUN[H 24PP&#I($L*W4N.
MR6E0PQ RJ)W=Y-1)742$'=D9_R%#Z,&>E(Y&J)@HM1;7C08"$(CFO([I!!HM
M54I5!LI3 @H9ZLY! !.HL$#I^2%CS 0,O*%N,8\+4,$PF"4/>($7+$&HB5H=
MG!ZN>4M?HMXV9=.LS4OVQ%,]%:JWK$KPW)HG^H^IY%,D!MM\X26W)( ))&86
MF  \#!MUH46A:L8@JJ$ 8.:JLBHISELBA$,"E8!_^<;MT09S!D UB .HD.=!
MO.<.G(-Z,F,_T&8M-H'O>=N:Y-LP(DQM6$$Q8F,$ &L)%,'O$6/"%$$)+",S
MIE]Y9.M!.%^RTB9UAE\ [.;)$$!JLH .$*NY^N*Q!D WA*/MI2;V18 W'$PK
MCFL1@(3KM\EBOOHKM8)*$>R N')C;3+,??HK2P7 ,"JHN JHN!5837$,!XV0
M=S#*LPG5XCC1/49)C'F9EVV1D?R14YW(C&YHTW!('D$50&X(1^J1D!1)W !=
M7+$H"UP@HYT(%E'(B-[<D>!HA4H<T"A(.]3 .<R"'NC!/(   _!@2PYIU Z.
M3.[_@)YLTDT>BD0XJ94RG6BPP$34F4!@CDE,*6P8P*LU"MH^RMG"SD<P'4%X
M4$%,2N[D$E4Z&DP<UZE6UV%UY5=>P K\@%GVJ1?LP0K405JFY0LXHKF@RGHU
M"_>$(K&97E9B8F:(Q7DU1IQ*'F(8Y@!%KCQ%GEIH#V0H%PX,0Q;@0!OHVE6<
MA?W0%E\T7EJTZNS2KK/-&P$T03@T 8"2D"V^I[^RYVWP!KP%K[DV0._1W_FE
MYDGT@W=&HVN)@Q48P.XJZ$D!9VP$;S5X9VYN;W0DIVT4KVQ(WRQ@7RP6W_V1
M*SAR7WWHP?/"9@ 0@/ A$/;6XG0":#0ZY_W!)OVQ9_*^_Z]K/>\Y1._YX>9O
M*&P,-8(5Y$:V=E]Y)-^$O9_$T%Y_28<,E2U0+9'@3(DA?5F3[..2,,@?;>B-
M-<V.\:R&XEP#7MG%:9&&OHV$I/ 6 <G:H&@@U4V,+LV6:5F%%E*"_(P!NA:H
M/(,#=$,W7$ .LF29%>G0H=F:/0X17JT$(436*:$6^EEH5&F41FE.,MI$I(9!
M2 3I+,I%Q,Y'S(/;P>VB&80'P5TOJ02#5**L&48;:H ,V"D(> %9EF6?KH 7
MK  -W("HL26E"1,@!J*SS%>QC4^MA<MZE<\Y6<6HK(H#A:*WA$NO!!0@ZD^B
M5EY>'I 5X$ 69$'L6JJO[8\#3?_J7]3N*K.R0U48#B5"$\@JAQUH]G$K;ZCG
M\MUR;.C _)7;P19!&^!&-<C?060G??)R!/#K;!R,<?Y>,WH;Q1+C,I8 '-"B
M[]$&,=/&,=\>^KI;^\%G;;QF!" #<>PF AE _/*&>,XJ;G!S.9HK^19KO>9;
M!!!G,.:?:[UG$RCH 7N?+LO&,*Z'O'K##=5&QUBE02OT?% 4;@P:M%D)X1C(
MWT!<!PLMQM28D0BDW<!-7!5)D3P5QNV8S2$)"UM(SVH(5+$@A83H'W71S18D
M"^[84H'P GXLC%$)@<0& _"T!-R \Q (T3VMU/K@GL )FNP  Q@$PB4$E_:+
MFUR63DK_'49PBM=J'9]0L>R,A&H\A.M@(1>:3E/2TJ+5CML]&NYLBMQ1%[<X
M%P.L %"XQ1)<  \$;N .[@JX(: J[CW=9>Q64W/5G;*Y+N<I&W6Y%WSQ);@<
M%V(8&^?5Y6+0S[!1Q6.8@"@KIB/.%JDJAB-7KNRV\F>#MA3/!X)F!Z!4+WD0
M<S4$;VGR[^X90#BB7VMSV_/=;RPVJT/K0/KQ!C$&)_?E&VY<KVR0(VN";S:2
MXYIX'^\&H_#!6\3 <^0PL/V"(W'/[_RV9K="H_ M-W;L+_&.YVW4,W%O=W3P
M1CO\)VWX\W_9(G]:,#(4@7]1Q[@-T8/%4(<YV 5C<!*O6$5/_VB.[@W&'8E,
M+PU3Z; 58=G(RNR-!7@6W8T#]E'<++B&<)&$2+B%9BB&ULV&8)%=*94-0IQK
M'00X2, +,,!P$9>1*K%+MB0C-0X$5(-2OQE^YPM"T,F3ID/8$<2DB$861R$
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M"OS])V!Z! J87W_PU39  PWL4$, !GQE0(37D=5.A#=0DPX"$[)@&X0;AFB
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MJWBT!29^>(&+QS=?MM)Z5SGDP4+;70TF$&#"?9-_IV #WG3S_^#?Y>)Z@T
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M=?(S4'&%/S(][7-1?;(E.O,1Z] &!-  ](-D;'):50A11')CK54DWI:!GH(
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M?Z)\5T*.4R>^V.:L M"X77$#(L #2?"C%H">;N:W)/0"&F"DM\N^3+6D_OL
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M &&B 2D< EB !3:@$U-@ QX0!0:'X &NX(*ZB@,>J*"NU>&!GZ>#;LGH*>G
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MXAP=M"<\[CR$)U8C_11S\,QM<Q(]U48_?;EU]ERT"<  -@ "Y[GW-1F],24
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MZ^ZL!X8,&9OI!@:NNV_;=E*=/X<>7?KS/7R2-'@!@L83$-PI?>_>G=(%[A=
MF"]/7L*%["\NF'</(O[[]_\OX(%H8$7*_EQ)/B5)PHX?W'AA.@,/1#!!!1=D
MD*AZ'GCP 0DC?( <"*'[@3@7NEE" PTZI$2#%Y88KX]A>$#Q!Q1Y\((**[R
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MVC7XGOL%QP@\Q4X)5*(24:C$N[1W8/\29*$H<4 ->)6.\@7E:@@(  -8P*L
M=)17\,.)3HR5/Q;HI&3NH-]8CL(5KH3E*],RBU@.F$#@@$LU> E8;)+C&L)X
MR 8K"($;0D!4HWI  @RH6 *3C*]OT28O)B" %9+LFB7"AH&:08X>ZCH<2EB
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M0]V)>OPO?(0XX_PXX'34X/0X R3(>[R( =!'DS2""NR J!/"HZ+.>;3'D&N
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MF,ZFI Z]F1;%?8I;P%7UZ,4F305=;%*K@,7PN$_W3,M>:4]>$9E?H=:N\ 4
M#1@-N$ #R("H[%OMO,JTP!MFP($.%($.Y  <;%PQ(0 "X )[>%\"=(,$_*%F
MY5NVK(Y+I!SZF1</%,=HV)HXW98 V11@V-P!X10(A!>5"08\Q=/_!9V/]),
M\H<_[8=^/%U^'""ZW(?7Q!1^-$:F49TP4MT$6IWZO  5[MVHJ5J)" 7HJ=6*
M6,[4U, *M$$;6,$U?MQ^!0:3:( 5N8$5G(.ES$-.E(@.+J,ZDIJ#,16$&6$2
M/IZ'R=$[%EZU$=Z'/9X]_PI>WQRA&HG8'Y%8Y:UCE!2%I(Q5Z(356/$$Z'U>
MZ+1A7[72ZP&9IW32]%1<EOE*6K +C6UD[;B>QI527UT<D<&%7!D3>ZQ?V,A
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MT^K,*C9'GRU,D6R'GRF0!#&H)..3R>PO<YWE=>3E/(C"=XB'+5 7?JPMV]Z
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M52Y!-]"6N2-'C&"G&\" *3I'SJT-PC",3/7(__G(!5#9'&!W3"N4"<73<[U
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M 0]^X 4O[*$//# E^7Y@!SN\SPJBJ ,\G)0_*U$)9T:YV5%VUK.?(66 !02
M/G083&'.)1VPJ,<QD9E,9.+%&W H@=2@V:^H#0.:!.A'GYQ)J&%NDYM[^2 '
M/VBV%[KM4B:$X=M>""D2LDULZ/P4."'CF@8T8 <UP!L.]=9-K2&@AKW!@.!J
M"+C"(6ASB'O/[+X3Q?!\AT"3ZXZPPG5$T=$K0IF;EL^%W,6Z!#A40 6-'+?
MB%$CAO2B[(D0>-)3K-11CHCD$6E_1F<N#14J ![Z$!_Q<@,I)$$&!).!B@@F
MHR4P; D[F-[#&I+4ZE$">Q>3))$H\;V.@< "--B#^>SP22_P8*M;-:57N3I*
M4H+R 5*P0YOPEY/[O0 >^3,3]UYV USN4DU,J0/+])E7O5ZE'OYX@%__^H#
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M/W\?;C&"==A@ D<[E<_/T@"!5;I@&FA!3_U/D8;J89YND)9*Z3XB>YZ*ZN;
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M#0+!"-IR;WXQ&,/B!]IKD(K1!>AKD7J"D1AI(28F(OK+(S0F(S*B#FC #J0
M'+N1!_I JU"TZ[YJJ\@A["AS&$!0K*A@$]R@EM[1P^9.'D'3JF)P.X44*_RJ
MV?IN'_UA+L[A\*#&-K, !WX0"7ZP\1RH-FF3 $K 3TI@'H94"7&! 2@2!D)
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MNX]P'9=O\W9R'9%Q%9=R Q=S-7=P"[=S)?=R05<7*V $.D #$H@:>NY#K!4
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M_EW?C\A>_EU ]EU>&'Z)D.7@)_[A[=T_+MY>^KWC\R,!;DB' @"FA2?/K<(
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MGFO.0H^!^0&">N&S8HD,#2ZZ+>'/7PL:"/@?)4N(<&""E!@HPPLWO"##$A>
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M,<$2^4,3%J (RF1^0($ <I86T!06(8@Z[6!-5U%U2.$;7P%L@38?\2%]>M
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MRIW< *6<RJ.\#JB<RE;0"-+6!/TPRJ),!Z'<RI^,RF3C?.);%.G0H\@!I.>
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M&D@$ &[>3,<303H$ VY0,X# P%&D2(52 YKN8TVH4:5.I5K5JLAV [(*,"
M08*O",2"%0"OK%BQ9<DB,$L6'EJU8<V^15!6@%N[<\_:98N  !(! M81H!8#
MG D<=1W$0&"X;#\D5I#4A9SV[9%J<:HAJ':$&MJZ46*L$ULM1K6_<-?%N5M7
M[^N\>4%;/NO::UBP8]GRY=K.0-:L+Q$T_ZCF8,>\HR*3JPR0[NISZ"$#&*AJ
MX)R> -D3"-!S-\%W\.'%CR=?WOQY].G5KV??WOU[]]P31*>_4D:2/3)DI.C@
M1H;_%/1S0X07&)"@P -%<,,%#318PL%!EHB0!DJ6 &&)"S#$D(8?-J'BAP\_
MY.&'/GXXXH<?O" QAD1JH:61&)"A)8\7V_B!@!15#*2-/?KPPD>$@DPHH3VH
M*.,"B5Z80\F,,KIH(PLVZBBG^JJT\DHLL[SRJ0% HN:CGISKDCKJ?@(@IR^[
MO*E++[5T\TTXJ]1*J]^Z*LJVW<S"+2S7^(1-3['F^DJVV/3B,P% ,4.@L'48
M. (!)!Y%X @K"O]K0 #3P,&!  &\.0W/38\(S+2ZO+HMCG5NPPR'Q$Q%P@2T
M_BR4+[!J_<I01,_*+4^T<B.KJSG/>6F !KSIIH;I1EHNI0!NBO-99:FCRH
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M4%85=FMJ8V"\>'BH5;5JL\F&ZSPENU#Z!4[G6$)64A__Q=H (")I5W*#603
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M?WSD U\=R6?^!H+Q^^<W7_K)Q[=?^V $&'R:$KE0%_]2P#__W/SF_D.@"XB
MYIP';(%L_GG!#H:A/23!86X  "4@YK 1J:@6B9 #<ANAW(-B+N<ZM T2"!8:
M"*S+NDTH XBX (YZ@8 !&*\C.TQK$GB@@;3;.PW4.P,PM5(KM;E#-50;-0],
MM6[;0!2,B6K[/,"[J=9HO R+C<-CMD&2MF$;I,G[M0'+,%WC-:%R*C.*G,)C
MMI^*P?]:Z["XN"G-J9/@<(G/\893FX[Z.D'5RSN2J $J] 9Q>RERFXH P(XH
ML(%U,()V>P-X0[@-0$,U_#TT3$/?:T,X?$,Y[+TXI,,Y=$,[Q,,UU,,\1+@]
M9,,\Y$,_[$-"Y$,\#(8V]#U$#+Y%!+Y&A+Y$5$0U5 =Z>X-;,+GL^[07: -Q
MD *76Q#^\1]0!,4T2S,B<!#U^Q>@<R"?"Z .^:T]. H86('A B@>& 9:\+,8
MB+H9>2[F"ID-8J%^4!$>^!$>* ,JL ,W "^O<T 'K"T,D;2*J,",V ./2$%L
M5#$#(+514S54.[4/K %W<(=PW %PH,)L3$>3R"^OXHK#>T?_Q3.\UC ;QZ''
M(_R.Q;.\7(''>OPB?KR5 4.4"1N4?WP<6OF*>JR5?E3(0XF\A=3'P "6$'/"
M!H" :I@O$T-'D=A"E?"&^ $).MA" T""67":6:B!EWB[E-@!;]!(;I,)9(&D
MYSB' #B'3<(]W7NWXTO$.L1#G^Q)H+S#GOR]7 #$HNR]HQR^00R^-DS*Z6-*
M.53#YUO*))A*/;1*J73#I02^)""Y-SBYE-LR*^ #=4FMU.(?-$O+M%R"!<*Y
M=G*@GM.0G[L &I"""NJ#>>"V)5"1A]&@$FD#.,"#&'BN$@*97_1%XZJN U0T
M'J"SF:F9.FC&K[N '9JTFLDTCM@#_W7<S*NH!\_\3- $S:HXAP^,NW!$-7<0
M07,T3;NK 5?C3-@,B78XAW; !3W8'1   0\8A-P$ =[L3=\$SM_\S=X<3N ,
MSMPT3N04SN0L3@_030^(3NF<3ND<A.BTSMVDSNG$3N[43N_\3NVTSN4DSO%$
M3O(TS_),S^7<'0FP39D2%HHL*]$Q "8B$[5RR0'H!F'  6^H@6KP!FGP!G#P
MAEDHO1KP!@>0!B2 3Y(XATV) V\ "1.@ Y2H 1Q  HXDB1NP4)<T"1PH20#H
M0JF@EG:(@DK /5&2 BF8PT'D ]]ST0TX2AE%2AJ-T1J=41O-41S=4=_+A3AT
MRI]$2H0#4O\[;,-'I-$AM4,813@77<-(?$KI:\0U7(,W^ %,7#L,:(-P2((^
M8)< 0<O5<H.:J[E3_!<'6:"?\SF <:<+<(,D^"U*0  ]8( 5\,N^;$RF@P,]
M+0*G$[0:N:[%',:LH[,?<$8/> %GE,R,4A*-VB'QFH@Z<(,]J*_8K-27J(<'
M\(=,W51-[=1ZX#MW&#4&\$ 1E+NZ\\"Z"YT.M50-I(!VT /L8$\/H $/N(=:
MG=5;M55:U55>S=59[=5>W55<U55?%59C'01=1=99558:8%80N(==/9ADY=5G
M_=5?;59;G8%>U=9JU58/\%8:R%9H)59R'=9AC=9B)==P/==;-=;_6\U-!H!5
M<&@'T6L)TC,]<HN]C>Q(!P  <* #)% D/4 ".G"6&K "13H';ZB&DM@!)\#"
M&C@"<<,!!BT)$XC0E-#7DS  '& !F7P.[;!-7* K&&, $3!9$:"$;A"!DQT$
M!J $NI( 2A@$2A !$+!9$*A9FA4!FIW9FLU9GM592O!9FQ7:H"5:H,U9NKK9
MH659WJS9H8V"E*4$J359&*,$I9U:E97:E#59NAI:F"U:ELW:*)!9EOU:EMU:
MK1W:'5A;DP5;L'U;N W;N3W9E+U;$8@"JK5;$9  $&" V['-MFL .. #'@ _
M_ED",16_>&G+FDM3N%Q3R:5,A5'&;GB!__H#D?OC,\T=!A39@Q(H*,)\(1+I
MAQ1Y&(CA 3NP R+(*!"(3,I,U N@-,C4(8K(B$@M [1B5=Y="4U] . -7N$%
MWG(K3513-59;-=5$WF^DNPSMW6R<S=J\3;^53EHU5UR]5>N-3EJ]7N[]7NDD
M5NWU7N^UU?$%7_--W^PUW_,57_"-3O;UWO/-7O1]W_E57_I=W_=U7_9MU_J-
MSMV!U?<<JV*)0@/8W9=D#DH="3H 40"8!6>A!@<> %%@T%G8MG20AAT(B0FE
M!@B- R2@C@!  AR@4#IP@CCX!FI  A V@0=F%1P  "AL/6\ 80O% 7%C 1@F
M$\0H!<( "1&5BO_LN VOH 8CGJH]*I6_2V(F9C:>JBJ>(N(U@F(T<N)#BB,E
MEF(I)JJD8J//B*.().*NR*-2:8? (&(!,&,R3N,M=F(T@AU$TCL$2 0^\ *T
M)$7R*T6<.Z %.M,'@5QW:L4YB+\?V .8U8,BL47\*^2^1!' M)'\XX'B.EU)
M_@$[V(0EL(#7=<#(](#8_3K8=<"OFX-(XRB(4(0RR$OH7>63&%Y7!MY/M:30
M*<?LF*]4([6Y^\!3*\$=^$A63D':S X)8 #?G %M->9[.&9C5N9E3F9Z0&9H
MGH%G?F9F3N9DAN9ICN9E-N9GMN9M_F9F_N9KEN9M'F=Q!F=E-F=SUF8=:%YG
M;CYF;V[F:I[G9<[F<6Y6$!AF7)C7BEVQBKS_R'Q=U69)B=(#B0%=DUEP8 ,P
M 8\U  >@T)'8@3@0"1SXAG.( 6]H!XDU &EPAW2(@^PX@G9883HX!R20!FX[
MAP % (H-@",0T",P@7.(@UDP  *8!1:84):F@YR.X8^]"FJ!G>TX8VTAZJ(>
MZNU0X\!0:J-N:J=^:J@.C*1N:J96:C/>%C;.EJ?NCFRY:JT^8Z3.ZJ%FZJ5^
MZK$FZK,&ZS-6ZJ'.:K1>Z[ 6@+VC!BE(@@8 Q=52W)L;4_1#H#0-9%9<TPOH
M@R08AF7,SZS;7,]MY#LED?M3$<ANM*Q;71N0M$0% =GE9,U>5(V""$K; V!8
MX%]>94PM[0<P;=,>_U$0!$=P< >:Q*33!$?D7;52>][1UKMS  >IA0$;P+T*
M^&W@#F[A'F[B+F[C/F[D3F[E7F[F;F[G?N[A-H(.Z  ;R%MPZ&>5P+;YC!:U
MLL*0& #3.^G__ 8KL((,+= =4-#2.\>0\ 87#@EI.(=9\&D".% <L&_KB.&9
M[A)OP%CWUHDX&(#Y-IHC\-C[]@8D $DDP "4EF&,#=%5G8D:../NJ/"E%NK8
MR:.XWI8,WPX+__!R 7$1#W$2M_ .)W$.3_%R86,/3V,,;_&NYO"R%FH7]^JV
M;G$:+Q<:[XX.CQTS[HX4_W%MN>H>;W$?1VHU]N6VJX'N&R=V$;_R$[^<\__K
M)3C%]M.0#,F0@WF!%7C3%7@!%\B@S1T1D_F1TWVH,Z=D/?N0A<FAW:++30[E
MV,5L1*V9V(5=':J#/9C4V^YSX"6'/W\ 0!_TTQ9B#T1>=\ D15?-<MQEN^OE
M/M? =M!M$[6!#K@KZ,YT3=]T3N]T3\_T3S("&ZB$"6" ZQZ6?SX]U%.KE: &
M_Z0.";Y@D@!OE 2 <Y#I]DYPD'" &"9) !B .&@'$T "!+T)!']AD(B#?MT!
MG[90 "!V *@!%Z8&'!A)$"7)67AOFBZ=")>)>8 =I^9JJ:YQ[D"D%:?PJ$YW
M=7?JJ39J-6YKHQ9WL*Z+M';Q&=?Q4M&#I3+C(S?_ZJ2^<;&V=V-;<;(8:R37
MZG8_^*+6P!MXTQ9 7/]I@<4](#5[7)QS(#1E136ER]V*5!5%70WRW#T;D=)M
M9!411A]!73NPRWIQ0,R67<P..U'^9,K,*%*V>1HH R^(]-O&U%<67G^0BENF
M.P:8KP#  $R"N^15S5$K1^SF>5#+[2@(P][&]#[X[:L_[JRO@*WO>N#V>J['
M>K$?>VKZ>K/_;5 *[JTO>[)?^[77>K(_>[D/>[H'[K2G^[?/>K '>[R/[A#@
M[:D'!]M.B>&H!GEH'1-3J["D"@@.B8BM@7.H@3A R0L=R03G3[#J$E^?A6#W
M%.LX@AK@[\L7MV.?Z6</_^',2(=J( 2%/0+2">(1Q8T,%_<,-X"X_FH+#PRN
MWGW=[_T5Y_W?]WW>!W<8!_)R.?)^[WVNSO B]PH@'Y2R%G<XQFJI%O(,[WW;
MSY;L'Q0AC_X+;YRM\:_NR'[B#W\Y96-%VCOZL9\[UNLGU^LQ=5P^#FPU]3DM
MMQ (M(,W_8%AN"" ^/&#AT""7G[T&:CP($&$!.TDZ?/" H@+%2]@M)AQ(T>,
M=3R^J%-G"3 W $ZB3*ER)<N6+E_"C"ES)LV:-F_BS*D39;T'/<GY?""TI]"=
M* W4V+$#W X&2@- C1I@QU2J.Y+6<'=5J8.D!HR"#2MV+-FR9,^!BQ*ED@U=
M1O^,5(@;%VZ%/G'WQ+4K-RZBO7+I5@ \]R]AOW4'&]:+U_!AOX+EZFUL=W'A
MQG,C(XJ,6/+FP)H9!P9-EZ[=MR-L5)H0!=PYFP8:5)OE+L#7HP9JPPR0SBR
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M%<=DHC.=ZFP) I42_YRII>28*M'-.EE"P7KB,Y_!&D82/$BZ)?WS2:D#F09
M9E PQ8Z362)3EL84RER"K'DO<UGR$D#$(A(Q>43DY=*>&"BE(0U,SJ,!+ATZ
MII&(J0Y5+ $X].E220FC'C*MAS^(8M.L=?$!-97I X1QDZHP155IRPK:SB9-
M:3J@*8\"BS?VA@/NH*17!$ ) /6'DG/$ *HOW2I7'PF;;M2 <2K!W$NZJ4^R
M=C6M:JU) _BPA]+)H'1+VEC(ZGI03K9.=F"BA)=P23NYWDZ7+CNB1FRI$>89
M]J%C>AXIH4C27&*D3!ZA 172I(2U8M8HS["%/[C&*:%\ME-<\X<MGE&3VO]@
M\WWJL^;YX(>^UL8OK&"AQML <(2\N00'9W#)$;2:V=\"-U@(J!<U66  6'U%
MGBE!Y$OO&=SGKG4>1^(@=3-6R8,J"794(J&4M,2EP'XIO"Z80I,DN@1*(/9Y
MZBUL1T% 6,)61%!A0AKU'KNREETD2S_8Q">&01WH O@E0H"&%W%:X*!P"AI"
MF(G#OF;4I&#3'4QQ+1NWTJJN*$6Y-+DM +#:TI8<(9QZTV-5 VSB$X,%D/(
MAUCCJ>&%81&?:$4QC=$Y##ZL8&,R2 $E2]BQ@P+926[8 \<6BCN^FK*%+M#
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:V_PHU>(5-\+))NAK!9>6:5TOB$2-)P(" #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>abvx-20251231_g4.gif
<TEXT>
begin 644 abvx-20251231_g4.gif
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MI+7\81;&6<*:WO24>YQF49OZ6XZV[4(,F^-3B[K)X&1OJRD3+^\))&L)RQ<
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M9PIY/=>)&$C%=_!VB_9),%<% -,6 +VX ,43C%4E+P<A;_NV+0[C02;$ M)
MEA7@0<,8KF1I3PB@;19P=@:'2Y"%K'B&9'X**](@$$"3K2U';:,$=D2C.<"Y
MK$1QC]6BC!24J@J+3W0*G;G"2QM#I*)8$!9P<L;#07X9AQ60#M<'L! 0 147
ML4^$7MX$7=>CHBBK8Z'_VJ^1LI;T0Q"\M#;!!B]'$YS4%'V XU,G4 WSLS:<
M,U 0T$ ORV .^67521"REK19)UNQ9Y&;PD$0.C]"TP%$"K!+%0%:Y+5;-+0#
MD0X(L (G %H]NVLP";4S4:(:>1#1RK8F=G&8)K.N(3'LM !@2Q!BZSITI0U
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MN#41U5$G>@07*&TERFV14E?U8UL4!?FU*88.)P1ZBE.2-1!M.$"-MU3*!10
M1OU 22 %P(DE'\A&&A7@9H!L$R#G9,0/FA)Z?(P='T/_Z#AE/DR*)R1D%0>R
M +E,$@#IR,P)DL,>@@!&(.E @): Q!FY,!*6,7(FJ5!9%H5Y$F#01&(&XSFK
M?9(J=:FTVC6S.=#]E=,E$7!D0:I"Q@1.I2H( *!+?G0]1X&Q&IK*Y =#",@1
MFA"#?.RGG4(JJI'J:6]+JR;P2MA*P6DS*,,)0$(/TAS_;$DK*L$HD)"#O6:=
MDT=Y\F@'-RE".2J$9_8<VDEH"M1I&?0ZT_N1]?@EIY*6J:HBA>8\U4<U@>8/
MFP4M4#]&=U4Q;72(*5V-[S)20$LQ:J))090E(<"R ;I'3V3-*!OQ6E8W-JZC
M 5UE2PDZUD,MQY7$/ OYV!&>T-HA%30(X>:UC%001NJ02=C;3%8B$C6!6#8
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MA.*P&CS$!4"'/]73/#V ;RW4!?C6<277<C57<A547577136KURR(CH0(BKD
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M/H+5")AC+]88TXX].L>44PI&@Y$]4C&84787!)!. P!8A14"1@FHT0L6? #
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M,T.E90@Q=\SC-7I7QU6:T6!+2-;?%0"UU?$5.Q"<D@^HZ7P8;A>1 Y9FH2[
M'="3#T7@T>!!/7@G=0YKW5PY_]R@2, #6Y,B5BK0U3_=&2?K?5P8&;LL1%OL
M@?2%%4\[.]B374Z__)U12FG"@0D08P+94@&G)Z "  C!TT-82*D/&5W'/LYB
M*-(-1U5U(IMB)!J1%B_E]DNEY!SSI%@",%B9ULJ3C-8B+FR)B2\<@3)']3YK
MCM>S$1H]AE"*(OQX0(L)/=9H!\6L(VXV323P @1X@ $I1@ +)+R^%U>3U4@V
M%D8MZ*'%#NG)"^$LE(S&S="2#(0G]6;1BCT1Q%ID"#-P" <.WI )<   FT[&
M#(0@!#$  -1M2@H"T@,?/WG@/1U>2%7!X>:>W-)8M.RB=:=).CO:&P#XQER+
M/*CO_O_Y&LN-T3*>5QFF/3_$)%'-CMAF&( "!)3;1F>F-=[!$'T\P&QG7C<2
MC^Z3)08W:E)?2*%O(CKW&GE8KEH=O-T2)%ICA+#DG1QX.<>BS86LD.=-23)
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M@ %ZVL7]W4)8GVZ"Q0)H_V $M !#U-"].*-B<8C8:=>[Q<^\V:"QN,HKAI0
M68X 818M=A9( 6!&J(#!T69L,F%*#. <+L2FJ<"F&8-=,H08# %O!L-\K"!)
MG)Y)^IPG1J9]WN=13"1^3@1\W@U&[D0#>$ Z7(46.I?2-!YGUD7.L 9'@9'+
M:*,9<A9)B4P;5BBT:,D/ON1$6!\'S&0&0(,]-%)J[22/:* %6,-",( F-40%
MU!:ZN*BA.5Y(4M=;>.0$W5$>K8Y'X9]?"98?@93M7-H;$N%ZJD &I).(IH3U
M(>-";,#?65]=MN-N^AUWCN=DB"([04=&).;T_.=05,0^L$"8CJF8EBF9GJEE
MB/\I.H1I9JQIFNZ#F[8IFZIIF.ZGG=;G"=ZI0XAB93['!_C9^8!2O[ -7MP2
MD(P=_N!&9,F1-:7%:'+>2O8180368>P8"&GGPAF1!U05!/C) B#D TBAA4$
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M(2EL>A=-K/N@!L.=2T_$\R]$'=KC$. A].LFS@?['E;<SU/<\L,C0*B8( 3
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MG&2"\C<C$<(&.9E-,A;J*PZ$I)N\Z2Q>(4HXUYO(!;5IKP4X(%*=&]^5%%
MQ01,,Q6@B 6B!!%\:B8B^\QE1/YYO%$5<U5,))6J2L.JV2V4-1(CP#$E0CU<
M\>97CH16%JN)+'2FDZ/VB<;_FK6K9S6(6A&LVR4K:L&.HL6.DNH(1/DC2YJP
M  &=LE- A3@J^A4S-@TM52"/N+J@ZD5D4ZEBV; (0%PQ<%H"Y,I(@C&=E4[U
M>!^]79O\YZO^,96!M@N\G5.30Y&-4E4M//-9OB8C4SM)H"4ZL8!* @9$B$3
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MW[6MYB=98\UJ%HOCJPD:BF+R+@!^E^A'9O>DI0T;99GCG$.3F;,3FN HQ\+
MZ_]>=\<5Q<<,=X):,D<#1[;$HTL^0MZ=$"V(*RV50GUKE%@7EL]XJ775;@U@
M'7.:?\$Y;B1'*EI+$E>!H)Z($(P7D<(-BP,< $:)3%@B#W4K(E6N#KSJ11[U
M2/O#E#[@=-74/[#)[9NCO.A)H7E1<YM3>).V,J1<*ADTL\4#X(# O?&-;Z3-
MUBP)DXB='Y*.@L'Y @L .  ,P(**)"F?V_QE:R ^R/GQ%[$3GUT4=4+-Y9)M
MI&GJJJ<9!&%OC_PAQ=D5-46:9;I!5MW \C#)'\*SQL3[E<B:]T34W.*.ZA?
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M>5,)0-)B0 96,BPQ;O,H5%;L@*Q8H67_>J9I^DZ\1QKXX8XE CITVFEB6F<
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M  \))5A ^0(<50\? $#[#D#?.X((& * @("@!P\ PI?'B%VZ_OW\H[<061X
MY8A$7T$B-31@1@7VQR!/Q7WPP5#L*,>2<D7UUUY/!$'78(<>?O@79P1Q1B(
M5XDH$8H@KMA@-(4-P UEA#W&& R(O6C8C)7M>%AE,28V43)XX>190Q/$TE5>
MP1$4BFERL:957</--D%MM.4F7 :B =" 5L/)%0QQ"SCP0@-#78B47^X$P&:;
M;K(9((L1<2AG3M[%25 UU0'@G3, ($30 A!8  $\XO4%:$3ZB"<!/" )" \
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M541#G%4;NQ-D\!I!&X2]=C0WV?,3A&<V=#-5+$  >.""0Y!JJT 7[4(U UO
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M-\$G_ZOQ);24#>6H24]JRL!U+AL 0, 1]_>W08$#/=5 H!M16A&\_7!O(P4
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M\&+39IWL[@:3P0[D,DBY14NFYV9:'WB4AP6$ @=V/W34AD!@(][!3J-T)=X
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M@L*)H=@?0[@W91@1Q2:*J8A243A5JNB*&T6&A(B)KTB+O^2&M8B+\@=O?J6
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M*&ARK,M)[@&4I_FP,YJC'RT%8M<['8@B7I.I0')J ;L9I#-VE0L$C*( %Q@
M'B?!!E77P@Z(.,\!D>WD[>8H*V:1Z%E78=IO>K-"#VCC!5LU0%?=8E<&1+*C
M .#IU*#:&;T.Y%\+:2U%GF(!Q_8%(?CCU12G9H&R(L2HDHHM(6E;F.>%DK7(
MA<V"-@FXN]UG0=?S#%W-@I 'G,0%91%* 58+PJ.%:X]0DIO=J*N\CX;58QCS
M7#T><-Z^O"2A*+6)..F;7+ Z!H5:"Y_ ,IHG7]9CK\>#R285@,!ZK""W_VGY
MKTSFXH*??( _Z/",>' KS,$0Q4=/32@(&WHEFE'GH9WAB!#%80!X_N6_2 $
MA]N8T%3:AI@?2 <$2E+;8IV@'A4TS06?2\@$E=)C\!U4@&]7XQNK4IPO)O)A
M.%P>:5"0J#JUS7Y_VY&4L-C%M,J>F1;LH/+VM3-$M @_<EHYTCSLS/1(ZRD%
MLA+GG20;_XFS =ZZ&0DSE2+:-<G3]%1<BA2 )]<-C=/LZ1B\RM)S'Y%&05C
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MO4.5;5. .]J>0,R/YX.(,ZHBBH$9=P@@S\"J.C2\L#**5&*\R_M$G4JL,Y(
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MPT[.<(7K^P '0QC"_P7Q?0.\X@O+%\'N8(![">P"+LMWPPM&L(<K8 $'_[L
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M(4KP0U/T1 S.YT,]P&P XA!9GW+N3'/_\B9T(H0L&H2*;)-N((#U3%+R/&>
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M.A"O%;=>PET$[,EE=^@%?JK)"="27\:O?RPPKH9B!R#/E\HF:MK&&8/J"DD
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MK#N[-7&[XF[QE]*!H/>6"CAZ>1=5;VVF?"/.T;J*B^<*'.6%WO'SUB#P35
MGF\IS%>/YTIY3UN6_?!'LX-A!P'S P#[E(:;9CVK+"':UEK04R_F*(M$R8-7
M E&E_S;+,>=_7DF'@;07'&P :V[UZ\K1\B:C%A[G>B\1E#8"5YR>=85H1YO?
M EQ70Q0U[C@0H #\Y$<YNRTGA%U)301>&!S6&>=]7T%* *%3PA6UR71P^L_Y
MKI,V"#@@'=33E\Z2UI(/7.!C33Q.[%CS@71(CRMPU)]XZB?'W*RM-?OZ0/A<
M<@(;)= E$,A*^5@C-^#$4&(&4EQ+WI&W).)F;X$RH*C"<[,()-!X%U/4S^;X
M, 5"QV;'82(  -F246;E*Z5T'/9^0T7DF0M5B#2C"E?#1MRXLB7AX9\"53E*
MC[&'0K.2#UKL4:W5V -UORE;%[W'O9:DHVH#&V,NA^<W[__@,6I@D:,NEV/(
MX,C2*Y?TY7+JT0'M/+*/^XC.X,J%+XLM2I"O \#$R*A) )PQC=\!8G&XPTI2
M?K(X[XA<"N/2 C6V$J [2JC$"!F<T>E(F),ZW:TZF*\/4'%\ * A /YW2@-5
M;WRJ:9]W,!B<WF24*SQT21C!V;K@8%,N"( >-*.YL]YX"9"X9!X*V:; ?O)/
M/.BRCCNS=] :\6L!OKQ> !&P+D"^P'872M[TO'.^W S5I@U" #PXJHV+;7"A
M<B%:;L:'/3BNJ:+@..A:2EJ<LG(%C4#55^]PRM7?/!!#\GH3DL)2&PLN)UL9
M%(\\%V"Y[E1OGA%#P,8,$+'P1.Q=I]IYQ^^*LP"OSC6E.C.4/W-3)>;0C:B6
MY6@+JKC6JU;4>SX,6$-S6;_>8'0KK^NH:I**,M6$=([Z\,X^@Z/65(8U-[=;
MCF4OQL>7C)-OP&6-NK[Z%9T:YUU TJL"_^B53.:$\B6'@N,E >!'BYW(CO^\
M)S AH$ZR#7"YJ@GO.W<Y1^Q-,DB4;0UW,$;*\'&)OC:*X7,+R=/6/,RX\X37
MP]R)SNP!RBOY>PE?8H@ U00PC"T!YP+*A$CN:@>[O[GLH!0&MVFT2\'B#<Y8
M67.Q[BUX8W1;Y"PY*Q=;;DE?)VZM5PQ@NY$I-Y7 C%"DADFI"5+0NKA9I@14
M"@!P8"< ^K ./UI"CX%RE+;ATX:,H0-3AP%37!1^98M;X\WCK.>]OD&NWA",
MQ(5Z%SKLO!MJM<L>[O+EN[/D"B#E*,C=!H"ORXEL5U2Y'"N+%9@/?4D'3&L_
M',OEPQ*&;V*C,_]"Z9+E:],*\G&XB"B6FBO"CV-/RBZ$4D:?=](O,52A="Q@
M18\'G(CU'0P?T\L'6TFC%Z(B?U?SJ^,<5=&Y2DV^X+5HUEC G-J<Y.L">-B(
MG>!QXU%8A1<V9N98M;-/AO)H [FR/N>&Q+C1QOP,+$L#LT99:M';_%3]$FX>
MM]!X<E9>X?,!:06Y6G\]3EM/_=U1?U?%O;M <]%Q1'E*2+Y#.V*?]Q&^/1?'
M'?Y=C@%]&0$%=2[=)59MA*%SPY2ZUM(+B.'K--T2>$@- )ZFM7%X^YMOBQB$
MT@;./CZ(\N.^8W.'CLLX^3MR#4?\/UBLE;RKRF9$W0.-[?(N:O]'9_+_LK8X
M+PX+U4"&,J$US9I/O&/ @QOE@45 COV@X^.H'A<O=W9E(=2RG%M" 96WIAYE
MMMXDX1R>!=@-PFYK:BZ9G;!@9R?#P5DOL53IRFOC)CR&,PX]PB?<KIC]E;H-
M#EV,65F#TU*TAU,MF$K=-6@50*( :/Q:QI:=(7-T>(I\04L1>\J6HQG@S"D'
M,/N\S2,:Y^O&67%++CLRYK2,.8@'RPD.L,Z'ETOP+DDR (!>2C@3?6H7JC/2
M@[.>'Q<'J[^E7,N-(\>_=PKG<9'ZTX16<^9#,OOMB6BM;$-1=W:G9">*\"-]
M6>.0']T[2I>+'*WHWI;4/[[ @:KP(Y8_ZRCY_V70Q>;6HGFPS4 4+/H X%Y,
M*7)\#4N,:MALI.D8#0&H3\3 Q_XX"N:T ]KD0AN8C*->;YYZ9P'?JKU&C):V
M))#:9?O&B\-D[BOD#RS(2VA\RR5T)@"&2&("C#7P"E+@HT@4(,_"HH)";34"
M2X;,A;Z<P:),36)8@-=VYH@H+O68@TN(15W4IR4NX!Z8P[.02/&R<)X4R-F"
M _]P1F9V;:4F#WB0+H<*"%5DBPQ)J-/@3SM*3G;F1U6N+S@,[SBN$#O$L"4Z
M8 .]$ ;#8@%_BG4&$#>BBW2@)0BKZS_RSF*Z)P*.",TX[6V.9_GB#[UP Z6@
M3FMB2!17#3A29F5XQO]&F@9[&!$L8B\N:H_#1)!J0*?R6$;MDM!MX(R4[%!A
M/DAD;L?"PD\N*)$U>*9WZ"L ^"AI%*]O#G&3&@ XDJ9=E%%?'@QS7HD-A>,3
M8PKD2$WQ3$EE9@FSFN\6<PY:RD&"*F4U>"[IE@61.,=?/$>DOHJV3J_WM.//
MYF\<.:IWC(88OP(6YZNX5I K/" @:2P7I['49D3%S.LXU R'V,P2CX@7-=%B
MKE'Y[# [\) U0JP79^8;CV,?MZ,?A<MS9,(0H2-I*N95'N?[5D/08J1TR,\(
M@Z,#TX3>F*7KTJ0 $\4 [LXKI,$!S20GS23;=+(;T\0'=XPL]$$:^,$=Q<;_
M6K1C)_O$ RRP3[XE7!(R1BS.W%(P33Q22P0Q45J03L[P!R-HYVY2_U!+3V10
M2TH22@923-(N+$"R3XSQ3I+23.3R2LC2.V;%36YC"-W#+=<",*>$+H'$+K\D
MDA)%(B^.J.YD/3:O3RK'5:"Q1V;21<9/TBC* Q:+-$O3-$\3-5-3-5>3-4G3
M&BZC-6-3-F=S-ED (EB -G-3-W73  P -W<3.(,3-:WA!%Q@6"Y).),S.8\B
M K*! I03.G7S,D8S.JMS-ET *:Q3.UN3=M@--C[ &=+B4MHB,<,B6[83/5/S
M'AY@&WXS/=]SL7K3/>$3/5D ,:R!/M^3+MS0)^8S'S^M4RO^,SVSH3.LX1X$
M5#M9H#<-%$&M4QQ4\A&C93;__*H\<8/I- U#,U1#-Y1#.]1#/Q1$0U1$1Y1$
M2]1$3Q1%3U0$N8(W4M1%7Q1&8U1&9Y1&:]1&[>D'XR-$XNV8*E0@;Q1(@U1(
MAY1(BU1&%<XE>L)(EY1)F]1)G_1%>1!%:C(T^2-'D.0PL;0E#I,KM!0 D,28
MP'1+6R),R71,-6]+:R,:D'"B;,5-R^]-VQ1.YS0_O-1.SQ1)V"$:.$IGY-1/
M7<(^T!0 ]/1+U91+OW10 2 :VD)1&751#=52D,36XM0E_I12S111!151"=51
M.Q52&_53HR$RM^=E+!4 Q$U1UV)/6V)/T8-30]530556'[4E>*,<TG168Y56
M,]5+__'T3%_"5"UU'\Q%W'356)\O+(*U4I?U4M>#.)3U3?G*2S$S4K=E3V$5
M6T%52-BM+,Z!_#BO*K.CK>1T6Y 54%VB3 >U5;.55MOU6/D47<\T7>=57L]T
M5;WB3GG55_5UGH"%7C/U7\7T*^ZU53%58 _68.\/4*"53IEU3KDB4(WI57,U
M6RT&Z7#%8>\U-PZ67=_572$50AA69.,U804584T64P=5,PN58EOV8W]U8$\V
M8!.6'1Y :$;V4C.U2SN69U,5/;1A&AZ-+45D*J%C-QJH3Q832K:54QY32W O
MP8I23%8O' DE/*0A5)26<<Z1/UZCQ]CA4/'51^MD;#FD,?][Q&FO!"]#Q2=.
M)?@(13"G) )ZTDPFE5-.0"AC!#3EM$3@\DZTMD>RTE60-"TA<!NU9 $YQ2_%
MY"KUA&F=<@&",,C(LVRY @DYI07H5DSL%BB]TD7 <I.X3$SB%DK,DE#0,DT<
M+4(CD4*W"&F/XP*@D#\ 5VTT]TO2=DI&=>T.UWY^KV^I3$\6]TMH]T9(UVC9
M 1U>H,?@ MXJUSR6,F" ]SO.5D=P%TIT5T_:EG JLSAB]S^<-53>845]A3-U
MQ!'9!-*RZ$W3 V.S:_:V\'W!XG4J8'RCHW%7HT6Y1$E'LKX6J!_ORG9C\&(@
M$CG()7\%Q )P]#=^TH%,K"7HHKG_7.(< D!G]E=Z5^,,<>T&)RF!"1@L F@%
MN%;U_'8U+@:%]G=E]JU@  ""I?941-=EKI%% P!81C)_RQ< +C<W)EB&6^(R
M8LPEE+%;6C@FOZ(I#P0_X*, WJTUBO8W=M)L#D<LL^M6+0"'5R-S/0]"GU=?
M9)=O8&TY$GB%I5B!]<9S%ZR, >"'(_@/^?.]XG??+ABIX+4\C'<M> .@+@:,
M1>GL?F.-@3=_]]@X4->/ZZ(K\K>(Y4(-T7=HG]5Y[YC-N%)1Y%.1>7>-H#<L
M3F \G FN$*@W@,G_#!F 3:JU#"9Y'HXWSJ:V^K4Y"'<M)*!WPF3LNL)"Z,I<
MA/<KL%<;__EE+R2'?*@DD8W#4*H6?21P8Q @P.(JNTIYE8 #' K(BT7%?R20
MM*+/ 'RW-8CW?N8("@N@728KUUYB? I(CBGO65X@T@A5+L#VD1\8'H\&P3BH
MG(6/>_4Q@$L, O+68IBYFUSYOS[*OTA81A9R:QB+H"N1.28S+,]/DNG.-ROY
M>T58PZ1.#74YN+02."Z*D2C+FK'9B:YX>PR "A4-.ZPCFEU(5MHM\]:W/-I7
M^!;% BC,1L2X@J_Q=4JIA<?C!="HAY4)D^5BI&WJ)7C#)59 :$XN2NXY+&9/
MD"! '#Q.M6:YL_Q9+D@QX&QS[%Q)F7,C@R-P]BZ)BM;8)2#80JX<:X@Y:1T"
M8%@#0)!;XRA7PY?J!Y5F<)X)!X:U;V56 *S_IAX;! *Z\(E_&J_CR,V6Q]48
M1J++0^<,,R[VU(ES0X<[2<<N@#L43X6!Y8?7 U%\Z8>'6*VLZ3>F0:EGSL$.
M*GZ="%RR0ZKSY69*ZPX7"IDKSHTE+VUB6IYH.DEM&H':97]KE:>W>&L2NS4<
M[-J(>L:0J(_UKM3B\:0_.CHH^]^0XZA!VB4\\XH@<5[_6I<_*/&U-D9Z-FJV
M &#UQF,]=ON>;.<Y#*4>ZUJ QS8 ;A7%?/GJ7$+WIH[5M$K65B!?/,>=^% N
MK-<KX*AIMFSL>-$)N?J@]9*&E$H\F"J6GP.K'FMGRD2C.0K"X<9BFGLU^!(W
MX"%B5L]S3(D>U^ZNU^P<8-=&B/KOJ.@H_''Q!'LM@AJQ#$ 6LXI_["JX.01Y
MO_--S)4M!K6=6?B=8=F\M&R1$"N N.DH=&N4%NO^'.LQ#JXULI@Y5*H,ZVTY
M&'@YMEKX+D;#@<.B34JU7)@U%'J3SN^BO'LKP-MV5&.\>]&\5[EZN&.]&;)R
M55R!9EG*V:9^BZ/<Q!$ Q+="_Z@ZO43EI T*=*24J\\X.ZB4;\NCTHR;NS@.
MO+9BG#;JVK2LSBR9*^X7??*\U(Q[VG()H^6">A.IWJ@H '4L 7-#RW.#RU&F
M=Y*\6_[MRN.BJ]W&CQKLP2*&%Z^G[R*&Y5*J[DPIF(=:H*],?!8&3?X')/_\
MOZ8XIJ3,O,,R8_2%"8$CLCVFY3Y&: Q !WFDP\KWB"TO/ICX/AX;-Z!8/ JK
M)1(#WQ9&I5RI.\;LE")GRDQQX<2L$&F9T5&FK?NPI]>LM5'Z]D";ST9[+4"7
MGX6O "0]8BA=SBZ]VD'G0NYMGCC]VJ'#NZZMW[8,B4K]-ZJAIOA,7T PN9Z-
M/:)[U/]W)KE;8Y'CY2G55]TI#6F[@\$P#<D>AZ-6AO=$;-G>+Y!(RZ<K]-P"
M*6_DJ)% I\^3VCCJ>]8V9L5D*=9Q \"YPL#Z*?(*?%"@'8,3?)(BK-AT*X!2
M,J@V),GM)NB'$3BH%OK\99O*9)P\G+Y??BW"0QJ#8[-.L,\2\#&LX]C'&L:_
M(I4GTC>H,'YOW9RY-=+@ C._PJ] +0G'0W%0*LGR+>,='@ ([?Z::Y91SX$4
M_BM\"2&_HK[[^0[%\@2JH7,.FFW.L;%\SVT/QS=R?CR.C^<OK+O4J90TL<[T
M^Y>8 P%@+=-;S@2-8VZU(SRH[.\# /B#B+I; LT,P(/'J0+_(2ZE::5*T^-H
MSP]1FJJ4AJ[ -B3" &GN)ESH4<8:!*@\Z0)[]A[9BQK'%3\L3CTDNWQD6D6>
M$$DMM0\@+  82+"@P8, (AA "*! @(0!(DK\  $!06T.&&HD:"#"1FD!%A@\
M(7)!R L#*P(P(+(@ G@$52XX 0!!NH$+%DH((&%@!(\;->H+4"#HQITM >SL
M"6 !2@008EJL^=#H1I-,K1Y\$>!#3(D2>R(E")6@4ZT'K050@'9K5X;I1*H<
M^+9@R+8%/53%RY>A@@4.]#60H, >VF@*V/;=2&%MP:4)(?RD^P%RP;D WD9X
M!T"R3X]G!\9=W +E8H,7P$8\B&#O_VF#$!Z\UAC@A<9T!V9S!*K[,<^#)GO;
MG<H0JT&B-=.572FR+L') UG6C!HAZO2&>S'C;2W\@>K? [F:-:T[@C;A!K4E
MO8Z3_&P(UF?O5!T?P(KXT'5KXXU^]M\7^JQ#6#3L )!8?QMQY95=1?$3T8(7
MB%2=0<9%$$!N95%@'00W?9#="HNQX%A?W!WDF4$>$N2A5SN5LY@'[N$508R7
M314!39'11=QI%0BT&'RH7<1?4PM1A9-K>!E0P5%W%63 /G0UJ1(",7I85&L6
M+7#3<A#H!-X['2S&55%]<66;DT 98-&* 'C8TXRZ&=>7G*Q9-]291S(%9%\B
M*L87G35-Y?^ABR52<-YEAY*()()!_?=!98FQDXQ6[/B)7I^^]>0A>,B=2%95
M$ 2@#P >>#17 * 5"< )N?4%(Z/0P9D0C;KU*%P$Z.39&4P>M%1B;TH*!\&9
M)5[ VP4[]C:/!U<Y1]>H#M8588X%57CA== 9$%6**26+5FN6]K9<B0%,I=RM
M..JV@J !N BGG'OJ%B]ZT^[:IJA*(0?LD(SR]9<#+PQVX$#A]CN0 \YFMJ!"
M'+44:D3665@N!"(M9T!$##LDU6)J%:R5:D6R^2E81T:T'EZO]C6?1/5U1MS%
M 139&E@GH^6"CWQQ!99',Z,*''D2@]=71QMY>+)T1G;KDT0R8QS_@44L% DS
MPY9MME@Y":,%CVIB2<1;SRS2MQB@;:5&LDL;<@U11*KRU9C'5IDM490/?K4:
M $.Q_9H'\QALU5\+!#B@5I,.W%_'F:84G[XP^]R9R09X%4&8*T? +#HWB5:S
M5M/0.ENL7H+5\FD0@"/<RN !&>W=PA'=&]9S1P<4V;J5VVQ6E/F4*-(/!Q!Q
M1%!5;)W746FLM**,CEM5Y>A%D'EO8"U<9-!MOS>Z;KQ;9Y+)]/+KMU;_"D:8
M8H9_C[>^YAN,:?H&I\Q^O[:^WV^P&HTE/X)#C7I_?R8MN+]PZ_N?N!8E/W:@
MXP6/(@P[[%$@J]@#;J\)H !G4YH)"N=FA!8$UI(R.)ME-<M_'$1>"$]SHQ&2
M3C8F')KW,FB/!2P@@8:#(((4E$*^2+"&5G$?#K4" 9SMT"JN8XB'Z/%#K="P
MB$:A'1+3,J(E:D0O$T2,"PL@H/)MI$!6[,W;G+@1'7+11"C\(D*"*,;C>*M:
M0BOCI]1X$/.P$3;7*^-^</@?P2F 0/\&DF%_COA& -Q0C5YD8_SZN)(-,L1^
M?1P*F?JH1#'^L8R_^M^_ C8^ !C&*LG0(Y^:^,9 JG&0?:0?(3VH$9.L@Y!4
MT202G8?*SL11C&0,(0/1 3"!^4F5O4&8 <!A@5[Z\I? [.4#? D/7PXSF,1$
MIC*7B<R+,?.9T(RF-)GIS&DJ$QZ\["4VB9E-:UKS A?P9C"/V<UM*O.8XD0F
M. (01H1XR #21&<WQVG,9*83FO6(V3V9B<Y]2O-B\/3G [HY4&/.,YC%]&<U
M_2G->1YTGR<@(/LJ!1CQ%08 DPH*@;*H&[WP\YSV!*DPZ\E07T:TI @-:4)1
M^DMPLG29_7S_J2_!&5.&HG.E,@6FXQ@BHA-\E)[:C"9.9;K0G!I5F2<]*C!K
MRE*7*O6IO_1=#3.Y#P#9DB <[=<%W,%5%U3 !5X-ZU<K,-:Q>K4"V!"K6,U*
MUK26]:QE90 V*@ !NMJUKGBE*UCI>@&\>C6O@+UK!1BPUK.JE:V&)>MA_RK8
MP/J5K!8X@3N\Z@YLN*.QF"5L6^EZV;E"X+)H9<!D%4O:LD* L8X5+&&]:@$#
MB/6TF WL:,O*5;1R]JVD+2Q;Z^I9V_+6KI2-Y4$NH-G%XO:L7<TM8LLZ5[@Z
ME[25M6MTZSK="ES6JQ<8:V4OF]K )O:XI35N7%$;6]6Z(+M>M6QY_V5+6M&.
MU;U>%>UWS]K<]Y(WM9J%0%\'>]_R%C>\RD7N;&N+6^KVMKH(!H?GTF</>1S0
MHI)"BZ1PB98/$)>QHSTL>&T[7[8R%[=C/;"(I5O?UKY6KX!U08IE2]\6MU6W
MW5WO8-UJ8MM.5\5WQ;%?\QK=#G=XQC*.L5?AN5?8QIC'ZJVKANN[W.T&&;/1
MK4 Z<K41]'[5N#[>[',]S.0L&YC$8.:M?N/;WR/;];\__FYUS<S>UFX6P2/^
M\I?%J]L0/SFUK'4M?^\,Y3IG>:[1E:MUYRKH0 -ZKG.M@ &8E<), J8<5R58
M*R=-Z4I;^M*8SK2F#Y(,"2R 'OJ0 &$,T\+ C4SJ@9M.M:I7S>I6N_K51E&
MIP,CZEMF%=:XSK6N=\WK7OM- 2]8P M>4&L%9!23M_:ULI?-[&8[F]7F>,$!
M/]  9\20PL_.MK:WS>UN[T\!Z!!VJ DCX3QBV]OH3K>ZU\WN@@ .0!+@!UNB
M8: \MOO>^,ZWOIVM@'X< &"0*DRIP7?N?1O\X A/.!+9X0P7(E "T%! J1-3
M<(5;_.(8SWB_@$W+<D@CWI>T"KTI/G"-F_SD*$_Y8A10#A?JHS+RN/^CNY.M
M\IK;_.875P +Q"TP!EJR+8D).<Z'3O2BXQLQ^Q!V.:KH<X)1W.A0C[K4LPUL
MAX_;V,<V"A:?/O6N>_WKK>:XN&N==7-7'.QH3[O:0Z@ :.S< >4(. !*_C>N
MK_WN>,_["!/S]I>/+\)8M;O>!T_XPF\<<&.O)+W18IC$.,,<AH^\Y"?O+\3#
MNY('20SF*<_YSG,>V$D/7, 96':MF*,?UCZ[YU?/>J(#>^>B'U\RA%YO6=.\
M];C//<X34XYP"[LRFV]+X3+9#W+K_OC('WIB]+'S87^@BG"C>+&33_WJ9UQ2
M'X ] C\>\]F_)C'\"+[UQT_^>\_^ Z%W  PL!>X7S8N__/"//]7_$OH7>!SB
M RN]5=BQ46?4FO;R%X "R&N)00\N)&X?)WC_".%^'Z"  _B $+AI#^1I!P@@
MP!<IDT)W:#%[YA!^Y^" $1B"(HA*B2$/"Z!]?O=W/Z<1)2@! :=Z(QB#,G@_
M;)$8+P![2O=QBO<:&;5 LN:"ZP"",SB$1&A!-?AZ%7A_XQ,-^N=N>20/+O@H
M%"=P>$1J]"8I53AW5Y@,>(1'*XB%<S<I7GA)8!AA8S@092B&#42&7!B& '"&
M8;B%;[B&:-B&9DB'<>B&<)B&<S@0;"B'>VB':NB'=0B(>,B'@6B(A)B'=[B(
MB'B(@MB'7QB)B:B'D*B(DXB)5AB'!;*)::B)A6B)CDB)ERB*F6B*?XB*H=B(
MI\B*J>B*JSB(K2B+_Z](B[$HB;6(B[=8B;#(B+;HB[H(C+SXB_PG:?5VC.1C
MC,F(C.8F 06 @P"3@HE!($V(%X6C /[W* T8= MTAVKXC;,8C(\XBJ HC*78
MB^,8CL,HCJ1(CJIHCNZ(CNVHCN=(C/.8B^N8C_7(CEO8C[[HC_)8CNF(C_NH
MC_%HCP)YC[M8D QYD/SXC@.YD YID/0XD?4(D(*(D1K)B;.G>=EW@-%X@>SW
M-P_D#/RP#A]0  \WA2S9DB[YDE-8*3!)<C-)DS4I<3>)DS<IDS7)DS/IDS )
ME"\IE"Y)E"UIE"R)E#&9DTIIDSW)E%"YDSDYE9$2E4\IE5AYE5KYDU;)E?]9
MZ95;&91=*99?299A.914F98W*6K!=H!6-VXJ*!P9B!C])@$HJ9(OJ)95699H
MR9=%.99]>99_Z9='"9B#*9B%29A):9B)B9AZ>9A@&9EF*9F!29F0.9F869F9
M>9F:V9F<^9F-:9FA^9BD^9)LZ4+I9X&#D7H::&HM* '2\ 'Z$&QMZ9:V>9NX
MF9NZN9N\V9N^^9O &9S".9S$69S&>9S(F9S*N9S,V9S.^9S0&9W2.9W4.9PA
M"7RIQQ8 J!L\*6JQJ0\ 4YWB.9[D69[F>9[HF9[JN9[LV9[NZ9X.$(WZ( V#
M(6\2QX08911,N'4_&(4?,&S#!C .(&P$&FP#:J#_!>IP"CJ@+G2@@$&@$,J@
M#@JA;2FA%*J@#_J@;;FA#=JA'!JA'HJA%1JB%YJA$_JA%OJA(ZJA(MJA+%JB
M*=JB)EJB*WJB&!JC,$JB**JC-\JC(/JB.PJD"YJ@#EJD$"JD/VJC24JC+JJD
M-<JD,ZJB30JE.!JD3CJE4AJE,EJE/8JD3YJE7+JD8.JC7[JE9(JE,LJA+W"@
M;"IL;;JF;DJ@ \JFPZ8/+Z>#XP-Y!B.&TB=J'R -=@J@ EJD"(J@(:JD85JF
M.>JE:+JH5ZJECDJE9PJI5BJIC$JI7?JHB=JHE3JFE[JIF"JG1"JJA?JBGSJI
MH)JJJ+JJI]JJFLJJK^JJ_Y8:J[0ZJ[;JJ;4JI0Y:JD;*JZ3*HA-*IP!RIZ+&
M#Q$W;XO!A10'A1+0 -1FIW8JFW9:#K.I#P4@K=<:J"]'K;,IF]>:K198K1]
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M:[[72[[L.[_Q"[_BV[[TJ[WZ>[_]F[_V"\#KR[_*.[S6RVN\WKN\]=NLZ"O
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?ZU:N7;U^!1M6[%BR9<V>19M6[5JV;=V^A1MW:T  .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>abvx-20251231_g5.gif
<TEXT>
begin 644 abvx-20251231_g5.gif
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M[\[>]Z7.WK6]]];>YM;%Q6-*[RDQ6J7.]THZ0L[>UIR4I:VUI7N$<]8  !
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M^_;SX]^OOS____X%"."  A9(X($&)HC@@@HVR."#"8@GX8045FCA0(IQQQT
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M5Q$V13A%QEWN5EU@]H4T"9,VF9/.=I-TAF3JQI-?!G \.45"J9.^9Y3D-I1
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M:@5 NR&  ,Z  &H< AP8 K(;NZA6";++Q9:P ZY&X+&[ _&ZQ11- .A$NSL
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M?;?H'#Y(S#+L/1&G"W1_N0]PT. @;5EQ2M(C0+O_=O!8:=/%Y23174P <(
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MT:%$P8TK'<=HT6QK&9-#.4:RIIVTT9R\#GN$##U:MG%5#O#@F7+0C>F0C?+
M5URZ5TR2C\0@F[!9IV;ZC'_-&[U8FO(PG'^]5_"(G+^8!&305WY-G.#0#5R"
MF7AEI8JMU\F(5X0=OVC#F1X<,/K0+W&=QW.MQZ($T@93SW-:K6)#)VE2'(QS
MV.AC2FM-T@O)2B<-//V9U,634I__LU1*O=2M=*"_JY$&0A8QX2"JC!1^@%JF
M%0"IU1$=T2BD':LHG=JF_;M( 3RO!5NF'9ZKK5HB^R"P;5+'7,(I_=H9\2H4
MD5HK<UM_RI&=+5JBQ=NA91*J\BHL[,38N0!^ (&<+3[**US.,CZH2+3B@ZO:
MK!<;0 !.8]6!\+3(K9?0\\UM00 +  'AS-Q;]19)<X:0(-W)-=U(PS2@&(C1
MM0 ?PI=PQ$[L7%9KX3S:1=S%I=8+VY C-"L1"!WRJ\%C$S_%@5'R/)KYU%9#
MBAEQ4IP?!%*9=='A7:T=G,"8W<'@,M@.K5[ZL$^.55D>Y)F"NU!S\E[DU1ET
M&#D5O!R;_UD9\ W?[0T_QLB;'BW*<Y@0Z4U!^V3>\%59&Y1/EV/1HJ3!\S3?
MZCLVS7@YF9$Y)/1.F\U9KA@2*.E9SP3:GV72H\W;N]5;$\M2K*Q@OAV>N=-:
M&N&'$'K$,@LA$C'AJ$Q:&0DA0&TSL**1? IAP LA?N#4J,1"&E&'.7WA2+U@
M2-U2QAN>*&DSI:7;VODJL=+@)LY@2GW23!42L#P6>\C9I-@8+H)69:68T"*T
M<61-0"L]9S'=IGA=TF67@0@*TR5CGSA=-\:*-$;=,CY=GHC&A&"A4XU676.*
MN=KBH8 #/=Z6Q?7C#,%9U/JCOZB+EFL<RP$;(1W*V8K1_G4PD/\#2$'RBP##
M(PC31_-49/@4L#O:N)*[C/]8G&KKH_Y 2@4A2IL$)YP1RN[5F4W^+TPF'74-
MR&?+9$Z&63NZ9)4#9:-IT9YT9'6UP0([AR%$0C8"M@<VBR"AX501VFG>5*U]
MX@V^YA2SG0VX2J%%Q:K4VGZ"0ZG*6HUZ!QR^V@O0*"I>8JIR0C=KTG4>*Z3[
MX* 29[#%LU)!XJI4VBC>4HTR87H^11'SL ["8&Q&:">N5 CR1,#KQ*\4W =N
M(=K%F-J]F+7RK-#":,3=F,PMO<WSS3,.K9'V,S$FZ6(<SG)AO;C:/%&MH>GT
MK,--OI 97 _!L&LUG);]4725Q_$<3Y&]C5]W8MY"TJ9LVBVCSL?JRXR?R8P=
MC-&WB-'8\FF Y"UNX[:A423#>>K'^5V>E%]S6FK,H<  7FIW>M&=L>JW$."8
MG5%ILM^=)NJC1D^SOK8@S8SV"][J13:-@]ZW-E\6I; DO6EG)@OA83-_AN82
M^=ND]5F%=NQL/A(GI%OY06)4-.Q3K.P\TVR^M4K*OF>=FV$9WFP0]JI]]N?%
MSFQRCF;.5&(6>T3.3N+%DV )5CS(3FC;?C/8.9*K'&@K_[YB,]*\S!-D0!9C
M,R(C01YN415I+_)H9\4UDW;ID[8*?S$7PH*L71NT0/[BX.8\MNKCPC6(W.V*
M(]4P>T",HF%DG?3'FIQ9&TW?JS9K338:H=QJJEX_NQ@Y:@O([FM18&;OH]P9
M?]1O;$)O>9R.O2YP;$KO?!SFW0+76_8O<@(=9-,/&U1E6!ZVQ;&M_Y:<_0U2
M;94VPR#75D[D@"29IVQ*PBX+KMU9!\KG5*EF@W[LVZ9Q8/G*#]M$RN;L*3[-
M??Y*NF72A^;M)7:S&S\Z<G;Q-2OB)['G+ 1+<3;R?I:J'R?M1'0@G:-@W-;R
M&L<J2=UM?A8 57Q*%,KH[J[H;?^A799VJ\4MM.&+Z>F$JX_IK.-SW*H0:3@>
M:4R#E]&-SN,+1\4MZ>GT\\0=(R\&D<%&9'H,S[0.I_750?$$/ZF&,.PS$/?C
M+;EQ]'KD/@/NT=Z:0>-%L*L&';\VWU'?Z:!NSP%661P,8.L=OQQ-U[$>)*)9
MWYCQZP#+T:(^ZO:=P$V/Q_P"IZ:V=/1CT4L/F@'&K1[L]'QD5[I@7DAO"P]X
MX"-U8&>FX I6J&+!\J958AZ?\6^_YFTW8M0^<K45GF]&=Q &YTWT<9X3;7:F
MY]26<K<E9]7N64CE5+E=["FO;#"OYFS/=BG><G#G\F#9LB=5$LP6@)I^X$\%
MXX?'Z'+_##1Q1(I8A&[&+:,S,O/O'C0]+L<UI@C$(@C7A%97)/,V[V)I=6YF
M%0KQ'N_==<IK/=>=;-@>O".4>U_U.SF=M'G\YEX'$^595C#MJVL]HO34LN_%
M.7J7E8V]MNM/IN]8MW#C979?9M?B3; $^5YMO?!]/+];KAR1'3^<?-F U*VR
MSZ9C9L?2*0<;R-D45_&QB.R<.V*J#%J[O?:!UWM+E6:&OJ?,YNQ]U]1^C_<G
M]_$/*N@>!UPG1_*ZG4HI__'%A^W&7^U^0G>'AG''=\+-+WB"]WP<,>*#'A:Q
M\FV)#CXXE\TZO^AD]2(RUVB,63Z-AETW+W,U%_11W;5PH<V)_V=IXI/%H)!S
MV*?-UE\61*\GX85JNBC8=#UF5,]?#:5/;I,,Z5_70J+?#P_2K6_OHYY!'"WV
M".-6"=GT[75K9=/J7X;?O+%^/V)! C:PCT7[\&^PH_^MM6[UV:)D3DZ0%=PE
M5 >(5@<.M"IWX-S @>@4(APH;N Y=.=:21PH\,!"B!#- >CH\2/(D")')BB9
M)P&YD2I7L@0I8(. ES%A"K@@\R9-FS%MPNPI$R;/G36'ZLR)<R;2HTII,DW:
M=*G3J%"G/JTJU2K5JUJS9O7I4V;0FQ?&VBQK%NQ/HC7'$F5+=BW<LT#)NHTK
M%.E;H&#=GN4[U.C1N7R#ZIV[=K!=O?]EX]8=O)@P6K5&BPJES!4KYJV9+VON
MS/GSYM">13=5'-:JX0T66K)F[6(?"!>Q9\.6+;LV;!!P9K_F[7N?;1"U?=O&
M'=MX[^3(?S._S7NX\MG'CQ<G/KUZ\.S"K0_/C1UZ<..\HU_GWKPZB-;D2K)O
MW5)$PHP1"2:<GY ^_OL''=9'=[%<*PW==Q%^!&9TT47V)42@1O<I&!]$\BTT
M'X(' &@1A@7N=Y!_#FYH7T,"5<@AB1@*J!]^$058'XHDV@=@0P(^N*%\+-IX
M(D$X"J2BA1=-V"%&"I5H8XD7%CC?C SRJ&&00O8XH(D9EO@@D#&BR*"4&0J$
MSB0BN/?E1^O_L9< F&6JI%5F7MTU%%YI%7:47*/)"=J<HM%YIYUY>K88G%'U
MU==?;-+5UF-_FM686GY!IIB?;3$69TYCO8/68W85ZBB@B+W)EFF9IL6GFX%1
M"AF>=9I:*JIZIGKJ9G%2"A6G;.K5@9FUTG9;>-;)1MNMPN'*W:_ ]2HL=-OE
M&NRQYOV*K+&\!MMLL=TMZ^MXOA([[*[",BOM;\'N-FVQ7K9F4DDIU0K20QO>
M5]&.!&74)+L288GE@A89E&%%^S7T[KL(412?@%O*F.&) P.\[KXMYN?AB%#>
M6U&^]14$98$&O:NEO%DVJ"7!(P8<Y(@(0FQ1Q/I5A*.5$F><GX 7_Z.(8\D0
MLM@NP@?3=S&6$S48LKH+0XSC0/N<^R6Y* U]+E:G)56IFE_I):MD2%EEF:I5
MLWKUJEE;'>K33N^D:)R4=5KHGYCN92A<1@D&=E!O*0JU89\:VG;:AQWJ*:*'
M8IHIJ30YVF;76&\]N."%:VUX4Q<P*A9:I,&UVM'N=?<<Y<HE1QQTRR5;K':7
M=UY>=*%C#JRSE<?6^7*<&PN;ZI^_YEQVJFO>;+/:Y>:>F.U%WA&3-+>8,M#U
M]K?BCQ^Z#&2".]^H4/(<4\AQA0)>:#"/2';(([\+(N0RQ?0^J*"_"CMI9(79
MSYC1NP3*F+W&ZZZX8?0+\=RB_ 1C-+^(,?]6J9&1PK_O^XT.E*'I24@_ZI.?
MP2)T#H[LCB6Y*TD#RP25- 5*)Y6JBYKZ!K6;O$1IA_L@X4"(N,Y8,"92VZ!I
M& .W1)%M;W9[5=LNE;A$J?""93-,"1E5-J;1D&][J>"@[E;#"D;%:V]*BPB3
M&,(ECC")?"*,!JG6*)OP(ST1;(D+;-<K[72K=MO9#;:4!2W;,0MV7236LZ:E
M1FKEZEID+)WKQDBMX9R.C5T,SQJSN!TTSD9<XTK 28RV.Y.%R%[N"A^3%I0O
M=NE'1_="I,P:AK,LU:])*!J9)04(I8:)ST,:F=@G#](\C.Q+9Q !9<](!DF$
MM"QAZI(115BIKXF/,=*3.MK/*/\EONW)3)&RM*3/2FG)>6F2E,8LF0#S)4E>
M=G(B(PN>B XID'+X\8HB&9,@K=D2KP5**72##-T6%Q9 H48H3%1B$\^I3C2%
M*E X!%O=HH88O;UM,3@D% _!^<,@PM,O/F';#8%(3WK*DX;W%,RG#M--*:*S
MH>MT:#KEI#AWWB6')ZP+XWQB#VW_K@0$J_/-;B8GNF29\7++@4/FI&-29<WN
M<ZV+5GE:ZJR4?N>C-=T52J?3')'2,:0QK2-VJMF2!Y)I=_"Q",JXU\L?,>A]
M+4+0C+2WL?E,+T?H:Q#*!F*D@DVU/R6Z*H>@BE2.&5!FY/N8D)J*H0!-2$C/
MHP]7>W>E]@U/2ZPT'Y#J93V/:61)PFM(NH@T,/OX3I@YNF1A\>5)?3$O?/2B
MSX[8IQ\$<%0D8@ID95MBPCY-T)P976@[C:C"&4*TM \][9P$=4+&7>IM_VSM
M"_OI-D*-JG%J@6%K!VJI&LJ0A;ZM9UX<A=!Y]M"V]C1M1)&K7-1V,S)-XVQI
M]"D R&4V_R2O:\X9MR6;D&KQ6^:!HQS-J*TS@A>/'LVC';5[1SO61KQO'-UP
MP.C27;TQ6]H1:DO8<Q)S12XBA8P8)$^FO(W=S%^8E-@AF\3)X#%6K@DF*\]6
M-EA1FFRI##&F)6%&,1LMDIF-O&1:?>:D88YX9;J4F<M,:<![;9C$2B)PPV+I
MX"O5\I8IJA>_?CEC5Z:OEQ1^Y4 F4=V08)._0P8)-Y-<F:?1351L^BS4^%2:
MY#*WRE0VU7.+>+;1JG:XLV5;8A3:PKQI<%,[/+,+O[S/&/(VMWBSU*!T:%S/
MPDG*5U[NG:U,IRDC4;5*>\K2;G+DD,RTCJS3E4=]ZAR5R@Z.J/\#ZNBPXT7/
M(8>F-N4<3$<*+=^8CM*=1D_H+.TY]GH4OPX$I.XB=]01EZ]'A80LBX#4UI>)
M>+%!>AZ%"*O86_=X2@6,:HRAI./PZ7BLA:Q>A"Z\,*?:F*^IO%Z#(9E*3ZY(
MECR:UY#>^B%U:1)]/J+UNGH9V:<BM8 *\]<M%>3MY>U'P'3=4CF$-F@ 7!:"
M\W:)W+IBP@S"\(1\/F@'XZGG@>>YX*Q=87%WB,_?BMF':J8+;(-+F=SRMN)N
MB]7=%"[;(?*-GXT16YCUZ<&>C-S@!,<S1"?>)JY!=[5QH^Z]75HM-ZHTTG.T
M+VVXZU$^.H>/W +7>GU^<^P>&KTB?>/_>$LJ1UZ-M^GR)?4:QVNF(ALU7R?J
ME\+0%[R/U=*8-%.QNYN926L3:6$$/J63TO<PM 8[D5LB]XU?W+T#!/9E#4O7
MJZ-Y81,K<JYFSTC=X4<C X<O[+C<=H$T>>R%<=W'*G/FJ_%%O0$W3,6T)'Q]
M&'AOJM_;(UB9"JE0V,Y*"7?E)C\]RJT\4351-(;S_.:69:O;C,M3Y *W^,;O
MB2@=!O3U=8.X$"/NJMY^UF]/*2%#3ZY\U*/VWXSKLLOIK!<K=MXC(K@^]K,/
M@.QSWX_:]Q+XN;_][6,?).'O/OJ[/_[OL__ZY$\_^M\/__/+O_[@)[_]YW]_
M^*^__!WYOOSIZE^M$-45Q=]&A5\ "I7X:9_U->#X69_WG9_^^5\$IM]'3.!'
M;)0#_A_^<> #7J 'B@0#AD0%BI_Y\=\'NI__?6 'IN#_B<L!4N &:J %.J#W
M-6#\7:#[J<0*5I,) L !0N (0B (=J  LN#[;6 (_N"\$6#U/2$41J$43B$5
M5J$57B$69J$6;B$7=J$7?B$8ND?1&%D8EJ$9GB$:IJ$:YA>J9=,:OB$<QJ$<
MSB$=UJ$=WB$>YJ$>#A4V[:$?_B$@!B(5.J$@%J(A'B(B)J(B+B(C-B(<ZI<;
M.J(D3B(EKN$85B(F9J(F;B(G=N.B)W[BH!$B*(XB*9;BEXBB*::B*JXB*[:B
M*[[BO%TB+,XB+3(B)))A+>:B+NXB+_:B+^(A*OZB, XC&*Y'(!45,2:C,BXC
M,S:C,[(A>^#B,TXC-5X1YU4C-F:C-FXC-R)BO2%C-X:C.(9)'XZC.9XC.J:C
M.L;BF$CC.KXC,<HB/,XC/=9C(0Z*.@A /NZC/O8C/_ZC/P8D0 ZD0!8D01ZD
M028D0BZD0C8D0SZD0T8D1 [D1*E#15[ .UAD1BI.2'RC/7YD+P8C2(XD298D
M& J 268A2A)9.Z:D2ZKB+;ZD3,XD3:8>V074I!1N0$>6(T[V)"6*I$\&I5 .
M94>L)%$>F5%^A#P>)5,"XE(V)51&)4C>I%1RU#OLY)A4I5;6(5!NI5=^938F
M)5@.#56"Q%..)5IZX36F)5NVI3#JI%N:25EZ1%?&I5U6GT?>I5[N)2N*)5^>
MR361BSO^)6%JTUH6)F(F9B/.I6)^!%R2XS$VIF0V4%Y.IF5>IA[ZI61JYF%B
MIF>R1&=^IFB._R88/N9EJ@-6IAIIKB9=\B1KOB9L5J%F-B9GMN%@QJ9EGB5N
M[B9O5A9C3N95@D1=]F9B#B=Q'B=R?LEL*N9O D!,)F=NVB9T3B=UMH9I?@0&
M+  W+(!V<N=V+H A#%IV8L"\/0 )X"$$A.<3_J9Q5F=<MJ=[QB=QSB8&R,-(
M0, "*,!(9.<"D"=(&,("0(![),,"7&=F/0 #X.$ +  4-J=NRN==/BB$3B@#
M5*B%7BB&8FAB-B< 9$."B@1^+H!F0L I&,"'>H0#*, "#(![-$!_1HX#&$!+
M(&AK<(,)E"%^0J%?PN>$@B6/]BB0JL2)$N9L-D $W"=W:F8_+( ),"?H1QC
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M9\OPBM-L9[LX"\.XS[XXT 8MC0^MC<=XC<MX0NLXCO.XT-XXT>9XS'[VBA.
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MF6W0O:(&JJQH YFC,<#7BM)5BRTFOX?]+GC!YTTGD3U/WUORF6TJ*D)KH6+
M37_F5\ K $H[C?<*4+:HSIH[@[H-D&E.7TG3G?RAII]TA@$DB  )IL$^BWR
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M_>CW6)OE1B<&J/+Q>+PFK#KP:',%@$-]8A!F$JAQ&V3/<T9UD/3D69XK06U
M(Y<2324.T,02"'PVU1+:+CJ=B/9SW&K(VR1>DW E(8_5IO/.Q>%S($>!9WJH
M9M Z)W19Q:DN5V2L+29SE]5762*ISW.26"]NUK66]:UIC6M;YYK7N_:UKH'=
MZV#_6MC%)O:QAYW_;&,K&]G+YO5!<$!(H,!9*L%378]8Y"*I K5&^F@=C6ST
M/.ZI-!MID9T!\C%BM*1;PI6$QXR8Y]*UWB0:[ [Q425L )Z2N")&Q9A;J*'M
MQ@S,2>=K,9"?0F2++."Q"@<*CA%N$R%7I:VJ!$=<L^5F:E6R*6ZZLDTZDYL
MNF8"$62-/U9C$>?-4HLF*(T"2/&!FIB 3#TY<YG4T1,(E(CG)G@E *[[$RA.
MRM3F$="DI$LIQ!' A63[#]UJ))(1I!,R]CF("^DF3M8J"EFRM2& O!Y$@:06
MB@*!#*TL\</TB&36BVMP=U9EW".F'0!4HWNQ$F)US79PU%;LDT'>IA5J_VMK
MXZTV?%3@</3VM)?QC7?\XR$?><F;%^EF#TK0IX*8M@3,OXW1ER0R=D?^ON4H
M"T[+H#B<;_/Q5Z7 0TOQJ%&3G^8E81;N20Y:GY8/Y[O"_/ZI?3??>:EN,C']
MK:I.W!R_4BX@::@,*P;:&M8<@V8T#P!D13# _(I(?]X5<3@ ; P '"?C)SA>
M #=^84KQA]40K7R ]!>P2O=3,*S7]S[[11;]!:  &V]]0/3-1^&R3S#4*D.6
M++L.3RH&+R="C3INH.@,I#@>$-IN8B/J"6[(J8AN(M$X)9(F#23V)CF\PYW8
MB033*6SZ1E(HT&^L*56>0^]4XE- L% L[6]P@O^)I,C46N) )O"9@BLK,$_5
M$# !B5 I4@4".:7M"D()K2-JFE"SF# *QV,)I_ )C44*GXL*L] *G08+G= +
MH; *P? *Q; ,MW ,N] ,OU -PW!Q$$K1I$TG4BTGR 4I[NO;[A"D8$3@0H\M
MSNTM+N-&;*HBB$K=:NET<N^1IN>D<,=>]LU\[DTM$A'?7,^G7(H:^"AWUD)\
M@(\O.&D/V<*JJH($'LL$X@\ !F !]&K!MF^L'F T/N 49\9\&*XB&(#,;.+[
M:K&M4JLG#.%#Q$K\#.'CB&SBY._^>@;BO*^5*@X LF^4&F !3@')N*&5^@>5
MH,0$ A!U*$3C-(/CBK#_(@8@J42C8W(B"'LB#9WFLXANU!!D(!J)T@HD42P"
MMCQ*6/XNGE[%MRZB/4(%[-+)Z]1)'T;K)-*)M 2"M=:Q\M2)AC)"<=#)(C(B
M/> @Z8R#/!J'(0NBC$"F\,+Q(WNB[ SDUF*BSMSQ)(,#)55")26")4=R)5,R
M)F%R)EM2)FN2)E_R)G4R)WE2@W#2)W<2*&5B[P[B67IB\!C HTP@Y3[J+43J
M+XJOO^!EOQX,8@P 2@3, !K,P*8GX S@44;O*! LD0PQ+0Z)++T$+2YE]-JB
M>'2O*T4L+0V CV0*,.PEJNJH7?;EDE@L*[+O,@Q QLIJR*(,!+0/-,#B%WP)
M_\=X3!=[AO]^PA@18# =(*NRX<B:1Q:3C/J&#)!P3&1JXQ@KHJUBQ1:SJAD'
M$P ,H+(PY "Q)*) 4N44P 0V  (8X%QR8@YUPFN&\KD4"G+<<?(<L&E,[9O\
MQCLX9>SB@[/*H^W,8R5(C3H>);.^YC>+@T "3RO0$5L>I(MB\SMM CB&(R*8
M)C@#[3S="P(1"FK0<T#4\SW;,PGC\Z#@,SWG4SGL,S_=\S[94S_ETS_IDS_7
MTS?M3&UN J-LHA^\P0*2P?I^KB=TQ#"P+:K\Q0\A5!LJ(GJ4JGE2S_5J234-
MP$I<"J8\5"[B#2U\RO7$LD/3@J9<[T0QL=^H2H\X,?]\ZLLM1+$JWD_Z+B,U
M;<)'K<_[1N,S 6 :X"^L),@QFV<<]*HG.L,B^&$P=Q3^FLH8-_,5ARQEG _^
MP )+1].M;N+B+((QCS$9P)1#O+$HP+$(20"9'B#-WBPIG(&9"+2S%@^:GG,A
MI[ ]BF[7BFVZGDT@Q",B\,,F!B=!  U0"?0B X1 ^^2SLG @Q@  #N514:)9
MD(6#,N(E0B .M4(WL<4CP1,D8:N\M% H4951@U)5>Y)54[4W5Q566U567Q6Z
M9M56:]4E<]4F;U577?57&U51&;)0<4(W(4"-DL\G+BDJA>\M-DDN9,]0?<\F
M-D 1"XD:\H@JC\\B;NM:&P,: X["PB[L)F2J]0YI]URO]H"*+N?H,)J5CEC_
MQ)-T-$0V $Q]=.%<\4,4LWE::3,M*ZX68  *Z3!UP@'RQ,=&R4MOPACAJB+R
MP?YHS!AMXF%5[DPMHF'+90&R@7?<Z@,PKC4Q(Y; LRPLXG3<#$&!HE09M0?1
M<P++<W$^J#R8QCIBXFFRPR21 SII=3X,->E2XE*H@V:1L)F02%4%I'!$$EG^
M*4_+XP<%[V,RHXM@<U0_4@2R@\[&$S_%ZU3;T.CZ] W!]FO%MM3(]E+'UFS+
MUFO3MFO9E@S1]FW5%F[;5AWCMFZ1(VJ8EFA7HA=O LZ2 0,:H %,I &R 4XA
M]$;QD. R*4+!K<S6#7?2(O?6 J70(JB$BMV,)Y-@_^1$TX)]6F02)XD<7A3[
M?,_?"B/;HO)TNV],K2(U_Q( 8@PG@%2+-/8!!#:F3F&!N,$FLL]*8E?G=C=C
M1TE^<B(5/83=%);&HG&N_+4?+-8T50XSP>\>9C-*O+&+UI0(C2<?',@SY' I
MYHDA:55\:Q4CB3(BK"A8J^A.FY.Z%G4\_N3H>)!5AQ:ZZLP) \74'B=0LG-!
M.K*NLI=J6>W5GBD??;)^A3.!%7B!&;B!$>HXZBRS^K<B,$\!C@&-*N :T(@;
ME96^G/4OR(=A6*0J 6Z$[T*E^N&04JPOJ ';/)@ML-4L'RS%*!213O=9MQ4G
MS'&^@!%,32"5,,Q\%("F0/_#_LH"B+?O0S(L)Q8@JZ;/>L+/^Y )QQXK&*EX
M>EH)!333_;2(R$C EZXR,ZFG 4X!B3VDB0E1BQB@E$2&%%:W05RS9$;5 @:@
M1/@H)Q;0)_SC)1!XO5A6 AUO0(5#//#T?=]1O!I'D'?0SIYM/7?PD5>(,D!5
M6E9-@(MP:0F$0)"097LS;-?6;>T6E.>6:T69 ,1AG]J&(6@BE4>9:=;&'E*9
M)BIB##Z9;EOY;$/9EDM9EWF9E'69DW>V:;[W*J;*VI+DVVIXI%YXVUC'6A:&
MCYZJCJ29OFIT1NW(OFJT?,IGX!(C1Z?"_!; %+.1&\)J8S.S%A6V ;B!L+9/
M^GK_0@&DK[+ ^5XKH@1XU!]\"IQQT<@\A(NS=,BD3V9.(*P4P!J>%P#(8J#1
M^'<6@)U#(T.NUZXLN2>VTR?TH14(65&G2POM%.D@XE@BAWUGLO+:D4]9PAVI
ML&:#$I"CT^AXE7P]BU%OECQ@^B!:X5$H(X^O150GNM5":U>)LFGZ9'[YY(")
MVDYK"*F'VJB96E6WYR9HF>GX":E[4ZD%8E)M@E9*$T!P=:D9U:J+^JN/>JR;
MNJK)6JS+&E>GJ)8!"B<6T (P "R2U7$W\=\, (=35R[J>IFELC'N6+@0EZ_A
ME:]55_/2XE]6^"[:15Y[>D.4,4KB^'(^LDU)8,KLR!_@_W22?<(#-JN E45F
MAQ:8@5DFAE9 ^FZ14[+HK -R5CM T9,\=5!K:7HE83LZ5]MIK0MJA["Q6^T(
M&;EH7=LWYZPZB#NDC=N]BELEK 0=)LUO(-)5Z73JANL_@ ,^"NJX(16YL3LY
MM]LBL_N[N5N[ 72T%PH"J=!  0!EK><!M@0 %"#B#G=\+@8O82<Q1$J;:[0O
M8&>;F>=W2-@I.=%UQ$>:ZWM&LMF.DAD/C5FO[^BL>'M#8G%*TO1]8G,#+$ =
M-@ #LF$#DB$;/,HF=!HHT.&?S-,=,_6S4?RY+#5O73K%T8L+:]4Y W6#-DOQ
MUIHG$WF".?)C>/K!(;IH'NB!M/\"F[905L474(02"97\MUN:Q5U<I G@*$1H
MTLKF.4  OBIE(%R%'(2(!L\I(IR+ *:.[6 "/A @M>1C>Z:< '#: R2MD)O\
MR0UYR>'<R3>5QG&R\B3G)N;P_T"#=SXVOHW/@SG/7E(,8OKE74!/8YB9T478
M\]@%*BFT63UQ+^THKW'8*2L&T0W[C0%@AWW<0GX7LD-6:JNB ^+Z ZH!@UB]
MU5W]U6$]UAF  S[ !##@04FC!"863M5;*1A%'.P@! A9:(4:M?NSAEH;O'GU
M?;E0D4VU54MR."-0)C.YCSEE#'"@Z2BDHBGY-:<VU#,D AX6'"SH)@R7*>@L
M;\M34X'_VW$@D+SA_=WEG;93N[8<0M*<-L_4ICF>4-KNAF?M SGWA&\KHI*$
M100X[KKCG=Y;<MX;GN&G_>'W4U;)FU7W',1U0EP($5VZ)YGW^U_JZ%W\(L$7
M/+!9!'9$W@!27D+'IYH_42]HU(4[?6,,#MR_,TTE^BD$  (^X-:C-4HL0  P
MP $@X.<J^TU@1@%^3K.O8I_V22MD[^=U8I\"^)6Y:>HA)>J!0NJO/BBXWB9P
M&B>TOD.8?DIZW.8I1 $^O%@Q0-8O*,)R@IG,TWS7L<[EG,X/.>_C7*W#?'$@
M8Q_:VC\DIP LX2A<R^EZ4V],F1P.15%\LV\R)9T>99HJ8E,D,^=0F=S.YSSS
M[Y[SMS:HV>,<Y; :-D#IQX+C/YC39YZPQR</6?_1H:I>.(F^+-V:1]Z::_^8
ML=$^'"/[VYUB SC@K[<E&7H>)P2@!$B$< OW04-\]YT_*)I?2KI3LI^_01A
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MD2-SG[RM$&5'X0^)G^2M&[GQD<@AINR- X ]WP<1$/   ,3"ZB%^6F].P!X
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MYPS;,N':>:&##<J#,:L '1T3R2DR_%@6&ITM./&0'4<",L$/U,T8#KW1VZD
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M\2'&[!9D 3D/OQ8*,"2TF>Y17N55/MDLST+$:9R,,<\EP T-8 UJ#A  %D
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MB^#_9W)0P!I.;H<3?% $KM*"%?TP6,2!@/MVA"5-LD!DC4(?FVY10@HBFHT
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MB8M9O,6M\N'NFUZ.2!JESG$(E.-T=0J-U@V>I$>>; CN!$%_C0GNC%K?*&4
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M@3L# B!R, #A8D,&$$/861@B!  ".)J.&$$ 0"NF" A,;5K  @ +(D18<(K
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M)E%:NGEFE1IA&=%#3=H3YY%>,D3 "'GBL , <&"55 $$[""74DR)@ -6(8@
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MF0<]Z#N_>=!@7C0\%/WG-0>:SX2>M*'37.8SNT\ /^62"4B  4]#X &;+HH
M3 "/4YLZS/#X!0H@T&I70P#6[ILUK04SF%OC>@-8V[6N=2V 7P,[V)IV6P=^
MZ P:SK2&Y,4LV<1!*:=81#H]!*BDO@+$Z,K-40E-:$-=L \/@/NAF>QN5/3[
MI,HR:76.D:KM4!.>B*;&P^Y-8X6A!9^J?JZ-H,M>:= 3L))Z!O]STEOCN/6=
M&?LLQB]?:0X ^BB^7HEFE/>)C%3%8SHO4D]>WB-=:UQJGGU!5#X\->5$&L
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M_AA BFQ ?RR$-4CDPEI(1&HDT&7D8$V,1T($!M332"Y 27*#-2Q-3 + CB[
M"QF  S#$ TR=TCB=TZ4L0YA U$5=43[= AR& "P .G$=2G #SW+#3WS  WP
M-\"/"6!=S$Z$ 4B=3,## N##S\*H&>IDE? D8HPB$%KI9OH#-(S09J(M45;(
M+U!$-&2J /C#L7*  F2# ^3$ [#D ^1@1<A*.8E6UY5A1%A  RB>((KI'O8E
M8=H=8F8E7R9J64KNX^9IH8HE63YN7U*NZ9FI6#Y>5Q9BH 8JFGI>XX8NGI*N
MGP)JZC;N(<:3DZ06 #!  X# /%T1[<U)V([M?CCA@$VH1)Z4@#],@X\JP,]
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M/OMX@>A"'#='?5M]WC?FO.==N"MG'#1]QQ\Z-K1'KYOF^/,$*R"XJZM(<TY
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M4%G !9 "#?EZ+5D0#1"EQ1X&JR7LP2\0,:D629):@C>D)90 IA]\PZK*9=0
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M3<N%W@*FK8 O+#<T(17N[M0M+^"E^+;46&0#";W4PJSEO()R4E*,C(KR)BR
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M&U)4;?95_S L.8Q?C_$M@64X(%05^2@0C_ 4RXM/[\I<LB5%0W6\_A-3,PF
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M0$54;.O/C@?-,> NP.]O3KD2T #V0X\E%]&T.<2SPC5\,W*M-9ZC)>@H)02
M*L@[&D%$2!!"ARKSF8/4 #S_LV_;"8>8N7"O1#*63DE$:R""*&V^1DIXE!H*
MMT1L8+F 7&ZKSJUM#AZ9RZ[[A";X)+M&PG,B6R(\HK_Z) +2YG% HB%FY0&H
MPB-<9DT(FRHH(B,H8G(! )WOA2H>QT5$0DM(H,7?/,RQ''SZI'-BHBX:9<]!
M0B16V[G8F7K+^V9,%ZF]5*H%%D,?<B\X5GV+&[E_NXT+6J'7-])A,9;3]R0?
MNK\Y_<]FC3$D&D V8 /@ M71]HWX&(6*::,G!881'3PR0O*24H0$)!L.MDOG
M#J:]-HQS6CP9W'<Q^8%K=1.C%A8IE%LV"3 >;'L7MA6G,I-;(_& ]GB3!Y6_
M5A0W_YSZ_*P8]1=^Y]NA@5N5@V-C_X(2-6+E6'8ABFT *R3/H(99+_.L9]Q*
M9.ZM@RQ*'--*PB&WD%6BZ$EJVC9<W\D ]F1JKL(#3_!*:+R+0E.K?Q@ ED(E
M9(PD]CRRGQ(".EK*[8PE,IXA(M<C?"<A%N)QU((!C@0!%@ '02"S3<<F-N!<
MU<?*1R>RZ\($>IB&-9X@QGQSLCO-7.<]:7V!$& #O@V8_4708#= @=H/?]EH
M8=>,*[V._5 M79IA!?B@JSO<,3F-.6TQ4* !!(![A[@PP]L%<T;%C5X], TJ
M 60&.?R,W?*^,5W<8Y=/[W23DU;3&U*F[X^JM0< QBHO-O\-K2KVC 0@-5;F
M+AS#>L3693!),!P&?=22/,63,SALO\OT/X&WIG7:OR\U=@&<>LASPR\:)Q"
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M[&/UN:#Z!A*!? R$/0043L'8UP& S:93)KS/^G3CL \8X#EMTLVIWF. <8B
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M:TJ[N\$%2C29- I)&Y00;X0*;G>*R,?J=T_=K.\\V.F'Q!J8SW4)$#@1=1-
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M'-V\PP8<&T_6 <!!90_[H"(EZ6^ /9M\CFO\[.4)2^E/:YG5*KW#!P%M>3>
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M YD<2-H@**6+RVF>%%#R<>&'+\L>4300A1D1B.?*6X,P6,"0!:*?7OKH63*
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MR,#_EI=% G06KZE!\D#^6%G1?/&M<#V@7]A7D+42P)I@-,V.1C."0.)-GP2
M@SW)>1JSZOA&*DHH[OIF@6L,:G!LF;$RFY5>/]E4 2/LK4<$(F@3).BC"E#
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M:$"(RJ6+IDF2E95>JFE94F)4D?PTD)0AY2$(!_,E U&)0A-:@N" .CN("U
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M_ZJ>\&BEZ8E%#4.P$S* $9.N/\0\3N(&X-LP\$?_!4"<X*__4!NB7QKC$0X
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M6EZ"#**:0%K^/O[\^O?_3NB7H  +O&9602;@!H!N!&6S0$0/]%;0:GTM0!8
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MTH^(U",B$: 21)E@(PQPG4+BF"::B<MFZELA*#^5#P5\C6DP^EI>() HI#P
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ML3/>%;6UI)=*4D %$M5GC9/\O",O.5(-/9QE>V155($056*N ']$)!DS%X
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M72$69J$6_WK$6VTA"@U>F91$%#+>:U@;67 *5>A<XA5$-EQ>[$R>I 1=K40
MV!C :2B> '#44'E$%%K !N!.DX'$T[%>\&E=\OD+O!W<O0U$#OI+K,G>")!@
MQW!= =R>O16,[S7B#S8B]\68'1VB!0K,PO4> )1@PQ5<\V$B(XJ@\@& V8U
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MXO#S#D3U)D9XVDGUQ$Z*]8[E!\VLG:AG1'CQL#EM#%/'_)%H2-0JJ#C9!I!
M S0 !K@QB:$Q0NPF2I'N((4:#W8,0;#@NSJL"/IO _LO\_A@YIXI /A+;%KI
MW@+C;R4N4%(?F/(1!V>KEP;2]51P+1XRMUH P$J?:W5,;SX<U7WB]\R@(C\L
MZM*?6,SP&+.?ZY8<H!J$H"8MR ( -ZRE#;_-#P/J[\8R>?ZN?18O@+PE!4A+
M061J@3*O7M$L "CMSU)C,VDJT9JG ,RG,&_O6#+_;8:E#3<CDS=W,SA_LSB'
M,SF/LSF7,SJ?LSJG,SNOLSNW,SR_LSS',SW+\P7(JDE K)C42Y\\V^6I8_R
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M#D(TN/"@0C@3'5:<J!%A1X\/*1:4&%)A1S@./PHD>/+@QXX.)8YL6<##/A$
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MU)D"5:-'@>C+A@)1> /8P+/X\L+\Y#%7KFGG2_4B0)C.E*8UK=7''K:G #E
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M'=I:T?).M+J<;V^[R=]>VI>_Q9PF+J?ZPP$#4[]I)3""O7E5^JYVO\B\\ #
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M[1!N#' ;O?$;#<4!=<\H'"#(_,5#6 2^*@-83"TH@*6[S&T1 : :%* =BR)
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M,_IP<FQ2)S9C135CEHI1)W+(MU[1'G 1)TIN&'.'(,DHY+:H'ULQ=UZ0GR
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M.)XU*&DE"5C+JE:&A&8W<ITG=>(*UK5RAJRIZ:-?Z=@@K?QUL(0MK&&OLK@
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MV&:)!8]WP5C_*+I'TGB7 -@0V6=&*:)X#40Q[5>4NP=A.K:33G1D?_@B.F0
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MWNDG^0O.@1ABD^DZF2<,</7PY$$)P3+Q<C[B[29+KLA-O8^8$<E\(^)!K<6
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M<9WFN<L'5-'7+!X]M1<-?93P2HHZ]1=FU-T,=1<([$:+JUMZZ5J[O9$'[:F
M@RD_.E5(I+U$DB21NTR+!2K7&TQM[4A>7"-N35K=_=Y%4M9]!$&KA<(.R<;Q
M*J[J-1]VS6 .%E+0/!(E[6#&:-9&O5J6E!ZJP$I^/6 *EE#:U4, _5KZ@T+E
M:17:P4NR_^S"@QS(.LRY]8,D*%U.D !7\Z..HES3OSQ(?@S*B7.>6TR09B7@
M+KU&Y'1(^1U(RQ7'\<Q)Z#18MBA,YKE3VH0+$<;$Q#BJ,E8O##"$!5@ -EX
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M>VX [79LX&9P]:89.*;LS#YN2<GM!2#K-A[NN#AOUP!QKEZ6XE9LW,9P01:
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M!G8X66_)=W!QIJ9LSX9N04;-=@W03X:M<_ XOIH(_ZCC"HAWT<=K QCN2P$
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MF+4&R157_I )L,$'(YRPP@LOEA![7C(<L<03%X0!9\ )INN2CD$\&; 41SF
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MY:2L -E<VN78O*)BP-E=YH4JOE\!HA(KP4,CD4 [<HH_.("Y522Z_64*-J8
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M7 @*V(.H; 1G2MW5H9_2\6S4>>C5^6S.[FS3_2PJ\JQH[FR!#B+.SAIUNF,
MDFA\T2J2U.746BW#5"U'$>G5NHN^8)] #)-C=A7]N(3$$HP%Y(L".,#_F.;
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M+\QP#?NPQ':H>7Z !5BK O2#)%6 'A%8&O&KX)Y2?-C96-&/>6* /NA+)2F
M.V"QB6R%B)[_EP+ IIM(Z(XEEGYR&E6R5=+&#Y7V(=<I\ELQLB$#4SP:UGUZ
MVJDZIR4MFZB-TJXBW77B[_"TV2B;LJMD+608@#WH0PF-$ AYD-J=W=O1LG3:
M,MBY<B[',B$)# E0JZ*BJB6YFI5"0-!@P 80JP(S2RM; $9<GP4<Z!TW\U;
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M3B O:6+L#S/P![=NZT) \\ZI :1/4_C#,9R;=$U  ]LN*<&PB-*P3=>L$HO
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M [/)_UU^?2DJ4G:$VZ?8(;**,:<!G2_[T+I&E?+.^_QD@/C/YX7_<L Y#80
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M@_$05,>H"N0:CP2X0%*  7+LL>@B#A&ZYD'TJ%)'GQ<5\@>#_R0:;T&_5H3
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-',\1'=-1'>LO(   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>abvx-20251231_g6.gif
<TEXT>
begin 644 abvx-20251231_g6.gif
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MKJ2HK*JKJ[*RLKV]O<W-S;FYN>+BXMO;V^/CXP
M
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M@KH1B!,0(N<B>9N7":.0 [E RD0)S$^&4B VU1E#6Q;,@Z1!E5/SY4-[!DO
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MG3B.04O'T7O'9OQNZ]W1U%-Y<@:T2?N]9LPS[,HR::R7C+G3+SMTGZKGNIK
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MCT8Z::679KIIIWDN:5=IX8OM9:NOQCIKK;?FNFNOOP;[#@Z!Y.\OY/9P(E@
M[A586(??9E.4//*H1*0JYJ;;)"7P5B(DO*OP>Q:X!V?-;<(/1SSQA9=3O'''
M'V^[)(BS?$VLB9 (.W/--^>\<\\_!UWCF TC(@V:2478<,@75D)PD^3&NVX
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M'#QQ?,RW5#P@<;;28<+C^(^T8<>CTK^WV84T2JA*X!^V$H68>DJ0^(19J((
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MM1S;UO+;WG(YSFV1UNWZ"I,2!W%X87%[=O$Q)_$UUVTV[^MR_? 0+W/A=NC
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MQIN.95H<8A\9/S6!O'*\I.L?FE<N@[5)Z'<R7PA8,^TP2<0I-"(M5.9 &))
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MO=ZM]M[C6B,N7C"8VR!^W:6@I<D#/N!+/4V'7>06:=9E M95S>%GXLE78A:
MY^(/BL@]KJ94?1>"G(!AM, 2*LBWK]@QCZ91>9C4<:"+8F+OA2%.8?+M65^Z
MTN2+$YY]]=F$M6"\*U18X\FBLS-.H2R+RRV:Q25B&4/ YQ1LM!)FH0$^(?=8
M-J'C9V%2H]IU=NG1MZM$@]S3%^K?UX77=:/=M6;N2_H@W5OP?@DG'< JW>OM
MG8O!^2(J8<;_!\(GG42%6J&V#MZE6B'4[<7MM>2FV-[5S87N7]/N96+6:<YI
M0$Y)1$$E9-\@R%9+%$()AF?B 0) GBH 1.T"@+#/080,&SI\"#&B1(2S)EJ\
MB#$C1"(/TZB9 )(($I$D1R(Q69)( Y(K2:HDDA* REUY*C98*0K/290K>;KL
MR1(FT)9!3Y9$.;)H2HZ@8.Y,*M,HU)<R.<Z:E2>/DI4R 5CZ1"3/RE:BA!*A
M!!9 )26?**DD-8LL3"65&LPR>(KHRI9[.9KEZY=H50!]_II]B1APXL.*&S-^
MO#AR9+TP)Q]&3!BQY<V..4/N#/JSZ,6480ZNC!IF"I 3@"E14J6*_U^-M"5R
MK(T[]\0^NGLW1 4\N/#AQ(L;/RX<-ZOES)L[?PX]NO3FOG.;KHY=8\6)6@%\
MXMVP3R6!! V&K_AI_*[QK?( J.)>H!*&:S&"SXX_XR>"^?L_O.U?@ _=)^!#
M-67%WT/PY0%>?6IEQ1!6W0&@1%:?-"1*@@5>1."& 0+8T&H@/2#52T@AE9)1
M+:F(&A)Z:(5:)7FT8I9//BF5U(D_U<@C4";^2 1O+J&4$E$M$E&)*  @4PE,
M$K;BG5L-M()'50V(!=-::SEY%2DKT:52 Z?L\E)IJ9EI&&I"5M:99VZ&]N9H
M@,$YIUEK*A9GGG3*R6>>5)G&)J!=P92&B%<3[/):;"IYN!&C 7;HZ&_(34II
MI< I-UVFFFZZ7*0-7>=I=9 V1)>,2D9481X7%L0?'GF<2AB""-&4QT((Q7?1
M=J'BE]:NNH'JJZBA5C%>L,8Z-.JQM('_R! 1K*5X%+1#'392G0W(6)A*9,%H
MHU(_=@M8M4Y%NUB).7*4;9E%NA287V')Y(0HU\Y2&0"G+ /3+J>\1$N3*^41
MUEY:*J'25::)T@IE+<G$5;UF,9Q:5]E"K&>?>U:\F<6H+9SMQ1YKC/''EAFY
M<6H.$V&H&;NTTHH,0C40*K/*:I1LI);>C'-RM7'*<\_4[0KLS/9-M,NJ0D=4
M\]$3[:?T14$WG6NHNR0-]:-5:R0S (:2B**.7>^8U(HD?9(5'K-0(@J$/(I[
M(]O0AATM4.):-C<1H$0UKH]])85:*TT2 :9=6<'4QX5(&@[XW^E="5-[UQ),
MA"A;P>0>H(&:_XSFGT1E4E6?(8,LLF,? [;FYZ:'#OIHZE+L;N>HL69&HK(%
MF_75#ND:;,ZZ6XJIS[YKZFOMMB>TFZVV4SV\=QHF/QCS$B'O?/012M^H0VDX
M&U+<(GT]+8LE B6#JUF-[\JX;KO]K5(]M;WNCNYSE6Y?T9[[%!*[E%70Y"_5
M.LN^R\A;F?9P!$:2FY>89F&7NLSE;ZBQDN8NTQ>2H2M-J#L=R#)6FC:1+#,8
MLZ '*[BPRYQ,,(!*&3)8QB:8>4IXR8->@78'0^3T[G<TA$[P6'@UW%$O/#MT
M"-.HA\,6]G"(R"+B1+9FKA1]C4A$DAM) $"*2DBQ#ZI(7_KF=CYH??^K6RS:
M'F+.)23*H&AOXSJ%++*"P,<\J'+?60G95#66K)R"86E3DFFNTK#,/89D>22<
MZT"8.@QZ3G0:(\J=(..F#P:R@I=C70--EC+9!?%#1'2A@&*(2>+,L(:<[!30
M)MDT2]I.ASO\8?2>1CU1&C&4J\P:]B;@Q21Z[4=.%%O==E++6'HKE^>[D8_@
M9L7UH8MO#D1?M-0"I?>5S'+J4A<)'7DFS?11,^W:8&'D!TC3?4Z#$$0D_"3#
M346*\V)_HN:?7#<H0[D&-K-;U HKJ:Q,RO-2.^ND/5GA*Z[L4)55XZ?23.D\
M5$J/E*N,GC^/EC4D:D\J*)+60D4"AEF(1XK_4MP#,)V(12")+5P[FE:Y)!/&
MRXD-;V++P[D(J9D_+E."?>2C.>L4S<Z53F3C]*;JPHE-T1S2,]GLZ2)%B!ES
MCLMDL),D*/-SU*81U%/SE.<F[_F[&_;PH$JCZLQZ=4H5PK.@/5SJ*3OR2J<L
M48FT;)_84C6^\2DAHV[;J/EX],6@P-66<1T) )KRUO:!S:R70R3%*&:M:)93
M82*<)E4Z-LB?2C.0BQ5DGSCHN9I*%J?N,E+#6N>7ZZE3DK3;JK&:FLFG0M5G
M4MVA5Z5G564!E'D"-2A7I]I*B""1>_-[6S!)<HJR452*:\41M72DM[UR%(N]
MU$Q([;H4,I9UC\S$P5-A^QI"-(50I.Y:IE!VFL&;*A9.(Q--3E47),!ZE[J3
MW2YX@RI8DZG!4+N@!1A4(1LD $"^[QQB:GT#6DR*=K0\"YY]N7I:YJTV>:UU
MWGU?ZZD#=_8_SV*H+LW55H="148562Q&/\K6![,/?8JYZ 3/=1B\U78JU"0A
M:5*:)@<&RL0D=.Y@#]O=\E:L31ECKF4(PUW+FE?&>'*,BA_X1,L9ZA.<I6]]
M87NL_,9PO_S=5&E3R54%^PJK7S5B@!',2B/_)I0U)!JQ21K*R_91 D9RY>)>
MORS7X*(YE\*]C)"\QR[E>A2])>YF=76\XCPC\L1XKDSIZKSC;(XWQHT%Z7=1
M2ED>*Y:\$3,91R+)3G?&C(A7WI"28<CD)F?JR:B-\BKI!<2D0DW*6-Y0I6TG
ML^L]2\-O0S.'TTP$,.1A7SF]L#!].:3:TE7-&_[P6T-(/S!?QH$_[K&>Y==,
MFQK;<GWA8*T#O>CO@I.ZV5T,CLF[[&K[U(.>^3'$JC*5JFPVTEV9]'^3?&G=
M95K3TN%T]$X]/%*':L##*S#SY%UJJVE9MER692S'JM&E(*$/:</#;M?"4;%=
MT3!C];?"Y>:V-W^-_^$]LC.@.X=20!N&QC#%>*#^C.<<0ULR)XXQ83/6!VGO
M:=LLCRR=2\:WUX$$49'6ZI'W&<]TYVS=[+8AT,[]Z552F;6BSG*^A;AO!H?$
MP?[^'JM]<JVTIA5RPC9*^H@2X;EUKT:X-DUAX#8W$:.9T"QF],G_^M)&3MO.
MD'6@R+4YNN>N'=FAN7;)W]YRN//IQX(ZF4PT"[N5M<PT1G94T86&;XWH?.?U
M['E_/XGD52;>4:18'FN#?G2D$W'+(YHET[WH4""-9*('K\0>PHSK;BT<[&5>
MFV'>['J*:[V;T^6IW)_K\6R;/+R.A>FV$^E[&Y^\32E?._!'GG<71[?1CO]^
M9>S([=\APCM B\<9SQW_LY@=_EB3CU3W/42*[;L;YYD?WO2AENJP/IVL6:?6
MZD2?-PF[G\U9=.MR;S3!UM\Z_F3'=E_O7G)ITEAF4AJ0I6W0Q5AXEX "&!H-
MD D(V$S)-W(5PW>U9SDR,6Z*4FXW!V7H5GV5<GW8YTFAHD_4<W[])'265V_B
M-S/?5WZ]X8*[,ENM]F"VM2+5\@EQ41GB(AY@T&9M,T8CMD7)]5!6!WO(Q5S
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M!3=_>MO,7BB-^33>0Y5O]%J9<YE-E?Q^DRBW?'\&8155V,V-[F;U:QG-;A9
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M\@P'G(NU3PE2-$Q#JIC-#>$S<LI<)LJ^B%'_:#J.C#.C9C%'9TU9H;16?)P
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MZ1IV*9/D1 5")*66W SG=)5Q.\38LSW"Q!3##"Z^L+^@/+3N1+X/9;3EB['
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MK2$"I_YAK@MU40?\9T[\#.?]#1]^4:;ZX-?RQ5<R@  @<"#!@@8/(DRH<"&
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M0"@A3:<*V9(H OF;J4M*-)3'ORX&M20I09>V4D4>)J((ZKCVC;KNGJ<ZJNM
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MC6 G7F8GGR:NBRXNXA(J1/ L0?BLP.+LC8 KY(IK"9)KHL(@,TX']7"F: (
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MW9-9O_:=&7?ENG##BGV0\.-#C<N3,U=8*<^NDBTU#MU(T6%%[1E!:K=(5.%
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MK@NO3EG@5<&84#$^($'SJ@):@'FWBEDC5'BYI=1NQ8:8C$)/I7>**U]!>DC
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M0B WK]MUEG [V\.=C=P]TMQ3KZS#>(%:,Z4MD<15'?NB[,Q73K[/2D-D'5.
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ME9I21FHM2ZJD%+B4_2BJN4*JBZ&+I^HKJ0H6J\HDK=I-L F'71I;O24*>X1
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M:G5!W-B7V?N7+:J#+KRQB=9X"5.)^G<AX=E_M)MZ1C:%W]JC\OBH*Q*_%QC
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MQ0U.$$]:50/&%3I6C%72LDJE$D#&R67,"Q85'TVSG,05H641U\*-.NBZ-.(
M@"8,G6MK7+YYD1H-P0T1K!;"H9(YDDJI9)HPCZA(B5+6349BB$J%CC8BF<#B
MBAW.EKI("H[P)+EJLX1=JS7UG8#"R+8P \9SO(0"3#\N#/=M4.+_VL9E/%X_
MYJH/0Y!";$]D/@R_"\0\EB4V;DX&$<RD*]>F*1\'1&$/<1,;!:$W293O\0T,
M:F?6P>$&A XB[6&U.HJ*! \_066S<-IEH&7A#.515HIT!(^-J37*/:=7\^5_
M EZT.$XL9,YCMN;! +@LL5II+IQG]N-R<UX$L2?4&]N)KF.;LY*)>U7 [5;*
M 99*HT9'GJ9%?JX+DB[QHA-LS"!HFK36@=S+'2]3OAGG"&65*8[@S I!&0JN
M\ZHB76AZ.E)OJ669*#=9>V5T 6-+61^T>!?-S,@YU>B[Z&J1/B).!>NQWHRO
M)NL'8L9(<ZZQ4F'T:>LPDL $I*;:D*I,_U9G/#&KZ:H<=@3JFUG'5*;D57/3
M1D&;%WKBI6Y'HQ:7(XV?<0EHQ)Y".DJ)=_FZR2FH^- ]PC#KLUZ@S.9L)=KL
MSSX@9A3<PZ0JGC =9)'K<)T-T5&=Z]()U)$(J!+2UD:1.1J4H'84<B+H>QV2
M: D7R&93(A%E(;$?+QY.R':9@%J+A[8C^$ 5D]47T:9NH0GMZGX<S\9N(TKK
M#8+1T"G,V+XB<0VA3H,Z*9K&26;IUB8=[\'1Y\#MOU9JL4GH)S:KPNY=HE8C
M609-J@[HXZYJ'Z%"<1(H]& /]X"/ 3KC[3[K2V+PL=;N!W<@9#*31+Z)*!)O
MF9;!.Z2D4UO"F?\FH9ENN@]Z1M1F;YA6$S[![;YNM3'ZE,-.(U2V[R:&(Z'^
M8OG&[_ (\,=.O'3$0LPVYC[6CS9#5/7%O#LKI=!JIU$@B)KR"T5J,OYM\D4Z
M8('C,-3S7H*H*+74+:8-UCA>XU^%N H^B"LG" M#2L>(\,/(.M.*)>."\BE'
MM_1+1@Q>8)>29@#&M^J\IH)PJ;]-B//M\RZ'3V(BP&4&1,XRLF^[;KYHI]92
M) I+\EVB7$!\N<)8*>-:*=B*)4TU<TH'5O%=-+Y@VSTD\X'H=#KGYD_'TX:3
M: !@FK5^:]6&#9WH]+;R*G;M Q-/F"S2DY.XXHO()"FF"-;*"2],ZHK?"EB:
MYIQT]$PC)8\7.:\J[;.AV/2U>/.?@/*?X"5BMTQ6JF^K!K#(]*.4T"=B+\)R
MU*?*5=(S#8J/FK8M3>Y_O.>^68O5>&[,7M#]4+ZV"SZLL[%2"ZVX@N,_XN:$
MD+<4>]U6BJDN7ZJ>:K*>K3*#MXN$;_53;W7CXK 36Z0YA'@0J[B%:O2[\$*;
MVG@%3K&&U\>0)PR9?71*;[*#E?,O?'F^(#/.DMDOGTJ:I'*0=+V8.ND% Q""
MQZB<$WA1#\"['8R,TK*,8K&3O^,4DWC;P_B]4.8TS"B3W^"L/V O=__Z!8=U
M1-XT22ZAP^6PQA.E;@R\-&'MJOF)5:($D(BE94A3(M2(CD*"U^5&TK&(%ZG(
MS1T[:#_H75MY/UK[!CA[DJ@EOF*XM<>\FN+E&D]8R75(/QH%)<W6/Y(KDMBD
MM]<D_LYO6*YW11$>XQ1>;AMY@DA]A; W?1OUV/K>KL)3HA7?R=-SA5@IH9)$
M*.VXRSL(/!BE3)]R7>JMW2_ @\C]_MQ@8K(Q?=)4X(]5M*1SH6J]-"S&R!!K
MS:C6 @3^BT^QURJ(6+W^P%"D47HY0<[.E%JYRVI#1@MDI,)?I#6W8J2W[6<Q
M0YH%VF//0\=C_0<(47E. 2AH\"#"A H3$B'_LO AQ(@1*^7YE+!*GCX&\W#,
MH\0@Q5T(9W%L!8!B)8D0E7 4V2=/2I9Y1)+,8Q"/*) =9VW,PW,7QX(89P(@
MF5/E0HHY6[4$\#)E09P 9+J$J9,CSX)4BP9%ZC6BPX0I)I!]@ 0)$;1GTZI-
M2Z1!0[AMT<IUJU9F*X$<W1(1A0< TYT ^F:LB[8CXH&#^<*M^Y9(X#R4W%+*
MTPIN39AQ6>9LZ)DC09E*W,)U2-IS7,^E5Z-FS3KUX\:P4\O\U. 4S :T.-JN
M65J4I<$-*&(MC97(,HYP _?.T_DQ=-G18;^N3OWZ]-MY+,'EW:#X)XZC&V3R
M2+@2$;QOPW/D_E@@_WKFUJU/KU_:/G;ZKZ'/7MS0_W]$C$76+DHH4445_WVU
MH$)A,?B@0C)QI$I! E61$% B#44<& 99F)!1!84HD4!^5510<C8!,-2%+XET
M448 E(B'3P;)A&%7+"XTXXE<'273A04A]N**,1Y$D485.D>C15-Q="&0$'JE
MH)15^JC5DT4FR6.33A%U4)112DDCD3V]2%%6%(G($45_*5FFF06A*9%,Q 6)
M9$'AI?12DB!:=M!0'SD)4Y9>0O64E6 YF&B5'R*489&$_JEDD :-."*C>$89
MV(48;;EDCS<FQ)Y0A3+(7J4Z)>EI0GC*"&J789K*J$2+&D0$61,TI-9<=O_Q
MU59=I0';D(2(B0*7*I)!UEY)#= X&;")=03M::FMA01QDJ$%@"7'$E$9H>BA
M%=YDJ7V7QS(-\59?=OA=M]]]B\'KF7"MO4719.JIA]$I;PG4K4_$[B5= ^PM
MU^QL]^F7'W;N5F=)1;$M:]ZKL\!%45S"L?=634JI1N,L#@D4,KL.,VPRRO/1
MNS++IODWX 2?&(B@0TC0BI2M-R,ET$MY=)I85@!4]C."XI6*6-"<GF1D1):(
M!/*:1P%@M%YL'@0I'D_7F*=S/5,2=4^")N0T % #$)Z;8!CM9<]=0HJE<P=E
M7?;64Q-%2MPZ-YBSWA&1Y&9@'[T]M]FO=@25W33_Y0WA4)D=+2B?0D(U2TIH
M'\V>BI%"SO1#+ T:Y,@% 973R!V)O?1!N-7M.5ZB=U5XWXO%ON!0@A7T$M&!
M'FV[TJY:*9/438TXN-99&=4S05P'[Q&$6"$$O$%OPRTUX74G?O;BLS.DT .Y
MFC47KVRQ11=CNY+?5IUP@7M9>!8%SB9A?3R&EJ_#DC\_8WH*1 E:3,E_F_PJ
M4PFZJ*XC;L$7$F3B!/K0[V3[:1=_7B,OU#QF,=!3%[H:$"(BA&<7<!&%!T-'
MA..!9C$;/-=HW(6RE#DP-8')S%L"UQ"(3>8[E;@/8<PSPAO^K5X";$#@5,:N
MA;&PB I#C7\ A$/3P,P,_S-+$ !LIKWM31$B).D#4'P&@"PB9DMN,DBRF+=%
M:?4I,U;Y"I,*@K<OMJ1V'9$:[N36(ZXD)B4]%-*7'I+&,3*O9R+AS%"(%$>X
M34J.L4I,%0ORED1")(L?\:.74D6W)KF1(S]"9)4J^23=&0HPUN.*FS2I14XB
M"BEBVF,6Z988(IWQ=I9,B)@ 4$#.Q8YOC'P4&2LDM8($SG6)29(9$?>[CIAD
M4!TQR"!OTB/,'6Y-;,SC5^X()F*Z,E42*J8RNV3,KMQ2D0W*E0RNU:M>0:<M
M]2'?;LR3P))\RS(34P)[=D&C4PA+8N>KUC@/DP=5/&L]$7,9;@;X%AHEYC)$
M2/^,$NA'OWK"98(JK!=_5FBNB*:G([2 2['RT)C*M"(U= N9!J6%'A]])F)$
MG)<16QA#:;D3- VH$Q%V0[*&0FP@L@FI*)!8M7^6[*0J]:D*6>.?>$7T9;DR
MPRY:X81O4.F6MDSDC;)X(9),;I.T'$HQJ;HF+2X-,9)LVM;PMKP"=64K9=OE
M1PW"GI\\R7)XU*9"(!:TG39%/(&\"5KYF)#0;;4C<*KE4V])5Z*((J]F$]56
MS A-!@WE*%@AI55(@DWE'<VQ-8*L,"-RRJVEDJ 70@F6@J:JYYF*H,><8E.[
M.9(SUJ1H?7K<FJJJQ6S-RDJII*-?=;G7K=6$K5H,S_+_X(H4V%WM=7G5ZT'X
MVM>FJ)9O,)/!KL3'*_()ZY[EG(MZ=%,2&07GG40@#L]DHT]I$<1\^"L-FN*7
MELHL$#5/<8MXWE+"=':DO(YQC&I.IL2)#M&C]C+-?38VPL1\HB%^D0YA>#)@
MGQ2,G3V4;T6 2L24XB<PG2F.8G-#DO&HYESI\LR##X:8&^)'PC\]L0K[8R\
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MV "<@PCS#JDF9E""\YZ%Y[)8.]$C,8&0PH:-CV_GG]V0!WM7.\(W>%![3Q\
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MRHX@..E%SUXX]9RHSCOC1>]. #:\-+WUW%KQ0?\NHK0^7'LJ;*N8E!J*P,0
M1%@L#AL8ZJ=9& P* #SRL _@4@45J#^9P,IX)_ML'=&F&!=4B1:Q&J:YH@9Z
M!5988^W2V>>_A V:8AR!/$C9HQ(@XMPD)ZM,2.&HM792E93 ;+^.1<-:M0 U
MP^HG<L,%U[;_J7?Z!+4-L]2:-*QH ILVH&R+VNW@VHH+,YH!(%LFLT$6\>Z8
M9JDI#[OGAMK<Y,YT2'&-\@RO3ND^6K,N?.^LG/'+._HNW7P=YY.\@H84*RB)
M9AF)0H,D1G09AA1FM&6YB&"0$I(HM93(0E>GL(_V" VV@8X-$G6@D/ @D3W$
M-%3)](/0JA76WAFF>:"6?9Q+:)YGO%Y[HG7\^=A?3RKI:(/.?;9IN75#WTNO
M9:KD,IMPJH)JT>2'>^L\=MELEP/S*!Q;@7:CMYCD[S1HPU+]JE::_>6A"OYK
MC>AJ(S8'_D9BF1%+ P6HDOR5A8 K4DG@8C5!X% +.8]9SN;0A)X]_TEN/)OC
ME^7L%,,\:2=?;[H7FR)WIX(\I14%(9A:L&*4 =T'842<S\(,9!]4B<)F\E'9
MQ!*3E(MHS&Q8>1';@/>QD DD8$$TT"P,HA/ZY.%#N)J9B(R'L+R)I%$\F16+
MBA;'[7DO,'.T8\^"14<YXK%Z1EM68LYEAEVTHB>RD59PU*>E^KGO?0&"WW"X
MEAFL9(9!@1/AER1(&Y!9LC7$ ]L"VW;)TT"0-ID4Y6TJ^#<&:I&3FBD+([7X
M0<'!\I2WH=:Y$C<O72XN3_J2$^=TF;E^P5!SC[-<XS@7G7K%Z3L'>E3)4F>@
MW$DS0CBA$,H8M),,#3&/%3-;2>#3 +U%A?]!M C>37(BH30.[R>JLI5,1M(R
M@0CP4=)CF/7TV#WL?6^?>JQC/GE4K#^*CPAI6)H2P- *&1CED(CD5EM&DAG\
M-3)^\YMD3"*JBOE=9E'XR0S9,*-!_:E$,QBZ3#;[AQGV)5!T,8F*1"&&&0QM
MQ6R7>5@H%153;YD2-B;E#,A.L4!#P?0FGKP,6GCRT9@03BIFR0RG!J=2J@'N
MI!N-9<@X@Q4,&HI3[O-:58&R5)D:*B8VQ6A($W49GWJ-<$#5R4C0$DJVCG46
M- 6 4$LU&Y[6<C:I/*I*MMK*S,2*I #PBBA 9K80\M66AWL,"B&[+_&HD$Z3
M;=,RWZ7">D6NF"S_Q*&_)N*0AYU'( 03(E&\F3"$(=&P9AD(6I81DO-4,#!2
M#!)61%:6P,6.:D8!*A?9&,37R@2,JE6)K*AGE*TH:'IPM*<^MW='O/Q(NCNJ
MKHS^61<A#91\SH+67AN[K<1ZYF4 0.!=J>*^\P*@G8V$YV4B*=647@8,(D6J
MW_ ZO_L>]Z\[860&J_8PP*I5F]ZR4FXVV9FR[ V^/XFH@(>ZQO9=)K_V$V #
M*XS5]?[DI9E9X%;3\M[ZI87 +A7<3JHVH,O4KX$"CBA4,;H3L[Y7PBAF7T1A
M U[&ML:OK5UE@CD3*YL$V#\)7NR.2^G8">1R74VF++XT%Y'K5+:SH?6E_[Q\
M"5G-=4Z&)>%L7?BYF+F01&#;3=9@P+R8.))9S9"J$1Y])Q><Y3'-S.*>0'"&
MSSY2EVC]Y/-TK[M'00O-+V@F$D$-@B2$.F&A &CH"+DE4@6C\[P+?.E3 *!1
MN.FD@1<4RV4FR=Z):B;#>64* =N"$Q4+;G8IN@RGJG:BRQ L?WWKM"SWL\;
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MJ4+C\<O>["Z4!0_3$+O*T#1)+GP$LB'!CR#]\3/OK"!;-"'O:.8"<KNFS[L
M<5K"A6PZZ)$X<CC[)_[<:PD!CO)$S15GT CA!J4R0^MFIZD82*?0"ND*$,A0
MJI6F!DFOA2=5(X.PJO\%6[ ]C0HY&RA 9:),75 2 0Z6/DP!VW)(:0E(\7(
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>abvx-20251231_g7.gif
<TEXT>
begin 644 abvx-20251231_g7.gif
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MPM'1T=[>WL72XMW=W8J8I[.SLYVKOMG>YO+T]N;J[L'*UF=]FLK2W.#DZK;
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MJ;N[NP
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M(7Y8 [[X>EA^?:.5]%K#-0& 69#Q(2'%O=IO;ZFRV1(DL)D4B&(;!EB!>18
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M$U9URDIRIG:O@R6R_+(&@H!Y;?BQ9"AQL?A> 7JX=+9_U75[X_).:T>,'W
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MX07O4951<9!]GEP0$UBEX77S@UP8#]!;5/2IISZV'I7L@KP*A[5.&C[E_0T
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M:4A%BL!>)72=7K0-%(\U4I:VU()//"F+9$8S](EOHQQU:4YUNE.>]O2:65E
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M5>U4V,WN^,K9RI5G#V]GL#0^4?Q,?ZQA)I!@TWQ.2-CGF[WN!W_HDV7.%8#
M/?.KG:L[[XYRGA2U)X\N0T"V4?AE(VNV:%X(85ZV9A3UAPMU+@/U#F0&)Y]F
M7:[RC]/C6I<^B0V6-$2QV7##7R\P9J4W/?UJ8)^Q>+,LK,6[C%:S^@:O0F"V
M.09!)=NVDI:ZC0-FQDLR/M2X[O)T\1);7.<_*A=W$"ZM&V2MU!HA8V=W_^I*
M1Y^U]VWP=H^QM;ST<9Q#[RX"6L<1?B^X\#)LL"/L O3W<A^W6S=XV/_C;Q0A
M)'8:'WJ'^/H"5#EMX5G34S:/>!>S263O:]D--/#NM&]W+G.X8* 3>?#:](0G
M.7)7><K+[X7HU,:JI[_$C8RW^?<Z<"5CA'J3]YN'L2M.+A*"5" %>8TNTI,W
MMY://H17^CP.7FZVJXU_-9^G^H;&A!FWM8NO^A8;X*6\<:V%KH*/KH$O2J3W
MKI1O>G5C^;0?N\T+JJ1T+-.N^:VG^[I?P^VVK +6XCI$>Y#K]*.?=;;//*87
M?+#C2X8'S)BR^\5G? >$F3@4QGP'M =X^?+\>R$U^^[J^\('M[7G?)7;/%SB
M*EYO_-(W_=%S&;(J8 LD^ASW8L"W[\_/X\J-EWVR2Q\LAPW4XC?(.OW>]WV;
M4WVFDID%TRRP?RZQARY4@'U0V_S:+S7/=WZ1HWT .$#A=; !;J(1T_[MA["9
M]WX5"_[4/['QO[X+^_Y,C-=@S'[N9W_=VC%D[S%-1WZ:F'_GRGQ(O/]ZK?_H
M]S+"!P@  @<2+&CP(,*$"A<R;.CP(<2($B=2K&CQ(L(._PJ!3>@(K,.'#@]
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MR##+_#+-(@]:\\TVOS7NIW'$D*YC0 ?H+K[[$4T@O$4KO71%KS+]--01C:J
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M-9Q-36,?6ZF\7-I3E/=+(![KF<L'PG2>3-3J+WL908WJ4UTD_)2,3SM(U(@
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M#H0OF.W-EFT?DNP>=U'C_K*L5)T?C->\_FR]&C,Q+[(31S2 ZN:_YBK\8=G
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M2Y&17@%@ZC.2]P%*S[B57^E['?%A.TD\UF&)1;A!1K-Y$S6 2_B.38AU\EB
MDA%OX#0ZS76/JJ@KH<AS+\ET>;D77EB6_V>4MWB4A[F0B8)D#LE[M*:&4!F5
M'_B&56D@>U?9%<GX9&"Y%1\Y%B&IF9\YAQSA!X6F<Y.(?HFV(J(0.2VAFJ1
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MS%YO\>2.K"8UUJ%0 F5J%F51ZN%KNB:#/FAMVN:'#!S!Z69>3.6WL*5B;"@
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MU4_)DRG?7/48\^"KF3EW?FS(<VC1HTD/KGP:M<[+I3,/9/U:-&BRA+9RZ@7
M$"'=N@%P,J>5D^"MO63W*M0U>-=OQP&0_Z(]6#9LT:-TW^;::[=UK[I!?]L-
MEM-SZ:3'?OWP%"HPB0,K#F5)\R5)BA<EUJ<81RA]I/OC&UWZWCU2UHO)O:.,
M:DJI^39:L*.(&&POJ:(B!%!" )6ZD,#^_FOJOY)2^Q!$FS)TB<01+SR10!3Y
M\P^]";29JJH8)AH/L_)H?.RNM]Z**ZZV](KKKQP# ZPO(OWB*RW/&EN2R287
M\RRR$*7L:;4;R]K,RBQQTY+++C&+<LHP<:K22ZT$*I/+Z+Z*@Y#?>ADE+$-
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M5*LRE=C*/-W 7!K-+FQ>RWEUE5EK'1W7YK7YM77N>AO'O@2I 3%_:B0T-[T
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MT2.!C[&!%>@=%TA@+R@GY':'?M@89$00O%<<%D:'=7A4W61"TP5E@J02*$%
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M%V9!1VLG&3@IN1 4*"Q+"2>@^$Q$F!"[-V_STSZ@4#YGE)-*IX=J59C;M))
MV9F4P8W>(H $86A]DCI<"$(:@09K5Q(VLW\D=X7'10CXJ)J$L L:02@=$)O_
MV 'W<B!SIP;3QQ*E%E[KM&.A@XJ&=Y!3F)"3AY2FN80.F4XK=WDL-Y'$)F4P
M=)@#N)&@QX8?^31<]HNH)U@=.!DZ.1E"B6U%<Y?$_R*"SD00[/9W.M5N\S)O
M*WA<Q\%GV7B9V[B'>"*:GAF@V9&>X4:4!I%OK^F69:$2<S<*\X.#]M(+?C*)
M 3F+##(^P8<1A$(1&#HOWP 2QU65\C:<E=AX!V1X9$DQ K**LH"6596@\1>+
M]F>ATPES%'F+_I>+V.E)>&5S[ (MPB,UP9AER/.7KE22B92,XVAEG)D<R_0-
M8D00OH=&YO-I!Z$OHP OS$ 0\D9&^C)OR'&>DD&@]=:-32J@:'H09-IZ!DH0
MJQ41E(90;Z44),$9A$ +&L$,A. )/@9Y<FII+TE:%D&-#-$!+SD*;#5W$Q-Q
MX_>5CE><-*-QA00JNJ5XS/]I:U=8HEDXHP]9H^ 4AN85IPF$7A:I7F78IG(B
M+<23-,!C43PWDE*#I$PTF&:CF0GQ7^$"I0.QF 2Q6>9C?%?Z2K$)IH\SG^@C
M?,4AIH^QIA'HDVGZK,@!FCZ*$!L6*Z=9<([($G)C??=!"%,@0+AFB6K9$9PF
M*WKQ 2"&(20J=_=BH4M6J1O'?ATF%"SJHBXSKNO$EEWHG-9IB]@7$[I899[7
MBT JI'Q)-<68L']V&\KJ&,PZA\NX-E'*4Q"64PL1GWD&IF'*GY_IGV[BC= :
MLF/JL7RH$*0YJM(95LWX //C"Q^ !O/3=AB"?O*8:[C",>[$:3K[KSH#717R
MLXC_1WB62H4*F98,N3#12:-M*9&UR'_7"1$7B1C'AJIQ8J0)V$HB":M!%)AK
M1JM:8ZL(H9W"\CAAXJO!I1#PXG=V@ZS)RK'H2;($ Z B.[<+\; H2;6%8Y37
ME[*W<V>T<#<[<I 5^I!)58I[VYQI6;AD24@JNC'U&J/["G<QYSJ<JJ 0J3 3
M*I<O]YR!L:-W99?3ZBU:JX#BR65&"I@,Z[:2(:UR<G350[92.H*4":P),:P1
M%C^^!X+#T;"-8;>$::9T&[RK"[<?6W9P*KDU.A8J9@YQL)2$\ F31J'QZ%NP
M.+E#<3E%:Z_(:4?)*84:=*F3EZF)"Q))ZZF7Z[3^BK(</Z%Y.'*JO,@N1CIZ
M6%NPY%F_5<.U0>:U,@.V77*FV<&K Q&?)%%-&&L0P05-Z&.ENZNZC\&ZW"*W
MPAO! ."[M?^*M]5ZE.<;%0\0!Y(6 Y] "J20$A+2,T9&N*^)CN1J%_8*HW*Q
MN%[5N.YWEI#+KS":KY4;N7/:M/WZE#)1EP  P3WBO\5!O\*H"T%JL*?;@/@K
M8/H;,/S+)D*<'  \$%$*+SY%$@H<P/RAL0,Q*+C+3)%)'+Q;M\2K+E$LP6.L
M$!3\M51[LHLXO?OFA"U<8BK'PC-,O?QV,]D;H]WGPG9$J8F'$2RZQPQ453$C
M>9UJN2P$JB@4JLC; 63(7GB[)O'+)-"FM?BUQ-;5Q.?RQ 6!JQ)KK%T\-UY$
M$J%@9_RAM@8Q"L Z*/ZR@F+,P Y;QD#2AVO3H1 387,SC8=2$/3_X5F6*9AM
MEIEXFV^%6[T>$P</,PH2^E6[Q<,V&WT.%&Q'&T??Y,=/V'YS\;B#^Z(T:,.(
MK,CIB'DX.D>/HHL4\;[AHI?D2;I$;+H*"W2I*\S61,M=<\;% ;L%$9LI:$99
M# "V:Q!>K,7'<;8+3,_]2<P:2$6XK&=FM,LLZ*V!^#:3B8>RW+OV3$.W:LPF
M_,T?T;QWTPN3Z,P^B,=\W,U_^LAW'%;8W+V5*LC@B\+>K*D74[[B["!,2\[I
M&Q^1G)&3+"96:\GSB\FQJLGZA8&U9V7L&:!A/,KN)JM#Q,G9XLG"!5/P8C_R
M,GX'$9GX.1!S!\S!W+5(K8SJ7)3'*ZK _U;-0_&2M%"LBZ)D),R$1:9HX1M>
MSUG#\0J%,+S-,HS2JT-_,:&O2 F6F5O8FF2C=PW)GDMS2TTP>3EMX/E#Q)C$
MKV'48S;62QI*^$RW:9P0:[R_P'M2\\.V[5.9!K&"6SE-_=P=G8T0#APG<DN:
MK877#&(OAO  13 OT6"M,ZN^C\='U?MV)3V7?;R]4?C2"$FTB"N^ADR^G,JW
M_*K#TJV6#"7)94TL09TDI">>&V6_4+U!4NTJ5#T08BO!2W31"_':7V++=":[
M")&[[L.E+*%B\?.EX-'::IK1M8R(AP;'"FHO;6<O4=6G7P5E<YVS+=1K)7Q>
MUHR*V3RO&\'-@\YWK[3-*C<\V)7GFM-]?N+JPT#\4#]:OT*-40A(V4H\SV)=
MSPHM+*YKWK&,T#NIW]\!LM43WPE!?>E#Q>]YK.:!WP;QV4Y,M6_*)X5LODQ5
M$A4!X#_6*.-EQS%A#N8P!5 NY5 >Y5->Y5).Y59>Y5M.Y5I^Y5C.Y5M^Y7^A
MX/9T>-'U5<A=73%]S#,]OA=ATS@\SDT.AHZ\.!V17IRWV>-VAI<,SY%-U$6-
MXOF+V3W)I"Z^L3#^MBNN5Q\>+NNC$/I,CV#]4U/0X^BM$.J]G?\)(8/4%==@
M&7!;/!$"/FGV9,Y<. 59ONJJ;N6L[NJMKNJQ_NJR/NNV?NLM@>#I1T\I2CHK
MVM<3_M<\VP&"?;F$79T;GJ-TN=A>PN>'>'.PZLY(',^H"QL^7A! WLD1F^B6
M;6W#S'2P[>S),;&/L4SER>.8ON@CV^@EFQ"R?<P53NK\\0EH8 [%2N]H4.]Q
M $_(CG:N_N^S#O!>#O $/_!9_N\%;PYU##.4:MQ>14>#O-P+B84U_=Q**W@Y
MW>_]/A3%)K6@W.[P&\]K>+#L3-3?C3WAW2KCS1"-S>WFF>F>+>/>P=YK8^Z4
M8>/Y0@A?_-2*GN*PD>U37<Q(=:_*#A7_VT=. ]Z(!MY.^K'J47[P 0_U4)_P
M3C_U5?_T5NYAC2QK'%=(\B208@7L*TWA'AU_Q6[DZ*O-@;>Y:X_,G0L14\;8
MH4LL)<]SK(2P)E[MYZWN#2SSM^3R!^WS,<[N8D+C/^K>Y=Z8!FQ\J6W0^\GW
MCK'IA6^\1#X[*D=_3K6:HUZ6)>;D%T'U!2_UYL ,6-_JI!_KI7_UJ)_E)1H5
M0#N6W'N<MA+QF#KQ-,U=%H_VXZOQU)G@[+OG&AGR20SH==_=XTE*)^\\*5\G
M*__Q@/_RD-\8DA_$CTXL]/'/\FFEA H B5(9.@\ @_)*3?WX@L_HX#ZPG3[T
M),)6AOP O@#"__ ?__$_.2.=0EK?(%)?]:IO]:"_^@!A;LH4@0()#C1HKL.'
MA0L9/FP(\4&'#A,K7L1H42-&CA,A,IPH2^1(DB5-GD294B5)ART_/(09\>-'
MEQ%EWGSIDJ$JGCU]_@0:5.A0HCYMYHR9M";2I1>9SCS:5"G4I%,9 IN0=8VS
M*=_B4.P X , LF7-GD6;5JW:L&O=OH6+MM=<NKU\U<5K]^Y=NKIZ^07\5W!@
MPH,'QTV[4O%BQB01HTU55/)DRCU7/<:,F&)FSIT]?P9MMO%HTB8]1ZZ<6K7/
MRZ$[,W0=6ZTH0IS0<B(TBBPI0KU]]T);2#> 7H1( 2A$2#;9TLU)G_]>'3UU
MZ^69VZ;]@#4K,*I2HUH]BA3DQ8GE6WILB/YI>/8/"QY\'_\@?(0$F<DW=W\^
M_OKRIXC':2J*+!JPP(P,W,BB\1A:R#D'2Z,I0IR6BK"J"27\0#H-5Y.JNZ<\
MQ'#!F]0[CST2U^M.NPFTX4J-KZZK#C,88\2L,!L-\\L77P++JT<???3L02%3
M@FY#(X.BCD:X-E.R22==&S+*DHH\LDJ>DGSRK(6R!&T40@RYC9!"RBK.-W/D
M(@0X ,SY$@!",*E.2CEE\<Q*.U7!DDLMW5(@JPF H= F]2P4$$6;*&*PH:@4
M#+##\-ZC;[_^)HU/OT@A38B^3!7R\+L#-SK]$$$#$<5HO#E/%4DG53^\T#OP
M ,SI3EEY:B_05UT-\;M<*VP4116WZNK%E_1DB]BWZ.+K1[S\JNM&9W'$,4A4
MA:QS5B/S-'8B8]4RIUMOOP4W7''')9=<::=UL%IK-<262]BVA9<L+\TJ4[DX
MT4VW,]36C:Y=8F<TJX,^MP/14UX+;<H\A05%5,1=+]R4TDLEY2_3B2V6#]95
M)1*U8_-"-2\FB_"5$D-=+SSX5@SYM=)1E0L^\>%.$3:T*A59G,+%& "&E^=X
MGWUV+A[G2C9998'LC&3GJ&1YNGC+8O)ILLJENFJKQSU7Z=&8;IHR?Y_<4FJQ
MG=2Z-*Z[ENQK+O]])DM%0%G=E>95TXN*5+J=:J]0J![ 5%**-45(OXHGG7B_
M6IG"&^11"0055 8W*OO!C>>&N]6"8=T);0T/O]S6PYVBR:/0$[85O%^Y\@HL
M !Z0FNUMCRYZV6:A!9KVO[*.7+&S-1]*;;!=US._;K\1GGCB[S.^>'..7[YY
MY)UOGOGDG[\/]]Q5VIUW))]^=VSO[[U>]\ZT]WKLL=3*SD_N4 :=<\H-ICMD
M QTV^."%!N?/;_^$K^]BB0W2&*L2QSB/@:5Q#2L5HL('(?AU#D6$<E5$R,>A
M![+O92>SW\QP5;^&G"YG+_(>\(A5NZ Q"W;(0B'14&B]!9I&7Q,LBN__G%01
M[WGK/E?#80Z_Q<(6.F9\,"2*#&D4MN\5$4H])-(+@2@4(3;)=0/[4P0S:+*<
M/( 4GF &0>+ ,8@4*"=XHXK><**__D4L?_@CW!D)XCZE)*B H4K@1DR%Q,5,
M+H SHV(85;5$RK#1<Y5;D,PLMT%"1<B#J=O,^>(E0CW9!2]&.YKM2"A)'M)1
M77S\21.'R,@G=>N&T*.>\NX32E*"TI32.U/2Z'B2["U1D\OIGA%EJ<I53DF)
MF&3-V-@F,/7MS8X8G INS.$)0BCD1&"\&WIB9KF/H'%_9?3?WPJ7L0L.T(!O
M=&-'2#6R6JJ$BGZLX!T;B,NBN.R/#AR1B=3I_TL-VLQ/VJC"!Z/6NB).,FB1
MQ"=>*HG$5@+QE=6AX=B$USP=%M1J^^QA/V'XS]@0<98/?4PW;<D9<F92EVYQ
M6P/S)L6'X,86R?D$&M!@CI&*U!Q?X>+\.'@Y,I+1C!(#7#0Q]CF.W4UQ-P5C
M34,B4938\8+M+-T>*RH4<#I0D#0[:E!9=4@0<E))3GU2/I5E3TE&BY8\5>@$
M&2J;>3[-D^":7O24ATJRCM6LJ$1H"R]9T:V&)I80A:M;>#J2K)*OK0U=2_H(
M)L::]>HCM/%-8 6+AF,JR&$J6XHS9;K89[X4@*\:78$.>%,"2JA!<S7)-XVZ
M44!^9ZA$#><YV;?,#/\.LF9Y[. [41>'G;%.;%!U$E5OE$)'JE"J=$GK NNJ
MO;N&IJOQLB%!#3I<<>4V?+OE76\]X]"X-A<MF*73+=EZT;5 <7WLY"QJ^298
M[O9&(7B3HZ)"^ZJ68@QP+YWFW_K&*=-^ZIJ4%16C2+13Z([$IZ(%*MPL]-F@
M%-6"A*3;>D3', $KU9!^ A8BP^+:11;QD0^V;6V%5E79WNZJ$ETK.97[&6V-
MC7G?&N4IA5=*YI%XQ"<FGG&OAUS-;9@S;W5NC $ W0SCTL6>421:>+F=]P70
MP#(A'DA)*E(BHV&+EE5FK\SY <7V39KK3:-+#R+.*MIMLE<>%?W0TX'ZDD1+
ML_\-)V(CQ%^@+'FS2,4@30&<,A5% @WRA.T0ZTGAJDHU=A'FBR]4G#L6H^W&
MG/DMO(+[8>(6.I6<H?$//_OGQS!7QLY--&?V-=W7_V*TEQI%IX<>0 M.,,,A
M+P'UXP+\Y?$^I+S05&/$& O--7:./-B$=6%)]8$NVQ=SE,/C2N]+YI_X]Z>C
M3G,[90;!G#!5=3G>5IR5).';HK#"0-MSY/K<-4;+2-G5^6JXROJ\;8N5VV<5
M:[3+-NVF53LN,'YT7".=F4EKF+K8R2B !NQC/0HP)W'H!2ELX>EO@K?'&6SR
MJ54-9?]!BLHVG2Q\M7G8B]1:)*3&KU_;^Q!>&Z748!8V,JN,79&I62DW:Q$(
MWSVV9T.KV9$4M];(S3)S:X;!4AOTB0T]W)0K;>7\:OE;'/VTDO><SC4G68TQ
MF?.X/%%]F);XL"MB",&.XO\_!)8B,\=H7BDW-LH#CVE!/C=?6,/7<:%RN"SN
M"\C27FZ_%:?5F2.>\;*OF=@+,;9#*OV]'T'R:#ZW$=#Q)70^$EWGUUY.ML55
M8A&'F/"'/W&(JW?A;O+=E=P#?'7FLHO)5[X7E)_P[#3?%]G9%O.8MS"B,7OS
M=?E=YVO9<10WKN2XN0JP36>&B)!YS/$>)>!4)WCNJ_X?Q&X9RPI/H*@=$G:(
MDSV[$U\(VM,^18RGD^T>3ZH[LX(SG44>K]_#NV!H>V>IZAU=I+>6Z5'_<J_>
M,'G$&^C,<^C]:8%_5N+7,;*EQBQF89[^G#?AT/2O?9/?G_+L1Q7WDQ7X*Y:U
MB+?_10&FJ(L)7^@-4>B%D?H$+QD%\8JC;3*S53DU]5JU#9RI3N$ZA<,R^6H)
MC B[L<LTU"JDEE ^5?"UM6N5>0,V+AH=_0J4N%LP>J*[NK [">,^.I,M #P5
M ;P3 M0QZW.-X1&73PJEL&)"Z&G"\VL>()P3(;03(BP+=(L7[;._S.,_+O3"
M+@3#VC*ARY-".7$\?S*?O'*;&:2I>FLC1" $5%"8;_"2;YB]NLDU#+D]5M,]
MK'.L@3@X$4FXWZNLCF$(XD,ZXW-#Y,L0Y;O 7SNM8#.MZ*L)#W*10$NV.<L^
M.]N^%6*\6J)"*['"@#'"T/@6]$,_F5._@_K$53K#A7J:_YW+PLP#O<O3/AXI
M#,/H/\/(,[_XOU:T).ERM[E3"^MJ" "0Q,ZJ-]Q @RYZ &'RH@H,)#9*B@S\
M0S^\NO_ICZU3%% !/D:Y0X8IP5L+Q+:#+*%"NQ94Q!B$OF3\L8^P0;' 0>]A
MMI-3H>P#C#*4DE?4*K'I,+$)L?1+/_-SPH+LMN0A*%0\M,Q8-\QH-QN#/ <S
MH2T$O3$<0R^\R"]TI#'<!7V,DE"LDE$,&-2SKD21.K,C'=H@A9B(@]Z(O6@L
M,(_[CCV4,@[<O4!,H%<#P62"NH= 1%([05P;)T>\.$C,E65"RG6:.)BXF7BZ
MQ%($#:@,#7P,0WO$+6#D)V&$R#'6D4K/ #$D)$C!4[]/RC:/'!*0/!*1E$5X
MN3];K+S\P[_.,[D)"XR]R!$U$;VYXD>[_QHYM(BW4&M#1GR<76C (?.%4,B-
M-K) 4:-!<K1&;<1&FS0<#V08 H(C;V04+6N(<4S!=92;QHR)%53'3%NS20PV
M8KL*!%NMS>A*ZW"PO.C!2*)*73!+:M'*H7NMUN0,)!1(LO3-PA.EX/PD0JO-
M!]E+WHI(NMM"6[1(SHO+MI2=C-2^NZ!-K$RHV^R[OC0+O?H3!LE#"Z*9Y.@N
MPI+$S%3 B*!)\XK,/HP4G+1,S"R@\$JIAG.XX@M*G!PSHF0^H]2XZ/-/70.Y
M8&DM[>0Y'Z2S3HPPE+-.M<+.QVL=\@.NX!*NYP'+L02742K.?)$T_E)+^7L:
MR^,_RH-+C<R\7/^D2\'@"Q/*T*5I4#0DQK0P1E!+QOM\B!@ A:;KA<641B]:
M1%AYS/-ZLB#]0_A0,T($/G\;C[OAS+'[(XY*NLQ)1[7SS!<DG0*STAZ-B'B$
MT']Y37SB/J.9S15MCN-,KMRL(8+Z36])Q:]:0H,TJ^#L%C$UFQ:%Q7C!0K:L
MO(K4O/W;O[R0SEL,/88</44;*I&\0I*\--9S4H01G6_8!5(@!7, S-(RS[Z*
MD/1$M6Q<+,#!SR3U1FURK^ KD8KX24RCT2;-SRC=S[7[3W.D1/%HLS=[RA#2
M1 .])R]%4#U;4-VBTWY\T#/-M@];4T(KM#4=*#E]#D*EM)[QT"S\/%K_Y+_F
ME,O9FJVZ0-:MZ56^?%&_/+JPT#5R=!GO=(@M2RD19,P>K4;<RU2KLTG<TRCX
M#-7?8\Q0.42',T$P6]1=(\KF@\3V<55W!,V;B,=F71L'B\UFHTY;I9UK;0RT
MO!8S'1L*35/>/$6Q.LB$!*NO8EC&<-@-$<D[W99G=4MI=<Y<_%/^ ]/#V-7C
MRE;DW-;M7$.P4,9OE1 2";!NI%*9O%0@52,AU50H,[C.Q-E!A#5/M;+-K,]$
M/-69_0C1+$I6/9FDY+@2R2^("-!9)="?4=C:L4I]6MD5:]DRY4I@#:[AK%AC
MU:$;HM!C_5H^"]L6BT6"?9VV?%:X'-$]G4L3\U6AC5T,,H7;ES6+&)51AINW
MSSQ* JLIV8-!<DQ7/ES7=LW&]4*Z+=O)KDLR^JRU>Q4S%-37*.57%T2S?]W/
M0HF[89G'L:D[VL(G?.1;\:$H#O5'W<P,-17(8<U8Q1-.C!5(@6S=E?!;/TM.
M>AS9/-V\+NS3'KG(O&M;:7M;X 5<LDB]]4E$\$35NI'/R,HOV^/9K,M4R-5
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MI#O3U2YWQ=A^/\N.4/J.[]VU;P(6/+2](1]_W2A?9?S]8EV\OU.'Y3"NY+D
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M?,_N2*CH2SNC7&3HSD*EA[9N+1HR^*7:3M,Q*8X=6NS@0\%56-NFKO8B/P-
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M.B4/>;8]>9<]TU=?8#1TI)57^S<D?R0-GP-W?U<QA#=\\U6 U=*!<[ $68-
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MP!Q^KP-\DPW@RK>X_ EQB/C##1&/B,3(32Z)3&RBXO;'FX\)*G85F]L,68-
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M?X,(/B?2<%F)$1,IEAT*EQ_Q %[YGOP)H8EQ)V.QJFCI&'1!+%ZIGP*1+*
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1VLK.C$&>;-F>;=KVNX   #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>abvx-20251231_g8.gif
<TEXT>
begin 644 abvx-20251231_g8.gif
M1TE&.#EAQ 4  G   "'Y! $  +$ +     #$!0 "A____V%-TO[^_]SI^,C=
M]+;2\*?([<?<]-GG]_S]_N7O^L+9\\#8\N3N^NSS^ZC)[?/W_+_7\M7E]M?F
M]L;<]+;1\$528@   "(I,%!@<9NYVUIK?RXX0I&MS8"9M0L-$&1WC1<;(8BC
MP3E$46V#FW>.J+RUXC\KK&E:OIR1U)*&T'UPQU-!M>CE]5Y-N7)DPDDVL,C"
MY];2[;&IW8A\S*:=V;70[\3:\_'V_+W6\KS5\?'W_.GQ^N'L^;[6\N#L^?O\
M_L/9\['.[Z[,[MK:VI"0D'=W=R8F)JBHJ,'!P4%!05Q<7+Z^OG]_?YB8F)V=
MG>;FYGY^?KBXN(6%A8" @(2$A#0T-&AH:$Y.3IN;F\/#PVEI:8F)B4='1^OK
MZ\W-S=W=W2,C(Z>GI[2TM*"@H+FYN<"X[8" @7]_@/[^_F%.T&%-T?W]_6%.
MT9:6EJRLK+>WM_#P\(&!@F%-S_S\_&%-T./CX^_O[ZNKJ["PL&IJ:EE967)R
M<HV-C9^?GV%A8<[.SH*"@^KJZH&!@V%.SH& @OO[^Z:FIF%.SWQ\?.SL[*VY
MRN#EZ[;!T,7.VN[P]-;<Y+[(U<W4W_?W]X*"@F).SX" @F).T.+BXK6UM>GI
MZ;&QL;^_O]G9V8:&AI65E7EY>;.SLY>*X;RT[,:_[W1CU]S8]?GX_>[K^J6:
MY;*HZ>CE^,_)\>+?]X=XW?/R_-70\P
M
M
M
M
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MZ7.FLYV]"O9BVCIL_9KY>X4]0S_#_'>%436+37:Z?^(/H7%WWV$MMK:S/>#
M:4:IS74.[]2J3@-#T-DQ71XNPQN-8<4N?'UY[E%+WC#RR8OGN(-J[N0J*/%@
MQ1)P:1?TQQN'XHCWP,4)'[8/0)[-! /YZ$RYR_<^((@"1WN(IBMMIEB7*=C-
M@*X_7"\X7H#1ADP8=UJ'N-N#BZE/_%?$'N!?ZBFN;Q;/8Z;!Y<7K%7CRRT0H
MP(9P,"S=T #$7.;H+T "ZK?+BJ#MU[Y/-_.2M9^U%9Y\4!TWR?G)UP.(!UH
MQ5ITY$#_&*!^1=1 (*8!F]5J_E88U!0U6$(Y(C _K7-ZY0-?'F=B"^A\W&<
MTH,!NI9"MX,WZ50NA(1WL@<PQ4$Y'#!#;A,Q5F=?@X8S0] !1<1!%&B!3K.
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M<Y;$(OJ!>$Z0U;D(HB]6N8IF5E@5'QA2LX8/++&('<'"_O(718;H@75M4]M
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MV5E_L!]S(B8JX4H?K,ND!"!#0"@W-AA(O@:[59,2FB1T(% QO6#L*8EKE)^
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M'2W5E%%9HQ\&C"%B$ C!J!<YV%0XJI=H!Z2FHC'XG7="4U?$,%9$CH() #X
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M<5H)E\>?(_R!9FH[D^'0Y$&5_QTQB3,AFEQ>5;_%S:J&T]L?$[^BA,!\SH0
MT%RC&O:7R!3%;E<4BVOB!K[O449\A:%0B[Y@!1*^Q#U4E$\9 >#$+U0)7>+S
M21F, !<GJ*LR^%'":>9F*"4TCWDW^^!,VE7'D^302Y-$V1:;ED!P ?&$GAM,
MZ+CX)/7Q189W1-7[2KG ('TLBB"[(0TC&0#TH:R2A&/,(9OR':1TH2J@&PSI
M4"FOUB#%<P_\(?/B]+K/D<=S=8'E29SHP=PP)X4)^01<['7"[+A)3ILQ2/*2
M%T.EO#*2-VP?+34FOJ&$*#';"TH"#5A",C9IB6TY)S#+0L]EX>$/%MC#%?*
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M^)4A@[@T+$_U8'TVS]3Q\IB[;:/JMAX\6JW>\,TWPO'I!CVZ+[[CT","\H4
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MJ1HJ?7IS"*J,"JJ+U^F@K2J;;G&G*4BH!_&"-*I 5AH6.\0V1&$<P2&B\(1
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M(#X@$^ 6;/O68)?S;#5W*/06Y4X58/EV;/]V=!_W+PL7%V\V9[FT1&$7.94
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L?. %/WC"%][PAT=\XA6_>,8WWO&/AWSD)3]YRE?>\I?'?.8UOWG.'SX@ #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>abvx-20251231_g9.gif
<TEXT>
begin 644 abvx-20251231_g9.gif
M1TE&.#EAY03S 7   "'Y! $  /\ +     #E!/,!A____U)KC&-*UJ64YM[>
M]TI*2D)"0@   ,7%Q6MC8U)*2I2<G-[6UG-S:UI:6IRMM>_F[Y24C.;>[\[.
MWH2$A*VMK>;O[[6MM7MS>X12M;T9M809M<[.SF-[E'N$I6-2UH2,A%J]I5J]
M<S$I&1 A&3I2&1GOI6,90AGO<Q!2&;W>C(S>C+W.&1G.0KV$&1F$0HS.&1G.
M$(R$&1F$$+W6SM[>YF,0:ZV]SEKOI3J,I5KO<SJ,<YREI1",I1",<[W.6EK.
M0KV$C+V$6EJ$0AD0YHS.6EK.$(R$6EJ$$!D0M912$)09$/?W[XS.WCK.WHR$
MWCJ$WF/.WA#.WF.$WA"$WKW>K8S>K;WO&1GO0KVE&1FE0HSO&1GO$(RE&1FE
M$(24K4):YF-":Q!:YD):M1!:M4H0YF-2$$H0M;7F[\52$.\0Q>_>$.\04L49
M$.\0C.^E$.\0&;52E+WO6EKO0KV$K;VE6EJE0L6MYADQYG-2E(SO6EKO$(RE
M6EJE$!DQM912,909,912<Y09<[49E',9E)124I094JU2YG-2YJT9YG,9YJU2
MM<[>YHSOWCKOWHREWCJEWF/OWA#OWF.EWA"EWF.,<^^<G$HQYADA0F-2,;VM
MC$HQM2F]I6,I$"F]<Q ($ B]I6,($ B]<\52<[V$SN]SQ>_><V.4I>]S4L52
M,>\QQ>_>,>\Q4L49,<49<^]2[^\QC.^E,>\Q&>]SC.^E<^]S&>\9[^^,[\52
M4N]2Q>_>4N]24L494N]2C.^E4N]2&5IC8\Y2YI12YLX9YI09YLY2M3I:C!!:
MC#I:8Q!:8SH0C.^<SN_FG! 0C#H08Q 08^^][[V$[SH(&>^]G*VMQ3HQC.^]
MSN_FO1 QC#HQ8Q Q8XRMA"%:0JVM[^__.N__O6M22F-[K92$K>_FUE(QE$(9
M0H2MM91[A&-:M7-C>V-:[P ((5IS<Z5[[\[.[\ZMQ=[O[TI:0I2<K5)C2M[O
MUN;__Z64]U)KE$I"0L[%Q0 ( '-S>][>_TI*0D)"2@    CV  $('$BPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRI<N7
M,&/*G$FSILV;.'/JW,FSI\^?0(,*'4JTJ-&C2),J7<JTJ=.G4*-*G4JUJM6K
M6+-JW<JUJ]>O8,.*'3LT@-FS:-.J7<NVK=NW<./*G4NWKMV[>//JW<NWK]^_
M@ ,+'DRXL.'#B!,K7LRXL>/'D"-+GDRY\MV$EC-KWLRYL^?/H$.+'DVZM.G3
MJ%.K7LT9,^O7L&/+GDV[MNW;N'/KWLV[]UG7OH,+'TZ\N/'CR),K7\Y<,O#F
MT*-+GTZ]NO7KV+,O_W^NO;OW[^##BQ]/OGQR[N;3JU_/OKW[]_#7HX]/O[[]
M^_CSZ]_?>#[__P &*." !!98G7\&)JC@@@PVZ."#C"$(X8045FCAA1CJ)^%T
M'M0 P4 0U.!!6@\,](!9)0IT(ETI K B8 ,QTE:+!T% 0P>,?0@ !((Q,M!C
M$Q#$(V\Z"B3C6C'^9J1;"86(XUTTT("6CD,2%N5H+;Z(%@TFIE5D#5[^^)>/
M MG500WU#%3#%V]EZ1>5A77 B)9)+J80!(R,2*1 54H6) !/UDFC0H-N6"0
M1QKF9F!UQM7!DMUM&!V9!TEY%C4#46,6I@)I2A>G '@*HT 3M 5JDT\F!LMG
M8'\"\-BA .B9VZ-"LC50J6;=RN1";,YUSP,?XFK6JH(!"X"PH($J*EH>-!H
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MGT6IAF7R'F=+'HU,-I"C40>SR)%  ]ER#WF\K$52Q."):'2I@4B1A(5$&\_
M5MJD.12?#9%;!ZAUWRH/Z50\.]F.3N3F[P)UK3'C5GZ)6>7GPH,#Z"I:CTF%
M(VGJK[9SSJ!;F%Q<X<;V;XIVD3%:-*1[\0R)2M8@XHQ1M"&=# (GRJ^HV;+
M !B#4O]+V)^CFJB$EKG45#Y8QLK9T0[0NERGDI*NFVABKDF6TFRA%O%HZMMQ
MT7F*#'V6G-NBYISI2$IQW7*SG\VO5DGI'LLS"P<& N9CNZ6ML)Q1UC1\_SUX
MEZO6_BV2Z8S9.5PI<43Y]&(3HVHI5N?:BHFB: ?4:\J%*N1=@^:3?Z%Z[K-\
M(412$^IK)^X[A2^ZD!#G-\G_C;B?"=RQX:;XBOHHJS\Q+40TV"S,LUI>Y^XU
M+KT. + MWF^TX8I@POKA([IT"I;:SBR7G%(-<MXS1B0O:2.L@>"./!TT'Z=(
M<C&FF%_6*N))%\,/N =,/WLU1-53+9]5=E #T&B%$ ]NLH+;V+E&*1JP74<2
MV+3IR@T!,YN<!A+FKZL*.>0Z:W? 9E\S6JG--=#RW=3FS!G<OD<I/14)7;VE
M5-K-LCG)GP6A9JF["LD[;(;X->Y^?KRL<[:WY_^N"\,-"US/N$4EP].%U)!7
M:4A;A"PK/J(MV"J]U0@&)KCAB&!]@KY9%(L6:AVI55;<HUH*!=NT+%T@\M"?
M@$^VX&BEZK^PEZUX9]\G1L!C KUJ4?@?"G4+9[Y*XV_]0H2%=^L*)'EDXWM5
M=G-BHEE3@B_YQR]!='Y0-64UP'8!8'V9EV\PIS5NP3X+U7U1A56=PX$<-!!/
MXE(+527DAWPJPP,O$T!G02V6TBH62'_@I7/;%5Y=USK7845RX2:-<WS=)BN:
M=C5U=R*M4E=JX0'-4R0O0EYJD4[#@SW2E6,91G P)RO<1E.T-"?[,TU4EQ;F
M(S]HP0[4-V ^:'KU%U+_V41OTY4TK4*% A%XT=5 (OAH,K5I0U)[!VB&:T$L
MCE0VPB9[H8,03"!A1CAN"H86Y68Z>FA9548\<N<Y5<,$6,@B-%!R4WAZ/\)N
M)G5: , #^@9^]J6);[A6B?@CT((LTM=M N86$]5X;%$!L><N!3=]!G86];96
M<-8Y5H<,7.=XC@.#O66)ZP5>L5A@!]%&IV![> @M)W*%DQ,R7OB+^&-AK+A^
M$3B+*YA(RH<L#+ N.(@6T@1RB3=A?!A4L4:,/G>'?:*'P@B#-]4\W65RHK4N
MK_0DWYA"$E8N4V8_\,<6&.5+-F@=8!<7K 0 C\ .Q@ JG#A@[V2&WO*#;7$F
M_QHE*G^&=@%P"N5V0'>8$(A'D3M'A\+GAI)U$'GR8#7R/>:#7&=A#*3FD I)
MC$P#*@:3-"S96^467G4"C32ECBC94DIH@.RH?P?A/=@C)_E($$E(-X ';ALF
MA8!&>9Z3:C$B@YLR5=OS0RUIE56F?5 X ;P$/F6F@E&5$%] 77Q#7_O%+&J2
M/$5#2&DH6QE#7!U33J R?U-D/-GH%A@F15-D*6?T,F])*II47N]&*86'%D]5
M*?< E1[D0I;7BR:7=DJ8E84(@QT#)V0Y@6JA4?"@E8_620XU$&Y(C![H<3UI
M?\36.=P2/#8H?SO&)LR7D02QF:@I<D)B=6EQB-GA=?_&X9->XCTCTF9=XDQ6
M^4.WB)59""(3 #=ZZ5"2\UD$!8O;M5N-(RHLR6V_&$X4<T(, XR+-V]X>'\=
M&9Y+Z'IL]WV.:97EU(]U.7M+M"K<)I[KPQ"+PWISQW!OH6@0D)P#(0^[9YC?
MQ1":8EIFP9'VB44!)H"4\D'4P&TL:3Y6"9P+EYET%%J;1BF> J#4M7@8](YM
M@8%F80RGJ!80&D55-XR5B8WT9*)^R#A!J*+A=FHKHH0Q$H[K1SB^DRH7B1"X
M<@HGQB8CJI?(E#'.)*/\$I>)E*&SMWAH@423A7F,@PSJ&9E(IF*C688*,9]T
M4R[2) $W@%P'R5*OJ2/?PZ0/!T$\"5-*!,$$3T(XZGEF__]8'5M5A+$F?WO7
MBU;ID'2Z0VVQ-_%G(FPGI6=1=Z)"(R5$97 '*GIIE<"GGF]SF&43/+#B*5UH
M;R7:DO")C NA)RC82HIWAZ9CAZ2)5WIHA:#3C7GH>L-8H.7%EIC:IVY)-^4$
MEFQQBR)'#7\*1_<PB9/E7"?3,#$3FG<J)GIZ%E?F61W:7E9J83'32TO*4FO1
M*H4W;'IHG+Q(ET3J,VQ#:(])BW!IC6L!*@5YJSX#?&91K";UEQ4WC/=P+PWC
MH6_1J,U5J]Y89O<0AL0JC5GZ>&P#)\KW@IC)%D=8$'55B_ 0F)/95TG6AG"1
M7:EXK>6W(_KCG4I*J\@&.Z87L/\"=;#@PT)<0[ &RSHFY#H5U#)6I"G3>0_L
M8)XKTJ J8Y[4H';. @%^-"+V*J#4^*U>XS?T:)I0Q)_B"3F$ XUI\7&F1UMU
M8CZ].J]X%:S?:5<-(4FL&8UX^*N:^#T^^9XTU2HOHFAL@6\&@2Y]F*[LF&U<
M0[$9@YM"!SI+VB(\*)D:VU(!J19%0T"$UZEV^TK%ATUI02\O61"V%:)K(8$F
M*! X0BDTRD:8VA88)I'Y^J)H0T#_)7*6@HE'AX;<,P&YY:S$Q9L!,&6VA:ZL
M.D6+(TTKTG]S0;3#-XT!R;F>.[;E\KAMF3/VNA:F"DKQ=JH0FZH+5:7EV+4.
M ;:-*R/_<6BI-@LMY+H6X12C*WIJZ<@G--H<NFD<K5(/(:>:^.(F7PI^R3.<
M)^B7IB9D!N: ).F4H4N@;<=8.\8$.=0A^>FJYQDVO56+$*!)7^ ^?C>^TO(V
M'H(6QM!-\Z4R5C0!R0,W5<*R36MR^Z6M3?F^>'B*KL9EK$BNY0:2(#)GAZ(W
M/!L K^1EL@>4&FA69^$.R#-%UM(KJP(J\*!E'[2%+9*0;KN!&JS![L-YDF<,
M:[ACVV/ 2EHDJ^4WG)EJ1S1-_D=A&KS">F)TR8,IC!!RW;9CS,J=(&0]G9AA
M&JNE(,(F-#(D3:=QR,8O!_<S(]N8I=(KY>)P%:EG_9G&Y25,_Q/8:@.AOBC7
MOFPE1C3L029W+.LJ.R:':V?LI ZKB869Q6=(*@/,!-AVD?M# _# -"WB>W\R
MAVJ\4#38.:')%IW'D]:(KE(RO'$[EP3$35KB 9/(R/8&;>X#, #EGXB2FV]J
M'2=&J5(HH$P[L2_#A,>&-K8*-0VUO*1GLYJX4<GJMSC"E-6)+V2SK@3A*0\P
M9:72*NI#<4_BD%Y+@=Q[P*'(3VJA32^LJ(ZVB@3QFU":.<1RF-%B>@JL%JU[
ML(#Z4!"X%KB,B0!P!\+76N&<-MD%)B/Z(M]7#Z)RF.TT8U.F@3S5 =-FAK,\
MQ CAKQ.8B0OM50GQ+HI)7#_DG4R@<__*%S1MH;*1'&(ZMM &P7L/?6.+ES#D
MW+"-RZJ$TS&*]E$*,7$$,6,Z@BNV;'^OW">:O&D(83HAJ:-LVD!%(L"%I(Y*
MJZ1O^W,J=H[5:*A.:\=[Z:),\ 44!\PPJWZG4C9%8IO3AG_QTB*P([54/$5G
M&1W1>QPN5IC6-! \2*LZ'+OAVL64E5P)X0YCR[^@\@5Z18G7G)U9J3_HZ6B]
MY;4-\\H^:ZG%593P9))APY+5I[8B)R,V6\R&2E]F?34X:3^!^9Q\XJZ3M\IK
M8:'J7)_#IL%7JGB=XK')TP&&[;PB-WH!L*D ,-AS]0" [1:OK*353-0@A3;F
MT,[9G(K)"C#_]Y#:;@77/<1V/Z1\DRS:9>H6KB@0CQ"8-TW<()+*O\PG,4V+
MP@T!!'28GT5>M5@0\%!55_1GR@=;4*,_4]75RKV= SI8;UU )1W>NILP1P4!
M&(5O8!6WI"?<_05*E'JSNYNPU?*Q0[N+G@W@5NRWF$>QX-9+]8H0$'",3>W6
M$ .!)R.5T-O*UT$UXU-)M%AW%0"/X8F)OI:R7E._;\R8&@Q](F*N@<++(LXX
M+PTXOK-%I%=WL!TV=<M^!:3(%*5"O5-!Y&.WM.@^\*3B34SD: &3Q"@MB*KD
M0LN^F?T_Y=33N4MZ$V!]ZH55VKP6KU1B'0SC1=U2+&Z$EBMTN3,B_\=,BRSD
M1VBQN&SGRV+$Q;3E-RD$%UG.)SQSW4D.GS2T(SSCK&NA.)B,5"+:YG_$X6JB
M)59INFN!2XO^%H(J?GXHI#5P5Q_D 4\W7="W13'C1BPT=8RSC4CEAF>T2&Z>
M@;-)C&SI/#2.G$-Y T_E/;'%SY:C=0KC.W_TQ[1XZ8NIZ8Y62$9.1UJBWZ\^
M$/S@X6TAIJNN1LF=TJJ-P0+A>U]>Q1=##?VC7H>&391B>,V3C\DNWL*BZ'Q2
M X,M5)!\'6,-'KS=%N'8[F9!X&\1F.W,=O!.& 3TO-$!@?>>%O*>%_KNJ7LA
M[_4N%_].%P>O&?V^%@DO'@LO%P]O'_ >A'(!SQ@-CQ@3D]P /Q@7/^\5+WQ(
MS1<21B:A*]8:CB$?3WJZ$?'#D?)W 2S8UL4E'Q<N[Q8U+Z*U<?,9LAY,:1DZ
M_Q>EE^Z@\?,J#_%%\\&%H2,8GN$AN_-.7QL1G<%//_7FX<O+03 ".!R%0O1X
MT2X:;_*634_U8K\:WGQ88W_VXL'@RQ&27Q\<]_*BC$$F1%B#88_V=H\E153N
MG'GW?"\= [GWQ4$F3 \!"ET8=_7$((NL?;_XC-_X:,_R+8\,T@'Y";+NCG_Y
MF)_YFC_TFY\;EM_YH!_ZHC_ZI$_WBE_ZJ)_ZJK_ZK-\;G]_ZL!_[LC_[M"\8
MKU_[N)_[NK_[LW_[O/_[P!_\PM_WM[X__,9__,B?_ I"%LS?_,[__- ?_=(_
M_=1?_=9__=B?_=J__=S?_=[__> ?_N(__N1?_N9__NB?_NJ__NS?_N[__O ?
M__(___1?__9___B?__J___S?_P !0.! @@4-'D284.%"A@T=/H084>)$BA4M
M7L284>-&CAT]?@094N1(DB5-GD294N5*EBU=OH094^9,FC5MWL294^=.GCU]
M_@0:5.A0HD6-'D6:5.E2IDV=/H4:5>I4JF-5K5[%FE7K5JY=O7X%&U;L6+)E
MS9Y%FU;M6K9MW;Z%&U?N7+IU[=[%FU?O7KY]_?X%'%CP8,*%#1]&G%CQ8L:-
M'3^&'%GR9,J5+5_&G%GS9LZ=/7\&'5KT:-*E39]&G5KU:M8_K5V_AAU;]FS:
MM6W?QIU;]V[>O7W_!AY<^'#BQ8T?1YY<^7+FS9T_AQY=^G3JU:U?QYY=^W;N
MW;U_!Q]>_'CR_^7-GT>?7OUZ]NW=OX<?7_Y\^O7M-Z5@P,""B_H-=*R!@@L$
MNL"_D?Q#4+\$*(! J03T&_ ^"2>D,*@%'# @@O[TX^B"!VD0B -_XOE/) ,*
M,&!$ S!4,0%ZDL* 1! KI+%&&V-:0#_^+%JQ1(T,()$# N/Q1X$#,<10@1-9
M](>"I!(H,I\;IZ2R2I%R5&#'BE#T,:,"BHSP)"Z%'"A !PIP ,81P[2R33??
M?&@!)7D0*+_]+L! P0H*NO!$!HE,$X "#4B (/_"Y,!.0JD1*,<>,>3@ A+]
M(:B&"(!14$N!_(,@ @P-8#"A'LD<2%)_*!V(AP<- &9/@O D<44,:M@8R,X%
M*E@5 T:8("C13S%PE4 %:XAQ14T%Q=0 ##A@)QX%2$U4OP(HV%78_>PL% !5
M_4M@ 5KA!#=<]G@P(,M&,4R 1"))#-;.>%!,0,D2.5 @'G8,U6]&>DET0,4]
M%RB22" OX*#',C%5DDL7!P*24/_ZG4?4-2NE0$D,:M5/164'J@#(4T\$DLP^
M5VU8@6^9H.93+N.Y6" $($[2'_V<%*CC=5>,UY\(.4!2Q6=#Y+=?E@'(KX O
M8\V6+0,M&C1IC? <R%&G/1K4 #KQ-8#-CQQ-4#]@EUK_6ERX:O O'@D,PK9.
M!1%2-,$$@G4HP# /[6B!8Q6J^N[6(E!R1RR;!  "#/PIH.6.'7! 2@Z,QI#
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MSAIFU/^,M:D5A8D=O=.;$6M)."(IJ0*"E!5!'E2 !F%(A!4HI.P<H*D&# P
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M X#Y(10R ;\5T:=8S(\Z/)Y/X0_W$35Z(XA,*L6@4Z'E\:"]^J)Z&1!)431
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M>2D7(:+++JFKF?2>>6"_!$L8[9D :6HT@BA,OE.2>?C#LR@7-MRQ@>@G<Z'
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M^O2)'\LB/HL'GB*FGY23V)0E&IL]CSF'"J@ SIK*7:HE$#&Y6L*0%G,S:4%
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MA ANX<P0LF$0]-7N]%9OIFBA9?-NU70M\D9LT82M MFK!'C(]=;O_1Z*/$D
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M=HLW\XZ']Y[?^3S7=[0G\Z,7@)!W[>AVE,@& 'AH[\<N$.%!'!M6"ZW?>LD
M_)<=?*#(^6Z']J/_]7:_^6D_?%X?\UQ7_,;_^<C?=7^_B7H@6''B/0. OH-@
M)>53>9*;[[\/_-#0!V6?>:E0^\L/=,9'^UF_];>'=DZW^+&_^=S7_8['"29
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M##^[&EP [Q>6_"FP@0Z$2@18D@#=K2=X7E'2"'Y'DODIZ",0<-"UA&>9\T$
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M#EYB9L'2/@69E2,W( P O(A%(RTH5@W@J@@OH-9#08!5JP1 6"O\6! E;[%
M!*X;AVE'Z,76;L%I'G6CHCR9"8Y8,[S;NX)ZS)<&2%C\.:*C'JSD[M6 7Q!
M +\ND \HF]$I5PU+#9H8@<N&%  G0=)D9<*A$6]DBY<D3X+*AY(M7>##FP5)
M^LP'G03X(R<@+B.8&AS8ON3SEL'T\WV,NA !)UC_6,&*;W^M4F"%TO:V?TV8
M 6]KT#<J-)_VS#%\]+SD3<N*H@FH3'5";8!T5K/*B^ML"3"L706=&+0&X"YT
M1@V P4!&E6'2]"\IC3%+S1!4GB+JRP)WM=SN#39>^;5]B9TG=7UN:CO.6SV-
MK+6J+7B9G+[VXLRV  ZDX[D88,=SU6M5K+(..QF]P 0!X+OS->:*'CF?8Q @
M'94J5T3%XG'6\$0X_-+E@ >.TXW?A!!,/Z70#J-CO_<MV^<AL([_8W0^><A@
M;%-\R2,PM>(2E-&.:- CF_0(3G!R$NE:6T2_Y=EMV[2U8?_6N,)$ZH[ERQL!
M(+DJ]9"GGFC;HZ?9EK;!\=HQN286XQ;6N^)&3QP'$$#RIXR $=[K[+6JNI$)
M27TCV510 S[+@9HXH (Z^>RMG3;,?2N,L;%Q6*[>)+'Z:NZP']ACH),-(Z'"
M"-D'3Q>[4F?0O13]Z'Y?6@5 BA)_\*[4WDOS@J0^215SA*,*RJ0J*6J >'!S
MXB&*%*+OYO--X9:6Q 76UH2C<IUZ9; $UIEOD$JIF&D^]$:=>;)6_/?9_XQD
M $C /!)0@%9+!1,\4: 7,02/DT2Q)^2[Y/PFXP"++O]+N,[*B^'9[V#QF7^3
M0O8\]7HKW!)DC_Q]9\0['WZ EPY QCK_X!)6;232OOW_(<M'MAK$68Q:Y>(.
MS!)T%K]TCKM[(Q]FC+NA5]]UB%K8T^BA'2VY7="!WE'Y&6Q@'Y%E3 \YF_3Q
M')#AQ<RY$+[5%)T$V<(0G'L\G_N-H(E@!Y,\QKS5WP1X3P1$%P"DV4P,W[64
ME._,V76]Q$8X!I)HE6D-('Q$WZ00%=G9DOK%4P 9VL,5U?KY%\P%V  !D,-1
MF[Z1R^CP%]4HG ^2H!9V"SQ<R__=0#R<&69A7.*DS^.)$ @A1OMHQ(2A1(5A
M1]N$4)8XWXB$#I %%[79DXW4F'#IALX-W4&47L\A&L"]T&WLG)N$GFMAS7VI
MCNQM(21&BYN5#/R0H5)@@B7&_TT-<!0%C-F"<-=W* 9T9!E**,"6;80#S(/X
MY,-)^ .YC8@(7D6"O=Q [8BDV(Q0V=6?-10=[04(-L4N_="D(""@H8X&?I_X
M4<P'X-' /6(D/N.L0$ %5,!I],M5V!\T=D@L*MJ^-=M1]=3.N%S"Z5#FZ<>,
MU<=NZ1J\#%7/N)!,/:!?<4K:V5<A)D069B,^)H[O_:)//,$ ^"- _J- !B1!
M#J1!%B1"'J1")B1#_J.#;>-9C!_Y-=:0G1_G,!I!#9#Z\0<_+@5L+)N"(94N
MULG"09I>#%"NW&,^KB2A2", W$0#B)OA/<4 U*1-WB1.YJ1.[B1/]J1/\N1#
MBLB+I-(+I;"=VZ$<L/0*/.$2S:1=HIV%@/D&10@AM.&;345@SJ$>7:@D2W;E
MF31 -%% =5#(5&#B4S#!3Z:E6JXE6^)D1T821%)%$ *(@BF4ZT4-?O'51U9,
M]W6%P.%5#M$=?RF6YSQAT#': 07)#+UE?'BE8PK*_&A+/*3# MA>58Q /D!%
M33[!(_QC9W*F9X8F:()F:)8F:9YF9YIF:J+F9GZF:XIF9P:ER<TC3+W0(L;0
M;/747EG@;_527-1<502'/4WE81(8!MYBSXSC4CJ/L3GC8S[_)Y<P08)@P/PL
M /S06U08  UH9EOB9&IZ9W>&YTWZHVR&"+55&MX=YA3NE55.87KFT; P)E)(
MC=;<7</%4US8D];0$UO,25$)57PZ)W0.J(GDPX4T#K_(VF5FYE.09FL^J&IN
MID":)H2R9H3")H1FJ$V6)X@TY<*TT,JY7E%V'E&Z$5*E(]E))5")*&P=8#SN
M$@7V6VMQ)8'6*(CXP^195&547528)4WZXP \ I "Z806*9'6Y&KFY)$FJ4TR
MZ7C:I#]^9Y0"J7PN45S^T\&]$WS)V#PAF+M$'#$J5M=T!> (IFPH%L*A:55F
MY!$B(7\5!' ZDHW.:0DZ %5U50(L_\IE@EU30&E;IJ:3!JF@/NF2%JF$?N>3
M[B2'PL=0#I<'7DKKY9?+N9V-S:7":<INZ9P?SE5QW>;U<*JF1LT%9N53RBF=
MGJJ)[)]3:.=9YF1GOJJ@PNIWDH*A?J:?PFJ3UNJ@'NJN!BF0 NJBPL?#*.#W
M[5KZQ1'#+*.D$"(]S=!%E!X1YMM#()B 2>2?W=M$RM.OT"BJ=JNID"53Y.H_
MTNIFDNNX0BFBUJ2Y'JFY;B8UB*L_TBJBDJNM2BA !NM[#-<:31NS76JE# 0L
MC:B0X 908029&J4MV@U_(!C.Y=P=UDC-%*7F)425CL>5>BO&#@4T@9.#D-I4
M@.M2^*J2)OFJA-ZDD"(ID5+#K_YJ3;:#H:(LDD[HD:HL3N*K>S#E>CX<NOBG
M<@I1 >E08NU'Q0Z%,1U:H:U+GX'D26XD^:$.MV8LU'8&!Q1  L /\5T+U5J%
M 3"H4Q!INJKED>*DRY8LV0[ NPXIR8KKV$*I5RRDVS8DW+ZMW,8M0:K'Q4)%
MBS4M,34$4.72LWGHI&I.RV'J!&X?Z_EF;LU5>N*<(6+*COQ&4-&<@$8MY0K*
M"&PG3<HLS(KLYI[LYL:L3J;K$ZRM3P;JH'I%V(JGZJZN3MKMFB3MP]EAOKFI
M7^BGTDYD?_J<0\"=< G48-$N726A7EP/7 #FT+K&W5;_KO)N!L@F!5J"[DXZ
M*'BB:Y&*;J^";I0^:$!"+Y5V!>M^+_BR+<>(W>(.2<3RG*;JC: =A#?ZF5Z4
M'N',2/3!WA_^S=AEI?TZY?0\[?+VKUA<P ($< #S*%0T;U*4K.=ZKI]RKKKN
MY,FR;-DJ<-F"9_9N: _![,EF\)2*K 9S\ 9W< =S;@)_, DSL.O:6W%2FM[.
MF('I['ZYD^&^DT(<;U!<Y,(FXJXI',Y:88R0SO!^Z=M-KO\.<5B<C0%8B[5L
MW%,8\%$\[P"TJ]>:K!13KZ"&+0279LQ^IZVF)A2+KU:$[^I6,.O2<& DKU,T
MZL0FY3$>$P2^'OK&S(PP#[ )_Z+F>&FP^6'T]!K#+-P>VN)0E6J(F#$15ZYT
M^(.W-0 &\%YV\FFX[BJB;K&?TBP#AZV4BNN$D@*1IF[J@F[;CG#GKNPGA[((
M@S(">^V2;O+)GG"()*-ZHN1]]5C<]=G]"MVT26"N\<^AZ>>B\0AN>&GN-JM^
MZ50*RP49IX8@#W+43D#6=@43&T4]D"V1MBO9CNTF5S'WTJM. NG97B]HUFLQ
M]^,"&VDX9_(XE_/UAG/U&NEK6C!Z'/-28!Y@[ERGS,PN=LK-X,UP3B6QH.CS
MN&]RPHO 360]AFI,?2A$\"\R)[14-( #O*)4-+-1F"PI9Z\TNZI =O&NHJT$
M_^/:TO]K-0] VX(Q6V9ONF[T1WNM*G<H/"I$8<IP/;*=7OIP52X@U3B65FAD
M0BFN70YCP#$6+$4:+]X)Z7PS:;BS0GLK<CQ' [ #VVAMY;TS.O?D:*:KN5)U
M&)>T0*9FG$J%$\MJK'ZU5X<U6'_U/[[KD]8K6><JKGHQT#A-4D5?.=;&WL)Q
M;IX.3<%H0<"O$";N'Q[7!;YUJ-QQSV3@L"#T41^V4HQ# 4Q>M5@+=A8P(X>L
M J,U6N-D"4^H A=J%$\VR5KQ !#U2) M)MOD:*LKNT8S:M]D:1MDNYIU1EOS
M60-I2G<(G020'0K)+R.<B:Z>W[P7HR&8]YFHW%UA1<KPL0AHVFXWH^4A-G-/
M167LR[_XB]82\ &GK3I;LE0KZ6J:=:!^[7AN<TWN5MH>J6>C<WD[,*&.LVN+
ML4V"-E@8M?,^+D,YY7]UH(TY[O3(U'_!:"!VA3PV+F[!'"+Z6.0F)>0>>#@N
M(8G =W/_$R@#V$]60/10I.Y:5W)6?_04+S U2W% >O($A[1WBS1/5K,F&ZHT
MS_8/:J0/[W7JA$ZRS@QCT:6:]I-?*N4N!^Q%UI>T_=FO%>'#/*L0-[B0#X6=
M+0 -1%DF(D4\4#=20&A5ORQ61ZB#2J]%EW5W/D%(#ZF4KB:78_&4=_F%:F@#
MA[B6;R:*NP<: YOZ*N)4]K8\9]^?Y53=0*MQZ33U]&%MQ9S>2 _>U-"A;36(
M,/B0/V;C5,L13YZV5(6$!X43P^S,DC.BDK-E>R<H<W'+QNP&,[#(AK2K8KA$
M9S.HEZTI1_4YR_;XVIN1[1J:QIVH.F \&5SYT:5_\.[<U5TB_YIH]5VD#J>I
MYS'LI[AW: CZH'LE!U@+\56+$J\JDQ^%=1MD1M/J%6>QM),X%D-Y3P([2$QU
M!&OOH&KV(U?[B(?N GLWMAN,4%*E &5K;?)Y"@\;G'1>;*"H00...:8QP<;C
M8K'+8=48D?7W<@\[P*/&H@>%ID/O!',X;/,DK%:S%C]Q]68ZIV-WM%M[.I,W
M!X_RIV^OO3(PH*N&L!O%7[UI;BO6JYN=+NW<G=C1G92[1]"[+1I08A8A/N$Y
M3-4Z8BT$RW?&QP<\2^;# E"CJC)% 2S[4#1ZA8I[DV*TPQ=D=T^ZZ;YL>%]P
M]D:QJ'-WMUNV:WMWM%/Y=U?YF;N'<O\N8'VNN(SHTM4X;G'N.U'J-;,5HLOS
M];V'ZBOK[K_6\HT8-L_S/ >P! 8@@"I:!>5Q9Z]N,MJ2;4FGK&I+J"0WNP2C
M=<YS1$Y*LL5/\),#Z8:GM75#L(4G_..WDEOC9_RNWF"BRU_M9@X+[V%VOD;D
MT1_EN+)JZRS.NYL*)GSQ;%X'>=[GOD;4! :0S 4X@!A"A3\0_80G:<.OLX;&
MZSD?)**V0R9_>\7G)*<7OKLN/T ^?>+SJI6GM:1/^DU^O8LT[,[@2@_SI:;N
M)J=J*_81;E:@L0 %B%,>-Z2F<.A/3],J=\G5J)EQ!)[I/D  $#B08$&#!PUR
M,) .@0$,#3'&()0X$:&#"A0Q&APPX,G&C:0\;NRX\5%(DP,>=1QY,N3*D"4Y
MHA3)<@"UD2DSYLQ)TN3*E2EI_B3Y4Z5'D#-#'I6I].70C4QT1I4Z]> !JE>Q
M9A6PZ<.'K5W!"@@+UNM7KUR]DA4[MJM8M +@DGT+-Z[;MF8%0,TJM2TZNF+A
MOIU+]B[=#VC?$@Z;6(!?NG['OH7<6,!>RY>E6L6\F7-GSY\[7S PFH/ &A0<
MC$Y0^B""!*,-7!"X('8% SP$\K@-FG=OW[^!_P<7CE5A@WSQV%V(U\"W@8N;
MF33UJ)):3YDB89Y\DITE=Z0<C\+L*-[D\.@N@VKWGMTE>NS6MT_GR;%D1Z8#
MAO?6G%\XV[)K-P$0,,6Z0JPLR Z#"\$$"XQ+K@/7.DRNRH;[3\ 'P>(*, <-
M) S L@HD+,"_2$RK,!+Y2Y&@_51LT<47HYH'-MD :  VV QBHH8;1[L( P,
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ML/"F3Y1$\.TPY"VR[WU:2OQ\12#2B'2<"65*YN9^1&4,@ E> ZG>;P=Y,'2
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MJO2^\")%[S4?CL>($*)*ZQZWKT3_W21*E^3?5TP?'R,IE^_E)V1?W6$ #@B
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MSF.Z8($%(@B]@M\RW;3F7D>L642Y-FQ=J9EU9<OUH"Y$$56E<ATY9[9P;TO
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M>JSTS=6:N#W:8)%92VR>;*P7S")"$XPP8J8DT7BICO!K<0X)CQJM4S\")HJ
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M)2YEOZB!"J" !-@@?_#/O=!#S2Q$'N(96IXER1TZ"\POD7%9G77'^F4+2^S
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M,2B6:7B.[XE^",*B$U$%X#11@[2""*>ZKNT,%8FJHJ9:3$,UE66V24IT;'S
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M!OHO896,3L(F^+=Z_N\S<*I3'R7(($ARIE^-ZY\CJP3!>G')2PR4$R;+V1
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M-L&%89=H/,G7:!8*CO;:88+X4SY3%54TB+M'=7\H1MM3NJIE?$FD85?$4_S
MM;@K'QR  ')S 5]+ 0%)'200MH.A+FTI; TTB@V+9'>CL853F5?V=]S'H[-J
MBAOK3N)'5Q/$)L_KI( E6*249I@W2JQ'65%*OL^(2W)V$5T:;70FAS5C6&!(
MH C88-2X6;XH )E+-L2T=2_R*@^*%DUKIQS8-!YX=O\@6K3$$KLZHI1(TS.
M<77 Y4T S+F[]Z96L[2YN\&&X5R6VA"^:P +\)SC$)VK*K?0,:O5ZS>S(:H
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M">4WP_'KSNN.SNX.'^A?;C\GSQ/T8^@X_N1M5  .(?%%;O6ZG@#C/I8U /<
M0 -;K^U+'O;0WA!%[EQ0#_$,$_0.SP.<'A%%__!>9>Q=#P ^7S\/ >:=;@"V
M[E4;__,RGN1EF>W<KO->S^7M/I:7ZE7V,_*<SNPU*/AXCNZB#^S_W/*U2A+O
M1<X(   .!O#M#J'M@,X CC_L!$\37A7J2H_ED$Y=R3X"SQ[LP<[MX,[V-%'U
M9E/HB@_L7H[VT$Z\9Z[N%S_J[\/X.WY.8"7D#9'I , (3J_W(LSMB#[IQK[H
MR?XVV^[\R1[J%:_\?U*6K:_G )_H$?'V!H  GGY. '$.   ,!@P:1 "@QD&#
M"08:S%?0P< %# TX')A1XT:.'3U^!!E2Y$B2)4V>_+@P000#&#):[*C 0 T>
M+2LN .# P, +%ET"2,!P1 T %2XR,ECAH<4+*)V6U-DTY\Z>&#T:=8G5X$"=
M&8TFU1C/H+^,% S@_#KPJT&I3]V^A1M7_^Y<NG7MWL6;=VY-@T1[[IS:=F#0
MIG];#A1+]&10I7KK+@2L$@!+G!_-*BU8T*'D@07[9H1\>*!,&@0O=F;H6/5J
MUD[-6IS)>+ !P;/9 KAA0.Q/#[ =PJ8-P&"! @829I27NK5)EC KPN2X=2O+
M"A4;;P50%8!9"K.;Z@PZ$77WY>7-GW\YLR+YT)\W%JP 7R5GLSP0&V"P,)[:
MPT:#&K!/H1$ 0T^DH'""K :CG@M.(R;T,ZT"PNBSZ#J&Q"LH@J_\@JU #S\$
M,4011V2-(0X4,F"$@8HK3:.; *BHH/V$$V^[@P0[R*J@[#-KQM<,.E%$)FXS
M:J*"&.P(*P 2V_]J0=L,&BH[G[BBS2SQ&&R(1"VWU.A'$\UR";+C7#PH/0,:
MT^2TC8JK3;B9C *F(_>V;"Z!KIJ;C3R-#CRM)PR"XM"B H""32F=LAP( 8;T
MY++1$:F;3+0=8<1.(ZQT8F#),PV(X#ZFULJQ*(;:^J]2$D$%$M69.)*IAL06
M='*J$SEH4C3X;/POR"(=Y;577W\%%J6"%,6/(H8JTT@[PG2BQT_4&$J(5H8P
M8NPY_BXDT;.#!O72U('T@W#8@IJ"4%27ZKN/*/!TRZ@@1H.%=[F_$CUH0*N2
M193055>L4%2&9DR1$4*5*K5,7VLECS*.&*S, )UF)!:F@@W"2:R+SL0_U^!X
M-[[KT'_=S-1-CD*;4=OC9*I0U4'Y"F^C>0Y"=L2OXDE@*+Y0^TFC(QUF JD$
MS"(7.-,LPDE; MW,EV.E_Y=FNNFWE#0H9*-SUDBZG:RS;BF>3EMOMM*"^B\C
MEJC6\C6)3,,(K(UD8DD@HR(H[MII-64*@.+RC=B =YWF^R1%:PRM@8\HSJ@B
M!=8\*$!_*_VLW%)GY#(H#R+M#K+98M[Z-GU_LGPCLSI=FS8:V.5(K#;[1EU.
MV X72ZFT-F+"8H$6STBVC#F"<V#<U6RTJWP,F(>_O=?Z2:RN &  N!J,-NA<
M@X 1S<P&4Z>^>NL;)1U( !0=5-/&]CRKSY8 E5)0?1DB^*##OV6(;!(E4]C&
M[]M-' "DP!N(+VQ11G^JB^<WS-&N-T "E@=5BF&>1S3VG.\QSR5(L8BZ#%":
M(_\-33D%)""8!M*<@^P- .<P2( @8Y4 8F=B:#F-Y=IC$-"-*#.B2MNJ-+B1
MT#3&,U;1GD;&QI$,@8R'9\%@$(4XQ+BHZDPL21BG%@:SASR,7AV:F-[T=2"-
M2"N'(6J=:7!"+"K-3VZ*L5AEYK41VVDD*K3JWD9,1T0VMO$I' S9LP0(/A+.
MR8(Y2QXF<N@/ ^1#:S;2F!O[%B.O'*2%&^&+8C05,\-@ GP&(8]_-BC%]GCP
M0R5L4;>"Y*"#*.8K+>Q6#$=E(Q0Z1%6G$V0J57D]+!VD D;I'MLX8ABI_.<G
MTN((=P!0#_!5 ((=>9D7/=2;"TZL(Z&AW_1.6#[E&(2^@D!DWAQ7.4UJYH4)
MU<2FHZ[9J[4(!HX>Z=$VQ:3#4$GO..[R#@!J,B#C9-.=[UQ:BA33(=41B(')
M/$B88$,4V6B0@YT<$1-^1$:#U"@Z4KP602&9D0!F)"I_]!(\)3I1BE;4HHVJ
MQS8ONE&.]LH@ N.7M^C(4#N:18_D>9")9M,8G1#%2S70:$ +!(&.UM2F-\5I
M3G6Z4YZR,:8]!6I0A3I4HA;5J$=%:E*5NE2F-M6I3X5J5*4Z5:I6U:I7Q?]J
M5K6Z5:Z:IX3!RUSTNCI6LI;5K&=%:UH[TAP]J@E5[E-K7.4Z5[K6U:X3G90:
M#_.73;[S9:,<R%\-T->[AJA;>M(6*@N[6,8VUK&L*0Y,-3).[P$R8B=BHIDH
M8"WK':2MQ^$C0Q3YV/,L\WR:<R?S%)=8TK;6M2>!S28O^-K6K%",[J%B*X'3
ME"'!QJ"H&Z-&-T0HN-)6+U?,7%,T T^+I0ACIYV><:4++'HN1:337.&^JCM=
MO>@OG]O+85!<TAREL P TL))149P Q21CGI&V=MRU<FN&@SH A;KCF? *D?(
M*):[G2,3Q+ #2?W2KG 'D98EE0897F9,N080''?_)>RH1F+'B@:!7#5KD@ F
M\'*;KUF*@B<,%Y9@Y#4U^(MB@M(=SOY%*F+IU(H/O#[J)3!/F6NO19IKJ]V.
MF"/>;9!\(2A!X"@'53K!7-.TLY&*"!@P2?FK\TRE/\B(V,=7'LD.8^J9I0A3
ME?$#WT\JXA"^,M&6.NLD:K$\6;;\;K"7BQ1@W-PBF>!$O&)SF/4\=I!,R1B\
M^(&@*/F99\C\Y#]CPG(TE6(6C"0O.(>RS:+[TMOUO>:03OOGON0+&<S"9L<8
MX0L[Q9+D-9<Z)+?2:V5>R!<K-J6#&OEK OC:MX+16">@VU7>#K)C\D0SNCZ^
M,_(0(JWC%$<I+!$/L:2"061"Z:DB9*F>YA;: -'PU=$6$C.[*C @T*CYRGX.
MRGX8/1!B:^HG9RM??E![Z]1%L2GC/N]MQF+=!P-&+-UKSJ5-_[UOCWPZ/8T9
M\^(NU+_3WFVT3!/:(A/Z%Y=8<2F"*[1M$.WCYL 4Q.;^,U%Z,Z._^!$ LGQ.
MT/)<P(+$R<]<["^5?L*2P[U.V.WD=T(+$F%.3Z4R9H&VM#A0<RKIFVG%"5"6
MX#U.PA$*(VF!C,>G,KF8-YV&GN[R)"?RR?(!;*\&8?JA&/!3CDDK4^C]N!+G
MNQ-E+X7IX[X9^W[M8]@$Z*U2?^*RQ6X1F= 8N.X9-[R-LA]IM4@GY.G-U"LE
M+?].5VUIJ4CWQEAGU(@GQ8YNBUB8;KV*3 3>7G=38]CAUJU /B.R='KHRY<Y
MI8306#OYRHD@TQ@9-YFD!@ I]>[,;O]_97PIH%NNRQT]\2LW5S"&R1FR,U=L
M(%J7!Y7O+(3;BQ.^".S."QF!QXNS<D(W3^*F#DKWLD2LTL#[[P.QTA-/9+S3
M^WS!FF/)H!+_Q*4$*"CL2&C?'2IVT=?_/I-36\#3+BW6'T;X3XPCIG$Y&0NV
M$DNWI;BYTT@[^_$V^W,-TS,ZZ\DTR-FQ54FYJ2 /SC*:NRD\Z2JA?9F8XV V
M&U&\ST 5QD,=L8BA[OB+A"@Y .BM_@,U["B.]2$F4G/ *\.3GG,3W).BUX$,
M]Y,BPWD]PE*:!"L?I> L9B.6(&$A\%,^Z"./0\O!M[@P5[H>_=FO)PD21_,[
MT?@_0$H >D#FB'UKC_>XD?10M9%3E"BA'=#K&U6I'8LX#@@,B@A['52!L2K<
MM[]P'8BPD?4!B[2KK^>2L;^H#(LYN*5A'AR"CA2[/=2($T#"L ;DPY*XP@YT
M)VF9Q-2[Q*<PF-6CGH9",]12F\V;00)9B[ SOT_DKHGA''IZG6N[L=,Z%"-<
M&@9YE] BD#:DAQ"#0JNX(<IRQ:>J0-XIQI+HENN2J%!4FV3T,6VYM(.HD9OI
M&0BDMISY#PKXBP"$IT#+'^2"QJ4JF.(:QX_H#7:2IHGRM7-TQXT8'='@K(HZ
MQGMYQZ5JL'M4JN=@)WW_U$?@,$=W*A@K\\>"-,B#1$C5L B"3,B&=,B'A,B(
ME,B)I,B*M,B+Q,B,U,B-Y,B.],B/!,F0%$G5X  'B <%\+*15,F59,F#I(!X
M.!Z*@,GB@\$:,*@*B#"U@,D"\* $J(P*8,B6_,0%@,F4%,JCQ,@%$ \*P BE
M_!8'0);J\ H'R)D*< #%<(!WH0"HI @[^2VD;*,+,,F@Y)CG.B^3Y,JJD4D%
MN,IM8@"81$F> )VO!,NZI,@$^)YY4"YD60!A]#@,* "J+ L]L<ID<0"?[ PE
M),MJ(LJ87+,%8$L"H0 %F$D'4 !DP8"FH!63G!\,@,F<Q(C,M!X,<(#O*4V%
M$CA-<F.QJU0(!0 C:D!-U]G*M/^TR]J\2]CD"B/D :M(-H>@ $LJ3(>2$,7Y
MEH!LE 8(S)/D3)>)&:#LDIA!3I-DKXT02\G" *4KM>#D ;IDRCW9GGBHI<:@
M@'-S"028S<4,%@EQ -SLR\+)&6[,"<59 !:SBO&$D9]@3=O,)JNDR3W1Q&"A
M2WC" %QT+1[P$;K\F40AFP@H+@P(ONY 3* @B@7 P6!Q4 ?Q '"(F0AHBZW$
MS)^@!G"H#9-4,3M!3]**T)SPHI)4).>\T(&@@<UP@"#A@'BH 1K $*/DF =Q
M  1(S0C0DWR G 0@BGA0N@NPQ\EP"1Z0"F[D.OV\GIWPS/?X"< @TIC:2MXK
MB?F4$\G_&@S\Z9(__+Z-P,F,B$[EQ!BQ3%(10=*.:  O:P!&N8 J-4F[>PG%
MJ#SEC ?R@,E%I*WM/,R.V,JR\"+[7)C\#$Z\_!:87%-X"<Z,R(?#),XT<H!*
M198>+8M#8DK6M$E^:A%^2\W:813XQ #%88"V-$P4PS7BY!L,P(G4+%70<$V%
MP(A0;<]DF8<3B0BN@%(AXH#\<H!TT"&RL4>@Y-"G4,J](=%VP8@+V$)3RL^L
MM!3![ @,( _[:-0/\=%)U)E0+1QIS0@>,)0 \8 TX@H'\,:!D(<K(0@";:T$
M!0!J< #LW,I-(M*-8-!#_1X%:)$4[1O:Y H)018.$#,(9=5V_R%,!\!1;UP
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MJ8#)B]2$N('N30 9UF'J"56;-,D$AN&1K=3)VEE<_^YF>"GEHL (R#G:K(P
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)UN[M7K.    [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover page<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Abivax SA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">I0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7-11 boulevard Haussmann<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">75009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Paris<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">FR<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">78,536,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001956827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Marc de Garidel<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7-11 boulevard Haussmann<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">75009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Paris<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">FR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">1 53 83 09 63<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=abvx_AmericanDepositorySharesNASDAQGlobalMarketMember', window );">American Depositary Shares, each representing one ordinary share, nominal value &#8364;0.01 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing one ordinary share, nominal value &#8364;0.01 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABVX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=abvx_OrdinarySharesNASDAQGlobalMarketMember', window );">Ordinary shares, nominal value &#8364;0.01 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, nominal value &#8364;0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_NoTradingSymbolFlag', window );">No Trading Symbol Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_NoTradingSymbolFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a security having no trading symbol.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_NoTradingSymbolFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:trueItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=abvx_AmericanDepositorySharesNASDAQGlobalMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=abvx_AmericanDepositorySharesNASDAQGlobalMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=abvx_OrdinarySharesNASDAQGlobalMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=abvx_OrdinarySharesNASDAQGlobalMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Auditor information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers Audit<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Neuilly-sur-Seine, France<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1347<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">&#8364; 18,419<span></span>
</td>
<td class="nump">&#8364; 18,419<span></span>
</td>
<td class="nump">&#8364; 18,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">6,605<span></span>
</td>
<td class="nump">6,606<span></span>
</td>
<td class="nump">6,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment</a></td>
<td class="nump">2,090<span></span>
</td>
<td class="nump">2,666<span></span>
</td>
<td class="nump">878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialAssets', window );">Other financial assets</a></td>
<td class="nump">5,358<span></span>
</td>
<td class="nump">5,919<span></span>
</td>
<td class="nump">12,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentNonfinancialAssets', window );">Other non-current assets</a></td>
<td class="nump">625<span></span>
</td>
<td class="nump">948<span></span>
</td>
<td class="nump">2,320<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">33,097<span></span>
</td>
<td class="nump">34,558<span></span>
</td>
<td class="nump">41,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Other financial assets</a></td>
<td class="nump">21,415<span></span>
</td>
<td class="nump">7,554<span></span>
</td>
<td class="nump">9,186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_CurrentReceivablesAndCurrentPrepaidExpenses', window );">Other receivables and assets</a></td>
<td class="nump">13,144<span></span>
</td>
<td class="nump">18,896<span></span>
</td>
<td class="nump">24,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">516,685<span></span>
</td>
<td class="nump">144,221<span></span>
</td>
<td class="nump">251,942<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">551,244<span></span>
</td>
<td class="nump">170,671<span></span>
</td>
<td class="nump">285,972<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">584,341<span></span>
</td>
<td class="nump">205,228<span></span>
</td>
<td class="nump">327,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="nump">785<span></span>
</td>
<td class="nump">633<span></span>
</td>
<td class="nump">629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharePremium', window );">Premiums related to share capital</a></td>
<td class="nump">1,190,593<span></span>
</td>
<td class="nump">478,905<span></span>
</td>
<td class="nump">478,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation', window );">Translation reserve</a></td>
<td class="nump">2,309<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod', window );">Retained earnings</a></td>
<td class="num">(402,380)<span></span>
</td>
<td class="num">(262,637)<span></span>
</td>
<td class="num">(135,209)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarningsProfitLossForReportingPeriod', window );">Net loss for the period</a></td>
<td class="num">(336,102)<span></span>
</td>
<td class="num">(176,242)<span></span>
</td>
<td class="num">(147,740)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">455,205<span></span>
</td>
<td class="nump">40,584<span></span>
</td>
<td class="nump">196,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisionsForEmployeeBenefits', window );">Retirement benefit obligations</a></td>
<td class="nump">627<span></span>
</td>
<td class="nump">756<span></span>
</td>
<td class="nump">629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherLongtermProvisions', window );">Provisions</a></td>
<td class="nump">28,849<span></span>
</td>
<td class="nump">819<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings', window );">Borrowings</a></td>
<td class="nump">554<span></span>
</td>
<td class="nump">29,056<span></span>
</td>
<td class="nump">2,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NonCurrentConvertibleLoansNotes', window );">Convertible loan notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">23,370<span></span>
</td>
<td class="nump">21,643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities', window );">Derivative instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,620<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NonCurrentRoyaltyCertificates', window );">Royalty certificates</a></td>
<td class="nump">30,237<span></span>
</td>
<td class="nump">13,023<span></span>
</td>
<td class="nump">12,229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialLiabilities', window );">Other financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets', window );">Deferred tax liabilities</a></td>
<td class="nump">5,848<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">66,114<span></span>
</td>
<td class="nump">70,645<span></span>
</td>
<td class="nump">40,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings', window );">Borrowings</a></td>
<td class="nump">1,302<span></span>
</td>
<td class="nump">22,195<span></span>
</td>
<td class="nump">1,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_CurrentPortionOfNonCurrentConvertibleLoansNotes', window );">Convertible loan notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,574<span></span>
</td>
<td class="nump">29,605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Derivative instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,166<span></span>
</td>
<td class="nump">2,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Other financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherShorttermProvisions', window );">Provisions</a></td>
<td class="nump">17,030<span></span>
</td>
<td class="nump">532<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade payables and other current liabilities</a></td>
<td class="nump">37,552<span></span>
</td>
<td class="nump">43,824<span></span>
</td>
<td class="nump">47,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_CurrentTaxAndEmployeeBenefitLiabilities', window );">Tax and employee-related payables</a></td>
<td class="nump">7,137<span></span>
</td>
<td class="nump">4,709<span></span>
</td>
<td class="nump">6,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities', window );">Deferred income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">63,021<span></span>
</td>
<td class="nump">93,999<span></span>
</td>
<td class="nump">90,695<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</a></td>
<td class="nump">&#8364; 584,341<span></span>
</td>
<td class="nump">&#8364; 205,228<span></span>
</td>
<td class="nump">&#8364; 327,062<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_CurrentPortionOfNonCurrentConvertibleLoansNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Portion Of Non-Current Convertible Loans Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_CurrentPortionOfNonCurrentConvertibleLoansNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_CurrentReceivablesAndCurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Receivables And Current Prepaid Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_CurrentReceivablesAndCurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_CurrentTaxAndEmployeeBenefitLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Tax And Employee Benefit Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_CurrentTaxAndEmployeeBenefitLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities (Assets) Net of Unrecognized Liabilities (Assets)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NonCurrentConvertibleLoansNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Current Convertible Loans Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NonCurrentConvertibleLoansNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NonCurrentRoyaltyCertificates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Current Royalty Certificates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NonCurrentRoyaltyCertificates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current deferred income other than current contract liabilities. [Refer: Deferred income other than contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2025-01-01<br> -Paragraph 134<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2025-01-01<br> -Paragraph 135<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2025-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 254<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_254_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 255<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_255_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 254<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_254_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 255<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_255_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current other borrowings. [Refer: Other borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisionsForEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions for employee benefits. [Refer: Provisions for employee benefits]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisionsForEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current other borrowings and the current portion of non-current other borrowings. [Refer: Other borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherLongtermProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions other than provisions for employee benefits. [Refer: Non-current provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherLongtermProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentNonfinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentNonfinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherShorttermProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions other than provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherShorttermProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant and equipment including right-of-use assets whose underlying assets would be presented as property, plant and equipment if they were owned. [Refer: Property, plant and equipment; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2025-01-01<br> -Paragraph 52<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_52_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 218<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_218_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 218<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_218_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity&#8217;s cumulative undistributed earnings or deficit excluding the profit or loss for the reporting period. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarningsProfitLossForReportingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity&#8217;s undistributed profit or loss for the reporting period. [Refer: Retained earnings; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarningsProfitLossForReportingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF INCOME (LOSS) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other operating income</a></td>
<td class="nump">&#8364; 4,570<span></span>
</td>
<td class="nump">&#8364; 12,449<span></span>
</td>
<td class="nump">&#8364; 4,621<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAndOperatingIncome', window );">Total operating income</a></td>
<td class="nump">4,570<span></span>
</td>
<td class="nump">12,449<span></span>
</td>
<td class="nump">4,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="num">(5,194)<span></span>
</td>
<td class="num">(5,954)<span></span>
</td>
<td class="num">(6,431)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(177,761)<span></span>
</td>
<td class="num">(146,532)<span></span>
</td>
<td class="num">(103,176)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="num">(67,670)<span></span>
</td>
<td class="num">(32,946)<span></span>
</td>
<td class="num">(22,390)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Total operating expenses</a></td>
<td class="num">(250,626)<span></span>
</td>
<td class="num">(185,433)<span></span>
</td>
<td class="num">(131,997)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating loss</a></td>
<td class="num">(246,056)<span></span>
</td>
<td class="num">(172,984)<span></span>
</td>
<td class="num">(127,376)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Financial expenses</a></td>
<td class="num">(111,743)<span></span>
</td>
<td class="num">(16,991)<span></span>
</td>
<td class="num">(27,875)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Financial income</a></td>
<td class="nump">27,545<span></span>
</td>
<td class="nump">13,732<span></span>
</td>
<td class="nump">7,511<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Financial gain (loss)</a></td>
<td class="num">(84,198)<span></span>
</td>
<td class="num">(3,258)<span></span>
</td>
<td class="num">(20,364)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Net loss before tax</a></td>
<td class="num">(330,254)<span></span>
</td>
<td class="num">(176,242)<span></span>
</td>
<td class="num">(147,740)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax</a></td>
<td class="num">(5,848)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="num">&#8364; (336,102)<span></span>
</td>
<td class="num">&#8364; (176,242)<span></span>
</td>
<td class="num">&#8364; (147,740)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Loss per share (&#8364;/share)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of outstanding shares used for computing basic loss per share (in shares)</a></td>
<td class="nump">69,527,315<span></span>
</td>
<td class="nump">63,046,350<span></span>
</td>
<td class="nump">43,066,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of outstanding shares used for computing diluted loss per share (in shares)</a></td>
<td class="nump">69,527,315<span></span>
</td>
<td class="nump">63,046,350<span></span>
</td>
<td class="nump">43,066,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic loss per share (in euro per share)</a></td>
<td class="num">&#8364; (4.83)<span></span>
</td>
<td class="num">&#8364; (2.80)<span></span>
</td>
<td class="num">&#8364; (3.43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted loss per share (in euro per share)</a></td>
<td class="num">&#8364; (4.83)<span></span>
</td>
<td class="num">&#8364; (2.80)<span></span>
</td>
<td class="num">&#8364; (3.43)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 192<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_192&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 192<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_192&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2025-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2025-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2025-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 266<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_266&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 266<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_266&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAndOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAndOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfComprehensiveIncomeAbstract', window );"><strong>Statement of comprehensive income [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="num">&#8364; (336,102)<span></span>
</td>
<td class="num">&#8364; (176,242)<span></span>
</td>
<td class="num">&#8364; (147,740)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax', window );">Items that will not be reclassified to profit or loss</a></td>
<td class="nump">93<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Actuarial gains and losses on retirement benefit obligations</a></td>
<td class="nump">93<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Items that are or may be reclassified subsequently to profit or loss</a></td>
<td class="nump">2,384<span></span>
</td>
<td class="num">(187)<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Foreign currency translation differences</a></td>
<td class="nump">2,384<span></span>
</td>
<td class="num">(187)<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income (loss)</a></td>
<td class="nump">2,477<span></span>
</td>
<td class="num">(219)<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income (loss) for the period</a></td>
<td class="num">&#8364; (333,625)<span></span>
</td>
<td class="num">&#8364; (176,461)<span></span>
</td>
<td class="num">&#8364; (147,516)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [domain]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2025-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Heights convertible notes</div></th>
<th class="th"><div>Kreos OCABSA</div></th>
<th class="th"><div>Kreos A &amp; B BSA</div></th>
<th class="th"><div>Kreos &amp; Claret financing</div></th>
<th class="th"><div>Other equity agreement</div></th>
<th class="th"><div>SHARE CAPITAL</div></th>
<th class="th">
<div>SHARE CAPITAL </div>
<div>Heights convertible notes</div>
</th>
<th class="th">
<div>SHARE CAPITAL </div>
<div>Kreos OCABSA</div>
</th>
<th class="th">
<div>SHARE CAPITAL </div>
<div>Kreos A &amp; B BSA</div>
</th>
<th class="th">
<div>SHARE CAPITAL </div>
<div>Other equity agreement</div>
</th>
<th class="th"><div>PREMIUMS RELATED TO SHARE CAPITAL</div></th>
<th class="th">
<div>PREMIUMS RELATED TO SHARE CAPITAL </div>
<div>Heights convertible notes</div>
</th>
<th class="th">
<div>PREMIUMS RELATED TO SHARE CAPITAL </div>
<div>Kreos OCABSA</div>
</th>
<th class="th">
<div>PREMIUMS RELATED TO SHARE CAPITAL </div>
<div>Kreos A &amp; B BSA</div>
</th>
<th class="th">
<div>PREMIUMS RELATED TO SHARE CAPITAL </div>
<div>Kreos &amp; Claret financing</div>
</th>
<th class="th">
<div>PREMIUMS RELATED TO SHARE CAPITAL </div>
<div>Other equity agreement</div>
</th>
<th class="th"><div>TRANSLATION RESERVE</div></th>
<th class="th"><div>RETAINED EARNINGS</div></th>
<th class="th">
<div>RETAINED EARNINGS </div>
<div>Kreos OCABSA</div>
</th>
<th class="th"><div>NET LOSS FOR THE YEAR</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued at beginning of period (in shares) at Dec. 31, 2022</a></td>
<td class="nump">22,313,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract', window );"><strong>Reconciliation of number of shares outstanding [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease', window );">Capital increase from issuance of ordinary shares (in shares)</a></td>
<td class="nump">40,325,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants', window );">Exercises of share warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued at end of period (in shares) at Dec. 31, 2023</a></td>
<td class="nump">62,928,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period at Dec. 31, 2022</a></td>
<td class="nump">&#8364; 7,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 150,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="num">&#8364; (82,770)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (60,740)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInEquityAbstract', window );"><strong>Changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="num">(147,740)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(147,740)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income (loss)</a></td>
<td class="nump">225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income (loss) for the period</a></td>
<td class="num">(147,516)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(147,740)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings', window );">Appropriation of prior period net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60,740)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Capital increase from issuance of ordinary shares</a></td>
<td class="nump">353,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ShareIssueRelatedCostCredit', window );">Transaction costs related to capital increase</a></td>
<td class="num">(28,111)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,111)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfConvertibleInstruments', window );">Issue of convertible notes</a></td>
<td class="nump">1,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Exercises of shares warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="nump">&#8364; 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Shares based compensation expense</a></td>
<td class="nump">8,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions', window );">Transactions on treasury shares</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period at Dec. 31, 2023</a></td>
<td class="nump">&#8364; 196,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="num">(135,210)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(147,740)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract', window );"><strong>Reconciliation of number of shares outstanding [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants', window );">Exercises of share warrants (in shares)</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfFreeSharesIssued', window );">Issue of free shares (in shares)</a></td>
<td class="nump">415,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued at end of period (in shares) at Dec. 31, 2024</a></td>
<td class="nump">63,347,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInEquityAbstract', window );"><strong>Changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="num">&#8364; (176,242)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(176,242)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income (loss)</a></td>
<td class="num">(219)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(187)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income (loss) for the period</a></td>
<td class="num">(176,461)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(187)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(176,242)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings', window );">Appropriation of prior period net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(147,740)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ShareIssueRelatedCostCredit', window );">Transaction costs related to capital increase</a></td>
<td class="nump">446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughIssuanceOfWarrantsEquity', window );">Issue of share warrants</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Exercises of shares warrants</a></td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseFromFreeSharesIssued', window );">Issue of free shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Shares based compensation expense</a></td>
<td class="nump">20,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions', window );">Transactions on treasury shares</a></td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period at Dec. 31, 2024</a></td>
<td class="nump">&#8364; 40,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="num">(262,638)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(176,242)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract', window );"><strong>Reconciliation of number of shares outstanding [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease', window );">Capital increase from issuance of ordinary shares (in shares)</a></td>
<td class="nump">11,679,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants', window );">Exercises of share warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,913<span></span>
</td>
<td class="nump">257,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments', window );">Conversion of convertible instruments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">920,377<span></span>
</td>
<td class="nump">1,178,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfFreeSharesIssued', window );">Issue of free shares (in shares)</a></td>
<td class="nump">627,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued at end of period (in shares) at Dec. 31, 2025</a></td>
<td class="nump">78,536,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInEquityAbstract', window );"><strong>Changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="num">&#8364; (336,102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(336,102)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income (loss)</a></td>
<td class="nump">2,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,384<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income (loss) for the period</a></td>
<td class="num">(333,625)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,384<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(336,102)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings', window );">Appropriation of prior period net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(176,242)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Capital increase from issuance of ordinary shares</a></td>
<td class="nump">637,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">637,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ShareIssueRelatedCostCredit', window );">Transaction costs related to capital increase</a></td>
<td class="num">(40,306)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,306)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughIssuanceOfWarrantsEquity', window );">Issue of share warrants</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Exercises of shares warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 33,768<span></span>
</td>
<td class="nump">&#8364; 3,346<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 33,763<span></span>
</td>
<td class="nump">&#8364; 3,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments', window );">Conversion of Kreos Claret OCABSA and Heights notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 53,921<span></span>
</td>
<td class="nump">&#8364; 24,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 9<span></span>
</td>
<td class="nump">&#8364; 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 53,912<span></span>
</td>
<td class="nump">&#8364; 23,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseFromFreeSharesIssued', window );">Issue of free shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Shares based compensation expense</a></td>
<td class="nump">35,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period at Dec. 31, 2025</a></td>
<td class="nump">&#8364; 455,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,190,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,309<span></span>
</td>
<td class="num">&#8364; (402,380)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (336,102)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IncreaseDecreaseFromFreeSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) From Free Shares Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IncreaseDecreaseFromFreeSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Number Of Ordinary Shares Issued Through Capital Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Number Of Shares Issued Through Conversion Of Convertible Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Number Of Shares Issued Through Exercise Of Share Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IncreaseDecreaseThroughIssuanceOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Issuance of Warrants, Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IncreaseDecreaseThroughIssuanceOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfFreeSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Free Shares Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfFreeSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ShareIssueRelatedCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Issue Related Cost (Credit)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ShareIssueRelatedCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the appropriation of retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the conversion of convertible instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfConvertibleInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The change in equity resulting from the issuing of convertible instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfConvertibleInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2025-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS<br> &#8364; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows provided by (used in) operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="num">&#8364; (336,102)<span></span>
</td>
<td class="num">&#8364; (176,242)<span></span>
</td>
<td class="num">&#8364; (147,740)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Amortization of intangibles and depreciation of property, plant and equipment</a></td>
<td class="nump">1,072<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities', window );">Retirement benefit obligations</a></td>
<td class="num">(65)<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based compensation expenses</a></td>
<td class="nump">35,397<span></span>
</td>
<td class="nump">20,224<span></span>
</td>
<td class="nump">8,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_AdjustmentsForNetGainOnSaleOfTreasuryShares', window );">Net gain on sale of treasury shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_AdjustmentsForOtherFinanceCosts', window );">Interest expenses and other financial expenses</a></td>
<td class="nump">45,697<span></span>
</td>
<td class="nump">14,203<span></span>
</td>
<td class="nump">24,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_AdjustmentsForOtherFinanceIncome', window );">Financial income</a></td>
<td class="num">(23,782)<span></span>
</td>
<td class="num">(11,609)<span></span>
</td>
<td class="num">(2,953)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances', window );">Effect of unwinding the discount related to advances</a></td>
<td class="num">(153)<span></span>
</td>
<td class="num">(710)<span></span>
</td>
<td class="num">(355)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFairValueGainsLosses', window );">Increase/(decrease) in derivatives and liabilities measured at fair value</a></td>
<td class="nump">62,330<span></span>
</td>
<td class="nump">1,416<span></span>
</td>
<td class="num">(1,158)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_AdjustmentsForForgivenessOfConditionalAdvances', window );">Forgiveness of conditional advances</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,140)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForProvisions', window );">Changes in provisions</a></td>
<td class="nump">44,706<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncomeTaxExpense', window );">Current and deferred taxes expenses</a></td>
<td class="nump">5,848<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAdjustmentsForNoncashItems', window );">Other</a></td>
<td class="nump">270<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital', window );">Cash flows provided by (used in) operating activities before change in working capital requirements</a></td>
<td class="num">(164,780)<span></span>
</td>
<td class="num">(155,495)<span></span>
</td>
<td class="num">(118,395)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables', window );">Decrease / (increase) in other receivables and related accounts</a></td>
<td class="nump">7,042<span></span>
</td>
<td class="nump">4,591<span></span>
</td>
<td class="num">(14,231)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable', window );">Increase / (decrease) in trade payables</a></td>
<td class="num">(6,210)<span></span>
</td>
<td class="num">(3,444)<span></span>
</td>
<td class="nump">31,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities', window );">Increase / (decrease) in tax and social security liabilities</a></td>
<td class="nump">2,110<span></span>
</td>
<td class="num">(1,487)<span></span>
</td>
<td class="nump">3,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities', window );">Changes in deferred income and other liabilities</a></td>
<td class="nump">710<span></span>
</td>
<td class="nump">1,763<span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInWorkingCapital', window );">Changes in working capital requirements</a></td>
<td class="nump">3,651<span></span>
</td>
<td class="nump">1,423<span></span>
</td>
<td class="nump">21,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities', window );">Income taxes paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Cash flows provided by (used in) operating activities</a></td>
<td class="num">(161,129)<span></span>
</td>
<td class="num">(154,072)<span></span>
</td>
<td class="num">(97,130)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows provided by (used in) investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Acquisitions of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Acquisitions of property, plant and equipment</a></td>
<td class="num">(142)<span></span>
</td>
<td class="num">(640)<span></span>
</td>
<td class="num">(265)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations', window );">Advances reimbursed by / (made to) CROs</a></td>
<td class="nump">71<span></span>
</td>
<td class="num">(231)<span></span>
</td>
<td class="num">(1,620)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_CashPaymentsForDeposits', window );">Increase in deposits</a></td>
<td class="num">(14,152)<span></span>
</td>
<td class="num">(591)<span></span>
</td>
<td class="num">(9,351)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ProceedsFromReimbursementsOfDeposits', window );">Decrease in deposits</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">9,050<span></span>
</td>
<td class="nump">741<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsInvestingActivities', window );">Interest received</a></td>
<td class="nump">5,530<span></span>
</td>
<td class="nump">8,178<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Cash flows provided by (used in) investing activities</a></td>
<td class="num">(8,193)<span></span>
</td>
<td class="nump">15,762<span></span>
</td>
<td class="num">(8,095)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows provided by (used in) financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Capital increases</a></td>
<td class="nump">648,124<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">353,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_PaymentsForProceedsFromShareIssueRelatedCostsCredit', window );">Transaction costs related to capital increase</a></td>
<td class="num">(40,914)<span></span>
</td>
<td class="nump">446<span></span>
</td>
<td class="num">(28,111)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NetProceedsFromNonConvertibleLoansNotes', window );">Net proceeds from non-convertible bond loans</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">47,944<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RepaymentsOfNonConvertibleLoansNotes', window );">Repayments of non-convertible bond loans</a></td>
<td class="num">(53,920)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,635)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NetProceedsFromConvertibleLoanNotes', window );">Net proceeds from convertible loan notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">55,841<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RepaymentsOfConvertibleLoansNotes', window );">Repayments of convertible loan notes</a></td>
<td class="num">(2,188)<span></span>
</td>
<td class="num">(8,750)<span></span>
</td>
<td class="num">(27,188)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RepaymentsOfPGE', window );">Repayment of PGE</a></td>
<td class="num">(2,514)<span></span>
</td>
<td class="num">(1,250)<span></span>
</td>
<td class="num">(1,250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RepaymentsOfConditionalAdvances', window );">Repayments of conditional advances</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,708)<span></span>
</td>
<td class="num">(110)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payments of the lease liabilities</a></td>
<td class="num">(911)<span></span>
</td>
<td class="num">(458)<span></span>
</td>
<td class="num">(529)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares', window );">Net proceeds from sale of treasury shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">434<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities', window );">Interest paid</a></td>
<td class="num">(6,490)<span></span>
</td>
<td class="num">(7,696)<span></span>
</td>
<td class="num">(5,279)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="nump">5,820<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities', window );">Other</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">245<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Cash flows provided by (used in) financing activities</a></td>
<td class="nump">547,307<span></span>
</td>
<td class="nump">28,207<span></span>
</td>
<td class="nump">335,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Effect of movements in exchange rates on cash held</a></td>
<td class="num">(10,251)<span></span>
</td>
<td class="nump">2,382<span></span>
</td>
<td class="num">(5,072)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RevaluationOfCashEquivalentsMeasuredAtFairValue', window );">Revaluation of cash equivalents measured at fair value</a></td>
<td class="nump">4,730<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">372,464<span></span>
</td>
<td class="num">(107,720)<span></span>
</td>
<td class="nump">224,992<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at the beginning of the year</a></td>
<td class="nump">144,221<span></span>
</td>
<td class="nump">251,942<span></span>
</td>
<td class="nump">26,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at the end of the year</a></td>
<td class="nump">&#8364; 516,685<span></span>
</td>
<td class="nump">&#8364; 144,221<span></span>
</td>
<td class="nump">&#8364; 251,942<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_AdjustmentsForForgivenessOfConditionalAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Forgiveness Of Conditional Advances</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_AdjustmentsForForgivenessOfConditionalAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Increase (Decrease) In Deferred Income And Other Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Increase (Decrease) In Tax And Social Security Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_AdjustmentsForNetGainOnSaleOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Net Gain On Sale Of Treasury Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_AdjustmentsForNetGainOnSaleOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_AdjustmentsForOtherFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Other Finance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_AdjustmentsForOtherFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_AdjustmentsForOtherFinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Other Finance Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_AdjustmentsForOtherFinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Unwinding Of Discount Related To Conditional Advances</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_CashPaymentsForDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Payments For Deposits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_CashPaymentsForDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NetProceedsFromConvertibleLoanNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Proceeds From Convertible Loan Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NetProceedsFromConvertibleLoanNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NetProceedsFromNonConvertibleLoansNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Proceeds From Non-Convertible Loans Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NetProceedsFromNonConvertibleLoansNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Advances Reimbursed (Made to) Contract Research Organizations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_PaymentsForProceedsFromShareIssueRelatedCostsCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For (Proceeds From) Share Issue Related Costs (Credit)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_PaymentsForProceedsFromShareIssueRelatedCostsCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ProceedsFromReimbursementsOfDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Reimbursements Of Deposits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ProceedsFromReimbursementsOfDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_RepaymentsOfConditionalAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments Of Conditional Advances</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_RepaymentsOfConditionalAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_RepaymentsOfConvertibleLoansNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments Of Convertible Loans Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_RepaymentsOfConvertibleLoansNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_RepaymentsOfNonConvertibleLoansNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments Of Non-Convertible Loans Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_RepaymentsOfNonConvertibleLoansNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_RepaymentsOfPGE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments Of PGE</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_RepaymentsOfPGE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_RevaluationOfCashEquivalentsMeasuredAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revaluation Of Cash Equivalents Measured At Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_RevaluationOfCashEquivalentsMeasuredAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFairValueGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFairValueGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncomeTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncomeTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in employee benefit liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) from the entity's operations before changes in working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 14<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_14_f&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAdjustmentsForNoncashItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAdjustmentsForNoncashItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inflows (outflows) of cash, classified as financing activities, that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 21<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_21&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of share purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale or issuing of treasury shares. [Refer: Sale or issue of treasury shares; Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2025-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Group<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Corporate information and statement of IFRS compliance [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory', window );">The Group</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:68.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">The Group </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 1.1. Information on the Group and its business </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:142.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">ABIVAX SA (the &#8220;Company&#8221;) is a soci&#233;t&#233; anonyme incorporated under the laws of France on December 4, 2013. Its registered office </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:152.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">is located at 7-11 Boulevard Haussmann&#8212;75009 Paris, France. The Company is developing therapeutics that harness the body&#8217;s </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:162.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:184.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">These consolidated financial statements as of and for the year ended December 31, 2025 comprise the Company and ABIVAX LLC </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:194.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(the &#8220;Subsidiary&#8221;), </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.97pt;position:var(--position);text-decoration:none;white-space:pre">the</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:126.17pt;position:var(--position);text-decoration:none;white-space:pre"> United States subsidiary of ABIVAX SA, created on March 20, 2023 under the laws of the State of Delaware </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:204.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(together referred to as the &#8220;Group&#8221;).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:226.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group has incurred losses since its inception and had shareholders&#8217; equity of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:363.17pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;455,205</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:400.67pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:403.17pt;position:var(--position);text-decoration:none;white-space:pre">thousand as of December 31, 2025. The </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:236.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Group anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its drug candidates </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:246.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">which are currently under development. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:198.03pt;position:var(--position);text-decoration:none;white-space:pre">Substantial additional financing will be needed by the Group to fund its operations and to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:256.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">commercially develop its drug candidates. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:278.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group's future operations are highly dependent on a combination of factors, including: (i)&#160;the success of its research and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:288.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">development activities; (ii)&#160;regulatory approval and market acceptance of its proposed future products; (iii)&#160;the timely and successful </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:298.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">completion of additional financing and (iv)&#160;the development of competitive therapies by other biotechnology and pharmaceutical </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:308.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">companies. As a result, the Group is, and expects to continue to be, in the short to mid-term, financed through the issuance of new </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:318.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">equity or debt instruments. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:340.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group is focusing its efforts on the following areas: </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:362.56pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Completion of the Phase 3 clinical trial program (ABTECT) for obefazimod in moderately to severely active ulcerative colitis </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:376pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(&#8220;UC&#8221;). </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:389.44pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Continuation of the Phase 2b clinical trial (ENHANCE-CD) of obefazimod in Crohn&#8217;s disease (&#8220;CD&#8221;). </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:402.88pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Evaluating combination therapy candidates with obefazimod in UC.</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:416.32pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Selecting a follow-on candidate for obefazimod. </span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 1.2. Date of authorization of issuance </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:475.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The consolidated financial statements and related notes (the &#8220;financial statements&#8221;) have been prepared under the responsibility of </span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">management of the Group and were approved and authorized for issuance by the Group&#8217;s board of directors on </span>March 19, 2026.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 128<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_128&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 51<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_51&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of preparation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Corporate information and statement of IFRS compliance [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of preparation</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:68.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Basis of preparation </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:535.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Except for share data and per share amounts, the financial statements are presented in thousands of euros. Amounts are rounded up or </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:546.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">down the nearest whole number for the calculation of certain financial data and other information contained in these accounts. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:558.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Accordingly, the total amounts presented in certain tables may not be the exact sum of the preceding figures. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:569.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:581.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Statement of compliance </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:603.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The consolidated financial statements of the Group as of and for the years ended December 31, 2023, 2024 and 2025 have been </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:614.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">prepared in accordance with both International Financial Reporting Standards (&#8220;IFRS&#8221;) as issued by the International Accounting </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:625.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Standard Board (&#8220;IASB&#8221;) and IFRS as adopted by the European Union (&#8220;EU&#8221;) regulation n&#176;1606/2002 of July 19, 2002. The term </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:636.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8220;IFRS&#8221; refers collectively to International Accounting Standards (&#8220;IAS&#8221;) and IFRS as well as the interpretations issued by the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:648.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Standing Interpretations Committee (&#8220;SIC&#8221;) and the International Financial Reporting Interpretations Standards Committee (&#8220;IFRS </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:659.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">IC&#8221;), whose application is mandatory for the year ended December 31, 2025. </span></div><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Preparation of the financial statements </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:92.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The consolidated financial statements of the Group were prepared on a historical cost basis, with the exception of certain asset and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:103.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">liability categories and in accordance with the provisions set out in IFRS such as employee benefits measured using the projected unit </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:114.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">credit method, the Heights notes (classified under "Convertible loan notes") measured at fair value and derivative financial instruments </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">measured at fair value. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.47pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:155.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Going concern </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:177.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group has incurre</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:126.19pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">d substantial operating losses since inception and expects to continue to incur significant operating losses for the </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:189.36pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">foreseeab</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:74.27000000000001pt;position:var(--position);text-decoration:none;white-space:pre">le future and may never become profitable. For the year ended December 31, 2025, the Group had a net loss of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:519.9100000000001pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;336,102 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:201.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72.09pt;position:var(--position);text-decoration:none;white-space:pre">.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:74.59pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:77.09pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:225.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Since inception, the Group has financed its operations through the issuance of ordinary shares with gross aggregate proceeds of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:237.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,194.7 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:102.35pt;position:var(--position);text-decoration:none;white-space:pre">, of which </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:145.1pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;130&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:196.45pt;position:var(--position);text-decoration:none;white-space:pre"> of gross proceeds were from offerings of its ordinary shares on Euronext Paris in February </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:249.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">2023, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:61pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;223.3&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:119.85pt;position:var(--position);text-decoration:none;white-space:pre"> of gross proceeds were from its offering of ordinary shares in the form of American Depository Shares ("ADS") </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:261.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">on the Nasdaq Global Market as well as ordinary shares in Europe (including France) and countries outside of the United States in a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:273.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">private placement in October 2023, and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:196.64pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;637.5 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:255.49pt;position:var(--position);text-decoration:none;white-space:pre"> of gross proceeds were from the offering of the Group's ordinary shares in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:285.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">form of ADS on the Nasdaq Global Market in July 2025 ("the Offering"), </span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:332.83pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">ba</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:342.26pt;position:var(--position);text-decoration:none;white-space:pre">nk borrowings and structured loans</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:483.27pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.77pt;position:var(--position);text-decoration:none;white-space:pre">for </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:499.93pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;175.0&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:558.78pt;position:var(--position);text-decoration:none;white-space:pre">, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:297.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">reimbursements of Research Tax Credits (Cr&#233;dit d&#8217;Imp&#244;t Recherche (&#8220;CIR&#8221;)) in an aggregate amo</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:430.47pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">unt of </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:456.57pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;41.2 million</span><span style="background-color:#ffff00;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:510.42pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">,</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:512.9200000000001pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> subsidies </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:309.36pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">received from Banque Publique d&#8217;Investissement (&#8220;Bpifrance&#8221;) (inclu</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:316.2pt;position:var(--position);text-decoration:none;white-space:pre">ding </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:336.47pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;17.1&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:390.32pt;position:var(--position);text-decoration:none;white-space:pre"> of subsidies and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:459.72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1.8&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:508.57pt;position:var(--position);text-decoration:none;white-space:pre"> of conditional </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:321.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">advances) and royalty certificates in an amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:237.95pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;2.9&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:286.8pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:345.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Based on the Group&#8217;s existing cash and cash equivalents </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:264.93pt;position:var(--position);text-decoration:none;white-space:pre">and other short-</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:328.21pt;position:var(--position);text-decoration:none;white-space:pre">term investments</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:396.73pt;position:var(--position);text-decoration:none;white-space:pre"> of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:410.06pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;530.4 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:468.91pt;position:var(--position);text-decoration:none;white-space:pre"> a</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:475.84pt;position:var(--position);text-decoration:none;white-space:pre">s of December 31, 2025, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:356.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the Group expects, as of the date of issuance of these financial statements, to be able to fund its forecasted cash flow requirements into </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:368.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the fourth quarter of 20</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.25pt;position:var(--position);text-decoration:none;white-space:pre">27. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:144.25pt;position:var(--position);text-decoration:none;white-space:pre">This take</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:181.14pt;position:var(--position);text-decoration:none;white-space:pre">s into account management's assumptions</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:347.76pt;position:var(--position);text-decoration:none;white-space:pre"> of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:361.09pt;position:var(--position);text-decoration:none;white-space:pre">continued</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:400.49pt;position:var(--position);text-decoration:none;white-space:pre"> R&amp;D expenditure related to the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:379.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">continuation of the Phase 3 clinical trials of obefazimod in UC, progression of the Phase 2b clinical trials for CD and the initial stages </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:391.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of the scale up of the commercial organization as the Group prepares for a potential launch of obefazimod in UC.</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:488.78pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#160; </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:414.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Based on the above, these financial statements have been prepared on a going concern basis.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:444.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Impact of the Ukraine/Russia Hostilities on the Group </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:466.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In February 2022, Russia invaded Ukraine. The conflict has already had major implications for the global economy and the rate of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:478.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">inflation, particularly in relation to the supply of energy, raw materials and food products. It has also caused intense volatility on the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:489.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">financial markets, something that is still ongoing at the reporting date and has pushed down stock market prices around the world. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:511.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Given these developments, the Group has decided not to include Russia and Belarus in its global Phase 3 program for obefazimod in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:522.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">UC. However, the global scale of this conflict cannot be predicted at this stage. The Group, therefore, cannot rule out an adverse </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:534.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">impact of this conflict on its business, including in terms of access to raw materials, logistics, the performance of clinical studies and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:545.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in relation to any future financing the Group may seek. </span></div><div style="font-size:12pt;line-height:11pt;position:var(--position);top:567.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The long-term safety and efficacy extension of the</span><span style="color:#ff0000;font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:237.68pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:240.16pt;position:var(--position);text-decoration:none;white-space:pre">Phase 2b maintenance trial of obefazimod in moderately to severely active UC is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:579.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the Group&#8217;s only clinical trial with patients currently enrolled in Ukraine.&#160; The Phase 2b 12-month assessment was carried out in all </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:591.18pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the Ukrainian patients before the war broke out and these patients are therefore included in the one-year maintenance results that were </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:602.38pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">reported on April 6, 2022. Ukrainian patients who completed the two-year Phase 2b maintenance trial have been transitioned to the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:613.58pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">long-term safety and efficacy trial that is still on-going. The Group also has a few Ukrainian sites active in the western part of Ukraine </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:624.78pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in the ABTECT Phase 3 clinical trials.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:189.95pt;position:var(--position);text-decoration:none;white-space:pre"> None of these sites are located in the Crimea Region of Ukraine, the so-called Donetsk </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:635.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">People&#8217;s Republic, or the so-called Luhansk People&#8217;s Republic. We continue to monitor developments in the region, but any </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:647.18pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">instability as a result of the war may have material adverse impacts on these clinical sites, which could negatively impact our Phase 3 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:658.38pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">clinical trials.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:680.78pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Together with its contract research organizations ("</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:240.91pt;position:var(--position);text-decoration:none;white-space:pre">CROs")</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:272.75pt;position:var(--position);text-decoration:none;white-space:pre">, the Group is making considerable efforts to ensure the follow-up of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:691.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">patients who are unable to come to the study centers. Monitoring takes place through a remote monitoring system that was established </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:703.18pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and used successfully during the COVID-19 pandemic.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:257.19pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:259.69pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">N</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:42.66pt;position:var(--position);text-decoration:none;white-space:pre">ew, revised or amended Standards and Interpreta</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:241.12pt;position:var(--position);text-decoration:none;white-space:pre">tions </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:92.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group applied the amendment to IAS 21 The Effects of Changes in Foreign Exchange Rates &#8211; Lack of Exchangeability that is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:103.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">effective as of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:95.07pt;position:var(--position);text-decoration:none;white-space:pre">December&#160;31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:173.61pt;position:var(--position);text-decoration:none;white-space:pre">.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:176.11pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:178.61pt;position:var(--position);text-decoration:none;white-space:pre">The Group assessed the impacts resulting from the application of this issued accounting </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:114.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">pronouncement and concluded that they are not material.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:144.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">New standards, amendments and interpretations issued by IASB but not yet mandatory for financial years starting from January 1, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:154.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">2025 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:170.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group did not elect for early application of the following new standards, amendments and interpretations, which were issued but </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:180.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">not mandatory as of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:118.15pt;position:var(--position);text-decoration:none;white-space:pre">December&#160;31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:196.69pt;position:var(--position);text-decoration:none;white-space:pre">: </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:201.66pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre">Amendments to IFRS 9 Financial Instruments and IFRS 7 Financial Instruments: Disclosures &#8211; Amendments to the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:215.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre">Classification and Measurement of Financial Instruments, whose application is for annual reporting periods beginning on </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:228.54pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre">or after January 1, 2026, as approved by the EU on May 27, 2025; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:241.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre">Amendments to IFRS 9 Financial Instruments and IFRS 7 Financial Instruments: Disclosures &#8211; Contracts Referencing </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:253.18pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre">Nature-dependent Electricity, whose application is for annual reporting periods beginning on or after January 1, 2026, as </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:264.38pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre">approved by the EU on June 30, 2025; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:275.58pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre">IFRS 18 Presentation and Disclosure in Financial Statements, whose application is for annual reporting periods </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:286.78pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre">beginning on or after January 1, 2027, as approved by the EU on February 16, 2026; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:297.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre">IFRS 19 Subsidiaries without Public Accountability: Disclosures, whose application is for annual reporting periods </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:309.18pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre">beginning on or after January 1, 2027 (not yet approved by the UE), and</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:320.38pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre;width:3.5pt">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre;width:485.99pt">Annual Improvements Volume 11, whose application is for annual reporting periods beginning on or after January 1,</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.99pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:331.38pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre;width:25pt">2026, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:115pt;position:var(--position);text-decoration:none;white-space:pre;width:157.69pt">as approved by the EU on July 9, 2025.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:355.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">These texts have not been early adopted. The application of the standards and interpretations issued respectively by the IASB and the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:367.02pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">IFRS IC that are not yet effective as of December 31, 2025 is not expected to have a material impact on the Group&#8217;s consolidated </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:378.22pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">financial statements. IFRS 18, issued in April 2024 and effective from January 1, 2027, will modify the presentation of the </span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Consolidated statements of income (loss) and the Consolidated statements of cash flows</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:388.1pt;position:var(--position);text-decoration:none;white-space:pre">.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_AccountingPrinciplesAbstract', window );"><strong>Accounting Principles [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfSignificantEventsForThePeriodReportedAndEventsAfterReportingPeriodTextBlock', window );">Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent event</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:140.48pt;position:var(--position);text-decoration:none;white-space:pre">Significant events for the years ended</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:300.07pt;position:var(--position);text-decoration:none;white-space:pre"> December 31, 2023, 2024 and 2025 </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:451.95pt;position:var(--position);text-decoration:none;white-space:pre">and subsequent events </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 3.1. For the year ended December 31, 2023 </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:480.62pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Company announces successful oversubscribed </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:246.1pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;130.0&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:304.4pt;position:var(--position);text-decoration:none;white-space:pre"> cross-over financing at market price with top-tier U.S. and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:492.62pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">European Biotech investors &#8211; February 2023 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:510.62pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On February&#160;22, 2023, the Company announced the successful pricing of an oversubscribed </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:405.97pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;130.0&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:464.82pt;position:var(--position);text-decoration:none;white-space:pre"> financing with high-</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:520.62pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">quality U.S. and European biotech specialist investors, led by TCGX, with participation from existing investors Invus, Deep Track </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:530.62pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Capital, Sofinnova Partners, and Venrock Healthcare Capital Partners, as well as from new investors Great Point Partners, LLC, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:540.62pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Deerfield Management Company, Commodore Capital, Samsara BioCapital, Boxer Capital and others, by way of a reserved capital </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:550.62pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:82.03999999999999pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;130&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:133.39pt;position:var(--position);text-decoration:none;white-space:pre"> through the issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:231.36pt;position:var(--position);text-decoration:none;white-space:pre">20,000,000</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:276.36pt;position:var(--position);text-decoration:none;white-space:pre"> newly-issued ordinary shares with a nominal value of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:495.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.01</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:517.81pt;position:var(--position);text-decoration:none;white-space:pre"> per share, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:560.62pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">representing </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:87.88pt;position:var(--position);text-decoration:none;white-space:pre">89.6%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.71pt;position:var(--position);text-decoration:none;white-space:pre"> of its current share capital, at a subscription price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:326.21pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.50</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:348.71pt;position:var(--position);text-decoration:none;white-space:pre"> per share. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:582.62pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Related transaction costs amounted to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:189.96pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.7&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:238.81pt;position:var(--position);text-decoration:none;white-space:pre"> and were deducted from the share premiums. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:610.62pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Change in governance and management &#8211; February-August 2023 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:626.62pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On April&#160;5, 2023, the Company announced the appointment of Marc de Garidel as Chief Executive Officer (&#8220;CEO&#8221;) and Interim </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:636.62pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Board Chair, effective May&#160;5, 2023. Corinna zur Bonsen-Thomas stepped down as acting Chair, a position she held since August </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:646.62pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">2022, and remains a Board Member. Prof. Hartmut J. Ehrlich, M.D., retired from the CEO position, which he held since the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:656.62pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Company&#8217;s founding in 2013, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.45pt;position:var(--position);text-decoration:none;white-space:pre">and stayed on as a strategic advisor during the transition period, which ended on December 31, 2023. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:678.62pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On February 17, 2023, and April 18, 2023, the Company respectively announced the appointments of Dr. Sheldon Sloan, M.D., M. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:689.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Bioethics as new Chief Medical Officer and Michael Ferguson as new Chief Commercial Officer. </span></div><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On July 11, 2023, the Group announced the appointments of June Lee, M.D. and Troy Ignelzi as new independent members of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:81.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Group&#8217;s Board of Directors, replacing Joy Amundson and Jean-Jacques Bertrand. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:104.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On August 23, 2023, the Group announced the appointment of Patrick Malloy as new Senior Vice President Investor Relations.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Creation of Abivax LLC &#8211; March 2023 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:144.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On March&#160;20, 2023, Abivax LLC (or the "Subsidiary&#8221;), was incorporated as a</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:347.31pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:349.81pt;position:var(--position);text-decoration:none;white-space:pre">limited liability company</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:450.77pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:453.27pt;position:var(--position);text-decoration:none;white-space:pre">under the laws of Delaware. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:154.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of the issuance of the financial statements, the Company has full ownership over the Subsidiary. The Subsidiary hosts the Group&#8217;s </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:164.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">operations in the United States. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:192.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Cashless exercise of the Kreos A&amp;B BSA &#8211; May 2023 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:214.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On May 24, 2023, Kreos Capital V UK Ltd (or &#8220;Kreos&#8221;) opted for the cashless exercise option of the share warrants they held (as </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:225.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">defined in Note 15.3), implemented through the repurchase by the Group of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:341.27pt;position:var(--position);text-decoration:none;white-space:pre">43,070</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:368.77pt;position:var(--position);text-decoration:none;white-space:pre"> tranche A share warrants (&#8220;Kreos A BSA&#8221;) and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:236.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">43,070</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:63.5pt;position:var(--position);text-decoration:none;white-space:pre"> tranche B share warrants (&#8220;Kreos B BSA&#8221;) and the issuance of respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:370.07pt;position:var(--position);text-decoration:none;white-space:pre">67,887</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:397.57pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:417pt;position:var(--position);text-decoration:none;white-space:pre">31,696</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:444.5pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares, as a result of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:248.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the exercise by Kreos of the outstanding Kreos A &amp; B BSA. The accounting treatment of the operation is set forth in </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:504.67pt;position:var(--position);text-decoration:none;white-space:pre">Note 15.3</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:544.0899999999999pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:270.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Free shares compensation plans &#8211; July-December 2023 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:292.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In July, September and December 2023, the Group issued </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:269.40999999999997pt;position:var(--position);text-decoration:none;white-space:pre">five</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:284.94pt;position:var(--position);text-decoration:none;white-space:pre"> free shares compensation plans (</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:417.84pt;position:var(--position);text-decoration:none;white-space:pre">attributions gratuites d&#8217;actions</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:542.1800000000001pt;position:var(--position);text-decoration:none;white-space:pre">, or </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:304.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8220;AGAs&#8221;) to certain of its officers and employees, representing a maximum of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:349.24pt;position:var(--position);text-decoration:none;white-space:pre">2,601,296</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:389.24pt;position:var(--position);text-decoration:none;white-space:pre"> shares in the aggregate. The detailed terms </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:315.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and conditions and the accounting treatment of these plans are presented in Note 14.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:337.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group secures financing up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:177.57pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;150&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:228.37pt;position:var(--position);text-decoration:none;white-space:pre"> from </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:252.25pt;position:var(--position);text-decoration:none;white-space:pre">two</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:266.68pt;position:var(--position);text-decoration:none;white-space:pre"> structured debt financing transactions &#8211; August 2023 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:360.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On August 20, 2023, the Group concurrently signed </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:246.43pt;position:var(--position);text-decoration:none;white-space:pre">two</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:261.41999999999996pt;position:var(--position);text-decoration:none;white-space:pre"> structured debt financing transactions for a total amount of up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:523.9100000000001pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;150&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.26pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:371.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">consisting of (i) up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:124.55pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;75&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:170.9pt;position:var(--position);text-decoration:none;white-space:pre"> from Kreos Capital and Claret European Growth Capital (the &#8220;Kreos / Claret Financing&#8221;) together </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:382.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">with the issuance of warrants (&#8220;the Kreos / Claret BSA&#8221;) exercisable to receive ordinary shares of the Company, for an aggregate </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:393.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">exercise price of up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.27pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;8&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:168.62pt;position:var(--position);text-decoration:none;white-space:pre"> and (ii) up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:225.52pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;75&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:271.87pt;position:var(--position);text-decoration:none;white-space:pre"> from a fund advised by Heights Capital Management, Inc. (the &#8220;Heights </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:404.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Financing&#8221; and together with the Kreos / Claret Financing, the &#8220;Transaction&#8221;). The detailed structure and characteristics of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:416.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Transaction are set forth</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:133.36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> in Notes 15.1 and 15.2.</span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:438.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The first tranches of the Kreos / Claret Financing and the Heights Financing, for </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:359.25pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;25&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:405.6pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:425.03pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;35&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:471.38pt;position:var(--position);text-decoration:none;white-space:pre">, respectively, were </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:449.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">drawn on August 22, 2023, and August 24, 2023, respectively. In addition, the Group concurrently granted to Kreos and Claret, for no </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:460.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">additional consideration, warrants exercisable to receive ordinary shares of the Company for an aggregate exercise price of up to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:472.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;4&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:77.35pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:494.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As part of the Transaction, the Group is also repaying in full a total outstanding amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:399.52pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;33&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:445.87pt;position:var(--position);text-decoration:none;white-space:pre"> under (i) the pre-existing debt </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:505.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">agreements with Kreos for a total amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:215.24pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;8&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:256.59000000000003pt;position:var(--position);text-decoration:none;white-space:pre"> and (ii) the pre-existing OCEANE bonds for a total amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:509.68pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;25&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:556.03pt;position:var(--position);text-decoration:none;white-space:pre"> by </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:516.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">way of set-off with the Heights Financing, thereby fully repaying such pre-existing indebtedness. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:539.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The net proceeds of the drawdown of the first tranche of the Kreos / Claret Financing and of the Heights Financing which, net of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:550.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">refinancing of the existing indebtedness, amount to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:243pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;27&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:289.35pt;position:var(--position);text-decoration:none;white-space:pre"> in the aggregate, are expected to be allocated mainly to the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:561.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">development of obefazimod for the treatment of adults with moderately to severely active UC and other potential chronic </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:572.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">inflammatory indications, as well for working capital and general corporate purposes of the Group. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:595.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On November 2, 2023, the Group granted additional warrants to Kreos and Claret, for an aggregate exercise price of up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:526.5899999999999pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;4&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:567.94pt;position:var(--position);text-decoration:none;white-space:pre">, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:606.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in order to secure the future drawdown of the third tranche of the Kreos / Claret debt financing. The detailed characteristics of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:617.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">issuance is set forth in Note 15.1.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:640.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group announces closing of its Initial Public Offering on the Nasdaq Global Market &#8211; October 2023&#160;  </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:662.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On October 24, 2023, the Group announced the closing of its previously announced initial public offering on the Nasdaq Global </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:674.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Market by way of a capital increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:191.9pt;position:var(--position);text-decoration:none;white-space:pre">20,325,500</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:236.9pt;position:var(--position);text-decoration:none;white-space:pre"> new ordinary shares, consisting of a public offering of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:458.65pt;position:var(--position);text-decoration:none;white-space:pre">18,699,460</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:503.65pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:685.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in the form of American Depositary Shares (&#8220;ADSs&#8221;), each representing the right to receive </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:405.83pt;position:var(--position);text-decoration:none;white-space:pre">one</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:420.26pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary share, in the United States </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:697.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(the &#8220;U.S. Offering&#8221;), and a concurrent offering of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:240.51pt;position:var(--position);text-decoration:none;white-space:pre">1,626,040</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:280.51pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares in certain jurisdictions outside of the United States to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:708.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">certain investors (the &#8220;European Private Placement&#8221;, and together with the U.S. offering, the &#8220;Global Offering&#8221;). The offering price </span></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">was set at </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:77.33pt;position:var(--position);text-decoration:none;white-space:pre">$11.60</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:104.83pt;position:var(--position);text-decoration:none;white-space:pre"> per ADS in the U.S. Offering and a corresponding offering price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:378.77pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;10.9864</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:416.27pt;position:var(--position);text-decoration:none;white-space:pre"> per ordinary share in the European </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:82.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Private Placement. All of the ADSs and ordinary shares in the Global Offering were offered by the Group. The ADSs began trading on </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:93.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the Nasdaq Global Market on October 20, 2023. The aggregate gross proceeds were approximately </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:434.47pt;position:var(--position);text-decoration:none;white-space:pre">$235.8&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:493.32pt;position:var(--position);text-decoration:none;white-space:pre">, equivalent to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:105.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">approximately </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.2pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;223.3&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.05pt;position:var(--position);text-decoration:none;white-space:pre"> based on the exchange rate then in effect, before deduction of underwriting commissions and expenses </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:116.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">payable by the Group.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:140.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The net proceeds of the Global Offering were</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:218.28pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:220.78pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">$212.2&#160;million</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:279.63pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> (</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:285.46000000000004pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;202.0&#160;million</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:344.31pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">), after deducting </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:415.33pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">$23.6&#160;million</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:469.18pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> (</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:475.01pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;21.3&#160;million</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:528.86pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">) i</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:537.46pt;position:var(--position);text-decoration:none;white-space:pre">n </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:151.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">transaction costs. These costs were deducted from the share premiums.</span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 3.2. For the year ended December 31, 2024 </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:238.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Changes in governance &#8211; February-December 2024 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:263.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On February 7, 2024, the Group announced the appointment of Ana Sharma as Vice President, Global Head of Quality. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:289.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On April 2, 2024, the Group announced the appointment of Camilla Soenderby as Independent Board Member and also a member of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:299.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the Appointments and Compensation Committee. Ms. Soenderby replaces Sant&#233; Holdings S.R.L., represented by Mr. Paolo Rampulla, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:309.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">who will continue to contribute to the work of the Board of Directors as an observer alongside Mr. Maurizio PetitBon from Kreos </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:319.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Capital/Blackrock.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:339.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In July 2024, the Group announced the appointment of Sylvie Gr&#233;goire as Independent Board Member, Chairman of the Board and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:347.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">also a member of the Audit Committee. Dr. Gr&#233;goire replaces Ms. Brosgart as Director, Mr. de Garidel as Chairman, and Mr. Hong as </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:355.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">member of the Audit Committee. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:374.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On November 13, 2024, the Group announced the appointment of Mark Stenhouse as Board Observer &amp; Advisor to the Group.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:394.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On December 23, 2024, the Group announced the resignation of Dr. Philippe Pouletty, representative of Truffle Capital, as director of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:404.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the Group, effective on December 31, 2024. </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:427.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Share-based compensation plans</span><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:italic;font-weight:normal;left:168.14pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:174.14pt;position:var(--position);text-decoration:none;white-space:pre">&#8211; February-September 2024 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:456.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In February, March, May, July and September 2024, the Group issued </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:318.85pt;position:var(--position);text-decoration:none;white-space:pre">seven</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:341.6pt;position:var(--position);text-decoration:none;white-space:pre"> free-share compensation plans to certain of its officers </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:466.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and employees, representing a maximum of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:213.3pt;position:var(--position);text-decoration:none;white-space:pre">1,946,125</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:253.3pt;position:var(--position);text-decoration:none;white-space:pre"> shares in the aggregate, the vesting of which is subject to the following service </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:476.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">condition: </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:79.00999999999999pt;position:var(--position);text-decoration:none;white-space:pre">50%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:97.34pt;position:var(--position);text-decoration:none;white-space:pre"> of the AGAs vest at the end of a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:231.1pt;position:var(--position);text-decoration:none;white-space:pre">two</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:246.09pt;position:var(--position);text-decoration:none;white-space:pre">-year</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:266.61pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation date, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:397.27pt;position:var(--position);text-decoration:none;white-space:pre">25%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:415.6pt;position:var(--position);text-decoration:none;white-space:pre"> at the end of a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:477.19pt;position:var(--position);text-decoration:none;white-space:pre">three</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:497.15pt;position:var(--position);text-decoration:none;white-space:pre">-year</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:517.6700000000001pt;position:var(--position);text-decoration:none;white-space:pre"> period from </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:486.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the allocation date and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:128.63pt;position:var(--position);text-decoration:none;white-space:pre">25%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:146.95999999999998pt;position:var(--position);text-decoration:none;white-space:pre"> at the end of a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:208.55pt;position:var(--position);text-decoration:none;white-space:pre">four</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:225.21pt;position:var(--position);text-decoration:none;white-space:pre">-year</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:245.73pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation date (with the exception of the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:479.04pt;position:var(--position);text-decoration:none;white-space:pre">20,000</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:506.54pt;position:var(--position);text-decoration:none;white-space:pre"> 2024-6 AGAs, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:496.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">whose vesting conditions are set forth in Note 14).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:516.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In March 2024, the Group granted its independent Board members the right to subscribe up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:414.27pt;position:var(--position);text-decoration:none;white-space:pre">77,820</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:441.77pt;position:var(--position);text-decoration:none;white-space:pre"> share warrants (BSA) in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:526.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">aggregate, the vesting of which (if subscribed) is subject to a service condition of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:363.13pt;position:var(--position);text-decoration:none;white-space:pre">four years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:403.37pt;position:var(--position);text-decoration:none;white-space:pre">, by tranches of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:467.48pt;position:var(--position);text-decoration:none;white-space:pre">25%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.81pt;position:var(--position);text-decoration:none;white-space:pre"> each, vested on each </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:536.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">anniversary date. All the BSAs have been subscribed.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:559.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Drawdown of Tranches B and C of the Kreos / Claret Financing &#8211; March-June 2024 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:585.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On March 28, 2024 and June 21, 2024, the Group drew down </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:284.5pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;25&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:330.85pt;position:var(--position);text-decoration:none;white-space:pre"> related to tranche B and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:431.26pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;25&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:477.61pt;position:var(--position);text-decoration:none;white-space:pre"> related to tranche C of </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:596.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">senior secured non-convertible bonds from the Kreos / Claret Financing.</span><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:325.7pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:331.7pt;position:var(--position);text-decoration:none;white-space:pre">These second and third tranches each consist of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:524.25pt;position:var(--position);text-decoration:none;white-space:pre">25,000,000</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:569.25pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:610.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">senior secured non-convertible bonds with a par value of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:265.49pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1.00</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:287.99pt;position:var(--position);text-decoration:none;white-space:pre"> each, that will not be listed on any market.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:621.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The detailed characteristics of these bond loans and their accounting treatments are set forth in Note 15.1.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:646.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Bpifrance RNP-VIR and Carena conditional advances &#8211; June 2024</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:671.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In June 2024, the Group and Bpifrance renegotiated the RNP-VIR and CARENA conditional advances:</span></div><div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Between September 2017 and November 2019, the Group had received repayable conditional advances amounting </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:84.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;4,032&#160;thousands</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:141.98000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> and subsidies amounting to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:256.06pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,123&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:322.15pt;position:var(--position);text-decoration:none;white-space:pre"> in relation to the RNP-VIR project, which aimed at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:98.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">discovering new molecules for the treatment of viral infectious diseases through the development of the &#8220;Modulation of RNA </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:111.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">biogenesis&#8221; platform. In June 2024, the Group and Bpifrance agreed to terminate the project due to technical failure, and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:125.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Bpifrance agreed to waive </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:179.62pt;position:var(--position);text-decoration:none;white-space:pre">60%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:197.95pt;position:var(--position);text-decoration:none;white-space:pre"> of the remaining advances. See Note 15.7 "Conditional Advances".</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:153.36pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Between December 2013 and June 2016, the Group had received repayable conditional advances amounting </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:167.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;2,187&#160;thousands</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:141.98000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> in relation to the CARENA project, which aimed at developing an anti-HIV-AIDS therapeutic program </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:180.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">with the compound ABX464 up to the Phase 2b study. In June 2024, the Group and Bpifrance agreed to terminate the project </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:194.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">due to technical failure, and Bpifrance agreed to waive </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:293.34000000000003pt;position:var(--position);text-decoration:none;white-space:pre">60%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:311.66999999999996pt;position:var(--position);text-decoration:none;white-space:pre"> of the remaining conditional advance. See Note 15.7 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:208.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">"Conditional Advances".</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:233.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group fully reimbursed the remaining conditional advances for both programs during the last quarter of 2024. The subsidy </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:245.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">income recognized over the period, corresponding to the amounts waived by Bpifrance and related interests, amounts to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:256.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;4,123&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:102.09pt;position:var(--position);text-decoration:none;white-space:pre"> in the aggregate (see Note 18).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:291.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Establishment of an At-the-Market ("ATM") Program on Nasdaq - November 2024</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:314.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On November 19, 2024, the Group announced the implementation of an At-The-Market program (&#8220;ATM Program&#8221;) allowing the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:325.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Group to issue and sell, including with unsolicited investors who have expressed an interest, ordinary shares in the form of ADSs, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:337.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">each ADS representing </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:131.17000000000002pt;position:var(--position);text-decoration:none;white-space:pre">one</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:145.6pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary share, nominal value </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:269.90999999999997pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.01</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:292.41pt;position:var(--position);text-decoration:none;white-space:pre"> per share, of the Group, with aggregate gross sales proceeds of up to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:348.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">$150,000&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.09pt;position:var(--position);text-decoration:none;white-space:pre"> (subject to French regulatory limits and within the limits of the investors&#8217; requests expressed in the context of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:360.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">program), from time to time, pursuant to the terms of an equity distribution agreement with Piper Sandler &amp; Co. (&#8220;Piper Sandler&#8221;), </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:371.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">acting as sales agent. The timing of any issuances in the form of ADSs will depend on a variety of factors. The ATM Program will be </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:383.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">effective until terminated in accordance with the equity distribution agreement or if ADSs representing the maximum gross sales </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:394.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">proceeds have been sold thereunder. To the extent that ADSs are sold pursuant to the ATM Program, the Group currently intends to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:406.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">use the net proceeds (after deduction of fees and expenses), if any, of sales of ADSs issued under the ATM Program primarily to fund </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:417.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the research and development of the Group's product candidates, for working capital and general corporate purposes, at its discretion.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:440.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">A shelf registration statement on Form F-3, including a base prospectus relating to the Group's securities and an equity distribution </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:452.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">agreement prospectus relating to the ATM Program, was filed with the SEC and went into effect during 2024. The base prospectus </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:463.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">provides for the potential sale of ADSs of the Group with aggregate gross sales proceeds of up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:426.75pt;position:var(--position);text-decoration:none;white-space:pre">$350,000&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:502.84pt;position:var(--position);text-decoration:none;white-space:pre"> (including the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:475.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">$150,000&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.09pt;position:var(--position);text-decoration:none;white-space:pre"> covered by the equity distribution agreement prospectus) to grant additional flexibility to the Group in connection </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:486.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">with its financing strategy. The specific terms of any securities to be offered pursuant to the base prospectus will be specified in one or </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:498.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">more prospectus supplements to the base prospectus. As of the date of issuance of these financial statements, the Group has not </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:509.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">utilized the ATM Program. </span></div></div><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 3.3</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:70.42pt;position:var(--position);text-decoration:none;white-space:pre">. For the year ended December 31, 2025 </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:92.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Share-based compensation plans</span><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:italic;font-weight:normal;left:168.14pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:171.14pt;position:var(--position);text-decoration:none;white-space:pre">&#8211; January-</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:214.72pt;position:var(--position);text-decoration:none;white-space:pre">November </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:258.28pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:118.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In January 2025, the Group granted its independent Board members, as well as one of its Board Observers and Advisor, the right to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:130.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">subscribe up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:99.00999999999999pt;position:var(--position);text-decoration:none;white-space:pre">125,000</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:131.51pt;position:var(--position);text-decoration:none;white-space:pre"> share warrants (BSA) in the aggregate, the vesting of which is subject to a service condition of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:514.69pt;position:var(--position);text-decoration:none;white-space:pre">four years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:554.93pt;position:var(--position);text-decoration:none;white-space:pre">, by </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:142.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">tranches of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:82.61pt;position:var(--position);text-decoration:none;white-space:pre">25%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:100.94pt;position:var(--position);text-decoration:none;white-space:pre"> each, vested on January 1 of each year.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:166.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In February, March, May, August and November 2025,</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:257.8pt;position:var(--position);text-decoration:none;white-space:pre"> the Group issued </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:330.53pt;position:var(--position);text-decoration:none;white-space:pre">eight</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:350.5pt;position:var(--position);text-decoration:none;white-space:pre"> free-share compensation plans to certain of its officers </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:178.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and employees, representing a maximum o</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:207.47pt;position:var(--position);text-decoration:none;white-space:pre">f </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:213.3pt;position:var(--position);text-decoration:none;white-space:pre">6,280,727</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:253.3pt;position:var(--position);text-decoration:none;white-space:pre"> shares in the aggregate, the vesting of which is subject to the following service </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:190.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">condition: </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:79.00999999999999pt;position:var(--position);text-decoration:none;white-space:pre">50%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:97.34pt;position:var(--position);text-decoration:none;white-space:pre"> of the AGAs vest at the end of a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:231.1pt;position:var(--position);text-decoration:none;white-space:pre">two</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:246.09pt;position:var(--position);text-decoration:none;white-space:pre">-year</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:266.61pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation date, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:397.27pt;position:var(--position);text-decoration:none;white-space:pre">25%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:415.6pt;position:var(--position);text-decoration:none;white-space:pre"> at the end of a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:477.19pt;position:var(--position);text-decoration:none;white-space:pre">three</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:497.15pt;position:var(--position);text-decoration:none;white-space:pre">-year</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:517.6700000000001pt;position:var(--position);text-decoration:none;white-space:pre"> period from </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:202.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the allocation date and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:128.63pt;position:var(--position);text-decoration:none;white-space:pre">25%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:146.95999999999998pt;position:var(--position);text-decoration:none;white-space:pre"> at the end of a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:208.55pt;position:var(--position);text-decoration:none;white-space:pre">four</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:225.21pt;position:var(--position);text-decoration:none;white-space:pre">-year</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:245.73pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation date (with the exception of the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:479.04pt;position:var(--position);text-decoration:none;white-space:pre">123,102</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:511.54pt;position:var(--position);text-decoration:none;white-space:pre"> 2025-2 AGAs, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:214.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">which vest at the end of a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.6pt;position:var(--position);text-decoration:none;white-space:pre">two</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.59pt;position:var(--position);text-decoration:none;white-space:pre">-year</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:176.11pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation date, and the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:338.4pt;position:var(--position);text-decoration:none;white-space:pre">50,000</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:365.9pt;position:var(--position);text-decoration:none;white-space:pre"> 2025-5 AGAs , which vest only upon the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:226.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">achievement of milestones related to clinical studies). Moreover, the vesting of almost half of the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:426.88pt;position:var(--position);text-decoration:none;white-space:pre">4,319,500</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:466.88pt;position:var(--position);text-decoration:none;white-space:pre"> 2025-1 AGAs is subject to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:238.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the occurrence of a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.77pt;position:var(--position);text-decoration:none;white-space:pre">tender offer on the securities issued by the Group and resulting in a change of control of the Group</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:509.38pt;position:var(--position);text-decoration:none;white-space:pre"> before a certain </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:250.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">date. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:274.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In April 2025, the Group granted to one of its Board members the right to subscribe up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:395.98pt;position:var(--position);text-decoration:none;white-space:pre">39,370</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:423.48pt;position:var(--position);text-decoration:none;white-space:pre"> share warrants (BSA), the vesting of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:286.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">which is subject to a service condition of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:201.92pt;position:var(--position);text-decoration:none;white-space:pre">four years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:242.16pt;position:var(--position);text-decoration:none;white-space:pre">, by tranches of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:306.27pt;position:var(--position);text-decoration:none;white-space:pre">25%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:324.6pt;position:var(--position);text-decoration:none;white-space:pre"> each, vested on May 1 of each year. The BSAs were </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:298.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">subscribed in May 2025.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:322.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The detailed terms and conditions of these plans are set forth in Note 14.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:346.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Change in management &#8211; April 2025</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:369.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On April 22, 2025, the Group announced the appointment of Dominik H&#246;chli, MD to the Board of Directors of Abivax, effective </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:381.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">immediately.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:405.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Completion of enrollment for the Phase 3 ABTECT trials in patients with moderately to severely active UC - April 2025</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:429.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On April 29, 2025, the Group announced the completion of enrollment for the Phase 3 ABTECT trials in patients with moderately to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:441.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">severely active UC.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:465.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Publication of positive Phase 3 results from both ABTECT 8-week induction trials investigating obefazimod, in moderate to severely </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:477.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">active UC </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:78.71000000000001pt;position:var(--position);text-decoration:none;white-space:pre">&#8211;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:83.71000000000001pt;position:var(--position);text-decoration:none;white-space:pre"> July 2025 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:501.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On July 22, 2025, the Group announced the positive results of the ABTECT-1 and ABTECT-2 induction trials in patients with </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:513.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">moderately to severely active UC. ABTECT-1 and 2 are global, multicenter, randomized, double-blind, placebo-controlled trials </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:525.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">assessing once-daily oral administration of obefazimod at 25 mg or 50 mg doses in adult patients with moderately to severely active </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:537.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">UC. Eligible participants had inadequate response, loss of response, or intolerance to conventional and/or advanced therapies.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:561.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Following this announcement and that of its Offering completed on July 28, 2025 (see </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:383.19pt;position:var(--position);text-decoration:none;white-space:pre">Completion of a public offering &#8211; July 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:558.31pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:573.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">within this section), the Group&#8217;s share price increased significantly, from </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:330.66pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.64</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:353.16pt;position:var(--position);text-decoration:none;white-space:pre"> as of June 30, 2025, to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:448.4pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;57.00</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:475.9pt;position:var(--position);text-decoration:none;white-space:pre"> as of July 28, 2025.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:584.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">At the same time, the Group reassessed the probability of success (&#8220;POS&#8221;) of obtaining a future market authorization for obefazimod </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:595.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in UC, to reflect a reduced level of uncertainty following positive Phase 3 results.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:618.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The main financial effects of this event on the Group&#8217;s financial statements are the following:</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:640.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">A significant increase in the carrying value of the royalty certificates, measured at amortized cost, reflecting an increase in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:652.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">projected probability-weighted cash flows of the instrument, following the reassessment of the POS (see Note 15.9),</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:674.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Significant changes in the carrying value of the Group&#8217;s financial liabilities measured at fair value through profit or loss, i.e. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:685.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the Kreos / Claret BSA, the Kreos / Claret MRI and the Heights convertible notes (the latter as well as the Kreos / Claret BSA </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:697.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">being converted into ordinary shares at the request of the noteholders in July and August 2025, see </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:468.85pt;position:var(--position);text-decoration:none;white-space:pre">Conversion of the Heights </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:708.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">convertible notes, Kreos / Claret OCABSA and Kreos / Claret BSA &#8211;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:346.71pt;position:var(--position);text-decoration:none;white-space:pre"> July-August 2025 below </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:448.29pt;position:var(--position);text-decoration:none;white-space:pre">and Notes 15.1 and 15.2</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:545.46pt;position:var(--position);text-decoration:none;white-space:pre">),</span></div></div><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:82.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Significant changes in the disclosure of the fair values of other financial instruments measured at amortized cost (i.e. the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:93.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">royalty certificates, the debt components of (i) the Kreos / Claret OCABSA (Tranche A, converted into shares in August </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:104.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">2025) and (ii) Tranche B and C bond loans; these fair value changes are not expected directly to impact the future financial </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:115.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">position and net loss of the Group - see Note 15),</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:138.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">A significant increase in provisions related to employer contributions on AGAs (the contribution being based on the vesting </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:149.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">date share price - see Note 14).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:182.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Completion of a public offering </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:164.49pt;position:var(--position);text-decoration:none;white-space:pre">&#8211;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:169.49pt;position:var(--position);text-decoration:none;white-space:pre"> July 2025 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:206.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On July 28, 2025, the Group announced the completion of an underwritten public offering of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:409.86pt;position:var(--position);text-decoration:none;white-space:pre">11,679,400</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:454.86pt;position:var(--position);text-decoration:none;white-space:pre"> ADSs (the &#8220;Offering&#8221;) at a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:218.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:69.28999999999999pt;position:var(--position);text-decoration:none;white-space:pre">$64.00</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.78999999999999pt;position:var(--position);text-decoration:none;white-space:pre"> per ADS (corresponding to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:210.33pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;54.58</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:237.83pt;position:var(--position);text-decoration:none;white-space:pre"> per ordinary share, based on the exchange rate of &#8364;1.00 = $</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:477.12pt;position:var(--position);text-decoration:none;white-space:pre">1.1726</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:504.62pt;position:var(--position);text-decoration:none;white-space:pre"> as published by </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:230.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the European Central Bank on July 23, 2025). The aggregate gross proceeds amounted to approximately </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:455.3pt;position:var(--position);text-decoration:none;white-space:pre">$747.5&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:514.15pt;position:var(--position);text-decoration:none;white-space:pre">, equivalent to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:242.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">approximately </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.2pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;637.5&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.05pt;position:var(--position);text-decoration:none;white-space:pre">, before deduction of underwriting commissions and estimated expenses, and the net proceeds, after </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:254.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">deducting underwriting commissions and estimated offering expenses, were approximately </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:402.26pt;position:var(--position);text-decoration:none;white-space:pre">$700.3&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:461.11pt;position:var(--position);text-decoration:none;white-space:pre">, equivalent to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:266.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">approximately </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.2pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;597.2&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.05pt;position:var(--position);text-decoration:none;white-space:pre">. The net cash from the Offering of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:297.4pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;607.2</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:324.9pt;position:var(--position);text-decoration:none;white-space:pre"> million presented within the Consolidated Statements of Cash </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:278.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Flows also includes the effect of a net foreign exchange gain </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:280.98pt;position:var(--position);text-decoration:none;white-space:pre">resulting from the favorable change in the euro to U.S. dollar exchange </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:290.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">rate between the closing of the Offering and the date of receipt of funds.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:314.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group believes that the net proceeds from the Offering, together with its current cash and cash equivalents, will allow it to finance </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:326.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">its operations into the fourth quarter of 2027, allowing it to reach 12 months of expected cash runway following the planned NDA </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:338.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">submission for UC, assuming positive results from its Phase 3 maintenance trial (see Note 2 above "Going concern").</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:374.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Conversion of the Heights convertible notes, Kreos OCABSA and Kreos / Claret BSA and prepayment of the Kreos / Claret Tranches </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:386.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">B and C bond loans &#8211;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:122.92pt;position:var(--position);text-decoration:none;white-space:pre"> July-December 2025 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:409.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On July 23 and July 30, 2025, the Group received notices from entities affiliated with Heights Capital Management, which hold </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:421.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">amortizing senior convertible notes of the Group issued in August 2023 (the &#8220;Height convertible notes&#8221;), for the immediate conversion </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:433.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:97.58pt;position:var(--position);text-decoration:none;white-space:pre">150</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.58pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:132.01pt;position:var(--position);text-decoration:none;white-space:pre">200</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:147.01pt;position:var(--position);text-decoration:none;white-space:pre"> convertible notes (corresponding to the entirety of the outstanding principal amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:497.47pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;21.9&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:551.32pt;position:var(--position);text-decoration:none;white-space:pre">) into </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:445.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">920,377</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:68.5pt;position:var(--position);text-decoration:none;white-space:pre"> new ordinary shares of the Group at a conversion price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:303.83pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;23.7674</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:341.33pt;position:var(--position);text-decoration:none;white-space:pre"> per ordinary share in accordance with the terms and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:457.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">conditions of the convertible notes.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:481.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.96pt">On August 8, 2025, Kreos Capital VII (UK) Limited converted its portion of the Tranche A of the Kreos / Claret Financing (the Kreos</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.96pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:492.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:163.21pt">OCABSA), resulting in the issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:199.21pt;position:var(--position);text-decoration:none;white-space:pre;width:32.5pt">785,389</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:231.71pt;position:var(--position);text-decoration:none;white-space:pre;width:344.2pt"> ordinary shares. In addition, on July 30, 2025, Kreos Capital VII Aggregator SCSp</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.91pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:503.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:414.04pt">exercised its share warrants (the tranche A-B BSA and tranche C BSA) resulting in the issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:450.04pt;position:var(--position);text-decoration:none;white-space:pre;width:32.5pt">319,251</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:482.54pt;position:var(--position);text-decoration:none;white-space:pre;width:93.36pt"> ordinary shares of the</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.9pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:514.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:28.05pt">Group.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:537.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On August 28, 2025, Claret European Growth Capital Fund III SCSp exercised its share warrants (the tranche A-B BSA and tranche C </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:549.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">BSA) resulting in the issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:170.87pt;position:var(--position);text-decoration:none;white-space:pre">206,662</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:203.37pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares of the Group.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:573.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On November 25, 2025, Claret European Growth Capital Fund III SCSp converted its portion of the Tranche A portion of the Kreos / </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:584.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Claret Financing (the Claret OCABSA), resulting in the issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:308.74pt;position:var(--position);text-decoration:none;white-space:pre">392,695</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:341.24pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares of the Group. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:607.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On December 23, 2025, the Group completed the full prepayment of the outstanding balances of Tranches B and C of the Kreos / </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:619.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Claret Financing. The repayment amount, including end-of-loan exit fees and prepayment fees, amounts to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:465.22pt;position:var(--position);text-decoration:none;white-space:pre">33,823&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:531.31pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:643.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Following these transactions, the Group no longer holds any debt related to the Kreos / Claret and Heights Financings.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:666.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The impacts of these operations on the Group's financial statements are set forth in Note 15.1 and 15.2.</span></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Admission to the CAC Mid 60 and SBF 120 indices - September 2025</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:94.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Following the annual review of the Euronext Paris indices on September 11, 2025, the Scientific Council of the Indices has decided to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:106.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">admit the Company to the CAC Mid 60 and SBF 120 indices. This decision took effect on Friday, September 19, 2025, after market </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:118.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">close. The CAC Mid 60 and SBF 120 are key indices on the Euronext Paris exchange, representing mid-sized listed companies and a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:130.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">broader selection of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:117.84pt;position:var(--position);text-decoration:none;white-space:pre">120</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:132.84pt;position:var(--position);text-decoration:none;white-space:pre"> major securities, respectively.</span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 3.4. Subsequent events&#160; </span><div style="font-size:12pt;line-height:12pt;position:var(--position);top:226.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Share-based compensation plans</span><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:italic;font-weight:normal;left:168.14pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:171.14pt;position:var(--position);text-decoration:none;white-space:pre">&#8211; February 2026</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:252.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In February 2026, the Group issued a new free-share compensation plan to certain of its officers and employees, representing a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:264.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">maximum of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:89.84pt;position:var(--position);text-decoration:none;white-space:pre">47,500</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:117.34pt;position:var(--position);text-decoration:none;white-space:pre"> shares in the aggregate, the vesting of which is subject to the following service condition: </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:479.98pt;position:var(--position);text-decoration:none;white-space:pre">50%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:498.31pt;position:var(--position);text-decoration:none;white-space:pre"> of the AGAs vest </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:276.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">at the end of a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:95.09pt;position:var(--position);text-decoration:none;white-space:pre">two</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:110.08pt;position:var(--position);text-decoration:none;white-space:pre">-year</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:130.6pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation date, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:261.26pt;position:var(--position);text-decoration:none;white-space:pre">25%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:279.59000000000003pt;position:var(--position);text-decoration:none;white-space:pre"> at the end of a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:341.18pt;position:var(--position);text-decoration:none;white-space:pre">three</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:361.14pt;position:var(--position);text-decoration:none;white-space:pre">-year</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:381.66pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation date and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:526.75pt;position:var(--position);text-decoration:none;white-space:pre">25%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:545.0799999999999pt;position:var(--position);text-decoration:none;white-space:pre"> at the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:288.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">end of a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:70.69pt;position:var(--position);text-decoration:none;white-space:pre">four</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:87.35pt;position:var(--position);text-decoration:none;white-space:pre">-year</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:107.87pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation date.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:312.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In February 2026,</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:107.91pt;position:var(--position);text-decoration:none;white-space:pre"> the Group granted its independent Board members, as well as one of its Board Observers and Advisor, the right to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:324.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">subscribe up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:99.00999999999999pt;position:var(--position);text-decoration:none;white-space:pre">23,477</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:126.51pt;position:var(--position);text-decoration:none;white-space:pre"> share warrants (BSA) in the aggregate, the vesting of which (if subscribed) is subject to a service condition of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:336.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">four</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:52.66pt;position:var(--position);text-decoration:none;white-space:pre"> years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:76.24000000000001pt;position:var(--position);text-decoration:none;white-space:pre">, by tranches of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.35pt;position:var(--position);text-decoration:none;white-space:pre">25%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.68pt;position:var(--position);text-decoration:none;white-space:pre"> each, vested on each February 1st thereafter. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:360.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:underline;white-space:pre">Changes in Management - March</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:384.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In March 2026, the Group appointed Michael Nesrallah, MBA, as Chief Commercial Officer, Keith Fournier, Ph.D., as Senior Vice </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:395.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">President of Global Regulatory Affairs, and Maurus de la Rosa, Ph.D., Senior Vice President of Research.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:417.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In March 2026, Sofinnova Partners, represented by Dr. Kinam Hong, stepped down from the Group's Board of Directors.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:440.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In light of Mr. Didier Scherrer's departure from his role as Chief Scientific Officer, the Group entered into a settlement agreement </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:451.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">("protocole d&#8217;accord transactionnel") with Mr. Didier Scherrer under which:</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:462.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Mr. Scherrer received a balance of notice pay in the total gross amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:368.58pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;278 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:427.17pt;position:var(--position);text-decoration:none;white-space:pre">, together with a contractual </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:473.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">severance indemnity of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:167.70999999999998pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;240 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:226.3pt;position:var(--position);text-decoration:none;white-space:pre"> (net);</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:485.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the Group waived the continued employment condition attached to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:341.41pt;position:var(--position);text-decoration:none;white-space:pre">77,050</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:368.91pt;position:var(--position);text-decoration:none;white-space:pre"> free shares previously granted to Mr. Scherrer;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:496.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the Group waived the continued employment condition for a further </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:346.16pt;position:var(--position);text-decoration:none;white-space:pre">40,200</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:373.66pt;position:var(--position);text-decoration:none;white-space:pre"> free shares, subject to specific performance </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:507.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">conditions;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:518.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the remaining </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.7pt;position:var(--position);text-decoration:none;white-space:pre">217,750</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:162.2pt;position:var(--position);text-decoration:none;white-space:pre"> free shares previously granted to Mr. Scherrer are lapsed; and</span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span>Mr. Scherrer irrevocably waived all claims and renounced any legal action against the Group.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_AccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting Principles [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_AccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DisclosureOfSignificantEventsForThePeriodReportedAndEventsAfterReportingPeriodTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Significant Events For The Period Reported And Events After Reporting Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DisclosureOfSignificantEventsForThePeriodReportedAndEventsAfterReportingPeriodTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting principles<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_AccountingPrinciplesAbstract', window );"><strong>Accounting Principles [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory', window );">Accounting principles</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:68.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Accounting principles </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 4.1. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre">Goodwill </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:591.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Following initial recognition, goodwill is stated at cost less any accumulated impairment losses (see Note 4.4). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:613.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In respect of business combinations prior to January 1, 2020, in accordance with IFRS 1 exemption, goodwill is included on the basis </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:623.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of its deemed cost, which represents the amount recorded under the prior basis of accounting, French GAAP, (&#8220;Previous GAAP&#8221;). </span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 4.2. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre">Intangible assets </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:667.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Pursuant to IAS 38&#8212;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:122.36pt;position:var(--position);text-decoration:none;white-space:pre">Intangible Assets</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:190.9pt;position:var(--position);text-decoration:none;white-space:pre">, intangible assets acquired are recognized as assets on the statements of financial position at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:677.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">their acquisition cost. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Licenses, patents and development costs </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:86.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Payments for separately acquired research and development are capitalized within &#8220;intangible assets&#8221; provided that they meet the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:96.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">definition of an intangible asset: a resource that is (i)&#160;controlled by the Group, (ii) expected to provide future economic benefits for the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:106.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Group and (iii)&#160;identifiable (i.e., it is either separable or arises from contractual or legal rights). In accordance with paragraph 25 of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:116.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">IAS 38&#8212;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:74.61pt;position:var(--position);text-decoration:none;white-space:pre">Intangible Assets</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:143.15pt;position:var(--position);text-decoration:none;white-space:pre">, the recognition criterion relating to the likelihood of future economic benefits generated by the intangible </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">asset, is presumed to be achieved for research and development activities when they are acquired separately. In this context, amounts </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:136.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">paid to third parties in the form of initial payments or milestone payments relating to pharmaceutical specialties that have not yet </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:146.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">obtained a marketing authorization are recognized as intangible assets. These rights will be amortized on a straight-line basis, after </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:156.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">obtaining the marketing authorization, over their useful life. Unamortized rights (before marketing authorization) are subject to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:166.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">impairment tests in accordance with the method defined in Note 4.4.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:188.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Research and development costs</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:206.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Pursuant to IAS 38 &#8211; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:122.36pt;position:var(--position);text-decoration:none;white-space:pre">Intangible Assets</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:190.9pt;position:var(--position);text-decoration:none;white-space:pre">, research costs are expensed in the period during which they are incurred. Development costs </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:216.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">are only recognized as intangible assets if the following criteria are met: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:232.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">it is technically feasible to complete the development of the project; </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:248.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">it is th</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:116.02000000000001pt;position:var(--position);text-decoration:none;white-space:pre">e Group&#8217;s intention to complete the project and to utilize it; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:264.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">it has capacity to utilize the intangible asset; </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:280.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">there is proof of the probability of future economic benefits associated with the asset </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:296.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">there is availability of the technical, financial and other resources for completing the project; and </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:312.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">there is a reliable evaluation of the development expenses. </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:334.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The initial measurement of the asset is the sum of expenses incurred starting on the date on which the development project meets the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:344.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">above criteria. Because of the risks and uncertainties related to regulatory authorizations and to the research and development process, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:354.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the Group believes that the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:146.14pt;position:var(--position);text-decoration:none;white-space:pre">six</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:157.8pt;position:var(--position);text-decoration:none;white-space:pre"> criteria stipulated by IAS 38 have not been fulfilled to date and the application of this principle has </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:364.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">resulted in all development costs being expensed as incurred in all periods presented. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:392.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Other intangible assets </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:408.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Other intangible assets mainly consist of acquired software. Costs related to the acquisition of software licenses are recognized as </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:418.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">assets based on the costs incurred to acquire and set up the related software. Other intangible assets are amortized using the straight-</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:428.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">line method over a period of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:151.99pt;position:var(--position);text-decoration:none;white-space:pre">one year</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:186.11pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 4.3. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre">Property, plant and equipment </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:472.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Pursuant to IAS 16 &#8211; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:122.36pt;position:var(--position);text-decoration:none;white-space:pre">Property, Plant and Equipment</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:247.8pt;position:var(--position);text-decoration:none;white-space:pre">, property, plant and equipment are recognized at their acquisition cost (purchase </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:482.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">price and directly attributable costs) or at their production cost by the Group, as applicable. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:504.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Property, plant and equipment are depreciated using the straight-line method over the estimated useful life of the asset. The principal </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:514.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">useful lives applied are as follows: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:524.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="position:var(--position);top:534.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:324pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:150.75pt"></td><td style="padding:0;width:95.25pt"></td><td style="padding:0;width:78pt"></td></tr><tr style="height:15.75pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:15.75pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td colspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:15.75pt;width:173.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:173.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;position:var(--position);text-decoration:none;white-space:pre">DEPRECIATION PERIOD</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:30pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Buildings</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:30pt;width:95.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:30pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:44.25pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Office fixtures and fittings</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:44.25pt;width:95.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:3.67pt;width:95.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:45.13pt;position:var(--position);text-decoration:none;white-space:pre">3 years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:73.71pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span><span style="font-family:'Times New Roman', serif;font-size:6.5pt;font-style:normal;font-weight:normal;left:76.21pt;position:var(--position);text-decoration:none;top:-2.4254999999999995pt;vertical-align:super;white-space:pre">(1)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:44.25pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:58.5pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Equipment</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:58.5pt;width:95.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:58.5pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:72.75pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Industrial materials and equipment</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:72.75pt;width:95.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:21.95pt;position:var(--position);text-decoration:none;white-space:pre">5</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:26.95pt;position:var(--position);white-space:pre"> to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.72pt;position:var(--position);text-decoration:none;white-space:pre">10 years</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:72.75pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:87pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Technical facilities</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:87pt;width:95.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:21.95pt;position:var(--position);text-decoration:none;white-space:pre">5</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:26.95pt;position:var(--position);white-space:pre"> to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.72pt;position:var(--position);text-decoration:none;white-space:pre">10 years</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:87pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:101.25pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Furniture and computer equipment:</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:101.25pt;width:95.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:101.25pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:115.5pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Office equipment</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:115.5pt;width:95.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:21.95pt;position:var(--position);text-decoration:none;white-space:pre">5</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:26.95pt;position:var(--position);white-space:pre"> to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.72pt;position:var(--position);text-decoration:none;white-space:pre">10 years</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:115.5pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:129.75pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">IT equipment</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:129.75pt;width:95.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;  &#160;&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:45.13pt;position:var(--position);text-decoration:none;white-space:pre">3 years</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:129.75pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:144pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Furniture</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:144pt;width:95.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:22.08pt;position:var(--position);white-space:pre">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.58pt;position:var(--position);text-decoration:none;white-space:pre">10 years</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:144pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:35.95pt;position:var(--position)">(1)<span style="display:inline-block;height:6.93pt;width:12.84pt"></span></span><span style="left:60.45pt;position:var(--position)">Office fixtures and fittings estimated useful lives correspond to the Paris headquarters and Boston offices residual estimated </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:80.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:60.45pt;position:var(--position);text-decoration:none;white-space:pre">lease terms. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:102.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The useful lives of property, plant and equipment as well as any residual values are reviewed at each year-end and, in the event of a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:112.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">significant change, the depreciation schedule is revised prospectively. </span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 4.4. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre">Impairment of goodwill, intangible assets, property and plant and equipment </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:156.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Goodwill and intangible assets not yet available for use are not amortized and are tested for impairment annually. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:178.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In addition, the Group assesses at the end of each reporting period whether there is an indication that intangible assets and property, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:188.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">plant and equipment may be impaired. Pursuant to IAS 36&#8212;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:278.56pt;position:var(--position);text-decoration:none;white-space:pre">Impairment of Assets</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:362.93pt;position:var(--position);text-decoration:none;white-space:pre">, criteria for assessing indication of loss in value may </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:198.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">notably include performance levels lower than forecast, a significant change in market data or the regulatory environment, or </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:208.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">obsolescence or physical damage of the asset not included in the amortization/depreciation schedule. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:230.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">For the purpose of impairment testing, goodwill and intangible assets not yet available for use are allocated to each of the Group&#8217;s </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:240.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">CGUs expected to benefit from synergies arising from the business combination or from the use of the intangible assets. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:262.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">An impairment loss is recognized when the carrying amount of a CGU, including the goodwill, exceeds the recoverable amount of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:272.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">CGU. The recoverable amount of a CGU is the higher of the CGU&#8217;s fair value less cost to sell and value-in-use. The total impairment </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:282.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">loss of a CGU is allocated first to reduce the carrying amount of goodwill allocated to the CGU and then to the other assets of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:292.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">CGU pro-rata on the basis of the carrying amount of each asset in the CGU. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:314.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">An impairment loss on goodwill is not reversed in a subsequent period. Impairment losses on intangible assets and property, plant and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:324.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">equipment shall be reversed subsequently if the impairment loss no longer exists or has decreased. </span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 4.5. Financial assets </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:368.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Financial assets at amortized cost </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:384.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Other financial assets (advances, loans and deposits granted to third parties and other short-term investments) and other receivables are </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:394.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">non-derivative financial assets with fixed or determinable payments that are not listed on an active market. They are initially </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:404.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">recognized at fair value plus transaction costs that are directly attributable to the acquisition or issue of the financial asset. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:420.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">IFRS 9 &#8211; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:74.61pt;position:var(--position);text-decoration:none;white-space:pre">Financial Instruments </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:165.64pt;position:var(--position);text-decoration:none;white-space:pre">requires an entity to recognize a loss allowance for expected credit losses on a financial asset at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:430.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">amortized cost at each statement of financial position date. The amount of the loss allowance for expected credit losses equal to: (i)&#160;the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:440.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">12&#8212;month expected credit losses or (ii)&#160;the full lifetime expected credit losses. The latter applies if credit risk has increased </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:450.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">significantly since initial recognition of the financial instrument. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:478.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Cash and cash equivalents </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:494.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group classifies investments as cash equivalents in the statements of financial position and statements of cash flows when they </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:504.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">meet the conditions of IAS 7&#8212;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:161.17000000000002pt;position:var(--position);text-decoration:none;white-space:pre">Statement of Cash Flows, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:265.8pt;position:var(--position);text-decoration:none;white-space:pre">i.e., when they are: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:520.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">held in order to face short-term cash commitments; and </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:536.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">short term and highly liquid assets at acquisition date, readily convertible into known amount of cash and not exposed to </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:546.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">any material risk of change in value. </span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 4.6. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre">Share capital </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:590.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Ordinary shares are classified in shareholders&#8217; equity. Costs associated with the issuance of new shares are directly accounted for in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:600.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">shareholders&#8217; equity in diminution of issuance premium. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:622.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group&#8217;s own shares bought in the context of a brokering/liquidity agreement entered with an independent broker are presented as </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:632.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">a reduction of shareholders&#8217; equity until their cancellation, their reissuance or their disposal. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 4.7. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre">Share-based payments </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:96.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Since its inception, the Group has established several plans for compensation settled in equity instruments in the form of founders&#8217; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:106.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">share subscription warrants (&#8220;bons de souscription de parts de cr&#233;ateur d&#8217;entreprise&#8221; or &#8220;BCE&#8221;), share subscription warrants (&#8220;Bons de </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:116.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">souscription d&#8217;actions,&#8221; or &#8220;BSA&#8221;) and free shares (&#8220;Attributions gratuites d&#8217;actions,&#8221; or &#8220;AGA&#8221;), granted to its employees, corporate </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">officers and scientific consultants. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:148.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Pursuant to IFRS 2&#8212;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:122.36pt;position:var(--position);text-decoration:none;white-space:pre">Share-based Payment, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:214.78pt;position:var(--position);text-decoration:none;white-space:pre">these awards are measured at their fair value on the date of grant. The values of the equity </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:158.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">instruments are determined using the option pricing model (in particular, a Black and Scholes model for the BCE and BSA plans and a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:168.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Monte-Carlo simulation for the AGA plans which include market performance vesting conditions) based on the value of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:178.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">underlying equity instrument at grant date, the volatility observed in a sample of comparable listed companies and the estimated life of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:188.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the related equity instruments. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:210.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group recognizes the fair value of these awards as a share-based compensation expense over the period in which the related </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:220.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">services are received, i.e. over the vesting period, with a corresponding increase in shareholders&#8217; equity. Share-based compensation is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:230.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">recognized by installments in consistency with their graded vesting schedule, when applicable. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:252.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:262.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">performance conditions are expected to be met, such that the amount ultimately recognized is based on the number of awards that meet </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:272.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the related service and non-market performance conditions at the vesting date. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:294.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">For share-based payment awards with market vesting conditions and non-vesting conditions, the grant-date fair value of the share-</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:304.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">based payment is measured to reflect such conditions and there is no true-up for differences between expected and actual outcome. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:314.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The measurement of the fair value of BSA, BCE and AGA incorporates the market-based vesting conditions and non-vesting </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:324.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">conditions as described in Note 4.15 &#8220;Use of judgments and estimates&#8221;. </span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 4.8. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre">Financial liabilities </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:374.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:underline;white-space:pre">Note 4.8.1. Financial liabilities at amortized cost</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:402.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Pursuant to IFRS 9 &#8211; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:122.36pt;position:var(--position);text-decoration:none;white-space:pre">Financial Instruments, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:215.89pt;position:var(--position);text-decoration:none;white-space:pre">the borrowings, the debt component of the Kreos / Claret OCABSA (classified as </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:412.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">convertible loan notes &#8211; see </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:149.47pt;position:var(--position);text-decoration:none;white-space:pre">Compound instruments </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:244.98pt;position:var(--position);text-decoration:none;white-space:pre">Compound instruments below), royalty certificates and Other financial liabilities </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:422.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(conditional advances) other than financial derivative liabilities are measured at amortized cost. They are initially recognized at fair </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:432.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">value and subsequently measured at amortized cost calculated using the effective interest rate (&#8220;EIR&#8221;) method. The transaction costs </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:442.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">that are directly attributable to the issue of the financial liability reduce that financial liability. These expenses are then amortized over </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:452.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the lifetime of the liability, on the basis of the EIR. The EIR is the rate that exactly discounts estimated future cash payments through </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:462.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the expected life of the financial liability to the amortized cost of a financial liability. Financial liabilities that are due within one year </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:472.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">are presented as current financial liabilities in the statements of financial position.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:500.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Royalty certificates </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:516.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Royalty certificates meet the definition of financial liabilities. The Group concluded that they do not include embedded derivatives </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:526.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">related to the variability of royalties that are based on future net sales. In addition, the Group concluded that the prepayment options </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:536.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">were separate derivative instruments as their redemption price did not reimburse holders for an amount up to the approximate present </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:546.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">value of lost interest for the remaining term of the host contracts. However, their value at inception and subsequent dates is nil and has </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:556.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">no impact on the financial statements. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:585.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Royalty certificates are initially measured at fair value (refer to note 15.9 for valuation model applied). They are subsequently </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:597.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">measured at amortized cost calculated using the EIR method. The EIR is calculated based on future cash flows, which are estimated on </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:609.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the basis of development and commercialization plans and budgets approved by the Board of Directors of the Group, and probability-</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:621.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">weighted to reflect the probability of success of clinical studies and any other uncertainty affecting them. If there is a change in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:633.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">timing or amount of estimated cash flows, then the gross carrying amount of the amortized cost of the financial liability is adjusted in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:645.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the period of change to reflect the revised actual and estimated cash flows, with a corresponding income or expense being recognized </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:657.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in profit or loss. The revised gross carrying amount of the amortized cost of the financial liability is calculated by discounting the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:669.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">future revised estimated cash flows at the original EIR. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:699.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Conditional advances and State guaranteed loan &#8211; &#8220;PGE&#8221; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Accounting treatment for conditional advances and the State-guaranteed loan (Pr&#234;t garanti par l'Etat, or "PGE") is set forth in Note 4.9. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:98.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Leases </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:114.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Accounting treatment for lease liabilities is set forth in Note 4.12.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:146.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:underline;white-space:pre">Note 4.8.2. Financial liabilities measured at fair value through profit or loss </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:344.9pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:169.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Derivative instruments</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:127.27pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:186.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">BSA attached to Kreos 1 bonds, the conversion option of OCEANE, certain prepayment options of bonds, the Kreos / Claret warrants </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:196.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and the Kreos / Claret Minimum Return Indemnifications ("MRI") are derivatives instruments. Derivatives are recognized initially at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:206.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">fair value at the date the derivative contract is entered into and are subsequently remeasured to their fair value at each reporting date. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:216.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The resulting gain or loss from change in the fair value is recognized in profit or loss immediately, as financial expenses or income. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:244.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Hybrid instruments </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:272.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">OCEANE bonds </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:105.41pt;position:var(--position);text-decoration:none;white-space:pre">and Heights convertible notes (whose characteristics are described in Note 15.2 and Note 15.5)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.25pt;position:var(--position);text-decoration:none;white-space:pre"> are hybrid </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:282.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">instruments. A &#8220;hybrid contract&#8221; is a contract that includes both a non-derivative host contract and one or more embedded derivatives. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:292.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Embedded derivatives are required to be separated from the host contract (bifurcated) if: the economic characteristics and risks of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:302.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">embedded derivative are not closely related to those of the host, a separate instrument with the same terms as the embedded derivative </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:312.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">would meet the definition of a derivative, and the hybrid contract is not measured at fair value through profit or loss. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:334.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Separable embedded derivatives are required to be measured at fair value at each reporting date, with changes in fair value recognized </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:344.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in profit or loss. The initial bifurcation of a separable embedded derivative does not result in any gain or loss being recognized. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:354.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Because the embedded derivative component is measured at fair value on initial recognition, the carrying amount of the host contract </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:364.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">on initial recognition is the difference between the carrying amount of the hybrid instrument and the fair value of the embedded </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:374.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">derivative. If the fair values of the hybrid instrument and host contract are more reliably measurable than that of the derivative </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:384.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">component - e.g. because of the availability of quoted market prices - then it may be acceptable to use those values to determine the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:394.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">fair value of the derivative on initial recognition indirectly - i.e. as a residual amount. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:416.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Heights convertible notes issued on August 24, 2023 included embedded derivatives as detailed in Note 15. The Group concluded </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:428.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">that these features were embedded derivatives that would modify the cash flows required under the contract and require to be </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:439.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">bifurcated from their host contract. The Group being unable to reliably value each embedded derivative at issuance date and on </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:450.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">subsequent reporting dates, it measured the whole hybrid instrument at fair value through profit or loss (&#8220;FVTPL&#8221;) as permitted by </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:461.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">IFRS 9. Instruments measured at FVTPL under these conditions are measured at their fair value on issuance and on subsequent </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:472.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">reporting dates, with changes in fair value recognized in profit or loss.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:495.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Compound instruments </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:519.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Kreos / Claret OCABSA are compound instruments (whose characteristics are describ</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:398.62pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">ed in Note 15.1). </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:468.57pt;position:var(--position);text-decoration:none;white-space:pre">A &#8220;compound contract&#8221; is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:530.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">a contract that includes both a debt component and an equity component.&#160; The debt component (excluding the conversion option and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:542.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the attached OCABSA warrants) is initially recognized at fair value and subsequently measured at amortized cost calculated using the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:553.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">EIR method. The equity component corresponding to the conversion option and the attached OCABSA warrants is recorded in equity, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:564.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">for the difference between the whole instrument&#8217;s fair value (its nominal value) and the standalone fair value of the debt component.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:593.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Fair value measurement </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:609.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">When measuring the fair value of an asset or a liability, the Company uses market observable data as far as possible. Fair values are </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:619.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:635.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">level 1: fair value calculated using quoted prices in an active market for identical assets and liabilities; </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:651.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">level 2: fair value calculated using valuation techniques based on observable market data such as prices for assets and </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:661.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">liabilities or similar parameters quoted in an active market; &#160;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:671.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">level 3: fair value calculated using valuation techniques based in whole or in part on unobservable inputs such as prices </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:681.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">in an inactive market or a valuation based on multiples of unlisted securities. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:703.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">See Note 12 Financial assets and liabilities and Note 15 Financial liabilities. </span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 4.9. Research tax credit, subsidies and conditional advances </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:86.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Research tax credit </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:102.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group benefits from the provisions of Article 244 </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:255.53pt;position:var(--position);text-decoration:none;white-space:pre">quater </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:284.12pt;position:var(--position);text-decoration:none;white-space:pre">B of the French General Tax Code relating to the French research tax </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:112.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">credit (&#8220;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:68.99000000000001pt;position:var(--position);text-decoration:none;white-space:pre">Cr&#233;dit d&#8217;Imp&#244;t Recherche</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:173.3pt;position:var(--position);text-decoration:none;white-space:pre">&#8221; or &#8220;CIR&#8221;). The CIR is granted to companies in order to encourage them to conduct technical and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:122.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">scientific research. Companies that prove that they have expenditures which meet the required criteria (research expenditures located </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:132.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in France or, since January 1, 2005, within the European Union or in another state that is a party to the Agreement on the European </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:142.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Economic Area and has concluded a tax treaty with France that contains an administrative assistance clause) receive a tax credit that </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:152.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">can be used for the payment of the corporate tax due for the fiscal year in which the expenditures were made and the next three fiscal </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:162.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">years, or as applicable, companies may receive cash reimbursement for any excess portion at the three-year period following the fiscal </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:172.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">year of the expenditures. Only those companies meeting the EU definition of a small or medium-sized entity (&#8220;SME&#8221;) are eligible for </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:182.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">payment in cash of their research tax credit (to the extent not used to offset corporate tax payables) in the year following the request </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:192.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">for reimbursement. The expenditures taken into account for the calculation of the CIR involve only research expenses. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:214.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The CIR is presented under &#8220;Other operating income&#8221; in the statements of income (loss) as it is accounted for as a government grant </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:224.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">as defined in IAS 20 &#8211; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:128.16pt;position:var(--position);text-decoration:none;white-space:pre">Accounting for Government Grants and Disclosure of Government Assistanc</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:435.67pt;position:var(--position);text-decoration:none;white-space:pre">e, and as &#8220;Other receivables and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:234.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">assets&#8221; in the statement of financial position until its payment is received. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:262.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Subsidies </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:278.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Subsidies are non-repayable grants received by the Group and recognized in the financial statements when there exists reasonable </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:288.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">assurance that the Group will comply with the conditions attached to the subsidies and the subsidies will be received. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:310.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Subsidies that are upfront payments are presented as deferred income and recognized through &#8220;Other operating income&#8221; for the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:320.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">amount of the expenses incurred as part of the research program to which the subsidy relates. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:342.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">A subsidy that is to be received either as compensation for expenses or for losses already incurred, or for immediate financial support </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:352.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of the Group without associated future costs, is recognized in the Statements of income (loss) as &#8220;Other operating income&#8221; when there </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:362.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">exists reasonable assurance that the subsidies will be received. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:390.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Conditional advances and PGE </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:406.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group receives conditional advances to finance at below market interest rate research and development projects. Due to the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:416.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">innovative nature of its drug candidate development programs, the Group has benefited from certain sources of financial assistance </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:426.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">from Bpifrance. Bpifrance provides financial assistance and support to emerging French enterprises to facilitate the development and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:436.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">commercialization of innovative technologies. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:458.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Funds received from Bpifrance in the form of conditional advances are recognized as financial liabilities, as the Group has a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:468.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">contractual obligation to reimburse Bpifrance for such conditional advances in cash based on a repayment schedule. Each award of an </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:478.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">advance is made to help fund a specific development milestone. More de</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:327.3pt;position:var(--position);text-decoration:none;white-space:pre">tails </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:346.43pt;position:var(--position);text-decoration:none;white-space:pre">on conditional advances are provided in Note 15.7. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:488.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Receipts or reimbursements of conditional advances are reflected as financing transactions in the statements of cash flows. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:510.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The difference between the present value of the advance at market rate (i.e., present value of contractual cash flows including principal </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:520.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and interests, discounted using a market rate as effective interest rate in accordance with IFRS 9) and the amount received as cash </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:530.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">from the Bpifrance constitutes a subsidy within the meaning of IAS 20. Considering that these advances do not finance fixed assets, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:540.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">these subsidies are presented as &#8220;Deferred income&#8221; in the statement of financial position and recognized in the statement of net income </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:550.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(loss) as &#8220;Other operating income&#8220; on a systematic basis over the periods in which the Group recognizes as expenses the related costs </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:560.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">for which the grants are intended to compensate. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:582.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The incremental interest expense resulting from the difference between (a)&#160;the market interest rate and the (b)&#160;below-market rate is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:592.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">spread over the contractual period until the last repayment and recognized in the statement of income (loss) accordingly, using the EIR </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:602.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">method. In the event of a change in estimate of contractual cash flows due under the conditional advances, the Group recalculates the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:612.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">book value of the debt resulting from the discounting of the anticipated new future cash flows at the initial EIR. The adjustment is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:622.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">recognized in the statements of income (loss) for the period during which the modification is recognized. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:644.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In the statements of financial position, these conditional advances are recorded in &#8220;Other financial liabilities&#8221; as current or non-current </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:654.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">portion depending on their maturity. In the event Bpifrance waived the repayment of the advance, the corresponding liability is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:664.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">derecognized and treated as a subsidy in the statements of income (loss). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:686.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The benefit resulting from the low interest of PGE loans is also recognized as a subsidy corresponding to the difference between the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:696.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">present value of the PGE at market rate and the amount received as cash. The accounting treatment is therefore similar to the above-</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">mentioned accounting treatment for conditional advances. PGE are recorded in &#8220;Borrowings&#8221; as current or non-current portion </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:80.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">depending on their maturity. </span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 4.10. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:80.42pt;position:var(--position);text-decoration:none;white-space:pre">Employee benefits </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:124.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group&#8217;s employees in France benefit from retirement benefits provided under French law, which consist in the following: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:140.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">compensation paid by the Group to employees upon their retirement (a defined benefit plan); and </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:156.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">payments of retirement pensions by the social security agencies, which are financed by the contributions made by the </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:166.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">Group and employees. As they meet the definition of a defined contribution plan, the liabilities are presented as Tax and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:176.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">employee-related payables in the statement of financial position. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:198.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In accordance with IAS 19 &#8211; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:153.11pt;position:var(--position);text-decoration:none;white-space:pre">Employee Benefits</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:227.15pt;position:var(--position);text-decoration:none;white-space:pre">, the liability with respect to defined benefit plans is estimated by using the projected </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:208.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">credit unit method. According to this method, the cost of the retirement benefit is recognized in the statements of income (loss). The </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:218.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">retirement benefit commitments are valued at the current value of the estimated future payments, discounted using the market rate for </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:228.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">high quality corporate bonds with a term and currency that correspond to that estimated for the payment of the benefits. The Group </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:238.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">applied the decision of the IFRS IC, published on May&#160;24, 2021, that concluded that, in the case that no rights were acquired in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:248.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">event of departure before retirement age and that the rights were capped after a certain number of years of seniority (&#8220;30 years&#8221;), the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:258.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">commitment would only be recognized for the last 30 years of the employee&#8217;s career within the Group. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:280.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The difference between the amount of the provision at the beginning of a period and at the close of that period is recognized through </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:290.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">operating expenses for the portion representing the costs of services rendered and financial expenses for the net interest costs, and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:300.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">through other comprehensive income (loss) for the portion representing the actuarial gains and losses due to changes in assumptions </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:310.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and experience adjustments. </span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 4.11. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:80.42pt;position:var(--position);text-decoration:none;white-space:pre">Provisions </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:348.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Provisions correspond to commitments resulting from litigation and various risks to which the Group may face in the context of its </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:358.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">operations, as well as taxes and employer contributions related to AGAs that become due upon the vesting of the awards. In </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:368.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">accordance with IAS 37 &#8211; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:142.28pt;position:var(--position);text-decoration:none;white-space:pre">Provisions, Contingent Liabilities and</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:294.92pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:297.42pt;position:var(--position);text-decoration:none;white-space:pre">Contingent Assets, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:374.29pt;position:var(--position);text-decoration:none;white-space:pre">a provision is recorded when the Group has an </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:378.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">obligation to a third party resulting from a past event that will likely result in an outflow of resources to the third party, and for which </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:388.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">future cash outflows may be estimated reliably. The amount recorded as a provision is an estimate of the expenditure required to settle </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:398.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the obligation, discounted where necessary at year end. For AGA taxes, the taxes are based on the vesting date share price, and the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:408.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">provision is estimated based on the spot listed price at year-end multiplied by the number of AGAs which are expected to vest. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:418.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Contingent</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:80.4pt;position:var(--position);text-decoration:none;white-space:pre"> liabilities are not recognized, but are disclosed in the notes to the financial statements unless the possibility of an outflow </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:428.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of economic resources is remote. </span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 4.12. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:80.42pt;position:var(--position);text-decoration:none;white-space:pre">Leases </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:472.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As lessee, the Group assesses whether a contract contains a lease at inception of a contract and upon the modification of a contract. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:482.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group elected to allocate the consideration in the contract to the lease and non-lease components on the basis of the relative </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:492.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">standalone price. The Group recognizes a right-of-use asset and a corresponding lease liability for all arrangements in which it is a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:502.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">lessee, except for leases with a term of 12 months or less (short-term leases) and low-value leases (value of the underlying asset below </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:512.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.0 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:92.09pt;position:var(--position);text-decoration:none;white-space:pre">). For these short-term and low-value leases, the Group recognizes the lease payments as an operating expense on a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:522.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">straight-line basis over the term of the lease. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:544.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The lease liability is initially measured at the present value of the future lease payments as from the commencement date of the lease </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:554.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">to the end of the lease term. The lease terms used by the Group reflect the non-cancellable terms of each contract, plus any extension </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:564.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">or termination options that the Group is reasonably certain to exercise or not exercise for all of the leases periods covered by the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:574.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">extension options. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:584.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Group incremental borrowing rate for the asset subject to the lease in the respective markets. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:606.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever there is a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:616.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">change to the lease terms or expected payments under the lease, or a modification that is not accounted for as a separate lease. The </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:626.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">portion of the lease payments attributable to the repayment of lease liabilities and the portion attributable to payment of interests are </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:636.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">recognized in cash flows used in financing activities. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:658.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Right-of-use assets are initially recognized on the balance sheet at cost, which comprises the amount of the initial measurement of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:668.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">corresponding lease liability, adjusted for any lease payments made at or prior to the commencement date of the lease, any lease </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:678.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">incentives received and any initial direct costs incurred by the Group, and expected costs for obligations to dismantle and remove </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:688.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">right-of-use assets when they are no longer used. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Right-of-use assets are depreciated on a straight-line basis from the commencement date of the lease over the shorter of the useful life </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:80.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of the right-of-use asset or the end of the lease term. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:102.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Right-of-use assets are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:112.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">recoverable using cash flow projections. </span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 4.13. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:80.42pt;position:var(--position);text-decoration:none;white-space:pre">Translation of transactions denominated in foreign currency </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:156.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Pursuant to IAS 21</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.36pt;position:var(--position);text-decoration:none;white-space:pre"> &#8211; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:122.36pt;position:var(--position);text-decoration:none;white-space:pre">The Effects of Changes in Foreign Exchange Rates</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:326.3pt;position:var(--position);text-decoration:none;white-space:pre">, transactions performed by the Company and the Subsidiary </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:166.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in currencies other than their functional currencies, which are respectively the Euro and the U.S. dollar, are translated at the prevailing </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:176.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">exchange rate on the transaction date. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:198.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Trade receivables and payables and liabilities denominated in a currency other than the functional currency are translated at the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:208.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">period-end exchange rate. Unrealized gains and losses arising on translation are recognized in net financial income / (loss). </span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 4.14. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:80.42pt;position:var(--position);text-decoration:none;white-space:pre">Current and deferred tax </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:246.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:256.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">French tax authorities, using tax rates and tax laws enacted or substantively enacted at the end of the reporting period in accordance </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:266.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">with IAS 12 &#8211; Income Tax. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:288.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The income tax charge for the period comprises current tax due and the deferred tax charge. The tax expense is recognized in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:298.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">statement of income (loss) unless it relates to items recorded in other comprehensive income (loss) or directly in equity, in which case </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:308.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the tax is also recorded in other comprehensive income (loss) or directly in equity. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:336.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Current taxes </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:352.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The current tax expense is calculated based on taxable profit for the period, using tax rates enacted or substantively enacted at the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:362.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">statement of financial position date. Considering the level of tax loss of the Group, no current tax expense is recognized. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:390.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Deferred taxes </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:406.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Deferred taxes are recognized when there are temporary differences between the carrying amount of assets and liabilities in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:416.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Group&#8217;s financial statements and the corresponding tax basis used to calculate taxable profit. Deferred taxes are not recognized if they </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:426.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">arise from the initial recognition of an asset or liability in a transaction other than a business combination which, at the time of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:436.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">transaction, does not affect either the accounting or the taxable profit (tax loss). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:446.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group applies the Amendments to IAS 12 &#8211; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:232.23pt;position:var(--position);text-decoration:none;white-space:pre">Deferred Tax related to Assets and Liabilities arising from a Single Transaction</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:552.79pt;position:var(--position);text-decoration:none;white-space:pre">, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:456.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">issued on May 7, 2021, and presents the deferred tax assets and liabilities arising from such transactions separately within Note 22 </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:559.6pt;position:var(--position);text-decoration:none;white-space:pre">- </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:466.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Income tax, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.11pt;position:var(--position);text-decoration:none;white-space:pre">rather than on a net basis. The Amendments have no impact on the Statements of financial position and the Statement of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:476.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">comprehensive income (loss) for the periods presented.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:504.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Deferred tax assets </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:520.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Deferred tax assets are recognized for all deductible temporary differences, unused tax losses and unused tax credits to the extent that </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:530.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">it is probable that the temporary difference will reverse in the foreseeable future and that taxable profit will be available against which </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:540.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the deductible temporary difference, unused tax losses or unused tax credits can be utilized. In this regard, the Group applies the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:550.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">decision of the IFRS IC, published on January 29, 2021, on the amount of deferred tax assets recognized from unused tax losses as a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:560.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">result of suitable taxable temporary differences, in the case when the use of such tax losses is restricted or limited by the tax law. See </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:570.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 4.15. Use of judgments and estimates and Note 22 Income tax. </span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 4.15. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:80.42pt;position:var(--position);text-decoration:none;white-space:pre">Use of judgments and estimates </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:614.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In order to prepare financial statements in accordance with IFRS, estimates, judgments and assumptions were made by the Group&#8217;s </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:624.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">management which could affect the reported amounts of assets, liabilities, contingent liabilities, income and expenses. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:646.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">These estimates are based on the assumption of going concern and are prepared in accordance with information available at the date </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:656.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the financial statements were prepared. They are reviewed on an ongoing basis using past experience and various other factors </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:666.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">considered to be reasonable as the basis to measure the carrying amount of assets and liabilities. Estimates may be revised due to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:676.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">changes in the underlying circumstances or subsequent to new information. Actual results may differ significantly from these </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:686.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">estimates in line with assumptions or different conditions. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">This note provides an overview of the areas that involved a higher degree of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:342.88pt;position:var(--position);text-decoration:none;white-space:pre">judgment </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:383.12pt;position:var(--position);text-decoration:none;white-space:pre">or complexity, and of items which are more </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:80.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">likely to be materially adjusted due to changes in estimates and assumptions. Detailed information about each of these estimates and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:90.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">judgments </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:80.13pt;position:var(--position);text-decoration:none;white-space:pre">is included in other notes together with information about the basis of calculation for each affected line item in the financial </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:100.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">statements. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:116.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Recognition and measurement of impairment of CGUs. The main assumptions used for the impairment test include </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">(a)&#160;the amount of cash flows that are set on the basis of the development and commercialization plans and budgets </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:136.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">approved by Board of Directors, (b)&#160;assumptions related to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:329.16pt;position:var(--position);text-decoration:none;white-space:pre">the</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:341.36pt;position:var(--position);text-decoration:none;white-space:pre"> achievement of the clinical trials and the launch of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:146.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">commercialization, (c)&#160;the discount rate, (d) assumptions on risk related to the development and (e)&#160;for the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:156.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">commercialization, selling price and volume of sales. The sensitivity analysis in respect of the recoverable amount of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:166.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">CGUs is presented in Note 6. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:182.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Measurement of share-based payments granted to employees, corporate officers and scientific consultants, such as BCE, </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:194.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">BSA and AGA, which is based on actuarial models; these models require the use by the Group of certain calculation </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:205.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">assumptions such as the estimated vesting, the occurrence dates of a change of control or a M&amp;A transaction dates, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:554.11pt;position:var(--position);text-decoration:none;white-space:pre">the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:217.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">percentage of success (&#8220;POS&#8221;) of obefazimod,</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:276.94pt;position:var(--position);text-decoration:none;white-space:pre"> the expected volatility and maturity of the underlying equity instrument </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:228.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">(see Note 4.7 and Note 14), </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:246.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Fair value measurement at inception and after of derivative financial instruments resulting from (i)&#160;the warrants issued </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:257.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">concomitantly with the issuance of the straight and convertible bonds to Kreos on July 24, 2018 (or &#8220;Kreos 1&#8221;), </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.25pt;position:var(--position);text-decoration:none;white-space:pre">(ii) the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:269.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">Kreos / Claret BSA issued on August 21, 2023 and November 2, 2023, related to tranches A-B and tranche C, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:280.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">respectively, and (iii) the Kreos / Claret Minimum Return Indemnifications related to tranches B and C, issued in March </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:292.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">2024 and June 2024, respectively,</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:309.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Amortized cost measurement a</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:215.04000000000002pt;position:var(--position);text-decoration:none;white-space:pre">nd fair value</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:265.53000000000003pt;position:var(--position);text-decoration:none;white-space:pre"> of royalty certificates, based on the following assumptions: (a)&#160;future cash </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:319.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">flows, estimated on the basis of development and commercialization plans and budgets approved by the Board of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:329.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">Directors, (b)&#160;the effective interest rate (for the amortized cost measurement) and (c) the discount rate (for the fair </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:339.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">value). The sensitivity analyses in respect of the amortized cost measurement and fair value of royalty certificates is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:349.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">presented in Note 15,&#160; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:365.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Fair value measurement of other financial liabilities at inception, </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:352.32pt;position:var(--position);text-decoration:none;white-space:pre">and after, for the Heights convertible notes measured at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:377.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">fair value at each reporting period, with fair value changes recognized in profit or loss, as well as for disclosure purposes </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:388.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">(see Note 15), </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:406.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Estimation of CIR, based on internal and external expenses, which meet the required criteria, incurred by the Group each </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:416.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">year (see Note 4.9), </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:432.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Recognition of deferred tax assets: availability and timing of future taxable profit against which deductible temporary </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:442.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">differences and tax losses carried forward can be utilized and whether sufficient evidence exists (see Note 22),</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:458.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72.69999999999999pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">Recognition of deferred tax assets: tax deductibility of future royalty payments related to the royalty certificates issued in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:470.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">September 2022 (see Notes 15 and 22),</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:488.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72.69999999999999pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">Determination of the terms of the leases, including whether the Group is reasonably certain to exercise extension and/or </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:500.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">termination options (see Note 15.8).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:536.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The main critical judgments made by the Group&#8217;s management impact the following items: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:564.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72.69999999999999pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">Accounting treatment of specific conditions of share-based compensation plans (see Notes 4.7 and 14),</span></div><div style="font-size:12pt;line-height:10.5pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:582.06pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:10.5pt;font-style:normal;font-weight:normal;left:72.69999999999999pt;position:var(--position);text-decoration:none;white-space:pre;width:3.67pt">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre;width:484.88pt">Accounting treatment of the royalty certificates and August 2023 Kreos / Claret and Heights Financings (see Notes 4.8</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.93pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:593.61pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre;width:32.76pt">and 15).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_AccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting Principles [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_AccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of material accounting policy information applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 176<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_176&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Disclosure of operating segments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory', window );">Segment information</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:68.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Segment information </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:663.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The assessment of the Group&#8217;s performance and the decisions about resources to be allocated are made by the chief operating decision </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:673.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">maker, based on the management reporting system of the Group. The Group identified the Chief Executive Officer of the Group as </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8220;chief operating decision maker&#8221;. The chief operating decision maker reviews on an aggregated basis the incurred expenses for </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:80.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">allocating and evaluating performance of the Group. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:102.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group operates in a single operating segment: R&amp;D of pharmaceutical products in order to market them in the future. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:124.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023 and 2024, substantially all operations, assets, liabilities, and losses of the Group were located in France. As </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:135.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of December 31, 2025, the U.S. Subsidiary's contributions to the Group&#8217;s l</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:334.53pt;position:var(--position);text-decoration:none;white-space:pre">iabilities and net losse</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:423.01pt;position:var(--position);text-decoration:none;white-space:pre">s </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:429.4pt;position:var(--position);text-decoration:none;white-space:pre">were less than </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:488.49pt;position:var(--position);text-decoration:none;white-space:pre">10%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:506.82pt;position:var(--position);text-decoration:none;white-space:pre">, and its </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:146.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">contribution to the Group's assets were </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:193.76pt;position:var(--position);text-decoration:none;white-space:pre">29%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:212.09pt;position:var(--position);text-decoration:none;white-space:pre"> (consisting predominantly of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:332.54pt;position:var(--position);text-decoration:none;white-space:pre">cash and cash equivalents)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:438.79pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IFRS08_g20-24_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and impairment test<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract', window );"><strong>Intangible assets and goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGoodwillExplanatory', window );">Goodwill and impairment test</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:68.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Goodwill and impairment test </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:204.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Goodwill relates to the acquisition of Splicos SAS and Wittycel SAS that occurred in 2014 (i.e., prior the transition date to IFRS), </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:214.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">which were merged into the Group in the same year. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:236.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Goodwill from Splicos SAS and Wittycel SAS acquisition corresponds to the &#8220;Modulation of RNA biogenesis / splicing&#8221; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:246.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">technological platform and the &#8220;iNKT agonists&#8221; technological platform, respectively, from which derived the lead drug candidates of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:256.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the Group: ABX464 and ABX196, respectively. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:278.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">IFRS 3 was not applied to acquisitions of subsidiaries deemed to be a business within the meaning of IFRS, carried out before the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:288.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">IFRS transition date, i.e., January&#160;1 2020. Due to the application of this exemption, the previous accounting for business combinations </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:298.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in accordance with French GAAP remains unchanged (no identified Intellectual Property, Research&#160;&amp; Development (&#8220;IPR&amp;D&#8221;) assets </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:308.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">are recognized in the statement of financial position).</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:249.03pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:330.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The impairment test carried out as of December&#160;31, 2022 resulted in the full impairment of the goodwill resulting from the acquisition </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:340.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of Wittycell SAS and other assets included in the ABX196 CGU, i.e. an impairment loss of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:403.69pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;13,632&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:474.78pt;position:var(--position);text-decoration:none;white-space:pre"> as of December&#160;31, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:350.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">2022 (</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:61.83pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;13,586&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:132.92000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> related to goodwill and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:230.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;45&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:283.9pt;position:var(--position);text-decoration:none;white-space:pre"> related to other assets). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:360.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Consequently, the carrying amount of the Group's goodwill of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:287.03999999999996pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;18,419&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:358.13pt;position:var(--position);text-decoration:none;white-space:pre"> as of December&#160;31, 2023, 2024 and 2025 solely </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:372.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">relates to the acquisition of Splicos SAS. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:395.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In accordance with IAS 36, goodwill is allocated to CGUs at a level corresponding to the lead drug candidates. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:481.88pt;position:var(--position);text-decoration:none;white-space:pre">Thus, goodwill from </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:406.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Splicos SAS is allocated to the ABX464 CGU.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:429.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Goodwill impairment tests are undertaken annually or more frequently if events or changes in circumstances indicate a potential </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:439.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">impairment, in accordance with IAS 36. The carrying amount of goodwill is compared to the recoverable amount, which is the higher </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:449.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">value in use and the fair value less costs to disposal. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:471.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2025, the Group has not identified any indication of impairment loss related to goodwill, intangible or tangible </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:482.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">assets. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:505.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, 2024 and 2025 the recoverable amount used for the impairment test of each CGU was the value in use. This </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:517.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">value in use was based on a net present value calculation, using the following assumptions as of December 31, 2023, 2024 and 2025: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:535.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Cash flows are set on the basis of the development and commercialization plans and budgets approved by Board of </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:545.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">Directors; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:561.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05000000000001pt;position:var(--position);text-decoration:none;white-space:pre">A discount rate (or &#8220;WACC&#8221;) o</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:218.41000000000003pt;position:var(--position);text-decoration:none;white-space:pre">f</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:221.74pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:226.74pt;position:var(--position);text-decoration:none;white-space:pre">15%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:245.07pt;position:var(--position);text-decoration:none;white-space:pre"> as of December 31, 2023, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:352.76pt;position:var(--position);text-decoration:none;white-space:pre">11.5%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:378.59pt;position:var(--position);text-decoration:none;white-space:pre"> as of December 31, 2024 and of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:511.53999999999996pt;position:var(--position);text-decoration:none;white-space:pre">10.0%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:537.37pt;position:var(--position);text-decoration:none;white-space:pre"> as of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:572.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">December 31, 2025;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:590.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">A risk of development is taken into consideration by applying probabilities of success (or &#8220;POS&#8221;) of reaching future </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:600.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">phases of development to cash flows related to the commercialization phase. Those average probabilities of success of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:610.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">R&amp;D projects are based on public sources</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:259.2pt;position:var(--position);text-decoration:none;white-space:pre">;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:626.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">For the commercialization phase, selling price and sales volume are estimated on the basis of the potential market and </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:636.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">the observed performances of comparable drugs currently on the market. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:658.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The impairment tests resulted in </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:167.21pt;position:var(--position);text-decoration:none;white-space:pre">no</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:177.21pt;position:var(--position);text-decoration:none;white-space:pre"> impairment charges as of December 31, 2023, 2024, and 2025.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Sensitivity testing as of December&#160;31, 2023, 2024 and 2025:</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:96.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As the product is currently under development, a clinical trial failure or a failure to obtain a marketing approval could result in an </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:107.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">impairment of the goodwill allocated to the ABX464 CGU. The results of the impairment test indicate a headroom level that is high </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:118.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">enough so that any reasonably possible change in any of the key assumptions (except clinical failure) would not lead to any </span></div>impairment.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory', window );">Intangible assets</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:68.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Intangible assets </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:186.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Intangible assets are mainly comprised of the intellectual property underlying: </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:220.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:66.55pt;position:var(--position);text-decoration:none;white-space:pre">(i)</span><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:75.97999999999999pt;position:var(--position);text-decoration:none;white-space:pre">&#160; &#160;  </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90.97999999999999pt;position:var(--position);text-decoration:none;white-space:pre">The exclusive license agreement with the Scripps Research Institute, University of Chicago and Brigham Young </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:230.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">University for which the Group paid a milestone of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.35pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;45 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:351.94pt;position:var(--position);text-decoration:none;white-space:pre"> in September 2019 as a result of an IND filling of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:240.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">ABX196. The value in use and the fair value less costs to disposal of the ABX196 CGU being </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:470.43pt;position:var(--position);text-decoration:none;white-space:pre">nil</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:480.97pt;position:var(--position);text-decoration:none;white-space:pre"> as of December 31, </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:250.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">2022, a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:122.97999999999999pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;45&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:176.57pt;position:var(--position);text-decoration:none;white-space:pre"> impairment loss was recorded during the year ended December 31, 2022 (see Note 6).</span><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:522.87pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:266.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:66.55pt;position:var(--position)">(ii)<span style="display:inline-block;height:6.93pt;width:12.3pt"></span></span><span style="left:91.05pt;position:var(--position)">The collaboration and license agreement with the CNRS, Montpellier 2 university and the Curie for which the Group </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:276.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">paid a milestone of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:169.84pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;40&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:223.43pt;position:var(--position);text-decoration:none;white-space:pre"> in September 2019 as a result of the entry in phase 2 of ABX464. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:292.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:66.55pt;position:var(--position)">(iii)<span style="display:inline-block;height:6.93pt;width:9.53pt"></span></span><span style="left:91.05pt;position:var(--position)">Patents acquired through the acquisition of Prosynergia SARL (or "Prosynergia") on April 1, 2022 and amounting to </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:302.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6,529&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:157.14pt;position:var(--position);text-decoration:none;white-space:pre">. Considering that Prosynergia only owned patent rights and did not enter into any employee contract, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:312.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">research agreement, collaboration agreement or out-licensed agreement, this</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:395.87pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:398.37pt;position:var(--position);text-decoration:none;white-space:pre">acquisition did not meet the definition of a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:322.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">business under IFRS 3. Consequently, the acquisition cost of this group of assets was mostly allocated to the acquired </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:332.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">patents, which cover alternative synthesis process for obefazimod and a family of close chemical analogues. They also </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:342.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">cover alternative forms of obefazimod (salts thereof and crystalline forms of said salts), the pharmaceutical composition </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:352.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">comprising them, that could be of interest to the Group for future development.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:362.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">The patents are not yet amortized, similarly to licenses, and are included in the ABX464 CGU for impairment test </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:372.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">purposes. All patents will expire in 2037.</span></div><div style="font-size:12pt;line-height:1pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:71.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Licenses and patents recognized as Intangible assets are not amortized since they are not operating in a manner intended by the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:81.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">management. As a consequence, and in accordance with IAS 36, those assets were subject to an annual impairment test as of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:91.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">December 31, 2023, 2024 and 2025, which did </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:226.16pt;position:var(--position);text-decoration:none;white-space:pre">not</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:238.93pt;position:var(--position);text-decoration:none;white-space:pre"> result in any impairment loss being recognized</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:428.43pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><div style="position:var(--position);top:113.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:464.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:194.25pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td></tr><tr style="height:32.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.48pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:45.59pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.86pt;position:var(--position);text-decoration:none;white-space:pre">LICENSES</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.75pt;position:var(--position);text-decoration:none;white-space:pre">SOFTWARE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.2pt;position:var(--position);text-decoration:none;white-space:pre">PATENTS</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.63pt;position:var(--position);text-decoration:none;white-space:pre">TOTAL</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:32.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">GROSS VALUES</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:44.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY 1, 2023</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:44.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.88pt"></span></span><span style="left:49.510000000000005pt;position:var(--position)">120<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:44.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)">24<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:44.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">6,529<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:44.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">6,673<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:65.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:65.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.88pt"></span></span><span style="left:49.510000000000005pt;position:var(--position)">120<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:65.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)">24<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:65.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">6,529<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:65.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">6,673<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:86.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Acquisition</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:86.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:86.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.88pt"></span></span><span style="left:57.510000000000005pt;position:var(--position)">3<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:86.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:86.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.88pt"></span></span><span style="left:57.510000000000005pt;position:var(--position)">3<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:23.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:98.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.02pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:98.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.88pt"></span></span><span style="left:49.510000000000005pt;position:var(--position)">120<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:98.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)">27<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:98.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">6,529<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:98.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">6,677<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:23.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:121.5pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.82pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:13.42pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:121.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.88pt"></span></span><span style="left:49.510000000000005pt;position:var(--position)">120<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:121.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)">27<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:121.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">6,529<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:121.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">6,677<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:277.94pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:464.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:194.25pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td></tr><tr style="height:35.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:26.48pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:45.59pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.8pt;position:var(--position);text-decoration:none;white-space:pre">LICENSES</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.69pt;position:var(--position);text-decoration:none;white-space:pre">SOFTWARE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.14pt;position:var(--position);text-decoration:none;white-space:pre">PATENTS</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:19.57pt;position:var(--position);text-decoration:none;white-space:pre">TOTAL</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:35.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AMORTIZATION</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:23.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:47.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.82pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:13.42pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY 1, 2023</span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:47.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.22pt"></span></span><span style="left:50.85pt;position:var(--position)">(45)<span style="display:inline-block;height:5.41pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:47.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.55pt"></span></span><span style="left:51.18pt;position:var(--position)">(21)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:47.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:47.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.55pt"></span></span><span style="left:51.18pt;position:var(--position)">(66)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:70.5pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Increase </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:70.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:70.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.55pt"></span></span><span style="left:55.18pt;position:var(--position)">(3)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:70.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:70.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.55pt"></span></span><span style="left:55.18pt;position:var(--position)">(3)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:82.5pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:82.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.22pt"></span></span><span style="left:50.85pt;position:var(--position)">(45)<span style="display:inline-block;height:5.41pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:82.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.55pt"></span></span><span style="left:51.18pt;position:var(--position)">(24)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:82.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:82.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.55pt"></span></span><span style="left:51.18pt;position:var(--position)">(70)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:103.5pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Increase </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:103.5pt;width:65.25pt"><div><div style="line-height:9pt;position:var(--position);top:2.35pt;width:65.25pt"><span style="color:#000000;font-family:'Arial', sans-serif;font-size:9pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.55pt;width:49.88pt"></span></span><span style="left:52.510000000000005pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.55pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:103.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.55pt"></span></span><span style="left:55.18pt;position:var(--position)">(1)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:103.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:103.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.55pt"></span></span><span style="left:55.18pt;position:var(--position)">(1)</span></span></div></div></div></td></tr><tr style="height:24pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:115.5pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.2pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:13.8pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:115.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:15.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.22pt"></span></span><span style="left:50.85pt;position:var(--position)">(45)<span style="display:inline-block;height:5.41pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:115.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:15.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.55pt"></span></span><span style="left:51.18pt;position:var(--position)">(25)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:115.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:15.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:115.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:15.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.55pt"></span></span><span style="left:51.18pt;position:var(--position)">(70)</span></span></div></div></div></td></tr><tr style="height:12.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:139.5pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.99pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Increase </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:139.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:139.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.55pt"></span></span><span style="left:55.18pt;position:var(--position)">(1)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:139.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:139.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.55pt"></span></span><span style="left:55.18pt;position:var(--position)">(1)</span></span></div></div></div></td></tr><tr style="height:24pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:152.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.2pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:13.8pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:152.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:15.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.22pt"></span></span><span style="left:50.85pt;position:var(--position)">(45)<span style="display:inline-block;height:5.41pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:152.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:15.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.55pt"></span></span><span style="left:51.18pt;position:var(--position)">(26)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:152.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:15.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:152.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:15.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.55pt"></span></span><span style="left:51.18pt;position:var(--position)">(71)</span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:485.79pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:464.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:194.25pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td></tr><tr style="height:35.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:26.48pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:45.59pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.8pt;position:var(--position);text-decoration:none;white-space:pre">LICENSES</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.69pt;position:var(--position);text-decoration:none;white-space:pre">SOFTWARE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.14pt;position:var(--position);text-decoration:none;white-space:pre">PATENTS</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:19.57pt;position:var(--position);text-decoration:none;white-space:pre">TOTAL</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:35.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">NET BOOK VALUES</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:47.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY 1, 2023</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:47.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">75</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:47.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.62pt;position:var(--position);text-decoration:none;white-space:pre">3</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:47.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre">6,529</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:47.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre">6,607</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:68.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:68.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">75</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:68.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.62pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:68.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre">6,529</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:68.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre">6,604</span></div></div></div></td></tr><tr style="height:29.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:89.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:6.82pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:16.42pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:89.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:11.56pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">75</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:89.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:11.56pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.62pt;position:var(--position);text-decoration:none;white-space:pre">3</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:89.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:11.56pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre">6,529</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:89.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:11.56pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre">6,606</span></div></div></div></td></tr><tr style="height:29.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:118.5pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:6.82pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:16.42pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:118.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:11.56pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">75</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:118.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:11.56pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.62pt;position:var(--position);text-decoration:none;white-space:pre">2</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:118.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:11.56pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre">6,529</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:118.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:11.56pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre">6,605</span></div></div></div></td></tr></tbody></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IAS38_g118-128_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">Property, plant and equipment</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:68.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Property, plant and equipment</span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:695.64pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:44pt;position:var(--position);text-decoration:none;white-space:pre">The following tables present changes in property, plant and equipment including the right of use of assets (or &#8220;ROU&#8221;) as of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:705.64pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:44pt;position:var(--position);text-decoration:none;white-space:pre">December 31, 2023, 2024 and 2025:</span></div><div><div style="position:var(--position);top:85.19pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:525.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:213.75pt"></td><td style="padding:0;width:60pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:60pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:60pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:60pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:60pt"></td></tr><tr style="height:41.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:32.48pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:55.34pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);width:60pt"><div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.57pt;position:var(--position);text-decoration:none;white-space:pre">BUILDINGS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);width:60pt"><div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.35pt;position:var(--position);text-decoration:none;white-space:pre">EQUIPMENT</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3.82pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.25pt;position:var(--position);text-decoration:none;white-space:pre">FURNITURE </span></div><div style="line-height:8pt;position:var(--position);top:13.42pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.34pt;position:var(--position);text-decoration:none;white-space:pre">AND </span></div><div style="line-height:8pt;position:var(--position);top:23.02pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.69pt;position:var(--position);text-decoration:none;white-space:pre">COMPUTER </span></div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.35pt;position:var(--position);text-decoration:none;white-space:pre">EQUIPMENT</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);width:60pt"><div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.01pt;position:var(--position);text-decoration:none;white-space:pre">TOTAL</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);width:60pt"><div><div style="line-height:8pt;position:var(--position);top:23.02pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.79pt;position:var(--position);text-decoration:none;white-space:pre">OF WHICH </span></div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.12pt;position:var(--position);text-decoration:none;white-space:pre">ROU</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:41.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">GROSS VALUES</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:53.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY 1, 2023</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:53.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)">1,618<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:53.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">436<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:53.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">346<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:53.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)">2,400<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:53.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)">1,561<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:74.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Acquisition</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:74.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">350<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:74.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">103<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:74.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">161<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:74.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">614<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:74.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">350<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:86.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Disposal</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:86.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.97pt"></span></span><span style="left:41.6pt;position:var(--position)">(622)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:86.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.97pt"></span></span><span style="left:45.6pt;position:var(--position)">(27)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:86.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.63pt"></span></span><span style="left:48.260000000000005pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:86.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.97pt"></span></span><span style="left:41.6pt;position:var(--position)">(649)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:86.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.97pt"></span></span><span style="left:41.6pt;position:var(--position)">(649)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:98.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:98.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)">1,346<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:98.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">513<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:98.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">507<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:98.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)">2,366<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:98.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)">1,262<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:119.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Acquisition</span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:119.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)">2,578<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:119.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.63pt"></span></span><span style="left:48.260000000000005pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:119.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">292<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:119.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)">2,870<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:119.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)">2,217<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:131.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Disposal</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:131.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.97pt"></span></span><span style="left:35.6pt;position:var(--position)">(1,110)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:131.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.63pt"></span></span><span style="left:48.260000000000005pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:131.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.97pt"></span></span><span style="left:41.6pt;position:var(--position)">(119)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:131.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.97pt"></span></span><span style="left:35.6pt;position:var(--position)">(1,229)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:131.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.97pt"></span></span><span style="left:41.6pt;position:var(--position)">(975)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:143.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Effect of the change in foreign currency exchange rates</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:143.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:49.63pt"></span></span><span style="left:52.260000000000005pt;position:var(--position)">4<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:143.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.63pt"></span></span><span style="left:48.260000000000005pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:143.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.63pt"></span></span><span style="left:48.260000000000005pt;position:var(--position)">17<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:143.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.63pt"></span></span><span style="left:48.260000000000005pt;position:var(--position)">22<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:143.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.63pt"></span></span><span style="left:48.260000000000005pt;position:var(--position)">22<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:155.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:155.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)">2,818<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:155.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">513<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:155.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">698<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:155.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)">4,029<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:155.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)">2,526<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:176.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Acquisition</span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:176.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">436<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:176.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.63pt"></span></span><span style="left:48.260000000000005pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:176.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">123<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:176.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">559<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:176.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">424<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:188.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Disposal</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:188.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.63pt"></span></span><span style="left:48.260000000000005pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:188.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.97pt"></span></span><span style="left:45.6pt;position:var(--position)">(49)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:188.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.97pt"></span></span><span style="left:41.6pt;position:var(--position)">(203)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:188.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.97pt"></span></span><span style="left:41.6pt;position:var(--position)">(252)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:188.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.97pt"></span></span><span style="left:45.6pt;position:var(--position)">(34)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:200.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Effect of the change in foreign currency exchange rates</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:200.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.97pt"></span></span><span style="left:45.6pt;position:var(--position)">(50)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:200.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.63pt"></span></span><span style="left:48.260000000000005pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:200.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.97pt"></span></span><span style="left:45.6pt;position:var(--position)">(12)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:200.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.97pt"></span></span><span style="left:45.6pt;position:var(--position)">(62)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:200.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.97pt"></span></span><span style="left:45.6pt;position:var(--position)">(50)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:212.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:212.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)">3,204<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:212.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">463<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:212.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">607<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:212.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)">4,274<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:212.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)">2,865<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:338.07pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:528.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:201.75pt"></td><td style="padding:0;width:63pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63pt"></td></tr><tr style="height:41.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:32.48pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:49.34pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);width:63pt"><div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.07pt;position:var(--position);text-decoration:none;white-space:pre">BUILDINGS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);width:63pt"><div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.85pt;position:var(--position);text-decoration:none;white-space:pre">EQUIPMENT</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.82pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.75pt;position:var(--position);text-decoration:none;white-space:pre">FURNITURE </span></div><div style="line-height:8pt;position:var(--position);top:13.42pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.84pt;position:var(--position);text-decoration:none;white-space:pre">AND </span></div><div style="line-height:8pt;position:var(--position);top:23.02pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.19pt;position:var(--position);text-decoration:none;white-space:pre">COMPUTER </span></div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.85pt;position:var(--position);text-decoration:none;white-space:pre">EQUIPMENT</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);width:63pt"><div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.51pt;position:var(--position);text-decoration:none;white-space:pre">TOTAL</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);width:63pt"><div><div style="line-height:8pt;position:var(--position);top:23.02pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.29pt;position:var(--position);text-decoration:none;white-space:pre">OF WHICH </span></div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.62pt;position:var(--position);text-decoration:none;white-space:pre">ROU</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:41.25pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DEPRECIATION</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:53.25pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY 1, 2023</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);top:53.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(259)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:53.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(378)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:53.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(171)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:53.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(808)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:53.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(290)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:74.25pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Increase </span></div></div></div></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);top:74.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(578)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:74.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.3pt"></span></span><span style="left:48.93pt;position:var(--position)">(36)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:74.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.3pt"></span></span><span style="left:48.93pt;position:var(--position)">(94)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:74.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(707)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:74.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(498)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:86.25pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Disposal</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);top:86.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:86.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">27<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:86.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:86.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">27<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:86.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">27<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:98.25pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);top:98.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(837)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:98.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(387)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:98.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(265)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:98.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.3pt"></span></span><span style="left:38.93pt;position:var(--position)">(1,488)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:98.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(761)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:119.25pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Increase </span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);top:119.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(886)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:119.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.3pt"></span></span><span style="left:48.93pt;position:var(--position)">(32)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:119.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(171)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:119.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.3pt"></span></span><span style="left:38.93pt;position:var(--position)">(1,089)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:119.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(788)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:131.25pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Disposal</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);top:131.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)">1,111<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:131.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:131.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">104<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:131.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)">1,215<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:131.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">975<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:143.25pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);top:143.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(613)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:143.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(419)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:143.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(332)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:143.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.3pt"></span></span><span style="left:38.93pt;position:var(--position)">(1,363)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:143.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(575)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:164.25pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Increase </span></div></div></div></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);top:164.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(903)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:164.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.3pt"></span></span><span style="left:48.93pt;position:var(--position)">(35)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:164.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(158)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:164.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.3pt"></span></span><span style="left:38.93pt;position:var(--position)">(1,095)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:164.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(797)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:176.25pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Disposal</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);top:176.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:176.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">49<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:176.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">203<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:176.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">252<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:176.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">53<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:188.25pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Effect of the change in foreign currency exchange rates</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);top:188.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">17<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:188.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:188.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.96pt"></span></span><span style="left:55.59pt;position:var(--position)">5<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:188.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">22<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:188.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.99pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">17<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:201pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);top:201pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.3pt"></span></span><span style="left:38.93pt;position:var(--position)">(1,498)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:201pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(404)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:201pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(281)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:201pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.3pt"></span></span><span style="left:38.93pt;position:var(--position)">(2,184)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:201pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.3pt"></span></span><span style="left:38.93pt;position:var(--position)">(1,302)</span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:577.07pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:529.5pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:200.25pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:56.25pt"></td></tr><tr style="height:41.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:17.55pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:48.59pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:200.25pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.2pt;position:var(--position);text-decoration:none;white-space:pre">BUILDINGS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.98pt;position:var(--position);text-decoration:none;white-space:pre">EQUIPMENT</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:336.75pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.82pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.87pt;position:var(--position);text-decoration:none;white-space:pre">FURNITURE </span></div><div style="line-height:8pt;position:var(--position);top:13.42pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.97pt;position:var(--position);text-decoration:none;white-space:pre">AND </span></div><div style="line-height:8pt;position:var(--position);top:23.02pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.31pt;position:var(--position);text-decoration:none;white-space:pre">COMPUTER </span></div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.98pt;position:var(--position);text-decoration:none;white-space:pre">EQUIPMENT</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:405pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.63pt;position:var(--position);text-decoration:none;white-space:pre">TOTAL</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);width:56.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.02pt;width:56.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.91pt;position:var(--position);text-decoration:none;white-space:pre">OF WHICH </span></div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:56.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:19.24pt;position:var(--position);text-decoration:none;white-space:pre">ROU</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:41.25pt;width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">NET BOOK VALUES</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:53.25pt;width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY 1, 2023</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:200.25pt;position:var(--position);top:53.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">1,359<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:265.5pt;overflow:hidden;position:var(--position);top:53.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:53.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">59<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:333.75pt;overflow:hidden;position:var(--position);top:53.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:336.75pt;position:var(--position);top:53.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)">175<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:402pt;overflow:hidden;position:var(--position);top:53.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:405pt;position:var(--position);top:53.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">1,592<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:470.25pt;overflow:hidden;position:var(--position);top:53.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:53.25pt;width:56.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:56.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.21pt"></span></span><span style="left:34.84pt;position:var(--position)">1,270<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:74.25pt;width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:200.25pt;position:var(--position);top:74.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)">509<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:265.5pt;overflow:hidden;position:var(--position);top:74.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:74.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)">126<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:333.75pt;overflow:hidden;position:var(--position);top:74.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:336.75pt;position:var(--position);top:74.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)">242<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:402pt;overflow:hidden;position:var(--position);top:74.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:405pt;position:var(--position);top:74.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)">878<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:470.25pt;overflow:hidden;position:var(--position);top:74.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:74.25pt;width:56.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:56.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.21pt"></span></span><span style="left:40.84pt;position:var(--position)">501<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:95.25pt;width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:200.25pt;position:var(--position);top:95.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">2,205<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:265.5pt;overflow:hidden;position:var(--position);top:95.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:95.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">94<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:333.75pt;overflow:hidden;position:var(--position);top:95.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:336.75pt;position:var(--position);top:95.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)">366<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:402pt;overflow:hidden;position:var(--position);top:95.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:405pt;position:var(--position);top:95.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">2,666<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:470.25pt;overflow:hidden;position:var(--position);top:95.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:95.25pt;width:56.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:56.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.21pt"></span></span><span style="left:34.84pt;position:var(--position)">1,950<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:116.25pt;width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:200.25pt;position:var(--position);top:116.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">1,706<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:265.5pt;overflow:hidden;position:var(--position);top:116.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:116.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">59<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:333.75pt;overflow:hidden;position:var(--position);top:116.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:336.75pt;position:var(--position);top:116.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)">325<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:402pt;overflow:hidden;position:var(--position);top:116.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:405pt;position:var(--position);top:116.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">2,090<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:470.25pt;overflow:hidden;position:var(--position);top:116.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:116.25pt;width:56.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:56.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.21pt"></span></span><span style="left:34.84pt;position:var(--position)">1,563<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:83.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Right of use assets relate to buildings, vehicles and furniture. The net book value of right of use assets related to buildings amounted to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:95.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;453&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.59pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:99.59pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,846&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:165.68pt;position:var(--position);text-decoration:none;white-space:pre"> and</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:182.61pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:185.11pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,473 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:251.2pt;position:var(--position);text-decoration:none;white-space:pre"> as of December 31, 2023, 2024 and 2025 respectively. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:119.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Acquisitions over the year ended December 31, 2023 mainly include the right of use asset related to the new Boston offices entered </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:131.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">into in November 2023. Decreases mainly include the remeasurement of the right of use asset related to the reassessment of the Paris </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:143.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Headquarters lease term, for an amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:206.9pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;622&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:265.49pt;position:var(--position);text-decoration:none;white-space:pre"> (see Note 15.8).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:167.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Acquisitions over the period ended December 31, 2024 mainly include the right of use assets related to the new Paris headquarters and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:179.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Montpellier offices entered into in May and April 2024 respectively, as well as the 1-year renewal of the Boston offices lease (see </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:191.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 15.8). Disposals over the period ended December 31, 2024 mainly include the right of use asset related to the former Paris </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:203.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">headquarters lease, which ended in June 2024.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:227.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Acquisitions over the period ended December 31, 2025 mainly include right of use assets related to the renewal of the hosting </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:239.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">agreement with the CNRS </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:143.65pt;position:var(--position);text-decoration:none;white-space:pre">(French National Centre for Scientific Research)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:338.09pt;position:var(--position);text-decoration:none;white-space:pre"> research laboratories based in Montpellier (which </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:251.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">previously fell under the IFRS 16 short-term lease exemption), as well as new office equipment leases. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:263.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Disposals over the period ended December 31, 2025 of the period mainly relate to the decommissioning of obsolete IT equipments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other financial assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsAbstract', window );"><strong>Disclosure of financial assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherAssetsExplanatory', window );">Other financial assets</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:68.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Other financial assets</span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:323.46pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Other financial assets break down as follows:</span></div><div style="font-size:12pt;line-height:11pt;position:var(--position);top:334.76pt;width:612pt"><span style="font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="position:var(--position);top:351.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:445.5pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:243.75pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:243.75pt"><div><div style="line-height:8pt;position:var(--position);top:21.98pt;width:243.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:70.34pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:243.75pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.97pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.97pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.97pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:30.75pt;width:243.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:243.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">OTHER FINANCIAL ASSETS</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:243.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:243.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Advances related to CRO contracts</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:243.75pt;position:var(--position);top:42.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.88pt"></span></span><span style="left:39.510000000000005pt;position:var(--position)">12,172<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:309pt;overflow:hidden;position:var(--position);top:42.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:42.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">4,929<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:377.25pt;overflow:hidden;position:var(--position);top:42.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:42.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">4,665<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:243.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:243.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Deposits</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:243.75pt;position:var(--position);top:54.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.88pt"></span></span><span style="left:49.510000000000005pt;position:var(--position)">574<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:309pt;overflow:hidden;position:var(--position);top:54.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:54.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.88pt"></span></span><span style="left:49.510000000000005pt;position:var(--position)">863<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:377.25pt;overflow:hidden;position:var(--position);top:54.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:54.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.88pt"></span></span><span style="left:49.510000000000005pt;position:var(--position)">693<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:243.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:243.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:243.75pt;position:var(--position);top:66.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.88pt"></span></span><span style="left:49.510000000000005pt;position:var(--position)">124<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:309pt;overflow:hidden;position:var(--position);top:66.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:66.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.88pt"></span></span><span style="left:49.510000000000005pt;position:var(--position)">126<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:377.25pt;overflow:hidden;position:var(--position);top:66.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:66.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:243.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:243.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total other non-current financial assets</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:243.75pt;position:var(--position);top:78.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.88pt"></span></span><span style="left:39.510000000000005pt;position:var(--position)">12,870<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:78.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">5,919<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:78.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">5,358<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90.75pt;width:243.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:243.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Advances related to CRO contracts</span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:243.75pt;position:var(--position);top:90.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:309pt;overflow:hidden;position:var(--position);top:90.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:90.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">7,418<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:377.25pt;overflow:hidden;position:var(--position);top:90.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:90.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">7,717<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102.75pt;width:243.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:243.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Deposits</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:243.75pt;position:var(--position);top:102.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.88pt"></span></span><span style="left:49.510000000000005pt;position:var(--position)">136<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:102.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.88pt"></span></span><span style="left:49.510000000000005pt;position:var(--position)">136<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:102.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:114.75pt;width:243.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:243.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other investments</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:243.75pt;position:var(--position);top:114.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">9,050<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:309pt;overflow:hidden;position:var(--position);top:114.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:114.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:377.25pt;overflow:hidden;position:var(--position);top:114.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:114.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.88pt"></span></span><span style="left:39.510000000000005pt;position:var(--position)">13,698<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:126.75pt;width:243.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:243.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total other current financial assets</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:243.75pt;position:var(--position);top:126.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">9,186<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:126.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">7,554<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:126.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.88pt"></span></span><span style="left:39.510000000000005pt;position:var(--position)">21,415<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:138.75pt;width:243.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:243.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial assets</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:243.75pt;position:var(--position);top:138.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.88pt"></span></span><span style="left:39.510000000000005pt;position:var(--position)">22,055<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:138.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.88pt"></span></span><span style="left:39.510000000000005pt;position:var(--position)">13,473<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:138.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.88pt"></span></span><span style="left:39.510000000000005pt;position:var(--position)">26,772<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:531.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Advances related to CRO contracts </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:544.61pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">A</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43.22pt;position:var(--position);text-decoration:none;white-space:pre">dvances granted in 2022 for a total undiscounted amount of </span><span style="color:#008080;font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:283.55pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:289.55pt;position:var(--position);text-decoration:none;white-space:pre">12,187 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:355.64pt;position:var(--position);text-decoration:none;white-space:pre"> f</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:361.47pt;position:var(--position);text-decoration:none;white-space:pre">or clinical studies are to be recovered at the end of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:558.05pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the studies after final reconciliation with pass-through costs, which are being invoiced and paid as studies are carried out. These long-</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:569.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">term advances were measured at fair value on initial recognition, using discount rates ranging from </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:434.4pt;position:var(--position);text-decoration:none;white-space:pre">0.19%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:460.23pt;position:var(--position);text-decoration:none;white-space:pre"> to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:473pt;position:var(--position);text-decoration:none;white-space:pre">7.16%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:498.83pt;position:var(--position);text-decoration:none;white-space:pre">, and are </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:580.45pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">subsequently measured at amortized cost.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:597.65pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">During the first half of 2023, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:153.97pt;position:var(--position);text-decoration:none;white-space:pre">additional advances related to CRO contracts</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:334.54pt;position:var(--position);text-decoration:none;white-space:pre"> amounting to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:392.55pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,620&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:458.64pt;position:var(--position);text-decoration:none;white-space:pre"> were made (undiscounted </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:609.65pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">amount). These long-term advances were measured at fair value on initial recognition, using discount rates ranging from </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:520.15pt;position:var(--position);text-decoration:none;white-space:pre">7.09%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:545.98pt;position:var(--position);text-decoration:none;white-space:pre"> to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:621.65pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">7.59%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:61.83pt;position:var(--position);text-decoration:none;white-space:pre">, and are subsequently measured at amortized cost. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:639.65pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">At inception, a prepaid expenses asset was recognized for the difference between the advances&#8217; nominal value and fair value, and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:652.95pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">spread over the term of the advances, at the rate of recognition of the related R&amp;D expenses (see Note 10).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:672.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In March 2024</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:95.41pt;position:var(--position);text-decoration:none;white-space:pre">, a change order was signed with the CRO, extending the scope (addition of maintenance studies) and end date of one of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:684.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the studies to 2029, thus postponing the recovery date of the corresponding advance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:384.85pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5,538&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:450.94pt;position:var(--position);text-decoration:none;white-space:pre"> (undiscounted amount) from </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:696.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">June 2026 to June 2029. The Group considered that this asset modification met the criteria for derecognition, and recognized a new </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:708.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">financial asset at fair value on that date, using a discount rate of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:292.87pt;position:var(--position);text-decoration:none;white-space:pre">6.83%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:318.7pt;position:var(--position);text-decoration:none;white-space:pre">. Since the Group considers that these advances are made in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">exchange for a discount on future services to be received from the CROs, a prepaid expense asset was also recognized for the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:82.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">difference between the derecognized asset carrying value and new asset fair value, and spread over </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:433.79pt;position:var(--position);text-decoration:none;white-space:pre">the term of the advanc</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:523.11pt;position:var(--position);text-decoration:none;white-space:pre">e </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:530.04pt;position:var(--position);text-decoration:none;white-space:pre">(equal to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:94.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the period of service) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:123.67pt;position:var(--position);text-decoration:none;white-space:pre">in a similar manner.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:112.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2025, the recovery dates of these advances are spread from 2026 to 2030.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:131.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The credit risk related to these advances is deemed insignificant</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:291.46000000000004pt;position:var(--position);text-decoration:none;white-space:pre"> due to the CROs' credit ratings.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:155.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Other investments</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:179.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, other investments consist of 6-month term deposits that do not qualify for a classification under cash and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:191.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">cash equivalents.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:215.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2025 other investments consist of 9-month and 12-month term deposits that do not qualify for a classification </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:227.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">under cash and cash equivalents.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:251.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Deposits</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:269.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Deposits include the Paris and Boston offices lease contracts, the ATM Program deposit, as well as other security deposits.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other assets. [Refer: Other assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other receivables and other assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesAbstract', window );"><strong>Trade and other receivables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory', window );">Other receivables and other assets</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Other receivables and other assets</span><div style="font-size:12pt;line-height:11pt;position:var(--position);top:328.96pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:42pt;position:var(--position);text-decoration:none;white-space:pre">Other receivables and other assets break down as follows:</span><span style="font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:273.4pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="position:var(--position);top:340.84pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:435pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:233.25pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:233.25pt"><div><div style="line-height:8pt;position:var(--position);top:21.98pt;width:233.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:65.09pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:233.25pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.97pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:301.5pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.97pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:369.75pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.97pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:30.75pt;width:233.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:233.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">OTHER RECEIVABLES AND ASSETS</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:233.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:233.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Prepaid expenses - non current</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:233.25pt;position:var(--position);top:42.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">2,320<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:301.5pt;position:var(--position);top:42.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)">948<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:366.75pt;overflow:hidden;position:var(--position);top:42.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:369.75pt;position:var(--position);top:42.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)">625<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:233.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:233.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total other non-current assets</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:233.25pt;position:var(--position);top:54.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">2,320<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:301.5pt;position:var(--position);top:54.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)">948<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:369.75pt;position:var(--position);top:54.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)">625<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:233.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:233.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Research tax credit ("CIR")</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:233.25pt;position:var(--position);top:66.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">4,600<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:301.5pt;position:var(--position);top:66.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">5,774<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:366.75pt;overflow:hidden;position:var(--position);top:66.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:369.75pt;position:var(--position);top:66.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">3,196<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:233.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:233.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">VAT receivables</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:233.25pt;position:var(--position);top:78.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">14,439<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:301.5pt;position:var(--position);top:78.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">9,841<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:366.75pt;overflow:hidden;position:var(--position);top:78.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:369.75pt;position:var(--position);top:78.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">6,870<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90.75pt;width:233.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:233.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Prepaid expenses </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:233.25pt;position:var(--position);top:90.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">5,746<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:301.5pt;position:var(--position);top:90.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">3,233<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:366.75pt;overflow:hidden;position:var(--position);top:90.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:369.75pt;position:var(--position);top:90.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">2,649<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102.75pt;width:233.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:233.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Employee-related receivables</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:233.25pt;position:var(--position);top:102.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:301.5pt;position:var(--position);top:102.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:369.75pt;position:var(--position);top:102.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)">429<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:114.75pt;width:233.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:233.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Credit notes</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:233.25pt;position:var(--position);top:114.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">60<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:301.5pt;position:var(--position);top:114.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">48<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:369.75pt;position:var(--position);top:114.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:126.75pt;width:233.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:233.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total current other receivables and assets</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:233.25pt;position:var(--position);top:126.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">24,845<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:301.5pt;position:var(--position);top:126.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">18,896<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:369.75pt;position:var(--position);top:126.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">13,144<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:138.75pt;width:233.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:233.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other receivables and assets</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:233.25pt;position:var(--position);top:138.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">27,164<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:301.5pt;position:var(--position);top:138.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">19,843<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:369.75pt;position:var(--position);top:138.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">13,769<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:506.59pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Research tax credit (&#8220;CIR&#8221;) </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:522.59pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The CIR is recognized as Other Operating Income (see note 4.9) in the year to which the eligible research expense relates. The Group </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:532.59pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">received the payments of the CIR for 2023 and 2024 tax years in the amount of respectively&#160; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:408.38pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;4,493&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:474.47pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:493.9pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5,640&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:559.99pt;position:var(--position);text-decoration:none;white-space:pre"> in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:542.59pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">respectively 2024 and 2025 and expects to receive the CIR for the 2025 tax year o</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:364.25pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">f </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:370.08pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3,196 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:436.17pt;position:var(--position);text-decoration:none;white-space:pre"> in 2026. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:570.59pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">VAT Receivables </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:586.59pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Value-added tax (&#8220;VAT&#8221;) receivables relate primarily to the deductible VAT and VAT refunds claimed.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:620.59pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Prepaid expenses </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:644.59pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Prepaid expenses as of December 31, 2023 include prepaid expenses related to CRO contracts for an amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:484.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,347&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:550.21pt;position:var(--position);text-decoration:none;white-space:pre"> (see </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:655.79pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 9) and deferred transactions costs related to tranches B and C of the Kreos / Claret financings for an amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:502.68pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3,152&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:568.77pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:666.99pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(most of which represents the issuance date fair value of the tranche A-B and C Kreos / Claret BSA, representing origination fees for </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:678.19pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the future drawdowns of the tranches B and C of the Kreos / Claret Financing, See Note</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:387.57pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> 15.1) and other expenses from various </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:689.39pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">suppliers amounting to </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:130.09pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;3,567&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:196.18pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">.</span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Prepaid expenses as of December 31, 2024 include prepaid expenses related to CRO contracts for an amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:484.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,577&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:550.21pt;position:var(--position);text-decoration:none;white-space:pre"> (see </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:81.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 9) </span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:68.75pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">and other expenses from various suppliers amounting to </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:295.22pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;2,604&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:361.31pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">.</span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:104.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The decrease in prepaid expenses over the year ended December 31, 2024 mainly corresponds to the reclassification of the deferred </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:115.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">transaction costs of tranche B of the Kreos / Claret Financing, from prepaid expenses to a reduction of the initial carrying value of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">tranche B </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:77.05pt;position:var(--position);text-decoration:none;white-space:pre">debt </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.75pt;position:var(--position);text-decoration:none;white-space:pre">component, in accordance with the effective interest rate method, for an amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:429.92pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,546&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:496.01pt;position:var(--position);text-decoration:none;white-space:pre">, and to the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:137.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">amortization of the deferred transaction costs related to tranche C (already fully amortized on the date of drawdown).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:160.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Prepaid expenses as of December 31, 2025 include prepaid expenses related to CRO contracts for an amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:484.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,068&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:550.21pt;position:var(--position);text-decoration:none;white-space:pre"> (see </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:171.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 9) and other expenses from various suppliers amounting to</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:292.72pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:295.22pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;2,207&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:361.31pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other receivables. [Refer: Trade and other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and cash equivalents<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory', window );">Cash and cash equivalents</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Cash and cash equivalents</span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:227.8pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:41pt;position:var(--position);text-decoration:none;white-space:pre">Cash and cash equivalents break down as follows:</span></div><div style="position:var(--position);top:261.7pt;width:612pt"><div style="font-size:0pt;left:41pt;position:var(--position);width:474pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:243pt"></td><td style="padding:0;width:75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:75pt"></td></tr><tr style="height:30.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:243pt"><div><div style="line-height:8pt;position:var(--position);top:21.98pt;width:243pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:69.96pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:243pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.84pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.5pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:321pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.84pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.5pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.84pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.5pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:30.75pt;width:243pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:243pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">CASH AND CASH EQUIVALENTS</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:243pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:243pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cash equivalents</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:243pt;position:var(--position);top:42.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:50.37pt;position:var(--position);text-decoration:none;white-space:pre">18,105</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:321pt;position:var(--position);top:42.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:50.37pt;position:var(--position);text-decoration:none;white-space:pre">87,265</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:396pt;overflow:hidden;position:var(--position);top:42.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:42.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.37pt;position:var(--position);text-decoration:none;white-space:pre">478,541</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:243pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:243pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cash</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:243pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.37pt;position:var(--position);text-decoration:none;white-space:pre">233,837</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:321pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:50.37pt;position:var(--position);text-decoration:none;white-space:pre">56,956</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:396pt;overflow:hidden;position:var(--position);top:54.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:50.37pt;position:var(--position);text-decoration:none;white-space:pre">38,144</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:243pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:243pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cash and cash equivalents</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:243pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:46.37pt;position:var(--position);text-decoration:none;white-space:pre">251,942</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:321pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:46.37pt;position:var(--position);text-decoration:none;white-space:pre">144,221</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:396pt;overflow:hidden;position:var(--position);top:66.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:46.37pt;position:var(--position);text-decoration:none;white-space:pre">516,685</span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:356.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Cash equivalents mainly include term deposits with short-term maturities (measured at amortized cost) and highly liquid investments </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:368.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in mutual funds and structured notes (measured at fair value through profit or loss) denominated in euros and U.S. dollars.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:391.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, 2024 and 2025, in addition to the Group&#8217;s bank accounts, cash includes notice accounts amounting to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:402.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;231,562 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.09pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:117.09pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;44,239 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:188.18pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:207.61pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5,744 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:273.7pt;position:var(--position);text-decoration:none;white-space:pre"> respectively. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:329.45pt;position:var(--position);text-decoration:none;white-space:pre">These funds are available on demand within 24 hours and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:414.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">without penalty.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:437.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The increase in cash and cash equivalents over the year ended December 31, 2025 is mainly explained by the proceeds from the&#160; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:448.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Offering completed on July 28, 2025 (see N</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:211.97pt;position:var(--position);text-decoration:none;white-space:pre">ote 3.3 - </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:247.5pt;position:var(--position);text-decoration:none;white-space:pre">Completion of a public offering </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:375.99pt;position:var(--position);text-decoration:none;white-space:pre">&#8211;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:380.99pt;position:var(--position);text-decoration:none;white-space:pre"> July 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:422.62pt;position:var(--position);text-decoration:none;white-space:pre">).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:472.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, 2024 and 2025, the impact of the revaluation of cash and cash equivalents held in U.S. dollars by the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:483.75pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Company into the its functional</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:162.53pt;position:var(--position);text-decoration:none;white-space:pre"> currency</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:199.98pt;position:var(--position);text-decoration:none;white-space:pre"> (euro) is a net financial expense of</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:340.63pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:343.13pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3,196 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:409.22pt;position:var(--position);text-decoration:none;white-space:pre">, a net financial income of </span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;2,035&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:102.09pt;position:var(--position);text-decoration:none;white-space:pre"> and a net financial expense of</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:223.59pt;position:var(--position);text-decoration:none;white-space:pre"> &#8364;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:231.09pt;position:var(--position);text-decoration:none;white-space:pre">8,639&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:292.18pt;position:var(--position);text-decoration:none;white-space:pre"> respectively.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial assets and liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_FairValueMeasurementAbstract', window );"><strong>Fair Value Measurement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory', window );">Financial assets and liabilities</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Financial assets and liabilities</span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:549.75pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">The following table shows the carrying amounts and fair value of financial assets and financial liabilities, including their </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:561.75pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">levels in the fair value hierarchy.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:573.75pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">Tax and employee-related payables are non-financial liabilities and are therefore excluded from the tables below. They are </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:585.75pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">presented in Note 17.2.</span></div><div><div style="position:var(--position);top:70.56pt;width:612pt"><div style="font-size:0pt;left:39pt;position:var(--position);width:534pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:189.75pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:71.25pt"></td></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td colspan="9" style="font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);width:344.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:344.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:160.47pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:344.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:134.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td></tr><tr style="height:69pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:60.23pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:43.34pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.42pt;position:var(--position);text-decoration:none;white-space:pre">AMOUNT </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.31pt;position:var(--position);text-decoration:none;white-space:pre">RECOGNIZED </span></div><div style="line-height:8pt;position:var(--position);top:31.57pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.74pt;position:var(--position);text-decoration:none;white-space:pre">IN THE </span></div><div style="line-height:8pt;position:var(--position);top:41.17pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.53pt;position:var(--position);text-decoration:none;white-space:pre">STATEMENT </span></div><div style="line-height:8pt;position:var(--position);top:50.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.43pt;position:var(--position);text-decoration:none;white-space:pre">OF&#160;FINANCIAL </span></div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.08pt;position:var(--position);text-decoration:none;white-space:pre">POSITION</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.87pt;position:var(--position);text-decoration:none;white-space:pre">FAIR&#160;VALUE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.64pt;position:var(--position);text-decoration:none;white-space:pre">ASSETS/ </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.97pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.31pt;position:var(--position);text-decoration:none;white-space:pre">AT FAIR </span></div><div style="line-height:8pt;position:var(--position);top:31.57pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.64pt;position:var(--position);text-decoration:none;white-space:pre">VALUE </span></div><div style="line-height:8pt;position:var(--position);top:41.17pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.75pt;position:var(--position);text-decoration:none;white-space:pre">THROUGH </span></div><div style="line-height:8pt;position:var(--position);top:50.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.87pt;position:var(--position);text-decoration:none;white-space:pre">PROFIT&#160;AND </span></div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.41pt;position:var(--position);text-decoration:none;white-space:pre">LOSS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:41.17pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.2pt;position:var(--position);text-decoration:none;white-space:pre">ASSETS AT </span></div><div style="line-height:8pt;position:var(--position);top:50.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.53pt;position:var(--position);text-decoration:none;white-space:pre">AMORTIZED </span></div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.74pt;position:var(--position);text-decoration:none;white-space:pre">COST</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:21pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:41.17pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.97pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES </span></div><div style="line-height:8pt;position:var(--position);top:50.77pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.98pt;position:var(--position);text-decoration:none;white-space:pre">AT&#160;AMORTIZED </span></div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.74pt;position:var(--position);text-decoration:none;white-space:pre">COST</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial assets (2)</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">22,055</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">22,394</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">22,394</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:90pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:60.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other receivables and assets (2)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:102pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">27,164</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:102pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">27,164</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:102pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:102pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">27,164</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:102pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:60.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:114pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cash and cash equivalents (1)</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:114pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">251,942</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:114pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">251,942</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:114pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:114pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">251,942</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:114pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:60.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:126pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial assets</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:126pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">301,161</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:126pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">301,500</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:126pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:126pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">301,500</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:126pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:60.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:138pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial liabilities&#8212;non-current portion (4, Note 15)</span></div></div></div></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:138pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">39,697</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:138pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">40,622</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:138pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">18,506</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:138pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:138pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.62pt;position:var(--position);text-decoration:none;white-space:pre">42,768</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:150pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial liabilities&#8212;current portion (3, Note 15)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:150pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">37,348</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:150pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">37,348</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:150pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">11,531</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:150pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:150pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:50.62pt;position:var(--position);text-decoration:none;white-space:pre">5,165</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:162pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Trade payables and other current liabilities (3)</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:162pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">47,221</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:162pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">47,221</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:162pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:162pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:162pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.62pt;position:var(--position);text-decoration:none;white-space:pre">47,221</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:174pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial liabilities</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:174pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">124,266</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:174pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">125,191</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:174pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">30,037</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:174pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:174pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:46.62pt;position:var(--position);text-decoration:none;white-space:pre">95,154</span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:273.56pt;width:612pt"><div style="font-size:0pt;left:39pt;position:var(--position);width:534pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:189.75pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:71.25pt"></td></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td colspan="9" style="font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);width:344.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:344.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:160.47pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:344.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:134.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td></tr><tr style="height:71.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:62.48pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:43.34pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.42pt;position:var(--position);text-decoration:none;white-space:pre">AMOUNT </span></div><div style="line-height:8pt;position:var(--position);top:24.22pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.31pt;position:var(--position);text-decoration:none;white-space:pre">RECOGNIZED </span></div><div style="line-height:8pt;position:var(--position);top:33.82pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.74pt;position:var(--position);text-decoration:none;white-space:pre">IN THE </span></div><div style="line-height:8pt;position:var(--position);top:43.42pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.53pt;position:var(--position);text-decoration:none;white-space:pre">STATEMENT </span></div><div style="line-height:8pt;position:var(--position);top:53.02pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.43pt;position:var(--position);text-decoration:none;white-space:pre">OF&#160;FINANCIAL </span></div><div style="line-height:8pt;position:var(--position);top:62.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.08pt;position:var(--position);text-decoration:none;white-space:pre">POSITION</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:62.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.87pt;position:var(--position);text-decoration:none;white-space:pre">FAIR&#160;VALUE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.02pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.64pt;position:var(--position);text-decoration:none;white-space:pre">ASSETS/ </span></div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.97pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES </span></div><div style="line-height:8pt;position:var(--position);top:24.22pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.31pt;position:var(--position);text-decoration:none;white-space:pre">AT FAIR </span></div><div style="line-height:8pt;position:var(--position);top:33.82pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.64pt;position:var(--position);text-decoration:none;white-space:pre">VALUE </span></div><div style="line-height:8pt;position:var(--position);top:43.42pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.75pt;position:var(--position);text-decoration:none;white-space:pre">THROUGH </span></div><div style="line-height:8pt;position:var(--position);top:53.02pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.87pt;position:var(--position);text-decoration:none;white-space:pre">PROFIT&#160;AND </span></div><div style="line-height:8pt;position:var(--position);top:62.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.41pt;position:var(--position);text-decoration:none;white-space:pre">LOSS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:43.42pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.2pt;position:var(--position);text-decoration:none;white-space:pre">ASSETS AT </span></div><div style="line-height:8pt;position:var(--position);top:53.02pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.53pt;position:var(--position);text-decoration:none;white-space:pre">AMORTIZED </span></div><div style="line-height:8pt;position:var(--position);top:62.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.74pt;position:var(--position);text-decoration:none;white-space:pre">COST</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:21pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:43.42pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.97pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES </span></div><div style="line-height:8pt;position:var(--position);top:53.02pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.98pt;position:var(--position);text-decoration:none;white-space:pre">AT&#160;AMORTIZED </span></div><div style="line-height:8pt;position:var(--position);top:62.62pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.74pt;position:var(--position);text-decoration:none;white-space:pre">COST</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:92.25pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial assets (2)</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:92.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">13,473</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:92.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">12,690</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:92.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:92.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">12,690</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:92.25pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:60.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:104.25pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other receivables and assets (2)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:104.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">19,843</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:104.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">19,843</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:104.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:104.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">19,843</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:104.25pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:60.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:116.25pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cash and cash equivalents (1)</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:116.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">144,221</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:116.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">144,221</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:116.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:116.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">144,221</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:116.25pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:60.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:128.25pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial assets</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:128.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">177,537</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:128.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">176,754</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:128.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:128.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">176,754</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:128.25pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:60.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:140.25pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial liabilities&#8212;non-current portion (4, Note 15)</span></div></div></div></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:140.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">69,069</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:140.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">73,497</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:140.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre">3,620</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:140.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:140.25pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.62pt;position:var(--position);text-decoration:none;white-space:pre">69,877</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:152.25pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial liabilities&#8212;current portion (3, Note 15)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:152.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">44,935</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:152.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">44,935</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:152.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">21,183</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:152.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:152.25pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.62pt;position:var(--position);text-decoration:none;white-space:pre">23,752</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:164.25pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Trade payables and other current liabilities (3)</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:164.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">43,824</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:164.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">43,824</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:164.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:164.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:164.25pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.62pt;position:var(--position);text-decoration:none;white-space:pre">43,824</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:176.25pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial liabilities</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:176.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">157,828</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:176.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">162,256</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:176.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">24,803</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:176.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:176.25pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:42.62pt;position:var(--position);text-decoration:none;white-space:pre">137,453</span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:478.81pt;width:612pt"><div style="font-size:0pt;left:40.12pt;position:var(--position);width:531.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:189.75pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:69pt"></td></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td colspan="9" style="font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);width:342pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:342pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:159.34pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:342pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:132.91pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td></tr><tr style="height:69pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:60.23pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:43.34pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.42pt;position:var(--position);text-decoration:none;white-space:pre">AMOUNT </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.31pt;position:var(--position);text-decoration:none;white-space:pre">RECOGNIZED </span></div><div style="line-height:8pt;position:var(--position);top:31.57pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.74pt;position:var(--position);text-decoration:none;white-space:pre">IN THE </span></div><div style="line-height:8pt;position:var(--position);top:41.17pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.53pt;position:var(--position);text-decoration:none;white-space:pre">STATEMENT </span></div><div style="line-height:8pt;position:var(--position);top:50.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.43pt;position:var(--position);text-decoration:none;white-space:pre">OF&#160;FINANCIAL </span></div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.08pt;position:var(--position);text-decoration:none;white-space:pre">POSITION</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.87pt;position:var(--position);text-decoration:none;white-space:pre">FAIR&#160;VALUE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.64pt;position:var(--position);text-decoration:none;white-space:pre">ASSETS/ </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.97pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.31pt;position:var(--position);text-decoration:none;white-space:pre">AT FAIR </span></div><div style="line-height:8pt;position:var(--position);top:31.57pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.64pt;position:var(--position);text-decoration:none;white-space:pre">VALUE </span></div><div style="line-height:8pt;position:var(--position);top:41.17pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.75pt;position:var(--position);text-decoration:none;white-space:pre">THROUGH </span></div><div style="line-height:8pt;position:var(--position);top:50.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.87pt;position:var(--position);text-decoration:none;white-space:pre">PROFIT&#160;AND </span></div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.41pt;position:var(--position);text-decoration:none;white-space:pre">LOSS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:41.17pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.2pt;position:var(--position);text-decoration:none;white-space:pre">ASSETS AT </span></div><div style="line-height:8pt;position:var(--position);top:50.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.53pt;position:var(--position);text-decoration:none;white-space:pre">AMORTIZED </span></div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.74pt;position:var(--position);text-decoration:none;white-space:pre">COST</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:21pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:41.17pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.85pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES </span></div><div style="line-height:8pt;position:var(--position);top:50.77pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.86pt;position:var(--position);text-decoration:none;white-space:pre">AT&#160;AMORTIZED </span></div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">COST</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial assets (2)</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">26,772<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">27,141<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">27,141<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:90pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.96pt"></span></span><span style="left:57.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other receivables and assets (2)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:102pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">13,769<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:102pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">13,769<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:102pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:102pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">13,769<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:102pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.96pt"></span></span><span style="left:57.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:114pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cash and cash equivalents (1)</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:114pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">516,685<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:114pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">516,685<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:114pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">437,031<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:114pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">79,654<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:114pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.96pt"></span></span><span style="left:57.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:126pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial assets</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:126pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">557,226<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:126pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">557,595<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:126pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">437,031<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:126pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">120,565<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:126pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:54.96pt"></span></span><span style="left:57.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:138pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial liabilities&#8212;non-current portion (4, Note 15)</span></div></div></div></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:138pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">30,790<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:138pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">102,555<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:138pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:138pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:138pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">102,555<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:150pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial liabilities&#8212;current portion (3, Note 15)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:150pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">1,302<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:150pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">1,302<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:150pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:150pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:150pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">1,302<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:162pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Trade payables and other current liabilities (3)</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:162pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">37,552<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:162pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">37,552<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:162pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:162pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:162pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.96pt"></span></span><span style="left:43.59pt;position:var(--position)">37,552<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:174pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial liabilities</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:174pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">69,644<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:174pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">141,409<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:174pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:174pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:174pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">141,409<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:681.81pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(1)&#160; &#160;  The fair value of cash and cash equivalents is determined based on Level 1 fair value measurement and corresponds to the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:693.81pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">market value of the assets. </span></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(2)&#160; &#160;  The carrying amount of financial assets measured at amortized cost is deemed to be a reasonable estimate of fair value, except </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:82.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">for the long-term advances made to CROs, whose fair value is determined based on Level 3 fair value measurement and is estimated </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:93.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">based on future cash-flows discounted at market rates, using credit spreads ranging from </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:392.29pt;position:var(--position);text-decoration:none;white-space:pre">104</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:407.29pt;position:var(--position);text-decoration:none;white-space:pre"> bp to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:432.56pt;position:var(--position);text-decoration:none;white-space:pre">218</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:447.56pt;position:var(--position);text-decoration:none;white-space:pre"> bp as of December 31, 2023, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:105.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">131</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:51pt;position:var(--position);text-decoration:none;white-space:pre"> bp to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:76.27000000000001pt;position:var(--position);text-decoration:none;white-space:pre">271</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.27000000000001pt;position:var(--position);text-decoration:none;white-space:pre"> bp as of December 31, 2024 and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:225.89pt;position:var(--position);text-decoration:none;white-space:pre">34</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:235.89pt;position:var(--position);text-decoration:none;white-space:pre"> bp to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:261.15999999999997pt;position:var(--position);text-decoration:none;white-space:pre">131</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:276.15999999999997pt;position:var(--position);text-decoration:none;white-space:pre"> bp as of December 31, 2025. As of December 31, 2023, 2024, and 2025, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:116.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">an increase in the credit spread by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:174.42pt;position:var(--position);text-decoration:none;white-space:pre">+100</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:195.05pt;position:var(--position);text-decoration:none;white-space:pre"> bp would result in a decrease in the advances fair value by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:433.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;23&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:486.96pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:491.96pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;235&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:550.55pt;position:var(--position);text-decoration:none;white-space:pre">, and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:128.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;231&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.59pt;position:var(--position);text-decoration:none;white-space:pre">, respectively. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:151.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(3)&#160; &#160;  The carrying amount of short-term financial liabilities measured at amortized cost was deemed to be a reasonable estimate of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:163.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">fair value. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:187.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(4)&#160; &#160;  The fair value of the royalty certificates, Heights convertible notes, Kreos / Claret BSA and Minimum Return Indemnifications </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:199.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">is based on Level 3 fair value measurement and is estimated based on models and assumptions detailed in Note 15. The fair value of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:211.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">other long-term financial liabilities is determined based on Level 3 fair value measurement and is estimated based on future cash-flows </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:223.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">discounted at market rates, using the following assumptions: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:247.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">For the debt components of the Kreos / Claret OCABSA (tranche A) and the tranches B and C of the Kreos / Claret straight </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:259.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">bond loans, a credit spread of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:192.16pt;position:var(--position);text-decoration:none;white-space:pre">960</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:207.16pt;position:var(--position);text-decoration:none;white-space:pre"> bp as of August 22, 2023, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:315.19pt;position:var(--position);text-decoration:none;white-space:pre">900</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:330.19pt;position:var(--position);text-decoration:none;white-space:pre"> bp as of December 31, 2023 and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:464.81pt;position:var(--position);text-decoration:none;white-space:pre">750</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:479.81pt;position:var(--position);text-decoration:none;white-space:pre"> bp as of December 31, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:271.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">2024. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:283.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">As of August 22, 2023, December 31, 2023 (tranche A) and December 31, 2024 (all </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:410.9pt;position:var(--position);text-decoration:none;white-space:pre">three</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:430.86pt;position:var(--position);text-decoration:none;white-space:pre"> tranches), an increase in the credit </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:295.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">spread by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.08pt;position:var(--position);text-decoration:none;white-space:pre">+100</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:133.71pt;position:var(--position);text-decoration:none;white-space:pre"> bp would result in a decrease in the Kreos / Claret debt components fair value by respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:512.69pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;624&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:571.28pt;position:var(--position);text-decoration:none;white-space:pre">,&#160; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:307.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;538&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:130.59pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:150.01999999999998pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;958&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:208.61pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:331.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">For the conditional advances and the PGE loan, a credit spread of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:336.42pt;position:var(--position);text-decoration:none;white-space:pre">900</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:351.42pt;position:var(--position);text-decoration:none;white-space:pre"> bp as of December 31, 2023, and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:488.54pt;position:var(--position);text-decoration:none;white-space:pre">730</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:503.54pt;position:var(--position);text-decoration:none;white-space:pre"> bp as of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:343.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">December 31, 2024. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.54000000000002pt;position:var(--position);text-decoration:none;white-space:pre">An i</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:173.03pt;position:var(--position);text-decoration:none;white-space:pre">ncrease in the credit spread by</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:294.25pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:296.75pt;position:var(--position);text-decoration:none;white-space:pre">+100</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:317.38pt;position:var(--position);text-decoration:none;white-space:pre"> bp w</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:339.6pt;position:var(--position);text-decoration:none;white-space:pre">ould result in the following: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:355.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:76.5pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.5pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, and 2024, a decrease in the PGE loan fair value by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:407.25pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;39&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:460.84pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:480.27pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;21&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:533.86pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:367.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.5pt;position:var(--position);text-decoration:none;white-space:pre">respectively. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:379.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:76.5pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.5pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, a decrease in the RNP-VIR conditional advance fair value by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:449.38pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;15&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:502.97pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:391.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:76.5pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.5pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, a decrease in the CARENA conditional advance fair value by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:450.48pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;37&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:504.07pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:76.5pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.5pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, a decrease in the Ebola conditional advance fair value by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:432.7pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1&#160;thousand</span>.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_FairValueMeasurementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurement [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_FairValueMeasurementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the fair value of financial instruments. [Refer: Classes of financial instruments [domain]; At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">Shareholders&#8217; equity</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Shareholders&#8217; equity</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 13.1. Share capital issued<span id="i0fdb1d24fb1f4032bcb05504b8034ab4"></span></span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:490.76pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group manages its capital to ensure that the Group will be able to continue as a going concern while maximizing the return to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:502.76pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">shareholders through the optimization of the debt and equity balance.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:526.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, the Group&#8217;s share capital amounted to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.8pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;629&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:357.39pt;position:var(--position);text-decoration:none;white-space:pre"> divided into </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:410.4pt;position:var(--position);text-decoration:none;white-space:pre">62,928,818</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:455.4pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares issued with a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:540.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">par value of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:86.22pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.01</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108.72pt;position:var(--position);text-decoration:none;white-space:pre"> each, fully paid up, after taking into account the various capital increases that took place since the inception (see </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:553.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 13.2). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:578.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2024, the Group&#8217;s share capital amounted to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.8pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;633&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:357.39pt;position:var(--position);text-decoration:none;white-space:pre"> divided into </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:410.4pt;position:var(--position);text-decoration:none;white-space:pre">63,347,837</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:455.4pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares issued with a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:589.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">par value of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:86.22pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.01</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108.72pt;position:var(--position);text-decoration:none;white-space:pre"> each, fully paid up, after taking into account the various capital increases that took place since the inception (see </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:601.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 13.2). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:622.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2025, the Group&#8217;s share capital amounted to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.8pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;785&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:357.39pt;position:var(--position);text-decoration:none;white-space:pre"> divided into </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:410.4pt;position:var(--position);text-decoration:none;white-space:pre">78,536,412</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:455.4pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares issued with a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:633.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">par value of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:86.22pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.01</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108.72pt;position:var(--position);text-decoration:none;white-space:pre"> each, fully paid up, after taking into account the various capital increases that took place since inception (see Note </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:644.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">13.2).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:667.96pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Share capital does not include founders&#8217; share subscription warrants (&#8220;Bons de souscription de parts de cr&#233;ateur d&#8217;entreprise&#8221; or </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:679.96pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8220;BCE&#8221;), share subscription warrants (&#8220;Bons de souscription d&#8217;actions,&#8221; or &#8220;BSA&#8221;) and free shares (&#8220;Attributions gratuites </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:691.96pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">d&#8217;actions,&#8221; or &#8220;AGA&#8221;) that have been granted to certain investors or natural persons, both employees and non-employees of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:703.96pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Group, but not yet exercised.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:99.86pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Treasury shares</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:121.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group held </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:101.78pt;position:var(--position);text-decoration:none;white-space:pre">11,339</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.28pt;position:var(--position);text-decoration:none;white-space:pre"> of its own shares as of December 31, 2023. The Group held </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:372.7pt;position:var(--position);text-decoration:none;white-space:pre">none</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:392.13pt;position:var(--position);text-decoration:none;white-space:pre"> of its own shares as of December 31, 2024 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:133.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and December 31, 2025.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:155.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The number of outstanding ordinary shares (excluding treasury shares held by the Group) was </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:414.55pt;position:var(--position);text-decoration:none;white-space:pre">62,928,818</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:459.55pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:464.55pt;position:var(--position);text-decoration:none;white-space:pre">63,347,837</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:509.55pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:512.05pt;position:var(--position);text-decoration:none;white-space:pre">and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:528.98pt;position:var(--position);text-decoration:none;white-space:pre">78,536,412</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:573.98pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:576.48pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:166.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">as of December 31, 2023, 2024 and 2025, respectively. </span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 13.2. Change in share capital<span id="ie3ec27c85b104470b4ffdcd1d8b63baf"></span></span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:235.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The increases in the share capital for the year ended December 31, 2023 relate to: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:253.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The completion of a capital increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:230.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;130,000&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:306.46000000000004pt;position:var(--position);text-decoration:none;white-space:pre"> on February 22, 2023 by issuing </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:440.86pt;position:var(--position);text-decoration:none;white-space:pre">20,000,000</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.86pt;position:var(--position);text-decoration:none;white-space:pre"> new ordinary shares </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:264.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">with a par value of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:149.41pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.01</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:171.91pt;position:var(--position);text-decoration:none;white-space:pre"> per share and a subscription price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:321.75pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.50</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:344.25pt;position:var(--position);text-decoration:none;white-space:pre"> per share; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:281.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The cash-less exercise of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:174.63pt;position:var(--position);text-decoration:none;white-space:pre">67,887</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:202.13pt;position:var(--position);text-decoration:none;white-space:pre"> Kreos A BSA and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:279.59000000000003pt;position:var(--position);text-decoration:none;white-space:pre">31,696</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:307.09000000000003pt;position:var(--position);text-decoration:none;white-space:pre"> Kreos B BSA on</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:377.06pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> May 24, 20</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:425.38pt;position:var(--position);text-decoration:none;white-space:pre">23, resulting in a capital increase of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:292.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,850&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:138.09pt;position:var(--position);text-decoration:none;white-space:pre"> by issuing </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:183.91pt;position:var(--position);text-decoration:none;white-space:pre">99,583</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:211.41pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares with a par value of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:355.15pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.01</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:377.65pt;position:var(--position);text-decoration:none;white-space:pre"> per share and an average subscription price of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:303.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;18.57</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:99.5pt;position:var(--position);text-decoration:none;white-space:pre"> per share, which includes the impact of the derecognition of the BSA derivative financial liability; and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:321.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The completion of the Group&#8217;s Global Offering on the Nasdaq Global Market on October 24, 2023, by way of a capital </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:332.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:118.03999999999999pt;position:var(--position);text-decoration:none;white-space:pre">20,325,500</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:163.04000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> new ordinary shares, consisting of the U.S. Offering of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:387.59pt;position:var(--position);text-decoration:none;white-space:pre">18,699,460</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:432.59pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares in the form of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:343.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ADSs, and the European Private Placement of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:259.02pt;position:var(--position);text-decoration:none;white-space:pre">1,626,040</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:299.02pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares, with a par value of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:445.26pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.01</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:467.76pt;position:var(--position);text-decoration:none;white-space:pre"> per share and an offering </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:354.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">price set at </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:117.75pt;position:var(--position);text-decoration:none;white-space:pre">$11.60</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:145.25pt;position:var(--position);text-decoration:none;white-space:pre"> per ADS in the U.S. Offering and a corresponding offering price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:419.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;10.9864</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:456.69pt;position:var(--position);text-decoration:none;white-space:pre"> per ordinary share in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:365.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">European Private Placement. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:383.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The exercise of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:136.07pt;position:var(--position);text-decoration:none;white-space:pre">1,906</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.57pt;position:var(--position);text-decoration:none;white-space:pre"> other share warrants, by issuing </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:290.4pt;position:var(--position);text-decoration:none;white-space:pre">190,550</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:322.9pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares with a par value of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:466.64pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.01</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:489.14pt;position:var(--position);text-decoration:none;white-space:pre"> per share and an </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:394.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">average subscription price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:190.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.01</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:212.69pt;position:var(--position);text-decoration:none;white-space:pre"> per share (see Note 14). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:411.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Incremental costs directly attributable to the issue of new shares, including underwriting commissions and offering expenses related to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:422.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the Global Offering, were classified as a deduction of shareholders&#8217; equity and amounted to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:405.3pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;28,111&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:476.39pt;position:var(--position);text-decoration:none;white-space:pre"> for the period ended </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:433.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">December 31, 2023. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:456.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The increases in the share capital</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:168.28pt;position:var(--position);text-decoration:none;white-space:pre"> for the year ended December 31, 2024 relate to</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:359.16pt;position:var(--position);text-decoration:none;white-space:pre">:</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:467.56pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the issue and subscription by members of the Board of Directors of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:342.86pt;position:var(--position);text-decoration:none;white-space:pre">77,820</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:370.36pt;position:var(--position);text-decoration:none;white-space:pre"> share warrants, with a subscription price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:547.6700000000001pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;2.57</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:570.1700000000001pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:481pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">each (see Note 14);</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:494.44pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">a credit note received for transaction fees related to the Global Offering, amounting to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:418.48pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;446 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:477.07pt;position:var(--position);text-decoration:none;white-space:pre"> and classified in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:507.88pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">share premiums; and</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:521.32pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the exercise of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:132.74pt;position:var(--position);text-decoration:none;white-space:pre">4,000</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.24pt;position:var(--position);text-decoration:none;white-space:pre"> other share warrants, by issuing </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:287.07pt;position:var(--position);text-decoration:none;white-space:pre">4,000</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:309.57pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares with a par value of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:453.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.01</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:475.81pt;position:var(--position);text-decoration:none;white-space:pre"> per share and an </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:534.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">average subscription price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:190.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;11.14</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:217.69pt;position:var(--position);text-decoration:none;white-space:pre"> per share (see Note 14).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:548.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the issue of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.00999999999999pt;position:var(--position);text-decoration:none;white-space:pre">415,019</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:152.51pt;position:var(--position);text-decoration:none;white-space:pre"> vested free shares, as part of the AGA plans issued by the Group to certain of its officers and employees. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:570.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The increases in the share capital</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:168.28pt;position:var(--position);text-decoration:none;white-space:pre"> for the year ended December 31, 2025 relate to</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:359.16pt;position:var(--position);text-decoration:none;white-space:pre">:</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:581.8pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the completion of the July 28, 2025 Offering, by issuing </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:299.06pt;position:var(--position);text-decoration:none;white-space:pre">11,679,400</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:344.06pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:346.56pt;position:var(--position);text-decoration:none;white-space:pre">ADSs</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:370.45pt;position:var(--position);text-decoration:none;white-space:pre"> a</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:377.38pt;position:var(--position);text-decoration:none;white-space:pre">t a price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:422.87pt;position:var(--position);text-decoration:none;white-space:pre">$64.00</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:450.37pt;position:var(--position);text-decoration:none;white-space:pre"> per ADS (corresponding to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:595.24pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;54.58</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:99.5pt;position:var(--position);text-decoration:none;white-space:pre"> per ordinary share, based on the exchange rate of &#8364;1.00 = $</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:338.79pt;position:var(--position);text-decoration:none;white-space:pre">1.1726</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:366.29pt;position:var(--position);text-decoration:none;white-space:pre"> as published by the European Central Bank on July </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:608.68pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">23, 2025);</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:625.12pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the conversion of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:143.88pt;position:var(--position);text-decoration:none;white-space:pre">150</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.88pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:178.31pt;position:var(--position);text-decoration:none;white-space:pre">200</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:193.31pt;position:var(--position);text-decoration:none;white-space:pre"> of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:206.64pt;position:var(--position);text-decoration:none;white-space:pre">Heights notes o</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:268.81pt;position:var(--position);text-decoration:none;white-space:pre">n respectively July 23 and July 30, 2025 (corresponding to the entirety of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:637.12pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the outstanding principal amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:217.13pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;21.9&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:270.98pt;position:var(--position);text-decoration:none;white-space:pre">). This conversion resulted in the issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:452.18pt;position:var(--position);text-decoration:none;white-space:pre">920,377</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:484.68pt;position:var(--position);text-decoration:none;white-space:pre"> new ordinary shares </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:649.12pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of the Group at a conversion price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:221.85pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;23.7674</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:259.35pt;position:var(--position);text-decoration:none;white-space:pre"> per ordinary share in accordance with the terms and conditions of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:661.12pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">convertible notes;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:676.12pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:84.2pt;position:var(--position);text-decoration:none;white-space:pre"> conversion, on </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:148.05pt;position:var(--position);text-decoration:none;white-space:pre">August 8, 2025, by Kreos Capital VII (UK) Limited of its portion of the Tranche A of the Kreos / Claret </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:688.12pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Financing (the Kreos OCABSA), at a conversion price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:304pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;21.2209</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:341.5pt;position:var(--position);text-decoration:none;white-space:pre">,</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:344pt;position:var(--position);text-decoration:none;white-space:pre"> resulting in the issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:456.1pt;position:var(--position);text-decoration:none;white-space:pre">785,389</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:488.6pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:700.12pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the Group, . </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the exercise, on July 30, 2025, by Kreos Capital VII Aggregator SCSp of its share warrants (the tranche A-B Kreos BSA and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:82.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">tranche C Kreos BSA) resulting in the issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:274.28999999999996pt;position:var(--position);text-decoration:none;white-space:pre">319,251</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:306.78999999999996pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares of the Group;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:97.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the exercise, o</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.41pt;position:var(--position);text-decoration:none;white-space:pre">n August 28, 2025, by Claret European Growth Capital Fund III SCSp of its share warrants (the tranche A-B </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:109.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Claret BSA and tranche C Claret BSA) resulting in the issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:340.57pt;position:var(--position);text-decoration:none;white-space:pre">206,662</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:373.07pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares of the Group;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:124.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the conversion, on November 25, 2025, by Claret European Growth Capital Fund III SCSp of its portion of the Tranche A of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:136.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the Kreos / Claret Financing (the Claret OCABSA), at a conversion price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:377.75pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;21.2209</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:415.25pt;position:var(--position);text-decoration:none;white-space:pre">,</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:417.75pt;position:var(--position);text-decoration:none;white-space:pre"> resulting in the issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:529.85pt;position:var(--position);text-decoration:none;white-space:pre">392,695</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:562.35pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:148.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ordinary shares of the Group.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:163.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the issue of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.00999999999999pt;position:var(--position);text-decoration:none;white-space:pre">627,714</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:152.51pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.01pt;position:var(--position);text-decoration:none;white-space:pre">vested free shares, as part of the AGA plans issued by the Group to certain of its officers and employees;</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:178.56pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the exercise of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:132.74pt;position:var(--position);text-decoration:none;white-space:pre">257,087</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:165.24pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:167.74pt;position:var(--position);text-decoration:none;white-space:pre">other share warrants, by issuing </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:297.07pt;position:var(--position);text-decoration:none;white-space:pre">257,087</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:329.57pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares with a par value of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:473.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.01</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:495.81pt;position:var(--position);text-decoration:none;white-space:pre"> per share and an </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:192.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">average subscription price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:190.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;13.02</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:217.69pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:220.19pt;position:var(--position);text-decoration:none;white-space:pre">per share (see Note 14).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:233.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Distribution of dividends </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:255.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group did not distribute any dividends for any of the periods presented, does not have any present plan to pay any cash dividends </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:267.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">on its equity securities in the foreseeable future and currently intends to retain all available funds and any future earnings to operate </span></div>and expand our business.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ShareBasedPaymentArrangementsAbstract', window );"><strong>Share-Based Payment Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Share-based payments</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Share-based payments</span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:332.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group has granted BCEs, BSAs and free shares (</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:250.25pt;position:var(--position);text-decoration:none;white-space:pre">attributions gratuites d&#8217;actions</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:374.59pt;position:var(--position);text-decoration:none;white-space:pre">, or &#8220;AGAs&#8221;). These plans qualify as &#8220;equity </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:343.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">settled&#8221; under IFRS 2. The Group does not have any obligation to purchase these instruments in the event of departure or if a specific </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:354.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">event does not occur. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:375.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Valuation methods of BCEs, BSAs and AGAs </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:398.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The fair value of share-based awards was determined at grant date using the Black Scholes model for the BCEs and BSAs and the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:409.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Monte-Carlo simulation for AGAs plans with market performance conditions.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:431.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The assumptions used to estimate the fair value of the instruments are presented below and include: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:454.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Expected maturity of the options;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:465.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:60.1pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Expected volatility based on the historical market share price available; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:476.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:60.1pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Expected dividends based on management best estimate; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:487.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:60.1pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Risk-free interest rate based on French OAT rates measured at grant dates; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:499.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:60.1pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Share price</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:117.21000000000001pt;position:var(--position);text-decoration:none;white-space:pre">, including offered </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:193.8pt;position:var(--position);text-decoration:none;white-space:pre">in case of change of control (only for the market conditions applicable to the free-share plan </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:510.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-1</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:124.49000000000001pt;position:var(--position);text-decoration:none;white-space:pre">), i</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:135.59pt;position:var(--position);text-decoration:none;white-space:pre">s based on Monte-Carlo simulations and taking into account a change of control premium based on the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:521.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">management best estimate. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:543.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">BCEs </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:566.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The following tables summarize the data relating to BCEs as well as the assumptions used for the measurement thereof in accordance </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:577.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">with IFRS 2 &#8211; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:94.87pt;position:var(--position);text-decoration:none;white-space:pre">Share-based Payment</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:182.29pt;position:var(--position);text-decoration:none;white-space:pre">: </span></div><div><div style="position:var(--position);top:70.56pt;width:612pt"><div style="font-size:0pt;left:43pt;position:var(--position);width:524.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:45pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:47.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:51pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:51pt"></td><td style="padding:0;width:51pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:51pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:51pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:51pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:51pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:51pt"></td></tr><tr style="height:89.25pt"><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:45pt"><div><div style="line-height:8pt;position:var(--position);top:52.2pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.18pt;position:var(--position);text-decoration:none;white-space:pre">GRANT&#160;D</span></div><div style="line-height:8pt;position:var(--position);top:61.8pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.28pt;position:var(--position);text-decoration:none;white-space:pre">ATE </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:48pt;position:var(--position);width:47.25pt"><div><div style="line-height:8pt;position:var(--position);top:57pt;width:47.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.97pt;position:var(--position);text-decoration:none;white-space:pre">TYPE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:98.25pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:47.4pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:57pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.18pt;position:var(--position);text-decoration:none;white-space:pre">OF BCEs </span></div><div style="line-height:8pt;position:var(--position);top:66.6pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.07pt;position:var(--position);text-decoration:none;white-space:pre">ISSUED</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:152.25pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:33pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:42.6pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.73pt;position:var(--position);text-decoration:none;white-space:pre">OF BCE </span></div><div style="line-height:8pt;position:var(--position);top:52.2pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.3pt;position:var(--position);text-decoration:none;white-space:pre">OUTSTAND</span></div><div style="line-height:8pt;position:var(--position);top:61.8pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.29pt;position:var(--position);text-decoration:none;white-space:pre">ING AS OF </span></div><div style="line-height:8pt;position:var(--position);top:71.4pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.19pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY </span></div><div style="line-height:8pt;position:var(--position);top:81pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.5pt;position:var(--position);text-decoration:none;white-space:pre">1, 2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:203.25pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:32.02pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:41.62pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.52pt;position:var(--position);text-decoration:none;white-space:pre">OF ISSUED </span></div><div style="line-height:8pt;position:var(--position);top:51.22pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.73pt;position:var(--position);text-decoration:none;white-space:pre">BCEs</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:257.25pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:32.02pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:41.62pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.19pt;position:var(--position);text-decoration:none;white-space:pre">OF LAPSED </span></div><div style="line-height:8pt;position:var(--position);top:51.22pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.73pt;position:var(--position);text-decoration:none;white-space:pre">BCEs</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:311.25pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:27.22pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:36.82pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:19.95pt;position:var(--position);text-decoration:none;white-space:pre">OF </span></div><div style="line-height:8pt;position:var(--position);top:46.42pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.07pt;position:var(--position);text-decoration:none;white-space:pre">EXERCISE</span></div><div style="line-height:8pt;position:var(--position);top:56.02pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.84pt;position:var(--position);text-decoration:none;white-space:pre">D BCEs</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:365.25pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:27.22pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:36.82pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.18pt;position:var(--position);text-decoration:none;white-space:pre">OF BCEs </span></div><div style="line-height:8pt;position:var(--position);top:46.42pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.3pt;position:var(--position);text-decoration:none;white-space:pre">OUTSTAND</span></div><div style="line-height:8pt;position:var(--position);top:56.02pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.95pt;position:var(--position);text-decoration:none;white-space:pre">ING </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:419.25pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:27.22pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:36.82pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.18pt;position:var(--position);text-decoration:none;white-space:pre">OF BCEs </span></div><div style="line-height:8pt;position:var(--position);top:46.42pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.85pt;position:var(--position);text-decoration:none;white-space:pre">EXERCISA</span></div><div style="line-height:8pt;position:var(--position);top:56.02pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.5pt;position:var(--position);text-decoration:none;white-space:pre">BLE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.22pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.96pt;position:var(--position);text-decoration:none;white-space:pre">MAXIMUM </span></div><div style="line-height:8pt;position:var(--position);top:12.82pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:22.42pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.96pt;position:var(--position);text-decoration:none;white-space:pre">OF SHARES </span></div><div style="line-height:8pt;position:var(--position);top:32.02pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.39pt;position:var(--position);text-decoration:none;white-space:pre">TO BE </span></div><div style="line-height:8pt;position:var(--position);top:41.62pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.07pt;position:var(--position);text-decoration:none;white-space:pre">ISSUED IF </span></div><div style="line-height:8pt;position:var(--position);top:51.22pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.28pt;position:var(--position);text-decoration:none;white-space:pre">ALL </span></div><div style="line-height:8pt;position:var(--position);top:60.82pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.85pt;position:var(--position);text-decoration:none;white-space:pre">CONDITIO</span></div><div style="line-height:8pt;position:var(--position);top:70.42pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.96pt;position:var(--position);text-decoration:none;white-space:pre">NS ARE </span></div><div style="line-height:8pt;position:var(--position);top:80.02pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.39pt;position:var(--position);text-decoration:none;white-space:pre">MET</span></div></div></div></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td colspan="5" style="font-size:0;text-align:left;vertical-align:top"><div style="left:203.25pt;position:var(--position);top:89.25pt;width:159pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:159pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.1pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED DECEMBER 31, 2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td colspan="5" style="font-size:0;text-align:left;vertical-align:top"><div style="left:365.25pt;position:var(--position);top:89.25pt;width:159pt"><div><div style="line-height:8pt;position:var(--position);top:7.57pt;width:159pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:67.84pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:17.17pt;width:159pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:120pt;width:45pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2016-11-07</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:48pt;position:var(--position);top:120pt;width:47.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:47.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BCE-2016-1</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:98.25pt;position:var(--position);top:120pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)">84,000</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:152.25pt;position:var(--position);top:120pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)">18,796</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:203.25pt;position:var(--position);top:120pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.62pt"></span></span><span style="left:42.25pt;position:var(--position)">&#8212;</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:257.25pt;position:var(--position);top:120pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:311.25pt;position:var(--position);top:120pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:20.3pt"></span></span><span style="left:22.93pt;position:var(--position)">(18,796)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:365.25pt;position:var(--position);top:120pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:419.25pt;position:var(--position);top:120pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:120pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:132pt;width:45pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2017-01-23</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:48pt;position:var(--position);top:132pt;width:47.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:47.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BCE-2017-1</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:98.25pt;position:var(--position);top:132pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)">67,374</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:152.25pt;position:var(--position);top:132pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)">67,000</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:203.25pt;position:var(--position);top:132pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.62pt"></span></span><span style="left:42.25pt;position:var(--position)">&#8212;</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:257.25pt;position:var(--position);top:132pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:311.25pt;position:var(--position);top:132pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:20.3pt"></span></span><span style="left:22.93pt;position:var(--position)">(33,313)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:365.25pt;position:var(--position);top:132pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">33,687<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:419.25pt;position:var(--position);top:132pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">33,687<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:132pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">33,687<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:144pt;width:45pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2017-11-20</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:48pt;position:var(--position);top:144pt;width:47.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:47.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BCE-2017-2</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:98.25pt;position:var(--position);top:144pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:21.62pt"></span></span><span style="left:24.25pt;position:var(--position)">150,000</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:152.25pt;position:var(--position);top:144pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:21.62pt"></span></span><span style="left:24.25pt;position:var(--position)">112,500</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:203.25pt;position:var(--position);top:144pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.62pt"></span></span><span style="left:42.25pt;position:var(--position)">&#8212;</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:257.25pt;position:var(--position);top:144pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:311.25pt;position:var(--position);top:144pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:365.25pt;position:var(--position);top:144pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)">112,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:419.25pt;position:var(--position);top:144pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)">112,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:144pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)">112,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:156pt;width:45pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2017-11-20</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:48pt;position:var(--position);top:156pt;width:47.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:47.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BCE-2017-4</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:98.25pt;position:var(--position);top:156pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)">67,374</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:152.25pt;position:var(--position);top:156pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)">67,373</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:203.25pt;position:var(--position);top:156pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.62pt"></span></span><span style="left:42.25pt;position:var(--position)">&#8212;</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:257.25pt;position:var(--position);top:156pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:311.25pt;position:var(--position);top:156pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:20.3pt"></span></span><span style="left:22.93pt;position:var(--position)">(33,686)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:365.25pt;position:var(--position);top:156pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">33,687<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:419.25pt;position:var(--position);top:156pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:156pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">33,687<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:168pt;width:45pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2017-11-20</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:48pt;position:var(--position);top:168pt;width:47.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:47.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BCE-2017-5</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:98.25pt;position:var(--position);top:168pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)">67,374</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:152.25pt;position:var(--position);top:168pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)">33,687</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:203.25pt;position:var(--position);top:168pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.62pt"></span></span><span style="left:42.25pt;position:var(--position)">&#8212;</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:257.25pt;position:var(--position);top:168pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:311.25pt;position:var(--position);top:168pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:20.3pt"></span></span><span style="left:22.93pt;position:var(--position)">(16,843)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:365.25pt;position:var(--position);top:168pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">16,844<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:419.25pt;position:var(--position);top:168pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:168pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">16,844<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:180pt;width:45pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2018-03-15</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:48pt;position:var(--position);top:180pt;width:47.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:47.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BCE-2018-1</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:98.25pt;position:var(--position);top:180pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)">22,000</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:152.25pt;position:var(--position);top:180pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)">11,980</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:203.25pt;position:var(--position);top:180pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.62pt"></span></span><span style="left:42.25pt;position:var(--position)">&#8212;</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:257.25pt;position:var(--position);top:180pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:311.25pt;position:var(--position);top:180pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:24.3pt"></span></span><span style="left:26.93pt;position:var(--position)">(9,440)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:365.25pt;position:var(--position);top:180pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.96pt"></span></span><span style="left:29.59pt;position:var(--position)">2,540<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:419.25pt;position:var(--position);top:180pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.96pt"></span></span><span style="left:29.59pt;position:var(--position)">2,540<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:180pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.96pt"></span></span><span style="left:29.59pt;position:var(--position)">2,540<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:192pt;width:45pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2018-05-14</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:48pt;position:var(--position);top:192pt;width:47.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:47.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BCE-2018-4</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:98.25pt;position:var(--position);top:192pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)">16,843</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:152.25pt;position:var(--position);top:192pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)">16,843</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:203.25pt;position:var(--position);top:192pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.62pt"></span></span><span style="left:42.25pt;position:var(--position)">&#8212;</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:257.25pt;position:var(--position);top:192pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:311.25pt;position:var(--position);top:192pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:24.3pt"></span></span><span style="left:26.93pt;position:var(--position)">(8,422)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:365.25pt;position:var(--position);top:192pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.96pt"></span></span><span style="left:29.59pt;position:var(--position)">8,421<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:419.25pt;position:var(--position);top:192pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.96pt"></span></span><span style="left:29.59pt;position:var(--position)">8,421<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:192pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.96pt"></span></span><span style="left:29.59pt;position:var(--position)">8,421<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:204pt;width:45pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2018-05-14</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:48pt;position:var(--position);top:204pt;width:47.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:47.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BCE-2018-5</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:98.25pt;position:var(--position);top:204pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)">22,000</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:152.25pt;position:var(--position);top:204pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.62pt"></span></span><span style="left:32.25pt;position:var(--position)">2,000</span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:203.25pt;position:var(--position);top:204pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.62pt"></span></span><span style="left:42.25pt;position:var(--position)">&#8212;</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:257.25pt;position:var(--position);top:204pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:311.25pt;position:var(--position);top:204pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:24.3pt"></span></span><span style="left:26.93pt;position:var(--position)">(2,000)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:365.25pt;position:var(--position);top:204pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:419.25pt;position:var(--position);top:204pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:204pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:48pt;position:var(--position);top:216pt;width:47.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:47.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total BCEs</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:98.25pt;position:var(--position);top:216pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:21.62pt"></span></span><span style="left:24.25pt;position:var(--position)">496,965</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:152.25pt;position:var(--position);top:216pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:21.62pt"></span></span><span style="left:24.25pt;position:var(--position)">330,179</span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:203.25pt;position:var(--position);top:216pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:39.62pt"></span></span><span style="left:42.25pt;position:var(--position)">&#8212;</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:257.25pt;position:var(--position);top:216pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:311.25pt;position:var(--position);top:216pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:16.3pt"></span></span><span style="left:18.93pt;position:var(--position)">(122,500)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:365.25pt;position:var(--position);top:216pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)">207,679<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:419.25pt;position:var(--position);top:216pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)">157,148<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:216pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)">207,679<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:338.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The BCEs include a service condition under which the beneficiary must still be an employee, a corporate officer or a scientific </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:349.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">consultant of the Group at the time of vesting. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:372.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The exercise rights for most of the BCEs are vested annually and have the following vesting terms: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:394.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">25%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90.33pt;position:var(--position);text-decoration:none;white-space:pre"> of the award vests on the first anniversary of the date of grant for all currently issued BCEs; and </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:405.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">For the remaining </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:146.09pt;position:var(--position);text-decoration:none;white-space:pre">75%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:164.42000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> of the award, the BCEs vest 1/48th per month over </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:372.56pt;position:var(--position);text-decoration:none;white-space:pre">four years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:412.8pt;position:var(--position);text-decoration:none;white-space:pre"> from the anniversary date of the grant. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:432.74pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Most of the BCEs plans include or partially include non-market performance conditions (obtaining financing of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:484.68pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;100&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:536.03pt;position:var(--position);text-decoration:none;white-space:pre">, positive </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:443.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">results on clinic studies, signature of informed consent in a clinical phase, signing a license agreement, FDA authorization). The level </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:455.14pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of achievement of the non-market performance conditions are taken into account in determining the number of BCEs allocated </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:466.34pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">initially and reassessed at each closing date. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:488.74pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In the event of a change of control or a M&amp;A transaction, all the BCEs will become immediately exercisable. A change of control is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:499.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">defined as a new investor/company holding directly or indirectly more than </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:339.82pt;position:var(--position);text-decoration:none;white-space:pre">50%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:358.15pt;position:var(--position);text-decoration:none;white-space:pre"> of the share capital or voting rights. As such the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:511.14pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">probable vesting date of each plan corresponds to the weighted average of probable change of control dates. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:535.24pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">BSAs</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:549.89pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The following tables summarize the data relating to BSAs as well as the assumptions used for the measurement thereof in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:561.89pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">accordance with IFRS 2&#8212;</span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:142.28pt;position:var(--position);text-decoration:none;white-space:pre">Share-based Payment</span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:229.7pt;position:var(--position);text-decoration:none;white-space:pre">:</span></div></div><div><div style="position:var(--position);top:70.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:537pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:52.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:52.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:51pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:51pt"></td><td style="padding:0;width:51pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:51pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:51pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:51pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:51pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:51pt"></td></tr><tr style="height:69pt"><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:42.07pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.05pt;position:var(--position);text-decoration:none;white-space:pre">GRANT&#160;DA</span></div><div style="line-height:8pt;position:var(--position);top:51.67pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.92pt;position:var(--position);text-decoration:none;white-space:pre">TE </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:55.5pt;position:var(--position);width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:46.87pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.59pt;position:var(--position);text-decoration:none;white-space:pre">TYPE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:111pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:32.47pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.39pt;position:var(--position);text-decoration:none;white-space:pre">Total </span></div><div style="line-height:8pt;position:var(--position);top:42.07pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:51.67pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.62pt;position:var(--position);text-decoration:none;white-space:pre">OF BSAs </span></div><div style="line-height:8pt;position:var(--position);top:61.27pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.07pt;position:var(--position);text-decoration:none;white-space:pre">ISSUED</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:165pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:22.87pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:32.47pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.62pt;position:var(--position);text-decoration:none;white-space:pre">OF BSAs </span></div><div style="line-height:8pt;position:var(--position);top:42.07pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.3pt;position:var(--position);text-decoration:none;white-space:pre">OUTSTAND</span></div><div style="line-height:8pt;position:var(--position);top:51.67pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.29pt;position:var(--position);text-decoration:none;white-space:pre">ING AS OF </span></div><div style="line-height:8pt;position:var(--position);top:61.27pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.19pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY </span></div><div style="line-height:8pt;position:var(--position);top:70.87pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.5pt;position:var(--position);text-decoration:none;white-space:pre">1, 2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:21.9pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:31.5pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.52pt;position:var(--position);text-decoration:none;white-space:pre">OF ISSUED </span></div><div style="line-height:8pt;position:var(--position);top:41.1pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.17pt;position:var(--position);text-decoration:none;white-space:pre">BSAs</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:270pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:21.9pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:31.5pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.19pt;position:var(--position);text-decoration:none;white-space:pre">OF LAPSED </span></div><div style="line-height:8pt;position:var(--position);top:41.1pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.17pt;position:var(--position);text-decoration:none;white-space:pre">BSAs</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:324pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:17.1pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:26.7pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:19.95pt;position:var(--position);text-decoration:none;white-space:pre">OF </span></div><div style="line-height:8pt;position:var(--position);top:36.3pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.07pt;position:var(--position);text-decoration:none;white-space:pre">EXERCISE</span></div><div style="line-height:8pt;position:var(--position);top:45.9pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.29pt;position:var(--position);text-decoration:none;white-space:pre">D&#160; BSAs</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:17.1pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:26.7pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.62pt;position:var(--position);text-decoration:none;white-space:pre">OF BSAs </span></div><div style="line-height:8pt;position:var(--position);top:36.3pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.3pt;position:var(--position);text-decoration:none;white-space:pre">OUTSTAND</span></div><div style="line-height:8pt;position:var(--position);top:45.9pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.95pt;position:var(--position);text-decoration:none;white-space:pre">ING </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:432pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:17.1pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:26.7pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.62pt;position:var(--position);text-decoration:none;white-space:pre">OF BSAs </span></div><div style="line-height:8pt;position:var(--position);top:36.3pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.85pt;position:var(--position);text-decoration:none;white-space:pre">EXERCISA</span></div><div style="line-height:8pt;position:var(--position);top:45.9pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.5pt;position:var(--position);text-decoration:none;white-space:pre">BLE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="height:69pt;left:486pt;overflow:hidden;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:-6.9pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.96pt;position:var(--position);text-decoration:none;white-space:pre">MAXIMUM </span></div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.96pt;position:var(--position);text-decoration:none;white-space:pre">OF SHARES </span></div><div style="line-height:8pt;position:var(--position);top:21.9pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.39pt;position:var(--position);text-decoration:none;white-space:pre">TO BE </span></div><div style="line-height:8pt;position:var(--position);top:31.5pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.07pt;position:var(--position);text-decoration:none;white-space:pre">ISSUED IF </span></div><div style="line-height:8pt;position:var(--position);top:41.1pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.28pt;position:var(--position);text-decoration:none;white-space:pre">ALL </span></div><div style="line-height:8pt;position:var(--position);top:50.7pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.85pt;position:var(--position);text-decoration:none;white-space:pre">CONDITIO</span></div><div style="line-height:8pt;position:var(--position);top:60.3pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.96pt;position:var(--position);text-decoration:none;white-space:pre">NS ARE </span></div><div style="line-height:8pt;position:var(--position);top:69.9pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.39pt;position:var(--position);text-decoration:none;white-space:pre">MET</span></div></div></div></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td colspan="5" style="font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:69pt;width:159pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:159pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.1pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED DECEMBER 31, 2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td colspan="5" style="font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:69pt;width:159pt"><div><div style="line-height:8pt;position:var(--position);top:7.57pt;width:159pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:67.84pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:17.17pt;width:159pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:99.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2015-12-04</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:55.5pt;position:var(--position);top:99.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2015-11</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:111pt;position:var(--position);top:99.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">96,924<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:165pt;position:var(--position);top:99.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">96,924<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:99.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:270pt;position:var(--position);top:99.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:324pt;position:var(--position);top:99.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:20.3pt"></span></span><span style="left:22.93pt;position:var(--position)">(96,924)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:99.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:432pt;position:var(--position);top:99.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:486pt;position:var(--position);top:99.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:111.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2015-12-04</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:55.5pt;position:var(--position);top:111.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2015-12</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:111pt;position:var(--position);top:111.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">82,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:165pt;position:var(--position);top:111.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">16,400<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:111.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:270pt;position:var(--position);top:111.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:324pt;position:var(--position);top:111.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:20.3pt"></span></span><span style="left:22.93pt;position:var(--position)">(16,400)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:111.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:432pt;position:var(--position);top:111.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:486pt;position:var(--position);top:111.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:123.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2017-09-18</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:55.5pt;position:var(--position);top:123.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2017-1</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:111pt;position:var(--position);top:123.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">16,400<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:165pt;position:var(--position);top:123.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">16,400<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:123.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:270pt;position:var(--position);top:123.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:324pt;position:var(--position);top:123.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:20.3pt"></span></span><span style="left:22.93pt;position:var(--position)">(16,400)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:123.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:432pt;position:var(--position);top:123.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:486pt;position:var(--position);top:123.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:135.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2018-01-22</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:55.5pt;position:var(--position);top:135.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2018-1</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:111pt;position:var(--position);top:135.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">49,200<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:165pt;position:var(--position);top:135.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">16,400<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:135.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:270pt;position:var(--position);top:135.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:324pt;position:var(--position);top:135.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:135.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">16,400<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:432pt;position:var(--position);top:135.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">16,400<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:486pt;position:var(--position);top:135.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">16,400<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:147.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2024-04-04</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:55.5pt;position:var(--position);top:147.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2024-1</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:111pt;position:var(--position);top:147.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">58,365<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:165pt;position:var(--position);top:147.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">58,365<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:147.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:270pt;position:var(--position);top:147.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:324pt;position:var(--position);top:147.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:24.3pt"></span></span><span style="left:26.93pt;position:var(--position)">(4,863)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:147.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">53,502<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:432pt;position:var(--position);top:147.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.96pt"></span></span><span style="left:29.59pt;position:var(--position)">9,726<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:486pt;position:var(--position);top:147.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">53,502<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:159.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2024-04-04</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:55.5pt;position:var(--position);top:159.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2024-2</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:111pt;position:var(--position);top:159.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">19,455<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:165pt;position:var(--position);top:159.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">19,455<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:159.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:270pt;position:var(--position);top:159.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:324pt;position:var(--position);top:159.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:159.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">19,455<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:432pt;position:var(--position);top:159.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.96pt"></span></span><span style="left:29.59pt;position:var(--position)">4,863<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:486pt;position:var(--position);top:159.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">19,455<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:171.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2025-01-13</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:55.5pt;position:var(--position);top:171.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2025-1</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:111pt;position:var(--position);top:171.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)">100,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:165pt;position:var(--position);top:171.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:171.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)">100,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:270pt;position:var(--position);top:171.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:324pt;position:var(--position);top:171.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:171.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)">100,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:432pt;position:var(--position);top:171.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:486pt;position:var(--position);top:171.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)">100,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:183.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2025-01-13</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:55.5pt;position:var(--position);top:183.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2025-2</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:111pt;position:var(--position);top:183.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">25,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:165pt;position:var(--position);top:183.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:183.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">25,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:270pt;position:var(--position);top:183.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:324pt;position:var(--position);top:183.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:183.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">25,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:432pt;position:var(--position);top:183.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:486pt;position:var(--position);top:183.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">25,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:195.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2025-04-22</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:55.5pt;position:var(--position);top:195.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2025-3</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:111pt;position:var(--position);top:195.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">39,370<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:165pt;position:var(--position);top:195.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:195.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">39,370<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:270pt;position:var(--position);top:195.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:324pt;position:var(--position);top:195.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:195.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">39,370<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:11.25pt;left:429pt;overflow:hidden;position:var(--position);top:195.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:432pt;position:var(--position);top:195.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:11.25pt;left:483pt;overflow:hidden;position:var(--position);top:195.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:-45.51pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">3</span></div><div style="line-height:8pt;position:var(--position);top:-35.91pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">9</span></div><div style="line-height:8pt;position:var(--position);top:-26.31pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.63pt;position:var(--position);text-decoration:none;white-space:pre">,</span></div><div style="line-height:8pt;position:var(--position);top:-16.71pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">3</span></div><div style="line-height:8pt;position:var(--position);top:-7.11pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">7</span></div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:486pt;position:var(--position);top:195.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">39,370<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:55.5pt;position:var(--position);top:207pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total BSAs</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:111pt;position:var(--position);top:207pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)">486,714<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:165pt;position:var(--position);top:207pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)">223,944<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:207pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)">164,370<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:11.25pt;left:267pt;overflow:hidden;position:var(--position);top:207pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:270pt;position:var(--position);top:207pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:324pt;position:var(--position);top:207pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:16.3pt"></span></span><span style="left:18.93pt;position:var(--position)">(134,587)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:207pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)">253,727<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:11.25pt;left:429pt;overflow:hidden;position:var(--position);top:207pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:432pt;position:var(--position);top:207pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">30,989<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:11.25pt;left:483pt;overflow:hidden;position:var(--position);top:207pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:486pt;position:var(--position);top:207pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)">253,727<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:307.11pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">BSAs issued prior to January 1, 2024</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:333.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">These BSAs include a service condition under which the beneficiary must still be an employee, a corporate officer or a scientific </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:344.91pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">consultant of the Group at the time of vesting. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:367.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The exercise rights for most of these BSAs are vested annually and have the following vesting terms: </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:378.51pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">25%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90.33pt;position:var(--position);text-decoration:none;white-space:pre"> of the award vests on the first anniversary of the date of grant for all currently issued BSAs; and </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:391.95pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">For the remaining </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:146.09pt;position:var(--position);text-decoration:none;white-space:pre">75%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:164.42000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> of the award, the BSAs vest 1/48th per month over </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:372.58pt;position:var(--position);text-decoration:none;white-space:pre">four years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:412.82pt;position:var(--position);text-decoration:none;white-space:pre"> from the anniversary date of the grant. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:418.69pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">All of these BSAs plans include or partially include non-market performance conditions (positive results on clinic studies, signature of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:429.89pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">informed consent in a clinical phase, signing a license agreement, FDA authorization). The level of achievement of the non-market </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:441.09pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">performance conditions are taken into account in determining the number of BSAs allocated initially and reassessed at each closing </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:452.29pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">date. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:474.69pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In the event of a change of control or a M&amp;A transaction, all these BSAs will become immediately exercisable. A change of control is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:485.89pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">defined as a new investor/company holding directly or indirectly more than </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:339.82pt;position:var(--position);text-decoration:none;white-space:pre">50%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:358.15pt;position:var(--position);text-decoration:none;white-space:pre"> of the share capital or voting rights. As such the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:497.09pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">probable vesting date of each plan corresponds to the weighted average of probable change of control dates. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:519.49pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">BSAs granted in March 2024</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:544.49pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In March 2024, the Group granted its independent Board members the right to subscribe up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:414.27pt;position:var(--position);text-decoration:none;white-space:pre">77,820</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:441.77pt;position:var(--position);text-decoration:none;white-space:pre"> share warrants (BSA) in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:555.99pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">aggregate, the vesting of which is subject to a service condition of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:302.63pt;position:var(--position);text-decoration:none;white-space:pre">four years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:342.87pt;position:var(--position);text-decoration:none;white-space:pre">, by tranches of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:406.98pt;position:var(--position);text-decoration:none;white-space:pre">25%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:425.31pt;position:var(--position);text-decoration:none;white-space:pre"> each, vested on each anniversary </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:567.49pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">date. Additionally, the BSAs are subject to a vesting acceleration condition in case of a tender offer on the securities issued by the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:578.99pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Group and resulting in a change of control of the Group. All of the granted BSAs were subscribed by the beneficiaries in April 2024.</span></div></div><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">BSAs granted in January and April 2025</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:92.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In January 2025, the Group granted its independent Board members, as well as one of its Board Observers and Advisor, the right to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:104.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">subscribe up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:99.00999999999999pt;position:var(--position);text-decoration:none;white-space:pre">125,000</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:131.51pt;position:var(--position);text-decoration:none;white-space:pre"> BSAs in the aggregate, the vesting of which is subject to a service condition of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:451.44pt;position:var(--position);text-decoration:none;white-space:pre">four years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:491.68pt;position:var(--position);text-decoration:none;white-space:pre">, by tranches of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:555.79pt;position:var(--position);text-decoration:none;white-space:pre">25%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:574.12pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:115.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">each, vested on January 1 of each year. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:194.7pt;position:var(--position);text-decoration:none;white-space:pre">All of the granted BSAs were subscribed by the beneficiaries in February 2025.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:137.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In April 2025, the Group granted to one of its Board members the right to subscribe up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:395.98pt;position:var(--position);text-decoration:none;white-space:pre">39,370</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:423.48pt;position:var(--position);text-decoration:none;white-space:pre"> BSAs, the vesting of which is subject </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:148.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">to a service condition of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:135.05pt;position:var(--position);text-decoration:none;white-space:pre">four years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:175.29pt;position:var(--position);text-decoration:none;white-space:pre">, by tranches of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:239.4pt;position:var(--position);text-decoration:none;white-space:pre">25%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:257.73pt;position:var(--position);text-decoration:none;white-space:pre"> each, vested on May 1 of each year. The BSAs were subscribed in May 2025.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:171.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Additionally, the BSAs are subject to a vesting acceleration condition in case of a tender offer on the securities issued by the Group </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:182.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and resulting in a change of control of the Group.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:204.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The fair value of the BSAs was determined at grant date using the Black Scholes model, with the following assumptions:</span></div><div style="position:var(--position);top:227.36pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:540pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:51pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:60.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:58.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:58.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:58.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:58.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:53.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:58.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:58.5pt"></td></tr><tr style="height:41.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:51pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.84pt;position:var(--position);white-space:pre">TYPE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:54pt;position:var(--position);width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:60.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.62pt;position:var(--position);white-space:pre">FAIR VALUE </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:60.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.38pt;position:var(--position);white-space:pre">OF THE </span></div><div style="line-height:8pt;position:var(--position);top:21.83pt;width:60.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.07pt;position:var(--position);white-space:pre">UNDERLYING </span></div><div style="line-height:8pt;position:var(--position);top:31.43pt;width:60.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.61pt;position:var(--position);white-space:pre">SHARE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:117.75pt;position:var(--position);width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.5pt;position:var(--position);white-space:pre">FAIR VALUE </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.49pt;position:var(--position);white-space:pre">OF THE BSA</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:179.25pt;position:var(--position);width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.94pt;position:var(--position);white-space:pre">NUMBER OF </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:19.92pt;position:var(--position);white-space:pre">BSAs</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.27pt;position:var(--position);white-space:pre">SUBSCRIPTI</span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.82pt;position:var(--position);white-space:pre">ON PRICE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:302.25pt;position:var(--position);width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.15pt;position:var(--position);white-space:pre">STRIKE </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.83pt;position:var(--position);white-space:pre">PRICE PER </span></div><div style="line-height:8pt;position:var(--position);top:21.83pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.48pt;position:var(--position);white-space:pre">SHARE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:363.75pt;position:var(--position);width:53.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:53.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.2pt;position:var(--position);white-space:pre">RISK FREE </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:53.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.52pt;position:var(--position);white-space:pre">RATE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:420pt;position:var(--position);width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.49pt;position:var(--position);white-space:pre">EXPECTED </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.05pt;position:var(--position);white-space:pre">MATURITY</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:481.5pt;position:var(--position);width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.71pt;position:var(--position);white-space:pre">VOLATILITY</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:41.25pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA 2024-1</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:54pt;position:var(--position);top:41.25pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;14.06</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:117.75pt;position:var(--position);top:41.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:11.26pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:13.92pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.7</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:27.92pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:30.58pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.5</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.58pt;position:var(--position);white-space:pre">]</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:179.25pt;position:var(--position);top:41.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:18.25pt;position:var(--position);text-decoration:none;white-space:pre">58,365</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);top:41.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;2.57</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:302.25pt;position:var(--position);top:41.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:19.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;13.10</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:363.75pt;position:var(--position);top:41.25pt;width:53.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:53.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.23pt;position:var(--position);text-decoration:none;white-space:pre">4.30%</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:420pt;position:var(--position);top:41.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.15pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.8100000000000005pt;position:var(--position);text-decoration:none;white-space:pre">5.4</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.810000000000002pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.47pt;position:var(--position);text-decoration:none;white-space:pre">6.9</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:30.47pt;position:var(--position);white-space:pre"> years]</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:481.5pt;position:var(--position);top:41.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.86pt;position:var(--position);text-decoration:none;white-space:pre">60.41%</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:53.25pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:51pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA 2024-2</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:54pt;position:var(--position);top:53.25pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;14.06</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:117.75pt;position:var(--position);top:53.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:11.26pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:13.92pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.8</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:27.92pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:30.58pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.6</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.58pt;position:var(--position);white-space:pre">]</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:179.25pt;position:var(--position);top:53.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:18.25pt;position:var(--position);text-decoration:none;white-space:pre">19,455</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);top:53.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;2.57</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:302.25pt;position:var(--position);top:53.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:19.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;13.10</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:363.75pt;position:var(--position);top:53.25pt;width:53.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:53.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.23pt;position:var(--position);text-decoration:none;white-space:pre">4.30%</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:420pt;position:var(--position);top:53.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.15pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.8100000000000005pt;position:var(--position);text-decoration:none;white-space:pre">5.5</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.810000000000002pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.47pt;position:var(--position);text-decoration:none;white-space:pre">7.0</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:30.47pt;position:var(--position);white-space:pre"> years]</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:481.5pt;position:var(--position);top:53.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.86pt;position:var(--position);text-decoration:none;white-space:pre">60.41%</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:65.25pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2025-1</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:54pt;position:var(--position);top:65.25pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:22.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.13</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:117.75pt;position:var(--position);top:65.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:11.26pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:13.92pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3.5</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:27.92pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:30.58pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3.9</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.58pt;position:var(--position);white-space:pre">]</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:179.25pt;position:var(--position);top:65.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:16.25pt;position:var(--position);text-decoration:none;white-space:pre">100,000</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);top:65.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;2.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:302.25pt;position:var(--position);top:65.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.63</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:363.75pt;position:var(--position);top:65.25pt;width:53.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:53.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.23pt;position:var(--position);text-decoration:none;white-space:pre">4.65%</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:420pt;position:var(--position);top:65.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.15pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.8100000000000005pt;position:var(--position);text-decoration:none;white-space:pre">5.5</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.810000000000002pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.47pt;position:var(--position);text-decoration:none;white-space:pre">7.0</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:30.47pt;position:var(--position);white-space:pre"> years]</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:481.5pt;position:var(--position);top:65.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.86pt;position:var(--position);text-decoration:none;white-space:pre">60.88%</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:77.25pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2025-2</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:54pt;position:var(--position);top:77.25pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:22.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.13</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:117.75pt;position:var(--position);top:77.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:11.26pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:13.92pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3.5</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:27.92pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:30.58pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3.9</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.58pt;position:var(--position);white-space:pre">]</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:179.25pt;position:var(--position);top:77.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:18.25pt;position:var(--position);text-decoration:none;white-space:pre">25,000</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);top:77.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;2.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:302.25pt;position:var(--position);top:77.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.63</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:363.75pt;position:var(--position);top:77.25pt;width:53.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:53.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.23pt;position:var(--position);text-decoration:none;white-space:pre">4.65%</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:420pt;position:var(--position);top:77.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.15pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.8100000000000005pt;position:var(--position);text-decoration:none;white-space:pre">5.5</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.810000000000002pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.47pt;position:var(--position);text-decoration:none;white-space:pre">7.0</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:30.47pt;position:var(--position);white-space:pre"> years]</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:481.5pt;position:var(--position);top:77.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.86pt;position:var(--position);text-decoration:none;white-space:pre">60.88%</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:89.25pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2025-3</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:54pt;position:var(--position);top:89.25pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:22.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.48</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:117.75pt;position:var(--position);top:89.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:11.26pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:13.92pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3.7</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:27.92pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:30.58pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;4.1</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.58pt;position:var(--position);white-space:pre">]</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:179.25pt;position:var(--position);top:89.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:18.25pt;position:var(--position);text-decoration:none;white-space:pre">39,370</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);top:89.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1.27</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:302.25pt;position:var(--position);top:89.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.41</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:363.75pt;position:var(--position);top:89.25pt;width:53.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:53.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.23pt;position:var(--position);text-decoration:none;white-space:pre">3.92%</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:420pt;position:var(--position);top:89.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.15pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.8100000000000005pt;position:var(--position);text-decoration:none;white-space:pre">5.5</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.810000000000002pt;position:var(--position);white-space:pre">- </span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.47pt;position:var(--position);text-decoration:none;white-space:pre">7.0</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.47pt;position:var(--position);white-space:pre">years]</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:481.5pt;position:var(--position);top:89.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.86pt;position:var(--position);text-decoration:none;white-space:pre">60.69%</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:361.06pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">AGAs</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:379.56pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">The following tables summarize the data relating to AGAs as well as the assumptions used for the measurement thereof in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:391.56pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">accordance with IFRS 2&#8212;</span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:149.28pt;position:var(--position);text-decoration:none;white-space:pre">Share-based Payment</span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:236.7pt;position:var(--position);text-decoration:none;white-space:pre">:</span></div></div><div><div style="position:var(--position);top:70.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:537.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:64.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:64.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:64.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:64.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:64.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:64.5pt"></td><td style="padding:0;width:5.25pt"></td><td style="padding:0;width:65.25pt"></td></tr><tr style="height:47.25pt"><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:38.25pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.72pt;position:var(--position);text-decoration:none;white-space:pre">GRANT&#160;DATE </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:38.25pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.59pt;position:var(--position);text-decoration:none;white-space:pre">TYPE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:28.65pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.38pt;position:var(--position);text-decoration:none;white-space:pre">Total NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:38.25pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.26pt;position:var(--position);text-decoration:none;white-space:pre">OF AGAs </span></div><div style="line-height:8pt;position:var(--position);top:47.85pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.82pt;position:var(--position);text-decoration:none;white-space:pre">ISSUED</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:25.87pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.31pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER OF </span></div><div style="line-height:8pt;position:var(--position);top:35.47pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.19pt;position:var(--position);text-decoration:none;white-space:pre">AGAs </span></div><div style="line-height:8pt;position:var(--position);top:45.07pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.87pt;position:var(--position);text-decoration:none;white-space:pre">OUTSTANDING </span></div><div style="line-height:8pt;position:var(--position);top:54.67pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.97pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:64.27pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.31pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY 1, </span></div><div style="line-height:8pt;position:var(--position);top:73.87pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:15.82pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.94pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER OF </span></div><div style="line-height:8pt;position:var(--position);top:25.42pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.38pt;position:var(--position);text-decoration:none;white-space:pre">ISSUED AGAs</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:15.82pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.94pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER OF </span></div><div style="line-height:8pt;position:var(--position);top:25.42pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.05pt;position:var(--position);text-decoration:none;white-space:pre">LAPSED AGAs</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:15.82pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.94pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER OF </span></div><div style="line-height:8pt;position:var(--position);top:25.42pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.83pt;position:var(--position);text-decoration:none;white-space:pre">VESTED AGAs</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:11.02pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.31pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER OF </span></div><div style="line-height:8pt;position:var(--position);top:20.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.19pt;position:var(--position);text-decoration:none;white-space:pre">AGAs </span></div><div style="line-height:8pt;position:var(--position);top:30.22pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.87pt;position:var(--position);text-decoration:none;white-space:pre">OUTSTANDING </span></div></div></div></td></tr><tr style="height:35.25pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td colspan="6" style="font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:47.25pt;width:204.75pt"><div><div style="line-height:8pt;position:var(--position);top:26.62pt;width:204.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:37.92pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED DECEMBER 31, 2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:47.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:6.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.91pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:16.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.47pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.56pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:82.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">07/11/23</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:82.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2023-1</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:82.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.46pt"></span></span><span style="left:29.09pt;position:var(--position)">1,382,796<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:82.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">780,040<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:82.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:82.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:82.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.8pt"></span></span><span style="left:32.43pt;position:var(--position)">(230,464)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:82.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">549,576<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:94.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">07/11/23</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:94.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2023-2</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:94.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.46pt"></span></span><span style="left:35.09pt;position:var(--position)">100,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:94.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">75,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:94.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:94.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.8pt"></span></span><span style="left:36.43pt;position:var(--position)">(75,000)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:94.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:94.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:106.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">09/28/23</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:106.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2023-3</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:106.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.46pt"></span></span><span style="left:35.09pt;position:var(--position)">731,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:106.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">485,875<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:106.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:106.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.8pt"></span></span><span style="left:36.43pt;position:var(--position)">(34,750)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:106.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.8pt"></span></span><span style="left:32.43pt;position:var(--position)">(251,125)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:106.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">200,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:118.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">09/28/23</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:118.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2023-4</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:118.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.46pt"></span></span><span style="left:35.09pt;position:var(--position)">254,250<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:118.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">213,250<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:118.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:118.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.8pt"></span></span><span style="left:36.43pt;position:var(--position)">(15,000)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:118.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.8pt"></span></span><span style="left:32.43pt;position:var(--position)">(108,500)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:118.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">89,750<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:130.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">12/01/23</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:130.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2023-5</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:130.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.46pt"></span></span><span style="left:35.09pt;position:var(--position)">132,750<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:130.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">81,250<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:130.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:130.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.8pt"></span></span><span style="left:36.43pt;position:var(--position)">(26,000)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:130.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.8pt"></span></span><span style="left:36.43pt;position:var(--position)">(27,625)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:130.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">27,625<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:142.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">02/01/24</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:142.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-1</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:142.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.46pt"></span></span><span style="left:29.09pt;position:var(--position)">1,549,125<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:142.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:27.21pt"></span></span><span style="left:29.84pt;position:var(--position)">1,355,625<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:142.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:142.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.8pt"></span></span><span style="left:32.43pt;position:var(--position)">(134,125)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:142.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:142.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:27.21pt"></span></span><span style="left:29.84pt;position:var(--position)">1,221,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:154.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">03/28/24</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:154.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-2</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:154.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)">22,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:154.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">22,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:154.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:154.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:154.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:154.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">22,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:166.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">05/23/24</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:166.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-3</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:166.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)">38,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:166.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">38,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:166.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:166.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.8pt"></span></span><span style="left:36.43pt;position:var(--position)">(13,000)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:166.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:166.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">25,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:178.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">07/11/24</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:178.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-4</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:178.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)">93,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:178.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">93,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:178.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:178.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:178.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:178.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">93,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:190.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">07/11/24</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:190.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-5</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:190.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)">25,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:190.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">25,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:190.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:190.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:190.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:190.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">25,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:202.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">07/11/24</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:202.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-6</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:202.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)">20,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:202.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">20,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:202.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:202.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:202.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.8pt"></span></span><span style="left:36.43pt;position:var(--position)">(10,000)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:202.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">10,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:214.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">09/05/24</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:214.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-7</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:214.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.46pt"></span></span><span style="left:35.09pt;position:var(--position)">198,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:214.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">198,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:214.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:214.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:214.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:214.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">198,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:226.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">02/06/25</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:226.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-1</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:226.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.46pt"></span></span><span style="left:29.09pt;position:var(--position)">4,319,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:226.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:226.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.46pt"></span></span><span style="left:29.09pt;position:var(--position)">4,319,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:226.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.8pt"></span></span><span style="left:32.43pt;position:var(--position)">(217,500)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:226.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:226.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:27.21pt"></span></span><span style="left:29.84pt;position:var(--position)">4,102,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:238.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">02/06/25</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:238.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-2</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:238.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.46pt"></span></span><span style="left:35.09pt;position:var(--position)">123,102<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:238.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:238.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.46pt"></span></span><span style="left:35.09pt;position:var(--position)">123,102<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:238.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:238.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:238.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">123,102<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:250.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">02/06/25</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:250.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-3</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:250.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)">17,625<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:250.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:250.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)">17,625<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:250.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:250.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:250.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">17,625<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:262.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">02/06/25</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:262.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-4</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:262.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)">30,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:262.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:262.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)">30,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:262.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:262.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:262.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">30,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:274.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">03/20/25</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:274.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-5</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:274.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)">50,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:274.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:274.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)">50,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:274.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.8pt"></span></span><span style="left:36.43pt;position:var(--position)">(50,000)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:274.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:274.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:286.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">05/30/25</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:286.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-6</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:286.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)">25,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:286.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:286.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)">25,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:286.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:286.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:286.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">25,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:298.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">08/01/25</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:298.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-7</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:298.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.46pt"></span></span><span style="left:29.09pt;position:var(--position)">1,711,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:298.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:298.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.46pt"></span></span><span style="left:29.09pt;position:var(--position)">1,711,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:298.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.8pt"></span></span><span style="left:36.43pt;position:var(--position)">(80,000)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:298.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:298.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:27.21pt"></span></span><span style="left:29.84pt;position:var(--position)">1,631,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:310.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">11/13/25</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:310.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-8</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:310.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.46pt"></span></span><span style="left:43.09pt;position:var(--position)">4,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:310.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:310.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.46pt"></span></span><span style="left:43.09pt;position:var(--position)">4,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:310.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:310.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:310.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">4,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:322.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total AGAs</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:132pt;overflow:hidden;position:var(--position);top:322.5pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:322.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:22.46pt"></span></span><span style="left:25.09pt;position:var(--position)">10,828,148<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:322.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:27.21pt"></span></span><span style="left:29.84pt;position:var(--position)">3,388,040<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:322.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:26.46pt"></span></span><span style="left:29.09pt;position:var(--position)">6,280,727<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:322.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.8pt"></span></span><span style="left:32.43pt;position:var(--position)">(645,375)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:322.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.8pt"></span></span><span style="left:32.43pt;position:var(--position)">(627,714)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:322.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:27.21pt"></span></span><span style="left:29.84pt;position:var(--position)">8,395,678<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div></div><div><div style="position:var(--position);top:70.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:540pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:72pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:75pt"></td></tr><tr style="height:41.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:17.62pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.84pt;position:var(--position);text-decoration:none;white-space:pre">TYPE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);width:72pt"><div><div style="line-height:8pt;position:var(--position);top:3.22pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.7pt;position:var(--position);text-decoration:none;white-space:pre">FAIR&#160;VALUE&#160;OF </span></div><div style="line-height:8pt;position:var(--position);top:12.82pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:27.56pt;position:var(--position);text-decoration:none;white-space:pre">THE </span></div><div style="line-height:8pt;position:var(--position);top:22.42pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.69pt;position:var(--position);text-decoration:none;white-space:pre">UNDERLYING </span></div><div style="line-height:8pt;position:var(--position);top:32.02pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.23pt;position:var(--position);text-decoration:none;white-space:pre">SHARE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:12.82pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.2pt;position:var(--position);text-decoration:none;white-space:pre">FAIR&#160;VALUE OF </span></div><div style="line-height:8pt;position:var(--position);top:22.42pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:19.18pt;position:var(--position);text-decoration:none;white-space:pre">THE AGA</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:17.62pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.19pt;position:var(--position);text-decoration:none;white-space:pre">AGA PRICE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:17.62pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.3pt;position:var(--position);text-decoration:none;white-space:pre">MATURITY</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:17.62pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.96pt;position:var(--position);text-decoration:none;white-space:pre">VOLATILITY </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:17.62pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.97pt;position:var(--position);text-decoration:none;white-space:pre">RISK&#160;FREE&#160;RATE</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:41.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:1.73pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-1 </span></div><div style="line-height:9pt;position:var(--position);top:12.98pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(Tranches 1-4)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:41.25pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;15.98</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:41.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;15.98</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:41.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:41.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:41.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:41.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:63pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:1.73pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-1 </span></div><div style="line-height:9pt;position:var(--position);top:12.98pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(Tranche 5)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:63pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;15.98</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:63pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3.62</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:63pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:63pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:16.51pt;position:var(--position);text-decoration:none;white-space:pre">2024-12-31</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:63pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:26.82pt;position:var(--position);text-decoration:none;white-space:pre">67.2%</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:63pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:26.82pt;position:var(--position);text-decoration:none;white-space:pre">3.20%</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:84.75pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:1.73pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-1 </span></div><div style="line-height:9pt;position:var(--position);top:12.98pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(Tranche 6)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:84.75pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;15.98</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:84.75pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.74</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:84.75pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:84.75pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:16.51pt;position:var(--position);text-decoration:none;white-space:pre">2024-07-11</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:84.75pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:26.82pt;position:var(--position);text-decoration:none;white-space:pre">67.2%</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:84.75pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:26.82pt;position:var(--position);text-decoration:none;white-space:pre">3.20%</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:106.5pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:1.73pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-2 </span></div><div style="line-height:9pt;position:var(--position);top:12.98pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(Tranche 1)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:106.5pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;15.98</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:106.5pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;15.98</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:106.5pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:106.5pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:106.5pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:106.5pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:128.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:1.73pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-2 </span></div><div style="line-height:9pt;position:var(--position);top:12.98pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(Tranche 2)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:128.25pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;15.98</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:128.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;9.59</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:128.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:128.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:128.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:128.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:150pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-3</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:150pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;14.92</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:150pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;14.92</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:150pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:150pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:150pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:150pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:162pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-4</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:162pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;14.92</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:162pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;14.92</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:162pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:162pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:162pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:162pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:174pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-5</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:174pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;9.16</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:174pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;9.16</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:174pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:174pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:174pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:174pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:186pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2024-1</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:186pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.26</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:186pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.26</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:186pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:186pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:186pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:186pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:198pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2024-2</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:198pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;13.40</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:198pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;13.40</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:198pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:198pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:198pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:198pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:210pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-3</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:210pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.76</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:210pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.76</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:210pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:210pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:210pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:210pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:222pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-4</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:222pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.54</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:222pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.54</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:222pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:222pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:222pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:222pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:234pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-5</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:234pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.54</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:234pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.54</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:234pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:234pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:234pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:234pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:246pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-6</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:246pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.54</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:246pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.54</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:246pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:246pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:246pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:246pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:258pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-7</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:258pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;10.80</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:258pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;10.80</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:258pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:258pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:258pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:258pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:270pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-1</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:270pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.82</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:270pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.82</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:270pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:270pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:270pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:270pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:282pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-2</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:282pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.82</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:282pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.82</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:282pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:282pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:282pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:282pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:294pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-3</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:294pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.82</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:294pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.82</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:294pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:294pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:294pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:294pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:306pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-4</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:306pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.82</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:306pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.82</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:306pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:306pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:306pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:306pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:318pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-5</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:318pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.17</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:318pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.17</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:318pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:318pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:318pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:318pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:330pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-6</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:330pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.17</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:330pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.17</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:330pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:330pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:330pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:330pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:342pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-7</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:342pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;61.20</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:342pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;61.20</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:342pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:342pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:342pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:342pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:354pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-8</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:354pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;89.40</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:354pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;89.40</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:354pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:354pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:354pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:354pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:468.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">AGAs granted in July 2023</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:490.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(a) Pursuant to a Board decision on July 11, 2023, the Group allocated a total number of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:390.95pt;position:var(--position);text-decoration:none;white-space:pre">1,382,796</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:430.95pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs to Mr. Marc de Garidel, as </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:501.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the Group&#8217;s Chief Executive Officer, to which performance conditions and service conditions apply (AGA plan 2023-1):</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:524.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">For </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:88.39pt;position:var(--position);text-decoration:none;white-space:pre">212,738</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.89pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs 2023-1 (tranche 1): the acquisition period shall end on the first anniversary of the allocation date; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:535.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">For </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:88.39pt;position:var(--position);text-decoration:none;white-space:pre">638,214</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.89pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs 2023-1 (tranche 2): the AGAs 2023-1 shall progressively be definitively acquired on a monthly basis over </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:546.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">a period of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:117.78999999999999pt;position:var(--position);text-decoration:none;white-space:pre">three years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:161.32999999999998pt;position:var(--position);text-decoration:none;white-space:pre"> starting after the first anniversary of the allocation date;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:557.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">For </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:88.39pt;position:var(--position);text-decoration:none;white-space:pre">212,738</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.89pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs 2023-1 (tranche 3): the acquisition period shall end on the latest date between (i) the first anniversary of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:568.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the allocation date, and (ii) the date on which a specific performance condition related to regulatory approval is fulfilled; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:580.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">For </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:88.39pt;position:var(--position);text-decoration:none;white-space:pre">106,369</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.89pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs 2023-1 (tranche 4): the acquisition period shall end on the latest date between (i) the first anniversary of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:591.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the allocation date, and (ii) the date on which the Group successfully completes a public offering raising at least </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:521.4200000000001pt;position:var(--position);text-decoration:none;white-space:pre">$100&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:572.77pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:602.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">in gross proceeds (the condition was met on October 24, 2023); </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:613.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">For </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:88.39pt;position:var(--position);text-decoration:none;white-space:pre">106,369</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.89pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs 2023-1 (tranche 5): the acquisition period shall end on the latest date between (i) the first anniversary of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:624.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the allocation date, and (ii) the date on which a specific performance condition related to the Group&#8217;s market capitalization is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:636.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">fulfilled; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:647.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">For </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:88.39pt;position:var(--position);text-decoration:none;white-space:pre">106,368</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.89pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs 2023-1 (tranche 6): the acquisition period shall end on the first anniversary of the allocation date subject </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:658.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to the completion, prior to such date, of a tender offer on the securities issued by the Group, at a predetermined minimum </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:669.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">price, and resulting in a change of control of the Group; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:680.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Additionally, AGAs related to tranches 1 to 5 are subject to a vesting acceleration condition in case of a tender offer on the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:692.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">securities issued by the Group and resulting in a change of control of the Group.</span></div></div><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group qualified those conditions under IFRS 2 principles as follows:</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:92.96pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Conditions related to tranches 1 and 2 qualify as service conditions under IFRS 2 principles.</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:106.4pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Conditions related to tranches 3 and 4 qualify as service and non-market performance conditions. Their levels of achievement </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:119.84pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">are reflected in the number of instruments that are expected to vest and were estimated by management based on observable </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:133.28pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">industry-specific data.</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:146.72pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Conditions related to tranches 5 and 6 qualify as service and market performance conditions. The levels of achievement of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:160.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">market conditions are reflected in the unit fair value of the free shares and were estimated by management using the valuation </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:173.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">methods and assumptions set out above. The valuation of tranche 6 also incorporates management&#8217;s estimate of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:187.04pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">probability of a M&amp;A transaction prior to the limit date.</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:200.48pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The vesting acceleration condition in case of a tender offer on the securities issued by the Group and resulting in a change of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:213.92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">control of the Group qualifies as a non-market performance condition.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:241.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(b) Pursuant to a Board decision on July 11, 2023, the Group allocated a total number of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:391.52pt;position:var(--position);text-decoration:none;white-space:pre">100,000</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:424.02pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs to Mr. Hartmut Ehrlich, as the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:252.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Group&#8217;s former Chief Executive Officer, to which the following conditions apply (AGA plan 2023-2):</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:274.76pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">For </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:88.39pt;position:var(--position);text-decoration:none;white-space:pre">25,000</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:115.89pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs 2023-2 (tranche 1): the acquisition period shall end on the first anniversary of the allocation date, and is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:288.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">not subject to a future service condition; </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:301.64pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">For </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:88.39pt;position:var(--position);text-decoration:none;white-space:pre">75,000</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:115.89pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs 2023-2 (tranche 2): the acquisition period shall end on the latest date between (i) the first anniversary of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:315.08pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the allocation date, and (ii) the date on which a specific condition, related to positive results on clinical studies, is fulfilled. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:328.52pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The acquisition is not subject to a future service condition. Additionally, the tranche is subject to a vesting acceleration </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:341.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">condition in case of a tender offer on the securities issued by the Group and resulting in a change of control of the Group.&#160; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:355.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">This tranche qualifies as a non-vesting condition. Its level of achievement is reflected in the unit fair value of the free shares, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:368.84pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and was estimated by management based on observable industry-specific data.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:395.72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">AGAs granted in September and December 2023</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:418.12pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On September 28, 2023 and December 1, 2023, certain of the Group&#8217;s officers and employees were allocated respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:525.72pt;position:var(--position);text-decoration:none;white-space:pre">985,750</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:558.22pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:429.32pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">AGAs (AGA plans 2023-3 and 2023-4) and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:213.98pt;position:var(--position);text-decoration:none;white-space:pre">132,750</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:246.48pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs (AGA plan 2023-5) in the aggregate, the vesting of which is subject to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:440.52pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">certain conditions: </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:462.92pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Subject to remaining employed with the Group, each such officer or employee&#8217;s AGAs will be vested as follows: (i) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.28pt;position:var(--position);text-decoration:none;white-space:pre">50%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:557.61pt;position:var(--position);text-decoration:none;white-space:pre"> at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:476.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the end of a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:121.39pt;position:var(--position);text-decoration:none;white-space:pre">two</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:136.38pt;position:var(--position);text-decoration:none;white-space:pre">-year</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:156.9pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation date, (ii) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:302.26pt;position:var(--position);text-decoration:none;white-space:pre">25%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:320.59000000000003pt;position:var(--position);text-decoration:none;white-space:pre"> at the end of a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:382.18pt;position:var(--position);text-decoration:none;white-space:pre">three</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:402.14pt;position:var(--position);text-decoration:none;white-space:pre">-year</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:422.66pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation date and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:489.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(iii) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:89.47pt;position:var(--position);text-decoration:none;white-space:pre">25%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:107.8pt;position:var(--position);text-decoration:none;white-space:pre"> at the end of a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:169.39pt;position:var(--position);text-decoration:none;white-space:pre">four</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:186.05pt;position:var(--position);text-decoration:none;white-space:pre">-year</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:206.57pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation date (service condition). </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:514.44pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Of the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:99.75pt;position:var(--position);text-decoration:none;white-space:pre">1,118,500</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:139.75pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:172.8pt;position:var(--position);text-decoration:none;white-space:pre">254,250</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:205.3pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs are subject to an additional non-market performance condition of the successful </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:527.88pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">completion of a public offering raising at least </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:259.53999999999996pt;position:var(--position);text-decoration:none;white-space:pre">$200&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:310.89pt;position:var(--position);text-decoration:none;white-space:pre"> in gross proceeds. This condition was met on October 24, 2023.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:552.52pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Additionally, all the 2023-3, 2023-4 and 2023-5 AGAs are subject to a vesting acceleration condition in case of a tender offer on the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:564.52pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">securities issued by the Group and resulting in a change of control of the Group.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:589.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">AGAs granted in February, March, May, July and September 2024</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:612.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On February 1, 2024, March 28, 2024, May 23, 2024, July 11, 2024 and September 5, 2024 certain of the Group&#8217;s officers and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:623.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">employees were allocated respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:192.41pt;position:var(--position);text-decoration:none;white-space:pre">1,549,125</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:232.41pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs (AGA plans 2024-1), </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:350.7pt;position:var(--position);text-decoration:none;white-space:pre">22,500</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:378.2pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs (AGA plan 2024-2), </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:492.6pt;position:var(--position);text-decoration:none;white-space:pre">38,500</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:520.1pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs (AGA </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:634.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">plans 2024-3), </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.25pt;position:var(--position);text-decoration:none;white-space:pre">138,000</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:128.75pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs (AGA plans 2024-4, 5 and 6) and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:295.9pt;position:var(--position);text-decoration:none;white-space:pre">198,000</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:328.4pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs (AGA plans 2024-7), in the aggregate, the vesting of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:645.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">which is subject to certain conditions: </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:670.96pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Subject to remaining employed with the Group, each such officer or employee&#8217;s AGAs (with the exception of AGAs 2024-6) </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:684.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">will be vested as follows: (i) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:187.98000000000002pt;position:var(--position);text-decoration:none;white-space:pre">50%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:206.31pt;position:var(--position);text-decoration:none;white-space:pre"> at the end of a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:267.9pt;position:var(--position);text-decoration:none;white-space:pre">two years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:306.47pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation date, (ii) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:451.83pt;position:var(--position);text-decoration:none;white-space:pre">25%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:470.16pt;position:var(--position);text-decoration:none;white-space:pre"> at the end of a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:531.75pt;position:var(--position);text-decoration:none;white-space:pre">three</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:551.71pt;position:var(--position);text-decoration:none;white-space:pre">-year</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:572.23pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div></div><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">period from the allocation date and (iii) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:232.06pt;position:var(--position);text-decoration:none;white-space:pre">25%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:250.39pt;position:var(--position);text-decoration:none;white-space:pre"> at the end of a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:311.98pt;position:var(--position);text-decoration:none;white-space:pre">four years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:352.22pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation date (service condition).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:97.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90.03pt;position:var(--position);text-decoration:none;white-space:pre">20,000</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:117.53pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs 2024-6 granted to an employee are composed of (i) a first tranche of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:423.61pt;position:var(--position);text-decoration:none;white-space:pre">10,000</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:451.11pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs not subject to any </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:108.64pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">presence of performance condition and (ii) a second tranche of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:325.02pt;position:var(--position);text-decoration:none;white-space:pre">10,000</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:352.52pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs subject to a non-vesting condition, the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:119.84pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">achievement of which was deemed certain on grant date.</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:144.84pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Additionally, all the 2024-1 to 2024-7 AGA plans are subject to a vesting acceleration condition in case of a tender offer on </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:159.24pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the securities issued by the Group and resulting in a change of control of the Group.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:183.64pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">A</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:42.1pt;position:var(--position);text-decoration:none;white-space:pre">GAs granted in February, March, May, August and November 2025</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:206.04pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">From February to November 2025, certain of the Group&#8217;s officers and employees were allocated </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:424.75pt;position:var(--position);text-decoration:none;white-space:pre">4,319,500</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:464.75pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs (AGA plan </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:217.24pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">2025-1), </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72.66pt;position:var(--position);text-decoration:none;white-space:pre">123,102</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:105.16pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs (AGA plan 2025-2), </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:219.56pt;position:var(--position);text-decoration:none;white-space:pre">17,625</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:247.06pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs (AGA plans 2025-3), </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:365.35pt;position:var(--position);text-decoration:none;white-space:pre">30,500</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:392.85pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs (AGA plan 2025-4), </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:507.25pt;position:var(--position);text-decoration:none;white-space:pre">25,000</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:534.75pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:228.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(AGA plan 2025-6), </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:119.85pt;position:var(--position);text-decoration:none;white-space:pre">1,711,000</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:159.85pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs (AGA plan 2025-7) and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:288.68pt;position:var(--position);text-decoration:none;white-space:pre">4,000</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:311.18pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs (AGA plan 2025-8) in the aggregate, the vesting of which </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:239.64pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">is subject to certain conditions: </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:262.04pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Subject to remaining employed with the Group, each such officer or employee&#8217;s AGAs will be vested as follows: (i) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.28pt;position:var(--position);text-decoration:none;white-space:pre">50%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:557.61pt;position:var(--position);text-decoration:none;white-space:pre"> at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:275.48pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the end of a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:121.39pt;position:var(--position);text-decoration:none;white-space:pre">two</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:136.38pt;position:var(--position);text-decoration:none;white-space:pre">-year</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:156.9pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation date, (ii) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:302.26pt;position:var(--position);text-decoration:none;white-space:pre">25%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:320.59000000000003pt;position:var(--position);text-decoration:none;white-space:pre"> at the end of a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:382.18pt;position:var(--position);text-decoration:none;white-space:pre">three</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:402.14pt;position:var(--position);text-decoration:none;white-space:pre">-year</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:422.66pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation date and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:288.92pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(iii) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:89.47pt;position:var(--position);text-decoration:none;white-space:pre">25%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:107.8pt;position:var(--position);text-decoration:none;white-space:pre"> at the end of a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:169.39pt;position:var(--position);text-decoration:none;white-space:pre">four</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:186.05pt;position:var(--position);text-decoration:none;white-space:pre">-year</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:206.57pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation date (service condition). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:302.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">B</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:78.66pt;position:var(--position);text-decoration:none;white-space:pre">y exception to the above, the vesting of almost half of the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:310.9pt;position:var(--position);text-decoration:none;white-space:pre">4,319,500</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:350.9pt;position:var(--position);text-decoration:none;white-space:pre"> 2025-1 AGAs is subject to the occurrence of a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:541.27pt;position:var(--position);text-decoration:none;white-space:pre">tender </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:313.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">offer on the securities issued by the Group and resulting in a change of control of the Group</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:439.15pt;position:var(--position);text-decoration:none;white-space:pre"> before a certain date, and the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:324.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">123,102</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:104.5pt;position:var(--position);text-decoration:none;white-space:pre"> 2025-2 AGAs will vest entirely at the end of a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:294.59000000000003pt;position:var(--position);text-decoration:none;white-space:pre">two</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:309.58000000000004pt;position:var(--position);text-decoration:none;white-space:pre">-year</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:330.1pt;position:var(--position);text-decoration:none;white-space:pre"> period from the allocation dat</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:451.33pt;position:var(--position);text-decoration:none;white-space:pre">e, subject to future service </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:335.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">condition.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:347.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Additionally, all the AGA plans granted in 2025 are subject to a vesting acceleration condition in case of a tender offer on the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:359.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">securities issued by the Group and resulting in a change of control of the Group.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:383.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In March 2025, a Group employee was allocated </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:233.29pt;position:var(--position);text-decoration:none;white-space:pre">50,000</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:260.78999999999996pt;position:var(--position);text-decoration:none;white-space:pre"> AGAs (AGA plan 2025-5),</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:372.69pt;position:var(--position);text-decoration:none;white-space:pre"> the vesting of which is subject to the achievement </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:394.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of certain milestones related to clinical studies and market authorization of ABX464 in UC and CD as well as future service.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:533.98pt;position:var(--position);text-decoration:none;white-space:pre"> These </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:405.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">AGAs are also s</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:101.22pt;position:var(--position);text-decoration:none;white-space:pre">ubject to a vesting acceleration condition in case of a tender offer on the securities issued by the Group and resulting </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:416.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in a change of control of the Group. Following the departure of the beneficiary during the period, the expense related to this plan has </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:427.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">been reversed.</span></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Social taxes related to AGAs</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:94.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">AGA plans granted to the Group's officers and employees are subject to employer's taxes, measured in accordance with the same </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:106.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">principles as the AGA plans. These taxes a</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:207.46pt;position:var(--position);text-decoration:none;white-space:pre">re paid </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:237.42pt;position:var(--position);text-decoration:none;white-space:pre">upon the vesting date of the awards and their amount is based on the fair value of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:118.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the underlying share at that date. They are therefore remeasured at every reporting date,</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:386.34pt;position:var(--position);text-decoration:none;white-space:pre"> using the listed share price at that date</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:541.6700000000001pt;position:var(--position);text-decoration:none;white-space:pre">. They </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:130.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">are classified as provisions before they are due.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:154.56pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre;width:439.91pt">Breakdown of the compensation expenses accounted for the period ended December 31, 2023, 2024 and 2025</span></div><div style="position:var(--position);top:177.91pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:321pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:119.25pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td></tr><tr style="height:41.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.02pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">TYPE</span></div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:119.25pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:8.02pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.32pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:17.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:27.22pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:187.5pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:8.02pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.32pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:17.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:27.22pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:255.75pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:8.02pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.32pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:17.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:27.22pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:41.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BCEs</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:119.25pt;position:var(--position);top:41.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.55pt"></span></span><span style="left:47.18pt;position:var(--position)">(112)</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:187.5pt;position:var(--position);top:41.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.55pt"></span></span><span style="left:47.18pt;position:var(--position)">(112)</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:252.75pt;overflow:hidden;position:var(--position);top:41.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:255.75pt;position:var(--position);top:41.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:53.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSAs</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:119.25pt;position:var(--position);top:53.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:187.5pt;position:var(--position);top:53.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.55pt"></span></span><span style="left:47.18pt;position:var(--position)">(211)</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:252.75pt;overflow:hidden;position:var(--position);top:53.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:255.75pt;position:var(--position);top:53.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.55pt"></span></span><span style="left:47.18pt;position:var(--position)">(289)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:65.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGAs</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:119.25pt;position:var(--position);top:65.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.55pt"></span></span><span style="left:41.18pt;position:var(--position)">(8,067)</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:187.5pt;position:var(--position);top:65.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:34.55pt"></span></span><span style="left:37.18pt;position:var(--position)">(19,900)</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:252.75pt;overflow:hidden;position:var(--position);top:65.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:255.75pt;position:var(--position);top:65.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:35.3pt;position:var(--position);text-decoration:none;white-space:pre">(35,108)</span></div></div></div></td></tr><tr style="height:12.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:77.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Social taxes related to AGAs</span></div></div></div></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:119.25pt;position:var(--position);top:77.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.55pt"></span></span><span style="left:47.18pt;position:var(--position)">(426)</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:187.5pt;position:var(--position);top:77.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.55pt"></span></span><span style="left:47.18pt;position:var(--position)">(717)</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="height:12.75pt;left:252.75pt;overflow:hidden;position:var(--position);top:77.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:255.75pt;position:var(--position);top:77.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:35.3pt;position:var(--position);text-decoration:none;white-space:pre">(48,990)</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total</span></div></div></div></td><td style="background-color:#CCECFF;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:119.25pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:38.55pt"></span></span><span style="left:41.18pt;position:var(--position)">(8,605)</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:187.5pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:34.55pt"></span></span><span style="left:37.18pt;position:var(--position)">(20,941)</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:252.75pt;overflow:hidden;position:var(--position);top:90pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="background-color:#CCECFF;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:255.75pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:35.3pt;position:var(--position);text-decoration:none;white-space:pre">(84,387)</span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:294.91pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The significant amount of social taxes related to AGAs (and related provisions) for the year ended December 31, 2025 is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:304.91pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">predominantly attributable to the increase in the price of the underlying shares over the period.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:324.91pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Provisions for social taxes related to AGAs are classified within the Current Provisions and Non-current Provisions line items in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:334.91pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">balance sheet, which </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:121.43pt;position:var(--position);text-decoration:none;white-space:pre">amount</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:151.4pt;position:var(--position);text-decoration:none;white-space:pre"> to</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:161.67000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> respective</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:204.65pt;position:var(--position);text-decoration:none;white-space:pre">ly</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:212.42pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:214.92pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;16,467&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:286.01pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:288.51pt;position:var(--position);text-decoration:none;white-space:pre">and</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:302.94pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:305.44pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;28,718&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:376.53pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:379.03pt;position:var(--position);text-decoration:none;white-space:pre">as of December 31, 20</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:469.22pt;position:var(--position);text-decoration:none;white-space:pre">25.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ShareBasedPaymentArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ShareBasedPaymentArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 44<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract', window );"><strong>Disclosure of financial liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">Financial liabilities</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Financial liabilities</span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:90.36pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:41pt;position:var(--position);text-decoration:none;white-space:pre">Financial liabilities break down as follows:</span></div><div style="font-size:12pt;line-height:11pt;position:var(--position);top:101.66pt;width:612pt"><span style="font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div><div style="position:var(--position);top:110.46pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:422.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:191.25pt"></td><td style="padding:0;width:75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:75pt"></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:44.09pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">FINANCIAL LIABILITIES&#160;</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:12pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.84pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.5pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:12pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.84pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.5pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:12pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.84pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.5pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos &amp; Claret bond loans </span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:42.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:42.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">26,373<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:42.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Lease liabilities</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)">160<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">1,431<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)">554<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">PGE</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">2,402<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">1,252<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Borrowings</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:78.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">2,563<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:78.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">29,056<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:78.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)">554<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos &amp; Claret convertible notes (OCABSA)</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:90.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">21,643<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:90.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">23,370<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:90.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Convertible loan notes</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:102.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">21,643<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:102.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">23,370<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:102.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:114.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos &amp; Claret minimal return indemnifications </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:114.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:114.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">3,620<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:114.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:126.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Derivative instruments</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:126.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:126.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">3,620<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:126.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:138.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Conditional advances Bpifrance</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:138.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">3,262<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:138.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:138.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:150.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Royalty certificates</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:150.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">12,229<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:150.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:50.37pt;position:var(--position);text-decoration:none;white-space:pre">13,023</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:150.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">30,237<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:162.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial liabilities</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:162.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">15,491<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:162.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">13,023<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:162.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">30,237<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:174.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total non-current financial liabilities</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:174.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">39,697<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:174.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">69,069<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:174.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">30,790<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:6.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:193.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos &amp; Claret bond loans </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:193.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:193.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">20,028<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:193.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:205.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Lease liabilities</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:205.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)">379<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:205.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)">932<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:205.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">1,302<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:217.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">PGE</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:217.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">1,276<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:217.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">1,235<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:217.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:229.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Borrowings</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:229.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">1,655<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:229.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">22,195<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:229.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">1,302<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:241.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Heights convertible notes </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:241.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">29,605<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:241.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">21,574<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:241.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:253.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Convertible loan notes</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:253.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">29,605<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:253.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">21,574<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:253.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:265.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Conditional advances Bpifrance</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:265.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">3,509<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:265.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:265.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:277.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial liabilities</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:277.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">3,509<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:277.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:277.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:289.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos &amp; Claret BSA</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:289.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">2,579<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:289.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">1,166<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:289.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:301.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Derivative instruments</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:301.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">2,579<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:301.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">1,166<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:301.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:313.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total current financial liabilities</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:313.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">37,348<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:313.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">44,935<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:313.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">1,302<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:325.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial liabilities</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:325.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">77,045<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:325.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.96pt"></span></span><span style="left:45.59pt;position:var(--position)">114,004<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:325.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">32,093<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 15.1. Structured debt financing with </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:209.22pt;position:var(--position);text-decoration:none;white-space:pre">Kreos &amp; Claret subscribed in August 2023 &#8211; &#8220;Kreos / Claret Financing&#8221;</span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:530pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On August 20, 2023, the Group entered into a structured debt financing agreement with Kreos and Claret (the Kreos / Claret </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:541.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Financing), for up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:121.22pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;75,000&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:192.31pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:563.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On August 22, 2023, the Group repaid in full the pre-existing debt agreements with Kreos for a total amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:482.81pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;7,661&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:548.9pt;position:var(--position);text-decoration:none;white-space:pre">. The </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:574.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">accounting treatment of this transaction is explained in Note 15.3.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:597.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Kreos / Claret Financing consists of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:199.99pt;position:var(--position);text-decoration:none;white-space:pre">three</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:219.95pt;position:var(--position);text-decoration:none;white-space:pre"> tranches of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:269.06pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;25,000&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:340.15pt;position:var(--position);text-decoration:none;white-space:pre"> each in aggregate principal amount:</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:619.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The first tranche (&#8220;tranche A&#8221;) in aggregate principal amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:330.53pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;25,000&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:401.62pt;position:var(--position);text-decoration:none;white-space:pre"> takes the form of senior secured </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:630.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">convertible bonds with warrants attached (the &#8220;Kreos / Claret OCABSA&#8221;) and was drawn on August 22, 2023. The Kreos / </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:642pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Claret OCABSA are convertible into ordinary shares at any time from their issuance at the request of their holders at a fixed </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:653.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">conversion price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:151.64pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;21.2209</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:189.14pt;position:var(--position);text-decoration:none;white-space:pre">, subject to standard adjustments, including anti-dilution and dividend protections. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:675.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Interest on the Kreos / Claret OCABSA accrues at a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:282.28999999999996pt;position:var(--position);text-decoration:none;white-space:pre">9.00%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:308.12pt;position:var(--position);text-decoration:none;white-space:pre"> annual fixed interest rate, payable in quarterly installments. The </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:686.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Kreos / Claret OCBSA&#8217;s maturity date is March 31, 2027, it being specified that the scheduled date of final repayment is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:698pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">January 1, 2027.</span></div><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The Group is allowed to prepay the amounts due under the Kreos / Claret OCABSA at any time. In such case, the Group will </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:81.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">be required to pay a sum equal to (i) the principal outstanding at the time of the prepayment (plus accrued interests), plus (ii) </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:92.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">an aggregate of all remaining interest payments that would have been paid throughout the remainder of the term of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:104.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">tranche, discounted to present value by applying a discount rate of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:339.48pt;position:var(--position);text-decoration:none;white-space:pre">4%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:352.81pt;position:var(--position);text-decoration:none;white-space:pre">, plus (iii) an end-of-loan exit fee equal to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:522.05pt;position:var(--position);text-decoration:none;white-space:pre">8.0%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:542.88pt;position:var(--position);text-decoration:none;white-space:pre"> of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:115.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">amounts drawn thereunder. In case of prepayment, the holders of the Kreos / Claret OCABSA will have the option to request </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">a conversion of their Kreos / Claret OCABSA instead of a cash repayment, in which case, the end-of-loan exit fee is not </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:137.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">payable by the Group.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:160.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The warrants included in the Kreos / Claret OCABSA will only become exercisable in case of prepayment in cash of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:171.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Kreos / Claret convertible bonds by the Group. Upon exercise of the warrants, their holders will be able to subscribe to the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:183.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">same number of ordinary shares (and at the same price conditions) as they would have been able to subscribe had they </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:194.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">converted the Kreos / Claret OCABSA which have been prepaid in cash. Any warrants not exercised on or prior to January 1, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:206.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">2027 will become automatically null and void. For the avoidance of doubt, if the Group does not prepay any Kreos / Claret </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:217.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">OCABSA in cash prior to their scheduled repayment dates, none of the warrants will be exercisable.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:240.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The second tranche (&#8220;tranche B&#8221;) in aggregate principal amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:341.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;25,000&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:412.72pt;position:var(--position);text-decoration:none;white-space:pre"> takes the form of senior secured non-</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:251.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">convertible bonds and was drawn on March 28, 2024. The drawdown of the second tranche was subject to a maximum </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:548.79pt;position:var(--position);text-decoration:none;white-space:pre">10%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:567.12pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:263.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Debt-To-Market Capitalization Ratio at the time of drawdown. The &#8220;Debt-To-Market Capitalization Ratio&#8221; is calculated on </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:274.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">any relevant date, by dividing (i) the indebtedness of the Group (including amounts due under the Kreos / Claret Financing </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:285.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">but excluding amounts due under the Heights Financing), by (ii) the market capitalization of the Group calculated by </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:296.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">multiplying the number of outstanding ordinary shares by the closing price of the ordinary shares on such relevant date. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:319.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The third tranche (&#8220;tranche C&#8221;) in aggregate principal amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:332.75pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;25,000&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:403.84pt;position:var(--position);text-decoration:none;white-space:pre"> takes the form of senior secured non-</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:330.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">convertible bonds and was drawn on June 21, 2024. The drawdown of the third tranche was subject to a maximum </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:532.15pt;position:var(--position);text-decoration:none;white-space:pre">10%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:550.48pt;position:var(--position);text-decoration:none;white-space:pre"> Debt-</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:341.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">To-Market Capitalization Ratio at the time of drawdown (excluding the Heights Financing) and was conditional on the Group </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:352.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">raising a minimum of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:160.8pt;position:var(--position);text-decoration:none;white-space:pre">$125,000&#160;thousand</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:236.89pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> in gross proceeds through a listing on Nasdaq before June 30, 2024. This condition </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:363.86pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">was met on October 24, 2023 (see Note 3.3 - </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:253.52pt;position:var(--position);text-decoration:none;white-space:pre">Conversion of the Heights convertible notes, Kreos OCABSA and Kreos / Claret </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:375.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">BSA and prepayment of the Kreos / Claret Tranches B and C bond loans &#8211;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:370.12pt;position:var(--position);text-decoration:none;white-space:pre"> July-December 2025</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:456.13pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">).</span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:397.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">A variable interest rate of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:176.56pt;position:var(--position);text-decoration:none;white-space:pre">7.5%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:197.39pt;position:var(--position);text-decoration:none;white-space:pre"> + European Central Bank Base Rate (MRO) (with a floor at </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:441.07pt;position:var(--position);text-decoration:none;white-space:pre">2.5%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:461.9pt;position:var(--position);text-decoration:none;white-space:pre"> and a cap at </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:514.3199999999999pt;position:var(--position);text-decoration:none;white-space:pre">4%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:527.65pt;position:var(--position);text-decoration:none;white-space:pre">) applies to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:408.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the second and third tranche. These </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:215.99pt;position:var(--position);text-decoration:none;white-space:pre">two</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:230.98pt;position:var(--position);text-decoration:none;white-space:pre"> tranches will be repaid monthly through March 31, 2027, after a deferred repayment </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:419.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">of the principal until February 1, 2025.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:442.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The Group is allowed to prepay the amounts due under the second and third tranches of the Kreos / Claret Financing at any </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:453.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">time. In such case, The Group will be required to pay a sum equal to (i) the principal outstanding at the time of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:464.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">prepayment (plus accrued interests), plus (ii) an aggregate of all remaining interest payments that would have been paid </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:475.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">throughout the remainder of the term of the applicable tranche, discounted to present value by applying a discount rate of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:558.9300000000001pt;position:var(--position);text-decoration:none;white-space:pre">4%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:572.26pt;position:var(--position);text-decoration:none;white-space:pre">, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:487.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">plus (iii) an end-of-loan exit fee equal to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:236.24pt;position:var(--position);text-decoration:none;white-space:pre">6.0%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:257.07pt;position:var(--position);text-decoration:none;white-space:pre"> of the amounts drawn under the applicable tranche.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:509.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Kreos / Claret Financing also provides for a Minimal Return Indemnification ("MRI") to the benefit of the bondholders. The </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:520.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Minimum Cash Return amount is defined as follows:</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:531.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(i) with respect to tranche A and tranche B, 1.4 times the amount of the cumulated principal drawn under the relevant </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:543.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">i</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:74.77pt;position:var(--position);text-decoration:none;white-space:pre">nstrument, and; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:554.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(ii) with respect to tranche C, 1.3 times the amount of the cumulated principal drawn under the relevant instrument.&#160; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:579.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In the event the amount of the cash generated by the tranche A (the Kreos / Claret OCABSA), tranche B or tranche C bond loans, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:590.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">including principal and interest payments, transaction fees, and the end-of-loan exit fees, (the &#8220;Actual Return&#8221; calculated as at the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:601.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">earlier of (i) March 31, 2027, or (ii) the date of any prepayment or acceleration of the tranche B and C bond loans or more generally </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:612.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">such earlier date as the same shall become repayable ("the Redemption Date")), is lower than the Minimum Cash Return, the Group </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:624.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">shall indemnify the bondholders for the difference between the Minimum Cash Return and the Actual Return (the &#8220;Minimal Return </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:635.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Indemnification"). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:646.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">If at the time of the Minimum Return Indemnification payment, the warrants related to both the OCABSA Bonds and the Tranche B </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:657.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">amortized bonds (the &#8220;Kreos / Claret A-B warrants&#8221;) or the Kreos / Claret Tranche C warrants are still outstanding, the exercise price </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:668.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">for such warrants shall be adjusted up by the amount of the Minimum Return Indemnification divided by the number of warrants </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:680.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">outstanding. For any Kreos / Claret A-B or C warrants that were exercised prior to the last Redemption Date, any capital gains made </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:691.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">from the exercise of such warrants will be added to the Minimum Cash Return amount.</span></div></div><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Unless the repayment of the Tranche A and B bond loans results from a change of control (in which case the calculation of the Actual </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:81.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Return shall only include (i) interest accrued prior to conversion of any Tranche A OCABSA, (ii) transaction and end-of-loan exit </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:92.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">fees, and (iii) the net capital gain derived from the sale of shares underlying the Tranche A OCABSA within the framework of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:104.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">change of control transaction), neither the principal subscribed under Tranche A nor the Actual Return generated by Tranche A shall </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:115.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">be included in the calculation of the Minimum Return Indemnification (i.e. the Minimum Cash Return and the Actual Return shall </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">only be calculated, and the Minimum Return Indemnification shall only apply to Tranche B and Tranche C).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:137.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Kreos / Claret Financing provides for certain restrictive covenants (subject to customary exceptions) which include, among other </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:148.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">things, restrictions on the incurrence of indebtedness, cross-default, the distribution of dividends and the grant of security interests. As </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:160.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">security for the Kreos / Claret Financing, the lenders benefit from the grant of first-ranking collateral on The Group&#8217;s principal </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:171.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">tangible and intangible assets, including pledges over The Group&#8217;s business (</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:344.86pt;position:var(--position);text-decoration:none;white-space:pre">fonds de commerce</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:422pt;position:var(--position);text-decoration:none;white-space:pre">) as a going concern and intellectual </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:182.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">property rights in The Group's lead drug candidate, as well as pledges over The Group&#8217;s bank accounts and receivables. Such </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:193.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">securities apply to all tranches of the Kreos / Claret Financing.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:216.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In addition to the Kreos / Claret OCABSA, the Group has issued warrants (the &#8220;tranche A-B BSA&#8221;) for a global subscription price of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:227.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1.00</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:58.5pt;position:var(--position);text-decoration:none;white-space:pre">, giving Kreos and Claret the right to subscribe to up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:281.35pt;position:var(--position);text-decoration:none;white-space:pre">214,198</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:313.85pt;position:var(--position);text-decoration:none;white-space:pre"> new ordinary shares at an exercise price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:489.46pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;18.6744</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:526.96pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:239.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(corresponding to a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:116.21pt;position:var(--position);text-decoration:none;white-space:pre">10%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:134.54000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> premium over the 15-day VWAP prior to the date on which their issuance was decided). On November 2, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:250.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">2023, a second tranche of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.9pt;position:var(--position);text-decoration:none;white-space:pre">405,832</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:173.4pt;position:var(--position);text-decoration:none;white-space:pre"> Kreos / Claret warrants (the &#8220;tranche C BSA&#8221;) was issued. The exercise price of the additional </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:262.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">warrants is equal to approximately </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:176.66pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;9.86</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:199.16pt;position:var(--position);text-decoration:none;white-space:pre"> (corresponding to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:274.94pt;position:var(--position);text-decoration:none;white-space:pre">110%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.27pt;position:var(--position);text-decoration:none;white-space:pre"> of the 15-day VWAP prior to the date on which their issuance was </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:273.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">decided). The number of warrants issued corresponds to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:262.73pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;4,000,000</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:307.73pt;position:var(--position);text-decoration:none;white-space:pre"> divided by the aforementioned exercise price (i.e. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:510.79pt;position:var(--position);text-decoration:none;white-space:pre">405,832</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:543.29pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:285.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">warrants). Of these additional warrants, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:196.64pt;position:var(--position);text-decoration:none;white-space:pre">50%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:214.97pt;position:var(--position);text-decoration:none;white-space:pre"> are exercisable immediately and the remaining </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:406.61pt;position:var(--position);text-decoration:none;white-space:pre">50%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:424.94pt;position:var(--position);text-decoration:none;white-space:pre"> (&#8220;the conditional warrants&#8221;) shall </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:296.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">only be exercisable if the third tranche of the Kreos / Claret Financing is drawn by the Group.&#160; The Kreos / Claret warrants can be </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:308.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">exercised over a period of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:142.26pt;position:var(--position);text-decoration:none;white-space:pre">7 years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:170.84pt;position:var(--position);text-decoration:none;white-space:pre"> from their issuance date or up until the date of the successful closing of a tender offer for the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:319.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">ordinary shares, whichever is earlier. At the time of exercise of the Kreos / Claret warrants, the holders of the warrants are eligible to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:331.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">sell part of their warrants to the Group in accordance with a put option agreement to allow for a cashless exercise. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:353.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Settlement of the liabilities</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:377.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On August 8, 2025, Kreos Capital VII (UK) Limited converted the Tranche A portion of the Kreos / Claret Financing (the Kreos / </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:389.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Claret OCABSA), resulting in the issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:221.36pt;position:var(--position);text-decoration:none;white-space:pre">785,389</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:253.86pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares and an increase in equity by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:434.5pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;16,058&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:505.59pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:413.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On July 30, 2025, Kreos Capital VII Aggregator SCSp opted for the cashless exercise of its share warrants (the tranche A-B BSA and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:425.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">tranche C BSA), implemented through the repurchase by the Group of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:319.61pt;position:var(--position);text-decoration:none;white-space:pre">94,117</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:347.11pt;position:var(--position);text-decoration:none;white-space:pre"> tranche A-B and C BSA and the issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:528.04pt;position:var(--position);text-decoration:none;white-space:pre">319,251</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:560.54pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:437.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">ordinary shares of the Group and an increase in equity by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:267.72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;19,570&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:338.81pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:461.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On August 28, 2025, Claret European Growth Capital Fund III SCSp, exercised its share warrants (the tranche A-B BSA and tranche </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:473.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">C BSA), resulting in the issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:182.53pt;position:var(--position);text-decoration:none;white-space:pre">206,662</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:215.03pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:281.36pt;position:var(--position);text-decoration:none;white-space:pre">of the Group and an increase in equity by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:449.25pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;14,198&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:520.3399999999999pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:497.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In August 2025, as a result of (i) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:168.41pt;position:var(--position);text-decoration:none;white-space:pre">the repayments of principal and interests </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:333.2pt;position:var(--position);text-decoration:none;white-space:pre">made until that date under the Kreos / Claret Financing, (ii) </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:509.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the exercise of the Tranche A-B and C BSA and (iii) the conversion of the Kreos OCABSA, the cash generated thereby met the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:521.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Minimum Cash Return due to the Kreos / Claret bondholders. Consequently, as no further payment could be due by the Group in </span></div></div><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">relation to the Kreos / Claret Minimal Return Indemnification, the MRI derivatives were derecognized, resulting in a financial income </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:82.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:46.83pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3,620&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.92pt;position:var(--position);text-decoration:none;white-space:pre"> for the year ended December 31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:268.87pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:106.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On November 25, 2025, Claret European Growth Capital Fund III SCSp converted its portion of the Tranche A portion of the Kreos / </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:117.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Claret Financing (the Claret OCABSA), resulting in the issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:308.74pt;position:var(--position);text-decoration:none;white-space:pre">392,695</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:341.24pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares and an increase in equity by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:521.88pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;8,296 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:128.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72.09pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:152.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On November 28, 2025, the Group notified the bondholders of its intention to prepay in full the outstanding balances of Tranches B </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:164.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and C of the Kreos / Claret Financing. The transaction was completed on December 23, 2025. The total amount paid by the Group</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:556.83pt;position:var(--position);text-decoration:none;white-space:pre"> at</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:566.53pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:176.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">that date amounted to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:124.77pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;33,823&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:195.86pt;position:var(--position);text-decoration:none;white-space:pre">, consisting of:</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:188.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the outstanding principal of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:184.66pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;29,903 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:255.75pt;position:var(--position);text-decoration:none;white-space:pre">, from which the deposit amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:398.96pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,081 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:465.05pt;position:var(--position);text-decoration:none;white-space:pre"> initially paid by the Group </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:200.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to Kreos and Claret was deducted,</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:212.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">future interests discounted at a discount rate of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:261.21000000000004pt;position:var(--position);text-decoration:none;white-space:pre">4%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:274.53999999999996pt;position:var(--position);text-decoration:none;white-space:pre"> as</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:285.36pt;position:var(--position);text-decoration:none;white-space:pre"> per the terms of the prepayment option, amounting</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:490.98pt;position:var(--position);text-decoration:none;white-space:pre"> to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:503.75pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;2,001 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:569.8399999999999pt;position:var(--position);text-decoration:none;white-space:pre">, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:224.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:236.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">end-of-loan exit fees of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:168pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3,000 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:234.09pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:260.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Following the aforementioned transactions, the Group no longer holds any debt related to the Kreos Claret Financing.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:283.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Accounting treatment</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:305.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">Kreos / Claret </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.53pt;position:var(--position);text-decoration:none;white-space:pre">OCABSA</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:328.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">The Kreos / Claret OCABSA are issued at market conditions: the net issuance proceeds reflect the fair value of the instruments at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:339.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">inception. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:361.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">The OCABSA are compound instruments, split between (i) a debt component (then measured at amortized cost) and (ii) an equity </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:372.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">component corresponding to the conversion option and the attached OCABSA warrants. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:395.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">As the adjustment provisions of the OCABSA conversion ratio are aimed at preserving the rights of the bondholders and are anti-</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:406.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">dilutive in nature rather than a down-round protection, the Group determined that the conversion option of the OCABSA is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:417.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">considered to result in the delivery of a fixed number of shares, and is therefore an equity instrument (the equity component of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:428.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">bonds).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:451.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">The OCABSA warrants were attached to each bond issued in the Tranche A closing and are not transferrable until after a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:462.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">prepayment. The OCABSA warrants become exercisable (i) upon the Group electing to prepay the bonds and (ii) in the event of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:473.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">the absence of the conversion notice from the bondholders for the full amount of the prepayment. As such, the warrants are not </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:484.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">freely transferable until the prepayment is made. Thus, the OCABSA warrants are considered as an embedded component of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:496.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">bonds rather than a separate stand-alone financial instrument. In all scenarios under which the exercisability conditions are </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:507.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">satisfied, and whereby the bondholder&#8217;s option to elect to convert the bonds was considered, the number of total ordinary shares </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:518.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">issuable upon warrant exercise as a result of prepayment and/or conversion option exercise remains fixed. Thus, the warrants </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:529.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">represent an equity-classified component of the bonds.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:552.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">The issuer prepayment option was deemed closely related to the host debt instrument and therefore does not meet the definition of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:563.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">a derivative instrument to be bifurcated.&#160; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:586.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">On their conversion dates, the carrying values of the debt components of the Kreos and Claret OCABSA, amounting to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:598.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:104.75pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;16,058&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:175.84pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:195.27pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;8,296 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:261.36pt;position:var(--position);text-decoration:none;white-space:pre">, were reclassified to equity.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:621.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">Kreos / Claret B and C tranches</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:643.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">The initial right granted to the Group to issue the amortized bonds under tranches B and C, upon meeting certain conditions, did </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:654.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">not meet the definition of a liability and was considered an off-balance sheet loan commitment received from the issuer as of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:665.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">December 31, 2023.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:688.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">The interest rate collars related to tranches B and C were determined to be closely related to the host debt instruments and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:699.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">therefore do not meet the definition of a derivative instrument to be bifurcated.</span></div></div><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:84.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">The prepayment options related to tranches B and C were not determined to be closely related to the host debt instruments and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:95.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">therefore meet the definition of derivative instruments to be bifurcated. The Group determined that their fair value is insignificant </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:106.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">at issuance and as of December 31, 2024.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:131.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">The Minimum Return Indemnifications are embedded derivative instruments, which are not deemed closely related to the host </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:142.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">debt instruments and therefore meet the definition of derivative instruments to be bifurcated. They are classified as derivative </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:154.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">financial liabilities and measured at fair value through profit or loss.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:179.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">The Kreos / Claret second and third tranches are therefore hybrid instruments, split between (i) debt host contracts accounted for </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:190.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">at amortized cost and (ii) bifurcated embedded derivatives accounted for at fair value through profit and loss, corresponding to the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:201.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">Minimal Return Indemnifications and the prepayment options (the fair value of the prepayment options being deemed </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:212.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">insignificant at issuance and as of December 31, 2024).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:235.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">On December 23, 2025, the Group recognized a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:248.26pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3,838&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:314.35pt;position:var(--position);text-decoration:none;white-space:pre"> loss on the derecognition </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:419.53pt;position:var(--position);text-decoration:none;white-space:pre">of Tranches B and C bonds as a result </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:247.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">of their redemption,</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:133.63pt;position:var(--position);text-decoration:none;white-space:pre"> corresponding to the difference between their carrying amount </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:388.6pt;position:var(--position);text-decoration:none;white-space:pre">on redemption date of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:479.06pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;29,985 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:550.15pt;position:var(--position);text-decoration:none;white-space:pre"> and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:259.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">the cash consideration of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:156.1pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;33,823&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:227.19pt;position:var(--position);text-decoration:none;white-space:pre">. The difference is </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:302.36pt;position:var(--position);text-decoration:none;white-space:pre">primarily due to (i) the payment of future interests as per the terms </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:271.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">of the prepayment option and (ii) unamortized end-of-loan exit fees and issuance fees, reducing the carrying value of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:283.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">liabilities.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:308.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">Kreos / Claret BSA</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:331.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">As the A-B and C warrants (the Kreos / Claret BSA) are contractually transferable separately from the bonds and are redeemable </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:342.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">in a variable number of ordinary shares of the Group, they are classified as standalone derivative financial liabilities.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:364.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">As the A-B and C warrants (the Kreos / Claret BSA) represent compensation for the realized and future bond issuances of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:376.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">respectively tranches A-B and C and are an integral part of generating such bond issuances, the Group determined that they are in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:387.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">nature origination fees. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:412pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">As the A-B warrants are associated with both the OCABSA issued under tranche A and the amortized bonds issued under tranche </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:423.2pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">B, the Group allocated the initial fair value of the A-B warrants based on the pro-rata value of the proceeds to be received under </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:434.4pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">each tranche. At inception, the respective initial fair values of the A-B warrants allocated to tranche A and B were deferred and </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:445.6pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">subsequently accounted for as an adjustment to the EIR of the related debt components upon their drawdown (on August 20, 2023 </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:456.8pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">and March 28, 2024 for tranches A and B respectively). </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:279.34000000000003pt;position:var(--position);text-decoration:none;white-space:pre">Subsequent changes in the fair value will be recognized through profit or </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:468pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">loss. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:490.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">On November 2, 2023 (issuance date of the Kreos / Claret tranche C BSA), a derivative financial liability was recognized for their </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:501.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">initial fair value with a counterparty in prepaid expenses. On that date, the Group, based on management&#8217;s latest projections, did </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:512.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">not consider the drawdown of the tranche C bonds to be probable. Therefore, the amount of prepaid expenses allocated to the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:524pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">tranche C BSA </span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:116.99000000000001pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> has been amortized on a straight-line basis until the drawdown of the tranche C bonds.</span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:546.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">At the exercise dates of the BSA held by Kreos and Claret (respectively July 30, 2025 and August 28, 2025), the fair value of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:558.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">exercised warran</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:121.95pt;position:var(--position);text-decoration:none;white-space:pre">ts at the exercise dates </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:213.74pt;position:var(--position);text-decoration:none;white-space:pre">of respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:275.32pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;15,143&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:346.41pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:365.84pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;11,531&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:436.93pt;position:var(--position);text-decoration:none;white-space:pre"> was reclassified from derivative </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:570.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">financial liabilities to equity. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:594.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Measurement of the debt and equity components of the OCABSA</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:617.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">At inception, the fair value of the debt component of the OCABSA amounts to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:353.18pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;23,995&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:424.27pt;position:var(--position);text-decoration:none;white-space:pre">, using a market rate assumption of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:628.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">12.6%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:61.83pt;position:var(--position);text-decoration:none;white-space:pre">. The equity component amounts to the difference between the whole instrument&#8217;s fair value at inception (its nominal value of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:640pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;25,000&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:107.09pt;position:var(--position);text-decoration:none;white-space:pre">) and the standalone fair value of the debt component. Therefore, the equity component amounts to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:504.97pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,005&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:571.06pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:651.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">It is not subsequently remeasured.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:673.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On the same date, using the same assumptions and an increase in market rate by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:358.39pt;position:var(--position);text-decoration:none;white-space:pre">100</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:373.39pt;position:var(--position);text-decoration:none;white-space:pre"> bp would result in a decrease in the fair value of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:684.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the debt component and an increase in the value of the equity compone</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:320.1pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">nt by </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:342.87pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;624&#160;thousand</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:401.46pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div></div><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Measurement of the Kreos / Claret second and third tranches hybrid instruments</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:95.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">At inception, the net cash proceeds are the tranches' initial fair values. The fair values of the Minimal Return Indemnifications were </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:107.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">deducted from the initial carrying values of the debt components of each tranche, which were subsequently measured at amortized cost </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:119.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">using the EIR method.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:131.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The fair value of the Minimum Return Indemnifications was measured using the following assumptions:</span></div><div style="position:var(--position);top:155.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:521.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:222.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:146.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:146.25pt"></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);white-space:pre">Tranche B Minimum Return Indemnification (issued in March </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);white-space:pre">2024)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.93pt;position:var(--position);text-decoration:none;white-space:pre">AS OF MARCH 28, 2024</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.38pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2024</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Final redemption scenario probability</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:21pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:128.18pt;position:var(--position)"></span><span style="left:128.18pt;position:var(--position)">95<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span><span style="left:138.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:21pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:128.18pt;position:var(--position)"></span><span style="left:128.18pt;position:var(--position)">95<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span><span style="left:138.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:33pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Minimal return</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:33pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:125.62pt;position:var(--position);text-decoration:none;white-space:pre">1.40</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:139.62pt;position:var(--position);white-space:pre">x</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:33pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:125.62pt;position:var(--position);text-decoration:none;white-space:pre">1.40</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:139.62pt;position:var(--position);white-space:pre">x</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:45pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Discount rate</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:45pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:128.18pt;position:var(--position)"></span><span style="left:128.18pt;position:var(--position)">13<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span><span style="left:138.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:45pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:132.18pt;position:var(--position)"></span><span style="left:132.18pt;position:var(--position)">8<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span><span style="left:138.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:57pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Probability-weighted present value of shortfall payment (in </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">thousands of &#8364;)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:57pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:63.45pt;position:var(--position);text-decoration:none;white-space:pre">1,959</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.31pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:88.13pt;position:var(--position);text-decoration:none;white-space:pre">68</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.13pt;position:var(--position);white-space:pre"> (Tender offer)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:57pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:63.45pt;position:var(--position);text-decoration:none;white-space:pre">2,635</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.31pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:84.13pt;position:var(--position);text-decoration:none;white-space:pre">136</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.13pt;position:var(--position);white-space:pre"> (Tender offer)</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Probability-weighted fair value of tranche A-B warrants with MRI </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">(in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:78.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:63.45pt;position:var(--position);text-decoration:none;white-space:pre">1,066</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div></div></div></td><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:78.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:69.45pt;position:var(--position);text-decoration:none;white-space:pre">104</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:99.75pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Probability-weighted fair value of tranche A-B warrants without </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">MRI (in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:99.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:63.45pt;position:var(--position);text-decoration:none;white-space:pre">1,410</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:99.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:69.45pt;position:var(--position);text-decoration:none;white-space:pre">241</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:120.75pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Total fair value of MRI (in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:120.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:29.41pt;position:var(--position);text-decoration:none;white-space:pre">1,615</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:47.41pt;position:var(--position);white-space:pre"> (Final redemption, i.e. a+b-c)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.31pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:88.13pt;position:var(--position);text-decoration:none;white-space:pre">68</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.13pt;position:var(--position);white-space:pre"> (Tender offer)</span></div></div></div></td><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:120.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:29.41pt;position:var(--position);text-decoration:none;white-space:pre">2,499</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:47.41pt;position:var(--position);white-space:pre"> (Final redemption, i.e. a+b-c)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.31pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:84.13pt;position:var(--position);text-decoration:none;white-space:pre">136</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.13pt;position:var(--position);white-space:pre"> (Tender offer)</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:142.5pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);white-space:pre">Fair value of Tranche B MRI (in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:142.5pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:115.55pt"></span></span><span style="left:118.17999999999999pt;position:var(--position)">1,683<span style="display:inline-block;height:5.41pt;width:9.32pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:142.5pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:115.55pt"></span></span><span style="left:118.17999999999999pt;position:var(--position)">2,636<span style="display:inline-block;height:5.41pt;width:9.32pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:342.66pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:521.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:222.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:146.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:146.25pt"></td></tr><tr style="height:21.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);white-space:pre">Tranche C Minimum Return Indemnification (issued in June </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);white-space:pre">2024)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:35.03pt;position:var(--position);text-decoration:none;white-space:pre">AS OF JUNE 21, 2024</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.38pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2024</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21.75pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Final redemption scenario probability</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:21.75pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:128.18pt;position:var(--position)"></span><span style="left:128.18pt;position:var(--position)">95<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span><span style="left:138.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:21.75pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:128.18pt;position:var(--position)"></span><span style="left:128.18pt;position:var(--position)">95<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span><span style="left:138.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:33.75pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Minimal return</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:33.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:125.62pt;position:var(--position);text-decoration:none;white-space:pre">1.30</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:139.62pt;position:var(--position);white-space:pre">x</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:33.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:125.62pt;position:var(--position);text-decoration:none;white-space:pre">1.30</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:139.62pt;position:var(--position);white-space:pre">x</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:45.75pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Discount rate</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:45.75pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:128.18pt;position:var(--position)"></span><span style="left:128.18pt;position:var(--position)">15<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span><span style="left:138.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:45.75pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:132.18pt;position:var(--position)"></span><span style="left:132.18pt;position:var(--position)">8<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span><span style="left:138.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:57.75pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">(a) Probability-weighted present value of shortfall payment (in </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">thousands of &#8364;)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:57.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:69.45pt;position:var(--position);text-decoration:none;white-space:pre">741</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.31pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:92.13pt;position:var(--position);text-decoration:none;white-space:pre">0</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.13pt;position:var(--position);white-space:pre"> (Tender offer)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:57.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:63.45pt;position:var(--position);text-decoration:none;white-space:pre">1,160</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.31pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:88.13pt;position:var(--position);text-decoration:none;white-space:pre">43</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.13pt;position:var(--position);white-space:pre"> (Tender offer)</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:79.5pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">(b) Probability-weighted fair value of tranche C warrants with MRI </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">(in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:79.5pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:63.45pt;position:var(--position);text-decoration:none;white-space:pre">2,948</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div></div></div></td><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:79.5pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:69.45pt;position:var(--position);text-decoration:none;white-space:pre">684</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:101.25pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">(c) Probability-weighted fair value of tranche C warrants without </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">MRI (in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:101.25pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:63.45pt;position:var(--position);text-decoration:none;white-space:pre">3,250</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:101.25pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:69.45pt;position:var(--position);text-decoration:none;white-space:pre">903</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:123pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Total fair value of MRI (in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:123pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:35.41pt;position:var(--position);text-decoration:none;white-space:pre">475</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:47.41pt;position:var(--position);white-space:pre"> (Final redemption, i.e. a+b-c)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.31pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:92.13pt;position:var(--position);text-decoration:none;white-space:pre">0</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.13pt;position:var(--position);white-space:pre"> (Tender offer)</span></div></div></div></td><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:123pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:35.41pt;position:var(--position);text-decoration:none;white-space:pre">941</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:47.41pt;position:var(--position);white-space:pre"> (Final redemption, i.e. a+b-c)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.31pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:88.13pt;position:var(--position);text-decoration:none;white-space:pre">43</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.13pt;position:var(--position);white-space:pre"> (Tender offer)</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:144.75pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);white-space:pre">Fair value of Tranche C MRI (in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:144.75pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:121.55pt"></span></span><span style="left:124.17999999999999pt;position:var(--position)">475<span style="display:inline-block;height:5.41pt;width:9.32pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:144.75pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:121.55pt"></span></span><span style="left:124.17999999999999pt;position:var(--position)">984<span style="display:inline-block;height:5.41pt;width:9.32pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:518.21pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">For the purpose of measuring the fair value of the MRI (shortfall payment), the fair value of the tranche A-B and C BSA was </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:530.21pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">measured with a Black Scholes model under the Final redemption scenario and with a Monte Carlo model under the Tender offer </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:542.21pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">scenario. As of March 28, 2024, the following assumptions were used: a share price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:384.57pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;13.40</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:412.07pt;position:var(--position);text-decoration:none;white-space:pre">, a volatility of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:473.38pt;position:var(--position);text-decoration:none;white-space:pre">60.3%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:499.21pt;position:var(--position);text-decoration:none;white-space:pre"> (Black Scholes) </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:554.21pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:46.83pt;position:var(--position);text-decoration:none;white-space:pre">61.9%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72.66pt;position:var(--position);text-decoration:none;white-space:pre"> (Monte Carlo), and a risk-free rate of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:226.09pt;position:var(--position);text-decoration:none;white-space:pre">2.6%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:246.92pt;position:var(--position);text-decoration:none;white-space:pre"> (Black Scholes) or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:326.28pt;position:var(--position);text-decoration:none;white-space:pre">2.8%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:347.11pt;position:var(--position);text-decoration:none;white-space:pre"> (Monte Carlo).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:566.21pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of June 21, 2024, the following assumptions were used: a share price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:338.53pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.94</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:366.03pt;position:var(--position);text-decoration:none;white-space:pre">, a volatility of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:427.34pt;position:var(--position);text-decoration:none;white-space:pre">60.1%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:453.17pt;position:var(--position);text-decoration:none;white-space:pre"> (Black Scholes) or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:532.53pt;position:var(--position);text-decoration:none;white-space:pre">59.9%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:558.36pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:578.21pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(Monte Carlo), and a risk-free rate of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:186.93pt;position:var(--position);text-decoration:none;white-space:pre">3.0%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:207.76pt;position:var(--position);text-decoration:none;white-space:pre"> (Black Scholes) or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:287.12pt;position:var(--position);text-decoration:none;white-space:pre">3.1%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:307.95pt;position:var(--position);text-decoration:none;white-space:pre"> (Monte Carlo).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:590.21pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The assumptions used for the valuations as of December 31, 2024 are set forth below:</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:616.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of March 28, 2024, using the same assumption with an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:317.15pt;position:var(--position);text-decoration:none;white-space:pre">+</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:322.78pt;position:var(--position);text-decoration:none;white-space:pre">1%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:336.11pt;position:var(--position);text-decoration:none;white-space:pre"> volatility, &#8364;+</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:390.29pt;position:var(--position);text-decoration:none;white-space:pre">1</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:395.29pt;position:var(--position);text-decoration:none;white-space:pre"> share price, +</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:451.96pt;position:var(--position);text-decoration:none;white-space:pre">1%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:465.29pt;position:var(--position);text-decoration:none;white-space:pre"> risk-free rate, +</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:529.72pt;position:var(--position);text-decoration:none;white-space:pre">5%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:543.05pt;position:var(--position);text-decoration:none;white-space:pre"> in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:628.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">probability of achieving the Final redemption scenario and +</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:278.57pt;position:var(--position);text-decoration:none;white-space:pre">1%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:291.9pt;position:var(--position);text-decoration:none;white-space:pre"> discount rate would result in changes of the MRI B value by </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:640.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">respectively &#8364;+</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:97.38pt;position:var(--position);text-decoration:none;white-space:pre">4&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.97pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:145.97pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;-30&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:202.89pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:207.89pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;-3&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:259.81pt;position:var(--position);text-decoration:none;white-space:pre">, +</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:270.44pt;position:var(--position);text-decoration:none;white-space:pre">35&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:319.03pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:338.46pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;-53&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:395.38pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:665.81pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of June 21, 2024, using the same assumption with an increase of +</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:315.02pt;position:var(--position);text-decoration:none;white-space:pre">1%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:328.35pt;position:var(--position);text-decoration:none;white-space:pre"> volatility, &#8364;+</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:382.53pt;position:var(--position);text-decoration:none;white-space:pre">1</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:387.53pt;position:var(--position);text-decoration:none;white-space:pre"> share price, +</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:444.2pt;position:var(--position);text-decoration:none;white-space:pre">1%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:457.53pt;position:var(--position);text-decoration:none;white-space:pre"> risk-free rate, +</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:521.96pt;position:var(--position);text-decoration:none;white-space:pre">5%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:535.29pt;position:var(--position);text-decoration:none;white-space:pre"> i</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:540.56pt;position:var(--position);text-decoration:none;white-space:pre">n the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:677.81pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">probability of achieving the Final redemption scenario and +</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:278.57pt;position:var(--position);text-decoration:none;white-space:pre">1%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:291.9pt;position:var(--position);text-decoration:none;white-space:pre">discount rate would result in changes of the MRI C fair value by </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:689.81pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">respectively &#8364;+</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:97.38pt;position:var(--position);text-decoration:none;white-space:pre">4&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.97pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:145.97pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;-16&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:202.89pt;position:var(--position);text-decoration:none;white-space:pre">, &#8364;+</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:218.52pt;position:var(--position);text-decoration:none;white-space:pre">8&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:262.11pt;position:var(--position);text-decoration:none;white-space:pre">, &#8364;+</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:277.74pt;position:var(--position);text-decoration:none;white-space:pre">46&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:326.33pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:345.76pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;-13&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:402.68pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div></div><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2024, using the same assumption with an increase of +</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:337.74pt;position:var(--position);text-decoration:none;white-space:pre">1%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:351.07pt;position:var(--position);text-decoration:none;white-space:pre"> volatility, &#8364;+</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:405.25pt;position:var(--position);text-decoration:none;white-space:pre">1</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:410.25pt;position:var(--position);text-decoration:none;white-space:pre"> share price, +</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:466.92pt;position:var(--position);text-decoration:none;white-space:pre">1%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:480.25pt;position:var(--position);text-decoration:none;white-space:pre"> risk-free rate, +</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:544.6800000000001pt;position:var(--position);text-decoration:none;white-space:pre">10%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:563.01pt;position:var(--position);text-decoration:none;white-space:pre"> in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:82.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the probability of achieving the Final redemption scenario and</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:285.14pt;position:var(--position);text-decoration:none;white-space:pre"> +</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:293.27pt;position:var(--position);text-decoration:none;white-space:pre">1%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:306.6pt;position:var(--position);text-decoration:none;white-space:pre"> discount rate would result in changes of the MRI B and C fair </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:94.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">value by respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:123.38pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;-1&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:175.3pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:180.3pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;-3&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:232.22pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:237.22pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;-3&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:289.14pt;position:var(--position);text-decoration:none;white-space:pre">, &#8364;+</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:304.77pt;position:var(--position);text-decoration:none;white-space:pre">3&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:348.36pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:367.79pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;-82&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:424.71pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:118.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Measurement of the Kreos / Claret tranche A-B-C BSA </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:140.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Kreos / Claret tranche A-B and tranche C BSA are measured at fair value using a Black-Scholes valuation model. The model </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:152.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">considers </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:76.24000000000001pt;position:var(--position);text-decoration:none;white-space:pre">two</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.22999999999999pt;position:var(--position);text-decoration:none;white-space:pre"> probability-weighted scenarios, i.e. (i) the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:263.52pt;position:var(--position);text-decoration:none;white-space:pre">7 years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:292.1pt;position:var(--position);text-decoration:none;white-space:pre"> expiry of the BSA and (ii) an earlier exercise upon a tender offer. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:558.17pt;position:var(--position);text-decoration:none;white-space:pre">The </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:163.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">main data and assumptions are the following:</span></div><div style="position:var(--position);top:211.46pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:522pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:137.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:125.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:125.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:125.25pt"></td></tr><tr style="height:24pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.2pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos/Claret Tranche A-B BSA - </span></div><div style="line-height:8pt;position:var(--position);top:13.8pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">August 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.32pt;position:var(--position);text-decoration:none;white-space:pre">AS OF AUGUST 22, 2023 </span></div><div style="line-height:8pt;position:var(--position);top:14pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:37.65pt;position:var(--position);text-decoration:none;white-space:pre">(Tranche A-B)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:9pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.88pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:9pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.88pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2024</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Number of outstanding BSA</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:24pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.62pt;position:var(--position);text-decoration:none;white-space:pre">214,198</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:24pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.62pt;position:var(--position);text-decoration:none;white-space:pre">214,198</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:24pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.62pt;position:var(--position);text-decoration:none;white-space:pre">214,198</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:39.75pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Exercise price per share</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:39.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:100.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;18.67</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:39.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:100.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;18.67</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:39.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:100.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;18.67</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:55.5pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Ordinary share price</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:55.5pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:100.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;17.10</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:55.5pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;9.82</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:55.5pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.76</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:71.25pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Exercise date</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:71.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.44pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:19.99pt;position:var(--position);text-decoration:none;white-space:pre">19/08/2030 (expiry) 18/02/2027 </span></div><div style="line-height:8pt;position:var(--position);top:12.44pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:79.79pt;position:var(--position);text-decoration:none;white-space:pre">(tender offer)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:71.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.43pt;position:var(--position);text-decoration:none;white-space:pre">19/08/2030 (expiry)</span></div><div style="line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:41.35pt;position:var(--position);text-decoration:none;white-space:pre">18/02/2027 (tender offer)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:71.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.43pt;position:var(--position);text-decoration:none;white-space:pre">19/08/2030 (expiry)</span></div><div style="line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:41.35pt;position:var(--position);text-decoration:none;white-space:pre">18/02/2027 (tender offer)</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:92.25pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">7-year expiry scenario probability</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:92.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">50</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:92.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">95</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:92.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">95</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:108pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Volatility</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:108pt;width:125.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:74.21pt;position:var(--position);text-decoration:none;white-space:pre">71.9%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.86999999999999pt;position:var(--position);white-space:pre"> (expiry) </span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:57.13pt;position:var(--position);text-decoration:none;white-space:pre">65.2%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.79pt;position:var(--position);white-space:pre"> (tender offer)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:108pt;width:125.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:74.21pt;position:var(--position);text-decoration:none;white-space:pre">59.5%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.86999999999999pt;position:var(--position);white-space:pre"> (expiry)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:57.13pt;position:var(--position);text-decoration:none;white-space:pre">64.9%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.79pt;position:var(--position);white-space:pre"> (tender offer)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:108pt;width:125.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:74.21pt;position:var(--position);text-decoration:none;white-space:pre">44.3%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.86999999999999pt;position:var(--position);white-space:pre"> (expiry)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:57.13pt;position:var(--position);text-decoration:none;white-space:pre">44.3%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.79pt;position:var(--position);white-space:pre"> (tender offer)</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:129pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Dividend</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:129pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">&#8212;</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:129pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">&#8212;</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:129pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">&#8212;</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:144.75pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Risk-free rate</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:144.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)">3.00</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:144.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)">2.30</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="height:17.25pt;left:396.75pt;overflow:hidden;position:var(--position);top:144.75pt;width:125.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:0.52pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:78.21pt;position:var(--position);text-decoration:none;white-space:pre">2.9%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.86999999999999pt;position:var(--position);white-space:pre"> (expiry)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:10.6pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:61.13pt;position:var(--position);text-decoration:none;white-space:pre">2.9%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.79pt;position:var(--position);white-space:pre"> (tender offer)</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:162pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Fair value of issued Kreos/Claret </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Tranche A-B BSA</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:162pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:97.21pt"></span></span><span style="left:99.83999999999999pt;position:var(--position)">2,092<span style="display:inline-block;height:5.41pt;width:6.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:162pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:103.21pt"></span></span><span style="left:105.83999999999999pt;position:var(--position)">920<span style="display:inline-block;height:5.41pt;width:6.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:162pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:103.21pt"></span></span><span style="left:105.83999999999999pt;position:var(--position)">243<span style="display:inline-block;height:5.41pt;width:6.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:421.86pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:522pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:137.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:125.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:125.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:125.25pt"></td></tr><tr style="height:24pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.2pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos/Claret Tranche C BSA - </span></div><div style="line-height:8pt;position:var(--position);top:13.8pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">November 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:9pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.43pt;position:var(--position);text-decoration:none;white-space:pre">AS OF NOVEMBER 2, 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:9pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.88pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:9pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.88pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2024</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Number of outstanding BSA</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:24pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.62pt;position:var(--position);text-decoration:none;white-space:pre">405,832</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:24pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.62pt;position:var(--position);text-decoration:none;white-space:pre">405,832</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:24pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.62pt;position:var(--position);text-decoration:none;white-space:pre">405,832</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:39.75pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">of which, number of conditional BSA</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:39.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.8pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:96.62pt;position:var(--position);text-decoration:none;white-space:pre">202,915</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:39.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.8pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:96.62pt;position:var(--position);text-decoration:none;white-space:pre">202,916</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:39.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.8pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:118.62pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:55.5pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Exercise price per share</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:55.5pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:6.99pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;9.86</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:55.5pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:6.99pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;9.86</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:55.5pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:6.99pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;9.86</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:71.25pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Ordinary share price</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:71.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;8.89</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:71.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;9.82</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:71.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.67</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:87pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Exercise date</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:87pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.43pt;position:var(--position);white-space:pre">01/11/2030 (expiry) </span></div><div style="line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:41.35pt;position:var(--position);white-space:pre">18/02/2027 (tender offer)</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:87pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.43pt;position:var(--position);text-decoration:none;white-space:pre">01/11/2030 (expiry)</span></div><div style="line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:41.35pt;position:var(--position);text-decoration:none;white-space:pre">18/02/2027 (tender offer)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:87pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.43pt;position:var(--position);text-decoration:none;white-space:pre">01/11/2030 (expiry)</span></div><div style="line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:41.35pt;position:var(--position);text-decoration:none;white-space:pre">18/02/2027 (tender offer)</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:108pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">7-year expiry scenario probability</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:108pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">95</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:108pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">95</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:108pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">95</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:123.75pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Probability of Drawdown of Tranche C </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">credit facility</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:123.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">30</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:123.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">30</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:123.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.09pt;position:var(--position);text-decoration:none;white-space:pre">Drawn on June 21, 2024</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:144.75pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Volatility</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:144.75pt;width:125.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:74.21pt;position:var(--position);text-decoration:none;white-space:pre">67.3%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.86999999999999pt;position:var(--position);white-space:pre"> (expiry)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:57.13pt;position:var(--position);text-decoration:none;white-space:pre">64.3%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.79pt;position:var(--position);white-space:pre"> (tender offer)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:144.75pt;width:125.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:74.21pt;position:var(--position);text-decoration:none;white-space:pre">67.4%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.86999999999999pt;position:var(--position);white-space:pre"> (expiry)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:57.13pt;position:var(--position);text-decoration:none;white-space:pre">64.9%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.79pt;position:var(--position);white-space:pre"> (tender offer)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:144.75pt;width:125.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:74.21pt;position:var(--position);text-decoration:none;white-space:pre">44.3%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.86999999999999pt;position:var(--position);white-space:pre"> (expiry)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:57.13pt;position:var(--position);text-decoration:none;white-space:pre">44.3%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.79pt;position:var(--position);white-space:pre"> (tender offer)</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:165.75pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Dividend</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:165.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">&#8212;</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:165.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">&#8212;</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:165.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">&#8212;</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:24pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:181.5pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:8.93pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Risk-free rate</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:181.5pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:8.93pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)">3.00</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:181.5pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:8.93pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)">2.30</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:181.5pt;width:125.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:3.89pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:78.21pt;position:var(--position);text-decoration:none;white-space:pre">2.9%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.86999999999999pt;position:var(--position);white-space:pre"> (expiry)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:13.97pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:61.13pt;position:var(--position);text-decoration:none;white-space:pre">2.9%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.79pt;position:var(--position);white-space:pre"> (tender offer)</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:205.5pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:137.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Fair value of issued Kreos/Claret </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:137.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Tranche C BSA</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:205.5pt;width:125.25pt"><div><div style="line-height:9pt;position:var(--position);top:7.05pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.09pt;width:94.96pt"></span></span><span style="left:97.58999999999999pt;position:var(--position)">1,493<span style="display:inline-block;height:6.09pt;width:6.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:205.5pt;width:125.25pt"><div><div style="line-height:9pt;position:var(--position);top:7.05pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.09pt;width:94.96pt"></span></span><span style="left:97.58999999999999pt;position:var(--position)">1,659<span style="display:inline-block;height:6.09pt;width:6.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:205.5pt;width:125.25pt"><div><div style="line-height:9pt;position:var(--position);top:7.05pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.09pt;width:101.71pt"></span></span><span style="left:104.33999999999999pt;position:var(--position)">923<span style="display:inline-block;height:6.09pt;width:6.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:664.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of August 20, 2023 (date of issuance of the tranche A-B BSA), using the same assumption with an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:491.98pt;position:var(--position);text-decoration:none;white-space:pre">+1%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:510.94pt;position:var(--position);text-decoration:none;white-space:pre"> volatility, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:554.49pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:676.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">+1</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:46.63pt;position:var(--position);text-decoration:none;white-space:pre">share price, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:95.17pt;position:var(--position);text-decoration:none;white-space:pre">+1%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.13pt;position:var(--position);text-decoration:none;white-space:pre"> risk-free rate or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:181.26pt;position:var(--position);text-decoration:none;white-space:pre">+5%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:200.22pt;position:var(--position);text-decoration:none;white-space:pre"> in the probability of achieving the</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:338.39pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:340.89pt;position:var(--position);text-decoration:none;white-space:pre">7 years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:369.47pt;position:var(--position);text-decoration:none;white-space:pre"> expiry scenario would result in an increase of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:688.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">tranche A-B BSA fair value by respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:213.28pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;48&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:266.87pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:271.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;197&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:330.46pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:335.46pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;64&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:389.05pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:408.48pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;64&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:462.07pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of November 2, 2023 (date of issuance of the tranche C BSA), using the same assumption with an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:489.73pt;position:var(--position);text-decoration:none;white-space:pre">+1%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:508.69pt;position:var(--position);text-decoration:none;white-space:pre"> volatility, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:552.24pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:82.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">+1</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:46.63pt;position:var(--position);text-decoration:none;white-space:pre">share price, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:95.17pt;position:var(--position);text-decoration:none;white-space:pre">+1%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.13pt;position:var(--position);text-decoration:none;white-space:pre"> risk-free rate or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:181.26pt;position:var(--position);text-decoration:none;white-space:pre">+5%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:200.22pt;position:var(--position);text-decoration:none;white-space:pre"> in the probability of achieving the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:340.89pt;position:var(--position);text-decoration:none;white-space:pre">7</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:345.89pt;position:var(--position);text-decoration:none;white-space:pre">-year</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:366.41pt;position:var(--position);text-decoration:none;white-space:pre"> expiry scenario would result in an increase of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:94.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">tranche A-B BSA fair value by respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:213.28pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;28&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:266.87pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:271.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;232&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:330.46pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:335.46pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;42&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:389.05pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:408.48pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;36&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:462.07pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:118.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, using the same assumption with an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:332.11pt;position:var(--position);text-decoration:none;white-space:pre">+1%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:351.07pt;position:var(--position);text-decoration:none;white-space:pre"> volatility, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:394.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;+1</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:410.25pt;position:var(--position);text-decoration:none;white-space:pre">share price, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:458.79pt;position:var(--position);text-decoration:none;white-space:pre">+1%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:477.75pt;position:var(--position);text-decoration:none;white-space:pre"> risk-free rate and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:550.98pt;position:var(--position);text-decoration:none;white-space:pre">+5%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:569.94pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:130.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in the probability of achieving the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:174.17pt;position:var(--position);text-decoration:none;white-space:pre">7</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:179.17pt;position:var(--position);text-decoration:none;white-space:pre">-year</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:199.69pt;position:var(--position);text-decoration:none;white-space:pre"> expiry scenario would result in an increase of Kreos / Claret A-B and C BSA fair value by </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:142.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:86.75pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;96&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.34pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:145.34pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;401&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:203.93pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:208.93pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;95&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:262.52pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:281.95pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;76&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:335.54pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:166.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2024, using the same assumption with an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:332.11pt;position:var(--position);text-decoration:none;white-space:pre">+1%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:351.07pt;position:var(--position);text-decoration:none;white-space:pre"> volatility, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:394.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;+1</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:410.25pt;position:var(--position);text-decoration:none;white-space:pre"> share price, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:461.29pt;position:var(--position);text-decoration:none;white-space:pre">+1%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:480.25pt;position:var(--position);text-decoration:none;white-space:pre"> risk-free rate and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:178.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">+</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:41.63pt;position:var(--position);text-decoration:none;white-space:pre">10%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:59.96pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:62.46pt;position:var(--position);text-decoration:none;white-space:pre">in the probability of achieving the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:200.63pt;position:var(--position);text-decoration:none;white-space:pre">7</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:205.63pt;position:var(--position);text-decoration:none;white-space:pre">-year</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:226.15pt;position:var(--position);text-decoration:none;white-space:pre"> expiry scenario would result in an increase of Kreos / Claret A-B and C BSA fair </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:190.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">value by respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:123.38pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;37&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:176.97pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:181.97pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;350&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:240.56pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:245.56pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;61&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:299.15pt;position:var(--position);text-decoration:none;white-space:pre"> and</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:316.08pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;75 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:369.67pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:226.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of the exercise dates of the Kreos / Claret BSA (July 30, 2025 and August 28, 2025), due to the put options (allowing for a cashless </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:238.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">exercise) being exercised by the holders, the fair value of the BSAs is deemed equal to their intrinsic value, which is equal to the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:250.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">difference between the listed share price on the exercise dates and their exercise price.</span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 15.2.&#160; Heights convertible notes&#160; </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:314.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On August 20, 2023, the Group entered into a convertible notes subscription agreement with Heights, which provided for up to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:325.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;75,000&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:107.09pt;position:var(--position);text-decoration:none;white-space:pre"> in financing, consisting of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:216.44pt;position:var(--position);text-decoration:none;white-space:pre">two</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:231.43pt;position:var(--position);text-decoration:none;white-space:pre"> tranches: </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:348.16pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The first tranche (&#8220;tranche A&#8221;) of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:208.47pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;35,000&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:279.56pt;position:var(--position);text-decoration:none;white-space:pre"> in aggregate principal amount was drawn on August 24, 2023 and is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:361.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">composed of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:125.85pt;position:var(--position);text-decoration:none;white-space:pre">350</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.85pt;position:var(--position);text-decoration:none;white-space:pre"> amortizing senior convertible notes with a nominal value of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:384.45pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;100,000</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:421.95pt;position:var(--position);text-decoration:none;white-space:pre"> each and a fixed conversion price of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:375.04pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;23.7674</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:109.5pt;position:var(--position);text-decoration:none;white-space:pre"> (corresponding to a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:192.20999999999998pt;position:var(--position);text-decoration:none;white-space:pre">40%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:210.54pt;position:var(--position);text-decoration:none;white-space:pre"> premium over the 15-day VWAP prior to the date on which their issuance is decided, and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:388.48pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">subject to standard adjustments, including anti-dilution and dividend protections).</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:413.12pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">The second tranche (&#8220;tranche B&#8221;) of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:219.57pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;40,000&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:290.65999999999997pt;position:var(--position);text-decoration:none;white-space:pre"> in aggregate principal amount is composed of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:478.23pt;position:var(--position);text-decoration:none;white-space:pre">400</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:493.23pt;position:var(--position);text-decoration:none;white-space:pre"> amortizing senior </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:426.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">convertible notes with a nominal value of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:240.41pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;100,000</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:277.90999999999997pt;position:var(--position);text-decoration:none;white-space:pre"> each, and a conversion price (if any) that is be equal to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:501.52pt;position:var(--position);text-decoration:none;white-space:pre">130%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:524.85pt;position:var(--position);text-decoration:none;white-space:pre"> of the 15-</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:440pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">day VWAP immediately preceding the date on which their issuance is decided.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:453.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">It may be drawn during the period from the date immediately following the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:375.27pt;position:var(--position);text-decoration:none;white-space:pre">three</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:395.23pt;position:var(--position);text-decoration:none;white-space:pre">-month</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:424.1pt;position:var(--position);text-decoration:none;white-space:pre"> anniversary of the issuance of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:464.64pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">first tranche to the first-year anniversary of the issuance of the first tranche (i.e. August 24, 2024), in up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:499.33pt;position:var(--position);text-decoration:none;white-space:pre">two</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:514.3199999999999pt;position:var(--position);text-decoration:none;white-space:pre"> separate </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:475.84pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">closings to provide the Group with additional flexibility to request a partial drawdown.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:487.04pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">On the limit date for the drawdown of the second tranche of the Heights Financing (i.e. August 4, 2024), the Group had not </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:498.24pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">drawn down this tranche and has therefore forgone its right to do so in the future.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:531.84pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Interest on the Heights convertible notes accrues at a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:249.32pt;position:var(--position);text-decoration:none;white-space:pre">6.00%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:275.15pt;position:var(--position);text-decoration:none;white-space:pre"> annual fixed interest rate payable in quarterly installments in cash or, at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:543.04pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the option of the Group, in ordinary shares.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:565.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Heights convertible notes will be repaid through </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:249.65pt;position:var(--position);text-decoration:none;white-space:pre">sixteen</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:277.94pt;position:var(--position);text-decoration:none;white-space:pre"> quarterly installment payments, beginning </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:451.63pt;position:var(--position);text-decoration:none;white-space:pre">three months</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:503.52pt;position:var(--position);text-decoration:none;white-space:pre"> after their </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:576.64pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">issuance date (corresponding, for the first tranche, to a final repayment date on August 24, 2027). Installments are payable in cash or, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:587.84pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">at the option of the Group, in ordinary shares.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:610.24pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Any interest or installment payments in shares will be made on the basis of a share price equal to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:425.81pt;position:var(--position);text-decoration:none;white-space:pre">90%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:444.14pt;position:var(--position);text-decoration:none;white-space:pre"> of the Market Price of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:621.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">ordinary shares at the time of payment, where &#8220;Market Price&#8221; refers to the arithmetic average of the daily volume weighted average </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:632.64pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">price (&#8220;VWAP&#8221;) for the ordinary shares on the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:225.8pt;position:var(--position);text-decoration:none;white-space:pre">two</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:240.79pt;position:var(--position);text-decoration:none;white-space:pre"> (</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:246.62pt;position:var(--position);text-decoration:none;white-space:pre">2</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:251.62pt;position:var(--position);text-decoration:none;white-space:pre">) days with the lowest daily VWAPs out of the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:440.9pt;position:var(--position);text-decoration:none;white-space:pre">five</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:456.43pt;position:var(--position);text-decoration:none;white-space:pre"> (</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:462.26pt;position:var(--position);text-decoration:none;white-space:pre">5</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:467.26pt;position:var(--position);text-decoration:none;white-space:pre">) trading days immediately </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:643.84pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">preceding the applicable date, but in no event greater than the VWAP of the ordinary shares on the applicable date. The Market Price </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:655.04pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">may not be higher than the applicable conversion price. Issuances of ordinary shares may not be made at a price lower than a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:537.62pt;position:var(--position);text-decoration:none;white-space:pre">15%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:555.95pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:666.24pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">discount to the 15-day VWAP at the time of the decision to issue the Heights convertible notes (i.e., </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:438.06pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;14.4303</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:475.56pt;position:var(--position);text-decoration:none;white-space:pre"> per ordinary share.).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:688.64pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Heights convertible notes include the following conversion and settlement options:</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:699.84pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Conversion at the option of the noteholders: the notes are convertible into the Group&#8217;s ordinary shares at the option of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:711.04pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">noteholders at any time during the period beginning on the tranche A notes closing until the fifth business day prior to the </span></div><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">maturity date. The ordinary shares issued would be equal to the product of (i) the conversion ratio in effect on the exercise </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:81.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">date, (ii) a fraction, the numerator of which is the outstanding principal amount per note and the denominator of which is the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:92.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">initial principal amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:179.07999999999998pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;100,000</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:216.58pt;position:var(--position);text-decoration:none;white-space:pre"> per note, and (iii) the number of notes for which the conversion right has been exercised.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:115.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Settlement in shares at the option of the Group: the Group has the option to settle any interest or principal due with its own </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:127.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">ordinary shares (with respect to all but not some of the notes outstanding), subject to a price limit. The ordinary shares </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:139.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">issuable will be the lower of the conversion ratio or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:280.1pt;position:var(--position);text-decoration:none;white-space:pre">90%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.43pt;position:var(--position);text-decoration:none;white-space:pre"> of the fair market value of the Group&#8217;s ordinary shares. </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:162.56pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Settlement in shares at the option of the noteholders (&#8220;SSO Investor Price Limit Option&#8221;): the noteholders may require a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:176pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">principal payment to be settled in shares in the event the share settlement price on any principal payment date is below the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:189.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">price limit in effect (initially </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:188.18pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;14.4303</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:225.68pt;position:var(--position);text-decoration:none;white-space:pre">, subject to adjustments as described in the key terms below) and the Cash Carve-Out </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:202.88pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(i.e. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90.03pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;13.125&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:153.88pt;position:var(--position);text-decoration:none;white-space:pre"> &#8211; the amount of cash permitted to be paid to Heights for principal payments) has been utilized such that </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:216.32pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">it does not allow payment in full of the principal payment. The majority noteholder may agree to waive the cash payment </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:229.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(which would otherwise be deferred until the original maturity date) and require the Group to exercise the share settlement </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:243.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">option for the principal payment required. A number of the ordinary shares issuable is based on the price limit in effect.</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:267.84pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Repayment of the notes upon an Event of Default (as defined below): the noteholder may notify the Group of their decision </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:281.28pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">to cause the notes to become payable at a price equal to the Early Redemption Amount (as defined below) upon an Event of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:294.72pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Default. The Early Redemption Amount means an amount equal to the greater of (a) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:411.86pt;position:var(--position);text-decoration:none;white-space:pre">120%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:435.19pt;position:var(--position);text-decoration:none;white-space:pre"> of the outstanding principal of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:308.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">note and (b) the market price of a number of shares issuable per note had the conversion right been exercised. Events of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:321.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Default include the following: default in any payment due on the notes, failure to deliver shares upon exercise of conversion </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:335.04pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">right or share settlement option, default of the Group on any obligation under the agreement, and other events.</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:359.68pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Repayment or purchase of the notes upon change of control, a delisting, or free float event (each, a &#8220;Put Event&#8221;): Upon a Put </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:373.12pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Event, the noteholder has an option to require the Group to redeem or, at the Group&#8217;s option, to purchase all of the notes at </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:386.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">the total aggregate amount equal to the outstanding principal and interest accrued through the date of a Put Event.</span><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:526.15pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:413.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Heights Financing is a senior, unsecured financing. The terms and conditions of the Heights convertible notes include a standard </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:425pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">negative pledge providing that any security granted in favor of other borrowed debt or debt instruments should also be granted in favor </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:436.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of the Heights convertible notes on an equal basis (with the exception of the securities issued pursuant to the Kreos / Claret Financing, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:447.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">as detailed above).</span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:469.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On August 24,</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.6pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> 2023, the Group repaid in full an outstanding amount of</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:320.81pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:323.81pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;25,102&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:394.9pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">, corresponding to the outstanding OCEANE </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:483.24pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">bonds, by way of set-off with the Heights Financing. The accounting treatment for this transaction is explained in Note 15.5.</span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:505.64pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On July 23 and July 30, 2025, the noteholders requested the conversion of respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:385.7pt;position:var(--position);text-decoration:none;white-space:pre">150</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:400.7pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:420.13pt;position:var(--position);text-decoration:none;white-space:pre">200</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:435.13pt;position:var(--position);text-decoration:none;white-space:pre"> convertible notes (corresponding </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:517.64pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">to the entirety of the outstanding principal amount of approximately </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:310.13pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;21.9&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:363.98pt;position:var(--position);text-decoration:none;white-space:pre">) into </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:387.85pt;position:var(--position);text-decoration:none;white-space:pre">920,377</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:420.35pt;position:var(--position);text-decoration:none;white-space:pre"> new ordinary shares of the Group at a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:529.64pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">conversion price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:115.64pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;23.7674</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:153.14pt;position:var(--position);text-decoration:none;white-space:pre"> per ordinary share (see Note 3.3 - </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:292.17pt;position:var(--position);text-decoration:none;white-space:pre">Conversion of the Heights convertible notes, Kreos OCABSA and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:541.64pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Kreos / Claret BSA and prepayment of the Kreos / Claret Tranches B and C bond loans &#8211;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:393.78pt;position:var(--position);text-decoration:none;white-space:pre"> July-December 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:479.79pt;position:var(--position);text-decoration:none;white-space:pre">).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:571.64pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Accounting treatment and measurement</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:593.64pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In application of the Amendments to IAS 1 Presentation of Financial Statements &#8211; Classification of Liabilities as Current or Non-</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:604.84pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">current, and Non-current Liabilities with Covenants, the Heights convertible notes are classified as current financial liabilities as of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:616.04pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">December 31, 2023 and 2024.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:638.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group concluded that, except for the repayment or purchase option of the notes upon a Put Event, the above-mentioned </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:649.64pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">conversion and settlement options represented embedded derivatives that required to be bifurcated from their host contract. The Group </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:660.84pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">being unable to reliably value each embedded derivative at issuance date and on subsequent reporting dates, it measured the whole </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:672.04pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">instrument at fair value through profit or loss (&#8220;FVTPL&#8221;) as permitted by IFRS 9. Instruments measured at FVTPL under these </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:683.24pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">conditions are measured at their fair value on issuance and on subsequent reporting dates, and the amount of change in the fair value of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:694.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the financial liability is presented in profit or loss.</span></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">At inception, the Heights convertible notes were measured at fair value, which differs from the issuance procee</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:480.43pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">ds by </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:504.32pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;2,359&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:570.41pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">. </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:81.76pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">Since the fair value measurement of the instrument is evidenced by a valuation technique that does not only use data from observable </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:92.96pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">markets, the carrying amount was adjusted to defer the difference between the fair value measurement and the transaction price, and </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:104.16pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">the day one gain is therefore recognized in financial income on a straight-line basis over the term of the instrument. </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:115.36pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">As of December 31, 2023 and 2024, the amounts by which the carrying value of the notes is adjusted to take into account the </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">unrecognized day one gain are </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:160.57pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;2,147&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:226.66pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:246.09pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,557&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:312.18pt;position:var(--position);text-decoration:none;white-space:pre">, respectively.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:148.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The fair value of the Heights convertible notes (including the embedded features) has been measured with a Monte Carlo model, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:160.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">considering </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.12pt;position:var(--position);text-decoration:none;white-space:pre">two</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:100.11pt;position:var(--position);text-decoration:none;white-space:pre"> probability-weighted scenarios: (i) a Put Event or Default/Dissolution scenario and (ii) a voluntary conversion at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:171.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">maturity scenario. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:110.62pt;position:var(--position);text-decoration:none;white-space:pre">The main data and assumptions are the following: </span></div><div style="position:var(--position);top:193.76pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:519pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:143.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:128.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:119.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:119.25pt"></td></tr><tr style="height:17.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.62pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Heights convertible notes - August 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.62pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:19.82pt;position:var(--position);text-decoration:none;white-space:pre">AS OF AUGUST 24, 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.62pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.88pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.62pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.88pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2024</span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:17.25pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Number of outstanding notes</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:17.25pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:113.62pt;position:var(--position);text-decoration:none;white-space:pre">350</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:17.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">350</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:17.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">350</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:34.5pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Original principal amount (in thousands of </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:34.5pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:103.62pt;position:var(--position);text-decoration:none;white-space:pre">35,000</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:34.5pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.62pt;position:var(--position);text-decoration:none;white-space:pre">35,000</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:34.5pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.62pt;position:var(--position);text-decoration:none;white-space:pre">35,000</span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:55.5pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest rate</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:55.5pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:116.84pt;position:var(--position)"></span><span style="left:116.84pt;position:var(--position)">6</span><span style="left:120.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:55.5pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:107.84pt;position:var(--position)"></span><span style="left:107.84pt;position:var(--position)">6</span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:55.5pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:107.84pt;position:var(--position)"></span><span style="left:107.84pt;position:var(--position)">6</span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:72.75pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Conversion price per share</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:72.75pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:103.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;23.77</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:72.75pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;23.77</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:72.75pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;23.77</span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Ordinary share price</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:90pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:103.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;16.74</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:90pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:98.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;9.82</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:90pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:98.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.76</span></div></div></div></td></tr><tr style="height:27pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:107.25pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:10.43pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Maturity date</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:107.25pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.63pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:13.88pt;position:var(--position);text-decoration:none;white-space:pre">24/08/2025 (put event) 24/08/2027 </span></div><div style="line-height:8pt;position:var(--position);top:15.23pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:32.58pt;position:var(--position);text-decoration:none;white-space:pre">(HTM/voluntary conversion)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:27pt;left:277.5pt;overflow:hidden;position:var(--position);top:107.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:0.84pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:43.32pt;position:var(--position);text-decoration:none;white-space:pre">24/08/2025 (put event)</span></div><div style="line-height:8pt;position:var(--position);top:10.44pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:24.89pt;position:var(--position);text-decoration:none;white-space:pre">24/08/2027 (HTM/voluntary </span></div><div style="line-height:8pt;position:var(--position);top:20.04pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:78.87pt;position:var(--position);text-decoration:none;white-space:pre">conversion)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:27pt;left:399.75pt;overflow:hidden;position:var(--position);top:107.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:0.84pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:43.32pt;position:var(--position);text-decoration:none;white-space:pre">24/08/2025 (put event)</span></div><div style="line-height:8pt;position:var(--position);top:10.44pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:24.89pt;position:var(--position);text-decoration:none;white-space:pre">24/08/2027 (HTM/voluntary </span></div><div style="line-height:8pt;position:var(--position);top:20.04pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:78.87pt;position:var(--position);text-decoration:none;white-space:pre">conversion)</span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:17.25pt;overflow:hidden;position:var(--position);top:134.25pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:0.76pt;width:143.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Held to maturity / voluntary conversion </span></div><div style="line-height:8pt;position:var(--position);top:10.36pt;width:143.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">scenario probability</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:134.25pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:112.84pt;position:var(--position)"></span><span style="left:112.84pt;position:var(--position)">75</span><span style="left:120.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:134.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)">75</span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:134.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)">75</span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:151.5pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Initial price limit</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:151.5pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:103.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;14.43</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:151.5pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;14.43</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:151.5pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;14.43</span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:168.75pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Early redemption amount (put event)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:168.75pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.84pt;position:var(--position)"></span><span style="left:108.84pt;position:var(--position)">120</span><span style="left:120.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:168.75pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:99.84pt;position:var(--position)"></span><span style="left:99.84pt;position:var(--position)">120</span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:168.75pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:99.84pt;position:var(--position)"></span><span style="left:99.84pt;position:var(--position)">120</span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:186pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Volatility</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:186pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:112.84pt;position:var(--position)"></span><span style="left:112.84pt;position:var(--position)">50</span><span style="left:120.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:186pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)">50</span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:186pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)">50</span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:203.25pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Credit spread</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:203.25pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:112.84pt;position:var(--position)"></span><span style="left:112.84pt;position:var(--position)">20</span><span style="left:120.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:203.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)">20</span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:203.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)">25</span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:220.5pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Risk-free rate</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:220.5pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:110.84pt;position:var(--position)"></span><span style="left:110.84pt;position:var(--position)">2.9</span><span style="left:120.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:220.5pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:101.84pt;position:var(--position)"></span><span style="left:101.84pt;position:var(--position)">2.3</span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:220.5pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:101.84pt;position:var(--position)"></span><span style="left:101.84pt;position:var(--position)">2.9</span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:237.75pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Fair value of Heights convertible notes </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:237.75pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:96.21pt"></span></span><span style="left:98.83999999999999pt;position:var(--position)">32,641<span style="display:inline-block;height:5.41pt;width:6.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:237.75pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:87.21pt"></span></span><span style="left:89.83999999999999pt;position:var(--position)">27,456<span style="display:inline-block;height:5.41pt;width:6.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:237.75pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:87.21pt"></span></span><span style="left:89.83999999999999pt;position:var(--position)">20,017<span style="display:inline-block;height:5.41pt;width:6.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:468.71pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">As of August 24, 2023, using the same assumptions with an increase of </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:323.84pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">+1%</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:342.8pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> volatility, </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:386.35pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;+1</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:401.98pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> share price, </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:453.02pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">+1%</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:471.98pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> risk-free rate and </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:545.21pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">+1%</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:564.17pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:479.91pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">probability of achieving the held to maturity scenario would result in a change in the Heights convertible notes fair value by </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:491.11pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">respectively </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:86.75pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;+239&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:150.97pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">, </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.97pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;+1,069&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:227.69pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">, </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:232.69pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;-239&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:294.61pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> and </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:314.04pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;-80&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:370.96pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">.</span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:513.51pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">As of December 31, 2023, using the same assumptions with an increase of </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:336pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">+1%</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:354.96pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> volatility, </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:398.51pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;+1</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:414.14pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> share price, </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:465.18pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">+1%</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:484.14pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> risk-free rate and </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:524.71pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">+1%</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.96pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> probability of achieving the held to maturity scenario would result in a change in the Heights convertible notes fair value by </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:535.91pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">respectively </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:86.75pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;+18&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:145.97pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">, </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:150.97pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;+352&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:215.19pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">, </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:220.19pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;-366&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:282.11pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> and </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:301.54pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;-364&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:363.46pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">.</span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:558.31pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">As of December 31, 2024, using the same assumptions with an increase of </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:336pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">+1%</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:354.96pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> volatility, </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:398.51pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;+1</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:414.14pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> share price, </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:465.18pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">+1%</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:484.14pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> risk-free rate and </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:569.51pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">+10%</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:59.96pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> probability of achieving the held to maturity scenario would result in a change in the Heights convertible notes fair value by </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:580.71pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">respectively </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:86.75pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;+</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:97.38pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">2&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.97pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">, </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:145.97pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;+</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:156.6pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">39&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:205.19pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">, </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:210.19pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;-219&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:272.11pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> and </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:291.53999999999996pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;-631&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:353.46pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">.</span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:603.11pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">At the conversion dates of the Heights notes, the fair value of the converted notes of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:374.79pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;53,921&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:445.88pt;position:var(--position);text-decoration:none;white-space:pre"> was reclassified from financial </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:614.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">liabilities to equity. On the conversion dates, due to the put option being exercised by the holders, the fair values of the Heights notes </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:625.51pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">were deemed equal to th</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:133.64pt;position:var(--position);text-decoration:none;white-space:pre">e listed market prices</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:218.78pt;position:var(--position);text-decoration:none;white-space:pre"> of the issued shares.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:636.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As a result of the derecognition of the Heights notes, the outstanding day-one gain was entirely amortized, resulting in a financial </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:648.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">income of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:78.72999999999999pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,262&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:144.82pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:672.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">For the year ended December 31, 2025, changes in the fair value of the Heights notes (including the remeasurement at conversion </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:684.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">date) resulted in a financial expense of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:192.72pt;position:var(--position);text-decoration:none;white-space:pre">36,015&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:258.81pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 15.3</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre">. Structured debt financing with Kreos subscribed i</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:284.72pt;position:var(--position);text-decoration:none;white-space:pre">n July 2018 &#8211; &#8220;Kreos 1&#8221; </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:93.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Kreos 1 bond loans</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:116.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On July 24, 2018, the Group entered into a Venture Loan Agreement, a Straight Bonds Issue Agreement and a Convertible Bonds </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:127.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Issue Agreement with Kreos Capital V (UK) Ltd., (or &#8220;Kreos&#8221;), which provided for up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:395.67pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;20,000&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:466.76pt;position:var(--position);text-decoration:none;white-space:pre"> in financing. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:149.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Pursuant to the terms of the agreements, Kreos agreed to subscribe for </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:319.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;16,000&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:390.4pt;position:var(--position);text-decoration:none;white-space:pre"> in non-convertible bonds and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:160.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;4,000&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:102.09pt;position:var(--position);text-decoration:none;white-space:pre"> in convertible bonds, to be issued by the Group in </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:306.38pt;position:var(--position);text-decoration:none;white-space:pre">two</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:321.37pt;position:var(--position);text-decoration:none;white-space:pre"> tranches of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:370.48pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;10,000&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:441.57pt;position:var(--position);text-decoration:none;white-space:pre"> each. The tranches were issued </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:172.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in July 2018 and May 2019, respectively.&#160; The convertible bonds were convertible into new ordinary shares of the Group at any time </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:183.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">from their issuance and at the discretion of their holders. In October 2020, Kreos required the conversion of all the convertible bonds </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:194.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">they held and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:92.33pt;position:var(--position);text-decoration:none;white-space:pre">464,309</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:124.83pt;position:var(--position);text-decoration:none;white-space:pre"> shares were issued. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:216.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The straight bond tranches were split between i) a debt component (then measured at amortized cost), and ii) a premium corresponding </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:228.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">to the initial fair value of attached BSA (then remeasured at fair value through profit and loss).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:251.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2022, the A tranche of the Kreos 1 bond loan has come to maturity and was repaid in full. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:273.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On August, 21, 2023, the B tranche of the Kreos 1 bond loan as well as the A &amp; B tranches of the Kreos 2 bond loan were repaid in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:284.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">full, for an amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:124.26pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;7,661&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:190.35pt;position:var(--position);text-decoration:none;white-space:pre">, using the proceeds from the new Kreos / Claret Fin</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:399.86pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">ancing (</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:432.32pt;position:var(--position);text-decoration:none;white-space:pre">see Note 3.1</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:481.99pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">). </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:307.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As the differences identified between the terms of the Kreos 1 &amp; 2 bond loans and the new Kreos / Claret Financing were considered </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:318.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">substantial, the repayment transaction on August 21, 2023 was accounted for as a debt extinguishment. The repayment of the Kreos 1 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:329.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&amp; 2 bond loans led to the recognition of a loss on extinguishment amounting to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:355.45pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;170&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:414.04pt;position:var(--position);text-decoration:none;white-space:pre">, primarily due to (i) the payment of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:340.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">future interests as per the terms of the prepayment option and (ii) unamortized exit and issuance fees, reducing the carrying value of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:352.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the liabilities.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:385.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Kreos A &amp; B BSA</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:408.16pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">In connection with each tranche, the Group issued </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:238.83pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">110,957</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:271.33000000000004pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> tranche A share warrants (or &#8220;Kreos A BSA&#8221;) and </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:477.23pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">74,766</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:504.73pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> tranche B share </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:419.66pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">warrants (or &#8220;Kreos B BSA&#8221;), each, for a global subscription price of </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:315.71pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;1</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:325.71pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">. Each Kreos A BSA and Kreos B BSA gives rights to </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:544.72pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">one</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:559.15pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:431.16pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">new ordinary share at an exercise price of </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:205.22pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;7.21</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:227.72pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> less a discount and </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:307.92pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;10.70</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:335.42pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> less a discount, respectively. In addition, the Group granted </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:442.66pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">to the holders of the Kreos A BSA and the Kreos B </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:243.61pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">BSA the option to sell to the Group, upon each exercise of all or parts of the Kreos </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:454.16pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">A BSA, at the put price defined in the agreement, a proportion of the number of the warrants, for the sole purpose of implementing a </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:465.66pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">cash less exercise of the Kreos A BSA and Kreos B BSA</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:264.4pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">. </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:488.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The BSA attached to all tranches (both straight and convertible) did not meet the &#8220;fixed for fixed&#8221; criteria (non cash settlement option </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:499.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">which may result in exchanging a variable number of shares, for a variable price), and were accounted for as standalone derivative </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:511.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">instruments.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:533.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On May 24, 2023, the holders opted for the cashless exercise option of the share warrants they held, implemented through the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:544.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">repurchase by the Group of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:147.85pt;position:var(--position);text-decoration:none;white-space:pre">43,070</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:175.35pt;position:var(--position);text-decoration:none;white-space:pre"> Kreos A BSA and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.81pt;position:var(--position);text-decoration:none;white-space:pre">43,070</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:280.31pt;position:var(--position);text-decoration:none;white-space:pre"> Kreos B BSA and the issuance by the Group of respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:525.0799999999999pt;position:var(--position);text-decoration:none;white-space:pre">67,887</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:552.58pt;position:var(--position);text-decoration:none;white-space:pre"> and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:555.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">31,696</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:63.5pt;position:var(--position);text-decoration:none;white-space:pre"> ordinary shares, as the result of the cashless exercise by Kreos of the outstanding </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:392.04pt;position:var(--position);text-decoration:none;white-space:pre">67,887</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:419.54pt;position:var(--position);text-decoration:none;white-space:pre"> Kreos A &amp; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:468.4pt;position:var(--position);text-decoration:none;white-space:pre">31,696</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:495.9pt;position:var(--position);text-decoration:none;white-space:pre"> B BSA. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:578.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">At this date, the fair value of exercised warrants of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:241.01pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,850&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:307.1pt;position:var(--position);text-decoration:none;white-space:pre"> was reclassified from derivative financial liabilities to equity. As </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:589.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of this date, due to the put option being exercised by the holders, the fair value of the BSAs is deemed equal to their intrinsic value, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:600.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">which is equal to the difference between the share price on May 24, 2023 and their exercise price.</span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 15.4 Structured debt financing with Kreos subscribed in October 2020 &#8211; &#8220;Kreos 2&#8221; </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:92.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On October 13, 2020, the Group obtained a straight bond loan of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:297.47pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;15,000&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:368.56pt;position:var(--position);text-decoration:none;white-space:pre"> from Kreos corresponding to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:489.31pt;position:var(--position);text-decoration:none;white-space:pre">two</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:504.3pt;position:var(--position);text-decoration:none;white-space:pre"> tranches of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:104.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;10,000&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:107.09pt;position:var(--position);text-decoration:none;white-space:pre"> (&#8220;Tranche A&#8221;) and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:186.98pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5,000&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:253.07pt;position:var(--position);text-decoration:none;white-space:pre"> (&#8220;Tranche B&#8221;), with an option for an additional </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:446.73pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5,000&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:512.8199999999999pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Kreos 2 straight bonds were initially measured at fair value, which corresponds to the net cash proceeds, and subsequently </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:137.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">measured at amortized cost. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:160.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On August, 21, 2023, the B tranche of the Kreos 1 bond loan as well as the A &amp; B tranches of the Kreos 2 bond loan were repaid in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:171.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">full, for an amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:124.26pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;7,661&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:190.35pt;position:var(--position);text-decoration:none;white-space:pre">, using the proce</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:256.4pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">eds from the new Kreos / Claret Financing (</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:432.32pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">see Note 3.1 and 15.1)</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:522.25pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">. The </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:182.56pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">accounting treatment of the extinguishment of these liabilities is set forth in Note 15.3.</span></span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 15.5. OCEANE </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:234.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On July 30, 2021, the Group received a gross proceed of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:264.44pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;85,000&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:335.53pt;position:var(--position);text-decoration:none;white-space:pre"> through (i)&#160;the issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:445.43pt;position:var(--position);text-decoration:none;white-space:pre">1,964,031</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.43pt;position:var(--position);text-decoration:none;white-space:pre"> shares with a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:244.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">subscription price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.64pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;30.55</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:148.14pt;position:var(--position);text-decoration:none;white-space:pre"> per share (see Note 13.2 (changes in share capital)) for gross amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:438.67pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;60,000&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:509.76pt;position:var(--position);text-decoration:none;white-space:pre">, and (ii)&#160;the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:254.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:83.17pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;25,000&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:154.26pt;position:var(--position);text-decoration:none;white-space:pre"> in OCEANE, maturing on July 30, 2026. The proceeds of the transaction mainly serve to finance the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:264.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">progress of ABX464 clinical trials in chronic inflammatory diseases.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:286.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The OCEANE were convertible into new ordinary shares and/or exchanged for existing ordinary shares of the group at any time from </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:296.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">their issuance and at the discretion of their holders. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:312.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As the conversion ratio was adjusted </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:185.29pt;position:var(--position);text-decoration:none;white-space:pre">18 months</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:227.22pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:232.22pt;position:var(--position);text-decoration:none;white-space:pre">24 months</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:274.15pt;position:var(--position);text-decoration:none;white-space:pre">, and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:296.08pt;position:var(--position);text-decoration:none;white-space:pre">36 months</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:338.01pt;position:var(--position);text-decoration:none;white-space:pre"> after the issuance date of the OCEANE bond with the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:322.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">weighted average price of the shares and is subject to a floor and a cap, the conversion did not result in the delivery of a fixed number </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:332.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of shares. Consequently, the OCEANE bond was recorded as an hybrid instrument which includes i) a debt host contract accounted for </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:342.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">at amortized cost, and ii) a conversion option which was a embedded derivative accounted for at fair value through profit and loss. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:364.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">At inception, the net cash proceeds reflected the OCEANE initial fair value. The fair value of the bifurcated conversion option at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:374.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">inception has been measured with a Monte Carlo model using a Longstaff Schwartz algorithm, with a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:444.71pt;position:var(--position);text-decoration:none;white-space:pre">53%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:463.04pt;position:var(--position);text-decoration:none;white-space:pre"> share price volatility, a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:384.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">1,400</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:58.5pt;position:var(--position);text-decoration:none;white-space:pre"> bp credit spread assumption and a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:199.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;31.50</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:226.69pt;position:var(--position);text-decoration:none;white-space:pre"> share price. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:404.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of August 24, 2023, the date at which the OCEANE were repaid, the fair value of conversion option amounts to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:498.9pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,762&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:564.99pt;position:var(--position);text-decoration:none;white-space:pre">, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:416.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">based on the same valuation model, a risk-free rate of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.67pt;position:var(--position);text-decoration:none;white-space:pre">3.22%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:278.5pt;position:var(--position);text-decoration:none;white-space:pre">, a credit spread assumption of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:403.09pt;position:var(--position);text-decoration:none;white-space:pre">1,398</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:425.59pt;position:var(--position);text-decoration:none;white-space:pre"> bp, a share price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:506.89pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;16.74</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:534.39pt;position:var(--position);text-decoration:none;white-space:pre">, and a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:427.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">price volatility of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:107.84pt;position:var(--position);text-decoration:none;white-space:pre">37%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:126.17pt;position:var(--position);text-decoration:none;white-space:pre">. As of August 24, 2023, using the same assumptions, an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:401.25pt;position:var(--position);text-decoration:none;white-space:pre">+1%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:420.21pt;position:var(--position);text-decoration:none;white-space:pre"> volatility, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:463.76pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;+1</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:479.39pt;position:var(--position);text-decoration:none;white-space:pre"> share price and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:544.86pt;position:var(--position);text-decoration:none;white-space:pre">+1%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:563.82pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:438.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">risk free rate would result in an increase of the OCEANE conversion option fair value of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:392.82pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;80&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:446.41pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:451.41pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;364&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:510pt;position:var(--position);text-decoration:none;white-space:pre">, and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:449.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;121&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.59pt;position:var(--position);text-decoration:none;white-space:pre"> respectively. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:472.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On August 24, 2023, the outstanding OCEANE including accrued interests were repaid in full, for an amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:486.42pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;25,102&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:557.51pt;position:var(--position);text-decoration:none;white-space:pre">, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:483.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">using the proceeds from the new Heights Financings (see Note 3.1). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:494.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As the differences identified between the terms of the OCEANE and the new Heights convertible notes were considered substantial, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:505.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the transaction was accounted for as a debt extinguishment. The repayment of the OCEANE led to the recognition of a loss on </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:516.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">extinguishment amounting to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.61pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3,069&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:221.7pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 15.6. State guaranteed loan &#8211; &#8220;PGE&#8221;<span id="idf2ef93091c34d489c34e04dfef676a3"></span></span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:572.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In June 2020, the Group subscribed to a PGE from Soci&#233;t&#233; G&#233;n&#233;rale with an initial maturity of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:416.72pt;position:var(--position);text-decoration:none;white-space:pre">12 months</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:458.65pt;position:var(--position);text-decoration:none;white-space:pre"> at </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:470.85pt;position:var(--position);text-decoration:none;white-space:pre">0.25%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:496.68pt;position:var(--position);text-decoration:none;white-space:pre"> and a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:523.04pt;position:var(--position);text-decoration:none;white-space:pre">five</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:538.5699999999999pt;position:var(--position);text-decoration:none;white-space:pre">-year</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:559.09pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:582.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">extension option. In March 2021, the Group exercised the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:269.4pt;position:var(--position);text-decoration:none;white-space:pre">five</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:284.93pt;position:var(--position);text-decoration:none;white-space:pre">-year</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:305.45pt;position:var(--position);text-decoration:none;white-space:pre"> extension option with a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:403.97pt;position:var(--position);text-decoration:none;white-space:pre">one</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:418.4pt;position:var(--position);text-decoration:none;white-space:pre">-year</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:438.92pt;position:var(--position);text-decoration:none;white-space:pre"> deferral of the principal </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:592.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">repayment, with the following conditions: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:608.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Rate: </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.61pt;position:var(--position);text-decoration:none;white-space:pre">0.58%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.44pt;position:var(--position);text-decoration:none;white-space:pre"> per annum excluding insurance and state guaranteed premium, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:624.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">State guaranteed premium of </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:209.23000000000002pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;138&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:267.82pt;position:var(--position);text-decoration:none;white-space:pre"> to be paid by installments over the contract period starting in June 2021, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:634.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:650.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Reimbursement by yearly installments from June 2021 to June 2026. </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:672.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The benefit resulting from the low interest nature of the award as a subsidy was recognized as other income during the period ended </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:682.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">December&#160;31, 2020 for an amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:186.43pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;377&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:245.02pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The variation in the PGE loan over the periods ended December 31, 2023, 2024 is primarily related to the reimbursement of capital </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:81.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and interests. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:104.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">During the fourth quarter of 2025, the Group prepaid in full the outstanding principal of the PGE loan of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:456.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,264&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:522.28pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 15.7. Conditional advances<span id="i4379b0e22e6542cb9131970a4d5b89f6"></span></span><div style="font-size:12pt;line-height:11pt;position:var(--position);top:154.06pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Conditional advances as of December 31, 2023, 2024 and 2025 are as </span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:317.41pt;position:var(--position);text-decoration:none;white-space:pre">follows</span><span style="font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:347.39pt;position:var(--position);text-decoration:none;white-space:pre">:</span></div><div style="font-size:12pt;line-height:11pt;position:var(--position);top:165.06pt;width:612pt"><span style="font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div><div style="position:var(--position);top:195.07pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:336pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:134.25pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:15.59pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">CONDITIONAL ADVANCES</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:134.25pt;position:var(--position);top:12pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.92pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.97pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.52pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:12pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.92pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.97pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.52pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:270.75pt;position:var(--position);top:12pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.92pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.97pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.52pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">RNP VIR &#8211; Bpifrance</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:134.25pt;position:var(--position);top:42.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">4,232<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:42.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:270.75pt;position:var(--position);top:42.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">CARENA &#8211; Bpifrance</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:134.25pt;position:var(--position);top:54.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">2,485<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:54.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:270.75pt;position:var(--position);top:54.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">EBOLA &#8211; Bpifrance</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:134.25pt;position:var(--position);top:66.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">55<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:66.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:270.75pt;position:var(--position);top:66.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total conditional advances</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:134.25pt;position:var(--position);top:78.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">6,771<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:78.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:270.75pt;position:var(--position);top:78.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:328.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">RNP-VIR &#8211; Bpifrance </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:344.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Under the RNP-VIR contract, the Group was eligible to receive up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:315.41pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.3&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:364.26pt;position:var(--position);text-decoration:none;white-space:pre"> in conditional advances to further develop methods </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:354.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">for the discovery of new molecules for the treatment of viral infectious diseases through the development of the &#8220;Modulation of RNA </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:364.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">biogenesis&#8221; platform. As of December 31, 2022, the Group had received </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:328.49pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;4,032&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:394.58pt;position:var(--position);text-decoration:none;white-space:pre">, of which </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:437.33pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,756&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:503.42pt;position:var(--position);text-decoration:none;white-space:pre"> was received in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:374.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">September 2017, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:106.22pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;346&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:164.81pt;position:var(--position);text-decoration:none;white-space:pre"> in August&#160;2018 and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:248.39pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,930&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:314.48pt;position:var(--position);text-decoration:none;white-space:pre"> in November 2019. The repayment of these funds is spread from </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:384.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the date on which the repayments are called by BPI. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:406.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In June 2024, the Group and Bpifrance agreed to terminate the project due to technical failure. Bpifrance claimed the reimbursement </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:418.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:46.83pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,241 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.92pt;position:var(--position);text-decoration:none;white-space:pre"> corresponding to overpayments of conditional advances and subsidies (for which the Group had not incurred the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:430.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">corresponding R&amp;D expenses) and agreed to waive </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:244.4pt;position:var(--position);text-decoration:none;white-space:pre">60%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:262.73pt;position:var(--position);text-decoration:none;white-space:pre"> of the remaining advances of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:383.7pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;2,945&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:449.79pt;position:var(--position);text-decoration:none;white-space:pre"> and accrued interests, which </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:442.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">resulted in a subsidy income of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:163.1pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,872&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:229.19pt;position:var(--position);text-decoration:none;white-space:pre"> in the aggregate (see Note 18). </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:356.81pt;position:var(--position);text-decoration:none;white-space:pre">The outstanding amount was fully repaid by the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:454.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Group during the second half of 2024.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:478.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">See Note 25.2. Commitments under BPI conditional advances. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:506.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">CARENA &#8211; Bpifrance </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:522.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Under the CARENA agreement, the Group was eligible to receive up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:325.94pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3,840&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:392.03pt;position:var(--position);text-decoration:none;white-space:pre"> to develop a therapeutic HIV treatment </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:532.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">program with ABX464. As of December 31, 2022, the Group received </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:320.77pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;2,187&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:386.86pt;position:var(--position);text-decoration:none;white-space:pre">, of which </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:429.61pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,150&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:495.7pt;position:var(--position);text-decoration:none;white-space:pre"> was received in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:542.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">December 2013, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:104.54pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,008&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:170.63pt;position:var(--position);text-decoration:none;white-space:pre"> in September 2014 and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:268.05pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;29&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:321.64pt;position:var(--position);text-decoration:none;white-space:pre"> received in June 2016. </span></div><div style="font-size:12pt;line-height:1pt;position:var(--position);top:564.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:566.02pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The repayment of the advance is spread from the date on which the repayments are called by Bpifrance. An additional repayment is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:576.02pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">provided for based on the income the Group generates through this research and development program.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:598.02pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In June 2024, the Group and Bpifrance agreed to terminate the project due to technical failure. Bpifrance granted an additional amount </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:609.52pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:46.83pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,068&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.92pt;position:var(--position);text-decoration:none;white-space:pre"> payable to the Group to reimburse additional expenses incurred as part of the project, and agreed to waive </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:541.3pt;position:var(--position);text-decoration:none;white-space:pre">60%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:559.63pt;position:var(--position);text-decoration:none;white-space:pre"> of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:621.02pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the remaining conditional advance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:187.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3,255&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:253.28pt;position:var(--position);text-decoration:none;white-space:pre"> and accrued interests, which resulted in a subsidy income of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:498.56pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;2,251&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:564.65pt;position:var(--position);text-decoration:none;white-space:pre"> in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:632.52pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the aggregate (see Note 18).</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:148.35pt;position:var(--position);text-decoration:none;white-space:pre"> The outstanding amount was fully repaid by the Group during the second half of 2024.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:662.02pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">EBOLA &#8211; Bpifrance </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:678.02pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Under the Bpifrance and Occitanie region joint aid agreement, the Group received a total of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:404.94pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;390&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:463.53pt;position:var(--position);text-decoration:none;white-space:pre"> (</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:469.36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;300&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:527.95pt;position:var(--position);text-decoration:none;white-space:pre"> as of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:688.02pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">December 31, 2017 and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:133.97pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;90&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:187.56pt;position:var(--position);text-decoration:none;white-space:pre"> as of December 31, 2019). The reimbursement was spread from 2019 to June 2024. </span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 15.8. Lease liabilities<span id="ifc3224d03a4e46d99a832b8e540a70e5"></span></span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:119.86pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The variations in lease liabilities are set forth below:</span></div><div style="position:var(--position);top:133.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:301.5pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:216.75pt"></td><td style="padding:0;width:84.75pt"></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:216.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:56.84pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:216.75pt;position:var(--position);width:84.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:84.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.18pt;position:var(--position);text-decoration:none;white-space:pre"> LEASE LIABILITY</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:216.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY 1, 2023</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:216.75pt;position:var(--position);top:12pt;width:84.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:84.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.71pt"></span></span><span style="left:63.34pt;position:var(--position)">1,384<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:33pt;width:216.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(+) Increase </span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:216.75pt;position:var(--position);top:33pt;width:84.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:84.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.71pt"></span></span><span style="left:69.33999999999999pt;position:var(--position)">350<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:45pt;width:216.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(-) Decrease</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:216.75pt;position:var(--position);top:45pt;width:84.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:84.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.05pt"></span></span><span style="left:60.68pt;position:var(--position)">(1,194)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:57pt;width:216.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:216.75pt;position:var(--position);top:57pt;width:84.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:84.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:66.71pt"></span></span><span style="left:69.33999999999999pt;position:var(--position)">540<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78pt;width:216.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(+) Increase </span></div></div></div></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:216.75pt;position:var(--position);top:78pt;width:84.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:84.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.71pt"></span></span><span style="left:63.34pt;position:var(--position)">2,221<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90pt;width:216.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(-) Decrease</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:216.75pt;position:var(--position);top:90pt;width:84.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:84.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:64.05pt"></span></span><span style="left:66.67999999999999pt;position:var(--position)">(398)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102pt;width:216.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:216.75pt;position:var(--position);top:102pt;width:84.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:84.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.71pt"></span></span><span style="left:63.34pt;position:var(--position)">2,363<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:123pt;width:216.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(+) Increase </span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:216.75pt;position:var(--position);top:123pt;width:84.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:84.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.71pt"></span></span><span style="left:69.33999999999999pt;position:var(--position)">444<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:135pt;width:216.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(-) Decrease</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:216.75pt;position:var(--position);top:135pt;width:84.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:84.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:64.05pt"></span></span><span style="left:66.67999999999999pt;position:var(--position)">(950)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:147pt;width:216.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:216.75pt;position:var(--position);top:147pt;width:84.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:84.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.71pt"></span></span><span style="left:63.34pt;position:var(--position)">1,856<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:318.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Lease liabilities mainly relate the Group&#8217;s headquarters in Paris, the Boston office entered into in November 2023, the Montpellier </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:329.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">offices entered into in April 2024, the new Paris headquarters entered into in May 2024 and to a lesser extent to vehicles, parking lots </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:340.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and printer</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:79.56pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">s (see Note 8).</span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:351.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The lease for the Group&#8217;s corporate headquarters in Paris, France at 7-11 Boulevard Haussmann, 75009 Paris started in July 2022. It </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:365.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">had a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:59.86pt;position:var(--position);text-decoration:none;white-space:pre">three</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:79.82pt;position:var(--position);text-decoration:none;white-space:pre">-year</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:100.34pt;position:var(--position);text-decoration:none;white-space:pre"> duration, with a tacit renewal option for approximately </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:324.51pt;position:var(--position);text-decoration:none;white-space:pre">two years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:363.08pt;position:var(--position);text-decoration:none;white-space:pre"> and the possibility to break the contract </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:525.6600000000001pt;position:var(--position);text-decoration:none;white-space:pre">one year</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:559.78pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:378.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">before the end. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:98.15pt;position:var(--position);text-decoration:none;white-space:pre">In September 2023, the Group was notified by the lessor of its intention to exercise its option to terminate the contract </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:391.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">on June 30, 2024. Consequently, the Group reassessed the lease term and recorded a decrease in the related lease liability by </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:404.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;622&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.59pt;position:var(--position);text-decoration:none;white-space:pre"> and a corresponding decrease in the right of use asset for the same amount. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:417.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">A new lease for different premises within the same building was entered into on May 2, 2024. It has a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:445.58pt;position:var(--position);text-decoration:none;white-space:pre">three</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:465.54pt;position:var(--position);text-decoration:none;white-space:pre">-year</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:486.06pt;position:var(--position);text-decoration:none;white-space:pre"> duration, and no </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:431.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">renewal option. The Group also benefits from an initial eight-month rent-free period.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:455.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In November 2023, the Subsidiary entered a lease contract for its new Boston offices. It has a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:411.98pt;position:var(--position);text-decoration:none;white-space:pre">two</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:426.97pt;position:var(--position);text-decoration:none;white-space:pre">-year</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:447.49pt;position:var(--position);text-decoration:none;white-space:pre"> duration, with an option to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:466.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">renew the contract for an additional period of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:219.66pt;position:var(--position);text-decoration:none;white-space:pre"><span style="-sec-ix-hidden:f-2257">one</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:234.09pt;position:var(--position);text-decoration:none;white-space:pre"> or </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:247.42pt;position:var(--position);text-decoration:none;white-space:pre">two years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:285.99pt;position:var(--position);text-decoration:none;white-space:pre">. In December 2024, the Group exercised its option to extend the lease </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:478.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">up until December 2026. P</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:143.41pt;position:var(--position);text-decoration:none;white-space:pre">er Management, additional renewal options are not reasonably certain due to the forecasted development of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:489.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the Subsidiary, which may lead it to relocate at the end of the current term.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:511.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In April 2024, the Company entered a lease contract for a new Montpellier office. It has an initial </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:427.73pt;position:var(--position);text-decoration:none;white-space:pre">six</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:439.39pt;position:var(--position);text-decoration:none;white-space:pre">-year</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:459.91pt;position:var(--position);text-decoration:none;white-space:pre"> duration, with the option for </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:522.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the Company to terminate the lease at any time with a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:253.74pt;position:var(--position);text-decoration:none;white-space:pre">six</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:265.4pt;position:var(--position);text-decoration:none;white-space:pre">-month</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:294.27pt;position:var(--position);text-decoration:none;white-space:pre"> notice period, and a tacit renewal option for an additional period of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:534.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">six years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:71.24000000000001pt;position:var(--position);text-decoration:none;white-space:pre">. Based on Management's estimate, the initial lease period of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:316.04pt;position:var(--position);text-decoration:none;white-space:pre">six years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:351.28pt;position:var(--position);text-decoration:none;white-space:pre"> is considered reasonably certain and is therefore used </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:545.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">for the measurement of the lease&#160; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:567.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In December 2025, the Company renewed the lease contract with the CNRS </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:343.14pt;position:var(--position);text-decoration:none;white-space:pre">(French National Centre for Scientific Research)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:537.5799999999999pt;position:var(--position);text-decoration:none;white-space:pre"> research </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:578.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">laboratories based in Montpellier until December 31, 2026. A lease liability was recognized as of 31 December 2025.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:601.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, 2024 and 2025, the lease liabilities of the Paris headquarters and Boston offices represented </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:512.72pt;position:var(--position);text-decoration:none;white-space:pre">93%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:531.05pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:536.05pt;position:var(--position);text-decoration:none;white-space:pre">93%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:554.38pt;position:var(--position);text-decoration:none;white-space:pre"> and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:612.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">70%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.33pt;position:var(--position);text-decoration:none;white-space:pre"> of t</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:70.43pt;position:var(--position);text-decoration:none;white-space:pre">he total lease liability, respectively.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:634.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Lease expenses related to contracts for which a lease liability and right of use asset is recognized under IFRS 16 were </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:508.46pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;548&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:567.05pt;position:var(--position);text-decoration:none;white-space:pre">, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:646.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;730&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.59pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.02pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;808&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:172.61pt;position:var(--position);text-decoration:none;white-space:pre"> for the years ended December 31, 2023, 2024 and 2025, respectively. They were recognized for (i) </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:657.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;498&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.59pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:99.59pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;788&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.18pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:177.61pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;744&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:236.2pt;position:var(--position);text-decoration:none;white-space:pre"> as Depreciation expenses and (ii) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:373.8pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;13&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:427.39pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:432.39pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;61&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.98pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:505.41pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;64&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:559pt;position:var(--position);text-decoration:none;white-space:pre"> as </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:668.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Interest expenses, for the years ended December 31, 2023, 2024 and 2025, respectively.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:690.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Lease expenses related to short-term lease contracts and low value assets that are not included in the valuation of the lease liability </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:702.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">amount to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:78.74000000000001pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;334&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:137.32999999999998pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:142.32999999999998pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;352&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:200.92pt;position:var(--position);text-decoration:none;white-space:pre"> and</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:217.85pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:220.35pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;349&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:278.94pt;position:var(--position);text-decoration:none;white-space:pre"> for the years ended December 31, 2023, 2024 and 2025, respectively. </span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 15.9. Royalty certificates <span id="ib234ca1988eb4c919128d1c27cbc1aa4"></span></span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:107.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On September 2, 2022, the Group completed a financing of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:275.78pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;49,162&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:346.87pt;position:var(--position);text-decoration:none;white-space:pre">, consisting of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:405.72pt;position:var(--position);text-decoration:none;white-space:pre">two</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:420.71pt;position:var(--position);text-decoration:none;white-space:pre"> transactions: </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:130.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">a reserved capital increase of a gross amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:264.25pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;46,231&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:335.34pt;position:var(--position);text-decoration:none;white-space:pre"> through the issuance of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:433.31pt;position:var(--position);text-decoration:none;white-space:pre">5,530,000</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:473.31pt;position:var(--position);text-decoration:none;white-space:pre"> new shares with a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:143.7pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">nominal value of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:142.2pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.01</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:164.7pt;position:var(--position);text-decoration:none;white-space:pre"> per share at a subscription price of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:307.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;8.36</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:329.81pt;position:var(--position);text-decoration:none;white-space:pre"> per share; and </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:157.14pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">an issue of royalty certificates with a subscription price amounting to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:350.83pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;2,931&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:416.92pt;position:var(--position);text-decoration:none;white-space:pre">. The royalty certificates give right to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:170.58pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">their holders to royalties equal to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:206.28pt;position:var(--position);text-decoration:none;white-space:pre">2%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:219.61pt;position:var(--position);text-decoration:none;white-space:pre"> of the future net sales of obefazimod (worldwide and for all indications) as from the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:184.02pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">commercialization of such product. The amount of royalties that may be paid under the royalty certificates is capped at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:197.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;172,000&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:148.09pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:222.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Related transaction costs amounted to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:189.96pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3,280&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:256.05pt;position:var(--position);text-decoration:none;white-space:pre"> and are recorded in equity, since entirely related to the reserved capital </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:233.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">increase. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:255.7pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In April 2023, the Group reassessed its estimate of the probability of future royalty cash flows related to the royalty c</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:504.65pt;position:var(--position);text-decoration:none;white-space:pre">ertificates. </span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:549pt;position:var(--position);text-decoration:none;white-space:pre">This </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:266.9pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">change reflected the higher probability to reach the objectives of the development and commercialization plans following the recent </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:278.1pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">changes in management and governance, as well as results from its Phase 2b open-label maintenance trial in UC, as released in April </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:289.3pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">2023. Subsequently, in June 2023 and December 2023, the Group revised </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:333.01pt;position:var(--position);text-decoration:none;white-space:pre">the development and commercialization plans of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:300.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">obefazimod and reassessed its estimate of future royalty cash flows accordingly. These changes in estimates resulted in a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:311.7pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">remeasurement of the certificates&#8217; amortized costs, using the original EIR of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:343.91pt;position:var(--position);text-decoration:none;white-space:pre">34%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:362.24pt;position:var(--position);text-decoration:none;white-space:pre"> calculated at the date of issuance, which led to an </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:322.9pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">increase by</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:81.21000000000001pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:83.71000000000001pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;6,421 thousand</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:149.8pt;position:var(--position);text-decoration:none;white-space:pre"> of the royalty certificates liability. The expense was recorded within the interest expenses in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:334.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Statements of Income (Loss).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:345.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Consequently, the total interest expense (including the unwinding of discount) related to royalty certificates amounts to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:356.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;8,942&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:102.09pt;position:var(--position);text-decoration:none;white-space:pre"> for the year ended December 31, 2023.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:379.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In December 2024, the Group </span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.12pt;position:var(--position);text-decoration:none;white-space:pre">revised </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:189.47pt;position:var(--position);text-decoration:none;white-space:pre">the development and commercialization plans of obefazimod to take into account the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:391pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">progression in the ongoing clinical trials, reassessment of the commercial schedule and forecasts&#160; and reassessed its estimate of future </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:402.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">royalty cash flows accordingly.</span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:161.42000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> This</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:181.68pt;position:var(--position);text-decoration:none;white-space:pre"> change in estimate resulted in a remeasurement of the certificates&#8217; amortized costs, using the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:413.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">original EIR of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:98.99000000000001pt;position:var(--position);text-decoration:none;white-space:pre">34%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:117.32pt;position:var(--position);text-decoration:none;white-space:pre"> calculated at the date of issuance, which led to a decrease by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:364.17pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3,404&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:430.26pt;position:var(--position);text-decoration:none;white-space:pre"> of the royalty certificates liability. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:424.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The expense was recorded within the interest expenses in the Statements of Income (Loss).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:435.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Consequently, the total interest expense related to royalty certificates (including the effect of the unwinding of discount, amounting to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:447.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;4,198&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:102.09pt;position:var(--position);text-decoration:none;white-space:pre">) amounts to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:154.55pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;794&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:213.14pt;position:var(--position);text-decoration:none;white-space:pre"> for the year ended December 31, 2024.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:470.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">During the third quarter of 2025, the Group revised the probability of success (&#8220;POS&#8221;) of the obefazimod clinical trials to take into </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:481.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">account the Phase 3 results announced in July 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:241.37pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:243.87pt;position:var(--position);text-decoration:none;white-space:pre">and reassessed its estimate of future royalty cash flows accordingly. This change </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:492.7pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in estimate resulted in a remeasurement of the certificates&#8217; amortized costs, using the original EIR of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:441.26pt;position:var(--position);text-decoration:none;white-space:pre">34%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:459.59pt;position:var(--position);text-decoration:none;white-space:pre"> calculated at the date of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:503.9pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">issuance, which led to an increase by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:186.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;11,286&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:257.46000000000004pt;position:var(--position);text-decoration:none;white-space:pre"> of the royalty certificates liability. The expense was recorded within the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:515.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">financial expenses in the Statements of Income (Los</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:244.9pt;position:var(--position);text-decoration:none;white-space:pre">s).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:537.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2025, using the same future royalty cash flows assumptions with an increase of +</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:443.75pt;position:var(--position);text-decoration:none;white-space:pre">5</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:448.75pt;position:var(--position);text-decoration:none;white-space:pre"> points of POS and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:526.78pt;position:var(--position);text-decoration:none;white-space:pre">+5%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:545.74pt;position:var(--position);text-decoration:none;white-space:pre"> of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:548.7pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">peak penetration (best case scenario) would result in an increase in the royalty certificates carrying value by respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:520.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:559.9pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">+809&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:95.22pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.65pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;+2,616&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:186.37pt;position:var(--position);text-decoration:none;white-space:pre">. Using the same assumptions with a decrease of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:382.27pt;position:var(--position);text-decoration:none;white-space:pre">(5)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:393.93pt;position:var(--position);text-decoration:none;white-space:pre"> points in POS and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:471.4pt;position:var(--position);text-decoration:none;white-space:pre">(5)%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:491.39pt;position:var(--position);text-decoration:none;white-space:pre"> in peak penetration </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:571.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(worst case scenario) would result in a decrease in the royalty certificates carrying value by respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:454.3pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(1,712)&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:527.05pt;position:var(--position);text-decoration:none;white-space:pre"> and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:582.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(4,154)&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108.75pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:605.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Fair value </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:630.14pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The fair value of the royalty certificates amounts to</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:241.26pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:243.76pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;12,395 thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:314.85pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> as </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:328.17pt;position:var(--position);text-decoration:none;white-space:pre">of December 31, 2023, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:422.54pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;7,313&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:488.63pt;position:var(--position);text-decoration:none;white-space:pre"> as of December 31, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:641.34pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">2024 and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:75.43pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;102,001</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.93pt;position:var(--position);text-decoration:none;white-space:pre"> thousands as of December 31, 2025.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:663.74pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The fair value of the royalty certificates is based on the net present value of royalties, which depends on assumptions made by the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:674.94pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Group with regards to the probability of success of its studies (&#8220;POS&#8221;), the commercialization budget of obefazimod (&#8220;peak </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:686.14pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">penetration&#8221;) and the discount rate. In addition, as of December 31 2023 and 2024, royalty projections have been adjusted to reflect </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:697.34pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the significant difference between the Group&#8217;s value derived from management projections and the Group&#8217;s market capitalization. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2025, following the increase in the Group's share price and the business plan update, such adjustment was no </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:82.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">longer required. Management ensured that the discount rate of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:287.37pt;position:var(--position);text-decoration:none;white-space:pre">7.5%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:308.2pt;position:var(--position);text-decoration:none;white-space:pre"> used at that date</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:375.32pt;position:var(--position);text-decoration:none;white-space:pre"> is reasonable based on the specific risk profile of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:93.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the royalties certificates.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:116.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The decrease in fair value of the royalty certificates over the year ended December 31, 2024 is mainly driven by the decrease in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:128.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Group's share price over the period, while the increase over the year ended December 31, 2025 is primarily explained by (i) the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:139.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">revised </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:67.35pt;position:var(--position);text-decoration:none;white-space:pre">POS</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.69pt;position:var(--position);text-decoration:none;white-space:pre">, reflecting the results of the Phase 3 trials, which resulted in the increase in the Group's share price during the second half </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:151.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of 2025, and (ii) a decrease in the discount rate consistent with the increase in the Group's market capitalization (see Note 3.3 </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:539.38pt;position:var(--position);text-decoration:none;white-space:pre">- </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:162.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Publication of positive Phase 3 results from both ABTECT 8-week induction trials investigating obefazimod, in moderate to severely </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:174.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">active UC </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:78.71000000000001pt;position:var(--position);text-decoration:none;white-space:pre">&#8211;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:83.71000000000001pt;position:var(--position);text-decoration:none;white-space:pre"> July 2025)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:128.67000000000002pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:196.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, using the same assumptions with an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:336pt;position:var(--position);text-decoration:none;white-space:pre">+5</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:346.63pt;position:var(--position);text-decoration:none;white-space:pre"> points of POS, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:410.23pt;position:var(--position);text-decoration:none;white-space:pre">+5%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:429.19pt;position:var(--position);text-decoration:none;white-space:pre"> of peak penetration (best case </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:207.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">scenario), </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:77.61pt;position:var(--position);text-decoration:none;white-space:pre">+1%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.57pt;position:var(--position);text-decoration:none;white-space:pre"> WACC and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:148.47pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;+1</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:164.1pt;position:var(--position);text-decoration:none;white-space:pre"> share price would result in a change in the royalty certificates fair value by respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:518.6pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:219.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">+1104&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:100.22pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:105.22pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;+1757&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:174.44pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:179.44pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(577) thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:244.69pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:264.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;+1325&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:333.34pt;position:var(--position);text-decoration:none;white-space:pre">. Using the same assumptions with a decrease of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:529.24pt;position:var(--position);text-decoration:none;white-space:pre">(5)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:540.9pt;position:var(--position);text-decoration:none;white-space:pre"> points </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:230.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of POS, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:70.17pt;position:var(--position);text-decoration:none;white-space:pre">(5)%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90.16pt;position:var(--position);text-decoration:none;white-space:pre"> of peak penetration (worst case scenario) and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:276.03999999999996pt;position:var(--position);text-decoration:none;white-space:pre">(1)%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:296.03pt;position:var(--position);text-decoration:none;white-space:pre"> WACC and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:347.93pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(1)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:364.59pt;position:var(--position);text-decoration:none;white-space:pre"> share price would result in a change in the royalty </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:241.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">certificates fair value by respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:186.02pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(1,104) thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:258.77pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:263.77pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(2,311) thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:336.52pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:341.52pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;+612&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:405.74pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:425.17pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(1,325) thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:497.92pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:263.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2024, using the same assumptions with an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:336pt;position:var(--position);text-decoration:none;white-space:pre">+5</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:346.63pt;position:var(--position);text-decoration:none;white-space:pre"> points of POS, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:410.23pt;position:var(--position);text-decoration:none;white-space:pre">+5%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:429.19pt;position:var(--position);text-decoration:none;white-space:pre"> of peak penetration (best case </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:275.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">scenario), </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:77.61pt;position:var(--position);text-decoration:none;white-space:pre">+1%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.57pt;position:var(--position);text-decoration:none;white-space:pre"> WACC and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:148.47pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;+1</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:164.1pt;position:var(--position);text-decoration:none;white-space:pre"> share price would result in a change in the royalty certificates fair value by respectively &#8364;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:286.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">+</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:41.63pt;position:var(--position);text-decoration:none;white-space:pre">572&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:95.22pt;position:var(--position);text-decoration:none;white-space:pre">, &#8364;+</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:110.85pt;position:var(--position);text-decoration:none;white-space:pre">1,735&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:171.94pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:176.94pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(314) thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:242.19pt;position:var(--position);text-decoration:none;white-space:pre"> and &#8364;+</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:272.25pt;position:var(--position);text-decoration:none;white-space:pre">1,160&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:333.34pt;position:var(--position);text-decoration:none;white-space:pre">. Using the same assumptions with a decrease of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:529.24pt;position:var(--position);text-decoration:none;white-space:pre">(5)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:540.9pt;position:var(--position);text-decoration:none;white-space:pre"> points </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:297.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of POS, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:70.17pt;position:var(--position);text-decoration:none;white-space:pre">(5)%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90.16pt;position:var(--position);text-decoration:none;white-space:pre"> of peak penetration (worst case scenario) and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:276.03999999999996pt;position:var(--position);text-decoration:none;white-space:pre">(1)%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:296.03pt;position:var(--position);text-decoration:none;white-space:pre"> WACC and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:347.93pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(1)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:364.59pt;position:var(--position);text-decoration:none;white-space:pre"> share price would result in a change in the royalty </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:308.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">certificates fair value by respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:186.02pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(572) thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:251.27pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:256.27pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(2,527) thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:329.02pt;position:var(--position);text-decoration:none;white-space:pre">, &#8364;+</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:344.65pt;position:var(--position);text-decoration:none;white-space:pre">332&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:398.24pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:417.67pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(1,160) thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:490.42pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:331.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2025, using the same assumptions with an increase of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:336pt;position:var(--position);text-decoration:none;white-space:pre">+5</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:346.63pt;position:var(--position);text-decoration:none;white-space:pre"> points of POS, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:410.23pt;position:var(--position);text-decoration:none;white-space:pre">+5%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:429.19pt;position:var(--position);text-decoration:none;white-space:pre"> of peak penetration (best case </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:342.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">scenario) and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:92.03999999999999pt;position:var(--position);text-decoration:none;white-space:pre">+1%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:111pt;position:var(--position);text-decoration:none;white-space:pre"> WACC would result in a change in the royalty certificates fair value by respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:451.93pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;+5810&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:521.15pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:526.15pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:353.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">+2830&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:100.22pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:119.65pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(4,940) thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:192.4pt;position:var(--position);text-decoration:none;white-space:pre">. Using the same assumptions with a decrease of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:388.3pt;position:var(--position);text-decoration:none;white-space:pre">(5)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:399.96pt;position:var(--position);text-decoration:none;white-space:pre"> points of POS, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:463.56pt;position:var(--position);text-decoration:none;white-space:pre">(5)%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:483.55pt;position:var(--position);text-decoration:none;white-space:pre"> of peak penetration </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:364.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(worst case scenario) and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:139.76pt;position:var(--position);text-decoration:none;white-space:pre">(1)%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:159.75pt;position:var(--position);text-decoration:none;white-space:pre"> WACC would result in a change in the royalty certificates fair value by respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:500.68pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(5,810) thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:573.43pt;position:var(--position);text-decoration:none;white-space:pre">, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:375.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;(5,590) thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108.75pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:128.18pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;+5,251 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:199.9pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 15.10. Change in financial liabilities<span id="i9405cec2ec7c4be98c07cac8c184a2de"></span></span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:433.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:44pt;position:var(--position);text-decoration:none;white-space:pre">Changes in financial liabilities, excluding derivative instruments, are presented below as of December 31, 2023, 2024 and 2025:</span></div><div style="position:var(--position);top:444.86pt;width:612pt"><div style="font-size:0pt;left:17pt;position:var(--position);width:558.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:96.75pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td></tr><tr style="height:21.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:96.75pt"><div><div style="line-height:7pt;position:var(--position);top:13.88pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:italic;font-weight:normal;left:2.9pt;position:var(--position);text-decoration:none;white-space:pre">(Amounts in thousands of euros) </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:44.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21.75pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:9.52pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.73pt;position:var(--position);text-decoration:none;white-space:pre">FINANCIAL </span></div><div style="line-height:8pt;position:var(--position);top:19.12pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.96pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES (excluding </span></div><div style="line-height:8pt;position:var(--position);top:28.72pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.97pt;position:var(--position);text-decoration:none;white-space:pre">derivatives instruments)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:15.36pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:3.78pt;position:var(--position);text-decoration:none;white-space:pre">Kreos 1 &amp; 2 </span></div><div style="line-height:7pt;position:var(--position);top:23.76pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:5.51pt;position:var(--position);text-decoration:none;white-space:pre">bond loans</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:10.68pt;position:var(--position);text-decoration:none;white-space:pre">Oceane</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:2.76pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:11.85pt;position:var(--position);text-decoration:none;white-space:pre">Kreos/</span></div><div style="line-height:7pt;position:var(--position);top:11.16pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:12.24pt;position:var(--position);text-decoration:none;white-space:pre">Claret </span></div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:5.05pt;position:var(--position);text-decoration:none;white-space:pre">convertible </span></div><div style="line-height:7pt;position:var(--position);top:27.96pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:13.98pt;position:var(--position);text-decoration:none;white-space:pre">notes </span></div><div style="line-height:7pt;position:var(--position);top:36.36pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:4.85pt;position:var(--position);text-decoration:none;white-space:pre">(OCABSA)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:11.16pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:9.03pt;position:var(--position);text-decoration:none;white-space:pre">Kreos &amp; </span></div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:3.78pt;position:var(--position);text-decoration:none;white-space:pre">Claret bond </span></div><div style="line-height:7pt;position:var(--position);top:27.96pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:13.97pt;position:var(--position);text-decoration:none;white-space:pre">loans </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:11.16pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:10.29pt;position:var(--position);text-decoration:none;white-space:pre">Heights </span></div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:5.05pt;position:var(--position);text-decoration:none;white-space:pre">convertible </span></div><div style="line-height:7pt;position:var(--position);top:27.96pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:13.98pt;position:var(--position);text-decoration:none;white-space:pre">notes</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:14.56pt;position:var(--position);text-decoration:none;white-space:pre">PGE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:11.16pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:4.06pt;position:var(--position);text-decoration:none;white-space:pre">Conditional </span></div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:8.15pt;position:var(--position);text-decoration:none;white-space:pre">advances </span></div><div style="line-height:7pt;position:var(--position);top:27.96pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:15.92pt;position:var(--position);text-decoration:none;white-space:pre">BPI</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:15.36pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:13.21pt;position:var(--position);text-decoration:none;white-space:pre">Lease </span></div><div style="line-height:7pt;position:var(--position);top:23.76pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:8.16pt;position:var(--position);text-decoration:none;white-space:pre">liabilities</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:15.36pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:10.09pt;position:var(--position);text-decoration:none;white-space:pre">Royalty </span></div><div style="line-height:7pt;position:var(--position);top:23.76pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:5.45pt;position:var(--position);text-decoration:none;white-space:pre">certificates</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:13.78pt;position:var(--position);text-decoration:none;white-space:pre">Total </span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY 1, 2023</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">12,982<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">19,957<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">4,838<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">6,783<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">1,384<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">3,287<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">49,231<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:87pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Proceeds</span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">23,119<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">35,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">58,119<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:99pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Repayments </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:99pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:12.8pt"></span></span><span style="left:15.43pt;position:var(--position)">(11,635)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:99pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:12.8pt"></span></span><span style="left:15.43pt;position:var(--position)">(23,238)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:99pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:99pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:99pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(2,188)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:99pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(1,250)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:99pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.8pt"></span></span><span style="left:25.43pt;position:var(--position)">(110)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:99pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.8pt"></span></span><span style="left:25.43pt;position:var(--position)">(573)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:99pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:99pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:12.8pt"></span></span><span style="left:15.43pt;position:var(--position)">(38,993)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:111pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest paid</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:111pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(2,278)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:111pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(1,602)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:111pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.8pt"></span></span><span style="left:25.43pt;position:var(--position)">(818)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:111pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:111pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.8pt"></span></span><span style="left:25.43pt;position:var(--position)">(525)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:111pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.8pt"></span></span><span style="left:29.43pt;position:var(--position)">(43)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:111pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:111pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.8pt"></span></span><span style="left:29.43pt;position:var(--position)">(12)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:111pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:111pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(5,278)</span></span></div></div></div></td></tr><tr style="height:50.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:123pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.09pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: </span></div><div style="line-height:8pt;position:var(--position);top:12.69pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">classification of embedded </span></div><div style="line-height:8pt;position:var(--position);top:22.29pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">derivatives as separate </span></div><div style="line-height:8pt;position:var(--position);top:31.89pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">derivative financial </span></div><div style="line-height:8pt;position:var(--position);top:41.49pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">instruments</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:123pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:22.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:123pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:22.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:123pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:22.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(1,046)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:123pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:22.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:123pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:22.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:123pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:22.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:123pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:22.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:123pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:22.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:123pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:22.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:123pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:22.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(1,046)</span></span></div></div></div></td></tr><tr style="height:30.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:173.25pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.79pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: (gain)/</span></div><div style="line-height:8pt;position:var(--position);top:12.39pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">loss on recognition or </span></div><div style="line-height:8pt;position:var(--position);top:21.99pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">derecognition</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:173.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.46pt"></span></span><span style="left:28.09pt;position:var(--position)">170<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:173.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">3,069<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:173.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:173.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:173.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.8pt"></span></span><span style="left:25.43pt;position:var(--position)">(212)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:173.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:173.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:173.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:173.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:173.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">3,027<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:204pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.64pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: interest </span></div><div style="line-height:8pt;position:var(--position);top:12.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">expense and other</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:204pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.46pt"></span></span><span style="left:28.09pt;position:var(--position)">760<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:204pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">1,814<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:204pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">1,393<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:204pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:204pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.46pt"></span></span><span style="left:28.09pt;position:var(--position)">727<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:204pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.46pt"></span></span><span style="left:28.09pt;position:var(--position)">133<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:204pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">98<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:204pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">12<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:204pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">2,521<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:204pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">7,459<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:30.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:225pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.79pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: </span></div><div style="line-height:8pt;position:var(--position);top:12.39pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">recognition of earn-out </span></div><div style="line-height:8pt;position:var(--position);top:21.99pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">liability</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:225pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:225pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:225pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(1,005)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:225pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:225pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:225pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:225pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:225pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:225pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:225pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(1,005)</span></span></div></div></div></td></tr></tbody></table></div></div></div><div><div style="position:var(--position);top:70.56pt;width:612pt"><div style="font-size:0pt;left:17pt;position:var(--position);width:558.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:96.75pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td></tr><tr style="height:21.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:96.75pt"><div><div style="line-height:7pt;position:var(--position);top:13.88pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:italic;font-weight:normal;left:2.9pt;position:var(--position);text-decoration:none;white-space:pre">(Amounts in thousands of euros) </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:44.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21.75pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:9.52pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.73pt;position:var(--position);text-decoration:none;white-space:pre">FINANCIAL </span></div><div style="line-height:8pt;position:var(--position);top:19.12pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.96pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES (excluding </span></div><div style="line-height:8pt;position:var(--position);top:28.72pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.97pt;position:var(--position);text-decoration:none;white-space:pre">derivatives instruments)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:15.36pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:3.78pt;position:var(--position);text-decoration:none;white-space:pre">Kreos 1 &amp; 2 </span></div><div style="line-height:7pt;position:var(--position);top:23.76pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:5.51pt;position:var(--position);text-decoration:none;white-space:pre">bond loans</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:10.68pt;position:var(--position);text-decoration:none;white-space:pre">Oceane</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:2.76pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:11.85pt;position:var(--position);text-decoration:none;white-space:pre">Kreos/</span></div><div style="line-height:7pt;position:var(--position);top:11.16pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:12.24pt;position:var(--position);text-decoration:none;white-space:pre">Claret </span></div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:5.05pt;position:var(--position);text-decoration:none;white-space:pre">convertible </span></div><div style="line-height:7pt;position:var(--position);top:27.96pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:13.98pt;position:var(--position);text-decoration:none;white-space:pre">notes </span></div><div style="line-height:7pt;position:var(--position);top:36.36pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:4.85pt;position:var(--position);text-decoration:none;white-space:pre">(OCABSA)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:11.16pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:9.03pt;position:var(--position);text-decoration:none;white-space:pre">Kreos &amp; </span></div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:3.78pt;position:var(--position);text-decoration:none;white-space:pre">Claret bond </span></div><div style="line-height:7pt;position:var(--position);top:27.96pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:13.97pt;position:var(--position);text-decoration:none;white-space:pre">loans </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:11.16pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:10.29pt;position:var(--position);text-decoration:none;white-space:pre">Heights </span></div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:5.05pt;position:var(--position);text-decoration:none;white-space:pre">convertible </span></div><div style="line-height:7pt;position:var(--position);top:27.96pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:13.98pt;position:var(--position);text-decoration:none;white-space:pre">notes</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:14.56pt;position:var(--position);text-decoration:none;white-space:pre">PGE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:11.16pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:4.06pt;position:var(--position);text-decoration:none;white-space:pre">Conditional </span></div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:8.15pt;position:var(--position);text-decoration:none;white-space:pre">advances </span></div><div style="line-height:7pt;position:var(--position);top:27.96pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:15.92pt;position:var(--position);text-decoration:none;white-space:pre">BPI</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:15.36pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:13.21pt;position:var(--position);text-decoration:none;white-space:pre">Lease </span></div><div style="line-height:7pt;position:var(--position);top:23.76pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:8.16pt;position:var(--position);text-decoration:none;white-space:pre">liabilities</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:15.36pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:10.09pt;position:var(--position);text-decoration:none;white-space:pre">Royalty </span></div><div style="line-height:7pt;position:var(--position);top:23.76pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:5.45pt;position:var(--position);text-decoration:none;white-space:pre">certificates</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:13.78pt;position:var(--position);text-decoration:none;white-space:pre">Total </span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">amortized cost </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.8pt"></span></span><span style="left:25.43pt;position:var(--position)">(543)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">6,421<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">5,878<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:87pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.64pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: other </span></div><div style="line-height:8pt;position:var(--position);top:12.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">fair value remeasurement</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(3,198)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(3,198)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:108pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.64pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non cash changes: </span></div><div style="line-height:8pt;position:var(--position);top:12.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">additional leases</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:108pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:108pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:108pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:108pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:108pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:108pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:108pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:108pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.46pt"></span></span><span style="left:28.09pt;position:var(--position)">272<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:108pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:108pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.46pt"></span></span><span style="left:28.09pt;position:var(--position)">272<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:129pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:129pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:129pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:129pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">21,643<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:129pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:129pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">29,605<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:129pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">3,678<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:129pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">6,771<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:129pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:25.46pt"></span></span><span style="left:28.09pt;position:var(--position)">540<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:129pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">12,229<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:129pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">74,466<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:150pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Proceeds</span></div></div></div></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:150pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:150pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:150pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:150pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">47,444<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:150pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:150pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:150pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:150pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:150pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:150pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">47,444<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:162pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Repayments </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:162pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:162pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:162pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:162pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:162pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(8,750)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:162pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(1,250)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:162pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(2,708)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:162pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.8pt"></span></span><span style="left:25.43pt;position:var(--position)">(459)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:162pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:162pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:12.8pt"></span></span><span style="left:15.43pt;position:var(--position)">(13,167)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:174pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest paid</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:174pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:174pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:174pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(2,250)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:174pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(3,639)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:174pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(1,772)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:174pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.8pt"></span></span><span style="left:29.43pt;position:var(--position)">(18)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:174pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:174pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.8pt"></span></span><span style="left:29.43pt;position:var(--position)">(17)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:174pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:174pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(7,696)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:186pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">classification of embedded </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:186pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:186pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:186pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:186pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(3,204)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:186pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:186pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:186pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:186pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:186pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:186pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(3,204)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:207pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: (gain)/</span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">loss on recognition or </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:207pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:207pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:207pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:207pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:207pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.8pt"></span></span><span style="left:25.43pt;position:var(--position)">(590)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:207pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:207pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:207pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:207pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:207pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.8pt"></span></span><span style="left:25.43pt;position:var(--position)">(590)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:228pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.64pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: interest </span></div><div style="line-height:8pt;position:var(--position);top:12.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">expense and other</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:228pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:228pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:228pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">3,977<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:228pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">5,800<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:228pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">1,714<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:228pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">77<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:228pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.46pt"></span></span><span style="left:36.09pt;position:var(--position)">7<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:228pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">61<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:228pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">4,198<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:228pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">15,834<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:30.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:249pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.79pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: </span></div><div style="line-height:8pt;position:var(--position);top:12.39pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">amortized cost </span></div><div style="line-height:8pt;position:var(--position);top:21.99pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">remeasurement</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:249pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:249pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:249pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:249pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:249pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:249pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:249pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:249pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:249pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(3,404)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:249pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(3,404)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:279.75pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.64pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: other </span></div><div style="line-height:8pt;position:var(--position);top:12.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">fair value remeasurement</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:279.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:279.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:279.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:279.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:279.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">1,367<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:279.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:279.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:279.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:279.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:279.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">1,367<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:300.75pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.64pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes&#160;: </span></div><div style="line-height:8pt;position:var(--position);top:12.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">subsidies </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:300.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:300.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:300.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:300.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:300.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:300.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:300.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(4,070)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:300.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:300.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:300.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(4,070)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:321.75pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.64pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non cash changes: </span></div><div style="line-height:8pt;position:var(--position);top:12.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">additional leases</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:321.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:321.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:321.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:321.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:321.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:321.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:321.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:321.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">2,221<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:321.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:321.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">2,221<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:342.75pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non cash changes : Effect </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">of the change in foreign </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:342.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:342.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:342.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:342.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:342.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:342.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:342.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:342.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">17<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:342.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:342.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">17<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:363.75pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:363.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:363.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:363.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">23,370<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:363.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">46,401<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:363.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">21,574<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:363.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">2,488<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:363.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:363.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">2,363<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:363.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">13,023<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:363.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:11.46pt"></span></span><span style="left:14.09pt;position:var(--position)">109,218<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:384.75pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Proceeds</span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:384.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:384.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:384.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:384.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:384.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:384.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:384.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:384.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:384.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:384.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:396.75pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Repayments </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:396.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:396.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:396.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:396.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:12.8pt"></span></span><span style="left:15.43pt;position:var(--position)">(53,920)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:396.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(2,188)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:396.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(2,514)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:396.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:396.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.8pt"></span></span><span style="left:25.43pt;position:var(--position)">(910)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:396.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:396.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:12.8pt"></span></span><span style="left:15.43pt;position:var(--position)">(59,532)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:408.75pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest paid</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:408.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:408.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:408.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(1,875)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:408.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(3,791)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:408.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.8pt"></span></span><span style="left:25.43pt;position:var(--position)">(689)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:408.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.8pt"></span></span><span style="left:29.43pt;position:var(--position)">(72)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:408.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:408.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.8pt"></span></span><span style="left:29.43pt;position:var(--position)">(64)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:408.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:408.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(6,491)</span></span></div></div></div></td></tr><tr style="height:30.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:420.75pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.79pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: (gain)/</span></div><div style="line-height:8pt;position:var(--position);top:12.39pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">loss on recognition or </span></div><div style="line-height:8pt;position:var(--position);top:21.99pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">derecognition</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:420.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:420.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:420.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:420.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">3,838<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:420.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(1,557)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:420.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:420.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:420.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:420.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:420.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">2,281<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:451.5pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.64pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: interest </span></div><div style="line-height:8pt;position:var(--position);top:12.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">expense and other</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:451.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:451.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:451.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">2,860<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:451.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">7,472<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:451.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.46pt"></span></span><span style="left:28.09pt;position:var(--position)">778<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:451.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">99<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:451.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:451.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">64<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:451.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">5,927<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:451.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">17,200<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:30.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:472.5pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.79pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: </span></div><div style="line-height:8pt;position:var(--position);top:12.39pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">amortized cost </span></div><div style="line-height:8pt;position:var(--position);top:21.99pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">remeasurement</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:472.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:472.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:472.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:472.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:472.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:472.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:472.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:472.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:30.8pt"></span></span><span style="left:33.43pt;position:var(--position)">(7)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:472.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">11,286<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:472.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">11,278<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:503.25pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.64pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: other </span></div><div style="line-height:8pt;position:var(--position);top:12.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">fair value remeasurement</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:503.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:503.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:503.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:503.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:503.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">36,002<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:503.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:503.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:503.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:503.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:503.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">36,002<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:524.25pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.64pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: </span></div><div style="line-height:8pt;position:var(--position);top:12.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">conversion into shares</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:524.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:524.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:524.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:12.8pt"></span></span><span style="left:15.43pt;position:var(--position)">(24,354)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:524.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:524.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:12.8pt"></span></span><span style="left:15.43pt;position:var(--position)">(53,921)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:524.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:524.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:524.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:524.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:524.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:12.8pt"></span></span><span style="left:15.43pt;position:var(--position)">(78,275)</span></span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:545.25pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.81pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non cash changes: </span></div><div style="line-height:8pt;position:var(--position);top:12.81pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">additional leases</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:545.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:545.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:545.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:545.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:545.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:545.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:545.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:545.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.46pt"></span></span><span style="left:28.09pt;position:var(--position)">444<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:545.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:545.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.46pt"></span></span><span style="left:28.09pt;position:var(--position)">444<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:32.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:567pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.49pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non cash changes : Effect </span></div><div style="line-height:8pt;position:var(--position);top:13.49pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">of the change in foreign </span></div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">currency exchange rates</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:567pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:13.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:567pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:13.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:567pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:13.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:567pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:13.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:567pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:13.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:567pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:13.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:567pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:13.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:567pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:13.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.8pt"></span></span><span style="left:29.43pt;position:var(--position)">(33)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:567pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:13.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:567pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:13.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.8pt"></span></span><span style="left:29.43pt;position:var(--position)">(33)</span></span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:599.25pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.52pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:13.12pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:599.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.87pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:599.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.87pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:599.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.87pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:599.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.87pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:599.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.87pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:599.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.87pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:599.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.87pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:599.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.87pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">1,856<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:599.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.87pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">30,237<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:599.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.87pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">32,093<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">For the year ended December 31, 2023, proceeds from the issuance of the Kreos / Claret OCABSA are presented net of transaction </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:81.76pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">costs, amounting to </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:116.49pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;1,881&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:182.58pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">. Net proceeds from convertible loan notes of </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:365.99pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;55,841</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:398.49pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> disclosed in the Consolidated Statements of </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:92.96pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">Cash Flows also include transaction fees of (i) </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:223.57pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;750&#160;thousands</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:286.05pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> related to the Kreos / Claret B and C tranches and recorded in prepaid </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:104.16pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">expenses (see Note 10) and (ii) </span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:162.53pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#8364;1,528&#160;thousand</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:228.62pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> related to the Heights convertible notes.</span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">For the year ended December 31, 2023, repayments of the OCEANE are presented net of the repurchase of the conversion option, </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:137.76pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">value</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:57.629999999999995pt;position:var(--position);text-decoration:none;white-space:pre">d at </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:74.83pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,762&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.92000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> on the date of repayment, which is presented in Note 15.11. The aggregate repayment amounts to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:148.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;25,000&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:107.09pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:171.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">For the year ended December 31, 2024, proceeds from the issuance of the Kreos / Claret tranches B and C bond loans are presented </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:182.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">net of transaction costs and deposits (corresponding to the prepayments of half of the last debt installments on issuance date) included </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:193.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in the debt discount using the EIR method, and amounting to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:281.89pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,475&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:347.98pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:367.41pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,081 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:433.5pt;position:var(--position);text-decoration:none;white-space:pre"> respectively. Net proceeds from </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:204.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">non-convertible bond loans of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.68pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;48,544</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:191.18pt;position:var(--position);text-decoration:none;white-space:pre"> thousand disclosed in the Unaudited Condensed Consolidated Statements of Cash Flows do not </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:216.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">include transaction fees of (i) </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.56pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;500&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:214.15pt;position:var(--position);text-decoration:none;white-space:pre"> related to the Kreos / Claret tranche A-B warrants classified as prepaid expenses as of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:227.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">December 31, 2023.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:249.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">For the year ended December 31,2025, repayments of the Kreos / Claret tranches B and C bond loans include end-of loan exit fees and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:260.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">future interests discounted at a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:160.56pt;position:var(--position);text-decoration:none;white-space:pre">4%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:173.89pt;position:var(--position);text-decoration:none;white-space:pre"> rate, as per the terms of the prepayment option </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:365.05pt;position:var(--position);text-decoration:none;white-space:pre">(see Note 15.1).</span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 15.11. Change in derivative instruments<span id="ie479f271640a417bac703cd042645514"></span></span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:304.91pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Changes in derivative instruments, are presented below as of December 31, 2023, 2024 and 2025 :</span></div><div style="position:var(--position);top:326.91pt;width:612pt"><div style="font-size:0pt;left:44pt;position:var(--position);width:534.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:96pt"></td><td style="padding:0;width:69.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:69.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:69.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:69.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:69.75pt"></td></tr><tr style="height:24.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:96pt"><div><div style="line-height:8pt;position:var(--position);top:4.5pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:7.68pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of </span></div><div style="line-height:8pt;position:var(--position);top:14.1pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:37.78pt;position:var(--position);text-decoration:none;white-space:pre">euros)</span></div></div></div></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12pt;position:var(--position);text-decoration:none;white-space:pre">Kreos A BSA</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.22pt;position:var(--position);text-decoration:none;white-space:pre">Kreos B BSA</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:19.57pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.78pt;position:var(--position);text-decoration:none;white-space:pre">OCEANE </span></div><div style="line-height:8pt;position:var(--position);top:29.17pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.56pt;position:var(--position);text-decoration:none;white-space:pre">conversion option</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.53pt;position:var(--position);text-decoration:none;white-space:pre">Kreos/Claret BSA</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.67pt;position:var(--position);text-decoration:none;white-space:pre">Kreos/Claret </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.01pt;position:var(--position);text-decoration:none;white-space:pre">Minimal Return </span></div><div style="line-height:8pt;position:var(--position);top:33.97pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.01pt;position:var(--position);text-decoration:none;white-space:pre">Indemnifications</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.77pt;position:var(--position);text-decoration:none;white-space:pre">Total </span></div></div></div></td></tr><tr style="height:30pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.4pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DERIVATIVE </span></div><div style="line-height:8pt;position:var(--position);top:12pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">FINANCIAL </span></div><div style="line-height:8pt;position:var(--position);top:21.6pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">INSTRUMENTS</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY 1, 2023</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:54.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.71pt"></span></span><span style="left:54.34pt;position:var(--position)">275<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:54.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.71pt"></span></span><span style="left:54.34pt;position:var(--position)">149<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:54.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.71pt"></span></span><span style="left:54.34pt;position:var(--position)">142<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:54.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:54.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.71pt"></span></span><span style="left:54.34pt;position:var(--position)">566<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:75.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(+) Issuance</span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:75.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:75.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:75.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:75.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">3,585<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:75.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:75.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)">3,585<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:87.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(+) Increase in fair value</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:87.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.71pt"></span></span><span style="left:54.34pt;position:var(--position)">986<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:87.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.71pt"></span></span><span style="left:54.34pt;position:var(--position)">440<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:87.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)">1,620<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:87.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:87.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:87.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)">3,046<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:99.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(-) Decrease in fair value</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:99.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:99.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:99.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:99.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(1,006)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:99.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:99.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:43.05pt"></span></span><span style="left:45.68pt;position:var(--position)">(1,006)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:111.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(-) Repurchases</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:111.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:49.05pt"></span></span><span style="left:51.68pt;position:var(--position)">(489)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:111.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:49.05pt"></span></span><span style="left:51.68pt;position:var(--position)">(339)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:111.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:43.05pt"></span></span><span style="left:45.68pt;position:var(--position)">(1,762)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:111.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:111.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:111.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:43.05pt"></span></span><span style="left:45.68pt;position:var(--position)">(2,591)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:123.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(-) Exercises</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:123.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:49.05pt"></span></span><span style="left:51.68pt;position:var(--position)">(771)</span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:123.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:49.05pt"></span></span><span style="left:51.68pt;position:var(--position)">(250)</span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:123.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:123.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:123.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:123.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:43.05pt"></span></span><span style="left:45.68pt;position:var(--position)">(1,021)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:135.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:135.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:135.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:135.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:135.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">2,579<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:135.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:135.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)">2,579<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:156.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(+) Issuance</span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:156.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:156.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:156.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:156.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:156.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)">2,158<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:156.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)">2,158<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:168.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(+) Increase in fair value</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:168.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:168.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:168.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:168.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:168.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)">1,462<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:168.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)">1,462<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:180.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(-) Decrease in fair value</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:180.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:180.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:180.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:180.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(1,413)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:180.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:180.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:43.05pt"></span></span><span style="left:45.68pt;position:var(--position)">(1,413)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:192.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:192.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:192.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:192.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:192.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">1,166<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:192.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)">3,620<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:192.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)">4,786<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:213.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(+) Increase in fair value</span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:213.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:213.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:213.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:213.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">29,935<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:213.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:213.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.71pt"></span></span><span style="left:44.34pt;position:var(--position)">29,935<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:225.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(-) Decrease in fair value</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:225.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:225.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:225.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:225.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:225.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:43.05pt"></span></span><span style="left:45.68pt;position:var(--position)">(3,620)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:225.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:43.05pt"></span></span><span style="left:45.68pt;position:var(--position)">(3,620)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:237.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(-) Repurchases</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:237.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:237.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:237.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:237.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(4,427)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:237.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:237.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:43.05pt"></span></span><span style="left:45.68pt;position:var(--position)">(4,427)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:249.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(-) Exercises</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:249.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:249.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:249.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:249.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.3pt"></span></span><span style="left:46.93pt;position:var(--position)">(26,674)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:249.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:249.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.05pt"></span></span><span style="left:41.68pt;position:var(--position)">(26,674)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:261.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:261.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:261.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:261.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:261.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:261.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:261.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:11pt;position:var(--position);top:614.66pt;width:612pt"><span style="font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:44pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:639.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Details related to these instruments' accounting treatments and terms and conditions are set forth in Notes 15.1 to 15.5.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:650.3pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The repurchases of the Kreos A&amp;B BSA (2023) and Kreos BSA (2025) were carried as part of the implementation of the cashless </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:661.5pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">exercises of these share warrants and were therefore not settled in cash.</span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 15.12. Breakdown of financial liabilities by maturity<span id="i93807e77712e4fd38fa20547dc122790"></span></span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:95.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The following are the remaining contractual maturities of financial liabilities as of December 31, 2023, 2024 and 2025. The amounts </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:107.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">are gross and undiscounted, and include contractual interest payments. </span></div><div style="position:var(--position);top:128.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:543pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:147pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:69pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:60.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:59.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63pt"></td></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:147pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.88pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td colspan="11" style="font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);width:393pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:393pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:145.75pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2023</span></div></div></div></td></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">CURRENT AND NON-CURRENT </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">FINANCIAL LIABILITIES</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:21pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.95pt;position:var(--position);text-decoration:none;white-space:pre">GROSS </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.29pt;position:var(--position);text-decoration:none;white-space:pre">AMOUNT </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:21pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.2pt;position:var(--position);text-decoration:none;white-space:pre">CONTRACTUAL </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.96pt;position:var(--position);text-decoration:none;white-space:pre">CASH FLOWS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:21pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.18pt;position:var(--position);text-decoration:none;white-space:pre">LESS THAN 1 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.18pt;position:var(--position);text-decoration:none;white-space:pre">YEAR</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:21pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.39pt;position:var(--position);text-decoration:none;white-space:pre">FROM 1 TO 2 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.83pt;position:var(--position);text-decoration:none;white-space:pre">YEARS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:21pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.64pt;position:var(--position);text-decoration:none;white-space:pre">FROM 2 TO 5 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.08pt;position:var(--position);text-decoration:none;white-space:pre">YEARS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:21pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:5.17pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.18pt;position:var(--position);text-decoration:none;white-space:pre">LONGER </span></div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.95pt;position:var(--position);text-decoration:none;white-space:pre">THAN 5 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.96pt;position:var(--position);text-decoration:none;white-space:pre">YEARS </span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Heights convertible notes</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:54pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.37pt;position:var(--position);text-decoration:none;white-space:pre">29,605</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:54pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.96pt"></span></span><span style="left:43.59pt;position:var(--position)">36,750<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:54pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:34.96pt"></span></span><span style="left:37.59pt;position:var(--position)">10,522<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:54pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.71pt"></span></span><span style="left:39.34pt;position:var(--position)">9,997<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:54pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:31.21pt"></span></span><span style="left:33.84pt;position:var(--position)">16,231<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:54pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos/Claret convertible notes (OCABSA)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:66pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.37pt;position:var(--position);text-decoration:none;white-space:pre">21,643</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:66pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.96pt"></span></span><span style="left:43.59pt;position:var(--position)">30,903<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:66pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)">2,250<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:66pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.71pt"></span></span><span style="left:39.34pt;position:var(--position)">2,250<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:66pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:31.21pt"></span></span><span style="left:33.84pt;position:var(--position)">26,403<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:66pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">PGE</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:78pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:42.37pt;position:var(--position);text-decoration:none;white-space:pre">3,678</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:78pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">3,880<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:78pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)">1,293<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:78pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.71pt"></span></span><span style="left:39.34pt;position:var(--position)">1,293<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:78pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.21pt"></span></span><span style="left:37.84pt;position:var(--position)">1,293<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:78pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Conditional advances Bpifrance</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:90pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:42.37pt;position:var(--position);text-decoration:none;white-space:pre">6,771</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:90pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">6,813<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:90pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)">3,697<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:90pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.71pt"></span></span><span style="left:39.34pt;position:var(--position)">1,490<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:90pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.21pt"></span></span><span style="left:37.84pt;position:var(--position)">1,626<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:90pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Royalty certificates</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:102pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.37pt;position:var(--position);text-decoration:none;white-space:pre">12,229</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:102pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.96pt"></span></span><span style="left:57.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:102pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:102pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.71pt"></span></span><span style="left:49.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:102pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.21pt"></span></span><span style="left:47.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:102pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:114pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Lease liabilities</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:114pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:48.37pt;position:var(--position);text-decoration:none;white-space:pre">540</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:114pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">575<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:114pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">406<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:114pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.71pt"></span></span><span style="left:45.34pt;position:var(--position)">162<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:114pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:49.21pt"></span></span><span style="left:51.84pt;position:var(--position)">7<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:114pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:126pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Derivative instruments</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:126pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:42.37pt;position:var(--position);text-decoration:none;white-space:pre">2,579</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:126pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">2,579<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:126pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)">2,579<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:126pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.71pt"></span></span><span style="left:49.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:126pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.21pt"></span></span><span style="left:47.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:126pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:138pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial liabilities </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:138pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:38.37pt;position:var(--position);text-decoration:none;white-space:pre">77,045</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:138pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.96pt"></span></span><span style="left:43.59pt;position:var(--position)">81,500<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:138pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:34.96pt"></span></span><span style="left:37.59pt;position:var(--position)">20,747<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:138pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:32.71pt"></span></span><span style="left:35.34pt;position:var(--position)">15,192<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:138pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:31.21pt"></span></span><span style="left:33.84pt;position:var(--position)">45,561<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:138pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:295.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:543pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:142.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:69pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:60pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:62.25pt"></td></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.63pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td colspan="11" style="font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);width:397.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:397.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:187.09pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:397.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:160.66pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">CURRENT AND NON-CURRENT </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">FINANCIAL LIABILITIES</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:21pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.33pt;position:var(--position);text-decoration:none;white-space:pre">GROSS </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.67pt;position:var(--position);text-decoration:none;white-space:pre">AMOUNT </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:21pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.2pt;position:var(--position);text-decoration:none;white-space:pre">CONTRACTUAL </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.96pt;position:var(--position);text-decoration:none;white-space:pre">CASH FLOWS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:21pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.56pt;position:var(--position);text-decoration:none;white-space:pre">LESS THAN 1 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.55pt;position:var(--position);text-decoration:none;white-space:pre">YEAR</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:21pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.89pt;position:var(--position);text-decoration:none;white-space:pre">FROM 1 TO 2 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.33pt;position:var(--position);text-decoration:none;white-space:pre">YEARS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:21pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.01pt;position:var(--position);text-decoration:none;white-space:pre">FROM 2 TO 5 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.46pt;position:var(--position);text-decoration:none;white-space:pre">YEARS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:21pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.17pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.8pt;position:var(--position);text-decoration:none;white-space:pre">LONGER </span></div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.58pt;position:var(--position);text-decoration:none;white-space:pre">THAN 5 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.58pt;position:var(--position);text-decoration:none;white-space:pre">YEARS </span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Heights convertible notes</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:54pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">21,574<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:54pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.96pt"></span></span><span style="left:43.59pt;position:var(--position)">24,063<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:54pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)">8,750<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:54pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)">8,750<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:54pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.96pt"></span></span><span style="left:38.59pt;position:var(--position)">6,563<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:54pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:20.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.26pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos/Claret convertible notes </span></div><div style="line-height:8pt;position:var(--position);top:11.86pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(OCABSA)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:66pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.06pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">23,370<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:66pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:7.06pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.96pt"></span></span><span style="left:43.59pt;position:var(--position)">30,653<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:66pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.06pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)">2,250<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:66pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.06pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">19,943<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:66pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.06pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.96pt"></span></span><span style="left:38.59pt;position:var(--position)">8,460<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:66pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.06pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:86.25pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos/Claret bond loans</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:86.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">46,401<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:86.25pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.96pt"></span></span><span style="left:43.59pt;position:var(--position)">58,080<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:86.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">24,016<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:86.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">25,715<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:86.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.96pt"></span></span><span style="left:38.59pt;position:var(--position)">8,348<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:86.25pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:98.25pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">PGE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:98.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)">2,488<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:98.25pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">2,586<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:98.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)">1,293<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:98.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)">1,293<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:98.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.96pt"></span></span><span style="left:48.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:98.25pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:110.25pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Royalty certificates (1)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:110.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">13,023<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:110.25pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.96pt"></span></span><span style="left:57.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:110.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:49.71pt"></span></span><span style="left:52.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:110.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:49.71pt"></span></span><span style="left:52.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:110.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.96pt"></span></span><span style="left:48.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:110.25pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:122.25pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Lease liabilities</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:122.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)">2,363<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:122.25pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">2,512<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:122.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)">993<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:122.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)">996<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:122.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.96pt"></span></span><span style="left:44.59pt;position:var(--position)">516<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:122.25pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">7<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:134.25pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Derivative instruments</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:134.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)">4,786<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:134.25pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">4,786<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:134.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)">1,166<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:134.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:49.71pt"></span></span><span style="left:52.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:134.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.96pt"></span></span><span style="left:38.59pt;position:var(--position)">3,620<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:134.25pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:146.25pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial liabilities </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:146.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:31.71pt"></span></span><span style="left:34.34pt;position:var(--position)">114,004<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:146.25pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">122,680<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:146.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">38,468<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:146.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">56,698<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:146.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:31.96pt"></span></span><span style="left:34.59pt;position:var(--position)">27,507<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:146.25pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">7<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:470.81pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:543pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:141.75pt"></td><td style="padding:0;width:63pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:71.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63pt"></td></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:141.75pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:141.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.25pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td colspan="11" style="font-size:0;text-align:left;vertical-align:top"><div style="left:141.75pt;position:var(--position);width:401.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:401.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:149.88pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2025</span></div></div></div></td></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21pt;width:141.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:141.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">CURRENT AND NON-CURRENT </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:141.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">FINANCIAL LIABILITIES</span></div></div></div></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:141.75pt;position:var(--position);top:21pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.95pt;position:var(--position);text-decoration:none;white-space:pre">GROSS </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.29pt;position:var(--position);text-decoration:none;white-space:pre">AMOUNT </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:207.75pt;position:var(--position);top:21pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.32pt;position:var(--position);text-decoration:none;white-space:pre">CONTRACTUAL </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.09pt;position:var(--position);text-decoration:none;white-space:pre">CASH FLOWS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:282pt;position:var(--position);top:21pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.18pt;position:var(--position);text-decoration:none;white-space:pre">LESS THAN 1 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.18pt;position:var(--position);text-decoration:none;white-space:pre">YEAR</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:348pt;position:var(--position);top:21pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.51pt;position:var(--position);text-decoration:none;white-space:pre">FROM 1 TO 2 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.96pt;position:var(--position);text-decoration:none;white-space:pre">YEARS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:414pt;position:var(--position);top:21pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.51pt;position:var(--position);text-decoration:none;white-space:pre">FROM 2 TO 5 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.96pt;position:var(--position);text-decoration:none;white-space:pre">YEARS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:21pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:5.17pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.18pt;position:var(--position);text-decoration:none;white-space:pre">LONGER </span></div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.95pt;position:var(--position);text-decoration:none;white-space:pre">THAN 5 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.96pt;position:var(--position);text-decoration:none;white-space:pre">YEARS </span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66pt;width:141.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:141.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Royalty certificates</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:141.75pt;position:var(--position);top:66pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:34.96pt"></span></span><span style="left:37.59pt;position:var(--position)">30,237<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:207.75pt;position:var(--position);top:66pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:57.21pt"></span></span><span style="left:59.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282pt;position:var(--position);top:66pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:348pt;position:var(--position);top:66pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:414pt;position:var(--position);top:66pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:66pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78pt;width:141.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:141.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Lease liabilities</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:141.75pt;position:var(--position);top:78pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)">1,856<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:207.75pt;position:var(--position);top:78pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)">1,906<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282pt;position:var(--position);top:78pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)">1,340<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:348pt;position:var(--position);top:78pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">450<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:414pt;position:var(--position);top:78pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">116<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:78pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90.75pt;width:141.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:141.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial liabilities </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:141.75pt;position:var(--position);top:90.75pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:34.96pt"></span></span><span style="left:37.59pt;position:var(--position)">32,093<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:207.75pt;position:var(--position);top:90.75pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)">1,906<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282pt;position:var(--position);top:90.75pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)">1,340<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:348pt;position:var(--position);top:90.75pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">450<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:414pt;position:var(--position);top:90.75pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">116<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:90.75pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:11pt;position:var(--position);top:578.56pt;width:612pt"><span style="font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:591.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The contractual cash flows above do not include potential future royalty payments related to the royalty certificates, amounting to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:556.99pt;position:var(--position);text-decoration:none;white-space:pre">2%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:570.32pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:602.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of the future net sales of obefazimod (worldwide and for all indications). The amount of royalties that may be paid under the royalty </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:614.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">certificates is capped at </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:131.93pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;172.0&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:190.78pt;position:var(--position);text-decoration:none;white-space:pre"> in the aggregate. Royalty payments are expected to take place before the expiry date of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:625.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">certificates, which is </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.86pt;position:var(--position);text-decoration:none;white-space:pre">15 years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:154.44pt;position:var(--position);text-decoration:none;white-space:pre"> after their issuance date (September 2, 2037), and would be included in the "from 2 to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:502.88pt;position:var(--position);text-decoration:none;white-space:pre">5 years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:531.46pt;position:var(--position);text-decoration:none;white-space:pre">" and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:636.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">"longer than 5 years" maturity categories according to management's projections.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement benefit obligations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract', window );"><strong>Disclosure of defined benefit plans [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory', window );">Retirement benefit obligations</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Retirement benefit obligations</span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:90.36pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:42pt;position:var(--position);text-decoration:none;white-space:pre">Retirement benefit obligations include the liability for the defined benefit plan, measured based on the provisions stipulated </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:102.36pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:42pt;position:var(--position);text-decoration:none;white-space:pre">under the applicable collective agreements, i.e. the French pharmaceutical industry&#8217;s collective agreement. This commitment </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:114.36pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:42pt;position:var(--position);text-decoration:none;white-space:pre">only applies to employees subject to French law. </span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:239.28pt;position:var(--position);text-decoration:none;white-space:pre">The main actuarial assumptions used to measure the retirement benefit </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.36pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:42pt;position:var(--position);text-decoration:none;white-space:pre">obligations are as follows:</span></div><div style="position:var(--position);top:150.36pt;width:612pt"><div style="font-size:0pt;left:42pt;position:var(--position);width:480.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:159.75pt"></td><td style="padding:0;width:105pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:105pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:105pt"></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:159.75pt"><div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:159.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">ACTUARIAL ASSUMPTIONS</span></div></div></div></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:159.75pt;position:var(--position);width:105pt"><div><div style="line-height:8pt;position:var(--position);top:7.57pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.19pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:17.17pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);width:105pt"><div><div style="line-height:8pt;position:var(--position);top:7.57pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.19pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:17.17pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);width:105pt"><div><div style="line-height:8pt;position:var(--position);top:7.57pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.19pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:17.17pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td></tr><tr style="height:30.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:30.75pt;width:159.75pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:159.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Retirement age</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:159.75pt;position:var(--position);top:30.75pt;width:105pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:7.51pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:3.09pt;position:var(--position);text-decoration:none;white-space:pre">65 years</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:29.96pt;position:var(--position);text-decoration:none;white-space:pre"> for key management / </span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:17.11pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:6.09pt;position:var(--position);text-decoration:none;white-space:pre">63 years</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:32.96pt;position:var(--position);text-decoration:none;white-space:pre"> for other employees</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:30.75pt;width:105pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:7.51pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:3.09pt;position:var(--position);text-decoration:none;white-space:pre">65 years</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:29.96pt;position:var(--position);text-decoration:none;white-space:pre"> for key management / </span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:17.11pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:6.09pt;position:var(--position);text-decoration:none;white-space:pre">64 years</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:32.96pt;position:var(--position);text-decoration:none;white-space:pre"> for other employees</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:30.75pt;width:105pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:7.51pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:3.09pt;position:var(--position);text-decoration:none;white-space:pre">65 years</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:29.96pt;position:var(--position);text-decoration:none;white-space:pre"> for key management / </span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:17.11pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:6.09pt;position:var(--position);text-decoration:none;white-space:pre">64 years</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:32.96pt;position:var(--position);text-decoration:none;white-space:pre"> for other employees</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:61.5pt;width:159.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:159.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Collective agreement</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:159.75pt;position:var(--position);top:61.5pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:13.75pt;position:var(--position);text-decoration:none;white-space:pre">Pharmaceutical&#160;industry</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:61.5pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:13.75pt;position:var(--position);text-decoration:none;white-space:pre">Pharmaceutical&#160;industry</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:61.5pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:13.75pt;position:var(--position);text-decoration:none;white-space:pre">Pharmaceutical&#160;industry</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:73.5pt;width:159.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:159.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Discount Rate (IBoxx Corporates AA)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:159.75pt;position:var(--position);top:73.5pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:43.11pt;position:var(--position);text-decoration:none;white-space:pre">0.90%</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:73.5pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:43.11pt;position:var(--position);text-decoration:none;white-space:pre">3.34%</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:73.5pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:43.11pt;position:var(--position);text-decoration:none;white-space:pre">3.70%</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:85.5pt;width:159.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:159.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Mortality rate table</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:159.75pt;position:var(--position);top:85.5pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:22.85pt;position:var(--position);text-decoration:none;white-space:pre">INSEE 2016-2018 </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:85.5pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:22.85pt;position:var(--position);text-decoration:none;white-space:pre">INSEE 2016-2018 </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:85.5pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:22.85pt;position:var(--position);text-decoration:none;white-space:pre">INSEE 2016-2018 </span></div></div></div></td></tr><tr style="height:42pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:97.5pt;width:159.75pt"><div><div style="line-height:8pt;position:var(--position);top:17.93pt;width:159.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Salary increase rate</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:159.75pt;position:var(--position);top:97.5pt;width:105pt"><div><div style="font-size:12pt;line-height:9pt;position:var(--position);top:11.85pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:6.04pt;position:var(--position);text-decoration:none;white-space:pre">3%</span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:18.03pt;position:var(--position);white-space:pre"> for key management / </span></div><div style="font-size:12pt;line-height:9pt;position:var(--position);top:23.1pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:3.79pt;position:var(--position);text-decoration:none;white-space:pre">2.55%</span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.029999999999998pt;position:var(--position);white-space:pre"> for other employees</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:97.5pt;width:105pt"><div><div style="font-size:12pt;line-height:9pt;position:var(--position);top:11.85pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:6.04pt;position:var(--position);text-decoration:none;white-space:pre">3%</span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:18.03pt;position:var(--position);white-space:pre"> for key management / </span></div><div style="font-size:12pt;line-height:9pt;position:var(--position);top:23.1pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:3.79pt;position:var(--position);text-decoration:none;white-space:pre">2.55%</span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.029999999999998pt;position:var(--position);white-space:pre"> for other employees</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:97.5pt;width:105pt"><div><div style="line-height:9pt;position:var(--position);top:17.47pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:41.82pt;position:var(--position);text-decoration:none;white-space:pre">3.00%</span></div></div></div></td></tr><tr style="height:56.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:139.5pt;width:159.75pt"><div><div style="line-height:8pt;position:var(--position);top:25.06pt;width:159.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Turnover rate</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:159.75pt;position:var(--position);top:139.5pt;width:105pt"><div><div style="font-size:12pt;line-height:9pt;position:var(--position);top:13.35pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:5.3pt;position:var(--position);white-space:pre">Decreasing from </span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:67.72pt;position:var(--position);text-decoration:none;white-space:pre">5.80%</span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:90.96pt;position:var(--position);white-space:pre"> at </span></div><div style="font-size:12pt;line-height:9pt;position:var(--position);top:24.6pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.91pt;position:var(--position);white-space:pre">20 years-old to </span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:59.120000000000005pt;position:var(--position);text-decoration:none;white-space:pre">0.05%</span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:82.36pt;position:var(--position);white-space:pre"> from </span></div><div style="line-height:9pt;position:var(--position);top:35.85pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.14pt;position:var(--position);white-space:pre">55 years-old</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:139.5pt;width:105pt"><div><div style="line-height:9pt;position:var(--position);top:7.72pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:9.68pt;position:var(--position);white-space:pre">Decreasing rates by age </span></div><div style="font-size:12pt;line-height:9pt;position:var(--position);top:18.97pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:13.16pt;position:var(--position);white-space:pre">and </span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:28.4pt;position:var(--position);text-decoration:none;white-space:pre">zero</span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:43.870000000000005pt;position:var(--position);white-space:pre"> from age 55, </span></div><div style="line-height:9pt;position:var(--position);top:30.22pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:5.18pt;position:var(--position);white-space:pre">generating an average exit </span></div><div style="font-size:12pt;line-height:9pt;position:var(--position);top:41.47pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:11.66pt;position:var(--position);white-space:pre">rate for 2025 of </span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:70.1pt;position:var(--position);text-decoration:none;white-space:pre">2.05%</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:139.5pt;width:105pt"><div><div style="line-height:9pt;position:var(--position);top:7.72pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:9.68pt;position:var(--position);white-space:pre">Decreasing rates by age </span></div><div style="font-size:12pt;line-height:9pt;position:var(--position);top:18.97pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:13.16pt;position:var(--position);white-space:pre">and </span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:28.4pt;position:var(--position);text-decoration:none;white-space:pre">zero</span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:43.870000000000005pt;position:var(--position);white-space:pre"> from age 55, </span></div><div style="line-height:9pt;position:var(--position);top:30.22pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:5.18pt;position:var(--position);white-space:pre">generating an average exit </span></div><div style="font-size:12pt;line-height:9pt;position:var(--position);top:41.47pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:10.53pt;position:var(--position);white-space:pre">rate for 2025 of </span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:68.97pt;position:var(--position);text-decoration:none;white-space:pre">2.02%</span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:92.21000000000001pt;position:var(--position);white-space:pre">.</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:195.75pt;width:159.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:159.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Employee contribution rate</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:159.75pt;position:var(--position);top:195.75pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.11pt;position:var(--position);text-decoration:none;white-space:pre">45%</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:195.75pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.11pt;position:var(--position);text-decoration:none;white-space:pre">45%</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:195.75pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.11pt;position:var(--position);text-decoration:none;white-space:pre">45%</span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:374.41pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:42pt;position:var(--position);text-decoration:none;white-space:pre">Changes in the projected benefit obligation for the periods presented were as follows:</span></div><div style="font-size:12pt;line-height:11pt;position:var(--position);top:393.71pt;width:612pt"><span style="font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="position:var(--position);top:402.51pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:321.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:153.75pt"></td><td style="padding:0;width:168pt"></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:39.67pt;position:var(--position);text-decoration:none;white-space:pre">(In thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);width:168pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.72pt;position:var(--position);text-decoration:none;white-space:pre">RETIREMENT BENEFIT OBLIGATIONS</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY 1, 2023</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:12pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:149.96pt"></span></span><span style="left:152.59pt;position:var(--position)">610<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:33pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Service cost </span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:33pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:149.96pt"></span></span><span style="left:152.59pt;position:var(--position)">109<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:45pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.56pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest cost </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:45pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:2.56pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:153.96pt"></span></span><span style="left:156.59pt;position:var(--position)">23<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:56.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Actuarial gains and losses </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:56.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:147.3pt"></span></span><span style="left:149.93pt;position:var(--position)">(112)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:68.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:68.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:149.96pt"></span></span><span style="left:152.59pt;position:var(--position)">629<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:89.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Service cost </span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:89.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:149.96pt"></span></span><span style="left:152.59pt;position:var(--position)">115<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:101.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest cost </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:101.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:153.96pt"></span></span><span style="left:156.59pt;position:var(--position)">22<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:113.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Benefits paid</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:113.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:151.3pt"></span></span><span style="left:153.93pt;position:var(--position)">(41)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:125.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Actuarial gains and losses </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:125.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:153.96pt"></span></span><span style="left:156.59pt;position:var(--position)">31<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:137.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:137.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:149.96pt"></span></span><span style="left:152.59pt;position:var(--position)">756<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:158.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Current service cost </span></div></div></div></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:158.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:149.96pt"></span></span><span style="left:152.59pt;position:var(--position)">141<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:170.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Past services cost</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:170.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:147.3pt"></span></span><span style="left:149.93pt;position:var(--position)">(205)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:182.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest cost </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:182.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:153.96pt"></span></span><span style="left:156.59pt;position:var(--position)">29<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:194.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Actuarial gains and losses </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:194.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:151.3pt"></span></span><span style="left:153.93pt;position:var(--position)">(93)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:206.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:206.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:149.96pt"></span></span><span style="left:152.59pt;position:var(--position)">627<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:642.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Employees in the U.S. benefit from defined contribution plans (401(k)).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for employee benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IAS19_g2-7_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Payables and other current liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract', window );"><strong>Trade and other current payables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">Payables and other current liabilities</a></td>
<td class="text"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:79.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Payables and other current liabilities</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 17.1. Trade payables and other current liabilities<span id="ic8bc591b9eda49aa9427069a2f444203"></span></span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:705.76pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:42pt;position:var(--position);text-decoration:none;white-space:pre">Trade payables and other current liabilities break down as follows:</span></div><div style="position:var(--position);top:84.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:447pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:200.25pt"></td><td style="padding:0;width:80.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:48.59pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">TRADE PAYABLES AND OTHER CURRENT </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:200.25pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:366.75pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:33pt;width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Trade payables </span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:200.25pt;position:var(--position);top:33pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">21,953<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:280.5pt;overflow:hidden;position:var(--position);top:33pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:33pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">30,748<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:363.75pt;overflow:hidden;position:var(--position);top:33pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:366.75pt;position:var(--position);top:33pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">23,388<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:45pt;width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Accrued invoices</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:200.25pt;position:var(--position);top:45pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">25,268<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:280.5pt;overflow:hidden;position:var(--position);top:45pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:45pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">13,049<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:363.75pt;overflow:hidden;position:var(--position);top:45pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:366.75pt;position:var(--position);top:45pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">14,159<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:57pt;width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:200.25pt;position:var(--position);top:57pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:280.5pt;overflow:hidden;position:var(--position);top:57pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:57pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)">26<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:363.75pt;overflow:hidden;position:var(--position);top:57pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:366.75pt;position:var(--position);top:57pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:70.21pt"></span></span><span style="left:72.83999999999999pt;position:var(--position)">4<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:69pt;width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Trade payables and other current liabilities</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:200.25pt;position:var(--position);top:69pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">47,221<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:280.5pt;overflow:hidden;position:var(--position);top:69pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:69pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">43,824<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:363.75pt;overflow:hidden;position:var(--position);top:69pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:366.75pt;position:var(--position);top:69pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">37,552<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:185.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">No discount was applied to payables and related accounts for which maturity does not exceed one year. As a result, their fair value </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:196.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">approximates their carrying amount. </span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 17.2. Tax and employee-related payables<span id="i66385b0b949642f7af2ce7ab417684b3"></span></span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:256.9pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">Tax and employee-related payables are presented below:</span></div><div style="font-size:12pt;line-height:11pt;position:var(--position);top:268.2pt;width:612pt"><span style="font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="position:var(--position);top:279.53pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:441.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:195pt"></td><td style="padding:0;width:80.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:195pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:195pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:45.96pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:195pt"><div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:195pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">TAX AND EMPLOYEE-RELATED PAYABLES</span></div></div></div></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:195pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.92pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.52pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:278.25pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.92pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.52pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:361.5pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.92pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.52pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:195pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:195pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Employee-related payables</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:195pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.87pt"></span></span><span style="left:61.5pt;position:var(--position)">3,694</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:278.25pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.87pt"></span></span><span style="left:61.5pt;position:var(--position)">2,742</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:361.5pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">4,816<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:195pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:195pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Social security and other</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:195pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.87pt"></span></span><span style="left:61.5pt;position:var(--position)">2,251</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:278.25pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.87pt"></span></span><span style="left:61.5pt;position:var(--position)">1,783</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:361.5pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">2,304<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:195pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:195pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other tax and related payments</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:195pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:64.87pt"></span></span><span style="left:67.5pt;position:var(--position)">127</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:278.25pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:64.87pt"></span></span><span style="left:67.5pt;position:var(--position)">184</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:361.5pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)">17<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:195pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:195pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">TAX AND EMPLOYEE-RELATED PAYABLES</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:195pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:58.87pt"></span></span><span style="left:61.5pt;position:var(--position)">6,073</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:278.25pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:58.87pt"></span></span><span style="left:61.5pt;position:var(--position)">4,709</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:361.5pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">7,137<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:385.28pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43.1pt;position:var(--position);text-decoration:none;white-space:pre">The increase in employee-related, social security and other payables over the year ended December 31, 2025 is mainly related to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:396.48pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43.1pt;position:var(--position);text-decoration:none;white-space:pre">year-end bonus accruals.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other operating income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenue [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory', window );">Other operating income</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Other operating income</span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:456.28pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Other operating income is composed as below:</span></div><div style="font-size:12pt;position:var(--position);top:478.28pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"> </span><div style="font-size:0pt;left:38.5pt;position:var(--position);width:381pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:134.25pt"></td><td style="padding:0;width:80.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:15.59pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">OPERATING INCOME</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:134.25pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:300.75pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Research tax credit ("CIR")</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:134.25pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">4,493<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">6,651<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:300.75pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">3,061<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Subsidies</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:134.25pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)">81<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">4,140<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:300.75pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Depositary service fees</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:134.25pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">1,634<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:300.75pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">1,509<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:134.25pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)">47<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)">23<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:300.75pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90.75pt;width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total operating income</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:134.25pt;position:var(--position);top:90.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">4,621<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:90.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">12,449<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:300.75pt;position:var(--position);top:90.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">4,570<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:597.05pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Operating income is composed as follows: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:619.45pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Research tax credit (&#8220;CIR&#8221;) </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:641.85pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group carries out research and development projects. As such, it has benefited from a research tax credit for the years ended </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:653.05pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Decem</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:64.28pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">ber 31, 2023, 2024 and 2025 for an</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:205.06pt;position:var(--position);text-decoration:none;white-space:pre"> amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:250.86pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;4,493&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:316.95pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:321.95pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5,668&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:388.04pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:407.47pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3,197&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:473.56pt;position:var(--position);text-decoration:none;white-space:pre">, respectively (see Note </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:664.25pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">4.9). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:675.45pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">During the year ended December 31, 2024, the Group also received an additional tax credit payment related to the 2021 tax year for an </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:686.65pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:79.3pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;984&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:137.89pt;position:var(--position);text-decoration:none;white-space:pre"> after a claim from the Group following a clarification of "public subsidy" definition.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:697.85pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The lower amount of CIR recognized in 2025 is mainly due to (i)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:296.85pt;position:var(--position);text-decoration:none;white-space:pre"> the maximum amount of eligible outsourced research and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:709.05pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">development expenses being capped, (ii) a decrease in internal research and development costs, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:420.21pt;position:var(--position);text-decoration:none;white-space:pre">(iii) the reimbursement of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">CARENA and RNP-VIR conditional advances, deducted from the 2024 CIR calculation and (iv) a change in the CIR regulation </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:81.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">related to eligible expenses.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:104.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Subsidies</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Subsidies primarily relate to the Bpifrance RNP-VIR and CARENA conditional advances, the repayments of which were partly </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:137.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">waived by Bpifrance in June 2024, for </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:191.98pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,872&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:258.07pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:277.5pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;2,251&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:343.59pt;position:var(--position);text-decoration:none;white-space:pre"> respectively (see Notes 3.3 and 15.7).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:160.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Depositary services fees </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:182.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">For the years ended December 31, 2024 and 2025, this line item includes issuance, cancellation and depositary service fees collected </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:194.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">from ADS holders by Citibank, who is acting as the Group's exclusive depositary for its publicly listed ADSs. As part of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:205.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">depositary agreement between Citibank and the Group, the latter is entitled to receive a portion of the aforementioned fees collected </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:216.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">by Citibank. The amounts recognized for the years ended December 31, 2024 and 2025 reflect the large amounts of ADS transactions </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:227.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">following, respectively, (i) the Group's </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:193.48pt;position:var(--position);text-decoration:none;white-space:pre">Initial Public Offering on the Nasdaq Global Market</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:402.97pt;position:var(--position);text-decoration:none;white-space:pre"> in October 2023 and (ii) the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:238.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">announcement of Phase 3 results and the Group's Offering in July 2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNatureAbstract', window );"><strong>Expenses by nature [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory', window );">Operating expenses</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Operating expenses</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 19.1. Sales and marketing<span id="i3c9108f67d8f42d7b78379593d90f92b"></span></span><div style="position:var(--position);top:355.69pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:474pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:224.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:60.59pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">SALES AND MARKETING</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Personnel costs</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">1,710<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">2,323<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">3,347<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Consulting and professional fees </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:224.25pt;overflow:hidden;position:var(--position);top:54.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">4,012<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">2,699<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">1,623<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other sales and marketing expenses</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:224.25pt;overflow:hidden;position:var(--position);top:66.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)">709<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)">932<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)">224<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Sales &amp; Marketing</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:224.25pt;overflow:hidden;position:var(--position);top:78.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">6,431<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">5,954<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">5,194<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:461.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Sales and marketing expenses consist primarily of personnel expenses, including salaries, benefits, and share-based compensation </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:471.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">expenses, for employees engaged in sales and marketing activities, as well as consulting costs associated with market research in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:481.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">preparation for the Group's potential future sales and commercialization efforts in the U.S. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:503.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The decrease for the year ended was primarily </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:223.52pt;position:var(--position);text-decoration:none;white-space:pre">driven by the reduction in the headcount of the Group's sales and marketing department </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:515.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">part way through 2024. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:539.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The increase in personnel costs for the year ended December 31, 2025 is primarily driven by taxes and social contributions related to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:551.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">AGAs (see Note 14), while the decrease in consulting and professional fees is mainly explained by one-time costs that were incurred </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:563.44pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in 2024 for the Group's corporate re-branding, including its new website.</span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 19.2. Research and development<span id="ic2e4d6b2de844eaa908459b8d08cd756"></span></span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:626.74pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Research and development expenses break down as follows: </span></div><div style="position:var(--position);top:70.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:474pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:224.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:60.59pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">RESEARCH AND DEVELOPMENT EXPENSES</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Sub-contracting, studies and research</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">85,726<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)">110,993<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)">112,033<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Personnel costs</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">8,048<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">18,455<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">49,616<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Consulting and professional fees </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">6,561<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">12,581<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">12,791<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Intellectual property fees</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">1,645<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">1,741<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">1,025<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other research and development expenses</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:90.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">1,196<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:90.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">2,761<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:90.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">2,297<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Research and development expenses </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:102.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)">103,176<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:102.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)">146,532<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:102.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)">177,761<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:224.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Research and development expenses consist primarily of the following items: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:240.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Personnel expenses, including salaries, benefits, and share-based compensation expenses, for employees engaged in </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:250.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">research and development activities; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:266.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Sub-contracting, collaboration and consultant expenses that primarily include the cost of third-party contractors such as </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:276.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">CROs who conduct our non-clinical studies and clinical trials, and research related to proprietary platforms, as well as </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:286.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">investigative sites and consultants that conduct our preclinical studies and clinical trials; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:302.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Expenses incurred under agreements with contract manufacturing organizations (&#8220;CMOs&#8221;), including manufacturing </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:312.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">scale-up expenses and the cost of acquiring and manufacturing preclinical study and clinical trial materials; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:328.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Expenses relating to preclinical studies and clinical trials; </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:344.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Expenses relating to regulatory affairs; </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:360.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Allocated expenses for facility costs, including rent, utilities and maintenance; and </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:376.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Expenses relating to the implementation of the quality assurance system. </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:409.51pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The increase in research and development expenses for the years ended December 31, 2024 and 2025 is primarily due to (i) the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:420.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">increase in UC expenses (of respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:201.34pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;32,030 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:272.43pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:291.86pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,587</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:319.36pt;position:var(--position);text-decoration:none;white-space:pre"> thousand), due to the progress of Phase 3 clinical trials for </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:431.91pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">obefazimod in UC, (ii) the increase in CD expenses (of respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:309.55pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;4,620 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:375.64pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:395.07pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;10,200</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:427.57pt;position:var(--position);text-decoration:none;white-space:pre"> thousand), due to the planning costs </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:443.11pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and progression of the Phase 2b CD trial, (iii) the increase in transversal activities of respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:426.89pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;8,233 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:492.98pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:512.4100000000001pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12,987</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:544.9100000000001pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:454.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">thousand) related to (a) the overall expansion of the research and development headcount to support the Group's organizational growth </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:465.51pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and the issuance of new equity awards to officers and employees in research and development for the year ended December 31, 2024 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:476.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and (b) increased chemistry, manufacturing and controls ("CMC") and supply chain costs related to the progression of clinical trials </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:487.91pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and anticipation of future commercial launch for the year ended December 31, 2025, and (iv) the development of new indications for </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:499.11pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">obefazimod, including the combination therapy (increasing by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:287.38pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;4,122&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:353.47pt;position:var(--position);text-decoration:none;white-space:pre"> for the year ended December 31, 2025).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:521.51pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">These increases for the year ended December 31, 2025 also resulted from increasing p</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:380.59pt;position:var(--position);text-decoration:none;white-space:pre">ersonnel costs, mainly explained by the rise in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:532.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">employer tax and social contributions related to AGAs by</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:266.86pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:269.36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;20,131 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:340.45pt;position:var(--position);text-decoration:none;white-space:pre">, resulting predominantly from (i) the uptick in the Group's </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:543.91pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">share price during the second half of 2025 (see Note 14), and to a lesser extent by (ii) the increase in the employer contribution rate on </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:555.11pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">AGAs in France.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:566.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 19.3. General and administrative<span id="ia87a43e321ec4db3a0cdfb8251386316"></span></span><span style="font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:198.66pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span><div style="position:var(--position);top:618.14pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:474pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:224.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:60.59pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">GENERAL AND ADMINISTRATIVE EXPENSES</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Personnel costs</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">13,105<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">19,434<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">52,817<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Consulting and professional fees </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">6,393<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">7,990<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">9,984<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other general and administrative expenses </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">2,893<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">5,522<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">4,870<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">General and administrative expenses </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">22,391<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">32,946<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">67,670<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:94.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">General and administrative expenses consist primarily of personnel-related expenses, including salaries, benefits and share-based </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:104.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">compensation expenses, for personnel other than employees engaged in research and development activities. General and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:114.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">administrative expenses also include fees for professional services, mainly related to audit and legal services, consulting costs, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:124.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">communications and travel costs, allocated expenses for facility costs, including rent, utilities and maintenance, directors&#8217; attendance </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:134.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">fees, and insurance costs. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:156.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The increase in general and administrative expenses for the year ended December 31, 2024 was primarily due to the increase in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:167.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">personnel costs,</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:99.83pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:102.33pt;position:var(--position);text-decoration:none;white-space:pre">representing</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:151.70999999999998pt;position:var(--position);text-decoration:none;white-space:pre"> the full year impact of the build out of the Group's general and administrative organization (increased </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:178.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">headcount and equity based compensation costs), which started in late 2023 to support the expansion of the Group, as well as </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:190.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">increased legal and professional fees and other costs associated with operating as a dual-listed public company.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:212.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.94pt">The increase for the year ended December 31, 2025 was primarily due to an increase in personnel costs, mainly explained by the</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.94pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:223.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:280.6pt">increase in employer tax and social contributions related to AGAs by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:316.6pt;position:var(--position);text-decoration:none;white-space:pre;width:71.25pt">&#8364;27,299 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:387.85pt;position:var(--position);text-decoration:none;white-space:pre;width:8.49pt">, r</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:396.34pt;position:var(--position);text-decoration:none;white-space:pre;width:179.66pt">esulting predominantly from (i) the uptick in</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:576pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:234.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:297.46pt">the Group's share price during the second half of 2025 (see Note 14), </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:333.46pt;position:var(--position);text-decoration:none;white-space:pre;width:242.36pt">and to a lesser extent by (ii) the increase in the employer</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.82pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:246.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.84pt">contribution rate on AGAs in France, as well as an increase in legal and professional fees associated with building the Group's</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.84pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:257.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:222.57pt">infrastructure to support future growth in its operations.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:279.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group's principal audit fees paid to its joint statutory auditors PricewaterhouseCoopers Audit and Agili3f, are set forth below:</span></div><div style="position:var(--position);top:303.76pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:524.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:275.25pt"></td><td style="padding:0;width:81pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:81pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:81pt"></td></tr><tr style="height:34.5pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:275.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.18pt;width:275.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:86.09pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:275.25pt;position:var(--position);width:81pt"><div><div style="line-height:8pt;position:var(--position);top:4.65pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.19pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:14.25pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:23.85pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.5pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:359.25pt;position:var(--position);width:81pt"><div><div style="line-height:8pt;position:var(--position);top:4.65pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.19pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:14.25pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:23.85pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.5pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:443.25pt;position:var(--position);width:81pt"><div><div style="line-height:8pt;position:var(--position);top:4.65pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.19pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:14.25pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:23.85pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.5pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:34.5pt;width:275.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:275.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Audit fees</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:275.25pt;position:var(--position);top:34.5pt;width:81pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)">1,848<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:359.25pt;position:var(--position);top:34.5pt;width:81pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)">1,144<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:443.25pt;position:var(--position);top:34.5pt;width:81pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)">1,255<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:46.5pt;width:275.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:275.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Audit-related fees</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:359.25pt;position:var(--position);top:46.5pt;width:81pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:70.37pt;position:var(--position);text-decoration:none;white-space:pre">82</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:443.25pt;position:var(--position);top:46.5pt;width:81pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.96pt"></span></span><span style="left:65.59pt;position:var(--position)">129<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:58.5pt;width:275.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:275.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Tax fees</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:70.5pt;width:275.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:275.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">All other fees</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:275.25pt;position:var(--position);top:70.5pt;width:81pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.96pt"></span></span><span style="left:65.59pt;position:var(--position)">492<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:359.25pt;position:var(--position);top:70.5pt;width:81pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:70.96pt"></span></span><span style="left:73.58999999999999pt;position:var(--position)">7<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:443.25pt;position:var(--position);top:70.5pt;width:81pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.96pt"></span></span><span style="left:69.58999999999999pt;position:var(--position)">34<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:82.5pt;width:275.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.87pt;width:275.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:275.25pt;position:var(--position);top:82.5pt;width:81pt"><div><div style="line-height:8pt;position:var(--position);top:4.87pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:60.37pt;position:var(--position);text-decoration:none;white-space:pre">2,340</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:359.25pt;position:var(--position);top:82.5pt;width:81pt"><div><div style="line-height:8pt;position:var(--position);top:4.87pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:60.37pt;position:var(--position);text-decoration:none;white-space:pre">1,233</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:443.25pt;position:var(--position);top:82.5pt;width:81pt"><div><div style="line-height:8pt;position:var(--position);top:4.87pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:60.37pt;position:var(--position);text-decoration:none;white-space:pre">1,418</span></div></div></div></td></tr></tbody></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNatureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNatureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employees<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberAndAverageNumberOfEmployeesAbstract', window );"><strong>Number and average number of employees [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory', window );">Employees</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Employees</span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:450.51pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">The Group&#8217;s average workforce during the periods ended December 31, 2023, 2024 and 2025 was as follows:</span></div><div style="position:var(--position);top:472.26pt;width:612pt"><div style="font-size:0pt;left:43pt;position:var(--position);width:360pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:88.5pt"></td><td style="padding:0;width:88.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:88.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:88.5pt"></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">HEADCOUNT</span></div></div></div></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:88.5pt;position:var(--position);width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.57pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.94pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:17.17pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.16pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:180pt;position:var(--position);width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.57pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.94pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:17.17pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.16pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:271.5pt;position:var(--position);width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.57pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.94pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:17.17pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.16pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:30.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">France </span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:88.5pt;position:var(--position);top:30.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.87pt;position:var(--position);text-decoration:none;white-space:pre">28</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:180pt;position:var(--position);top:30.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.87pt;position:var(--position);text-decoration:none;white-space:pre">38</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:271.5pt;position:var(--position);top:30.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.87pt;position:var(--position);text-decoration:none;white-space:pre">41</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">United States</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:88.5pt;position:var(--position);top:42.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.87pt;position:var(--position);text-decoration:none;white-space:pre">12</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:180pt;position:var(--position);top:42.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.87pt;position:var(--position);text-decoration:none;white-space:pre">29</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:271.5pt;position:var(--position);top:42.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.87pt;position:var(--position);text-decoration:none;white-space:pre">27</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:88.5pt;position:var(--position);top:54.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:77.87pt;position:var(--position);text-decoration:none;white-space:pre">40</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:180pt;position:var(--position);top:54.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:77.87pt;position:var(--position);text-decoration:none;white-space:pre">67</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:271.5pt;position:var(--position);top:54.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:77.87pt;position:var(--position);text-decoration:none;white-space:pre">68</span></div></div></div></td></tr></tbody></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberAndAverageNumberOfEmployeesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberAndAverageNumberOfEmployeesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial gain (loss)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_FinancialIncomeLossAbstract', window );"><strong>Financial Income (Loss) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory', window );">Financial gain (loss)</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Financial gain (loss)</span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:90.06pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">The financial loss breaks down as follows:</span></div><div style="position:var(--position);top:112.66pt;width:612pt"><div style="font-size:0pt;left:43pt;position:var(--position);width:510pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:279pt"></td><td style="padding:0;width:75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:75pt"></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:279pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:87.96pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"> FINANCIAL GAIN (LOSS)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:12pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.19pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.5pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:12pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.19pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.5pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:12pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.19pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.5pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest on bond loans</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:42.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.3pt"></span></span><span style="left:56.93pt;position:var(--position)">(760)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:42.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(5,800)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:432pt;overflow:hidden;position:var(--position);top:42.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:42.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(7,472)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest on convertible loan notes</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(3,935)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(5,691)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:432pt;overflow:hidden;position:var(--position);top:54.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(3,638)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest on conditional advances and PGE</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.3pt"></span></span><span style="left:56.93pt;position:var(--position)">(176)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.3pt"></span></span><span style="left:60.93pt;position:var(--position)">(85)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:432pt;overflow:hidden;position:var(--position);top:66.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.3pt"></span></span><span style="left:60.93pt;position:var(--position)">(95)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest on royalty certificates</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:78.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(8,942)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:78.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.3pt"></span></span><span style="left:56.93pt;position:var(--position)">(794)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:78.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.3pt"></span></span><span style="left:46.93pt;position:var(--position)">(17,213)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest on lease liabilities</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:90.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.3pt"></span></span><span style="left:60.93pt;position:var(--position)">(13)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:90.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.3pt"></span></span><span style="left:60.93pt;position:var(--position)">(61)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:90.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.3pt"></span></span><span style="left:60.93pt;position:var(--position)">(64)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(Increase) / decrease in derivatives fair value</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:102.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(3,046)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:102.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(1,462)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:102.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.3pt"></span></span><span style="left:46.93pt;position:var(--position)">(29,935)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:114.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(Increase) / decrease in other liabilities / (assets) at fair value through profit and loss</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:114.75pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.35pt;width:75pt"><span style="color:#000000;font-family:'Arial', sans-serif;font-size:9pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.55pt;width:56.62pt"></span></span><span style="left:59.25pt;position:var(--position)">&#8212;</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:114.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(1,367)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:114.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.3pt"></span></span><span style="left:46.93pt;position:var(--position)">(36,015)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:126.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Loss on derecognition of financial liabilities</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:126.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(3,431)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:126.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:126.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(3,838)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:138.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Transaction costs</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:138.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(1,924)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:138.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(1,615)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:138.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:150.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Foreign exchange losses</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:150.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(5,573)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:150.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.3pt"></span></span><span style="left:60.93pt;position:var(--position)">(51)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:150.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.3pt"></span></span><span style="left:46.93pt;position:var(--position)">(13,444)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:162.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial expense</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:162.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.3pt"></span></span><span style="left:60.93pt;position:var(--position)">(73)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:162.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.3pt"></span></span><span style="left:60.93pt;position:var(--position)">(64)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:162.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.3pt"></span></span><span style="left:60.93pt;position:var(--position)">(29)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:174.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial expenses</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:174.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:44.3pt"></span></span><span style="left:46.93pt;position:var(--position)">(27,875)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:174.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:44.3pt"></span></span><span style="left:46.93pt;position:var(--position)">(16,991)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:432pt;overflow:hidden;position:var(--position);top:174.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:174.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.3pt"></span></span><span style="left:42.93pt;position:var(--position)">(111,743)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:186.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest income</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:186.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">2,418<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:186.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">8,246<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:186.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">5,600<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:198.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(Increase) / decrease in derivatives fair value</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:198.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">1,006<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:198.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">1,413<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:198.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">3,620<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:210.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(Increase) / decrease in other liabilities / (assets) at fair value through profit and loss</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:210.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">3,198<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:210.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:210.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">4,730<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:222.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Effect of unwinding the discount related to advances made to CROs</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:222.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)">355<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:222.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)">710<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:222.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)">153<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:234.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Day-one gain on recognition of financial liabilities</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:234.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)">212<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:234.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)">590<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:234.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">1,557<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:246.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Gain on derecognition of financial liabilities</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:246.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)">192<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:246.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:246.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:258.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Foreign exchange gains </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:258.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:258.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">2,774<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:258.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">11,886<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:270.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial income</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:270.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)">130<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:270.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:270.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:282.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial income </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:282.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">7,511<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:282.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">13,732<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:282.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">27,545<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:294.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial gain (loss)</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:294.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:44.3pt"></span></span><span style="left:46.93pt;position:var(--position)">(20,364)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:294.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(3,258)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:294.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:44.3pt"></span></span><span style="left:46.93pt;position:var(--position)">(84,198)</span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:435.71pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Financial expenses</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:459.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Interest on bond loans consists of interests from the Kreos 1 and 2 bond loans redeemed in August 2023 (see Notes 15.3 and 15.4) and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:471.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">from </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:57.93pt;position:var(--position);text-decoration:none;white-space:pre">Kreos / Claret B and C tranches (non-convertible bonds),</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:286.3pt;position:var(--position);text-decoration:none;white-space:pre"> drawn down in March and June 2024, respectively and redeemed in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:483.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">December 2025 (see Note 15</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:152.54000000000002pt;position:var(--position);text-decoration:none;white-space:pre">.1). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:507.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Interests on convertible loan notes corresponds to interests from the OCEANE bond loans (see Note 15.5) converted in August 2023 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:519.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">as well as from the Kreos / Claret OCABSA (tranche A) and the Height notes converted in August 2025 (see Notes 15.1 and 15.2).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:82.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Interests on royalty certificates are detailed in Note 15.9.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:262.9pt;position:var(--position);text-decoration:none;white-space:pre"> They include the impacts of the remeasurements of the royalty certificates </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:94.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">following changes in the Group's estimates of future cash flows during the years ended December 31, 2023, 2024 and 2025 (see Note </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:106.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">15.9).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:130.56pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In</span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:44.33pt;position:var(--position);text-decoration:none;white-space:pre">creases and decreases in the fair value of derivatives are detailed </span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:304.75pt;position:var(--position);text-decoration:none;white-space:pre">in Notes 15.1, 15.3, 15.5 and 15.11. As of December 31, 2025, the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:142.56pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;29,935 thousand</span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:107.09pt;position:var(--position);text-decoration:none;white-space:pre"> expense relates to the increase in the fair value of the Kreos / Claret BSA following the increase in the Group's share </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:154.56pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">price in the third quarter of 2025.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:178.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Increases in other liabilities at FVTPL relate to t</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:229.04pt;position:var(--position);text-decoration:none;white-space:pre">he convertible Heights note</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:339.18pt;position:var(--position);text-decoration:none;white-space:pre">s for the years ended December 31, 2024 and 2025 (see </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:190.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 15.2). The notes were converted by the noteholders in July 2025.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:214.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Losses on the derecognition</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:147.82999999999998pt;position:var(--position);text-decoration:none;white-space:pre"> of financial liabilitie</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:231.84pt;position:var(--position);text-decoration:none;white-space:pre">s are detailed in Notes 15.1 to 15.5, and relate to the August 2023 refinancing for </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:226.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the year ended December 31, 2023 and to the redemption of the Kreos / Claret B and C tranches for the year ended December 31, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:238.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">2025.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:262.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Transaction costs for the year ended December 31, 2023 mainly</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:291.82pt;position:var(--position);text-decoration:none;white-space:pre"> related </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:323.98pt;position:var(--position);text-decoration:none;white-space:pre">to the Heights notes, and t</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:428.32pt;position:var(--position);text-decoration:none;white-space:pre">ransaction costs for the year ended </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:274.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">December 31, 2024 mainly </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:147.28pt;position:var(--position);text-decoration:none;white-space:pre">related</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:174.44pt;position:var(--position);text-decoration:none;white-space:pre"> to the amortization of the prepaid expenses related to the transaction costs of the Kreos / Claret </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:286.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">tranche C bond loans (see Note 15.1).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:310.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Foreign exchange losses for the year ended </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:211.09pt;position:var(--position);text-decoration:none;white-space:pre">December</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.13pt;position:var(--position);text-decoration:none;white-space:pre"> 31, 2023 mainly relate to the translation of cash and cash equivalents </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:532.9100000000001pt;position:var(--position);text-decoration:none;white-space:pre">held in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:321.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">U.S. dollars</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:83.47pt;position:var(--position);text-decoration:none;white-space:pre"> into the Company's functional currency as of December 31, 2023 (see Note 11), resulting in a loss of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:491.27pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3,196&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:557.36pt;position:var(--position);text-decoration:none;white-space:pre">, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:332.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and to a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:70.13pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,488&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:136.22pt;position:var(--position);text-decoration:none;white-space:pre"> loss resulting from foreign exchange transactions.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:344.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Foreign exchange losses for the year ended December 31, 2025 relate to the translation of cash and cash equivalents held in U.S. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:355.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">dollars into the Company's functional currency as of December 31, 2025, resulting in a net financial loss of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:466.79pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;8,639 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:532.88pt;position:var(--position);text-decoration:none;white-space:pre">, and to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:366.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">other realized and unrealized losses on foreign exchange transactions (see Note 11).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:389.76pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Financial income</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:413.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Interest income mainly relates to the invested proceeds from </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:279.84000000000003pt;position:var(--position);text-decoration:none;white-space:pre">(i) the Group's </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:340.21pt;position:var(--position);text-decoration:none;white-space:pre">i</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:342.98pt;position:var(--position);text-decoration:none;white-space:pre">nitial public offering on the Nasdaq Global Market and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:425.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the concurrent European Private Placement from October 2023, (ii) the Kreos / Claret and Heights Financings and (iii) the Group's </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:437.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">public Offering from July 2025. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:461.76pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Incr</span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:52.09pt;position:var(--position);text-decoration:none;white-space:pre">eases and decreases in the fair value of derivatives are detailed in Notes 15.1, 15.3, 15.5 and 15.11. The </span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:468.29pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3,620 thousand</span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:534.38pt;position:var(--position);text-decoration:none;white-space:pre"> income </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:473.76pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">for the year ended December 31, 2025 related to the extinguishment of the Kreos / Claret MRI following the conversion of the Kreos </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:485.76pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Tranche A and the exercises of the Kreos / Claret BSA in August 2025.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:509.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The decrease in other liabilities at FVTPL relates to t</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:248.17pt;position:var(--position);text-decoration:none;white-space:pre">he Height notes</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:310.88pt;position:var(--position);text-decoration:none;white-space:pre"> for the year ended December 31, 2023.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:521.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The increase in assets at FVTPL for the year ended December 31, 2025 relates to the revaluation of cash equivalents measured at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:533.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">FVTPL.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:557.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The day-one gain on recognition of financial liabilities relates to the Heights notes. The amount recorded for the year ended December </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:569.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">31, 2025 includes the amortization of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:187.79pt;position:var(--position);text-decoration:none;white-space:pre">the outstanding day-one gain</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:303.51pt;position:var(--position);text-decoration:none;white-space:pre"> upon the conversion of the notes (see Note 15.2).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:593.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Foreign exchange gains for the year ended December 31, 2024 mainly relate to the translation of cash and cash equivalents held in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:604.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">U.S. dollars into the Group's presentation currency as of December 31, 2024 (see Note 11), resulting in a gain of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:487.93pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;2,035&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:554.02pt;position:var(--position);text-decoration:none;white-space:pre">, and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:616.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">to a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:53.2pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;714&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:111.79pt;position:var(--position);text-decoration:none;white-space:pre"> gain resulting from foreign exchange transactions.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:639.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Foreign exchange gains for the year ended December 31, 2025 mainly relate to the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:369.22pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;10,663&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:440.31pt;position:var(--position);text-decoration:none;white-space:pre"> gain resulting from the favorable </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:651.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">change in the euro to U.S. dollar exchange rate between the closing of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:318.72pt;position:var(--position);text-decoration:none;white-space:pre">the Group's July 2025 Offering (date of recognition of the share </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:663.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">capital increase)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:101.14pt;position:var(--position);text-decoration:none;white-space:pre"> and the date of receipt of funds.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_FinancialIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Income (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_FinancialIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundAbstract', window );"><strong>Income taxes paid (refund) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Income tax</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Income tax</span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:90.11pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The income tax rate applicable to the Company is the French corporate income tax rate, i.e. 25% for the years ended December 31, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:101.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">2023, 2024 and 2025. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:123.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The income tax rates applicable to the U.S. Subsidia</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:245.18pt;position:var(--position);text-decoration:none;white-space:pre">ry</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:253.51pt;position:var(--position);text-decoration:none;white-space:pre"> are the federal income tax rate of 21% and the State income tax rates of 4.35%, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:135.21pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">5.36% and 8.06% i.e. a total of 25.35%, 26.36% and 29.06% for the years ended December 31, 2023, 2024 and 2025 respectively.</span></div><div style="position:var(--position);top:158.71pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:522.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:214.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:99.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:99.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:99.75pt"></td></tr><tr style="height:26.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:17.48pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:39.07pt;position:var(--position);text-decoration:none;white-space:pre">(In thousands of euros, except percentage)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:5.32pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.57pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:14.92pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.78pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:5.32pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.57pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:14.92pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.78pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:5.32pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.57pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:14.92pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.78pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:26.25pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Loss before tax </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:26.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:65.05pt"></span></span><span style="left:67.67999999999999pt;position:var(--position)">(147,740)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);top:26.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:65.05pt"></span></span><span style="left:67.67999999999999pt;position:var(--position)">(176,242)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:26.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:65.05pt"></span></span><span style="left:67.67999999999999pt;position:var(--position)">(330,254)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:38.25pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:8.63pt;position:var(--position);text-decoration:none;white-space:pre">Statutory French tax rate</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:38.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:78.34pt;position:var(--position)"></span><span style="left:78.34pt;position:var(--position)">25</span><span style="left:86.34pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);top:38.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:78.34pt;position:var(--position)"></span><span style="left:78.34pt;position:var(--position)">25</span><span style="left:86.34pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:38.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:78.34pt;position:var(--position)"></span><span style="left:78.34pt;position:var(--position)">25</span><span style="left:86.34pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:12.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:50.25pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Nominal income tax using statutory French tax rate</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:50.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:71.71pt"></span></span><span style="left:74.33999999999999pt;position:var(--position)">36,935<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);top:50.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:71.71pt"></span></span><span style="left:74.33999999999999pt;position:var(--position)">44,061<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:50.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:71.71pt"></span></span><span style="left:74.33999999999999pt;position:var(--position)">82,563<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:63pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Tax effect of:</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:75pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Tax rates in foreign jurisdictions</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);top:75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:79.05pt"></span></span><span style="left:81.67999999999999pt;position:var(--position)">(153)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:87pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Share-based payment</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:87pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:73.05pt"></span></span><span style="left:75.67999999999999pt;position:var(--position)">(2,045)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);top:87pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:73.05pt"></span></span><span style="left:75.67999999999999pt;position:var(--position)">(5,056)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:87pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:73.05pt"></span></span><span style="left:75.67999999999999pt;position:var(--position)">(8,849)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:99pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">CIR</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:99pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:75.71pt"></span></span><span style="left:78.33999999999999pt;position:var(--position)">1,123<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);top:99pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:75.71pt"></span></span><span style="left:78.33999999999999pt;position:var(--position)">1,663<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:99pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)">765<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:111pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Transaction costs related to capital increase </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:111pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:75.71pt"></span></span><span style="left:78.33999999999999pt;position:var(--position)">3,073<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);top:111pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:79.05pt"></span></span><span style="left:81.67999999999999pt;position:var(--position)">(112)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:111pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:71.71pt"></span></span><span style="left:74.33999999999999pt;position:var(--position)">10,077<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:20.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:123pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:1.89pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Decrease / (increase) in derivatives and other liabilities measured </span></div><div style="line-height:8pt;position:var(--position);top:11.49pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">at FVTPL</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:123pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.06pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)">748<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);top:123pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.06pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:79.05pt"></span></span><span style="left:81.67999999999999pt;position:var(--position)">(207)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:123pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.06pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:69.05pt"></span></span><span style="left:71.67999999999999pt;position:var(--position)">(17,087)</span></span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:143.25pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.39pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-recognition of deferred tax assets related to tax losses and </span></div><div style="line-height:8pt;position:var(--position);top:12.99pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">temporary differences</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:143.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:69.05pt"></span></span><span style="left:71.67999999999999pt;position:var(--position)">(39,612)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);top:143.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:69.05pt"></span></span><span style="left:71.67999999999999pt;position:var(--position)">(40,399)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:143.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:69.05pt"></span></span><span style="left:71.67999999999999pt;position:var(--position)">(61,320)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:165pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:165pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:79.05pt"></span></span><span style="left:81.67999999999999pt;position:var(--position)">(222)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);top:165pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)">49<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:2pt solid #FFFFFF;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:165pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:79.05pt"></span></span><span style="left:81.67999999999999pt;position:var(--position)">(148)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:177pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Effective income tax (loss)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:177pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);top:177pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:177pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:73.05pt"></span></span><span style="left:75.67999999999999pt;position:var(--position)">(5,848)</span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:364.71pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:522.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:216pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:99.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:99.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:98.25pt"></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:70.79pt;position:var(--position);text-decoration:none;white-space:pre">(In thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:27pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:5.7pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DEFERRED TAX ASSETS AND LIABILITIES BY </span></div><div style="line-height:8pt;position:var(--position);top:15.3pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">NATURE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:12pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:5.7pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:39.16pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:15.3pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.72pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:12pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:5.7pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:39.16pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:15.3pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.72pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:12pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.7pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.38pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:15.3pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.12pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:39pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Retirement benefit obligation</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:39pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)">157<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:39pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)">189<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:39pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:79.88pt"></span></span><span style="left:82.50999999999999pt;position:var(--position)">157<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:51pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Leases</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:51pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)">135<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:51pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)">591<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:51pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:79.88pt"></span></span><span style="left:82.50999999999999pt;position:var(--position)">476<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:63pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial liabilities</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:63pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:85.12pt;position:var(--position);text-decoration:none;white-space:pre">351</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:63pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:75.71pt"></span></span><span style="left:78.33999999999999pt;position:var(--position)">1,678<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:63pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:83.88pt"></span></span><span style="left:86.50999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:75pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Provisions for AGA taxes</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:89.12pt;position:var(--position);text-decoration:none;white-space:pre">83</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)">142<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:75pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:73.62pt;position:var(--position);text-decoration:none;white-space:pre">11,454</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:87pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Tax losses carryforward</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:87pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:71.12pt;position:var(--position);text-decoration:none;white-space:pre">114,946</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:87pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:67.71pt"></span></span><span style="left:70.33999999999999pt;position:var(--position)">152,372<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:87pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:69.62pt;position:var(--position);text-decoration:none;white-space:pre">228,239</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:99pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other items</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:99pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)">335<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:99pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)">744<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:99pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.62pt;position:var(--position);text-decoration:none;white-space:pre">1,568</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:111pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Deferred tax assets</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:111pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:67.71pt"></span></span><span style="left:70.33999999999999pt;position:var(--position)">116,006<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:111pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:67.71pt"></span></span><span style="left:70.33999999999999pt;position:var(--position)">155,715<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:111pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:69.62pt;position:var(--position);text-decoration:none;white-space:pre">241,894</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:123pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Subsidies</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:123pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)">24<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:123pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)">12<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:123pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:83.88pt"></span></span><span style="left:86.50999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:135pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Leases</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:135pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)">124<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:135pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)">485<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:135pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:83.62pt;position:var(--position);text-decoration:none;white-space:pre">396</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:147pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Royalty certificates</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:147pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:147pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:147pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:73.62pt;position:var(--position);text-decoration:none;white-space:pre">17,208</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:159pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial liabilities</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:159pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)">285<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:159pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:75.71pt"></span></span><span style="left:78.33999999999999pt;position:var(--position)">1,075<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:159pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:83.88pt"></span></span><span style="left:86.50999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:171pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other items</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:171pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)">10<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:171pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)">12<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:171pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:87.62pt;position:var(--position);text-decoration:none;white-space:pre">11</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:183pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Deferred tax liabilities</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:183pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)">444<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:183pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:75.71pt"></span></span><span style="left:78.33999999999999pt;position:var(--position)">1,584<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:183pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:69.88pt"></span></span><span style="left:72.50999999999999pt;position:var(--position)">17,616<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:195pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Deferred tax assets, net</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:195pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:67.71pt"></span></span><span style="left:70.33999999999999pt;position:var(--position)">115,562<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:195pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:67.71pt"></span></span><span style="left:70.33999999999999pt;position:var(--position)">154,131<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:195pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:69.62pt;position:var(--position);text-decoration:none;white-space:pre">224,279</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:207pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Unrecognized deferred tax assets</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:207pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:65.05pt"></span></span><span style="left:67.67999999999999pt;position:var(--position)">(115,562)</span></span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:207pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:65.05pt"></span></span><span style="left:67.67999999999999pt;position:var(--position)">(154,131)</span></span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:207pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:63.22pt"></span></span><span style="left:65.85pt;position:var(--position)">(230,127)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:219pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total deferred taxes, net recognized in the statement of </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">financial position</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:219pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:219pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:219pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:71.22pt"></span></span><span style="left:73.85pt;position:var(--position)">(5,848)<span style="display:inline-block;height:5.41pt;width:0.33pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:621.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group incurred tax losses in the reporting periods ended December 31, 2023, 2024 and 2025. As the recoverability of these tax </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:633.21pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">losses is not considered probable in subsequent periods due to the uncertainties inherent in the Group&#8217;s business, the Group has not </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:644.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">recognized deferred tax assets beyond deferred tax liabilities arising within the same taxable entity under the same taxable regime and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:656.21pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">with consistent timing of reversal, after considering, if applicable, limitations in the use of deductible tax losses carried forward from </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:667.71pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">prior periods applicable under tax laws in France and in the U.S..</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:691.21pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2025, the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.68pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;17,208&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:229.77pt;position:var(--position);text-decoration:none;white-space:pre"> deferred tax liability on royalty certificates results from the difference between (i) the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:703.21pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">amount already deducted from the Company's taxable income as of December 31, 2025 (based on the certificates' fair value minus the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">subscription price) and (ii) the amount of the related financial liability recognized in the Group's Statements of Financial Position at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:82.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">that date (measured at amortized cost using the original EIR). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:94.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2024 and 2023, this difference resulted in a deferred tax asset of respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:428.61pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,427&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:494.7pt;position:var(--position);text-decoration:none;white-space:pre"> (classified within </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:106.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the "Other financial liabilities" line item) and &#8364;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:224.15pt;position:var(--position);text-decoration:none;white-space:pre">0</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:229.15pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:130.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2025, the Group has assessed the expected reversal of temporary taxable and deductible differences existing at the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:142.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">reporting date. The timing of reversal of the taxable difference on royalty certificates was estimated under the same cash flow schedule </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:154.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and discount rate assumptions as the certificates' fair value as of December 31, 2025 (see Note 15.9).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:166.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Based on this assessment, under the above recoverability assumption and after taking into account the limitations on the use of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:178.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">deductible tax losses carried forward in France, the Group determined that deferred tax assets amounting to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:467.42pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;11,720&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:538.51pt;position:var(--position);text-decoration:none;white-space:pre"> should </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:190.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">be recognized as the related deductible temporary differences and losses carried forward will reverse and be utilized against future </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:202.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">taxable temporary differences in the same periods in this jurisdiction.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:214.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As a result, the net deferred tax position of the Group as of December 31, 2025 is a deferred tax liability of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:465.53pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5,848 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:531.62pt;position:var(--position);text-decoration:none;white-space:pre">, relating </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:226.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">to royalty certificates.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:250.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The accumulated tax loss carry</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:160.26pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> forwards for the Company amount to </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:313.75pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;459,752 thousand</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:389.84pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">,</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:392.34pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:394.84pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;609,390 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:470.93pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:473.43pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">an</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:482.86pt;position:var(--position);text-decoration:none;white-space:pre">d </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:490.36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;911,776 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:566.45pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:262.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">as of December 31, 2023, 2024 and 2025,</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:203.12pt;position:var(--position);text-decoration:none;white-space:pre"> respectively. In France, unused tax losses do not have any expiration date; however, their </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:274.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">annual utilization is limited to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.32pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:199.67pt;position:var(--position);text-decoration:none;white-space:pre"> plus </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:221.33pt;position:var(--position);text-decoration:none;white-space:pre">50%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:239.66pt;position:var(--position);text-decoration:none;white-space:pre"> of the taxable profit exceeding that amount.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:298.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The accumulated tax loss carry forwards for the U.S. Subsidiary consist of federal Net Operating Loss ("NOL") carry forwards and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:310.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">amount to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:78.74000000000001pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;38 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:132.32999999999998pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:137.32999999999998pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;112 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:195.92pt;position:var(--position);text-decoration:none;white-space:pre"> and</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:212.85pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:215.35pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,083 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:281.44pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:283.94pt;position:var(--position);text-decoration:none;white-space:pre">as of December 31, 2023, 2024 and 2025, respectively. They do not </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:322.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">have any expiration date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income (loss) per share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">Income (loss) per share</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Income (loss) per share</span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:378.11pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Basic losses per share is calculated by dividing income (loss) attributable to equity holders of the Group by the weighted-</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:390.11pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">average number of outstanding ordinary shares for the year.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:413.61pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Diluted losses per share are calculated by adjusting the weighted average number of ordinary outstanding shares to assume </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:425.61pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">conversion of all dilutive potential ordinary shares.</span></div><div style="position:var(--position);top:449.61pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:419.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:207pt"></td><td style="padding:0;width:64.5pt"></td><td style="padding:0;width:9.75pt"></td><td style="padding:0;width:64.5pt"></td><td style="padding:0;width:9pt"></td><td style="padding:0;width:64.5pt"></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:207pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:207pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:21.76pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros, except share data)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:207pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:207pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BASIC AND DILUTED LOSS PER SHARE</span></div></div></div></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:207pt;position:var(--position);top:12pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.94pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.16pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.25pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:281.25pt;position:var(--position);top:12pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.94pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.16pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.25pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:354.75pt;position:var(--position);top:12pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.94pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.16pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.25pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:207pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:207pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Weighted average number of outstanding shares</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:207pt;position:var(--position);top:42.75pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.46pt"></span></span><span style="left:25.09pt;position:var(--position)">43,066,012<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:281.25pt;position:var(--position);top:42.75pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.46pt"></span></span><span style="left:25.09pt;position:var(--position)">63,046,350<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:354.75pt;position:var(--position);top:42.75pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.46pt"></span></span><span style="left:25.09pt;position:var(--position)">69,527,315<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:207pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:207pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Net loss for the period</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:207pt;position:var(--position);top:54.75pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.8pt"></span></span><span style="left:32.43pt;position:var(--position)">(147,740)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:281.25pt;position:var(--position);top:54.75pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.8pt"></span></span><span style="left:32.43pt;position:var(--position)">(176,242)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:354.75pt;position:var(--position);top:54.75pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.8pt"></span></span><span style="left:32.43pt;position:var(--position)">(336,102)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:207pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:207pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Basic and diluted loss per share (&#8364;/share) </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:207pt;position:var(--position);top:66.75pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.8pt"></span></span><span style="left:44.43pt;position:var(--position)">(3.43)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:281.25pt;position:var(--position);top:66.75pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.8pt"></span></span><span style="left:44.43pt;position:var(--position)">(2.80)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:354.75pt;position:var(--position);top:66.75pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.8pt"></span></span><span style="left:44.43pt;position:var(--position)">(4.83)</span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:557.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">Potential dilutive instruments (BCEs, BSAs, AGAs, BSA Kreos 1, OCEANE, Kreos/Claret BSA, Kreos/Claret OCABSA and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:568.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">Height notes) have been excluded from the computation of diluted weighted-average shares outstanding because such instruments </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:579.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">had an antidilutive impact due to the losses reported. As of December 31, 2023, 2024 and 2025, the number of potential dilutive </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:590.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">instruments were </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.03pt;position:var(--position);text-decoration:none;white-space:pre">28,754,280</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:159.03pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:164.03pt;position:var(--position);text-decoration:none;white-space:pre">29,570,132</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:209.03pt;position:var(--position);text-decoration:none;white-space:pre"> and</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:225.96pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:228.46pt;position:var(--position);text-decoration:none;white-space:pre">8,857,084</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:268.46000000000004pt;position:var(--position);text-decoration:none;white-space:pre"> respectively, giving rights to a maximum number of shares to be issued of </span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">6,510,658</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:83pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:88pt;position:var(--position);text-decoration:none;white-space:pre">6,760,392</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:128pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:147.43pt;position:var(--position);text-decoration:none;white-space:pre">8,857,084</span> respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Related party transactions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Related parties</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Related parties</span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:90.11pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">The aggregate compensation of the members of the Group&#8217;s Board of Directors and to the Chief Executive Officer includes the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:101.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">following: </span></div><div style="position:var(--position);top:122.51pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:488.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:241.5pt"></td><td style="padding:0;width:80.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:241.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:83.54pt;position:var(--position);text-decoration:none;white-space:pre">(In thousands of euros)</span></div></div></div></td><td colspan="3" style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:241.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">COMPENSATION</span></div></div></div></td><td style="border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:408pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:241.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Fixed compensation owed </span></div></div></div></td><td style="background-color:#cceeff;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)">471<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)">578<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:408pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)">601<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:241.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Variable compensation owed </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)">282<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:408pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)">450<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:241.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Contributions in-kind </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)">32<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)">68<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:408pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)">111<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:241.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Employer contributions </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:408pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90.75pt;width:241.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Attendance fees&#8212;board of directors </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:90.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)">375<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);top:90.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)">495<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:408pt;position:var(--position);top:90.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)">608<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102.75pt;width:241.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Share-based payments </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:102.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">6,561<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);top:102.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">10,517<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:408pt;position:var(--position);top:102.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">8,098<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:114.75pt;width:241.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Consulting fees </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:114.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">1,210<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);top:114.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:408pt;position:var(--position);top:114.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:126.75pt;width:241.5pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:126.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">8,930<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);top:126.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">11,657<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:408pt;position:var(--position);top:126.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">9,869<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:278.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, 2024 and 2025, there was <span id="i658c175374ed4bf5bd441dc128bb2ec4_1893"></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:248.91pt;position:var(--position);text-decoration:none;white-space:pre">no</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:258.90999999999997pt;position:var(--position);text-decoration:none;white-space:pre"> liability related to post-employment defined benefit obligations for members </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:289.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of the Group&#8217;s Board of Directors and Chief Executive Officer. No other post-employment benefits are granted.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:311.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Other arrangements with our Directors and Executive Officers </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:334.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group entered into an intellectual property assignment agreement with CEO Hartmut Ehrlich on July 7, 2021. The purpose of this </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:345.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">agreement is to transfer to the Group all the intellectual property rights held by Hartmut Ehrlich on certain patents of which he is a co-</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:356.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">inventor. No compensation has been paid in respect of this transfer. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:367.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In connection with Dr. Hartmut Ehrlich&#8217;s retirement as CEO, the Group entered into a transition protocol with Dr. Ehrlich in April </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:379.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">2023. Pursuant to the transition protocol, Dr. Ehrlich remained a Group employee on a part-time basis until December 31, 2023 in a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:390.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">capacity as advisor to the new Chief Executive Officer against payment of a total compensation of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:431.59pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;100</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:451.59pt;position:var(--position);text-decoration:none;white-space:pre"> thousand, and a departure </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:401.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">indemnity equal to&#160; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:115.91pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,210</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:143.41pt;position:var(--position);text-decoration:none;white-space:pre"> thousand was stated.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:412.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group entered into a management contract with CEO Marc de Garidel on April 18, 2023. In 2023, 2024 and 2025 the Group also </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:423.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">granted AGA plans to its CEO (see terms and conditions in Note 14).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:435.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group entered into a management contract with Chairman of the Board Sylvie Gr&#233;goire in July 2024. In 2024 and 2025, the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:446.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Group also granted BSA plans to its Chairman of the Board (see terms and conditions in Note 14).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Off-balance sheet commitments given<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_OffBalanceSheetCommitmentsAbstract', window );"><strong>Off-Balance Sheet Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsExplanatory', window );">Off-balance sheet commitments given</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Off-balance sheet </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:150.63pt;position:var(--position);text-decoration:none;white-space:pre">commitments given</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 25.1. Commitments under collaboration, research, service provision and licensing agreements granted by the Group </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:523.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Collaboration, research and development, and licensing agreements, and licensing options related to the &#8220;Modulation of RNA </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:533.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">biogenesis&#8221; platform. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:549.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:91.05000000000001pt;position:var(--position);text-decoration:none;white-space:pre">Exclusive licensing agreement with the CNRS, the University of Montpellier and the Institut Curie</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:496.21pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:565.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">On December 4, 2008, the French National Centre for Scientific Research (CNRS), the University of Montpellier and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:575.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">the Institut Curie granted the Group </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:236.45pt;position:var(--position);text-decoration:none;white-space:pre">four</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:253.11pt;position:var(--position);text-decoration:none;white-space:pre"> exclusive licenses. These licenses cover the use of their technology and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:585.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">products by the Group in the field of human and veterinary health relating to the use of synthetic products modifying </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:595.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">mRNA splicing, for research, diagnosis, prevention and treatment of any possible indication. The licensing agreement </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:605.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">includes low single-digit royalties based on future net sales to be paid by the Group. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:621.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72.7pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:76.2pt;position:var(--position)"><span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:91.05000000000001pt;position:var(--position);text-decoration:none;white-space:pre">Research and development contract with license option with the CNRS, the University of Montpellier and Theradiag</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:568.94pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:631.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">The CNRS, the University of Montpellier, the Group and Theradiag conducted since 2013 a collaborative project </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:642.51pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">notably in the fields of HIV and HTLV-1 called CARENA, in connection with a funding obtained through Bpifrance. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:654.01pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">The overall project provided for co-ownership and cross-licenses on the project's results through various instruments. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:665.51pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">The Group met all obligations and the project was closed in December 2024. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Exclusive licensing contract with &#8220;The Scripps Research Institute, University of Chicago and Brigham Young University&#8221; with the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:80.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8220;Immune Stimulation&#8221; platform (ABX196 product) </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:96.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On 11&#160;November 2006, The Scripps Research Institute (La Jolla, California, USA), in agreement with the University of Chicago </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:106.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(Chicago, Illinois, USA) and Brigham Young University (Provo, Utah, USA), granted the Group an exclusive license in the field of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:116.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">human and veterinary health on its technology and products relating to the use of iNKT agonists for research, diagnosis, prevention </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and treatment of all possible indications. In consideration for the licensing rights granted to it under the agreement, the Group had to: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:142.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">pay The Scripps Research Institute milestones at different stages of clinical and regulatory development of the first </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:152.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">product (the milestones amount to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:230.07pt;position:var(--position);text-decoration:none;white-space:pre">$50&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:283.66pt;position:var(--position);text-decoration:none;white-space:pre"> at IND filing, paid in September 2019 and capitalized, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:505.62pt;position:var(--position);text-decoration:none;white-space:pre">$300&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:564.21pt;position:var(--position);text-decoration:none;white-space:pre"> at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:162.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">Phase 3 and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:141.29pt;position:var(--position);text-decoration:none;white-space:pre">$500&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:199.88pt;position:var(--position);text-decoration:none;white-space:pre"> at IND approval) and low single-digit royalties for vaccines, diagnostic tests and therapeutic </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:172.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">products, according to the amount of net sales, and </span><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:296.67pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:188.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">give The Scripps Research Institute, University of Chicago and Brigham Young University an equitable interest in the </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:198.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">Group (as of the date of these financial statements, these </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:319.36pt;position:var(--position);text-decoration:none;white-space:pre">three</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:339.32pt;position:var(--position);text-decoration:none;white-space:pre"> academic institutions hold </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:449.18pt;position:var(--position);text-decoration:none;white-space:pre">0.41%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:475.01pt;position:var(--position);text-decoration:none;white-space:pre"> of the Group&#8217;s </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:208.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">undiluted capital). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:230.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">During the year ended December 31, 2022, the Group made the decision to freeze the development program for ABX196 in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:240.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">treatment of hepatocellular cancer. Subsequently, in 2024, the licensing contract was terminated.</span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 25.2. Commitments under BPI conditional advances </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:296.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Bpifrance CARENA contract </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:312.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As part of the development of therapeutic and diagnostic solutions targeting alternative splicing and RNA interference in the fields of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:322.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">virology (HIV-AIDS, HTLV-1) and metabolism (obesity), SPLICOS (absorbed by the Group on 31&#160;October 2014) has entered into a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:332.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Master Support Agreement with Bpifrance as well as a conditional advance contract in the name of the &#8220;CARENA&#8221; Strategic </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:342.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Industrial Innovation Project dated December 16, 2013. The Group, acting as project leader for the CARENA project, was associated </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:352.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">as part of a consortium contract with Theradiag, a Group specializing in in vitro diagnostics and the development of theranostic tests </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:362.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">for monitoring biotherapies, as well as at the CNRS and the University of Montpellier. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:384.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The CARENA project aimed to develop the anti-HIV-AIDS therapeutic program with the compound ABX464 up to the Phase 2b </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:394.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">study, as well as a companion test set up by Theradiag simultaneously with the clinical development. Beyond the anti-HIV-AIDS </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:404.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">program, the CARENA project could extend its pharmacological investigations to another retrovirus that could be combated by the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:414.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">same approach: HTLV-1. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:436.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group is committed to reimbursing the received conditional advances up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:357.85pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3,840&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:423.94pt;position:var(--position);text-decoration:none;white-space:pre">. The Group will also have to pay an </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:448.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">annuity of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:79.3pt;position:var(--position);text-decoration:none;white-space:pre">50%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:97.63pt;position:var(--position);text-decoration:none;white-space:pre"> of the proceeds from the sale of the intellectual property rights resulting from the project, as well as the sale of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:460.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">prototypes, preproduction and models produced under the project; the sum due to Bpifrance under this provision will be deducted </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:472.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">from the repayment of the conditional advances. In addition, if the advance is repaid under the conditions outlined above, the Group </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:484.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">will pay to Bpifrance, over a period of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:191.66pt;position:var(--position);text-decoration:none;white-space:pre"><span style="-sec-ix-hidden:f-3336">five</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:207.19pt;position:var(--position);text-decoration:none;white-space:pre"> consecutive years after the date on which the repayment schedule ends and provided that </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:496.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the Group has reached cumulative pre-tax revenue greater than or equal to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:335.05pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;50&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:381.4pt;position:var(--position);text-decoration:none;white-space:pre">, an amount equal to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:465.2pt;position:var(--position);text-decoration:none;white-space:pre">1.20%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:491.03pt;position:var(--position);text-decoration:none;white-space:pre"> of the annual </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:508.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">revenue generated from the sale of the products developed as part of the project. This supplementary payment amount is capped at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:520.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6,800&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:102.09pt;position:var(--position);text-decoration:none;white-space:pre">. The total period, including fixed payments and incentive payments, is limited to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:429.48pt;position:var(--position);text-decoration:none;white-space:pre">15 years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:463.06pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:544.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In June 2024, the Group and Bpifrance agreed to terminate the project due to technical failure. Termination became effective in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:556.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">December 2024 after the Group refunded&#160; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:206.1pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;234&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:264.69pt;position:var(--position);text-decoration:none;white-space:pre"> corresponding to a portion of the funding received. The Group is therefore </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:567.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">released of its obligations to pay an annuities on the proceeds from the sale of the intellectual property rights resulting from the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:579.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">project. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:608.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Bpifrance RNP-VIR contract </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:624.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In pursuit of the CARENA project, focused on the clinical development of a drug molecule and demonstrating the validity of an </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:634.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">innovative therapeutic approach targeting viral RNPs, the Group has entered into a Master Support Agreement with Bpifrance as well </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:644.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">as a beneficiary agreement with conditional advance for the &#8220;RNP-VIR&#8221; structuring research and development project for </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:654.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">competitiveness dated December 16, 2016. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:676.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The RNP-VIR project aimed to further the discovery of new molecules for the treatment of multiple infectious diseases by the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:686.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">development of the antiviral technology platform. The Group, acting as project leader of the RNP-VIR project, was associated in a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:696.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">consortium contract with the CNRS and the University of Montpellier. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group is committed to reimburse the received conditional advances up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:349.51pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6,576&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:415.6pt;position:var(--position);text-decoration:none;white-space:pre">. If applicable, the Group will also have </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:80.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">to pay an annuity of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:118.43pt;position:var(--position);text-decoration:none;white-space:pre">50%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:136.76pt;position:var(--position);text-decoration:none;white-space:pre"> of the proceeds from the sale of the intellectual property rights resulting from the project, as well as the sale </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:90.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of the prototypes, preproduction and models produced under the project. The sum due to Bpifrance under this provision will be </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:100.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">deducted from the last payment (and if needed from the previous payments). </span></div><div style="font-size:12pt;line-height:1pt;position:var(--position);top:122.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:123.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">If the advance is repaid under the conditions outlined above, the Group will pay to Bpifrance, over a period of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:478.3pt;position:var(--position);text-decoration:none;white-space:pre"><span style="-sec-ix-hidden:f-3344">five</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:493.83pt;position:var(--position);text-decoration:none;white-space:pre"> consecutive years </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:133.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">following the date on which the repayment schedule ends and provided that the Group has reached cumulative pre-tax revenue greater </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:143.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">than or equal to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:100.93pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;25&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:147.28pt;position:var(--position);text-decoration:none;white-space:pre">, an amount equal to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:231.08pt;position:var(--position);text-decoration:none;white-space:pre">3%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:244.41pt;position:var(--position);text-decoration:none;white-space:pre"> of the annual revenue generated from the sale of products developed as part of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:153.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">project. The supplementary payments amount is capped at </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:270.99pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5,500&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:337.08pt;position:var(--position);text-decoration:none;white-space:pre">. The total period, including fixed payments and incentive </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:163.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">payments, is limited to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.5pt;position:var(--position);text-decoration:none;white-space:pre">15 years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:163.07999999999998pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:185.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In June 2024, the Group and Bpifrance agreed to terminate the project due to technical failure. Termination became effective in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:197.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">December 2024. The Group is therefore released of its obligations to pay an annuities on the proceeds from the sale of the intellectual </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:208.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">property rights resulting from the project. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:238.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Bpifrance Ebola </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:254.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Bpifrance and Occitanie Region joint support agreement granted on June 2, 2017 consists of conditional advances to the Group </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:264.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">for a total amount of up to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:143.4pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;390&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:201.99pt;position:var(--position);text-decoration:none;white-space:pre">, based on the success of the program (respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:407.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;130&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:466.46pt;position:var(--position);text-decoration:none;white-space:pre"> from the Languedoc </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:274.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Roussillon Midi Pyr&#233;n&#233;es Region and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:190.04pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;260&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:248.63pt;position:var(--position);text-decoration:none;white-space:pre"> from Bpifrance). In September 2019, the Group decided to terminate this </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:284.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">program, due to the existence of a vaccine in the process of being licensed for this indication as well as changes in the macroeconomic </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:294.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">climate for public funding. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:316.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The reimbursement of the conditional advance was spread until June 2024. </span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 25.3. Pledge assets to Kreos, Claret and Heights </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:360.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As part of the KREOS 1 &amp; 2 bonds, Kreos benefits from first-rate collateral on the Group&#8217;s principal tangible and intangible assets, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:370.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">including its commercial fund, intellectual property rights in its principal drug candidates, as well as a pledge of the Group&#8217;s bank </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:380.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">accounts and claims. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:390.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">On August 21, 2023, the outstanding Kreos 1 &amp; 2 bond loans were repaid in full, using the proceeds from the new Kreos / Claret </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:402.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Financing (see Note 3.1).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:425.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Kreos / Claret Financing provides for certain restrictive covenants (subject to customary exceptions) which include, among other </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:436.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">things, restrictions on the incurrence of indebtedness, cross-default, the distribution of dividends and the grant of security interests, and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:447.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">which would cause the bonds to become repayable on demand in case of breach. As of December 31, 2024, the Group complied with </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:459.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">these restrictive covenants.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:470.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As security for the Kreos / Claret Financing, the lenders benefit from the grant of first-ranking collateral on the Group&#8217;s principal </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:481.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">tangible and intangible assets, including pledges over the Group&#8217;s business (</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:341.53pt;position:var(--position);text-decoration:none;white-space:pre">fonds de commerce</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:418.67pt;position:var(--position);text-decoration:none;white-space:pre">) as a going concern and intellectual </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:492.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">property rights in the Group's lead drug candidate, as well as pledges over the Group&#8217;s bank accounts and receivables. Such securities </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:503.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">apply to all tranches of the Kreos / Claret Financing. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:515.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Following the conversion of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:151.47pt;position:var(--position);text-decoration:none;white-space:pre">Tranche A bonds</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:220.3pt;position:var(--position);text-decoration:none;white-space:pre"> in August and November 2025, the exercise of the Kreos / Claret BSA in August 2025 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:526.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and the repayment of Tranches B and C bonds in December 2025, the Group no longer holds any debt related to the Kreos / Claret </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:537.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Financin</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:70.96000000000001pt;position:var(--position);text-decoration:none;white-space:pre">g and is therefore released from the aforementioned commitments.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:559.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Heights Financing is a senior, unsecured financing. The terms and conditions of the Heights convertible notes include a standard </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:571.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">negative pledge providing that any security granted in favor of other borrowed debt or debt instruments should also be granted in favor </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:582.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of the Heights convertible notes on an equal basis (with the exception of the securities issued pursuant to the Kreos / Claret Financing, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:593.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">as detailed above).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:604.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Following the conversion of Tranche A in July 2025, the Group no longer holds any debt related to the Heights Financing and is </span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">therefore released from the aforementioned commitment.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 25.4. Other commitments related to research and partnership arrangements </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:661.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In the ordinary course of business, the Group regularly uses the services of subcontractors and enters into research and partnership </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:671.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">arrangements with various contract research organizations, or CROs, and with public- sector partners or subcontractors, who conduct </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:681.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">clinical trials and studies in relation to the drug candidates. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:691.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">At December 31, 2023, 2024, and 2025 the Group&#8217;s commitments amounted to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:355.47pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;201,777&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:431.56pt;position:var(--position);text-decoration:none;white-space:pre">,</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:434.06pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:436.56pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;234,908&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:512.65pt;position:var(--position);text-decoration:none;white-space:pre"> and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:703.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">205,131&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:107.09pt;position:var(--position);text-decoration:none;white-space:pre">. The cost of services performed by CROs is recognized as an operating expense as incurred.</span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Note 25.5. Leases </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:124.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Following the end (in December 31, 2021) of the Framework agreement with </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:347.64pt;position:var(--position);text-decoration:none;white-space:pre">CNRS </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:376.24pt;position:var(--position);text-decoration:none;white-space:pre">(French National Centre for Scientific Research) </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:135.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and the University of Montpellier for research collaboration to create a cooperative laboratory, a hosting agreement was signed in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:146.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">2022 with CNRS</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:104.86pt;position:var(--position);text-decoration:none;white-space:pre">, so that the Group can continue its research program at the CNRS</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:369.29pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:371.79pt;position:var(--position);text-decoration:none;white-space:pre">center for the year 2023, and was subsequently </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:157.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">renewed for 2024, 2025 and 2026. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:175.93pt;position:var(--position);text-decoration:none;white-space:pre">The lease fell under the IFRS 16 short-term lease exemption until the 2025 renewal. As of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:168.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">December 31, 2025 a right-of-use asset and a lease liability were recognized.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:192.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">I</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.33pt;position:var(--position);text-decoration:none;white-space:pre">n December 2022, following the end of the Research collaboration contract with the CNRS, the University of Montpellier and the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:204.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Institut Curie, the Company and the Institut Curie concluded a new contract for a duration of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:409.19pt;position:var(--position);text-decoration:none;white-space:pre">one year</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:443.31pt;position:var(--position);text-decoration:none;white-space:pre">, renewable by amendment, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:216.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">granting the Company access to some of the Institute&#8217;s equipment and consumables. The contract was subsequently renewed for 2024, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:228.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">2025 and 2026, under similar conditions.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:200.05pt;position:var(--position);text-decoration:none;white-space:pre"> Since the Group's right to use the equipment is non-exclusive, t</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:455.49pt;position:var(--position);text-decoration:none;white-space:pre">his agreement does not meet </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:240.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the definition of a lease under IFRS 16, and the related rental expenses are therefore recognized in operating expenses as incur</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:541.19pt;position:var(--position);text-decoration:none;white-space:pre">red. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:264.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group's commitments in relation to the above lease are not significant. Information on other ongoing leases recognized in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:276.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">balance sheet are set forth in Note 15.8 and 15.12.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_OffBalanceSheetCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Off-Balance Sheet Commitments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_OffBalanceSheetCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Off-balance sheet commitments received and contingent assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_OffBalanceSheetCommitmentsAbstract', window );"><strong>Off-Balance Sheet Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory', window );">Off-balance sheet commitments received and contingent assets</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Off-balance sheet commitments received and contingent assets </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:318.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The maximum amounts receivable by the Group after December 31, 2023 under the &#8220;RNP-VIR&#8221; and &#8220;CARENA&#8221; and innovation </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:328.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">agreements entered into with Bpifrance, subject to the provision of evidence to support the forecast expenses and the achievement of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:338.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">scientific milestones, are </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:137.5pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3,255&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:203.59pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:223.02pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,853&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:289.11pt;position:var(--position);text-decoration:none;white-space:pre">, respectively. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:347.36pt;position:var(--position);text-decoration:none;white-space:pre">In June 2024, the Group and Bpifrance agreed to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:348.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">terminate the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90.9pt;position:var(--position);text-decoration:none;white-space:pre">two</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:105.89pt;position:var(--position);text-decoration:none;white-space:pre"> projects due to technical failures (see Note 15.7).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:370.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As part of the Kreos / Claret Financing agreement, the Group has received loan commitments from Kreos and Claret for the tranches B </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:382.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and C, of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;25,000&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:146.51pt;position:var(--position);text-decoration:none;white-space:pre"> in aggregate principal amount each (subject to the conditions set forth in Note 15.1.). The B and C </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:394.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">tranches were drawn in March 2024 and June 2024, respectively. The Group redeemed all the tranches drawn as part of the Kreos / </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:406.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Claret Financing agreement during the year ended December 31, 2025.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:418.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As part of the Heights Financing agreement, the Group has received a loan commitment from Heights for the tranche B, of up to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:430.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;40,000&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:107.09pt;position:var(--position);text-decoration:none;white-space:pre"> in aggregate principal amount (subject to the conditions set forth in Note 15.2.). </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:430.91pt;position:var(--position);text-decoration:none;white-space:pre">On the limit date for the drawdown </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:442.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of the second tranche of the Heights Financing (i.e. August 4, 2024), the Group had not drawn down this tranche and has therefore </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:454.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">forgone its right to do so in the future. Tranche A was converted by the noteholders in July 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:421.5pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:478.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group has not received any significant off-balance sheet commitment and has no significant contingent asset as of December 31, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:490.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_OffBalanceSheetCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Off-Balance Sheet Commitments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_OffBalanceSheetCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other provisions, contingent liabilities and contingent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2025-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IAS37_g84-92_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Management and assessment of financial risks<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_FinancialRiskManagementAbstract', window );"><strong>Financial Risk Management [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory', window );">Management and assessment of financial risks</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre">Management and assessment of financial risks </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:550.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The principal financial instruments held by the Group are cash and cash equivalents. The purpose of holding these instruments is to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:561.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">finance the ongoing business activities of the Group. It is not the Group&#8217;s policy to invest in financial instruments for speculative </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:572.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">purposes. The Group does not use derivative financial instruments for hedging purposes. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:594.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The principal risks to which the Group is exposed to are liquidity risk, foreign currency exchange risk and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:462.51pt;position:var(--position);text-decoration:none;white-space:pre">credit</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.24pt;position:var(--position);text-decoration:none;white-space:pre"> risk. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:624.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Liquidity risk </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:646.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Liquidity risk management aims to ensure that the Group disposes of sufficient liquidity and financial resources to be able to meet </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:657.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">present and future obligations. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:679.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group prepares short-term cash forecasts and annual operating cash flow forecasts as part of its budget procedures.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Prudent liquidity risk management involves maintaining sufficient liquidity, having access to financial resources through appropriate </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:81.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">credit facilities and being able to unwind market positions.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:104.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group&#8217;s operations have consumed substantial amounts of cash since inception. Developing pharmaceutical drug candidates, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:115.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">including conducting clinical trials, is expensive, lengthy and risky, and the Group expects its research and development expenses to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">increase substantially in connection with its ongoing activities. Accordingly, the Group will continue to require substantial additional </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:137.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">capital to continue its clinical development activities and potentially engage in commercialization activities.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:160.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group's estimate of its cash runway as of the date of approval of these financial statements is set forth in Note 2</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:500.59pt;position:var(--position);text-decoration:none;white-space:pre"> - Going concern.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:189.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Interest rate risk </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:212.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, following the full repayment of the Kreos 1 bonds, all the Group&#8217;s non-derivative financial liabilities </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:224pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">accounted for at amortized cost bore fixed interest rates. Therefore, the Group had limited exposure.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:246.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Over the year ended December 31, 2024, the Group had drawn down the second and third tranches of the Kreos / Claret Financing, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:257.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">bearing variable interest rates (consisting of a fixed margin of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:285.13pt;position:var(--position);text-decoration:none;white-space:pre">7.5%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:305.96pt;position:var(--position);text-decoration:none;white-space:pre"> + European Central Bank Base Rate (MRO), with a floor at </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:548.81pt;position:var(--position);text-decoration:none;white-space:pre">2.5%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:569.64pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:268.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and a cap at </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.92pt;position:var(--position);text-decoration:none;white-space:pre">4%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:99.25pt;position:var(--position);text-decoration:none;white-space:pre">) and had therefore performed a reassessment of its exposure to interest rate risk. Due to the interest rate collar having </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:280pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">a range of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:78.45pt;position:var(--position);text-decoration:none;white-space:pre">150</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:93.45pt;position:var(--position);text-decoration:none;white-space:pre"> bp, the Group concluded that it still had limited exposure.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:302.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2025, the Group had reimbursed all its interest-bearing liabilities.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:313.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group's investments are short-term, highly liquid, and predominantly classified within Cash &amp; cash equivalents.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:324.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Accordingly, the Group has very limited exposure to interest rate risk.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:354pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Foreign currency risk</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:123.67pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:370pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group is exposed to a risk of exchange rates fluctuations on commercial transactions performed in currencies different from the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:380pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">functional currency of the Group entity recording the transactions. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:402pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:60.44pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:62.94pt;position:var(--position);text-decoration:none;white-space:pre">December 31, 2025, the monetary assets and liabilities denominated in U.S. dollars held by the Company amounted to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:414pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:86.75pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;327,222 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:162.84pt;position:var(--position);text-decoration:none;white-space:pre"> (of which cash and cash equivalents of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:322.67pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;143,180 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:398.76pt;position:var(--position);text-decoration:none;white-space:pre"> and intercompany receivables</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:520.53pt;position:var(--position);text-decoration:none;white-space:pre"> of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:533.86pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;194,712 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:426pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72.09pt;position:var(--position);text-decoration:none;white-space:pre">) and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.85pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;24,368 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:165.94pt;position:var(--position);text-decoration:none;white-space:pre"> (of which intercompany payables of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:315.23pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;22,726 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:386.32pt;position:var(--position);text-decoration:none;white-space:pre">)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:389.65pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:438pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As a result, a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90.66pt;position:var(--position);text-decoration:none;white-space:pre">10%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108.99pt;position:var(--position);text-decoration:none;white-space:pre"> adverse change in the euro c</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:224.95pt;position:var(--position);text-decoration:none;white-space:pre">losing exchange rate </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:309.56pt;position:var(--position);text-decoration:none;white-space:pre">against the U.S. dollar would have resulted in a foreign exchange </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:450pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">loss of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:64.88pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;29,747 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:135.97pt;position:var(--position);text-decoration:none;white-space:pre">, while a </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:172.59pt;position:var(--position);text-decoration:none;white-space:pre">10%</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:190.92pt;position:var(--position);text-decoration:none;white-space:pre"> favorable change would have resulted in a foreign exchange gain of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:466.71pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;36,358 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:537.8pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:462pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The U.S. Subsi</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.53pt;position:var(--position);text-decoration:none;white-space:pre">diar</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.06pt;position:var(--position);text-decoration:none;white-space:pre">y does not hold any monetary asset or liability denominated in currencies different from its functioning currency </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:474pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(the U.S. dollar).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:498pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">At this stage, the Group has not adopted any recurring mechanism of hedging to protect its activity against currency fluctuations. From </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:508pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">time to time, the Group may nevertheless subscribe currency term accounts in order to cover a commitment in currency as described </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:518pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">above. The Group may consider in the future using a suitable policy to hedge exchange risks in a more significant manner if needed. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:546pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Credit risk </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:568pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The credit risk related to the Group&#8217;s cash and cash equivalents is not significant in light of the quality of the co-contracting financial </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:579.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">institutions. As of December 31, 2025, substantially all of the Group&#8217;s cash and cash equivalents were maintained with </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:514.1pt;position:var(--position);text-decoration:none;white-space:pre">five</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:529.63pt;position:var(--position);text-decoration:none;white-space:pre"> financial </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:590.4pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">institutions in France and in the United States. While the Group&#8217;s deposit accounts are i</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:386.43pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">nsured up to the legal limit, the maintained </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:601.6pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">balances may, at times, exceed this insured limit. As of December </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:302.31pt;position:var(--position);text-decoration:none;white-space:pre">31, 2025, the Group maintained</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:429.43pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:431.93pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;92,482&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:503.02pt;position:var(--position);text-decoration:none;white-space:pre"> in bank deposit </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:612.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">accounts that are in excess of the legally insured limit in </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:263.19pt;position:var(--position);text-decoration:none;white-space:pre">five</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:278.72pt;position:var(--position);text-decoration:none;white-space:pre"> legally insured financial institutions, in addition to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.42pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;437,032&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:561.51pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:624pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">invested in mutual funds and structured notes, all invested with well-established financial institutions. The Group has not experienced </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:635.2pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">any losses in such accounts and does not believe that it is exposed to any significant credit risk related to these instruments.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:657.6pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The credit risk related to the Group&#8217;s </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:186.65pt;position:var(--position);text-decoration:none;white-space:pre">O</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:193.87pt;position:var(--position);text-decoration:none;white-space:pre">ther</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:209.96pt;position:var(--position);text-decoration:none;white-space:pre"> receivables and related accounts</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:344.24pt;position:var(--position);text-decoration:none;white-space:pre"> is minimal. In particular, the credit risk related to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:668.8pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">advances made to C</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:116.17pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">ROs (see Note 9) is</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:194.43pt;position:var(--position);text-decoration:none;white-space:pre"> deemed insignificant due to their credit ratings.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_FinancialRiskManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Risk Management [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_FinancialRiskManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the entity's financial risk management practices and policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialRiskManagementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We have implemented and maintain various information security processes designed to identify, assess and </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:358pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">manage material </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.76pt;position:var(--position);text-decoration:none;white-space:pre">risks</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:159.64pt;position:var(--position);text-decoration:none;white-space:pre"> from cybersecurity threats to our critical information systems, third party hosted services, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:368pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">communications systems, hardware and software, and our critical data (including intellectual property, confidential </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:378pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">information that is proprietary, strategic or competitive in nature, and data related to our clinical trials and products) </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:388pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">(collectively, &#8220;Information Systems and Data&#8221;).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:404pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our Chief Financial Officer as well as our external Data Protection Officer (&#8220;DPO&#8221;) and Information </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:414pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">Technology Director (&#8220;IT Director&#8221;), and other independent service providers help identify, assess and manage the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:424pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">our cybersecurity threats and risks. Individuals in these roles identify and assess risks from cybersecurity threats by </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:434pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">monitoring and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:135.84pt;position:var(--position);text-decoration:none;white-space:pre">evaluating</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:177.44pt;position:var(--position);text-decoration:none;white-space:pre"> our threat environment using various methods including, for example, maintaining </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:444pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">manual and automated tools, conducting scans of our threat environment, and conducting vulnerability assessments.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:460pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Depending on the environment, we implement and maintain various technical, physical, and organizational </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:470pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:480pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">threats to our Information Systems and Data. These measures, processes, standards, and policies include, for </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:490pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">example: incident </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:145.76999999999998pt;position:var(--position);text-decoration:none;white-space:pre">response</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:180.74pt;position:var(--position);text-decoration:none;white-space:pre"> plans and policies, personnel training, phishing test campaigns, penetration testing, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:500pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">system backups, cybersecurity insurance, network security controls, segmentation for certain systems and data </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:510pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">access controls and physical security controls.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:526pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.55pt;position:var(--position);text-decoration:none;white-space:pre">assessment</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.94pt;position:var(--position);text-decoration:none;white-space:pre"> and management of material risks from cybersecurity threats are integrated into our overall </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:536pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">risk management processes.&#160; For example, our external DPO and IT Director work with management in an effort to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:546pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:556pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">impact to our business.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:572pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">We use independent service provider</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:244.65pt;position:var(--position);text-decoration:none;white-space:pre">s</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:248.54pt;position:var(--position);text-decoration:none;white-space:pre"> to assist us from time to time to identify, assess, and manage material </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:582pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">risks from </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:115.31pt;position:var(--position);text-decoration:none;white-space:pre">cybersecurity</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:169.12pt;position:var(--position);text-decoration:none;white-space:pre"> threats, including for example: professional service firms, including legal counsel, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:592pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">penetration testing firms, dark web monitoring services, cybersecurity consultants, and cybersecurity software </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:602pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">providers.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:624pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Further, we use independent service providers to perform a variety of functions throughout our business, such </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:634pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">as hosting companies and contract research organizations. We undertake efforts designed to manage cybersecurity </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:644pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">risks associated with our use of these providers.&#160; For certain vendors, these efforts include security questionnaires, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:654pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">reviews of vendors&#8217; written security programs, reviews of security assessments, audits, and vulnerability scans </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:664pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">related to the vendors. Depending on the nature of the services provided, the sensitivity of the Information Systems </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:674pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and Data at issue, and the identity of the provider, our vendor management process may involve different levels of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:684pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">assessment designed to help identify cybersecurity risks associated with a provider and impose contractual </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:694pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">obligations related to cybersecurity on the provider.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Depending on the environment, we implement and maintain various technical, physical, and organizational </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:470pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:480pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">threats to our Information Systems and Data. These measures, processes, standards, and policies include, for </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:490pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">example: incident </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:145.76999999999998pt;position:var(--position);text-decoration:none;white-space:pre">response</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:180.74pt;position:var(--position);text-decoration:none;white-space:pre"> plans and policies, personnel training, phishing test campaigns, penetration testing, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:500pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">system backups, cybersecurity insurance, network security controls, segmentation for certain systems and data </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:510pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">access controls and physical security controls.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:526pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.55pt;position:var(--position);text-decoration:none;white-space:pre">assessment</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.94pt;position:var(--position);text-decoration:none;white-space:pre"> and management of material risks from cybersecurity threats are integrated into our overall </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:536pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">risk management processes.&#160; For example, our external DPO and IT Director work with management in an effort to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:546pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:556pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">impact to our business.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our Board addresses our cybersecurity risk management as part of its general oversight function. The Board is </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:170pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:180pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">from cybersecurity threats.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:179.36pt;position:var(--position);text-decoration:none;white-space:pre"> Our</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:197.41pt;position:var(--position);text-decoration:none;white-space:pre"> Committee of Executives (&#8220;COMEX&#8221;)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:355.54pt;position:var(--position);text-decoration:none;white-space:pre">, in addition to those identified below, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:190pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">provides </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108.92pt;position:var(--position);text-decoration:none;white-space:pre">input</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.46pt;position:var(--position);text-decoration:none;white-space:pre"> to the Board on cybersecurity threats. Our Committee of Executives consists of all our company's </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:200pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">officers along with our heads of manufacturing and quality.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:216pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our cybersecurity risk assessment and management processes are implemented and maintained by certain </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:226pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">management team members, including our</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:242.62pt;position:var(--position);text-decoration:none;white-space:pre"> Chief Financial Officer (&#8220;CFO&#8221;)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:375.77pt;position:var(--position);text-decoration:none;white-space:pre"> who oversees our external </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.38pt;position:var(--position);text-decoration:none;white-space:pre">IT Director </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:236pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and DPO</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108.93pt;position:var(--position);text-decoration:none;white-space:pre">. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.93pt;position:var(--position);text-decoration:none;white-space:pre">Our </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:131.98pt;position:var(--position);text-decoration:none;white-space:pre">CFO</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:151.42000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> has prior significant experience in strategic business operations</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:406.66pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:252pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our CFO as </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:147.31pt;position:var(--position);text-decoration:none;white-space:pre">well</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:164.5pt;position:var(--position);text-decoration:none;white-space:pre"> as our external IT Director and DPO are responsible for helping to integrate cybersecurity </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:262pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">risk considerations into our overall risk management strategy, and communicating key priorities to relevant </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:272pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">personnel. Our CFO is responsible for approving cybersecurity-related budgets, approving cybersecurity processes, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:282pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and reviewing security assessments and other security-related reports.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:298pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our cybersecurity incident response procedures are designed to escalate certain cybersecurity incidents to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:308pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">members of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:121.95pt;position:var(--position);text-decoration:none;white-space:pre">management</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:172.98000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> depending on circumstances, including our CFO. Our CFO works with our incident </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:318pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">responders (such as the external IT Director and DPO) to help us mitigate and remediate cybersecurity incidents of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:328pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">which they are notified.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:166.88pt;position:var(--position);text-decoration:none;white-space:pre"> In addition, our incident response process includes reporting to the Board for certain </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:338pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">cybersecurity incidents.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:354pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The Board </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:141.45pt;position:var(--position);text-decoration:none;white-space:pre">receives</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:174.16pt;position:var(--position);text-decoration:none;white-space:pre"> periodic communications from the CFO and others (such as the IT Director and DPO)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:520.48pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:364pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">concerning our significant cybersecurity threats, risk and the processes we have implemented in an effort to address </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:374pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">them.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our Board addresses our cybersecurity risk management as part of its general oversight function. The Board is </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:170pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:180pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">from cybersecurity threats.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:179.36pt;position:var(--position);text-decoration:none;white-space:pre"> Our</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:197.41pt;position:var(--position);text-decoration:none;white-space:pre"> Committee of Executives (&#8220;COMEX&#8221;)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:355.54pt;position:var(--position);text-decoration:none;white-space:pre">, in addition to those identified below, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:190pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">provides </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108.92pt;position:var(--position);text-decoration:none;white-space:pre">input</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.46pt;position:var(--position);text-decoration:none;white-space:pre"> to the Board on cybersecurity threats. Our Committee of Executives consists of all our company's </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:200pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">officers along with our heads of manufacturing and quality.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our cybersecurity incident response procedures are designed to escalate certain cybersecurity incidents to </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:308pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">members of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:121.95pt;position:var(--position);text-decoration:none;white-space:pre">management</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:172.98000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> depending on circumstances, including our CFO. Our CFO works with our incident </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:318pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">responders (such as the external IT Director and DPO) to help us mitigate and remediate cybersecurity incidents of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:328pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">which they are notified.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:166.88pt;position:var(--position);text-decoration:none;white-space:pre"> In addition, our incident response process includes reporting to the Board for certain </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:338pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">cybersecurity incidents.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:354pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">The Board </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:141.45pt;position:var(--position);text-decoration:none;white-space:pre">receives</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:174.16pt;position:var(--position);text-decoration:none;white-space:pre"> periodic communications from the CFO and others (such as the IT Director and DPO)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:520.48pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:364pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">concerning our significant cybersecurity threats, risk and the processes we have implemented in an effort to address </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:374pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">them.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our cybersecurity risk assessment and management processes are implemented and maintained by certain </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:226pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">management team members, including our</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:242.62pt;position:var(--position);text-decoration:none;white-space:pre"> Chief Financial Officer (&#8220;CFO&#8221;)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:375.77pt;position:var(--position);text-decoration:none;white-space:pre"> who oversees our external </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.38pt;position:var(--position);text-decoration:none;white-space:pre">IT Director </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:236pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and DPO</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108.93pt;position:var(--position);text-decoration:none;white-space:pre">. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.93pt;position:var(--position);text-decoration:none;white-space:pre">Our </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:131.98pt;position:var(--position);text-decoration:none;white-space:pre">CFO</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:151.42000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> has prior significant experience in strategic business operations</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:406.66pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:252pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our CFO as </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:147.31pt;position:var(--position);text-decoration:none;white-space:pre">well</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:164.5pt;position:var(--position);text-decoration:none;white-space:pre"> as our external IT Director and DPO are responsible for helping to integrate cybersecurity </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:262pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">risk considerations into our overall risk management strategy, and communicating key priorities to relevant </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:272pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">personnel. Our CFO is responsible for approving cybersecurity-related budgets, approving cybersecurity processes, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:282pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and reviewing security assessments and other security-related reports.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:298pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our cybersecurity incident response procedures are designed to escalate certain cybersecurity incidents to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:308pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">members of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:121.95pt;position:var(--position);text-decoration:none;white-space:pre">management</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:172.98000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> depending on circumstances, including our CFO. Our CFO works with our incident </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:318pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">responders (such as the external IT Director and DPO) to help us mitigate and remediate cybersecurity incidents of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:328pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">which they are notified.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:166.88pt;position:var(--position);text-decoration:none;white-space:pre"> In addition, our incident response process includes reporting to the Board for certain </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:338pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">cybersecurity incidents.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our cybersecurity risk assessment and management processes are implemented and maintained by certain </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:226pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">management team members, including our</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:242.62pt;position:var(--position);text-decoration:none;white-space:pre"> Chief Financial Officer (&#8220;CFO&#8221;)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:375.77pt;position:var(--position);text-decoration:none;white-space:pre"> who oversees our external </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.38pt;position:var(--position);text-decoration:none;white-space:pre">IT Director </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:236pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and DPO</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108.93pt;position:var(--position);text-decoration:none;white-space:pre">. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.93pt;position:var(--position);text-decoration:none;white-space:pre">Our </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:131.98pt;position:var(--position);text-decoration:none;white-space:pre">CFO</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:151.42000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> has prior significant experience in strategic business operations</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:406.66pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:252pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our CFO as </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:147.31pt;position:var(--position);text-decoration:none;white-space:pre">well</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:164.5pt;position:var(--position);text-decoration:none;white-space:pre"> as our external IT Director and DPO are responsible for helping to integrate cybersecurity </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:262pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">risk considerations into our overall risk management strategy, and communicating key priorities to relevant </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:272pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">personnel. Our CFO is responsible for approving cybersecurity-related budgets, approving cybersecurity processes, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:282pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">and reviewing security assessments and other security-related reports.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.93pt;position:var(--position);text-decoration:none;white-space:pre">Our </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:131.98pt;position:var(--position);text-decoration:none;white-space:pre">CFO</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:151.42000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> has prior significant experience in strategic business operations</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre">Our cybersecurity incident response procedures are designed to escalate certain cybersecurity incidents to </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:308pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">members of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:121.95pt;position:var(--position);text-decoration:none;white-space:pre">management</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:172.98000000000002pt;position:var(--position);text-decoration:none;white-space:pre"> depending on circumstances, including our CFO. Our CFO works with our incident </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:318pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">responders (such as the external IT Director and DPO) to help us mitigate and remediate cybersecurity incidents of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:328pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">which they are notified.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:166.88pt;position:var(--position);text-decoration:none;white-space:pre"> In addition, our incident response process includes reporting to the Board for certain </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:338pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">cybersecurity incidents.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting principles (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_AccountingPrinciplesAbstract', window );"><strong>Accounting Principles [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory', window );">Goodwill</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre">Goodwill </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:591.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Following initial recognition, goodwill is stated at cost less any accumulated impairment losses (see Note 4.4). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:613.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In respect of business combinations prior to January 1, 2020, in accordance with IFRS 1 exemption, goodwill is included on the basis </span></div>of its deemed cost, which represents the amount recorded under the prior basis of accounting, French GAAP, (&#8220;Previous GAAP&#8221;).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory', window );">Intangible assets</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre">Intangible assets </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:667.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Pursuant to IAS 38&#8212;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:122.36pt;position:var(--position);text-decoration:none;white-space:pre">Intangible Assets</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:190.9pt;position:var(--position);text-decoration:none;white-space:pre">, intangible assets acquired are recognized as assets on the statements of financial position at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:677.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">their acquisition cost. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Licenses, patents and development costs </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:86.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Payments for separately acquired research and development are capitalized within &#8220;intangible assets&#8221; provided that they meet the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:96.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">definition of an intangible asset: a resource that is (i)&#160;controlled by the Group, (ii) expected to provide future economic benefits for the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:106.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Group and (iii)&#160;identifiable (i.e., it is either separable or arises from contractual or legal rights). In accordance with paragraph 25 of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:116.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">IAS 38&#8212;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:74.61pt;position:var(--position);text-decoration:none;white-space:pre">Intangible Assets</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:143.15pt;position:var(--position);text-decoration:none;white-space:pre">, the recognition criterion relating to the likelihood of future economic benefits generated by the intangible </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">asset, is presumed to be achieved for research and development activities when they are acquired separately. In this context, amounts </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:136.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">paid to third parties in the form of initial payments or milestone payments relating to pharmaceutical specialties that have not yet </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:146.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">obtained a marketing authorization are recognized as intangible assets. These rights will be amortized on a straight-line basis, after </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:156.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">obtaining the marketing authorization, over their useful life. Unamortized rights (before marketing authorization) are subject to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:166.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">impairment tests in accordance with the method defined in Note 4.4.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:188.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Research and development costs</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:206.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Pursuant to IAS 38 &#8211; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:122.36pt;position:var(--position);text-decoration:none;white-space:pre">Intangible Assets</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:190.9pt;position:var(--position);text-decoration:none;white-space:pre">, research costs are expensed in the period during which they are incurred. Development costs </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:216.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">are only recognized as intangible assets if the following criteria are met: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:232.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">it is technically feasible to complete the development of the project; </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:248.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">it is th</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:116.02000000000001pt;position:var(--position);text-decoration:none;white-space:pre">e Group&#8217;s intention to complete the project and to utilize it; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:264.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">it has capacity to utilize the intangible asset; </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:280.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">there is proof of the probability of future economic benefits associated with the asset </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:296.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">there is availability of the technical, financial and other resources for completing the project; and </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:312.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">there is a reliable evaluation of the development expenses. </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:334.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The initial measurement of the asset is the sum of expenses incurred starting on the date on which the development project meets the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:344.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">above criteria. Because of the risks and uncertainties related to regulatory authorizations and to the research and development process, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:354.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the Group believes that the </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:146.14pt;position:var(--position);text-decoration:none;white-space:pre">six</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:157.8pt;position:var(--position);text-decoration:none;white-space:pre"> criteria stipulated by IAS 38 have not been fulfilled to date and the application of this principle has </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:364.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">resulted in all development costs being expensed as incurred in all periods presented. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:392.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Other intangible assets </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:408.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Other intangible assets mainly consist of acquired software. Costs related to the acquisition of software licenses are recognized as </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:418.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">assets based on the costs incurred to acquire and set up the related software. Other intangible assets are amortized using the straight-</span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">line method over a period of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:151.99pt;position:var(--position);text-decoration:none;white-space:pre">one year</span>.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property, plant and equipment</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre">Property, plant and equipment </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:472.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Pursuant to IAS 16 &#8211; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:122.36pt;position:var(--position);text-decoration:none;white-space:pre">Property, Plant and Equipment</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:247.8pt;position:var(--position);text-decoration:none;white-space:pre">, property, plant and equipment are recognized at their acquisition cost (purchase </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:482.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">price and directly attributable costs) or at their production cost by the Group, as applicable. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:504.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Property, plant and equipment are depreciated using the straight-line method over the estimated useful life of the asset. The principal </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:514.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">useful lives applied are as follows: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:524.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="position:var(--position);top:534.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:324pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:150.75pt"></td><td style="padding:0;width:95.25pt"></td><td style="padding:0;width:78pt"></td></tr><tr style="height:15.75pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:15.75pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td colspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:15.75pt;width:173.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:173.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;position:var(--position);text-decoration:none;white-space:pre">DEPRECIATION PERIOD</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:30pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Buildings</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:30pt;width:95.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:30pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:44.25pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Office fixtures and fittings</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:44.25pt;width:95.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:3.67pt;width:95.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:45.13pt;position:var(--position);text-decoration:none;white-space:pre">3 years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:73.71pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span><span style="font-family:'Times New Roman', serif;font-size:6.5pt;font-style:normal;font-weight:normal;left:76.21pt;position:var(--position);text-decoration:none;top:-2.4254999999999995pt;vertical-align:super;white-space:pre">(1)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:44.25pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:58.5pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Equipment</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:58.5pt;width:95.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:58.5pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:72.75pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Industrial materials and equipment</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:72.75pt;width:95.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:21.95pt;position:var(--position);text-decoration:none;white-space:pre">5</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:26.95pt;position:var(--position);white-space:pre"> to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.72pt;position:var(--position);text-decoration:none;white-space:pre">10 years</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:72.75pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:87pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Technical facilities</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:87pt;width:95.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:21.95pt;position:var(--position);text-decoration:none;white-space:pre">5</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:26.95pt;position:var(--position);white-space:pre"> to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.72pt;position:var(--position);text-decoration:none;white-space:pre">10 years</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:87pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:101.25pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Furniture and computer equipment:</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:101.25pt;width:95.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:101.25pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:115.5pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Office equipment</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:115.5pt;width:95.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:21.95pt;position:var(--position);text-decoration:none;white-space:pre">5</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:26.95pt;position:var(--position);white-space:pre"> to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.72pt;position:var(--position);text-decoration:none;white-space:pre">10 years</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:115.5pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:129.75pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">IT equipment</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:129.75pt;width:95.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;  &#160;&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:45.13pt;position:var(--position);text-decoration:none;white-space:pre">3 years</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:129.75pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:144pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Furniture</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:144pt;width:95.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:22.08pt;position:var(--position);white-space:pre">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.58pt;position:var(--position);text-decoration:none;white-space:pre">10 years</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:144pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:35.95pt;position:var(--position)">(1)<span style="display:inline-block;height:6.93pt;width:12.84pt"></span></span><span style="left:60.45pt;position:var(--position)">Office fixtures and fittings estimated useful lives correspond to the Paris headquarters and Boston offices residual estimated </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:80.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:60.45pt;position:var(--position);text-decoration:none;white-space:pre">lease terms. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:102.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The useful lives of property, plant and equipment as well as any residual values are reviewed at each year-end and, in the event of a </span></div>significant change, the depreciation schedule is revised prospectively.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory', window );">Impairment of goodwill, intangible assets, property and plant and equipment</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre">Impairment of goodwill, intangible assets, property and plant and equipment </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:156.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Goodwill and intangible assets not yet available for use are not amortized and are tested for impairment annually. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:178.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In addition, the Group assesses at the end of each reporting period whether there is an indication that intangible assets and property, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:188.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">plant and equipment may be impaired. Pursuant to IAS 36&#8212;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:278.56pt;position:var(--position);text-decoration:none;white-space:pre">Impairment of Assets</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:362.93pt;position:var(--position);text-decoration:none;white-space:pre">, criteria for assessing indication of loss in value may </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:198.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">notably include performance levels lower than forecast, a significant change in market data or the regulatory environment, or </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:208.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">obsolescence or physical damage of the asset not included in the amortization/depreciation schedule. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:230.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">For the purpose of impairment testing, goodwill and intangible assets not yet available for use are allocated to each of the Group&#8217;s </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:240.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">CGUs expected to benefit from synergies arising from the business combination or from the use of the intangible assets. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:262.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">An impairment loss is recognized when the carrying amount of a CGU, including the goodwill, exceeds the recoverable amount of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:272.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">CGU. The recoverable amount of a CGU is the higher of the CGU&#8217;s fair value less cost to sell and value-in-use. The total impairment </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:282.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">loss of a CGU is allocated first to reduce the carrying amount of goodwill allocated to the CGU and then to the other assets of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:292.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">CGU pro-rata on the basis of the carrying amount of each asset in the CGU. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:314.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">An impairment loss on goodwill is not reversed in a subsequent period. Impairment losses on intangible assets and property, plant and </span></div>equipment shall be reversed subsequently if the impairment loss no longer exists or has decreased.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory', window );">Financial assets at amortized cost</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Financial assets at amortized cost </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:384.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Other financial assets (advances, loans and deposits granted to third parties and other short-term investments) and other receivables are </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:394.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">non-derivative financial assets with fixed or determinable payments that are not listed on an active market. They are initially </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:404.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">recognized at fair value plus transaction costs that are directly attributable to the acquisition or issue of the financial asset. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:420.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">IFRS 9 &#8211; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:74.61pt;position:var(--position);text-decoration:none;white-space:pre">Financial Instruments </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:165.64pt;position:var(--position);text-decoration:none;white-space:pre">requires an entity to recognize a loss allowance for expected credit losses on a financial asset at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:430.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">amortized cost at each statement of financial position date. The amount of the loss allowance for expected credit losses equal to: (i)&#160;the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:440.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">12&#8212;month expected credit losses or (ii)&#160;the full lifetime expected credit losses. The latter applies if credit risk has increased </span></div>significantly since initial recognition of the financial instrument.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Cash and cash equivalents </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:494.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group classifies investments as cash equivalents in the statements of financial position and statements of cash flows when they </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:504.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">meet the conditions of IAS 7&#8212;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:161.17000000000002pt;position:var(--position);text-decoration:none;white-space:pre">Statement of Cash Flows, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:265.8pt;position:var(--position);text-decoration:none;white-space:pre">i.e., when they are: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:520.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">held in order to face short-term cash commitments; and </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:536.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">short term and highly liquid assets at acquisition date, readily convertible into known amount of cash and not exposed to </span></span></div>any material risk of change in value.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory', window );">Share capital</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre">Share capital </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:590.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Ordinary shares are classified in shareholders&#8217; equity. Costs associated with the issuance of new shares are directly accounted for in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:600.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">shareholders&#8217; equity in diminution of issuance premium. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:622.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group&#8217;s own shares bought in the context of a brokering/liquidity agreement entered with an independent broker are presented as </span></div>a reduction of shareholders&#8217; equity until their cancellation, their reissuance or their disposal.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share-based payments</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre">Share-based payments </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:96.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Since its inception, the Group has established several plans for compensation settled in equity instruments in the form of founders&#8217; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:106.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">share subscription warrants (&#8220;bons de souscription de parts de cr&#233;ateur d&#8217;entreprise&#8221; or &#8220;BCE&#8221;), share subscription warrants (&#8220;Bons de </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:116.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">souscription d&#8217;actions,&#8221; or &#8220;BSA&#8221;) and free shares (&#8220;Attributions gratuites d&#8217;actions,&#8221; or &#8220;AGA&#8221;), granted to its employees, corporate </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">officers and scientific consultants. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:148.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Pursuant to IFRS 2&#8212;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:122.36pt;position:var(--position);text-decoration:none;white-space:pre">Share-based Payment, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:214.78pt;position:var(--position);text-decoration:none;white-space:pre">these awards are measured at their fair value on the date of grant. The values of the equity </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:158.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">instruments are determined using the option pricing model (in particular, a Black and Scholes model for the BCE and BSA plans and a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:168.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Monte-Carlo simulation for the AGA plans which include market performance vesting conditions) based on the value of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:178.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">underlying equity instrument at grant date, the volatility observed in a sample of comparable listed companies and the estimated life of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:188.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the related equity instruments. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:210.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group recognizes the fair value of these awards as a share-based compensation expense over the period in which the related </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:220.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">services are received, i.e. over the vesting period, with a corresponding increase in shareholders&#8217; equity. Share-based compensation is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:230.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">recognized by installments in consistency with their graded vesting schedule, when applicable. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:252.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:262.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">performance conditions are expected to be met, such that the amount ultimately recognized is based on the number of awards that meet </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:272.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the related service and non-market performance conditions at the vesting date. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:294.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">For share-based payment awards with market vesting conditions and non-vesting conditions, the grant-date fair value of the share-</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:304.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">based payment is measured to reflect such conditions and there is no true-up for differences between expected and actual outcome. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:314.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The measurement of the fair value of BSA, BCE and AGA incorporates the market-based vesting conditions and non-vesting </span></div>conditions as described in Note 4.15 &#8220;Use of judgments and estimates&#8221;.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory', window );">Financial liabilities</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre">Financial liabilities </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:374.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:underline;white-space:pre">Note 4.8.1. Financial liabilities at amortized cost</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:402.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Pursuant to IFRS 9 &#8211; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:122.36pt;position:var(--position);text-decoration:none;white-space:pre">Financial Instruments, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:215.89pt;position:var(--position);text-decoration:none;white-space:pre">the borrowings, the debt component of the Kreos / Claret OCABSA (classified as </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:412.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">convertible loan notes &#8211; see </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:149.47pt;position:var(--position);text-decoration:none;white-space:pre">Compound instruments </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:244.98pt;position:var(--position);text-decoration:none;white-space:pre">Compound instruments below), royalty certificates and Other financial liabilities </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:422.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(conditional advances) other than financial derivative liabilities are measured at amortized cost. They are initially recognized at fair </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:432.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">value and subsequently measured at amortized cost calculated using the effective interest rate (&#8220;EIR&#8221;) method. The transaction costs </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:442.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">that are directly attributable to the issue of the financial liability reduce that financial liability. These expenses are then amortized over </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:452.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the lifetime of the liability, on the basis of the EIR. The EIR is the rate that exactly discounts estimated future cash payments through </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:462.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the expected life of the financial liability to the amortized cost of a financial liability. Financial liabilities that are due within one year </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:472.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">are presented as current financial liabilities in the statements of financial position.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:500.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Royalty certificates </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:516.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Royalty certificates meet the definition of financial liabilities. The Group concluded that they do not include embedded derivatives </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:526.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">related to the variability of royalties that are based on future net sales. In addition, the Group concluded that the prepayment options </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:536.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">were separate derivative instruments as their redemption price did not reimburse holders for an amount up to the approximate present </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:546.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">value of lost interest for the remaining term of the host contracts. However, their value at inception and subsequent dates is nil and has </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:556.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">no impact on the financial statements. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:585.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Royalty certificates are initially measured at fair value (refer to note 15.9 for valuation model applied). They are subsequently </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:597.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">measured at amortized cost calculated using the EIR method. The EIR is calculated based on future cash flows, which are estimated on </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:609.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the basis of development and commercialization plans and budgets approved by the Board of Directors of the Group, and probability-</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:621.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">weighted to reflect the probability of success of clinical studies and any other uncertainty affecting them. If there is a change in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:633.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">timing or amount of estimated cash flows, then the gross carrying amount of the amortized cost of the financial liability is adjusted in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:645.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the period of change to reflect the revised actual and estimated cash flows, with a corresponding income or expense being recognized </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:657.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in profit or loss. The revised gross carrying amount of the amortized cost of the financial liability is calculated by discounting the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:669.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">future revised estimated cash flows at the original EIR. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:699.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Conditional advances and State guaranteed loan &#8211; &#8220;PGE&#8221; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Accounting treatment for conditional advances and the State-guaranteed loan (Pr&#234;t garanti par l'Etat, or "PGE") is set forth in Note 4.9. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:98.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Leases </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:114.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Accounting treatment for lease liabilities is set forth in Note 4.12.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:146.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:underline;white-space:pre">Note 4.8.2. Financial liabilities measured at fair value through profit or loss </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:344.9pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:169.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Derivative instruments</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:127.27pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:186.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">BSA attached to Kreos 1 bonds, the conversion option of OCEANE, certain prepayment options of bonds, the Kreos / Claret warrants </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:196.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and the Kreos / Claret Minimum Return Indemnifications ("MRI") are derivatives instruments. Derivatives are recognized initially at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:206.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">fair value at the date the derivative contract is entered into and are subsequently remeasured to their fair value at each reporting date. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:216.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The resulting gain or loss from change in the fair value is recognized in profit or loss immediately, as financial expenses or income. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:244.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Hybrid instruments </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:272.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">OCEANE bonds </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:105.41pt;position:var(--position);text-decoration:none;white-space:pre">and Heights convertible notes (whose characteristics are described in Note 15.2 and Note 15.5)</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.25pt;position:var(--position);text-decoration:none;white-space:pre"> are hybrid </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:282.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">instruments. A &#8220;hybrid contract&#8221; is a contract that includes both a non-derivative host contract and one or more embedded derivatives. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:292.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Embedded derivatives are required to be separated from the host contract (bifurcated) if: the economic characteristics and risks of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:302.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">embedded derivative are not closely related to those of the host, a separate instrument with the same terms as the embedded derivative </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:312.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">would meet the definition of a derivative, and the hybrid contract is not measured at fair value through profit or loss. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:334.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Separable embedded derivatives are required to be measured at fair value at each reporting date, with changes in fair value recognized </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:344.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in profit or loss. The initial bifurcation of a separable embedded derivative does not result in any gain or loss being recognized. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:354.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Because the embedded derivative component is measured at fair value on initial recognition, the carrying amount of the host contract </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:364.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">on initial recognition is the difference between the carrying amount of the hybrid instrument and the fair value of the embedded </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:374.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">derivative. If the fair values of the hybrid instrument and host contract are more reliably measurable than that of the derivative </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:384.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">component - e.g. because of the availability of quoted market prices - then it may be acceptable to use those values to determine the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:394.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">fair value of the derivative on initial recognition indirectly - i.e. as a residual amount. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:416.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Heights convertible notes issued on August 24, 2023 included embedded derivatives as detailed in Note 15. The Group concluded </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:428.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">that these features were embedded derivatives that would modify the cash flows required under the contract and require to be </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:439.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">bifurcated from their host contract. The Group being unable to reliably value each embedded derivative at issuance date and on </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:450.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">subsequent reporting dates, it measured the whole hybrid instrument at fair value through profit or loss (&#8220;FVTPL&#8221;) as permitted by </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:461.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">IFRS 9. Instruments measured at FVTPL under these conditions are measured at their fair value on issuance and on subsequent </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:472.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">reporting dates, with changes in fair value recognized in profit or loss.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:495.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Compound instruments </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:519.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Kreos / Claret OCABSA are compound instruments (whose characteristics are describ</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:398.62pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">ed in Note 15.1). </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:468.57pt;position:var(--position);text-decoration:none;white-space:pre">A &#8220;compound contract&#8221; is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:530.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">a contract that includes both a debt component and an equity component.&#160; The debt component (excluding the conversion option and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:542.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the attached OCABSA warrants) is initially recognized at fair value and subsequently measured at amortized cost calculated using the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:553.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">EIR method. The equity component corresponding to the conversion option and the attached OCABSA warrants is recorded in equity, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:564.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">for the difference between the whole instrument&#8217;s fair value (its nominal value) and the standalone fair value of the debt component.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:593.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Fair value measurement </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:609.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">When measuring the fair value of an asset or a liability, the Company uses market observable data as far as possible. Fair values are </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:619.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:635.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">level 1: fair value calculated using quoted prices in an active market for identical assets and liabilities; </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:651.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">level 2: fair value calculated using valuation techniques based on observable market data such as prices for assets and </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:661.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">liabilities or similar parameters quoted in an active market; &#160;</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:671.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">level 3: fair value calculated using valuation techniques based in whole or in part on unobservable inputs such as prices </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:681.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">in an inactive market or a valuation based on multiples of unlisted securities. </span></div>See Note 12 Financial assets and liabilities and Note 15 Financial liabilities.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants', window );">Research tax credit and subsidies</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Research tax credit </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:102.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group benefits from the provisions of Article 244 </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:255.53pt;position:var(--position);text-decoration:none;white-space:pre">quater </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:284.12pt;position:var(--position);text-decoration:none;white-space:pre">B of the French General Tax Code relating to the French research tax </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:112.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">credit (&#8220;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:68.99000000000001pt;position:var(--position);text-decoration:none;white-space:pre">Cr&#233;dit d&#8217;Imp&#244;t Recherche</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:173.3pt;position:var(--position);text-decoration:none;white-space:pre">&#8221; or &#8220;CIR&#8221;). The CIR is granted to companies in order to encourage them to conduct technical and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:122.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">scientific research. Companies that prove that they have expenditures which meet the required criteria (research expenditures located </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:132.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in France or, since January 1, 2005, within the European Union or in another state that is a party to the Agreement on the European </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:142.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Economic Area and has concluded a tax treaty with France that contains an administrative assistance clause) receive a tax credit that </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:152.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">can be used for the payment of the corporate tax due for the fiscal year in which the expenditures were made and the next three fiscal </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:162.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">years, or as applicable, companies may receive cash reimbursement for any excess portion at the three-year period following the fiscal </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:172.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">year of the expenditures. Only those companies meeting the EU definition of a small or medium-sized entity (&#8220;SME&#8221;) are eligible for </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:182.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">payment in cash of their research tax credit (to the extent not used to offset corporate tax payables) in the year following the request </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:192.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">for reimbursement. The expenditures taken into account for the calculation of the CIR involve only research expenses. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:214.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The CIR is presented under &#8220;Other operating income&#8221; in the statements of income (loss) as it is accounted for as a government grant </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:224.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">as defined in IAS 20 &#8211; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:128.16pt;position:var(--position);text-decoration:none;white-space:pre">Accounting for Government Grants and Disclosure of Government Assistanc</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:435.67pt;position:var(--position);text-decoration:none;white-space:pre">e, and as &#8220;Other receivables and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:234.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">assets&#8221; in the statement of financial position until its payment is received. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:262.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Subsidies </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:278.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Subsidies are non-repayable grants received by the Group and recognized in the financial statements when there exists reasonable </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:288.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">assurance that the Group will comply with the conditions attached to the subsidies and the subsidies will be received. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:310.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Subsidies that are upfront payments are presented as deferred income and recognized through &#8220;Other operating income&#8221; for the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:320.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">amount of the expenses incurred as part of the research program to which the subsidy relates. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:342.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">A subsidy that is to be received either as compensation for expenses or for losses already incurred, or for immediate financial support </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:352.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of the Group without associated future costs, is recognized in the Statements of income (loss) as &#8220;Other operating income&#8221; when there </span></div>exists reasonable assurance that the subsidies will be received.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory', window );">Conditional advances and PGE</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Conditional advances and PGE </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:406.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group receives conditional advances to finance at below market interest rate research and development projects. Due to the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:416.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">innovative nature of its drug candidate development programs, the Group has benefited from certain sources of financial assistance </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:426.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">from Bpifrance. Bpifrance provides financial assistance and support to emerging French enterprises to facilitate the development and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:436.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">commercialization of innovative technologies. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:458.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Funds received from Bpifrance in the form of conditional advances are recognized as financial liabilities, as the Group has a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:468.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">contractual obligation to reimburse Bpifrance for such conditional advances in cash based on a repayment schedule. Each award of an </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:478.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">advance is made to help fund a specific development milestone. More de</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:327.3pt;position:var(--position);text-decoration:none;white-space:pre">tails </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:346.43pt;position:var(--position);text-decoration:none;white-space:pre">on conditional advances are provided in Note 15.7. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:488.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Receipts or reimbursements of conditional advances are reflected as financing transactions in the statements of cash flows. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:510.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The difference between the present value of the advance at market rate (i.e., present value of contractual cash flows including principal </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:520.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and interests, discounted using a market rate as effective interest rate in accordance with IFRS 9) and the amount received as cash </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:530.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">from the Bpifrance constitutes a subsidy within the meaning of IAS 20. Considering that these advances do not finance fixed assets, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:540.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">these subsidies are presented as &#8220;Deferred income&#8221; in the statement of financial position and recognized in the statement of net income </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:550.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(loss) as &#8220;Other operating income&#8220; on a systematic basis over the periods in which the Group recognizes as expenses the related costs </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:560.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">for which the grants are intended to compensate. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:582.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The incremental interest expense resulting from the difference between (a)&#160;the market interest rate and the (b)&#160;below-market rate is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:592.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">spread over the contractual period until the last repayment and recognized in the statement of income (loss) accordingly, using the EIR </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:602.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">method. In the event of a change in estimate of contractual cash flows due under the conditional advances, the Group recalculates the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:612.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">book value of the debt resulting from the discounting of the anticipated new future cash flows at the initial EIR. The adjustment is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:622.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">recognized in the statements of income (loss) for the period during which the modification is recognized. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:644.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In the statements of financial position, these conditional advances are recorded in &#8220;Other financial liabilities&#8221; as current or non-current </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:654.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">portion depending on their maturity. In the event Bpifrance waived the repayment of the advance, the corresponding liability is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:664.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">derecognized and treated as a subsidy in the statements of income (loss). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:686.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The benefit resulting from the low interest of PGE loans is also recognized as a subsidy corresponding to the difference between the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:696.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">present value of the PGE at market rate and the amount received as cash. The accounting treatment is therefore similar to the above-</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">mentioned accounting treatment for conditional advances. PGE are recorded in &#8220;Borrowings&#8221; as current or non-current portion </span></div>depending on their maturity.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory', window );">Employee benefits</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:80.42pt;position:var(--position);text-decoration:none;white-space:pre">Employee benefits </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:124.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group&#8217;s employees in France benefit from retirement benefits provided under French law, which consist in the following: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:140.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">compensation paid by the Group to employees upon their retirement (a defined benefit plan); and </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:156.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">payments of retirement pensions by the social security agencies, which are financed by the contributions made by the </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:166.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">Group and employees. As they meet the definition of a defined contribution plan, the liabilities are presented as Tax and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:176.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">employee-related payables in the statement of financial position. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:198.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In accordance with IAS 19 &#8211; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:153.11pt;position:var(--position);text-decoration:none;white-space:pre">Employee Benefits</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:227.15pt;position:var(--position);text-decoration:none;white-space:pre">, the liability with respect to defined benefit plans is estimated by using the projected </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:208.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">credit unit method. According to this method, the cost of the retirement benefit is recognized in the statements of income (loss). The </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:218.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">retirement benefit commitments are valued at the current value of the estimated future payments, discounted using the market rate for </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:228.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">high quality corporate bonds with a term and currency that correspond to that estimated for the payment of the benefits. The Group </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:238.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">applied the decision of the IFRS IC, published on May&#160;24, 2021, that concluded that, in the case that no rights were acquired in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:248.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">event of departure before retirement age and that the rights were capped after a certain number of years of seniority (&#8220;30 years&#8221;), the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:258.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">commitment would only be recognized for the last 30 years of the employee&#8217;s career within the Group. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:280.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The difference between the amount of the provision at the beginning of a period and at the close of that period is recognized through </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:290.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">operating expenses for the portion representing the costs of services rendered and financial expenses for the net interest costs, and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:300.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">through other comprehensive income (loss) for the portion representing the actuarial gains and losses due to changes in assumptions </span></div>and experience adjustments.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory', window );">Provisions</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:80.42pt;position:var(--position);text-decoration:none;white-space:pre">Provisions </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:348.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Provisions correspond to commitments resulting from litigation and various risks to which the Group may face in the context of its </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:358.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">operations, as well as taxes and employer contributions related to AGAs that become due upon the vesting of the awards. In </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:368.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">accordance with IAS 37 &#8211; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:142.28pt;position:var(--position);text-decoration:none;white-space:pre">Provisions, Contingent Liabilities and</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:294.92pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:297.42pt;position:var(--position);text-decoration:none;white-space:pre">Contingent Assets, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:374.29pt;position:var(--position);text-decoration:none;white-space:pre">a provision is recorded when the Group has an </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:378.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">obligation to a third party resulting from a past event that will likely result in an outflow of resources to the third party, and for which </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:388.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">future cash outflows may be estimated reliably. The amount recorded as a provision is an estimate of the expenditure required to settle </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:398.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the obligation, discounted where necessary at year end. For AGA taxes, the taxes are based on the vesting date share price, and the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:408.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">provision is estimated based on the spot listed price at year-end multiplied by the number of AGAs which are expected to vest. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:418.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Contingent</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:80.4pt;position:var(--position);text-decoration:none;white-space:pre"> liabilities are not recognized, but are disclosed in the notes to the financial statements unless the possibility of an outflow </span></div>of economic resources is remote.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:80.42pt;position:var(--position);text-decoration:none;white-space:pre">Leases </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:472.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">As lessee, the Group assesses whether a contract contains a lease at inception of a contract and upon the modification of a contract. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:482.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group elected to allocate the consideration in the contract to the lease and non-lease components on the basis of the relative </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:492.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">standalone price. The Group recognizes a right-of-use asset and a corresponding lease liability for all arrangements in which it is a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:502.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">lessee, except for leases with a term of 12 months or less (short-term leases) and low-value leases (value of the underlying asset below </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:512.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.0 thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:92.09pt;position:var(--position);text-decoration:none;white-space:pre">). For these short-term and low-value leases, the Group recognizes the lease payments as an operating expense on a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:522.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">straight-line basis over the term of the lease. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:544.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The lease liability is initially measured at the present value of the future lease payments as from the commencement date of the lease </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:554.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">to the end of the lease term. The lease terms used by the Group reflect the non-cancellable terms of each contract, plus any extension </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:564.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">or termination options that the Group is reasonably certain to exercise or not exercise for all of the leases periods covered by the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:574.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">extension options. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:584.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Group incremental borrowing rate for the asset subject to the lease in the respective markets. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:606.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever there is a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:616.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">change to the lease terms or expected payments under the lease, or a modification that is not accounted for as a separate lease. The </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:626.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">portion of the lease payments attributable to the repayment of lease liabilities and the portion attributable to payment of interests are </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:636.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">recognized in cash flows used in financing activities. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:658.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Right-of-use assets are initially recognized on the balance sheet at cost, which comprises the amount of the initial measurement of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:668.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">corresponding lease liability, adjusted for any lease payments made at or prior to the commencement date of the lease, any lease </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:678.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">incentives received and any initial direct costs incurred by the Group, and expected costs for obligations to dismantle and remove </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:688.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">right-of-use assets when they are no longer used. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Right-of-use assets are depreciated on a straight-line basis from the commencement date of the lease over the shorter of the useful life </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:80.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of the right-of-use asset or the end of the lease term. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:102.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Right-of-use assets are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be </span></div>recoverable using cash flow projections.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Translation of transactions denominated in foreign currency</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:80.42pt;position:var(--position);text-decoration:none;white-space:pre">Translation of transactions denominated in foreign currency </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:156.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Pursuant to IAS 21</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.36pt;position:var(--position);text-decoration:none;white-space:pre"> &#8211; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:122.36pt;position:var(--position);text-decoration:none;white-space:pre">The Effects of Changes in Foreign Exchange Rates</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:326.3pt;position:var(--position);text-decoration:none;white-space:pre">, transactions performed by the Company and the Subsidiary </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:166.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in currencies other than their functional currencies, which are respectively the Euro and the U.S. dollar, are translated at the prevailing </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:176.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">exchange rate on the transaction date. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:198.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Trade receivables and payables and liabilities denominated in a currency other than the functional currency are translated at the </span></div>period-end exchange rate. Unrealized gains and losses arising on translation are recognized in net financial income / (loss).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory', window );">Current taxes</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to the </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:256.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">French tax authorities, using tax rates and tax laws enacted or substantively enacted at the end of the reporting period in accordance </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:266.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">with IAS 12 &#8211; Income Tax. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:288.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The income tax charge for the period comprises current tax due and the deferred tax charge. The tax expense is recognized in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:298.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">statement of income (loss) unless it relates to items recorded in other comprehensive income (loss) or directly in equity, in which case </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:308.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the tax is also recorded in other comprehensive income (loss) or directly in equity. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:336.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Current taxes </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:352.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The current tax expense is calculated based on taxable profit for the period, using tax rates enacted or substantively enacted at the </span></div>statement of financial position date. Considering the level of tax loss of the Group, no current tax expense is recognized.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory', window );">Deferred taxes</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Deferred taxes </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:406.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Deferred taxes are recognized when there are temporary differences between the carrying amount of assets and liabilities in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:416.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Group&#8217;s financial statements and the corresponding tax basis used to calculate taxable profit. Deferred taxes are not recognized if they </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:426.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">arise from the initial recognition of an asset or liability in a transaction other than a business combination which, at the time of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:436.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">transaction, does not affect either the accounting or the taxable profit (tax loss). </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:446.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group applies the Amendments to IAS 12 &#8211; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:232.23pt;position:var(--position);text-decoration:none;white-space:pre">Deferred Tax related to Assets and Liabilities arising from a Single Transaction</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:552.79pt;position:var(--position);text-decoration:none;white-space:pre">, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:456.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">issued on May 7, 2021, and presents the deferred tax assets and liabilities arising from such transactions separately within Note 22 </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:559.6pt;position:var(--position);text-decoration:none;white-space:pre">- </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:466.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Income tax, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.11pt;position:var(--position);text-decoration:none;white-space:pre">rather than on a net basis. The Amendments have no impact on the Statements of financial position and the Statement of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:476.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">comprehensive income (loss) for the periods presented.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:504.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Deferred tax assets </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:520.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Deferred tax assets are recognized for all deductible temporary differences, unused tax losses and unused tax credits to the extent that </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:530.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">it is probable that the temporary difference will reverse in the foreseeable future and that taxable profit will be available against which </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:540.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the deductible temporary difference, unused tax losses or unused tax credits can be utilized. In this regard, the Group applies the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:550.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">decision of the IFRS IC, published on January 29, 2021, on the amount of deferred tax assets recognized from unused tax losses as a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:560.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">result of suitable taxable temporary differences, in the case when the use of such tax losses is restricted or limited by the tax law. See </span></div>Note 4.15. Use of judgments and estimates and Note 22 Income tax.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfAccountingPolicyForAccountingJudgementsAndEstimatesExplanatoryPolicyTextBlock', window );">Use of judgments and estimates</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:80.42pt;position:var(--position);text-decoration:none;white-space:pre">Use of judgments and estimates </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:614.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In order to prepare financial statements in accordance with IFRS, estimates, judgments and assumptions were made by the Group&#8217;s </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:624.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">management which could affect the reported amounts of assets, liabilities, contingent liabilities, income and expenses. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:646.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">These estimates are based on the assumption of going concern and are prepared in accordance with information available at the date </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:656.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the financial statements were prepared. They are reviewed on an ongoing basis using past experience and various other factors </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:666.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">considered to be reasonable as the basis to measure the carrying amount of assets and liabilities. Estimates may be revised due to </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:676.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">changes in the underlying circumstances or subsequent to new information. Actual results may differ significantly from these </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:686.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">estimates in line with assumptions or different conditions. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">This note provides an overview of the areas that involved a higher degree of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:342.88pt;position:var(--position);text-decoration:none;white-space:pre">judgment </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:383.12pt;position:var(--position);text-decoration:none;white-space:pre">or complexity, and of items which are more </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:80.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">likely to be materially adjusted due to changes in estimates and assumptions. Detailed information about each of these estimates and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:90.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">judgments </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:80.13pt;position:var(--position);text-decoration:none;white-space:pre">is included in other notes together with information about the basis of calculation for each affected line item in the financial </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:100.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">statements. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:116.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Recognition and measurement of impairment of CGUs. The main assumptions used for the impairment test include </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">(a)&#160;the amount of cash flows that are set on the basis of the development and commercialization plans and budgets </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:136.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">approved by Board of Directors, (b)&#160;assumptions related to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:329.16pt;position:var(--position);text-decoration:none;white-space:pre">the</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:341.36pt;position:var(--position);text-decoration:none;white-space:pre"> achievement of the clinical trials and the launch of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:146.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">commercialization, (c)&#160;the discount rate, (d) assumptions on risk related to the development and (e)&#160;for the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:156.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">commercialization, selling price and volume of sales. The sensitivity analysis in respect of the recoverable amount of the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:166.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">CGUs is presented in Note 6. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:182.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Measurement of share-based payments granted to employees, corporate officers and scientific consultants, such as BCE, </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:194.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">BSA and AGA, which is based on actuarial models; these models require the use by the Group of certain calculation </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:205.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">assumptions such as the estimated vesting, the occurrence dates of a change of control or a M&amp;A transaction dates, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:554.11pt;position:var(--position);text-decoration:none;white-space:pre">the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:217.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">percentage of success (&#8220;POS&#8221;) of obefazimod,</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:276.94pt;position:var(--position);text-decoration:none;white-space:pre"> the expected volatility and maturity of the underlying equity instrument </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:228.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">(see Note 4.7 and Note 14), </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:246.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Fair value measurement at inception and after of derivative financial instruments resulting from (i)&#160;the warrants issued </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:257.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">concomitantly with the issuance of the straight and convertible bonds to Kreos on July 24, 2018 (or &#8220;Kreos 1&#8221;), </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.25pt;position:var(--position);text-decoration:none;white-space:pre">(ii) the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:269.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">Kreos / Claret BSA issued on August 21, 2023 and November 2, 2023, related to tranches A-B and tranche C, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:280.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">respectively, and (iii) the Kreos / Claret Minimum Return Indemnifications related to tranches B and C, issued in March </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:292.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">2024 and June 2024, respectively,</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:309.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Amortized cost measurement a</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:215.04000000000002pt;position:var(--position);text-decoration:none;white-space:pre">nd fair value</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:265.53000000000003pt;position:var(--position);text-decoration:none;white-space:pre"> of royalty certificates, based on the following assumptions: (a)&#160;future cash </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:319.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">flows, estimated on the basis of development and commercialization plans and budgets approved by the Board of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:329.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">Directors, (b)&#160;the effective interest rate (for the amortized cost measurement) and (c) the discount rate (for the fair </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:339.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">value). The sensitivity analyses in respect of the amortized cost measurement and fair value of royalty certificates is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:349.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">presented in Note 15,&#160; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:365.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Fair value measurement of other financial liabilities at inception, </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:352.32pt;position:var(--position);text-decoration:none;white-space:pre">and after, for the Heights convertible notes measured at </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:377.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">fair value at each reporting period, with fair value changes recognized in profit or loss, as well as for disclosure purposes </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:388.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">(see Note 15), </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:406.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Estimation of CIR, based on internal and external expenses, which meet the required criteria, incurred by the Group each </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:416.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">year (see Note 4.9), </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:432.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:72.7pt;position:var(--position)">&#8226;<span style="display:inline-block;height:6.93pt;width:14.85pt"></span></span><span style="left:91.05000000000001pt;position:var(--position)">Recognition of deferred tax assets: availability and timing of future taxable profit against which deductible temporary </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:442.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">differences and tax losses carried forward can be utilized and whether sufficient evidence exists (see Note 22),</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:458.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72.69999999999999pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">Recognition of deferred tax assets: tax deductibility of future royalty payments related to the royalty certificates issued in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:470.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">September 2022 (see Notes 15 and 22),</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:488.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72.69999999999999pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">Determination of the terms of the leases, including whether the Group is reasonably certain to exercise extension and/or </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:500.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">termination options (see Note 15.8).</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:536.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The main critical judgments made by the Group&#8217;s management impact the following items: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:564.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72.69999999999999pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre">Accounting treatment of specific conditions of share-based compensation plans (see Notes 4.7 and 14),</span></div><div style="font-size:12pt;line-height:10.5pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:582.06pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:10.5pt;font-style:normal;font-weight:normal;left:72.69999999999999pt;position:var(--position);text-decoration:none;white-space:pre;width:3.67pt">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre;width:484.88pt">Accounting treatment of the royalty certificates and August 2023 Kreos / Claret and Heights Financings (see Notes 4.8</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.93pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:593.61pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre;width:32.76pt">and 15).</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfIFRSCompliance', window );">Statement of compliance</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Statement of compliance </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:603.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The consolidated financial statements of the Group as of and for the years ended December 31, 2023, 2024 and 2025 have been </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:614.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">prepared in accordance with both International Financial Reporting Standards (&#8220;IFRS&#8221;) as issued by the International Accounting </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:625.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Standard Board (&#8220;IASB&#8221;) and IFRS as adopted by the European Union (&#8220;EU&#8221;) regulation n&#176;1606/2002 of July 19, 2002. The term </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:636.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8220;IFRS&#8221; refers collectively to International Accounting Standards (&#8220;IAS&#8221;) and IFRS as well as the interpretations issued by the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:648.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Standing Interpretations Committee (&#8220;SIC&#8221;) and the International Financial Reporting Interpretations Standards Committee (&#8220;IFRS </span></div>IC&#8221;), whose application is mandatory for the year ended December 31, 2025.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock', window );">Going concern</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Going concern </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:177.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group has incurre</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:126.19pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">d substantial operating losses since inception and expects to continue to incur significant operating losses for the </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:189.36pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">foreseeab</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:74.27000000000001pt;position:var(--position);text-decoration:none;white-space:pre">le future and may never become profitable. For the year ended December 31, 2025, the Group had a net loss of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:519.9100000000001pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;336,102 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:201.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72.09pt;position:var(--position);text-decoration:none;white-space:pre">.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:74.59pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:77.09pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:225.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Since inception, the Group has financed its operations through the issuance of ordinary shares with gross aggregate proceeds of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:237.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1,194.7 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:102.35pt;position:var(--position);text-decoration:none;white-space:pre">, of which </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:145.1pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;130&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:196.45pt;position:var(--position);text-decoration:none;white-space:pre"> of gross proceeds were from offerings of its ordinary shares on Euronext Paris in February </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:249.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">2023, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:61pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;223.3&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:119.85pt;position:var(--position);text-decoration:none;white-space:pre"> of gross proceeds were from its offering of ordinary shares in the form of American Depository Shares ("ADS") </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:261.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">on the Nasdaq Global Market as well as ordinary shares in Europe (including France) and countries outside of the United States in a </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:273.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">private placement in October 2023, and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:196.64pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;637.5 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:255.49pt;position:var(--position);text-decoration:none;white-space:pre"> of gross proceeds were from the offering of the Group's ordinary shares in the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:285.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">form of ADS on the Nasdaq Global Market in July 2025 ("the Offering"), </span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:332.83pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">ba</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:342.26pt;position:var(--position);text-decoration:none;white-space:pre">nk borrowings and structured loans</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:483.27pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.77pt;position:var(--position);text-decoration:none;white-space:pre">for </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:499.93pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;175.0&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:558.78pt;position:var(--position);text-decoration:none;white-space:pre">, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:297.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">reimbursements of Research Tax Credits (Cr&#233;dit d&#8217;Imp&#244;t Recherche (&#8220;CIR&#8221;)) in an aggregate amo</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:430.47pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">unt of </span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:456.57pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;41.2 million</span><span style="background-color:#ffff00;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:510.42pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">,</span></span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:512.9200000000001pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit"> subsidies </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:309.36pt;width:612pt"><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">received from Banque Publique d&#8217;Investissement (&#8220;Bpifrance&#8221;) (inclu</span></span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:316.2pt;position:var(--position);text-decoration:none;white-space:pre">ding </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:336.47pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;17.1&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:390.32pt;position:var(--position);text-decoration:none;white-space:pre"> of subsidies and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:459.72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1.8&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:508.57pt;position:var(--position);text-decoration:none;white-space:pre"> of conditional </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:321.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">advances) and royalty certificates in an amount of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:237.95pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;2.9&#160;million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:286.8pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:345.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Based on the Group&#8217;s existing cash and cash equivalents </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:264.93pt;position:var(--position);text-decoration:none;white-space:pre">and other short-</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:328.21pt;position:var(--position);text-decoration:none;white-space:pre">term investments</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:396.73pt;position:var(--position);text-decoration:none;white-space:pre"> of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:410.06pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;530.4 million</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:468.91pt;position:var(--position);text-decoration:none;white-space:pre"> a</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:475.84pt;position:var(--position);text-decoration:none;white-space:pre">s of December 31, 2025, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:356.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the Group expects, as of the date of issuance of these financial statements, to be able to fund its forecasted cash flow requirements into </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:368.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the fourth quarter of 20</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.25pt;position:var(--position);text-decoration:none;white-space:pre">27. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:144.25pt;position:var(--position);text-decoration:none;white-space:pre">This take</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:181.14pt;position:var(--position);text-decoration:none;white-space:pre">s into account management's assumptions</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:347.76pt;position:var(--position);text-decoration:none;white-space:pre"> of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:361.09pt;position:var(--position);text-decoration:none;white-space:pre">continued</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:400.49pt;position:var(--position);text-decoration:none;white-space:pre"> R&amp;D expenditure related to the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:379.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">continuation of the Phase 3 clinical trials of obefazimod in UC, progression of the Phase 2b clinical trials for CD and the initial stages </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:391.36pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">of the scale up of the commercial organization as the Group prepares for a potential launch of obefazimod in UC.</span><span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:488.78pt;position:var(--position);text-decoration:none;white-space:pre"><span style="background-color:inherit">&#160; </span></span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:414.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Based on the above, these financial statements have been prepared on a going concern basis.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfImpactOfTheUkraineRussiaHostilitiesOnTheGroupPolicyTextBlock', window );">Impact of the Ukraine/Russia Hostilities on the Group</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Impact of the Ukraine/Russia Hostilities on the Group </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:466.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">In February 2022, Russia invaded Ukraine. The conflict has already had major implications for the global economy and the rate of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:478.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">inflation, particularly in relation to the supply of energy, raw materials and food products. It has also caused intense volatility on the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:489.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">financial markets, something that is still ongoing at the reporting date and has pushed down stock market prices around the world. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:511.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Given these developments, the Group has decided not to include Russia and Belarus in its global Phase 3 program for obefazimod in </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:522.86pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">UC. However, the global scale of this conflict cannot be predicted at this stage. The Group, therefore, cannot rule out an adverse </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:534.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">impact of this conflict on its business, including in terms of access to raw materials, logistics, the performance of clinical studies and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:545.26pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in relation to any future financing the Group may seek. </span></div><div style="font-size:12pt;line-height:11pt;position:var(--position);top:567.66pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The long-term safety and efficacy extension of the</span><span style="color:#ff0000;font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:237.68pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:240.16pt;position:var(--position);text-decoration:none;white-space:pre">Phase 2b maintenance trial of obefazimod in moderately to severely active UC is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:579.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the Group&#8217;s only clinical trial with patients currently enrolled in Ukraine.&#160; The Phase 2b 12-month assessment was carried out in all </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:591.18pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">the Ukrainian patients before the war broke out and these patients are therefore included in the one-year maintenance results that were </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:602.38pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">reported on April 6, 2022. Ukrainian patients who completed the two-year Phase 2b maintenance trial have been transitioned to the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:613.58pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">long-term safety and efficacy trial that is still on-going. The Group also has a few Ukrainian sites active in the western part of Ukraine </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:624.78pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">in the ABTECT Phase 3 clinical trials.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:189.95pt;position:var(--position);text-decoration:none;white-space:pre"> None of these sites are located in the Crimea Region of Ukraine, the so-called Donetsk </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:635.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">People&#8217;s Republic, or the so-called Luhansk People&#8217;s Republic. We continue to monitor developments in the region, but any </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:647.18pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">instability as a result of the war may have material adverse impacts on these clinical sites, which could negatively impact our Phase 3 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:658.38pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">clinical trials.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:680.78pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Together with its contract research organizations ("</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:240.91pt;position:var(--position);text-decoration:none;white-space:pre">CROs")</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:272.75pt;position:var(--position);text-decoration:none;white-space:pre">, the Group is making considerable efforts to ensure the follow-up of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:691.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">patients who are unable to come to the study centers. Monitoring takes place through a remote monitoring system that was established </span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">and used successfully during the COVID-19 pandemic.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfAccountingPolicyForNewRevisedOrAmendedStandardsAndInterpretationsPolicyTextBlock', window );">New, revised or amended Standards and Interpretations</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">N</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:42.66pt;position:var(--position);text-decoration:none;white-space:pre">ew, revised or amended Standards and Interpreta</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:241.12pt;position:var(--position);text-decoration:none;white-space:pre">tions </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:92.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group applied the amendment to IAS 21 The Effects of Changes in Foreign Exchange Rates &#8211; Lack of Exchangeability that is </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:103.76pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">effective as of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:95.07pt;position:var(--position);text-decoration:none;white-space:pre">December&#160;31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:173.61pt;position:var(--position);text-decoration:none;white-space:pre">.</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:176.11pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:178.61pt;position:var(--position);text-decoration:none;white-space:pre">The Group assessed the impacts resulting from the application of this issued accounting </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:114.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">pronouncement and concluded that they are not material.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedByIASBButNotYetMandatoryPolicyTextBlock', window );">New standards, amendments and interpretations issued by IASB but not yet mandatory for financial years starting from January 1, 2023</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">New standards, amendments and interpretations issued by IASB but not yet mandatory for financial years starting from January 1, </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:154.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">2025 </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:170.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group did not elect for early application of the following new standards, amendments and interpretations, which were issued but </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:180.16pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">not mandatory as of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:118.15pt;position:var(--position);text-decoration:none;white-space:pre">December&#160;31, 2025</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:196.69pt;position:var(--position);text-decoration:none;white-space:pre">: </span></div><div style="font-size:12pt;line-height:12pt;position:var(--position);top:201.66pt;width:612pt"><span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre">Amendments to IFRS 9 Financial Instruments and IFRS 7 Financial Instruments: Disclosures &#8211; Amendments to the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:215.1pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre">Classification and Measurement of Financial Instruments, whose application is for annual reporting periods beginning on </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:228.54pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre">or after January 1, 2026, as approved by the EU on May 27, 2025; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:241.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre">Amendments to IFRS 9 Financial Instruments and IFRS 7 Financial Instruments: Disclosures &#8211; Contracts Referencing </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:253.18pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre">Nature-dependent Electricity, whose application is for annual reporting periods beginning on or after January 1, 2026, as </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:264.38pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre">approved by the EU on June 30, 2025; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:275.58pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre">IFRS 18 Presentation and Disclosure in Financial Statements, whose application is for annual reporting periods </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:286.78pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre">beginning on or after January 1, 2027, as approved by the EU on February 16, 2026; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:297.98pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre">IFRS 19 Subsidiaries without Public Accountability: Disclosures, whose application is for annual reporting periods </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:309.18pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre">beginning on or after January 1, 2027 (not yet approved by the UE), and</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:320.38pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre;width:3.5pt">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre;width:485.99pt">Annual Improvements Volume 11, whose application is for annual reporting periods beginning on or after January 1,</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.99pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:331.38pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre;width:25pt">2026, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:115pt;position:var(--position);text-decoration:none;white-space:pre;width:157.69pt">as approved by the EU on July 9, 2025.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:355.82pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">These texts have not been early adopted. The application of the standards and interpretations issued respectively by the IASB and the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:367.02pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">IFRS IC that are not yet effective as of December 31, 2025 is not expected to have a material impact on the Group&#8217;s consolidated </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:378.22pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">financial statements. IFRS 18, issued in April 2024 and effective from January 1, 2027, will modify the presentation of the </span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Consolidated statements of income (loss) and the Consolidated statements of cash flows</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:388.1pt;position:var(--position);text-decoration:none;white-space:pre">.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_AccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting Principles [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_AccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description Of Accounting Policy For Going Concern</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DisclosureOfAccountingPolicyForAccountingJudgementsAndEstimatesExplanatoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Accounting Policy For Accounting Judgements And Estimates Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DisclosureOfAccountingPolicyForAccountingJudgementsAndEstimatesExplanatoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DisclosureOfAccountingPolicyForNewRevisedOrAmendedStandardsAndInterpretationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Accounting Policy For New, Revised Or Amended Standards And Interpretations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DisclosureOfAccountingPolicyForNewRevisedOrAmendedStandardsAndInterpretationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DisclosureOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedByIASBButNotYetMandatoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Accounting Policy For New Standards, Amendments And For Financial Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DisclosureOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedByIASBButNotYetMandatoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DisclosureOfImpactOfTheUkraineRussiaHostilitiesOnTheGroupPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Impact Of The Ukraine/Russia Hostilities On The Group</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DisclosureOfImpactOfTheUkraineRussiaHostilitiesOnTheGroupPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for deferred income tax. [Refer: Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2025-01-01<br> -Paragraph 39<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_39_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 216<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_216_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 216<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_216_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for issued capital. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 46<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_46&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 170<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_170&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 170<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_170&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfIFRSCompliance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfIFRSCompliance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting principles (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_AccountingPrinciplesAbstract', window );"><strong>Accounting Principles [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Disclosure of depreciation period of property, plant and equipment</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Property, plant and equipment are depreciated using the straight-line method over the estimated useful life of the asset. The principal </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:514.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">useful lives applied are as follows: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:524.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div><div style="position:var(--position);top:534.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:324pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:150.75pt"></td><td style="padding:0;width:95.25pt"></td><td style="padding:0;width:78pt"></td></tr><tr style="height:15.75pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:15.75pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td colspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:15.75pt;width:173.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:173.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;position:var(--position);text-decoration:none;white-space:pre">DEPRECIATION PERIOD</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:30pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Buildings</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:30pt;width:95.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:30pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:44.25pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Office fixtures and fittings</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:44.25pt;width:95.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:3.67pt;width:95.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:45.13pt;position:var(--position);text-decoration:none;white-space:pre">3 years</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:73.71pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span><span style="font-family:'Times New Roman', serif;font-size:6.5pt;font-style:normal;font-weight:normal;left:76.21pt;position:var(--position);text-decoration:none;top:-2.4254999999999995pt;vertical-align:super;white-space:pre">(1)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:44.25pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:58.5pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Equipment</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:58.5pt;width:95.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:58.5pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:72.75pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Industrial materials and equipment</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:72.75pt;width:95.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:21.95pt;position:var(--position);text-decoration:none;white-space:pre">5</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:26.95pt;position:var(--position);white-space:pre"> to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.72pt;position:var(--position);text-decoration:none;white-space:pre">10 years</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:72.75pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:87pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Technical facilities</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:87pt;width:95.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:21.95pt;position:var(--position);text-decoration:none;white-space:pre">5</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:26.95pt;position:var(--position);white-space:pre"> to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.72pt;position:var(--position);text-decoration:none;white-space:pre">10 years</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:87pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:101.25pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Furniture and computer equipment:</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:101.25pt;width:95.25pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:101.25pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:115.5pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Office equipment</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:115.5pt;width:95.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:21.95pt;position:var(--position);text-decoration:none;white-space:pre">5</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:26.95pt;position:var(--position);white-space:pre"> to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.72pt;position:var(--position);text-decoration:none;white-space:pre">10 years</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:115.5pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:129.75pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">IT equipment</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:129.75pt;width:95.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;  &#160;&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:45.13pt;position:var(--position);text-decoration:none;white-space:pre">3 years</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:129.75pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:144pt;width:150.75pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre">Furniture</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:150.75pt;position:var(--position);top:144pt;width:95.25pt"><div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:22.08pt;position:var(--position);white-space:pre">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.58pt;position:var(--position);text-decoration:none;white-space:pre">10 years</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:246pt;position:var(--position);top:144pt;width:78pt"><div><div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre">&#160;</span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:35.95pt;position:var(--position)">(1)<span style="display:inline-block;height:6.93pt;width:12.84pt"></span></span><span style="left:60.45pt;position:var(--position)">Office fixtures and fittings estimated useful lives correspond to the Paris headquarters and Boston offices residual estimated </span></span></div>lease terms.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_AccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting Principles [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_AccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 73<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory', window );">Disclosure of reconciliation of intangible assets</a></td>
<td class="text"><div style="font-size:0pt;left:36pt;position:var(--position);width:464.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:194.25pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td></tr><tr style="height:32.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.48pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:45.59pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.86pt;position:var(--position);text-decoration:none;white-space:pre">LICENSES</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.75pt;position:var(--position);text-decoration:none;white-space:pre">SOFTWARE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.2pt;position:var(--position);text-decoration:none;white-space:pre">PATENTS</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.63pt;position:var(--position);text-decoration:none;white-space:pre">TOTAL</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:32.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">GROSS VALUES</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:44.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY 1, 2023</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:44.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.88pt"></span></span><span style="left:49.510000000000005pt;position:var(--position)">120<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:44.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)">24<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:44.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">6,529<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:44.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">6,673<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:65.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:65.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.88pt"></span></span><span style="left:49.510000000000005pt;position:var(--position)">120<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:65.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)">24<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:65.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">6,529<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:65.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">6,673<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:86.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Acquisition</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:86.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:86.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.88pt"></span></span><span style="left:57.510000000000005pt;position:var(--position)">3<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:86.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:86.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.88pt"></span></span><span style="left:57.510000000000005pt;position:var(--position)">3<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:23.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:98.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.02pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:98.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.88pt"></span></span><span style="left:49.510000000000005pt;position:var(--position)">120<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:98.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)">27<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:98.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">6,529<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:98.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">6,677<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:23.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:121.5pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.82pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:13.42pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:121.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.88pt"></span></span><span style="left:49.510000000000005pt;position:var(--position)">120<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:121.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)">27<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:121.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">6,529<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:121.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">6,677<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div><div style="position:var(--position);top:277.94pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:464.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:194.25pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td></tr><tr style="height:35.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:26.48pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:45.59pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.8pt;position:var(--position);text-decoration:none;white-space:pre">LICENSES</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.69pt;position:var(--position);text-decoration:none;white-space:pre">SOFTWARE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.14pt;position:var(--position);text-decoration:none;white-space:pre">PATENTS</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:19.57pt;position:var(--position);text-decoration:none;white-space:pre">TOTAL</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:35.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AMORTIZATION</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:23.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:47.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.82pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:13.42pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY 1, 2023</span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:47.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.22pt"></span></span><span style="left:50.85pt;position:var(--position)">(45)<span style="display:inline-block;height:5.41pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:47.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.55pt"></span></span><span style="left:51.18pt;position:var(--position)">(21)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:47.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:47.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.55pt"></span></span><span style="left:51.18pt;position:var(--position)">(66)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:70.5pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Increase </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:70.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:70.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.55pt"></span></span><span style="left:55.18pt;position:var(--position)">(3)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:70.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:70.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.55pt"></span></span><span style="left:55.18pt;position:var(--position)">(3)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:82.5pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:82.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.22pt"></span></span><span style="left:50.85pt;position:var(--position)">(45)<span style="display:inline-block;height:5.41pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:82.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.55pt"></span></span><span style="left:51.18pt;position:var(--position)">(24)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:82.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:82.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.55pt"></span></span><span style="left:51.18pt;position:var(--position)">(70)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:103.5pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Increase </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:103.5pt;width:65.25pt"><div><div style="line-height:9pt;position:var(--position);top:2.35pt;width:65.25pt"><span style="color:#000000;font-family:'Arial', sans-serif;font-size:9pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.55pt;width:49.88pt"></span></span><span style="left:52.510000000000005pt;position:var(--position)">&#8212;<span style="display:inline-block;height:6.55pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:103.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.55pt"></span></span><span style="left:55.18pt;position:var(--position)">(1)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:103.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:103.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.55pt"></span></span><span style="left:55.18pt;position:var(--position)">(1)</span></span></div></div></div></td></tr><tr style="height:24pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:115.5pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.2pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:13.8pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:115.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:15.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.22pt"></span></span><span style="left:50.85pt;position:var(--position)">(45)<span style="display:inline-block;height:5.41pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:115.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:15.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.55pt"></span></span><span style="left:51.18pt;position:var(--position)">(25)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:115.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:15.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:115.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:15.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.55pt"></span></span><span style="left:51.18pt;position:var(--position)">(70)</span></span></div></div></div></td></tr><tr style="height:12.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:139.5pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.99pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Increase </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:139.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:139.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.55pt"></span></span><span style="left:55.18pt;position:var(--position)">(1)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:139.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:139.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.55pt"></span></span><span style="left:55.18pt;position:var(--position)">(1)</span></span></div></div></div></td></tr><tr style="height:24pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:152.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.2pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:13.8pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:152.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:15.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.22pt"></span></span><span style="left:50.85pt;position:var(--position)">(45)<span style="display:inline-block;height:5.41pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:152.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:15.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.55pt"></span></span><span style="left:51.18pt;position:var(--position)">(26)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:152.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:15.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:152.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:15.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.55pt"></span></span><span style="left:51.18pt;position:var(--position)">(71)</span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:485.79pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:464.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:194.25pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td></tr><tr style="height:35.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:26.48pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:45.59pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.8pt;position:var(--position);text-decoration:none;white-space:pre">LICENSES</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.69pt;position:var(--position);text-decoration:none;white-space:pre">SOFTWARE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.14pt;position:var(--position);text-decoration:none;white-space:pre">PATENTS</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:19.57pt;position:var(--position);text-decoration:none;white-space:pre">TOTAL</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:35.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">NET BOOK VALUES</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:47.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY 1, 2023</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:47.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">75</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:47.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.62pt;position:var(--position);text-decoration:none;white-space:pre">3</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:47.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre">6,529</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:47.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre">6,607</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:68.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:68.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">75</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:68.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.62pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:68.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre">6,529</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:68.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre">6,604</span></div></div></div></td></tr><tr style="height:29.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:89.25pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:6.82pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:16.42pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:89.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:11.56pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">75</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:89.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:11.56pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.62pt;position:var(--position);text-decoration:none;white-space:pre">3</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:89.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:11.56pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre">6,529</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:89.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:11.56pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre">6,606</span></div></div></div></td></tr><tr style="height:29.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:118.5pt;width:194.25pt"><div><div style="line-height:8pt;position:var(--position);top:6.82pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:16.42pt;width:194.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:194.25pt;position:var(--position);top:118.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:11.56pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">75</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:var(--position);top:118.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:11.56pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.62pt;position:var(--position);text-decoration:none;white-space:pre">2</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:330.75pt;position:var(--position);top:118.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:11.56pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre">6,529</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:118.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:11.56pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre">6,605</span></div></div></div></td></tr></tbody></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInPropertyPlantAndEquipmentIncludingRightofuseAssetsExplanatory', window );">Disclosure of reconciliation of property, plant and equipment</a></td>
<td class="text"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:44pt;position:var(--position);text-decoration:none;white-space:pre">The following tables present changes in property, plant and equipment including the right of use of assets (or &#8220;ROU&#8221;) as of </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:705.64pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:44pt;position:var(--position);text-decoration:none;white-space:pre">December 31, 2023, 2024 and 2025:</span></div><div><div style="position:var(--position);top:85.19pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:525.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:213.75pt"></td><td style="padding:0;width:60pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:60pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:60pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:60pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:60pt"></td></tr><tr style="height:41.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:32.48pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:55.34pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);width:60pt"><div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.57pt;position:var(--position);text-decoration:none;white-space:pre">BUILDINGS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);width:60pt"><div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.35pt;position:var(--position);text-decoration:none;white-space:pre">EQUIPMENT</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3.82pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.25pt;position:var(--position);text-decoration:none;white-space:pre">FURNITURE </span></div><div style="line-height:8pt;position:var(--position);top:13.42pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.34pt;position:var(--position);text-decoration:none;white-space:pre">AND </span></div><div style="line-height:8pt;position:var(--position);top:23.02pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.69pt;position:var(--position);text-decoration:none;white-space:pre">COMPUTER </span></div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.35pt;position:var(--position);text-decoration:none;white-space:pre">EQUIPMENT</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);width:60pt"><div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.01pt;position:var(--position);text-decoration:none;white-space:pre">TOTAL</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);width:60pt"><div><div style="line-height:8pt;position:var(--position);top:23.02pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.79pt;position:var(--position);text-decoration:none;white-space:pre">OF WHICH </span></div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.12pt;position:var(--position);text-decoration:none;white-space:pre">ROU</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:41.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">GROSS VALUES</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:53.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY 1, 2023</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:53.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)">1,618<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:53.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">436<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:53.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">346<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:53.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)">2,400<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:53.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)">1,561<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:74.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Acquisition</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:74.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">350<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:74.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">103<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:74.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">161<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:74.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">614<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:74.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">350<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:86.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Disposal</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:86.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.97pt"></span></span><span style="left:41.6pt;position:var(--position)">(622)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:86.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.97pt"></span></span><span style="left:45.6pt;position:var(--position)">(27)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:86.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.63pt"></span></span><span style="left:48.260000000000005pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:86.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.97pt"></span></span><span style="left:41.6pt;position:var(--position)">(649)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:86.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.97pt"></span></span><span style="left:41.6pt;position:var(--position)">(649)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:98.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:98.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)">1,346<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:98.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">513<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:98.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">507<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:98.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)">2,366<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:98.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)">1,262<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:119.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Acquisition</span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:119.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)">2,578<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:119.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.63pt"></span></span><span style="left:48.260000000000005pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:119.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">292<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:119.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)">2,870<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:119.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)">2,217<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:131.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Disposal</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:131.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.97pt"></span></span><span style="left:35.6pt;position:var(--position)">(1,110)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:131.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.63pt"></span></span><span style="left:48.260000000000005pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:131.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.97pt"></span></span><span style="left:41.6pt;position:var(--position)">(119)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:131.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.97pt"></span></span><span style="left:35.6pt;position:var(--position)">(1,229)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:131.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.97pt"></span></span><span style="left:41.6pt;position:var(--position)">(975)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:143.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Effect of the change in foreign currency exchange rates</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:143.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:49.63pt"></span></span><span style="left:52.260000000000005pt;position:var(--position)">4<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:143.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.63pt"></span></span><span style="left:48.260000000000005pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:143.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.63pt"></span></span><span style="left:48.260000000000005pt;position:var(--position)">17<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:143.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.63pt"></span></span><span style="left:48.260000000000005pt;position:var(--position)">22<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:143.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.63pt"></span></span><span style="left:48.260000000000005pt;position:var(--position)">22<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:155.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:155.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)">2,818<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:155.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">513<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:155.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">698<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:155.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)">4,029<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:155.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)">2,526<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:176.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Acquisition</span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:176.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">436<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:176.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.63pt"></span></span><span style="left:48.260000000000005pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:176.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">123<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:176.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">559<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:176.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">424<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:188.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Disposal</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:188.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.63pt"></span></span><span style="left:48.260000000000005pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:188.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.97pt"></span></span><span style="left:45.6pt;position:var(--position)">(49)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:188.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.97pt"></span></span><span style="left:41.6pt;position:var(--position)">(203)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:188.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.97pt"></span></span><span style="left:41.6pt;position:var(--position)">(252)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:188.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.97pt"></span></span><span style="left:45.6pt;position:var(--position)">(34)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:200.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Effect of the change in foreign currency exchange rates</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:200.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.97pt"></span></span><span style="left:45.6pt;position:var(--position)">(50)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:200.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.63pt"></span></span><span style="left:48.260000000000005pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:200.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.97pt"></span></span><span style="left:45.6pt;position:var(--position)">(12)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:200.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.97pt"></span></span><span style="left:45.6pt;position:var(--position)">(62)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:200.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.97pt"></span></span><span style="left:45.6pt;position:var(--position)">(50)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:212.25pt;width:213.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:213.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:213.75pt;position:var(--position);top:212.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)">3,204<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:276.75pt;position:var(--position);top:212.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">463<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:339.75pt;position:var(--position);top:212.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.63pt"></span></span><span style="left:44.260000000000005pt;position:var(--position)">607<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:212.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)">4,274<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:212.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.63pt"></span></span><span style="left:38.260000000000005pt;position:var(--position)">2,865<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:338.07pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:528.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:201.75pt"></td><td style="padding:0;width:63pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63pt"></td></tr><tr style="height:41.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:32.48pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:49.34pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);width:63pt"><div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.07pt;position:var(--position);text-decoration:none;white-space:pre">BUILDINGS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);width:63pt"><div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.85pt;position:var(--position);text-decoration:none;white-space:pre">EQUIPMENT</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.82pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.75pt;position:var(--position);text-decoration:none;white-space:pre">FURNITURE </span></div><div style="line-height:8pt;position:var(--position);top:13.42pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.84pt;position:var(--position);text-decoration:none;white-space:pre">AND </span></div><div style="line-height:8pt;position:var(--position);top:23.02pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.19pt;position:var(--position);text-decoration:none;white-space:pre">COMPUTER </span></div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.85pt;position:var(--position);text-decoration:none;white-space:pre">EQUIPMENT</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);width:63pt"><div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.51pt;position:var(--position);text-decoration:none;white-space:pre">TOTAL</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);width:63pt"><div><div style="line-height:8pt;position:var(--position);top:23.02pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.29pt;position:var(--position);text-decoration:none;white-space:pre">OF WHICH </span></div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.62pt;position:var(--position);text-decoration:none;white-space:pre">ROU</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:41.25pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DEPRECIATION</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:53.25pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY 1, 2023</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);top:53.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(259)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:53.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(378)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:53.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(171)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:53.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(808)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:53.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(290)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:74.25pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Increase </span></div></div></div></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);top:74.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(578)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:74.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.3pt"></span></span><span style="left:48.93pt;position:var(--position)">(36)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:74.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.3pt"></span></span><span style="left:48.93pt;position:var(--position)">(94)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:74.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(707)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:74.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(498)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:86.25pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Disposal</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);top:86.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:86.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">27<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:86.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:86.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">27<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:86.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">27<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:98.25pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);top:98.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(837)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:98.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(387)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:98.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(265)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:98.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.3pt"></span></span><span style="left:38.93pt;position:var(--position)">(1,488)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:98.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(761)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:119.25pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Increase </span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);top:119.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(886)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:119.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.3pt"></span></span><span style="left:48.93pt;position:var(--position)">(32)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:119.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(171)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:119.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.3pt"></span></span><span style="left:38.93pt;position:var(--position)">(1,089)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:119.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(788)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:131.25pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Disposal</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);top:131.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)">1,111<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:131.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:131.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">104<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:131.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)">1,215<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:131.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">975<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:143.25pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);top:143.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(613)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:143.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(419)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:143.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(332)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:143.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.3pt"></span></span><span style="left:38.93pt;position:var(--position)">(1,363)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:143.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(575)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:164.25pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Increase </span></div></div></div></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);top:164.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(903)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:164.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.3pt"></span></span><span style="left:48.93pt;position:var(--position)">(35)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:164.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(158)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:164.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.3pt"></span></span><span style="left:38.93pt;position:var(--position)">(1,095)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:164.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(797)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:176.25pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Disposal</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);top:176.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:176.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">49<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:176.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">203<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:176.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">252<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:176.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">53<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:188.25pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Effect of the change in foreign currency exchange rates</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);top:188.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">17<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:188.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:188.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.96pt"></span></span><span style="left:55.59pt;position:var(--position)">5<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:188.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">22<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:188.25pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.99pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">17<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:201pt;width:201.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:201.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:201.75pt;position:var(--position);top:201pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.3pt"></span></span><span style="left:38.93pt;position:var(--position)">(1,498)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:201pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(404)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:333.75pt;position:var(--position);top:201pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.3pt"></span></span><span style="left:44.93pt;position:var(--position)">(281)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:201pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.3pt"></span></span><span style="left:38.93pt;position:var(--position)">(2,184)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465.75pt;position:var(--position);top:201pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.3pt"></span></span><span style="left:38.93pt;position:var(--position)">(1,302)</span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:577.07pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:529.5pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:200.25pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:56.25pt"></td></tr><tr style="height:41.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:17.55pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:48.59pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:200.25pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.2pt;position:var(--position);text-decoration:none;white-space:pre">BUILDINGS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.98pt;position:var(--position);text-decoration:none;white-space:pre">EQUIPMENT</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:336.75pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.82pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.87pt;position:var(--position);text-decoration:none;white-space:pre">FURNITURE </span></div><div style="line-height:8pt;position:var(--position);top:13.42pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.97pt;position:var(--position);text-decoration:none;white-space:pre">AND </span></div><div style="line-height:8pt;position:var(--position);top:23.02pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.31pt;position:var(--position);text-decoration:none;white-space:pre">COMPUTER </span></div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.98pt;position:var(--position);text-decoration:none;white-space:pre">EQUIPMENT</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:405pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.63pt;position:var(--position);text-decoration:none;white-space:pre">TOTAL</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);width:56.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.02pt;width:56.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.91pt;position:var(--position);text-decoration:none;white-space:pre">OF WHICH </span></div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:56.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:19.24pt;position:var(--position);text-decoration:none;white-space:pre">ROU</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:41.25pt;width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">NET BOOK VALUES</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:53.25pt;width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY 1, 2023</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:200.25pt;position:var(--position);top:53.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">1,359<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:265.5pt;overflow:hidden;position:var(--position);top:53.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:53.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">59<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:333.75pt;overflow:hidden;position:var(--position);top:53.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:336.75pt;position:var(--position);top:53.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)">175<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:402pt;overflow:hidden;position:var(--position);top:53.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:405pt;position:var(--position);top:53.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">1,592<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:470.25pt;overflow:hidden;position:var(--position);top:53.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:53.25pt;width:56.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:56.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.21pt"></span></span><span style="left:34.84pt;position:var(--position)">1,270<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:74.25pt;width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:200.25pt;position:var(--position);top:74.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)">509<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:265.5pt;overflow:hidden;position:var(--position);top:74.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:74.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)">126<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:333.75pt;overflow:hidden;position:var(--position);top:74.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:336.75pt;position:var(--position);top:74.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)">242<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:402pt;overflow:hidden;position:var(--position);top:74.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:405pt;position:var(--position);top:74.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)">878<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:470.25pt;overflow:hidden;position:var(--position);top:74.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:74.25pt;width:56.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:56.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.21pt"></span></span><span style="left:40.84pt;position:var(--position)">501<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:95.25pt;width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:200.25pt;position:var(--position);top:95.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">2,205<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:265.5pt;overflow:hidden;position:var(--position);top:95.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:95.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">94<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:333.75pt;overflow:hidden;position:var(--position);top:95.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:336.75pt;position:var(--position);top:95.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)">366<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:402pt;overflow:hidden;position:var(--position);top:95.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:405pt;position:var(--position);top:95.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">2,666<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:470.25pt;overflow:hidden;position:var(--position);top:95.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:95.25pt;width:56.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:56.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.21pt"></span></span><span style="left:34.84pt;position:var(--position)">1,950<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:116.25pt;width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:200.25pt;position:var(--position);top:116.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">1,706<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:265.5pt;overflow:hidden;position:var(--position);top:116.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:116.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">59<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:333.75pt;overflow:hidden;position:var(--position);top:116.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:336.75pt;position:var(--position);top:116.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)">325<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:402pt;overflow:hidden;position:var(--position);top:116.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:405pt;position:var(--position);top:116.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">2,090<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:21pt;left:470.25pt;overflow:hidden;position:var(--position);top:116.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:116.25pt;width:56.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:56.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.21pt"></span></span><span style="left:34.84pt;position:var(--position)">1,563<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfChangesInPropertyPlantAndEquipmentIncludingRightofuseAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the reconciliation of changes in property, plant and equipment, including right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfChangesInPropertyPlantAndEquipmentIncludingRightofuseAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other financial assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsAbstract', window );"><strong>Disclosure of financial assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory', window );">Disclosure of other financial assets</a></td>
<td class="text"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Other financial assets break down as follows:</span><div style="font-size:12pt;line-height:11pt;position:var(--position);top:334.76pt;width:612pt"><span style="font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="position:var(--position);top:351.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:445.5pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:243.75pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:243.75pt"><div><div style="line-height:8pt;position:var(--position);top:21.98pt;width:243.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:70.34pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:243.75pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.97pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.97pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.97pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:30.75pt;width:243.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:243.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">OTHER FINANCIAL ASSETS</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:243.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:243.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Advances related to CRO contracts</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:243.75pt;position:var(--position);top:42.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.88pt"></span></span><span style="left:39.510000000000005pt;position:var(--position)">12,172<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:309pt;overflow:hidden;position:var(--position);top:42.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:42.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">4,929<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:377.25pt;overflow:hidden;position:var(--position);top:42.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:42.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">4,665<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:243.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:243.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Deposits</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:243.75pt;position:var(--position);top:54.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.88pt"></span></span><span style="left:49.510000000000005pt;position:var(--position)">574<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:309pt;overflow:hidden;position:var(--position);top:54.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:54.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.88pt"></span></span><span style="left:49.510000000000005pt;position:var(--position)">863<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:377.25pt;overflow:hidden;position:var(--position);top:54.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:54.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.88pt"></span></span><span style="left:49.510000000000005pt;position:var(--position)">693<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:243.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:243.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:243.75pt;position:var(--position);top:66.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.88pt"></span></span><span style="left:49.510000000000005pt;position:var(--position)">124<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:309pt;overflow:hidden;position:var(--position);top:66.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:66.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.88pt"></span></span><span style="left:49.510000000000005pt;position:var(--position)">126<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:377.25pt;overflow:hidden;position:var(--position);top:66.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:66.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:243.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:243.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total other non-current financial assets</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:243.75pt;position:var(--position);top:78.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.88pt"></span></span><span style="left:39.510000000000005pt;position:var(--position)">12,870<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:78.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">5,919<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:78.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">5,358<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90.75pt;width:243.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:243.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Advances related to CRO contracts</span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:243.75pt;position:var(--position);top:90.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:309pt;overflow:hidden;position:var(--position);top:90.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:90.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">7,418<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:377.25pt;overflow:hidden;position:var(--position);top:90.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:90.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">7,717<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102.75pt;width:243.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:243.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Deposits</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:243.75pt;position:var(--position);top:102.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.88pt"></span></span><span style="left:49.510000000000005pt;position:var(--position)">136<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:102.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.88pt"></span></span><span style="left:49.510000000000005pt;position:var(--position)">136<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:102.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:114.75pt;width:243.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:243.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other investments</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:243.75pt;position:var(--position);top:114.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">9,050<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:309pt;overflow:hidden;position:var(--position);top:114.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:114.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.88pt"></span></span><span style="left:53.510000000000005pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:377.25pt;overflow:hidden;position:var(--position);top:114.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:114.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.88pt"></span></span><span style="left:39.510000000000005pt;position:var(--position)">13,698<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:126.75pt;width:243.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:243.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total other current financial assets</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:243.75pt;position:var(--position);top:126.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">9,186<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:126.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.88pt"></span></span><span style="left:43.510000000000005pt;position:var(--position)">7,554<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:126.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.88pt"></span></span><span style="left:39.510000000000005pt;position:var(--position)">21,415<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:138.75pt;width:243.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:243.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial assets</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:243.75pt;position:var(--position);top:138.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.88pt"></span></span><span style="left:39.510000000000005pt;position:var(--position)">22,055<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:312pt;position:var(--position);top:138.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.88pt"></span></span><span style="left:39.510000000000005pt;position:var(--position)">13,473<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:380.25pt;position:var(--position);top:138.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.88pt"></span></span><span style="left:39.510000000000005pt;position:var(--position)">26,772<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 43<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_43&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 43<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_43&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other receivables and other assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesAbstract', window );"><strong>Trade and other receivables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfDetailedInformationAboutOtherReceivablesAndOtherAssetsTableTextBlock', window );">Disclosure of other receivables and other assets</a></td>
<td class="text"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:42pt;position:var(--position);text-decoration:none;white-space:pre">Other receivables and other assets break down as follows:</span><span style="font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:273.4pt;position:var(--position);text-decoration:none;white-space:pre"> </span><div style="position:var(--position);top:340.84pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:435pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:233.25pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:233.25pt"><div><div style="line-height:8pt;position:var(--position);top:21.98pt;width:233.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:65.09pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:233.25pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.97pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:301.5pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.97pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:369.75pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.97pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:30.75pt;width:233.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:233.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">OTHER RECEIVABLES AND ASSETS</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:233.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:233.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Prepaid expenses - non current</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:233.25pt;position:var(--position);top:42.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">2,320<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:301.5pt;position:var(--position);top:42.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)">948<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:366.75pt;overflow:hidden;position:var(--position);top:42.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:369.75pt;position:var(--position);top:42.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)">625<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:233.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:233.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total other non-current assets</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:233.25pt;position:var(--position);top:54.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">2,320<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:301.5pt;position:var(--position);top:54.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)">948<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:369.75pt;position:var(--position);top:54.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)">625<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:233.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:233.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Research tax credit ("CIR")</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:233.25pt;position:var(--position);top:66.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">4,600<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:301.5pt;position:var(--position);top:66.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">5,774<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:366.75pt;overflow:hidden;position:var(--position);top:66.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:369.75pt;position:var(--position);top:66.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">3,196<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:233.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:233.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">VAT receivables</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:233.25pt;position:var(--position);top:78.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">14,439<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:301.5pt;position:var(--position);top:78.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">9,841<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:366.75pt;overflow:hidden;position:var(--position);top:78.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:369.75pt;position:var(--position);top:78.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">6,870<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90.75pt;width:233.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:233.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Prepaid expenses </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:233.25pt;position:var(--position);top:90.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">5,746<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:301.5pt;position:var(--position);top:90.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">3,233<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:366.75pt;overflow:hidden;position:var(--position);top:90.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:369.75pt;position:var(--position);top:90.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">2,649<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102.75pt;width:233.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:233.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Employee-related receivables</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:233.25pt;position:var(--position);top:102.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:301.5pt;position:var(--position);top:102.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:369.75pt;position:var(--position);top:102.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)">429<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:114.75pt;width:233.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:233.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Credit notes</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:233.25pt;position:var(--position);top:114.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">60<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:301.5pt;position:var(--position);top:114.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">48<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:369.75pt;position:var(--position);top:114.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:126.75pt;width:233.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:233.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total current other receivables and assets</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:233.25pt;position:var(--position);top:126.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">24,845<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:301.5pt;position:var(--position);top:126.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">18,896<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:369.75pt;position:var(--position);top:126.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">13,144<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:138.75pt;width:233.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:233.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other receivables and assets</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:233.25pt;position:var(--position);top:138.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">27,164<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:301.5pt;position:var(--position);top:138.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">19,843<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:369.75pt;position:var(--position);top:138.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">13,769<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DisclosureOfDetailedInformationAboutOtherReceivablesAndOtherAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Other Receivables And Other Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DisclosureOfDetailedInformationAboutOtherReceivablesAndOtherAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and cash equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfCompositionOfCashAndCashEquivalentsTableTextBlock', window );">Disclosure of composition of cash and cash equivalents</a></td>
<td class="text"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:41pt;position:var(--position);text-decoration:none;white-space:pre">Cash and cash equivalents break down as follows:</span><div style="position:var(--position);top:261.7pt;width:612pt"><div style="font-size:0pt;left:41pt;position:var(--position);width:474pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:243pt"></td><td style="padding:0;width:75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:75pt"></td></tr><tr style="height:30.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:243pt"><div><div style="line-height:8pt;position:var(--position);top:21.98pt;width:243pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:69.96pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:243pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.84pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.5pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:321pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.84pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.5pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.84pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.5pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:30.75pt;width:243pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:243pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">CASH AND CASH EQUIVALENTS</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:243pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:243pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cash equivalents</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:243pt;position:var(--position);top:42.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:50.37pt;position:var(--position);text-decoration:none;white-space:pre">18,105</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:321pt;position:var(--position);top:42.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:50.37pt;position:var(--position);text-decoration:none;white-space:pre">87,265</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:396pt;overflow:hidden;position:var(--position);top:42.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:42.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.37pt;position:var(--position);text-decoration:none;white-space:pre">478,541</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:243pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:243pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cash</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:243pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.37pt;position:var(--position);text-decoration:none;white-space:pre">233,837</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:321pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:50.37pt;position:var(--position);text-decoration:none;white-space:pre">56,956</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:396pt;overflow:hidden;position:var(--position);top:54.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:50.37pt;position:var(--position);text-decoration:none;white-space:pre">38,144</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:243pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:243pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cash and cash equivalents</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:243pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:46.37pt;position:var(--position);text-decoration:none;white-space:pre">251,942</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:321pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:46.37pt;position:var(--position);text-decoration:none;white-space:pre">144,221</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:396pt;overflow:hidden;position:var(--position);top:66.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:399pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:46.37pt;position:var(--position);text-decoration:none;white-space:pre">516,685</span></div></div></div></td></tr></tbody></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DisclosureOfCompositionOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Composition Of Cash And Cash Equivalents</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DisclosureOfCompositionOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial assets and liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_FairValueMeasurementAbstract', window );"><strong>Fair Value Measurement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory', window );">Disclosure of carrying amounts and fair value of financial assets</a></td>
<td class="text"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">The following table shows the carrying amounts and fair value of financial assets and financial liabilities, including their </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:561.75pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">levels in the fair value hierarchy.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:573.75pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">Tax and employee-related payables are non-financial liabilities and are therefore excluded from the tables below. They are </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:585.75pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">presented in Note 17.2.</span></div><div><div style="position:var(--position);top:70.56pt;width:612pt"><div style="font-size:0pt;left:39pt;position:var(--position);width:534pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:189.75pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:71.25pt"></td></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td colspan="9" style="font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);width:344.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:344.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:160.47pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:344.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:134.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td></tr><tr style="height:69pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:60.23pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:43.34pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.42pt;position:var(--position);text-decoration:none;white-space:pre">AMOUNT </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.31pt;position:var(--position);text-decoration:none;white-space:pre">RECOGNIZED </span></div><div style="line-height:8pt;position:var(--position);top:31.57pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.74pt;position:var(--position);text-decoration:none;white-space:pre">IN THE </span></div><div style="line-height:8pt;position:var(--position);top:41.17pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.53pt;position:var(--position);text-decoration:none;white-space:pre">STATEMENT </span></div><div style="line-height:8pt;position:var(--position);top:50.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.43pt;position:var(--position);text-decoration:none;white-space:pre">OF&#160;FINANCIAL </span></div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.08pt;position:var(--position);text-decoration:none;white-space:pre">POSITION</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.87pt;position:var(--position);text-decoration:none;white-space:pre">FAIR&#160;VALUE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.64pt;position:var(--position);text-decoration:none;white-space:pre">ASSETS/ </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.97pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.31pt;position:var(--position);text-decoration:none;white-space:pre">AT FAIR </span></div><div style="line-height:8pt;position:var(--position);top:31.57pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.64pt;position:var(--position);text-decoration:none;white-space:pre">VALUE </span></div><div style="line-height:8pt;position:var(--position);top:41.17pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.75pt;position:var(--position);text-decoration:none;white-space:pre">THROUGH </span></div><div style="line-height:8pt;position:var(--position);top:50.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.87pt;position:var(--position);text-decoration:none;white-space:pre">PROFIT&#160;AND </span></div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.41pt;position:var(--position);text-decoration:none;white-space:pre">LOSS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:41.17pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.2pt;position:var(--position);text-decoration:none;white-space:pre">ASSETS AT </span></div><div style="line-height:8pt;position:var(--position);top:50.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.53pt;position:var(--position);text-decoration:none;white-space:pre">AMORTIZED </span></div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.74pt;position:var(--position);text-decoration:none;white-space:pre">COST</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:21pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:41.17pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.97pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES </span></div><div style="line-height:8pt;position:var(--position);top:50.77pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.98pt;position:var(--position);text-decoration:none;white-space:pre">AT&#160;AMORTIZED </span></div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.74pt;position:var(--position);text-decoration:none;white-space:pre">COST</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial assets (2)</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">22,055</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">22,394</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">22,394</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:90pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:60.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other receivables and assets (2)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:102pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">27,164</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:102pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">27,164</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:102pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:102pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">27,164</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:102pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:60.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:114pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cash and cash equivalents (1)</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:114pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">251,942</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:114pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">251,942</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:114pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:114pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">251,942</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:114pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:60.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:126pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial assets</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:126pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">301,161</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:126pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">301,500</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:126pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:126pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">301,500</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:126pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:60.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:138pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial liabilities&#8212;non-current portion (4, Note 15)</span></div></div></div></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:138pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">39,697</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:138pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">40,622</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:138pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">18,506</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:138pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:138pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.62pt;position:var(--position);text-decoration:none;white-space:pre">42,768</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:150pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial liabilities&#8212;current portion (3, Note 15)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:150pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">37,348</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:150pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">37,348</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:150pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">11,531</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:150pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:150pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:50.62pt;position:var(--position);text-decoration:none;white-space:pre">5,165</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:162pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Trade payables and other current liabilities (3)</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:162pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">47,221</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:162pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">47,221</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:162pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:162pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:162pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.62pt;position:var(--position);text-decoration:none;white-space:pre">47,221</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:174pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial liabilities</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:174pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">124,266</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:174pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">125,191</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:174pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">30,037</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:174pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:174pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:46.62pt;position:var(--position);text-decoration:none;white-space:pre">95,154</span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:273.56pt;width:612pt"><div style="font-size:0pt;left:39pt;position:var(--position);width:534pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:189.75pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:71.25pt"></td></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td colspan="9" style="font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);width:344.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:344.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:160.47pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:344.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:134.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td></tr><tr style="height:71.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:62.48pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:43.34pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.42pt;position:var(--position);text-decoration:none;white-space:pre">AMOUNT </span></div><div style="line-height:8pt;position:var(--position);top:24.22pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.31pt;position:var(--position);text-decoration:none;white-space:pre">RECOGNIZED </span></div><div style="line-height:8pt;position:var(--position);top:33.82pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.74pt;position:var(--position);text-decoration:none;white-space:pre">IN THE </span></div><div style="line-height:8pt;position:var(--position);top:43.42pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.53pt;position:var(--position);text-decoration:none;white-space:pre">STATEMENT </span></div><div style="line-height:8pt;position:var(--position);top:53.02pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.43pt;position:var(--position);text-decoration:none;white-space:pre">OF&#160;FINANCIAL </span></div><div style="line-height:8pt;position:var(--position);top:62.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.08pt;position:var(--position);text-decoration:none;white-space:pre">POSITION</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:62.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.87pt;position:var(--position);text-decoration:none;white-space:pre">FAIR&#160;VALUE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.02pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.64pt;position:var(--position);text-decoration:none;white-space:pre">ASSETS/ </span></div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.97pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES </span></div><div style="line-height:8pt;position:var(--position);top:24.22pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.31pt;position:var(--position);text-decoration:none;white-space:pre">AT FAIR </span></div><div style="line-height:8pt;position:var(--position);top:33.82pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.64pt;position:var(--position);text-decoration:none;white-space:pre">VALUE </span></div><div style="line-height:8pt;position:var(--position);top:43.42pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.75pt;position:var(--position);text-decoration:none;white-space:pre">THROUGH </span></div><div style="line-height:8pt;position:var(--position);top:53.02pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.87pt;position:var(--position);text-decoration:none;white-space:pre">PROFIT&#160;AND </span></div><div style="line-height:8pt;position:var(--position);top:62.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.41pt;position:var(--position);text-decoration:none;white-space:pre">LOSS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:43.42pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.2pt;position:var(--position);text-decoration:none;white-space:pre">ASSETS AT </span></div><div style="line-height:8pt;position:var(--position);top:53.02pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.53pt;position:var(--position);text-decoration:none;white-space:pre">AMORTIZED </span></div><div style="line-height:8pt;position:var(--position);top:62.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.74pt;position:var(--position);text-decoration:none;white-space:pre">COST</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:21pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:43.42pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.97pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES </span></div><div style="line-height:8pt;position:var(--position);top:53.02pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.98pt;position:var(--position);text-decoration:none;white-space:pre">AT&#160;AMORTIZED </span></div><div style="line-height:8pt;position:var(--position);top:62.62pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.74pt;position:var(--position);text-decoration:none;white-space:pre">COST</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:92.25pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial assets (2)</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:92.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">13,473</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:92.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">12,690</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:92.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:92.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">12,690</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:92.25pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:60.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:104.25pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other receivables and assets (2)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:104.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">19,843</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:104.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">19,843</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:104.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:104.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">19,843</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:104.25pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:60.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:116.25pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cash and cash equivalents (1)</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:116.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">144,221</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:116.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">144,221</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:116.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:116.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">144,221</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:116.25pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:60.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:128.25pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial assets</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:128.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">177,537</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:128.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">176,754</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:128.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:128.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">176,754</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:128.25pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:60.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:140.25pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial liabilities&#8212;non-current portion (4, Note 15)</span></div></div></div></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:140.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">69,069</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:140.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">73,497</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:140.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre">3,620</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:140.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:140.25pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.62pt;position:var(--position);text-decoration:none;white-space:pre">69,877</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:152.25pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial liabilities&#8212;current portion (3, Note 15)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:152.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">44,935</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:152.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">44,935</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:152.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">21,183</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:152.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:152.25pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.62pt;position:var(--position);text-decoration:none;white-space:pre">23,752</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:164.25pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Trade payables and other current liabilities (3)</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:164.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">43,824</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:164.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">43,824</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:164.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:164.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:164.25pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.62pt;position:var(--position);text-decoration:none;white-space:pre">43,824</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:176.25pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial liabilities</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:176.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">157,828</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:176.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">162,256</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:176.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">24,803</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:176.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:176.25pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:42.62pt;position:var(--position);text-decoration:none;white-space:pre">137,453</span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:478.81pt;width:612pt"><div style="font-size:0pt;left:40.12pt;position:var(--position);width:531.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:189.75pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:69pt"></td></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td colspan="9" style="font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);width:342pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:342pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:159.34pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:342pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:132.91pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td></tr><tr style="height:69pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:60.23pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:43.34pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.42pt;position:var(--position);text-decoration:none;white-space:pre">AMOUNT </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.31pt;position:var(--position);text-decoration:none;white-space:pre">RECOGNIZED </span></div><div style="line-height:8pt;position:var(--position);top:31.57pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.74pt;position:var(--position);text-decoration:none;white-space:pre">IN THE </span></div><div style="line-height:8pt;position:var(--position);top:41.17pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.53pt;position:var(--position);text-decoration:none;white-space:pre">STATEMENT </span></div><div style="line-height:8pt;position:var(--position);top:50.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.43pt;position:var(--position);text-decoration:none;white-space:pre">OF&#160;FINANCIAL </span></div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.08pt;position:var(--position);text-decoration:none;white-space:pre">POSITION</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.87pt;position:var(--position);text-decoration:none;white-space:pre">FAIR&#160;VALUE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.64pt;position:var(--position);text-decoration:none;white-space:pre">ASSETS/ </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.97pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.31pt;position:var(--position);text-decoration:none;white-space:pre">AT FAIR </span></div><div style="line-height:8pt;position:var(--position);top:31.57pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.64pt;position:var(--position);text-decoration:none;white-space:pre">VALUE </span></div><div style="line-height:8pt;position:var(--position);top:41.17pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.75pt;position:var(--position);text-decoration:none;white-space:pre">THROUGH </span></div><div style="line-height:8pt;position:var(--position);top:50.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.87pt;position:var(--position);text-decoration:none;white-space:pre">PROFIT&#160;AND </span></div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.41pt;position:var(--position);text-decoration:none;white-space:pre">LOSS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:41.17pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.2pt;position:var(--position);text-decoration:none;white-space:pre">ASSETS AT </span></div><div style="line-height:8pt;position:var(--position);top:50.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.53pt;position:var(--position);text-decoration:none;white-space:pre">AMORTIZED </span></div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.74pt;position:var(--position);text-decoration:none;white-space:pre">COST</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:21pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:41.17pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.85pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES </span></div><div style="line-height:8pt;position:var(--position);top:50.77pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.86pt;position:var(--position);text-decoration:none;white-space:pre">AT&#160;AMORTIZED </span></div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">COST</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial assets (2)</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">26,772<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">27,141<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">27,141<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:90pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.96pt"></span></span><span style="left:57.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other receivables and assets (2)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:102pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">13,769<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:102pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">13,769<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:102pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:102pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">13,769<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:102pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.96pt"></span></span><span style="left:57.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:114pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cash and cash equivalents (1)</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:114pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">516,685<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:114pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">516,685<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:114pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">437,031<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:114pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">79,654<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:114pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.96pt"></span></span><span style="left:57.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:126pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial assets</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:126pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">557,226<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:126pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">557,595<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:126pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">437,031<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:126pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">120,565<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:126pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:54.96pt"></span></span><span style="left:57.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:138pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial liabilities&#8212;non-current portion (4, Note 15)</span></div></div></div></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:138pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">30,790<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:138pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">102,555<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:138pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:138pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:138pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">102,555<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:150pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial liabilities&#8212;current portion (3, Note 15)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:150pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">1,302<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:150pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">1,302<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:150pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:150pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:150pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">1,302<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:162pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Trade payables and other current liabilities (3)</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:162pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">37,552<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:162pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">37,552<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:162pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:162pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:162pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.96pt"></span></span><span style="left:43.59pt;position:var(--position)">37,552<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:174pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial liabilities</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:174pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">69,644<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:174pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">141,409<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:174pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:174pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:174pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">141,409<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:681.81pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(1)&#160; &#160;  The fair value of cash and cash equivalents is determined based on Level 1 fair value measurement and corresponds to the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:693.81pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">market value of the assets. </span></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(2)&#160; &#160;  The carrying amount of financial assets measured at amortized cost is deemed to be a reasonable estimate of fair value, except </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:82.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">for the long-term advances made to CROs, whose fair value is determined based on Level 3 fair value measurement and is estimated </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:93.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">based on future cash-flows discounted at market rates, using credit spreads ranging from </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:392.29pt;position:var(--position);text-decoration:none;white-space:pre">104</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:407.29pt;position:var(--position);text-decoration:none;white-space:pre"> bp to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:432.56pt;position:var(--position);text-decoration:none;white-space:pre">218</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:447.56pt;position:var(--position);text-decoration:none;white-space:pre"> bp as of December 31, 2023, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:105.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">131</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:51pt;position:var(--position);text-decoration:none;white-space:pre"> bp to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:76.27000000000001pt;position:var(--position);text-decoration:none;white-space:pre">271</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.27000000000001pt;position:var(--position);text-decoration:none;white-space:pre"> bp as of December 31, 2024 and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:225.89pt;position:var(--position);text-decoration:none;white-space:pre">34</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:235.89pt;position:var(--position);text-decoration:none;white-space:pre"> bp to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:261.15999999999997pt;position:var(--position);text-decoration:none;white-space:pre">131</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:276.15999999999997pt;position:var(--position);text-decoration:none;white-space:pre"> bp as of December 31, 2025. As of December 31, 2023, 2024, and 2025, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:116.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">an increase in the credit spread by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:174.42pt;position:var(--position);text-decoration:none;white-space:pre">+100</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:195.05pt;position:var(--position);text-decoration:none;white-space:pre"> bp would result in a decrease in the advances fair value by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:433.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;23&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:486.96pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:491.96pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;235&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:550.55pt;position:var(--position);text-decoration:none;white-space:pre">, and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:128.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;231&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.59pt;position:var(--position);text-decoration:none;white-space:pre">, respectively. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:151.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(3)&#160; &#160;  The carrying amount of short-term financial liabilities measured at amortized cost was deemed to be a reasonable estimate of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:163.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">fair value. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:187.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(4)&#160; &#160;  The fair value of the royalty certificates, Heights convertible notes, Kreos / Claret BSA and Minimum Return Indemnifications </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:199.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">is based on Level 3 fair value measurement and is estimated based on models and assumptions detailed in Note 15. The fair value of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:211.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">other long-term financial liabilities is determined based on Level 3 fair value measurement and is estimated based on future cash-flows </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:223.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">discounted at market rates, using the following assumptions: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:247.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">For the debt components of the Kreos / Claret OCABSA (tranche A) and the tranches B and C of the Kreos / Claret straight </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:259.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">bond loans, a credit spread of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:192.16pt;position:var(--position);text-decoration:none;white-space:pre">960</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:207.16pt;position:var(--position);text-decoration:none;white-space:pre"> bp as of August 22, 2023, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:315.19pt;position:var(--position);text-decoration:none;white-space:pre">900</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:330.19pt;position:var(--position);text-decoration:none;white-space:pre"> bp as of December 31, 2023 and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:464.81pt;position:var(--position);text-decoration:none;white-space:pre">750</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:479.81pt;position:var(--position);text-decoration:none;white-space:pre"> bp as of December 31, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:271.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">2024. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:283.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">As of August 22, 2023, December 31, 2023 (tranche A) and December 31, 2024 (all </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:410.9pt;position:var(--position);text-decoration:none;white-space:pre">three</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:430.86pt;position:var(--position);text-decoration:none;white-space:pre"> tranches), an increase in the credit </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:295.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">spread by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.08pt;position:var(--position);text-decoration:none;white-space:pre">+100</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:133.71pt;position:var(--position);text-decoration:none;white-space:pre"> bp would result in a decrease in the Kreos / Claret debt components fair value by respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:512.69pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;624&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:571.28pt;position:var(--position);text-decoration:none;white-space:pre">,&#160; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:307.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;538&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:130.59pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:150.01999999999998pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;958&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:208.61pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:331.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">For the conditional advances and the PGE loan, a credit spread of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:336.42pt;position:var(--position);text-decoration:none;white-space:pre">900</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:351.42pt;position:var(--position);text-decoration:none;white-space:pre"> bp as of December 31, 2023, and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:488.54pt;position:var(--position);text-decoration:none;white-space:pre">730</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:503.54pt;position:var(--position);text-decoration:none;white-space:pre"> bp as of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:343.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">December 31, 2024. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.54000000000002pt;position:var(--position);text-decoration:none;white-space:pre">An i</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:173.03pt;position:var(--position);text-decoration:none;white-space:pre">ncrease in the credit spread by</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:294.25pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:296.75pt;position:var(--position);text-decoration:none;white-space:pre">+100</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:317.38pt;position:var(--position);text-decoration:none;white-space:pre"> bp w</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:339.6pt;position:var(--position);text-decoration:none;white-space:pre">ould result in the following: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:355.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:76.5pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.5pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, and 2024, a decrease in the PGE loan fair value by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:407.25pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;39&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:460.84pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:480.27pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;21&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:533.86pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:367.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.5pt;position:var(--position);text-decoration:none;white-space:pre">respectively. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:379.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:76.5pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.5pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, a decrease in the RNP-VIR conditional advance fair value by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:449.38pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;15&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:502.97pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:391.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:76.5pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.5pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, a decrease in the CARENA conditional advance fair value by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:450.48pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;37&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:504.07pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:76.5pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.5pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, a decrease in the Ebola conditional advance fair value by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:432.7pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1&#160;thousand</span>.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory', window );">Disclosure of carrying amounts and fair value of financial liabilities</a></td>
<td class="text"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">The following table shows the carrying amounts and fair value of financial assets and financial liabilities, including their </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:561.75pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">levels in the fair value hierarchy.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:573.75pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">Tax and employee-related payables are non-financial liabilities and are therefore excluded from the tables below. They are </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:585.75pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">presented in Note 17.2.</span></div><div><div style="position:var(--position);top:70.56pt;width:612pt"><div style="font-size:0pt;left:39pt;position:var(--position);width:534pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:189.75pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:71.25pt"></td></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td colspan="9" style="font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);width:344.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:344.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:160.47pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:344.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:134.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td></tr><tr style="height:69pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:60.23pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:43.34pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.42pt;position:var(--position);text-decoration:none;white-space:pre">AMOUNT </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.31pt;position:var(--position);text-decoration:none;white-space:pre">RECOGNIZED </span></div><div style="line-height:8pt;position:var(--position);top:31.57pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.74pt;position:var(--position);text-decoration:none;white-space:pre">IN THE </span></div><div style="line-height:8pt;position:var(--position);top:41.17pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.53pt;position:var(--position);text-decoration:none;white-space:pre">STATEMENT </span></div><div style="line-height:8pt;position:var(--position);top:50.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.43pt;position:var(--position);text-decoration:none;white-space:pre">OF&#160;FINANCIAL </span></div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.08pt;position:var(--position);text-decoration:none;white-space:pre">POSITION</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.87pt;position:var(--position);text-decoration:none;white-space:pre">FAIR&#160;VALUE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.64pt;position:var(--position);text-decoration:none;white-space:pre">ASSETS/ </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.97pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.31pt;position:var(--position);text-decoration:none;white-space:pre">AT FAIR </span></div><div style="line-height:8pt;position:var(--position);top:31.57pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.64pt;position:var(--position);text-decoration:none;white-space:pre">VALUE </span></div><div style="line-height:8pt;position:var(--position);top:41.17pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.75pt;position:var(--position);text-decoration:none;white-space:pre">THROUGH </span></div><div style="line-height:8pt;position:var(--position);top:50.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.87pt;position:var(--position);text-decoration:none;white-space:pre">PROFIT&#160;AND </span></div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.41pt;position:var(--position);text-decoration:none;white-space:pre">LOSS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:41.17pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.2pt;position:var(--position);text-decoration:none;white-space:pre">ASSETS AT </span></div><div style="line-height:8pt;position:var(--position);top:50.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.53pt;position:var(--position);text-decoration:none;white-space:pre">AMORTIZED </span></div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.74pt;position:var(--position);text-decoration:none;white-space:pre">COST</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:21pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:41.17pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.97pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES </span></div><div style="line-height:8pt;position:var(--position);top:50.77pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.98pt;position:var(--position);text-decoration:none;white-space:pre">AT&#160;AMORTIZED </span></div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.74pt;position:var(--position);text-decoration:none;white-space:pre">COST</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial assets (2)</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">22,055</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">22,394</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">22,394</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:90pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:60.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other receivables and assets (2)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:102pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">27,164</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:102pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">27,164</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:102pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:102pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">27,164</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:102pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:60.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:114pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cash and cash equivalents (1)</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:114pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">251,942</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:114pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">251,942</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:114pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:114pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">251,942</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:114pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:60.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:126pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial assets</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:126pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">301,161</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:126pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">301,500</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:126pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:126pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">301,500</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:126pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:60.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:138pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial liabilities&#8212;non-current portion (4, Note 15)</span></div></div></div></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:138pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">39,697</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:138pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">40,622</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:138pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">18,506</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:138pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:138pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.62pt;position:var(--position);text-decoration:none;white-space:pre">42,768</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:150pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial liabilities&#8212;current portion (3, Note 15)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:150pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">37,348</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:150pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">37,348</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:150pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">11,531</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:150pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:150pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:50.62pt;position:var(--position);text-decoration:none;white-space:pre">5,165</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:162pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Trade payables and other current liabilities (3)</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:162pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">47,221</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:162pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">47,221</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:162pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:162pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:162pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.62pt;position:var(--position);text-decoration:none;white-space:pre">47,221</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:174pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial liabilities</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:174pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">124,266</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:174pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">125,191</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:174pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">30,037</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:174pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:174pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:46.62pt;position:var(--position);text-decoration:none;white-space:pre">95,154</span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:273.56pt;width:612pt"><div style="font-size:0pt;left:39pt;position:var(--position);width:534pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:189.75pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:71.25pt"></td></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td colspan="9" style="font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);width:344.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:344.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:160.47pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:344.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:134.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td></tr><tr style="height:71.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:62.48pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:43.34pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.42pt;position:var(--position);text-decoration:none;white-space:pre">AMOUNT </span></div><div style="line-height:8pt;position:var(--position);top:24.22pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.31pt;position:var(--position);text-decoration:none;white-space:pre">RECOGNIZED </span></div><div style="line-height:8pt;position:var(--position);top:33.82pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.74pt;position:var(--position);text-decoration:none;white-space:pre">IN THE </span></div><div style="line-height:8pt;position:var(--position);top:43.42pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.53pt;position:var(--position);text-decoration:none;white-space:pre">STATEMENT </span></div><div style="line-height:8pt;position:var(--position);top:53.02pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.43pt;position:var(--position);text-decoration:none;white-space:pre">OF&#160;FINANCIAL </span></div><div style="line-height:8pt;position:var(--position);top:62.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.08pt;position:var(--position);text-decoration:none;white-space:pre">POSITION</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:62.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.87pt;position:var(--position);text-decoration:none;white-space:pre">FAIR&#160;VALUE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.02pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.64pt;position:var(--position);text-decoration:none;white-space:pre">ASSETS/ </span></div><div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.97pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES </span></div><div style="line-height:8pt;position:var(--position);top:24.22pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.31pt;position:var(--position);text-decoration:none;white-space:pre">AT FAIR </span></div><div style="line-height:8pt;position:var(--position);top:33.82pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.64pt;position:var(--position);text-decoration:none;white-space:pre">VALUE </span></div><div style="line-height:8pt;position:var(--position);top:43.42pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.75pt;position:var(--position);text-decoration:none;white-space:pre">THROUGH </span></div><div style="line-height:8pt;position:var(--position);top:53.02pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.87pt;position:var(--position);text-decoration:none;white-space:pre">PROFIT&#160;AND </span></div><div style="line-height:8pt;position:var(--position);top:62.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.41pt;position:var(--position);text-decoration:none;white-space:pre">LOSS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:43.42pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.2pt;position:var(--position);text-decoration:none;white-space:pre">ASSETS AT </span></div><div style="line-height:8pt;position:var(--position);top:53.02pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.53pt;position:var(--position);text-decoration:none;white-space:pre">AMORTIZED </span></div><div style="line-height:8pt;position:var(--position);top:62.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.74pt;position:var(--position);text-decoration:none;white-space:pre">COST</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:21pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:43.42pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.97pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES </span></div><div style="line-height:8pt;position:var(--position);top:53.02pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.98pt;position:var(--position);text-decoration:none;white-space:pre">AT&#160;AMORTIZED </span></div><div style="line-height:8pt;position:var(--position);top:62.62pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.74pt;position:var(--position);text-decoration:none;white-space:pre">COST</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:92.25pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial assets (2)</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:92.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">13,473</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:92.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">12,690</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:92.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:92.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">12,690</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:92.25pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:60.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:104.25pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other receivables and assets (2)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:104.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">19,843</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:104.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">19,843</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:104.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:104.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">19,843</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:104.25pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:60.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:116.25pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cash and cash equivalents (1)</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:116.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">144,221</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:116.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">144,221</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:116.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:116.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">144,221</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:116.25pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:60.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:128.25pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial assets</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:128.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">177,537</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:128.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">176,754</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:128.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:128.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">176,754</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:128.25pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:60.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:140.25pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial liabilities&#8212;non-current portion (4, Note 15)</span></div></div></div></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:140.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">69,069</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:140.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">73,497</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:140.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre">3,620</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:140.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:140.25pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.62pt;position:var(--position);text-decoration:none;white-space:pre">69,877</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:152.25pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial liabilities&#8212;current portion (3, Note 15)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:152.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">44,935</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:152.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">44,935</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:152.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">21,183</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:152.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:152.25pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.62pt;position:var(--position);text-decoration:none;white-space:pre">23,752</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:164.25pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Trade payables and other current liabilities (3)</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:164.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">43,824</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:164.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">43,824</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:164.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:164.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:164.25pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.62pt;position:var(--position);text-decoration:none;white-space:pre">43,824</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:176.25pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial liabilities</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:176.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">157,828</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:176.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:36.62pt;position:var(--position);text-decoration:none;white-space:pre">162,256</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:176.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:40.62pt;position:var(--position);text-decoration:none;white-space:pre">24,803</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:176.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:176.25pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:42.62pt;position:var(--position);text-decoration:none;white-space:pre">137,453</span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:478.81pt;width:612pt"><div style="font-size:0pt;left:40.12pt;position:var(--position);width:531.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:189.75pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:69pt"></td></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td colspan="9" style="font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);width:342pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:342pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:159.34pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:342pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:132.91pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td></tr><tr style="height:69pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:60.23pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:43.34pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.42pt;position:var(--position);text-decoration:none;white-space:pre">AMOUNT </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.31pt;position:var(--position);text-decoration:none;white-space:pre">RECOGNIZED </span></div><div style="line-height:8pt;position:var(--position);top:31.57pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.74pt;position:var(--position);text-decoration:none;white-space:pre">IN THE </span></div><div style="line-height:8pt;position:var(--position);top:41.17pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.53pt;position:var(--position);text-decoration:none;white-space:pre">STATEMENT </span></div><div style="line-height:8pt;position:var(--position);top:50.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.43pt;position:var(--position);text-decoration:none;white-space:pre">OF&#160;FINANCIAL </span></div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.08pt;position:var(--position);text-decoration:none;white-space:pre">POSITION</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.87pt;position:var(--position);text-decoration:none;white-space:pre">FAIR&#160;VALUE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.64pt;position:var(--position);text-decoration:none;white-space:pre">ASSETS/ </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.97pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.31pt;position:var(--position);text-decoration:none;white-space:pre">AT FAIR </span></div><div style="line-height:8pt;position:var(--position);top:31.57pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.64pt;position:var(--position);text-decoration:none;white-space:pre">VALUE </span></div><div style="line-height:8pt;position:var(--position);top:41.17pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.75pt;position:var(--position);text-decoration:none;white-space:pre">THROUGH </span></div><div style="line-height:8pt;position:var(--position);top:50.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.87pt;position:var(--position);text-decoration:none;white-space:pre">PROFIT&#160;AND </span></div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.41pt;position:var(--position);text-decoration:none;white-space:pre">LOSS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:21pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:41.17pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.2pt;position:var(--position);text-decoration:none;white-space:pre">ASSETS AT </span></div><div style="line-height:8pt;position:var(--position);top:50.77pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.53pt;position:var(--position);text-decoration:none;white-space:pre">AMORTIZED </span></div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.74pt;position:var(--position);text-decoration:none;white-space:pre">COST</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:21pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:41.17pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.85pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES </span></div><div style="line-height:8pt;position:var(--position);top:50.77pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.86pt;position:var(--position);text-decoration:none;white-space:pre">AT&#160;AMORTIZED </span></div><div style="line-height:8pt;position:var(--position);top:60.37pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">COST</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial assets (2)</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">26,772<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">27,141<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">27,141<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:90pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.96pt"></span></span><span style="left:57.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other receivables and assets (2)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:102pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">13,769<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:102pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">13,769<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:102pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:102pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">13,769<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:102pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.96pt"></span></span><span style="left:57.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:114pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Cash and cash equivalents (1)</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:114pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">516,685<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:114pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">516,685<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:114pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">437,031<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:114pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">79,654<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:114pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.96pt"></span></span><span style="left:57.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:126pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial assets</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:126pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">557,226<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:126pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">557,595<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:126pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">437,031<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:126pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">120,565<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:126pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:54.96pt"></span></span><span style="left:57.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:138pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial liabilities&#8212;non-current portion (4, Note 15)</span></div></div></div></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:138pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">30,790<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:138pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">102,555<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:138pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:138pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:138pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">102,555<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:150pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial liabilities&#8212;current portion (3, Note 15)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:150pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">1,302<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:150pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">1,302<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:150pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:150pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:150pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">1,302<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:162pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Trade payables and other current liabilities (3)</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:162pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">37,552<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:162pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">37,552<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:162pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:162pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:162pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.96pt"></span></span><span style="left:43.59pt;position:var(--position)">37,552<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:174pt;width:189.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:189.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial liabilities</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:174pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">69,644<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:258pt;position:var(--position);top:174pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">141,409<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:326.25pt;position:var(--position);top:174pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:394.5pt;position:var(--position);top:174pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:462.75pt;position:var(--position);top:174pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">141,409<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:681.81pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(1)&#160; &#160;  The fair value of cash and cash equivalents is determined based on Level 1 fair value measurement and corresponds to the </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:693.81pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">market value of the assets. </span></div></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(2)&#160; &#160;  The carrying amount of financial assets measured at amortized cost is deemed to be a reasonable estimate of fair value, except </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:82.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">for the long-term advances made to CROs, whose fair value is determined based on Level 3 fair value measurement and is estimated </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:93.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">based on future cash-flows discounted at market rates, using credit spreads ranging from </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:392.29pt;position:var(--position);text-decoration:none;white-space:pre">104</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:407.29pt;position:var(--position);text-decoration:none;white-space:pre"> bp to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:432.56pt;position:var(--position);text-decoration:none;white-space:pre">218</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:447.56pt;position:var(--position);text-decoration:none;white-space:pre"> bp as of December 31, 2023, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:105.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">131</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:51pt;position:var(--position);text-decoration:none;white-space:pre"> bp to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:76.27000000000001pt;position:var(--position);text-decoration:none;white-space:pre">271</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.27000000000001pt;position:var(--position);text-decoration:none;white-space:pre"> bp as of December 31, 2024 and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:225.89pt;position:var(--position);text-decoration:none;white-space:pre">34</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:235.89pt;position:var(--position);text-decoration:none;white-space:pre"> bp to </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:261.15999999999997pt;position:var(--position);text-decoration:none;white-space:pre">131</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:276.15999999999997pt;position:var(--position);text-decoration:none;white-space:pre"> bp as of December 31, 2025. As of December 31, 2023, 2024, and 2025, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:116.56pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">an increase in the credit spread by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:174.42pt;position:var(--position);text-decoration:none;white-space:pre">+100</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:195.05pt;position:var(--position);text-decoration:none;white-space:pre"> bp would result in a decrease in the advances fair value by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:433.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;23&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:486.96pt;position:var(--position);text-decoration:none;white-space:pre">, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:491.96pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;235&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:550.55pt;position:var(--position);text-decoration:none;white-space:pre">, and </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:128.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;231&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.59pt;position:var(--position);text-decoration:none;white-space:pre">, respectively. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:151.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(3)&#160; &#160;  The carrying amount of short-term financial liabilities measured at amortized cost was deemed to be a reasonable estimate of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:163.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">fair value. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:187.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">(4)&#160; &#160;  The fair value of the royalty certificates, Heights convertible notes, Kreos / Claret BSA and Minimum Return Indemnifications </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:199.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">is based on Level 3 fair value measurement and is estimated based on models and assumptions detailed in Note 15. The fair value of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:211.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">other long-term financial liabilities is determined based on Level 3 fair value measurement and is estimated based on future cash-flows </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:223.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">discounted at market rates, using the following assumptions: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:247.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">For the debt components of the Kreos / Claret OCABSA (tranche A) and the tranches B and C of the Kreos / Claret straight </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:259.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">bond loans, a credit spread of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:192.16pt;position:var(--position);text-decoration:none;white-space:pre">960</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:207.16pt;position:var(--position);text-decoration:none;white-space:pre"> bp as of August 22, 2023, </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:315.19pt;position:var(--position);text-decoration:none;white-space:pre">900</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:330.19pt;position:var(--position);text-decoration:none;white-space:pre"> bp as of December 31, 2023 and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:464.81pt;position:var(--position);text-decoration:none;white-space:pre">750</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:479.81pt;position:var(--position);text-decoration:none;white-space:pre"> bp as of December 31, </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:271.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">2024. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:283.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">As of August 22, 2023, December 31, 2023 (tranche A) and December 31, 2024 (all </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:410.9pt;position:var(--position);text-decoration:none;white-space:pre">three</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:430.86pt;position:var(--position);text-decoration:none;white-space:pre"> tranches), an increase in the credit </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:295.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">spread by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.08pt;position:var(--position);text-decoration:none;white-space:pre">+100</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:133.71pt;position:var(--position);text-decoration:none;white-space:pre"> bp would result in a decrease in the Kreos / Claret debt components fair value by respectively </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:512.69pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;624&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:571.28pt;position:var(--position);text-decoration:none;white-space:pre">,&#160; </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:307.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;538&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:130.59pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:150.01999999999998pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;958&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:208.61pt;position:var(--position);text-decoration:none;white-space:pre">.</span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:331.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">For the conditional advances and the PGE loan, a credit spread of </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:336.42pt;position:var(--position);text-decoration:none;white-space:pre">900</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:351.42pt;position:var(--position);text-decoration:none;white-space:pre"> bp as of December 31, 2023, and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:488.54pt;position:var(--position);text-decoration:none;white-space:pre">730</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:503.54pt;position:var(--position);text-decoration:none;white-space:pre"> bp as of </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:343.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre">December 31, 2024. </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.54000000000002pt;position:var(--position);text-decoration:none;white-space:pre">An i</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:173.03pt;position:var(--position);text-decoration:none;white-space:pre">ncrease in the credit spread by</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:294.25pt;position:var(--position);text-decoration:none;white-space:pre"> </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:296.75pt;position:var(--position);text-decoration:none;white-space:pre">+100</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:317.38pt;position:var(--position);text-decoration:none;white-space:pre"> bp w</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:339.6pt;position:var(--position);text-decoration:none;white-space:pre">ould result in the following: </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:355.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:76.5pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.5pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, and 2024, a decrease in the PGE loan fair value by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:407.25pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;39&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:460.84pt;position:var(--position);text-decoration:none;white-space:pre"> and </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:480.27pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;21&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:533.86pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:367.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.5pt;position:var(--position);text-decoration:none;white-space:pre">respectively. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:379.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:76.5pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.5pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, a decrease in the RNP-VIR conditional advance fair value by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:449.38pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;15&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:502.97pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><div style="font-size:12pt;line-height:10pt;position:var(--position);top:391.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:76.5pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.5pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, a decrease in the CARENA conditional advance fair value by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:450.48pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;37&#160;thousand</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:504.07pt;position:var(--position);text-decoration:none;white-space:pre">. </span></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:76.5pt;position:var(--position);text-decoration:none;white-space:pre">&#8226;</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.5pt;position:var(--position);text-decoration:none;white-space:pre">As of December 31, 2023, a decrease in the Ebola conditional advance fair value by </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:432.7pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1&#160;thousand</span>.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_FairValueMeasurementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurement [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_FairValueMeasurementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the fair value measurement of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the fair value measurement of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ShareBasedPaymentArrangementsAbstract', window );"><strong>Share-Based Payment Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory', window );">Disclosure of reconciliation of other equity instruments</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The following tables summarize the data relating to BCEs as well as the assumptions used for the measurement thereof in accordance </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:577.46pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">with IFRS 2 &#8211; </span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:94.87pt;position:var(--position);text-decoration:none;white-space:pre">Share-based Payment</span><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:182.29pt;position:var(--position);text-decoration:none;white-space:pre">: </span></div><div style="position:var(--position);top:70.56pt;width:612pt"><div style="font-size:0pt;left:43pt;position:var(--position);width:524.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:45pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:47.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:51pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:51pt"></td><td style="padding:0;width:51pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:51pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:51pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:51pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:51pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:51pt"></td></tr><tr style="height:89.25pt"><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:45pt"><div><div style="line-height:8pt;position:var(--position);top:52.2pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.18pt;position:var(--position);text-decoration:none;white-space:pre">GRANT&#160;D</span></div><div style="line-height:8pt;position:var(--position);top:61.8pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.28pt;position:var(--position);text-decoration:none;white-space:pre">ATE </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:48pt;position:var(--position);width:47.25pt"><div><div style="line-height:8pt;position:var(--position);top:57pt;width:47.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.97pt;position:var(--position);text-decoration:none;white-space:pre">TYPE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:98.25pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:47.4pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:57pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.18pt;position:var(--position);text-decoration:none;white-space:pre">OF BCEs </span></div><div style="line-height:8pt;position:var(--position);top:66.6pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.07pt;position:var(--position);text-decoration:none;white-space:pre">ISSUED</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:152.25pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:33pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:42.6pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.73pt;position:var(--position);text-decoration:none;white-space:pre">OF BCE </span></div><div style="line-height:8pt;position:var(--position);top:52.2pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.3pt;position:var(--position);text-decoration:none;white-space:pre">OUTSTAND</span></div><div style="line-height:8pt;position:var(--position);top:61.8pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.29pt;position:var(--position);text-decoration:none;white-space:pre">ING AS OF </span></div><div style="line-height:8pt;position:var(--position);top:71.4pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.19pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY </span></div><div style="line-height:8pt;position:var(--position);top:81pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.5pt;position:var(--position);text-decoration:none;white-space:pre">1, 2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:203.25pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:32.02pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:41.62pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.52pt;position:var(--position);text-decoration:none;white-space:pre">OF ISSUED </span></div><div style="line-height:8pt;position:var(--position);top:51.22pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.73pt;position:var(--position);text-decoration:none;white-space:pre">BCEs</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:257.25pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:32.02pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:41.62pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.19pt;position:var(--position);text-decoration:none;white-space:pre">OF LAPSED </span></div><div style="line-height:8pt;position:var(--position);top:51.22pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.73pt;position:var(--position);text-decoration:none;white-space:pre">BCEs</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:311.25pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:27.22pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:36.82pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:19.95pt;position:var(--position);text-decoration:none;white-space:pre">OF </span></div><div style="line-height:8pt;position:var(--position);top:46.42pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.07pt;position:var(--position);text-decoration:none;white-space:pre">EXERCISE</span></div><div style="line-height:8pt;position:var(--position);top:56.02pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.84pt;position:var(--position);text-decoration:none;white-space:pre">D BCEs</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:365.25pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:27.22pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:36.82pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.18pt;position:var(--position);text-decoration:none;white-space:pre">OF BCEs </span></div><div style="line-height:8pt;position:var(--position);top:46.42pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.3pt;position:var(--position);text-decoration:none;white-space:pre">OUTSTAND</span></div><div style="line-height:8pt;position:var(--position);top:56.02pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.95pt;position:var(--position);text-decoration:none;white-space:pre">ING </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:419.25pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:27.22pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:36.82pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.18pt;position:var(--position);text-decoration:none;white-space:pre">OF BCEs </span></div><div style="line-height:8pt;position:var(--position);top:46.42pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.85pt;position:var(--position);text-decoration:none;white-space:pre">EXERCISA</span></div><div style="line-height:8pt;position:var(--position);top:56.02pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.5pt;position:var(--position);text-decoration:none;white-space:pre">BLE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.22pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.96pt;position:var(--position);text-decoration:none;white-space:pre">MAXIMUM </span></div><div style="line-height:8pt;position:var(--position);top:12.82pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:22.42pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.96pt;position:var(--position);text-decoration:none;white-space:pre">OF SHARES </span></div><div style="line-height:8pt;position:var(--position);top:32.02pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.39pt;position:var(--position);text-decoration:none;white-space:pre">TO BE </span></div><div style="line-height:8pt;position:var(--position);top:41.62pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.07pt;position:var(--position);text-decoration:none;white-space:pre">ISSUED IF </span></div><div style="line-height:8pt;position:var(--position);top:51.22pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.28pt;position:var(--position);text-decoration:none;white-space:pre">ALL </span></div><div style="line-height:8pt;position:var(--position);top:60.82pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.85pt;position:var(--position);text-decoration:none;white-space:pre">CONDITIO</span></div><div style="line-height:8pt;position:var(--position);top:70.42pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.96pt;position:var(--position);text-decoration:none;white-space:pre">NS ARE </span></div><div style="line-height:8pt;position:var(--position);top:80.02pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.39pt;position:var(--position);text-decoration:none;white-space:pre">MET</span></div></div></div></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td colspan="5" style="font-size:0;text-align:left;vertical-align:top"><div style="left:203.25pt;position:var(--position);top:89.25pt;width:159pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:159pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.1pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED DECEMBER 31, 2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td colspan="5" style="font-size:0;text-align:left;vertical-align:top"><div style="left:365.25pt;position:var(--position);top:89.25pt;width:159pt"><div><div style="line-height:8pt;position:var(--position);top:7.57pt;width:159pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:67.84pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:17.17pt;width:159pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:120pt;width:45pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2016-11-07</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:48pt;position:var(--position);top:120pt;width:47.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:47.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BCE-2016-1</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:98.25pt;position:var(--position);top:120pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)">84,000</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:152.25pt;position:var(--position);top:120pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)">18,796</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:203.25pt;position:var(--position);top:120pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.62pt"></span></span><span style="left:42.25pt;position:var(--position)">&#8212;</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:257.25pt;position:var(--position);top:120pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:311.25pt;position:var(--position);top:120pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:20.3pt"></span></span><span style="left:22.93pt;position:var(--position)">(18,796)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:365.25pt;position:var(--position);top:120pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:419.25pt;position:var(--position);top:120pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:120pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:132pt;width:45pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2017-01-23</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:48pt;position:var(--position);top:132pt;width:47.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:47.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BCE-2017-1</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:98.25pt;position:var(--position);top:132pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)">67,374</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:152.25pt;position:var(--position);top:132pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)">67,000</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:203.25pt;position:var(--position);top:132pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.62pt"></span></span><span style="left:42.25pt;position:var(--position)">&#8212;</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:257.25pt;position:var(--position);top:132pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:311.25pt;position:var(--position);top:132pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:20.3pt"></span></span><span style="left:22.93pt;position:var(--position)">(33,313)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:365.25pt;position:var(--position);top:132pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">33,687<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:419.25pt;position:var(--position);top:132pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">33,687<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:132pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">33,687<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:144pt;width:45pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2017-11-20</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:48pt;position:var(--position);top:144pt;width:47.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:47.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BCE-2017-2</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:98.25pt;position:var(--position);top:144pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:21.62pt"></span></span><span style="left:24.25pt;position:var(--position)">150,000</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:152.25pt;position:var(--position);top:144pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:21.62pt"></span></span><span style="left:24.25pt;position:var(--position)">112,500</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:203.25pt;position:var(--position);top:144pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.62pt"></span></span><span style="left:42.25pt;position:var(--position)">&#8212;</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:257.25pt;position:var(--position);top:144pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:311.25pt;position:var(--position);top:144pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:365.25pt;position:var(--position);top:144pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)">112,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:419.25pt;position:var(--position);top:144pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)">112,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:144pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)">112,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:156pt;width:45pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2017-11-20</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:48pt;position:var(--position);top:156pt;width:47.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:47.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BCE-2017-4</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:98.25pt;position:var(--position);top:156pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)">67,374</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:152.25pt;position:var(--position);top:156pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)">67,373</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:203.25pt;position:var(--position);top:156pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.62pt"></span></span><span style="left:42.25pt;position:var(--position)">&#8212;</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:257.25pt;position:var(--position);top:156pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:311.25pt;position:var(--position);top:156pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:20.3pt"></span></span><span style="left:22.93pt;position:var(--position)">(33,686)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:365.25pt;position:var(--position);top:156pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">33,687<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:419.25pt;position:var(--position);top:156pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:156pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">33,687<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:168pt;width:45pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2017-11-20</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:48pt;position:var(--position);top:168pt;width:47.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:47.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BCE-2017-5</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:98.25pt;position:var(--position);top:168pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)">67,374</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:152.25pt;position:var(--position);top:168pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)">33,687</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:203.25pt;position:var(--position);top:168pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.62pt"></span></span><span style="left:42.25pt;position:var(--position)">&#8212;</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:257.25pt;position:var(--position);top:168pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:311.25pt;position:var(--position);top:168pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:20.3pt"></span></span><span style="left:22.93pt;position:var(--position)">(16,843)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:365.25pt;position:var(--position);top:168pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">16,844<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:419.25pt;position:var(--position);top:168pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:168pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">16,844<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:180pt;width:45pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2018-03-15</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:48pt;position:var(--position);top:180pt;width:47.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:47.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BCE-2018-1</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:98.25pt;position:var(--position);top:180pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)">22,000</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:152.25pt;position:var(--position);top:180pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)">11,980</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:203.25pt;position:var(--position);top:180pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.62pt"></span></span><span style="left:42.25pt;position:var(--position)">&#8212;</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:257.25pt;position:var(--position);top:180pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:311.25pt;position:var(--position);top:180pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:24.3pt"></span></span><span style="left:26.93pt;position:var(--position)">(9,440)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:365.25pt;position:var(--position);top:180pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.96pt"></span></span><span style="left:29.59pt;position:var(--position)">2,540<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:419.25pt;position:var(--position);top:180pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.96pt"></span></span><span style="left:29.59pt;position:var(--position)">2,540<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:180pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.96pt"></span></span><span style="left:29.59pt;position:var(--position)">2,540<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:192pt;width:45pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2018-05-14</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:48pt;position:var(--position);top:192pt;width:47.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:47.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BCE-2018-4</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:98.25pt;position:var(--position);top:192pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)">16,843</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:152.25pt;position:var(--position);top:192pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)">16,843</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:203.25pt;position:var(--position);top:192pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.62pt"></span></span><span style="left:42.25pt;position:var(--position)">&#8212;</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:257.25pt;position:var(--position);top:192pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:311.25pt;position:var(--position);top:192pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:24.3pt"></span></span><span style="left:26.93pt;position:var(--position)">(8,422)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:365.25pt;position:var(--position);top:192pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.96pt"></span></span><span style="left:29.59pt;position:var(--position)">8,421<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:419.25pt;position:var(--position);top:192pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.96pt"></span></span><span style="left:29.59pt;position:var(--position)">8,421<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:192pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.96pt"></span></span><span style="left:29.59pt;position:var(--position)">8,421<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:204pt;width:45pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:45pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2018-05-14</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:48pt;position:var(--position);top:204pt;width:47.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:47.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BCE-2018-5</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:98.25pt;position:var(--position);top:204pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.62pt"></span></span><span style="left:28.25pt;position:var(--position)">22,000</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:152.25pt;position:var(--position);top:204pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.62pt"></span></span><span style="left:32.25pt;position:var(--position)">2,000</span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:203.25pt;position:var(--position);top:204pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.62pt"></span></span><span style="left:42.25pt;position:var(--position)">&#8212;</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:257.25pt;position:var(--position);top:204pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:311.25pt;position:var(--position);top:204pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:24.3pt"></span></span><span style="left:26.93pt;position:var(--position)">(2,000)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:365.25pt;position:var(--position);top:204pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:419.25pt;position:var(--position);top:204pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:204pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:48pt;position:var(--position);top:216pt;width:47.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:47.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total BCEs</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:98.25pt;position:var(--position);top:216pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:21.62pt"></span></span><span style="left:24.25pt;position:var(--position)">496,965</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:152.25pt;position:var(--position);top:216pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:21.62pt"></span></span><span style="left:24.25pt;position:var(--position)">330,179</span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:203.25pt;position:var(--position);top:216pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:39.62pt"></span></span><span style="left:42.25pt;position:var(--position)">&#8212;</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:257.25pt;position:var(--position);top:216pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:311.25pt;position:var(--position);top:216pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:16.3pt"></span></span><span style="left:18.93pt;position:var(--position)">(122,500)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:365.25pt;position:var(--position);top:216pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)">207,679<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:419.25pt;position:var(--position);top:216pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)">157,148<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:473.25pt;position:var(--position);top:216pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)">207,679<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The following tables summarize the data relating to BSAs as well as the assumptions used for the measurement thereof in </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:561.89pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">accordance with IFRS 2&#8212;</span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:142.28pt;position:var(--position);text-decoration:none;white-space:pre">Share-based Payment</span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:229.7pt;position:var(--position);text-decoration:none;white-space:pre">:</span></div><div style="position:var(--position);top:70.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:537pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:52.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:52.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:51pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:51pt"></td><td style="padding:0;width:51pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:51pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:51pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:51pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:51pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:51pt"></td></tr><tr style="height:69pt"><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:42.07pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.05pt;position:var(--position);text-decoration:none;white-space:pre">GRANT&#160;DA</span></div><div style="line-height:8pt;position:var(--position);top:51.67pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.92pt;position:var(--position);text-decoration:none;white-space:pre">TE </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:55.5pt;position:var(--position);width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:46.87pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.59pt;position:var(--position);text-decoration:none;white-space:pre">TYPE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:111pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:32.47pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.39pt;position:var(--position);text-decoration:none;white-space:pre">Total </span></div><div style="line-height:8pt;position:var(--position);top:42.07pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:51.67pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.62pt;position:var(--position);text-decoration:none;white-space:pre">OF BSAs </span></div><div style="line-height:8pt;position:var(--position);top:61.27pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.07pt;position:var(--position);text-decoration:none;white-space:pre">ISSUED</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:165pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:22.87pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:32.47pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.62pt;position:var(--position);text-decoration:none;white-space:pre">OF BSAs </span></div><div style="line-height:8pt;position:var(--position);top:42.07pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.3pt;position:var(--position);text-decoration:none;white-space:pre">OUTSTAND</span></div><div style="line-height:8pt;position:var(--position);top:51.67pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.29pt;position:var(--position);text-decoration:none;white-space:pre">ING AS OF </span></div><div style="line-height:8pt;position:var(--position);top:61.27pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.19pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY </span></div><div style="line-height:8pt;position:var(--position);top:70.87pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.5pt;position:var(--position);text-decoration:none;white-space:pre">1, 2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:21.9pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:31.5pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.52pt;position:var(--position);text-decoration:none;white-space:pre">OF ISSUED </span></div><div style="line-height:8pt;position:var(--position);top:41.1pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.17pt;position:var(--position);text-decoration:none;white-space:pre">BSAs</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:270pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:21.9pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:31.5pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.19pt;position:var(--position);text-decoration:none;white-space:pre">OF LAPSED </span></div><div style="line-height:8pt;position:var(--position);top:41.1pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.17pt;position:var(--position);text-decoration:none;white-space:pre">BSAs</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:324pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:17.1pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:26.7pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:19.95pt;position:var(--position);text-decoration:none;white-space:pre">OF </span></div><div style="line-height:8pt;position:var(--position);top:36.3pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.07pt;position:var(--position);text-decoration:none;white-space:pre">EXERCISE</span></div><div style="line-height:8pt;position:var(--position);top:45.9pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.29pt;position:var(--position);text-decoration:none;white-space:pre">D&#160; BSAs</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:17.1pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:26.7pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.62pt;position:var(--position);text-decoration:none;white-space:pre">OF BSAs </span></div><div style="line-height:8pt;position:var(--position);top:36.3pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.3pt;position:var(--position);text-decoration:none;white-space:pre">OUTSTAND</span></div><div style="line-height:8pt;position:var(--position);top:45.9pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.95pt;position:var(--position);text-decoration:none;white-space:pre">ING </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:432pt;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:17.1pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:26.7pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.62pt;position:var(--position);text-decoration:none;white-space:pre">OF BSAs </span></div><div style="line-height:8pt;position:var(--position);top:36.3pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.85pt;position:var(--position);text-decoration:none;white-space:pre">EXERCISA</span></div><div style="line-height:8pt;position:var(--position);top:45.9pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.5pt;position:var(--position);text-decoration:none;white-space:pre">BLE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="height:69pt;left:486pt;overflow:hidden;position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:-6.9pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.96pt;position:var(--position);text-decoration:none;white-space:pre">MAXIMUM </span></div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.74pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.96pt;position:var(--position);text-decoration:none;white-space:pre">OF SHARES </span></div><div style="line-height:8pt;position:var(--position);top:21.9pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.39pt;position:var(--position);text-decoration:none;white-space:pre">TO BE </span></div><div style="line-height:8pt;position:var(--position);top:31.5pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.07pt;position:var(--position);text-decoration:none;white-space:pre">ISSUED IF </span></div><div style="line-height:8pt;position:var(--position);top:41.1pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.28pt;position:var(--position);text-decoration:none;white-space:pre">ALL </span></div><div style="line-height:8pt;position:var(--position);top:50.7pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.85pt;position:var(--position);text-decoration:none;white-space:pre">CONDITIO</span></div><div style="line-height:8pt;position:var(--position);top:60.3pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.96pt;position:var(--position);text-decoration:none;white-space:pre">NS ARE </span></div><div style="line-height:8pt;position:var(--position);top:69.9pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.39pt;position:var(--position);text-decoration:none;white-space:pre">MET</span></div></div></div></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td colspan="5" style="font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:69pt;width:159pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:159pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.1pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED DECEMBER 31, 2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td colspan="5" style="font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:69pt;width:159pt"><div><div style="line-height:8pt;position:var(--position);top:7.57pt;width:159pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:67.84pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:17.17pt;width:159pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:99.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2015-12-04</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:55.5pt;position:var(--position);top:99.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2015-11</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:111pt;position:var(--position);top:99.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">96,924<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:165pt;position:var(--position);top:99.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">96,924<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:99.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:270pt;position:var(--position);top:99.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:324pt;position:var(--position);top:99.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:20.3pt"></span></span><span style="left:22.93pt;position:var(--position)">(96,924)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:99.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:432pt;position:var(--position);top:99.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:486pt;position:var(--position);top:99.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:111.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2015-12-04</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:55.5pt;position:var(--position);top:111.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2015-12</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:111pt;position:var(--position);top:111.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">82,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:165pt;position:var(--position);top:111.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">16,400<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:111.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:270pt;position:var(--position);top:111.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:324pt;position:var(--position);top:111.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:20.3pt"></span></span><span style="left:22.93pt;position:var(--position)">(16,400)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:111.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:432pt;position:var(--position);top:111.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:486pt;position:var(--position);top:111.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:123.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2017-09-18</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:55.5pt;position:var(--position);top:123.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2017-1</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:111pt;position:var(--position);top:123.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">16,400<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:165pt;position:var(--position);top:123.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">16,400<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:123.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:270pt;position:var(--position);top:123.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:324pt;position:var(--position);top:123.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:20.3pt"></span></span><span style="left:22.93pt;position:var(--position)">(16,400)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:123.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:432pt;position:var(--position);top:123.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:486pt;position:var(--position);top:123.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:135.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2018-01-22</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:55.5pt;position:var(--position);top:135.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2018-1</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:111pt;position:var(--position);top:135.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">49,200<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:165pt;position:var(--position);top:135.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">16,400<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:135.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:270pt;position:var(--position);top:135.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:324pt;position:var(--position);top:135.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:135.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">16,400<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:432pt;position:var(--position);top:135.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">16,400<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:486pt;position:var(--position);top:135.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">16,400<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:147.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2024-04-04</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:55.5pt;position:var(--position);top:147.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2024-1</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:111pt;position:var(--position);top:147.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">58,365<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:165pt;position:var(--position);top:147.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">58,365<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:147.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:270pt;position:var(--position);top:147.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:324pt;position:var(--position);top:147.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:24.3pt"></span></span><span style="left:26.93pt;position:var(--position)">(4,863)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:147.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">53,502<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:432pt;position:var(--position);top:147.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.96pt"></span></span><span style="left:29.59pt;position:var(--position)">9,726<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:486pt;position:var(--position);top:147.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">53,502<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:159.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2024-04-04</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:55.5pt;position:var(--position);top:159.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2024-2</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:111pt;position:var(--position);top:159.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">19,455<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:165pt;position:var(--position);top:159.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">19,455<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:159.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:270pt;position:var(--position);top:159.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:324pt;position:var(--position);top:159.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:159.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">19,455<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:432pt;position:var(--position);top:159.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.96pt"></span></span><span style="left:29.59pt;position:var(--position)">4,863<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:486pt;position:var(--position);top:159.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">19,455<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:171.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2025-01-13</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:55.5pt;position:var(--position);top:171.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2025-1</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:111pt;position:var(--position);top:171.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)">100,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:165pt;position:var(--position);top:171.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:171.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)">100,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:270pt;position:var(--position);top:171.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:324pt;position:var(--position);top:171.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:171.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)">100,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:432pt;position:var(--position);top:171.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:486pt;position:var(--position);top:171.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)">100,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:183.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2025-01-13</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:55.5pt;position:var(--position);top:183.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2025-2</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:111pt;position:var(--position);top:183.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">25,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:165pt;position:var(--position);top:183.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:183.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">25,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:270pt;position:var(--position);top:183.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:324pt;position:var(--position);top:183.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:183.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">25,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:432pt;position:var(--position);top:183.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:486pt;position:var(--position);top:183.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">25,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:195.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2025-04-22</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:55.5pt;position:var(--position);top:195.75pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2025-3</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:111pt;position:var(--position);top:195.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">39,370<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:165pt;position:var(--position);top:195.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:195.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">39,370<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:270pt;position:var(--position);top:195.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:324pt;position:var(--position);top:195.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:195.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">39,370<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:11.25pt;left:429pt;overflow:hidden;position:var(--position);top:195.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:432pt;position:var(--position);top:195.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:11.25pt;left:483pt;overflow:hidden;position:var(--position);top:195.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:-45.51pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">3</span></div><div style="line-height:8pt;position:var(--position);top:-35.91pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">9</span></div><div style="line-height:8pt;position:var(--position);top:-26.31pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.63pt;position:var(--position);text-decoration:none;white-space:pre">,</span></div><div style="line-height:8pt;position:var(--position);top:-16.71pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">3</span></div><div style="line-height:8pt;position:var(--position);top:-7.11pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">7</span></div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:486pt;position:var(--position);top:195.75pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.49pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">39,370<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:55.5pt;position:var(--position);top:207pt;width:52.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:52.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total BSAs</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:111pt;position:var(--position);top:207pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)">486,714<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:165pt;position:var(--position);top:207pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)">223,944<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:207pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)">164,370<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:11.25pt;left:267pt;overflow:hidden;position:var(--position);top:207pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:270pt;position:var(--position);top:207pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:324pt;position:var(--position);top:207pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:16.3pt"></span></span><span style="left:18.93pt;position:var(--position)">(134,587)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:378pt;position:var(--position);top:207pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)">253,727<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:11.25pt;left:429pt;overflow:hidden;position:var(--position);top:207pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:432pt;position:var(--position);top:207pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:22.96pt"></span></span><span style="left:25.59pt;position:var(--position)">30,989<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:11.25pt;left:483pt;overflow:hidden;position:var(--position);top:207pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:486pt;position:var(--position);top:207pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.62pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:18.96pt"></span></span><span style="left:21.59pt;position:var(--position)">253,727<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">The following tables summarize the data relating to AGAs as well as the assumptions used for the measurement thereof in </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:391.56pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">accordance with IFRS 2&#8212;</span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:149.28pt;position:var(--position);text-decoration:none;white-space:pre">Share-based Payment</span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:236.7pt;position:var(--position);text-decoration:none;white-space:pre">:</span></div><div><div style="position:var(--position);top:70.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:537.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:64.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:64.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:64.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:64.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:64.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:64.5pt"></td><td style="padding:0;width:5.25pt"></td><td style="padding:0;width:65.25pt"></td></tr><tr style="height:47.25pt"><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:38.25pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.72pt;position:var(--position);text-decoration:none;white-space:pre">GRANT&#160;DATE </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:38.25pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.59pt;position:var(--position);text-decoration:none;white-space:pre">TYPE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:28.65pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.38pt;position:var(--position);text-decoration:none;white-space:pre">Total NUMBER </span></div><div style="line-height:8pt;position:var(--position);top:38.25pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.26pt;position:var(--position);text-decoration:none;white-space:pre">OF AGAs </span></div><div style="line-height:8pt;position:var(--position);top:47.85pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.82pt;position:var(--position);text-decoration:none;white-space:pre">ISSUED</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:25.87pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.31pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER OF </span></div><div style="line-height:8pt;position:var(--position);top:35.47pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.19pt;position:var(--position);text-decoration:none;white-space:pre">AGAs </span></div><div style="line-height:8pt;position:var(--position);top:45.07pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.87pt;position:var(--position);text-decoration:none;white-space:pre">OUTSTANDING </span></div><div style="line-height:8pt;position:var(--position);top:54.67pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.97pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:64.27pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.31pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY 1, </span></div><div style="line-height:8pt;position:var(--position);top:73.87pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:15.82pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.94pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER OF </span></div><div style="line-height:8pt;position:var(--position);top:25.42pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.38pt;position:var(--position);text-decoration:none;white-space:pre">ISSUED AGAs</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:15.82pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.94pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER OF </span></div><div style="line-height:8pt;position:var(--position);top:25.42pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.05pt;position:var(--position);text-decoration:none;white-space:pre">LAPSED AGAs</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:15.82pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.94pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER OF </span></div><div style="line-height:8pt;position:var(--position);top:25.42pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.83pt;position:var(--position);text-decoration:none;white-space:pre">VESTED AGAs</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:11.02pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.31pt;position:var(--position);text-decoration:none;white-space:pre">NUMBER OF </span></div><div style="line-height:8pt;position:var(--position);top:20.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.19pt;position:var(--position);text-decoration:none;white-space:pre">AGAs </span></div><div style="line-height:8pt;position:var(--position);top:30.22pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.87pt;position:var(--position);text-decoration:none;white-space:pre">OUTSTANDING </span></div></div></div></td></tr><tr style="height:35.25pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td colspan="6" style="font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:47.25pt;width:204.75pt"><div><div style="line-height:8pt;position:var(--position);top:26.62pt;width:204.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:37.92pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED DECEMBER 31, 2025</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:47.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:6.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:21.91pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:16.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.47pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.56pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:82.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">07/11/23</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:82.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2023-1</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:82.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.46pt"></span></span><span style="left:29.09pt;position:var(--position)">1,382,796<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:82.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">780,040<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:82.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:82.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:82.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.8pt"></span></span><span style="left:32.43pt;position:var(--position)">(230,464)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:82.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">549,576<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:94.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">07/11/23</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:94.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2023-2</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:94.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.46pt"></span></span><span style="left:35.09pt;position:var(--position)">100,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:94.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">75,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:94.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:94.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.8pt"></span></span><span style="left:36.43pt;position:var(--position)">(75,000)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:94.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:94.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:106.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">09/28/23</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:106.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2023-3</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:106.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.46pt"></span></span><span style="left:35.09pt;position:var(--position)">731,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:106.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">485,875<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:106.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:106.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.8pt"></span></span><span style="left:36.43pt;position:var(--position)">(34,750)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:106.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.8pt"></span></span><span style="left:32.43pt;position:var(--position)">(251,125)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:106.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">200,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:118.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">09/28/23</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:118.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2023-4</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:118.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.46pt"></span></span><span style="left:35.09pt;position:var(--position)">254,250<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:118.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">213,250<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:118.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:118.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.8pt"></span></span><span style="left:36.43pt;position:var(--position)">(15,000)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:118.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.8pt"></span></span><span style="left:32.43pt;position:var(--position)">(108,500)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:118.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">89,750<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:130.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">12/01/23</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:130.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2023-5</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:130.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.46pt"></span></span><span style="left:35.09pt;position:var(--position)">132,750<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:130.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">81,250<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:130.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:130.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.8pt"></span></span><span style="left:36.43pt;position:var(--position)">(26,000)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:130.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.8pt"></span></span><span style="left:36.43pt;position:var(--position)">(27,625)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:130.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">27,625<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:142.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">02/01/24</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:142.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-1</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:142.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.46pt"></span></span><span style="left:29.09pt;position:var(--position)">1,549,125<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:142.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:27.21pt"></span></span><span style="left:29.84pt;position:var(--position)">1,355,625<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:142.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:142.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.8pt"></span></span><span style="left:32.43pt;position:var(--position)">(134,125)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:142.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:142.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:27.21pt"></span></span><span style="left:29.84pt;position:var(--position)">1,221,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:154.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">03/28/24</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:154.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-2</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:154.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)">22,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:154.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">22,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:154.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:154.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:154.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:154.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">22,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:166.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">05/23/24</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:166.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-3</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:166.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)">38,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:166.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">38,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:166.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:166.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.8pt"></span></span><span style="left:36.43pt;position:var(--position)">(13,000)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:166.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:166.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">25,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:178.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">07/11/24</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:178.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-4</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:178.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)">93,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:178.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">93,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:178.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:178.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:178.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:178.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">93,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:190.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">07/11/24</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:190.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-5</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:190.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)">25,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:190.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">25,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:190.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:190.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:190.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:190.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">25,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:202.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">07/11/24</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:202.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-6</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:202.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)">20,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:202.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">20,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:202.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:202.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:202.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.8pt"></span></span><span style="left:36.43pt;position:var(--position)">(10,000)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:202.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">10,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:214.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">09/05/24</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:214.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-7</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:214.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.46pt"></span></span><span style="left:35.09pt;position:var(--position)">198,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:214.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">198,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:214.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:214.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:214.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:214.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">198,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:226.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">02/06/25</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:226.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-1</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:226.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.46pt"></span></span><span style="left:29.09pt;position:var(--position)">4,319,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:226.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:226.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.46pt"></span></span><span style="left:29.09pt;position:var(--position)">4,319,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:226.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.8pt"></span></span><span style="left:32.43pt;position:var(--position)">(217,500)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:226.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:226.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:27.21pt"></span></span><span style="left:29.84pt;position:var(--position)">4,102,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:238.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">02/06/25</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:238.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-2</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:238.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.46pt"></span></span><span style="left:35.09pt;position:var(--position)">123,102<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:238.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:238.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:32.46pt"></span></span><span style="left:35.09pt;position:var(--position)">123,102<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:238.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:238.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:238.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.21pt"></span></span><span style="left:35.84pt;position:var(--position)">123,102<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:250.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">02/06/25</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:250.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-3</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:250.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)">17,625<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:250.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:250.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)">17,625<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:250.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:250.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:250.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">17,625<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:262.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">02/06/25</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:262.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-4</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:262.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)">30,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:262.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:262.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)">30,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:262.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:262.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:262.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">30,500<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:274.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">03/20/25</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:274.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-5</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:274.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)">50,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:274.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:274.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)">50,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:274.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.8pt"></span></span><span style="left:36.43pt;position:var(--position)">(50,000)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:274.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:274.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:286.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">05/30/25</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:286.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-6</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:286.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)">25,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:286.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:286.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.46pt"></span></span><span style="left:39.09pt;position:var(--position)">25,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:286.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:286.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:286.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:37.21pt"></span></span><span style="left:39.84pt;position:var(--position)">25,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:298.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">08/01/25</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:298.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-7</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:298.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.46pt"></span></span><span style="left:29.09pt;position:var(--position)">1,711,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:298.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:298.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.46pt"></span></span><span style="left:29.09pt;position:var(--position)">1,711,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:298.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.8pt"></span></span><span style="left:36.43pt;position:var(--position)">(80,000)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:298.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:298.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:27.21pt"></span></span><span style="left:29.84pt;position:var(--position)">1,631,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:310.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">11/13/25</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:310.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-8</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:310.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.46pt"></span></span><span style="left:43.09pt;position:var(--position)">4,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:310.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:310.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.46pt"></span></span><span style="left:43.09pt;position:var(--position)">4,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:310.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:310.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.46pt"></span></span><span style="left:53.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:310.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">4,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:67.5pt;position:var(--position);top:322.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total AGAs</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:132pt;overflow:hidden;position:var(--position);top:322.5pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8212;</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:135pt;position:var(--position);top:322.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:22.46pt"></span></span><span style="left:25.09pt;position:var(--position)">10,828,148<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:322.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:27.21pt"></span></span><span style="left:29.84pt;position:var(--position)">3,388,040<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:322.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:26.46pt"></span></span><span style="left:29.09pt;position:var(--position)">6,280,727<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:335.25pt;position:var(--position);top:322.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.8pt"></span></span><span style="left:32.43pt;position:var(--position)">(645,375)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:402.75pt;position:var(--position);top:322.5pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.8pt"></span></span><span style="left:32.43pt;position:var(--position)">(627,714)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:472.5pt;position:var(--position);top:322.5pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:27.21pt"></span></span><span style="left:29.84pt;position:var(--position)">8,395,678<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory', window );">Disclosure of main data and assumptions used for the measurement of other equity instruments</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The fair value of the BSAs was determined at grant date using the Black Scholes model, with the following assumptions:</span><div style="position:var(--position);top:227.36pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:540pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:51pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:60.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:58.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:58.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:58.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:58.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:53.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:58.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:58.5pt"></td></tr><tr style="height:41.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:51pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.84pt;position:var(--position);white-space:pre">TYPE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:54pt;position:var(--position);width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:60.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.62pt;position:var(--position);white-space:pre">FAIR VALUE </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:60.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.38pt;position:var(--position);white-space:pre">OF THE </span></div><div style="line-height:8pt;position:var(--position);top:21.83pt;width:60.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.07pt;position:var(--position);white-space:pre">UNDERLYING </span></div><div style="line-height:8pt;position:var(--position);top:31.43pt;width:60.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.61pt;position:var(--position);white-space:pre">SHARE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:117.75pt;position:var(--position);width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.5pt;position:var(--position);white-space:pre">FAIR VALUE </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.49pt;position:var(--position);white-space:pre">OF THE BSA</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:179.25pt;position:var(--position);width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.94pt;position:var(--position);white-space:pre">NUMBER OF </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:19.92pt;position:var(--position);white-space:pre">BSAs</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.27pt;position:var(--position);white-space:pre">SUBSCRIPTI</span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.82pt;position:var(--position);white-space:pre">ON PRICE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:302.25pt;position:var(--position);width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.15pt;position:var(--position);white-space:pre">STRIKE </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.83pt;position:var(--position);white-space:pre">PRICE PER </span></div><div style="line-height:8pt;position:var(--position);top:21.83pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.48pt;position:var(--position);white-space:pre">SHARE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:363.75pt;position:var(--position);width:53.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:53.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.2pt;position:var(--position);white-space:pre">RISK FREE </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:53.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.52pt;position:var(--position);white-space:pre">RATE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:420pt;position:var(--position);width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.49pt;position:var(--position);white-space:pre">EXPECTED </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.05pt;position:var(--position);white-space:pre">MATURITY</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:481.5pt;position:var(--position);width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.71pt;position:var(--position);white-space:pre">VOLATILITY</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:41.25pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA 2024-1</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:54pt;position:var(--position);top:41.25pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;14.06</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:117.75pt;position:var(--position);top:41.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:11.26pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:13.92pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.7</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:27.92pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:30.58pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.5</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.58pt;position:var(--position);white-space:pre">]</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:179.25pt;position:var(--position);top:41.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:18.25pt;position:var(--position);text-decoration:none;white-space:pre">58,365</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);top:41.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;2.57</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:302.25pt;position:var(--position);top:41.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:19.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;13.10</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:363.75pt;position:var(--position);top:41.25pt;width:53.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:53.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.23pt;position:var(--position);text-decoration:none;white-space:pre">4.30%</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:420pt;position:var(--position);top:41.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.15pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.8100000000000005pt;position:var(--position);text-decoration:none;white-space:pre">5.4</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.810000000000002pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.47pt;position:var(--position);text-decoration:none;white-space:pre">6.9</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:30.47pt;position:var(--position);white-space:pre"> years]</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:481.5pt;position:var(--position);top:41.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.86pt;position:var(--position);text-decoration:none;white-space:pre">60.41%</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:53.25pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:51pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA 2024-2</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:54pt;position:var(--position);top:53.25pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;14.06</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:117.75pt;position:var(--position);top:53.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:11.26pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:13.92pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.8</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:27.92pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:30.58pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.6</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.58pt;position:var(--position);white-space:pre">]</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:179.25pt;position:var(--position);top:53.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:18.25pt;position:var(--position);text-decoration:none;white-space:pre">19,455</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);top:53.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;2.57</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:302.25pt;position:var(--position);top:53.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:19.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;13.10</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:363.75pt;position:var(--position);top:53.25pt;width:53.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:53.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.23pt;position:var(--position);text-decoration:none;white-space:pre">4.30%</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:420pt;position:var(--position);top:53.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.15pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.8100000000000005pt;position:var(--position);text-decoration:none;white-space:pre">5.5</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.810000000000002pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.47pt;position:var(--position);text-decoration:none;white-space:pre">7.0</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:30.47pt;position:var(--position);white-space:pre"> years]</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:481.5pt;position:var(--position);top:53.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.86pt;position:var(--position);text-decoration:none;white-space:pre">60.41%</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:65.25pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2025-1</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:54pt;position:var(--position);top:65.25pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:22.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.13</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:117.75pt;position:var(--position);top:65.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:11.26pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:13.92pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3.5</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:27.92pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:30.58pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3.9</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.58pt;position:var(--position);white-space:pre">]</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:179.25pt;position:var(--position);top:65.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:16.25pt;position:var(--position);text-decoration:none;white-space:pre">100,000</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);top:65.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;2.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:302.25pt;position:var(--position);top:65.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.63</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:363.75pt;position:var(--position);top:65.25pt;width:53.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:53.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.23pt;position:var(--position);text-decoration:none;white-space:pre">4.65%</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:420pt;position:var(--position);top:65.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.15pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.8100000000000005pt;position:var(--position);text-decoration:none;white-space:pre">5.5</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.810000000000002pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.47pt;position:var(--position);text-decoration:none;white-space:pre">7.0</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:30.47pt;position:var(--position);white-space:pre"> years]</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:481.5pt;position:var(--position);top:65.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.86pt;position:var(--position);text-decoration:none;white-space:pre">60.88%</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:77.25pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2025-2</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:54pt;position:var(--position);top:77.25pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:22.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.13</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:117.75pt;position:var(--position);top:77.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:11.26pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:13.92pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3.5</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:27.92pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:30.58pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3.9</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.58pt;position:var(--position);white-space:pre">]</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:179.25pt;position:var(--position);top:77.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:18.25pt;position:var(--position);text-decoration:none;white-space:pre">25,000</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);top:77.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;2.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:302.25pt;position:var(--position);top:77.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.63</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:363.75pt;position:var(--position);top:77.25pt;width:53.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:53.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.23pt;position:var(--position);text-decoration:none;white-space:pre">4.65%</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:420pt;position:var(--position);top:77.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.15pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.8100000000000005pt;position:var(--position);text-decoration:none;white-space:pre">5.5</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.810000000000002pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.47pt;position:var(--position);text-decoration:none;white-space:pre">7.0</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:30.47pt;position:var(--position);white-space:pre"> years]</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:481.5pt;position:var(--position);top:77.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.86pt;position:var(--position);text-decoration:none;white-space:pre">60.88%</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:89.25pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2025-3</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:54pt;position:var(--position);top:89.25pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:22.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.48</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:117.75pt;position:var(--position);top:89.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:11.26pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:13.92pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3.7</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:27.92pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:30.58pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;4.1</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.58pt;position:var(--position);white-space:pre">]</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:179.25pt;position:var(--position);top:89.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:18.25pt;position:var(--position);text-decoration:none;white-space:pre">39,370</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);top:89.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1.27</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:302.25pt;position:var(--position);top:89.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.41</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:363.75pt;position:var(--position);top:89.25pt;width:53.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:53.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.23pt;position:var(--position);text-decoration:none;white-space:pre">3.92%</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:420pt;position:var(--position);top:89.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.15pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.8100000000000005pt;position:var(--position);text-decoration:none;white-space:pre">5.5</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.810000000000002pt;position:var(--position);white-space:pre">- </span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.47pt;position:var(--position);text-decoration:none;white-space:pre">7.0</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.47pt;position:var(--position);white-space:pre">years]</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:481.5pt;position:var(--position);top:89.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.86pt;position:var(--position);text-decoration:none;white-space:pre">60.69%</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr></tbody></table></div></div></div><div style="font-size:0pt;left:36pt;position:var(--position);width:540pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:72pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:75pt"></td></tr><tr style="height:41.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:17.62pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.84pt;position:var(--position);text-decoration:none;white-space:pre">TYPE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);width:72pt"><div><div style="line-height:8pt;position:var(--position);top:3.22pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.7pt;position:var(--position);text-decoration:none;white-space:pre">FAIR&#160;VALUE&#160;OF </span></div><div style="line-height:8pt;position:var(--position);top:12.82pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:27.56pt;position:var(--position);text-decoration:none;white-space:pre">THE </span></div><div style="line-height:8pt;position:var(--position);top:22.42pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.69pt;position:var(--position);text-decoration:none;white-space:pre">UNDERLYING </span></div><div style="line-height:8pt;position:var(--position);top:32.02pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.23pt;position:var(--position);text-decoration:none;white-space:pre">SHARE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:12.82pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.2pt;position:var(--position);text-decoration:none;white-space:pre">FAIR&#160;VALUE OF </span></div><div style="line-height:8pt;position:var(--position);top:22.42pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:19.18pt;position:var(--position);text-decoration:none;white-space:pre">THE AGA</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:17.62pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.19pt;position:var(--position);text-decoration:none;white-space:pre">AGA PRICE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:17.62pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.3pt;position:var(--position);text-decoration:none;white-space:pre">MATURITY</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:17.62pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.96pt;position:var(--position);text-decoration:none;white-space:pre">VOLATILITY </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:17.62pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.97pt;position:var(--position);text-decoration:none;white-space:pre">RISK&#160;FREE&#160;RATE</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:41.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:1.73pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-1 </span></div><div style="line-height:9pt;position:var(--position);top:12.98pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(Tranches 1-4)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:41.25pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;15.98</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:41.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;15.98</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:41.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:41.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:41.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:41.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:63pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:1.73pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-1 </span></div><div style="line-height:9pt;position:var(--position);top:12.98pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(Tranche 5)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:63pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;15.98</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:63pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3.62</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:63pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:63pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:16.51pt;position:var(--position);text-decoration:none;white-space:pre">2024-12-31</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:63pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:26.82pt;position:var(--position);text-decoration:none;white-space:pre">67.2%</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:63pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:26.82pt;position:var(--position);text-decoration:none;white-space:pre">3.20%</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:84.75pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:1.73pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-1 </span></div><div style="line-height:9pt;position:var(--position);top:12.98pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(Tranche 6)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:84.75pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;15.98</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:84.75pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.74</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:84.75pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:84.75pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:16.51pt;position:var(--position);text-decoration:none;white-space:pre">2024-07-11</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:84.75pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:26.82pt;position:var(--position);text-decoration:none;white-space:pre">67.2%</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:84.75pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:26.82pt;position:var(--position);text-decoration:none;white-space:pre">3.20%</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:106.5pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:1.73pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-2 </span></div><div style="line-height:9pt;position:var(--position);top:12.98pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(Tranche 1)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:106.5pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;15.98</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:106.5pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;15.98</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:106.5pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:106.5pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:106.5pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:106.5pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:128.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:1.73pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-2 </span></div><div style="line-height:9pt;position:var(--position);top:12.98pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(Tranche 2)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:128.25pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;15.98</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:128.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;9.59</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:128.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:128.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:128.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:128.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:150pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-3</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:150pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;14.92</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:150pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;14.92</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:150pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:150pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:150pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:150pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:162pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-4</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:162pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;14.92</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:162pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;14.92</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:162pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:162pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:162pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:162pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:174pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-5</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:174pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;9.16</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:174pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;9.16</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:174pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:174pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:174pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:174pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:186pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2024-1</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:186pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.26</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:186pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.26</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:186pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:186pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:186pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:186pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:198pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2024-2</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:198pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;13.40</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:198pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;13.40</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:198pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:198pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:198pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:198pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:210pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-3</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:210pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.76</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:210pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.76</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:210pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:210pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:210pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:210pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:222pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-4</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:222pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.54</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:222pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.54</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:222pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:222pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:222pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:222pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:234pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-5</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:234pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.54</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:234pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.54</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:234pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:234pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:234pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:234pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:246pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-6</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:246pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.54</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:246pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.54</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:246pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:246pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:246pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:246pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:258pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-7</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:258pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;10.80</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:258pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;10.80</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:258pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:258pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:258pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:258pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:270pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-1</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:270pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.82</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:270pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.82</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:270pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:270pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:270pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:270pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:282pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-2</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:282pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.82</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:282pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.82</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:282pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:282pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:282pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:282pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:294pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-3</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:294pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.82</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:294pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.82</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:294pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:294pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:294pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:294pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:306pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-4</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:306pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.82</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:306pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.82</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:306pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:306pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:306pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:306pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:318pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-5</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:318pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.17</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:318pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.17</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:318pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:318pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:318pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:318pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:330pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-6</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:330pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.17</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:330pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.17</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:330pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:330pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:330pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:330pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:342pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-7</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:342pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;61.20</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:342pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;61.20</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:342pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:342pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:342pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:342pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:354pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-8</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:354pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;89.40</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:354pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;89.40</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:354pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:354pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:354pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:354pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr></tbody></table></div></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The fair value of the Minimum Return Indemnifications was measured using the following assumptions:</span><div style="position:var(--position);top:155.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:521.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:222.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:146.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:146.25pt"></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);white-space:pre">Tranche B Minimum Return Indemnification (issued in March </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);white-space:pre">2024)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.93pt;position:var(--position);text-decoration:none;white-space:pre">AS OF MARCH 28, 2024</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.38pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2024</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Final redemption scenario probability</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:21pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:128.18pt;position:var(--position)"></span><span style="left:128.18pt;position:var(--position)">95<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span><span style="left:138.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:21pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:128.18pt;position:var(--position)"></span><span style="left:128.18pt;position:var(--position)">95<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span><span style="left:138.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:33pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Minimal return</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:33pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:125.62pt;position:var(--position);text-decoration:none;white-space:pre">1.40</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:139.62pt;position:var(--position);white-space:pre">x</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:33pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:125.62pt;position:var(--position);text-decoration:none;white-space:pre">1.40</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:139.62pt;position:var(--position);white-space:pre">x</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:45pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Discount rate</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:45pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:128.18pt;position:var(--position)"></span><span style="left:128.18pt;position:var(--position)">13<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span><span style="left:138.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:45pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:132.18pt;position:var(--position)"></span><span style="left:132.18pt;position:var(--position)">8<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span><span style="left:138.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:57pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Probability-weighted present value of shortfall payment (in </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">thousands of &#8364;)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:57pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:63.45pt;position:var(--position);text-decoration:none;white-space:pre">1,959</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.31pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:88.13pt;position:var(--position);text-decoration:none;white-space:pre">68</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.13pt;position:var(--position);white-space:pre"> (Tender offer)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:57pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:63.45pt;position:var(--position);text-decoration:none;white-space:pre">2,635</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.31pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:84.13pt;position:var(--position);text-decoration:none;white-space:pre">136</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.13pt;position:var(--position);white-space:pre"> (Tender offer)</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Probability-weighted fair value of tranche A-B warrants with MRI </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">(in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:78.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:63.45pt;position:var(--position);text-decoration:none;white-space:pre">1,066</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div></div></div></td><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:78.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:69.45pt;position:var(--position);text-decoration:none;white-space:pre">104</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:99.75pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Probability-weighted fair value of tranche A-B warrants without </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">MRI (in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:99.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:63.45pt;position:var(--position);text-decoration:none;white-space:pre">1,410</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:99.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:69.45pt;position:var(--position);text-decoration:none;white-space:pre">241</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:120.75pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Total fair value of MRI (in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:120.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:29.41pt;position:var(--position);text-decoration:none;white-space:pre">1,615</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:47.41pt;position:var(--position);white-space:pre"> (Final redemption, i.e. a+b-c)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.31pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:88.13pt;position:var(--position);text-decoration:none;white-space:pre">68</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.13pt;position:var(--position);white-space:pre"> (Tender offer)</span></div></div></div></td><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:120.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:29.41pt;position:var(--position);text-decoration:none;white-space:pre">2,499</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:47.41pt;position:var(--position);white-space:pre"> (Final redemption, i.e. a+b-c)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.31pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:84.13pt;position:var(--position);text-decoration:none;white-space:pre">136</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.13pt;position:var(--position);white-space:pre"> (Tender offer)</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:142.5pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);white-space:pre">Fair value of Tranche B MRI (in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:142.5pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:115.55pt"></span></span><span style="left:118.17999999999999pt;position:var(--position)">1,683<span style="display:inline-block;height:5.41pt;width:9.32pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:142.5pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:115.55pt"></span></span><span style="left:118.17999999999999pt;position:var(--position)">2,636<span style="display:inline-block;height:5.41pt;width:9.32pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:342.66pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:521.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:222.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:146.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:146.25pt"></td></tr><tr style="height:21.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);white-space:pre">Tranche C Minimum Return Indemnification (issued in June </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);white-space:pre">2024)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:35.03pt;position:var(--position);text-decoration:none;white-space:pre">AS OF JUNE 21, 2024</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.38pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2024</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21.75pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Final redemption scenario probability</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:21.75pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:128.18pt;position:var(--position)"></span><span style="left:128.18pt;position:var(--position)">95<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span><span style="left:138.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:21.75pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:128.18pt;position:var(--position)"></span><span style="left:128.18pt;position:var(--position)">95<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span><span style="left:138.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:33.75pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Minimal return</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:33.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:125.62pt;position:var(--position);text-decoration:none;white-space:pre">1.30</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:139.62pt;position:var(--position);white-space:pre">x</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:33.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:125.62pt;position:var(--position);text-decoration:none;white-space:pre">1.30</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:139.62pt;position:var(--position);white-space:pre">x</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:45.75pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Discount rate</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:45.75pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:128.18pt;position:var(--position)"></span><span style="left:128.18pt;position:var(--position)">15<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span><span style="left:138.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:45.75pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:132.18pt;position:var(--position)"></span><span style="left:132.18pt;position:var(--position)">8<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span><span style="left:138.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:57.75pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">(a) Probability-weighted present value of shortfall payment (in </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">thousands of &#8364;)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:57.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:69.45pt;position:var(--position);text-decoration:none;white-space:pre">741</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.31pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:92.13pt;position:var(--position);text-decoration:none;white-space:pre">0</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.13pt;position:var(--position);white-space:pre"> (Tender offer)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:57.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:63.45pt;position:var(--position);text-decoration:none;white-space:pre">1,160</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.31pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:88.13pt;position:var(--position);text-decoration:none;white-space:pre">43</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.13pt;position:var(--position);white-space:pre"> (Tender offer)</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:79.5pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">(b) Probability-weighted fair value of tranche C warrants with MRI </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">(in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:79.5pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:63.45pt;position:var(--position);text-decoration:none;white-space:pre">2,948</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div></div></div></td><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:79.5pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:69.45pt;position:var(--position);text-decoration:none;white-space:pre">684</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:101.25pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">(c) Probability-weighted fair value of tranche C warrants without </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">MRI (in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:101.25pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:63.45pt;position:var(--position);text-decoration:none;white-space:pre">3,250</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:101.25pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:69.45pt;position:var(--position);text-decoration:none;white-space:pre">903</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:123pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Total fair value of MRI (in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:123pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:35.41pt;position:var(--position);text-decoration:none;white-space:pre">475</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:47.41pt;position:var(--position);white-space:pre"> (Final redemption, i.e. a+b-c)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.31pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:92.13pt;position:var(--position);text-decoration:none;white-space:pre">0</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.13pt;position:var(--position);white-space:pre"> (Tender offer)</span></div></div></div></td><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:123pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:35.41pt;position:var(--position);text-decoration:none;white-space:pre">941</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:47.41pt;position:var(--position);white-space:pre"> (Final redemption, i.e. a+b-c)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.31pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:88.13pt;position:var(--position);text-decoration:none;white-space:pre">43</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.13pt;position:var(--position);white-space:pre"> (Tender offer)</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:144.75pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);white-space:pre">Fair value of Tranche C MRI (in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:144.75pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:121.55pt"></span></span><span style="left:124.17999999999999pt;position:var(--position)">475<span style="display:inline-block;height:5.41pt;width:9.32pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:144.75pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:121.55pt"></span></span><span style="left:124.17999999999999pt;position:var(--position)">984<span style="display:inline-block;height:5.41pt;width:9.32pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:558.17pt;position:var(--position);text-decoration:none;white-space:pre">The </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:163.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">main data and assumptions are the following:</span></div><div style="position:var(--position);top:211.46pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:522pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:137.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:125.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:125.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:125.25pt"></td></tr><tr style="height:24pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.2pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos/Claret Tranche A-B BSA - </span></div><div style="line-height:8pt;position:var(--position);top:13.8pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">August 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.32pt;position:var(--position);text-decoration:none;white-space:pre">AS OF AUGUST 22, 2023 </span></div><div style="line-height:8pt;position:var(--position);top:14pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:37.65pt;position:var(--position);text-decoration:none;white-space:pre">(Tranche A-B)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:9pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.88pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:9pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.88pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2024</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Number of outstanding BSA</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:24pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.62pt;position:var(--position);text-decoration:none;white-space:pre">214,198</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:24pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.62pt;position:var(--position);text-decoration:none;white-space:pre">214,198</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:24pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.62pt;position:var(--position);text-decoration:none;white-space:pre">214,198</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:39.75pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Exercise price per share</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:39.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:100.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;18.67</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:39.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:100.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;18.67</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:39.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:100.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;18.67</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:55.5pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Ordinary share price</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:55.5pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:100.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;17.10</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:55.5pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;9.82</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:55.5pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.76</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:71.25pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Exercise date</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:71.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.44pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:19.99pt;position:var(--position);text-decoration:none;white-space:pre">19/08/2030 (expiry) 18/02/2027 </span></div><div style="line-height:8pt;position:var(--position);top:12.44pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:79.79pt;position:var(--position);text-decoration:none;white-space:pre">(tender offer)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:71.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.43pt;position:var(--position);text-decoration:none;white-space:pre">19/08/2030 (expiry)</span></div><div style="line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:41.35pt;position:var(--position);text-decoration:none;white-space:pre">18/02/2027 (tender offer)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:71.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.43pt;position:var(--position);text-decoration:none;white-space:pre">19/08/2030 (expiry)</span></div><div style="line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:41.35pt;position:var(--position);text-decoration:none;white-space:pre">18/02/2027 (tender offer)</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:92.25pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">7-year expiry scenario probability</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:92.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">50</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:92.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">95</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:92.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">95</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:108pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Volatility</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:108pt;width:125.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:74.21pt;position:var(--position);text-decoration:none;white-space:pre">71.9%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.86999999999999pt;position:var(--position);white-space:pre"> (expiry) </span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:57.13pt;position:var(--position);text-decoration:none;white-space:pre">65.2%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.79pt;position:var(--position);white-space:pre"> (tender offer)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:108pt;width:125.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:74.21pt;position:var(--position);text-decoration:none;white-space:pre">59.5%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.86999999999999pt;position:var(--position);white-space:pre"> (expiry)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:57.13pt;position:var(--position);text-decoration:none;white-space:pre">64.9%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.79pt;position:var(--position);white-space:pre"> (tender offer)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:108pt;width:125.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:74.21pt;position:var(--position);text-decoration:none;white-space:pre">44.3%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.86999999999999pt;position:var(--position);white-space:pre"> (expiry)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:57.13pt;position:var(--position);text-decoration:none;white-space:pre">44.3%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.79pt;position:var(--position);white-space:pre"> (tender offer)</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:129pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Dividend</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:129pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">&#8212;</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:129pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">&#8212;</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:129pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">&#8212;</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:144.75pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Risk-free rate</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:144.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)">3.00</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:144.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)">2.30</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="height:17.25pt;left:396.75pt;overflow:hidden;position:var(--position);top:144.75pt;width:125.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:0.52pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:78.21pt;position:var(--position);text-decoration:none;white-space:pre">2.9%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.86999999999999pt;position:var(--position);white-space:pre"> (expiry)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:10.6pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:61.13pt;position:var(--position);text-decoration:none;white-space:pre">2.9%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.79pt;position:var(--position);white-space:pre"> (tender offer)</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:162pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Fair value of issued Kreos/Claret </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Tranche A-B BSA</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:162pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:97.21pt"></span></span><span style="left:99.83999999999999pt;position:var(--position)">2,092<span style="display:inline-block;height:5.41pt;width:6.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:162pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:103.21pt"></span></span><span style="left:105.83999999999999pt;position:var(--position)">920<span style="display:inline-block;height:5.41pt;width:6.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:162pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:103.21pt"></span></span><span style="left:105.83999999999999pt;position:var(--position)">243<span style="display:inline-block;height:5.41pt;width:6.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:421.86pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:522pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:137.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:125.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:125.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:125.25pt"></td></tr><tr style="height:24pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.2pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos/Claret Tranche C BSA - </span></div><div style="line-height:8pt;position:var(--position);top:13.8pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">November 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:9pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.43pt;position:var(--position);text-decoration:none;white-space:pre">AS OF NOVEMBER 2, 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:9pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.88pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:9pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.88pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2024</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Number of outstanding BSA</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:24pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.62pt;position:var(--position);text-decoration:none;white-space:pre">405,832</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:24pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.62pt;position:var(--position);text-decoration:none;white-space:pre">405,832</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:24pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.62pt;position:var(--position);text-decoration:none;white-space:pre">405,832</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:39.75pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">of which, number of conditional BSA</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:39.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.8pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:96.62pt;position:var(--position);text-decoration:none;white-space:pre">202,915</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:39.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.8pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:96.62pt;position:var(--position);text-decoration:none;white-space:pre">202,916</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:39.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.8pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:118.62pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:55.5pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Exercise price per share</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:55.5pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:6.99pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;9.86</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:55.5pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:6.99pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;9.86</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:55.5pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:6.99pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;9.86</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:71.25pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Ordinary share price</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:71.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;8.89</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:71.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;9.82</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:71.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.67</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:87pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Exercise date</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:87pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.43pt;position:var(--position);white-space:pre">01/11/2030 (expiry) </span></div><div style="line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:41.35pt;position:var(--position);white-space:pre">18/02/2027 (tender offer)</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:87pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.43pt;position:var(--position);text-decoration:none;white-space:pre">01/11/2030 (expiry)</span></div><div style="line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:41.35pt;position:var(--position);text-decoration:none;white-space:pre">18/02/2027 (tender offer)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:87pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.43pt;position:var(--position);text-decoration:none;white-space:pre">01/11/2030 (expiry)</span></div><div style="line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:41.35pt;position:var(--position);text-decoration:none;white-space:pre">18/02/2027 (tender offer)</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:108pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">7-year expiry scenario probability</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:108pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">95</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:108pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">95</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:108pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">95</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:123.75pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Probability of Drawdown of Tranche C </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">credit facility</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:123.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">30</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:123.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">30</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:123.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.09pt;position:var(--position);text-decoration:none;white-space:pre">Drawn on June 21, 2024</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:144.75pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Volatility</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:144.75pt;width:125.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:74.21pt;position:var(--position);text-decoration:none;white-space:pre">67.3%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.86999999999999pt;position:var(--position);white-space:pre"> (expiry)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:57.13pt;position:var(--position);text-decoration:none;white-space:pre">64.3%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.79pt;position:var(--position);white-space:pre"> (tender offer)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:144.75pt;width:125.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:74.21pt;position:var(--position);text-decoration:none;white-space:pre">67.4%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.86999999999999pt;position:var(--position);white-space:pre"> (expiry)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:57.13pt;position:var(--position);text-decoration:none;white-space:pre">64.9%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.79pt;position:var(--position);white-space:pre"> (tender offer)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:144.75pt;width:125.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:74.21pt;position:var(--position);text-decoration:none;white-space:pre">44.3%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.86999999999999pt;position:var(--position);white-space:pre"> (expiry)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:57.13pt;position:var(--position);text-decoration:none;white-space:pre">44.3%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.79pt;position:var(--position);white-space:pre"> (tender offer)</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:165.75pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Dividend</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:165.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">&#8212;</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:165.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">&#8212;</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:165.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">&#8212;</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:24pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:181.5pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:8.93pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Risk-free rate</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:181.5pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:8.93pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)">3.00</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:181.5pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:8.93pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)">2.30</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:181.5pt;width:125.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:3.89pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:78.21pt;position:var(--position);text-decoration:none;white-space:pre">2.9%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.86999999999999pt;position:var(--position);white-space:pre"> (expiry)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:13.97pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:61.13pt;position:var(--position);text-decoration:none;white-space:pre">2.9%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.79pt;position:var(--position);white-space:pre"> (tender offer)</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:205.5pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:137.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Fair value of issued Kreos/Claret </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:137.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Tranche C BSA</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:205.5pt;width:125.25pt"><div><div style="line-height:9pt;position:var(--position);top:7.05pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.09pt;width:94.96pt"></span></span><span style="left:97.58999999999999pt;position:var(--position)">1,493<span style="display:inline-block;height:6.09pt;width:6.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:205.5pt;width:125.25pt"><div><div style="line-height:9pt;position:var(--position);top:7.05pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.09pt;width:94.96pt"></span></span><span style="left:97.58999999999999pt;position:var(--position)">1,659<span style="display:inline-block;height:6.09pt;width:6.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:205.5pt;width:125.25pt"><div><div style="line-height:9pt;position:var(--position);top:7.05pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.09pt;width:101.71pt"></span></span><span style="left:104.33999999999999pt;position:var(--position)">923<span style="display:inline-block;height:6.09pt;width:6.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss', window );">Disclosure of breakdown of the compensation expenses</a></td>
<td class="text"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre;width:439.91pt">Breakdown of the compensation expenses accounted for the period ended December 31, 2023, 2024 and 2025</span><div style="position:var(--position);top:177.91pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:321pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:119.25pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td></tr><tr style="height:41.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:23.02pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">TYPE</span></div><div style="line-height:8pt;position:var(--position);top:32.62pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:119.25pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:8.02pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.32pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:17.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:27.22pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:187.5pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:8.02pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.32pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:17.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:27.22pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:255.75pt;position:var(--position);width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:8.02pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.32pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:17.62pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:27.22pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:41.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BCEs</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:119.25pt;position:var(--position);top:41.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.55pt"></span></span><span style="left:47.18pt;position:var(--position)">(112)</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:187.5pt;position:var(--position);top:41.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.55pt"></span></span><span style="left:47.18pt;position:var(--position)">(112)</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:252.75pt;overflow:hidden;position:var(--position);top:41.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:255.75pt;position:var(--position);top:41.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:53.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSAs</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:119.25pt;position:var(--position);top:53.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:187.5pt;position:var(--position);top:53.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.55pt"></span></span><span style="left:47.18pt;position:var(--position)">(211)</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:252.75pt;overflow:hidden;position:var(--position);top:53.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:255.75pt;position:var(--position);top:53.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.55pt"></span></span><span style="left:47.18pt;position:var(--position)">(289)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:65.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGAs</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:119.25pt;position:var(--position);top:65.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.55pt"></span></span><span style="left:41.18pt;position:var(--position)">(8,067)</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:187.5pt;position:var(--position);top:65.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:34.55pt"></span></span><span style="left:37.18pt;position:var(--position)">(19,900)</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:252.75pt;overflow:hidden;position:var(--position);top:65.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:255.75pt;position:var(--position);top:65.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:35.3pt;position:var(--position);text-decoration:none;white-space:pre">(35,108)</span></div></div></div></td></tr><tr style="height:12.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:77.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Social taxes related to AGAs</span></div></div></div></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:119.25pt;position:var(--position);top:77.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.55pt"></span></span><span style="left:47.18pt;position:var(--position)">(426)</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:187.5pt;position:var(--position);top:77.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.55pt"></span></span><span style="left:47.18pt;position:var(--position)">(717)</span></span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="height:12.75pt;left:252.75pt;overflow:hidden;position:var(--position);top:77.25pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:255.75pt;position:var(--position);top:77.25pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:35.3pt;position:var(--position);text-decoration:none;white-space:pre">(48,990)</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total</span></div></div></div></td><td style="background-color:#CCECFF;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:119.25pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:38.55pt"></span></span><span style="left:41.18pt;position:var(--position)">(8,605)</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:187.5pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:34.55pt"></span></span><span style="left:37.18pt;position:var(--position)">(20,941)</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:252.75pt;overflow:hidden;position:var(--position);top:90pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="background-color:#CCECFF;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:255.75pt;position:var(--position);top:90pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:35.3pt;position:var(--position);text-decoration:none;white-space:pre">(84,387)</span></div></div></div></td></tr></tbody></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ShareBasedPaymentArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ShareBasedPaymentArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's other equity instruments (ie other than share options).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The explanation that enables users of financial statements to understand the effect of share-based payment transactions on the entity's profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 50<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_50&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract', window );"><strong>Disclosure of financial liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory', window );">Disclosure of financial liabilities breakdown</a></td>
<td class="text"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:41pt;position:var(--position);text-decoration:none;white-space:pre">Financial liabilities break down as follows:</span><div style="font-size:12pt;line-height:11pt;position:var(--position);top:101.66pt;width:612pt"><span style="font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div><div style="position:var(--position);top:110.46pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:422.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:191.25pt"></td><td style="padding:0;width:75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:75pt"></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:44.09pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">FINANCIAL LIABILITIES&#160;</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:12pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.84pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.5pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:12pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.84pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.5pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:12pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.84pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.5pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos &amp; Claret bond loans </span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:42.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:42.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">26,373<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:42.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Lease liabilities</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)">160<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">1,431<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)">554<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">PGE</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">2,402<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">1,252<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Borrowings</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:78.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">2,563<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:78.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">29,056<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:78.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)">554<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos &amp; Claret convertible notes (OCABSA)</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:90.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">21,643<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:90.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">23,370<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:90.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Convertible loan notes</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:102.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">21,643<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:102.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">23,370<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:102.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:114.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos &amp; Claret minimal return indemnifications </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:114.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:114.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">3,620<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:114.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:126.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Derivative instruments</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:126.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:126.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">3,620<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:126.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:138.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Conditional advances Bpifrance</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:138.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">3,262<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:138.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:138.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:150.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Royalty certificates</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:150.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">12,229<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:150.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:50.37pt;position:var(--position);text-decoration:none;white-space:pre">13,023</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:150.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">30,237<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:162.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial liabilities</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:162.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">15,491<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:162.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">13,023<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:162.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">30,237<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:174.75pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total non-current financial liabilities</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:174.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">39,697<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:174.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">69,069<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:174.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">30,790<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:6.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:193.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos &amp; Claret bond loans </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:193.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:193.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">20,028<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:193.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:205.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Lease liabilities</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:205.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)">379<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:205.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)">932<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:205.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">1,302<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:217.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">PGE</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:217.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">1,276<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:217.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">1,235<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:217.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:229.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Borrowings</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:229.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">1,655<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:229.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">22,195<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:229.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">1,302<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:241.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Heights convertible notes </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:241.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">29,605<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:241.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">21,574<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:241.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:253.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Convertible loan notes</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:253.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">29,605<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:253.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">21,574<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:253.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:265.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Conditional advances Bpifrance</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:265.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">3,509<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:265.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:265.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:277.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial liabilities</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:277.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">3,509<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:277.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:277.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:289.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos &amp; Claret BSA</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:289.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">2,579<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:289.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">1,166<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:289.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:301.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Derivative instruments</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:301.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">2,579<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:301.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">1,166<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:301.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:313.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total current financial liabilities</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:313.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">37,348<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:313.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">44,935<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:313.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">1,302<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:325.5pt;width:191.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:191.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial liabilities</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:191.25pt;position:var(--position);top:325.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">77,045<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:269.25pt;position:var(--position);top:325.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:42.96pt"></span></span><span style="left:45.59pt;position:var(--position)">114,004<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:347.25pt;position:var(--position);top:325.5pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">32,093<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory', window );">Disclosure of main data and assumptions used for the measurement of other equity instruments</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The fair value of the BSAs was determined at grant date using the Black Scholes model, with the following assumptions:</span><div style="position:var(--position);top:227.36pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:540pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:51pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:60.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:58.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:58.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:58.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:58.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:53.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:58.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:58.5pt"></td></tr><tr style="height:41.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:51pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.84pt;position:var(--position);white-space:pre">TYPE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:54pt;position:var(--position);width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:60.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.62pt;position:var(--position);white-space:pre">FAIR VALUE </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:60.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.38pt;position:var(--position);white-space:pre">OF THE </span></div><div style="line-height:8pt;position:var(--position);top:21.83pt;width:60.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.07pt;position:var(--position);white-space:pre">UNDERLYING </span></div><div style="line-height:8pt;position:var(--position);top:31.43pt;width:60.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.61pt;position:var(--position);white-space:pre">SHARE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:117.75pt;position:var(--position);width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.5pt;position:var(--position);white-space:pre">FAIR VALUE </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.49pt;position:var(--position);white-space:pre">OF THE BSA</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:179.25pt;position:var(--position);width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.94pt;position:var(--position);white-space:pre">NUMBER OF </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:19.92pt;position:var(--position);white-space:pre">BSAs</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.27pt;position:var(--position);white-space:pre">SUBSCRIPTI</span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.82pt;position:var(--position);white-space:pre">ON PRICE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:302.25pt;position:var(--position);width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.15pt;position:var(--position);white-space:pre">STRIKE </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.83pt;position:var(--position);white-space:pre">PRICE PER </span></div><div style="line-height:8pt;position:var(--position);top:21.83pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.48pt;position:var(--position);white-space:pre">SHARE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:363.75pt;position:var(--position);width:53.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:53.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.2pt;position:var(--position);white-space:pre">RISK FREE </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:53.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.52pt;position:var(--position);white-space:pre">RATE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:420pt;position:var(--position);width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.49pt;position:var(--position);white-space:pre">EXPECTED </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.05pt;position:var(--position);white-space:pre">MATURITY</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:481.5pt;position:var(--position);width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.71pt;position:var(--position);white-space:pre">VOLATILITY</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:41.25pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA 2024-1</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:54pt;position:var(--position);top:41.25pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;14.06</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:117.75pt;position:var(--position);top:41.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:11.26pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:13.92pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.7</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:27.92pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:30.58pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.5</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.58pt;position:var(--position);white-space:pre">]</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:179.25pt;position:var(--position);top:41.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:18.25pt;position:var(--position);text-decoration:none;white-space:pre">58,365</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);top:41.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;2.57</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:302.25pt;position:var(--position);top:41.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:19.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;13.10</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:363.75pt;position:var(--position);top:41.25pt;width:53.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:53.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.23pt;position:var(--position);text-decoration:none;white-space:pre">4.30%</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:420pt;position:var(--position);top:41.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.15pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.8100000000000005pt;position:var(--position);text-decoration:none;white-space:pre">5.4</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.810000000000002pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.47pt;position:var(--position);text-decoration:none;white-space:pre">6.9</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:30.47pt;position:var(--position);white-space:pre"> years]</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:481.5pt;position:var(--position);top:41.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.86pt;position:var(--position);text-decoration:none;white-space:pre">60.41%</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:53.25pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:51pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA 2024-2</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:54pt;position:var(--position);top:53.25pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;14.06</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:117.75pt;position:var(--position);top:53.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:11.26pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:13.92pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.8</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:27.92pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:30.58pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.6</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.58pt;position:var(--position);white-space:pre">]</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:179.25pt;position:var(--position);top:53.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:18.25pt;position:var(--position);text-decoration:none;white-space:pre">19,455</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);top:53.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;2.57</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:302.25pt;position:var(--position);top:53.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:19.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;13.10</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:363.75pt;position:var(--position);top:53.25pt;width:53.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:53.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.23pt;position:var(--position);text-decoration:none;white-space:pre">4.30%</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:420pt;position:var(--position);top:53.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.15pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.8100000000000005pt;position:var(--position);text-decoration:none;white-space:pre">5.5</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.810000000000002pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.47pt;position:var(--position);text-decoration:none;white-space:pre">7.0</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:30.47pt;position:var(--position);white-space:pre"> years]</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:481.5pt;position:var(--position);top:53.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.86pt;position:var(--position);text-decoration:none;white-space:pre">60.41%</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:65.25pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2025-1</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:54pt;position:var(--position);top:65.25pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:22.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.13</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:117.75pt;position:var(--position);top:65.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:11.26pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:13.92pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3.5</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:27.92pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:30.58pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3.9</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.58pt;position:var(--position);white-space:pre">]</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:179.25pt;position:var(--position);top:65.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:16.25pt;position:var(--position);text-decoration:none;white-space:pre">100,000</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);top:65.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;2.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:302.25pt;position:var(--position);top:65.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.63</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:363.75pt;position:var(--position);top:65.25pt;width:53.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:53.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.23pt;position:var(--position);text-decoration:none;white-space:pre">4.65%</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:420pt;position:var(--position);top:65.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.15pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.8100000000000005pt;position:var(--position);text-decoration:none;white-space:pre">5.5</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.810000000000002pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.47pt;position:var(--position);text-decoration:none;white-space:pre">7.0</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:30.47pt;position:var(--position);white-space:pre"> years]</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:481.5pt;position:var(--position);top:65.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.86pt;position:var(--position);text-decoration:none;white-space:pre">60.88%</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:77.25pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2025-2</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:54pt;position:var(--position);top:77.25pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:22.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.13</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:117.75pt;position:var(--position);top:77.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:11.26pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:13.92pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3.5</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:27.92pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:30.58pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3.9</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.58pt;position:var(--position);white-space:pre">]</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:179.25pt;position:var(--position);top:77.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:18.25pt;position:var(--position);text-decoration:none;white-space:pre">25,000</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);top:77.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;2.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:302.25pt;position:var(--position);top:77.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.63</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:363.75pt;position:var(--position);top:77.25pt;width:53.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:53.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.23pt;position:var(--position);text-decoration:none;white-space:pre">4.65%</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:420pt;position:var(--position);top:77.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.15pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.8100000000000005pt;position:var(--position);text-decoration:none;white-space:pre">5.5</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.810000000000002pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.47pt;position:var(--position);text-decoration:none;white-space:pre">7.0</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:30.47pt;position:var(--position);white-space:pre"> years]</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:481.5pt;position:var(--position);top:77.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.86pt;position:var(--position);text-decoration:none;white-space:pre">60.88%</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:89.25pt;width:51pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:51pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BSA-2025-3</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:54pt;position:var(--position);top:89.25pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:22.31pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.48</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:117.75pt;position:var(--position);top:89.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:11.26pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:13.92pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3.7</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:27.92pt;position:var(--position);white-space:pre">-</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:30.58pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;4.1</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.58pt;position:var(--position);white-space:pre">]</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:179.25pt;position:var(--position);top:89.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:18.25pt;position:var(--position);text-decoration:none;white-space:pre">39,370</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:240.75pt;position:var(--position);top:89.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;1.27</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:302.25pt;position:var(--position);top:89.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:21.19pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.41</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:363.75pt;position:var(--position);top:89.25pt;width:53.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:53.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.23pt;position:var(--position);text-decoration:none;white-space:pre">3.92%</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:420pt;position:var(--position);top:89.25pt;width:58.5pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.15pt;position:var(--position);white-space:pre">[</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.8100000000000005pt;position:var(--position);text-decoration:none;white-space:pre">5.5</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.810000000000002pt;position:var(--position);white-space:pre">- </span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.47pt;position:var(--position);text-decoration:none;white-space:pre">7.0</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.47pt;position:var(--position);white-space:pre">years]</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:481.5pt;position:var(--position);top:89.25pt;width:58.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:58.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:17.86pt;position:var(--position);text-decoration:none;white-space:pre">60.69%</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr></tbody></table></div></div></div><div style="font-size:0pt;left:36pt;position:var(--position);width:540pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:72pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:75pt"></td></tr><tr style="height:41.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:17.62pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.84pt;position:var(--position);text-decoration:none;white-space:pre">TYPE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);width:72pt"><div><div style="line-height:8pt;position:var(--position);top:3.22pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.7pt;position:var(--position);text-decoration:none;white-space:pre">FAIR&#160;VALUE&#160;OF </span></div><div style="line-height:8pt;position:var(--position);top:12.82pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:27.56pt;position:var(--position);text-decoration:none;white-space:pre">THE </span></div><div style="line-height:8pt;position:var(--position);top:22.42pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.69pt;position:var(--position);text-decoration:none;white-space:pre">UNDERLYING </span></div><div style="line-height:8pt;position:var(--position);top:32.02pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.23pt;position:var(--position);text-decoration:none;white-space:pre">SHARE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:12.82pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.2pt;position:var(--position);text-decoration:none;white-space:pre">FAIR&#160;VALUE OF </span></div><div style="line-height:8pt;position:var(--position);top:22.42pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:19.18pt;position:var(--position);text-decoration:none;white-space:pre">THE AGA</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:17.62pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.19pt;position:var(--position);text-decoration:none;white-space:pre">AGA PRICE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:17.62pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.3pt;position:var(--position);text-decoration:none;white-space:pre">MATURITY</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:17.62pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.96pt;position:var(--position);text-decoration:none;white-space:pre">VOLATILITY </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:17.62pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.97pt;position:var(--position);text-decoration:none;white-space:pre">RISK&#160;FREE&#160;RATE</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:41.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:1.73pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-1 </span></div><div style="line-height:9pt;position:var(--position);top:12.98pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(Tranches 1-4)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:41.25pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;15.98</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:41.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;15.98</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:41.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:41.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:41.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:41.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:63pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:1.73pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-1 </span></div><div style="line-height:9pt;position:var(--position);top:12.98pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(Tranche 5)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:63pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;15.98</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:63pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;3.62</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:63pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:63pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:16.51pt;position:var(--position);text-decoration:none;white-space:pre">2024-12-31</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:63pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:26.82pt;position:var(--position);text-decoration:none;white-space:pre">67.2%</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:63pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:26.82pt;position:var(--position);text-decoration:none;white-space:pre">3.20%</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:84.75pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:1.73pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-1 </span></div><div style="line-height:9pt;position:var(--position);top:12.98pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(Tranche 6)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:84.75pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;15.98</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:84.75pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.74</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:84.75pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:84.75pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:16.51pt;position:var(--position);text-decoration:none;white-space:pre">2024-07-11</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:84.75pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:26.82pt;position:var(--position);text-decoration:none;white-space:pre">67.2%</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:84.75pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:26.82pt;position:var(--position);text-decoration:none;white-space:pre">3.20%</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:106.5pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:1.73pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-2 </span></div><div style="line-height:9pt;position:var(--position);top:12.98pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(Tranche 1)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:106.5pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;15.98</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:106.5pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;15.98</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:106.5pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:106.5pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:106.5pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:106.5pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:128.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:1.73pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-2 </span></div><div style="line-height:9pt;position:var(--position);top:12.98pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(Tranche 2)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:128.25pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;15.98</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:128.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;9.59</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:128.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:128.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:128.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:128.25pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:7.35pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:150pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-3</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:150pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;14.92</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:150pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;14.92</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:150pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:150pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:150pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:150pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:162pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-4</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:162pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;14.92</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:162pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;14.92</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:162pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:162pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:162pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:162pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:174pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2023-5</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:174pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;9.16</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:174pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;9.16</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:174pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:174pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:174pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:174pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:186pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2024-1</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:186pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.26</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:186pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.26</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:186pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:186pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:186pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:186pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:198pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA 2024-2</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:198pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;13.40</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:198pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;13.40</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:198pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:198pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:198pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:198pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:210pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-3</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:210pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.76</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:210pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.76</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:210pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:210pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:210pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:210pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:222pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-4</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:222pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.54</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:222pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.54</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:222pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:222pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:222pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:222pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:234pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-5</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:234pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.54</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:234pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.54</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:234pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:234pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:234pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:234pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:246pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-6</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:246pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.54</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:246pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;12.54</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:246pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:246pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:246pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:246pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:258pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2024-7</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:258pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;10.80</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:258pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;10.80</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:258pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:258pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:258pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:258pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:270pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-1</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:270pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.82</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:270pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.82</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:270pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:270pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:270pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:270pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:282pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-2</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:282pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.82</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:282pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.82</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:282pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:282pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:282pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:282pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:294pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-3</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:294pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.82</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:294pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.82</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:294pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:294pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:294pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:294pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:306pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-4</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:306pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.82</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:306pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.82</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:306pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:306pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:306pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:306pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:318pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-5</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:318pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.17</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:318pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.17</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:318pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:318pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:318pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:318pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:330pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-6</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:330pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.87pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.17</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:330pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;5.17</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:330pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:330pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:330pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:330pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:342pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-7</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:342pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;61.20</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:342pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;61.20</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:342pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:342pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:342pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:342pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:354pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AGA-2025-8</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:78pt;position:var(--position);top:354pt;width:72pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:72pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:23.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;89.40</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153pt;position:var(--position);top:354pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:25.12pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;89.40</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:231pt;position:var(--position);top:354pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.37pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;0.00</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:309pt;position:var(--position);top:354pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:387pt;position:var(--position);top:354pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:29.76pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:354pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.48pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.7pt;position:var(--position);text-decoration:none;white-space:pre">N/A</span></div></div></div></td></tr></tbody></table></div></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The fair value of the Minimum Return Indemnifications was measured using the following assumptions:</span><div style="position:var(--position);top:155.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:521.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:222.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:146.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:146.25pt"></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);white-space:pre">Tranche B Minimum Return Indemnification (issued in March </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);white-space:pre">2024)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.93pt;position:var(--position);text-decoration:none;white-space:pre">AS OF MARCH 28, 2024</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.38pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2024</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Final redemption scenario probability</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:21pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:128.18pt;position:var(--position)"></span><span style="left:128.18pt;position:var(--position)">95<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span><span style="left:138.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:21pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:128.18pt;position:var(--position)"></span><span style="left:128.18pt;position:var(--position)">95<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span><span style="left:138.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:33pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Minimal return</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:33pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:125.62pt;position:var(--position);text-decoration:none;white-space:pre">1.40</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:139.62pt;position:var(--position);white-space:pre">x</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:33pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:125.62pt;position:var(--position);text-decoration:none;white-space:pre">1.40</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:139.62pt;position:var(--position);white-space:pre">x</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:45pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Discount rate</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:45pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:128.18pt;position:var(--position)"></span><span style="left:128.18pt;position:var(--position)">13<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span><span style="left:138.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:45pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:132.18pt;position:var(--position)"></span><span style="left:132.18pt;position:var(--position)">8<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span><span style="left:138.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:57pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Probability-weighted present value of shortfall payment (in </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">thousands of &#8364;)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:57pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:63.45pt;position:var(--position);text-decoration:none;white-space:pre">1,959</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.31pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:88.13pt;position:var(--position);text-decoration:none;white-space:pre">68</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.13pt;position:var(--position);white-space:pre"> (Tender offer)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:57pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:63.45pt;position:var(--position);text-decoration:none;white-space:pre">2,635</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.31pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:84.13pt;position:var(--position);text-decoration:none;white-space:pre">136</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.13pt;position:var(--position);white-space:pre"> (Tender offer)</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Probability-weighted fair value of tranche A-B warrants with MRI </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">(in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:78.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:63.45pt;position:var(--position);text-decoration:none;white-space:pre">1,066</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div></div></div></td><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:78.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:69.45pt;position:var(--position);text-decoration:none;white-space:pre">104</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:99.75pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Probability-weighted fair value of tranche A-B warrants without </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">MRI (in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:99.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:63.45pt;position:var(--position);text-decoration:none;white-space:pre">1,410</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:99.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:69.45pt;position:var(--position);text-decoration:none;white-space:pre">241</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:120.75pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Total fair value of MRI (in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:120.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:29.41pt;position:var(--position);text-decoration:none;white-space:pre">1,615</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:47.41pt;position:var(--position);white-space:pre"> (Final redemption, i.e. a+b-c)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.31pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:88.13pt;position:var(--position);text-decoration:none;white-space:pre">68</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.13pt;position:var(--position);white-space:pre"> (Tender offer)</span></div></div></div></td><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:120.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:29.41pt;position:var(--position);text-decoration:none;white-space:pre">2,499</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:47.41pt;position:var(--position);white-space:pre"> (Final redemption, i.e. a+b-c)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.31pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:84.13pt;position:var(--position);text-decoration:none;white-space:pre">136</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.13pt;position:var(--position);white-space:pre"> (Tender offer)</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:142.5pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);white-space:pre">Fair value of Tranche B MRI (in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:142.5pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:115.55pt"></span></span><span style="left:118.17999999999999pt;position:var(--position)">1,683<span style="display:inline-block;height:5.41pt;width:9.32pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:142.5pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:115.55pt"></span></span><span style="left:118.17999999999999pt;position:var(--position)">2,636<span style="display:inline-block;height:5.41pt;width:9.32pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:342.66pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:521.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:222.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:146.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:146.25pt"></td></tr><tr style="height:21.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);white-space:pre">Tranche C Minimum Return Indemnification (issued in June </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);white-space:pre">2024)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:35.03pt;position:var(--position);text-decoration:none;white-space:pre">AS OF JUNE 21, 2024</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:22.38pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2024</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21.75pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Final redemption scenario probability</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:21.75pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:128.18pt;position:var(--position)"></span><span style="left:128.18pt;position:var(--position)">95<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span><span style="left:138.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:21.75pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:128.18pt;position:var(--position)"></span><span style="left:128.18pt;position:var(--position)">95<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span><span style="left:138.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:33.75pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Minimal return</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:33.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:125.62pt;position:var(--position);text-decoration:none;white-space:pre">1.30</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:139.62pt;position:var(--position);white-space:pre">x</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:33.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:125.62pt;position:var(--position);text-decoration:none;white-space:pre">1.30</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:139.62pt;position:var(--position);white-space:pre">x</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:45.75pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Discount rate</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:45.75pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:128.18pt;position:var(--position)"></span><span style="left:128.18pt;position:var(--position)">15<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span><span style="left:138.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:45.75pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:132.18pt;position:var(--position)"></span><span style="left:132.18pt;position:var(--position)">8<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span><span style="left:138.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:57.75pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">(a) Probability-weighted present value of shortfall payment (in </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">thousands of &#8364;)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:57.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:69.45pt;position:var(--position);text-decoration:none;white-space:pre">741</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.31pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:92.13pt;position:var(--position);text-decoration:none;white-space:pre">0</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.13pt;position:var(--position);white-space:pre"> (Tender offer)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:57.75pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:63.45pt;position:var(--position);text-decoration:none;white-space:pre">1,160</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.31pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:88.13pt;position:var(--position);text-decoration:none;white-space:pre">43</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.13pt;position:var(--position);white-space:pre"> (Tender offer)</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:79.5pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">(b) Probability-weighted fair value of tranche C warrants with MRI </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">(in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:79.5pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:63.45pt;position:var(--position);text-decoration:none;white-space:pre">2,948</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div></div></div></td><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:79.5pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:69.45pt;position:var(--position);text-decoration:none;white-space:pre">684</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:101.25pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">(c) Probability-weighted fair value of tranche C warrants without </span></div><div style="line-height:8pt;position:var(--position);top:12.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">MRI (in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:101.25pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:63.45pt;position:var(--position);text-decoration:none;white-space:pre">3,250</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:101.25pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:69.45pt;position:var(--position);text-decoration:none;white-space:pre">903</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:81.45pt;position:var(--position);white-space:pre"> (Final redemption)</span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:123pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);white-space:pre">Total fair value of MRI (in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:123pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:35.41pt;position:var(--position);text-decoration:none;white-space:pre">475</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:47.41pt;position:var(--position);white-space:pre"> (Final redemption, i.e. a+b-c)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.31pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:92.13pt;position:var(--position);text-decoration:none;white-space:pre">0</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.13pt;position:var(--position);white-space:pre"> (Tender offer)</span></div></div></div></td><td style="background-color:#ccecff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:123pt;width:146.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.63pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:35.41pt;position:var(--position);text-decoration:none;white-space:pre">941</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:47.41pt;position:var(--position);white-space:pre"> (Final redemption, i.e. a+b-c)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.31pt;width:146.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:88.13pt;position:var(--position);text-decoration:none;white-space:pre">43</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.13pt;position:var(--position);white-space:pre"> (Tender offer)</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:144.75pt;width:222.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:222.75pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);white-space:pre">Fair value of Tranche C MRI (in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:225.75pt;position:var(--position);top:144.75pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:121.55pt"></span></span><span style="left:124.17999999999999pt;position:var(--position)">475<span style="display:inline-block;height:5.41pt;width:9.32pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:375pt;position:var(--position);top:144.75pt;width:146.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:146.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:121.55pt"></span></span><span style="left:124.17999999999999pt;position:var(--position)">984<span style="display:inline-block;height:5.41pt;width:9.32pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:558.17pt;position:var(--position);text-decoration:none;white-space:pre">The </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:163.96pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">main data and assumptions are the following:</span></div><div style="position:var(--position);top:211.46pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:522pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:137.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:125.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:125.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:125.25pt"></td></tr><tr style="height:24pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.2pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos/Claret Tranche A-B BSA - </span></div><div style="line-height:8pt;position:var(--position);top:13.8pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">August 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.32pt;position:var(--position);text-decoration:none;white-space:pre">AS OF AUGUST 22, 2023 </span></div><div style="line-height:8pt;position:var(--position);top:14pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:37.65pt;position:var(--position);text-decoration:none;white-space:pre">(Tranche A-B)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:9pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.88pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:9pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.88pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2024</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Number of outstanding BSA</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:24pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.62pt;position:var(--position);text-decoration:none;white-space:pre">214,198</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:24pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.62pt;position:var(--position);text-decoration:none;white-space:pre">214,198</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:24pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.62pt;position:var(--position);text-decoration:none;white-space:pre">214,198</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:39.75pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Exercise price per share</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:39.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:100.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;18.67</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:39.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:100.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;18.67</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:39.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:100.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;18.67</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:55.5pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Ordinary share price</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:55.5pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:100.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;17.10</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:55.5pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;9.82</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:55.5pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.76</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:71.25pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Exercise date</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:71.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.44pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:19.99pt;position:var(--position);text-decoration:none;white-space:pre">19/08/2030 (expiry) 18/02/2027 </span></div><div style="line-height:8pt;position:var(--position);top:12.44pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:79.79pt;position:var(--position);text-decoration:none;white-space:pre">(tender offer)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:71.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.43pt;position:var(--position);text-decoration:none;white-space:pre">19/08/2030 (expiry)</span></div><div style="line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:41.35pt;position:var(--position);text-decoration:none;white-space:pre">18/02/2027 (tender offer)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:71.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.43pt;position:var(--position);text-decoration:none;white-space:pre">19/08/2030 (expiry)</span></div><div style="line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:41.35pt;position:var(--position);text-decoration:none;white-space:pre">18/02/2027 (tender offer)</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:92.25pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">7-year expiry scenario probability</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:92.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">50</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:92.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">95</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:92.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">95</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:108pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Volatility</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:108pt;width:125.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:74.21pt;position:var(--position);text-decoration:none;white-space:pre">71.9%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.86999999999999pt;position:var(--position);white-space:pre"> (expiry) </span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:57.13pt;position:var(--position);text-decoration:none;white-space:pre">65.2%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.79pt;position:var(--position);white-space:pre"> (tender offer)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:108pt;width:125.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:74.21pt;position:var(--position);text-decoration:none;white-space:pre">59.5%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.86999999999999pt;position:var(--position);white-space:pre"> (expiry)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:57.13pt;position:var(--position);text-decoration:none;white-space:pre">64.9%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.79pt;position:var(--position);white-space:pre"> (tender offer)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:108pt;width:125.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:74.21pt;position:var(--position);text-decoration:none;white-space:pre">44.3%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.86999999999999pt;position:var(--position);white-space:pre"> (expiry)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:57.13pt;position:var(--position);text-decoration:none;white-space:pre">44.3%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.79pt;position:var(--position);white-space:pre"> (tender offer)</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:129pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Dividend</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:129pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">&#8212;</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:129pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">&#8212;</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:129pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">&#8212;</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:144.75pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Risk-free rate</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:144.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)">3.00</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:144.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)">2.30</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="height:17.25pt;left:396.75pt;overflow:hidden;position:var(--position);top:144.75pt;width:125.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:0.52pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:78.21pt;position:var(--position);text-decoration:none;white-space:pre">2.9%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.86999999999999pt;position:var(--position);white-space:pre"> (expiry)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:10.6pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:61.13pt;position:var(--position);text-decoration:none;white-space:pre">2.9%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.79pt;position:var(--position);white-space:pre"> (tender offer)</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:162pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Fair value of issued Kreos/Claret </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Tranche A-B BSA</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:162pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:97.21pt"></span></span><span style="left:99.83999999999999pt;position:var(--position)">2,092<span style="display:inline-block;height:5.41pt;width:6.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:162pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:103.21pt"></span></span><span style="left:105.83999999999999pt;position:var(--position)">920<span style="display:inline-block;height:5.41pt;width:6.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:162pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:103.21pt"></span></span><span style="left:105.83999999999999pt;position:var(--position)">243<span style="display:inline-block;height:5.41pt;width:6.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:421.86pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:522pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:137.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:125.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:125.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:125.25pt"></td></tr><tr style="height:24pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.2pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos/Claret Tranche C BSA - </span></div><div style="line-height:8pt;position:var(--position);top:13.8pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">November 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:9pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.43pt;position:var(--position);text-decoration:none;white-space:pre">AS OF NOVEMBER 2, 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:9pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.88pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:9pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.88pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2024</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Number of outstanding BSA</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:24pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.62pt;position:var(--position);text-decoration:none;white-space:pre">405,832</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:24pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.62pt;position:var(--position);text-decoration:none;white-space:pre">405,832</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:24pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:96.62pt;position:var(--position);text-decoration:none;white-space:pre">405,832</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:39.75pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">of which, number of conditional BSA</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:39.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.8pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:96.62pt;position:var(--position);text-decoration:none;white-space:pre">202,915</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:39.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.8pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:96.62pt;position:var(--position);text-decoration:none;white-space:pre">202,916</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:39.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.8pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:118.62pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:55.5pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Exercise price per share</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:55.5pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:6.99pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;9.86</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:55.5pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:6.99pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;9.86</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:55.5pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:6.99pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;9.86</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:71.25pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Ordinary share price</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:71.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;8.89</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:71.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;9.82</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:71.25pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.67</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:87pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Exercise date</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:87pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.43pt;position:var(--position);white-space:pre">01/11/2030 (expiry) </span></div><div style="line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:41.35pt;position:var(--position);white-space:pre">18/02/2027 (tender offer)</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:87pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.43pt;position:var(--position);text-decoration:none;white-space:pre">01/11/2030 (expiry)</span></div><div style="line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:41.35pt;position:var(--position);text-decoration:none;white-space:pre">18/02/2027 (tender offer)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:87pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.43pt;position:var(--position);text-decoration:none;white-space:pre">01/11/2030 (expiry)</span></div><div style="line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:41.35pt;position:var(--position);text-decoration:none;white-space:pre">18/02/2027 (tender offer)</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:108pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">7-year expiry scenario probability</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:108pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">95</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:108pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">95</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:108pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">95</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:123.75pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Probability of Drawdown of Tranche C </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">credit facility</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:123.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">30</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:123.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">30</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:123.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.09pt;position:var(--position);text-decoration:none;white-space:pre">Drawn on June 21, 2024</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:144.75pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Volatility</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:144.75pt;width:125.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:74.21pt;position:var(--position);text-decoration:none;white-space:pre">67.3%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.86999999999999pt;position:var(--position);white-space:pre"> (expiry)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:57.13pt;position:var(--position);text-decoration:none;white-space:pre">64.3%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.79pt;position:var(--position);white-space:pre"> (tender offer)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:144.75pt;width:125.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:74.21pt;position:var(--position);text-decoration:none;white-space:pre">67.4%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.86999999999999pt;position:var(--position);white-space:pre"> (expiry)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:57.13pt;position:var(--position);text-decoration:none;white-space:pre">64.9%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.79pt;position:var(--position);white-space:pre"> (tender offer)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:144.75pt;width:125.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:2.4pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:74.21pt;position:var(--position);text-decoration:none;white-space:pre">44.3%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.86999999999999pt;position:var(--position);white-space:pre"> (expiry)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:12.48pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:57.13pt;position:var(--position);text-decoration:none;white-space:pre">44.3%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.79pt;position:var(--position);white-space:pre"> (tender offer)</span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:165.75pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Dividend</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:165.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">&#8212;</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:165.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">&#8212;</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:165.75pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.81pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:109.84pt;position:var(--position)"></span><span style="left:109.84pt;position:var(--position)">&#8212;</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:24pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:181.5pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:8.93pt;width:137.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Risk-free rate</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:181.5pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:8.93pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)">3.00</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:181.5pt;width:125.25pt"><div><div style="line-height:8pt;position:var(--position);top:8.93pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)">2.30</span><span style="left:117.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:181.5pt;width:125.25pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:3.89pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:78.21pt;position:var(--position);text-decoration:none;white-space:pre">2.9%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.86999999999999pt;position:var(--position);white-space:pre"> (expiry)</span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:13.97pt;width:125.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:61.13pt;position:var(--position);text-decoration:none;white-space:pre">2.9%</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.79pt;position:var(--position);white-space:pre"> (tender offer)</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:205.5pt;width:137.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:137.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Fair value of issued Kreos/Claret </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:137.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Tranche C BSA</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:140.25pt;position:var(--position);top:205.5pt;width:125.25pt"><div><div style="line-height:9pt;position:var(--position);top:7.05pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.09pt;width:94.96pt"></span></span><span style="left:97.58999999999999pt;position:var(--position)">1,493<span style="display:inline-block;height:6.09pt;width:6.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:268.5pt;position:var(--position);top:205.5pt;width:125.25pt"><div><div style="line-height:9pt;position:var(--position);top:7.05pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.09pt;width:94.96pt"></span></span><span style="left:97.58999999999999pt;position:var(--position)">1,659<span style="display:inline-block;height:6.09pt;width:6.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:396.75pt;position:var(--position);top:205.5pt;width:125.25pt"><div><div style="line-height:9pt;position:var(--position);top:7.05pt;width:125.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.09pt;width:101.71pt"></span></span><span style="left:104.33999999999999pt;position:var(--position)">923<span style="display:inline-block;height:6.09pt;width:6.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfIndirectMeasurementOfConvertibleLoansInstrumentsTableTextBlock', window );">Disclosure of main data and assumptions used for the measurement of convertible loan notes</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:110.62pt;position:var(--position);text-decoration:none;white-space:pre">The main data and assumptions are the following: </span><div style="position:var(--position);top:193.76pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:519pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:143.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:128.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:119.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:119.25pt"></td></tr><tr style="height:17.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.62pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Heights convertible notes - August 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.62pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:19.82pt;position:var(--position);text-decoration:none;white-space:pre">AS OF AUGUST 24, 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.62pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.88pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.62pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.88pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2024</span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:17.25pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Number of outstanding notes</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:17.25pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:113.62pt;position:var(--position);text-decoration:none;white-space:pre">350</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:17.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">350</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:17.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:104.62pt;position:var(--position);text-decoration:none;white-space:pre">350</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:34.5pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Original principal amount (in thousands of </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:34.5pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:103.62pt;position:var(--position);text-decoration:none;white-space:pre">35,000</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:34.5pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.62pt;position:var(--position);text-decoration:none;white-space:pre">35,000</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:34.5pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.62pt;position:var(--position);text-decoration:none;white-space:pre">35,000</span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:55.5pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest rate</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:55.5pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:116.84pt;position:var(--position)"></span><span style="left:116.84pt;position:var(--position)">6</span><span style="left:120.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:55.5pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:107.84pt;position:var(--position)"></span><span style="left:107.84pt;position:var(--position)">6</span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:55.5pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:107.84pt;position:var(--position)"></span><span style="left:107.84pt;position:var(--position)">6</span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:72.75pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Conversion price per share</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:72.75pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:103.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;23.77</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:72.75pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;23.77</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:72.75pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;23.77</span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Ordinary share price</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:90pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:103.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;16.74</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:90pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:98.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;9.82</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:90pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:98.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;6.76</span></div></div></div></td></tr><tr style="height:27pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:107.25pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:10.43pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Maturity date</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:107.25pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.63pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:13.88pt;position:var(--position);text-decoration:none;white-space:pre">24/08/2025 (put event) 24/08/2027 </span></div><div style="line-height:8pt;position:var(--position);top:15.23pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:32.58pt;position:var(--position);text-decoration:none;white-space:pre">(HTM/voluntary conversion)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:27pt;left:277.5pt;overflow:hidden;position:var(--position);top:107.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:0.84pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:43.32pt;position:var(--position);text-decoration:none;white-space:pre">24/08/2025 (put event)</span></div><div style="line-height:8pt;position:var(--position);top:10.44pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:24.89pt;position:var(--position);text-decoration:none;white-space:pre">24/08/2027 (HTM/voluntary </span></div><div style="line-height:8pt;position:var(--position);top:20.04pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:78.87pt;position:var(--position);text-decoration:none;white-space:pre">conversion)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:27pt;left:399.75pt;overflow:hidden;position:var(--position);top:107.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:0.84pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:43.32pt;position:var(--position);text-decoration:none;white-space:pre">24/08/2025 (put event)</span></div><div style="line-height:8pt;position:var(--position);top:10.44pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:24.89pt;position:var(--position);text-decoration:none;white-space:pre">24/08/2027 (HTM/voluntary </span></div><div style="line-height:8pt;position:var(--position);top:20.04pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:78.87pt;position:var(--position);text-decoration:none;white-space:pre">conversion)</span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:17.25pt;overflow:hidden;position:var(--position);top:134.25pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:0.76pt;width:143.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Held to maturity / voluntary conversion </span></div><div style="line-height:8pt;position:var(--position);top:10.36pt;width:143.25pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">scenario probability</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:134.25pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:112.84pt;position:var(--position)"></span><span style="left:112.84pt;position:var(--position)">75</span><span style="left:120.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:134.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)">75</span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:134.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)">75</span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:151.5pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Initial price limit</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:151.5pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:103.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;14.43</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:151.5pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;14.43</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:151.5pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:94.62pt;position:var(--position);text-decoration:none;white-space:pre">&#8364;14.43</span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:168.75pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Early redemption amount (put event)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:168.75pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:108.84pt;position:var(--position)"></span><span style="left:108.84pt;position:var(--position)">120</span><span style="left:120.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:168.75pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:99.84pt;position:var(--position)"></span><span style="left:99.84pt;position:var(--position)">120</span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:168.75pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:99.84pt;position:var(--position)"></span><span style="left:99.84pt;position:var(--position)">120</span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:186pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Volatility</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:186pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:112.84pt;position:var(--position)"></span><span style="left:112.84pt;position:var(--position)">50</span><span style="left:120.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:186pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)">50</span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:186pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)">50</span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:203.25pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Credit spread</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:203.25pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:112.84pt;position:var(--position)"></span><span style="left:112.84pt;position:var(--position)">20</span><span style="left:120.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:203.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)">20</span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:203.25pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:103.84pt;position:var(--position)"></span><span style="left:103.84pt;position:var(--position)">25</span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:17.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:220.5pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Risk-free rate</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:220.5pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:110.84pt;position:var(--position)"></span><span style="left:110.84pt;position:var(--position)">2.9</span><span style="left:120.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:220.5pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:101.84pt;position:var(--position)"></span><span style="left:101.84pt;position:var(--position)">2.3</span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:220.5pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.56pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:101.84pt;position:var(--position)"></span><span style="left:101.84pt;position:var(--position)">2.9</span><span style="left:111.84pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:237.75pt;width:143.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Fair value of Heights convertible notes </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:143.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(in thousands of &#8364;)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:146.25pt;position:var(--position);top:237.75pt;width:128.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:128.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:96.21pt"></span></span><span style="left:98.83999999999999pt;position:var(--position)">32,641<span style="display:inline-block;height:5.41pt;width:6.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:277.5pt;position:var(--position);top:237.75pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:87.21pt"></span></span><span style="left:89.83999999999999pt;position:var(--position)">27,456<span style="display:inline-block;height:5.41pt;width:6.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:399.75pt;position:var(--position);top:237.75pt;width:119.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:119.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:87.21pt"></span></span><span style="left:89.83999999999999pt;position:var(--position)">20,017<span style="display:inline-block;height:5.41pt;width:6.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBorrowingsExplanatory', window );">Disclosure of conditional advances</a></td>
<td class="text"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Conditional advances as of December 31, 2023, 2024 and 2025 are as </span><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:317.41pt;position:var(--position);text-decoration:none;white-space:pre">follows</span><span style="font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:347.39pt;position:var(--position);text-decoration:none;white-space:pre">:</span><div style="font-size:12pt;line-height:11pt;position:var(--position);top:165.06pt;width:612pt"><span style="font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div><div style="position:var(--position);top:195.07pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:336pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:134.25pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:65.25pt"></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:15.59pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">CONDITIONAL ADVANCES</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:134.25pt;position:var(--position);top:12pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.92pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.97pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.52pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:12pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.92pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.97pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.52pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:270.75pt;position:var(--position);top:12pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.92pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.97pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.52pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.53pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.62pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">RNP VIR &#8211; Bpifrance</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:134.25pt;position:var(--position);top:42.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">4,232<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:42.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:270.75pt;position:var(--position);top:42.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">CARENA &#8211; Bpifrance</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:134.25pt;position:var(--position);top:54.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">2,485<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:54.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:270.75pt;position:var(--position);top:54.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">EBOLA &#8211; Bpifrance</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:134.25pt;position:var(--position);top:66.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">55<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:66.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:270.75pt;position:var(--position);top:66.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total conditional advances</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:134.25pt;position:var(--position);top:78.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.21pt"></span></span><span style="left:43.84pt;position:var(--position)">6,771<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:202.5pt;position:var(--position);top:78.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:270.75pt;position:var(--position);top:78.75pt;width:65.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:65.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.21pt"></span></span><span style="left:53.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfLeasesForLesseeTableTextBlock', window );">Disclosure of variation in lease liabilities</a></td>
<td class="text"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The variations in lease liabilities are set forth below:</span><div style="position:var(--position);top:133.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:301.5pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:216.75pt"></td><td style="padding:0;width:84.75pt"></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:216.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:56.84pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:216.75pt;position:var(--position);width:84.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:84.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.18pt;position:var(--position);text-decoration:none;white-space:pre"> LEASE LIABILITY</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:216.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY 1, 2023</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:216.75pt;position:var(--position);top:12pt;width:84.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:84.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.71pt"></span></span><span style="left:63.34pt;position:var(--position)">1,384<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:33pt;width:216.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(+) Increase </span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:216.75pt;position:var(--position);top:33pt;width:84.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:84.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.71pt"></span></span><span style="left:69.33999999999999pt;position:var(--position)">350<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:45pt;width:216.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(-) Decrease</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:216.75pt;position:var(--position);top:45pt;width:84.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:84.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.05pt"></span></span><span style="left:60.68pt;position:var(--position)">(1,194)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:57pt;width:216.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:216.75pt;position:var(--position);top:57pt;width:84.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:84.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:66.71pt"></span></span><span style="left:69.33999999999999pt;position:var(--position)">540<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78pt;width:216.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(+) Increase </span></div></div></div></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:216.75pt;position:var(--position);top:78pt;width:84.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:84.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.71pt"></span></span><span style="left:63.34pt;position:var(--position)">2,221<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90pt;width:216.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(-) Decrease</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:216.75pt;position:var(--position);top:90pt;width:84.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:84.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:64.05pt"></span></span><span style="left:66.67999999999999pt;position:var(--position)">(398)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102pt;width:216.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:216.75pt;position:var(--position);top:102pt;width:84.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:84.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.71pt"></span></span><span style="left:63.34pt;position:var(--position)">2,363<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:123pt;width:216.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(+) Increase </span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:216.75pt;position:var(--position);top:123pt;width:84.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:84.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.71pt"></span></span><span style="left:69.33999999999999pt;position:var(--position)">444<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:135pt;width:216.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(-) Decrease</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:216.75pt;position:var(--position);top:135pt;width:84.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:84.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:64.05pt"></span></span><span style="left:66.67999999999999pt;position:var(--position)">(950)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:147pt;width:216.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:216.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:216.75pt;position:var(--position);top:147pt;width:84.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:84.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.71pt"></span></span><span style="left:63.34pt;position:var(--position)">1,856<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory', window );">Disclosure of reconciliation of liabilities arising from financing activities</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:44pt;position:var(--position);text-decoration:none;white-space:pre">Changes in financial liabilities, excluding derivative instruments, are presented below as of December 31, 2023, 2024 and 2025:</span><div style="position:var(--position);top:444.86pt;width:612pt"><div style="font-size:0pt;left:17pt;position:var(--position);width:558.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:96.75pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td></tr><tr style="height:21.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:96.75pt"><div><div style="line-height:7pt;position:var(--position);top:13.88pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:italic;font-weight:normal;left:2.9pt;position:var(--position);text-decoration:none;white-space:pre">(Amounts in thousands of euros) </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:44.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21.75pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:9.52pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.73pt;position:var(--position);text-decoration:none;white-space:pre">FINANCIAL </span></div><div style="line-height:8pt;position:var(--position);top:19.12pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.96pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES (excluding </span></div><div style="line-height:8pt;position:var(--position);top:28.72pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.97pt;position:var(--position);text-decoration:none;white-space:pre">derivatives instruments)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:15.36pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:3.78pt;position:var(--position);text-decoration:none;white-space:pre">Kreos 1 &amp; 2 </span></div><div style="line-height:7pt;position:var(--position);top:23.76pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:5.51pt;position:var(--position);text-decoration:none;white-space:pre">bond loans</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:10.68pt;position:var(--position);text-decoration:none;white-space:pre">Oceane</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:2.76pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:11.85pt;position:var(--position);text-decoration:none;white-space:pre">Kreos/</span></div><div style="line-height:7pt;position:var(--position);top:11.16pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:12.24pt;position:var(--position);text-decoration:none;white-space:pre">Claret </span></div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:5.05pt;position:var(--position);text-decoration:none;white-space:pre">convertible </span></div><div style="line-height:7pt;position:var(--position);top:27.96pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:13.98pt;position:var(--position);text-decoration:none;white-space:pre">notes </span></div><div style="line-height:7pt;position:var(--position);top:36.36pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:4.85pt;position:var(--position);text-decoration:none;white-space:pre">(OCABSA)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:11.16pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:9.03pt;position:var(--position);text-decoration:none;white-space:pre">Kreos &amp; </span></div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:3.78pt;position:var(--position);text-decoration:none;white-space:pre">Claret bond </span></div><div style="line-height:7pt;position:var(--position);top:27.96pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:13.97pt;position:var(--position);text-decoration:none;white-space:pre">loans </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:11.16pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:10.29pt;position:var(--position);text-decoration:none;white-space:pre">Heights </span></div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:5.05pt;position:var(--position);text-decoration:none;white-space:pre">convertible </span></div><div style="line-height:7pt;position:var(--position);top:27.96pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:13.98pt;position:var(--position);text-decoration:none;white-space:pre">notes</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:14.56pt;position:var(--position);text-decoration:none;white-space:pre">PGE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:11.16pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:4.06pt;position:var(--position);text-decoration:none;white-space:pre">Conditional </span></div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:8.15pt;position:var(--position);text-decoration:none;white-space:pre">advances </span></div><div style="line-height:7pt;position:var(--position);top:27.96pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:15.92pt;position:var(--position);text-decoration:none;white-space:pre">BPI</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:15.36pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:13.21pt;position:var(--position);text-decoration:none;white-space:pre">Lease </span></div><div style="line-height:7pt;position:var(--position);top:23.76pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:8.16pt;position:var(--position);text-decoration:none;white-space:pre">liabilities</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:15.36pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:10.09pt;position:var(--position);text-decoration:none;white-space:pre">Royalty </span></div><div style="line-height:7pt;position:var(--position);top:23.76pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:5.45pt;position:var(--position);text-decoration:none;white-space:pre">certificates</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:13.78pt;position:var(--position);text-decoration:none;white-space:pre">Total </span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY 1, 2023</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">12,982<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">19,957<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">4,838<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">6,783<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">1,384<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">3,287<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">49,231<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:87pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Proceeds</span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">23,119<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">35,000<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">58,119<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:99pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Repayments </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:99pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:12.8pt"></span></span><span style="left:15.43pt;position:var(--position)">(11,635)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:99pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:12.8pt"></span></span><span style="left:15.43pt;position:var(--position)">(23,238)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:99pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:99pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:99pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(2,188)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:99pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(1,250)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:99pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.8pt"></span></span><span style="left:25.43pt;position:var(--position)">(110)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:99pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.8pt"></span></span><span style="left:25.43pt;position:var(--position)">(573)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:99pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:99pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:12.8pt"></span></span><span style="left:15.43pt;position:var(--position)">(38,993)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:111pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest paid</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:111pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(2,278)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:111pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(1,602)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:111pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.8pt"></span></span><span style="left:25.43pt;position:var(--position)">(818)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:111pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:111pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.8pt"></span></span><span style="left:25.43pt;position:var(--position)">(525)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:111pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.8pt"></span></span><span style="left:29.43pt;position:var(--position)">(43)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:111pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:111pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.8pt"></span></span><span style="left:29.43pt;position:var(--position)">(12)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:111pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:111pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(5,278)</span></span></div></div></div></td></tr><tr style="height:50.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:123pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.09pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: </span></div><div style="line-height:8pt;position:var(--position);top:12.69pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">classification of embedded </span></div><div style="line-height:8pt;position:var(--position);top:22.29pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">derivatives as separate </span></div><div style="line-height:8pt;position:var(--position);top:31.89pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">derivative financial </span></div><div style="line-height:8pt;position:var(--position);top:41.49pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">instruments</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:123pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:22.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:123pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:22.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:123pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:22.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(1,046)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:123pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:22.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:123pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:22.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:123pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:22.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:123pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:22.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:123pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:22.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:123pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:22.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:123pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:22.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(1,046)</span></span></div></div></div></td></tr><tr style="height:30.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:173.25pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.79pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: (gain)/</span></div><div style="line-height:8pt;position:var(--position);top:12.39pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">loss on recognition or </span></div><div style="line-height:8pt;position:var(--position);top:21.99pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">derecognition</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:173.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.46pt"></span></span><span style="left:28.09pt;position:var(--position)">170<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:173.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">3,069<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:173.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:173.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:173.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.8pt"></span></span><span style="left:25.43pt;position:var(--position)">(212)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:173.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:173.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:173.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:173.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:173.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">3,027<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:204pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.64pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: interest </span></div><div style="line-height:8pt;position:var(--position);top:12.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">expense and other</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:204pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.46pt"></span></span><span style="left:28.09pt;position:var(--position)">760<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:204pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">1,814<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:204pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">1,393<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:204pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:204pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.46pt"></span></span><span style="left:28.09pt;position:var(--position)">727<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:204pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.46pt"></span></span><span style="left:28.09pt;position:var(--position)">133<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:204pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">98<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:204pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">12<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:204pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">2,521<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:204pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">7,459<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:30.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:225pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.79pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: </span></div><div style="line-height:8pt;position:var(--position);top:12.39pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">recognition of earn-out </span></div><div style="line-height:8pt;position:var(--position);top:21.99pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">liability</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:225pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:225pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:225pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(1,005)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:225pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:225pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:225pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:225pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:225pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:225pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:225pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(1,005)</span></span></div></div></div></td></tr></tbody></table></div></div></div><div><div style="position:var(--position);top:70.56pt;width:612pt"><div style="font-size:0pt;left:17pt;position:var(--position);width:558.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:96.75pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:43.5pt"></td></tr><tr style="height:21.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:96.75pt"><div><div style="line-height:7pt;position:var(--position);top:13.88pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:italic;font-weight:normal;left:2.9pt;position:var(--position);text-decoration:none;white-space:pre">(Amounts in thousands of euros) </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:44.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21.75pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:9.52pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.73pt;position:var(--position);text-decoration:none;white-space:pre">FINANCIAL </span></div><div style="line-height:8pt;position:var(--position);top:19.12pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.96pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES (excluding </span></div><div style="line-height:8pt;position:var(--position);top:28.72pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.97pt;position:var(--position);text-decoration:none;white-space:pre">derivatives instruments)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:15.36pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:3.78pt;position:var(--position);text-decoration:none;white-space:pre">Kreos 1 &amp; 2 </span></div><div style="line-height:7pt;position:var(--position);top:23.76pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:5.51pt;position:var(--position);text-decoration:none;white-space:pre">bond loans</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:10.68pt;position:var(--position);text-decoration:none;white-space:pre">Oceane</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:2.76pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:11.85pt;position:var(--position);text-decoration:none;white-space:pre">Kreos/</span></div><div style="line-height:7pt;position:var(--position);top:11.16pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:12.24pt;position:var(--position);text-decoration:none;white-space:pre">Claret </span></div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:5.05pt;position:var(--position);text-decoration:none;white-space:pre">convertible </span></div><div style="line-height:7pt;position:var(--position);top:27.96pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:13.98pt;position:var(--position);text-decoration:none;white-space:pre">notes </span></div><div style="line-height:7pt;position:var(--position);top:36.36pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:4.85pt;position:var(--position);text-decoration:none;white-space:pre">(OCABSA)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:11.16pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:9.03pt;position:var(--position);text-decoration:none;white-space:pre">Kreos &amp; </span></div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:3.78pt;position:var(--position);text-decoration:none;white-space:pre">Claret bond </span></div><div style="line-height:7pt;position:var(--position);top:27.96pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:13.97pt;position:var(--position);text-decoration:none;white-space:pre">loans </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:11.16pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:10.29pt;position:var(--position);text-decoration:none;white-space:pre">Heights </span></div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:5.05pt;position:var(--position);text-decoration:none;white-space:pre">convertible </span></div><div style="line-height:7pt;position:var(--position);top:27.96pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:13.98pt;position:var(--position);text-decoration:none;white-space:pre">notes</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:14.56pt;position:var(--position);text-decoration:none;white-space:pre">PGE</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:11.16pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:4.06pt;position:var(--position);text-decoration:none;white-space:pre">Conditional </span></div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:8.15pt;position:var(--position);text-decoration:none;white-space:pre">advances </span></div><div style="line-height:7pt;position:var(--position);top:27.96pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:15.92pt;position:var(--position);text-decoration:none;white-space:pre">BPI</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:15.36pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:13.21pt;position:var(--position);text-decoration:none;white-space:pre">Lease </span></div><div style="line-height:7pt;position:var(--position);top:23.76pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:8.16pt;position:var(--position);text-decoration:none;white-space:pre">liabilities</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:15.36pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:10.09pt;position:var(--position);text-decoration:none;white-space:pre">Royalty </span></div><div style="line-height:7pt;position:var(--position);top:23.76pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:5.45pt;position:var(--position);text-decoration:none;white-space:pre">certificates</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:21.75pt;width:43.5pt"><div><div style="line-height:7pt;position:var(--position);top:19.56pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:7pt;font-style:normal;font-weight:bold;left:13.78pt;position:var(--position);text-decoration:none;white-space:pre">Total </span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">amortized cost </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.8pt"></span></span><span style="left:25.43pt;position:var(--position)">(543)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">6,421<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:66pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">5,878<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:87pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.64pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: other </span></div><div style="line-height:8pt;position:var(--position);top:12.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">fair value remeasurement</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(3,198)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:87pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(3,198)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:108pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.64pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non cash changes: </span></div><div style="line-height:8pt;position:var(--position);top:12.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">additional leases</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:108pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:108pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:108pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:108pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:108pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:108pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:108pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:108pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.46pt"></span></span><span style="left:28.09pt;position:var(--position)">272<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:108pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:108pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.46pt"></span></span><span style="left:28.09pt;position:var(--position)">272<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:129pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:129pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:129pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:129pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">21,643<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:129pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:129pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">29,605<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:129pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">3,678<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:129pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">6,771<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:129pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:25.46pt"></span></span><span style="left:28.09pt;position:var(--position)">540<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:129pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">12,229<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:129pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">74,466<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:150pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Proceeds</span></div></div></div></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:150pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:150pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:150pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:150pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">47,444<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:150pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:150pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:150pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:150pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:150pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:150pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">47,444<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:162pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Repayments </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:162pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:162pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:162pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:162pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:162pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(8,750)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:162pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(1,250)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:162pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(2,708)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:162pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.8pt"></span></span><span style="left:25.43pt;position:var(--position)">(459)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:162pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:162pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:12.8pt"></span></span><span style="left:15.43pt;position:var(--position)">(13,167)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:174pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest paid</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:174pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:174pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:174pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(2,250)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:174pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(3,639)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:174pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(1,772)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:174pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.8pt"></span></span><span style="left:29.43pt;position:var(--position)">(18)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:174pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:174pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.8pt"></span></span><span style="left:29.43pt;position:var(--position)">(17)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:174pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:174pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(7,696)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:186pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">classification of embedded </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:186pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:186pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:186pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:186pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(3,204)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:186pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:186pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:186pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:186pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:186pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:186pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(3,204)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:207pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: (gain)/</span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">loss on recognition or </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:207pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:207pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:207pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:207pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:207pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.8pt"></span></span><span style="left:25.43pt;position:var(--position)">(590)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:207pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:207pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:207pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:207pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:207pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.8pt"></span></span><span style="left:25.43pt;position:var(--position)">(590)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:228pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.64pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: interest </span></div><div style="line-height:8pt;position:var(--position);top:12.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">expense and other</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:228pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:228pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:228pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">3,977<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:228pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">5,800<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:228pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">1,714<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:228pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">77<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:228pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:33.46pt"></span></span><span style="left:36.09pt;position:var(--position)">7<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:228pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">61<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:228pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">4,198<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:228pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">15,834<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:30.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:249pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.79pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: </span></div><div style="line-height:8pt;position:var(--position);top:12.39pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">amortized cost </span></div><div style="line-height:8pt;position:var(--position);top:21.99pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">remeasurement</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:249pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:249pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:249pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:249pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:249pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:249pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:249pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:249pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:249pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(3,404)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:249pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(3,404)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:279.75pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.64pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: other </span></div><div style="line-height:8pt;position:var(--position);top:12.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">fair value remeasurement</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:279.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:279.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:279.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:279.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:279.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">1,367<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:279.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:279.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:279.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:279.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:279.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">1,367<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:300.75pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.64pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes&#160;: </span></div><div style="line-height:8pt;position:var(--position);top:12.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">subsidies </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:300.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:300.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:300.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:300.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:300.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:300.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:300.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(4,070)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:300.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:300.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:300.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(4,070)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:321.75pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.64pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non cash changes: </span></div><div style="line-height:8pt;position:var(--position);top:12.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">additional leases</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:321.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:321.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:321.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:321.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:321.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:321.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:321.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:321.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">2,221<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:321.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:321.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">2,221<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:342.75pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.63pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non cash changes : Effect </span></div><div style="line-height:8pt;position:var(--position);top:12.23pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">of the change in foreign </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:342.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:342.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:342.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:342.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:342.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:342.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:342.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:342.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">17<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:342.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:342.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">17<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:363.75pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:363.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:363.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:363.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">23,370<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:363.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">46,401<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:363.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">21,574<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:363.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">2,488<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:363.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:363.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">2,363<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:363.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">13,023<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:363.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:11.46pt"></span></span><span style="left:14.09pt;position:var(--position)">109,218<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:384.75pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Proceeds</span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:384.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:384.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:384.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:384.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:384.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:384.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:384.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:384.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:384.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:384.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:396.75pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Repayments </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:396.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:396.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:396.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:396.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:12.8pt"></span></span><span style="left:15.43pt;position:var(--position)">(53,920)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:396.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(2,188)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:396.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(2,514)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:396.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:396.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.8pt"></span></span><span style="left:25.43pt;position:var(--position)">(910)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:396.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:396.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:12.8pt"></span></span><span style="left:15.43pt;position:var(--position)">(59,532)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:408.75pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest paid</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:408.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:408.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:408.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(1,875)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:408.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(3,791)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:408.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.8pt"></span></span><span style="left:25.43pt;position:var(--position)">(689)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:408.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.8pt"></span></span><span style="left:29.43pt;position:var(--position)">(72)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:408.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:408.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.8pt"></span></span><span style="left:29.43pt;position:var(--position)">(64)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:408.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:408.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(6,491)</span></span></div></div></div></td></tr><tr style="height:30.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:420.75pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.79pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: (gain)/</span></div><div style="line-height:8pt;position:var(--position);top:12.39pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">loss on recognition or </span></div><div style="line-height:8pt;position:var(--position);top:21.99pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">derecognition</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:420.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:420.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:420.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:420.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">3,838<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:420.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:16.8pt"></span></span><span style="left:19.43pt;position:var(--position)">(1,557)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:420.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:420.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:420.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:420.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:420.75pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">2,281<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:451.5pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.64pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: interest </span></div><div style="line-height:8pt;position:var(--position);top:12.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">expense and other</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:451.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:451.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:451.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">2,860<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:451.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">7,472<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:451.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.46pt"></span></span><span style="left:28.09pt;position:var(--position)">778<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:451.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">99<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:451.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:451.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">64<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:451.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">5,927<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:451.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">17,200<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:30.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:472.5pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.79pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: </span></div><div style="line-height:8pt;position:var(--position);top:12.39pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">amortized cost </span></div><div style="line-height:8pt;position:var(--position);top:21.99pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">remeasurement</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:472.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:472.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:472.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:472.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:472.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:472.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:472.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:472.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:30.8pt"></span></span><span style="left:33.43pt;position:var(--position)">(7)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:472.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">11,286<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:472.5pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">11,278<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:503.25pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.64pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: other </span></div><div style="line-height:8pt;position:var(--position);top:12.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">fair value remeasurement</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:503.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:503.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:503.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:503.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:503.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">36,002<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:503.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:503.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:503.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:503.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:503.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">36,002<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:524.25pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.64pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-cash changes: </span></div><div style="line-height:8pt;position:var(--position);top:12.24pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">conversion into shares</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:524.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:524.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:524.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:12.8pt"></span></span><span style="left:15.43pt;position:var(--position)">(24,354)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:524.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:524.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:12.8pt"></span></span><span style="left:15.43pt;position:var(--position)">(53,921)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:524.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:524.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:524.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:524.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:524.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.43pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:12.8pt"></span></span><span style="left:15.43pt;position:var(--position)">(78,275)</span></span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:545.25pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.81pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non cash changes: </span></div><div style="line-height:8pt;position:var(--position);top:12.81pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">additional leases</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:545.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:545.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:545.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:545.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:545.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:545.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:545.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:545.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.46pt"></span></span><span style="left:28.09pt;position:var(--position)">444<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:545.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:545.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:25.46pt"></span></span><span style="left:28.09pt;position:var(--position)">444<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:32.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:567pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.49pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non cash changes : Effect </span></div><div style="line-height:8pt;position:var(--position);top:13.49pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">of the change in foreign </span></div><div style="line-height:8pt;position:var(--position);top:23.49pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">currency exchange rates</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:567pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:13.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:567pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:13.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:567pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:13.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:567pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:13.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:567pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:13.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:567pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:13.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:567pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:13.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:567pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:13.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.8pt"></span></span><span style="left:29.43pt;position:var(--position)">(33)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:567pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:13.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:567pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:13.06pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:26.8pt"></span></span><span style="left:29.43pt;position:var(--position)">(33)</span></span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:599.25pt;width:96.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.52pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:13.12pt;width:96.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96.75pt;position:var(--position);top:599.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.87pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:143.25pt;position:var(--position);top:599.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.87pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:189.75pt;position:var(--position);top:599.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.87pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:236.25pt;position:var(--position);top:599.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.87pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282.75pt;position:var(--position);top:599.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.87pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:329.25pt;position:var(--position);top:599.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.87pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:599.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.87pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:29.46pt"></span></span><span style="left:32.09pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:422.25pt;position:var(--position);top:599.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.87pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:19.46pt"></span></span><span style="left:22.09pt;position:var(--position)">1,856<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:468.75pt;position:var(--position);top:599.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.87pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">30,237<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:515.25pt;position:var(--position);top:599.25pt;width:43.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.87pt;width:43.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:15.46pt"></span></span><span style="left:18.09pt;position:var(--position)">32,093<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfChangesInDerivativeFinancialInstrumentsTableTextBlock', window );">Disclosure of changes in derivative instruments</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Changes in derivative instruments, are presented below as of December 31, 2023, 2024 and 2025 :</span><div style="position:var(--position);top:326.91pt;width:612pt"><div style="font-size:0pt;left:44pt;position:var(--position);width:534.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:96pt"></td><td style="padding:0;width:69.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:69.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:69.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:69.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:69.75pt"></td></tr><tr style="height:24.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:96pt"><div><div style="line-height:8pt;position:var(--position);top:4.5pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:7.68pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of </span></div><div style="line-height:8pt;position:var(--position);top:14.1pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:37.78pt;position:var(--position);text-decoration:none;white-space:pre">euros)</span></div></div></div></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12pt;position:var(--position);text-decoration:none;white-space:pre">Kreos A BSA</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.22pt;position:var(--position);text-decoration:none;white-space:pre">Kreos B BSA</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:19.57pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.78pt;position:var(--position);text-decoration:none;white-space:pre">OCEANE </span></div><div style="line-height:8pt;position:var(--position);top:29.17pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.56pt;position:var(--position);text-decoration:none;white-space:pre">conversion option</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);width:75pt"><div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.53pt;position:var(--position);text-decoration:none;white-space:pre">Kreos/Claret BSA</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.67pt;position:var(--position);text-decoration:none;white-space:pre">Kreos/Claret </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.01pt;position:var(--position);text-decoration:none;white-space:pre">Minimal Return </span></div><div style="line-height:8pt;position:var(--position);top:33.97pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.01pt;position:var(--position);text-decoration:none;white-space:pre">Indemnifications</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:25.77pt;position:var(--position);text-decoration:none;white-space:pre">Total </span></div></div></div></td></tr><tr style="height:30pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:24.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.4pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DERIVATIVE </span></div><div style="line-height:8pt;position:var(--position);top:12pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">FINANCIAL </span></div><div style="line-height:8pt;position:var(--position);top:21.6pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">INSTRUMENTS</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY 1, 2023</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:54.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.71pt"></span></span><span style="left:54.34pt;position:var(--position)">275<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:54.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.71pt"></span></span><span style="left:54.34pt;position:var(--position)">149<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:54.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.71pt"></span></span><span style="left:54.34pt;position:var(--position)">142<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:54.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:54.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:51.71pt"></span></span><span style="left:54.34pt;position:var(--position)">566<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:75.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(+) Issuance</span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:75.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:75.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:75.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:75.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">3,585<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:75.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:75.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)">3,585<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:87.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(+) Increase in fair value</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:87.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.71pt"></span></span><span style="left:54.34pt;position:var(--position)">986<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:87.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:51.71pt"></span></span><span style="left:54.34pt;position:var(--position)">440<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:87.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)">1,620<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:87.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:87.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:87.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)">3,046<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:99.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(-) Decrease in fair value</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:99.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:99.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:99.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:99.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(1,006)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:99.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:99.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:43.05pt"></span></span><span style="left:45.68pt;position:var(--position)">(1,006)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:111.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(-) Repurchases</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:111.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:49.05pt"></span></span><span style="left:51.68pt;position:var(--position)">(489)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:111.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:49.05pt"></span></span><span style="left:51.68pt;position:var(--position)">(339)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:111.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:43.05pt"></span></span><span style="left:45.68pt;position:var(--position)">(1,762)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:111.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:111.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:111.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:43.05pt"></span></span><span style="left:45.68pt;position:var(--position)">(2,591)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:123.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(-) Exercises</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:123.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:49.05pt"></span></span><span style="left:51.68pt;position:var(--position)">(771)</span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:123.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:49.05pt"></span></span><span style="left:51.68pt;position:var(--position)">(250)</span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:123.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:123.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:123.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:123.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:43.05pt"></span></span><span style="left:45.68pt;position:var(--position)">(1,021)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:135.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:135.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:135.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:135.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:135.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">2,579<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:135.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:135.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)">2,579<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:156.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(+) Issuance</span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:156.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:156.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:156.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:156.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:156.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)">2,158<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:156.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)">2,158<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:168.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(+) Increase in fair value</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:168.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:168.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:168.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:168.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:168.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)">1,462<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:168.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)">1,462<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:180.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(-) Decrease in fair value</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:180.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:180.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:180.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:180.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(1,413)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:180.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:180.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:43.05pt"></span></span><span style="left:45.68pt;position:var(--position)">(1,413)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:192.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:192.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:192.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:192.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:192.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">1,166<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:192.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)">3,620<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:192.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)">4,786<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:213.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(+) Increase in fair value</span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:213.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:213.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:213.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:213.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">29,935<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:213.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:213.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.71pt"></span></span><span style="left:44.34pt;position:var(--position)">29,935<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:225.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(-) Decrease in fair value</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:225.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:225.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:225.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:225.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:225.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:43.05pt"></span></span><span style="left:45.68pt;position:var(--position)">(3,620)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:225.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:43.05pt"></span></span><span style="left:45.68pt;position:var(--position)">(3,620)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:237.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(-) Repurchases</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:237.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:237.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:237.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:237.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(4,427)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:237.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:237.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:43.05pt"></span></span><span style="left:45.68pt;position:var(--position)">(4,427)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:249.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(-) Exercises</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:249.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:249.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:249.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:249.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.3pt"></span></span><span style="left:46.93pt;position:var(--position)">(26,674)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:249.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:249.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.05pt"></span></span><span style="left:41.68pt;position:var(--position)">(26,674)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:261.75pt;width:96pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:96pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:96pt;position:var(--position);top:261.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:168.75pt;position:var(--position);top:261.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:261.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:314.25pt;position:var(--position);top:261.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:392.25pt;position:var(--position);top:261.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:465pt;position:var(--position);top:261.75pt;width:69.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:69.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:55.71pt"></span></span><span style="left:58.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities', window );">Disclosure of remaining contractual maturities of derivative financial liabilities</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The following are the remaining contractual maturities of financial liabilities as of December 31, 2023, 2024 and 2025. The amounts </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:107.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">are gross and undiscounted, and include contractual interest payments. </span></div><div style="position:var(--position);top:128.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:543pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:147pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:69pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:60.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:59.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63pt"></td></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:147pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.88pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td colspan="11" style="font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);width:393pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:393pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:145.75pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2023</span></div></div></div></td></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">CURRENT AND NON-CURRENT </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">FINANCIAL LIABILITIES</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:21pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.95pt;position:var(--position);text-decoration:none;white-space:pre">GROSS </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.29pt;position:var(--position);text-decoration:none;white-space:pre">AMOUNT </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:21pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.2pt;position:var(--position);text-decoration:none;white-space:pre">CONTRACTUAL </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.96pt;position:var(--position);text-decoration:none;white-space:pre">CASH FLOWS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:21pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.18pt;position:var(--position);text-decoration:none;white-space:pre">LESS THAN 1 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.18pt;position:var(--position);text-decoration:none;white-space:pre">YEAR</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:21pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.39pt;position:var(--position);text-decoration:none;white-space:pre">FROM 1 TO 2 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.83pt;position:var(--position);text-decoration:none;white-space:pre">YEARS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:21pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.64pt;position:var(--position);text-decoration:none;white-space:pre">FROM 2 TO 5 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.08pt;position:var(--position);text-decoration:none;white-space:pre">YEARS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:21pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:5.17pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.18pt;position:var(--position);text-decoration:none;white-space:pre">LONGER </span></div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.95pt;position:var(--position);text-decoration:none;white-space:pre">THAN 5 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.96pt;position:var(--position);text-decoration:none;white-space:pre">YEARS </span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Heights convertible notes</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:54pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.37pt;position:var(--position);text-decoration:none;white-space:pre">29,605</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:54pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.96pt"></span></span><span style="left:43.59pt;position:var(--position)">36,750<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:54pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:34.96pt"></span></span><span style="left:37.59pt;position:var(--position)">10,522<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:54pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.71pt"></span></span><span style="left:39.34pt;position:var(--position)">9,997<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:54pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:31.21pt"></span></span><span style="left:33.84pt;position:var(--position)">16,231<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:54pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos/Claret convertible notes (OCABSA)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:66pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.37pt;position:var(--position);text-decoration:none;white-space:pre">21,643</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:66pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.96pt"></span></span><span style="left:43.59pt;position:var(--position)">30,903<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:66pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)">2,250<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:66pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.71pt"></span></span><span style="left:39.34pt;position:var(--position)">2,250<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:66pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:31.21pt"></span></span><span style="left:33.84pt;position:var(--position)">26,403<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:66pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">PGE</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:78pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:42.37pt;position:var(--position);text-decoration:none;white-space:pre">3,678</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:78pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">3,880<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:78pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)">1,293<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:78pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.71pt"></span></span><span style="left:39.34pt;position:var(--position)">1,293<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:78pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.21pt"></span></span><span style="left:37.84pt;position:var(--position)">1,293<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:78pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Conditional advances Bpifrance</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:90pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:42.37pt;position:var(--position);text-decoration:none;white-space:pre">6,771</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:90pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">6,813<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:90pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)">3,697<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:90pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.71pt"></span></span><span style="left:39.34pt;position:var(--position)">1,490<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:90pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.21pt"></span></span><span style="left:37.84pt;position:var(--position)">1,626<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:90pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Royalty certificates</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:102pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.37pt;position:var(--position);text-decoration:none;white-space:pre">12,229</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:102pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.96pt"></span></span><span style="left:57.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:102pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:102pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.71pt"></span></span><span style="left:49.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:102pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.21pt"></span></span><span style="left:47.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:102pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:114pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Lease liabilities</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:114pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:48.37pt;position:var(--position);text-decoration:none;white-space:pre">540</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:114pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">575<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:114pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">406<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:114pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.71pt"></span></span><span style="left:45.34pt;position:var(--position)">162<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:114pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:49.21pt"></span></span><span style="left:51.84pt;position:var(--position)">7<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:114pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:126pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Derivative instruments</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:126pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:42.37pt;position:var(--position);text-decoration:none;white-space:pre">2,579</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:126pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">2,579<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:126pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)">2,579<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:126pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.71pt"></span></span><span style="left:49.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:126pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.21pt"></span></span><span style="left:47.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:126pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:138pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial liabilities </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:138pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:38.37pt;position:var(--position);text-decoration:none;white-space:pre">77,045</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:138pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.96pt"></span></span><span style="left:43.59pt;position:var(--position)">81,500<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:138pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:34.96pt"></span></span><span style="left:37.59pt;position:var(--position)">20,747<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:138pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:32.71pt"></span></span><span style="left:35.34pt;position:var(--position)">15,192<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:138pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:31.21pt"></span></span><span style="left:33.84pt;position:var(--position)">45,561<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:138pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:295.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:543pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:142.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:69pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:60pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:62.25pt"></td></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.63pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td colspan="11" style="font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);width:397.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:397.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:187.09pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:397.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:160.66pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">CURRENT AND NON-CURRENT </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">FINANCIAL LIABILITIES</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:21pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.33pt;position:var(--position);text-decoration:none;white-space:pre">GROSS </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.67pt;position:var(--position);text-decoration:none;white-space:pre">AMOUNT </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:21pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.2pt;position:var(--position);text-decoration:none;white-space:pre">CONTRACTUAL </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.96pt;position:var(--position);text-decoration:none;white-space:pre">CASH FLOWS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:21pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.56pt;position:var(--position);text-decoration:none;white-space:pre">LESS THAN 1 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.55pt;position:var(--position);text-decoration:none;white-space:pre">YEAR</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:21pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.89pt;position:var(--position);text-decoration:none;white-space:pre">FROM 1 TO 2 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.33pt;position:var(--position);text-decoration:none;white-space:pre">YEARS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:21pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.01pt;position:var(--position);text-decoration:none;white-space:pre">FROM 2 TO 5 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.46pt;position:var(--position);text-decoration:none;white-space:pre">YEARS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:21pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.17pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.8pt;position:var(--position);text-decoration:none;white-space:pre">LONGER </span></div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.58pt;position:var(--position);text-decoration:none;white-space:pre">THAN 5 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.58pt;position:var(--position);text-decoration:none;white-space:pre">YEARS </span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Heights convertible notes</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:54pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">21,574<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:54pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.96pt"></span></span><span style="left:43.59pt;position:var(--position)">24,063<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:54pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)">8,750<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:54pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)">8,750<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:54pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.96pt"></span></span><span style="left:38.59pt;position:var(--position)">6,563<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:54pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:20.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.26pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos/Claret convertible notes </span></div><div style="line-height:8pt;position:var(--position);top:11.86pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(OCABSA)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:66pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.06pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">23,370<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:66pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:7.06pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.96pt"></span></span><span style="left:43.59pt;position:var(--position)">30,653<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:66pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.06pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)">2,250<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:66pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.06pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">19,943<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:66pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.06pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.96pt"></span></span><span style="left:38.59pt;position:var(--position)">8,460<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:66pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.06pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:86.25pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos/Claret bond loans</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:86.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">46,401<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:86.25pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.96pt"></span></span><span style="left:43.59pt;position:var(--position)">58,080<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:86.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">24,016<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:86.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">25,715<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:86.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.96pt"></span></span><span style="left:38.59pt;position:var(--position)">8,348<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:86.25pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:98.25pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">PGE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:98.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)">2,488<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:98.25pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">2,586<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:98.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)">1,293<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:98.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)">1,293<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:98.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.96pt"></span></span><span style="left:48.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:98.25pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:110.25pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Royalty certificates (1)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:110.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">13,023<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:110.25pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.96pt"></span></span><span style="left:57.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:110.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:49.71pt"></span></span><span style="left:52.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:110.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:49.71pt"></span></span><span style="left:52.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:110.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.96pt"></span></span><span style="left:48.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:110.25pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:122.25pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Lease liabilities</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:122.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)">2,363<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:122.25pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">2,512<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:122.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)">993<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:122.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)">996<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:122.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.96pt"></span></span><span style="left:44.59pt;position:var(--position)">516<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:122.25pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">7<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:134.25pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Derivative instruments</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:134.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)">4,786<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:134.25pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">4,786<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:134.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)">1,166<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:134.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:49.71pt"></span></span><span style="left:52.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:134.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.96pt"></span></span><span style="left:38.59pt;position:var(--position)">3,620<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:134.25pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:146.25pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial liabilities </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:146.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:31.71pt"></span></span><span style="left:34.34pt;position:var(--position)">114,004<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:146.25pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">122,680<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:146.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">38,468<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:146.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">56,698<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:146.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:31.96pt"></span></span><span style="left:34.59pt;position:var(--position)">27,507<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:146.25pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">7<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:470.81pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:543pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:141.75pt"></td><td style="padding:0;width:63pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:71.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63pt"></td></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:141.75pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:141.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.25pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td colspan="11" style="font-size:0;text-align:left;vertical-align:top"><div style="left:141.75pt;position:var(--position);width:401.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:401.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:149.88pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2025</span></div></div></div></td></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21pt;width:141.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:141.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">CURRENT AND NON-CURRENT </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:141.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">FINANCIAL LIABILITIES</span></div></div></div></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:141.75pt;position:var(--position);top:21pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.95pt;position:var(--position);text-decoration:none;white-space:pre">GROSS </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.29pt;position:var(--position);text-decoration:none;white-space:pre">AMOUNT </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:207.75pt;position:var(--position);top:21pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.32pt;position:var(--position);text-decoration:none;white-space:pre">CONTRACTUAL </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.09pt;position:var(--position);text-decoration:none;white-space:pre">CASH FLOWS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:282pt;position:var(--position);top:21pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.18pt;position:var(--position);text-decoration:none;white-space:pre">LESS THAN 1 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.18pt;position:var(--position);text-decoration:none;white-space:pre">YEAR</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:348pt;position:var(--position);top:21pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.51pt;position:var(--position);text-decoration:none;white-space:pre">FROM 1 TO 2 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.96pt;position:var(--position);text-decoration:none;white-space:pre">YEARS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:414pt;position:var(--position);top:21pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.51pt;position:var(--position);text-decoration:none;white-space:pre">FROM 2 TO 5 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.96pt;position:var(--position);text-decoration:none;white-space:pre">YEARS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:21pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:5.17pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.18pt;position:var(--position);text-decoration:none;white-space:pre">LONGER </span></div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.95pt;position:var(--position);text-decoration:none;white-space:pre">THAN 5 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.96pt;position:var(--position);text-decoration:none;white-space:pre">YEARS </span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66pt;width:141.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:141.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Royalty certificates</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:141.75pt;position:var(--position);top:66pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:34.96pt"></span></span><span style="left:37.59pt;position:var(--position)">30,237<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:207.75pt;position:var(--position);top:66pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:57.21pt"></span></span><span style="left:59.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282pt;position:var(--position);top:66pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:348pt;position:var(--position);top:66pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:414pt;position:var(--position);top:66pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:66pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78pt;width:141.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:141.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Lease liabilities</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:141.75pt;position:var(--position);top:78pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)">1,856<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:207.75pt;position:var(--position);top:78pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)">1,906<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282pt;position:var(--position);top:78pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)">1,340<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:348pt;position:var(--position);top:78pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">450<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:414pt;position:var(--position);top:78pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">116<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:78pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90.75pt;width:141.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:141.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial liabilities </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:141.75pt;position:var(--position);top:90.75pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:34.96pt"></span></span><span style="left:37.59pt;position:var(--position)">32,093<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:207.75pt;position:var(--position);top:90.75pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)">1,906<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282pt;position:var(--position);top:90.75pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)">1,340<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:348pt;position:var(--position);top:90.75pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">450<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:414pt;position:var(--position);top:90.75pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">116<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:90.75pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities', window );">Disclosure of remaining contractual maturities of non-derivative financial liabilities</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The following are the remaining contractual maturities of financial liabilities as of December 31, 2023, 2024 and 2025. The amounts </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:107.06pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">are gross and undiscounted, and include contractual interest payments. </span></div><div style="position:var(--position);top:128.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:543pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:147pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:69pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:60.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:59.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63pt"></td></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:147pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.88pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td colspan="11" style="font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);width:393pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:393pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:145.75pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2023</span></div></div></div></td></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">CURRENT AND NON-CURRENT </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">FINANCIAL LIABILITIES</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:21pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.95pt;position:var(--position);text-decoration:none;white-space:pre">GROSS </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.29pt;position:var(--position);text-decoration:none;white-space:pre">AMOUNT </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:21pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.2pt;position:var(--position);text-decoration:none;white-space:pre">CONTRACTUAL </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.96pt;position:var(--position);text-decoration:none;white-space:pre">CASH FLOWS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:21pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.18pt;position:var(--position);text-decoration:none;white-space:pre">LESS THAN 1 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.18pt;position:var(--position);text-decoration:none;white-space:pre">YEAR</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:21pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.39pt;position:var(--position);text-decoration:none;white-space:pre">FROM 1 TO 2 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.83pt;position:var(--position);text-decoration:none;white-space:pre">YEARS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:21pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.64pt;position:var(--position);text-decoration:none;white-space:pre">FROM 2 TO 5 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.08pt;position:var(--position);text-decoration:none;white-space:pre">YEARS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:21pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:5.17pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.18pt;position:var(--position);text-decoration:none;white-space:pre">LONGER </span></div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.95pt;position:var(--position);text-decoration:none;white-space:pre">THAN 5 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.96pt;position:var(--position);text-decoration:none;white-space:pre">YEARS </span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Heights convertible notes</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:54pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.37pt;position:var(--position);text-decoration:none;white-space:pre">29,605</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:54pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.96pt"></span></span><span style="left:43.59pt;position:var(--position)">36,750<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:54pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:34.96pt"></span></span><span style="left:37.59pt;position:var(--position)">10,522<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:54pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.71pt"></span></span><span style="left:39.34pt;position:var(--position)">9,997<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:54pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:31.21pt"></span></span><span style="left:33.84pt;position:var(--position)">16,231<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:54pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos/Claret convertible notes (OCABSA)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:66pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.37pt;position:var(--position);text-decoration:none;white-space:pre">21,643</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:66pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.96pt"></span></span><span style="left:43.59pt;position:var(--position)">30,903<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:66pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)">2,250<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:66pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.71pt"></span></span><span style="left:39.34pt;position:var(--position)">2,250<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:66pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:31.21pt"></span></span><span style="left:33.84pt;position:var(--position)">26,403<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:66pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">PGE</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:78pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:42.37pt;position:var(--position);text-decoration:none;white-space:pre">3,678</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:78pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">3,880<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:78pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)">1,293<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:78pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.71pt"></span></span><span style="left:39.34pt;position:var(--position)">1,293<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:78pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.21pt"></span></span><span style="left:37.84pt;position:var(--position)">1,293<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:78pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Conditional advances Bpifrance</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:90pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:42.37pt;position:var(--position);text-decoration:none;white-space:pre">6,771</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:90pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">6,813<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:90pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)">3,697<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:90pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:36.71pt"></span></span><span style="left:39.34pt;position:var(--position)">1,490<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:90pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.21pt"></span></span><span style="left:37.84pt;position:var(--position)">1,626<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:90pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Royalty certificates</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:102pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:38.37pt;position:var(--position);text-decoration:none;white-space:pre">12,229</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:102pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.96pt"></span></span><span style="left:57.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:102pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:102pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.71pt"></span></span><span style="left:49.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:102pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.21pt"></span></span><span style="left:47.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:102pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:114pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Lease liabilities</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:114pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:48.37pt;position:var(--position);text-decoration:none;white-space:pre">540</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:114pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">575<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:114pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">406<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:114pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:42.71pt"></span></span><span style="left:45.34pt;position:var(--position)">162<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:114pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:49.21pt"></span></span><span style="left:51.84pt;position:var(--position)">7<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:114pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:126pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Derivative instruments</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:126pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:42.37pt;position:var(--position);text-decoration:none;white-space:pre">2,579</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:126pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">2,579<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:126pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)">2,579<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:126pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.71pt"></span></span><span style="left:49.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:126pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.21pt"></span></span><span style="left:47.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:126pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:138pt;width:147pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:147pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial liabilities </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:150pt;position:var(--position);top:138pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:38.37pt;position:var(--position);text-decoration:none;white-space:pre">77,045</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:216pt;position:var(--position);top:138pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.96pt"></span></span><span style="left:43.59pt;position:var(--position)">81,500<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:288pt;position:var(--position);top:138pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:34.96pt"></span></span><span style="left:37.59pt;position:var(--position)">20,747<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:354pt;position:var(--position);top:138pt;width:60.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:60.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:32.71pt"></span></span><span style="left:35.34pt;position:var(--position)">15,192<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:138pt;width:59.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:59.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:31.21pt"></span></span><span style="left:33.84pt;position:var(--position)">45,561<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:138pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:295.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:543pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:142.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:69pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:60pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:62.25pt"></td></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.63pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td colspan="11" style="font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);width:397.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:397.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:187.09pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:397.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:160.66pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">CURRENT AND NON-CURRENT </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">FINANCIAL LIABILITIES</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:21pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.33pt;position:var(--position);text-decoration:none;white-space:pre">GROSS </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.67pt;position:var(--position);text-decoration:none;white-space:pre">AMOUNT </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:21pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.2pt;position:var(--position);text-decoration:none;white-space:pre">CONTRACTUAL </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.96pt;position:var(--position);text-decoration:none;white-space:pre">CASH FLOWS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:21pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.56pt;position:var(--position);text-decoration:none;white-space:pre">LESS THAN 1 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.55pt;position:var(--position);text-decoration:none;white-space:pre">YEAR</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:21pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.89pt;position:var(--position);text-decoration:none;white-space:pre">FROM 1 TO 2 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.33pt;position:var(--position);text-decoration:none;white-space:pre">YEARS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:21pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.01pt;position:var(--position);text-decoration:none;white-space:pre">FROM 2 TO 5 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.46pt;position:var(--position);text-decoration:none;white-space:pre">YEARS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:21pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.17pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.8pt;position:var(--position);text-decoration:none;white-space:pre">LONGER </span></div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.58pt;position:var(--position);text-decoration:none;white-space:pre">THAN 5 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.58pt;position:var(--position);text-decoration:none;white-space:pre">YEARS </span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Heights convertible notes</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:54pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">21,574<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:54pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.96pt"></span></span><span style="left:43.59pt;position:var(--position)">24,063<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:54pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)">8,750<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:54pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)">8,750<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:54pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.96pt"></span></span><span style="left:38.59pt;position:var(--position)">6,563<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:54pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:20.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.26pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos/Claret convertible notes </span></div><div style="line-height:8pt;position:var(--position);top:11.86pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(OCABSA)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:66pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.06pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">23,370<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:66pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:7.06pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.96pt"></span></span><span style="left:43.59pt;position:var(--position)">30,653<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:66pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.06pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)">2,250<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:66pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.06pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">19,943<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:66pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:7.06pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.96pt"></span></span><span style="left:38.59pt;position:var(--position)">8,460<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:66pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.06pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:86.25pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Kreos/Claret bond loans</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:86.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">46,401<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:86.25pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:40.96pt"></span></span><span style="left:43.59pt;position:var(--position)">58,080<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:86.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">24,016<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:86.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">25,715<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:86.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.96pt"></span></span><span style="left:38.59pt;position:var(--position)">8,348<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:86.25pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:98.25pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">PGE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:98.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)">2,488<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:98.25pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">2,586<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:98.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)">1,293<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:98.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)">1,293<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:98.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.96pt"></span></span><span style="left:48.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:98.25pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:110.25pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Royalty certificates (1)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:110.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">13,023<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:110.25pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.96pt"></span></span><span style="left:57.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:110.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:49.71pt"></span></span><span style="left:52.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:110.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:49.71pt"></span></span><span style="left:52.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:110.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.96pt"></span></span><span style="left:48.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:110.25pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:122.25pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Lease liabilities</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:122.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)">2,363<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:122.25pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">2,512<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:122.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)">993<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:122.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:45.71pt"></span></span><span style="left:48.34pt;position:var(--position)">996<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:122.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:41.96pt"></span></span><span style="left:44.59pt;position:var(--position)">516<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:122.25pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">7<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:134.25pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Derivative instruments</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:134.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)">4,786<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:134.25pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">4,786<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:134.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:39.71pt"></span></span><span style="left:42.34pt;position:var(--position)">1,166<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:134.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:49.71pt"></span></span><span style="left:52.34pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:134.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:35.96pt"></span></span><span style="left:38.59pt;position:var(--position)">3,620<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:134.25pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:146.25pt;width:142.5pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:142.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial liabilities </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:145.5pt;position:var(--position);top:146.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:31.71pt"></span></span><span style="left:34.34pt;position:var(--position)">114,004<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:212.25pt;position:var(--position);top:146.25pt;width:69pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:69pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:36.96pt"></span></span><span style="left:39.59pt;position:var(--position)">122,680<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:284.25pt;position:var(--position);top:146.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">38,468<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:351pt;position:var(--position);top:146.25pt;width:63.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:35.71pt"></span></span><span style="left:38.34pt;position:var(--position)">56,698<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:417.75pt;position:var(--position);top:146.25pt;width:60pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:60pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:31.96pt"></span></span><span style="left:34.59pt;position:var(--position)">27,507<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:480.75pt;position:var(--position);top:146.25pt;width:62.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:62.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">7<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="position:var(--position);top:470.81pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:543pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:141.75pt"></td><td style="padding:0;width:63pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:71.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:63pt"></td></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:141.75pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:141.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.25pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td colspan="11" style="font-size:0;text-align:left;vertical-align:top"><div style="left:141.75pt;position:var(--position);width:401.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:401.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:149.88pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, 2025</span></div></div></div></td></tr><tr style="height:21pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:21pt;width:141.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:141.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">CURRENT AND NON-CURRENT </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:141.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">FINANCIAL LIABILITIES</span></div></div></div></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:141.75pt;position:var(--position);top:21pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.95pt;position:var(--position);text-decoration:none;white-space:pre">GROSS </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.29pt;position:var(--position);text-decoration:none;white-space:pre">AMOUNT </span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:207.75pt;position:var(--position);top:21pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.32pt;position:var(--position);text-decoration:none;white-space:pre">CONTRACTUAL </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.09pt;position:var(--position);text-decoration:none;white-space:pre">CASH FLOWS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:282pt;position:var(--position);top:21pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.18pt;position:var(--position);text-decoration:none;white-space:pre">LESS THAN 1 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:20.18pt;position:var(--position);text-decoration:none;white-space:pre">YEAR</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:348pt;position:var(--position);top:21pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.51pt;position:var(--position);text-decoration:none;white-space:pre">FROM 1 TO 2 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.96pt;position:var(--position);text-decoration:none;white-space:pre">YEARS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:414pt;position:var(--position);top:21pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.51pt;position:var(--position);text-decoration:none;white-space:pre">FROM 2 TO 5 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.96pt;position:var(--position);text-decoration:none;white-space:pre">YEARS</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td rowspan="2" style="font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:21pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:5.17pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.18pt;position:var(--position);text-decoration:none;white-space:pre">LONGER </span></div><div style="line-height:8pt;position:var(--position);top:14.77pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.95pt;position:var(--position);text-decoration:none;white-space:pre">THAN 5 </span></div><div style="line-height:8pt;position:var(--position);top:24.37pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.96pt;position:var(--position);text-decoration:none;white-space:pre">YEARS </span></div></div></div></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66pt;width:141.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:141.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Royalty certificates</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:141.75pt;position:var(--position);top:66pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:34.96pt"></span></span><span style="left:37.59pt;position:var(--position)">30,237<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:207.75pt;position:var(--position);top:66pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:57.21pt"></span></span><span style="left:59.84pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:282pt;position:var(--position);top:66pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:348pt;position:var(--position);top:66pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:414pt;position:var(--position);top:66pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:66pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78pt;width:141.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:141.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Lease liabilities</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:141.75pt;position:var(--position);top:78pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)">1,856<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:207.75pt;position:var(--position);top:78pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)">1,906<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282pt;position:var(--position);top:78pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)">1,340<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:348pt;position:var(--position);top:78pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">450<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:414pt;position:var(--position);top:78pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">116<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:78pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3.31pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90.75pt;width:141.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:141.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total financial liabilities </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:141.75pt;position:var(--position);top:90.75pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:34.96pt"></span></span><span style="left:37.59pt;position:var(--position)">32,093<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:207.75pt;position:var(--position);top:90.75pt;width:71.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:71.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:47.21pt"></span></span><span style="left:49.84pt;position:var(--position)">1,906<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:282pt;position:var(--position);top:90.75pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:38.96pt"></span></span><span style="left:41.59pt;position:var(--position)">1,340<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:348pt;position:var(--position);top:90.75pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">450<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:414pt;position:var(--position);top:90.75pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:44.96pt"></span></span><span style="left:47.59pt;position:var(--position)">116<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:480pt;position:var(--position);top:90.75pt;width:63pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:63pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.96pt"></span></span><span style="left:51.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DisclosureOfChangesInDerivativeFinancialInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Changes In Derivative Financial Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DisclosureOfChangesInDerivativeFinancialInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DisclosureOfIndirectMeasurementOfConvertibleLoansInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DisclosureOfIndirectMeasurementOfConvertibleLoansInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DisclosureOfLeasesForLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Leases For Lessee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DisclosureOfLeasesForLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBorrowingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBorrowingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 43<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_43&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 43<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_43&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's other equity instruments (ie other than share options).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the reconciliation of liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 44D<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_44D&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 166<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_166&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 166<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_166&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a maturity analysis for derivative financial liabilities, including the remaining contractual maturities for those derivative financial liabilities for which contractual maturities are essential for an understanding of the timing of the cash flows. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 39<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_39_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 72<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_72_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 72<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_72_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 72<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_72_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 39<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_39_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 72<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_72_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement benefit obligations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract', window );"><strong>Disclosure of defined benefit plans [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory', window );">Disclosure of main actuarial assumptions used to measure the retirement benefit obligations</a></td>
<td class="text"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:239.28pt;position:var(--position);text-decoration:none;white-space:pre">The main actuarial assumptions used to measure the retirement benefit </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.36pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:42pt;position:var(--position);text-decoration:none;white-space:pre">obligations are as follows:</span></div><div style="position:var(--position);top:150.36pt;width:612pt"><div style="font-size:0pt;left:42pt;position:var(--position);width:480.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:159.75pt"></td><td style="padding:0;width:105pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:105pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:105pt"></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:159.75pt"><div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:159.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">ACTUARIAL ASSUMPTIONS</span></div></div></div></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:159.75pt;position:var(--position);width:105pt"><div><div style="line-height:8pt;position:var(--position);top:7.57pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.19pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:17.17pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);width:105pt"><div><div style="line-height:8pt;position:var(--position);top:7.57pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.19pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:17.17pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);width:105pt"><div><div style="line-height:8pt;position:var(--position);top:7.57pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:26.19pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:17.17pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td></tr><tr style="height:30.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:30.75pt;width:159.75pt"><div><div style="line-height:8pt;position:var(--position);top:12.31pt;width:159.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Retirement age</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:159.75pt;position:var(--position);top:30.75pt;width:105pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:7.51pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:3.09pt;position:var(--position);text-decoration:none;white-space:pre">65 years</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:29.96pt;position:var(--position);text-decoration:none;white-space:pre"> for key management / </span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:17.11pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:6.09pt;position:var(--position);text-decoration:none;white-space:pre">63 years</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:32.96pt;position:var(--position);text-decoration:none;white-space:pre"> for other employees</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:30.75pt;width:105pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:7.51pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:3.09pt;position:var(--position);text-decoration:none;white-space:pre">65 years</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:29.96pt;position:var(--position);text-decoration:none;white-space:pre"> for key management / </span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:17.11pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:6.09pt;position:var(--position);text-decoration:none;white-space:pre">64 years</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:32.96pt;position:var(--position);text-decoration:none;white-space:pre"> for other employees</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:30.75pt;width:105pt"><div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:7.51pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:3.09pt;position:var(--position);text-decoration:none;white-space:pre">65 years</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:29.96pt;position:var(--position);text-decoration:none;white-space:pre"> for key management / </span></div><div style="font-size:12pt;line-height:8pt;position:var(--position);top:17.11pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:6.09pt;position:var(--position);text-decoration:none;white-space:pre">64 years</span><span style="font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:32.96pt;position:var(--position);text-decoration:none;white-space:pre"> for other employees</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:61.5pt;width:159.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:159.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Collective agreement</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:159.75pt;position:var(--position);top:61.5pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:13.75pt;position:var(--position);text-decoration:none;white-space:pre">Pharmaceutical&#160;industry</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:61.5pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:13.75pt;position:var(--position);text-decoration:none;white-space:pre">Pharmaceutical&#160;industry</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:61.5pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:13.75pt;position:var(--position);text-decoration:none;white-space:pre">Pharmaceutical&#160;industry</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:73.5pt;width:159.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:159.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Discount Rate (IBoxx Corporates AA)</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:159.75pt;position:var(--position);top:73.5pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:43.11pt;position:var(--position);text-decoration:none;white-space:pre">0.90%</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:73.5pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:43.11pt;position:var(--position);text-decoration:none;white-space:pre">3.34%</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:73.5pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:43.11pt;position:var(--position);text-decoration:none;white-space:pre">3.70%</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:85.5pt;width:159.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:159.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Mortality rate table</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:159.75pt;position:var(--position);top:85.5pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:22.85pt;position:var(--position);text-decoration:none;white-space:pre">INSEE 2016-2018 </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:85.5pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:22.85pt;position:var(--position);text-decoration:none;white-space:pre">INSEE 2016-2018 </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:85.5pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:22.85pt;position:var(--position);text-decoration:none;white-space:pre">INSEE 2016-2018 </span></div></div></div></td></tr><tr style="height:42pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:97.5pt;width:159.75pt"><div><div style="line-height:8pt;position:var(--position);top:17.93pt;width:159.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Salary increase rate</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:159.75pt;position:var(--position);top:97.5pt;width:105pt"><div><div style="font-size:12pt;line-height:9pt;position:var(--position);top:11.85pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:6.04pt;position:var(--position);text-decoration:none;white-space:pre">3%</span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:18.03pt;position:var(--position);white-space:pre"> for key management / </span></div><div style="font-size:12pt;line-height:9pt;position:var(--position);top:23.1pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:3.79pt;position:var(--position);text-decoration:none;white-space:pre">2.55%</span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.029999999999998pt;position:var(--position);white-space:pre"> for other employees</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:97.5pt;width:105pt"><div><div style="font-size:12pt;line-height:9pt;position:var(--position);top:11.85pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:6.04pt;position:var(--position);text-decoration:none;white-space:pre">3%</span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:18.03pt;position:var(--position);white-space:pre"> for key management / </span></div><div style="font-size:12pt;line-height:9pt;position:var(--position);top:23.1pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:3.79pt;position:var(--position);text-decoration:none;white-space:pre">2.55%</span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:27.029999999999998pt;position:var(--position);white-space:pre"> for other employees</span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:97.5pt;width:105pt"><div><div style="line-height:9pt;position:var(--position);top:17.47pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:41.82pt;position:var(--position);text-decoration:none;white-space:pre">3.00%</span></div></div></div></td></tr><tr style="height:56.25pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:139.5pt;width:159.75pt"><div><div style="line-height:8pt;position:var(--position);top:25.06pt;width:159.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Turnover rate</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:159.75pt;position:var(--position);top:139.5pt;width:105pt"><div><div style="font-size:12pt;line-height:9pt;position:var(--position);top:13.35pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:5.3pt;position:var(--position);white-space:pre">Decreasing from </span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:67.72pt;position:var(--position);text-decoration:none;white-space:pre">5.80%</span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:90.96pt;position:var(--position);white-space:pre"> at </span></div><div style="font-size:12pt;line-height:9pt;position:var(--position);top:24.6pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:2.91pt;position:var(--position);white-space:pre">20 years-old to </span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:59.120000000000005pt;position:var(--position);text-decoration:none;white-space:pre">0.05%</span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:82.36pt;position:var(--position);white-space:pre"> from </span></div><div style="line-height:9pt;position:var(--position);top:35.85pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:30.14pt;position:var(--position);white-space:pre">55 years-old</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:139.5pt;width:105pt"><div><div style="line-height:9pt;position:var(--position);top:7.72pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:9.68pt;position:var(--position);white-space:pre">Decreasing rates by age </span></div><div style="font-size:12pt;line-height:9pt;position:var(--position);top:18.97pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:13.16pt;position:var(--position);white-space:pre">and </span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:28.4pt;position:var(--position);text-decoration:none;white-space:pre">zero</span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:43.870000000000005pt;position:var(--position);white-space:pre"> from age 55, </span></div><div style="line-height:9pt;position:var(--position);top:30.22pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:5.18pt;position:var(--position);white-space:pre">generating an average exit </span></div><div style="font-size:12pt;line-height:9pt;position:var(--position);top:41.47pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:11.66pt;position:var(--position);white-space:pre">rate for 2025 of </span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:70.1pt;position:var(--position);text-decoration:none;white-space:pre">2.05%</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:139.5pt;width:105pt"><div><div style="line-height:9pt;position:var(--position);top:7.72pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:9.68pt;position:var(--position);white-space:pre">Decreasing rates by age </span></div><div style="font-size:12pt;line-height:9pt;position:var(--position);top:18.97pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:13.16pt;position:var(--position);white-space:pre">and </span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:28.4pt;position:var(--position);text-decoration:none;white-space:pre">zero</span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:43.870000000000005pt;position:var(--position);white-space:pre"> from age 55, </span></div><div style="line-height:9pt;position:var(--position);top:30.22pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:5.18pt;position:var(--position);white-space:pre">generating an average exit </span></div><div style="font-size:12pt;line-height:9pt;position:var(--position);top:41.47pt;width:105pt"><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:10.53pt;position:var(--position);white-space:pre">rate for 2025 of </span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:68.97pt;position:var(--position);text-decoration:none;white-space:pre">2.02%</span><span style="font-family:'Times New Roman', serif;font-size:9pt;font-style:normal;font-weight:normal;left:92.21000000000001pt;position:var(--position);white-space:pre">.</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:195.75pt;width:159.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:159.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Employee contribution rate</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:159.75pt;position:var(--position);top:195.75pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.11pt;position:var(--position);text-decoration:none;white-space:pre">45%</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:267.75pt;position:var(--position);top:195.75pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.11pt;position:var(--position);text-decoration:none;white-space:pre">45%</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:375.75pt;position:var(--position);top:195.75pt;width:105pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:105pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:46.11pt;position:var(--position);text-decoration:none;white-space:pre">45%</span></div></div></div></td></tr></tbody></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory', window );">Disclosure of changes in projected benefit obligation</a></td>
<td class="text"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:42pt;position:var(--position);text-decoration:none;white-space:pre">Changes in the projected benefit obligation for the periods presented were as follows:</span><div style="font-size:12pt;line-height:11pt;position:var(--position);top:393.71pt;width:612pt"><span style="font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="position:var(--position);top:402.51pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:321.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:153.75pt"></td><td style="padding:0;width:168pt"></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:39.67pt;position:var(--position);text-decoration:none;white-space:pre">(In thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);width:168pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.72pt;position:var(--position);text-decoration:none;white-space:pre">RETIREMENT BENEFIT OBLIGATIONS</span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">JANUARY 1, 2023</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:12pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:149.96pt"></span></span><span style="left:152.59pt;position:var(--position)">610<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:33pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Service cost </span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:33pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:149.96pt"></span></span><span style="left:152.59pt;position:var(--position)">109<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:11.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:45pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.56pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest cost </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:45pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:2.56pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:153.96pt"></span></span><span style="left:156.59pt;position:var(--position)">23<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:56.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Actuarial gains and losses </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:56.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:147.3pt"></span></span><span style="left:149.93pt;position:var(--position)">(112)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:68.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:68.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:149.96pt"></span></span><span style="left:152.59pt;position:var(--position)">629<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:89.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Service cost </span></div></div></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:89.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:149.96pt"></span></span><span style="left:152.59pt;position:var(--position)">115<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:101.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest cost </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:101.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:153.96pt"></span></span><span style="left:156.59pt;position:var(--position)">22<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:113.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Benefits paid</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:113.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:151.3pt"></span></span><span style="left:153.93pt;position:var(--position)">(41)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:125.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Actuarial gains and losses </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:125.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:153.96pt"></span></span><span style="left:156.59pt;position:var(--position)">31<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:137.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:137.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:149.96pt"></span></span><span style="left:152.59pt;position:var(--position)">756<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:158.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Current service cost </span></div></div></div></td><td style="background-color:#cceeff;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:158.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:149.96pt"></span></span><span style="left:152.59pt;position:var(--position)">141<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:170.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Past services cost</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:170.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:147.3pt"></span></span><span style="left:149.93pt;position:var(--position)">(205)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:182.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest cost </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:182.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:153.96pt"></span></span><span style="left:156.59pt;position:var(--position)">29<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:194.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Actuarial gains and losses </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:194.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:151.3pt"></span></span><span style="left:153.93pt;position:var(--position)">(93)</span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:206.25pt;width:153.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:153.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:153.75pt;position:var(--position);top:206.25pt;width:168pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:168pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:149.96pt"></span></span><span style="left:152.59pt;position:var(--position)">627<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of defined benefit plans. [Refer: Defined benefit plans [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 138<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_138&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 204<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_204&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 204<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_204&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 140<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_140_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 206<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_206_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 206<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_206_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Payables and other current liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract', window );"><strong>Trade and other current payables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfBreakdownOfTradeAndOtherPayablesTableTextBlock', window );">Disclosure of breakdown of trade and other payables</a></td>
<td class="text"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:42pt;position:var(--position);text-decoration:none;white-space:pre">Trade payables and other current liabilities break down as follows:</span><div style="position:var(--position);top:84.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:447pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:200.25pt"></td><td style="padding:0;width:80.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:48.59pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:21pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">TRADE PAYABLES AND OTHER CURRENT </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">LIABILITIES</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:200.25pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:366.75pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:33pt;width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Trade payables </span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:200.25pt;position:var(--position);top:33pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">21,953<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:280.5pt;overflow:hidden;position:var(--position);top:33pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:33pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">30,748<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:363.75pt;overflow:hidden;position:var(--position);top:33pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:366.75pt;position:var(--position);top:33pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">23,388<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:45pt;width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Accrued invoices</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:200.25pt;position:var(--position);top:45pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">25,268<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:280.5pt;overflow:hidden;position:var(--position);top:45pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:45pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">13,049<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:363.75pt;overflow:hidden;position:var(--position);top:45pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:366.75pt;position:var(--position);top:45pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">14,159<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:57pt;width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:200.25pt;position:var(--position);top:57pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:280.5pt;overflow:hidden;position:var(--position);top:57pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:57pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)">26<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:363.75pt;overflow:hidden;position:var(--position);top:57pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:366.75pt;position:var(--position);top:57pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:70.21pt"></span></span><span style="left:72.83999999999999pt;position:var(--position)">4<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:69pt;width:200.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:200.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Trade payables and other current liabilities</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:200.25pt;position:var(--position);top:69pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">47,221<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:280.5pt;overflow:hidden;position:var(--position);top:69pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:283.5pt;position:var(--position);top:69pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">43,824<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:363.75pt;overflow:hidden;position:var(--position);top:69pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:-3.63pt;position:var(--position);text-decoration:none;white-space:pre">0</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:366.75pt;position:var(--position);top:69pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">37,552<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfTaxAndEmployeeRelatedPayablesExplanatoryTableTextBlock', window );">Disclosure of tax and employee-related payables</a></td>
<td class="text"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">Tax and employee-related payables are presented below:</span><div style="font-size:12pt;line-height:11pt;position:var(--position);top:268.2pt;width:612pt"><span style="font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre"> </span></div><div style="position:var(--position);top:279.53pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:441.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:195pt"></td><td style="padding:0;width:80.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:195pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:195pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:45.96pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:195pt"><div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:195pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">TAX AND EMPLOYEE-RELATED PAYABLES</span></div></div></div></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:195pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.92pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.52pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:278.25pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.92pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.52pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:361.5pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.92pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.52pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:195pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:195pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Employee-related payables</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:195pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.87pt"></span></span><span style="left:61.5pt;position:var(--position)">3,694</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:278.25pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.87pt"></span></span><span style="left:61.5pt;position:var(--position)">2,742</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:361.5pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">4,816<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:195pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:195pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Social security and other</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:195pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.87pt"></span></span><span style="left:61.5pt;position:var(--position)">2,251</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:278.25pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.87pt"></span></span><span style="left:61.5pt;position:var(--position)">1,783</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:361.5pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">2,304<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:195pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:195pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other tax and related payments</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:195pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:64.87pt"></span></span><span style="left:67.5pt;position:var(--position)">127</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:278.25pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:64.87pt"></span></span><span style="left:67.5pt;position:var(--position)">184</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:361.5pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)">17<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:195pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:195pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">TAX AND EMPLOYEE-RELATED PAYABLES</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:195pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:58.87pt"></span></span><span style="left:61.5pt;position:var(--position)">6,073</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:278.25pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:58.87pt"></span></span><span style="left:61.5pt;position:var(--position)">4,709</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:361.5pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">7,137<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DisclosureOfBreakdownOfTradeAndOtherPayablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Breakdown Of Trade And Other Payables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DisclosureOfBreakdownOfTradeAndOtherPayablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DisclosureOfTaxAndEmployeeRelatedPayablesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Tax And Employee-Related Payables Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DisclosureOfTaxAndEmployeeRelatedPayablesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other operating income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenue [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfDetailedInformationOfOperatingIncomeExplanatoryTableTextBlock', window );">Disclosure of breakdown of operating income</a></td>
<td class="text"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Other operating income is composed as below:</span><div style="font-size:12pt;position:var(--position);top:478.28pt;width:612pt"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"> </span><div style="font-size:0pt;left:38.5pt;position:var(--position);width:381pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:134.25pt"></td><td style="padding:0;width:80.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:15.59pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">OPERATING INCOME</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:134.25pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:300.75pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Research tax credit ("CIR")</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:134.25pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">4,493<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">6,651<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:300.75pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">3,061<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Subsidies</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:134.25pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)">81<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">4,140<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:300.75pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Depositary service fees</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:134.25pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">1,634<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:300.75pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">1,509<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:134.25pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)">47<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)">23<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:300.75pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90.75pt;width:134.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:134.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total operating income</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:134.25pt;position:var(--position);top:90.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">4,621<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:90.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">12,449<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:300.75pt;position:var(--position);top:90.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">4,570<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DisclosureOfDetailedInformationOfOperatingIncomeExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information Of Operating Income Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DisclosureOfDetailedInformationOfOperatingIncomeExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNatureAbstract', window );"><strong>Expenses by nature [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory', window );">Disclosure of expenses by nature</a></td>
<td class="text"><div style="font-size:0pt;left:36pt;position:var(--position);width:474pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:224.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:60.59pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">SALES AND MARKETING</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Personnel costs</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">1,710<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">2,323<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">3,347<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Consulting and professional fees </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:224.25pt;overflow:hidden;position:var(--position);top:54.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">4,012<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">2,699<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">1,623<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other sales and marketing expenses</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:224.25pt;overflow:hidden;position:var(--position);top:66.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)">709<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)">932<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)">224<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Sales &amp; Marketing</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:224.25pt;overflow:hidden;position:var(--position);top:78.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"></span><span style="left:2.63pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">6,431<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">5,954<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">5,194<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">Research and development expenses break down as follows: </span><div style="position:var(--position);top:70.56pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:474pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:224.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:60.59pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">RESEARCH AND DEVELOPMENT EXPENSES</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Sub-contracting, studies and research</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">85,726<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)">110,993<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)">112,033<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Personnel costs</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">8,048<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">18,455<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">49,616<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Consulting and professional fees </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">6,561<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">12,581<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">12,791<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Intellectual property fees</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">1,645<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">1,741<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">1,025<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other research and development expenses</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:90.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">1,196<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:90.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">2,761<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:90.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">2,297<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Research and development expenses </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:102.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)">103,176<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:102.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)">146,532<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:102.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.21pt"></span></span><span style="left:50.84pt;position:var(--position)">177,761<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div style="font-size:0pt;left:36pt;position:var(--position);width:474pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:224.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:60.59pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">GENERAL AND ADMINISTRATIVE EXPENSES</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Personnel costs</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">13,105<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">19,434<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">52,817<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Consulting and professional fees </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">6,393<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">7,990<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">9,984<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other general and administrative expenses </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">2,893<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">5,522<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">4,870<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:224.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:224.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">General and administrative expenses </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:227.25pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">22,391<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:310.5pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">32,946<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:393.75pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">67,670<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfPrincipalAuditFeesAndServicesTableTextBlock', window );">Disclosure of principal audit fees and services</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre">The Group's principal audit fees paid to its joint statutory auditors PricewaterhouseCoopers Audit and Agili3f, are set forth below:</span><div style="position:var(--position);top:303.76pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:524.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:275.25pt"></td><td style="padding:0;width:81pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:81pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:81pt"></td></tr><tr style="height:34.5pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:275.25pt"><div><div style="line-height:8pt;position:var(--position);top:14.18pt;width:275.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:86.09pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:275.25pt;position:var(--position);width:81pt"><div><div style="line-height:8pt;position:var(--position);top:4.65pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.19pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:14.25pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:23.85pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.5pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:359.25pt;position:var(--position);width:81pt"><div><div style="line-height:8pt;position:var(--position);top:4.65pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.19pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:14.25pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:23.85pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.5pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:443.25pt;position:var(--position);width:81pt"><div><div style="line-height:8pt;position:var(--position);top:4.65pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.19pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:14.25pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:23.85pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.5pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:34.5pt;width:275.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:275.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Audit fees</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:275.25pt;position:var(--position);top:34.5pt;width:81pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)">1,848<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:359.25pt;position:var(--position);top:34.5pt;width:81pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)">1,144<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:443.25pt;position:var(--position);top:34.5pt;width:81pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)">1,255<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:46.5pt;width:275.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:275.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Audit-related fees</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:359.25pt;position:var(--position);top:46.5pt;width:81pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:70.37pt;position:var(--position);text-decoration:none;white-space:pre">82</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:443.25pt;position:var(--position);top:46.5pt;width:81pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.96pt"></span></span><span style="left:65.59pt;position:var(--position)">129<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:58.5pt;width:275.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:275.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Tax fees</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:70.5pt;width:275.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:275.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">All other fees</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:275.25pt;position:var(--position);top:70.5pt;width:81pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.96pt"></span></span><span style="left:65.59pt;position:var(--position)">492<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:359.25pt;position:var(--position);top:70.5pt;width:81pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:70.96pt"></span></span><span style="left:73.58999999999999pt;position:var(--position)">7<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:443.25pt;position:var(--position);top:70.5pt;width:81pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.96pt"></span></span><span style="left:69.58999999999999pt;position:var(--position)">34<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:15.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:82.5pt;width:275.25pt"><div><div style="line-height:8pt;position:var(--position);top:4.87pt;width:275.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:275.25pt;position:var(--position);top:82.5pt;width:81pt"><div><div style="line-height:8pt;position:var(--position);top:4.87pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:60.37pt;position:var(--position);text-decoration:none;white-space:pre">2,340</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:359.25pt;position:var(--position);top:82.5pt;width:81pt"><div><div style="line-height:8pt;position:var(--position);top:4.87pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:60.37pt;position:var(--position);text-decoration:none;white-space:pre">1,233</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:443.25pt;position:var(--position);top:82.5pt;width:81pt"><div><div style="line-height:8pt;position:var(--position);top:4.87pt;width:81pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:60.37pt;position:var(--position);text-decoration:none;white-space:pre">1,418</span></div></div></div></td></tr></tbody></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DisclosureOfPrincipalAuditFeesAndServicesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Principal Audit Fees And Services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DisclosureOfPrincipalAuditFeesAndServicesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfExpensesByNatureExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNatureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNatureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employees (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberAndAverageNumberOfEmployeesAbstract', window );"><strong>Number and average number of employees [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfAverageNumberOfEmployeesTableTextBlock', window );">Disclosure of average workforce during the periods</a></td>
<td class="text"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">The Group&#8217;s average workforce during the periods ended December 31, 2023, 2024 and 2025 was as follows:</span><div style="position:var(--position);top:472.26pt;width:612pt"><div style="font-size:0pt;left:43pt;position:var(--position);width:360pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:88.5pt"></td><td style="padding:0;width:88.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:88.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:88.5pt"></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">HEADCOUNT</span></div></div></div></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:88.5pt;position:var(--position);width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.57pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.94pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:17.17pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.16pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:180pt;position:var(--position);width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.57pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.94pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:17.17pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.16pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:271.5pt;position:var(--position);width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:7.57pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:17.94pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:17.17pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:6.16pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:30.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">France </span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:88.5pt;position:var(--position);top:30.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.87pt;position:var(--position);text-decoration:none;white-space:pre">28</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:180pt;position:var(--position);top:30.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.87pt;position:var(--position);text-decoration:none;white-space:pre">38</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:271.5pt;position:var(--position);top:30.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.87pt;position:var(--position);text-decoration:none;white-space:pre">41</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">United States</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:88.5pt;position:var(--position);top:42.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.87pt;position:var(--position);text-decoration:none;white-space:pre">12</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:180pt;position:var(--position);top:42.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.87pt;position:var(--position);text-decoration:none;white-space:pre">29</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:271.5pt;position:var(--position);top:42.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.87pt;position:var(--position);text-decoration:none;white-space:pre">27</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:88.5pt;position:var(--position);top:54.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:77.87pt;position:var(--position);text-decoration:none;white-space:pre">40</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:180pt;position:var(--position);top:54.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:77.87pt;position:var(--position);text-decoration:none;white-space:pre">67</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:271.5pt;position:var(--position);top:54.75pt;width:88.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:88.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:77.87pt;position:var(--position);text-decoration:none;white-space:pre">68</span></div></div></div></td></tr></tbody></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DisclosureOfAverageNumberOfEmployeesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Average Number Of Employees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DisclosureOfAverageNumberOfEmployeesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberAndAverageNumberOfEmployeesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberAndAverageNumberOfEmployeesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial gain (loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_FinancialIncomeLossAbstract', window );"><strong>Financial Income (Loss) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfDetailedInformationAboutFinanceIncomeCostTableTextBlock', window );">Disclosure of net financial income (loss)</a></td>
<td class="text"><span style="color:#231f20;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">The financial loss breaks down as follows:</span><div style="position:var(--position);top:112.66pt;width:612pt"><div style="font-size:0pt;left:43pt;position:var(--position);width:510pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:279pt"></td><td style="padding:0;width:75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:75pt"></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:279pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:87.96pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:22.12pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"> FINANCIAL GAIN (LOSS)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:12pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.19pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.5pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:12pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.19pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.5pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:12pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.19pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.41pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.5pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest on bond loans</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:42.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.3pt"></span></span><span style="left:56.93pt;position:var(--position)">(760)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:42.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(5,800)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:432pt;overflow:hidden;position:var(--position);top:42.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:42.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(7,472)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest on convertible loan notes</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(3,935)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(5,691)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:432pt;overflow:hidden;position:var(--position);top:54.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:54.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(3,638)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest on conditional advances and PGE</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.3pt"></span></span><span style="left:56.93pt;position:var(--position)">(176)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.3pt"></span></span><span style="left:60.93pt;position:var(--position)">(85)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:432pt;overflow:hidden;position:var(--position);top:66.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:66.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.3pt"></span></span><span style="left:60.93pt;position:var(--position)">(95)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest on royalty certificates</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:78.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(8,942)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:78.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:54.3pt"></span></span><span style="left:56.93pt;position:var(--position)">(794)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:78.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.3pt"></span></span><span style="left:46.93pt;position:var(--position)">(17,213)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest on lease liabilities</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:90.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.3pt"></span></span><span style="left:60.93pt;position:var(--position)">(13)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:90.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.3pt"></span></span><span style="left:60.93pt;position:var(--position)">(61)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:90.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.3pt"></span></span><span style="left:60.93pt;position:var(--position)">(64)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(Increase) / decrease in derivatives fair value</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:102.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(3,046)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:102.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(1,462)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:102.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.3pt"></span></span><span style="left:46.93pt;position:var(--position)">(29,935)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:114.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(Increase) / decrease in other liabilities / (assets) at fair value through profit and loss</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:114.75pt;width:75pt"><div><div style="line-height:9pt;position:var(--position);top:2.35pt;width:75pt"><span style="color:#000000;font-family:'Arial', sans-serif;font-size:9pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:6.55pt;width:56.62pt"></span></span><span style="left:59.25pt;position:var(--position)">&#8212;</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:114.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(1,367)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:114.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.3pt"></span></span><span style="left:46.93pt;position:var(--position)">(36,015)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:126.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Loss on derecognition of financial liabilities</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:126.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(3,431)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:126.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:126.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(3,838)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:138.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Transaction costs</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:138.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(1,924)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:138.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(1,615)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:138.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:150.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Foreign exchange losses</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:150.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(5,573)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:150.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.3pt"></span></span><span style="left:60.93pt;position:var(--position)">(51)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:150.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:44.3pt"></span></span><span style="left:46.93pt;position:var(--position)">(13,444)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:162.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial expense</span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:162.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.3pt"></span></span><span style="left:60.93pt;position:var(--position)">(73)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:162.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.3pt"></span></span><span style="left:60.93pt;position:var(--position)">(64)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:162.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:58.3pt"></span></span><span style="left:60.93pt;position:var(--position)">(29)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:174.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial expenses</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:174.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:44.3pt"></span></span><span style="left:46.93pt;position:var(--position)">(27,875)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:174.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:44.3pt"></span></span><span style="left:46.93pt;position:var(--position)">(16,991)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="height:12pt;left:432pt;overflow:hidden;position:var(--position);top:174.75pt;width:3pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:3pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:-1.75pt;position:var(--position);text-decoration:none;white-space:pre">&#160; </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:174.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:40.3pt"></span></span><span style="left:42.93pt;position:var(--position)">(111,743)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:186.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Interest income</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:186.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">2,418<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:186.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">8,246<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:186.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">5,600<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:198.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(Increase) / decrease in derivatives fair value</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:198.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">1,006<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:198.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">1,413<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:198.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">3,620<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:210.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">(Increase) / decrease in other liabilities / (assets) at fair value through profit and loss</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:210.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">3,198<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:210.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:210.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">4,730<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:222.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Effect of unwinding the discount related to advances made to CROs</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:222.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)">355<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:222.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)">710<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:222.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)">153<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:234.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Day-one gain on recognition of financial liabilities</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:234.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)">212<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:234.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)">590<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:234.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">1,557<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:246.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Gain on derecognition of financial liabilities</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:246.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)">192<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:246.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:246.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:258.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Foreign exchange gains </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:258.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:258.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">2,774<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#CCECFF;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:258.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">11,886<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:270.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial income</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:270.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.96pt"></span></span><span style="left:59.59pt;position:var(--position)">130<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:270.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:270.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:60.96pt"></span></span><span style="left:63.59pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:282.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial income </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:282.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:50.96pt"></span></span><span style="left:53.59pt;position:var(--position)">7,511<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:282.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">13,732<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:282.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:46.96pt"></span></span><span style="left:49.59pt;position:var(--position)">27,545<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:294.75pt;width:279pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:279pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Financial gain (loss)</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:279pt;position:var(--position);top:294.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:44.3pt"></span></span><span style="left:46.93pt;position:var(--position)">(20,364)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:357pt;position:var(--position);top:294.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:48.3pt"></span></span><span style="left:50.93pt;position:var(--position)">(3,258)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:435pt;position:var(--position);top:294.75pt;width:75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:44.3pt"></span></span><span style="left:46.93pt;position:var(--position)">(84,198)</span></span></div></div></div></td></tr></tbody></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DisclosureOfDetailedInformationAboutFinanceIncomeCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Finance Income (Cost)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DisclosureOfDetailedInformationAboutFinanceIncomeCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_FinancialIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Income (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_FinancialIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundAbstract', window );"><strong>Income taxes paid (refund) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock', window );">Disclosure of reconciliation of effective income tax (loss)</a></td>
<td class="text"><div style="font-size:0pt;left:36pt;position:var(--position);width:522.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:214.5pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:99.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:99.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:99.75pt"></td></tr><tr style="height:26.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:17.48pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:39.07pt;position:var(--position);text-decoration:none;white-space:pre">(In thousands of euros, except percentage)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:5.32pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.57pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:14.92pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.78pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:5.32pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.57pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:14.92pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.78pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:5.32pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:23.57pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:14.92pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.78pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:26.25pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Loss before tax </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:26.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:65.05pt"></span></span><span style="left:67.67999999999999pt;position:var(--position)">(147,740)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);top:26.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:65.05pt"></span></span><span style="left:67.67999999999999pt;position:var(--position)">(176,242)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:26.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:65.05pt"></span></span><span style="left:67.67999999999999pt;position:var(--position)">(330,254)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:38.25pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:8.63pt;position:var(--position);text-decoration:none;white-space:pre">Statutory French tax rate</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:38.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:78.34pt;position:var(--position)"></span><span style="left:78.34pt;position:var(--position)">25</span><span style="left:86.34pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);top:38.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:78.34pt;position:var(--position)"></span><span style="left:78.34pt;position:var(--position)">25</span><span style="left:86.34pt;position:var(--position)">%</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:38.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:78.34pt;position:var(--position)"></span><span style="left:78.34pt;position:var(--position)">25</span><span style="left:86.34pt;position:var(--position)">%</span></span></div></div></div></td></tr><tr style="height:12.75pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:50.25pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Nominal income tax using statutory French tax rate</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:50.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:71.71pt"></span></span><span style="left:74.33999999999999pt;position:var(--position)">36,935<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);top:50.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:71.71pt"></span></span><span style="left:74.33999999999999pt;position:var(--position)">44,061<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:50.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:71.71pt"></span></span><span style="left:74.33999999999999pt;position:var(--position)">82,563<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:63pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Tax effect of:</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:75pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Tax rates in foreign jurisdictions</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);top:75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:79.05pt"></span></span><span style="left:81.67999999999999pt;position:var(--position)">(153)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:87pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Share-based payment</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:87pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:73.05pt"></span></span><span style="left:75.67999999999999pt;position:var(--position)">(2,045)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);top:87pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:73.05pt"></span></span><span style="left:75.67999999999999pt;position:var(--position)">(5,056)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:87pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:73.05pt"></span></span><span style="left:75.67999999999999pt;position:var(--position)">(8,849)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:99pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">CIR</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:99pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:75.71pt"></span></span><span style="left:78.33999999999999pt;position:var(--position)">1,123<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);top:99pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:75.71pt"></span></span><span style="left:78.33999999999999pt;position:var(--position)">1,663<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:99pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)">765<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:111pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Transaction costs related to capital increase </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:111pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:75.71pt"></span></span><span style="left:78.33999999999999pt;position:var(--position)">3,073<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);top:111pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:79.05pt"></span></span><span style="left:81.67999999999999pt;position:var(--position)">(112)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:111pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:71.71pt"></span></span><span style="left:74.33999999999999pt;position:var(--position)">10,077<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:20.25pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:123pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:1.89pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Decrease / (increase) in derivatives and other liabilities measured </span></div><div style="line-height:8pt;position:var(--position);top:11.49pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">at FVTPL</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:123pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.06pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)">748<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);top:123pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.06pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:79.05pt"></span></span><span style="left:81.67999999999999pt;position:var(--position)">(207)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:123pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.06pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:69.05pt"></span></span><span style="left:71.67999999999999pt;position:var(--position)">(17,087)</span></span></div></div></div></td></tr><tr style="height:21.75pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:143.25pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.39pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Non-recognition of deferred tax assets related to tax losses and </span></div><div style="line-height:8pt;position:var(--position);top:12.99pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">temporary differences</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:143.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:69.05pt"></span></span><span style="left:71.67999999999999pt;position:var(--position)">(39,612)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);top:143.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:69.05pt"></span></span><span style="left:71.67999999999999pt;position:var(--position)">(40,399)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:143.25pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.81pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:69.05pt"></span></span><span style="left:71.67999999999999pt;position:var(--position)">(61,320)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:165pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:165pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:79.05pt"></span></span><span style="left:81.67999999999999pt;position:var(--position)">(222)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);top:165pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)">49<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:2pt solid #FFFFFF;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:165pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:79.05pt"></span></span><span style="left:81.67999999999999pt;position:var(--position)">(148)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:177pt;width:214.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:214.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Effective income tax (loss)</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:217.5pt;position:var(--position);top:177pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:320.25pt;position:var(--position);top:177pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:var(--position);top:177pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:73.05pt"></span></span><span style="left:75.67999999999999pt;position:var(--position)">(5,848)</span></span></div></div></div></td></tr></tbody></table></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory', window );">Disclosure of deferred tax assets and liabilities by nature</a></td>
<td class="text"><div style="font-size:0pt;left:36pt;position:var(--position);width:522.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:216pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:99.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:99.75pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:98.25pt"></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:70.79pt;position:var(--position);text-decoration:none;white-space:pre">(In thousands of euros)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:27pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:5.7pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">DEFERRED TAX ASSETS AND LIABILITIES BY </span></div><div style="line-height:8pt;position:var(--position);top:15.3pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">NATURE</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:12pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:5.7pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:39.16pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:15.3pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.72pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2023</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:12pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:5.7pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:39.16pt;position:var(--position);text-decoration:none;white-space:pre">AS OF </span></div><div style="line-height:8pt;position:var(--position);top:15.3pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.72pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, 2024</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:12pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:5.7pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.38pt;position:var(--position);text-decoration:none;white-space:pre">AS OF DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:15.3pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:41.12pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:39pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Retirement benefit obligation</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:39pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)">157<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:39pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)">189<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:39pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:79.88pt"></span></span><span style="left:82.50999999999999pt;position:var(--position)">157<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:51pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Leases</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:51pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)">135<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:51pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)">591<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:51pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:79.88pt"></span></span><span style="left:82.50999999999999pt;position:var(--position)">476<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:63pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial liabilities</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:63pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:85.12pt;position:var(--position);text-decoration:none;white-space:pre">351</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:63pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:75.71pt"></span></span><span style="left:78.33999999999999pt;position:var(--position)">1,678<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:63pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:83.88pt"></span></span><span style="left:86.50999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:75pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Provisions for AGA taxes</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:89.12pt;position:var(--position);text-decoration:none;white-space:pre">83</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:75pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)">142<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:75pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:73.62pt;position:var(--position);text-decoration:none;white-space:pre">11,454</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:87pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Tax losses carryforward</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:87pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:71.12pt;position:var(--position);text-decoration:none;white-space:pre">114,946</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:87pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:67.71pt"></span></span><span style="left:70.33999999999999pt;position:var(--position)">152,372<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:87pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:69.62pt;position:var(--position);text-decoration:none;white-space:pre">228,239</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:99pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other items</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:99pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)">335<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:99pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)">744<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:99pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:77.62pt;position:var(--position);text-decoration:none;white-space:pre">1,568</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:111pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Deferred tax assets</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:111pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:67.71pt"></span></span><span style="left:70.33999999999999pt;position:var(--position)">116,006<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:111pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:67.71pt"></span></span><span style="left:70.33999999999999pt;position:var(--position)">155,715<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:111pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:69.62pt;position:var(--position);text-decoration:none;white-space:pre">241,894</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:123pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Subsidies</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:123pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)">24<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:123pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)">12<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:123pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:83.88pt"></span></span><span style="left:86.50999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:135pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Leases</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:135pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)">124<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:135pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)">485<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:135pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:83.62pt;position:var(--position);text-decoration:none;white-space:pre">396</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:147pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Royalty certificates</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:147pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:147pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:147pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:73.62pt;position:var(--position);text-decoration:none;white-space:pre">17,208</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:159pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other financial liabilities</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:159pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)">285<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:159pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:75.71pt"></span></span><span style="left:78.33999999999999pt;position:var(--position)">1,075<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:159pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:83.88pt"></span></span><span style="left:86.50999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:171pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Other items</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:171pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)">10<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:171pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)">12<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:171pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:87.62pt;position:var(--position);text-decoration:none;white-space:pre">11</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:183pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Deferred tax liabilities</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:183pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:81.71pt"></span></span><span style="left:84.33999999999999pt;position:var(--position)">444<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:183pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:75.71pt"></span></span><span style="left:78.33999999999999pt;position:var(--position)">1,584<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:183pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:69.88pt"></span></span><span style="left:72.50999999999999pt;position:var(--position)">17,616<span style="display:inline-block;height:5.41pt;width:2.99pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:195pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Deferred tax assets, net</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:195pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:67.71pt"></span></span><span style="left:70.33999999999999pt;position:var(--position)">115,562<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:195pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:67.71pt"></span></span><span style="left:70.33999999999999pt;position:var(--position)">154,131<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:195pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:69.62pt;position:var(--position);text-decoration:none;white-space:pre">224,279</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:207pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Unrecognized deferred tax assets</span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:207pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:65.05pt"></span></span><span style="left:67.67999999999999pt;position:var(--position)">(115,562)</span></span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:207pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:65.05pt"></span></span><span style="left:67.67999999999999pt;position:var(--position)">(154,131)</span></span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:207pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:3.24pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:63.22pt"></span></span><span style="left:65.85pt;position:var(--position)">(230,127)<span style="display:inline-block;height:5.54pt;width:0.33pt"></span></span></span></div></div></div></td></tr><tr style="height:21pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:219pt;width:216pt"><div><div style="line-height:8pt;position:var(--position);top:2.7pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total deferred taxes, net recognized in the statement of </span></div><div style="line-height:8pt;position:var(--position);top:12.3pt;width:216pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">financial position</span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:219pt;position:var(--position);top:219pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:321.75pt;position:var(--position);top:219pt;width:99.75pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:99.75pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:85.71pt"></span></span><span style="left:88.33999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;font-size:0;text-align:left;vertical-align:top"><div style="left:424.5pt;position:var(--position);top:219pt;width:98.25pt"><div><div style="line-height:8pt;position:var(--position);top:7.5pt;width:98.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:71.22pt"></span></span><span style="left:73.85pt;position:var(--position)">(5,848)<span style="display:inline-block;height:5.41pt;width:0.33pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Reconciliation Of Accounting Profit Multiplied By Applicable Tax Rates And Average Effective Tax Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_g&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_f&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_f&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income (loss) per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">Schedule of earnings per share</a></td>
<td class="text"><div style="font-size:0pt;left:36pt;position:var(--position);width:419.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:207pt"></td><td style="padding:0;width:64.5pt"></td><td style="padding:0;width:9.75pt"></td><td style="padding:0;width:64.5pt"></td><td style="padding:0;width:9pt"></td><td style="padding:0;width:64.5pt"></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:207pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:207pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:21.76pt;position:var(--position);text-decoration:none;white-space:pre">(amounts in thousands of euros, except share data)</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:207pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:207pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">BASIC AND DILUTED LOSS PER SHARE</span></div></div></div></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:207pt;position:var(--position);top:12pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.94pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.16pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.25pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:281.25pt;position:var(--position);top:12pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.94pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.16pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.25pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:354.75pt;position:var(--position);top:12pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:5.94pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.16pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:24.25pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:207pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:207pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Weighted average number of outstanding shares</span></div></div></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:207pt;position:var(--position);top:42.75pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.46pt"></span></span><span style="left:25.09pt;position:var(--position)">43,066,012<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:281.25pt;position:var(--position);top:42.75pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.46pt"></span></span><span style="left:25.09pt;position:var(--position)">63,046,350<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:354.75pt;position:var(--position);top:42.75pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:22.46pt"></span></span><span style="left:25.09pt;position:var(--position)">69,527,315<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:207pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:207pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Net loss for the period</span></div></div></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:207pt;position:var(--position);top:54.75pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.8pt"></span></span><span style="left:32.43pt;position:var(--position)">(147,740)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:281.25pt;position:var(--position);top:54.75pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.8pt"></span></span><span style="left:32.43pt;position:var(--position)">(176,242)</span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:354.75pt;position:var(--position);top:54.75pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:29.8pt"></span></span><span style="left:32.43pt;position:var(--position)">(336,102)</span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:207pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:207pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Basic and diluted loss per share (&#8364;/share) </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:207pt;position:var(--position);top:66.75pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.8pt"></span></span><span style="left:44.43pt;position:var(--position)">(3.43)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:281.25pt;position:var(--position);top:66.75pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.8pt"></span></span><span style="left:44.43pt;position:var(--position)">(2.80)</span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:354.75pt;position:var(--position);top:66.75pt;width:64.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.37pt;width:64.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:41.8pt"></span></span><span style="left:44.43pt;position:var(--position)">(4.83)</span></span></div></div></div></td></tr></tbody></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Related party transactions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory', window );">Disclosure of aggregate compensation of the members of the Group&#8217;s Board of Directors and CEO</a></td>
<td class="text"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">The aggregate compensation of the members of the Group&#8217;s Board of Directors and to the Chief Executive Officer includes the </span><div style="font-size:12pt;line-height:10pt;position:var(--position);top:101.31pt;width:612pt"><span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:43pt;position:var(--position);text-decoration:none;white-space:pre">following: </span></div><div style="position:var(--position);top:122.51pt;width:612pt"><div style="font-size:0pt;left:36pt;position:var(--position);width:488.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tbody><tr style="height:0"><td style="padding:0;width:241.5pt"></td><td style="padding:0;width:80.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td><td style="padding:0;width:3pt"></td><td style="padding:0;width:80.25pt"></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);width:241.5pt"><div><div style="line-height:8pt;position:var(--position);top:3.23pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:83.54pt;position:var(--position);text-decoration:none;white-space:pre">(In thousands of euros)</span></div></div></div></td><td colspan="3" style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:30.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:12pt;width:241.5pt"><div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">COMPENSATION</span></div></div></div></td><td style="border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2023</span></div></div></div></td><td style="border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2024</span></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:408pt;position:var(--position);top:12pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.77pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.82pt;position:var(--position);text-decoration:none;white-space:pre">YEAR ENDED </span></div><div style="line-height:8pt;position:var(--position);top:12.37pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:11.03pt;position:var(--position);text-decoration:none;white-space:pre">DECEMBER 31, </span></div><div style="line-height:8pt;position:var(--position);top:21.97pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:32.12pt;position:var(--position);text-decoration:none;white-space:pre">2025</span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:42.75pt;width:241.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Fixed compensation owed </span></div></div></div></td><td style="background-color:#cceeff;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)">471<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)">578<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:408pt;position:var(--position);top:42.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)">601<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:54.75pt;width:241.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Variable compensation owed </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)">282<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:408pt;position:var(--position);top:54.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)">450<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:66.75pt;width:241.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Contributions in-kind </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)">32<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)">68<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:408pt;position:var(--position);top:66.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)">111<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:78.75pt;width:241.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Employer contributions </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:408pt;position:var(--position);top:78.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:90.75pt;width:241.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Attendance fees&#8212;board of directors </span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:90.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)">375<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);top:90.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)">495<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="left:408pt;position:var(--position);top:90.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:62.21pt"></span></span><span style="left:64.84pt;position:var(--position)">608<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:102.75pt;width:241.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Share-based payments </span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:102.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">6,561<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);top:102.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">10,517<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="left:408pt;position:var(--position);top:102.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">8,098<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:114.75pt;width:241.5pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Consulting fees </span></div></div></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:114.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">1,210<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);top:114.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:408pt;position:var(--position);top:114.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:2.93pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.54pt;width:66.21pt"></span></span><span style="left:68.83999999999999pt;position:var(--position)">&#8212;<span style="display:inline-block;height:5.54pt;width:2.66pt"></span></span></span></div></div></div></td></tr><tr style="height:12pt"><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"><div style="position:var(--position);top:126.75pt;width:241.5pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:241.5pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre">Total </span></div></div></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:241.5pt;position:var(--position);top:126.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">8,930<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:324.75pt;position:var(--position);top:126.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:52.21pt"></span></span><span style="left:54.84pt;position:var(--position)">11,657<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td><td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:408pt;position:var(--position);top:126.75pt;width:80.25pt"><div><div style="line-height:8pt;position:var(--position);top:3pt;width:80.25pt"><span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><span style="left:2.63pt;position:var(--position)"><span style="display:inline-block;height:5.41pt;width:56.21pt"></span></span><span style="left:58.84pt;position:var(--position)">9,869<span style="display:inline-block;height:5.41pt;width:2.66pt"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Paragraph 18<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_18&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 230<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_230&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 230<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_230&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>The Group (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Corporate information and statement of IFRS compliance [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="nump">&#8364; 455,205<span></span>
</td>
<td class="nump">&#8364; 40,584<span></span>
</td>
<td class="nump">&#8364; 196,010<span></span>
</td>
<td class="nump">&#8364; 7,189<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of preparation (Details)<br> &#8364; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">145 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 24, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 24, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 02, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jul. 31, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Feb. 28, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 336,102<span></span>
</td>
<td class="nump">&#8364; 176,242<span></span>
</td>
<td class="nump">&#8364; 147,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Capital increases</a></td>
<td class="nump">&#8364; 223,300<span></span>
</td>
<td class="nump">$ 235.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">648,124<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">&#8364; 353,377<span></span>
</td>
<td class="nump">&#8364; 1,194,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ProceedsFromResearchTaxCredit', window );">Proceeds from research tax credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,640<span></span>
</td>
<td class="nump">&#8364; 4,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NetProceedsFromSaleOfRoyaltyCertificates', window );">Net proceeds from sale of royalty certificates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_CashAndCashEquivalentsAndOtherShortTermInvestments', window );">Cash and cash equivalents and other short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 530,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">530,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abvx_BanquePubliqueDInvestissementBPIMember', window );">Conditional advances Bpifrance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities', window );">Proceeds from government grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ProceedsFromConditionalAdvances', window );">Proceeds from conditional advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_SaleOfStockAxis=abvx_RegisteredDirectOfferingMember', window );">Registered direct offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Capital increases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 637,500<span></span>
</td>
<td class="nump">&#8364; 223,300<span></span>
</td>
<td class="nump">&#8364; 130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_CashAndCashEquivalentsAndOtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents And Other Short-Term Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_CashAndCashEquivalentsAndOtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NetProceedsFromSaleOfRoyaltyCertificates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Proceeds From Sale Of Royalty Certificates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NetProceedsFromSaleOfRoyaltyCertificates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ProceedsFromConditionalAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Conditional Advances</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ProceedsFromConditionalAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ProceedsFromResearchTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Research Tax Credit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ProceedsFromResearchTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from government grants, classified as financing activities. [Refer: Government [member]; Government grants]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2025-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abvx_BanquePubliqueDInvestissementBPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abvx_BanquePubliqueDInvestissementBPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_SaleOfStockAxis=abvx_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_SaleOfStockAxis=abvx_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events - For the year ended 2023 (Details)<br> &#8364; / shares in Units, $ / shares in Units, &#8364; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">30 Months Ended</th>
<th class="th" colspan="1">145 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 28, 2025 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 02, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 24, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 24, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 24, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Aug. 22, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Aug. 21, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Aug. 20, 2023 </div>
<div>EUR (&#8364;) </div>
<div>transaction </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>May 24, 2023 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 22, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 30, 2021 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares </div>
<div>plan </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>EUR (&#8364;) </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jul. 28, 2025 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 19, 2024 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Oct. 24, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Capital increase from issuance of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 637,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 353,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease', window );">Capital increase from issuance of ordinary shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,325,500<span></span>
</td>
<td class="nump">20,325,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,679,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,325,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityIssuanceSubscriptionPricePerShare', window );">Equity issuance, subscripion price per share (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 28,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants', window );">Exercises of share warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">464,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RepaymentsOfConvertibleLoansNotes', window );">Repayments of convertible loan notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,188<span></span>
</td>
<td class="nump">&#8364; 8,750<span></span>
</td>
<td class="nump">27,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Capital increases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 223,300<span></span>
</td>
<td class="nump">$ 235.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 648,124<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">353,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,194,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants', window );">Capital increases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202,000<span></span>
</td>
<td class="nump">212.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Payments for share issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 21,300<span></span>
</td>
<td class="nump">$ 23.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_FreeSharesAGAMember', window );">Total AGAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfShareBasedCompensationPlansIssued', window );">Number of share-based compensation plans issued | plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,601,296<span></span>
</td>
<td class="nump">6,280,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,828,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=abvx_AmericanDepositorySharesMember', window );">ADS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease', window );">Capital increase from issuance of ordinary shares (in shares) | shares</a></td>
<td class="nump">11,679,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,699,460<span></span>
</td>
<td class="nump">18,699,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfSharesReceivedPerADS', window );">Number of shares received per ADS (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IssueOfEquityOfferingPricePerShare', window );">Issue of equity, offering price per share (in dollar/euro per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease', window );">Capital increase from issuance of ordinary shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,626,040<span></span>
</td>
<td class="nump">1,626,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IssueOfEquityOfferingPricePerShare', window );">Issue of equity, offering price per share (in dollar/euro per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 54.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10.9864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_Kreos1ConvertibleBondLoansTrancheAMember', window );">Kreos 1, convertible bond loans, tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfOtherShareWarrantsRepurchased', window );">Number of other share warrants repurchased (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants', window );">Exercises of share warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_Kreos1ConvertibleBondLoansTrancheBMember', window );">Kreos 1, convertible bond loans, tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfOtherShareWarrantsRepurchased', window );">Number of other share warrants repurchased (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants', window );">Exercises of share warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RepaymentsOfConvertibleLoansNotes', window );">Repayments of convertible loan notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 7,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingMember', window );">Kreos &amp; Claret financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsMaximumBorrowingCapacity', window );">Borrowings, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_AggregateExercisePriceOtherEquityInstrumentsGranted', window );">Aggregate exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingMember', window );">Kreos &amp; Claret financing | Kreos C BSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IssuanceOfOtherShareWarrants', window );">Issuance of other share warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingMember', window );">Kreos &amp; Claret financing | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_AggregateExercisePriceOtherEquityInstrumentsGranted', window );">Aggregate exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_HeightsConvertibleNotesMember', window );">Heights convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityIssuanceSubscriptionPricePerShare', window );">Equity issuance, subscripion price per share (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.4303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsMaximumBorrowingCapacity', window );">Borrowings, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_HeightsConvertibleNotesMember', window );">Heights convertible notes | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityIssuanceSubscriptionPricePerShare', window );">Equity issuance, subscripion price per share (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.4303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheAMember', window );">Kreos &amp; Claret convertible notes (OCABSA)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_OCEANEMember', window );">OCEANE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease', window );">Capital increase from issuance of ordinary shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,964,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityIssuanceSubscriptionPricePerShare', window );">Equity issuance, subscripion price per share (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 30.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RepaymentsOfConvertibleLoansNotes', window );">Repayments of convertible loan notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Capital increases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingAndHeightsConvertibleNotesMember', window );">Kreos &amp; Claret financing and Heights convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ProceedsFromBorrowingsNetOfRefinancingOfExistingIndebteness', window );">Proceeds from borrowings, net of refinancing of existing indebteness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember', window );">Share premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Capital increase from issuance of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 637,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 352,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_FinancialAgreementAxis=abvx_A130.0MillionCrossOverFinancingFebruary2023Member', window );">&#8364;130.0&#160;million cross-over financing, february 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_FinancialAgreementAmount', window );">Financial agreement, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Capital increase from issuance of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease', window );">Capital increase from issuance of ordinary shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityIssuanceSubscriptionPricePerShare', window );">Equity issuance, subscripion price per share (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_FinancialAgreementAxis=abvx_A130.0MillionCrossOverFinancingFebruary2023Member', window );">&#8364;130.0&#160;million cross-over financing, february 2023 | Share premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_FinancialAgreementAxis=abvx_A49.2MillionCrossOverFinancingSeptember2022Member', window );">&#8364;49.2 million cross-over financing, september 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityIssuancePercentageOfCurrentShareCapital', window );">Equity issuance, percentage of current share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_FinancialAgreementAxis=abvx_A150.0MillionFinancingAugust2023Member', window );">&#8364;150.0&#160;million financing, august 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_FinancialAgreementAmount', window );">Financial agreement, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_FinancialAgreementNumberOfTransactions', window );">Financial agreement, number of transactions | transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_AggregateExercisePriceOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Exercise Price, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_AggregateExercisePriceOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Maximum Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_EquityIssuancePercentageOfCurrentShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Issuance, Percentage Of Current Share Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_EquityIssuancePercentageOfCurrentShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_EquityIssuanceSubscriptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Issuance, Subscription Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_EquityIssuanceSubscriptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_FinancialAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Agreement, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_FinancialAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_FinancialAgreementNumberOfTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Agreement, Number Of Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_FinancialAgreementNumberOfTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Number Of Ordinary Shares Issued Through Capital Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Number Of Shares Issued Through Exercise Of Share Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IssuanceOfOtherShareWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Other Share Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IssuanceOfOtherShareWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IssueOfEquityOfferingPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Offering Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IssueOfEquityOfferingPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfOtherShareWarrantsRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Other Share Warrants Repurchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfOtherShareWarrantsRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfShareBasedCompensationPlansIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Share-Based Compensation Plans Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfShareBasedCompensationPlansIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfSharesReceivedPerADS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Received Per ADS</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfSharesReceivedPerADS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ProceedsFromBorrowingsNetOfRefinancingOfExistingIndebteness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Borrowings, Net Of Refinancing Of Existing Indebteness</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ProceedsFromBorrowingsNetOfRefinancingOfExistingIndebteness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuing Shares Other Than Through Exercise Of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_RepaymentsOfConvertibleLoansNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments Of Convertible Loans Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_RepaymentsOfConvertibleLoansNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_a_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160_a_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for share issue costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_FreeSharesAGAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_FreeSharesAGAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=abvx_AmericanDepositorySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=abvx_AmericanDepositorySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_Kreos1ConvertibleBondLoansTrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_Kreos1ConvertibleBondLoansTrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_Kreos1ConvertibleBondLoansTrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_Kreos1ConvertibleBondLoansTrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_WarrantsAxis=abvx_KreosCBSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_WarrantsAxis=abvx_KreosCBSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_HeightsConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_HeightsConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_OCEANEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_OCEANEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingAndHeightsConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingAndHeightsConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_FinancialAgreementAxis=abvx_A130.0MillionCrossOverFinancingFebruary2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_FinancialAgreementAxis=abvx_A130.0MillionCrossOverFinancingFebruary2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_FinancialAgreementAxis=abvx_A49.2MillionCrossOverFinancingSeptember2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_FinancialAgreementAxis=abvx_A49.2MillionCrossOverFinancingSeptember2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_FinancialAgreementAxis=abvx_A150.0MillionFinancingAugust2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_FinancialAgreementAxis=abvx_A150.0MillionFinancingAugust2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events - For the year ended 2024 (Details)<br> &#8364; / shares in Units, &#8364; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">27 Months Ended</th>
<th class="th" colspan="1">31 Months Ended</th>
<th class="th" colspan="1">73 Months Ended</th>
<th class="th" colspan="1">109 Months Ended</th>
<th class="th" colspan="1">145 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 19, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 11, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 21, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Apr. 04, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 28, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Aug. 31, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>shares </div>
<div>plan</div>
</th>
<th class="th">
<div>Nov. 30, 2025 </div>
<div>plan</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>EUR (&#8364;) </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Nov. 19, 2024 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Oct. 24, 2023 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Aug. 20, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>May 24, 2023 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Feb. 22, 2023 </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfFreeSharesPlansIssued', window );">Number of free shares plans issued | plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Income from government grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 4,140<span></span>
</td>
<td class="nump">&#8364; 81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfADSPerOrdinaryShares', window );">Number of ADS per ordinary shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_SaleOfStockAxis=abvx_AtTheMarketATMProgramMember', window );">At-The-Market (ATM) Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExpectedProceedsFromShareIssuance', window );">Expected proceeds from share issuance | $</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExpectedProceedsFromShareIssuanceShelfRegistration', window );">Expected proceeds from share issuance, shelf registration | $</a></td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RNPVIRConditionalAdvanceBPIMember', window );">RNP-VIR conditional advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ProceedsFromConditionalAdvances', window );">Proceeds from conditional advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,930<span></span>
</td>
<td class="nump">&#8364; 346<span></span>
</td>
<td class="nump">&#8364; 1,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities', window );">Proceeds from government grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_PercentageOfConditionalAdvancesWaived', window );">Percentage of conditional advances waived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Income from government grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_CARENAConditionalAdvanceBPIMember', window );">CARENA conditional advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ProceedsFromConditionalAdvances', window );">Proceeds from conditional advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 29<span></span>
</td>
<td class="nump">&#8364; 1,008<span></span>
</td>
<td class="nump">&#8364; 1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_PercentageOfConditionalAdvancesWaived', window );">Percentage of conditional advances waived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Income from government grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RNPVIRConditionalAdvanceBPIAndCARENAConditionalAdvanceBPIMember', window );">RNP-VIR conditional advance and CARENA conditional advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Income from government grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheBMember', window );">Kreos &amp; Claret financing, tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheCMember', window );">Kreos &amp; Claret financing, tranche C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsMaximumBorrowingCapacity', window );">Borrowings, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheBAndCMember', window );">Kreos &amp; Claret financing, tranche B and C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsMaximumBorrowingCapacity', window );">Borrowings, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA2024Member', window );">AGA-2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,946,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA2024Member', window );">AGA-2024 | Tranche 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA2024Member', window );">AGA-2024 | Tranche 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA2024Member', window );">AGA-2024 | Tranche 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20246Member', window );">AGA-2024-6</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20241Member', window );">BSA-2024-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Maximum Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ExpectedProceedsFromShareIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected Proceeds From Share Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ExpectedProceedsFromShareIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ExpectedProceedsFromShareIssuanceShelfRegistration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected Proceeds From Share Issuance, Shelf Registration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ExpectedProceedsFromShareIssuanceShelfRegistration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfADSPerOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of ADS per Ordinary Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfADSPerOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfFreeSharesPlansIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Free Shares Plans Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfFreeSharesPlansIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_PercentageOfConditionalAdvancesWaived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Conditional Advances Waived</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_PercentageOfConditionalAdvancesWaived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ProceedsFromConditionalAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Conditional Advances</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ProceedsFromConditionalAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Vesting Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Vesting Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_a_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160_a_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from government grants, classified as financing activities. [Refer: Government [member]; Government grants]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2025-01-01<br> -Paragraph 39<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_39_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_SaleOfStockAxis=abvx_AtTheMarketATMProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_SaleOfStockAxis=abvx_AtTheMarketATMProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RNPVIRConditionalAdvanceBPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RNPVIRConditionalAdvanceBPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_CARENAConditionalAdvanceBPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_CARENAConditionalAdvanceBPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RNPVIRConditionalAdvanceBPIAndCARENAConditionalAdvanceBPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RNPVIRConditionalAdvanceBPIAndCARENAConditionalAdvanceBPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheBAndCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheBAndCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_TranchesAxis=abvx_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_TranchesAxis=abvx_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_TranchesAxis=abvx_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_TranchesAxis=abvx_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_TranchesAxis=abvx_TrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_TranchesAxis=abvx_TrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20246Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20246Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20241Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20241Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events - For the year ended 2025 (Details)<br> &#8364; / shares in Units, $ / shares in Units, &#8364; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">110 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 23, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Nov. 25, 2025 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 28, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 08, 2025 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 30, 2025 </div>
<div>EUR (&#8364;) </div>
<div>note </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 30, 2025 </div>
<div>EUR (&#8364;) </div>
<div>note </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 28, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 28, 2025 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 20, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 06, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>plan</div>
</th>
<th class="th">
<div>Nov. 30, 2025 </div>
<div>shares </div>
<div>plan</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>shares</div>
</th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 28, 2025 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 23, 2025 </div>
<div>note</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Oct. 24, 2023 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Oct. 24, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 22, 2023 </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfFreeSharesPlansIssued', window );">Number of free shares plans issued | plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_SharePrice1', window );">Share price (euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 57.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Closing foreign exchange rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from issue of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 747.5<span></span>
</td>
<td class="nump">&#8364; 637,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NetProceedsFromIssueOfOrdinaryShares', window );">Net proceeds from issue of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700.3<span></span>
</td>
<td class="nump">597,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingOtherEquityInstruments', window );">Proceeds from issuing other equity instruments | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 607,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=abvx_AmericanDepositorySharesMember', window );">ADS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Increase (decrease) in number of ordinary shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,679,400<span></span>
</td>
<td class="nump">11,679,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IssueOfEquityOfferingPricePerShare', window );">Issue of equity, offering price per share (in dollar/euro per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IssueOfEquityOfferingPricePerShare', window );">Issue of equity, offering price per share (in dollar/euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 54.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10.9864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_HeightsConvertibleNotesMember', window );">Heights convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Increase (decrease) in number of ordinary shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">920,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfConvertibleNotesConverted', window );">Number of convertible notes converted | note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 21,900<span></span>
</td>
<td class="nump">&#8364; 21,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsFixedConversionPrice', window );">Borrowings, fixed conversion price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 23.7674<span></span>
</td>
<td class="nump">&#8364; 23.7674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheAMember', window );">Kreos &amp; Claret convertible notes (OCABSA)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsFixedConversionPrice', window );">Borrowings, fixed conversion price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 21.2209<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheAMember', window );">Kreos &amp; Claret convertible notes (OCABSA) | Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Increase (decrease) in number of ordinary shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">392,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">785,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsFixedConversionPrice', window );">Borrowings, fixed conversion price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 21.2209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 21.2209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosABCBSAMember', window );">Kreos A &amp; B &amp; C BSA | Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Increase (decrease) in number of ordinary shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingBAndCMember', window );">Kreos/Claret financing B and C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | &#8364;</a></td>
<td class="nump">&#8364; 29,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Repayments of borrowings, classified as financing activities | &#8364;</a></td>
<td class="nump">&#8364; 33,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_ShareSubscriptionWarrantsBSAMember', window );">Total BSAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">486,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_ShareSubscriptionWarrantsBSAMember', window );">Total BSAs | Tranche 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_ShareSubscriptionWarrantsBSAMember', window );">Total BSAs | Tranche 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_ShareSubscriptionWarrantsBSAMember', window );">Total BSAs | Board member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA2025Member', window );">AGA-2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,280,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA2025Member', window );">AGA-2025 | Tranche 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA2025Member', window );">AGA-2025 | Tranche 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA2025Member', window );">AGA-2025 | Tranche 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20252Member', window );">AGA-2025-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,102<span></span>
</td>
<td class="nump">123,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20255Member', window );">AGA-2025-5</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20251Member', window );">AGA-2025-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,319,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,319,500<span></span>
</td>
<td class="nump">4,319,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsFixedConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Fixed Conversion Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsFixedConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IssueOfEquityOfferingPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Offering Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IssueOfEquityOfferingPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NetProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Proceeds From Issue Of Ordinary Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NetProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfConvertibleNotesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Convertible Notes Converted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfConvertibleNotesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfFreeSharesPlansIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Free Shares Plans Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfFreeSharesPlansIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_SharePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Price1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_SharePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Vesting Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Vesting Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClosingForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClosingForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingOtherEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing equity instruments that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingOtherEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=abvx_AmericanDepositorySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=abvx_AmericanDepositorySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_HeightsConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_HeightsConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosABCBSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_KreosABCBSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingBAndCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingBAndCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_ShareSubscriptionWarrantsBSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_ShareSubscriptionWarrantsBSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_TranchesAxis=abvx_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_TranchesAxis=abvx_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_TranchesAxis=abvx_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_TranchesAxis=abvx_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=abvx_BoardMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=abvx_BoardMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_TranchesAxis=abvx_TrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_TranchesAxis=abvx_TrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20252Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20252Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20255Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20255Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20251Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20251Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events - Subsequent events (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">30 Months Ended</th>
<th class="th" colspan="1">110 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 23, 2026 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2026 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>shares</div>
</th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_FreeSharesAGAMember', window );">Free shares (AGA)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,601,296<span></span>
</td>
<td class="nump">6,280,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,828,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_ShareSubscriptionWarrantsBSAMember', window );">BSAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,370<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">486,714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_ShareSubscriptionWarrantsBSAMember', window );">BSAs | Board member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_ShareSubscriptionWarrantsBSAMember', window );">BSAs | Tranche 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_ShareSubscriptionWarrantsBSAMember', window );">BSAs | Tranche 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=abvx_MajorShareBasedTransactionsMember', window );">Major share-based transactions | Free shares (AGA)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=abvx_MajorShareBasedTransactionsMember', window );">Major share-based transactions | Free shares (AGA) | Tranche 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=abvx_MajorShareBasedTransactionsMember', window );">Major share-based transactions | Free shares (AGA) | Tranche 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=abvx_MajorShareBasedTransactionsMember', window );">Major share-based transactions | Free shares (AGA) | Tranche 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=abvx_MajorShareBasedTransactionsMember', window );">Major share-based transactions | BSAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=abvx_MajorShareBasedTransactionsMember', window );">Major share-based transactions | BSAs | Board member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=abvx_CSOSettlementAgreementMember', window );">CSO, settlement agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits', window );">Termination benefits | &#8364;</a></td>
<td class="nump">&#8364; 278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_KeyManagementPersonnelCompensationContractualSeveranceIndemnity', window );">Contractual severance indemnity | &#8364;</a></td>
<td class="nump">&#8364; 240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=abvx_CSOSettlementAgreementMember', window );">CSO, settlement agreement | Free shares (AGA)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfSharesWaived', window );">Number of shares waived (in shares)</a></td>
<td class="nump">77,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfSharesWithPerformanceConditionsWaived', window );">Number of shares with performance conditions waived (in shares)</a></td>
<td class="nump">40,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfSharesLapsed', window );">Number of shares lapsed (in shares)</a></td>
<td class="nump">217,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_KeyManagementPersonnelCompensationContractualSeveranceIndemnity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Key Management Personnel Compensation, Contractual Severance Indemnity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_KeyManagementPersonnelCompensationContractualSeveranceIndemnity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfSharesLapsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Lapsed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfSharesLapsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfSharesWaived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Waived</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfSharesWaived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfSharesWithPerformanceConditionsWaived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares With Performance Conditions Waived</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfSharesWithPerformanceConditionsWaived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Vesting Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Vesting Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_FreeSharesAGAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_FreeSharesAGAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_ShareSubscriptionWarrantsBSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_ShareSubscriptionWarrantsBSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=abvx_BoardMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=abvx_BoardMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_TranchesAxis=abvx_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_TranchesAxis=abvx_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_TranchesAxis=abvx_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_TranchesAxis=abvx_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=abvx_MajorShareBasedTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=abvx_MajorShareBasedTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_TranchesAxis=abvx_TrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_TranchesAxis=abvx_TrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=abvx_CSOSettlementAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=abvx_CSOSettlementAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting principles - Intangible assets (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>criteria</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ResearchAndDevelopmentCostsRecognitionInitialMeasurementNumberOfCriterias', window );">Research and development costs recognition, initial measurement, number of criterias</a></td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember', window );">Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life measured as period of time, intangible assets other than goodwill</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ResearchAndDevelopmentCostsRecognitionInitialMeasurementNumberOfCriterias">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Costs Recognition, Initial Measurement, Number Of Criterias</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ResearchAndDevelopmentCostsRecognitionInitialMeasurementNumberOfCriterias</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting principles - Disclosure of depreciation period of property, plant and equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember', window );">Office fixtures and fittings</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Useful life measured as period of time, property, plant and equipment</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=abvx_IndustrialMaterialsAndEquipmentMember', window );">Industrial materials and equipment | Bottom of range</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Useful life measured as period of time, property, plant and equipment</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=abvx_IndustrialMaterialsAndEquipmentMember', window );">Industrial materials and equipment | Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Useful life measured as period of time, property, plant and equipment</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=abvx_TechnicalFacilitiesMember', window );">Technical facilities | Bottom of range</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Useful life measured as period of time, property, plant and equipment</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=abvx_TechnicalFacilitiesMember', window );">Technical facilities | Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Useful life measured as period of time, property, plant and equipment</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office equipment | Bottom of range</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Useful life measured as period of time, property, plant and equipment</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office equipment | Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Useful life measured as period of time, property, plant and equipment</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">IT equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Useful life measured as period of time, property, plant and equipment</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=abvx_FurnitureMember', window );">Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Useful life measured as period of time, property, plant and equipment</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 73<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_73_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=abvx_IndustrialMaterialsAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=abvx_IndustrialMaterialsAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=abvx_TechnicalFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=abvx_TechnicalFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=abvx_FurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=abvx_FurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfOperatingSegment', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ContributionToGroupsAssetsPercentage', window );">Contribution to Group's assets, percentage</a></td>
<td class="nump">29.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ContributionToGroupsLiabilitiesPercentage', window );">Contribution to Group's liabilities, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ContributionToGroupsNetProfitsLossesPercentage', window );">Contribution to Group's net profits (losses), percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ContributionToGroupsAssetsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contribution To Group's Assets, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ContributionToGroupsAssetsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ContributionToGroupsLiabilitiesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contribution To Group's Liabilities, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ContributionToGroupsLiabilitiesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ContributionToGroupsNetProfitsLossesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contribution To Group's Net Profits (Losses), Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ContributionToGroupsNetProfitsLossesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfOperatingSegment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Operating Segment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfOperatingSegment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeographicalAreasLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeographicalAreasLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and impairment test (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems', window );"><strong>Disclosure of information for cash-generating units [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment loss recognised in profit or loss, intangible assets and goodwill</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">&#8364; 18,419<span></span>
</td>
<td class="nump">&#8364; 18,419<span></span>
</td>
<td class="nump">&#8364; 18,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections', window );">Discount rate (WACC)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">11.50%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis=abvx_WittycelSASABX196Member', window );">Wittycel SAS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems', window );"><strong>Disclosure of information for cash-generating units [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment loss recognised in profit or loss, intangible assets and goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill', window );">Impairment loss recognised in profit or loss, goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Impairment loss recognised in profit or loss, intangible assets other than goodwill</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis=abvx_SplicosSASABX464Member', window );">Splicos SAS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems', window );"><strong>Disclosure of information for cash-generating units [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">&#8364; 18,419<span></span>
</td>
<td class="nump">&#8364; 18,419<span></span>
</td>
<td class="nump">&#8364; 18,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The discount rate applied to cash flow projections for a cash-generating unit (group of units). [Refer: Total for all cash-generating units [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2025-01-01<br> -Paragraph 134<br> -Subparagraph d<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_134_d_v&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2025-01-01<br> -Paragraph 134<br> -Subparagraph e<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_134_e_v&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 254<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_254_d_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 254<br> -Subparagraph f<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_254_f_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 254<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_254_d_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 254<br> -Subparagraph f<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_254_f_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2025-01-01<br> -Paragraph 134<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2025-01-01<br> -Paragraph 135<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2025-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 254<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_254_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 255<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_255_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 254<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_254_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 255<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_255_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2025-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B67_d_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 37<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_37_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 37<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_37_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis=abvx_WittycelSASABX196Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis=abvx_WittycelSASABX196Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis=abvx_SplicosSASABX464Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis=abvx_SplicosSASABX464Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets - Narrative (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_AssetsAcquisitionsAxis=abvx_ProsynergiaMember', window );">Prosynergia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TechnologyBasedIntangibleAssetsAssetsAcquisitions', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6,529<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_PrincipalAgreementsAxis=abvx_ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember', window );">Exclusive licensing contract with the Scripps Research Institute, University of Chicago and Brigham Young University</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_CollaborationAgreementsDevelopmentMilestonePaymentINDApproval', window );">Collaboration agreements, development milestone payment, IND approval</a></td>
<td class="nump">&#8364; 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_PrincipalAgreementsAxis=abvx_ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember', window );">Exclusive licensing agreement with CNRS, University of Montpellier and Institut Curie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_CollaborationAgreementsDevelopmentMilestonePaymentPhase2', window );">Collaboration agreements, development milestone payment, Phase 2</a></td>
<td class="nump">&#8364; 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis=abvx_WittycelSASABX196Member', window );">Wittycel SAS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife', window );">Intangible assets with indefinite useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Impairment loss recognised in profit or loss, intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_CollaborationAgreementsDevelopmentMilestonePaymentINDApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, Development Milestone Payment, IND Approval</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_CollaborationAgreementsDevelopmentMilestonePaymentINDApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_CollaborationAgreementsDevelopmentMilestonePaymentPhase2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, Development Milestone Payment, Phase 2</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_CollaborationAgreementsDevelopmentMilestonePaymentPhase2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_TechnologyBasedIntangibleAssetsAssetsAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Technology-Based Intangible Assets, Assets Acquisitions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_TechnologyBasedIntangibleAssetsAssetsAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets assessed as having an indefinite useful life. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2025-01-01<br> -Paragraph 134<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_134_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2025-01-01<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 122<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_122_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 254<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_254_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 264<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_264_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 255<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_255_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 254<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_254_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 255<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_255_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 264<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_264_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_AssetsAcquisitionsAxis=abvx_ProsynergiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_AssetsAcquisitionsAxis=abvx_ProsynergiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_PrincipalAgreementsAxis=abvx_ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_PrincipalAgreementsAxis=abvx_ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_PrincipalAgreementsAxis=abvx_ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_PrincipalAgreementsAxis=abvx_ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis=abvx_WittycelSASABX196Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis=abvx_WittycelSASABX196Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets - Disclosure of reconciliation of intangible assets (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at beginning of period</a></td>
<td class="nump">&#8364; 6,606<span></span>
</td>
<td class="nump">&#8364; 6,604<span></span>
</td>
<td class="nump">&#8364; 6,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at end of period</a></td>
<td class="nump">6,605<span></span>
</td>
<td class="nump">6,606<span></span>
</td>
<td class="nump">6,604<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesMember', window );">LICENSES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at beginning of period</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at end of period</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">SOFTWARE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at beginning of period</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at end of period</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember', window );">PATENTS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at beginning of period</a></td>
<td class="nump">6,529<span></span>
</td>
<td class="nump">6,529<span></span>
</td>
<td class="nump">6,529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at end of period</a></td>
<td class="nump">6,529<span></span>
</td>
<td class="nump">6,529<span></span>
</td>
<td class="nump">6,529<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">GROSS VALUES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at beginning of period</a></td>
<td class="nump">6,677<span></span>
</td>
<td class="nump">6,673<span></span>
</td>
<td class="nump">6,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at end of period</a></td>
<td class="nump">6,677<span></span>
</td>
<td class="nump">6,677<span></span>
</td>
<td class="nump">6,673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">GROSS VALUES | LICENSES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at beginning of period</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at end of period</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">GROSS VALUES | SOFTWARE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at beginning of period</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at end of period</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">GROSS VALUES | PATENTS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at beginning of period</a></td>
<td class="nump">6,529<span></span>
</td>
<td class="nump">6,529<span></span>
</td>
<td class="nump">6,529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at end of period</a></td>
<td class="nump">6,529<span></span>
</td>
<td class="nump">6,529<span></span>
</td>
<td class="nump">6,529<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">AMORTIZATION</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at beginning of period</a></td>
<td class="num">(70)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Increase</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at end of period</a></td>
<td class="num">(71)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">AMORTIZATION | LICENSES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at beginning of period</a></td>
<td class="num">(45)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Increase</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at end of period</a></td>
<td class="num">(45)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">AMORTIZATION | SOFTWARE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at beginning of period</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Increase</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at end of period</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">AMORTIZATION | PATENTS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at beginning of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Increase</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at end of period</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment - Disclosure of reconciliation of property, plant and equipment (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at beginning of period</a></td>
<td class="nump">&#8364; 2,666<span></span>
</td>
<td class="nump">&#8364; 878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at end of period</a></td>
<td class="nump">2,090<span></span>
</td>
<td class="nump">2,666<span></span>
</td>
<td class="nump">&#8364; 878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis=ifrs-full_PropertyPlantAndEquipmentMember', window );">Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at beginning of period</a></td>
<td class="nump">2,666<span></span>
</td>
<td class="nump">878<span></span>
</td>
<td class="nump">1,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at end of period</a></td>
<td class="nump">2,090<span></span>
</td>
<td class="nump">2,666<span></span>
</td>
<td class="nump">878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis=ifrs-full_RightofuseAssetsMember', window );">ROU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at beginning of period</a></td>
<td class="nump">1,950<span></span>
</td>
<td class="nump">501<span></span>
</td>
<td class="nump">1,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at end of period</a></td>
<td class="nump">1,563<span></span>
</td>
<td class="nump">1,950<span></span>
</td>
<td class="nump">501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember', window );">BUILDINGS | Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at beginning of period</a></td>
<td class="nump">2,205<span></span>
</td>
<td class="nump">509<span></span>
</td>
<td class="nump">1,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at end of period</a></td>
<td class="nump">1,706<span></span>
</td>
<td class="nump">2,205<span></span>
</td>
<td class="nump">509<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">EQUIPMENT | Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at beginning of period</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at end of period</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=abvx_FurnitureAndComputerEquipmentMember', window );">FURNITURE AND COMPUTER EQUIPMENT | Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at beginning of period</a></td>
<td class="nump">366<span></span>
</td>
<td class="nump">242<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at end of period</a></td>
<td class="nump">325<span></span>
</td>
<td class="nump">366<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">GROSS VALUES | Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at beginning of period</a></td>
<td class="nump">4,029<span></span>
</td>
<td class="nump">2,366<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Acquisition</a></td>
<td class="nump">559<span></span>
</td>
<td class="nump">2,870<span></span>
</td>
<td class="nump">614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Disposal</a></td>
<td class="num">(252)<span></span>
</td>
<td class="num">(1,229)<span></span>
</td>
<td class="num">(649)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Effect of the change in foreign currency exchange rates</a></td>
<td class="num">(62)<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at end of period</a></td>
<td class="nump">4,274<span></span>
</td>
<td class="nump">4,029<span></span>
</td>
<td class="nump">2,366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">GROSS VALUES | ROU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at beginning of period</a></td>
<td class="nump">2,526<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
<td class="nump">1,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Acquisition</a></td>
<td class="nump">424<span></span>
</td>
<td class="nump">2,217<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Disposal</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(975)<span></span>
</td>
<td class="num">(649)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Effect of the change in foreign currency exchange rates</a></td>
<td class="num">(50)<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at end of period</a></td>
<td class="nump">2,865<span></span>
</td>
<td class="nump">2,526<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">GROSS VALUES | BUILDINGS | Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at beginning of period</a></td>
<td class="nump">2,818<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
<td class="nump">1,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Acquisition</a></td>
<td class="nump">436<span></span>
</td>
<td class="nump">2,578<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Disposal</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,110)<span></span>
</td>
<td class="num">(622)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Effect of the change in foreign currency exchange rates</a></td>
<td class="num">(50)<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at end of period</a></td>
<td class="nump">3,204<span></span>
</td>
<td class="nump">2,818<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">GROSS VALUES | EQUIPMENT | Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at beginning of period</a></td>
<td class="nump">513<span></span>
</td>
<td class="nump">513<span></span>
</td>
<td class="nump">436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Disposal</a></td>
<td class="num">(49)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Effect of the change in foreign currency exchange rates</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at end of period</a></td>
<td class="nump">463<span></span>
</td>
<td class="nump">513<span></span>
</td>
<td class="nump">513<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">GROSS VALUES | FURNITURE AND COMPUTER EQUIPMENT | Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at beginning of period</a></td>
<td class="nump">698<span></span>
</td>
<td class="nump">507<span></span>
</td>
<td class="nump">346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Acquisition</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">292<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Disposal</a></td>
<td class="num">(203)<span></span>
</td>
<td class="num">(119)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Effect of the change in foreign currency exchange rates</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at end of period</a></td>
<td class="nump">607<span></span>
</td>
<td class="nump">698<span></span>
</td>
<td class="nump">507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">DEPRECIATION | Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at beginning of period</a></td>
<td class="num">(1,363)<span></span>
</td>
<td class="num">(1,488)<span></span>
</td>
<td class="num">(808)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Increase</a></td>
<td class="num">(1,095)<span></span>
</td>
<td class="num">(1,089)<span></span>
</td>
<td class="num">(707)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Disposal</a></td>
<td class="nump">252<span></span>
</td>
<td class="nump">1,215<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Effect of the change in foreign currency exchange rates</a></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at end of period</a></td>
<td class="num">(2,184)<span></span>
</td>
<td class="num">(1,363)<span></span>
</td>
<td class="num">(1,488)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">DEPRECIATION | ROU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at beginning of period</a></td>
<td class="num">(575)<span></span>
</td>
<td class="num">(761)<span></span>
</td>
<td class="num">(290)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Increase</a></td>
<td class="num">(797)<span></span>
</td>
<td class="num">(788)<span></span>
</td>
<td class="num">(498)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Disposal</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">975<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Effect of the change in foreign currency exchange rates</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at end of period</a></td>
<td class="num">(1,302)<span></span>
</td>
<td class="num">(575)<span></span>
</td>
<td class="num">(761)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">DEPRECIATION | BUILDINGS | Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at beginning of period</a></td>
<td class="num">(613)<span></span>
</td>
<td class="num">(837)<span></span>
</td>
<td class="num">(259)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Increase</a></td>
<td class="num">(903)<span></span>
</td>
<td class="num">(886)<span></span>
</td>
<td class="num">(578)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Disposal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,111<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Effect of the change in foreign currency exchange rates</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at end of period</a></td>
<td class="num">(1,498)<span></span>
</td>
<td class="num">(613)<span></span>
</td>
<td class="num">(837)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">DEPRECIATION | EQUIPMENT | Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at beginning of period</a></td>
<td class="num">(419)<span></span>
</td>
<td class="num">(387)<span></span>
</td>
<td class="num">(378)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Increase</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Disposal</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Effect of the change in foreign currency exchange rates</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at end of period</a></td>
<td class="num">(404)<span></span>
</td>
<td class="num">(419)<span></span>
</td>
<td class="num">(387)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">DEPRECIATION | FURNITURE AND COMPUTER EQUIPMENT | Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at beginning of period</a></td>
<td class="num">(332)<span></span>
</td>
<td class="num">(265)<span></span>
</td>
<td class="num">(171)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Increase</a></td>
<td class="num">(158)<span></span>
</td>
<td class="num">(171)<span></span>
</td>
<td class="num">(94)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Disposal</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Effect of the change in foreign currency exchange rates</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at end of period</a></td>
<td class="num">&#8364; (281)<span></span>
</td>
<td class="num">&#8364; (332)<span></span>
</td>
<td class="num">&#8364; (265)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment including right-of-use assets other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment including right-of-use assets resulting from disposals. [Refer: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in property, plant and equipment including right-of-use assets resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant and equipment including right-of-use assets whose underlying assets would be presented as property, plant and equipment if they were owned. [Refer: Property, plant and equipment; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis=ifrs-full_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis=ifrs-full_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis=ifrs-full_RightofuseAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis=ifrs-full_RightofuseAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=abvx_FurnitureAndComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=abvx_FurnitureAndComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment - Narrative (Details) - Buildings - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">&#8364; 453<span></span>
</td>
<td class="nump">&#8364; 1,473<span></span>
</td>
<td class="nump">&#8364; 1,846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=abvx_LeaseFacilitiesParisMember', window );">Lease facilities, Paris</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DecreaseThroughReassessmentOfLeaseTermRightOfUseAssets', window );">Decrease through reassessment of lease term</a></td>
<td class="nump">&#8364; 622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DecreaseThroughReassessmentOfLeaseTermRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease Through Reassessment Of Lease Term, Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DecreaseThroughReassessmentOfLeaseTermRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=abvx_LeaseFacilitiesParisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=abvx_LeaseFacilitiesParisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other financial assets - Disclosure of other financial assets (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsAbstract', window );"><strong>Disclosure of financial assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NonCurrentAdvancesToCROContractsUndiscountedAmount', window );">Advances related to CRO contracts</a></td>
<td class="nump">&#8364; 4,665<span></span>
</td>
<td class="nump">&#8364; 4,929<span></span>
</td>
<td class="nump">&#8364; 12,172<span></span>
</td>
<td class="nump">&#8364; 12,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermDeposits', window );">Deposits</a></td>
<td class="nump">693<span></span>
</td>
<td class="nump">863<span></span>
</td>
<td class="nump">574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_OtherNonCurrentMiscellaneousFinancialAssets', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialAssets', window );">Total other non-current financial assets</a></td>
<td class="nump">5,358<span></span>
</td>
<td class="nump">5,919<span></span>
</td>
<td class="nump">12,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_CurrentAdvancesToCROContracts', window );">Advances related to CRO contracts</a></td>
<td class="nump">7,717<span></span>
</td>
<td class="nump">7,418<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents', window );">Deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_OtherCurrentInvestments', window );">Other investments</a></td>
<td class="nump">13,698<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Total other current financial assets</a></td>
<td class="nump">21,415<span></span>
</td>
<td class="nump">7,554<span></span>
</td>
<td class="nump">9,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinancialAssets', window );">Other financial assets</a></td>
<td class="nump">&#8364; 26,772<span></span>
</td>
<td class="nump">&#8364; 13,473<span></span>
</td>
<td class="nump">&#8364; 22,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_CurrentAdvancesToCROContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Advances To CRO Contracts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_CurrentAdvancesToCROContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NonCurrentAdvancesToCROContractsUndiscountedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Current Advances To CRO Contracts, Undiscounted Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NonCurrentAdvancesToCROContractsUndiscountedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_OtherCurrentInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Current Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_OtherCurrentInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_OtherNonCurrentMiscellaneousFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Non-Current Miscellaneous Financial Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_OtherNonCurrentMiscellaneousFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of long-term deposits held by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of short-term deposits held by the entity that are not classified as cash equivalents. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other financial assets - Narrative (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NonCurrentAdvancesToCROContractsUndiscountedAmount', window );">Advances related to CRO contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,665<span></span>
</td>
<td class="nump">&#8364; 4,929<span></span>
</td>
<td class="nump">&#8364; 12,172<span></span>
</td>
<td class="nump">&#8364; 12,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DiscountRateAppliedToLongTermAdvances', window );">Disount rate applied to long-term advances</a></td>
<td class="nump">6.83%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_PaymentsForAdvancesMadeToContractResearchOrganizationsUndiscountedAmount', window );">Cash advances and loans made to CRO</a></td>
<td class="nump">&#8364; 5,538<span></span>
</td>
<td class="nump">&#8364; 1,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DiscountRateAppliedToLongTermAdvances', window );">Disount rate applied to long-term advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.09%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.19%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DiscountRateAppliedToLongTermAdvances', window );">Disount rate applied to long-term advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.59%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.16%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DiscountRateAppliedToLongTermAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount Rate Applied To Long-Term Advances</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DiscountRateAppliedToLongTermAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NonCurrentAdvancesToCROContractsUndiscountedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Current Advances To CRO Contracts, Undiscounted Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NonCurrentAdvancesToCROContractsUndiscountedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_PaymentsForAdvancesMadeToContractResearchOrganizationsUndiscountedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Advances Made to Contract Research Organizations, Undiscounted Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_PaymentsForAdvancesMadeToContractResearchOrganizationsUndiscountedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other receivables and other assets - Disclosure of other receivables and other assets (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesAbstract', window );"><strong>Trade and other receivables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NonCurrentPrepaidExpenses', window );">Prepaid expenses - non current</a></td>
<td class="nump">&#8364; 625<span></span>
</td>
<td class="nump">&#8364; 948<span></span>
</td>
<td class="nump">&#8364; 2,320<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentNonfinancialAssets', window );">Total other non-current assets</a></td>
<td class="nump">625<span></span>
</td>
<td class="nump">948<span></span>
</td>
<td class="nump">2,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_CurrentResearchTaxCreditReceivables', window );">Research tax credit ("CIR")</a></td>
<td class="nump">3,196<span></span>
</td>
<td class="nump">5,774<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentValueAddedTaxReceivables', window );">VAT receivables</a></td>
<td class="nump">6,870<span></span>
</td>
<td class="nump">9,841<span></span>
</td>
<td class="nump">14,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">2,649<span></span>
</td>
<td class="nump">3,233<span></span>
</td>
<td class="nump">5,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_CurrentReceivablesForEmployeeBenefits', window );">Employee-related receivables</a></td>
<td class="nump">429<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_CurrentReceivablesFromCreditNotes', window );">Credit notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_CurrentReceivablesAndCurrentPrepaidExpenses', window );">Total current other receivables and assets</a></td>
<td class="nump">13,144<span></span>
</td>
<td class="nump">18,896<span></span>
</td>
<td class="nump">24,845<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Other receivables and assets</a></td>
<td class="nump">&#8364; 13,769<span></span>
</td>
<td class="nump">&#8364; 19,843<span></span>
</td>
<td class="nump">&#8364; 27,164<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_CurrentReceivablesAndCurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Receivables And Current Prepaid Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_CurrentReceivablesAndCurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_CurrentReceivablesForEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Receivables for Employee Benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_CurrentReceivablesForEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_CurrentReceivablesFromCreditNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Receivables From Credit Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_CurrentReceivablesFromCreditNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_CurrentResearchTaxCreditReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Research Tax Credit Receivables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_CurrentResearchTaxCreditReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NonCurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Current Prepaid Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NonCurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentValueAddedTaxReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current value added tax receivables. [Refer: Value added tax receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentValueAddedTaxReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentNonfinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentNonfinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other receivables and other assets - Narrative (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">145 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems', window );"><strong>Disclosure Of Other Receivables And Other Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ProceedsFromResearchTaxCredit', window );">Proceeds from research tax credit</a></td>
<td class="nump">&#8364; 5,640<span></span>
</td>
<td class="nump">&#8364; 4,493<span></span>
</td>
<td class="nump">&#8364; 41,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_CurrentResearchTaxCreditReceivables', window );">Research tax credit ("CIR")</a></td>
<td class="nump">3,196<span></span>
</td>
<td class="nump">5,774<span></span>
</td>
<td class="nump">3,196<span></span>
</td>
<td class="nump">&#8364; 4,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_CurrentPrepaidExpensesRelatedToCRO', window );">Current prepaid expenses related to CRO</a></td>
<td class="nump">1,068<span></span>
</td>
<td class="nump">1,577<span></span>
</td>
<td class="nump">1,068<span></span>
</td>
<td class="nump">1,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAdvancesToSuppliers', window );">Current advances to suppliers</a></td>
<td class="nump">&#8364; 2,207<span></span>
</td>
<td class="nump">2,604<span></span>
</td>
<td class="nump">&#8364; 2,207<span></span>
</td>
<td class="nump">3,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheBMember', window );">Kreos &amp; Claret financing, tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems', window );"><strong>Disclosure Of Other Receivables And Other Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ReclassificationOfPrepaidExpensesToCarryingValueOfDebtComponent', window );">Reclassification of prepaid expenses to carrying value of debt component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=abvx_DeferredFinancingCostsNettingMember', window );">Deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems', window );"><strong>Disclosure Of Other Receivables And Other Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,152<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_CurrentPrepaidExpensesRelatedToCRO">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Prepaid Expenses Related To CRO</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_CurrentPrepaidExpensesRelatedToCRO</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_CurrentResearchTaxCreditReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Research Tax Credit Receivables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_CurrentResearchTaxCreditReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Other Receivables And Other Assets [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ProceedsFromResearchTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Research Tax Credit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ProceedsFromResearchTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ReclassificationOfPrepaidExpensesToCarryingValueOfDebtComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of Prepaid Expenses to Carrying Value of Debt Component</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ReclassificationOfPrepaidExpensesToCarryingValueOfDebtComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAdvancesToSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current advances made to suppliers before goods or services are received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAdvancesToSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=abvx_DeferredFinancingCostsNettingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=abvx_DeferredFinancingCostsNettingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and cash equivalents - Disclosure of composition of cash and cash equivalents (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashEquivalents', window );">Cash equivalents</a></td>
<td class="nump">&#8364; 478,541<span></span>
</td>
<td class="nump">&#8364; 87,265<span></span>
</td>
<td class="nump">&#8364; 18,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash</a></td>
<td class="nump">38,144<span></span>
</td>
<td class="nump">56,956<span></span>
</td>
<td class="nump">233,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">&#8364; 516,685<span></span>
</td>
<td class="nump">&#8364; 144,221<span></span>
</td>
<td class="nump">&#8364; 251,942<span></span>
</td>
<td class="nump">&#8364; 26,950<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and cash equivalents - Narrative (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfCashAndCashEquivalentsLineItems', window );"><strong>Disclosure Of Cash And Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCashAndCashEquivalents', window );">Notice accounts</a></td>
<td class="nump">&#8364; 5,744<span></span>
</td>
<td class="nump">&#8364; 44,239<span></span>
</td>
<td class="nump">&#8364; 231,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Effect of movements in exchange rates on cash held</a></td>
<td class="num">(10,251)<span></span>
</td>
<td class="nump">2,382<span></span>
</td>
<td class="num">(5,072)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">United States of America, Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfCashAndCashEquivalentsLineItems', window );"><strong>Disclosure Of Cash And Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Effect of movements in exchange rates on cash held</a></td>
<td class="num">&#8364; (8,639)<span></span>
</td>
<td class="nump">&#8364; 2,035<span></span>
</td>
<td class="num">&#8364; (3,196)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DisclosureOfCashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Cash And Cash Equivalents [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DisclosureOfCashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash and cash equivalents that the entity does not separately disclose in the same statement or note. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial assets and liabilities (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;) </div>
<div>tranche</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Aug. 22, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Financial assets</a></td>
<td class="nump">&#8364; 205,228<span></span>
</td>
<td class="nump">&#8364; 327,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 584,341<span></span>
</td>
<td class="nump">&#8364; 205,228<span></span>
</td>
<td class="nump">&#8364; 327,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">176,754<span></span>
</td>
<td class="nump">301,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">557,595<span></span>
</td>
<td class="nump">176,754<span></span>
</td>
<td class="nump">301,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="nump">&#8364; 162,256<span></span>
</td>
<td class="nump">&#8364; 125,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 141,409<span></span>
</td>
<td class="nump">&#8364; 162,256<span></span>
</td>
<td class="nump">&#8364; 125,191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis=ifrs-full_DiscountedCashFlowMember', window );">Discounted cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible increase in unobservable input, liabilities</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_CreditSpreadMeasurementInputMember', window );">Credit spread | Discounted cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets', window );">Percentage of reasonably possible increase in unobservable input, assets</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible increase in unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_NonCurrentFinancialLiabilitiesMember', window );">Financial liabilities-non current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="nump">&#8364; 73,497<span></span>
</td>
<td class="nump">&#8364; 40,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 102,555<span></span>
</td>
<td class="nump">&#8364; 73,497<span></span>
</td>
<td class="nump">&#8364; 40,622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosClaretFinancingTrancheABAndCMember', window );">Kreos &amp; Claret Financing, Tranche A,B and C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_CurrentFinancialLiabilitiesMember', window );">Financial liabilities-current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="nump">&#8364; 44,935<span></span>
</td>
<td class="nump">37,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,302<span></span>
</td>
<td class="nump">44,935<span></span>
</td>
<td class="nump">37,348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_TradePayablesAndOtherCurrentLiabilitiesMember', window );">Trade payables and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="nump">43,824<span></span>
</td>
<td class="nump">47,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,552<span></span>
</td>
<td class="nump">43,824<span></span>
</td>
<td class="nump">47,221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember', window );">LIABILITIES AT FAIR VALUE THROUGH PROFIT&#160;AND LOSS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="nump">24,803<span></span>
</td>
<td class="nump">30,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,803<span></span>
</td>
<td class="nump">30,037<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember', window );">LIABILITIES AT FAIR VALUE THROUGH PROFIT&#160;AND LOSS | Financial liabilities-non current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="nump">3,620<span></span>
</td>
<td class="nump">18,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,620<span></span>
</td>
<td class="nump">18,506<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember', window );">LIABILITIES AT FAIR VALUE THROUGH PROFIT&#160;AND LOSS | Financial liabilities-current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="nump">21,183<span></span>
</td>
<td class="nump">11,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,183<span></span>
</td>
<td class="nump">11,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember', window );">LIABILITIES AT FAIR VALUE THROUGH PROFIT&#160;AND LOSS | Trade payables and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember', window );">LIABILITIES AT&#160;AMORTIZED COST</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="nump">137,453<span></span>
</td>
<td class="nump">95,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,409<span></span>
</td>
<td class="nump">137,453<span></span>
</td>
<td class="nump">95,154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember', window );">LIABILITIES AT&#160;AMORTIZED COST | Financial liabilities-non current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="nump">69,877<span></span>
</td>
<td class="nump">42,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,555<span></span>
</td>
<td class="nump">69,877<span></span>
</td>
<td class="nump">42,768<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember', window );">LIABILITIES AT&#160;AMORTIZED COST | Financial liabilities-current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="nump">23,752<span></span>
</td>
<td class="nump">5,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,302<span></span>
</td>
<td class="nump">23,752<span></span>
</td>
<td class="nump">5,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember', window );">LIABILITIES AT&#160;AMORTIZED COST | Trade payables and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="nump">43,824<span></span>
</td>
<td class="nump">47,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,552<span></span>
</td>
<td class="nump">43,824<span></span>
</td>
<td class="nump">47,221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember', window );">ASSETS AT FAIR VALUE THROUGH PROFIT&#160;AND LOSS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">437,031<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">ASSETS AT AMORTIZED COST</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">176,754<span></span>
</td>
<td class="nump">301,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,565<span></span>
</td>
<td class="nump">176,754<span></span>
</td>
<td class="nump">301,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Recurring fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Financial assets</a></td>
<td class="nump">177,537<span></span>
</td>
<td class="nump">301,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">557,226<span></span>
</td>
<td class="nump">177,537<span></span>
</td>
<td class="nump">301,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Financial liabilities</a></td>
<td class="nump">157,828<span></span>
</td>
<td class="nump">124,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,644<span></span>
</td>
<td class="nump">157,828<span></span>
</td>
<td class="nump">124,266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Recurring fair value measurement | Financial liabilities-non current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Financial liabilities</a></td>
<td class="nump">&#8364; 69,069<span></span>
</td>
<td class="nump">&#8364; 39,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,790<span></span>
</td>
<td class="nump">&#8364; 69,069<span></span>
</td>
<td class="nump">&#8364; 39,697<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Recurring fair value measurement | Kreos &amp; Claret Financing, Tranche A,B and C | Credit spread | Discounted cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">0.0750<span></span>
</td>
<td class="nump">0.0900<span></span>
</td>
<td class="nump">0.0960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0750<span></span>
</td>
<td class="nump">0.0900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Decrease in financial liabilities at fair value</a></td>
<td class="nump">&#8364; 958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Recurring fair value measurement | Kreos &amp; Claret convertible notes (OCABSA) | Credit spread | Discounted cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Decrease in financial liabilities at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 538<span></span>
</td>
<td class="nump">&#8364; 624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Recurring fair value measurement | Conditional advances and PGE loan | Credit spread | Discounted cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">0.0730<span></span>
</td>
<td class="nump">0.0900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0730<span></span>
</td>
<td class="nump">0.0900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Recurring fair value measurement | PGE | Credit spread | Discounted cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Decrease in financial liabilities at fair value</a></td>
<td class="nump">&#8364; 21<span></span>
</td>
<td class="nump">&#8364; 39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Recurring fair value measurement | RNP-VIR conditional advance | Credit spread | Discounted cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Decrease in financial liabilities at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Recurring fair value measurement | CARENA conditional advance | Credit spread | Discounted cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Decrease in financial liabilities at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Recurring fair value measurement | Ebola conditional advance | Credit spread | Discounted cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Decrease in financial liabilities at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Recurring fair value measurement | Financial liabilities-current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Financial liabilities</a></td>
<td class="nump">44,935<span></span>
</td>
<td class="nump">37,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,302<span></span>
</td>
<td class="nump">&#8364; 44,935<span></span>
</td>
<td class="nump">&#8364; 37,348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Recurring fair value measurement | Trade payables and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Financial liabilities</a></td>
<td class="nump">43,824<span></span>
</td>
<td class="nump">47,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,552<span></span>
</td>
<td class="nump">43,824<span></span>
</td>
<td class="nump">47,221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=abvx_OtherFinancialAssetsMember', window );">Other financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">12,690<span></span>
</td>
<td class="nump">22,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,141<span></span>
</td>
<td class="nump">12,690<span></span>
</td>
<td class="nump">22,394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=abvx_OtherFinancialAssetsMember', window );">Other financial assets | ASSETS AT FAIR VALUE THROUGH PROFIT&#160;AND LOSS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=abvx_OtherFinancialAssetsMember', window );">Other financial assets | ASSETS AT AMORTIZED COST</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">12,690<span></span>
</td>
<td class="nump">22,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,141<span></span>
</td>
<td class="nump">12,690<span></span>
</td>
<td class="nump">22,394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=abvx_OtherFinancialAssetsMember', window );">Other financial assets | Recurring fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Financial assets</a></td>
<td class="nump">13,473<span></span>
</td>
<td class="nump">22,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,772<span></span>
</td>
<td class="nump">13,473<span></span>
</td>
<td class="nump">22,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=abvx_OtherReceivablesAndAssetsMember', window );">Other receivables and assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">19,843<span></span>
</td>
<td class="nump">27,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,769<span></span>
</td>
<td class="nump">19,843<span></span>
</td>
<td class="nump">27,164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=abvx_OtherReceivablesAndAssetsMember', window );">Other receivables and assets | ASSETS AT FAIR VALUE THROUGH PROFIT&#160;AND LOSS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=abvx_OtherReceivablesAndAssetsMember', window );">Other receivables and assets | ASSETS AT AMORTIZED COST</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">19,843<span></span>
</td>
<td class="nump">27,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,769<span></span>
</td>
<td class="nump">19,843<span></span>
</td>
<td class="nump">27,164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=abvx_OtherReceivablesAndAssetsMember', window );">Other receivables and assets | Recurring fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Financial assets</a></td>
<td class="nump">19,843<span></span>
</td>
<td class="nump">27,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,769<span></span>
</td>
<td class="nump">19,843<span></span>
</td>
<td class="nump">27,164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=abvx_CashAndCashEquivalentMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">144,221<span></span>
</td>
<td class="nump">251,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">516,685<span></span>
</td>
<td class="nump">144,221<span></span>
</td>
<td class="nump">251,942<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=abvx_CashAndCashEquivalentMember', window );">Cash and cash equivalents | ASSETS AT FAIR VALUE THROUGH PROFIT&#160;AND LOSS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">437,031<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=abvx_CashAndCashEquivalentMember', window );">Cash and cash equivalents | ASSETS AT AMORTIZED COST</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">144,221<span></span>
</td>
<td class="nump">251,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,654<span></span>
</td>
<td class="nump">144,221<span></span>
</td>
<td class="nump">251,942<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=abvx_CashAndCashEquivalentMember', window );">Cash and cash equivalents | Recurring fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Financial assets</a></td>
<td class="nump">&#8364; 144,221<span></span>
</td>
<td class="nump">&#8364; 251,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">516,685<span></span>
</td>
<td class="nump">144,221<span></span>
</td>
<td class="nump">251,942<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=abvx_NonCurrentAdvancesToCROContractsMember', window );">Long-term advances made to CROs | Recurring fair value measurement | Credit spread | Discounted cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets', window );">Decrease in financial assets at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 231<span></span>
</td>
<td class="nump">&#8364; 235<span></span>
</td>
<td class="nump">&#8364; 23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=abvx_NonCurrentAdvancesToCROContractsMember', window );">Long-term advances made to CROs | Recurring fair value measurement | Bottom of range | Credit spread | Discounted cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputAssets', window );">Significant unobservable input, assets</a></td>
<td class="nump">0.0131<span></span>
</td>
<td class="nump">0.0104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0034<span></span>
</td>
<td class="nump">0.0131<span></span>
</td>
<td class="nump">0.0104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=abvx_NonCurrentAdvancesToCROContractsMember', window );">Long-term advances made to CROs | Recurring fair value measurement | Top of range | Credit spread | Discounted cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputAssets', window );">Significant unobservable input, assets</a></td>
<td class="nump">0.0271<span></span>
</td>
<td class="nump">0.0218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0131<span></span>
</td>
<td class="nump">0.0271<span></span>
</td>
<td class="nump">0.0218<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Fair Value Measurement Of Assets And Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial assets. [Refer: At fair value [member]; Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in the fair value measurement of assets due to a reasonably possible increase in an unobservable input.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in the fair value measurement of liabilities due to a reasonably possible increase in an unobservable input.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of a reasonably possible increase in an unobservable input used in fair value measurement of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of a reasonably possible increase in an unobservable input used in fair value measurement of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantUnobservableInputAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of significant unobservable input used in the measurement of the fair value of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantUnobservableInputAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of significant unobservable input used in the measurement of the fair value of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis=ifrs-full_DiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis=ifrs-full_DiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_CreditSpreadMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_CreditSpreadMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_NonCurrentFinancialLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=abvx_NonCurrentFinancialLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosClaretFinancingTrancheABAndCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosClaretFinancingTrancheABAndCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_CurrentFinancialLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=abvx_CurrentFinancialLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_TradePayablesAndOtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=abvx_TradePayablesAndOtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosClaretFinancingTrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosClaretFinancingTrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_ConditionalAdvancesAndPGELoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=abvx_ConditionalAdvancesAndPGELoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_PretGarantiParLEtatPGEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=abvx_PretGarantiParLEtatPGEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_RNPVIRConditionalAdvanceBPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=abvx_RNPVIRConditionalAdvanceBPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_CARENAConditionalAdvanceBPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=abvx_CARENAConditionalAdvanceBPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_EbolaConditionalAdvanceBPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=abvx_EbolaConditionalAdvanceBPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=abvx_OtherFinancialAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=abvx_OtherFinancialAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=abvx_OtherReceivablesAndAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=abvx_OtherReceivablesAndAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=abvx_CashAndCashEquivalentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=abvx_CashAndCashEquivalentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=abvx_NonCurrentAdvancesToCROContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=abvx_NonCurrentAdvancesToCROContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Shareholders&#8217; equity - Share capital issued (Details) - EUR (&#8364;)<br> &#8364; / shares in Units, &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 19, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Oct. 24, 2023</div></th>
<th class="th"><div>May 24, 2023</div></th>
<th class="th"><div>Feb. 22, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="nump">&#8364; 785<span></span>
</td>
<td class="nump">&#8364; 633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued (in shares)</a></td>
<td class="nump">78,536,412<span></span>
</td>
<td class="nump">63,347,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,928,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,313,185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (in euro per share)</a></td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfTreasurySharesHeld', window );">Number of treasury shares held (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfTreasurySharesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Treasury Shares Held</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfTreasurySharesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_a_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160_a_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; equity - Change in share capital (Details)<br> &#8364; / shares in Units, &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 25, 2025 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 28, 2025 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 08, 2025 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 30, 2025 </div>
<div>EUR (&#8364;) </div>
<div>note </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 30, 2025 </div>
<div>EUR (&#8364;) </div>
<div>note </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 28, 2025 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 24, 2023 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 24, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 22, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 28, 2025 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 23, 2025 </div>
<div>note</div>
</th>
<th class="th">
<div>Nov. 19, 2024 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Oct. 24, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 22, 2023 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Aug. 20, 2023 </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Capital increase from issuance of ordinary shares | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 637,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 353,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease', window );">Capital increase from issuance of ordinary shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,325,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,679,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,325,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityIssuanceSubscriptionPricePerShare', window );">Equity issuance, subscripion price per share (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Exercises of the Kreos/Claret and other share warrants | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants', window );">Exercises of share warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">464,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 28,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ShareIssueRelatedCostCredit', window );">Transaction costs related to capital increase | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (40,306)<span></span>
</td>
<td class="nump">&#8364; 446<span></span>
</td>
<td class="num">(28,111)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfFreeSharesIssued', window );">Issue of free shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">627,714<span></span>
</td>
<td class="nump">415,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Closing foreign exchange rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_HeightsConvertibleNotesMember', window );">Heights convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityIssuanceSubscriptionPricePerShare', window );">Equity issuance, subscripion price per share (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.4303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfConvertibleNotesConverted', window );">Number of convertible notes converted | note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 21,900<span></span>
</td>
<td class="nump">&#8364; 21,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Increase (decrease) in number of ordinary shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">920,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsFixedConversionPrice', window );">Borrowings, fixed conversion price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 23.7674<span></span>
</td>
<td class="nump">&#8364; 23.7674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheAMember', window );">Kreos &amp; Claret convertible notes (OCABSA)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsFixedConversionPrice', window );">Borrowings, fixed conversion price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 21.2209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=abvx_AmericanDepositorySharesMember', window );">ADS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease', window );">Capital increase from issuance of ordinary shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,679,400<span></span>
</td>
<td class="nump">18,699,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IssueOfEquityOfferingPricePerShare', window );">Issue of equity, offering price per share (in dollar/euro per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Increase (decrease) in number of ordinary shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,679,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease', window );">Capital increase from issuance of ordinary shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,626,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IssueOfEquityOfferingPricePerShare', window );">Issue of equity, offering price per share (in dollar/euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 54.58<span></span>
</td>
<td class="nump">&#8364; 10.9864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary shares | Kreos &amp; Claret convertible notes (OCABSA)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Increase (decrease) in number of ordinary shares issued (in shares)</a></td>
<td class="nump">392,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">785,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsFixedConversionPrice', window );">Borrowings, fixed conversion price (in euro per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 21.2209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 21.2209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary shares | Kreos A &amp; B &amp; C BSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Increase (decrease) in number of ordinary shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20241AndBSA20242Member', window );">BSA-2024-1 and BSA-2024-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ShareWarrantsSubscriptionPricePerShare', window );">Share warrants, subscription price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_FinancialAgreementAxis=abvx_Kreos1Member', window );">Kreos A &amp; B BSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Exercises of the Kreos/Claret and other share warrants | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants', window );">Exercises of share warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_OtherShareWarrantsSubscriptionPricePerShare', window );">Other share warrants, subscripion price per share (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 18.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_FinancialAgreementAxis=abvx_Kreos1Member', window );">Kreos A &amp; B BSA | Kreos A BSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfWarrantsExercised', window );">Number of warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_FinancialAgreementAxis=abvx_Kreos1Member', window );">Kreos A &amp; B BSA | Kreos B BSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfWarrantsExercised', window );">Number of warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_FinancialAgreementAxis=abvx_OtherEquityAgreementsMember', window );">Other equity agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfWarrantsExercised', window );">Number of warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257,087<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">1,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Exercises of the Kreos/Claret and other share warrants | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants', window );">Exercises of share warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257,087<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">190,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_OtherShareWarrantsSubscriptionPricePerShare', window );">Other share warrants, subscripion price per share (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.02<span></span>
</td>
<td class="nump">&#8364; 11.14<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsFixedConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Fixed Conversion Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsFixedConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_EquityIssuanceSubscriptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Issuance, Subscription Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_EquityIssuanceSubscriptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Number Of Ordinary Shares Issued Through Capital Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Number Of Shares Issued Through Exercise Of Share Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IssueOfEquityOfferingPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Offering Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IssueOfEquityOfferingPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfConvertibleNotesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Convertible Notes Converted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfConvertibleNotesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfFreeSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Free Shares Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfFreeSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_OtherShareWarrantsSubscriptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Share Warrants, Subscription Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_OtherShareWarrantsSubscriptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ShareIssueRelatedCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Issue Related Cost (Credit)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ShareIssueRelatedCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ShareWarrantsSubscriptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Warrants, Subscription Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ShareWarrantsSubscriptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClosingForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClosingForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_a_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160_a_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_HeightsConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_HeightsConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=abvx_AmericanDepositorySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=abvx_AmericanDepositorySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosABCBSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_KreosABCBSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20241AndBSA20242Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20241AndBSA20242Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_FinancialAgreementAxis=abvx_Kreos1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_FinancialAgreementAxis=abvx_Kreos1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_KreosABSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_KreosABSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_KreosBBSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_KreosBBSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_FinancialAgreementAxis=abvx_OtherEquityAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_FinancialAgreementAxis=abvx_OtherEquityAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Disclosure of reconciliation of BCEs (Details) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">110 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 14, 2018</div></th>
<th class="th"><div>Mar. 15, 2018</div></th>
<th class="th"><div>Nov. 20, 2017</div></th>
<th class="th"><div>Jan. 23, 2017</div></th>
<th class="th"><div>Nov. 07, 2016</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_FoundersShareSubscriptionWarrantsBCEMember', window );">Total BCEs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">496,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(122,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207,679<span></span>
</td>
<td class="nump">207,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of instruments exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,148<span></span>
</td>
<td class="nump">157,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet', window );">Maximum number of shares to be issued if all conditions are met (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207,679<span></span>
</td>
<td class="nump">207,679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BCE20161Member', window );">BCE-2016-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,796)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of instruments exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet', window );">Maximum number of shares to be issued if all conditions are met (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BCE20171Member', window );">BCE-2017-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,313)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,687<span></span>
</td>
<td class="nump">33,687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of instruments exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,687<span></span>
</td>
<td class="nump">33,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet', window );">Maximum number of shares to be issued if all conditions are met (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,687<span></span>
</td>
<td class="nump">33,687<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BCE20172Member', window );">BCE-2017-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,500<span></span>
</td>
<td class="nump">112,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of instruments exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,500<span></span>
</td>
<td class="nump">112,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet', window );">Maximum number of shares to be issued if all conditions are met (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,500<span></span>
</td>
<td class="nump">112,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BCE20174Member', window );">BCE-2017-4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,686)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,687<span></span>
</td>
<td class="nump">33,687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of instruments exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet', window );">Maximum number of shares to be issued if all conditions are met (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,687<span></span>
</td>
<td class="nump">33,687<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BCE20175Member', window );">BCE-2017-5</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,843)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,844<span></span>
</td>
<td class="nump">16,844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of instruments exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet', window );">Maximum number of shares to be issued if all conditions are met (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,844<span></span>
</td>
<td class="nump">16,844<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BCE20181Member', window );">BCE-2018-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,440)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,540<span></span>
</td>
<td class="nump">2,540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of instruments exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,540<span></span>
</td>
<td class="nump">2,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet', window );">Maximum number of shares to be issued if all conditions are met (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,540<span></span>
</td>
<td class="nump">2,540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BCE20184Member', window );">BCE-2018-4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="nump">16,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,422)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,421<span></span>
</td>
<td class="nump">8,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of instruments exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,421<span></span>
</td>
<td class="nump">8,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet', window );">Maximum number of shares to be issued if all conditions are met (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,421<span></span>
</td>
<td class="nump">8,421<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BCE20185Member', window );">BCE-2018-5</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="nump">22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of instruments exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet', window );">Maximum number of shares to be issued if all conditions are met (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Number Of Other Equity Instruments To Be Issued In Share-Based Payment Arrangement If All Conditions Are Met</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_FoundersShareSubscriptionWarrantsBCEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_FoundersShareSubscriptionWarrantsBCEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BCE20161Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BCE20161Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BCE20171Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BCE20171Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BCE20172Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BCE20172Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BCE20174Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BCE20174Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BCE20175Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BCE20175Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BCE20181Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BCE20181Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BCE20184Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BCE20184Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BCE20185Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BCE20185Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Narrative (Details)<br> &#8364; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">30 Months Ended</th>
<th class="th" colspan="1">110 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 13, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 01, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 30, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 22, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 20, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 06, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 05, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 11, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 23, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 28, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 02, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 01, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 28, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 11, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 01, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th"><div>Sep. 05, 2024</div></th>
<th class="th">
<div>Nov. 30, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherShorttermProvisions', window );">Provisions | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 17,030<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 17,030<span></span>
</td>
<td class="nump">&#8364; 17,030<span></span>
</td>
<td class="nump">&#8364; 532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherLongtermProvisions', window );">Other non-current provisions | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 28,849<span></span>
</td>
<td class="nump">&#8364; 30<span></span>
</td>
<td class="nump">&#8364; 28,849<span></span>
</td>
<td class="nump">&#8364; 28,849<span></span>
</td>
<td class="nump">&#8364; 819<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_FoundersShareSubscriptionWarrantsBCEMember', window );">Total BCEs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementChangeOfControlMinimumThreshold', window );">Change of control, minimum percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">496,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BCEExceptBCE20142Member', window );">BCE except BCE 2014-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementPerformanceConditionsMinimumFinancing', window );">Performance conditions, minimum financing | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_ShareSubscriptionWarrantsBSAMember', window );">Total BSAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementChangeOfControlMinimumThreshold', window );">Change of control, minimum percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">486,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20241AndBSA20242Member', window );">BSA-2024-1 and BSA-2024-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20251AndBSA20252Member', window );">BSA-2025-1 and BSA-2025-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20253Member', window );">BSA-2025-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_FreeSharesAGAMember', window );">Total AGAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,601,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,280,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,828,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherShorttermProvisions', window );">Provisions | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 16,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 16,467<span></span>
</td>
<td class="nump">&#8364; 16,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherLongtermProvisions', window );">Other non-current provisions | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 28,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 28,718<span></span>
</td>
<td class="nump">&#8364; 28,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20231Member', window );">AGA-2023-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,382,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20231Member', window );">AGA-2023-1 | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,382,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20232Member', window );">AGA-2023-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20232Member', window );">AGA-2023-2 | Former Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20233AGA20234AndAGA20235Member', window );">AGA-2023-3 , AGA-2023-4 and AGA-2023-5</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementPerformanceConditionsMinimumFinancing', window );">Performance conditions, minimum financing | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,118,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfOtherEquityInstrumentsGrantedSubjectToNonMarketPerformanceCondition', window );">Number of instruments issued subject to non-market performance condition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20233AndAGA20234Member', window );">AGA-2023-3 and AGA-2023-4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">985,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20235Member', window );">AGA-2023-5</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20241Member', window );">AGA-2024-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,549,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20242Member', window );">AGA-2024-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20243Member', window );">AGA-2024-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20244AGA20245AndAGA20246Member', window );">AGA-2024-4, AGA-2024-5 and AGA-2024-6</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20247Member', window );">AGA-2024-7</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20246Member', window );">AGA-2024-6</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20246Member', window );">AGA-2024-6 | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20251Member', window );">AGA-2025-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,319,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,319,500<span></span>
</td>
<td class="nump">4,319,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20252Member', window );">AGA-2025-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,102<span></span>
</td>
<td class="nump">123,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20253Member', window );">AGA-2025-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,625<span></span>
</td>
<td class="nump">17,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20254Member', window );">AGA-2025-4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,500<span></span>
</td>
<td class="nump">30,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20256Member', window );">AGA-2025-6</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20257Member', window );">AGA-2025-7</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,711,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,711,000<span></span>
</td>
<td class="nump">1,711,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20258Member', window );">AGA-2025-8</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20255Member', window );">AGA-2025-5</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TranchesAxis=abvx_TrancheOneMember', window );">Tranche 1 | Total BCEs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TranchesAxis=abvx_TrancheOneMember', window );">Tranche 1 | Total BSAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TranchesAxis=abvx_TrancheOneMember', window );">Tranche 1 | AGA-2023-1 | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TranchesAxis=abvx_TrancheOneMember', window );">Tranche 1 | AGA-2023-2 | Former Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TranchesAxis=abvx_TrancheOneMember', window );">Tranche 1 | AGA-2023-3 , AGA-2023-4 and AGA-2023-5</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TranchesAxis=abvx_TrancheOneMember', window );">Tranche 1 | AGA-2024-1, AGE-2024-2, AGA-2024-3, AGA-2024-4, AGA-2024-5 and AGA-2024-7</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TranchesAxis=abvx_TrancheOneMember', window );">Tranche 1 | AGA-2024-6 | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TranchesAxis=abvx_TrancheOneMember', window );">Tranche 1 | AGA-2025-1, AGA-2025-3, AGA-2025-4, AGA-2025-6, AGA-2025-7 and AGA-2025-8</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TranchesAxis=abvx_TrancheTwoMember', window );">Tranche 2 | Total BCEs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentagePerMonth', window );">Vesting percentage per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0833%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TranchesAxis=abvx_TrancheTwoMember', window );">Tranche 2 | Total BSAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentagePerMonth', window );">Vesting percentage per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0833%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TranchesAxis=abvx_TrancheTwoMember', window );">Tranche 2 | AGA-2023-1 | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">638,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementServicePeriod', window );">Service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TranchesAxis=abvx_TrancheTwoMember', window );">Tranche 2 | AGA-2023-2 | Former Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TranchesAxis=abvx_TrancheTwoMember', window );">Tranche 2 | AGA-2023-2 | Former Chief Executive Officer | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TranchesAxis=abvx_TrancheTwoMember', window );">Tranche 2 | AGA-2023-3 , AGA-2023-4 and AGA-2023-5</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TranchesAxis=abvx_TrancheTwoMember', window );">Tranche 2 | AGA-2024-1, AGE-2024-2, AGA-2024-3, AGA-2024-4, AGA-2024-5 and AGA-2024-7</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TranchesAxis=abvx_TrancheTwoMember', window );">Tranche 2 | AGA-2024-6 | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TranchesAxis=abvx_TrancheTwoMember', window );">Tranche 2 | AGA-2025-1, AGA-2025-3, AGA-2025-4, AGA-2025-6, AGA-2025-7 and AGA-2025-8</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TranchesAxis=abvx_TrancheThreeMember', window );">Tranche 3 | AGA-2023-1 | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TranchesAxis=abvx_TrancheThreeMember', window );">Tranche 3 | AGA-2023-1 | Chief Executive Officer | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TranchesAxis=abvx_TrancheThreeMember', window );">Tranche 3 | AGA-2023-3 , AGA-2023-4 and AGA-2023-5</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TranchesAxis=abvx_TrancheThreeMember', window );">Tranche 3 | AGA-2024-1, AGE-2024-2, AGA-2024-3, AGA-2024-4, AGA-2024-5 and AGA-2024-7</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TranchesAxis=abvx_TrancheThreeMember', window );">Tranche 3 | AGA-2025-1, AGA-2025-3, AGA-2025-4, AGA-2025-6, AGA-2025-7 and AGA-2025-8</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TranchesAxis=abvx_TrancheFourMember', window );">Tranche 4 | AGA-2023-1 | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementPerformanceConditionsMinimumFinancing', window );">Performance conditions, minimum financing | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TranchesAxis=abvx_TrancheFourMember', window );">Tranche 4 | AGA-2023-1 | Chief Executive Officer | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TranchesAxis=abvx_TrancheFiveMember', window );">Tranche 5 | AGA-2023-1 | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TranchesAxis=abvx_TrancheFiveMember', window );">Tranche 5 | AGA-2023-1 | Chief Executive Officer | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TranchesAxis=abvx_TrancheSixMember', window );">Tranche 6 | AGA-2023-1 | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfOtherEquityInstrumentsGrantedSubjectToNonMarketPerformanceCondition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Other Equity Instruments Granted Subject To Non-Market Performance Condition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfOtherEquityInstrumentsGrantedSubjectToNonMarketPerformanceCondition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_VestingRequirementsForShareBasedPaymentArrangementChangeOfControlMinimumThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Change Of Control, Minimum Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_VestingRequirementsForShareBasedPaymentArrangementChangeOfControlMinimumThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_VestingRequirementsForShareBasedPaymentArrangementPerformanceConditionsMinimumFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Performance Conditions, Minimum Financing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_VestingRequirementsForShareBasedPaymentArrangementPerformanceConditionsMinimumFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_VestingRequirementsForShareBasedPaymentArrangementServicePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Service Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_VestingRequirementsForShareBasedPaymentArrangementServicePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Vesting Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentagePerMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Vesting Percentage Per Month</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentagePerMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Vesting Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherLongtermProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions other than provisions for employee benefits. [Refer: Non-current provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherLongtermProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherShorttermProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions other than provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherShorttermProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_FoundersShareSubscriptionWarrantsBCEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_FoundersShareSubscriptionWarrantsBCEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BCEExceptBCE20142Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BCEExceptBCE20142Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_ShareSubscriptionWarrantsBSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_ShareSubscriptionWarrantsBSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20241AndBSA20242Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20241AndBSA20242Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20251AndBSA20252Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20251AndBSA20252Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20253Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20253Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_FreeSharesAGAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_FreeSharesAGAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20231Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20231Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20232Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20232Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=abvx_FormerChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=abvx_FormerChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20233AGA20234AndAGA20235Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20233AGA20234AndAGA20235Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20233AndAGA20234Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20233AndAGA20234Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20235Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20235Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20241Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20241Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20242Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20242Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20243Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20243Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20244AGA20245AndAGA20246Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20244AGA20245AndAGA20246Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20247Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20247Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20246Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20246Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=abvx_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=abvx_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20251Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20251Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20252Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20252Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20253Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20253Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20254Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20254Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20256Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20256Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20257Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20257Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20258Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20258Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20255Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20255Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_TranchesAxis=abvx_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_TranchesAxis=abvx_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20241AGE20242AGA20243AGA20244AGA20245AndAGA20247Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20241AGE20242AGA20243AGA20244AGA20245AndAGA20247Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20251AGA20253AGA20254AGA20256AGA20257AndAGA20258Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20251AGA20253AGA20254AGA20256AGA20257AndAGA20258Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_TranchesAxis=abvx_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_TranchesAxis=abvx_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_TranchesAxis=abvx_TrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_TranchesAxis=abvx_TrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_TranchesAxis=abvx_TrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_TranchesAxis=abvx_TrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_TranchesAxis=abvx_TrancheFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_TranchesAxis=abvx_TrancheFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_TranchesAxis=abvx_TrancheSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_TranchesAxis=abvx_TrancheSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Disclosure of reconciliation of BSAs (Details) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">110 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 22, 2025</div></th>
<th class="th"><div>Jan. 13, 2025</div></th>
<th class="th"><div>Apr. 04, 2024</div></th>
<th class="th"><div>Jan. 22, 2018</div></th>
<th class="th"><div>Sep. 18, 2017</div></th>
<th class="th"><div>Dec. 04, 2015</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_ShareSubscriptionWarrantsBSAMember', window );">Total BSAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,370<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,370<span></span>
</td>
<td class="nump">486,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(134,587)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253,727<span></span>
</td>
<td class="nump">253,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of instruments exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,989<span></span>
</td>
<td class="nump">30,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet', window );">Maximum number of shares to be issued if all conditions are met (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253,727<span></span>
</td>
<td class="nump">253,727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA201511Member', window );">BSA-2015-11</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(96,924)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of instruments exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet', window );">Maximum number of shares to be issued if all conditions are met (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA201512Member', window );">BSA-2015-12</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of instruments exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet', window );">Maximum number of shares to be issued if all conditions are met (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20171Member', window );">BSA-2017-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of instruments exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet', window );">Maximum number of shares to be issued if all conditions are met (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20181Member', window );">BSA-2018-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,400<span></span>
</td>
<td class="nump">16,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of instruments exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,400<span></span>
</td>
<td class="nump">16,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet', window );">Maximum number of shares to be issued if all conditions are met (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,400<span></span>
</td>
<td class="nump">16,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20241Member', window );">BSA-2024-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,820<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,863)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,502<span></span>
</td>
<td class="nump">53,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of instruments exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,726<span></span>
</td>
<td class="nump">9,726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet', window );">Maximum number of shares to be issued if all conditions are met (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,502<span></span>
</td>
<td class="nump">53,502<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20242Member', window );">BSA-2024-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,455<span></span>
</td>
<td class="nump">19,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of instruments exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,863<span></span>
</td>
<td class="nump">4,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet', window );">Maximum number of shares to be issued if all conditions are met (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,455<span></span>
</td>
<td class="nump">19,455<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20251Member', window );">BSA-2025-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of instruments exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet', window );">Maximum number of shares to be issued if all conditions are met (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20252Member', window );">BSA-2025-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of instruments exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet', window );">Maximum number of shares to be issued if all conditions are met (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20253Member', window );">BSA-2025-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="nump">39,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,370<span></span>
</td>
<td class="nump">39,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of instruments exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet', window );">Maximum number of shares to be issued if all conditions are met (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,370<span></span>
</td>
<td class="nump">39,370<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Number Of Other Equity Instruments To Be Issued In Share-Based Payment Arrangement If All Conditions Are Met</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_ShareSubscriptionWarrantsBSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_ShareSubscriptionWarrantsBSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA201511Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA201511Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA201512Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA201512Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20171Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20171Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20181Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20181Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20241Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20241Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20242Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20242Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20251Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20251Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20252Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20252Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20253Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20253Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Disclosure of assumptions used for the measurement of BSAs (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 22, 2025 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jan. 13, 2025 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Apr. 04, 2024 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Apr. 30, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20241Member', window );">BSA-2024-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE UNDERLYING SHARE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">NUMBE OF BSAs ( in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,820<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted', window );">BSA SUBSCRIPTION PRICE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentStrikePriceOtherEquityInstrumentsGranted', window );">STRIKE PRICE PER SHARE ( in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">RISK&#160;FREE&#160;RATE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">VOLATILITY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20241Member', window );">BSA-2024-1 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE BSA (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExpectedMaturityOtherEquityInstrumentsGranted', window );">EXPECTED MATURITY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20241Member', window );">BSA-2024-1 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE BSA (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExpectedMaturityOtherEquityInstrumentsGranted', window );">EXPECTED MATURITY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20242Member', window );">BSA-2024-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE UNDERLYING SHARE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">NUMBE OF BSAs ( in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted', window );">BSA SUBSCRIPTION PRICE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentStrikePriceOtherEquityInstrumentsGranted', window );">STRIKE PRICE PER SHARE ( in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">RISK&#160;FREE&#160;RATE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">VOLATILITY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20242Member', window );">BSA-2024-2 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE BSA (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExpectedMaturityOtherEquityInstrumentsGranted', window );">EXPECTED MATURITY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20242Member', window );">BSA-2024-2 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE BSA (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExpectedMaturityOtherEquityInstrumentsGranted', window );">EXPECTED MATURITY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20251Member', window );">BSA-2025-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE UNDERLYING SHARE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">NUMBE OF BSAs ( in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted', window );">BSA SUBSCRIPTION PRICE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentStrikePriceOtherEquityInstrumentsGranted', window );">STRIKE PRICE PER SHARE ( in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">RISK&#160;FREE&#160;RATE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">VOLATILITY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.88%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20251Member', window );">BSA-2025-1 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE BSA (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExpectedMaturityOtherEquityInstrumentsGranted', window );">EXPECTED MATURITY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20251Member', window );">BSA-2025-1 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE BSA (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExpectedMaturityOtherEquityInstrumentsGranted', window );">EXPECTED MATURITY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20252Member', window );">BSA-2025-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE UNDERLYING SHARE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">NUMBE OF BSAs ( in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted', window );">BSA SUBSCRIPTION PRICE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentStrikePriceOtherEquityInstrumentsGranted', window );">STRIKE PRICE PER SHARE ( in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">RISK&#160;FREE&#160;RATE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">VOLATILITY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.88%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20252Member', window );">BSA-2025-2 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE BSA (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExpectedMaturityOtherEquityInstrumentsGranted', window );">EXPECTED MATURITY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20252Member', window );">BSA-2025-2 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE BSA (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExpectedMaturityOtherEquityInstrumentsGranted', window );">EXPECTED MATURITY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20253Member', window );">BSA-2025-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE UNDERLYING SHARE (in euro per share)</a></td>
<td class="nump">&#8364; 6.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">NUMBE OF BSAs ( in shares) | shares</a></td>
<td class="nump">39,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted', window );">BSA SUBSCRIPTION PRICE (in euro per share)</a></td>
<td class="nump">&#8364; 1.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentStrikePriceOtherEquityInstrumentsGranted', window );">STRIKE PRICE PER SHARE ( in euro per share)</a></td>
<td class="nump">&#8364; 6.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">RISK&#160;FREE&#160;RATE</a></td>
<td class="nump">3.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">VOLATILITY</a></td>
<td class="nump">60.69%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20253Member', window );">BSA-2025-3 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE BSA (in euro per share)</a></td>
<td class="nump">&#8364; 3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExpectedMaturityOtherEquityInstrumentsGranted', window );">EXPECTED MATURITY</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20253Member', window );">BSA-2025-3 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE BSA (in euro per share)</a></td>
<td class="nump">&#8364; 4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExpectedMaturityOtherEquityInstrumentsGranted', window );">EXPECTED MATURITY</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Instrument Fair Value, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Instrument Price, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_EquityInstrumentStrikePriceOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Instrument Strike Price, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_EquityInstrumentStrikePriceOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ExpectedMaturityOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected Maturity, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ExpectedMaturityOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ExpectedVolatilityOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected Volatility, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ExpectedVolatilityOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risk Free Interest Rate, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underlying Share Fair Value, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20241Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20241Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20242Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20242Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20251Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20251Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20252Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20252Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20253Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_BSA20253Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Disclosure of reconciliation of AGAs (Details) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">30 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 13, 2025</div></th>
<th class="th"><div>Aug. 01, 2025</div></th>
<th class="th"><div>May 30, 2025</div></th>
<th class="th"><div>Mar. 20, 2025</div></th>
<th class="th"><div>Feb. 06, 2025</div></th>
<th class="th"><div>Sep. 05, 2024</div></th>
<th class="th"><div>Jul. 11, 2024</div></th>
<th class="th"><div>May 23, 2024</div></th>
<th class="th"><div>Mar. 28, 2024</div></th>
<th class="th"><div>Jan. 02, 2024</div></th>
<th class="th"><div>Dec. 01, 2023</div></th>
<th class="th"><div>Sep. 28, 2023</div></th>
<th class="th"><div>Jul. 11, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_FreeSharesAGAMember', window );">Total AGAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,388,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,601,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,280,727<span></span>
</td>
<td class="nump">10,828,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(645,375)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(627,714)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,395,678<span></span>
</td>
<td class="nump">8,395,678<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20231Member', window );">AGA-2023-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">780,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,382,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(230,464)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">549,576<span></span>
</td>
<td class="nump">549,576<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20232Member', window );">AGA-2023-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20233Member', window );">AGA-2023-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">485,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">731,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(251,125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20234Member', window );">AGA-2023-4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">213,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(108,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,750<span></span>
</td>
<td class="nump">89,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20235Member', window );">AGA-2023-5</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,625)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,625<span></span>
</td>
<td class="nump">27,625<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20241Member', window );">AGA-2024-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,355,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,549,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(134,125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,221,500<span></span>
</td>
<td class="nump">1,221,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20242Member', window );">AGA-2024-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,500<span></span>
</td>
<td class="nump">22,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20243Member', window );">AGA-2024-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,500<span></span>
</td>
<td class="nump">25,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20244Member', window );">AGA-2024-4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,000<span></span>
</td>
<td class="nump">93,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20245Member', window );">AGA-2024-5</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20246Member', window );">AGA-2024-6</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20247Member', window );">AGA-2024-7</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,000<span></span>
</td>
<td class="nump">198,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20251Member', window );">AGA-2025-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,319,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,319,500<span></span>
</td>
<td class="nump">4,319,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(217,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,102,000<span></span>
</td>
<td class="nump">4,102,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20252Member', window );">AGA-2025-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,102<span></span>
</td>
<td class="nump">123,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,102<span></span>
</td>
<td class="nump">123,102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20253Member', window );">AGA-2025-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,625<span></span>
</td>
<td class="nump">17,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,625<span></span>
</td>
<td class="nump">17,625<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20254Member', window );">AGA-2025-4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,500<span></span>
</td>
<td class="nump">30,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,500<span></span>
</td>
<td class="nump">30,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20255Member', window );">AGA-2025-5</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20256Member', window );">AGA-2025-6</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20257Member', window );">AGA-2025-7</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,711,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,711,000<span></span>
</td>
<td class="nump">1,711,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,631,000<span></span>
</td>
<td class="nump">1,631,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20258Member', window );">AGA-2025-8</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of instruments issued (in shares)</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of instruments lapsed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of instruments exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of instruments outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_FreeSharesAGAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_FreeSharesAGAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20231Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20231Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20232Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20232Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20233Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20233Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20234Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20234Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20235Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20235Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20241Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20241Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20242Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20242Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20243Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20243Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20244Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20244Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20245Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20245Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20246Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20246Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20247Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20247Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20251Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20251Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20252Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20252Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20253Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20253Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20254Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20254Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20255Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20255Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20256Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20256Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20257Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20257Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20258Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20258Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share-based payments - Disclosure of assumptions used for the measurement of AGAs (Details) - &#8364; / shares<br></strong></div></th>
<th class="th"><div>Nov. 13, 2025</div></th>
<th class="th"><div>Aug. 01, 2025</div></th>
<th class="th"><div>May 30, 2025</div></th>
<th class="th"><div>Mar. 20, 2025</div></th>
<th class="th"><div>Feb. 06, 2025</div></th>
<th class="th"><div>Sep. 05, 2024</div></th>
<th class="th"><div>Jul. 11, 2024</div></th>
<th class="th"><div>May 23, 2024</div></th>
<th class="th"><div>Mar. 28, 2024</div></th>
<th class="th"><div>Jan. 02, 2024</div></th>
<th class="th"><div>Dec. 01, 2023</div></th>
<th class="th"><div>Sep. 28, 2023</div></th>
<th class="th"><div>Jul. 11, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20231Member', window );">AGA-2023-1 | Tranches 1-4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE UNDERLYING SHARE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE AGA (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted', window );">AGA PRICE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20231Member', window );">AGA-2023-1 | Tranche 5</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE UNDERLYING SHARE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE AGA (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted', window );">AGA PRICE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">VOLATILITY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">RISK&#160;FREE&#160;RATE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20231Member', window );">AGA-2023-1 | Tranche 6</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE UNDERLYING SHARE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE AGA (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted', window );">AGA PRICE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">VOLATILITY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">RISK&#160;FREE&#160;RATE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20232Member', window );">AGA-2023-2 | Tranche 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE UNDERLYING SHARE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE AGA (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted', window );">AGA PRICE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20232Member', window );">AGA-2023-2 | Tranche 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE UNDERLYING SHARE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE AGA (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted', window );">AGA PRICE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20233Member', window );">AGA-2023-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE UNDERLYING SHARE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE AGA (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted', window );">AGA PRICE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20234Member', window );">AGA-2023-4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE UNDERLYING SHARE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE AGA (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted', window );">AGA PRICE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20235Member', window );">AGA-2023-5</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE UNDERLYING SHARE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 9.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE AGA (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted', window );">AGA PRICE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20241Member', window );">AGA-2024-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE UNDERLYING SHARE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 12.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE AGA (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted', window );">AGA PRICE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20242Member', window );">AGA-2024-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE UNDERLYING SHARE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE AGA (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted', window );">AGA PRICE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20243Member', window );">AGA-2024-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE UNDERLYING SHARE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 12.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE AGA (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted', window );">AGA PRICE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20244Member', window );">AGA-2024-4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE UNDERLYING SHARE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 12.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE AGA (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted', window );">AGA PRICE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20245Member', window );">AGA-2024-5</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE UNDERLYING SHARE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE AGA (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted', window );">AGA PRICE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20246Member', window );">AGA-2024-6</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE UNDERLYING SHARE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE AGA (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted', window );">AGA PRICE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20247Member', window );">AGA-2024-7</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE UNDERLYING SHARE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE AGA (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted', window );">AGA PRICE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20251Member', window );">AGA-2025-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE UNDERLYING SHARE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE AGA (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted', window );">AGA PRICE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20252Member', window );">AGA-2025-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE UNDERLYING SHARE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE AGA (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted', window );">AGA PRICE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20253Member', window );">AGA-2025-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE UNDERLYING SHARE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE AGA (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted', window );">AGA PRICE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20254Member', window );">AGA-2025-4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE UNDERLYING SHARE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE AGA (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted', window );">AGA PRICE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20255Member', window );">AGA-2025-5</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE UNDERLYING SHARE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE AGA (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted', window );">AGA PRICE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20256Member', window );">AGA-2025-6</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE UNDERLYING SHARE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE AGA (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted', window );">AGA PRICE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20257Member', window );">AGA-2025-7</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE UNDERLYING SHARE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 61.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE AGA (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted', window );">AGA PRICE (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20258Member', window );">AGA-2025-8</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE UNDERLYING SHARE (in euro per share)</a></td>
<td class="nump">&#8364; 89.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted', window );">FAIR VALUE OF THE AGA (in euro per share)</a></td>
<td class="nump">89.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted', window );">AGA PRICE (in euro per share)</a></td>
<td class="nump">&#8364; 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Instrument Fair Value, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Instrument Price, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ExpectedVolatilityOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected Volatility, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ExpectedVolatilityOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risk Free Interest Rate, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underlying Share Fair Value, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20231Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20231Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_TranchesAxis=abvx_TranchesOneToFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_TranchesAxis=abvx_TranchesOneToFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_TranchesAxis=abvx_TrancheFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_TranchesAxis=abvx_TrancheFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_TranchesAxis=abvx_TrancheSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_TranchesAxis=abvx_TrancheSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20232Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20232Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_TranchesAxis=abvx_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_TranchesAxis=abvx_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_TranchesAxis=abvx_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_TranchesAxis=abvx_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20233Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20233Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20234Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20234Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20235Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20235Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20241Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20241Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20242Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20242Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20243Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20243Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20244Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20244Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20245Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20245Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20246Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20246Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20247Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20247Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20251Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20251Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20252Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20252Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20253Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20253Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20254Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20254Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20255Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20255Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20256Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20256Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20257Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20257Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20258Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA20258Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Disclosure of breakdown of the compensation expenses (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Total</a></td>
<td class="num">&#8364; (84,387)<span></span>
</td>
<td class="num">&#8364; (20,941)<span></span>
</td>
<td class="num">&#8364; (8,605)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_FoundersShareSubscriptionWarrantsBCEMember', window );">BCEs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Share-based compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(112)<span></span>
</td>
<td class="num">(112)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_ShareSubscriptionWarrantsBSAMember', window );">BSAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Share-based compensation expense</a></td>
<td class="num">(289)<span></span>
</td>
<td class="num">(211)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_FreeSharesAGAMember', window );">AGAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Share-based compensation expense</a></td>
<td class="num">(35,108)<span></span>
</td>
<td class="num">(19,900)<span></span>
</td>
<td class="num">(8,067)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes', window );">Social taxes related to AGAs</a></td>
<td class="num">&#8364; (48,990)<span></span>
</td>
<td class="num">&#8364; (717)<span></span>
</td>
<td class="num">&#8364; (426)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense From Equity-Settled Share-Based Payment Transactions, Social Taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 34<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_34_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 34<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_34_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_FoundersShareSubscriptionWarrantsBCEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_FoundersShareSubscriptionWarrantsBCEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_ShareSubscriptionWarrantsBSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_ShareSubscriptionWarrantsBSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_FreeSharesAGAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_FreeSharesAGAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial liabilities - Disclosure of financial liabilities breakdown (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialLiabilities', window );">Non-current financial liabilities</a></td>
<td class="nump">&#8364; 30,790<span></span>
</td>
<td class="nump">&#8364; 69,069<span></span>
</td>
<td class="nump">&#8364; 39,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialLiabilities', window );">Current financial liabilities</a></td>
<td class="nump">1,302<span></span>
</td>
<td class="nump">44,935<span></span>
</td>
<td class="nump">37,348<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">32,093<span></span>
</td>
<td class="nump">114,004<span></span>
</td>
<td class="nump">77,045<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_Borrowings1Member', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialLiabilities', window );">Non-current financial liabilities</a></td>
<td class="nump">554<span></span>
</td>
<td class="nump">29,056<span></span>
</td>
<td class="nump">2,563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialLiabilities', window );">Current financial liabilities</a></td>
<td class="nump">1,302<span></span>
</td>
<td class="nump">22,195<span></span>
</td>
<td class="nump">1,655<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_Kreos1ClaretBondLoansMember', window );">Kreos &amp; Claret bond loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialLiabilities', window );">Non-current financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,373<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialLiabilities', window );">Current financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,028<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialLiabilities', window );">Non-current financial liabilities</a></td>
<td class="nump">554<span></span>
</td>
<td class="nump">1,431<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialLiabilities', window );">Current financial liabilities</a></td>
<td class="nump">1,302<span></span>
</td>
<td class="nump">932<span></span>
</td>
<td class="nump">379<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_PretGarantiParLEtatPGEMember', window );">PGE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialLiabilities', window );">Non-current financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,252<span></span>
</td>
<td class="nump">2,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialLiabilities', window );">Current financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,235<span></span>
</td>
<td class="nump">1,276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_ConvertibleLoansNotesMember', window );">Convertible loan notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialLiabilities', window );">Non-current financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">23,370<span></span>
</td>
<td class="nump">21,643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialLiabilities', window );">Current financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,574<span></span>
</td>
<td class="nump">29,605<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretFinancingTrancheAMember', window );">Kreos &amp; Claret convertible notes (OCABSA)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialLiabilities', window );">Non-current financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">23,370<span></span>
</td>
<td class="nump">21,643<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_HeightsConvertibleNotesMember', window );">Heights convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialLiabilities', window );">Current financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,574<span></span>
</td>
<td class="nump">29,605<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_DerivativesMember', window );">Derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialLiabilities', window );">Non-current financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,620<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialLiabilities', window );">Current financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,166<span></span>
</td>
<td class="nump">2,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember', window );">Kreos &amp; Claret minimal return indemnifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialLiabilities', window );">Non-current financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,620<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretFinancingBSAMember', window );">Kreos &amp; Claret BSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialLiabilities', window );">Current financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,166<span></span>
</td>
<td class="nump">2,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_OtherFinancialLiabilitiesMember', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialLiabilities', window );">Non-current financial liabilities</a></td>
<td class="nump">30,237<span></span>
</td>
<td class="nump">13,023<span></span>
</td>
<td class="nump">15,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialLiabilities', window );">Current financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,509<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_ConditionalAdvancesMember', window );">Conditional advances Bpifrance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialLiabilities', window );">Non-current financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialLiabilities', window );">Current financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,509<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RoyaltyCertificatesMember', window );">Royalty certificates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialLiabilities', window );">Non-current financial liabilities</a></td>
<td class="nump">&#8364; 30,237<span></span>
</td>
<td class="nump">&#8364; 13,023<span></span>
</td>
<td class="nump">&#8364; 12,229<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_Borrowings1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_Borrowings1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_Kreos1ClaretBondLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_Kreos1ClaretBondLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_PretGarantiParLEtatPGEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_PretGarantiParLEtatPGEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_ConvertibleLoansNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_ConvertibleLoansNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretFinancingTrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretFinancingTrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_HeightsConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_HeightsConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_DerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_DerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretFinancingBSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretFinancingBSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_OtherFinancialLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_OtherFinancialLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_ConditionalAdvancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_ConditionalAdvancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RoyaltyCertificatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RoyaltyCertificatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial liabilities - Kreos / Claret Financing (Details)<br> &#8364; / shares in Units, &#8364; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">145 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 23, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Nov. 25, 2025 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 28, 2025 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 08, 2025 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 30, 2025 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jun. 21, 2024 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jun. 21, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 28, 2024 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Nov. 02, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 22, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Aug. 20, 2023 </div>
<div>EUR (&#8364;) </div>
<div>tranche </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Aug. 31, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Aug. 24, 2023 </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants', window );">Exercises of share warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">464,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Exercises of the Kreos/Claret and other share warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Interest expense on borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 95<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">&#8364; 176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid', window );">Loss of extinguishment</a></td>
<td class="nump">&#8364; 3,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 162,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 125,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,409<span></span>
</td>
<td class="nump">162,256<span></span>
</td>
<td class="nump">125,191<span></span>
</td>
<td class="nump">&#8364; 141,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: other fair value remeasurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,002<span></span>
</td>
<td class="nump">1,367<span></span>
</td>
<td class="num">(3,198)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=abvx_Kreos1ClaretBondLoansMember', window );">Kreos &amp; Claret bond loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: other fair value remeasurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=abvx_MarketRateMeasurementInputMember', window );">Market rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible increase in unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=abvx_SharePriceMeasurementInputMember', window );">Ordinary share price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Amount of reasonably possible increase in unobservable input, liabilities (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible increase in unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=abvx_RiskFreeInterestRateMeasurementInputMember', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible increase in unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=abvx_FinalRedemptionScenarioProbabilityMeasurementInputMember', window );">Final redemption scenario probability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible increase in unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_DiscountRateMeasurementInputMember', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible increase in unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=abvx_ExpiryScenarioProbablityMeasurementInputMember', window );">7-year expiry scenario probability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible increase in unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosABBSAMember', window );">Kreos A &amp; B BSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 23,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConvertibleLoansNotes', window );">Convertible loans notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConvertibleLoansNotesCarryingAmountOfTheEquityComponent', window );">Carrying amount of the equity component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosABBSAMember', window );">Kreos A &amp; B BSA | Market rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosABBSAMember', window );">Kreos A &amp; B BSA | Ordinary share price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets', window );">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosABBSAMember', window );">Kreos A &amp; B BSA | Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets', window );">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosABBSAMember', window );">Kreos A &amp; B BSA | Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets', window );">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosABBSAMember', window );">Kreos A &amp; B BSA | 7-year expiry scenario probability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets', window );">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember', window );">Kreos &amp; Claret minimal return indemnifications | Ordinary share price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets', window );">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember', window );">Kreos &amp; Claret minimal return indemnifications | Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets', window );">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember', window );">Kreos &amp; Claret minimal return indemnifications | Volatility | Black Scholes Model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember', window );">Kreos &amp; Claret minimal return indemnifications | Volatility | Monte Carlo Model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember', window );">Kreos &amp; Claret minimal return indemnifications | Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets', window );">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember', window );">Kreos &amp; Claret minimal return indemnifications | Risk-free rate | Black Scholes Model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember', window );">Kreos &amp; Claret minimal return indemnifications | Risk-free rate | Monte Carlo Model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember', window );">Kreos &amp; Claret minimal return indemnifications | Final redemption scenario probability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets', window );">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember', window );">Kreos &amp; Claret minimal return indemnifications | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets', window );">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (82)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosABCBSAMember', window );">Kreos A &amp; B &amp; C BSA | Ordinary share price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets', window );">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosABCBSAMember', window );">Kreos A &amp; B &amp; C BSA | Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets', window );">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosABCBSAMember', window );">Kreos A &amp; B &amp; C BSA | Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets', window );">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosABCBSAMember', window );">Kreos A &amp; B &amp; C BSA | 7-year expiry scenario probability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets', window );">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosCBSAMember', window );">Kreos C BSA | Ordinary share price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets', window );">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosCBSAMember', window );">Kreos C BSA | Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets', window );">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosCBSAMember', window );">Kreos C BSA | Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets', window );">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosCBSAMember', window );">Kreos C BSA | 7-year expiry scenario probability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets', window );">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TranchesAxis=abvx_KreosClaretFinancingTrancheABAndCMember', window );">Kreos &amp; Claret Financing, Tranche A,B and C | Kreos &amp; Claret minimal return indemnifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding', window );">Fair value of other equity instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_FinancialAgreementAxis=abvx_KreosClaretFinancingMember', window );">Kreos &amp; Claret financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants', window );">Exercises of share warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Exercises of the Kreos/Claret and other share warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 33,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_WarrantsAxis=abvx_KreosABBSAMember', window );">Kreos A &amp; B BSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding', window );">Fair value of other equity instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 243<span></span>
</td>
<td class="nump">&#8364; 920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted', window );">Expiry scenario period, other equity instruments granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_WarrantsAxis=abvx_KreosCBSAMember', window );">Kreos C BSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding', window );">Fair value of other equity instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,659<span></span>
</td>
<td class="nump">&#8364; 1,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 923<span></span>
</td>
<td class="nump">&#8364; 1,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted', window );">Expiry scenario period, other equity instruments granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_WarrantsAxis=abvx_KreosABCBSAMember', window );">Kreos A &amp; B &amp; C BSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted', window );">Expiry scenario period, other equity instruments granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingMember', window );">Kreos &amp; Claret financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsMaximumBorrowingCapacity', window );">Borrowings, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsNumberOfTranches', window );">Borrowings, number of tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsMaximumBorrowingCapacityPerTranche', window );">Borrowings, maximum borrowing capacity per tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_OtherShareWarrantsExercisePeriod', window );">Other share warrants, exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingMember', window );">Kreos &amp; Claret financing | Kreos A &amp; B BSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_OtherShareWarrantsSubscriptionPricePerShare', window );">Other share warrants, subscripion price per share (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfWarrantsGranted', window );">Number of warrants granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price, other equity instruments granted (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 18.6744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted', window );">Exercise price, percentage of premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingMember', window );">Kreos &amp; Claret financing | Kreos C BSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfWarrantsGranted', window );">Number of warrants granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">405,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price, other equity instruments granted (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 9.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted', window );">Exercise price, percentage of 15-day WVAP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IssuanceOfOtherShareWarrants', window );">Issuance of other share warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsPercentageExercisableImmediately', window );">Number of instruments granted, percentage exercisable immediately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsRemainingPercentageExercisable', window );">Number of instruments granted, remaining percentage exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheAMember', window );">Kreos &amp; Claret convertible notes (OCABSA)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsFixedConversionPrice', window );">Borrowings, fixed conversion price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 21.2209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsEarlyRepaymentDiscountRate', window );">Borrowings, early repayment, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsExitFeePercentage', window );">Borrowings, exit fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheAMember', window );">Kreos &amp; Claret convertible notes (OCABSA) | Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsFixedConversionPrice', window );">Borrowings, fixed conversion price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 21.2209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 21.2209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments', window );">Conversion of convertible instruments (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">392,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">785,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments', window );">Increase (decrease) through conversion of convertible instruments, equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 16,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheBMember', window );">Kreos &amp; Claret financing, tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsDebtToMarketCapitalizationRatio', window );">Borrowings, debt-to-market capitalization ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheCMember', window );">Kreos &amp; Claret financing, tranche C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsMaximumBorrowingCapacity', window );">Borrowings, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsDebtToMarketCapitalizationRatio', window );">Borrowings, debt-to-market capitalization ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsPerformanceConditionsMinimumFinancing', window );">Performance conditions, minimum financing | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember', window );">Kreos &amp; Claret financing, tranche B and C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsNumberOfTranches', window );">Borrowings, number of tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsEarlyRepaymentDiscountRate', window );">Borrowings, early repayment, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsExitFeePercentage', window );">Borrowings, exit fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsDiscountRate', window );">Borrowings, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember', window );">Kreos &amp; Claret financing, tranche B and C | European Central Bank base rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsAdjustmentToInterestRateBasis', window );">Borrowings, adjustment to interest rate basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember', window );">Kreos &amp; Claret financing, tranche B and C | European Central Bank base rate | Bottom of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsBasisInterestRate', window );">Borrowings, interest rate basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember', window );">Kreos &amp; Claret financing, tranche B and C | European Central Bank base rate | Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsBasisInterestRate', window );">Borrowings, interest rate basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_Kreos1BondLoansMember', window );">Kreos 1 bond loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RepaymentsOfBondLoans', window );">Repayments of bond loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 7,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosABCBSAMember', window );">Kreos A &amp; B &amp; C BSA | Kreos &amp; Claret financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfWarrantsRepurchased', window );">Number of warrants repurchased (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosABCBSAMember', window );">Kreos A &amp; B &amp; C BSA | Ordinary shares | Kreos &amp; Claret financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants', window );">Exercises of share warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Exercises of the Kreos/Claret and other share warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 19,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingBAndCMember', window );">Kreos/Claret financing B and C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Repayments of borrowings, classified as financing activities</a></td>
<td class="nump">33,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">29,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsDeposit', window );">Deposit paid, borrowing</a></td>
<td class="nump">&#8364; 1,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsDiscountRate', window );">Borrowings, discount rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Interest expense on borrowings</a></td>
<td class="nump">&#8364; 2,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsExitFeeAmount', window );">Borrowings, exit fee amount</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">&#8364; 29,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Fair Value, Other Equity Instruments Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_AggregateFairValueOtherEquityInstrumentsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount Of Reasonably Possible Increase In Unobservable Input, Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsBasisInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Basis Interest Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsBasisInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsDebtToMarketCapitalizationRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Debt-To-Market Capitalization Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsDebtToMarketCapitalizationRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Deposit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsEarlyRepaymentDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Early Repayment, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsEarlyRepaymentDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsExitFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Exit Fee Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsExitFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsExitFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Exit Fee Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsExitFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsFixedConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Fixed Conversion Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsFixedConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Maximum Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsMaximumBorrowingCapacityPerTranche">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Maximum Borrowing Capacity Per Tranche</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsMaximumBorrowingCapacityPerTranche</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Number Of Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsPerformanceConditionsMinimumFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Performance Conditions, Minimum Financing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsPerformanceConditionsMinimumFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ConvertibleLoansNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Loans Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ConvertibleLoansNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ConvertibleLoansNotesCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Loans Notes, Carrying Amount Of The Equity Component</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ConvertibleLoansNotesCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ExercisePriceOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise Price, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ExercisePriceOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise Price, Percentage Of 15-Day WVAP, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise Price, Percentage Of Premium Over 15-Day VWAP, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry Scenario Period, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Number Of Shares Issued Through Conversion Of Convertible Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Number Of Shares Issued Through Exercise Of Share Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IssuanceOfOtherShareWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Other Share Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IssuanceOfOtherShareWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsPercentageExercisableImmediately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Instruments Granted, Other Equity Instruments, Percentage Exercisable Immediately</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsPercentageExercisableImmediately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsRemainingPercentageExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Instruments Granted, Other Equity Instruments, Remaining Percentage Exercisable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsRemainingPercentageExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfWarrantsRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants Repurchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfWarrantsRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_OtherShareWarrantsExercisePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Share Warrants, Exercise Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_OtherShareWarrantsExercisePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_OtherShareWarrantsSubscriptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Share Warrants, Subscription Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_OtherShareWarrantsSubscriptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_RepaymentsOfBondLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments Of Bond Loans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_RepaymentsOfBondLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsAdjustmentToInterestRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The adjustment to the basis (reference rate) used for calculation of the interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsAdjustmentToInterestRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gain (loss) arising from the difference between the carrying amount of the financial liability extinguished and the measurement of the consideration paid (equity instruments issued) to the creditor. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRIC<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 11<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRIC&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_11&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in the fair value measurement of assets due to a reasonably possible increase in an unobservable input.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in the fair value measurement of liabilities due to a reasonably possible increase in an unobservable input.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from changes in fair values. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 44B<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_44B_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 166<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_166_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 166<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_166_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the conversion of convertible instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of a reasonably possible increase in an unobservable input used in fair value measurement of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of significant unobservable input used in the measurement of the fair value of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=abvx_Kreos1ClaretBondLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=abvx_Kreos1ClaretBondLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_MarketRateMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_MarketRateMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_SharePriceMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_SharePriceMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_RiskFreeInterestRateMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_RiskFreeInterestRateMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_FinalRedemptionScenarioProbabilityMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_FinalRedemptionScenarioProbabilityMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_DiscountRateMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_DiscountRateMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_ExpiryScenarioProbablityMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_ExpiryScenarioProbablityMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosABBSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosABBSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis=abvx_BlackScholesModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis=abvx_BlackScholesModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis=abvx_MonteCarloModel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis=abvx_MonteCarloModel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosABCBSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosABCBSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosCBSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosCBSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_TranchesAxis=abvx_KreosClaretFinancingTrancheABAndCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_TranchesAxis=abvx_KreosClaretFinancingTrancheABAndCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_FinancialAgreementAxis=abvx_KreosClaretFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_FinancialAgreementAxis=abvx_KreosClaretFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_WarrantsAxis=abvx_KreosABBSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_WarrantsAxis=abvx_KreosABBSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_WarrantsAxis=abvx_KreosCBSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_WarrantsAxis=abvx_KreosCBSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_WarrantsAxis=abvx_KreosABCBSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_WarrantsAxis=abvx_KreosABCBSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=abvx_EuropeanCentralBankBaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=abvx_EuropeanCentralBankBaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_Kreos1BondLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_Kreos1BondLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosABCBSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_KreosABCBSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingBAndCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingBAndCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial liabilities - Disclosure of the main data and assumptions, Kreos / Claret minimum return indemnifications (Details) - Kreos &amp; Claret minimal return indemnifications<br> &#8364; in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 21, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 28, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember', window );">Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding', window );">Fair value of other equity instruments</a></td>
<td class="nump">&#8364; 2,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember', window );">Tranche C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding', window );">Fair value of other equity instruments</a></td>
<td class="nump">&#8364; 984<span></span>
</td>
<td class="nump">&#8364; 475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember', window );">Final redemption scenario probability | Amortized cost (EIR method) | Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">0.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember', window );">Final redemption scenario probability | Amortized cost (EIR method) | Tranche C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">0.95<span></span>
</td>
<td class="nump">0.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember', window );">Minimal return | Amortized cost (EIR method) | Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">1.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember', window );">Minimal return | Amortized cost (EIR method) | Tranche C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">1.30<span></span>
</td>
<td class="nump">1.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember', window );">Discount rate | Amortized cost (EIR method) | Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember', window );">Discount rate | Amortized cost (EIR method) | Tranche C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">0.08<span></span>
</td>
<td class="nump">0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember', window );">Probability-weighted present value of shortfall payment, final redemption | Amortized cost (EIR method) | Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">2,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,959<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember', window );">Probability-weighted present value of shortfall payment, final redemption | Amortized cost (EIR method) | Tranche C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">1,160<span></span>
</td>
<td class="nump">741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember', window );">Probability-weighted present value of shortfall payment, tender offer | Amortized cost (EIR method) | Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember', window );">Probability-weighted present value of shortfall payment, tender offer | Amortized cost (EIR method) | Tranche C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember', window );">Final redemption, probability-weighted fair value with MRI | Amortized cost (EIR method) | Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember', window );">Final redemption, probability-weighted fair value with MRI | Amortized cost (EIR method) | Tranche C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">684<span></span>
</td>
<td class="nump">2,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember', window );">Final redemption, probability-weighted fair value without MRI | Amortized cost (EIR method) | Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember', window );">Final redemption, probability-weighted fair value without MRI | Amortized cost (EIR method) | Tranche C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">903<span></span>
</td>
<td class="nump">3,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember', window );">Total fair value of MRI, final redemption | Amortized cost (EIR method) | Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">2,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember', window );">Total fair value of MRI, final redemption | Amortized cost (EIR method) | Tranche C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">941<span></span>
</td>
<td class="nump">475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember', window );">Total fair value of MRI, tender offer | Amortized cost (EIR method) | Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember', window );">Total fair value of MRI, tender offer | Amortized cost (EIR method) | Tranche C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Fair Value, Other Equity Instruments Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_AggregateFairValueOtherEquityInstrumentsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of significant unobservable input used in the measurement of the fair value of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_TranchesAxis=abvx_TrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_TranchesAxis=abvx_TrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_TranchesAxis=abvx_TrancheCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_TranchesAxis=abvx_TrancheCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_FinalRedemptionScenarioProbabilityMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_FinalRedemptionScenarioProbabilityMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis=abvx_AmortizedCostEIRMethodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis=abvx_AmortizedCostEIRMethodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_MinimalReturnMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_MinimalReturnMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_DiscountRateMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_DiscountRateMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_FinalRedemptionFairValueOfMRIMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_FinalRedemptionFairValueOfMRIMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_TenderOfferFairValueOfMRIMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_TenderOfferFairValueOfMRIMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial liabilities - Disclosure of the main data and assumptions, Kreos / Claret BSA (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 02, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Aug. 20, 2023</div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>scenario</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 22, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosABBSAMember', window );">Kreos A &amp; B BSA | Option pricing model | Exercise price per share (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfWarrantsArrangementsLineItems', window );"><strong>Disclosure Of Warrants Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.67<span></span>
</td>
<td class="nump">18.67<span></span>
</td>
<td class="nump">18.67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosABBSAMember', window );">Kreos A &amp; B BSA | Option pricing model | Ordinary share price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfWarrantsArrangementsLineItems', window );"><strong>Disclosure Of Warrants Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.76<span></span>
</td>
<td class="nump">9.82<span></span>
</td>
<td class="nump">17.10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosABBSAMember', window );">Kreos A &amp; B BSA | Option pricing model | 7-year expiry scenario probability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfWarrantsArrangementsLineItems', window );"><strong>Disclosure Of Warrants Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.95<span></span>
</td>
<td class="nump">0.95<span></span>
</td>
<td class="nump">0.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosABBSAMember', window );">Kreos A &amp; B BSA | Option pricing model | Volatility, expiry</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfWarrantsArrangementsLineItems', window );"><strong>Disclosure Of Warrants Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.443<span></span>
</td>
<td class="nump">0.595<span></span>
</td>
<td class="nump">0.719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosABBSAMember', window );">Kreos A &amp; B BSA | Option pricing model | Volatility, tender offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfWarrantsArrangementsLineItems', window );"><strong>Disclosure Of Warrants Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.443<span></span>
</td>
<td class="nump">0.649<span></span>
</td>
<td class="nump">0.652<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosABBSAMember', window );">Kreos A &amp; B BSA | Option pricing model | Dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfWarrantsArrangementsLineItems', window );"><strong>Disclosure Of Warrants Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosABBSAMember', window );">Kreos A &amp; B BSA | Option pricing model | Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfWarrantsArrangementsLineItems', window );"><strong>Disclosure Of Warrants Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0230<span></span>
</td>
<td class="nump">0.0300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosABBSAMember', window );">Kreos A &amp; B BSA | Option pricing model | Risk-free rate, expiry</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfWarrantsArrangementsLineItems', window );"><strong>Disclosure Of Warrants Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosABBSAMember', window );">Kreos A &amp; B BSA | Option pricing model | Risk-free rate, tender offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfWarrantsArrangementsLineItems', window );"><strong>Disclosure Of Warrants Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosCBSAMember', window );">Kreos C BSA | Option pricing model | Exercise price per share (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfWarrantsArrangementsLineItems', window );"><strong>Disclosure Of Warrants Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">9.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.86<span></span>
</td>
<td class="nump">9.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosCBSAMember', window );">Kreos C BSA | Option pricing model | Ordinary share price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfWarrantsArrangementsLineItems', window );"><strong>Disclosure Of Warrants Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">8.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.67<span></span>
</td>
<td class="nump">9.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosCBSAMember', window );">Kreos C BSA | Option pricing model | 7-year expiry scenario probability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfWarrantsArrangementsLineItems', window );"><strong>Disclosure Of Warrants Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">0.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.95<span></span>
</td>
<td class="nump">0.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosCBSAMember', window );">Kreos C BSA | Option pricing model | Probability of Drawdown of Tranche C credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfWarrantsArrangementsLineItems', window );"><strong>Disclosure Of Warrants Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosCBSAMember', window );">Kreos C BSA | Option pricing model | Volatility, expiry</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfWarrantsArrangementsLineItems', window );"><strong>Disclosure Of Warrants Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">0.673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.443<span></span>
</td>
<td class="nump">0.674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosCBSAMember', window );">Kreos C BSA | Option pricing model | Volatility, tender offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfWarrantsArrangementsLineItems', window );"><strong>Disclosure Of Warrants Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">0.643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.443<span></span>
</td>
<td class="nump">0.649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosCBSAMember', window );">Kreos C BSA | Option pricing model | Dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfWarrantsArrangementsLineItems', window );"><strong>Disclosure Of Warrants Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosCBSAMember', window );">Kreos C BSA | Option pricing model | Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfWarrantsArrangementsLineItems', window );"><strong>Disclosure Of Warrants Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">0.0300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosCBSAMember', window );">Kreos C BSA | Option pricing model | Risk-free rate, expiry</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfWarrantsArrangementsLineItems', window );"><strong>Disclosure Of Warrants Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosCBSAMember', window );">Kreos C BSA | Option pricing model | Risk-free rate, tender offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfWarrantsArrangementsLineItems', window );"><strong>Disclosure Of Warrants Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_WarrantsAxis=abvx_KreosABBSAMember', window );">Kreos A &amp; B BSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfWarrantsArrangementsLineItems', window );"><strong>Disclosure Of Warrants Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfProbabilityWeightedScenarios', window );">Number of probability-weighted scenarios | scenario</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted', window );">Expiry scenario period, other equity instruments granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfWarrantsOutstanding', window );">Number of outstanding warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,198<span></span>
</td>
<td class="nump">214,198<span></span>
</td>
<td class="nump">214,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding', window );">Fair value of other equity instruments | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 243<span></span>
</td>
<td class="nump">&#8364; 920<span></span>
</td>
<td class="nump">&#8364; 2,092<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_WarrantsAxis=abvx_KreosCBSAMember', window );">Kreos C BSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfWarrantsArrangementsLineItems', window );"><strong>Disclosure Of Warrants Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted', window );">Expiry scenario period, other equity instruments granted</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfWarrantsOutstanding', window );">Number of outstanding warrants (in shares) | shares</a></td>
<td class="nump">405,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">405,832<span></span>
</td>
<td class="nump">405,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfWarrantsOutstandingSubjectToNonMarketPerformanceCondition', window );">Number of outstanding warrants subject to non-market performance condition (in shares) | shares</a></td>
<td class="nump">202,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">202,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding', window );">Fair value of other equity instruments | &#8364;</a></td>
<td class="nump">&#8364; 1,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 923<span></span>
</td>
<td class="nump">&#8364; 1,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_AggregateFairValueOtherEquityInstrumentsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Fair Value, Other Equity Instruments Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_AggregateFairValueOtherEquityInstrumentsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DisclosureOfWarrantsArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Warrants Arrangements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DisclosureOfWarrantsArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry Scenario Period, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfProbabilityWeightedScenarios">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Probability-Weighted Scenarios</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfProbabilityWeightedScenarios</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfWarrantsOutstandingSubjectToNonMarketPerformanceCondition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants Outstanding Subject To Non-Market Performance Condition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfWarrantsOutstandingSubjectToNonMarketPerformanceCondition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of significant unobservable input used in the measurement of the fair value of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosABBSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosABBSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis=ifrs-full_OptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis=ifrs-full_OptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_ExercisePricePerShareMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_ExercisePricePerShareMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_SharePriceMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_SharePriceMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_ExpiryScenarioProbablityMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_ExpiryScenarioProbablityMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_VolatilityForSharesMeasurementInputExpiryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_VolatilityForSharesMeasurementInputExpiryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_VolatilityForSharesMeasurementInputTenderOfferMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_VolatilityForSharesMeasurementInputTenderOfferMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_ExpectedDividendMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_ExpectedDividendMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_RiskFreeInterestRateMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_RiskFreeInterestRateMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_RiskFreeInterestRateMeasurementInputExpiryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_RiskFreeInterestRateMeasurementInputExpiryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_RiskFreeInterestRateMeasurementInputTenderOfferMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_RiskFreeInterestRateMeasurementInputTenderOfferMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosCBSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=abvx_KreosCBSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_DrawdownProbablityMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_DrawdownProbablityMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_WarrantsAxis=abvx_KreosABBSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_WarrantsAxis=abvx_KreosABBSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_WarrantsAxis=abvx_KreosCBSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_WarrantsAxis=abvx_KreosCBSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial liabilities - Heights convertible notes (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 30, 2025 </div>
<div>EUR (&#8364;) </div>
<div>note </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Aug. 24, 2023 </div>
<div>EUR (&#8364;) </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Aug. 20, 2023 </div>
<div>EUR (&#8364;) </div>
<div>installment </div>
<div>shares </div>
<div>tranche </div>
<div>closing </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jul. 30, 2021 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>EUR (&#8364;) </div>
<div>scenario </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jul. 23, 2025 </div>
<div>note</div>
</th>
<th class="th">
<div>Jun. 21, 2024 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Mar. 28, 2024 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Nov. 02, 2023 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Feb. 22, 2023 </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NetProceedsFromConvertibleLoansNotes', window );">Net proceeds from convertible loan notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 55,841,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityIssuanceSubscriptionPricePerShare', window );">Equity issuance, subscripion price per share (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RepaymentsOfConvertibleLoansNotes', window );">Repayments of convertible loan notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 33,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,188,000<span></span>
</td>
<td class="nump">&#8364; 8,750,000<span></span>
</td>
<td class="nump">27,188,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_GainsArisingFromRecognitionOfFinancialLiabilities', window );">Day-one gain on recognition of financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,557,000<span></span>
</td>
<td class="nump">590,000<span></span>
</td>
<td class="nump">212,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss', window );">Losses on financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (36,015,000)<span></span>
</td>
<td class="num">(1,367,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_HeightsConvertibleNotesTrancheAMember', window );">Heights convertible notes, tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 35,000,000<span></span>
</td>
<td class="nump">&#8364; 35,000,000,000<span></span>
</td>
<td class="nump">&#8364; 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 35,000,000<span></span>
</td>
<td class="nump">&#8364; 35,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible increase in unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember', window );">Volatility | Heights convertible notes, tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets', window );">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,000<span></span>
</td>
<td class="nump">&#8364; 18,000<span></span>
</td>
<td class="nump">&#8364; 239,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=abvx_SharePriceMeasurementInputMember', window );">Ordinary share price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Amount of reasonably possible increase in unobservable input, liabilities (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=abvx_SharePriceMeasurementInputMember', window );">Ordinary share price (in euro per share) | Heights convertible notes, tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets', window );">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 39,000<span></span>
</td>
<td class="nump">&#8364; 352,000<span></span>
</td>
<td class="nump">&#8364; 1,069,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=abvx_RiskFreeInterestRateMeasurementInputMember', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible increase in unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=abvx_RiskFreeInterestRateMeasurementInputMember', window );">Risk-free rate | Heights convertible notes, tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets', window );">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (219,000)<span></span>
</td>
<td class="num">&#8364; (366,000)<span></span>
</td>
<td class="num">&#8364; (239,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=abvx_VoluntaryConversionScenarioProbabilityMeasurementInputMember', window );">Held to maturity / voluntary conversion scenario probability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible increase in unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=abvx_VoluntaryConversionScenarioProbabilityMeasurementInputMember', window );">Held to maturity / voluntary conversion scenario probability | Heights convertible notes, tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets', window );">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (631,000)<span></span>
</td>
<td class="num">&#8364; (364,000)<span></span>
</td>
<td class="num">&#8364; (80,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_HeightsConvertibleNotesMember', window );">Heights convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsMaximumBorrowingCapacity', window );">Borrowings, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsNumberOfTranches', window );">Borrowings, number of tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConvertibleLoansNotesNominalValue', window );">Convertible loan notes, nominal value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsFixedConversionPrice', window );">Borrowings, fixed conversion price (in euro per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 23.7674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">&#8364; 21,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsNumberOfQuarterlyInstallments', window );">Borrowings, number of quarterly installments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsMaturityDeferralPeriod', window );">Borrowings maturity, deferral period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsPercentageOfMarketPrice', window );">Borrowings, percentage of market price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsMarketPriceNumberOfDaysWithLowestDailyVWAP', window );">Borrowings, market price, number of days with lowest daily VWAP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsMarketPriceNumberOfTradingDays', window );">Borrowings, market price, number of trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityIssuanceSubscriptionPricePerShare', window );">Equity issuance, subscripion price per share (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.4303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfConvertibleNotesConverted', window );">Number of convertible notes converted | note</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Increase (decrease) in number of ordinary shares issued (in shares) | shares</a></td>
<td class="nump">920,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_GainsArisingFromRecognitionOfFinancialLiabilities', window );">Day-one gain on recognition of financial liabilities</a></td>
<td class="nump">&#8364; 1,262,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,359,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_UnrecognitionDayOneGainOfFinancialLiabilities', window );">Unrecognition day-one gain of financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,557,000<span></span>
</td>
<td class="nump">&#8364; 2,147,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfProbabilityWeightedScenarios', window );">Number of probability-weighted scenarios | scenario</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments', window );">Increase (decrease) through conversion of convertible instruments, equity</a></td>
<td class="nump">&#8364; 53,921,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 53,921,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConvertibleLoansNotesConversionOptionMaximumPeriodPriorToMaturityDate', window );">Conversion option, maximum period prior to maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss', window );">Losses on financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 36,015,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_HeightsConvertibleNotesMember', window );">Heights convertible notes | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IssuancePricePercentageOfDiscountTo15DayWVAP', window );">Issuance price, percentage of discount to 15-day WVAP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConvertibleLoansNotesEarlyRedemptionAmountPercentageOfOutstandongPrincipal', window );">Early redemption amount, percentage of outstandong principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_HeightsConvertibleNotesMember', window );">Heights convertible notes | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityIssuanceSubscriptionPricePerShare', window );">Equity issuance, subscripion price per share (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.4303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConvertibleLoansNotesSettlementInSharesPercentageOfFairMarketValue', window );">Settlement in shares, percentage of fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityIssuanceCashCarveOut', window );">Equity issuance, cash carve-out</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_HeightsConvertibleNotesTrancheAMember', window );">Heights convertible notes, tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NetProceedsFromConvertibleLoansNotes', window );">Net proceeds from convertible loan notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfConvertibleNotesIssued', window );">Number of convertible notes issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConvertibleLoansNotesNominalValue', window );">Convertible loan notes, nominal value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsFixedConversionPrice', window );">Borrowings, fixed conversion price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 23.7674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted', window );">Exercise price, percentage of premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_HeightsConvertibleNotesTrancheBMember', window );">Heights convertible notes, tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfConvertibleNotesIssued', window );">Number of convertible notes issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConvertibleLoansNotesNominalValue', window );">Convertible loan notes, nominal value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted', window );">Exercise price, percentage of 15-day WVAP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_HeightsConvertibleNotesTrancheBMember', window );">Heights convertible notes, tranche B | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConvertibleLoansNotesPeriod', window );">Convertible loan notes, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConvertibleLoansNotesNumberOfSeparateClosings', window );">Convertible loan notes, number of separate closings | closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_HeightsConvertibleNotesTrancheBMember', window );">Heights convertible notes, tranche B | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConvertibleLoansNotesPeriod', window );">Convertible loan notes, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_OCEANEMember', window );">OCEANE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NetProceedsFromConvertibleLoansNotes', window );">Net proceeds from convertible loan notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityIssuanceSubscriptionPricePerShare', window );">Equity issuance, subscripion price per share (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 30.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RepaymentsOfConvertibleLoansNotes', window );">Repayments of convertible loan notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,102,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount Of Reasonably Possible Increase In Unobservable Input, Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsFixedConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Fixed Conversion Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsFixedConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsMarketPriceNumberOfDaysWithLowestDailyVWAP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Market Price, Number Of Days With Lowest Daily VWAP</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsMarketPriceNumberOfDaysWithLowestDailyVWAP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsMarketPriceNumberOfTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Market Price, Number Of Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsMarketPriceNumberOfTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsMaturityDeferralPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings Maturity, Deferral Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsMaturityDeferralPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Maximum Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsNumberOfQuarterlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Number Of Quarterly Installments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsNumberOfQuarterlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Number Of Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsPercentageOfMarketPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Percentage Of Market Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsPercentageOfMarketPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ConvertibleLoansNotesConversionOptionMaximumPeriodPriorToMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Loans Notes, Conversion Option, Maximum Period Prior To Maturity Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ConvertibleLoansNotesConversionOptionMaximumPeriodPriorToMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ConvertibleLoansNotesEarlyRedemptionAmountPercentageOfOutstandongPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Loans Notes, Early Redemption Amount, Percentage Of Outstandong Principal</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ConvertibleLoansNotesEarlyRedemptionAmountPercentageOfOutstandongPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ConvertibleLoansNotesNominalValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Loans Notes, Nominal Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ConvertibleLoansNotesNominalValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ConvertibleLoansNotesNumberOfSeparateClosings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Loans Notes, Number Of Separate Closings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ConvertibleLoansNotesNumberOfSeparateClosings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ConvertibleLoansNotesPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Loans Notes, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ConvertibleLoansNotesPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ConvertibleLoansNotesSettlementInSharesPercentageOfFairMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Loans Notes, Settlement In Shares, Percentage Of Fair Market Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ConvertibleLoansNotesSettlementInSharesPercentageOfFairMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_EquityIssuanceCashCarveOut">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Issuance, Cash Carve-Out</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_EquityIssuanceCashCarveOut</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_EquityIssuanceSubscriptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Issuance, Subscription Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_EquityIssuanceSubscriptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise Price, Percentage Of 15-Day WVAP, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise Price, Percentage Of Premium Over 15-Day VWAP, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_GainsArisingFromRecognitionOfFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains Arising From Recognition Of Financial Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_GainsArisingFromRecognitionOfFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IssuancePricePercentageOfDiscountTo15DayWVAP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Price, Percentage Of Discount To 15-Day WVAP</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IssuancePricePercentageOfDiscountTo15DayWVAP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Losses On Financial Liabilities (Assets) At Fair Value Through Profit Or Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NetProceedsFromConvertibleLoansNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Proceeds From Convertible Loans Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NetProceedsFromConvertibleLoansNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfConvertibleNotesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Convertible Notes Converted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfConvertibleNotesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfConvertibleNotesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Convertible Notes Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfConvertibleNotesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfProbabilityWeightedScenarios">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Probability-Weighted Scenarios</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfProbabilityWeightedScenarios</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_RepaymentsOfConvertibleLoansNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments Of Convertible Loans Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_RepaymentsOfConvertibleLoansNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_UnrecognitionDayOneGainOfFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognition Day-One Gain Of Financial Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_UnrecognitionDayOneGainOfFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in the fair value measurement of assets due to a reasonably possible increase in an unobservable input.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the conversion of convertible instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of a reasonably possible increase in an unobservable input used in fair value measurement of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_HeightsConvertibleNotesTrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_HeightsConvertibleNotesTrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_SharePriceMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_SharePriceMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_RiskFreeInterestRateMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_RiskFreeInterestRateMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_VoluntaryConversionScenarioProbabilityMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_VoluntaryConversionScenarioProbabilityMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_HeightsConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_HeightsConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_HeightsConvertibleNotesTrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_HeightsConvertibleNotesTrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_HeightsConvertibleNotesTrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_HeightsConvertibleNotesTrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_OCEANEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_OCEANEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial liabilities - Disclosure of the main data and assumptions, Heights convertible loan notes (Details) - Heights convertible notes, tranche A<br> &#8364; in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 24, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfConvertibleNotesOutstanding', window );">Number of outstanding notes (in shares) | shares</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Original principal amount | &#8364;</a></td>
<td class="nump">&#8364; 35,000<span></span>
</td>
<td class="nump">&#8364; 35,000,000<span></span>
</td>
<td class="nump">&#8364; 35,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_AggregateFairValueConvertibleNotes', window );">Fair value of convertible notes | &#8364;</a></td>
<td class="nump">&#8364; 20,017<span></span>
</td>
<td class="nump">&#8364; 27,456<span></span>
</td>
<td class="nump">&#8364; 32,641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_HeightsConvertibleNotesTrancheAMember', window );">Interest rate | Monte Carlo model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">0.06<span></span>
</td>
<td class="nump">0.06<span></span>
</td>
<td class="nump">0.06<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_HeightsConvertibleNotesTrancheAMember', window );">Conversion price per share (in euro per share) | Monte Carlo model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">23.77<span></span>
</td>
<td class="nump">23.77<span></span>
</td>
<td class="nump">23.77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_HeightsConvertibleNotesTrancheAMember', window );">Ordinary share price (in euro per share) | Monte Carlo model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">6.76<span></span>
</td>
<td class="nump">9.82<span></span>
</td>
<td class="nump">16.74<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_HeightsConvertibleNotesTrancheAMember', window );">Held to maturity / voluntary conversion scenario probability | Monte Carlo model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">0.75<span></span>
</td>
<td class="nump">0.75<span></span>
</td>
<td class="nump">0.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_HeightsConvertibleNotesTrancheAMember', window );">Initial price limit (in euro per share) | Monte Carlo model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">14.43<span></span>
</td>
<td class="nump">14.43<span></span>
</td>
<td class="nump">14.43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_HeightsConvertibleNotesTrancheAMember', window );">Early redemption amount (put event) | Monte Carlo model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">1.20<span></span>
</td>
<td class="nump">1.20<span></span>
</td>
<td class="nump">1.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_HeightsConvertibleNotesTrancheAMember', window );">Volatility | Monte Carlo model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">0.50<span></span>
</td>
<td class="nump">0.50<span></span>
</td>
<td class="nump">0.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_HeightsConvertibleNotesTrancheAMember', window );">Credit spread | Monte Carlo model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">0.25<span></span>
</td>
<td class="nump">0.20<span></span>
</td>
<td class="nump">0.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_HeightsConvertibleNotesTrancheAMember', window );">Risk-free rate | Monte Carlo model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">0.029<span></span>
</td>
<td class="nump">0.023<span></span>
</td>
<td class="nump">0.029<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_AggregateFairValueConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Fair Value, Convertible Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_AggregateFairValueConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfConvertibleNotesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Convertible Notes Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfConvertibleNotesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of significant unobservable input used in the measurement of the fair value of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_HeightsConvertibleNotesTrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_HeightsConvertibleNotesTrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_InterestRateMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_InterestRateMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis=abvx_MonteCarloModelIFRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis=abvx_MonteCarloModelIFRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_ConversionPricePerShareMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_ConversionPricePerShareMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_SharePriceMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_SharePriceMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_VoluntaryConversionScenarioProbabilityMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_VoluntaryConversionScenarioProbabilityMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_InitialPriceLimitMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_InitialPriceLimitMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_EarlyRedemptionAmountMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_EarlyRedemptionAmountMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_CreditSpreadMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_CreditSpreadMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_RiskFreeInterestRateMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_RiskFreeInterestRateMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial liabilities - Kreos 1 (Details)<br> &#8364; / shares in Units, &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 23, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Aug. 28, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jul. 30, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Aug. 24, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Aug. 21, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>May 24, 2023 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jul. 24, 2018 </div>
<div>EUR (&#8364;) </div>
<div>tranche</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants', window );">Exercises of share warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">464,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RepaymentsOfConvertibleLoansNotes', window );">Repayments of convertible loan notes | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,188<span></span>
</td>
<td class="nump">&#8364; 8,750<span></span>
</td>
<td class="nump">&#8364; 27,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid', window );">Loss of extinguishment | &#8364;</a></td>
<td class="nump">&#8364; 3,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Exercises of the Kreos/Claret and other share warrants | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11,531<span></span>
</td>
<td class="nump">&#8364; 15,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfSharesPerShareWarrant', window );">Number of shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_WarrantsAxis=abvx_KreosABSAMember', window );">Kreos A BSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfShareWarrantsIssued', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price, share options granted (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 7.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_WarrantsAxis=abvx_KreosBBSAMember', window );">Kreos B BSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfShareWarrantsIssued', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price, share options granted (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_WarrantsAxis=abvx_KreosABBSAMember', window );">Kreos A &amp; B BSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ShareWarrantsSubscriptionPricePerShare', window );">Share warrants, subscription price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_Kreos1Member', window );">Kreos A &amp; B BSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsMaximumBorrowingCapacity', window );">Borrowings, maximum borrowing capacity | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsNumberOfTranches', window );">Borrowings, number of tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsMaximumBorrowingCapacityPerTranche', window );">Borrowings, maximum borrowing capacity per tranche | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_Kreos1NonConvertibleBondLoansMember', window );">Kreos 1, non-convertible bond loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsMaximumBorrowingCapacity', window );">Borrowings, maximum borrowing capacity | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_Kreos1ConvertibleBondLoansMember', window );">Kreos 1, convertible bond loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsMaximumBorrowingCapacity', window );">Borrowings, maximum borrowing capacity | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_Kreos1ConvertibleBondLoansTrancheBMember', window );">Kreos 1, convertible bond loans, tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants', window );">Exercises of share warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RepaymentsOfConvertibleLoansNotes', window );">Repayments of convertible loan notes | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8,000<span></span>
</td>
<td class="nump">&#8364; 7,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfOtherShareWarrantsRepurchased', window );">Number of other share warrants repurchased (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfOtherShareWarrantsConverted', window );">Number of other share warrants converted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_Kreos12BondLoansMember', window );">Kreos 1 &amp; 2 bond loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid', window );">Loss of extinguishment | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_Kreos1ConvertibleBondLoansTrancheAMember', window );">Kreos 1, convertible bond loans, tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants', window );">Exercises of share warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfOtherShareWarrantsRepurchased', window );">Number of other share warrants repurchased (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfOtherShareWarrantsConverted', window );">Number of other share warrants converted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Exercises of the Kreos/Claret and other share warrants | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Maximum Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsMaximumBorrowingCapacityPerTranche">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Maximum Borrowing Capacity Per Tranche</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsMaximumBorrowingCapacityPerTranche</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Number Of Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Number Of Shares Issued Through Exercise Of Share Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfOtherShareWarrantsConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Other Share Warrants Converted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfOtherShareWarrantsConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfOtherShareWarrantsRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Other Share Warrants Repurchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfOtherShareWarrantsRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfShareWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Share Warrants Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfShareWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfSharesPerShareWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares per Share Warrant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfSharesPerShareWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_RepaymentsOfConvertibleLoansNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments Of Convertible Loans Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_RepaymentsOfConvertibleLoansNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ShareWarrantsSubscriptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Warrants, Subscription Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ShareWarrantsSubscriptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gain (loss) arising from the difference between the carrying amount of the financial liability extinguished and the measurement of the consideration paid (equity instruments issued) to the creditor. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRIC<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 11<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRIC&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_11&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_WarrantsAxis=abvx_KreosABSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_WarrantsAxis=abvx_KreosABSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_WarrantsAxis=abvx_KreosBBSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_WarrantsAxis=abvx_KreosBBSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_WarrantsAxis=abvx_KreosABBSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_WarrantsAxis=abvx_KreosABBSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_Kreos1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_Kreos1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_Kreos1NonConvertibleBondLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_Kreos1NonConvertibleBondLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_Kreos1ConvertibleBondLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_Kreos1ConvertibleBondLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_Kreos1ConvertibleBondLoansTrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_Kreos1ConvertibleBondLoansTrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_Kreos12BondLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_Kreos12BondLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_Kreos1ConvertibleBondLoansTrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_Kreos1ConvertibleBondLoansTrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial liabilities - Kreos 2 (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 24, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Aug. 21, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 13, 2020 </div>
<div>EUR (&#8364;) </div>
<div>tranche</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RepaymentsOfConvertibleLoansNotes', window );">Repayments of convertible loan notes</a></td>
<td class="nump">&#8364; 33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,188<span></span>
</td>
<td class="nump">&#8364; 8,750<span></span>
</td>
<td class="nump">&#8364; 27,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_Kreos2Member', window );">Kreos 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsNumberOfTranches', window );">Borrowings, number of tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsAdditionalTrancheAmount', window );">Borrowings, additional tranche mount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_Kreos2TrancheAMember', window );">Kreos 2, tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_Kreos2TrancheBMember', window );">Kreos 2, tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_Kreos1ConvertibleBondLoansTrancheBMember', window );">Kreos 1, convertible bond loans, tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RepaymentsOfConvertibleLoansNotes', window );">Repayments of convertible loan notes</a></td>
<td class="nump">&#8364; 8,000<span></span>
</td>
<td class="nump">&#8364; 7,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsAdditionalTrancheAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Additional Tranche Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsAdditionalTrancheAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Number Of Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_RepaymentsOfConvertibleLoansNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments Of Convertible Loans Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_RepaymentsOfConvertibleLoansNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_Kreos2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_Kreos2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_Kreos2TrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_Kreos2TrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_Kreos2TrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_Kreos2TrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_Kreos1ConvertibleBondLoansTrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_Kreos1ConvertibleBondLoansTrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial liabilities - OCEANE (Details)<br> &#8364; / shares in Units, &#8364; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">145 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 23, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 24, 2023 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 24, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 24, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Feb. 22, 2023 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 30, 2021 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jun. 21, 2024 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Mar. 28, 2024 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Nov. 02, 2023 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Aug. 20, 2023 </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease', window );">Capital increase from issuance of ordinary shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,325,500<span></span>
</td>
<td class="nump">20,325,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,679,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,325,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityIssuanceSubscriptionPricePerShare', window );">Equity issuance, subscripion price per share (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Capital increases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 223,300<span></span>
</td>
<td class="nump">$ 235.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 648,124<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 353,377<span></span>
</td>
<td class="nump">&#8364; 1,194,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NetProceedsFromConvertibleLoansNotes', window );">Net proceeds from convertible loan notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RepaymentsOfConvertibleLoansNotes', window );">Repayments of convertible loan notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,188<span></span>
</td>
<td class="nump">&#8364; 8,750<span></span>
</td>
<td class="nump">&#8364; 27,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid', window );">Loss of extinguishment</a></td>
<td class="nump">&#8364; 3,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible increase in unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=abvx_SharePriceMeasurementInputMember', window );">Ordinary share price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Amount of reasonably possible increase in unobservable input, liabilities (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=abvx_RiskFreeInterestRateMeasurementInputMember', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible increase in unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_OCEANEMember', window );">OCEANE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_AggregateFairValueConvertibleNotes', window );">Fair value of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_OCEANEMember', window );">OCEANE | Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets', window );">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_OCEANEMember', window );">OCEANE | Volatility | Monte Carlo model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_OCEANEMember', window );">OCEANE | Credit spread | Monte Carlo model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_OCEANEMember', window );">OCEANE | Ordinary share price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets', window );">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_OCEANEMember', window );">OCEANE | Ordinary share price (in euro per share) | Monte Carlo model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_OCEANEMember', window );">OCEANE | Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets', window );">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_OCEANEMember', window );">OCEANE | Risk-free rate | Monte Carlo model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_OCEANEMember', window );">OCEANE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ProceedsFromIssuingSharesAndConvertibleLoansNotes', window );">Proceeds from issuing shares and convertible loan notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease', window );">Capital increase from issuance of ordinary shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,964,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityIssuanceSubscriptionPricePerShare', window );">Equity issuance, subscripion price per share (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 30.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Capital increases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NetProceedsFromConvertibleLoansNotes', window );">Net proceeds from convertible loan notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RepaymentsOfConvertibleLoansNotes', window );">Repayments of convertible loan notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid', window );">Loss of extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_OCEANEMember', window );">OCEANE | After 18 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConversionPriceAdjustmentPeriod', window );">Conversion price, adjustment, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_OCEANEMember', window );">OCEANE | After 24 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConversionPriceAdjustmentPeriod', window );">Conversion price, adjustment, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_OCEANEMember', window );">OCEANE | After 36 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConversionPriceAdjustmentPeriod', window );">Conversion price, adjustment, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_AggregateFairValueConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Fair Value, Convertible Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_AggregateFairValueConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount Of Reasonably Possible Increase In Unobservable Input, Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ConversionPriceAdjustmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion Price, Adjustment, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ConversionPriceAdjustmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_EquityIssuanceSubscriptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Issuance, Subscription Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_EquityIssuanceSubscriptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Number Of Ordinary Shares Issued Through Capital Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NetProceedsFromConvertibleLoansNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Proceeds From Convertible Loans Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NetProceedsFromConvertibleLoansNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ProceedsFromIssuingSharesAndConvertibleLoansNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuing Shares And Convertible Loans Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ProceedsFromIssuingSharesAndConvertibleLoansNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_RepaymentsOfConvertibleLoansNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments Of Convertible Loans Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_RepaymentsOfConvertibleLoansNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gain (loss) arising from the difference between the carrying amount of the financial liability extinguished and the measurement of the consideration paid (equity instruments issued) to the creditor. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRIC<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 11<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRIC&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_11&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in the fair value measurement of assets due to a reasonably possible increase in an unobservable input.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of a reasonably possible increase in an unobservable input used in fair value measurement of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of significant unobservable input used in the measurement of the fair value of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_SharePriceMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_SharePriceMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_RiskFreeInterestRateMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_RiskFreeInterestRateMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_OCEANEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_OCEANEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis=abvx_MonteCarloModelIFRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis=abvx_MonteCarloModelIFRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_CreditSpreadMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_CreditSpreadMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_OCEANEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_OCEANEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_RemeasurementPeriodAxis=abvx_After18MonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_RemeasurementPeriodAxis=abvx_After18MonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_RemeasurementPeriodAxis=abvx_After24MonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_RemeasurementPeriodAxis=abvx_After24MonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_RemeasurementPeriodAxis=abvx_After36MonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_RemeasurementPeriodAxis=abvx_After36MonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial liabilities - State guaranteed loan &#8211; &#8220;PGE&#8221; (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Subsidies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 4,140<span></span>
</td>
<td class="nump">&#8364; 81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_PretGarantiParLEtatPGEMember', window );">PGE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsMaturityTerm', window );">Borrowings, maturity term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="nump">0.58%<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsMaturityExtensionTerm', window );">Borrowings maturity, extension term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsMaturityDeferralPeriod', window );">Borrowings maturity, deferral period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsStateGuaranteedPremium', window );">Borrowings, state guaranteed premium</a></td>
<td class="nump">&#8364; 138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Subsidies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Repayments of borrowings, classified as financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsMaturityDeferralPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings Maturity, Deferral Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsMaturityDeferralPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsMaturityExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings Maturity, Extension Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsMaturityExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings Maturity, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsStateGuaranteedPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, State Guaranteed Premium</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsStateGuaranteedPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2025-01-01<br> -Paragraph 39<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_39_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_PretGarantiParLEtatPGEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_PretGarantiParLEtatPGEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial liabilities - Disclosure of conditional advances (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConditionalAdvances', window );">Conditional advances</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6,771<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RNPVIRConditionalAdvanceBPIMember', window );">RNP VIR &#8211; Bpifrance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConditionalAdvances', window );">Conditional advances</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">&#8364; 2,945<span></span>
</td>
<td class="nump">4,232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_CARENAConditionalAdvanceBPIMember', window );">CARENA &#8211; Bpifrance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConditionalAdvances', window );">Conditional advances</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">&#8364; 3,255<span></span>
</td>
<td class="nump">2,485<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_EbolaConditionalAdvanceBPIMember', window );">EBOLA &#8211; Bpifrance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConditionalAdvances', window );">Conditional advances</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 55<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ConditionalAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conditional Advances</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ConditionalAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RNPVIRConditionalAdvanceBPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RNPVIRConditionalAdvanceBPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_CARENAConditionalAdvanceBPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_CARENAConditionalAdvanceBPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_EbolaConditionalAdvanceBPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_EbolaConditionalAdvanceBPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial liabilities - Conditional advances (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="9">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">25 Months Ended</th>
<th class="th" colspan="1">27 Months Ended</th>
<th class="th" colspan="1">31 Months Ended</th>
<th class="th" colspan="1">73 Months Ended</th>
<th class="th" colspan="1">109 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 02, 2017</div></th>
<th class="th"><div>Dec. 16, 2016</div></th>
<th class="th"><div>Dec. 16, 2013</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConditionalAdvances', window );">Conditional advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 6,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Income from government grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,140<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RNPVIRConditionalAdvanceBPIMember', window );">RNP-VIR conditional advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity', window );">Maximum drawdown capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ProceedsFromConditionalAdvances', window );">Proceeds from conditional advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,930<span></span>
</td>
<td class="nump">&#8364; 346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RepaymentOfExcessConditionalAdvancesClaimed', window );">Excess conditional advances claimed</a></td>
<td class="nump">&#8364; 1,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_PercentageOfConditionalAdvancesWaived', window );">Percentage of conditional advances waived</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConditionalAdvances', window );">Conditional advances</a></td>
<td class="nump">&#8364; 2,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Income from government grants</a></td>
<td class="nump">1,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_CARENAConditionalAdvanceBPIMember', window );">CARENA conditional advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity', window );">Maximum drawdown capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ProceedsFromConditionalAdvances', window );">Proceeds from conditional advances</a></td>
<td class="nump">&#8364; 1,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 29<span></span>
</td>
<td class="nump">&#8364; 1,008<span></span>
</td>
<td class="nump">&#8364; 1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_PercentageOfConditionalAdvancesWaived', window );">Percentage of conditional advances waived</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConditionalAdvances', window );">Conditional advances</a></td>
<td class="nump">&#8364; 3,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Income from government grants</a></td>
<td class="nump">&#8364; 2,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_EbolaConditionalAdvanceBPIMember', window );">Ebola conditional advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity', window );">Maximum drawdown capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ProceedsFromConditionalAdvances', window );">Proceeds from conditional advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConditionalAdvances', window );">Conditional advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ConditionalAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conditional Advances</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ConditionalAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Liabilities, Maximum Drawdown Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_PercentageOfConditionalAdvancesWaived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Conditional Advances Waived</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_PercentageOfConditionalAdvancesWaived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ProceedsFromConditionalAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Conditional Advances</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ProceedsFromConditionalAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_RepaymentOfExcessConditionalAdvancesClaimed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment Of Excess Conditional Advances Claimed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_RepaymentOfExcessConditionalAdvancesClaimed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2025-01-01<br> -Paragraph 39<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_39_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RNPVIRConditionalAdvanceBPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RNPVIRConditionalAdvanceBPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_CARENAConditionalAdvanceBPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_CARENAConditionalAdvanceBPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_EbolaConditionalAdvanceBPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_EbolaConditionalAdvanceBPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial liabilities - Disclosure of variation in lease liabilities (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract', window );"><strong>Disclosure of financial liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities at beginning of period</a></td>
<td class="nump">&#8364; 2,363<span></span>
</td>
<td class="nump">&#8364; 540<span></span>
</td>
<td class="nump">&#8364; 1,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseInLeaseLiabilities', window );">Increase</a></td>
<td class="nump">444<span></span>
</td>
<td class="nump">2,221<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DecreaseInLeaseLiabilities', window );">Decrease</a></td>
<td class="num">(950)<span></span>
</td>
<td class="num">(398)<span></span>
</td>
<td class="num">(1,194)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities at end of period</a></td>
<td class="nump">&#8364; 1,856<span></span>
</td>
<td class="nump">&#8364; 2,363<span></span>
</td>
<td class="nump">&#8364; 540<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease In Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IncreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase In Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IncreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial liabilities - Lease liabilities (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 02, 2024</div></th>
<th class="th"><div>Apr. 30, 2024</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfLeaseLiabilitiesLineItems', window );"><strong>Disclosure Of Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExpenseOnLeaseLiabilities', window );">Expense on lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 808<span></span>
</td>
<td class="nump">&#8364; 730<span></span>
</td>
<td class="nump">&#8364; 548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DepreciationExpenseLease', window );">Depreciation expense, lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">744<span></span>
</td>
<td class="nump">788<span></span>
</td>
<td class="nump">498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest expense on lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed', window );">Expense relating to short-term leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 349<span></span>
</td>
<td class="nump">&#8364; 352<span></span>
</td>
<td class="nump">&#8364; 334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=abvx_LeaseFacilitiesParisMember', window );">Lease facilities, Paris</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfLeaseLiabilitiesLineItems', window );"><strong>Disclosure Of Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_LeaseDurationPeriod', window );">Lease, duration period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_LeaseTacitRenewalPeriod', window );">Lease, tacit renewal period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_LeaseBreakClausePeriod', window );">Lease, break clause period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DecreaseInLeaseLiabilitiesThroughModificationOfTerm', window );">Decrease in lease liabilities through modification of term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=abvx_LeaseFacilitiesBostonMember', window );">Lease facilities, Boston</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfLeaseLiabilitiesLineItems', window );"><strong>Disclosure Of Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_LeaseDurationPeriod', window );">Lease, duration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=abvx_LeaseFacilitiesBostonMember', window );">Lease facilities, Boston | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfLeaseLiabilitiesLineItems', window );"><strong>Disclosure Of Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_LeaseExtensionPeriod', window );">Lease, extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=abvx_LeaseFacilitiesBostonMember', window );">Lease facilities, Boston | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfLeaseLiabilitiesLineItems', window );"><strong>Disclosure Of Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_LeaseExtensionPeriod', window );">Lease, extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=abvx_LeaseFacilitiesMontpellierMember', window );">Lease facilities, Montpellier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfLeaseLiabilitiesLineItems', window );"><strong>Disclosure Of Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_LeaseDurationPeriod', window );">Lease, duration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_LeaseTacitRenewalPeriod', window );">Lease, tacit renewal period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_LeaseBreakClausePeriod', window );">Lease, break clause period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=abvx_LeaseFacilitiesMember', window );">Lease facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfLeaseLiabilitiesLineItems', window );"><strong>Disclosure Of Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_LeaseLiabilityPercentageOfTotal', window );">Lease liability, percentage of total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">93.00%<span></span>
</td>
<td class="nump">93.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DecreaseInLeaseLiabilitiesThroughModificationOfTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease In Lease Liabilities Through Modification Of Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DecreaseInLeaseLiabilitiesThroughModificationOfTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DepreciationExpenseLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation Expense, Lease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DepreciationExpenseLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DisclosureOfLeaseLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Lease Liabilities [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DisclosureOfLeaseLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense On Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense Relating To Short-Term Leases And Low Value Assets For Which Recognition Exemption Has Been Used</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_LeaseBreakClausePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Break Clause Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_LeaseBreakClausePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_LeaseDurationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Duration Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_LeaseDurationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_LeaseExtensionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Extension Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_LeaseExtensionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_LeaseLiabilityPercentageOfTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Liability, Percentage Of Total</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_LeaseLiabilityPercentageOfTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_LeaseTacitRenewalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Tacit Renewal Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_LeaseTacitRenewalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=abvx_LeaseFacilitiesParisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=abvx_LeaseFacilitiesParisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=abvx_LeaseFacilitiesBostonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=abvx_LeaseFacilitiesBostonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=abvx_LeaseFacilitiesMontpellierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=abvx_LeaseFacilitiesMontpellierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=abvx_LeaseFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=abvx_LeaseFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial liabilities - Royalty certificates (Details)<br> &#8364; / shares in Units, &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1">145 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Oct. 24, 2023 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 22, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 02, 2022 </div>
<div>EUR (&#8364;) </div>
<div>transaction </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th">
<div>Nov. 19, 2024 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jun. 21, 2024 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Mar. 28, 2024 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Nov. 02, 2023 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Aug. 24, 2023 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Aug. 20, 2023 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>May 24, 2023 </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Capital increase from issuance of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 637,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 353,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease', window );">Capital increase from issuance of ordinary shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,325,500<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,679,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,325,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (in euro per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityIssuanceSubscriptionPricePerShare', window );">Equity issuance, subscripion price per share (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NetProceedsFromSaleOfRoyaltyCertificates', window );">Net proceeds from sale of royalty certificates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RoyaltyCertificatePercentageOfFutureSales', window );">Royalty certificate, percentage of future sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RoyaltyCertificateMaximumAmount', window );">Royalty certificate, maximum amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 28,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities', window );">Increase (decrease) through amortization cost remeasurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11,278<span></span>
</td>
<td class="num">&#8364; (3,404)<span></span>
</td>
<td class="nump">5,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_InterestExpenseOnRoyaltyCertificatesIncludingTheUnwindingOfDiscount', window );">Interest expense on royalty certificates, including the unwinding of discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">794<span></span>
</td>
<td class="nump">8,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_UnwindingOfDiscountOnRoyalties', window );">Unwinding of discount on royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="nump">&#8364; 162,256<span></span>
</td>
<td class="nump">&#8364; 125,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 141,409<span></span>
</td>
<td class="nump">&#8364; 162,256<span></span>
</td>
<td class="nump">&#8364; 125,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 141,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_DiscountRateMeasurementInputMember', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible increase in unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=abvx_SharePriceMeasurementInputMember', window );">Ordinary share price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Amount of reasonably possible increase in unobservable input, liabilities (in euro per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=abvx_RoyaltyCertificatesMember', window );">Royalty certificates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities', window );">Increase (decrease) through amortization cost remeasurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11,286<span></span>
</td>
<td class="num">&#8364; (3,404)<span></span>
</td>
<td class="nump">&#8364; 6,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember', window );">PREMIUMS RELATED TO SHARE CAPITAL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Capital increase from issuance of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">637,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 352,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RoyaltyCertificatesMember', window );">Royalty certificates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 49,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_OtherLiabilitiesNumberOfTransactions', window );">Other liabilities, number of transactions | transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Capital increase from issuance of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 46,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease', window );">Capital increase from issuance of ordinary shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_EquityIssuanceSubscriptionPricePerShare', window );">Equity issuance, subscripion price per share (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RoyaltyCertificatePercentageOfFutureSales', window );">Royalty certificate, percentage of future sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RoyaltyCertificateMaximumAmount', window );">Royalty certificate, maximum amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RoyaltyCertificatesEIR', window );">Royalty certificates, EIR</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="nump">&#8364; 7,313<span></span>
</td>
<td class="nump">&#8364; 12,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 102,001<span></span>
</td>
<td class="nump">&#8364; 7,313<span></span>
</td>
<td class="nump">&#8364; 12,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 102,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_UnobservableInputLiabilitiesDiscountRate', window );">Unobservable input, liabilities, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RoyaltyCertificatesMember', window );">Royalty certificates | POS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible increase in unobservable input, liabilities</a></td>
<td class="nump">0.05%<span></span>
</td>
<td class="nump">0.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.05%<span></span>
</td>
<td class="nump">0.05%<span></span>
</td>
<td class="nump">0.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Increase (decrease) in carrying value due to reasonably possible increase in unobservable input liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible decrease in unobservable input, liabilities</a></td>
<td class="num">(0.05%)<span></span>
</td>
<td class="num">(0.05%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.05%)<span></span>
</td>
<td class="num">(0.05%)<span></span>
</td>
<td class="num">(0.05%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.05%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities', window );">Increase (decrease) in carrying value due to reasonably possible decrease in unobservable input liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (1,712)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Increase (decrease) in financial liabilities at fair value due to reasonably possible increase in unobservable input</a></td>
<td class="nump">&#8364; 572<span></span>
</td>
<td class="nump">&#8364; 1,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities', window );">Increase (decrease) in financial liabilities at fair value due to reasonably possible decrease in unobservable input</a></td>
<td class="num">&#8364; (572)<span></span>
</td>
<td class="num">&#8364; (1,104)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (5,810)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RoyaltyCertificatesMember', window );">Royalty certificates | Peak penetration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible increase in unobservable input, liabilities</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Increase (decrease) in carrying value due to reasonably possible increase in unobservable input liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible decrease in unobservable input, liabilities</a></td>
<td class="num">(5.00%)<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities', window );">Increase (decrease) in carrying value due to reasonably possible decrease in unobservable input liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (4,154)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Increase (decrease) in financial liabilities at fair value due to reasonably possible increase in unobservable input</a></td>
<td class="nump">&#8364; 1,735<span></span>
</td>
<td class="nump">&#8364; 1,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities', window );">Increase (decrease) in financial liabilities at fair value due to reasonably possible decrease in unobservable input</a></td>
<td class="num">&#8364; (2,527)<span></span>
</td>
<td class="num">&#8364; (2,311)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (5,590)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RoyaltyCertificatesMember', window );">Royalty certificates | WACC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible increase in unobservable input, liabilities</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible decrease in unobservable input, liabilities</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Increase (decrease) in financial liabilities at fair value due to reasonably possible increase in unobservable input</a></td>
<td class="num">&#8364; (314)<span></span>
</td>
<td class="num">&#8364; (577)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (4,940)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities', window );">Increase (decrease) in financial liabilities at fair value due to reasonably possible decrease in unobservable input</a></td>
<td class="nump">&#8364; 332<span></span>
</td>
<td class="nump">&#8364; 612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RoyaltyCertificatesMember', window );">Royalty certificates | Ordinary share price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Amount of reasonably possible increase in unobservable input, liabilities (in euro per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Increase (decrease) in financial liabilities at fair value due to reasonably possible increase in unobservable input</a></td>
<td class="nump">&#8364; 1,160<span></span>
</td>
<td class="nump">&#8364; 1,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_AmountOfReasonablyPossibleDecreaseInUnobservableInputLiabilities', window );">Amount of reasonably possible decrease in unobservable input, liabilities (in euro per share) | &#8364; / shares</a></td>
<td class="num">&#8364; (1)<span></span>
</td>
<td class="num">&#8364; (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (1)<span></span>
</td>
<td class="num">&#8364; (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities', window );">Increase (decrease) in financial liabilities at fair value due to reasonably possible decrease in unobservable input</a></td>
<td class="num">&#8364; (1,160)<span></span>
</td>
<td class="num">&#8364; (1,325)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RoyaltyCertificatesMember', window );">Royalty certificates | PREMIUMS RELATED TO SHARE CAPITAL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_AmountOfReasonablyPossibleDecreaseInUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount Of Reasonably Possible Decrease In Unobservable Input, Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_AmountOfReasonablyPossibleDecreaseInUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount Of Reasonably Possible Increase In Unobservable Input, Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_EquityIssuanceSubscriptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Issuance, Subscription Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_EquityIssuanceSubscriptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Carrying Value Due To Reasonably Possible Decrease In Unobservable Input Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Carrying Value Due To Reasonably Possible Increase In Unobservable Input Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Number Of Ordinary Shares Issued Through Capital Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Amortization Cost Remeasurement, Liabilities Arising From Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_InterestExpenseOnRoyaltyCertificatesIncludingTheUnwindingOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Expense On Royalty Certificates, Including The Unwinding Of Discount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_InterestExpenseOnRoyaltyCertificatesIncludingTheUnwindingOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NetProceedsFromSaleOfRoyaltyCertificates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Proceeds From Sale Of Royalty Certificates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NetProceedsFromSaleOfRoyaltyCertificates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_OtherLiabilitiesNumberOfTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Liabilities, Number Of Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_OtherLiabilitiesNumberOfTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_RoyaltyCertificateMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Certificate, Maximum Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_RoyaltyCertificateMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_RoyaltyCertificatePercentageOfFutureSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Certificate, Percentage Of Future Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_RoyaltyCertificatePercentageOfFutureSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_RoyaltyCertificatesEIR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Certificates, EIR</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_RoyaltyCertificatesEIR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_UnobservableInputLiabilitiesDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unobservable Input, Liabilities, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_UnobservableInputLiabilitiesDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_UnwindingOfDiscountOnRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unwinding Of Discount On Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_UnwindingOfDiscountOnRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in the fair value measurement of liabilities due to a reasonably possible decrease in an unobservable input.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in the fair value measurement of liabilities due to a reasonably possible increase in an unobservable input.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_a_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160_a_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of a reasonably possible decrease in an unobservable input used in fair value measurement of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of a reasonably possible increase in an unobservable input used in fair value measurement of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_DiscountRateMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_DiscountRateMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_SharePriceMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_SharePriceMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=abvx_RoyaltyCertificatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=abvx_RoyaltyCertificatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RoyaltyCertificatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RoyaltyCertificatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_ProbabilityOfSuccessMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_ProbabilityOfSuccessMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=abvx_PeakPenetrationMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=abvx_PeakPenetrationMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_WeightedAverageCostOfCapitalMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_WeightedAverageCostOfCapitalMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial liabilities - Disclosure of reconciliation of liabilities arising from financing activities (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at beginning of period</a></td>
<td class="nump">&#8364; 109,218<span></span>
</td>
<td class="nump">&#8364; 74,466<span></span>
</td>
<td class="nump">&#8364; 49,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities', window );">Proceeds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">47,444<span></span>
</td>
<td class="nump">58,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities', window );">Repayments</a></td>
<td class="num">(59,532)<span></span>
</td>
<td class="num">(13,167)<span></span>
</td>
<td class="num">(38,993)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities', window );">Interest paid</a></td>
<td class="num">(6,491)<span></span>
</td>
<td class="num">(7,696)<span></span>
</td>
<td class="num">(5,278)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: classification of embedded derivatives as separate derivative financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,204)<span></span>
</td>
<td class="num">(1,046)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: (gain)/loss on recognition or derecognition</a></td>
<td class="nump">2,281<span></span>
</td>
<td class="num">(590)<span></span>
</td>
<td class="nump">3,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: interest expense and other</a></td>
<td class="nump">17,200<span></span>
</td>
<td class="nump">15,834<span></span>
</td>
<td class="nump">7,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: recognition of earn-out liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,005)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: amortized cost remeasurement</a></td>
<td class="nump">11,278<span></span>
</td>
<td class="num">(3,404)<span></span>
</td>
<td class="nump">5,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: other fair value remeasurement</a></td>
<td class="nump">36,002<span></span>
</td>
<td class="nump">1,367<span></span>
</td>
<td class="num">(3,198)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes&#160;: subsidies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,070)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: conversion into shares</a></td>
<td class="num">(78,275)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities', window );">Non cash changes: additional leases</a></td>
<td class="nump">444<span></span>
</td>
<td class="nump">2,221<span></span>
</td>
<td class="nump">272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Non cash changes : Effect of the change in foreign currency exchange rates</a></td>
<td class="num">(33)<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at end of period</a></td>
<td class="nump">32,093<span></span>
</td>
<td class="nump">109,218<span></span>
</td>
<td class="nump">74,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=abvx_Kreos12BondLoansMember', window );">Kreos 1 &amp; 2 bond loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at beginning of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities', window );">Proceeds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities', window );">Repayments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,635)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities', window );">Interest paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,278)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: classification of embedded derivatives as separate derivative financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: (gain)/loss on recognition or derecognition</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: interest expense and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: recognition of earn-out liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: amortized cost remeasurement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: other fair value remeasurement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes&#160;: subsidies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: conversion into shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities', window );">Non cash changes: additional leases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Non cash changes : Effect of the change in foreign currency exchange rates</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=abvx_OCEANEMember', window );">OCEANE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at beginning of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities', window );">Proceeds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities', window );">Repayments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(23,238)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities', window );">Interest paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,602)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: classification of embedded derivatives as separate derivative financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: (gain)/loss on recognition or derecognition</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: interest expense and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: recognition of earn-out liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: amortized cost remeasurement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: other fair value remeasurement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes&#160;: subsidies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: conversion into shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities', window );">Non cash changes: additional leases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Non cash changes : Effect of the change in foreign currency exchange rates</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=abvx_KreosClaretFinancingTrancheAMember', window );">Kreos &amp; Claret convertible notes (OCABSA)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at beginning of period</a></td>
<td class="nump">23,370<span></span>
</td>
<td class="nump">21,643<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities', window );">Proceeds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">23,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities', window );">Repayments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities', window );">Interest paid</a></td>
<td class="num">(1,875)<span></span>
</td>
<td class="num">(2,250)<span></span>
</td>
<td class="num">(818)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: classification of embedded derivatives as separate derivative financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,046)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: (gain)/loss on recognition or derecognition</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: interest expense and other</a></td>
<td class="nump">2,860<span></span>
</td>
<td class="nump">3,977<span></span>
</td>
<td class="nump">1,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: recognition of earn-out liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,005)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: amortized cost remeasurement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: other fair value remeasurement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes&#160;: subsidies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: conversion into shares</a></td>
<td class="num">(24,354)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities', window );">Non cash changes: additional leases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Non cash changes : Effect of the change in foreign currency exchange rates</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">23,370<span></span>
</td>
<td class="nump">21,643<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=abvx_Kreos1ClaretBondLoansMember', window );">Kreos &amp; Claret bond loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at beginning of period</a></td>
<td class="nump">46,401<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities', window );">Proceeds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">47,444<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities', window );">Repayments</a></td>
<td class="num">(53,920)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities', window );">Interest paid</a></td>
<td class="num">(3,791)<span></span>
</td>
<td class="num">(3,639)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: classification of embedded derivatives as separate derivative financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,204)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: (gain)/loss on recognition or derecognition</a></td>
<td class="nump">3,838<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: interest expense and other</a></td>
<td class="nump">7,472<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: recognition of earn-out liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: amortized cost remeasurement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: other fair value remeasurement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes&#160;: subsidies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: conversion into shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities', window );">Non cash changes: additional leases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Non cash changes : Effect of the change in foreign currency exchange rates</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">46,401<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=abvx_HeightsConvertibleNotesMember', window );">Heights convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at beginning of period</a></td>
<td class="nump">21,574<span></span>
</td>
<td class="nump">29,605<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities', window );">Proceeds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities', window );">Repayments</a></td>
<td class="num">(2,188)<span></span>
</td>
<td class="num">(8,750)<span></span>
</td>
<td class="num">(2,188)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities', window );">Interest paid</a></td>
<td class="num">(689)<span></span>
</td>
<td class="num">(1,772)<span></span>
</td>
<td class="num">(525)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: classification of embedded derivatives as separate derivative financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: (gain)/loss on recognition or derecognition</a></td>
<td class="num">(1,557)<span></span>
</td>
<td class="num">(590)<span></span>
</td>
<td class="num">(212)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: interest expense and other</a></td>
<td class="nump">778<span></span>
</td>
<td class="nump">1,714<span></span>
</td>
<td class="nump">727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: recognition of earn-out liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: amortized cost remeasurement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: other fair value remeasurement</a></td>
<td class="nump">36,002<span></span>
</td>
<td class="nump">1,367<span></span>
</td>
<td class="num">(3,198)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes&#160;: subsidies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: conversion into shares</a></td>
<td class="num">(53,921)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities', window );">Non cash changes: additional leases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Non cash changes : Effect of the change in foreign currency exchange rates</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,574<span></span>
</td>
<td class="nump">29,605<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=abvx_PretGarantiParLEtatPGEMember', window );">PGE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at beginning of period</a></td>
<td class="nump">2,488<span></span>
</td>
<td class="nump">3,678<span></span>
</td>
<td class="nump">4,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities', window );">Proceeds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities', window );">Repayments</a></td>
<td class="num">(2,514)<span></span>
</td>
<td class="num">(1,250)<span></span>
</td>
<td class="num">(1,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities', window );">Interest paid</a></td>
<td class="num">(72)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: classification of embedded derivatives as separate derivative financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: (gain)/loss on recognition or derecognition</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: interest expense and other</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: recognition of earn-out liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: amortized cost remeasurement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: other fair value remeasurement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes&#160;: subsidies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: conversion into shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities', window );">Non cash changes: additional leases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Non cash changes : Effect of the change in foreign currency exchange rates</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,488<span></span>
</td>
<td class="nump">3,678<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=abvx_ConditionalAdvancesMember', window );">Conditional advances Bpifrance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at beginning of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,771<span></span>
</td>
<td class="nump">6,783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities', window );">Proceeds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities', window );">Repayments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,708)<span></span>
</td>
<td class="num">(110)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities', window );">Interest paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: classification of embedded derivatives as separate derivative financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: (gain)/loss on recognition or derecognition</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: interest expense and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: recognition of earn-out liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: amortized cost remeasurement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: other fair value remeasurement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes&#160;: subsidies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,070)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: conversion into shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities', window );">Non cash changes: additional leases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Non cash changes : Effect of the change in foreign currency exchange rates</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,771<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at beginning of period</a></td>
<td class="nump">2,363<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="nump">1,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities', window );">Proceeds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities', window );">Repayments</a></td>
<td class="num">(910)<span></span>
</td>
<td class="num">(459)<span></span>
</td>
<td class="num">(573)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities', window );">Interest paid</a></td>
<td class="num">(64)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: classification of embedded derivatives as separate derivative financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: (gain)/loss on recognition or derecognition</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: interest expense and other</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: recognition of earn-out liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: amortized cost remeasurement</a></td>
<td class="num">(7)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(543)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: other fair value remeasurement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes&#160;: subsidies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: conversion into shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities', window );">Non cash changes: additional leases</a></td>
<td class="nump">444<span></span>
</td>
<td class="nump">2,221<span></span>
</td>
<td class="nump">272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Non cash changes : Effect of the change in foreign currency exchange rates</a></td>
<td class="num">(33)<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at end of period</a></td>
<td class="nump">1,856<span></span>
</td>
<td class="nump">2,363<span></span>
</td>
<td class="nump">540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=abvx_RoyaltyCertificatesMember', window );">Royalty certificates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at beginning of period</a></td>
<td class="nump">13,023<span></span>
</td>
<td class="nump">12,229<span></span>
</td>
<td class="nump">3,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities', window );">Proceeds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities', window );">Repayments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities', window );">Interest paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: classification of embedded derivatives as separate derivative financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: (gain)/loss on recognition or derecognition</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: interest expense and other</a></td>
<td class="nump">5,927<span></span>
</td>
<td class="nump">4,198<span></span>
</td>
<td class="nump">2,521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: recognition of earn-out liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: amortized cost remeasurement</a></td>
<td class="nump">11,286<span></span>
</td>
<td class="num">(3,404)<span></span>
</td>
<td class="nump">6,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: other fair value remeasurement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes&#160;: subsidies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities', window );">Non-cash changes: conversion into shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities', window );">Non cash changes: additional leases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Non cash changes : Effect of the change in foreign currency exchange rates</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at end of period</a></td>
<td class="nump">&#8364; 30,237<span></span>
</td>
<td class="nump">&#8364; 13,023<span></span>
</td>
<td class="nump">&#8364; 12,229<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease Through Interest Paid, Liabilities Arising From Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease Through Repayments, Liabilities Arising From Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Amortization Cost Remeasurement, Liabilities Arising From Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Classification of Embedded Derivatives as Separate Financial Instruments, Liabilities Arising From Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Conversion Into Shares, Liabilities Arising From Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Gain (Loss) On Recognition/Derecognition, Liabilities Arising From Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Recognition of Earn Out Liability, Liabilities Arising From Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Subsidies, Liabilities Arising From Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase Through Proceeds, Liabilities Arising From Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from changes in fair values. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 44B<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_44B_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 166<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_166_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 166<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_166_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 44B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_44B_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 166<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_166_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 166<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_166_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 44B<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_44B_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 166<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_166_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 166<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_166_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 44B<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_44B&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 44D<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_44D&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 166<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_166&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 166<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_166&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=abvx_Kreos12BondLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=abvx_Kreos12BondLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=abvx_OCEANEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=abvx_OCEANEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=abvx_KreosClaretFinancingTrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=abvx_KreosClaretFinancingTrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=abvx_Kreos1ClaretBondLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=abvx_Kreos1ClaretBondLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=abvx_HeightsConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=abvx_HeightsConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=abvx_PretGarantiParLEtatPGEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=abvx_PretGarantiParLEtatPGEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=abvx_ConditionalAdvancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=abvx_ConditionalAdvancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=abvx_RoyaltyCertificatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=abvx_RoyaltyCertificatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial liabilities - Change in financial liabilities (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 24, 2023</div></th>
<th class="th"><div>Jul. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NetProceedsFromConvertibleLoansNotes', window );">Net proceeds from convertible loan notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 55,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RepurchaseOfDerivativeInstruments', window );">Repurchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RepaymentsOfConvertibleLoansNotes', window );">Repayments of convertible loan notes</a></td>
<td class="nump">&#8364; 33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,188<span></span>
</td>
<td class="nump">&#8364; 8,750<span></span>
</td>
<td class="nump">27,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_GrossProceedsFromNonConvertibleLoansNotes', window );">Proceeds from the issuance of non-convertible bond loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_OceaneConversionOptionMember', window );">Oceane conversion option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RepurchaseOfDerivativeInstruments', window );">Repurchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheAMember', window );">Kreos &amp; Claret convertible notes (OCABSA)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForDebtIssueCosts', window );">Payments for debt issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember', window );">Kreos &amp; Claret financing, tranche B and C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForDebtIssueCosts', window );">Payments for debt issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsDiscountRate', window );">Borrowings, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_HeightsConvertibleNotesMember', window );">Heights convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForDebtIssueCosts', window );">Payments for debt issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_OCEANEMember', window );">OCEANE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NetProceedsFromConvertibleLoansNotes', window );">Net proceeds from convertible loan notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RepaymentsOfConvertibleLoansNotes', window );">Repayments of convertible loan notes</a></td>
<td class="nump">&#8364; 25,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheBMember', window );">Kreos &amp; Claret financing, tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForDebtIssueCosts', window );">Payments for debt issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheCMember', window );">Kreos &amp; Claret financing, tranche C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForDebtIssueCosts', window );">Payments for debt issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheABMember', window );">Kreos &amp; Claret financing, tranche A-B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForDebtIssueCosts', window );">Payments for debt issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_GrossProceedsFromNonConvertibleLoansNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross Proceeds From Non-Convertible Loans Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_GrossProceedsFromNonConvertibleLoansNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NetProceedsFromConvertibleLoansNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Proceeds From Convertible Loans Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NetProceedsFromConvertibleLoansNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_RepaymentsOfConvertibleLoansNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments Of Convertible Loans Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_RepaymentsOfConvertibleLoansNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_RepurchaseOfDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repurchase Of Derivative Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_RepurchaseOfDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForDebtIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt issue costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForDebtIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_OceaneConversionOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_OceaneConversionOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_HeightsConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_HeightsConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_OCEANEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_OCEANEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial liabilities - Disclosure of changes in derivative instruments (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities at beginning of period</a></td>
<td class="nump">&#8364; 4,786<span></span>
</td>
<td class="nump">&#8364; 2,579<span></span>
</td>
<td class="nump">&#8364; 566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IssuanceOfDerivativeInstruments', window );">Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,158<span></span>
</td>
<td class="nump">3,585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LossesOnChangeInFairValueOfDerivatives', window );">Increase in fair value</a></td>
<td class="nump">29,935<span></span>
</td>
<td class="nump">1,462<span></span>
</td>
<td class="nump">3,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsOnChangeInFairValueOfDerivatives', window );">Decrease in fair value</a></td>
<td class="num">(3,620)<span></span>
</td>
<td class="num">(1,413)<span></span>
</td>
<td class="num">(1,006)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RepurchaseOfDerivativeInstruments', window );">Repurchases</a></td>
<td class="num">(4,427)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,591)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExerciseOfDerivativeInstruments', window );">Exercises</a></td>
<td class="num">(26,674)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,021)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities at end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,786<span></span>
</td>
<td class="nump">2,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosABSAMember', window );">Kreos A BSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities at beginning of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IssuanceOfDerivativeInstruments', window );">Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LossesOnChangeInFairValueOfDerivatives', window );">Increase in fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsOnChangeInFairValueOfDerivatives', window );">Decrease in fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RepurchaseOfDerivativeInstruments', window );">Repurchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(489)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExerciseOfDerivativeInstruments', window );">Exercises</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(771)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities at end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosBBSAMember', window );">Kreos B BSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities at beginning of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IssuanceOfDerivativeInstruments', window );">Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LossesOnChangeInFairValueOfDerivatives', window );">Increase in fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsOnChangeInFairValueOfDerivatives', window );">Decrease in fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RepurchaseOfDerivativeInstruments', window );">Repurchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(339)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExerciseOfDerivativeInstruments', window );">Exercises</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities at end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_OceaneConversionOptionMember', window );">OCEANE conversion option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities at beginning of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IssuanceOfDerivativeInstruments', window );">Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LossesOnChangeInFairValueOfDerivatives', window );">Increase in fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsOnChangeInFairValueOfDerivatives', window );">Decrease in fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RepurchaseOfDerivativeInstruments', window );">Repurchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,762)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExerciseOfDerivativeInstruments', window );">Exercises</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities at end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretFinancingTrancheAMember', window );">Kreos/Claret BSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities at beginning of period</a></td>
<td class="nump">1,166<span></span>
</td>
<td class="nump">2,579<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IssuanceOfDerivativeInstruments', window );">Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LossesOnChangeInFairValueOfDerivatives', window );">Increase in fair value</a></td>
<td class="nump">29,935<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsOnChangeInFairValueOfDerivatives', window );">Decrease in fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,413)<span></span>
</td>
<td class="num">(1,006)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RepurchaseOfDerivativeInstruments', window );">Repurchases</a></td>
<td class="num">(4,427)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExerciseOfDerivativeInstruments', window );">Exercises</a></td>
<td class="num">(26,674)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities at end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,166<span></span>
</td>
<td class="nump">2,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember', window );">Kreos/Claret Minimal Return Indemnifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities at beginning of period</a></td>
<td class="nump">3,620<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IssuanceOfDerivativeInstruments', window );">Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,158<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LossesOnChangeInFairValueOfDerivatives', window );">Increase in fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,462<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsOnChangeInFairValueOfDerivatives', window );">Decrease in fair value</a></td>
<td class="num">(3,620)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RepurchaseOfDerivativeInstruments', window );">Repurchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ExerciseOfDerivativeInstruments', window );">Exercises</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities at end of period</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 3,620<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ExerciseOfDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise Of Derivative Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ExerciseOfDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IssuanceOfDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Derivative Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IssuanceOfDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_RepurchaseOfDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repurchase Of Derivative Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_RepurchaseOfDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The losses resulting from changes in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosABSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosABSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosBBSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosBBSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_OceaneConversionOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_OceaneConversionOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretFinancingTrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretFinancingTrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial liabilities - Disclosure of remaining contractual maturities of financial liabilities (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConditionalAdvances', window );">Conditional advances</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 6,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConditionalAdvancesUndiscountedCashFlows', window );">Conditional advances, undiscounted cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NonCurrentRoyaltyCertificates', window );">Royalty certificates</a></td>
<td class="nump">30,237<span></span>
</td>
<td class="nump">13,023<span></span>
</td>
<td class="nump">12,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RoyaltyCertificatesUndiscountedCashFlows', window );">Royalty certificates, undiscounted cash flows</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">1,856<span></span>
</td>
<td class="nump">2,363<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="nump">&#8364; 1,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Gross lease liabilities</a></td>
<td class="nump">1,906<span></span>
</td>
<td class="nump">2,512<span></span>
</td>
<td class="nump">575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,786<span></span>
</td>
<td class="nump">2,579<span></span>
</td>
<td class="nump">566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Derivative financial liabilities, undiscounted cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,786<span></span>
</td>
<td class="nump">2,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">32,093<span></span>
</td>
<td class="nump">114,004<span></span>
</td>
<td class="nump">77,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_FinancialLiabilitiesUndiscountedCashFlows', window );">Financial liabilities, undiscounted cash flows</a></td>
<td class="nump">1,906<span></span>
</td>
<td class="nump">122,680<span></span>
</td>
<td class="nump">81,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">LESS THAN 1 YEAR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConditionalAdvancesUndiscountedCashFlows', window );">Conditional advances, undiscounted cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RoyaltyCertificatesUndiscountedCashFlows', window );">Royalty certificates, undiscounted cash flows</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Gross lease liabilities</a></td>
<td class="nump">1,340<span></span>
</td>
<td class="nump">993<span></span>
</td>
<td class="nump">406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Derivative financial liabilities, undiscounted cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,166<span></span>
</td>
<td class="nump">2,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_FinancialLiabilitiesUndiscountedCashFlows', window );">Financial liabilities, undiscounted cash flows</a></td>
<td class="nump">1,340<span></span>
</td>
<td class="nump">38,468<span></span>
</td>
<td class="nump">20,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">FROM 1 TO 2 YEARS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConditionalAdvancesUndiscountedCashFlows', window );">Conditional advances, undiscounted cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RoyaltyCertificatesUndiscountedCashFlows', window );">Royalty certificates, undiscounted cash flows</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Gross lease liabilities</a></td>
<td class="nump">450<span></span>
</td>
<td class="nump">996<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Derivative financial liabilities, undiscounted cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_FinancialLiabilitiesUndiscountedCashFlows', window );">Financial liabilities, undiscounted cash flows</a></td>
<td class="nump">450<span></span>
</td>
<td class="nump">56,698<span></span>
</td>
<td class="nump">15,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember', window );">FROM 2 TO 5 YEARS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConditionalAdvancesUndiscountedCashFlows', window );">Conditional advances, undiscounted cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RoyaltyCertificatesUndiscountedCashFlows', window );">Royalty certificates, undiscounted cash flows</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Gross lease liabilities</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">516<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Derivative financial liabilities, undiscounted cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,620<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_FinancialLiabilitiesUndiscountedCashFlows', window );">Financial liabilities, undiscounted cash flows</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">27,507<span></span>
</td>
<td class="nump">45,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">LONGER THAN 5 YEARS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConditionalAdvancesUndiscountedCashFlows', window );">Conditional advances, undiscounted cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RoyaltyCertificatesUndiscountedCashFlows', window );">Royalty certificates, undiscounted cash flows</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Gross lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Derivative financial liabilities, undiscounted cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_FinancialLiabilitiesUndiscountedCashFlows', window );">Financial liabilities, undiscounted cash flows</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_HeightsConvertibleNotesMember', window );">Heights convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConvertibleLoansNotes', window );">Convertible loans notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,574<span></span>
</td>
<td class="nump">29,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConvertibleLoansNotesUndiscountedCashFlows', window );">Convertible loans notes, undiscounted cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,063<span></span>
</td>
<td class="nump">36,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_HeightsConvertibleNotesMember', window );">Heights convertible notes | LESS THAN 1 YEAR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConvertibleLoansNotesUndiscountedCashFlows', window );">Convertible loans notes, undiscounted cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,750<span></span>
</td>
<td class="nump">10,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_HeightsConvertibleNotesMember', window );">Heights convertible notes | FROM 1 TO 2 YEARS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConvertibleLoansNotesUndiscountedCashFlows', window );">Convertible loans notes, undiscounted cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,750<span></span>
</td>
<td class="nump">9,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_HeightsConvertibleNotesMember', window );">Heights convertible notes | FROM 2 TO 5 YEARS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConvertibleLoansNotesUndiscountedCashFlows', window );">Convertible loans notes, undiscounted cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,563<span></span>
</td>
<td class="nump">16,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_HeightsConvertibleNotesMember', window );">Heights convertible notes | LONGER THAN 5 YEARS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConvertibleLoansNotesUndiscountedCashFlows', window );">Convertible loans notes, undiscounted cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretFinancingTrancheAMember', window );">Kreos &amp; Claret convertible notes (OCABSA)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConvertibleLoansNotes', window );">Convertible loans notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,370<span></span>
</td>
<td class="nump">21,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConvertibleLoansNotesUndiscountedCashFlows', window );">Convertible loans notes, undiscounted cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,653<span></span>
</td>
<td class="nump">30,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">1,166<span></span>
</td>
<td class="nump">2,579<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretFinancingTrancheAMember', window );">Kreos &amp; Claret convertible notes (OCABSA) | LESS THAN 1 YEAR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConvertibleLoansNotesUndiscountedCashFlows', window );">Convertible loans notes, undiscounted cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretFinancingTrancheAMember', window );">Kreos &amp; Claret convertible notes (OCABSA) | FROM 1 TO 2 YEARS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConvertibleLoansNotesUndiscountedCashFlows', window );">Convertible loans notes, undiscounted cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,943<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretFinancingTrancheAMember', window );">Kreos &amp; Claret convertible notes (OCABSA) | FROM 2 TO 5 YEARS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConvertibleLoansNotesUndiscountedCashFlows', window );">Convertible loans notes, undiscounted cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,460<span></span>
</td>
<td class="nump">26,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretFinancingTrancheAMember', window );">Kreos &amp; Claret convertible notes (OCABSA) | LONGER THAN 5 YEARS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConvertibleLoansNotesUndiscountedCashFlows', window );">Convertible loans notes, undiscounted cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretBondLoansMember', window );">Kreos/Claret bond loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConvertibleLoansNotes', window );">Convertible loans notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConvertibleLoansNotesUndiscountedCashFlows', window );">Convertible loans notes, undiscounted cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretBondLoansMember', window );">Kreos/Claret bond loans | LESS THAN 1 YEAR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConvertibleLoansNotesUndiscountedCashFlows', window );">Convertible loans notes, undiscounted cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretBondLoansMember', window );">Kreos/Claret bond loans | FROM 1 TO 2 YEARS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConvertibleLoansNotesUndiscountedCashFlows', window );">Convertible loans notes, undiscounted cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretBondLoansMember', window );">Kreos/Claret bond loans | FROM 2 TO 5 YEARS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConvertibleLoansNotesUndiscountedCashFlows', window );">Convertible loans notes, undiscounted cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretBondLoansMember', window );">Kreos/Claret bond loans | LONGER THAN 5 YEARS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ConvertibleLoansNotesUndiscountedCashFlows', window );">Convertible loans notes, undiscounted cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_PretGarantiParLEtatPGEMember', window );">PGE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,488<span></span>
</td>
<td class="nump">3,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings, undiscounted cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,586<span></span>
</td>
<td class="nump">3,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_PretGarantiParLEtatPGEMember', window );">PGE | LESS THAN 1 YEAR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings, undiscounted cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,293<span></span>
</td>
<td class="nump">1,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_PretGarantiParLEtatPGEMember', window );">PGE | FROM 1 TO 2 YEARS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings, undiscounted cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,293<span></span>
</td>
<td class="nump">1,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_PretGarantiParLEtatPGEMember', window );">PGE | FROM 2 TO 5 YEARS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings, undiscounted cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_PretGarantiParLEtatPGEMember', window );">PGE | LONGER THAN 5 YEARS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings, undiscounted cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ConditionalAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conditional Advances</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ConditionalAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ConditionalAdvancesUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conditional Advances, Undiscounted Cash Flows</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ConditionalAdvancesUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ConvertibleLoansNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Loans Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ConvertibleLoansNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ConvertibleLoansNotesUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Loans Notes, Undiscounted Cash Flows</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ConvertibleLoansNotesUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_FinancialLiabilitiesUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Liabilities, Undiscounted Cash Flows</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_FinancialLiabilitiesUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NonCurrentRoyaltyCertificates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Current Royalty Certificates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NonCurrentRoyaltyCertificates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_RoyaltyCertificatesUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Certificates, Undiscounted Cash Flows</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_RoyaltyCertificatesUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BankBorrowingsUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to bank borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph IG31A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_IG31A&amp;doctype=Implementation%20Guidance<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph B11D<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B11D&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BankBorrowingsUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 72<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_72_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 39<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_39_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 72<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_72_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 58<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_58&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph B11D<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B11D_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 119<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_119&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 119<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_119&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_HeightsConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_HeightsConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretFinancingTrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretFinancingTrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretBondLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_KreosClaretBondLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_PretGarantiParLEtatPGEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_PretGarantiParLEtatPGEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial liabilities - Breakdown of financial liabilities by maturity (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th">
<div>Sep. 02, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RoyaltyCertificatePercentageOfFutureSales', window );">Royalty certificate, percentage of future sales</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RoyaltyCertificateMaximumAmount', window );">Royalty certificate, maximum amount</a></td>
<td class="nump">&#8364; 172,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RoyaltyCertificatesMember', window );">Royalty certificates</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RoyaltyCertificatePercentageOfFutureSales', window );">Royalty certificate, percentage of future sales</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RoyaltyCertificateMaximumAmount', window );">Royalty certificate, maximum amount</a></td>
<td class="nump">&#8364; 172,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RoyaltyCertificateExpirationPeriod', window );">Royalty certificate, expiration period</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_RoyaltyCertificateExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Certificate, Expiration Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_RoyaltyCertificateExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_RoyaltyCertificateMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Certificate, Maximum Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_RoyaltyCertificateMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_RoyaltyCertificatePercentageOfFutureSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Certificate, Percentage Of Future Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_RoyaltyCertificatePercentageOfFutureSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RoyaltyCertificatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RoyaltyCertificatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement benefit obligations - Disclosure of main actuarial assumptions used to measure the retirement benefit obligations (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfDiscountRates', window );">Discount Rate (IBoxx Corporates AA)</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.34%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases', window );">Salary increase rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ActuarialAssumptionOfExpectedRatesOfTurnoverAverageExitRate', window );">Turnover rate, average exit rate</a></td>
<td class="nump">2.02%<span></span>
</td>
<td class="nump">2.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ActuarialAssumptionOfEmployeeContributionRate', window );">Employee contribution rate</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ActuarialAssumptionOfExpectedRatesOfTurnover', window );">Turnover rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ActuarialAssumptionOfExpectedRatesOfTurnover', window );">Turnover rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.05%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ManagementMember', window );">Key magement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfRetirementAge2019', window );">Retirement age</a></td>
<td class="text">65 years<span></span>
</td>
<td class="text">65 years<span></span>
</td>
<td class="text">65 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases', window );">Salary increase rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=abvx_OtherEmployeesMember', window );">Other employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfRetirementAge2019', window );">Retirement age</a></td>
<td class="text">64 years<span></span>
</td>
<td class="text">64 years<span></span>
</td>
<td class="text">63 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases', window );">Salary increase rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.55%<span></span>
</td>
<td class="nump">2.55%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ActuarialAssumptionOfEmployeeContributionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Actuarial Assumption Of Employee Contribution Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ActuarialAssumptionOfEmployeeContributionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ActuarialAssumptionOfExpectedRatesOfTurnover">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Actuarial Assumption Of Expected Rates Of Turnover</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ActuarialAssumptionOfExpectedRatesOfTurnover</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ActuarialAssumptionOfExpectedRatesOfTurnoverAverageExitRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Actuarial Assumption Of Expected Rates Of Turnover, Average Exit Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ActuarialAssumptionOfExpectedRatesOfTurnoverAverageExitRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfDiscountRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 144<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfDiscountRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected rate of salary increases used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [domain]; Defined benefit obligation, at present value; Actuarial assumptions [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 144<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfRetirementAge2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The retirement age used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 144<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfRetirementAge2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=abvx_OtherEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=abvx_OtherEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement benefit obligations - Disclosure of changes in projected benefit obligation (Details) - RETIREMENT BENEFIT OBLIGATIONS - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net defined benefit liability (asset) at beginning of period</a></td>
<td class="nump">&#8364; 756<span></span>
</td>
<td class="nump">&#8364; 629<span></span>
</td>
<td class="nump">&#8364; 610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Service cost</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset', window );">Past services cost</a></td>
<td class="num">(205)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset', window );">Interest cost</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset', window );">Benefits paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Actuarial gains and losses</a></td>
<td class="num">(93)<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="num">(112)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net defined benefit liability (asset) at end of period</a></td>
<td class="nump">&#8364; 627<span></span>
</td>
<td class="nump">&#8364; 756<span></span>
</td>
<td class="nump">&#8364; 629<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from employee service in the current period. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 141<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_141_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 207<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_207_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 207<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_207_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_141_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 207<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_207_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 207<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_207_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 141<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_141_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 207<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_207_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 207<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_207_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 140<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_140_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 206<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_206_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 206<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_206_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilityAssetOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from past service cost. Past service cost is the change in the present value of the defined benefit obligation for employee service in prior periods, resulting from a plan amendment (the introduction or withdrawal of, or changes to, a defined benefit plan) or a curtailment (a significant reduction by the entity in the number of employees covered by a plan). [Refer: Net defined benefit liability (asset); Defined benefit plans [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 141<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_141_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 207<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_207_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 207<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_207_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from payments from the plan. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 141<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_141_g&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 207<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_207_f&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 207<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_207_f&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PresentValueOfDefinedBenefitObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PresentValueOfDefinedBenefitObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Payables and other current liabilities - Disclosure of breakdown of trade and other payables (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract', window );"><strong>Trade and other current payables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">&#8364; 23,388<span></span>
</td>
<td class="nump">&#8364; 30,748<span></span>
</td>
<td class="nump">&#8364; 21,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccrualsClassifiedAsCurrent', window );">Accrued invoices</a></td>
<td class="nump">14,159<span></span>
</td>
<td class="nump">13,049<span></span>
</td>
<td class="nump">25,268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_OtherCurrentPayablesIncludingAdjustments', window );">Other</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade payables and other current liabilities</a></td>
<td class="nump">&#8364; 37,552<span></span>
</td>
<td class="nump">&#8364; 43,824<span></span>
</td>
<td class="nump">&#8364; 47,221<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_OtherCurrentPayablesIncludingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Current Payables, Including Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_OtherCurrentPayablesIncludingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccrualsClassifiedAsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accruals classified as current. [Refer: Accruals]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccrualsClassifiedAsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Payables and other current liabilities - Disclosure of tax and employee-related payables (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract', window );"><strong>Trade and other current payables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsAccruals', window );">Employee-related payables</a></td>
<td class="nump">&#8364; 4,816<span></span>
</td>
<td class="nump">&#8364; 2,742<span></span>
</td>
<td class="nump">&#8364; 3,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax', window );">Social security and other</a></td>
<td class="nump">2,304<span></span>
</td>
<td class="nump">1,783<span></span>
</td>
<td class="nump">2,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_CurrentPayablesOnOtherTaxAndRelatedPayments', window );">Other tax and related payments</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_CurrentTaxAndEmployeeBenefitLiabilities', window );">TAX AND EMPLOYEE-RELATED PAYABLES</a></td>
<td class="nump">&#8364; 7,137<span></span>
</td>
<td class="nump">&#8364; 4,709<span></span>
</td>
<td class="nump">&#8364; 6,073<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_CurrentPayablesOnOtherTaxAndRelatedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Payables On Other Tax And Related Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_CurrentPayablesOnOtherTaxAndRelatedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_CurrentTaxAndEmployeeBenefitLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Tax And Employee Benefit Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_CurrentTaxAndEmployeeBenefitLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables on social security and taxes other than incomes tax. [Refer: Payables on social security and taxes other than income tax]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other operating income - Disclosure of breakdown of operating income (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenue [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncomeFromResearchTaxCredit', window );">Research tax credit ("CIR")</a></td>
<td class="nump">&#8364; 3,061<span></span>
</td>
<td class="nump">&#8364; 6,651<span></span>
</td>
<td class="nump">&#8364; 4,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Subsidies</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,140<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncomeFromDepositaryServiceFees', window );">Depositary service fees</a></td>
<td class="nump">1,509<span></span>
</td>
<td class="nump">1,634<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Total operating income</a></td>
<td class="nump">&#8364; 4,570<span></span>
</td>
<td class="nump">&#8364; 12,449<span></span>
</td>
<td class="nump">&#8364; 4,621<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IncomeFromDepositaryServiceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income From Depositary Service Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IncomeFromDepositaryServiceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IncomeFromResearchTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income From Research Tax Credit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IncomeFromResearchTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2025-01-01<br> -Paragraph 39<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_39_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other operating income - Narrative (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfOperatingIncomeLineItems', window );"><strong>Disclosure Of Operating Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncomeFromResearchTaxCredit', window );">Research tax credit ("CIR")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,061<span></span>
</td>
<td class="nump">&#8364; 6,651<span></span>
</td>
<td class="nump">&#8364; 4,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Subsidies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,140<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RNPVIRConditionalAdvanceBPIMember', window );">RNP-VIR conditional advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfOperatingIncomeLineItems', window );"><strong>Disclosure Of Operating Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Subsidies</a></td>
<td class="nump">&#8364; 1,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_CARENAConditionalAdvanceBPIMember', window );">CARENA conditional advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfOperatingIncomeLineItems', window );"><strong>Disclosure Of Operating Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Subsidies</a></td>
<td class="nump">&#8364; 2,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_CIRTaxYearAxis=abvx_A2021TaxYearMember', window );">Tax Year 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfOperatingIncomeLineItems', window );"><strong>Disclosure Of Operating Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncomeFromResearchTaxCredit', window );">Research tax credit ("CIR")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_CIRTaxYearAxis=abvx_A2022TaxYearMember', window );">Tax Year 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfOperatingIncomeLineItems', window );"><strong>Disclosure Of Operating Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncomeFromResearchTaxCredit', window );">Research tax credit ("CIR")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_CIRTaxYearAxis=abvx_A2023TaxYearMember', window );">Tax Year 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfOperatingIncomeLineItems', window );"><strong>Disclosure Of Operating Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncomeFromResearchTaxCredit', window );">Research tax credit ("CIR")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_CIRTaxYearAxis=abvx_A2024TaxYearMember', window );">Tax Year 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfOperatingIncomeLineItems', window );"><strong>Disclosure Of Operating Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncomeFromResearchTaxCredit', window );">Research tax credit ("CIR")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DisclosureOfOperatingIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Operating Income [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DisclosureOfOperatingIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IncomeFromResearchTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income From Research Tax Credit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IncomeFromResearchTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2025-01-01<br> -Paragraph 39<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_39_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RNPVIRConditionalAdvanceBPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RNPVIRConditionalAdvanceBPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_CARENAConditionalAdvanceBPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_CARENAConditionalAdvanceBPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_CIRTaxYearAxis=abvx_A2021TaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_CIRTaxYearAxis=abvx_A2021TaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_CIRTaxYearAxis=abvx_A2022TaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_CIRTaxYearAxis=abvx_A2022TaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_CIRTaxYearAxis=abvx_A2023TaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_CIRTaxYearAxis=abvx_A2023TaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_CIRTaxYearAxis=abvx_A2024TaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_CIRTaxYearAxis=abvx_A2024TaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expenses - Disclosure of sales and marketing expenses (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems', window );"><strong>Disclosure of attribution of expenses by nature to their function [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Operating expenses</a></td>
<td class="nump">&#8364; 250,626<span></span>
</td>
<td class="nump">&#8364; 185,433<span></span>
</td>
<td class="nump">&#8364; 131,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=abvx_SalesAndMarketingExpenseMember', window );">Sales and marketing expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems', window );"><strong>Disclosure of attribution of expenses by nature to their function [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Personnel costs</a></td>
<td class="nump">3,347<span></span>
</td>
<td class="nump">2,323<span></span>
</td>
<td class="nump">1,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfessionalFeesExpense', window );">Consulting and professional fees</a></td>
<td class="nump">1,623<span></span>
</td>
<td class="nump">2,699<span></span>
</td>
<td class="nump">4,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other sales and marketing expenses</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">932<span></span>
</td>
<td class="nump">709<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Operating expenses</a></td>
<td class="nump">&#8364; 5,194<span></span>
</td>
<td class="nump">&#8364; 5,954<span></span>
</td>
<td class="nump">&#8364; 6,431<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 133<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_133_a_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfessionalFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfessionalFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=abvx_SalesAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=abvx_SalesAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expenses - Disclosure of research and development expenses (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems', window );"><strong>Disclosure of attribution of expenses by nature to their function [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Operating expenses</a></td>
<td class="nump">&#8364; 250,626<span></span>
</td>
<td class="nump">&#8364; 185,433<span></span>
</td>
<td class="nump">&#8364; 131,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=abvx_ResearchAndDevelopmentExpensesMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems', window );"><strong>Disclosure of attribution of expenses by nature to their function [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_SubContractingStudiesAndResearchExpenses', window );">Sub-contracting, studies and research</a></td>
<td class="nump">112,033<span></span>
</td>
<td class="nump">110,993<span></span>
</td>
<td class="nump">85,726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Personnel costs</a></td>
<td class="nump">49,616<span></span>
</td>
<td class="nump">18,455<span></span>
</td>
<td class="nump">8,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfessionalFeesExpense', window );">Consulting and professional fees</a></td>
<td class="nump">12,791<span></span>
</td>
<td class="nump">12,581<span></span>
</td>
<td class="nump">6,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IntellectualPropertyFees', window );">Intellectual property fees</a></td>
<td class="nump">1,025<span></span>
</td>
<td class="nump">1,741<span></span>
</td>
<td class="nump">1,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other research and development expenses</a></td>
<td class="nump">2,297<span></span>
</td>
<td class="nump">2,761<span></span>
</td>
<td class="nump">1,196<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Operating expenses</a></td>
<td class="nump">&#8364; 177,761<span></span>
</td>
<td class="nump">&#8364; 146,532<span></span>
</td>
<td class="nump">&#8364; 103,176<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IntellectualPropertyFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intellectual Property Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IntellectualPropertyFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_SubContractingStudiesAndResearchExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sub-Contracting, Studies And Research Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_SubContractingStudiesAndResearchExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 133<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_133_a_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfessionalFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfessionalFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=abvx_ResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=abvx_ResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expenses - Narrative (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=abvx_ResearchAndDevelopmentExpensesMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems', window );"><strong>Disclosure of attribution of expenses by nature to their function [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInUlcerativeColitisExpenses', window );">Increase (decrease) in Ulcerative Colitis expenses</a></td>
<td class="nump">&#8364; 1,587<span></span>
</td>
<td class="nump">&#8364; 32,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInCrohnsDiseaseResearchExpenses', window );">Increase (decrease) in Crohn's Disease research expenses</a></td>
<td class="nump">10,200<span></span>
</td>
<td class="nump">4,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInTransversalActivities', window );">Increase (decrease) in transversal activities</a></td>
<td class="nump">12,987<span></span>
</td>
<td class="nump">&#8364; 8,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInTransversalActivitiesCombinationTherapy', window );">Increase (decrease) in transversal activities, combination therapy</a></td>
<td class="nump">4,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInEmployerTaxAndSocialContributions', window );">Increase (decrease) in employer tax and social contributions</a></td>
<td class="nump">20,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=abvx_GeneralAndAdministrativeExpensesMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems', window );"><strong>Disclosure of attribution of expenses by nature to their function [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_IncreaseDecreaseInEmployerTaxAndSocialContributions', window );">Increase (decrease) in employer tax and social contributions</a></td>
<td class="nump">&#8364; 27,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IncreaseDecreaseInCrohnsDiseaseResearchExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Crohn's Disease Research Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IncreaseDecreaseInCrohnsDiseaseResearchExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IncreaseDecreaseInEmployerTaxAndSocialContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Employer Tax And Social Contributions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IncreaseDecreaseInEmployerTaxAndSocialContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IncreaseDecreaseInTransversalActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Transversal Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IncreaseDecreaseInTransversalActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IncreaseDecreaseInTransversalActivitiesCombinationTherapy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Transversal Activities, Combination Therapy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IncreaseDecreaseInTransversalActivitiesCombinationTherapy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_IncreaseDecreaseInUlcerativeColitisExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Ulcerative Colitis Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_IncreaseDecreaseInUlcerativeColitisExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=abvx_ResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=abvx_ResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=abvx_GeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=abvx_GeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expenses - Disclosure of general and administrative expenses (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems', window );"><strong>Disclosure of attribution of expenses by nature to their function [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Operating expenses</a></td>
<td class="nump">&#8364; 250,626<span></span>
</td>
<td class="nump">&#8364; 185,433<span></span>
</td>
<td class="nump">&#8364; 131,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=abvx_GeneralAndAdministrativeExpensesMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems', window );"><strong>Disclosure of attribution of expenses by nature to their function [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Personnel costs</a></td>
<td class="nump">52,817<span></span>
</td>
<td class="nump">19,434<span></span>
</td>
<td class="nump">13,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfessionalFeesExpense', window );">Consulting and professional fees</a></td>
<td class="nump">9,984<span></span>
</td>
<td class="nump">7,990<span></span>
</td>
<td class="nump">6,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other general and administrative expenses</a></td>
<td class="nump">4,870<span></span>
</td>
<td class="nump">5,522<span></span>
</td>
<td class="nump">2,893<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Operating expenses</a></td>
<td class="nump">&#8364; 67,670<span></span>
</td>
<td class="nump">&#8364; 32,946<span></span>
</td>
<td class="nump">&#8364; 22,391<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 133<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_133_a_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfessionalFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfessionalFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=abvx_GeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=abvx_GeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expenses - Disclosure of principal audit fees and services (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNatureAbstract', window );"><strong>Expenses by nature [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemunerationForAuditServices', window );">Audit fees</a></td>
<td class="nump">&#8364; 1,255<span></span>
</td>
<td class="nump">&#8364; 1,144<span></span>
</td>
<td class="nump">&#8364; 1,848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_AuditorsRemunerationForAuditRelatedFees', window );">Audit-related fees</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemunerationForTaxServices', window );">Tax fees</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemunerationForOtherServices', window );">All other fees</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemuneration', window );">Total auditor's remuneration</a></td>
<td class="nump">&#8364; 1,418<span></span>
</td>
<td class="nump">&#8364; 1,233<span></span>
</td>
<td class="nump">&#8364; 2,340<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_AuditorsRemunerationForAuditRelatedFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor's Remuneration For Audit-Related Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_AuditorsRemunerationForAuditRelatedFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemuneration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemuneration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemunerationForAuditServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemunerationForAuditServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemunerationForOtherServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemunerationForOtherServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemunerationForTaxServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemunerationForTaxServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNatureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNatureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employees (Details) - employee<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfEmployeeWorkforceLineItems', window );"><strong>Disclosure Of Employee Workforce [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageNumberOfEmployees', window );">Average number of employees</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_FR', window );">France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfEmployeeWorkforceLineItems', window );"><strong>Disclosure Of Employee Workforce [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageNumberOfEmployees', window );">Average number of employees</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfEmployeeWorkforceLineItems', window );"><strong>Disclosure Of Employee Workforce [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageNumberOfEmployees', window );">Average number of employees</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DisclosureOfEmployeeWorkforceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Employee Workforce [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DisclosureOfEmployeeWorkforceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageNumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of personnel employed by the entity during a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageNumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial gain (loss) - Disclosure of net financial income (loss) (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_FinancialIncomeLossAbstract', window );"><strong>Financial Income (Loss) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBonds', window );">Interest on bond loans</a></td>
<td class="num">&#8364; (7,472)<span></span>
</td>
<td class="num">&#8364; (5,800)<span></span>
</td>
<td class="num">&#8364; (760)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnDebtInstrumentsIssued', window );">Interest on convertible loan notes</a></td>
<td class="num">(3,638)<span></span>
</td>
<td class="num">(5,691)<span></span>
</td>
<td class="num">(3,935)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Interest on conditional advances and PGE</a></td>
<td class="num">(95)<span></span>
</td>
<td class="num">(85)<span></span>
</td>
<td class="num">(176)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_InterestExpenseOnRoyaltyCertificates', window );">Interest on royalty certificates</a></td>
<td class="num">(17,213)<span></span>
</td>
<td class="num">(794)<span></span>
</td>
<td class="num">(8,942)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest on lease liabilities</a></td>
<td class="num">(64)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LossesOnChangeInFairValueOfDerivatives', window );">(Increase) / decrease in derivatives fair value</a></td>
<td class="num">(29,935)<span></span>
</td>
<td class="num">(1,462)<span></span>
</td>
<td class="num">(3,046)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss', window );">(Increase) / decrease in other liabilities / (assets) at fair value through profit and loss</a></td>
<td class="num">(36,015)<span></span>
</td>
<td class="num">(1,367)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_LossesArisingFromDerecognitionOfFinancialLiabilities', window );">Loss on derecognition of financial liabilities</a></td>
<td class="num">(3,838)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,431)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TransactionCosts', window );">Transaction costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,615)<span></span>
</td>
<td class="num">(1,924)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ForeignExchangeLoss', window );">Foreign exchange losses</a></td>
<td class="num">(13,444)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="num">(5,573)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinanceCost', window );">Other financial expense</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Financial expenses</a></td>
<td class="num">(111,743)<span></span>
</td>
<td class="num">(16,991)<span></span>
</td>
<td class="num">(27,875)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromInterest', window );">Interest income</a></td>
<td class="nump">5,600<span></span>
</td>
<td class="nump">8,246<span></span>
</td>
<td class="nump">2,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsOnChangeInFairValueOfDerivatives', window );">(Increase) / decrease in derivatives fair value</a></td>
<td class="nump">3,620<span></span>
</td>
<td class="nump">1,413<span></span>
</td>
<td class="nump">1,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_GainsOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss', window );">(Increase) / decrease in other liabilities / (assets) at fair value through profit and loss</a></td>
<td class="nump">4,730<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_UnwindingEffectOfDiscountRelatedToAdvancesMadeToCROs', window );">Effect of unwinding the discount related to advances made to CROs</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">710<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_GainsArisingFromRecognitionOfFinancialLiabilities', window );">Day-one gain on recognition of financial liabilities</a></td>
<td class="nump">1,557<span></span>
</td>
<td class="nump">590<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_GainsArisingFromDerecognitionOfFinancialLiabilities', window );">Gain on derecognition of financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ForeignExchangeGain', window );">Foreign exchange gains</a></td>
<td class="nump">11,886<span></span>
</td>
<td class="nump">2,774<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncome', window );">Other financial income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Financial income</a></td>
<td class="nump">27,545<span></span>
</td>
<td class="nump">13,732<span></span>
</td>
<td class="nump">7,511<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Financial gain (loss)</a></td>
<td class="num">&#8364; (84,198)<span></span>
</td>
<td class="num">&#8364; (3,258)<span></span>
</td>
<td class="num">&#8364; (20,364)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_FinancialIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Income (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_FinancialIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_GainsArisingFromDerecognitionOfFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains Arising From Derecognition Of Financial Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_GainsArisingFromDerecognitionOfFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_GainsArisingFromRecognitionOfFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains Arising From Recognition Of Financial Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_GainsArisingFromRecognitionOfFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_GainsOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains On Financial Liabilities At Fair Value Through Profit Or Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_GainsOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_InterestExpenseOnRoyaltyCertificates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Expense On Royalty Certificates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_InterestExpenseOnRoyaltyCertificates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_LossesArisingFromDerecognitionOfFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Losses Arising From Derecognition Of Financial Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_LossesArisingFromDerecognitionOfFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Losses On Financial Liabilities (Assets) At Fair Value Through Profit Or Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_UnwindingEffectOfDiscountRelatedToAdvancesMadeToCROs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unwinding Effect Of Discount Related To Advances Made To CROs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_UnwindingEffectOfDiscountRelatedToAdvancesMadeToCROs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ForeignExchangeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2025-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 218<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_218_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 218<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_218_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ForeignExchangeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ForeignExchangeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2025-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 218<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_218_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 218<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_218_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ForeignExchangeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnBonds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnBonds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnDebtInstrumentsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnDebtInstrumentsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The losses resulting from changes in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial gain (loss) - Narrative (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFinancialGainLossLineItems', window );"><strong>Disclosure Of Financial Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LossesOnChangeInFairValueOfDerivatives', window );">Losses on change in fair value of derivatives</a></td>
<td class="nump">&#8364; 29,935<span></span>
</td>
<td class="nump">&#8364; 1,462<span></span>
</td>
<td class="nump">&#8364; 3,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ForeignExchangeLoss', window );">Foreign exchange loss</a></td>
<td class="nump">13,444<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="nump">5,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsOnChangeInFairValueOfDerivatives', window );">Gains on change in fair value of derivatives</a></td>
<td class="nump">3,620<span></span>
</td>
<td class="nump">1,413<span></span>
</td>
<td class="nump">1,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ForeignExchangeGain', window );">Foreign exchange gains</a></td>
<td class="nump">11,886<span></span>
</td>
<td class="nump">2,774<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=abvx_KreosClaretFinancingBSAMember', window );">Kreos &amp; Claret BSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFinancialGainLossLineItems', window );"><strong>Disclosure Of Financial Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LossesOnChangeInFairValueOfDerivatives', window );">Losses on change in fair value of derivatives</a></td>
<td class="nump">29,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember', window );">Kreos &amp; Claret minimal return indemnifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFinancialGainLossLineItems', window );"><strong>Disclosure Of Financial Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsOnChangeInFairValueOfDerivatives', window );">Gains on change in fair value of derivatives</a></td>
<td class="nump">3,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">United States of America, Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfFinancialGainLossLineItems', window );"><strong>Disclosure Of Financial Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ForeignExchangeLoss', window );">Foreign exchange loss</a></td>
<td class="nump">8,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_ForeignExchangeGainsLossesOnTranslationOfForeignOperations', window );">Foreign currency translation differences gains (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">714<span></span>
</td>
<td class="num">&#8364; (1,488)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ForeignExchangeGain', window );">Foreign exchange gains</a></td>
<td class="nump">&#8364; 10,663<span></span>
</td>
<td class="nump">&#8364; 2,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DisclosureOfFinancialGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Financial Gain (Loss) [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DisclosureOfFinancialGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_ForeignExchangeGainsLossesOnTranslationOfForeignOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign Exchange Gains (Losses) On Translation Of Foreign Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_ForeignExchangeGainsLossesOnTranslationOfForeignOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ForeignExchangeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2025-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 218<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_218_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 218<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_218_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ForeignExchangeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ForeignExchangeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2025-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 218<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_218_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 218<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_218_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ForeignExchangeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The losses resulting from changes in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=abvx_KreosClaretFinancingBSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=abvx_KreosClaretFinancingBSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=abvx_KreosClaretMinimumReturnIndemnificationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax - Disclosure of reconciliation of effective income tax (loss) (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundAbstract', window );"><strong>Income taxes paid (refund) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccountingProfit', window );">Loss before tax</a></td>
<td class="num">&#8364; (330,254)<span></span>
</td>
<td class="num">&#8364; (176,242)<span></span>
</td>
<td class="num">&#8364; (147,740)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Statutory French tax rate</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate', window );">Nominal income tax using statutory French tax rate</a></td>
<td class="nump">&#8364; 82,563<span></span>
</td>
<td class="nump">&#8364; 44,061<span></span>
</td>
<td class="nump">&#8364; 36,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectOfForeignTaxRates', window );">Tax rates in foreign jurisdictions</a></td>
<td class="num">(153)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TaxEffectOfShareBasedPayment', window );">Share-based payment</a></td>
<td class="num">(8,849)<span></span>
</td>
<td class="num">(5,056)<span></span>
</td>
<td class="num">(2,045)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TaxEffectOfResearchTaxCredit', window );">CIR</a></td>
<td class="nump">765<span></span>
</td>
<td class="nump">1,663<span></span>
</td>
<td class="nump">1,123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TaxEffectOfTransactionCostsRelatedToCapitalIncrease', window );">Transaction costs related to capital increase</a></td>
<td class="nump">10,077<span></span>
</td>
<td class="num">(112)<span></span>
</td>
<td class="nump">3,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TaxEffectOfChangesInDerivativeFairValueAndOtherLiabilitiesMeasuredAtFVTPL', window );">Decrease / (increase) in derivatives and other liabilities measured at FVTPL</a></td>
<td class="num">(17,087)<span></span>
</td>
<td class="num">(207)<span></span>
</td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferences', window );">Non-recognition of deferred tax assets related to tax losses and temporary differences</a></td>
<td class="num">(61,320)<span></span>
</td>
<td class="num">(40,399)<span></span>
</td>
<td class="num">(39,612)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome', window );">Other</a></td>
<td class="num">(148)<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="num">(222)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Effective income tax (loss)</a></td>
<td class="num">&#8364; (5,848)<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_TaxEffectOfChangesInDerivativeFairValueAndOtherLiabilitiesMeasuredAtFVTPL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Changes In Derivative Fair Value And Other Liabilities Measured At FVTPL</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_TaxEffectOfChangesInDerivativeFairValueAndOtherLiabilitiesMeasuredAtFVTPL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Non-Recognition Of Deferred Tax Assets Related To Tax Losses And Temporary Differences</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_TaxEffectOfResearchTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Research Tax Credit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_TaxEffectOfResearchTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_TaxEffectOfShareBasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Share-Based Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_TaxEffectOfShareBasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_TaxEffectOfTransactionCostsRelatedToCapitalIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Transaction Costs Related To Capital Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_TaxEffectOfTransactionCostsRelatedToCapitalIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccountingProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccountingProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 192<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_192&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 192<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_192&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfForeignTaxRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfForeignTaxRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxExpenseIncomeAtApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R121.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income tax - Disclosure of deferred tax assets and liabilities by nature (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">&#8364; 241,894<span></span>
</td>
<td class="nump">&#8364; 155,715<span></span>
</td>
<td class="nump">&#8364; 116,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">17,616<span></span>
</td>
<td class="nump">1,584<span></span>
</td>
<td class="nump">444<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax assets, net</a></td>
<td class="nump">224,279<span></span>
</td>
<td class="nump">154,131<span></span>
</td>
<td class="nump">115,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_UnrecognizedDeferredTaxAssets', window );">Unrecognized deferred tax assets</a></td>
<td class="num">(230,127)<span></span>
</td>
<td class="num">(154,131)<span></span>
</td>
<td class="num">(115,562)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition', window );">Total deferred taxes, net recognized in the statement of financial position</a></td>
<td class="num">(5,848)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=abvx_RetirementBenefitObligationsRelatedTemporaryDifferencesMember', window );">Retirement benefit obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=abvx_SubsidiesRelatedTemporaryDifferencesMember', window );">Subsidies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=abvx_LeasesRelatedTemporaryDifferencesMember', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">476<span></span>
</td>
<td class="nump">591<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">396<span></span>
</td>
<td class="nump">485<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=abvx_RoyaltyCertificatesRelatedTemporaryDifferencesMember', window );">Royalty certificates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,427<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">17,208<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=abvx_OtherFinancialLiabilitiesRelatedTemporaryDifferencesMember', window );">Other financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,678<span></span>
</td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,075<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=abvx_ProvisionsForAGATaxesRelatedTemporaryDifferencesMember', window );">Provisions for AGA taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">11,454<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember', window );">Tax losses carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">228,239<span></span>
</td>
<td class="nump">152,372<span></span>
</td>
<td class="nump">114,946<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_OtherTemporaryDifferencesMember', window );">Other items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">1,568<span></span>
</td>
<td class="nump">744<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">&#8364; 11<span></span>
</td>
<td class="nump">&#8364; 12<span></span>
</td>
<td class="nump">&#8364; 10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Deferred Tax Assets (Liabilities) Recognised In Financial Position</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_UnrecognizedDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Deferred Tax Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_UnrecognizedDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph f<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_f_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph f<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_f_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph f<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_f_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph f<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_f_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph f<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_f_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph f<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_f_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=abvx_RetirementBenefitObligationsRelatedTemporaryDifferencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=abvx_RetirementBenefitObligationsRelatedTemporaryDifferencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=abvx_SubsidiesRelatedTemporaryDifferencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=abvx_SubsidiesRelatedTemporaryDifferencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=abvx_LeasesRelatedTemporaryDifferencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=abvx_LeasesRelatedTemporaryDifferencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=abvx_RoyaltyCertificatesRelatedTemporaryDifferencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=abvx_RoyaltyCertificatesRelatedTemporaryDifferencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=abvx_OtherFinancialLiabilitiesRelatedTemporaryDifferencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=abvx_OtherFinancialLiabilitiesRelatedTemporaryDifferencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=abvx_ProvisionsForAGATaxesRelatedTemporaryDifferencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=abvx_ProvisionsForAGATaxesRelatedTemporaryDifferencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_OtherTemporaryDifferencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_OtherTemporaryDifferencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R122.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income tax - Narrative (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">&#8364; 17,616<span></span>
</td>
<td class="nump">&#8364; 1,584<span></span>
</td>
<td class="nump">&#8364; 444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">241,894<span></span>
</td>
<td class="nump">155,715<span></span>
</td>
<td class="nump">116,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition', window );">Net deferred tax liabilities</a></td>
<td class="nump">5,848<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses for which no deferred tax asset recognised</a></td>
<td class="nump">911,776<span></span>
</td>
<td class="nump">609,390<span></span>
</td>
<td class="nump">459,752<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=abvx_RoyaltyCertificatesRelatedTemporaryDifferencesMember', window );">Royalty certificates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">17,208<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,427<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=abvx_RoyaltyCertificatesRelatedTemporaryDifferencesMember', window );">Royalty certificates | France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">11,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=abvx_AbivaxLLCMember', window );">Abivax LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses for which no deferred tax asset recognised</a></td>
<td class="nump">&#8364; 1,083<span></span>
</td>
<td class="nump">&#8364; 112<span></span>
</td>
<td class="nump">&#8364; 38<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Deferred Tax Assets (Liabilities) Recognised In Financial Position</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph f<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_f_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph f<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_f_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph f<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_f_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph f<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_f_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=abvx_RoyaltyCertificatesRelatedTemporaryDifferencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=abvx_RoyaltyCertificatesRelatedTemporaryDifferencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=abvx_AbivaxLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=abvx_AbivaxLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R123.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income (loss) per share - Schedule of earnings per share (Details) - EUR (&#8364;)<br> &#8364; / shares in Units, &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of outstanding shares, basic loss per share (in shares)</a></td>
<td class="nump">69,527,315<span></span>
</td>
<td class="nump">63,046,350<span></span>
</td>
<td class="nump">43,066,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of outstanding shares, diluted loss per share (in shares)</a></td>
<td class="nump">69,527,315<span></span>
</td>
<td class="nump">63,046,350<span></span>
</td>
<td class="nump">43,066,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="num">&#8364; (336,102)<span></span>
</td>
<td class="num">&#8364; (176,242)<span></span>
</td>
<td class="num">&#8364; (147,740)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic loss per share (in euro per share)</a></td>
<td class="num">&#8364; (4.83)<span></span>
</td>
<td class="num">&#8364; (2.80)<span></span>
</td>
<td class="num">&#8364; (3.43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted loss per share (in euro per share)</a></td>
<td class="num">&#8364; (4.83)<span></span>
</td>
<td class="num">&#8364; (2.80)<span></span>
</td>
<td class="num">&#8364; (3.43)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2025-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R124.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income (loss) per share - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsThatAreAntidilutiveInPeriodPresented', window );">Number of instruments that are antidilutive in period presented (in shares)</a></td>
<td class="nump">8,857,084<span></span>
</td>
<td class="nump">29,570,132<span></span>
</td>
<td class="nump">28,754,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_MaximumNumberOfSharesToBeIssued', window );">Maximum number of shares to be issued (in shares)</a></td>
<td class="nump">8,857,084<span></span>
</td>
<td class="nump">6,760,392<span></span>
</td>
<td class="nump">6,510,658<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_MaximumNumberOfSharesToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Number Of Shares To Be Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_MaximumNumberOfSharesToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsThatAreAntidilutiveInPeriodPresented">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of (units of) instruments that are antidilutive in the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsThatAreAntidilutiveInPeriodPresented</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R125.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related parties - Disclosure of aggregate compensation of the members of the Group&#8217;s Board of Directors and CEO (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Related party transactions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_KeyManagementPersonnelCompensationFixedCompensation', window );">Fixed compensation owed</a></td>
<td class="nump">&#8364; 601<span></span>
</td>
<td class="nump">&#8364; 578<span></span>
</td>
<td class="nump">&#8364; 471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_KeyManagementPersonnelCompensationVariableCompensation', window );">Variable compensation owed</a></td>
<td class="nump">450<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_KeyManagementPersonnelCompensationInKindContributions', window );">Contributions in-kind</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Employer contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_KeyManagementPersonnelCompensationAttendanceFees', window );">Attendance fees&#8212;board of directors</a></td>
<td class="nump">608<span></span>
</td>
<td class="nump">495<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share-based payments</a></td>
<td class="nump">8,098<span></span>
</td>
<td class="nump">10,517<span></span>
</td>
<td class="nump">6,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_KeyManagementPersonnelCompensationConsultingFees', window );">Consulting fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,210<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Total</a></td>
<td class="nump">&#8364; 9,869<span></span>
</td>
<td class="nump">&#8364; 11,657<span></span>
</td>
<td class="nump">&#8364; 8,930<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_KeyManagementPersonnelCompensationAttendanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Key Management Personnel Compensation, Attendance Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_KeyManagementPersonnelCompensationAttendanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_KeyManagementPersonnelCompensationConsultingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Key Management Personnel Compensation, Consulting Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_KeyManagementPersonnelCompensationConsultingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_KeyManagementPersonnelCompensationFixedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Key Management Personnel Compensation, Fixed Compensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_KeyManagementPersonnelCompensationFixedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_KeyManagementPersonnelCompensationInKindContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Key Management Personnel Compensation, In-Kind Contributions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_KeyManagementPersonnelCompensationInKindContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_KeyManagementPersonnelCompensationVariableCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Key Management Personnel Compensation, Variable Compensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_KeyManagementPersonnelCompensationVariableCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 227<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_227&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 227<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_227&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R126.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related parties - Narrative (Details) - Key management personnel - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=abvx_BoardOfDirectorsAndChiefExecutiveOfficerMember', window );">Board of Directors and Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan', window );">Net defined benefit liability</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=abvx_AdvisorToTheChiefExecutiveOfficerMember', window );">Advisor to the Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Total compensation</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits', window );">Termination benefits</a></td>
<td class="nump">&#8364; 1,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deficit in a defined benefit plan. [Refer: Defined benefit plans [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=abvx_BoardOfDirectorsAndChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=abvx_BoardOfDirectorsAndChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=abvx_AdvisorToTheChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=abvx_AdvisorToTheChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R127.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Off-balance sheet commitments given (Details)<br> &#8364; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 16, 2016 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 16, 2013 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Nov. 11, 2006 </div>
<div>USD ($) </div>
<div>academic_institution</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 02, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 04, 2008 </div>
<div>license</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems', window );"><strong>Disclosure Of Off-Balance Sheet Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RepaymentsOfConditionalAdvances', window );">Repayments of conditional advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 2,708<span></span>
</td>
<td class="nump">&#8364; 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CapitalCommitments', window );">Capital commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 205,131<span></span>
</td>
<td class="nump">234,908<span></span>
</td>
<td class="nump">&#8364; 201,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_CARENAConditionalAdvanceBPIMember', window );">CARENA conditional advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems', window );"><strong>Disclosure Of Off-Balance Sheet Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacityIncludingInterest', window );">Maximum drawdown capacity including interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_OtherFinancialLiabilitiesAnnualPercentageOfProceedsFromSaleOfIntellectualPropertyRight', window );">Annual percentage of proceeds from sale of intellectual property right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_OtherFinancialLiabilitiesAnnualRevenueFromSaleOfProductsDevelopedPeriod', window );">Annual revenue from sale of products developed, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDeveloped', window );">Percentage of annual revenue from sale of products developed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_RepaymentsOfConditionalAdvances', window );">Repayments of conditional advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity', window );">Maximum drawdown capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_CARENAConditionalAdvanceBPIMember', window );">CARENA conditional advance | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems', window );"><strong>Disclosure Of Off-Balance Sheet Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDevelopedPreTaxRevenueThreshold', window );">Pre-tax revenue threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_CARENAConditionalAdvanceBPIMember', window );">CARENA conditional advance | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems', window );"><strong>Disclosure Of Off-Balance Sheet Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_OtherFinancialLiabilitiesPayableAnnualRevenueFromSaleOfProductsDeveloped', window );">Annual revenue from sale of products developed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_OtherFinancialLiabilitiesRepaymentPeriod', window );">Repayment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RNPVIRConditionalAdvanceBPIMember', window );">RNP-VIR conditional advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems', window );"><strong>Disclosure Of Off-Balance Sheet Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacityIncludingInterest', window );">Maximum drawdown capacity including interest</a></td>
<td class="nump">&#8364; 6,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_OtherFinancialLiabilitiesAnnualPercentageOfProceedsFromSaleOfIntellectualPropertyRight', window );">Annual percentage of proceeds from sale of intellectual property right</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_OtherFinancialLiabilitiesAnnualRevenueFromSaleOfProductsDevelopedPeriod', window );">Annual revenue from sale of products developed, period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDeveloped', window );">Percentage of annual revenue from sale of products developed</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity', window );">Maximum drawdown capacity</a></td>
<td class="nump">&#8364; 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RNPVIRConditionalAdvanceBPIMember', window );">RNP-VIR conditional advance | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems', window );"><strong>Disclosure Of Off-Balance Sheet Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDevelopedPreTaxRevenueThreshold', window );">Pre-tax revenue threshold</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RNPVIRConditionalAdvanceBPIMember', window );">RNP-VIR conditional advance | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems', window );"><strong>Disclosure Of Off-Balance Sheet Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_OtherFinancialLiabilitiesPayableAnnualRevenueFromSaleOfProductsDeveloped', window );">Annual revenue from sale of products developed</a></td>
<td class="nump">&#8364; 5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_OtherFinancialLiabilitiesRepaymentPeriod', window );">Repayment period</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_EbolaConditionalAdvanceBPIMember', window );">Ebola conditional advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems', window );"><strong>Disclosure Of Off-Balance Sheet Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity', window );">Maximum drawdown capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_EbolaConditionalAdvanceBPILanguedocRoussillonMember', window );">Ebola conditional advance, BPI Languedoc-Roussillon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems', window );"><strong>Disclosure Of Off-Balance Sheet Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity', window );">Maximum drawdown capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_EbolaConditionalAdvanceBPIFranceMember', window );">Ebola conditional advance, BPI France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems', window );"><strong>Disclosure Of Off-Balance Sheet Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity', window );">Maximum drawdown capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=abvx_TheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember', window );">The Scripps Research Institute, University of Chicago and Brigham Young University</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems', window );"><strong>Disclosure Of Off-Balance Sheet Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests', window );">Proportion of ownership interests held by non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_PrincipalAgreementsAxis=abvx_ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember', window );">Exclusive licensing agreement with CNRS, University of Montpellier and Institut Curie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems', window );"><strong>Disclosure Of Off-Balance Sheet Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfExclusiveLicenses', window );">Number of exclusive licenses | license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_PrincipalAgreementsAxis=abvx_ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember', window );">Exclusive licensing contract with the Scripps Research Institute, University of Chicago and Brigham Young University</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems', window );"><strong>Disclosure Of Off-Balance Sheet Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDFiling', window );">Potential development milestone payment, IND filing | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentPhase3', window );">Potential development milestone payment, phase 3 | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDApproval', window );">Potential development milestone payment, IND approval | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfAcademicInstitutions', window );">Number of academic institutions | academic_institution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, Potential Development Milestone Payment, IND Approval</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDFiling">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, Potential Development Milestone Payment, IND Filing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDFiling</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentPhase3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, Potential Development Milestone Payment, Phase 3</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentPhase3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Off-Balance Sheet Commitments [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfAcademicInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Academic Institutions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfAcademicInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfExclusiveLicenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Exclusive Licenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfExclusiveLicenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_OtherFinancialLiabilitiesAnnualPercentageOfProceedsFromSaleOfIntellectualPropertyRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Liabilities, Annual Percentage Of Proceeds From Sale Of Intellectual Property Right</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_OtherFinancialLiabilitiesAnnualPercentageOfProceedsFromSaleOfIntellectualPropertyRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_OtherFinancialLiabilitiesAnnualRevenueFromSaleOfProductsDevelopedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Liabilities, Annual Revenue From Sale Of Products Developed, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_OtherFinancialLiabilitiesAnnualRevenueFromSaleOfProductsDevelopedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Liabilities, Maximum Drawdown Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacityIncludingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Liabilities, Maximum Drawdown Capacity Including Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacityIncludingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_OtherFinancialLiabilitiesPayableAnnualRevenueFromSaleOfProductsDeveloped">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Liabilities, Payable, Annual Revenue From Sale Of Products Developed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_OtherFinancialLiabilitiesPayableAnnualRevenueFromSaleOfProductsDeveloped</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDeveloped">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Liabilities, Percentage Of Annual Revenue From Sale Of Products Developed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDeveloped</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDevelopedPreTaxRevenueThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Liabilities, Percentage Of Annual Revenue From Sale Of Products Developed, Pre-Tax Revenue Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDevelopedPreTaxRevenueThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_OtherFinancialLiabilitiesRepaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Liabilities, Repayment Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_OtherFinancialLiabilitiesRepaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_RepaymentsOfConditionalAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments Of Conditional Advances</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_RepaymentsOfConditionalAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of future capital expenditures that the entity is committed to make.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interests in a subsidiary held by non-controlling interests. [Refer: Total for all subsidiaries [member]; Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 12<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_12_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_CARENAConditionalAdvanceBPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_CARENAConditionalAdvanceBPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RNPVIRConditionalAdvanceBPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RNPVIRConditionalAdvanceBPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_EbolaConditionalAdvanceBPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_EbolaConditionalAdvanceBPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_EbolaConditionalAdvanceBPILanguedocRoussillonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_EbolaConditionalAdvanceBPILanguedocRoussillonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_EbolaConditionalAdvanceBPIFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_EbolaConditionalAdvanceBPIFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=abvx_TheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=abvx_TheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_PrincipalAgreementsAxis=abvx_ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_PrincipalAgreementsAxis=abvx_ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_PrincipalAgreementsAxis=abvx_ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_PrincipalAgreementsAxis=abvx_ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R128.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Off-balance sheet commitments received and contingent assets (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>project</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfCommitmentsReceivedLineItems', window );"><strong>Disclosure Of Commitments Received [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfProjectsTerminated', window );">Number of projects terminated | project</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingMember', window );">Kreos &amp; Claret financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfCommitmentsReceivedLineItems', window );"><strong>Disclosure Of Commitments Received [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UndrawnBorrowingFacilities', window );">Undrawn borrowing facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_HeightsConvertibleNotesTrancheBMember', window );">Heights convertible notes, tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfCommitmentsReceivedLineItems', window );"><strong>Disclosure Of Commitments Received [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UndrawnBorrowingFacilities', window );">Undrawn borrowing facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RNPVIRConditionalAdvanceBPIMember', window );">RNP-VIR conditional advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfCommitmentsReceivedLineItems', window );"><strong>Disclosure Of Commitments Received [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UndrawnBorrowingFacilities', window );">Undrawn borrowing facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_CARENAConditionalAdvanceBPIMember', window );">CARENA conditional advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_DisclosureOfCommitmentsReceivedLineItems', window );"><strong>Disclosure Of Commitments Received [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UndrawnBorrowingFacilities', window );">Undrawn borrowing facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,853<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_DisclosureOfCommitmentsReceivedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Commitments Received [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_DisclosureOfCommitmentsReceivedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfProjectsTerminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Projects Terminated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfProjectsTerminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UndrawnBorrowingFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of undrawn borrowing facilities that may be available for future operating activities and to settle capital commitments. [Refer: Capital commitments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 50<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_50_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UndrawnBorrowingFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_HeightsConvertibleNotesTrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_HeightsConvertibleNotesTrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RNPVIRConditionalAdvanceBPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_RNPVIRConditionalAdvanceBPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_CARENAConditionalAdvanceBPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=abvx_CARENAConditionalAdvanceBPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R129.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Management and assessment of financial risks (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>EUR (&#8364;) </div>
<div>financial_institution</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><div>Aug. 20, 2023</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCreditRiskExposureLineItems', window );"><strong>Disclosure of credit risk exposure [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Assets</a></td>
<td class="nump">&#8364; 584,341<span></span>
</td>
<td class="nump">&#8364; 205,228<span></span>
</td>
<td class="nump">&#8364; 327,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">&#8364; 516,685<span></span>
</td>
<td class="nump">&#8364; 144,221<span></span>
</td>
<td class="nump">&#8364; 251,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 26,950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember', window );">Kreos &amp; Claret financing, tranche B and C | European Central Bank base rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCreditRiskExposureLineItems', window );"><strong>Disclosure of credit risk exposure [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsAdjustmentToInterestRateBasis', window );">Borrowings, adjustment to interest rate basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_InterestRateCollarRange', window );">Interest rate collar range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember', window );">Kreos &amp; Claret financing, tranche B and C | European Central Bank base rate | Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCreditRiskExposureLineItems', window );"><strong>Disclosure of credit risk exposure [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsBasisInterestRate', window );">Borrowings, interest rate basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember', window );">Kreos &amp; Claret financing, tranche B and C | European Central Bank base rate | Bottom of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCreditRiskExposureLineItems', window );"><strong>Disclosure of credit risk exposure [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BorrowingsBasisInterestRate', window );">Borrowings, interest rate basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember', window );">Credit risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCreditRiskExposureLineItems', window );"><strong>Disclosure of credit risk exposure [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_NumberOfFinancialInstitutionsToMaintainCash', window );">Number of financial institutions to maintain cash | financial_institution</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_BalancesWithBanksInExcessOfLegallyInsuredLimit', window );">Balances with banks in excess of legally insured limit</a></td>
<td class="nump">&#8364; 92,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_InvestmentsInMutualFundsAndStructuredNotes', window );">Investments in mutual funds and structured notes</a></td>
<td class="nump">437,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">United States of America, Dollars | Currency risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCreditRiskExposureLineItems', window );"><strong>Disclosure of credit risk exposure [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Assets</a></td>
<td class="nump">327,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">143,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties', window );">Receivables due from related parties</a></td>
<td class="nump">194,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Liabilities</a></td>
<td class="nump">24,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToRelatedParties', window );">Payables to related parties</a></td>
<td class="nump">&#8364; 22,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent', window );">Reasonably possible change in risk variable, percent</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_SensitivityAnalysisForTypesOfMarketRisk10AdverseChangeInExchangeRateImpactOnForeignExchangeGainLoss', window );">Adverse change in exchange rate, impact on foreign exchange loss</a></td>
<td class="nump">&#8364; 29,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abvx_SensitivityAnalysisForTypesOfMarketRisk10FavorableChangeInExchangeRateImpactOnForeignExchangeGainLoss', window );">Favorable change in exchange rate, impact on foreign exchange gain</a></td>
<td class="nump">&#8364; 36,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BalancesWithBanksInExcessOfLegallyInsuredLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balances With Banks In Excess Of Legally Insured Limit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BalancesWithBanksInExcessOfLegallyInsuredLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_BorrowingsBasisInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Basis Interest Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_BorrowingsBasisInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_InterestRateCollarRange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Rate Collar Range</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_InterestRateCollarRange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_InvestmentsInMutualFundsAndStructuredNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments In Mutual Funds And Structured Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_InvestmentsInMutualFundsAndStructuredNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_NumberOfFinancialInstitutionsToMaintainCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Financial Institutions To Maintain Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_NumberOfFinancialInstitutionsToMaintainCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_SensitivityAnalysisForTypesOfMarketRisk10AdverseChangeInExchangeRateImpactOnForeignExchangeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sensitivity Analysis For Types Of Market Risk, 10% Adverse Change in Exchange Rate, Impact On Foreign Exchange Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_SensitivityAnalysisForTypesOfMarketRisk10AdverseChangeInExchangeRateImpactOnForeignExchangeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_SensitivityAnalysisForTypesOfMarketRisk10FavorableChangeInExchangeRateImpactOnForeignExchangeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sensitivity Analysis For Types Of Market Risk, 10% Favorable Change in Exchange Rate, Impact On Foreign Exchange Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_SensitivityAnalysisForTypesOfMarketRisk10FavorableChangeInExchangeRateImpactOnForeignExchangeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvx_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvx_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsAdjustmentToInterestRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The adjustment to the basis (reference rate) used for calculation of the interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsAdjustmentToInterestRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCreditRiskExposureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCreditRiskExposureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payables due to related parties. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables due from related parties. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=abvx_EuropeanCentralBankBaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=abvx_EuropeanCentralBankBaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1319</ContextCount>
  <ElementCount>608</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>288</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>20</UnitCount>
  <MyReports>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/Coverpage</Role>
      <ShortName>Cover page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Auditor information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/Auditorinformation</Role>
      <ShortName>Auditor information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952151 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952152 - Statement - CONSOLIDATED STATEMENTS OF INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952153 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952154 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - The Group</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/TheGroup</Role>
      <ShortName>The Group</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Basis of preparation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/Basisofpreparation</Role>
      <ShortName>Basis of preparation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequentevents</Role>
      <ShortName>Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Accounting principles</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/Accountingprinciples</Role>
      <ShortName>Accounting principles</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Segment information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/Segmentinformation</Role>
      <ShortName>Segment information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Goodwill and impairment test</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/Goodwillandimpairmenttest</Role>
      <ShortName>Goodwill and impairment test</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/Intangibleassets</Role>
      <ShortName>Intangible assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Property, plant and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/Propertyplantandequipment</Role>
      <ShortName>Property, plant and equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Other financial assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/Otherfinancialassets</Role>
      <ShortName>Other financial assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Other receivables and other assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/Otherreceivablesandotherassets</Role>
      <ShortName>Other receivables and other assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Cash and cash equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/Cashandcashequivalents</Role>
      <ShortName>Cash and cash equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Financial assets and liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/Financialassetsandliabilities</Role>
      <ShortName>Financial assets and liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Shareholders??? equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/Shareholdersequity</Role>
      <ShortName>Shareholders??? equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Share-based payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/Sharebasedpayments</Role>
      <ShortName>Share-based payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Financial liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/Financialliabilities</Role>
      <ShortName>Financial liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Retirement benefit obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/Retirementbenefitobligations</Role>
      <ShortName>Retirement benefit obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9952172 - Disclosure - Payables and other current liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/Payablesandothercurrentliabilities</Role>
      <ShortName>Payables and other current liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9952173 - Disclosure - Other operating income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/Otheroperatingincome</Role>
      <ShortName>Other operating income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9952174 - Disclosure - Operating expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/Operatingexpenses</Role>
      <ShortName>Operating expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9952175 - Disclosure - Employees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/Employees</Role>
      <ShortName>Employees</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9952176 - Disclosure - Financial gain (loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/Financialgainloss</Role>
      <ShortName>Financial gain (loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9952177 - Disclosure - Income tax</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/Incometax</Role>
      <ShortName>Income tax</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9952178 - Disclosure - Income (loss) per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/Incomelosspershare</Role>
      <ShortName>Income (loss) per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9952179 - Disclosure - Related parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/Relatedparties</Role>
      <ShortName>Related parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9952180 - Disclosure - Off-balance sheet commitments given</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/Offbalancesheetcommitmentsgiven</Role>
      <ShortName>Off-balance sheet commitments given</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9952181 - Disclosure - Off-balance sheet commitments received and contingent assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/Offbalancesheetcommitmentsreceivedandcontingentassets</Role>
      <ShortName>Off-balance sheet commitments received and contingent assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9952182 - Disclosure - Management and assessment of financial risks</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/Managementandassessmentoffinancialrisks</Role>
      <ShortName>Management and assessment of financial risks</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Accounting principles (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/AccountingprinciplesPolicies</Role>
      <ShortName>Accounting principles (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.abivax.com/role/Accountingprinciples</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Accounting principles (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/AccountingprinciplesTables</Role>
      <ShortName>Accounting principles (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abivax.com/role/Accountingprinciples</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Intangible assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/IntangibleassetsTables</Role>
      <ShortName>Intangible assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abivax.com/role/Intangibleassets</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Property, plant and equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/PropertyplantandequipmentTables</Role>
      <ShortName>Property, plant and equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abivax.com/role/Propertyplantandequipment</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Other financial assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/OtherfinancialassetsTables</Role>
      <ShortName>Other financial assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abivax.com/role/Otherfinancialassets</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Other receivables and other assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/OtherreceivablesandotherassetsTables</Role>
      <ShortName>Other receivables and other assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abivax.com/role/Otherreceivablesandotherassets</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Cash and cash equivalents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/CashandcashequivalentsTables</Role>
      <ShortName>Cash and cash equivalents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abivax.com/role/Cashandcashequivalents</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Financial assets and liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/FinancialassetsandliabilitiesTables</Role>
      <ShortName>Financial assets and liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abivax.com/role/Financialassetsandliabilities</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Share-based payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/SharebasedpaymentsTables</Role>
      <ShortName>Share-based payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abivax.com/role/Sharebasedpayments</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Financial liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/FinancialliabilitiesTables</Role>
      <ShortName>Financial liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abivax.com/role/Financialliabilities</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Retirement benefit obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/RetirementbenefitobligationsTables</Role>
      <ShortName>Retirement benefit obligations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abivax.com/role/Retirementbenefitobligations</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Payables and other current liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/PayablesandothercurrentliabilitiesTables</Role>
      <ShortName>Payables and other current liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abivax.com/role/Payablesandothercurrentliabilities</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Other operating income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/OtheroperatingincomeTables</Role>
      <ShortName>Other operating income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abivax.com/role/Otheroperatingincome</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Operating expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/OperatingexpensesTables</Role>
      <ShortName>Operating expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abivax.com/role/Operatingexpenses</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Employees (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/EmployeesTables</Role>
      <ShortName>Employees (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abivax.com/role/Employees</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Financial gain (loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/FinancialgainlossTables</Role>
      <ShortName>Financial gain (loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abivax.com/role/Financialgainloss</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Income tax (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/IncometaxTables</Role>
      <ShortName>Income tax (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abivax.com/role/Incometax</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Income (loss) per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/IncomelosspershareTables</Role>
      <ShortName>Income (loss) per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abivax.com/role/Incometax</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Related parties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/RelatedpartiesTables</Role>
      <ShortName>Related parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abivax.com/role/Relatedparties</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - The Group (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/TheGroupDetails</Role>
      <ShortName>The Group (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abivax.com/role/TheGroup</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Basis of preparation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/BasisofpreparationDetails</Role>
      <ShortName>Basis of preparation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abivax.com/role/Basisofpreparation</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events - For the year ended 2023 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details</Role>
      <ShortName>Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events - For the year ended 2023 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events - For the year ended 2024 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details</Role>
      <ShortName>Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events - For the year ended 2024 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events - For the year ended 2025 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details</Role>
      <ShortName>Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events - For the year ended 2025 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events - Subsequent events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails</Role>
      <ShortName>Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events - Subsequent events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequentevents</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Accounting principles - Intangible assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/AccountingprinciplesIntangibleassetsDetails</Role>
      <ShortName>Accounting principles - Intangible assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Accounting principles - Disclosure of depreciation period of property, plant and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails</Role>
      <ShortName>Accounting principles - Disclosure of depreciation period of property, plant and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Segment information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/SegmentinformationDetails</Role>
      <ShortName>Segment information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abivax.com/role/Segmentinformation</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Goodwill and impairment test (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/GoodwillandimpairmenttestDetails</Role>
      <ShortName>Goodwill and impairment test (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abivax.com/role/Goodwillandimpairmenttest</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Intangible assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/IntangibleassetsNarrativeDetails</Role>
      <ShortName>Intangible assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Intangible assets - Disclosure of reconciliation of intangible assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails</Role>
      <ShortName>Intangible assets - Disclosure of reconciliation of intangible assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Property, plant and equipment - Disclosure of reconciliation of property, plant and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails</Role>
      <ShortName>Property, plant and equipment - Disclosure of reconciliation of property, plant and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Property, plant and equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails</Role>
      <ShortName>Property, plant and equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Other financial assets - Disclosure of other financial assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails</Role>
      <ShortName>Other financial assets - Disclosure of other financial assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Other financial assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails</Role>
      <ShortName>Other financial assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Other receivables and other assets - Disclosure of other receivables and other assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails</Role>
      <ShortName>Other receivables and other assets - Disclosure of other receivables and other assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Other receivables and other assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails</Role>
      <ShortName>Other receivables and other assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Cash and cash equivalents - Disclosure of composition of cash and cash equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/CashandcashequivalentsDisclosureofcompositionofcashandcashequivalentsDetails</Role>
      <ShortName>Cash and cash equivalents - Disclosure of composition of cash and cash equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - Cash and cash equivalents - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/CashandcashequivalentsNarrativeDetails</Role>
      <ShortName>Cash and cash equivalents - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Financial assets and liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/FinancialassetsandliabilitiesDetails</Role>
      <ShortName>Financial assets and liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abivax.com/role/FinancialassetsandliabilitiesTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - Shareholders??? equity - Share capital issued (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/ShareholdersequitySharecapitalissuedDetails</Role>
      <ShortName>Shareholders??? equity - Share capital issued (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - Shareholders??? equity - Change in share capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails</Role>
      <ShortName>Shareholders??? equity - Change in share capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - Share-based payments - Disclosure of reconciliation of BCEs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails</Role>
      <ShortName>Share-based payments - Disclosure of reconciliation of BCEs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - Share-based payments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails</Role>
      <ShortName>Share-based payments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - Share-based payments - Disclosure of reconciliation of BSAs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails</Role>
      <ShortName>Share-based payments - Disclosure of reconciliation of BSAs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9955556 - Disclosure - Share-based payments - Disclosure of assumptions used for the measurement of BSAs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails</Role>
      <ShortName>Share-based payments - Disclosure of assumptions used for the measurement of BSAs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9955557 - Disclosure - Share-based payments - Disclosure of reconciliation of AGAs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails</Role>
      <ShortName>Share-based payments - Disclosure of reconciliation of AGAs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9955558 - Disclosure - Share-based payments - Disclosure of assumptions used for the measurement of AGAs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails</Role>
      <ShortName>Share-based payments - Disclosure of assumptions used for the measurement of AGAs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9955559 - Disclosure - Share-based payments - Disclosure of breakdown of the compensation expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails</Role>
      <ShortName>Share-based payments - Disclosure of breakdown of the compensation expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9955560 - Disclosure - Financial liabilities - Disclosure of financial liabilities breakdown (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails</Role>
      <ShortName>Financial liabilities - Disclosure of financial liabilities breakdown (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9955561 - Disclosure - Financial liabilities - Kreos / Claret Financing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails</Role>
      <ShortName>Financial liabilities - Kreos / Claret Financing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9955562 - Disclosure - Financial liabilities - Disclosure of the main data and assumptions, Kreos / Claret minimum return indemnifications (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails</Role>
      <ShortName>Financial liabilities - Disclosure of the main data and assumptions, Kreos / Claret minimum return indemnifications (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>9955563 - Disclosure - Financial liabilities - Disclosure of the main data and assumptions, Kreos / Claret BSA (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails</Role>
      <ShortName>Financial liabilities - Disclosure of the main data and assumptions, Kreos / Claret BSA (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>9955564 - Disclosure - Financial liabilities - Heights convertible notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails</Role>
      <ShortName>Financial liabilities - Heights convertible notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>9955565 - Disclosure - Financial liabilities - Disclosure of the main data and assumptions, Heights convertible loan notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails</Role>
      <ShortName>Financial liabilities - Disclosure of the main data and assumptions, Heights convertible loan notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>9955566 - Disclosure - Financial liabilities - Kreos 1 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/FinancialliabilitiesKreos1Details</Role>
      <ShortName>Financial liabilities - Kreos 1 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>9955568 - Disclosure - Financial liabilities - Kreos 2 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/FinancialliabilitiesKreos2Details</Role>
      <ShortName>Financial liabilities - Kreos 2 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>9955569 - Disclosure - Financial liabilities - OCEANE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails</Role>
      <ShortName>Financial liabilities - OCEANE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>9955570 - Disclosure - Financial liabilities - State guaranteed loan ??? ???PGE??? (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/FinancialliabilitiesStateguaranteedloanPGEDetails</Role>
      <ShortName>Financial liabilities - State guaranteed loan ??? ???PGE??? (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>9955571 - Disclosure - Financial liabilities - Disclosure of conditional advances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/FinancialliabilitiesDisclosureofconditionaladvancesDetails</Role>
      <ShortName>Financial liabilities - Disclosure of conditional advances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>9955572 - Disclosure - Financial liabilities - Conditional advances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails</Role>
      <ShortName>Financial liabilities - Conditional advances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>9955573 - Disclosure - Financial liabilities - Disclosure of variation in lease liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/FinancialliabilitiesDisclosureofvariationinleaseliabilitiesDetails</Role>
      <ShortName>Financial liabilities - Disclosure of variation in lease liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>9955574 - Disclosure - Financial liabilities - Lease liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails</Role>
      <ShortName>Financial liabilities - Lease liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>9955575 - Disclosure - Financial liabilities - Royalty certificates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails</Role>
      <ShortName>Financial liabilities - Royalty certificates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>9955576 - Disclosure - Financial liabilities - Disclosure of reconciliation of liabilities arising from financing activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails</Role>
      <ShortName>Financial liabilities - Disclosure of reconciliation of liabilities arising from financing activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>9955577 - Disclosure - Financial liabilities - Change in financial liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails</Role>
      <ShortName>Financial liabilities - Change in financial liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>9955578 - Disclosure - Financial liabilities - Disclosure of changes in derivative instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails</Role>
      <ShortName>Financial liabilities - Disclosure of changes in derivative instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>9955579 - Disclosure - Financial liabilities - Disclosure of remaining contractual maturities of financial liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails</Role>
      <ShortName>Financial liabilities - Disclosure of remaining contractual maturities of financial liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>9955580 - Disclosure - Financial liabilities - Breakdown of financial liabilities by maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/FinancialliabilitiesBreakdownoffinancialliabilitiesbymaturityDetails</Role>
      <ShortName>Financial liabilities - Breakdown of financial liabilities by maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>9955581 - Disclosure - Retirement benefit obligations - Disclosure of main actuarial assumptions used to measure the retirement benefit obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails</Role>
      <ShortName>Retirement benefit obligations - Disclosure of main actuarial assumptions used to measure the retirement benefit obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>9955582 - Disclosure - Retirement benefit obligations - Disclosure of changes in projected benefit obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofchangesinprojectedbenefitobligationDetails</Role>
      <ShortName>Retirement benefit obligations - Disclosure of changes in projected benefit obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>9955583 - Disclosure - Payables and other current liabilities - Disclosure of breakdown of trade and other payables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails</Role>
      <ShortName>Payables and other current liabilities - Disclosure of breakdown of trade and other payables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>9955584 - Disclosure - Payables and other current liabilities - Disclosure of tax and employee-related payables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails</Role>
      <ShortName>Payables and other current liabilities - Disclosure of tax and employee-related payables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>9955585 - Disclosure - Other operating income - Disclosure of breakdown of operating income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/OtheroperatingincomeDisclosureofbreakdownofoperatingincomeDetails</Role>
      <ShortName>Other operating income - Disclosure of breakdown of operating income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>9955586 - Disclosure - Other operating income - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails</Role>
      <ShortName>Other operating income - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>9955587 - Disclosure - Operating expenses - Disclosure of sales and marketing expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails</Role>
      <ShortName>Operating expenses - Disclosure of sales and marketing expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>112</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>9955588 - Disclosure - Operating expenses - Disclosure of research and development expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails</Role>
      <ShortName>Operating expenses - Disclosure of research and development expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>113</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>9955589 - Disclosure - Operating expenses - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/OperatingexpensesNarrativeDetails</Role>
      <ShortName>Operating expenses - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>114</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>9955590 - Disclosure - Operating expenses - Disclosure of general and administrative expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails</Role>
      <ShortName>Operating expenses - Disclosure of general and administrative expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>115</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>9955591 - Disclosure - Operating expenses - Disclosure of principal audit fees and services (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/OperatingexpensesDisclosureofprincipalauditfeesandservicesDetails</Role>
      <ShortName>Operating expenses - Disclosure of principal audit fees and services (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>116</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>9955592 - Disclosure - Employees (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/EmployeesDetails</Role>
      <ShortName>Employees (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abivax.com/role/EmployeesTables</ParentRole>
      <Position>117</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>9955593 - Disclosure - Financial gain (loss) - Disclosure of net financial income (loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails</Role>
      <ShortName>Financial gain (loss) - Disclosure of net financial income (loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abivax.com/role/FinancialgainlossTables</ParentRole>
      <Position>118</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>9955594 - Disclosure - Financial gain (loss) - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/FinancialgainlossNarrativeDetails</Role>
      <ShortName>Financial gain (loss) - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abivax.com/role/FinancialgainlossTables</ParentRole>
      <Position>119</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>9955595 - Disclosure - Income tax - Disclosure of reconciliation of effective income tax (loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails</Role>
      <ShortName>Income tax - Disclosure of reconciliation of effective income tax (loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>120</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R121.htm</HtmlFileName>
      <LongName>9955596 - Disclosure - Income tax - Disclosure of deferred tax assets and liabilities by nature (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails</Role>
      <ShortName>Income tax - Disclosure of deferred tax assets and liabilities by nature (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>121</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R122.htm</HtmlFileName>
      <LongName>9955597 - Disclosure - Income tax - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/IncometaxNarrativeDetails</Role>
      <ShortName>Income tax - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>122</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R123.htm</HtmlFileName>
      <LongName>9955598 - Disclosure - Income (loss) per share - Schedule of earnings per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/IncomelosspershareScheduleofearningspershareDetails</Role>
      <ShortName>Income (loss) per share - Schedule of earnings per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abivax.com/role/IncometaxTables</ParentRole>
      <Position>123</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R124.htm</HtmlFileName>
      <LongName>9955599 - Disclosure - Income (loss) per share - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/IncomelosspershareNarrativeDetails</Role>
      <ShortName>Income (loss) per share - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abivax.com/role/IncometaxTables</ParentRole>
      <Position>124</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R125.htm</HtmlFileName>
      <LongName>9955600 - Disclosure - Related parties - Disclosure of aggregate compensation of the members of the Group???s Board of Directors and CEO (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails</Role>
      <ShortName>Related parties - Disclosure of aggregate compensation of the members of the Group???s Board of Directors and CEO (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>125</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R126.htm</HtmlFileName>
      <LongName>9955601 - Disclosure - Related parties - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/RelatedpartiesNarrativeDetails</Role>
      <ShortName>Related parties - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>126</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R127.htm</HtmlFileName>
      <LongName>9955602 - Disclosure - Off-balance sheet commitments given (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails</Role>
      <ShortName>Off-balance sheet commitments given (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abivax.com/role/Offbalancesheetcommitmentsgiven</ParentRole>
      <Position>127</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R128.htm</HtmlFileName>
      <LongName>9955603 - Disclosure - Off-balance sheet commitments received and contingent assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/OffbalancesheetcommitmentsreceivedandcontingentassetsDetails</Role>
      <ShortName>Off-balance sheet commitments received and contingent assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abivax.com/role/Offbalancesheetcommitmentsreceivedandcontingentassets</ParentRole>
      <Position>128</Position>
    </Report>
    <Report instance="abvx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R129.htm</HtmlFileName>
      <LongName>9955604 - Disclosure - Management and assessment of financial risks (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails</Role>
      <ShortName>Management and assessment of financial risks (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abivax.com/role/Managementandassessmentoffinancialrisks</ParentRole>
      <Position>129</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="20-F" isDefinitelyFs="true" isIfrs="true" isUsgaap="true" original="abvx-20251231.htm">abvx-20251231.htm</File>
    <File>abvx-20251231.xsd</File>
    <File>abvx-20251231_cal.xml</File>
    <File>abvx-20251231_def.xml</File>
    <File>abvx-20251231_lab.xml</File>
    <File>abvx-20251231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>abvx-20251231_g1.gif</File>
    <File>abvx-20251231_g10.gif</File>
    <File>abvx-20251231_g11.gif</File>
    <File>abvx-20251231_g12.gif</File>
    <File>abvx-20251231_g13.jpg</File>
    <File>abvx-20251231_g2.gif</File>
    <File>abvx-20251231_g3.gif</File>
    <File>abvx-20251231_g4.gif</File>
    <File>abvx-20251231_g5.gif</File>
    <File>abvx-20251231_g6.gif</File>
    <File>abvx-20251231_g7.gif</File>
    <File>abvx-20251231_g8.gif</File>
    <File>abvx-20251231_g9.gif</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="46">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="1">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
    <BaseTaxonomy items="2140">https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>167
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "abvx-20251231.htm": {
   "nsprefix": "abvx",
   "nsuri": "http://www.abivax.com/20251231",
   "dts": {
    "inline": {
     "local": [
      "abvx-20251231.htm"
     ]
    },
    "schema": {
     "local": [
      "abvx-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/rol_ifrs_ea-dim_2025-03-27.xsd",
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2025-03-27.xsd",
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/currency/2025/currency-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "abvx-20251231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "abvx-20251231_def.xml"
     ],
     "remote": [
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/dim_ifrs_ea_2025-03-27_role-995000.xml",
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/dim_full_ifrs_2025-03-27_role-995000.xml"
     ]
    },
    "labelLink": {
     "local": [
      "abvx-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abvx-20251231_pre.xml"
     ]
    }
   },
   "keyStandard": 334,
   "keyCustom": 274,
   "axisStandard": 39,
   "axisCustom": 8,
   "memberStandard": 53,
   "memberCustom": 194,
   "hidden": {
    "total": 23,
    "http://www.abivax.com/20251231": 18,
    "http://xbrl.sec.gov/dei/2025": 5
   },
   "contextCount": 1319,
   "entityCount": 1,
   "segmentCount": 288,
   "elementCount": 1172,
   "unitCount": 20,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 2140,
    "http://xbrl.sec.gov/dei/2025": 46,
    "http://xbrl.sec.gov/cyd/2025": 15,
    "http://xbrl.sec.gov/ecd/2025": 1
   },
   "report": {
    "R1": {
     "role": "http://www.abivax.com/role/Coverpage",
     "longName": "0000001 - Document - Cover page",
     "shortName": "Cover page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.abivax.com/role/Auditorinformation",
     "longName": "0000002 - Document - Auditor information",
     "shortName": "Auditor information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
     "longName": "9952151 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION",
     "shortName": "CONSOLIDATED STATEMENTS OF FINANCIAL POSITION",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:Goodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:NoncurrentAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS",
     "longName": "9952152 - Statement - CONSOLIDATED STATEMENTS OF INCOME (LOSS)",
     "shortName": "CONSOLIDATED STATEMENTS OF INCOME (LOSS)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:OtherIncome",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueAndOperatingIncome",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
     "longName": "9952153 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
     "longName": "9952154 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS\u2019 EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-11",
      "name": "ifrs-full:Equity",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.abivax.com/role/TheGroup",
     "longName": "9952156 - Disclosure - The Group",
     "shortName": "The Group",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.abivax.com/role/Basisofpreparation",
     "longName": "9952157 - Disclosure - Basis of preparation",
     "shortName": "Basis of preparation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequentevents",
     "longName": "9952158 - Disclosure - Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events",
     "shortName": "Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "abvx:DisclosureOfSignificantEventsForThePeriodReportedAndEventsAfterReportingPeriodTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "abvx:DisclosureOfSignificantEventsForThePeriodReportedAndEventsAfterReportingPeriodTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.abivax.com/role/Accountingprinciples",
     "longName": "9952159 - Disclosure - Accounting principles",
     "shortName": "Accounting principles",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.abivax.com/role/Segmentinformation",
     "longName": "9952160 - Disclosure - Segment information",
     "shortName": "Segment information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.abivax.com/role/Goodwillandimpairmenttest",
     "longName": "9952161 - Disclosure - Goodwill and impairment test",
     "shortName": "Goodwill and impairment test",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.abivax.com/role/Intangibleassets",
     "longName": "9952162 - Disclosure - Intangible assets",
     "shortName": "Intangible assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.abivax.com/role/Propertyplantandequipment",
     "longName": "9952163 - Disclosure - Property, plant and equipment",
     "shortName": "Property, plant and equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.abivax.com/role/Otherfinancialassets",
     "longName": "9952164 - Disclosure - Other financial assets",
     "shortName": "Other financial assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.abivax.com/role/Otherreceivablesandotherassets",
     "longName": "9952165 - Disclosure - Other receivables and other assets",
     "shortName": "Other receivables and other assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.abivax.com/role/Cashandcashequivalents",
     "longName": "9952166 - Disclosure - Cash and cash equivalents",
     "shortName": "Cash and cash equivalents",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.abivax.com/role/Financialassetsandliabilities",
     "longName": "9952167 - Disclosure - Financial assets and liabilities",
     "shortName": "Financial assets and liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.abivax.com/role/Shareholdersequity",
     "longName": "9952168 - Disclosure - Shareholders\u2019 equity",
     "shortName": "Shareholders\u2019 equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.abivax.com/role/Sharebasedpayments",
     "longName": "9952169 - Disclosure - Share-based payments",
     "shortName": "Share-based payments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.abivax.com/role/Financialliabilities",
     "longName": "9952170 - Disclosure - Financial liabilities",
     "shortName": "Financial liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.abivax.com/role/Retirementbenefitobligations",
     "longName": "9952171 - Disclosure - Retirement benefit obligations",
     "shortName": "Retirement benefit obligations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.abivax.com/role/Payablesandothercurrentliabilities",
     "longName": "9952172 - Disclosure - Payables and other current liabilities",
     "shortName": "Payables and other current liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.abivax.com/role/Otheroperatingincome",
     "longName": "9952173 - Disclosure - Other operating income",
     "shortName": "Other operating income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.abivax.com/role/Operatingexpenses",
     "longName": "9952174 - Disclosure - Operating expenses",
     "shortName": "Operating expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.abivax.com/role/Employees",
     "longName": "9952175 - Disclosure - Employees",
     "shortName": "Employees",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.abivax.com/role/Financialgainloss",
     "longName": "9952176 - Disclosure - Financial gain (loss)",
     "shortName": "Financial gain (loss)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.abivax.com/role/Incometax",
     "longName": "9952177 - Disclosure - Income tax",
     "shortName": "Income tax",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.abivax.com/role/Incomelosspershare",
     "longName": "9952178 - Disclosure - Income (loss) per share",
     "shortName": "Income (loss) per share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.abivax.com/role/Relatedparties",
     "longName": "9952179 - Disclosure - Related parties",
     "shortName": "Related parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.abivax.com/role/Offbalancesheetcommitmentsgiven",
     "longName": "9952180 - Disclosure - Off-balance sheet commitments given",
     "shortName": "Off-balance sheet commitments given",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCommitmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCommitmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.abivax.com/role/Offbalancesheetcommitmentsreceivedandcontingentassets",
     "longName": "9952181 - Disclosure - Off-balance sheet commitments received and contingent assets",
     "shortName": "Off-balance sheet commitments received and contingent assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.abivax.com/role/Managementandassessmentoffinancialrisks",
     "longName": "9952182 - Disclosure - Management and assessment of financial risks",
     "shortName": "Management and assessment of financial risks",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.abivax.com/role/AccountingprinciplesPolicies",
     "longName": "9955511 - Disclosure - Accounting principles (Policies)",
     "shortName": "Accounting principles (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DescriptionOfAccountingPolicyForGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DescriptionOfAccountingPolicyForGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.abivax.com/role/AccountingprinciplesTables",
     "longName": "9955512 - Disclosure - Accounting principles (Tables)",
     "shortName": "Accounting principles (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.abivax.com/role/IntangibleassetsTables",
     "longName": "9955513 - Disclosure - Intangible assets (Tables)",
     "shortName": "Intangible assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.abivax.com/role/PropertyplantandequipmentTables",
     "longName": "9955514 - Disclosure - Property, plant and equipment (Tables)",
     "shortName": "Property, plant and equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfReconciliationOfChangesInPropertyPlantAndEquipmentIncludingRightofuseAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfReconciliationOfChangesInPropertyPlantAndEquipmentIncludingRightofuseAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.abivax.com/role/OtherfinancialassetsTables",
     "longName": "9955515 - Disclosure - Other financial assets (Tables)",
     "shortName": "Other financial assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.abivax.com/role/OtherreceivablesandotherassetsTables",
     "longName": "9955516 - Disclosure - Other receivables and other assets (Tables)",
     "shortName": "Other receivables and other assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "abvx:DisclosureOfDetailedInformationAboutOtherReceivablesAndOtherAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "abvx:DisclosureOfDetailedInformationAboutOtherReceivablesAndOtherAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.abivax.com/role/CashandcashequivalentsTables",
     "longName": "9955517 - Disclosure - Cash and cash equivalents (Tables)",
     "shortName": "Cash and cash equivalents (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "abvx:DisclosureOfCompositionOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "abvx:DisclosureOfCompositionOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.abivax.com/role/FinancialassetsandliabilitiesTables",
     "longName": "9955518 - Disclosure - Financial assets and liabilities (Tables)",
     "shortName": "Financial assets and liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFairValueMeasurementOfAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFairValueMeasurementOfAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.abivax.com/role/SharebasedpaymentsTables",
     "longName": "9955519 - Disclosure - Share-based payments (Tables)",
     "shortName": "Share-based payments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.abivax.com/role/FinancialliabilitiesTables",
     "longName": "9955520 - Disclosure - Financial liabilities (Tables)",
     "shortName": "Financial liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.abivax.com/role/RetirementbenefitobligationsTables",
     "longName": "9955521 - Disclosure - Retirement benefit obligations (Tables)",
     "shortName": "Retirement benefit obligations (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.abivax.com/role/PayablesandothercurrentliabilitiesTables",
     "longName": "9955522 - Disclosure - Payables and other current liabilities (Tables)",
     "shortName": "Payables and other current liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "abvx:DisclosureOfBreakdownOfTradeAndOtherPayablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "abvx:DisclosureOfBreakdownOfTradeAndOtherPayablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.abivax.com/role/OtheroperatingincomeTables",
     "longName": "9955523 - Disclosure - Other operating income (Tables)",
     "shortName": "Other operating income (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "abvx:DisclosureOfDetailedInformationOfOperatingIncomeExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "abvx:DisclosureOfDetailedInformationOfOperatingIncomeExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.abivax.com/role/OperatingexpensesTables",
     "longName": "9955524 - Disclosure - Operating expenses (Tables)",
     "shortName": "Operating expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.abivax.com/role/EmployeesTables",
     "longName": "9955525 - Disclosure - Employees (Tables)",
     "shortName": "Employees (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "abvx:DisclosureOfAverageNumberOfEmployeesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "abvx:DisclosureOfAverageNumberOfEmployeesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.abivax.com/role/FinancialgainlossTables",
     "longName": "9955526 - Disclosure - Financial gain (loss) (Tables)",
     "shortName": "Financial gain (loss) (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "abvx:DisclosureOfDetailedInformationAboutFinanceIncomeCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "abvx:DisclosureOfDetailedInformationAboutFinanceIncomeCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.abivax.com/role/IncometaxTables",
     "longName": "9955527 - Disclosure - Income tax (Tables)",
     "shortName": "Income tax (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "abvx:DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "abvx:DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.abivax.com/role/IncomelosspershareTables",
     "longName": "9955528 - Disclosure - Income (loss) per share (Tables)",
     "shortName": "Income (loss) per share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.abivax.com/role/RelatedpartiesTables",
     "longName": "9955529 - Disclosure - Related parties (Tables)",
     "shortName": "Related parties (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.abivax.com/role/TheGroupDetails",
     "longName": "9955530 - Disclosure - The Group (Details)",
     "shortName": "The Group (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:Equity",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R57": {
     "role": "http://www.abivax.com/role/BasisofpreparationDetails",
     "longName": "9955531 - Disclosure - Basis of preparation (Details)",
     "shortName": "Basis of preparation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-67",
      "name": "ifrs-full:ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details",
     "longName": "9955532 - Disclosure - Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events - For the year ended 2023 (Details)",
     "shortName": "Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events - For the year ended 2023 (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-451",
      "name": "ifrs-full:IssueOfEquity",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-88",
      "name": "abvx:ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details",
     "longName": "9955533 - Disclosure - Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events - For the year ended 2024 (Details)",
     "shortName": "Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events - For the year ended 2024 (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-93",
      "name": "abvx:NumberOfFreeSharesPlansIssued",
      "unitRef": "plan",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-108",
      "name": "abvx:NumberOfADSPerOrdinaryShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details",
     "longName": "9955534 - Disclosure - Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events - For the year ended 2025 (Details)",
     "shortName": "Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events - For the year ended 2025 (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-93",
      "name": "abvx:NumberOfFreeSharesPlansIssued",
      "unitRef": "plan",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-123",
      "name": "abvx:SharePrice1",
      "unitRef": "eurPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails",
     "longName": "9955535 - Disclosure - Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events - Subsequent events (Details)",
     "shortName": "Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events - Subsequent events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-74",
      "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-137",
      "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.abivax.com/role/AccountingprinciplesIntangibleassetsDetails",
     "longName": "9955536 - Disclosure - Accounting principles - Intangible assets (Details)",
     "shortName": "Accounting principles - Intangible assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "abvx:ResearchAndDevelopmentCostsRecognitionInitialMeasurementNumberOfCriterias",
      "unitRef": "criteria",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "abvx:ResearchAndDevelopmentCostsRecognitionInitialMeasurementNumberOfCriterias",
      "unitRef": "criteria",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails",
     "longName": "9955537 - Disclosure - Accounting principles - Disclosure of depreciation period of property, plant and equipment (Details)",
     "shortName": "Accounting principles - Disclosure of depreciation period of property, plant and equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-146",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-146",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.abivax.com/role/SegmentinformationDetails",
     "longName": "9955538 - Disclosure - Segment information (Details)",
     "shortName": "Segment information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-157",
      "name": "abvx:ContributionToGroupsAssetsPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-157",
      "name": "abvx:ContributionToGroupsAssetsPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.abivax.com/role/GoodwillandimpairmenttestDetails",
     "longName": "9955539 - Disclosure - Goodwill and impairment test (Details)",
     "shortName": "Goodwill and impairment test (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill",
       "ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill",
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill",
       "ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill",
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.abivax.com/role/IntangibleassetsNarrativeDetails",
     "longName": "9955540 - Disclosure - Intangible assets - Narrative (Details)",
     "shortName": "Intangible assets - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-165",
      "name": "abvx:TechnologyBasedIntangibleAssetsAssetsAcquisitions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-165",
      "name": "abvx:TechnologyBasedIntangibleAssetsAssetsAcquisitions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails",
     "longName": "9955541 - Disclosure - Intangible assets - Disclosure of reconciliation of intangible assets (Details)",
     "shortName": "Intangible assets - Disclosure of reconciliation of intangible assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails",
     "longName": "9955542 - Disclosure - Property, plant and equipment - Disclosure of reconciliation of property, plant and equipment (Details)",
     "shortName": "Property, plant and equipment - Disclosure of reconciliation of property, plant and equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-302",
      "name": "ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails",
     "longName": "9955543 - Disclosure - Property, plant and equipment - Narrative (Details)",
     "shortName": "Property, plant and equipment - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-319",
      "name": "ifrs-full:RightofuseAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-319",
      "name": "ifrs-full:RightofuseAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails",
     "longName": "9955544 - Disclosure - Other financial assets - Disclosure of other financial assets (Details)",
     "shortName": "Other financial assets - Disclosure of other financial assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "abvx:NonCurrentAdvancesToCROContractsUndiscountedAmount",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:LongtermDeposits",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails",
     "longName": "9955545 - Disclosure - Other financial assets - Narrative (Details)",
     "shortName": "Other financial assets - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "abvx:NonCurrentAdvancesToCROContractsUndiscountedAmount",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-329",
      "name": "abvx:DiscountRateAppliedToLongTermAdvances",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails",
     "longName": "9955546 - Disclosure - Other receivables and other assets - Disclosure of other receivables and other assets (Details)",
     "shortName": "Other receivables and other assets - Disclosure of other receivables and other assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "abvx:NonCurrentPrepaidExpenses",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "abvx:NonCurrentPrepaidExpenses",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails",
     "longName": "9955547 - Disclosure - Other receivables and other assets - Narrative (Details)",
     "shortName": "Other receivables and other assets - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "abvx:ProceedsFromResearchTaxCredit",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "abvx:CurrentPrepaidExpensesRelatedToCRO",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.abivax.com/role/CashandcashequivalentsDisclosureofcompositionofcashandcashequivalentsDetails",
     "longName": "9955548 - Disclosure - Cash and cash equivalents - Disclosure of composition of cash and cash equivalents (Details)",
     "shortName": "Cash and cash equivalents - Disclosure of composition of cash and cash equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:CashEquivalents",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:CashEquivalents",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.abivax.com/role/CashandcashequivalentsNarrativeDetails",
     "longName": "9955549 - Disclosure - Cash and cash equivalents - Narrative (Details)",
     "shortName": "Cash and cash equivalents - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:OtherCashAndCashEquivalents",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:OtherCashAndCashEquivalents",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails",
     "longName": "9955550 - Disclosure - Financial assets and liabilities (Details)",
     "shortName": "Financial assets and liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "ifrs-full:Assets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:FinancialAssetsAtFairValue",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.abivax.com/role/ShareholdersequitySharecapitalissuedDetails",
     "longName": "9955551 - Disclosure - Shareholders\u2019 equity - Share capital issued (Details)",
     "shortName": "Shareholders\u2019 equity - Share capital issued (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:IssuedCapital",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "abvx:NumberOfTreasurySharesHeld",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "abvx:NumberOfTreasurySharesHeld",
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails",
     "longName": "9955552 - Disclosure - Shareholders\u2019 equity - Change in share capital (Details)",
     "shortName": "Shareholders\u2019 equity - Change in share capital (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-451",
      "name": "ifrs-full:IssueOfEquity",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-461",
      "name": "abvx:ShareWarrantsSubscriptionPricePerShare",
      "unitRef": "eurPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails",
     "longName": "9955553 - Disclosure - Share-based payments - Disclosure of reconciliation of BCEs (Details)",
     "shortName": "Share-based payments - Disclosure of reconciliation of BCEs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-500",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-500",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails",
     "longName": "9955554 - Disclosure - Share-based payments - Narrative (Details)",
     "shortName": "Share-based payments - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "ifrs-full:OtherShorttermProvisions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-501",
      "name": "abvx:VestingRequirementsForShareBasedPaymentArrangementChangeOfControlMinimumThreshold",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails",
     "longName": "9955555 - Disclosure - Share-based payments - Disclosure of reconciliation of BSAs (Details)",
     "shortName": "Share-based payments - Disclosure of reconciliation of BSAs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-543",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-544",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails",
     "longName": "9955556 - Disclosure - Share-based payments - Disclosure of assumptions used for the measurement of BSAs (Details)",
     "shortName": "Share-based payments - Disclosure of assumptions used for the measurement of BSAs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-522",
      "name": "abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted",
      "unitRef": "eurPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-522",
      "name": "abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted",
      "unitRef": "eurPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails",
     "longName": "9955557 - Disclosure - Share-based payments - Disclosure of reconciliation of AGAs (Details)",
     "shortName": "Share-based payments - Disclosure of reconciliation of AGAs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-641",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-641",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
     "longName": "9955558 - Disclosure - Share-based payments - Disclosure of assumptions used for the measurement of AGAs (Details)",
     "shortName": "Share-based payments - Disclosure of assumptions used for the measurement of AGAs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-644",
      "name": "abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted",
      "unitRef": "eurPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-644",
      "name": "abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted",
      "unitRef": "eurPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails",
     "longName": "9955559 - Disclosure - Share-based payments - Disclosure of breakdown of the compensation expenses (Details)",
     "shortName": "Share-based payments - Disclosure of breakdown of the compensation expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails",
     "longName": "9955560 - Disclosure - Financial liabilities - Disclosure of financial liabilities breakdown (Details)",
     "shortName": "Financial liabilities - Disclosure of financial liabilities breakdown (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:NoncurrentFinancialLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:NoncurrentFinancialLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
     "longName": "9955561 - Disclosure - Financial liabilities - Kreos / Claret Financing (Details)",
     "shortName": "Financial liabilities - Kreos / Claret Financing (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-63",
      "name": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-753",
      "name": "ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails",
     "longName": "9955562 - Disclosure - Financial liabilities - Disclosure of the main data and assumptions, Kreos / Claret minimum return indemnifications (Details)",
     "shortName": "Financial liabilities - Disclosure of the main data and assumptions, Kreos / Claret minimum return indemnifications (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c-774",
      "name": "abvx:AggregateFairValueOtherEquityInstrumentsOutstanding",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-774",
      "name": "abvx:AggregateFairValueOtherEquityInstrumentsOutstanding",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails",
     "longName": "9955563 - Disclosure - Financial liabilities - Disclosure of the main data and assumptions, Kreos / Claret BSA (Details)",
     "shortName": "Financial liabilities - Disclosure of the main data and assumptions, Kreos / Claret BSA (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c-841",
      "name": "ifrs-full:SignificantUnobservableInputLiabilities",
      "unitRef": "eurPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-841",
      "name": "ifrs-full:SignificantUnobservableInputLiabilities",
      "unitRef": "eurPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
     "longName": "9955564 - Disclosure - Financial liabilities - Heights convertible notes (Details)",
     "shortName": "Financial liabilities - Heights convertible notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "abvx:NetProceedsFromConvertibleLoansNotes",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-978",
      "name": "ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails",
     "longName": "9955565 - Disclosure - Financial liabilities - Disclosure of the main data and assumptions, Heights convertible loan notes (Details)",
     "shortName": "Financial liabilities - Disclosure of the main data and assumptions, Heights convertible loan notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c-933",
      "name": "abvx:NumberOfConvertibleNotesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-933",
      "name": "abvx:NumberOfConvertibleNotesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.abivax.com/role/FinancialliabilitiesKreos1Details",
     "longName": "9955566 - Disclosure - Financial liabilities - Kreos 1 (Details)",
     "shortName": "Financial liabilities - Kreos 1 (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c-986",
      "name": "abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-992",
      "name": "abvx:NumberOfSharesPerShareWarrant",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.abivax.com/role/FinancialliabilitiesKreos2Details",
     "longName": "9955568 - Disclosure - Financial liabilities - Kreos 2 (Details)",
     "shortName": "Financial liabilities - Kreos 2 (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c-83",
      "name": "abvx:RepaymentsOfConvertibleLoansNotes",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-993",
      "name": "ifrs-full:NotionalAmount",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails",
     "longName": "9955569 - Disclosure - Financial liabilities - OCEANE (Details)",
     "shortName": "Financial liabilities - OCEANE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c-88",
      "name": "abvx:IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1004",
      "name": "abvx:AggregateFairValueConvertibleNotes",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R95": {
     "role": "http://www.abivax.com/role/FinancialliabilitiesStateguaranteedloanPGEDetails",
     "longName": "9955570 - Disclosure - Financial liabilities - State guaranteed loan \u2013 \u201cPGE\u201d (Details)",
     "shortName": "Financial liabilities - State guaranteed loan \u2013 \u201cPGE\u201d (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromGovernmentGrants",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1013",
      "name": "abvx:BorrowingsMaturityTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.abivax.com/role/FinancialliabilitiesDisclosureofconditionaladvancesDetails",
     "longName": "9955571 - Disclosure - Financial liabilities - Disclosure of conditional advances (Details)",
     "shortName": "Financial liabilities - Disclosure of conditional advances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "abvx:ConditionalAdvances",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R97": {
     "role": "http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails",
     "longName": "9955572 - Disclosure - Financial liabilities - Conditional advances (Details)",
     "shortName": "Financial liabilities - Conditional advances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "abvx:ConditionalAdvances",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-104",
      "name": "abvx:RepaymentOfExcessConditionalAdvancesClaimed",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.abivax.com/role/FinancialliabilitiesDisclosureofvariationinleaseliabilitiesDetails",
     "longName": "9955573 - Disclosure - Financial liabilities - Disclosure of variation in lease liabilities (Details)",
     "shortName": "Financial liabilities - Disclosure of variation in lease liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "ifrs-full:LeaseLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "abvx:IncreaseInLeaseLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails",
     "longName": "9955574 - Disclosure - Financial liabilities - Lease liabilities (Details)",
     "shortName": "Financial liabilities - Lease liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "abvx:ExpenseOnLeaseLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "abvx:ExpenseOnLeaseLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R100": {
     "role": "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails",
     "longName": "9955575 - Disclosure - Financial liabilities - Royalty certificates (Details)",
     "shortName": "Financial liabilities - Royalty certificates (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "c-451",
      "name": "ifrs-full:IssueOfEquity",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-9",
      "name": "abvx:InterestExpenseOnRoyaltyCertificatesIncludingTheUnwindingOfDiscount",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R101": {
     "role": "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails",
     "longName": "9955576 - Disclosure - Financial liabilities - Disclosure of reconciliation of liabilities arising from financing activities (Details)",
     "shortName": "Financial liabilities - Disclosure of reconciliation of liabilities arising from financing activities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R102": {
     "role": "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails",
     "longName": "9955577 - Disclosure - Financial liabilities - Change in financial liabilities (Details)",
     "shortName": "Financial liabilities - Change in financial liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "abvx:NetProceedsFromConvertibleLoansNotes",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-9",
      "name": "abvx:GrossProceedsFromNonConvertibleLoansNotes",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R103": {
     "role": "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails",
     "longName": "9955578 - Disclosure - Financial liabilities - Disclosure of changes in derivative instruments (Details)",
     "shortName": "Financial liabilities - Disclosure of changes in derivative instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "ifrs-full:DerivativeFinancialLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-9",
      "name": "abvx:IssuanceOfDerivativeInstruments",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R104": {
     "role": "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails",
     "longName": "9955579 - Disclosure - Financial liabilities - Disclosure of remaining contractual maturities of financial liabilities (Details)",
     "shortName": "Financial liabilities - Disclosure of remaining contractual maturities of financial liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "104",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "abvx:ConditionalAdvances",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "abvx:ConditionalAdvancesUndiscountedCashFlows",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R105": {
     "role": "http://www.abivax.com/role/FinancialliabilitiesBreakdownoffinancialliabilitiesbymaturityDetails",
     "longName": "9955580 - Disclosure - Financial liabilities - Breakdown of financial liabilities by maturity (Details)",
     "shortName": "Financial liabilities - Breakdown of financial liabilities by maturity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "105",
     "firstAnchor": {
      "contextRef": "c-1055",
      "name": "abvx:RoyaltyCertificatePercentageOfFutureSales",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1053",
      "name": "abvx:RoyaltyCertificateExpirationPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R106": {
     "role": "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails",
     "longName": "9955581 - Disclosure - Retirement benefit obligations - Disclosure of main actuarial assumptions used to measure the retirement benefit obligations (Details)",
     "shortName": "Retirement benefit obligations - Disclosure of main actuarial assumptions used to measure the retirement benefit obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "106",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:ActuarialAssumptionOfDiscountRates",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:ActuarialAssumptionOfDiscountRates",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R107": {
     "role": "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofchangesinprojectedbenefitobligationDetails",
     "longName": "9955582 - Disclosure - Retirement benefit obligations - Disclosure of changes in projected benefit obligation (Details)",
     "shortName": "Retirement benefit obligations - Disclosure of changes in projected benefit obligation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "107",
     "firstAnchor": {
      "contextRef": "c-1238",
      "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1234",
      "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R108": {
     "role": "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails",
     "longName": "9955583 - Disclosure - Payables and other current liabilities - Disclosure of breakdown of trade and other payables (Details)",
     "shortName": "Payables and other current liabilities - Disclosure of breakdown of trade and other payables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "108",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R109": {
     "role": "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails",
     "longName": "9955584 - Disclosure - Payables and other current liabilities - Disclosure of tax and employee-related payables (Details)",
     "shortName": "Payables and other current liabilities - Disclosure of tax and employee-related payables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "109",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:ShorttermEmployeeBenefitsAccruals",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:ShorttermEmployeeBenefitsAccruals",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R110": {
     "role": "http://www.abivax.com/role/OtheroperatingincomeDisclosureofbreakdownofoperatingincomeDetails",
     "longName": "9955585 - Disclosure - Other operating income - Disclosure of breakdown of operating income (Details)",
     "shortName": "Other operating income - Disclosure of breakdown of operating income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "110",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "abvx:IncomeFromResearchTaxCredit",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "abvx:IncomeFromDepositaryServiceFees",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R111": {
     "role": "http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails",
     "longName": "9955586 - Disclosure - Other operating income - Narrative (Details)",
     "shortName": "Other operating income - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "111",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "abvx:IncomeFromResearchTaxCredit",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1244",
      "name": "abvx:IncomeFromResearchTaxCredit",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R112": {
     "role": "http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails",
     "longName": "9955587 - Disclosure - Operating expenses - Disclosure of sales and marketing expenses (Details)",
     "shortName": "Operating expenses - Disclosure of sales and marketing expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "112",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:OperatingExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1247",
      "name": "ifrs-full:EmployeeBenefitsExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R113": {
     "role": "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails",
     "longName": "9955588 - Disclosure - Operating expenses - Disclosure of research and development expenses (Details)",
     "shortName": "Operating expenses - Disclosure of research and development expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "113",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:OperatingExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1250",
      "name": "abvx:SubContractingStudiesAndResearchExpenses",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R114": {
     "role": "http://www.abivax.com/role/OperatingexpensesNarrativeDetails",
     "longName": "9955589 - Disclosure - Operating expenses - Narrative (Details)",
     "shortName": "Operating expenses - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "114",
     "firstAnchor": {
      "contextRef": "c-1250",
      "name": "abvx:IncreaseDecreaseInUlcerativeColitisExpenses",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1250",
      "name": "abvx:IncreaseDecreaseInUlcerativeColitisExpenses",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R115": {
     "role": "http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails",
     "longName": "9955590 - Disclosure - Operating expenses - Disclosure of general and administrative expenses (Details)",
     "shortName": "Operating expenses - Disclosure of general and administrative expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "115",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:OperatingExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1253",
      "name": "ifrs-full:EmployeeBenefitsExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R116": {
     "role": "http://www.abivax.com/role/OperatingexpensesDisclosureofprincipalauditfeesandservicesDetails",
     "longName": "9955591 - Disclosure - Operating expenses - Disclosure of principal audit fees and services (Details)",
     "shortName": "Operating expenses - Disclosure of principal audit fees and services (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "116",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AuditorsRemunerationForAuditServices",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AuditorsRemunerationForAuditServices",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R117": {
     "role": "http://www.abivax.com/role/EmployeesDetails",
     "longName": "9955592 - Disclosure - Employees (Details)",
     "shortName": "Employees (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "117",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AverageNumberOfEmployees",
      "unitRef": "employee",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AverageNumberOfEmployees",
      "unitRef": "employee",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R118": {
     "role": "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails",
     "longName": "9955593 - Disclosure - Financial gain (loss) - Disclosure of net financial income (loss) (Details)",
     "shortName": "Financial gain (loss) - Disclosure of net financial income (loss) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "118",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:InterestExpenseOnBonds",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:InterestExpenseOnBonds",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R119": {
     "role": "http://www.abivax.com/role/FinancialgainlossNarrativeDetails",
     "longName": "9955594 - Disclosure - Financial gain (loss) - Narrative (Details)",
     "shortName": "Financial gain (loss) - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "119",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:LossesOnChangeInFairValueOfDerivatives",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1260",
      "name": "ifrs-full:LossesOnChangeInFairValueOfDerivatives",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R120": {
     "role": "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails",
     "longName": "9955595 - Disclosure - Income tax - Disclosure of reconciliation of effective income tax (loss) (Details)",
     "shortName": "Income tax - Disclosure of reconciliation of effective income tax (loss) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "120",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AccountingProfit",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "abvx:DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AccountingProfit",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "abvx:DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R121": {
     "role": "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails",
     "longName": "9955596 - Disclosure - Income tax - Disclosure of deferred tax assets and liabilities by nature (Details)",
     "shortName": "Income tax - Disclosure of deferred tax assets and liabilities by nature (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "121",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:DeferredTaxAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:DeferredTaxLiabilityAsset",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R122": {
     "role": "http://www.abivax.com/role/IncometaxNarrativeDetails",
     "longName": "9955597 - Disclosure - Income tax - Narrative (Details)",
     "shortName": "Income tax - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "122",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:DeferredTaxLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R123": {
     "role": "http://www.abivax.com/role/IncomelosspershareScheduleofearningspershareDetails",
     "longName": "9955598 - Disclosure - Income (loss) per share - Schedule of earnings per share (Details)",
     "shortName": "Income (loss) per share - Schedule of earnings per share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "123",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:WeightedAverageShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "ifrs-full:AdjustedWeightedAverageShares",
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "ifrs-full:EarningsPerShareExplanatory",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R124": {
     "role": "http://www.abivax.com/role/IncomelosspershareNarrativeDetails",
     "longName": "9955599 - Disclosure - Income (loss) per share - Narrative (Details)",
     "shortName": "Income (loss) per share - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "124",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:NumberOfInstrumentsThatAreAntidilutiveInPeriodPresented",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:NumberOfInstrumentsThatAreAntidilutiveInPeriodPresented",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R125": {
     "role": "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails",
     "longName": "9955600 - Disclosure - Related parties - Disclosure of aggregate compensation of the members of the Group\u2019s Board of Directors and CEO (Details)",
     "shortName": "Related parties - Disclosure of aggregate compensation of the members of the Group\u2019s Board of Directors and CEO (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "125",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "abvx:KeyManagementPersonnelCompensationFixedCompensation",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "abvx:KeyManagementPersonnelCompensationFixedCompensation",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R126": {
     "role": "http://www.abivax.com/role/RelatedpartiesNarrativeDetails",
     "longName": "9955601 - Disclosure - Related parties - Narrative (Details)",
     "shortName": "Related parties - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "126",
     "firstAnchor": {
      "contextRef": "c-1290",
      "name": "ifrs-full:RecognisedLiabilitiesDefinedBenefitPlan",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1290",
      "name": "ifrs-full:RecognisedLiabilitiesDefinedBenefitPlan",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R127": {
     "role": "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails",
     "longName": "9955602 - Disclosure - Off-balance sheet commitments given (Details)",
     "shortName": "Off-balance sheet commitments given (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "127",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "abvx:RepaymentsOfConditionalAdvances",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:CapitalCommitments",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    },
    "R128": {
     "role": "http://www.abivax.com/role/OffbalancesheetcommitmentsreceivedandcontingentassetsDetails",
     "longName": "9955603 - Disclosure - Off-balance sheet commitments received and contingent assets (Details)",
     "shortName": "Off-balance sheet commitments received and contingent assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "128",
     "firstAnchor": {
      "contextRef": "c-1310",
      "name": "abvx:NumberOfProjectsTerminated",
      "unitRef": "project",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1310",
      "name": "abvx:NumberOfProjectsTerminated",
      "unitRef": "project",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R129": {
     "role": "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails",
     "longName": "9955604 - Disclosure - Management and assessment of financial risks (Details)",
     "shortName": "Management and assessment of financial risks (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "129",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:Assets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1313",
      "name": "abvx:InterestRateCollarRange",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abvx-20251231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "abvx_A130.0MillionCrossOverFinancingFebruary2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "A130.0MillionCrossOverFinancingFebruary2023Member",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "\u20ac130.0\u00a0million cross-over financing, february 2023",
        "label": "\u20ac130.0\u00a0Million Cross-Over Financing, February 2023 [Member]",
        "documentation": "\u20ac130.0\u00a0Million Cross-Over Financing, February 2023"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_A150.0MillionFinancingAugust2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "A150.0MillionFinancingAugust2023Member",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "\u20ac150.0\u00a0million financing, august 2023",
        "label": "\u20ac150.0\u00a0Million Financing, August 2023 [Member]",
        "documentation": "\u20ac150.0\u00a0Million Financing, August 2023"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_A2021TaxYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "A2021TaxYearMember",
     "presentation": [
      "http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Year 2021",
        "label": "2021, Tax Year [Member]",
        "documentation": "Tax Year 2021"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_A2022TaxYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "A2022TaxYearMember",
     "presentation": [
      "http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Year 2022",
        "label": "2022, Tax Year [Member]",
        "documentation": "Tax Year 2022"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_A2023TaxYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "A2023TaxYearMember",
     "presentation": [
      "http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Year 2023",
        "label": "2023, Tax Year [Member]",
        "documentation": "Tax Year 2023"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_A2024TaxYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "A2024TaxYearMember",
     "presentation": [
      "http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Year 2024",
        "label": "2024, Tax Year [Member]",
        "documentation": "2024, Tax Year"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_A49.2MillionCrossOverFinancingSeptember2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "A49.2MillionCrossOverFinancingSeptember2022Member",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "\u20ac49.2 million cross-over financing, september 2022",
        "label": "\u20ac49.2\u00a0Million Cross-Over Financing, September 2022 [Member]",
        "documentation": "\u20ac49.2\u00a0Million Cross-Over Financing, September 2022"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AGA20231Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AGA20231Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA-2023-1",
        "label": "AGA-2023-1 [Member]",
        "documentation": "AGA-2023-1"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AGA20232Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AGA20232Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA-2023-2",
        "label": "AGA-2023-2 [Member]",
        "documentation": "AGA-2023-2"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AGA20233AGA20234AndAGA20235Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AGA20233AGA20234AndAGA20235Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA-2023-3 , AGA-2023-4 and AGA-2023-5",
        "label": "AGA-2023-3 , AGA-2023-4 And AGA-2023-5 [Member]",
        "documentation": "AGA-2023-3 , AGA-2023-4 And AGA-2023-5"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AGA20233AndAGA20234Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AGA20233AndAGA20234Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA-2023-3 and AGA-2023-4",
        "label": "AGA-2023-3 And AGA-2023-4 [Member]",
        "documentation": "AGA-2023-3 And AGA-2023-4"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AGA20233Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AGA20233Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA-2023-3",
        "label": "AGA-2023-3 [Member]",
        "documentation": "AGA-2023-3"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AGA20234Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AGA20234Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA-2023-4",
        "label": "AGA-2023-4 [Member]",
        "documentation": "AGA-2023-4"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AGA20235Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AGA20235Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA-2023-5",
        "label": "AGA-2023-5 [Member]",
        "documentation": "AGA-2023-5"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AGA20241AGE20242AGA20243AGA20244AGA20245AndAGA20247Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AGA20241AGE20242AGA20243AGA20244AGA20245AndAGA20247Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA-2024-1, AGE-2024-2, AGA-2024-3, AGA-2024-4, AGA-2024-5 and AGA-2024-7",
        "label": "AGA-2024-1, AGE-2024-2, AGA-2024-3, AGA-2024-4, AGA-2024-5 and AGA-2024-7 [Member]",
        "documentation": "AGA-2024-1, AGE-2024-2, AGA-2024-3, AGA-2024-4, AGA-2024-5 and AGA-2024-7"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AGA20241Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AGA20241Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA-2024-1",
        "label": "AGA-2024-1 [Member]",
        "documentation": "AGA-2024-1"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AGA20242Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AGA20242Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA-2024-2",
        "label": "AGA-2024-2 [Member]",
        "documentation": "AGA-2024-2"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AGA20243Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AGA20243Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA-2024-3",
        "label": "AGA-2024-3 [Member]",
        "documentation": "AGA-2024-3"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AGA20244AGA20245AndAGA20246Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AGA20244AGA20245AndAGA20246Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA-2024-4, AGA-2024-5 and AGA-2024-6",
        "label": "AGA-2024-4, AGA-2024-5 and AGA-2024-6 [Member]",
        "documentation": "AGA-2024-4, AGA-2024-5 and AGA-2024-6"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AGA20244Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AGA20244Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA-2024-4",
        "label": "AGA-2024-4 [Member]",
        "documentation": "AGA-2024-4"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AGA20245Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AGA20245Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA-2024-5",
        "label": "AGA-2024-5 [Member]",
        "documentation": "AGA-2024-5"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AGA20246Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AGA20246Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA-2024-6",
        "label": "AGA-2024-6 [Member]",
        "documentation": "AGA-2024-6"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AGA20247Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AGA20247Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA-2024-7",
        "label": "AGA-2024-7 [Member]",
        "documentation": "AGA-2024-7"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AGA2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AGA2024Member",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA-2024",
        "label": "AGA-2024 [Member]",
        "documentation": "AGA-2024"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AGA20251AGA20253AGA20254AGA20256AGA20257AndAGA20258Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AGA20251AGA20253AGA20254AGA20256AGA20257AndAGA20258Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA-2025-1, AGA-2025-3, AGA-2025-4, AGA-2025-6, AGA-2025-7 and AGA-2025-8",
        "label": "AGA-2025-1, AGA-2025-3, AGA-2025-4, AGA-2025-6, AGA-2025-7 and AGA-2025-8 [Member]",
        "documentation": "AGA-2025-1, AGA-2025-3, AGA-2025-4, AGA-2025-6, AGA-2025-7 and AGA-2025-8"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AGA20251Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AGA20251Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA-2025-1",
        "label": "AGA-2025-1 [Member]",
        "documentation": "AGA-2025-1"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AGA20252Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AGA20252Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA-2025-2",
        "label": "AGA-2025-2 [Member]",
        "documentation": "AGA-2025-2"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AGA20253Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AGA20253Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA-2025-3",
        "label": "AGA-2025-3 [Member]",
        "documentation": "AGA-2025-3"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AGA20254Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AGA20254Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA-2025-4",
        "label": "AGA-2025-4 [Member]",
        "documentation": "AGA-2025-4"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AGA20255Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AGA20255Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA-2025-5",
        "label": "AGA-2025-5 [Member]",
        "documentation": "AGA-2025-5"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AGA20256Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AGA20256Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA-2025-6",
        "label": "AGA-2025-6 [Member]",
        "documentation": "AGA-2025-6"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AGA20257Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AGA20257Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA-2025-7",
        "label": "AGA-2025-7 [Member]",
        "documentation": "AGA-2025-7"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AGA20258Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AGA20258Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA-2025-8",
        "label": "AGA-2025-8 [Member]",
        "documentation": "AGA-2025-8"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AGA2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AGA2025Member",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA-2025",
        "label": "AGA-2025 [Member]",
        "documentation": "AGA-2025"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AbivaxLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AbivaxLLCMember",
     "presentation": [
      "http://www.abivax.com/role/IncometaxNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Abivax LLC",
        "label": "Abivax LLC [Member]",
        "documentation": "Abivax LLC"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AccountingPrinciplesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AccountingPrinciplesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Principles [Abstract]",
        "label": "Accounting Principles [Abstract]",
        "documentation": "Accounting Principles [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AccountingProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AccountingProfit",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss before tax",
        "label": "Accounting profit"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r2",
      "r3",
      "r201",
      "r202"
     ]
    },
    "ifrs-full_AccrualsClassifiedAsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AccrualsClassifiedAsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued invoices",
        "label": "Accruals classified as current"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of accruals classified as current. [Refer: Accruals]"
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember",
     "presentation": [
      "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AMORTIZATION",
        "label": "Accumulated depreciation, amortisation and impairment [member]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r12",
      "r57",
      "r68",
      "r71",
      "r207",
      "r238",
      "r247",
      "r250"
     ]
    },
    "ifrs-full_AccumulatedDepreciationAndAmortisationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AccumulatedDepreciationAndAmortisationMember",
     "presentation": [
      "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DEPRECIATION",
        "label": "Accumulated depreciation and amortisation [member]"
       }
      }
     },
     "auth_ref": [
      "r12",
      "r493",
      "r499",
      "r502",
      "r503"
     ]
    },
    "ifrs-full_ActuarialAssumptionOfDiscountRates": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ActuarialAssumptionOfDiscountRates",
     "presentation": [
      "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount Rate (IBoxx Corporates AA)",
        "label": "Actuarial assumption of discount rates"
       }
      },
      "en": {
       "role": {
        "documentation": "The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [domain]]"
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "abvx_ActuarialAssumptionOfEmployeeContributionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ActuarialAssumptionOfEmployeeContributionRate",
     "presentation": [
      "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee contribution rate",
        "label": "Actuarial Assumption Of Employee Contribution Rate",
        "documentation": "Actuarial Assumption Of Employee Contribution Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ActuarialAssumptionOfExpectedRatesOfSalaryIncreases",
     "presentation": [
      "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Salary increase rate",
        "label": "Actuarial assumption of expected rates of salary increases"
       }
      },
      "en": {
       "role": {
        "documentation": "The expected rate of salary increases used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [domain]; Defined benefit obligation, at present value; Actuarial assumptions [domain]]"
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "abvx_ActuarialAssumptionOfExpectedRatesOfTurnover": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ActuarialAssumptionOfExpectedRatesOfTurnover",
     "presentation": [
      "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Turnover rate",
        "label": "Actuarial Assumption Of Expected Rates Of Turnover",
        "documentation": "Actuarial Assumption Of Expected Rates Of Turnover"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ActuarialAssumptionOfExpectedRatesOfTurnoverAverageExitRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ActuarialAssumptionOfExpectedRatesOfTurnoverAverageExitRate",
     "presentation": [
      "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Turnover rate, average exit rate",
        "label": "Actuarial Assumption Of Expected Rates Of Turnover, Average Exit Rate",
        "documentation": "Actuarial Assumption Of Expected Rates Of Turnover, Average Exit Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ActuarialAssumptionOfRetirementAge2019": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ActuarialAssumptionOfRetirementAge2019",
     "presentation": [
      "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement age",
        "label": "Actuarial assumption of retirement age"
       }
      },
      "en": {
       "role": {
        "documentation": "The retirement age used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [domain]]"
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition",
        "label": "Additions other than through business combinations, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r58",
      "r239"
     ]
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition",
        "label": "Additions other than through business combinations, property, plant and equipment including right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment including right-of-use assets other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Address Type [Domain]",
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustedWeightedAverageShares",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS",
      "http://www.abivax.com/role/IncomelosspershareScheduleofearningspershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average number of outstanding shares used for computing diluted loss per share (in shares)",
        "terseLabel": "Weighted average number of outstanding shares, diluted loss per share (in shares)",
        "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease / (increase) in other receivables and related accounts",
        "label": "Adjustments for decrease (increase) in trade and other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForDepreciationAndAmortisationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangibles and depreciation of property, plant and equipment",
        "label": "Adjustments for depreciation and amortisation expense"
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "ifrs-full_AdjustmentsForFairValueGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForFairValueGainsLosses",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase/(decrease) in derivatives and liabilities measured at fair value",
        "label": "Adjustments for fair value losses (gains)"
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "abvx_AdjustmentsForForgivenessOfConditionalAdvances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AdjustmentsForForgivenessOfConditionalAdvances",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgiveness of conditional advances",
        "label": "Adjustments For Forgiveness Of Conditional Advances",
        "documentation": "Adjustments For Forgiveness Of Conditional Advances"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForIncomeTaxExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForIncomeTaxExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current and deferred taxes expenses",
        "label": "Adjustments for income tax expense"
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "abvx_AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in deferred income and other liabilities",
        "label": "Adjustments For Increase (Decrease) In Deferred Income And Other Liabilities",
        "documentation": "Adjustments For Increase (Decrease) In Deferred Income And Other Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement benefit obligations",
        "label": "Adjustments for increase (decrease) in employee benefit liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in employee benefit liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "abvx_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase / (decrease) in tax and social security liabilities",
        "label": "Adjustments For Increase (Decrease) In Tax And Social Security Liabilities",
        "documentation": "Adjustments For Increase (Decrease) In Tax And Social Security Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase / (decrease) in trade payables",
        "label": "Adjustments for increase (decrease) in trade accounts payable"
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "abvx_AdjustmentsForNetGainOnSaleOfTreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AdjustmentsForNetGainOnSaleOfTreasuryShares",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net gain on sale of treasury shares",
        "label": "Adjustments For Net Gain On Sale Of Treasury Shares",
        "documentation": "Adjustments For Net Gain On Sale Of Treasury Shares"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AdjustmentsForOtherFinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AdjustmentsForOtherFinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expenses and other financial expenses",
        "label": "Adjustments For Other Finance Costs",
        "documentation": "Adjustments For Other Finance Costs"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AdjustmentsForOtherFinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AdjustmentsForOtherFinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Financial income",
        "label": "Adjustments For Other Finance Income",
        "documentation": "Adjustments For Other Finance Income"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForProvisions",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in provisions",
        "label": "Adjustments for provisions"
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments for:",
        "label": "Adjustments to reconcile profit (loss) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expenses",
        "label": "Adjustments for share-based payments"
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "abvx_AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of unwinding the discount related to advances",
        "label": "Adjustments For Unwinding Of Discount Related To Conditional Advances",
        "documentation": "Adjustments For Unwinding Of Discount Related To Conditional Advances"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AdvisorToTheChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AdvisorToTheChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.abivax.com/role/RelatedpartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advisor to the Chief Executive Officer",
        "label": "Advisor To The Chief Executive Officer [Member]",
        "documentation": "Advisor To The Chief Executive Officer"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_After18MonthsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "After18MonthsMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After 18 months",
        "label": "After 18 Months [Member]",
        "documentation": "After 18 Months"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_After24MonthsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "After24MonthsMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After 24 months",
        "label": "After 24 Months [Member]",
        "documentation": "After 24 Months"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_After36MonthsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "After36MonthsMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After 36 months",
        "label": "After 36 Months [Member]",
        "documentation": "After 36 Months"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AggregateExercisePriceOtherEquityInstrumentsGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AggregateExercisePriceOtherEquityInstrumentsGranted",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate exercise price",
        "label": "Aggregate Exercise Price, Other Equity Instruments Granted",
        "documentation": "Aggregate Exercise Price, Other Equity Instruments Granted"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AggregateFairValueConvertibleNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AggregateFairValueConvertibleNotes",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of convertible notes",
        "label": "Aggregate Fair Value, Convertible Notes",
        "documentation": "Aggregate Fair Value, Convertible Notes"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AggregateFairValueOtherEquityInstrumentsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AggregateFairValueOtherEquityInstrumentsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of other equity instruments",
        "label": "Aggregate Fair Value, Other Equity Instruments Outstanding",
        "documentation": "Aggregate Fair Value, Other Equity Instruments Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r398",
      "r409",
      "r419",
      "r452"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r401",
      "r412",
      "r422",
      "r455"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "abvx_AgreementPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AgreementPeriod",
     "presentation": [
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement, period",
        "label": "Agreement, Period",
        "documentation": "Agreement, Period"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2025",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://www.abivax.com/role/CashandcashequivalentsNarrativeDetails",
      "http://www.abivax.com/role/FinancialgainlossNarrativeDetails",
      "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Currencies [Domain]",
        "label": "All Currencies [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r402",
      "r413",
      "r423",
      "r447",
      "r456",
      "r460",
      "r468"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AmericanDepositorySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AmericanDepositorySharesMember",
     "presentation": [
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ADS",
        "label": "American Depository Shares [Member]",
        "documentation": "American Depository Shares"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AmericanDepositorySharesNASDAQGlobalMarketMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AmericanDepositorySharesNASDAQGlobalMarketMember",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "American Depositary Shares, each representing one ordinary share, nominal value \u20ac0.01 per share",
        "label": "American Depository Shares, NASDAQ Global Market [Member]",
        "documentation": "American Depository Shares, NASDAQ Global Select Market [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AmortisationIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Increase",
        "label": "Amortisation, intangible assets other than goodwill"
       }
      }
     },
     "auth_ref": [
      "r60",
      "r241"
     ]
    },
    "abvx_AmortizedCostEIRMethodMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AmortizedCostEIRMethodMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized cost (EIR method)",
        "label": "Amortized Cost (EIR Method) [Member]",
        "documentation": "Amortized Cost (EIR Method)"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AmountOfReasonablyPossibleDecreaseInUnobservableInputLiabilities": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AmountOfReasonablyPossibleDecreaseInUnobservableInputLiabilities",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amount of reasonably possible decrease in unobservable input, liabilities (in euro per share)",
        "label": "Amount Of Reasonably Possible Decrease In Unobservable Input, Liabilities",
        "documentation": "Amount Of Reasonably Possible Decrease In Unobservable Input, Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails",
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of reasonably possible increase in unobservable input, liabilities (in euro per share)",
        "label": "Amount Of Reasonably Possible Increase In Unobservable Input, Liabilities",
        "documentation": "Amount Of Reasonably Possible Increase In Unobservable Input, Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ApplicableTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ApplicableTaxRate",
     "presentation": [
      "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory French tax rate",
        "label": "Applicable tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r202"
     ]
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails",
      "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "terseLabel": "Financial assets",
        "verboseLabel": "Assets",
        "label": "Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104",
      "r106",
      "r165",
      "r167",
      "r270",
      "r271",
      "r296"
     ]
    },
    "ifrs-full_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AssetsAcquisitionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AssetsAcquisitionsAxis",
     "presentation": [
      "http://www.abivax.com/role/IntangibleassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets Acquisitions [Axis]",
        "label": "Assets Acquisitions [Axis]",
        "documentation": "Assets Acquisitions"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AssetsAcquisitionsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AssetsAcquisitionsDomain",
     "presentation": [
      "http://www.abivax.com/role/IntangibleassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets Acquisitions [Domain]",
        "label": "Assets Acquisitions [Domain]",
        "documentation": "Assets Acquisitions [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_AtTheMarketATMProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AtTheMarketATMProgramMember",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-The-Market (ATM) Program",
        "label": "At-The-Market (ATM) Program [Member]",
        "documentation": "At-The-Market (ATM) Program"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis",
     "presentation": [
      "http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails",
      "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails",
      "http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails",
      "http://www.abivax.com/role/OperatingexpensesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attribution of expenses by nature to their function [axis]",
        "label": "Attribution of expenses by nature to their function [axis]"
       }
      }
     },
     "auth_ref": [
      "r516",
      "r519"
     ]
    },
    "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AttributionOfExpensesByNatureToTheirFunctionDomain",
     "presentation": [
      "http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails",
      "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails",
      "http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails",
      "http://www.abivax.com/role/OperatingexpensesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attribution of expenses by nature to their function [domain]",
        "label": "Attribution of expenses by nature to their function [domain]"
       }
      }
     },
     "auth_ref": [
      "r516",
      "r519"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.abivax.com/role/Auditorinformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r381",
      "r382",
      "r405"
     ]
    },
    "abvx_AuditorInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AuditorInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Information [Abstract]",
        "documentation": "Auditor Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.abivax.com/role/Auditorinformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r381",
      "r382",
      "r405"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://www.abivax.com/role/Auditorinformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r381",
      "r382",
      "r405"
     ]
    },
    "ifrs-full_AuditorsRemuneration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AuditorsRemuneration",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/OperatingexpensesDisclosureofprincipalauditfeesandservicesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abivax.com/role/OperatingexpensesDisclosureofprincipalauditfeesandservicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total auditor's remuneration",
        "label": "Auditor's remuneration"
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "abvx_AuditorsRemunerationForAuditRelatedFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "AuditorsRemunerationForAuditRelatedFees",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/OperatingexpensesDisclosureofprincipalauditfeesandservicesDetails": {
       "parentTag": "ifrs-full_AuditorsRemuneration",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/OperatingexpensesDisclosureofprincipalauditfeesandservicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Audit-related fees",
        "label": "Auditor's Remuneration For Audit-Related Fees",
        "documentation": "Auditor's Remuneration For Audit-Related Fees"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AuditorsRemunerationForAuditServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AuditorsRemunerationForAuditServices",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/OperatingexpensesDisclosureofprincipalauditfeesandservicesDetails": {
       "parentTag": "ifrs-full_AuditorsRemuneration",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/OperatingexpensesDisclosureofprincipalauditfeesandservicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Audit fees",
        "label": "Auditor's remuneration for audit services"
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "ifrs-full_AuditorsRemunerationForOtherServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AuditorsRemunerationForOtherServices",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/OperatingexpensesDisclosureofprincipalauditfeesandservicesDetails": {
       "parentTag": "ifrs-full_AuditorsRemuneration",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/OperatingexpensesDisclosureofprincipalauditfeesandservicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All other fees",
        "label": "Auditor's remuneration for other services"
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "ifrs-full_AuditorsRemunerationForTaxServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AuditorsRemunerationForTaxServices",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/OperatingexpensesDisclosureofprincipalauditfeesandservicesDetails": {
       "parentTag": "ifrs-full_AuditorsRemuneration",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/OperatingexpensesDisclosureofprincipalauditfeesandservicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax fees",
        "label": "Auditor's remuneration for tax services"
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "ifrs-full_AverageNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AverageNumberOfEmployees",
     "presentation": [
      "http://www.abivax.com/role/EmployeesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average number of employees",
        "label": "Average number of employees"
       }
      },
      "en": {
       "role": {
        "documentation": "The average number of personnel employed by the entity during a period."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "abvx_BCE20161Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BCE20161Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BCE-2016-1",
        "label": "BCE-2016-1 [Member]",
        "documentation": "BCE-2016-1"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BCE20171Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BCE20171Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BCE-2017-1",
        "label": "BCE-2017-1 [Member]",
        "documentation": "BCE-2017-1"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BCE20172Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BCE20172Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BCE-2017-2",
        "label": "BCE-2017-2 [Member]",
        "documentation": "BCE-2017-2"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BCE20174Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BCE20174Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BCE-2017-4",
        "label": "BCE-2017-4 [Member]",
        "documentation": "BCE-2017-4"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BCE20175Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BCE20175Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BCE-2017-5",
        "label": "BCE-2017-5 [Member]",
        "documentation": "BCE-2017-5"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BCE20181Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BCE20181Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BCE-2018-1",
        "label": "BCE-2018-1 [Member]",
        "documentation": "BCE-2018-1"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BCE20184Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BCE20184Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BCE-2018-4",
        "label": "BCE-2018-4 [Member]",
        "documentation": "BCE-2018-4"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BCE20185Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BCE20185Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BCE-2018-5",
        "label": "BCE-2018-5 [Member]",
        "documentation": "BCE-2018-5"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BCEExceptBCE20142Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BCEExceptBCE20142Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BCE except BCE 2014-2",
        "label": "BCE Except BCE 2014-2 [Member]",
        "documentation": "BCE Except BCE 2014-2"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BSA201511Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BSA201511Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSA-2015-11",
        "label": "BSA-2015-11 [Member]",
        "documentation": "BSA-2015-11"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BSA201512Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BSA201512Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSA-2015-12",
        "label": "BSA-2015-12 [Member]",
        "documentation": "BSA-2015-12"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BSA20171Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BSA20171Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSA-2017-1",
        "label": "BSA-2017-1 [Member]",
        "documentation": "BSA-2017-1"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BSA20181Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BSA20181Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSA-2018-1",
        "label": "BSA-2018-1 [Member]",
        "documentation": "BSA-2018-1"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BSA20241AndBSA20242Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BSA20241AndBSA20242Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails",
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSA-2024-1 and BSA-2024-2",
        "label": "BSA-2024-1 And BSA-2024-2 [Member]",
        "documentation": "BSA-2024-1 And BSA-2024-2"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BSA20241Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BSA20241Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSA-2024-1",
        "label": "BSA-2024-1 [Member]",
        "documentation": "BSA-2024-1"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BSA20242Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BSA20242Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSA-2024-2",
        "label": "BSA-2024-2 [Member]",
        "documentation": "BSA-2024-2"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BSA20251AndBSA20252Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BSA20251AndBSA20252Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSA-2025-1 and BSA-2025-2",
        "label": "BSA-2025-1 And BSA-2025-2 [Member]",
        "documentation": "BSA-2025-1 And BSA-2025-2"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BSA20251Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BSA20251Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSA-2025-1",
        "label": "BSA-2025-1 [Member]",
        "documentation": "BSA-2025-1"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BSA20252Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BSA20252Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSA-2025-2",
        "label": "BSA-2025-2 [Member]",
        "documentation": "BSA-2025-2"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BSA20253Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BSA20253Member",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSA-2025-3",
        "label": "BSA-2025-3 [Member]",
        "documentation": "BSA-2025-3"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BalancesWithBanksInExcessOfLegallyInsuredLimit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BalancesWithBanksInExcessOfLegallyInsuredLimit",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balances with banks in excess of legally insured limit",
        "label": "Balances With Banks In Excess Of Legally Insured Limit",
        "documentation": "Balances With Banks In Excess Of Legally Insured Limit"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BankBorrowingsUndiscountedCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BankBorrowingsUndiscountedCashFlows",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": {
       "parentTag": "abvx_FinancialLiabilitiesUndiscountedCashFlows",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings, undiscounted cash flows",
        "label": "Bank borrowings, undiscounted cash flows"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to bank borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r356",
      "r359"
     ]
    },
    "abvx_BanquePubliqueDInvestissementBPIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BanquePubliqueDInvestissementBPIMember",
     "presentation": [
      "http://www.abivax.com/role/BasisofpreparationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conditional advances Bpifrance",
        "label": "Banque Publique d\u2019Investissement (BPI) [Member]",
        "documentation": "Banque Publique d\u2019Investissement (BPI)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS",
      "http://www.abivax.com/role/IncomelosspershareScheduleofearningspershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic loss per share (in euro per share)",
        "label": "Basic earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41"
     ]
    },
    "abvx_BlackScholesModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BlackScholesModelMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Black Scholes Model",
        "label": "Black Scholes Model [Member]",
        "documentation": "Black Scholes Model"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BoardMemberMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BoardMemberMember",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Board member",
        "label": "Board Member [Member]",
        "documentation": "Board Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BoardOfDirectorsAndChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BoardOfDirectorsAndChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.abivax.com/role/RelatedpartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Board of Directors and Chief Executive Officer",
        "label": "Board Of Directors And Chief Executive Officer [Member]",
        "documentation": "Board Of Directors And Chief Executive Officer"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Borrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Borrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Borrowings",
        "terseLabel": "Borrowings",
        "label": "Borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of outstanding funds that the entity is obligated to repay."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "abvx_Borrowings1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "Borrowings1Member",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings",
        "label": "Borrowings1 [Member]",
        "documentation": "Borrowings by name"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BorrowingsAdditionalTrancheAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BorrowingsAdditionalTrancheAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreos2Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings, additional tranche mount",
        "label": "Borrowings, Additional Tranche Amount",
        "documentation": "Borrowings, Additional Tranche Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BorrowingsAdjustmentToInterestRateBasis": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BorrowingsAdjustmentToInterestRateBasis",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings, adjustment to interest rate basis",
        "label": "Borrowings, adjustment to interest rate basis"
       }
      },
      "en": {
       "role": {
        "documentation": "The adjustment to the basis (reference rate) used for calculation of the interest rate on borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "abvx_BorrowingsBasisInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BorrowingsBasisInterestRate",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings, interest rate basis",
        "label": "Borrowings, Basis Interest Rate",
        "documentation": "Borrowings, Basis Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BorrowingsByNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BorrowingsByNameAxis",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreos1Details",
      "http://www.abivax.com/role/FinancialliabilitiesKreos2Details",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails",
      "http://www.abivax.com/role/FinancialliabilitiesStateguaranteedloanPGEDetails",
      "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails",
      "http://www.abivax.com/role/OffbalancesheetcommitmentsreceivedandcontingentassetsDetails",
      "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails",
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings by name [axis]",
        "label": "Borrowings by name [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "ifrs-full_BorrowingsByNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BorrowingsByNameDomain",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreos1Details",
      "http://www.abivax.com/role/FinancialliabilitiesKreos2Details",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails",
      "http://www.abivax.com/role/FinancialliabilitiesStateguaranteedloanPGEDetails",
      "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails",
      "http://www.abivax.com/role/OffbalancesheetcommitmentsreceivedandcontingentassetsDetails",
      "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails",
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings by name [domain]",
        "label": "Borrowings by name [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "abvx_BorrowingsDebtToMarketCapitalizationRatio": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BorrowingsDebtToMarketCapitalizationRatio",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings, debt-to-market capitalization ratio",
        "label": "Borrowings, Debt-To-Market Capitalization Ratio",
        "documentation": "Borrowings, Debt-To-Market Capitalization Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BorrowingsDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BorrowingsDeposit",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposit paid, borrowing",
        "label": "Borrowings, Deposit",
        "documentation": "Borrowings, Deposit"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BorrowingsDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BorrowingsDiscountRate",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings, discount rate",
        "label": "Borrowings, Discount Rate",
        "documentation": "Borrowings, Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BorrowingsEarlyRepaymentDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BorrowingsEarlyRepaymentDiscountRate",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings, early repayment, discount rate",
        "label": "Borrowings, Early Repayment, Discount Rate",
        "documentation": "Borrowings, Early Repayment, Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BorrowingsExitFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BorrowingsExitFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings, exit fee amount",
        "label": "Borrowings, Exit Fee Amount",
        "documentation": "Borrowings, Exit Fee Amount"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BorrowingsExitFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BorrowingsExitFeePercentage",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings, exit fee percentage",
        "label": "Borrowings, Exit Fee Percentage",
        "documentation": "Borrowings, Exit Fee Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BorrowingsFixedConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BorrowingsFixedConversionPrice",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings, fixed conversion price (in euro per share)",
        "label": "Borrowings, Fixed Conversion Price",
        "documentation": "Borrowings, Fixed Conversion Price"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BorrowingsInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BorrowingsInterestRate",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/FinancialliabilitiesStateguaranteedloanPGEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings, interest rate",
        "label": "Borrowings, interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The interest rate on borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "abvx_BorrowingsMarketPriceNumberOfDaysWithLowestDailyVWAP": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BorrowingsMarketPriceNumberOfDaysWithLowestDailyVWAP",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings, market price, number of days with lowest daily VWAP",
        "label": "Borrowings, Market Price, Number Of Days With Lowest Daily VWAP",
        "documentation": "Borrowings, Market Price, Number Of Days With Lowest Daily VWAP"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BorrowingsMarketPriceNumberOfTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BorrowingsMarketPriceNumberOfTradingDays",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings, market price, number of trading days",
        "label": "Borrowings, Market Price, Number Of Trading Days",
        "documentation": "Borrowings, Market Price, Number Of Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BorrowingsMaturityDeferralPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BorrowingsMaturityDeferralPeriod",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesStateguaranteedloanPGEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings maturity, deferral period",
        "label": "Borrowings Maturity, Deferral Period",
        "documentation": "Borrowings Maturity, Deferral Period"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BorrowingsMaturityExtensionTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BorrowingsMaturityExtensionTerm",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesStateguaranteedloanPGEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings maturity, extension term",
        "label": "Borrowings Maturity, Extension Term",
        "documentation": "Borrowings Maturity, Extension Term"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BorrowingsMaturityTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BorrowingsMaturityTerm",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesStateguaranteedloanPGEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings, maturity term",
        "label": "Borrowings Maturity, Term",
        "documentation": "Borrowings Maturity, Term"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BorrowingsMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BorrowingsMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreos1Details",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings, maximum borrowing capacity",
        "label": "Borrowings, Maximum Borrowing Capacity",
        "documentation": "Borrowings, Maximum Borrowing Capacity"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BorrowingsMaximumBorrowingCapacityPerTranche": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BorrowingsMaximumBorrowingCapacityPerTranche",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreos1Details",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings, maximum borrowing capacity per tranche",
        "label": "Borrowings, Maximum Borrowing Capacity Per Tranche",
        "documentation": "Borrowings, Maximum Borrowing Capacity Per Tranche"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BorrowingsNumberOfQuarterlyInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BorrowingsNumberOfQuarterlyInstallments",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings, number of quarterly installments",
        "label": "Borrowings, Number Of Quarterly Installments",
        "documentation": "Borrowings, Number Of Quarterly Installments"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BorrowingsNumberOfTranches": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BorrowingsNumberOfTranches",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreos1Details",
      "http://www.abivax.com/role/FinancialliabilitiesKreos2Details",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings, number of tranches",
        "label": "Borrowings, Number Of Tranches",
        "documentation": "Borrowings, Number Of Tranches"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BorrowingsPercentageOfMarketPrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BorrowingsPercentageOfMarketPrice",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings, percentage of market price",
        "label": "Borrowings, Percentage Of Market Price",
        "documentation": "Borrowings, Percentage Of Market Price"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BorrowingsPerformanceConditionsMinimumFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BorrowingsPerformanceConditionsMinimumFinancing",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance conditions, minimum financing",
        "label": "Borrowings, Performance Conditions, Minimum Financing",
        "documentation": "Borrowings, Performance Conditions, Minimum Financing"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_BorrowingsStateGuaranteedPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "BorrowingsStateGuaranteedPremium",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesStateguaranteedloanPGEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings, state guaranteed premium",
        "label": "Borrowings, State Guaranteed Premium",
        "documentation": "Borrowings, State Guaranteed Premium"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails",
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails",
      "http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails",
      "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bottom of range",
        "label": "Bottom of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r109",
      "r122",
      "r130",
      "r195",
      "r342",
      "r344",
      "r514"
     ]
    },
    "ifrs-full_BuildingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BuildingsMember",
     "presentation": [
      "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails",
      "http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BUILDINGS",
        "verboseLabel": "Buildings",
        "label": "Buildings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of plant, property and equipment representing depreciable buildings and similar structures for use in operations. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Contact",
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r382",
      "r405"
     ]
    },
    "abvx_CARENAConditionalAdvanceBPIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "CARENAConditionalAdvanceBPIMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofconditionaladvancesDetails",
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails",
      "http://www.abivax.com/role/OffbalancesheetcommitmentsreceivedandcontingentassetsDetails",
      "http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CARENA conditional advance",
        "verboseLabel": "CARENA \u2013 Bpifrance",
        "label": "CARENA Conditional Advance, BPI [Member]",
        "documentation": "CARENA Conditional Advance, BPI"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_CIRTaxYearAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "CIRTaxYearAxis",
     "presentation": [
      "http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CIR Tax Year [Axis]",
        "label": "CIR Tax Year [Axis]",
        "documentation": "CIR Tax Year"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_CIRTaxYearDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "CIRTaxYearDomain",
     "presentation": [
      "http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CIR Tax Year [Domain]",
        "label": "CIR Tax Year [Domain]",
        "documentation": "CIR Tax Year [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_CSOSettlementAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "CSOSettlementAgreementMember",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CSO, settlement agreement",
        "label": "CSO, Settlement Agreement [Member]",
        "documentation": "CSO, Settlement Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CapitalCommitments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CapitalCommitments",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital commitments",
        "label": "Capital commitments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of future capital expenditures that the entity is committed to make."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
     "presentation": [
      "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails",
      "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails",
      "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]",
        "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r57",
      "r61",
      "r67",
      "r68",
      "r69",
      "r70",
      "r71",
      "r137",
      "r145",
      "r146",
      "r207",
      "r208",
      "r238",
      "r242",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r256",
      "r264",
      "r265"
     ]
    },
    "ifrs-full_CarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CarryingAmountMember",
     "presentation": [
      "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails",
      "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails",
      "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount [member]",
        "label": "Carrying amount [member]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r61",
      "r67",
      "r69",
      "r70",
      "r137",
      "r145",
      "r146",
      "r208",
      "r242",
      "r246",
      "r248",
      "r249",
      "r256",
      "r264",
      "r265"
     ]
    },
    "ifrs-full_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CashandcashequivalentsDisclosureofcompositionofcashandcashequivalentsDetails": {
       "parentTag": "ifrs-full_CashAndCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CashandcashequivalentsDisclosureofcompositionofcashandcashequivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Cash"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]"
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "abvx_CashAndCashEquivalentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "CashAndCashEquivalentMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash And Cash Equivalent [Member]",
        "documentation": "Cash And Cash Equivalent"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.abivax.com/role/CashandcashequivalentsDisclosureofcompositionofcashandcashequivalentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.abivax.com/role/CashandcashequivalentsDisclosureofcompositionofcashandcashequivalentsDetails",
      "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "periodStartLabel": "Cash and cash equivalents at the beginning of the year",
        "periodEndLabel": "Cash and cash equivalents at the end of the year",
        "totalLabel": "Cash and cash equivalents",
        "label": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r82",
      "r97",
      "r196",
      "r292"
     ]
    },
    "ifrs-full_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_CashAndCashEquivalentsAndOtherShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "CashAndCashEquivalentsAndOtherShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/BasisofpreparationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents and other short-term investments",
        "label": "Cash And Cash Equivalents And Other Short-Term Investments",
        "documentation": "Cash And Cash Equivalents And Other Short-Term Investments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CashandcashequivalentsDisclosureofcompositionofcashandcashequivalentsDetails": {
       "parentTag": "ifrs-full_CashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CashandcashequivalentsDisclosureofcompositionofcashandcashequivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash flows provided by (used in) financing activities",
        "label": "Cash flows from (used in) financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r84"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows provided by (used in) financing activities",
        "label": "Cash flows from (used in) financing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash flows provided by (used in) investing activities",
        "label": "Cash flows from (used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r84"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows provided by (used in) investing activities",
        "label": "Cash flows from (used in) investing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash flows provided by (used in) operating activities",
        "label": "Cash flows from (used in) operating activities"
       }
      }
     },
     "auth_ref": [
      "r72",
      "r84"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows provided by (used in) operating activities",
        "label": "Cash flows from (used in) operating activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash flows provided by (used in) operating activities before change in working capital requirements",
        "label": "Cash flows from (used in) operations before changes in working capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r507"
     ]
    },
    "abvx_CashPaymentsForDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "CashPaymentsForDeposits",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Increase in deposits",
        "label": "Cash Payments For Deposits",
        "documentation": "Cash Payments For Deposits"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfFinancialAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialAssetsAxis",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of financial assets [axis]",
        "label": "Categories of financial assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r262"
     ]
    },
    "ifrs-full_CategoriesOfFinancialAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialAssetsDomain",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of financial assets [domain]",
        "label": "Categories of financial assets [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r160",
      "r262"
     ]
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesAxis",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of financial liabilities [axis]",
        "label": "Categories of financial liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r262"
     ]
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesDomain",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of financial liabilities [domain]",
        "label": "Categories of financial liabilities [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r160",
      "r262"
     ]
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesAxis",
     "presentation": [
      "http://www.abivax.com/role/RelatedpartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of related parties [axis]",
        "label": "Categories of related parties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r225"
     ]
    },
    "ifrs-full_CategoriesOfRelatedPartiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesDomain",
     "presentation": [
      "http://www.abivax.com/role/RelatedpartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of related parties [domain]",
        "label": "Categories of related parties [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r225"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "ifrs-full_ChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ChangesInEquityAbstract",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in equity [abstract]",
        "label": "Changes in equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief Executive Officer",
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfAssetsAxis",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails",
      "http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of assets [axis]",
        "label": "Classes of assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r108",
      "r116",
      "r178",
      "r228",
      "r272"
     ]
    },
    "ifrs-full_ClassesOfAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfAssetsDomain",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails",
      "http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of assets [domain]",
        "label": "Classes of assets [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r108",
      "r116",
      "r178",
      "r228",
      "r272"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.abivax.com/role/FinancialgainlossNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of financial instruments [axis]",
        "label": "Classes of financial instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r147",
      "r148",
      "r149",
      "r264",
      "r266"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.abivax.com/role/FinancialgainlossNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of financial instruments [domain]",
        "label": "Classes of financial instruments [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r145",
      "r147",
      "r148",
      "r149",
      "r264",
      "r266"
     ]
    },
    "ifrs-full_ClassesOfFinancialLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfFinancialLiabilitiesAxis",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesBreakdownoffinancialliabilitiesbymaturityDetails",
      "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofconditionaladvancesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails",
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails",
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails",
      "http://www.abivax.com/role/OffbalancesheetcommitmentsreceivedandcontingentassetsDetails",
      "http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of financial liabilities [axis]",
        "label": "Classes of financial liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r172",
      "r173"
     ]
    },
    "ifrs-full_ClassesOfFinancialLiabilitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfFinancialLiabilitiesDomain",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesBreakdownoffinancialliabilitiesbymaturityDetails",
      "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofconditionaladvancesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails",
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails",
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails",
      "http://www.abivax.com/role/OffbalancesheetcommitmentsreceivedandcontingentassetsDetails",
      "http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of financial liabilities [domain]",
        "label": "Classes of financial liabilities [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r172",
      "r173"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesIntangibleassetsDetails",
      "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of intangible assets other than goodwill [axis]",
        "label": "Classes of intangible assets other than goodwill [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r243"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillDomain",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesIntangibleassetsDetails",
      "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of intangible assets other than goodwill [domain]",
        "label": "Classes of intangible assets other than goodwill [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r243"
     ]
    },
    "ifrs-full_ClassesOfLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfLiabilitiesAxis",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of liabilities [axis]",
        "label": "Classes of liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r272"
     ]
    },
    "ifrs-full_ClassesOfLiabilitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfLiabilitiesDomain",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of liabilities [domain]",
        "label": "Classes of liabilities [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r108",
      "r272"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails",
      "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of property, plant and equipment [axis]",
        "label": "Classes of property, plant and equipment [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r209"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentDomain",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails",
      "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of property, plant and equipment [domain]",
        "label": "Classes of property, plant and equipment [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Classes of property, plant and equipment' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r209"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalAxis",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreos1Details",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of share capital [axis]",
        "label": "Classes of share capital [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r274",
      "r306"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalDomain",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreos1Details",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of share capital [domain]",
        "label": "Classes of share capital [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r274",
      "r306"
     ]
    },
    "ifrs-full_ClosingForeignExchangeRate": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClosingForeignExchangeRate",
     "presentation": [
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Closing foreign exchange rate",
        "label": "Closing foreign exchange rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "abvx_CollaborationAgreementsDevelopmentMilestonePaymentINDApproval": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "CollaborationAgreementsDevelopmentMilestonePaymentINDApproval",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/IntangibleassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreements, development milestone payment, IND approval",
        "label": "Collaboration Agreements, Development Milestone Payment, IND Approval",
        "documentation": "Collaboration Agreements, Development Milestone Payment, IND Approval"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_CollaborationAgreementsDevelopmentMilestonePaymentPhase2": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "CollaborationAgreementsDevelopmentMilestonePaymentPhase2",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/IntangibleassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreements, development milestone payment, Phase 2",
        "label": "Collaboration Agreements, Development Milestone Payment, Phase 2",
        "documentation": "Collaboration Agreements, Development Milestone Payment, Phase 2"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDApproval": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDApproval",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential development milestone payment, IND approval",
        "label": "Collaboration Agreements, Potential Development Milestone Payment, IND Approval",
        "documentation": "Collaboration Agreements, Potential Development Milestone Payment, IND Approval"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDFiling": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDFiling",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential development milestone payment, IND filing",
        "label": "Collaboration Agreements, Potential Development Milestone Payment, IND Filing",
        "documentation": "Collaboration Agreements, Potential Development Milestone Payment, IND Filing"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentPhase3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "CollaborationAgreementsPotentialDevelopmentMilestonePaymentPhase3",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential development milestone payment, phase 3",
        "label": "Collaboration Agreements, Potential Development Milestone Payment, Phase 3",
        "documentation": "Collaboration Agreements, Potential Development Milestone Payment, Phase 3"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of equity [axis]",
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "ifrs-full_ComponentsOfEquityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComponentsOfEquityDomain",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of equity [domain]",
        "label": "Components of equity [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "ifrs-full_ComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive income (loss) for the period",
        "label": "Comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r89",
      "r95",
      "r227",
      "r252",
      "r280",
      "r310",
      "r335"
     ]
    },
    "ifrs-full_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "IT equipment",
        "label": "Computer equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "ifrs-full_ComputerSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComputerSoftwareMember",
     "presentation": [
      "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SOFTWARE",
        "label": "Computer software [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "abvx_ConditionalAdvances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ConditionalAdvances",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofconditionaladvancesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conditional advances",
        "label": "Conditional Advances",
        "documentation": "Conditional Advances"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ConditionalAdvancesAndPGELoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ConditionalAdvancesAndPGELoanMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conditional advances and PGE loan",
        "label": "Conditional Advances And PGE Loan [Member]",
        "documentation": "Conditional Advances And PGE Loan"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ConditionalAdvancesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ConditionalAdvancesMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conditional advances Bpifrance",
        "label": "Conditional Advances [Member]",
        "documentation": "Conditional Advances"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ConditionalAdvancesUndiscountedCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ConditionalAdvancesUndiscountedCashFlows",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": {
       "parentTag": "abvx_FinancialLiabilitiesUndiscountedCashFlows",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conditional advances, undiscounted cash flows",
        "label": "Conditional Advances, Undiscounted Cash Flows",
        "documentation": "Conditional Advances, Undiscounted Cash Flows"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contact Personnel Name",
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ContributionToGroupsAssetsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ContributionToGroupsAssetsPercentage",
     "presentation": [
      "http://www.abivax.com/role/SegmentinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contribution to Group's assets, percentage",
        "label": "Contribution To Group's Assets, Percentage",
        "documentation": "Contribution To Group's Assets, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ContributionToGroupsLiabilitiesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ContributionToGroupsLiabilitiesPercentage",
     "presentation": [
      "http://www.abivax.com/role/SegmentinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contribution to Group's liabilities, percentage",
        "label": "Contribution To Group's Liabilities, Percentage",
        "documentation": "Contribution To Group's Liabilities, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ContributionToGroupsNetProfitsLossesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ContributionToGroupsNetProfitsLossesPercentage",
     "presentation": [
      "http://www.abivax.com/role/SegmentinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contribution to Group's net profits (losses), percentage",
        "label": "Contribution To Group's Net Profits (Losses), Percentage",
        "documentation": "Contribution To Group's Net Profits (Losses), Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ConversionPriceAdjustmentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ConversionPriceAdjustmentPeriod",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price, adjustment, period",
        "label": "Conversion Price, Adjustment, Period",
        "documentation": "Conversion Price, Adjustment, Period"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ConversionPricePerShareMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ConversionPricePerShareMeasurementInputMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price per share (in euro per share)",
        "label": "Conversion Price Per Share, Measurement Input [Member]",
        "documentation": "Conversion Price Per Share, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ConvertibleLoansNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ConvertibleLoansNotes",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible loans notes",
        "label": "Convertible Loans Notes",
        "documentation": "Convertible Loans Notes"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ConvertibleLoansNotesCarryingAmountOfTheEquityComponent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ConvertibleLoansNotesCarryingAmountOfTheEquityComponent",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount of the equity component",
        "label": "Convertible Loans Notes, Carrying Amount Of The Equity Component",
        "documentation": "Convertible Loans Notes, Carrying Amount Of The Equity Component"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ConvertibleLoansNotesConversionOptionMaximumPeriodPriorToMaturityDate": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ConvertibleLoansNotesConversionOptionMaximumPeriodPriorToMaturityDate",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion option, maximum period prior to maturity date",
        "label": "Convertible Loans Notes, Conversion Option, Maximum Period Prior To Maturity Date",
        "documentation": "Convertible Loans Notes, Conversion Option, Maximum Period Prior To Maturity Date"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ConvertibleLoansNotesEarlyRedemptionAmountPercentageOfOutstandongPrincipal": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ConvertibleLoansNotesEarlyRedemptionAmountPercentageOfOutstandongPrincipal",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Early redemption amount, percentage of outstandong principal",
        "label": "Convertible Loans Notes, Early Redemption Amount, Percentage Of Outstandong Principal",
        "documentation": "Convertible Loans Notes, Early Redemption Amount, Percentage Of Outstandong Principal"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ConvertibleLoansNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ConvertibleLoansNotesMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible loan notes",
        "label": "Convertible Loans Notes [Member]",
        "documentation": "Convertible Loans Notes"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ConvertibleLoansNotesNominalValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ConvertibleLoansNotesNominalValue",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible loan notes, nominal value",
        "label": "Convertible Loans Notes, Nominal Value",
        "documentation": "Convertible Loans Notes, Nominal Value"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ConvertibleLoansNotesNumberOfSeparateClosings": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ConvertibleLoansNotesNumberOfSeparateClosings",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible loan notes, number of separate closings",
        "label": "Convertible Loans Notes, Number Of Separate Closings",
        "documentation": "Convertible Loans Notes, Number Of Separate Closings"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ConvertibleLoansNotesPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ConvertibleLoansNotesPeriod",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible loan notes, period",
        "label": "Convertible Loans Notes, Period",
        "documentation": "Convertible Loans Notes, Period"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ConvertibleLoansNotesSettlementInSharesPercentageOfFairMarketValue": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ConvertibleLoansNotesSettlementInSharesPercentageOfFairMarketValue",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement in shares, percentage of fair market value",
        "label": "Convertible Loans Notes, Settlement In Shares, Percentage Of Fair Market Value",
        "documentation": "Convertible Loans Notes, Settlement In Shares, Percentage Of Fair Market Value"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ConvertibleLoansNotesUndiscountedCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ConvertibleLoansNotesUndiscountedCashFlows",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": {
       "parentTag": "abvx_FinancialLiabilitiesUndiscountedCashFlows",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible loans notes, undiscounted cash flows",
        "label": "Convertible Loans Notes, Undiscounted Cash Flows",
        "documentation": "Convertible Loans Notes, Undiscounted Cash Flows"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember",
     "presentation": [
      "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PATENTS",
        "label": "Copyrights, patents and other industrial property rights, service and operating rights [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing copyrights, patents and other industrial property rights, service and operating rights. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CorporateInformationAndStatementOfIFRSComplianceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate information and statement of IFRS compliance [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.abivax.com/role/BasisofpreparationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CreditRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CreditRiskMember",
     "presentation": [
      "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit risk",
        "label": "Credit risk [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r351"
     ]
    },
    "ifrs-full_CreditSpreadMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CreditSpreadMeasurementInputMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit spread",
        "label": "Credit spread, measurement input [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the credit spread used as a measurement input."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://www.abivax.com/role/CashandcashequivalentsNarrativeDetails",
      "http://www.abivax.com/role/FinancialgainlossNarrativeDetails",
      "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency [Axis]",
        "label": "Currency [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrencyRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrencyRiskMember",
     "presentation": [
      "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency risk",
        "label": "Currency risk [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r126",
      "r161"
     ]
    },
    "abvx_CurrentAdvancesToCROContracts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "CurrentAdvancesToCROContracts",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails": {
       "parentTag": "ifrs-full_OtherCurrentFinancialAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advances related to CRO contracts",
        "label": "Current Advances To CRO Contracts",
        "documentation": "Current Advances To CRO Contracts"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAdvancesToSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentAdvancesToSuppliers",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current advances to suppliers",
        "label": "Current advances to suppliers"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current advances made to suppliers before goods or services are received."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r91",
      "r300",
      "r335"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "label": "Current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentDeferredIncomeOtherThanCurrentContractLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income",
        "label": "Current deferred income other than current contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current deferred income other than current contract liabilities. [Refer: Deferred income other than contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r522",
      "r525"
     ]
    },
    "ifrs-full_CurrentDerivativeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentDerivativeFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative instruments",
        "label": "Current derivative financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "ifrs-full_CurrentFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current financial liabilities",
        "label": "Current financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current financial liabilities. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "abvx_CurrentFinancialLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "CurrentFinancialLiabilitiesMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities-current portion",
        "label": "Current Financial Liabilities [Member]",
        "documentation": "Current Financial Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r301",
      "r335"
     ]
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities",
        "label": "Current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_CurrentPayablesOnOtherTaxAndRelatedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "CurrentPayablesOnOtherTaxAndRelatedPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails": {
       "parentTag": "abvx_CurrentTaxAndEmployeeBenefitLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other tax and related payments",
        "label": "Current Payables On Other Tax And Related Payments",
        "documentation": "Current Payables On Other Tax And Related Payments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails": {
       "parentTag": "abvx_CurrentTaxAndEmployeeBenefitLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Social security and other",
        "label": "Current payables on social security and taxes other than income tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current payables on social security and taxes other than incomes tax. [Refer: Payables on social security and taxes other than income tax]"
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "abvx_CurrentPortionOfNonCurrentConvertibleLoansNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "CurrentPortionOfNonCurrentConvertibleLoansNotes",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible loan notes",
        "label": "Current Portion Of Non-Current Convertible Loans Notes",
        "documentation": "Current Portion Of Non-Current Convertible Loans Notes"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails": {
       "parentTag": "abvx_CurrentReceivablesAndCurrentPrepaidExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Current prepaid expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "abvx_CurrentPrepaidExpensesRelatedToCRO": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "CurrentPrepaidExpensesRelatedToCRO",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current prepaid expenses related to CRO",
        "label": "Current Prepaid Expenses Related To CRO",
        "documentation": "Current Prepaid Expenses Related To CRO"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_CurrentReceivablesAndCurrentPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "CurrentReceivablesAndCurrentPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails": {
       "parentTag": "ifrs-full_OtherAssets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables and assets",
        "totalLabel": "Total current other receivables and assets",
        "label": "Current Receivables And Current Prepaid Expenses",
        "documentation": "Current Receivables And Current Prepaid Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_CurrentReceivablesForEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "CurrentReceivablesForEmployeeBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails": {
       "parentTag": "abvx_CurrentReceivablesAndCurrentPrepaidExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee-related receivables",
        "label": "Current Receivables for Employee Benefits",
        "documentation": "Current Receivables for Employee Benefits"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_CurrentReceivablesFromCreditNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "CurrentReceivablesFromCreditNotes",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails": {
       "parentTag": "abvx_CurrentReceivablesAndCurrentPrepaidExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit notes",
        "label": "Current Receivables From Credit Notes",
        "documentation": "Current Receivables From Credit Notes"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_CurrentResearchTaxCreditReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "CurrentResearchTaxCreditReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails": {
       "parentTag": "abvx_CurrentReceivablesAndCurrentPrepaidExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails",
      "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research tax credit (\"CIR\")",
        "label": "Current Research Tax Credit Receivables",
        "documentation": "Current Research Tax Credit Receivables"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentServiceCostNetDefinedBenefitLiabilityAsset",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofchangesinprojectedbenefitobligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service cost",
        "label": "Increase in net defined benefit liability (asset) resulting from current service cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from employee service in the current period. [Refer: Net defined benefit liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r17",
      "r213"
     ]
    },
    "abvx_CurrentTaxAndEmployeeBenefitLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "CurrentTaxAndEmployeeBenefitLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax and employee-related payables",
        "totalLabel": "TAX AND EMPLOYEE-RELATED PAYABLES",
        "label": "Current Tax And Employee Benefit Liabilities",
        "documentation": "Current Tax And Employee Benefit Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentValueAddedTaxReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentValueAddedTaxReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails": {
       "parentTag": "abvx_CurrentReceivablesAndCurrentPrepaidExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "VAT receivables",
        "label": "Current value added tax receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current value added tax receivables. [Refer: Value added tax receivables]"
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r390",
      "r479"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r390",
      "r479"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r392",
      "r481"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r392",
      "r481"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r394",
      "r483"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r392",
      "r481"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r385",
      "r474"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r386",
      "r475"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r386",
      "r475"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r384",
      "r473"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r384",
      "r473"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r384",
      "r473"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r387",
      "r476"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r389",
      "r478"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r389",
      "r478"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r390",
      "r479"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r393",
      "r482"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r391",
      "r480"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r388",
      "r477"
     ]
    },
    "abvx_DecreaseInLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DecreaseInLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofvariationinleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decrease",
        "label": "Decrease In Lease Liabilities",
        "documentation": "Decrease In Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_DecreaseInLeaseLiabilitiesThroughModificationOfTerm": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DecreaseInLeaseLiabilitiesThroughModificationOfTerm",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in lease liabilities through modification of term",
        "label": "Decrease In Lease Liabilities Through Modification Of Term",
        "documentation": "Decrease In Lease Liabilities Through Modification Of Term"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest paid",
        "label": "Decrease Through Interest Paid, Liabilities Arising From Financing Activities",
        "documentation": "Decrease Through Interest Paid, Liabilities Arising From Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_DecreaseThroughReassessmentOfLeaseTermRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DecreaseThroughReassessmentOfLeaseTermRightOfUseAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease through reassessment of lease term",
        "label": "Decrease Through Reassessment Of Lease Term, Right-Of-Use Assets",
        "documentation": "Decrease Through Reassessment Of Lease Term, Right-Of-Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayments",
        "label": "Decrease Through Repayments, Liabilities Arising From Financing Activities",
        "documentation": "Decrease Through Repayments, Liabilities Arising From Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_DeferredFinancingCostsNettingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DeferredFinancingCostsNettingMember",
     "presentation": [
      "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred financing costs",
        "label": "Deferred Financing Costs, Netting [Member]",
        "documentation": "Deferred Financing Costs, Netting"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DeferredTaxAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails": {
       "parentTag": "ifrs-full_DeferredTaxLiabilityAsset",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails",
      "http://www.abivax.com/role/IncometaxNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets",
        "verboseLabel": "Deferred tax assets",
        "label": "Deferred tax assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r5",
      "r204",
      "r295",
      "r297"
     ]
    },
    "ifrs-full_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails": {
       "parentTag": "ifrs-full_DeferredTaxLiabilityAsset",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails",
      "http://www.abivax.com/role/IncometaxNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred tax liabilities",
        "label": "Deferred tax liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]"
       }
      }
     },
     "auth_ref": [
      "r5",
      "r204",
      "r295",
      "r297"
     ]
    },
    "abvx_DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred tax liabilities",
        "label": "Deferred Tax Liabilities (Assets) Net of Unrecognized Liabilities (Assets)",
        "documentation": "Deferred Tax Liabilities (Assets) Net of Unrecognized Liabilities (Assets)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DeferredTaxLiabilityAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails": {
       "parentTag": "abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Deferred tax assets, net",
        "label": "Deferred tax liability (asset)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]"
       }
      }
     },
     "auth_ref": [
      "r5",
      "r204"
     ]
    },
    "abvx_DepreciationExpenseLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DepreciationExpenseLease",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense, lease",
        "label": "Depreciation Expense, Lease",
        "documentation": "Depreciation Expense, Lease"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets",
     "presentation": [
      "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Increase",
        "label": "Depreciation, property, plant and equipment including right-of-use assets"
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "ifrs-full_DerivativeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DerivativeFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Derivative financial liabilities at beginning of period",
        "periodEndLabel": "Derivative financial liabilities at end of period",
        "terseLabel": "Derivative financial liabilities",
        "label": "Derivative financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DerivativeFinancialLiabilitiesUndiscountedCashFlows",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": {
       "parentTag": "abvx_FinancialLiabilitiesUndiscountedCashFlows",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative financial liabilities, undiscounted cash flows",
        "label": "Derivative financial liabilities, undiscounted cash flows"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to derivative financial liabilities. [Refer: Derivative financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r151",
      "r268"
     ]
    },
    "ifrs-full_DerivativesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DerivativesMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative instruments",
        "label": "Derivatives [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for financial instruments or other contracts within the scope of IFRS 9 with all three of the following characteristics: (a) Their value changes in response to the change in a specified interest rate, financial instrument price, commodity price, foreign exchange rate, index of prices or rates, credit rating or credit index, or other variable, provided in the case of a non-financial variable that the variable is not specific to a party to the contract (sometimes called the \u2018underlying\u2019); (b) They require no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; (c) They are settled at a future date. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r337",
      "r343",
      "r353",
      "r360"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForBorrowingsExplanatory",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conditional advances and PGE",
        "label": "Description of accounting policy for borrowings [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred taxes",
        "label": "Description of accounting policy for deferred income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for deferred income tax. [Refer: Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee benefits",
        "label": "Description of accounting policy for employee benefits [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinancialAssetsExplanatory",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets at amortized cost",
        "label": "Description of accounting policy for financial assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities",
        "label": "Description of accounting policy for financial liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for financial liabilities. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Translation of transactions denominated in foreign currency",
        "label": "Description of accounting policy for foreign currency translation [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for foreign currency translation."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "abvx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Going concern",
        "label": "Description Of Accounting Policy For Going Concern [Policy Text Block]",
        "documentation": "Description Of Accounting Policy For Going Concern"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForGoodwillExplanatory",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Description of accounting policy for goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForGovernmentGrants",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research tax credit and subsidies",
        "label": "Description of accounting policy for government grants [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]"
       }
      }
     },
     "auth_ref": [
      "r23",
      "r218"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of goodwill, intangible assets, property and plant and equipment",
        "label": "Description of accounting policy for impairment of non-financial assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current taxes",
        "label": "Description of accounting policy for income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for income tax."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Description of accounting policy for intangible assets other than goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIssuedCapitalExplanatory",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "label": "Description of accounting policy for issued capital [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for issued capital. [Refer: Issued capital]"
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Description of accounting policy for leases [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment",
        "label": "Description of accounting policy for property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions",
        "label": "Description of accounting policy for provisions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for provisions. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payments",
        "label": "Description of accounting policy for share-based payment transactions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]"
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r83",
      "r197"
     ]
    },
    "ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfDiscountRatesAppliedToCashFlowProjections",
     "presentation": [
      "http://www.abivax.com/role/GoodwillandimpairmenttestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate (WACC)",
        "label": "Discount rate applied to cash flow projections"
       }
      },
      "en": {
       "role": {
        "documentation": "The discount rate applied to cash flow projections for a cash-generating unit (group of units). [Refer: Total for all cash-generating units [member]]"
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r231",
      "r232"
     ]
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS",
      "http://www.abivax.com/role/IncomelosspershareScheduleofearningspershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted loss per share (in euro per share)",
        "label": "Diluted earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41"
     ]
    },
    "abvx_DisclosureOfAccountingPolicyForAccountingJudgementsAndEstimatesExplanatoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfAccountingPolicyForAccountingJudgementsAndEstimatesExplanatoryPolicyTextBlock",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of judgments and estimates",
        "label": "Disclosure Of Accounting Policy For Accounting Judgements And Estimates Explanatory [Policy Text Block]",
        "documentation": "Disclosure Of Accounting Policy For Accounting Judgements And Estimates Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_DisclosureOfAccountingPolicyForAssetsAcquisitionsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfAccountingPolicyForAssetsAcquisitionsPolicyTextBlock",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting of Prosynergia acquisition",
        "label": "Disclosure Of Accounting Policy For Assets Acquisitions [Policy Text Block]",
        "documentation": "Disclosure Of Accounting Policy For Assets Acquisitions"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_DisclosureOfAccountingPolicyForNewRevisedOrAmendedStandardsAndInterpretationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfAccountingPolicyForNewRevisedOrAmendedStandardsAndInterpretationsPolicyTextBlock",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New, revised or amended Standards and Interpretations",
        "label": "Disclosure Of Accounting Policy For New, Revised Or Amended Standards And Interpretations [Policy Text Block]",
        "documentation": "Disclosure Of Accounting Policy For New, Revised Or Amended Standards And Interpretations"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_DisclosureOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedByIASBButNotYetMandatoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedByIASBButNotYetMandatoryPolicyTextBlock",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New standards, amendments and interpretations issued by IASB but not yet mandatory for financial years starting from January 1, 2023",
        "label": "Disclosure Of Accounting Policy For New Standards, Amendments And Interpretations Issued By IASB But Not Yet Mandatory [Policy Text Block]",
        "documentation": "Disclosure Of Accounting Policy For New Standards, Amendments And For Financial Years"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems",
     "presentation": [
      "http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails",
      "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails",
      "http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails",
      "http://www.abivax.com/role/OperatingexpensesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of attribution of expenses by nature to their function [line items]",
        "label": "Disclosure of attribution of expenses by nature to their function [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable",
     "presentation": [
      "http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails",
      "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails",
      "http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails",
      "http://www.abivax.com/role/OperatingexpensesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of attribution of expenses by nature to their function [table]",
        "label": "Disclosure of attribution of expenses by nature to their function [table]"
       }
      }
     },
     "auth_ref": [
      "r516",
      "r519"
     ]
    },
    "abvx_DisclosureOfAverageNumberOfEmployeesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfAverageNumberOfEmployeesTableTextBlock",
     "presentation": [
      "http://www.abivax.com/role/EmployeesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of average workforce during the periods",
        "label": "Disclosure Of Average Number Of Employees [Table Text Block]",
        "documentation": "Disclosure Of Average Number Of Employees"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "presentation": [
      "http://www.abivax.com/role/Basisofpreparation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of preparation",
        "label": "Disclosure of basis of preparation of financial statements [text block]"
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "ifrs-full_DisclosureOfBorrowingsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfBorrowingsExplanatory",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of conditional advances",
        "label": "Disclosure of borrowings [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "abvx_DisclosureOfBreakdownOfTradeAndOtherPayablesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfBreakdownOfTradeAndOtherPayablesTableTextBlock",
     "presentation": [
      "http://www.abivax.com/role/PayablesandothercurrentliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of breakdown of trade and other payables",
        "label": "Disclosure Of Breakdown Of Trade And Other Payables [Table Text Block]",
        "documentation": "Disclosure Of Breakdown Of Trade And Other Payables"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfCashAndCashEquivalentsExplanatory",
     "presentation": [
      "http://www.abivax.com/role/Cashandcashequivalents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Disclosure of cash and cash equivalents [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "abvx_DisclosureOfCashAndCashEquivalentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfCashAndCashEquivalentsLineItems",
     "presentation": [
      "http://www.abivax.com/role/CashandcashequivalentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Cash And Cash Equivalents [Line Items]",
        "label": "Disclosure Of Cash And Cash Equivalents [Line Items]",
        "documentation": "Disclosure Of Cash And Cash Equivalents [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_DisclosureOfCashAndCashEquivalentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfCashAndCashEquivalentsTable",
     "presentation": [
      "http://www.abivax.com/role/CashandcashequivalentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Cash And Cash Equivalents [Table]",
        "label": "Disclosure Of Cash And Cash Equivalents [Table]",
        "documentation": "Disclosure Of Cash And Cash Equivalents [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_DisclosureOfChangesInDerivativeFinancialInstrumentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfChangesInDerivativeFinancialInstrumentsTableTextBlock",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of changes in derivative instruments",
        "label": "Disclosure Of Changes In Derivative Financial Instruments [Table Text Block]",
        "documentation": "Disclosure Of Changes In Derivative Financial Instruments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "presentation": [
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of classes of share capital [line items]",
        "label": "Disclosure of classes of share capital [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "presentation": [
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of classes of share capital [table]",
        "label": "Disclosure of classes of share capital [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r274",
      "r306"
     ]
    },
    "ifrs-full_DisclosureOfCommitmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfCommitmentsExplanatory",
     "presentation": [
      "http://www.abivax.com/role/Offbalancesheetcommitmentsgiven"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Off-balance sheet commitments given",
        "label": "Disclosure of commitments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of commitments."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "abvx_DisclosureOfCommitmentsReceivedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfCommitmentsReceivedLineItems",
     "presentation": [
      "http://www.abivax.com/role/OffbalancesheetcommitmentsreceivedandcontingentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Commitments Received [Line Items]",
        "label": "Disclosure Of Commitments Received [Line Items]",
        "documentation": "Disclosure Of Commitments Received [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_DisclosureOfCommitmentsReceivedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfCommitmentsReceivedTable",
     "presentation": [
      "http://www.abivax.com/role/OffbalancesheetcommitmentsreceivedandcontingentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Commitments Received [Table]",
        "label": "Disclosure Of Commitments Received [Table]",
        "documentation": "Disclosure Of Commitments Received [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_DisclosureOfCompositionOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfCompositionOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://www.abivax.com/role/CashandcashequivalentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of composition of cash and cash equivalents",
        "label": "Disclosure Of Composition Of Cash And Cash Equivalents [Table Text Block]",
        "documentation": "Disclosure Of Composition Of Cash And Cash Equivalents"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfCreditRiskExposureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfCreditRiskExposureLineItems",
     "presentation": [
      "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of credit risk exposure [line items]",
        "label": "Disclosure of credit risk exposure [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfCreditRiskExposureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfCreditRiskExposureTable",
     "presentation": [
      "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of credit risk exposure [table]",
        "label": "Disclosure of credit risk exposure [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the credit risk exposure."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r266"
     ]
    },
    "ifrs-full_DisclosureOfDefinedBenefitPlansAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDefinedBenefitPlansAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of defined benefit plans [abstract]",
        "label": "Disclosure of defined benefit plans [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDefinedBenefitPlansExplanatory",
     "presentation": [
      "http://www.abivax.com/role/RetirementbenefitobligationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of main actuarial assumptions used to measure the retirement benefit obligations",
        "label": "Disclosure of defined benefit plans [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of defined benefit plans. [Refer: Defined benefit plans [domain]]"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r210"
     ]
    },
    "ifrs-full_DisclosureOfDefinedBenefitPlansLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDefinedBenefitPlansLineItems",
     "presentation": [
      "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofchangesinprojectedbenefitobligationDetails",
      "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of defined benefit plans [line items]",
        "label": "Disclosure of defined benefit plans [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDefinedBenefitPlansTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDefinedBenefitPlansTable",
     "presentation": [
      "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofchangesinprojectedbenefitobligationDetails",
      "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of defined benefit plans [table]",
        "label": "Disclosure of defined benefit plans [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to defined benefit plans."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r210"
     ]
    },
    "abvx_DisclosureOfDetailedInformationAboutAssetsAcquisitionsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfDetailedInformationAboutAssetsAcquisitionsExplanatoryTableTextBlock",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of allocation of acquisition cost",
        "label": "Disclosure Of Detailed Information About Assets Acquisitions Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Detailed Information About Assets Acquisitions Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesBreakdownoffinancialliabilitiesbymaturityDetails",
      "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofconditionaladvancesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails",
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreos1Details",
      "http://www.abivax.com/role/FinancialliabilitiesKreos2Details",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails",
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesStateguaranteedloanPGEDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about borrowings [line items]",
        "label": "Disclosure of detailed information about borrowings [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesBreakdownoffinancialliabilitiesbymaturityDetails",
      "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofconditionaladvancesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails",
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreos1Details",
      "http://www.abivax.com/role/FinancialliabilitiesKreos2Details",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails",
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesStateguaranteedloanPGEDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about borrowings [table]",
        "label": "Disclosure of detailed information about borrowings [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of borrowings."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "abvx_DisclosureOfDetailedInformationAboutFinanceIncomeCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfDetailedInformationAboutFinanceIncomeCostTableTextBlock",
     "presentation": [
      "http://www.abivax.com/role/FinancialgainlossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of net financial income (loss)",
        "label": "Disclosure Of Detailed Information About Finance Income (Cost) [Table Text Block]",
        "documentation": "Disclosure Of Detailed Information About Finance Income (Cost)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
     "presentation": [
      "http://www.abivax.com/role/IntangibleassetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reconciliation of intangible assets",
        "label": "Disclosure of detailed information about intangible assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r62",
      "r243"
     ]
    },
    "abvx_DisclosureOfDetailedInformationAboutOtherReceivablesAndOtherAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfDetailedInformationAboutOtherReceivablesAndOtherAssetsTableTextBlock",
     "presentation": [
      "http://www.abivax.com/role/OtherreceivablesandotherassetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of other receivables and other assets",
        "label": "Disclosure Of Detailed Information About Other Receivables And Other Assets [Table Text Block]",
        "documentation": "Disclosure Of Detailed Information About Other Receivables And Other Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of depreciation period of property, plant and equipment",
        "label": "Disclosure of detailed information about property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r11",
      "r209"
     ]
    },
    "abvx_DisclosureOfDetailedInformationOfOperatingIncomeExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfDetailedInformationOfOperatingIncomeExplanatoryTableTextBlock",
     "presentation": [
      "http://www.abivax.com/role/OtheroperatingincomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of breakdown of operating income",
        "label": "Disclosure Of Detailed Information Of Operating Income Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Detailed Information Of Operating Income Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "presentation": [
      "http://www.abivax.com/role/Incomelosspershare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income (loss) per share",
        "label": "Disclosure of earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfEmployeeBenefitsExplanatory",
     "presentation": [
      "http://www.abivax.com/role/Retirementbenefitobligations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement benefit obligations",
        "label": "Disclosure of employee benefits [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for employee benefits."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "abvx_DisclosureOfEmployeeWorkforceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfEmployeeWorkforceLineItems",
     "presentation": [
      "http://www.abivax.com/role/EmployeesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Employee Workforce [Line Items]",
        "label": "Disclosure Of Employee Workforce [Line Items]",
        "documentation": "Disclosure Of Employee Workforce [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_DisclosureOfEmployeeWorkforceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfEmployeeWorkforceTable",
     "presentation": [
      "http://www.abivax.com/role/EmployeesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Employee Workforce [Table]",
        "label": "Disclosure Of Employee Workforce [Table]",
        "documentation": "Disclosure Of Employee Workforce [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfEntitysReportableSegmentsExplanatory",
     "presentation": [
      "http://www.abivax.com/role/Segmentinformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment information",
        "label": "Disclosure of entity's operating segments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for operating segments."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "ifrs-full_DisclosureOfExpensesByNatureExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfExpensesByNatureExplanatory",
     "presentation": [
      "http://www.abivax.com/role/OperatingexpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of expenses by nature",
        "label": "Disclosure of expenses by nature [text block]"
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]",
        "label": "Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]",
        "documentation": "Disclosure Of Fair Value Measurement Of Assets And Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Fair Value Measurement Of Assets And Liabilities [Table]",
        "label": "Disclosure Of Fair Value Measurement Of Assets And Liabilities [Table]",
        "documentation": "Disclosure Of Fair Value Measurement Of Assets And Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfAssetsExplanatory",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of carrying amounts and fair value of financial assets",
        "label": "Disclosure of fair value measurement of assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the fair value measurement of assets."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r272"
     ]
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of carrying amounts and fair value of financial liabilities",
        "label": "Disclosure of fair value measurement of liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the fair value measurement of liabilities."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r272"
     ]
    },
    "ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFairValueOfFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.abivax.com/role/Financialassetsandliabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets and liabilities",
        "label": "Disclosure of fair value of financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the fair value of financial instruments. [Refer: Classes of financial instruments [domain]; At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinanceIncomeExpenseExplanatory",
     "presentation": [
      "http://www.abivax.com/role/Financialgainloss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial gain (loss)",
        "label": "Disclosure of finance income (cost) [text block]"
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "ifrs-full_DisclosureOfFinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsExplanatory",
     "presentation": [
      "http://www.abivax.com/role/OtherfinancialassetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of other financial assets",
        "label": "Disclosure of financial assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r155",
      "r257"
     ]
    },
    "ifrs-full_DisclosureOfFinancialAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsLineItems",
     "presentation": [
      "http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of financial assets [line items]",
        "label": "Disclosure of financial assets [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsTable",
     "presentation": [
      "http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of financial assets [table]",
        "label": "Disclosure of financial assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to financial assets."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r257"
     ]
    },
    "abvx_DisclosureOfFinancialGainLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfFinancialGainLossLineItems",
     "presentation": [
      "http://www.abivax.com/role/FinancialgainlossNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Financial Gain (Loss) [Line Items]",
        "label": "Disclosure Of Financial Gain (Loss) [Line Items]",
        "documentation": "Disclosure Of Financial Gain (Loss) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_DisclosureOfFinancialGainLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfFinancialGainLossTable",
     "presentation": [
      "http://www.abivax.com/role/FinancialgainlossNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Financial Gain (Loss) [Table]",
        "label": "Disclosure Of Financial Gain (Loss) [Table]",
        "documentation": "Disclosure Of Financial Gain (Loss) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.abivax.com/role/Financialliabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities",
        "label": "Disclosure of financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsLineItems",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about financial instruments [line items]",
        "label": "Disclosure of detailed information about financial instruments [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsTable",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about financial instruments [table]",
        "label": "Disclosure of detailed information about financial instruments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r147",
      "r155",
      "r257"
     ]
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of financial liabilities [abstract]",
        "label": "Disclosure of financial liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialLiabilitiesExplanatory",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of financial liabilities breakdown",
        "label": "Disclosure of financial liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of financial liabilities. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r155",
      "r257"
     ]
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialLiabilitiesLineItems",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of financial liabilities [line items]",
        "label": "Disclosure of financial liabilities [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialLiabilitiesTable",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of financial liabilities [table]",
        "label": "Disclosure of financial liabilities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to financial liabilities."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r257"
     ]
    },
    "ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialRiskManagementExplanatory",
     "presentation": [
      "http://www.abivax.com/role/Managementandassessmentoffinancialrisks"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Management and assessment of financial risks",
        "label": "Disclosure of financial risk management [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the entity's financial risk management practices and policies."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
     "presentation": [
      "http://www.abivax.com/role/TheGroup"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Group",
        "label": "Disclosure of general information about financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for general information about financial statements."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r289"
     ]
    },
    "ifrs-full_DisclosureOfGeographicalAreasLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfGeographicalAreasLineItems",
     "presentation": [
      "http://www.abivax.com/role/SegmentinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of geographical areas [line items]",
        "label": "Disclosure of geographical areas [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfGeographicalAreasTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfGeographicalAreasTable",
     "presentation": [
      "http://www.abivax.com/role/SegmentinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of geographical areas [table]",
        "label": "Disclosure of geographical areas [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to geographical areas."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "ifrs-full_DisclosureOfGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfGoodwillExplanatory",
     "presentation": [
      "http://www.abivax.com/role/Goodwillandimpairmenttest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and impairment test",
        "label": "Disclosure of goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "abvx_DisclosureOfImpactOfTheUkraineRussiaHostilitiesOnTheGroupPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfImpactOfTheUkraineRussiaHostilitiesOnTheGroupPolicyTextBlock",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of the Ukraine/Russia Hostilities on the Group",
        "label": "Disclosure Of Impact Of The Ukraine/Russia Hostilities On The Group [Policy Text Block]",
        "documentation": "Disclosure Of Impact Of The Ukraine/Russia Hostilities On The Group"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "presentation": [
      "http://www.abivax.com/role/Incometax"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax",
        "label": "Disclosure of income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "abvx_DisclosureOfIndirectMeasurementOfConvertibleLoansInstrumentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfIndirectMeasurementOfConvertibleLoansInstrumentsTableTextBlock",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of main data and assumptions used for the measurement of convertible loan notes",
        "label": "Disclosure Of Indirect Measurement Of Convertible Loans Instruments [Table Text Block]",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesTables",
      "http://www.abivax.com/role/SharebasedpaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of main data and assumptions used for the measurement of other equity instruments",
        "label": "Disclosure of indirect measurement of fair value of goods or services received, other equity instruments granted during period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's other equity instruments (ie other than share options)."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfInformationAboutEmployeesExplanatory",
     "presentation": [
      "http://www.abivax.com/role/Employees"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees",
        "label": "Disclosure of information about employees [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about employees."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems",
     "presentation": [
      "http://www.abivax.com/role/GoodwillandimpairmenttestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of information for cash-generating units [line items]",
        "label": "Disclosure of information for cash-generating units [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesTable",
     "presentation": [
      "http://www.abivax.com/role/GoodwillandimpairmenttestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of information for cash-generating units [table]",
        "label": "Disclosure of information for cash-generating units [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to cash-generating units."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r233"
     ]
    },
    "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsExplanatory",
     "presentation": [
      "http://www.abivax.com/role/Intangibleassets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Disclosure of intangible assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for intangible assets."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "ifrs-full_DisclosureOfIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsLineItems",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesIntangibleassetsDetails",
      "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails",
      "http://www.abivax.com/role/IntangibleassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about intangible assets [line items]",
        "label": "Disclosure of detailed information about intangible assets [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsTable",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesIntangibleassetsDetails",
      "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails",
      "http://www.abivax.com/role/IntangibleassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about intangible assets [table]",
        "label": "Disclosure of detailed information about intangible assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of intangible assets."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r243"
     ]
    },
    "abvx_DisclosureOfLeaseLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfLeaseLiabilitiesLineItems",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Lease Liabilities [Line Items]",
        "label": "Disclosure Of Lease Liabilities [Line Items]",
        "documentation": "Disclosure Of Lease Liabilities [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_DisclosureOfLeaseLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfLeaseLiabilitiesTable",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Lease Liabilities [Table]",
        "label": "Disclosure Of Lease Liabilities [Table]",
        "documentation": "Disclosure Of Lease Liabilities [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_DisclosureOfLeasesForLesseeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfLeasesForLesseeTableTextBlock",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of variation in lease liabilities",
        "label": "Disclosure Of Leases For Lessee [Table Text Block]",
        "documentation": "Disclosure Of Leases For Lessee"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory",
     "presentation": [
      "http://www.abivax.com/role/Accountingprinciples"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting principles",
        "label": "Disclosure of material accounting policy information [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure of material accounting policy information applied by the entity."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r276",
      "r286"
     ]
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of maturity analysis for derivative financial liabilities [line items]",
        "label": "Disclosure of maturity analysis for derivative financial liabilities [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of maturity analysis for derivative financial liabilities [table]",
        "label": "Disclosure of maturity analysis for derivative financial liabilities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the maturity analysis for derivative financial liabilities."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r268"
     ]
    },
    "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory",
     "presentation": [
      "http://www.abivax.com/role/RetirementbenefitobligationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of changes in projected benefit obligation",
        "label": "Disclosure of net defined benefit liability (asset) [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of a net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r16",
      "r212"
     ]
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems",
     "presentation": [
      "http://www.abivax.com/role/BasisofpreparationDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of non-adjusting events after reporting period [line items]",
        "label": "Disclosure of non-adjusting events after reporting period [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable",
     "presentation": [
      "http://www.abivax.com/role/BasisofpreparationDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of non-adjusting events after reporting period [table]",
        "label": "Disclosure of non-adjusting events after reporting period [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r199"
     ]
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reconciliation of other equity instruments",
        "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfOffBalanceSheetCommitmentsLineItems",
     "presentation": [
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Off-Balance Sheet Commitments [Line Items]",
        "label": "Disclosure Of Off-Balance Sheet Commitments [Line Items]",
        "documentation": "Disclosure Of Off-Balance Sheet Commitments [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_DisclosureOfOffBalanceSheetCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfOffBalanceSheetCommitmentsTable",
     "presentation": [
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Off-Balance Sheet Commitments [Table]",
        "label": "Disclosure Of Off-Balance Sheet Commitments [Table]",
        "documentation": "Disclosure Of Off-Balance Sheet Commitments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_DisclosureOfOperatingIncomeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfOperatingIncomeLineItems",
     "presentation": [
      "http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Operating Income [Line Items]",
        "label": "Disclosure Of Operating Income [Line Items]",
        "documentation": "Disclosure Of Operating Income [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_DisclosureOfOperatingIncomeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfOperatingIncomeTable",
     "presentation": [
      "http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Operating Income [Table]",
        "label": "Disclosure Of Operating Income [Table]",
        "documentation": "Disclosure Of Operating Income [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOtherAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfOtherAssetsExplanatory",
     "presentation": [
      "http://www.abivax.com/role/Otherfinancialassets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other financial assets",
        "label": "Disclosure of other assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other assets. [Refer: Other assets]"
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfOtherOperatingExpenseExplanatory",
     "presentation": [
      "http://www.abivax.com/role/Operatingexpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "label": "Disclosure of other operating expense [text block]"
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfOtherOperatingIncomeExplanatory",
     "presentation": [
      "http://www.abivax.com/role/Otheroperatingincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating income",
        "label": "Disclosure of other operating income [text block]"
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
     "presentation": [
      "http://www.abivax.com/role/Offbalancesheetcommitmentsreceivedandcontingentassets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Off-balance sheet commitments received and contingent assets",
        "label": "Disclosure of other provisions, contingent liabilities and contingent assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for other provisions, contingent liabilities and contingent assets."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfOtherReceivablesAndOtherAssetsLineItems",
     "presentation": [
      "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Other Receivables And Other Assets [Line Items]",
        "label": "Disclosure Of Other Receivables And Other Assets [Line Items]",
        "documentation": "Disclosure Of Other Receivables And Other Assets [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_DisclosureOfOtherReceivablesAndOtherAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfOtherReceivablesAndOtherAssetsTable",
     "presentation": [
      "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Other Receivables And Other Assets [Table]",
        "label": "Disclosure Of Other Receivables And Other Assets [Table]",
        "documentation": "Disclosure Of Other Receivables And Other Assets [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_DisclosureOfPrincipalAuditFeesAndServicesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfPrincipalAuditFeesAndServicesTableTextBlock",
     "presentation": [
      "http://www.abivax.com/role/OperatingexpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of principal audit fees and services",
        "label": "Disclosure Of Principal Audit Fees And Services [Table Text Block]",
        "documentation": "Disclosure Of Principal Audit Fees And Services"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.abivax.com/role/Propertyplantandequipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment",
        "label": "Disclosure of property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails",
      "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [line items]",
        "label": "Disclosure of detailed information about property, plant and equipment [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails",
      "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [table]",
        "label": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r209"
     ]
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems",
     "presentation": [
      "http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of quantitative information about right-of-use assets [line items]",
        "label": "Disclosure of quantitative information about right-of-use assets [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable",
     "presentation": [
      "http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of quantitative information about right-of-use assets [table]",
        "label": "Disclosure of quantitative information about right-of-use assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to right-of-use assets."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r178"
     ]
    },
    "abvx_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock",
     "presentation": [
      "http://www.abivax.com/role/IncometaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reconciliation of effective income tax (loss)",
        "label": "Disclosure Of Reconciliation Of Accounting Profit Multiplied By Applicable Tax Rates And Average Effective Tax Rate [Table Text Block]",
        "documentation": "Disclosure Of Reconciliation Of Accounting Profit Multiplied By Applicable Tax Rates And Average Effective Tax Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInPropertyPlantAndEquipmentIncludingRightofuseAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfReconciliationOfChangesInPropertyPlantAndEquipmentIncludingRightofuseAssetsExplanatory",
     "presentation": [
      "http://www.abivax.com/role/PropertyplantandequipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reconciliation of property, plant and equipment",
        "label": "Disclosure of reconciliation of changes in property, plant and equipment, including right-of-use assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the reconciliation of changes in property, plant and equipment, including right-of-use assets."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reconciliation of liabilities arising from financing activities",
        "label": "Disclosure of reconciliation of liabilities arising from financing activities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the reconciliation of liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r194",
      "r331"
     ]
    },
    "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reconciliation of liabilities arising from financing activities [line items]",
        "label": "Disclosure of reconciliation of liabilities arising from financing activities [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reconciliation of liabilities arising from financing activities [table]",
        "label": "Disclosure of reconciliation of liabilities arising from financing activities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the reconciliation of liabilities arising from financing activities."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r331"
     ]
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "presentation": [
      "http://www.abivax.com/role/Relatedparties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related parties",
        "label": "Disclosure of related party [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "presentation": [
      "http://www.abivax.com/role/Shareholdersequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders\u2019 equity",
        "label": "Disclosure of share capital, reserves and other equity interest [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r275",
      "r307"
     ]
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "presentation": [
      "http://www.abivax.com/role/Sharebasedpayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payments",
        "label": "Disclosure of share-based payment arrangements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "abvx_DisclosureOfSignificantEventsForThePeriodReportedAndEventsAfterReportingPeriodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfSignificantEventsForThePeriodReportedAndEventsAfterReportingPeriodTextBlock",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequentevents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent event",
        "label": "Disclosure Of Significant Events For The Period Reported And Events After Reporting Period [Text Block]",
        "documentation": "Disclosure Of Significant Events For The Period Reported And Events After Reporting Period"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_DisclosureOfTaxAndEmployeeRelatedPayablesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfTaxAndEmployeeRelatedPayablesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.abivax.com/role/PayablesandothercurrentliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of tax and employee-related payables",
        "label": "Disclosure Of Tax And Employee-Related Payables Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Tax And Employee-Related Payables Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
     "presentation": [
      "http://www.abivax.com/role/IncometaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of deferred tax assets and liabilities by nature",
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r205"
     ]
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems",
     "presentation": [
      "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails",
      "http://www.abivax.com/role/IncometaxNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]",
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable",
     "presentation": [
      "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails",
      "http://www.abivax.com/role/IncometaxNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]",
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r205"
     ]
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [line items]",
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [table]",
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r253"
     ]
    },
    "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTradeAndOtherPayablesExplanatory",
     "presentation": [
      "http://www.abivax.com/role/Payablesandothercurrentliabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payables and other current liabilities",
        "label": "Disclosure of trade and other payables [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]"
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory",
     "presentation": [
      "http://www.abivax.com/role/Otherreceivablesandotherassets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables and other assets",
        "label": "Disclosure of trade and other receivables [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]"
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
     "presentation": [
      "http://www.abivax.com/role/RelatedpartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of aggregate compensation of the members of the Group\u2019s Board of Directors and CEO",
        "label": "Disclosure of transactions between related parties [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r32",
      "r223"
     ]
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems",
     "presentation": [
      "http://www.abivax.com/role/RelatedpartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of transactions between related parties [line items]",
        "label": "Disclosure of transactions between related parties [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable",
     "presentation": [
      "http://www.abivax.com/role/RelatedpartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of transactions between related parties [table]",
        "label": "Disclosure of transactions between related parties [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to transactions between related parties."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r225"
     ]
    },
    "abvx_DisclosureOfWarrantsArrangementsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfWarrantsArrangementsLineItems",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Warrants Arrangements [Line Items]",
        "label": "Disclosure Of Warrants Arrangements [Line Items]",
        "documentation": "Disclosure Of Warrants Arrangements"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_DisclosureOfWarrantsArrangementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DisclosureOfWarrantsArrangementsTable",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Warrants Arrangements [Table]",
        "label": "Disclosure Of Warrants Arrangements [Table]",
        "documentation": "Disclosure Of Warrants Arrangements"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_DiscountRateAppliedToLongTermAdvances": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DiscountRateAppliedToLongTermAdvances",
     "presentation": [
      "http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disount rate applied to long-term advances",
        "label": "Discount Rate Applied To Long-Term Advances",
        "documentation": "Discount Rate Applied To Long-Term Advances"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DiscountRateMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DiscountRateMeasurementInputMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Discount rate, measurement input [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a discount rate used as a measurement input used in valuation techniques based on a present value calculation."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "ifrs-full_DiscountedCashFlowMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DiscountedCashFlowMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discounted cash flow",
        "label": "Discounted cash flow [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a specific valuation technique consistent with the income approach that involves analysing future cash flow amounts through the application of present value techniques and inputs (for example, weighted average cost of capital, long-term revenue growth rate, long-term pre-tax operating margin, discount for lack of marketability, control premium). [Refer: Income approach [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r338",
      "r344"
     ]
    },
    "ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Disposal",
        "label": "Disposals, property, plant and equipment including right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in property, plant and equipment including right-of-use assets resulting from disposals. [Refer: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Accounting Standard",
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r382",
      "r405"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r382",
      "r405",
      "r448"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Registration Statement",
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Shell Company Report",
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "abvx_DrawdownProbablityMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "DrawdownProbablityMeasurementInputMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Probability of Drawdown of Tranche C credit facility",
        "label": "Drawdown Probablity, Measurement Input [Member]",
        "documentation": "Drawdown Probablity, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "abvx_EarlyRedemptionAmountMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "EarlyRedemptionAmountMeasurementInputMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Early redemption amount (put event)",
        "label": "Early Redemption Amount, Measurement Input [Member]",
        "documentation": "Early Redemption Amount, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss per share (\u20ac/share)",
        "label": "Earnings per share [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EarningsPerShareExplanatory",
     "presentation": [
      "http://www.abivax.com/role/IncomelosspershareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of earnings per share",
        "label": "Earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of earnings per share."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "abvx_EbolaConditionalAdvanceBPIFranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "EbolaConditionalAdvanceBPIFranceMember",
     "presentation": [
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ebola conditional advance, BPI France",
        "label": "Ebola Conditional Advance, BPI France [Member]",
        "documentation": "Ebola Conditional Advance, BPI France"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_EbolaConditionalAdvanceBPILanguedocRoussillonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "EbolaConditionalAdvanceBPILanguedocRoussillonMember",
     "presentation": [
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ebola conditional advance, BPI Languedoc-Roussillon",
        "label": "Ebola Conditional Advance, BPI Languedoc-Roussillon [Member]",
        "documentation": "Ebola Conditional Advance, BPI Languedoc-Roussillon"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_EbolaConditionalAdvanceBPIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "EbolaConditionalAdvanceBPIMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofconditionaladvancesDetails",
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ebola conditional advance",
        "verboseLabel": "EBOLA \u2013 Bpifrance",
        "label": "Ebola Conditional Advance, BPI [Member]",
        "documentation": "Ebola Conditional Advance, BPI"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.abivax.com/role/CashandcashequivalentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of movements in exchange rates on cash held",
        "label": "Effect of exchange rate changes on cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r74",
      "r75"
     ]
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EmployeeBenefitsExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails",
      "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails",
      "http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Personnel costs",
        "label": "Employee benefits expense"
       }
      }
     },
     "auth_ref": [
      "r187",
      "r279",
      "r314",
      "r369"
     ]
    },
    "abvx_EmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "EmployeeMember",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee",
        "label": "Employee [Member]",
        "documentation": "Employee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitiesTable",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entities [Table]",
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Addresses, Address Type [Axis]",
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Information [Line Items]",
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Listings, Exchange [Axis]",
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.abivax.com/role/TheGroupDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shareholders\u2019 equity",
        "periodStartLabel": "Equity at beginning of period",
        "periodEndLabel": "Equity at end of period",
        "terseLabel": "Equity",
        "label": "Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r88",
      "r103",
      "r104",
      "r106",
      "r226",
      "r251",
      "r270",
      "r271",
      "r278",
      "r296",
      "r304"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EquityAbstract",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders\u2019 equity",
        "label": "Equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY",
        "label": "Equity and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EquityAndLiabilitiesAbstract",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY",
        "label": "Equity and liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "EquityInstrumentFairValueOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "FAIR VALUE OF THE BSA (in euro per share)",
        "terseLabel": "FAIR VALUE OF THE AGA (in euro per share)",
        "label": "Equity Instrument Fair Value, Other Equity Instruments Granted",
        "documentation": "Equity Instrument Fair Value, Other Equity Instruments Granted"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "EquityInstrumentPriceOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "BSA SUBSCRIPTION PRICE (in euro per share)",
        "terseLabel": "AGA PRICE (in euro per share)",
        "label": "Equity Instrument Price, Other Equity Instruments Granted",
        "documentation": "Equity Instrument Price, Other Equity Instruments Granted"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_EquityInstrumentStrikePriceOtherEquityInstrumentsGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "EquityInstrumentStrikePriceOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STRIKE PRICE PER SHARE ( in euro per share)",
        "label": "Equity Instrument Strike Price, Other Equity Instruments Granted",
        "documentation": "Equity Instrument Strike Price, Other Equity Instruments Granted"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_EquityIssuanceCashCarveOut": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "EquityIssuanceCashCarveOut",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity issuance, cash carve-out",
        "label": "Equity Issuance, Cash Carve-Out",
        "documentation": "Equity Issuance, Cash Carve-Out"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_EquityIssuancePercentageOfCurrentShareCapital": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "EquityIssuancePercentageOfCurrentShareCapital",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity issuance, percentage of current share capital",
        "label": "Equity Issuance, Percentage Of Current Share Capital",
        "documentation": "Equity Issuance, Percentage Of Current Share Capital"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_EquityIssuanceSubscriptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "EquityIssuanceSubscriptionPricePerShare",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails",
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails",
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity issuance, subscripion price per share (in euro per share)",
        "label": "Equity Issuance, Subscription Price Per Share",
        "documentation": "Equity Issuance, Subscription Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r398",
      "r409",
      "r419",
      "r452"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r395",
      "r406",
      "r416",
      "r449"
     ]
    },
    "abvx_EuropeanCentralBankBaseRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "EuropeanCentralBankBaseRateMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "European Central Bank base rate",
        "label": "European Central Bank Base Rate [Member]",
        "documentation": "European Central Bank Base Rate"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange [Domain]",
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember",
     "presentation": [
      "http://www.abivax.com/role/IntangibleassetsNarrativeDetails",
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exclusive licensing agreement with CNRS, University of Montpellier and Institut Curie",
        "label": "Exclusive Licensing Agreement With CNRS, University Of Montpellier And Institut Curie [Member]",
        "documentation": "Exclusive Licensing Agreement With CNRS, University Of Montpellier And Institut Curie"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember",
     "presentation": [
      "http://www.abivax.com/role/IntangibleassetsNarrativeDetails",
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exclusive licensing contract with the Scripps Research Institute, University of Chicago and Brigham Young University",
        "label": "Exclusive Licensing Contract With The Scripps Research Institute, University Of Chicago And Brigham Young University [Member]",
        "documentation": "Exclusive Licensing Contract With The Scripps Research Institute, University Of Chicago And Brigham Young University"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "abvx_ExerciseOfDerivativeInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ExerciseOfDerivativeInstruments",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Exercises",
        "label": "Exercise Of Derivative Instruments",
        "documentation": "Exercise Of Derivative Instruments"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ExercisePriceOtherEquityInstrumentsGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ExercisePriceOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price, other equity instruments granted (in euro per share)",
        "label": "Exercise Price, Other Equity Instruments Granted",
        "documentation": "Exercise Price, Other Equity Instruments Granted"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ExercisePricePerShareMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ExercisePricePerShareMeasurementInputMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price per share (in euro per share)",
        "label": "Exercise Price Per Share, Measurement Input [Member]",
        "documentation": "Exercise Price Per Share, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price, percentage of 15-day WVAP",
        "label": "Exercise Price, Percentage Of 15-Day WVAP, Other Equity Instruments Granted",
        "documentation": "Exercise Price, Percentage Of 15-Day WVAP, Other Equity Instruments Granted"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price, percentage of premium",
        "label": "Exercise Price, Percentage Of Premium Over 15-Day VWAP, Other Equity Instruments Granted",
        "documentation": "Exercise Price, Percentage Of Premium Over 15-Day VWAP, Other Equity Instruments Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExercisePriceShareOptionsGranted2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ExercisePriceShareOptionsGranted2019",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreos1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price, share options granted (in euro per share)",
        "label": "Exercise price, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of share options granted."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "abvx_ExpectedDividendMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ExpectedDividendMeasurementInputMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend",
        "label": "Expected Dividend, Measurement Input [Member]",
        "documentation": "Expected Dividend, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ExpectedMaturityOtherEquityInstrumentsGranted": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ExpectedMaturityOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EXPECTED MATURITY",
        "label": "Expected Maturity, Other Equity Instruments Granted",
        "documentation": "Expected Maturity, Other Equity Instruments Granted"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ExpectedProceedsFromShareIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ExpectedProceedsFromShareIssuance",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected proceeds from share issuance",
        "label": "Expected Proceeds From Share Issuance",
        "documentation": "Expected Proceeds From Share Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ExpectedProceedsFromShareIssuanceShelfRegistration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ExpectedProceedsFromShareIssuanceShelfRegistration",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected proceeds from share issuance, shelf registration",
        "label": "Expected Proceeds From Share Issuance, Shelf Registration",
        "documentation": "Expected Proceeds From Share Issuance, Shelf Registration"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ExpectedVolatilityOtherEquityInstrumentsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ExpectedVolatilityOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "VOLATILITY",
        "label": "Expected Volatility, Other Equity Instruments Granted",
        "documentation": "Expected Volatility, Other Equity Instruments Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseByNatureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ExpenseByNatureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Expenses by nature [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails": {
       "parentTag": "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Social taxes related to AGAs",
        "label": "Expense From Equity-Settled Share-Based Payment Transactions, Social Taxes",
        "documentation": "Expense From Equity-Settled Share-Based Payment Transactions, Social Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails": {
       "parentTag": "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation expense",
        "label": "Expense from equity-settled share-based payment transactions"
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Expense from share-based payment transactions"
       }
      }
     },
     "auth_ref": [
      "r135",
      "r254"
     ]
    },
    "abvx_ExpenseOnLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ExpenseOnLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense on lease liabilities",
        "label": "Expense On Lease Liabilities",
        "documentation": "Expense On Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense relating to short-term leases",
        "label": "Expense Relating To Short-Term Leases And Low Value Assets For Which Recognition Exemption Has Been Used",
        "documentation": "Expense Relating To Short-Term Leases And Low Value Assets For Which Recognition Exemption Has Been Used"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ExpiryScenarioPeriodOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiry scenario period, other equity instruments granted",
        "label": "Expiry Scenario Period, Other Equity Instruments Granted",
        "documentation": "Expiry Scenario Period, Other Equity Instruments Granted"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ExpiryScenarioProbablityMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ExpiryScenarioProbablityMeasurementInputMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "7-year expiry scenario probability",
        "label": "Expiry Scenario Probablity, Measurement Input [Member]",
        "documentation": "Expiry Scenario Probablity, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of breakdown of the compensation expenses",
        "label": "Explanation of effect of share-based payments on entity's profit or loss [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The explanation that enables users of financial statements to understand the effect of share-based payment transactions on the entity's profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "country_FR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "FR",
     "presentation": [
      "http://www.abivax.com/role/EmployeesDetails",
      "http://www.abivax.com/role/IncometaxNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "France",
        "label": "FRANCE"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_FairValueMeasurementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "FairValueMeasurementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement [Abstract]",
        "documentation": "Fair Value Measurement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_FinalRedemptionFairValueOfMRIMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "FinalRedemptionFairValueOfMRIMeasurementInputMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total fair value of MRI, final redemption",
        "label": "Final Redemption, Fair Value Of MRI , Measurement Input [Member]",
        "documentation": "Final Redemption, Fair Value Of MRI , Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Final redemption, probability-weighted fair value with MRI",
        "label": "Final Redemption, Probability-Weighted Fair Value With MRI , Measurement Input [Member]",
        "documentation": "Final Redemption, Probability-Weighted Fair Value With MRI , Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Final redemption, probability-weighted fair value without MRI",
        "label": "Final Redemption, Probability-Weighted Fair Value Without MRI , Measurement Input [Member]",
        "documentation": "Final Redemption, Probability-Weighted Fair Value Without MRI , Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Probability-weighted present value of shortfall payment, final redemption",
        "label": "Final Redemption, Probability-Weighted Present Value Of Shortfall Payment, Measurement Input [Member]",
        "documentation": "Final Redemption,Probability-Weighted Present Value Of Shortfall Payment, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_FinalRedemptionScenarioProbabilityMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "FinalRedemptionScenarioProbabilityMeasurementInputMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Final redemption scenario probability",
        "label": "Final Redemption Scenario Probability, Measurement Input [Member]",
        "documentation": "Final Redemption Scenario Probability, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS",
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Financial expenses",
        "negatedTotalLabel": "Financial expenses",
        "label": "Finance costs"
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "ifrs-full_FinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS",
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial income",
        "totalLabel": "Financial income",
        "label": "Finance income"
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "ifrs-full_FinanceIncomeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinanceIncomeCost",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS",
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Financial gain (loss)",
        "label": "Finance income (cost)"
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "abvx_FinancialAgreementAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "FinancialAgreementAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial agreement, amount",
        "label": "Financial Agreement, Amount",
        "documentation": "Financial Agreement, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_FinancialAgreementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "FinancialAgreementAxis",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Agreement [Axis]",
        "label": "Financial Agreement [Axis]",
        "documentation": "Financial Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_FinancialAgreementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "FinancialAgreementDomain",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Agreement [Domain]",
        "label": "Financial Agreement [Domain]",
        "documentation": "Financial Agreement [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_FinancialAgreementNumberOfTransactions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "FinancialAgreementNumberOfTransactions",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial agreement, number of transactions",
        "label": "Financial Agreement, Number Of Transactions",
        "documentation": "Financial Agreement, Number Of Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinancialAssetsAtAmortisedCostCategoryMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS AT AMORTIZED COST",
        "label": "Financial assets at amortised cost, category [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets at amortised cost category. [Refer: Financial assets at amortised cost]"
       }
      }
     },
     "auth_ref": [
      "r158",
      "r260"
     ]
    },
    "ifrs-full_FinancialAssetsAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinancialAssetsAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets, at fair value",
        "label": "Financial assets, at fair value"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value of financial assets. [Refer: At fair value [member]; Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS AT FAIR VALUE THROUGH PROFIT\u00a0AND LOSS",
        "label": "Financial assets at fair value through profit or loss, category [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets at fair value through profit or loss category. [Refer: Financial assets at fair value through profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r156",
      "r258"
     ]
    },
    "abvx_FinancialIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "FinancialIncomeLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Income (Loss) [Abstract]",
        "documentation": "Financial Income (Loss)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial liabilities",
        "label": "Financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinancialLiabilitiesAtAmortisedCostCategoryMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AT\u00a0AMORTIZED COST",
        "label": "Financial liabilities at amortised cost, category [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities at amortised cost category. [Refer: Financial liabilities at amortised cost]"
       }
      }
     },
     "auth_ref": [
      "r159",
      "r261"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinancialLiabilitiesAtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities, at fair value",
        "label": "Financial liabilities, at fair value"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AT FAIR VALUE THROUGH PROFIT\u00a0AND LOSS",
        "label": "Financial liabilities at fair value through profit or loss, category [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities at fair value through profit or loss category. [Refer: Financial liabilities at fair value through profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r157",
      "r259"
     ]
    },
    "abvx_FinancialLiabilitiesUndiscountedCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "FinancialLiabilitiesUndiscountedCashFlows",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Financial liabilities, undiscounted cash flows",
        "label": "Financial Liabilities, Undiscounted Cash Flows",
        "documentation": "Financial Liabilities, Undiscounted Cash Flows"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_FinancialRiskManagementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "FinancialRiskManagementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Risk Management [Abstract]",
        "documentation": "Financial Risk Management [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FixturesAndFittingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FixturesAndFittingsMember",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office fixtures and fittings",
        "label": "Fixtures and fittings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing fixtures and fittings that are not permanently attached to real property. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "ifrs-full_ForeignExchangeGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ForeignExchangeGain",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": {
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails",
      "http://www.abivax.com/role/FinancialgainlossNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange gains",
        "label": "Foreign exchange gain"
       }
      }
     },
     "auth_ref": [
      "r24",
      "r219",
      "r288"
     ]
    },
    "abvx_ForeignExchangeGainsLossesOnTranslationOfForeignOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ForeignExchangeGainsLossesOnTranslationOfForeignOperations",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialgainlossNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation differences gains (loss)",
        "label": "Foreign Exchange Gains (Losses) On Translation Of Foreign Operations",
        "documentation": "Foreign Exchange Gains (Losses) On Translation Of Foreign Operations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ForeignExchangeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ForeignExchangeLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails",
      "http://www.abivax.com/role/FinancialgainlossNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Foreign exchange losses",
        "terseLabel": "Foreign exchange loss",
        "label": "Foreign exchange loss"
       }
      }
     },
     "auth_ref": [
      "r24",
      "r219",
      "r288"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r402",
      "r413",
      "r423",
      "r456"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r402",
      "r413",
      "r423",
      "r456"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r402",
      "r413",
      "r423",
      "r456"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r402",
      "r413",
      "r423",
      "r456"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r402",
      "r413",
      "r423",
      "r456"
     ]
    },
    "abvx_FormerChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "FormerChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Former Chief Executive Officer",
        "label": "Former Chief Executive Officer [Member]",
        "documentation": "Former Chief Executive Officer"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_FoundersShareSubscriptionWarrantsBCEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "FoundersShareSubscriptionWarrantsBCEMember",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total BCEs",
        "verboseLabel": "BCEs",
        "label": "Founders\u2019 Share Subscription Warrants (BCE) [Member]",
        "documentation": "Founders\u2019 Share Subscription Warrants (BCE)"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "abvx_FreeSharesAGAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "FreeSharesAGAMember",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total AGAs",
        "netLabel": "Free shares (AGA)",
        "verboseLabel": "AGAs",
        "label": "Free Shares (AGA) [Member]",
        "documentation": "Free Shares (AGA)"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_FurnitureAndComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "FurnitureAndComputerEquipmentMember",
     "presentation": [
      "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FURNITURE AND COMPUTER EQUIPMENT",
        "label": "Furniture And Computer Equipment [Member]",
        "documentation": "Furniture And Computer Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_FurnitureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "FurnitureMember",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture",
        "label": "Furniture [Member]",
        "documentation": "Furniture"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreos1Details",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss of extinguishment",
        "label": "Gain (loss) arising from difference between carrying amount of financial liability extinguished and consideration paid"
       }
      },
      "en": {
       "role": {
        "documentation": "The gain (loss) arising from the difference between the carrying amount of the financial liability extinguished and the measurement of the consideration paid (equity instruments issued) to the creditor. [Refer: Carrying amount [member]]"
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofchangesinprojectedbenefitobligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Actuarial gains and losses",
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r19",
      "r215"
     ]
    },
    "abvx_GainsArisingFromDerecognitionOfFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "GainsArisingFromDerecognitionOfFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": {
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on derecognition of financial liabilities",
        "label": "Gains Arising From Derecognition Of Financial Liabilities",
        "documentation": "Gains Arising From Derecognition Of Financial Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_GainsArisingFromRecognitionOfFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "GainsArisingFromRecognitionOfFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": {
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails",
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Day-one gain on recognition of financial liabilities",
        "label": "Gains Arising From Recognition Of Financial Liabilities",
        "documentation": "Gains Arising From Recognition Of Financial Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsOnChangeInFairValueOfDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GainsOnChangeInFairValueOfDerivatives",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": {
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails",
      "http://www.abivax.com/role/FinancialgainlossNarrativeDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease in fair value",
        "terseLabel": "(Increase) / decrease in derivatives fair value",
        "verboseLabel": "Gains on change in fair value of derivatives",
        "label": "Gains on change in fair value of derivatives"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "abvx_GainsOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "GainsOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": {
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Increase) / decrease in other liabilities / (assets) at fair value through profit and loss",
        "label": "Gains On Financial Liabilities At Fair Value Through Profit Or Loss",
        "documentation": "Gains On Financial Liabilities At Fair Value Through Profit Or Loss"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "General and administrative",
        "label": "General and administrative expense"
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "abvx_GeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "GeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails",
      "http://www.abivax.com/role/OperatingexpensesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expense",
        "label": "General And Administrative Expenses [Member]",
        "documentation": "General And Administrative Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GeographicalAreasAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GeographicalAreasAxis",
     "presentation": [
      "http://www.abivax.com/role/EmployeesDetails",
      "http://www.abivax.com/role/SegmentinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical areas [axis]",
        "label": "Geographical areas [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r317",
      "r345",
      "r350",
      "r363"
     ]
    },
    "ifrs-full_GeographicalAreasDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GeographicalAreasDomain",
     "presentation": [
      "http://www.abivax.com/role/EmployeesDetails",
      "http://www.abivax.com/role/SegmentinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical areas [domain]",
        "label": "Geographical areas [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r317",
      "r345",
      "r350",
      "r363"
     ]
    },
    "ifrs-full_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.abivax.com/role/GoodwillandimpairmenttestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r47",
      "r52",
      "r137",
      "r229",
      "r234",
      "r256",
      "r290"
     ]
    },
    "ifrs-full_GrossCarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GrossCarryingAmountMember",
     "presentation": [
      "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails",
      "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GROSS VALUES",
        "label": "Gross carrying amount [member]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r57",
      "r68",
      "r71",
      "r137",
      "r146",
      "r148",
      "r207",
      "r238",
      "r247",
      "r250",
      "r265",
      "r266",
      "r352"
     ]
    },
    "ifrs-full_GrossLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GrossLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": {
       "parentTag": "abvx_FinancialLiabilitiesUndiscountedCashFlows",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross lease liabilities",
        "label": "Gross lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r117",
      "r179",
      "r355"
     ]
    },
    "abvx_GrossProceedsFromNonConvertibleLoansNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "GrossProceedsFromNonConvertibleLoansNotes",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the issuance of non-convertible bond loans",
        "label": "Gross Proceeds From Non-Convertible Loans Notes",
        "documentation": "Gross Proceeds From Non-Convertible Loans Notes"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_HeightsConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "HeightsConvertibleNotesMember",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Heights convertible notes",
        "label": "Heights Convertible Notes [Member]",
        "documentation": "Heights Convertible Notes"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_HeightsConvertibleNotesTrancheAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "HeightsConvertibleNotesTrancheAMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Heights convertible notes, tranche A",
        "label": "Heights Convertible Notes, Tranche A [Member]",
        "documentation": "Heights Convertible Notes, Tranche A"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_HeightsConvertibleNotesTrancheBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "HeightsConvertibleNotesTrancheBMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/OffbalancesheetcommitmentsreceivedandcontingentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Heights convertible notes, tranche B",
        "label": "Heights Convertible Notes, Tranche B [Member]",
        "documentation": "Heights Convertible Notes, Tranche B"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "HistoricalVolatilityForSharesMeasurementInputMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility",
        "label": "Historical volatility for shares, measurement input [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the historical volatility for shares used as a measurement input."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r381",
      "r382",
      "r405"
     ]
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLossGoodwill",
     "presentation": [
      "http://www.abivax.com/role/GoodwillandimpairmenttestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss recognised in profit or loss, goodwill",
        "label": "Impairment loss recognised in profit or loss, goodwill"
       }
      }
     },
     "auth_ref": [
      "r136",
      "r255"
     ]
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill",
     "presentation": [
      "http://www.abivax.com/role/GoodwillandimpairmenttestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss recognised in profit or loss, intangible assets and goodwill",
        "label": "Impairment loss recognised in profit or loss, intangible assets and goodwill"
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://www.abivax.com/role/GoodwillandimpairmenttestDetails",
      "http://www.abivax.com/role/IntangibleassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Impairment loss recognised in profit or loss, intangible assets other than goodwill",
        "label": "Impairment loss recognised in profit or loss, intangible assets other than goodwill"
       }
      }
     },
     "auth_ref": [
      "r59",
      "r240"
     ]
    },
    "abvx_IncomeFromDepositaryServiceFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "IncomeFromDepositaryServiceFees",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/OtheroperatingincomeDisclosureofbreakdownofoperatingincomeDetails": {
       "parentTag": "ifrs-full_OtherIncome",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/OtheroperatingincomeDisclosureofbreakdownofoperatingincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depositary service fees",
        "label": "Income From Depositary Service Fees",
        "documentation": "Income From Depositary Service Fees"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_IncomeFromResearchTaxCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "IncomeFromResearchTaxCredit",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/OtheroperatingincomeDisclosureofbreakdownofoperatingincomeDetails": {
       "parentTag": "ifrs-full_OtherIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/OtheroperatingincomeDisclosureofbreakdownofoperatingincomeDetails",
      "http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research tax credit (\"CIR\")",
        "label": "Income From Research Tax Credit",
        "documentation": "Income From Research Tax Credit"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS",
      "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income tax",
        "negatedTotalLabel": "Effective income tax (loss)",
        "label": "Tax expense (income)"
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r37",
      "r101",
      "r164",
      "r200",
      "r201",
      "r202",
      "r312"
     ]
    },
    "ifrs-full_IncomeTaxesPaidRefundAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncomeTaxesPaidRefundAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes paid (refund) [abstract]",
        "label": "Income taxes paid (refund) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income taxes paid",
        "label": "Income taxes paid (refund), classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]"
       }
      }
     },
     "auth_ref": [
      "r77",
      "r323"
     ]
    },
    "abvx_IncreaseDecreaseFromFreeSharesIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "IncreaseDecreaseFromFreeSharesIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issue of free shares",
        "label": "Increase (Decrease) From Free Shares Issued",
        "documentation": "Increase (Decrease) From Free Shares Issued"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "IncreaseDecreaseInCarryingValueDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in carrying value due to reasonably possible decrease in unobservable input liabilities",
        "label": "Increase (Decrease) In Carrying Value Due To Reasonably Possible Decrease In Unobservable Input Liabilities",
        "documentation": "Increase (Decrease) In Carrying Value Due To Reasonably Possible Decrease In Unobservable Input Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "IncreaseDecreaseInCarryingValueDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in carrying value due to reasonably possible increase in unobservable input liabilities",
        "label": "Increase (Decrease) In Carrying Value Due To Reasonably Possible Increase In Unobservable Input Liabilities",
        "documentation": "Increase (Decrease) In Carrying Value Due To Reasonably Possible Increase In Unobservable Input Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (decrease) in cash and cash equivalents",
        "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r82",
      "r196"
     ]
    },
    "abvx_IncreaseDecreaseInCrohnsDiseaseResearchExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "IncreaseDecreaseInCrohnsDiseaseResearchExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/OperatingexpensesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in Crohn's Disease research expenses",
        "label": "Increase (Decrease) In Crohn's Disease Research Expenses",
        "documentation": "Increase (Decrease) In Crohn's Disease Research Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_IncreaseDecreaseInEmployerTaxAndSocialContributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "IncreaseDecreaseInEmployerTaxAndSocialContributions",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/OperatingexpensesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in employer tax and social contributions",
        "label": "Increase (Decrease) In Employer Tax And Social Contributions",
        "documentation": "Increase (Decrease) In Employer Tax And Social Contributions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in financial liabilities at fair value due to reasonably possible decrease in unobservable input",
        "label": "Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of increase (decrease) in the fair value measurement of liabilities due to a reasonably possible decrease in an unobservable input."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decrease in financial assets at fair value",
        "terseLabel": "Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets",
        "label": "Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of increase (decrease) in the fair value measurement of assets due to a reasonably possible increase in an unobservable input."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decrease in financial liabilities at fair value",
        "verboseLabel": "Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, liabilities",
        "terseLabel": "Increase (decrease) in financial liabilities at fair value due to reasonably possible increase in unobservable input",
        "label": "Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of increase (decrease) in the fair value measurement of liabilities due to a reasonably possible increase in an unobservable input."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssued",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in number of ordinary shares issued (in shares)",
        "label": "Increase (decrease) in number of ordinary shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails",
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails",
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital increase from issuance of ordinary shares (in shares)",
        "label": "Increase (Decrease) In Number Of Ordinary Shares Issued Through Capital Increase",
        "documentation": "Increase (Decrease) In Number Of Ordinary Shares Issued Through Capital Increase"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible instruments (in shares)",
        "label": "Increase (Decrease) In Number Of Shares Issued Through Conversion Of Convertible Instruments",
        "documentation": "Increase (Decrease) In Number Of Shares Issued Through Conversion Of Convertible Instruments"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.abivax.com/role/FinancialliabilitiesKreos1Details",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercises of share warrants (in shares)",
        "label": "Increase (Decrease) In Number Of Shares Issued Through Exercise Of Share Warrants",
        "documentation": "Increase (Decrease) In Number Of Shares Issued Through Exercise Of Share Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_IncreaseDecreaseInTransversalActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "IncreaseDecreaseInTransversalActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/OperatingexpensesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in transversal activities",
        "label": "Increase (Decrease) In Transversal Activities",
        "documentation": "Increase (Decrease) In Transversal Activities"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_IncreaseDecreaseInTransversalActivitiesCombinationTherapy": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "IncreaseDecreaseInTransversalActivitiesCombinationTherapy",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/OperatingexpensesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in transversal activities, combination therapy",
        "label": "Increase (Decrease) In Transversal Activities, Combination Therapy",
        "documentation": "Increase (Decrease) In Transversal Activities, Combination Therapy"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_IncreaseDecreaseInUlcerativeColitisExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "IncreaseDecreaseInUlcerativeColitisExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/OperatingexpensesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in Ulcerative Colitis expenses",
        "label": "Increase (Decrease) In Ulcerative Colitis Expenses",
        "documentation": "Increase (Decrease) In Ulcerative Colitis Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseInWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInWorkingCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Changes in working capital requirements",
        "label": "Increase (decrease) in working capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in working capital."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Increase (decrease) through amortization cost remeasurement",
        "terseLabel": "Non-cash changes: amortized cost remeasurement",
        "label": "Increase (Decrease) Through Amortization Cost Remeasurement, Liabilities Arising From Financing Activities",
        "documentation": "Increase (Decrease) Through Amortization Cost Remeasurement, Liabilities Arising From Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughAppropriationOfRetainedEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Appropriation of prior period net loss",
        "label": "Increase (decrease) through appropriation of retained earnings, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the appropriation of retained earnings. [Refer: Retained earnings]"
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash changes: other fair value remeasurement",
        "label": "Increase (decrease) through changes in fair values, liabilities arising from financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from changes in fair values. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r79",
      "r192"
     ]
    },
    "abvx_IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash changes: classification of embedded derivatives as separate derivative financial instruments",
        "label": "Increase (Decrease) Through Classification of Embedded Derivatives as Separate Financial Instruments, Liabilities Arising From Financing Activities",
        "documentation": "Increase (Decrease) Through Classification of Embedded Derivatives as Separate Financial Instruments, Liabilities Arising From Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash changes: conversion into shares",
        "label": "Increase (Decrease) Through Conversion Into Shares, Liabilities Arising From Financing Activities",
        "documentation": "Increase (Decrease) Through Conversion Into Shares, Liabilities Arising From Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughConversionOfConvertibleInstruments",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Conversion of Kreos Claret OCABSA and Heights notes",
        "terseLabel": "Increase (decrease) through conversion of convertible instruments, equity",
        "label": "Increase (decrease) through conversion of convertible instruments, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the conversion of convertible instruments."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non cash changes : Effect of the change in foreign currency exchange rates",
        "label": "Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r78",
      "r191"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.abivax.com/role/FinancialliabilitiesKreos1Details",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercises of shares warrants",
        "terseLabel": "Exercises of the Kreos/Claret and other share warrants",
        "label": "Increase (decrease) through exercise of warrants, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of warrants."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "abvx_IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash changes: (gain)/loss on recognition or derecognition",
        "label": "Increase (Decrease) Through Gain (Loss) On Recognition/Derecognition, Liabilities Arising From Financing Activities",
        "documentation": "Increase (Decrease) Through Gain (Loss) On Recognition/Derecognition, Liabilities Arising From Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_IncreaseDecreaseThroughIssuanceOfWarrantsEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "IncreaseDecreaseThroughIssuanceOfWarrantsEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issue of share warrants",
        "label": "Increase (Decrease) Through Issuance of Warrants, Equity",
        "documentation": "Increase (Decrease) Through Issuance of Warrants, Equity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of the change in foreign currency exchange rates",
        "label": "Increase (decrease) through net exchange differences, property, plant and equipment including right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in property, plant and equipment including right-of-use assets resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash changes: interest expense and other",
        "label": "Increase (decrease) through other changes, liabilities arising from financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r80",
      "r193"
     ]
    },
    "abvx_IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash changes: recognition of earn-out liability",
        "label": "Increase (Decrease) Through Recognition of Earn Out Liability, Liabilities Arising From Financing Activities",
        "documentation": "Increase (Decrease) Through Recognition of Earn Out Liability, Liabilities Arising From Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares based compensation expense",
        "label": "Increase (decrease) through share-based payment transactions, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      }
     },
     "auth_ref": [
      "r283"
     ]
    },
    "abvx_IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash changes\u00a0: subsidies",
        "label": "Increase (Decrease) Through Subsidies, Liabilities Arising From Financing Activities",
        "documentation": "Increase (Decrease) Through Subsidies, Liabilities Arising From Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughTreasuryShareTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transactions on treasury shares",
        "label": "Increase (decrease) through treasury share transactions, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "abvx_IncreaseInLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "IncreaseInLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofvariationinleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase",
        "label": "Increase In Lease Liabilities",
        "documentation": "Increase In Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non cash changes: additional leases",
        "label": "Increase through new leases, liabilities arising from financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r329",
      "r333"
     ]
    },
    "abvx_IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds",
        "label": "Increase Through Proceeds, Liabilities Arising From Financing Activities",
        "documentation": "Increase Through Proceeds, Liabilities Arising From Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis",
     "presentation": [
      "http://www.abivax.com/role/GoodwillandimpairmenttestDetails",
      "http://www.abivax.com/role/IntangibleassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash-generating units [axis]",
        "label": "Cash-generating units [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r233"
     ]
    },
    "ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain",
     "presentation": [
      "http://www.abivax.com/role/GoodwillandimpairmenttestDetails",
      "http://www.abivax.com/role/IntangibleassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash-generating units [domain]",
        "label": "Cash-generating units [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Cash-generating units' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r54",
      "r233",
      "r236"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r402",
      "r413",
      "r423",
      "r447",
      "r456",
      "r460",
      "r468"
     ]
    },
    "abvx_IndustrialMaterialsAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "IndustrialMaterialsAndEquipmentMember",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Industrial materials and equipment",
        "label": "Industrial Materials And Equipment [Member]",
        "documentation": "Industrial Materials And Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_InitialPriceLimitMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "InitialPriceLimitMeasurementInputMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial price limit (in euro per share)",
        "label": "Initial Price Limit, Measurement Input [Member]",
        "documentation": "Initial Price Limit, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r383",
      "r472"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r383",
      "r472"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r383",
      "r472"
     ]
    },
    "ifrs-full_IntangibleAssetsAndGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IntangibleAssetsAndGoodwillAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets and goodwill [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "periodStartLabel": "Intangible assets other than goodwill at beginning of period",
        "periodEndLabel": "Intangible assets other than goodwill at end of period",
        "label": "Intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r61",
      "r242",
      "r290"
     ]
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwillAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets other than goodwill [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IntangibleAssetsWithIndefiniteUsefulLife",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/IntangibleassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets with indefinite useful life",
        "label": "Intangible assets with indefinite useful life"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of intangible assets assessed as having an indefinite useful life. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r48",
      "r53",
      "r63",
      "r230",
      "r235",
      "r244"
     ]
    },
    "abvx_IntellectualPropertyFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "IntellectualPropertyFees",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intellectual property fees",
        "label": "Intellectual Property Fees",
        "documentation": "Intellectual Property Fees"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InterestExpenseIncomeNetDefinedBenefitLiabilityAsset",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofchangesinprojectedbenefitobligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest cost",
        "label": "Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)"
       }
      }
     },
     "auth_ref": [
      "r18",
      "r214"
     ]
    },
    "ifrs-full_InterestExpenseOnBonds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InterestExpenseOnBonds",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest on bond loans",
        "label": "Interest expense on bonds"
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "ifrs-full_InterestExpenseOnBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InterestExpenseOnBorrowings",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense on borrowings",
        "negatedTerseLabel": "Interest on conditional advances and PGE",
        "label": "Interest expense on borrowings"
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "ifrs-full_InterestExpenseOnDebtInstrumentsIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InterestExpenseOnDebtInstrumentsIssued",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest on convertible loan notes",
        "label": "Interest expense on debt instruments issued"
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "ifrs-full_InterestExpenseOnLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InterestExpenseOnLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails",
      "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense on lease liabilities",
        "negatedTerseLabel": "Interest on lease liabilities",
        "label": "Interest expense on lease liabilities"
       }
      }
     },
     "auth_ref": [
      "r114",
      "r176"
     ]
    },
    "abvx_InterestExpenseOnRoyaltyCertificates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "InterestExpenseOnRoyaltyCertificates",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest on royalty certificates",
        "label": "Interest Expense On Royalty Certificates",
        "documentation": "Interest Expense On Royalty Certificates"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_InterestExpenseOnRoyaltyCertificatesIncludingTheUnwindingOfDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "InterestExpenseOnRoyaltyCertificatesIncludingTheUnwindingOfDiscount",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense on royalty certificates, including the unwinding of discount",
        "label": "Interest Expense On Royalty Certificates, Including The Unwinding Of Discount",
        "documentation": "Interest Expense On Royalty Certificates, Including The Unwinding Of Discount"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestPaidClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InterestPaidClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest paid",
        "label": "Interest paid, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as financing activities."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "abvx_InterestRateCollarRange": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "InterestRateCollarRange",
     "presentation": [
      "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate collar range",
        "label": "Interest Rate Collar Range",
        "documentation": "Interest Rate Collar Range"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestRateMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InterestRateMeasurementInputMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Interest rate, measurement input [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an interest rate used as a measurement input."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "ifrs-full_InterestReceivedClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InterestReceivedClassifiedAsInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest received",
        "label": "Interest received, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from interest received, classified as investing activities."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "abvx_InvestmentsInMutualFundsAndStructuredNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "InvestmentsInMutualFundsAndStructuredNotes",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in mutual funds and structured notes",
        "label": "Investments In Mutual Funds And Structured Notes",
        "documentation": "Investments In Mutual Funds And Structured Notes"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_IssuanceOfDerivativeInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "IssuanceOfDerivativeInstruments",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance",
        "label": "Issuance Of Derivative Instruments",
        "documentation": "Issuance Of Derivative Instruments"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_IssuanceOfOtherShareWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "IssuanceOfOtherShareWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of other share warrants",
        "label": "Issuance Of Other Share Warrants",
        "documentation": "Issuance Of Other Share Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_IssuancePricePercentageOfDiscountTo15DayWVAP": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "IssuancePricePercentageOfDiscountTo15DayWVAP",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance price, percentage of discount to 15-day WVAP",
        "label": "Issuance Price, Percentage Of Discount To 15-Day WVAP",
        "documentation": "Issuance Price, Percentage Of Discount To 15-Day WVAP"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssueOfConvertibleInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IssueOfConvertibleInstruments",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issue of convertible notes",
        "label": "Issue of convertible instruments"
       }
      },
      "en": {
       "role": {
        "documentation": "The change in equity resulting from the issuing of convertible instruments."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "ifrs-full_IssueOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IssueOfEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails",
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital increase from issuance of ordinary shares",
        "label": "Issue of equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in equity through the issue of equity instruments."
       }
      }
     },
     "auth_ref": [
      "r283"
     ]
    },
    "abvx_IssueOfEquityOfferingPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "IssueOfEquityOfferingPricePerShare",
     "presentation": [
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issue of equity, offering price per share (in dollar/euro per share)",
        "label": "Issue Of Equity, Offering Price Per Share",
        "documentation": "Issue Of Equity, Offering Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.abivax.com/role/ShareholdersequitySharecapitalissuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "label": "Issued capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r374"
     ]
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHARE CAPITAL",
        "label": "Issued capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Key management personnel compensation"
       }
      }
     },
     "auth_ref": [
      "r31",
      "r222"
     ]
    },
    "abvx_KeyManagementPersonnelCompensationAttendanceFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "KeyManagementPersonnelCompensationAttendanceFees",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attendance fees\u2014board of directors",
        "label": "Key Management Personnel Compensation, Attendance Fees",
        "documentation": "Key Management Personnel Compensation, Attendance Fees"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_KeyManagementPersonnelCompensationConsultingFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "KeyManagementPersonnelCompensationConsultingFees",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Consulting fees",
        "label": "Key Management Personnel Compensation, Consulting Fees",
        "documentation": "Key Management Personnel Compensation, Consulting Fees"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_KeyManagementPersonnelCompensationContractualSeveranceIndemnity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "KeyManagementPersonnelCompensationContractualSeveranceIndemnity",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual severance indemnity",
        "label": "Key Management Personnel Compensation, Contractual Severance Indemnity",
        "documentation": "Key Management Personnel Compensation, Contractual Severance Indemnity"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_KeyManagementPersonnelCompensationFixedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "KeyManagementPersonnelCompensationFixedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed compensation owed",
        "label": "Key Management Personnel Compensation, Fixed Compensation",
        "documentation": "Key Management Personnel Compensation, Fixed Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_KeyManagementPersonnelCompensationInKindContributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "KeyManagementPersonnelCompensationInKindContributions",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributions in-kind",
        "label": "Key Management Personnel Compensation, In-Kind Contributions",
        "documentation": "Key Management Personnel Compensation, In-Kind Contributions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employer contributions",
        "label": "Key management personnel compensation, post-employment benefits"
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payments",
        "label": "Key management personnel compensation, share-based payment"
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/RelatedpartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total compensation",
        "label": "Key management personnel compensation, short-term employee benefits"
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationTerminationBenefits",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/RelatedpartiesNarrativeDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination benefits",
        "label": "Key management personnel compensation, termination benefits"
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "abvx_KeyManagementPersonnelCompensationVariableCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "KeyManagementPersonnelCompensationVariableCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable compensation owed",
        "label": "Key Management Personnel Compensation, Variable Compensation",
        "documentation": "Key Management Personnel Compensation, Variable Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_KeyManagementPersonnelOfEntityOrParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelOfEntityOrParentMember",
     "presentation": [
      "http://www.abivax.com/role/RelatedpartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Key management personnel",
        "label": "Key management personnel of entity or parent [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of that entity."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r224"
     ]
    },
    "abvx_Kreos12BondLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "Kreos12BondLoansMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreos1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kreos 1 &amp; 2 bond loans",
        "label": "Kreos 1 &amp; 2 Bond Loans [Member]",
        "documentation": "Kreos 1 &amp; 2 Bond Loans"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_Kreos1BondLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "Kreos1BondLoansMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kreos 1 bond loans",
        "label": "Kreos 1 Bond Loans [Member]",
        "documentation": "Kreos 1 Bond Loans"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_Kreos1ClaretBondLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "Kreos1ClaretBondLoansMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kreos &amp; Claret bond loans",
        "label": "Kreos 1 &amp; Claret Bond Loans [Member]",
        "documentation": "Kreos 1 &amp; Claret Bond Loans"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_Kreos1ConvertibleBondLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "Kreos1ConvertibleBondLoansMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreos1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kreos 1, convertible bond loans",
        "label": "Kreos 1, Convertible Bond Loans [Member]",
        "documentation": "Kreos 1, Convertible Bond Loans"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_Kreos1ConvertibleBondLoansTrancheAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "Kreos1ConvertibleBondLoansTrancheAMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreos1Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kreos 1, convertible bond loans, tranche A",
        "label": "Kreos 1, Convertible Bond Loans, Tranche A [Member]",
        "documentation": "Kreos 1, Convertible Bond Loans, Tranche A"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_Kreos1ConvertibleBondLoansTrancheBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "Kreos1ConvertibleBondLoansTrancheBMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreos1Details",
      "http://www.abivax.com/role/FinancialliabilitiesKreos2Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kreos 1, convertible bond loans, tranche B",
        "label": "Kreos 1, Convertible Bond Loans, Tranche B [Member]",
        "documentation": "Kreos 1, Convertible Bond Loans, Tranche B"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_Kreos1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "Kreos1Member",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.abivax.com/role/FinancialliabilitiesKreos1Details",
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kreos A &amp; B BSA",
        "label": "Kreos 1 [Member]",
        "documentation": "Kreos 1"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_Kreos1NonConvertibleBondLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "Kreos1NonConvertibleBondLoansMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreos1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kreos 1, non-convertible bond loans",
        "label": "Kreos 1, Non-Convertible Bond Loans [Member]",
        "documentation": "Kreos 1, Non-Convertible Bond Loans"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_Kreos2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "Kreos2Member",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreos2Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kreos 2",
        "label": "Kreos 2 [Member]",
        "documentation": "Kreos 2"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_Kreos2TrancheAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "Kreos2TrancheAMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreos2Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kreos 2, tranche A",
        "label": "Kreos 2, Tranche A [Member]",
        "documentation": "Kreos 2, Tranche A"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_Kreos2TrancheBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "Kreos2TrancheBMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreos2Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kreos 2, tranche B",
        "label": "Kreos 2, Tranche B [Member]",
        "documentation": "Kreos 2, Tranche B"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_KreosABBSAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "KreosABBSAMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreos1Details",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kreos A &amp; B BSA",
        "label": "Kreos A &amp; B BSA [Member]",
        "documentation": "Kreos A &amp; B BSA"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_KreosABCBSAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "KreosABCBSAMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kreos A &amp; B &amp; C BSA",
        "label": "Kreos A &amp; B &amp; C BSA [Member]",
        "documentation": "Kreos A &amp; B &amp; C BSA"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_KreosABSAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "KreosABSAMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreos1Details",
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kreos A BSA",
        "label": "Kreos A BSA [Member]",
        "documentation": "Kreos A BSA"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_KreosBBSAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "KreosBBSAMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreos1Details",
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kreos B BSA",
        "label": "Kreos B BSA [Member]",
        "documentation": "Kreos B BSA"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_KreosCBSAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "KreosCBSAMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kreos C BSA",
        "label": "Kreos C BSA [Member]",
        "documentation": "Kreos C BSA"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_KreosClaretBondLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "KreosClaretBondLoansMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kreos/Claret bond loans",
        "label": "Kreos &amp; Claret bond loans [Member]",
        "documentation": "Kreos &amp; Claret bond loans"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_KreosClaretFinancingAndHeightsConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "KreosClaretFinancingAndHeightsConvertibleNotesMember",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kreos &amp; Claret financing and Heights convertible notes",
        "label": "Kreos &amp; Claret Financing And Heights Convertible Notes [Member]",
        "documentation": "Kreos &amp; Claret Financing And Heights Convertible Notes"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_KreosClaretFinancingBAndCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "KreosClaretFinancingBAndCMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kreos/Claret financing B and C",
        "label": "Kreos/Claret Financing B And C [Member]",
        "documentation": "Kreos/Claret Financing B And C"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_KreosClaretFinancingBSAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "KreosClaretFinancingBSAMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialgainlossNarrativeDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kreos &amp; Claret BSA",
        "label": "Kreos &amp; Claret Financing, BSA [Member]",
        "documentation": "Kreos &amp; Claret Financing, BSA"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_KreosClaretFinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "KreosClaretFinancingMember",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/OffbalancesheetcommitmentsreceivedandcontingentassetsDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kreos &amp; Claret financing",
        "label": "Kreos &amp; Claret Financing [Member]",
        "documentation": "Kreos &amp; Claret Financing"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kreos &amp; Claret financing, tranche B and C",
        "label": "Kreos &amp; Claret Financing, Senior Secured Non-Convertible Loans [Member]",
        "documentation": "Kreos &amp; Claret Financing, Senior Secured Non-Convertible Loans"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_KreosClaretFinancingTrancheABAndCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "KreosClaretFinancingTrancheABAndCMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kreos &amp; Claret Financing, Tranche A,B and C",
        "label": "Kreos &amp; Claret Financing, Tranche A,B and C [Member]",
        "documentation": "Kreos &amp; Claret Financing, Tranche A,B and C"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_KreosClaretFinancingTrancheABMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "KreosClaretFinancingTrancheABMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kreos &amp; Claret financing, tranche A-B",
        "label": "Kreos &amp; Claret Financing, Tranche A-B [Member]",
        "documentation": "Kreos &amp; Claret Financing, Tranche A-B"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_KreosClaretFinancingTrancheAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "KreosClaretFinancingTrancheAMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kreos &amp; Claret convertible notes (OCABSA)",
        "netLabel": "Kreos/Claret BSA",
        "label": "Kreos &amp; Claret Financing, Tranche A [Member]",
        "documentation": "Kreos &amp; Claret Financing, Tranche A"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_KreosClaretFinancingTrancheBAndCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "KreosClaretFinancingTrancheBAndCMember",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kreos &amp; Claret financing, tranche B and C",
        "label": "Kreos &amp; Claret Financing, Tranche B and C [Member]",
        "documentation": "Kreos &amp; Claret Financing, Tranche B and C"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_KreosClaretFinancingTrancheBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "KreosClaretFinancingTrancheBMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kreos &amp; Claret financing, tranche B",
        "label": "Kreos &amp; Claret Financing, Tranche B [Member]",
        "documentation": "Kreos &amp; Claret Financing, Tranche B"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_KreosClaretFinancingTrancheCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "KreosClaretFinancingTrancheCMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kreos &amp; Claret financing, tranche C",
        "label": "Kreos &amp; Claret Financing, Tranche C [Member]",
        "documentation": "Kreos &amp; Claret Financing, Tranche C"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_KreosClaretMinimumReturnIndemnificationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "KreosClaretMinimumReturnIndemnificationsMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialgainlossNarrativeDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kreos &amp; Claret minimal return indemnifications",
        "verboseLabel": "Kreos/Claret Minimal Return Indemnifications",
        "label": "Kreos &amp; Claret Minimum Return Indemnifications [Member]",
        "documentation": "Kreos &amp; Claret Minimum Return Indemnifications"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_KreosOCABSAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "KreosOCABSAMember",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kreos OCABSA",
        "label": "Kreos OCABSA [Member]",
        "documentation": "Kreos OCABSA"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LaterThanFiveYearsMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LONGER THAN 5 YEARS",
        "label": "Later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than five years."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r128",
      "r181",
      "r184",
      "r354",
      "r357",
      "r359"
     ]
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FROM 1 TO 2 YEARS",
        "label": "Later than one year and not later than two years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than two years."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r128",
      "r354",
      "r359",
      "r519"
     ]
    },
    "ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LaterThanTwoYearsAndNotLaterThanFiveYearsMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FROM 2 TO 5 YEARS",
        "label": "Later than two years and not later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than two years and not later than five years."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "abvx_LeaseBreakClausePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "LeaseBreakClausePeriod",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease, break clause period",
        "label": "Lease, Break Clause Period",
        "documentation": "Lease, Break Clause Period"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_LeaseDurationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "LeaseDurationPeriod",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease, duration period",
        "label": "Lease, Duration Period",
        "documentation": "Lease, Duration Period"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_LeaseExtensionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "LeaseExtensionPeriod",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease, extension period",
        "label": "Lease, Extension Period",
        "documentation": "Lease, Extension Period"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_LeaseFacilitiesBostonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "LeaseFacilitiesBostonMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease facilities, Boston",
        "label": "Lease Facilities, Boston [Member]",
        "documentation": "Lease Facilities, Boston"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_LeaseFacilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "LeaseFacilitiesMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease facilities",
        "label": "Lease Facilities [Member]",
        "documentation": "Lease Facilities"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_LeaseFacilitiesMontpellierMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "LeaseFacilitiesMontpellierMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease facilities, Montpellier",
        "label": "Lease Facilities, Montpellier [Member]",
        "documentation": "Lease Facilities, Montpellier"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_LeaseFacilitiesParisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "LeaseFacilitiesParisMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails",
      "http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease facilities, Paris",
        "label": "Lease Facilities, Paris [Member]",
        "documentation": "Lease Facilities, Paris"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofvariationinleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Lease liabilities at beginning of period",
        "periodEndLabel": "Lease liabilities at end of period",
        "terseLabel": "Lease liabilities",
        "label": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "ifrs-full_LeaseLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LeaseLiabilitiesMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Lease liabilities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r330",
      "r334"
     ]
    },
    "abvx_LeaseLiabilityPercentageOfTotal": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "LeaseLiabilityPercentageOfTotal",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability, percentage of total",
        "label": "Lease Liability, Percentage Of Total",
        "documentation": "Lease Liability, Percentage Of Total"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_LeaseTacitRenewalPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "LeaseTacitRenewalPeriod",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease, tacit renewal period",
        "label": "Lease, Tacit Renewal Period",
        "documentation": "Lease, Tacit Renewal Period"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_LeasesRelatedTemporaryDifferencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "LeasesRelatedTemporaryDifferencesMember",
     "presentation": [
      "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Leases Related Temporary Differences [Member]",
        "documentation": "Leases Related Temporary Differences"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Liabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails",
      "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities",
        "verboseLabel": "Liabilities",
        "label": "Liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104",
      "r106",
      "r165",
      "r168",
      "r270",
      "r271",
      "r296"
     ]
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Liabilities arising from financing activities at beginning of period",
        "periodEndLabel": "Liabilities arising from financing activities at end of period",
        "label": "Liabilities arising from financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r194",
      "r331"
     ]
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LiabilitiesArisingFromFinancingActivitiesAxis",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities arising from financing activities [axis]",
        "label": "Liabilities arising from financing activities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r331"
     ]
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LiabilitiesArisingFromFinancingActivitiesDomain",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities arising from financing activities [domain]",
        "label": "Liabilities arising from financing activities [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for liabilities arising from financing activities. It also represents the standard value for the 'Liabilities arising from financing activities' axis if no other member is used. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r194",
      "r331"
     ]
    },
    "ifrs-full_LiabilityAssetOfDefinedBenefitPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LiabilityAssetOfDefinedBenefitPlans",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofchangesinprojectedbenefitobligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Net defined benefit liability (asset) at beginning of period",
        "periodEndLabel": "Net defined benefit liability (asset) at end of period",
        "label": "Net defined benefit liability (asset)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [domain]]"
       }
      }
     },
     "auth_ref": [
      "r16",
      "r212"
     ]
    },
    "ifrs-full_LicencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LicencesMember",
     "presentation": [
      "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LICENSES",
        "label": "Licences [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing the right to use certain intangible assets owned by another entity. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LongtermDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LongtermDeposits",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails": {
       "parentTag": "ifrs-full_OtherNoncurrentFinancialAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits",
        "label": "Long-term deposits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of long-term deposits held by the entity."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "abvx_LossesArisingFromDerecognitionOfFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "LossesArisingFromDerecognitionOfFinancialLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on derecognition of financial liabilities",
        "label": "Losses Arising From Derecognition Of Financial Liabilities",
        "documentation": "Losses Arising From Derecognition Of Financial Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LossesOnChangeInFairValueOfDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LossesOnChangeInFairValueOfDerivatives",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails",
      "http://www.abivax.com/role/FinancialgainlossNarrativeDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Increase in fair value",
        "negatedTerseLabel": "(Increase) / decrease in derivatives fair value",
        "netLabel": "Losses on change in fair value of derivatives",
        "label": "Losses on change in fair value of derivatives"
       }
      },
      "en": {
       "role": {
        "documentation": "The losses resulting from changes in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails",
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Losses on financial liabilities",
        "negatedTerseLabel": "(Increase) / decrease in other liabilities / (assets) at fair value through profit and loss",
        "label": "Losses On Financial Liabilities (Assets) At Fair Value Through Profit Or Loss",
        "documentation": "Losses On Financial Liabilities (Assets) At Fair Value Through Profit Or Loss"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_MajorShareBasedTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "MajorShareBasedTransactionsMember",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major share-based transactions",
        "label": "Major Share-Based Transactions [Member]",
        "documentation": "Major Share-Based Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ManagementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ManagementMember",
     "presentation": [
      "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Key magement",
        "label": "Management [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_MarketRateMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "MarketRateMeasurementInputMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market rate",
        "label": "Market Rate, Measurement Input [Member]",
        "documentation": "Market Rate, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MaturityAnalysisForDerivativeFinancialLiabilities",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of remaining contractual maturities of derivative financial liabilities",
        "label": "Disclosure of maturity analysis for derivative financial liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of a maturity analysis for derivative financial liabilities, including the remaining contractual maturities for those derivative financial liabilities for which contractual maturities are essential for an understanding of the timing of the cash flows. [Refer: Derivative financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r151",
      "r268"
     ]
    },
    "ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MaturityAnalysisForNonderivativeFinancialLiabilities",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of remaining contractual maturities of non-derivative financial liabilities",
        "label": "Disclosure of maturity analysis for non-derivative financial liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r150",
      "r267"
     ]
    },
    "ifrs-full_MaturityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MaturityAxis",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity [axis]",
        "label": "Maturity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r128",
      "r140",
      "r152",
      "r174",
      "r175",
      "r182",
      "r185",
      "r263",
      "r299",
      "r318",
      "r354"
     ]
    },
    "ifrs-full_MaturityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MaturityDomain",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity [domain]",
        "label": "Maturity [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r128",
      "r140",
      "r174",
      "r175",
      "r182",
      "r185",
      "r263",
      "r299",
      "r318",
      "r354",
      "r358"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails",
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum number of shares to be issued if all conditions are met (in shares)",
        "label": "Maximum Number Of Other Equity Instruments To Be Issued In Share-Based Payment Arrangement If All Conditions Are Met",
        "documentation": "Maximum Number Of Other Equity Instruments To Be Issued In Share-Based Payment Arrangement If All Conditions Are Met"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_MaximumNumberOfSharesToBeIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "MaximumNumberOfSharesToBeIssued",
     "presentation": [
      "http://www.abivax.com/role/IncomelosspershareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum number of shares to be issued (in shares)",
        "label": "Maximum Number Of Shares To Be Issued",
        "documentation": "Maximum Number Of Shares To Be Issued"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "ifrs-full_MeasurementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MeasurementAxis",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement [axis]",
        "label": "Measurement [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r70",
      "r103",
      "r249",
      "r270"
     ]
    },
    "ifrs-full_MeasurementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MeasurementDomain",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement [domain]",
        "label": "Measurement [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r70",
      "r103",
      "r249",
      "r270"
     ]
    },
    "abvx_MinimalReturnMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "MinimalReturnMeasurementInputMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimal return",
        "label": "Minimal Return, Measurement Input [Member]",
        "documentation": "Minimal Return, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails",
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MiscellaneousOtherOperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MiscellaneousOtherOperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails",
      "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails",
      "http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Other sales and marketing expenses",
        "terseLabel": "Other research and development expenses",
        "verboseLabel": "Other general and administrative expenses",
        "label": "Miscellaneous other operating expense"
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "ifrs-full_MiscellaneousOtherOperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MiscellaneousOtherOperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/OtheroperatingincomeDisclosureofbreakdownofoperatingincomeDetails": {
       "parentTag": "ifrs-full_OtherIncome",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/OtheroperatingincomeDisclosureofbreakdownofoperatingincomeDetails",
      "http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Miscellaneous other operating income"
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "abvx_MonteCarloModel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "MonteCarloModel1Member",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monte Carlo Model",
        "label": "Monte Carlo Model1 [Member]",
        "documentation": "Monte Carlo Model"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_MonteCarloModelIFRSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "MonteCarloModelIFRSMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monte Carlo model",
        "label": "Monte Carlo Model IFRS [Member]",
        "documentation": "Monte Carlo Model IFRS"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails",
      "http://www.abivax.com/role/IncometaxNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred taxes, net recognized in the statement of financial position",
        "negatedTerseLabel": "Net deferred tax liabilities",
        "label": "Net Deferred Tax Assets (Liabilities) Recognised In Financial Position",
        "documentation": "Net Deferred Tax Assets (Liabilities) Recognised In Financial Position"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NetDefinedBenefitLiabilityAssetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NetDefinedBenefitLiabilityAssetAxis",
     "presentation": [
      "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofchangesinprojectedbenefitobligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net defined benefit liability (asset) [axis]",
        "label": "Net defined benefit liability (asset) [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r212"
     ]
    },
    "ifrs-full_NetDefinedBenefitLiabilityAssetDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NetDefinedBenefitLiabilityAssetDomain",
     "presentation": [
      "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofchangesinprojectedbenefitobligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net defined benefit liability (asset) [domain]",
        "label": "Net defined benefit liability (asset) [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the net defined benefit liability (asset). It also represents the standard value for the 'Net defined benefit liability (asset)' axis if no other member is used. [Refer: Net defined benefit liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r16",
      "r212"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NetProceedsFromConvertibleLoanNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NetProceedsFromConvertibleLoanNotes",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from convertible loan notes",
        "label": "Net Proceeds From Convertible Loan Notes",
        "documentation": "Net Proceeds From Convertible Loan Notes"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NetProceedsFromConvertibleLoansNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NetProceedsFromConvertibleLoansNotes",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from convertible loan notes",
        "label": "Net Proceeds From Convertible Loans Notes",
        "documentation": "Net Proceeds From Convertible Loans Notes"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NetProceedsFromIssueOfOrdinaryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NetProceedsFromIssueOfOrdinaryShares",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from issue of ordinary shares",
        "label": "Net Proceeds From Issue Of Ordinary Shares",
        "documentation": "Net Proceeds From Issue Of Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NetProceedsFromNonConvertibleLoansNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NetProceedsFromNonConvertibleLoansNotes",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from non-convertible bond loans",
        "label": "Net Proceeds From Non-Convertible Loans Notes",
        "documentation": "Net Proceeds From Non-Convertible Loans Notes"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NetProceedsFromSaleOfRoyaltyCertificates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NetProceedsFromSaleOfRoyaltyCertificates",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/BasisofpreparationDetails",
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from sale of royalty certificates",
        "label": "Net Proceeds From Sale Of Royalty Certificates",
        "documentation": "Net Proceeds From Sale Of Royalty Certificates"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "No Trading Symbol Flag",
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NonCurrentAdvancesToCROContractsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NonCurrentAdvancesToCROContractsMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term advances made to CROs",
        "label": "Non-Current Advances To CRO Contracts [Member]",
        "documentation": "Non-Current Advances To CRO Contracts"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NonCurrentAdvancesToCROContractsUndiscountedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NonCurrentAdvancesToCROContractsUndiscountedAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails": {
       "parentTag": "ifrs-full_OtherNoncurrentFinancialAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails",
      "http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advances related to CRO contracts",
        "label": "Non-Current Advances To CRO Contracts, Undiscounted Amount",
        "documentation": "Non-Current Advances To CRO Contracts, Undiscounted Amount"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NonCurrentConvertibleLoansNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NonCurrentConvertibleLoansNotes",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible loan notes",
        "label": "Non-Current Convertible Loans Notes",
        "documentation": "Non-Current Convertible Loans Notes"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NonCurrentFinancialLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NonCurrentFinancialLiabilitiesMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities-non current portion",
        "label": "Non-Current Financial Liabilities [Member]",
        "documentation": "Non-Current Financial Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NonCurrentPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NonCurrentPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails": {
       "parentTag": "ifrs-full_OtherNoncurrentNonfinancialAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses - non current",
        "label": "Non-Current Prepaid Expenses",
        "documentation": "Non-Current Prepaid Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NonCurrentRoyaltyCertificates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NonCurrentRoyaltyCertificates",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty certificates",
        "label": "Non-Current Royalty Certificates",
        "documentation": "Non-Current Royalty Certificates"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r402",
      "r413",
      "r423",
      "r447",
      "r456"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-adjusting events after reporting period [axis]",
        "label": "Non-adjusting events after reporting period [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r199"
     ]
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodDomain",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-adjusting events after reporting period [domain]",
        "label": "Non-adjusting events after reporting period [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r199"
     ]
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "label": "Non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r92",
      "r300",
      "r335"
     ]
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current assets",
        "label": "Non-current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentDerivativeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentDerivativeFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative instruments",
        "label": "Non-current derivative financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "ifrs-full_NoncurrentFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-current financial liabilities",
        "label": "Non-current financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current financial liabilities. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "ifrs-full_NoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current liabilities",
        "label": "Non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r94",
      "r301",
      "r335"
     ]
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentLiabilitiesAbstract",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities",
        "label": "Non-current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentPortionOfOtherNoncurrentBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings",
        "label": "Non-current portion of other non-current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The non-current portion of non-current other borrowings. [Refer: Other borrowings]"
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "ifrs-full_NoncurrentProvisionsForEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentProvisionsForEmployeeBenefits",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement benefit obligations",
        "label": "Non-current provisions for employee benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current provisions for employee benefits. [Refer: Provisions for employee benefits]"
       }
      }
     },
     "auth_ref": [
      "r277",
      "r303"
     ]
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NotLaterThanOneYearMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LESS THAN 1 YEAR",
        "label": "Not later than one year [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r128",
      "r180",
      "r183",
      "r298",
      "r354",
      "r359"
     ]
    },
    "ifrs-full_NotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NotionalAmount",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreos2Details",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails",
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notional amount",
        "verboseLabel": "Original principal amount",
        "label": "Notional amount"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "ifrs-full_NumberAndAverageNumberOfEmployeesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberAndAverageNumberOfEmployeesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Number and average number of employees [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NumberOfADSPerOrdinaryShares": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NumberOfADSPerOrdinaryShares",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of ADS per ordinary shares (in shares)",
        "label": "Number of ADS per Ordinary Shares",
        "documentation": "Number of ADS per Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NumberOfAcademicInstitutions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NumberOfAcademicInstitutions",
     "presentation": [
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of academic institutions",
        "label": "Number Of Academic Institutions",
        "documentation": "Number Of Academic Institutions"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NumberOfConvertibleNotesConverted": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NumberOfConvertibleNotesConverted",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of convertible notes converted",
        "label": "Number Of Convertible Notes Converted",
        "documentation": "Number Of Convertible Notes Converted"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NumberOfConvertibleNotesIssued": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NumberOfConvertibleNotesIssued",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of convertible notes issued (in shares)",
        "label": "Number Of Convertible Notes Issued",
        "documentation": "Number Of Convertible Notes Issued"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NumberOfConvertibleNotesOutstanding": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NumberOfConvertibleNotesOutstanding",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of outstanding notes (in shares)",
        "label": "Number Of Convertible Notes Outstanding",
        "documentation": "Number Of Convertible Notes Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NumberOfExclusiveLicenses": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NumberOfExclusiveLicenses",
     "presentation": [
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of exclusive licenses",
        "label": "Number Of Exclusive Licenses",
        "documentation": "Number Of Exclusive Licenses"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NumberOfFinancialInstitutionsToMaintainCash": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NumberOfFinancialInstitutionsToMaintainCash",
     "presentation": [
      "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of financial institutions to maintain cash",
        "label": "Number Of Financial Institutions To Maintain Cash",
        "documentation": "Number Of Financial Institutions To Maintain Cash"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NumberOfFreeSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NumberOfFreeSharesIssued",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issue of free shares (in shares)",
        "label": "Number Of Free Shares Issued",
        "documentation": "Number Of Free Shares Issued"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NumberOfFreeSharesPlansIssued": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NumberOfFreeSharesPlansIssued",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of free shares plans issued",
        "label": "Number Of Free Shares Plans Issued",
        "documentation": "Number Of Free Shares Plans Issued"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsPercentageExercisableImmediately": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NumberOfInstrumentsGrantedOtherEquityInstrumentsPercentageExercisableImmediately",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of instruments granted, percentage exercisable immediately",
        "label": "Number Of Instruments Granted, Other Equity Instruments, Percentage Exercisable Immediately",
        "documentation": "Number Of Instruments Granted, Other Equity Instruments, Percentage Exercisable Immediately"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsRemainingPercentageExercisable": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NumberOfInstrumentsGrantedOtherEquityInstrumentsRemainingPercentageExercisable",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of instruments granted, remaining percentage exercisable",
        "label": "Number Of Instruments Granted, Other Equity Instruments, Remaining Percentage Exercisable",
        "documentation": "Number Of Instruments Granted, Other Equity Instruments, Remaining Percentage Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails",
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of instruments issued (in shares)",
        "verboseLabel": "NUMBE OF BSAs ( in shares)",
        "label": "Number of other equity instruments granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r512"
     ]
    },
    "ifrs-full_NumberOfInstrumentsThatAreAntidilutiveInPeriodPresented": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfInstrumentsThatAreAntidilutiveInPeriodPresented",
     "presentation": [
      "http://www.abivax.com/role/IncomelosspershareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of instruments that are antidilutive in period presented (in shares)",
        "label": "Number of instruments that are antidilutive in period presented"
       }
      },
      "en": {
       "role": {
        "documentation": "Number of (units of) instruments that are antidilutive in the period presented."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "abvx_NumberOfOperatingSegment": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NumberOfOperatingSegment",
     "presentation": [
      "http://www.abivax.com/role/SegmentinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segment",
        "documentation": "Number of Operating Segment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of instruments exercisable (in shares)",
        "label": "Number of other equity instruments exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Number of instruments exercised (in shares)",
        "label": "Number of other equity instruments exercised or vested in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Number of instruments lapsed (in shares)",
        "label": "Number of other equity instruments expired in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) expired in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "abvx_NumberOfOtherEquityInstrumentsGrantedSubjectToNonMarketPerformanceCondition": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NumberOfOtherEquityInstrumentsGrantedSubjectToNonMarketPerformanceCondition",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of instruments issued subject to non-market performance condition (in shares)",
        "label": "Number Of Other Equity Instruments Granted Subject To Non-Market Performance Condition",
        "documentation": "Number Of Other Equity Instruments Granted Subject To Non-Market Performance Condition"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of instruments outstanding, beginning balance (in shares)",
        "periodEndLabel": "Number of instruments outstanding, ending balance (in shares)",
        "label": "Number of other equity instruments outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "abvx_NumberOfOtherShareWarrantsConverted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NumberOfOtherShareWarrantsConverted",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreos1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of other share warrants converted (in shares)",
        "label": "Number Of Other Share Warrants Converted",
        "documentation": "Number Of Other Share Warrants Converted"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NumberOfOtherShareWarrantsRepurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NumberOfOtherShareWarrantsRepurchased",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreos1Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of other share warrants repurchased (in shares)",
        "label": "Number Of Other Share Warrants Repurchased",
        "documentation": "Number Of Other Share Warrants Repurchased"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NumberOfProbabilityWeightedScenarios": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NumberOfProbabilityWeightedScenarios",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails",
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of probability-weighted scenarios",
        "label": "Number Of Probability-Weighted Scenarios",
        "documentation": "Number Of Probability-Weighted Scenarios"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NumberOfProjectsTerminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NumberOfProjectsTerminated",
     "presentation": [
      "http://www.abivax.com/role/OffbalancesheetcommitmentsreceivedandcontingentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of projects terminated",
        "label": "Number Of Projects Terminated",
        "documentation": "Number Of Projects Terminated"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NumberOfShareBasedCompensationPlansIssued": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NumberOfShareBasedCompensationPlansIssued",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of share-based compensation plans issued",
        "label": "Number Of Share-Based Compensation Plans Issued",
        "documentation": "Number Of Share-Based Compensation Plans Issued"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NumberOfShareWarrantsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NumberOfShareWarrantsIssued",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreos1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued (in shares)",
        "label": "Number Of Share Warrants Issued",
        "documentation": "Number Of Share Warrants Issued"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.abivax.com/role/ShareholdersequitySharecapitalissuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of shares issued at beginning of period (in shares)",
        "periodEndLabel": "Number of shares issued at end of period (in shares)",
        "terseLabel": "Number of shares issued (in shares)",
        "label": "Number of shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "abvx_NumberOfSharesLapsed": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NumberOfSharesLapsed",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares lapsed (in shares)",
        "label": "Number Of Shares Lapsed",
        "documentation": "Number Of Shares Lapsed"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NumberOfSharesPerShareWarrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NumberOfSharesPerShareWarrant",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreos1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares (in shares)",
        "label": "Number Of Shares per Share Warrant",
        "documentation": "Number Of Shares per Share Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NumberOfSharesReceivedPerADS": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NumberOfSharesReceivedPerADS",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares received per ADS (in shares)",
        "label": "Number Of Shares Received Per ADS",
        "documentation": "Number Of Shares Received Per ADS"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NumberOfSharesWaived": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NumberOfSharesWaived",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares waived (in shares)",
        "label": "Number Of Shares Waived",
        "documentation": "Number Of Shares Waived"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NumberOfSharesWithPerformanceConditionsWaived": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NumberOfSharesWithPerformanceConditionsWaived",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares with performance conditions waived (in shares)",
        "label": "Number Of Shares With Performance Conditions Waived",
        "documentation": "Number Of Shares With Performance Conditions Waived"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NumberOfTranches": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NumberOfTranches",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of tranches",
        "label": "Number Of Tranches",
        "documentation": "Number Of Tranches"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NumberOfTreasurySharesHeld": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NumberOfTreasurySharesHeld",
     "presentation": [
      "http://www.abivax.com/role/ShareholdersequitySharecapitalissuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of treasury shares held (in shares)",
        "label": "Number Of Treasury Shares Held",
        "documentation": "Number Of Treasury Shares Held"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NumberOfWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NumberOfWarrantsExercised",
     "presentation": [
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of warrants exercised (in shares)",
        "label": "Number Of Warrants Exercised",
        "documentation": "Number Of Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NumberOfWarrantsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NumberOfWarrantsGranted",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of warrants granted (in shares)",
        "label": "Number Of Warrants Granted",
        "documentation": "Number Of Warrants Granted"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NumberOfWarrantsOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NumberOfWarrantsOutstanding",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of outstanding warrants (in shares)",
        "label": "Number Of Warrants Outstanding",
        "documentation": "Number Of Warrants Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NumberOfWarrantsOutstandingSubjectToNonMarketPerformanceCondition": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NumberOfWarrantsOutstandingSubjectToNonMarketPerformanceCondition",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of outstanding warrants subject to non-market performance condition (in shares)",
        "label": "Number Of Warrants Outstanding Subject To Non-Market Performance Condition",
        "documentation": "Number Of Warrants Outstanding Subject To Non-Market Performance Condition"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_NumberOfWarrantsRepurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "NumberOfWarrantsRepurchased",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of warrants repurchased (in shares)",
        "label": "Number Of Warrants Repurchased",
        "documentation": "Number Of Warrants Repurchased"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_OCEANEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "OCEANEMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OCEANE",
        "label": "OCEANE [Member]",
        "documentation": "OCEANE"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_OceaneConversionOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "OceaneConversionOptionMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oceane conversion option",
        "verboseLabel": "OCEANE conversion option",
        "label": "Oceane Conversion Option [Member]",
        "documentation": "Oceane Conversion Option"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_OffBalanceSheetCommitmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "OffBalanceSheetCommitmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Off-Balance Sheet Commitments [Abstract]",
        "documentation": "Off-Balance Sheet Commitments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails",
      "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office equipment",
        "verboseLabel": "EQUIPMENT",
        "label": "Office equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "ifrs-full_OperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS",
      "http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails",
      "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails",
      "http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total operating expenses",
        "totalLabel": "Operating expenses",
        "label": "Operating expense"
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "ifrs-full_OptionPricingModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OptionPricingModelMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option pricing model",
        "label": "Option pricing model [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a specific valuation technique consistent with the income approach that involves analysing future amounts with option pricing models, such as the Black-Scholes-Merton formula or a binominal model (ie a lattice model), that incorporate present value techniques and reflect both the time value and intrinsic value of an option. [Refer: Income approach [member]]"
       }
      }
     },
     "auth_ref": [
      "r339",
      "r344"
     ]
    },
    "ifrs-full_OrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OrdinarySharesMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreos1Details",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares",
        "label": "Ordinary shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "abvx_OrdinarySharesNASDAQGlobalMarketMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "OrdinarySharesNASDAQGlobalMarketMember",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, nominal value \u20ac0.01 per share",
        "label": "Ordinary Shares, NASDAQ Global Market [Member]",
        "documentation": "Ordinary Shares, NASDAQ Global Market [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherAdjustmentsForNoncashItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherAdjustmentsForNoncashItems",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other adjustments for non-cash items"
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "ifrs-full_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other receivables and assets",
        "label": "Other assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "ifrs-full_OtherCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/CashandcashequivalentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notice accounts",
        "label": "Other cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash and cash equivalents that the entity does not separately disclose in the same statement or note. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive income (loss)",
        "terseLabel": "Other comprehensive income (loss)",
        "label": "Other comprehensive income"
       }
      }
     },
     "auth_ref": [
      "r96",
      "r282",
      "r309",
      "r313"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation differences",
        "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r302",
      "r313"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial gains and losses on retirement benefit obligations",
        "label": "Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [domain]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r302",
      "r313",
      "r495"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Items that are or may be reclassified subsequently to profit or loss",
        "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r375",
      "r376"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Items that will not be reclassified to profit or loss",
        "label": "Other comprehensive income that will not be reclassified to profit or loss, net of tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r375",
      "r376"
     ]
    },
    "ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings",
        "label": "Other current borrowings and current portion of other non-current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current other borrowings and the current portion of non-current other borrowings. [Refer: Other borrowings]"
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "ifrs-full_OtherCurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherCurrentFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails": {
       "parentTag": "ifrs-full_OtherFinancialAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other financial assets",
        "totalLabel": "Total other current financial assets",
        "label": "Other current financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]"
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "ifrs-full_OtherCurrentFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherCurrentFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other financial liabilities",
        "label": "Other current financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r98",
      "r294"
     ]
    },
    "abvx_OtherCurrentInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "OtherCurrentInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails": {
       "parentTag": "ifrs-full_OtherCurrentFinancialAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other investments",
        "label": "Other Current Investments",
        "documentation": "Other Current Investments"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_OtherCurrentPayablesIncludingAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "OtherCurrentPayablesIncludingAdjustments",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Current Payables, Including Adjustments",
        "documentation": "Other Current Payables, Including Adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_OtherEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "OtherEmployeesMember",
     "presentation": [
      "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other employees",
        "label": "Other Employees [Member]",
        "documentation": "Other Employees"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_OtherEquityAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "OtherEquityAgreementsMember",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other equity agreement",
        "label": "Other Equity Agreements [Member]",
        "documentation": "Other Equity Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherFinanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherFinanceCost",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other financial expense",
        "label": "Other finance cost"
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "ifrs-full_OtherFinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherFinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": {
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other financial income",
        "label": "Other finance income"
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "ifrs-full_OtherFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other financial assets",
        "label": "Other financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "abvx_OtherFinancialAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "OtherFinancialAssetsMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other financial assets",
        "label": "Other Financial Assets [Member]",
        "documentation": "Other Financial Assets"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_OtherFinancialLiabilitiesAnnualPercentageOfProceedsFromSaleOfIntellectualPropertyRight": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "OtherFinancialLiabilitiesAnnualPercentageOfProceedsFromSaleOfIntellectualPropertyRight",
     "presentation": [
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual percentage of proceeds from sale of intellectual property right",
        "label": "Other Financial Liabilities, Annual Percentage Of Proceeds From Sale Of Intellectual Property Right",
        "documentation": "Other Financial Liabilities, Annual Percentage Of Proceeds From Sale Of Intellectual Property Right"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_OtherFinancialLiabilitiesAnnualRevenueFromSaleOfProductsDevelopedPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "OtherFinancialLiabilitiesAnnualRevenueFromSaleOfProductsDevelopedPeriod",
     "presentation": [
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual revenue from sale of products developed, period",
        "label": "Other Financial Liabilities, Annual Revenue From Sale Of Products Developed, Period",
        "documentation": "Other Financial Liabilities, Annual Revenue From Sale Of Products Developed, Period"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "OtherFinancialLiabilitiesMaximumDrawdownCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails",
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum drawdown capacity",
        "label": "Other Financial Liabilities, Maximum Drawdown Capacity",
        "documentation": "Other Financial Liabilities, Maximum Drawdown Capacity"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacityIncludingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "OtherFinancialLiabilitiesMaximumDrawdownCapacityIncludingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum drawdown capacity including interest",
        "label": "Other Financial Liabilities, Maximum Drawdown Capacity Including Interest",
        "documentation": "Other Financial Liabilities, Maximum Drawdown Capacity Including Interest"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_OtherFinancialLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "OtherFinancialLiabilitiesMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Other Financial Liabilities [Member]",
        "documentation": "Other Financial Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_OtherFinancialLiabilitiesPayableAnnualRevenueFromSaleOfProductsDeveloped": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "OtherFinancialLiabilitiesPayableAnnualRevenueFromSaleOfProductsDeveloped",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual revenue from sale of products developed",
        "label": "Other Financial Liabilities, Payable, Annual Revenue From Sale Of Products Developed",
        "documentation": "Other Financial Liabilities, Payable, Annual Revenue From Sale Of Products Developed"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDeveloped": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDeveloped",
     "presentation": [
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of annual revenue from sale of products developed",
        "label": "Other Financial Liabilities, Percentage Of Annual Revenue From Sale Of Products Developed",
        "documentation": "Other Financial Liabilities, Percentage Of Annual Revenue From Sale Of Products Developed"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDevelopedPreTaxRevenueThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDevelopedPreTaxRevenueThreshold",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-tax revenue threshold",
        "label": "Other Financial Liabilities, Percentage Of Annual Revenue From Sale Of Products Developed, Pre-Tax Revenue Threshold",
        "documentation": "Other Financial Liabilities, Percentage Of Annual Revenue From Sale Of Products Developed, Pre-Tax Revenue Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_OtherFinancialLiabilitiesRelatedTemporaryDifferencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "OtherFinancialLiabilitiesRelatedTemporaryDifferencesMember",
     "presentation": [
      "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other financial liabilities",
        "label": "Other Financial Liabilities Related Temporary Differences [Member]",
        "documentation": "Other Financial Liabilities Related Temporary Differences"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_OtherFinancialLiabilitiesRepaymentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "OtherFinancialLiabilitiesRepaymentPeriod",
     "presentation": [
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayment period",
        "label": "Other Financial Liabilities, Repayment Period",
        "documentation": "Other Financial Liabilities, Repayment Period"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": {
       "parentTag": "ifrs-full_RevenueAndOperatingIncome",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.abivax.com/role/OtheroperatingincomeDisclosureofbreakdownofoperatingincomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS",
      "http://www.abivax.com/role/OtheroperatingincomeDisclosureofbreakdownofoperatingincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating income",
        "totalLabel": "Total operating income",
        "label": "Other income"
       }
      }
     },
     "auth_ref": [
      "r36",
      "r369",
      "r370"
     ]
    },
    "ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other inflows (outflows) of cash, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "Inflows (outflows) of cash, classified as financing activities, that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ifrs-full_OtherIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherIntangibleAssetsMember",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesIntangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other intangible assets",
        "label": "Other intangible assets [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "abvx_OtherLiabilitiesNumberOfTransactions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "OtherLiabilitiesNumberOfTransactions",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities, number of transactions",
        "label": "Other Liabilities, Number Of Transactions",
        "documentation": "Other Liabilities, Number Of Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherLongtermProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherLongtermProvisions",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions",
        "verboseLabel": "Other non-current provisions",
        "label": "Other non-current provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current provisions other than provisions for employee benefits. [Refer: Non-current provisions]"
       }
      }
     },
     "auth_ref": [
      "r277",
      "r303"
     ]
    },
    "abvx_OtherNonCurrentMiscellaneousFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "OtherNonCurrentMiscellaneousFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails": {
       "parentTag": "ifrs-full_OtherNoncurrentFinancialAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Non-Current Miscellaneous Financial Assets",
        "documentation": "Other Non-Current Miscellaneous Financial Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherNoncurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherNoncurrentFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails": {
       "parentTag": "ifrs-full_OtherFinancialAssets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other financial assets",
        "totalLabel": "Total other non-current financial assets",
        "label": "Other non-current financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets]"
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "ifrs-full_OtherNoncurrentFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherNoncurrentFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other financial liabilities",
        "label": "Other non-current financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r99",
      "r294"
     ]
    },
    "ifrs-full_OtherNoncurrentNonfinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherNoncurrentNonfinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails": {
       "parentTag": "ifrs-full_OtherAssets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "totalLabel": "Total other non-current assets",
        "label": "Other non-current non-financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "abvx_OtherReceivablesAndAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "OtherReceivablesAndAssetsMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables and assets",
        "label": "Other Receivables And Assets [Member]",
        "documentation": "Other Receivables And Assets"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_OtherShareWarrantsExercisePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "OtherShareWarrantsExercisePeriod",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other share warrants, exercise period",
        "label": "Other Share Warrants, Exercise Period",
        "documentation": "Other Share Warrants, Exercise Period"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_OtherShareWarrantsSubscriptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "OtherShareWarrantsSubscriptionPricePerShare",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other share warrants, subscripion price per share (in euro per share)",
        "label": "Other Share Warrants, Subscription Price Per Share",
        "documentation": "Other Share Warrants, Subscription Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherShorttermProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherShorttermProvisions",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions",
        "label": "Other current provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current provisions other than provisions for employee benefits. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r277",
      "r303"
     ]
    },
    "ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other tax effects for reconciliation between accounting profit and tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r2",
      "r201"
     ]
    },
    "ifrs-full_OtherTemporaryDifferencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherTemporaryDifferencesMember",
     "presentation": [
      "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other items",
        "label": "Other temporary differences [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for temporary differences that the entity does not separately disclose in the same statement or note. [Refer: Temporary differences [member]]"
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r400",
      "r411",
      "r421",
      "r454"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r403",
      "r414",
      "r424",
      "r457"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r403",
      "r414",
      "r424",
      "r457"
     ]
    },
    "ifrs-full_ParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ParValuePerShare",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails",
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails",
      "http://www.abivax.com/role/ShareholdersequitySharecapitalissuedDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Par value per share (in euro per share)",
        "label": "Par value per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r273",
      "r305"
     ]
    },
    "ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PastServiceCostNetDefinedBenefitLiabilityAsset",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofchangesinprojectedbenefitobligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Past services cost",
        "label": "Increase (decrease) in net defined benefit liability (asset) resulting from past service cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from past service cost. Past service cost is the change in the present value of the defined benefit obligation for employee service in prior periods, resulting from a plan amendment (the introduction or withdrawal of, or changes to, a defined benefit plan) or a curtailment (a significant reduction by the entity in the number of employees covered by a plan). [Refer: Net defined benefit liability (asset); Defined benefit plans [domain]]"
       }
      }
     },
     "auth_ref": [
      "r20",
      "r216"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "abvx_PaymentsForAdvancesMadeToContractResearchOrganizationsUndiscountedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "PaymentsForAdvancesMadeToContractResearchOrganizationsUndiscountedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash advances and loans made to CRO",
        "label": "Payments For Advances Made to Contract Research Organizations, Undiscounted Amount",
        "documentation": "Payments For Advances Made to Contract Research Organizations, Undiscounted Amount"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advances reimbursed by / (made to) CROs",
        "label": "Payments For Advances Reimbursed (Made to) Contract Research Organizations",
        "documentation": "Payments For Advances Reimbursed (Made to) Contract Research Organizations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PaymentsForDebtIssueCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PaymentsForDebtIssueCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for debt issue costs",
        "label": "Payments for debt issue costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for debt issue costs."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "abvx_PaymentsForProceedsFromShareIssueRelatedCostsCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "PaymentsForProceedsFromShareIssueRelatedCostsCredit",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Transaction costs related to capital increase",
        "label": "Payments For (Proceeds From) Share Issue Related Costs (Credit)",
        "documentation": "Payments For (Proceeds From) Share Issue Related Costs (Credit)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PaymentsForShareIssueCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PaymentsForShareIssueCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for share issue costs",
        "label": "Payments for share issue costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for share issue costs."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PaymentsFromPlanNetDefinedBenefitLiabilityAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofchangesinprojectedbenefitobligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Benefits paid",
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from payments from plan"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from payments from the plan. [Refer: Net defined benefit liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r21",
      "r217"
     ]
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments of the lease liabilities",
        "label": "Payments of lease liabilities, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "abvx_PeakPenetrationMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "PeakPenetrationMeasurementInputMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peak penetration",
        "label": "Peak Penetration, Measurement Input [Member]",
        "documentation": "Peak Penetration, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "abvx_PercentageOfConditionalAdvancesWaived": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "PercentageOfConditionalAdvancesWaived",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of conditional advances waived",
        "label": "Percentage Of Conditional Advances Waived",
        "documentation": "Percentage Of Conditional Advances Waived"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Percentage of reasonably possible decrease in unobservable input, liabilities",
        "label": "Percentage of reasonably possible decrease in unobservable input, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of a reasonably possible decrease in an unobservable input used in fair value measurement of liabilities."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of reasonably possible increase in unobservable input, assets",
        "label": "Percentage of reasonably possible increase in unobservable input, assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of a reasonably possible increase in an unobservable input used in fair value measurement of assets."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails",
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of reasonably possible increase in unobservable input, liabilities",
        "label": "Percentage of reasonably possible increase in unobservable input, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of a reasonably possible increase in an unobservable input used in fair value measurement of liabilities."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "ifrs-full_PresentValueOfDefinedBenefitObligationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PresentValueOfDefinedBenefitObligationMember",
     "presentation": [
      "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofchangesinprojectedbenefitobligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RETIREMENT BENEFIT OBLIGATIONS",
        "label": "Present value of defined benefit obligation [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the present value of a defined benefit obligation. The present value of a defined benefit obligation is the present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r211"
     ]
    },
    "abvx_PretGarantiParLEtatPGEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "PretGarantiParLEtatPGEMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesStateguaranteedloanPGEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PGE",
        "label": "Pr\u00eat Garanti Par l'Etat (PGE) [Member]",
        "documentation": "Pr\u00eat Garanti Par l'Etat (PGE)"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_PrincipalAgreementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "PrincipalAgreementsAxis",
     "presentation": [
      "http://www.abivax.com/role/IntangibleassetsNarrativeDetails",
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal Agreements [Axis]",
        "label": "Principal Agreements [Axis]",
        "documentation": "Principal Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_PrincipalAgreementsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "PrincipalAgreementsDomain",
     "presentation": [
      "http://www.abivax.com/role/IntangibleassetsNarrativeDetails",
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal Agreements [Domain]",
        "label": "Principal Agreements [Domain]",
        "documentation": "Principal Agreements [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ProbabilityOfSuccessMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ProbabilityOfSuccessMeasurementInputMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "POS",
        "label": "Probability Of Success, Measurement Input [Member]",
        "documentation": "Probability Of Success, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/BasisofpreparationDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from borrowings",
        "label": "Proceeds from borrowings, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "abvx_ProceedsFromBorrowingsNetOfRefinancingOfExistingIndebteness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ProceedsFromBorrowingsNetOfRefinancingOfExistingIndebteness",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from borrowings, net of refinancing of existing indebteness",
        "label": "Proceeds From Borrowings, Net Of Refinancing Of Existing Indebteness",
        "documentation": "Proceeds From Borrowings, Net Of Refinancing Of Existing Indebteness"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ProceedsFromConditionalAdvances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ProceedsFromConditionalAdvances",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/BasisofpreparationDetails",
      "http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from conditional advances",
        "label": "Proceeds From Conditional Advances",
        "documentation": "Proceeds From Conditional Advances"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProceedsFromExerciseOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants",
        "label": "Proceeds from exercise of warrants"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of share purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/BasisofpreparationDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from government grants",
        "label": "Proceeds from government grants, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from government grants, classified as financing activities. [Refer: Government [member]; Government grants]"
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "ifrs-full_ProceedsFromIssueOfOrdinaryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProceedsFromIssueOfOrdinaryShares",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issue of ordinary shares",
        "label": "Proceeds from issue of ordinary shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "ifrs-full_ProceedsFromIssuingOtherEquityInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProceedsFromIssuingOtherEquityInstruments",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuing other equity instruments",
        "label": "Proceeds from issuing other equity instruments"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing equity instruments that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProceedsFromIssuingShares",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/BasisofpreparationDetails",
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital increases",
        "label": "Proceeds from issuing shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "abvx_ProceedsFromIssuingSharesAndConvertibleLoansNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ProceedsFromIssuingSharesAndConvertibleLoansNotes",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuing shares and convertible loan notes",
        "label": "Proceeds From Issuing Shares And Convertible Loans Notes",
        "documentation": "Proceeds From Issuing Shares And Convertible Loans Notes"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital increases",
        "label": "Proceeds From Issuing Shares Other Than Through Exercise Of Warrants",
        "documentation": "Proceeds From Issuing Shares Other Than Through Exercise Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ProceedsFromReimbursementsOfDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ProceedsFromReimbursementsOfDeposits",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in deposits",
        "label": "Proceeds From Reimbursements Of Deposits",
        "documentation": "Proceeds From Reimbursements Of Deposits"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ProceedsFromResearchTaxCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ProceedsFromResearchTaxCredit",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/BasisofpreparationDetails",
      "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from research tax credit",
        "label": "Proceeds From Research Tax Credit",
        "documentation": "Proceeds From Research Tax Credit"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProceedsFromSaleOrIssueOfTreasuryShares",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from sale of treasury shares",
        "label": "Proceeds from sale or issue of treasury shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the sale or issuing of treasury shares. [Refer: Sale or issue of treasury shares; Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "ifrs-full_ProfessionalFeesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfessionalFeesExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails",
      "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails",
      "http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consulting and professional fees",
        "label": "Professional fees expense"
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abivax.com/role/BasisofpreparationDetails",
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS",
      "http://www.abivax.com/role/IncomelosspershareScheduleofearningspershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss for the period",
        "terseLabel": "Net loss for the period",
        "negatedLabel": "Net loss",
        "label": "Profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r87",
      "r89",
      "r165",
      "r166",
      "r227",
      "r252",
      "r281",
      "r308",
      "r335",
      "r348"
     ]
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss before tax",
        "label": "Profit (loss) before tax"
       }
      }
     },
     "auth_ref": [
      "r138",
      "r361",
      "r362",
      "r369",
      "r370"
     ]
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossFromOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Profit (loss) from operating activities"
       }
      }
     },
     "auth_ref": [
      "r319",
      "r527"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipmentIncludingRightofuseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment",
        "periodStartLabel": "Property, plant and equipment including right-of-use assets at beginning of period",
        "periodEndLabel": "Property, plant and equipment including right-of-use assets at end of period",
        "label": "Property, plant and equipment including right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of property, plant and equipment including right-of-use assets whose underlying assets would be presented as property, plant and equipment if they were owned. [Refer: Property, plant and equipment; Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r112",
      "r494",
      "r521"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis",
     "presentation": [
      "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment including right-of-use assets [axis]",
        "label": "Property, plant and equipment including right-of-use assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain",
     "presentation": [
      "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment including right-of-use assets [domain]",
        "label": "Property, plant and equipment including right-of-use assets [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of asset representing property, plant and equipment including right-of-use assets whose underlying assets would be presented as property, plant and equipment if they were owned. [Refer: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipmentMember",
     "presentation": [
      "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment",
        "label": "Property, plant and equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r11",
      "r209",
      "r320",
      "r347",
      "r365",
      "r366"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProportionOfOwnershipInterestsHeldByNoncontrollingInterests",
     "presentation": [
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proportion of ownership interests held by non-controlling interests",
        "label": "Proportion of ownership interests held by non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interests in a subsidiary held by non-controlling interests. [Refer: Total for all subsidiaries [member]; Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "abvx_ProsynergiaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ProsynergiaMember",
     "presentation": [
      "http://www.abivax.com/role/IntangibleassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prosynergia",
        "label": "Prosynergia [Member]",
        "documentation": "Prosynergia"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ProvisionsForAGATaxesRelatedTemporaryDifferencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ProvisionsForAGATaxesRelatedTemporaryDifferencesMember",
     "presentation": [
      "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions for AGA taxes",
        "label": "Provisions For AGA Taxes Related Temporary Differences [Member]",
        "documentation": "Provisions For AGA Taxes Related Temporary Differences"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisitions of intangible assets",
        "label": "Purchase of intangible assets, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisitions of property, plant and equipment",
        "label": "Purchase of property, plant and equipment, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "abvx_RNPVIRConditionalAdvanceBPIAndCARENAConditionalAdvanceBPIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "RNPVIRConditionalAdvanceBPIAndCARENAConditionalAdvanceBPIMember",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RNP-VIR conditional advance and CARENA conditional advance",
        "label": "RNP-VIR Conditional Advance, BPI And CARENA Conditional Advance, BPI [Member]",
        "documentation": "RNP-VIR Conditional Advance, BPI And CARENA Conditional Advance, BPI"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_RNPVIRConditionalAdvanceBPIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "RNPVIRConditionalAdvanceBPIMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofconditionaladvancesDetails",
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails",
      "http://www.abivax.com/role/OffbalancesheetcommitmentsreceivedandcontingentassetsDetails",
      "http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RNP-VIR conditional advance",
        "verboseLabel": "RNP VIR \u2013 Bpifrance",
        "label": "RNP-VIR Conditional Advance, BPI [Member]",
        "documentation": "RNP-VIR Conditional Advance, BPI"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails",
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails",
      "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails",
      "http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails",
      "http://www.abivax.com/role/SegmentinformationDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [axis]",
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r109",
      "r122",
      "r130",
      "r195",
      "r342",
      "r344",
      "r514"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails",
      "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RangeDomain",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails",
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails",
      "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails",
      "http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails",
      "http://www.abivax.com/role/SegmentinformationDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [domain]",
        "label": "Range [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r109",
      "r122",
      "r130",
      "r195",
      "r342",
      "r344",
      "r514"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails",
      "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ReclassificationOfPrepaidExpensesToCarryingValueOfDebtComponent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ReclassificationOfPrepaidExpensesToCarryingValueOfDebtComponent",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of prepaid expenses to carrying value of debt component",
        "label": "Reclassification of Prepaid Expenses to Carrying Value of Debt Component",
        "documentation": "Reclassification of Prepaid Expenses to Carrying Value of Debt Component"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RecognisedLiabilitiesDefinedBenefitPlan",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/RelatedpartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net defined benefit liability",
        "label": "Net defined benefit liability"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deficit in a defined benefit plan. [Refer: Defined benefit plans [domain]]"
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract",
     "presentation": [
      "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of changes in intangible assets other than goodwill [abstract]",
        "label": "Reconciliation of changes in intangible assets other than goodwill [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract",
     "presentation": [
      "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of changes in property, plant and equipment [abstract]",
        "label": "Reconciliation of changes in property, plant and equipment [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ReconciliationOfNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of number of shares outstanding [abstract]",
        "label": "Reconciliation of number of shares outstanding [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r395",
      "r406",
      "r416",
      "r449"
     ]
    },
    "ifrs-full_RecurringFairValueMeasurementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RecurringFairValueMeasurementMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recurring fair value measurement",
        "label": "Recurring fair value measurement [member]"
       }
      }
     },
     "auth_ref": [
      "r103",
      "r270"
     ]
    },
    "abvx_RegisteredDirectOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "RegisteredDirectOfferingMember",
     "presentation": [
      "http://www.abivax.com/role/BasisofpreparationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Registered direct offering",
        "label": "Registered Direct Offering [Member]",
        "documentation": "Registered Direct Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party transactions [abstract]",
        "label": "Related party transactions [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_RemeasurementPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "RemeasurementPeriodAxis",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remeasurement Period [Axis]",
        "label": "Remeasurement Period [Axis]",
        "documentation": "Remeasurement Period"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_RemeasurementPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "RemeasurementPeriodDomain",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remeasurement Period [Domain]",
        "label": "Remeasurement Period [Domain]",
        "documentation": "Remeasurement Period [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_RepaymentOfExcessConditionalAdvancesClaimed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "RepaymentOfExcessConditionalAdvancesClaimed",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Excess conditional advances claimed",
        "label": "Repayment Of Excess Conditional Advances Claimed",
        "documentation": "Repayment Of Excess Conditional Advances Claimed"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_RepaymentsOfBondLoans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "RepaymentsOfBondLoans",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayments of bond loans",
        "label": "Repayments Of Bond Loans",
        "documentation": "Repayments Of Bond Loans"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/FinancialliabilitiesStateguaranteedloanPGEDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayments of borrowings, classified as financing activities",
        "label": "Repayments of borrowings, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "abvx_RepaymentsOfConditionalAdvances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "RepaymentsOfConditionalAdvances",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayments of conditional advances",
        "terseLabel": "Repayments of conditional advances",
        "label": "Repayments Of Conditional Advances",
        "documentation": "Repayments Of Conditional Advances"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_RepaymentsOfConvertibleLoansNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "RepaymentsOfConvertibleLoansNotes",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreos1Details",
      "http://www.abivax.com/role/FinancialliabilitiesKreos2Details",
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayments of convertible loan notes",
        "terseLabel": "Repayments of convertible loan notes",
        "label": "Repayments Of Convertible Loans Notes",
        "documentation": "Repayments Of Convertible Loans Notes"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_RepaymentsOfNonConvertibleLoansNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "RepaymentsOfNonConvertibleLoansNotes",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayments of non-convertible bond loans",
        "label": "Repayments Of Non-Convertible Loans Notes",
        "documentation": "Repayments Of Non-Convertible Loans Notes"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_RepaymentsOfPGE": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "RepaymentsOfPGE",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayment of PGE",
        "label": "Repayments Of PGE",
        "documentation": "Repayments Of PGE"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.abivax.com/role/BasisofpreparationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_RepurchaseOfDerivativeInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "RepurchaseOfDerivativeInstruments",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchases",
        "negatedLabel": "Repurchases",
        "label": "Repurchase Of Derivative Instruments",
        "documentation": "Repurchase Of Derivative Instruments"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ResearchAndCollaborationAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ResearchAndCollaborationAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember",
     "presentation": [
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and collaboration agreement with CNRS, University of Montpellier and Institut Curie",
        "label": "Research And Collaboration Agreement With CNRS, University Of Montpellier And Institut Curie [Member]",
        "documentation": "Research And Collaboration Agreement With CNRS, University Of Montpellier And Institut Curie"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ResearchAndDevelopmentCostsRecognitionInitialMeasurementNumberOfCriterias": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ResearchAndDevelopmentCostsRecognitionInitialMeasurementNumberOfCriterias",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesIntangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development costs recognition, initial measurement, number of criterias",
        "label": "Research And Development Costs Recognition, Initial Measurement, Number Of Criterias",
        "documentation": "Research And Development Costs Recognition, Initial Measurement, Number Of Criterias"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Research and development",
        "label": "Research and development expense"
       }
      }
     },
     "auth_ref": [
      "r64",
      "r245"
     ]
    },
    "abvx_ResearchAndDevelopmentExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ResearchAndDevelopmentExpensesMember",
     "presentation": [
      "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails",
      "http://www.abivax.com/role/OperatingexpensesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Research And Development Expenses [Member]",
        "documentation": "Research And Development Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ReserveOfExchangeDifferencesOnTranslation",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Translation reserve",
        "label": "Reserve of exchange differences on translation"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r25",
      "r220"
     ]
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ReserveOfExchangeDifferencesOnTranslationMember",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TRANSLATION RESERVE",
        "label": "Reserve of exchange differences on translation [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r25",
      "r220",
      "r371"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r396",
      "r407",
      "r417",
      "r450"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r397",
      "r408",
      "r418",
      "r451"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r404",
      "r415",
      "r425",
      "r458"
     ]
    },
    "ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RetainedEarningsExcludingProfitLossForReportingPeriod",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained earnings",
        "label": "Retained earnings, excluding profit (loss) for reporting period"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity\u2019s cumulative undistributed earnings or deficit excluding the profit or loss for the reporting period. [Refer: Retained earnings]"
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RetainedEarningsExcludingProfitLossForReportingPeriodMember",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RETAINED EARNINGS",
        "label": "Retained earnings, excluding profit (loss) for reporting period [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit, excluding profit or loss for the reporting period. [Refer: Retained earnings [member]]"
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "ifrs-full_RetainedEarningsProfitLossForReportingPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RetainedEarningsProfitLossForReportingPeriod",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss for the period",
        "label": "Retained earnings, profit (loss) for reporting period"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity\u2019s undistributed profit or loss for the reporting period. [Refer: Retained earnings; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RetainedEarningsProfitLossForReportingPeriodMember",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NET LOSS FOR THE YEAR",
        "label": "Retained earnings, profit (loss) for reporting period [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing the entity\u2019s undistributed profit or loss for the reporting period. [Refer: Retained earnings [member]; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "abvx_RetirementBenefitObligationsRelatedTemporaryDifferencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "RetirementBenefitObligationsRelatedTemporaryDifferencesMember",
     "presentation": [
      "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement benefit obligation",
        "label": "Retirement Benefit Obligations Related Temporary Differences [Member]",
        "documentation": "Retirement Benefit Obligations Related Temporary Differences"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_RevaluationOfCashEquivalentsMeasuredAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "RevaluationOfCashEquivalentsMeasuredAtFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revaluation of cash equivalents measured at fair value",
        "label": "Revaluation Of Cash Equivalents Measured At Fair Value",
        "documentation": "Revaluation Of Cash Equivalents Measured At Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RevenueAndOperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RevenueAndOperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating income",
        "label": "Revenue and other operating income"
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "ifrs-full_RevenueFromGovernmentGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RevenueFromGovernmentGrants",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/OtheroperatingincomeDisclosureofbreakdownofoperatingincomeDetails": {
       "parentTag": "ifrs-full_OtherIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesStateguaranteedloanPGEDetails",
      "http://www.abivax.com/role/OtheroperatingincomeDisclosureofbreakdownofoperatingincomeDetails",
      "http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income from government grants",
        "terseLabel": "Subsidies",
        "label": "Income from government grants"
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "ifrs-full_RevenueFromInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RevenueFromInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": {
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Interest income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income arising from interest."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r163",
      "r169",
      "r519"
     ]
    },
    "ifrs-full_RightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RightofuseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "label": "Right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r115",
      "r177"
     ]
    },
    "ifrs-full_RightofuseAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RightofuseAssetsMember",
     "presentation": [
      "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ROU",
        "label": "Right-of-use assets [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "abvx_RiskFreeInterestRateMeasurementInputExpiryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "RiskFreeInterestRateMeasurementInputExpiryMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free rate, expiry",
        "label": "Risk-Free Interest Rate, Measurement Input, Expiry [Member]",
        "documentation": "Risk-Free Interest Rate, Measurement Input, Expiry"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_RiskFreeInterestRateMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "RiskFreeInterestRateMeasurementInputMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails",
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free rate",
        "label": "Risk-Free Interest Rate, Measurement Input [Member]",
        "documentation": "Risk-Free Interest Rate, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_RiskFreeInterestRateMeasurementInputTenderOfferMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "RiskFreeInterestRateMeasurementInputTenderOfferMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free rate, tender offer",
        "label": "Risk-Free Interest Rate, Measurement Input, Tender Offer [Member]",
        "documentation": "Risk-Free Interest Rate, Measurement Input, Tender Offer"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "RiskFreeInterestRateOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RISK\u00a0FREE\u00a0RATE",
        "label": "Risk Free Interest Rate, Other Equity Instruments Granted",
        "documentation": "Risk Free Interest Rate, Other Equity Instruments Granted"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_RoyaltyCertificateExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "RoyaltyCertificateExpirationPeriod",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesBreakdownoffinancialliabilitiesbymaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty certificate, expiration period",
        "label": "Royalty Certificate, Expiration Period",
        "documentation": "Royalty Certificate, Expiration Period"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_RoyaltyCertificateMaximumAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "RoyaltyCertificateMaximumAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesBreakdownoffinancialliabilitiesbymaturityDetails",
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty certificate, maximum amount",
        "label": "Royalty Certificate, Maximum Amount",
        "documentation": "Royalty Certificate, Maximum Amount"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_RoyaltyCertificatePercentageOfFutureSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "RoyaltyCertificatePercentageOfFutureSales",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesBreakdownoffinancialliabilitiesbymaturityDetails",
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty certificate, percentage of future sales",
        "label": "Royalty Certificate, Percentage Of Future Sales",
        "documentation": "Royalty Certificate, Percentage Of Future Sales"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_RoyaltyCertificatesEIR": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "RoyaltyCertificatesEIR",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty certificates, EIR",
        "label": "Royalty Certificates, EIR",
        "documentation": "Royalty Certificates, EIR"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_RoyaltyCertificatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "RoyaltyCertificatesMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesBreakdownoffinancialliabilitiesbymaturityDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty certificates",
        "label": "Royalty Certificates [Member]",
        "documentation": "Royalty Certificates"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_RoyaltyCertificatesRelatedTemporaryDifferencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "RoyaltyCertificatesRelatedTemporaryDifferencesMember",
     "presentation": [
      "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails",
      "http://www.abivax.com/role/IncometaxNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty certificates",
        "label": "Royalty Certificates Related Temporary Differences [Member]",
        "documentation": "Royalty Certificates Related Temporary Differences"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_RoyaltyCertificatesUndiscountedCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "RoyaltyCertificatesUndiscountedCashFlows",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": {
       "parentTag": "abvx_FinancialLiabilitiesUndiscountedCashFlows",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty certificates, undiscounted cash flows",
        "label": "Royalty Certificates, Undiscounted Cash Flows",
        "documentation": "Royalty Certificates, Undiscounted Cash Flows"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "abvx_SaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "SaleOfStockAxis",
     "presentation": [
      "http://www.abivax.com/role/BasisofpreparationDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale Of Stock [Axis]",
        "label": "Sale Of Stock [Axis]",
        "documentation": "Sale Of Stock"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_SaleOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "SaleOfStockDomain",
     "presentation": [
      "http://www.abivax.com/role/BasisofpreparationDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale Of Stock [Domain]",
        "label": "Sale Of Stock [Domain]",
        "documentation": "Sale Of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SalesAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SalesAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Sales and marketing",
        "label": "Sales and marketing expense"
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "abvx_SalesAndMarketingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "SalesAndMarketingExpenseMember",
     "presentation": [
      "http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales and marketing expenses",
        "label": "Sales And Marketing Expense [Member]",
        "documentation": "Sales And Marketing Expense"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.abivax.com/role/IncometaxNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_SensitivityAnalysisForTypesOfMarketRisk10AdverseChangeInExchangeRateImpactOnForeignExchangeGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "SensitivityAnalysisForTypesOfMarketRisk10AdverseChangeInExchangeRateImpactOnForeignExchangeGainLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Adverse change in exchange rate, impact on foreign exchange loss",
        "label": "Sensitivity Analysis For Types Of Market Risk, 10% Adverse Change in Exchange Rate, Impact On Foreign Exchange Gain (Loss)",
        "documentation": "Sensitivity Analysis For Types Of Market Risk, 10% Adverse Change in Exchange Rate, Impact On Foreign Exchange Gain (Loss)"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_SensitivityAnalysisForTypesOfMarketRisk10FavorableChangeInExchangeRateImpactOnForeignExchangeGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "SensitivityAnalysisForTypesOfMarketRisk10FavorableChangeInExchangeRateImpactOnForeignExchangeGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Favorable change in exchange rate, impact on foreign exchange gain",
        "label": "Sensitivity Analysis For Types Of Market Risk, 10% Favorable Change in Exchange Rate, Impact On Foreign Exchange Gain (Loss)",
        "documentation": "Sensitivity Analysis For Types Of Market Risk, 10% Favorable Change in Exchange Rate, Impact On Foreign Exchange Gain (Loss)"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent",
     "presentation": [
      "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reasonably possible change in risk variable, percent",
        "label": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Percent",
        "documentation": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ShareBasedPaymentArrangementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ShareBasedPaymentArrangementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangements [Abstract]",
        "label": "Share-Based Payment Arrangements [Abstract]",
        "documentation": "Share-Based Payment Arrangements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareIssueRelatedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ShareIssueRelatedCost",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails",
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share issue related cost",
        "label": "Share issue related cost"
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "abvx_ShareIssueRelatedCostCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ShareIssueRelatedCostCredit",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Transaction costs related to capital increase",
        "label": "Share Issue Related Cost (Credit)",
        "documentation": "Share Issue Related Cost (Credit)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharePremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SharePremium",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Premiums related to share capital",
        "label": "Share premium"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r374"
     ]
    },
    "ifrs-full_SharePremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SharePremiumMember",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PREMIUMS RELATED TO SHARE CAPITAL",
        "verboseLabel": "Share premium",
        "label": "Share premium [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "abvx_SharePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "SharePrice1",
     "presentation": [
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price (euro per share)",
        "label": "Share Price1",
        "documentation": "Share Price1"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_SharePriceMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "SharePriceMeasurementInputMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails",
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails",
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary share price (in euro per share)",
        "label": "Share Price, Measurement Input [Member]",
        "documentation": "Share Price, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ShareSubscriptionWarrantsBSAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ShareSubscriptionWarrantsBSAMember",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total BSAs",
        "verboseLabel": "BSAs",
        "label": "Share Subscription Warrants (BSA) [Member]",
        "documentation": "Share Subscription Warrants (BSA)"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_ShareWarrantsSubscriptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "ShareWarrantsSubscriptionPricePerShare",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreos1Details",
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share warrants, subscription price (in euro per share)",
        "label": "Share Warrants, Subscription Price Per Share",
        "documentation": "Share Warrants, Subscription Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ShorttermDepositsNotClassifiedAsCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails": {
       "parentTag": "ifrs-full_OtherCurrentFinancialAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits",
        "label": "Short-term deposits, not classified as cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of short-term deposits held by the entity that are not classified as cash equivalents. [Refer: Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "ifrs-full_ShorttermEmployeeBenefitsAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ShorttermEmployeeBenefitsAccruals",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails": {
       "parentTag": "abvx_CurrentTaxAndEmployeeBenefitLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee-related payables",
        "label": "Short-term employee benefits accruals"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]"
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SignificantInvestmentsInSubsidiariesAxis",
     "presentation": [
      "http://www.abivax.com/role/IncometaxNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiaries [axis]",
        "label": "Subsidiaries [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r102",
      "r269"
     ]
    },
    "ifrs-full_SignificantInvestmentsInSubsidiariesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SignificantInvestmentsInSubsidiariesDomain",
     "presentation": [
      "http://www.abivax.com/role/IncometaxNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiaries [domain]",
        "label": "Subsidiaries [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r102",
      "r269"
     ]
    },
    "ifrs-full_SignificantUnobservableInputAssets": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SignificantUnobservableInputAssets",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant unobservable input, assets",
        "label": "Significant unobservable input, assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The value of significant unobservable input used in the measurement of the fair value of assets."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "ifrs-full_SignificantUnobservableInputLiabilities": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SignificantUnobservableInputLiabilities",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant unobservable input, liabilities",
        "label": "Significant unobservable input, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The value of significant unobservable input used in the measurement of the fair value of liabilities."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "abvx_SplicosSASABX464Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "SplicosSASABX464Member",
     "presentation": [
      "http://www.abivax.com/role/GoodwillandimpairmenttestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Splicos SAS",
        "label": "Splicos SAS - ABX464 [Member]",
        "documentation": "Splicos SAS - ABX464"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.abivax.com/role/IncometaxNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [line items]",
        "label": "Statement of changes in equity [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [table]",
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "ifrs-full_StatementOfComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of comprehensive income [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfIFRSCompliance": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfIFRSCompliance",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of compliance",
        "label": "Statement of IFRS compliance [text block]"
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r399",
      "r410",
      "r420",
      "r453"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_SubContractingStudiesAndResearchExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "SubContractingStudiesAndResearchExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sub-contracting, studies and research",
        "label": "Sub-Contracting, Studies And Research Expenses",
        "documentation": "Sub-Contracting, Studies And Research Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_SubsidiesRelatedTemporaryDifferencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "SubsidiesRelatedTemporaryDifferencesMember",
     "presentation": [
      "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidies",
        "label": "Subsidies Related Temporary Differences [Member]",
        "documentation": "Subsidies Related Temporary Differences"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "abvx_TaxEffectOfChangesInDerivativeFairValueAndOtherLiabilitiesMeasuredAtFVTPL": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "TaxEffectOfChangesInDerivativeFairValueAndOtherLiabilitiesMeasuredAtFVTPL",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease / (increase) in derivatives and other liabilities measured at FVTPL",
        "label": "Tax Effect Of Changes In Derivative Fair Value And Other Liabilities Measured At FVTPL",
        "documentation": "Tax Effect Of Changes In Derivative Fair Value And Other Liabilities Measured At FVTPL"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxEffectOfForeignTaxRates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TaxEffectOfForeignTaxRates",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax rates in foreign jurisdictions",
        "label": "Tax effect of foreign tax rates"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r2",
      "r201"
     ]
    },
    "abvx_TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferences": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferences",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Non-recognition of deferred tax assets related to tax losses and temporary differences",
        "label": "Tax Effect Of Non-Recognition Of Deferred Tax Assets Related To Tax Losses And Temporary Differences",
        "documentation": "Tax Effect Of Non-Recognition Of Deferred Tax Assets Related To Tax Losses And Temporary Differences"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_TaxEffectOfResearchTaxCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "TaxEffectOfResearchTaxCredit",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CIR",
        "label": "Tax Effect Of Research Tax Credit",
        "documentation": "Tax Effect Of Research Tax Credit"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_TaxEffectOfShareBasedPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "TaxEffectOfShareBasedPayment",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment",
        "label": "Tax Effect Of Share-Based Payment",
        "documentation": "Tax Effect Of Share-Based Payment"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_TaxEffectOfTransactionCostsRelatedToCapitalIncrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "TaxEffectOfTransactionCostsRelatedToCapitalIncrease",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction costs related to capital increase",
        "label": "Tax Effect Of Transaction Costs Related To Capital Increase",
        "documentation": "Tax Effect Of Transaction Costs Related To Capital Increase"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TaxExpenseIncomeAtApplicableTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nominal income tax using statutory French tax rate",
        "label": "Tax expense (income) at applicable tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r2",
      "r201"
     ]
    },
    "abvx_TechnicalFacilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "TechnicalFacilitiesMember",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Technical facilities",
        "label": "Technical Facilities [Member]",
        "documentation": "Technical Facilities"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_TechnologyBasedIntangibleAssetsAssetsAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "TechnologyBasedIntangibleAssetsAssetsAcquisitions",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/IntangibleassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patents",
        "label": "Technology-Based Intangible Assets, Assets Acquisitions",
        "documentation": "Technology-Based Intangible Assets, Assets Acquisitions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis",
     "presentation": [
      "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails",
      "http://www.abivax.com/role/IncometaxNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits [axis]",
        "label": "Temporary difference, unused tax losses and unused tax credits [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r205"
     ]
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain",
     "presentation": [
      "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails",
      "http://www.abivax.com/role/IncometaxNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits [domain]",
        "label": "Temporary difference, unused tax losses and unused tax credits [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r205"
     ]
    },
    "abvx_TenderOfferFairValueOfMRIMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "TenderOfferFairValueOfMRIMeasurementInputMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total fair value of MRI, tender offer",
        "label": "Tender Offer, Fair Value Of MRI , Measurement Input [Member]",
        "documentation": "Tender Offer, Fair Value Of MRI , Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Probability-weighted present value of shortfall payment, tender offer",
        "label": "Tender Offer, Probability-Weighted Present Value Of Shortfall Payment, Measurement Input [Member]",
        "documentation": "Tender Offer, Probability-Weighted Present Value Of Shortfall Payment, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_TheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "TheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember",
     "presentation": [
      "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Scripps Research Institute, University of Chicago and Brigham Young University",
        "label": "The Scripps Research Institute, University Of Chicago And Brigham Young University [Member]",
        "documentation": "The Scripps Research Institute, University Of Chicago And Brigham Young University"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.abivax.com/role/RelatedpartiesNarrativeDetails",
      "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title and Position [Axis]",
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.abivax.com/role/RelatedpartiesNarrativeDetails",
      "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title and Position [Domain]",
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails",
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails",
      "http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails",
      "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails",
      "http://www.abivax.com/role/SegmentinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Top of range",
        "label": "Top of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r109",
      "r122",
      "r130",
      "r195",
      "r342",
      "r344",
      "r514"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentPayables",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade payables and other current liabilities",
        "totalLabel": "Trade payables and other current liabilities",
        "label": "Trade and other current payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other current payables [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Trade payables",
        "label": "Current trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]"
       }
      }
     },
     "auth_ref": [
      "r372",
      "r525"
     ]
    },
    "ifrs-full_TradeAndOtherPayablesToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TradeAndOtherPayablesToRelatedParties",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payables to related parties",
        "label": "Payables to related parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of payables due to related parties. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "ifrs-full_TradeAndOtherReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TradeAndOtherReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other receivables [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TradeAndOtherReceivablesDueFromRelatedParties",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables due from related parties",
        "label": "Receivables due from related parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of receivables due from related parties. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r367",
      "r373"
     ]
    },
    "abvx_TradePayablesAndOtherCurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "TradePayablesAndOtherCurrentLiabilitiesMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade payables and other current liabilities",
        "label": "Trade Payables And Other Current Liabilities [Member]",
        "documentation": "Trade Payables And Other Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.abivax.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "abvx_TrancheBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "TrancheBMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche B",
        "label": "Tranche B [Member]",
        "documentation": "Tranche B"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_TrancheCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "TrancheCMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche C",
        "label": "Tranche C [Member]",
        "documentation": "Tranche C"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_TrancheFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "TrancheFiveMember",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche 5",
        "label": "Tranche Five [Member]",
        "documentation": "Tranche Five"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_TrancheFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "TrancheFourMember",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche 4",
        "label": "Tranche Four [Member]",
        "documentation": "Tranche Four"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_TrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "TrancheOneMember",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche 1",
        "label": "Tranche One [Member]",
        "documentation": "Tranche One"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_TrancheSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "TrancheSixMember",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche 6",
        "label": "Tranche Six [Member]",
        "documentation": "Tranche Six"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_TrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "TrancheThreeMember",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche 3",
        "label": "Tranche Three [Member]",
        "documentation": "Tranche Three"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_TrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "TrancheTwoMember",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche 2",
        "label": "Tranche Two [Member]",
        "documentation": "Tranche Two"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_TranchesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "TranchesAxis",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranches [Axis]",
        "label": "Tranches [Axis]",
        "documentation": "Tranches"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_TranchesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "TranchesDomain",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranches [Domain]",
        "label": "Tranches [Domain]",
        "documentation": "Tranches [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_TranchesOneToFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "TranchesOneToFourMember",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranches 1-4",
        "label": "Tranches One To Four [Member]",
        "documentation": "Tranches One To Four"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_TransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "TransactionCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Transaction costs",
        "label": "Transaction Costs",
        "documentation": "Transaction Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "ifrs-full_TypesOfContractsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfContractsAxis",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails",
      "http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of contracts [axis]",
        "label": "Types of contracts [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r349",
      "r364"
     ]
    },
    "ifrs-full_TypesOfContractsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfContractsDomain",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails",
      "http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of contracts [domain]",
        "label": "Types of contracts [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of contracts with customers. It also represents the standard value for the 'Types of contracts' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r349",
      "r364"
     ]
    },
    "ifrs-full_TypesOfInterestRatesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfInterestRatesAxis",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of interest rates [axis]",
        "label": "Types of interest rates [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "ifrs-full_TypesOfInterestRatesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfInterestRatesDomain",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of interest rates [domain]",
        "label": "Types of interest rates [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of interest rates. It also represents the standard value for the 'Types of interest rates' axis if no other member is used. [Refer: Interest rate risk [member]]"
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "ifrs-full_TypesOfRisksAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfRisksAxis",
     "presentation": [
      "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of risks [axis]",
        "label": "Types of risks [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r123",
      "r124",
      "r125",
      "r127",
      "r139",
      "r143",
      "r144",
      "r221"
     ]
    },
    "ifrs-full_TypesOfRisksDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfRisksDomain",
     "presentation": [
      "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of risks [domain]",
        "label": "Types of risks [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r123",
      "r124",
      "r125",
      "r127",
      "r139",
      "r143",
      "r144",
      "r221"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails",
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of share-based payment arrangements [axis]",
        "label": "Types of share-based payment arrangements [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r253"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsDomain",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails",
      "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of share-based payment arrangements [domain]",
        "label": "Types of share-based payment arrangements [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r253"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "US",
     "presentation": [
      "http://www.abivax.com/role/EmployeesDetails",
      "http://www.abivax.com/role/SegmentinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "currency_USD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2025",
     "localname": "USD",
     "presentation": [
      "http://www.abivax.com/role/CashandcashequivalentsNarrativeDetails",
      "http://www.abivax.com/role/FinancialgainlossNarrativeDetails",
      "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States of America, Dollars",
        "label": "United States of America, Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "UnderlyingShareFairValueOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails",
      "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FAIR VALUE OF THE UNDERLYING SHARE (in euro per share)",
        "label": "Underlying Share Fair Value, Other Equity Instruments Granted",
        "documentation": "Underlying Share Fair Value, Other Equity Instruments Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UndrawnBorrowingFacilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "UndrawnBorrowingFacilities",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/OffbalancesheetcommitmentsreceivedandcontingentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Undrawn borrowing facilities",
        "label": "Undrawn borrowing facilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of undrawn borrowing facilities that may be available for future operating activities and to settle capital commitments. [Refer: Capital commitments]"
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "abvx_UnobservableInputLiabilitiesDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "UnobservableInputLiabilitiesDiscountRate",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unobservable input, liabilities, discount rate",
        "label": "Unobservable Input, Liabilities, Discount Rate",
        "documentation": "Unobservable Input, Liabilities, Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UnobservableInputsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "UnobservableInputsAxis",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails",
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails",
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unobservable inputs [axis]",
        "label": "Unobservable inputs [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r511"
     ]
    },
    "ifrs-full_UnobservableInputsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "UnobservableInputsDomain",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails",
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails",
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unobservable inputs [domain]",
        "label": "Unobservable inputs [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r511"
     ]
    },
    "abvx_UnrecognitionDayOneGainOfFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "UnrecognitionDayOneGainOfFinancialLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognition day-one gain of financial liabilities",
        "label": "Unrecognition Day-One Gain Of Financial Liabilities",
        "documentation": "Unrecognition Day-One Gain Of Financial Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_UnrecognizedDeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "UnrecognizedDeferredTaxAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails": {
       "parentTag": "abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrecognized deferred tax assets",
        "label": "Unrecognized Deferred Tax Assets",
        "documentation": "Unrecognized Deferred Tax Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
     "presentation": [
      "http://www.abivax.com/role/IncometaxNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unused tax losses for which no deferred tax asset recognised",
        "label": "Unused tax losses for which no deferred tax asset recognised"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r4",
      "r203"
     ]
    },
    "ifrs-full_UnusedTaxLossesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "UnusedTaxLossesMember",
     "presentation": [
      "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax losses carryforward",
        "label": "Unused tax losses [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for tax losses that have been incurred and are carried forward for use against future taxable profit."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r205"
     ]
    },
    "abvx_UnwindingEffectOfDiscountRelatedToAdvancesMadeToCROs": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "UnwindingEffectOfDiscountRelatedToAdvancesMadeToCROs",
     "crdr": "credit",
     "calculation": {
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": {
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of unwinding the discount related to advances made to CROs",
        "label": "Unwinding Effect Of Discount Related To Advances Made To CROs",
        "documentation": "Unwinding Effect Of Discount Related To Advances Made To CROs"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_UnwindingOfDiscountOnRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "UnwindingOfDiscountOnRoyalties",
     "crdr": "debit",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unwinding of discount on royalties",
        "label": "Unwinding Of Discount On Royalties",
        "documentation": "Unwinding Of Discount On Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesIntangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful life measured as period of time, intangible assets other than goodwill",
        "label": "Useful life measured as period of time, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r56",
      "r237"
     ]
    },
    "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
     "presentation": [
      "http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful life measured as period of time, property, plant and equipment",
        "label": "Useful life measured as period of time, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r8",
      "r206"
     ]
    },
    "ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ValuationTechniquesUsedInFairValueMeasurementAxis",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation techniques used in fair value measurement [axis]",
        "label": "Valuation techniques used in fair value measurement [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ValuationTechniquesUsedInFairValueMeasurementDomain",
     "presentation": [
      "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation techniques used in fair value measurement [domain]",
        "label": "Valuation techniques used in fair value measurement [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for valuation techniques used by the entity to measure fair value. It also represents the standard value for the 'Valuation techniques used in fair value measurement' axis if no other member is used. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "abvx_VestingRequirementsForShareBasedPaymentArrangementChangeOfControlMinimumThreshold": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "VestingRequirementsForShareBasedPaymentArrangementChangeOfControlMinimumThreshold",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change of control, minimum percentage",
        "label": "Vesting Requirements For Share-Based Payment Arrangement, Change Of Control, Minimum Threshold",
        "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Change Of Control, Minimum Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_VestingRequirementsForShareBasedPaymentArrangementPerformanceConditionsMinimumFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "VestingRequirementsForShareBasedPaymentArrangementPerformanceConditionsMinimumFinancing",
     "crdr": "credit",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance conditions, minimum financing",
        "label": "Vesting Requirements For Share-Based Payment Arrangement, Performance Conditions, Minimum Financing",
        "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Performance Conditions, Minimum Financing"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_VestingRequirementsForShareBasedPaymentArrangementServicePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "VestingRequirementsForShareBasedPaymentArrangementServicePeriod",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service period",
        "label": "Vesting Requirements For Share-Based Payment Arrangement, Service Period",
        "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Service Period"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "VestingRequirementsForShareBasedPaymentArrangementVestingPercentage",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting percentage",
        "label": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Percentage",
        "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentagePerMonth": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "VestingRequirementsForShareBasedPaymentArrangementVestingPercentagePerMonth",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting percentage per month",
        "label": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Percentage Per Month",
        "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Percentage Per Month"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "VestingRequirementsForShareBasedPaymentArrangementVestingPeriod",
     "presentation": [
      "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Period",
        "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Period"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_VolatilityForSharesMeasurementInputExpiryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "VolatilityForSharesMeasurementInputExpiryMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility, expiry",
        "label": "Volatility For Shares Measurement Input, Expiry [Member]",
        "documentation": "Volatility For Shares Measurement Input, Expiry"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_VolatilityForSharesMeasurementInputTenderOfferMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "VolatilityForSharesMeasurementInputTenderOfferMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility, tender offer",
        "label": "Volatility For Shares Measurement Input, Tender Offer [Member]",
        "documentation": "Volatility For Shares Measurement Input, Tender Offer"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_VoluntaryConversionScenarioProbabilityMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "VoluntaryConversionScenarioProbabilityMeasurementInputMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails",
      "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Held to maturity / voluntary conversion scenario probability",
        "label": "Voluntary Conversion Scenario Probability, Measurement Input [Member]",
        "documentation": "Voluntary Conversion Scenario Probability, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "abvx_WarrantsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "WarrantsAxis",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreos1Details",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants [Axis]",
        "label": "Warrants [Axis]",
        "documentation": "Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "abvx_WarrantsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "WarrantsDomain",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails",
      "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails",
      "http://www.abivax.com/role/FinancialliabilitiesKreos1Details",
      "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails",
      "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants [Domain]",
        "label": "Warrants [Domain]",
        "documentation": "Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageCostOfCapitalMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WeightedAverageCostOfCapitalMeasurementInputMember",
     "presentation": [
      "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WACC",
        "label": "Weighted average cost of capital, measurement input [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the weighted average cost of capital used as a measurement input."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r344"
     ]
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS",
      "http://www.abivax.com/role/IncomelosspershareScheduleofearningspershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average number of outstanding shares used for computing basic loss per share (in shares)",
        "terseLabel": "Weighted average number of outstanding shares, basic loss per share (in shares)",
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "abvx_WittycelSASABX196Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abivax.com/20251231",
     "localname": "WittycelSASABX196Member",
     "presentation": [
      "http://www.abivax.com/role/GoodwillandimpairmenttestDetails",
      "http://www.abivax.com/role/IntangibleassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wittycel SAS",
        "label": "Wittycel SAS - ABX196 [Member]",
        "documentation": "Wittycel SAS - ABX196"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2025-01-01",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2025-03-27"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "75",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_75_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI",
   "URIDate": "2025-03-27"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "138",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "140",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_140_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "140",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_140_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "141",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "141",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "141",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "141",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "141",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_g&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS19_g2-7_TI",
   "URIDate": "2025-03-27"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "20",
   "IssueDate": "2025-01-01",
   "Paragraph": "39",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2025-en-r&anchor=para_39_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2025-01-01",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2025-01-01",
   "Paragraph": "52",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2025-01-01",
   "Paragraph": "A19",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_A19_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Paragraph": "18",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_18&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Paragraph": "19",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_19_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2025-03-27"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_iv&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2025-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "70",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI",
   "URIDate": "2025-03-27"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2025-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2025-01-01",
   "Paragraph": "130",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2025-01-01",
   "Paragraph": "134",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2025-01-01",
   "Paragraph": "134",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2025-01-01",
   "Paragraph": "134",
   "Subparagraph": "d",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134_d_v&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2025-01-01",
   "Paragraph": "134",
   "Subparagraph": "e",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134_e_v&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2025-01-01",
   "Paragraph": "134",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2025-01-01",
   "Paragraph": "135",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_135_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2025-01-01",
   "Paragraph": "135",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_135_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2025-01-01",
   "Paragraph": "135",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_135&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS37_g84-92_TI",
   "URIDate": "2025-03-27"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_iv&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_vi&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "122",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_122_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI",
   "URIDate": "2025-03-27"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2025-01-01",
   "Paragraph": "32A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_32A&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2025-01-01",
   "Paragraph": "76",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2025-01-01",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "44B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44B_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "44B",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44B_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "44B",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44B_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "44H",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44H_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "46",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_46&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRIC",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRIC&num=19&code=ifrs-tx-2025-en-r&anchor=para_11&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "12",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_12_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ix",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B13",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_b&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B13",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_c&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B13",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B4",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "h",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_h_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2025-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2025-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "120",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "53",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "58",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_58&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "97",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "109",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "109A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "124",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "125",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "128",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_128_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "51",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_51_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2025-01-01",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B67_d_v&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2025-01-01",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2025-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "21C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "36",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "39",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_39_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "39",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_39_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "42I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42I&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "8",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "8",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "8",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "8",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_g&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "8",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Section": "Defined terms",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI",
   "URIDate": "2025-03-27"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI",
   "URIDate": "2025-03-27"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "23",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI",
   "URIDate": "2025-03-27"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2025-01-01",
   "Paragraph": "7.2.34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.34&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2025-01-01",
   "Paragraph": "7.2.42",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.42&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2026-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "30A",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_30A_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "108",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_108_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "115",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "115",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "115",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "119",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_119&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "122",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "122",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "122",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "124",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "124",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "124",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "128",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_128&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "133",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_133_a_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "166",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_166_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "166",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_166_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "166",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_166_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "166",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_166&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "168",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_168_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "169",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_169&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "170",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_170&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "176",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_176&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "190",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_190&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "192",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_192&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "194",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "194",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "194",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "194",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "194",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "200",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "200",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "200",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "200",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "204",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_204&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "206",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_206_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "206",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_206_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "207",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_207_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "207",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_207_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "207",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_207_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "207",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_207_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "207",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_207_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "216",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_216_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "218",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_218_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "218",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_218_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "223",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_223_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "227",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_227&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "230",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_230&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "231",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_231_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "231",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_231&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "250",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_250&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "254",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "254",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "254",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254_d_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "254",
   "Subparagraph": "f",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254_f_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "254",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "255",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_255_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "255",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_255_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "255",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_255&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "263",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "263",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "263",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "263",
   "Subparagraph": "e",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_iv&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "263",
   "Subparagraph": "e",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_vi&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "263",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "263",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "264",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_264_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "266",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_266&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "269",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_269&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "271",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_271_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "271",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_271_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "273",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_273&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "274",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_274_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "34",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_34_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "37",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_37_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "43",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_43&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "44",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "44",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "44",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "44",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "64A",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_64A_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "71",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "72",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_72_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "72",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_72_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "75",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_75_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "95",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "95",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "95",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iii&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B13",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B13&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B9",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_e&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B9",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_16&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_35&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "51",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_51&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_k&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "m",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_m&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "o",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_o&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "56",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_56&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_66&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_69&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_7&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_91_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_99&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "37",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37_g&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "37",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37_h&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2025-01-01",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2025-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2025-03-27"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2025-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "119",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_119_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "119",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_119_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "14",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_14_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "44B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44B&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "44C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44C&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "44D",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44D&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "50",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI",
   "URIDate": "2025-03-27"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Section": "C Reconciliation of liabilities arising from financing activities",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C_TI",
   "URIDate": "2025-03-27"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "B11",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B11_a&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "B11",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B11_b&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "B36",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B36_a&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "B36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B36_b&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "IE60",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_IE60&doctype=Illustrative%20Examples",
   "URIDate": "2025-03-27"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2025-03-27"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "B89",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "B89",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_d&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "96",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_96_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "96",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_96_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B11D",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11D_a&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B11D",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11D&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B35",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "IG31A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2025-03-27"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "IG40B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG40B&doctype=Implementation%20Guidance",
   "URIDate": "2025-03-27"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "103",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "103",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "115",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "251",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_251&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B9",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B9",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_102&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_70&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "82A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82A&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2025-03-27"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r492": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r493": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r494": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r495": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "135",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_135_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r496": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "144",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_144&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r497": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "20",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r498": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "20",
   "IssueDate": "2025-01-01",
   "Paragraph": "39",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2025-en-r&anchor=para_39_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r499": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r500": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_iv&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r501": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "119",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_119&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r502": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r503": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r504": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r505": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r506": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r507": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r508": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r509": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "h",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_h_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_h&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "39",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_10_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_85&doctype=Standard",
   "URIDate": "2025-03-27"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>168
<FILENAME>0001956827-26-000012-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001956827-26-000012-xbrl.zip
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M@U#E83G7A2"F$S;_\DYI5DPF=2P6II]<3$#S3; LD(&:<X!5TP](W\-NG4%
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MV?5YO0<M:W:6^[^N):CU1FF3THM%@(V,13#%E ^6>>%Z3)?S@A)]%;-B@!3
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M<A,R(=D/W"@ADPH+I2%G6![S_,/VX?&GYP0UXD)@#U<3&>6MYL>U8?I7*A,
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MG*YA=!>;LRN?9^&N/'3XFX,U%,<%!EHY9[CU&"U[3.@#:V@%*[YP6U1M6Z1
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MNPR4H(@R 6P&2MJ$Q$DL!6$2:5([DC94VA9&."HU6GF\C(P.183'ENT (9$
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M!S6_ZWGW3H0%$1C[-RI3=HUSL22+76X]2Z2(V<6<0*_*\I468N?:7[K@\8K
M[O]MJVX6]^[[GR3MNY]"_0902P,$%     @ SH9W7)+N"/-_!   K1   !P
M  !A8FEV87@M,C R-3(P>&9X97@Q,S%C96\N:'1MW5A;;]LV%'[?K^ 2+'4
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M?N[#Z5$9NP]B"GB+9_""'@=CWK7RYF ,%'X7OCH!O9LLX-_A;*:"T,]5Q#>
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MDG/_O>U63?:.\$U! :OXQK_!N)'R BDH8C\=3V&;U*V*DCF!KG%#8'V_D D
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M%5+C"W#V^*CB$FV$]3&%U>B2GE=3YB":68)(--3#X.;!9T!<0&%E.8@DBG
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M$7M,U"/1EJHPGC8FH<#93G/.4:QJ[:LF173XC!41= 4+I-6R,PF8;+M1-"?
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MX9/>U?DCNG3/?F8#=TOH09A9A]6X\:0FJ<(QC+&Z27)* G&&F=+0O6_"IVT
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MG<N?4].!(/3<?GL!?^H,@BZ8$96"]<(4NXSSSCD&Z/W6M*+W8FTJ!P58[K1
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M_Q)_3\*OF >8)85%Q%A.$,]<+>)V8O6L8-IY@&I<H-NZ>6*FZ4$WY#D6V>]
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MN!F@0LD*+!"-QY0/TTV>7-1$%=1ZV<+'"RN"2*HX@)?0V G.M+%B8YB1C3!
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M5%W%(MZ]W30\&3O9E)2DJ0T,UV,!WS/]<\1K%".%%=+=QK0\U.8=SLK?P:;
M=DRI!4;Z_I_0J+6R*$2'C@X6+*3F$6DZ??<]=.Q81DEF@:%!+D,&+9,X$IX)
MAP],8"-N_##.<DMBM:OJ1C69!ZYN&.%)*+N=(F0$6.$OK.GJHS2C_R9,!Z6:
M8#50I<1&W\@0QE VJ/(!XV#I,(UZ'LM],,P'J)_XOJ2C$G+42?2Q"T: )0YO
MXL87V_ABS],7&_[7Y]'5;]Z'X>6E=_5^ -[7V=![/_CPEJ :"/#P3@>?1MCV
M_W1\L)XG5B$AS:$R!YA*MH(I5_!#%G2@L3GTWP5I(M ]&8]Y(S<(=!$15J'J
M<51-:][*F3,C##N3I$B]%_LO)8]N, WWL63H%6K3AV_9LZ&D=\X5K)''FJ@7
M(GSN!0=%#B<*<T:VVPFV*NH>?(2::S26!K>"<@T()&Q^S?M-3O0^;,L$P/[^
M5E_OUEN<.3#%*\U42KMVF@1JQ= A\4DD%TK&BT>\5BHP$\O=\7-WF I9R(5?
M2GJ/G4>B5ZL):9DHT6Q#,SP.9FX!7HSN(6C+:V6'!084;&* (F:R44,<A;$*
M;-TD]1$,(MY.JJZ+,,KI<>184<>UOCO\CDDXG31.ZTG;]D9ZX*5#=:QG/\U4
MSEZ<=@W@P:75"5WL.1P$SFZZ\\J:!<)BQ.??XC<TOY#&9#$U@Z8<UGO-7'D+
M>$6Z:(CJ*9;$(]+0RBZ&N9F"02DUW[2]A7G!E"'&9<17#<+'\AE7HU8VY>2F
M<O)N%\O)?SW$B#!&OX[.WHS.WFU]_F22!Q]&X*>\<2%";T:7G["[9N.[;WSW
M9^F[5\])WSDG3\5=_SQ/]/SP>5AV%&F@21B#/P/A/EM :U2$-J_E[$?+N3+6
MEMS5AIQG<^;-RE?J9RB'.4DS-8V(QAXE%5#O&[$72>^LG2!UFJ^9LG .+D1J
M)3("A7<(X[9D,%P9&W#Y\^"Z$/L-M]8'!5>Q+?!L1^>ECGA"4/L84,TDY:-:
M<Y:H=V^Y<;$!NC\>_3P\=CQ,P_X ^G +\&+1XY-9$K(-R-\F S:H]VC"[7?X
M)W%26P '>I@]#4FD1-BRX870@TX*SO3KC@ M26IEA#(&&:#RJ&[58( V\BK/
MM0?6FOUM#F]VC_?WMPZJ<0T1LF%(L\FJ;2SS\[3,S:YI=VWP@.I(V;S0-3^:
MU(CLPS;<I\Z;AO +F:]8H!E']6?;20VY<52Z(&L<4T>EO9)#QOEBM7%*"%XP
MUS56:=SV=/YDXH>VM9TJ7;5A$Q^L*(5)GP@H][1,=XSA#F"QXYP3!BN /YN8
MN2EF[K?'S'^_3H(E_&>:SZ)__']02P,$%     @ SH9W7)>N,@1V@   S'<#
M !X   !A8FEV87@M,C!X9GAE>#(Q9&5S8W)I<'1I;RYH=&WLO6ES&\G5)OK]
M_HJZ[;"'G #1(BEJ]>L(MJ2V%='=ZB'5UOC3C0*0 ,LJ5,&U$()__3UK+K6
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MO48O6TP9GF81DZ;"QQ2C,CL3YX5R6CI-^,8J'#*^/?J&4IH4XWJ.'M0Q!N!
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M2@K-'R",FXDI;/S3IGI5P4M594?ZK<-B9;&1U!FBV8L[=LG;#/HJYA QF9!
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MECJ&%VS"<;#77C2-ZRX)<4;"ZHZ1T22]3"$*L/%4>=!&/B"[\ ^2KMGR*UJ
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MQVK2\=WCX<GSI[U?/QH>]_]TS;"/GPR?'O?_]'.'/3T;/GE^LM&P/]).\&[
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M+!Y&;RO2XM7CJBTC<+1JF=MA!@0[99NKXS"\^J#I^H!S424.1.^9Q"LM"*?
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MVE47RA56HC0:%/@*IZMDLTD6316BW6N(*(>G-FF4XW<5532HM%OE0MI3J*L
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M>WW$;G^^-Y[OQ+!]Q)<,A-6T3KG59/'_MW=M36T;4?BO[&,SHZ8O;1\[HX
MIX[-&).41QG)H-18J2X0__ONN>ZN))M+9PH$OY14EK3:V]ES^;YS7 $(KBL!
MC](VC'0ZL6;%6N=3"E#"[W=IQ8Y5\,>  60EJ&"3W(*PT]K:AK0%/)2=KX98
M*_IBUW*QOK6:$S8&=4PAR%>7EP4*!*Z' S?0FNVC<.4UM[9[&7:PLE9@!9K:
M8'E+M]:;]#M%EOYI<W1)<BU(3,>K,)T!^K..F37_K!*"K15^74_[OU:O 6C&
MAIN3A/Q>$54[GIBP_A%Q:VD8*U\$+0):H96 1RW3 I>\->*Y1-_"CMIQ1OF%
M7-Q9!:&#O(+B2[)%:$D4&">'&%[=R&FTEUKWC;$(KX[L*I80PRNKK;H#1V\(
M;V$G8U%D=@QH0V+03AT[6$VYN"U6</VR*L ]M&+JV(:J* (8J0"QYI?31'RZ
M5+$MK!#,2HY1\O3+3DTY"'I-!B0'!MG'==]F76PX&"M[5,.$D=;ZAAZV6 "8
M[X&JUT'YQX@!0>Y5_6?UQ;V61"XL-C]#94D%YH<W"+-.PF.#M7_Z'Z(CM#3'
M)<Z6/2F\#)]!N&>1;TH@7% T'\@8^^TQM#UZ(^RE(*0\$DZ>RT^1P(OL@83'
MK>IA2XR[;U&JZ3=O>?"58('4#U\A;WQ")0*S96)%ZQ _- PU_QL!4HPMD,1&
M&6+1\"Y7#3 L'$B5O$"HU?DJ$OD&0%!:$(P?9'D!4W=&;FE*!\Z[&NX,Z\RA
MD&BMP55A)6*-+J"W&5TT0,U664*[G1M;V'[DMR0D.4X+[O*N)4"P$H!4Y V7
M[43EA)3$H;Z_\<6%]'!=6>&J(B7:$R!:.!"'&4"]S3 *,0(?:0[NT8@Q 2J]
MY3E1@!"I& 2K=E0Y!:>J?<8J6(]!9?:;0%_+FYYW0G%R46*PWD.A0HF8[*6[
M"K I:];N(XV:ZWRJ0:<[E/;@5;YNP6KD>*$K>E@75VO2P7HU(RE*3]#S)Y?@
M_E%F:-?.1 55+$S$\\%PM@!WL<.<I3>I4!7@3@AG7:K9NK<M)FY<Z1B!0>I
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M@=R.47H9LV\O$IXZ$</U)T,OT[<+'NIHXG8Z_[AHT&GVI!T:\UDZ,;N%WJF
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M*#6W8]YC-1^/U=YEQ8](T5/N%N4S9+)?N*>.F#?V7Q_=F'^Y]']02P,$%
M  @ SH9W7**W$UC=!P  %"(  !X   !A8FEV87@M,C!X9GAE>#0Q-W-U;6UA
M<GEO9BYH=&WM6MMRVT82?<]73*R*+561- %2HDPJJM(J=M5N)5[7.IL\I@9
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M'T=CW2<,)#D+YN!D;9['W#Z;_]O>4=V#PX]#YLW@/U^&P=W_ 5!+ P04
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M2.OK1%^--Y9J/MC[,'MQ,11'\<L3(2^L3_OQE8'DA?6U+S("<?^MZ<Y&+-Z
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M:(H JF@<31% DXBF"&0^;^AHBD!>V6F*0 TY2DT1M)F#"I*/U!Q!BQ2.(/&
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MDZQ(RBQ_G/'I;>Q!:UU0(>",^PU!/0TZSV-B4=26$>!L&XXRK5_/8C#*Z4+
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M/Q^-B&FO.Q5 6(?,<VFL \(Z&MX_')Y,\S0IISD-8A;AJ(2@A\PF:M"_%_2
M  :9Y=0 VWQ='EQ!IFTUK@!YZU;R+P -02T;,G6N50*D2G!/UD H!N12A%8,
M0(HA(K,#H2&0JT1:0UI, T&@$7*13*.1?\X( H2ZP <9A(""AK8+?"PW(3JZ
MP*=1#BUGY(5U7>#36 >;!O("O2[PJ0AZ0 #3!3[( &NUP,<45[K !QE7@+QU
M^P4^09W)'5W@TRH!+5D#H1BZP*<5 VQF!T)#=(%/10V1%8VZP <9C2T7^$2!
M4!?X((,04-#0=H&/Y3%\5Q?X-,JAY8R\L*X+?!KK8-- 7J#7!3X500\(8+K
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MNQ(8 4QZ@7?KUSF*\05Z7!2!J[KP'!52@@$RN;9?HO  ,VH*NGOEX .9C%/
M]2N'%TT=RE1O\31G!UL^FBR3X^@#R]YCG@P$F6)++ALI)MGF.KG!(1O]!7UO
MG=QHT$271&<=F$I>!E9+P77W9:.P9'3.<B-$-I9*"@\M-R0 $U&0W73[YQZ8
M2ATRGZ7JF@/FJ%1PSY*C S*9):-KEAP.@(DVD ?3F"Z^HD26\)(<4R$!YI?D
M.IC&5"J N1] Z02XDPLL,1! YJ'V0P*R\3QR;V93!36 J2 5]K"I A/ W!%X
M%Z\$ " 367NP_+(Q17([=R4@ YA-4L&S*X$1P*07>+<.X7@"4S! )M?V3!2
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M1&!*2%0*S^CAAW8$$7GYF0#S!;P\O;84?/S*T,4K[X.6A&RGYL!A04A"OE%
M\JO!5 M,LI)_(*YHT-!Z"UH2DG3"FOAJ)+V%)$V>@2,T34V>B5M[39Y!D((F
MS^#)1)-GHD5@:?)L'^+ 5;QLB0-7A^X4!UJ:/-,0VA%"FCS38&(&)DV>:6AQ
M@I8FSS22V"!)DV=,<B2771>(P-+DF;BUU^09!"EH\@R>3#1Y)EH$MB;/E(\#
MW:YADO_JQ($;T-HI#K0U>:8AM".$-'FFP<0,3)H\T]#B!"U-GFDDL4$2./*L
M$LH?*,])CO%,3OVCHZN^HI( 1YF)D,1*VFEWC:!K66S23G"<F/#%99C3@Z.Z
M!"\NPW[*@2TA9U6M]?$#SJ.DF"6V%WA&DHB]-Z".Y!M\Y#NZ3SR]^7Q^BQOY
MD/2F3ML4.,;4D9##TY $"$EV5M*1E?O3D(0$29:.VY&52VR5CM8XY.ZM9:4A
M-0X!X)"A/920L]0XA(%#IGX9'.-9.U2<)/GC>C6FI6*,1B5W+PV._=6HE!65
M#&TE.-I<HU).5#+UX.#J#35166/3X RX&I8RNG!9*S4U8+ER$;3&IH38=&4M
MV6B3"0^6[#RY*VO91IM,];$I:_U&FTQHL&29_+BREG.TR50?F[*6>(@]Q%&)
MX\_)/?VT6--$*N0\$A=Z-!IAH)&A;92XP*/1" &-3#VUK(4=00==-2*Y>VM9
MBSH:D: 0R=!&REK/J8-(S0!)Z[L]66LY=7"I*2#)P0FNHO/F6=!!"^=LS:[!
M)D3RP%4DA*\M.]R"H]7%KBU3FR O+0SN<%X-P2OJI9A:4GFI88U(2(AD9R/E
MI8<U(L$@DJG7EI4BAG)>;W]AR-15R\H+:Q@"@"$[:R@K&:QA*!J&+)VR+ROW
M>PSR0-[^@I*EB_;!<;X:E+*"DIVE!$>6:U!*"4JF[AM<E:$F*#_GZ$><_4@U
M'$7#D:GCEK4PH^$("([LK*.L51F@)^[V&I7LC*2LE1G(!^XT-)E 4]82C3:8
M\%#)SHW+6K'1!E-Y:,I:Q=$&$Q@J6;)"@:Q%'6TPE8>FQ*4=0*>6]Q>,+-.=
M0.*2C@8C##"RLXRREG(T&&& D:F;EK60 ^_P_/X"DJFKEK64HP$)"I#L+*2L
M51RHS1SV%Y9,';>L%1S0O1PT-IE@4\(ZSM.(7Y.BS,BRHW$-EI*S&Z-=L@PV
M,I&U@/'N8RAPUCZ4E:9G$-,"DH+$C#2+?=V ) &.CGVS94J=!D_O6%RR@'GY
MF6C4"\O[]-IRG>)7ABY>>9\D).0B^7CJ]P22)TF*TBA!XQV[@\D*'EFYPU9/
MMNX[2#2?I^'2 "ZRLFT"#]_M.V0D9,)@L@WLJCBAA R06+:!X=K+RO0 8!N8
M22$T9.5\@+ -#"4!CO<1T*!UPU&OK>[;CGIMZ"Z..C3 T3ZJD0T*8T="H@HF
MUZ P1F3EHP!3#0JC159B"CC3H#!B).2F(!(-#+>:A(:$Y(](HH'IVLM*\@@G
M&IA*05:Z!P31P%(2)CC*9\NVAG9<]>KZ;G'5JT-W<M4F.,Y'-:I!:?1(2%3!
M)!N41HFLE!1@ND%IO,A*3P$G')3&S)Z35+L%]R[+X!X<^2,^N'?J*X7#4BDD
MY'QT< \&/;*R5OL9W(M"B:RLVKX']X+P8H'C_G1P#QXS@$G*HRS/LQ])>E,<
M/9ZA.[PBEU]Q<G-;%H,LO<=YF1!0G64E+JY)'$HFV\XF<Z=>(K8V=#=9 :8$
M(<GJV8G1Y?+OE'U9@+FV=R__40O+S^3 ;FB!HZZ*O#R\1.G-?+7IC]^2-+F;
MWK%S5) $"^"@36@!)J.:RTI1&8&CJ6!JJJ+2!\>,O21]]*">]'DY7G!DU;ZH
M,R^! N:5("S[IA4UR7]M%]ULP%P..!DY]67$DCNQ 7,G=0DN59)S&S W(H<L
MV)6I;<!$B0RR8+D?V ;'FC2I4[=30'I'B]0*(]_H4@]0/LZJUJBG)Y=7[5<H
ME#'@@(D=#53I@<K0HH)CMS10E0$J4]</CHBKN1U@MO+%O/,XOL"SC6D:KN#@
MRC0  $<S:K@J!U>&UA4PB:KAJ@1<608##F ^6?B.8XU0 /[? <RF:X3*BU"&
M-A1PC4$C5%:$,O7R@"LO;R+T]VP\34N4/SY%I^O' 1*^YP$T>B%$ !+6JC1Z
MY48O0]LK80%+HU=F]#*-'"2L:E4".$V)2-"XBFZ_)G?T21JHP(#*-$B0M:JE
M@2H#4!E:5%GK61JH\('*U/7+6LDZ)@!XO,0QOJNN*>_?922.U6 %!U:6[M^5
MM8ZEP2H+6-E95E?6DI8&JQQ@91D&N!)6MX1WM-/(A1 32%CUTLB5%[D,;:Z$
M%2^-7%F1RS1:D+#:M2*M',=)>37),8HU4,$!E6EP(&%A2P-5&J RM*@2%K8T
M4"4!*E/7+VMAJ]VVU!JK$+R_K+4MC55)L,K.KGJREK8T5J7 *LL8P).PL@7Q
M&FJ6OLZ3L( C\AIJIFLO80D"QC743*4@(9W.;PL^(+E(318#ORQM+Z]"\21D
M=<%=H+:?R)&09@5\J=I^8DA6!E3T43^-JK=0)2%7"3.G9L=S^+)R<L)R:H9K
M+R''!"6G9B@%65DED#DU0[E(R#CIG+IF_%'[*EB65\[XLK)G.J<6C1P)^3V=
M4P/#D*R,GLZI(:-*5K8/8/3*<O^ +R&#IJ/7FI?QU=9TEI?Q^1*R9SIZA8"<
M0%:.3T>O<# D*U>IHU?(J +'O<*\2GV.@J-6ZH)&'11L#-T-!8"9WC=D]5N.
ML\+DF9&80=?P6>U1"P"SGUM7^2Q+5W3B*$OCKQE*N=Y(SW;Q 1.(6Q=?[I7G
M3KLUM;)&US1J7N9>#67E:P$S1>^"8*M.L2:QMS9T-W$!)I"VBLOB:"= " <<
M%U,M_A\H)SJQEOY4\N@?7?%.(%QBT6H:-9=A A&"HS;>%,21NH( QP]LT0@N
MDE@I)K@,BPDAN#3Y!7ZCHGD':)*4:+Q93SC/XR1%^>.B@"#+NDN<F%I<5[D*
M3$V;S2I+G)A:K1QL9KK:$F>B%K^0G]=J ][T\<9JGP^.^V?'G",5DV;Y=BVV
M<6/H;I&*G'DP+Y&L ']CE7<#OISI:ZU5KA=Z7I+OMBPJ751KM_)!_5&)<S.@
M/3MN^09$3*4*+N\%*%7+D4NJ)I&(%NM6L=J>=&(%EY-+L =-ZNY+<@4)!*&
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M!!6%QW3?H >8<=A5>%])L(D5,9" J0BYQ<36% +F*.06$UNC!YB\V%5,52>
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M<TV"UC8)^FS%9VT5WS ;QS/A66[0,X/=I??][/3Z^'/GZKI_?7PUFWVU?&&
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M@\?MCDJ2X-'S>H:K@T<AP:/OA3ZR3-MV1K83N&9@X=@);-?WD!^C.)H'CQ:
MX''[5,4'C]OG>#X:T?Y^M+U:052FJ(+$XX?)["@AA5VUR5-TN&@[/9OU[7@\
MXD7;;7HF6PC9:E4TYDI\T_[:-H_)R)R;GMD4'H?1.0N(PV0)T#9<K0[0> 9H
MVYV!+T> YH<]R],!FI  ;>C8HU%@.5$0#9THCH*1;R,SBCTT#-W('\T#-!M
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M0LB)8V,8&2B,1K&/#'?D!OX\-O, Q&;;IRH^-ML^QZT'#(_O)N/L$6,(D9F
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M?9EIRU+,]LV>K_)M!Y!#3,<*[9%O.)9KNXX=V<.1;=J^Y82.:T:^8<Q#S!!
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M,1VXGC?PIYX<P(VN:D)OOX?(XM&'??=5;HBX+W.6:;*A*26U]\NYA3 C$&D
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MO-N>4YK,^BULP?X31'B#_K"-)/]4'KQ!?]I&/^C4D1]XSMG8+H?-94GQ!H_
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M;=O3!/-6^G*S (,U&O8<^#AC^E^/% #^,FKC<GHG+_.#_]T*3-PAD! ^?.0
M]PB3\78^@&M,8Y(!:'HU]<M6"*./VQP^K4B#S);+<X??KUKL">^%JN5]>/_I
M5E7R7O;0#(19ALG*8D=6H"[&&Q!R$3>D]]<$_G#*][NY_:M^O[[S*V@?&A:T
M/P?MCBW1NQT2_3WD)D=U]_?^;=]928CV1 01&7Q9;M%RBTK\6PB@_7 +F6 I
M>?JIO]W<?*S$_UM-[+9D/>J0K$T7QU+/X!\L=EFD"07"/<BB&YTR^CGX AR
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M.NF\X OP@*EJ49,T&V%D&6 V)/U:1?U/"BBW1 M)%\:6Y%M-8:W /%)'\<&
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M5\1-QAID!^+NL@%<+?)U7OP"!Y<G5((RKM2QX/ H%NN;3F$RZ/HIX+X_X@+
M+"?@ +IRRH:!B@MRY/ B+@X#P88X=9HI?MB8.6:W('JP3A$>X:&K=:YC:+7@
M8N,8OL3)?22#E>PAC#",-0@:D5EI6)OLB26'3F;*D\I0,9T=2C6=%1HTQI6>
MV4U/.E]U>1??A6D24YS41N(R'+F6F$ >L(9!&%"=SF3!*;^O!@G!W;H/04+.
MI#Z=KQDI''S@(+ )7=J:FXQX=1^L76!5OSJ.\GM [CQA&59EI$L>1N=+1RJ;
M.;#0F=8N[93SVFXC<("T1?1 S*>ZFBQISGTX?35V9RWAC>-5AMBW(]0XWW8:
MG:\'*,#.0F3AL<G+;Y/2,R!Q^D-1\ZM &+-R!_4O"!7M521H9$0$0:HP(P\%
MOK@7,4]EO(+OB=4V#I7C'!N _[8CZ#RE$PM4( 2;P%'Y.LP4]KI7+DY(99*N
M1$RHXLHP<YAFML94KHFCE^N0LA:#9O],)]!Y7J<J[(40&"QULI-<&=&@UDU"
M=40J0M%L)@[*4U^7<O<&T9RNK?2=/]8AF'F%'[E/TB\TG7FN)'W2>98G;7>D
M&E [8&,R!_RC_T6A,J5.&/'?&;()92%X5KHWOH@Q\"18%MPH] ?E@5847&>K
MJ$\[3_VD.3:(K!*'D-FT4!135FTU;L=P&=0VAG1\KQROS!DG!/6%E,U3N#+]
M)U>F_Q-[<%:8_H>M,/U_FZ5I4^J6(J!:R,DPM<-1IJZ\FM^_@=")ND(*:8B&
M"VY^G!4;7=GRDRQ7/N,\YG[6]4-@G!I$^WZ-LA7R GC$(-LGU*5 R& $A .
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MSCKD-0K&1#"7DJM447Y%&AM:*5UV5IVUC&B%]+Y].8()_J9H>-SYQLA] QU
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MZTE_P-,W!@F:51KUKA]"P"$TLQ?+= 5JS9T@0[%3N=&LNZ3B2J7U=_!T?\E
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M*#3[0'PHU!SBE5((F4,A1N$2='OG1[+&MJ9Z=9J4&O<4[FUXL!;L>9UGGM#
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M=XR.A-%H)_@/Y7]P<D?.K&<SW!N/NRYU'W'%/B<K44DP'YBZ2^L54<*(_\;
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MMB7W:=?ESCDME?NHN$ON,LQSJ0I\BZ0<W,5U= F/N$B_X+H'@H+#.SRC$(D
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M"$K(KUSK[^?OWK[SG3]JD4A-Q .*#[)VJ'%K/P^C#[8HSGO1/?$[^+%V81W
MJ\Y,1?J@:-*9J<S2=E(#CJBJ_4& %($^<89/Z;9<[DX'J?N,W: TTDB+;FI*
MGNM%<N2V8!ZI2&Y(Z;BD[CYJ2 M MEO;9O$"&YK:[!5WSP3VMRUVGP#7^Z!5
ME%5Y/LDD_W(4.'>WEV<'\G3SCM1_)2%7F7V<!#WDV;8N+>0C^/BJMPL,M\P
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M^/(\*^XA&.=!(._BZV5GJJRNX%A0O.[MKT91F;KM#;:*BOF._4A4P,'=^U"
MU\:DDT8@<H2.^EU/]AP.T#J*'HZB*.C$@+^F*2WY)I():AD_>>X>3(D868(A
MYS!OZM8((1<ZL H^-^]JXI6/9X%J$FM53)U.VIE1 D*3)N*#R=8XF]S5?L0A
MHK-E''14"+9-V[U 6XW=S"[G$@NF6U6=K?H"=2^-\(^J$86>TNPJG@1NR:&H
MBNU$'P4G-)TN',8DC]AZP#)*%1GF%O;K))4=-9[0U,T>2EQ@NQ_"Q*8?D65'
M[7DPXY'.,4&>%'!@CPM P O@CE9-C8\T=>OO;U\MTQQW?OY)BK"^KH>QVUY%
M=N?T4,V\:+OX&1E#D[14=%7!*;RI*L1Q_6RX]U!EWZ/ZQ-5+K73R[KB#\T>W
M^?=TWIE/@P64;57,YWU#(BC$@B(^NO,E<NIHBY85*1IL#:8G\[4U$M^Y%8J&
M[S6I<8\[-']TFWODC&,C0!MAD.MZT TSH40TVFK4E:?L>.D$:F_WG4)P&KAA
MQ14$+_'Q3N%[H53T &XUQLI3VETEWX[ LWTE&%CQQVBS68'@,9QD:-M^P_D%
MNP^_-F$> O=\['*<P^&BN!I19>HV'V[K?VX_Q\S1^'<X8JN8&<6A-;0,?YFZ
MX3N4]NU<:''X@KS(OOO(RW%C#%-TT!H,%_;,,GIF&?T78!F].K.,'M^S_)G8
M)!_"KI\\>$R^=/ICD$RR;1SE;0I2J=J#/S"$D?BU<7T\"Z'[F5^+EJEAO<1O
M]/9:9*6I&]^960@EX-X+8:2F%LCE<8NB1T\.WQ6E\=)TCPM0SWVAU%/ P!8M
M*+*;$6H!P[]^WA4"R=VN=ZV=VP+AY&M3E-V:P"9J++%I6YXI#J(F+=8U,:XS
M"R?+N^%\$P']IJ(9#MC6Q:+>4G"W<5H(-!/.K46OF\>1((&J8%$5]_M)T>,Z
M*;V+HB%@KF<T7"D3N B^&=23:VPNXJ1,8PZ>D0.[W"WOF:S4[_=/V.<"R73^
MA*?;<76HS\B:1(SJQ[=:PP?.%F;5&%HF]/EGIE)?_V_;&K8G>FD"\Y&WP#F)
M,/GE;-IZQ3%K2D('D@H1+Q68+8=4$E)Y2R >24/#>A!JMF6$R9FOU,4A 7;)
MP"?TT^B6>?O3"J"G*;*51;=$1 (8I%QDOR&70%F"A1GQC644U#R-2F-MSW"4
M#?SNG6(!\3E0E7+9-I8Z1F;O:MX0Q)A@(20#A=BURU>OB8\4E@GC:SPG<!*J
M?F,:!!]3DQ=B;'A#'^@$_HQYC9%EY8! 9]K2H#JTJ9V+D2CDAY'ZM"!O7#.G
MP.:P^7N/^*<226,)4@49T9:"R@&G,E\5\*"I--6>TJ<L;;"%UC-=$+'$T(#4
M$@):1)[)[>N^PP$CVK3&*F.VP2$YFAA^)&2,_CS\O)_(JG72>JV2>N(@NA[I
M#9#+7S=U9>?9 -?MQAOX=J4VAJ&KH*AZ+ ?T2";+ RGHO#BM.M(BG(JE20]4
M0A-Z3,-.8%=?1\FS6=^1BPCC4GGV9C;[OQ8\R'>ES?['$F_D?]?KJJTK)I/[
MCV*S?>V^E6<_+>'O:F@U?BG>FT5QD;TUS?S](P']GUN0DS(DJ6@:U?.U]/!_
M@2CG+^^*"EP,;7,$$48P-I*S=1DJP?%].Z\Q<Q9M_7MO^==3?//+_UR^@2"G
M-/.^-.W%U!CI<0UT^_+NXNNO_[R14'!/C0XV]1WCNE64EO!YIC A)T%TI(<I
MFG)'<Z6$8VP-["/X;UD_F(89']M\<ER2XF:'*L-\'J>CM.Q^JAEOO=B8,V\P
M;9Q+$$ZL*P1;/3-<]< QCA=>LR)T(+'9"'\S-M<XPG!5D+@&J#A"<'72X6GU
MW1YR$C<;$Y+$NHKZN[R_8U^)L1IU";B+(]H*&$= *H[=TB6.&M#BJ1'EIFY[
MUT'WQ;SAMHZ![1P?>Q@[ROW.)='C^0.J@L-2H;C7I/ U=L>-W@#'U4E!5"JA
M6@/16/7";6+R(UK&^3KM>?2_,5&/)^<)##RRT9QZ!-Z#H[8+'/V-('6F-J*:
MC:]/.C.MD[#].-3\(8(=T^ X%UU4"S,NK;$?GEB7BTS6+/#J1HNF1J*;>O\U
MEG6;#3".]S46SJCL4#2V]4.)0^F*E:D# U6D']1ZNG^Z)!^*AG+N7]^C%I2:
MS[U.?F :=_@/30&9K'#E,%9UY&ZV:P-?F*J@P;D'BJ];WX0).URJJ9"WS2 !
MHTH<K%2/#_FWT&.N?0ZVQZ2%Z\O2%,SFN-G!??P:PUEG==_MK<K>)2!2&+92
MD[BXOCUS7CX)4=7:-HL7F,[N(G8R+OOUE=,$Y&R 2R)@#PQ##Q$!27VQ+2#G
M^GN/W!%=5"/4V1MWSX'XDKKWP58X'4QS893;#LV_@)_@!#%=++A6@=-;5@.<
MXM][.W^/41@NWY(  6H0YNM3*9&H6CRZXUF-(]9W<5"U3Y%&DR39,ETIE=4A
M;5,S^K-0]ZB7LFV]K3Z%T/"#4..75Q1]ZUGIR2]CKNYKT9^]O%:VQ_GBG/Y0
MM9,O&5^ U$_P/!I$'U.4$(\&ND]XEPX<-PD.]<U\7;0'$8[:#(^7)]L>VN2J
M YHQ_$78;&L,Q*4YW)QFLRWK'3./569%PQ-1NE"9![I"_X+<&@9'N#ER885+
MPHJWK=Z$_,W5\S#[?5'V _[133%O:I\6>,3XI]VD495(C4'X>=A[$LZI9:.;
MKT]J(YVRF;&T#\%Y1GLN)P&J!EOMV$7_5)G;29%,Q6#ZYO:TEM=5OO6U $7N
MW-MGL#/?\)@,YAI<91&3B8 (7U74HIP9?T5A^D:[,DPLN%VZ%(HC)@7'7?M=
MCV(\6$%3X\X]K>$U-N:O%^\NXDJBV%EF47F@6NI=;%+WX.3RN!%6;&E&,KJ1
M,+G@\[56X.OT5P#IMG#$ R.K61?9U4&W&5W#_%P&A0A0(;,3!QX>KUT\A]-C
M$3%=G?6\CJUA28-J;H:*<'^2O.ME^FL0MS \7 ^KXYO:EGLZV='.'K6@:(&:
M@H;_N&0B:0K=KD6SR]HUY#N*S&E7E\<U_M$;IM]$4IC,_5\C%ZQO<S  C;G_
M_R+$_S%8V]--?3!B4>/>3=WD(72;"$OR6$OT2,+GMS>OGD'$\DV0YR%=*Z?#
M0^H[K)M O5#1B>3=_8@O<<MRD;T9RJ4+AE*--O>TQM=JR,F]R.["L8@ZVD09
M-ULA#,B@0G6D5$8,)BX'7V##&LUKD?R[KD9=:UJTB^P=5F35N'/3M[_C;)TF
M9-W#M41A(ZG D3Z<+(%#?-IJT;<T$1B"4?U*Q^VK](T_642M%CFSB[+;R#^I
M+_/HA:#*&_U5^N8_[M5X=^R&Q/$9 :,F(>G=$@X67+3Y@]T&,XPP['6 SQ)O
M@3ORR$:^? ZUO!]C!A'(^="M=LCK0/7F47)"$%DB8R667%<-&<0:-(V'3V*8
MW?*,:J&6J]]=I5_&&VQA'DN?F>[!&$[5J9BRJ$NDT7'I(-J9RRBC_1^]L'5H
M\;FHYTK$MS.(AM.R_W7Z]F<!+'$P9HSO=-)/,51Q46=M/2REP)ZOB!4"!]_I
MAI/*%BY55B /<=MI3O[>G;AUH%4GY,Z[[&^.+P;CUXYUC5$=!QJT==^1M!'\
MF%W09/O+]R#5:';37X(0LV&#W*D.4:"=.^(,>"/26L'!!G'FPN<O&G,[BJ97
M=;V@%@W\6?>DSHR0V]$2<S*E1[J;_@HLS$<XC;V3\K!_4MP!(:0/+P8Z+[<:
MBGR]SZ$U])MQM )KLU@QBB2**N'MI$ NV3]67"B6 9O'CT(R7[4%X\_H[GY8
MFPJ%7/!9@WF_'E]O^C5Q6R%%"?>+"P^\R02?,S!F3Z#_(EB:T0[@A:HH!OH;
M\:'@OZ-R.QR"85PT[LZ=^4SK,Y_I*?A,K\]\IL=W,DC_@F],WAV9"*5EZ2<Y
MRYU3C:L?<^72)HH<RR.5AS.?J1._1,MKE CK8U=LCBL0=?2:V&^4'-$$8B&R
MQ%6_F3$2:WJDA)-9SR/3N$8H;&N>-H*D"G&P\'Z(VX)?!\LTUV.K2IP&U1F2
MK?;@.T*V(@6NUKH8GB=%<02.!_D;8L3K(HTT7!XFL-"DF;U*GW8SQ.7U _D
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MH_&.(&6Y>Y) 'C4\@FT2-9KJM"T^J7NN1B6=_JBT$#*NX>WAGA_P,@XCXGR
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M:P(NS@W2LM+"B.ZEPP8/WZ.@N^#JY?7+B^R=085N-<LGG[PBZOQ%8]OW3J(
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MH<\&@<U#T42YTJ;XO6["_OVD(B8NU7U?5@YG7.M-[*?/[,Q_JJE@%Q,?'_<
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MV]X1[]!(.G:?EPAUS1:,+\+JQP)6ZO]G[]U[W#B.[N&O0N0'/)  :JV]2HJ
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MVH+_\__.;UZ^G<P3ED,5QEK!G,6)*O_:CG]M_/S6G]DIE6H6ADG4P'%#EA.
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MF&OGY=M??OKP\P_\]?G;YS#ZLDJ$[-KO8FZLZSZO5V75\#;/HD- O@B+E[%
MG"B])?294Y8^]S>V?S!//"9V+O_5V%="G'8%PJU,'LA^^VSR;5O!<&M&M&6?
M[Y-8V9!7L)A\^_4[*:C<TK/X4C&4 ;@^JC29R=PYW9EYMLR0H6M,'GGNSAFU
M1>H$7?*WI)FO7OR:_(9:X3ORZJG (9):$LVB3D*$SV%G*8-AQA?NF[%;G@V<
MMI7G6<5&C=@U*W>;H7Q:E7,6TT.TK^D2L/YA8=0OM1OD!@O<#!(2S=RNU/:<
M%9'.47-9$T?3.9A>!L38'47,LF73PWY%;9J0J1LA1SV_&D:@/N+4<0L[ALZQ
M&U^<<)*?37XH,+!2N'UW/8%L<,YGX45PVMZ2R;KDHX+Z0M]G%?OGP8S\<NQF
ME_VL^2H/KC!B=LKQ2Q%Z]D.("I.MW](7W?T)@J6M8UK,.0\')#QYM']KF)%@
M/@G;8U>*M3O"!48,[?F9R"&%(R'-YU[\HN>!%_1;F08.\V-(?<WX-<=N?C*I
M=(Y5!YC%FP\Z]H.U!/;DT9I$&3*>P'VCJ43SEK?LZ'-:#A71:D_#*!QWD35Z
M40?M_9)&+CY'BB(83K!XO-$Q"6^UBPMF&'QA,BI:I,R,(.-F]&FMM#.9^Z_3
M5F.<[&^ ,3<K->S&I5D"@I%(*A1V!5LC#,J['=?&K['+1P'S07S]^)-8[^MK
MX5/83?Y)L7V=>@:7+7-:A#)R=!FLHKFOBC=S44Z6;8(RA(N8'M3_(.HQHR8=
MN]5[5,/=7);F4U.ANDB6%=DQZ,<G=4T9%0O&T!U Z\*.1R[:.)*L5Y[XCBM"
M</:6]-6C3V A"@=?$JPC32;4@46C9V#085/UQ"=:GOA$C\$G>GGB$WT,W,!/
M8/U($7-O.WZ<@ B041U7</?4[:N@"\<"-_%*E(835-=]Z09,"WTX]/3$).KK
MBJ'CTQ'MWPO:B)%Q':!.2&#%[B[]"E-N-:T3(L*ONZ*E;5'WJ(,4QDU47[D-
MRL-:4?%]N'<:%X9TD_M0C$-D\:225480["6@P-13@>'^;&E'S37Z"8I^D%VY
M?T;*9=R$JP>5E5Z?^UU.X2.0REN0A_AHCTDRR @E*YVWA<YX5:[>E(4E?/]\
M].,3BO::_5.R\FZWS^)Q-L1!(#66F% 7B1Y-"Z#21I ]2NXOM$AV9-B\.Q_]
M\ 09.>XL*[!9;E:Z>REZ;EIT(V@?U[P6FRIC)%+30>X8IX3&Q\ZAP4$[GV?#
MP45$GIZV//W-Z'EF1*1CM[TH;RF3J,Z'D^/A ]#Q'"L]2T"<)Y7JK -3J<,4
M<BV@'%EP+:;@C<^\75D>'0LS(M*QFS[V#Y(_B<.O'.5<?E91.-/ K1LE\K0J
M3N&FV1"]IPBSOM*&L>FOGY#IA>&5-<PIG#E_[:N+R:)1I$  X['[P"T:FJ-B
M5HGOIXI YZ!^SI2E.#VT1DF>>Z;9Q&X1;L:^", 7<7](:5:8=X[?:(G.JK "
M\I7,MHYW='7HCM6%0YJ%R$>J[Y@EK<XF?\\^NFT&DFHK\X]>*6.[<D5(38N0
MAT;3N"@ JV/9:>$W:Z2PJZT][AQYC<=%YK>XRCQJ_D8O\Z\6I7E#+M[1I[=J
MQ5 _G_C;5>U-,27/'79FE, >X%3ZA8S? LB'N+^)A,)EM6*;"[3 RO+C3VY1
M1E>=]6799$F0;Y!Q+H2(JS('3DQ3KK &W$5"M#D8"*/7O65O))A))EW'DXUL
M?C'Z]#8KF!.-MZ-,XW;\ '&T[Z?T/-^-\#0H.=I]Y1\E6Q?20'%2= 0*LQ3W
M8O0I[I:V;2^,AV6U3B91NEBY%QHMRKMY&CZC)L=M*ZL5&'V:V]'42Q52'FQ'
MX')Q5%4,*PIO\@P>WU*#B]MU0';:C+'E8NA+M#L_JUX\24N-SZV,/WI=C*Y5
M?YOD6<I$.!1*%ZRWJM0X9Q-EV.%!W+(2#JA$&..X^L4-RKI1<9F[7L<'FW:Z
M)!>CU\6(VTI*<7C0]R*<BWWTL'1 @0FN00G=0794=<PD!=X*&U_  ALW!_C(
M;!%&3Q/ W8Z4A5]XQ&NJ\Z>2)'FEDKGV[;@.#%WKEH<X)(:AI*AE91.7D87G
MS/C2N7[Y<5;PV4@L<Z*+T?,%8&?G>;F%D=::W\RS:MZN$5W+2%[D>Q@YZJ%A
MTP$1^'R5%$M1/B*+JOZ:]8CPQ>A9 EC[G+YJ>N,$,F*]J)*UVY9THRZ1ZQ?"
M%'WH2KV/VZB[CKL!8ROS'U7UT6A".T]UT\>W*NW]5GDP!HPD_F8(%79A#;PO
M"J<7T[,A X"L.F!)R3AZ*4BO*<)L9X%W!'= AL9J$ZEDQ+-A9Y/OZ:(M(] C
MES%9+,.G6I%>&)*NM+0,.B]'KP/I&4+OW<#JM&MR1Q.DL4G$IA9F!@8#E7O"
M;I/H:K<R_^AE()EOL<V1"CF@/!+AYA ^1YD>< M6CM& 75?$U\#<;Y2-Z?K$
MXGA>^RZK.S$'PVK,Y>CU'X-2;%>+85O*M&\HQGQI[47KE!JBIF;=C\O19[LA
M A=6DSC,5 )ZZ6/LQ)!*<-!W)WZ&P].>!H*J?9#P?V[IHTYRV!1UWE.4XO[5
M,B!O&KL18&H0XFR56T8IV=([]_TGN&'-.*;'CFF_US-XYPUE&&UQ1YM9AF1@
MXT.[^E<7.73%AUA9??13'%T%K:\&SL[DSW9TT2^/8Z?/,T+OO;!ISU^^/GMU
MSZ?ZTU^8MN3F;>^IN+/R9/?GK&#SS/)R_M%/+-R<O;D,-CB_.GM]+;!UM:_\
ML_\^+EZ=O;Q^V?UW'PC_3W\!EA*N/^KS^32J**%L':5@'>=F1-ZA8)U S)G5
M=>O2MY/!^_QB[NHC*2;]P;;#77VQZ/H9.MH.A2ZT(\J%(<-<[)OS7;\T:+TW
M+HZIIB4&-G"KH?^SN*L@+O;OP/WWAL9OS3SQL2"(?["CYT_:YPV"Z!R?U-#V
M"'WCM$A[5;V\R&9C'!4@:77N[DF1WAIV[H[&+?T'.T5<0D,[:L!R+VE )>V5
M>RK.OZ,687R:CMK8LCI->T5-I<"&/Q(=U$FD\A.))Y$3>\@"P]51![AM"@R_
M*B<!&)7@H&@/9@(M*R?EG,*PJ91R8I!9)UKGQ=FDMC/42>556E;EMEG9T6F?
M'RF%,[1YK_?:!_0]\Q!L+FNN-WFY<ZY^KN;GQE8U29J&?M7X5I<3=I0ZP)#C
M-HP9H_,QS6[8+E%VVN*^0,ASU IL&")M$&FG%+:!3&?1B.9@VY$<MG6 MW8E
M'CL*LNO12[>S]V4]4D 3>'98&N78S7U66^XU.:!&ZD@4"_ZI?U(@/EXQ(V7I
M$5+[]/1FW,YC7X#A%?KL0$@"'$B=+0L_T):Z7$ @)5^Q1;*&)Y+&K*5 PE'%
MW&T\^C>\ 87 D&>.I0F2\&[=32A0P6Z'&FFQP.Z7M&"=U9'03WJ/N@)%/($=
MP:P3=3UZZ784W M6I.&>-;W%%QAZ;=<\4^;[V!YU1D9L"WH>9L51ECR;O"MV
M$X0[RS ;I>T^P,Z6297FK@[3XV9DS6.WNMK3@_9RE[!;C]75YF4-WY)H6(BV
ME2.[)A+RQ.J\Q2)O71%\-R^4#+YZV(@94?/8[>X?+Z)695UGLUS:47X)!'50
M9Y5PI@9QI0HT1G/)?7[B&<L(,,4-%Q!L/X0^WO6;L5L]TL);T?MN:T]NX#L;
M,Y?X ;):@O#(I;!=75+3YS.[,&^,!VH>W:3_\__.;UZ^/52<^<+M\ D)XK,+
MB^2-Q9H729;+\/X:#+B!6:Z<Y;KT@00P#,W5VLL( C'82-JWO^/>-^,P?M"B
MZH,K/VO0JD0Y<1;@Z]H84.;^>Y7Q;4+W>-5N9!T4*A&J$H+ZI]^LLDW=+9VL
M!'G$J:'ZW\W#LEP\N.7UBB\[56T); %06X,;)Y&*6VQ@.T=W5*B4G6)EI!*_
M::NZ]?#  +H?$IJ!Y/G%+ &<)R+DYCTO\B(J[%6:0O)O1C\'Q.J2KF!";*'*
MFKL S.?CS2E:YY#1D=&>9RF>@/YP5K9PWLJ=(Z4=+GRJK^[Z9#,[#SWZ\1_8
M^/T_?OPIS#&@,JSS:M_3WT7])V,IG/0KG;C_3FT\>=^2V^9*FL=^>XZ*.^1;
MY^4+,]KAL1L>$, *=YGWT *+P$Y7'CD$$Q*.AEG]SURI \MD5GZX&?T$D,*6
M,(*"ZLW,+9)_9^O2\TNH@P>+UHGV]D1[^U] >WMUHKU]G$E\M"M\9H<#6"48
MD?)(>(8-<_U&XL*@DZ49B+0TA+X?L4H:I+=U(ER5YE2<XD1[ZW,5;^BL"($$
M-[7WF.&%<X;N.]8$378^"%\X'H#R96 1[^O/X_=U<T^TMV+[,'[ 4D"W62DI
M-B+D-C2FH^*(68YX?M0)2BL,!I>"I+P!)@B4<O'OS&D#B7[@W0F"Y#+/DYF^
M9IS.:'C78P@J1?!=*^QFM+5CC]TH2&;ZSDF8G)^7Z[6KT'+(_AU&NCW+3QFH
ME 8R66>3GUCEH%L$+"5J([1614NOB&S2C*]V[&:/7,!4]2'JN!(R)==+CT -
M;SI1QSS=7YHIK08S2TPG]&%=W= ?FTZJ<I?DS0XO/ OIOAUMX>@G)S/,IB9J
M6B\_7KMY*R95%,7:)]Z"3HPKVB7W/Q@=P'3F_VHS.A$M>YFU<TVOIF5&5CMV
ML\.5XS/7,AT)X3=L9@X-_;[F:8:D+H4PVRUH)?KT S!Z? Q<-/&G(_C3'B;&
MC+!V[.;GHF"B0R*^A,<$*,)LK<')#-1+:OAIOR% /@:\5R!JIAC2!2IG+@IZ
M+"0$$V@)YRL%<IAQU8[=_CYPB:Y(]B!LTPXNU\]I]I^D/!$S')0UY5%":I9G
MZTP&7/IU=C.JVK%;_V[_$9@[N,X78T:5GQ;!>]-+9;O5L(O?GP"&&C BOWVS
M0 74V4T<?R:9(_> \QU#(+T']_U-;2K'=0)N:*3]$H!92',Q>CUGSQL6#P)Z
MN7%@&5D?DH(1KW3#IT"0[!  [3N-_OF(23X'X;\9,^KHS1_RH*GW, %7%$;.
M^@GIMALD8!D$U+?*=5"6C/3/O>8PK:6"^>PX:4<OZBQ<5-/.BY/#*!K:[+FV
MXW5&)FBQ:+3.5IQ3J"D;/ [8AU=$<&9F)*MC-[HO*FK(^!G%@7=%*!DBREF6
M\/N_9Y;&C&-U]+;W URW7#S/)&?UF)-ICV>LD.&:VK-'2@72=T'55R'W!5^'
M(8OPS?AGD[Y62DYAI\WK<I)42%5GKME"&DCS_WY^)&#INTD.O18%BI$AF#3C
M[AS[;$:(JJ,NA1GER<6Q8,]_Y!'AP3B]P#X/IK6#,>".3_2%YVMBZI/:FOKD
M\EBZ"'^P;>&UI0.GXF^-SB@+>*0WK[GS]Q+X!'G$38:%IH-)H3[JU7AC'%6M
MP6IB7!J0]^M>](&!GK=.Q66B&^L.\* 9%<K1J##_8$<QD.?IL)+WQ1'44+EP
M%.@\%%L1-QXU7V_=X8:'S;8X:KO)ZB#VL/9V1^;Z2-G,'_#(A'YLKQ/(2 /(
MX49.LJT'8&N7QG=;5H3)"S\Q8'QBCLKW:75B/JLB\UG5!TESMSRO >+5K#$D
MA#@NT:>5L4%&7B_0Y@!<X^!6MW-:;T[DDX^5B06Y43HKG: N"^SN],+O.:>W
M?%2,N9=>GC+OQUKO;@8B7G N5<FPZ<>BW+Y8E5OY;C A@5?X9YF!>11<+YF,
M3.MU]I#L7,?B'WT8=B[E0-/+J*L.XFA%94-/CF9'PW54)?$'H81R7S0U7/9J
M"@>F9L=.XFE7>N6-^A%,%*J9A'EN]YMV,_TP&OKQ=:8SW?4!O"?49-MZ[C9-
MIJP :SB83>X&93W#73]Z)?&?L<VUZ066A;R-;VF/YA\8$-#\KGK*)1ON5%2"
MIT-CK4BJJMQ*X+M%YR+/W*TS[!Y?C5X_?";-]U"P[@L+X%>4JKE;("<^Q\6P
MC!+N3EJ# V:?F6+/KT8O']ZU*@-&(LZMNW9!6(2H1>0R><)";X3/;29;67_T
M8T(Q5<'!MO$=7>-AT[@3L,H60<E0)H8>E,SC:O3#0CW\;#PY%(<V7A@<OF6]
M2;)JB-8*N-Y>P,DU^JJ"@J&28IIM_>O1:XDG<X0H0ESDJK4PG6C\TA:>T(@"
M'#2@%JU03=R%'^4HE=T+:"H>%"AW/7H)\;@J]_O\]B?=U5TH%SOJU[$;_V'0
M/M</VZ!Y<&J?7UV7NM )7G 0QPUGQ=;WFLY^<O;3'=4HT90T*F/&+$JU[)@K
M'W8FZ,%-SREDQ!(7!&] (9?O IOE)+!91LCEZ&),79[P@"WG^.JJ=?7,V%G'
M;>KXSO)S(GLH33-JS_'/,JA(O=K,QP(JO ,XH'!/^9LIBL=\I'#W7,D#R+A>
MCU[YS(-\>K0"G2[/8<=Z-OF.H2H=!YOGD/ +YJ?:/.F=C[E1\?*!GAG'Y]C7
MP M&][8N BSZ9A(FQ?'#N#OKIS3!OLK78WEWLS:\LA5YTN@G=[P^=!1S[.U^
MWO,OA )!3H(=M^!1!0W,>"-0)<V*EH_SG/)>M&":*8;J?7Z=TE/9/2>-:LS3
M<S$V64"QN&[:-+CFK00<&<I/G:@Q9=BLO6;&B#EVO+9B7))9>0M6S!K,^3,9
M8D7K492(=19M0/((5^ 9!N^\)\\FOWJ:MI7+-X83.#>CUS$XG'YPF)P'!>@\
MV5*B'.H;98&!-,',=/-I7IM)H3$[2"+0W3IO\Z3RC+X1P,F,8W/L*Z!PR07%
M?<6R?F[GD(^J1F#FD/<D?A]'V?;F6&7Y/Q[8I)(@NB@%9;0?M?RN$HD,V_-4
M8'^XT!9J<G/4IH$AU$293M:.HL<4I!#1Q1D50JL8\BC#%PD3"<5RZOV%$$(*
M$2<RLOJKHW8,K*P.&D(1DHAJA-)_I^\[KC>)B[*0M'KUIE;APHG$D<#^SK#3
M8>@T62=+7:(32>J))/6_@"3U^D22^CA^A8$]8%V**,$YZ8P+)Y$;UY2*/D.[
M@ 9XY?PS#Y9=NLOB*1"D6AE=+\XPD CT&WW1UA["D)H!WM^<YMH>/20-:GXA
MWO11J02K=T6A7/\);2ALC%E29[6 \8QCT>-2MMIYKWX<E&>^%Z+!4A?^O#T0
MWGP!!^AI]NW19M\BY4L]86$T>.K55W"$]@_4=E5*_;5W[IXA@G:_)0 96Y^J
MH[+K6)VJH?]Z/A72D%^*C$RWGGS-*_+B'[0B$Z4J>?%CAQW^0#']?#=YQCOJ
MY=M?OO[Q W]Y_O8YJ^!E]/$3\H7\,#MFV*.2ZUB9'CEST4_O$M4,-..R''_/
MY;NB3R!_N-C383L"Q$X8STJSBM_YL71$_V#W0$W&CJ U4UK,C_QO#9D<?%$N
M%E+!6[#09NYD>LPCIC0/P0]#RT>0$(RD<&D/HFJS-XZJ=6IV%ZQ<2$H.GS.S
M5.7B1(?S.$$5%_XB$K P?[DJ\U3&&CZ%,IS28[>.@?<RBA5>3.&,MF?IXDD0
MXK2%F)ZA/\@)BYQM%?U4QD[:8I'<TFLQ#?F\+,IU-H^PQNSCD-'8(0PO3OPW
MCW+V*G>+&3FO$;TLAJJ3_G;ZJ@?:*ZNIK[S-$V7X"$%Z+,HWM3YX3X0 !]EC
M'P.&C.:VS-(8^_0?8*MEC@!.SXPD]"E8'-.ZHD[+"NGL[@"F?M$'4T,LN*BS
M6S>-L-68-%+!>B'8Q:,5YV=($SI^F/#?LPZ\COX@D,$="W<2Z5!L:'_Z+M^S
M2(6K<E@;_<US7H.9PV\BZC4SBM"Q@R6SXI]MP<FXX39\6#Z:!T?V?Q @$@^R
M^="/0IG4_:ME%0GFT6^<'N=#],$>Q(YY (ELL)7]"R3KLI4<'][#K%AT^7+<
M9H]8Q9FPO<'!!YIBULHH/FJDLPYD+K^$I;D-@2I>K>TY+ Z72+P05$3^'LD=
MF.WXRZ/RK=@XWO^E#2S16']_=OSN?A*@IZK5*"P5JQ=9&3$A?4(((=(_>_QA
M9@R7Q[2['>BQ#IN6KRD,<7;J[ (?HJ@"DE@*!T8]:$6Q T:Z%N2H]IZ$GD)O
MJC8]FWQKEUI=7H[=\-HKF2HX(!8'[ZU&)[ZLN-Z:/7YP] N,V&(%=('H52Y>
M7KX,;?#A2ULMP-78%^"@C3W\#G;%[$S/J->:F&Q J9<P0![W0$96[2;+]R$;
M9Y-?S3CA+Z_';G9D)Q(#\R7+M-'"0(2K,XY\-#?_I<A0)OVI$;]2I$Q+D=PF
M68Z;6+3A^ :>X]JHI$<)Y( .A9F1<([=]$$3L9M(8K6X/2N+4_H:E^:'*IN[
MR7L?8Z+[3XY%(]2?:9TF/T*D4A5;W\WYVCY_\_K*CHYS]&:'@!90H_'V[C8^
MNYH-#L0"(?S.)55-U^RN5 <N;T<\40Q'U5?SU9*L%LDXT<$Q5,^^/&K+Q22P
M9[DE;K6D6M.;/..<:!>XZ<C"W6_K27A*VE:AW46?A&X(LGY8N^=GD[_YDCU'
MKE(UG.5VUG\S>NNW=*-6F53V^F+EWW[]+L0IO_STX><?#OI\*6-AL9 (W"8Y
MSE"LIJ5_8-?=!&,G.K54D9,K<1HR6&;<$MPZPU AR%#[,3ZOZL#A?'0W\W!U
M=^5V0KD+1$GD<%@1Q,SN1TUG;:*<8#IE!-<+=^K9H,1@ZY+YG<1OQT]:T:?=
M2NY+]RN'D$&W**Y.=/4'*]N//J7]#PHQ4N,1O"FJOC.&G-+1$%5I037P2]Q9
MZ['C?!V[_9E18Q;Y"ZX6M(M%-L_H"(R%)_0Q:(K85 R]U",=%W;O;9JA%T'/
M_2>%)S6%+8UZC:ILETP^@%MT6U9Y&HLECH,E],$-/ZCC^KHX.5,5BO^T^8&2
M\\%*?PU"ZLE+.@YFT >W>.<F[4[_ZV.V=&U*WM]F@K.+$W/A8EFX(NT1AQ2'
M^)V\%^@*'WCVG3[!C*9S[-+AG7/<^L$06H)5-N,N&OQ OX7^.=Z8\2;=0I"]
M:Z]TK=F,&5GGV,VOI;PPE).#QDF#7Q9/3@K5+;DC':P5[<!AF9_)K3SFBQ/]
M_>?9D:&=CWT!?#D/&@9KYMES?;T^'4J\XV93HK--6]6MDP,RBWH,<5!LR,5U
M+#"=F=4]C9R,DI?;HD^4LV@KY!:2J),#*C%\$[008S*I"&W5N*K".O:*WC*=
M(VLQ#DK01VSWB+9RXT,]+GRH-"*EAW53E;B$%<A^V(_\O'*UZY8!ZR4@C*BL
M(LB+<;""/A)1;50%^4Q*D0AT(;3!N!YZR:3D3#*S0J^W%MCU.!A"'Z7\QXZ^
M6)Y-ON&,A0EK]QTW2_&F8778E7O*J/XM,(V6<3+/DVP=+::5W6_&;G?371T/
M7_+VKLM)M+!/@F_T@;2&\F1;!S X@"L AW=!N@]DM.AR[ZII4ZT&YEFUCA,[
M!S]ZHE'89N%25X'JG1Q+C;M2['_X$OU>I'#6]"FQ%!RSN(+7Q@'L!1Q_1N<A
MD8!RECN!!$2PC1/C:'2[=C6#3V6J'A'DST//OW-T0QG9$A3)N[IQZ^X 1<TD
M*].?C]WT/6K%B*<\LI5Z&9X^DA';*/0,H)<ZTFD^O()Q!&O&%3MV^S./999
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M7Y5Y5(GA@*5(.Z2&&</MV'FDZ?]J<A6;1CL&/$<:A.JRA0C<WB+JP"Q,4E7
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MP[TJ%;BPVB6E[.(#+I DG9]+DO37-EVZ!FZ[H0#$"W'@]X<R(TV,#@E.YG8
MHJNC#ET9)4C)DNY!S)B((V]\$![@0X$9""J''F1QAABR[CUGJZ0?I8?O8SDW
M59;+:I[S:E[BV*B+-Z.@'OLJL(.F4!&U%/J?FJ^E8#(GFUW2.6B+G*$JW2WX
MOE^LD?8RQ3)-\M$59@[FN!339@6O@'KF*W/CJ]\8T(\A*6+!35O5+8>"94Z1
MNH];.,B)D:1:>T=NU/ ]F\RKTJ[Z<ERB:5O BO<602Y8)SH9\J8Y#V637;F1
M:0<8R;5V:_HK19IT?><?%@L()9+[_SXT[)\&T[15.B27Y92!0!JOR&[N>G(<
M58LB4^Q6VD*+NJ*L-&CK]V[K)CI75M8?/SBN[TY6X$@MBK*5^B%Y['C4Z.X!
MW'AL&78&;>6 _L,N%;T>/32NQ,PA=F15MDL*^]2KO&C*%QT_-_EMSHN>_5RU
MZ\V/OSV?ZG4@E+=U#R?=Z5O"5<VKC DH91W,>+G';O;O*<]_\6UR6R*+_X?L
M>"\([-"CQB8EER&R\4I1P;X(%@X,B:F[=7FYH=<H@JX&UPXZMR22#H;2&:/'
MQ"V8>L+O<MW# )"S7J$?-J*?5UG :'DL3 5X8>O(H?^@%9PYMT'F76 CMT:2
MUXK,)7^_L.OH78\>#J>WX.39^?.N1DNQ")B;4/XE8\V=S@0$O;SZ[>39Q7-=
M-CSA;W_[*>);Y:=KO"E'QHR>?.SFWG?"4F/L//XM*NHRRD\7<)-)R9$,?OE<
M]'EX_I<>M%BP* ]^5G&MO7\)>_X6L_3T9OSC7;1#GUT]C^GS$9-\3YGF1!M.
MRN6\F[P#()>2T[7*PP0@[4\(B=QR-_E12%5!?)'44CK[R6T:(2B6!J$98_G8
M+0]/PHY%,LN8_"/R%>2A*]ARX@IV.S)^5!P,@OJ;G?&F38:S858RN!E]WOHN
MQ!WYKI_F#*)[N3>!! ,J)H7-0UL)93!4>R?*M8TJQ/\BW=*CPJ6U#WE23)6"
M6W"/:;8PI#,?^TI$\,9[8LVIWI;1\0CM)"E:1C@[GF\)F=:T.SQF=.9C-WIO
MJ@B%EIB6<NK78^!)6%<A4D;@V@$MQPLZ/B\X)'65Y]IVBEOEXV%&:#YVLX,J
MN_+X=&QN,? NB"[+=$H5E"C6CI*IE.4K6"AOK]<QJ+I)7.]KFF:DYF.W.VID
M?7BIUGJY.,"Q)A\#5"TCD2G!H*K<8%>6T7AGLLS+&4>3D@W7$OUX]2HSCO.Q
M&U\FRU7*G9%AN?,N61F[LF@4FHMD=>.1TF%>L<KJCP$Y\!TPEH5#+'G%R/>_
MX_F3OU;X!&:F'WT&^PU<,O@7Z*W=GDU^3#)R(&DY[5A$?VJ!<W04T[04L"\1
MO(33D0;<,(_BX6YPTB<)TQ\^1#6>(K@9?3(KLUXA\.CF&G4\L0^R[KA<H]83
M=PA9LZ+/%'"PLWJBABY/U-#'H(8^/U%#/T:#^YU@K&4>/4<Q?1HP3-R89O!2
M=ZOF8/"OAQA'5F_Q*%;78ZHB%^\GQ,R:3J-'+LT5B30LJ9 9O:A<5T[L4M6.
MZ$*2J[+R#:A.=('#>]1L*&K,& ;\%$BB+8P>^AM 1O?S)3^,Y"VNLS#"<N&%
M%A ]<I,D+X&-[-2LO>J"!TURBLK1XY-@C3:9P0-^'9R K)_8.02R&T4A%.UI
M35W<":,U)!OE%:M\[C-K\X^1ZM;AD.4_-_,3 "P-H,][9()#?*]2[QR$]\9Z
M+_38-@=$;[(N#>G01U_OI<2PK"!+Q(JIV,CSBAY"D:E*FL6=Z+3<%MNDXAFP
MFGU(67ABZ;G2DFX=EX8!9%HH/6.RX1%V.Y;8T==VU4\+/4Z D<+:_7N0'4D
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M;R II<XV_KAI#ZKV[JO5>J]6$_PAXHIXA4'M/L6&U"S:T2;D_E^_04C>S,V
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M*IW-3IP),1Q*'J<KHWF)#16[-+";.^SGMK=^I%"W=^,.9!;#J VM'>8<<=F
MMZ?_D88Y$;*T7DT=@)E\P7U(Y-&@X[.OI[<_$J@;C6VZ'GG+!;>JP70(#,U4
M_$'H,RBUAHH2RLT-5N<H/T^2:$T^4VD)=DXK[*; RPG7!1_:C3_F?[!JZ9B@
MQQX17>%SJ+=K>9V\VM$('4"=#\E&S"QUIL29;IQ1G0.G,_"MCY15_*PFRO@Z
M?$YIE#'B9JNVB!9L=N<Z(T8(Q=< *V:A+EHZ)YX>1\Y,1!31T6_>0C#"O0U<
M7GK+3X.*%V#5/1W!Y#1TUE>(''QQTO!S]")R.0$-R]W-6[O3!$?T=ZSOF[I8
M4L(./X$8)4Z6BB)6K>-%7F3%7&!A<)[(S22[QPR6-[MD>SJ4@W*M>^FV6/V%
MG=0HIAES\[9K[;1RHYC9KNENMMJTU'QZ3V<0//&Z4SV9W?;O^Z(]PGA/V@RX
M,IQ^P(>F9BI\=W1J;>]0 MO_QE'W6_-@[>DX@J=B_[B 8TX*KQ5Y:NH%/!;V
M-1L9/T%ZU&0UL9.UI]1G#W\@3_J\TPB>I?U^075Z%ES)2W3])O77!YX<E+'-
M4];SB8TOBBY_-&G\ <(+KCK-*=FG!B97"6ZQ9I97!SYW50]+Y.YG5U5SL'6<
MM\FEX8#]@2T($P:07@^M6R@DZ6RF"3E  ]C8>0:./.Z.G'&Y0H4O"0H\*Q5C
M@N>B[DM5$]2"VL.S#)E>F=N]2S&#X+ 5(S4(U6@$'S;X&6H?\:$=6=QW=("M
M]A=OBR7ZMJB[JT?PQ:(IC< 7=8P)QIN2* R%'=GT:+ =5]ZFLI+C7<DX? 9W
M-RF!7V@##KZ4"]&V8;@,PHT[%JN'CS<]A1(".@GPNH_RS1E0K1<JFWGKY)\=
M%!/IK9-/DS@(T?0+SE2:1<\*M!7:,-90VY+A*8?'K^KD.=%;W3]9*EJYY?9Z
M]D;&'CHZ8)>(]##ZH2@U5DS8M*Q6J6P B($'W)*TS9ZB[+D^F=UHTM#B$E-1
MPEGZX]<["QX*N37^[.AX\UW+)4^NYTK:.@:OXRQD.(N2M'J]UH:<8,>Q^+)^
M\(#(CG^B;U+/$;/U^P+-@/F9DU)V*MWSDR02V>$ZL8:F7W[%?\^"AT)V_?S>
M?>K[UH>G34T#<=KGH%/ZUA%EWMGS]V7ZX+&/@EOO5OX#QNH.W)54!;:NR>PH
M+>LT!81JZ?D+ES[5Z>D3'>@)&QX_2)<5O-;GG1L\(F])+<9RFM;\,KADX7=+
MJA=N1POJ);ALN>AU" NDUXCN7N$O]\*R.#M+?IUTTZ_Q#\I@[@?]FX!UN(ZJ
MZK*@&(WA!)N./<&-&\CJ"S,=I^6F2H(5LX_9.;D='FI2L349_I' W#8=5TTM
M,UF3MM!]"X%'Y30CA&AO"%<?#O59P1#YN*GJ8@E6?]'=G3<UUY'%?"?E&*:&
M[6)OVNY =1HV+ZS)'<N*!*KD/DN4Q"9J3[-CG#1Q7?GC$0Y^QX\X,\"I<1B(
M801^1YDDF6X-&76FL?&>;_BV1.NF.4;\S0L;5@C.%L,Q$'^YRR?1Z^T<R<O[
MY"?+(N$:U:V2O%%=/_4T:%IDB3\C_9Q6'U!>TXXQ?EHCL\@B7:&_XB3NYM5[
M;G;A!X@Q0T5>^'_2^:'=WI>T%B-ET!OA%W\G#/O>V*W#MO-;7)JV]O/&>[S7
M3FM:0VR/]VD4ZE0D!5WP"/71M_8FP2D-S8NMYK89&=A;AS/G>8$@18%"8H"=
M(:]C1?L7>5XT1AC,&^=QV#;'&RFN!]WVT3K-,FRP+E2YQ"Z'@?BL2ESX%P2B
M=#&PC\09,/PLM!U' Y[)>XNK%U\ J\)OFO3FN8^-Q3;6"BQ\F(%K4IG6E/"N
MNC+.*WO,^)&*&=%0+<PFL\$$500SQ1[)P"H^^./Y"S[G<B;$+F"*<M-./"EH
M%)S>RC(NTF*F&6Y"YR*=Q%6(=+[IN6G!/ZJT1';>F(U#MSP%YUP:;Z8]JBE*
MHWJ@=5OXBZ"X(^Q_1[!$>- @N5VF527?YASG+$5])*]:NA=?P@RA=R.Z?OV&
MZ(:P[,!9)?QK=]VXH,@V[2V)MF<WQU30!B.,86T/Q!NC<>AV;V-%EX.[Z_0*
M24;F!;=%75\WE'_P,UO*2UZR,Z^#F#6'7 ;>'Q4)TY5/.HN+X$<([1:76J$R
MGI+QC9,B1ID"QUZP>*;< ,R[(,FFN5F7RFWS]6Z!J3^G#WYX4#1UA5*BDA+2
M/FB1H5) MM-^.$R;$E4HBB]0!J-K,C4R=R]7?)VVH*(8F<%[R9 W N/0C=]S
M6K228VH&C6]H9@9'5*HIQ'9BFZ/T1=)/=XSV;?!$N1]GM\[OPJ+6IU?#RP?^
M*E&HOWC1^=8DK2!QWWR;YF2>:5;$'PQ#Z<7P>F)M,#H;7ITS3:78M]IBUA!Q
M[<OAZ?EI^W\/D6[BTP?Q[5:E&4V98[7":M'I)6+*)9]$+ZA+Q$92)8S7>DDB
MV4YSUCW[(T5L<:2(/01%[/F1(O88WOB7(I(QXIJ=<>Y+(T):YC!#DR:K*YM\
M=&M'\Q*MRIA9 #J]0\LI-]@= ,/DL&4+^\!YN\S\\"V28U3Q0B=-QB2(#.ZN
M6@[R-$Y7C,KGLTB5X.=Q#5%-\4<6ED[!WVCJH,AN7Q9WAJI"V,;M*IU#0@VU
M'WPO@0W6BR)::EWWM5UUEL[E\D3"/0(A>!N\'HS3]BN+>/A0.+6]*61I0[VC
MZO@2:EINB0VB-Z]NG,:FV^W$[>K40-/=QJ0?ISAH9]C7<R=U)8D3%3-_3\RA
M1-*^MB>&B1H,'-&LDU+M@V2:E:&G[G \W%/T? 87Z8&H,[ZVT^XR.RKF%*^:
MF:5:@9(MI6J85E=Q.R&A#ZM&2%6)L7FYPN)44D2U=LAM2*;2LW,<E%?(7T;(
M#2:5-S-D?"MMTR\IFSG*["5I@@TE?R'T\D"+U5_90T49OBQ*V3ZNDZ]S?@^5
MU$H6966JT9\RS7J@OP[(PH]''"K3_PH]@M$=U'$W-7>[W"Z($$Z=Z()%#%A5
M@#_@"]!A!G;$WH8,&LY@_Q$*&I<WSXMSC ^Z9NHKS"*)O5G9M?,LVZOPQ_%X
M4#Y,3_R[A!8S.X0&+F:FUXD["]F)!C/(IP?#&5UNOHP>O'!R>\N;26@",6&#
M$+$.?JS?G;,X6_-M?6!971+E70LPPT\2TM0;J6GHMD?+?1K"SOEU_PL^NOUF
MK7O'-?YFN0"5(3Y#'B<DEIL)))E7WJ@=S$S^&R%&(TP>09EG&B>G&3%;(&9&
MW5F(7G<?MZ4@VM-Q[)<;<^_'8=86[K.JN]EI1:*,$(G'>^\J?);%[XDBD6AM
M4LC-F#QE@U:D2G>C53E OH1,JZJ.+L__:NZR.0JA&:.G562>!_G,,WE,S*F
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M<Z-X8W[^$HQM[P1,+[D]5] LC)B>L8N?91WS]5>__WO[C0^T2?_5WQVL1F>
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M&*(2^-#A\-^QX#-P3P,_3;?4++TC8 6>).T%$[B"7UDCCU]N&ZU?!-NRCP.
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MPS7-\3NNC9>&1!:4887C66'7&I,F5,;2N,\EGQ,$JL=-KG'PZA(8,7!?;B!
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M!CM<:J(X0VUH.]]0"+?6\2(OLF).:#$^!G^LTN%7Q5B^R@X26!C#0SW8U:%
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M_\RP5MTRZ=[93U>OSZ\\S6E><J!K4O,[=USQDYHWC)/8VFB);^59%JB'9/G
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M>)AE&'1K7@8W4F-?W8@_NVJ__=C^/ZCJPS^^PSX[RJ3</R6IB*,.M #^$2Q
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M.5%3M+G%DP]F0YT3#0O?>%>*K$)'A%>&G EB$3#?3CDEY*S_/$%BN2Q/'NH
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MZ51V-=^66'=15K=]39EG62YGNCD /#,8-'T)%+$/P^0SN)-HV(QH3E17J2S
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M@@70A(E9,<--O2@(8PJ;6<S;Q=I35.;KZQ#^[(PD$*E(N@37(XTD"%&1P+%
M0$%Y/'@^1U.*(E]HNG2GT3HY N-G'!0HKN$OVUGM8&L6GB;EMS3.W4FM^#4$
M8@?A!,6I.O ?,]B&463=GT17MBZ%$HA8F.B?O-<%$A6%W+=YEZ00!I_!%8M@
M2,36I/,V$CYLO/.+]YE+%:<Z@M\#[>NM?:DZ8'%H&,RWA(G+,$=W6>RU2?'Y
M&7>-F> ([EAFZT E!7?Z0D>P *:KGN5@]#!%FG(()C-&*OV,-(C5%.4#B5:
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MHK)SPS8"ET:J"+6Y=K;%2X*]5KB%-E29SHHI4F1B0;\D(\EF*3P7+AWE6?G
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MBA53RS)LEVN<YH:W)^W=[ V_MKWAED#.\/7+=/_)>V7CR7=3F%?6N7.H%C:
M[_=T]AXIRHZ%F&,#C%,FZAJH8Z@:87&^W=(GU-7%6:4ZWG%]QOJ]6L^8FZ[.
MJT*H+"2[KZO#R!*[:4,IK36%,%-C'^'6!)1+$>?!H%YS.T)<52&"FML50238
M/Z "#>ED)Q2IQ2&&'RW5I?FLRPEQ FN!.6*1%=1J@+\NXKD:C=+HSXT(TX<
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M:9B_@$>\Q&+@QNB.OU.FX_&(\>]62]"TD)YD=VJ\%Q:;\,;Q,[X,)-(?A(!
M=-UJ'$RY4OM&GLMMD%+0FZ8^[),[B""?N3&SR71T'F'#"@EM[S_^S:8GHW&$
MGSZ%',\2M3M%LX<AW1!ETX54"KF)0;(M"?T[!(6FBTP5M0Z\!!$NE DN/TK9
MC"K5[O42VL)W=!MX.D)LPX,0<8C5X;#ZP3N&EBK5]:CIJ$Q&!S WE64<<1V2
MAO,+'"GTZ-NT S?L;NW^>=L?5-$A2H]C:T4:S2^BA1ZZ;?5*I)C><26<N>$1
MD,UYJ< >%/PE.">F+GD0X@ZQKO[+WY*\JYD-T/=D0@?D,F:B@JVLPLD-9Z'@
M#:9NVKVZB?'RP,$/B7_U)<AM'$[_'M.1S#4QA%7KM:XS(QQY7J(2BB$##Q8\
M&GR,#T+D(<HP 7O7NE ;7+QUEYLO+7)JWN1F@EL,A\>X8K0OM2\_<99"(?X@
MY!ZBP",^^MT/Y6@<T>G@,K6]KF:16L?DCV<K+P('@]U ^YYTJ[G"RSQ1]7P&
M/\:T7EG@*>!6<.D.RRBLY;'.:KU":P"7:(1XK7<HP3P_P+QLD-%-YLHFVN#^
M>/!#S)[I4X+UK71!C\%< G H&^QR(]ODQNXW0H]KTV 01CX>Q\G.AT:;V0<H
M$T].1K,O@\QB]&,L:3S]D;_N_=CMH FO.\U3U5IS%[C!6&-*9([0S3]N+$;L
MJE HEA,X1J;CL[25UM=&E'DZ_@L7W+MC _!N09G<VRZ^QT'"\7AT%&%WXS"(
MO/'I9'1Z=.[_]V7/>J^)#F=1ZZ:A:=]>LEKNN=.<PRJS(L]Y*DA5MV\133QE
M0)>Y!PE@Z;8]4"0IH#$L8#QG3C?2^G3O)/XVK)-%R"9X0MP./E75T:13!F1E
MOG,_^O312C_<.E,*4J202@_].9Q2RZ ]EU!%$TL9D(V_-(F,D#M%DTD9D)EO
MDR^^]GWD-!R,AID''!<?B\T]:@V^!MUU0Z-525J(0:&,J(\R(%.3SU2+5G0+
M],>-J9VX[ VI'#MBV>BQFQG6M$(ZP=N&UQX4RGS,475H_L(MA1L9V402THF"
M2U<2;$B\I$T;K==X,K[3+>Q[F#F_I>5U;".^N .JXH,NZD4?-2,/%T5[C/![
MLBL2EV.!!LO.T'0%4P?8C3U$$\.+ VE2=P#1U "&OI^WJ3:8&%'4D<Y&80@T
M29%*)?[2OBXA?VUENSIY6\"OZ20"7K]U @%J66,%$1(5N[T?_V'/'75C-$F
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M/UOTF7ZV,OI2XK*)EK%,![]7YX<KP:J!V[3G!DH3I-HUJK9K;%U)6M@UC$*
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MBEAV'_S.3.@>YMJJ(J5V#YU82BQ=F>,:1XRN'>0U\'6G8)4CX@[.CY/)L(U
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M;9_:YX&RGZ OC7"Q6F4MRX1:LO(4/W!9U4OAI*N3#(K+(B8I^>!'!G?)0OM
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M89O1D;PJ@71F6]AD2,E'7Q9T/W>P)T?G-.",=[3W/NGC1?M8K$KCH\CV^#Q
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MU[X3X&L;OB&T+&YK8LH>#)?%006JEC'IT >/:N%+W*#217B#?[&L]$'!0_(
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M?<.4@F.5==3+H.C8,UZWD1&PA<221\?I^LI V8K,Q]?;9Q9Y\7CX;*,.3AQ
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MQUWJHMK$HV8<NOF9(X R1:.6)410DQ'7G&/U8[^_Y[Z/DM]OL+3M.81H8$$
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MMTZR0IDU*80E7*7X?0;JR),$X2MZZ7-^Z06RH/2C]OZ@'5>A\/CL(2BZ^A!
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MH")U7!N[6!72,$4;;$T.A::+NYP9.&)[F[=,*[O7?)6W-BZW7XO["'!*U[*
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M2/\X.6C5&L/P?0X[ 9Y9%3U6@' LO<@VVU1%3G43-A'A1RH3&OO53( GM5A
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M$\$%8SOF!RRW0M'KMX4J4X$+\[)Z;A;7MK- ^>@=YIK#+VEM,Y*C9> G'$Z
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MH>=5D<>SZ&NH_(B5!)$7;VO,FMMX-+8'S=LB[<G!Y9*JC)_D7"-\,^DVB(^
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M',4CO1VZ]:^U@A3=T7? WPHP?)N@]6@MV12T[0>NO'SF*)[=4T$RPH;E&.@
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M;<8]NM!Q5UK>RK C&L'G\*&.%Q#!PCD000)V&N6-S]\\:#]AU:UGU17V#BD
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M)G#,8ZA^SB:SN3H]5^/SQ?18J7-U>GIT/MGY:;YZO6EVX$QR]H7]F)\KARZ
M(/,()'@$$OP5@ 3'!P$2[(\=Z!5O'3?.OCYNW+NZPYW'C./1GXL8)Z.CR:TB
MQB=;#5L_]>WCU4F,:/7+AE!PD-1@\O[*E)!8(OGU.WUIX-CPBV_KBM#DS6[\
M&A_/5#X^/CZ9'ZO9Z?G\+%/3V23+CZ?GB_%TL5NU?\W=PQN@"K,LG5OW7WI6
MJ*:5M\AW!;%PIQW<SVC.Q^B;V*;F;#J:D8OX_ZLN:5955R#\0_%T<%$5$"3P
M%.'Z9"BRQ-44)J8+=Z89<IA3.Y6Q(TUG-V?Y$@AX#U[V[ZXDN<0[*-P_8S*X
M.:/SK^[,B=&("AR*^(/=OO'=#A ^8\NOKWGLY3LY'9V?XD_/H/;>K6IP[K#6
MMON)UY%2$LA_RZJUFW:0U3"<!KZLBT9SFXMJ?-,D%V79D=/95#644V7R"@4E
M)D?/7HT.= 6_>@[WE[F"=RN/>*]7\!Q_^M>^U8$8;[@^;46,5KBLCO\T?B>]
MV2V2;&ZIBFM<J,6D7IF2-FJO%.3,155]P#<$MQK;7 >ZA5^-_O_+W,*[E8R\
MSUM(?9I_UGI1H(X:^D+(U\HF333\OMBF9S](3;1%,TIP[(%KVG!!;<BU?A)>
M3W1NBT1?TE7+**SG9K'0N.#=:BPB<86OKM;PCJK1A[F(9Y.(&RE_F3MYMY*:
M]^H9R92J;$UF-G:PQ![P)K<V2E[!K:QJ]F]R\S+5H6Y337ZQ-G.H,86;J]%R
M+769.6CL@6[C>:RD^O!7</9PKB#]].2C;+35Y 4KKB)WDS[%25]-25]*&^0F
MZPI5%]?V^C:LV@YWU+2XAR005*K:IZ,7^-?QY+MWIOEPH)LXN=U>_; NY?&#
MN)23L^/1"?WTXN@L9!EOHURD]TB/"G?P9RA4< BI&.+_2KSF3^(UWWNO*1]R
M_]=M>GQ*O\Y?[H[AC3F;'0RQ%&.P]\NEKJG=%0TW>#1XM,[OFM6KD@Q^=RRO
MX!]72YW,#2I9K<JJJ);7#KBYJ,#AHT!$F>20RQ;51M9F:K4ANC%),U:J+I'
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M+T5*&9-TV'^#.:+C6JPC9L@L\=VL^,<*PMD(# 8O80LN[.1S":Y#]^&!)0[
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M8D7<\=SG19-'E!X@JC\_5/)@ H99J@Z1.7A?%5<@7;D%UTV0[GV*?$#*TL<
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MF4#,@&Y+(QP.+OJ:#/IA8$]Y A3U]@%^]8:;9IO3UVQ,_J0I3=EA"F+E)DF
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M,<7B]3HQNRU9D652/R^G)XRY8RI$D56B*$)EVQF^IVMV!*^Y(Y:/:ZZWM ,
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M:PC'3];^Y M8IF40E<, 30G"O#&Y38JC-HR%XNHVP3$.LE!@,E%553X%9.!
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MA2_'2RKT"_\?7\]D?4N_L89G!*'7,<MTE'G#R+CQRSQ.O""BCN8&+O>TX$R
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M'78KB*)?5U4NDZ,A,M9$& [=:ACX<:8J]93&O"?#84S*<-S[$82GX0&3]9"
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M9..&:W3@*"<R&A5T]Z303V'UDN??)[Z/-OG( ^S)/#O3$OFJAN0(>7Q K@(
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M#^<$?( "0#/WPS;H;A4P@K,GV3X,K*6;PPD]>X^K:5Y-#Z>SF>GZ^K<4Q9Z
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MG"[T5:GI',.I-L*>K2,KO#1!.M66LF.LZJ5,3;TTR\ZOA1/@#VW5F7 /%:P
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M;6IIC*R]QJBC_1"!I1ONQ9(\+NI3S8YNTE1-ML=-.6N;/3P [QX=+U4S9$/
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ME9V_N/@SA0MT]GB9_7U5_J9+,HU#/TWHU7IQWGOV)R.2NE27WW,2J1OX<^7
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M!AID'T]V!]E;';8*4NJ"AVHL*P*NK"[N*D.132%U?=4$"*G[#1GZ9K9DQ<_
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MJ\4NX]U8T*73!$1<,(E5WCHI<:3T$K[/S5 !#E5A>S$9^E[D4JJPW26P$PY
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MZ$YP)(N:@/C)]QE,XISP#HT2@O>-%SGI D?7H5^17RY> ,;]'FZMQQ%#:X\
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M1]_SRQG],R](*7[-/J\V(/@P1E4;?-!I3<@8*67QU1#K,_ALZBS6BO+&8&!
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MROYML::GN8.;#:IU+&.J5>GPF]K2_;O)2D)WFM+G[6;3S1S:&6QD06M[ULR
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MEE=A)#,B>1="7HR6"WV'N#><'U'B'[POFQL2@QL2Q=IG2 HY5\X-?M^'ZR+
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M7>Z$D5QS>F6/.;!U*SSRH(YW]6]BW?=P.+,.=V9U!K5^+95)X[1Z5.<4>4%
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MPS\GR(],'9!$AX/\)C_"94R_NWX:@Q<  >8N!.P_@V22?68F>^V/%!Q:DM7
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M7<)@W-H3,Q4;?-FI7P.UMYXQ0-WU47?54@;MZZY;/WF\JM0SEZBWF<VIE!)
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MIBX[B1_#R'^AV= G[LJC+W0A5Y-L!>=MJ[)J#\EYJ^B\&W;>_XK"9_ !,:-
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M,DFSP.100^!5:22Y-$H(S(.[S)JH,(_7D_1U9!_)\XD'92(28?4>5(6UTU0
MJZ_('7?P"4Q;5FH6GA:LB8GT2J45670@>$U7+G</J2;W;'>@@\<WS=H]6IB;
M./#/,?@/'X*7^/&LU5_>3]:5(RL_&1RSRZI99C;1LFK68F>:[[ 6M\Q"/Q8/
M<E3L8_'-[* :C;^IJ#]3E/]@APVR'=NCXPC*WD&$7?R6O7F:TVL^7;I(-ZWL
M2,.GLV<>M#8./.P_\N7@Y&H"8V]G?W?/1A,8N\4)JT^L-\#_!<MN*2!KVE[5
MQ?1:8>'!\!"ID=)-6U*)JNK9WE9UG9P(#GEZ1 +_PZ8 _4&][0A1*^;$79QV
MP@8&;%>J)M<SJR+5]5N^4\UVIWID80<Z&K2I[<WP5XXG'>GI[VE )9,'5M<J
M=+NV*0[[&I%-@5NL=UKHIY!$"[;B^-F#-5H21C&O#V$U)95-ZS@[MN1?LW9L
MKJ3#>[8Y_TU2U7<8G:ZU>!96M\9E=ZK!#[N\+QX15=>F=BN+:=U5>)Y"8@5I
MO%ZP<$EBI*%U[)%UV:E7I+/UQ#V+;4HV>[]^5IWHCC:QIU;/ QO+*9>VCL+'
M:FI6W%%=6;^1R(5P1OJ51-Z"^CVSIWT5M6E2[SH)(=; *FZA#<3J'&5\5J?+
M>KTEQ=<W_\4#HXM^_$'3]=ES"/-9STQO7T]H>A=,[\:F?ZV9W%0;G\D9<MV(
M<>'12/K)#X/^37/["D);&["MJ8HQ/F.SZD:57\C<"Z7/)"'^PNN9L1UH"*UM
MR-:F6J.S-MV1U7JUX/],5K1WJ9 #U:"9"3<S737;[-6CC2]= D%D/4O[.<T/
M 83+[8F+#3Q N.B;]6FW9$ZNGYAM(!M9\S2JIL C**6O>LG)'W]P-,V:M7XH
M%;QZS32JIFH36W>D<M%^5H3!MD)\GP] =@JUO*]ES*I5A%Y5M&K+MHJ:;D73
MENY,--4XK^G-[J 7J'I.I05=>H&79#\3]X_4B[(3R41:PV.MV%4D]F*)'7B
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MWGWU"&J]DM;[#SVRF\@3]RFTN"/JD=U9+KE?I6IW@CURFL@T]ZG( ;E'B,'
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M),D<;UG^3Y%'?) Y">*'0\$KLUSM]I1--6L2/7L!.'OXB^R6TO:[60@.%O[
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MW!@6!&\AAP5/Y;]G/MCS$%A1,_1#^8HQ<@(+@K?0X:/#?T?9_+Z'0(\_ADT
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M[3-[$)](7T/&@(GF+39UJC;!.>V7C>#66J79R\&RD,&5A3A8%C*2C.,4RT+
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M*7$>'%,]UP!!337&0)'0O?4>NP@W5BSN2'[PD\:8N?D1ZJ!"<L,K!#(L,VD
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M/\BH7@@[=&?<4\R%YZQI2\T@X/,>5+K-*=<66'"!RU=K0#F7S'L?<C4V:.F
M"1GJZ!E"E9 7ND<"W]:,A(,***L9'S8$ODKA4*FE957JL<K2!5\DX/8^],(E
M6"H'3JSU8;3MQX"1;NN\R/(8K$J:MF?3<^'!4!0@(E[S8SB #P<& \/FD1K
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M.'G.QIG4K<Q9MAGLE/9SC9^S<2CU7_B_;A7D,P^@<\E_TG_YU[/X1QE!YZ/
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M$8KQJ%LQ'WCXMTU+='!\_(GM[GU\]EU:1:KOPA>,OQ8G\?!@RE84Q=HLRN8
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M\1OXL!R2"WF3QOASNGVK<7AM_VS2G_9?^NV@$,$+#0=#RR @:P/7%)8BIIL
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MR[/AWC;; 2CSY*+9A@L^WZ8/M5FGKN,>$2NS7RA[UMZ):F^_:/:L/D;UG4)
M.WE)+(C\,>VG^_@VDM;/V5__XGK>Z^LTRF07\==X;#L/$B"?1EL<WF8G8>*!
MDSSP-D=>O]KB^)89\H1CAK;CQ\@GCAW-GEPH.SFSF)YL/+17-'M6X.DJ<+^
M]JS!EQ?33L^4O@_H\;_*1%J_2'DQON2(9 ZOTH)C[2*4/;"4Z-D3;^]AZ=.(
MON$]=U!+/AAL &_S8=K9TXBX\6U.F2W@J)5E>/\G%7Z?9@P^?=FLGHS8B-%@
M-IF<6@3>E?IZH+#3PT*<E=5G\(,[/)/3/K@K(TOOK0_7B8S_'5U,ND";CN'*
M[V0JZ<!:IF_WC.UU?%( TU.,H]:<PSF0ZED@U9W^>J"QDXNDSMKJ>2CEG*E(
M=^KO39I%22*L?Y>9]5.:Y#)Y]><-O,'\8MK)K+_CSNS)\<M_!V,$<,"OBT[V
M83&JX^&T_^D74_%]>ET4?0_$,N#[Y""B/68X3>^Y Z#KR07-SDMF$V2.F$]M
MP=A9>7T-GL^*>S%QM/=5?)DLH?0Q]<D46./;BX7U*95)*+/Y_<6,(Z ^.%"=
M(<'"R0>J,W[NI&/&6/#V'P:,'J=D>7(AE_<U7*W?I/\_S3KE67_]#;S.NGM)
ML9?O=P6S[%_H]39=1DGTV?K;7__B^N/7P4W,,2%_\+3Y>&)/>T!;"H>X<]K*
M SOO4WMR_&U0A\]G3>WIN&/!'CJK-;5GS'R@A^,;#C;?7HR4S>SAL+\)#KY]
MAIOVJ0G.Z68ZK?OY'&SM-H'3'"X[Z^]T];=?NG-6X$L;+7,-P] 9NK%5D5=Q
M;(6MC2VIWMAB"?C7NL[2<F5=S-0.D!7\/$WR3FK0SLRS1Z?/:(5OLX.,[7"T
M! ?+[5$A"#/?'DX:P>_SU<I/+C!L.['SQ?1 "7S@.*/!T#VUK:9G%>ZO0MM_
ME,S]^*'A67\'Z&^X%QG_#\4\#>_QOV(>RVV/W3?*\ZFNH*7HN$8Q6VP$'J8^
MZ<.U/WJET<AI:9G>IGG->9J%,GL%VHG%*I<_FB]>KVU*I2>9W:C#X?<8]JJ/
MO1$8#ULA\4J$891<@UFOO9O=2\]<,M'6J^BW.4^+(EW^J"S=RM,X"JV627''
MWMLEN..</ PL7(^V&R_ZA(#I0'(!VV,(-_9:I'?XT6B*\N%WB4?%F;4<F3XM
M3Y#DWF'\5R\KGCXX?8:]M^9S'EI5/+)'?O79(1'U1OOL*IZ-]]]P]=U_?I3P
M.7*9%+DUEXF$;"H2L97>)9 \W40K2+"L6.:Y5=S GW&^MZVU/_]$_;J3%Z??
M__65^H5,S.?7[Y45IB7>!+=I 0[:RO O6Q%DRT4A@AL96D5J2?C*RN1UE!<R
M@Q^!&XX2D=U;^8W(I'4AOP02/'&129&7YL>7:!/T4C<R#JTH@>^EE8BE1*/!
MKW/\FAY[D\;@V)EMQQMU93N5'AZ.Q/:RL$6:@2[@D(D<)'R76O=29'GCG#U-
M2+[WX@[8A7/Y=4=L9@^]+2?LZ?6,PPWGZUN.?\+!BI(%OAX^0IT[.(2+-"V2
MM)!X(.<BQU.<6,+ZA&>\A//O>#];BRB&G]]%Q0V=ST_OWN"#?DMOY7(.Q]/Q
M!Y8+V:@UO[?^?/.S]29+\QQ^F5D___'!^C"P?OGE#9==CB#\<T[X\&[(_>*[
M=9%8'[Z['*P)ZGV9A"0I^P_;6G_*EL>38#]L/!)?G!X-$E=/81+[V&GE<*<O
M]G51[1(M2(L*PF]N9&+]=VESE"D/^VSN=/H([GC?^<0DAXLXQUOTZ!_"<T<'
M#OF-!_YH/!C-QFM10W[T]^X/I_:L"3]YD 9N/V6HV&;#'WXXOF9\+-4?I!D\
M#N/1: !I,Y?[F R;N6T/W,>:3>Y2YX?C>PO/L8<<G!\;%PH89Y33_7X-"5T&
MV=Q*9 5\A0YEW8S11I;B'G(_*Y1RJ=*!&W$KV2QF9C=)_4_.8O:3LDJ>!A!L
MW<J\6$*Z/"#18>A)+P4"6Z5W(%(*KL#25C(H4):@AQR2(!F4&3Q,0F"O;RBC
MI#R%X P^JKC&]&RI(K$-39%:F50"]]3HE/.FK8YLPTA5:KJIF*_4R_']N0N^
ME*,KN,52-CP D^7,)O;HE(/V_22VVQT^Y _970"/3D9#$,HI1_3[Z>1K_.$.
M;7V-8V#2A3.R_5,.C_;3Q8.FB^6'518E0;0"OS(O<Q!0GELB##/\+RB*BHE;
M%;:>_!X_ZO)]UW9&^Z8(&Y+9S-XI(^7+ST>N;WNG'"X]D)]_Z" I<KSI(VPO
M>Z9YZ!O>9K:.RX[_.:8CVVVFKH=E>JX_LGZY+XHTL:YNI3VP/I7P",L;#0?6
M'R).K:NX2 ?6FRMKYGM#Y_A5!1]R5PY"%JYCYGG43'M157&7MRK^Q+Y3LXKE
M#6:N.YC-1NLE(@WFC.^KO/Q#<EOFUA_E/(X"Z]V_2KIU3,T/<;SN\+5^S#OZ
MUGE]:6]_EG45WD9YFN5K=6L6 X)[Q.M_)+PNT4ID1K0#Q-7N*"68)PVL -YE
MEL9Y]2-RIR((2-W7\?U@,TJKF\V@_?1.-0^9E(.0B_Z'Q+M*5T;(QNQ_CM,Y
M:.97#)FERDO0WHUN-WZ]H=LMP7:E2":-C(>VV__ N'8HFQ9O?H>F/_@:VU]7
M-S77-U^>2R$S%3?U6R&/2M:V/L$-@_?'+_8;B(O,H<"?)OL<A"V'J]*]_AV3
M1O""/^6JW'X:J07%>Q V]+#Y8DQZF$X4%W>_];!Y$'Z%[.:CN%^FF.G(^5PD
M\B'#IQ/2,';Z?A^=,JD!Y##L_QV^OX$K^>[AT+  LZ7:@B\,QT)%OAA^%803
M ?E'8<GFI<;#$64+/5=+)A<2Q!W(<"M\9C(:6K_(+V#A.J-.2C@KWK"XL=['
M:9H-Z!/]=YI]AJ_^VW*&0]>U%5R62\Z.WJ[TDA)4[V03U(OHTO)'DX'G;J:H
M\+\R)NCD(DN7=*P0S8@_@&?J>$*A*N'[,H?SC=6PJ[<?=7RA?*@(X$_ELBAB
M972!R&\&EOPBLR#*":I?PNF->=/4,=CEK/]!Q7^)I$2-N&/"ITT&")@46(8.
MI%:"-_9?CW&6435E+B+0J#L8>N/!>#H]4*>HFE=&53L5S*0AS[%G_0\WMEG[
M-NN^*J_+O'A4D6-[-+&9!.P/[6DW@<3S>5+_=#VIN+2F,W\PG/H;IXX*&((>
M]E[.,W6DIV0)8W5JYY>6-T(\&9Q+*5OQ$7;QJ%<'OG,\M$)QO_E"O+[3G]G3
M_H<Z*%RNLOD8QPI?6E0R.NFSY#C>P!EM8"OW.TOE"E,(SX,[<++Q"E&>E\HS
MKU*5EVAW+9O 4QZ[ 8?>D=UP'J4[D64"!Z7((2'((%I"FA:)0D)RUKSLTJSU
M[2-NB_6(3OR7=T3')WM$U0E33+8'GC &:^(]I%/W)1S2YS]A.('_TD[8Y'S"
MCG#"9IV%3YV<L!T#X*]>_1-RP&AQ_Z/^[^OZ/?PHYGD:EX5\/1?!9Z1S2L)7
MFE/B/?WS6G$$_.BLOAAF@#?PSVM,.R5\[MLHC^91'!7W/XJR2%\OXE04ZI,T
MA7N512(&@8HD?[7!3F1,?3)#WH6ER*ZC!,DIOECXDE;UU6LL!, ?N/OQ)@I#
MF;RN61"J#Y3)6"#:L*GTUW?P&5[=96+UXSR3XO,K_/X FK").UPGC5"O[B.@
M^+N=%OHXPP?D//XF.<43+/10FC X(@PFZGC^7J:XVP7MENW:2WV].YBP"OH$
M+I'IR5XBF$GY@^G8>TH>Y2!;T^8K'#&/F@Y[?WGT(8>:3E_8P9R=[,%\0G27
MKO#U5*_S(*MB/9*S<>^/Y*&G[+%&9^/RQQONL #$<5A]W*%+C<8<T<?5=L$-
M]$"%-<=2-EIPF5F?D_0NEN&U'%AW8-\0#R_!:)4=.Y/!R)T,_.G0/#HMB[P
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MI:'[0)=Q(V-B.^#;Q^QVA2UE,\4HJ9A+%!*3>.7 &Y-<!T@F@Q&%*C7<@+O
M6GJ6(IU$U6..3,Q+3A9?Q8@^4HPT\'41IYGFFX++45:/X**,Z&KHC=$?9P:P
M00$<^EI3E\0"LJRRE3LIXD(E'Q>97,4B4"0>C0IF$XO;>+C03)Q<0G?Z+O3_
M$DDILON__L49#U\[R,_K3"\'E6&W8H\JZ[N.%HH(,)0"!!N6!$[:<#OD;2)]
MK-1K"C4+O, =\: .+C6X?5<#B%<O&3$<5FU1-AB9-'P<PVL1@YF']^N$C?L?
M%B[Y>WV7_WY>8^MAH8.@;#LIB>>Z71X!F4/>VBAM!7&:EQF?\#NE@F,Q_GD<
M7:NT4'&Z-JJP6RH!(@PSK $V3LDC3 V4M!IO=&:#,XFGCG8^+.K&X9K+1A'K
ML96!^IF49,9SR#W!B2,_%CVOS*[W:#>>&>&,[->VOS?OQ)8=8QR$Y9GLP1(Y
MJH\MF?*.OGCC>5HY6PA=-ILWBLYPJ]-OZ6&=)BG*"2T3XFW-QOG6I=RY2([>
MX'QW0D+_219W4JIHYF?$%R8T^;!M H:,&&(6<-FDDNU/T>KCDG=7@%TV>7^4
MJQ*NSJ"*UJ]NTR@T0.>W:8G7G^$_J^3Z1R:-AC!0@0L6S/_=K:!+ECHV'^MA
M<7BVS!F-W.]J*I%-Z+J5CM)\8R)V,-[R&BY'%1AZ$!DZLYFOMV,$8BG5=#ZH
M"5636&]E0!M1]..']/@1-8OAP4EH*"G9,"%^5Y0HG&Q2RAL76'PITB"-6\-6
MA!?3OT"%M$-U#V/UX6Q@Z8/RW9_(1'7_W65U*M#C7Y=1*%&P.("9ETH+7!IP
M^ZZ!M7!;E,5-JCE?5 D->3W;?'3T-5R55TF"XV\?*1/" _ >WAMHY-5[MJC%
M[Q3LS1.UO#<3*V9JR<BOSH(&U=H%,RW8@)N86<*E% EXDCI(CU5;SX2*%5?=
M!?Q!3J; +E7 DQ%)XM<0N2Z!/3:H_:-UX5PJ'X-LJO6D)Y)@1;FA" S@7?Q;
M4O?.,#0/K O7/-,RJ_LBQHOVZ, U]JJ &86DZ<?[RFAK)5EMR>VCL($5Z*?C
MRV?7(H%/1QDO?*] AEP*Z&HF@M7A&[3EEH@]HP!%I4V%8AY=OY#5,K>  O@W
M:9PNYY$ P_>TX=<@KD8!DS3(1N_8=QULFG*% [CP*_^AJS6XK I;T5E!<;QN
M/;75ADY)5\7D%YD%*/U5%BDNX'*%PY&JCW7+>!1F?5=#A #N<!DE:-!U.@6/
MK:8+R6ZK 1UQJ\9%3)1TKVMCM,I"U&",!H.\!>\B4K@Y'%,M^3+=T;#O\E<M
M51#U#7G]6X'3DC+6,T]@Z K;I3UXH_A+6L%@/R_!P#\V=X@05J9UF;1/"AL;
M9=^%KXR:S2F/.EVNR0360$_;(&Z@2+J>2# 12VU<S<?N$Z=<THQ?KK<0LK%G
M]AXZJS/UFDA:^]&F?&DAN_D)L9.B+VT^HD;.T;[ 4*YP,TBU(P]CFI(;)SKJ
M_39-(U%3,B$$G"H ;&J!VDIMAG3*AYIJH)YI0T_MWU*\KTY!WXDJ65?)#I0]
MWU1"W>B]8;2RWGG[NH83E^![OTES5^>M)C[FNQ^[XJ1_1A0_16342(@I$FXR
M\>A3WICSR2LL3!._6,74#48\?*SJ-+-19?8=6;N%>G!0 T I,HF5NU U<%TE
M!"G7,Y:ZM/A+M7#!HG:>>IRI,A(&DK2+>8TPBWP9K\SQT:?BN96A1*P7MM+,
M3V.^HC&SK?D>51:C8.6:TT&I2NQB;U!WZ#;ZAB>*_NB3\L\ ZU5(:MMZH[=/
MM"<S&QM&YF5!\J<-(R3Q@7IP@[EQL(.HK>)F8R/E[+OD'Z"WVZ]$2POV: QQ
MG1EY8&TEP6;CS>R]Z&M!@4A?:7)*7>=6A8_!CB4L@ZIXM88F%7$ALX28GRRL
M@"W+);YX_7@NZ?=^D@N;/BIX5CN^FVLQP+KS4B255*OB*UP#H*0XO9=249-9
MZ4I5J(R+H0KY&KL=6VC>&1DH<WFJ00AW$8("@B*^'U!'3GU-7$CWEBC G<_)
MXB^MT??KW'"W*0%U(30-/N/O-A_Q(I@V63*BLL#*-:64RFYUT#ZP]E@,4WL/
M4AN5<M6$>?991_2-I^I?* P>FPJZ6G#P[-0T%7X P\YUSK"&6*GH;?ZH*L#D
M]PE(OX@"\S@X1&:="^/4V+C3')>)I6;+'IM+VJ@];S4TS?([-:;7F(HVE"#K
ME8,SV61Z)IOLB&QR=B:;/$9]K)6)[C\_D:^5<;=5;Y^%.*_W.(H'-^XVKL0'
MB=S6Z-ND]NS41B*B&]2-"?"9)-][Z,1&+3%_L)C(Q]QV])E07N:V=PI9A>;Z
M,X[;*B0^?OLGQAL+F>D?L=$&]G_LYT-B6KL#Q8&KY-0^XI %TORR2@@1&J*\
M@)IE3M>[EI2?W!&_1YV-S]G.M^/W'1?>"'6;X^$(+4Y 7A&Y2U4QTE1@5. >
MJ-X[QL-K\3)V-QM \Y:2&#VK,^J[Y!NS5O-GFK6J1HS8^#3[+O0CS%HIU\^'
M^W$ZG>CD&;JJ/$E>78D@H) Z ;^!]=;C5*Z/XU23Z;9QJH.FB-A8.OLN?31P
M/;%F36F2RK^LF#@O(@U#IJF?-"%<O<I.]/VKADS"=!D%4:R:Q)KC2"BRK (^
M-)Z/I?ALE&"N$#;2SK[K8$U4-XKO$!N0%+?09-M%U-1%<R6[Q!0S)]D/U/-B
MQ5F!B]HC/54$F618!GJ_L]D;8)D=5&STG;W7Q-Z]^$8+>C_I/2H\=T9A,I_X
M.D@'T3[9N#>'S/(X=I;WONK%_EE7D7,BZF;C:9P>74;\F=T?C?;I%19D(-IR
MO1%.0EK_W]NUH%71G(?2NMBV>.6)'Q=;7%&P\^-ZKF./&#XPO?_KO_[%];S7
MB?I/1C,BN14M5_ #WW]=Y,_P^1Y1I^\.[;'W],]W:5TTD&;O_WRC*T$06)CJ
M9<[(VNV.NST%+"TG#6-JEBNK,75AC%]!0.Z;46V*%6,:\-*KSQ0Q@6Y5:<P>
MDH:9 >%+MM3#G?1?[DI:6*5'>FG%^2(:0"3=FM8^Z-W?U6BD);\H[MA&ZWJI
MV'H#9.B%2/BZ)F*[^O4](M+X"%'[+W8IB#P#XJC&,"..MFOH=</A_PHO4! 5
M%:2&]96J[H"FF_GU?>5G+DFCINY4YR2$MF0C1^V_&H:V]WV+J_%X;]]QAO;P
MP;MFX]TBJA.KA:J9-K3][ROROJM5%L66P_ QQK8_\=>6MAW0J_7!*!X-]5^Y
MMN_.X%&W$L,=$;^"L.,Z^9%F=+<488OCJ\<=N?;TP0^R\3:Q>.".+CNP)7?J
MV82Y>FHM)&G@)XMFS-YT-'^^_[,1SRBRX/ Y/O4CT2C8J3V9<8"I,="&/R6.
MK[F1X]ACAL^@.CEL;,O]]^Q$7(T!9$U+K4,5C>33D&&,9*0,<S1N;^R_=E0.
M/X_BF&K=%*>W*:T<<T'?2Y'! 8!?-D$+ZF7Q=WRLA:[_ M+<*PHQ&P2RF8SE
M+>:]%;);SY&P:XJ-"KA;/7 <C,>,%LO9U!;+;W#&@<BM(*YO$Y!3LTW1V<8"
M=&K0@H;;@11]A^O!*(E@(P/NO_C7#'2B@@;KXJ??/[RZ^NVW__,*0BY_/+FT
MK0^%SG)Q!_P\NH4H]=.56EOUL"^#QYLC8@];AX3/(8V/7YOD=TA_2^\D6*YJ
M$/PF\E#\R_HY3N<0_/Q*\AU@-JPRY(I$6*7) S/5IE#?Q>[,EZW:X$VZE3G+
M9I02![BI.*/K!Z9 4Q9E)FT^MMD78)Y7.55B$#$Y:&_ ;1M>HX*0!^E*FDL/
MXG3;^CO-O>H'(^/50'F$=B&2<?C#FW4K>RXF@ET('BU9=,0Q[DX1>=V5W.9#
MC*/8X1[XZ, ZB!%YVT4?Y77-0/6VY)P[]?V7<%]]4(=<E0V1E*XR1F-C%3?4
MH.9N-$@%Q;REBN2[2^M671!F8\[L_[VUO3;>8EG4$=D#Y=Q?W[]IE67!F90)
M1' KB33M#=MG8\GLO^#U]AT-$,DT[^[0=KY'0L F$ ?/@,125!(8R[[+HJ*0
MB:)Q)!##A2YAB:"0IH:%TZI!B?J4$0V]U^5R/HR._P*"-QR*Q+U@2C@#Y8+@
M&JRX7K_:TRAZ@AU'C(TN\P5HX#F\S0-'C(TBL_^B!Q-%85=3P6K,'6U6HV2W
MN!L^UJ3A"\EGUIOUV)*O2QNM)O2[,H-7^5)8?^#ZV('V%E&^K3N]Y1BP$5SV
M/YMI>(2!GONJ+LW\AH8_YD_S$\1\%>G:7_7:;)2:_5?![MA$7&=2.XNKN+@A
M-"K*-UUH<OO&WH:Z+-NNQJYO+& ,WD=>_X6?1S$!6!.U;V"51A@)8L'UW6\?
M7[W]]<_??WWE#U\Y]*_K_S#T?W"'+J+ J0Z@CT@FEXA/,D&0H3AN%ES8R#3[
M+W.!"QV7:CH$[)6\Q!9OPG=#3OI?_<#I&347^0^UJ(L1*#OJ. 3CB2 ^11AL
M;5M4.6CZP^92T./#$MRI8T\G#'=&A82UP-\0K05$0H6"R\)5FUFQH+5M92([
M@,HZODU;?YX,E476\SF.]V5RA=PZ(0'=V%@6^Y]Z'+8$N@N+'XUL!E-H&'S;
MNJUHN4R1OP5MWWV==6#NV%$:,B"L+MENO'''F0G?+LLJAJ+T(8&WB':,)6V1
M9>F=0CLVK5T3YUZ@GS"X<?VS$(/I4.\_V'S.)9OT7T!2@@N;\(4AN::1N2:;
M7(-;SLS(-?>!Q/(:16O806L&V 2R<823X,"P5HE8IB4$W) WQA*Q(FQ\EOW7
M )BI06H,O.%P,(3;BH_[T'T!_N&G+!4A\BDTRA,5G0K5CT(UG5XM3C#VB'1#
MVC<@+$;13@X::\P(;%:5G]FH#[N5.D^\H;:XY0JJ1YT0(@9HLN]MKSR;Z37?
M^JDJ1/_Y9K!>B-X2NK#Q'O9?_AU%<;/'YA'Z'\6Y[M#V&5*SRT:/,$H,\TM%
M4 :?-ZH976Y%7)H2$3)_5I5O!-V87A@;]63_S1_2'1 0QA;@4[:%?<;)S,8C
M2/[_^A=G,G[=\#808G]"LM#:ZY/[J0853!;UYQL;5[423[1J:'(I8=9_):!-
M*G*X:*6)S5IZB15[ GPD9_A]50QM,N523PP.P4KB'X*G&%/'RUD?@M9+,DE_
M,NR_])M6;RAYP'X7DA:.P._*O"HZ&[$B52+8-[)S@W0U=&V!7^S"!VZI(YRY
M6L]<K2?!U>H/SURM1QC^[K1LZ#@SVV$PEI....% CACF^RX-DIL0GVJWT86^
M%AK)L ))U$W]QK)0@B[S[4/O/6DNUAE/IX3N3(?V;-H8N^8 '9SPN? <Q_:=
M6?T/2RNIRLHN!Z?9*?%GDT>FRK]*M;V@8WY$-"PP[5,R<6?LV!R>7PVBW*A9
MM<9V5P/XIYV##=H<JN43):0EX^@ZJC9%:\Y?K'H2C(YS&;W3^RW<INHYP,F>
M4"YHY=_Z8J/V;5O?Q0T>!!K$IT[61739$OR%T#CI,-6[,I !GTL!O=_$O:/]
M1/TFJC2XHZK2L#;97Y-6J(86U1@NYA5?I,8L$IPK3%5FC(Q06.'@)EYV^ZZ'
MBAP33'HE,P@T"=W\ "_D-E9(I8((CD E_C6EF8ZMT@>5+_BZ@X[7=S5@3]NT
M3$=#%'^@&:PIG*F4$Z>!WAA8#6:DV4ZAZ\*;%CIX)5Q\M^/OL)' ]UT5JG!/
M=?S!CB[Y0-$P/:(:ONNVTV7?S[0F1NV!>6Q13+K_NN^:"9"-X+WOJ[ZK@'%C
M_PN\3JF@N7K?2T7=WMQ9<$*IU'#"PGFU.TMF(ZA_5J,Y0EIU KF4.[3=R1HK
MW<E \=SA\$2AYYMX.SBL<,3_P,7/RS3!D/EO>G?B<;1:OW-GYMN38:,$-'VZ
M3M\8(BDNS3JGO#=H*YI2.VI%% HY3Z#VBKI#=PR!2)&E88E88D%^&TP!!(G1
MX7#VN@K\=61N"@FKAK'<K!G+4^7KGBYA_N[]TRJZQO3^1MQ*?96JZ1;JO]+L
MUGHNM :! D->I31$5^\VK?8<-%^7C4V^1Y+>E&4'5XXWL\<3WHJ\'A[KHA8Y
MM4>'D<VNVZXF1VB8L'(A$&U'D!K)9*=9$V5TUEATSV;3)[Q>; N%R)+V5,W-
M\+.BSZ,E8%0YR3LP<A>":(^A2 VFT<&;=Q[KK6X:=5XN3<%O(<"[Z@%RRNVI
MIEMCAA&:E$.R))-RB1@FO#3;%R/;$HL>F7$3<B2J*G@0IS4B::$V@1&9)(8>
M*@TW*UUQ6U+)QO3FGO2^W.TUCRZXQL?VA"&\UM6:#CZ /[5]=]_+>//8]Z.\
MY)XPJ.*Q2M*.\E$7M\+(GC"4!XJT"WRZ9_L/GM-M-YIF@ #1;\O4 N:4V'-<
MVSO1<L>>,X>&[ACYHB.BY0C98E+/&QY=//RU^5HL*Q&MLW>I"!^>W,56AI$]
M.LQ/$4]9HKW4G#9S4Z=8+4VOYK\:5"H=#-.//'O,X+.JR:T!)P>,YW=KTAQG
MOH;-;&YTQ@O+>$N* PKDF-+\1C7-+M9[$(* (6VXX3:.:"Q8"S\LE\<X9M/T
M^5J\WNB4+63WSJLN(G''=AA.NI[ 7H$>$8S4IE)L^+*F1S" #+C IZ=@QF/;
M>W 6[_AF/#Z;\9'->-<X]C83MJW]PA(LO OL:[P*4CU^=LMW&4Y.V4;VI%&B
M]CVBA&26146:W;= CR"^>@OI]-70NFK-<J=4!R9$7D&<#VJA>_/UL,9;DW_!
MZS6F-%TV34S[KXEY5)70<K&4&W(GZ&\=N[1I&O<)7R:C[Q%DH_=<L%'\]U_R
MVZ#1N6(TB5612$_9J NGR*VRFK_1)-*_8$5?9Y*)]9-^G*:5KJ'"6#3"DK(Z
M"8WY'2YVW6'_M6%</RFC&;-\#11[Y^(&.&P4^PP4E)B/6MKIOP; 46QX$G0B
M PMWMNAMNFMK,+9['JD !N2!+DB!>9!%<VQ]R3B]XX/=4 39^U++^EC?H$6O
MN\/'(X%F.Q;"?NQC Q]<<O>ZE3N'N;<<S=>X&<4QM"4AT0^#N*C2T("3T=#W
M^R]]Q16F\K>;:&4D>_@J;[/X1"X6X)<@S(^)""&!;T"7U(G@,_M1_P6_WQ!'
M/<+4="/(T]D8,@#)UX&I<?I(KC#Z7DT@I-:(EG2P;3/IO_@W9$INN9FZHJ.
M<Y'O(N.K1C4>HEVIYSY>*S6R+3'IOPJ:TJ<U=+&(EA2V+"# 5U,<#U"K:^EJ
M3D.ZEA$,HDGF\O5+(J/,F&V#2?_%#^)Q5.R-;B)"BJ![QC49QV]-\@>$R$G5
M2DK)'9O"6+-@AI'YD[,FMD49W<J>I3'<#, 1UZ@H['.JE:O0FHB)Z/NU\L!
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M)$W,V7TA_.;SJNT^G$)R6 $9_S/=B:7IIR!H >2=D/Y4W(E.B5N"_'84&&8
MV#FQ6\.I]/F.PQY2J8?H0\+:UCMKX[@V_0!:6AZ088FK:B&M+.Y)AE5$A7'J
MP'?Y/#RGLQ:)*)Y DV,%C?T3)VKXB V[1KFH*FACN39=_"T])N$T.D"#W,2"
M;);G/4S@JZ:"I4(L[I871-@A<2UF &W-K_EAL9N!57?<$L)?)KG&M1%;FRYV
MP1Z2\GDAQ(I5-[CV!*P&!#=%D6!4"E+D=Z#)5RR@Y+459E'@9ZL]IE-QC/+
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MQE1 9H)J.%-C;^XC,WI+\EKR]"+$!ES!C=AK0&J"U>CD2.?T:>?@F=Y0XDB
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M5+6UAIVM3!X:(W#SF=8_L/>S%I'GXG9RA:H.TAA<0%EUZ%&U7-O&*>\HF'/
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M9&?.2&["+#NP,I^,:7!,%\IL2)O)04*P5P901+N&1QLUFNFRYQ9X)J4KD*T
M69L!L@UZ')RMY09(MSA@$\<.E.GIGN4'OB[@[95586%H)!9?&SV:Z8(7I5<P
M,-NR^ IZ+S*6BJ.YL6!<IGF<;IG)475Z]Z1VG#."N) Y$RKTT,KFG%_:.-%,
M%[T@K+?<Z%#LHHTV<51>:&UQX(;I#\(A.BP\<%>LV!OAFKN[NSN;K)A5_6K'
MQ08##$Z5P)>WLI %6<J ^(^I,#?HH-KR+>#OVJC*3!_Y>L.CNT\/17=O.5/W
MW@L@.B&5514%TD(#6J#(F?#OF3$ L@H>@)-US6?P,))D>K_1QU)FNN3[4;(*
M5.QL*+9/Q6RH6!]-8N"QI2W0:-;3[:2@8A&)VLV&+J!.@C[CF9^1RKFG^FA&
MD*N\):U4Y4J2I*25V,"X^[/0X$0B5UQ6E^:"K 4>I=$W^.P9S^TL>"?B(X6U
M4^FPS)_^ 'P*"P^:DOT4Y?VE-C9X6VPV+%P&FR"=(J064BFOP!-6-+:OB]N7
MPD@4XE4R7>\R=&U,6*:/'/1S:0FT>J!0-!-DS2S[P%R$"%8)I& JBYPYNA[Y
M 1CS[X)X25,XMP-1:TV 8,(^;$\!0<3R<E!F"":41:RBB"IIW &FQ5ZI;9[&
M'W4%O3;J647*1)#BY13"!E*R)U?!;0G A"3L"G^L8\F^82DU6)"Z)O$-+X#
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M+NS@\@E:PY$(6D^G05B.P=9P^GIZIZ>GAH%&X?F/QR#?P7A^WS=-4=0415U
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MR]$VR;#'7_[K",_N1EKL/=K!IA2V\8!%9-\__Z?SP]!^I)IZTBT)'3L:X5/
MJ(263^%&SFMQR\$MU3>DML!3V\_EF; 5.\5B%QN+!5,LIEGC@S$U7GLL]IV%
M.2Y3O2G,&3G,F4]ASF6'.>XBM$=P# :'.5$XA3F7'.;X4YBC6>/G8VK\%.8\
M8L!9FCJ%.2.'.8LIS+GP,,?W;&<*<TXP^DOWNPES0$Z5B!9&,)%S%O)H,)$R
MSN&Z,&9_+3IU'=UL#-,>N8\\YA/$/D;&Y"_MZ$1R&I*/H?!^N+2/,ZL_0?(C
M1/>!SR[P:>,;8RA\$'B//.8PL;=^G[F9?]B?;<%N53V3HPF=,1V-CNP" Z=Q
M7(OCVI$&&]?6@NQ@Q%2"17RA.S1'NH@KQ^S2"8]\:EH7CG<6GAO8_OEG%K\A
M UIH4/]QW*3G^[96?1FQV^$MYG:D(6*W2EIM:5RGMS2[GUDK4C&[6N08Q9-;
MEIE>LS_SO&&)*OT:WY"<_9N](53#GLL]N::[)[I>,XE:9*1$WF5>1<<EO93T
MQUW.[>!H'#ZTXC5&N<O3\NR7DA-Y"\=>ZC [(R5*CF/[&ES I21*_GQQG$]Y
MX.>QK3>51< 7-%D]8X=CD809_XI:KO.OEC#[QRS^B2;>,]W$@WOL^\.U*'TI
M"9Q%KDF:5S5^G39E8=T53998-\RQ"EGS;A)I^TG]]\R*JN=#-#M:W_13(-MM
M67Q--TQ6V?TH32;/UHA_M)TQVTJN?>IJ-E!Y" E&<:R>]PAS]$FR=V:^E+W\
M6,',DM_LDG3Y3=_690K#<R/:.LX1'5?P;4F3M+8^I=47;=YAU.ZWGD;(;\SB
MQUPT)8BFI!D!8U\7V/F+276#(1#^A?[>I+<DHWE=66EEY45M5<P9I.LT)GD-
M#B*#QP1/ )[D=Y:,I?6]["+&Q2M=@E\8#SM@[UV2&+NIZS0G>9RRQ!5\<%HW
M\',51CI,<H>3&_8AFE55,ZFSGV,NA?W/(^=U1TNJ3?&7ILM_P^*=FOT_T_2[
MM+ZQZKOB@7, K?X 6VDIRC7E%8?>D@?;^N=-FE$\@(3BHU@DC@&DPX+5$@+2
MJBF5,O 3Q1\YIHN_V8*! 4%F])H)/$LW:7U0I[GI6)'\2RO:%<G@."J(02F8
MJINT:D6,[V0?]/,K$G^Y+MFI)*_$(/$:_WO]W,T71PL.YOAG2?,;]IA,$_I6
MHU.Y<\<]H;-XI*"P]PG!N#U/!A&YEWMC]L3 [?L=M10C-4;/96$[S]/ 6'IV
MV(.MC-$?<!\I/>YG$<ST]^Q0:^(1<</M/-HDG@NWUHV9LIYU4NL3Y[R/H1:\
MT3J]I2,\O><\TD5XN.NDV91X!IF27?T['.+,L+23)/@NX)A'N(_S2&.! F 9
MSL@6QO?#D^L4:7Y+*U%JVS0U]++6S,57&'E6==G$-1XC2[PPZM06T$>^04J-
M54G(/0&.4J:4Q8()D] ]5B$Y.*5JXALE!&?28^XT*?"G5C1+*7L']A6PV>Q-
MBHHGO/ >:CZKYL6Z!!T8)&BE%L"<685Y#%/"#>23]AB5OT +;$_;64;FXV ?
M*?\4[-Q+]L68IK= V,/ODGR1N&!0"MJD><H>S;8^YM:6 ,-4DY&2#ZT\QS6:
MF]X14 1-DEN>SVY( B,^UMM/OV!]+:%T@\Y -4I)0\6%3,M6M C+KW8!WP_0
M*KUZ]3\-<_[K^Q_%GZ^[Q_^1K*HB:VKZ>C];_H#_O5X594++']WM5XN]-$VL
M/[UE_[V&BA8S#*]NTRI=I5#W^Y$T=?%ZG16DYD)03^5-R:(0=A(DKU[MD6A+
MTJDYM@PWI+Q.<SBDKQ:\I=7^[75Q2TOV"^Y^O$F3A.:OMQ#%Y-?L'=H/A()F
M,:NJ+:_OV&=X=5>2[8^KDI(OK^#?)W#_S[V6[4R^GK][$"UVOW$JMMY&9L"Q
M5-M;+G28%3=8#E+%AW[-,=GNO-7A]VO5F!\7^T$K3?[M13HGCA,EA"8K/PD\
M-R*!ZRU6\\@+YMXB3.;_[4;1BR>;I_FYC_!)Q'5'S=F+OWRLZ<9R/?O;J.)<
M6VRQ>(2]SG6.T]5](U%=-.AW!\<@Z0"BJ.(RW6)VQ!+[SS1N2O8]=FR_H']D
M^7]NO?^]@5Y']\W>KT/E(^NE/Y^OG7#A+X+(87=M'2S#1>*L_947^O$^H=XP
M_5Y&I^CW\NGZ#;]PI%;@\OC##;H";VSE4!8Q\[J+.4D681@P][&*@GD<1Z&W
MB*.$!O2H^CSG)SU^(P;C?U;U 9U\XOF[X/\N-O+=$\+/+.L; ]WHVSH6&I/M
M-F.A'XN^'V[E'[8+;G"*XYM[3S<,[MF#%[V6X2?5,H2NYX;+U=HG;A+,_=5R
M3>(H#JF_(LD\"HG9EN&?I"R)K(Y\@M^@S3I$YW8/DW7X%NNP6)QB'4(-U@%^
MH\'6X:UJ'9(%\1(2+A=QL Q<NEXR^2UC&O@KNF;!1&*V=>"!K?; P7/'3&XG
MTS#0-'A^<(II6#S=-.!O--@TO%-- XVB*(Q]-PI7\X"LUF01NG/'F0<!3;S8
MV\_SC#(-;S;L$6+VP.]X'YR4+.N](:4^(Q%>LI$8Z"K8JP$L,(/AJJ05U,PJ
MZ75:U;3D<5="LQ3&%[#8_N;=Y\JVWI/X!O[*7LG>J4+L'OL55E$F:0ZRKD#6
M\CWU@<J\:$RIZRBI(Y!/"MYZWY3%EEK;+)Y961'SAD5MN=;/1<E>]T] E_UG
M0]B1O&M63%3L.Q^A5IPG2#B$O< F!C!'4>(IQDU5%TE*\G:"0I?DSUXNU"WY
M3L$5_;U+F81)5A6=)J-4>4^I:D.+&<>J%K+;M(5S*^M[#JO9D'MK1:T;FB76
MZEZKV!??D]BAD=?]^\]_6GCN_#53VJ+<%CBB4Y=,?ZUBO4ZAU<0DR]Z.G10(
M% P//RXF:9) +P],%%R8DJJ7QU\LM$E_:;KT_UI2FM^!##_7[*_U#!_POXKR
M2_<WRW4<5]L(AN^<.W_2[QC?=/"YZQ+ZFV 5-D5^;345;Q=W6HPN4BBH=<.B
M&/"4%06'V-0[W[!*+&& H;ZC8'B.D)*<*'5W3*GKF@&4XF$2+9B[N\;7MSA%
MU9*TNIN1.^L:.JQYI;Y(/;CN?&!>@5F;[?W1,< 3)>]]#Y+?%QO"U5O+C'ZM
MI&L*/)04%)< C/0F7;$?PDX_>_T;SFSPB;U760/MP0?VI);GO/IPA.7M1&F'
MYR[J#QWPVF=OHP*)\I;%PM=4WU4WJW+Y!E6ELX$SZ[YHQBA8 *!; S +0I Q
MF \6]HGD:2N8BOZ]24L.X-D2'IBNBRPK[G"D"Q2TR1/*$P463&UV;6UG#WY\
M6'V/:^MB;N\'40=QSB"1(1=- "V6H(ARFQ]N:FOG3A#\ XB@C&PK^J/\R^N=
MECS^D(0 .,Z_LC<3F]_J4KZ7N);."W5U88?@$>OO A<?YH>C+P)' 2_!'7-[
MO\$-;(]_H.XMQ =9%75=;'YTX'=(.!/L%A3?1ID]],V2/_X#WX43VON>BG$Z
M=3'C(Z<F!?74'8QBC>'NFZKW\2QK&(?L5!QH5S[3\I9E/8/79YJG&UQ8_+ >
MN][\LNA5$_&6XRB)ZP1:W ]$%4-V6.[9EW#Y7=L7WMBWE;F7[\C6]"(!+=;F
M8U4U."[,_#U65JZH?6TC5TW:_Y;5; O@5-'5=_?MQ?<G3ADNP21PKP1>S:3\
M.MH?D8Q>52]U40UXH>U\?T*MBU<[_01\.5:^UZ+Z+;'_I&+O.X/!QJR!J$M?
MLJ5N>_Y>) O76EYSK$9)LBI08!8DUV6Z:MK:2WL(FF0:B)4+WY=,^75_^8>/
MWPXXXN\CEM.O,O] @@FD.,-1<^^UM:788L7;29-O"O0$G-QD33NJ"'/?GH*\
M8?U]L.]9AB_9"_2L^-!WU\H:FRG2.QCI(1@".P@=O$&V@Q^(]J8P[W@P J'P
MR='>Y&GWC.'D:$]VM,(*?J.O]0)[_KT759SEY&\'XBN5S G\ T*&F(C2A (_
M1@L>$E]7TZS)YQZ1JPA9A&NM2(:U*14L@&*E>9W6&7:KICSLT-V=W,/)[@$@
M?5,6=M#23,7V;_4+F&EMFQ(*<(B>N4I?2L2TZBTFIW!$J-SFKTM*6]$I#A73
MAJN4R95^I66<5JK+4,C#IHSL@&B9:K+\M:(MW1K)4&<GGWK \$U.]7Q.]8^0
M;LV=R:]^HU_MQC5$1H"<)^AMBU*_\?\^_>I#QM_:R<*V:?ZJ6*^G1.O0K9V<
MPN04=#J%Y>01!@,;!)!RBE;W-&>R2M]DE=H%GBU5 9"-LJ-]ID#BNY!I0FIZ
M5;'TNP*4?5K=T'8T5IF=@R'H;S+ZP?R[1[-Z[M*>CV+WQ]6O/57ZA&P$I0I4
ML-@_\VH-HY;]L+3<>>T90_T+DQJ.] @I8>U+<#K 0N*[G$GN)MW*8N1,,\AW
M2%GLTL2EB K3G31G/N'=;V^?:[<J,X#,FSSX 5S?L?W3)KX@ZK& J(.,,%TW
MATWR)SWN 63'&4&[%Z9^$Z;E8<<WA:TGAZU7<+5P=1^/74M:K%^V[J#\1K3+
M'V"$R(OF4\3UE[=%#GY$;5?"'$!.\4DHAXG*+Y-<J_$V,-020E$CT;@GP5]A
MV03)K/<=0H6+[X\;;X$&?6BR?9E@6'! AG_<V. 3A39'##AC48@']BJD;%OC
MWCV!,A94=^<<T[DP2;V1; 4O>?@.Z(#LOO5[6+KA.C924+_T;/>TCS1F4._Y
MGNU[0[<K[CWZ2WL*9W=#BBF6U13+<N=0#XMD?Q"T'C\@X\?!URK_JYS+M(5H
MVD+TH.)KVD(4.J-L(;KP94%/Y9P:@Q';L=VC);"!C-@C[ %UW:4=^HJG/\KL
MO<\UM4OOU=&J(@M5Q<)Y9NHR*HFH8F:Z"0M;8T&-QE=A5D=(ID[<_7-NHNZ>
MNAY]O$/K8#TO>CW"H1\GVMXOD9.OD.6FN>184!JB+-QFCKGB;(M;FI,,8%@O
ME>D,3M((P3E+A,6YO]96-'!"9=!A.G)M1PZDG&I+#3GC2(6,Q^NRV%@U>T0D
M@(0_5WR[^'I-X[HEH-YMR>T0I,CN.@=QZ]('=SZB-IPJ9=F:P]NB7"H0:]OG
M/" YV']:BF-@$LS)ADK^OI8'?(^N5MMVK<6H-^Y4&2/=NF@VY<6&?58@/]P*
MY=N0+V#0NIENL8\YK6^2DMPQ3S9#-\;TFL7'V;T^PQ6<F\_TCV"VVO "KA&[
M 32C7_% UR2N4O:0HC6^22LL+RI;#NYQ87=>Z71.H3LYIV=R3N"/9NV1L4=@
MWR$)D'1CL-*%'S+2W..21@P2O/"' @C_$3L(? XPAP7P$LY KVWKF&^0S11K
M#0A.I<%%F5DK=FUBW(- UNLT2X&T_[!(7\JR=+^,SZ("]F#L:C8E4$EKM*3S
M8+IESQ8" CH!8Q*X41A<;."@BZ9^5:S9C\=?:-U>0R .A^-]"/$'FL&T(J>\
MIH<K471IP6),<NR3_52Q8<$>DBVB$.A7P1L#%<*RR"!V;C+!@M_9,O'5HKR7
M#,\X\[X3.NJF;7.7<Z,B/LF_B#TS$-ZAG5"?:$S3+9/=U8LW[SY5+UZ^[K6&
MGMJ7=9:317I&OR^<.OM+48F0?:@-FNVF2?W< $R4+B7P'*/NS:YEYG2EGR F
MNB[)1MLJ!\^_Y$4Q!T=+UG*E@XPFUSAE_A)EM,.;*YK,.(..JG:(;@U*'OR]
M$KY%@T+;B_E:;4(.+G<[R4%,R-U-L1EIG66DH9O#3G"$A_=">W&:-G?JQYDF
MH:PKU+1JF9];BEA>Q^TK:'M8G2)+*BU\,VW0)H,4>%> ZIVO7MK6QST95U+^
M#T;*'(4^:S=)M69&9YP2&23DGB'=L\@B9QT!+.-Y]D+#YM*$)DVLX!K.^ G"
MA8V-LQ/,"!:?^U1F&Y*P_..F+)KK&ZZZ<#[B7':<G;;EE ;I+\R4; $0&J?L
M$6L8DBLA"[F%"G2[Z7!%X9_".(A.RH&?A*;K@9]K3?%,XXXY[^R;T7688JYX
M,V@SK>@-R=:R7K6B.5TS49*,#T1="3<G=TQ*5166^8#PA1*3."Z:O-8(4O66
MADE:J3P<$BL+!T!(9=*5.C"2*(N86;M2F/ M@KSBKDB[(W)L/.J++,9=5'FB
MD$5/E?"-DM!LM:V#&0F3CVA4[7/YJYLJ9:6;O<&A+.0/L)9R3\9R>2=I%5!1
M:[[L&J>^8;1Y+Y;;VYH ))\\:B,;:1X.O.<?8 OE?IZWI[2 9>=A3]?.7C=
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MU/216L/3;,L%LQX/D_F:9<<X<(SC!PV,B&>D[GAXB[94S_?6,JN^3F$E4\O
M^_G]6[#\+3K U^TI%Y<*(]D3)OO<(7.!65;<O0+ A%[$B+<T#3'R[PV+6(5"
MA!@1 /5 B;<2"H:Y]0\U%7XC^?=X1PWW1SJO#[\$O^F^?LGU\#\H"%H;G9X_
M*C;G1*7[E90UTA'_QW^\G5F_IM!D^$SR)&-__IELMJ^MMRSPA>K!7YOK:YHS
M*6PDG@PI7/'GB$(.@:#6-N"K8'"1V8BV:@&_2]LZ#X,$G9,-Q?&UDJ;Y;&?G
M\!A]/\<.PJ'9YC!O )=IA%:$L["]T\ZBOR 3QSU)1[G[MMAL86P.../WTCI
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M/>O@/ZL-[9;1:8,R&B3@@[G@8YK8GHIM_7+*RWF66*77N;[HSS,I1U28C<?
M,X:VALRP(\H>([M=V,Z)\'QVSYL2V^(P$U,F7:P-2Q"PFP=Z?TA=)3TO>Z,M
MZ795 U<+= ?)T5WV3XJP/9,2QTYT+<2<KT%C^L0-P[8IV<_3@UOKSZ]%OKMX
M9-1S*"$2?CQX!?N,!V(H8$G($Z9SE77UXN.'3Y]?O'PN?;G@''C@^&_%MT:T
M:PSZTGT3XU28*E1K5<#_,LF^^?R3(/L (6,A(BFVRE*?=IS\'WEZ;/KC:6=P
MP5GQL#.X>O'^'R]>:IOR/#O?V9/"^)]H3 2R.JW!4@'NA 6'6;I):\Y#-SLA
MU &Z?*B/L??F2ZI+%OK40&G^/-KG.V-*^]15INRJMZYBC$'%A1T.'DP;=G?L
M$3Z&_[3YNC=95<P@(/T?*KE^UDBO+_M%/-SIIPBX!J&&0N.6/7V1\/TS5;/Z
M'TG7C_QEU1<^>* -&&N0=K<56&73-+,0,L]?=89&;)85V%FQE7.&6Y#D^N.$
MXA9.##LW6Q:RMH$31J8L#@4V9WUX38/DS,2D%'?Y(CZHD".(T+;>MYV)7:M=
M63'[2#(3*_+LOK?^ITT8]C91Z"L2^+Y!@E;S'RRAD!1$+\'QW$P<R@)TA1+^
MJ+1>3ZP(SI3K2EAP  @%*;3B"!#B"-1A)JI7&O'#)M%,<;L(=:2QNNR^]PA"
M?UC0T'.M8S3; ]L_3;5/+A$^W(-O*EF*T:7#)K%WQ3@YE)*N.= -#^PU:5[A
MEZXY./Y#23;TKBB_6%>>X_HO=_+FM\"(5-<\9O@,?8@"9QET"=DD=JE?RFN2
MI_]+VN@6!/0;\_7)'8L6WK;<4=:5@#^]_>7S+W*4SK9^ZMBYTDJ)BF=JOZ>/
M(L'+H4O4)C%,#3<(,%"^AQPY9")@Q2J$78=P#[I$/.H,Z:D G18YPU$DFF00
MC,IQ=#KUQKX^0%^)*$N,,8,B8K-L&VNUW\<I3V2L/4O#-3"))*:]IC,![A1Y
M*%!S<GQ7FR>Q=Y'C4&(K<G<R:H%'A@P'VP2XD!JL@2YA^P8)>T5E>1#<3#E*
M(!L]0BXW+)#EI<U1B,T!5'5B2Q#26*MF3Y+!'LXJU9:G!J-RZWS3(N]#SI4O
M,FUY+XB5D?@+7..K]*6:>*6;;8;W>+]6R$N "L9"EX0OF&'D,/20N:>K3R",
M-ZTP7LZ8))DH<7XXFUE)$3<;;@5Z8J4"<@L_..L#.YG92-GG4NI?N@0<&23@
M*YD@O0&E2X&_@<N6";=JUMS?UYT0<2MO HLVUBQ(B,D6"]EB"_VFR6'A4'^P
M.Z?PDT"8RGZT:K:(H],EZKE!HL;5)4V.C0)!&S &%VID:Q@:DX'?.*LM3N2F
M;Z_]@PG5U4=UGS=4#5MEAO?$+UVEMR_E/5!YPI^JP@N#5+B[^1)_.4/9)"P$
MRXHM,O+)5("T!L6Z^CO3^)H7410[@R00U<,.5)>$EP9)&#HEN+8M8Y&5R-Z[
MZ$&QR'F#F3YG,5M3+,*03.S^9A\.23ZW3*S,'&=P/-B6W\W7-(DX//O([Q-$
M_"4O[C*:7-.959<20BRHD,N42OH7,-<YY?$;B"O-^6D E08S%L!J<JB*>PU&
M)L?F5^M;=4G9-4C*[_/;M"QR#-:T,;>%P:4RMPUSFY_X=!*ZF?=KID5UI4P)
MK)UY%(?APO7G- C"U<I=K7R7+-9T'D9T[NB>$@A'[5B=G&M]S.58 )6M9.&/
M@ SV@!/I%9GKHF#9E&(VB4!L0$"[@4XVU=E)"4WJI#SH%LY91@EM#1@B,+YC
M@*I].SPQ*#T4AK(T5#;T[BDI+9I#4V2OJJ_/G"Z,JEOS:%'>VW&..=+ 2IOR
M=M<XH^%.,'1)V=YSSZQ54V-D#N5F1'5B>#036SF!I13XM9X'GAF.&L:?K*R?
M1)BH-H[/F^9K(?-M2FA=C)'F^R<7I5$+T[PE<"0<\3X"_>3<L9='UV\.-137
M$/*P/"-F#[@:8<[#=^W@M#VB]S_J\DZ1N[3']$^N&YQXYQ'W$+T>X[J?MICV
M;RE?LYAPP"P+0GYO2,8#:7F#6#)< 1MM!GLM8@XU8FF+>&$L\?RPO%39,W^4
M,N'$\_<=>\QYD.,L<X<:OQF])3"_G"=-59?W2D7A-0A&EUQ"SQ[3%7[']^)7
M!#3CU6 /6#8Q=#< OX2#4IS/MK@NR0:'\V S_4U:<BP$A'2\D@0UH;*0Z_:@
M>B16)^LZ_U$GU4Z]%0IFX;ZJZ0;;<)Q,6>G,8=-N%V.NJZ<<+;U1#<GIZ_(D
MVEFVRP3^8YQ5P L=,-VO8_6+/"^P3QWK(<EM6A5EA0L&E)VZLON#4"CHX<O2
M<=MOQKDU2BKL)^MK$LV=<37X5$J$_ 9#B)-@SCMIXT1/74STU"=>=5WTU,$H
M]-2G"7OAV?,Q?=K1![R@"/#$<$70RHF0+;O'J4((Y?+K/__)C9S7'!7+7GM#
M\^H03 L(&K(,WH7T L.85#>]F29-OF'I&Y4E';#\L[W!S))>-YG,,-<E:1()
M\Y0 C8)E5I+9 $Z@XALE\#!TL2(Z 4)E3)&LHH.("5[1'@X.R277<O)%C-1)
MN(%5X/0Q;NE1$%Z8XJ!X4>C-%G<UZI(ORR-'S6-/SN]!*4MF$R"NZ1!Q[09Z
M)FEP]M>=Q'Y@6:(RH2S4NBAA6O;W)BTYA'NFC6$Y&K5@]AW[!&2[K6I2PDTZ
M$OMW6L$AD3R15=U 1?EF\52,5#1\998VON?(7AITIQ"E= M=>V:3(!B6V%R8
M"6.!.)=3A]&UK8^YF &&N]@E:.HA*&5- ?+51D8\M\=LZY\LW0Z"!]9>,-W*
M F\"(^DU^@M1?L&J%:Z]Y&T?T'A.%"3<K=1PCI>6/(#:6(@7R*YFBG1W.,VZ
M[E-_0$??W5XLIY#_^4+^_1H/+V-@WP,+&1U$N*;Q35YDQ?5]"Q6L:"V8[12L
M,7Z#ESTU5H,\QZS&2,Q2(18V$FM3E.IN>5D1HAU44"Z%%1")2E",("I&8C6!
M/V>_RZMQ0-MS7:,"_[93QP>M*8O3KTL"T*&VY*YV\""F7[,3P5442HS"':_$
M(L5DR[D=F??0QF?F>UB@F2R8=@N&&1_SZ%EQ+R^:TL ZAE+F>2#[*EZMG%J"
M-HD=F#+3DZJ0JR<3SOKC-O9/%"\S.$F)4_:B:'S <#&1E45S?5,T7'J%PIO
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MZ_I3=#DLNHRFLJA@_2=?O[^8,IIR8]-\\!133OH\Z?,?(;"<E'E29LW!Y?/
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M%9^?"LE/ V?.<O)H.J 1=76["Q0F0X9:.OPKS;/,LPG_*,CM@S1+FQ:7T3+
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MQN_'1\0F@EBVJ-)P9>\:F=YNFW2FMZ^V?4+V';Y"NJ T0+P<LW1Y]^OP7_F
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ME6EXQ,HG7-_LQ.D>BCTNQ>=E?S%:$.-E\RM34V &7&_;F5B)O<H:N56E[:2
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MS9_^&B]F\";>#@DSKNP.*#N9C#_+''V#&E"7=FG DP+4'52(=L<4(F8.5;?
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M6/?DUIK?0H7$LBC_G2%0[J#>^P ]R1DIA5=)FDQ:0<Y_.#O]S,R..T^_D!=
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M-(S@?:2+T?&:D]A[0IXFU!OH47JL3GJLT?)8O029/U/'G] R[F6U.2&@[I<
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MC +-)OG0_+WV#.U!G8J4AZHU.*18MB31HJ .CIUQ$2^G[LB.;;FV-E8EW=&
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M:LJBV4+NRMVK,"YR0J97(#LX4), 8>X[*8[G($+AU+2V)^5 J%O"4>) [HJ
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MQ@-K;LE(C'<95#7$_$NM3*"H^W<'4&,"1309X0$=IXI/-A ?A()YL=??;Q%
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MN\P;+XG*C[T(S) 8&8$ 3+Q$"$?PM/%[ZJ]%/BJ M4'I3EA?- -81E<M<X(
M5@6\P9- +>IZA7929B;]B,)G+T92[3J,AK.Y'[X!\"V5>?$N$UUC>@0JT\ D
MB&)Q8'8:F =#62< 4T>-K@8'9C6Q+ [,3@/S8$#K!&#BH>';K19M:(:M/*"E
M\&98DL&I.<?5'L@ZSO-4J'?0=,KSU+H1CSS.\Z3/&UR/[M 3!NG4"8/JU(F#
MGN==,@71]S!X2D T6PFV77K3[%VH)Y5+\.%*'(=-XY!51[,$#JW>A24S&_%A
M&X@$CB4'8CWU^,T4+QUT+-\%8LG2";MWH5A]2^-3EW:B3..MR(?!^"V,HO"E
MD7%+QSF:&O5>IDXYFGI7 [8DCB9]WN!ZE9WQAF52G*B3+0SN)EC5KOZ^DG9E
ME:TBH0F'NL'L+CJFP4OBG7+P=MDH+I,&I0]>&8+7[DL\5UJ92\O1V^784IE<
M*0%ZMP&J]"YT_:2NG.XF3'7ZS>?=\V,OPP"?\L@'@A_"+Q*$20-= ,?YM'KW
MFJ98\6F9CA63^+3T>8,K5G;,XG=\6F?T_(ITZF6J.PO"[3N4;?$MDFVEC6 5
M&L%RW]"8=6&9QBJ)"\NQVF6LON/"5H)5M$]#[:LF+X:HRF'E6.UR4=([#FMY
MK$Z\5^">_0=$X2Z8ZKT+/.A*.6^EZUIY"M:@W[S>/=?U"M[#,WS!,Q"\($ZB
M!6I";4LZUJ"^,IF[KFV("9.XKO1Y@ZM8=E1LB73L2L)=>X$3C#W'_[X:U5%&
MX1I,*-S6HI;$B>6H[7(118D\;!G4$KBTJ+:_;RC,>K1L Y? H^7 [;*Z+9&"
MI:=N+2;4+;NI69-/5B*8K!2^.7[R)HS144_@8;<G,6OR>4H\,5L;;W!URTZR
MARPQFXFVRX)D*VT7H]TU2E]A=\ 2TT@E\6@Y4KN,5+*T+ 6DJA+:@=&7%%Y
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ME1(8#8%5&5=KU+&2>8=T]XL.#B:?4B""RS!.R@MS!0ISLV^9>DOCVLVZ1QR
M'P" ![-+)P%0A5Z0T;?M2D;UM!> )$X.1Q_O_SH1?1I$GRSW3>WHO"Z[J2.%
MSP4I[\NDFP-.\60ZET*JR9E1>#?OA]_@ELGRXT81VWKOPNSK<M=VN-7ES'
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M'+'U(58Q1,4FTM*6:,L4M/0N^"JD\"W9TX:&^>I27S.W>\,YOJOK+3^8V>0
MKP_@FH+C:00J61,-BBI9/0;3$^\5N&?_ 5&X"\Y&[P+W6RGG',XUPOE CQW'
M<GW*.JT*()B9)HG2_IEIY3K1->)6]",UM=F[L)2^:4KM'A!1'RH/9W@Y,#\
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M):WMRS8:S+9PO-:&5P96:FPG7AJ"K/X^9+F.KCYSPU'?0AOVI+Q-%3B?>*_
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M;5.\*3LL-\57XO([%9Y6&3Q;OJFDKOJ6P%8'4SCMRF6V&P85BEL" P(#?<9
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MYC43G0>B/^<= :1BR4E@1&#D_6*D4FE)0$1 Y-U"I&()26!$8.3]8J1"&48
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MMDAGZX.1I=E#6Q63A1R+= *]_2_2[5KQ5UJ+_Q)'\VWL;CNS!H:G ":W4IS
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MN.NH9,6JJPQ-5Q<XKQ7G%4N; NBU&>AF5F%9"B=L:X.1-M3?MM=*X)I+H5:
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MNB]G:U!J9T?8]SB:!NEO&'!'-YU80#EK#VV#9]=F.P%V(%4F -9W@&T-,?$
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MC8L@(D51[SQT1X15Y=6$I,I&M08_0U::;9[]/=>$M]//F1K\0;7@?705X=_
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MY?J'1;EDSZJ]Z%Y#DOV27,\&HC>7N7VQ&K0O! EML"ZVL=:B;M61*;4A;A[
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MGA2PGH/T49H\QE&(78H@G,Z\^9R^(@X1($Q/9$Z"<(SN"P)?='R>V J0J)M
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MH%"TS9"): O;"I?%\L[*C1M'T"J*7]4/8D22Y1"8[X9PC<5L1Y,U!C9VS_W
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M=X.:G#<4'KR&%N^YIJPPX.;)1[!I%3F?PVX@VV_K,HMU'4T4*FQ+/M#:T]9
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M/RJOO+-JJMT/F M;QS#@,%9(=CE!]!N:3*;F%?F49Q_"0UI[P2\P#Y;SY%6
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M<)5+WW/:-6]R#S'>@D /RECA^OTE3Y#P?<"S)(+37?:\J_[VIEQU<>GV8/X
M3NDN#)1%EU6"WC\$LX3NI/0FJIG[L:+,X<[%M4?FN(69]4/63*[1@'U1[->3
MBRBCDS?.,RVB>$/;G+3!6W%:66]]=0UWW(/YE6==[QO_!]3[:)^03P ]G.A6
MONH,32;Q81B(TH'/P[G7B'T7>"&UV 33:A!ES.8Z(Y!)#\:'R&5A1+TH893)
MTK*;M9B)@_,/%^%<+?*MU<@/SGV&_G!!8MU,A3=##EDM$F_+*R#PR;"FH8MP
M9W+\9FN9I+5CS(J5&-+(=IRT:5R4T0D19\'?9?6O L@24L>H1J8%67VW*".
M,DT0VD/=D.6'J%+D8'_^%+,S2JQN;AS:?IRE%X2E%X2EPR$LN7U"6)HT(BQ-
MGXBP]*#<GXBPU,JXY2R)@O8L%0VD.J:C(7K<^]GAY-P6QI5,K%:1E47.'F1#
M!:-;[L@ZG*[ TX3]/;4/+_VV/14E)^<8)P2TS<?BC.L2:'_<RK*H_:3O9(TF
MIM5&^GN8"UU'5;!:^>@E'*8/=BU=GQ_^F]B6:[:QXE0.&'?P%;R):;= .(7F
M0Q?@3 ]R$%SKY=>4#.V3B2H'.)]PSR#_@S\IY5O0"_B3/LV0\0[Y++&6?1%
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MW.>U)F>[-J=.;V--KMM=,&<XZF1:R#[\,ICS;*:%'-MM95IH<Q?LH[^U!T;
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MGXH#GQQ]^B\^NN=,"5J3,WGRK+[<+^7U3EE@^=^K*^/T]W^>&;^%RY":"!4
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MY,UX/!@^"UI7C*5::9?C&IW<QEDAW@<8Q&A=]L[A#JDQIRY#,^UX,^+%T/R
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M(T4;"S@\Q[T1R>&<9"A(=/A41#DEHU5"XYY(J%S]5VZ^:7R*H[78<5:D!7%
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MRJG.@"$T&MJG&6\[*]8/27QX,UL8.O6PYR!G-($+I /S2U2,N%C.& '3$X4
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M]@C?'VBYG7G_]^'U]::LSZ^CO=.2-<!V-NZLAL> R%=AT,VY-Y.QR@<PF#S
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M-9?141G%H#8QS.5Z//<F4LQ\7H.EKMLR@R)@3NK=0"Z;4.\5J/?;.'WQAC;
MZSB?1YK<BRG\0V3LA=(/?[Y^<8E,N]& YRV]_$YT=5LZ$%/'IDO$^0B/6I_P
M,!U&AU;/'Z-[P7'F%!LR6=JH1("DHW!)52@1]I:(\RLA^<?+S2O_9^A6^U-,
M.<V+X4Y38@V=&H8I0P9QT6/*?*MN:IMYO]SIQ;_=P,\K#+:.N_G"NNU*;]X^
MLL"Z23</E=Y@X9]0CET#2DPV*$FC?_+L!+@.[F!RN+_)#A?/V1*33<1DDUHF
MFQ@=FVR":?_RR #5-LT[\5;(MI[PK;!V"=O-#SS6'=LR4=D+=8?))1]+T>Y
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M-W_A-B+?+SO]^#3?SZZ[9A?+D67S</\,V1*]^@?\/T/6NK8^'*8J5.0 [D*
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MJ3Y9ASA3ST+40WR$?W(G[LO8#39C0"(.&6((X#)!=+"'2W>"C?/YJ\SI% ?
M;O\Q/IP@7S=Z"UI9Y/,@&7&E5]<))'<Q14909JFE%P=9VZ^21WQCE[P^:UNE
M3:L5L<=^2A_]<(7@X<]FW@2M!'+IW "]@M/NJ*#]N^,MT/)Y"^D>[0S9!+P!
M,MX3Y%N&Z'[S]L)]07];XV\+LB=T&X0OB*X8IM_UU0F\D-?^:!UP5?YPG>F_
MUDZ !#F4YGA+)/3C2Q]K;*2,8E<"+V<-&E=!#G!-9]P;G7G.^,>ORT1X1\^!
MO_[^_)B2NX?99_(7M(3D$'R8?3OD".B]@0&SG-IUFW6X-E5CL/+2N]!U$?21
MWPN0P_A>Y@1$PVP_$/./L26Z,7_ZQD&FT1UD8=Y)%BG&YS3ZL>G!:8/,#M@9
M7]"UE^Y\[J$-V#< DE/NB_-*EG&X#+QYM$5I.ZZ/C;^?Z!KX.]X)<$'LE,!%
M6^+,DT-KS\J(M#*!$J?ML3M@:*2TC/3)"]';D>IF"Z1]'&&G!EV$IXT!E0[8
M&,\9&Z,OH1=-GN/M0,#YZWKADIW@=$1 >)Y'A+XOV13'PYXV>D;:R%M\YR7@
M:@>.!N=[X$;.RD]O]4Q6[?K^\:F.N!#R28S#50-43_3N%DD! N@]>1$2AFOT
M= %1>=+3Q$/_\-#A)#VZ(3J_)L_OJW]25;5DA86-&L3/(,V=,7ZI'WCH3L=(
M2Q'-E#[VWT5:BQ,2] Z<PNA_/SSDMB"-,\-VSAIII4A-W=TB0 !#"I_]8'6!
M?<S8L'%_N2]+\AD[YA$V4B,+2'*38H;H'2&O<!@T.G#8'FO[Z(F>CU\5GQ?;
M="7^&_[4EQ<O#-'GXK, O<7'M1 N>LG=:+M!X=[QG2VXR$M*;\HJR";8T8$0
M.<F>Z2B*,77<Z5B=:A 8C@:@-38-J)G0TJ?F_ZD6[#$7!+N&0VG;><[,'+81
M4LA-DZ74'5LSII:CV?I4FT!S;$Y,17=MI'@T.)M-,I4%453B?HV,7*3K=R,D
M(!OU1Y(WF?LX;O<P>T!2$T1QCYM?R[FSP'KU=1OX,**("Y(+=SI<Q;_#%W7#
MB;-$EUT%Z_T2"YY+;EBR9MJIK_([0)9 FGD+9S'QG'EL;&V6>&=Q$P'.+[&(
MER9GP2##P@L5JK*6%?H20G";//L!03!SGLLL$(2XY JJ8 :/KCVL027G2X)$
MJJNDJ?]S@<^[F3^?^S_#R],$!"\9M2@<SAMB45 UV3Q"_UT[<V\<>/_Y1LD:
M^<!JE_QM"^'P@R,;3,\^>.ZZ*DE]^.'[C0O?--+MGQ3FDLK%30TQJ1G$A81S
M9QFZE\D/5WNE8>1-23&8HOR&&7*B2L@,@8ZRPYZS+?R+2R^UJ$.U]^'0JY*6
MCX,O4BN_2CYCD*I$3Y2^2&JKV'$#[:U@63H@D"YG3%V55ZFUMT(//'D3>J8B
MJX?JEFF]QRAK%&+_*<EBD*RWNP[\\'U!D6^JNCY"QMA?K?R72Z1%DJ+:]%J4
MXD.(5[P(OHQ:JJ!L;NF?:FFI2M$;*;)M,HA),:9_:LSZJ++.FOZ)S2IAG=&8
M58*:;# HBL%% =1:X4C4?ZA4HZC@X'((=2+4B5 G%:@3^FELS58G5A%5G] H
M0J,(C5*!1BEB[LQW3.,(0IU4MK%OS-AU5=-0J,!SK8"K]6'T!P+"[=W]\/[Z
M;OA9&CX]W8R>RO>"QZ<$T2!ECX@//&2)[J+B,?(^\638\QYSK$$^L(=:S;#?
MJ51EPV$]_>$L<*E=JA+F^O&!9"9P36Y80@<P&_%8&*K*;CHSJ] 63$!Y=!"&
M;%E4=!"VK ,E]76X1_R82O4WJ-Y(G?J]O[A>!X&[6"4"/O*16%\G4OUM@1YU
M$K4*#TG$]NA&+:LW + /S&P-^ZFL$#CURI".A=WTF"B/1K:3U!T=Q0:TBTL&
M9$ [F*R+#(BA"HY:'J0&*-J"")[0LE7SK2F46A8=D+RT[!O4:U5I6;LWT/HV
M9$>CW 8E:YHGL*YU6,]>@"+[KVV*MC"V*73M&>K:-WCI*]*UFH)UK6&PHS4^
M0=<V-I2H:SQB"CMH[$I,X9-+WE$F=,!LZ@=5Z&!W;X6BY:MH:4,'6N6A@VTM
M[V=_\1TW:B2BG*<N06^@FUI3#5-V=,"EO/]=:'7**FV*]\]LCD:Q]R\4Y9DI
MRD+B=1I%"7L#BR%Y;AL4Y4D>?(=U96,\>&;*DLJ#%_KRS/1EX60Y&GVI]@:&
M7:N^;&QFWS"$%WY,ZUWY6&<#&E&R&R\T:><UZ:'L/A'M;4#TBQ=.W/G<6;C^
M.MSKO,W3KYAB%3;6<6](VGX7<,(8Y9A.JKLS1^C7,]2OA_+Z)?6KCO4KNXGV
M;="O)_G[0L5V2,52Q0.$EJU0R^JT&7V]GHS^45HVG<J?>;_<Z<6_W<#/T[[&
M=BQ@&R,(O//XIL6E-Z#F\ 'K?J"1O\(TF(2]![WB8A+)Z-N<3F4[A&+-C&Y=
MFOIK3!&3K!7+II53HP^[0L-(;]>LM(G(-$%E:V!KLS2WK6 ;PDWT=HR)@ZJ:
MHNK*)'T$EEEJL'!J#1N2(#NJ(ZTN]%,XQ@+ZU4"_"?67A=ENQM"W>@.];X-2
MQ>T"^1S]-0'^\P%_8>J6,?AM#'Y5M^H$?V/SO#8GX@;1P5TB>A8KKWU%79$/
MMBL2(G;6^=C9H0SPP5:8(Z)ENM*(:%D+\L&[\!/)"O[)"E[JEL+I%;KVS#H/
M#V6#C]"UQ6:O#GH#LZ^!4F9OZ]3M2>EAH7$[HW&I@@U"Z9Z9TCV4'&:K="%6
MNB8P148XC]I4$71QG6WMWMM<H54[7]A8F+]]PF/XTCTX]_[J>NZ$H3?SW.DP
MO';"YYM_K;T?2(LN<BL<=;4W &IC*QQYIFVJ\#X%9L\-LX6)5P:8U01F^?HO
M K;G%J$O3)D>#5OZP+W>B,!]8Q.H '#AJ^JD4Q,-J?06/]QP14;YMJ#?@-+[
M 8* X+QB2H5MLW%@Z6XK[4='DXS>P.XK>JF"U=:%\(_/F.Z!3P3P6]W?1>&V
M"F5[9O9O80]MD;(];.*:C3!QVY$L%<JV2\J6+MX@]&V%^K8)K5F%W;0,C%L\
MUD7M&W:M!2K-S95"+@1<76Z?/?/6V3V)$3TT7>ZAH>N=O6;20*/;. P!K%(I
M'=$]Q\T;%K@_']S3-<ZRP;VAX&(V72]%X"=PS],Q$] _'[H,NK991M 'O0$$
M?0V4&E'4V:99H IN(^IT+T-W+#<L=E@WU]=&NR<D0CEW63G3^6-EM3)$6AGV
M%;U6K<Q>\1989 U!/8TK)B!_/I"G<\7*0IX4P/<UL]24"@%YKEZ80/WYH)[.
M"RN+>@T=]$;?-&'M[M>'U=B?ON+O#H)6[FO1'>(U\A9K)[K%E,AO12ZJ.T@A
M "A%$-!5(*O;AS!BSR^] D?*/?G,E.![*P3_R9OU *I1W@DJ9 W:JQ.@7#R*
M"8*:;'!=O()B"B:+EP=QOK>-?#MX>'&I[CS9]>^!@P=%2]Y"@@J$6!%(#I(!
MG+9<IR9)2PX9)2WY,RGOF3?:WD+_':OMB; <4>MMJ;+.I S&4@WMJOHMA);-
MY &..1> 4NM(<8.,@N@#*]MY+JV>_77H+*;5;X2JZ[*AE=\(:5;#O1M ULSR
M]X[P/D&:&]N:Z,;74P_=IA.X^!@8N^A0F.#J.XS_%=HH5W(7T[0...I,*#Y0
M=4M6]):?"7B5-@LY6\41QCE92F1SS3WR9NFGMWJ6EDX87JR>D6_Q_1D!-ER%
M?0E=</),MF#L>HOON!W%]R9X!]#2+QT/_1#N[-3$"0(/_=U?KV1I].R&KC3W
M%]\O..V184<^1ZOWR U>)"<Y W\B 9=>7"=<QX(^<[Q ^N',UZZ$=@J!8^7%
M&_A]03ZG+ZU#O#>)6I30IV$3REE\Q[^>!?Y+[C')VS309 ;:[,UC!:GYL9LY
M652HIH\6;>=D^10OT"-:G^%R.4=R.O+QZ,L1VH'DL-F<%Q=P>V 8O8$BYS B
M_U;#NAK(S6:0;\ ZM8:[-QG<^M$RH?&0";,W,&60K?.I0R9L2[88+&R?J'6L
MQCFI:TN1M;:KZW ]#MU_K9%].G_=4=3(*0E6Z*:FY/"4.2VA;<I&VY?PTSK
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M[<?TI:E%C"(C(>D&-"Y>T#T]1^;<-)[N$X?@?&GAKR1L7GBSU]@_F<13?^(
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M@+ZJF0UT+A02;RY]7I,@%2<HZ[ILMAW*N%M#LM^3$V/JSEPD8PB5@;,((TE
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M']?8F3T:9 [UG=G"-4!])_G*!NQO93>J,B2/#EQEMY:-B9?:V>J/Z%V.F>A
M*=M(P+1C?#?Q<WP*72=S X&2,P^TF:X+[W"($&/V8ES<J516C(W>P#+[T&B
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M?&T/E=;VT-G:'H6<IJ>&W_3>0 =&W[!R)N\VP]!H[X +FN"<P&[GL4O/B,G
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M.'PREB,)Q:6"=-([M2N,@89@*^YXM1XH[#4J$Z*#H#=0S;ZN-];;;R^#"4T
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M>IXH>_F69%F<@[58RJOQ01 F;U G@8H;=0^_4>2HN%'6A-39,HR(XQ>5RWI
M@[)RF@.WJGQ.IJ.AE4;9=#1A< [9TJ^ >Y&&7$HD*H$X1LA& BS$/_[F(Q>?
M'\0M0!O<@HP:7_K=IG3.Y>]C-)?#!<'@\VO^]>,TNDV.$=XE&@+R:=2 -@2S
M2/E/'I)I1@V;@OWR"R+(L?O55B%K-/X1<>]ODK6-;LLZR5K 9&VS)[YJ82/$
M*:^Z<@O;<B@JV/V#_NDGT]XDT1O=B362:,SRQ%O"(=42S7C  D+H-C/N3]&
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MQ,YF3=>GG<G<% _9V%OB9PJ :[Y&#_03HC3+Q_%ZY_E,Q\G+LN)ZW0%^#'G
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M+XMH=V;UE[IEAT]/(^H0L+KF;'H)4P:=F5\PDL:X(L!1&RB(P 4[2@ =B#I
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MLR8)O<8@F18[-XQ89J70Q/FU<H^77;G(U(Q&R2!DB1I)N^*Z-CKU7:&K-S.
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MRX\_4G=P6BAV]G,:Y2'4*P8VB!/%1I?L!-Z^$Z0E4#Q<L$T\3GFC6<R3#O/
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MT\E>1^O,?8<FC; <0C?J% (#ZBHM>TY;;A$6(8/<ED6E\BA@]BL=1KF1UW6
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MHK$&I)) ]Z*SWD#F()48(-<>R$1;4@ETZHGOMY%*#!1K'UW+[OM5'C!#H$7
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M38VI1@U0#*X-KM4Q5(C^W%*]$<[!4#$(K[T/KF\K4.(:UUPV1<4 O/8F_%B
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M-74@H::NM7#SU=1K+]PZU-0/$.YC:NI 1DU=;QGGJJFOR;BIJ8O+/KNR:^I
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M\76<_;A,H^B*OB.-LLEU..&TV,MR[#O,"X6;)GN?'.O,G?)QT4+%Y,],_DQ
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M$*18UV]G:83'%9!)9QO>\(KJ;-T8"@!#5-=:5&=*$-49KR>JL[H7U=G(' H
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MU ]76\:Z*)U&M$9*>_C!P^,R>@[@XY(AB4T3!$P''C&CH+LB8'8RP6\[V9*
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M%%FE(V QT!O(*IO;;L>B+,I=[]&>MC/I"-B9] :RRN9O?B"K[-+:N2BR2D?
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M.-+.P/91UYME5H.N][E#Y6A,1V>/=*CLH4-U2#%TC0MB@NC$BW6+ZJ:48V&
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M&OTMI9<Z,$YEUH]3636#MV=9*$=3K:Y'>#^*V0$PY.!OHR=L_B,\-@ 6GO@
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M$V[YBY_,_7\ITP#N(*".WM VCCXLF8:-+>!B$FSC6$5?T,VQL!4-;PV;XH>
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M(V]4.!&DP.!0'0;4$R_@P]P.Y"[M+27^G G:[:):ISTYF#-T".8P850M:92
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M<7@'IH8*/D2QO+ [33J>O/? JE/9"_+G2OZ3//PYPM4]O,5TRT!MH2&!+XC
MT..&^U.88DE/[[<!(@DBW-9JE'*] 6'=6:&J?7CMO#$[($-#?>V7^[YLD2#P
MBNB 15K:B:NV[+=$8>HGE,B<9J;1);PM?[?%G^%VTVFQ8NN*WC7?.S9,U7SE
M=TQ &C.-4I5K//R7P7Z/LW@A=W<U=Y[47GI)4J(=W7Z?+RYA@,<L".%[Q::E
M'G9J_;_B9#U-@G^M(22$B&5G$(H@U95@F[..V<?/W_*KS0=H=W%%<N1(D(5Y
M[#]A&&'E KYUO;Z#%U.01E?_.%^O9:N'MV_Z?[U8AW[W8U!CY-(I'AKL%Z%I
MIGGEP/6-NGLO+9;''4\US!*9)H.^[_="Q)79O;^Z"Y(<I+3DH)["Y3)S,?F<
M3G5"EA?$K* =,7:%3#PYS VY4COBA^4_G]N5\B7ZF0V'9:;OHBBEYQWYFJ0]
M=Y W)'T?;^^35@LFSV27O23"66(?\A)=2]./>%#Y+Z<F6B59B:]09QCC!!U#
MI]/N23A7 DK""2)/4+@@ \=7."Y7OHK8%CZF?T?8P0K\2^PR$T*"\,\@IPGC
MA^9@Z>B(%Y3_BO#J3MY9IT,[>5"1J<U&3VA*2-,%..$IKE>27BF=Q!_G&62&
MF+Q[I3OQ*;?^E86Z;M.V3%-MZUE0=*7KMNIYI1""P3!$PVA+N??Q#'JP*M4H
M(H)2#*>%W^@EEA)L',*DA"=]1)I5KE&R9=J=]Z_7:1F_F7K4(OW$XGD?+.?*
M]+D*='BQ5;']ZQK^,FAR8I&'Y0D+#9ZM-^,:YC!>:*QNY^\EOY!YEO\+&(9"
MNNHQ&("CA' U0B8@1=(-U6$S$B(8MA(YEFH@00.AW@M!!3]F]W^[^$=6T_I(
M\/%.'U)S1A/=&NNF?$-J!O8)#-RF(+!*PV:#M?D2N;(TX7+E@ESI8\O0I9,K
MT\@P8LZ5JRS-W4P5D.$.[IOBEM/]6D3]HO@&YI,;S/.Q=LJ91]<"S_3O=)/^
MH83'3PK?V,KM,JGM,!MRPE+3':'E%R;DW96N4K5MN$.'NDTG2)/YI(Q0WN()
M6(:JNX)<C7[,U516(T'5K]-/<+Y_Q\=[NFOQ1A-DC#VONN0BW+4@DPE ]5A9
M4]:YG%>:H"Z"GUD_%%R6O)"07:&%.A;*O%=^Z<1@582WP.-K)/C[9DW];ZMH
MBNE??0+A_;A.2T)=".LEVDBKK4$@A-0J5/>?VA=/6U==!H$/W?JHL':63.#^
ME4;EZ3Y:EC%XBH)TR>#Z)6NL7(0I9CIY "NRY%WNL#&.7Z=EGZ4)]Z<_?[TK
M0=;_%OFKY$N4OF 7RM;!9EMC3=.DL]FZYJ@:@UVH-\5H6&FR^%@446D*'-(J
M ;L'FJEZ8@@77B"5NY@,<+0T>[W)3_-TN<5<'B"V\H4:EJ,SV6/FE6K9EGYD
M.E%^8_J94&OBOM_6@!).OBB:&2_4<,?H?$9%J:&4!'0V:TS3D+;XYB::S=9@
M\#0Z+4;A-G<Y\)V*J L;EJL:#/S"R=&H4;9[9C4:_1K$,Q!$_RZX77R#XXI6
M$(P^?XV2A/+*T#/\O&H6JIHE8V> L:OQT +.'A2 Q=DKTT?E*5HOYR4*>SR]
MLA&SMAIIMFMV/J^J*8+4*"Y^U%;$LQW22-2C-Y#& J.@85L>3JMDQR0Z!1.I
M+H,8K^$QO"@4-$]M9WQ>%?6E4KWTPSKX$9UM,LOAH3F:V,AL&!RV7X[2=-5D
M$2,.Q! #,82<Q!!>KX@AW'IB"(\U,82C<5X&%],':XR+7$5"[B?1 Y_6V K.
MEN!,%8MQ&<YT<<#_6;>)1<O&-:M9QT!YR4(6+Z8'I_LW-,?X-^D6#5QV^LT)
MF,M+=CE? 3GWK<I'&<5]!^>:T_WH@GFZ6-S/IO"!E]8> H@+>56.,.U&S7GM
M<3F&9^-@>M?EX&^;G3OE'[5-^V/T'7B&IY#JS44MHN62H,*5RU3OBCO;$_H>
M.&:S_IBM$V)!W:KU)K6B@X^_P<EF00H$F<C*7VSROU,*6I-E<B0(OR2,?X])
M\"[_XFHGUB)/RJ,K3?L3O%@ZC>;/\$^<OU8FQAK^V;SXS$4D39^,$"(TXJ.W
MAQYE''N ;MKT0[%[F;=I7/-I$(TC-R]Q.(_/\@XBTQ CW:W>X7NZ(MT,R"^S
M[\%]-Y2,G4.K!HIE W)X1@0CFE&,V\J+GF$*W*.68!HMY]DL[A&(W:K29TL*
M[X\H.EUT"W#(EVVB[K6_)YV7CE34J0,C$/K[TYRWZ9R'*+_EKA\9K*5%SO^8
MP2N4FJ6VE%ZT?/G91Z1+0*>6\DX2!8_)5.OU=^7VD_+[];>;_RZVM?LJ+\;K
M%1:D&@P&!JFP?/AX\_'W]Q^_%1P=1^2EWH]FX<RA>Y]!MLG+CU)6E3I3WCV'
MNK7><JJ'^$0&K4I8[<DL6/EQ&&6;K*3B>H9%>-DE'K$(#"2CH0?9D9,>68?L
M6R_H]F1+;N[A(>1-L?5%SSVUC6Z5>T:(\5 GY&TUX\>-:]&0R&W6$.#J[9I2
M=/60#/?P0M%H,U-ZEGK.I%7/(PY[T,V.Z*;-4S?M3NOFBX,CGD4&BNT\!$<%
M?V!,J@Q]S8N:14%&K5$\H9S-Q/!RE0\=#L)FL!M^LH%T&!M(K60?\<:W:G(9
M\SOQ= WOR.E6#O)77U6N060SZ!L_?7,YZIO;8WV3MI1C6D.T,OD0)@0]CDS1
MO^Z234D>AK10UK30XYD6>F"&JR W74D+^URR&72S5G30RW6SP7-/U$U;XZB;
MCC::5%FMNZ*:^\9"\OA 9-'&<H8P:/)UT[?*7B^8*SD%43$MEMQ'<;KPE\N"
M[O'B$)--!\9$SCJT?'F%3(=F2SNO>'!D1YGZFH#;AFHR *H\:;O+/HH@U-BW
MG+C=[^AXN]^S//&YN:L?.?CJ;NO%;J?^S5YC=8Y,@NTR:GMJ[9T-9!H,)IM.
M$TK$3"AKY Z-)G9-P-.VT'GVD8.M$;H? 6$]BC"X3V_]08.D97 &?/3.$.8,
MC-$$C6VCIG4\. .)G($IP!D<W3\_QQF8N#!5Q8?KG3=X\?H$[UZ!X]+@?\B3
M:_+DG96JG"NOS*9'B&I^__;Y]2;+%P3WA&W"W(.FR[9B#6$20X]D"0N3+(*(
M9TO@L#B$2:^J[_)*U-,3H)XVSX#1QC!M5="A7NJ?E#NW!-K#&X+&<X/&:'T
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M]34G%X&/X;+;I*N.BWKZ:.+T%!^C-^MQ'FI_/<[EN1[GH=%$@AK00 5P#A7
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MW:OB/+Q*R3\:7PV"SU/PG=8$W^4B^"]SYS((_O'8<9!\GI+OMB;YWHLE_YQ
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MC.*RT@!>%*?/%[-/=<"[FXA&UA!-$P@IJJDG ,5R'ZRN6^2*\[<H7,PE<*I
MECU4BR':I]63DN+%*!Y'/F^C<!\BRAPQWE"1GF^F0^=1^.1[<#&T=7!MN&(S
M:E0CAFSU_5P.\*.M-;$:2\R_#Z.(N1KQ9_>G/UO,\@=N7?A4/WG9>]VRCCU6
MQE!1NA?NJXK%-[J^-A;S VGB!VXP!D(-D=XQV#%T.UKI$ (KQ="Q&RL9IL!,
MFSEKM:-CR5I?6,7Q?O*#7R:N%G> K?+B3K6/0S<&U\ESV(%.#J*ILBX";3&E
M:'QYF++;W,N#RDZW974/9<?0X?]S#3P\^[@]JJAB6N<A<KPZ_@E; MJD?F"$
MX4=@/#-$LS?L?D#U90AG[&_UZFU+"@/A65I*3Y,U,S1,9WRAR=<H'%/JQ9^B
M<':[="Q^#X$ST5>,]S=()B:?.VF0B.4(R>&R4F6V-!T#([!,<XA+7=95)SV[
M$-A&[G. P57FU^DI3CQ&5GY3N07-5.4V?2X1XCP.9_ 6\%!;D545W%9;0/YX
MK9"RV#NNRBG99-PSDUZ04":<=W&\P.Z-&B-NU9> VAE-$T%1E"ZX]7^CWP>>
MBP_Q2S42XCWD\,<,_,7I,N?4!J28+NLMS8)L9J9:-?^%4XPE\W=3^45F8RUE
M2JW.;Z&CCXB9PI&H.WYD^MH%_^(G:"3.;S'2/TV>-84OJUF&K.@]U^0[L.Y:
M&*$R"^MK0IU/>"RW^:E\Q4.I95 'H2UER[2JZ[+:B(O!#1' GV_@!=C<$P8>
MZQ;$Y% +=^,0F2C.\D= _7+?;MHRMZSN'>8);,8<Q:[:KQ&=^8O9/3"/:GQP
M7_[XQ\W7+5V2->VTAH+3NEUHIR6J(F2L#70;(XR$V\=8&E(U+CSW14("H>(#
MRYM68/C.HR#-+:;%FVS_$2OOC#'9.&RP[UVS4^S+/FO*>#'Z)QTG2-8X 5JY
M$1@=#]?7,?X;8E?D=,&D'#C1O_#\Z8(G>X&N0$D@,OQG'H$E9^P7OSVLOKPU
MT:&KFLPWS)T3':TD.F)X$=;FUF0ZWK><Z5#!LK65Z=@Z9@^.+ES%G?+AM[T3
M&X:*FKZ;B0U'D4VC8(-%#%%N3G+X6#)L,U+7+5LF34[NK(O4-;&1NL'@/CH1
M.#F:$(K61.K-V'Z][6XG,?FN[B8QL&%7Q-*6U^OSYI,8AM:E) :Q+-E1!&MT
M3&@,TXQ&)9?QQI_ 4R]OP8UWF7H?T66[51NK,%4A4#![AY+: :$DBQ__\<=!
M\:,.;*=U(H TB"XF4YLV^4'8V)#>Q_W&O5;Z>3CMSV;4\\'#FKY@W#VF7C;X
MN6-LW5 CL6YHO,FASU2^2Z09$!H4&2_'>8LHH^Z<#<5*DRB<+:E=/(Q)F'4%
M[SR%2_3M)HH/X^XV;VL8QVV8L@R9"# SR6-$:1NH*X80[_5B!A_PV/[0K0[:
M6,2^/#<(?+3T;O22*>;5%>4-J1!3E\V^JY!R8TF:]F0/LMGL7:B[TIOBRU1>
MZ0K0WV*&;Z4=\YAQGR-K34;2XVF(J%]57TO?W\5/X^OO=.XBHLHMO_3>36Z&
MV94F-T/594TM>/H"9#Y.J=.49(.EL/LNV2E3QBAS:5=TH>>:Q^">Y_.4H329
MTI]^BM$!;X@@,J(@P*X$A$Y\> %Z&%[X'#3EC]E6_PO"]]D4RLQ/N,>%7>C,
M_4JIE^G,E31W^F@VJ_ I:P8N:].E,EV>XZ/K85:E*4%P;)GT_512WQBIGSQ"
M8)$1'?,$CVZ,Q(PH'!0[K0>XA.3#&43X75 4O%"*PVP-]621+*+5*2%1U#8T
MM5VU(V*DX(X-<P"WIH-7:^=O)'<\CA;X.VFEKD]T\ J.GX I=[GKU2K.LOLC
M(^4WT"3UN15K<&W*-?F\-JKS8#,%#:8'F)3C'4E^QDW,VL_=%QRJ1F'\UP+L
M$HT@D/6#.'&G4Y:(PF=PO%4*HR'R54-RJFOMVBHAV['1[/")JM3Z,(/"''5P
M*\$"(9 1*Q$UI>Y,H]T4C @R_MBHXI[]Z133,Q'XJSY.G *)'QY;4G9FDVV_
M!2E\[5S/_\E$^ZX@V7O'/_;@.H:74AIT( 9BU0X1K4NU:@_U8MI',Z(//D3L
MX#FVL5A/*-3DNB2DL7;B$%PS"%\^T F-(G>Z5R;22=-Z$DN.Q96T6 OE(4W0
MIH!)PKO<&D.3,RRSW3R8D%UG65*+A6WESM-A'L:54EU#WI$Z845LU/!,"/.Z
M1CD%9KV5I:(^DQA"P=*?R;V6ALX(PNO>AQ;@T+7OM9B(OMUW2MX$+TO7.HQJ
MC0F2E%,R=V-FKI<#:HS<V&>(-6X);J/%BKJ.HTT"*@JO"NC6NS?%>OIG-_H3
M9Q.+[?S%P,Y4!M=.)\(Z7==E583GDHHKOW/I:S9>TEQYQB1J_\.+%9TFI2HP
M@>^*U$ME%<$O0):EM%FV2..T7Q;L$WA%<5;@<<%1>IS1!-PK%T(6X,GL+#P7
MB('[)<#SD?A-01B>O:BAD])(_QV(M,DH/0+L?<A;E3/O8?4P4TW:0CB"FE)
M"@'K2VVT[(E8WRV]:>.[FT(6IQP<(>56)XNU/[@O\3] %_P>/H,K\ &%'UFW
M-FKRW)>"A5('UZ3],(E@S"F HF]!\;VDG:FLA,/HD6I#I A(*T+J35J26!VX
M7@#33_RG%CI7=,,4 W/2@LCJ)I&) /,@3F1_1"X&I2BY.X@I*>QK;T],==,2
M0L6W&'NS#D(FKL5^MH9<$UWK?]Q<[KMTY_.I/V9Y!TQ5#*71@NTF"$*)/F$
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MEJ#9_=\^^B,/)(%%64.:QYJJAFE73CY*&]4W*U< D;+YR&7#))<$UG%R@1>
M-]"FO$E3/ZV0M7X;!1X&MP1 2&1ZSV-M;9'_Q/KD8MX7E\TZIQ@-(W\"Q^;B
M>R91.$MG3A_#..%]Y1"\\5HAYX>F=@,I_3<'(\K7";"Q)];GC9H:E^HRZ#AL
MO:\[%LS5E)?0LRF/ '%O8JP%LOGT>1@E?/T="\/\)/.B>)GP^3&<-K9JS2+]
MMP/+ADZD-P/VX\>2]77/HW#B,S4V#>,E<MNG/WY\_3U?Z OF=HEQ,GJ1[CY]
M^RXYLG17:!?-SP4^A[U[.<K3&%ZZN;T+HOM'5&B31C>H2$>NE JGQCH24IG9
M05PR&*@"7@V?GDEQHXI7;LR=<O3^.P9\3<JJ)_J"[2%+V^,'*]*TXFIMWI]R
MWIQRWIQRO,TI6O\VIVQ=GZ*O69]B#,1IL[8WIPA)4+'Y:9J-VVT,S)_IBDE:
MFHQABN3O^9,)-G!E;O320H$V'-/:_=LM]2;JMB($*'G'_D0O1F>I>QVSAJ)S
M%+C.=C^S!>%KVY]_<\&M!?N$>\P^ ==]@R_Z$+"O?C_)LX"%;-3^[=#FX)H,
M-6-=3T9WNZ$-T%#Z\3K;Y6;;G+<O1#K]+N?OJ*Q7W?5"+2'+-Q5"/>Q:?O+!
MWQKS>,UE[^(6,Z'CQ\#_%PL!W0*28AA R(Y04A [N%R9AQ!91$\LKF_TE+=O
M5SK]4^;8,FFB?.Q&T4MAB.@9!^P9!C#/7S%013Z2S8PO'K0THLDS0LILX)0L
M'BQVN+,^D&&YIMW$(:M@=+9  IW^*?,I^A<0-BH]@!5+MY9%%.P39I69'?MW
M.F6;QYN@ -B:E8"-1T<NWL$%4C\='L4@BY\KC695=="PCMYAE]+I'^Q-S+$/
MUU5=AH4\#/,*"UNP,F$OK=I(Q^++<I^X?Z8K=M,)EC*$5R.G2[;B8IS^Z2Z"
M@FB6Y!<S=AN<P(;[O$R(1@5T0AWDH#L;'/2_9_3"ZWQP7^X#BCZ[*.?<0N=<
MU:NMK?7.^?$.A("PF"+6W+<SUT)T4U8$M <=PD\KC?1'Y2<$KQ\:1O?X25.)
MD*T=P]($75,[%76[W26IHCH RE61S?FQ-QRX)EO"GM<Y)Q2QS6D1Y#_/HK'6
M&%?ZC * RSFFH30+/3IM"JX#S42K8)R"JF2QC]7CP@C7\>[ -N0M2!^O'"09
MT\"-_'!5+1K&+C-_7Z-PE%:D_L&^._6^IQ<L:\.+F(Y1(V(U):9!;2>[ U'*
M<]B%+G9%8<6&UW>Q+\F3?@YNVL@(=,G6?Q<Z=+!ZE^*,OOO@QZS:AH>5O2-;
M<8MO>H(G@P2[XXMM*DU!"*J6VNXB2Q&"G"]]R.BY#$\YRWW!+>'^>'5@H\3Y
M<"[C:8CJ]'YR%W@^N ?)YV6BHXJ*4>A4^($)K1]PY?=8YEIROJU4ZD?X('XR
M!3F9PV?#)5:#AH9E0%5D4X#BX6M/(%YAR3UD8#>.%[/YLNU@!4DW9^#2F60,
M75^%2ZFU>Y56Q=[Z*C_7B@O2;0<>3,N'")\]2$N&"4M@9C$>JXUC?#=UYS&]
MS/YSM5("96_*BIZ*\E>X6#(*O1?X%6772N56P>>\_(;S G?Z9MPC8L"W>;?I
M5=JV%ZC$%G(9U1%]F7=)5$,4U>(O*%ZEV#_ V-:=^@_!)9[J%1-6,$;I8\ =
M._+1"I73,U]3V]_L2F,'/9>VRD6+$I_F.!3VLV^.P]XJ_J-PZJ7AF&P*J%6N
M]UTO<E OA6CK2_CO$N\5IUCBHU3Z1F&2A+-+L.U9@TJ1F =R"->7$,&2C9.F
M*^(DE%^6%VV%7T H;0&VXN:[=/])NOG[;W___@/QWDZ(/8AER;MP1Z;>A'+'
M\J*M<(<M9 T>9XX/'V\_?G[_\5N>YSX-]M <1[;._"&>/_0M_+&[#U&M-8S'
ME$XFKSK\+4&77( ,%N=H%(HJ[3@:I<RO$%?C2[X-I0@9PYR-G16$J -^M]-%
M4Y7"SKD-;Z2&P81Y)D4&:\4S*0>RFI! =D\H%F<M%,M&T*S[)?O6Y<AL"'*U
M#3AJOQ23;_6I:GA<F/TL\G@K]K.<L-3;X7'2!(^3,X_OX1B>F;QI)M>:8'+M
M(":O=U>)NM57+?;%-.&K:KHLWE5-?</3<E7OLQW4%4##-VPVCE?\-Z,,[$5%
ME<CD],B8=GJ\?855.$PFME@% 8*VAP=?%CM!#KS%)U4ZX\ K#3OPM4U!:GU3
MT'ITS3U;?VP=#<!0V8"!>VHLO9._7N9H09Y,F:-;]V2<AAV96H8F33!T 4O6
M-GXYAM[-.3]S=$,<K36MHLU#.;K+667#:,!3/\FD\EVVD1)>13N:?3B2GUEF
MFI-+%!\PLI'FEDV.HK3N/I=P!0>]=^V6!I9TJ&I$O:@1254A?@<^8$B$0?+W
M8#EC>1?,%TFICSU5AA>DH VMP;6Y4W,FOSVB;+N]OV[%<.BW:.WD[Y8EZ^0R
M=P=+EF(=+ED[O'=?R3*:E"Q[/\E2U5]=LG9SO,^BU0O1,IL4+:<ET7I-!-!T
MKMXB7'C.(< ^2/U\:P7N)6!UHE/-:>P6#ZRPT,D%!$(3SZ]8%N)HEF#M6*A!
M.@I?';)^4<^I,?=.'OD*;Y^<WR R8?<JUK8;9&WU5V/MW5SB,V\?B;>=!GF;
M',C;7<Y*.\K9(=VM>Z2T$XLYI:<:Y>_FBA8YY^R'-J70=*5!A:8-KE53WK#
M[M0X>R<_M,C8)VJH[?;Y6FV0KW$5JFR37X:M=_-!SWQ]#+XF#?*U,;@&=;T^
MK[I?\[+5>D(4L]H-3-JI2JE)YT0\T,\9BHKWNJZ(3D?3.\[/*0T-T)F=ZK_5
MA,SG$OV=8K_#[:/2&] Q$D7$H[=2_K EJMW=*+6[MTX^C<B& /*]^=N/S^_J
M0)].L0.^8!JN2@YS9:G+/N(IR-DH+4YKW]D LR)BHT*]> H22:6XAZE]DA%=
MM@6 C194UXITBB$;48I;X-HGFV7+M@#,WU],=>5!T5EWG77767?]*KJKY6)+
M^?/VU#V:WD0XK!01%]=$PSV(?_]&IVPC0HXF^JX>BU68^M%.@6HYA&T!$O=4
MTZ [)@]6I.SD:E>'#U605PQ5;'_OGOVINM9@?ZIC#JXMXSQ5(1SU9T6X3J[.
M<'CSM_:*YN_M[]U7N)J<6'*L/87K/%BQ(]S06;KZ(5U-3BTY=EO2U>79"M50
MS^/5NXY7P\LY#M*82E-_YB<GF _<)R(H\\[)!03=:683/7)6;(YP!M>J+NO:
M+]-YOIM#7N;MD_,8NM)XKC<W+Z0JRJ_&VCNZPV?>/@YO-S<PI"KJ@;S=Y:$*
MU;3/D[X[,N9'-YJ^2!'U*-]-E8-RKBLHGD[0OZ-WNL),)^>>'A[TVZ\(^K>_
M=]^@7_3H62'H5Q4":I*LQT,[)ZP/]8]7I.ODG(A#I0L\L$.%:X>W[BE;AN@I
MJ))L:?O*UCE?O:.#?A:N/@B7Z%&LDG#IK0E7I]/5=JTG?PX/5F7GCW *3[^R
M:Z73N8X=HP"[UEO_U4. ;K6L&**'_TJ:U!A<;UA<TE($T&G1VBT"L&N=B5_<
M0^E81=UHL!E,5<P])>LH_G^G)6M'__\L6CT0K09;P53%:DNTNEP?((IVWC"[
M*Q)H1#T_D6+XP_5.-9VR6PRPRC;G,*"C84"#[7^J8@^NSX4 \6' JG"=W96.
MNBL-PI:KBK.G<)TK ;M% F?IZHETB6YC*TJ7BKC7Y\[U5=$  WV.!782GV]^
M_.?%)*+TM9O!FLRMI'O)1V&2A+-+(GXU^8[!0IFMSK%"KE2V^L,;%-+V]^ZK
M<$N]E36[%%^E<!&-77:Z%BST6OIV"R;*PG?V=G*/9:M%W^#M;'_OOL+G-"E\
M"!<OK^]K/L&R0N/"MV.P<9:^/DB?J30I?=J^IJ_A8(.H[9<=-*N)L00B6RU'
M&J-PZHF,,SZY?B0]N=,%E<*)]#?V(7&*,93XP()2$";PK05!#8&5.#$"OO$#
M*7D,%[$;>#'2,!T_ZNHH1]EP 0$D+US@.6<43U_ V+VUB&Y%? 6%=%9]F'AL
M[CO4J&UAV)6W>'X\G[HOEW[ :#2:AN,_KU)*&;*NYI1PX$2XQB[K_&H_KBW;
MX)8L?PZSD711LZ&SU)A[D5M(=_3T\_+FX2&B#VY"45G]@;KJ=JF?OJ!Z&D@3
MI'4")O4G^ Z+V847,A+C!7.CJ15LICZXULC0U-6JV3R(B*9LFC4T/.N @^/*
M%14@R+6UZMWE7UP%V-:.*L!VFE,!Y,@JP "WV1KJ1LV2B;,*:%@%[!C=GG7
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M(B<P=W)I_!EB#Y8>V(146ZZ *F3T_;_V9"_'W):)!E4_ID'B/M#[R3<@4!@
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MK<W:XN8Z0CJ')8[HO0(6F?&%6A@R1S2>AWS'386E\=-1,2UPI6*<@IGR]39
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MI J@:PHZQB,EEJFIX@<=G<LJI**L-G-,JBE@3OOH]0#9E/#H-3SM3F(-";,
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MK]%.M'G<;>@DVH2B%7#7'/=:;40EX X=1)O0O@+NFN->JWVH!-RA<V@3*EC
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MGV_X)!V_)[.M.)9Q>@!&>T<'<)CS4?E O-73X#8YP+-+7K/Y.XTL%Q3E3P[
MVBU6])*0#?F_\= 8).EFJ;B!R3DU56=>B5TZZN'"B!NUKO+7:85_F>_E;.&N
MR&Y^B%_(O\ZG,555BKG*KWXK?*4'6K$IY !VW6&OT0A? NSJ-\)7&W8FX2/
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M3>((K.O.^@YE<_.L0^]+4:PSRAJ!]8;FK,C*DZ(=BF8!K+,D4?Q.S_&[CN,
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M3DH)#.ONB'=(*1MD&'5Z'@*(Q8DC 6*]C\P[Q9&*')EMW.DY710& +DX.21
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MES:A6 7@]0>^3O=2"<#[ 'P#VE4 _@2 K]$<00+P 0#?@,@5@#\!X&NT.94
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MYAL(!IA-+0P :^[9ZP^OE^C9U=<3M]<P,(J-P3!H[ME;X-;M8]RZTHU6PU!
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MGC9=R]+R-6Y.L._@KKX-JP?#CHNK2Q@6?NK^D5,:*^STL-LE>TT]&BR_6D3
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M\!&)@B604$VRN4\@+MH!, (2QP_[ELW3!K DG7+9J;]]BQ',@"PSP%9K@HA
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M:N&<3L]U2N0XFNY2EKQX<9="7EQ07IRUQ[G+M<?Y7F9^FR9IR@2.2\#Q2R8
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MTPM0U[6.:AI;6+U6Z9CD8<Y0?M#-QRF&N<U:6+0;TN>+)CWH]+#5]9VC%(M
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M[07%UO.V&]@+I-]5"NEU6X=GC5\?G0LF!;2<)$H%U8D,18GT ]#,G)S8VG=
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MAUEJI37"9>_M6219E"B@ZF9R/?GV>?) /.-TE@G(HM6:95(237CF,@%D(/=
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M_-\ &;1VN,*_O,RC><O#YEBUU.Z+UMQ?()V.!RO%19(AEAZ\CG^@\VCY]U!
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MDZ;)P2^DL:-S=Q]#50U9X;&YA&^#[G?*47?CV_J$?DR\[#HAUPT^OHWN:4O
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MGB1I'$4DO&DP.V7_YB^ZL&1<Y^S*L-4]1]'E*6];0^SV%G.>1/SX17P)N4V
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M;4#+%#:@Y>S3@!8RIV*[]1<7"12U0M \?$$ZSF$MU87(X-!)TQK66CD[(WY
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MCO<]23:=8S)-U0Q9/73OH%V3(>!*G3=;:HHH5OU0%A+!5$\):,[?%Y>+][%
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MKM5F.8%Q@WT$WLK0"RFB<SI!_8AGCB$^''*&>'4,1Q#G<*C8PS>J]FKGQ.L
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MN0^<$8BB.3@I=ZPQ( Q SB6_7!?-<)K8)GEA^[Z.(%2HP7!QOV.I#5?JW?-
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MN#PM,(;I[V_MHV)'UG62/&&%3?,(=-6/23.\J(^_N<]B0D)_H=$*G+J1ES*
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M"L0A(U7]9[E?31.0KGPE$6<J"I]IV OIKW&A_D<DB40QE^,*MI4[2%S>4IB
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M*Q"DWQ!$/4F1(19;;@B" ;&E;]]8IG-M-H3#0"$FT3"4 2^&(69\<3QVKG\
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MIE<2V6I[?R11O)X/#,%0#=S!PYSEX_T1I@N'; #9_/#GI67*NB^Q7"T<.2K
M06)M&*,8?TZ0*#(@;DKSTFP6O-4!PCWY*[Z>H1MCY;90_:GZUT[DB8BZ:J5*
MWNH+83DA@BJ2K,IM?]I]8<J+*A3:"1!S_32O2KK@ 'M*N:ZN<L__L3F2U(&
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M6Q\ZJTB;SB[_Y1F&?+;\T]&XS.90+L[.1N^FDW@QF]')?CZ?Y\5\Q)&AX+I
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MKU-C%(L*@LP>$$/)0OF L3_8[<' @(:J]X3!KJ7<ZKJ%UK[ U=#W.^3\MGK
ME9XO7N-X]@_Z7"8WP$<EE00>5 :K!(=0.V=E(QW+WBM3[O1:>?#Z9:>%!W3S
MWBE^.A=*_[Z9CXYYC1PL+Q$49@7(:[>3$)D2UB9]]\9N8+[97DFSBQD=^YIM
M>3-9T*&OM^6K02DW0]Y-VY4RX\J5 -+4QDH8&&"1%K33G.=:BE7Z"RGW9F-(
M4R4ZP.F&5%LO F^9UKTB^/UL2@'?XGM]E+L@/5:US;*CYE.4!Q:SRI&\)I5B
MM5D" F.QCO",QD>O+.NQ:/Q@?@9>,=PE9GN!0/,Z],L"A0]Y_"5<S&B7?L.4
M3Z>7H]@O^\2>S#[A9/P_Z\YU&DMQW&B0SI'7S^GD>:WK3#$5;:SU]#)LY<(<
M2LF XK(.X=:_T!H-@J,MN4'VRWP^G8_KG#,EDRHZ0F(IU?'4KE;!,@B1R.-)
M\KQE@>$#"PR\[+@I+%KL<2.M<N.F[ J95ZTKUF2AU8H'\N"%E:+.A%7@'9>
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M:U&X[,^B[X*>'1W:.FWT,1_[[Y.TONG+M=23_DO'W297VT)'5+R.(W. P17
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M?RQ3)KK$M=YR&.P.BQ[=W^H<-YV*H8MQ''<;S%PZBR/#LT%62P'K8 AE+4+
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M"2DH7_KS6;:C>7B9HQ9 ZD!>;<S0)6$;KU26\VF?N%A1VF$M4P(,M?.>9'0
M?#$0K&;:.,[9W<32 R;J4$J&ET$ZT'SU*IJ6:-HQ2\I%=BH$,KG9) *]=(""
M,_"%9RV]3<YNU^9DG]6'EV-J@IH.1= &*3=&4J\8MEE;98A#G@HQS$,$QV4
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M#\%2G.4=FBR-+D5O-VIPC\4'5/UR7/P<)I:^P$,NW_SBK%[=+>TWIQ#<&<[
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MR(Y1ZGKL#')<C:;[MU%:(]1)IM>&!JI-Y/JC^71+/)LV%MX'C#Z;3T=EE)'
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M-DA2/'\5,@&:\!^8SLPTJRI^[[&G"NW^NNNF5X/BZT5!!I$ 7.-"9EVB09C
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M]6E%),<H\1$2$1FR!:F,$<T<[:/J^M018%NUTWG7IU5AT)^T"0+17D"T*JG
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M.V6I,MZC[,>([@9CI&]P=U%?;5!??8^7UQ/<>7X=Q**6X>?9'78?9R</G[[
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M$^1,M^H_1!K^K<)&>8R+ZC .+@>S5P(7U=7/ULO4WV?8ZLG\K>?><[X_#[C
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M'7E,1/]LM=;UMG=XQ1ROU5H7!1FO_U4;5#];K4VN#^T:8?4A<SQ5,YSG$'P
MHQ2Z1D0F<$0'R"P(PZV@:L3HL'-HM3: AG7AL+9[^TO*Q0Z/6V=L_OG58H7V
M=UJO\?=;?#PQ&8,J@7"N[/T>O2%#'"BG(N7HD\FHVYF#CP_V9+I==2)E,:!$
M![D%?[E8+A=_E8C'ES]^=U^O'GL\T=1YGR&2[,H9;\$*%D *J52B1C(U7@OW
M)H1G8"D=3<P@20W[J':O RUPC6[G-&.=RM(YGL]'5>0(,@9Z:&W$EYDB"9<
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MQHY7<:@%X"ELD2.IO5\FNC(OP[2%=.OT>;&<%1MLS]7=K!;.2*8*K3"J WI
M1N32B\Q"H @P$:_%P4"0VH58#H(],TNE)G7#I,$\#'"[P-I G*"BU".PIRLO
M59'P+NIT!%L#E8QZ#*JV7#*J&&2E$"HM*TMJ"H$($HP6))KQ'*J)%*I%,:EI
M]:D+28/HT?ZDU]<;^+:9V?OE(L_6[Y:_;HIF;>;SX_H.(3.T($M#9V5 <!7
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M?[FS$#PZM_&]^['9=);+XE-ML#9M0")KL*7[!QH2)$5ELHSCW8NT17V2=MC
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M&K3@Z PE'4&KP(RP2N-QWH7)L_! >DEOJ'1V?A>+ F92!BTM >-I*#&/(M/
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M?IM@XU:B&[#N9B<3S.MR?923!\N4 &JX\-01GW2[)\AG9/ .I@/#B'WT&.>
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M@$JYSG6U&F1T0K%D6>Z8IMBURBE\MMZM-.E#Q:W?!3].<1P_WY3W9>X$X3Q
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M5A^:/CC")H.3"M^)51/%R',$+EC6"H,0JMO DTLB%=[/Y"U5W!^I\(N41DM
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MXC^DP-)SQS*SD6,W I1'EWH6B&BK\-;)[GNZJK=E,UAU;;D1=!/F7-F DO>
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MBU&))1"J2F:Y)J&R@1)<1,6SX[%;7]79,0@VMTMW.L%]E#H$T^A*38!%+41
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M:/<GE!\5RH&%I$KDO<SB%9XXYO"0%%I%)JV.LK\:AE\^/VHSBLU*(#'%8F@
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MOL3)X,>/Z=W6[_##XRU>ELNKUV/<WJO)X/J;__Y_QC>CZX>_L7F?.N CEU3
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MM:C<)BVQOHB?2"N49FB1")<HYT) 1!]/,B%@,VKLK5 ^,@+"W:<\ MM8I/I
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MI=BH$)[,@CW@L2WXCU8C'C]LFX7L5$%@;64JPK.)T;L[!'.ZHW#16,1+3A]
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M%!N4ZM"*1AL>>A%-<$KK;+2EU89IQA6;H1C@F]OAZV1]-.:K8P+2$FG!T1\
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MUS#4M.4(;D-YAW%,O674!HL(2 T:S:! E$;,4'[4'Y,?A4R7=S4_SI&_7 X
MCS%!.*:CRS;I_[:T%(]ZQ\M1Q&22(JILP..UHJA#DF\3?5$RHT&&MA6]'!]N
MH38C=#+/HF]5 U.U4F7N:L(3<(8?V2Z*<FT#'BC^P6K_G7^ W\%KX?\^ "+3
MEHS6YK'E@EW4$ 9DG-Y7SKG,T/NHM07,KE>]0?FBO53GZ!QN[MN\R9Z8MR@7
MYYJH__3CTAT3H__HC)_<2;0T-M&_3/R?>56:G<>CDACB$JRI4H0?)^GPC7C#
M;BJ93L[A#\&*]8F*]:80C!S>Y:S!N60FUTD? [Q?>'A^!MD2%I\YKO"L704+
M?D688;8&7J$7+K?&G7P<*BXU^/K%[/#8TUX^ E.^N%S^ZKQKE94<R9)\RE5^
M,NQ>.>($H^K1Z'U2]9"97<2UUI#JN0)^ZDIZX(?QGZCX9]%/-2@F1,QO>^*7
M;67&&AS4^&>H>$!)E;7#@2AQ=_5$.^5F0G"'NP9+"PZT!NFU1N(UUM:&AG9N
M]JD&=AY]]MT_["+Z'-=_.#ZO?1AP^X#4R$'8^(&4AXNRD9N1AP>KD<Q2KQ5%
M0J17:X& TN'M<> 60\%BA$-:;'?N6MB@$FJ1MENJBU"I?ELX.NKO-VOOQKI7
M]*,'2=&_)C_U[7*O6'MI+7%4S#ZB[&$ZEWG\70*A0\1'T/TFTX72[/S?KB_?
MR ?,&B!%XP4]Y04=XP77X_W,_R']M49TK.RP"J?IY[JHX=9LYLEL0-BQ)Q'6
MSV]7TQQ3[:ZM26$?"URQ]*3"8\.F/&QDAS(64"XN,&N_YC&IJ&^HL%E2CZ",
M0^9I2/@8:FT8S;G_#L-K8Q&YJ_W=BJAOJSC?JKZ35K=P,!.<T4ZXL-+QH,3-
M?$F*,'_X-0+R&!5UIDVR'3Y?8=ET!BPU&V[R&1TT&UW<PBDX'?<7FX4F@[!'
MYXDJ[6W=N?JU\D-<H@#:;3^4F,Y0V6V51$66.L3NVDJTO]G2WEMZ"D\-,W:G
M?ZR1YTZLY#%4WD.V&#PZDUBJXS2=6P:G@S(X$TVX*OJ+>E8JM[_E9(8IB]ZV
MB)#;RP8:9)^BVU[SYY8;@$Q</S$)N-FK[X\G2XJ[NN,-OL/#EZ1']KPFF_7A
MDO9IC<K<D[<OE\S442RB^N'*U6I7'I<[?[[*Y;];[W]OX=^ZK%5;Q;AY'VTD
M[J;I^,4$'_2[ZZ<=G?1O-B"S]JF>GZ(:RX<$,S<J+W"MPY]G1.XO1UZ_CW_A
MJ0H.T#@\<^YH4=;:.CADDENJPR&WY-LTT?=FT4B[T5A%T;\%8P;:8D8$8Z?:
M8EL%XR:\XY8>XC;;XN /'SJ&[577YI@X79H^\VMG7ZU8\>NO(9VB!=&ADZ[W
M 98_IQJWIZY]3C/V2;472K,7RK 6RO!ZS+ 72HUY3$]^3,M^S/+SR39_3$\7
MRJE]S'%O3RT3RBUZ3,.5R#WPR;MXS#UXS&U$R%D3RG,7RD,3SB5]*@C]G'[_
M6/ ?  = ^+\G.J3[N:$O^IW_>:1'^J6C.:/[N:=/.JA_NJB'.JF/NJFK>9S_
MN9B7>9BK^:IKN04(]4_/^HI]U% @9?4Z8L<RXE( 4&'D53><U;0(@*\+2P\]
MP!__J&A4-59?M2+_K^QD_/&,NO4HN^BRMV@D7Z_[@&Q2@_5B+1J$@VQ;1SN_
M-J;+6A:<ICN?_FF>MGN?NCN[O[N\QSN]N^F\VWN]QRF\XSN_DV9B<YME&"J
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MV[]?GZY=\X,U"-KI0W >@9,'Z-VGUQREW8-VY]4CL&]^?6;^[>CC#SWZ\D.
M#382LBBA.\ 9@$&(%FS_$,*%&G00G(4&N#!!>QB,2"(%$_1PHP8[L@BC#$,$
MD<(4)13HP0]AG"C%!%ODL,$*01*H104AU''##RDDJ$(-,132( UO]#!%(4'<
M44D@93S1((BF1/''*Y^4J$,,7_QP2RQ!1*C#& D:$T,R0ZQRH ZW%.E,@\;,
ML,<!V)@0Q2\SE("?FUIZB<\^:_(S)D$#/0DOO0!S#"FDXCJ,J,.:<(H=)P)
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MM*4-[6E!FUK2HG:UJC6M:UG[VM9F1H'2HD]_XB.@"E:P/N4Q(#714Z#SG.>
M%\P,@LZISG=ZJ(Q%DM'*5O@Q?,H-H1^"XQ&%&-T0=0F[[/^L6W+-9K024NA"
M&8N3<W<$3Q^M\$8/C:?0<IA&BVHLC!TL:7(MYDXJEA2[&ZPIE/";7"9&J;H_
MPR%&ZKLR)JXL:T"%KXX(,N"*Q3=M09JH!GU47IS:L5!\]).'/QRXF<BU)ZA*
M):/>@CB>0"YRHX)  *3 C@#0(ZN2:LL^+D.Y*$1!E8^9Z[#XFKBSV*IPB@G>
MZA"S5J::=9.JA,M88JE)3J[%*&XY5%S6BN51ZI4L9?V*8 <;K6E%]C32"F9M
MH%5F-:>9S6AVLVK:#.<WGUG.=:;SG:F%YS'GF<][]K.9^PSH/Z]YSH$FM)T-
M'6<]"YK1AUZTHQ-=Z$$K.M*(GK3=I!M]FP YL!T "N<XK2E.>+UK7IV^[1H<
MB!YP9N: E_&TP2QJ8)7E#*0X#%'1&CRTF!%8H#T56<*8AF",?K<B4K.N=6/Z
M1.MRS6+.;78<(^S3'J53BC,ZH7AG#20G.32_1\.A2-=+M1@![:#+QJA$G6@T
MFHKQI%<:J$)OFK'T/FG7$ADP@7=]LX&P(0. ,RK?CBJ3O15U3[R#E;'$6F)%
M508"[(CD&JY"F89_*@!KL(NO$*XJ3PK+=:R,BZW24F1$];4Q'7?=*8&'UV(9
MIJY0?17K_'+CP=FU+D\&3++_P&P9.L^O6H^F]*4MG6E,0QKH/A_ZSX4>=*(G
MW>A*1_K2H?YTJ1^=ZDZO>M.Q7NFL%UWK7;]T?<Z#&; 'C#-.*)A^[M4? E53
M/6/GM'HNV%L#'?O6,C7G%6MFHQ'NW2)$<C *?4C3: OTA7)4D!7'JUUOZWVB
M-*,;RPI\X>9FJ>[$7N]R1ZC<?&I4N8&/KZ[I_>"#(6F)6H(NDAR?D9[1%VGN
M#J$-+URW 8]I8WBJIX9JB!$N8LF]33N1!0@%X@[O,?AZY$<G?[77X!&YR:TL
MU5!\AV);L;R4J0RKP7<5UV*E$OG"(O(AE94Z\?^XDRDNZ^#82CO:C2YT+!<=
MJ]+2_ZM9BB7G6Q'TSBOK'?+HOSOCZ3]WP&/__"\ _R\\^(\ $5 \ % !#7
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MQG3Q-7?VS33P CW= D&] D6= DD] 3L]U$M] DV=(%%-0 +UU1^ -R< 4R>
MC2V@MFF[C>%QL]?  L!ADA^@4(G3&7%Y +)A#6@@&:DI"B+7(235D(D3'6*&
M#6KY&*@]"HJ!(#"#<@.$/2*5/LZXEM.C=F5U7Z(@DBDWUMM(/>B$E94=CB$B
M ,[1MO4CCPMB2KCAEZ]!LWM3WH/;-.I# NJ$V9U ._5#UC&#4M#C=KF[X"W5
M"22WUUMSVV5DD@?U5O\#XYGQ/^BEMLH]4%/UF%4-7H!5,]A@@@6"XIPB"D#
M&2?<L5,2(\"A 1X 0X:<&RA\0R-I*^B!!@H"P['_UMD8NDB&7H?((2I^%1EN
M[>51^%<EMWM'[V?PM81P;][ZD"$:8+T)&86C0"*8?N5O%^DK0^F;Y7;M00-8
M#+<%0NPI0^D? !V454:3"T>[*X[>1E_7=862TIUP\F3(>;FH50I!.O$\1*"A
M2Z 5+Z?X%7JG%:"A!"(0T8^2*BL#Y1$_#!9?9:HL1P"$F"MUHAE@C!T^)9(
M'9(:![HA:0TNYQTDR5*V A\8QW*T0@%V@E*< BE>K DH[OQ4'@HH!7(T (5]
MPO8# !\X)0"H6B>D@*OH81_*@:HFB7$TY<Y%O_B#_W(H)?85X"BZ82M(6)<H
M#JQ)N/LMQQF(O]$G8Z^&!D5)#4[+4O\I9[/%K0\U3^F__NV_7)#S@("WM_@%
ME $"G;UL%P9<0V;O@A-R]B;H:_?@FCTV42PD=()@S80!$]:P&0 2)!LV""B
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ML -% $VPTT0 ^#C3E#.I0L%.J H(4*D SCBAZJ91Q&JJHXYB&H S M 3@ :
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M;M$H1;,7<8U?/Y4;P1YSU@9Q3^"P@'SU"%_YYGV^\[T[ ?C(XE &/K_G&A>
M'[PM"O^8'5((0#. 54IO&=Y=4G!\MF8Y243FRY );D(K4;F/ *S!D>4R).,5
MP(X,=\/TBP\ %+H%K R?GO$S=K(S2LS_^@UGV/4*"  ^#OSZ?FF+DO,2I"PS
M:4MV%+EAOCRRL]-".R0/1J0EU)M:6L0&"6!$ABLM2-X.TO,*?&2'X7P<EO>L
MCY\,H"[IQ\C2G$0!PT&(YZ:6*DWIZ=>U I9J"0F.4D?"4I,A$E1#@&. E&>2
MFV=J!_&8,JU@$/&X@*Z0  :9@*!1/X&0IG98'"=!F>G+"9':H8"2"10R*8)H
M&990*VC**OL;*\GXJ>2@B,IX@)58&8KQIK?PIWIB*_[[C,V0CK70GH[3B'$[
M' 'AMGDJ#+_R.*H9'"=Q JA!#8J8OKK0B'Q;G+(@D*AXG><PCHO0)A92P*+Q
M#)%CJ8((+;49_QF8R F)R(E?RHV&J(X=G*J8L BU JN!XQSKV2LM5(N=4BO.
MH+=Y0K*]J#C>H K=T)[PH),^$:_R*B[ATA_N KO+$KNADRR6.Z'6.CM[8"[B
M&A7P(I7D:J#^V:W<RKK((JWD*JWOZBS-VA_F<JZX^Q.:&Y1$@<3;,A6TXQ]!
MJ<66,[L,BL2G@ZZ9^\1/M(=,N:U-62^T$ZV3(Q1ES*[A(CO0PD3TBL9AI!,\
MRB.[X[N\NZ/[\CMZ<18)TY908I=R1"56\K%SZ:/8DQ=JB25]23 %")<?J[!Q
M,:5FR; -XZ]F"3U!<C!W499N"( F<(9W&<C.RR][&4AZP <%8P<(T/^P<$1(
M9Y H4(HP@<$\_5*7C!P7=)P695&^Y7.(B)&WAC/)[:@=L'$29**+K8@3:T.(
MAWH2"1 UFT$ #7B2"OB_:R@C-2NGF4"(F J< !C*VK$27*L8#RD:\<@,MRJ=
M/_L+R@"J[T@=W?&.?4LW<O(RFGDSD@B CQJS$ 09>X _B5JM<;.J*.B( 7B"
MGH0S$_$R3*LRP[$/[XB"%,D&LJP D*&))_FWP3B:?R.XCD,,UDFSX=F-C),>
M0+/!R?"F+BO+[$&XZ[&KRV&+VW&XS R;L0%+J[0=[*DWDDPJ73)!"7 R;( *
M"]"']&D=)[,/@0!+MC@:@;.-MT(=\4&;L7G_*(_@MZTQD5*K@ _;B=X,@)&X
M!C^;C/JI'-J1'1@\C!#I"L/DCM.!';.H'Y5\G\SI-KS@-N4)S>.@3.=QMGNZ
MCJRKD^C*(9UC(*E#(JB+N_?THC0J(O)X%/K,++.#3_:4NILSE&,,11ZB1/:4
ME/74Q3;".J2[SP2MN;ES.QV".@1"H0(]HS7JF_AD()W[SV,4HZZS$@2*Q"JZ
M.E/!(>7BNOV\Q2P:+CJ9+LJ:4*+316ML$2:"T4.Y3RU:T#^I.>-RHU;IQOC*
M1F_<N[O3%7Z8EFT9,4BB1\);%G5AO HY!P$PD0  ,5^)@OS AV*1* 4#DV61
M4M$3 (=$ '>9TH$\_X\U>"1VX+WS@ !WL5(U78!Q3!;&ZSQZZ#W;"P (2+XH
M&$@%6)9SZ#U^= ;>:P*%&50CM3!DX;UB8#PI$ "$M!9#U9(^#;)\.21"XK C
M14?A0Q:1U!)YDQCO,:O:B S#^E1GDJC&>J;7>"8VQ(B/>J:"D*BTH*?N7(B/
M:AV*84&$$,.*H(Z_  W7H*E;Q0W-P2G+9*OA(-9[$H[D*33/Z NEH@C$4-7+
M>-74F(QJ=3+IY(O8:)W9  PG!*G R*N".-6UR:=C>M6],@BM%)ZY@*;98,/"
M4LP=9(V<8$.=X FY,*BQ*)K3<)+L.PBKF DNJPOX8 .V) @G"2BMB)&.Z?\H
M9<(U]EN(\>@JAX"TXG@HI.##<'L)P)B^C"@:96(*VL(UXF0)U\D?FK (D/BW
MA- (&C"F_8":(BQ!C6$?R"BLU1BJT8A#/BR(S=@+P]BE67V.JQ&.;HN^Y/B+
MFSH-7VVLWIF.L^B3)K*L)^'$4HQ%&,4L3P24.F$CZ((34)D)YF+16KR4J+M1
M,%HOG+-$2=Q1'FI$5*&L#;TMK^-$JJ6B_N0BF",/%LU;2;1:+H(*12F/K^6M
MNJV@2.1$4,%%:'2[%(5&GR,NM;NBL;,3(X**R^4LK$VB54PB%CVO5/23.<F3
M"<@ .;J57:&C.^H[U=V[6T&^3@HD_5+(25H'BZ#_,3O-W=L3@ "@ASO5L1+;
ML#4(@&&1*'QP@-\%EO-P!BE8@SYML=;;!][;L/.8L?,X) :31W:P4M\SD6[P
MW2CHW@!XEOXX,#\JTQ-SES+5 $I%I3)=@.<]L8@L!F%17XI4@#78,'$Q/G%\
M%\\#X']!I$$:EN+M5/8IK.V(3LF ']5)*G.[#6 #-*K1P^ZAG!B,CG*+B]?!
M3=N@*Y2,*XB #'(S'M?A';V2*M#48$!$M'I+3*S!X$%#GHM3.$"D&><\G[5:
M*^IA3 KN'!VFGT&KC/*0@,0JIP*9&?#A,XQ33J:%C..AJ\ID89J!S"K.,_&@
M@8K)(8$[&D-)FO1[P)DT_Q0+6,DX$<P'X$S@%)LM)A%W.K3%R;6+00B\9 H&
M(0JM;)K_\^*O0"<G&#/RF)EX"X X1HBVZ8H[:QN@T0CA<;) >[1PFAK\J3]=
M.XR)@SX:]@[6.#1^>S;U,1QN4YU"(T\,1I\W'!Z'V+;Y@1Z""#D-HL^=T\\E
M<J*KR!/ZO&7QBJQHG-PS6E'0=12B8SLR.MQA=JTHREPA4H_S:L0!Y;KU/*$@
MBM#ZG- +I5!"B2V4,SEHM$^4FU%*O&4FRN4H\JPLZJ[(ZJXQ MUD!KJO?=SV
M=*.R(\59EB!FOE%.\>:F:^>F&U"=<]%9SD4;A47Y[#EPD #8_5$AU3N$9EV_
M>_\5)B6]:#&E<IQ=7XF]9>D/=RDQ+*W(_$B^ )@\!8O(/A4 '%, AWR &%L#
MUNN\??%=,?V5W+7(?3 1 @;I#:L0?&"'$LO3\R"QWIO?_IT6AYS2:OF"_! E
M$6,'HR9JQEL'9Z!(,#V/\2TP=W'(A,2DQ#.78(F\=@&E5,(76T+@\XB,N<HK
ML_I@:"U6S.G6Q  LJW'BM58+WI"+''0J?2(KP3#KV6CDC9&=O6!K[[1#B=D_
MH#*.ZY#6"29AU+ .>AJ(U6!!!7:-8%WL#P9:GM)@)5.RM9*GM9@)D_HI"9B)
MK-C.ZQ@.OQA$Z3%$ILV)LRB_PZ H!("*?%L)<+!2;R+_-;&)@K7,;7"B &>"
M!XT 2X5BV=S>J*)! +IAV)E SAFLBQD<6DXSFPV>5> N[J^X 'UHUW;XBBH,
MF2B(V#2V!YRPAI1BX>3.'S9@MX4 AXUP@I^X@.%8C-D ;C8H#8U+*M  6GUJ
M5;G8-63E6>B!0<R8"U&MJYQ"0:4*6MAY*C>DM[Y>#O# 7,/-VDV\+DO96TTT
MW.P27?S,6K6EV@M*([/59:5;%?_D$Z7KDT;,+L$]E1GEVP*9+K;56@E=NCLA
MYJ5@KK'UE*[MN@Y=E!2UQ@#-46FT1LR].6@^+J@P6Z^M\%T<<EY$%.KB'R9'
M<N]B4;SUK,B:<0E-+BZW$CCR>$:&MB]NS$8?A16O/D=*4J4!CI;5 [TQP8<Z
M!=X/VP<K!9;G50#</3T!B$AZ4-X'8%XG$(!WT+!9.FELF5(X'Q:<'KY]B#WR
M=0 !J%/7(^J2UNAT&98K[:\K-;R.['3<I5\%@^GSP <C!19$#S%Z.1=7&B1Q
MW#'^2O\6L6;@T<!-S7:>C?,V]WG"ZK'DI\Q,3IZ:U^DS\:R8PBH=[1%BH!*T
MVTE,@5@KV_FST(PW:L<<V5EAH  10.Z_59[3[N2),;AHD[=O$[30 >5G2QK'
MGLH5KLI?)[=A[X\[4X[Z<3)?JTYM\V'<Z62GA/>K_,FN2*@\XYLOX4SH1+8)
M>D#DKAO7N#-(QHIH$IN!^+]VBXIKLC4>8K@'>$O,V=9WLJBF";50PS=)>PEK
MR$"2*:B_?,KH;!GX-IRM0;-UV_A(QBG$:*=@#[8:1JM/-N7(>!_F><+9^4Y/
MWF&$>VNTFDK,S(SU:<T%7\X'N/=YB&VMC6:IP[IG%E$) JZHW^6X.__&V&KF
M?;9$51E=M3W1$&\[JVM;LG_EDI.4Q!TMLG/;W8(4!970S*U$K/_Z9,2BJ\>N
MDU/[(YK1_@SHMO,?6'Y[958@\=+GK]_0"D4ZO=^49ZY&"X7G_5'/Z(HB<,B
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MD0YZ*J?%;"J IYBNZD"C$ 30A#.:XK/LIIT^ZRFB"GC:JJ&BKH&JH_N,JJT
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MZ5*6]+%;E$(4(F^$[R5,/ F?V%I6/*9H8,73)Y=9]T$6B<9'2 364#1?NCT
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ME #[I*QI C;*/@5KPCK[&R"* '8+ AQVHE@ 6,+L!/Q54'BKW29:N]G5@%8
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MF"D..2:5())&)9Y7@JDCG8-N26B1@)9(Z)I<@NCGI9LVR2&BC]8YII>D^::
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MXH5?0$E7%DV@6D:=!*W1-@W2.,U@8F;37@;33 :;$H)B+&9C1.:>U@F<&LT
M;P8O/X9E_URFT'"MU4RB9U0-URBJUEQ"U7R&:I2F:*BF!7W&U!SS)1[S,6,-
MUWQ-;7"0U\S&-,GF-%F*I'!0;4IS!G=BV<[BX+0"=_ &Y6QJ",VBW-IB;J!
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MU7_=3V&X_*?;15](.-%"YB['FM,.TX/=$B$@[2W9TL_A<F/X_&90QF5:1E\
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MT>,]ZT,@4,)N_=,C"'29,X(A$I1N K2$,N) !\) ]H,C]>9 +Z(_Y58 FGE
M_X:9^O-N^S- Q7!"W]!P:*(GIG6&:5@FGX6&I35Q+L0G9?AP<A(HMREP)+2%
M$H=;L65$*-=:;SB'3"2'2J1:<"B=DL(/FA2+[L)SDD2,38=<".!<: 1U&V&(
MI+@/^[(/:"0%[$"(T95=^Y!U^-")1B>(Z^5<RI)UW>  ]N(,BT0/W**> 2
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MBY94&;?QT'84/&3?C";:\U6?G\THHUUM\N!Q'TL?>Z2:_^R:_=D(E3I#,P3
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M:C+^6A*A9C*BA$(H #50&:K]>**@P&]J8L)KU"_2+LK_'&W2H#(IN2*D^"\
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MZMI8;8"/,-L(.@G)MZ"E)PG9BJ[4"GLQ_#(A&EH'NEHA\Z(!."]BVC"^RWS
M4X=D*.I4*$)O_\OG9.C?S&=%7@BQV.ZVS"2$U[.".^M$Q9/MW!,YLVOL>MC
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MU%GN0#JER%G/1XC;3-FV!K:#,HUKY)FPDL)C-*#M;7,91MSE!'=3]03';6O
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MVU"T)J-)[:O)Z&.J21V=_H _@EPJSTD.P9$\X"%*4TT0H;*'#PD1J]*J\A%
MK'JJ]7F?\\DJ6PNV'T% !%3 L3(V (++ )K+ Z228-61,!FL']Q (:*@N,H@
M6KF365&L$\HKR?)'"( 4!O+';L@VR&F"'>RW!%H#6E$ .ODAS,HV-1$39\#6
M%7JLP<PV9^B&  !7#02M=B77>F779I@5)V!7?YP5"$A6+(D"/AG-Q3)!9N5
MTZR5K '#5.I"9\F7]O*:7HHPN3DP0Z*:MN.6RH"Z 7,7U2*Q?1''V K2JBG$
MBITQM-'%3"P[YCI%!, -;K (#K6'U#G_F<*HBX1QFI[9+7%!AME@%@D86K8A
MEJ%9F(Z9V"_Z&?;\F/B:I'IA+>A*&[R+V95% %?\1*VE#26<Q 95E]\C!\FP
MEJH@0P2P@'Z2QI[(%HV8#0T8BBCXO5=,ETB$F'ZQ+TC$"AEE.<7K,(A-"@L
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M4]\ ' .[O@B.Z)$<A?&-:#%DWE&7V4BQ7['!KK%E JQK#Z# SIF_1DELOW;
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M8QP[S'D=^2^$'4R96IN.5?I6F )9>"R0HW&%W58P5$JN8+S1&HJ/(KO2)#=
M_R6;Y\+F&:Z%K6_XA0S8JL(&&"VOJ$QM$IAFVJ'IL2]]V),0_@08IB5I+ZH.
M59[SRE2FII*(HFL^7X:.Q+_H8:]&'%610Z.J/N"IJ'\%%)*+ "@B.OV.S+Z;
M4?N6FKT?$7IZW2LJDJ27)^<9.GF'!JFE,40#!7JP@Q1\U%@5.$$),NJ"JKY@
M5V=]:EC["58FO.L(=5U7NMI5KG9=X0?AJE=?MRHDX/KM%&&KK(X(0 K_:U"
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MR5%M=?6431D>&@B"V$.5U?.!=D5!%G1PY",^]H8>_V9 7$F#91F$Y2-"H25
M)O2"JV6"4SAN3 B6X39954@_HA5P\U9 X&.6'F19A967=-EMXC:%8%EPD&4^
M_U>((5XT=1"QB;A"3?SB1QFG<S848!V!1JR4>>2X*-'()BT4>,J4<:0T+H2R
M15H(2[4$2\.4=Q#Q2/$B29&4<;14=_$B=JG$=F:W1IO4+F"D=&676Q6'0Y 4
M=T1TFL+4$64X+6XW1;4">E='2#]G7CWGFC<T=&G7F_H@=,O$35LD<7W$<3AA
M*\LB8E=W=3&T=V\71;_D1)9D<=$TFXT20]R)78ZW*-OE*M/4$:MI*B63<JD4
MFFF$G@\ G,F$GHTRH$MT+'VT=U?W1F>W8=\I1FAF4%]3-*K'9;Q79O:(CS7S
M3J[W92':$*_G-/]$CV.6CF"V3[(7:&R&?0853W7&C_\"M6@V*C4.:346"5(7
M"GQ;\U'0]T_,%WS>MS;8%U%BP7P&U6@RI5/N-WZ-\SF"0U-->G^D]E/[EU.0
M1G[[EU+T!Y-3.G]>*E/V)Q>J-H&:D8"[AI14-59+M1MN2ANPEJ83&%4+^*;!
M,6P/B( DB(%226T?*!UTE95SE1W)EE9^BI7P-EJ-Y81*:'!]!6[=$ZF;U3X"
MH $!( 62JF_NUCT)AUB')9BG587XAE<Y*%CGL"."A0\!< Z-55GR=AZI:B!-
M0*DOHH,"@"%X%2$00!X;8B!.T%==0EEAPD .MY@&THJE&2^:8E]@>"G;F&)^
M4F)8)YD9$UR2^7?\57?*%"W_FI(0GJ(HS04SKQ)BI=1;]T4I. 8P0]8OS$@K
M?U2:BI@PY'DLS_(JJO)<.Y8QOS4PK3@JVS@IG,0H]A6;US@SRA*AY*5>H=*-
M9Z=CXT6)^=)WKN2'B,(RRKA*] JMPFBPZP)AZVJOTCJ'^74PNK)-M7@RU^B)
MR@@KR,5*!1J'H@@H@#*A%M-AZK5CIS0S^/J-"CM=LJBM\QHOTB)B$]8L^O4J
M$",GZ!A[6D9E0;,S319/__1.'$H0];B.]R@3KW=/]L1FY^0T6X:.8B&D)'4W
M>M,31QI]>*-GWF>0C):094$-.$-29 .1>H-G<.8V>3-GX<10#ME]/HJE*>5^
MCH.2_Z2FDH-#DY'A.9*F-QOI:ANIDH7S.*+SDBUIN&8JI9M6#$8Y:W<J&[/6
M.PM(E%,5;+<AE#L9;+ A:[ZVDZ\;/#<I.U.)@82:;%)YJ-$&@M.V5DW);$]9
M6:>J<)NEA 4W/V.I;B88/Y6Z  *"'DV@("<461^$EI?5E?M#JJ_E#$T  <O;
MEP*@(_@P0%F" (C50&/R/@:"'JRZ!@47 &N@J7QU(SP21^41!<%Z(_(A(>@1
M $VPO[5J(E]P6@0LO,B:K%ED<:K$FZQ$F]392H/BH(IRG!+7>,LD2> $1C,4
M=Z)B<_'BG)TTFGA$<\VJ*%=W<X"(, G6=K[TF)K4>/WIG_^A-$.V$DI85&)T
M=Z#*9$:IY$:V)$4N_"U3M"RX%$VO%$,'ZG,O/,/:68F_(DVE4H9'5YS;M)EU
MDIFLN2]6IRB2E$3&M)K#])H[ABW7:2@OG,2#9T,RQ'8;MG56AR9F-YLMW)HM
M',$OW'@SA,+3N$:0)WDQ1S).Y$TF<L=5-$IR%'B@."H88W(FAT]A%K5?>V9G
M5K?L.&55=C.^%Q83E4^/'$XML7KWJ#2^9S,#M68@-36FK#4?]7TWM5$62E"S
MUU!N$Z-8\T\?Y9 +A5$[VLJFS(_$)Q;O]U)FBA7CUWXJY3=T<5.%D7]2*CF'
MP<QB"A?VYS@Y57Y^4Q;JUU.GX7[_C3.!8Z6FP1%6O=& :XJ M]8:Y5QL587.
MQ"95=TJZ5F6H%XB557EMWP&\N.N!=/6G]URHR",-)^27C:I9<,F\X_9O15C
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M5&7*QBR=C:2<T6G4DZ'6M]F))BO+5$L8*X.;R RFMIG+QPW=7;5,? D)(GL
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M>";N,.H9B^R6)N&RB05ZC@'PZU3LX,)AN6LC(QKSQG*S:^:8P&N&CEB2]^7
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M8Y1$@^L4:O-X$SDO3YM<$3P50_0RILZ( CA/.*$R(SU[6#(@F,VZJ3;%;I1
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MA9S%GY'PU"(ELK!-+Y(38CM+'\;J2#N)"I*C**O$U_IH07'T$)NR$UI# 6A
MQ'60FM2T'_8!ET*(/:YVQO-7(T%'?:X540 8&Z?B:$<X"$H.9CNDH0<Q2H#_
M<]*7(L3<&0%'/LQE+WJ75RC"1D@\2F+4&\M3H!CQ5;::)6UATZM?X%2H06Q
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MAFJII)%& :D" 4C!J:>;V@ILIY]Z.FD3 3A0[+";2E',I) V*JFPF8H:+:W
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M'4D;%8 ?#5(A'=(@.5*B-%DC&1*0.6#_DBT*(A4*/\R2MW22K[#++^$2LP0
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M4D"%-2 '3ZA$O2!D1V66._+<2A0. IC&3/)$\;R%0V*B=L33./4B EA <51
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MJD#NF"=$YT'J:5#KN@ZM(4HO:NT:R&0/;E V4"ZTCZ&BA,+>N:Y)%;S_[&Y
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M9#?(8T/@1[$(;C?8K3B0*DV6:DOT;W^^8['8L@:)0ZO*+3D.2X% 9$^PQ*V
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MA?SGV%X'N7Y-5F,G!K^MU()(UA)W>=22<9.HU:IH>1 3B "(3,Q$>EX76-F
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M%@6BP,Z .4%>"""'/2;P2XH9S2$/"X"MV* B8%U@4 [!AD"DE:^!&2P $)$
M/=OY2WA.4DXHLX>:&"G.AF$#9+T<)D2<L :?@2"BT1R S"X0,2=DU&F3Y,8
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M3!\RE L$@ 8CS>,.@?:0)SC!";R2F!,:_;!V%-,:04/V4$;RY&M )$ZQ8M3
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M8P'\00\**>A>=JCP1)C/88/J"_H 0$%!^8EJ :/$#A:R8[U*0C(-H63"]RB
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M[$0M,56W8]1,EL.0__6011T,7Y=Z52%!U2IC4BI8=_16=#LF+V;!J65FTM2
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MS3VN'U#XH^&D1$,V9)Y=7]PLA4DIVME46M=(6M6DC:79#4I<E$\PFNXMQ4)
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M8S]5K8U"5$)9+8[2U$EV))Z%G]U 6MQ$!:8M!9'_7I1-6&E&DB3S9:38A-1
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M5[]]Y?;%:[@OX+EGSS8>W)9O8<J&$U,&RYBN@+=H^VH.;9BQW+UZQ^(E'#9
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MN)0F0<&I0>JQSWA:I!^M1B<^1+)08'6TNJ:R"'1+PAQC*>2AW^ 4K1OZ#N:
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M@ 2$7:"*5[O4L0Y[+DSLX9#:.9N6!\U8+M3T+GJ["Z+).K=YG$89^$$+,LF
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M01FK14;H1[Y/I\:J!.\L0AQ4JSJ$K#+40C-4HRRK Y5/_TEXQ$L42T,XJCS
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MRE.:LDE,1P*J_;MOT^ 5%4RSN_156SU5_W=6 VA65+5K:E6 72554R55O2:
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MAC'$> '$G:N7.O\*.G1I1)W#&8@ )8@HL([;+X<1,/?J)-,$&$^$+YZ8F9:
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M3$(IY9EMIMDDFT9RJ26:2>)I9)E10IFEGF[VJ"6740:*I))V,FFD %@2:J4
M 4 :J:239A1321ZY9!,"3C0U$Z>:VM1.  M ]+]&[8A:$*CM-(7JJ:.*])!(
M&TDDU5-.;%2JJDV)1.M#%8D44Z9-[2I62YL^\-!,E?;Z*:U3B<2J5 \M6Q&F
M!8T:J[2E;NI55/_ 4A7K3 D9&Q6OQAI;T[*?WE0L5<1N6U-!J2;4J;FYJKMN
M4>XVZ^Z]RZH;*[S,ECMMIP$7VZY!#Y6J[L$:A2NM1PRS6^G#[)+45*J]NMM.
MN?66ZVJF0-6T<< 1*;3LKR03Z^JF8N4[E%3HUJ2PLQ6-#&J_4V&54*T)9232
MQ4WQ/.V^8ND*EK@+OTO54-0F';-8Y8+FUE^51>WN88/U5=-NBD&$%V2@Q>4U
M H:YY6[5<%D-EV20R;5;:'YI5E@3>]5UG&[4_+7;7K;]UMAF<UL&6."^;0WW
MV*CEG?=OOFD&^-Y^!>YW;\]91YMRXL&W'>5S'S=:Y^$4 ][GH8,>'NG_X7U^
M.76CFSY==Y2'QSEWTXE'.NFR)=?/A1=&N/N#]CV887WZ/<A[?1$Z"'SROA./
MG_("'C_\\;KGOJ#O_?5CWXTLRHCCC-V/Z**,XF\__HSD=\]]^>:K?^.':R)I
M)?P].GFEDO%+R2699_YI?Y%N6LE.?A+3E!B%)P#F#TI"TE+]NB0_.RF04?=K
M$OSZQ"9V0#!0CJ(3GNHTI32EJ8%E,E0$XZ=!(@EP2Y1:8:30PI(UT"1D&_&*
MU4)BE:=XA%;:PN%)?O*JJ,R0)<-Z"4/$ A.C7,HD3\.8#=,6LJMH92$_,99(
M@%B2)O;05TP15E""6,2G('$E-\091"QV%:#(_ZJ(&"O*1XRH$8+ !(@"D2)%
MCO(MG#5Q)SBKU$EX.$5W&:52%0G*&>6(%)R4BXT@N0I*&#(3I5 %+1?YX\=@
M$C(TZLQ=%P&CR_Z8+97<ZXTR'*,BI<@1LX1EB+WZV%$<4BM/AO&4;*SCT798
M2V-9$E0G*0M)7I42?=",B4N#2:7JF)2F+,5IWA)B3=A@#WL, )K/O(,TGVG-
M:T8SF]&<YC:K>8=L8K.:TNPF-;=)SFNBDYK6O$ _W&8VN41M+9>9FVMBLQ=Z
M?D9RGUF<:3*#., I+I]S>TT3ZC(:R.GF,8$;CFLZLT_8-,<R<2/.ZXZ#G?$$
MYCG-Z0[JO!,?YYS'=?\BU:AWW,.<Y.@F/K!K#TLYVM*,4BYSQPG>AK!'(0DE
MB$ $NE#RIK<@G#)H0AKRST\WI* )&=5!Q.NI@? C/A?%"'TU"I_WJ)JC&*DO
MJC:ZZE;/]ST>]8]^: +4EAR5J P::H,%3-21Y"<_,R6J@V$BH (_"*4\@2FO
MB.K@784$)T)A"4X [)-9]Y0_107I?XJ2DV*U]"6S\O5.<%V4D%C(PF'I"U?0
M*HBR2!6K9>%*5:HRU[] EJFH;(QH[M(9MK*UL&7=,285>:VZ8 LS:&T$8;D*
M[:C"-3!0P;8@]1):K^IUE:)!K):D15FZC*4S:'7JE\(EEW!3QC1 "C<KTW7_
M[0^!AK-EL:IIUL6N,8MULWCA*XF?RI6]O-LS[0;WAYF,R0S3!9'GIHU;P7W9
MO^B%-**EJBDZ7%@:-R6O<M&VC,R5K2:=%A/D?E*+6.$8TT0[6_2J*EKW+0ER
M/X4P;KE*(4C#K:WJ"]I+0LS#%69M1:@Q@!=#\\4#<*:,:VQC;<;XF3>><8QW
M+.,>@W/'0+8Q&VIL#V0H1#%<@\QH[%G/X/1--6K1&SW]5M"[!2=NK0F,8?86
MFKJ 3G&E\\S4=M-DQH1.+WYYV]YB5SK87:XZ\+'==$A7F\[AN71Z]BCG7$<-
MU27'SIS+'.WJK-(_(P?/=;,S3:5GO 45=7H;4JJC;*-'O>7]CGC7PS12I7=I
MGEJHT_!PW_K MZ/RH2_5Z4/UJM<'U54_U=0B&E)@U]HG0$70K7/*$ZWOMR0U
MN=6Q8:H2"0\[P$7-KWX49&"PYQK9.=TIL0)D$JX'R.Q?RPE.1,)@8M'DP6-C
MFX0/7/^#92E%RY^$]I-:64DP-05#5$:Q(:B49!(WZ<I;YJPD00&E+*52QXX]
M4BLVA")-HIA%?ILECTF99"@EC&XX[E'$@SS:1G:B$L]RI5.^9 I:LD7$5XU2
ME;_LY;]#=98RDK&)+G,7,Q=B$Y*X'+.9BB)#@NGO@[BRE_S^%5=\A6XC]H3?
M6Y3(Q7\(LJ"T.X=&'TA)D**5&):\5T+,.59.#LBO6-(H3;3E)W'(<N5F$6$N
M_WC'EP9(BL^RA@H.%[Q!/N&A?U>;0?XQW><^Y""/$\8XGCO?]YYCO?L]FMFX
MQCNS]IC2Z(TV:ZE-8X2C.+S-4S3!V5IQHOR;V<!&-K]9VUW_)+>9TC0.HG0I
MZ&K*0Y>'7CG1*_5.HME#'N-XE*3B"4_L8#<>]Y@']NK)CIQ-VM+7_[[0W&$]
M43ET4^@E"$(8ZM#R;YI\G!K?IC5UWO&+WY_>[52IH4Y.K*OZ55*[^GM<Q:I5
MIYI54G,5_"#BAS3\NMC""DJQ;^6UM>WJIP0FEK)[BN"NMZTH8FN08M7:6^E:
MEV@0G)@0_-45!=E5CXB5K1W*8M458G5)9 E*8!U@_Q#@/I0;I5!%SPP+?DD8
M@46+0J!7K(P$$TW+"@X+; &1;K66S]C$RHW6=IV$L9P+@$W80TA,B$$75L!,
MB>&@O*P,S@G8RGE<=3T,A*%731C,_[*(!:O@X!#-$;O<S RI&&P1X78=2W;I
MT'PA"XDA#,)\UJO@UB>]E]"DRTBTX'!%EX!U"D^DBK,,%[OPQ'7A8;WTTADF
M34=DBL- C&N=5M $(HJ=(*GD"LN(2]+ ELL4D[P4#1MFV$&0(8$=#0Y9F'8Y
MET+4X4L86+X1785YC!U9Q+Q,A;^,5Z9$8JU(# *\&#C(7=[%HI#)W8T-68_=
M 2SFHHV!0X\!&2S6XBW:PP2LC5I4V=D4 #T1Q^4=#NA,V>*$#F"P66_\QFY@
MWI59X]CH#6; S6F$69J-V3723>/A334^!N0E!GMT5.L@6D=Q5$;MF:)UU)NA
M5'S06:!=#O]X6,?IQ)[I?%2=M8YSA Y'%4CP9$^$ (_S("2HW<>%6$_N^$ZG
M-5]]4!JF\8Y.(23V](Y!2J1^A)]4:16KQ5KWM9JJF=KWP5K[P$BOX95;01::
MR$^2X-\'$="@$%#^%1"MZ<F0"-N6X)^2L%5-8LE>^0C^J8F=))":6!">*!O^
M2* &[A4*@8F44&4!T8FS0=O\E-5B=>"DF!)78$3)@(5-:%TJF4I#-)TQ56(I
MF9(>)6$.6=VP (L/E5P9N5#-.1)<(IC7,=W.))' C25-= I+2!W%%1P:;9'+
M/,4D*8VP7)(5H=)@IH0?UM<J;1C1=<P,:9T?;@5:X" E]LHD947_:/ZEI622
M'F&=<*5$)ET*3&C<)4UA(-V;UZ6%$C&%M!!33G2<$H$F3ER<USDF9L7E1?@;
M)\U1I2 %,UD,Q(D2R4A+'VF$IKCE,4&1%YG%1!"%5Z!%241A=3K-;LK0R4TG
M1WP205#BNB#+3119CP&CD;T8+L@8?$H3.'Q3-L'B?-*=+][G?483?]IGW?48
M+K2G+-H#!8R-$QU&<'"C:(R>XP6',IH&/^63@M+31 D.XG >0KU-.3X4;Y#'
M9=3&AK*&7TPH2)&43*&.[SD'02Y'/9)4H2''>JA42/%>[&%4G\E'HOW9<Y@4
MZSD']&C:]%!:4BT5\Q4/3075@%!:3HD:_T9F'T,2"/8)U3?P@_>83XZ<Y%=A
M*8V$I/F!WTB:'U6I'P%4Z0-I8%N)%?^XI$[*55H9&V3Q3P(!Y?\0%@!MD++-
M%5*"B;;=&DW"7TQVVU^ME;1M9?V55?S I &2T*[Y29JZ'U]UI:1<DAX6URCJ
MX5C,$,6-E[W(H''AEU2$UFQ=A<OHD!-RRVBA1;W4B[QHS!+^4&I)C*WP!(>9
M(<EL8;Z8ZAQ]BC$UUV-BC&RIBB=V6+Z\8(3=T:SRT<ME(DITRDC\UH+1%\61
M(1X&RR<*YQIRBX+5X*[*S+5B8LWPBZEL6+M\$A A%])@URCJ$$G,EG]%Q='$
M(1L22VS55JJ BO^#(>$C*4RSXJJEC$I/L"**N=N\H@NZO)>G1D4Q/2>[_"'2
MM.+&8$4KWI&Z;"(17DJ1X=T ]*+&ZITLON+& A[=T2<PPB?@ >,NUE@N0A,P
M_EW?]=@%P(->H$W90,1!:9DVBBC>D.CF)5Y"Q8V5_<7I <?F-=YF@%F%ULV7
MA<<S7J-!/48TID;0R@9 SIY HDXTNE3JG,= ?DY IJB>W4Z@T5[7LDY'W6/M
MB"UW6(ZA(63T-,]]M.W;>AKU\%3S)!7<"FG=9EKT8-JE <_;ZA2G28.6GEJ7
MEI^LM4^6*NZK@23[D,^*F$F<-*I3,E8$2B4%!6!?#24(;64#(=L%-IO_!PU*
M9 T0H+*5".4580VJL&U;_: NKD7N!LDI7^$?LS4E7(5N_41JI!@3&\T1P)%E
MQ<$1'(U=S.E;6K(7T&FGJ3C= VP2&B4BT<40=+X;0>QF*,(04)BG;])0>-K;
M69P1)6T<S9D=T[7K:H8E#N72UVE+=IEF@26G')GB?)EET07=OWT%$9DF#96%
M*^673\2EN<+E:]:,=G;$%/U<=E;*=/81%^'1\C915=!0IV1$6<YES+722M@F
MPV77QK61RY2<Q7'$':J2:E:7'.6F+TUOPJ51?3'$&'WE4\@;RZ4$:4:8$-U+
MB'F+TSFAM"AF.ZP%Q]I8C-'GW<&8?+HGQ]I#_\GRYS@!F3TT<7_"(GUJ4\G*
M'2Q:L31-@+OL!M@8!H:.'GE$&>2)WFE48^3UD^+,!M *5!G?AI=-Z)HU%&ED
M'AQ/#=^$*$BYSNU=E.MH5-5&Q]1:E#OZ,>R-5* -'WF\SHZF:'M\%.X4&O')
MWCPDWW\T7R53Y/-U"$4J::A5B/91")->7U!M)(#<QR<KJ8$8WY66)$K2""N3
M9)AZWXX\KHZ\VIAF@)N^WYFV:>FZU9LH5@8BX)'P#__@+D[6VI-@+@ :E@3J
M#_WQ%:,&ZK?1Y)RDJ5Z!$*\=LU;FJ9X@<Y'L+J2TR@K"7*^6YW5AS P-5]
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M^_1&I.%IZ82E?(IWS<0<3@NHFG.63X7\Q@P5E<P6/EB3FS2L+M=E!J=K#7G
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M: P[SO&8*!"%:0]0"F=.VA3U5]09#.HQ%,!JWL9H'J,;BL)HX*\)[FPH!#
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M#18@+[L!*(KAH!S#"5+*;293*?#U :+@+!\#'S@C<.9"H%9J'R:6'9R@T 3
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M4^5/XV55OI?QB&4?3ZPA)>Q=U&7&9(7%E*E?*A(B];=@8,Q@<$Q6))4D=8^
M$3A_?\Q> /CU_,5B."8GGVECO&QB=%4FM8R<M*QC;E7)?-7*0CB#@[( A+7,
M3MC,TDPII?)8U6R>XLDH\0DEI"8JIN8IR'+]<"HM7.K.U,^B)L,!R')M)@,?
M",U<%8W0 +9M%(!I&#8H'B.D]')=$Z,;*.,IFA@NUR$N %, !%;^\O5J$"<
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M;P*^&W4% :2P6Q" ._3D]("'CW/XK8/<<OLH$)]SSH 7!7("!."$,_!QMT^
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M0&SP&:P$!%GP0 4#)1NG0A3,.>B4;2Y*)T55SDDIDX(NNJ2A;#:I#S*J$OK
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MW*!E229%YC=G3G!)OD(EI'(!]U00<8)C1E*4H!*!7<,&;- .$=-E0+,LN"*
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MV076>+8< :Y5JMMA8\+6V"@"Z/6< / 1@)X FGA6 6GW>78->+OQ5=E]SF4
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MN3)@49U'*R=@@1<(^">*V:>+(9F &IF1D265F1A[TAB BD&3R1=?,36$^@W
MJ*N4^)S6V*NA^PCBN*@%@@B5&IV)P 9[2(BK&0"%\(J1R@9[D*FQ@3:C&8 )
MJ ![V$*;<H@*F(HU<(AKV F.:$($L(:#J "): C_;& JQ= ,P#".K0*)X&&J
MP+*.YOF+TJH(K8(.FR@.W;$-Z#A$DTL)U:"K/H0>E,@HNH"+TRJ,BUB+070M
MF]B,]7&J0:2,)33"Q1FZT]A$Z6DHX&"ZG=)#W7$KZ,$*NMHJC_@)AFH)V3*?
M5.P(B7*Z7LQ%5B2KXBBXSV*ZV?H<D1NL@5N-07R-PV()VCF+UF M(H2>Z0&L
M@],;WF!&O4BZV9HIN=!#HC*MCV@>XJ *Z$$ -L@@L;N/$/J/Z3JN_S@[ZRJI
MLX.N#\([^:A'\L#'^="@I\FN)@(\:K"0&OD\RM,1$2F2S[L\A.ROS^NN(D)(
M\'*B'7+(\]H0%I$0(B*B_Q%Y+P;1(BH9$P#S(B^ADCBJ,#<IDY14DQJ!D37!
M/3)9$@JK/2*!,/^BDA1YR9BDHP##DQK;$S\*2A4;I#\9%$<Z)$6:E!2K,1%C
M2D'J!T1!%.6SE*MTRD2"RDWY/O/3OJ[\/E/ZL5 22R&[L:_TI"#S%%GBM():
MEH+:-!F,"08TF32+EGTPP"T+LV'Z,GI!EVL1- $XLX7Y%2M; &-"ES<+  <0
M -5Q $># CSKP'TX,U6ZIGYY%_W+,WOZI;U4EKPDP37 %Q%4IQ!$%\I$&'JR
M& S401ILF=5\LB<3F!?$08+*EY*Y&%#[F""4F?P)K.5IB>]I'9/KM\L1FK((
MBO^HN8 !L "ZX88!8(.EH4*G&0!K4$-[D(!^@\(  !LV>$X+8,>:>K7N\(HN
M)!Z#R)KC1(WEC$(]!)[:V1_ON8ZI4[J"Z[>Y&8JL<RW+DARJ\YF[$8GYZ9_\
M@9W8B3F4FQO%N8T  AP!BIRC4L+^*8RE0H[;N:Q4:YUHA(U]FT\-W8SB 3K*
M$5"F<YRJBQW*<2VVZAWM\9^=TS?#"2#\? O]$="[F=$!NL6)\PA%;+=QVSC;
M81SW.9QYVPZDF-"C,KK L3<]5$6QF;JS>-*CJE#,0(Z(2AV5Z)ZCHSB-LS=@
MN[M_C*"ZFT>OD*!Y#$@ L0=\;$?UZ,<&"LCH,E-PN #_%2$(%!D\CJ2A&H&\
M%^H\@YR\!@&]_?*A(<+3%/(AQS/4/*VAS,O3'I$C0YT1'@&B-LG3&QJ]!=$B
M-)(B.D*2+9H2+6J2UIL2*E(C*1K5*$$34AVP.5(C#MNB!&,CDHP]-L'*/HJ^
MX%,D0$J^/@F^.DJ^0\&CYF.^8!U6J1P204J^/)*&;_#*[!,_''N5\CO+[H/6
M\6M6:"6R:4T_3%.6VP2U;6I+?!(6 Y27@V$8F>@5)^BE_QNS!U"6 %C79^D&
M9WB6_G."99&*7W&7<L S:*(S9ZA ;7JF+T!,?&$R;O&FO?0R&GP6<!JGS%27
M8<I,9)% =G@FMXP_>7I-B9F7_WN*I8 "6?BS-+B<M);1V!<$0MZ$F>UP#MV1
MQ&!$1.+(T6UL0G34B&>; -HYFBH\B)]80P0XB*K1B.6T@(Q@ S9HB&M0J6.
MMK.@B(:X *9X .@<'9P2#J:= )%@J*QZC;D@G[L2MZQC"Y0P'Z.ZCHR*K9V"
M1"5DGZ[-*)UY#:I"'_HIQN$(*EH\'[>"QCL<.)N0'[^J'6K4J(A@C:OP15Q$
M0K6B1;#B".8XK>K8B. P*FMKW#S,1;3:"'"LT!R5V=JZQ4;T#3UDCLB@7*K3
M&ZI@JK+]BPV=T,,A1LDUW+GHC<[-#;-%BM1:70.=V[$]C:GX'=7I6[R9GFC,
M#JZJQ?_&?0UVW" ..@CE<E.Q&X!^!-/T*%/H D@X]4?HQ8_CHB[]N(:!^!""
MN+R(S! ?H1'/^Q&#U*$FXJX2BI#UHC#)^Q#NVCS\PA#SO1$, =0%2:'$8Z$?
M,E\,(R.3W#T!XTDH@1"4Q+ D$3 G43 &KI(K,DF?M)((?N +$S (N\D9DQ2C
M_),5 [%$XB-+">&AA!03<S%$V1/J:S$8 Z13(K\@R]92^DII+3_TZ[%H#3\9
M'C0^JT'Y:S\='#0#C)>!@:<H\!4OX\M?P27 =)?$/!EJB0)]Z<P'H+/&7!?!
MM$ F?A8(S$U^\9<FT,S)U)5KB1EV,>,L=A:8F>*$3:97\E;_E'&_'>P8D,&G
MVJPGV;Q!E-4TE*T8E67CX!$XY%FUF$,=ELN<N-FV 0 WX'E.+M0'L&%.)Z"!
MHY4*:@N "7"/DWC. ?C>-9A"KPB )L2U EV#.*3"J%&I6CM.GEB#)PC#^F2=
MR(B,GY.ZP#(=L84<="NKS'DWVE);X#VZ%@4YX*$LN^E#\/DX)(VXMY XW4&Y
M 6*Z&16*WEBUN]!1T@JJ^IPY9?9E%I6?VAE0@P,ZO4&Z?&.-0D8ZOD&Z]YRI
MQ&*YU?F;\''GOTG0OXD>I_.;:S[FP E.XHRK A4@F=,JXB ?Q-&>X?RZA%9F
MU, XV$EDR0DLY-%=CV#90*RW0R:*_W];7@@BT^."#W=4H.U-.SC5Q^6UWNUU
MT^JU!QH82 1X(1,2B(@TH^W"D0"&+\,;U$,-$0G)$!P2"";J/!K94\/[2#^]
M$,4#DOQUHD'5D$[-HE>5:C Q/01FO3<IU5BM(BR2U0[;DI3,(ECEHD_](CDJ
ML*]&HT;*U:%<ZT 2UN=384#YH^M+OA,>X:1TE.L3UJ7$54D15DWB/ARN5J\D
M2[.\X6O-/O1+2VWEA[>$,F\U*(D1F9:YXQ_DIQXFEF'9&"_#-(S)V&'Q6-"^
MF- &EH:A[(Z=F(\-8M4$[6/QV%C*6-<>)]E^RW^Z37*"P4N#,E*+S9#=P1S,
M0<]V34"FEO_<Q9L ,E#&HJSBT*K$B,,!Z F":(?EY!J'N(",V)HK= *' (L'
M*"EN.PQK<(^HC0+^F(R96 ,+L _Q8*EVJ%F34)O",JV,FK?!@@KVF:WI>+C\
M!"RR%2W%*L?@U(U/-%#,2JM&; I.U,.(LPV].L+8O2SJ</#8@-)<],;I$0Y#
MS/"=<N:M10G8FJG,^ISH\"F:*=Q2U(P)U]T4CRWQ0;A;'/&"@PJ[V)G)08[;
MS:I%K$7+Y8B7X(MFO-N.T R<4XVY@/&R L<DG*C1I1P0OPVMC=W#HJLF!9J,
M'IZ-%HC><B#UX _G8@^\XUZO4-/?XO*[\P\  2Z["\CJ_8\Y_3O0%O$[%D&O
M%"K?Q /4B?PA)GJOGI81)6JA\E60 ?LN0VTB_64B][HA/EU(/I=4!<L2(Q%5
M__(O,&$3 !NCG*R0]'V25DVP29<]2E\P"[Z25=WT# Z'$.X30_G5K)P^5,?K
MY5-*%+,3I(SUN':DMFXD2<(39SU+L;3A3HIA7T=+P ;V&08R4@F67O&T4:,R
MX+;,VIZG2=/-00/N=@T94+-M::=V8<FTD&&R4+/C3+/-?8HR:(?-U<P85R*6
M3AMW; \8<?7L2H.R95]-<&69U;QC@O\B[F>9.O_IY1\M4?SD.?K4BT4N.M51
M[^N*FZNY[JGU9)Y9SJ#%N;<9FS",NI2[Y/2(F@=03]5A3W7S'ZEB<.U ;ML9
M.FRTMW!#7<. *\J29I'(4JG[&W/C">)!7:"0Y@'-G;YJM>NY.:>+TA/]NEON
MCJ"3;H=BN>&DT?_4&X;S4)&;QL-IYZ73NN0AB?,ISKS*'M*A'+\9TJ?(W.C1
M*ER>:''&.EY.>?X4')X3GW;6NH##9YA7YJGG'82#:/-I+0AE4GX3Y LU>6D6
M7A;-'GNST67TFP-!:;:[ S15\^C%H+9[CX^.H/Y@_#%W_,FGN_3HQS3]#_D8
M(9@6W[]S2//_36H.B3ST;:(0(1-";Q(BXFFBYE/^%:) -3S#ZSPC6FH>VI M
MXB$*>2/1(U4W>1"2#.M3?<DR"C '%M7>>R.?]J+6%U4KJI(DL3TQ29)3Q6L6
MME5"0B2W)K[@.[ZVCK[N]V ]<KZU9DKO7\I>7VP8UF'#AO_"/K+ -LL=GM94
M*BA.B[)[WW]Q!8A] M@)$$AP'T*"[/8Y2R@08<.! QT$0"#1(,*!#/<IW%AP
M8<.%%R6*A$BR($>2#PM>W'A09<&0)R&FI,G1XT.;&S&V? @2(4:#&AWJ_+FS
M8X"D2I<RK8C@P1H$[:),;8?@:CNH5[<BT/<4@9.K3K)*C<+5JQ.M_V&K1EF3
M-NK3J@_:I?4Z%ZS6J'H1M+WJ]@'6BEZW1DV;UFK6-53GM@LPMV([KUX+>TV,
M-VK6QF '%]:Z=:UG)X.I#BX;^2G<N'>I(BCLE[#4N:1C8ZY<&NSKSIHMFR9[
M6+1ILU(OOS[=.K#8JU1G=_V<US1@J78U8ZV\."S>JIN/I_9,&[=<J]^]JY5-
MG?7;UU>? X\[_0%VW'S;D34-MBIVRJBEGCZ,.?IQZE&GG';M::>>6'.!9I5:
M6STF'5? :<765 E6R-5ZJ>WGVH'[.<>@9FI9QAQVA\5U%1O@V'/' . ,@,L
M]@S08HLRSFCCC#G*Z.*-,>98XX\PMN@BD?\Z&FGDCC+B>&2,$VP5#@+4;-7$
M5@4@ *654&)9##7S() E O-(&4X36I9Y)0)<<FEEF4U00R8UU'#9!)?AJ!FF
MG/- Z>6;9Q9P9C%>FAEHEU&F*::<B4;)I9@%.%J G@4$&HZ>@3H:SJ.32CK/
MI9%J^B>FEE;*Z::40GHJJ9"&JB>I=G(ZJ:B.6JIJ,9N62JLT!?0#CZ[2]%,
MK_WX"JRCO.;Z*['"]KKLK[P&FZROO";KK*._*KNKKL'F*BVUV ;+;;;,-DL
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M^9^:2>-P2*3[; WN5$U"LD[J0)IDU)-Y(".<(:15]$Z/.%L#W8$"/9M=^=H
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MY;F;7]\^?_;MUN5CS[_QNB.PN@+A$T\] ]>S;\ !_Q,L$#S[V NON__2,T_
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MBAM.Y#!'.8Q"]*(1A6@&^!&[Z?_AIT/]J1WJ!G0\9Z1T==(YJ?-T)Z#O<,A
M_[D/?: W.M>);J7BN<[JP!.?T%&(0^W!W7NJ]R#Q%%4_$^J0A'!:TM=)KS[I
MT9[V<+4H-PUQ7^LR%JU2U$5()0I'QNJ@'Y<HPC^=*4GNHE&1;$0G9Y'I1JKB
MU)2F!2E!<4I(?!(AHI88K'F9R5N)6J*-C'2G6T5)2Y#J:Y)PU"0?X:]112R3
MG]18I13IRH9A?2!;Z5HH-SJV5#Q:ZQD=^ZQPF8E+1%2?CQ*%)$2I:U'90E.Z
M8BLH2LZIKWC*%%WE=$ [/6J)W-(L^QX+6T=1$DW@8]22%*L_O^Z(K@V94Z:J
M1:XT]97_17U5[+AF]=MUN6M66QKA#/]ZV\3.*H_W A^PBK1$2+7R8:CD),DD
M<C%FSL1A^O572!SF$_]JY&+W#27"6#DPC6C$7PPYR-%(%A>1D6R8'/G+R4J&
MDIM%DV49KLK,"H+,"X]89S;32HE'9C*5*628'V:)T]QBM*BM!6E_V1K8CL:5
M"\\%;6O),5]L-I:A 7DN<L&+D7LRMKLLF9Q"9MN3X189N4EY,?A<#92A?.6\
MO<8UG#E-X 9WT#!?)C(9U9R9-?JXBD)G<Y#C:)N'T[B*KOG,MH'I3)5'(=9Y
M)Z:MXW/S_ P[T#6/><HSJH<J=*#=N:=X3LT0[? ,Z/PLE3_X_VGI]%!J4J>Z
M9T(W#31*8\J=F_KT0"D=WNB,RIVK9@^+FFJ(#R^9(R?B\(D+--(6V8=$-786
MC[U.(PFAB,*N1I!/ I3OE$P4Q_D1\(<G3)^\\/>^,:)*7J6Z-0WS>+\@UH^+
M2F0CKN=+R;.^"]AE?)*/@OU$8M&OV:"J$;& ^-L #I%&1ZP?_^BH;C[9\8^F
MPM*KN\K$$];OB49RX!I+6$@)>JJ&#W0V^CYX;%GU2)(SM.ZWQ><^2$'14R'L
M];]OR"P"-M!'WD(AN@"5;[S2ZX3V<F#!W8BB1$+RW)XJGQDW#KXU\FF"MH+@
MO'7H<UDG+):XI!*#'>9@HK<2:"V26/\JF3FPE*#R)2;A6"N3+O6H-V29)&,Q
M3WSI$H18LV8_XV5"?,GAA 1EFB(;)M!*<A"<C-W%.FGF0(3B8:V4I9QDN[$Y
MPU;/N R>+8'Q2EK2V61Z>L7&.J9+/<&9%W(6;2]P28CAMIP8?UZ9,:-I36DX
MSYK'>!XVHY>R0%]3&7T"[O20P<Q I<%1X<C><A2-:.8F6F?.X9XY&,U<FP<M
MTM;Q!](WG2F@*;T@EY:T/O(9_O&#VKO/"96FJG->4Y\*NN$__SREGG2I$9WI
M4;_'/H:>_J'_HZ#9X132SD=^5$&T:A(IZE/GE=-GV;5 +B6J22:*K3[VA%%N
MB%*N)5B:A/__+&A(;(2,+&A6P.54GJ1)OF5*H U02FZUD*10Y*M<N@JSJ,OD
MH&M4F(6Q^@171*O_]$K_JH5,RJJYM(I)X,50')"Z,*5.5&1'7N7BVNM/=L17
M\F2^*D57S,NX1.5.)(L$P<N#HF"K,A!61K!1\*JRABY09BB^>(12<K!2@(0%
MU^6RZB])5DZ&[H0">>0'%8M7;.0!\.H,V8OEUF2)KHBO3LCGK"N^HN3?$D7F
M!HM=+,A1>LOBZ(_GG"1/^ OKFNY@QJXCK(XA#*Q@$%%A].N5$D;K$*9%3,F4
M+ 9C%"(2]6MH*&PF>B;"8 8IEF+L:@(EV$YG5FSNS YG9.)FV.YFJ4Q,))!&
M[%JQPGQL'M!&QFB,,(9FQQIOR9Q&;'("+7(,F[9&+89,G7CL;'+QG-2")9J,
M;(KF+OCI]/;I-+#,;_Q&R]XFH;[,-+0LRA1*<%(O;L+,,<Q,HN0,S6:OSM:1
M]]YQHB1'HG+/-FRGJL(/=T[GJ5(->*2J^3RGJCI-IK!C_-9/^Q1$JFR*=FQG
MT[A/SY1*T*1G^J+O/Y9/=+;/T9)G0BS$.X@*TRC_1/[F#^;XC>"\90/W"()"
M3G^J#09?<M;>K=8P20(K*(4RI>,.*..\S5EDC=U 90,-KM9^98*$B)!LA=O4
M9%6LR$F4"'QH1">K[=^P2'SNT(K&:B8+KGT^:XB\2/^P3=L,1=NN:(GHR.2T
M+5/2Y]OF:H7FS;J6#=@>Y:P\98C$;8:&<DNF)-Y.B$8P"7Z,LN9HK8WXT.&D
MQ=Z KD7>)X5R;H'L\N%^\D2ZD(.@J(DNT(2H1("4"-MV#M:ZRN+D"^<RZU;R
M#W]D+E-84C%M+N6\$HQFZ)4:4982\9,F(B4&C&$<(L%(PB+@KBAB*2*:@C:9
M[L ^B;]2D9EDHB"24V1._^R:%.)GIHED0C$G:F8Z26;MVLXBL*(JEDGN< GO
MHG,EL@)HO*)J& ]M#,,PR((NTI/OJI$]ERP]R[,]T=-JVC,M?%'R)F\PN&8S
M4(^A4"\R  JAN,R?3$]NIBSUO(R@- _V2$_S,$\:'BKWZM&C?(-Q[C%#YQ%S
MV'&C?L]Q1 JEG(?X%J2JB&="$"W0J(,\4DI$-<3/RD/]=,HZPJ_Y+&VG&B0@
ML0]%GV\^4C1%H\=%:93[2DI"2)0@BVK[R -%490D1X1+*.4E]P17NJM=YBI*
M;9!,8B0-784)4XM/^LJRBL1;5&4QU2M9;&1,2! OJP6 9LL%4XX'ZT0QE:1-
M^/_(!ETN32X.1]JJ!?-PK*(P2>C*6$H(317%O-!'_R3KC,)+MHY$32?Q2.BH
MKI:22V'0*#DK!W6E>^B$XZXE5M+MXB#U3 R(4.;'3G?%@_R/O10UV/I02],-
M1JK%K%BE?YH(A)I079H$3'X%O*;(?&QE3W#07C"P4-KT2EG+DAX0#*F$@I(5
MY-*P4$_HE9;3(S8&P3JB(B+")RK&Z5Q)$2=Q( 0FZT!)OQ;QE0J"DW@I9J1)
MF&HF9BJL8-CU.J&S91X,F.[5999"94:,*D2Q9<P.Q00"*G!"(+9I;(8L&0GC
M:(Z1G)!F+7;,9!P6+ZY&87,QFW)1:M!":_QB\(RL8I__IA@@M&W$D6\"Y_3(
M3,H4"G"^,6Y28QR[#$(%])ZT$1UIEG#@\4+E,<TZE$/;T6<G9T.?PQYUUC9@
MYQ^[;Z3([\XF#48MQ,^(QS]LY]38H3Y"371&)VOOXR$1!*=(2D%&E'<:)'1&
MM/H@DG<>Q*ELM$!^ZL]J*OINQSN<5$3HA^1DS5)(CGV&2%H\\U;X[5<PJ4SV
M:.=^#N!098_V*&^M2X3\:H2DY8(F"XENS>/^2(-\Y#-'CB8753,SZ"G?C2OM
MJ#*)LN#@<%+?C7P<CC2STM4:"=[,Z$6VZ">1Q%Y:J*NHR+)<,N$(Z7R(A8[$
MJ+58KC6?S8;&R#7KYU9M]P:Q_TT%*_/8-DYW8>YX3VZ^7H2%0.Y5S>B(PB>,
M=O)>OI)/S:T+3<B1I-?6DBC?J.5RW>V27%,),:Z%]JA]RM=(A+=%DLTK@^WI
M#@Q@ @;JSH25"E%<$[$A- (BSNXA3 GN>/-<&:8DIHX1F=/K;BDI,B+MF.DE
M0L::2F*9VO4GC$DG,ICM7J)@E_,JOC,J0A$ZAX(_^V(_#Z^;QN*%8[@:SV8^
M)X\]]<)L" .>TDGP^*+)?!&=#N-E1>\:!=3+#!0T#"HUCKB(%S0=56.@P@PS
MMLPQ4L-"*Q1H;4^C:J^C-M1".ZH=&2?[EF\AC_1VPB_5/O)SPN\B\2PBC\<C
M'ZVG^/]10HJ/J(@/_I2*^CA-IHP/0%BGC7W4/%A*1BN$_9*/=MA/IHIJ;D-$
M1;X44<>KK\I%2<[EXJ(K31I(3_-OM7JE2MUD2<AD4;2T3H#DDC>U3EJED]-T
MM;JE4=@%3F(7=[T*"+\+",ED2A+PN,ID5RO%4I>22KQ+ :$0K&@5"'=%E@G+
MXJ(R6!R%1F2$ I=+LS@YO>YD5E/P5$1%K&S03#5+O*CYL4:U=!L%1F)9_RJ9
MM()5BIQ0CX3P4%W-M1YUM7S+52R+4E\E>>,E1WH0KV+760E5EJ-PE?^PDH=%
M6'.$4ZQ0FT7W5P88P'*I(2Q,8D+"))[S?_]K(1CLZC1Z8(K_X820;EPET6 T
M9K\:C!9'<5]G BIJ,16IPF:<Z>RHX<$2PL)"!F:\<Z)I^J8)MIDR&&<N&F4J
M]FOHHLD"X\>442]R3!F/T1GE BS,AA>U)AD?=A=SS,@D+&%[3&0+X!L@=!M%
M8V51MF_([&7-VF4/YV0[[ZO_QC_!#/789LJ"MO=^ELWD$?=X%D,O1\T\M(O?
MS#:@UFUMIT4!$B1W1VF/EOQ&K:8:C?O:-J7LF$$>+4.VHT/V([!?)R.=]GF:
M"C_N#$* 1T,@$FP!\J502DFI;Q\<N>((3EZX97^4Y"P-:>@N2UJ<:'A9R&^-
M!)HS:-RH\G-;<RBE:Y#<2'O)B(?N_^5,&DEY\8I%(HDKJY"+G"@-%9< ]7"^
M"I>$%M4I]78U#0DS%>@.7RM^QN<M8?G7B(A5P+2]?H6RZ/?;2"Z%WDJ%?@61
MV+F"NM=.*A=VSW=Y/:@A[&TG9Q=^=2XIR6V-*%??XNV"6(Y/""XUZ5N H@0E
M?]?5,&F..)6')O<LH<6<ZYMV\6?B:M5Z,RB[Q=)SJQ=:"([@3AIB3HF SZ0@
M))'N2()A7JF^5J+!-D(V?;/!2@*6_(67G&Z99#$<I"+N-"P\E0*#C3QD8J84
M0;&FT6XFL/.7H"F%)U@J2/'#2%&8UI,FW&(O7JS';+@\V>EK#.\]8^P^S=R%
ML<GRQJ*FB_^Z[^2I<*@8,@JT0$,OKD4/]*B,])+8,J1!'/LI&P&'-)"8,72V
MKHO6'H=60R]J]R"=9SGT0VDCT1I21%&;TMBO=1CRI()JJ9Y''PN2T,J8.\A8
MU'\*M06-I80TU%.]C%L4CYFT=V14J@ $U4]-D5L=L5_'.E:[ ?EYFY\DKJ20
M3P7Q>_;$PY&7!],W!NTPF:'%7D:Y4K@0FDUY$&$KN(ZDL1@N2RQ%4 A06@2U
M=X_%6F(+N. K,[DDFC6+DJ*K41WZ5#/H3TU52]MY7-KJW*^Y4<3]"7M[M13Z
MX^84O#Y53UN0DWN95"QP+E7WO/!HE7UEOMQ4D2QYG:'9"OM44-?_- 6315BB
M$! YZTMNY0C!BJZ,DJY>DEUXT.!_$-^+^:[X,)7_A+DDD)[!2G !B0#I_5<H
MQL9KDSA;25UY_"1L7)->?"0^">D<<:/!%1*#O"@@K,5BXJ7?%2%^)H/A519G
MNNJ+,3>I@H)# IEL8L6D_"="QB8^QB&4DVD85L:(FAF'<6J<D2Z$L2R"3*F]
M1A=CF"_F?AFOYIOF0N^?46/)HF3?FF8-1S/(6FW$D7"ZD9_(;!Q;UF[..LM,
MHW#TJ1_NFAYY+Z_CS-+K&LXP5*_!6&<%(&HO.T("^4)8=!\=+?T*;7E"E/S0
M.+ YS?@B.\_&;]<Y$FUW/6V[[[*53_?S_WBDCL>Q_PS]9NJPT6.UJW#>P2C?
MY"? [6=PF:U*PDAQ-_S5ZM)U"_.];CN0U.U9'+ZV)1/ /_.&:I!/B75XW;^*
M$ GG&JC[OW^'$O.1\HC% ZDU 0(! GWMH@A$T.Z!$P1K#C)\X#!*NX,-!:YY
MD'"A18@"]3G)V'&BP  B"X)< ]*D0H$8!VITZ%'@2X(3+QX4Z1*!PI,K#TI\
MB"  PX<)31JL*)2B0(D<.R[4!]2ASH47)\:L.-0B4)-%/^Y<67&BRJ B,4HT
MB!"M4H]%(1+\V1,KR;-BT3:T2=(AUK<UAR8D"W%BWI!9$?Q$V-2F8K,;IVJU
M^9#J3L=2$81#0/^M">9BFJD);'(9- +-Q2I3*^;9\V6'I1$4.)A:H&>!J&D?
M;(UY].S/N6G'QIU[-X)YJ$];'G[:,W%J\X8??XVZB7+/KY-'9UXZG'3CRYM#
MMXZ]0.;+Q(>C;J[Z^6G0TK>7%M_\/;4"!>85"#=O'O[[]O7;AU\,?@$2)Z"
M_!5#GVOUT:?=@OL96&!]_B&(7S@+TB?A?\3U1^"$!](G33\%P",B/""6V$^(
M(Q8@#8DCEEA BC"NJ&*(,JZ(HXDWZEBCB"*J2"*0].DXHXXQKFBBB00LR60&
M!#@)Y9-,3BGEDDY2*>656$ZI99-<>@DFE5I&F:6596JY3YK[.*,F._O_L"/
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M9$@[-/]B+&'9K">1?%ACW-@2FX@$*5<TC"_)MLRCY023%]&(30B"D9F\L2M
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M-$?!"EKP@ABLR7HTT(^];0<Y:AK/^.@E$)-I %"#(9M C-2W@]1-,+E9$IB
MI[IQ"60]QUK-NU+GLGY$  #+&(S6!,*F_QTD3 ?1CP;D19DOK?!I(*S7NLS4
MF%%!B89 XJ"6PO0KL$E.9V%;8@0I8\"(7"IMF@K3 DHFG7X(:2!9TT[8P%&:
M)J7PC48CS-NH11A V:M$9!(,#\\( #:Y"4O]F%V; !4W#P*@';MI_T'[,DC)
M2EKRDIAL"/;BX[)4U>U&K5-(TT[70A=:"#D>^%2+"!*!\U$K6Z8SUM"N^"0
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MB,)THR<OP-F7CI$\1O^')YWU3TFCZ]J-OJ>=Q<K[(2Z;@98DP,)^'!([):N
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MNJ[JFJ[M"J_HRJ[S^J[TZJ[Q>J_RBJ_UFJ_V^J_^&K#].K#\6K#[>K#ZFK
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MKXW@2 +[\UZ"9(0C!952N3UB[G(?4M'C"70!%W#0-A>PW>L:H+D#80(OVVD
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M)<=F=G!G0AOZTYM1[%T_0^="<Z;3OTITH!%0ZU^%NHZ.[C.D%3V<S8BBD$D
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M\<(JVJR<.G9:S%!=K57&@%)L5:JZK56VNKJMJBU2=9/TJ[L,0S?=V-KBK:_
MJJ44J$?QS5?_7YO2RPX,]MK)#[WF\L.OO1"G(Z\]_?1+;S\3!UY8N@H?AL\^
MAPFL^&)Z-"QQP_DRMGC# J_3T.(.RTM8OGX/_JZ^"4>VK\203]2/NX+9BPY
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MXD$E/([C #'I<N+IA/'B(* =AD[I4B+Q>J+E3"_^H,X+"R_[" X1(?_@!3]
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M4LF458F54VF55*F567F51OF3.VB3/4>"3H$!X<  #]"2:O2.+AF&=R&32_$
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MH U'@00#P*E'493?JJ1'D0'(.0!"J0#SU@='H0N)>J@#0 M-0:><"IT]-ZT
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M:'9NZ+%(D:Y]_SMOCUFQ?8>/QSL PD.G'"MO^'BE \"QTWE_1Y$"\W:=Z3H
M9>FW/4=UFUP&97FE^7:Q=I>UWUC'>XS'J*S']9G*VEAY&\B[C3< R.J&#WM_
MM9FP8+&=96 +:=?+:_?+;1?,9#?,O.S+QPS,R"S,RDS,S&S,R0S-RQS-S0R@
MM+NP<J'&55ATQPJIC4JIW]S-DNJG8]?) Y"M9/>F>R>4^>BM1S$,^DJN \ .
M1[%\IKD"A>?-X0S.DZK/_2R:@<BLNJO- FJ6D<6R>_2B3!#"3%&S#7"S2]$
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M 6T=] IZ]S$M =50^&F-Z;W@9%@.%1) #"'L]$SA^&=OHA@ZHJ]*(W%M]2V
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M#W?I3H$+O QGZN6 GN6K--\!_X '(-".!GP&/;$) =(VPC39Z*Q##DL91R@
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ML0IJ]F"B#_9'_(@H/J:RG/H/_=UIPXTH%H, <^B ]VMK"$A#.;)9!6 '5A8
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M=!=^F4=_\W=EZ1?F]D?E\__X?X__M$?F[)=_'C_W\O_]UKY]@$@A((4] 0H
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M(\A?0EH  ?!Y0 (PH,9!1! "\"T -0TIP?=RXQS8,<%8"[A :, CKAE,2UT
M"(&Z-G#)WSP/ -!(Y6]H!2V%G($"$3!6)CT3'H2 1U:&7.9#<ID0)D!G!^J"
MID70L;^%T"-D6C)9WA:4L)F8)2K?[$@X3S+.QTWHG(?Q6EC^]BATJK%H( ,,
MJ!""!*'4,R'9]!D5?=0ILA5$  CQG\JTF4^$9%, XU#(1S( @!6P+)[KU!+"
MZG2SE[USH@4K*$G&V<T'M7-G;((0.KN2-;[9PZ',7"E+,\..M)@)1P7-$8?^
M>;A')69! 'J91RTJ3O^; 72C!I/H2'5V*;D]A2> )! @ 8"$&0U5@@8#C)TZ
M55&H4O6B6>592"F(T1;-]*ID$T!.$6=5I!H)C#DZJL,VE%*(8,!RF&LI71L2
MO[KB=3P+8%5>ZWK7"_"+!@MX'@6<J3_Y*$0!,2V36I1DF*IT[&PP/915"BA9
M-;+,2R/#D58P>)?*@I5E_7$*01B"CH,Q)$OX60F/OMB_'_GI)*"ZIPY/B!\6
M#B2UZ6C:0F0+@&Q.%H.2+9EK(1M!O>QIN+B]R6U/&B0MLLP^4GF1%[W8U+YB
MEZY(T-11BP@YE'0V4B4,8Y[0TC;DEM>**@KHUZ[XVN"2L494_$_;BGJ2Z_[_
MI*E(")0(LR*3UIZP0DF*;8!A&\8P!2C!;663DEHKE@,I^,'K7<R (G03HRCI
M/ALZF&,E?*),T65+2TIK%:^;$%&A +'9I6L)5+SB%YMG>S!>)B(18@ *>,
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MT6[B@Y*$2C&>=,FNR_W,PS5, \&%=Y7>P\'SFHY5<]9SX&Y3O;ZE"&58'PD
M'-?RT^Q@E.S7I>WGD0!EB]30@6A<#M&CKHH)?+'7S/+0@2[SB(7O:D9?GB3=
M:[;7$SM>XZ%9?O8'-R-$EG HYJ5<WT[=OIYO^=I)@,AF"*7P3B[=PY4TUNCT
MN\WQX#;_*H$5,(XX=-G8A#P>]$CV7D)K!$I*=56W%/!)0/[H&%4_Q'S^5CJ:
M$P\)C$_ZDS0'JT@5BLF\V5[PL&! K9JF3 *'-0 W: ;Q&M4(&(MH&SX6(N)H
MKO/EYQ0!9?7][N9:(D.&W\DAIP->L3SQ$]C*I80<KL9P+105Y:4I=M>RU;8)
MZ#]:M4G::3IAJK71JKRZ9LW2)A1*'6:;;^(,W@ZM$Y4EW3RO%S^QJ6U/5!)&
MM"DV5V89S%T+Y+)N<?31:FKCAZP:][N>E'XD)1K?9[RR$73_)-W(JJX](6Q:
M5<-D-@1Z-KV1YV>;!WB+-TO-,F;$QY"EA=LA]6;%8:3H&G=Y_Q:.$F^F54I_
MPG5&U\2E3F0_#Z^FTM$6+<QM?=%B(#04:PJ/^&FZU0T8+XHW[E^^< AY]5%&
M9F^FU>X+;3: 78Q^X]&(L!9_J:QFZ4BCW(>99$C[CK?Q-;1%>:FDU$C*GHV&
M>V2'V-%?TBX4UO@=@5Q!QU>-*G*F\K"/;EW$F751!XD]%[!^0+!6DDWX/J3V
M?CB+)&IKU^5'3;F$"&]!__3TJ:;VC5\R"Z[4"NX<[G>#+S0 H)@%I_@HK7F;
M U$N70-T,(%ZT#D$3,,"A+#^ $P1SFL8%^  ]@7&X(75NC5*F9Y:R^6,('>Q
M%65JAY KYK/V=39KPT13]9"QY>!:V/^X-C5ZXB+MIKD3T "Z?HYX+/)PX!PW
ME7>-K?DO#M\Q/"UA8K#9#;.QFW^:G8:;V&3ATW8=((_R4D^WD1EZ0F)W4G(W
M/W/I:<?PR@XK'@*[5*S,Q!!VR-J$V;9#L%DAA=_N:M_WI)Q3G\1L&4.S$0%P
M1HU[H4/07%!A6RR&+>I,K2,$VMHZ1)3WO-N[E)S'!G#&!A# O>##O9# "-3[
M0@P QR[$"M3'H8][:X%CQC5PR:IK1H^C-O$M4*]B7>\AC!1D<E&GD(N7/^]V
M)M_I9Q4U=L+V],7-B]=AEW-8C.>=H(*8Q%<75-D:AFU8E^=(2-D1601S7XAY
M3M##F=][=B%:/)L]4>#YNNLYN$T.M4W2L%%-O(Q>?'4A.3OR1=_&EP)%LQ1Y
M2!-O]@ C%]G&^ _&O$&NYFG:L]VP'LS7(=+W[8&#,N"2%[;M[F<Q;NF1^0G2
M/)'Z2="'B@0/_SU#<'7@$[YF0,/ 9P1-.L1[W2H2VB??E!-J3[QLDV;,@K4]
M:G=VVFH]BX1J>AY<M 2K!3:&T/$[HKP7"3MTF363"+8")F#/=^>F4[ZBW^I8
MW]\]B]@+ Y4_I<!-6OY:9(C0%WY?K77'[_"IX?=RX_[8B/9/H;L"S6-M#R7$
MH/W@>LD+%W?S&_EH"OMJS;6K;U^*A#+6Q5OSP^5TTZ![*ZV(&QFK<>2609N,
MP+^OQR"H-W98@VR! OA/%+A"  0T% SV80!P$&%"A0L9-G3X$&)$B1,I0C10
M$6-&C1LY=O3X$61(D2,/EF@HH84$!RU>.5" <0 TAROHI;"78IR]F_\";HZS
M>5,GSIX]?P;EF>+HT: ^[0GXB=.FTZ914Z23>I7JU*E'TU7%JM5ISJ=)=P*]
MV94LTJ%9PY:UJ18NUJ](U08UVG2G5[I G?+,*];OWKY9B4ZU^C9MVK4\OP[6
M&G<M7[!4%<-EZC9QY,9&XR*>RI0MU72<KQHNW1:RY:J>D=)#0A)V;-FS:5=$
M4O,N:[%HS0K^&_JP5J"ICP+&?!SNTK%N@TO53'CUY.;0%>O,6_;Z6[QT1ZM>
M.K1W9KIDMV9-/A@P:YU2Z8+.;/=Z9.N=E6+O>]UYT=[(\>Y_>E<XP81RZK#\
M[%(J*N2,:^PML5R3"(-G&#"HM@HM[,BD"T/_DL"#7JC1X(*$./001!$]:* 7
M#R0 :81XB&E  Q41LL9#%*D1YXP6&&*B 0H6HJ"7D.#I)<2#/J#&1A1U!(!#
M%&74$$J&+E+(  \6Z& !"""89H$E*1H (IH0K(^__=A3BD'K^"HJS39# VNR
M.-=4BC?(Q,O-GLM"(] FIOAD+\_.MAK.SY\8$Q2^\=9CDS![ZO2IN#XE#11/
MK+J:#,W_'!,PJ4LA-4NK0I6SBZE2$4MP4M"L.[-.I2Y+ZDU-S2,3M'38B1+7
M7'75D)[&ZBSKJ^TH733.K]S[=:=6^0MVT#>#=3;!^U+3,U !/!U/4EB%<X]8
MYRC];R]1GX7UTM*\_[OK5\>\Y7:LN-"2%;-WFYU37KFR8A?6I-1-CC #DZ-4
M*E6_#?A?UM \Z]:),""(PET=OG#*ARDJH<<6=KB@@2(IIL!BC#5N8)H66EA
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M*NE"2B8WJ1$,[.,9#?OD.J7$SJ'Y""'P:  \ $ !>!Y$GO04APP10H$%+,0
M&Y@!T\!Q@18D$0 $:( U%G*!!9@$8PMQ(3\/<B(%F$-E"9E&#1,"CYTU8 $>
M((#6%C("<;AP! @)*4/V_YD0?[K3(RQTV@= $D68WA2G.=7I3GG:4Y_^%*A!
M%>I027+."3VD&@U(@%*KL52G-E6I3'6J5*.: *@^=:I6S>I5J8K5JG)5JU_=
MZEC%6M8$./6L&CCK61="4B@!"4E$V@C&W'H0NAI@H0D9 4</8@V0UE4A/$*H
M7OEZD)@A!(,>   ,?8:0$!06 $S;P& 5(H$76A8&",G8B310@9?@E:$(V2M1
M&X+0$LS  1^Q*6E9VUK7OA:VL97M;&E;6]L*A&$/24 Y=KM6WO+VK+_U;6^#
M2]S> O>XPT6N<(N[7.,R-[G-5>YTI5O<!/AAK=E- $!U132FB2.E&9& /\[
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ML B7$ F94 F;$ C7@09M,"-P2]/J#?@^3=9 C>&\;@NW$/BP[@N)C^'$L.K
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M_]OW/S&QP5T*S##\;P.(_=,D__U<5D'VN_7?_F)VR;___?N?  -(0  :_W"
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M/AIPF0UPF4 1 L30@^VP 1<0#RAW@)2A 0 ) "$PCD Q=?F8$R, =/Y0A"U
M#"V@ ;T@FD:S \3@  ! D+XD 2Q(#!HP D#!_Y I!PY;UP(S1PR]]!.W.74>
M<"RAF13W1PV?20,Y<0&]M #8"9X   /4<'/369V4X9P- )U*MP'D.0W)TH-D
MIAQIIAO&E(L]8S_K 7=9Y54"&E8!2J!?A45>X3-LN*#@)'""*))AF#AA&(HN
MY:!%!1?]67O7YI^.V#:/R%+6%%':)*)G0Z*!F%$F"E,4Q1W75*(9RA&FB)0R
M:DO=\"+19$;B\J$I"J)BV%4[^J,^&J0=!:1#NE/01(@BE:,CVAX"!CL9X:(%
MP7O<Q$Q$BJ)":J5%FJ58NJ725*4JVH@%\%$->A(DM1MKE7"W\XS#N*;"B'%W
MM5ATQ:82QSN .8QZ1?^,W&-7@D4]=/J7H(&-?;&8[(B.WB..$EF<#<"<NA$!
MH;F/N/&;O9&H?9&#!- ;$@!TP D $D -). ;+= !W=@<UQ":$B"?&I ;.T!U
M)AB"+=  /N$ *9@9&E!U$G!_]CA_'M "+1 "#9!TN*JK$(".$G@!I4J"TB*/
M-$""^/ *M[D .1$!_;"<S%J/X:F# /"K+1"L*DB/N;JKO9H3]&<-K_"8RJ&"
M$;D<2)A=:L1:GU<S,?9B,O:N#B:O+C:O+09WS1>)LY=:_45:_<4>7]A ,GFO
MWV4N,:8X:BEWDH)Y\D6O,V:O\!JQ]KJ4BP26B30>CC2C&FM+'*:6I!5:#1O_
MKR(KL?5:L@]KL@X;8V]&+E<D-VF#;+/FL?Z%$5I9DA8;LB1[LCJ;LB,+L3Y;
MLA4+6D$9DKK5&SL&E[=#?L.B?;PSC8E1#LFS/(F1A(G12N8HM:GQ$R( &.8H
M 52&C''U*=5R!K\"F(A12=_7/4 !9@ @J'?!C>1ZK5/GFAN /@0) [LQ@OD(
M W'[$Y89J7@;'=NY&_+9J'?Q"@W0 B-P#_37M^!@K?ZGJ !@ !,8F9GZ$Z]
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MY-H+RVG#K=KAE!FH5&W6Y_G)6ZT;@EQ'K4J<1IV.!0D4L+H#L*J"5>W)* X
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M,O.CJ^13* R5+$8)Z^Z2W+H(N4 2'\VQ=;I)F(9W=)[16QX A"X'DV:,. 7
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M?BH:!;4>?$<[7E-'SO5PXCV]#\XH8%QB</SGT ]+(.F]V,&6LGS-)DO_YX+
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MO QJN<'B--BE@X$@;!D[TX$L[-W_I)H-;)9':DD"^ E<\G9G*51W*;?*L/M
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MSCHKI0K H $3I3(A3P3]?*# -1K(\^P%"I30[:3M(.&6 A3$PU>Z+;7:3P7
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M!C0O,8&;4"]LV1'$.-,P"Z) !")0-P42F&W_B5D3A..TRO'J>,<\[K&/QZ:
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MXTSFUCMS,^9OW^$>%NX][Y>;SC7P_]5X8N8LOBXT MG?K33S1R:8O_E)AV4
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M('O,1SW[<48RZT,.>,ZKL.9.AAX<C!"#0#C6*99 A"<$T8F88!BDM@  (6B
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M[OJYTG+VSK4L7;'\EA/2MQZIA6KF(!E#K<4T>JD#J*'@PL240Q28QF%" #0
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M800N80]F81!6808VX15&X1F&X0\6X0VNX1R.X1:F81Y^X1WV7R'68.%EAVB
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MCF=X;F5][N=[+F=ZYN>!]F>!_N>"_P[H=$[H?#YHAUYHA.;?*6YDUIW@=L@
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MEPWJ8 [ZH _V(.(%(1$:H;$!X1$F(1+^8!,6X0XZH1)&(10*(0VZ'6T5BP'
MX!9R84Q)4*OUEW,IW>C1X##,H"O13W81WOF\CQJRFOBT8:O1%ANFH1R>81Q>
MX1W681[2H?BXX1S"X1ZN82#ZH1WVX7CQ82!J'K AT+(-0&%9",88S!1-&'[L
M$%6%S&C@AF>-A(0E1$@$$5B!F#XM#@DLA#Z9_^)@&" 3"419,<&1Z%.]E0 1
M-8]>?0"Y]8- B)_D%,3^'=]"4$ _+,#]'=S&;1$1)1P[H( ^(6#+J4X9D0"Y
MM1L["-\"D-P'Z!,2"83#D0 2[-\"9,! "%F],6-!H.*1:)$IKALK1H2<&-9H
M)9+M40@AR>,G3J*C&=9\U)R!],L>+02*="%22,K\S. *0!T-7M[XD.$96J']
M()M"'MOA^:%#!N)"2J0<'AY$#F+D861"ZN ;<J3;+5Y(,B(:6N1&\IVQ76'5
M!&1+NN0"D0OXB!I" M[2*5WYC"'\.!WED6'7\:1.HD].+EU0DD]/[J105MU/
M#J5,%B50,J5&)N48IO_/3OJ:1[$D=/B2ZD43A\2$M;631<A.0LF%MNU)0W!6
MB4135XV@6@A204 B8%"3.JD.$\0%6(5<05C./6 ..JF..B(!Q\7%Z6"$^3&!
MPVF :678 C3:0DC9/026+^8&8RB97$9<7++3GA 1EUV#ZL" 9=".!MA.7.YE
M;RP175+?B946/;0 -\G9XM!39KH?D.&EZNC9A"52:/"CC] >8>R>:KQE&GV1
MA<6%>L#%"K8@95C42Q(%N40>L(V737[>XAWD19IA=!K;=%[>TW%>38*==4;=
M=EX>=G)D=4KD3<[/Z%UA=SXG5'8> !UD3]+@I)22<M)G?=J(1J$A>S*D'4K_
MPM^!I-O)UD:VYTA.I!@**'<:V]L%*$@.:((6Z(("XB(2*!AV7GEBG6P9:% R
MW14^BB-B#UM*4UOLHZ*-B.@T&3 14X2\8Q1]QT.8J&$<$A")XL:)F.'H$V*L
M8KL=V4/H4V"UIF)*' 3,&Q'!Q%>=V(B<WY+1P\0M@#HFTET=B5X]A/@U2;IQ
M65GY:"NJ3F 9:;L)A &&&/[56T%DV#W 1(^JG)>5$4$@'$P8H 9 5F79HU9=
M6TTPAJ+]A5G6$%VXT83HQC#X')P<E$&8:&]0R O:IT_@IW->(>%MJ/N(YX+V
M)(1>'2.VG:\AI'I.Y*5:*J3JFDIB*N=I*B)&*'M=_QZ$!AZ"ZEJ&8JBI,B2R
M766BRNJLKDC<'9MK45YV=I3B'23GP99X-J5VZNI\ 2M4DB="_JJK-9VJ$JNR
M"BM'ZF"Q\@,9>J>Q20H+G07"G.A*))2&P*AP0A/BD,Y9^HB)NH5?,4GPW2@2
M2&F<\%GSF%A ;=E P";RL5,[P( P+L UC #UY1\]G )M&D8&0("ZP=L]E, Y
M0=_VA59<5&#SP.:\&D0ZW0,;,5Q S>8"=-,V+4"5A<[#_J7JO*8\T1-?=FS&
M!A3)K&"@M(>BJ466((B(<(9[>*5@B8E>R)Q;$"=JT2I/V*H.]IWC(>5N"6%Z
MYN%'"FT38N31PB=XJ61)^O_7X/&@T3I>TTYAX;%=(5(D'=;@XJ5G!UFE!/3L
MV)(M=:A01[Z6'3YHUG:DKPYHT*(MLKYM&VYM4<YM&M:M0MYM@59K06YHAC)A
M=W)>K#Z'CB3$RWV(6N&'H?K+RX4KGW*;(-$I%L'HR[%E<:)$$ U1Y(I<N4G$
M$K&<%IT"CZK.Z)JCYS9.8-'#DP$IP\4I2\Q8Q<XEXII6*PICO<U08FH$N6E
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M5E].D\#"5=>L4&B^K0@+-4&,=(R8ICW_M,&GR'6E\&T ;-4E#*4M_=) =;4
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M$2GTBV<Q94J13YL:-"B5W<^F/Y]2[<GU*9B(5D6"'>OT)U2S3J>.Y;IS@%L
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MH] .8$&@9P@E;00#$BE1< \%]%R@YP[#L,/$GDA<HQ";)/2C 0EX*O3!5^Q
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M0KU!RX#_-X"M ZH-6"\I=*K!2)@."B;G%8'N)Q7QPHH6ZF5:N:/U929)1+H
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M?'(O#Z@6>:(! -<.'F!1_-1]WG2S#,>TO8@ZV9>))7HZ-,NSJZ.BA&QQ.C@
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M0K!55ZU3P$#%S!N-O_-HY6\%[]0[#[[OWK,55_=FY6[78M<C#+;\Z ,OP,D
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MU$.U6)4U_,$QY" A5,!!:I #5*FOT#W'"\'/49W*H['164#6,Z'P4\'4F;T
M5"P _$)/L43;$YI,;"QX:ZR/"K\P<SE:&\*:8QG $K-%-*%,?,0QJRA;*[O!
M BF^(D4AQ,36^8F+H[B.*JRMB, ]),9B-,9C1,9D5,;R41!EL+62*3#7^9R7
MP;((42$!!$:=822A(2&8><". QU<C#PQQ*A/1)58>[G54T<.@CR>VSDA%*1O
MI,0<;$?"4D,((:'_GM$0?70L!5N*:"Q"8"1$#[(;F>,C='2=Q6N*,XN]FZ,0
MK5"S993(B:3(BK3(BTQ&TB,9GQN1J'B]"DG"<E3!#[*0D0)'4:'"=-3%<$04
M0XRLQ!)!4]M%4Q-)1]0_$ (5402*6#O :MRXD>1%2900-[PH?62PBKL0;\0H
M4'R\%(3%<K3)EYFC!MNHF+P9GSQ$:Y0XS,/(KO3*KP3+L!3+1+N@1Y)'A:0<
M5"Q$IS!!_JK*=-RY=01",%M*A31'GW0U$>)$(N&Y:6Q!55R\:OP<(RH=$'%#
M-2R*>.PHF%2D'[(YC_R1+=/$)?2R2<Q!Q_-"(W)$DQ$*1/)+<Z2\5H3+YG:D
MAV$<R]-$S=14S=5DS>C0R,<JQ$WTJ'?D*)C#E*'\Q)Q 1YS(O4(\RRL\L[JT
MQYY<2*@4,YTC*7[,* +<1=D[Q</,.:#<*&J<1Z1(,!2LR]C43(940=U;-8]P
MP'M<Q 5T2;M!SGX4J98PS=9DS_9TS_>$SXLT 06QAXL*3G,$2((TL'*$M1X3
MR)P3K ,#34I,RFQDR97P3KY<O:4 $_[*12Y*S$EDJS=L00[J0 A]LH6+Q95$
M2P3=N9A[-3"TN5+#H(8\P]8!R (T0O-T/)O;3UK\0ZR$1$*,P<T9!P4Q@4*+
MSQWE_]$>]=$?W3P64) 4X!0S9"M\=!!;O$FC$$*7 :ENE+V2?,4))3.CR3@L
MZS)N_(KKU"@#I*L751G4J\0&),2*LYD2=3)2M#BCP)G>JT:/(DZSZDW!S*@I
M(\ 0H<Y-8<2![$>'TPI?C,1HHT%/G$T-9<Z;L(>QT 4@9=1&==1'A53EP@ %
M>8!2$Y5 195U%!'%8TM6,T&_FB.&LYN/)$F8/,^2T5!+_$:9LT1$[$9 A-(G
MV](J!<<HC$F33$.X)$ EK,G]/$.-^ZC\1+Q6S9!0I5$C @,?24AK1!-A1:$5
M[4N6:-#5,5"@0 $%P8!(U=9MY=9N]58$2=0!,(%7C4*TLO]'@=14A^LK%6S%
M'(1. N.B!A6SPAS4% S/,>S-$A(DSKE$G O0[_P<,25(Y30=K(2YE[12W%/*
M$0(+SWRUDP3)G+!%"O7)"9'8-ZVU[-14_ZQ-Y2P[$$&=++V)^1P  ?C6DT79
ME%79E>6'5<F 04+!P21!O*S.2]U.%\S4+\PR6U/1[TR5CTR9-O6R;H2X2T%(
M,MQ84TNP52W#=W2Y?CU1YC12T[G36*S06%P]JIQ,J]5&$90Y/V(UG(7$2\W+
M1NJCB%S9M%7;M67;]Q32 7@ *+%*I11-T&2L=270AD32,HW)+P7$_RS(JL73
M VM83,G29^U$BDL=.QW<@H,*6=7_USK%S>4,U:4M1=91Q0!<SE>-4RF,BI!R
M).6$*HX[O?"DD"Y$2@E]  5A@;9UW=>%W=B=R'#=2)),W";%LF=-O!%42I-A
MQ\<50YL%"X#,-15IS*!UB0+K%%_LW:XM4(Z%/+ -36C=4\K1N0II4)@T56G\
MBD^ER8Q*RP_1BA3E(CK*3I[;KYL5P63%N48AU?-=5Y=8%7N0W?JUW_O%7PJ$
M!I+%@,9L+!KJ4Z9P/9E,7-(53HV*3=1]+ H90ENDTZ?5W65U4Z@XK$&ZV]W3
M7'>$PI=C7%=[TSP]&1!YN+=T0;ZBT">M33JEQ)WDV8']0_%L"7J=Q,'L6@#]
MLKL=G4D5:]?\Y>$>]N$?#KD,6!44D%L6BC4H1%=CU=*JE%7V#4(%Y:/OM+S*
M$Y7&&\4/==&876$"TUX)';-%(M;$(ZG%!-$LA=9"C5^94<NL'</&LF+'XC*0
M?-A%&DS,/$4(=1">O$O-.4J620&7!>) _Q;D02;D2GK;9!@'C#51H/0KZV71
M6RO:RDS!OV77\#M*5$U@4<Q<L>7(R15<53,I.46LV(S$=7U"..[9%.G/-T6]
MZ_UBZ]5C-L9D=D57D&5D" W43VEE.5Y)K@C).F;21!'3!Q& 9%"012WD9%;F
M96;F]B'9 7C9SW30!/Q.&4[>N/QB=^39]'.P$9Y-5+[&FM/&!C/($<X*49U5
M<P3"<U3G;4Y*=HU<NUW(BCTA,([2&'1,9FU$%CPD;?ZO)9P0QM7. ;0)U-49
MH,N*G] ]$JT0 5@5$^"'9I;HB:;HBI8+>5B5 2!26_W2CAKF0_P@'+YES+32
M5>S8^S13*B;,7__<S@4%1<R5-0CAF2F%V2;UX"Z-.(PBVK+=1\_!&3Q6))1Q
M8,0T9<T-,VQTPNCE*<#D6 U&9=[4/U-IAS^^((NVZJO&ZF9.U)'!@&C&PGP.
M8P0>UJ&X4%%^8! 34=]-WA#,XJ<&7-!17B)TZADVSA7^S"XFXYR.Z<4U7$+B
MWCQ&P[V^YD>ZXJF<:YC4H)V]D+%=WT_Q$EI;T,=L-6E-9Z90O6B(0VC.ZLWF
M[,[F805XY@'HWT"JZ7[%7>M,1 OV,E$U5>Q%4;8D1SZE6WI.4LC&5:),YQ"$
MYV .9H1T2X'LX"D%1HV[6544Q$@L97XT19EN&>3FV\A[0_O<;=^D9:7VA=*@
M> !CQM%V\.SN]N[O5ML5>-N'1H$4R(#1B6OB+=(:%4"<A6)2P>3 ?LNY/,$1
M5N&96SU9[=N8*17BI$=WQIF<VU?\=DB=9M9[M#PL5&0026R 3<5U=='+=,YH
MO<]4 2R8]NN;I6>,Q;B5&(<40('0'H#6!>\2-_$3C]0,$/&,9G%;:'$6A_$8
ME_$9SV@7I_$;KW$<UW$=M_$=]_$?!_(@%_(A)_(A[_$B1_(D_W$3R  4=_(G
MA_+XW('Q5O+,UO&1&9F,SO(?W_(MGW$OKW(P)PLLK_(A!W,NAW$O/_,S7Q4V
M+W(W+W,KOW$XCW,X9X$=B/(\U]?S/3]-=+ '#$B"9R;S-H_Q,9<D0K?R0==R
M.5_T1#]T,#\!16]T%L]R,K?T25?S0Y?Q2]?T1_=T2G=T23+T4&=T1!?S22?U
M3]]R91#U3V=T1<_T11_U09=T.:]T1Q_U4+_U5E?U7M]U<64!#-@!=.#S8C?V
M8\?(00,T/P,U4?NT9Y\TM^@T9^<T (AH3_,T-UOV3'.T:7\+':UV<)<+;*?V
M:K>L3+LT/#-W0_-V9L>S;->T<Y\.<4?V>K?W>\?W?-?W?>?W?O?W?P?X@!?X
M@2?X@C=XM0T( #M02P,$%     @ SX9W7'(799YLB@$ I(L! !4   !A8G9X
M+3(P,C4Q,C,Q7V<Q,2YG:6845W54%%X3I5FZ8^GN+@'I9FDDETYI2:7\2><2
MTMU+-RS=W2U(ERPI(2"E[.?WSCUSWLP?=^;<,R]&55U%7,)&$!T=Q1,)B?$)
M#1D)"8'$@_1O_3\6C4 @YE9WH%#HO\#JZJH=:/7AX6%G9P<.AX^.CEY=7>7E
MY4$@$!BL#EI7!]8'S\W-,3(RNKJZ*B@H("$!TM+2@B(B>GMAKCZN@H*"G)R<
M04$^0$*@OC[(S@X,( 2 %!0$)24C(N9\P*O0M!T%0B#()P@&VX'4[1 &P8/L
MYO3A<" <3@@"$D8 ]6%P( P> 8?K$P;I$]9!(#LP2) "4+\74@>" 'O_01*8
M!H2"[("]_T#X;Q_4"YY+ \Y!TO((@^H(%4!0:!UL9Z<7!B&, ($CX()!<"!A
MD +A/UM'2 COC0 %20(CP$ ()"T" DP#0R/^D8"#]!6">N$0?86Z7DE0+UQR
M% CMA4GVPNQZ[?ZY=KV$_RSAZ+]<L']V+L@.5-?;&Q04 9($]H*OTH!75^"(
M*S#P"AAQ!01>Y45<Y0%7=^""/G5 A2"P:UW$_Y/^DP$^"H8"%>H@<*#DOW(4
MX! 84!(&C" $C8*#[/Y%X$ [&) 0!@2Z!A$"%2"PNJN=B*L=X!48=@4&C?[+
M H1= 4%7>;"K/!#(!^3*"!^%P"'P?X0@R?^C3A)6!X$%0>!!$!A(\A_@09*P
M(#M8G1W\'T"$_T<=X3_W7_"?\# 0X3_ @PAA05>K,#"D#@*^@M7U7NV @)"@
MJPCX%1#^3TL[\,X5#'X%@A,B"=;MP.9@<#O]N;D=&'SG"A0!AE\]],Y!'Q!S
MKA%!5PB%N3K8W"I\=77GX0I^M;.S>O6OEQ"N=D&""OJNH"M]2<DT2% 0Q.<*
M@=!7 #,R @0E"0F!G(R$@+E1F((^. CRKY%&Y_ZI_*^Q@(S_*/YQP:_^53>'
MN'J !/DHV($A:3Z2^B!7GP@@$J 7"G4%S>5%Y,WMK.ZLSC$2,LZMSHV.PN#P
M51BTSA7L*JB@P GD1 (@K<[-"2H(ID6D0=(@.SMS#U</JZMS=J"Y?ST/0" A
M VC4&HL&PP$D7.83C<7#T83,H#RUII+1>$IAEZV)IM+Q) ;%.!KUYK+)5(YW
MU>:3S=#I3 &[J3SUEO+97'&?LZW)EHKY0KEP;%I0:^5BJ5HJE\54:]5RA6XI
M*!\$J_Y68]+BLCT%JUEKL!Z.H]5HJUVOQ!X@XR8OJMML]SR<RM=HK]_N]K\]
MVYYN;]CM#T'%H=/L:-P?CB'AMISY[MEDV3]'KMG=UG0TG27LNC/3V7(\7Z08
MCV&.:VZ?N(="Z=7=]?T,J7YS+.IO8-O/C0Z'X_*Z[C=7N^V?,3'[@CIN#B8B
MV=GK>R1NC\?S5:/[@KONS[Y#WU?4][Y]N%KKC49@]G_N>?IU,EK!WK#SX-J^
MQU+QWV[@WZ??%[>[:Q_Z95__(CV/[WY!P5#;"T5E<RH*0Q>+V0LCO/QM:79C
M<S?MUJ5)*1?E[M6Q[TH7!3B(H4UYM(GE**@LB>%L[BB)Y1L#'$)XEQYM$\1W
M*DLA$K\Z2A-D,+!^)$L3/]E]5:.K*DM6%^HL^ZJM@G64IJ7_9)_.$?A]U:4A
MGRT#A=*%@S7#.$.B/-NHH,HQQRVELSS7O03K.,][]:D\WVNGZGU!\-)D<899
MU]&14O]$>G'&75.Y4Q&DNJVR-(&-ZK0T1<'%&9JE7WU:EF?95561[TAU5E$2
MYN)259E2?5996]!575-7GDYU7M,\Y.):U[%4?5[;L]-5T^#Y%[A69$G6=5+<
M^3N'IW&&[_RB89X+YV?KDM$F#VP-3.W>MN5QSMNVZX)SV>#!6(-3.B)CSQ-'
M<GGZOM"_C_M#SUV7&7_/;WC\5=_MV29__\-K_%&GBF?6B0L->2F2R1CV)M_
M*P:/UPBIHEO3 (E5GN 8F4^MUSAUH5KCH"?CUBKR*4+L[J0S(PKWUS3]^,7-
M#-^TN?"LP*&;S]R;-UW[&3PD?\A-DLAG;Q??LM?=+DDSS[8N:W'3WB\;M<W\
M"E*@H E1ZA6/XREC><D[, M)M*B/XDI)^+CN7$A+L>G9P/NPZ8-IUK[A>^S>
MON-_]?/3;DCWW_:]T%QW_\WH\=DW^Q#V_SX=QJC6/^XE\EM*'*7(_A>PGVVV
M(P%/S:2Y<P73=SOP6_HEW+NP-YK=P9.CZ;KAA3Y\;R\ZUF2ZC]O/"X*N!I;I
MI*Z&*'3^W!11%TK]:N/>E;KMYN>7/JY.F'/Z_L'PD=!" 6$NO4!%3O/?^D&\
MS.L3O )A]'2>>B7S_'-X?N/E##'/+_MX?TC_Y?7;[JXLXJ*%'NFTO1\%>R'D
M^6T1"LG$ ()Q(10GPAH555P>124YC'B& >.-TR#V<U(X_441:D-;'YIWK(-E
M*$W,U-$@<M1U)!]D'U6>8Q@G+CE*N*<8WR9+D6YC(9KWP@8O_'&8T<4S6F7$
MABAR8H15\FO,,[--K,DJXY\Z%1H"O9"U#E(.KHRY(/;GDL%*<97VV)L(1Q9F
MJG7HV%638()G<"G-\/<QX:ZOB5XCAS33'>.B9S=)P6AE]*CJ$_)4OQ(CE7XP
M_IR8D)042HIU8V&A>)J0X?J5DM)JSX8>.PGR]D[]>F?/,?N8L1JJ9W]N]MTH
M<%"9+-L-$9^?9\\CR@D"31&GM94=\;I*3.O\(L[LI8'R19].6U"E9@WQL GY
M5,TXLMUFST0X"I2JSSH'SKXW_W,0;;!.:)32Q%ON!BU5HZ!HA5WXV6H<2WQS
MGOLX-9I_%%PA=:@^GS*[7'#/8R.SV#GWWQ!)(=*W]W)/3SJA5&E%#U(<;TGB
M%C[SK12_VI\H8DKJ1:J0EJ"[<RCS2RY\Y>4*EL-!.C,Z[252;W( UE6J\.;H
M)S8;E/!95&D:@I:S5ENAXI'.VH+5RP6_[BJHMYUU/TL:%/6M5 K#JO1]0$,^
M>D3Z#<"J*116[0$O ,H7)J*7L4I#<O?[" L\;NI1D&JSMU^M$X+7%3Q?O=K6
M?%]G;>%JOBUIW)'86._?6V/9WV7<\/RM-N"HQAK!M=:'LMH827MA0Y9K,K1$
MUI3DX&9/ZVK\VR8]+XY8STA]@LS.P,_!O=/-CD)C?2"#O#E=NL[^G<;&:N)O
M6*J?NYO--'@CQZ@-EE_GX3.]N;E!#NO;=O<,PMDZ *\JEE\P.1+]GJJ3B(AD
MI06B2:8AA9+CHC#D7-ZWXHA=.CZ8[/S4]7\C8FF1]M"SIW7U\=NFQ>__/O5>
MNW\(WN7>?5YZZ#OP^_#?<;?5RV^*_A_?/H0\O;5&D%,.P,D\P[!ZK%'?4 Z>
M.'A&T$K9 +@[AA"SUZ&B?_;^IK@-;DBQ(N0ZAQ2PH[3T:7<:X][-V.(V?!_E
M[6N$L$K98:]]'Q*9:TKP@QS2OG2,R\$%(-'!=HP43Z.JB8))"3WV+-%ZOEOH
M&[Z%4U!;MZN1;3M2QW4,PUJ7]6F+C!*B 4U)H0^3,]7RMUFCM7"QEJ=9JRB?
MK$/-8XG-SAGO,9_\^^!CX>/U^2 ,W\+E/^\5,#<6PBUOB\GRG=[P;RPF\(F4
M/FDZRQM3+686M$+?)#AKNW8M%[VV5GYSFU]J:D@W\\")'?VX9:P@N=SPV[=6
M4?I<3Z-KM:,/5D_?>ZYV^[S6AR]6&R3M9DUA]KV9[6-S0J^;_3)X?=[Q8^4W
M# YX1F,ZAR]@=6<A ^D9+<'MV[?RJGZ)8J_,CL^,=;:=#2H>OLS$T N9AS]+
M?UO\EM].>Y R]USU7GW:W-R]7'WH1Z>[_CA/O8?)[C^$5^ 1^29O_RFJH_.;
MA6> [-8!T?CCR+F%5QR_^>'-[\=1Y0*OE \TN^Q7[</]%+8UAID]T.D<O@[B
M6[BM3Q[M\>.X%IUW?M+6,2MFX!0FWTU!Z=8)%[]D?RS^+^CQGQ/MW<Z%KW.^
M!:I_CW55Q5=3=WSK,*7/N>F?ESL]_!KB+<ZLC;O6@^B6/@G,V3>0"I,C@$SX
MO.P#BCM&I-7W_^GGZ=S :\Z[Q0G0'UNP=O0C5#D/M#Z[#U.\7L41_#F4]?6?
M5-VYR8P.[J2P"ICYL/.K\"'X4%0V<$I'YJ:8O7='N3_PV[OT^X9/O;M:A0$;
M%3N_H:J?+X&[@5L/E@_]QY\O^%]6/MF+MOH7IA%!^J%U*[2Y)>XN9)_I@\[F
MZ1Z_C;_>1_;_G9O^[WH+L_^ACO]U.;KP%D[?_WO:ZN6^M/_O,>;?RV_T7[Y_
MDOW[&"W[]Z$0L=EM]3HX_N5YG&.95<9RA0-XX)![K'+<+,U$[K?K*#KHK77"
M(F+P6XPT2YN\4I?:)!38H4U;&4K?(<8<$RJF&L:.< JKB CCK@RC$ _E!(3S
M<H3SJXFQJH73^(>+48:_%0^7-@D_QH@@98^@48U@!(1)4D9(3(2#3D(UQ2,T
M3L)U(ST0<&G,2A>S&] :U(%5-%*6,E(E*T+W)$)?/(KI,4(9$.6B%F43$Z4Z
M$>9N$N4\$>7J'^7]&,5G$JUV$F4K'OV1,CJD,MJ3(R9 +3JJ4ON\56$-%L(8
M9@&&$QXD:QWZAH"_*>^)Q!Y$6.#[?,HVD4$;CLTHB?7$C+MBC+M7B?.PB2N,
MD:ZNI*JD!!><Q-52QJM<QR$7Q=4JHG(UXKPNQ'?+H6XTQK:H^:,QH_2>$##M
MD?=\CQ=AB,_G@,R+QPTC.!(6*2W,AX)5K"'C'0FOC3A<R9!VM?BV[W$P\80*
MI\0:RH3C9LB$$R?[=0)T.)%)-^X@)G&.,N[>).$T)FEA(FGE).FX,NE!+>FO
M6C+"*9E5.=AQV2?E)'$NG6Q^W#O&6&22%0SH3**02*[*2D**_4IMFDP?D,P(
M3*:M^MIX(L RD,"U'L]51,6YGL"L"QG_GG+$D2QJFH)HH6+VA(@41=JTI/9F
M0>@"4IC4TV13D5@$4,XH5=@'$C8&O@+79=D94%@81"Z^IQX"TAE/#0[3TF8J
MJ#:=4O8!*2H2:7:F:>_54X !J:[9Z?;9&8[JB1Y5HD+&/HUE$M@ BG)?AV5$
MIJF/C268F6TK\L-'-;V(SFA\ORP>IZS8RC"(LS8R \J%/Z3'!(=%5\"#/9RU
MU()+%TG^E"-_/9YE+TOO,2MV/:LK.3N>.(?K-!NVD%!JFM.L'E4.I.#RA)27
MX30(H'0WXC15I78$Q,(D<B/5\V(D\EJ=\^*K\A[*<+97/8U.R#M/R47><XBW
M1TZBR\>IYTRNYX^>YH]/YN54Z7#&8G*?$A2L)R)?I[P*H&0#<]"1$J5C\BS*
M<MP'$_NSX\Y1TUX%<J:Q"E3D4& #\8NP;%F?W'$3I%E $?4O_"N.'+M5\C_
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MN':(_6*((KCO^R%'CE,+]+'+4%ER[E/^PI&8OD$X,\\0AN8(B=N(0-X0#\V
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MNI93)R:9 LMCBP8RLXGJNG.JPQN;1 #?8TF,<;8![9?;R=\,-C?R(U9V3@D
MNS"\V0CZQ(=O*SEQ3^H.QI9#[I'I(=Y5CWD1>C:PG3CDF$/:7/>N)S9=#HN
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M5"/>A0F6&D[C+C7_4O5*Q9CZ']3R2_$U3.]#:,?^"J;N6T2MG"^:"R'&ZO=
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MZO>FMF+'MM?D7(TCBYC8];5H+K))2W\DG"DZ&IS<6[$3J^P<.=WA$K#!FZQ
M(0M4R+-,$1Q1*T+62&P?O10TR\P.^!IDD'AU&QPU(T0X:C0T&T7\/8F4:M#5
MB $\<MQ&1PH<[CXR Y+B4?@?0M -!%Q%2ICQ1\Q @\;8:-3,/D@A<H:./E8"
M(>0^/DC!]?AVJ)9<MVBRIZDB)>N2!VF.[,M"Y4V()0$*83BJFJ(")I-IHBV5
M; 1>$A1K6(5!^TARH=[$Q8M(MP3_W&L.&RU;I8I@^GT:2)XB16]QFQF%+_K;
MI"F7\Z2@470HI67<E$?),]V"C3V&RB+$BTZ?Q25AZ7@CF\'R^USE@/FS;?D;
MK-@#HV;S,K;L8O!-\>;['QLS53S37:RIE@.H_G)G&"& 3TWK?,._B;G]$JT5
M.XX:A-"R\$>F,)PD,9%LM*O,0.<7^NS&!".V8:>K^-Z"_D@B,Q>F_8U"U*%F
M?$Q)Y%<8=IZS74=@DG(9&5NZYD@S\E"@SOGQLZCXPVTK"N\TWP@VIAQ_T6#K
M[U*L0QZK<]C4I?>[D0L<A*J[OW;5E()7_O,-.+Z$FTY.=I5'2NU4KM)YMJ1-
MDD3PKP?:F(JU8*B3-YOAG8FU$%ERZZR.+4IF4SK6&1J&%@._-1,:NVNU6UC=
M4.QR?CUN('W,(]:ISH9O5TA:I4FF_$ #?_X.IQ4U4(;D"SJ2%=\ <DB5Y\/8
M\9QG.P@Y:4YPJNV@!]M;L*CVK8VM*(X2\T<O_':H$";27,8Q*46[7Q0GQLRP
MXI[-;#V/V[*2.4YH$UALYH#1'M%F6U@7,G>)ZH1JEW@0*MN&J5E%J'D;9C*
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MO8P *BL.VG1$I9^S_,"K'E/K0K,Z)TLLVG/Z/(Z<NX.*53'AM8(]ON JOY;
MOXP=[?L<I:ET<_$G.D.W/]?<M^<[*)T<Q K.XM7&5<RB]I(55NH+^ H*4S?T
M8S9M&/-772(QINZ:6WA$ VGBX^4?J@LMBG%L1J*^QNTU_[T3*E-@9::D44[
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MDZEQE:E+W: 7>P#8 Z!( Y'3)7X+ &"\(&+>E'S?=&I*@_N\D.?6 ,3Y"4$
M*HR//1/]=WJL7OIA-=!QE=$F MH" *(K %1*0IH&LF/3QVDA&(4 .!Y)ZI;9
MNWLD^H& M6QF 2D4#.#/]Y#L>0 Z1[0.@3DV\<&SDSG3X.1^5KV=;MRKR3"+
MS<RGB>C?X.Q#136R*^" #42$R@8\0%1(0'=3[QP$<D!DG;?2@J^,<#QDTWN!
M#JE\%5 ^GI9W?CQK #*AR2 >9\\HRR@^^QN A\R:G\Q#\:943ZG!Z#!&?N>T
MW*=<?PM!Q6;Z]89AEF8&&D54Z(<03[W'Y07AP0$<!"B^EN1K*6@!!L4!0.12
MQ2N!V2(50.D80,F++^,!>EZ: O!X043(_'-/ EQ>? *I#_*EV; 68)\=]$$O
MSW\IK=D?P-<"'3Q\>(=M3.111(K(V.P%'&!HU"W %_9$7 2(^ H/#Y'16YWN
MH5RDN9B>)90K1JI'\8<DH%:_LY:$%@>@PREST<LU%,DEG]8GKROCZHP@QC%Z
MRQZ*0X<Q+Y57RP2BT,K#1J0 R P:)&CUJGRV5A8*3Z&!I7S!!E'S@A3^ +BP
M?#)>T"H,1+=7 7@ >"@0#0Q$@ 1N'%EIC(TRC-((>4'4,. _-A AO(*Z%'K^
M%9 O ,UX@&I\0,>&4,HK )(0#,<):864I]D"BE<X&I; J0<67#;I&1>9I24=
M[^D+Q>?-46\EP-7"TU@$.K0*M_> N#_Z(5OZ;'6&$UKH"J5JZRW 'LQ@G[=N
M6K?&7JJF8+H6"U['Z&08IF(H;?0>YPKO%H!&UP(J1GG0--"@?^7KA/_C1J-.
M(Q&+PJ.^ J$C060M#;@P$#HO0-1"4' *4,(;]VL:=\2 5Y3"'\2,R.F@:T$9
M-1T$1/#&93K,US[_U]>PC 1JC+.ID2"4<?.GDYS\R>#F$R@.'&"6 NOCY*/A
M8OJ4 I-I)+M7N UP:"-<6#<_?2"_; \.""%P*_H::H(P:!!H6"C<1;HV (89
M"X-.\K+B(.KL/"![I6T"CJW/7O(98!0 VU,;E"I.$#7DH,9;TP(#I6W[>U#*
M_M;=E@;G5=P]&!XS+YB]OPT'U>$-S_:V$AZ&8?I<O3JW!.P?,&*O<)5PXU^=
MO0\5?8]#]^%<2P6+[@./(TCS@80<52E& L6E@U+Q0FTX@"$/$ $,%):8HMQ*
M0(!("_N+IPP"R=>!"+7* V2:TGT!%*PRD3JO0A045@\BUO+&@A=1TE46G%?E
MXO84)@1W!\;9G9-T31L*[>%OIF'Y\.(3TJ$!'AA4+:6SO/BK ,X^' NS#L3B
M ;Z%8VA<]\#'<!T],.VTH"@M-!88=!? G&T!$2) \PCHD <&(1W>O!3&\P,O
MM!$ MM.P6/;PZ.$@0EB'AUZ)[QA@$M1+BBSGCJ\V%S/$@H-CM4!K<+1I9XPO
M:2U^6E \U$!1D+Y?*8B,%[H!QZ)"H %:Z(1PT H=E&(/WQX&[>S'HT/B492"
M9   UC^T"@=1>>!W.(75_#4D[0M9X0"1 R!L5!7[Y@B7VI#*-8YWH6Q%?L$M
M$L!% ?L @4P+0-!2A(_,^_$ 4*-&%5V*L/H H5E:4<>2#ZN@ZRE@!&),30?]
MXU&JYVB\OSD*P3%>0$"_BE;#Q-J)5$B#>X/V87@+<.C:%E0&J59&-8&.P"7C
M96V 8^W &^4\:C0(/SHRUSO"&Y_1X6C9.,#Z'EZL&GBTL)69;N*DA7;? R-#
M B"!HTT!!J3.!GA(T$$- 2$<H$X#,6V.Q$7C^>U-H&M!H::3*0V3SIW3WZ1
MZ!Z0."G-"6#"BPM#WP1]F7>JQFF*"MY8(#&34#D27=DWLHY+Q LE1D"YE0E
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M'S5SS=_\\3W;:+0_^?3?G_Q1=E6RC4ZAJP<D_I_WNJF[1Q%Y9'.V/7'AL@
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M9K-RZ[U7?70:H[9_O!YC?*;VFF!N+CCK?5$2XCTG?O(#E*NYM7<UP5>]X]-
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MJXT?FG'8VJV3M#$0TK+4?Z1_6G__QOB[P#1@R<Y:\!4=K(T;COZ('J1;HRZ
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M]G08!J)+ED!@I?JJ'LE5 7%7RN#" *+0$>84E8Q3!.R\GPP.&]DZ\M\V?)3
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M8.&&M76#ZJW?QF_#31]:_CNR%K4(DU"%)'>5G"H#P0<:?RMU'E S"V]5]B*
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MG]T",35EVN\51XO\FFBNL12?AP(223K7BDJT2.X#_[R&0O&QQS3@%BAN/(N
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M8U?W#B*7(;UW7K@_1@,:,K,], YT>!JP^.I<+U1J68@X'W]UBO[Z0F]L1G.
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M/$+];"JO]-G@U'6%NKX%R>T7KZ;__2B-WI:1 ?/29W]55NDY]1."R2\58R%
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MX7VF7#R,'^J+C^/(4-X04 VW'8_!)7]P8FL<LRLVC#MCE^/UR%2N*A640$R
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M$'Q2EU9]0<V[YN/C3=7M[ZV;<)PD7@XRZ%%CZ:A>D::YV..=)9BD6 ^L5_.
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M8.0$L"2($-,OS+POO7R2=O5/5?RU@_^%[>:W(5KI:4'I";2(+9-LQ\575>&
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M6J'8,F%C,$JG^<DW$]_6QK7$R>V[CR7VKIP8\K'GO5H3A7*[VXV(*HT6MH_
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MG T/OCGU7GT,0=!YE#+G3X4.!$%G;<!-WXMN?XUV2O2>^NJJ($<N&0)=HLG
MDI_"BXM0R1O\8WSVQ68I 1MP,-<Q#G9RGT3G$1##F)T7JZD+@J>_YX,15_\$
M[Y6LEN@"D<S/!^''(/H ,J^.#V."53:E))36(3;!*@5]'Q0NVLBO+C ,ZVWE
MZKOJ"C&)GEEJWT1BV+8!1O)03M=<L51\=4K5(YT\D5/ #WW,CP96)VC6G^4
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MG"'4PKZJ?:,*#*??K?S?M/YI&%H2=7:;_&5ZKN;V5O;BC)+[0G.:/ G(+Q\
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M_4P*BETE?.I]$"5'O]XD<)X[-"XN *(WNB+,D L?$P>#XJNW>6:/R0]%*YE
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MDTPHJPGGK?W5),&OAAU[>0:V%OV^LY/55-AGE/Z A0%2%J5JUDC11F<J&BX
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M@96V1I/(NI6YMX)TKX=/XW,6,A^B7GE#IO$RL>>E%73[^-"Y,KXLJ!;1)-C
MQ9*8HSW3#Y!BB2Y=G$E&YKBX.M^$[FCXK5CY&FHSZ12DD\$66ZD*-=I<8!K!
M4L=6*M"? DEPT1#6GLADB[,MX^(@56NOWY^+0@-T.9>%"'OE@"NZYG-I3$K#
MF56)C(K(=2>%3$=&7]:%#V(-Y45+, _LL454NDA1MM&"EXU+>B195ZJUB<Z/
MK90[:KKTT3@S;^ #K#I KHXX\4K["2\%CN8S[=RQKDYM6F.GB_[5/91B\O)B
MKL-A@N!L-JT>!VZ)13B18+B!@-JZ( 5_#W-S?4F$8,$K/G$N8E$Q:W @@"\?
M2A"1O_I\J+TM"FIJ2K0[G;%$E@H\(^AK.T1G>#PW+QO[B]03OLJ/C=JF2R^.
ME9<Y=%VHR[]5@=/OV3%&?GA05<'(Q4[BH6.D]HW3SLP)5O#M8BG<%=&IT"Q/
M).];&,HLZVAN9 JPW4)<EO76YN#OG&#8":O<5S;I5/Q&JYE^LT </>W1UQ45
MJ!=D-0#.6@UEE3J'Z.V&4=7%R?+A#!1OJM!&C*3;";T:I^F7*]5NK\SMO?D;
M3"LT>!W3R&Q71'</!N6:7C<&;X[EKIUDA$G6UL,P5IA_3 [A=>)1S;%ZN)$S
MCF6\E6G4>AK_7^K;BI2K$X$7/X&A_4& ]I2&&H$ ?T11W3NN8^)'0^F.SS\3
MQW5OAM.;"\N[\$RBMQ2XWWMYP'GQ$,V[(G*=1&'3;L&G-VPSCN_ES])..^F1
M3R91QJK"8F(G^KHL!SGBN(2SG9&558'7%-Y!$TN?4?JR_M=)'(Z<G%7'#?#+
MSV)R?-! KU?4-@]R 6_,KYN2;:N/7[G)W7EHXUW B]>J?I6.8J>489E+#X:X
M^/TD Q]X*/W\^I'(!6:F/"07,-JQ,@'T<T.AH7$&IY1_:SN<Y1!M*Z+CB^%"
MT3^&"$KA7=6)*[$AU!NL^VJ$?LZ[O*=*>7;?Y8?757-6U$%Q(@-6BRZ/HY#O
MY*=<:&3)"E.$?JF=G*WM9%T%AG03JM!S<-^\[H0N"R>U_12&$_E%/3&4(3M7
M2#>!;6.2QG<M@F0:5P6[P%L+"7C'/-=?JD=4OBH.B<)>8 Z^FC__F-&"2:VV
M0N&&0"81*$3K\KRJIX!&L>@5U<[S9&,GV<-R\+I ;,#T!XC(:J.,O6[%]OXS
MFL!C.&DM@SI-,;4X?ZO@F!12=^FDKCET=.8\<P4%^2MI-,NZ#/IX3F,W8C(H
MRF8E<>5W%/ C=<APQ]6X,BH%G27?J:;\-XWV]!5/_A8DC@HG18RN=VRG>KZ)
MC7'=FE_46C;,/;S8'4SW621PEJ?PE8R [._(?_TP*_<Y2L0T>4&N4Q&'^!N.
M@.+C'P>B@0&'Q^D:"]6$ISR8.V??.$RF"4[G'<DASE[4&1UI=X\\B[UV -2K
M%[:ZVMGQ0IK.I-#MH^!AHO7VI2YX17G\5.AFO'P 9)[Z>$[/JE1:*-HC!E\N
M)%YF5-<@N%C_]3[8S[Q&-%7S&].FG[.7O^LQI@XL 75?DQR':"1+CH.7V#2Y
M!0A+E]("U9)7OM+X ,KDU/AHR%VW@][^ >S[X'4?C#/81^V;?+"0@OG_M,&=
M?W$4\^ I%2Q:J<I';-T7OA;U47/D(Y-F [)?Y>Q5 Q+<F#K E2EX7C_^NS+Y
MX@%U>(<+R%Z#FM\0]8)!3=3$GMY9T'4,A,&AUTL*NCS!$>6[)$_-3<KV?4^Q
MGU>LBC6ED:2=T+V4>T<34(I2&"AT5PMW6@+&"H%8TKL)$_NA)H"9=ZRTUF=Z
MPHLCO:[X/=UQ5[V<>@P%-+,[$&VUO5_>Z)4?"!FAI6D[FI6N:1NE)^$1!\Z[
M^U:E;23?7FO9*\M""S3K%)&7(#_3KX?TV'*!$R9-]"54\F7_GO04V8,-W ?W
M[[M/<[]'L[\28</E+XM=YS1R62[/,!!E4)25G64;:$?T<^1[EU .K) "&7B9
M(R[]R__HAFB<(:[)/P+V)?V20^\QB/ND8;IV?K;O@*P]!:-*;:-OYI1*,GV6
M_4WY_#Q1;'3!"35K"HIG<,RL%KV "*@=Y3?'"4H[%G3MRS$%8B9,WM=_N\#V
M<S.161AB6*($Q.K[=G.2P'GQ]S*] 1UM#UU-H0BYD(C=R_L90N/2W;L!@O?E
M1#JVWTA^!3,T\U<=2U])_%+U37"XOO.L6GA8OHY274&60U,!"^LF%=!RL/B[
M!4<#?E=QGKY]_\=2.M&^LI<1 9A$8S$P#N$VP!7\%5'D6YYOD)PK.W!VWZ#\
MF%/!MQ:\_X80GVY)Y>_\U%?59?"QT"L?JH=(S;7LG8?(385::?Z/&C9'-(^@
M0Z#CKXF'C9AB]^',LK!D_>9B%YZPS'!X_54N::N% =6U 362A)JKO(.\/T9Y
MG5]1%[>MQ2U:+A$O%4.JUNR5T1H^=/[(+_9$J/TG_UU>.'C" C-3H@PO9T<"
MO%."!:YRH&@)CI"A#@-G1:K^SSZN/L"!3F+]"X&J2X$R[5!H7+H9OC U)'9"
MJ4Q61EB&_W96S52M(,4SUAK<9JOM;C!%/##JM4J'?3HR#K; ]&C01,\LG%'>
M7@J\%  JOFU/(_DU >796US"?'SD7[V(^S.> LM[?(S1_Z2S^*_'I6[&R]U6
ME+.T+!J-/JI* 9GH40+NZ7I^_]<A/,A!;<U!-@+A&J>^0Z29L_)WNND)0BGN
MV4;WW\V)"P?='+89^94->;\(47L/>1XL%G$ZV#0#42N3"9^)61]WOU)4AJ!W
MYN0%1R$QZ,J1U^TE%UW^A0"9]\6FV*JY[Y2T& 5D]55@BV6=]R->L"99A*QQ
M^]$/KI\^EX5?RF*'N7.<I@*@(L,S /,0N#ZJRUF$G7J4EQKLV0OW&(TO.SB-
M'\J&&"L:^1.YW@P)L:%D?;?OX:>$:)B-44%73+PPE_8!?LX!QWZOX,+!26%2
MN %S_<Y6?0:AP'%-2*PX?_;[JL4]T=X,Z1I+KUR4:.7H748M&O<CS(LHN7@+
MV=?>.OUTBD-?!3R?J@PV*CYN^=$C7$_C7-]+"TYO^7B_["HLNN' -/3BZQ$-
M>/VZUOJRBUF+PK5VR"9IX#G:Q+W@4*U'812<85+5 +Z8M6/LWV+3%:''!.#K
M[W/@@K2-T@''.-TFB=(^ST@AYZ;FPAE8M#3D0#N[6#I#8C334"B&3>'L,0<N
M5E-(!*>M5Y^$00(SCX?BXE.UN^8M&T>=0!@NT.N>\V;1NNDX$=&I"W\K\+J1
MKKC>RD3O>CWZ\[V38U>>RQ*!;[+1W]I9DL]"^&F>\DNNZU?C^>@8[F?+]DNJ
M&$).!:3K4N'L<D.*=U50QI SP+3?YKVKE8' F6Z:+YNG)6'GS';&^CJIEDGS
MYOP]NI:YFUK4IM_WA"P\30/3,+P$<+R/>;*D!]6T61Z2D1VX0JVI3GY^[>>@
M_>CKJ] A8$'#)?U^ 1@*YA4!P,HAUP,1W]C56(8%#RA7^'<%72= Z?P2'=0
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MA=A_NCMZHI4ORHQ[&*/!S[MWBUB%07M<U"%I;I7F)NS$O75S(76,E]DO V'
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M_R,!B2SP^?^Q5#RT(">?CU^"81[0Y7)3S2\XN'#ERD\Q%]/F8"[S9.E8'^,
MT]S+A*PQY*7 $JX$2/)%>B9!ALC$.[T':J:>XVY]Q8?XLD"Y ?],]]Z3;__?
M;=$LEF:USH$2O5G.<??W()CN-=Z3NJN-//0*S3/4MVS.DOP>D0&K0;Z<@_I%
MU@&%$(R9BM>GW9BZO=4+W>5@.(4_H+=["4[^*097J2QXRI.LKTLQ$G/BO2BR
MX77^:HH]'L.3RL_VG]R-LBVI)M0::;I%\#<"'#&KL-KK)\E7\Y@'X#9<' BX
MV/T%^)OG4,)7-J%;7YDA95,&RB SP;U> G=,=JV)4=6#ZXUS/1)0.2Z1A4M[
M]&Q&H>Q!KP[%)IP/AQG]Y@82/G9^__4(((R>1CO:>'P)$@M=@HOT3@:;>$S;
MCCQY)G9US,8S_EU&WX.:YI@W:(=KX<[_";-:DN*AP,XYIXZ#"M/+3=7;\*.-
M>&DW8DN/S@?$H48)=,)W;?8\*U^.Z+A.XI45HRE')+"$41_G&+\VTD^75P)8
MP*]ALI,%W_EB,SYWR?[$J;&0827W==;#P!<CHM%-Z^[W!T\_L36Z$+NM?&*W
M3Z#]Q]EZ6 (;Y(!\P;[JL>.21&8T\0/L*[%477S'^9T*P!K/HH27A@,<(0!<
MQ!-"EL.9N*PC<"Z($7J$"&(3UGI?S3Y7TRICHA-N/4U8N!"$@)9$C.Y&/BX8
M_RGS]MTGDP]T"FIWLD9^54I>9-@B_$Y.[!_?P_'<P[3;:E-#0FN' WY&FAQ1
M\PG_XT<Z7O<L>.Q"06$M@-:C'$BAG5D:53SC[QKZX?I(0.T( ?KZ"0>GTP$3
M48($QI."P0Y!B.\\I4@]%BC&;HPX^AS0(!-5;^[A1??1O+I'WP\T!Q8GCH64
MJCU/FKKC?C+U?<K]65I35FVH4_T/\Z.G;UG/-3F)W-^Z&+186Z15(W?Q8>S?
M=KLMH>=/'[Q!CI-<  7BP%TO"D:8P;PFBG[\S1>',&P$S:Q"CO-L?2J]T>K]
M5IP%=HUMP;0 )G)T<+JWDP6K*2@*56,#Z9GG0RO^#QG.^P-"$ 4MTPB%Q*MV
MU.E\D9 "+-ZE%"_5_C1)Z6D"A/L+Y\=$6K;EKH:F![B],_*3NQ;P.+3I6_NR
M\,%-[7)T-_,*EQEXM_=\N@N\ TUP/AVT2V%H)S[P4V##KG="WD<?,8/HGG"N
M5\\NK%G8IL+E ;ZA>X]+\^F8/4.8+)X<?(2UA\;NKTM_DC<1IWV;U2#"Y_95
MZ_,RDMP_QL *UU4GU!O!<S,OP*G].P9/%,.S'LK-;#9Z+-^"?^_F3'XE#-<#
M]+ EO?W^:WFJ,2LX=O@$N RDW6U@0&NZP_+XZDE ;RU:*"B3>_%S21QKIG)Q
M!QX@ 0B[HY9S)>JFR42XX818E[>[^.NMYX^X]KUU1ZF/ZR^P=U("($V#+# P
MA 6R:0!<BR*)LB[#I%[+8*)9<AP;LF#]+>  7A$ZR\DG#_+MLS10;\\#)5Z2
MK5O:;<GA3"F<"0R. E0/41Z?<WN\,^P/H#.?&K[1%>;($HHE/] 3TY^M)4_(
MMN<;H5YN-6!9P(?@_'N+3_[KZ/*,QUTPK[O8@H.;:T].L^#'64K>$,;S\0($
M,3UOFA4#(I4X@>[#-UYP%/(=YR)2%V5)< ;4]EN,.=&]7"#/7Y41>B6I+O@)
MWU[I=;$ZI#'+K+?1=%'G/ N:']'EG1'D&VB?M4JY;4]5/80/W9"*<4X"^J'0
MW/_W,H,16<EH@0B1 !9#6O.!T&42I='4)0@=@@$Y,(T?'P.H+. 6$TKDTY/L
MUCKA!AV<_C\*DG&&2T_I*[T<SDG\O^]'L  (#G&E/&8L0N4L@-M9^MQ\P8EI
MG5=B/;0SA@LOU"^D&+2Q:I<QY2"C>!D#_6!#M0MBJ+< [U><5SE!;^^FE @@
M39$A14$KCW&<HD#$ONY_0$'2!D4F LTITO<J:_#H: 87,=?35YR4#4'!0%(!
MA'BG^J 9M?5!A51^;V3X!O<0Y15DRF%NND@&KD#<:$BO(M PT-Y$/B;/W;,U
ME/"(Z0E1$I*,U$O^%2;/&6;4BS7!([OA+(@C,I&C"@<*IX@M N0_6NL;B1MB
MNE6ZC8^MCG"0DF,8  IH1)?IKG?H!M*,Z622Q"2FEWD%X)X?@E>B QN?C5#C
MCT4 TAM&6$JQ0\2!(3+A^;P]]$07>F-/C=B!_$C)H?L9_S=#R!(7',4Y3 'X
M1HO8HJ0@-H ::HE?@3 3@-X''$C,XE:PDK*TPI/0OB,X5&T2MA%=[98!STHK
M^6 Z2].*3H$.?<1A*%9UG.1.HO6=UJ[A@L&0K9% -H3->A8WB?Z; L5HF/7-
M "S'C'\C .>\U2RY^$\D='\@XU\:X-X]9/'%+/!7QS5Q@=#P1U'A[4 '9)D'
M\RE3,>0S=G* Z%FM<55&5X8&UH:&T!THBBAZF#+^;@>EP=#J-*PKW[=>PJ"Y
M-R"VZ.#-F"?K6<9O8,8U5IUK;"I'1Y(['> )!UXIX?VB#QX_:3XI5#+&-C<!
M]YO7'7(QP$N.!0P7/SZWTGHD M<^B6[8?;+,LL"R >Q0"X)-JH&/S&Y  J*
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M/K.%[,/A=)^4QT_/\R0;P@',$!1$FZ\>PP9O"X+[D-$9B+L ZAJM#]T' AG
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MT7(3,PN\3^.F$[D).U!QB],<!C)^V=CT3T:QUGJF$9#057J1_J3D5]>35F\
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M# A#V[%@UE^ATH];+G>R(52CT(/ !**<_#!N7S .&Q[C"3HV\QI^_ %,IB?
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MWLKEP(.FF77\<=A%01JL.\?\[0EYH*].6?>="05;E?+??5^FCR7 @"E 00$
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M91+B(C7J'V.'XIK_^4/I@@I8GM%N)J+XXMD"L-&4$K<W^6;19SNE-'S[J&@
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M!:Z'M8@ZE&0 ,F18F7EKF(*TEQ9J05)DJ.G[D+>6GT#0T90-HJ8:BT\[#_$
M80&8BG?"Q7$C[D )+8XR^ \!:@9(6G=,.W$!$/_G#3>:?1,H>84NF772HB,$
M$I142> 'Z5T )G>E!+5_.5*,"+7N2AK6;$[/+*V1 >2(DK#,M#I-"@1SO[6K
M:H ^M4^ L],8<4 ,_RKAQY9-.$_";5T*QB?2TE! D(ZZ=14.BTE"_="-1MR*
M9;J\)@Q56S+1]EFJIL1^Y..W-]?G#>AAER!)L;E-V:C"HV[_H,C<=2PH943%
M,-AC8]4CB50B(R#N-\2]73[1M]U#8OM";96=_YB%$ALD?F]ZP.U8S^I?L%K]
M]=\L>24K)H9(TB6KN"!Q3JYEDZ<<55:U@6*7\E.AZBB\ZV&2$1W1VP;9"(LS
MD@?6#FBAV#_)%+R42*Q:"<4Z<U3TH0^/4*%YE% SEX<JDQC#"*!, 8F\WWI+
M3PC-FITCGTN[F2SK!EO7Y49PJ&D+V3&D)FA3-6;2NOE!5,:(%,C]Y+\A6&42
M"?>-!0I F25=V4,MEUM5\0"!7,@G;_&H30D(-(FYDQQ(5-JT96947_T/DC2(
MNJJ&M)@-/L9CG%W%/JZ"BU3-8$Q\I@F'+)WM@D<A-?HI[24@A3$ZB2Y>*Z<K
MER:@]4)W3K4?E")/I@7+2LV1Z>=E2*GT$ZG""X3"DO5N\)).!:>DPZB>#"ZM
MTT:(_\@>!SE:>JUN*)3+%-H'D.73:?*@$+I\.F?IYO:88_KG)HG;F(GE[Y'V
MU.A#H9].Q5SLI<I"S2PN [)>A4)@3%M;A_"X9'&IG*]-.:3<Q41]2#XR(T%/
MA#D$LQHQ\50\$H-BQ%-!\3H5DA"@@V\:4,AO!IE0%1E,^#BU)"SN_3HLPH3V
MLZK(Z]=:.JQB+_,,IQHRF'>(#?HPTIUKQ%8-<1_,/18W'%M=O1/T7EHN>T=)
M *=$7J3^2EI5+.[6.[^^2!HLT'O"8+ @WS?K%0?^O(# :D+8& W&^F+:MX93
M$=PJU-.M C[]MF9M,_C'S@_#%_5[J-Q/\?MB0P(G(;>O&!IS<H3J=3!;)I1!
M/&;B2V%H8S::-C+-1)*=)V3,R"+U_W\V6_H\7$;NTN+$WKBS900C#K"7(2I=
MYL- X__1T+D\%7!X05GJZ\#P3FP5'RZ'*65'>U'LCL)A)6 6PYYA7$#A%\V_
MPN*4\HI>RF18)"\0,2_N"UUGWH1"A;M*[.ZF&KCXI>-6BKCR@(K,5H:=H@27
M:2<6J%  CMZ^&JPSR 1YL8Q<;P;:<V<P4%Y"(3T7AH8[9,U?!8ZC",%"XL:H
MOH3!V)1J&*&#%BT79GZWK?XM#X,JNE1:4]4-Y>^^3&R=,]_6X,3.R^!RH#I]
M4.V -V1-S#=ZO*2NJ__<PQ$O+*1RZ!G&H+9FPJ)N' _1GSD;,;34EWH=:=1N
MHYF:Z=W'-TZ2TN_= \)6/;F/$@JNB/!^C&OE'M7(ES.SR"^.JXFU3]M.[RN2
MXF<\.S2X6*[3X@IPH6S/5@[K2KWC&$UX)L8>$9H?O.N>]IW%6#3E50&NX=0]
MD/?OH 6\74'_G>5:S!"%YJ;/880"KI >1LHL+AM\>=.VV3'T,8J+]%^H+P7=
MO2JH+SN,"9O\HF+U9UZPE.J,-'D?=XO@9#03<DE'>5?PR)&H_,36-C#NXJ <
MR//XI.HY1:6TTL9_^ZH)G(PS,;HW7XGRN)%A/4AQHRN$_Y\-1*!]6A]Q+63V
MNL\/IX''FTK6!?%%MFAZU>M47'#Q=MB9L.SN%JT>_#41=[@%+4^X)TUX'D_T
M *#]\0T@1AIO5!W.ZHW./:+2+-'OB>_$$ZFI<O*'#%<1W%RX/)JR0LW0\GVX
MY=5KE!@WL>V>*855V>6[5_ ""$: ?V1[.\8#U5NJ15>FAQI&=I>B5W<-NZD&
M*@R]Y[X(M+J=>PLJ(3UE;BP#%%A?U3(-!0(>P-;-W'4H,)@J<!]M!Z&'!B"A
M%-%+&^L-5?XADWZFSR/$E+0OH.(M) :[P.R23(UAV(H@ZDWUFLM&O==JA !>
M@K/FSR.<$'UXU'S;"'UVA4I*O6UF*H\(:=F>LJY.6FRLRU6520F)^AH7=8NP
MX0(!9JSNB+-A>$B@2MY'DH+>?9NUAO]@0C_Z*V7Y%^:*2-O@X9MRJ:'DEW(&
MDOMEB D_R3/TG1^5 HVE/XQN03?=H(U=OL,)$'(DSW3#*9J4)H2R:OUL)(:>
MPW_D\[Q:0/=R[Z0&:FCB$D.\.$R76:\S"=!'>-:BQ23,Q#X%\4)N10U]R6MH
M#MH64(C)#^ZQPY29BESA%.X&]]V$&''605!^A7)Z$%631(?>U'T8D>S1Y@ZD
M5=B%, *DBRY7$Z^2LU7.55G]B"Z1LRAU*>RN62S(_H*&A1(8^B7-0MUK9R05
MEB0[5!K?5KVN&<M4N%,EY(Z8BDL+\EGEP 9)D Q'@%O;W8<P9@=5O!#?<INY
ME?#C58A/E6V,%^1(\O5_,8/5A6@2T \AJ18)<&FO($^6+&422&Z\/[!LPA(H
M%@%:#P<(VUJ147Y_,%?R$]; ]QDH93J[=7/)DV7:4Y,T].J;FC7%(^8/J"A.
M@9'N;O2I,H%=#VHC :"YB#YF27X+/VP0=[6U449D06E!]) F:9#M-N2' (]@
M&:AJB5@U@@XM"8A08,Q,Q*"*:D(]K\B1CLIF8 41JG_A+BD6;^]IP&MA&DY%
MX@Y*--4FGE#T"]6QH(>\Q\KT;*8H!250=ZAN29M3VBQ[,+X>M#K[:%G\\2?7
MESE5(E+!I++8[4X S9,&@1FN'ZU4V#Y4=["8^S\1@%\;)>)R"QBH$Z\4D>@,
MX'UKK7E?%S2T,L9 Q.X- IY12!8#D?<M@MHQ&#;2C!WYY%W5E<98WZ.^*13F
M4!-E:Q/K\.:VIK&"IJ]9VZY LG,5#3:P7Z(;\_Q:P&'S.9MI5[#,[A#SVT<O
MT0KNJ#)!Z5-W/F(Y@A?@9L&A57W"IV)])=9BE*7(RT8N0B0VX6[1?32D(1+Y
M2$Y:54FFP^TN+X#D?RZX?A$-/N\*0L%?^PE+,F+1DP;?W]P]1V3P5*U8:J(?
M-3ZOY(V2&;OWTY 9>*>#^ 'FGZ#+%T"(H0*O\KK!>SJ5W1Y[#@S4\VJEW]U[
MK:7V1E?I%% 8 7=>58Q @QGOS! O#. 6 0+Z#C#7]L7I)RSY;8U"?H(8#,3\
MD[E6F3'>@V<S,G1LZ?:0HAA=%%+LMX:_3Y F3CQK5=N>U:JST;)3\752CVN=
M&R\*!=K>R0KR.(^QK@J(=KSC"8Y4"6][:J<H*B*7)?J6NARM/IA%FQ0O/1]A
MR%8E03$DERD#%-I4*LPP3-FO"0&!K(KIZGER*\F\(G]^I^H#T<;>%<+*W$_O
MAE*A(!,?U=^(@G+!+C-KAC?TW:@ A@DO;60Y9TZ&,OES1XY72T2Z@%:W"A?K
M%<:*\/<&O)_<0'>A<SDB;S$>A1VO" N4;-5A6-G@V_4$?%JPU;]>^/?$\W:K
MGJQ8N;!KMP18.F5[WYIZ)$,$+5JOW/"[[UD&-:-D?ZS_[UV5%7^R)$$@S-N@
MD!&PN3TU<>&M+&5F588"H(UH"#Q-6&1+7Y5"+]3]76\7())\)=4=2&%'-PA
MELOMUG?-BTLE>B&&7Q\(5G3[4[OS5 BB]R'2 1-"Q'143I65GV?!]"NCUG19
M\RM:<4.J>8."?M$:XU36;S8@54L:$*SO;H7^CFQ/5,67"B;796]MSTKC@3*-
MH5(B53<4C3O=5[Y)"%X]6E&#52!:*27^?X0A\D4]A>#+936Q0J=)YI&^8)4
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M78,0VQ]WOXJ$(!O1O1GZX'2NZ)BJ6 7:/>1:CW!4)R@+)0ODPK"0L@,(06"
MOJGW[MU>#^>A3T5#X0B[O#=#6A\/=@4Q H3=LQF4FB>TC_->>]7@:0/(06H9
M=_:+6!$HVKS_T[[PFD+SW[D1IL[<,\3HEXMO8MA'HX\A,VESD<)GHY(NHNL]
ME+FJ_0]G1CT07Z3_C;>C+S"/-9F(DKM%'TM4RHSXC,V-AI4<U=F>34IJ.9_#
M@6#H)(/\$.VOP9M:K_=U(>;?OCW;OQO'9^?@WI7B(L:(33^*2:3G?9O]>,IX
M-J\@]U'X,_(#EYEH<;EVKUGCYB\CJ&_7G"<O_YN=_0&MZ^+N/IV=U4*?<TKJ
M$L:O6<V"+T?F_XWC'L_M:>7-#-W.UDKY%;_X$)TZ:]A!C5QZC0:.YN%-C\G;
M6DMJ&Q)"F,^"Y^-*(N/5_W[Q$FBD%E8N:T]2/Q/B0Z[>I)SF%&REKN2T*5ZS
M7EB[?K[FA%R_>6/]UH7V^MWB]<"%]7O%&P\7-D0AW"+N%IG.F\G%F^D1FUD+
MF]G(K=R%K4+D=OZ-[9*([?*%38?#Q52M%&NK*=.%G0\+OL;O?Z&0/[(K9)\O
MY8A<^?FM^.?LPL]%Y.[*C=V-XMV=A5U^@&?WQJ_?VK^^O?\U>?Y+5)2\5_R3
M>I%,S[_W;4%%"OOU[UDH)7%N\,:^:,F"X.+"QK/])T*RZPT.??T'E_D/]5P/
MKY0<FBX>7N/_;>WZ6\/UM]/B[_JU [?% Z\G*3X?-!L>' 5^.+I_<>11\L?W
M@Z-NY<[?=RV*B\?IKN_D/TST(__FEO780" L ++LR4EER<G+Q9.6#R>O^4\[
M7$_?8OG//KB>=9:<]7PX^\1_UGD9;!  9Q;_+?*?K[B>;Y2<SSXYJ>:'U%T@
MRBY?G/*C4,1H/ FA$TG#S*&I&D#0C::%J_.VRY5J,_*P =/]3>6?TE%Z2;S&
MS16?L\2L<YQ)%U@OTVPYCX$B;BO!+X6J][:5_M)[M3[#7$.(J2G5C):+)#]0
M(K#5CE?SW-8U^!Q49YO'R.$\/_"J_EL^7 GK<_+J^?<6'[4;-4<_;LZ\#FC)
M,:O.EIIKH4-BV@=5Q&+H;9@.#4)+NXSN.E)_<$'=+X?21K&7>Q$)>PX=F25V
M7X8Z#KX#"$W<@=F;P]E7W%?KBSM"A=8GK3LMI^G#?]_*I./2CWM\NA+)\*I:
MPF@^0R=NOBLC*@3[^D=4\&=?.B/>SC>_T^%HH\9'G6\?IG.JRAU'=*KT3ZW>
ME2!A-+06Z65-DSP"9-NCT8+AX,/T+-5/E,.H3ZYF2'].SOO08D[7*-C11?8\
M%*(L)G"3$T9:C'E6RID9RI76NJ -Z N:*^GY"J$3@3Q5]T2!ACSW9+$Z+L$4
MJ>+CLE3EWQ3$!(WSWI5T;:KO*W@,B[AGAA%R:\60DW0S$W*B[SW^U-+V[W*V
MC;NO5X[SG:VU;-Z@0YXK+GZ^WOD^$?GK^7YMG]>SQ<O<N*&'-,I/DT/*\C:>
MA1U]WBC1VA<?3A9DK+,LC4G*JRG54DC:+$W2'=@T9 HAV3DBS+F\XXO,?\]"
M<A](^#G"I3RF:S)OGY0 -6$)EG80LT]CD/'/=)(OZ(<<;S6\GDFJ?_EV.*F^
M\3WC[,[+_MTZ_^:.@6W_EA'&T^>MHS(6% B:S(M6$/KN@:2_W6(8_6[[<@[/
M;L?J<($M,[U1(^E*:*7DRXZ#,M-?G4?K3K_>+_05[$"0]FT8*ACN[8^N(?1S
MN99^Y$Y #_S726-OWWJ8(175^\IM7'[;]IXY7<"?O7Z+6+-]%[[PUKV:'34
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MN3GB#L'S2!@%4H]<82[U!V,9'HC<::!A&L,R0+  2 :F2  G*-"S=\?S85*
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MG-<X&/A-,S],TO/SF)M=:C"/=&(:4?<42SR.AUWC (:R@9@)!_8R4-W@VF0
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M"45EMW&-WD<?^B\+91Q*_\VSI\^/+AE'5?#9NN=B"_YLE;:*3SMA+JGW531
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M>PVPMM.@;XU=AJI)=G^FNSXHPL+:$)6 B9ZN?352@=@O7!OX<)S,LMM#_:A
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MG>0\?Y/T(T;MC_ZG_?J24B[DK)':6TWEHZ;/U?(I!B=BDF6=9122V[ \:VZ
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M=+@5]+YK!M07O9_PW4O/S_8-""J:H.FIT=4^J7AXE&7IIY<6@2IZ-RQ3P4N
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M+Q+E74VE!2H?=A:*S8G]M.\_5*O_DCK#31O9M=HK5:#U"EH_$2Q7WUGYZ<B
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M $+CH#(93)M9F:]%C'4W'U!:\''0QIC_"4H%6Y?J4J^I(4X8^58"80C3>@D
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M,#(U,3(S,5]G,3(N9VEF %! K[]'248X.6&$!.<!<   (?D$ 0  _P L
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M\1QT,083O=+.1KJ=8 TG6\[Z9F<U_VL %OY:Y"N+J/%+D=0N=#. I).\JC$
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M,?0ISE"R9E.RXW(:E\29-<@'DX&/.(J-U%2SZU E @'#^W**-0"00]*9V0%
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MX%/_\"*L",YF.Y2SK)&R2PU9.HN&PB.)VS@Y";HAT1>LA)E1:1A5^JA*3;M
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MI-&%.=GL9UVR^,,._,89*Y V3CG0P 5'JYA;]H+QR1@Z\0N;UDS40$IPX8$
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ME%5 02R41WW!\[T50_F= TA90< :!D#B<@6 1U7:;3C?!?2AK/75B&%+&U[
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M'G(42[MT1^D45I65:L6V//#A'=3U97<43[1V4'464MFU26\65M7U4W_T'0;
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MW'G2,> >2* $L@&D,SO.(8 #Z,&P._S#,: *0#MF2+H$#GQ?2D"\W=P#*MS
M/<"W!R $-@,";* $'N'SIAH##%RWVQRU%WV= 3W1H7U&SSG:]_G9.WD<C*$
M/* *()TB H#,[R'<Q7VN%P!FQN$=A%NW':,*L'H!MKV\.4 =/MJBG[L$@)N<
MF2%[42[@ SP@RTF< E1@ DS['4P=FN4! QB I,/:C54  T9@' 9@'.!: >AA
M 28 LY=[M8O<K:F]XUD4T0T=Y FYQ!<  K)T 91\(AA@KEF^Y0N@W%\FL!G
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MB*PPCF#"X?;<5S/I#2Z&2:M?>&I(QR8AK2)/]!$&X+:;'VEL*FS,#!R_\\A
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M])?)'3.6,MDURE;%-7P$Z!)R.H/X-M%;B&/I:MN9XI2Z2$8VTI%Q@$0D-AJ
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M%&917:,B)Q=*GD+!;GWJIW;8I\7C(4LJ)7AIB[9I'7@2 AYPEH3&DPM )0.
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M-%!(G6QXZI Z&15&0A0[F@UE!#5C0$3B>$=!"B26 AE'#&U).)/P:922"4
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MR]3%9KT 0\=5='Q\4]T_F[B;;G)JR563GM7KVW2[.;,Q/\,5CEJ(W'A_^QW
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M@:'4U&U[DT8%UA><*FTJYX[JF@[PP/3U["K@/H=+.W8#JH'3S@6CNV&BY-P
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M?MTR"G5F<&8OQ<O/9+!R\:P3_ZR.GOAN&JR[#\>R"5P#A4^"8=I64:,'0YW
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MZMG; G <NE%#16?7B3:5H_";4\!^/9V %E(%3:_K\[V[O5:A WEX^[1NF94
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MINUO\]Z6Y6LAR EGN,QPW0Q':8E,^+Z-(J1?'=T\@':5U C$&8C4?^>=(&-
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MI'B))6]S[KCC\ZP\.)E?,E*]/AX'I'&@3:Y(DNS7F?Z5%Z/-901P10[0?=E
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MBL'M 2B3U+:+-:(29!J2\G8 *GD!&-K?Z?G:[+IJ]Y=[H&?H!$0ID,IK ]O
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MJ6&R3*0O:I4B8&EC$\@@"^P1U>LY<FFM#O-99+"*?^*6L48;X$>/#^%%W7+
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M\D$\H4 I J[15 2H"&%^@ZKN-+,9>TF$1)0\Q-=Z %K)B%1C46,29DC]_T2
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M9//-J;DZDKK1W.CDAFMHJ.8O*TM6$! S2@3;)OR?,]Y+OS(C%'V'QB--%$S
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M<QS-;CYD'A-F0<QG"A%-VUSN:/*:7GIZ$_+TR+W;%7=A;S.KS?&T[PTB1X7
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M=$\>?6#H8X5M#%.6P$934^-3GE3LQ[R@6F"Z&KW:)!97C=YS!,"Q2=?%9JR
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ME"%(;,")9S#P 1+@'>TV)T"<C").5CN3=]-,1[:WAR%Q.3UDO_\M?U>A)1#
M4#)# @Q(0)S$WS+PGU$B38ZKMHN)'$QD/PJ'_?>1($!3BU]Q6)PL-DQN<U+8
MOBR',R1@ ;7=\,NL0]]F&7^;-0,[Y"W87 ]CKNA=S]\+'#,L31G)C*W21 I1
MMW,KFSW-Y1:^$MP7G^5:8B8+*S630@4HF+'/SQS]LT/-?P8)"?MOK69(0CR2
M@P3\W&OF8W87.:6%F]D+=JY9-^[/\__&$M?)FE^:S21Q$$)8-3\)>.5<1D19
MS&45)6CZHL0+/FO\40UPY>2(<55_PV!GCJP.V2QFMR_#WZ.W17=R]MS?D("N
ML!>SIEZP1.N>><?-'+,T]Q\UZ?RI5Q"81K+BBA(E?[F#6*T!2,"'B(GVW7U#
MR-ELC"GX3;K'FI _WT)8FXU#MUG\E4G E2'7/?;23AT;E0<;[$96^_XP%_D=
M!_/+"Z%8 T)\@ FQPA(Y=]ITATN@/3NI5"7E76[OC,!?P*/_"F@E\7"B;@V*
M!/Q\7U:%J86O'@+=B'5OQG8DG'IA8F355\(C?KDQ2P!IB:<13,@!1;+ITI)R
M-QIHRWBGQ6YVZE^WF&M#X-TIY]:B24 J(,6.5/G]-SR_9N6%83,(/H>H6TTV
M5U92->N91P+HHV>Z/@VFZI,E=BWZ[E^@[^97%^X)_X,TSJ/9R/;N"8CYN0_G
M(X&*!!R2"84O\I'5,S.Q0GS1SG T$R697OLC&R,Y4S-8B2U#$3F:,^>JJ5X5
M]U9INA<CAH=&LLZP?F1FB*1\-;6IC,F0Q.I#FP(5\/W-"$&PNP'.5#-QHB,]
MALB2KQKN8>EW(<J&S,^2,W>\V-K4CUPWAH65@V%JNK@CV/<J"O7Y[9GJZVS:
M5-3Q'Z4>,NDP#NR82> 06!(0J@ )#=P?W!0HWQ4:L:$/D[A>5E&)DIB.+?YP
M7AE6:Q8;V+ZSB<GRAX)EN+'&%)].!223CI=4==J:<+:4;50JX*%J+B%,*8GN
M)/#A2N%7R(B^[K3>*PD^6M;YTM53)@B[A?8_<:+V0[-CVE6TF?<"HL]]C,=;
MMOU<?Q4\>V!L1,7JR_P38K=OT!W.?EJ:4).TWA[[P".=!'V150>+U,+,/CD^
MI^RRA,MUXO/1%!/O\J<9C?6UG1&;EYT1GU5B8ZM(@-**R^ZQ!? "-!RF[/HE
M&&L6(]W",@>3[;0T*C**)0%LXLV)IIZ?;MQ2G8QX5;1.0+*J28H^R74\W*CB
M.B#_Q8+^4ZQ[FE55Q%9"6Z"Q.J/.^%@XD04,%VA,X\9+)V&RWS:VYHP(CR+Z
M'2:K;U1VW831$]OA$#7U?%"[H:E:M']#^+'%O$O18$"U\74'6YO8D'8-1E/0
M,L?)%[*4>F-?$>2^^^Y;@I*<GNOXW@*+(?;*8UE,F^KMKNBKJ_G0"W,US/YR
M+^V]!ENCW^6,S"G*'+*RUKI5P,Z ]E>E"AF*=M/O4[-T%6O8TVE,$>E]1Z#+
M^>3C<)O/YV%+*;W$AWDZ#ASZO4&1.<$#S_$F;"L"=V_A0K$!?T"D1%GT8AJ[
M6WW9I^DK9L/6BJ@^>(COO/G1:RWN#HV41]D'A)PK;P]Q-YDI--GP;7J!0;D$
M8U!F L&Q(.&2DI;K*)KJ;/CL5!G+ZCU=JAB+9O XWM("O]5H@/(5S!'(^^)M
M9Z['=]B5Q^SXXP;6J:*6]G2.V%WN^8OAN[($>/ARNBZ\N':@"QCSJ>2=J;&M
M7'""1\&AC5O,M09ADT*Z0B;$9[Z3#R0%D._1D3LK#PB6&2!M;<J%PB)LE*U8
MN7:-9W3?^Y$3#M-"UR/7C5KRT8S]V!LQX5>#FUTG&"TU4T2EO-+IQA-I 0X:
MX;9Q'YY]5?V-*7M)Y 1]R$^OU^-M5[\N7C1HDX]^;C]S>&?QUY6YQ*5VA?4D
M@@COR1[GE\B2)=B01V5+&9M,LI!1?$B[FJ]AZ16'3BV.TS_TE;=( "]RZLD\
M>J.+;"[/'BJ<)'M@^#]Y8)/9R__M<)^Z_]D.]O^KP[T"CC7S*C74,(XX56ST
M?Y$?<JZ<,G7@CM.XFY>>*/SP&(WCX#RSM<[-.=&Q$FV1*&$^_ER>MN[V0._)
MA-H4\T3[-"4>;;XS+?P!6M= I=H=:,,2NP,,VHWM+L%+MDYER7T=7K85"5<6
M2RLM5F@T=%Z[<2:8GW&1%O9T$KT=Z/[^3A(Y*JV2S/-.,L33M,7PI[S/N.8^
M5(F1/=EM^92X=/>F37R;K"KOU*&]^$"6AGSS>=WQ '67FV^XM>?4JG)&;&,\
M^Z_.UZ9L)%\WM['SW(^2O50)L7!^U^AE^.Q5Q2>VR/PL2KY9OZ[75%P6..F0
M22G+TST;C,K2,B67+)QAQHLU=M<J=0%F"/\=1CMO<A N=A\FH?C(_T*&Y8)4
M]C!]OIR<RN/KW'5\9];Y!=7S,9F/^?MC8'R@W:1KZ) F'A;CFC]W(WB_Z(?!
MABQ)"8:<89;+*^0XV@X1BF#<N-ZKIC#A%R!I?,8:\D;G:('DX:>O;.U$BN?O
MZ#BNVU[)TQ6BZ(E'?<*MH-R17 Y+ 9F.GA79*1\[DI=$+C&?R6%X2_M"[5K"
M0VX+9-W*OKE 2 ]!RCE]Z'EP;DF,G^WG93$'ILO%G$=U803/@GS(_CD5NY L
MW-=WA:V\JJY%!<5GEG93*SV7A8O&L85.9R>7Z14@M]5N9<QVG3#:3O%W$VG4
M.&-U7?OK)>YC\',>62=[\ '0S>.@0OK8X.@<D3ZZ;[KO0@JGE<;B_5MW]IM(
MJ^Q>P+ 1/Z#W$VY,ZFLB^M2@ GV8%_ G'G?*^HV2+;E;Z,2A#S%7F_M7,R.$
M*D]$68YC[BFL4 Z"2L:XI<*,B4I3ECH;CPJ$.-,3J_!; 5MVHZ^) L36&L9
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MP;,FJ3^[Y^=O( ,%Z<O_ U!+ P04    " #/AG=<:X'IG!GT  "&]   %
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ML2A["=Q$)1_9:\CHQMP!SR4XRLGJT$1\;)GL(D]YC/;\4"D$!Q;E^OBQ"[3
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M;I]*WVO!WJM;/'-VZA91@"0(/3N;B7Q/'@3((%/?D-4I6][. 66AIMS$CW^
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M@/9J@+8W7ET.0:DQTVH_,:#[%C)AW@])L@OE8#<E8"N/$]2?>A_,D/7))7G
M$GWW<_TE0?0S@2P-3+_/%R34;SU@8F0<#I'KQY_[U#-(8F7@#NS0V0#"-PV^
MQ7=2ZF>ALE'F_@8N!AU>_PR'<- 6"*6 (Y^)E3UE@4M\#P\BX5HDFY0]D33&
MPQZHZW22!>57][J&:>:CS_02('%J-.4> 5^7_IW-*P,TRE_(4G[JU\-%*@GJ
M, %0W$)!-M#=Z72_' +_O43XM6]ZWMY5_5E87\MOVBXE5N&?R)].'TJJ"[ &
M#4VZH\$T'.^A%V%<56CF^*);\T[=G5H,/_XKVE(R3;_*G3=%ZYR%N+W*%>]N
MH/8)_E6J'G*_U%LPWGT4SXJ^\-()%9K4$0TZO0'YZ=X14H/@X0 BU\LC(IB+
MC0BRU)E]]5TAD?R1=]?BOB<_4%_Q$AGVTO /,DD?3J 1&<KA7<OB5-0H<UV^
M9),&KL3BWU/TIH:=N]3UD\EC53FOLO6"TSF+S"C'@Z&,OU.O9)L97MS"4DAB
M V&]3Y>#<Z#A=9M797/?X^ZCJZRTNS_]K&7Y6':/I\PSCQQ%5OI._T7ZPQKF
MJKP&W'VE>G3$FY#_SG^A0M!0>"_9O<$7*K^K\W^I8NH>Z5TH,ERUJ[R.S 5F
MZD#%$H8](T*-U\F*=.<(BU?RT)B[_5>#UM7E[^0?_;J<MKCHOO]GO#U&)R0,
MR<=E?K8O OTQ ?T[D_CBH6;M\?9&=478K/7?Q6OFT).ZFQ,2<5YV)BZ12^U_
MURN9^MJK;I;[O+_X^T&E</+5[1ZECZN5_..OELF+GQ5QI^Y*,.Y"_]L?2=8C
M[?J8?,WY1C1 ZVGTK\=32;#D EJ<D+-W>A7ZK00N$GAR[GVCUX9"=I7J:<;C
M]%_A]\$5!1+1@^E^]D^?93GGG4%A !A*38DZY>['4M J-;:=(@>3Z 3,ZKRD
M7L<!9! KP-J%!PU0 Q95W#/$N!1AZV:_@^^NH#@DR0Q[E*2G'L;<ZPUWQP^^
MF6*U1#HQGS/!N3*]%]+^R3/HJ6P*2DG!H'=]<K'K8>YBP@WW+"I=1S+%?,]%
MU[(1(8?8?&Z2*3 X>(92ZA:1I",8]*6,?&M=BYW&:P]?G>5)@9'P\M3). ^>
MZX&J@$=M;/EW)C,TP9*2NUMQ%(@OX/WV8/ >99!L2\#UUU^R7U::LUES9T)\
M,&#J;2&%JN+V69C+?7J)@#\=1T)MT/JICME;:$IND97AF+DRU-B<KI)6$0B]
M0Z%(KSS*(M'EMC,:C&:WP7BB3\@::QM4@OH9>A$DN6&GBCLZ.<A6)K5"1A,,
M>&FUG3N.2NG2V=.$T/H,1# $J(-(@L,M5"Y0E\@D9,T+0 B"9S1^B!3* &)8
MXWEG'O\AEU%]N&XJD&% GXO- \VYM+].JC/5FLG8GF(N\_NVQ>@(M!E* <D*
M:0QV:A Z=]1#<@5N[DS'AU=\N:.+$?;Q)"AZ8VNP?ZEA@@8Y,W]A\/A89B2$
M3Q+SA%01/A5"2HXC>J]<V[8XD"UD8"G3P,^;/Z'NF,4YO@Q-+E]SY]Z51<=F
M9NZB'MZAX.6H5)C#<L2$:([DX+;*!\LK\%V_A.LH$ !5'BEET#,2)?;6$E..
MX5\BC=RL1 0@K5"V$YIFJI=A,$L)+]*UTEJFT7WW!H9.X]V5B0=M!RW9-&IY
M:%21:%;PYJ-(+.B/34O J*D'LYW9A[>_YB4)M[,3=$2[__[Z'1A,9G#+)7[4
MX+0@T)]:<PH$W/XCZ3Z01N&FFP BOG:1UG68<[RYVE%H $WNXHV4<2%OTL^E
MTZ*+.7/YPS4NIGB:AOH[:.^E?$T:Q!E&LB<CKIXWK"PSJ]E]QJ]OOACQ3,%?
M-"";W]09<4=VT=+^D:S&5MC#%I I^+*R-ZY/'N,D<J.,=\F[UO L5]=<EBAS
M[<4YN&<J0=DNMQEUU"O_X='OO^U)=,T:)2 2!?3'>A,:/H6M9[?_4]AYKG_W
M:L=?_^<YQ-!7\T$#I]E_BOLE*7>5#LIOK#>N4[),VV]K/0IO/VB:N'O[*V']
M\6_S1S6MAI :XSC+?FWDL]O?AMB>*'\?*YWLT.O82+Y$&8?N=WY?M']RYWS5
M5Z5@=\K:AIA'P<->""(UL?SO:J_T[9M?7Y]<W_U]VLVE\O?'NH3*?S\_/WG[
MW]\?U]?_@?=50. @-)DH-YB\BD@B+HFAC"DFF1+H(\])C^VLYB:3J%(EMRJ/
MX1 E0E6\5,E?2\12*2,AIE[]#-09<3R3Q3?T82IDA>D)<G4M2.K J@'V[__,
MTQ<D_(G@(#==<-*Q&T"7!>MG#H G&/$BR6T[^H5J&I/-6F\R-E0-B8;0ICB]
MWV;NA@U+)3>E"I<A7Y-9O[$'I7/W"%/(4DAB%.>:TB)Z>#A_5(W<^=Z4_O@/
M#S>)T*@J77-&@C+O3?KJ44WIYN=I,;R\/$)CNF;-F3D]O/RWJL<,0YJS7O[A
M%53/TR5QB#.P[(0>O1[I?*WC'UT?PR?J)C1AJU86S9R7?-CVMJQ17HLJHO4/
MGV2<T*2+59I5-1L1LJ.5\8W1(W(PAE^F5&C*^^XDL+!>Y'VZ U1^,Q-L*.57
M&!":#LZD5VMKA0401PPP=7.&RZ("RI^$WD7-T0N1H39V*1X\L_#1"5;S]KA#
M(CR#H<,5M]S,/5FKJH@0GWQ!^DA0@T=XUL9N'I<0YZ2BB'WW-*2UE/-OU==I
M6UK2,^J\/PRC2HG?8W^@6\O%'PD97$<8QZ[ZZ)MDO33-99XO^MY:>??GLNJ&
M)V#&>VT>0T&?O/%8B8G$YI-12S4*_"8X$Z)@6>T35V.!_R4L:BDK:.,X:OU,
M0-+<".W=?7;?)*S&,D>9&V18?FB_00&$FBQ:4 0328*<G]5Y)M8\_NGK>CQ.
M7<4/0!%!545T\!7FA7!\.K).UD2V]&WL@*P%59V;RIDU,807M.+B!_Y"@9L0
MQ[:Z]I+9"<3JFWWY44'Y]_/M6]'/V[X/-"B<BJ@ &6EKAVG<6[ ^!I^4.'<X
M+T?!3Y%[-&JE;[?17+F/8)8M:TL0&_TVCR9\#O4<R]MS)NE9@C@VC6U1Q930
ML, Q_H Q<S,;W=8=<^-0#R8_@HLP%UQ B48*-#MN8*Q:KR&J6F U$_1/?DCK
M.6L227X!^B6P!1Q$!GB/W$#_M_="U()/-,XE;'6X;;B5T0F.@6;&0LI4I=BI
MDQ-I,[=33#J"&0WMV&\$ 5-B/ZI40?N)$M+;]48=C8N:.H%D\.TQ!B8\LM@G
M041M,5**":HRW626H[S]6;H-;!@1:)=#Z?';"W'3\'&S?E<A7*K6O<OYL42.
M0/.SQY* L<"0D,BW[EULS*<V/E:=)_/!]N?<[IWP-W26NJ6N-6N16NNR?A8&
MZ]N* KMM0DF Y6_((AQ]/@TD$=-*:VZ;Q<35Q.8=%IDU6N,2AO&,D@E2H* =
M=P5N$L/>60>&VVB.^\7-9?S7=2[^5 #I_E5#Z32UB\@6M5:I31-YWXB]02%
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ML/Z>ZN8KPU8[_T<:;BP4'2!/HUQ!U;X.%T(Y6G(SAV34 8;E?BI'(6B$-JA
MK_*A$P4!EWCV!R4+-T;=26,$B8#0]Z1RCQ#MIP^7Y#)*GU-X@R?W4)3$B&_J
M9$E,%IT#&!O[?)LJL$Q!I"23=\94?#PJ ;=^</5,Q_+#;4[*I9_CF)>"Q5K3
M$8CXC?#XKWQH3B8J?=+#Q<;UW1VZ\Q*&N&;(@&1->>:TY!R'R3'K%JW H-=
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M\00U>4H"X %UIN4@\$!<I94O1*?^=L174"N^WBQ80YE/40CXT1;,NQS(L]S
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MC>U&(I4Q\SU@0;Z0H0SO97:7)BRNP7K);\V\[%AT2QQX'19$5$4A39FD$?I
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MD(3P(O&XS /N+5191\;;'!'24MYU?:^;K*'>*R5ST7[':$7^;#LV4Q_7^[#
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MW/GEP<#[P2V'PJ@ZB]4?FJLQ6%C0\5?4J^%>ZVA7"L2!-/SFXU4Q8\KI5@<
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M;\B;SRZ/'25;U=8I6+:U-]8I?)_ELTI8U1X 5D^# UZ#_0"@CZ[1-B"$,WY
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M%]XDJ/B*>GDWS&E^NQ2)W%&E:W' JZ>Y[^2#/[$A%Q_N6/^9SG$%'9O@R2X
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MX4!K/'Y N*7[I.*N46J$08Y"2Y*@3BBLPLG;^/9UK4?3:]\@<=B19X:!%)C
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M*2BI %L="3JJCK;QYJ8^M A"@"V-)KPL(-),F/JY\ 1:G,8!N8K[[YJL+>3
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MHQ>W/[6+CQ5=?O.\QO?Y-TIV<@4_VVWA'^?H@-NY& CUW$'CD<T1N7&+MX3
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MY] <?&($D.=*D"T<5QA)N6^Y ]['D:,_&A=8V@6NKEZKSGKT\I)3&[ Q(ZD
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MF1?M/E@2,Q"C+T/UYF=%E&% F'[!>(L28,A5Y^TQ9UR&!J@.HD2=,TZ.?)/
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M]"UQH1.D&BF([$6C<O<B'4)BA59O>)^'85=ETMU$#:=ES$^]K6Y^TR@R!N(
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M_4EX&TS^UQ2\?^CGI+"]+">-IZ<KK;[($=#Y'/C'Y4RK7/,?A=.#8-YWVBV
MFOLU'4A[.5%-SUJ/DP :&ZA\]07)?7Q*D5_JYB/I?##Y1:2]LO[,@-7HL&\:
MG2P]:HS\\C4[[6*Q>:S1>F>1VON,K(\^ >:$*\V?A]7><18M\JLU0-X\ZU7U
M%N&F=W]A_ZW]I0<7T[.T/5[ZNE?M\'4/ZP37#ZO0!E=8YXD,!VFX_\S[D(XW
M<UX3A4=\%P4&1:KN 1 X%UZ-1@ QZ<O'$/-BB%;=+)?Y+SEE27]XO:YWQEB-
M,;<W4680"].-V]E*7]6FM.=A$[C<3.#JVDMV#>;O/$QQGK9X8(_;R[Q$-X%/
M-9+'V[+B:K[:G=\\/M95^A^$+9OU8MB\11M\IAOT,&Q:Y:Y8*R5S!SP?)K+F
M:S>? 'N[K'7#Z2I%5I\3B?43*MT/[[LIH0*N]](NTV^RY!50"+/ 74F$2-G.
M ;$?%_.1:K;6 >3-[YZ"9?NR0TV]T2P<(OH-ILL+=WPXU3WN.9,C?0*6.PM_
M;Y[\D6K2=1R;:UC59@G\,!(K39( CPHH.H_]31.KX@?#%ED)6ROW.\,@D)9P
M@T"1GN/OD,'FVY=7[O_]]O[EK/H9MK]W(2\C\W_M/^S0A29LI.E&Z)!YW/6Q
M,>UEH6T@ :WQN?54N5;J68[K'*P?XJ#AYX""*AY%$LBR+L&SD-8Z(7'EHV@@
MXS7Z5E%Z/R9W04*12V7.(A8;">^AF*LT $1L/!PUE.MJ#F)U#98Z)>)X@M.;
M:(A@KNYA?.T.3"SFDC*U!$G(AR4EE$K%LB*(!\&CTIP4;?'H4KTM$[&T.>?*
MHL,W4C!+62PSLWE/8_JX#N)B5O^#77R*#*+)04>&5^PZ.':":J\3W;'E6A)O
MZN:\]@[=QAB6ER=$L$+XQH /]?\Y(,F*& Y'4!9&UF''-@G?@4=@]'U=FL?2
M&D M? X-:W,3^G^2F*>='.74YKRNIB 7]!%<$WYE!R:+RT2NDOG-#F%^4@2-
M[,+\F7'\K>/KTIUKG>$O=<VZCE:LS"[>FV]^='.O9Z/^LN$_*WXXN*H,Q(KC
M239P\K\#:,?P3M&1NHB@L^%X'P[DZ03 ))$'" 4\G-1V7_W=SK*197/CKC03
M<DR%:BR7%FJ <.6()1:2-D,\-3\(;1EE5UJ#F+F<L9%,958'@T9JL8!4#(\T
M/K882;SPN3QC;C.#5E9O"C/5C([P3BF4M7/[U!0B*G[=W>Z!X&Y;V8)$BJ[>
MW/9N37EZZ&W$SSJ9=R+ S:3 SH_#24E=D40G!4R3U_2LC0>B)I87;GAV-E&Y
MAUHZEN>EG3*F<<YV_F;FQ3=Q4[:.CZ/1KIERS[UO R VODU;@?[%[(QX[66$
M#6"N4EFV>_D+L'ME97/TJME_/Q?8'[WZAH2)7]Q>9IY+WDDZ(Y*LRS!G<N$I
MUY9XLG)MYK2;R7)<8Y/CYNZX>*K3FVOS)&\->1K LLYU5Y#9P6GWRBON50"A
M2CEG7>;!FIR?+MM0AD6P$F^]GK^JT@!V+7<W:H=A)BQ=TR@1*29BGQ=FS2D9
M-;&*8F:E[PS+(4^E!/2,B';=4%ED],7Y<8D'"P)P#B+AS+\TI_)!*+[I@"YZ
M4"MON)3%!CGB:V_ILW)R!L&TKER1#J:QK/CRLJV3XVUYH3QQQ&0<)H2+OVB"
MA7?/QC/U%EH]&)HZ1*%(VS'(TRUQ3$Y;//Q.9^7FQST@SJ#U$HP:49=/6F39
M[DK'V/C@]E\&?%:)"0+P/=F\GJ'YHWMS_S?W$/D$2U@N&Q,5R,->0B836&)C
M"K5" P$N.HXC/.*FD-9>*V!T2U#X#UKC])]Z4\;)1_=XGH^*A9./SF')!FPQ
M\ZDZ7,W0=;CGA;,H-EM U[=G+UHWVD6GW!T9\" P!F)G5:COFJ'>7>5M)3VH
M7=EK@I[[['>^NZ1X)D>7E96<]VO*,R O,%Z78'0[,IH')?Y<S_ ' ^QON,5]
M<;I*9)/99G)OY.;>_Q9E-!%J#'-##$8\2SPFB=K1&9_@9U\/6WN$/FT&(1+/
M%DY;I%M=;#N[XVP XY!U8?V3/*%P9^'=D@:)1R>M)!1FJV6HA]+T6'4/R^LH
M_J[(6SWP78Q$&+JH2*)(RF'C5 B!T=;5EJ2MJP.XT*!XC4"@9N, /0!7!+QV
MZL^_A*3V1SF<SNKJ;,#E!J>@*HQKO(P: U7N27 (U$2TE@$/MAS,[) 2YW)'
M&NE;:>NT04UO*_^\ZN1:8&07@2H30#R6VH&AQFD@P9[RN !SP6*_4O*Y<:Q(
M6/97O^7T%,T6 G,:96KEGWZNF'20E4^"-WWGP/RED#H42^O6VZ=%^U-70QK9
MX/A7%F1E[U11K%QLC=:G_K=H:&IV.B_"NOO"C.&$_/THX9U Z=EYH]BGW[)O
M6_($ H0U<OI2)@<^B<7PU,?,>>'[HX>)UX0I H.$^BO@MHX.A$ZY<G$,EAD/
M5_DO2P ;OB@Z =2MD3)^*-1V?#:(^^3HFF.SD:>)TKF9F2_%?_J=3KXR+)#F
M3(CV#3CG=54&4[3*(WG[@;FOI-!3C\Z?W7X.WN+"+325D)S7D1D]$+(K):%*
MUCBH'"<83^B^R7*AJ@,>:N42EL2LT6?>?SXTR&E5YRPG$R48IQLWB3"N(:1#
MD]MHQC3G,A<'!N3;C:RW,J,4-NO7("2/@RK6[G&SLZX5)YT!W:]5MFQ0];[*
M4N&R#X"4;<GQW>:>%WP:JA\8"&]_2RB@JS"8X,0@@)/ZFFD1UGC)DY#(Q?"O
M;5O:4S'GX;E[7*^M@-VO2/ _VU5'@'D&68/S:XTO"1LR74JR&G>:V^  _S*Y
M+HC3D4C2N9#R?=&9^T7J6B]$8MS]U-,TIS)9AA[GR"^X$NP8Z^_-R'XI1^;I
M8JZKM,,Z*6M:!UE$T47X7T"8)AC^^P1H#<PJ;XPG#DI+<U V[?"\5$\J'U"V
M96^BL0DZNTW$<;0W%ZE:_=0IT=VW_36<F3',A8WF83[. =FN>1I$OB70'_@;
M7J&=Y<.Z*< +54=8F45;.1@@'+?1*2;&I?2RL(:Q.1/J7W59C5;MO 2I<33.
M_1R[UWUFXIR$YDO#GQP]GYNE0,H:]_Y^C6Y8+EP-X[[ *:JK-5\NH1'45!RG
MQR9&)[,>D'ZO<CU/0<[ER*1+;]W^+*KQX-R$' T\O3YN_(N @3FMCX.4+[P+
MC'_X;PU]6E\4_LM/]O5Q8H5*1-4@M_] NNX7U08+$(^/802-N/#S@+?+G%C)
M1,L0I9?GC?3D/?G#OLCY2O )24-/7_GH0"*O/_>59>^^ QKFTB<S0_AIO[3S
MGQKRKY)N[MS-K5$RCXDI>%Y9;23 1/WE:9%QYF7/BW@5D3( H3AG_Z1 UJ16
M'8D@: M5/@(NQO"\8@3LUK[ ]KT0X4Q$51]<$D]LV+(^[E'8(T7U=B=AXX-A
M9<%.?2G$VX? 5Z:;[)L\_JIMI!\:P";2?_/&QH07@RGL[4]H W ;R<+Y(>=C
MY1DT\'F5[1T/"?I05T1?EN41$BCW,PAU_Q,64^_SL;YCS,#C-([\+Z; V0L[
M]BUV+H!=@;VPM'=G:Q>;U?_5:*LHQ\-H'& 5]9(X'#,S7OWR#W*<1\I*&^>H
M6!?9!7AXOJGQF26P)<H/&LN+*8Z".49Y:A6VY:"A)![@ZQHFM5/GK>+?G;=&
MMRL(./9CXN:4+/-WHJKIW@_T*%,.P*;6?QSWE</*@K=8=+95'!P5B!&BY=IN
M_@IS8[FF=%3]#:Y'^.-,\XA4(EO3R%T<E%0Q&/%9H3(1+L@>3=?[NO--X%/J
M@$[2UUW.Q55O,W?99:(VTW& C3D7_VLE_-XJ!Q7W@J=>D$_A31XL,>;90>HS
MJP:B=:0S9&\5V40#]&E<W5[!8B,3Z\:W46?W%?ZZ0GA,F'E-5*V1F[:!.$/Y
MS1R@M?PVK"]=5 8%%,G_8B.]SI*'Q9M*E[X5+4GE84A:99B89!C^\9'P!+-[
MSJ6<R]NG;,8\;JOZM["[T]8/?VHQ,+7;> $6I\A!7!CW^ROV[14'19;$\516
M3 Z%"4B2_Q<'RG5.@!L%NK*5U$V6F-YZA(I_5*Z-^-MC=^C7]5$6HJ\ T0V$
M_/+#.CI#X"83<,M-<W/YK_1QI_I-+0:41N-+X#C*F51@;^ M$<U=V*X]/8Z_
M@MGD.U5>"75FY@#EA_7RFRFS28;D>_238_0\+VQ0BO0DZA,&&.8#%T07(^'_
MMF['CNTMCF-- L#+"XJP1 AQ%:G\GX527Z.4(^%].5D>O3=2;2D?DR0WUU."
M,@HR94ZR-J^T<VZ_\26)L%:JI0AQO65;>0Z;^P49XQRVHOQH?3*U)42>:U+^
M6AE+U*W?C$:UM^>.X P>U3=N!/TZ8J4V 74QR41(9Q5N3E"^:9SO4#-_PXI)
MI_MM@-_C73/Q<</'EJ62[Z3@N1)+^LVF/6,M8U#)80]/8HD9A?#%F, \3D#
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M*")* TG)GB5?G@Y/^D#ZK$Y>CZ=T\-V7\"('QM\34WK JOB0U_FN!AK%FP:
ML.Y5GF2V0,H>CW5OI4J5;K"Y ?]"MM\.C1^'I"RH,2OBT2#L1=%]X%L@ M1
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MOL%B]6$H(U;4.W3>?$0J-Y9CZUH"8)X=B\X>@=U79LV/;+NGV)8T'A,NITV
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M\864%U#0^0K\!K5;X#^CV4EF]^VZD,.<)=_IT?Z04Y.!TNJ.TG[)XZ<"L(9
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MP)KR1Q\_#,!'(!UZ[L< E$3+K,LTW)$D!>K__!'/.#<DLD(N)SRT4/?J:Q.
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M'*@ RC$KVKA 7ZL+:$B1@ZC 5-+0DX#1#1//@F 'M_!-CGE4]V"'0LD7!P6
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MQ%.HMZ-%$&[/>>N]-]]]^_UW8[XB[*Z0[Y%]893L$"P=6$P/.U*S2%9]I]$
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MWJ<OV(W+BHI3DTVTNB)K2$!G">G>S"L9G+BW7X'^.ITJ0U)];"$% DMX#)
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M\L@$D*:"_L=M@N9OJB0*CF4+8F2$;FAN#.0"-$E),B2'\@9(GJ5CS!L='24
M1.$&?L("6.:(QBAD:"9]-DE5'J:,\L0]U&5DK,8ML:@MBN!R<F:.%JE+)L("
MH&2-&,-S&JG.Z6=C0J2*:F?S>6@Y9".67JF69BF7;JF7=BF8?JF8ABF9CJF9
MEBF:GJF:IBF;KJF;MBF<OJF<QBF=SJF==JD]O*,]W"F?UJF?]BF@_O^IH 8J
MH0ZJH18JHL+I<BX .,A#D_"F;SII9-SF?P*H,[8A?+9@.3A".W:JIWXJJ(:J
MJ(XJJ9:JJ9XJJJ:JJJXJJ[:JJ[XJK,:JK)ZJ-FX#:\XJKN:JKNXJK_:JK_XJ
ML*ZJ-G9)52ZDL<*#"\"#LB;KLBHKLCHKLSYKLTZKM%9KM%XKM&8KM6+KMFJK
MM7HKMWYKMXZKN)9KN')K=1*$$IPKN+8KN;+KN[JKN<HKO,YKO-ZKO>8KLTK
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M(Y;$0SU;_?:?/_KSC XX0'O*D?]TM!]:R?C7<_K7O_WK#6S\>$^[1OC__R)
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MOEID>&GL6LBOO0X;[+'%+AOLKKF.%ZUY9_[9;:[?EC?NMN&N6VZ[Z;Y;[[S
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M47]*U* FU:5.-2I4?1K3IE(5J5(%ZE676M6G:E6I466J5ZT*UJT*M(@BM-I
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MREX2HP>C^*9U$9+-^(</]975T$2C>$(F,  "X0[%M4N5R926*3<!< X,R(\
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ML=M"L08@WZT2(UDY<GVVMZU(X=JXP1#YE0YJD/F8/ 8Y /)8B!(CLD/$E03
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M5$03XH781#A6A4, >V.5BA5.CEUZ^26888KI4'X[,.#2#3"-N2:;L_G$7(]
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M%"(@+;C$ X* $I0  0,&8<!%&A*!#,3%!-9QB])Y@1((<*-:$." $?2A S9
MXB 8T,!$KL,(*W 2)E/9I73P9D:V X"-5"G+@PAA;(>YDQ4%TJ,?.8-_%T%
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M:D3?=D )=O8%N( !:&4PVB7?P @%Y/$,SFMB703BQ@C$H(YAT WL_KB^"9
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M3H$+(- <K-0<U($&V%\\D@0R"D0 #%X6,B'+;=_U(<H1D$4U3J% 2(.[_]3
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MM", U ++X=1+I$.XLH! # "Y H"HH"< 5(NH#,!24(.HN YZ[D6UL*M E*-
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M/9U#<?^M?'66TZF3UV83!"80%F=Q!W(@:>J!LU40&*LFX( B@A*@Y>5M11B
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M@V<4;3Y$OJVG) #P1! BP(<,*ID4KAANQI!ROZHPVZ#QTL#SHLVFJ1\++>Z
MG):LS82?Y28IG()D3Z0+R6$F=2ND#)B)%&B@JF*]6M!)&==X8C*::.;6BI"\
M9I@#9XK'Z<3T8P15!G;:D'D "<[V\CY/9KE@=N#*CU-6! %<//!$/*>J3QP0
M5GQ;$J*-K^&.Z>1WPHD&-WKN%^\Z.06VOS/[+:J9F.OY4+! URJ94KB=[X6
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MT>$![EU38A?J;XH=O,DP:3&QL<G%QTYFR8OO.3@)VK$V2P8A-4=?^:'GNNJ
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M!L>RI)WLP%Z+=%Q,&8#AT_4-YKI3;^8*H.*/3AK1"%/HC<TOGD]6*I"".!_
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MV-=>W,7W>;@LKCZ<94\^X20(?4K@51FR9TNT9WO.C/?K5TR66"=-7PQ/7\J
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MGE=E*Q)YK?J 1W8/<%]E54B7#<-APL_]8&6K?E64;/@V9ET)!!R0EO6'$&5
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M-,57!EJVBQ.$P_2>P.K;& _.BN21ETE1.!(WB_;[I+D?I/#X1E.SYOQ'/#4
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MB>4^GJBYI<[RCS!N3\%LTC%B5D3, < $9$#4Y9'HP]%;-AJYP.'GUPD3AWB
MWB0&<NA!QUUY$_1U%4/?>KT9?CSAGG136F[JZ+_3/-\_GW\9](]D99_^D5?-
MIR*CPON!2_]=FPS\54=?6Z,!IAWLS]J+"YJYUPB*F7($ 5;Q @'*:KKF:KJK
MT3ZI+*36"!V<LJ)]"PE6Z>KV;P$@ 2ZY>$SZ,' DA94,=3$$<'"A-)& &"2
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M6I';R)+T8:'Z,XD<OSBM?Q_U0598-XL D-E>6H\RFAS$J9I2(7XX6J<WNR$
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M"[QER?G%B'MA[EE/X0?R,SB.LS12$KC)8.!!.S]K-N")")K(F8+%PYN%R)*
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M3:>HQ8ON<L,53LU1AU8D;=3!95"BUQ%Q501;_.RB91$=C9B-?U&=6<3YHUW
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ME-=0LS6SA?(1J>=0,Y-ANZ2^3\0OWWXY=.^<%B_[\XFS;$=;,/H'SNT$Z<$
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MHQ1>5XSPA>U0]ZK"[OTOW=$9KR VKPLA8DV#5?8X>RAK?7)-O]<GIN*:-2P
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M41:+WD<A/+W^4T4:?D@O*>=0WM_&]K_5HZ/1U1,9N'&#)@(0XO/=S[R"%\$
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MH*7D"  U!SX(D2]2NH5 /R%#H>S8&;LWL#J1RRX#GC7Q.R,*2<GZY5,UWG,
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M41@[(ZA^!] R I[?79 2TB%"_O0XO(Q43K]4_%4X_5HZ<"A$B0S?U_0R0!"
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MUGL\<?>0@TXSB6WPX;0#PUO0]8L1&M^*7)!3&M0K5Z%[^M?FF#+_^KW16*/
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MJ<BX+-PG%89I:63GZ!*("HE1S#,6GV^6-')!BY&94HG:4&LM1<R@&O9I<?'
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M<CO)&-% $NWM+[(K5JXV+4],;KI;Y(^:7OMQK[#(L QLE>*_0)%6&A4TI1L
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M?_[*L4-R?)6N#-,+C7>4Z&^QIJ%:S9R;J!I\L'"/!ESWQ1,ONA'/I34)Y(E
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M&7E$_PE:CCB0K[@>NX^^+%T.H2I 7J&:4+!TCKCH8M4SB12%-W^>8E)LS9M
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M)HG'SM;W7>$-G!?+OV4(H=]Z,_ *8.V^R&\L:1[N)OR*P+"(?UF8&IV'X7$
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M@ZOLJ1*]Z["0O6%+AVG+[6;!7R ]R+95+XC1Q$!8_X^6Y@LD^4@!T:20TK9
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MFY<C^K+Q5<^QWQ5TE*1S6 [U9>7#[^='>M\3'FO7^:0E,##C+H5.]( >OI
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M_9WS_ _W==^OZYS[7-<[B4?5QF$_0Y^%=\?,CD0^X&[[+:%<*/'=)>D_XH-
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M#B/3O"]Y/L '0YA4#4UZ5G\U!JP /"A!)?&2A'\_,G^4K5)S(M32P3M8 ^M
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MQ,9BKU$7S<WFC! JB,L"M(W(YR)!N<CUXB0"0RS?]3\$_; ^JH_^;F&?'I7
M<<Z''<3O]S>..#SVT+ZH$O^5ZDO_G#N653N6+7BMX$JMF0.6S?^@+611XK<V
M:X)'P1<K 5JRHO/?L<C60OR00.KB0ZB-5)Q5QW_Q@G'.%*9L\X2>0LN%*J%$
M;1XZ$%<'85R33&-"9K&&E^H,D"PL;HV5@^:$O B<Q4&T)?M"G:3)&YU<RC:R
MCS)EWJ&T6[0'NP89LN<!OK!!9@H186$IS&C!!%A6$F7"+0<;9;CS>[@7N'6V
M_(&H7SD-9=6,.KV"TJ.+J.[P 2[=+)T>WC)Q729/+$$\#S]<WNH<F?L*#,12
M^K1PI5U&M5"<A=: <4E<F7FW&+J9Q\%?WL%>[E62[(MX%E9O$V@IK0/U NJ/
M38LBP[3)UK8(T,&H";STV2LPR/J=7*P_:$7V1;OSC&;GTXV=I[1;O/"OT/>B
M]%9T^EQA$*0E7ARESWO2S; "Z5^M_^BACS/)W_H&7JK/?SJ<KT5YZ5I+:$+*
MA^ZW03,@09XS[Q)S,DCFT8?M[T\-P@(GWB>B$^5F8YPGTLG)V0':-58@+OP@
M,[<-TK__H!Y@:4W-%.E,7[C4.O6@!25=FF[1C%.Z@.,# S@;K)AYK>YI1S:3
MUTHFPU!6W,D%4*/BL=<U,HQB]<+B:UT=\4SK8<VK%MSG/?*JGK0+2:!?YP\/
M"*#6#]QB!5RA;B*C"3(<1O<V<$S0L/'Z^8N>Z;56%R.\P !!\]TP+_'>L4W>
M01Y1#RK3!,W]$LOBT)&RY"BFY"Y7._4$60.:^_/$BIJ,P=T7+TUZY9Z&$BAO
M-E&S"1Y%/,7SQ1*%@%1)^WF9XIQ(A*GA*2]]$\(./5% @NWY$(3\337F$$P=
MCUB$D3T#@,:<&(=WWYSG,WV2DW:*OB )Q( 7%6B"R C(\P/MGS2)-5*5BKT+
MQAL9\7\5$Y,U=_YJ4F\M44\U(6*3"4_207/FA:I$^D,\^?_:*V?C>B;R@O "
MB,[D)2F3*K9F['#7"GUK^G!) 2<CAJ''2CMGIKO!IV82;354R@#?3^7AAM8<
MX)%S*36\%R!1LAV\-"T=:2GJBRH?DZZ4F>LH9WBHVB=G)$F+P_\D0:,'E!GL
MVUB?2I<E6BJ?O@E;S7Z/P^M9\,GXY(J3^YP'D1J'%:1">Y?;.7S]QM*Q8$O1
M?+T9D:8Q$0/>^C8'ZPI#DQGE7!G'MM?6P. M (I"UB!!@X>IK\I;,#J\(V,F
MHW\)RB=.M\7="DB '4;^[9J:8C&<M#*;7XKT21+3T.2;?:?CWM.C>06D>;-<
MC[1XY\2-)* @N)+D$I^K]Y2@G:<WGZD V7KV6GK5^)ZF]09E4\QVR\:6V6EB
MJV<M)6DIEQOXS<[^,&N0/7W0=N-U*.N;C!-!EW"\0#]]8=:%NY;W&_[IS"ZL
MM!^2@6<I*6,,"*V9 ZFI4*XP\1<(;R!JHJ7X#%>=Z>7>,F/M><)&*F;N"0X.
MI@JK5%B1RK<98G%X#DRV>)XJ>G#L>VD:'\7*;C$I4TGY;&F81V2NG\]S 4\;
M/"Z?$PZQ=4=R81L$ME#/Z;CU"K,'&C+X<'@I8I( MQQ!H/6$F\7!?G5)Q*32
MDN4W HO, PUW<Z$X4J*Y\R7M11FHFQ/&C%&?<LBG%:>W&SA)8%S>I>TWRY&(
M5 ==,6^+X;*PU3P+>F"2R%BSVMWDQG4R _HQ([22%#T^_N#1HO9'0K\;F*$?
M</=3X'=S/^^E_A?9T5KESNQWL=1RTQEBT]]"XPT5Y:#' 8B3O!?C8+E]9WI&
MBRW"!)Y!*Q177+ SR^"5EREB!WRCKXS4^E/&R>DDBZ^9JB26_N@I%<DIC2P#
MJ:H1.;@)4K;L?!1E4?W!-&D?R5LZ9"/N\L32RW_R0BCUKQ9S5CS%6_F7M>:X
MVF1<M7I<E.5D?R3+K >"8J- ,J45W&[$91MW/7^ =L6G9V0KKY06F5[KN9\T
M9L]G4"=B%0L>_5;75I,WF8A/OL(2FC+.M9]\:3?9=O^#W3&4.Q;$A<NMR\^U
MHDM&'24[,R=?-B,./9G&8--$7HUI]8-XI)+TYM(,S9:B3Z#OG.JC40_R+0Q9
MARY )&[@/I )\T_20ZC/BNE7-A "9C>X\(2/T^.>SM0M'_4/VNX'275:9(@&
M]6-$8V_S$=7498^Q<6TG<:EM?(W YDT$TKIXWAIW$I!T!*EC_.\EC.5'- OC
M@VO2G2FJ>WMDCT?8)C]OZ1+W)HX*VE[_SG_.(L,N74IR5E1,-Q0';" )\ [0
MY'\"(_:RC5;+/\9JEGN[P1R,ZZ\N*T1 9#3SG;]5! TM,W?59%<S/AR1X>NJ
M63H79FFJY5I)8OM4[[\.\9Y!8@_3T)% PM=[#,] 5AU$,6J29QZ8"]>C>CCZ
M.GG3<UV/H<RKJDE..G9,G9K,>OYA/@C$Q2TZ[7,Q:I67BF)R=$"#'+"T;LQ0
M,6X"3'/'A5C'MP^3P8*2]/U3^?&_'J6M?T_^PP'_]O5)%5K) P2$\"  ,SXN
M%%&\%!0 NR2#P04?)]V9&V_< NF01RK#ZWY2D!'ZA\O'LJS7.Z)@_L2>H[C!
M*@2, K/98[Z<#L(\+% M0G++7$&%(/ @2.&-;4(.'R:#U\QE-/6H?,7;*RZS
MZ.5 NEE6!\+G!M.[P?/)5U*EQ7=(3ZG^>,^'AO9?,MDV/?0&'\ERIW?>YZQM
MJAN;BL:G<=@ORC27S=43]4D5>F&CKH. 5I\*F77H[16[V3F(:!A!>],8D>=4
M^[1"\':#MG]:8,<%46Z?E@WP:V4%SM7P(7E@?2I$DSLU!,W2"T=R1_64.XQ^
MIRY<:3'U&'ORFUHJA4V#E4((1+QX6-)0:[C:B!Q#4JL "8)<:67HQD,1A!L6
M[T?&\J$=> X MEQ]/%YYU50&SBK:68^E?W "_TW(B%J!;..OSZKV@1K'&4K!
MGI[/&K=60S9YWK0]TR*!Y%Y_T\NM L\<_5M?BWMV9'E[B;O-V4 C?8,SW2!@
MVU")Z%=%-)G'\X8M,;/YQV!*KMR!Z\<P_T?(Z,0UN?8>IW$R@.F!$1<CKL&:
M?Q]<\MQ.UL2S18B$D#Q\?M-^0_+K6TPZ4)$OB01"5U,]@P6!K6F%C[T)Z;*
MC%UEX"<R3A=;:C'8*P?16N75_U>RZ,DHOM-UXC+"0-L!!M-UAVC6#C2D<G5
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MW8F7D].J:Y$&M#F^1F6%57[8.Z!(6Q8%W6A[XW L$C+7P,);G:G4)HEY^G$
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M&2:6@#;B=3M5:<6 :GT2D\:5 ^(X'>.A1(U7;_Y#FS@S9KUV=6,H9_;C42&
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MQ,*J6H!M<%&)Z;;"&]<NFNC<N,J@]3I\-+ BBR5Z19BW4^;7ZXBXAEMU_[
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MD2'LIWHC#; !TN@9? $@OCO&LAWHA='OU.6;?.?:"0MQ85#@@4D[.YA=O(K
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M#0X=U&8\7ZNK3HY?<Z^IU0SSJ"L-(_&H*7*T?-Q0$4;BWMR<J=M0FUWB\0J
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M'_2"XLB@&,92XN3+8)2D;)6G (OLEA0/CA2!AI !$/$MH&G\F19;A&D?ZI$
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MDMR#;1K40'914%85=FMJ8V"\>'BH5;5JL\F&ZSPENU#Z!4[G6$)64A__Q=H
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MMG20AAT(B0FE!@B- R2@C@!  AR@4#IP@CCX!FI  A V@0=F%1P  "AL/6\
M80O% 7%C 1@F$\0H!<( "1&5BO_LN VOH 8CGJH]*I6_2V(F9C:>JBJ>(N(U
M@F(T<N)#BB,EEF(I)JJD8J//B*.().*NR*-2:8? (&(!,&,R3N,M=F(T@AU$
MTCL$2 0^\ *T)$7R*T6<.Z %.M,'@5QW:L4YB+\?V .8U8,BL47\*^2^1!'
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MHP9JPPR0SBR  0:\G<-=+0X!)#4 I$."1!J2 0!8$,!A@@4  L>IF9#F#0D
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M155IRPK:SB9-:3J@*8\"BS?VA@/NH*17!$ ) /6'DG/$ *HOW2I7'PF;;M2
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MA?OZM.<LK,-Z38W%.>@ZI'.[ED=ZMSM!#)S!$4B#[E)[N-8;6,FX6-,X602
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M4*1>%+G!= PPCSALB%_["MM!Z+:A,W1F@SG4X8QVTYL=[$AQ8Z%@1H 4DTJ
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MGA-J"+#-,-*:\9QFJG(T28U5\B*75-HIY=E/?_Z3:2P01H)F:4R8*$D? !@
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MU E@I!B *2RNZ;JCN@EM2H4YW&$/KQ*0Y60!60TPV1*#%KWNM&%&8Q '0CA
M'V*-Z72>^V$; RBO^MWOC7G<8Q^[;IR S.58=V3:UIZC'378TEO;RR$Z?",X
MW8GICZG<GTB*;\/7K?*6N=QE.4VGI26M[B8-@('?LD )#O &'4I!"#JP80=+
MJ:Y4)TP19WH9SWTQBC<<$&>^YAG0@18T?ZRBG)(ZI55S=FA#Y\'0<T.+ARE!
M,NB@*3V4BE7# >+[ZC,KW6E/?_HN6A/G3L7Z:%.;FF(MK3.H6=T3O55#QQIK
M]:QI7>N8^$W5% 'DBV):4J@>&J6ZMLIQ)FUK8S?%8K_Y\[&9W>Q6[SJ\-U U
MC.R5':MH.*%");:SN6T1HT#  1BM6W:WR5WN+9OL53"Z97C9/1WA;+O&YF[V
MJX-K  W_3=[YUK>-[_PBZH"7MRCT-Q\KHK5]/YLW\L#R/0_><(=3>-/]?CBY
M]>: 6.-[XAG7>(75O?%:LZ !#?!-&_GK<9.?'.4IAR," G"463"@5>-6^<QI
M7G.; QD<%ENXK&_><Y__'.BF,D UCK(#5H54RT%7^M*9WG3 [*;HE>5KTIU>
M=:M?'>LW<0H=&M#G +"90)S<H7K6R5YVLR_= #LX"JQ)2LF2GQWN<9?[S*'N
MP^K&NYQSU_O>^;YQ S" Z]6(\SP&<.>&]AWQB5>\L\.TCK6+NY*'7_SD*5_Y
M0>\ "4?)=-MA\MNQ6Q[TH1<]=)UB@J.LBO,G+.GH6=]ZU]=6.R%?9M_PZ12^
MO1[WN=>]/']:#<<+'J2NHDFT4K][XQ\?^7C%/&\$OU=__R-'B+?_?/*I7WWK
M6SCMIB]Z\*];3MA>'_SA%[^X_.A[YN_ -R;5.O%W\/;QOQ_^\;]/.1N0>6]T
MP^B%?4JQ\>V4R?K9_>1/  >0 .UBJ'9 ^XHNSOKFWFPB.?X/ #FM ">0 BM0
M-X1([1S/&Y B_Y;"X'#B!OPO &H _=HO[V+% E-0!2D0/ R@'=0N\QH  I"B
M!C &.%#0)L(IS**%!&>! VO@!D]-"(>0"(O0"(\0"9-0"9>0"9O0"9\0"J-0
M"J>0"JO0"J\0"[-0"[>0"[O0"[\0#,-0#,>0#,O0#,\0#=-0#6UO!V:A 4S/
M&]9.\#"&I,9I)TS&^_@&_>0!*?_B, YE#Q #41 'D1 +T1 /$1$341$7D1$;
MT1$?$1(C41(GD1(KT1(O$1,S41,WD1,[T1,_$11#411'D11+T11/$1534157
MD15;<1%C4/8V$"EFX6(<J.VF[R+>+0])< <<H!L< "FJ80,WD/F(<1B)[AB+
M$1F%<1F-D1F5$1J341J?<1J=T1J;$1NCD1JW\1JUL1NK,1O!T1O#D1O)\1O+
M<1S341S7$1W9\1S?T1SC41W;D1[A<1[MT1WE,1_O41_KL1_QT1_Y42#WD2 #
MLB !$B'_42$'TB ;,B$9\B$/<B$E$B(GTB$M,B(OLB(WDB([4B,],B-#$B-'
MDB,_TB0/17(C^S 8!4_PT,^!@G"E_X*B.@HM#P.  7BQ! 6O&VA1)WER!W9R
M!WHR*'_2)X%2*(^2*(?2*),2*9?2*8L2*I4R*IMR*IG2*I]2*K.2*K7R*JL2
M*[<2++N2*[]2+,.2+,_2*]-R+-72+-FR+-\2+==2+MMR+N'2+>.2+O/2+NL2
M+_=2+_L2,.]2,/ER,/^R,/T2,0.3,!?3,!DS,0]3,1M3,A_3,2.3,B?3,C,3
M,C>S,CD3,SWS,D-3,X=2\&AQ)QT &'NQSTK0%A\J[^C"W4+0*2Z+;VJ@!I0B
MSF[3Z!B  7(38W(SSH S (23.$<P.(US.)&S.$DP.9ES.8_3.953.J.3.J'3
M.IOS.I\3._^W4SN[<SJS\SNY,SR]LSK%LSS)$SS/<SS74SW;,SW?TSSA$SWC
MDS[GTS[94S[QLS[U\S[=<S_]LS_S$T#YDT 'U$ %%$'_,T$#5$$;E$$?M$ 7
M-$(==$(A]$ I]$(M5$(SM$([E$,_=$-#%$-%5$/W<S=W !Q^<P1O4BELT;!,
MRF0D#BC$*:<:*K!22[$NZ\0D*[3F0;CXQD=[]$<+:TB#%$B+%$F%5$F/=$F)
MM$F-U$F95$JCE$JAU$J3=$JO]$FQM$JY5$NSU$O#=$O'%$S)M$O-]$O/M$S7
M5$W;-$W?5$S9%$[1-$[=M$[G5$[O5$_IE$_SM$_M]$_Q%%#]E%#_!]50!151
M][10$S50%?50'951%Q52)[51*U52+?51,352,_52.Y53/W530W5/)>NL J =
M2*NR$(L%],\I;$K5<-%H_&BAHNR/3NW7UA!7<U57=Y57>]57?Q58@U58AY58
MB]58CQ59DU59H6I6&VI6'6VE9/0NM,/.J,,JJD,Y9$HXLNW?A"K5=LU;PW7*
MQ!5<Q]5<RQ5=A^U<U35=OY5=W]5=XY5<X75>Y75=[;5=ZU5?[W5?\Y5?_]5?
M Y9> 79@!19?"Q9A#U9A^S5A&79A"?9A#=9A)Q9B*59B*Q9C+U9C&S9C.79C
M(]9C0Q9D1]9B1;9D2;9C4?9C3Y9E4[9E-5?696,69F?69&6V9FE696]69W,6
M96EL6U.-1JLCV_PHU>(5-\+))NAK!9>6:5TOB$2-)P(" #M02P,$%     @
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MF7>,VSWT+;-<XK,H9*Y%?<"Z,2\XF<_K;OA7:V%"- &KT/*]>PU?2N+'HX$
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MN*NM1MGW]5Q)$@VVBB11[SE)?EN/%I-268DYC,['K[]7,1P>1YM*L0"I@\&
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MT!ZHC*L9PUO-#44.DU;BQ*T9FPYE'ZUV Q#E6OFTYHD)_KM#[?RE3ZO1/%&
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M+^K"_1VN-PB(_M4L-,V2U9N$L)/=<$>J>=S81PMNUCLDBO1+.R8_PK<ZOE8
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MM$K>FS/@"0;1\WIQ#7NE&9I=.EK2$/UJYHNEX $%)QBE2\*\I!')GXR'B6@
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MH+6S%K',O)+0P)L^6=)?B_<*)I?9:26@6_CF)&.8ZO=4C<45;5,.*LD(<RG
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M'VS/=*(!G:$W:<:7!/,F9%%CUWQ"&]2/_6_)=A.&MCC'I]KZU*)3S\KR?VN
MM1Y6$:VT(T#J77UCI9ZC*Q+CDX]'/YV-;43KNIZ-G^[J?3O2,XX?U3AB;OJ.
MOB$=![M.C(7J_6K2_6ZEO[!S)ZO 2>HBU@?Y.T'Z-VFQ;S*1@3]D,_=#,91$
M;KP>-/:+,^\P6F_04^?CGZ2M,ZWEU4F&-P89))/+,E7Q/E/WO.IH)*?N/9]D
M*6<^<$!,#9*03NK7:&/"[(!<SM-< 89<U@">Y&D^9R!_\S0_;EH@>1J^-RV,
MP\QP</Q "A"UHJFE#?O\]=B:1VX$I]XR%_SF3"0:%//E'/-6GHFJF&Z<G)&3
M2V2<GF$DF"6"SBK2SB*Y9AE_3"N;&.^XC5":U,UNCQRN3#UUFER6G6(-,!*Q
M')JZ35+?4YSR^0Q8[!PV:&1,GS:20X<A(+S.$<8J$+,8$Y/D.;,W)B:2<RJX
M.2NN!<SO>HBH%I0Q!+JQG>929DQ5JZMU:="SJK>TI,/]()&^=93_R4R,743T
M=AVC;!\1(DYA;D96#OU,:);H9MZ7:\%/TLR/UMC:9$%%LGI!$),2#4UH U"V
M0E!YIO)&^I+68Y*>1D[DTX[/M>INT &#%,1&(N3B*<;.<WQ$LWYK<?XQBYB
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MV0I?;0N#=T3H=D3[XR)%(?YHL*,^4&P33<Q 0$=LK"27*)OL*$-A]N3*2+;
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MXML0Z98@-JE_;#*=+)KGTF4J0>Y>'\H)^M '"J%83R7V 0#>ZO:31;.!Q "
M62]-$H)I0E:%EYMR]VW43;JW\ 6KT^9-1R4![S5DGBPS 6[ZK1)E*T[_W?UB
M'$F>$B\P@[^34^CC-!A+671A0!. L"NJ3]])KG?#PF2[/)_:/*)Z?9+!!7[D
M;FBK7OR,0^::\:7Y!]3]+VM4G"C'Z+K=?.:@QP,E8S$UJ?LZ&N*(OVW1CY2A
M?0P!E29L8';0SB8UC,#$7%0D-A01#&5X"<(WZQ4P>V==).(7W:P>+DM(^3KM
MPS7^9&]$&*,6$ _P(Q%"QJ)$K_-MQ]6-9\I/S&5NOG]XM-U$;W@<5V>WRQ)[
M=OB,8_N\3?[PD4;F6"QG:+/$A]WE8WU'5H&VK*PD%1;9I#NG_:_LI]Y0:NF;
M=W)K/H<[?T^[SW[V,>F^*3/;)=+YR"Y!U_/3L[?O+E'(?^[LGO4(]V%LNVGX
M2W%?&MVN!MY&R#WIRU_1#$&H]\6,0!>$A#FK&( %8%X8)AI#$A\MAS7-.6-6
M"44 NN %@]0F-S8G86S.KG9'DB!2=&^<RGWHL'*!3@Q19#9D./K@2VY)VKAG
MU\2W.E3HDNT)C8[NO0$?,D-\\>Q*=]\[OCP@"? :V'4M9D=X<O^&BXBT2RFD
M%>TUI-8AVM<\9J$-U9*>3%/E0ZD0:Y!/+S LF66:IX2GD>TS@U:<*9HQ!=H8
M($XRFED<](2A%Y27RS"*< (IB>A;52U!/O&F@QBS6YNB)<H2B<JR<P4=$L*8
M%<N+.#]HDUL,$U: 2=M=&0#&4> &.A)=!\T@IE/K-5)O=CC=D/66G:=KTI\^
MRY$E]9]$DQH&%I#S;.PFA1W(3A7+^#@BMR\>);Z;#R3H(@-%P1B*#8,2E,R[
M C>-E Z(]?J80N0R_\Z"!?JS5/)C$@Y6D@:WEU4*67WG7UN3:L.8M;&Y]Q(4
M>:,3+X%*A+H 46V$:!^25P(@*L_FD\PP*TJCB24MLH[Y_$N9+Y)#T449* N0
MED478MD L_I(TS<*BOF"M)P<8G=I/A%O]<F=M* CE:)+!Z'6DMTH@9;A/1/E
M&@;]5V(;@[<&$YX%T@;1W?% 2 6:Y(Q0(KNWE8$9<$0&6;66+6!D=-*234'U
M75KK*W<1F@.DI*-_2?9M5!02"T>#1+.#NV.U(@R2?=?2Y(S"SN]I@8WNCI?#
MB*AK^T 0C*+@)*?H*J>J-R,N7O']7G&O#@+\I92D+_)]91=9'BK\B$5#=JF^
MO,^OW#RA#6%/Q?UG+5K5D-,Q9=HA5LU19IJ??*6;;! B2U,BRZVI/LF_G4:?
M,_PG;$N 8-6N@\+EDG'R>0',(9H "F0\*GXO9Z\ZBO#T1@.#EW%_UY#FA=Z1
M. +7.SM0$T!I=K)#NM3!%[/HMM".F_BR5%3?.BP0BP58I #LZ80"Z=2!=JH5
MZ.XI%T]Q>TVR36;AOG>57>_@4=;BT0QDP&?@WM :-HV\ HW?>3RJ[\+6]PVT
M.<-U0:'KY*HGRH1!"!FK&#J9K&D)EJ?S*N-U8+6(M!'74K@?G4:\-I,I;Y/K
M$&7GKK(Y*V34"8R(DI,P=#_F?.U:1&3>BQ1%<TLJ$\W2?6ZM*'YLHVZX8!FT
M"UHS8*E-4=LJM"7.9(W 'ELM,U%M!5<AP&49F'?1E^P[2,^N#0M;ZY8=[]_W
M7Z3L.V$XGBBJJ7+B?][NZQOWR=<ALE,JLS/Y<@HJG3%W?#+1;BXU;KDG46];
M^-Y6N66?O,^?WR=>KU3".#C+#T!NEGZA#;_6D=NL4J4FW?^WJ>HTE"99CG/U
M6]>\NF</FK<_8H"Z[?? TR#&M*";(0*V74+UXAA%@*QVE)ZZZ5-=>N&U[.W-
MN=)T;K]-,R%4(J/*]PR?(=T\+A4R-M$;#C%^YHJVG37RB#<I1',:=FZ5F=G6
MT416") @H,?JG2GLOJ=)'[ ,W.)2W6+3[UH4^RD6W.I7W1I^Z'Q0V3:]U))_
M^$QR[-/9 Q-U!'?!Q']:(RB^#_NPE]K,AH9Q6L]NEK09>V$Y5189!4^*7AE8
MG&!27Y-$,ZG@Y[DV"(5<,=@[C*3J48-GJ8:D[=U42<^[^Q](5#P3EG5_.+0X
M=:VE/;7IW(_(>Q/*R/3K9B<*T;64^C8A7JWC!R@<VP\<_3;>6>D\^HV &3WI
MI^I\5#-.)43*X)7+7_M9RJNB[+#M-Q>J?*Y09W!^M:;C ]E?WH.0/3*_\3?W
MIPY<;31<[.%+IDL9T $X7+E7U46"C[ADGE+8U\LZH%S5V.*? 07TG.G1AT$X
M'$P6ZFF@'MW1O#I['^KN!@IK</GR;R=(N0MG(J!R6],:*^"6%^L,K9T,%M@#
M'^-C5??=3XH>"WU;'MC<J_Q\];Z=0Z7-"EV4!CITQD<@*6SFIIGMC5F^3:_@
MT_[F+'C!YU(4R:;+V]@_.J&<;/8.R$;HEJ;:N1C_^= SA5.G!M#C*_*3NMB1
M8N3L!<KI%$<"7M$@P:YW@3&R)@ "NUI$))\[YS&^X;0YX=OODEC\^,<I%_!?
MBMJGFQ\7L<)WFODN+%2%NK6&!SK^SI#F[W3%!$,_IC?NCQTOX,! 99Y!??XW
MQOM'#&,7 12JV3N<VS$GNIZ5G*S.<][GS2K/2_!0WW51(%\FSOW5EE6=-9@Z
MX)D*;W46A8$*)O:ICS!EE+#+EX_["2>4&Q\I/53O6,ZG_IXRW?>@OK.X;Z(\
M:-I*V"0^<7Q.*FE@MLW[5& ;;*5--SZ9K78OLXP<O.)E@S_"KL"9@@V<GOO2
M"-?'G!^?^ ^K@)[U:7!DN+7D/]M,49=D1=J=(H32NBLR54'<!$:@?7<P+.H#
M9:'J7Y>3/[']M\'>+B O9S8Q;H6W5#QIL^$B)NJ$10XQN4D?E"G(=HRQQ1R)
MJP4)$@8S?<H\C@S4KE[4*_FU@]ACH%?=EG T"8S0MB3Z$JXT0G?OA*I0;&%Z
M88JFL6Q\469C_Y(1.&3UR(3G'<N\<"'LVY 2Z?*6%+U*3IN.ZJ9:[COP7LH%
MQ8M#Z=.CYI->//AX8OVT^;L/]T0C:?J'[W>!C7H_+7+D3LA?L*VLGO#M5R/B
MSDSY45U7_:<<1Z\3ZGVA?.#WON0??=FCED5L^\AXF;$I5)5GTW1SPA=4$B ^
MD5(2096RK28TESD!7RWOC*KF\RL6C 0OE-Q,66% .2'"RIAE6+G(_U;*3V_D
M]"]=+4>O/Y<_6(XUP,.KX1Y1'8_" *D@DRFTJH5/QV_8['[;>4A\6>3R\8#Q
MB%2:\Z,M]5$QUL2#$E7])E6KGXBAI%7##/_QPITYO7%9=_/K"CR-LB^-6FR)
M5W/7V8'D,#)MZ'MD# C4U6''EN5@K>+D??M/8BJSWZ7+7_:KOS[DW(7MDCBG
MTJ64+\=4_#;EH>N=4J!KW!4DTO\[WI&:LL5(A.FW_'&'E*D65V')^LFQJ>#B
MF)E5F;*>+XPT:U9L:?QT.>^<T4XO91E@L^$UC:\< ^#" +U"?63/46#F3[+;
MSM<YR[KB5I[C8\414*%ZA]+<U9 IL(8"J%N7].,95N]RRJQ?MS;UG/53DQZ6
M,8AC[MTW-1(BRC( =VL :"/53_4+6H<F,$)&>3P3K'<GX6[U@2NKD3-1&)8A
MY?**TLVS.N9/'<6+ZE@1Z;C2B^CW%CP9#":A""!G(.U]WB1GR6\''O25*0_O
M)8(:1</CZ\<Z5E_O^1&\U*X<8U]34>W5 > N=_V,K&2E5L,(E7HKFZWO?CN(
M^]@ZP91P0INK04U]X W+_U%P5F%1-@P3?G:II9=N6+H;E!*7[N[N[B[1I9?N
M!FFD&Z19$)"6;I!26@$!0?'E__[#.9F#N>YKYFQFQFQ5UNQ6%(0K!)/L!52[
M;&RR#T6-T,/=T-,JW//Y9[D"\I7Q?DG4WLOO999PP%?JIG6SHS3WM/&Y[X]"
MZPF"/)T94&+MPA\]/;]@MIYX/OSW]F&[G[-LB[^2(C06*]2N<)S #M-53 *Y
MXZ=1,6D 1Z#USUXP^:FQ%AQIY"BG( \O,8-LG*E*]K-5G,<Q-63P@L;NJH-"
M"R@?N$S7;-))*K*YQ'_O5TF"H_C1X 7/+%L-U$.!1&/C%'5*T+F96 )9KA.'
MS,:1[79GCJ:OH\1,!@4?T]ZV?$+$$ZJD:4DZR/<^8(-+M>1MT3$)/@0^:T='
MB?$-'O<-_I0<^MTW]"R)PNI'$4H-4_0/,TB-L/>/\$M]>ODT5,*'%.Q$$K8$
M.T?AG;*C*GW[(XX.(UK4-WZ<*%\=KX@^ISVAR[E:\\;QK15/X$C&*S[6E-WA
M18,!>Y2?<) <M*_&Q*IP_:F6M\]\<#V[A&!"*TVTFLM]8JSS-S7JTMJRPC[;
MX-@N+431^P1]6\5]CM%KL3KLH-\OT:J&R,Z]X!B] YN?[>^:GVGKC;R(M\D!
MD\%+&H$)#,2M=:E1J;P-0U<-AZBZNS+:J]VO?U_YX@S& O_MO;;<)QG<RPU2
M>- 'O7I[I3AXJ"9]I#6HY2,AQS&XSRY]P/_?/AG6VV.OP>-/\M]RI;^5#'XK
M_,_Z#8SDV8K%6'NV. @>H74WI7VQO2@HT]PK&N[M!90=K=4U_-*G7Q-K*GDT
M[V66 T*$W OHZ6DM7VP#&1\^V=RB9T4UJ[H4_'W3;K6F6#S7MKQ 1I'HB<O)
MR.D>2J'1\+<4\U.QFM;H+WYYNLU#Z![C[3G;'-9?>L/M+WK;-Y^8X35Y,'14
M&O8P0B,/!)^0 0@9%;/$TFWE,7 MWSS 9$"2863<7  GD2R"@E#M+<+XYF@B
M'I.I-.GTQ@8H>.GS?5E<UT(L /UMW3D5Z8EVJ4(X/5F!2,U"M7IZW18V$<,@
MR*#9=*S7P&VMP:HG\HZ:_*M^N]-"M4$?^8>E&M4=/E8N"C[]YPKI=W]NQ44W
MC8=L09G_N!_.@*XX(O;JD(7A1$Q:!>FDAFY;58!?%7.^P6/8?BK+XRVYA8\S
MU8#L- ^K=6A-[W*P37W@JUN1"R')>E\: 7B0P=<'ZX=!ZJ>7@[LC'QV_*?:?
MS6)/,OTO,I_Q:.Q1R(LB:V\($$$R.K-W-?\'W1JOL5Z@IMPZ)!) H2FOA_O_
M2YB\0IMX%GC]]AGZ?$XH\=\3M_?KXF[5IFZ,ODW5EP=-$C\^@B(ESWL*5YF;
M^['%G)5C[*EQ,!%4HVFI<@_C41S2@%@>BC)JKI _B@0C-+4MD7S>B2Y%FMJ;
M);#<YG-[.A2" J=+0:Q!2#P(O*3V6007B"R2;?^BFA *5N7G=3GT5=ML0Q>F
MY?_4<%G3CK/$-2NZXIXY^W(GZ5<=]VG#DB;/P+*0EN D;::60 ^>2$UMA@YT
M3NZ;.JG.[@_W9>GQVQ#UB FVQJ6V.&DD3'66Q7NY@>N5!3=5CZED<J>NF5TC
M'O@JE->@^FJQEG^O#B=%XXCM%C_V94]MITRCLZHC..&-?H-Q;@J^P88D64>=
MT>Y>97:]1?H6K^;7&6+R#W@Z29[@^T@J"""HJN[<3V+ DSZ&+23 @08XTHY0
M4H_]NRA/>E&755R8T>JDG,8R?P%&-X:@ '2HLQ#BW6NT ),Q\U^<G1OF:*X'
M!ISCQG;+SSS?Q>P2>7>G>114+#OLQ1DT3;X5X;EO?,NU2=EP&-1\L?&]P&A.
MG#V,W!C./ &S->Y08SSX'(4KHJ=RG$!K^:<ZA?4_W]HU\U>-(G"+8MZB-6^[
MEH^[L7*:'QNJ-03FG)U[YT\[-RRGC0Z142W<V,G,83*0_/:M$7M.(>51G[B8
MB6W[T3SKWJM-&J_8&,1IRFB<J4CU^#TBWT<JXK_!5B>ZB'%.*D8_4^NE!;0K
MQ%SUUJH*AZ!.([[ZJD5J\7+50W5M?;\/18JX2^,4'??7@8P)"6+Q":F[P_0/
M2^]'\MPLUXZ_?M]Y/,E'*Z3!5Z&-'#C*'<CUPXA$+]654 O-8")_7M3Y$[S<
MLY9ZEV071M;YP,JVXEKFC<OCV;=4F>WN6FB0=XC.[7TI#/OM:U#4L(XC9EV_
MXO/'J,@2]-ET@ZM4+1:>=#G\0>HB/B: 6C;M9[23%#['%SD\V_?D ^=1,)&%
M8&T!:(<+@17\[X3&4Q6)LSS@4MB&RM ,@K]-KC6H$C2H[_:OBU]I?ENOQ^1A
M&%.-><T?T?V'C*SQH0M'8Y1V7CN"TIU%7C#EFJW]9I.*0D0&NUS'*$803WYF
MF# B;4$SR4?]>-2I%JA)3;IP*\G)>>AM+',-C*+56[%$$RU9;F**-]6.YKA5
M%OTO5FPZ9(O&HOR%A.>-C=UIR8XOQE2+^/.)8>>F6=>M'[DB%Z[2USZ;%BDF
MD5R./30,8Z6*)V6EFC*NM-HV*ZW0VER]"!=;61-6Y>#?L*^T'XQ6]#19_"J*
M["-O7C(3C6"*YVL(D9]Q$T17%O:?\E@RJHJM%4Y@=+HT8XC!=(MIOF:3:@-C
MZ.K"9*5(C')THC>N;$Q_9QSD_POIUR'S,U!GR:Y3_52WP9LE2LR,$F25?65^
M_=TH)=J0O#Z>Q[\ZL^(^?ORYH+/>211I2M2PQ<KM.IQ2/I:2<0:1?V16*V@!
M0,5M>O 8,:X_9,(O\'D-8*G=O:5G"O9ZM;8;+1"XN:"W*?AH2CE2L#A;\RZ8
M8<"B\.FX_C_![(@NW/YBO4RY]&1= UZI7R:#;,QZDBJEK!*M"%4PICQ2'@40
MQB-> '"CO@/1YH#9<PS/R*7E :V\Z*<,F? _U/V0E3Q(6[GQ$9NFBTQF4'3$
M\* 0MEZ;YPMVHX:C:*9Z2;F(%P7K0HELXI+3 5TD;\2),DR5=#-\MU5:L-!9
M!')'Y-^[-N92V/&LO%7K2[<Q:"NK-!-7,-ETK75A&8#8N9;1<(7)I_8Z;A4'
M4,FK-+[1:"A(]E06N'D>N!KP,^&1P457Q]*NNK9+#7NC_%H=#/P& ]37 2H>
M:SEX:PI)K62)U*Y_W+1!6DE &WBZG:U&'\?P92(I+RMHB,9F&[77_9;SPP:'
M*7>F:R=/-'5]-,,(@?]R"_,]ZD+#&C<C8^)7M=[*YMF/Q=ZUX29VE1XK]PQ?
M<B<?L7HB^S/#R5H;@B@6JN'@'\J#=O03^%H-?.K*(;V9([_Q;!AAJ]4&[7W5
M.)*B/>#*ZLY 82(/DQ!VWC&[A&9]Z0Y*>!, R=/XIA8!H$Q4O&*1&<Z17SL;
MO[.;V,VZDB<>UF-3)]C>\ %O<T^4'']75N'3..0?%LEEYK>3%.QQ?!Y!G3];
M!GTF&_N,%Q1I*J2$IM0U6J$F+;M;#.5%<O-FRX:[91E3Y'P)K@U8\<2WIO,K
M>#<L[LFBQ&6J1FP44?H>"4VB2!_!3T2C!13CU8V9" .XF0R:"/K/%.COE/]^
MRI+>\U]9?MTR>5E8T7^B4A:BXU>H%YS9)51ISD4ETCZ&MH= #5PG>U7.KO)@
M9R*+&3)2(H<?P;B &("'BDQ@X2S9>G)P@TE//%Y3M)*46) &R,Y^R_"H=#FK
M^T"%;N.5^L0XMD$FJE#@T"MCN(.Z$9AD&&D?'_V;/5'P6WYY^R#EC )%REYM
MKHYQ6ZO0?QRY>JTKB /7]BV0&53T](,S13,7UCS[G,8C9<<-'$9U*KU1 F7)
MT9V7T=8DW[$NIME3/[DT[<X>!M4[YWTQ"=3_?>'TL[_'5$BN5^,ZG8D?F6'^
MC^ XCE8*0!MJ'SY^\R#EU<91MZF[XDMC3?V<.Y1\Z;ZK+&XB@$43^NZZNO*;
MIF,]8C&"YF?'=FC%O7R)[]'DU?O*4/G,\%I3=GXX:F>MW.E'^F1\%+U(?INA
M\RIH90>IF4E--U/J=WRV5N;_7M3 VEU031Z6H&>TSQ5YQV[V 73YN(IW0O+'
M2YBP"D>*:^++5XU#_Y<!#/!<32G]I_A@+Z6]PE<_%LHY<8\DORH+EVC>V@RR
MC*A@>LU=3,\1"%S_<,M\\SR5&UIG$%IWG88\T:QP>_^YOD,M$<E;K\K/+:_Y
M="8/OM=B8MH#\:# IK8@'H"6!S:P'8'Q8=2C374BQRMT A.MT$%&'^<[#*-1
MD\?XRHN)H)0:W4O$GS $<PJ)?AH.57T;6(^M485R5OSDJ5 Y6AZ!<N=NN#)L
MJ?G$)7L6:.M#+XL'8I^$E2O,1;W>JYCZGQ2#Q4P0H&^P4<TH/V;()7-<$#RS
M3W#,) M@PWMG6?41E.8UKR!$OI!K+S&X12 3(^4":TLJ(Y)QP]BU^,?$#UD!
MP!%\#$:,^=HRD%XQXF"RV@J JX]V+[@P=02;;;U!IR>YH3CD5N[8:)=?B)]/
MYZG=DRD;%X34%PXPSX34")I'T;CV,"Y<F@SA3/K:3,;P?: 47">#*<BU<S'O
MWH5;'YI^IY@B*%WZGZLG2V3T_0R8]F):.@4:4E3>PO7E(UACW#Y.*Z'V(<-M
M/2=Q+8L3+2ZY[3T.2Y(Z>U,C?F>3?$*5@K0\$U,K3/7(S':?*":=2<H:@[<4
M\FL*3 _07D05G@D6R+KU"?Q\^:/UMCMRIXF@/.<2+1;&^-F;D2U.WA&=4@S
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M PVOOAV7YWB_?#LN)Z +7BA[$X1JCT<&\?<#"IJ,V7NM%[%>4HM!O;YIG>S
MVPQ'O?\JDU];2(/SU][(\ &RGQ/?^PND[JQ6?:H7-JS\4>$5_MC1%"2^[WI?
M@0=][9O-'7G[R0J8& @);B9>[7O[H$OT,',VRV"^(W([ZC6HLL1W8&-A#>KP
M4KX+TXH )OB!Y;6W<MU#Q/N2[YYN#[@F]7Q/JY;0Z2-U&7Y-$KYS_V[Q;V%R
M_N[Q*#RR,@KC$0MUV^P%?&1C\&@3OG9"^+;9W9)+WE*04+5910<AB)3M57*=
MFF[ 'B/@CJ!W:Q3 T\?PG=\1Q!R13;JA/#:$]NQTYWOA5S9$UOVR"&9(E!QZ
M&-X#!2Z*_R\IH"P:AE(*DUI_)PB)IA<R'W$D%<DC%B<!)-$(LFX0,B?1\>CA
MBYA"W8MB+Y2A"#TH7D3,NP-Z,TH0\C[:AI+N'7D0IV_HNV'^8O98-TK9OE_L
M0AUQ0*D2%!/%EHL%^%,"@<%Q[N6Q[B=QX?M^;V,L>2,BGX8CWR&1_<S>"VM"
MF'"W>$@\7KDK+LJ54]'4B9(NCC*^4$Q$F$,D<B2^;)U!KONE R71&%M"+5)7
M1\R@[B2!1B$V&AG?K)PX=!3;B4R\P?)Z6X6H=(CN@23)M"-U*9/&($H<C@GX
MK<'C$TF>1OP[9&&S',D*).Y2"L@AL>0-8_8&9/+F23*#K\=&3A)ZF>=7YY3B
M":/]YR7GXXD4N4._FWNCXV/)G?64NQH#4LJ0^YK48:%X:(:' F.@"$GR7^4T
M_(-XC/BT_!O859[,DEPJ-G;ZB^%D(I5TV**$;%D0WN\TLLET7I]$.NR,15#@
M9PIC1I>,.<&DQA,3GPG#(R>  K!^B[2],28R",IX66N''LM/\ZC X WB=P$P
MH:!?#L"Q(ADQ_#6%-8CHBH/H*E.K-G36!F!/(V OQ:=(8\!)R\*$9G\G!<%#
M0'&46:O+%)$W&5 $,0.0P[_!H(F=([UD:CB9M9>-L%6":K^09RC%#WU(T%/)
MZ11+#[X#R[B 9%R ZR@ <QZT:),7:P(C@^?)<")TXZFR[K0),:$P*#0?T]KL
M]Q&!3 @X9C([")E_]SLS&9LXJB?_'R@_.5Z 7CL_UR4+=1\(84U$PQ;"+,77
M#P%CZC#(G#(R (4RIR *79!!+;[!1O9?HCAK<?'(FTPR:*9)0)%A/@$4(2 C
M7KS "&KL+)2;I-=ZS&CGI..W+N[?@/+/@_1=0 10RV>&1T/7D) ;%WP>[:Q%
M02YS, %[2TC5!B,J7W]S0U=F,K/B5S9V&?!)I>"="AD$ 2BDYU74$LJ>,EK5
M<N/ \H=.D9N=R$,(X+XJB6F='QN??:,"3U8I*V OE^DI^F-3$L=9#B7"KZ/*
M.K56"+G+9I;(3A#.H<NHR W)VVC-/Z*B<\6NQ$PC(& I8*K#3T6:<9J4LHCD
ML<]#,U1 LE1E-UGOZ02RB_(=)(:K<K'RMWI*H:@2" RT8H*O5$9(!GM/<57%
M RHE6@!S<H' !>\'\O')H06W5^ KZPH.&8$#$P0:>CZ$I"PH&$Q8AG^G+7YY
MG>FLHD ED9?H0N1C;/;\Q%F\BOI@*E%J\)C)NT%L1UT:6).?*9KC.)7M8IKM
M5D#OB9/C$ZK5"J%L%Y, <X$*-D!LFXQ[>U8Q*E4 O"X@(^]C=3YO&MZN8$%P
M0 W#GVR-B ]XQ*"_U@3W>_\#0&M#FS!S@S%J(X/>&PR%DY)I$\JKFF"%&/5/
MD:8\E'-P$;X9^2"1\%K5AN#.&XQQTQ#W2)#,2O0FH;S<I?FD%* :!M^29;75
M$2=C$Q+6A?"(QF%>\=_TE M,E>AM %$N;HUDE<3H^;29U9@HJ%IH_BMF!@[5
M-FVB,M@UB RW+76]J;RG4J8@#R)85#Q);!.:1P\0WXN+F_^1^6\S#P@#/X/5
M6C#= (B:9H2RRYJQ]+HI]!M7B8%_WG-FZ9LZ?#)4J<YU X8-<&]/%/,(+IC,
MQK]JP+@!D<&S^_()['%([B<%B2+*H&9M&D=96(RY^-KX^B8@6'II?S[!)JK1
M^C:;X&]Y90]A6D@ST0+]N\3BV>OR1A8"S*LN,IV/1-X?0PH)PA))]TRSW]%T
M"Y3ES*'GD\*A4?F51,/@5TM$%'M@!I3T)@!Z3,_KK\4O-]6."#$B22@G*P7B
M74#K907K.A_(KIIN3BM?7F<36A=QX,2>:F?=6!/&N"A,EN:3[C6:)W9P,I;'
MA.3?+C00)K+7]8!Q8"6C?02;)@U^QC6Q">7/-*I%,)DFJ-\'FKH0:R3)C0HG
M!JR\C"JKXWO?7P$ZF1[P10LA2J6.Q+6=1Z8I>1(J/"W +M#SYW?_0E@> WP
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M.I_QG\SUE2P(NOIUDZZ6E!J7FYX2ZMW5U':6F;!G,K2U$UO4-.D,OK3HC2,
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M5Y6*U[V&E;-6'>I6F2K:L_[UIZ.-ZE]K>MK4 E:K7)6K8VOKU;':-K=@#4"
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MVQ8PK6=LZQ&W6<[6UG:9(>P"5I.ZR/(^\H[K361ZW]L%/;:WD?D];W_CN]]
MKH"2!;< WU@:<6/4IQA!,D<]>L"(A+1S)2W06X3<!("$5 Y%N8A(/8*DDKE$
M%?K,^9:!]B?DB8QX)2F>2(M7,E\ *_#31JG(D4I&0*UBA'8EZVDQ<J;OG'A2
M)R&+24B6)Q+1/7?V@7(F1J+K\>-L-#K$,W8^.!H49 ]/B$)92IN2K5SB>H3
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MZ<Y%U[*%Q+'RA\KK/;RL0)Q "9/D;-PAO&JSJD*C5X!#=<@A JBA #.@]1W
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M^5@C-^#$4&(&4EQ+WI&W).)F;X$RH*C"<[,()-!X%U/4S^;X, 5"QV;'82(
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MS@2-8VZU(SRH[.\# /B#B+I; LT,P(/'J0+_(2ZE::5*T^-HSP]1FJJ4AJ[
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MK2B+_Z](B[$HB;6(B[=8B;#(B+;HB[H(C+SXB_PG:?5VC.1CC,F(C.8F 06
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MR(3MMH5:&(93Z(1G6%1=*(902(;1EH9@J&YLZ(1NZ(5C*(=&!#!N-PD3R!&
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MH+\[EHU>92('5,D$>EH3I*;Q@ I@P'F0ZM,[!""/,HD('F42U/7:]P!OB&B
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MV A\<8C*X@C34S47L(!CQ!=]62P<X,5&PR*"@$:(08 G HE;[*Q7_!A;%#1
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M>LU1)2.]"H&/N(F!& @[ "P"H#0E"CT+T)>/X"%_>=67*)A54XI%8Z)&@Z*
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M-.H"H*8 <*<A/(!'T.@#8&I'C*='A"AW:ND'=&>A@L2H7NJG>N>B H !K"H
MI.=-5BIX<BJK0H">KNH#6"I5YBBL>H0!E"I'[6C1F&DJ9JBQ'FN%OF%E$BNS
M"FEBTF>;IJJ(@B@W6 ,#/"H T"B7&L*'XB=Y5NJ-RJI.9F<V=(0"?&BD_H)'
M3"L *, T=(0)8&E1&H*Z9BNGTN@ <,-*?H!^@@27 @ #..F=MFEVT@H$L"@\
ML.L". # RBL 1 "F"O\ O7;$IG9$I-*IO79$E**DE][IC0) I:II X%I2V8C
M N" '80  :PL 5@"R[;LR[HLR\KLRM(LS,YLS.8LSNYLS>ILS_+LS?ZLT 8M
MT=JLT?ILT2+MT0+MT@YMTR8M 81 "(P 94EAM)XAF38KLUZM7G*HD8X$"B0I
MB(KH!KQHI38  ,SIJPILQIH MI8M>29K1\0#-UCLNXH$ W JOWJ$"=!J-NAK
MMFHI-M"I/S"LOV*LVG8$?LYECG[$ [BJVP( @:ZD/PBH ]#JY++JB<JI4?K#
MHC9NWG;$E0Z9L+9A-HZ RA+ #C"MTK8NZ[ZNT[IN[,(NU,ZN[=8N[CZM[LK_
M+NZ^[ Z, ,S=&]>&X;)JK?%V!)IJTS@8P/(V+_,^K_-&+_1.K_16+_5>K_5F
M+_9NK_9V+_=^K_>&+_A"+V"*! 9P[9N.+4J>*P#L[9T*:.BB*)9. ZV2*ZM*
M*G>:J^$6I:1RJ@,X;*[B+TK2*,#F@Z"RZT=P:0G$J4><+4A$*JWB;WZ:ZZ)F
M)\5*\/I^[-KB[XUV; , KC]H<&61;#12HP>L[L]:0NJ^+ NWL N_, S'L S/
M, W7L W?, [GL ZS< C P1,FKR66[/$>KWUJDP$<,1(GL1(O,1,WL1,_,11'
ML11/,157L15?\1&KA)HV #@@*>"&1'JB9).VZPDP_RK\TBH 1&[\ D#9HJT"
MB+!'>&X#*VI'Q&_D4NS5/D 7L[&(]JU(<.D&?#'(!NI'6(-V"NB_?L0)8*H)
M?"@!/["K-BY(2+("?$ '&,)R-E#IJF8SM@(/N_#NTFXHW^XHYR[OEC(JG[(J
MB[(JAX#+VBP.!.^0#6\QMB$X#K'67JT)1( )&"6PM@06![,P#S,Q%[,Q8W'Y
MA@0&?*<$<R<^P"E*"@ WY.JZ"N@)L"V-GD"_'K!.5FQ(*,#^=FP!B^XV7ZM(
M/("6IBV_NFH"TVFE8JPDAT3HLF](=("(&@!<FO,WNZJ+&J@D,P X;W-FD6P@
MW>8OX@#/JC +WT#-IJY"$_\ 0Z^LRCYT1$=MRZ9N14\T1K.L1J]L1E^T1W,T
M2$.T2%-T26^T1(_T1YMT2K.T1;MT1Y-T2Z/T2]-T3*_T"J<T"^- YP&Q&CXG
M+FNM3XMN/I@ "9  7 HT,!\S4S>U4S\U5&-K2' H )  /C3S.(@M&']QKIXH
MERY MTYK-DBIK)*GB](I!* K/R\ VN(GITIRI1IN W!J/IRH/&@U2"A &=>Q
MP"[ 7GM$!- I^^(GVJ:QJS[ &//OQY8 IQ:NXV*K :"D))<M'9-N:MI;)P>M
M*R^TS;)L12\T#'\V:+^P:+]L:7MV:*<V::NV"Y]V2*\V;+<V:[=P:7?V9A,
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M11Z/6S5#[CGO!AZ3(N53XVTC)%J?_\3;)_HAJ6)\R7(;R7F6'\W'AWBZ3(X
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M\_O&6+15_7?KMY'IQ%N3WTPC@4I64 KK'J[\WW<O#@^L[UD':671%CA!*M\
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M9$G%NXV,[\\SQUFJCM,@*+E-? KR,P 8&3ID>6GIK8=A!IC JE0>N)<2(&>
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M_6I2XVJ_!PVTD0$WE>2FOB+H_/___B["891,9)<1,YQH8. 2("T!0K>GZ3:
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M(<EB48W8 2#F\]1+)%,^6A1H_&<%\W4-6HT-DTT;6K0^J^A=V8%5SE4[PF0
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MX#HKK#WZ(Y-;*/AH9H<P;D?:\='2C\-!XD\3/X*4B+F'0G:P;^DS#YQ:Z?]
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M_!;24#2"K-20X& K]/A(R"M*"N@1$? QE5>&,-XRDE#\_AVH!L*FQ@;T0\3
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M(@89QNZK(9AJ5+"I+%;ACM?.JC[TH:_$O,[&'49K@14\!<$PUE'3A+=3^:"
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MJ3=[S]],M3V&!+-LW0[.K;W9IZK=4QBZOARTJQA:%A@,%'CQL]WK/]NG<#'
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M4QH!B4,V;(3-\CQ @ (D<#3U% @A12,@<9)3C0 (S18MV!J!IHA1(:C(!SY
M.Z0]H ,'R:&=Q 44P:#R69J<8@<,X!@A9D\@PE30":!10@5AP  <*.$)[4'"
MC;:/I4F;0 4F8 !^8("EG+0H+"@!0QF2<H86#<K&&A !A+1R4#MDP )F.4R$
M2/$B.U3+!Z#(DF+JA8HSP<P5068/2MFK-JKRGXK>(9#VX"V0!(B?DNQACM7H
M0YL :$47LPF W#@# /,D@%L+8)H0X$!)B21 *]2J&G2HU0Y*XJ9IOCG7+^IS
MK.T;_T@?33,) -A -)0% '/F2!H; , %HE&2EP2$UT[%+JRQ@U1JWXA0BD1
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M$'_<=R",UC!_4YU4I0)  2>,P FA^KP%_"(CO7;  DZH@&D8Y '<.%8Q=PF
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M4P0 ONM$A# ]!B"!"""!:>B]A_"XG*D1YO@LJ6,M(!LCTK"#'T,C@MA%LYK
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MZ!:.=$;H&7&7UK"#CKT( 8@ ;]BE:2A@VNJ+]\9!,\=T#1&!C<Y"95ARA6B
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M< ?FR(<R'P@,9XMNWPFE5OW<1XS\!OF+]RT#*";I29JP:#7J0ISZNJ^Q.+
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MGG4=.;U,S]33V"TUIS%MZN%Y[Z9"UN.Y:K(!H!)53.1%M%>D3.A=0P?!8H+
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MP8@"[(8\<)O,W2-!5 -5!):[X-P!UHK,__E#DO&CN[C."4A;Z(&)7LW:E)"
ME.!?K35$[>D;$T+2C@D,]0U/K*'@0 #C#R:/"Y:@V17 "Q: [T'B\E&7#V+?
M]1%$\F#?2Z84[14,";J@(R*$"+0"]<5BR:S@R/C@'*TD"OI>!?JBW+$="BYE
M4QKB"(CD4)"??N"=;^A:.V8E%E)C-,K$ GPC!00;"3#CH%$&6(H86$  6%(
M_!T&!91E2A@ !3"@G[&C5N(,&!;>2%"ECL0<MQG @2U>BOC#,?Q,S"T>IJCA
MY?'#S V$XOG4Y1VF"30&543:3.B( *# 9&XF;1W$&!I$#9J@C"6/C3E/)OZ.
M#]8>3_J+"TIBJ_\)ST!0F@H.D@K^8 CNBU02!"1.S)$U(DH>A/2UYBH6  @$
M9PM.C ]^Q[O=I$H>)W'^X$OMF 6&(G4FGU9\YGU8G%Z&!3K>I7>NWP90@)1]
M)5F,(P4TR5LJP'D*%EL"$#FBQC8R8S:()WQ^ #,FQEBN)TPT8SEZHUR"XT!
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MB?R< .XFQ';'GJF%,"*]7IIJL*K=:9V>=\% [MI-W\%"J0;WL2(A(L$HXO%
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M"$0(_+!V\]OA#G7'0R,F<8=+%"(1>8C$'DZ1BE6T(A2/Z,,A)E&(7:R=%R$
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M$U1^1?#XC/09CV>*6M^;RT>V9_+BZNYCW/QBT4#OG'+N !5P 4<F\TSG*"K
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M<=]MM]XKW=329/?IQ?5.O!Z.N'X-OO5@XHX_#O]YY)+[!V#C^\W%7P<9#O4
M":\QJR^%0_4#C>@ 0"#07"4H0() '9) H;1%13N4-<^&+GL%%'YP.L$46@N
M[B5B*+., / CT&QKH6[A\09,(&/6S0]H$M]ZIG:D/W3/-@$ Y,*CY6QE^C-C
M01:1B= &V@5F-D)9KQ^8 3I9Z)L!&/TD @<Q OD+8(4)9J:$> P:_F-?NO2G
M "#1*# F:))O"L. .ZVO8+,1%$+T!\!V.9!]91(;D3 X'_61KR 3T(Z%L"0"
MZ/@&2?;PWP,C@!.; 9 ! F2?8!@V$0O!;R %L=+Z!"4"U)6) 44"R@.N]([
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M;T'(843:3$2B +  8$HL+H;&AM8+ 0S)1C(F*>[T->Y KG;L4=+,,H <RN8
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MJG$9QG-9N(L<$I]")XCKJA9Z$D?<@0 "@I:LR:4BO%/KPL/+CDIK%,IU.M=
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M@PHH,N"#ACBXAJ).4>W& #DSHGKL">(% .J9-E# ! O@5& #FM\# %J43'A
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MNY[7$I'<KD25O&IYG:1)BIE7O>N=4E,U0\JKHK=)\V.O>GW$77(1Q&HZO(9
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M2:DE+KR-?GJ]/4(>K1 !",BHVK,SK5+">/%"K? IGR(4.SR/.8RIVR N2E+
MD!(SV<DRXZ$IY]$R0!3$/;L1Z+FT#70)+T01A.#!YDL^2:Q$2QP?X9.T2_2>
M[S(/?H.*BSA >KF]-?FCB;"5QN.W-EJ]0[)"15RIY;+"WF% Z*NE2[L]J@#"
M-+2_/5RCVQN]--R-D]@^+VR1&GFGAXA%%107#;$11N*S7:1 X3J>1$0XF;@7
MGO^:N.[RO*7@PK8PQ5:T/58[0X_3,P>\LSK:N(YZL^/;Q)+#07>,1WG<DE/:
M)"-AOGFT&$P+$5(<0@H,JN>Z/MJC,S&,#G[LES4K/6AL*98BR$Z4PS-[(Q_Q
MLX*)OH2))4#ZEBD,I/#X,XC<HY7"PS6[PWBIPZ":0R_+$8^*I>C2P[L:+X?$
M,K4H2- ;"#8@EU@2*3G;D8\\CS]$%U#T1I-TQ9OL1(4CD7Q,.4)3OJ1L2J<\
MC4PTDDE[2H<)2'M@ W_;+H 3.<SC(Q$QPIWT0114O8BL"A#LQ8A3"@0\+@=D
MQ*Q"R*6@0I*<QIM2RQ9T*84I0B#Y1H31O.F8P#>,O33_1"X8Z<,]-!!U_#<^
M[,9,X[B X<K@FJ1/I,"2#,I2M,.60BYJ')=VI$J9>Q_/#$W1C(QZ3"]-',TQ
MJ1=9'$J+#*J%>;.ZE*,_XL-OH8X-M#T<V4N#-)XG-+A$K,4\ \J8J@GIJLDN
M9$2/6DR%Z\W96T+QXT:?>@N$I$8MO!Z6:A6M"IZ&'!X244&<,LSG8,TB-,P?
MF<ZM_$$^2JD:@2K4-"]*;$_XC,_@FQBF? U\E,\FJ3B;0I-;K+T\6QZCH,R-
MJ\@823@&#+F8F"2W- ^[_,#."\X4 5"_=*01/!=#6D4*+$P?U,K;_(['],[1
M>XJ+Y,"CE,5N%-&^-$0H_,W$_US Z'*N1OPM8^3%DFRDYVQ)5GR^B<0?Y;2>
MD>()_"PO> Q2(FW/D[-'(M'!(FT2$?#(%2%(XNG$Y!08%2'+O8Q)A<1#(G2_
M1Y)2+C-"M_A/7'Q(5WP=,_0H/9K0YU21&]T-O)P=KNA#XNQ.0OI)Y6P>K!P*
M/Z(SG5(S##O)\&R7F'1#77PE$LDOC9,ICY)0CU2XT-,=H&A4]ES2H8I*2KU4
MJEQ*FL-4(\G1"[10-=I2CHH>$=4RQV0X[#M*S<PN#!O1.^)(IN@\Q&1 '/6)
MA;/5<>3/7%7/+^R.\&) ,$V0 TE3J?!5WRG18#4DI'BS&KW5<3DX^[/ 453$
M=1$D%!64$._(GH\S4(ASG8/#EV4%4W\[P2;_Y516*DUS3==\'%+9N$]UM0RN
MP)X(-<0KE(Z1%)$X?43>U$:%W)<_P[\.S;EL=</D:2G,](Z Y$K<'%0?=<-T
M^<J:PIX$74GK*LN2%"GLE%#AE-*#I$.7+$'PU$:'95'<+$B8'#.1)--0A:2"
M+4?/PQ#8Y$V8?-=5LE2:O=D:M%FJFE2<E8P@ <F59<5(6CA'C<B(1<=<[5&R
MV)#L DR^)*F%C-;Q4\\S6Y.MV@FL=,QQ1:1(_2BYW-:*W!WJ$DXJQ$:TE$*4
M%=I^449F7,RF\$.!8ZXP=;\*^3A'(D'*A#UH',L^HE5EG2Z4Z%E.0E?!+=SB
M(]S3--S)6,R$T\M%_^7)-J/%DO5)2AK/E@78%R$I1[RS8H2>\6K<-!U">RW(
MX]Q7HU34]=NC.E3=U_-8,?33MMU&J_#<BT5)L5W.+CW+,>PS-.O3\E15B&5.
M@@PS.)W)5H19RG5-GU!<2])9YGW>0W->V'!7Z"6,JD55!)W:XG&=YKG+!U31
MURP>/;47#7V4\$J*.O479M3=#'47".Q&BZM;>NE:N[V1!^VI@(,I/SI52*2]
M1)(DD;M,BP4JUQM,;>U(7EPC;DU:W?W>15+6?01!JX7"#LG&\2JNZC4?=LU@
M#A92T#P2)>U@QFC61KU:EI0>JL!*?CU@"I90VM5# /U:^H-"Y6D5VL%+LO_L
MPH,<R#K,N?6#)"A=3I  5_.CCJ)<T[\\2'X,RHESGEM,D&8EX"Z]1N1T2/D=
M2,L5Q_',2>@T6+8H3.:Y4]J$"Q'&Q,0XJC)6+PPPA 58 #9> $EY@#=FXPB@
MBS5>@ ^X"P-PXS8VA&FPBS5^@-<P@3GN8P'H"S8.C$#6BSCYGC..-*E,8^OM
MWA,MT3QS6\FD(QLY0=2E8@+%OPD^V_\%51&\6PJF5;7@T5"6QMNYQ1 45Z>M
M3>/26+8-1U#D,U:-(XZ="LE]V+!LN";D459E,^SCY$9TP11%S";V#AI=WTOS
M0V3U+O:0Y.[98&IFI1(XA3;6Y@6XF@?@9FZN@+G_8 !\. 7J50!PQ@=NR&,D
MB0=M+N<V7@ DXHLVIHP'6(#:D QKML]K9KE&NXLA.3[?ZTR GHO.#&B#IHMV
M=+2%C@N&_F>Y*-?B<&B[(.A_%FB(1FB(5NB"QNB!WNB$#NF*+NBZL&B.EFB0
MINB$UFB,YFB1INB6ANF,CFB'1NF4/FF9UNB(_FB=OFB:)FF?+FF<U@N6%HR>
M)NB>7NF@7NI^3IGW;&JB2@9\$&2Z> !\ )RX:&,(D(L%4(![S@:[, !\Z("X
MV("NQIH%D.,%R 9N$&02P&,W7I:W-H1\)N0^C@M"5NL]QH"XF( %X&NYZ(<%
MD(>Z$ !#""TWOIJX>&NX,%X  ##L:W)CR8F+.UZ .A:KM 8 $^"&:%#KK6;L
MJ;Z;!>"'QWCJ(IE*J#XTZDUMUO]N[2/99]>NGP;([*I>@!*0"PBP[+C(;0:(
M!]VN"P58@$,&@&PX:P:(YP?8@- ^[@7@YN".Y\=N;N0& '>&YU]8@#\&@+.>
M"]ZN"VO@YGCF:P>(9^D&@ YH8WA> !, @-P&;T$N;D'V[7@^!4,  'DXA7'(
M[.#&:L: [=/8P=@VKV4)< (O\-?05 /'I!(@[WH&@'OF;[.FZGMN .UV;.!F
M</6F&3BF[,P^;DG)[04@ZS8>[K@X;]< <:Y>EN)6;-S&<$$6@#8&G'O>:@,X
M!<!!<1A? , Q@07(!]&.AZS6<0S([/;.:GRHI =WY"5!DM6.C*S;DZOY +H*
M#"DG;<G_Z#2Z&!!QQHL/X.L)D!2_D')/F>SX'/ $/W,T;XPC-<TT;Q^S+F=\
M:/"W!FP F.T77X#Y.>Y^N'#R/H&X..ZMWK4.7X"MCO"X"&X2W^8PZ>X_7P $
M.&XZW^T%R._\SFP8/QD>EYSM!H XCVZJUF[7V/3-A@!#1X%N7NR_!H!\L.W)
M0-P<!/#)X!^P1C8(H)-Y_@M;GXQKH0LZ(8^[H*9\!HR%(.UL, [Y;/(V3W9E
MIPOI77:1&7(PGXLDE_0H;^XX;V,6EXO@)FNZ '0.EQ1OA_9#%^Y+!P!K..O<
MKH86EQ8+GXL!6  .*.SM_H ,W_1ZAO%H/^M-IW<($'=&3_)I_Y>,9F<-6)>,
M?@)K 3".3CED$M@3,'\ *(\+B#\5 .@4$C@6TFZ6;JEJA]?L3D,[AW+X8*&+
M:Y@&'I.+B6< =M*5"".![=CJ=R)M30GVBO>AQ984 S"42)D ]DXKFG'X*=_$
M@G=VHD]S_RYZB#%TNIASN=CCK58 ?+CV2K]P$I<+!N"&0#?T:B!T0:=J1+\'
M/&;OLS;U;._J4Z<+LI?W >?Q/ [NV\;Q-N;KW!;DX [T-BX!0V?T5:\-2&]U
M2)LOUE 6OJ;U=Q* -61O\J 3XB8/#GCOQ%> K7X GA]YP<?M.@9V.%EOR7=P
M<::F;,^&;D%&S78-T$^&K7/P.+Z:"/^HXPJ(=]'':P,8[DL! *]>;$%6EA+
MH:T6NUNOQ&-">N!?=M,.?HP9\D]'>0R7E-FN*F_@^KFH<6NH"V_';'#G>G&G
M?>&F=_(^\;-O] 5 @;J  &[ < @H=P X@5-8;_2/Y_R.;@;?:A"/YSQ.AAX7
M>W5W\ 6@<.86Y#VN>H  (' @P8(& 21(F)#<P88.'T($H,!>Q(H0(1A0X,_
M-P .% @ L"&C@FPD2!!\D#$C!!,&.@ P4=) -H$&.!#$H"!C"8PU23R0:,+F
M!X(,%  0X \"@),$(2C8 . !2I< #/Q2JF"K GX#'?CS"H!!4'\XFP;U:36F
MOY 6W\*-*W?_+MV(!NKBS:MW+]^^?O\"#BQX,.'"A@\C3JSX(3F%"1=#CBQY
M,N6Y&Q8$+4AB ;Y3"Q8P$,A@P="!$# 75+# +<%J"YB*1#V:Z>7,JD-Z&[=@
M@[?5IT,/1/'Y( 1\^!;H_@Q!P *D,1><$"CON G/29MST%TZMF[@#5 +!_Y@
M08/8J%6+S=LXC\+*S@M#\%=SH(FV#,+^,M @ LJ!%2(05%](+HU4GD1G 2!/
M6[_XTT!\Y0%U56D*( B /_[LI !*#/0G4'X83(62 !0BQ8\!0U$4H %N\2>1
M/ )%^*!, KG$6F4W C8 !#LJL",$ ^ 8I)!#$EFDD4<BF:22>2G$=1Y#2T(9
MI9134I;, AT"QMQ[23:9P).2W6481E)]]5*$]67C4@<"8,4!4AAUX !6 %PS
MC84X034?6C'1Y-.>$:1UDVDTT=@66 *P^8M.-5$%HX8"_9=@9H5ZE>A51>WI
M4C8-S/E 6%1*R4%&%ZY4(:BGHIJJJO^KLMKJD8TYYJJLL])ZI&NP!:;EDK"V
M-YD]6PX&%8CTM97-3A$8P-0T&9U5@49,R42"1B&-N!.N &23$0G^H/#@GOP<
M2^% T@[4P8D +"NN1"<V"L O/0I4[8H!9GCN@0)M@.&VY7W#;)BU!LD55_Z0
M";#!!R.<L,(++Y80>UXR'+'$$Q>$ 6? ":;KDHY!/!FP%$<Y@#_) ,#!I" ;
MYJ; =J+<LLLOPQPSCKP^)K/--^.<)*P/5_9OSD1*NU4)/_?U*X89J4.TTDLS
MW;3$''_IM-134QT1U)1-5+76H,K#E:E;@QVVV&/[M7/-9*.=-LHT)^">VF]7
M]FM&!<-=M]W@=TM]-=Y[\PVJPPM1YG/?@_/U@0(8$YZXXHN[:G;;C$,^UVB?
M_3M:/U,M,"QQW( #%W."G_;99X8@+A<$I'N^@.!#LDW9KTB:VQ\)%<@E[4JE
M"]9NY'S]2O?NOP,?/&5Z"U^\3:(O8!T $;R6<7,%]8/\*=3A_'?'DGTLI%9,
M11A7]PP.75@%6*IJ@?GVF']^^A:@GW[[ZKN__OOLRU]__/?#GS_]^.^O/_K_
M[Z]] H3?  -(P ,:,($%7" "&:C !D+P@1)T( 4C6,$)6C"#&-S@!3NH00]R
M\(,B#"$).RC_ N/9K'4H+)X)GB>0XX1F-I@#D0(,$;HP_48@H;.A0"PV.FHM
MP!\%R2&^4 . T&7N>!_X#(!48P@=@D8@JED #Z_SP^O\RP"B&\@#;#BZQ:AP
M,JL3$K@,$)3N.<L H3'74=18D C0+BE+B<E.9+>3T)3 '[:#31K7J,8[2M&,
MC<K/5@# #W]4P #WL(4!-J(D]@'0'I&<)/TD64E*_@^3D+PD)S/9R4UZTI.@
M9)\(T"<"^I6RDI4$0215:0]6NG*5K8PD+&?)OEK&\I6V_!\N9]E+5_Z2EKN\
MY3!UF4MB'M.8NPRF+)/)3%X6\YG(7&8TJ^E,:U+SFMK,)C>3N4*9_UDO:M^,
MG %.80W3Y$,TS1M/3:8HNJ%$+S3P$)UGRB,]I&C,- NHQD"^$Q0?BBXD[OS,
M%$^1EBA.CC/DN<IGIK> ZS@'>9\)R0,\\QE\?*TPQ(M,UHS$)E+T"%![ZH _
M3* 4 +G)1MWS"9R$LJAL$$PG.$EIA$AJ4G_8B:9(R=8T.)6T!W" 32P[!DXJ
MD%$AO7*52N7E4F_9U*0R-:I.E2I4IVK5JD(5JR!0Y2G-=TIE-A.LT)QF6(-9
M2[..59AD32M:USK-MHKUK;Y,:UGGZE9EPC6O=HTK7O>J5V#2E:U^'2Q@[WI6
MPJJ5KX<E)2G'Z;(P.C9RPSG(K3!7'M4,I?^% ,IA/IH7CR@29!S8P&)!A"/1
M=>XF-J'![%B>MP%\( 4%J!N/[Y0W$%VUL#^C"<T#\!$:BYW,,(YSVY%&9()H
M:"@H]HK&!$R4V7D-9!H9FB,'CD:A$6V$*<;2+DWL18()L.FY @"J0*@B$Y*0
M0"FE"1J DG0^$*3RE?&%+R_G:]_ZXO>6]]5O?N7;7_JB$I7]M4!\1PG 5 I8
M?0@VY0 73. &0UC!$4XPA1DLX0M7^,$8MG"&'>SA"7,XQ!KN,(A'+.(/;]C$
M*D8QB5/,XA.7^,4KCC&-7=S@ )M2P>J#I04BV[)P^EBR#SW(:%" .:F4\YS^
M/*(A^*F:ADSQ+OG_A")GDC.0@9YG-<\9BJY.PT\D#KFUG\F,KD9#)N:DD[80
M;9ACQ+F8,0;)N9Q20% 4L-X'&)<MX-I)-D3JDE\ 0!L?DU9).<64!A"LI##"
MLYWI*( *8.H!$:@/,VYKKR-N)8Y' J#Z!NCI3H-:E:+F-*D-^.E1!U $N RU
M5%6=8WNHNL*L[*HN:3WK]\(:U[;.-3%W[6M= [O7P:[UL&\M[&,3&]G&3C:S
ME^UL7C<;VL_^M;*E;6UJ1QO;TR[VM;FM[6Y7^]OB!G9B&?N_KY(2UD&>&&37
MG;C;#"1;ZN1>$N%=&P"$1R)A'LADAS/E(T;Q%Y\A$Y:1 N\3+* H70:M_YB;
M)\6 ,D>(HQD6<X+261!]3C'#]57V@J3>DBF =A&XAAQ-X%P^J32.RQ+ NS!@
M+@CD!\DFT E*1+4GXYK+ 2BW.0;TF"T@G>CC%GH16=P;7PLC7<-)+S#3#^ST
M!"_]Z4F792J9#G5D@OK6IVXEJDO]Z:UW'=1@][K861WV6(9][*8N>]K-3G:T
MDUWM<G?[VN&^]KFW/>]QISO>2ZU?^@%XL>@^G[LCUB4W%WYO2WS/9V*(6JG
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M-A767O7D3\YC2G834"H=@+ED.G(= /V2*BVE4B8EX#TE^C0E5(;=5$IE5%J
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MB=#/!>AM*=FL0F=$$4_SB; V(NV[VE.[ 9R2.FM\O!JK[4+\X<!:T.2#/90
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M"BYL;6NKK&TLJZHKJ:BIJJYN:FKJ[>V=G9WM[.P\/#S<VMHZ.CH"_#]#^ )
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MEGX+)!3\<<':S0#@R)?/X-7>VUAYGZSY=$]!IKIW'*E4O-SYZ;7TW\VV(<U
MN0'ZJZWZ6::[3"JOF429P<>S/BB"8[[-O#T<+)<NU 5&[Z8&TR8KP8DZ.>_K
MQ%-;ZENB'_&XA:7 ;9UR1CC[G$N8VC=8RZ8'A(RY,5+Z\QS)"?'RG*>YLV%Y
MYM"XHQF%>*VYB/R%(<&WIAK5J2KG,'_2/(0V5C2S:5L1K6KSXIKPH<=R$-/T
M@PXR@1G487#5FFG]LD8--'$MU:85AU>F4YOR# @O]&<Q#0(ZNT)5^.A+_K@?
M_06$\OY98++68CT=&J%+XR_G@1_#C2J1\8OU*(*_+##[Q;_0/!+H[-R^XO3Q
M[)_>X@.5%@1_;RLH'O;W6$Z/.P+1B\.YP885(8P(8G']%+3E'LB<+,<%"&%U
MQ2\;CZ[K,!6C]9D9^P5R"N]<#GC$M= !_7I\E&K[P]$W$J-2\6OS!)R"!P_]
MK RB#@ I:T*[*[=YR9)ZV1FEHL>[XZ^V(D0XRQN8ZP/Y#,O;=6C%@S3HP@['
M+7Z2!30NPR'>64-&X4;-]>V<\ ^QY7<ZK#,R.$E>@WS.?'^.J8,SXM*]ON(-
M\$)8Z)1Z&XS97/&-UG7NQNU_OKIRA(? .;MF\P33N;*@I@$L6Y#/@!+0;A($
MDNA<=QIUO.@<EM:%U&K_626>XYHS4<(<>_V&;K3,AE.E5=-C*38'%L)-6OJT
M:6A;#\AT+CMX:&IRE"I'B'HOJ]MAF_]^/7.!P="S2XC,H4+AQ8[[R88J:1D(
M8/.+ :"41W(<6L82>1B:G*<:/ <:T ?L:P:XGX _0.%KH2D@L$Z<5OPT$%X7
M$F]AKJO3P:GY%T8=02&K'-V /_JE/0U>5.TL/7H'GA.Z7#9\C2-MU>%YU"G3
M.T8506,UU1WV3Y0K3Z2&.KH[-D@,._;\/@,-_RO9L?W779K<U>LO52]\75[T
M$4OOUO"X6S"ZH%;0**ZF.:RV^%_EW+ $P+Y"VYDQ-'N(.)[<502'^CI@Q%,V
MGCKZ9TB(-C@W(1(=A)Z(IIDP*(/>J)[(69S'_NBVO>8&KY4X\09#CZ<XA)XZ
M.^E26,G!X!)*"6,<;"X0#I2DY4<_;$GZX\T1=N>0BZ_YJEGP\0;SUJ+KC"/7
MY,%!,F&&29B#2J88/)F#^@:3;1$!@V'BQ:\/A9BU16]Z^%=9A%]9B2?7I--=
MO4-W#R'?"AS?'67;(:.DT18)T^@>D0B.('<%TZ8)MVF7N]F7CN8IP<14_S5_
M@ 78O&4F5!H;G5BH:'UQ-G=PA"7('<-&+:V8<""AT(O@YP SP&=YZB#'A3"I
M<]%89._8\_0\BHB2TLB,-!S. 1%Y3Z2<#1?7ZU#S2P_K43XW+8N8,VD5D#)\
M#74Z25<PI#5'/"(V/S)>6*TBE;ZPAR"/7R</PR</;BJG"3$WGX[3KJJ\ZC6O
M\2W0N,I:<[WJ'I+/(&:#U::H%(D.KY/002#7 XATE++%L,('\5>8@&V])&/X
M$3@'[N!NS0O%(M+U),*RNSC8"%P07_V<*FN>6GUX5N#<151NSYR@2V6YIVPB
MP?&A&4HYF85P?/H1LK59H3I^VC&;8!V72CB\AF#AY$Q[/%517/N0#G2G@:]@
MGN2J^,I"V+9H9>E*H[ HJ<W$'AV)!TU'"E-JHD./G,BJK[18SZHZ;Z0REB5G
MT$NYG0Z8RC-U/1J]A*$8CC%YU\QP5D8I#3_%T,+@FZ6!2W@E8[4<TW#$M\CR
M+2Z]@LW@<INJLLX\U^CBL(DR[/.0DHK\G8N2VN<L!A-\LU,05C@%/3F"PTBN
MFT#]D67JYAG'M3L"+KX2>I=A-J[)JELV)Z63+;5A'543L#/_3"MU1B8.;!5C
M=Q?^5S;ZEL?AFLO6Y-)BEUK6XZ,.C@^,W=%!_N'[DA58NA)X9=$14XF^B-@!
M+%3P\>4(+# ,MRWMT&XHX\KD#&GX^U>+M+LK4^Y+27"\ ;  >*\L%08Y"DA8
M,(RX7XTUJDIGHX'K:^ [/ZU=V +C [,"N9$!,:UMJ?0A+-FE,V_* X&)HJ6!
MSY6Z&Y7Z_-7Z@EM=:!GH]3YF$+@FD^G$>>URUJ6@''K.!;E,A>XJ80M-9=^6
M=WI%==^8DQ(6#BZHD!'1BI?6"H(:,\8PS]$F%P;TM33M62(-#F\XKXW?R+H]
M-;15;S(]K3&UNR6U,P0ZYXP^>F]**P7M^N\P880&RM'%D=/VT5M=;?!AOY'[
MF(FCD@7KX/'A-WQE>L^C$.]MH[P2IJ:LB"Z[0L\X-,H*=64Y;:H*A1@3,-WQ
MRY"S5.0]5[+Z>J71+=6_J.LF)1KX+4>Y;?^^0OU[Z?Z>G2_&*.NL5;N"9YT:
MT4.[Y3*Y[/#&F/RV[A*-U/?L[CW=I?#BW(MV64OP.;[TP6F=@SX.M*RS' UM
MXQBZ&V7 &OL4&)>9X0@;"$E&"46<S,G(#N XE=N9RN\7!X$*X/#5":R?0&H,
MF([ MB6-!$>9* 3G\"T!RS;J<3E?CBPZ9>).!1C1O())&0V[7+OHD,"7D'S&
M:'A(5,Z3 ]KH8(FMN5?4R#)>7NAK$7V(@PAAOB1U?0U#SY.9@1,<RH$ .NE^
MZP^8EI./SKJLAEKB0O4K[SB=C"K&A->(]/IW&!ND>B0AMVZ[X+R)>ON+F'C@
M5ZQI&H^D74$F%0HW/&!$2GU ;M:;H4@(*<NMH<.!J?\BNQ- !CV"Z&B]T72>
M7C'(8U!NVT^2\X<XUMXWZP_;!^?UB!75E9-=8&*$94N3M15B[X(@RF)ES)_'
M+1]>/3M>)/FP1B7MM>QONCTG7/2FEM4 H0(:_@&,_U*GUO],OQ0S)WM:\5?E
M(#FB7$3I(W)F2P+O(GSY-^*9/0L+.K4D+ARJX&O.(_M;(05TCT4YZHGLJ-FB
M=.@<\,LW3 DKLNKT[PH<:?)[L0'9N$6>^%Z6>L-BC#6@!!LA2F7_VL7!M$7\
MJ96G[3F=*4\V=!.[?7"]P'Q"12&^72#F21V-GJWE/KR,BW]5R:SX%TZUFB2E
MD+Z0I5I7M5E.8,;%+.V2HHV1Y2&> >Z$C M!LZ-?E7-"Y)9<Z;J&WK[5^")S
M&#8="GU6<*./+!=@,\+9'M**\!R9L8W?JU##Z:30GT[3#)?8DHI4Q6_3"7=O
MF[0]Q^8J"U"H.\9O-,*)>R50$D?UH!KFAU!(=R\@*1K1H2.LX..V;D>@HRI[
M-R*[0SHX]#(,.HS-)%/'/#K68<ASCW$;VBQTH]:"NF&WW6&W,;,= LE0EC(.
MZ_V5M2U_Z[S!T,S%ZBET8?8NGA%J1!'9):3*>.+HV-C@9P+C3FEDQ;^!^TA&
M8)E0,DMV2,*3 7>3 LEC3)3*YJE36#<C7]=,\CBOPUH,;7H,*U$K?295'*DK
M@)R4F9,)N?7:@'(":Z=0LP>8<MC>;B8L^")")=#H8"]S9Z&W1<NQ9U'6K(U?
M/P-6:"Y?O*C<^!_?<8M/A\N=/\MJWBYP+3(?O18SG%=3'-8UZ;&=2ZR";OE5
MIUU9 Z535334Z-',$'J8/5W%VA-=R!%0*$FM6B%T"MO"&"@+0?H#B)'(8!K^
M/:2C*LYB36V!;EE1"1!)T6;.*Z,]MX\,%R5(E);ZT9NY^#AY0(.;X+P0"FVL
M:PX>FK%>-+D\^<$2=N>//V&/3RVGG-.M+?<MZQ!;PGX@O.ODBC_9CHGRO.$S
M,I[?OS^48\$9_<NF8;+1WT>:2?F][HXA^:K9H #8&N/*$I1&#K, WL*/^47K
M"A?+X!71[>/1=?X8$ '_%TH7+]K:0=XLJR=64F5ZY/#JGSD.O66"8B^UE.H_
M2UN?'.A\>2O6<IQ:E@GF'4Z^BC0E[7@<ZHOBO(#\S7O26Q.]LX. V9I8_\D"
M*W-K95A*:4OX<E.^/-4GRGTY,X+RGE8&\@T5U(  YB#WA6S:K(&'MFO"V3\^
MZ8_T#8^9,2,3(-_F[!C&9T#;,Z#/+Z*<RD__EW><["#KG"6;9=G@&!SSLVI;
MV";C,#*NUJM^_,"Y8G/",YP'HS]3GS,KW6L)VI\?69V'P+?$,ED2*9\O#Z7@
MFKQ3!KF^Y@^ C^%F=K\)DC3,X+'J?['9I@%;/SK&LW.==.[AYEC:R[\"LXD7
MNMSO'SU/ASND5^L+E-6TB;^XKH$+,S3[R44LP26M2KT>:X[\%I$BITB\QK_^
M@4-,*8NXH7&DXH#B>+9;6[?_WI4XG<$9@'OQ?9%@6-3O3-)  $8H=)20^FL#
MU$@8/8T>EW@UF)$ A D $*@>2R=1*Z399:B>R*8QZ_>%$JA!Y+.XB88 &V3Q
M"GD__/MBB]$'LO-_;@6:::F?JY8IY$[Y 41FU4("13!+L\"7&DFXK,(BP:&1
M6DVF4?)^'>!KG3;[G;ZP2]59Y=8!D2%I HQE"IT6-%9%0!E()I4!0^F[9 [?
MC<E87'X9>M3*_7&*$^BBA.F.+A ^\\<OBVDX,Z)6+A$6Z-QW>AF*7[-I8?\Y
M%=ILMMKO&?AQ5:ZB 50K0BO:'0DI#&BO%B=4/$P@L^*'X=][SXE*+$LXXY,?
MH;+GLST-X5ESWV%;D:@CI!P3CD/ZC2;[?J&R_^?W_GSMN,*HP@,Z&K"Z)I>G
M.X4#70G#H('81&'QS!I$X;4_Y,+7IW3H*.!91]B&E^D$&#LB8\6_H9Q@BP6+
M8,E@@L1Q-,T:)? ,0S&^NNHHB!EK7LDP+[OQ/8\;QT/?+QK$(O\AH0P, :SV
M0=3BAZ-2M/FA'++TY3UH0S'?@Z]_$-$6-<FQWFY5#^]'<CH0#*J_06HPT]4?
MY'CW0CD5^4^%K,;J:68:F4C.CYN5VAYBZ*!ZW]6@4<#Q\DFS6/^9M:A(D8:I
MCR7J="]*RMG..+=)\YYPE>V' C%'OKYQRZM@"4IP@\&:YMRESYO9;'W$NJ6M
M:B)A>M*HLK2OH*@?ZN?2(FKPV*'I8C82/-KFZ>Z+4X@-->R;3328R^*V]:,\
MNO;M)VVZCOVPO'K.X]3M>J[S$KSZ[FOFO!TV?T/^DA_-\#U.<$>,\AKZ_SUI
M_S+\]07+9Q0$3]-A%((FR6<<AF?182P1YZJD83W>56P2PSK&9QK'"^DP_?T3
MCM\L48JFTRQ929+?/%73HM,\71NNI1X)D;NE 80<(*VIOW72:9G_"T[ JC""
MILNJ^+>D@'5IND67=;DWB[6F]4',M7EU_9B ;6T[I,NVOA_NX]NWH.-;UN,7
M)PHMP V.EE;$GH5:BM!#!:B$ 5*V145]IT%!U5-]YXO; 6\Y:S^$)B5T'Y:N
MUN,\3NK83179[*=0$Y6 (.@ZRWO:XSK_$U[_* .5D@(U2T9BW6D"3T/,*?EX
MK-L!<#,F^%M8>K/T10A0#L(&,"3ZIPE)#GV\K,!K_(?D=9)N:5!RG!TA_/5^
M5IKWNM@D-B[L>]U^VN?;\(-*=[?_# P]2^:<]OU -IRU,K73\A<IX.!R-]L_
M\?BF^[<0L!Z(!E"\)P&\:"8I =G\WTRVH7 Z!D9__ Y""R4;4!_/BW&CTDBW
M"?S+U2'ZS6,A9!-K66Q!E9P<(PJ7V[6@7Q5?E(=>]%>WR,P.=(<P/M)" %EG
M]I?D(OP7%!K@G1*1^FYLB)HZ(5(*5)04FP&BX6GDKRK^OD(G%8JF\2=:<\0$
M5PI76"3J0M/&5'= XPP$V9Z+H,4P^*XCFM0[R4+E>PES96,UO+,SZTY.7_#I
M(#TV')OX^U=L 2D4_P2\&(8&7F@<+DZGM"2/B^_71R9"760!7!8_N8(T1P89
M(D$2 \*<OS]GU#\[7LS-( ZJFZ5<>O$A<9XY>__ K>,2+@(YG3J'J-:1$RBP
M);&5-H-&/-""+8Q_)MWYC[@!EZ$61^;T"#X:H,BI3,9J8K)S]C[.%6;[4SH3
M'G](,74&99)YD%]Q/"HYY]1NFP6-GIT(')EQ&VHI=&+-+@TW28E42%;O%]85
M,IN4 ':"T+Y42!TASKNW---PPYP)\P93Q0/0S]!0O11_%2T59?9L2'!'\XEK
M5+DTLD\+20BH)AFPZ]YNXKP%4F>SR3H5/X10?V+J_!PX, [DZ:&482J4_,'S
MY, &I$!GMIE+QTTU G$WVZ@F:B;Y25X%DS-;JY<*@!<2'<A7L@@2D<*Z8B4=
MBO]\YG^3:.K;Y%?W=(\UO+%I'P/#*7O]Q&:48*Q2[V)PKG,?O8P2>*^9&K4D
MYR$\U[;%BXS&$6LH>H4AYVM#Z,%X,0V>#:$#%@;]AC5Q"'LE,R.JYA";F6UD
M'<XVD?*(%(OTR%O'5'6>D8QY**V$8G:OE%SR6G7\Y^  %[JC8XV'V0H13?V)
M&J7@;?-'&K+2\5_7I7/JEVV1/K^[22]*C<67,KN(%0]:QLHZJ8V4]F]M7@S&
MNPR/1T#DC(YG%SW,T/8<\F8GE+%9: *1ET15.E+<'=/8.0Y2]\7*R8NGEO2S
M8Z "M!$4'I]-DBOJ"0=.[9G82\]**XL'JP?"3F)[]^JHN->IQ<$W'5ZTRQ\;
M2,N^W#U0IF:%))4!ZL0YWKG*_-)6 P%?J7HPK.D#W+AW<<YV1NZ[B$I\11G2
M*CWL"+Q#)A$9<%>8S@BQHNL-B?Y7V_+50;2G0=T#Q$TK A_&5P<*?>4KO_T_
MBL#8)IC^@I*/@4L]%B43&;-\N]6A[[+D%7-8CC?4#Y&L<% ]SATF:;/#Y$:6
MFU]Q.P2F#3"W:5#W9D/1:T.!PB-H1K21XLIO;0%](10CU;NLC%E_O+H?2/*8
MC&,)LDQUQT)*']$15/>"6ESE@-2@F1-!NS<T1G1',@1]=C$$:,?@5Y=1>50K
M(WF8A?:Z=;2Y+EN3:#9Y=/*EUSDS4=[JNUG'U?O6RRQ[^U/W8*ZFW;B1Q7TC
M7NUY/%^.2&XV7M'MP4F\.?'.*/^()\F7-4\GMU&7VFX1JJ(AW.QG[1/=VVVD
MP\F <'U6I!^\6*XUN_^MYH:B09V-763N_ZLC(6(INVI6/#(IVVV_P68![:1F
M9^0?*CO):T%L*-NWK"$OTS&$KIFT[O6].3I^A$Q:,3A?_*;H_VHJ3MLB!6M\
M'>0A6FF:RN8T\#WHJ1K /MZ:VZW@],9V=]90"6/V^^"_Z'U]#J,Y 9$&=$-G
M^3]\%VL9-P/A@YO0YT)&\14V^/:O>^S+F988Q^!8]XQA\7GM]TJ%V_FP23R(
MYYJ$CE(WHVLT0(/1]YFI?Z.$U7<?TL?](-S]WG.>!H_-=WYG$C]]%EWSO$=K
MO0.M<]X+)>US#W!C!,-JM&.<B4>61[=&R?X[[;36N\ZR]ZP5]6_T0S,8\J_#
M#SL=8T?(Q\,?;M<:0M[ZV!/'G9__V35ZA_LL:)3S(5;._?((@(J!RCKS!+18
MU_?MDL=H#J%_^T<"1+.P+7UQ^TJ_HGT<R(+\]S,>4B-5_@4S$'/!WB=&9;71
MV7S1Z:H[<((EZ-&<89U!1%G=U_Q>HRT'C*47OA?X^9:=S3K](U8E5((.&"M8
M[S,]$),X<%^%ORXJ$'??$(0L:FQ;7Q32&G,@J./;$5/9W7 91E RV($L]L8@
M["G8/A)#^]Z%L]*%<&S%'&75Z:_=&S()M*\>.L$8@ *6,RV+N6PREA<1YF;W
M"AGQQ)!W;G$.@9OQ&T)JE!FY!]]A1+Q$=9<&*HF$T,WXKEU%-$.Z-SL%X7I"
M2-7%BVU;>:F&XQ$[?G^('!2W1E>V8YD-0(IY18B;,(L%<$=Z)7-^CNJRBVRD
M?AZ6FZ/IY/W;8E>5+V=19V$!25A\,8@@JK )V#9PR/.( /N?A_@FAK@DA$#Q
MF:U;6P-"*&)"CR+DQ#T@.B#F,J= S?"]+\>>;H<0NF3<!H<)L236Y6A,IV1_
MS C&M.2/V':C'M"WY!&RE%%CG2'?:)[8#!ZZE)XC=HD1E>K0)G)>BNH$:4KP
M!4P;0X:G/#%8;U0K:^A72:G&"'^"3R1<C*2K[<CQ</90=TCU4DVM[UCH"/[5
MHX0@-JMQ3C_ZB$@)T;A#2T9U#$QGXL1>L;0=4$P<"V2CUQ\]V(<] WK0D1%_
MDA1B''(FEDSV+4_QY>GOB!R@:_[4S<MQR=%'*/CQ4$L:7"C["@2LAVUEAJEE
MD)!LUH9\D<M.W$L% 4MJEF7%NCIS'DLCK1K"E_#SF_'%"OANH 4M:_"+MT9C
M-T9BO4?,/X/D1H;;CR=<Y7@-BB5.ACNZKC(Z1C*LER7>Q+@ZFSO>C@9P4YH2
MA(8DB(6<_6;:U87(G-L6C8>.7G^W&(\7+_:W;X1QR5;([I.V889E^,@FO(9J
M5P0#5(.[!F&T"/-ZK<.B*/ #0,3+EU.9R!,[,Z5E/@P_1*4ACVS(KM-77366
M3.,R>A,3/2,#(3/&?@,25Z(Z,#(CV\)>Q3_LMX>-L9D+U/@Z/L3GD>:W!*;[
ML/IO;7\*]L!LQ0C3"X;BA=+FJ;/+4C0KVXVO#,X&016M A%;OW0HOX!1ZRA1
MLH!2;:W9,F"@1@40[IEH=W/>/VIA\$!VSZRHN4&YJZNS(?0' ^%P\@QHPJ?_
M>":#&(4+'S@6USEG^"GI\B09@\'2,\@7U2)MO<UT'<K4=Z4XF,T7(#>VU35Z
M!ORY<SZ0@R+%N3R]20]R3:'J1<=6H2>=B!'S/U<([IP*Y5=(P,^;PHI:SLF-
M:LJ'XU9.R CC<,]=0XE22Y *RE3NJ%Q ^5'$&[9$Q2#28%3.1,X;?\"W@Q$F
M%CGVM(1_,@WS.V2:\#B#D%HXUFZ&W._/,>/@] 5L@VM]YS)^+.7RP!-;NORD
MA#NW[%V["  HL=!LX-<JA!YZ"]/Q\^N.UQ0$OA5:U+8;454(I=B9Q*$L).]$
M4!;"+%3/X_D/KPJ%K!6:F+54*-$HO_N-I&TH1$-+(4)UP4PB@Y&YG'^'CK]4
M@^)]BC2F-Z2DRL&<X'SI.^AYM1X#2PD[/_\)9TXHAEZB8-X._R]4E*PTG4I&
MV&9H?@8T0.B,:/&3?# SK&L#]KVS,.A0"=*X:FM>P""A92?!1EK]O7D@R3E5
M*WEC^KIP.>J$\+VG:E&T3!]GU, ]@R.72*UGG'6T,!&U3@B=426:GDL"W] ]
M(T1__2EQ(Q-<@)J*0_^@''NR@40U?=6YGC>:Y=I3/O/T.VX=V6,4+PP'WYH[
MPX^*,L,>?P>^15NO:J,J]2O/T77]&S5RX;-.+#\/^G\YEY^;:><RU*&+ !D2
M3_,,)G>*<G!.]:C.2>)6)[?66C59+FI[T\E67RF#;FO:/^EO]+-*$XDZ1P+;
M<$U;>B:;H[,Z/;D 9!-:Z_NMJ5:]T>Z5_^@*:;!16D_ GLMM(^",,7<])JJ=
MQ5Y=P<Q ^ [BYHZ<JL[M]=0=R:K^ 9)\_76$H>>90A3]D!_ZR\_]>[ &NC9:
M?1<)^SD[QV #QFB$Z>W?'UB[,$02]B%; ;&[!R=TI:,&X>YIP3G-SKJ[=SB&
M-_<)-+,SS8TEA'\,U#H-_#%VNGP,0PLWKWL77DKW5C*)7ZWT0_RR_CT;%E3B
MBF)\[?L2[D/3[$>(T!<B[L/P[,,)[Q?]MX=PDS;#;%B\P_#YH;7 G;@KL-!\
MT;_=))5"K18,+GB]IOWHW0NOW,*FR;'+W7;*CL2_02<H.R!H.R <.R!:/2"&
M')"\''S?U5B4"22G.:3@,:&X01<M3*.R.*0V,#D,-)F)/:3[?BB"2/Z[XY!A
M5PL>8@)'L\\"9\KZ?9]NUX2=QY1-XY!4X^B[Q1&WQQ%/^!'OB[&2'@+YN=8S
M\_9XXFHX8=1N5G9?9NTA>11^'%/F)I%R5R7&6-D3^X&\F#&N ;$TA+)67__;
MCUU^& ZK/V:1)\?$Y\?R_XX57HY5X,Q5<4]4X<S)5$X<$?6/-,+W85ETM,+-
M@1[I^UHFFA[FM'VT^HI'!A:'P#%Y/6%3UGAS'1:(:9HYXK<L@3JCSTU:E#G3
M\?/^WHTCJ$72HI+*Q I29G!Q[P:LXRIE\D2(95C>Q0F=3)VAF\=7$2KJW'KD
MD6>:J5?:J1<N%L&-C*4I1+KIP$>#O>_,$L>5Q_#E1'?LD"O-F H7PF9@PDY@
M%,ZBTV)UILMR:#QWHK^*%O3O));&2C_-V*^-UA_N'()C_?N;==+W\]_"YTF2
MY\N',F)OJ5R(,<_@%"F>U'_5H1%BL7B$B)V)4@?L><\$* [O5(*;99WLEM8O
M^N[Q:ED:%_.HM%J#9I?LTFK?3JK*+JHE3]16;:KG;.3GT'S;<,FBSGY!3IL,
MS&/JTL)>3G'D;)L,+MLU&L,M3 (<+CM?3ML4C<(\;$W#;5OZSF#"K;K;SER8
MU_K8KO*$KG#DKH8DK\8T[.P+]]&T:PWOO]:M''+^NZ3Z^V<\R:E4>(YH)#*?
MJXNDD$,#G]!24O&B[!M5F<;U#@FB0=5WV)C?WF7V/G77FQX[;,WFB<)V'QR7
MO197 XI7?74)7/^NCVYLXP/:C@T<FB2MC^%N^L8N^\ML+S0N(0975QYV8P%7
M-Y";VQ=+?YZ]3[(4NNN9TL,=DFA-X;;L_L[\$B&4SD[9?4+$IBI@94J>)$O&
MF[V]_H7CC?_UVO1&Q8U-S:X-S.D%#.L=["WUCWNSAH"V9<*;,[BS'=SD0X^;
M5AX'2/A-$X\5TJT3PIX3^NE=&,\-1OXEUNEIZ^[IW3_+CO![O/1[G'QG4\);
M)/9L_RJ[M54C19>OW.W!-0T.LK]1U4D-E?]\Z5I-;F$$+G MKK\@Z3CA#T*[
M.)K Z8A6XJW5AZU=%_XY^\35ZW>D9$QX9R]C9U^/>W;:>^XU>Y[;2Y?_[M!9
M70\\S@:^.>BLWOA[W#3MNN*>/O[\^RA"2N0:AV?)XXB?;,WC[4(-52T<60EZ
MR=XY@("#W9(2LO_!U/U7Z BW>%NL\T1ON*D$[\Y@SD 89;,A>:=N>0>T= =K
MWL'U)_*TWS73/.[E.=WM7C>G/>H[/NH8VK+WNQM:NNJFNT.$74W*[\V4'LUO
MGRT<G8=6M[TR2[S/]4"31O^IW[911#TGRK8B(79N7+W/P7S21*G=D0I2?%W
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M$NI*UM;V2B,?;)^>ISSV'VHL/8W8IL(FD*SMM8A_UC*REP?$1W#E';)7T-F
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M<X(QYFDU5I,:?M.$J?ZW9V1BYU2FKFC0)\AD*] ,2;CG2M:/$<:1H0:>#S9
MAU9XP'J?OLP$?7<XJ^+GD'\FFY\B NKP/_IYGZ.X<3;V+>*YL1M0D&#9V8'R
M,/Y8*A/!+LQ"^;E27)IR[_BBU4B;*(\GD/-H1*MVD?=K?_==0J]$'A#$&C4
M@O5%APK$+FAC_1QFS9$$__"/0,1105C"8.:G13^12?&DH> QKSO*U+[$1]>R
MJ/S;<8#!(#LOB7MWLT<ELY]%G1M:.R_[Q8_=S>KS/4=;G!3KM<,ZMD??:,?0
M,9[R\A@&51N-,,JU?^?_,A"-&MN 2$8I!%%M^4#H"D%0@GFLY(,?>&7:$=#I
M8+OS>P.(@A'6'+VEM=.EHQ1I>,&"N96B>Q6%> 'JC==>L\5_/-QFO%ELO(LI
M^T.*_<0]NQJ\"2AG'PH*(Q&H@F CIO:!H!C?,[FXY0:*NZ/:KT(;^0JB^_%>
MHX* ^$'<3T0X?7BMV2Q WC+PMD1 D./-G--#.*U'^"QXHZR+8JOB>C/SAG G
MO.>%(HI$S%C3XQ4AQ\23-,2JGMK#1V+7A9Y/'-I;2^Q+7,C_D]9PX'=II)^5
M&)#U&!C3Z$5*-:!0]<<ME%6WTL[?/"XA>:#@/!%0@J[<I* (RT.<^O9/B4 4
M_Q[D+7Y!%H2_ _>K^J68WR<363WI2_1;:\H\GK%$V,@ EL^6G5Z<R[G?C-UU
MWQ1 Y*D"@&#!@GD0BC(H"N$L@WDJ&90XD6)%BQ.)7-2XD6-'@WT\AA0YDF1)
MDQIWM3JY,B21C"QAQI0YDV9-FS<]OI1(9$)/&4B(( $Z-&A0H"Z+$FU0E,C2
MID675LIS:N#3I42))GVJU.A6ETNO0A4[E"O7H@#Z)#7K%*C3ITC=NOWJ$L!<
MIW*1OKW[EJ[5O'._5E+9-^[?IW4SSJT+5N]>P(SU H[LF/+CR)8K5WZ+-J]F
MSY9!?[XL&C+IT' ['\Y[E&?/7;3 J*KR%2=%G;5G@MG$O9OW1(8($:HL*#6/
M<(E5@"<DV$?@K#Q*"#J'WAOC;>HE=5_7OGUC2NXCZ7X7/YY\>=[6":;H.4&&
M5J'N$[^7+Y8IUE//D1XMZ_5HV*QFY\J*K<CVFP\DIOP+4,'$["(,M;_V6FPT
MU/!2;#(B\GC0KPU3X\O#PC:4RS0-1[R0KQ'E.A!$%$]KD<7+7(R1+PG_0@PQ
M]7KZ1 DE5&F/H :H0\^\B[(;TLB+G,N#((8< @ YX ::Z#Z% $!H%P"D F"7
M/)J$:+SPCK2HR##)C,F[,G<"$LTUV6SS_[R)TFAM@@>NPFHK_>!+D+&VB-AR
M%J_V!(S/]_@#U"6A^J./3ZT2S H 4 Y]ZZBZ)D6P0<E"3,PQ"#%+34*\0#VQ
M0[\0*VRO34',=$)534/U4A;16E%&5U=]\3-;06.PP5+SPG$",V"3S:CKA&1S
M3#?-DZI)@Y1 B+@H)6+HD^7R "G++:=E;KKOED(V.F_![<XX-L$,U]QST2U(
M2%_;P\K.=_.L3])/&.ICEGOO;<6K?1T;5% \*TM4P+'>.I H2E%+M$)31WVP
M6U910\RPARUD6%?(.A2QT\Q(;''5CT^5C%;-B.BC-(=GE;'6E%D6K2_#(B;"
M5V"4V*/'IK0K=O_-9;=#Q>>?@0Y:Z*&)+AKHDA#Z!$J"F@6@V>(HLC(Z+YFK
M0CKDCLU99S*S3M?;7: E=VNOR2Z[//324&,]&>J$CRRU#"6X+>*20T@)=^\4
M5%)+(<Y[T$2URB@M^B[-BM1+7U654Q-W%3745#%^F&,844Y\95Q'7GG"6"LO
M$5?--?\\PICKHM$E7U^S>38D&E#SS7"[YLWHV6FO_6>DZWZ.683"/BB/*P%0
M&H\E&T)+(/+*;3-VL]$\T\VQF8]>>NY\?>#=M_'&\^V]CJ*[;B44953!]\+:
M&W# &R7P+5 05@UNC!?G$,;13W8<Y@\Y/-GBSD'[--?0,Z8R$\EJ?I+_,1D
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M!+G/F%K!)>-5H5F+I,DIUV117VH';,C"Z$9%(HJ$KO!X#+F25*[TT$J6]'<
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MRM:]VWN]WWN^V1L4V-N]V3N^]?N ]]MLX5MMX1N^^?N_XYO W3O _?ML$7R
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M8F+OA2%.8?+M65^ZTN2+$YY]]=F$M6"\*U18X\FBLS-.H2R+RRV:Q25B&4/
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M%V_4$FE38?]^,<0,$\0QXA[MX18R(AL "F@'^K_>;-GD?$'GQ<P)H$[NE<4
M<)@>@L_F^LX2:M2CA=13.<O/.]K6$=H/C"&P8B#=06&Q4A%842P0L2#SL=8
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MU9ZL4Y]%6I$82J$=6CL]2KS]VYQPUNP3'6KED/N\/V[*5F#L3\.(CEGP#F3
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MV=@AU8U\PBXL9$,RY$,Z9$1"Y$1*9$52)&R5'[M%F-HMH[IE)-RUF]Q-6(]
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M3;;DF#+%!+&?E.QQ\@TA "0 V+9U^Q9N7+EMB<RU>Q<OVUV?=O7EN[<OX+^
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MN\2O9;CD#5N0,D?0_+JS#SXO64ZM[SP?T=NVA>3X1+W2DQ&)0NV4BEUH%)=
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M'"%=1^GMCQ$A#=V]2NR [+U6A;TV3'=8HK9>[C4S3.9#RW<I =<J6M& #OB
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MA2@K'4K(55YVJ'Z4['#QPSP N1C$L_!D*W!9VX'@U;2+Z>V+P1K*%'>RCTK
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M(:GJ8Z^V?OJ$0:6(8$I3K42ZBKT.8Z(DT)@L"3(L%FUZR2"Q5 D1P5?'*FI
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M-L5H2!-U&9]ZC7! U<E(T!)*MHYU%C0%@%!+-1N>UG(VJ3RJ2K;:RLS$BJ0
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MOS[D%Q@T\YX)C*O)+R"A][N9%A+>XBL2X56"5FYTU?MUSZN/I^UP8;>;XI\
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M1%MI1&%.G9TT*Z;G5#LND'<8EEI3(I UW7!%L>8EB+ $Z_=AH/R#JK84LAO
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M@\>$^%_>>].-.')%:-%^C+?J5"9%83@^<^G=D,,'.M%4C$#FC-+X!9BE0$G
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MYOJ!I&=[J/S7H>X2N-)%9[%97UN?Y7^;3T.>W>AZJU_^6X0(UYQ8P%=?GA#
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MSP(.$2[3,J!\>4D2:%@>M)\T*MHS)HHT];(V^1@U=6\C(Z<+383(GP$5!N"
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M*\QE[K5J]O%V'0-7/WE!15+"D$:Q%O.'O*#Y+MS#:I?"^)/_7+*Y_/K]3\F
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MX!)KG9<\=O2[+.[**6[VZ<7WLT73TU'BD*8=4Z("TRI4YM]@< 0L,0HE.=(
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M."U9]UY6_L*SU\^8D';&[ZG(VZS^,HMP4+F[7;.1YT)AB:Y3O=!M+4MU-D6
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M,L6>-.&<Q%-Y[S]HE5HV:<QRYW]V703LK"#H5RF.P-/#OX<,[\:K/:_)%+]
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M2Y&17@%@ZC.2]P%*S[B57^E['?%A.TD\UF&)1;A!1K-Y$S6 2_B.38AU\EB
MDA%OX#0ZS76/JJ@KH<AS+\ET>;D77EB6_V>4MWB4A[F0B8)D#LE[M*:&4!F5
M'_B&56D@>U?9%<GX9&"Y%1\Y%B&IF9\YAQSA!X6F<Y.(?HFV(J(0.2VAFJ1
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M'@@H?OA W. U+[JE[H0@,0UJ5,,:3-E.5%D:9 SQ99%'@20X Z&(21[@PX4
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M],( C0)O<(?IW5O-(6",:5;_/9UKF4?/=1ZB_1PD"5E%C-YJ@8<04AI^P4X
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M;#JK'4XKM8(%;C87MM9%LQQ?O X&<)[/O!HBS>IL!U+_ZN%9:J'5#6B9@RB
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M^RI&!['8 F89OC1O#<0Z$^@ (VL!U[.<*O#O(G?*PF%AV^DG#Q]08S!E_P1
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M2MWF?PG6J?/_SO3'UKNB9V/<_C4F;[("][MM_CM >7KU%CK[H#U/<#KR1[;
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MQI YU'F-0BECRAM]T*%G:5U*X[0OC,)28MGA2BUM^;&OV+"!O:C@+\'2 3U
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M1T?[,$^>3#3 !_]H&N[OB),_\:-CY'DLCI7I4M6=BHT0HN$!PBKGH@?<-@\
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M+\?1R*X1UZJ)$J%3)*[RR2H00CYQR+J,-[V2+07B 8@3]3[ <AP(O62&+3_
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M;FR=N)#:4TGM3'[WA7?7-H(W:()[ZFW55E;EUG9O\"NV]((--)#_$R+"0Q1
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M5:\OW ,90C< A"(T?AQY\^>OOKT ,$J\[?O[[_;<#YZ>X0G#+*M/N/.(2AY
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MUG$8\GY4@7XC)W\@8G^J8'"")U[G](4\TUP%4FP-U5Z?%WIH:'KUM3Q,,FU
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MIWA(!JDAJVB%KOA'^R2+)Y9_=2&&7MA_F3<80;->,F2&$)6&S+8D4#,M3(*
M;F@9QQA+<O@ZA@@9=N@=XP,G+08YC4%U\S9WYJ!V/D5-UJ&-E"&._&5[X/B3
M<<*39?]&CGIB=C1(BSE!"E1W-^9P?2:652 Q/IH(BIU8%'KW .,#$_LA"A]P
M:GKC7'_2;Z]6>!.BBJO8BMOUBF7ED #9EBJT?W").+A8$;K8$,B&)P1H7Z?W
M+#RW<S\79D%':R<9."FY$!0H+$L))Z#X3$28$+LW;_/3/J!0/F>4DTJGAVI5
MF-NTDD#9F93!C=XB@ 1A:'V2.EP(0AJ!!FM7$C:S?R1WA<=%"/BHFH2P"QI!
M*!T0F__8 ?=R('.G!M/'$J467NNT8Z&#BH9WD%.8D).'E*:YA Z93BMW>2PW
MD<0F93!TF .XD:#'AA_Y-%SVBZ@G6!TX&3HY&4*);45SE\3_(H+.1!#L]G<Z
MU6[S,F\K>%S'P6?9>)G;N(=X(IJ>&:#9D9[A1I0&D6^OZ99EH1)S-PKS@X/V
MT@M^,HD!.8L,,C[!AQ&$0A$8.B_? !+'597R-IR5V'@'9'AD23$"LHJR@)95
ME:#Q%XOV9Z'3"7,4>8O^EXO8Z4EX97/L BW"(S7!F&7(\Y>N5)*)E(SC:&6<
MF1S+] UB1!"^AT;F\VD'H2^C "_,0!#R1D;Z,F_(<9Z20:#UUHU-*J!H>A!D
MVGH&2A"K%1&4AE!OI10DP1F$0 L:P0R$X D^!GER:FDO25H608T,T0$O.0IL
M-7<3$W'C]Y6.5YPTHW&%!"JZI7C,_VEK5UBB63BC#UFCX!2&YA6G"81>%JE>
M9=BF<B(MQ),TP&-1/#>24H.D3#289J.9"?%?X0*E [&8!+%9YF-\5_I*L0FF
MCS.?Z"-\Q2&FC[&F$>B3:?JLR &:/HH0&Q8KIUEPCL@2<F-]]T$(4R! N&:)
M:MD1G"8K>O$!((8A)"IW]V*A2U:I&\=^'284+.JB+C.NZ\267>B<UFF+V!<3
MNEAEGM>+0"JD?$DUQ9BP?W8;RNH8S#J'R[@V4<I3$)93"Q&?>0:F8<J?G^F?
M;N*-T!JR8^JQ?*@0I#FJTAE6S?@ \^,+'X &\]-V&()^\IAKN,(Q[L1I.ONO
M.@-=%?*SB/]'>)9*A0J9E@RY,-%)HVTID;7(?]<)$1>)&,>&JG%BI G82B()
MJT$4F&M&JUICJPBAG<+R.&'BJ\&E$/#B=W:#K,G*L>A)L@0#H"([MPOQL"A)
MM85CE->7LK=S9[1P-SMRD!7ZD$E5BGO;G&E9N&1)2"JZ,?4:H_L*=S'G.IRJ
MH!"I,!,JER_WG(&QHW=EE]/J+5JK@.+)948*F SKMI(AK7)R=-5#ME(Z@I0)
MK DQK!$6/[X'@L/1L(UAMX1IIG0;O*L+MQ];=G JN34Z%BIF#G&PE(3P"9-&
MH?'H6[ XN4-Q.45KK\AI1\DIA1ITJ9.7J8D+$DGKJ9?KM/Z*LAP_H7DX<JJ\
MR"Y&.GI86[#D6;]5P[5!YK4R [9=<J;9P:L#$9\D44T8:Q#!!4WH8Z6[J[J/
MP;K<(K?"&\$ X+NU_XJWU7J4YQL5#Q 'DA8#GT *I) 2$M(S1D:XKXF.Y&H7
M]@JC<K&X7M6X[G>6D,NO,)JOE1NY<]JT_?J4,E&7  #!/>*_Q4&_PJ@+06JP
MI]N ^"M@^ALP_,LF0IP< #P040HO/D42"AS _*&Q S$HN,M,D4D<O%NWQ*LN
M42S!8ZP0%/RU5'NRBSB]^^:$+5QB*L?",TR]_'8SV1NCW>?"=D2IB8<1++K'
M#%15,2-YG6JY+ 2J*!2JR-L!9,A>>+LF\<LDT*:U^+7$UM7$Y_+$!8&K$FNL
M73PW7D02H6!G_*&V!C$*P#HH_K*"8LS #EO&0-*':].A$!-A<S.-AU(0]/_A
M698IF&V6F7B;;X5;O1X3!P\S"A+Z5;O%PS8;?0X4;$<;1]_DQT_8?G/QN(/[
MHC1HPXBLR.F(>3@Z1X^BBQ3QON&BE^1)ND1LN@H+=*DKS-9$RUUSQL4!NP41
MFREH1ED, +9K$%ZLQ<=QM@M,S_U)S!I(1;BL9V:TRRSHK8'X-I.)A[+<N_9,
M0[=JS";\S1_1O'?3"Y/HS#Z(QWS<S7_ZR'<<5MC<O94JR."+PMZLJ1=3ON+L
M($Q+SND;'Y&<D9,L)E9KR?.+R;&JR?J%@;5G9>P9H&$\RNXFJT/$R=GBR<(%
M4_!B/_(R?@<1F?@Y$','S,'<M4BMC.I<E,<KJL#_5LU#\9*T4*R+HF0DS(1%
MIFCA&U[/6</Q"H4PO,TRC-*K0W\QH:]("9:96]B:9*-W#<F>2W-+33!Y.6W@
M^4/$F,2O8=1C-M9+&DKX3+=IG!!KO+_ >U+SP[;M4YD&L8);.4W]W!V=C1 .
M'"=R2YJMA=<,8B^&\ !%,"_18*TSJ[Z/QT?5^W8E/9=]O+U1^-((2;2(*[Z&
M3+Z<RK?\JL/2K98,)<EE32Q!G22D)YX;9;]0O4%2[2I4/1!B*\%+=-$+\=I?
M8LMT)KL(D;ONPZ4LH6+Q\Z7@T=IJFM&UC(B'!L<*:B]M9R]1U:=?!65SG;,M
MU&LE?%[6C(K9/*\;P<V#SG>OM,TJ-SS8E>>:TWU^XNK#0/Q0/UJ_0HU1"$C9
M2CS/8EW/"BTLKFO>L8S0.ZG?WP&RU1/?"4%]Z4/%[WFLYH'?!O'93DRU;\HG
MA6R^3%42%0'@/]8HXV7',6$.YC %4"[E4![E4U[E4D[E5E[E6T[E6G[E6,[E
M6W[E?Z'@]G1XT?55R%U=,7W,,SV^%V'3.#S.30Z&CKPX'9%>G+?9XW:&EPS/
MD4W418WB^8O9/<FD+KZQ,/ZV*ZY7'QXNZZ,0^DR/8/U34]#CZ*T0ZKV=_PDA
M@]05UV 9<%L\$0(^:?9DSEPX!5F^ZJINY:SNZJVNZK'^ZK(^Z[9^ZRV!X.E'
M3RE*.BO:UQ/^USS; 8)]N81=G1N>HW2YV%["YX=X<[#JSD@<SZ@+&SY>$$#>
MR1&;Z)9M;</,=+#M[,DQL8^Q3.7)XYB^Z"/;Z"6;$+)]S!5.ZOSQ"6A@#L5*
M[VA0[W$ 3\@ "4#VOXYVKO[OLP[P7@[P!#_P6?[O!6\.=0PSE&K<7D5'@[S<
M"XF%-?W<2BMX.=WO_3X4Q2:UH-SN\!O/:WBP[$S4WXT]X=TJX\T0C<WMYIGI
MGBWCWL'>:V/NE&'C^4((7_S4BI[BL)'M4UW,2'6OR@X5_]M'3@/>B ;>3OJQ
MZE%^\ $/]5"?\$X_]57_]%;N88TL:QQ72/(DD&(%["M-X1X=?\5NY.BKS8&W
MN6N/S)T+$5/&V*%++"7/<ZR$L"9>[>>M[@TL\[?D\@?M\S'.[F)"XS_JWN7>
MF 9L?*EMT/O)]XZQZ85OO$0^.RI'?TZUFJ->EB7FY!=!]04O]>; #%C?ZJ0?
MZZ5_]:B?Y24:%4 [EMQ[G+82\9@Z\33-71:/]N.K\=29X.R[YQH9\DD,Z'7?
MW>-)2B?O/"E?)RO_\8#_\I#?&)(?Q(].+/3QS_)II80* (E2&3H/ (/R2DW]
M^(+/Z. ^L)T^]"3"5H;\ +X PO_P'__Q/SDCG4):WR!27_6J;_6@O_H 86[*
M%($""0XT:*[#AX4+&3YL"/%!APX3*U[$:%$C1HX3(3*<*$OD2)(E39Y$F5(E
M28<M/SR$&?'C1Y<19=Y\Z9*A*IX]??X$&E3H4*(^;>:,F;0FTJ47F<X\VE0I
MU*13&0*;D'6-LRG?XE#L . # +)ES9Y%FU:MVK!KW;Z%B[;77+J]?-7%:_?N
M7;JZ>OD%_%=P8,*#!\=-NU+Q8L8D$:--553R9,H]5SW&C)AB9LZ=/7\&;;;Q
M:-(F/4>NG%JUS\NA.S-T'5NM*$*<T'(B-(HL*4*]??="6T@W@%Z$2 $H1$@V
MV=+-29__7AT]=>OEF=NF_8 U*S"J4J-:/8H4Y,6)Y5MZ;(C^:7CV#PL>?!__
M('R$!)G)-W=_/O[Z\J>(QVDJBBP:L,",#-S(HO$86L@Y!TNC*4*<EHJPJ@DE
M_$ Z#5>3JKNG/,1PP9O4.X\]$M?K3KL)M.%*C:^NJPXS&&/$K# ;#?/+%U\"
MRZM''WWT[$$A4X)N0R.#HHY&N#93LDDG71LRRI**/+)*GI)\\JR%L@1M%$(,
MN8V00LHJSC=SY"($. #,^1( 0C"I3DHY9?',2CM5P9)++=U2(*L)@*'0)O4L
M%!!%FRABL*&H% RPP_#>HV^__B:-3[]((4V(ODP5\O"[ S<Z_1!! Q'%:+PY
M3Q5))U4_O- [\ #,Z4Y9>6HOT%==#?&[7"ML%$45M^KJQ9?T9(O8M^CBZT>\
M_*KK1F=QQ#%(5(6L<U8C\S1V(F/5,J=;;[\%-UQQQR677&FG=;!::S7$EDO8
MMH67+"_-*E.Y.-%-MS/4UHVN76)G-*N#/K<#T5->"VW*/(4%153$72_<E-)+
M)>4OTXDME@_65242M6/S0C4O)HOPE1)#72\\^%8,^;72494+/O'A3A$VM"H5
M69S"Q1@ AI?G>)]]=BX>YTHV666![(QDYZAD>;IXRV+R:;+*I;IJJ\<]5^G1
MF&Z:,G^?W%)JL9W4NC2NNY;L:R[_?29+14!9W97F5=.+BE2ZG6JO4*@>P%12
MBC5%2+^*)YUXOUJ9PAOD40D$%50&-RK[P8WGAKO5@F'="6T-#[_<UL.=HLFC
MT!.V%;Q?N?(*+  >D)KM;8\N>MEFH06:]K^RCERQLS4?2FVP7=<SOVZ_$9YX
MXN\SOGASCE^^>>2=;Y[YY)^_#_?<5=J==R2??G=L[^^]7O?.M/=Z[+'4RLY/
M[E &G7/*#:8[9 ,=-OC@A0;GSV__A*_O8HD-TABK$L<XCX&E<0TK%:+"!R'X
M=0Y%A')51,C'H0>R[V4GL]_,<%6_AIPN9R_R'O"(5;N@,0MVR$(AT5!HO06:
M1E\3+(KO_YQ4$>]YZSY7PV$.O\7"%CIF?# DB@QI%+;O%1%*/232"X$H%"$V
MR74#^U,$,VBRG#R %)Y@!D'BP#&(%"@G>*.*WG"BO_Y%+'_X(]P9">(^I22H
M@*%*X$9,A<3%3"Z ,Z-B&%6U1,JPT7.56Y#,++=!0D7(@ZG;S/GB)4(]V04O
M1CN:[4@H21[245U\_$D3A\C()W7KAM"CGO+N$TI2@M*4TCM3TNAXDNPM49/+
MZ9X19:G*54Y)B9ADS=C8)C#U[<V.&)P*;LSA"4(HY$1@O!MZ8F:YCZ!Q?V7T
MW]\*E[$+#M" ;W1C1T@ULEJJA(I^K. =&XC+HKCLCPX<D8G4Z?]+#=K,3]JH
MP@>CUKHB3C)HD<0G7BJ)Q%8"\975H>'8A-<\'1;4:OOL83]A^,_8$'&6#WU,
M-VW)&7)F4I=N<5L#\R;%A^#&%LGY!!K08(Z1BM0<7^'B_#AX.3*2T8P2 UPT
M,?8YCMU-<3<%8TU#(E&4V/&"[2S='BLJ%' Z4) T.VI0675($')224Y]4CZ5
M94])1HN6/%7H!!DJFWD^S9/@FE[TE(=*LH[5K*A$: LO6=&MAB:6$(6K6W@Z
MDJR2KZT-74OZ"";&FO7J([3Q36 %BX9C*LAA*EN*,V6ZV&>^%("O&EV!#GA3
M DJH07,UR3>-NE% ?F>H1 WG.=FWS S_#K)F>>S@.U$7AYVQ3FQ0=1)5;Y1"
M1ZI0JG1)ZP+KJKV[AJ:K\;(A00TZ7''E-GR[Y5UO/>/0N#87+9BETRW9>M&U
M0'%][.0L:ODF6.[V1B%XDZ.B0ONJEF(,<"^=YM_ZQBG3?NJ:E!45HTBT4^B.
MQ*>B!2K<+/39H!35@H2DVWI$QS !*]60?@(6(L/BVD46\9$/MFUMA595V=[N
MJA)=*SF5^QEMC8UYWQKE*8572N:1>,0G)IYQKX=<S6V8,V]U;HP! -T,X]+%
MGE$D6GBYG?<%T, R(1Y(22I2(J-ABY959J_,^0'%]DV:ZTVC2P\BSBK:;;)7
M'A7]T-.!^I)$2[/_#2=B(\1?H"QYLTC%($T!G#(510(-\H3M$.M)X:I*-781
MYHLO5)P[%J/MQISY+;R"^V'B%CJ5G*'Q#S_[Y\<P5\;.331G]C7=U_]BM)<:
M1:>''D +3C##(2\!]>,"_.7Q/J2\T%1CQ!@+S35VCCS8A'5A2?6!+ML7<Y3#
MXTKO2^:?^/>GHTYS.V4&P9PP574YWE:<E23AVZ*PPD#;<^3ZW#5&RTC9U?EJ
MN,KZO&V+E=MG%6NTRS;MIE4[+C!^=%PCG9E):YBZV,DH@ ;L8ST*,"=QZ 4I
M;.'I;X*WQQEL\JE5#67_08K*-ITL?+5YV(O46B2DQJ]?V_L07ANEU& 6-C*K
MC%V1J5DI-VL1"-\]MF=#J]F1%+?6R,TR<VN&P5(;](D-/=R4*VWE_&KY6QS]
MM)+WG,XU)UF-,9GSN#Q1?9B6^+ K8@C!CN+_/P26(C/':%XI-S;* X]I03XW
M7UC#UW&A<K@L[@O(TEYNOQ6GU9DCGO&RKYG8"S&V0RK]O1]!\F@^MQ'0\25T
M/A)=Y]=>3K;%56(1AYCPAS]QB*MWX6[RW97< WQUYK*+R5>^%Y2?\.PTWQ?9
MV1;SF+<PHC%[\W7Y7>=KV7$4-Z[DN+D*L$UGAHB0><SQ'B7@5"=X[JO^'\1N
M&<L*3Z"H'1)VB),]NQ-?"-K3/D6,IY/M'D^J.[.",YU%'J_?P[M@:'MGJ>H=
M7:2WENE1_W*OWC!YQ!OHS'/H_6F!?U;BUS&RI<8L9F&>_IPWX=#TKWV3WY_R
M[$<5]Y,5^"N6M8BW_T4!IJB+"5_H#5'HA9'Z!"\9!?&*HVTRLU4Y-?5:M0V<
MJ4[A.H7#,OEJ"8P(N['+--0JI)90/E7PM;5KE7D#-BX:'?T*E+A;,'JBN[JP
M.PGC/CJ3+0 \%0&\$P+4,>MSC>$1ET\*I;!B0NAIPO-K'B"<$R&T$R(L"W2+
M%^VSO\SC/R[TPBX$P]HRH<N30CEQ/'\RG[QRFQFDJ7IK(T0@!%10F&_PDF^8
MO;K)-0RY/5;3/:QSK($X.!%)N-^KK(YA".)#.N-S0^3+$.6[P%\[K6 SK>BK
M"0]RD4!+MCG+/CO;OA5BO%JB0BNQPH QPM#X%O1#/YE3OX/ZQ%4ZPX5ZFO^=
MR\+, [W+TSX>*0S#Z#_#R#._^+]6M"3I<K>Y4POK:@@ D,3.JC?<0(,N>@!A
M\J(*#"0V2HH,_$,_O+K_Z8^M4Q10 3Y&N4.&*<%;"\2V@RRA0KL65,08A+YD
M_+&/L$&QP$'O8;:34Z'L XPRE))7U"JQZ3"Q";'T2S_S<\*"[+;D(2A4/+3,
M6#?,:#<;@SP',Z$M!+TQ'$,OO,@O=*0QW 5]C))0K))1#!C4LZY$D3JS(QW:
M((68B(/>B+UH+#"/^XX]E#(.W+U 3*!7 \%D@KJ'0$12.T%<&R='O#A(S)5E
M0LIUFCB8N)EXNL12! VH# U\#$-[Q"U@Y"=AA,@QUI%*SP Q)"1(P5._3\HV
MCQP2D#P2D91%>+D_6ZR\_,._SC.Y"0N,O<@1-1&]N>)'N_\:.;2(MU!K0T9\
MG%UHP"'SA5#(C3:R0%&C07*T1FW$1ILT' ]D& *"(V]D%"UKB'%,P764F\:,
MB154QTQ;LTD,-F*["@1;K<WH2NMPL+SHP4BB2ETP2VK1RJ%[K=;D#"042++T
MS<(3I>#\)$*KS0?92]Z*2+K;0ENT2,Z+R[:4G8S4OKN@3:Q,J-OLN[XT"[WZ
M$P;)0PNBF>3H+L*2Q,Q4P(B@2?.*S#Z,%)RT3,PLH/!*J89SN.(+2IP<,Z)D
M/J/4N.CS3UT#N6!I+>WD.1^DLTZ,,)2S3K7"SL=K'?(#KN 2KN<!R[$$EU$J
MSGR1-/Y22_E[&LOC/\J#2XW,O%S_I$O!X L3RM"E:5 T),:T,$902\;[?(@8
M (6FZX7%E$8O6D18><SS>K(@_4/X4#-"!#Y_&X^[X<RQ^R..2KK,24>U\\P7
M))T"L](>C8AXA-!_>4U\XCZCF<T5;8[C3*[<K"&"^DUO2<6O6D*#-*O@[!8Q
M-9L6A<5XP4*VK+R*U+S]V[^\D,Y;##V&'#U%&RJ1O$*2O#36<U*$$9UOV 52
M( 5S ,S2,L^^BI#T1+5L7"S P<\D]49M<J_@*Y&*^$E,H]$FS<\HW<^U^T]S
MI$3Q:+,W>\H0TD0#O2<O15 ]6U#=HM-^?- SS;8/6U-"*[0U'2@Y?0Y"I;2>
M\= L_#Q:_^2_YI3+V9JMND#6K>E5OGQ1OSRZL- U<G09[W2(+4LI$63,'JU&
MW,M4J[-)W-,H^ S5WV/,4#E$AS-!,%O472/*YH/$]G%5=P3-FXC'9ET;!XO-
M9J-.6Z6=:VT,M+P6,QT;"DU3WCQ%L3K(A 2KKV)8QG#8#1').]V69W5+:77.
M7/Q3_@/3P]C5X\I6Y-S6[5Q#L%#&;Y40$@FP;J12F;Q4(%4C(=54*#.XSL39
M080U3[6RS:S/1#S5F?T(T2Q*5CV9I.2X$LDOB C06270GU'8VK%*?5K9%6O9
M,N5*8 VNX:Q88]6A&Z+08_U:/@O;%HM%@GV=MGQ6N!S1/9U+$_-5H8U=##*%
MVY<UBQB548:;M\\\2@*K*=F#07),5SY<UW;-QO5"NBW;R:Y+,OJLM7L5,Q34
MURCE5Q=$LW_=ST*)NV&9Q[&I.]K")WSD6_&A* [U1]W,##45R&'-6,433HP5
M2(%LW97P6S]+3GH<V3S=O"[LTQZYR+QK6VE[6^ %7+)(O?5)1/!$U;J1S\C*
M+]OCV:S+5,C50,:]0R.]*>$S6BY+6J#$5W"UU.33S]$<K78479UE2M7ZH)VA
M5>S;VCK#,]7]D=[%GN:E-H@5F]Z<T(H=KM],Q>?QWR3:T$6+VSFS/+MU3EWD
MPA*J2KP45+T$X'+_R]JVZ59DW-RE5-0J8YB;]5?-_='!\5XG2XCIM<S*/==H
M+)4E!=\05KI;<]K/G5(!6=P3GD893+J6T-+3%1N$1= 3[;D%1HF.91<!ACDV
M_4KEJ5 H+*M4)%;>7=YQVV"6"U[4U<+B!=2X)-$)OD>5S4NL4M9AE!J"Y4[I
M!5TLO5*EC,GL;:;M?2:?A=R@_:5!D2S+%=7K-=]:L\_T1<VA5%7W%;/2#%WY
M32VM"#E,-!;9Y8S9O& ?^5(,QHR&?(R'Q,U?%:@UG5BQU"%0AAZ"4F)62N.M
M9%8(WD()+M'H1&+CI>"K/&,,VV*<ZV  $-Q.%6&3809#X 11^ 0$-.'%_^U,
M4U-7#63/59/<XD.XQ8'F:*Q4I,W<&K[/TYR<'.;/WE/D;@Y8>%3-8#DV(I::
M([;'A$WB+%:Y5.[D6)3DQZ!=@C3;>=9=5!(N45[34W:A!B[4+BYBMZQ%6:Y@
M@9;EC"0,?9XH=H/=YT7&DIPU0@[BU6,(-@DL3J ):ZH]*L)4/%[FEZKAFX77
M SJ@CEN04M6LI:5CIUU5SSS<J95HJNUE[H0G.+M?[Z'DH>E:A/8A?E[61=K2
M;0D7LC16LHSB)$1"*\[8A<SD0>5I-4XVN366MC19,D[>S:OJN_3$6FX\=LY.
MA@: C/)6&\Y7+A(%4=B%D2*%43"')$M<ZG7,9/^^QI_EZ#)Z5YR-UX[AT;N1
M$!H66F7D7/#59JA-Y$B,7Y1<JG!&)&3T:F,YH025S?S-1W6VN5LN/2?V*GN^
MYP_[-B7TML&+.6_1:;KB:@>%%Y!E[(F<UA/=Q1'%Z865[*"C[/#KX#9.E!V&
MXT_X!IK@A%[PB#@H!$G%6:--4F=F,CM.KQ569D#LZYPD$*\[6L7TR?,U58C&
MSZ-0:40.%-*"W^VVGP#UB@%=[!&";/WE0?[-B] 6"2:6#D-%QG=&#,^F6%'^
M[ M%4PF-9_2.KJ96Y:=^31&=,#W%2#^U:C'N$?Q6[W[)Y5T6Z_5E"-P0!?;Z
M -X8!4[ C5'X"AB<YF/?QD"XADRYQL9FKFN>%-\>'FYJ[C+-1=6_3L' 9NGT
MK=(9A''$C6BX0^P7N<%8-%@CWM_GW%H#'VT7?9I_E!J"3."*E6=5'*B ',CY
M5NJ(8FJ%=F [=>_'"%$0A4XPQ&GH;$[EU6I0_/$Z76-$)9B'7O 4- <XK WR
MC(/7&P7>)G.8U+A$W.CUG&M.34$^%K[*#2^NJU=!5EKJ'FP):E\I)4W"YNZ8
MCE6:SN6H'N];C:0[T]4N=\78?C_+CE#ZCN_=M6\"%CRTO2$??]TH7V7\_6)=
MO+]3A^4PKN2Y '4H[_]GKP9K$$[Q7JZ(;[C1W-B%BH@#@6#K$_8]S45FQTUN
M.J?SR82?X-;S]ZI9G.7K7_)KFLWF?=WF)B5Q;[YATZGQ<<;Q'#3GDT/G'G_M
MO:/T ;1T0<-LI$8_PZMOI Y+X0JK. WW[QOW(?3G<@8]D07CJQ;P"7:65G?(
MA2;G*XQ9!"ISH9P(6_<23/"%+7IS9RSAS]3>@*O)CDYNWIN<R_T]^)I/<C7I
M!D)I1KQN0G?QER9Y^BEY *5?K UO/;GI63XY?]]D@/=ILJ5=42;JFL_T=K]Y
MY(%YQ.#DKAYUX?7%5]YR L];52_OGH\+,F-OQ:ZNHYO4[V1P0?F &$CKWB#_
MA3BH=A'LS[%+82!%[L::W*--=G_3:\P]<6NF;FS&86D7[.HU].<S[ -S9'&6
MNX"?Q<:NQ[N#;*6'"Z8O=Z ^ZJ)6<LS.[-TM\GOV^[< ?"EWL%K$=Y>O:N2E
M?"[/8#36[W;>]K2(7G&]YAJ> F 6!5MXB3BX^E$PA&\8,#Y']N*;<P^7:SMW
M]E$5OI!N?>&FB(Y7\9,,=(H;=!V&F4-?Y*IUB*MEK2E?DEIM^2/>05:/]_:;
M]RI\K9\VEGMV]R6'[YP__/1#O\5WBY\G;?XF=5S42#Z-90D^64QV<@W.?*#?
M_+2(];6?>HKV#4\HCP?P!4SHC2E 0" &B X?/@@D_SBP(,*#'Z:8F\+08<.'
M$AM2?!BQHD6($S=>U,A0($B%'3H\ %D2),F4*D^69!G2H$J",07*JFGS)LZ<
M.G?R['DSH<&@"8>*% KS*%*@"%4Q;>KT*=2H4J=2=1J2:%*C6*]J)5BR:$JP
M7X^&S=J5(+ ):M<XF_(MSL@. !X J&OW+MZ\>O?NE<OW+^# >7L1]D7X,.+$
MAPT77HQ85R_(DB-3GFQ9L%Z?FC=SOHDY;ZJJHD>3;KKJ,VK,(U.S#FSN]6MF
ML+_!?DW;G&S:N6O?CHV[]N_@YGJ;:PV@,_+D.8V'+NW\N=/3QJ<#($C]^EW"
MNPYO[]6],N7'AR$K'J_8<O]EX\K7)S<._?USZ=B-?^#[(:U:8#*W=N5OE* H
MG.SR&BFC,!/7 Q_H$HHY9,'TU4L.$L55115FA%%'&6F((4<:63B%0DF%A=!)
M*JT4EXD0)G72026Q]Z)R$LJ8U80A\L=52/#I"%V--!;EXXPX@M4?D36^!!)^
M$[ UA1IP^36?<4]":1QZ58)GI97E:<E8+X:I!R.8.S&W(YE2R3?E9ZNAR=IP
M;=HV&W"R ?<FG'+^)IN=PKGY99A]VN1>F8%&MZ9J]1'*&GGD>4<89-\Q"EYX
M5T(ZF9:$\>EGGV,**NB9AP(F95X*J#4!, 792*2/7!G$22\M%H)&2R-]\ !<
M7IG_)*209B6T$:\=6>BKA\%N>*&'JAYIZXDIN:2LK _>BM*RF$K[TZG_'=LC
MKC\J=="FW5H%Y+7:]C=6KN4Z&*2U0R:YY%MQ5>=I8*#""UAY7')9*;Z&82FI
M9)=.^R*@WI+9Z;QYE52P:[S!EJ=N"_]&''%T G?;;K#Y^^]ZF@JL(\$(5R>O
MQX-U1ZFCE%:JZ'GB87DQQNVUUMS&\'4<,@ @U]6!J/G)=&ZX_A%%"B&C<,))
MT$4@>**$$*IX5K:_$LMAA\,".RRQIR(THDS+CE0BU]F2*.O6';2,J8SFWIAN
MJ@[&O"FV3+MM9(O&JOCUBL:B>]^HVE3!I),T]^4W7_L*1LZOI/A6RO+8G&F\
M=GR WZ6FXW;I*5S$>,X)\9UO-NP;G,6UECA[BS->VLP%"Q1Y7MU]-W*DA%.:
M9>N.-88XZ#X%/+ISI7O_;'-=298J5[@\%VE4'*(0<OPHO3 ;E[.V)FWWM@;U
MZA&P'W(X]?740^0UB\^ZM&RL83N?[/BU@QG]MF?#[;.-N),)O;AGHPM_S\/K
MJNVZ;;4+/.HUTQQ#'-XBP #&H8 &/" "$ZC !1;P+=%X( 0A2,!H$)"  [R@
M!3.(P0UJL(,<_* '0_C!")*PA"8\(0I3J,(5LK"%$712'"@(PAF*L(9O82 .
M<QC#!%)0AP:DH N#*,0A$K&(1CPB$H4(PR8UB89.M&$'%]@D!-[0ASJ\(19W
M.,4G<A&*7?RB%^.@!B"&$8QF%"'OIL0[O.F,>>!ZXUD^$(>&'.1$<R.+TKPV
M_Z20.*V/VI.:L++W-(=4ZRIY3!8BP]<UF(PH+.:#4=F$I[Y"#B]'[M-1V^07
M/*S!;7YI6Y](DJ0-_<4A!B3IG_]0J<I5LK*5KLS+*5\IRUG2LI;4.9TM<ZG+
M7?+R9G_)&:E,];9AZM&0XKO5^&) QF4NL(=6?"8TH\G# O;0F<RLY@ZQ2<9L
M K&;,5SF [^9Q'&N,)L[/"<UT]G#*6)3G>DT)SRM:<XF49">8M0B/NN9SWOJ
MLY_\_*<] RK-'#;+;,[#XX3(U;S[.2A_;G&27.@2N33VLJ(6O>B\((?1C7*T
MH_2AJ$=#*M*1OJLOP-0/V-ZX24J.;UG(8F2)4"33F?_2M*8VO2E.<ZK3G?+4
MIN +F_>8%<EB#K6HN$+)?G*:U)XJ-:5,?2I4HZK3HGJR?IW,5E"2% DT\$VC
M$R4I6,,Z4J^*M:QFG24NSZK6M<HRC;Y;S4KC:E28'@V9=F16K"0YHX'PM:]^
M_2M@ RO8P0;%5K$Z+%X3BUBM=:^1C+3;0>DF%(5&-FXVHBQ0"JM9OPJ3KYTE
M;&"'HMC1+I:TIBUM7HFJVKKML;55=1O3'+H_N1C*<2!E*VYS.Z^#Z;:WOCV4
M=7XKW.&JT3Z^VT_\AL30]$%H>7-S*5;9)Q2D@HVZUMU9=;%[W>QR5T(SH6NR
M&!NV[X$MM7F<ZVK3BUY&E@WS1]M]+]K4*]_USC>ZK3T6:X]TQ_%5,I1Y:TN3
MR JXVQ*WP :&)8$/K&#?IG7!#GYP*O=R4F%.\I.H*B^*S@M4\UXUDO%E*?I
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M8J^B;/(6QUM:K_=2HT].@32::<Q.2=;2HD_F*LF>[8ZVK7<2 LV(9%8VI><
MY?Y*I4CF8F^>8S0Z*G8,Y#.:;%W@ZSSJ+M&^;S/Z['MR*J$^V]V.YUCJ[UMF
MY2X&\'K:J=5ZS/*.[]RB[_+*;<#ZI !/R6B"ITXZ\)'^(GG:9YKN(G76;<?9
M)2':8/M=8*W-'G6]5.HVZ ?,[Y\" %02PB[(!34:1#3J A0?3_P![U!H&&+)
M6HQ:8FI!BX5F)'D*HT%8:$5>9&8^0+E^0#22PJPT<;O^Y;N>8K@YR!@C3Q6#
M0ER *PD?_^2M?D"Y/D ;%Z9VVA?O.J@DG5QK@B:B,>P&F\[QBB/W5FQT7BK;
MJJ4E(TSU'BJI]J8UTJ?;IJD#?VU7AN]UZ&1[EF_S>B\HLR>>9JI=S"PK#:$L
M*?'L)JI=0"K)(F<N:Z?'F&O9>@X+%W!=O&7*WK+VRF.M*O!UT&-R?FQ]TK!(
MDBP]GN-T%O-Q1J5=1*,RHP[5LA+2TB)XRO*N9F7/BJTI>\H25^PRMN>N@F<K
MU[!UPC(V\^^4R"KBLK-[WG(-VW-O9F69&BTGES".FI3UD5^\CM]_KMBMJ!_J
M#MQ U&Y:C@3&?L5TEL3Q**A 7/2, F3WD!Q0F=CH:8W_[>)! O)RT"0(/)ZN
MA48#251G2<#C-SR )Q!"*)R$2.Z"WH6HPFK+@M9;O=;,2G> Z()"2ZRGOMHL
M050G0<AT!Q -)N"TN-9,_NT1VHFA^\EA7[:D68B2XQ5O33ZL<W:E6HID-YJU
M7=#PO+QI!M^%\:2G]GH.T83"/FNJKJ[MH8BD;!P/,]2%]AYS5F;R?7;O%&SS
MRT)>_$*)1)=PF]J%46XOVY+LKG9M7J]SG*8I,T@P-)?R!-NS*S/SE)BL-->M
M83ZP9L^L6IMO'CXR..-L+-^U-LOEDLIJP:3E7O1J1@^T7+MCKW;VO/BR+T>V
M*Z<G/9-R;O9V0?_OQ5N!!56''7H1ZR'Y(RKNW)8MMF8R,2$<I$"PZ[T6LD$0
MI/'-(=PYY!9JEQ<W2_-8J+T6Q.4^ %3J,4H3 D@@IT!H+ZR\MU= ZA.GKOS!
M:QU++O 0<D6^]WS/[DBHZ$L[HUQDZ,Y"I8>V;BT:,OBEVD[3,2F.'5KLX$/!
M55C;IJ[V(C\#0&;OK/N6<&].,KRP=>"D*7W*(R(0)2RCYUTTMJ>(MF;3I\?F
M=JGR]7 _*@^[:AXF]GR0<U[0.-MRKUKK\[S<*E^8[S37,V>[*FT?RB\JK<W6
M!52"YY-O=FK3ZM0*^97R,%[(N%W0N)'+,\+8]E[0L(X+-MSZ> D#^9K_&.K:
MTO!@7W+^]BB<FC9!&^]>Y*V("&YLNBOLL1\F N["X9B%XHI!'H1^0[A.%_CB
M3OA&!M6S;*&&D<^Y;<TNTC59P.YW$@2"?P!R-G5F?D"C;[>XHB3J,F(+PFAC
M<2B>UC0G? 5X+_I21Z6IDR:"1N5)0.KIPGH,MF9"3W>BXV4'.!H!GND!/JR1
MGFIL[WA]XOFH3CN\W/!?E*5N]SB>DW(YPXNH:JF.\G+VUNTY]R;V0KF9^J K
M[2)?"'3W"G.G=F\W$PJ3\T69;CDYYW8F+S.\./#:FJI ZWN:CG!GM[5ML?8J
MK:E>$#DJOSE9UW9NYNDJ?[*YOSD];S:\_**L_PXJM],S//HDO+=XQOEP,"%D
M[ZI<\'6Q4\T9*';D48SZ56 W)Q@$B@X$?1/$S8>W*K;\>,%9K!5Z/Y*$>@?N
MK'AK?*=$SMOW ]QG0:!Q'"=T?UNX)A[5<XGN89:EJO-Z?'^W@@, @YNGTV^T
M=IZAP*FDL5>UG:U]3X<$P[)[USTL7>_%+.ZRCLHB;[)PC?<D7I!R;]*EF\\]
M+$-JDNKXJS[\.6H[)7.VM!=V#<\]^TJ[9R.V+1$Y7N3J,N+O]VJV\ZJSF$N[
MO&<EP7MV;A]P/8/V=.BXNP- S=HSO-.CEI]VFLIB7P-EO3O.-Z]2OX\Y"[^E
M/-*G.7OYH<ABU]+SG?\O/@#(M"N?8^2_*9H(-"F;[_&?,]O2)2F_I7ER*I!Z
ML]?MYW11.MMIJPD"^'B[&D07[O'T!S6Z<:_+MZB+*\ZG]*N[Z$IB^L\;>G>1
M!#S>]%'4-$",>M!!%R%"YCYT &4PX0>#H@86//B!E$%2 PT2VC7P0\,.#3V&
M_ CR8TF2'4>F/&E2I4J2'3@1&@6 H$%S#\S9_"#*8,F%A#I@)&0HH41S'2H2
M(D4SX\:6*%>&%"F594*.54U.K:H5ZE:L)S\ FS V$IHI:N)TZ " ;5NW;^'&
ME3N7[5JZ=_'FS1NST-R,?PE]<PO88!R]A]_R)#P3P.*VO6RRY<LVCD6VA@#_
MCQJ*&*_BOX(!5 8\F! HMI /2B;4%\"WS 8YQSZL5G;MV)@)S2U$F% OMYH!
M@[9]-REAML#_MF5FT-=EV&P-&F);W*!F3L/A4C?H&SI@PVQW7V]M4)?SW*%?
M$_J.??A']N_IHC8G%S=@Z6WK9UP*/VY.WO/S,TBXZ$Z+#(#)QOL+./X 0.VO
M_0! SL #5Z/,,@"2^BZ]^1BTS2ZYQ!H+F*>ZFHHJKKX*JB052RSI*JO40K'%
MJ+)BZ8&?M (@%-YV*2E"PHXZT:4:N4)Q(!61//+(A&Q4:TD6790P(XC\^PN4
MAGXJR2!0@O+%(#2"PD1!\DXL\RDB93PS*AD_J#(C_U".C.DO7;#L*:B'UMK%
MIK5VS @X.HD\DR.M!FW22#5=1'1&$H<D*<0)UG!FBF_2HNV##F?#%-.8&(O+
MHI]2>ZL^\31M:S?"6/O1(%(!D @TGA@3#4+<9MKM/OZH6Z^[Y]HB$  O"6%&
MM5#:JO(;6W@M];"!E&4/-]V&*HX[MS[QLUG5>&M+3IG<\H^[GWK=C"V)<N.)
MU?<<#+4MY'0-CRUOS6M+M-Y0T_5:N1*Z%SO4A!-UM2IO+?8O>S'5+B,.<R7M
M/OE42]78I#IT<UILU:4PU@LS#%<IURK6=ZX/X0IKK F 8;-11J$""ZLGH7P1
M2I2N<EGEF0/-<J4.- .EN/^-/'J@.(&^$K+$-&-VTN@DC891)"A;YI@P.#M0
MXT&/<$QHRXB^'.@!X$")QB"G9C1YT91/AMFKF9G\P&FEE%0H(U^T=IN0AJ(K
M:L^@N/9:HT+7#/KE0$62N4;!29)9:<#/[N!1;21%BS:/Y0(9\LDIK_RMW2"T
M_+V*.M6\K<<]#UUT!F,*>'394!O=O=-9;UTVSEV7S3^"-9?\+05&'E%HOVE,
M\W 6"6TRQ=X5-3/L!Q[H2'DV:1YZ^,.O0EKZMO]6VOJCXWX1I.6MEPJED<Q&
M/BB.T3"^T2(51;QO](M&.N[A77(9^8XX1@AP]/%?V5!$M><]<;)G]*A(3:I2
M'?'*G.UBE\#6^><^R^F- NFR(+;LZ%P'1" $,4@YT8A'5AF,BYR^PZG1Y<N#
M)=2<! '@+A/BQT#/8MT%:8([$0'P?/]#&_]BE+2_]>]P81.:[Q"70^*9Z'Z#
M2Q^,5L2R(TU/AVD3GA*QDJ(:)<J)M"#/0)+RC;&)#7_-RQ\-M2*]0/%M:59)
MBBX^DD7_F4U(AJL>_,:FON(];R2+:UP<8@!#C^EQA7W$%&\ZM\( &418IPN*
M'Q&I+"DE:X4&>Z#H5I=(279HD(%!9+KTT_\Z/3Y*=W+\(1SUQR2^[0^)T2-B
MVG8'P-YMCW=>].0:D8;$4C(123T3GBB+%SQ;.E%K:.#-E<RGRE;",7 H,V;[
MEA3'-I;$ET^C8BJ/J$LJ(LZ-NRRF\\"8$ %*BE)J6<L#:C=)<79(0A5LI'<T
MR<=QKO,NV^*6)#')(=&1D)WUC(UV:%="-SV2=9?"%R?9]TIA@C%129QF#XU&
M1AL*%$UG:]Y";[@2P;W,(TBR*/60:=!97@^:U\SA ]9&"%HD$Z(-/:4K3VE,
M7![M>S0BG(U"2HHW8O-_-45H-0\ZQY2F=)MGJ10D[1E4H=;SD$,UZE$S&$FD
M+I6IKM.C#$E6MF'_*C-%T1OE+I^YHI.JM(9;]"1*CTC1)M92AQB5GBV?:%!8
MWC24.M0IRKI(S#5"LVUFE9^A))I#K9:4H&STJ-CHN-,B]K6GW;14.)N:6,5:
M<+&-=6RIZ/E8R4[V/3#L %1+QA*:!-.A7;UE64F94*D"EHN!]=TG^]I6LQ64
M>K7L(4*9=E4YOA2M"!VBFH88T93@U'DN4^L2@8A5-K:,K\ +K&J]0EO;+M>T
MBZN"3T&'6,I.E[J<B6YUL9O=S6J7N]VE"5TX.<6/=I:JRVR9+SWQ $^0!TE9
MK.B:.#NT5#Y4MS3=J7#).LN+CE666;6M<?%K)JOBU:3Q':U-57HH_2YO_X<U
MC>5<$<Q#Y'(TE%\<;-\*^U-U*FO#WO4P4YGU81$K-K(C-G%382BR&7HON 66
M*ED'8L6+K-<@@[)B8(I&%?7U;; 01BU<N5J]I9D5Q@B>Z5IS6LPD1Y.\Y%T?
M7_%+Y+\*F:Q'?O)M"U=5_Q'.PECVB!T)F$=P'I!UY,J(&M9U9KC$!,UIWH5;
MS&R0-JOJ/,-!#JOT-B>W5*0Y;>%)P.:5D6G51YZ'H<Y;JF1. .@ID#D1!5N
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MBN\!7.5K.&*?K@0;E>(C)")KAXMX2.J]L&=MBTS)@(5C/O,V$^(GKH+-ZE1
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M@-72@7.P!%F#0(C7-K"V* GQ$5?V>/D5[42M6><2+L+K&5W,9+B4$&;O:#N
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MWLG-Z39$:$KO. V7ZU99?3=VF<:!3Z[)W*,AW;T(Z?(=BM#XW<G7ZTX>ISN
M[\D)7??(Z3?T0KFIY]_]%GB][<=;@/;)AR!P3"7(8'$-D<+;)QY!F-M/UH5'
M87_)90@ =1XUN!MT#;F7&T\-_0< ,^KY9A=O)@JH6WIB-?B6;S7R5EY#W %
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M)X0+00A<84*9=5K9Z(WNZ%D7A8OT]80=%85PUV?G-S%6") YY9-!N5O&2)2
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MDB,4C.^//MP=C.Y-/AT^KB?.$2 =S!DJ[Q'QX1+CD?*W[>):[MW_FQW^.^\
M )Y;?B K/A\]\N(N+_1<8AT773#4O5L-_W_ B'[ JFT(&N'RNM#PD/[D_]6B
MN#=%T ZPZ/U[M/NOW$=RH-,[PF,5"M%K,AF&S36:&)$R2>$Z4;%:Q1. LPF3
MJODJ)N%&2L%1RH0\5-N=0I4[SS25J0SBE4F+.+FY.IEO@8*<^.NN[>/3GQ <
M7LD,X:[7.Z(1)USC9.[!)[P;QJO7@O[G71(?+:+:P^W'.J(;*K+6G/$E#[SO
M=0X>KG_U#T+1D:X^"-\=/MTE% +T , 9!*\;LZ_QS5WQ?RS<G/ ?.7(A-<[Z
MN>'Z$$+FGB\*H*\=*'_1=[(>X/X6%X+QLU_8NG$GR^$2J1_T*%(C.4(AW]_0
M8>(A%^+=[H_S.31N[PE-Z/_%]*:/W4\/$ !($2)$2E=! (4(F5-(* X @IP
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MI @_   *>)DO3$N __/(2H1)&/S!S<O*C/S!CPS+$!PQX,S%O$2]BW,:="3
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M28E\$>II4XS)$%H 62\:D -1UT:O-\X1^E9";C6._LO M872Q@^8BVWO_"%
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M>B."1@C8SNB#9R3XWRT%)FN0_]-TN2E14D9A)U@"$MF0&SZ&F3)Z6^UX.>X
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M0<_.$YO_&%(6OW_\9?QCZ*V_Y/9QWCB;H3I@=O!;2RL%^I<MF,'-J2X6ZUD
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M9$.B!,13I=\]B:@U#'X6%JKL&\R3;7"X'71"&G(>KY?!X\WKX>M=C71]E7;
ME_GSWZ G*SH]4L\+HAVB.[!G IPNK &% +^._P2V030VI1;JZ0%E048&8N U
MB 8"7BP>U('>8LPC\)%<.EAH&!22%5/)\>E4[+GM#5LL9S!Q#H(2.)3,(TLB
M-)*J,9)F(4OF-Y1>U/,M5#83?PC5!*!N3\=P._S"&48PC46H @Q<C?O^*DL
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M\6_FQM^FN&I$'EF ]G'6CM\<R+.<!+,?Z-6AEFI]) B_VV9D$00[[S@CVZQ
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MAI,U?F@T4C)3^=P'R=_V^<X]I/4E3HN-)/WL/ *777':_)_WB-EO KG_ PY
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M4M*56&<M9>'2$=9RA$X41Y.*W-_>RH?2,2$4>3I]GTJ9P]/R0/-_$'VGZ_\
MV4>A#LXI+ZHG]L+P 1M*[PM82 I9P@#$I '5I+)D)JJX1,V!K(=T7YB1$ZQ8
ME4%%;CNT>M+NBH.6<PY&D331ZN)\*J6\\FA'HUNH'N5F5/7-+:EGW.MIU *7
MD IR+5C8W=$"FI2[1NRP!ZGL3 J**"Y0: ]BG&%1!D6_]_UJ(!=%HT_4,E
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MN)^_TBV-.F+H *E;O_V,QLRHCK1KVS9#6G#>W6ISNY;K^W?!.TZLA+%BQ#,
M+DS#[!DJ\##IXL[OD&4:N* 6*TZL1OY[->NG.TJ46!>./F+P])\'$>(-/^5Z
M]J.]XH1></+Q@8=O.I:<TT",_2?0? Y1LEI\"HYD('UQL02&%?DY9]A-=.%A
M'&.$%61388,5ID08RK%GU4V+G?9%B58XUE,9DSDVV5,.+B32'/7-Z%"#.,8U
MTHX^@O29$;<-2>1%>QEDUX)*ZOBC>DT^"9X6"3'U'4]A:#%9&8.$D1V4[#'I
M)4Q)*JE@(F'&!69"&Q;_9=!D!<JD%0"'#3793E?X9D25 Z5I%ID+'GGF6!!Q
M(:. (B;47Z$$':>G@)<!P%1AQDGI8',_1<?84%8!\,4'0'$5J$"KW1@J 'R6
M*M&HJ-+'%F:Q%0FK;>MQX>>"IZ)ZZZIM68K<B !(5>4=5EF12!EQZII:KL@6
M-$BM"BJ[+$&M$L3%)QS<Y&M!>0ZT8D$;<GH5'H]""E2W !C+X;B"*86@L_!!
M&ZVI $B(Y+<']7>:MQ06U)-C'P(08K;"86>034J (:QED%Y5%!?DF5=JC9B9
MB2J!\<[4X\6MP2N1$13%"O)&@.KF+F_Y:JPMRJE9&B!!3"UQKQ5[W,'4$8JJ
M__P5QY_1_(&Y #PL9LF\38MSCO7:8:J$QC85&)<#*4$@A@.A6Q!WAWG&)G^'
M&D3Q3&,*K=;(12MDA'X:[GLO8@C=U%5!'XP[&40*S\@4?D]3!N!5/7W1HDU=
M!JIJ9F,/;E#@A+_FJFPA+W[1>E^#C9;.4$I^.$-W:&;W$F@3I(05EX=Q!Q<A
M"%RYD[^5D6&7U'UP17976&%((A]X-MC?$M$*^5V4Z^J;N5<CI-BB=N\!E[C:
M7O7[<E<-M,?)>[*;8.YG[8ZJ\WSU5*A--^W(:W("W01=45<E; 47QEKOI<1]
M45\ZCAFW3Q;[#S%.?T5B%RA];Y7+#S]!XO_-%*IP*&$,0]E#9+1 P/ZYA'\.
M"=%-LJ.9XX3A"-:A4!^<ACVOY2\M75/@\[RE-=)QH6WGVII H+8G/3&%6Q Y
MS+BH=I .ON1Q&S3)_>#'0(VQ;#^5<5H)E\>?(_R!9FH[D^'0Y$&5_QTQB3,A
MFEQ>5;_%S:J&T]L?$[^BA,!\SH0 T%RC&O:7R!3%;E<4BVOB!K[O449\A:%0
MB[Y@!1*^Q#U4E$\9 >#$+U0)7>+S21F, !<GJ*LR^%'":>9F*"4TCWDW^^!,
MVE7'D^302Y-$V1:;ED!P ?&$GAM,Z+CX)/7Q189W1-7[2KG ('TLBB"[(0TC
M&0#TH:R2A&/,(9OR':1TH2J@&PSI4"FOUB#%<P_\(?/B]+K/D<=S=8'E29SH
MP=PP)X4)^01<['7"[+A)3ILQ2/*2%T.EO#*2-VP?+34FOJ&$*#';"TH"#5A"
M,C9IB6TY)S#+0L]EX>$/%MC#%?* Q,3-AO^5L7*<,TUBS]\D%&=:R,!-4&@H
MGWS'"%;H$AB8XK-[IJPU-F%)&A,E)RIQ"@O'P8/?E-*L@Y)DH3O*C2\!],M.
M[61;VOK.MY##(9N>ICAD@YY*&51&:&H48%K4S$R/<P<BDA",D!)C)M,7 !NM
MKU1$/((?!@(T!9ZR5'C(1$'*T#P_.,$)2[!=6.PI)(*VLD\_#0!+DS74N,[H
MK46!6#$!QIA&G0^.EI%G0\991U(J,#<KP@E#>H(V>V4(1DV1B0,+M8=&#D2P
M'6NK2,I9NK>&RI9$84QVD%(EJWSNESC*9_S8L[2*<FHQ30'*IEYJJC  0DR
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M;=\:5^#72],5?[03LZLN&@TN!93?"Z'QVID>'4\3#;_!7(]'SC\]@X\0A1_
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MZG =FXG'0@/#FC0JX58+\^)BVVN1PU;>??X\QR(?G'_F4C6(M87B + "Q9V
M%P#@(0Q:^\G1D>YRSO]=)<,&H<R8G.G\:G[9@L?.T-7G^NH,&-<%+AWPN:)M
MI?\W&&\,3/4>XKIG5V?0M5/?J;)")&^?\CWK+Y>:%>H"!L\7Q#]H7\) _@.
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MTIXMQ**\SF]YI/'_0V56:6R\H6C(MFC)1NS$5NSRCJX9BSBI07#;4' H87
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MQAZ;[*; +0&1$V%X=-Q'983A!!ACWO%!G2ZQURU'K8*KU('B0N4I5N$AQJ?
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M@^01>WO<F; \V3H?N?,O+9T=*2UW2 ..5)%!]=[4:L.[W.!4()/TJ/$LB:X
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M;_[@#P=W4/YX\ 9[$ B]K_9FKP0W\/N*L B%\/F8CP%AKP43$ J?$ $!$ P
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MPN GOH N[?(#=HU)_F PZW(@[D /ZO(*4O$:$Q,P[4 @/J ,]@4/E, Q(1,
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M=Q*1F>,<).$LB%8\FW;W8+PIW)V;UUGW@39;?4%<0.Q2;MYS#()=[0,YW49
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M&[(R&!]%Z#I$(Q7(%1BI+<K#@FCD;-F#>&/2M;'JPM.@ZT09!;I67"'(0%*
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MRXNNBR[8A2@:V4573FWMD.C;=EUO!ET@WCA17DL0KV5<+8P6(E-;>W$!%[V
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MA3(J$A4;8*,9>LG@)H_EL$(Z.HW,9DB$J)!)PS*KR>N:)H7L&.4FKXX\M #
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M4<#P^ETG"EV1=Z5Z.$+A<(:*'.+;^9@BBE),!4;28@,+%,$(P<\JNC1!PIQ
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MQX"A\LDVM"%F (A_Q4F6R,\%([0U!XH8]7.%91UZU$(X,2ZDLVX+0)&Y4XL
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MAUP:._'Y"E62"_DSQ]=0VC2NI;%^Z6PS+*VZ#4N).H9")7K AAQBU-<=\2'
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MXT*,&@<>/ ES8LJ++5.Z;$DRI\[_G3Q[@CS@,ZC0H4$_"!"PZ8/2#TF9*A6
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MB0*6DQ/&^G.RA9A,)8BZ"<K 4\$(@LYH^M'<Q1YFG@]RQT\8I,_)_(01!0)
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M'_^TY2[>C T:!*)2,MLH+FN.23GT@J-P?D2N>MWFFKAA3C#/B4XTU8 "#<
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M1#Q *(@D9SDMN25.3CEO>4-4:D-JT!*#./A\2%R"\):"A&C%SU<<8"S,T)$
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MZ:Q5N<(F#R&;BT?'-=*K<&530:9K<<@C,CU-#I,X_5:Q'#LYD+@UOBN.SCM
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MK"'1ZNO$S&Z-I )%+G)OG6*^4ZPB4]2^%7T>$TT?:9ZTI)%7K?P6_=TE,_<
M$$#OOPZ*P!S"NZX5_AO*HPXQW Z/%&+Z@2MX@(9YFC_7SJI^J@Y0?1='.E5H
M9(]!(;G-0W1V5PDNZR"W]@ZYSHG%VKUT''7=LU]$7+!;ID>-(G.5>+U HYE]
M1YE9,CK#(L1!DR55WYP.:TA")4OGF31_=#13A&FN _B4Z!H.2\YIF<LP!^T!
M/T)DV32-OY1E%P[QI)/$:UM]NHCFZCCXC&&(&7<\&<_"@=&J>"J([;P?+BSB
MJ=YP8=LG+;PU-6K_=Z1'"=%;@/:UC^@^4WP?D(Q2L#@%7> !&NZ&,!CR[MB!
MUBQ&Q(GB(>X.E<X%P=UI^-&"U]+BHN=!UZ^,;(<#=M1P+2G"Z>?Q+;?CXQ<-
MR[CWXSCF-&,1V$[5R)DT24;27N0"7$21<\(5*V(T"+M]R0!4VTEV;1CNH\.'
MZA]S.7U.>L]'W$BG]Q[/F3T[;%'I^CLE)9LIK%[6\4I4"G]OLP&FBAV".I0A
M>UP^^2W9)7S]X)EF2-XJR"Z/R. $FV3:A S&M&(!0DOM['5=>ROQ8$?MJY3_
M#<:,ZEHMDW?QPL<+8O946$("8F LW#WYR\UW9Y"CV[-2".@RO_0,?X$X_\->
M_7SZUX^GGV(\+>EX%)5IK6Z >#)@X "!! T2)/BHX$"# !Y"C"AQ(L6*$@LN
M') Q(4*&"3\6I,;QX,"-&C\^(8518<.6+ =:C"ES)LV:$@_8S*ESITTF GZB
M$_#AIX"@18D2_:#TJ-*FFX8V_? TZE*A5JDJW914:M:H0C_P#/L0*U>J2+,"
MM<JTZ5>J3]6F73N5;5>N5P4P$:MWKUZ<?/_JY%<#F@3!_ S7X >-G[O"A1LC
MYB?!G6'&D14C7ER8L&3!CPLG#@T:<VC&@&V.-DRY1FK6B!U3COW8\&+*E?E!
MT"S9MN')KS$?[FW9W>GBQH\C3ZY\.?/F.9E<,/]@/"&ICB4[6D](S6#VEQT?
M?0]_DN!V@O6<0R3I$23[A L%MKONLOQZE>O5K\^8$>%Y],O]^A<@ $,A52!2
M1AUUUE5*&6765 _6M2"#/V'UTU0"""C47%Y!.-1<1%T85U >NM65@6VE5594
M$ K8XD0 NBB6;8E91F-IBB6VF6J=Y<ACC8?96!EEBU6V&(U 7I:C@+9!IIME
M1@J)F02.=:9CCE"6EIAFOC%&99 U0!9983&26::99Z*9)D0TC%!</>VMY)Z<
M[[G$T7YT'F12G?AY%!]! 3(AIZ!Y$KIG>];=">="&]G7D$@-J;D7C)$"II:)
M)A(U!E$C2@44@7&M19;_4W%]6M2GZ'B%EW],N&6I66QQ6M6)*+:5JJ9UO46A
M5Q52VMRDO58T6I-(!OECCUI:QN5H1-[H6FE8 ED;DI:9%J!BA44&V;/)BKD:
MM,7.B.2,.G*YVF&^V488<<"RVZZ[[Y89W73@#8J007@.T.B@]Y6$TDD;T<N2
MOM<)V*]\^+K''4B+GD3??8C>VQ$IBV*74%[PSO0KQC8)T&%=4!68*UNS?@K5
MA0V.G&#(LI8E(,A.1:AB@4:-:!7--B=U8:D5:CBARE9=O#%?&L.+K&0W4N:;
M!#T^*6:R25\6VV%0-]NE<$E?R8^ I9E+967'3@OU;4CK:+5CS/8&38^-Z;;T
M_[E"PQVWW,G5\! /"US0' W2%6>=0'IN],2C]_H[WGAX,CQ0HP@E_K?! A6L
M,'[O(=SO$_OUR5YV]HZT9W9S4T0TZ!*Q6B%6FR!8XE=:)8C6QUMI-6K/H5+X
M(:"KU[JBZJ7JROJ)'Z.U^LLRG_4@AJ/S)+J[Q(I;96>=43VM:U,"9Z-NA,U&
MH]+4@HVE@+UA*ZUO04HKF&ZE<6EUEME'=B.WO86[+O+STU\_ !0T , "!BA@
M  ?,Y:--Q9'/2/!D$#_QB22<(T]V C8 A^E+<@,)FG/48Y+*&<PDW5E8!AN8
M+S@E; #V4Q[]EF(R$W:,+G"!6<IB5:L40F4I&TK94/]01J!-N*PM#8H5B5BH
ME@T)0%,]BV%5=(>K5,$0*_:S"0G9%;_#J(TT5H.,VX04OFQ][3+4,UNR9@.E
MKVUM:D<3#I',E2-L)69(8IR,!*#T1>?=YD=4"M=LQK3$.^+Q71 P0/X<D  ,
M&( "S+D!WP 3*,(Y[B"/*A2A$FDPCWR'7WX2R.5 *,( 55)QEON(2@SX$I9D
M,I0?O$_C$M60P/VI?DU$7EDV%#L3MC)4* R>B&K%.IX1B);"4TH.434K7<'2
MA*C;U5E&=<3<F8YXN515'BVRREY-"6JMX=;U?L09<PF'?949WS6=%STL?@\R
MV#2CU]*X&Q^=47K38F/2I#8*&.C19DIUA$TSZ_]ISS-=(!X8V.,"\J%/  KP
M-!P<Y4 0^!$'/G(A*ND.)1>VN1 &K& A9*!"(ND1^^BI<QIA'+\LF1T*CNZ9
MH"/+"W-I%@K!4&>R4E!4&F2A(\**5B!ECH%2UR$8K@6E(7*IJ&*&LR&RY:;W
M#-W<.O,MX61).')$FA2_2,7@I#.*U&/J8Y;DO+8USS96RJ)LPO:9<TGIG.C[
M$;?4*(&AHC6MS>&  M@1G0OL+0',V=MT3H(=/542<][YH ?9@TH09O(C@!K/
M C?8D,7M9Z%VS2B<&AJG4SYN(2.\)^X^!B%+]0Z7PMME[&;6TY6:2$"<NJ6*
M2&H@(K:N0\8K4:>V,LO_5JD5(B*-5/LPHU7NA<TS\)S::*K6S:Z1M7Q:JN/W
MMNH:<W$FFI<IWQR_VJ/QT>9YR-KB]"0CK-AB-[M\H0?_$A /".3#  L Z'00
M4AX)6G"3BEK@(QU)+X2VA&(#F.ER#.703UH2)'^+I$ <YB\'^FVR]@0FBDX7
M(2"JUHBL55D/K7)3MM!7.:X%9ED:=*$+R]"DGZTA,D_X :/HK%81KN=LU83-
M;ED72D-B&M2D^KZJ48]ZT4-?N-(I(+>!2[KF VM2E8M5+Z:MMC5^GSA]I-TC
M(SDG^U. !P#@S[HMAP.8*$Z@$F)00C'*KY"MDRE30LK&,O:2_M&OX>KDV,=N
M_YDA85Z/1?6[R, *N)Y,2=#-.IQ,DI[NA;6C<&F-^9,,7<HN(Y,9GE?DJES!
M95.[+!D+<Y7=$J=)2E)[7A2C^R4C"<M'Y3,7U%I,K6QBLS;?XZIUR:I;WM!H
MQN+#XMBJ!-SQ;;6J29XUK2G"@?\!H 907DX ZPI?,E=4S?FJ&$@6Q\'J]$N^
MH/2(1!-G7\ 2T& 8/9B6U6R=*V\TSLW\Y8%T>F"?UEG#."5B*U-%Q*F,&#G
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MM-Q,],3VHL(^;_'Z,;_QG2OR:!_S;G1M51CIZQKUH'&-JL$Q:12FQE-ISV9
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M-P%7P<$3QN4(]29&.%%D^EFOC)9BD'41WR$I-G=DF-B1G#/[3"2  3R[&!I
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M&HL$MF^YK3W2DL#<T$4ES[3Q;G#_LU*+CE1 )9U16FI94HZV6$A#R@L""4A
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M8)=E,9EQQ_QH;FK +80D6<P"'L"SR13S6[YH7QG3[^@F+^'JK,+WA_]'V33
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M:45Z5Z%:$F=TK*(XT7M>-$J*CA6AIBC%1S],HQHOQP$#.$!N )!'/-Y6'7W
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M@T*KN"'*<L6GJD#>*<:2Z);KDJA05)MD]#%MN;2#J)&;Z1D(I+:<^0\*^(L
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M J$ !9A)!U  9,& IJ 5DYP?#(#)G,2(S+0>#'" [RE-A1(X37)CL:M4" 4
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MNZ':>' ?"S:C_,WEO*CF.[ZY-N%DAPK>C7CFIB/=O&V7^:F R8O4A+B![DT
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M#OEW*<ANT6(# ]3IU&N8^M_+A!H'/?NY?+^9RXL"K%GO+%<@F0<WY<%3KLT
M\JU=$4 K _CT_<VE@>?QO<RIG9OR/<RMF6\S!]Z#CI!3!N;SFN; <<_%FH7@
M%)?N?^;E;84?[G**)?J2>'?!&Q&/1#Y)8<;5'?L@"V&J"O^&.,4"QRSVLM#^
MCOUAHHYWZ?WKW[<[+$B[7?(PQ?WY(VCJND?38F2V\8V&9^15^&%Y9[WY?H25
M-[SH/@S.\+WV$^]:.!7G9=%4.7E4F^]-^7-5/C[4._JI3\G MWR9A#3P!0Y@
M[*D:.S&-848PA\A+4.+'+/#UVM*:D76L2';Y4!9]R\F_U;MF^B:74')C8.;I
M ZMA?SN!RTRG["%ULT7JTRY25VZ1,K!NG2!F9ZI.A9R9N6D,P*#MJ#_:?(:@
ML81[5IWYVY9=<(/]QJ@11L*+(P33-H^*(5]:8WX*$R82*F),LU"KI^61\1WK
MR]V^J8%AA]@70&BHO7'BF>DW16I\%]P7,AIVP;67=7P7W..S:=X%][ <)[O@
MOGAMWBZXAWE^U07WR&/6#2L?JTI.VWM>Y4]R[I[XI@[@;E2')A%'/N'0(UD$
M$:(>Q%&60FF#)90S3\A_-O/@M.BZ=N(VQ'?/94Q=-CT$=;VVR7$Q-+(Z\H!M
MH1&;PI ZH6.;)J F(KOO!:K%S=PM04T@.M 9U.CU<551Y:!M.]UZY]#_YDY:
M-[=W71K79:42N<YQPV_+ZKG?IQ"+PHR%'N1"4(@P3F'&? ZS- H9\F@0,JW,
MJDFX<:QV%E^^?+CY A8WX./BXAK\8_'IUP_@YN_7E[_^_'=P=7WY\>+F3__J
MQ][?%I_?@T^77[[856&UFPA=/343O&;::UO#MFW07>\GJX&FXVR=0UI6;?KM
M&: ]>^#W^Q,VEW4QV%% S50VUH['-RDP.PK.8Z5HQPTZP;W_#1M7I;K3I$I&
MVA?".#J8N^6W=TU]:S8\] RX+X)Q4N8YKZD?9^;M[JF?!&CPHOKIMZU;)R3!
MVF&E(4E%0&$6>!PB)@3,/(0A%4$2<R\FU-=/ ]D?V_&VWM?@3Z!)6.*%]!HA
M"7N9S!;S5AS[U@G;635MG6 CWZC6"4/39M,ZX:4 &JT3-J_,W3KA):\'6B>\
M>L1LI3.>+\_533+-'>W5\RZ/%209\/MBNJWI*/,'=I^:T[_<ED\_R7?:?4?]
MT'X@[<?Q>J19/HVC JP_C.,/F'T6==4L?\'?5&>>=6E3EI(P2C'T5>X?2JF
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M2W8Q-1(&^FQ"1.P4VAADS#2:IJB#*NW4&//I-$UI]I2:[COV#2^BODA0Z*&
M^AF!,4X91+['($E8"%./1!%GF*+4M/33>FS'.FO=0P%&Y@TB(M/23S8RF2F>
MK3@C&E]$MJ6?;.0;U_IB8-JLFE]$QJ6?-J_,WOXB.EGZZ=4C]J5ARZI1]U'?
M\X>RSAMU^Z&MFB#U"F>+6M6<4VFW3WBE_,%EBBA#V*<PB4)IU$BK1NH#WX<,
MT8!CG_@1UG+5K#EP'<#OF3"O(VN&HVXLRB$Z9OJG900J3@#K63E3CBV@&VX
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M[2@#,^]QIX!XO=>=?,,B=4!U3]\KQ/R>]Z=[+PKM[91M7L:$^)GJ*^QQ=:M
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M,2B$CP.Y[2,BM#KZ'AG?=>J+W(,4,: (&P2/#@"A$9P;)Y[9RE.DSL!&/HL
MV0$9#>)<XV2U"U?IS:99J.FX'(,1HP.OS1?X.<[S7OQFX#&[_!%I%'0MOQ[*
M.F]46C*OGJ3F^<AY&T.@41(A2&B 89(*^1,*8TAQ2GWFDRCC6O$7'6*.M<:6
M)J@[HD!H5VW4 DM#F4P(@9EFZ0BOF_-MD.AI@X_3(F%VM#T5(M:'T];(&)\J
MZXAZZEQX<(Q93W9UI'EY-JOUCFV,HT]3OJKX \Y9[_C42R%]#H0BZ8 0+B#R
M5#R9B00R[,<QHX%4;EI7($X1<JS!>FIK%]TXX'D$'=W0Q'B9#=V0/J#YH"NV
M1>AA6";GT88CY&<., R#\#JF<.)YV\7;Q3D7I&YO%2QC7V[/7#6'0'ZB*K4&
MTD=A/B1!C#TA_9<XX6:+=I^ X\6Z^/+EP\T7TR7Z @/=I6DOF=F27/0U8'!/
M:=+T]\-".%^#+\C.O/8."_UZS1UYSB8<\+-R(9"_^/F#^C/H_Q[V?Z+^SVA1
ML/['I'<DXY1QYF<9Y"F2VRC+!,0\9% $44CE%HJ#3*L\U3@V7*_;GQ?*[$+0
M/P.2M^[G0/W<_WNX\S/:^3EJZT1N_IJ8..W64Z(3OY@#:$,U,A7&5A$2:[!-
M BES@&[G[[C_P UC-6.A&@[I6(\^8^1G+ +[ :+1HUEL*M>?K_YQ<7V^[7?5
MWQ1]=W6ARK<NKC]\7AS\[;KK)F(AR>36DL89@RB,Y-8B> 2Y%P<>\WV2H5![
M:QG)C.,-1G(')7N'FH-UE89;_@[]VD#)C9T/C7UE1I3-=I<UP#O$UW?#SX"D
M#Q9;E(\^8[&QC,7<8'N9$7N[36:*.9AH?YD(J\%=9BR-^?::B=#8VW&F&M/&
MF;GG54YQT8<3RW51E<^++^\7_^OG54GPZA=<_<$W2=])&H<HB"%G3%6+I"$D
M./(@#EF4DC!#)&7Z/HPA==>N2\_.7AB[9>@,<$SO5+&ZKA&H2G\J"_ZB!-$9
M*/I<J>[NQ)_^-0UC]#?O+YZO*HIW#YE8VJ:3H^/-.(3<T(EY@7:Y@W;'#>C8
M 1T_5KZ*\>=MX*(X1-+2,]%&] M?<=IH VOHD%@",^R'F XZH_MA*>^^UV$[
MB&VT^&6)X?4"$&%,?(&D?H\CB%(<0>S["%+/\V@@)#B98=3X,"'73L+EKZ:A
MXR. Z(:0QXMI:*4?JBWNH&'HL%S.H\M'R,\<91X&X76T^<3SUL>S%9=&X!=I
MA&!VY%)>1GP:2']?>OZ<JVIU 4R]3$ 446F+H !A9+A^3Q-UO)8[!D#=<F!\
M9GL:,NWSVTF!,#S+W<7@#.Q<O09Y=Q?4P=+7%]C]0>]I5N8^]-4&Y\ !L/Z[
MUML[;W!></8!5T779)RN'J6S<GM5E2)O/I5U_;&LKJ6U42EO9MW )_:#R(L0
M3$02]@U4,CD?&$NK #&&D6FBAQ4?KHV#GB?IU'5,&9L*5N!J6Q*N(3,T-%ZB
M)9WA-4>J?(!D"?RXDDS]&8BR4CYRQ]>I)EHVML@89-R;*E;<S6W)C('P@*$S
M:CB;@Q)^F]=RS7/V/J^D#WLIA!RSN%T?L6<A32)I^01^&$CWA4CW)963%=*4
MA 11CW']\-0P+>=*:DT<L)8Z*'OR)B'U8;1T3BDFP\!4ZVS$[PB#-66KHX5A
M'$Q.#B;#P_)@X"@N4X7[M00<CN8/#S%CL%Y+EOU8O-XK(Q-L7Z2I92A$L2\H
M#'%&($I\'^)89)")*&2"" ]'AM>&#])Q[:>-JB9P&!EMWVRLO(;NV)ZHCO+Y
M!F6:*[7V;;/[!B$XFE@[2:[?MM/3@C'Y*=179=W@U?^;/YR7C"\]%HHT0PQF
M7BP-C2@6D&19!%,689_&V"=<JX#8,!G'*[;O'-93/@,=;2") T7=M&O:0:"&
M5_!TXILM8%O)+9JF#0DVHF?:P6%G;IDV)-KKCFF#3]O'.9YX\<B--XP7[[DT
M9%M"CO:((V+,X.ONTYW=BSTH]B'_]/"#MI_;ML+,"T.%I$F(U<U.EH0)1"%1
ME5^0@,SS>1HPDL2!UHWPTZ0<[PF?1]>%.HJ1[MJ<0G*S1?I::$?K]91HSA?N
M409F7L&G@'B]E$^^81%-^J^*E_7BW;LOBSX2D&2Q(#S@,$R)2F\*U7TIQE5Q
MV"Q-28(]I%\7]N7HCE=N2PXLP)_P_</?P#L@Z1J$2%Y!H1$<&B.@V0(]()M-
M'.B5D :1GS'"VL5Z3";4+,AS3);!L,ZKE^8+Y!SC=R]T<_0AZPN5CTQEXM37
M_/Y1]251D_>QK-I2<_VMZWH9,R(BSZ<P17X$419@F$4^AMSWXBR@&178L*^E
M#EG'JF2Q6I>)U"_Q8(B;KC$P-1IF>J>G_F^J:=Z6?GO0U>'3E\*8]%*UB<CN
MKW?J,#/WI4\#@ Y<!35YVUIWL"Y=NVZ'O;G#15]'_YTJGBC=X//RGN1%2[R^
MJLH'7C7/5_+;:Q8%^_#/Q_RARPCHC]->)A0M/8RH)ZT1=7DT@(@S"G&2<LAB
M3M,L3A#2BS_-QK%KC44E!W4K@+&Z<CQ5VIKN^YD 0R6Y9KS7B8UD?=/:B?3,
M [K#?=MWH.5?_J0D:&]N\;4,JM9HGV!0O4YSG%35SH.Y>RWM6(ZY%?P\TW)@
M;YB)L.VVTC?(4W=/V7U>Y,H%5L4.^R(B2RSD+D 0A9%/,$38CV%*"($A$]Q/
M*.>81LN"WZK^OS<FN\,)PEK*)>N4RRORVHJF9Z)5%GB/#5.=?PI'79T]!2Q6
M.O<X%.LZ/U.J24TQG:NY4WS,K*8T87FM9G1?G*"CY45Q4^&B?I*K31+<=D^+
MXP@A3[JL-.8>1.HV7TH2 5F"F)_$"1.A5LZ!"5''-N"A#I.YM$2VK  \11N[
M8Y!J1,P< &6F-PZUDKLHP X7T[3Z.X;1B*9]$V U7?L]<\S&== [(;Q1+[QC
M8[U=5[L3T@WVISOU[A1-U;NZBUTM^$T;;VE.)4@D& :4"M4,5D""!(>QH)3C
M*,&99^B"GR+I7G_V'1[&]$0_B)6N/34E F:*<;^C^4ZSBSFZE0^).FLS\H.,
MO&&O\2%@AEN)#[YIJQ.N\'/;??QC6;77<R_J^I&K;ICU$B69P S%T!>9LJ<B
M##-I2L$T\&@B[2D_-#T'.$[,L1Y8$V[#W&W1 I KVFUG9^/3@ ',=+7"-$B8
MZ0-+$"P4P6GIG*N  19F7ORGP7B][#7>F<((>,^%NNKR3OIN(F]4T&>;VI*D
M:2AXY$EOBG HK0 ?9I0%D*C\GX#Z/LL2>UM@@+)C5;"_*[*.#T Z1MK0K5:F
MS$AT;:R'B3 ;8T18PS72FM 0?5:C8HB?-[0M-& :-C%T!K"(X'S U>IYVV%T
M<5\^%LV1N^M!E*1>%(2JCW4 $241)-2+(<<4X=B+Y2>H==W?E+!CM=-RLM.G
M&N"6%_"CNNJN4CJ;/QO$)DP U8CA.(+)3--T"&VY !T;$[6)-D',(*+C"#F[
MJ(X^@A.%="RD'PSKF(PW7VC'0LJ]\([-^Q9*=E^/-SA?<7912%O_OOV*%J1\
M;-HSP&M.>?ZDVOW5BX*U_]2=Y=VT+0#YM^:="@TL?2](*:<1Y+&0%B!#'*8I
M3J%4P")D,<$,Z\?3I^9N5BNQ2P*HMIRUAU3=OYIDE+N9)PT%_Y;H6]N;EP*L
M>04[S(*66]"U.=[AMRT@VOWKNBE!RS107(-WP]&N&:;)8%=YR^FRVWHFG+:)
M]B97& YN8),3G6^7<X77WE;HC(AM-.2B4#?CZ^8*Y^Q\)75Y+G+.%O7'KM5V
M<;MST)>%+ VY=$725"4HA@&%:4()])*,)+'O>R%/K#)1#)B8)RMES1!0W7Q,
M0R FD.J&0:9&R/*@>0>5,T W?$@; (@U)SH'\A;1$ L$G$=$3'B:.2IB =?K
MR(C-(#;1D2Y%YIJOL*HH=%-^N2NK1B[;^T_J-%@IP$_EUW^H LR=#OQ85K_=
MY?1.*LGRMFBS^SY\Z[V+O^/Z'>?%KS5G2\H]'"1I#'U&8XAPK-K=":2"N1GC
M*?6R1"N$ZY1+UW&7OGE]U?,-FA+4BG,H![L'JY9WDSB"J\G2"=-\!U-@&-/I
MT5^S#&Y*T#(-%=>@8[NU "7CH.5\;;Q+WD'+/-CA'FS8!Y)_H 0 2H+O80)-
MHD;?P41:AIC>>D(- U2.@1Z.9KDB/F/HRS%^^W$RU\2L<D\[$Z#G[;*X+I_Q
MJGD^YU4CK0'Y\4DKEJ:,A#CC<G>5FRTB%$/""(.,I3$*?>+'Q"1%79OPS,Z
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M5RL^+[BJ9U,6*I9R*52<7!T'RC]4/HYTR=6_+P.$$XH3 M,P$!#%B$(B8FD
M95$0>PGE4:P5I';!W!SG;VV6B_J!;^D:=Z6=;CITS]_>!F3#*/>61Y4:A#=<
M@H>6S;91-NLY5?],-\RJY^FQZ0&_-ZKE&!EN.6;3$G=R4-UWS9V.Y;D;ZTX.
M]H'>N]/3L+\34->/*LJM!I:N\!._?&R6(D,\">(4!DCU@,Q\7Q7_"B )$T(X
M"BDS*(ASG(YC1=IGZ>8]Y;-NQ5)%')8#)76-H-*P.J<!P$S)K3.4-[*WNTI+
M%UY.);MYMO=(#,9E=)MB896R/2"A3EKVH==G3[T>D.%0>O70XQ,<C=W<5>7C
M[5UW/5?9JA=%4WYI"UGM!-\655Y+':JR+0ZUG//\C$9)F$#"4@03GP<P]2(.
M(QR'*"(A#;#^'5H7'#K6A9_+ G;JKRW[6O]56C5K;D%>M.VQ%+\CSCXFF2>+
M\ZNYT1]_;M5S#+8L \4SZ)@^VSVO #W?0#$.-IR#A6'FG;L9&W%*-??,37<Z
M-<\,CCN3FA)=H[.H20B_W1G4E+@-GCU-2LABH_VOBI?U^4K2:S8CJWH\](XO
MWO5'%F&2!'XL8DC#1$"$0A^FE/J0Q2E"<92D)-0O ZQ!T/$VV'( _H3O'_X&
M.D:V+5S/VG)2DA>P@.\,M*H.C!K;VL3@F.U2!W#YN,7E9HN+S2F8#D &N\C$
M0-EM"MJ 3:3<#80>U-4ZX\RG>@VDVM.D)N]9'\:'X?HP7CH)4>!ED*5^"A&1
M_R$!XC#T0D8H85[HFQ[&K\>>YS ^A"856UY(KZ&Z[&4RTU);<>P/XS=R&1_&
MV\@WZC!^:-IL#N-?"J!Q&+]Y9>[#^)>\'CB,?_6([;'5$;NLM<2(_#OKR[#L
MUBI<4I&$81PSF"91(I4"9S#S? ^&+)9J(?6#@&.S RH;-ASKC\X8!2WU]AB$
M2\KMP0GOF@N:'DE90:U[^.0:0%O'?YM\W/1N8QMK@1VL?4&SO5JF9^VY4O,\
MY2G2&'2<GQ=9,3?SR= 8 %^? 8T:S;Z.LI)6.I:X.WM:%S#OUOE.^?+-Q<N4
M,YP$)(,DC3%$,0E@&B,"_3C*6)JD(L:&%<B->7"LX_;Y42>\Q::/0A<3W6NG
M,*;ZLBGXNHK/*:1F6F]Z-*UJ-EOB,4,19U/.9J_J; G=H3+/MD/97(+=9&BW
M7>-WKU%PBFC 0P%YY#.(HC2$6+IT$-,XP"&+$&7$M$_[<7):2VMT?\TU?9.;
ME\<1TG#Q1@ILF:BSO=714K6\I#,@N<GUTDD0L+Q):H6$X771D_(-WPP]_OJ,
MET!/RK!_W_/TXV:JB/%\^:%HVL3*UG#+U31?\2HOV9((1FCL(QB&D6KF$F0P
M$QF%)$P%98C(_VMYC$-$7&?4M&3!AV]@2QATE/76XR! PVIH*K'-=)"-Q-KK
M3D>D R9)S>E?;LNGG^3KK3&B?FA79+L:!P>=92GJB+5>AUK/3M;@<FV!\ =<
MR9WW?%6JH[5:VFLD1LB/8,15G5N"!,2(^3#"0<!)(&B<F518-R#M>,$>;7RY
M-<I[A@#M.1K=]?$8R!I6AC/HS!;]\>Z/FUYJ:V; N6O81C?.G "^J9MH6L X
M14O-$TA8M-<\-N);M]H\(:E&V\U3(XPL5/0RZ_EC66W_Z7\^LMNN.OJB8!_J
M)K^7'-0?OCW(STO-^G.?*<V_->]4MOTRY&$:9QA!C%515,SE3S[R50'M!(4>
M"5&D95JY9=.QKO]5N@52H?^WY*JK*:,N*? U6Y8U>J:=)QU'\WM W]!/W:OS
ML^40=!P R?;NOVX9;^MA;E@'.[R#W_MW%?O@W?"5DCEGT+(>TYO-Y!25FR:9
M40=%G9R JEW^:5KJ;U,HR@F"1TM*N:%F>Q;4ED!7-XPJ?J?N@#[QBX*6]_PS
M;R[%#?[VX5N7*OX^%X)77 );7Q:MB[;J%C^)N.>+((:4T03*'3:53E.((,DX
M%7&:13[C9D=#8UERO,'*^>+Y;0'H8Z6(]^TG.]* ;7DR/1@:/1.ZYT1SXFNV
MA79M%>@N:R!O>9.^*F^47=/@;ZIX0,?A+MQ E1+8F0GYK.AGJGS@78'A"?R*
MZ6%T?MHTFM&9#Y^F O;U6=1D(]MJV\\2@U9M-(NZYHUTZST_\2/BPP0C++5G
ME,),) )2+\JPR+( A_ZR*1N\TM6>+TD8:<,-(>TE>Z-> 86Z5]11!;@E:ZK]
M7B&CJ\W&R&NFG3[K"VFA3H[)X5P]O"(\\W(_)OCKY7OT2>M*%3MFV;H6QJ+
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M=9WII#*R1FOF7)H3MZM_*VO*7AE>IS!RL V'D-Q/Z^R$WI5"-D2'D-DG26L
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M)2&?[_A+<LY?\XKH7A\QM@9<W<^72YNM8+QNGU%=':BA1,4)Q1'4).<09YQ
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ME<(48V.;: 5Q0C0D6<1@G! 1$\4I0NZMEYU(CGP\&QZ :/GK5<SHPB:-6S[
ME<>[V0U%!_-E<&S\#O$&EG88XU,-R]T&EI VRV[X>!@N@^,49K6XX#60L>(E
M<:>EXK;2=&:*EV1[-HK?D^&-;\IO'Q:K'Z7M)_AGJ>3ULDE^:7<5O.2ET1QB
M/;-]KG3*;&\_&D&,6 1)JC.(LR25*F<LXIXC._T8F.!V%FC+#7@L5M_G4DG
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MI%(%"58II(B5EF-$BLWN))4#<K:"=(I,2[5.WZI'@_/R;_]!$US\HTUE''(
M&X9^R,%L=$R''-@VUR5$H]T96+3ZU2=)5;<8P*S5<9+TKT&037K(&Z;I.Q[^
M#H*V_U!XV-!C4&HMZOI9+9B]%-FT8^Q.7ZI9(E#!H9#8;-"D,+Y<KC7,=:D1
MS00JW4Z)@Z1'ILDFI%*MQ9L):^4/H<A3:(:0X8@8#:&]ZB!8DW";(P*3LM@I
MG=Z1KQSAZF<FUT&"[\^PE7JH%C-;A*CML7[#%C9VU=;.RG2JS"XXA3@3!22T
M+&!)F?EG0A->BH3+//>\27-"9&Q?<2/>3J=%HP!X;C0(KD9V$D=7RAD3'4\/
M<Q@P(;=O'&V-?P_GE")3W\AQ!.; W1S7)T,)HR:DS]7\P4R]IYM%]7VVK/OS
MX9P+7!)E>$)QPQ.&,2@W_X<PDCK)6%*4W(\GCDB*3 ];0;X4< R9NM<0QQP6
M>9+" INM&^,:0U9BELL2%YE&]]_5@E>38M.5Z+E5FU=S*%X6"UN\Y7ETO%R9
M<@0,_ @RR/@ 6CQA6'0V/"9_8A(\ <,^]YUZ("!6?CM;_OO30JFU^W=K"+73
M./UJ_ORR:D]>TI1)Q3F%*$$:$ITHR(JBA )AG!<RR[!''45WN9'IT"H"M=$$
MF!VHHT_FBYQ#J#T.'G[3OX;"*@'66@"KQAGH* )J34(.\SSP\HC;Q\$M+)SO
MCM](07Y_XWMC_Q[#37<DX&_CSDE!P./!V;'*?"W,=^9!V9TI6U9SQA]?;ZKE
MLNEXM>Z6]=N\XC8"Q^K?&OF=?(K[G&BF<XDAETA!PO+$;*-R!#-<TK1,$,?"
MZ=+EN&K%WI)N5&P<L[62X+G5T@:!FD9ULSEXZ2AJ_FTT/>M>:?+.W!WCM;EN
MZ:9^&7X+P#3O(22A>$38XF<@CZ'LU"G+(P)\(,=YS-$'MPD\U"*AC6$93U:0
M-"F@U@6!A508EEF!C6.K1)D2D1M'-[!MX'&IL<.!VZYZVRN@W4ZXP1%!!T"=
M@X+CPN09%QR,T)!&A*<MGJXQ88\N[]6H\#0\/8T+'1X.I9.W75#;?J=?U.KR
M1]->ZN-,:[/GM,DIQE=_5HO5ZXWYWJW.Y](>N3XW^T_Q^")M7=G9P[=5I5^6
MJFFV>%]0S' JS$:08P9)*DKC;:<$:BDI+CA%"'F&&R-K')G&+HUJ8F7GZ.J;
M:AMXV5V(O3,S>YB#)F(E7H%JC:G]>>_=8.S7ZDJ(?Z&7Y4>FVY;2<M-2>M7V
MC9ZKU?;UR*W^9S;.6%M@?K(VU#DN:FV%W74V9H"%M0-6&AI+VB:Q8Y+R1*A'
M)_38=DR\&$ST6O87DJD$^]=MJF_[5HO/]DMM@V1EGA2HY!1*09%9+@H-R\0L
M'(F2>9+(0A"WX.R!L2,3>RL-K,6YEV1ZBT$_MPZTS(\%G8WRJK9T1/V@$DMO
MQYJLKM(1([K%E(Y]).3:T)-:S 2;?U3/U=(.^MHTJ6\CS50SSNQQ1D)L#]0,
MEY 27$"2$//;,B^56YE%!UFQI]''KSXW:_IA<3BP&,]8SYG5R@5;P4W/C; ;
M1OTX^%PV&@V/P'M'1W$9ZPJ2DX']MY'ZAYCP8I*3+;MWE-P>":"H7]GBWZKO
M."S+N6)<<ECJ/#-K>U; 4B$%<TJR-#5>(4V(,TF=DA:9IAKQOF>M)R%R(*PQ
M#?>CK-;F$<]23^+A05QCXA)&7?WXC$1?KF;V$MC)0::C,%=[=DC,^:$ &OOR
M8D=HKQILFDG\7G=T7=61]2Q7! I)4UAPE$-:( R3$K$,44XX<4\>Z145F< :
MV9O[.4OPTVS>_NC8T,4!+0<Z&PT#/RYKS;_6ZTV7;>Q2_PA:V:.!X,%AHX$1
M1F #0/$C,2<[>QFL?X3IZ,O)DAWN<GLB@+AL>D@SZ/DOY^WZ6:1%GJ;&+RPT
MMVD8"D&*$@8QX4@3G"<Z<SH(/"8@,DG=V1IHP$CSN4%]" =+VR+%&-H&/K!(
M5 *ID@@JF@JL2LTUT?=SM8J(0MF@L!;BC$&=B+7F:"/2AYT/09&S4M""%%!I
M32$ID=F/%U3 DM%<T8*E&<[<LIS'^%($)3>/\(5P6)D&6N:W'M5O^6OG+8=L
MIP\9ZK'Z##0X;,W9,WRD):;'F-Z%Y=!STRTG/5KO+")]GPL]"?Y=V;"^DN=F
M3K*'=OA[@IB6J=2VZC&!1 @%N<Q2*!*1(9D4I=D#^UZ*."@I.FNLI0+6B 7S
MS1:X>EDM5VQ>'\VU5/MB&]_J:@%$]63\"OL7SI8ST138[/1"]-TVGP)<%$PQ
MC154.3& 8YE"9DN24J(9ET07,G>*DHP(=\#*[07VV430]I/^B(#Y<7\?5@L#
M$UN\[GPK#2R"/8J71];Y6JJ]#I5C'BCW(A+]&/BP](D/;WLAV#]R[?_X@+C$
MY0_Q^+*<?5>?9T+-E^9K7:H4<<8S0Q:IV=$))"#-"8824R&(X(A@_YC$GIC)
MXA%J+1D\MJ(#7/%]E#QB$8-L#XU#;(2"SV.:'1!]&&3^T,B#!PQA,8>CUCG%
M&_:?GC[6<-2"@W&&XY\.(*$/U6)1_6G7F5_9C]G3R]/F%Q?LF8G9ZO4^1RBC
MI7$HF<PP)&E>0(XUAXEA(<JSDF;:_93GM+S(M+15X P\-2H OOZ=+6I4*^$Q
M4QT0=&"J<7'QHZPN)*UTL/D=N(@"B0>+C0M-&)T-A,B/V-P-[F4XAV&FHSIW
MFW8XS^.Q,6I!W:FGYVIAMN?;[+G?YG:+?L=^V$KX=6VJS6\N%DK.5CN-.]/$
M;-R(H,:YD]Q6\\P@%UD.1<YIPE-59-BS9LN8ZD6FUMUR25(9%8T*MH=#FQ%;
M9\_N-%-]!4:SEQ[79HJ7YNI%OM>K\&/SW;>P6NO926L^ R^U8O6;>:R5K=],
MY[>B47B2XE9C03EI]:O!2K]C>:RQ .^OGS6:E.![=4VID'4=UKOJZ\OS\^/,
M\-I]KFB>)&4*<Y[GQLNF&I99:7, .,IPBC.5>8;DC@N+3+JMX$WQ9;"JP'(M
MV_OFW''(7$ER'"#\*"\,@Y"[<2>-BW\E[K@*4]^$.PG&@0MPIY\)OO?V],QF
M"[NUM^QRJT3U,)\9<KF:-YV,KA?V][]4E?QS9C[.C5M;$L%A1G0!29%S2 N5
M0$$*A%DI4EQZUC/P4R R+6R5:8+PBXTZ-MK\W/3:JA;U'\_ 0ZN4]Z4T/\Q=
M.20>DGZ\,C*((?>^@I"(?XW+3ZVI;V4%@7;@DE78.&,XHE?SE?DBVB($S86L
MNE_BO92HT$(B2$110D(1@HRGA7E%7"6\*%B9%.'>Y4&9$[N,*S9[K&?7MC<\
MX]6+O6FY5F[M2_ZQLOH-:JA]&.40=W P=D-\O%%A&^C,]0(QJ8=V6)-W=+MZ
MH>GWI?H?#26<?ZK77XVS]5 G6]^8R5O-Y^KQHGIZ5O-E_2VJ#SDY6]I2IJ_V
M4_<(8\YT5L)4(&ZV301!FJ8<)CE-$T6TIMR3@@*TB$Q*M3Q8"P3/C41O3RH$
M6U?BB8R8'Q499<#31AN;K-"H4Z?9K/4Y:Q(8=C$=DX(&0!*=E$)TFYBF!L"W
M3UQ#!@LXP>SRY(>%8O^6U9_S:WVW8%*M.TD8,98QW[9,Y[C(L"HR6&"[J5(B
MAR4K;$8UT@*G7'+"G$\VP_68=(_%UZK5T6&K7*=ORW.K7V"[>D_X'8Y%IP$U
M>/-UK<%&*_N/6J^Z17U3L7BM&OBC5@Y8[<"'_FCZJ!!['+-. W78\6L Y".=
MQ0Y'I?>,=L#PTYW=#L=@YTQWA.%"=[S;X^3[(C4;65E@2+-40L(I@[Q0#,I,
ME%BF>4)R<C]7#[:._YW/?G8KPVE>;&Z1O)$4D)K@NT?MH(&R-,$X(9 C6M@<
M905+7+"ZLA=*=(:E4'[;>D\8QDCH&6"_Z]8[S"J_]<7!H( =\K[FT3>^'9$3
M[V?WC=W?IA[XC'^UH\OY:K9Z_5T]/OYS;ECL:UU#5,FKY?)%+>Y5SJ@D5$.:
M9&9_F=A2>0)+F BD$"I$HKE3J;R3DB)/L48VL,+AOZUTL!8/&OGNI9'Z >N?
MAJ/"X#<GPQ'PJJ/D9%U05:7^D2>KL>1D8+?BDML# ]U&XYL^S59UG.=6"37[
MKN3GV5Q=K=33\EXQ5&0E55!()&S0G9J-0EK S/B.'.LTSU*GE"XOJ=.YA&8+
MW5$$K#4!?UA=0*U,J*_2"ZNG\S<66$-<O7?!*="#&PNO,?RU<-S"?347^YT]
ML][!WL</<['OJ-?E]/# RP2VGLO-8B;4^MK"1_:Z_'VV^O:Y^E,M5Q_9[/'U
M7[^?W]R+E!<L2RADQN>R1:2LUU$HF)<IY6G.,:?N_!JBP63^B;UP4!<4>K9:
MG75N!4JC&?C3J 8>:]W,+XQRP&H7F';O#+\##\<&-=0]LJGX-9XW#9[;.T=6
M*6"U HU:X.-D> 9>;(B!ZQA7'<;#-_P.A"\VSK<BG =^GWL2OG8?O3GA/5
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M\>=09FB/$R@RJ1DFYB_:J9:@F[A)TRAJ#;IW<@8F"1P&T('\1H7%C_O> Y'
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M1O"\T<8NTK+5!ZPJ@#,HV2NP.GDVI74&V6%]B 6=WWJP0:VML+]5Q(;'UJJ
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M*%0D*Q*6LAP+IW3D,/&15\V/ES>WEQ=7YW=7UU]\]ZU>*+IR2BQL/%??K19
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MRQ_/LT4MI[F&=4\QT8JAU"S Q*S'&A>0YSR!I2Y3J@I<,+?(K:.\V&E$C0)
M;#4X VJC@U<=)U<$'1;#<7'Q6]+6D%QT(=F*!S<1(/%84<:%)FQ=& B1'\F[
M&]Q+U0[#3$>X[C;MT*;'8P'D]]EV-# ^T:,95]ZII^=JP1:O'V=:JX4R-BW;
M0"9!"=)97;@S2R$A>099F2.H$XDQP:7Q5IPJV?@(C4R#C18><]H5*P>NBX"
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M0+A0(L4)]MSF^XB/3%3AG3:],'0EJEC(^%'43O'HZ9MDAH P92'IOUSCRQ#
M>DM*QVIF60<5;Q8SX[@\=PI5+IO]Z[W,229Q5D+.2@8)(@K21&<P)2K-I53*
M_-GY6.6HF,B,LI&[+6NZ]'0_3L#D<#HRBO%^I!'?;H]#CE'L#SO2",/![_3B
MI'F]9Q7'GY[N9.*D!3OG$*<_'<!#'[Z>)P@;;-:WL[A,\CP3D&=8&O9A9I]#
M&(*T$%QAC416NM]/?3-X[%W,5YLE@#.($X^9]A8 !UX98)8?FW0L"DGP>&N:
M!W4,,#&,,%Q>GA\]'#&AEQ3>/C,=%1S1=H< CGTFM*?>.O5^?:"68FK<&,UA
M0AB&1!($.642%AGBF*8L+0OW(M6')$0F@*9(TKJSBT^6P4$X')A@J)%^=-#8
MMQ$70@D'#?5ML3; X"$]T2Y/OMB =F5';#G=7^SM@Q,W!#NB]WX'KV,?#(V:
M_#:WK=OOV(_/U7*YS5)(4B28+F#!$86D1!GD)<\,B:A2%ARSC"N_\,A!.9$)
MQ#;'>ZS% <$6BU==+?YD"\<<[%,0N48_!AON1RJ-.+#:FAXCSMIK5/2PQ6'I
M$\<G>B'8#T3T?SPDB;LY(A7_YV6VG-65;\Y_S);W2)%,Z5Q#E&,.">$(EM)L
M^!/"DQ(1+ICP2.8^*"/RK&V$@JY4\(>5ZY4,?1@=ASW <)O])FQ,<WURP >;
M'9@+OF_^6$GAO1;U)X<??G3")/%>W7>3Q?L_&KHON&BBHU_5XOM,U.<W7]3J
MH]*SN9)M([YU#]'76H5[K'B),9%09ZJ A!,"F2AM?4IE6$>ALE1.@<X!.L3.
MPV@4J0\W?3<1_GBZ;C"BHN3'99O,Y]D<S-4*R$:+33/3Q[4>X*<Z&>MG8 9[
M>:R+"-H9 -9G,$L7I /V+<%81=_3^&LV\7XG&+K]O5#X4 '[I%_8S%#BPI#C
M_,%V-+Y5HGJ8SYJSH$/]D.]1J426XA2F>6%[1 @&RY(SB+,T(8)E!&,GYR=,
M?&0.^\A>8357X,'H!6S5EJT^]CA4;[(E'[<J>6Q$_-%VV))%Q="/X6I50*M+
MTZ*]HXV]\'JPU7M4!#UV>5&1#-L CHVHWR8Q&)#>_:/_J--M+8,MWMEUAH\2
MW+19V4V!NM:7/\0WF^O8J>QU/;=M+Y:/]3=O4Y=08Y9)#+-24$@2K2'CJ>VN
ME8C2MI<E%'GV=/;3('9PZ_;\R]?/YW=7UU_ [>77R]M_77JW?/:$U'5'&A$H
M/[9N%;$+FVI5 ;)3QM#PRVJK391(62 6\7M.>^HU=4OJ,-@.=*P.'"B4ICJ4
MUZ''37N><[&:?6_^:@,TB4P5T51#@JC9:F*"()5) C650E*>L#SW3$/TDA^9
MHCJZ -8N\+6;I]?J +;1!_S!W(->H7B[,E@T%/WX:U0  \@K"(;HU.6GU<3$
M%039/FV%#1.4N%A]G]GB5K8)ZODOYW?LATN57H1+D14T@X+@$A9)6D*:8F:;
M*18(:88$=Z_Z'*9#9/+:*@5TM0!&+7NHYN7*!6+KX!''1\R/J#I@?6K!JE4:
MOXQT(*9>:9:QL0W-P0S!>+3DS"&@G,C<#!IZRK3.(;:_R?D<-%1(3USU^BN;
MLZ:1]:;3[D7U9"M<U%_ "Z--$X/_I&STLV;V4D"F"@4+G$I8*JYL97^D49EG
M&9+WW]6"5V[M<3WE^\RCKA;.TV@K#FB_K#)O*!V(/"8\?A1N- %;53IMKKO*
MG($.?)\BP^?3(C<BC(&]<L>%T[-E;B <_;US?0>=L(ENH+V[W71#!PD-%;RY
MB/2F^,&]2"@52&6P4,H6@<TXY*GYB:8)12+#JJ1.5:U=!4;>3S=)G_I--0Y?
M=_\$9EF!,*<9@P8W#0G.<DA+)2!)*2EX(AE!_'Y5K=CC.V"V$>L>X[6/'+BB
M&!E%URC)>-CX+577X8 $!$'<K(P>]3BAQL1A#C=0]N,:CL\%;'2W0ZVO4ZTK
MY]9!7ALG,_1]CQ$RO&I8-<\+"8F0&+*2(H@30122A634_3JFF\S(Q-HI<+36
MX@S,-^6W5QU-/'9KCG Z;'''!\F/+;;XG&_QV1:HOHN*C\<>=GR<PG:N8^#E
MMUWUL[QWD^HXU'1;4S_;=C:DGH^&-#A5S^RUOGEZK;_4^]OOMID@?U2?*R/A
M2[5J P(D)1CR0F!8L*R G*8:IA@3IK.2$9+<S]5#$\-P['3J(-CIFUXVW_0]
M\1Y'Q&M-+%G6>XJM,H!7<PD>K4H^'3Y=4'4@SM% "CP[WP!C9KVMGM%1 -0:
M@%J%L9'QZ7XZ,D*!_4\'(^79 M7#ZOXFJ"X#3=@&U<.NW4:H/@\&>^O/=8W@
M^4-;'/@^U65*5,FAS)'Q-0T1PI(2"I-<Y+@DJD TW_"BE\OY1E(($0;[FFO9
MGM70>W"2E),RQ26T(0O;(IM B@L-<^.+EUB($A7$TR</ 2C<"[\>'Q-G#WN
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MJH4YJE:Q5YM:#;!H] #VNP*61A.[]CRWN@"Y5L:# D=[*P[+SWM@[;<,-:5
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MQPWH7)]?/#+?PGQ<UX,5^<1'@MM,%TRJQ4J6FX:K?2MT[QZT?0---S-*R64
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M*)L47ZP>G[9U8[@TRB.)*(<YR1.(A>U)*K4VRXF4E&-.)&=^W-4O=&+2:BD
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MOY=]Q=>-AF!9JAA(@\->BN?"-!O40]:E1DG0TM+^?J<GJ!0%+4W'6Y:&O8_
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M:F.OV6H#'HRN-AKA[,JQL<&XK\*!-]\"8#^*;30$1D70Z A^;9"MU02-GN!
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MLEARH:' 20YQ3%)(S?]@&LLX8SJ.A5MHN:.\B0G6R(9-N,2 :M_=D+FRWVA
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M^;/U:ELL>9D5=;/^5*R?'C=5!OE79;Z$JRV[4[9H199%AJJ(9 G$62XA3YB
M4810E!L20ZE[G+2+Q(F9JJV"):)2B?_8U+4KWME=::V(Q_FW$Y(.9_UCX^-'
M,0?0W.RA6=30?)T,&H\+@[$A"KM&& $JOXL&'[,[KQ^<!IKO4L+'KH.K"J\'
M@R\P"FFVJ\5S6>JY*<22:!+',N,P0HF&.,TQY-(X="+-,H19KM)(>M;".")F
M8AIL1()-*=/[RN(8,,[7%@/-];RZ.+04?'OHB<0(N<#HL&CZ2XQCPN>^R.@
MX,AE1M>G QR9K\6:5X=)SY?Z^DD(M3&CEAL,2^UEKXEF\K)441(IR!(=06Q_
MHE&D(4DYPX*P+-5.D]=3[L2S^>OEM<>2[ &7@\\R#0A^<[RE@\V#JK5X!UIZ
M5"U@0N*P/.#R\&.F@2W,FW&&;R1GQM_V3I?&8[CY'!M_&P_<FX#'QSC!.F>%
MO?6T/E1)SNW3DB2148P$ABDB!&*)-*0QII"FJ:1(,11CS_ZKCI(G)L^J@E'3
M3]3L_RI/8<BY4Q>,(8=.(X$SY,1)U2KL 9KEN,G!\EG/FKKT><.#)@>8ND^9
M7 8()1BS.=MLSEA1/!L)BP?;YJM>+TEB_"Y)%90:<XB3+(=<HPR*/-6IU%F:
MQYZW]2=E34PBGZXNKZ_!WQ>??SMW=,5<\''EBE&L]F.'4B00M4S 2J&3;*YZ
MC9N< $YK,/.4[X7B]23O?V2*)-W;2&$AXS2&$<78ME2FD*51!BF/<")4FF<$
M>18X[Q W\>0^3, M2QVORX!(42>@#HC(Z411YB**<I%#D@L-,<,2TDPJF&&L
M8YY$L:+,+^]P-!0#,@[?"D57%AT+&S\BK6!YC<;<Z<RSL6FG$G^@=.73G.KT
M5, YUI4R+[TL3G:I=PDXMRQ3J>*9A$33%&*41Y S8I,+$Y4RPP,\<@I:.BUB
M8OK<R[0;B7T*H<<9S'%D'$ZG!MOK-YE;IE[J5CK;8%,]3I8&FQQVB.1MNM^9
M4:=5G<=#QY^<[R2H4_.#0Y_N3P;W$K6%$H0EIQOVL^SGC41Y"I[#2",%L2(,
MFIV8A%F$TUC)"$GF6:+TE8R)*>7:?#F?[.84?#3D*[X#LS)Y=(GO L?56QAD
MLA^K[$7UVQG2[_.4)=.W]GPE>>XNGJ=,/]*P\^1'!^3"+GXN#;?'J9(I28R7
M3VT7WP1#'D<(Q@SK1$=:(^)4-/35R!-/PGW&J!46DB]:FN^PBH<:Y3?-1K(G
M(/O5UZX_5.YK6WFGS-?R@?GS7MMZ'LUZ/?A 2-=-OKYG9V;=7MK7PNX7\H=-
MUWO_]:*Y?$Y0JA'+H<AQ!G$LC$^/6 2-7Y]C$B<Q3MU3WOND33SY2_&V-D@C
M'[!* 9]6D7V Y5F2X$P3@U5J'17&(:52PAAI&><T43RA;J7=1H<LJ)+;^?O+
MSPOPYS^1&*&_@O>/9G49&S('-AT3!C^&K;XT+=&@EOT.&.DAE_.]>/BT%QT1
ME\!^HIWXC-4XU-',[DZA?8/,V!K4T9[#7J"N#P7ONH0HGMC]YNR>;39+O51R
ML:F/BFZS1.O(\#U,$**6VXSKE[(4QB)/28ICB;3GM5>'M(G7@5*RDF"Y^K%>
M"O^3VRZ<G+=BXUCON2FKA0*QDPK8ICF^'75_UF_>]#NU#AWFWK/UPW%D]^;P
MD'\YY\_F[=U__;Y>J:I:]*WBA*<T%A!)VR</860+.L<P$A%.*54TBIQB9(X-
M/O%$+L6!4AZH!+K7='Z%0_?,'6J=WT3U,,RKL/,I"X)*.[\:;+;BSJ?,:)=W
M/OF9T-7Q:[$62LG-1Z.*[=*R7-U5P<"W&$5"2B9@PHF901$R>R1N)A1-%9<,
M44Y%Y+<VGI0U\80Z8X]+VVMQN1*%8AO_I?$T2*X+XRBF^\VV1B2PWS*PK(3V
M91D$+(J]IDV^))[68.8%L1>*U\MA_R.A,_O+>ON9F=ER\YVM+E?JGXH5]4Z,
M)BQG&6>0)3R#F/,8$L8%9#0E2M(\R^/<;V:?E#7U4GE^?0UN_K;X A#XY_GB
MRG=BG\;(=6*/8KG?Q#8BP;V5";9&*+"KZ;,1.TG(5Z]YDT_NTQK,/+E[H7@]
MN?L?"<NQV3RO5'&W9$WPILRTP)&$E.$$8IQ'D&AL:UG96L@ZB9-<^:32' X_
M\11NR?-+!7D!@L-QVR#3O!??1E1@ILL+\_P26L+-#,Y;Z7V)WIDIQXWH2T!Y
M\=2L>2;'-7Z93G+B4T%A2DV]CKHHP>6^6L>5NJ^*:3X\K@M6/']8:JWL%?TN
M2S22:20C*2!.<MM+ 7-(28*ASM(,*488YC[A3 -4F9ABKKK*FG@%! V!VX&@
M9@/1C\Q:^-5Z@99BH-8,[%0#+=U"V&\8SEX!6C/A'1K(%8[[:,%>(R#4$Q0V
M1,*<P6,C(/$BR&R,$</*S335Y<O MB^VB_1A9L*EOOFNSO_]M-P^VQX>9H^Q
MVMZF6F)IKT<41LCXF0Q#CG()B4A3BE.M(N;N9P8J,?E1T6$:S5J7A;%4J439
ME:;4PJ_L2A#8#LO%#!#Z+13M#A*E1J!4Z1W8P5II9>-2C5Z@4@R<S0BK7X&;
MJ>$-KGDS#<S>E7"&X--7'"=H[%GKY0RQ_F4)G4%C!:P!BR>Y-._6+#0/3V8[
M4GX!/ZZ+\M?UXO-1V?0Q1(46*(.)RB*8IT*938)*H)(YUY2CA#.GLT(?H5-?
ME%MQL*B])ZU<[P.\<'.@[PG0\*/K6H'_L*[D7@5@=  51HV'^7$:C#RX> *L
MPKAW',S\B-;3^$YB=1UK/B+UM.Z .'V?#2#*]V?G<81R7.\NL= 9$=CXP%0J
MB!.<0YK0&+)(ZSQ1.$.1>^3HX=@3TYX1!JTTB#VF\@OK'5@MW"8_\MJ;$W+$
M\,(N#R8*MR^,<!Q>FQ^;'#>@DS1>/#(?-QS7]8 "3GPD8*;_RGXN'YX>FG;S
MU37LS?J]LO>R2MXJ,_?35&,8)2*&6%,$B8PYU#G%A&BM(^444N0B;&(NJ*6#
M52G>[G+KFGS;->"J#!8P2]@ORU7]^[]X3*T^&!TX9$1P_$BEP:627);@JG"Y
M68/W"E3B1\3"@W=&Q"2,B(9AX\=1CL9VDE;?&/.QF*,U![3F^DQH=,BQ[A^+
M[4>V+/[.[I_4S?=B_73W_6NQMN>2Q>>R=,E6W:V+YWK)1%)*S:F$0N7"UA71
MD&<J@W$B9!JE*9?**5=N/)6FCC6Y6+R_^'QQ<W%^#18WX./BXJHJ,P1N_G9U
M^=NGOX&O5Y<?+V[^_">417]=?/D /E]>>Y<@&OQ>NNGU;=#V(^&/I]I5::,<
M^&&U ]M*/?!8ZF>^^\ 6C7L'1*WC),$P8T$V><S,8$5G#JT9"]C7$3BCC1QR
MQ'9W5Y0=+<]_JD(L-^IKL12J+%52'>1=K#;;HER)-Y]LWJ-Q"%":152E%!*>
M(HA3RFQ51P1EQK,HQ8KGF5-!@% %ICYZ:S0"JE;)S."E5]Y="*HNAW'38N5Y
M,+>#J=$&E.J\ U7[S_I OZ42J'6:&$B?$[MI 0T\O1L?6,^CO'!4NH_U L:=
M\8@OW.K#X[X!XP2G#QXY8KQ%D7%QJ> 084O3.J&0$\)AA)FDN4!)FL1^Y>".
MB?$BXX R</81P'8'VD5+M'?RX#&47%W1H;:'WGHX&1R2)MAAS_3Y@<>$SYT8
MV ' D8S KD^'5']X*M:/BJW.# T4[/X]6_WK/=LH6RFFWB/%#.5$Y':SJG.(
M$P,E82*'(L8ZEA@SFCKU?W,3-[%/U<@'M0+ :@"X4<&C#I,C< Z.U*AP^,WL
MXTA8Z<"*#ZIJT N)3UF#,:$)K&O0#=%8A0U<#>VN;- [RHRE#5PM.JQMX/Q4
M ,U]6:_JO.ECF]R&Z:20(A-FJ<")83IIO!5")(*)S?,B499'S#W&VT7BQ&1W
M]&P(KM:K?;76=>$9UNT$I /SC0V/'_D9Z; 6#_8HM10(H3\G:#P8<&R(PDBP
M%ZJ1:-#'VDXF=!IH/C+TL>N #[T>'*.+RDY,U9#N\ZY!=HX4XRCE4'#)[%UN
M##FB"G+.6!ZG*<G0@!8JI\1.3(Z'?4+T[IM===0<K?'X25!=]WMC0^5'E&.@
M-+"72I_1LS92.:G,&W91Z0.HNX5*[],#BF4\JF+[;'O_;A<K:0^='NWZTV34
M(<HU%1HRPE*8LYQ 2@6#6N$448E2H9P2))PE3DPHC?1W95OK;5D;7S4:!!31
MZ 3/E3U&A,2/.#K1F.3"T='4.0IL=.HQ?YD-%UB.%MMP>C#8]5 ;42P?K3-Z
MJ1="V,#]Y>KNZ_I^*9X_KHN3\MMMR8@DF*:V]'!$,<2<(LAIIJ&@G.B4::UB
MIPC3<=7ZW\0TH[P&9V=F9G ]G9V]=M;;83O]S#[9*@CTNK!!%%W$-E5SN1&!
MF]YA&D/9N1VJ$0$^XG"-.7I(7/ZZ*-:_UYWRZC;CE_I75OQ+;<MKP=N,,18I
M@6 D>02QU#&DA&:0HC1'--42>:2K]HJ;F"#W\M_9QH^U!G9./Y0Z>,=1]./G
M<.0U*BI^S-8&9"_<AJ56XJN+_5$!\<D2&!.8P,2!80!Y)A6XVMN=9] [RHRI
M!ZX6'68C.#\U1L'&O;1V-=5Z^[NZ6XCM\D=YM':+$(EBRA1,5&*Y4&:0)0A#
M8MZ X.8?<IV$%W-TUF-Z+[)5\I#OM!I2[]$=8X\-[+3(>6]KCX+V[D4]9=TH
M9;S(1JNIZDAZPS)KC4EW[=ZP_J0WA-VU*?V'"R:X7>>MS[98:^N"H&\"$I+P
MG,G8=N5#$"L:06Z+E @62RD%%9B2VU490"9OO+@N5"6G64NK6?M*,?<9W&KJ
M9ZN5W%LEAS3Q#'\%SAPX*:)A/-A"\16"LY/A4'RF)\1@#><FQ:%0'B'&P4/Z
M5[@_-]OK[?/?U_=FG\V*YX_+>T,4MUJSV/PO@YE(),1YDMAJ3!A&BDDJN,P)
M=BK/<5+"U,%KI4RP$PHJJ>X%[X_#TDU#HQCK1RZ^=GK5O^^T):@(_O$19ZN$
MWVE0NQQ^]P?'#/G^N"YNV,]K5?RPO57*LC@BB044>6IO^K" 7*<::I[P2&2)
M0+%37)6/T(FGHI'D40S'"RU7KV!<#/QFZ/&P\/)\W+;ZW-0*3!TG?MS<-XD:
M?Z'*'R"&_#@X;A'E)YX-";RL<[++O),R,;OI6UC7\5+RED>),NLP@ZG.(XA9
MAB"32$.,,2$Y05E,G,Y;7 5.S U?=G4BUF6>5%D5 OS>M.D4C1J!)2-<$'4X
MC1X9)S_^V)=%J%+)2OE@U\ETI\'(L/@$7XX+3V#LY5"8/$,PW6WNCL!T&&?&
M $QWJP[C+SV>&T",K[/PCJ?H[8_(ZWP^V]/YXN%!R27;JOOG6XQ5)#D7,.4R
MA9@*"FF:V% (FBJ9Y2)V.[6>1+O9*'?9RD:]JS0^N -4>_7 <J]? -&,]N(\
MR/HM7D<HLQ_)"SZ=.7QPZ];2&5S\,=Y1P,KQ%N]JZ#(SWSL+6YG&QM1I&1M-
MZ/QKWMAX'5T@1Q<2>A1Q4;>L^Z"J/^N")6??S9==;2Y6NTHFFW:!DV*Y6:[N
M[+7-L3-ZG+,849K!..;4[$W,TLKSG$$B"-4)C]-$IGYG%Q-H.?7JNEY!P3;?
M@:AT_*]Z8],J,61+\S,;4!X2@CC%>W,]17GCM^&WN#;*@E]DK>Y?=L6=ZG=C
M'*#6>S$<?5 6JM*[NKR>^E9F0F0G/^&90O>9CX0FA/_U&=*4PD**2<G_>=IL
MRT7GX[KX;?7[<B7-X)?:)K[8V,NF8\CZ=2_US2UG>6SV4L@0?1J;C52D(<&9
M@BK6+$>,Y#KQJ.(^1)6I[Y.T5J)LV_'4Z%5>B<M:-="4?=^N :M5\JF9-.@M
M..R*9L/6\W!\KU99ZGRGF/6P&]7V#8G6H*4=6,R-LT^5JKGP#JQ7-2GNGJ6K
MQH"JNXC5( DSEK,: XG#PE:CC!BZR;!E#]7F<E6M;:VES<A7Q?*'^<[^,-,J
M4?\_<^_:W#:.K0O_%=3955/=5<89@@1)\)U/CN/T=NTD]G;<N^M4?W#A:NNT
M+'I(.1V?7_\")'6S) H "3H?9MJQ1:RU'H@/%H!U23@M!()(YJ:61!1#1G@&
M<T0BB6B<1AFY_RXK5MKO'.Q$N[QHVPJX>Z$[KJ:KTV^)(V6\D GF,*$9AMAT
M#R@XRR&+S6\ERG*9>H6IC0CFX)BT7U:0_@K^"5:NO8%7;#0)#W6$"A%%*84%
M$@7,&<X@40K!/&=<X8PQ*:B&>OF>""_=@&U5 *;B2:/$[E?6>#Y;" >"U78G
M.O[;[>:VC(.5QT;1S?#@>S]+=2;>SKF!M+]#<WQ^4([9Y8_9\I.4F_.^^YBC
M@LL<P213YA2M2"$3*(:$1SG35)YER+ZR4H^@P!NF[2PAJ66;$*"MRR6O_*E]
ML"QV/B-!X$80V]8;L:9KT]85P$C6>^6-#4)A>,:8"QJ^J6)'3;1,$MM__CW2
MPXY:<20Q[/CG/1AJ=3IUM7@;B=R=5WTIQ4S-.&WS=+4C]W2/HT0AI3A4/!(0
M%Z;V4:J)3"89$EP)3HK8FKD\% C,:!^WG,V]./[UV?+3EEI-WH16S.%U]\'=
M@@0#H^E&CFL@KQ:@46>GFERG$-C6J&DX&AY(!SX-#*@?SP8 UHV"!Z#22\T^
MXTY'V0.LWJ'R(>-X4'P3IV7*AHHN[>3<A&P]-->2]3FKEQ7ER_N(12C."@I5
MVH1*T0)2Q37'DT06$8X(9?8EC:U$!J;Q1@?8* $Z+<"V&N#/E2(N!2WMP+1@
MZM$A<N/F]T3'@7Y'1\F/<,= RXUAG0SOY52[D:9C42?+=GC3[4E?IFRJ+'S9
M1&Y<+9Y?5B7F$*98X2*!$<\5Q*F0D%$N8$R55$E,XX191;Y820O,C]>5F"U,
M)ED;B]^4?VG"[^5+59H=?/L'ES#\D_C9\N)(J'A0XJJ=RY9PT$CWJ7Y\$@]7
M)AP)EP$D>!2?,7G/PLS3E-<WR,1L9V'//M'9/.3?CCKMOH$2<Q;E1095KHAA
MM!P6F31%WCE)<T802NT9;7?LT >/J[[&J7O;YM2>C_QM<CQ)7)LSH!UUZLXK
M_O8-;$=]?-J\VE&G#OSPYI')VU&G/>_^D8_XYOO?RH>9<8P6RZ_T2=X7"=58
M"+W+H^9USW()B8P85%SQ-,Z3E'&KDG;'!(2.SFJSX#<R@1'JFNS_!I-^$AC#
M4C<F<#32(]/_L"4#$OW?##AQGO]A<_;3_(]\SC?J1>]$9OR25@MS*&_N$F^Z
MG+A[CE7!:!3I?4&.(8[S'%)9I#!'/.:"4!4QJP-R"UFA%UDCMVF-N]D1^&\2
M;+#K?QM'1L1QB6[ D)U,\(N!Y=<-"&/>_Y^T+OB5_W$-)K[E/PG%_L7^Z4=\
M JA_.]=@):ASL?)419E^OV&$,JE74HY,O6WM/0O$$1,R*K!5^_(#8P=^I[4P
MP^$)1"X!M;O66SC._C:YO94;<WP<YS=VN43^>MOG&<I[>MH<XW$/&M ?8+O[
MR(01LP=UW0V!/?P1W]5]:^=]_F-6WR-*%2:<PRS#'&*&(D@R+J!,E,I%PA(L
MJ=N:_D9"X+=^^\#F3ZKE.;?P>8N([4H]P$XW)G PT6-)/F)&\(7XK=R)E]\C
M9N\ONL<^Z!.4LM6+Y_JYJ;^S>+A:\/))WID$V?LBBR.&$P45H0G$*DTAC1F!
M498QDB*%"QS91Z"<D!8ZW&333LH4-5DI %H-P)^-#BY+VDGT+!;O,3%Q>XFG
MA\,E&F1$6#Q#/X;!XQCF86EN?TS'J4$F#."PM&<W6L/V(>]J@4WNCA1_R-G#
MH_[O^7<MY$$V&Y;ZGLHB)['I+)CIU0$S374DBPC$F"DI)!%I(5V39GHENGR'
MO7)E5E(!;<6"Q:8XV,NR7M(V0:VM @9>S)V[*:*G 7]^:;[K8C9_,<\?.)9P
M*AUF.P4\)DS%>J$1 A<FWT9 DN089E&>9*R@4<*18ZW&L2; 8[UQ@O]L<K!M
MO<K1('1;GOK0V[E0[[ZY&B9.Y_QE3G>^NNM#I""G1U;8A"\)V:O%U-4@;2 Y
M4 C2ZC&?TR2E7]TD^U(NEH^K/LB9B&4J)8$95GJ+F3$$"\XU\\LB09&(4L(<
MCI3V!80^5S(209*!IT:FRR', 3!L3IB&F>AXS+2RKA7G==9TP$R7 Z=AYGJ>
M.NV:/=;1TW%3^L^?#CPWX2'4<:UW3Z)Z/N=#%7SY0JNV&^W+4]<P[?+'L^2:
MD&[I4M;7ZNZE6I3?FPZR)%))RB')B>80F3!(4%284VH2%4D2$>I0J,-!<F!R
M68D!VO]V2:MR L^&<P)!XDA&*RW 1@VS'UPI AI-FJ#_3I=0D+GP5R#H/(EM
M/ @=N<\#AGY2=!EP0K;TL'.71GT&\.#7_Y*O7^B"MG'$-YJ:RL5"SB_T=E,N
MZN9+=;7XK]E"7&@^KV;LQ?RFOL\RDLLT%WH_2/7_I5A"4H@$YB1EJ62JP,B^
MM*R7"H$9=T>6WL? O[0"#C3B!ZL%!0<'RXV+M3I@HP]8*P2V-3H#5PMHE ([
M6@6'TX&>@\/JQ]-!X'5C[$'(]%*WW\C3<?@@RW?(?-A('JS^^Z*2O'Q8-+6.
M/M+7ZX7\C<[T"M+5U:/SK;R[^PQ)GE&SX8Y58HHQ4%A(1&$<)[E*%*9<*&LV
M=Q(=F,5W= &"OL)R(<&#5L<<6:F50N[-WCQ MN#V8-"Y<?HN:EH/J!4!1A/C
M$*YUV4Z[#8:: X4'0\^/NL=$T8VQO8#H96JW$:=C:"]+=YC9;X2QZE%O5=W9
M"B#X^"+OREO][W)!V?SUIJSKF2F,O5@]]/NB9*:C4E,NVR3&Z#V"7-;W28H4
MR?,"QAG)(&:,0):@! I-Z8HC4[#+KX-G6+VMWL7!)=6V"UMLF)\V&@"Z'%!-
M+?"L8B%,UF4.6293/:M)U#8I+&+.DX+I=Y6(807'WV$Z_=?T0R6O=PN3;14>
M!T+_>UF":FT&>.[LT ]MOA O6Z;H?VM;SKJOQD_V9;"](/QYIMC-]_A99G>$
M\N9A()^\TOG(9KQST?,PDW*Z_GD@N;Z.2--HUQPA7FFW=O%@A+8C-XTZ[A[I
MXK>R%'_/YO./Y9/VA^[SA"E,F-"+4,P@ED1"AD4&F6 LD@C'*+$Z\/-7(?2!
M7ZM.VS%JI=#*/6B[6RRU3N"A4PK\*1JUG .)G:&WI?R0@+J1^/A8>M"Q+QS!
M"=99L8DITQ>X?1+T'FE8,.&J$'@3I\*V*J;4]T+FD4PPAC$RQ?LXCV#!,(=$
MTBR6C&.1NS8>/B$R,&VUM7D:B4V,X.H\$<@?YF>/?L2G(+2EHS&!<;P?WBK[
M;V(GZRV,GCOIXP><G;9THIBS'D7>)>SL-##'(L\LGAQ4EGC5K^R_7VBEW[UY
MTYN,SN?M%YUSG!8LRV!>* 4QX0J2E*90153D%,FT2+A'B>)>H8'98KM$[29T
M\]\K39I>F2M5O*KW]B-J<00> "<W\MB&:-,&<:T$N H+D5>QX]&@&E[XV!LR
MWRK(5K9;5D3N'^L]JB-;67>D4K+=LSXA(Y4L:^W;57*Y:=.U$/_91 FO>B$;
M9^]KN92;\-ZB$!PQF#-*(%8JA92B""8\B1@B^K?"ZA336X/ U-JH!/Y!GY[_
M!5K-MOOI+03HE%MU>V^V1 NCGDL8A _R%JP;&D\W"CX Y5HK<+X%Y99BH-',
M)R[9"U.7R)+ V'H&EGAC/%98R0!8^J-*? :>,*AD@-V[,25#!O)@_0.ML[2X
MF]\N/Y=TL2+YE%*98P9C67"((QQ#6F0)+ BC6,59))A]5P\+@>&# -?MX%;M
M#ALNUTJ N=;"@69LX+-@ZI%!<3S7.] >KR$+@X=1P(=_;8!QH-N1 ?)CUY-
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M@A@1A6*:(%38-[#IDQ1X=5J);EZ.YG2@;0_P=R?>84?:BY?%EGXL%-SX80V
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MKS ;5;I>CV.'DCI-A>VYX'L!['AD:!.":M5L\]W"4GV ?/>052>E?[)P5A_
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MFI5">]IEI86=+T3[QW.E>;']K8GW;SYT)W\L/YBHJ?LTRU#.8@%%CC3'%Z2
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MRUYKCZ?Y57NJ]'G=:X\4F*<1C6!29%@OL )#RCB%B D5)0PE#/LU@+148-*
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M<P:QY!12E6+3RB\3,L[R-$5NR=Q>>@3FFC9=^!_TZ?E?H-5O=52V>#@#2]/
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M5U\+,U.)8>Y2!W;7>HLWW]\FM_=^8XY7?=M=NUR*UWK;Y]GRX?2T.9:9/6A
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M(@Q3'"N(&6>0"5YHG\QD+U""<\;6U[TN>;*G)/O<\'HDRCZ:3GE-0,[?K7C
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M3>!E[?;R[OSJZ^5'<'E^^_7JZV_.-XA#@+;=\TX$G]NJ=:#ID5SI];.T/_(
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MER_7]U_0[![-/MW<W7_\O^L/Z/W-EWNH3H 8M94-7SS!5&07$T]K&"9N@79
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MK6XN9T=Z1_(X#Z"DU^?LTNYT7N<!5A_XG8>TXYR9HU/K*&))E'!, IYA0KC
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MI#!]A>>SQ83^XH]/7TF$B_='GUX=_:]?3V<QG/X6YK_C\C<\BS@_L9;IE$,
MSZ(#9:0F&TJ^E:.3W"K-LS#FL:-^KY4'1,P!ZIWU)>NA@70\)\<_/,J2=LP;
ME!8<CQ84TCGL@@P0'"/3JTSDF!K!I]EZC4 CQ@R:#N0Z],&S,L!'.1,_"UQ<
M_N0S_<N5$9;HDD02DD$DT.>2( :/D%QDFDRR,5*UX)@\M/Z B&G1.6E%N@/C
M9(/TRTTDLTJ>=@O$F.E\9E(2\:8 D\)SJ;G!>%C4<F_)H=V4=O0X:TNH R/B
MQ<5B,B7J7\Y(">G*] GG<\S>0/0B@))D!+UQ&L@:9I2IV,C#0:C8NNQPR#A0
MA;,VY3F*H^3MM"8-KW)$^':)9XL3;4WFG&?P,;"U_8S1),@E6ZYXR2:W<8QL
M6[L1-.38CY"#I3HP-J[2S76?G'CT14GF('@2@ K&0$B1 2:CHW,%-1Z&ALW5
MACXT#M?<K 4QCD3]'_'+I*;_JC0^D1:P_N:)USP6<I7!65'=Y<(HLE(:. :=
M;%#9!]\*'K8N/["/V0U #A?T2!!S-)U>A-./%*3/ER=*6..) \A>(R$>-42F
M%/A4?#$L!8FZ%:!LKCKP =(-/O86ZTA@\0'GDUE^/<VO"-LG#IG4F",4:4@:
MDD4(42=@PDEN?-*BM&- ;BW;"!CJF0%C?\$.C(R7%_,JMC>310JG_XEA?L5#
M24QPSPWP4-&M#!(/04+2F<1! 5HZT&@\M'(C?.AG@H]6Q#L2X_%Y'J:+297+
MI0$,S-@2D@*",X5LSFCPEESUI/)**MJQV(Y#>F?E1A QSP0BK8AW)!#Y]!5/
M3U_.SL[#],<E%U[5&VE%SI,O"91-%.%K;R&SJ!ES%/,C;P4D]]=N!!/[S&!R
MH(A'D>QX,SG%]Q>K1 WWLA29/6 A$Z@P6_#91:#SDUG%6= .#X+'W14;@<(]
M$U <),Y10.$JXIHNWX<S/%&QL!*+!Q$"!>>>H.R,K25Q.9CD#=KL6H##[54;
M0<(_*T@<(-91P.+M-,WF9-QN(O&7LXOI<O[CY2SC231&6QXY>"\,L4.,A2C)
MX$DM<Q*RUD2VDA?=042S!!E[5JAI3^I#1S7KRP"*RA:SZ11/5YM AN SQ>K
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M.!MP"X'-T/3L,O&'JF(4>%J+ADB_C"QJ'<9D>D'>WJ7;5\L>2V9):!N >9M
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M*T>E#@S\2'H(BXOY2AV+X_(*2YV1=?GB^<-IJ$GO5 0Y2!8<UG==IK8^"MJ
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MC]/;PDOO!]?X7-OGG63&@O(R08K>@U(Z@9,V $>IA,W21S9,4GH+L6/*U+:
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MR_G%BJG5F7F)<PNE6 66W"APV9,KA8;I8$/DLK\GUH^2.W2>J.,[NU:U-7X
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MXZP3F8["Y#QLEM]-IOB6_HSVD9",NXQT0E.@JEAAX*,I((-6&"1*Q_I[7-.
MX*'OI;H]ZMK6V"A@^/ZB;I_CLNX*MB[D.A%8<LS.0]:%@[+90-!<D1'GDOXO
M)%;ZNQ[=1N'0MJUU*-P#V\%ZV1M=YZO[5>)POFSM@C[-*)PYG:PT=%QN\W9\
ML5PLP[16)US7Z?.8>6'.@N%T-"C:J1 U_0<+[="4DQ2Z/\?KR>2/]\JU+71V
MJ]&AO;>WTS3'L,!7N/[Q[?2*O^,Y,17F/S9WY>>O\]G%EZ^7U:]7__;$>V)+
M>Q)P40&4"8FVJ6/ F$5=O/"6YT9.7AO4#&TO.\;+;$CEC1>M6QA]_1WG:;+
MRS_\9YC/PW2Y.-$J8 RHZQ5+/5F"@:A\M8<J%)E(![[9Y6,;U QM/T>!UHZ4
M]ZS0NH[U%BLE;,1]&UG1FWRH8K13;18(,4H!6IL8C0T:#6L?N(\3-O1EUU@Q
MW+)*AX;S%:=OYHBW775C2W0A0C$L@HHR0$RV@$4T/)@4I?>-</G0"D.GE7L$
M6"M"'F^T;9DJCKB'H%*=0J@SA*1J8P;F37W?HG)_C0_WCK8'N;CO--I^BEX.
MC+9?3W-;HT16<CG)BNM24^Y!6PG*6P>!1PV^Z%Q']&;BIC=,K6D:VF!UCZ(]
M9#^B+,U#/1.<8BD(C*37.E('Z\B R!VPH#1/UH18>BPR:M*(8TR)Y[:PU89V
M1G$$;K0ZSA@X[8X,7)A:\BT2;12?P9@ZMY!I:V5_W5[&TW&Z%57O:C']%+F/
M C,/MC;37K/BC !N1'T77 30KQ@8'ZUS#K7%_F88'=1]KLMGVIW@J16=C )=
MVWOF*9LP4/A)L2@HJ1A$$PWDHB@$Y9&'/BMK]\14EV^N.\'4H9H81??"N^F0
MR\3'T?GY?'8^OPJ7[[YU/(F995_+^3RR.L/$!G!*6)#&!:9X=([W=QCNQ\/0
M'GXWH.Q!GZ,P@ZNH]^H][XGW.2NO!>A,$;!2A<(93N0'YCT/62B3^JOKOD7:
MT+Y^1RC;6_I#IT!7.9,5^1_QM([3K2/)7Q(1D^6)I!T01!0@6#7>3'#P7!8@
M%R')0,ZF5<VNE78L,G1SWS;QT*I QS06^1+>.S+^26"!G$0!JZROF>$,Z*2*
M5KK@>VSNNY/4H=O\=FI\6M#.T,;H@<.Z,ABFB7B\NC2]-+3.TVDL%8*+,H$*
MM2UV9!9,*J&(Z OWH9&!>N+"C7#DG@>..A?\.-RC[0S>W,G?85 H+0U/'(I!
M20Q: UZ0)(4U*(+3H?0X7OF)Q#="IW\>Z.Q'@R.9D/L BT^Y='?*9["F% B9
M.+8RF\3)XQ#87\)C;S::I6[9GP2Y+:MU4 QO/43>D(3O7?I+JYRQ-H-/UM7
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M3VF46'HR(<T ^6>ZYNE65V/'Y:M+FM;!YM4YLLEM1HW(N 2>+>W"1$Z_8]F
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MV?Y:/!T MPZO(3LN:3Y0*7N#ZQSGDUDFYN;+;B%FC7,LF>K+UADYS#&@T"M
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M-XH1')QA20C;=&S*KE7:M4S7*VV$/V^GM-+%O;O]DDTT*EF(NI[7LA9.)>E
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M(K=.!JFC[P2"NY\[=7^),4!P@"2G!L%VL-NEMRS18%':0C(E4T#GB7#C,@E
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M,;/$.QT/7CW\OF#[$S?CUTXIU2X4+OGZ.(#<3E(9@BIU^"DS,MOHO>QV]S@
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M,P2?+)C@LA&^&"-'?,'SU^G V!U6@W1@[*SCJ3WU0+W1[O"K& 1-ML*;I*U
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M,%M6OM:X.J1-R+.?.<"E[GYT#W:WN]MMYF2>KWLP7M^VB:QS)A3$X!2%X[Q
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M .V%9&( 9:,&+S5EH]&SD 2W)8]W?? LN<.>VCVZW/;1?;!6%D0(HLX@P^C
M!?)"5C*MDBY&Y!'G3W2F>^IT<EC,/7U^-Z &FXB"CU836A)3RNL$.H<,*M02
MN^0%9*806?9&FA%O"?\"%>=#(G.\TO-]8-+@AME>)6'.JKA4(&M4H(PI$+E(
M(+(40DNG[&Y#R'^7GD^ GVZEY_LHLPE(/E[GS"5ZQZT")X,#I=&#-]J"\JA%
MU,P%/]ZIQ<LJ/=\+!7N4GN^CDB;0]=AFG>?;^W7+G>711$4"HT14@'+$HM?%
M PO,,16CX3A>#>\^E$]]''P$#!Y-<4W \KKZY/'H?],56Y:L&$IPL78O\[4K
M-L\64E!<F51TU..]@.A&\]10'"^H'%Z%+P2:5P51 16+M;V(]+9N.DI+/?D"
MESV)3G'.3$O@;*QZ?$#4](!F#Q4V <Y7%R1?<C1757 \Z4CNA#:N(F H)7,U
M_ %RL09E0FWC>!C<(:Y]J/5!P3VP':*2)C#UH919PFNA;-E@W,?B$Z5FC (7
M*[*'X(F-(IP51I)LXGA)\8,D3NUI1\+7X>J9OK?:[Q?+^6Q-,0E)YZK<?9<C
M[9/E!0N4R,CDQ]HGVU!<DE 6$1DFL_LPX9%^5AT6F_I6_:C0.8K$F[!4CTKK
M[3R=7>2K$O%%N5A=->NJP83*2E N9H@Q0TF[(7$Z75@M I;*LOIJ'$<S9?UX
MF!JPHV45(ZCXA4)Y:Q%TLM)X'2%Z53>MR1",2!!5"C)+Q^R(;U?[<C%U:#@&
MR@: =@^5MPWNN\%+@5 =FM6ZD%>+!2AL43YCS"J-=\[X#+$O#ZI]4-,=K#U4
MV 0F=Z5T]8PL)B:4CY -IP"K6/)6FFDH7OL@G0IL=QK),=^P/$CCU'G.1 @<
M0&%- *]3Z/3N^GV/Y5J4: 183"0TBI@@V&*!A9 *.FNS+*,!<C_:IR[Z'"U(
M/:)*FX#LH]6SS]=J*6Z=8XX!BW7<(I>9=K^Q8)@7PD3GHA@/OOWYF-KK'Q-A
MW1\%#JON)J"]OS,[+29Q4Z\AT-7IW5*0&W,4]9OLK9'1*57&.V/?G_ZIH3P6
MN@;(M_92]4M]-]A#+"B-E3PX"*4.\DA<0W19UH$V+D=7D)?QC/J1F9TZVIYL
MN[0$HB9<Q>VRFQ[\9LZ\9\Z#%K7+9)0"'#(!OA#721CAQ'B''(?Q,O7I\V1[
M8D0(M/0:D:+/\\4JG/79YC'Z1'Y30)*>47XN X3D.8A43% ZNH#C14L',#)U
M,CL=YD=2?DN )XZ6&%;X&U[^OO5\[W']YL^T$?QOLT(D;AH"]I"+CM:Q:"WD
MVK9:26?!*8L@F"NUV[!-=KQ-<61FIYX.-=G&:0E$3010?8)$^B]+8\ H1@8D
MA@">V0#"2=*,S2*.6(%^).R;7Q#[1U;U"WS__CXL:]?"'WB,-^WW/OR8[]2?
MYF3$M^>8+0LY$B9S*!1=&$Z1=!*0HX^2<46_-G 0=YRWY__W!2TS6V_T\'9>
M%LOOEV8E+B[6NUOK\HJ#4;"%CIR$")&2#ZDM1"85U-JNC*GH@N,-U#F(E:E/
M,(=%YM/72<?5<Q-AP1?ZSA7YIL5\([S+TAJ2&PF*<W ^U;:&M4V\J;+T+KG(
MDH@CEAL_1.'4(!P1)/< >K#&FL3=MDJ!I&*=J>FJL!3X2*X@\N AHA?2H2%.
MQFMU\#"-4V/O</T_"ZD>RIAZ9/.[FN3]'FJXO9Y11A>6L^LW(%P5%VIK5A9J
M[RC+2$J^%EK[B#%GF8-_+OA[9HW6,-%'@8OAI=F$I;DN[[]5.ZJ-B10=&*BM
M%FOV+L$5*R&K(IT1E&3M3HD?X[7@GA7F([U;'=N_':JO%D&WW8]6BQ1R"2#5
MIDV^->"SDB #YB12(B9''*OY$(E3&[*#E?\<G'IHH@E [3YL+-Z'0/L)C,J1
M'+[6$*-F8+#DG)%'(F,T*+7ZUK2_RI]]6+J/_"=]\G>X47]W7=DF=5"(0D"*
MZ$#9(BG*)-^?K9<\9.'2B/79![,S]47ZE$YV7"PT84'OG7D[+HSC-@#J&LD&
M#.!K;3PG2V&%1Q'#>-<;K14*C@R09Q\<[*6MJ9/1G4O'3[CQ1ZMZ2OFA;'*K
M+[C\OF'Q0_G'-8N)O%-,25-XX\A#>4M)O$4+):FH4W"H[4Y7Z4<2U7[KO]2D
MXS#(C:6PP3 YZ(W9IKRPS.9AGF9A$S91O'2K%?+BH7_O?X=VR'(#W*H-QNU@
M]VRW,?_[U<+;W.>Z]WF)RN@B(//,0"E/ED\H"\XZQ3T9/^7'FQS2@>"#3.?[
MQ?SUQ;(:C)/\(]3BC"^+UY\^7)]L_6.>B8+:V WS98.W4T>;4*BLH62N0'''
M:1<*!:)HCRH(9W@WL[G_VBUYZ2'@<\<H'ED5302%[Q;SK_1YWW_#\\5J1B:=
MH[?<4%CM?9V0;'0$+YF#PGF.T6F&;+P7_;O4M>2AAX3;0/J8.NS;N)>;7?-W
MDA:>G84Y+BY6.^(Z=<YSYX,!K:PE,0GBRZ,'"F49D9ZT4,]ZTWT7;2GA'=Q:
M'4OX39BI*^;2)7.[_(ADK62A /=(0O/U]B^2%78BU!GOL@0_WG7&T[1.7<E]
M?!,VH*[Z8V^Q#F>'&[0GW7\=4V:MT1DT<Q*4)M-,\F$@?.4J.:MUMWO5)Y>9
MNH+YJ$9K. $W8:8^?ULLU[?=]_O%>G,8/RLSBA%7K\/J6ZW7^A'.B.O5:6"R
M,*5<+6Y-H%*V$+BD7Z*V)<7"BAAO2,N>Q$]=77Q\0W9,;381JFUWW]OY#URM
MOV]X(+NDG8\</.,9%&8/L5[PU*DWRGHGO2_=P[+["W1"C7UYJ!E,J$W8L=N,
M[/IO'YQG20K0*6I0A3MP27O E*RWR?!81HZU'B:T$]+<RT/:\%J:,,K:8>8>
M%UI&+Z(E^R)K>Z50JZZB %FX5[77%^?CG?P]1&$GD/D7#[)#]#(8NHY^[C_$
M(YE.GWNDD_R1GL9TP9SB/%II$8I*M3J$ !)*0$@E!,*,8EE/,WUPX"/[3HM<
MUBL8"@!HTR2PI08!6G"(T2C0@;9EUHRS,E[?W^>H?0GG^OM@[.D"D(/UU430
M]JF^KKPL&"P^ZB@B6?Q"YMFX!!%-A*0PT%<J6C5>F>4U60UCJH?&[Q=L]!)_
M.\C95@E&@;2=# -3.((208-S)8)FDB=I5'U#-BYVVBC,[:G>AV'20]9- .75
M8KU>?/]0-DQL"T%3#)I9;RC3*#6\- 9""A;0V&R=UCK[\0#S (%- *>/PN^7
MX!XH_28@]&5Q?I>#8+1PLIZ&9,O)ZG(!/G@!W''C38Q!Z1'?6NY0-_6%\W#@
M.4CN32#G"?_][KH"CJ4D)48&B:L 2L8,D6D#%!TZR9DPAD_3L/@QBJ=&V)&C
MHL&5-O7!>8^B(,;]YD8=HJ(PP;KD(6I/D&$E<-2VY-TF9'^%^JR>ZC^P0&L?
M74P-M=^VQ'\*:SPY/S^;8?ZRJ 5"M1;WBN-3-,D(RR@(#<Z#LLJ!=V3,BZ[=
M8PMCWJI.Z.JT7,/F:@! #2_QJ3'T,?S<W$']OEA>T?_WD)'VR7:3?"(-$GG?
M/BR_AOGL_[MLJ/K QC'>F1(DAZ(P@@K<$?M1@XG!A.@H_$B\$\R&HJCA8JX!
MD#B)WAHNT5]B0OIK"DA689XW=>J/E*\__IT'GNH/2,)0%P#'DLI@=P5?E@3:
MDWG>4/OIAH;K0UR3+/G?0MO"V I/PFA0W(!57MA@L[)AO!N^YZ@=*'#\N,3S
M,,MO_CS'^8K\"0O2"ZWK1$5IR)^0('Q1'%(VR-'YZ&*W.K)'EY@Z#!P4!H^$
M@(=(M8G\=J=NDOY4=JY=+X-7+:%PD\$**\!9XVK3<D^QJTA>CY?</DONU*'B
M44!W+'4U4NEZ%55\"7^^)@IFZUMR.S5%%%NX!J5CJ@W$/<4Q7D$HT1?,L@84
M^]2[/K78U-'=\2S6T))NPG9MF?K/<':!)YDB!V+K-D.Y.&VC4&!4+8VD0!@"
MYQX0I8S(C5=^O+9FSQ [=87^D>W6D*IJ"7N[_M\[I[%**;.$% 1P\O]LTP*^
MH+=.6)-&;''5/RP[8FG_.$@[1#%3'Y]<&^MKV5!"_H92QL5/Q%<XQS+;.OHD
M>: M0_O&*B' YZ1!:LN4LDIASOLYQJ>6F[KP?@37.)BT&\0/2?32X;]?K+$^
MQ7/:."+?&E4+=96"*)F%K)-@1C#-=;=SM6>7FKKT?E3<'"#E]C!#0GO$EHH0
M$&UMNT5NNQ;B*O 4'$*L-\.F<(F[#:DZH^?11:<NK!\31\-(OIT"^VUF:@NA
MOBA&F6E]5!Y5S2^B 1&D1\.#EFJ\FIU;A$U=3C_&D4$/%31<0O_HN?)@Q?3=
M5SCZJ?I(!?;/HI"+R.I\'9",%U ,Z[O8Q"!@BB4JLD AC;9]CWIH?ON2[=X"
MVS5O%ZOHI$/(7H'6M4:J>*Q%30H*_:DH)+D9V<D?[KEP\P?L^T#FWI7XL330
MQO$!;>J?L_G7R_O2DY0NOE^<U9%NM\<MTC\NU[/5Y9_G^>UWB@66FZ$;\_S'
M<K%:[7Q*K1..7L8@3 2TK-3GP!Z"CIQ^R<YFF9'9$<^\CL3E-, _/C+O'V:T
M ),&-\RVFM1)65**"9PQGNR+1@AD<*"(I)ST%".-V([Y(0JGMM!MX.<96/=0
MYM39\F_;-;<E./.OKQ<KBM1PO:8_;_F1*'1.9O-(K.[\Z"A-8P%,,)G+XJ3.
MMEM4\/QB;>&LCT(71Y1N$P;LU6*Y7/RK]C)_]?-]^'[YJH?"(QYB+)!9"=4[
M>/!*)-!*&X/<:6'&BZD?HG":Z_0)/.W!ZFD29-M''$48AB0%2)AH)^9$>U*[
M6HDL9;!(NW3,L04/TCBU!3M<_\]"JH<RIO9S_WN)B]7K,Y+A^MH84]8W3]_P
MU=806ZF1MA:)!X4#I2T9XL@3).ZST3X:M]M-ZA$W]_Q:K6&DCT(7QY/NU&#I
M;K#?79<J!\XBB\F"L4:2+R\2HK!DPU/ .GXF%NS6^:G'XM-4^XSFVT;1R=28
M^[A<),2\N7J[5]QTJIE"M-*!42K52_\$0?D,R)-5$FDWE6X754\N\R).(WJJ
M=W$464^-FB[5< R%\%C[/CK*:Y4/!:(FJ7'OR?G7,=T=YQ<.57<X=90] (*&
MEGLC.-JYI?V$FR.6S:O 4\=BS)SR5&8$):N2XD@7:%LHKS'KD%D.W1[*/;_6
MB_!GPZ%H**DWEKB=)DF)1?0"A.?U"4&]X[>%8LIH?%+2!VG'>YQR0]<T!:JC
MHNM@=>P/)7\)I3E^W8!W^ +5FS?*GR\V;TN7J]-B>0E297"FMN\@29&)K<W^
MM8YD=,G:LO$0]CB=TQ2J3H2X@=0UM4<D.6U[%:>-ICZ4'3--]GE[5KRI!?]0
M?L.X?KWX?KZ8$_NU3+=V<I3@%*OM1NK[*4,RM0X#\XA87+>I,@<2,DVYZ_B^
M=$Q]M?G0M_;3#O.<Z#>\::M]^REKJMRN9G49^N+A;^]?;C3H^@,4(QU/'H.5
M*E42:XWDW4[H-U4GKE;$"82@DZ+-P"P$X51]@5YX#%);.=ZERM.T#G$O?K<=
M/$4DUFM5('-.D2]'3<Y"4C8EI-?<):WS>).4^C3O/^HMY6"X>>A.N[\BFDA!
M*@.G1GL=A"2JE=2@L+:.$/2+SI0XQ9*+'K&O7J5HZO>\1\?,7B)O!BCW17):
MT#D9D7CW:3.64T*(E'.;X 2WQ1DEQK4\]VF<^GWOT<%TH%K:+/E^."(9HM2[
MXR<?+:H:J;3[&=A)0@!W!#LI:_*0E((@$R69CNO I.?"CC>1^SCQTKW$ZN%E
M+B_;O$"E4^UQB5+5Q_!(J79)(+(J*?O",':[->JX8.-AT3[P>/3N<2AY3^@
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ME;%S[]/8%[.YD512M^RO*NE(ZN[+,JP2IU))#<E42^?I?P<SF0N3F1D1C B
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M@'*0RFAP+I:J <R"2Q$9S*5TW'O%28]]OE^]Z6E*WDV/^R#E-8([VY]ZI)P
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M%S2:-" 3>JG<"LOV=\_Q0JC;R*#K!=XC\=1]--D("78A@HJY* 5W4% %(;4
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MJ#;&>(DNCNY5[K)N(98J+!BBRMHL^(1:"%_294 FL5Y[6SHD)'1L!?%%=N-
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MGO_^=Q2\FF7>W>6YDT5I7)XN!"#&>)&2,60__GQF[K5Q%SP.%SI1;  PM8_
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M"-\!:JJ-\-5=]H&K["LE6 LN60^9ZR!L8LGG'B6N;GVY 92'X'/@XG^8LII
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M'B]N#$R )E: ,8R 0%^5J""YLMUJ21X[DVZ4?B9/7/-C]ZR/@A?K==K<UX=
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M=/<Q^I)X<)AEC&)_QMJ+JQ]]NFI]ZR,EZYDG>Q,8*Y55]0@E%8"%DKA!6]R
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M1H\N,W9/IL% TQVSQX;->X+];TAZ<CU[C\O?WY"XWO]V?>TR9Z1$A>!05U<
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M0]:>>4'<J$3.'T<'DGLG0S29Q-7M_N.YI5I7!PP*FWX%W1HV3_@([ZZ;1)C
MDK,N@V6;*D,>('A3P&0="!S>)J$[(:?+:@UCK^'N47L7<VO</%61%3U*9XT
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MZ08/M:%Z#,2W F-9=>5$ J=")CU'-(S+J)\LD>K9-MV@K!N(7MH5_<&R/QI
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MM;Y!;X65^Z ]2G%3P]ZML8\ZEB21@L"DZ7#AJ8Y]).%P(TH(K!@IG^JZ/Q@
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M3###Z)"0Y-8+:XB(B/[)W@>=T?48 6V,68^*7?0MY890V;016_XX??/IBN(
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M66,TB*KCQ+H]%FWC/PZAY5LWZ4.)O75RYN-R-D^S;^'BY&R)N!76U2 ,QK@
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MK>;O1=#3./B>[5"3I7,1$<&K$D$9QB &F2$'[C1+*2@_WD# ?KI/#7]CW ]
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MF<T8!<,2.\&K^YJ-QK&.FA(<1/[#]RC<_:#^$<,*__?_^O]02P,$%     @
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M;V]K>&-O+FAT;5!+ 0(4 Q0    ( ,Z&=USX4@59?@<  &0I   <
M      "  0T_  !A8FEV87@M,C R-3(P>&9X97@Q,C%C96\N:'1M4$L! A0#
M%     @ SH9W7/ A*(1X!P  $24  !P              ( !Q48  &%B:79A
M>"TR,#(U,C!X9GAE>#$R,F-F;RYH=&U02P$"% ,4    " #.AG=<DNX(\W\$
M  "M$   '               @ %W3@  86)I=F%X+3(P,C4R,'AF>&5X,3,Q
M8V5O+FAT;5!+ 0(4 Q0    ( ,Z&=URK+0/4C@0  .X0   <
M  "  3!3  !A8FEV87@M,C R-3(P>&9X97@Q,S)C9F\N:'1M4$L! A0#%
M  @ SH9W7 [I6:6F2@  B58" !X              ( !^%<  &%B:79A>"TR
M,'AF>&5X,3%B>6QA=W,V9F5B+FAT;5!+ 0(4 Q0    ( ,Z&=UR7KC($=H
M ,QW P >              "  =JB  !A8FEV87@M,C!X9GAE>#(Q9&5S8W)I
M<'1I;RYH=&U02P$"% ,4    " #.AG=<X;5)FDX)  !Y20  '@
M    @ &,(P$ 86)I=F%X+3(P>&9X97@T,39S=6UM87)Y;V8N:'1M4$L! A0#
M%     @ SH9W7**W$UC=!P  %"(  !X              ( !%BT! &%B:79A
M>"TR,'AF>&5X-#$W<W5M;6%R>6]F+FAT;5!+ 0(4 Q0    ( ,Z&=URGNK8
ME0P  )^Y   >              "  2\U 0!A8FEV87@M,C!X9GAE>#0Q.'-U
M;6UA<GEO9BYH=&U02P$"% ,4    " #.AG=<>8Y,$R>#"0 6BHX $0
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M2P$"% ,4    " #/AG=<<A=EGFR* 0"DBP$ %0              @ &!XA
M86)V>"TR,#(U,3(S,5]G,3$N9VEF4$L! A0#%     @ SX9W7(Q$G?@\V0
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M>"TR,#(U,3(S,5]G,RYG:6902P$"% ,4    " #/AG=<H; ?$HK"  ")P@
M%               @ %_8!8 86)V>"TR,#(U,3(S,5]G-"YG:6902P$"% ,4
M    " #/AG=<K@' %IU+ 0# 2P$ %               @ $[(Q< 86)V>"TR
M,#(U,3(S,5]G-2YG:6902P$"% ,4    " #/AG=<'R7JSD4" 0!F @$ %
M            @ $*;Q@ 86)V>"TR,#(U,3(S,5]G-BYG:6902P$"% ,4
M" #/AG=<HQW(IHLH 0"<* $ %               @ &!<1D 86)V>"TR,#(U
M,3(S,5]G-RYG:6902P$"% ,4    " #/AG=<B$B,G_+)  "LR@  %
M        @ $^FAH 86)V>"TR,#(U,3(S,5]G."YG:6902P$"% ,4    " #/
MAG=<9+AD(0;4   'U   %               @ %B9!L 86)V>"TR,#(U,3(S
M,5]G.2YG:6902P$"% ,4    " #/AG=<L[BXG6_Z 0!S[A, %0
M    @ &:.!P 86)V>"TR,#(U,3(S,5]L86(N>&UL4$L! A0#%     @ SX9W
M7"*<P2/*> $ =@L2 !4              ( !/#,> &%B=G@M,C R-3$R,S%?
M<')E+GAM;%!+ 0(4 Q0    ( ,^&=UR4X$L-80(  )8&   9
M  "  3FL'P!P=V-?8V]N<V5N='@R,"UF>&9Y,C4N:'1M4$L%!@     > !X
*'P@  -&N'P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>169
<FILENAME>abvx-20251231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:abvx="http://www.abivax.com/20251231"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:currency="http://xbrl.sec.gov/currency/2025"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="abvx-20251231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">abvx:AmericanDepositorySharesNASDAQGlobalMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">abvx:OrdinarySharesNASDAQGlobalMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:Kreos1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:Kreos1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:Kreos1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:OtherEquityAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:OtherEquityAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:KreosClaretFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:KreosClaretFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:OtherEquityAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:OtherEquityAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:OtherEquityAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">abvx:KreosOCABSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">abvx:KreosOCABSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">abvx:KreosOCABSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">abvx:KreosOCABSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
        </entity>
        <period>
            <startDate>2013-12-04</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:SaleOfStockAxis">abvx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:SaleOfStockAxis">abvx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:SaleOfStockAxis">abvx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abvx:BanquePubliqueDInvestissementBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-12-04</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:A130.0MillionCrossOverFinancingFebruary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-22</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:A130.0MillionCrossOverFinancingFebruary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-22</startDate>
            <endDate>2023-02-22</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:A49.2MillionCrossOverFinancingSeptember2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-22</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:A130.0MillionCrossOverFinancingFebruary2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-22</startDate>
            <endDate>2023-02-22</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:Kreos1ConvertibleBondLoansTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-24</startDate>
            <endDate>2023-05-24</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:Kreos1ConvertibleBondLoansTrancheBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-24</startDate>
            <endDate>2023-05-24</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FreeSharesAGAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:A150.0MillionFinancingAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-20</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:A150.0MillionFinancingAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-20</startDate>
            <endDate>2023-08-20</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-20</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-20</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-20</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-22</startDate>
            <endDate>2023-08-22</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-24</startDate>
            <endDate>2023-08-24</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-24</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
        </entity>
        <period>
            <startDate>2023-08-24</startDate>
            <endDate>2023-08-24</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:Kreos1ConvertibleBondLoansTrancheBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-24</startDate>
            <endDate>2023-08-24</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:OCEANEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-24</startDate>
            <endDate>2023-08-24</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingAndHeightsConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-24</startDate>
            <endDate>2023-08-24</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-02</startDate>
            <endDate>2023-11-02</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
        </entity>
        <period>
            <startDate>2023-10-24</startDate>
            <endDate>2023-10-24</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">abvx:AmericanDepositorySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-24</startDate>
            <endDate>2023-10-24</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-24</startDate>
            <endDate>2023-10-24</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">abvx:AmericanDepositorySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-24</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-24</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20246Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-11</startDate>
            <endDate>2024-07-11</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20241Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingTrancheBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-28</startDate>
            <endDate>2024-03-28</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingTrancheCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-21</startDate>
            <endDate>2024-06-21</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingTrancheBAndCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-20</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-12-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIAndCARENAConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
        </entity>
        <period>
            <instant>2024-11-19</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:SaleOfStockAxis">abvx:AtTheMarketATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-19</startDate>
            <endDate>2024-11-19</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:ShareSubscriptionWarrantsBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:BoardMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:ShareSubscriptionWarrantsBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20252Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20255Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20251Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:ShareSubscriptionWarrantsBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:BoardMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:ShareSubscriptionWarrantsBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">abvx:AmericanDepositorySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-28</startDate>
            <endDate>2025-07-28</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">abvx:AmericanDepositorySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
        </entity>
        <period>
            <instant>2025-07-23</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
        </entity>
        <period>
            <startDate>2025-07-28</startDate>
            <endDate>2025-07-28</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-23</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-30</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-23</startDate>
            <endDate>2025-07-30</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-08</startDate>
            <endDate>2025-08-08</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosABCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-30</startDate>
            <endDate>2025-07-30</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosABCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-28</startDate>
            <endDate>2025-08-28</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-25</startDate>
            <endDate>2025-11-25</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingBAndCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-23</startDate>
            <endDate>2025-12-23</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">abvx:MajorShareBasedTransactionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FreeSharesAGAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-02-28</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">abvx:MajorShareBasedTransactionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FreeSharesAGAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-02-28</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">abvx:MajorShareBasedTransactionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FreeSharesAGAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-02-28</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">abvx:MajorShareBasedTransactionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FreeSharesAGAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-02-28</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">abvx:MajorShareBasedTransactionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:ShareSubscriptionWarrantsBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-02-28</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:BoardMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">abvx:MajorShareBasedTransactionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:ShareSubscriptionWarrantsBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-02-28</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">abvx:CSOSettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-01</startDate>
            <endDate>2026-03-23</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">abvx:CSOSettlementAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FreeSharesAGAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-23</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:IndustrialMaterialsAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:IndustrialMaterialsAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:TechnicalFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:TechnicalFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">abvx:WittycelSASABX196Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">abvx:SplicosSASABX464Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">abvx:SplicosSASABX464Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">abvx:SplicosSASABX464Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:PrincipalAgreementsAxis">abvx:ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">abvx:WittycelSASABX196Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:PrincipalAgreementsAxis">abvx:ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:AssetsAcquisitionsAxis">abvx:ProsynergiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">abvx:WittycelSASABX196Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">abvx:WittycelSASABX196Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">abvx:WittycelSASABX196Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">abvx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">abvx:LeaseFacilitiesParisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">abvx:DeferredFinancingCostsNettingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingTrancheBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherFinancialAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherReceivablesAndAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherReceivablesAndAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherReceivablesAndAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherReceivablesAndAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:CashAndCashEquivalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:CashAndCashEquivalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:CashAndCashEquivalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:TradePayablesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:TradePayablesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:TradePayablesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:TradePayablesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherFinancialAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherReceivablesAndAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherReceivablesAndAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherReceivablesAndAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherReceivablesAndAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:CashAndCashEquivalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:CashAndCashEquivalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:CashAndCashEquivalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:TradePayablesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:TradePayablesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:TradePayablesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:TradePayablesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherFinancialAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherReceivablesAndAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherReceivablesAndAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherReceivablesAndAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:OtherReceivablesAndAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:CashAndCashEquivalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:CashAndCashEquivalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:CashAndCashEquivalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:TradePayablesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:TradePayablesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:TradePayablesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:TradePayablesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:NonCurrentAdvancesToCROContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:NonCurrentAdvancesToCROContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:NonCurrentAdvancesToCROContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:NonCurrentAdvancesToCROContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:NonCurrentAdvancesToCROContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:NonCurrentAdvancesToCROContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:NonCurrentAdvancesToCROContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:NonCurrentAdvancesToCROContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">abvx:NonCurrentAdvancesToCROContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretFinancingTrancheABAndCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-22</instant>
        </period>
    </context>
    <context id="c-435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretFinancingTrancheABAndCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretFinancingTrancheABAndCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretFinancingTrancheABAndCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-22</instant>
        </period>
    </context>
    <context id="c-441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-22</startDate>
            <endDate>2023-08-22</endDate>
        </period>
    </context>
    <context id="c-442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretFinancingTrancheABAndCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:ConditionalAdvancesAndPGELoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:ConditionalAdvancesAndPGELoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:EbolaConditionalAdvanceBPIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
        </entity>
        <period>
            <startDate>2023-02-22</startDate>
            <endDate>2023-02-22</endDate>
        </period>
    </context>
    <context id="c-452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
        </entity>
        <period>
            <instant>2023-02-22</instant>
        </period>
    </context>
    <context id="c-453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:Kreos1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:KreosABSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-24</startDate>
            <endDate>2023-05-24</endDate>
        </period>
    </context>
    <context id="c-454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:Kreos1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:KreosBBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-24</startDate>
            <endDate>2023-05-24</endDate>
        </period>
    </context>
    <context id="c-455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:Kreos1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-24</startDate>
            <endDate>2023-05-24</endDate>
        </period>
    </context>
    <context id="c-456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
        </entity>
        <period>
            <instant>2023-05-24</instant>
        </period>
    </context>
    <context id="c-457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:Kreos1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-24</instant>
        </period>
    </context>
    <context id="c-458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
        </entity>
        <period>
            <instant>2023-10-24</instant>
        </period>
    </context>
    <context id="c-459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:OtherEquityAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20241AndBSA20242Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20241AndBSA20242Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:OtherEquityAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:OtherEquityAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-08</instant>
        </period>
    </context>
    <context id="c-465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-25</instant>
        </period>
    </context>
    <context id="c-466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:OtherEquityAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20161Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-07</startDate>
            <endDate>2016-11-07</endDate>
        </period>
    </context>
    <context id="c-468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20161Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20161Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-470">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20161Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-471">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20171Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-23</startDate>
            <endDate>2017-01-23</endDate>
        </period>
    </context>
    <context id="c-472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20171Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-473">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20171Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20171Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20172Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-20</startDate>
            <endDate>2017-11-20</endDate>
        </period>
    </context>
    <context id="c-476">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20172Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-477">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20172Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-478">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20172Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-479">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20174Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-20</startDate>
            <endDate>2017-11-20</endDate>
        </period>
    </context>
    <context id="c-480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20174Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-481">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20174Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20174Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-483">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20175Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-20</startDate>
            <endDate>2017-11-20</endDate>
        </period>
    </context>
    <context id="c-484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20175Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-485">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20175Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20175Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-15</startDate>
            <endDate>2018-03-15</endDate>
        </period>
    </context>
    <context id="c-488">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-491">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20184Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-14</startDate>
            <endDate>2018-05-14</endDate>
        </period>
    </context>
    <context id="c-492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20184Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20184Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20184Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-495">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20185Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-14</startDate>
            <endDate>2018-05-14</endDate>
        </period>
    </context>
    <context id="c-496">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20185Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20185Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-498">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCE20185Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-499">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FoundersShareSubscriptionWarrantsBCEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-07</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-500">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FoundersShareSubscriptionWarrantsBCEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FoundersShareSubscriptionWarrantsBCEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FoundersShareSubscriptionWarrantsBCEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FoundersShareSubscriptionWarrantsBCEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FoundersShareSubscriptionWarrantsBCEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BCEExceptBCE20142Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA201511Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-12-04</startDate>
            <endDate>2015-12-04</endDate>
        </period>
    </context>
    <context id="c-507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA201511Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA201511Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA201511Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA201512Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-12-04</startDate>
            <endDate>2015-12-04</endDate>
        </period>
    </context>
    <context id="c-511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA201512Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA201512Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA201512Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20171Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-18</startDate>
            <endDate>2017-09-18</endDate>
        </period>
    </context>
    <context id="c-515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20171Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20171Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20171Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-22</startDate>
            <endDate>2018-01-22</endDate>
        </period>
    </context>
    <context id="c-519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20241Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-04</startDate>
            <endDate>2024-04-04</endDate>
        </period>
    </context>
    <context id="c-523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20241Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20241Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20241Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20242Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-04</startDate>
            <endDate>2024-04-04</endDate>
        </period>
    </context>
    <context id="c-527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20242Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20242Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20242Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20251Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-13</startDate>
            <endDate>2025-01-13</endDate>
        </period>
    </context>
    <context id="c-531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20251Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-532">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20251Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-533">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20251Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-534">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20252Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-13</startDate>
            <endDate>2025-01-13</endDate>
        </period>
    </context>
    <context id="c-535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20252Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-536">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20252Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20252Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-538">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20253Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-22</startDate>
            <endDate>2025-04-22</endDate>
        </period>
    </context>
    <context id="c-539">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20253Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-540">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20253Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-541">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20253Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-542">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:ShareSubscriptionWarrantsBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-07</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-543">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:ShareSubscriptionWarrantsBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-544">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:ShareSubscriptionWarrantsBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-545">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:ShareSubscriptionWarrantsBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:ShareSubscriptionWarrantsBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-547">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:ShareSubscriptionWarrantsBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-548">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:ShareSubscriptionWarrantsBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-549">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20251AndBSA20252Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="c-550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20253Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="c-551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20241Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-04</startDate>
            <endDate>2024-04-04</endDate>
        </period>
    </context>
    <context id="c-552">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20241Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-04</startDate>
            <endDate>2024-04-04</endDate>
        </period>
    </context>
    <context id="c-553">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20242Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-04</startDate>
            <endDate>2024-04-04</endDate>
        </period>
    </context>
    <context id="c-554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20242Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-04</startDate>
            <endDate>2024-04-04</endDate>
        </period>
    </context>
    <context id="c-555">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20251Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-13</startDate>
            <endDate>2025-01-13</endDate>
        </period>
    </context>
    <context id="c-556">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20251Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-13</startDate>
            <endDate>2025-01-13</endDate>
        </period>
    </context>
    <context id="c-557">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20252Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-13</startDate>
            <endDate>2025-01-13</endDate>
        </period>
    </context>
    <context id="c-558">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20252Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-13</startDate>
            <endDate>2025-01-13</endDate>
        </period>
    </context>
    <context id="c-559">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20253Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-22</startDate>
            <endDate>2025-04-22</endDate>
        </period>
    </context>
    <context id="c-560">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:BSA20253Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-22</startDate>
            <endDate>2025-04-22</endDate>
        </period>
    </context>
    <context id="c-561">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-11</startDate>
            <endDate>2023-07-11</endDate>
        </period>
    </context>
    <context id="c-562">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-563">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-564">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-565">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20232Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-11</startDate>
            <endDate>2023-07-11</endDate>
        </period>
    </context>
    <context id="c-566">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20232Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20232Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20232Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-569">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20233Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-28</startDate>
            <endDate>2023-09-28</endDate>
        </period>
    </context>
    <context id="c-570">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20233Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-571">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20233Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-572">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20233Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-573">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20234Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-28</startDate>
            <endDate>2023-09-28</endDate>
        </period>
    </context>
    <context id="c-574">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20234Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20234Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20234Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-577">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20235Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-01</endDate>
        </period>
    </context>
    <context id="c-578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20235Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20235Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-580">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20235Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-581">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20241Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-02</startDate>
            <endDate>2024-01-02</endDate>
        </period>
    </context>
    <context id="c-582">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20241Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-583">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20241Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-584">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20241Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-585">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20242Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-28</startDate>
            <endDate>2024-03-28</endDate>
        </period>
    </context>
    <context id="c-586">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20242Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-587">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20242Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-588">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20242Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-589">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20243Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-23</startDate>
            <endDate>2024-05-23</endDate>
        </period>
    </context>
    <context id="c-590">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20243Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-591">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20243Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-592">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20243Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20244Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-11</startDate>
            <endDate>2024-07-11</endDate>
        </period>
    </context>
    <context id="c-594">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20244Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-595">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20244Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-596">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20244Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-597">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20245Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-11</startDate>
            <endDate>2024-07-11</endDate>
        </period>
    </context>
    <context id="c-598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20245Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-599">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20245Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-600">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20245Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20246Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20246Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20246Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20247Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-05</startDate>
            <endDate>2024-09-05</endDate>
        </period>
    </context>
    <context id="c-605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20247Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20247Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20247Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20251Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-06</startDate>
            <endDate>2025-02-06</endDate>
        </period>
    </context>
    <context id="c-609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20251Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20251Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20251Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-612">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20252Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-06</startDate>
            <endDate>2025-02-06</endDate>
        </period>
    </context>
    <context id="c-613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20252Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20252Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20252Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20253Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-06</startDate>
            <endDate>2025-02-06</endDate>
        </period>
    </context>
    <context id="c-617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20253Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20253Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20253Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-620">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20254Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-06</startDate>
            <endDate>2025-02-06</endDate>
        </period>
    </context>
    <context id="c-621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20254Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20254Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20254Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-624">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20255Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-03-20</endDate>
        </period>
    </context>
    <context id="c-625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20255Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20255Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20255Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20256Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-30</startDate>
            <endDate>2025-05-30</endDate>
        </period>
    </context>
    <context id="c-629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20256Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20256Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-631">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20256Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-632">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20257Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-08-01</endDate>
        </period>
    </context>
    <context id="c-633">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20257Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-634">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20257Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-635">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20257Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-636">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20258Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-13</startDate>
            <endDate>2025-11-13</endDate>
        </period>
    </context>
    <context id="c-637">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20258Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-638">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20258Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-639">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20258Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-640">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FreeSharesAGAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-11</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-641">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FreeSharesAGAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-642">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FreeSharesAGAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-643">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FreeSharesAGAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-644">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TranchesOneToFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-11</startDate>
            <endDate>2023-07-11</endDate>
        </period>
    </context>
    <context id="c-645">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-11</startDate>
            <endDate>2023-07-11</endDate>
        </period>
    </context>
    <context id="c-646">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-11</startDate>
            <endDate>2023-07-11</endDate>
        </period>
    </context>
    <context id="c-647">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20232Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-11</startDate>
            <endDate>2023-07-11</endDate>
        </period>
    </context>
    <context id="c-648">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20232Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-11</startDate>
            <endDate>2023-07-11</endDate>
        </period>
    </context>
    <context id="c-649">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-11</startDate>
            <endDate>2023-07-11</endDate>
        </period>
    </context>
    <context id="c-650">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-11</startDate>
            <endDate>2023-07-11</endDate>
        </period>
    </context>
    <context id="c-651">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-11</startDate>
            <endDate>2023-07-11</endDate>
        </period>
    </context>
    <context id="c-652">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-11</startDate>
            <endDate>2023-07-11</endDate>
        </period>
    </context>
    <context id="c-653">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-11</startDate>
            <endDate>2023-07-11</endDate>
        </period>
    </context>
    <context id="c-654">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-11</startDate>
            <endDate>2023-07-11</endDate>
        </period>
    </context>
    <context id="c-655">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-11</startDate>
            <endDate>2023-07-11</endDate>
        </period>
    </context>
    <context id="c-656">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20232Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-11</startDate>
            <endDate>2023-07-11</endDate>
        </period>
    </context>
    <context id="c-657">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20232Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-11</startDate>
            <endDate>2023-07-11</endDate>
        </period>
    </context>
    <context id="c-658">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20232Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-11</startDate>
            <endDate>2023-07-11</endDate>
        </period>
    </context>
    <context id="c-659">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20233AndAGA20234Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-28</startDate>
            <endDate>2023-09-28</endDate>
        </period>
    </context>
    <context id="c-660">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20233AGA20234AndAGA20235Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-28</startDate>
            <endDate>2023-12-01</endDate>
        </period>
    </context>
    <context id="c-661">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20233AGA20234AndAGA20235Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-28</startDate>
            <endDate>2023-12-01</endDate>
        </period>
    </context>
    <context id="c-662">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20233AGA20234AndAGA20235Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-28</startDate>
            <endDate>2023-12-01</endDate>
        </period>
    </context>
    <context id="c-663">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20233AGA20234AndAGA20235Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-28</startDate>
            <endDate>2023-12-01</endDate>
        </period>
    </context>
    <context id="c-664">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20244AGA20245AndAGA20246Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-11</startDate>
            <endDate>2024-07-11</endDate>
        </period>
    </context>
    <context id="c-665">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20241AGE20242AGA20243AGA20244AGA20245AndAGA20247Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-09-05</endDate>
        </period>
    </context>
    <context id="c-666">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20241AGE20242AGA20243AGA20244AGA20245AndAGA20247Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-09-05</endDate>
        </period>
    </context>
    <context id="c-667">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20241AGE20242AGA20243AGA20244AGA20245AndAGA20247Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-09-05</endDate>
        </period>
    </context>
    <context id="c-668">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20246Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-02</startDate>
            <endDate>2024-01-02</endDate>
        </period>
    </context>
    <context id="c-669">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20246Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-02</startDate>
            <endDate>2024-01-02</endDate>
        </period>
    </context>
    <context id="c-670">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20246Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-02</startDate>
            <endDate>2024-01-02</endDate>
        </period>
    </context>
    <context id="c-671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20253Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="c-672">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20254Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="c-673">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20256Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="c-674">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20257Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="c-675">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20258Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="c-676">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20251AGA20253AGA20254AGA20256AGA20257AndAGA20258Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="c-677">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20251AGA20253AGA20254AGA20256AGA20257AndAGA20258Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="c-678">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20251AGA20253AGA20254AGA20256AGA20257AndAGA20258Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="c-679">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20255Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-680">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FoundersShareSubscriptionWarrantsBCEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-681">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FoundersShareSubscriptionWarrantsBCEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-682">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:ShareSubscriptionWarrantsBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-683">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FreeSharesAGAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-684">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:FreeSharesAGAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-685">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:ShareSubscriptionWarrantsBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-686">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:ShareSubscriptionWarrantsBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-11</startDate>
            <endDate>2023-07-11</endDate>
        </period>
    </context>
    <context id="c-688">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-11</startDate>
            <endDate>2023-07-11</endDate>
        </period>
    </context>
    <context id="c-689">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20231Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-11</startDate>
            <endDate>2023-07-11</endDate>
        </period>
    </context>
    <context id="c-690">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">abvx:AGA20232Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-11</startDate>
            <endDate>2023-07-11</endDate>
        </period>
    </context>
    <context id="c-691">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:Kreos1ClaretBondLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-692">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:Kreos1ClaretBondLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-693">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:Kreos1ClaretBondLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-694">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-695">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-696">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-697">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-698">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-699">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-700">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:Borrowings1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:Borrowings1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:Borrowings1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-705">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:ConvertibleLoansNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-707">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:ConvertibleLoansNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-708">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:ConvertibleLoansNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-709">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-711">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-714">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:ConditionalAdvancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:ConditionalAdvancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:ConditionalAdvancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-721">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-722">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-724">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-725">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:Kreos1BondLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-22</startDate>
            <endDate>2023-08-22</endDate>
        </period>
    </context>
    <context id="c-731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-22</instant>
        </period>
    </context>
    <context id="c-732">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-20</instant>
        </period>
    </context>
    <context id="c-733">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingTrancheBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-28</instant>
        </period>
    </context>
    <context id="c-734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingTrancheCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-21</instant>
        </period>
    </context>
    <context id="c-735">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">abvx:EuropeanCentralBankBaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-20</instant>
        </period>
    </context>
    <context id="c-736">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">abvx:EuropeanCentralBankBaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-20</instant>
        </period>
    </context>
    <context id="c-737">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">abvx:EuropeanCentralBankBaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-20</instant>
        </period>
    </context>
    <context id="c-738">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-20</instant>
        </period>
    </context>
    <context id="c-739">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-20</instant>
        </period>
    </context>
    <context id="c-740">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-20</startDate>
            <endDate>2023-08-20</endDate>
        </period>
    </context>
    <context id="c-741">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-02</instant>
        </period>
    </context>
    <context id="c-742">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-20</startDate>
            <endDate>2023-08-20</endDate>
        </period>
    </context>
    <context id="c-743">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:KreosClaretFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosABCBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-30</startDate>
            <endDate>2025-07-30</endDate>
        </period>
    </context>
    <context id="c-744">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:KreosClaretFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosABCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-30</startDate>
            <endDate>2025-07-30</endDate>
        </period>
    </context>
    <context id="c-745">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:FinancialAgreementAxis">abvx:KreosClaretFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosABCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-28</startDate>
            <endDate>2025-08-28</endDate>
        </period>
    </context>
    <context id="c-746">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:KreosClaretFinancingTrancheABAndCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-31</instant>
        </period>
    </context>
    <context id="c-747">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingBAndCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-23</instant>
        </period>
    </context>
    <context id="c-748">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
        </entity>
        <period>
            <startDate>2025-12-23</startDate>
            <endDate>2025-12-23</endDate>
        </period>
    </context>
    <context id="c-749">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
        </entity>
        <period>
            <startDate>2025-07-30</startDate>
            <endDate>2025-07-30</endDate>
        </period>
    </context>
    <context id="c-750">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
        </entity>
        <period>
            <startDate>2025-08-28</startDate>
            <endDate>2025-08-28</endDate>
        </period>
    </context>
    <context id="c-751">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-20</instant>
        </period>
    </context>
    <context id="c-752">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:MarketRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-20</instant>
        </period>
    </context>
    <context id="c-753">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:MarketRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-20</instant>
        </period>
    </context>
    <context id="c-754">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:MarketRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-20</startDate>
            <endDate>2023-08-20</endDate>
        </period>
    </context>
    <context id="c-755">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-28</instant>
        </period>
    </context>
    <context id="c-756">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-757">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:MinimalReturnMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-28</instant>
        </period>
    </context>
    <context id="c-758">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:MinimalReturnMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-759">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-28</instant>
        </period>
    </context>
    <context id="c-760">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-761">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-28</instant>
        </period>
    </context>
    <context id="c-762">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-28</instant>
        </period>
    </context>
    <context id="c-763">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-764">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-765">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-28</instant>
        </period>
    </context>
    <context id="c-766">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-767">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-28</instant>
        </period>
    </context>
    <context id="c-768">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-769">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionFairValueOfMRIMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-28</instant>
        </period>
    </context>
    <context id="c-770">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:TenderOfferFairValueOfMRIMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-28</instant>
        </period>
    </context>
    <context id="c-771">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionFairValueOfMRIMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-772">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:TenderOfferFairValueOfMRIMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-773">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-28</instant>
        </period>
    </context>
    <context id="c-774">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-775">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-21</instant>
        </period>
    </context>
    <context id="c-776">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-777">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:MinimalReturnMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-21</instant>
        </period>
    </context>
    <context id="c-778">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:MinimalReturnMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-779">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-21</instant>
        </period>
    </context>
    <context id="c-780">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-781">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-21</instant>
        </period>
    </context>
    <context id="c-782">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-21</instant>
        </period>
    </context>
    <context id="c-783">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-784">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-785">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-21</instant>
        </period>
    </context>
    <context id="c-786">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-787">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-21</instant>
        </period>
    </context>
    <context id="c-788">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-789">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionFairValueOfMRIMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-21</instant>
        </period>
    </context>
    <context id="c-790">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:TenderOfferFairValueOfMRIMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-21</instant>
        </period>
    </context>
    <context id="c-791">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionFairValueOfMRIMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-792">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:TenderOfferFairValueOfMRIMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:AmortizedCostEIRMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-793">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-21</instant>
        </period>
    </context>
    <context id="c-794">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:TranchesAxis">abvx:TrancheCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-795">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-28</instant>
        </period>
    </context>
    <context id="c-796">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-28</instant>
        </period>
    </context>
    <context id="c-797">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-28</instant>
        </period>
    </context>
    <context id="c-798">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-28</instant>
        </period>
    </context>
    <context id="c-799">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-28</instant>
        </period>
    </context>
    <context id="c-800">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-21</instant>
        </period>
    </context>
    <context id="c-801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-21</instant>
        </period>
    </context>
    <context id="c-802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-21</instant>
        </period>
    </context>
    <context id="c-803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-21</instant>
        </period>
    </context>
    <context id="c-804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-21</instant>
        </period>
    </context>
    <context id="c-805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-28</instant>
        </period>
    </context>
    <context id="c-806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-28</instant>
        </period>
    </context>
    <context id="c-807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-28</instant>
        </period>
    </context>
    <context id="c-808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-28</instant>
        </period>
    </context>
    <context id="c-809">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-28</instant>
        </period>
    </context>
    <context id="c-810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-28</startDate>
            <endDate>2024-03-28</endDate>
        </period>
    </context>
    <context id="c-811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-28</startDate>
            <endDate>2024-03-28</endDate>
        </period>
    </context>
    <context id="c-812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-28</startDate>
            <endDate>2024-03-28</endDate>
        </period>
    </context>
    <context id="c-813">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-28</startDate>
            <endDate>2024-03-28</endDate>
        </period>
    </context>
    <context id="c-814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-28</startDate>
            <endDate>2024-03-28</endDate>
        </period>
    </context>
    <context id="c-815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-21</instant>
        </period>
    </context>
    <context id="c-816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-21</instant>
        </period>
    </context>
    <context id="c-817">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-21</instant>
        </period>
    </context>
    <context id="c-818">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-21</instant>
        </period>
    </context>
    <context id="c-819">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-21</instant>
        </period>
    </context>
    <context id="c-820">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-21</startDate>
            <endDate>2024-06-21</endDate>
        </period>
    </context>
    <context id="c-821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-21</startDate>
            <endDate>2024-06-21</endDate>
        </period>
    </context>
    <context id="c-822">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-21</startDate>
            <endDate>2024-06-21</endDate>
        </period>
    </context>
    <context id="c-823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-21</startDate>
            <endDate>2024-06-21</endDate>
        </period>
    </context>
    <context id="c-824">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-21</startDate>
            <endDate>2024-06-21</endDate>
        </period>
    </context>
    <context id="c-825">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-826">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-827">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-829">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-832">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-833">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:FinalRedemptionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-834">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-835">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-836">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-22</instant>
        </period>
    </context>
    <context id="c-837">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-838">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-839">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExercisePricePerShareMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-22</instant>
        </period>
    </context>
    <context id="c-840">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExercisePricePerShareMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-841">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExercisePricePerShareMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-842">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-22</instant>
        </period>
    </context>
    <context id="c-843">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-844">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-845">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpiryScenarioProbablityMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-22</instant>
        </period>
    </context>
    <context id="c-846">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpiryScenarioProbablityMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-847">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpiryScenarioProbablityMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-848">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VolatilityForSharesMeasurementInputExpiryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-22</instant>
        </period>
    </context>
    <context id="c-849">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VolatilityForSharesMeasurementInputTenderOfferMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-22</instant>
        </period>
    </context>
    <context id="c-850">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VolatilityForSharesMeasurementInputExpiryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-851">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VolatilityForSharesMeasurementInputTenderOfferMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-852">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VolatilityForSharesMeasurementInputExpiryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-853">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VolatilityForSharesMeasurementInputTenderOfferMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-854">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpectedDividendMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-22</instant>
        </period>
    </context>
    <context id="c-855">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpectedDividendMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-856">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpectedDividendMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-857">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-22</instant>
        </period>
    </context>
    <context id="c-858">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-859">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputExpiryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-860">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputTenderOfferMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-861">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-02</instant>
        </period>
    </context>
    <context id="c-862">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-863">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-864">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExercisePricePerShareMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-02</instant>
        </period>
    </context>
    <context id="c-865">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExercisePricePerShareMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-866">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExercisePricePerShareMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-867">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-02</instant>
        </period>
    </context>
    <context id="c-868">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-869">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-870">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpiryScenarioProbablityMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-02</instant>
        </period>
    </context>
    <context id="c-871">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpiryScenarioProbablityMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-872">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpiryScenarioProbablityMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-873">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:DrawdownProbablityMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-02</instant>
        </period>
    </context>
    <context id="c-874">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:DrawdownProbablityMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-875">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VolatilityForSharesMeasurementInputExpiryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-02</instant>
        </period>
    </context>
    <context id="c-876">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VolatilityForSharesMeasurementInputTenderOfferMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-02</instant>
        </period>
    </context>
    <context id="c-877">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VolatilityForSharesMeasurementInputExpiryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-878">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VolatilityForSharesMeasurementInputTenderOfferMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-879">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VolatilityForSharesMeasurementInputExpiryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-880">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VolatilityForSharesMeasurementInputTenderOfferMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-881">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpectedDividendMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-02</instant>
        </period>
    </context>
    <context id="c-882">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpectedDividendMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-883">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpectedDividendMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-884">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-02</instant>
        </period>
    </context>
    <context id="c-885">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-886">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputExpiryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-887">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputTenderOfferMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:OptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-888">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-20</instant>
        </period>
    </context>
    <context id="c-889">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-20</instant>
        </period>
    </context>
    <context id="c-890">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-20</instant>
        </period>
    </context>
    <context id="c-891">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpiryScenarioProbablityMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-20</instant>
        </period>
    </context>
    <context id="c-892">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-20</startDate>
            <endDate>2023-08-20</endDate>
        </period>
    </context>
    <context id="c-893">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-20</startDate>
            <endDate>2023-08-20</endDate>
        </period>
    </context>
    <context id="c-894">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-20</startDate>
            <endDate>2023-08-20</endDate>
        </period>
    </context>
    <context id="c-895">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-20</startDate>
            <endDate>2023-08-20</endDate>
        </period>
    </context>
    <context id="c-896">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpiryScenarioProbablityMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-20</startDate>
            <endDate>2023-08-20</endDate>
        </period>
    </context>
    <context id="c-897">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-02</instant>
        </period>
    </context>
    <context id="c-898">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-02</instant>
        </period>
    </context>
    <context id="c-899">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-02</instant>
        </period>
    </context>
    <context id="c-900">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpiryScenarioProbablityMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-02</instant>
        </period>
    </context>
    <context id="c-901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-02</startDate>
            <endDate>2023-11-02</endDate>
        </period>
    </context>
    <context id="c-902">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-02</startDate>
            <endDate>2023-11-02</endDate>
        </period>
    </context>
    <context id="c-903">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-02</startDate>
            <endDate>2023-11-02</endDate>
        </period>
    </context>
    <context id="c-904">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-02</startDate>
            <endDate>2023-11-02</endDate>
        </period>
    </context>
    <context id="c-905">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpiryScenarioProbablityMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-02</startDate>
            <endDate>2023-11-02</endDate>
        </period>
    </context>
    <context id="c-906">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-907">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-908">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-909">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpiryScenarioProbablityMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosABCBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-911">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-912">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-913">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-914">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpiryScenarioProbablityMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpiryScenarioProbablityMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-916">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosABCBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-917">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-918">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-919">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-920">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABCBSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ExpiryScenarioProbablityMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-921">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-24</startDate>
            <endDate>2023-08-24</endDate>
        </period>
    </context>
    <context id="c-922">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-24</instant>
        </period>
    </context>
    <context id="c-923">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesTrancheBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-20</instant>
        </period>
    </context>
    <context id="c-924">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesTrancheBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-20</startDate>
            <endDate>2023-08-20</endDate>
        </period>
    </context>
    <context id="c-925">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-20</startDate>
            <endDate>2023-08-20</endDate>
        </period>
    </context>
    <context id="c-926">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-20</startDate>
            <endDate>2023-08-20</endDate>
        </period>
    </context>
    <context id="c-927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-20</instant>
        </period>
    </context>
    <context id="c-928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-20</instant>
        </period>
    </context>
    <context id="c-929">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-931">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-24</instant>
        </period>
    </context>
    <context id="c-932">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-933">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-934">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-24</instant>
        </period>
    </context>
    <context id="c-935">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-936">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-937">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ConversionPricePerShareMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-24</instant>
        </period>
    </context>
    <context id="c-938">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ConversionPricePerShareMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-939">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ConversionPricePerShareMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-940">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-24</instant>
        </period>
    </context>
    <context id="c-941">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-942">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-943">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VoluntaryConversionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-24</instant>
        </period>
    </context>
    <context id="c-944">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VoluntaryConversionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-945">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VoluntaryConversionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-946">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:InitialPriceLimitMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-24</instant>
        </period>
    </context>
    <context id="c-947">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:InitialPriceLimitMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-948">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:InitialPriceLimitMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-949">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:EarlyRedemptionAmountMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-24</instant>
        </period>
    </context>
    <context id="c-950">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:EarlyRedemptionAmountMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-951">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:EarlyRedemptionAmountMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-952">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-24</instant>
        </period>
    </context>
    <context id="c-953">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-954">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-955">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-24</instant>
        </period>
    </context>
    <context id="c-956">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-957">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-958">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-24</instant>
        </period>
    </context>
    <context id="c-959">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-960">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-961">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-24</instant>
        </period>
    </context>
    <context id="c-962">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-24</instant>
        </period>
    </context>
    <context id="c-963">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-24</instant>
        </period>
    </context>
    <context id="c-964">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VoluntaryConversionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-24</instant>
        </period>
    </context>
    <context id="c-965">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-24</startDate>
            <endDate>2023-08-24</endDate>
        </period>
    </context>
    <context id="c-966">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-24</startDate>
            <endDate>2023-08-24</endDate>
        </period>
    </context>
    <context id="c-967">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-24</startDate>
            <endDate>2023-08-24</endDate>
        </period>
    </context>
    <context id="c-968">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VoluntaryConversionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-24</startDate>
            <endDate>2023-08-24</endDate>
        </period>
    </context>
    <context id="c-969">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-970">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-971">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-972">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VoluntaryConversionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-973">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-974">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-975">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-976">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VoluntaryConversionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-977">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VoluntaryConversionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-978">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-979">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-980">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-981">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:VoluntaryConversionScenarioProbabilityMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-982">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesTrancheBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-20</startDate>
            <endDate>2023-08-20</endDate>
        </period>
    </context>
    <context id="c-983">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:Kreos1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-24</instant>
        </period>
    </context>
    <context id="c-984">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:Kreos1NonConvertibleBondLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-24</instant>
        </period>
    </context>
    <context id="c-985">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:Kreos1ConvertibleBondLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-24</instant>
        </period>
    </context>
    <context id="c-986">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="c-987">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:Kreos1ConvertibleBondLoansTrancheBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-21</startDate>
            <endDate>2023-08-21</endDate>
        </period>
    </context>
    <context id="c-988">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:Kreos12BondLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-21</startDate>
            <endDate>2023-08-21</endDate>
        </period>
    </context>
    <context id="c-989">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosABSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-990">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosBBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-991">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:WarrantsAxis">abvx:KreosABBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-992">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-993">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:Kreos2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-13</instant>
        </period>
    </context>
    <context id="c-994">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:Kreos2TrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-13</instant>
        </period>
    </context>
    <context id="c-995">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:Kreos2TrancheBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-13</instant>
        </period>
    </context>
    <context id="c-996">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:OCEANEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="c-997">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:OCEANEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-30</instant>
        </period>
    </context>
    <context id="c-998">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:RemeasurementPeriodAxis">abvx:After18MonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:OCEANEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-30</instant>
        </period>
    </context>
    <context id="c-999">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:RemeasurementPeriodAxis">abvx:After24MonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:OCEANEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-30</instant>
        </period>
    </context>
    <context id="c-1000">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:RemeasurementPeriodAxis">abvx:After36MonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:OCEANEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-30</instant>
        </period>
    </context>
    <context id="c-1001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-30</instant>
        </period>
    </context>
    <context id="c-1002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-30</instant>
        </period>
    </context>
    <context id="c-1003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-30</instant>
        </period>
    </context>
    <context id="c-1004">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-24</instant>
        </period>
    </context>
    <context id="c-1005">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-24</instant>
        </period>
    </context>
    <context id="c-1006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:CreditSpreadMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-24</instant>
        </period>
    </context>
    <context id="c-1007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-24</instant>
        </period>
    </context>
    <context id="c-1008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">abvx:MonteCarloModelIFRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-24</instant>
        </period>
    </context>
    <context id="c-1009">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-24</startDate>
            <endDate>2023-08-24</endDate>
        </period>
    </context>
    <context id="c-1010">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-24</startDate>
            <endDate>2023-08-24</endDate>
        </period>
    </context>
    <context id="c-1011">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:RiskFreeInterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-24</startDate>
            <endDate>2023-08-24</endDate>
        </period>
    </context>
    <context id="c-1012">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:OCEANEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-1013">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c-1014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c-1015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-1016">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c-1017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-1018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-1019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:EbolaConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:EbolaConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:EbolaConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1028">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-16</instant>
        </period>
    </context>
    <context id="c-1029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-16</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1030">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="c-1031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="c-1032">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="c-1033">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-1034">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-12-16</instant>
        </period>
    </context>
    <context id="c-1035">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-12-16</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1036">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-12-01</startDate>
            <endDate>2013-12-31</endDate>
        </period>
    </context>
    <context id="c-1037">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-09-01</startDate>
            <endDate>2014-09-30</endDate>
        </period>
    </context>
    <context id="c-1038">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="c-1039">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-1040">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:EbolaConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-1041">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:EbolaConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c-1042">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:EbolaConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-1043">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">abvx:LeaseFacilitiesParisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="c-1044">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">abvx:LeaseFacilitiesParisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-1045">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">abvx:LeaseFacilitiesParisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-02</startDate>
            <endDate>2024-05-02</endDate>
        </period>
    </context>
    <context id="c-1046">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">abvx:LeaseFacilitiesBostonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c-1047">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">abvx:LeaseFacilitiesBostonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c-1048">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">abvx:LeaseFacilitiesBostonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c-1049">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">abvx:LeaseFacilitiesMontpellierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="c-1050">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">abvx:LeaseFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1051">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">abvx:LeaseFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1052">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">abvx:LeaseFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1053">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-02</instant>
        </period>
    </context>
    <context id="c-1054">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-02</startDate>
            <endDate>2022-09-02</endDate>
        </period>
    </context>
    <context id="c-1055">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
        </entity>
        <period>
            <startDate>2022-09-02</startDate>
            <endDate>2022-09-02</endDate>
        </period>
    </context>
    <context id="c-1056">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
        </entity>
        <period>
            <instant>2022-09-02</instant>
        </period>
    </context>
    <context id="c-1057">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1058">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1059">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-1060">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-1061">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-1062">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ProbabilityOfSuccessMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1063">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:PeakPenetrationMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1064">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ProbabilityOfSuccessMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-1065">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:PeakPenetrationMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-1066">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ProbabilityOfSuccessMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1067">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:PeakPenetrationMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1068">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:WeightedAverageCostOfCapitalMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1069">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1070">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ProbabilityOfSuccessMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1071">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:PeakPenetrationMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1072">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:WeightedAverageCostOfCapitalMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1073">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1074">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ProbabilityOfSuccessMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1075">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:PeakPenetrationMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1076">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:WeightedAverageCostOfCapitalMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1077">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1078">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:ProbabilityOfSuccessMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-1079">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:PeakPenetrationMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-1080">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:WeightedAverageCostOfCapitalMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-1081">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">abvx:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-1082">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:WeightedAverageCostOfCapitalMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1083">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:WeightedAverageCostOfCapitalMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-1084">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:Kreos12BondLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1085">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1086">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1087">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:Kreos1ClaretBondLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1088">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1089">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1090">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:ConditionalAdvancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1091">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1092">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1093">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:Kreos12BondLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1094">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1095">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1096">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:Kreos1ClaretBondLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1097">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1098">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1099">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:ConditionalAdvancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:Kreos12BondLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:Kreos1ClaretBondLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:ConditionalAdvancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:Kreos12BondLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-1111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-1112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-1113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:Kreos1ClaretBondLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-1114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-1115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-1116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:ConditionalAdvancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-1117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-1118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:Kreos12BondLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:Kreos1ClaretBondLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:ConditionalAdvancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:Kreos12BondLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-1128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-1129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-1130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:Kreos1ClaretBondLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-1131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-1132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-1133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:ConditionalAdvancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-1134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-1135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:Kreos12BondLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:OCEANEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:Kreos1ClaretBondLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:ConditionalAdvancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">abvx:RoyaltyCertificatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OceaneConversionOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:OCEANEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingTrancheCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-1149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingTrancheABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-1150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosBBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OceaneConversionOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosBBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosBBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OceaneConversionOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-1164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosBBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-1165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OceaneConversionOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-1166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-1167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-1168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosBBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OceaneConversionOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-1172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosBBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-1173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OceaneConversionOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-1174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-1175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-1176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosABSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosBBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:OceaneConversionOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:HeightsConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretFinancingTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretBondLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretBondLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretBondLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretBondLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:KreosClaretBondLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:PretGarantiParLEtatPGEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:OtherEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-1223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:OtherEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-1224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-1225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:OtherEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-1226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:OtherEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:OtherEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-1238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-1240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:CIRTaxYearAxis">abvx:A2022TaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:CIRTaxYearAxis">abvx:A2023TaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-1243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:CIRTaxYearAxis">abvx:A2024TaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-1244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:CIRTaxYearAxis">abvx:A2021TaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-1245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">abvx:SalesAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">abvx:SalesAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-1247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">abvx:SalesAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-1248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">abvx:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">abvx:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-1250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">abvx:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-1251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">abvx:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">abvx:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-1253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">abvx:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-1254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-1256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-1257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-1259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-1260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">abvx:KreosClaretFinancingBSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-1261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">abvx:KreosClaretMinimumReturnIndemnificationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-1262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:RetirementBenefitObligationsRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:RetirementBenefitObligationsRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:RetirementBenefitObligationsRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:LeasesRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:LeasesRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:LeasesRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:OtherFinancialLiabilitiesRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:OtherFinancialLiabilitiesRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:OtherFinancialLiabilitiesRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:ProvisionsForAGATaxesRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:ProvisionsForAGATaxesRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:ProvisionsForAGATaxesRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:SubsidiesRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:SubsidiesRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:SubsidiesRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:RoyaltyCertificatesRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:RoyaltyCertificatesRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:RoyaltyCertificatesRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">abvx:RoyaltyCertificatesRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">abvx:AbivaxLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">abvx:AbivaxLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">abvx:AbivaxLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:BoardOfDirectorsAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:BoardOfDirectorsAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:BoardOfDirectorsAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvx:AdvisorToTheChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-18</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:PrincipalAgreementsAxis">abvx:ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2008-12-04</instant>
        </period>
    </context>
    <context id="c-1295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abvx:PrincipalAgreementsAxis">abvx:ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2006-11-11</startDate>
            <endDate>2006-11-11</endDate>
        </period>
    </context>
    <context id="c-1296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abvx:TheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-1297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-12-16</startDate>
            <endDate>2013-12-16</endDate>
        </period>
    </context>
    <context id="c-1298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-12-16</startDate>
            <endDate>2013-12-16</endDate>
        </period>
    </context>
    <context id="c-1299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-12-16</instant>
        </period>
    </context>
    <context id="c-1300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-12-16</startDate>
            <endDate>2013-12-16</endDate>
        </period>
    </context>
    <context id="c-1301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:CARENAConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-1302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-16</startDate>
            <endDate>2016-12-16</endDate>
        </period>
    </context>
    <context id="c-1303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-16</startDate>
            <endDate>2016-12-16</endDate>
        </period>
    </context>
    <context id="c-1304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-16</instant>
        </period>
    </context>
    <context id="c-1305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:RNPVIRConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-16</startDate>
            <endDate>2016-12-16</endDate>
        </period>
    </context>
    <context id="c-1306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:EbolaConditionalAdvanceBPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-02</instant>
        </period>
    </context>
    <context id="c-1307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:EbolaConditionalAdvanceBPILanguedocRoussillonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-02</instant>
        </period>
    </context>
    <context id="c-1308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">abvx:EbolaConditionalAdvanceBPIFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-02</instant>
        </period>
    </context>
    <context id="c-1309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">abvx:LeaseFacilitiesMontpellierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-1311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:HeightsConvertibleNotesTrancheBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">abvx:EuropeanCentralBankBaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">abvx:EuropeanCentralBankBaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">abvx:KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">abvx:EuropeanCentralBankBaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-1316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-1318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-1319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001956827</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="eurPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="plan">
        <measure>abvx:plan</measure>
    </unit>
    <unit id="transaction">
        <measure>abvx:transaction</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="note">
        <measure>abvx:note</measure>
    </unit>
    <unit id="criteria">
        <measure>abvx:criteria</measure>
    </unit>
    <unit id="segment">
        <measure>abvx:segment</measure>
    </unit>
    <unit id="tranche">
        <measure>abvx:tranche</measure>
    </unit>
    <unit id="scenario">
        <measure>abvx:scenario</measure>
    </unit>
    <unit id="closing">
        <measure>abvx:closing</measure>
    </unit>
    <unit id="installment">
        <measure>abvx:installment</measure>
    </unit>
    <unit id="employee">
        <measure>abvx:employee</measure>
    </unit>
    <unit id="license">
        <measure>abvx:license</measure>
    </unit>
    <unit id="academic_institution">
        <measure>abvx:academic_institution</measure>
    </unit>
    <unit id="project">
        <measure>abvx:project</measure>
    </unit>
    <unit id="financial_institution">
        <measure>abvx:financial_institution</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-39">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-40">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-41">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-42">0001956827</dei:EntityCentralIndexKey>
    <dei:NoTradingSymbolFlag contextRef="c-4" id="f-43">true</dei:NoTradingSymbolFlag>
    <abvx:NumberOfOperatingSegment
      contextRef="c-1"
      decimals="INF"
      id="f-707"
      unitRef="segment">1</abvx:NumberOfOperatingSegment>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-503" id="f-1718">P1Y</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentagePerMonth
      contextRef="c-504"
      decimals="6"
      id="f-1719"
      unitRef="number">0.020833</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentagePerMonth>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-685" id="f-1720">P1Y</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentagePerMonth
      contextRef="c-686"
      decimals="6"
      id="f-1721"
      unitRef="number">0.020833</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentagePerMonth>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-650" id="f-1722">P1Y</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementServicePeriod contextRef="c-651" id="f-1723">P1Y</abvx:VestingRequirementsForShareBasedPaymentArrangementServicePeriod>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-687" id="f-1724">P1Y</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-688" id="f-1725">P1Y</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-689" id="f-1726">P1Y</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-655" id="f-1727">P1Y</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-657" id="f-1728">P1Y</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-690" id="f-1729">P1Y</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <abvx:ConvertibleLoansNotesPeriod contextRef="c-982" id="f-2144">P1Y</abvx:ConvertibleLoansNotesPeriod>
    <abvx:ConvertibleLoansNotesConversionOptionMaximumPeriodPriorToMaturityDate contextRef="c-79" id="f-2145">P5D</abvx:ConvertibleLoansNotesConversionOptionMaximumPeriodPriorToMaturityDate>
    <abvx:LeaseExtensionPeriod contextRef="c-1047" id="f-2257">P1Y</abvx:LeaseExtensionPeriod>
    <abvx:OtherFinancialLiabilitiesAnnualRevenueFromSaleOfProductsDevelopedPeriod contextRef="c-1297" id="f-3336">P5Y</abvx:OtherFinancialLiabilitiesAnnualRevenueFromSaleOfProductsDevelopedPeriod>
    <abvx:OtherFinancialLiabilitiesAnnualRevenueFromSaleOfProductsDevelopedPeriod contextRef="c-1302" id="f-3344">P5Y</abvx:OtherFinancialLiabilitiesAnnualRevenueFromSaleOfProductsDevelopedPeriod>
    <dei:DocumentType contextRef="c-1" id="f-1">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="c-1" id="f-2">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-3">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-5">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-6">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="c-1" id="f-7">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-8">001-41842</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-9">Abivax SA</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-10">I0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-11">7-11 boulevard Haussmann</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">75009</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-13">Paris</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c-1" id="f-14">FR</dei:EntityAddressCountry>
    <dei:ContactPersonnelName contextRef="c-2" id="f-15">Marc de Garidel</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="c-2" id="f-16">7-11 boulevard Haussmann</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode contextRef="c-2" id="f-17">75009</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown contextRef="c-2" id="f-18">Paris</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c-2" id="f-19">FR</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="c-2" id="f-20">+33</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-2" id="f-21">1 53 83 09 63</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-3" id="f-22">American Depositary Shares, each representing one ordinary share, nominal value &#x20ac;0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-3" id="f-23">ABVX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-3" id="f-24">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-4" id="f-25">Ordinary shares, nominal value &#x20ac;0.01 per share</dei:Security12bTitle>
    <dei:SecurityExchangeName contextRef="c-4" id="f-26">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-5" decimals="0" id="f-27" unitRef="shares">78536412</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-28">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-29">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-32">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-33">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-34">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-35">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-36">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentAccountingStandard contextRef="c-1" id="f-37">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="c-1" id="f-38">false</dei:EntityShellCompany>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-44">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c-1" id="f-45">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"&gt;We have implemented and maintain various information security processes designed to identify, assess and &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:358pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;manage material &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.76pt;position:var(--position);text-decoration:none;white-space:pre"&gt;risks&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:159.64pt;position:var(--position);text-decoration:none;white-space:pre"&gt; from cybersecurity threats to our critical information systems, third party hosted services, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:368pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;communications systems, hardware and software, and our critical data (including intellectual property, confidential &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:378pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;information that is proprietary, strategic or competitive in nature, and data related to our clinical trials and products) &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:388pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;(collectively, &#x201c;Information Systems and Data&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:404pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Our Chief Financial Officer as well as our external Data Protection Officer (&#x201c;DPO&#x201d;) and Information &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:414pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Technology Director (&#x201c;IT Director&#x201d;), and other independent service providers help identify, assess and manage the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:424pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;our cybersecurity threats and risks. Individuals in these roles identify and assess risks from cybersecurity threats by &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:434pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;monitoring and &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:135.84pt;position:var(--position);text-decoration:none;white-space:pre"&gt;evaluating&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:177.44pt;position:var(--position);text-decoration:none;white-space:pre"&gt; our threat environment using various methods including, for example, maintaining &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:444pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;manual and automated tools, conducting scans of our threat environment, and conducting vulnerability assessments.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:460pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Depending on the environment, we implement and maintain various technical, physical, and organizational &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:470pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:480pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;threats to our Information Systems and Data. These measures, processes, standards, and policies include, for &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:490pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;example: incident &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:145.76999999999998pt;position:var(--position);text-decoration:none;white-space:pre"&gt;response&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:180.74pt;position:var(--position);text-decoration:none;white-space:pre"&gt; plans and policies, personnel training, phishing test campaigns, penetration testing, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:500pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;system backups, cybersecurity insurance, network security controls, segmentation for certain systems and data &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:510pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;access controls and physical security controls.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:526pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Our &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.55pt;position:var(--position);text-decoration:none;white-space:pre"&gt;assessment&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.94pt;position:var(--position);text-decoration:none;white-space:pre"&gt; and management of material risks from cybersecurity threats are integrated into our overall &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:536pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;risk management processes.&#160; For example, our external DPO and IT Director work with management in an effort to &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:546pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:556pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;impact to our business.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:572pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"&gt;We use independent service provider&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:244.65pt;position:var(--position);text-decoration:none;white-space:pre"&gt;s&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:248.54pt;position:var(--position);text-decoration:none;white-space:pre"&gt; to assist us from time to time to identify, assess, and manage material &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:582pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;risks from &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:115.31pt;position:var(--position);text-decoration:none;white-space:pre"&gt;cybersecurity&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:169.12pt;position:var(--position);text-decoration:none;white-space:pre"&gt; threats, including for example: professional service firms, including legal counsel, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:592pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;penetration testing firms, dark web monitoring services, cybersecurity consultants, and cybersecurity software &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:602pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;providers.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:624pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Further, we use independent service providers to perform a variety of functions throughout our business, such &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:634pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;as hosting companies and contract research organizations. We undertake efforts designed to manage cybersecurity &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:644pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;risks associated with our use of these providers.&#160; For certain vendors, these efforts include security questionnaires, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:654pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;reviews of vendors&#x2019; written security programs, reviews of security assessments, audits, and vulnerability scans &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:664pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;related to the vendors. Depending on the nature of the services provided, the sensitivity of the Information Systems &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:674pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;and Data at issue, and the identity of the provider, our vendor management process may involve different levels of &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:684pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;assessment designed to help identify cybersecurity risks associated with a provider and impose contractual &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:694pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;obligations related to cybersecurity on the provider.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c-1" id="f-46">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Depending on the environment, we implement and maintain various technical, physical, and organizational &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:470pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:480pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;threats to our Information Systems and Data. These measures, processes, standards, and policies include, for &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:490pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;example: incident &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:145.76999999999998pt;position:var(--position);text-decoration:none;white-space:pre"&gt;response&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:180.74pt;position:var(--position);text-decoration:none;white-space:pre"&gt; plans and policies, personnel training, phishing test campaigns, penetration testing, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:500pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;system backups, cybersecurity insurance, network security controls, segmentation for certain systems and data &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:510pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;access controls and physical security controls.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:526pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Our &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.55pt;position:var(--position);text-decoration:none;white-space:pre"&gt;assessment&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.94pt;position:var(--position);text-decoration:none;white-space:pre"&gt; and management of material risks from cybersecurity threats are integrated into our overall &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:536pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;risk management processes.&#160; For example, our external DPO and IT Director work with management in an effort to &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:546pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:556pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;impact to our business.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c-1" id="f-47">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c-1" id="f-48">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c-1" id="f-49">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c-1" id="f-50">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c-1" id="f-52">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Our Board addresses our cybersecurity risk management as part of its general oversight function. The Board is &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:170pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:180pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;from cybersecurity threats.&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:179.36pt;position:var(--position);text-decoration:none;white-space:pre"&gt; Our&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:197.41pt;position:var(--position);text-decoration:none;white-space:pre"&gt; Committee of Executives (&#x201c;COMEX&#x201d;)&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:355.54pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, in addition to those identified below, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:190pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;provides &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108.92pt;position:var(--position);text-decoration:none;white-space:pre"&gt;input&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.46pt;position:var(--position);text-decoration:none;white-space:pre"&gt; to the Board on cybersecurity threats. Our Committee of Executives consists of all our company's &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:200pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;officers along with our heads of manufacturing and quality.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:216pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by certain &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:226pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;management team members, including our&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:242.62pt;position:var(--position);text-decoration:none;white-space:pre"&gt; Chief Financial Officer (&#x201c;CFO&#x201d;)&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:375.77pt;position:var(--position);text-decoration:none;white-space:pre"&gt; who oversees our external &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.38pt;position:var(--position);text-decoration:none;white-space:pre"&gt;IT Director &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:236pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;and DPO&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108.93pt;position:var(--position);text-decoration:none;white-space:pre"&gt;. &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.93pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Our &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:131.98pt;position:var(--position);text-decoration:none;white-space:pre"&gt;CFO&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:151.42000000000002pt;position:var(--position);text-decoration:none;white-space:pre"&gt; has prior significant experience in strategic business operations&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:406.66pt;position:var(--position);text-decoration:none;white-space:pre"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:252pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Our CFO as &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:147.31pt;position:var(--position);text-decoration:none;white-space:pre"&gt;well&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:164.5pt;position:var(--position);text-decoration:none;white-space:pre"&gt; as our external IT Director and DPO are responsible for helping to integrate cybersecurity &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:262pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;risk considerations into our overall risk management strategy, and communicating key priorities to relevant &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:272pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;personnel. Our CFO is responsible for approving cybersecurity-related budgets, approving cybersecurity processes, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:282pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;and reviewing security assessments and other security-related reports.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:298pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Our cybersecurity incident response procedures are designed to escalate certain cybersecurity incidents to &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:308pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;members of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:121.95pt;position:var(--position);text-decoration:none;white-space:pre"&gt;management&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:172.98000000000002pt;position:var(--position);text-decoration:none;white-space:pre"&gt; depending on circumstances, including our CFO. Our CFO works with our incident &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:318pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;responders (such as the external IT Director and DPO) to help us mitigate and remediate cybersecurity incidents of &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:328pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;which they are notified.&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:166.88pt;position:var(--position);text-decoration:none;white-space:pre"&gt; In addition, our incident response process includes reporting to the Board for certain &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:338pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;cybersecurity incidents.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:354pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Board &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:141.45pt;position:var(--position);text-decoration:none;white-space:pre"&gt;receives&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:174.16pt;position:var(--position);text-decoration:none;white-space:pre"&gt; periodic communications from the CFO and others (such as the IT Director and DPO)&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:520.48pt;position:var(--position);text-decoration:none;white-space:pre"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:364pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;concerning our significant cybersecurity threats, risk and the processes we have implemented in an effort to address &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:374pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;them.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-51">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Our Board addresses our cybersecurity risk management as part of its general oversight function. The Board is &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:170pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:180pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;from cybersecurity threats.&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:179.36pt;position:var(--position);text-decoration:none;white-space:pre"&gt; Our&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:197.41pt;position:var(--position);text-decoration:none;white-space:pre"&gt; Committee of Executives (&#x201c;COMEX&#x201d;)&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:355.54pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, in addition to those identified below, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:190pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;provides &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108.92pt;position:var(--position);text-decoration:none;white-space:pre"&gt;input&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.46pt;position:var(--position);text-decoration:none;white-space:pre"&gt; to the Board on cybersecurity threats. Our Committee of Executives consists of all our company's &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:200pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;officers along with our heads of manufacturing and quality.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-54">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by certain &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:226pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;management team members, including our&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:242.62pt;position:var(--position);text-decoration:none;white-space:pre"&gt; Chief Financial Officer (&#x201c;CFO&#x201d;)&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:375.77pt;position:var(--position);text-decoration:none;white-space:pre"&gt; who oversees our external &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.38pt;position:var(--position);text-decoration:none;white-space:pre"&gt;IT Director &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:236pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;and DPO&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108.93pt;position:var(--position);text-decoration:none;white-space:pre"&gt;. &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.93pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Our &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:131.98pt;position:var(--position);text-decoration:none;white-space:pre"&gt;CFO&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:151.42000000000002pt;position:var(--position);text-decoration:none;white-space:pre"&gt; has prior significant experience in strategic business operations&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:406.66pt;position:var(--position);text-decoration:none;white-space:pre"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:252pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Our CFO as &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:147.31pt;position:var(--position);text-decoration:none;white-space:pre"&gt;well&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:164.5pt;position:var(--position);text-decoration:none;white-space:pre"&gt; as our external IT Director and DPO are responsible for helping to integrate cybersecurity &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:262pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;risk considerations into our overall risk management strategy, and communicating key priorities to relevant &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:272pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;personnel. Our CFO is responsible for approving cybersecurity-related budgets, approving cybersecurity processes, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:282pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;and reviewing security assessments and other security-related reports.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c-1" id="f-53">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by certain &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:226pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;management team members, including our&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:242.62pt;position:var(--position);text-decoration:none;white-space:pre"&gt; Chief Financial Officer (&#x201c;CFO&#x201d;)&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:375.77pt;position:var(--position);text-decoration:none;white-space:pre"&gt; who oversees our external &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.38pt;position:var(--position);text-decoration:none;white-space:pre"&gt;IT Director &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:236pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;and DPO&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:108.93pt;position:var(--position);text-decoration:none;white-space:pre"&gt;. &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.93pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Our &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:131.98pt;position:var(--position);text-decoration:none;white-space:pre"&gt;CFO&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:151.42000000000002pt;position:var(--position);text-decoration:none;white-space:pre"&gt; has prior significant experience in strategic business operations&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:406.66pt;position:var(--position);text-decoration:none;white-space:pre"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:252pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Our CFO as &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:147.31pt;position:var(--position);text-decoration:none;white-space:pre"&gt;well&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:164.5pt;position:var(--position);text-decoration:none;white-space:pre"&gt; as our external IT Director and DPO are responsible for helping to integrate cybersecurity &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:262pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;risk considerations into our overall risk management strategy, and communicating key priorities to relevant &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:272pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;personnel. Our CFO is responsible for approving cybersecurity-related budgets, approving cybersecurity processes, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:282pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;and reviewing security assessments and other security-related reports.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:298pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Our cybersecurity incident response procedures are designed to escalate certain cybersecurity incidents to &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:308pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;members of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:121.95pt;position:var(--position);text-decoration:none;white-space:pre"&gt;management&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:172.98000000000002pt;position:var(--position);text-decoration:none;white-space:pre"&gt; depending on circumstances, including our CFO. Our CFO works with our incident &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:318pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;responders (such as the external IT Director and DPO) to help us mitigate and remediate cybersecurity incidents of &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:328pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;which they are notified.&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:166.88pt;position:var(--position);text-decoration:none;white-space:pre"&gt; In addition, our incident response process includes reporting to the Board for certain &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:338pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;cybersecurity incidents.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c-1" id="f-55">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c-1" id="f-56">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.93pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Our &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:131.98pt;position:var(--position);text-decoration:none;white-space:pre"&gt;CFO&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:151.42000000000002pt;position:var(--position);text-decoration:none;white-space:pre"&gt; has prior significant experience in strategic business operations&lt;/span&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-58">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Our cybersecurity incident response procedures are designed to escalate certain cybersecurity incidents to &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:308pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;members of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:121.95pt;position:var(--position);text-decoration:none;white-space:pre"&gt;management&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:172.98000000000002pt;position:var(--position);text-decoration:none;white-space:pre"&gt; depending on circumstances, including our CFO. Our CFO works with our incident &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:318pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;responders (such as the external IT Director and DPO) to help us mitigate and remediate cybersecurity incidents of &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:328pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;which they are notified.&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:166.88pt;position:var(--position);text-decoration:none;white-space:pre"&gt; In addition, our incident response process includes reporting to the Board for certain &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:338pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;cybersecurity incidents.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-57">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Our cybersecurity incident response procedures are designed to escalate certain cybersecurity incidents to &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:308pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;members of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:121.95pt;position:var(--position);text-decoration:none;white-space:pre"&gt;management&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:172.98000000000002pt;position:var(--position);text-decoration:none;white-space:pre"&gt; depending on circumstances, including our CFO. Our CFO works with our incident &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:318pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;responders (such as the external IT Director and DPO) to help us mitigate and remediate cybersecurity incidents of &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:328pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;which they are notified.&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:166.88pt;position:var(--position);text-decoration:none;white-space:pre"&gt; In addition, our incident response process includes reporting to the Board for certain &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:338pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;cybersecurity incidents.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:354pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Board &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:141.45pt;position:var(--position);text-decoration:none;white-space:pre"&gt;receives&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:174.16pt;position:var(--position);text-decoration:none;white-space:pre"&gt; periodic communications from the CFO and others (such as the IT Director and DPO)&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:520.48pt;position:var(--position);text-decoration:none;white-space:pre"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:364pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;concerning our significant cybersecurity threats, risk and the processes we have implemented in an effort to address &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:374pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;them.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c-1" id="f-59">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <dei:AuditorFirmId contextRef="c-1" id="f-60">1347</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-61">PricewaterhouseCoopers Audit</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-62">Neuilly-sur-Seine, France</dei:AuditorLocation>
    <ifrs-full:Goodwill contextRef="c-6" decimals="-3" id="f-63" unitRef="eur">18419000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-7" decimals="-3" id="f-64" unitRef="eur">18419000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-5" decimals="-3" id="f-65" unitRef="eur">18419000</ifrs-full:Goodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-6" decimals="-3" id="f-66" unitRef="eur">6604000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-7" decimals="-3" id="f-67" unitRef="eur">6606000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-5" decimals="-3" id="f-68" unitRef="eur">6605000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets contextRef="c-6" decimals="-3" id="f-69" unitRef="eur">878000</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets contextRef="c-7" decimals="-3" id="f-70" unitRef="eur">2666000</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets contextRef="c-5" decimals="-3" id="f-71" unitRef="eur">2090000</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:OtherNoncurrentFinancialAssets contextRef="c-6" decimals="-3" id="f-72" unitRef="eur">12870000</ifrs-full:OtherNoncurrentFinancialAssets>
    <ifrs-full:OtherNoncurrentFinancialAssets contextRef="c-7" decimals="-3" id="f-73" unitRef="eur">5919000</ifrs-full:OtherNoncurrentFinancialAssets>
    <ifrs-full:OtherNoncurrentFinancialAssets contextRef="c-5" decimals="-3" id="f-74" unitRef="eur">5358000</ifrs-full:OtherNoncurrentFinancialAssets>
    <ifrs-full:OtherNoncurrentNonfinancialAssets contextRef="c-6" decimals="-3" id="f-75" unitRef="eur">2320000</ifrs-full:OtherNoncurrentNonfinancialAssets>
    <ifrs-full:OtherNoncurrentNonfinancialAssets contextRef="c-7" decimals="-3" id="f-76" unitRef="eur">948000</ifrs-full:OtherNoncurrentNonfinancialAssets>
    <ifrs-full:OtherNoncurrentNonfinancialAssets contextRef="c-5" decimals="-3" id="f-77" unitRef="eur">625000</ifrs-full:OtherNoncurrentNonfinancialAssets>
    <ifrs-full:NoncurrentAssets contextRef="c-6" decimals="-3" id="f-78" unitRef="eur">41090000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c-7" decimals="-3" id="f-79" unitRef="eur">34558000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c-5" decimals="-3" id="f-80" unitRef="eur">33097000</ifrs-full:NoncurrentAssets>
    <ifrs-full:OtherCurrentFinancialAssets contextRef="c-6" decimals="-3" id="f-81" unitRef="eur">9186000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:OtherCurrentFinancialAssets contextRef="c-7" decimals="-3" id="f-82" unitRef="eur">7554000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:OtherCurrentFinancialAssets contextRef="c-5" decimals="-3" id="f-83" unitRef="eur">21415000</ifrs-full:OtherCurrentFinancialAssets>
    <abvx:CurrentReceivablesAndCurrentPrepaidExpenses contextRef="c-6" decimals="-3" id="f-84" unitRef="eur">24845000</abvx:CurrentReceivablesAndCurrentPrepaidExpenses>
    <abvx:CurrentReceivablesAndCurrentPrepaidExpenses contextRef="c-7" decimals="-3" id="f-85" unitRef="eur">18896000</abvx:CurrentReceivablesAndCurrentPrepaidExpenses>
    <abvx:CurrentReceivablesAndCurrentPrepaidExpenses contextRef="c-5" decimals="-3" id="f-86" unitRef="eur">13144000</abvx:CurrentReceivablesAndCurrentPrepaidExpenses>
    <ifrs-full:CashAndCashEquivalents contextRef="c-6" decimals="-3" id="f-87" unitRef="eur">251942000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-7" decimals="-3" id="f-88" unitRef="eur">144221000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-5" decimals="-3" id="f-89" unitRef="eur">516685000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentAssets contextRef="c-6" decimals="-3" id="f-90" unitRef="eur">285972000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c-7" decimals="-3" id="f-91" unitRef="eur">170671000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c-5" decimals="-3" id="f-92" unitRef="eur">551244000</ifrs-full:CurrentAssets>
    <ifrs-full:Assets contextRef="c-6" decimals="-3" id="f-93" unitRef="eur">327062000</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c-7" decimals="-3" id="f-94" unitRef="eur">205228000</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c-5" decimals="-3" id="f-95" unitRef="eur">584341000</ifrs-full:Assets>
    <ifrs-full:IssuedCapital contextRef="c-6" decimals="-3" id="f-96" unitRef="eur">629000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital contextRef="c-7" decimals="-3" id="f-97" unitRef="eur">633000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital contextRef="c-5" decimals="-3" id="f-98" unitRef="eur">785000</ifrs-full:IssuedCapital>
    <ifrs-full:SharePremium contextRef="c-6" decimals="-3" id="f-99" unitRef="eur">478218000</ifrs-full:SharePremium>
    <ifrs-full:SharePremium contextRef="c-7" decimals="-3" id="f-100" unitRef="eur">478905000</ifrs-full:SharePremium>
    <ifrs-full:SharePremium contextRef="c-5" decimals="-3" id="f-101" unitRef="eur">1190593000</ifrs-full:SharePremium>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation contextRef="c-6" decimals="-3" id="f-102" unitRef="eur">112000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation contextRef="c-7" decimals="-3" id="f-103" unitRef="eur">-75000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation contextRef="c-5" decimals="-3" id="f-104" unitRef="eur">2309000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriod contextRef="c-6" decimals="-3" id="f-105" unitRef="eur">-135209000</ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriod>
    <ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriod contextRef="c-7" decimals="-3" id="f-106" unitRef="eur">-262637000</ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriod>
    <ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriod contextRef="c-5" decimals="-3" id="f-107" unitRef="eur">-402380000</ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriod>
    <ifrs-full:RetainedEarningsProfitLossForReportingPeriod contextRef="c-6" decimals="-3" id="f-108" unitRef="eur">-147740000</ifrs-full:RetainedEarningsProfitLossForReportingPeriod>
    <ifrs-full:RetainedEarningsProfitLossForReportingPeriod contextRef="c-7" decimals="-3" id="f-109" unitRef="eur">-176242000</ifrs-full:RetainedEarningsProfitLossForReportingPeriod>
    <ifrs-full:RetainedEarningsProfitLossForReportingPeriod contextRef="c-5" decimals="-3" id="f-110" unitRef="eur">-336102000</ifrs-full:RetainedEarningsProfitLossForReportingPeriod>
    <ifrs-full:Equity contextRef="c-6" decimals="-3" id="f-111" unitRef="eur">196010000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-7" decimals="-3" id="f-112" unitRef="eur">40584000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-5" decimals="-3" id="f-113" unitRef="eur">455205000</ifrs-full:Equity>
    <ifrs-full:NoncurrentProvisionsForEmployeeBenefits contextRef="c-6" decimals="-3" id="f-114" unitRef="eur">629000</ifrs-full:NoncurrentProvisionsForEmployeeBenefits>
    <ifrs-full:NoncurrentProvisionsForEmployeeBenefits contextRef="c-7" decimals="-3" id="f-115" unitRef="eur">756000</ifrs-full:NoncurrentProvisionsForEmployeeBenefits>
    <ifrs-full:NoncurrentProvisionsForEmployeeBenefits contextRef="c-5" decimals="-3" id="f-116" unitRef="eur">627000</ifrs-full:NoncurrentProvisionsForEmployeeBenefits>
    <ifrs-full:OtherLongtermProvisions contextRef="c-6" decimals="-3" id="f-117" unitRef="eur">30000</ifrs-full:OtherLongtermProvisions>
    <ifrs-full:OtherLongtermProvisions contextRef="c-7" decimals="-3" id="f-118" unitRef="eur">819000</ifrs-full:OtherLongtermProvisions>
    <ifrs-full:OtherLongtermProvisions contextRef="c-5" decimals="-3" id="f-119" unitRef="eur">28849000</ifrs-full:OtherLongtermProvisions>
    <ifrs-full:NoncurrentPortionOfOtherNoncurrentBorrowings contextRef="c-6" decimals="-3" id="f-120" unitRef="eur">2563000</ifrs-full:NoncurrentPortionOfOtherNoncurrentBorrowings>
    <ifrs-full:NoncurrentPortionOfOtherNoncurrentBorrowings contextRef="c-7" decimals="-3" id="f-121" unitRef="eur">29056000</ifrs-full:NoncurrentPortionOfOtherNoncurrentBorrowings>
    <ifrs-full:NoncurrentPortionOfOtherNoncurrentBorrowings contextRef="c-5" decimals="-3" id="f-122" unitRef="eur">554000</ifrs-full:NoncurrentPortionOfOtherNoncurrentBorrowings>
    <abvx:NonCurrentConvertibleLoansNotes contextRef="c-6" decimals="-3" id="f-123" unitRef="eur">21643000</abvx:NonCurrentConvertibleLoansNotes>
    <abvx:NonCurrentConvertibleLoansNotes contextRef="c-7" decimals="-3" id="f-124" unitRef="eur">23370000</abvx:NonCurrentConvertibleLoansNotes>
    <abvx:NonCurrentConvertibleLoansNotes contextRef="c-5" decimals="-3" id="f-125" unitRef="eur">0</abvx:NonCurrentConvertibleLoansNotes>
    <ifrs-full:NoncurrentDerivativeFinancialLiabilities contextRef="c-6" decimals="-3" id="f-126" unitRef="eur">0</ifrs-full:NoncurrentDerivativeFinancialLiabilities>
    <ifrs-full:NoncurrentDerivativeFinancialLiabilities contextRef="c-7" decimals="-3" id="f-127" unitRef="eur">3620000</ifrs-full:NoncurrentDerivativeFinancialLiabilities>
    <ifrs-full:NoncurrentDerivativeFinancialLiabilities contextRef="c-5" decimals="-3" id="f-128" unitRef="eur">0</ifrs-full:NoncurrentDerivativeFinancialLiabilities>
    <abvx:NonCurrentRoyaltyCertificates contextRef="c-6" decimals="-3" id="f-129" unitRef="eur">12229000</abvx:NonCurrentRoyaltyCertificates>
    <abvx:NonCurrentRoyaltyCertificates contextRef="c-7" decimals="-3" id="f-130" unitRef="eur">13023000</abvx:NonCurrentRoyaltyCertificates>
    <abvx:NonCurrentRoyaltyCertificates contextRef="c-5" decimals="-3" id="f-131" unitRef="eur">30237000</abvx:NonCurrentRoyaltyCertificates>
    <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="c-6" decimals="-3" id="f-132" unitRef="eur">3262000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="c-7" decimals="-3" id="f-133" unitRef="eur">0</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="c-5" decimals="-3" id="f-134" unitRef="eur">0</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <abvx:DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets contextRef="c-6" decimals="-3" id="f-135" unitRef="eur">0</abvx:DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets>
    <abvx:DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets contextRef="c-7" decimals="-3" id="f-136" unitRef="eur">0</abvx:DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets>
    <abvx:DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets contextRef="c-5" decimals="-3" id="f-137" unitRef="eur">5848000</abvx:DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets>
    <ifrs-full:NoncurrentLiabilities contextRef="c-6" decimals="-3" id="f-138" unitRef="eur">40356000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c-7" decimals="-3" id="f-139" unitRef="eur">70645000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c-5" decimals="-3" id="f-140" unitRef="eur">66114000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings contextRef="c-6" decimals="-3" id="f-141" unitRef="eur">1655000</ifrs-full:OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings>
    <ifrs-full:OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings contextRef="c-7" decimals="-3" id="f-142" unitRef="eur">22195000</ifrs-full:OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings>
    <ifrs-full:OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings contextRef="c-5" decimals="-3" id="f-143" unitRef="eur">1302000</ifrs-full:OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings>
    <abvx:CurrentPortionOfNonCurrentConvertibleLoansNotes contextRef="c-6" decimals="-3" id="f-144" unitRef="eur">29605000</abvx:CurrentPortionOfNonCurrentConvertibleLoansNotes>
    <abvx:CurrentPortionOfNonCurrentConvertibleLoansNotes contextRef="c-7" decimals="-3" id="f-145" unitRef="eur">21574000</abvx:CurrentPortionOfNonCurrentConvertibleLoansNotes>
    <abvx:CurrentPortionOfNonCurrentConvertibleLoansNotes contextRef="c-5" decimals="-3" id="f-146" unitRef="eur">0</abvx:CurrentPortionOfNonCurrentConvertibleLoansNotes>
    <ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="c-6" decimals="-3" id="f-147" unitRef="eur">2579000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="c-7" decimals="-3" id="f-148" unitRef="eur">1166000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="c-5" decimals="-3" id="f-149" unitRef="eur">0</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities contextRef="c-6" decimals="-3" id="f-150" unitRef="eur">3509000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities contextRef="c-7" decimals="-3" id="f-151" unitRef="eur">0</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities contextRef="c-5" decimals="-3" id="f-152" unitRef="eur">0</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherShorttermProvisions contextRef="c-6" decimals="-3" id="f-153" unitRef="eur">0</ifrs-full:OtherShorttermProvisions>
    <ifrs-full:OtherShorttermProvisions contextRef="c-7" decimals="-3" id="f-154" unitRef="eur">532000</ifrs-full:OtherShorttermProvisions>
    <ifrs-full:OtherShorttermProvisions contextRef="c-5" decimals="-3" id="f-155" unitRef="eur">17030000</ifrs-full:OtherShorttermProvisions>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-6" decimals="-3" id="f-156" unitRef="eur">47221000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-7" decimals="-3" id="f-157" unitRef="eur">43824000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-5" decimals="-3" id="f-158" unitRef="eur">37552000</ifrs-full:TradeAndOtherCurrentPayables>
    <abvx:CurrentTaxAndEmployeeBenefitLiabilities contextRef="c-6" decimals="-3" id="f-159" unitRef="eur">6073000</abvx:CurrentTaxAndEmployeeBenefitLiabilities>
    <abvx:CurrentTaxAndEmployeeBenefitLiabilities contextRef="c-7" decimals="-3" id="f-160" unitRef="eur">4709000</abvx:CurrentTaxAndEmployeeBenefitLiabilities>
    <abvx:CurrentTaxAndEmployeeBenefitLiabilities contextRef="c-5" decimals="-3" id="f-161" unitRef="eur">7137000</abvx:CurrentTaxAndEmployeeBenefitLiabilities>
    <ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities contextRef="c-6" decimals="-3" id="f-162" unitRef="eur">52000</ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities>
    <ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities contextRef="c-7" decimals="-3" id="f-163" unitRef="eur">0</ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities>
    <ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities contextRef="c-5" decimals="-3" id="f-164" unitRef="eur">0</ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c-6" decimals="-3" id="f-165" unitRef="eur">90695000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c-7" decimals="-3" id="f-166" unitRef="eur">93999000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c-5" decimals="-3" id="f-167" unitRef="eur">63021000</ifrs-full:CurrentLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c-6" decimals="-3" id="f-168" unitRef="eur">327062000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c-7" decimals="-3" id="f-169" unitRef="eur">205228000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c-5" decimals="-3" id="f-170" unitRef="eur">584341000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:OtherIncome contextRef="c-8" decimals="-3" id="f-171" unitRef="eur">4621000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="c-9" decimals="-3" id="f-172" unitRef="eur">12449000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="c-1" decimals="-3" id="f-173" unitRef="eur">4570000</ifrs-full:OtherIncome>
    <ifrs-full:RevenueAndOperatingIncome contextRef="c-8" decimals="-3" id="f-174" unitRef="eur">4621000</ifrs-full:RevenueAndOperatingIncome>
    <ifrs-full:RevenueAndOperatingIncome contextRef="c-9" decimals="-3" id="f-175" unitRef="eur">12449000</ifrs-full:RevenueAndOperatingIncome>
    <ifrs-full:RevenueAndOperatingIncome contextRef="c-1" decimals="-3" id="f-176" unitRef="eur">4570000</ifrs-full:RevenueAndOperatingIncome>
    <ifrs-full:SalesAndMarketingExpense contextRef="c-8" decimals="-3" id="f-177" unitRef="eur">6431000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c-9" decimals="-3" id="f-178" unitRef="eur">5954000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c-1" decimals="-3" id="f-179" unitRef="eur">5194000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-8" decimals="-3" id="f-180" unitRef="eur">103176000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-9" decimals="-3" id="f-181" unitRef="eur">146532000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-182" unitRef="eur">177761000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c-8" decimals="-3" id="f-183" unitRef="eur">22390000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c-9" decimals="-3" id="f-184" unitRef="eur">32946000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-185" unitRef="eur">67670000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:OperatingExpense contextRef="c-8" decimals="-3" id="f-186" unitRef="eur">131997000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense contextRef="c-9" decimals="-3" id="f-187" unitRef="eur">185433000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense contextRef="c-1" decimals="-3" id="f-188" unitRef="eur">250626000</ifrs-full:OperatingExpense>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-8" decimals="-3" id="f-189" unitRef="eur">-127376000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-9" decimals="-3" id="f-190" unitRef="eur">-172984000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-1" decimals="-3" id="f-191" unitRef="eur">-246056000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceCosts contextRef="c-8" decimals="-3" id="f-192" unitRef="eur">27875000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-9" decimals="-3" id="f-193" unitRef="eur">16991000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-1" decimals="-3" id="f-194" unitRef="eur">111743000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceIncome contextRef="c-8" decimals="-3" id="f-195" unitRef="eur">7511000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-9" decimals="-3" id="f-196" unitRef="eur">13732000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-1" decimals="-3" id="f-197" unitRef="eur">27545000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncomeCost contextRef="c-8" decimals="-3" id="f-198" unitRef="eur">-20364000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost contextRef="c-9" decimals="-3" id="f-199" unitRef="eur">-3258000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost contextRef="c-1" decimals="-3" id="f-200" unitRef="eur">-84198000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-8" decimals="-3" id="f-201" unitRef="eur">-147740000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-9" decimals="-3" id="f-202" unitRef="eur">-176242000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-1" decimals="-3" id="f-203" unitRef="eur">-330254000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-8" decimals="-3" id="f-204" unitRef="eur">0</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-9" decimals="-3" id="f-205" unitRef="eur">0</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-1" decimals="-3" id="f-206" unitRef="eur">5848000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss contextRef="c-8" decimals="-3" id="f-207" unitRef="eur">-147740000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-9" decimals="-3" id="f-208" unitRef="eur">-176242000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-3" id="f-209" unitRef="eur">-336102000</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-8" decimals="0" id="f-210" unitRef="shares">43066012</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-8" decimals="0" id="f-211" unitRef="shares">43066012</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-9" decimals="0" id="f-212" unitRef="shares">63046350</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-9" decimals="0" id="f-213" unitRef="shares">63046350</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-1" decimals="0" id="f-214" unitRef="shares">69527315</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-1" decimals="0" id="f-215" unitRef="shares">69527315</ifrs-full:WeightedAverageShares>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-8"
      decimals="2"
      id="f-216"
      unitRef="eurPerShare">-3.43</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-8"
      decimals="2"
      id="f-217"
      unitRef="eurPerShare">-3.43</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-9"
      decimals="2"
      id="f-218"
      unitRef="eurPerShare">-2.80</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-9"
      decimals="2"
      id="f-219"
      unitRef="eurPerShare">-2.80</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-1"
      decimals="2"
      id="f-220"
      unitRef="eurPerShare">-4.83</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-1"
      decimals="2"
      id="f-221"
      unitRef="eurPerShare">-4.83</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:ProfitLoss contextRef="c-8" decimals="-3" id="f-222" unitRef="eur">-147740000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-9" decimals="-3" id="f-223" unitRef="eur">-176242000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-3" id="f-224" unitRef="eur">-336102000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="c-8" decimals="-3" id="f-225" unitRef="eur">112000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="c-9" decimals="-3" id="f-226" unitRef="eur">-31000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="c-1" decimals="-3" id="f-227" unitRef="eur">93000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="c-8" decimals="-3" id="f-228" unitRef="eur">112000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="c-9" decimals="-3" id="f-229" unitRef="eur">-31000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="c-1" decimals="-3" id="f-230" unitRef="eur">93000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-8" decimals="-3" id="f-231" unitRef="eur">112000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-9" decimals="-3" id="f-232" unitRef="eur">-187000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-1" decimals="-3" id="f-233" unitRef="eur">2384000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-8" decimals="-3" id="f-234" unitRef="eur">112000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-9" decimals="-3" id="f-235" unitRef="eur">-187000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-1" decimals="-3" id="f-236" unitRef="eur">2384000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-8" decimals="-3" id="f-237" unitRef="eur">225000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-9" decimals="-3" id="f-238" unitRef="eur">-219000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-1" decimals="-3" id="f-239" unitRef="eur">2477000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-8" decimals="-3" id="f-240" unitRef="eur">-147516000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-9" decimals="-3" id="f-241" unitRef="eur">-176461000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-1" decimals="-3" id="f-242" unitRef="eur">-333625000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:NumberOfSharesIssued contextRef="c-10" decimals="0" id="f-243" unitRef="shares">22313185</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity contextRef="c-11" decimals="-3" id="f-244" unitRef="eur">223000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-12" decimals="-3" id="f-245" unitRef="eur">150476000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-13" decimals="-3" id="f-246" unitRef="eur">0</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-14" decimals="-3" id="f-247" unitRef="eur">-82770000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-15" decimals="-3" id="f-248" unitRef="eur">-60740000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-10" decimals="-3" id="f-249" unitRef="eur">7189000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c-16" decimals="-3" id="f-250" unitRef="eur">-147740000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-8" decimals="-3" id="f-251" unitRef="eur">-147740000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-17" decimals="-3" id="f-252" unitRef="eur">112000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-18" decimals="-3" id="f-253" unitRef="eur">112000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-8" decimals="-3" id="f-254" unitRef="eur">225000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-17" decimals="-3" id="f-255" unitRef="eur">112000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-18" decimals="-3" id="f-256" unitRef="eur">112000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-16" decimals="-3" id="f-257" unitRef="eur">-147740000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-8" decimals="-3" id="f-258" unitRef="eur">-147516000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings contextRef="c-18" decimals="-3" id="f-259" unitRef="eur">-60740000</ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings>
    <ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings contextRef="c-16" decimals="-3" id="f-260" unitRef="eur">60740000</ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings>
    <ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings contextRef="c-8" decimals="-3" id="f-261" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings>
    <abvx:IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease contextRef="c-8" decimals="0" id="f-262" unitRef="shares">40325500</abvx:IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease>
    <ifrs-full:IssueOfEquity contextRef="c-19" decimals="-3" id="f-263" unitRef="eur">403000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-20" decimals="-3" id="f-264" unitRef="eur">352974000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-8" decimals="-3" id="f-265" unitRef="eur">353377000</ifrs-full:IssueOfEquity>
    <abvx:ShareIssueRelatedCostCredit contextRef="c-20" decimals="-3" id="f-266" unitRef="eur">28111000</abvx:ShareIssueRelatedCostCredit>
    <abvx:ShareIssueRelatedCostCredit contextRef="c-8" decimals="-3" id="f-267" unitRef="eur">28111000</abvx:ShareIssueRelatedCostCredit>
    <ifrs-full:IssueOfConvertibleInstruments contextRef="c-20" decimals="-3" id="f-268" unitRef="eur">1030000</ifrs-full:IssueOfConvertibleInstruments>
    <ifrs-full:IssueOfConvertibleInstruments contextRef="c-8" decimals="-3" id="f-269" unitRef="eur">1030000</ifrs-full:IssueOfConvertibleInstruments>
    <abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants contextRef="c-21" decimals="0" id="f-270" unitRef="shares">99583</abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c-22" decimals="-3" id="f-271" unitRef="eur">1000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c-23" decimals="-3" id="f-272" unitRef="eur">1849000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c-21" decimals="-3" id="f-273" unitRef="eur">1850000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants contextRef="c-24" decimals="0" id="f-274" unitRef="shares">190550</abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c-25" decimals="-3" id="f-275" unitRef="eur">2000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c-24" decimals="-3" id="f-276" unitRef="eur">2000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-18" decimals="-3" id="f-277" unitRef="eur">8179000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-8" decimals="-3" id="f-278" unitRef="eur">8179000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions contextRef="c-18" decimals="-3" id="f-279" unitRef="eur">10000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions contextRef="c-8" decimals="-3" id="f-280" unitRef="eur">10000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:NumberOfSharesIssued contextRef="c-6" decimals="0" id="f-281" unitRef="shares">62928818</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity contextRef="c-26" decimals="-3" id="f-282" unitRef="eur">629000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-27" decimals="-3" id="f-283" unitRef="eur">478218000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-28" decimals="-3" id="f-284" unitRef="eur">112000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-29" decimals="-3" id="f-285" unitRef="eur">-135210000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-30" decimals="-3" id="f-286" unitRef="eur">-147740000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-6" decimals="-3" id="f-287" unitRef="eur">196010000</ifrs-full:Equity>
    <ifrs-full:NumberOfSharesIssued contextRef="c-6" decimals="0" id="f-288" unitRef="shares">62928818</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity contextRef="c-26" decimals="-3" id="f-289" unitRef="eur">629000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-27" decimals="-3" id="f-290" unitRef="eur">478218000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-28" decimals="-3" id="f-291" unitRef="eur">112000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-29" decimals="-3" id="f-292" unitRef="eur">-135210000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-30" decimals="-3" id="f-293" unitRef="eur">-147740000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-6" decimals="-3" id="f-294" unitRef="eur">196010000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c-31" decimals="-3" id="f-295" unitRef="eur">-176242000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-9" decimals="-3" id="f-296" unitRef="eur">-176242000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-32" decimals="-3" id="f-297" unitRef="eur">-187000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-33" decimals="-3" id="f-298" unitRef="eur">-31000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-9" decimals="-3" id="f-299" unitRef="eur">-219000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-32" decimals="-3" id="f-300" unitRef="eur">-187000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-33" decimals="-3" id="f-301" unitRef="eur">-31000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-31" decimals="-3" id="f-302" unitRef="eur">-176242000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-9" decimals="-3" id="f-303" unitRef="eur">-176461000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings contextRef="c-33" decimals="-3" id="f-304" unitRef="eur">-147740000</ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings>
    <ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings contextRef="c-31" decimals="-3" id="f-305" unitRef="eur">147740000</ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings>
    <ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings contextRef="c-9" decimals="-3" id="f-306" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings>
    <abvx:ShareIssueRelatedCostCredit contextRef="c-34" decimals="-3" id="f-307" unitRef="eur">-446000</abvx:ShareIssueRelatedCostCredit>
    <abvx:ShareIssueRelatedCostCredit contextRef="c-9" decimals="-3" id="f-308" unitRef="eur">-446000</abvx:ShareIssueRelatedCostCredit>
    <abvx:IncreaseDecreaseThroughIssuanceOfWarrantsEquity contextRef="c-34" decimals="-3" id="f-309" unitRef="eur">200000</abvx:IncreaseDecreaseThroughIssuanceOfWarrantsEquity>
    <abvx:IncreaseDecreaseThroughIssuanceOfWarrantsEquity contextRef="c-9" decimals="-3" id="f-310" unitRef="eur">200000</abvx:IncreaseDecreaseThroughIssuanceOfWarrantsEquity>
    <abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants contextRef="c-9" decimals="0" id="f-311" unitRef="shares">4000</abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c-34" decimals="-3" id="f-312" unitRef="eur">45000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c-9" decimals="-3" id="f-313" unitRef="eur">45000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <abvx:NumberOfFreeSharesIssued contextRef="c-9" decimals="0" id="f-314" unitRef="shares">415019</abvx:NumberOfFreeSharesIssued>
    <abvx:IncreaseDecreaseFromFreeSharesIssued contextRef="c-35" decimals="-3" id="f-315" unitRef="eur">4000</abvx:IncreaseDecreaseFromFreeSharesIssued>
    <abvx:IncreaseDecreaseFromFreeSharesIssued contextRef="c-34" decimals="-3" id="f-316" unitRef="eur">-4000</abvx:IncreaseDecreaseFromFreeSharesIssued>
    <abvx:IncreaseDecreaseFromFreeSharesIssued contextRef="c-9" decimals="-3" id="f-317" unitRef="eur">1000</abvx:IncreaseDecreaseFromFreeSharesIssued>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-33" decimals="-3" id="f-318" unitRef="eur">20224000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-9" decimals="-3" id="f-319" unitRef="eur">20224000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions contextRef="c-33" decimals="-3" id="f-320" unitRef="eur">120000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions contextRef="c-9" decimals="-3" id="f-321" unitRef="eur">120000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:NumberOfSharesIssued contextRef="c-7" decimals="0" id="f-322" unitRef="shares">63347837</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity contextRef="c-36" decimals="-3" id="f-323" unitRef="eur">633000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-37" decimals="-3" id="f-324" unitRef="eur">478905000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-38" decimals="-3" id="f-325" unitRef="eur">-75000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-39" decimals="-3" id="f-326" unitRef="eur">-262638000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-40" decimals="-3" id="f-327" unitRef="eur">-176242000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-7" decimals="-3" id="f-328" unitRef="eur">40584000</ifrs-full:Equity>
    <ifrs-full:NumberOfSharesIssued contextRef="c-7" decimals="0" id="f-329" unitRef="shares">63347837</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity contextRef="c-36" decimals="-3" id="f-330" unitRef="eur">633000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-37" decimals="-3" id="f-331" unitRef="eur">478905000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-38" decimals="-3" id="f-332" unitRef="eur">-75000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-39" decimals="-3" id="f-333" unitRef="eur">-262638000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-40" decimals="-3" id="f-334" unitRef="eur">-176242000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-7" decimals="-3" id="f-335" unitRef="eur">40584000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c-41" decimals="-3" id="f-336" unitRef="eur">-336102000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-3" id="f-337" unitRef="eur">-336102000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-42" decimals="-3" id="f-338" unitRef="eur">2384000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-43" decimals="-3" id="f-339" unitRef="eur">93000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-1" decimals="-3" id="f-340" unitRef="eur">2477000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-42" decimals="-3" id="f-341" unitRef="eur">2384000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-43" decimals="-3" id="f-342" unitRef="eur">93000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-41" decimals="-3" id="f-343" unitRef="eur">-336102000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-1" decimals="-3" id="f-344" unitRef="eur">-333625000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings contextRef="c-43" decimals="-3" id="f-345" unitRef="eur">-176242000</ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings>
    <ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings contextRef="c-41" decimals="-3" id="f-346" unitRef="eur">176242000</ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings>
    <ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings contextRef="c-1" decimals="-3" id="f-347" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings>
    <abvx:IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease contextRef="c-1" decimals="0" id="f-348" unitRef="shares">11679400</abvx:IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease>
    <ifrs-full:IssueOfEquity contextRef="c-44" decimals="-3" id="f-349" unitRef="eur">117000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-45" decimals="-3" id="f-350" unitRef="eur">637345000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-1" decimals="-3" id="f-351" unitRef="eur">637462000</ifrs-full:IssueOfEquity>
    <abvx:ShareIssueRelatedCostCredit contextRef="c-45" decimals="-3" id="f-352" unitRef="eur">40306000</abvx:ShareIssueRelatedCostCredit>
    <abvx:ShareIssueRelatedCostCredit contextRef="c-1" decimals="-3" id="f-353" unitRef="eur">40306000</abvx:ShareIssueRelatedCostCredit>
    <abvx:IncreaseDecreaseThroughIssuanceOfWarrantsEquity contextRef="c-45" decimals="-3" id="f-354" unitRef="eur">300000</abvx:IncreaseDecreaseThroughIssuanceOfWarrantsEquity>
    <abvx:IncreaseDecreaseThroughIssuanceOfWarrantsEquity contextRef="c-1" decimals="-3" id="f-355" unitRef="eur">300000</abvx:IncreaseDecreaseThroughIssuanceOfWarrantsEquity>
    <abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants contextRef="c-46" decimals="0" id="f-356" unitRef="shares">525913</abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c-44" decimals="-3" id="f-357" unitRef="eur">5000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c-47" decimals="-3" id="f-358" unitRef="eur">33763000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c-46" decimals="-3" id="f-359" unitRef="eur">33768000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants contextRef="c-48" decimals="0" id="f-360" unitRef="shares">257087</abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c-49" decimals="-3" id="f-361" unitRef="eur">3000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c-50" decimals="-3" id="f-362" unitRef="eur">3343000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c-48" decimals="-3" id="f-363" unitRef="eur">3346000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments contextRef="c-51" decimals="0" id="f-364" unitRef="shares">1178084</abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="c-52" decimals="-3" id="f-365" unitRef="eur">12000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="c-53" decimals="-3" id="f-366" unitRef="eur">23338000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="c-54" decimals="-3" id="f-367" unitRef="eur">1009000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="c-51" decimals="-3" id="f-368" unitRef="eur">24359000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
    <abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments contextRef="c-55" decimals="0" id="f-369" unitRef="shares">920377</abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="c-56" decimals="-3" id="f-370" unitRef="eur">9000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="c-57" decimals="-3" id="f-371" unitRef="eur">53912000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="c-55" decimals="-3" id="f-372" unitRef="eur">53921000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
    <abvx:NumberOfFreeSharesIssued contextRef="c-1" decimals="0" id="f-373" unitRef="shares">627714</abvx:NumberOfFreeSharesIssued>
    <abvx:IncreaseDecreaseFromFreeSharesIssued contextRef="c-44" decimals="-3" id="f-374" unitRef="eur">6000</abvx:IncreaseDecreaseFromFreeSharesIssued>
    <abvx:IncreaseDecreaseFromFreeSharesIssued contextRef="c-45" decimals="-3" id="f-375" unitRef="eur">-6000</abvx:IncreaseDecreaseFromFreeSharesIssued>
    <abvx:IncreaseDecreaseFromFreeSharesIssued contextRef="c-1" decimals="-3" id="f-376" unitRef="eur">0</abvx:IncreaseDecreaseFromFreeSharesIssued>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-43" decimals="-3" id="f-377" unitRef="eur">35397000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-1" decimals="-3" id="f-378" unitRef="eur">35397000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:NumberOfSharesIssued contextRef="c-5" decimals="0" id="f-379" unitRef="shares">78536412</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity contextRef="c-58" decimals="-3" id="f-380" unitRef="eur">785000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-59" decimals="-3" id="f-381" unitRef="eur">1190593000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-60" decimals="-3" id="f-382" unitRef="eur">2309000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-61" decimals="-3" id="f-383" unitRef="eur">-402380000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-62" decimals="-3" id="f-384" unitRef="eur">-336102000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-5" decimals="-3" id="f-385" unitRef="eur">455205000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c-8" decimals="-3" id="f-386" unitRef="eur">-147740000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-9" decimals="-3" id="f-387" unitRef="eur">-176242000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-3" id="f-388" unitRef="eur">-336102000</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c-8" decimals="-3" id="f-389" unitRef="eur">707000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c-9" decimals="-3" id="f-390" unitRef="eur">1100000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c-1" decimals="-3" id="f-391" unitRef="eur">1072000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities contextRef="c-8" decimals="-3" id="f-392" unitRef="eur">109000</ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities contextRef="c-9" decimals="-3" id="f-393" unitRef="eur">74000</ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities contextRef="c-1" decimals="-3" id="f-394" unitRef="eur">-65000</ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c-8" decimals="-3" id="f-395" unitRef="eur">8179000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c-9" decimals="-3" id="f-396" unitRef="eur">20224000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c-1" decimals="-3" id="f-397" unitRef="eur">35397000</ifrs-full:AdjustmentsForSharebasedPayments>
    <abvx:AdjustmentsForNetGainOnSaleOfTreasuryShares contextRef="c-8" decimals="-3" id="f-398" unitRef="eur">-34000</abvx:AdjustmentsForNetGainOnSaleOfTreasuryShares>
    <abvx:AdjustmentsForNetGainOnSaleOfTreasuryShares contextRef="c-9" decimals="-3" id="f-399" unitRef="eur">-16000</abvx:AdjustmentsForNetGainOnSaleOfTreasuryShares>
    <abvx:AdjustmentsForNetGainOnSaleOfTreasuryShares contextRef="c-1" decimals="-3" id="f-400" unitRef="eur">0</abvx:AdjustmentsForNetGainOnSaleOfTreasuryShares>
    <abvx:AdjustmentsForOtherFinanceCosts contextRef="c-8" decimals="-3" id="f-401" unitRef="eur">24827000</abvx:AdjustmentsForOtherFinanceCosts>
    <abvx:AdjustmentsForOtherFinanceCosts contextRef="c-9" decimals="-3" id="f-402" unitRef="eur">14203000</abvx:AdjustmentsForOtherFinanceCosts>
    <abvx:AdjustmentsForOtherFinanceCosts contextRef="c-1" decimals="-3" id="f-403" unitRef="eur">45697000</abvx:AdjustmentsForOtherFinanceCosts>
    <abvx:AdjustmentsForOtherFinanceIncome contextRef="c-8" decimals="-3" id="f-404" unitRef="eur">2953000</abvx:AdjustmentsForOtherFinanceIncome>
    <abvx:AdjustmentsForOtherFinanceIncome contextRef="c-9" decimals="-3" id="f-405" unitRef="eur">11609000</abvx:AdjustmentsForOtherFinanceIncome>
    <abvx:AdjustmentsForOtherFinanceIncome contextRef="c-1" decimals="-3" id="f-406" unitRef="eur">23782000</abvx:AdjustmentsForOtherFinanceIncome>
    <abvx:AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances contextRef="c-8" decimals="-3" id="f-407" unitRef="eur">-355000</abvx:AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances>
    <abvx:AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances contextRef="c-9" decimals="-3" id="f-408" unitRef="eur">-710000</abvx:AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances>
    <abvx:AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances contextRef="c-1" decimals="-3" id="f-409" unitRef="eur">-153000</abvx:AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances>
    <ifrs-full:AdjustmentsForFairValueGainsLosses contextRef="c-8" decimals="-3" id="f-410" unitRef="eur">-1158000</ifrs-full:AdjustmentsForFairValueGainsLosses>
    <ifrs-full:AdjustmentsForFairValueGainsLosses contextRef="c-9" decimals="-3" id="f-411" unitRef="eur">1416000</ifrs-full:AdjustmentsForFairValueGainsLosses>
    <ifrs-full:AdjustmentsForFairValueGainsLosses contextRef="c-1" decimals="-3" id="f-412" unitRef="eur">62330000</ifrs-full:AdjustmentsForFairValueGainsLosses>
    <abvx:AdjustmentsForForgivenessOfConditionalAdvances contextRef="c-8" decimals="-3" id="f-413" unitRef="eur">0</abvx:AdjustmentsForForgivenessOfConditionalAdvances>
    <abvx:AdjustmentsForForgivenessOfConditionalAdvances contextRef="c-9" decimals="-3" id="f-414" unitRef="eur">-4140000</abvx:AdjustmentsForForgivenessOfConditionalAdvances>
    <abvx:AdjustmentsForForgivenessOfConditionalAdvances contextRef="c-1" decimals="-3" id="f-415" unitRef="eur">0</abvx:AdjustmentsForForgivenessOfConditionalAdvances>
    <ifrs-full:AdjustmentsForProvisions contextRef="c-8" decimals="-3" id="f-416" unitRef="eur">0</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForProvisions contextRef="c-9" decimals="-3" id="f-417" unitRef="eur">0</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForProvisions contextRef="c-1" decimals="-3" id="f-418" unitRef="eur">44706000</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForIncomeTaxExpense contextRef="c-8" decimals="-3" id="f-419" unitRef="eur">0</ifrs-full:AdjustmentsForIncomeTaxExpense>
    <ifrs-full:AdjustmentsForIncomeTaxExpense contextRef="c-9" decimals="-3" id="f-420" unitRef="eur">0</ifrs-full:AdjustmentsForIncomeTaxExpense>
    <ifrs-full:AdjustmentsForIncomeTaxExpense contextRef="c-1" decimals="-3" id="f-421" unitRef="eur">5848000</ifrs-full:AdjustmentsForIncomeTaxExpense>
    <ifrs-full:OtherAdjustmentsForNoncashItems contextRef="c-8" decimals="-3" id="f-422" unitRef="eur">22000</ifrs-full:OtherAdjustmentsForNoncashItems>
    <ifrs-full:OtherAdjustmentsForNoncashItems contextRef="c-9" decimals="-3" id="f-423" unitRef="eur">204000</ifrs-full:OtherAdjustmentsForNoncashItems>
    <ifrs-full:OtherAdjustmentsForNoncashItems contextRef="c-1" decimals="-3" id="f-424" unitRef="eur">270000</ifrs-full:OtherAdjustmentsForNoncashItems>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="c-8" decimals="-3" id="f-425" unitRef="eur">-118395000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="c-9" decimals="-3" id="f-426" unitRef="eur">-155495000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="c-1" decimals="-3" id="f-427" unitRef="eur">-164780000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables contextRef="c-8" decimals="-3" id="f-428" unitRef="eur">-14231000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables contextRef="c-9" decimals="-3" id="f-429" unitRef="eur">4591000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables contextRef="c-1" decimals="-3" id="f-430" unitRef="eur">7042000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c-8" decimals="-3" id="f-431" unitRef="eur">31757000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c-9" decimals="-3" id="f-432" unitRef="eur">-3444000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c-1" decimals="-3" id="f-433" unitRef="eur">-6210000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <abvx:AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities contextRef="c-8" decimals="-3" id="f-434" unitRef="eur">3821000</abvx:AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities>
    <abvx:AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities contextRef="c-9" decimals="-3" id="f-435" unitRef="eur">-1487000</abvx:AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities>
    <abvx:AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities contextRef="c-1" decimals="-3" id="f-436" unitRef="eur">2110000</abvx:AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities>
    <abvx:AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities contextRef="c-8" decimals="-3" id="f-437" unitRef="eur">-81000</abvx:AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities>
    <abvx:AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities contextRef="c-9" decimals="-3" id="f-438" unitRef="eur">1763000</abvx:AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities>
    <abvx:AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities contextRef="c-1" decimals="-3" id="f-439" unitRef="eur">710000</abvx:AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities>
    <ifrs-full:IncreaseDecreaseInWorkingCapital contextRef="c-8" decimals="-3" id="f-440" unitRef="eur">-21265000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital contextRef="c-9" decimals="-3" id="f-441" unitRef="eur">-1423000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital contextRef="c-1" decimals="-3" id="f-442" unitRef="eur">-3651000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="c-8" decimals="-3" id="f-443" unitRef="eur">0</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="c-9" decimals="-3" id="f-444" unitRef="eur">0</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="c-1" decimals="-3" id="f-445" unitRef="eur">0</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c-8" decimals="-3" id="f-446" unitRef="eur">-97130000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c-9" decimals="-3" id="f-447" unitRef="eur">-154072000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-448" unitRef="eur">-161129000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c-8" decimals="-3" id="f-449" unitRef="eur">0</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c-9" decimals="-3" id="f-450" unitRef="eur">3000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c-1" decimals="-3" id="f-451" unitRef="eur">0</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-8" decimals="-3" id="f-452" unitRef="eur">265000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-9" decimals="-3" id="f-453" unitRef="eur">640000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-1" decimals="-3" id="f-454" unitRef="eur">142000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <abvx:PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations contextRef="c-8" decimals="-3" id="f-455" unitRef="eur">-1620000</abvx:PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations>
    <abvx:PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations contextRef="c-9" decimals="-3" id="f-456" unitRef="eur">-231000</abvx:PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations>
    <abvx:PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations contextRef="c-1" decimals="-3" id="f-457" unitRef="eur">71000</abvx:PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations>
    <abvx:CashPaymentsForDeposits contextRef="c-8" decimals="-3" id="f-458" unitRef="eur">9351000</abvx:CashPaymentsForDeposits>
    <abvx:CashPaymentsForDeposits contextRef="c-9" decimals="-3" id="f-459" unitRef="eur">591000</abvx:CashPaymentsForDeposits>
    <abvx:CashPaymentsForDeposits contextRef="c-1" decimals="-3" id="f-460" unitRef="eur">14152000</abvx:CashPaymentsForDeposits>
    <abvx:ProceedsFromReimbursementsOfDeposits contextRef="c-8" decimals="-3" id="f-461" unitRef="eur">741000</abvx:ProceedsFromReimbursementsOfDeposits>
    <abvx:ProceedsFromReimbursementsOfDeposits contextRef="c-9" decimals="-3" id="f-462" unitRef="eur">9050000</abvx:ProceedsFromReimbursementsOfDeposits>
    <abvx:ProceedsFromReimbursementsOfDeposits contextRef="c-1" decimals="-3" id="f-463" unitRef="eur">500000</abvx:ProceedsFromReimbursementsOfDeposits>
    <ifrs-full:InterestReceivedClassifiedAsInvestingActivities contextRef="c-8" decimals="-3" id="f-464" unitRef="eur">2400000</ifrs-full:InterestReceivedClassifiedAsInvestingActivities>
    <ifrs-full:InterestReceivedClassifiedAsInvestingActivities contextRef="c-9" decimals="-3" id="f-465" unitRef="eur">8178000</ifrs-full:InterestReceivedClassifiedAsInvestingActivities>
    <ifrs-full:InterestReceivedClassifiedAsInvestingActivities contextRef="c-1" decimals="-3" id="f-466" unitRef="eur">5530000</ifrs-full:InterestReceivedClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-8" decimals="-3" id="f-467" unitRef="eur">-8095000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-9" decimals="-3" id="f-468" unitRef="eur">15762000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-469" unitRef="eur">-8193000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-8" decimals="-3" id="f-470" unitRef="eur">353377000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-9" decimals="-3" id="f-471" unitRef="eur">0</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-1" decimals="-3" id="f-472" unitRef="eur">648124000</ifrs-full:ProceedsFromIssuingShares>
    <abvx:PaymentsForProceedsFromShareIssueRelatedCostsCredit contextRef="c-8" decimals="-3" id="f-473" unitRef="eur">28111000</abvx:PaymentsForProceedsFromShareIssueRelatedCostsCredit>
    <abvx:PaymentsForProceedsFromShareIssueRelatedCostsCredit contextRef="c-9" decimals="-3" id="f-474" unitRef="eur">-446000</abvx:PaymentsForProceedsFromShareIssueRelatedCostsCredit>
    <abvx:PaymentsForProceedsFromShareIssueRelatedCostsCredit contextRef="c-1" decimals="-3" id="f-475" unitRef="eur">40914000</abvx:PaymentsForProceedsFromShareIssueRelatedCostsCredit>
    <abvx:NetProceedsFromNonConvertibleLoansNotes contextRef="c-8" decimals="-3" id="f-476" unitRef="eur">0</abvx:NetProceedsFromNonConvertibleLoansNotes>
    <abvx:NetProceedsFromNonConvertibleLoansNotes contextRef="c-9" decimals="-3" id="f-477" unitRef="eur">47944000</abvx:NetProceedsFromNonConvertibleLoansNotes>
    <abvx:NetProceedsFromNonConvertibleLoansNotes contextRef="c-1" decimals="-3" id="f-478" unitRef="eur">0</abvx:NetProceedsFromNonConvertibleLoansNotes>
    <abvx:RepaymentsOfNonConvertibleLoansNotes contextRef="c-8" decimals="-3" id="f-479" unitRef="eur">11635000</abvx:RepaymentsOfNonConvertibleLoansNotes>
    <abvx:RepaymentsOfNonConvertibleLoansNotes contextRef="c-9" decimals="-3" id="f-480" unitRef="eur">0</abvx:RepaymentsOfNonConvertibleLoansNotes>
    <abvx:RepaymentsOfNonConvertibleLoansNotes contextRef="c-1" decimals="-3" id="f-481" unitRef="eur">53920000</abvx:RepaymentsOfNonConvertibleLoansNotes>
    <abvx:NetProceedsFromConvertibleLoanNotes contextRef="c-8" decimals="-3" id="f-482" unitRef="eur">55841000</abvx:NetProceedsFromConvertibleLoanNotes>
    <abvx:NetProceedsFromConvertibleLoanNotes contextRef="c-9" decimals="-3" id="f-483" unitRef="eur">0</abvx:NetProceedsFromConvertibleLoanNotes>
    <abvx:NetProceedsFromConvertibleLoanNotes contextRef="c-1" decimals="-3" id="f-484" unitRef="eur">0</abvx:NetProceedsFromConvertibleLoanNotes>
    <abvx:RepaymentsOfConvertibleLoansNotes contextRef="c-8" decimals="-3" id="f-485" unitRef="eur">27188000</abvx:RepaymentsOfConvertibleLoansNotes>
    <abvx:RepaymentsOfConvertibleLoansNotes contextRef="c-9" decimals="-3" id="f-486" unitRef="eur">8750000</abvx:RepaymentsOfConvertibleLoansNotes>
    <abvx:RepaymentsOfConvertibleLoansNotes contextRef="c-1" decimals="-3" id="f-487" unitRef="eur">2188000</abvx:RepaymentsOfConvertibleLoansNotes>
    <abvx:RepaymentsOfPGE contextRef="c-8" decimals="-3" id="f-488" unitRef="eur">1250000</abvx:RepaymentsOfPGE>
    <abvx:RepaymentsOfPGE contextRef="c-9" decimals="-3" id="f-489" unitRef="eur">1250000</abvx:RepaymentsOfPGE>
    <abvx:RepaymentsOfPGE contextRef="c-1" decimals="-3" id="f-490" unitRef="eur">2514000</abvx:RepaymentsOfPGE>
    <abvx:RepaymentsOfConditionalAdvances contextRef="c-8" decimals="-3" id="f-491" unitRef="eur">110000</abvx:RepaymentsOfConditionalAdvances>
    <abvx:RepaymentsOfConditionalAdvances contextRef="c-9" decimals="-3" id="f-492" unitRef="eur">2708000</abvx:RepaymentsOfConditionalAdvances>
    <abvx:RepaymentsOfConditionalAdvances contextRef="c-1" decimals="-3" id="f-493" unitRef="eur">0</abvx:RepaymentsOfConditionalAdvances>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-8" decimals="-3" id="f-494" unitRef="eur">529000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-9" decimals="-3" id="f-495" unitRef="eur">458000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-1" decimals="-3" id="f-496" unitRef="eur">911000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromSaleOrIssueOfTreasuryShares contextRef="c-8" decimals="-3" id="f-497" unitRef="eur">10000</ifrs-full:ProceedsFromSaleOrIssueOfTreasuryShares>
    <ifrs-full:ProceedsFromSaleOrIssueOfTreasuryShares contextRef="c-9" decimals="-3" id="f-498" unitRef="eur">434000</ifrs-full:ProceedsFromSaleOrIssueOfTreasuryShares>
    <ifrs-full:ProceedsFromSaleOrIssueOfTreasuryShares contextRef="c-1" decimals="-3" id="f-499" unitRef="eur">0</ifrs-full:ProceedsFromSaleOrIssueOfTreasuryShares>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="c-8" decimals="-3" id="f-500" unitRef="eur">5279000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="c-9" decimals="-3" id="f-501" unitRef="eur">7696000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="c-1" decimals="-3" id="f-502" unitRef="eur">6490000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromExerciseOfWarrants contextRef="c-8" decimals="-3" id="f-503" unitRef="eur">0</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:ProceedsFromExerciseOfWarrants contextRef="c-9" decimals="-3" id="f-504" unitRef="eur">0</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:ProceedsFromExerciseOfWarrants contextRef="c-1" decimals="-3" id="f-505" unitRef="eur">5820000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="c-8" decimals="-3" id="f-506" unitRef="eur">163000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="c-9" decimals="-3" id="f-507" unitRef="eur">245000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="c-1" decimals="-3" id="f-508" unitRef="eur">300000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-8" decimals="-3" id="f-509" unitRef="eur">335290000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-9" decimals="-3" id="f-510" unitRef="eur">28207000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-511" unitRef="eur">547307000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-8" decimals="-3" id="f-512" unitRef="eur">-5072000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-9" decimals="-3" id="f-513" unitRef="eur">2382000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-1" decimals="-3" id="f-514" unitRef="eur">-10251000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <abvx:RevaluationOfCashEquivalentsMeasuredAtFairValue contextRef="c-8" decimals="-3" id="f-515" unitRef="eur">0</abvx:RevaluationOfCashEquivalentsMeasuredAtFairValue>
    <abvx:RevaluationOfCashEquivalentsMeasuredAtFairValue contextRef="c-9" decimals="-3" id="f-516" unitRef="eur">0</abvx:RevaluationOfCashEquivalentsMeasuredAtFairValue>
    <abvx:RevaluationOfCashEquivalentsMeasuredAtFairValue contextRef="c-1" decimals="-3" id="f-517" unitRef="eur">4730000</abvx:RevaluationOfCashEquivalentsMeasuredAtFairValue>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c-8" decimals="-3" id="f-518" unitRef="eur">224992000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c-9" decimals="-3" id="f-519" unitRef="eur">-107720000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c-1" decimals="-3" id="f-520" unitRef="eur">372464000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-10" decimals="-3" id="f-521" unitRef="eur">26950000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-6" decimals="-3" id="f-522" unitRef="eur">251942000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-7" decimals="-3" id="f-523" unitRef="eur">144221000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-6" decimals="-3" id="f-524" unitRef="eur">251942000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-7" decimals="-3" id="f-525" unitRef="eur">144221000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-5" decimals="-3" id="f-526" unitRef="eur">516685000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c-8" decimals="-3" id="f-527" unitRef="eur">224992000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c-9" decimals="-3" id="f-528" unitRef="eur">-107720000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c-1" decimals="-3" id="f-529" unitRef="eur">372464000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory contextRef="c-1" id="f-530">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:68.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Note 1.1. Information on the Group and its business &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:142.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;ABIVAX SA (the &#x201c;Company&#x201d;) is a soci&#xe9;t&#xe9; anonyme incorporated under the laws of France on December 4, 2013. Its registered office &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:152.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;is located at 7-11 Boulevard Haussmann&#x2014;75009 Paris, France. The Company is developing therapeutics that harness the body&#x2019;s &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:162.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:184.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;These consolidated financial statements as of and for the year ended December 31, 2025 comprise the Company and ABIVAX LLC &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:194.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;(the &#x201c;Subsidiary&#x201d;), &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.97pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:126.17pt;position:var(--position);text-decoration:none;white-space:pre"&gt; United States subsidiary of ABIVAX SA, created on March 20, 2023 under the laws of the State of Delaware &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:204.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;(together referred to as the &#x201c;Group&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:226.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group has incurred losses since its inception and had shareholders&#x2019; equity of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:363.17pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;455,205&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:400.67pt;position:var(--position);text-decoration:none;white-space:pre"&gt; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:403.17pt;position:var(--position);text-decoration:none;white-space:pre"&gt;thousand as of December 31, 2025. The &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:236.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Group anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its drug candidates &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:246.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;which are currently under development. &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:198.03pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Substantial additional financing will be needed by the Group to fund its operations and to &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:256.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;commercially develop its drug candidates. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:278.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group's future operations are highly dependent on a combination of factors, including: (i)&#160;the success of its research and &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:288.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;development activities; (ii)&#160;regulatory approval and market acceptance of its proposed future products; (iii)&#160;the timely and successful &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:298.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;completion of additional financing and (iv)&#160;the development of competitive therapies by other biotechnology and pharmaceutical &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:308.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;companies. As a result, the Group is, and expects to continue to be, in the short to mid-term, financed through the issuance of new &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:318.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;equity or debt instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:340.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group is focusing its efforts on the following areas: &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:12pt;position:var(--position);top:362.56pt;width:612pt"&gt;&lt;span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Completion of the Phase 3 clinical trial program (ABTECT) for obefazimod in moderately to severely active ulcerative colitis &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:376pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;(&#x201c;UC&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:12pt;position:var(--position);top:389.44pt;width:612pt"&gt;&lt;span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Continuation of the Phase 2b clinical trial (ENHANCE-CD) of obefazimod in Crohn&#x2019;s disease (&#x201c;CD&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:12pt;position:var(--position);top:402.88pt;width:612pt"&gt;&lt;span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Evaluating combination therapy candidates with obefazimod in UC.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:12pt;position:var(--position);top:416.32pt;width:612pt"&gt;&lt;span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Selecting a follow-on candidate for obefazimod. &lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Note 1.2. Date of authorization of issuance &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:475.76pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The consolidated financial statements and related notes (the &#x201c;financial statements&#x201d;) have been prepared under the responsibility of &lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;management of the Group and were approved and authorized for issuance by the Group&#x2019;s board of directors on &lt;/span&gt;March 19, 2026.</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
    <ifrs-full:Equity contextRef="c-5" decimals="-3" id="f-531" unitRef="eur">455205000</ifrs-full:Equity>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory contextRef="c-1" id="f-532">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:68.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Basis of preparation &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:535.76pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Except for share data and per share amounts, the financial statements are presented in thousands of euros. Amounts are rounded up or &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:546.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;down the nearest whole number for the calculation of certain financial data and other information contained in these accounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:558.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Accordingly, the total amounts presented in certain tables may not be the exact sum of the preceding figures. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:569.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:581.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Statement of compliance &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:603.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The consolidated financial statements of the Group as of and for the years ended December 31, 2023, 2024 and 2025 have been &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:614.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;prepared in accordance with both International Financial Reporting Standards (&#x201c;IFRS&#x201d;) as issued by the International Accounting &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:625.76pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Standard Board (&#x201c;IASB&#x201d;) and IFRS as adopted by the European Union (&#x201c;EU&#x201d;) regulation n&#xb0;1606/2002 of July 19, 2002. The term &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:636.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x201c;IFRS&#x201d; refers collectively to International Accounting Standards (&#x201c;IAS&#x201d;) and IFRS as well as the interpretations issued by the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:648.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Standing Interpretations Committee (&#x201c;SIC&#x201d;) and the International Financial Reporting Interpretations Standards Committee (&#x201c;IFRS &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:659.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;IC&#x201d;), whose application is mandatory for the year ended December 31, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Preparation of the financial statements &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:92.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The consolidated financial statements of the Group were prepared on a historical cost basis, with the exception of certain asset and &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:103.76pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;liability categories and in accordance with the provisions set out in IFRS such as employee benefits measured using the projected unit &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:114.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;credit method, the Heights notes (classified under "Convertible loan notes") measured at fair value and derivative financial instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;measured at fair value. &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.47pt;position:var(--position);text-decoration:none;white-space:pre"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:155.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Going concern &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:177.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group has incurre&lt;/span&gt;&lt;span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:126.19pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&lt;span style="background-color:inherit"&gt;d substantial operating losses since inception and expects to continue to incur significant operating losses for the &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:189.36pt;width:612pt"&gt;&lt;span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&lt;span style="background-color:inherit"&gt;foreseeab&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:74.27000000000001pt;position:var(--position);text-decoration:none;white-space:pre"&gt;le future and may never become profitable. For the year ended December 31, 2025, the Group had a net loss of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:519.9100000000001pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;336,102 &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:201.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;thousand&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72.09pt;position:var(--position);text-decoration:none;white-space:pre"&gt;.&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:74.59pt;position:var(--position);text-decoration:none;white-space:pre"&gt; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:77.09pt;position:var(--position);text-decoration:none;white-space:pre"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:225.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Since inception, the Group has financed its operations through the issuance of ordinary shares with gross aggregate proceeds of &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:237.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;1,194.7 million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:102.35pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, of which &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:145.1pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;130&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:196.45pt;position:var(--position);text-decoration:none;white-space:pre"&gt; of gross proceeds were from offerings of its ordinary shares on Euronext Paris in February &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:249.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;2023, &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:61pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;223.3&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:119.85pt;position:var(--position);text-decoration:none;white-space:pre"&gt; of gross proceeds were from its offering of ordinary shares in the form of American Depository Shares ("ADS") &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:261.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;on the Nasdaq Global Market as well as ordinary shares in Europe (including France) and countries outside of the United States in a &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:273.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;private placement in October 2023, and &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:196.64pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;637.5 million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:255.49pt;position:var(--position);text-decoration:none;white-space:pre"&gt; of gross proceeds were from the offering of the Group's ordinary shares in the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:285.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;form of ADS on the Nasdaq Global Market in July 2025 ("the Offering"), &lt;/span&gt;&lt;span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:332.83pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&lt;span style="background-color:inherit"&gt;ba&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:342.26pt;position:var(--position);text-decoration:none;white-space:pre"&gt;nk borrowings and structured loans&lt;/span&gt;&lt;span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:483.27pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&lt;span style="background-color:inherit"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.77pt;position:var(--position);text-decoration:none;white-space:pre"&gt;for &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:499.93pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;175.0&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:558.78pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:297.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;reimbursements of Research Tax Credits (Cr&#xe9;dit d&#x2019;Imp&#xf4;t Recherche (&#x201c;CIR&#x201d;)) in an aggregate amo&lt;/span&gt;&lt;span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:430.47pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&lt;span style="background-color:inherit"&gt;unt of &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:456.57pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;41.2 million&lt;/span&gt;&lt;span style="background-color:#ffff00;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:510.42pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&lt;span style="background-color:inherit"&gt;,&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:512.9200000000001pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&lt;span style="background-color:inherit"&gt; subsidies &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:309.36pt;width:612pt"&gt;&lt;span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&lt;span style="background-color:inherit"&gt;received from Banque Publique d&#x2019;Investissement (&#x201c;Bpifrance&#x201d;) (inclu&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:316.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;ding &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:336.47pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;17.1&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:390.32pt;position:var(--position);text-decoration:none;white-space:pre"&gt; of subsidies and &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:459.72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;1.8&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:508.57pt;position:var(--position);text-decoration:none;white-space:pre"&gt; of conditional &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:321.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;advances) and royalty certificates in an amount of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:237.95pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;2.9&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:286.8pt;position:var(--position);text-decoration:none;white-space:pre"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:345.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Based on the Group&#x2019;s existing cash and cash equivalents &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:264.93pt;position:var(--position);text-decoration:none;white-space:pre"&gt;and other short-&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:328.21pt;position:var(--position);text-decoration:none;white-space:pre"&gt;term investments&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:396.73pt;position:var(--position);text-decoration:none;white-space:pre"&gt; of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:410.06pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;530.4 million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:468.91pt;position:var(--position);text-decoration:none;white-space:pre"&gt; a&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:475.84pt;position:var(--position);text-decoration:none;white-space:pre"&gt;s of December 31, 2025, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:356.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the Group expects, as of the date of issuance of these financial statements, to be able to fund its forecasted cash flow requirements into &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:368.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the fourth quarter of 20&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.25pt;position:var(--position);text-decoration:none;white-space:pre"&gt;27. &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:144.25pt;position:var(--position);text-decoration:none;white-space:pre"&gt;This take&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:181.14pt;position:var(--position);text-decoration:none;white-space:pre"&gt;s into account management's assumptions&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:347.76pt;position:var(--position);text-decoration:none;white-space:pre"&gt; of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:361.09pt;position:var(--position);text-decoration:none;white-space:pre"&gt;continued&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:400.49pt;position:var(--position);text-decoration:none;white-space:pre"&gt; R&amp;amp;D expenditure related to the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:379.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;continuation of the Phase 3 clinical trials of obefazimod in UC, progression of the Phase 2b clinical trials for CD and the initial stages &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:391.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;of the scale up of the commercial organization as the Group prepares for a potential launch of obefazimod in UC.&lt;/span&gt;&lt;span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:488.78pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&lt;span style="background-color:inherit"&gt;&#160; &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:414.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Based on the above, these financial statements have been prepared on a going concern basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:444.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Impact of the Ukraine/Russia Hostilities on the Group &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:466.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;In February 2022, Russia invaded Ukraine. The conflict has already had major implications for the global economy and the rate of &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:478.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;inflation, particularly in relation to the supply of energy, raw materials and food products. It has also caused intense volatility on the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:489.26pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;financial markets, something that is still ongoing at the reporting date and has pushed down stock market prices around the world. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:511.66pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Given these developments, the Group has decided not to include Russia and Belarus in its global Phase 3 program for obefazimod in &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:522.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;UC. However, the global scale of this conflict cannot be predicted at this stage. The Group, therefore, cannot rule out an adverse &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:534.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;impact of this conflict on its business, including in terms of access to raw materials, logistics, the performance of clinical studies and &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:545.26pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;in relation to any future financing the Group may seek. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:11pt;position:var(--position);top:567.66pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The long-term safety and efficacy extension of the&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:237.68pt;position:var(--position);text-decoration:none;white-space:pre"&gt; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:240.16pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Phase 2b maintenance trial of obefazimod in moderately to severely active UC is &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:579.98pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the Group&#x2019;s only clinical trial with patients currently enrolled in Ukraine.&#160; The Phase 2b 12-month assessment was carried out in all &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:591.18pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the Ukrainian patients before the war broke out and these patients are therefore included in the one-year maintenance results that were &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:602.38pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;reported on April 6, 2022. Ukrainian patients who completed the two-year Phase 2b maintenance trial have been transitioned to the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:613.58pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;long-term safety and efficacy trial that is still on-going. The Group also has a few Ukrainian sites active in the western part of Ukraine &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:624.78pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;in the ABTECT Phase 3 clinical trials.&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:189.95pt;position:var(--position);text-decoration:none;white-space:pre"&gt; None of these sites are located in the Crimea Region of Ukraine, the so-called Donetsk &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:635.98pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;People&#x2019;s Republic, or the so-called Luhansk People&#x2019;s Republic. We continue to monitor developments in the region, but any &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:647.18pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;instability as a result of the war may have material adverse impacts on these clinical sites, which could negatively impact our Phase 3 &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:658.38pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;clinical trials.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:680.78pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Together with its contract research organizations ("&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:240.91pt;position:var(--position);text-decoration:none;white-space:pre"&gt;CROs")&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:272.75pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, the Group is making considerable efforts to ensure the follow-up of &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:691.98pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;patients who are unable to come to the study centers. Monitoring takes place through a remote monitoring system that was established &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:703.18pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;and used successfully during the COVID-19 pandemic.&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:257.19pt;position:var(--position);text-decoration:none;white-space:pre"&gt; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:259.69pt;position:var(--position);text-decoration:none;white-space:pre"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;N&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:42.66pt;position:var(--position);text-decoration:none;white-space:pre"&gt;ew, revised or amended Standards and Interpreta&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:241.12pt;position:var(--position);text-decoration:none;white-space:pre"&gt;tions &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:92.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group applied the amendment to IAS 21 The Effects of Changes in Foreign Exchange Rates &#x2013; Lack of Exchangeability that is &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:103.76pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;effective as of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:95.07pt;position:var(--position);text-decoration:none;white-space:pre"&gt;December&#160;31, 2025&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:173.61pt;position:var(--position);text-decoration:none;white-space:pre"&gt;.&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:176.11pt;position:var(--position);text-decoration:none;white-space:pre"&gt; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:178.61pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group assessed the impacts resulting from the application of this issued accounting &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:114.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;pronouncement and concluded that they are not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:144.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;New standards, amendments and interpretations issued by IASB but not yet mandatory for financial years starting from January 1, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:154.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;2025 &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:170.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group did not elect for early application of the following new standards, amendments and interpretations, which were issued but &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:180.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;not mandatory as of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:118.15pt;position:var(--position);text-decoration:none;white-space:pre"&gt;December&#160;31, 2025&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:196.69pt;position:var(--position);text-decoration:none;white-space:pre"&gt;: &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:12pt;position:var(--position);top:201.66pt;width:612pt"&gt;&lt;span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Amendments to IFRS 9 Financial Instruments and IFRS 7 Financial Instruments: Disclosures &#x2013; Amendments to the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:215.1pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Classification and Measurement of Financial Instruments, whose application is for annual reporting periods beginning on &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:228.54pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre"&gt;or after January 1, 2026, as approved by the EU on May 27, 2025; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:241.98pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Amendments to IFRS 9 Financial Instruments and IFRS 7 Financial Instruments: Disclosures &#x2013; Contracts Referencing &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:253.18pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Nature-dependent Electricity, whose application is for annual reporting periods beginning on or after January 1, 2026, as &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:264.38pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre"&gt;approved by the EU on June 30, 2025; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:275.58pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre"&gt;IFRS 18 Presentation and Disclosure in Financial Statements, whose application is for annual reporting periods &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:286.78pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre"&gt;beginning on or after January 1, 2027, as approved by the EU on February 16, 2026; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:297.98pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre"&gt;IFRS 19 Subsidiaries without Public Accountability: Disclosures, whose application is for annual reporting periods &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:309.18pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre"&gt;beginning on or after January 1, 2027 (not yet approved by the UE), and&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:320.38pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre;width:3.5pt"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre;width:485.99pt"&gt;Annual Improvements Volume 11, whose application is for annual reporting periods beginning on or after January 1,&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.99pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:331.38pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre;width:25pt"&gt;2026, &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:115pt;position:var(--position);text-decoration:none;white-space:pre;width:157.69pt"&gt;as approved by the EU on July 9, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:355.82pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;These texts have not been early adopted. The application of the standards and interpretations issued respectively by the IASB and the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:367.02pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;IFRS IC that are not yet effective as of December 31, 2025 is not expected to have a material impact on the Group&#x2019;s consolidated &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:378.22pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;financial statements. IFRS 18, issued in April 2024 and effective from January 1, 2027, will modify the presentation of the &lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Consolidated statements of income (loss) and the Consolidated statements of cash flows&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:388.1pt;position:var(--position);text-decoration:none;white-space:pre"&gt;.&lt;/span&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <ifrs-full:StatementOfIFRSCompliance contextRef="c-1" id="f-533">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Statement of compliance &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:603.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The consolidated financial statements of the Group as of and for the years ended December 31, 2023, 2024 and 2025 have been &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:614.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;prepared in accordance with both International Financial Reporting Standards (&#x201c;IFRS&#x201d;) as issued by the International Accounting &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:625.76pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Standard Board (&#x201c;IASB&#x201d;) and IFRS as adopted by the European Union (&#x201c;EU&#x201d;) regulation n&#xb0;1606/2002 of July 19, 2002. The term &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:636.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x201c;IFRS&#x201d; refers collectively to International Accounting Standards (&#x201c;IAS&#x201d;) and IFRS as well as the interpretations issued by the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:648.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Standing Interpretations Committee (&#x201c;SIC&#x201d;) and the International Financial Reporting Interpretations Standards Committee (&#x201c;IFRS &lt;/span&gt;&lt;/div&gt;IC&#x201d;), whose application is mandatory for the year ended December 31, 2025.</ifrs-full:StatementOfIFRSCompliance>
    <abvx:DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock contextRef="c-1" id="f-534">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Going concern &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:177.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group has incurre&lt;/span&gt;&lt;span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:126.19pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&lt;span style="background-color:inherit"&gt;d substantial operating losses since inception and expects to continue to incur significant operating losses for the &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:189.36pt;width:612pt"&gt;&lt;span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&lt;span style="background-color:inherit"&gt;foreseeab&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:74.27000000000001pt;position:var(--position);text-decoration:none;white-space:pre"&gt;le future and may never become profitable. For the year ended December 31, 2025, the Group had a net loss of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:519.9100000000001pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;336,102 &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:201.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;thousand&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72.09pt;position:var(--position);text-decoration:none;white-space:pre"&gt;.&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:74.59pt;position:var(--position);text-decoration:none;white-space:pre"&gt; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:77.09pt;position:var(--position);text-decoration:none;white-space:pre"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:225.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Since inception, the Group has financed its operations through the issuance of ordinary shares with gross aggregate proceeds of &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:237.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;1,194.7 million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:102.35pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, of which &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:145.1pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;130&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:196.45pt;position:var(--position);text-decoration:none;white-space:pre"&gt; of gross proceeds were from offerings of its ordinary shares on Euronext Paris in February &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:249.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;2023, &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:61pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;223.3&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:119.85pt;position:var(--position);text-decoration:none;white-space:pre"&gt; of gross proceeds were from its offering of ordinary shares in the form of American Depository Shares ("ADS") &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:261.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;on the Nasdaq Global Market as well as ordinary shares in Europe (including France) and countries outside of the United States in a &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:273.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;private placement in October 2023, and &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:196.64pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;637.5 million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:255.49pt;position:var(--position);text-decoration:none;white-space:pre"&gt; of gross proceeds were from the offering of the Group's ordinary shares in the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:285.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;form of ADS on the Nasdaq Global Market in July 2025 ("the Offering"), &lt;/span&gt;&lt;span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:332.83pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&lt;span style="background-color:inherit"&gt;ba&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:342.26pt;position:var(--position);text-decoration:none;white-space:pre"&gt;nk borrowings and structured loans&lt;/span&gt;&lt;span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:483.27pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&lt;span style="background-color:inherit"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.77pt;position:var(--position);text-decoration:none;white-space:pre"&gt;for &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:499.93pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;175.0&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:558.78pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:297.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;reimbursements of Research Tax Credits (Cr&#xe9;dit d&#x2019;Imp&#xf4;t Recherche (&#x201c;CIR&#x201d;)) in an aggregate amo&lt;/span&gt;&lt;span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:430.47pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&lt;span style="background-color:inherit"&gt;unt of &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:456.57pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;41.2 million&lt;/span&gt;&lt;span style="background-color:#ffff00;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:510.42pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&lt;span style="background-color:inherit"&gt;,&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:512.9200000000001pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&lt;span style="background-color:inherit"&gt; subsidies &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:309.36pt;width:612pt"&gt;&lt;span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&lt;span style="background-color:inherit"&gt;received from Banque Publique d&#x2019;Investissement (&#x201c;Bpifrance&#x201d;) (inclu&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:316.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;ding &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:336.47pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;17.1&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:390.32pt;position:var(--position);text-decoration:none;white-space:pre"&gt; of subsidies and &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:459.72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;1.8&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:508.57pt;position:var(--position);text-decoration:none;white-space:pre"&gt; of conditional &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:321.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;advances) and royalty certificates in an amount of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:237.95pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;2.9&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:286.8pt;position:var(--position);text-decoration:none;white-space:pre"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:345.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Based on the Group&#x2019;s existing cash and cash equivalents &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:264.93pt;position:var(--position);text-decoration:none;white-space:pre"&gt;and other short-&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:328.21pt;position:var(--position);text-decoration:none;white-space:pre"&gt;term investments&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:396.73pt;position:var(--position);text-decoration:none;white-space:pre"&gt; of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:410.06pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;530.4 million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:468.91pt;position:var(--position);text-decoration:none;white-space:pre"&gt; a&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:475.84pt;position:var(--position);text-decoration:none;white-space:pre"&gt;s of December 31, 2025, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:356.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the Group expects, as of the date of issuance of these financial statements, to be able to fund its forecasted cash flow requirements into &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:368.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the fourth quarter of 20&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.25pt;position:var(--position);text-decoration:none;white-space:pre"&gt;27. &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:144.25pt;position:var(--position);text-decoration:none;white-space:pre"&gt;This take&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:181.14pt;position:var(--position);text-decoration:none;white-space:pre"&gt;s into account management's assumptions&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:347.76pt;position:var(--position);text-decoration:none;white-space:pre"&gt; of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:361.09pt;position:var(--position);text-decoration:none;white-space:pre"&gt;continued&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:400.49pt;position:var(--position);text-decoration:none;white-space:pre"&gt; R&amp;amp;D expenditure related to the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:379.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;continuation of the Phase 3 clinical trials of obefazimod in UC, progression of the Phase 2b clinical trials for CD and the initial stages &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:391.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;of the scale up of the commercial organization as the Group prepares for a potential launch of obefazimod in UC.&lt;/span&gt;&lt;span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:488.78pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&lt;span style="background-color:inherit"&gt;&#160; &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:414.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Based on the above, these financial statements have been prepared on a going concern basis.&lt;/span&gt;&lt;/div&gt;</abvx:DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-3" id="f-535" unitRef="eur">-336102000</ifrs-full:ProfitLoss>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-63" decimals="-5" id="f-536" unitRef="eur">1194700000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-64" decimals="-6" id="f-537" unitRef="eur">130000000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-65" decimals="-5" id="f-538" unitRef="eur">223300000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-66" decimals="-5" id="f-539" unitRef="eur">637500000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-63" decimals="-5" id="f-540" unitRef="eur">175000000.0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <abvx:ProceedsFromResearchTaxCredit contextRef="c-63" decimals="-5" id="f-541" unitRef="eur">41200000</abvx:ProceedsFromResearchTaxCredit>
    <ifrs-full:ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities contextRef="c-67" decimals="-5" id="f-542" unitRef="eur">17100000</ifrs-full:ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities>
    <abvx:ProceedsFromConditionalAdvances contextRef="c-67" decimals="-5" id="f-543" unitRef="eur">1800000</abvx:ProceedsFromConditionalAdvances>
    <abvx:NetProceedsFromSaleOfRoyaltyCertificates contextRef="c-63" decimals="-5" id="f-544" unitRef="eur">2900000</abvx:NetProceedsFromSaleOfRoyaltyCertificates>
    <abvx:CashAndCashEquivalentsAndOtherShortTermInvestments contextRef="c-5" decimals="-5" id="f-545" unitRef="eur">530400000</abvx:CashAndCashEquivalentsAndOtherShortTermInvestments>
    <abvx:DisclosureOfImpactOfTheUkraineRussiaHostilitiesOnTheGroupPolicyTextBlock contextRef="c-1" id="f-546">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Impact of the Ukraine/Russia Hostilities on the Group &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:466.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;In February 2022, Russia invaded Ukraine. The conflict has already had major implications for the global economy and the rate of &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:478.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;inflation, particularly in relation to the supply of energy, raw materials and food products. It has also caused intense volatility on the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:489.26pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;financial markets, something that is still ongoing at the reporting date and has pushed down stock market prices around the world. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:511.66pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Given these developments, the Group has decided not to include Russia and Belarus in its global Phase 3 program for obefazimod in &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:522.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;UC. However, the global scale of this conflict cannot be predicted at this stage. The Group, therefore, cannot rule out an adverse &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:534.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;impact of this conflict on its business, including in terms of access to raw materials, logistics, the performance of clinical studies and &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:545.26pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;in relation to any future financing the Group may seek. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:11pt;position:var(--position);top:567.66pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The long-term safety and efficacy extension of the&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Calibri', sans-serif;font-size:11pt;font-style:normal;font-weight:normal;left:237.68pt;position:var(--position);text-decoration:none;white-space:pre"&gt; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:240.16pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Phase 2b maintenance trial of obefazimod in moderately to severely active UC is &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:579.98pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the Group&#x2019;s only clinical trial with patients currently enrolled in Ukraine.&#160; The Phase 2b 12-month assessment was carried out in all &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:591.18pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the Ukrainian patients before the war broke out and these patients are therefore included in the one-year maintenance results that were &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:602.38pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;reported on April 6, 2022. Ukrainian patients who completed the two-year Phase 2b maintenance trial have been transitioned to the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:613.58pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;long-term safety and efficacy trial that is still on-going. The Group also has a few Ukrainian sites active in the western part of Ukraine &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:624.78pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;in the ABTECT Phase 3 clinical trials.&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:189.95pt;position:var(--position);text-decoration:none;white-space:pre"&gt; None of these sites are located in the Crimea Region of Ukraine, the so-called Donetsk &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:635.98pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;People&#x2019;s Republic, or the so-called Luhansk People&#x2019;s Republic. We continue to monitor developments in the region, but any &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:647.18pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;instability as a result of the war may have material adverse impacts on these clinical sites, which could negatively impact our Phase 3 &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:658.38pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;clinical trials.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:680.78pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Together with its contract research organizations ("&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:240.91pt;position:var(--position);text-decoration:none;white-space:pre"&gt;CROs")&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:272.75pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, the Group is making considerable efforts to ensure the follow-up of &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:691.98pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;patients who are unable to come to the study centers. Monitoring takes place through a remote monitoring system that was established &lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;and used successfully during the COVID-19 pandemic.&lt;/span&gt;</abvx:DisclosureOfImpactOfTheUkraineRussiaHostilitiesOnTheGroupPolicyTextBlock>
    <abvx:DisclosureOfAccountingPolicyForNewRevisedOrAmendedStandardsAndInterpretationsPolicyTextBlock contextRef="c-1" id="f-547">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;N&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:42.66pt;position:var(--position);text-decoration:none;white-space:pre"&gt;ew, revised or amended Standards and Interpreta&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:241.12pt;position:var(--position);text-decoration:none;white-space:pre"&gt;tions &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:92.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group applied the amendment to IAS 21 The Effects of Changes in Foreign Exchange Rates &#x2013; Lack of Exchangeability that is &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:103.76pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;effective as of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:95.07pt;position:var(--position);text-decoration:none;white-space:pre"&gt;December&#160;31, 2025&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:173.61pt;position:var(--position);text-decoration:none;white-space:pre"&gt;.&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:176.11pt;position:var(--position);text-decoration:none;white-space:pre"&gt; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:178.61pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group assessed the impacts resulting from the application of this issued accounting &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:114.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;pronouncement and concluded that they are not material.&lt;/span&gt;&lt;/div&gt;</abvx:DisclosureOfAccountingPolicyForNewRevisedOrAmendedStandardsAndInterpretationsPolicyTextBlock>
    <abvx:DisclosureOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedByIASBButNotYetMandatoryPolicyTextBlock contextRef="c-1" id="f-548">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;New standards, amendments and interpretations issued by IASB but not yet mandatory for financial years starting from January 1, &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:154.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;2025 &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:170.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group did not elect for early application of the following new standards, amendments and interpretations, which were issued but &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:180.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;not mandatory as of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:118.15pt;position:var(--position);text-decoration:none;white-space:pre"&gt;December&#160;31, 2025&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:196.69pt;position:var(--position);text-decoration:none;white-space:pre"&gt;: &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:12pt;position:var(--position);top:201.66pt;width:612pt"&gt;&lt;span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Amendments to IFRS 9 Financial Instruments and IFRS 7 Financial Instruments: Disclosures &#x2013; Amendments to the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:215.1pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Classification and Measurement of Financial Instruments, whose application is for annual reporting periods beginning on &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:228.54pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre"&gt;or after January 1, 2026, as approved by the EU on May 27, 2025; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:241.98pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Amendments to IFRS 9 Financial Instruments and IFRS 7 Financial Instruments: Disclosures &#x2013; Contracts Referencing &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:253.18pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Nature-dependent Electricity, whose application is for annual reporting periods beginning on or after January 1, 2026, as &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:264.38pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre"&gt;approved by the EU on June 30, 2025; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:275.58pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre"&gt;IFRS 18 Presentation and Disclosure in Financial Statements, whose application is for annual reporting periods &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:286.78pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre"&gt;beginning on or after January 1, 2027, as approved by the EU on February 16, 2026; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:297.98pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre"&gt;IFRS 19 Subsidiaries without Public Accountability: Disclosures, whose application is for annual reporting periods &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:309.18pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre"&gt;beginning on or after January 1, 2027 (not yet approved by the UE), and&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:320.38pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre;width:3.5pt"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre;width:485.99pt"&gt;Annual Improvements Volume 11, whose application is for annual reporting periods beginning on or after January 1,&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.99pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:331.38pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:var(--position);text-decoration:none;white-space:pre;width:25pt"&gt;2026, &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:115pt;position:var(--position);text-decoration:none;white-space:pre;width:157.69pt"&gt;as approved by the EU on July 9, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:355.82pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;These texts have not been early adopted. The application of the standards and interpretations issued respectively by the IASB and the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:367.02pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;IFRS IC that are not yet effective as of December 31, 2025 is not expected to have a material impact on the Group&#x2019;s consolidated &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:378.22pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;financial statements. IFRS 18, issued in April 2024 and effective from January 1, 2027, will modify the presentation of the &lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Consolidated statements of income (loss) and the Consolidated statements of cash flows&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:388.1pt;position:var(--position);text-decoration:none;white-space:pre"&gt;.&lt;/span&gt;</abvx:DisclosureOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedByIASBButNotYetMandatoryPolicyTextBlock>
    <abvx:DisclosureOfSignificantEventsForThePeriodReportedAndEventsAfterReportingPeriodTextBlock contextRef="c-1" id="f-549">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:140.48pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Significant events for the years ended&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:300.07pt;position:var(--position);text-decoration:none;white-space:pre"&gt; December 31, 2023, 2024 and 2025 &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:451.95pt;position:var(--position);text-decoration:none;white-space:pre"&gt;and subsequent events &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Note 3.1. For the year ended December 31, 2023 &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:480.62pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Company announces successful oversubscribed &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:246.1pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;130.0&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:304.4pt;position:var(--position);text-decoration:none;white-space:pre"&gt; cross-over financing at market price with top-tier U.S. and &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:492.62pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;European Biotech investors &#x2013; February 2023 &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:510.62pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;On February&#160;22, 2023, the Company announced the successful pricing of an oversubscribed &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:405.97pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;130.0&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:464.82pt;position:var(--position);text-decoration:none;white-space:pre"&gt; financing with high-&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:520.62pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;quality U.S. and European biotech specialist investors, led by TCGX, with participation from existing investors Invus, Deep Track &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:530.62pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Capital, Sofinnova Partners, and Venrock Healthcare Capital Partners, as well as from new investors Great Point Partners, LLC, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:540.62pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Deerfield Management Company, Commodore Capital, Samsara BioCapital, Boxer Capital and others, by way of a reserved capital &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:550.62pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;increase of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:82.03999999999999pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;130&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:133.39pt;position:var(--position);text-decoration:none;white-space:pre"&gt; through the issuance of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:231.36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;20,000,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:276.36pt;position:var(--position);text-decoration:none;white-space:pre"&gt; newly-issued ordinary shares with a nominal value of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:495.31pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;0.01&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:517.81pt;position:var(--position);text-decoration:none;white-space:pre"&gt; per share, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:560.62pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;representing &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:87.88pt;position:var(--position);text-decoration:none;white-space:pre"&gt;89.6%&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:113.71pt;position:var(--position);text-decoration:none;white-space:pre"&gt; of its current share capital, at a subscription price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:326.21pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;6.50&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:348.71pt;position:var(--position);text-decoration:none;white-space:pre"&gt; per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:582.62pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Related transaction costs amounted to &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:189.96pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;6.7&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:238.81pt;position:var(--position);text-decoration:none;white-space:pre"&gt; and were deducted from the share premiums. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:610.62pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Change in governance and management &#x2013; February-August 2023 &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:626.62pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;On April&#160;5, 2023, the Company announced the appointment of Marc de Garidel as Chief Executive Officer (&#x201c;CEO&#x201d;) and Interim &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:636.62pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Board Chair, effective May&#160;5, 2023. Corinna zur Bonsen-Thomas stepped down as acting Chair, a position she held since August &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:646.62pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;2022, and remains a Board Member. Prof. Hartmut J. Ehrlich, M.D., retired from the CEO position, which he held since the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:656.62pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Company&#x2019;s founding in 2013, &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.45pt;position:var(--position);text-decoration:none;white-space:pre"&gt;and stayed on as a strategic advisor during the transition period, which ended on December 31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:678.62pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;On February 17, 2023, and April 18, 2023, the Company respectively announced the appointments of Dr. Sheldon Sloan, M.D., M. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:689.82pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Bioethics as new Chief Medical Officer and Michael Ferguson as new Chief Commercial Officer. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;On July 11, 2023, the Group announced the appointments of June Lee, M.D. and Troy Ignelzi as new independent members of the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:81.76pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Group&#x2019;s Board of Directors, replacing Joy Amundson and Jean-Jacques Bertrand. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:104.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;On August 23, 2023, the Group announced the appointment of Patrick Malloy as new Senior Vice President Investor Relations.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Creation of Abivax LLC &#x2013; March 2023 &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:144.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;On March&#160;20, 2023, Abivax LLC (or the "Subsidiary&#x201d;), was incorporated as a&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:347.31pt;position:var(--position);text-decoration:none;white-space:pre"&gt; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:349.81pt;position:var(--position);text-decoration:none;white-space:pre"&gt;limited liability company&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:450.77pt;position:var(--position);text-decoration:none;white-space:pre"&gt; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:453.27pt;position:var(--position);text-decoration:none;white-space:pre"&gt;under the laws of Delaware. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:154.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;As of the issuance of the financial statements, the Company has full ownership over the Subsidiary. The Subsidiary hosts the Group&#x2019;s &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:164.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;operations in the United States. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:192.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Cashless exercise of the Kreos A&amp;amp;B BSA &#x2013; May 2023 &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:214.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;On May 24, 2023, Kreos Capital V UK Ltd (or &#x201c;Kreos&#x201d;) opted for the cashless exercise option of the share warrants they held (as &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:225.76pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;defined in Note 15.3), implemented through the repurchase by the Group of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:341.27pt;position:var(--position);text-decoration:none;white-space:pre"&gt;43,070&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:368.77pt;position:var(--position);text-decoration:none;white-space:pre"&gt; tranche A share warrants (&#x201c;Kreos A BSA&#x201d;) and &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:236.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;43,070&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:63.5pt;position:var(--position);text-decoration:none;white-space:pre"&gt; tranche B share warrants (&#x201c;Kreos B BSA&#x201d;) and the issuance of respectively &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:370.07pt;position:var(--position);text-decoration:none;white-space:pre"&gt;67,887&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:397.57pt;position:var(--position);text-decoration:none;white-space:pre"&gt; and &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:417pt;position:var(--position);text-decoration:none;white-space:pre"&gt;31,696&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:444.5pt;position:var(--position);text-decoration:none;white-space:pre"&gt; ordinary shares, as a result of &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:248.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the exercise by Kreos of the outstanding Kreos A &amp;amp; B BSA. The accounting treatment of the operation is set forth in &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:504.67pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Note 15.3&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:544.0899999999999pt;position:var(--position);text-decoration:none;white-space:pre"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:270.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Free shares compensation plans &#x2013; July-December 2023 &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:292.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;In July, September and December 2023, the Group issued &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:269.40999999999997pt;position:var(--position);text-decoration:none;white-space:pre"&gt;five&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:284.94pt;position:var(--position);text-decoration:none;white-space:pre"&gt; free shares compensation plans (&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:417.84pt;position:var(--position);text-decoration:none;white-space:pre"&gt;attributions gratuites d&#x2019;actions&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:542.1800000000001pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, or &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:304.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x201c;AGAs&#x201d;) to certain of its officers and employees, representing a maximum of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:349.24pt;position:var(--position);text-decoration:none;white-space:pre"&gt;2,601,296&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:389.24pt;position:var(--position);text-decoration:none;white-space:pre"&gt; shares in the aggregate. The detailed terms &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:315.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;and conditions and the accounting treatment of these plans are presented in Note 14.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:337.76pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group secures financing up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:177.57pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;150&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:228.37pt;position:var(--position);text-decoration:none;white-space:pre"&gt; from &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:252.25pt;position:var(--position);text-decoration:none;white-space:pre"&gt;two&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:266.68pt;position:var(--position);text-decoration:none;white-space:pre"&gt; structured debt financing transactions &#x2013; August 2023 &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:360.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;On August 20, 2023, the Group concurrently signed &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:246.43pt;position:var(--position);text-decoration:none;white-space:pre"&gt;two&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:261.41999999999996pt;position:var(--position);text-decoration:none;white-space:pre"&gt; structured debt financing transactions for a total amount of up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:523.9100000000001pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;150&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.26pt;position:var(--position);text-decoration:none;white-space:pre"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:371.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;consisting of (i) up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:124.55pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;75&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:170.9pt;position:var(--position);text-decoration:none;white-space:pre"&gt; from Kreos Capital and Claret European Growth Capital (the &#x201c;Kreos / Claret Financing&#x201d;) together &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:382.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;with the issuance of warrants (&#x201c;the Kreos / Claret BSA&#x201d;) exercisable to receive ordinary shares of the Company, for an aggregate &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:393.76pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;exercise price of up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:127.27pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;8&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:168.62pt;position:var(--position);text-decoration:none;white-space:pre"&gt; and (ii) up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:225.52pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;75&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:271.87pt;position:var(--position);text-decoration:none;white-space:pre"&gt; from a fund advised by Heights Capital Management, Inc. (the &#x201c;Heights &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:404.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Financing&#x201d; and together with the Kreos / Claret Financing, the &#x201c;Transaction&#x201d;). The detailed structure and characteristics of the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:416.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Transaction are set forth&lt;/span&gt;&lt;span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:133.36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&lt;span style="background-color:inherit"&gt; in Notes 15.1 and 15.2.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:438.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The first tranches of the Kreos / Claret Financing and the Heights Financing, for &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:359.25pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;25&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:405.6pt;position:var(--position);text-decoration:none;white-space:pre"&gt; and &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:425.03pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;35&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:471.38pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, respectively, were &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:449.76pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;drawn on August 22, 2023, and August 24, 2023, respectively. In addition, the Group concurrently granted to Kreos and Claret, for no &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:460.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;additional consideration, warrants exercisable to receive ordinary shares of the Company for an aggregate exercise price of up to &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:472.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;4&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:77.35pt;position:var(--position);text-decoration:none;white-space:pre"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:494.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;As part of the Transaction, the Group is also repaying in full a total outstanding amount of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:399.52pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;33&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:445.87pt;position:var(--position);text-decoration:none;white-space:pre"&gt; under (i) the pre-existing debt &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:505.76pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;agreements with Kreos for a total amount of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:215.24pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;8&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:256.59000000000003pt;position:var(--position);text-decoration:none;white-space:pre"&gt; and (ii) the pre-existing OCEANE bonds for a total amount of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:509.68pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;25&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:556.03pt;position:var(--position);text-decoration:none;white-space:pre"&gt; by &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:516.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;way of set-off with the Heights Financing, thereby fully repaying such pre-existing indebtedness. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:539.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The net proceeds of the drawdown of the first tranche of the Kreos / Claret Financing and of the Heights Financing which, net of the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:550.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;refinancing of the existing indebtedness, amount to &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:243pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;27&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:289.35pt;position:var(--position);text-decoration:none;white-space:pre"&gt; in the aggregate, are expected to be allocated mainly to the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:561.76pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;development of obefazimod for the treatment of adults with moderately to severely active UC and other potential chronic &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:572.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;inflammatory indications, as well for working capital and general corporate purposes of the Group. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:595.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;On November 2, 2023, the Group granted additional warrants to Kreos and Claret, for an aggregate exercise price of up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:526.5899999999999pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;4&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:567.94pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:606.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;in order to secure the future drawdown of the third tranche of the Kreos / Claret debt financing. The detailed characteristics of the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:617.76pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;issuance is set forth in Note 15.1.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:640.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group announces closing of its Initial Public Offering on the Nasdaq Global Market &#x2013; October 2023&#160;  &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:662.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;On October 24, 2023, the Group announced the closing of its previously announced initial public offering on the Nasdaq Global &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:674.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Market by way of a capital increase of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:191.9pt;position:var(--position);text-decoration:none;white-space:pre"&gt;20,325,500&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:236.9pt;position:var(--position);text-decoration:none;white-space:pre"&gt; new ordinary shares, consisting of a public offering of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:458.65pt;position:var(--position);text-decoration:none;white-space:pre"&gt;18,699,460&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:503.65pt;position:var(--position);text-decoration:none;white-space:pre"&gt; ordinary shares &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:685.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;in the form of American Depositary Shares (&#x201c;ADSs&#x201d;), each representing the right to receive &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:405.83pt;position:var(--position);text-decoration:none;white-space:pre"&gt;one&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:420.26pt;position:var(--position);text-decoration:none;white-space:pre"&gt; ordinary share, in the United States &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:697.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;(the &#x201c;U.S. Offering&#x201d;), and a concurrent offering of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:240.51pt;position:var(--position);text-decoration:none;white-space:pre"&gt;1,626,040&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:280.51pt;position:var(--position);text-decoration:none;white-space:pre"&gt; ordinary shares in certain jurisdictions outside of the United States to &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:708.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;certain investors (the &#x201c;European Private Placement&#x201d;, and together with the U.S. offering, the &#x201c;Global Offering&#x201d;). The offering price &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;was set at &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:77.33pt;position:var(--position);text-decoration:none;white-space:pre"&gt;$11.60&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:104.83pt;position:var(--position);text-decoration:none;white-space:pre"&gt; per ADS in the U.S. Offering and a corresponding offering price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:378.77pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;10.9864&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:416.27pt;position:var(--position);text-decoration:none;white-space:pre"&gt; per ordinary share in the European &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:82.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Private Placement. All of the ADSs and ordinary shares in the Global Offering were offered by the Group. The ADSs began trading on &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:93.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the Nasdaq Global Market on October 20, 2023. The aggregate gross proceeds were approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:434.47pt;position:var(--position);text-decoration:none;white-space:pre"&gt;$235.8&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:493.32pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, equivalent to &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:105.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;223.3&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt; based on the exchange rate then in effect, before deduction of underwriting commissions and expenses &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:116.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;payable by the Group.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:140.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The net proceeds of the Global Offering were&lt;/span&gt;&lt;span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:218.28pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&lt;span style="background-color:inherit"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:220.78pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&lt;span style="background-color:inherit"&gt;$212.2&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:279.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&lt;span style="background-color:inherit"&gt; (&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:285.46000000000004pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&lt;span style="background-color:inherit"&gt;&#x20ac;202.0&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:344.31pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&lt;span style="background-color:inherit"&gt;), after deducting &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:415.33pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&lt;span style="background-color:inherit"&gt;$23.6&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:469.18pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&lt;span style="background-color:inherit"&gt; (&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:475.01pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&lt;span style="background-color:inherit"&gt;&#x20ac;21.3&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:528.86pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&lt;span style="background-color:inherit"&gt;) i&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:537.46pt;position:var(--position);text-decoration:none;white-space:pre"&gt;n &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:151.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;transaction costs. These costs were deducted from the share premiums.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Note 3.2. For the year ended December 31, 2024 &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:238.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Changes in governance &#x2013; February-December 2024 &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:263.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;On February 7, 2024, the Group announced the appointment of Ana Sharma as Vice President, Global Head of Quality. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:289.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;On April 2, 2024, the Group announced the appointment of Camilla Soenderby as Independent Board Member and also a member of &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:299.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the Appointments and Compensation Committee. Ms. Soenderby replaces Sant&#xe9; Holdings S.R.L., represented by Mr. Paolo Rampulla, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:309.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;who will continue to contribute to the work of the Board of Directors as an observer alongside Mr. Maurizio PetitBon from Kreos &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:319.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Capital/Blackrock.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:339.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;In July 2024, the Group announced the appointment of Sylvie Gr&#xe9;goire as Independent Board Member, Chairman of the Board and &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:347.46pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;also a member of the Audit Committee. Dr. Gr&#xe9;goire replaces Ms. Brosgart as Director, Mr. de Garidel as Chairman, and Mr. Hong as &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:355.76pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;member of the Audit Committee. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:374.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;On November 13, 2024, the Group announced the appointment of Mark Stenhouse as Board Observer &amp;amp; Advisor to the Group.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:394.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;On December 23, 2024, the Group announced the resignation of Dr. Philippe Pouletty, representative of Truffle Capital, as director of &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:404.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the Group, effective on December 31, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:12pt;position:var(--position);top:427.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Share-based compensation plans&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:italic;font-weight:normal;left:168.14pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:174.14pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2013; February-September 2024 &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:456.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;In February, March, May, July and September 2024, the Group issued &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:318.85pt;position:var(--position);text-decoration:none;white-space:pre"&gt;seven&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:341.6pt;position:var(--position);text-decoration:none;white-space:pre"&gt; free-share compensation plans to certain of its officers &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:466.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;and employees, representing a maximum of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:213.3pt;position:var(--position);text-decoration:none;white-space:pre"&gt;1,946,125&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:253.3pt;position:var(--position);text-decoration:none;white-space:pre"&gt; shares in the aggregate, the vesting of which is subject to the following service &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:476.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;condition: &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:79.00999999999999pt;position:var(--position);text-decoration:none;white-space:pre"&gt;50%&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:97.34pt;position:var(--position);text-decoration:none;white-space:pre"&gt; of the AGAs vest at the end of a &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:231.1pt;position:var(--position);text-decoration:none;white-space:pre"&gt;two&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:246.09pt;position:var(--position);text-decoration:none;white-space:pre"&gt;-year&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:266.61pt;position:var(--position);text-decoration:none;white-space:pre"&gt; period from the allocation date, &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:397.27pt;position:var(--position);text-decoration:none;white-space:pre"&gt;25%&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:415.6pt;position:var(--position);text-decoration:none;white-space:pre"&gt; at the end of a &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:477.19pt;position:var(--position);text-decoration:none;white-space:pre"&gt;three&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:497.15pt;position:var(--position);text-decoration:none;white-space:pre"&gt;-year&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:517.6700000000001pt;position:var(--position);text-decoration:none;white-space:pre"&gt; period from &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:486.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the allocation date and &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:128.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;25%&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:146.95999999999998pt;position:var(--position);text-decoration:none;white-space:pre"&gt; at the end of a &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:208.55pt;position:var(--position);text-decoration:none;white-space:pre"&gt;four&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:225.21pt;position:var(--position);text-decoration:none;white-space:pre"&gt;-year&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:245.73pt;position:var(--position);text-decoration:none;white-space:pre"&gt; period from the allocation date (with the exception of the &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:479.04pt;position:var(--position);text-decoration:none;white-space:pre"&gt;20,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:506.54pt;position:var(--position);text-decoration:none;white-space:pre"&gt; 2024-6 AGAs, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:496.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;whose vesting conditions are set forth in Note 14).&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:516.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;In March 2024, the Group granted its independent Board members the right to subscribe up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:414.27pt;position:var(--position);text-decoration:none;white-space:pre"&gt;77,820&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:441.77pt;position:var(--position);text-decoration:none;white-space:pre"&gt; share warrants (BSA) in the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:526.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;aggregate, the vesting of which (if subscribed) is subject to a service condition of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:363.13pt;position:var(--position);text-decoration:none;white-space:pre"&gt;four years&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:403.37pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, by tranches of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:467.48pt;position:var(--position);text-decoration:none;white-space:pre"&gt;25%&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.81pt;position:var(--position);text-decoration:none;white-space:pre"&gt; each, vested on each &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:536.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;anniversary date. All the BSAs have been subscribed.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:559.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Drawdown of Tranches B and C of the Kreos / Claret Financing &#x2013; March-June 2024 &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:585.66pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;On March 28, 2024 and June 21, 2024, the Group drew down &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:284.5pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;25&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:330.85pt;position:var(--position);text-decoration:none;white-space:pre"&gt; related to tranche B and &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:431.26pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;25&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:477.61pt;position:var(--position);text-decoration:none;white-space:pre"&gt; related to tranche C of &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:12pt;position:var(--position);top:596.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;senior secured non-convertible bonds from the Kreos / Claret Financing.&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:325.7pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:331.7pt;position:var(--position);text-decoration:none;white-space:pre"&gt;These second and third tranches each consist of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:524.25pt;position:var(--position);text-decoration:none;white-space:pre"&gt;25,000,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:569.25pt;position:var(--position);text-decoration:none;white-space:pre"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:610.3pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;senior secured non-convertible bonds with a par value of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:265.49pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;1.00&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:287.99pt;position:var(--position);text-decoration:none;white-space:pre"&gt; each, that will not be listed on any market.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:621.5pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The detailed characteristics of these bond loans and their accounting treatments are set forth in Note 15.1.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:646.5pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Bpifrance RNP-VIR and Carena conditional advances &#x2013; June 2024&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:671.5pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;In June 2024, the Group and Bpifrance renegotiated the RNP-VIR and CARENA conditional advances:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="font-size:12pt;line-height:12pt;position:var(--position);top:70.56pt;width:612pt"&gt;&lt;span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Between September 2017 and November 2019, the Group had received repayable conditional advances amounting &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:84.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;4,032&#160;thousands&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:141.98000000000002pt;position:var(--position);text-decoration:none;white-space:pre"&gt; and subsidies amounting to &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:256.06pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;1,123&#160;thousand&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:322.15pt;position:var(--position);text-decoration:none;white-space:pre"&gt; in relation to the RNP-VIR project, which aimed at &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:98.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;discovering new molecules for the treatment of viral infectious diseases through the development of the &#x201c;Modulation of RNA &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:111.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;biogenesis&#x201d; platform. In June 2024, the Group and Bpifrance agreed to terminate the project due to technical failure, and &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:125.76pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Bpifrance agreed to waive &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:179.62pt;position:var(--position);text-decoration:none;white-space:pre"&gt;60%&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:197.95pt;position:var(--position);text-decoration:none;white-space:pre"&gt; of the remaining advances. See Note 15.7 "Conditional Advances".&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:12pt;position:var(--position);top:153.36pt;width:612pt"&gt;&lt;span style="font-family:'Arial', sans-serif;font-size:12pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Between December 2013 and June 2016, the Group had received repayable conditional advances amounting &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:167.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;2,187&#160;thousands&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:141.98000000000002pt;position:var(--position);text-decoration:none;white-space:pre"&gt; in relation to the CARENA project, which aimed at developing an anti-HIV-AIDS therapeutic program &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:180.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;with the compound ABX464 up to the Phase 2b study. In June 2024, the Group and Bpifrance agreed to terminate the project &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:194.76pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;due to technical failure, and Bpifrance agreed to waive &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:293.34000000000003pt;position:var(--position);text-decoration:none;white-space:pre"&gt;60%&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:311.66999999999996pt;position:var(--position);text-decoration:none;white-space:pre"&gt; of the remaining conditional advance. See Note 15.7 &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:208.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;"Conditional Advances".&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:233.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group fully reimbursed the remaining conditional advances for both programs during the last quarter of 2024. The subsidy &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:245.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;income recognized over the period, corresponding to the amounts waived by Bpifrance and related interests, amounts to &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:256.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;4,123&#160;thousand&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:102.09pt;position:var(--position);text-decoration:none;white-space:pre"&gt; in the aggregate (see Note 18).&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:291.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Establishment of an At-the-Market ("ATM") Program on Nasdaq - November 2024&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:314.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;On November 19, 2024, the Group announced the implementation of an At-The-Market program (&#x201c;ATM Program&#x201d;) allowing the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:325.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Group to issue and sell, including with unsolicited investors who have expressed an interest, ordinary shares in the form of ADSs, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:337.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;each ADS representing &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:131.17000000000002pt;position:var(--position);text-decoration:none;white-space:pre"&gt;one&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:145.6pt;position:var(--position);text-decoration:none;white-space:pre"&gt; ordinary share, nominal value &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:269.90999999999997pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;0.01&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:292.41pt;position:var(--position);text-decoration:none;white-space:pre"&gt; per share, of the Group, with aggregate gross sales proceeds of up to &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:348.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;$150,000&#160;thousand&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.09pt;position:var(--position);text-decoration:none;white-space:pre"&gt; (subject to French regulatory limits and within the limits of the investors&#x2019; requests expressed in the context of the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:360.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;program), from time to time, pursuant to the terms of an equity distribution agreement with Piper Sandler &amp;amp; Co. (&#x201c;Piper Sandler&#x201d;), &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:371.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;acting as sales agent. The timing of any issuances in the form of ADSs will depend on a variety of factors. The ATM Program will be &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:383.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;effective until terminated in accordance with the equity distribution agreement or if ADSs representing the maximum gross sales &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:394.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;proceeds have been sold thereunder. To the extent that ADSs are sold pursuant to the ATM Program, the Group currently intends to &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:406.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;use the net proceeds (after deduction of fees and expenses), if any, of sales of ADSs issued under the ATM Program primarily to fund &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:417.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the research and development of the Group's product candidates, for working capital and general corporate purposes, at its discretion.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:440.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;A shelf registration statement on Form F-3, including a base prospectus relating to the Group's securities and an equity distribution &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:452.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;agreement prospectus relating to the ATM Program, was filed with the SEC and went into effect during 2024. The base prospectus &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:463.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;provides for the potential sale of ADSs of the Group with aggregate gross sales proceeds of up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:426.75pt;position:var(--position);text-decoration:none;white-space:pre"&gt;$350,000&#160;thousand&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:502.84pt;position:var(--position);text-decoration:none;white-space:pre"&gt; (including the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:475.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;$150,000&#160;thousand&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.09pt;position:var(--position);text-decoration:none;white-space:pre"&gt; covered by the equity distribution agreement prospectus) to grant additional flexibility to the Group in connection &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:486.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;with its financing strategy. The specific terms of any securities to be offered pursuant to the base prospectus will be specified in one or &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:498.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;more prospectus supplements to the base prospectus. As of the date of issuance of these financial statements, the Group has not &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:509.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;utilized the ATM Program. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Note 3.3&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:70.42pt;position:var(--position);text-decoration:none;white-space:pre"&gt;. For the year ended December 31, 2025 &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:12pt;position:var(--position);top:92.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Share-based compensation plans&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:italic;font-weight:normal;left:168.14pt;position:var(--position);text-decoration:none;white-space:pre"&gt; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:171.14pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2013; January-&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:214.72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;November &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:258.28pt;position:var(--position);text-decoration:none;white-space:pre"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:118.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;In January 2025, the Group granted its independent Board members, as well as one of its Board Observers and Advisor, the right to &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:130.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;subscribe up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:99.00999999999999pt;position:var(--position);text-decoration:none;white-space:pre"&gt;125,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:131.51pt;position:var(--position);text-decoration:none;white-space:pre"&gt; share warrants (BSA) in the aggregate, the vesting of which is subject to a service condition of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:514.69pt;position:var(--position);text-decoration:none;white-space:pre"&gt;four years&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:554.93pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, by &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:142.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;tranches of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:82.61pt;position:var(--position);text-decoration:none;white-space:pre"&gt;25%&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:100.94pt;position:var(--position);text-decoration:none;white-space:pre"&gt; each, vested on January 1 of each year.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:166.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;In February, March, May, August and November 2025,&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:257.8pt;position:var(--position);text-decoration:none;white-space:pre"&gt; the Group issued &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:330.53pt;position:var(--position);text-decoration:none;white-space:pre"&gt;eight&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:350.5pt;position:var(--position);text-decoration:none;white-space:pre"&gt; free-share compensation plans to certain of its officers &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:178.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;and employees, representing a maximum o&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:207.47pt;position:var(--position);text-decoration:none;white-space:pre"&gt;f &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:213.3pt;position:var(--position);text-decoration:none;white-space:pre"&gt;6,280,727&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:253.3pt;position:var(--position);text-decoration:none;white-space:pre"&gt; shares in the aggregate, the vesting of which is subject to the following service &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:190.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;condition: &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:79.00999999999999pt;position:var(--position);text-decoration:none;white-space:pre"&gt;50%&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:97.34pt;position:var(--position);text-decoration:none;white-space:pre"&gt; of the AGAs vest at the end of a &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:231.1pt;position:var(--position);text-decoration:none;white-space:pre"&gt;two&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:246.09pt;position:var(--position);text-decoration:none;white-space:pre"&gt;-year&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:266.61pt;position:var(--position);text-decoration:none;white-space:pre"&gt; period from the allocation date, &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:397.27pt;position:var(--position);text-decoration:none;white-space:pre"&gt;25%&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:415.6pt;position:var(--position);text-decoration:none;white-space:pre"&gt; at the end of a &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:477.19pt;position:var(--position);text-decoration:none;white-space:pre"&gt;three&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:497.15pt;position:var(--position);text-decoration:none;white-space:pre"&gt;-year&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:517.6700000000001pt;position:var(--position);text-decoration:none;white-space:pre"&gt; period from &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:202.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the allocation date and &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:128.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;25%&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:146.95999999999998pt;position:var(--position);text-decoration:none;white-space:pre"&gt; at the end of a &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:208.55pt;position:var(--position);text-decoration:none;white-space:pre"&gt;four&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:225.21pt;position:var(--position);text-decoration:none;white-space:pre"&gt;-year&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:245.73pt;position:var(--position);text-decoration:none;white-space:pre"&gt; period from the allocation date (with the exception of the &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:479.04pt;position:var(--position);text-decoration:none;white-space:pre"&gt;123,102&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:511.54pt;position:var(--position);text-decoration:none;white-space:pre"&gt; 2025-2 AGAs, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:214.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;which vest at the end of a &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.6pt;position:var(--position);text-decoration:none;white-space:pre"&gt;two&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.59pt;position:var(--position);text-decoration:none;white-space:pre"&gt;-year&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:176.11pt;position:var(--position);text-decoration:none;white-space:pre"&gt; period from the allocation date, and the &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:338.4pt;position:var(--position);text-decoration:none;white-space:pre"&gt;50,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:365.9pt;position:var(--position);text-decoration:none;white-space:pre"&gt; 2025-5 AGAs , which vest only upon the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:226.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;achievement of milestones related to clinical studies). Moreover, the vesting of almost half of the &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:426.88pt;position:var(--position);text-decoration:none;white-space:pre"&gt;4,319,500&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:466.88pt;position:var(--position);text-decoration:none;white-space:pre"&gt; 2025-1 AGAs is subject to &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:238.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the occurrence of a &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.77pt;position:var(--position);text-decoration:none;white-space:pre"&gt;tender offer on the securities issued by the Group and resulting in a change of control of the Group&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:509.38pt;position:var(--position);text-decoration:none;white-space:pre"&gt; before a certain &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:250.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;date. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:274.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;In April 2025, the Group granted to one of its Board members the right to subscribe up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:395.98pt;position:var(--position);text-decoration:none;white-space:pre"&gt;39,370&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:423.48pt;position:var(--position);text-decoration:none;white-space:pre"&gt; share warrants (BSA), the vesting of &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:286.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;which is subject to a service condition of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:201.92pt;position:var(--position);text-decoration:none;white-space:pre"&gt;four years&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:242.16pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, by tranches of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:306.27pt;position:var(--position);text-decoration:none;white-space:pre"&gt;25%&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:324.6pt;position:var(--position);text-decoration:none;white-space:pre"&gt; each, vested on May 1 of each year. The BSAs were &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:298.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;subscribed in May 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:322.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The detailed terms and conditions of these plans are set forth in Note 14.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:346.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Change in management &#x2013; April 2025&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:369.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;On April 22, 2025, the Group announced the appointment of Dominik H&#xf6;chli, MD to the Board of Directors of Abivax, effective &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:381.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;immediately.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:405.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Completion of enrollment for the Phase 3 ABTECT trials in patients with moderately to severely active UC - April 2025&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:429.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;On April 29, 2025, the Group announced the completion of enrollment for the Phase 3 ABTECT trials in patients with moderately to &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:441.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;severely active UC.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:465.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Publication of positive Phase 3 results from both ABTECT 8-week induction trials investigating obefazimod, in moderate to severely &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:477.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;active UC &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:78.71000000000001pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2013;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:83.71000000000001pt;position:var(--position);text-decoration:none;white-space:pre"&gt; July 2025 &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:501.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;On July 22, 2025, the Group announced the positive results of the ABTECT-1 and ABTECT-2 induction trials in patients with &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:513.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;moderately to severely active UC. ABTECT-1 and 2 are global, multicenter, randomized, double-blind, placebo-controlled trials &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:525.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;assessing once-daily oral administration of obefazimod at 25 mg or 50 mg doses in adult patients with moderately to severely active &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:537.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;UC. Eligible participants had inadequate response, loss of response, or intolerance to conventional and/or advanced therapies.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:561.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Following this announcement and that of its Offering completed on July 28, 2025 (see &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:383.19pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Completion of a public offering &#x2013; July 2025&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:558.31pt;position:var(--position);text-decoration:none;white-space:pre"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:573.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;within this section), the Group&#x2019;s share price increased significantly, from &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:330.66pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;6.64&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:353.16pt;position:var(--position);text-decoration:none;white-space:pre"&gt; as of June 30, 2025, to &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:448.4pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;57.00&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:475.9pt;position:var(--position);text-decoration:none;white-space:pre"&gt; as of July 28, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:584.26pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;At the same time, the Group reassessed the probability of success (&#x201c;POS&#x201d;) of obtaining a future market authorization for obefazimod &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:595.46pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;in UC, to reflect a reduced level of uncertainty following positive Phase 3 results.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:618.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The main financial effects of this event on the Group&#x2019;s financial statements are the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:640.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;A significant increase in the carrying value of the royalty certificates, measured at amortized cost, reflecting an increase in the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:652.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;projected probability-weighted cash flows of the instrument, following the reassessment of the POS (see Note 15.9),&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:674.76pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Significant changes in the carrying value of the Group&#x2019;s financial liabilities measured at fair value through profit or loss, i.e. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:685.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the Kreos / Claret BSA, the Kreos / Claret MRI and the Heights convertible notes (the latter as well as the Kreos / Claret BSA &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:697.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;being converted into ordinary shares at the request of the noteholders in July and August 2025, see &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:468.85pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Conversion of the Heights &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:708.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;convertible notes, Kreos / Claret OCABSA and Kreos / Claret BSA &#x2013;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:346.71pt;position:var(--position);text-decoration:none;white-space:pre"&gt; July-August 2025 below &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:448.29pt;position:var(--position);text-decoration:none;white-space:pre"&gt;and Notes 15.1 and 15.2&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:545.46pt;position:var(--position);text-decoration:none;white-space:pre"&gt;),&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:82.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Significant changes in the disclosure of the fair values of other financial instruments measured at amortized cost (i.e. the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:93.26pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;royalty certificates, the debt components of (i) the Kreos / Claret OCABSA (Tranche A, converted into shares in August &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:104.46pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;2025) and (ii) Tranche B and C bond loans; these fair value changes are not expected directly to impact the future financial &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:115.66pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;position and net loss of the Group - see Note 15),&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:138.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;A significant increase in provisions related to employer contributions on AGAs (the contribution being based on the vesting &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:149.26pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;date share price - see Note 14).&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:182.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Completion of a public offering &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:164.49pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2013;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:169.49pt;position:var(--position);text-decoration:none;white-space:pre"&gt; July 2025 &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:206.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;On July 28, 2025, the Group announced the completion of an underwritten public offering of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:409.86pt;position:var(--position);text-decoration:none;white-space:pre"&gt;11,679,400&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:454.86pt;position:var(--position);text-decoration:none;white-space:pre"&gt; ADSs (the &#x201c;Offering&#x201d;) at a &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:218.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:69.28999999999999pt;position:var(--position);text-decoration:none;white-space:pre"&gt;$64.00&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.78999999999999pt;position:var(--position);text-decoration:none;white-space:pre"&gt; per ADS (corresponding to &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:210.33pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;54.58&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:237.83pt;position:var(--position);text-decoration:none;white-space:pre"&gt; per ordinary share, based on the exchange rate of &#x20ac;1.00 = $&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:477.12pt;position:var(--position);text-decoration:none;white-space:pre"&gt;1.1726&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:504.62pt;position:var(--position);text-decoration:none;white-space:pre"&gt; as published by &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:230.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the European Central Bank on July 23, 2025). The aggregate gross proceeds amounted to approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:455.3pt;position:var(--position);text-decoration:none;white-space:pre"&gt;$747.5&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:514.15pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, equivalent to &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:242.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;637.5&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, before deduction of underwriting commissions and estimated expenses, and the net proceeds, after &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:254.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;deducting underwriting commissions and estimated offering expenses, were approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:402.26pt;position:var(--position);text-decoration:none;white-space:pre"&gt;$700.3&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:461.11pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, equivalent to &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:266.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;597.2&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;. The net cash from the Offering of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:297.4pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;607.2&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:324.9pt;position:var(--position);text-decoration:none;white-space:pre"&gt; million presented within the Consolidated Statements of Cash &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:278.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Flows also includes the effect of a net foreign exchange gain &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:280.98pt;position:var(--position);text-decoration:none;white-space:pre"&gt;resulting from the favorable change in the euro to U.S. dollar exchange &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:290.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;rate between the closing of the Offering and the date of receipt of funds.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:314.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group believes that the net proceeds from the Offering, together with its current cash and cash equivalents, will allow it to finance &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:326.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;its operations into the fourth quarter of 2027, allowing it to reach 12 months of expected cash runway following the planned NDA &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:338.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;submission for UC, assuming positive results from its Phase 3 maintenance trial (see Note 2 above "Going concern").&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:374.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Conversion of the Heights convertible notes, Kreos OCABSA and Kreos / Claret BSA and prepayment of the Kreos / Claret Tranches &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:386.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;B and C bond loans &#x2013;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:122.92pt;position:var(--position);text-decoration:none;white-space:pre"&gt; July-December 2025 &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:409.26pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;On July 23 and July 30, 2025, the Group received notices from entities affiliated with Heights Capital Management, which hold &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:421.26pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;amortizing senior convertible notes of the Group issued in August 2023 (the &#x201c;Height convertible notes&#x201d;), for the immediate conversion &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:433.26pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;of respectively &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:97.58pt;position:var(--position);text-decoration:none;white-space:pre"&gt;150&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.58pt;position:var(--position);text-decoration:none;white-space:pre"&gt; and &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:132.01pt;position:var(--position);text-decoration:none;white-space:pre"&gt;200&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:147.01pt;position:var(--position);text-decoration:none;white-space:pre"&gt; convertible notes (corresponding to the entirety of the outstanding principal amount of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:497.47pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;21.9&#160;million&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:551.32pt;position:var(--position);text-decoration:none;white-space:pre"&gt;) into &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:445.26pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;920,377&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:68.5pt;position:var(--position);text-decoration:none;white-space:pre"&gt; new ordinary shares of the Group at a conversion price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:303.83pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;23.7674&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:341.33pt;position:var(--position);text-decoration:none;white-space:pre"&gt; per ordinary share in accordance with the terms and &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:457.26pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;conditions of the convertible notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:481.26pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.96pt"&gt;On August 8, 2025, Kreos Capital VII (UK) Limited converted its portion of the Tranche A of the Kreos / Claret Financing (the Kreos&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.96pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:492.46pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:163.21pt"&gt;OCABSA), resulting in the issuance of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:199.21pt;position:var(--position);text-decoration:none;white-space:pre;width:32.5pt"&gt;785,389&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:231.71pt;position:var(--position);text-decoration:none;white-space:pre;width:344.2pt"&gt; ordinary shares. In addition, on July 30, 2025, Kreos Capital VII Aggregator SCSp&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.91pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:503.66pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:414.04pt"&gt;exercised its share warrants (the tranche A-B BSA and tranche C BSA) resulting in the issuance of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:450.04pt;position:var(--position);text-decoration:none;white-space:pre;width:32.5pt"&gt;319,251&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:482.54pt;position:var(--position);text-decoration:none;white-space:pre;width:93.36pt"&gt; ordinary shares of the&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.9pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:514.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:28.05pt"&gt;Group.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:537.26pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;On August 28, 2025, Claret European Growth Capital Fund III SCSp exercised its share warrants (the tranche A-B BSA and tranche C &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:549.26pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;BSA) resulting in the issuance of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:170.87pt;position:var(--position);text-decoration:none;white-space:pre"&gt;206,662&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:203.37pt;position:var(--position);text-decoration:none;white-space:pre"&gt; ordinary shares of the Group.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:573.26pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;On November 25, 2025, Claret European Growth Capital Fund III SCSp converted its portion of the Tranche A portion of the Kreos / &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:584.46pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Claret Financing (the Claret OCABSA), resulting in the issuance of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:308.74pt;position:var(--position);text-decoration:none;white-space:pre"&gt;392,695&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:341.24pt;position:var(--position);text-decoration:none;white-space:pre"&gt; ordinary shares of the Group. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:607.66pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;On December 23, 2025, the Group completed the full prepayment of the outstanding balances of Tranches B and C of the Kreos / &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:619.66pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Claret Financing. The repayment amount, including end-of-loan exit fees and prepayment fees, amounts to &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:465.22pt;position:var(--position);text-decoration:none;white-space:pre"&gt;33,823&#160;thousand&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:531.31pt;position:var(--position);text-decoration:none;white-space:pre"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:643.66pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Following these transactions, the Group no longer holds any debt related to the Kreos / Claret and Heights Financings.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:666.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The impacts of these operations on the Group's financial statements are set forth in Note 15.1 and 15.2.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Admission to the CAC Mid 60 and SBF 120 indices - September 2025&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:94.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Following the annual review of the Euronext Paris indices on September 11, 2025, the Scientific Council of the Indices has decided to &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:106.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;admit the Company to the CAC Mid 60 and SBF 120 indices. This decision took effect on Friday, September 19, 2025, after market &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:118.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;close. The CAC Mid 60 and SBF 120 are key indices on the Euronext Paris exchange, representing mid-sized listed companies and a &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:130.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;broader selection of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:117.84pt;position:var(--position);text-decoration:none;white-space:pre"&gt;120&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:132.84pt;position:var(--position);text-decoration:none;white-space:pre"&gt; major securities, respectively.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Note 3.4. Subsequent events&#160; &lt;/span&gt;&lt;div style="font-size:12pt;line-height:12pt;position:var(--position);top:226.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Share-based compensation plans&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:italic;font-weight:normal;left:168.14pt;position:var(--position);text-decoration:none;white-space:pre"&gt; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:171.14pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2013; February 2026&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:252.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;In February 2026, the Group issued a new free-share compensation plan to certain of its officers and employees, representing a &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:264.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;maximum of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:89.84pt;position:var(--position);text-decoration:none;white-space:pre"&gt;47,500&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:117.34pt;position:var(--position);text-decoration:none;white-space:pre"&gt; shares in the aggregate, the vesting of which is subject to the following service condition: &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:479.98pt;position:var(--position);text-decoration:none;white-space:pre"&gt;50%&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:498.31pt;position:var(--position);text-decoration:none;white-space:pre"&gt; of the AGAs vest &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:276.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;at the end of a &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:95.09pt;position:var(--position);text-decoration:none;white-space:pre"&gt;two&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:110.08pt;position:var(--position);text-decoration:none;white-space:pre"&gt;-year&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:130.6pt;position:var(--position);text-decoration:none;white-space:pre"&gt; period from the allocation date, &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:261.26pt;position:var(--position);text-decoration:none;white-space:pre"&gt;25%&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:279.59000000000003pt;position:var(--position);text-decoration:none;white-space:pre"&gt; at the end of a &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:341.18pt;position:var(--position);text-decoration:none;white-space:pre"&gt;three&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:361.14pt;position:var(--position);text-decoration:none;white-space:pre"&gt;-year&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:381.66pt;position:var(--position);text-decoration:none;white-space:pre"&gt; period from the allocation date and &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:526.75pt;position:var(--position);text-decoration:none;white-space:pre"&gt;25%&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:545.0799999999999pt;position:var(--position);text-decoration:none;white-space:pre"&gt; at the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:288.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;end of a &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:70.69pt;position:var(--position);text-decoration:none;white-space:pre"&gt;four&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:87.35pt;position:var(--position);text-decoration:none;white-space:pre"&gt;-year&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:107.87pt;position:var(--position);text-decoration:none;white-space:pre"&gt; period from the allocation date.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:312.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;In February 2026,&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:107.91pt;position:var(--position);text-decoration:none;white-space:pre"&gt; the Group granted its independent Board members, as well as one of its Board Observers and Advisor, the right to &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:324.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;subscribe up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:99.00999999999999pt;position:var(--position);text-decoration:none;white-space:pre"&gt;23,477&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:126.51pt;position:var(--position);text-decoration:none;white-space:pre"&gt; share warrants (BSA) in the aggregate, the vesting of which (if subscribed) is subject to a service condition of &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:336.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;four&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:52.66pt;position:var(--position);text-decoration:none;white-space:pre"&gt; years&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:76.24000000000001pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, by tranches of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.35pt;position:var(--position);text-decoration:none;white-space:pre"&gt;25%&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.68pt;position:var(--position);text-decoration:none;white-space:pre"&gt; each, vested on each February 1st thereafter. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:360.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:underline;white-space:pre"&gt;Changes in Management - March&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:384.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;In March 2026, the Group appointed Michael Nesrallah, MBA, as Chief Commercial Officer, Keith Fournier, Ph.D., as Senior Vice &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:395.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;President of Global Regulatory Affairs, and Maurus de la Rosa, Ph.D., Senior Vice President of Research.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:417.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;In March 2026, Sofinnova Partners, represented by Dr. Kinam Hong, stepped down from the Group's Board of Directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:440.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;In light of Mr. Didier Scherrer's departure from his role as Chief Scientific Officer, the Group entered into a settlement agreement &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:451.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;("protocole d&#x2019;accord transactionnel") with Mr. Didier Scherrer under which:&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:462.76pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Mr. Scherrer received a balance of notice pay in the total gross amount of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:368.58pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;278 thousand&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:427.17pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, together with a contractual &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:473.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;severance indemnity of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:167.70999999999998pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;240 thousand&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:226.3pt;position:var(--position);text-decoration:none;white-space:pre"&gt; (net);&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:485.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the Group waived the continued employment condition attached to &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:341.41pt;position:var(--position);text-decoration:none;white-space:pre"&gt;77,050&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:368.91pt;position:var(--position);text-decoration:none;white-space:pre"&gt; free shares previously granted to Mr. Scherrer;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:496.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the Group waived the continued employment condition for a further &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:346.16pt;position:var(--position);text-decoration:none;white-space:pre"&gt;40,200&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:373.66pt;position:var(--position);text-decoration:none;white-space:pre"&gt; free shares, subject to specific performance &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:507.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;conditions;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:518.76pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the remaining &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.7pt;position:var(--position);text-decoration:none;white-space:pre"&gt;217,750&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:162.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt; free shares previously granted to Mr. Scherrer are lapsed; and&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2022;&lt;/span&gt;Mr. Scherrer irrevocably waived all claims and renounced any legal action against the Group.</abvx:DisclosureOfSignificantEventsForThePeriodReportedAndEventsAfterReportingPeriodTextBlock>
    <abvx:FinancialAgreementAmount contextRef="c-68" decimals="-5" id="f-550" unitRef="eur">130000000.0</abvx:FinancialAgreementAmount>
    <abvx:FinancialAgreementAmount contextRef="c-68" decimals="-5" id="f-551" unitRef="eur">130000000.0</abvx:FinancialAgreementAmount>
    <ifrs-full:IssueOfEquity contextRef="c-69" decimals="-6" id="f-552" unitRef="eur">130000000</ifrs-full:IssueOfEquity>
    <abvx:IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease contextRef="c-69" decimals="0" id="f-553" unitRef="shares">20000000</abvx:IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease>
    <ifrs-full:ParValuePerShare
      contextRef="c-68"
      decimals="2"
      id="f-554"
      unitRef="eurPerShare">0.01</ifrs-full:ParValuePerShare>
    <abvx:EquityIssuancePercentageOfCurrentShareCapital contextRef="c-70" decimals="3" id="f-555" unitRef="number">0.896</abvx:EquityIssuancePercentageOfCurrentShareCapital>
    <abvx:EquityIssuanceSubscriptionPricePerShare
      contextRef="c-68"
      decimals="2"
      id="f-556"
      unitRef="eurPerShare">6.50</abvx:EquityIssuanceSubscriptionPricePerShare>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-71" decimals="-5" id="f-557" unitRef="eur">6700000</ifrs-full:ShareIssueRelatedCost>
    <abvx:NumberOfOtherShareWarrantsRepurchased contextRef="c-72" decimals="0" id="f-558" unitRef="shares">43070</abvx:NumberOfOtherShareWarrantsRepurchased>
    <abvx:NumberOfOtherShareWarrantsRepurchased contextRef="c-73" decimals="0" id="f-559" unitRef="shares">43070</abvx:NumberOfOtherShareWarrantsRepurchased>
    <abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants contextRef="c-72" decimals="0" id="f-560" unitRef="shares">67887</abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants>
    <abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants contextRef="c-73" decimals="0" id="f-561" unitRef="shares">31696</abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants>
    <abvx:NumberOfShareBasedCompensationPlansIssued contextRef="c-74" decimals="INF" id="f-562" unitRef="plan">5</abvx:NumberOfShareBasedCompensationPlansIssued>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-74"
      decimals="INF"
      id="f-563"
      unitRef="shares">2601296</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <abvx:FinancialAgreementAmount contextRef="c-75" decimals="-6" id="f-564" unitRef="eur">150000000</abvx:FinancialAgreementAmount>
    <abvx:FinancialAgreementNumberOfTransactions
      contextRef="c-76"
      decimals="INF"
      id="f-565"
      unitRef="transaction">2</abvx:FinancialAgreementNumberOfTransactions>
    <abvx:FinancialAgreementNumberOfTransactions
      contextRef="c-76"
      decimals="INF"
      id="f-566"
      unitRef="transaction">2</abvx:FinancialAgreementNumberOfTransactions>
    <abvx:FinancialAgreementAmount contextRef="c-75" decimals="-6" id="f-567" unitRef="eur">150000000</abvx:FinancialAgreementAmount>
    <abvx:BorrowingsMaximumBorrowingCapacity contextRef="c-77" decimals="-6" id="f-568" unitRef="eur">75000000</abvx:BorrowingsMaximumBorrowingCapacity>
    <abvx:AggregateExercisePriceOtherEquityInstrumentsGranted contextRef="c-78" decimals="-6" id="f-569" unitRef="eur">8000000</abvx:AggregateExercisePriceOtherEquityInstrumentsGranted>
    <abvx:BorrowingsMaximumBorrowingCapacity contextRef="c-79" decimals="-6" id="f-570" unitRef="eur">75000000</abvx:BorrowingsMaximumBorrowingCapacity>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-80" decimals="-6" id="f-571" unitRef="eur">25000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-81" decimals="-6" id="f-572" unitRef="eur">35000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <abvx:AggregateExercisePriceOtherEquityInstrumentsGranted contextRef="c-82" decimals="-6" id="f-573" unitRef="eur">4000000</abvx:AggregateExercisePriceOtherEquityInstrumentsGranted>
    <abvx:RepaymentsOfConvertibleLoansNotes contextRef="c-83" decimals="-6" id="f-574" unitRef="eur">33000000</abvx:RepaymentsOfConvertibleLoansNotes>
    <abvx:RepaymentsOfConvertibleLoansNotes contextRef="c-84" decimals="-6" id="f-575" unitRef="eur">8000000</abvx:RepaymentsOfConvertibleLoansNotes>
    <abvx:RepaymentsOfConvertibleLoansNotes contextRef="c-85" decimals="-6" id="f-576" unitRef="eur">25000000</abvx:RepaymentsOfConvertibleLoansNotes>
    <abvx:ProceedsFromBorrowingsNetOfRefinancingOfExistingIndebteness contextRef="c-86" decimals="-6" id="f-577" unitRef="eur">27000000</abvx:ProceedsFromBorrowingsNetOfRefinancingOfExistingIndebteness>
    <abvx:IssuanceOfOtherShareWarrants contextRef="c-87" decimals="-6" id="f-578" unitRef="eur">4000000</abvx:IssuanceOfOtherShareWarrants>
    <abvx:IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease contextRef="c-88" decimals="0" id="f-579" unitRef="shares">20325500</abvx:IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease>
    <abvx:IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease contextRef="c-89" decimals="0" id="f-580" unitRef="shares">18699460</abvx:IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease>
    <abvx:NumberOfSharesReceivedPerADS
      contextRef="c-89"
      decimals="INF"
      id="f-581"
      unitRef="shares">1</abvx:NumberOfSharesReceivedPerADS>
    <abvx:IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease contextRef="c-90" decimals="0" id="f-582" unitRef="shares">1626040</abvx:IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease>
    <abvx:IssueOfEquityOfferingPricePerShare
      contextRef="c-91"
      decimals="2"
      id="f-583"
      unitRef="usdPerShare">11.60</abvx:IssueOfEquityOfferingPricePerShare>
    <abvx:IssueOfEquityOfferingPricePerShare
      contextRef="c-92"
      decimals="4"
      id="f-584"
      unitRef="eurPerShare">10.9864</abvx:IssueOfEquityOfferingPricePerShare>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-88" decimals="-5" id="f-585" unitRef="usd">235800000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-88" decimals="-5" id="f-586" unitRef="eur">223300000</ifrs-full:ProceedsFromIssuingShares>
    <abvx:ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants contextRef="c-88" decimals="-5" id="f-587" unitRef="usd">212200000</abvx:ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants>
    <abvx:ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants contextRef="c-88" decimals="-5" id="f-588" unitRef="eur">202000000.0</abvx:ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants>
    <ifrs-full:PaymentsForShareIssueCosts contextRef="c-88" decimals="-5" id="f-589" unitRef="usd">23600000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsForShareIssueCosts contextRef="c-88" decimals="-5" id="f-590" unitRef="eur">21300000</ifrs-full:PaymentsForShareIssueCosts>
    <abvx:NumberOfFreeSharesPlansIssued contextRef="c-93" decimals="INF" id="f-591" unitRef="plan">7</abvx:NumberOfFreeSharesPlansIssued>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-94"
      decimals="INF"
      id="f-592"
      unitRef="shares">1946125</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage contextRef="c-95" decimals="2" id="f-593" unitRef="number">0.50</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-95" id="f-594">P2Y</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage contextRef="c-96" decimals="2" id="f-595" unitRef="number">0.25</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-96" id="f-596">P3Y</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage contextRef="c-97" decimals="2" id="f-597" unitRef="number">0.25</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-97" id="f-598">P4Y</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-98"
      decimals="INF"
      id="f-599"
      unitRef="shares">20000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-99"
      decimals="INF"
      id="f-600"
      unitRef="shares">77820</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-99" id="f-601">P4Y</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage contextRef="c-99" decimals="2" id="f-602" unitRef="number">0.25</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-100" decimals="-6" id="f-603" unitRef="eur">25000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-101" decimals="-6" id="f-604" unitRef="eur">25000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <abvx:BorrowingsMaximumBorrowingCapacity contextRef="c-102" decimals="-3" id="f-605" unitRef="eur">25000000</abvx:BorrowingsMaximumBorrowingCapacity>
    <ifrs-full:ParValuePerShare
      contextRef="c-102"
      decimals="2"
      id="f-606"
      unitRef="eurPerShare">1.00</ifrs-full:ParValuePerShare>
    <abvx:ProceedsFromConditionalAdvances contextRef="c-103" decimals="-3" id="f-607" unitRef="eur">4032000</abvx:ProceedsFromConditionalAdvances>
    <ifrs-full:ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities contextRef="c-103" decimals="-3" id="f-608" unitRef="eur">1123000</ifrs-full:ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities>
    <abvx:PercentageOfConditionalAdvancesWaived contextRef="c-104" decimals="2" id="f-609" unitRef="number">0.60</abvx:PercentageOfConditionalAdvancesWaived>
    <abvx:ProceedsFromConditionalAdvances contextRef="c-105" decimals="-3" id="f-610" unitRef="eur">2187000</abvx:ProceedsFromConditionalAdvances>
    <abvx:PercentageOfConditionalAdvancesWaived contextRef="c-106" decimals="2" id="f-611" unitRef="number">0.60</abvx:PercentageOfConditionalAdvancesWaived>
    <ifrs-full:RevenueFromGovernmentGrants contextRef="c-107" decimals="-3" id="f-612" unitRef="eur">4123000</ifrs-full:RevenueFromGovernmentGrants>
    <abvx:NumberOfADSPerOrdinaryShares
      contextRef="c-108"
      decimals="INF"
      id="f-613"
      unitRef="shares">1</abvx:NumberOfADSPerOrdinaryShares>
    <ifrs-full:ParValuePerShare
      contextRef="c-108"
      decimals="2"
      id="f-614"
      unitRef="eurPerShare">0.01</ifrs-full:ParValuePerShare>
    <abvx:ExpectedProceedsFromShareIssuance contextRef="c-109" decimals="-3" id="f-615" unitRef="usd">150000000</abvx:ExpectedProceedsFromShareIssuance>
    <abvx:ExpectedProceedsFromShareIssuanceShelfRegistration contextRef="c-109" decimals="-3" id="f-616" unitRef="usd">350000000</abvx:ExpectedProceedsFromShareIssuanceShelfRegistration>
    <abvx:ExpectedProceedsFromShareIssuance contextRef="c-109" decimals="-3" id="f-617" unitRef="usd">150000000</abvx:ExpectedProceedsFromShareIssuance>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-110"
      decimals="INF"
      id="f-618"
      unitRef="shares">125000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-111" id="f-619">P4Y</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage contextRef="c-111" decimals="2" id="f-620" unitRef="number">0.25</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage>
    <abvx:NumberOfFreeSharesPlansIssued contextRef="c-112" decimals="INF" id="f-621" unitRef="plan">8</abvx:NumberOfFreeSharesPlansIssued>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-113"
      decimals="INF"
      id="f-622"
      unitRef="shares">6280727</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage contextRef="c-114" decimals="2" id="f-623" unitRef="number">0.50</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-114" id="f-624">P2Y</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage contextRef="c-115" decimals="2" id="f-625" unitRef="number">0.25</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-115" id="f-626">P3Y</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage contextRef="c-116" decimals="2" id="f-627" unitRef="number">0.25</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-116" id="f-628">P4Y</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-117"
      decimals="INF"
      id="f-629"
      unitRef="shares">123102</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-117" id="f-630">P2Y</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-118"
      decimals="INF"
      id="f-631"
      unitRef="shares">50000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-119"
      decimals="INF"
      id="f-632"
      unitRef="shares">4319500</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-120"
      decimals="INF"
      id="f-633"
      unitRef="shares">39370</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-121" id="f-634">P4Y</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage contextRef="c-121" decimals="2" id="f-635" unitRef="number">0.25</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage>
    <abvx:SharePrice1
      contextRef="c-122"
      decimals="2"
      id="f-636"
      unitRef="eurPerShare">6.64</abvx:SharePrice1>
    <abvx:SharePrice1
      contextRef="c-123"
      decimals="2"
      id="f-637"
      unitRef="eurPerShare">57.00</abvx:SharePrice1>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c-124"
      decimals="INF"
      id="f-638"
      unitRef="shares">11679400</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <abvx:IssueOfEquityOfferingPricePerShare
      contextRef="c-125"
      decimals="2"
      id="f-639"
      unitRef="usdPerShare">64.00</abvx:IssueOfEquityOfferingPricePerShare>
    <abvx:IssueOfEquityOfferingPricePerShare
      contextRef="c-126"
      decimals="2"
      id="f-640"
      unitRef="eurPerShare">54.58</abvx:IssueOfEquityOfferingPricePerShare>
    <ifrs-full:ClosingForeignExchangeRate contextRef="c-127" decimals="4" id="f-641" unitRef="number">1.1726</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-128" decimals="-5" id="f-642" unitRef="usd">747500000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-128" decimals="-5" id="f-643" unitRef="eur">637500000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <abvx:NetProceedsFromIssueOfOrdinaryShares contextRef="c-128" decimals="-5" id="f-644" unitRef="usd">700300000</abvx:NetProceedsFromIssueOfOrdinaryShares>
    <abvx:NetProceedsFromIssueOfOrdinaryShares contextRef="c-128" decimals="-5" id="f-645" unitRef="eur">597200000</abvx:NetProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssuingOtherEquityInstruments contextRef="c-128" decimals="-5" id="f-646" unitRef="eur">607200000</ifrs-full:ProceedsFromIssuingOtherEquityInstruments>
    <abvx:NumberOfConvertibleNotesConverted contextRef="c-129" decimals="INF" id="f-647" unitRef="note">150</abvx:NumberOfConvertibleNotesConverted>
    <abvx:NumberOfConvertibleNotesConverted contextRef="c-130" decimals="INF" id="f-648" unitRef="note">200</abvx:NumberOfConvertibleNotesConverted>
    <ifrs-full:NotionalAmount contextRef="c-130" decimals="-5" id="f-649" unitRef="eur">21900000</ifrs-full:NotionalAmount>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c-131"
      decimals="INF"
      id="f-650"
      unitRef="shares">920377</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <abvx:BorrowingsFixedConversionPrice
      contextRef="c-130"
      decimals="4"
      id="f-651"
      unitRef="eurPerShare">23.7674</abvx:BorrowingsFixedConversionPrice>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c-132"
      decimals="INF"
      id="f-652"
      unitRef="shares">785389</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c-133"
      decimals="INF"
      id="f-653"
      unitRef="shares">319251</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c-134"
      decimals="INF"
      id="f-654"
      unitRef="shares">206662</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c-135"
      decimals="INF"
      id="f-655"
      unitRef="shares">392695</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="c-136" decimals="-3" id="f-656" unitRef="eur">33823000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-137"
      decimals="INF"
      id="f-657"
      unitRef="shares">47500</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage contextRef="c-138" decimals="2" id="f-658" unitRef="number">0.50</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-138" id="f-659">P2Y</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage contextRef="c-139" decimals="2" id="f-660" unitRef="number">0.25</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-139" id="f-661">P3Y</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage contextRef="c-140" decimals="2" id="f-662" unitRef="number">0.25</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-140" id="f-663">P4Y</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-141"
      decimals="INF"
      id="f-664"
      unitRef="shares">23477</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-142" id="f-665">P4Y</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage contextRef="c-142" decimals="2" id="f-666" unitRef="number">0.25</abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage>
    <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits contextRef="c-143" decimals="-3" id="f-667" unitRef="eur">278000</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
    <abvx:KeyManagementPersonnelCompensationContractualSeveranceIndemnity contextRef="c-143" decimals="-3" id="f-668" unitRef="eur">240000</abvx:KeyManagementPersonnelCompensationContractualSeveranceIndemnity>
    <abvx:NumberOfSharesWaived
      contextRef="c-144"
      decimals="INF"
      id="f-669"
      unitRef="shares">77050</abvx:NumberOfSharesWaived>
    <abvx:NumberOfSharesWithPerformanceConditionsWaived
      contextRef="c-144"
      decimals="INF"
      id="f-670"
      unitRef="shares">40200</abvx:NumberOfSharesWithPerformanceConditionsWaived>
    <abvx:NumberOfSharesLapsed
      contextRef="c-144"
      decimals="INF"
      id="f-671"
      unitRef="shares">217750</abvx:NumberOfSharesLapsed>
    <ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory contextRef="c-1" id="f-672">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:68.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Accounting principles &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Note 4.1. &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Goodwill &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:591.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Following initial recognition, goodwill is stated at cost less any accumulated impairment losses (see Note 4.4). &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:613.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;In respect of business combinations prior to January 1, 2020, in accordance with IFRS 1 exemption, goodwill is included on the basis &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:623.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;of its deemed cost, which represents the amount recorded under the prior basis of accounting, French GAAP, (&#x201c;Previous GAAP&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Note 4.2. &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Intangible assets &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:667.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Pursuant to IAS 38&#x2014;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:122.36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Intangible Assets&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:190.9pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, intangible assets acquired are recognized as assets on the statements of financial position at &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:677.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;their acquisition cost. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Licenses, patents and development costs &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:86.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Payments for separately acquired research and development are capitalized within &#x201c;intangible assets&#x201d; provided that they meet the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:96.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;definition of an intangible asset: a resource that is (i)&#160;controlled by the Group, (ii) expected to provide future economic benefits for the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:106.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Group and (iii)&#160;identifiable (i.e., it is either separable or arises from contractual or legal rights). In accordance with paragraph 25 of &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:116.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;IAS 38&#x2014;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:74.61pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Intangible Assets&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:143.15pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, the recognition criterion relating to the likelihood of future economic benefits generated by the intangible &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;asset, is presumed to be achieved for research and development activities when they are acquired separately. In this context, amounts &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:136.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;paid to third parties in the form of initial payments or milestone payments relating to pharmaceutical specialties that have not yet &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:146.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;obtained a marketing authorization are recognized as intangible assets. These rights will be amortized on a straight-line basis, after &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:156.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;obtaining the marketing authorization, over their useful life. Unamortized rights (before marketing authorization) are subject to &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:166.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;impairment tests in accordance with the method defined in Note 4.4.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:188.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Research and development costs&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:206.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Pursuant to IAS 38 &#x2013; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:122.36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Intangible Assets&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:190.9pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, research costs are expensed in the period during which they are incurred. Development costs &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:216.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;are only recognized as intangible assets if the following criteria are met: &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:232.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;it is technically feasible to complete the development of the project; &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:248.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;it is th&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:116.02000000000001pt;position:var(--position);text-decoration:none;white-space:pre"&gt;e Group&#x2019;s intention to complete the project and to utilize it; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:264.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;it has capacity to utilize the intangible asset; &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:280.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;there is proof of the probability of future economic benefits associated with the asset &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:296.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;there is availability of the technical, financial and other resources for completing the project; and &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:312.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;there is a reliable evaluation of the development expenses. &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:334.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The initial measurement of the asset is the sum of expenses incurred starting on the date on which the development project meets the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:344.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;above criteria. Because of the risks and uncertainties related to regulatory authorizations and to the research and development process, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:354.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the Group believes that the &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:146.14pt;position:var(--position);text-decoration:none;white-space:pre"&gt;six&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:157.8pt;position:var(--position);text-decoration:none;white-space:pre"&gt; criteria stipulated by IAS 38 have not been fulfilled to date and the application of this principle has &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:364.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;resulted in all development costs being expensed as incurred in all periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:392.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Other intangible assets &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:408.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Other intangible assets mainly consist of acquired software. Costs related to the acquisition of software licenses are recognized as &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:418.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;assets based on the costs incurred to acquire and set up the related software. Other intangible assets are amortized using the straight-&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:428.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;line method over a period of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:151.99pt;position:var(--position);text-decoration:none;white-space:pre"&gt;one year&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:186.11pt;position:var(--position);text-decoration:none;white-space:pre"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Note 4.3. &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Property, plant and equipment &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:472.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Pursuant to IAS 16 &#x2013; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:122.36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:247.8pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, property, plant and equipment are recognized at their acquisition cost (purchase &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:482.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;price and directly attributable costs) or at their production cost by the Group, as applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:504.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Property, plant and equipment are depreciated using the straight-line method over the estimated useful life of the asset. The principal &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:514.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;useful lives applied are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:524.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="position:var(--position);top:534.56pt;width:612pt"&gt;&lt;div style="font-size:0pt;left:36pt;position:var(--position);width:324pt"&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:0"&gt;&lt;td style="padding:0;width:150.75pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:95.25pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:78pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15.75pt"&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14.25pt"&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:15.75pt;width:150.75pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:150.75pt;position:var(--position);top:15.75pt;width:173.25pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:173.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;position:var(--position);text-decoration:none;white-space:pre"&gt;DEPRECIATION PERIOD&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14.25pt"&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:30pt;width:150.75pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre"&gt;Buildings&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:150.75pt;position:var(--position);top:30pt;width:95.25pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:246pt;position:var(--position);top:30pt;width:78pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14.25pt"&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:44.25pt;width:150.75pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre"&gt;Office fixtures and fittings&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:150.75pt;position:var(--position);top:44.25pt;width:95.25pt"&gt;&lt;div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:3.67pt;width:95.25pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:45.13pt;position:var(--position);text-decoration:none;white-space:pre"&gt;3 years&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:73.71pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:6.5pt;font-style:normal;font-weight:normal;left:76.21pt;position:var(--position);text-decoration:none;top:-2.4254999999999995pt;vertical-align:super;white-space:pre"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:246pt;position:var(--position);top:44.25pt;width:78pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14.25pt"&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:58.5pt;width:150.75pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre"&gt;Equipment&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:150.75pt;position:var(--position);top:58.5pt;width:95.25pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:246pt;position:var(--position);top:58.5pt;width:78pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14.25pt"&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:72.75pt;width:150.75pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre"&gt;Industrial materials and equipment&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:150.75pt;position:var(--position);top:72.75pt;width:95.25pt"&gt;&lt;div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:21.95pt;position:var(--position);text-decoration:none;white-space:pre"&gt;5&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:26.95pt;position:var(--position);white-space:pre"&gt; to &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;10 years&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:246pt;position:var(--position);top:72.75pt;width:78pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14.25pt"&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:87pt;width:150.75pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre"&gt;Technical facilities&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:150.75pt;position:var(--position);top:87pt;width:95.25pt"&gt;&lt;div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:21.95pt;position:var(--position);text-decoration:none;white-space:pre"&gt;5&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:26.95pt;position:var(--position);white-space:pre"&gt; to &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;10 years&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:246pt;position:var(--position);top:87pt;width:78pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14.25pt"&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:101.25pt;width:150.75pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre"&gt;Furniture and computer equipment:&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:150.75pt;position:var(--position);top:101.25pt;width:95.25pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:246pt;position:var(--position);top:101.25pt;width:78pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14.25pt"&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:115.5pt;width:150.75pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre"&gt;Office equipment&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:150.75pt;position:var(--position);top:115.5pt;width:95.25pt"&gt;&lt;div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:21.95pt;position:var(--position);text-decoration:none;white-space:pre"&gt;5&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:26.95pt;position:var(--position);white-space:pre"&gt; to &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;10 years&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:246pt;position:var(--position);top:115.5pt;width:78pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14.25pt"&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:129.75pt;width:150.75pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre"&gt;IT equipment&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:150.75pt;position:var(--position);top:129.75pt;width:95.25pt"&gt;&lt;div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;  &#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:45.13pt;position:var(--position);text-decoration:none;white-space:pre"&gt;3 years&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:246pt;position:var(--position);top:129.75pt;width:78pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14.25pt"&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:144pt;width:150.75pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre"&gt;Furniture&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:150.75pt;position:var(--position);top:144pt;width:95.25pt"&gt;&lt;div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:22.08pt;position:var(--position);white-space:pre"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.58pt;position:var(--position);text-decoration:none;white-space:pre"&gt;10 years&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:246pt;position:var(--position);top:144pt;width:78pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:35.95pt;position:var(--position)"&gt;(1)&lt;span style="display:inline-block;height:6.93pt;width:12.84pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:60.45pt;position:var(--position)"&gt;Office fixtures and fittings estimated useful lives correspond to the Paris headquarters and Boston offices residual estimated &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:80.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:60.45pt;position:var(--position);text-decoration:none;white-space:pre"&gt;lease terms. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:102.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The useful lives of property, plant and equipment as well as any residual values are reviewed at each year-end and, in the event of a &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:112.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;significant change, the depreciation schedule is revised prospectively. &lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Note 4.4. &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Impairment of goodwill, intangible assets, property and plant and equipment &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:156.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Goodwill and intangible assets not yet available for use are not amortized and are tested for impairment annually. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:178.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;In addition, the Group assesses at the end of each reporting period whether there is an indication that intangible assets and property, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:188.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;plant and equipment may be impaired. Pursuant to IAS 36&#x2014;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:278.56pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Impairment of Assets&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:362.93pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, criteria for assessing indication of loss in value may &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:198.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;notably include performance levels lower than forecast, a significant change in market data or the regulatory environment, or &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:208.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;obsolescence or physical damage of the asset not included in the amortization/depreciation schedule. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:230.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;For the purpose of impairment testing, goodwill and intangible assets not yet available for use are allocated to each of the Group&#x2019;s &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:240.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;CGUs expected to benefit from synergies arising from the business combination or from the use of the intangible assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:262.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;An impairment loss is recognized when the carrying amount of a CGU, including the goodwill, exceeds the recoverable amount of the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:272.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;CGU. The recoverable amount of a CGU is the higher of the CGU&#x2019;s fair value less cost to sell and value-in-use. The total impairment &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:282.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;loss of a CGU is allocated first to reduce the carrying amount of goodwill allocated to the CGU and then to the other assets of the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:292.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;CGU pro-rata on the basis of the carrying amount of each asset in the CGU. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:314.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;An impairment loss on goodwill is not reversed in a subsequent period. Impairment losses on intangible assets and property, plant and &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:324.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;equipment shall be reversed subsequently if the impairment loss no longer exists or has decreased. &lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Note 4.5. Financial assets &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:368.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Financial assets at amortized cost &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:384.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Other financial assets (advances, loans and deposits granted to third parties and other short-term investments) and other receivables are &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:394.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;non-derivative financial assets with fixed or determinable payments that are not listed on an active market. They are initially &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:404.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;recognized at fair value plus transaction costs that are directly attributable to the acquisition or issue of the financial asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:420.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;IFRS 9 &#x2013; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:74.61pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Financial Instruments &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:165.64pt;position:var(--position);text-decoration:none;white-space:pre"&gt;requires an entity to recognize a loss allowance for expected credit losses on a financial asset at &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:430.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;amortized cost at each statement of financial position date. The amount of the loss allowance for expected credit losses equal to: (i)&#160;the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:440.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;12&#x2014;month expected credit losses or (ii)&#160;the full lifetime expected credit losses. The latter applies if credit risk has increased &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:450.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;significantly since initial recognition of the financial instrument. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:478.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Cash and cash equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:494.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group classifies investments as cash equivalents in the statements of financial position and statements of cash flows when they &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:504.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;meet the conditions of IAS 7&#x2014;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:161.17000000000002pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Statement of Cash Flows, &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:265.8pt;position:var(--position);text-decoration:none;white-space:pre"&gt;i.e., when they are: &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:520.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;held in order to face short-term cash commitments; and &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:536.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;short term and highly liquid assets at acquisition date, readily convertible into known amount of cash and not exposed to &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:546.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;any material risk of change in value. &lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Note 4.6. &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Share capital &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:590.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Ordinary shares are classified in shareholders&#x2019; equity. Costs associated with the issuance of new shares are directly accounted for in &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:600.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;shareholders&#x2019; equity in diminution of issuance premium. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:622.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group&#x2019;s own shares bought in the context of a brokering/liquidity agreement entered with an independent broker are presented as &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:632.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;a reduction of shareholders&#x2019; equity until their cancellation, their reissuance or their disposal. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Note 4.7. &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Share-based payments &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:96.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Since its inception, the Group has established several plans for compensation settled in equity instruments in the form of founders&#x2019; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:106.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;share subscription warrants (&#x201c;bons de souscription de parts de cr&#xe9;ateur d&#x2019;entreprise&#x201d; or &#x201c;BCE&#x201d;), share subscription warrants (&#x201c;Bons de &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:116.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;souscription d&#x2019;actions,&#x201d; or &#x201c;BSA&#x201d;) and free shares (&#x201c;Attributions gratuites d&#x2019;actions,&#x201d; or &#x201c;AGA&#x201d;), granted to its employees, corporate &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;officers and scientific consultants. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:148.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Pursuant to IFRS 2&#x2014;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:122.36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Share-based Payment, &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:214.78pt;position:var(--position);text-decoration:none;white-space:pre"&gt;these awards are measured at their fair value on the date of grant. The values of the equity &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:158.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;instruments are determined using the option pricing model (in particular, a Black and Scholes model for the BCE and BSA plans and a &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:168.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Monte-Carlo simulation for the AGA plans which include market performance vesting conditions) based on the value of the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:178.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;underlying equity instrument at grant date, the volatility observed in a sample of comparable listed companies and the estimated life of &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:188.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the related equity instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:210.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group recognizes the fair value of these awards as a share-based compensation expense over the period in which the related &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:220.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;services are received, i.e. over the vesting period, with a corresponding increase in shareholders&#x2019; equity. Share-based compensation is &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:230.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;recognized by installments in consistency with their graded vesting schedule, when applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:252.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:262.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;performance conditions are expected to be met, such that the amount ultimately recognized is based on the number of awards that meet &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:272.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the related service and non-market performance conditions at the vesting date. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:294.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;For share-based payment awards with market vesting conditions and non-vesting conditions, the grant-date fair value of the share-&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:304.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;based payment is measured to reflect such conditions and there is no true-up for differences between expected and actual outcome. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:314.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The measurement of the fair value of BSA, BCE and AGA incorporates the market-based vesting conditions and non-vesting &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:324.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;conditions as described in Note 4.15 &#x201c;Use of judgments and estimates&#x201d;. &lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Note 4.8. &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Financial liabilities &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:374.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:underline;white-space:pre"&gt;Note 4.8.1. Financial liabilities at amortized cost&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:402.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Pursuant to IFRS 9 &#x2013; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:122.36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Financial Instruments, &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:215.89pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the borrowings, the debt component of the Kreos / Claret OCABSA (classified as &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:412.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;convertible loan notes &#x2013; see &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:149.47pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Compound instruments &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:244.98pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Compound instruments below), royalty certificates and Other financial liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:422.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;(conditional advances) other than financial derivative liabilities are measured at amortized cost. They are initially recognized at fair &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:432.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;value and subsequently measured at amortized cost calculated using the effective interest rate (&#x201c;EIR&#x201d;) method. The transaction costs &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:442.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;that are directly attributable to the issue of the financial liability reduce that financial liability. These expenses are then amortized over &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:452.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the lifetime of the liability, on the basis of the EIR. The EIR is the rate that exactly discounts estimated future cash payments through &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:462.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the expected life of the financial liability to the amortized cost of a financial liability. Financial liabilities that are due within one year &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:472.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;are presented as current financial liabilities in the statements of financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:500.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Royalty certificates &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:516.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Royalty certificates meet the definition of financial liabilities. The Group concluded that they do not include embedded derivatives &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:526.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;related to the variability of royalties that are based on future net sales. In addition, the Group concluded that the prepayment options &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:536.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;were separate derivative instruments as their redemption price did not reimburse holders for an amount up to the approximate present &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:546.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;value of lost interest for the remaining term of the host contracts. However, their value at inception and subsequent dates is nil and has &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:556.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;no impact on the financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:585.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Royalty certificates are initially measured at fair value (refer to note 15.9 for valuation model applied). They are subsequently &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:597.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;measured at amortized cost calculated using the EIR method. The EIR is calculated based on future cash flows, which are estimated on &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:609.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the basis of development and commercialization plans and budgets approved by the Board of Directors of the Group, and probability-&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:621.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;weighted to reflect the probability of success of clinical studies and any other uncertainty affecting them. If there is a change in the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:633.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;timing or amount of estimated cash flows, then the gross carrying amount of the amortized cost of the financial liability is adjusted in &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:645.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the period of change to reflect the revised actual and estimated cash flows, with a corresponding income or expense being recognized &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:657.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;in profit or loss. The revised gross carrying amount of the amortized cost of the financial liability is calculated by discounting the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:669.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;future revised estimated cash flows at the original EIR. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:699.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Conditional advances and State guaranteed loan &#x2013; &#x201c;PGE&#x201d; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Accounting treatment for conditional advances and the State-guaranteed loan (Pr&#xea;t garanti par l'Etat, or "PGE") is set forth in Note 4.9. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:98.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:114.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Accounting treatment for lease liabilities is set forth in Note 4.12.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:146.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:underline;white-space:pre"&gt;Note 4.8.2. Financial liabilities measured at fair value through profit or loss &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:344.9pt;position:var(--position);text-decoration:none;white-space:pre"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:169.76pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Derivative instruments&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:127.27pt;position:var(--position);text-decoration:none;white-space:pre"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:186.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;BSA attached to Kreos 1 bonds, the conversion option of OCEANE, certain prepayment options of bonds, the Kreos / Claret warrants &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:196.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;and the Kreos / Claret Minimum Return Indemnifications ("MRI") are derivatives instruments. Derivatives are recognized initially at &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:206.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;fair value at the date the derivative contract is entered into and are subsequently remeasured to their fair value at each reporting date. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:216.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The resulting gain or loss from change in the fair value is recognized in profit or loss immediately, as financial expenses or income. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:244.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Hybrid instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:272.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;OCEANE bonds &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:105.41pt;position:var(--position);text-decoration:none;white-space:pre"&gt;and Heights convertible notes (whose characteristics are described in Note 15.2 and Note 15.5)&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.25pt;position:var(--position);text-decoration:none;white-space:pre"&gt; are hybrid &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:282.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;instruments. A &#x201c;hybrid contract&#x201d; is a contract that includes both a non-derivative host contract and one or more embedded derivatives. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:292.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Embedded derivatives are required to be separated from the host contract (bifurcated) if: the economic characteristics and risks of the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:302.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;embedded derivative are not closely related to those of the host, a separate instrument with the same terms as the embedded derivative &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:312.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;would meet the definition of a derivative, and the hybrid contract is not measured at fair value through profit or loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:334.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Separable embedded derivatives are required to be measured at fair value at each reporting date, with changes in fair value recognized &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:344.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;in profit or loss. The initial bifurcation of a separable embedded derivative does not result in any gain or loss being recognized. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:354.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Because the embedded derivative component is measured at fair value on initial recognition, the carrying amount of the host contract &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:364.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;on initial recognition is the difference between the carrying amount of the hybrid instrument and the fair value of the embedded &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:374.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;derivative. If the fair values of the hybrid instrument and host contract are more reliably measurable than that of the derivative &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:384.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;component - e.g. because of the availability of quoted market prices - then it may be acceptable to use those values to determine the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:394.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;fair value of the derivative on initial recognition indirectly - i.e. as a residual amount. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:416.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Heights convertible notes issued on August 24, 2023 included embedded derivatives as detailed in Note 15. The Group concluded &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:428.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;that these features were embedded derivatives that would modify the cash flows required under the contract and require to be &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:439.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;bifurcated from their host contract. The Group being unable to reliably value each embedded derivative at issuance date and on &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:450.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;subsequent reporting dates, it measured the whole hybrid instrument at fair value through profit or loss (&#x201c;FVTPL&#x201d;) as permitted by &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:461.76pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;IFRS 9. Instruments measured at FVTPL under these conditions are measured at their fair value on issuance and on subsequent &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:472.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;reporting dates, with changes in fair value recognized in profit or loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:495.66pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Compound instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:519.66pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Kreos / Claret OCABSA are compound instruments (whose characteristics are describ&lt;/span&gt;&lt;span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:398.62pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&lt;span style="background-color:inherit"&gt;ed in Note 15.1). &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:468.57pt;position:var(--position);text-decoration:none;white-space:pre"&gt;A &#x201c;compound contract&#x201d; is &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:530.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;a contract that includes both a debt component and an equity component.&#160; The debt component (excluding the conversion option and &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:542.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the attached OCABSA warrants) is initially recognized at fair value and subsequently measured at amortized cost calculated using the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:553.26pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;EIR method. The equity component corresponding to the conversion option and the attached OCABSA warrants is recorded in equity, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:564.46pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;for the difference between the whole instrument&#x2019;s fair value (its nominal value) and the standalone fair value of the debt component.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:593.66pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Fair value measurement &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:609.66pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;When measuring the fair value of an asset or a liability, the Company uses market observable data as far as possible. Fair values are &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:619.66pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:635.66pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;level 1: fair value calculated using quoted prices in an active market for identical assets and liabilities; &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:651.66pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;level 2: fair value calculated using valuation techniques based on observable market data such as prices for assets and &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:661.66pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;liabilities or similar parameters quoted in an active market; &#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:671.66pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;level 3: fair value calculated using valuation techniques based in whole or in part on unobservable inputs such as prices &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:681.66pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;in an inactive market or a valuation based on multiples of unlisted securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:703.66pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;See Note 12 Financial assets and liabilities and Note 15 Financial liabilities. &lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Note 4.9. Research tax credit, subsidies and conditional advances &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:86.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Research tax credit &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:102.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group benefits from the provisions of Article 244 &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:255.53pt;position:var(--position);text-decoration:none;white-space:pre"&gt;quater &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:284.12pt;position:var(--position);text-decoration:none;white-space:pre"&gt;B of the French General Tax Code relating to the French research tax &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:112.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;credit (&#x201c;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:68.99000000000001pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Cr&#xe9;dit d&#x2019;Imp&#xf4;t Recherche&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:173.3pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x201d; or &#x201c;CIR&#x201d;). The CIR is granted to companies in order to encourage them to conduct technical and &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:122.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;scientific research. Companies that prove that they have expenditures which meet the required criteria (research expenditures located &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:132.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;in France or, since January 1, 2005, within the European Union or in another state that is a party to the Agreement on the European &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:142.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Economic Area and has concluded a tax treaty with France that contains an administrative assistance clause) receive a tax credit that &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:152.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;can be used for the payment of the corporate tax due for the fiscal year in which the expenditures were made and the next three fiscal &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:162.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;years, or as applicable, companies may receive cash reimbursement for any excess portion at the three-year period following the fiscal &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:172.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;year of the expenditures. Only those companies meeting the EU definition of a small or medium-sized entity (&#x201c;SME&#x201d;) are eligible for &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:182.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;payment in cash of their research tax credit (to the extent not used to offset corporate tax payables) in the year following the request &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:192.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;for reimbursement. The expenditures taken into account for the calculation of the CIR involve only research expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:214.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The CIR is presented under &#x201c;Other operating income&#x201d; in the statements of income (loss) as it is accounted for as a government grant &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:224.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;as defined in IAS 20 &#x2013; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:128.16pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Accounting for Government Grants and Disclosure of Government Assistanc&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:435.67pt;position:var(--position);text-decoration:none;white-space:pre"&gt;e, and as &#x201c;Other receivables and &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:234.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;assets&#x201d; in the statement of financial position until its payment is received. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:262.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Subsidies &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:278.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Subsidies are non-repayable grants received by the Group and recognized in the financial statements when there exists reasonable &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:288.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;assurance that the Group will comply with the conditions attached to the subsidies and the subsidies will be received. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:310.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Subsidies that are upfront payments are presented as deferred income and recognized through &#x201c;Other operating income&#x201d; for the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:320.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;amount of the expenses incurred as part of the research program to which the subsidy relates. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:342.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;A subsidy that is to be received either as compensation for expenses or for losses already incurred, or for immediate financial support &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:352.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;of the Group without associated future costs, is recognized in the Statements of income (loss) as &#x201c;Other operating income&#x201d; when there &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:362.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;exists reasonable assurance that the subsidies will be received. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:390.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Conditional advances and PGE &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:406.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group receives conditional advances to finance at below market interest rate research and development projects. Due to the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:416.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;innovative nature of its drug candidate development programs, the Group has benefited from certain sources of financial assistance &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:426.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;from Bpifrance. Bpifrance provides financial assistance and support to emerging French enterprises to facilitate the development and &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:436.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;commercialization of innovative technologies. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:458.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Funds received from Bpifrance in the form of conditional advances are recognized as financial liabilities, as the Group has a &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:468.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;contractual obligation to reimburse Bpifrance for such conditional advances in cash based on a repayment schedule. Each award of an &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:478.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;advance is made to help fund a specific development milestone. More de&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:327.3pt;position:var(--position);text-decoration:none;white-space:pre"&gt;tails &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:346.43pt;position:var(--position);text-decoration:none;white-space:pre"&gt;on conditional advances are provided in Note 15.7. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:488.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Receipts or reimbursements of conditional advances are reflected as financing transactions in the statements of cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:510.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The difference between the present value of the advance at market rate (i.e., present value of contractual cash flows including principal &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:520.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;and interests, discounted using a market rate as effective interest rate in accordance with IFRS 9) and the amount received as cash &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:530.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;from the Bpifrance constitutes a subsidy within the meaning of IAS 20. Considering that these advances do not finance fixed assets, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:540.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;these subsidies are presented as &#x201c;Deferred income&#x201d; in the statement of financial position and recognized in the statement of net income &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:550.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;(loss) as &#x201c;Other operating income&#x201c; on a systematic basis over the periods in which the Group recognizes as expenses the related costs &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:560.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;for which the grants are intended to compensate. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:582.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The incremental interest expense resulting from the difference between (a)&#160;the market interest rate and the (b)&#160;below-market rate is &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:592.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;spread over the contractual period until the last repayment and recognized in the statement of income (loss) accordingly, using the EIR &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:602.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;method. In the event of a change in estimate of contractual cash flows due under the conditional advances, the Group recalculates the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:612.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;book value of the debt resulting from the discounting of the anticipated new future cash flows at the initial EIR. The adjustment is &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:622.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;recognized in the statements of income (loss) for the period during which the modification is recognized. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:644.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;In the statements of financial position, these conditional advances are recorded in &#x201c;Other financial liabilities&#x201d; as current or non-current &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:654.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;portion depending on their maturity. In the event Bpifrance waived the repayment of the advance, the corresponding liability is &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:664.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;derecognized and treated as a subsidy in the statements of income (loss). &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:686.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The benefit resulting from the low interest of PGE loans is also recognized as a subsidy corresponding to the difference between the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:696.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;present value of the PGE at market rate and the amount received as cash. The accounting treatment is therefore similar to the above-&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;mentioned accounting treatment for conditional advances. PGE are recorded in &#x201c;Borrowings&#x201d; as current or non-current portion &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:80.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;depending on their maturity. &lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Note 4.10. &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:80.42pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Employee benefits &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:124.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group&#x2019;s employees in France benefit from retirement benefits provided under French law, which consist in the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:140.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;compensation paid by the Group to employees upon their retirement (a defined benefit plan); and &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:156.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;payments of retirement pensions by the social security agencies, which are financed by the contributions made by the &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:166.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Group and employees. As they meet the definition of a defined contribution plan, the liabilities are presented as Tax and &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:176.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;employee-related payables in the statement of financial position. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:198.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;In accordance with IAS 19 &#x2013; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:153.11pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Employee Benefits&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:227.15pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, the liability with respect to defined benefit plans is estimated by using the projected &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:208.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;credit unit method. According to this method, the cost of the retirement benefit is recognized in the statements of income (loss). The &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:218.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;retirement benefit commitments are valued at the current value of the estimated future payments, discounted using the market rate for &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:228.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;high quality corporate bonds with a term and currency that correspond to that estimated for the payment of the benefits. The Group &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:238.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;applied the decision of the IFRS IC, published on May&#160;24, 2021, that concluded that, in the case that no rights were acquired in the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:248.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;event of departure before retirement age and that the rights were capped after a certain number of years of seniority (&#x201c;30 years&#x201d;), the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:258.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;commitment would only be recognized for the last 30 years of the employee&#x2019;s career within the Group. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:280.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The difference between the amount of the provision at the beginning of a period and at the close of that period is recognized through &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:290.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;operating expenses for the portion representing the costs of services rendered and financial expenses for the net interest costs, and &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:300.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;through other comprehensive income (loss) for the portion representing the actuarial gains and losses due to changes in assumptions &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:310.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;and experience adjustments. &lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Note 4.11. &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:80.42pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Provisions &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:348.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Provisions correspond to commitments resulting from litigation and various risks to which the Group may face in the context of its &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:358.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;operations, as well as taxes and employer contributions related to AGAs that become due upon the vesting of the awards. In &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:368.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;accordance with IAS 37 &#x2013; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:142.28pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Provisions, Contingent Liabilities and&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:294.92pt;position:var(--position);text-decoration:none;white-space:pre"&gt; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:297.42pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Contingent Assets, &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:374.29pt;position:var(--position);text-decoration:none;white-space:pre"&gt;a provision is recorded when the Group has an &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:378.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;obligation to a third party resulting from a past event that will likely result in an outflow of resources to the third party, and for which &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:388.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;future cash outflows may be estimated reliably. The amount recorded as a provision is an estimate of the expenditure required to settle &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:398.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the obligation, discounted where necessary at year end. For AGA taxes, the taxes are based on the vesting date share price, and the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:408.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;provision is estimated based on the spot listed price at year-end multiplied by the number of AGAs which are expected to vest. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:418.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Contingent&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:80.4pt;position:var(--position);text-decoration:none;white-space:pre"&gt; liabilities are not recognized, but are disclosed in the notes to the financial statements unless the possibility of an outflow &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:428.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;of economic resources is remote. &lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Note 4.12. &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:80.42pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Leases &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:472.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;As lessee, the Group assesses whether a contract contains a lease at inception of a contract and upon the modification of a contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:482.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group elected to allocate the consideration in the contract to the lease and non-lease components on the basis of the relative &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:492.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;standalone price. The Group recognizes a right-of-use asset and a corresponding lease liability for all arrangements in which it is a &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:502.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;lessee, except for leases with a term of 12 months or less (short-term leases) and low-value leases (value of the underlying asset below &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:512.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;5.0 thousand&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:92.09pt;position:var(--position);text-decoration:none;white-space:pre"&gt;). For these short-term and low-value leases, the Group recognizes the lease payments as an operating expense on a &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:522.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;straight-line basis over the term of the lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:544.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The lease liability is initially measured at the present value of the future lease payments as from the commencement date of the lease &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:554.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;to the end of the lease term. The lease terms used by the Group reflect the non-cancellable terms of each contract, plus any extension &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:564.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;or termination options that the Group is reasonably certain to exercise or not exercise for all of the leases periods covered by the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:574.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;extension options. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:584.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Group incremental borrowing rate for the asset subject to the lease in the respective markets. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:606.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever there is a &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:616.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;change to the lease terms or expected payments under the lease, or a modification that is not accounted for as a separate lease. The &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:626.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;portion of the lease payments attributable to the repayment of lease liabilities and the portion attributable to payment of interests are &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:636.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;recognized in cash flows used in financing activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:658.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Right-of-use assets are initially recognized on the balance sheet at cost, which comprises the amount of the initial measurement of the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:668.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;corresponding lease liability, adjusted for any lease payments made at or prior to the commencement date of the lease, any lease &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:678.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;incentives received and any initial direct costs incurred by the Group, and expected costs for obligations to dismantle and remove &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:688.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;right-of-use assets when they are no longer used. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Right-of-use assets are depreciated on a straight-line basis from the commencement date of the lease over the shorter of the useful life &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:80.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;of the right-of-use asset or the end of the lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:102.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Right-of-use assets are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:112.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;recoverable using cash flow projections. &lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Note 4.13. &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:80.42pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Translation of transactions denominated in foreign currency &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:156.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Pursuant to IAS 21&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.36pt;position:var(--position);text-decoration:none;white-space:pre"&gt; &#x2013; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:122.36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Effects of Changes in Foreign Exchange Rates&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:326.3pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, transactions performed by the Company and the Subsidiary &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:166.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;in currencies other than their functional currencies, which are respectively the Euro and the U.S. dollar, are translated at the prevailing &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:176.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;exchange rate on the transaction date. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:198.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Trade receivables and payables and liabilities denominated in a currency other than the functional currency are translated at the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:208.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;period-end exchange rate. Unrealized gains and losses arising on translation are recognized in net financial income / (loss). &lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Note 4.14. &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:80.42pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Current and deferred tax &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:246.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:256.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;French tax authorities, using tax rates and tax laws enacted or substantively enacted at the end of the reporting period in accordance &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:266.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;with IAS 12 &#x2013; Income Tax. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:288.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The income tax charge for the period comprises current tax due and the deferred tax charge. The tax expense is recognized in the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:298.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;statement of income (loss) unless it relates to items recorded in other comprehensive income (loss) or directly in equity, in which case &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:308.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the tax is also recorded in other comprehensive income (loss) or directly in equity. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:336.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Current taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:352.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The current tax expense is calculated based on taxable profit for the period, using tax rates enacted or substantively enacted at the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:362.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;statement of financial position date. Considering the level of tax loss of the Group, no current tax expense is recognized. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:390.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Deferred taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:406.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Deferred taxes are recognized when there are temporary differences between the carrying amount of assets and liabilities in the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:416.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Group&#x2019;s financial statements and the corresponding tax basis used to calculate taxable profit. Deferred taxes are not recognized if they &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:426.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;arise from the initial recognition of an asset or liability in a transaction other than a business combination which, at the time of the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:436.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;transaction, does not affect either the accounting or the taxable profit (tax loss). &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:446.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group applies the Amendments to IAS 12 &#x2013; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:232.23pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Deferred Tax related to Assets and Liabilities arising from a Single Transaction&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:552.79pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:456.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;issued on May 7, 2021, and presents the deferred tax assets and liabilities arising from such transactions separately within Note 22 &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:559.6pt;position:var(--position);text-decoration:none;white-space:pre"&gt;- &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:466.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Income tax, &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.11pt;position:var(--position);text-decoration:none;white-space:pre"&gt;rather than on a net basis. The Amendments have no impact on the Statements of financial position and the Statement of &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:476.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;comprehensive income (loss) for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:504.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Deferred tax assets &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:520.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Deferred tax assets are recognized for all deductible temporary differences, unused tax losses and unused tax credits to the extent that &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:530.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;it is probable that the temporary difference will reverse in the foreseeable future and that taxable profit will be available against which &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:540.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the deductible temporary difference, unused tax losses or unused tax credits can be utilized. In this regard, the Group applies the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:550.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;decision of the IFRS IC, published on January 29, 2021, on the amount of deferred tax assets recognized from unused tax losses as a &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:560.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;result of suitable taxable temporary differences, in the case when the use of such tax losses is restricted or limited by the tax law. See &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:570.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Note 4.15. Use of judgments and estimates and Note 22 Income tax. &lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Note 4.15. &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:80.42pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Use of judgments and estimates &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:614.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;In order to prepare financial statements in accordance with IFRS, estimates, judgments and assumptions were made by the Group&#x2019;s &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:624.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;management which could affect the reported amounts of assets, liabilities, contingent liabilities, income and expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:646.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;These estimates are based on the assumption of going concern and are prepared in accordance with information available at the date &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:656.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the financial statements were prepared. They are reviewed on an ongoing basis using past experience and various other factors &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:666.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;considered to be reasonable as the basis to measure the carrying amount of assets and liabilities. Estimates may be revised due to &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:676.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;changes in the underlying circumstances or subsequent to new information. Actual results may differ significantly from these &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:686.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;estimates in line with assumptions or different conditions. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;This note provides an overview of the areas that involved a higher degree of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:342.88pt;position:var(--position);text-decoration:none;white-space:pre"&gt;judgment &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:383.12pt;position:var(--position);text-decoration:none;white-space:pre"&gt;or complexity, and of items which are more &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:80.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;likely to be materially adjusted due to changes in estimates and assumptions. Detailed information about each of these estimates and &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:90.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;judgments &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:80.13pt;position:var(--position);text-decoration:none;white-space:pre"&gt;is included in other notes together with information about the basis of calculation for each affected line item in the financial &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:100.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:116.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;Recognition and measurement of impairment of CGUs. The main assumptions used for the impairment test include &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;(a)&#160;the amount of cash flows that are set on the basis of the development and commercialization plans and budgets &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:136.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;approved by Board of Directors, (b)&#160;assumptions related to &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:329.16pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:341.36pt;position:var(--position);text-decoration:none;white-space:pre"&gt; achievement of the clinical trials and the launch of the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:146.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;commercialization, (c)&#160;the discount rate, (d) assumptions on risk related to the development and (e)&#160;for the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:156.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;commercialization, selling price and volume of sales. The sensitivity analysis in respect of the recoverable amount of the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:166.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;CGUs is presented in Note 6. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:182.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;Measurement of share-based payments granted to employees, corporate officers and scientific consultants, such as BCE, &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:194.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;BSA and AGA, which is based on actuarial models; these models require the use by the Group of certain calculation &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:205.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;assumptions such as the estimated vesting, the occurrence dates of a change of control or a M&amp;amp;A transaction dates, &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:554.11pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:217.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;percentage of success (&#x201c;POS&#x201d;) of obefazimod,&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:276.94pt;position:var(--position);text-decoration:none;white-space:pre"&gt; the expected volatility and maturity of the underlying equity instrument &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:228.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;(see Note 4.7 and Note 14), &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:246.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;Fair value measurement at inception and after of derivative financial instruments resulting from (i)&#160;the warrants issued &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:257.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;concomitantly with the issuance of the straight and convertible bonds to Kreos on July 24, 2018 (or &#x201c;Kreos 1&#x201d;), &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.25pt;position:var(--position);text-decoration:none;white-space:pre"&gt;(ii) the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:269.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Kreos / Claret BSA issued on August 21, 2023 and November 2, 2023, related to tranches A-B and tranche C, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:280.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;respectively, and (iii) the Kreos / Claret Minimum Return Indemnifications related to tranches B and C, issued in March &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:292.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;2024 and June 2024, respectively,&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:309.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;Amortized cost measurement a&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:215.04000000000002pt;position:var(--position);text-decoration:none;white-space:pre"&gt;nd fair value&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:265.53000000000003pt;position:var(--position);text-decoration:none;white-space:pre"&gt; of royalty certificates, based on the following assumptions: (a)&#160;future cash &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:319.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;flows, estimated on the basis of development and commercialization plans and budgets approved by the Board of &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:329.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Directors, (b)&#160;the effective interest rate (for the amortized cost measurement) and (c) the discount rate (for the fair &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:339.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;value). The sensitivity analyses in respect of the amortized cost measurement and fair value of royalty certificates is &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:349.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;presented in Note 15,&#160; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:365.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;Fair value measurement of other financial liabilities at inception, &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:352.32pt;position:var(--position);text-decoration:none;white-space:pre"&gt;and after, for the Heights convertible notes measured at &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:377.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;fair value at each reporting period, with fair value changes recognized in profit or loss, as well as for disclosure purposes &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:388.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;(see Note 15), &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:406.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;Estimation of CIR, based on internal and external expenses, which meet the required criteria, incurred by the Group each &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:416.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;year (see Note 4.9), &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:432.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;Recognition of deferred tax assets: availability and timing of future taxable profit against which deductible temporary &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:442.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;differences and tax losses carried forward can be utilized and whether sufficient evidence exists (see Note 22),&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:458.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72.69999999999999pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Recognition of deferred tax assets: tax deductibility of future royalty payments related to the royalty certificates issued in &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:470.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;September 2022 (see Notes 15 and 22),&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:488.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72.69999999999999pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Determination of the terms of the leases, including whether the Group is reasonably certain to exercise extension and/or &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:500.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;termination options (see Note 15.8).&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:536.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The main critical judgments made by the Group&#x2019;s management impact the following items: &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:564.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72.69999999999999pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Accounting treatment of specific conditions of share-based compensation plans (see Notes 4.7 and 14),&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10.5pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:582.06pt;width:612pt"&gt;&lt;span style="font-family:'Arial', sans-serif;font-size:10.5pt;font-style:normal;font-weight:normal;left:72.69999999999999pt;position:var(--position);text-decoration:none;white-space:pre;width:3.67pt"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre;width:484.88pt"&gt;Accounting treatment of the royalty certificates and August 2023 Kreos / Claret and Heights Financings (see Notes 4.8&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.93pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:593.61pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre;width:32.76pt"&gt;and 15).&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForGoodwillExplanatory contextRef="c-1" id="f-673">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Goodwill &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:591.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Following initial recognition, goodwill is stated at cost less any accumulated impairment losses (see Note 4.4). &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:613.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;In respect of business combinations prior to January 1, 2020, in accordance with IFRS 1 exemption, goodwill is included on the basis &lt;/span&gt;&lt;/div&gt;of its deemed cost, which represents the amount recorded under the prior basis of accounting, French GAAP, (&#x201c;Previous GAAP&#x201d;).</ifrs-full:DescriptionOfAccountingPolicyForGoodwillExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory contextRef="c-1" id="f-674">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Intangible assets &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:667.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Pursuant to IAS 38&#x2014;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:122.36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Intangible Assets&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:190.9pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, intangible assets acquired are recognized as assets on the statements of financial position at &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:677.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;their acquisition cost. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Licenses, patents and development costs &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:86.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Payments for separately acquired research and development are capitalized within &#x201c;intangible assets&#x201d; provided that they meet the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:96.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;definition of an intangible asset: a resource that is (i)&#160;controlled by the Group, (ii) expected to provide future economic benefits for the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:106.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Group and (iii)&#160;identifiable (i.e., it is either separable or arises from contractual or legal rights). In accordance with paragraph 25 of &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:116.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;IAS 38&#x2014;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:74.61pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Intangible Assets&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:143.15pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, the recognition criterion relating to the likelihood of future economic benefits generated by the intangible &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;asset, is presumed to be achieved for research and development activities when they are acquired separately. In this context, amounts &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:136.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;paid to third parties in the form of initial payments or milestone payments relating to pharmaceutical specialties that have not yet &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:146.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;obtained a marketing authorization are recognized as intangible assets. These rights will be amortized on a straight-line basis, after &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:156.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;obtaining the marketing authorization, over their useful life. Unamortized rights (before marketing authorization) are subject to &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:166.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;impairment tests in accordance with the method defined in Note 4.4.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:188.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Research and development costs&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:206.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Pursuant to IAS 38 &#x2013; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:122.36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Intangible Assets&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:190.9pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, research costs are expensed in the period during which they are incurred. Development costs &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:216.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;are only recognized as intangible assets if the following criteria are met: &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:232.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;it is technically feasible to complete the development of the project; &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:248.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;it is th&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:116.02000000000001pt;position:var(--position);text-decoration:none;white-space:pre"&gt;e Group&#x2019;s intention to complete the project and to utilize it; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:264.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;it has capacity to utilize the intangible asset; &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:280.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;there is proof of the probability of future economic benefits associated with the asset &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:296.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;there is availability of the technical, financial and other resources for completing the project; and &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:312.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;there is a reliable evaluation of the development expenses. &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:334.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The initial measurement of the asset is the sum of expenses incurred starting on the date on which the development project meets the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:344.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;above criteria. Because of the risks and uncertainties related to regulatory authorizations and to the research and development process, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:354.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the Group believes that the &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:146.14pt;position:var(--position);text-decoration:none;white-space:pre"&gt;six&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:157.8pt;position:var(--position);text-decoration:none;white-space:pre"&gt; criteria stipulated by IAS 38 have not been fulfilled to date and the application of this principle has &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:364.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;resulted in all development costs being expensed as incurred in all periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:392.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Other intangible assets &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:408.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Other intangible assets mainly consist of acquired software. Costs related to the acquisition of software licenses are recognized as &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:418.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;assets based on the costs incurred to acquire and set up the related software. Other intangible assets are amortized using the straight-&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;line method over a period of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:151.99pt;position:var(--position);text-decoration:none;white-space:pre"&gt;one year&lt;/span&gt;.</ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory>
    <abvx:ResearchAndDevelopmentCostsRecognitionInitialMeasurementNumberOfCriterias
      contextRef="c-1"
      decimals="INF"
      id="f-675"
      unitRef="criteria">6</abvx:ResearchAndDevelopmentCostsRecognitionInitialMeasurementNumberOfCriterias>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-145" id="f-676">P1Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory contextRef="c-1" id="f-677">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Property, plant and equipment &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:472.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Pursuant to IAS 16 &#x2013; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:122.36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:247.8pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, property, plant and equipment are recognized at their acquisition cost (purchase &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:482.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;price and directly attributable costs) or at their production cost by the Group, as applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:504.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Property, plant and equipment are depreciated using the straight-line method over the estimated useful life of the asset. The principal &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:514.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;useful lives applied are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:524.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="position:var(--position);top:534.56pt;width:612pt"&gt;&lt;div style="font-size:0pt;left:36pt;position:var(--position);width:324pt"&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:0"&gt;&lt;td style="padding:0;width:150.75pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:95.25pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:78pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15.75pt"&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14.25pt"&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:15.75pt;width:150.75pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:150.75pt;position:var(--position);top:15.75pt;width:173.25pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:173.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;position:var(--position);text-decoration:none;white-space:pre"&gt;DEPRECIATION PERIOD&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14.25pt"&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:30pt;width:150.75pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre"&gt;Buildings&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:150.75pt;position:var(--position);top:30pt;width:95.25pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:246pt;position:var(--position);top:30pt;width:78pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14.25pt"&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:44.25pt;width:150.75pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre"&gt;Office fixtures and fittings&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:150.75pt;position:var(--position);top:44.25pt;width:95.25pt"&gt;&lt;div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:3.67pt;width:95.25pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:45.13pt;position:var(--position);text-decoration:none;white-space:pre"&gt;3 years&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:73.71pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:6.5pt;font-style:normal;font-weight:normal;left:76.21pt;position:var(--position);text-decoration:none;top:-2.4254999999999995pt;vertical-align:super;white-space:pre"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:246pt;position:var(--position);top:44.25pt;width:78pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14.25pt"&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:58.5pt;width:150.75pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre"&gt;Equipment&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:150.75pt;position:var(--position);top:58.5pt;width:95.25pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:246pt;position:var(--position);top:58.5pt;width:78pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14.25pt"&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:72.75pt;width:150.75pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre"&gt;Industrial materials and equipment&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:150.75pt;position:var(--position);top:72.75pt;width:95.25pt"&gt;&lt;div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:21.95pt;position:var(--position);text-decoration:none;white-space:pre"&gt;5&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:26.95pt;position:var(--position);white-space:pre"&gt; to &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;10 years&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:246pt;position:var(--position);top:72.75pt;width:78pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14.25pt"&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:87pt;width:150.75pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre"&gt;Technical facilities&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:150.75pt;position:var(--position);top:87pt;width:95.25pt"&gt;&lt;div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:21.95pt;position:var(--position);text-decoration:none;white-space:pre"&gt;5&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:26.95pt;position:var(--position);white-space:pre"&gt; to &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;10 years&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:246pt;position:var(--position);top:87pt;width:78pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14.25pt"&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:101.25pt;width:150.75pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre"&gt;Furniture and computer equipment:&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:150.75pt;position:var(--position);top:101.25pt;width:95.25pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:246pt;position:var(--position);top:101.25pt;width:78pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14.25pt"&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:115.5pt;width:150.75pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre"&gt;Office equipment&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:150.75pt;position:var(--position);top:115.5pt;width:95.25pt"&gt;&lt;div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:21.95pt;position:var(--position);text-decoration:none;white-space:pre"&gt;5&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:26.95pt;position:var(--position);white-space:pre"&gt; to &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;10 years&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:246pt;position:var(--position);top:115.5pt;width:78pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14.25pt"&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:129.75pt;width:150.75pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre"&gt;IT equipment&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:150.75pt;position:var(--position);top:129.75pt;width:95.25pt"&gt;&lt;div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;  &#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:45.13pt;position:var(--position);text-decoration:none;white-space:pre"&gt;3 years&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:246pt;position:var(--position);top:129.75pt;width:78pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14.25pt"&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:144pt;width:150.75pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre"&gt;Furniture&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:150.75pt;position:var(--position);top:144pt;width:95.25pt"&gt;&lt;div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:22.08pt;position:var(--position);white-space:pre"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.58pt;position:var(--position);text-decoration:none;white-space:pre"&gt;10 years&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:246pt;position:var(--position);top:144pt;width:78pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:35.95pt;position:var(--position)"&gt;(1)&lt;span style="display:inline-block;height:6.93pt;width:12.84pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:60.45pt;position:var(--position)"&gt;Office fixtures and fittings estimated useful lives correspond to the Paris headquarters and Boston offices residual estimated &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:80.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:60.45pt;position:var(--position);text-decoration:none;white-space:pre"&gt;lease terms. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:102.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The useful lives of property, plant and equipment as well as any residual values are reviewed at each year-end and, in the event of a &lt;/span&gt;&lt;/div&gt;significant change, the depreciation schedule is revised prospectively.</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory contextRef="c-1" id="f-678">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Property, plant and equipment are depreciated using the straight-line method over the estimated useful life of the asset. The principal &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:514.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;useful lives applied are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:524.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="position:var(--position);top:534.56pt;width:612pt"&gt;&lt;div style="font-size:0pt;left:36pt;position:var(--position);width:324pt"&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:0"&gt;&lt;td style="padding:0;width:150.75pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:95.25pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:78pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15.75pt"&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14.25pt"&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:15.75pt;width:150.75pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:150.75pt;position:var(--position);top:15.75pt;width:173.25pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:173.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;position:var(--position);text-decoration:none;white-space:pre"&gt;DEPRECIATION PERIOD&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14.25pt"&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:30pt;width:150.75pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre"&gt;Buildings&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:150.75pt;position:var(--position);top:30pt;width:95.25pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:246pt;position:var(--position);top:30pt;width:78pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14.25pt"&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:44.25pt;width:150.75pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre"&gt;Office fixtures and fittings&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:150.75pt;position:var(--position);top:44.25pt;width:95.25pt"&gt;&lt;div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:3.67pt;width:95.25pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:45.13pt;position:var(--position);text-decoration:none;white-space:pre"&gt;3 years&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:73.71pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:6.5pt;font-style:normal;font-weight:normal;left:76.21pt;position:var(--position);text-decoration:none;top:-2.4254999999999995pt;vertical-align:super;white-space:pre"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:246pt;position:var(--position);top:44.25pt;width:78pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14.25pt"&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:58.5pt;width:150.75pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre"&gt;Equipment&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:150.75pt;position:var(--position);top:58.5pt;width:95.25pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:246pt;position:var(--position);top:58.5pt;width:78pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14.25pt"&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:72.75pt;width:150.75pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre"&gt;Industrial materials and equipment&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:150.75pt;position:var(--position);top:72.75pt;width:95.25pt"&gt;&lt;div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:21.95pt;position:var(--position);text-decoration:none;white-space:pre"&gt;5&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:26.95pt;position:var(--position);white-space:pre"&gt; to &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;10 years&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:246pt;position:var(--position);top:72.75pt;width:78pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14.25pt"&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:87pt;width:150.75pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre"&gt;Technical facilities&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:150.75pt;position:var(--position);top:87pt;width:95.25pt"&gt;&lt;div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:21.95pt;position:var(--position);text-decoration:none;white-space:pre"&gt;5&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:26.95pt;position:var(--position);white-space:pre"&gt; to &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;10 years&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:246pt;position:var(--position);top:87pt;width:78pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14.25pt"&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:101.25pt;width:150.75pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre"&gt;Furniture and computer equipment:&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:150.75pt;position:var(--position);top:101.25pt;width:95.25pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:246pt;position:var(--position);top:101.25pt;width:78pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14.25pt"&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:115.5pt;width:150.75pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre"&gt;Office equipment&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:150.75pt;position:var(--position);top:115.5pt;width:95.25pt"&gt;&lt;div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:21.95pt;position:var(--position);text-decoration:none;white-space:pre"&gt;5&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:26.95pt;position:var(--position);white-space:pre"&gt; to &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.72pt;position:var(--position);text-decoration:none;white-space:pre"&gt;10 years&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:246pt;position:var(--position);top:115.5pt;width:78pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14.25pt"&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:129.75pt;width:150.75pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre"&gt;IT equipment&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:150.75pt;position:var(--position);top:129.75pt;width:95.25pt"&gt;&lt;div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;  &#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:45.13pt;position:var(--position);text-decoration:none;white-space:pre"&gt;3 years&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:246pt;position:var(--position);top:129.75pt;width:78pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14.25pt"&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:144pt;width:150.75pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:150.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;position:var(--position);text-decoration:none;white-space:pre"&gt;Furniture&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:150.75pt;position:var(--position);top:144pt;width:95.25pt"&gt;&lt;div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:2.63pt;width:95.25pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:22.08pt;position:var(--position);white-space:pre"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:39.58pt;position:var(--position);text-decoration:none;white-space:pre"&gt;10 years&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:246pt;position:var(--position);top:144pt;width:78pt"&gt;&lt;div&gt;&lt;div style="line-height:10pt;position:var(--position);top:2.63pt;width:78pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:7.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:35.95pt;position:var(--position)"&gt;(1)&lt;span style="display:inline-block;height:6.93pt;width:12.84pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:60.45pt;position:var(--position)"&gt;Office fixtures and fittings estimated useful lives correspond to the Paris headquarters and Boston offices residual estimated &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;lease terms.</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c-146" id="f-679">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c-147" id="f-680">P5Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c-148" id="f-681">P10Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c-149" id="f-682">P5Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c-150" id="f-683">P10Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c-151" id="f-684">P5Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c-152" id="f-685">P10Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c-153" id="f-686">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c-154" id="f-687">P10Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory contextRef="c-1" id="f-688">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Impairment of goodwill, intangible assets, property and plant and equipment &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:156.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Goodwill and intangible assets not yet available for use are not amortized and are tested for impairment annually. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:178.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;In addition, the Group assesses at the end of each reporting period whether there is an indication that intangible assets and property, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:188.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;plant and equipment may be impaired. Pursuant to IAS 36&#x2014;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:278.56pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Impairment of Assets&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:362.93pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, criteria for assessing indication of loss in value may &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:198.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;notably include performance levels lower than forecast, a significant change in market data or the regulatory environment, or &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:208.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;obsolescence or physical damage of the asset not included in the amortization/depreciation schedule. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:230.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;For the purpose of impairment testing, goodwill and intangible assets not yet available for use are allocated to each of the Group&#x2019;s &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:240.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;CGUs expected to benefit from synergies arising from the business combination or from the use of the intangible assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:262.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;An impairment loss is recognized when the carrying amount of a CGU, including the goodwill, exceeds the recoverable amount of the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:272.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;CGU. The recoverable amount of a CGU is the higher of the CGU&#x2019;s fair value less cost to sell and value-in-use. The total impairment &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:282.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;loss of a CGU is allocated first to reduce the carrying amount of goodwill allocated to the CGU and then to the other assets of the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:292.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;CGU pro-rata on the basis of the carrying amount of each asset in the CGU. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:314.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;An impairment loss on goodwill is not reversed in a subsequent period. Impairment losses on intangible assets and property, plant and &lt;/span&gt;&lt;/div&gt;equipment shall be reversed subsequently if the impairment loss no longer exists or has decreased.</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory contextRef="c-1" id="f-689">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Financial assets at amortized cost &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:384.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Other financial assets (advances, loans and deposits granted to third parties and other short-term investments) and other receivables are &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:394.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;non-derivative financial assets with fixed or determinable payments that are not listed on an active market. They are initially &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:404.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;recognized at fair value plus transaction costs that are directly attributable to the acquisition or issue of the financial asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:420.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;IFRS 9 &#x2013; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:74.61pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Financial Instruments &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:165.64pt;position:var(--position);text-decoration:none;white-space:pre"&gt;requires an entity to recognize a loss allowance for expected credit losses on a financial asset at &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:430.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;amortized cost at each statement of financial position date. The amount of the loss allowance for expected credit losses equal to: (i)&#160;the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:440.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;12&#x2014;month expected credit losses or (ii)&#160;the full lifetime expected credit losses. The latter applies if credit risk has increased &lt;/span&gt;&lt;/div&gt;significantly since initial recognition of the financial instrument.</ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents contextRef="c-1" id="f-690">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Cash and cash equivalents &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:494.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group classifies investments as cash equivalents in the statements of financial position and statements of cash flows when they &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:504.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;meet the conditions of IAS 7&#x2014;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:161.17000000000002pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Statement of Cash Flows, &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:265.8pt;position:var(--position);text-decoration:none;white-space:pre"&gt;i.e., when they are: &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:520.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;held in order to face short-term cash commitments; and &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:536.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;short term and highly liquid assets at acquisition date, readily convertible into known amount of cash and not exposed to &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;any material risk of change in value.</ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents>
    <ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory contextRef="c-1" id="f-691">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Share capital &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:590.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Ordinary shares are classified in shareholders&#x2019; equity. Costs associated with the issuance of new shares are directly accounted for in &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:600.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;shareholders&#x2019; equity in diminution of issuance premium. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:622.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group&#x2019;s own shares bought in the context of a brokering/liquidity agreement entered with an independent broker are presented as &lt;/span&gt;&lt;/div&gt;a reduction of shareholders&#x2019; equity until their cancellation, their reissuance or their disposal.</ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory contextRef="c-1" id="f-692">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Share-based payments &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:96.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Since its inception, the Group has established several plans for compensation settled in equity instruments in the form of founders&#x2019; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:106.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;share subscription warrants (&#x201c;bons de souscription de parts de cr&#xe9;ateur d&#x2019;entreprise&#x201d; or &#x201c;BCE&#x201d;), share subscription warrants (&#x201c;Bons de &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:116.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;souscription d&#x2019;actions,&#x201d; or &#x201c;BSA&#x201d;) and free shares (&#x201c;Attributions gratuites d&#x2019;actions,&#x201d; or &#x201c;AGA&#x201d;), granted to its employees, corporate &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;officers and scientific consultants. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:148.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Pursuant to IFRS 2&#x2014;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:122.36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Share-based Payment, &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:214.78pt;position:var(--position);text-decoration:none;white-space:pre"&gt;these awards are measured at their fair value on the date of grant. The values of the equity &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:158.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;instruments are determined using the option pricing model (in particular, a Black and Scholes model for the BCE and BSA plans and a &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:168.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Monte-Carlo simulation for the AGA plans which include market performance vesting conditions) based on the value of the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:178.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;underlying equity instrument at grant date, the volatility observed in a sample of comparable listed companies and the estimated life of &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:188.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the related equity instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:210.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group recognizes the fair value of these awards as a share-based compensation expense over the period in which the related &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:220.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;services are received, i.e. over the vesting period, with a corresponding increase in shareholders&#x2019; equity. Share-based compensation is &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:230.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;recognized by installments in consistency with their graded vesting schedule, when applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:252.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:262.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;performance conditions are expected to be met, such that the amount ultimately recognized is based on the number of awards that meet &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:272.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the related service and non-market performance conditions at the vesting date. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:294.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;For share-based payment awards with market vesting conditions and non-vesting conditions, the grant-date fair value of the share-&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:304.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;based payment is measured to reflect such conditions and there is no true-up for differences between expected and actual outcome. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:314.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The measurement of the fair value of BSA, BCE and AGA incorporates the market-based vesting conditions and non-vesting &lt;/span&gt;&lt;/div&gt;conditions as described in Note 4.15 &#x201c;Use of judgments and estimates&#x201d;.</ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory contextRef="c-1" id="f-693">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:75.42pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Financial liabilities &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:374.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:underline;white-space:pre"&gt;Note 4.8.1. Financial liabilities at amortized cost&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:402.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Pursuant to IFRS 9 &#x2013; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:122.36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Financial Instruments, &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:215.89pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the borrowings, the debt component of the Kreos / Claret OCABSA (classified as &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:412.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;convertible loan notes &#x2013; see &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:149.47pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Compound instruments &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:244.98pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Compound instruments below), royalty certificates and Other financial liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:422.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;(conditional advances) other than financial derivative liabilities are measured at amortized cost. They are initially recognized at fair &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:432.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;value and subsequently measured at amortized cost calculated using the effective interest rate (&#x201c;EIR&#x201d;) method. The transaction costs &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:442.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;that are directly attributable to the issue of the financial liability reduce that financial liability. These expenses are then amortized over &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:452.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the lifetime of the liability, on the basis of the EIR. The EIR is the rate that exactly discounts estimated future cash payments through &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:462.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the expected life of the financial liability to the amortized cost of a financial liability. Financial liabilities that are due within one year &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:472.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;are presented as current financial liabilities in the statements of financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:500.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Royalty certificates &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:516.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Royalty certificates meet the definition of financial liabilities. The Group concluded that they do not include embedded derivatives &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:526.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;related to the variability of royalties that are based on future net sales. In addition, the Group concluded that the prepayment options &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:536.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;were separate derivative instruments as their redemption price did not reimburse holders for an amount up to the approximate present &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:546.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;value of lost interest for the remaining term of the host contracts. However, their value at inception and subsequent dates is nil and has &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:556.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;no impact on the financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:585.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Royalty certificates are initially measured at fair value (refer to note 15.9 for valuation model applied). They are subsequently &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:597.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;measured at amortized cost calculated using the EIR method. The EIR is calculated based on future cash flows, which are estimated on &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:609.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the basis of development and commercialization plans and budgets approved by the Board of Directors of the Group, and probability-&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:621.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;weighted to reflect the probability of success of clinical studies and any other uncertainty affecting them. If there is a change in the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:633.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;timing or amount of estimated cash flows, then the gross carrying amount of the amortized cost of the financial liability is adjusted in &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:645.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the period of change to reflect the revised actual and estimated cash flows, with a corresponding income or expense being recognized &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:657.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;in profit or loss. The revised gross carrying amount of the amortized cost of the financial liability is calculated by discounting the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:669.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;future revised estimated cash flows at the original EIR. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:699.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Conditional advances and State guaranteed loan &#x2013; &#x201c;PGE&#x201d; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Accounting treatment for conditional advances and the State-guaranteed loan (Pr&#xea;t garanti par l'Etat, or "PGE") is set forth in Note 4.9. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:98.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:114.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Accounting treatment for lease liabilities is set forth in Note 4.12.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:146.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:underline;white-space:pre"&gt;Note 4.8.2. Financial liabilities measured at fair value through profit or loss &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:344.9pt;position:var(--position);text-decoration:none;white-space:pre"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:169.76pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Derivative instruments&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:127.27pt;position:var(--position);text-decoration:none;white-space:pre"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:186.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;BSA attached to Kreos 1 bonds, the conversion option of OCEANE, certain prepayment options of bonds, the Kreos / Claret warrants &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:196.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;and the Kreos / Claret Minimum Return Indemnifications ("MRI") are derivatives instruments. Derivatives are recognized initially at &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:206.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;fair value at the date the derivative contract is entered into and are subsequently remeasured to their fair value at each reporting date. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:216.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The resulting gain or loss from change in the fair value is recognized in profit or loss immediately, as financial expenses or income. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:244.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Hybrid instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:272.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;OCEANE bonds &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:105.41pt;position:var(--position);text-decoration:none;white-space:pre"&gt;and Heights convertible notes (whose characteristics are described in Note 15.2 and Note 15.5)&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.25pt;position:var(--position);text-decoration:none;white-space:pre"&gt; are hybrid &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:282.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;instruments. A &#x201c;hybrid contract&#x201d; is a contract that includes both a non-derivative host contract and one or more embedded derivatives. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:292.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Embedded derivatives are required to be separated from the host contract (bifurcated) if: the economic characteristics and risks of the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:302.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;embedded derivative are not closely related to those of the host, a separate instrument with the same terms as the embedded derivative &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:312.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;would meet the definition of a derivative, and the hybrid contract is not measured at fair value through profit or loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:334.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Separable embedded derivatives are required to be measured at fair value at each reporting date, with changes in fair value recognized &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:344.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;in profit or loss. The initial bifurcation of a separable embedded derivative does not result in any gain or loss being recognized. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:354.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Because the embedded derivative component is measured at fair value on initial recognition, the carrying amount of the host contract &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:364.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;on initial recognition is the difference between the carrying amount of the hybrid instrument and the fair value of the embedded &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:374.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;derivative. If the fair values of the hybrid instrument and host contract are more reliably measurable than that of the derivative &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:384.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;component - e.g. because of the availability of quoted market prices - then it may be acceptable to use those values to determine the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:394.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;fair value of the derivative on initial recognition indirectly - i.e. as a residual amount. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:416.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Heights convertible notes issued on August 24, 2023 included embedded derivatives as detailed in Note 15. The Group concluded &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:428.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;that these features were embedded derivatives that would modify the cash flows required under the contract and require to be &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:439.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;bifurcated from their host contract. The Group being unable to reliably value each embedded derivative at issuance date and on &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:450.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;subsequent reporting dates, it measured the whole hybrid instrument at fair value through profit or loss (&#x201c;FVTPL&#x201d;) as permitted by &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:461.76pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;IFRS 9. Instruments measured at FVTPL under these conditions are measured at their fair value on issuance and on subsequent &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:472.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;reporting dates, with changes in fair value recognized in profit or loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:495.66pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Compound instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:519.66pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Kreos / Claret OCABSA are compound instruments (whose characteristics are describ&lt;/span&gt;&lt;span style="background-color:#ffffff;font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:398.62pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&lt;span style="background-color:inherit"&gt;ed in Note 15.1). &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:468.57pt;position:var(--position);text-decoration:none;white-space:pre"&gt;A &#x201c;compound contract&#x201d; is &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:530.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;a contract that includes both a debt component and an equity component.&#160; The debt component (excluding the conversion option and &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:542.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the attached OCABSA warrants) is initially recognized at fair value and subsequently measured at amortized cost calculated using the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:553.26pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;EIR method. The equity component corresponding to the conversion option and the attached OCABSA warrants is recorded in equity, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:564.46pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;for the difference between the whole instrument&#x2019;s fair value (its nominal value) and the standalone fair value of the debt component.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:593.66pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Fair value measurement &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:609.66pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;When measuring the fair value of an asset or a liability, the Company uses market observable data as far as possible. Fair values are &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:619.66pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:635.66pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;level 1: fair value calculated using quoted prices in an active market for identical assets and liabilities; &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:651.66pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;level 2: fair value calculated using valuation techniques based on observable market data such as prices for assets and &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:661.66pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;liabilities or similar parameters quoted in an active market; &#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:671.66pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;level 3: fair value calculated using valuation techniques based in whole or in part on unobservable inputs such as prices &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:681.66pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;in an inactive market or a valuation based on multiples of unlisted securities. &lt;/span&gt;&lt;/div&gt;See Note 12 Financial assets and liabilities and Note 15 Financial liabilities.</ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants contextRef="c-1" id="f-694">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Research tax credit &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:102.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group benefits from the provisions of Article 244 &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:255.53pt;position:var(--position);text-decoration:none;white-space:pre"&gt;quater &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:284.12pt;position:var(--position);text-decoration:none;white-space:pre"&gt;B of the French General Tax Code relating to the French research tax &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:112.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;credit (&#x201c;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:68.99000000000001pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Cr&#xe9;dit d&#x2019;Imp&#xf4;t Recherche&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:173.3pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x201d; or &#x201c;CIR&#x201d;). The CIR is granted to companies in order to encourage them to conduct technical and &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:122.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;scientific research. Companies that prove that they have expenditures which meet the required criteria (research expenditures located &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:132.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;in France or, since January 1, 2005, within the European Union or in another state that is a party to the Agreement on the European &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:142.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Economic Area and has concluded a tax treaty with France that contains an administrative assistance clause) receive a tax credit that &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:152.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;can be used for the payment of the corporate tax due for the fiscal year in which the expenditures were made and the next three fiscal &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:162.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;years, or as applicable, companies may receive cash reimbursement for any excess portion at the three-year period following the fiscal &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:172.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;year of the expenditures. Only those companies meeting the EU definition of a small or medium-sized entity (&#x201c;SME&#x201d;) are eligible for &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:182.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;payment in cash of their research tax credit (to the extent not used to offset corporate tax payables) in the year following the request &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:192.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;for reimbursement. The expenditures taken into account for the calculation of the CIR involve only research expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:214.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The CIR is presented under &#x201c;Other operating income&#x201d; in the statements of income (loss) as it is accounted for as a government grant &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:224.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;as defined in IAS 20 &#x2013; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:128.16pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Accounting for Government Grants and Disclosure of Government Assistanc&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:435.67pt;position:var(--position);text-decoration:none;white-space:pre"&gt;e, and as &#x201c;Other receivables and &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:234.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;assets&#x201d; in the statement of financial position until its payment is received. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:262.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Subsidies &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:278.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Subsidies are non-repayable grants received by the Group and recognized in the financial statements when there exists reasonable &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:288.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;assurance that the Group will comply with the conditions attached to the subsidies and the subsidies will be received. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:310.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Subsidies that are upfront payments are presented as deferred income and recognized through &#x201c;Other operating income&#x201d; for the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:320.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;amount of the expenses incurred as part of the research program to which the subsidy relates. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:342.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;A subsidy that is to be received either as compensation for expenses or for losses already incurred, or for immediate financial support &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:352.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;of the Group without associated future costs, is recognized in the Statements of income (loss) as &#x201c;Other operating income&#x201d; when there &lt;/span&gt;&lt;/div&gt;exists reasonable assurance that the subsidies will be received.</ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants>
    <ifrs-full:DescriptionOfAccountingPolicyForBorrowingsExplanatory contextRef="c-1" id="f-695">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Conditional advances and PGE &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:406.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group receives conditional advances to finance at below market interest rate research and development projects. Due to the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:416.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;innovative nature of its drug candidate development programs, the Group has benefited from certain sources of financial assistance &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:426.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;from Bpifrance. Bpifrance provides financial assistance and support to emerging French enterprises to facilitate the development and &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:436.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;commercialization of innovative technologies. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:458.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Funds received from Bpifrance in the form of conditional advances are recognized as financial liabilities, as the Group has a &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:468.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;contractual obligation to reimburse Bpifrance for such conditional advances in cash based on a repayment schedule. Each award of an &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:478.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;advance is made to help fund a specific development milestone. More de&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:327.3pt;position:var(--position);text-decoration:none;white-space:pre"&gt;tails &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:346.43pt;position:var(--position);text-decoration:none;white-space:pre"&gt;on conditional advances are provided in Note 15.7. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:488.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Receipts or reimbursements of conditional advances are reflected as financing transactions in the statements of cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:510.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The difference between the present value of the advance at market rate (i.e., present value of contractual cash flows including principal &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:520.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;and interests, discounted using a market rate as effective interest rate in accordance with IFRS 9) and the amount received as cash &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:530.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;from the Bpifrance constitutes a subsidy within the meaning of IAS 20. Considering that these advances do not finance fixed assets, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:540.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;these subsidies are presented as &#x201c;Deferred income&#x201d; in the statement of financial position and recognized in the statement of net income &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:550.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;(loss) as &#x201c;Other operating income&#x201c; on a systematic basis over the periods in which the Group recognizes as expenses the related costs &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:560.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;for which the grants are intended to compensate. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:582.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The incremental interest expense resulting from the difference between (a)&#160;the market interest rate and the (b)&#160;below-market rate is &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:592.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;spread over the contractual period until the last repayment and recognized in the statement of income (loss) accordingly, using the EIR &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:602.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;method. In the event of a change in estimate of contractual cash flows due under the conditional advances, the Group recalculates the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:612.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;book value of the debt resulting from the discounting of the anticipated new future cash flows at the initial EIR. The adjustment is &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:622.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;recognized in the statements of income (loss) for the period during which the modification is recognized. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:644.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;In the statements of financial position, these conditional advances are recorded in &#x201c;Other financial liabilities&#x201d; as current or non-current &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:654.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;portion depending on their maturity. In the event Bpifrance waived the repayment of the advance, the corresponding liability is &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:664.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;derecognized and treated as a subsidy in the statements of income (loss). &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:686.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The benefit resulting from the low interest of PGE loans is also recognized as a subsidy corresponding to the difference between the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:696.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;present value of the PGE at market rate and the amount received as cash. The accounting treatment is therefore similar to the above-&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;mentioned accounting treatment for conditional advances. PGE are recorded in &#x201c;Borrowings&#x201d; as current or non-current portion &lt;/span&gt;&lt;/div&gt;depending on their maturity.</ifrs-full:DescriptionOfAccountingPolicyForBorrowingsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory contextRef="c-1" id="f-696">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:80.42pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Employee benefits &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:124.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group&#x2019;s employees in France benefit from retirement benefits provided under French law, which consist in the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:140.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;compensation paid by the Group to employees upon their retirement (a defined benefit plan); and &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:156.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;payments of retirement pensions by the social security agencies, which are financed by the contributions made by the &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:166.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Group and employees. As they meet the definition of a defined contribution plan, the liabilities are presented as Tax and &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:176.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;employee-related payables in the statement of financial position. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:198.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;In accordance with IAS 19 &#x2013; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:153.11pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Employee Benefits&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:227.15pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, the liability with respect to defined benefit plans is estimated by using the projected &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:208.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;credit unit method. According to this method, the cost of the retirement benefit is recognized in the statements of income (loss). The &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:218.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;retirement benefit commitments are valued at the current value of the estimated future payments, discounted using the market rate for &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:228.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;high quality corporate bonds with a term and currency that correspond to that estimated for the payment of the benefits. The Group &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:238.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;applied the decision of the IFRS IC, published on May&#160;24, 2021, that concluded that, in the case that no rights were acquired in the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:248.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;event of departure before retirement age and that the rights were capped after a certain number of years of seniority (&#x201c;30 years&#x201d;), the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:258.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;commitment would only be recognized for the last 30 years of the employee&#x2019;s career within the Group. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:280.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The difference between the amount of the provision at the beginning of a period and at the close of that period is recognized through &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:290.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;operating expenses for the portion representing the costs of services rendered and financial expenses for the net interest costs, and &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:300.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;through other comprehensive income (loss) for the portion representing the actuarial gains and losses due to changes in assumptions &lt;/span&gt;&lt;/div&gt;and experience adjustments.</ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory contextRef="c-1" id="f-697">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:80.42pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Provisions &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:348.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Provisions correspond to commitments resulting from litigation and various risks to which the Group may face in the context of its &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:358.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;operations, as well as taxes and employer contributions related to AGAs that become due upon the vesting of the awards. In &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:368.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;accordance with IAS 37 &#x2013; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:142.28pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Provisions, Contingent Liabilities and&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:294.92pt;position:var(--position);text-decoration:none;white-space:pre"&gt; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:297.42pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Contingent Assets, &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:374.29pt;position:var(--position);text-decoration:none;white-space:pre"&gt;a provision is recorded when the Group has an &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:378.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;obligation to a third party resulting from a past event that will likely result in an outflow of resources to the third party, and for which &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:388.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;future cash outflows may be estimated reliably. The amount recorded as a provision is an estimate of the expenditure required to settle &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:398.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the obligation, discounted where necessary at year end. For AGA taxes, the taxes are based on the vesting date share price, and the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:408.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;provision is estimated based on the spot listed price at year-end multiplied by the number of AGAs which are expected to vest. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:418.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Contingent&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:80.4pt;position:var(--position);text-decoration:none;white-space:pre"&gt; liabilities are not recognized, but are disclosed in the notes to the financial statements unless the possibility of an outflow &lt;/span&gt;&lt;/div&gt;of economic resources is remote.</ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory contextRef="c-1" id="f-698">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:80.42pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Leases &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:472.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;As lessee, the Group assesses whether a contract contains a lease at inception of a contract and upon the modification of a contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:482.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group elected to allocate the consideration in the contract to the lease and non-lease components on the basis of the relative &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:492.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;standalone price. The Group recognizes a right-of-use asset and a corresponding lease liability for all arrangements in which it is a &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:502.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;lessee, except for leases with a term of 12 months or less (short-term leases) and low-value leases (value of the underlying asset below &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:512.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;5.0 thousand&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:92.09pt;position:var(--position);text-decoration:none;white-space:pre"&gt;). For these short-term and low-value leases, the Group recognizes the lease payments as an operating expense on a &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:522.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;straight-line basis over the term of the lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:544.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The lease liability is initially measured at the present value of the future lease payments as from the commencement date of the lease &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:554.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;to the end of the lease term. The lease terms used by the Group reflect the non-cancellable terms of each contract, plus any extension &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:564.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;or termination options that the Group is reasonably certain to exercise or not exercise for all of the leases periods covered by the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:574.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;extension options. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:584.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Group incremental borrowing rate for the asset subject to the lease in the respective markets. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:606.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever there is a &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:616.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;change to the lease terms or expected payments under the lease, or a modification that is not accounted for as a separate lease. The &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:626.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;portion of the lease payments attributable to the repayment of lease liabilities and the portion attributable to payment of interests are &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:636.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;recognized in cash flows used in financing activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:658.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Right-of-use assets are initially recognized on the balance sheet at cost, which comprises the amount of the initial measurement of the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:668.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;corresponding lease liability, adjusted for any lease payments made at or prior to the commencement date of the lease, any lease &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:678.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;incentives received and any initial direct costs incurred by the Group, and expected costs for obligations to dismantle and remove &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:688.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;right-of-use assets when they are no longer used. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Right-of-use assets are depreciated on a straight-line basis from the commencement date of the lease over the shorter of the useful life &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:80.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;of the right-of-use asset or the end of the lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:102.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Right-of-use assets are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be &lt;/span&gt;&lt;/div&gt;recoverable using cash flow projections.</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="c-1" id="f-699">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:80.42pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Translation of transactions denominated in foreign currency &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:156.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Pursuant to IAS 21&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.36pt;position:var(--position);text-decoration:none;white-space:pre"&gt; &#x2013; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:122.36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Effects of Changes in Foreign Exchange Rates&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:326.3pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, transactions performed by the Company and the Subsidiary &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:166.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;in currencies other than their functional currencies, which are respectively the Euro and the U.S. dollar, are translated at the prevailing &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:176.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;exchange rate on the transaction date. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:198.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Trade receivables and payables and liabilities denominated in a currency other than the functional currency are translated at the &lt;/span&gt;&lt;/div&gt;period-end exchange rate. Unrealized gains and losses arising on translation are recognized in net financial income / (loss).</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory contextRef="c-1" id="f-700">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to the &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:256.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;French tax authorities, using tax rates and tax laws enacted or substantively enacted at the end of the reporting period in accordance &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:266.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;with IAS 12 &#x2013; Income Tax. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:288.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The income tax charge for the period comprises current tax due and the deferred tax charge. The tax expense is recognized in the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:298.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;statement of income (loss) unless it relates to items recorded in other comprehensive income (loss) or directly in equity, in which case &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:308.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the tax is also recorded in other comprehensive income (loss) or directly in equity. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:336.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Current taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:352.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The current tax expense is calculated based on taxable profit for the period, using tax rates enacted or substantively enacted at the &lt;/span&gt;&lt;/div&gt;statement of financial position date. Considering the level of tax loss of the Group, no current tax expense is recognized.</ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory contextRef="c-1" id="f-701">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Deferred taxes &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:406.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Deferred taxes are recognized when there are temporary differences between the carrying amount of assets and liabilities in the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:416.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Group&#x2019;s financial statements and the corresponding tax basis used to calculate taxable profit. Deferred taxes are not recognized if they &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:426.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;arise from the initial recognition of an asset or liability in a transaction other than a business combination which, at the time of the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:436.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;transaction, does not affect either the accounting or the taxable profit (tax loss). &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:446.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group applies the Amendments to IAS 12 &#x2013; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:232.23pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Deferred Tax related to Assets and Liabilities arising from a Single Transaction&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:552.79pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:456.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;issued on May 7, 2021, and presents the deferred tax assets and liabilities arising from such transactions separately within Note 22 &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:559.6pt;position:var(--position);text-decoration:none;white-space:pre"&gt;- &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:466.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Income tax, &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.11pt;position:var(--position);text-decoration:none;white-space:pre"&gt;rather than on a net basis. The Amendments have no impact on the Statements of financial position and the Statement of &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:476.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;comprehensive income (loss) for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:504.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Deferred tax assets &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:520.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Deferred tax assets are recognized for all deductible temporary differences, unused tax losses and unused tax credits to the extent that &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:530.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;it is probable that the temporary difference will reverse in the foreseeable future and that taxable profit will be available against which &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:540.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the deductible temporary difference, unused tax losses or unused tax credits can be utilized. In this regard, the Group applies the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:550.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;decision of the IFRS IC, published on January 29, 2021, on the amount of deferred tax assets recognized from unused tax losses as a &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:560.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;result of suitable taxable temporary differences, in the case when the use of such tax losses is restricted or limited by the tax law. See &lt;/span&gt;&lt;/div&gt;Note 4.15. Use of judgments and estimates and Note 22 Income tax.</ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory>
    <abvx:DisclosureOfAccountingPolicyForAccountingJudgementsAndEstimatesExplanatoryPolicyTextBlock contextRef="c-1" id="f-702">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:bold;left:80.42pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Use of judgments and estimates &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:614.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;In order to prepare financial statements in accordance with IFRS, estimates, judgments and assumptions were made by the Group&#x2019;s &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:624.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;management which could affect the reported amounts of assets, liabilities, contingent liabilities, income and expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:646.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;These estimates are based on the assumption of going concern and are prepared in accordance with information available at the date &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:656.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the financial statements were prepared. They are reviewed on an ongoing basis using past experience and various other factors &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:666.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;considered to be reasonable as the basis to measure the carrying amount of assets and liabilities. Estimates may be revised due to &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:676.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;changes in the underlying circumstances or subsequent to new information. Actual results may differ significantly from these &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:686.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;estimates in line with assumptions or different conditions. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;This note provides an overview of the areas that involved a higher degree of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:342.88pt;position:var(--position);text-decoration:none;white-space:pre"&gt;judgment &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:383.12pt;position:var(--position);text-decoration:none;white-space:pre"&gt;or complexity, and of items which are more &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:80.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;likely to be materially adjusted due to changes in estimates and assumptions. Detailed information about each of these estimates and &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:90.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;judgments &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:80.13pt;position:var(--position);text-decoration:none;white-space:pre"&gt;is included in other notes together with information about the basis of calculation for each affected line item in the financial &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:100.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:116.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;Recognition and measurement of impairment of CGUs. The main assumptions used for the impairment test include &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:126.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;(a)&#160;the amount of cash flows that are set on the basis of the development and commercialization plans and budgets &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:136.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;approved by Board of Directors, (b)&#160;assumptions related to &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:329.16pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:341.36pt;position:var(--position);text-decoration:none;white-space:pre"&gt; achievement of the clinical trials and the launch of the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:146.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;commercialization, (c)&#160;the discount rate, (d) assumptions on risk related to the development and (e)&#160;for the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:156.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;commercialization, selling price and volume of sales. The sensitivity analysis in respect of the recoverable amount of the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:166.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;CGUs is presented in Note 6. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:182.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;Measurement of share-based payments granted to employees, corporate officers and scientific consultants, such as BCE, &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:194.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;BSA and AGA, which is based on actuarial models; these models require the use by the Group of certain calculation &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:205.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;assumptions such as the estimated vesting, the occurrence dates of a change of control or a M&amp;amp;A transaction dates, &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:554.11pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:217.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;percentage of success (&#x201c;POS&#x201d;) of obefazimod,&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:276.94pt;position:var(--position);text-decoration:none;white-space:pre"&gt; the expected volatility and maturity of the underlying equity instrument &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:228.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;(see Note 4.7 and Note 14), &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:246.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;Fair value measurement at inception and after of derivative financial instruments resulting from (i)&#160;the warrants issued &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:257.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;concomitantly with the issuance of the straight and convertible bonds to Kreos on July 24, 2018 (or &#x201c;Kreos 1&#x201d;), &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.25pt;position:var(--position);text-decoration:none;white-space:pre"&gt;(ii) the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:269.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Kreos / Claret BSA issued on August 21, 2023 and November 2, 2023, related to tranches A-B and tranche C, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:280.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;respectively, and (iii) the Kreos / Claret Minimum Return Indemnifications related to tranches B and C, issued in March &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:292.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;2024 and June 2024, respectively,&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:309.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;Amortized cost measurement a&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:215.04000000000002pt;position:var(--position);text-decoration:none;white-space:pre"&gt;nd fair value&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:265.53000000000003pt;position:var(--position);text-decoration:none;white-space:pre"&gt; of royalty certificates, based on the following assumptions: (a)&#160;future cash &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:319.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;flows, estimated on the basis of development and commercialization plans and budgets approved by the Board of &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:329.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Directors, (b)&#160;the effective interest rate (for the amortized cost measurement) and (c) the discount rate (for the fair &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:339.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;value). The sensitivity analyses in respect of the amortized cost measurement and fair value of royalty certificates is &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:349.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;presented in Note 15,&#160; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:365.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;Fair value measurement of other financial liabilities at inception, &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:352.32pt;position:var(--position);text-decoration:none;white-space:pre"&gt;and after, for the Heights convertible notes measured at &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:377.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;fair value at each reporting period, with fair value changes recognized in profit or loss, as well as for disclosure purposes &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:388.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;(see Note 15), &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:406.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;Estimation of CIR, based on internal and external expenses, which meet the required criteria, incurred by the Group each &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:416.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;year (see Note 4.9), &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:432.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;Recognition of deferred tax assets: availability and timing of future taxable profit against which deductible temporary &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:442.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;differences and tax losses carried forward can be utilized and whether sufficient evidence exists (see Note 22),&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:458.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72.69999999999999pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Recognition of deferred tax assets: tax deductibility of future royalty payments related to the royalty certificates issued in &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:470.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;September 2022 (see Notes 15 and 22),&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:488.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72.69999999999999pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Determination of the terms of the leases, including whether the Group is reasonably certain to exercise extension and/or &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:500.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;termination options (see Note 15.8).&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:536.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The main critical judgments made by the Group&#x2019;s management impact the following items: &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:564.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:72.69999999999999pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Accounting treatment of specific conditions of share-based compensation plans (see Notes 4.7 and 14),&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10.5pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:582.06pt;width:612pt"&gt;&lt;span style="font-family:'Arial', sans-serif;font-size:10.5pt;font-style:normal;font-weight:normal;left:72.69999999999999pt;position:var(--position);text-decoration:none;white-space:pre;width:3.67pt"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre;width:484.88pt"&gt;Accounting treatment of the royalty certificates and August 2023 Kreos / Claret and Heights Financings (see Notes 4.8&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.93pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:593.61pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre;width:32.76pt"&gt;and 15).&lt;/span&gt;&lt;/div&gt;</abvx:DisclosureOfAccountingPolicyForAccountingJudgementsAndEstimatesExplanatoryPolicyTextBlock>
    <ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory contextRef="c-1" id="f-703">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:68.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Segment information &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:663.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The assessment of the Group&#x2019;s performance and the decisions about resources to be allocated are made by the chief operating decision &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:673.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;maker, based on the management reporting system of the Group. The Group identified the Chief Executive Officer of the Group as &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x201c;chief operating decision maker&#x201d;. The chief operating decision maker reviews on an aggregated basis the incurred expenses for &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:80.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;allocating and evaluating performance of the Group. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:102.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The Group operates in a single operating segment: R&amp;amp;D of pharmaceutical products in order to market them in the future. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:124.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;As of December 31, 2023 and 2024, substantially all operations, assets, liabilities, and losses of the Group were located in France. As &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:135.76pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;of December 31, 2025, the U.S. Subsidiary's contributions to the Group&#x2019;s l&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:334.53pt;position:var(--position);text-decoration:none;white-space:pre"&gt;iabilities and net losse&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:423.01pt;position:var(--position);text-decoration:none;white-space:pre"&gt;s &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:429.4pt;position:var(--position);text-decoration:none;white-space:pre"&gt;were less than &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:488.49pt;position:var(--position);text-decoration:none;white-space:pre"&gt;10%&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:506.82pt;position:var(--position);text-decoration:none;white-space:pre"&gt;, and its &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:146.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;contribution to the Group's assets were &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:193.76pt;position:var(--position);text-decoration:none;white-space:pre"&gt;29%&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:212.09pt;position:var(--position);text-decoration:none;white-space:pre"&gt; (consisting predominantly of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:332.54pt;position:var(--position);text-decoration:none;white-space:pre"&gt;cash and cash equivalents)&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:438.79pt;position:var(--position);text-decoration:none;white-space:pre"&gt;.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory>
    <abvx:ContributionToGroupsLiabilitiesPercentage contextRef="c-155" decimals="2" id="f-704" unitRef="number">0.10</abvx:ContributionToGroupsLiabilitiesPercentage>
    <abvx:ContributionToGroupsNetProfitsLossesPercentage contextRef="c-156" decimals="2" id="f-705" unitRef="number">0.10</abvx:ContributionToGroupsNetProfitsLossesPercentage>
    <abvx:ContributionToGroupsAssetsPercentage contextRef="c-157" decimals="2" id="f-706" unitRef="number">0.29</abvx:ContributionToGroupsAssetsPercentage>
    <ifrs-full:DisclosureOfGoodwillExplanatory contextRef="c-1" id="f-708">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:68.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Goodwill and impairment test &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:204.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Goodwill relates to the acquisition of Splicos SAS and Wittycel SAS that occurred in 2014 (i.e., prior the transition date to IFRS), &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:214.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;which were merged into the Group in the same year. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:236.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Goodwill from Splicos SAS and Wittycel SAS acquisition corresponds to the &#x201c;Modulation of RNA biogenesis / splicing&#x201d; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:246.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;technological platform and the &#x201c;iNKT agonists&#x201d; technological platform, respectively, from which derived the lead drug candidates of &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:256.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the Group: ABX464 and ABX196, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:278.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;IFRS 3 was not applied to acquisitions of subsidiaries deemed to be a business within the meaning of IFRS, carried out before the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:288.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;IFRS transition date, i.e., January&#160;1 2020. Due to the application of this exemption, the previous accounting for business combinations &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:298.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;in accordance with French GAAP remains unchanged (no identified Intellectual Property, Research&#160;&amp;amp; Development (&#x201c;IPR&amp;amp;D&#x201d;) assets &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:308.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;are recognized in the statement of financial position).&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:249.03pt;position:var(--position);text-decoration:none;white-space:pre"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:330.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The impairment test carried out as of December&#160;31, 2022 resulted in the full impairment of the goodwill resulting from the acquisition &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:340.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;of Wittycell SAS and other assets included in the ABX196 CGU, i.e. an impairment loss of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:403.69pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;13,632&#160;thousand&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:474.78pt;position:var(--position);text-decoration:none;white-space:pre"&gt; as of December&#160;31, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:350.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;2022 (&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:61.83pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;13,586&#160;thousand&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:132.92000000000002pt;position:var(--position);text-decoration:none;white-space:pre"&gt; related to goodwill and &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:230.31pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;45&#160;thousand&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:283.9pt;position:var(--position);text-decoration:none;white-space:pre"&gt; related to other assets). &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:360.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Consequently, the carrying amount of the Group's goodwill of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:287.03999999999996pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;18,419&#160;thousand&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:358.13pt;position:var(--position);text-decoration:none;white-space:pre"&gt; as of December&#160;31, 2023, 2024 and 2025 solely &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:372.16pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;relates to the acquisition of Splicos SAS. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:395.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;In accordance with IAS 36, goodwill is allocated to CGUs at a level corresponding to the lead drug candidates. &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:481.88pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Thus, goodwill from &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:406.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Splicos SAS is allocated to the ABX464 CGU.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:429.76pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Goodwill impairment tests are undertaken annually or more frequently if events or changes in circumstances indicate a potential &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:439.76pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;impairment, in accordance with IAS 36. The carrying amount of goodwill is compared to the recoverable amount, which is the higher &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:449.76pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;value in use and the fair value less costs to disposal. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:471.76pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;As of December 31, 2025, the Group has not identified any indication of impairment loss related to goodwill, intangible or tangible &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:482.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:505.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;As of December 31, 2023, 2024 and 2025 the recoverable amount used for the impairment test of each CGU was the value in use. This &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:517.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;value in use was based on a net present value calculation, using the following assumptions as of December 31, 2023, 2024 and 2025: &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:535.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;Cash flows are set on the basis of the development and commercialization plans and budgets approved by Board of &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:545.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Directors; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:561.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05000000000001pt;position:var(--position);text-decoration:none;white-space:pre"&gt;A discount rate (or &#x201c;WACC&#x201d;) o&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:218.41000000000003pt;position:var(--position);text-decoration:none;white-space:pre"&gt;f&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:221.74pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:226.74pt;position:var(--position);text-decoration:none;white-space:pre"&gt;15%&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:245.07pt;position:var(--position);text-decoration:none;white-space:pre"&gt; as of December 31, 2023, &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:352.76pt;position:var(--position);text-decoration:none;white-space:pre"&gt;11.5%&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:378.59pt;position:var(--position);text-decoration:none;white-space:pre"&gt; as of December 31, 2024 and of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:511.53999999999996pt;position:var(--position);text-decoration:none;white-space:pre"&gt;10.0%&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:537.37pt;position:var(--position);text-decoration:none;white-space:pre"&gt; as of &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:572.86pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;December 31, 2025;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:590.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;A risk of development is taken into consideration by applying probabilities of success (or &#x201c;POS&#x201d;) of reaching future &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:600.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;phases of development to cash flows related to the commercialization phase. Those average probabilities of success of &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:610.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;R&amp;amp;D projects are based on public sources&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:259.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:626.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:72.7pt;position:var(--position)"&gt;&#x2022;&lt;span style="display:inline-block;height:6.93pt;width:14.85pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05000000000001pt;position:var(--position)"&gt;For the commercialization phase, selling price and sales volume are estimated on the basis of the potential market and &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:636.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;the observed performances of comparable drugs currently on the market. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:658.36pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The impairment tests resulted in &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:167.21pt;position:var(--position);text-decoration:none;white-space:pre"&gt;no&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:177.21pt;position:var(--position);text-decoration:none;white-space:pre"&gt; impairment charges as of December 31, 2023, 2024, and 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:70.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Sensitivity testing as of December&#160;31, 2023, 2024 and 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:96.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;As the product is currently under development, a clinical trial failure or a failure to obtain a marketing approval could result in an &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:107.76pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;impairment of the goodwill allocated to the ABX464 CGU. The results of the impairment test indicate a headroom level that is high &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:118.96pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;enough so that any reasonably possible change in any of the key assumptions (except clinical failure) would not lead to any &lt;/span&gt;&lt;/div&gt;impairment.</ifrs-full:DisclosureOfGoodwillExplanatory>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="c-158" decimals="-3" id="f-709" unitRef="eur">13632000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill contextRef="c-158" decimals="-3" id="f-710" unitRef="eur">13586000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-158" decimals="-3" id="f-711" unitRef="eur">45000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:Goodwill contextRef="c-159" decimals="-3" id="f-712" unitRef="eur">18419000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-160" decimals="-3" id="f-713" unitRef="eur">18419000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-161" decimals="-3" id="f-714" unitRef="eur">18419000</ifrs-full:Goodwill>
    <ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections contextRef="c-6" decimals="2" id="f-715" unitRef="number">0.15</ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections>
    <ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections contextRef="c-7" decimals="3" id="f-716" unitRef="number">0.115</ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections>
    <ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections contextRef="c-5" decimals="3" id="f-717" unitRef="number">0.100</ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="c-8" decimals="-3" id="f-718" unitRef="eur">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="c-9" decimals="-3" id="f-719" unitRef="eur">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="c-1" decimals="-3" id="f-720" unitRef="eur">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:DisclosureOfIntangibleAssetsExplanatory contextRef="c-1" id="f-721">&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:bold;left:68.47999999999999pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Intangible assets &lt;/span&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:186.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Intangible assets are mainly comprised of the intellectual property underlying: &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:12pt;position:var(--position);top:220.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:66.55pt;position:var(--position);text-decoration:none;white-space:pre"&gt;(i)&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:75.97999999999999pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160; &#160;  &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:90.97999999999999pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The exclusive license agreement with the Scripps Research Institute, University of Chicago and Brigham Young &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:230.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;University for which the Group paid a milestone of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.35pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;45 thousand&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:351.94pt;position:var(--position);text-decoration:none;white-space:pre"&gt; in September 2019 as a result of an IND filling of &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:240.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;ABX196. The value in use and the fair value less costs to disposal of the ABX196 CGU being &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:470.43pt;position:var(--position);text-decoration:none;white-space:pre"&gt;nil&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:480.97pt;position:var(--position);text-decoration:none;white-space:pre"&gt; as of December 31, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:12pt;position:var(--position);top:250.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;2022, a &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:122.97999999999999pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;45&#160;thousand&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:176.57pt;position:var(--position);text-decoration:none;white-space:pre"&gt; impairment loss was recorded during the year ended December 31, 2022 (see Note 6).&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:12pt;font-style:normal;font-weight:normal;left:522.87pt;position:var(--position);text-decoration:none;white-space:pre"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:266.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:66.55pt;position:var(--position)"&gt;(ii)&lt;span style="display:inline-block;height:6.93pt;width:12.3pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05pt;position:var(--position)"&gt;The collaboration and license agreement with the CNRS, Montpellier 2 university and the Curie for which the Group &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:276.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;paid a milestone of &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:169.84pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;40&#160;thousand&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:223.43pt;position:var(--position);text-decoration:none;white-space:pre"&gt; in September 2019 as a result of the entry in phase 2 of ABX464. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:292.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:66.55pt;position:var(--position)"&gt;(iii)&lt;span style="display:inline-block;height:6.93pt;width:9.53pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:91.05pt;position:var(--position)"&gt;Patents acquired through the acquisition of Prosynergia SARL (or "Prosynergia") on April 1, 2022 and amounting to &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:302.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#x20ac;6,529&#160;thousand&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:157.14pt;position:var(--position);text-decoration:none;white-space:pre"&gt;. Considering that Prosynergia only owned patent rights and did not enter into any employee contract, &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:312.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;research agreement, collaboration agreement or out-licensed agreement, this&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:395.87pt;position:var(--position);text-decoration:none;white-space:pre"&gt; &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:398.37pt;position:var(--position);text-decoration:none;white-space:pre"&gt;acquisition did not meet the definition of a &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:322.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;business under IFRS 3. Consequently, the acquisition cost of this group of assets was mostly allocated to the acquired &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:332.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;patents, which cover alternative synthesis process for obefazimod and a family of close chemical analogues. They also &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:342.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;cover alternative forms of obefazimod (salts thereof and crystalline forms of said salts), the pharmaceutical composition &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:352.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;comprising them, that could be of interest to the Group for future development.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:362.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;The patents are not yet amortized, similarly to licenses, and are included in the ABX464 CGU for impairment test &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:372.06pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.05pt;position:var(--position);text-decoration:none;white-space:pre"&gt;purposes. All patents will expire in 2037.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:1pt;position:var(--position);top:70.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:1pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:71.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Licenses and patents recognized as Intangible assets are not amortized since they are not operating in a manner intended by the &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:81.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;management. As a consequence, and in accordance with IAS 36, those assets were subject to an annual impairment test as of &lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:12pt;line-height:10pt;position:var(--position);top:91.56pt;width:612pt"&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre"&gt;December 31, 2023, 2024 and 2025, which did &lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:226.16pt;position:var(--position);text-decoration:none;white-space:pre"&gt;not&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:238.93pt;position:var(--position);text-decoration:none;white-space:pre"&gt; result in any impairment loss being recognized&lt;/span&gt;&lt;span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:428.43pt;position:var(--position);text-decoration:none;white-space:pre"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="position:var(--position);top:113.56pt;width:612pt"&gt;&lt;div style="font-size:0pt;left:36pt;position:var(--position);width:464.25pt"&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:0"&gt;&lt;td style="padding:0;width:194.25pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:65.25pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:3pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:65.25pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:3pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:65.25pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:3pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:65.25pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:32.25pt"&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:23.48pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:45.59pt;position:var(--position);text-decoration:none;white-space:pre"&gt;(amounts in thousands of euros)&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:194.25pt;position:var(--position);width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:23.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.86pt;position:var(--position);text-decoration:none;white-space:pre"&gt;LICENSES&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:262.5pt;position:var(--position);width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:23.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.75pt;position:var(--position);text-decoration:none;white-space:pre"&gt;SOFTWARE&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:330.75pt;position:var(--position);width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:23.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;PATENTS&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:399pt;position:var(--position);width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:23.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;TOTAL&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:32.25pt;width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:3pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;GROSS VALUES&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:44.25pt;width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:2.7pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;AS OF &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:8pt;position:var(--position);top:12.3pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;JANUARY 1, 2023&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:194.25pt;position:var(--position);top:44.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:46.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:49.510000000000005pt;position:var(--position)"&gt;120&lt;span style="display:inline-block;height:5.41pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:262.5pt;position:var(--position);top:44.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:50.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:53.510000000000005pt;position:var(--position)"&gt;24&lt;span style="display:inline-block;height:5.41pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:330.75pt;position:var(--position);top:44.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:40.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:43.510000000000005pt;position:var(--position)"&gt;6,529&lt;span style="display:inline-block;height:5.41pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:399pt;position:var(--position);top:44.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:40.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:43.510000000000005pt;position:var(--position)"&gt;6,673&lt;span style="display:inline-block;height:5.41pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:65.25pt;width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:2.77pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;AS OF &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:8pt;position:var(--position);top:12.37pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;DECEMBER 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:194.25pt;position:var(--position);top:65.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:46.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:49.510000000000005pt;position:var(--position)"&gt;120&lt;span style="display:inline-block;height:5.41pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:262.5pt;position:var(--position);top:65.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:50.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:53.510000000000005pt;position:var(--position)"&gt;24&lt;span style="display:inline-block;height:5.41pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:330.75pt;position:var(--position);top:65.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:40.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:43.510000000000005pt;position:var(--position)"&gt;6,529&lt;span style="display:inline-block;height:5.41pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:399pt;position:var(--position);top:65.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:40.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:43.510000000000005pt;position:var(--position)"&gt;6,673&lt;span style="display:inline-block;height:5.41pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:86.25pt;width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:2.93pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Acquisition&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:194.25pt;position:var(--position);top:86.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.54pt;width:50.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:53.510000000000005pt;position:var(--position)"&gt;&#x2014;&lt;span style="display:inline-block;height:5.54pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:262.5pt;position:var(--position);top:86.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.54pt;width:54.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:57.510000000000005pt;position:var(--position)"&gt;3&lt;span style="display:inline-block;height:5.54pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:330.75pt;position:var(--position);top:86.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.54pt;width:50.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:53.510000000000005pt;position:var(--position)"&gt;&#x2014;&lt;span style="display:inline-block;height:5.54pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:399pt;position:var(--position);top:86.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.54pt;width:54.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:57.510000000000005pt;position:var(--position)"&gt;3&lt;span style="display:inline-block;height:5.54pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23.25pt"&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:98.25pt;width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:5.02pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;AS OF &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:8pt;position:var(--position);top:14.62pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;DECEMBER 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:194.25pt;position:var(--position);top:98.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:46.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:49.510000000000005pt;position:var(--position)"&gt;120&lt;span style="display:inline-block;height:5.41pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:262.5pt;position:var(--position);top:98.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:50.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:53.510000000000005pt;position:var(--position)"&gt;27&lt;span style="display:inline-block;height:5.41pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:330.75pt;position:var(--position);top:98.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:40.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:43.510000000000005pt;position:var(--position)"&gt;6,529&lt;span style="display:inline-block;height:5.41pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:399pt;position:var(--position);top:98.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:40.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:43.510000000000005pt;position:var(--position)"&gt;6,677&lt;span style="display:inline-block;height:5.41pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23.25pt"&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:121.5pt;width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:3.82pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;AS OF &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:8pt;position:var(--position);top:13.42pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;DECEMBER 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:194.25pt;position:var(--position);top:121.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:46.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:49.510000000000005pt;position:var(--position)"&gt;120&lt;span style="display:inline-block;height:5.41pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:262.5pt;position:var(--position);top:121.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:50.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:53.510000000000005pt;position:var(--position)"&gt;27&lt;span style="display:inline-block;height:5.41pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:330.75pt;position:var(--position);top:121.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:40.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:43.510000000000005pt;position:var(--position)"&gt;6,529&lt;span style="display:inline-block;height:5.41pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:399pt;position:var(--position);top:121.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:40.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:43.510000000000005pt;position:var(--position)"&gt;6,677&lt;span style="display:inline-block;height:5.41pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="position:var(--position);top:277.94pt;width:612pt"&gt;&lt;div style="font-size:0pt;left:36pt;position:var(--position);width:464.25pt"&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:0"&gt;&lt;td style="padding:0;width:194.25pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:65.25pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:3pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:65.25pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:3pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:65.25pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:3pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:65.25pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:35.25pt"&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:26.48pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:45.59pt;position:var(--position);text-decoration:none;white-space:pre"&gt;(amounts in thousands of euros)&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:194.25pt;position:var(--position);width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.8pt;position:var(--position);text-decoration:none;white-space:pre"&gt;LICENSES&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:262.5pt;position:var(--position);width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.69pt;position:var(--position);text-decoration:none;white-space:pre"&gt;SOFTWARE&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:330.75pt;position:var(--position);width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.14pt;position:var(--position);text-decoration:none;white-space:pre"&gt;PATENTS&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:399pt;position:var(--position);width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:19.57pt;position:var(--position);text-decoration:none;white-space:pre"&gt;TOTAL&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:35.25pt;width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:3.37pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;AMORTIZATION&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23.25pt"&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:47.25pt;width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:3.82pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;AS OF &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:8pt;position:var(--position);top:13.42pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;JANUARY 1, 2023&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:194.25pt;position:var(--position);top:47.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:48.22pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:50.85pt;position:var(--position)"&gt;(45)&lt;span style="display:inline-block;height:5.41pt;width:0.33pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:262.5pt;position:var(--position);top:47.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:48.55pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:51.18pt;position:var(--position)"&gt;(21)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:330.75pt;position:var(--position);top:47.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:51.21pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:53.84pt;position:var(--position)"&gt;&#x2014;&lt;span style="display:inline-block;height:5.41pt;width:2.66pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:399pt;position:var(--position);top:47.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:48.55pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:51.18pt;position:var(--position)"&gt;(66)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:70.5pt;width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:2.93pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Increase &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:194.25pt;position:var(--position);top:70.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.54pt;width:50.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:53.510000000000005pt;position:var(--position)"&gt;&#x2014;&lt;span style="display:inline-block;height:5.54pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:262.5pt;position:var(--position);top:70.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.54pt;width:52.55pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:55.18pt;position:var(--position)"&gt;(3)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:330.75pt;position:var(--position);top:70.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.54pt;width:51.21pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:53.84pt;position:var(--position)"&gt;&#x2014;&lt;span style="display:inline-block;height:5.54pt;width:2.66pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:399pt;position:var(--position);top:70.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.54pt;width:52.55pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:55.18pt;position:var(--position)"&gt;(3)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:82.5pt;width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:2.7pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;AS OF &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:8pt;position:var(--position);top:12.3pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;DECEMBER 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:194.25pt;position:var(--position);top:82.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:48.22pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:50.85pt;position:var(--position)"&gt;(45)&lt;span style="display:inline-block;height:5.41pt;width:0.33pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:262.5pt;position:var(--position);top:82.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:48.55pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:51.18pt;position:var(--position)"&gt;(24)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:330.75pt;position:var(--position);top:82.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:51.21pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:53.84pt;position:var(--position)"&gt;&#x2014;&lt;span style="display:inline-block;height:5.41pt;width:2.66pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:399pt;position:var(--position);top:82.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:48.55pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:51.18pt;position:var(--position)"&gt;(70)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:103.5pt;width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:2.93pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Increase &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:194.25pt;position:var(--position);top:103.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:9pt;position:var(--position);top:2.35pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial', sans-serif;font-size:9pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:6.55pt;width:49.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:52.510000000000005pt;position:var(--position)"&gt;&#x2014;&lt;span style="display:inline-block;height:6.55pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:262.5pt;position:var(--position);top:103.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.54pt;width:52.55pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:55.18pt;position:var(--position)"&gt;(1)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:330.75pt;position:var(--position);top:103.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.54pt;width:51.21pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:53.84pt;position:var(--position)"&gt;&#x2014;&lt;span style="display:inline-block;height:5.54pt;width:2.66pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:399pt;position:var(--position);top:103.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.54pt;width:52.55pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:55.18pt;position:var(--position)"&gt;(1)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:115.5pt;width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:4.2pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;AS OF &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:8pt;position:var(--position);top:13.8pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;DECEMBER 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:194.25pt;position:var(--position);top:115.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:15.37pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:48.22pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:50.85pt;position:var(--position)"&gt;(45)&lt;span style="display:inline-block;height:5.41pt;width:0.33pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:262.5pt;position:var(--position);top:115.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:15.37pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:48.55pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:51.18pt;position:var(--position)"&gt;(25)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:330.75pt;position:var(--position);top:115.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:15.37pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:51.21pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:53.84pt;position:var(--position)"&gt;&#x2014;&lt;span style="display:inline-block;height:5.41pt;width:2.66pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:399pt;position:var(--position);top:115.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:15.37pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:48.55pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:51.18pt;position:var(--position)"&gt;(70)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.75pt"&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:139.5pt;width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:3.99pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Increase &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:194.25pt;position:var(--position);top:139.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:3.31pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.54pt;width:50.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:53.510000000000005pt;position:var(--position)"&gt;&#x2014;&lt;span style="display:inline-block;height:5.54pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:262.5pt;position:var(--position);top:139.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:3.31pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.54pt;width:52.55pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:55.18pt;position:var(--position)"&gt;(1)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:330.75pt;position:var(--position);top:139.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:3.31pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.54pt;width:51.21pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:53.84pt;position:var(--position)"&gt;&#x2014;&lt;span style="display:inline-block;height:5.54pt;width:2.66pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:399pt;position:var(--position);top:139.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:3.31pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.54pt;width:52.55pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:55.18pt;position:var(--position)"&gt;(1)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:152.25pt;width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:4.2pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;AS OF &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:8pt;position:var(--position);top:13.8pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;DECEMBER 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:194.25pt;position:var(--position);top:152.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:15.37pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:48.22pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:50.85pt;position:var(--position)"&gt;(45)&lt;span style="display:inline-block;height:5.41pt;width:0.33pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:262.5pt;position:var(--position);top:152.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:15.37pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:48.55pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:51.18pt;position:var(--position)"&gt;(26)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:330.75pt;position:var(--position);top:152.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:15.37pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:51.21pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:53.84pt;position:var(--position)"&gt;&#x2014;&lt;span style="display:inline-block;height:5.41pt;width:2.66pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:399pt;position:var(--position);top:152.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:15.37pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:48.55pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:51.18pt;position:var(--position)"&gt;(71)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="position:var(--position);top:485.79pt;width:612pt"&gt;&lt;div style="font-size:0pt;left:36pt;position:var(--position);width:464.25pt"&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:0"&gt;&lt;td style="padding:0;width:194.25pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:65.25pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:3pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:65.25pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:3pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:65.25pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:3pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:65.25pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:35.25pt"&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:26.48pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:45.59pt;position:var(--position);text-decoration:none;white-space:pre"&gt;(amounts in thousands of euros)&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:194.25pt;position:var(--position);width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.8pt;position:var(--position);text-decoration:none;white-space:pre"&gt;LICENSES&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:262.5pt;position:var(--position);width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.69pt;position:var(--position);text-decoration:none;white-space:pre"&gt;SOFTWARE&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:330.75pt;position:var(--position);width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.14pt;position:var(--position);text-decoration:none;white-space:pre"&gt;PATENTS&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:399pt;position:var(--position);width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:19.57pt;position:var(--position);text-decoration:none;white-space:pre"&gt;TOTAL&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:35.25pt;width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:3pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;NET BOOK VALUES&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:47.25pt;width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:2.7pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;AS OF &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:8pt;position:var(--position);top:12.3pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;JANUARY 1, 2023&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:194.25pt;position:var(--position);top:47.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre"&gt;75&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:262.5pt;position:var(--position);top:47.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.62pt;position:var(--position);text-decoration:none;white-space:pre"&gt;3&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:330.75pt;position:var(--position);top:47.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre"&gt;6,529&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:399pt;position:var(--position);top:47.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre"&gt;6,607&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:68.25pt;width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:2.7pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;AS OF &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:8pt;position:var(--position);top:12.3pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;DECEMBER 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:194.25pt;position:var(--position);top:68.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre"&gt;75&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:262.5pt;position:var(--position);top:68.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.62pt;position:var(--position);text-decoration:none;white-space:pre"&gt;0&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:330.75pt;position:var(--position);top:68.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre"&gt;6,529&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:399pt;position:var(--position);top:68.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:7.43pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre"&gt;6,604&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:29.25pt"&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:89.25pt;width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:6.82pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;AS OF &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:8pt;position:var(--position);top:16.42pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;DECEMBER 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:194.25pt;position:var(--position);top:89.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:11.56pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre"&gt;75&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:262.5pt;position:var(--position);top:89.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:11.56pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.62pt;position:var(--position);text-decoration:none;white-space:pre"&gt;3&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:330.75pt;position:var(--position);top:89.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:11.56pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre"&gt;6,529&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:399pt;position:var(--position);top:89.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:11.56pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre"&gt;6,606&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:29.25pt"&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:118.5pt;width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:6.82pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;AS OF &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:8pt;position:var(--position);top:16.42pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;DECEMBER 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:194.25pt;position:var(--position);top:118.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:11.56pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:54.62pt;position:var(--position);text-decoration:none;white-space:pre"&gt;75&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:262.5pt;position:var(--position);top:118.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:11.56pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:58.62pt;position:var(--position);text-decoration:none;white-space:pre"&gt;2&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:330.75pt;position:var(--position);top:118.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:11.56pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre"&gt;6,529&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:399pt;position:var(--position);top:118.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:11.56pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:44.62pt;position:var(--position);text-decoration:none;white-space:pre"&gt;6,605&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIntangibleAssetsExplanatory>
    <abvx:CollaborationAgreementsDevelopmentMilestonePaymentINDApproval contextRef="c-162" decimals="-3" id="f-722" unitRef="eur">45000</abvx:CollaborationAgreementsDevelopmentMilestonePaymentINDApproval>
    <ifrs-full:IntangibleAssetsWithIndefiniteUsefulLife contextRef="c-163" decimals="-3" id="f-723" unitRef="eur">0</ifrs-full:IntangibleAssetsWithIndefiniteUsefulLife>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-158" decimals="-3" id="f-724" unitRef="eur">45000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <abvx:CollaborationAgreementsDevelopmentMilestonePaymentPhase2 contextRef="c-164" decimals="-3" id="f-725" unitRef="eur">40000</abvx:CollaborationAgreementsDevelopmentMilestonePaymentPhase2>
    <abvx:TechnologyBasedIntangibleAssetsAssetsAcquisitions contextRef="c-165" decimals="-3" id="f-726" unitRef="eur">6529000</abvx:TechnologyBasedIntangibleAssetsAssetsAcquisitions>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-166" decimals="-3" id="f-727" unitRef="eur">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-167" decimals="-3" id="f-728" unitRef="eur">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-168" decimals="-3" id="f-729" unitRef="eur">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory contextRef="c-1" id="f-730">&lt;div style="font-size:0pt;left:36pt;position:var(--position);width:464.25pt"&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:0"&gt;&lt;td style="padding:0;width:194.25pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:65.25pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:3pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:65.25pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:3pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:65.25pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:3pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:65.25pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:32.25pt"&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:23.48pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:45.59pt;position:var(--position);text-decoration:none;white-space:pre"&gt;(amounts in thousands of euros)&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:194.25pt;position:var(--position);width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:23.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:12.86pt;position:var(--position);text-decoration:none;white-space:pre"&gt;LICENSES&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:262.5pt;position:var(--position);width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:23.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.75pt;position:var(--position);text-decoration:none;white-space:pre"&gt;SOFTWARE&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:330.75pt;position:var(--position);width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:23.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:14.2pt;position:var(--position);text-decoration:none;white-space:pre"&gt;PATENTS&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:399pt;position:var(--position);width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:23.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:18.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;TOTAL&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:32.25pt;width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:3pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;GROSS VALUES&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:44.25pt;width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:2.7pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;AS OF &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:8pt;position:var(--position);top:12.3pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;JANUARY 1, 2023&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:194.25pt;position:var(--position);top:44.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:46.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:49.510000000000005pt;position:var(--position)"&gt;120&lt;span style="display:inline-block;height:5.41pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:262.5pt;position:var(--position);top:44.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:50.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:53.510000000000005pt;position:var(--position)"&gt;24&lt;span style="display:inline-block;height:5.41pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:330.75pt;position:var(--position);top:44.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:40.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:43.510000000000005pt;position:var(--position)"&gt;6,529&lt;span style="display:inline-block;height:5.41pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:399pt;position:var(--position);top:44.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:40.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:43.510000000000005pt;position:var(--position)"&gt;6,673&lt;span style="display:inline-block;height:5.41pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:65.25pt;width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:2.77pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;AS OF &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:8pt;position:var(--position);top:12.37pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;DECEMBER 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:194.25pt;position:var(--position);top:65.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:46.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:49.510000000000005pt;position:var(--position)"&gt;120&lt;span style="display:inline-block;height:5.41pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:262.5pt;position:var(--position);top:65.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:50.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:53.510000000000005pt;position:var(--position)"&gt;24&lt;span style="display:inline-block;height:5.41pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:330.75pt;position:var(--position);top:65.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:40.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:43.510000000000005pt;position:var(--position)"&gt;6,529&lt;span style="display:inline-block;height:5.41pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:399pt;position:var(--position);top:65.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:12.37pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:40.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:43.510000000000005pt;position:var(--position)"&gt;6,673&lt;span style="display:inline-block;height:5.41pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:86.25pt;width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:2.93pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Acquisition&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:194.25pt;position:var(--position);top:86.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.54pt;width:50.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:53.510000000000005pt;position:var(--position)"&gt;&#x2014;&lt;span style="display:inline-block;height:5.54pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:262.5pt;position:var(--position);top:86.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.54pt;width:54.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:57.510000000000005pt;position:var(--position)"&gt;3&lt;span style="display:inline-block;height:5.54pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:330.75pt;position:var(--position);top:86.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.54pt;width:50.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:53.510000000000005pt;position:var(--position)"&gt;&#x2014;&lt;span style="display:inline-block;height:5.54pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:399pt;position:var(--position);top:86.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:3.24pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.54pt;width:54.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:57.510000000000005pt;position:var(--position)"&gt;3&lt;span style="display:inline-block;height:5.54pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23.25pt"&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:98.25pt;width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:5.02pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;AS OF &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:8pt;position:var(--position);top:14.62pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;DECEMBER 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:194.25pt;position:var(--position);top:98.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:46.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:49.510000000000005pt;position:var(--position)"&gt;120&lt;span style="display:inline-block;height:5.41pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:262.5pt;position:var(--position);top:98.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:50.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:53.510000000000005pt;position:var(--position)"&gt;27&lt;span style="display:inline-block;height:5.41pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:330.75pt;position:var(--position);top:98.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:40.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:43.510000000000005pt;position:var(--position)"&gt;6,529&lt;span style="display:inline-block;height:5.41pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:399pt;position:var(--position);top:98.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:40.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:43.510000000000005pt;position:var(--position)"&gt;6,677&lt;span style="display:inline-block;height:5.41pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23.25pt"&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:121.5pt;width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:3.82pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;AS OF &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:8pt;position:var(--position);top:13.42pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;DECEMBER 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:194.25pt;position:var(--position);top:121.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:46.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:49.510000000000005pt;position:var(--position)"&gt;120&lt;span style="display:inline-block;height:5.41pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:262.5pt;position:var(--position);top:121.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:50.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:53.510000000000005pt;position:var(--position)"&gt;27&lt;span style="display:inline-block;height:5.41pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:330.75pt;position:var(--position);top:121.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:40.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:43.510000000000005pt;position:var(--position)"&gt;6,529&lt;span style="display:inline-block;height:5.41pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:399pt;position:var(--position);top:121.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:40.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:43.510000000000005pt;position:var(--position)"&gt;6,677&lt;span style="display:inline-block;height:5.41pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="position:var(--position);top:277.94pt;width:612pt"&gt;&lt;div style="font-size:0pt;left:36pt;position:var(--position);width:464.25pt"&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:0"&gt;&lt;td style="padding:0;width:194.25pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:65.25pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:3pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:65.25pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:3pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:65.25pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:3pt"&gt;&lt;/td&gt;&lt;td style="padding:0;width:65.25pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:35.25pt"&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:26.48pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:italic;font-weight:normal;left:45.59pt;position:var(--position);text-decoration:none;white-space:pre"&gt;(amounts in thousands of euros)&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:194.25pt;position:var(--position);width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:13.8pt;position:var(--position);text-decoration:none;white-space:pre"&gt;LICENSES&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:262.5pt;position:var(--position);width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.69pt;position:var(--position);text-decoration:none;white-space:pre"&gt;SOFTWARE&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:330.75pt;position:var(--position);width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.14pt;position:var(--position);text-decoration:none;white-space:pre"&gt;PATENTS&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:399pt;position:var(--position);width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:26.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:19.57pt;position:var(--position);text-decoration:none;white-space:pre"&gt;TOTAL&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:35.25pt;width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:3.37pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;AMORTIZATION&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23.25pt"&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:47.25pt;width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:3.82pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;AS OF &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:8pt;position:var(--position);top:13.42pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;JANUARY 1, 2023&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:194.25pt;position:var(--position);top:47.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:48.22pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:50.85pt;position:var(--position)"&gt;(45)&lt;span style="display:inline-block;height:5.41pt;width:0.33pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:262.5pt;position:var(--position);top:47.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:48.55pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:51.18pt;position:var(--position)"&gt;(21)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:330.75pt;position:var(--position);top:47.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:51.21pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:53.84pt;position:var(--position)"&gt;&#x2014;&lt;span style="display:inline-block;height:5.41pt;width:2.66pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:399pt;position:var(--position);top:47.25pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:14.62pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:48.55pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:51.18pt;position:var(--position)"&gt;(66)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:70.5pt;width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:2.93pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Increase &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:194.25pt;position:var(--position);top:70.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.54pt;width:50.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:53.510000000000005pt;position:var(--position)"&gt;&#x2014;&lt;span style="display:inline-block;height:5.54pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:262.5pt;position:var(--position);top:70.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.54pt;width:52.55pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:55.18pt;position:var(--position)"&gt;(3)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:330.75pt;position:var(--position);top:70.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.54pt;width:51.21pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:53.84pt;position:var(--position)"&gt;&#x2014;&lt;span style="display:inline-block;height:5.54pt;width:2.66pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:399pt;position:var(--position);top:70.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.54pt;width:52.55pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:55.18pt;position:var(--position)"&gt;(3)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:82.5pt;width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:2.7pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;AS OF &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:8pt;position:var(--position);top:12.3pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;DECEMBER 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:194.25pt;position:var(--position);top:82.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:48.22pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:50.85pt;position:var(--position)"&gt;(45)&lt;span style="display:inline-block;height:5.41pt;width:0.33pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:262.5pt;position:var(--position);top:82.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:48.55pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:51.18pt;position:var(--position)"&gt;(24)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:330.75pt;position:var(--position);top:82.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:51.21pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:53.84pt;position:var(--position)"&gt;&#x2014;&lt;span style="display:inline-block;height:5.41pt;width:2.66pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:399pt;position:var(--position);top:82.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:7.5pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:48.55pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:51.18pt;position:var(--position)"&gt;(70)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:103.5pt;width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:2.93pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;Increase &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:194.25pt;position:var(--position);top:103.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:9pt;position:var(--position);top:2.35pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial', sans-serif;font-size:9pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:6.55pt;width:49.88pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:52.510000000000005pt;position:var(--position)"&gt;&#x2014;&lt;span style="display:inline-block;height:6.55pt;width:2.99pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:262.5pt;position:var(--position);top:103.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.54pt;width:52.55pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:55.18pt;position:var(--position)"&gt;(1)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:330.75pt;position:var(--position);top:103.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.54pt;width:51.21pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:53.84pt;position:var(--position)"&gt;&#x2014;&lt;span style="display:inline-block;height:5.54pt;width:2.66pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:399pt;position:var(--position);top:103.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:2.93pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.54pt;width:52.55pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="left:55.18pt;position:var(--position)"&gt;(1)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td style="background-color:#ffffff;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="position:var(--position);top:115.5pt;width:194.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:4.2pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;AS OF &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:8pt;position:var(--position);top:13.8pt;width:194.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;left:2.63pt;position:var(--position);text-decoration:none;white-space:pre"&gt;DECEMBER 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"&gt;&lt;div style="left:194.25pt;position:var(--position);top:115.5pt;width:65.25pt"&gt;&lt;div&gt;&lt;div style="line-height:8pt;position:var(--position);top:15.37pt;width:65.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman', serif;font-size:8pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"&gt;&lt;span style="left:2.63pt;position:var(--position)"&gt;&lt;span style="display:inline-block;height:5.41pt;width:48.22pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span